DrugMAP Full Data Download File
Title - DrugMAP molecular interaction atlas of all drug in raw format
Version 1.01 (2022.07.20)
Provided by Lab of Innovative Drug Reasearch and Bioinformatics (IDRB)
            College of Pharmaceutical Sciences
            Zhejiang University
            https://idrblab.org/
Any question about data provided here, please contact with:
Dr. Li (lifengcheng@zju.edu.cn) and Dr. Yin (yinjiayi@zju.edu.cn)

DI: Drug ID
DN: Drug Name
MI: Molecule ID
MN: Molecule Name
MT: Molecule Type
MA: Mode of Action
RN: Reference Name
RU: Reference URL

DMMHNU2	DI	DMMHNU2
DMMHNU2	DN	(S)-(+)-Dimethindene maleate
DMMHNU2	MI	TTTIBOJ
DMMHNU2	MN	Histamine H1 receptor (H1R)
DMMHNU2	MT	DTT
DMMHNU2	MA	Antagonist
DMMHNU2	RN	Analytical method for simultaneously measuring ex vivo drug receptor occupancy and dissociation rate: application to (R)-dimethindene occupancy of central histamine H1 receptors. J Recept Signal Transduct Res. 2009;29(2):84-93.
DMMHNU2	RU	https://pubmed.ncbi.nlm.nih.gov/19308787

DMIAHVU	DI	DMIAHVU
DMIAHVU	DN	2-deoxyglucose
DMIAHVU	MI	DTG3T6X
DMIAHVU	MN	Glucose transporter type 1, erythrocyte/brain (SLC2A1)
DMIAHVU	MT	DTP
DMIAHVU	MA	Substrate
DMIAHVU	RN	Glutamine 161 of Glut1 glucose transporter is critical for transport activity and exofacial ligand binding. J Biol Chem. 1994 Aug 12;269(32):20533-8.
DMIAHVU	RU	http://www.jbc.org/content/269/32/20533.long

DMIAHVU	DI	DMIAHVU
DMIAHVU	DN	2-deoxyglucose
DMIAHVU	MI	DT3BI6S
DMIAHVU	MN	Glucose transporter type 10 (SLC2A10)
DMIAHVU	MT	DTP
DMIAHVU	MA	Substrate
DMIAHVU	RN	Sequence and functional analysis of GLUT10: a glucose transporter in the Type 2 diabetes-linked region of chromosome 20q12-13.1. Mol Genet Metab. 2001 Sep-Oct;74(1-2):186-99.
DMIAHVU	RU	http://www.ncbi.nlm.nih.gov/pubmed/11592815

DMIAHVU	DI	DMIAHVU
DMIAHVU	DN	2-deoxyglucose
DMIAHVU	MI	DTA5QI0
DMIAHVU	MN	Glucose transporter type 12 (SLC2A12)
DMIAHVU	MT	DTP
DMIAHVU	MA	Substrate
DMIAHVU	RN	The human facilitative glucose transporter GLUT12: Expression and regulation in Caco-2 and 3T3-L1cells.
DMIAHVU	RU	https://2017.febscongress.org/abstract_preview.aspx?idAbstractEnc=4424170093096096098098424170

DMIAHVU	DI	DMIAHVU
DMIAHVU	DN	2-deoxyglucose
DMIAHVU	MI	DT18YD9
DMIAHVU	MN	Glucose transporter type 14 (SLC2A14)
DMIAHVU	MT	DTP
DMIAHVU	MA	Substrate
DMIAHVU	RN	The SLC2A14 gene, encoding the novel glucose/dehydroascorbate transporter GLUT14, is associated with inflammatory bowel disease. Am J Clin Nutr. 2017 Dec;106(6):1508-1513.
DMIAHVU	RU	http://www.ncbi.nlm.nih.gov/pubmed/28971850

DMIAHVU	DI	DMIAHVU
DMIAHVU	DN	2-deoxyglucose
DMIAHVU	MI	DTUJPOL
DMIAHVU	MN	Glucose transporter type 2, liver (SLC2A2)
DMIAHVU	MT	DTP
DMIAHVU	MA	Substrate
DMIAHVU	RN	GLUT2 (SLC2A2) is not the principal glucose transporter in human pancreatic beta cells: implications for understanding genetic association signals at this locus. Mol Genet Metab. 2011 Dec;104(4):648-53.
DMIAHVU	RU	http://www.ncbi.nlm.nih.gov/pubmed/21920790

DMIAHVU	DI	DMIAHVU
DMIAHVU	DN	2-deoxyglucose
DMIAHVU	MI	DT9SQ3L
DMIAHVU	MN	Glucose transporter type 3, brain (SLC2A3)
DMIAHVU	MT	DTP
DMIAHVU	MA	Substrate
DMIAHVU	RN	Ascorbic acid-dependent GLUT3 inhibition is a critical step for switching neuronal metabolism. J Cell Physiol. 2011 Dec;226(12):3286-94.
DMIAHVU	RU	http://www.ncbi.nlm.nih.gov/pubmed/21321936

DMIAHVU	DI	DMIAHVU
DMIAHVU	DN	2-deoxyglucose
DMIAHVU	MI	DT4827A
DMIAHVU	MN	Glucose transporter type 4, insulin-responsive (SLC2A4)
DMIAHVU	MT	DTP
DMIAHVU	MA	Substrate
DMIAHVU	RN	Need for GLUT4 activation to reach maximum effect of insulin-mediated glucose uptake in brown adipocytes isolated from GLUT4myc-expressing mice. Diabetes. 2002 Sep;51(9):2719-26.
DMIAHVU	RU	http://www.ncbi.nlm.nih.gov/pubmed/12196464

DMIAHVU	DI	DMIAHVU
DMIAHVU	DN	2-deoxyglucose
DMIAHVU	MI	DTS4MKQ
DMIAHVU	MN	Glucose transporter type 6 (SLC2A6)
DMIAHVU	MT	DTP
DMIAHVU	MA	Substrate
DMIAHVU	RN	Functional Properties and Genomics of Glucose Transporters. Curr Genomics. 2007 Apr; 8(2): 113128.
DMIAHVU	RU	http://www.ncbi.nlm.nih.gov/pubmed/18660845

DMIAHVU	DI	DMIAHVU
DMIAHVU	DN	2-deoxyglucose
DMIAHVU	MI	DT8SQBG
DMIAHVU	MN	Glucose transporter type 7 (SLC2A7)
DMIAHVU	MT	DTP
DMIAHVU	MA	Substrate
DMIAHVU	RN	Functional Properties and Genomics of Glucose Transporters. Curr Genomics. 2007 Apr; 8(2): 113128.
DMIAHVU	RU	http://www.ncbi.nlm.nih.gov/pubmed/18660845

DMIAHVU	DI	DMIAHVU
DMIAHVU	DN	2-deoxyglucose
DMIAHVU	MI	DT2I7BM
DMIAHVU	MN	Glucose transporter type 8 (SLC2A8)
DMIAHVU	MT	DTP
DMIAHVU	MA	Substrate
DMIAHVU	RN	Functional Properties and Genomics of Glucose Transporters. Curr Genomics. 2007 Apr; 8(2): 113128.
DMIAHVU	RU	http://www.ncbi.nlm.nih.gov/pubmed/18660845

DMIAHVU	DI	DMIAHVU
DMIAHVU	DN	2-deoxyglucose
DMIAHVU	MI	DTMSNOU
DMIAHVU	MN	Proton-associated sugar transporter A (SLC45A1)
DMIAHVU	MT	DTP
DMIAHVU	MA	Substrate
DMIAHVU	RN	Dysfunction of the Cerebral Glucose Transporter SLC45A1 in Individuals with Intellectual Disability and Epilepsy. Am J Hum Genet. 2017 May 4;100(5):824-830.
DMIAHVU	RU	http://www.ncbi.nlm.nih.gov/pubmed/28434495

DMIAHVU	DI	DMIAHVU
DMIAHVU	DN	2-deoxyglucose
DMIAHVU	MI	DTOKC04
DMIAHVU	MN	Sodium/glucose cotransporter 1 (SLC5A1)
DMIAHVU	MT	DTP
DMIAHVU	MA	Substrate
DMIAHVU	RN	The role of SGLT1 and GLUT2 in intestinal glucose transport and sensing. PLoS One. 2014 Feb 26;9(2):e89977.
DMIAHVU	RU	http://www.ncbi.nlm.nih.gov/pubmed/24587162

DMIAHVU	DI	DMIAHVU
DMIAHVU	DN	2-deoxyglucose
DMIAHVU	MI	DTO4FLB
DMIAHVU	MN	Sodium/glucose cotransporter 3 (SLC5A4)
DMIAHVU	MT	DTP
DMIAHVU	MA	Substrate
DMIAHVU	RN	The sodium/glucose cotransport family SLC5. Pflugers Arch. 2004 Feb;447(5):510-8.
DMIAHVU	RU	http://www.ncbi.nlm.nih.gov/pubmed/12748858

DMIAHVU	DI	DMIAHVU
DMIAHVU	DN	2-deoxyglucose
DMIAHVU	MI	DT1CP40
DMIAHVU	MN	Sodium/glucose cotransporter 4 (SLC5A9)
DMIAHVU	MT	DTP
DMIAHVU	MA	Substrate
DMIAHVU	RN	SLC5A9/SGLT4, a new Na+-dependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-D-glucitol, and fructose. Life Sci. 2005 Jan 14;76(9):1039-50.
DMIAHVU	RU	http://www.ncbi.nlm.nih.gov/pubmed/15607332

DMIAHVU	DI	DMIAHVU
DMIAHVU	DN	2-deoxyglucose
DMIAHVU	MI	DTQNIG7
DMIAHVU	MN	Sodium/glucose cotransporter 5 (SLC5A10)
DMIAHVU	MT	DTP
DMIAHVU	MA	Substrate
DMIAHVU	RN	The sodium/glucose cotransport family SLC5. Pflugers Arch. 2004 Feb;447(5):510-8.
DMIAHVU	RU	http://www.ncbi.nlm.nih.gov/pubmed/12748858

DMYFBMS	DI	DMYFBMS
DMYFBMS	DN	99mTc-fanolesomab
DMYFBMS	MI	TTNV1KZ
DMYFBMS	MN	Fucosyltransferase IV (CD15)
DMYFBMS	MT	DTT
DMYFBMS	RN	2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4.
DMYFBMS	RU	https://pubmed.ncbi.nlm.nih.gov/15756752

DMVZO01	DI	DMVZO01
DMVZO01	DN	99mTc-sestamibi
DMVZO01	MI	DTSYQGK
DMVZO01	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMVZO01	MT	DTP
DMVZO01	MA	Substrate
DMVZO01	RN	99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein. Br J Cancer. 1998;77(3):353-8.
DMVZO01	RU	https://doi.org/10.1038/bjc.1998.57

DMMN36E	DI	DMMN36E
DMMN36E	DN	Abacavir
DMMN36E	MI	DE017IC
DMMN36E	MN	Alcohol dehydrogenase class-V (ADH6)
DMMN36E	MT	DME
DMMN36E	MA	Metabolism
DMMN36E	RN	A review of the pharmacokinetics of abacavir. Clin Pharmacokinet. 2008;47(6):351-71.
DMMN36E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18479171

DMMN36E	DI	DMMN36E
DMMN36E	DN	Abacavir
DMMN36E	MI	DTI7UX6
DMMN36E	MN	Breast cancer resistance protein (ABCG2)
DMMN36E	MT	DTP
DMMN36E	MA	Substrate
DMMN36E	RN	QSAR analysis and molecular modeling of ABCG2-specific inhibitors. Adv Drug Deliv Rev. 2009 Jan 31;61(1):34-46.
DMMN36E	RU	https://doi.org/10.1016/j.addr.2008.10.004

DMMN36E	DI	DMMN36E
DMMN36E	DN	Abacavir
DMMN36E	MI	TT84ETX
DMMN36E	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMMN36E	MT	DTT
DMMN36E	MA	Inhibitor
DMMN36E	RN	Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only Curr HIV Res. 2009 May;7(3):320-6.
DMMN36E	RU	https://pubmed.ncbi.nlm.nih.gov/19442129

DMMN36E	DI	DMMN36E
DMMN36E	DN	Abacavir
DMMN36E	MI	DTCSGPB
DMMN36E	MN	Multidrug resistance-associated protein 4 (ABCC4)
DMMN36E	MT	DTP
DMMN36E	MA	Substrate
DMMN36E	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMMN36E	RU	https://doi.org/10.1007/s11095-012-0935-x

DMMN36E	DI	DMMN36E
DMMN36E	DN	Abacavir
DMMN36E	MI	DTUGYRD
DMMN36E	MN	P-glycoprotein 1 (ABCB1)
DMMN36E	MT	DTP
DMMN36E	MA	Substrate
DMMN36E	RN	The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res. 2009 May;82(2):A99-109.
DMMN36E	RU	https://doi.org/10.1016/j.antiviral.2008.12.013

DMMN36E	DI	DMMN36E
DMMN36E	DN	Abacavir
DMMN36E	MI	DEYGVN4
DMMN36E	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMMN36E	MT	DME
DMMN36E	MA	Metabolism
DMMN36E	RN	A review of the pharmacokinetics of abacavir. Clin Pharmacokinet. 2008;47(6):351-71.
DMMN36E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18479171

DMMN36E	DI	DMMN36E
DMMN36E	DN	Abacavir
DMMN36E	MI	DEB3CV1
DMMN36E	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMMN36E	MT	DME
DMMN36E	MA	Metabolism
DMMN36E	RN	Product characteristics of Triumeq.
DMMN36E	RU	https://www.ema.europa.eu/en/documents/product-information/triumeq-epar-product-information_en.pdf

DMOERGM	DI	DMOERGM
DMOERGM	DN	Abaloparatide
DMOERGM	MI	TTFPD47
DMOERGM	MN	Parathyroid hormone 1 receptor (PTH1R)
DMOERGM	MT	DTT
DMOERGM	MA	Modulator
DMOERGM	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMOERGM	RU	https://www.fda.gov/

DM2RX0I	DI	DM2RX0I
DM2RX0I	DN	Abametapir
DM2RX0I	MI	TT1GHVO
DM2RX0I	MN	Matrix metalloproteinase (MMP)
DM2RX0I	MT	DTT
DM2RX0I	MA	Inhibitor
DM2RX0I	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DM2RX0I	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206966lbl.pdf

DM5WFNP	DI	DM5WFNP
DM5WFNP	DN	Abarelix
DM5WFNP	MI	TT8R70G
DM5WFNP	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DM5WFNP	MT	DTT
DM5WFNP	MA	Modulator
DM5WFNP	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM5WFNP	RU	https://www.fda.gov/

DMSA8RU	DI	DMSA8RU
DMSA8RU	DN	Abatacept
DMSA8RU	MI	TTFZDNP
DMSA8RU	MN	Activation B7-1 antigen (CD80)
DMSA8RU	MT	DTT
DMSA8RU	MA	Binder
DMSA8RU	RN	Selective modulation of T-cell co-stimulation: a novel mode of action for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2009 May-Jun;27(3):510-8.
DMSA8RU	RU	https://pubmed.ncbi.nlm.nih.gov/19604448

DMSA8RU	DI	DMSA8RU
DMSA8RU	DN	Abatacept
DMSA8RU	MI	TTHGXBU
DMSA8RU	MN	T-lymphocyte activation antigen CD86 (FUN1)
DMSA8RU	MT	DTT
DMSA8RU	MA	Binder
DMSA8RU	RN	Selective modulation of T-cell co-stimulation: a novel mode of action for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2009 May-Jun;27(3):510-8.
DMSA8RU	RU	https://pubmed.ncbi.nlm.nih.gov/19604448

DMJO6GV	DI	DMJO6GV
DMJO6GV	DN	Abciximab
DMJO6GV	MI	TT38RM1
DMJO6GV	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DMJO6GV	MT	DTT
DMJO6GV	MA	Modulator
DMJO6GV	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMJO6GV	RU	https://www.fda.gov/

DM8V75C	DI	DM8V75C
DM8V75C	DN	ABIRATERONE
DM8V75C	MI	TTRA5BZ
DM8V75C	MN	Steroid 17-alpha-monooxygenase (S17AH)
DM8V75C	MT	DTT
DM8V75C	MA	Modulator
DM8V75C	RN	2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
DM8V75C	RU	https://pubmed.ncbi.nlm.nih.gov/22293555

DMANBZI	DI	DMANBZI
DMANBZI	DN	Abiraterone acetate
DMANBZI	MI	DE4LYSA
DMANBZI	MN	Cytochrome P450 3A4 (CYP3A4)
DMANBZI	MT	DME
DMANBZI	MA	Metabolism
DMANBZI	RN	Abiraterone for the treatment of metastatic castrate-resistant prostate cancer. Ann Pharmacother. 2012 Jul-Aug;46(7-8):1016-24.
DMANBZI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22714819

DMANBZI	DI	DMANBZI
DMANBZI	DN	Abiraterone acetate
DMANBZI	MI	DTPFTEQ
DMANBZI	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DMANBZI	MT	DTP
DMANBZI	MA	Substrate
DMANBZI	RN	The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer. Prostate. 2017 May;77(13):1303-1311.
DMANBZI	RU	http://www.ncbi.nlm.nih.gov/pubmed/28762529

DMANBZI	DI	DMANBZI
DMANBZI	DN	Abiraterone acetate
DMANBZI	MI	TTRA5BZ
DMANBZI	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMANBZI	MT	DTT
DMANBZI	MA	Modulator
DMANBZI	RN	CYP17A1 inhibitors in castration-resistant prostate cancer.Steroids.2015 Mar;95:80-7.
DMANBZI	RU	https://www.ncbi.nlm.nih.gov/pubmed/25560485

DMANBZI	DI	DMANBZI
DMANBZI	DN	Abiraterone acetate
DMANBZI	MI	DE0P6LK
DMANBZI	MN	Sulfotransferase 2A1 (SULT2A1)
DMANBZI	MT	DME
DMANBZI	MA	Metabolism
DMANBZI	RN	Abiraterone for the treatment of metastatic castrate-resistant prostate cancer. Ann Pharmacother. 2012 Jul-Aug;46(7-8):1016-24.
DMANBZI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22714819

DMZT2P0	DI	DMZT2P0
DMZT2P0	DN	Abobotulinum toxin A
DMZT2P0	MI	TTZJD1B
DMZT2P0	MN	Acetylcholine release (Ach rele)
DMZT2P0	MT	DTT
DMZT2P0	MA	Modulator
DMZT2P0	RN	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
DMZT2P0	RU	https://pubmed.ncbi.nlm.nih.gov/20118952

DM7GCVW	DI	DM7GCVW
DM7GCVW	DN	Acalabrutinib
DM7GCVW	MI	DE4LYSA
DM7GCVW	MN	Cytochrome P450 3A4 (CYP3A4)
DM7GCVW	MT	DME
DM7GCVW	MA	Metabolism
DM7GCVW	RN	FDA label of Acalabrutinib. The 2020 official website of the U.S. Food and Drug Administration.
DM7GCVW	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210259s006s007lbl.pdf

DM7GCVW	DI	DM7GCVW
DM7GCVW	DN	Acalabrutinib
DM7GCVW	MI	DEIBDNY
DM7GCVW	MN	Cytochrome P450 3A5 (CYP3A5)
DM7GCVW	MT	DME
DM7GCVW	MA	Metabolism
DM7GCVW	RN	FDA label of Acalabrutinib. The 2020 official website of the U.S. Food and Drug Administration.
DM7GCVW	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210259s006s007lbl.pdf

DM7GCVW	DI	DM7GCVW
DM7GCVW	DN	Acalabrutinib
DM7GCVW	MI	TTGM6VW
DM7GCVW	MN	Tyrosine-protein kinase BTK (ATK)
DM7GCVW	MT	DTT
DM7GCVW	MA	Inhibitor
DM7GCVW	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DM7GCVW	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DMO381I	DI	DMO381I
DMO381I	DN	Acamprosate
DMO381I	MI	TTAN6JD
DMO381I	MN	Glutamate receptor AMPA (GRIA)
DMO381I	MT	DTT
DMO381I	MA	Agonist
DMO381I	RN	Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators. Addict Biol. 2009 Jul;14(3):328-37.
DMO381I	RU	https://pubmed.ncbi.nlm.nih.gov/19523047

DMRM3AW	DI	DMRM3AW
DMRM3AW	DN	Acarbose
DMRM3AW	MI	TTXWASR
DMRM3AW	MN	Intestinal maltase-glucoamylase (MGAM)
DMRM3AW	MT	DTT
DMRM3AW	MA	Modulator
DMRM3AW	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMRM3AW	RU	https://www.fda.gov/

DM0TI4U	DI	DM0TI4U
DM0TI4U	DN	Acebutolol
DM0TI4U	MI	TTR6W5O
DM0TI4U	MN	Adrenergic receptor beta-1 (ADRB1)
DM0TI4U	MT	DTT
DM0TI4U	MA	Antagonist
DM0TI4U	RN	Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6.
DM0TI4U	RU	https://pubmed.ncbi.nlm.nih.gov/16268148

DM0TI4U	DI	DM0TI4U
DM0TI4U	DN	Acebutolol
DM0TI4U	MI	DECB0K3
DM0TI4U	MN	Cytochrome P450 2D6 (CYP2D6)
DM0TI4U	MT	DME
DM0TI4U	MA	Metabolism
DM0TI4U	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DM0TI4U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DM0TI4U	DI	DM0TI4U
DM0TI4U	DN	Acebutolol
DM0TI4U	MI	DTE2B1D
DM0TI4U	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DM0TI4U	MT	DTP
DM0TI4U	MA	Substrate
DM0TI4U	RN	Fruit juice inhibition of uptake transport: a new type of food-drug interaction. Br J Clin Pharmacol. 2010 Nov;70(5):645-55.
DM0TI4U	RU	http://www.ncbi.nlm.nih.gov/pubmed/21039758

DM0TI4U	DI	DM0TI4U
DM0TI4U	DN	Acebutolol
DM0TI4U	MI	DTT79CX
DM0TI4U	MN	Organic cation transporter 1 (SLC22A1)
DM0TI4U	MT	DTP
DM0TI4U	MA	Substrate
DM0TI4U	RN	Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
DM0TI4U	RU	https://doi.org/10.1016/j.canlet.2005.06.051

DM0TI4U	DI	DM0TI4U
DM0TI4U	DN	Acebutolol
DM0TI4U	MI	DTUGYRD
DM0TI4U	MN	P-glycoprotein 1 (ABCB1)
DM0TI4U	MT	DTP
DM0TI4U	MA	Substrate
DM0TI4U	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM0TI4U	RU	https://doi.org/10.1007/s11095-012-0935-x

DMOLNCZ	DI	DMOLNCZ
DMOLNCZ	DN	ACECLIDINE
DMOLNCZ	MI	TTZ9SOR
DMOLNCZ	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMOLNCZ	MT	DTT
DMOLNCZ	MA	Inhibitor
DMOLNCZ	RN	Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7.
DMOLNCZ	RU	https://pubmed.ncbi.nlm.nih.gov/8464038

DMOLNCZ	DI	DMOLNCZ
DMOLNCZ	DN	ACECLIDINE
DMOLNCZ	MI	TTYEG6Q
DMOLNCZ	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMOLNCZ	MT	DTT
DMOLNCZ	MA	Inhibitor
DMOLNCZ	RN	Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7.
DMOLNCZ	RU	https://pubmed.ncbi.nlm.nih.gov/8464038

DMOLNCZ	DI	DMOLNCZ
DMOLNCZ	DN	ACECLIDINE
DMOLNCZ	MI	TTQ13Z5
DMOLNCZ	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMOLNCZ	MT	DTT
DMOLNCZ	MA	Inhibitor
DMOLNCZ	RN	Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7.
DMOLNCZ	RU	https://pubmed.ncbi.nlm.nih.gov/8464038

DMOLNCZ	DI	DMOLNCZ
DMOLNCZ	DN	ACECLIDINE
DMOLNCZ	MI	TTQ3JTF
DMOLNCZ	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DMOLNCZ	MT	DTT
DMOLNCZ	MA	Inhibitor
DMOLNCZ	RN	Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7.
DMOLNCZ	RU	https://pubmed.ncbi.nlm.nih.gov/8464038

DMOLNCZ	DI	DMOLNCZ
DMOLNCZ	DN	ACECLIDINE
DMOLNCZ	MI	TTH18TF
DMOLNCZ	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMOLNCZ	MT	DTT
DMOLNCZ	MA	Inhibitor
DMOLNCZ	RN	Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7.
DMOLNCZ	RU	https://pubmed.ncbi.nlm.nih.gov/8464038

DMZDF0B	DI	DMZDF0B
DMZDF0B	DN	Aceclofenac
DMZDF0B	MI	DE5IED8
DMZDF0B	MN	Cytochrome P450 2C9 (CYP2C9)
DMZDF0B	MT	DME
DMZDF0B	MA	Metabolism
DMZDF0B	RN	Metabolism of aceclofenac in humans. Drug Metab Dispos. 1996 Aug;24(8):834-41.
DMZDF0B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8869816

DMZDF0B	DI	DMZDF0B
DMZDF0B	DN	Aceclofenac
DMZDF0B	MI	TTK0943
DMZDF0B	MN	Prostaglandin G/H synthase (COX)
DMZDF0B	MT	DTT
DMZDF0B	MA	Modulator
DMZDF0B	RN	Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. Clin Pharmacol Ther. 2003 Sep;74(3):222-35.
DMZDF0B	RU	https://pubmed.ncbi.nlm.nih.gov/12966366

DMH75KV	DI	DMH75KV
DMH75KV	DN	Acenocoumarol
DMH75KV	MI	DEJGDUW
DMH75KV	MN	Cytochrome P450 1A2 (CYP1A2)
DMH75KV	MT	DME
DMH75KV	MA	Metabolism
DMH75KV	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMH75KV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMH75KV	DI	DMH75KV
DMH75KV	DN	Acenocoumarol
DMH75KV	MI	DE5IED8
DMH75KV	MN	Cytochrome P450 2C9 (CYP2C9)
DMH75KV	MT	DME
DMH75KV	MA	Metabolism
DMH75KV	RN	Prediction of pharmacokinetic drug/drug interactions from In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants. Drug Metab Dispos. 2000 Feb;28(2):161-8.
DMH75KV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10640513

DMH75KV	DI	DMH75KV
DMH75KV	DN	Acenocoumarol
DMH75KV	MI	DE4LYSA
DMH75KV	MN	Cytochrome P450 3A4 (CYP3A4)
DMH75KV	MT	DME
DMH75KV	MA	Metabolism
DMH75KV	RN	Possible interaction between topical terbinafine and acenocoumarol. Ann Pharmacother. 2009 Nov;43(11):1911-2.
DMH75KV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19843835

DMH75KV	DI	DMH75KV
DMH75KV	DN	Acenocoumarol
DMH75KV	MI	DEGTFWK
DMH75KV	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMH75KV	MT	DME
DMH75KV	MA	Metabolism
DMH75KV	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMH75KV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMH75KV	DI	DMH75KV
DMH75KV	DN	Acenocoumarol
DMH75KV	MI	TTEUC8H
DMH75KV	MN	Vitamin K epoxide reductase complex 1 (VKORC1)
DMH75KV	MT	DTT
DMH75KV	MA	Inhibitor
DMH75KV	RN	Evaluation of a reverse-hybridization StripAssay for the detection of genetic polymorphisms leading to acenocoumarol sensitivity. Mol Biol Rep. 2010 Apr;37(4):1693-7.
DMH75KV	RU	https://pubmed.ncbi.nlm.nih.gov/19562511

DM1SRQT	DI	DM1SRQT
DM1SRQT	DN	Aceprometazine
DM1SRQT	MI	TTTIBOJ
DM1SRQT	MN	Histamine H1 receptor (H1R)
DM1SRQT	MT	DTT
DM1SRQT	MA	Antagonist
DM1SRQT	RN	Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
DM1SRQT	RU	https://pubmed.ncbi.nlm.nih.gov/17016423

DMUIE76	DI	DMUIE76
DMUIE76	DN	Acetaminophen
DMUIE76	MI	DE4OGUF
DMUIE76	MN	Cytochrome P450 102A1 (cyp102)
DMUIE76	MT	DME
DMUIE76	MA	Metabolism
DMUIE76	RN	The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities. Trends Biotechnol. 2007 Jul;25(7):289-98.
DMUIE76	RU	https://pubmed.ncbi.nlm.nih.gov/17532492

DMUIE76	DI	DMUIE76
DMUIE76	DN	Acetaminophen
DMUIE76	MI	DE6OQ3W
DMUIE76	MN	Cytochrome P450 1A1 (CYP1A1)
DMUIE76	MT	DME
DMUIE76	MA	Metabolism
DMUIE76	RN	Preferred orientations in the binding of 4'-hydroxyacetanilide (acetaminophen) to cytochrome P450 1A1 and 2B1 isoforms as determined by 13C- and 15N-NMR relaxation studies. J Med Chem. 1994 Mar 18;37(6):860-7.
DMUIE76	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8145237

DMUIE76	DI	DMUIE76
DMUIE76	DN	Acetaminophen
DMUIE76	MI	DEJGDUW
DMUIE76	MN	Cytochrome P450 1A2 (CYP1A2)
DMUIE76	MT	DME
DMUIE76	MA	Metabolism
DMUIE76	RN	PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
DMUIE76	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26049587

DMUIE76	DI	DMUIE76
DMUIE76	DN	Acetaminophen
DMUIE76	MI	DEJVYAZ
DMUIE76	MN	Cytochrome P450 2A6 (CYP2A6)
DMUIE76	MT	DME
DMUIE76	MA	Metabolism
DMUIE76	RN	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
DMUIE76	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28872689

DMUIE76	DI	DMUIE76
DMUIE76	DN	Acetaminophen
DMUIE76	MI	DE5IED8
DMUIE76	MN	Cytochrome P450 2C9 (CYP2C9)
DMUIE76	MT	DME
DMUIE76	MA	Metabolism
DMUIE76	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMUIE76	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMUIE76	DI	DMUIE76
DMUIE76	DN	Acetaminophen
DMUIE76	MI	DECB0K3
DMUIE76	MN	Cytochrome P450 2D6 (CYP2D6)
DMUIE76	MT	DME
DMUIE76	MA	Metabolism
DMUIE76	RN	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
DMUIE76	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28872689

DMUIE76	DI	DMUIE76
DMUIE76	DN	Acetaminophen
DMUIE76	MI	DEVDYN7
DMUIE76	MN	Cytochrome P450 2E1 (CYP2E1)
DMUIE76	MT	DME
DMUIE76	MA	Metabolism
DMUIE76	RN	Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55.
DMUIE76	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20166895

DMUIE76	DI	DMUIE76
DMUIE76	DN	Acetaminophen
DMUIE76	MI	DE4LYSA
DMUIE76	MN	Cytochrome P450 3A4 (CYP3A4)
DMUIE76	MT	DME
DMUIE76	MA	Metabolism
DMUIE76	RN	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
DMUIE76	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28872689

DMUIE76	DI	DMUIE76
DMUIE76	DN	Acetaminophen
DMUIE76	MI	DEIBDNY
DMUIE76	MN	Cytochrome P450 3A5 (CYP3A5)
DMUIE76	MT	DME
DMUIE76	MA	Metabolism
DMUIE76	RN	Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
DMUIE76	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17620348

DMUIE76	DI	DMUIE76
DMUIE76	DN	Acetaminophen
DMUIE76	MI	DE4ZHS1
DMUIE76	MN	Glutathione S-transferase alpha-1 (GSTA1)
DMUIE76	MT	DME
DMUIE76	MA	Metabolism
DMUIE76	RN	Retinoid X receptor alpha regulates the expression of glutathione s-transferase genes and modulates acetaminophen-glutathione conjugation in mouse liver. Mol Pharmacol. 2005 Dec;68(6):1590-6.
DMUIE76	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16157696

DMUIE76	DI	DMUIE76
DMUIE76	DN	Acetaminophen
DMUIE76	MI	DTFI42L
DMUIE76	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMUIE76	MT	DTP
DMUIE76	MA	Substrate
DMUIE76	RN	Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
DMUIE76	RU	http://www.ncbi.nlm.nih.gov/pubmed/15276087

DMUIE76	DI	DMUIE76
DMUIE76	DN	Acetaminophen
DMUIE76	MI	TTAWNKZ
DMUIE76	MN	Norepinephrine transporter (NET)
DMUIE76	MT	DTT
DMUIE76	MA	Inhibitor
DMUIE76	RN	Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
DMUIE76	RU	https://pubmed.ncbi.nlm.nih.gov/19517098

DMUIE76	DI	DMUIE76
DMUIE76	DN	Acetaminophen
DMUIE76	MI	TTK0943
DMUIE76	MN	Prostaglandin G/H synthase (COX)
DMUIE76	MT	DTT
DMUIE76	MA	Inhibitor
DMUIE76	RN	Mechanism of action of paracetamol. Am J Ther. 2005 Jan-Feb;12(1):46-55.
DMUIE76	RU	https://pubmed.ncbi.nlm.nih.gov/15662292

DMUIE76	DI	DMUIE76
DMUIE76	DN	Acetaminophen
DMUIE76	MI	TT3ROYC
DMUIE76	MN	Serotonin transporter (SERT)
DMUIE76	MT	DTT
DMUIE76	MA	Inhibitor
DMUIE76	RN	Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
DMUIE76	RU	https://pubmed.ncbi.nlm.nih.gov/19517098

DMUIE76	DI	DMUIE76
DMUIE76	DN	Acetaminophen
DMUIE76	MI	DEYWLRK
DMUIE76	MN	Sulfotransferase 1A1 (SULT1A1)
DMUIE76	MT	DME
DMUIE76	MA	Metabolism
DMUIE76	RN	Interindividual variability in acetaminophen sulfation by human fetal liver: implications for pharmacogenetic investigations of drug-induced birth defects. Birth Defects Res A Clin Mol Teratol. 2008 Mar;82(3):155-65.
DMUIE76	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18232020

DMUIE76	DI	DMUIE76
DMUIE76	DN	Acetaminophen
DMUIE76	MI	DEYGVN4
DMUIE76	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMUIE76	MT	DME
DMUIE76	MA	Metabolism
DMUIE76	RN	Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
DMUIE76	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28932176

DMUIE76	DI	DMUIE76
DMUIE76	DN	Acetaminophen
DMUIE76	MI	DESD26P
DMUIE76	MN	UDP-glucuronosyltransferase 1A6 (UGT1A6)
DMUIE76	MT	DME
DMUIE76	MA	Metabolism
DMUIE76	RN	UGT1A6 and UGT2B15 polymorphisms and acetaminophen conjugation in response to a randomized, controlled diet of select fruits and vegetables. Drug Metab Dispos. 2011 Sep;39(9):1650-7.
DMUIE76	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21666065

DMUIE76	DI	DMUIE76
DMUIE76	DN	Acetaminophen
DMUIE76	MI	DE85D2P
DMUIE76	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMUIE76	MT	DME
DMUIE76	MA	Metabolism
DMUIE76	RN	Polymorphic expression of UGT1A9 is associated with variable acetaminophen glucuronidation in neonates: a population pharmacokinetic and pharmacogenetic study. Clin Pharmacokinet. 2018 Oct;57(10):1325-1336.
DMUIE76	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29654492

DMUIE76	DI	DMUIE76
DMUIE76	DN	Acetaminophen
DMUIE76	MI	DENZ6B1
DMUIE76	MN	UDP-glucuronosyltransferase 2B15 (UGT2B15)
DMUIE76	MT	DME
DMUIE76	MA	Metabolism
DMUIE76	RN	Characterization of niflumic acid as a selective inhibitor of human liver microsomal UDP-glucuronosyltransferase 1A9: application to the reaction phenotyping of acetaminophen glucuronidation. Drug Metab Dispos. 2011 Apr;39(4):644-52.
DMUIE76	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21245288

DM1AF5U	DI	DM1AF5U
DM1AF5U	DN	Acetazolamide
DM1AF5U	MI	TTHQPL7
DM1AF5U	MN	Carbonic anhydrase I (CA-I)
DM1AF5U	MT	DTT
DM1AF5U	MA	Modulator
DM1AF5U	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM1AF5U	RU	https://www.fda.gov/

DM4SJ5Y	DI	DM4SJ5Y
DM4SJ5Y	DN	Acetic Acid, Glacial
DM4SJ5Y	MI	DEVDYN7
DM4SJ5Y	MN	Cytochrome P450 2E1 (CYP2E1)
DM4SJ5Y	MT	DME
DM4SJ5Y	MA	Metabolism
DM4SJ5Y	RN	Kinetics of cytochrome P450 2E1-catalyzed oxidation of ethanol to acetic acid via acetaldehyde. J Biol Chem. 1999 Aug 20;274(34):23833-40.
DM4SJ5Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10446146

DMR6N7H	DI	DMR6N7H
DMR6N7H	DN	Acetohexamide
DMR6N7H	MI	TTP835K
DMR6N7H	MN	ATP-binding cassette transporter C8 (ABCC8)
DMR6N7H	MT	DTT
DMR6N7H	MA	Modulator
DMR6N7H	RN	Diabetes and insulin secretion: the ATP-sensitive K+ channel (K ATP) connection.Diabetes.2005 Nov;54(11):3065-72.
DMR6N7H	RU	https://www.ncbi.nlm.nih.gov/pubmed/16249427

DMR6N7H	DI	DMR6N7H
DMR6N7H	DN	Acetohexamide
DMR6N7H	MI	DE5IED8
DMR6N7H	MN	Cytochrome P450 2C9 (CYP2C9)
DMR6N7H	MT	DME
DMR6N7H	MA	Metabolism
DMR6N7H	RN	Clinically and pharmacologically relevant interactions of antidiabetic drugs. Ther Adv Endocrinol Metab. 2016 Apr;7(2):69-83.
DMR6N7H	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27092232

DMR6N7H	DI	DMR6N7H
DMR6N7H	DN	Acetohexamide
DMR6N7H	MI	DEXPVUN
DMR6N7H	MN	Short-chain dehydrogenase/reductase retSDR1 (DHRS3)
DMR6N7H	MT	DME
DMR6N7H	MA	Metabolism
DMR6N7H	RN	Molecular and biochemical characterisation of human short-chain dehydrogenase/reductase member 3 (DHRS3). Chem Biol Interact. 2015 Jun 5;234:178-87.
DMR6N7H	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25451588

DMYX7NI	DI	DMYX7NI
DMYX7NI	DN	Acetohydroxamic Acid
DMYX7NI	MI	TTAS2UO
DMYX7NI	MN	Bacterial Urease (Bact ureC)
DMYX7NI	MT	DTT
DMYX7NI	MA	Inhibitor
DMYX7NI	RN	Enzymatic, immunological and phylogenetic characterization of Brucella suis urease. BMC Microbiol. 2008 Jul 19;8:121.
DMYX7NI	RU	https://pubmed.ncbi.nlm.nih.gov/18638408

DMZV2PJ	DI	DMZV2PJ
DMZV2PJ	DN	Acetophenazine
DMZV2PJ	MI	TTEX248
DMZV2PJ	MN	Dopamine D2 receptor (D2R)
DMZV2PJ	MT	DTT
DMZV2PJ	MA	Antagonist
DMZV2PJ	RN	Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38.
DMZV2PJ	RU	https://pubmed.ncbi.nlm.nih.gov/11873706

DMDF79Z	DI	DMDF79Z
DMDF79Z	DN	Acetylcholine
DMDF79Z	MI	DEQ2BAJ
DMDF79Z	MN	Acetylcholinesterase (ACHE)
DMDF79Z	MT	DME
DMDF79Z	MA	Metabolism
DMDF79Z	RN	How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMDF79Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17139284

DMDF79Z	DI	DMDF79Z
DMDF79Z	DN	Acetylcholine
DMDF79Z	MI	DT8KXR9
DMDF79Z	MN	Choline transporter-like protein 4 (SLC44A4)
DMDF79Z	MT	DTP
DMDF79Z	MA	Substrate
DMDF79Z	RN	Choline transporter-like protein 4 (CTL4) links to non-neuronal acetylcholine synthesis. J Neurochem. 2013 Aug;126(4):451-61.
DMDF79Z	RU	http://www.ncbi.nlm.nih.gov/pubmed/23651124

DMDF79Z	DI	DMDF79Z
DMDF79Z	DN	Acetylcholine
DMDF79Z	MI	TTOXS3C
DMDF79Z	MN	Muscarinic acetylcholine receptor (CHRM)
DMDF79Z	MT	DTT
DMDF79Z	MA	Agonist
DMDF79Z	RN	Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity. Mol Pharmacol. 2004 Jan;65(1):257-66.
DMDF79Z	RU	https://pubmed.ncbi.nlm.nih.gov/14722259

DMDF79Z	DI	DMDF79Z
DMDF79Z	DN	Acetylcholine
DMDF79Z	MI	DTT79CX
DMDF79Z	MN	Organic cation transporter 1 (SLC22A1)
DMDF79Z	MT	DTP
DMDF79Z	MA	Substrate
DMDF79Z	RN	Role of acetylcholine and polyspecific cation transporters in serotonin-induced bronchoconstriction in the mouse. Respir Res. 2006 Apr 12;7:65.
DMDF79Z	RU	http://www.ncbi.nlm.nih.gov/pubmed/16608531

DMDF79Z	DI	DMDF79Z
DMDF79Z	DN	Acetylcholine
DMDF79Z	MI	DT6201N
DMDF79Z	MN	Organic cation transporter 3 (SLC22A3)
DMDF79Z	MT	DTP
DMDF79Z	MA	Substrate
DMDF79Z	RN	Organic cation transporters: physiology, toxicology and special focus on ethidium as a novel substrate. Curr Drug Metab. 2009 Jul;10(6):617-31.
DMDF79Z	RU	http://www.ncbi.nlm.nih.gov/pubmed/19702534

DMDF79Z	DI	DMDF79Z
DMDF79Z	DN	Acetylcholine
DMDF79Z	MI	DT3T2K0
DMDF79Z	MN	Vesicular acetylcholine transporter (SLC18A3)
DMDF79Z	MT	DTP
DMDF79Z	MA	Substrate
DMDF79Z	RN	SLC18: Vesicular neurotransmitter transporters for monoamines and acetylcholine. Mol Aspects Med. 2013 Apr-Jun;34(2-3):360-72.
DMDF79Z	RU	http://www.ncbi.nlm.nih.gov/pubmed/23506877

DMHAUO0	DI	DMHAUO0
DMHAUO0	DN	Acetyldigitoxin
DMHAUO0	MI	TTWK8D0
DMHAUO0	MN	Sodium pump subunit alpha-1 (ATP1A1)
DMHAUO0	MT	DTT
DMHAUO0	MA	Modulator
DMHAUO0	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMHAUO0	RU	https://www.fda.gov/

DMYLOVR	DI	DMYLOVR
DMYLOVR	DN	Aciclovir
DMYLOVR	MI	DTW7AE3
DMYLOVR	MN	Alanine/serine/cysteine/threonine transporter 2 (SLC1A5)
DMYLOVR	MT	DTP
DMYLOVR	MA	Substrate
DMYLOVR	RN	Amino Acid Transporter ATB0,+ as a delivery system for drugs and prodrugs. Curr Drug Targets Immune Endocr Metabol Disord. 2005 Dec;5(4):357-64.
DMYLOVR	RU	http://www.ncbi.nlm.nih.gov/pubmed/16375689

DMYLOVR	DI	DMYLOVR
DMYLOVR	DN	Aciclovir
DMYLOVR	MI	DTI7UX6
DMYLOVR	MN	Breast cancer resistance protein (ABCG2)
DMYLOVR	MT	DTP
DMYLOVR	MA	Substrate
DMYLOVR	RN	Acyclovir is a substrate for the human breast cancer resistance protein (BCRP/ABCG2): implications for renal tubular transport and acyclovir-induced nephrotoxicity. Can J Physiol Pharmacol. 2011 Sep;89(9):675-80.
DMYLOVR	RU	https://doi.org/10.1139/y11-045

DMYLOVR	DI	DMYLOVR
DMYLOVR	DN	Aciclovir
DMYLOVR	MI	TTIU7X1
DMYLOVR	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMYLOVR	MT	DTT
DMYLOVR	MA	Modulator
DMYLOVR	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMYLOVR	RU	https://www.fda.gov/

DMYLOVR	DI	DMYLOVR
DMYLOVR	DN	Aciclovir
DMYLOVR	MI	DTZGT0P
DMYLOVR	MN	Multidrug and toxin extrusion protein 1 (SLC47A1)
DMYLOVR	MT	DTP
DMYLOVR	MA	Substrate
DMYLOVR	RN	Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
DMYLOVR	RU	http://www.ncbi.nlm.nih.gov/pubmed/17509534

DMYLOVR	DI	DMYLOVR
DMYLOVR	DN	Aciclovir
DMYLOVR	MI	DT3TX4H
DMYLOVR	MN	Multidrug and toxin extrusion protein 2 (SLC47A2)
DMYLOVR	MT	DTP
DMYLOVR	MA	Substrate
DMYLOVR	RN	Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
DMYLOVR	RU	http://www.ncbi.nlm.nih.gov/pubmed/17509534

DMYLOVR	DI	DMYLOVR
DMYLOVR	DN	Aciclovir
DMYLOVR	MI	DTFI42L
DMYLOVR	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMYLOVR	MT	DTP
DMYLOVR	MA	Substrate
DMYLOVR	RN	Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters. J Pharmacol Exp Ther. 2003 Aug;306(2):778-86.
DMYLOVR	RU	http://www.ncbi.nlm.nih.gov/pubmed/12750437

DMYLOVR	DI	DMYLOVR
DMYLOVR	DN	Aciclovir
DMYLOVR	MI	DTQ23VB
DMYLOVR	MN	Organic anion transporter 1 (SLC22A6)
DMYLOVR	MT	DTP
DMYLOVR	MA	Substrate
DMYLOVR	RN	Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
DMYLOVR	RU	http://www.ncbi.nlm.nih.gov/pubmed/11861798

DMYLOVR	DI	DMYLOVR
DMYLOVR	DN	Aciclovir
DMYLOVR	MI	DT0OC1Q
DMYLOVR	MN	Organic anion transporter 2 (SLC22A7)
DMYLOVR	MT	DTP
DMYLOVR	MA	Substrate
DMYLOVR	RN	Organic anion transporter 2 (SLC22A7) is a facilitative transporter of cGMP. Mol Pharmacol. 2008 Apr;73(4):1151-8.
DMYLOVR	RU	http://www.ncbi.nlm.nih.gov/pubmed/18216183

DMYLOVR	DI	DMYLOVR
DMYLOVR	DN	Aciclovir
DMYLOVR	MI	DTVP67E
DMYLOVR	MN	Organic anion transporter 3 (SLC22A8)
DMYLOVR	MT	DTP
DMYLOVR	MA	Substrate
DMYLOVR	RN	Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs. Drug Metab Dispos. 2012 Mar;40(3):617-24.
DMYLOVR	RU	http://www.ncbi.nlm.nih.gov/pubmed/22190696

DMYLOVR	DI	DMYLOVR
DMYLOVR	DN	Aciclovir
DMYLOVR	MI	DTT79CX
DMYLOVR	MN	Organic cation transporter 1 (SLC22A1)
DMYLOVR	MT	DTP
DMYLOVR	MA	Substrate
DMYLOVR	RN	Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
DMYLOVR	RU	http://www.ncbi.nlm.nih.gov/pubmed/11861798

DMYLOVR	DI	DMYLOVR
DMYLOVR	DN	Aciclovir
DMYLOVR	MI	TTHPJTK
DMYLOVR	MN	Varicella-zoster virus DNA polymerase (VZV ORF28)
DMYLOVR	MT	DTT
DMYLOVR	MA	Modulator
DMYLOVR	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMYLOVR	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM8BKU9	DI	DM8BKU9
DM8BKU9	DN	Acitretin
DM8BKU9	MI	TTH8FZW
DM8BKU9	MN	Signal transducer and activator of transcription 3 (STAT3)
DM8BKU9	MT	DTT
DM8BKU9	MA	Inhibitor
DM8BKU9	RN	Effects of acitretin on the expression of signaling pathway-related genes in epidermal squamous-cell carcinoma cells. Zhonghua Zhong Liu Za Zhi. 2006 Jan;28(1):21-4.
DM8BKU9	RU	https://pubmed.ncbi.nlm.nih.gov/16737614

DMLFZHD	DI	DMLFZHD
DMLFZHD	DN	Aclarubicin
DMLFZHD	MI	TT0IHXV
DMLFZHD	MN	DNA topoisomerase II (TOP2)
DMLFZHD	MT	DTT
DMLFZHD	MA	Inhibitor
DMLFZHD	RN	Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines. Anticancer Drug Des. 2001 Dec;16(6):305-15.
DMLFZHD	RU	https://pubmed.ncbi.nlm.nih.gov/12375883

DM7JT24	DI	DM7JT24
DM7JT24	DN	Acocantherin
DM7JT24	MI	DTE2B1D
DM7JT24	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DM7JT24	MT	DTP
DM7JT24	MA	Substrate
DM7JT24	RN	Molecular cloning and functional characterization of the mouse organic-anion-transporting polypeptide 1 (Oatp1) and mapping of the gene to chromosome X. Biochem J. 2000 Jan 1;345 Pt 1:115-20.
DM7JT24	RU	http://www.ncbi.nlm.nih.gov/pubmed/10600646

DM7JT24	DI	DM7JT24
DM7JT24	DN	Acocantherin
DM7JT24	MI	DT3D8F0
DM7JT24	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM7JT24	MT	DTP
DM7JT24	MA	Substrate
DM7JT24	RN	Regulation of Organic Anion Transporting Polypeptides (OATP) 1B1- and OATP1B3-Mediated Transport: An Updated Review in the Context of OATP-Mediated Drug-Drug Interactions. Int J Mol Sci. 2018 Mar 14;19(3). pii: E855.
DM7JT24	RU	http://www.ncbi.nlm.nih.gov/pubmed/29538325

DM7JT24	DI	DM7JT24
DM7JT24	DN	Acocantherin
DM7JT24	MI	DT9C1TS
DM7JT24	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM7JT24	MT	DTP
DM7JT24	MA	Substrate
DM7JT24	RN	Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
DM7JT24	RU	http://www.ncbi.nlm.nih.gov/pubmed/11159893

DM7JT24	DI	DM7JT24
DM7JT24	DN	Acocantherin
DM7JT24	MI	DTY0QMU
DM7JT24	MN	Organic anion transporting polypeptide 4C1 (SLCO4C1)
DM7JT24	MT	DTP
DM7JT24	MA	Substrate
DM7JT24	RN	Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3569-74.
DM7JT24	RU	http://www.ncbi.nlm.nih.gov/pubmed/14993604

DM7JT24	DI	DM7JT24
DM7JT24	DN	Acocantherin
DM7JT24	MI	TTWK8D0
DM7JT24	MN	Sodium pump subunit alpha-1 (ATP1A1)
DM7JT24	MT	DTT
DM7JT24	MA	Binder
DM7JT24	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM7JT24	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMTIGA0	DI	DMTIGA0
DMTIGA0	DN	Acrivastine
DMTIGA0	MI	TTTIBOJ
DMTIGA0	MN	Histamine H1 receptor (H1R)
DMTIGA0	MT	DTT
DMTIGA0	MA	Antagonist
DMTIGA0	RN	Clinical pharmacology of new histamine H1 receptor antagonists. Clin Pharmacokinet. 1999 May;36(5):329-52.
DMTIGA0	RU	https://pubmed.ncbi.nlm.nih.gov/10384858

DMTIGA0	DI	DMTIGA0
DMTIGA0	DN	Acrivastine
DMTIGA0	MI	DTUGYRD
DMTIGA0	MN	P-glycoprotein 1 (ABCB1)
DMTIGA0	MT	DTP
DMTIGA0	MA	Substrate
DMTIGA0	RN	Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.
DMTIGA0	RU	http://www.ncbi.nlm.nih.gov/pubmed/12438524

DMQMV1B	DI	DMQMV1B
DMQMV1B	DN	Adalimumab
DMQMV1B	MI	TTF8CQI
DMQMV1B	MN	Tumor necrosis factor (TNF)
DMQMV1B	MT	DTT
DMQMV1B	RN	Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation. J Eur Acad Dermatol Venereol. 2009 Dec;23(12):1394-7.
DMQMV1B	RU	https://pubmed.ncbi.nlm.nih.gov/19573024

DMX2358	DI	DMX2358
DMX2358	DN	Adapalene
DMX2358	MI	TTOD7B3
DMX2358	MN	Retinoic acid receptor (RAR)
DMX2358	MT	DTT
DMX2358	MA	Binder
DMX2358	RN	A review of adapalene in the treatment of acne vulgaris. J Adolesc Health. 2008 Nov;43(5):421-4.
DMX2358	RU	https://pubmed.ncbi.nlm.nih.gov/18848668

DMM278X	DI	DMM278X
DMM278X	DN	Adefovir
DMM278X	MI	DTI7UX6
DMM278X	MN	Breast cancer resistance protein (ABCG2)
DMM278X	MT	DTP
DMM278X	MA	Substrate
DMM278X	RN	ABC transporters and their role in nucleoside and nucleotide drug resistance. Biochem Pharmacol. 2012 Apr 15;83(8):1073-83.
DMM278X	RU	https://doi.org/10.1016/j.bcp.2011.12.042

DMM278X	DI	DMM278X
DMM278X	DN	Adefovir
DMM278X	MI	DTSYQGK
DMM278X	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMM278X	MT	DTP
DMM278X	MA	Substrate
DMM278X	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMM278X	RU	https://doi.org/10.1007/s11095-012-0935-x

DMM278X	DI	DMM278X
DMM278X	DN	Adefovir
DMM278X	MI	DTFI42L
DMM278X	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMM278X	MT	DTP
DMM278X	MA	Substrate
DMM278X	RN	Pharmacogenetics of membrane transporters: an update on current approaches. Mol Biotechnol. 2010 Feb;44(2):152-67.
DMM278X	RU	https://doi.org/10.1007/s12033-009-9220-6

DMM278X	DI	DMM278X
DMM278X	DN	Adefovir
DMM278X	MI	DTCSGPB
DMM278X	MN	Multidrug resistance-associated protein 4 (ABCC4)
DMM278X	MT	DTP
DMM278X	MA	Substrate
DMM278X	RN	Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol. 2007 Feb;71(2):619-27.
DMM278X	RU	http://www.ncbi.nlm.nih.gov/pubmed/17110501

DMM278X	DI	DMM278X
DMM278X	DN	Adefovir
DMM278X	MI	DTQ23VB
DMM278X	MN	Organic anion transporter 1 (SLC22A6)
DMM278X	MT	DTP
DMM278X	MA	Substrate
DMM278X	RN	Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol. 2000 Mar;11(3):383-93.
DMM278X	RU	http://www.ncbi.nlm.nih.gov/pubmed/10703662

DMM278X	DI	DMM278X
DMM278X	DN	Adefovir
DMM278X	MI	DTVP67E
DMM278X	MN	Organic anion transporter 3 (SLC22A8)
DMM278X	MT	DTP
DMM278X	MA	Substrate
DMM278X	RN	FDA Drug Development and Drug Interactions
DMM278X	RU	https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2

DMMAWY1	DI	DMMAWY1
DMMAWY1	DN	Adefovir dipivoxil
DMMAWY1	MI	DEY1FJO
DMMAWY1	MN	ATP-AMP transphosphorylase 2 (AK2)
DMMAWY1	MT	DME
DMMAWY1	MA	Metabolism
DMMAWY1	RN	Scientific discussion of Hepsera.
DMMAWY1	RU	https://www.ema.europa.eu/en/documents/scientific-discussion/hepsera-epar-scientific-discussion_en.pdf

DMMAWY1	DI	DMMAWY1
DMMAWY1	DN	Adefovir dipivoxil
DMMAWY1	MI	TT84ETX
DMMAWY1	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMMAWY1	MT	DTT
DMMAWY1	MA	Modulator
DMMAWY1	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMMAWY1	RU	https://www.fda.gov/

DMYQDBO	DI	DMYQDBO
DMYQDBO	DN	Ademetionine
DMYQDBO	MI	DEVDYN7
DMYQDBO	MN	Cytochrome P450 2E1 (CYP2E1)
DMYQDBO	MT	DME
DMYQDBO	MA	Metabolism
DMYQDBO	RN	Inhibition of CYP2E1 catalytic activity in vitro by S-adenosyl-L-methionine. Biochem Pharmacol. 2005 Apr 1;69(7):1081-93.
DMYQDBO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15763544

DMYQDBO	DI	DMYQDBO
DMYQDBO	DN	Ademetionine
DMYQDBO	MI	DEFQ8VO
DMYQDBO	MN	Thiopurine methyltransferase (TPMT)
DMYQDBO	MT	DME
DMYQDBO	MA	Metabolism
DMYQDBO	RN	Evolution of putrescine N-methyltransferase from spermidine synthase demanded alterations in substrate binding. FEBS Lett. 2009 Oct 20;583(20):3367-74.
DMYQDBO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19796640

DMYQDBO	DI	DMYQDBO
DMYQDBO	DN	Ademetionine
DMYQDBO	MI	TTX2N1T
DMYQDBO	MN	Transferase unspecific (TF)
DMYQDBO	MT	DTT
DMYQDBO	MA	Modulator
DMYQDBO	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2013
DMYQDBO	RU	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205123Orig1s000MedR.pdf

DMZLHKJ	DI	DMZLHKJ
DMZLHKJ	DN	Adenine
DMZLHKJ	MI	DTLMGFJ
DMZLHKJ	MN	Adenine nucleotide translocator 3 (SLC25A6)
DMZLHKJ	MT	DTP
DMZLHKJ	MA	Substrate
DMZLHKJ	RN	Adenine nucleotide (ADP/ATP) translocase 3 participates in the tumor necrosis factor induced apoptosis of MCF-7 cells. Mol Biol Cell. 2007 Nov;18(11):4681-9.
DMZLHKJ	RU	http://www.ncbi.nlm.nih.gov/pubmed/17855512

DMZLHKJ	DI	DMZLHKJ
DMZLHKJ	DN	Adenine
DMZLHKJ	MI	TTUTN1I
DMZLHKJ	MN	Human Deoxyribonucleic acid (hDNA)
DMZLHKJ	MT	DTT
DMZLHKJ	MA	Binder
DMZLHKJ	RN	Escherichia coli DNA adenine methyltransferase: intrasite processivity and substrate-induced dimerization and activation. Biochemistry. 2009 Aug 11;48(31):7399-410.
DMZLHKJ	RU	https://pubmed.ncbi.nlm.nih.gov/19580332

DMM2NSK	DI	DMM2NSK
DMM2NSK	DN	Adenosine
DMM2NSK	MI	TTNE7KG
DMM2NSK	MN	Adenosine A2b receptor (ADORA2B)
DMM2NSK	MT	DTT
DMM2NSK	MA	Modulator
DMM2NSK	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMM2NSK	RU	https://www.fda.gov/

DMM2NSK	DI	DMM2NSK
DMM2NSK	DN	Adenosine
DMM2NSK	MI	DEDQHBV
DMM2NSK	MN	Adenosine aminohydrolase (ADA)
DMM2NSK	MT	DME
DMM2NSK	MA	Metabolism
DMM2NSK	RN	A functional genetic variation of adenosine deaminase affects the duration and intensity of deep sleep in humans. Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15676-81.
DMM2NSK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16221767

DMM2NSK	DI	DMM2NSK
DMM2NSK	DN	Adenosine
DMM2NSK	MI	DTXD1TQ
DMM2NSK	MN	Equilibrative nucleoside transporter 1 (SLC29A1)
DMM2NSK	MT	DTP
DMM2NSK	MA	Substrate
DMM2NSK	RN	Nitric oxide reduces adenosine transporter ENT1 gene (SLC29A1) promoter activity in human fetal endothelium from gestational diabetes. J Cell Physiol. 2006 Aug;208(2):451-60.
DMM2NSK	RU	http://www.ncbi.nlm.nih.gov/pubmed/16688763

DMM2NSK	DI	DMM2NSK
DMM2NSK	DN	Adenosine
DMM2NSK	MI	DTYVM24
DMM2NSK	MN	Multidrug resistance-associated protein 5 (ABCC5)
DMM2NSK	MT	DTP
DMM2NSK	MA	Substrate
DMM2NSK	RN	Role of MRP4 and MRP5 in biology and chemotherapy. AAPS PharmSci. 2002;4(3):E14.
DMM2NSK	RU	http://www.ncbi.nlm.nih.gov/pubmed/12423063

DMM2NSK	DI	DMM2NSK
DMM2NSK	DN	Adenosine
DMM2NSK	MI	DEYWLRK
DMM2NSK	MN	Sulfotransferase 1A1 (SULT1A1)
DMM2NSK	MT	DME
DMM2NSK	MA	Metabolism
DMM2NSK	RN	Regulation of sulfate assimilation in plants: 7. Cysteine inactivation of adenosine 5'-phosphosulfate sulfotransferase in Lemna minor L. Plant Physiol. 1978 Mar;61(3):342-7.
DMM2NSK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16660289

DMNIJT0	DI	DMNIJT0
DMNIJT0	DN	Adenosine monophosphate
DMNIJT0	MI	DE2MV1R
DMNIJT0	MN	Adenine phosphoribosyltransferase (APRT)
DMNIJT0	MT	DME
DMNIJT0	MA	Metabolism
DMNIJT0	RN	Configuration of a scintillation proximity assay for the activity assessment of recombinant human adenine phosphoribosyltransferase. Assay Drug Dev Technol. 2006 Dec;4(6):661-9.
DMNIJT0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17199504

DMNIJT0	DI	DMNIJT0
DMNIJT0	DN	Adenosine monophosphate
DMNIJT0	MI	TTV1ZSQ
DMNIJT0	MN	Adenylate cyclase type 1 (ADCY1)
DMNIJT0	MT	DTT
DMNIJT0	MA	Binder
DMNIJT0	RN	Ecto- and cytosolic 5'-nucleotidases in normal and AMP deaminase-deficient human skeletal muscle. Biol Chem. 2006 Jan;387(1):53-8.
DMNIJT0	RU	https://pubmed.ncbi.nlm.nih.gov/16497164

DMNIJT0	DI	DMNIJT0
DMNIJT0	DN	Adenosine monophosphate
DMNIJT0	MI	DTYR5U7
DMNIJT0	MN	Peroxisomal membrane protein PMP34 (SLC25A17)
DMNIJT0	MT	DTP
DMNIJT0	MA	Substrate
DMNIJT0	RN	The human gene SLC25A17 encodes a peroxisomal transporter of coenzyme A, FAD and NAD+. Biochem J. 2012 Apr 1;443(1):241-7.
DMNIJT0	RU	http://www.ncbi.nlm.nih.gov/pubmed/22185573

DM79F6G	DI	DM79F6G
DM79F6G	DN	Adenosine triphosphate
DM79F6G	MI	TT3PJMV
DM79F6G	MN	Tyrosine-protein kinase ABL1 (ABL)
DM79F6G	MT	DTT
DM79F6G	MA	Inhibitor
DM79F6G	RN	Targeted chronic myeloid leukemia therapy: Seeking a cure. Am J Health Syst Pharm. 2007 Dec 15;64(24 Suppl 15):S9-15.
DM79F6G	RU	https://pubmed.ncbi.nlm.nih.gov/18056932

DMBHO9Y	DI	DMBHO9Y
DMBHO9Y	DN	Adinazolam
DMBHO9Y	MI	DE4LYSA
DMBHO9Y	MN	Cytochrome P450 3A4 (CYP3A4)
DMBHO9Y	MT	DME
DMBHO9Y	MA	Metabolism
DMBHO9Y	RN	Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man. J Pharm Pharmacol. 1998 Mar;50(3):265-74.
DMBHO9Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9600717

DMBHO9Y	DI	DMBHO9Y
DMBHO9Y	DN	Adinazolam
DMBHO9Y	MI	DEGTFWK
DMBHO9Y	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMBHO9Y	MT	DME
DMBHO9Y	MA	Metabolism
DMBHO9Y	RN	Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man. J Pharm Pharmacol. 1998 Mar;50(3):265-74.
DMBHO9Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9600717

DMBHO9Y	DI	DMBHO9Y
DMBHO9Y	DN	Adinazolam
DMBHO9Y	MI	TTPTXIN
DMBHO9Y	MN	Translocator protein (TSPO)
DMBHO9Y	MT	DTT
DMBHO9Y	MA	Agonist
DMBHO9Y	RN	Effects of antidepressants and benzodiazepine treatments on the dendritic structure of CA3 pyramidal neurons after chronic stress. Eur J Pharmacol. 1999 Apr 29;371(2-3):113-22.
DMBHO9Y	RU	https://pubmed.ncbi.nlm.nih.gov/10357248

DMVWHTG	DI	DMVWHTG
DMVWHTG	DN	Afamelanotide
DMVWHTG	MI	TT0MV2T
DMVWHTG	MN	Melanocortin receptor 1 (MC1R)
DMVWHTG	MT	DTT
DMVWHTG	MA	Modulator
DMVWHTG	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMVWHTG	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf

DMT3D5I	DI	DMT3D5I
DMT3D5I	DN	Aflibercept
DMT3D5I	MI	TT48I1Y
DMT3D5I	MN	Placenta growth factor (PlGF)
DMT3D5I	MT	DTT
DMT3D5I	MA	Modulator
DMT3D5I	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMT3D5I	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMT3D5I	DI	DMT3D5I
DMT3D5I	DN	Aflibercept
DMT3D5I	MI	TTOHSBA
DMT3D5I	MN	Vascular endothelial growth factor A (VEGFA)
DMT3D5I	MT	DTT
DMT3D5I	MA	Modulator
DMT3D5I	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMT3D5I	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMT3D5I	DI	DMT3D5I
DMT3D5I	DN	Aflibercept
DMT3D5I	MI	TTPJQHE
DMT3D5I	MN	Vascular endothelial growth factor B (VEGFB)
DMT3D5I	MT	DTT
DMT3D5I	MA	Modulator
DMT3D5I	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMT3D5I	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMPOD47	DI	DMPOD47
DMPOD47	DN	Ajmalicine
DMPOD47	MI	TTR6W5O
DMPOD47	MN	Adrenergic receptor beta-1 (ADRB1)
DMPOD47	MT	DTT
DMPOD47	MA	Modulator
DMPOD47	RN	Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81.
DMPOD47	RU	https://pubmed.ncbi.nlm.nih.gov/3879679

DMDJW5K	DI	DMDJW5K
DMDJW5K	DN	Ajmaline
DMDJW5K	MI	DECB0K3
DMDJW5K	MN	Cytochrome P450 2D6 (CYP2D6)
DMDJW5K	MT	DME
DMDJW5K	MA	Metabolism
DMDJW5K	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMDJW5K	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMDJW5K	DI	DMDJW5K
DMDJW5K	DN	Ajmaline
DMDJW5K	MI	DTUGYRD
DMDJW5K	MN	P-glycoprotein 1 (ABCB1)
DMDJW5K	MT	DTP
DMDJW5K	MA	Substrate
DMDJW5K	RN	ATP-dependent transport of amphiphilic cations across the hepatocyte canalicular membrane mediated by mdr1 P-glycoprotein. FEBS Lett. 1994 Apr 25;343(2):168-72.
DMDJW5K	RU	http://www.ncbi.nlm.nih.gov/pubmed/7909523

DML6SRO	DI	DML6SRO
DML6SRO	DN	Alacepril
DML6SRO	MI	TTL69WB
DML6SRO	MN	Angiotensin-converting enzyme (ACE)
DML6SRO	MT	DTT
DML6SRO	MA	Modulator
DML6SRO	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DML6SRO	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DMYZ57N	DI	DMYZ57N
DMYZ57N	DN	Albendazole
DMYZ57N	MI	DEJGDUW
DMYZ57N	MN	Cytochrome P450 1A2 (CYP1A2)
DMYZ57N	MT	DME
DMYZ57N	MA	Metabolism
DMYZ57N	RN	Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur J Clin Pharmacol. 2002 Nov;58(8):537-42.
DMYZ57N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12451431

DMYZ57N	DI	DMYZ57N
DMYZ57N	DN	Albendazole
DMYZ57N	MI	DE4LYSA
DMYZ57N	MN	Cytochrome P450 3A4 (CYP3A4)
DMYZ57N	MT	DME
DMYZ57N	MA	Metabolism
DMYZ57N	RN	Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
DMYZ57N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920490

DMYZ57N	DI	DMYZ57N
DMYZ57N	DN	Albendazole
DMYZ57N	MI	DEGTFWK
DMYZ57N	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMYZ57N	MT	DME
DMYZ57N	MA	Metabolism
DMYZ57N	RN	Danazol inhibits cytochrome P450 2J2 activity in a substrate-independent manner. Drug Metab Dispos. 2015 Aug;43(8):1250-3.
DMYZ57N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26048912

DMYZ57N	DI	DMYZ57N
DMYZ57N	DN	Albendazole
DMYZ57N	MI	DTUGYRD
DMYZ57N	MN	P-glycoprotein 1 (ABCB1)
DMYZ57N	MT	DTP
DMYZ57N	MA	Substrate
DMYZ57N	RN	The anthelminthic agent albendazole does not interact with p-glycoprotein. Drug Metab Dispos. 2002 Apr;30(4):365-9.
DMYZ57N	RU	http://www.ncbi.nlm.nih.gov/pubmed/11901088

DMYZ57N	DI	DMYZ57N
DMYZ57N	DN	Albendazole
DMYZ57N	MI	TTYFKSZ
DMYZ57N	MN	Tubulin beta (TUBB)
DMYZ57N	MT	DTT
DMYZ57N	MA	Binder
DMYZ57N	RN	Flubendazole interferes with a wide spectrum of cell homeostatic mechanisms in Echinococcus granulosus protoscoleces. Parasitol Int. 2009 Sep;58(3):270-7.
DMYZ57N	RU	https://pubmed.ncbi.nlm.nih.gov/19336257

DM1JEGF	DI	DM1JEGF
DM1JEGF	DN	Albiglutide
DM1JEGF	MI	TTVIMDE
DM1JEGF	MN	Glucagon-like peptide 1 receptor (GLP1R)
DM1JEGF	MT	DTT
DM1JEGF	MA	Modulator
DM1JEGF	RN	GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.Nat Rev Endocrinol.2012 Dec;8(12):728-42.
DM1JEGF	RU	https://www.ncbi.nlm.nih.gov/pubmed/22945360

DM5JTPU	DI	DM5JTPU
DM5JTPU	DN	Albumin Human
DM5JTPU	MI	TTFNGC9
DM5JTPU	MN	Serum albumin (ALB)
DM5JTPU	MT	DTT
DM5JTPU	MA	Modulator
DM5JTPU	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM5JTPU	RU	https://www.fda.gov/

DM5J1NH	DI	DM5J1NH
DM5J1NH	DN	Alcaftadine
DM5J1NH	MI	TTTIBOJ
DM5J1NH	MN	Histamine H1 receptor (H1R)
DM5J1NH	MT	DTT
DM5J1NH	MA	Antagonist
DM5J1NH	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DM5J1NH	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DMAE84F	DI	DMAE84F
DMAE84F	DN	Alclometasone
DMAE84F	MI	TTJL8VG
DMAE84F	MN	Corticosteroid-binding globulin (SERPINA6)
DMAE84F	MT	DTT
DMAE84F	MA	Binder
DMAE84F	RN	The anti-inflammatory effects of LY178002 and LY256548. Agents Actions. 1989 Jun;27(3-4):300-2.
DMAE84F	RU	https://pubmed.ncbi.nlm.nih.gov/2508442

DMAE84F	DI	DMAE84F
DMAE84F	DN	Alclometasone
DMAE84F	MI	DE4LYSA
DMAE84F	MN	Cytochrome P450 3A4 (CYP3A4)
DMAE84F	MT	DME
DMAE84F	MA	Metabolism
DMAE84F	RN	Prediction of cytochrome P450 isoform responsible for metabolizing a drug molecule. BMC Pharmacol. 2010 Jul 16;10:8.
DMAE84F	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20637097

DM2U4XQ	DI	DM2U4XQ
DM2U4XQ	DN	ALCURONIUM
DM2U4XQ	MI	TTLA931
DM2U4XQ	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DM2U4XQ	MT	DTT
DM2U4XQ	MA	Inhibitor
DM2U4XQ	RN	Pharmacological characteristics and binding modes of caracurine V analogues and related compounds at the neuronal alpha7 nicotinic acetylcholine re... J Med Chem. 2007 Sep 20;50(19):4616-29.
DM2U4XQ	RU	https://pubmed.ncbi.nlm.nih.gov/17722904

DM4YMIS	DI	DM4YMIS
DM4YMIS	DN	Aldesleukin
DM4YMIS	MI	TTF89GD
DM4YMIS	MN	Interleukin-2 (IL2)
DM4YMIS	MT	DTT
DM4YMIS	MA	Modulator
DM4YMIS	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM4YMIS	RU	https://www.fda.gov/

DM9S2JW	DI	DM9S2JW
DM9S2JW	DN	Aldosterone
DM9S2JW	MI	DE6TYUK
DM9S2JW	MN	Aldosterone synthase (CYP11B2)
DM9S2JW	MT	DME
DM9S2JW	MA	Metabolism
DM9S2JW	RN	Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis. J Med Chem. 2005 Oct 20;48(21):6632-42.
DM9S2JW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16220979

DM9S2JW	DI	DM9S2JW
DM9S2JW	DN	Aldosterone
DM9S2JW	MI	DE4LYSA
DM9S2JW	MN	Cytochrome P450 3A4 (CYP3A4)
DM9S2JW	MT	DME
DM9S2JW	MA	Metabolism
DM9S2JW	RN	Aldosterone receptor antagonists: effective but often forgotten. Circulation. 2010 Feb 23;121(7):934-9.
DM9S2JW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20177008

DM9S2JW	DI	DM9S2JW
DM9S2JW	DN	Aldosterone
DM9S2JW	MI	DEIBDNY
DM9S2JW	MN	Cytochrome P450 3A5 (CYP3A5)
DM9S2JW	MT	DME
DM9S2JW	MA	Metabolism
DM9S2JW	RN	CYP3A5 genotype is associated with elevated blood pressure. Pharmacogenet Genomics. 2005 Oct;15(10):737-41.
DM9S2JW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16141800

DM9S2JW	DI	DM9S2JW
DM9S2JW	DN	Aldosterone
DM9S2JW	MI	TT26PHO
DM9S2JW	MN	Mineralocorticoid receptor  (MR)
DM9S2JW	MT	DTT
DM9S2JW	MA	Agonist
DM9S2JW	RN	Stimulation of testosterone production in rat Leydig cells by aldosterone is mineralocorticoid receptor mediated. Mol Cell Endocrinol. 2005 Nov 24;243(1-2):35-42.
DM9S2JW	RU	https://pubmed.ncbi.nlm.nih.gov/16188378

DM9S2JW	DI	DM9S2JW
DM9S2JW	DN	Aldosterone
DM9S2JW	MI	DTUGYRD
DM9S2JW	MN	P-glycoprotein 1 (ABCB1)
DM9S2JW	MT	DTP
DM9S2JW	MA	Substrate
DM9S2JW	RN	MDR1 genotype-dependent regulation of the aldosterone system in humans. Pharmacogenet Genomics. 2007 Feb;17(2):137-44.
DM9S2JW	RU	http://www.ncbi.nlm.nih.gov/pubmed/17301693

DM9S2JW	DI	DM9S2JW
DM9S2JW	DN	Aldosterone
DM9S2JW	MI	TTS087L
DM9S2JW	MN	Solute carrier family 12 member 1 (SLC12A1)
DM9S2JW	MT	DTT
DM9S2JW	MA	Blocker
DM9S2JW	RN	Nongenomic effect of aldosterone on ion transport pathways of red blood cells. Cell Physiol Biochem. 2008;22(1-4):269-78.
DM9S2JW	RU	https://pubmed.ncbi.nlm.nih.gov/18769054

DM9S2JW	DI	DM9S2JW
DM9S2JW	DN	Aldosterone
DM9S2JW	MI	DEPE0RD
DM9S2JW	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM9S2JW	MT	DME
DM9S2JW	MA	Metabolism
DM9S2JW	RN	Quantitative assessment of CYP11B1 and CYP11B2 expression in aldosterone-producing adenomas. Eur J Endocrinol. 2002 Dec;147(6):795-802.
DM9S2JW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12457455

DM9S2JW	DI	DM9S2JW
DM9S2JW	DN	Aldosterone
DM9S2JW	MI	DEB3CV1
DM9S2JW	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DM9S2JW	MT	DME
DM9S2JW	MA	Metabolism
DM9S2JW	RN	Human uridine diphosphate-glucuronosyltransferase UGT2B7 conjugates mineralocorticoid and glucocorticoid metabolites. Endocrinology. 2003 Jun;144(6):2659-68.
DM9S2JW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12746330

DMP1I6Y	DI	DMP1I6Y
DMP1I6Y	DN	Alectinib
DMP1I6Y	MI	TTPMQSO
DMP1I6Y	MN	ALK tyrosine kinase receptor (ALK)
DMP1I6Y	MT	DTT
DMP1I6Y	MA	Inhibitor
DMP1I6Y	RN	CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell. 2011 May 17;19(5):679-90.
DMP1I6Y	RU	https://pubmed.ncbi.nlm.nih.gov/21575866

DMP1I6Y	DI	DMP1I6Y
DMP1I6Y	DN	Alectinib
DMP1I6Y	MI	DE4LYSA
DMP1I6Y	MN	Cytochrome P450 3A4 (CYP3A4)
DMP1I6Y	MT	DME
DMP1I6Y	MA	Metabolism
DMP1I6Y	RN	In vitro metabolism of alectinib, a novel potent ALK inhibitor, in human: contribution of CYP3A enzymes. Xenobiotica. 2018 Jun;48(6):546-554.
DMP1I6Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28657423

DMMYPWO	DI	DMMYPWO
DMMYPWO	DN	Alefacept
DMMYPWO	MI	TT5KSBY
DMMYPWO	MN	Surface glycoprotein LFA-3 (CD58)
DMMYPWO	MT	DTT
DMMYPWO	MA	Modulator
DMMYPWO	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMMYPWO	RU	https://www.fda.gov/

DMZL3IV	DI	DMZL3IV
DMZL3IV	DN	Alemtuzumab
DMZL3IV	MI	TTQT5S9
DMZL3IV	MN	Cambridge pathology 1 antigen (CD52)
DMZL3IV	MT	DTT
DMZL3IV	RN	Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. J Transl Med. 2009 Jun 19;7:49.
DMZL3IV	RU	https://pubmed.ncbi.nlm.nih.gov/19545375

DMY2KX9	DI	DMY2KX9
DMY2KX9	DN	Alendronate
DMY2KX9	MI	TTIKWV4
DMY2KX9	MN	Geranyltranstransferase (FDPS)
DMY2KX9	MT	DTT
DMY2KX9	MA	Modulator
DMY2KX9	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMY2KX9	RU	https://www.fda.gov/

DMCKPUR	DI	DMCKPUR
DMCKPUR	DN	Alfaferone
DMCKPUR	MI	TT95SOA
DMCKPUR	MN	Interferon alpha (IFNA)
DMCKPUR	MT	DTT
DMCKPUR	MA	Modulator
DMCKPUR	RN	Natural leukocyte interferon alpha (Alfaferone) combined with ribavirin in the treatment of patients with HCV-related cirrhosis: our experience. Infection. 2011 Oct;39(5):433-7.
DMCKPUR	RU	https://pubmed.ncbi.nlm.nih.gov/21739360

DMVO0UB	DI	DMVO0UB
DMVO0UB	DN	Alfentanil
DMVO0UB	MI	DE4LYSA
DMVO0UB	MN	Cytochrome P450 3A4 (CYP3A4)
DMVO0UB	MT	DME
DMVO0UB	MA	Metabolism
DMVO0UB	RN	Pharmacogenetic determinants of human liver microsomal alfentanil metabolism and the role of cytochrome P450 3A5. Anesthesiology. 2005 Mar;102(3):550-6.
DMVO0UB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15731592

DMVO0UB	DI	DMVO0UB
DMVO0UB	DN	Alfentanil
DMVO0UB	MI	DEIBDNY
DMVO0UB	MN	Cytochrome P450 3A5 (CYP3A5)
DMVO0UB	MT	DME
DMVO0UB	MA	Metabolism
DMVO0UB	RN	Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Clin Pharmacol Ther. 2007 Oct;82(4):410-26.
DMVO0UB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17554244

DMVO0UB	DI	DMVO0UB
DMVO0UB	DN	Alfentanil
DMVO0UB	MI	DERD86B
DMVO0UB	MN	Cytochrome P450 3A7 (CYP3A7)
DMVO0UB	MT	DME
DMVO0UB	MA	Metabolism
DMVO0UB	RN	Drug Interactions Flockhart Table
DMVO0UB	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMVO0UB	DI	DMVO0UB
DMVO0UB	DN	Alfentanil
DMVO0UB	MI	TTKWM86
DMVO0UB	MN	Opioid receptor mu (MOP)
DMVO0UB	MT	DTT
DMVO0UB	MA	Agonist
DMVO0UB	RN	Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain. 2001 Mar;91(1-2):177-87.
DMVO0UB	RU	https://pubmed.ncbi.nlm.nih.gov/11240090

DMZVMKF	DI	DMZVMKF
DMZVMKF	DN	Alfuzosin
DMZVMKF	MI	TT34BHT
DMZVMKF	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMZVMKF	MT	DTT
DMZVMKF	MA	Antagonist
DMZVMKF	RN	Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs. 2002;62(4):633-53.
DMZVMKF	RU	https://pubmed.ncbi.nlm.nih.gov/11893233

DMZVMKF	DI	DMZVMKF
DMZVMKF	DN	Alfuzosin
DMZVMKF	MI	DTI7UX6
DMZVMKF	MN	Breast cancer resistance protein (ABCG2)
DMZVMKF	MT	DTP
DMZVMKF	MA	Substrate
DMZVMKF	RN	In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2). Handb Exp Pharmacol. 2011;(201):325-71.
DMZVMKF	RU	https://doi.org/10.1007/978-3-642-14541-4_9

DM4LOD0	DI	DM4LOD0
DM4LOD0	DN	Alglucosidase alfa
DM4LOD0	MI	TT95ICL
DM4LOD0	MN	Mannose-6-phosphate receptor (M6PR)
DM4LOD0	MT	DTT
DM4LOD0	MA	Binder
DM4LOD0	RN	Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res. 2009 Sep;66(3):329-35.
DM4LOD0	RU	https://pubmed.ncbi.nlm.nih.gov/19542901

DM1BV7W	DI	DM1BV7W
DM1BV7W	DN	Aliskiren
DM1BV7W	MI	TTB2MXP
DM1BV7W	MN	Angiotensinogenase renin (REN)
DM1BV7W	MT	DTT
DM1BV7W	MA	Inhibitor
DM1BV7W	RN	Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patie... J Renin Angiotensin Aldosterone Syst. 2009 Sep;10(3):157-67.
DM1BV7W	RU	https://pubmed.ncbi.nlm.nih.gov/19617271

DM1BV7W	DI	DM1BV7W
DM1BV7W	DN	Aliskiren
DM1BV7W	MI	DE4LYSA
DM1BV7W	MN	Cytochrome P450 3A4 (CYP3A4)
DM1BV7W	MT	DME
DM1BV7W	MA	Metabolism
DM1BV7W	RN	Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet. 2008;47(8):515-31.
DM1BV7W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18611061

DM1BV7W	DI	DM1BV7W
DM1BV7W	DN	Aliskiren
DM1BV7W	MI	DTPFTEQ
DM1BV7W	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DM1BV7W	MT	DTP
DM1BV7W	MA	Substrate
DM1BV7W	RN	Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren. Br J Clin Pharmacol. 2011 May;71(5):718-26.
DM1BV7W	RU	http://www.ncbi.nlm.nih.gov/pubmed/21204914

DM1BV7W	DI	DM1BV7W
DM1BV7W	DN	Aliskiren
DM1BV7W	MI	DTUGYRD
DM1BV7W	MN	P-glycoprotein 1 (ABCB1)
DM1BV7W	MT	DTP
DM1BV7W	MA	Substrate
DM1BV7W	RN	Effects of the inhibition of intestinal P-glycoprotein on aliskiren pharmacokinetics in cynomolgus monkeys. Biopharm Drug Dispos. 2015 Jan;36(1):15-33.
DM1BV7W	RU	http://www.ncbi.nlm.nih.gov/pubmed/25264342

DMME8LH	DI	DMME8LH
DMME8LH	DN	Alitretinoin
DMME8LH	MI	DE4LYSA
DMME8LH	MN	Cytochrome P450 3A4 (CYP3A4)
DMME8LH	MT	DME
DMME8LH	MA	Metabolism
DMME8LH	RN	Alitretinoin in dermatology-an update. Indian J Dermatol. 2015 Sep-Oct;60(5):520.
DMME8LH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26538721

DMME8LH	DI	DMME8LH
DMME8LH	DN	Alitretinoin
DMME8LH	MI	TTISP28
DMME8LH	MN	Retinoic acid receptor beta (RARB)
DMME8LH	MT	DTT
DMME8LH	MA	Agonist
DMME8LH	RN	Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30-4.
DMME8LH	RU	https://pubmed.ncbi.nlm.nih.gov/8380496

DMME8LH	DI	DMME8LH
DMME8LH	DN	Alitretinoin
DMME8LH	MI	TT1Q3IE
DMME8LH	MN	Retinoic acid receptor gamma (RARG)
DMME8LH	MT	DTT
DMME8LH	MA	Modulator
DMME8LH	RN	Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30-4.
DMME8LH	RU	https://pubmed.ncbi.nlm.nih.gov/8380496

DMME8LH	DI	DMME8LH
DMME8LH	DN	Alitretinoin
DMME8LH	MI	TT6PEUO
DMME8LH	MN	Retinoic acid receptor RXR-alpha (RXRA)
DMME8LH	MT	DTT
DMME8LH	MA	Agonist
DMME8LH	RN	Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30-4.
DMME8LH	RU	https://pubmed.ncbi.nlm.nih.gov/8380496

DMME8LH	DI	DMME8LH
DMME8LH	DN	Alitretinoin
DMME8LH	MI	TTKLV96
DMME8LH	MN	Retinoic acid receptor RXR-beta (RXRB)
DMME8LH	MT	DTT
DMME8LH	MA	Agonist
DMME8LH	RN	Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30-4.
DMME8LH	RU	https://pubmed.ncbi.nlm.nih.gov/8380496

DMME8LH	DI	DMME8LH
DMME8LH	DN	Alitretinoin
DMME8LH	MI	TTH029C
DMME8LH	MN	Retinoic acid receptor RXR-gamma (RXRG)
DMME8LH	MT	DTT
DMME8LH	MA	Agonist
DMME8LH	RN	Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30-4.
DMME8LH	RU	https://pubmed.ncbi.nlm.nih.gov/8380496

DMB4HFI	DI	DMB4HFI
DMB4HFI	DN	Alkavervir
DMB4HFI	MI	TTNZRI3
DMB4HFI	MN	Synaptic vesicle amine transporter (SLC18A2)
DMB4HFI	MT	DTT
DMB4HFI	MA	Modulator
DMB4HFI	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMB4HFI	RU	https://www.fda.gov/

DMNLHAC	DI	DMNLHAC
DMNLHAC	DN	Allopregnanolone
DMNLHAC	MI	DE7WS3H
DMNLHAC	MN	Aldo-keto reductase 1B1 (AKR1B1)
DMNLHAC	MT	DME
DMNLHAC	MA	Metabolism
DMNLHAC	RN	FDA Label of Brexanolone. The 2020 official website of the U.S. Food and Drug Administration.
DMNLHAC	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211371lbl.pdf

DMNLHAC	DI	DMNLHAC
DMNLHAC	DN	Allopregnanolone
DMNLHAC	MI	TT1MPAY
DMNLHAC	MN	GABA(A) receptor alpha-1 (GABRA1)
DMNLHAC	MT	DTT
DMNLHAC	MA	Inhibitor
DMNLHAC	RN	Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (... J Med Chem. 2005 Apr 21;48(8):3051-9.
DMNLHAC	RU	https://pubmed.ncbi.nlm.nih.gov/15828844

DMNLHAC	DI	DMNLHAC
DMNLHAC	DN	Allopregnanolone
DMNLHAC	MI	TTZA1NY
DMNLHAC	MN	GABA(A) receptor beta-2 (GABRB2)
DMNLHAC	MT	DTT
DMNLHAC	MA	Inhibitor
DMNLHAC	RN	Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (... J Med Chem. 2005 Apr 21;48(8):3051-9.
DMNLHAC	RU	https://pubmed.ncbi.nlm.nih.gov/15828844

DMNLHAC	DI	DMNLHAC
DMNLHAC	DN	Allopregnanolone
DMNLHAC	MI	TTGXH6N
DMNLHAC	MN	GABA(A) receptor delta (GABRD)
DMNLHAC	MT	DTT
DMNLHAC	MA	Inhibitor
DMNLHAC	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMNLHAC	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMNLHAC	DI	DMNLHAC
DMNLHAC	DN	Allopregnanolone
DMNLHAC	MI	TT06RH5
DMNLHAC	MN	GABA(A) receptor gamma-2 (GABRG2)
DMNLHAC	MT	DTT
DMNLHAC	MA	Inhibitor
DMNLHAC	RN	Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (... J Med Chem. 2005 Apr 21;48(8):3051-9.
DMNLHAC	RU	https://pubmed.ncbi.nlm.nih.gov/15828844

DMNLHAC	DI	DMNLHAC
DMNLHAC	DN	Allopregnanolone
DMNLHAC	MI	TTEX6LM
DMNLHAC	MN	GABA(A) receptor gamma-3 (GABRG3)
DMNLHAC	MT	DTT
DMNLHAC	MA	Modulator
DMNLHAC	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMNLHAC	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMNLHAC	DI	DMNLHAC
DMNLHAC	DN	Allopregnanolone
DMNLHAC	MI	TTNJYV2
DMNLHAC	MN	Gamma-aminobutyric acid receptor (GAR)
DMNLHAC	MT	DTT
DMNLHAC	MA	Inhibitor
DMNLHAC	RN	Neurosteroid analogues. 11. Alternative ring system scaffolds: gamma-aminobutyric acid receptor modulation and anesthetic actions of benz[f]indenes. J Med Chem. 2006 Jul 27;49(15):4595-605.
DMNLHAC	RU	https://pubmed.ncbi.nlm.nih.gov/16854065

DMLPAOB	DI	DMLPAOB
DMLPAOB	DN	Allopurinol
DMLPAOB	MI	DT0OC1Q
DMLPAOB	MN	Organic anion transporter 2 (SLC22A7)
DMLPAOB	MT	DTP
DMLPAOB	MA	Substrate
DMLPAOB	RN	Isolation, characterization and differential gene expression of multispecific organic anion transporter 2 in mice. Mol Pharmacol. 2002 Jul;62(1):7-14.
DMLPAOB	RU	http://www.ncbi.nlm.nih.gov/pubmed/12065749

DMLPAOB	DI	DMLPAOB
DMLPAOB	DN	Allopurinol
DMLPAOB	MI	DTVP67E
DMLPAOB	MN	Organic anion transporter 3 (SLC22A8)
DMLPAOB	MT	DTP
DMLPAOB	MA	Substrate
DMLPAOB	RN	Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3. Drug Metab Dispos. 2004 May;32(5):479-83.
DMLPAOB	RU	http://www.ncbi.nlm.nih.gov/pubmed/15100168

DMLPAOB	DI	DMLPAOB
DMLPAOB	DN	Allopurinol
DMLPAOB	MI	DEZV4AP
DMLPAOB	MN	RNA cytidine acetyltransferase (hALP)
DMLPAOB	MT	DME
DMLPAOB	MA	Metabolism
DMLPAOB	RN	Xanthine oxidase inhibition by allopurinol affects the reliability of urinary caffeine metabolic ratios as markers for N-acetyltransferase 2 and CYP1A2 activities. Eur J Clin Pharmacol. 1999 Jan;54(11):869-76.
DMLPAOB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10027663

DMLPAOB	DI	DMLPAOB
DMLPAOB	DN	Allopurinol
DMLPAOB	MI	TT7RJY8
DMLPAOB	MN	Xanthine dehydrogenase/oxidase (XDH)
DMLPAOB	MT	DTT
DMLPAOB	MA	Inhibitor
DMLPAOB	RN	Allopurinol: xanthine oxidase inhibitor. Tex Med. 1966 Jan;62(1):100-1.
DMLPAOB	RU	https://pubmed.ncbi.nlm.nih.gov/5324754

DM0SYAN	DI	DM0SYAN
DM0SYAN	DN	Almitrine
DM0SYAN	MI	TTWK8D0
DM0SYAN	MN	Sodium pump subunit alpha-1 (ATP1A1)
DM0SYAN	MT	DTT
DM0SYAN	MA	Binder
DM0SYAN	RN	Almitrine, a new kind of energy-transduction inhibitor acting on mitochondrial ATP synthase. Biochim Biophys Acta. 1989 Aug 3;975(3):325-9.
DM0SYAN	RU	https://pubmed.ncbi.nlm.nih.gov/2527061

DM7I64Z	DI	DM7I64Z
DM7I64Z	DN	Almogran
DM7I64Z	MI	TT6MSOK
DM7I64Z	MN	5-HT 1D receptor (HTR1D)
DM7I64Z	MT	DTT
DM7I64Z	MA	Agonist
DM7I64Z	RN	Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study. Clin Ther. 2001 Nov;23(11):1867-75.
DM7I64Z	RU	https://pubmed.ncbi.nlm.nih.gov/11768838

DMFG5ST	DI	DMFG5ST
DMFG5ST	DN	Almotriptan malate
DMFG5ST	MI	DES5XRU
DMFG5ST	MN	Cytochrome P450 2C8 (CYP2C8)
DMFG5ST	MT	DME
DMFG5ST	MA	Metabolism
DMFG5ST	RN	Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos. 2003 Apr;31(4):404-11.
DMFG5ST	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12642466

DMFG5ST	DI	DMFG5ST
DMFG5ST	DN	Almotriptan malate
DMFG5ST	MI	DECB0K3
DMFG5ST	MN	Cytochrome P450 2D6 (CYP2D6)
DMFG5ST	MT	DME
DMFG5ST	MA	Metabolism
DMFG5ST	RN	Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. Clin Pharmacokinet. 2005;44(3):237-46.
DMFG5ST	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15762767

DMFG5ST	DI	DMFG5ST
DMFG5ST	DN	Almotriptan malate
DMFG5ST	MI	DEVDYN7
DMFG5ST	MN	Cytochrome P450 2E1 (CYP2E1)
DMFG5ST	MT	DME
DMFG5ST	MA	Metabolism
DMFG5ST	RN	Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos. 2003 Apr;31(4):404-11.
DMFG5ST	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12642466

DMFG5ST	DI	DMFG5ST
DMFG5ST	DN	Almotriptan malate
DMFG5ST	MI	DE4LYSA
DMFG5ST	MN	Cytochrome P450 3A4 (CYP3A4)
DMFG5ST	MT	DME
DMFG5ST	MA	Metabolism
DMFG5ST	RN	Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. Clin Pharmacokinet. 2005;44(3):237-46.
DMFG5ST	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15762767

DMFG5ST	DI	DMFG5ST
DMFG5ST	DN	Almotriptan malate
DMFG5ST	MI	DEP76YL
DMFG5ST	MN	Dimethylaniline oxidase 3 (FMO3)
DMFG5ST	MT	DME
DMFG5ST	MA	Metabolism
DMFG5ST	RN	Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos. 2003 Apr;31(4):404-11.
DMFG5ST	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12642466

DMFG5ST	DI	DMFG5ST
DMFG5ST	DN	Almotriptan malate
DMFG5ST	MI	DEGTFWK
DMFG5ST	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMFG5ST	MT	DME
DMFG5ST	MA	Metabolism
DMFG5ST	RN	Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos. 2003 Apr;31(4):404-11.
DMFG5ST	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12642466

DMFG5ST	DI	DMFG5ST
DMFG5ST	DN	Almotriptan malate
DMFG5ST	MI	DERE4TU
DMFG5ST	MN	Monoamine oxidase type A (MAO-A)
DMFG5ST	MT	DME
DMFG5ST	MA	Metabolism
DMFG5ST	RN	Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. Clin Pharmacokinet. 2005;44(3):237-46.
DMFG5ST	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15762767

DM8WI3R	DI	DM8WI3R
DM8WI3R	DN	Alogliptin
DM8WI3R	MI	DECB0K3
DM8WI3R	MN	Cytochrome P450 2D6 (CYP2D6)
DM8WI3R	MT	DME
DM8WI3R	MA	Metabolism
DM8WI3R	RN	An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus. Clin Exp Pharmacol Physiol. 2015 Dec;42(12):1225-38.
DM8WI3R	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26218204

DM8WI3R	DI	DM8WI3R
DM8WI3R	DN	Alogliptin
DM8WI3R	MI	DE4LYSA
DM8WI3R	MN	Cytochrome P450 3A4 (CYP3A4)
DM8WI3R	MT	DME
DM8WI3R	MA	Metabolism
DM8WI3R	RN	An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus. Clin Exp Pharmacol Physiol. 2015 Dec;42(12):1225-38.
DM8WI3R	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26218204

DM8WI3R	DI	DM8WI3R
DM8WI3R	DN	Alogliptin
DM8WI3R	MI	TTDIGC1
DM8WI3R	MN	Dipeptidyl peptidase 4 (DPP-4)
DM8WI3R	MT	DTT
DM8WI3R	MA	Inhibitor
DM8WI3R	RN	Clinical pipeline report, company report or official report of Takeda (2009).
DM8WI3R	RU	http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf

DML2A03	DI	DML2A03
DML2A03	DN	Alosetron
DML2A03	MI	TTPC4TU
DML2A03	MN	5-HT 3A receptor (HTR3A)
DML2A03	MT	DTT
DML2A03	MA	Antagonist
DML2A03	RN	Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2009 Jul;104(7):1831-43; quiz 1844.
DML2A03	RU	https://pubmed.ncbi.nlm.nih.gov/19471254

DML2A03	DI	DML2A03
DML2A03	DN	Alosetron
DML2A03	MI	DEJGDUW
DML2A03	MN	Cytochrome P450 1A2 (CYP1A2)
DML2A03	MT	DME
DML2A03	MA	Metabolism
DML2A03	RN	Optimizing outcomes with alosetron hydrochloride in severe diarrhea-predominant irritable bowel syndrome. Therap Adv Gastroenterol. 2010 May;3(3):165-72.
DML2A03	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21180598

DML2A03	DI	DML2A03
DML2A03	DN	Alosetron
DML2A03	MI	DE5IED8
DML2A03	MN	Cytochrome P450 2C9 (CYP2C9)
DML2A03	MT	DME
DML2A03	MA	Metabolism
DML2A03	RN	Effect of alosetron on the pharmacokinetics of fluoxetine. J Clin Pharmacol. 2001 Apr;41(4):455-8.
DML2A03	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11304903

DML2A03	DI	DML2A03
DML2A03	DN	Alosetron
DML2A03	MI	DE4LYSA
DML2A03	MN	Cytochrome P450 3A4 (CYP3A4)
DML2A03	MT	DME
DML2A03	MA	Metabolism
DML2A03	RN	Effect of alosetron on the pharmacokinetics of alprazolam. J Clin Pharmacol. 2001 Apr;41(4):452-4.
DML2A03	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11304902

DMEXMYK	DI	DMEXMYK
DMEXMYK	DN	Alpelisib
DMEXMYK	MI	DE4LYSA
DMEXMYK	MN	Cytochrome P450 3A4 (CYP3A4)
DMEXMYK	MT	DME
DMEXMYK	MA	Metabolism
DMEXMYK	RN	Comparison of 19F NMR and 14C measurements for the assessment of ADME of BYL719 (Alpelisib) in humans. Drug Metab Dispos. 2017 Aug;45(8):900-907.
DMEXMYK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28566285

DMEXMYK	DI	DMEXMYK
DMEXMYK	DN	Alpelisib
DMEXMYK	MI	TTEUNMR
DMEXMYK	MN	PI3-kinase alpha (PIK3CA)
DMEXMYK	MT	DTT
DMEXMYK	MA	Inhibitor
DMEXMYK	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMEXMYK	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212526s000lbl.pdf

DMXC1K9	DI	DMXC1K9
DMXC1K9	DN	Alpha 1-PI
DMXC1K9	MI	TTN9D8E
DMXC1K9	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMXC1K9	MT	DTT
DMXC1K9	MA	Antagonist
DMXC1K9	RN	NMDA receptor stimulation induces reversible fission of the neuronal endoplasmic reticulum. PLoS One. 2009;4(4):e5250.
DMXC1K9	RU	https://pubmed.ncbi.nlm.nih.gov/19381304

DMXC1K9	DI	DMXC1K9
DMXC1K9	DN	Alpha 1-PI
DMXC1K9	MI	TT3NKIB
DMXC1K9	MN	Pancreatic elastase 1 (CELA1)
DMXC1K9	MT	DTT
DMXC1K9	MA	Inhibitor
DMXC1K9	RN	Elastase inhibitors. J Soc Biol. 2001;195(2):143-50.
DMXC1K9	RU	https://pubmed.ncbi.nlm.nih.gov/11723826

DMAS02L	DI	DMAS02L
DMAS02L	DN	Alpha-acetyldigoxin
DMAS02L	MI	TTYHPRQ
DMAS02L	MN	Sodium pump (NaP)
DMAS02L	MT	DTT
DMAS02L	MA	Modulator
DMAS02L	RN	Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81.
DMAS02L	RU	https://pubmed.ncbi.nlm.nih.gov/3879679

DMN7Y9K	DI	DMN7Y9K
DMN7Y9K	DN	Alpidem
DMN7Y9K	MI	TTNJYV2
DMN7Y9K	MN	Gamma-aminobutyric acid receptor (GAR)
DMN7Y9K	MT	DTT
DMN7Y9K	MA	Inhibitor
DMN7Y9K	RN	Synthesis and binding affinity of 2-phenylimidazo[1,2-alpha]pyridine derivatives for both central and peripheral benzodiazepine receptors. A new se... J Med Chem. 1997 Sep 12;40(19):3109-18.
DMN7Y9K	RU	https://pubmed.ncbi.nlm.nih.gov/9301675

DMN7Y9K	DI	DMN7Y9K
DMN7Y9K	DN	Alpidem
DMN7Y9K	MI	TTPTXIN
DMN7Y9K	MN	Translocator protein (TSPO)
DMN7Y9K	MT	DTT
DMN7Y9K	MA	Inhibitor
DMN7Y9K	RN	Anxiolytic-like effects of N,N-dialkyl-2-phenylindol-3-ylglyoxylamides by modulation of translocator protein promoting neurosteroid biosynthesis. J Med Chem. 2008 Sep 25;51(18):5798-806.
DMN7Y9K	RU	https://pubmed.ncbi.nlm.nih.gov/18729350

DMC7XDN	DI	DMC7XDN
DMC7XDN	DN	Alprazolam
DMC7XDN	MI	DE5IED8
DMC7XDN	MN	Cytochrome P450 2C9 (CYP2C9)
DMC7XDN	MT	DME
DMC7XDN	MA	Metabolism
DMC7XDN	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMC7XDN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMC7XDN	DI	DMC7XDN
DMC7XDN	DN	Alprazolam
DMC7XDN	MI	DE4LYSA
DMC7XDN	MN	Cytochrome P450 3A4 (CYP3A4)
DMC7XDN	MT	DME
DMC7XDN	MA	Metabolism
DMC7XDN	RN	No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extract. Planta Med. 2005 Apr;71(4):331-7.
DMC7XDN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15856409

DMC7XDN	DI	DMC7XDN
DMC7XDN	DN	Alprazolam
DMC7XDN	MI	DEIBDNY
DMC7XDN	MN	Cytochrome P450 3A5 (CYP3A5)
DMC7XDN	MT	DME
DMC7XDN	MA	Metabolism
DMC7XDN	RN	Identification and phenotype characterization of two CYP3A haplotypes causing different enzymatic capacity in fetal livers. Clin Pharmacol Ther. 2005 Apr;77(4):259-70.
DMC7XDN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15903124

DMC7XDN	DI	DMC7XDN
DMC7XDN	DN	Alprazolam
DMC7XDN	MI	DERD86B
DMC7XDN	MN	Cytochrome P450 3A7 (CYP3A7)
DMC7XDN	MT	DME
DMC7XDN	MA	Metabolism
DMC7XDN	RN	Drug Interactions Flockhart Table
DMC7XDN	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMC7XDN	DI	DMC7XDN
DMC7XDN	DN	Alprazolam
DMC7XDN	MI	TTPTXIN
DMC7XDN	MN	Translocator protein (TSPO)
DMC7XDN	MT	DTT
DMC7XDN	MA	Agonist
DMC7XDN	RN	Comparison of five benzodiazepine-receptor agonists on buprenorphine-induced mu-opioid receptor regulation. J Pharmacol Sci. 2009 May;110(1):36-46.
DMC7XDN	RU	https://pubmed.ncbi.nlm.nih.gov/19443999

DMWH7NQ	DI	DMWH7NQ
DMWH7NQ	DN	Alprostadil
DMWH7NQ	MI	DTCSGPB
DMWH7NQ	MN	Multidrug resistance-associated protein 4 (ABCC4)
DMWH7NQ	MT	DTP
DMWH7NQ	MA	Substrate
DMWH7NQ	RN	The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9.
DMWH7NQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/12835412

DMWH7NQ	DI	DMWH7NQ
DMWH7NQ	DN	Alprostadil
DMWH7NQ	MI	DTQ23VB
DMWH7NQ	MN	Organic anion transporter 1 (SLC22A6)
DMWH7NQ	MT	DTP
DMWH7NQ	MA	Substrate
DMWH7NQ	RN	Prostaglandin transporter (OATP2A1/SLCO2A1) contributes to local disposition of eicosapentaenoic acid-derived PGE3. Prostaglandins Other Lipid Mediat. 2016 Jan;122:10-7.
DMWH7NQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/26692285

DMWH7NQ	DI	DMWH7NQ
DMWH7NQ	DN	Alprostadil
DMWH7NQ	MI	DT021JD
DMWH7NQ	MN	Organic anion transporting polypeptide 2A1 (SLCO2A1)
DMWH7NQ	MT	DTP
DMWH7NQ	MA	Substrate
DMWH7NQ	RN	Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT). J Clin Invest. 1996 Sep 1;98(5):1142-9.
DMWH7NQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/8787677

DMWH7NQ	DI	DMWH7NQ
DMWH7NQ	DN	Alprostadil
DMWH7NQ	MI	DTVNRXW
DMWH7NQ	MN	Organic anion transporting polypeptide 3A1 (SLCO3A1)
DMWH7NQ	MT	DTP
DMWH7NQ	MA	Substrate
DMWH7NQ	RN	Molecular characterization of human and rat organic anion transporter OATP-D. Am J Physiol Renal Physiol. 2003 Dec;285(6):F1188-97.
DMWH7NQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/14631946

DMWH7NQ	DI	DMWH7NQ
DMWH7NQ	DN	Alprostadil
DMWH7NQ	MI	DEHKSC6
DMWH7NQ	MN	Prostaglandin dehydrogenase 1 (HPGD)
DMWH7NQ	MT	DME
DMWH7NQ	MA	Metabolism
DMWH7NQ	RN	Effect of calcium ionophore A23187 on prostaglandin synthase type 2 and 15-hydroxy-prostaglandin dehydrogenase expression in human chorion trophoblast cells. Am J Obstet Gynecol. 2008 Nov;199(5):554.e1-8.
DMWH7NQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18639206

DMWH7NQ	DI	DMWH7NQ
DMWH7NQ	DN	Alprostadil
DMWH7NQ	MI	TT1ZAVI
DMWH7NQ	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DMWH7NQ	MT	DTT
DMWH7NQ	MA	Agonist
DMWH7NQ	RN	Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
DMWH7NQ	RU	https://pubmed.ncbi.nlm.nih.gov/17064227

DMWH7NQ	DI	DMWH7NQ
DMWH7NQ	DN	Alprostadil
DMWH7NQ	MI	TT2O84V
DMWH7NQ	MN	Thromboxane A2 receptor (TBXA2R)
DMWH7NQ	MT	DTT
DMWH7NQ	MA	Modulator
DMWH7NQ	RN	Flow after prostaglandin E1 is mediated by receptor-coupled adenylyl cyclase in human anterior segments. Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2622-6.
DMWH7NQ	RU	https://pubmed.ncbi.nlm.nih.gov/10509658

DMB47TQ	DI	DMB47TQ
DMB47TQ	DN	Alseroxylon
DMB47TQ	MI	TTNZRI3
DMB47TQ	MN	Synaptic vesicle amine transporter (SLC18A2)
DMB47TQ	MT	DTT
DMB47TQ	MA	Blocker
DMB47TQ	RN	Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
DMB47TQ	RU	https://pubmed.ncbi.nlm.nih.gov/17016423

DMRJ3YX	DI	DMRJ3YX
DMRJ3YX	DN	Alteplase
DMRJ3YX	MI	TTP86E2
DMRJ3YX	MN	Plasminogen (PLG)
DMRJ3YX	MT	DTT
DMRJ3YX	MA	Activator
DMRJ3YX	RN	Thrombolytic therapies: the current state of affairs. J Endovasc Ther. 2005 Apr;12(2):224-32.
DMRJ3YX	RU	https://pubmed.ncbi.nlm.nih.gov/15823070

DMKLAYG	DI	DMKLAYG
DMKLAYG	DN	Altretamine
DMKLAYG	MI	TTUTN1I
DMKLAYG	MN	Human Deoxyribonucleic acid (hDNA)
DMKLAYG	MT	DTT
DMKLAYG	MA	Breaker
DMKLAYG	RN	Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agen... Cancer Chemother Pharmacol. 2008 Dec;63(1):19-26.
DMKLAYG	RU	https://pubmed.ncbi.nlm.nih.gov/18305940

DMO9WDS	DI	DMO9WDS
DMO9WDS	DN	Altropane
DMO9WDS	MI	TTVBI8W
DMO9WDS	MN	Dopamine transporter (DAT)
DMO9WDS	MT	DTT
DMO9WDS	MA	Inhibitor
DMO9WDS	RN	Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse. 1998 Jun;29(2):128-41.
DMO9WDS	RU	https://pubmed.ncbi.nlm.nih.gov/9593103

DM6ECN9	DI	DM6ECN9
DM6ECN9	DN	Aluminium
DM6ECN9	MI	TTWK8D0
DM6ECN9	MN	Sodium pump subunit alpha-1 (ATP1A1)
DM6ECN9	MT	DTT
DM6ECN9	MA	Binder
DM6ECN9	RN	The inhibitory effect of aluminium on the (Na+/K+)ATPase activity of rat brain cortex synaptosomes. J Inorg Biochem. 2003 Sep 15;97(1):143-50.
DM6ECN9	RU	https://pubmed.ncbi.nlm.nih.gov/14507470

DMHR8KW	DI	DMHR8KW
DMHR8KW	DN	Alvimopan
DMHR8KW	MI	TTKWM86
DMHR8KW	MN	Opioid receptor mu (MOP)
DMHR8KW	MT	DTT
DMHR8KW	MA	Antagonist
DMHR8KW	RN	Alvimopan for postoperative ileus. Am J Health Syst Pharm. 2009 Jul 15;66(14):1267-77.
DMHR8KW	RU	https://pubmed.ncbi.nlm.nih.gov/19574601

DMS3YE9	DI	DMS3YE9
DMS3YE9	DN	Amantadine
DMS3YE9	MI	TTXT3PU
DMS3YE9	MN	Influenza M2 protein (Influ M)
DMS3YE9	MT	DTT
DMS3YE9	MA	Inhibitor
DMS3YE9	RN	Discovery of spiro-piperidine inhibitors and their modulation of the dynamics of the M2 proton channel from influenza A virus. J Am Chem Soc. 2009 Jun 17;131(23):8066-76.
DMS3YE9	RU	https://pubmed.ncbi.nlm.nih.gov/19469531

DMS3YE9	DI	DMS3YE9
DMS3YE9	DN	Amantadine
DMS3YE9	MI	DT9IDPW
DMS3YE9	MN	Organic cation transporter 2 (SLC22A2)
DMS3YE9	MT	DTP
DMS3YE9	MA	Substrate
DMS3YE9	RN	Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol Pharmacol. 1998 Aug;54(2):342-52.
DMS3YE9	RU	http://www.ncbi.nlm.nih.gov/pubmed/9687576

DMOP0BL	DI	DMOP0BL
DMOP0BL	DN	Ambenonium
DMOP0BL	MI	TT1RS9F
DMOP0BL	MN	Acetylcholinesterase (AChE)
DMOP0BL	MT	DTT
DMOP0BL	MA	Inhibitor
DMOP0BL	RN	Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. Neuropsychopharmacology. 2008 Aug;33(9):2158-66.
DMOP0BL	RU	https://pubmed.ncbi.nlm.nih.gov/18033235

DMD1QXW	DI	DMD1QXW
DMD1QXW	DN	Ambrisentan
DMD1QXW	MI	DE4LYSA
DMD1QXW	MN	Cytochrome P450 3A4 (CYP3A4)
DMD1QXW	MT	DME
DMD1QXW	MA	Metabolism
DMD1QXW	RN	Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. J Clin Pharmacol. 2012 Dec;52(12):1784-805.
DMD1QXW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22205719

DMD1QXW	DI	DMD1QXW
DMD1QXW	DN	Ambrisentan
DMD1QXW	MI	TTKRD0G
DMD1QXW	MN	Endothelin A receptor (EDNRA)
DMD1QXW	MT	DTT
DMD1QXW	MA	Antagonist
DMD1QXW	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMD1QXW	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMD1QXW	DI	DMD1QXW
DMD1QXW	DN	Ambrisentan
DMD1QXW	MI	DEGTFWK
DMD1QXW	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMD1QXW	MT	DME
DMD1QXW	MA	Metabolism
DMD1QXW	RN	Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. J Clin Pharmacol. 2012 Dec;52(12):1784-805.
DMD1QXW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22205719

DMD1QXW	DI	DMD1QXW
DMD1QXW	DN	Ambrisentan
DMD1QXW	MI	DTUGYRD
DMD1QXW	MN	P-glycoprotein 1 (ABCB1)
DMD1QXW	MT	DTP
DMD1QXW	MA	Substrate
DMD1QXW	RN	Potential for pharmacokinetic interactions between ambrisentan and cyclosporine. Clin Pharmacol Ther. 2010 Oct;88(4):513-20.
DMD1QXW	RU	http://www.ncbi.nlm.nih.gov/pubmed/20811346

DMD1QXW	DI	DMD1QXW
DMD1QXW	DN	Ambrisentan
DMD1QXW	MI	DEF2WXN
DMD1QXW	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMD1QXW	MT	DME
DMD1QXW	MA	Metabolism
DMD1QXW	RN	Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. J Clin Pharmacol. 2012 Dec;52(12):1784-805.
DMD1QXW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22205719

DMD1QXW	DI	DMD1QXW
DMD1QXW	DN	Ambrisentan
DMD1QXW	MI	DE85D2P
DMD1QXW	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMD1QXW	MT	DME
DMD1QXW	MA	Metabolism
DMD1QXW	RN	Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. J Clin Pharmacol. 2012 Dec;52(12):1784-805.
DMD1QXW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22205719

DMD1QXW	DI	DMD1QXW
DMD1QXW	DN	Ambrisentan
DMD1QXW	MI	DEB3CV1
DMD1QXW	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMD1QXW	MT	DME
DMD1QXW	MA	Metabolism
DMD1QXW	RN	Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. J Clin Pharmacol. 2012 Dec;52(12):1784-805.
DMD1QXW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22205719

DMWJE9D	DI	DMWJE9D
DMWJE9D	DN	Ambroxol
DMWJE9D	MI	DE4LYSA
DMWJE9D	MN	Cytochrome P450 3A4 (CYP3A4)
DMWJE9D	MT	DME
DMWJE9D	MA	Metabolism
DMWJE9D	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMWJE9D	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMM1JL9	DI	DMM1JL9
DMM1JL9	DN	Amcinonide
DMM1JL9	MI	DE4LYSA
DMM1JL9	MN	Cytochrome P450 3A4 (CYP3A4)
DMM1JL9	MT	DME
DMM1JL9	MA	Metabolism
DMM1JL9	RN	Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35.
DMM1JL9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20482443

DMM1JL9	DI	DMM1JL9
DMM1JL9	DN	Amcinonide
DMM1JL9	MI	TTP3UTW
DMM1JL9	MN	Steroid hormone receptor ERR (ESRR)
DMM1JL9	MT	DTT
DMM1JL9	MA	Modulator
DMM1JL9	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMM1JL9	RU	https://www.fda.gov/

DMIG6FY	DI	DMIG6FY
DMIG6FY	DN	Amdinocillin
DMIG6FY	MI	TTHWB7G
DMIG6FY	MN	Bacterial Penicillin binding protein 2 (Bact mrdA)
DMIG6FY	MT	DTT
DMIG6FY	MA	Inhibitor
DMIG6FY	RN	Growth of Escherichia coli: significance of peptidoglycan degradation during elongation and septation. J Bacteriol. 2008 Jun;190(11):3914-22.
DMIG6FY	RU	https://pubmed.ncbi.nlm.nih.gov/18390656

DM6I2WQ	DI	DM6I2WQ
DM6I2WQ	DN	Amezinium
DM6I2WQ	MI	TT2NUT5
DM6I2WQ	MN	Adrenergic receptor alpha-2C (ADRA2C)
DM6I2WQ	MT	DTT
DM6I2WQ	MA	Modulator
DM6I2WQ	RN	Pharmacology of amezinium, a novel antihypotensive drug. III. Studies on the mechanism of action. Arzneimittelforschung. 1981;31(9a):1558-65.
DM6I2WQ	RU	https://pubmed.ncbi.nlm.nih.gov/7197970

DM9YSNQ	DI	DM9YSNQ
DM9YSNQ	DN	Amfepramone
DM9YSNQ	MI	TTAWNKZ
DM9YSNQ	MN	Norepinephrine transporter (NET)
DM9YSNQ	MT	DTT
DM9YSNQ	MA	Inhibitor
DM9YSNQ	RN	Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418.
DM9YSNQ	RU	https://pubmed.ncbi.nlm.nih.gov/15977970

DM9YSNQ	DI	DM9YSNQ
DM9YSNQ	DN	Amfepramone
DM9YSNQ	MI	TT3ROYC
DM9YSNQ	MN	Serotonin transporter (SERT)
DM9YSNQ	MT	DTT
DM9YSNQ	MA	Inhibitor
DM9YSNQ	RN	Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418.
DM9YSNQ	RU	https://pubmed.ncbi.nlm.nih.gov/15977970

DMK08L3	DI	DMK08L3
DMK08L3	DN	Amifampridine
DMK08L3	MI	DE7OAB3
DMK08L3	MN	N-acetyltransferase 1 (NAT1)
DMK08L3	MT	DME
DMK08L3	MA	Metabolism
DMK08L3	RN	Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate. Pharmacol Res Perspect. 2015 Feb;3(1):e00099.
DMK08L3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25692017

DMK08L3	DI	DMK08L3
DMK08L3	DN	Amifampridine
DMK08L3	MI	DER7TA0
DMK08L3	MN	N-acetyltransferase 2 (NAT2)
DMK08L3	MT	DME
DMK08L3	MA	Metabolism
DMK08L3	RN	Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate. Pharmacol Res Perspect. 2015 Feb;3(1):e00099.
DMK08L3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25692017

DMK08L3	DI	DMK08L3
DMK08L3	DN	Amifampridine
DMK08L3	MI	TT1VOHK
DMK08L3	MN	Potassium channel unspecific (KC)
DMK08L3	MT	DTT
DMK08L3	MA	Blocker
DMK08L3	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMK08L3	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DM5FL14	DI	DM5FL14
DM5FL14	DN	Amifostine
DM5FL14	MI	DEVEFKM
DM5FL14	MN	Alkaline phosphatase (ALPL)
DM5FL14	MT	DME
DM5FL14	MA	Metabolism
DM5FL14	RN	Pharmacokinetic profile of amifostine. Semin Oncol. 1996 Aug;23(4 Suppl 8):18-22.
DM5FL14	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8783662

DM5FL14	DI	DM5FL14
DM5FL14	DN	Amifostine
DM5FL14	MI	TT0C9DV
DM5FL14	MN	Toxic reactive metabolite (TRM)
DM5FL14	MT	DTT
DM5FL14	MA	Modulator
DM5FL14	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DM5FL14	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM5PDRB	DI	DM5PDRB
DM5PDRB	DN	Amikacin
DM5PDRB	MI	DEWPAJD
DM5PDRB	MN	Aminoglycoside O-phosphotransferase (aphA6)
DM5PDRB	MT	DME
DM5PDRB	MA	Metabolism
DM5PDRB	RN	Relationship between antimicrobial resistance and aminoglycoside-modifying enzyme gene expressions in Acinetobacter baumannii. Chin Med J (Engl). 2005 Jan 20;118(2):141-5.
DM5PDRB	RU	https://pubmed.ncbi.nlm.nih.gov/15667800

DM5PDRB	DI	DM5PDRB
DM5PDRB	DN	Amikacin
DM5PDRB	MI	DE1C8Q4
DM5PDRB	MN	Endoglucanase A (EGA)
DM5PDRB	MT	DME
DM5PDRB	MA	Metabolism
DM5PDRB	RN	Expression of Clostridium thermocellum endoglucanase gene in Lactobacillus gasseri and Lactobacillus johnsonii and characterization of the genetically modified probiotic lactobacilli. Curr Microbiol. 2000 Apr;40(4):257-63.
DM5PDRB	RU	https://pubmed.ncbi.nlm.nih.gov/10688695

DM5PDRB	DI	DM5PDRB
DM5PDRB	DN	Amikacin
DM5PDRB	MI	DE2AZTG
DM5PDRB	MN	Endoglucanase Y (EGY)
DM5PDRB	MT	DME
DM5PDRB	MA	Metabolism
DM5PDRB	RN	Expression of Clostridium thermocellum endoglucanase gene in Lactobacillus gasseri and Lactobacillus johnsonii and characterization of the genetically modified probiotic lactobacilli. Curr Microbiol. 2000 Apr;40(4):257-63.
DM5PDRB	RU	https://pubmed.ncbi.nlm.nih.gov/10688695

DM5PDRB	DI	DM5PDRB
DM5PDRB	DN	Amikacin
DM5PDRB	MI	TTQ8KVI
DM5PDRB	MN	Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)
DM5PDRB	MT	DTT
DM5PDRB	MA	Binder
DM5PDRB	RN	Bacterial resistance to aminoglycosides and beta-lactams: the Tn1331 transposon paradigm. Front Biosci. 2000 Jan 1;5:D20-9.
DM5PDRB	RU	https://pubmed.ncbi.nlm.nih.gov/10702385

DMRTSGP	DI	DMRTSGP
DMRTSGP	DN	Amiloride
DMRTSGP	MI	TTRJYB6
DMRTSGP	MN	Acid-sensing ion channel 1 (ASIC1)
DMRTSGP	MT	DTT
DMRTSGP	MA	Modulator
DMRTSGP	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMRTSGP	RU	https://www.fda.gov/

DMRTSGP	DI	DMRTSGP
DMRTSGP	DN	Amiloride
DMRTSGP	MI	DTT79CX
DMRTSGP	MN	Organic cation transporter 1 (SLC22A1)
DMRTSGP	MT	DTP
DMRTSGP	MA	Substrate
DMRTSGP	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMRTSGP	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DMRTSGP	DI	DMRTSGP
DMRTSGP	DN	Amiloride
DMRTSGP	MI	DT9IDPW
DMRTSGP	MN	Organic cation transporter 2 (SLC22A2)
DMRTSGP	MT	DTP
DMRTSGP	MA	Substrate
DMRTSGP	RN	Characterization of regulatory mechanisms and states of human organic cation transporter 2. Am J Physiol Cell Physiol. 2006 Jun;290(6):C1521-31.
DMRTSGP	RU	http://www.ncbi.nlm.nih.gov/pubmed/16394027

DMFGND4	DI	DMFGND4
DMFGND4	DN	Aminocaproic acid
DMFGND4	MI	TTP86E2
DMFGND4	MN	Plasminogen (PLG)
DMFGND4	MT	DTT
DMFGND4	MA	Inhibitor
DMFGND4	RN	The blockage of the high-affinity lysine binding sites of plasminogen by EACA significantly inhibits prourokinase-induced plasminogen activation. Biochim Biophys Acta. 2002 Apr 29;1596(2):182-92.
DMFGND4	RU	https://pubmed.ncbi.nlm.nih.gov/12007600

DMFGND4	DI	DMFGND4
DMFGND4	DN	Aminocaproic acid
DMFGND4	MI	TTXAGYU
DMFGND4	MN	Tissue-type plasminogen activator (PLAT)
DMFGND4	MT	DTT
DMFGND4	MA	Inhibitor
DMFGND4	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMFGND4	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMWFHMZ	DI	DMWFHMZ
DMWFHMZ	DN	Aminoglutethimide
DMWFHMZ	MI	TTSZLWK
DMWFHMZ	MN	Aromatase (CYP19A1)
DMWFHMZ	MT	DTT
DMWFHMZ	MA	Inhibitor
DMWFHMZ	RN	Aminoglutethimide-induced protein free radical formation on myeloperoxidase: a potential mechanism of agranulocytosis. Chem Res Toxicol. 2007 Jul;20(7):1038-45.
DMWFHMZ	RU	https://pubmed.ncbi.nlm.nih.gov/17602675

DMWFHMZ	DI	DMWFHMZ
DMWFHMZ	DN	Aminoglutethimide
DMWFHMZ	MI	TTSYVO6
DMWFHMZ	MN	Cholesterol desmolase (CYP11A1)
DMWFHMZ	MT	DTT
DMWFHMZ	MA	Inhibitor
DMWFHMZ	RN	Breakdown of Th cell immune responses and steroidogenic CYP11A1 expression in CD4+ T cells in a murine model implanted with B16 melanoma. Cell Immunol. 2000 Nov 25;206(1):7-15.
DMWFHMZ	RU	https://pubmed.ncbi.nlm.nih.gov/11161433

DMS4BLQ	DI	DMS4BLQ
DMS4BLQ	DN	Aminolevulinic acid hci
DMS4BLQ	MI	TTJHKYD
DMS4BLQ	MN	Delta-aminolevulinic acid dehydratase (ALAD)
DMS4BLQ	MT	DTT
DMS4BLQ	MA	Inhibitor
DMS4BLQ	RN	Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat Biotechnol. 2003 May;21(5):566-9.
DMS4BLQ	RU	https://pubmed.ncbi.nlm.nih.gov/12665801

DMS4BLQ	DI	DMS4BLQ
DMS4BLQ	DN	Aminolevulinic acid hci
DMS4BLQ	MI	DT9G7XN
DMS4BLQ	MN	Peptide transporter 1 (SLC15A1)
DMS4BLQ	MT	DTP
DMS4BLQ	MA	Substrate
DMS4BLQ	RN	Transport of the photodynamic therapy agent 5-aminolevulinic acid by distinct H+-coupled nutrient carriers coexpressed in the small intestine. J Pharmacol Exp Ther. 2010 Jan;332(1):220-8.
DMS4BLQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/19789362

DMS4BLQ	DI	DMS4BLQ
DMS4BLQ	DN	Aminolevulinic acid hci
DMS4BLQ	MI	DT8QKNP
DMS4BLQ	MN	Peptide transporter 2 (SLC15A2)
DMS4BLQ	MT	DTP
DMS4BLQ	MA	Substrate
DMS4BLQ	RN	PEPT2-mediated transport of 5-aminolevulinic acid and carnosine in astrocytes. Brain Res. 2006 Nov 29;1122(1):18-23.
DMS4BLQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/17034769

DMS4BLQ	DI	DMS4BLQ
DMS4BLQ	DN	Aminolevulinic acid hci
DMS4BLQ	MI	DETBNY4
DMS4BLQ	MN	Porphobilinogen synthase (ALAD)
DMS4BLQ	MT	DME
DMS4BLQ	MA	Metabolism
DMS4BLQ	RN	Modifying effects of delta-Aminolevulinate dehydratase polymorphism on blood lead levels and ALAD activity. Toxicol Lett. 2018 Oct 1;295:351-356.
DMS4BLQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30025905

DMS4BLQ	DI	DMS4BLQ
DMS4BLQ	DN	Aminolevulinic acid hci
DMS4BLQ	MI	DT48WEM
DMS4BLQ	MN	Proton-coupled amino acid transporter 1 (SLC36A1)
DMS4BLQ	MT	DTP
DMS4BLQ	MA	Substrate
DMS4BLQ	RN	Delta-aminolevulinic acid is a substrate for the amino acid transporter SLC36A1 (hPAT1). Br J Pharmacol. 2010 Mar;159(6):1339-53.
DMS4BLQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/20128809

DMWNHPC	DI	DMWNHPC
DMWNHPC	DN	Aminolevulinic Acid Hydrochloride
DMWNHPC	MI	TTNFMS9
DMWNHPC	MN	Protoporphyrinogen oxidase (PPOX)
DMWNHPC	MT	DTT
DMWNHPC	MA	Modulator
DMWNHPC	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMWNHPC	RU	https://www.fda.gov/

DML2NIB	DI	DML2NIB
DML2NIB	DN	Aminophylline
DML2NIB	MI	DEJGDUW
DML2NIB	MN	Cytochrome P450 1A2 (CYP1A2)
DML2NIB	MT	DME
DML2NIB	MA	Metabolism
DML2NIB	RN	Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men. Pharmacotherapy. 1998 Nov-Dec;18(6):1237-48.
DML2NIB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9855322

DML2NIB	DI	DML2NIB
DML2NIB	DN	Aminophylline
DML2NIB	MI	DEVDYN7
DML2NIB	MN	Cytochrome P450 2E1 (CYP2E1)
DML2NIB	MT	DME
DML2NIB	MA	Metabolism
DML2NIB	RN	Theophylline metabolism in human liver microsomes: inhibition studies. J Pharmacol Exp Ther. 1996 Mar;276(3):912-7.
DML2NIB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8786569

DML2NIB	DI	DML2NIB
DML2NIB	DN	Aminophylline
DML2NIB	MI	TT06AWU
DML2NIB	MN	Phosphodiesterase 3A (PDE3A)
DML2NIB	MT	DTT
DML2NIB	MA	Inhibitor
DML2NIB	RN	Topical fat reduction from the waist. Diabetes Obes Metab. 2007 May;9(3):300-3.
DML2NIB	RU	https://pubmed.ncbi.nlm.nih.gov/17391155

DMENSL5	DI	DMENSL5
DMENSL5	DN	Aminosalicylic acid
DMENSL5	MI	TTYZVDJ
DMENSL5	MN	Dihydrofolate reductase (DHFR)
DMENSL5	MT	DTT
DMENSL5	MA	Modulator
DMENSL5	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMENSL5	RU	https://www.fda.gov/

DMENSL5	DI	DMENSL5
DMENSL5	DN	Aminosalicylic acid
DMENSL5	MI	DER7TA0
DMENSL5	MN	N-acetyltransferase 2 (NAT2)
DMENSL5	MT	DME
DMENSL5	MA	Metabolism
DMENSL5	RN	Importance of the evaluation of N-acetyltransferase enzyme activity prior to 5-aminosalicylic acid medication for ulcerative colitis. Inflamm Bowel Dis. 2016 Aug;22(8):1793-802.
DMENSL5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27416043

DMENSL5	DI	DMENSL5
DMENSL5	DN	Aminosalicylic acid
DMENSL5	MI	TT8NGED
DMENSL5	MN	Prostaglandin G/H synthase 1 (COX-1)
DMENSL5	MT	DTT
DMENSL5	MA	Modulator
DMENSL5	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMENSL5	RU	https://www.fda.gov/

DMENSL5	DI	DMENSL5
DMENSL5	DN	Aminosalicylic acid
DMENSL5	MI	TTVKILB
DMENSL5	MN	Prostaglandin G/H synthase 2 (COX-2)
DMENSL5	MT	DTT
DMENSL5	MA	Modulator
DMENSL5	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMENSL5	RU	https://www.fda.gov/

DMENSL5	DI	DMENSL5
DMENSL5	DN	Aminosalicylic acid
DMENSL5	MI	DTKWJH3
DMENSL5	MN	Sodium-coupled neutral amino acid transporter 3 (SLC38A3)
DMENSL5	MT	DTP
DMENSL5	MA	Substrate
DMENSL5	RN	Identification of amino acids imparting acceptor substrate selectivity to human arylamine acetyltransferases NAT1 and NAT2. Biochem J. 2000 May 15;348 Pt 1:159-66.
DMENSL5	RU	http://www.ncbi.nlm.nih.gov/pubmed/10794727

DMUTEX3	DI	DMUTEX3
DMUTEX3	DN	Amiodarone
DMUTEX3	MI	DE6OQ3W
DMUTEX3	MN	Cytochrome P450 1A1 (CYP1A1)
DMUTEX3	MT	DME
DMUTEX3	MA	Metabolism
DMUTEX3	RN	A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos. 2000 Nov;28(11):1303-10.
DMUTEX3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11038157

DMUTEX3	DI	DMUTEX3
DMUTEX3	DN	Amiodarone
DMUTEX3	MI	DEJGDUW
DMUTEX3	MN	Cytochrome P450 1A2 (CYP1A2)
DMUTEX3	MT	DME
DMUTEX3	MA	Metabolism
DMUTEX3	RN	Role of desethylamiodarone in the anticoagulant effect of concurrent amiodarone and warfarin therapy. J Cardiovasc Pharmacol Ther. 2001 Oct;6(4):363-7.
DMUTEX3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11907638

DMUTEX3	DI	DMUTEX3
DMUTEX3	DN	Amiodarone
DMUTEX3	MI	DES5XRU
DMUTEX3	MN	Cytochrome P450 2C8 (CYP2C8)
DMUTEX3	MT	DME
DMUTEX3	MA	Metabolism
DMUTEX3	RN	Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population. Drug Metab Dispos. 2005 May;33(5):630-6.
DMUTEX3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15716363

DMUTEX3	DI	DMUTEX3
DMUTEX3	DN	Amiodarone
DMUTEX3	MI	DE5IED8
DMUTEX3	MN	Cytochrome P450 2C9 (CYP2C9)
DMUTEX3	MT	DME
DMUTEX3	MA	Metabolism
DMUTEX3	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMUTEX3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMUTEX3	DI	DMUTEX3
DMUTEX3	DN	Amiodarone
DMUTEX3	MI	DECB0K3
DMUTEX3	MN	Cytochrome P450 2D6 (CYP2D6)
DMUTEX3	MT	DME
DMUTEX3	MA	Metabolism
DMUTEX3	RN	Potentially significant drug interactions of class III antiarrhythmic drugs. Drug Saf. 2003;26(6):421-38.
DMUTEX3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12688833

DMUTEX3	DI	DMUTEX3
DMUTEX3	DN	Amiodarone
DMUTEX3	MI	DE4LYSA
DMUTEX3	MN	Cytochrome P450 3A4 (CYP3A4)
DMUTEX3	MT	DME
DMUTEX3	MA	Metabolism
DMUTEX3	RN	The metabolism of amiodarone by various CYP isoenzymes of human and rat, and the inhibitory influence of ketoconazole. J Pharm Pharm Sci. 2008;11(1):147-59.
DMUTEX3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18445370

DMUTEX3	DI	DMUTEX3
DMUTEX3	DN	Amiodarone
DMUTEX3	MI	DEGTFWK
DMUTEX3	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMUTEX3	MT	DME
DMUTEX3	MA	Metabolism
DMUTEX3	RN	A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos. 2000 Nov;28(11):1303-10.
DMUTEX3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11038157

DMUTEX3	DI	DMUTEX3
DMUTEX3	DN	Amiodarone
DMUTEX3	MI	DTUGYRD
DMUTEX3	MN	P-glycoprotein 1 (ABCB1)
DMUTEX3	MT	DTP
DMUTEX3	MA	Substrate
DMUTEX3	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMUTEX3	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMUTEX3	DI	DMUTEX3
DMUTEX3	DN	Amiodarone
DMUTEX3	MI	TT1VOHK
DMUTEX3	MN	Potassium channel unspecific (KC)
DMUTEX3	MT	DTT
DMUTEX3	MA	Modulator
DMUTEX3	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMUTEX3	RU	https://www.fda.gov/

DMSJVAM	DI	DMSJVAM
DMSJVAM	DN	Amisulpride
DMSJVAM	MI	TTEX248
DMSJVAM	MN	Dopamine D2 receptor (D2R)
DMSJVAM	MT	DTT
DMSJVAM	MA	Antagonist
DMSJVAM	RN	Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20(5):389-409.
DMSJVAM	RU	https://pubmed.ncbi.nlm.nih.gov/16696579

DMSJVAM	DI	DMSJVAM
DMSJVAM	DN	Amisulpride
DMSJVAM	MI	DTUGYRD
DMSJVAM	MN	P-glycoprotein 1 (ABCB1)
DMSJVAM	MT	DTP
DMSJVAM	MA	Substrate
DMSJVAM	RN	Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
DMSJVAM	RU	http://www.ncbi.nlm.nih.gov/pubmed/15285840

DMK7F9S	DI	DMK7F9S
DMK7F9S	DN	Amitriptyline
DMK7F9S	MI	DEJGDUW
DMK7F9S	MN	Cytochrome P450 1A2 (CYP1A2)
DMK7F9S	MT	DME
DMK7F9S	MA	Metabolism
DMK7F9S	RN	The genetic profiles of CYP1A1, CYP1A2 and CYP2E1 enzymes as susceptibility factor in xenobiotic toxicity in Turkish population. Saudi Pharm J. 2017 Feb;25(2):294-297.
DMK7F9S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28344482

DMK7F9S	DI	DMK7F9S
DMK7F9S	DN	Amitriptyline
DMK7F9S	MI	DEPKLMQ
DMK7F9S	MN	Cytochrome P450 2B6 (CYP2B6)
DMK7F9S	MT	DME
DMK7F9S	MA	Metabolism
DMK7F9S	RN	Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
DMK7F9S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11259560

DMK7F9S	DI	DMK7F9S
DMK7F9S	DN	Amitriptyline
DMK7F9S	MI	DES5XRU
DMK7F9S	MN	Cytochrome P450 2C8 (CYP2C8)
DMK7F9S	MT	DME
DMK7F9S	MA	Metabolism
DMK7F9S	RN	The xenobiotic inhibitor profile of cytochrome P4502C8. Br J Clin Pharmacol. 2000 Dec;50(6):573-80.
DMK7F9S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11136296

DMK7F9S	DI	DMK7F9S
DMK7F9S	DN	Amitriptyline
DMK7F9S	MI	DE5IED8
DMK7F9S	MN	Cytochrome P450 2C9 (CYP2C9)
DMK7F9S	MT	DME
DMK7F9S	MA	Metabolism
DMK7F9S	RN	Cytochromes P450 mediating the N-demethylation of amitriptyline. Br J Clin Pharmacol. 1997 Feb;43(2):137-44.
DMK7F9S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9131945

DMK7F9S	DI	DMK7F9S
DMK7F9S	DN	Amitriptyline
DMK7F9S	MI	DECB0K3
DMK7F9S	MN	Cytochrome P450 2D6 (CYP2D6)
DMK7F9S	MT	DME
DMK7F9S	MA	Metabolism
DMK7F9S	RN	Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67.
DMK7F9S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18359012

DMK7F9S	DI	DMK7F9S
DMK7F9S	DN	Amitriptyline
DMK7F9S	MI	DEVDYN7
DMK7F9S	MN	Cytochrome P450 2E1 (CYP2E1)
DMK7F9S	MT	DME
DMK7F9S	MA	Metabolism
DMK7F9S	RN	Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4. J Clin Pharmacol. 1998 Feb;38(2):112-21.
DMK7F9S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9549641

DMK7F9S	DI	DMK7F9S
DMK7F9S	DN	Amitriptyline
DMK7F9S	MI	DE4LYSA
DMK7F9S	MN	Cytochrome P450 3A4 (CYP3A4)
DMK7F9S	MT	DME
DMK7F9S	MA	Metabolism
DMK7F9S	RN	Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67.
DMK7F9S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18359012

DMK7F9S	DI	DMK7F9S
DMK7F9S	DN	Amitriptyline
DMK7F9S	MI	DEIBDNY
DMK7F9S	MN	Cytochrome P450 3A5 (CYP3A5)
DMK7F9S	MT	DME
DMK7F9S	MA	Metabolism
DMK7F9S	RN	Effects of cytochrome b(5) on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7. Biochem Pharmacol. 2003 Dec 15;66(12):2333-40.
DMK7F9S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14637191

DMK7F9S	DI	DMK7F9S
DMK7F9S	DN	Amitriptyline
DMK7F9S	MI	DEGTFWK
DMK7F9S	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMK7F9S	MT	DME
DMK7F9S	MA	Metabolism
DMK7F9S	RN	A study on CYP2C19 and CYP2D6 polymorphic effects on pharmacokinetics and pharmacodynamics of amitriptyline in healthy Koreans. Clin Transl Sci. 2017 Mar;10(2):93-101.
DMK7F9S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28296334

DMK7F9S	DI	DMK7F9S
DMK7F9S	DN	Amitriptyline
DMK7F9S	MI	TTAWNKZ
DMK7F9S	MN	Norepinephrine transporter (NET)
DMK7F9S	MT	DTT
DMK7F9S	MA	Inhibitor
DMK7F9S	RN	Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
DMK7F9S	RU	https://pubmed.ncbi.nlm.nih.gov/18622371

DMK7F9S	DI	DMK7F9S
DMK7F9S	DN	Amitriptyline
DMK7F9S	MI	DTUGYRD
DMK7F9S	MN	P-glycoprotein 1 (ABCB1)
DMK7F9S	MT	DTP
DMK7F9S	MA	Substrate
DMK7F9S	RN	Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22.
DMK7F9S	RU	http://www.ncbi.nlm.nih.gov/pubmed/12954186

DMK7F9S	DI	DMK7F9S
DMK7F9S	DN	Amitriptyline
DMK7F9S	MI	TT3ROYC
DMK7F9S	MN	Serotonin transporter (SERT)
DMK7F9S	MT	DTT
DMK7F9S	MA	Inhibitor
DMK7F9S	RN	Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
DMK7F9S	RU	https://pubmed.ncbi.nlm.nih.gov/18622371

DMK7F9S	DI	DMK7F9S
DMK7F9S	DN	Amitriptyline
DMK7F9S	MI	DEYGVN4
DMK7F9S	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMK7F9S	MT	DME
DMK7F9S	MA	Metabolism
DMK7F9S	RN	Liquid chromatography-tandem mass spectrometry method for measurement of nicotine N-glucuronide: a marker for human UGT2B10 inhibition. J Pharm Biomed Anal. 2011 Jul 15;55(5):964-71.
DMK7F9S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21497036

DM0DQM5	DI	DM0DQM5
DM0DQM5	DN	Amlexanox
DM0DQM5	MI	TT78R5H
DM0DQM5	MN	Heat shock protein 90 alpha (HSP90A)
DM0DQM5	MT	DTT
DM0DQM5	MA	Inhibitor
DM0DQM5	RN	Hsp90 is a direct target of the anti-allergic drugs disodium cromoglycate and amlexanox. Biochem J. 2003 Sep 1;374(Pt 2):433-41.
DM0DQM5	RU	https://pubmed.ncbi.nlm.nih.gov/12803546

DMBDAZV	DI	DMBDAZV
DMBDAZV	DN	Amlodipine
DMBDAZV	MI	DE4LYSA
DMBDAZV	MN	Cytochrome P450 3A4 (CYP3A4)
DMBDAZV	MT	DME
DMBDAZV	MA	Metabolism
DMBDAZV	RN	Amlodipine metabolism in human liver microsomes and roles of CYP3A4/5 in the dihydropyridine dehydrogenation. Drug Metab Dispos. 2014 Feb;42(2):245-9.
DMBDAZV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24301608

DMBDAZV	DI	DMBDAZV
DMBDAZV	DN	Amlodipine
DMBDAZV	MI	TTFK1JQ
DMBDAZV	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMBDAZV	MT	DTT
DMBDAZV	MA	Blocker
DMBDAZV	RN	A first drug combination for the treatment of arterial hypertension with a calcium channel antagonist (amlodipine besylate) and an angiotensin receptor blocker (valsartan): Exforge. Rev Med Liege. 2007 Nov;62(11):688-94.
DMBDAZV	RU	https://pubmed.ncbi.nlm.nih.gov/18217647

DMOEVK6	DI	DMOEVK6
DMOEVK6	DN	Ammonia
DMOEVK6	MI	DTU6IF7
DMOEVK6	MN	Ammonium transporter Rh type B (SLC42A2)
DMOEVK6	MT	DTP
DMOEVK6	MA	Substrate
DMOEVK6	RN	Functional analysis of human RhCG: comparison with E. coli ammonium transporter reveals similarities in the pore and differences in the vestibule. Am J Physiol Cell Physiol. 2009 Sep;297(3):C537-47.
DMOEVK6	RU	http://www.ncbi.nlm.nih.gov/pubmed/19553567

DMOEVK6	DI	DMOEVK6
DMOEVK6	DN	Ammonia
DMOEVK6	MI	DTF3LTV
DMOEVK6	MN	Ammonium transporter Rh type C (SLC42A3)
DMOEVK6	MT	DTP
DMOEVK6	MA	Substrate
DMOEVK6	RN	Functional analysis of human RhCG: comparison with E. coli ammonium transporter reveals similarities in the pore and differences in the vestibule. Am J Physiol Cell Physiol. 2009 Sep;297(3):C537-47.
DMOEVK6	RU	http://www.ncbi.nlm.nih.gov/pubmed/19553567

DMOEVK6	DI	DMOEVK6
DMOEVK6	DN	Ammonia
DMOEVK6	MI	DE5UC73
DMOEVK6	MN	Glutamine synthetase (GLUL)
DMOEVK6	MT	DME
DMOEVK6	MA	Metabolism
DMOEVK6	RN	Ammonia metabolism capacity of HepG2 cells with high expression of human glutamine synthetase. Hepatobiliary Pancreat Dis Int. 2008 Dec;7(6):621-7.
DMOEVK6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19073408

DM0GQ8N	DI	DM0GQ8N
DM0GQ8N	DN	Amobarbital
DM0GQ8N	MI	TT1MPAY
DM0GQ8N	MN	GABA(A) receptor alpha-1 (GABRA1)
DM0GQ8N	MT	DTT
DM0GQ8N	MA	Antagonist
DM0GQ8N	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DM0GQ8N	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DME4RA8	DI	DME4RA8
DME4RA8	DN	Amodiaquine
DME4RA8	MI	DE4OGUF
DME4RA8	MN	Cytochrome P450 102A1 (cyp102)
DME4RA8	MT	DME
DME4RA8	MA	Metabolism
DME4RA8	RN	The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities. Trends Biotechnol. 2007 Jul;25(7):289-98.
DME4RA8	RU	https://pubmed.ncbi.nlm.nih.gov/17532492

DME4RA8	DI	DME4RA8
DME4RA8	DN	Amodiaquine
DME4RA8	MI	DE6OQ3W
DME4RA8	MN	Cytochrome P450 1A1 (CYP1A1)
DME4RA8	MT	DME
DME4RA8	MA	Metabolism
DME4RA8	RN	Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther. 2002 Feb;300(2):399-407.
DME4RA8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11805197

DME4RA8	DI	DME4RA8
DME4RA8	DN	Amodiaquine
DME4RA8	MI	DE9QHP6
DME4RA8	MN	Cytochrome P450 1B1 (CYP1B1)
DME4RA8	MT	DME
DME4RA8	MA	Metabolism
DME4RA8	RN	Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther. 2002 Feb;300(2):399-407.
DME4RA8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11805197

DME4RA8	DI	DME4RA8
DME4RA8	DN	Amodiaquine
DME4RA8	MI	DES5XRU
DME4RA8	MN	Cytochrome P450 2C8 (CYP2C8)
DME4RA8	MT	DME
DME4RA8	MA	Metabolism
DME4RA8	RN	Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin Pharmacol Ther. 2007 Aug;82(2):197-203.
DME4RA8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17361129

DME4RA8	DI	DME4RA8
DME4RA8	DN	Amodiaquine
DME4RA8	MI	DERQ52Z
DME4RA8	MN	Glutathione S-transferase mu-4 (GSTM4)
DME4RA8	MT	DME
DME4RA8	MA	Metabolism
DME4RA8	RN	Human glutathione S-transferases- and NAD(P)H:quinone oxidoreductase 1-catalyzed inactivation of reactive quinoneimines of amodiaquine and N-desethylamodiaquine: possible implications for susceptibility to amodiaquine-induced liver toxicity. Toxicol Lett. 2017 Jun 5;275:83-91.
DME4RA8	RU	https://pubmed.ncbi.nlm.nih.gov/28478157

DME4RA8	DI	DME4RA8
DME4RA8	DN	Amodiaquine
DME4RA8	MI	TT2B6EV
DME4RA8	MN	Histamine N-methyltransferase (HNMT)
DME4RA8	MT	DTT
DME4RA8	MA	Inhibitor
DME4RA8	RN	Effect of amodiaquine, a histamine N-methyltransferase inhibitor, on, Propionibacterium acnes and lipopolysaccharide-induced hepatitis in mice. Eur J Pharmacol. 2007 Mar 8;558(1-3):179-84.
DME4RA8	RU	https://pubmed.ncbi.nlm.nih.gov/17222819

DML8QSZ	DI	DML8QSZ
DML8QSZ	DN	Amosulalol
DML8QSZ	MI	TT2NUT5
DML8QSZ	MN	Adrenergic receptor alpha-2C (ADRA2C)
DML8QSZ	MT	DTT
DML8QSZ	MA	Modulator
DML8QSZ	RN	Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5.
DML8QSZ	RU	https://pubmed.ncbi.nlm.nih.gov/8095542

DML8QSZ	DI	DML8QSZ
DML8QSZ	DN	Amosulalol
DML8QSZ	MI	TTMXGCW
DML8QSZ	MN	Adrenergic receptor beta-3 (ADRB3)
DML8QSZ	MT	DTT
DML8QSZ	MA	Modulator
DML8QSZ	RN	Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5.
DML8QSZ	RU	https://pubmed.ncbi.nlm.nih.gov/8095542

DMKITQE	DI	DMKITQE
DMKITQE	DN	Amoxapine
DMKITQE	MI	DECB0K3
DMKITQE	MN	Cytochrome P450 2D6 (CYP2D6)
DMKITQE	MT	DME
DMKITQE	MA	Metabolism
DMKITQE	RN	Addition of amoxapine improves positive and negative symptoms in a patient with schizophrenia. Ther Adv Psychopharmacol. 2013 Dec;3(6):340-2.
DMKITQE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24294487

DMKITQE	DI	DMKITQE
DMKITQE	DN	Amoxapine
DMKITQE	MI	TTAWNKZ
DMKITQE	MN	Norepinephrine transporter (NET)
DMKITQE	MT	DTT
DMKITQE	MA	Inhibitor
DMKITQE	RN	Effects of acute and chronic treatment with amoxapine and cericlamine on the sleep-wakefulness cycle in the rat. Neuropharmacology. 1994 Aug;33(8):1017-25.
DMKITQE	RU	https://pubmed.ncbi.nlm.nih.gov/7845548

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	TTXT4D5
DMUYNEI	MN	Bacterial Cell membrane (Bact CM)
DMUYNEI	MT	DTT
DMUYNEI	MA	Modulator
DMUYNEI	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMUYNEI	RU	https://www.fda.gov/

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DED0TBR
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Major phenylpropanoid-derived metabolites in the human gut can arise from microbial fermentation of protein. Mol Nutr Food Res. 2013 Mar;57(3):523-35.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/23349065

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEX8KJO
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	The prevalence of beta-lactamase producing bacteria in subgingival plaque and their sensitivity to Augmentin. Br J Oral Maxillofac Surg. 1990 Jun;28(3):180-4.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/1983762

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEAYSTX
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	ACI-1 beta-lactamase is widespread across human gut microbiomes in Negativicutes due to transposons harboured by tailed prophages. Environ Microbiol. 2018 Jun;20(6):2288-2300.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/30014616

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DERGEVU
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers. Antimicrob Agents Chemother. 1990 Aug;34(8):1546-50.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/2221864

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEV0KWQ
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Detection and characterization of beta-lactamase genes in subgingival bacteria from patients with refractory periodontitis. FEMS Microbiol Lett. 2005 Jan 15;242(2):319-24.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/15621454

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEQMISO
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers. Antimicrob Agents Chemother. 1990 Aug;34(8):1546-50.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/2221864

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEHFJ4G
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers. Antimicrob Agents Chemother. 1990 Aug;34(8):1546-50.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/2221864

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEHPJRC
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers. Antimicrob Agents Chemother. 1990 Aug;34(8):1546-50.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/2221864

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEITMS0
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	ACI-1 from Acidaminococcus fermentans: characterization of the first beta-lactamase in Anaerobic cocci. Antimicrob Agents Chemother. 2000 Nov;44(11):3144-9.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/11036038

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DET9I1W
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019 Sep;25(9):1156.e9-1156.e13.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/30802650

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DE7IH52
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Detection and characterization of beta-lactamase genes in subgingival bacteria from patients with refractory periodontitis. FEMS Microbiol Lett. 2005 Jan 15;242(2):319-24.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/15621454

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DENJ2SQ
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019 Sep;25(9):1156.e9-1156.e13.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/30802650

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DE5HV8P
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019 Sep;25(9):1156.e9-1156.e13.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/30802650

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DE47ARF
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Presence of the cfxA gene in Bacteroides distasonis. Res Microbiol. 2003 Jun;154(5):369-74.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/12837513

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEG2PK9
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019 Sep;25(9):1156.e9-1156.e13.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/30802650

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEWHJ7A
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019 Sep;25(9):1156.e9-1156.e13.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/30802650

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEU1RXB
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019 Sep;25(9):1156.e9-1156.e13.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/30802650

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DETDS7E
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Detection and characterization of beta-lactamase genes in subgingival bacteria from patients with refractory periodontitis. FEMS Microbiol Lett. 2005 Jan 15;242(2):319-24.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/15621454

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DE37FJH
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers. Antimicrob Agents Chemother. 1990 Aug;34(8):1546-50.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/2221864

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEC7JEF
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Detection and characterization of beta-lactamase genes in subgingival bacteria from patients with refractory periodontitis. FEMS Microbiol Lett. 2005 Jan 15;242(2):319-24.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/15621454

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEP7MN1
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Prevotella strains and lactamic resistance gene distribution in different oral environments of children with pulp necrosis. Int Endod J. 2018 Nov;51(11):1196-1204.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/29737548

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEAILCM
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Prevotella strains and lactamic resistance gene distribution in different oral environments of children with pulp necrosis. Int Endod J. 2018 Nov;51(11):1196-1204.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/29737548

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DET4XFN
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Detection and characterization of beta-lactamase genes in subgingival bacteria from patients with refractory periodontitis. FEMS Microbiol Lett. 2005 Jan 15;242(2):319-24.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/15621454

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEACNTL
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	IncU plasmid harbouring bla CTX-M-8 in multidrug-resistant Shigella sonnei in Brazil. J Glob Antimicrob Resist. 2018 Sep;14:99-100.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/29964206

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEE8742
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	High prevalence of beta-lactam and macrolide resistance genes in human oral Capnocytophaga species. J Antimicrob Chemother. 2014 Feb;69(2):381-4.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/24013195

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEY09SU
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Detection and characterization of beta-lactamase genes in subgingival bacteria from patients with refractory periodontitis. FEMS Microbiol Lett. 2005 Jan 15;242(2):319-24.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/15621454

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEQLVCA
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Prevotella strains and lactamic resistance gene distribution in different oral environments of children with pulp necrosis. Int Endod J. 2018 Nov;51(11):1196-1204.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/29737548

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DE2IL34
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	High prevalence of beta-lactam and macrolide resistance genes in human oral Capnocytophaga species. J Antimicrob Chemother. 2014 Feb;69(2):381-4.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/24013195

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DE1NJIW
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Yersinia enterocolitica and Photorhabdus asymbiotica beta-lactamases BlaA are exported by the twin-arginine translocation pathway. Int J Med Microbiol. 2013 Jan;303(1):16-24.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/23276548

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEDIMN9
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019 Sep;25(9):1156.e9-1156.e13.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/30802650

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEJ8X2W
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019 Sep;25(9):1156.e9-1156.e13.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/30802650

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEFEVNH
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	High prevalence of beta-lactam and macrolide resistance genes in human oral Capnocytophaga species. J Antimicrob Chemother. 2014 Feb;69(2):381-4.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/24013195

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEAPGXV
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Detection and characterization of beta-lactamase genes in subgingival bacteria from patients with refractory periodontitis. FEMS Microbiol Lett. 2005 Jan 15;242(2):319-24.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/15621454

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DE0PDVC
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	High prevalence of beta-lactam and macrolide resistance genes in human oral Capnocytophaga species. J Antimicrob Chemother. 2014 Feb;69(2):381-4.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/24013195

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEQL32N
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	High prevalence of beta-lactam and macrolide resistance genes in human oral Capnocytophaga species. J Antimicrob Chemother. 2014 Feb;69(2):381-4.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/24013195

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DE9HF0I
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019 Sep;25(9):1156.e9-1156.e13.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/30802650

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DESHI6O
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019 Sep;25(9):1156.e9-1156.e13.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/30802650

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEZS3N4
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Detection and characterization of beta-lactamase genes in subgingival bacteria from patients with refractory periodontitis. FEMS Microbiol Lett. 2005 Jan 15;242(2):319-24.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/15621454

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DE5NSUX
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Detection and characterization of beta-lactamase genes in subgingival bacteria from patients with refractory periodontitis. FEMS Microbiol Lett. 2005 Jan 15;242(2):319-24.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/15621454

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEW193R
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Interspecies dissemination of a mobilizable plasmid harboring blaIMP-19 and the possibility of horizontal gene transfer in a single patient. Antimicrob Agents Chemother. 2016 Aug 22;60(9):5412-9.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/27381397

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEQ1CTE
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	High prevalence of cfxA beta-lactamase in aminopenicillin-resistant Prevotella strains isolated from periodontal pockets. Oral Microbiol Immunol. 2002 Apr;17(2):85-8.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/11929554

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEGTFWK
DMUYNEI	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
DMUYNEI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14696516

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEPCQ12
DMUYNEI	MN	Metallo-beta-lactamase (blaM)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Interspecies dissemination of a mobilizable plasmid harboring blaIMP-19 and the possibility of horizontal gene transfer in a single patient. Antimicrob Agents Chemother. 2016 Aug 22;60(9):5412-9.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/27381397

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEK9VG2
DMUYNEI	MN	Metallo-beta-lactamase (blaM)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Interspecies dissemination of a mobilizable plasmid harboring blaIMP-19 and the possibility of horizontal gene transfer in a single patient. Antimicrob Agents Chemother. 2016 Aug 22;60(9):5412-9.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/27381397

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEIU0XN
DMUYNEI	MN	N-acylhomoserine lactone acylase (lacA)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	A novel quorum-quenching N-acylhomoserine lactone acylase from Acidovorax sp. strain MR-S7 mediates antibiotic resistance. Appl Environ Microbiol. 2017 Jun 16;83(13). pii: e00080-17.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/28455333

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEBGCYQ
DMUYNEI	MN	New delhi metallo-beta-lactamase NDM-1 (blaNDM)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Genomic characterization of an extensively-drug resistance Salmonella enterica serotype Indiana strain harboring bla NDM-1 gene isolated from a chicken carcass in China. Microbiol Res. 2017 Nov;204:48-54.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/28870291

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DTQ23VB
DMUYNEI	MN	Organic anion transporter 1 (SLC22A6)
DMUYNEI	MT	DTP
DMUYNEI	MA	Substrate
DMUYNEI	RN	The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab Dispos. 2002 Jan;30(1):13-9.
DMUYNEI	RU	http://www.ncbi.nlm.nih.gov/pubmed/11744606

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DT9G7XN
DMUYNEI	MN	Peptide transporter 1 (SLC15A1)
DMUYNEI	MT	DTP
DMUYNEI	MA	Substrate
DMUYNEI	RN	Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab Dispos. 2006 Apr;34(4):547-55.
DMUYNEI	RU	http://www.ncbi.nlm.nih.gov/pubmed/16434549

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DT8QKNP
DMUYNEI	MN	Peptide transporter 2 (SLC15A2)
DMUYNEI	MT	DTP
DMUYNEI	MA	Substrate
DMUYNEI	RN	Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab Dispos. 2006 Apr;34(4):547-55.
DMUYNEI	RU	http://www.ncbi.nlm.nih.gov/pubmed/16434549

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DTUGYRD
DMUYNEI	MN	P-glycoprotein 1 (ABCB1)
DMUYNEI	MT	DTP
DMUYNEI	MA	Substrate
DMUYNEI	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMUYNEI	RU	https://doi.org/10.1007/s11095-012-0935-x

DMSZQAK	DI	DMSZQAK
DMSZQAK	DN	Amphetamine
DMSZQAK	MI	DECB0K3
DMSZQAK	MN	Cytochrome P450 2D6 (CYP2D6)
DMSZQAK	MT	DME
DMSZQAK	MA	Metabolism
DMSZQAK	RN	Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives. Xenobiotica. 1999 Jul;29(7):719-32.
DMSZQAK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10456690

DMSZQAK	DI	DMSZQAK
DMSZQAK	DN	Amphetamine
DMSZQAK	MI	DT6201N
DMSZQAK	MN	Organic cation transporter 3 (SLC22A3)
DMSZQAK	MT	DTP
DMSZQAK	MA	Substrate
DMSZQAK	RN	Interaction of organic cation transporter 3 (SLC22A3) and amphetamine. J Neurochem. 2010 Jul;114(1):142-9.
DMSZQAK	RU	http://www.ncbi.nlm.nih.gov/pubmed/20402963

DMSZQAK	DI	DMSZQAK
DMSZQAK	DN	Amphetamine
DMSZQAK	MI	DT3HUVD
DMSZQAK	MN	Organic cation/carnitine transporter 2 (SLC22A5)
DMSZQAK	MT	DTP
DMSZQAK	MA	Substrate
DMSZQAK	RN	Novel organic cation transporter 2-mediated carnitine uptake in placental choriocarcinoma (BeWo) cells. J Pharmacol Exp Ther. 2005 Jan;312(1):192-8.
DMSZQAK	RU	http://www.ncbi.nlm.nih.gov/pubmed/15316089

DMSZQAK	DI	DMSZQAK
DMSZQAK	DN	Amphetamine
DMSZQAK	MI	DT3BA8L
DMSZQAK	MN	Sodium-dependent dopamine transporter (SLC6A3)
DMSZQAK	MT	DTP
DMSZQAK	MA	Substrate
DMSZQAK	RN	Amphetamines, new psychoactive drugs and the monoamine transporter cycle. Trends Pharmacol Sci. 2015 Jan;36(1):41-50.
DMSZQAK	RU	http://www.ncbi.nlm.nih.gov/pubmed/25542076

DMSZQAK	DI	DMSZQAK
DMSZQAK	DN	Amphetamine
DMSZQAK	MI	DT9JBVI
DMSZQAK	MN	Sodium-dependent noradrenaline transporter (SLC6A2)
DMSZQAK	MT	DTP
DMSZQAK	MA	Substrate
DMSZQAK	RN	Amphetamines, new psychoactive drugs and the monoamine transporter cycle. Trends Pharmacol Sci. 2015 Jan;36(1):41-50.
DMSZQAK	RU	http://www.ncbi.nlm.nih.gov/pubmed/25542076

DMSZQAK	DI	DMSZQAK
DMSZQAK	DN	Amphetamine
DMSZQAK	MI	TTIU98M
DMSZQAK	MN	Trace amine-associated receptor-1 (TAAR1)
DMSZQAK	MT	DTT
DMSZQAK	MA	Modulator
DMSZQAK	RN	Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes. Neuropharmacology. 2014 Oct;85:499-507.
DMSZQAK	RU	https://pubmed.ncbi.nlm.nih.gov/24950453

DMSZQAK	DI	DMSZQAK
DMSZQAK	DN	Amphetamine
DMSZQAK	MI	DEB3TNR
DMSZQAK	MN	Tyramine oxidase (tynA)
DMSZQAK	MT	DME
DMSZQAK	MA	Metabolism
DMSZQAK	RN	Mechanistic elucidation of amphetamine metabolism by tyramine oxidase from human gut microbiota using molecular dynamics simulations. J Cell Biochem. 2019 Jan 30.
DMSZQAK	RU	https://pubmed.ncbi.nlm.nih.gov/30701587

DMTAJQE	DI	DMTAJQE
DMTAJQE	DN	Amphotericin B
DMTAJQE	MI	TTQKWA4
DMTAJQE	MN	Fungal Cell membrane ergosterol (Fung CME)
DMTAJQE	MT	DTT
DMTAJQE	MA	Modulator
DMTAJQE	RN	Comparative molecular dynamics simulations of amphotericin B-cholesterol/ergosterol membrane channels. Biochim Biophys Acta. 2002 Dec 23;1567(1-2):63-78.
DMTAJQE	RU	https://pubmed.ncbi.nlm.nih.gov/12488039

DMTAJQE	DI	DMTAJQE
DMTAJQE	DN	Amphotericin B
DMTAJQE	MI	DTUGYRD
DMTAJQE	MN	P-glycoprotein 1 (ABCB1)
DMTAJQE	MT	DTP
DMTAJQE	MA	Substrate
DMTAJQE	RN	Carotenoids reverse multidrug resistance in cancer cells by interfering with ABC-transporters. Phytomedicine. 2012 Aug 15;19(11):977-87.
DMTAJQE	RU	https://doi.org/10.1016/j.phymed.2012.05.010

DMHWE7P	DI	DMHWE7P
DMHWE7P	DN	Ampicillin
DMHWE7P	MI	DERI7LO
DMHWE7P	MN	AmpC beta-lactamase (ampC)
DMHWE7P	MT	DME
DMHWE7P	MA	Metabolism
DMHWE7P	RN	Characterization of the AmpC beta-Lactamase from Burkholderia multivorans. Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e01140-18.
DMHWE7P	RU	https://pubmed.ncbi.nlm.nih.gov/30012762

DMHWE7P	DI	DMHWE7P
DMHWE7P	DN	Ampicillin
DMHWE7P	MI	TTJP4SM
DMHWE7P	MN	Bacterial Penicillin binding protein (Bact PBP)
DMHWE7P	MT	DTT
DMHWE7P	MA	Binder
DMHWE7P	RN	Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci. Antimicrob Agents Chemother. 2002 May;46(5):1273-80.
DMHWE7P	RU	https://pubmed.ncbi.nlm.nih.gov/11959556

DMHWE7P	DI	DMHWE7P
DMHWE7P	DN	Ampicillin
DMHWE7P	MI	DET9I1W
DMHWE7P	MN	Beta-lactamase (blaB)
DMHWE7P	MT	DME
DMHWE7P	MA	Metabolism
DMHWE7P	RN	Purification and characterization of a new beta-lactamase from Bacteroides uniformis. Antimicrob Agents Chemother. 1995 Jul;39(7):1458-61.
DMHWE7P	RU	https://pubmed.ncbi.nlm.nih.gov/7492085

DMHWE7P	DI	DMHWE7P
DMHWE7P	DN	Ampicillin
DMHWE7P	MI	DE3FVRW
DMHWE7P	MN	Beta-lactamase (blaB)
DMHWE7P	MT	DME
DMHWE7P	MA	Metabolism
DMHWE7P	RN	Beta-lactamase production and antimicrobial susceptibility of subgingival bacteria from refractory periodontitis. Oral Microbiol Immunol. 2004 Oct;19(5):303-8.
DMHWE7P	RU	https://pubmed.ncbi.nlm.nih.gov/15327642

DMHWE7P	DI	DMHWE7P
DMHWE7P	DN	Ampicillin
DMHWE7P	MI	DETDS7E
DMHWE7P	MN	Beta-lactamase (blaB)
DMHWE7P	MT	DME
DMHWE7P	MA	Metabolism
DMHWE7P	RN	Beta-lactamase production and antimicrobial susceptibility of subgingival bacteria from refractory periodontitis. Oral Microbiol Immunol. 2004 Oct;19(5):303-8.
DMHWE7P	RU	https://pubmed.ncbi.nlm.nih.gov/15327642

DMHWE7P	DI	DMHWE7P
DMHWE7P	DN	Ampicillin
DMHWE7P	MI	DEQX0DG
DMHWE7P	MN	Beta-lactamase (blaB)
DMHWE7P	MT	DME
DMHWE7P	MA	Metabolism
DMHWE7P	RN	Beta-lactamase production and antimicrobial susceptibility of subgingival bacteria from refractory periodontitis. Oral Microbiol Immunol. 2004 Oct;19(5):303-8.
DMHWE7P	RU	https://pubmed.ncbi.nlm.nih.gov/15327642

DMHWE7P	DI	DMHWE7P
DMHWE7P	DN	Ampicillin
DMHWE7P	MI	DEC7JEF
DMHWE7P	MN	Beta-lactamase (blaB)
DMHWE7P	MT	DME
DMHWE7P	MA	Metabolism
DMHWE7P	RN	Beta-lactamase production and antimicrobial susceptibility of subgingival bacteria from refractory periodontitis. Oral Microbiol Immunol. 2004 Oct;19(5):303-8.
DMHWE7P	RU	https://pubmed.ncbi.nlm.nih.gov/15327642

DMHWE7P	DI	DMHWE7P
DMHWE7P	DN	Ampicillin
DMHWE7P	MI	DEXB2A9
DMHWE7P	MN	Beta-lactamase (blaB)
DMHWE7P	MT	DME
DMHWE7P	MA	Metabolism
DMHWE7P	RN	Beta-lactamase expression in Plesiomonas shigelloides. J Antimicrob Chemother. 2000 Jun;45(6):877-80.
DMHWE7P	RU	https://pubmed.ncbi.nlm.nih.gov/10837443

DMHWE7P	DI	DMHWE7P
DMHWE7P	DN	Ampicillin
DMHWE7P	MI	DEBKS91
DMHWE7P	MN	Beta-lactamase (blaB)
DMHWE7P	MT	DME
DMHWE7P	MA	Metabolism
DMHWE7P	RN	Drug-resistant genes carried by Acinetobacter baumanii isolated from patients with lower respiratory tract infection. Chin Med J (Engl). 2010 Sep;123(18):2571-5.
DMHWE7P	RU	https://pubmed.ncbi.nlm.nih.gov/21034630

DMHWE7P	DI	DMHWE7P
DMHWE7P	DN	Ampicillin
DMHWE7P	MI	DEWMGC3
DMHWE7P	MN	Beta-lactamase (blaB)
DMHWE7P	MT	DME
DMHWE7P	MA	Metabolism
DMHWE7P	RN	Beta-lactamase production and antimicrobial susceptibility of subgingival bacteria from refractory periodontitis. Oral Microbiol Immunol. 2004 Oct;19(5):303-8.
DMHWE7P	RU	https://pubmed.ncbi.nlm.nih.gov/15327642

DMHWE7P	DI	DMHWE7P
DMHWE7P	DN	Ampicillin
DMHWE7P	MI	DEWYT5M
DMHWE7P	MN	Beta-lactamase (blaB)
DMHWE7P	MT	DME
DMHWE7P	MA	Metabolism
DMHWE7P	RN	Beta-lactamase production and antimicrobial susceptibility of subgingival bacteria from refractory periodontitis. Oral Microbiol Immunol. 2004 Oct;19(5):303-8.
DMHWE7P	RU	https://pubmed.ncbi.nlm.nih.gov/15327642

DMHWE7P	DI	DMHWE7P
DMHWE7P	DN	Ampicillin
DMHWE7P	MI	DE52KD0
DMHWE7P	MN	Beta-lactamase (blaB)
DMHWE7P	MT	DME
DMHWE7P	MA	Metabolism
DMHWE7P	RN	Beta-lactamase production and antimicrobial susceptibility of subgingival bacteria from refractory periodontitis. Oral Microbiol Immunol. 2004 Oct;19(5):303-8.
DMHWE7P	RU	https://pubmed.ncbi.nlm.nih.gov/15327642

DMHWE7P	DI	DMHWE7P
DMHWE7P	DN	Ampicillin
DMHWE7P	MI	DEG5Y4W
DMHWE7P	MN	Beta-lactamase (blaB)
DMHWE7P	MT	DME
DMHWE7P	MA	Metabolism
DMHWE7P	RN	Beta-lactamase production and antimicrobial susceptibility of subgingival bacteria from refractory periodontitis. Oral Microbiol Immunol. 2004 Oct;19(5):303-8.
DMHWE7P	RU	https://pubmed.ncbi.nlm.nih.gov/15327642

DMHWE7P	DI	DMHWE7P
DMHWE7P	DN	Ampicillin
DMHWE7P	MI	DTFI42L
DMHWE7P	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMHWE7P	MT	DTP
DMHWE7P	MA	Substrate
DMHWE7P	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMHWE7P	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMHWE7P	DI	DMHWE7P
DMHWE7P	DN	Ampicillin
DMHWE7P	MI	DEIU0XN
DMHWE7P	MN	N-acylhomoserine lactone acylase (lacA)
DMHWE7P	MT	DME
DMHWE7P	MA	Metabolism
DMHWE7P	RN	A novel quorum-quenching N-acylhomoserine lactone acylase from Acidovorax sp. strain MR-S7 mediates antibiotic resistance. Appl Environ Microbiol. 2017 Jun 16;83(13). pii: e00080-17.
DMHWE7P	RU	https://pubmed.ncbi.nlm.nih.gov/28455333

DMHWE7P	DI	DMHWE7P
DMHWE7P	DN	Ampicillin
DMHWE7P	MI	DT9G7XN
DMHWE7P	MN	Peptide transporter 1 (SLC15A1)
DMHWE7P	MT	DTP
DMHWE7P	MA	Substrate
DMHWE7P	RN	Several hPepT1-transported drugs are substrates of the Escherichia coli proton-coupled oligopeptide transporter YdgR. Res Microbiol. 2017 Jun;168(5):443-449.
DMHWE7P	RU	http://www.ncbi.nlm.nih.gov/pubmed/28214542

DMHWE7P	DI	DMHWE7P
DMHWE7P	DN	Ampicillin
DMHWE7P	MI	DT8QKNP
DMHWE7P	MN	Peptide transporter 2 (SLC15A2)
DMHWE7P	MT	DTP
DMHWE7P	MA	Substrate
DMHWE7P	RN	Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60.
DMHWE7P	RU	http://www.ncbi.nlm.nih.gov/pubmed/16597710

DM5BS98	DI	DM5BS98
DM5BS98	DN	Ampiroxicam
DM5BS98	MI	TTK0943
DM5BS98	MN	Prostaglandin G/H synthase (COX)
DM5BS98	MT	DTT
DM5BS98	MA	Modulator
DM5BS98	RN	Premedication with cyclooxygenase-2 inhibitor meloxicam reduced postoperative pain in patients after oral surgery. Int J Oral Maxillofac Surg. 2006 Jul;35(7):613-7.
DM5BS98	RU	https://pubmed.ncbi.nlm.nih.gov/16540287

DMLMXE0	DI	DMLMXE0
DMLMXE0	DN	Amprenavir
DMLMXE0	MI	DE5IED8
DMLMXE0	MN	Cytochrome P450 2C9 (CYP2C9)
DMLMXE0	MT	DME
DMLMXE0	MA	Metabolism
DMLMXE0	RN	Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor. Clin Ther. 2000 May;22(5):549-72.
DMLMXE0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10868554

DMLMXE0	DI	DMLMXE0
DMLMXE0	DN	Amprenavir
DMLMXE0	MI	DECB0K3
DMLMXE0	MN	Cytochrome P450 2D6 (CYP2D6)
DMLMXE0	MT	DME
DMLMXE0	MA	Metabolism
DMLMXE0	RN	Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor. Clin Ther. 2000 May;22(5):549-72.
DMLMXE0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10868554

DMLMXE0	DI	DMLMXE0
DMLMXE0	DN	Amprenavir
DMLMXE0	MI	DE4LYSA
DMLMXE0	MN	Cytochrome P450 3A4 (CYP3A4)
DMLMXE0	MT	DME
DMLMXE0	MA	Metabolism
DMLMXE0	RN	Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):79-85.
DMLMXE0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16433896

DMLMXE0	DI	DMLMXE0
DMLMXE0	DN	Amprenavir
DMLMXE0	MI	DEIBDNY
DMLMXE0	MN	Cytochrome P450 3A5 (CYP3A5)
DMLMXE0	MT	DME
DMLMXE0	MA	Metabolism
DMLMXE0	RN	Oxidative metabolism of amprenavir in the human liver. Effect of the CYP3A maturation. Drug Metab Dispos. 2003 Mar;31(3):275-81.
DMLMXE0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12584153

DMLMXE0	DI	DMLMXE0
DMLMXE0	DN	Amprenavir
DMLMXE0	MI	TT5FNQT
DMLMXE0	MN	Human immunodeficiency virus Protease (HIV PR)
DMLMXE0	MT	DTT
DMLMXE0	MA	Inhibitor
DMLMXE0	RN	Darunavir: a review of its use in the management of HIV infection in adults. Drugs. 2009;69(4):477-503. 
DMLMXE0	RU	https://pubmed.ncbi.nlm.nih.gov/19323590

DMLMXE0	DI	DMLMXE0
DMLMXE0	DN	Amprenavir
DMLMXE0	MI	DTUGYRD
DMLMXE0	MN	P-glycoprotein 1 (ABCB1)
DMLMXE0	MT	DTP
DMLMXE0	MA	Substrate
DMLMXE0	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMLMXE0	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMZKYIV	DI	DMZKYIV
DMZKYIV	DN	Amsacrine
DMZKYIV	MI	DECB0K3
DMZKYIV	MN	Cytochrome P450 2D6 (CYP2D6)
DMZKYIV	MT	DME
DMZKYIV	MA	Metabolism
DMZKYIV	RN	Phase I pharmacokinetic study of the novel antitumor agent SR233377. Clin Cancer Res. 2000 Aug;6(8):3088-94.
DMZKYIV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10955788

DMZKYIV	DI	DMZKYIV
DMZKYIV	DN	Amsacrine
DMZKYIV	MI	TT0IHXV
DMZKYIV	MN	DNA topoisomerase II (TOP2)
DMZKYIV	MT	DTT
DMZKYIV	MA	Inhibitor
DMZKYIV	RN	Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity. Anticancer Drug Des. 2000 Dec;15(6):413-21.
DMZKYIV	RU	https://pubmed.ncbi.nlm.nih.gov/11716434

DMAWU35	DI	DMAWU35
DMAWU35	DN	Amtolmetin guacil
DMAWU35	MI	TTK0943
DMAWU35	MN	Prostaglandin G/H synthase (COX)
DMAWU35	MT	DTT
DMAWU35	MA	Modulator
DMAWU35	RN	Gastrointestinal safety of amtolmetin guacyl in comparison with celecoxib in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2005 Nov-Dec;23(6):809-18.
DMAWU35	RU	https://pubmed.ncbi.nlm.nih.gov/16396699

DMJKO05	DI	DMJKO05
DMJKO05	DN	Amyl nitrite
DMJKO05	MI	DEWYTJB
DMJKO05	MN	Aldehyde dehydrogenase 2 (ALDH2)
DMJKO05	MT	DME
DMJKO05	MA	Metabolism
DMJKO05	RN	Mitochondrial aldehyde dehydrogenase mediates vasodilator responses of glyceryl trinitrate and sodium nitrite in the pulmonary vascular bed of the rat. Am J Physiol Heart Circ Physiol. 2010 Sep;299(3):H819-26.
DMJKO05	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20543077

DMJKO05	DI	DMJKO05
DMJKO05	DN	Amyl nitrite
DMJKO05	MI	DE4ZHS1
DMJKO05	MN	Glutathione S-transferase alpha-1 (GSTA1)
DMJKO05	MT	DME
DMJKO05	MA	Metabolism
DMJKO05	RN	Subunit specificity and organ distribution of glutathione transferase-catalysed S-nitrosoglutathione formation from alkyl nitrites in the rat. Biochem Pharmacol. 1997 Jan 10;53(1):117-20.
DMJKO05	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8960071

DMJXIC9	DI	DMJXIC9
DMJXIC9	DN	Anagliptin
DMJXIC9	MI	TTDIGC1
DMJXIC9	MN	Dipeptidyl peptidase 4 (DPP-4)
DMJXIC9	MT	DTT
DMJXIC9	MA	Modulator
DMJXIC9	RN	Diabetes Treatment. Diabetes Care. 2009 March; 32(3): e25-e30.
DMJXIC9	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2646042/

DMSQ8MD	DI	DMSQ8MD
DMSQ8MD	DN	Anagrelide
DMSQ8MD	MI	DEJGDUW
DMSQ8MD	MN	Cytochrome P450 1A2 (CYP1A2)
DMSQ8MD	MT	DME
DMSQ8MD	MA	Metabolism
DMSQ8MD	RN	Open-label, dose-titration and continuation study to assess efficacy, safety, and pharmacokinetics of anagrelide in treatment-nae Japanese patients with essential thrombocythemia. Int J Hematol. 2013 Mar;97(3):360-8.
DMSQ8MD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23378182

DMSQ8MD	DI	DMSQ8MD
DMSQ8MD	DN	Anagrelide
DMSQ8MD	MI	TT06AWU
DMSQ8MD	MN	Phosphodiesterase 3A (PDE3A)
DMSQ8MD	MT	DTT
DMSQ8MD	MA	Inhibitor
DMSQ8MD	RN	Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45.
DMSQ8MD	RU	https://pubmed.ncbi.nlm.nih.gov/16000354

DMU8KOD	DI	DMU8KOD
DMU8KOD	DN	Anakinra
DMU8KOD	MI	TTWOTEA
DMU8KOD	MN	Interleukin 1 receptor type 1 (IL1R1)
DMU8KOD	MT	DTT
DMU8KOD	MA	Antagonist
DMU8KOD	RN	IL-1 receptor antagonism and muscle gene expression in patients with type 2 diabetes. Eur Cytokine Netw. 2009 Jun 1;20(2):81-87.
DMU8KOD	RU	https://pubmed.ncbi.nlm.nih.gov/19541594

DMV96ZH	DI	DMV96ZH
DMV96ZH	DN	Anapsos
DMV96ZH	MI	TTXL3MF
DMV96ZH	MN	Lymphoid cell adhesion molecule expression (LCDME)
DMV96ZH	MT	DTT
DMV96ZH	MA	Modulator
DMV96ZH	RN	Anapsos (Polypodium leucotomos) modulates lymphoid cells and the expression of adhesion molecules. Pharmacol Res. 2002 Aug;46(2):185-90.
DMV96ZH	RU	https://pubmed.ncbi.nlm.nih.gov/12220959

DMNP60F	DI	DMNP60F
DMNP60F	DN	Anastrozole
DMNP60F	MI	TTSZLWK
DMNP60F	MN	Aromatase (CYP19A1)
DMNP60F	MT	DTT
DMNP60F	MA	Inhibitor
DMNP60F	RN	Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright syndrome. J Pediatr Endocrinol Metab. 2002;15 Suppl 3:945-8.
DMNP60F	RU	https://pubmed.ncbi.nlm.nih.gov/12199354

DMNP60F	DI	DMNP60F
DMNP60F	DN	Anastrozole
DMNP60F	MI	DES5XRU
DMNP60F	MN	Cytochrome P450 2C8 (CYP2C8)
DMNP60F	MT	DME
DMNP60F	MA	Metabolism
DMNP60F	RN	In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol. 2010 Dec;70(6):854-69.
DMNP60F	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21175441

DMNP60F	DI	DMNP60F
DMNP60F	DN	Anastrozole
DMNP60F	MI	DE4LYSA
DMNP60F	MN	Cytochrome P450 3A4 (CYP3A4)
DMNP60F	MT	DME
DMNP60F	MA	Metabolism
DMNP60F	RN	In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol. 2010 Dec;70(6):854-69.
DMNP60F	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21175441

DMNP60F	DI	DMNP60F
DMNP60F	DN	Anastrozole
DMNP60F	MI	DEIBDNY
DMNP60F	MN	Cytochrome P450 3A5 (CYP3A5)
DMNP60F	MT	DME
DMNP60F	MA	Metabolism
DMNP60F	RN	In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol. 2010 Dec;70(6):854-69.
DMNP60F	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21175441

DMNP60F	DI	DMNP60F
DMNP60F	DN	Anastrozole
DMNP60F	MI	DT2EGUN
DMNP60F	MN	Putative sodium-coupled neutral amino acid transporter 7 (SLC38A7)
DMNP60F	MT	DTP
DMNP60F	MA	Substrate
DMNP60F	RN	Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPPL2. Clin Pharmacol Ther. 2019 Jan 16.
DMNP60F	RU	http://www.ncbi.nlm.nih.gov/pubmed/30648747

DMNP60F	DI	DMNP60F
DMNP60F	DN	Anastrozole
DMNP60F	MI	DEYGVN4
DMNP60F	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMNP60F	MT	DME
DMNP60F	MA	Metabolism
DMNP60F	RN	In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol. 2010 Dec;70(6):854-69.
DMNP60F	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21175441

DMNP60F	DI	DMNP60F
DMNP60F	DN	Anastrozole
DMNP60F	MI	DEF2WXN
DMNP60F	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMNP60F	MT	DME
DMNP60F	MA	Metabolism
DMNP60F	RN	In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol. 2010 Dec;70(6):854-69.
DMNP60F	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21175441

DMNP60F	DI	DMNP60F
DMNP60F	DN	Anastrozole
DMNP60F	MI	DEB3CV1
DMNP60F	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMNP60F	MT	DME
DMNP60F	MA	Metabolism
DMNP60F	RN	In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol. 2010 Dec;70(6):854-69.
DMNP60F	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21175441

DMLWQ27	DI	DMLWQ27
DMLWQ27	DN	Angiotensin Ii
DMLWQ27	MI	TT8DBY3
DMLWQ27	MN	Angiotensin II receptor type-1 (AGTR1)
DMLWQ27	MT	DTT
DMLWQ27	MA	Inhibitor
DMLWQ27	RN	The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1. J Med Chem. 2010 Mar 11;53(5):2063-75.
DMLWQ27	RU	https://pubmed.ncbi.nlm.nih.gov/20146480

DMLWQ27	DI	DMLWQ27
DMLWQ27	DN	Angiotensin Ii
DMLWQ27	MI	TTQVOEI
DMLWQ27	MN	Angiotensin II receptor type-2 (AGTR2)
DMLWQ27	MT	DTT
DMLWQ27	MA	Inhibitor
DMLWQ27	RN	The preparation of (perfluoroalkyl)imidazoles as nonpeptide angiotensin II receptor antagonists, Bioorg. Med. Chem. Lett. 3(5):895-898 (1993).
DMLWQ27	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00806885

DM8QM5U	DI	DM8QM5U
DM8QM5U	DN	Anidulafungin
DM8QM5U	MI	TT0SFXH
DM8QM5U	MN	Fungal 1,3-beta-glucan synthase (Fung GSC2)
DM8QM5U	MT	DTT
DM8QM5U	MA	Modulator
DM8QM5U	RN	2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
DM8QM5U	RU	https://pubmed.ncbi.nlm.nih.gov/17342860

DMBAUED	DI	DMBAUED
DMBAUED	DN	Anileridine
DMBAUED	MI	TTKWM86
DMBAUED	MN	Opioid receptor mu (MOP)
DMBAUED	MT	DTT
DMBAUED	MA	Agonist
DMBAUED	RN	Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
DMBAUED	RU	https://pubmed.ncbi.nlm.nih.gov/17016423

DMC128O	DI	DMC128O
DMC128O	DN	Anileridine Hydrochloride
DMC128O	MI	TTKWM86
DMC128O	MN	Opioid receptor mu (MOP)
DMC128O	MT	DTT
DMC128O	MA	Modulator
DMC128O	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMC128O	RU	https://www.fda.gov/

DMOIFW0	DI	DMOIFW0
DMOIFW0	DN	Aniracetam
DMOIFW0	MI	TTJQOD7
DMOIFW0	MN	5-HT 2A receptor (HTR2A)
DMOIFW0	MT	DTT
DMOIFW0	MA	Inhibitor
DMOIFW0	RN	Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
DMOIFW0	RU	https://pubmed.ncbi.nlm.nih.gov/11412837

DMOIFW0	DI	DMOIFW0
DMOIFW0	DN	Aniracetam
DMOIFW0	MI	TTEX248
DMOIFW0	MN	Dopamine D2 receptor (D2R)
DMOIFW0	MT	DTT
DMOIFW0	MA	Inhibitor
DMOIFW0	RN	Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
DMOIFW0	RU	https://pubmed.ncbi.nlm.nih.gov/11412837

DM2C48U	DI	DM2C48U
DM2C48U	DN	Anisindione
DM2C48U	MI	TT6L509
DM2C48U	MN	Coagulation factor IIa (F2)
DM2C48U	MT	DTT
DM2C48U	MA	Modulator
DM2C48U	RN	Anticoagulation with anisindione in a patient with a warfarin-induced skin eruption. Pharmacotherapy. 2003 Apr;23(4):533-6.
DM2C48U	RU	https://pubmed.ncbi.nlm.nih.gov/12680483

DMW51AX	DI	DMW51AX
DMW51AX	DN	Anisodamine
DMW51AX	MI	TTR6W5O
DMW51AX	MN	Adrenergic receptor beta-1 (ADRB1)
DMW51AX	MT	DTT
DMW51AX	MA	Modulator
DMW51AX	RN	Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81.
DMW51AX	RU	https://pubmed.ncbi.nlm.nih.gov/3879679

DMW51AX	DI	DMW51AX
DMW51AX	DN	Anisodamine
DMW51AX	MI	DECB0K3
DMW51AX	MN	Cytochrome P450 2D6 (CYP2D6)
DMW51AX	MT	DME
DMW51AX	MA	Metabolism
DMW51AX	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DMW51AX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DMNOSWU	DI	DMNOSWU
DMNOSWU	DN	Anisodine
DMNOSWU	MI	TTR6W5O
DMNOSWU	MN	Adrenergic receptor beta-1 (ADRB1)
DMNOSWU	MT	DTT
DMNOSWU	MA	Modulator
DMNOSWU	RN	Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81.
DMNOSWU	RU	https://pubmed.ncbi.nlm.nih.gov/3879679

DMNOSWU	DI	DMNOSWU
DMNOSWU	DN	Anisodine
DMNOSWU	MI	TTH18TF
DMNOSWU	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMNOSWU	MT	DTT
DMNOSWU	MA	Modulator
DMNOSWU	RN	Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81.
DMNOSWU	RU	https://pubmed.ncbi.nlm.nih.gov/3879679

DMIJRF0	DI	DMIJRF0
DMIJRF0	DN	Anisotropine Methylbromide
DMIJRF0	MI	TTH18TF
DMIJRF0	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMIJRF0	MT	DTT
DMIJRF0	MA	Binder
DMIJRF0	RN	Anisotropine methylbromide: a new antispasmodic for gastrointestinal disorders. Curr Ther Res Clin Exp. 1963 May;5:213-8.
DMIJRF0	RU	https://pubmed.ncbi.nlm.nih.gov/13966843

DM6Q4B0	DI	DM6Q4B0
DM6Q4B0	DN	Anistreplase
DM6Q4B0	MI	TTP86E2
DM6Q4B0	MN	Plasminogen (PLG)
DM6Q4B0	MT	DTT
DM6Q4B0	MA	Activator
DM6Q4B0	RN	Evaluation of thrombolytic agents. Drugs. 1997;54 Suppl 3:11-6; discussion 16-7.
DM6Q4B0	RU	https://pubmed.ncbi.nlm.nih.gov/9360848

DMUMOEV	DI	DMUMOEV
DMUMOEV	DN	Ansuvimab
DMUMOEV	MI	TT2F0AU
DMUMOEV	MN	Ebola virus Envelope glycoprotein (EV GP)
DMUMOEV	MT	DTT
DMUMOEV	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMUMOEV	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761172s000lbl.pdf

DMA04JS	DI	DMA04JS
DMA04JS	DN	Antazoline
DMA04JS	MI	TTTIBOJ
DMA04JS	MN	Histamine H1 receptor (H1R)
DMA04JS	MT	DTT
DMA04JS	MA	Antagonist
DMA04JS	RN	Histamine and the convulsive threshold or effectiveness of antiepileptic drugs. Przegl Lek. 2008;65(11):803-6.
DMA04JS	RU	https://pubmed.ncbi.nlm.nih.gov/19205365

DMNC64R	DI	DMNC64R
DMNC64R	DN	Antegren
DMNC64R	MI	TT4BT06
DMNC64R	MN	Integrin alpha-4 (ITGA4)
DMNC64R	MT	DTT
DMNC64R	RN	Very late antigen 4 (VLA4) antagonists as anti-inflammatory agents. Curr Opin Chem Biol. 1998 Aug;2(4):453-7.
DMNC64R	RU	https://pubmed.ncbi.nlm.nih.gov/9736917

DMH4CFE	DI	DMH4CFE
DMH4CFE	DN	Antithymocyte globulin
DMH4CFE	MI	TTBGTFN
DMH4CFE	MN	T-cell surface glycoprotein CD1a (CD1A)
DMH4CFE	MT	DTT
DMH4CFE	MA	Binder
DMH4CFE	RN	Acute sensory neuropathy associated with rabbit antithymocyte globulin. Am J Transplant. 2007 Feb;7(2):484-6.
DMH4CFE	RU	https://pubmed.ncbi.nlm.nih.gov/17283492

DM89JLN	DI	DM89JLN
DM89JLN	DN	Apixaban
DM89JLN	MI	DTI7UX6
DM89JLN	MN	Breast cancer resistance protein (ABCG2)
DM89JLN	MT	DTP
DM89JLN	MA	Substrate
DM89JLN	RN	Characterization of efflux transporters involved in distribution and disposition of apixaban. Drug Metab Dispos. 2013 Apr;41(4):827-35.
DM89JLN	RU	http://www.ncbi.nlm.nih.gov/pubmed/23382458

DM89JLN	DI	DM89JLN
DM89JLN	DN	Apixaban
DM89JLN	MI	TTCIHJA
DM89JLN	MN	Coagulation factor Xa (F10)
DM89JLN	MT	DTT
DM89JLN	MA	Inhibitor
DM89JLN	RN	Pfizer. Product Development Pipeline. March 31 2009.
DM89JLN	RU	http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf

DM89JLN	DI	DM89JLN
DM89JLN	DN	Apixaban
DM89JLN	MI	DEJGDUW
DM89JLN	MN	Cytochrome P450 1A2 (CYP1A2)
DM89JLN	MT	DME
DM89JLN	MA	Metabolism
DM89JLN	RN	Apixaban. Hosp Pharm. 2013 Jun;48(6):494-509.
DM89JLN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24421512

DM89JLN	DI	DM89JLN
DM89JLN	DN	Apixaban
DM89JLN	MI	DES5XRU
DM89JLN	MN	Cytochrome P450 2C8 (CYP2C8)
DM89JLN	MT	DME
DM89JLN	MA	Metabolism
DM89JLN	RN	Apixaban. Hosp Pharm. 2013 Jun;48(6):494-509.
DM89JLN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24421512

DM89JLN	DI	DM89JLN
DM89JLN	DN	Apixaban
DM89JLN	MI	DE5IED8
DM89JLN	MN	Cytochrome P450 2C9 (CYP2C9)
DM89JLN	MT	DME
DM89JLN	MA	Metabolism
DM89JLN	RN	Apixaban. Hosp Pharm. 2013 Jun;48(6):494-509.
DM89JLN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24421512

DM89JLN	DI	DM89JLN
DM89JLN	DN	Apixaban
DM89JLN	MI	DE4LYSA
DM89JLN	MN	Cytochrome P450 3A4 (CYP3A4)
DM89JLN	MT	DME
DM89JLN	MA	Metabolism
DM89JLN	RN	In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos. 2010 Mar;38(3):448-58.
DM89JLN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19940026

DM89JLN	DI	DM89JLN
DM89JLN	DN	Apixaban
DM89JLN	MI	DEIBDNY
DM89JLN	MN	Cytochrome P450 3A5 (CYP3A5)
DM89JLN	MT	DME
DM89JLN	MA	Metabolism
DM89JLN	RN	Apixaban. After hip or knee replacement: LMWH remains the standard treatment. Prescrire Int. 2012 Sep;21(130):201-2, 204.
DM89JLN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23016247

DM89JLN	DI	DM89JLN
DM89JLN	DN	Apixaban
DM89JLN	MI	DEGTFWK
DM89JLN	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM89JLN	MT	DME
DM89JLN	MA	Metabolism
DM89JLN	RN	Apixaban. Hosp Pharm. 2013 Jun;48(6):494-509.
DM89JLN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24421512

DM89JLN	DI	DM89JLN
DM89JLN	DN	Apixaban
DM89JLN	MI	DTUGYRD
DM89JLN	MN	P-glycoprotein 1 (ABCB1)
DM89JLN	MT	DTP
DM89JLN	MA	Substrate
DM89JLN	RN	Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa. Am J Cardiovasc Drugs. 2016 Apr;16(2):119-27.
DM89JLN	RU	http://www.ncbi.nlm.nih.gov/pubmed/26749408

DMX38HQ	DI	DMX38HQ
DMX38HQ	DN	Apomorphine
DMX38HQ	MI	TTEX248
DMX38HQ	MN	Dopamine D2 receptor (D2R)
DMX38HQ	MT	DTT
DMX38HQ	MA	Agonist
DMX38HQ	RN	Dopamine D(2/3) receptor occupancy of apomorphine in the nonhuman primate brain--a comparative PET study with [11C]raclopride and [11C]MNPA. Synapse. 2009 May;63(5):378-89.
DMX38HQ	RU	https://pubmed.ncbi.nlm.nih.gov/19173265

DMX38HQ	DI	DMX38HQ
DMX38HQ	DN	Apomorphine
DMX38HQ	MI	DEYWLRK
DMX38HQ	MN	Sulfotransferase 1A1 (SULT1A1)
DMX38HQ	MT	DME
DMX38HQ	MA	Metabolism
DMX38HQ	RN	Sulfation of apomorphine by human sulfotransferases: evidence of a major role for the polymorphic phenol sulfotransferase, SULT1A1. Xenobiotica. 2003 Nov;33(11):1139-48.
DMX38HQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14660177

DMO4PVE	DI	DMO4PVE
DMO4PVE	DN	Apraclonidine
DMO4PVE	MI	TTQ8AFT
DMO4PVE	MN	Adrenergic receptor Alpha-2 (ADRA2)
DMO4PVE	MT	DTT
DMO4PVE	MA	Agonist
DMO4PVE	RN	Apraclonidine attenuates the increases in spinal excitatory amino acid release in rats with adjuvant-induced inflammation. Anesth Analg. 2002 Mar;94(3):701-5; table of contents.
DMO4PVE	RU	https://pubmed.ncbi.nlm.nih.gov/11867401

DMTWS9E	DI	DMTWS9E
DMTWS9E	DN	Apremilast
DMTWS9E	MI	TT0PG8F
DMTWS9E	MN	Cyclin-dependent kinase 4 (CDK4)
DMTWS9E	MT	DTT
DMTWS9E	MA	Inhibitor
DMTWS9E	RN	Agreement signed with Prostagenics to develop prostate cancer treatment. Innovate Oncology, Inc. 2005.
DMTWS9E	RU	http://www.newsrx.com/newsletters/Law-and-Health-Weekly/2005-05-14/05092005333475LH.html

DMTWS9E	DI	DMTWS9E
DMTWS9E	DN	Apremilast
DMTWS9E	MI	TTO0FDJ
DMTWS9E	MN	Cyclin-dependent kinase 6 (CDK6)
DMTWS9E	MT	DTT
DMTWS9E	MA	Inhibitor
DMTWS9E	RN	Agreement signed with Prostagenics to develop prostate cancer treatment. Innovate Oncology, Inc. 2005.
DMTWS9E	RU	http://www.newsrx.com/newsletters/Law-and-Health-Weekly/2005-05-14/05092005333475LH.html

DMTWS9E	DI	DMTWS9E
DMTWS9E	DN	Apremilast
DMTWS9E	MI	DEJGDUW
DMTWS9E	MN	Cytochrome P450 1A2 (CYP1A2)
DMTWS9E	MT	DME
DMTWS9E	MA	Metabolism
DMTWS9E	RN	Apremilast (Otezla): a new oral treatment for adults with psoriasis and psoriatic arthritis. P T. 2015 Aug;40(8):495-500.
DMTWS9E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26236137

DMTWS9E	DI	DMTWS9E
DMTWS9E	DN	Apremilast
DMTWS9E	MI	DEJVYAZ
DMTWS9E	MN	Cytochrome P450 2A6 (CYP2A6)
DMTWS9E	MT	DME
DMTWS9E	MA	Metabolism
DMTWS9E	RN	Apremilast (Otezla): a new oral treatment for adults with psoriasis and psoriatic arthritis. P T. 2015 Aug;40(8):495-500.
DMTWS9E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26236137

DMTWS9E	DI	DMTWS9E
DMTWS9E	DN	Apremilast
DMTWS9E	MI	DE4LYSA
DMTWS9E	MN	Cytochrome P450 3A4 (CYP3A4)
DMTWS9E	MT	DME
DMTWS9E	MA	Metabolism
DMTWS9E	RN	Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor: a novel treatment option for nurse practitioners treating patients with psoriatic disease. J Am Assoc Nurse Pract. 2016 Dec;28(12):683-695.
DMTWS9E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27869356

DMTWS9E	DI	DMTWS9E
DMTWS9E	DN	Apremilast
DMTWS9E	MI	DTUGYRD
DMTWS9E	MN	P-glycoprotein 1 (ABCB1)
DMTWS9E	MT	DTP
DMTWS9E	MA	Substrate
DMTWS9E	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DMTWS9E	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DMTWS9E	DI	DMTWS9E
DMTWS9E	DN	Apremilast
DMTWS9E	MI	TTV5CGO
DMTWS9E	MN	Phosphodiesterase 4 (PDE4)
DMTWS9E	MT	DTT
DMTWS9E	MA	Inhibitor
DMTWS9E	RN	Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets. 2007 Mar;6(1):17-26.
DMTWS9E	RU	https://pubmed.ncbi.nlm.nih.gov/17352685

DM053KT	DI	DM053KT
DM053KT	DN	Aprepitant
DM053KT	MI	DEJGDUW
DM053KT	MN	Cytochrome P450 1A2 (CYP1A2)
DM053KT	MT	DME
DM053KT	MA	Metabolism
DM053KT	RN	Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos. 2004 Nov;32(11):1287-92.
DM053KT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304427

DM053KT	DI	DM053KT
DM053KT	DN	Aprepitant
DM053KT	MI	DE4LYSA
DM053KT	MN	Cytochrome P450 3A4 (CYP3A4)
DM053KT	MT	DME
DM053KT	MA	Metabolism
DM053KT	RN	Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Cancer Chemother Pharmacol. 2005 Jun;55(6):609-16.
DM053KT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15723220

DM053KT	DI	DM053KT
DM053KT	DN	Aprepitant
DM053KT	MI	DEGTFWK
DM053KT	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM053KT	MT	DME
DM053KT	MA	Metabolism
DM053KT	RN	Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos. 2004 Nov;32(11):1287-92.
DM053KT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304427

DM053KT	DI	DM053KT
DM053KT	DN	Aprepitant
DM053KT	MI	DTUGYRD
DM053KT	MN	P-glycoprotein 1 (ABCB1)
DM053KT	MT	DTP
DM053KT	MA	Substrate
DM053KT	RN	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
DM053KT	RU	https://doi.org/10.1016/j.addr.2011.12.008

DM053KT	DI	DM053KT
DM053KT	DN	Aprepitant
DM053KT	MI	TTZPO1L
DM053KT	MN	Substance-P receptor (TACR1)
DM053KT	MT	DTT
DM053KT	MA	Antagonist
DM053KT	RN	Potent, brain-penetrant, hydroisoindoline-based human neurokinin-1 receptor antagonists. J Med Chem. 2009 May 14;52(9):3039-46.
DM053KT	RU	https://pubmed.ncbi.nlm.nih.gov/19354254

DMBXWU8	DI	DMBXWU8
DMBXWU8	DN	Aprindine
DMBXWU8	MI	TTV3NH6
DMBXWU8	MN	Calmodulin (CALM)
DMBXWU8	MT	DTT
DMBXWU8	MA	Inhibitor
DMBXWU8	RN	Aprindine inhibits calmodulin-stimulated phosphodiesterase and Ca-ATPase activities. J Cardiovasc Pharmacol. 1983 Jan-Feb;5(1):151-6.
DMBXWU8	RU	https://pubmed.ncbi.nlm.nih.gov/6186851

DMBXWU8	DI	DMBXWU8
DMBXWU8	DN	Aprindine
DMBXWU8	MI	DECB0K3
DMBXWU8	MN	Cytochrome P450 2D6 (CYP2D6)
DMBXWU8	MT	DME
DMBXWU8	MA	Metabolism
DMBXWU8	RN	Nonlinear mixed effects model analysis of the pharmacokinetics of routinely administered bepridil in Japanese patients with arrhythmias. Biol Pharm Bull. 2006 Mar;29(3):517-21.
DMBXWU8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16508157

DMOWK6B	DI	DMOWK6B
DMOWK6B	DN	Aprobarbital
DMOWK6B	MI	TTAN6JD
DMOWK6B	MN	Glutamate receptor AMPA (GRIA)
DMOWK6B	MT	DTT
DMOWK6B	MA	Binder
DMOWK6B	RN	Determination of zidovudine/lamivudine/nevirapine in human plasma using ion-pair HPLC. J Pharm Biomed Anal. 2002 Jun 1;28(5):903-8.
DMOWK6B	RU	https://pubmed.ncbi.nlm.nih.gov/12039632

DM0QD4W	DI	DM0QD4W
DM0QD4W	DN	Aprotinin
DM0QD4W	MI	TTEMV5X
DM0QD4W	MN	Serine protease unspecific (SP)
DM0QD4W	MT	DTT
DM0QD4W	MA	Modulator
DM0QD4W	RN	Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding Clin Trials. 2005;2(3):218-29; discussion 229-32.
DM0QD4W	RU	https://pubmed.ncbi.nlm.nih.gov/16279145

DMHTXSL	DI	DMHTXSL
DMHTXSL	DN	Arbekacin
DMHTXSL	MI	TTA4FIU
DMHTXSL	MN	Ribosome A (hRA)
DMHTXSL	MT	DTT
DMHTXSL	MA	Modulator
DMHTXSL	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMHTXSL	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DMHTXSL	DI	DMHTXSL
DMHTXSL	DN	Arbekacin
DMHTXSL	MI	DEZV4AP
DMHTXSL	MN	RNA cytidine acetyltransferase (hALP)
DMHTXSL	MT	DME
DMHTXSL	MA	Metabolism
DMHTXSL	RN	The novel enzymatic 3''-N-acetylation of arbekacin by an aminoglycoside 3-N-acetyltransferase of Streptomyces origin and the resulting activity. J Antibiot (Tokyo). 1998 Aug;51(8):735-42.
DMHTXSL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9766465

DMOQK8Z	DI	DMOQK8Z
DMOQK8Z	DN	Arbidol
DMOQK8Z	MI	TTF4CAM
DMOQK8Z	MN	Influenza Hemagglutinin (Influ HA)
DMOQK8Z	MT	DTT
DMOQK8Z	MA	Inhibitor
DMOQK8Z	RN	Pharmacokinetic properties and bioequivalence of two formulations of arbidol: an open-label, single-dose, randomized-sequence, two-period crossover study in healthy Chinese male volunteers. Clin Ther. 2009 Apr;31(4):784-92.
DMOQK8Z	RU	https://pubmed.ncbi.nlm.nih.gov/19446151

DMCY8AF	DI	DMCY8AF
DMCY8AF	DN	Arbutamine
DMCY8AF	MI	TTR6W5O
DMCY8AF	MN	Adrenergic receptor beta-1 (ADRB1)
DMCY8AF	MT	DTT
DMCY8AF	MA	Stimulator
DMCY8AF	RN	Characterization of the adrenergic activity of arbutamine, a novel agent for pharmacological stress testing. Cardiovasc Drugs Ther. 1996 Mar;10(1):39-47.
DMCY8AF	RU	https://pubmed.ncbi.nlm.nih.gov/8723169

DM9GH25	DI	DM9GH25
DM9GH25	DN	Arcitumomab
DM9GH25	MI	TTPX7I5
DM9GH25	MN	Carcinoembryonic antigen CGM1 (CD66d)
DM9GH25	MT	DTT
DM9GH25	RN	In vivo near-infrared fluorescence imaging of carcinoembryonic antigen-expressing tumor cells in mice. Radiology. 2008 Jun;247(3):779-87.
DM9GH25	RU	https://pubmed.ncbi.nlm.nih.gov/18413884

DMYRX8B	DI	DMYRX8B
DMYRX8B	DN	Ardeparin
DMYRX8B	MI	TT4QPUL
DMYRX8B	MN	Antithrombin-III (ATIII)
DMYRX8B	MT	DTT
DMYRX8B	MA	Modulator
DMYRX8B	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMYRX8B	RU	https://www.fda.gov/

DMVMY7K	DI	DMVMY7K
DMVMY7K	DN	Arepanrix
DMVMY7K	MI	TT3J5ZI
DMVMY7K	MN	Cell mediated immunity response (CMIR)
DMVMY7K	MT	DTT
DMVMY7K	RN	Comparison of Pandemrix and Arepanrix, two pH1N1 AS03-adjuvanted vaccines differentially associated with narcolepsy development. Brain Behav Immun. 2015 Jul;47:44-57.
DMVMY7K	RU	https://pubmed.ncbi.nlm.nih.gov/25452148

DMYM974	DI	DMYM974
DMYM974	DN	Arformoterol
DMYM974	MI	TT2CJVK
DMYM974	MN	Adrenergic receptor beta-2 (ADRB2)
DMYM974	MT	DTT
DMYM974	MA	Agonist
DMYM974	RN	Arformoterol tartrate in the treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. Drugs Today (Barc). 2009 Jan;45(1):3-9.
DMYM974	RU	https://pubmed.ncbi.nlm.nih.gov/19271027

DMYM974	DI	DMYM974
DMYM974	DN	Arformoterol
DMYM974	MI	DEJVYAZ
DMYM974	MN	Cytochrome P450 2A6 (CYP2A6)
DMYM974	MT	DME
DMYM974	MA	Metabolism
DMYM974	RN	A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes. Drug Metab Dispos. 2007 Oct;35(10):1797-805.
DMYM974	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17627976

DMYM974	DI	DMYM974
DMYM974	DN	Arformoterol
DMYM974	MI	DECB0K3
DMYM974	MN	Cytochrome P450 2D6 (CYP2D6)
DMYM974	MT	DME
DMYM974	MA	Metabolism
DMYM974	RN	A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes. Drug Metab Dispos. 2007 Oct;35(10):1797-805.
DMYM974	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17627976

DMYM974	DI	DMYM974
DMYM974	DN	Arformoterol
DMYM974	MI	DEGTFWK
DMYM974	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMYM974	MT	DME
DMYM974	MA	Metabolism
DMYM974	RN	A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes. Drug Metab Dispos. 2007 Oct;35(10):1797-805.
DMYM974	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17627976

DMFI46A	DI	DMFI46A
DMFI46A	DN	Argatroban
DMFI46A	MI	TT6L509
DMFI46A	MN	Coagulation factor IIa (F2)
DMFI46A	MT	DTT
DMFI46A	MA	Inhibitor
DMFI46A	RN	Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. I. Effects on thrombin generation. J Biol Chem. 2002 Dec 27;277(52):50439-44.
DMFI46A	RU	https://pubmed.ncbi.nlm.nih.gov/12496240

DMFI46A	DI	DMFI46A
DMFI46A	DN	Argatroban
DMFI46A	MI	DE4LYSA
DMFI46A	MN	Cytochrome P450 3A4 (CYP3A4)
DMFI46A	MT	DME
DMFI46A	MA	Metabolism
DMFI46A	RN	Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban. J Clin Pharmacol. 1999 May;39(5):513-9.
DMFI46A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10234600

DMFI46A	DI	DMFI46A
DMFI46A	DN	Argatroban
DMFI46A	MI	DEIBDNY
DMFI46A	MN	Cytochrome P450 3A5 (CYP3A5)
DMFI46A	MT	DME
DMFI46A	MA	Metabolism
DMFI46A	RN	Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban. J Clin Pharmacol. 1999 May;39(5):513-9.
DMFI46A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10234600

DMRE4FC	DI	DMRE4FC
DMRE4FC	DN	Arginine
DMRE4FC	MI	DTDPJ3F
DMRE4FC	MN	Mitochondrial ornithine transporter 2 (SLC25A2)
DMRE4FC	MT	DTP
DMRE4FC	MA	Substrate
DMRE4FC	RN	Asymmetric dimethylarginine is transported by the mitochondrial carrier SLC25A2. Amino Acids. 2016 Feb;48(2):427-36.
DMRE4FC	RU	http://www.ncbi.nlm.nih.gov/pubmed/26403849

DMRE4FC	DI	DMRE4FC
DMRE4FC	DN	Arginine
DMRE4FC	MI	DT96BT4
DMRE4FC	MN	Mitochondrial ornithine transporter 3 (SLC25A29)
DMRE4FC	MT	DTP
DMRE4FC	MA	Substrate
DMRE4FC	RN	The human gene SLC25A29, of solute carrier family 25, encodes a mitochondrial transporter of basic amino acids. J Biol Chem. 2014 May 9;289(19):13374-84.
DMRE4FC	RU	http://www.ncbi.nlm.nih.gov/pubmed/24652292

DMRE4FC	DI	DMRE4FC
DMRE4FC	DN	Arginine
DMRE4FC	MI	DTF7MYK
DMRE4FC	MN	Sodium-coupled neutral amino acid transporter 9 (SLC38A9)
DMRE4FC	MT	DTP
DMRE4FC	MA	Substrate
DMRE4FC	RN	Metabolism. Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1. Science. 2015 Jan 9;347(6218):188-94.
DMRE4FC	RU	http://www.ncbi.nlm.nih.gov/pubmed/25567906

DM3NUMH	DI	DM3NUMH
DM3NUMH	DN	Aripiprazole
DM3NUMH	MI	DECB0K3
DM3NUMH	MN	Cytochrome P450 2D6 (CYP2D6)
DM3NUMH	MT	DME
DM3NUMH	MA	Metabolism
DM3NUMH	RN	Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64(15):1715-36.
DM3NUMH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15257633

DM3NUMH	DI	DM3NUMH
DM3NUMH	DN	Aripiprazole
DM3NUMH	MI	DE4LYSA
DM3NUMH	MN	Cytochrome P450 3A4 (CYP3A4)
DM3NUMH	MT	DME
DM3NUMH	MA	Metabolism
DM3NUMH	RN	Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64(15):1715-36.
DM3NUMH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15257633

DM3NUMH	DI	DM3NUMH
DM3NUMH	DN	Aripiprazole
DM3NUMH	MI	DEIBDNY
DM3NUMH	MN	Cytochrome P450 3A5 (CYP3A5)
DM3NUMH	MT	DME
DM3NUMH	MA	Metabolism
DM3NUMH	RN	Drug Interactions Flockhart Table
DM3NUMH	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM3NUMH	DI	DM3NUMH
DM3NUMH	DN	Aripiprazole
DM3NUMH	MI	DERD86B
DM3NUMH	MN	Cytochrome P450 3A7 (CYP3A7)
DM3NUMH	MT	DME
DM3NUMH	MA	Metabolism
DM3NUMH	RN	Drug Interactions Flockhart Table
DM3NUMH	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM3NUMH	DI	DM3NUMH
DM3NUMH	DN	Aripiprazole
DM3NUMH	MI	TTEX248
DM3NUMH	MN	Dopamine D2 receptor (D2R)
DM3NUMH	MT	DTT
DM3NUMH	MA	Agonist
DM3NUMH	RN	Aripiprazole acts as a selective dopamine D2 receptor partial agonist. Expert Opin Investig Drugs. 2007 Jun;16(6):771-5.
DM3NUMH	RU	https://pubmed.ncbi.nlm.nih.gov/17501690

DMGB035	DI	DMGB035
DMGB035	DN	Armodafinil
DMGB035	MI	TT34BHT
DMGB035	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMGB035	MT	DTT
DMGB035	MA	Agonist
DMGB035	RN	Mechanisms of modafinil: A review of current research. Neuropsychiatr Dis Treat. 2007 June; 3(3): 349-364.
DMGB035	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654794/

DMGB035	DI	DMGB035
DMGB035	DN	Armodafinil
DMGB035	MI	DE4LYSA
DMGB035	MN	Cytochrome P450 3A4 (CYP3A4)
DMGB035	MT	DME
DMGB035	MA	Metabolism
DMGB035	RN	Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects. Clin Pharmacokinet. 2008;47(1):61-74.
DMGB035	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18076219

DMGB035	DI	DMGB035
DMGB035	DN	Armodafinil
DMGB035	MI	DEIBDNY
DMGB035	MN	Cytochrome P450 3A5 (CYP3A5)
DMGB035	MT	DME
DMGB035	MA	Metabolism
DMGB035	RN	Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet. 2003;42(2):123-37.
DMGB035	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12537513

DMT81LZ	DI	DMT81LZ
DMT81LZ	DN	Arn-509
DMT81LZ	MI	TTS64P2
DMT81LZ	MN	Androgen receptor (AR)
DMT81LZ	MT	DTT
DMT81LZ	MA	Inhibitor
DMT81LZ	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMT81LZ	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMT81LZ	DI	DMT81LZ
DMT81LZ	DN	Arn-509
DMT81LZ	MI	DES5XRU
DMT81LZ	MN	Cytochrome P450 2C8 (CYP2C8)
DMT81LZ	MT	DME
DMT81LZ	MA	Metabolism
DMT81LZ	RN	Apalutamide: first global approval. Drugs. 2018 Apr;78(6):699-705.
DMT81LZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29626324

DMT81LZ	DI	DMT81LZ
DMT81LZ	DN	Arn-509
DMT81LZ	MI	DE4LYSA
DMT81LZ	MN	Cytochrome P450 3A4 (CYP3A4)
DMT81LZ	MT	DME
DMT81LZ	MA	Metabolism
DMT81LZ	RN	Apalutamide: first global approval. Drugs. 2018 Apr;78(6):699-705.
DMT81LZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29626324

DM1P6FR	DI	DM1P6FR
DM1P6FR	DN	Arry-162
DM1P6FR	MI	DTI7UX6
DM1P6FR	MN	Breast cancer resistance protein (ABCG2)
DM1P6FR	MT	DTP
DM1P6FR	MA	Substrate
DM1P6FR	RN	The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors. Int J Cancer. 2018 Jan 15;142(2):381-391.
DM1P6FR	RU	http://www.ncbi.nlm.nih.gov/pubmed/28921565

DM1P6FR	DI	DM1P6FR
DM1P6FR	DN	Arry-162
DM1P6FR	MI	DEJGDUW
DM1P6FR	MN	Cytochrome P450 1A2 (CYP1A2)
DM1P6FR	MT	DME
DM1P6FR	MA	Metabolism
DM1P6FR	RN	FDA Label of Binimetinib. The 2020 official website of the U.S. Food and Drug Administration.
DM1P6FR	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210498lbl.pdf

DM1P6FR	DI	DM1P6FR
DM1P6FR	DN	Arry-162
DM1P6FR	MI	TTZCRP3
DM1P6FR	MN	ERK activator kinase (MEK)
DM1P6FR	MT	DTT
DM1P6FR	MA	Inhibitor
DM1P6FR	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DM1P6FR	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DM1P6FR	DI	DM1P6FR
DM1P6FR	DN	Arry-162
DM1P6FR	MI	TTROQ37
DM1P6FR	MN	MAPK/ERK kinase kinase (MAP3K)
DM1P6FR	MT	DTT
DM1P6FR	MA	Modulator
DM1P6FR	RN	MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013; 6: 27.
DM1P6FR	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626705/

DM1P6FR	DI	DM1P6FR
DM1P6FR	DN	Arry-162
DM1P6FR	MI	DTUGYRD
DM1P6FR	MN	P-glycoprotein 1 (ABCB1)
DM1P6FR	MT	DTP
DM1P6FR	MA	Substrate
DM1P6FR	RN	The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors. Int J Cancer. 2018 Jan 15;142(2):381-391.
DM1P6FR	RU	http://www.ncbi.nlm.nih.gov/pubmed/28921565

DM1P6FR	DI	DM1P6FR
DM1P6FR	DN	Arry-162
DM1P6FR	MI	DEYGVN4
DM1P6FR	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM1P6FR	MT	DME
DM1P6FR	MA	Metabolism
DM1P6FR	RN	Binimetinib - European Medicines Agency - European Union
DM1P6FR	RU	https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-balimek-binimetinib_en.pdf

DMTL2Y1	DI	DMTL2Y1
DMTL2Y1	DN	Arsenic
DMTL2Y1	MI	DE9KJP3
DMTL2Y1	MN	Arsenite methyltransferase (AS3MT)
DMTL2Y1	MT	DME
DMTL2Y1	MA	Metabolism
DMTL2Y1	RN	Polymorphisms in arsenic(+III oxidation state) methyltransferase (AS3MT) predict gene expression of AS3MT as well as arsenic metabolism. Environ Health Perspect. 2011 Feb;119(2):182-8.
DMTL2Y1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21247820

DMTL2Y1	DI	DMTL2Y1
DMTL2Y1	DN	Arsenic
DMTL2Y1	MI	DEOT0QC
DMTL2Y1	MN	Methylarsonite methyltransferase N6AMT1 (N6AMT1)
DMTL2Y1	MT	DME
DMTL2Y1	MA	Metabolism
DMTL2Y1	RN	Interactive influence of N6AMT1 and As3MT genetic variations on arsenic metabolism in the population of Inner Mongolia, China. Toxicol Sci. 2017 Jan;155(1):124-134.
DMTL2Y1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27637898

DMTL2Y1	DI	DMTL2Y1
DMTL2Y1	DN	Arsenic
DMTL2Y1	MI	DEYLWI6
DMTL2Y1	MN	Serine sulfhydrase (CBS)
DMTL2Y1	MT	DME
DMTL2Y1	MA	Metabolism
DMTL2Y1	RN	Association of genetic variation in cystathionine-beta-synthase and arsenic metabolism. Environ Res. 2010 Aug;110(6):580-7.
DMTL2Y1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20670920

DM61TA4	DI	DM61TA4
DM61TA4	DN	Arsenic trioxide
DM61TA4	MI	TTJ3E9X
DM61TA4	MN	Inhibitor of nuclear factor kappa-B kinase beta (IKKB)
DM61TA4	MT	DTT
DM61TA4	MA	Inhibitor
DM61TA4	RN	How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer. 2002 Sep;2(9):705-13.
DM61TA4	RU	https://pubmed.ncbi.nlm.nih.gov/12209159

DM61TA4	DI	DM61TA4
DM61TA4	DN	Arsenic trioxide
DM61TA4	MI	DTFI42L
DM61TA4	MN	Multidrug resistance-associated protein 2 (ABCC2)
DM61TA4	MT	DTP
DM61TA4	MA	Substrate
DM61TA4	RN	MRP2 and acquired tolerance to inorganic arsenic in the kidney of killifish (Fundulus heteroclitus). Toxicol Sci. 2007 May;97(1):103-10.
DM61TA4	RU	http://www.ncbi.nlm.nih.gov/pubmed/17324950

DM61TA4	DI	DM61TA4
DM61TA4	DN	Arsenic trioxide
DM61TA4	MI	DTUGYRD
DM61TA4	MN	P-glycoprotein 1 (ABCB1)
DM61TA4	MT	DTP
DM61TA4	MA	Substrate
DM61TA4	RN	Arsenic trioxide induces apoptosis equally in T lymphoblastoid leukemia MOLT-4 cells and P-gp-expressing daunorubicin-resistant MOLT-4 cells. Cancer Chemother Pharmacol. 2003 Feb;51(2):119-26.
DM61TA4	RU	http://www.ncbi.nlm.nih.gov/pubmed/12647012

DMQLX7O	DI	DMQLX7O
DMQLX7O	DN	Arteether
DMQLX7O	MI	TT9X7H4
DMQLX7O	MN	Beta-hematin formation (BHF)
DMQLX7O	MT	DTT
DMQLX7O	MA	Modulator
DMQLX7O	RN	Lack of association of the S769N mutation in Plasmodium falciparum SERCA (PfATP6) with resistance to artemisinins. Antimicrob Agents Chemother. 2012 May;56(5):2546-52.
DMQLX7O	RU	https://pubmed.ncbi.nlm.nih.gov/22354307

DM48QOT	DI	DM48QOT
DM48QOT	DN	Artemether
DM48QOT	MI	DEPKLMQ
DM48QOT	MN	Cytochrome P450 2B6 (CYP2B6)
DM48QOT	MT	DME
DM48QOT	MA	Metabolism
DM48QOT	RN	Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
DM48QOT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27709010

DM48QOT	DI	DM48QOT
DM48QOT	DN	Artemether
DM48QOT	MI	DE5IED8
DM48QOT	MN	Cytochrome P450 2C9 (CYP2C9)
DM48QOT	MT	DME
DM48QOT	MA	Metabolism
DM48QOT	RN	Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial. HIV Med. 2013 Aug;14(7):421-9.
DM48QOT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23441978

DM48QOT	DI	DM48QOT
DM48QOT	DN	Artemether
DM48QOT	MI	DECB0K3
DM48QOT	MN	Cytochrome P450 2D6 (CYP2D6)
DM48QOT	MT	DME
DM48QOT	MA	Metabolism
DM48QOT	RN	The contribution of the enzymes CYP2D6 and CYP2C19 in the demethylation of artemether in healthy subjects. Eur J Drug Metab Pharmacokinet. 1998 Jul-Sep;23(3):429-36.
DM48QOT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9842988

DM48QOT	DI	DM48QOT
DM48QOT	DN	Artemether
DM48QOT	MI	DE4LYSA
DM48QOT	MN	Cytochrome P450 3A4 (CYP3A4)
DM48QOT	MT	DME
DM48QOT	MA	Metabolism
DM48QOT	RN	The effect of grapefruit juice on the time-dependent decline of artemether plasma levels in healthy subjects. Clin Pharmacol Ther. 1999 Oct;66(4):408-14.
DM48QOT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10546925

DM48QOT	DI	DM48QOT
DM48QOT	DN	Artemether
DM48QOT	MI	DEIBDNY
DM48QOT	MN	Cytochrome P450 3A5 (CYP3A5)
DM48QOT	MT	DME
DM48QOT	MA	Metabolism
DM48QOT	RN	Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women. Malar J. 2017 Jul 3;16(1):267.
DM48QOT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28673292

DM48QOT	DI	DM48QOT
DM48QOT	DN	Artemether
DM48QOT	MI	DEGTFWK
DM48QOT	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM48QOT	MT	DME
DM48QOT	MA	Metabolism
DM48QOT	RN	The contribution of the enzymes CYP2D6 and CYP2C19 in the demethylation of artemether in healthy subjects. Eur J Drug Metab Pharmacokinet. 1998 Jul-Sep;23(3):429-36.
DM48QOT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9842988

DM48QOT	DI	DM48QOT
DM48QOT	DN	Artemether
DM48QOT	MI	TTWK8D0
DM48QOT	MN	Sodium pump subunit alpha-1 (ATP1A1)
DM48QOT	MT	DTT
DM48QOT	MA	Binder
DM48QOT	RN	The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
DM48QOT	RU	https://pubmed.ncbi.nlm.nih.gov/18220771

DMOY7W3	DI	DMOY7W3
DMOY7W3	DN	Artemisinin
DMOY7W3	MI	DEJVYAZ
DMOY7W3	MN	Cytochrome P450 2A6 (CYP2A6)
DMOY7W3	MT	DME
DMOY7W3	MA	Metabolism
DMOY7W3	RN	Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin. Br J Clin Pharmacol. 1999 Oct;48(4):528-35.
DMOY7W3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10583023

DMOY7W3	DI	DMOY7W3
DMOY7W3	DN	Artemisinin
DMOY7W3	MI	DEPKLMQ
DMOY7W3	MN	Cytochrome P450 2B6 (CYP2B6)
DMOY7W3	MT	DME
DMOY7W3	MA	Metabolism
DMOY7W3	RN	Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol Pharmacol. 2005 Jun;67(6):1954-65.
DMOY7W3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15761118

DMOY7W3	DI	DMOY7W3
DMOY7W3	DN	Artemisinin
DMOY7W3	MI	DE4LYSA
DMOY7W3	MN	Cytochrome P450 3A4 (CYP3A4)
DMOY7W3	MT	DME
DMOY7W3	MA	Metabolism
DMOY7W3	RN	Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol Pharmacol. 2005 Jun;67(6):1954-65.
DMOY7W3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15761118

DMOY7W3	DI	DMOY7W3
DMOY7W3	DN	Artemisinin
DMOY7W3	MI	DE4ZHS1
DMOY7W3	MN	Glutathione S-transferase alpha-1 (GSTA1)
DMOY7W3	MT	DME
DMOY7W3	MA	Metabolism
DMOY7W3	RN	Inhibition of glutathione S-transferases by antimalarial drugs possible implications for circumventing anticancer drug resistance. Int J Cancer. 2002 Feb 10;97(5):700-5.
DMOY7W3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11807801

DMOY7W3	DI	DMOY7W3
DMOY7W3	DN	Artemisinin
DMOY7W3	MI	TT3PQ2Y
DMOY7W3	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DMOY7W3	MT	DTT
DMOY7W3	MA	Inhibitor
DMOY7W3	RN	The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
DMOY7W3	RU	https://pubmed.ncbi.nlm.nih.gov/18220771

DMOY7W3	DI	DMOY7W3
DMOY7W3	DN	Artemisinin
DMOY7W3	MI	TTZVSJ2
DMOY7W3	MN	Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A)
DMOY7W3	MT	DTT
DMOY7W3	MA	Inhibitor
DMOY7W3	RN	The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
DMOY7W3	RU	https://pubmed.ncbi.nlm.nih.gov/18220771

DMFETDK	DI	DMFETDK
DMFETDK	DN	Artemisinin SP
DMFETDK	MI	TTAN6JD
DMFETDK	MN	Glutamate receptor AMPA (GRIA)
DMFETDK	MT	DTT
DMFETDK	MA	Agonist
DMFETDK	RN	GABA(A) receptor ligands and their therapeutic potentials. Curr Top Med Chem. 2002 Aug;2(8):817-32.
DMFETDK	RU	https://pubmed.ncbi.nlm.nih.gov/12171573

DMFETDK	DI	DMFETDK
DMFETDK	DN	Artemisinin SP
DMFETDK	MI	TTZVSJ2
DMFETDK	MN	Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A)
DMFETDK	MT	DTT
DMFETDK	MA	Inhibitor
DMFETDK	RN	The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
DMFETDK	RU	https://pubmed.ncbi.nlm.nih.gov/18220771

DMR27C8	DI	DMR27C8
DMR27C8	DN	Artesunate
DMR27C8	MI	DEJVYAZ
DMR27C8	MN	Cytochrome P450 2A6 (CYP2A6)
DMR27C8	MT	DME
DMR27C8	MA	Metabolism
DMR27C8	RN	Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
DMR27C8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920490

DMR27C8	DI	DMR27C8
DMR27C8	DN	Artesunate
DMR27C8	MI	TTZVSJ2
DMR27C8	MN	Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A)
DMR27C8	MT	DTT
DMR27C8	MA	Inhibitor
DMR27C8	RN	The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
DMR27C8	RU	https://pubmed.ncbi.nlm.nih.gov/18220771

DMOKCVI	DI	DMOKCVI
DMOKCVI	DN	ARZOXIFENE
DMOKCVI	MI	TTZAYWL
DMOKCVI	MN	Estrogen receptor (ESR)
DMOKCVI	MT	DTT
DMOKCVI	MA	Inhibitor
DMOKCVI	RN	Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity. J Med Chem. 2007 May 31;50(11):2682-92.
DMOKCVI	RU	https://pubmed.ncbi.nlm.nih.gov/17489582

DMOKCVI	DI	DMOKCVI
DMOKCVI	DN	ARZOXIFENE
DMOKCVI	MI	TTOM3J0
DMOKCVI	MN	Estrogen receptor beta (ESR2)
DMOKCVI	MT	DTT
DMOKCVI	MA	Inhibitor
DMOKCVI	RN	Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity. J Med Chem. 2007 May 31;50(11):2682-92.
DMOKCVI	RU	https://pubmed.ncbi.nlm.nih.gov/17489582

DMV05SW	DI	DMV05SW
DMV05SW	DN	As-1670542
DMV05SW	MI	TTIHYA4
DMV05SW	MN	Thrombopoietin receptor (MPL)
DMV05SW	MT	DTT
DMV05SW	MA	Agonist
DMV05SW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1722).
DMV05SW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1722

DMCZIHT	DI	DMCZIHT
DMCZIHT	DN	Asasantin
DMCZIHT	MI	TTK0943
DMCZIHT	MN	Prostaglandin G/H synthase (COX)
DMCZIHT	MT	DTT
DMCZIHT	MA	Inhibitor
DMCZIHT	RN	Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
DMCZIHT	RU	https://pubmed.ncbi.nlm.nih.gov/16503827

DMSQZE2	DI	DMSQZE2
DMSQZE2	DN	Asenapine
DMSQZE2	MI	DEJGDUW
DMSQZE2	MN	Cytochrome P450 1A2 (CYP1A2)
DMSQZE2	MT	DME
DMSQZE2	MA	Metabolism
DMSQZE2	RN	Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol. 2014 Jun;10(6):893-903.
DMSQZE2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24793403

DMSQZE2	DI	DMSQZE2
DMSQZE2	DN	Asenapine
DMSQZE2	MI	DECB0K3
DMSQZE2	MN	Cytochrome P450 2D6 (CYP2D6)
DMSQZE2	MT	DME
DMSQZE2	MA	Metabolism
DMSQZE2	RN	Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol. 2014 Jun;10(6):893-903.
DMSQZE2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24793403

DMSQZE2	DI	DMSQZE2
DMSQZE2	DN	Asenapine
DMSQZE2	MI	DE4LYSA
DMSQZE2	MN	Cytochrome P450 3A4 (CYP3A4)
DMSQZE2	MT	DME
DMSQZE2	MA	Metabolism
DMSQZE2	RN	Asenapine for the treatment of manic and mixed episodes associated with bipolar I disorder: from clinical research to clinical practice. Expert Opin Pharmacother. 2013 Mar;14(4):489-504.
DMSQZE2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23356509

DMSQZE2	DI	DMSQZE2
DMSQZE2	DN	Asenapine
DMSQZE2	MI	TTXFI1K
DMSQZE2	MN	Hyaluronidase (HYAL)
DMSQZE2	MT	DTT
DMSQZE2	MA	Modulator
DMSQZE2	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMSQZE2	RU	https://www.fda.gov/

DMM4FXA	DI	DMM4FXA
DMM4FXA	DN	Asfotase alfa
DMM4FXA	MI	TTMR5UV
DMM4FXA	MN	Alkaline phosphatase tissue-nonspecific (ALPL)
DMM4FXA	MT	DTT
DMM4FXA	MA	Modulator
DMM4FXA	RN	Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med. 2012 Mar 8;366(10):904-13.
DMM4FXA	RU	https://pubmed.ncbi.nlm.nih.gov/22397652

DM672AH	DI	DM672AH
DM672AH	DN	Aspirin
DM672AH	MI	DE5IED8
DM672AH	MN	Cytochrome P450 2C9 (CYP2C9)
DM672AH	MT	DME
DM672AH	MA	Metabolism
DM672AH	RN	Polymorphisms of Aspirin-Metabolizing Enzymes CYP2C9, NAT2 and UGT1A6 in Aspirin-Intolerant Urticaria. Allergy Asthma Immunol Res. 2011 Oct;3(4):273-6.
DM672AH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21966608

DM672AH	DI	DM672AH
DM672AH	DN	Aspirin
DM672AH	MI	TTPADOQ
DM672AH	MN	HMG-CoA reductase (HMGCR)
DM672AH	MT	DTT
DM672AH	MA	Inhibitor
DM672AH	RN	Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
DM672AH	RU	https://pubmed.ncbi.nlm.nih.gov/16503827

DM672AH	DI	DM672AH
DM672AH	DN	Aspirin
DM672AH	MI	DEGTFWK
DM672AH	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM672AH	MT	DME
DM672AH	MA	Metabolism
DM672AH	RN	Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects. Clin Pharmacol Ther. 2003 Mar;73(3):264-71.
DM672AH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12621391

DM672AH	DI	DM672AH
DM672AH	DN	Aspirin
DM672AH	MI	DER7TA0
DM672AH	MN	N-acetyltransferase 2 (NAT2)
DM672AH	MT	DME
DM672AH	MA	Metabolism
DM672AH	RN	Polymorphisms of Aspirin-Metabolizing Enzymes CYP2C9, NAT2 and UGT1A6 in Aspirin-Intolerant Urticaria. Allergy Asthma Immunol Res. 2011 Oct;3(4):273-6.
DM672AH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21966608

DM672AH	DI	DM672AH
DM672AH	DN	Aspirin
DM672AH	MI	DT0OC1Q
DM672AH	MN	Organic anion transporter 2 (SLC22A7)
DM672AH	MT	DTP
DM672AH	MA	Substrate
DM672AH	RN	Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett. 1998 Jun 12;429(2):179-82.
DM672AH	RU	http://www.ncbi.nlm.nih.gov/pubmed/9650585

DM672AH	DI	DM672AH
DM672AH	DN	Aspirin
DM672AH	MI	DTUGYRD
DM672AH	MN	P-glycoprotein 1 (ABCB1)
DM672AH	MT	DTP
DM672AH	MA	Substrate
DM672AH	RN	Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22.
DM672AH	RU	http://www.ncbi.nlm.nih.gov/pubmed/12954186

DM672AH	DI	DM672AH
DM672AH	DN	Aspirin
DM672AH	MI	DTHE530
DM672AH	MN	Probable small intestine urate exporter (SLC17A4)
DM672AH	MT	DTP
DM672AH	MA	Substrate
DM672AH	RN	A Na+-phosphate cotransporter homologue (SLC17A4 protein) is an intestinal organic anion exporter. Am J Physiol Cell Physiol. 2012 Jun 1;302(11):C1652-60.
DM672AH	RU	http://www.ncbi.nlm.nih.gov/pubmed/22460716

DM672AH	DI	DM672AH
DM672AH	DN	Aspirin
DM672AH	MI	TTK0943
DM672AH	MN	Prostaglandin G/H synthase (COX)
DM672AH	MT	DTT
DM672AH	MA	Inhibitor
DM672AH	RN	Cyclooxygenase inhibitors: instrumental drugs to understand cardiovascular homeostasis and arterial thrombosis. Cardiovasc Hematol Disord Drug Targets. 2008 Dec;8(4):268-77.
DM672AH	RU	https://pubmed.ncbi.nlm.nih.gov/19075637

DM672AH	DI	DM672AH
DM672AH	DN	Aspirin
DM672AH	MI	DT8ARWJ
DM672AH	MN	Sodium-dependent phosphate transport protein 1 (SLC17A1)
DM672AH	MT	DTP
DM672AH	MA	Substrate
DM672AH	RN	Type 1 sodium-dependent phosphate transporter (SLC17A1 Protein) is a Cl(-)-dependent urate exporter. J Biol Chem. 2010 Aug 20;285(34):26107-13.
DM672AH	RU	http://www.ncbi.nlm.nih.gov/pubmed/20566650

DM672AH	DI	DM672AH
DM672AH	DN	Aspirin
DM672AH	MI	DEYWLRK
DM672AH	MN	Sulfotransferase 1A1 (SULT1A1)
DM672AH	MT	DME
DM672AH	MA	Metabolism
DM672AH	RN	Inhibition of human phenol and estrogen sulfotransferase by certain non-steroidal anti-inflammatory agents. Curr Drug Metab. 2006 Oct;7(7):745-53.
DM672AH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17073578

DM672AH	DI	DM672AH
DM672AH	DN	Aspirin
DM672AH	MI	DEYGVN4
DM672AH	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM672AH	MT	DME
DM672AH	MA	Metabolism
DM672AH	RN	Pharmacogenomics in aspirin intolerance. Curr Drug Metab. 2009 Nov;10(9):998-1008.
DM672AH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20214591

DM672AH	DI	DM672AH
DM672AH	DN	Aspirin
DM672AH	MI	DESD26P
DM672AH	MN	UDP-glucuronosyltransferase 1A6 (UGT1A6)
DM672AH	MT	DME
DM672AH	MA	Metabolism
DM672AH	RN	Polymorphisms of Aspirin-Metabolizing Enzymes CYP2C9, NAT2 and UGT1A6 in Aspirin-Intolerant Urticaria. Allergy Asthma Immunol Res. 2011 Oct;3(4):273-6.
DM672AH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21966608

DMSYRBX	DI	DMSYRBX
DMSYRBX	DN	Atazanavir
DMSYRBX	MI	DE5IED8
DMSYRBX	MN	Cytochrome P450 2C9 (CYP2C9)
DMSYRBX	MT	DME
DMSYRBX	MA	Metabolism
DMSYRBX	RN	Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2004 Dec;24(12):1732-47.
DMSYRBX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15585441

DMSYRBX	DI	DMSYRBX
DMSYRBX	DN	Atazanavir
DMSYRBX	MI	DE4LYSA
DMSYRBX	MN	Cytochrome P450 3A4 (CYP3A4)
DMSYRBX	MT	DME
DMSYRBX	MA	Metabolism
DMSYRBX	RN	Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos. 2005 Jun;33(6):764-70.
DMSYRBX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15764714

DMSYRBX	DI	DMSYRBX
DMSYRBX	DN	Atazanavir
DMSYRBX	MI	DEIBDNY
DMSYRBX	MN	Cytochrome P450 3A5 (CYP3A5)
DMSYRBX	MT	DME
DMSYRBX	MA	Metabolism
DMSYRBX	RN	Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos. 2005 Jun;33(6):764-70.
DMSYRBX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15764714

DMSYRBX	DI	DMSYRBX
DMSYRBX	DN	Atazanavir
DMSYRBX	MI	DERD86B
DMSYRBX	MN	Cytochrome P450 3A7 (CYP3A7)
DMSYRBX	MT	DME
DMSYRBX	MA	Metabolism
DMSYRBX	RN	Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos. 2005 Jun;33(6):764-70.
DMSYRBX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15764714

DMSYRBX	DI	DMSYRBX
DMSYRBX	DN	Atazanavir
DMSYRBX	MI	TT5FNQT
DMSYRBX	MN	Human immunodeficiency virus Protease (HIV PR)
DMSYRBX	MT	DTT
DMSYRBX	MA	Modulator
DMSYRBX	RN	Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacod... J Infect Dis. 2001 Apr 1;183(7):1126-9.
DMSYRBX	RU	https://pubmed.ncbi.nlm.nih.gov/11237841

DMSYRBX	DI	DMSYRBX
DMSYRBX	DN	Atazanavir
DMSYRBX	MI	DEYGVN4
DMSYRBX	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMSYRBX	MT	DME
DMSYRBX	MA	Metabolism
DMSYRBX	RN	In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos. 2005 Nov;33(11):1729-39.
DMSYRBX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16118329

DMNKG1Z	DI	DMNKG1Z
DMNKG1Z	DN	Atenolol
DMNKG1Z	MI	TTR6W5O
DMNKG1Z	MN	Adrenergic receptor beta-1 (ADRB1)
DMNKG1Z	MT	DTT
DMNKG1Z	MA	Antagonist
DMNKG1Z	RN	Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6.
DMNKG1Z	RU	https://pubmed.ncbi.nlm.nih.gov/16268148

DMNKG1Z	DI	DMNKG1Z
DMNKG1Z	DN	Atenolol
DMNKG1Z	MI	DECB0K3
DMNKG1Z	MN	Cytochrome P450 2D6 (CYP2D6)
DMNKG1Z	MT	DME
DMNKG1Z	MA	Metabolism
DMNKG1Z	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DMNKG1Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DMNKG1Z	DI	DMNKG1Z
DMNKG1Z	DN	Atenolol
DMNKG1Z	MI	DE4LYSA
DMNKG1Z	MN	Cytochrome P450 3A4 (CYP3A4)
DMNKG1Z	MT	DME
DMNKG1Z	MA	Metabolism
DMNKG1Z	RN	Metabolism of atenolol in man. Xenobiotica. 1978 May;8(5):313-20.
DMNKG1Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27019

DMNKG1Z	DI	DMNKG1Z
DMNKG1Z	DN	Atenolol
DMNKG1Z	MI	DTE2B1D
DMNKG1Z	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMNKG1Z	MT	DTP
DMNKG1Z	MA	Substrate
DMNKG1Z	RN	Fruit juice inhibition of uptake transport: a new type of food-drug interaction. Br J Clin Pharmacol. 2010 Nov;70(5):645-55.
DMNKG1Z	RU	http://www.ncbi.nlm.nih.gov/pubmed/21039758

DMNKG1Z	DI	DMNKG1Z
DMNKG1Z	DN	Atenolol
DMNKG1Z	MI	DTT79CX
DMNKG1Z	MN	Organic cation transporter 1 (SLC22A1)
DMNKG1Z	MT	DTP
DMNKG1Z	MA	Substrate
DMNKG1Z	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMNKG1Z	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DMNKG1Z	DI	DMNKG1Z
DMNKG1Z	DN	Atenolol
DMNKG1Z	MI	DTUGYRD
DMNKG1Z	MN	P-glycoprotein 1 (ABCB1)
DMNKG1Z	MT	DTP
DMNKG1Z	MA	Substrate
DMNKG1Z	RN	Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500.
DMNKG1Z	RU	http://www.ncbi.nlm.nih.gov/pubmed/11895100

DMMF8U0	DI	DMMF8U0
DMMF8U0	DN	Atezolizumab
DMMF8U0	MI	TT8ZLTI
DMMF8U0	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMMF8U0	MT	DTT
DMMF8U0	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMMF8U0	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761034s018lbl.pdf

DM5L6HI	DI	DM5L6HI
DM5L6HI	DN	Atomoxetine
DM5L6HI	MI	DECB0K3
DM5L6HI	MN	Cytochrome P450 2D6 (CYP2D6)
DM5L6HI	MT	DME
DM5L6HI	MA	Metabolism
DM5L6HI	RN	Atomoxetine: a review of its pharmacokinetics and pharmacogenomics relative to drug disposition. J Child Adolesc Psychopharmacol. 2016 May;26(4):314-26.
DM5L6HI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26859445

DM5L6HI	DI	DM5L6HI
DM5L6HI	DN	Atomoxetine
DM5L6HI	MI	DEGTFWK
DM5L6HI	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM5L6HI	MT	DME
DM5L6HI	MA	Metabolism
DM5L6HI	RN	Atomoxetine: a review of its pharmacokinetics and pharmacogenomics relative to drug disposition. J Child Adolesc Psychopharmacol. 2016 May;26(4):314-26.
DM5L6HI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26859445

DM5L6HI	DI	DM5L6HI
DM5L6HI	DN	Atomoxetine
DM5L6HI	MI	TTAWNKZ
DM5L6HI	MN	Norepinephrine transporter (NET)
DM5L6HI	MT	DTT
DM5L6HI	MA	Inhibitor
DM5L6HI	RN	Atomoxetine reverses attentional deficits produced by noradrenergic deafferentation of medial prefrontal cortex. Psychopharmacology (Berl). 2008 Sep;200(1):39-50.
DM5L6HI	RU	https://pubmed.ncbi.nlm.nih.gov/18568443

DM5L6HI	DI	DM5L6HI
DM5L6HI	DN	Atomoxetine
DM5L6HI	MI	DTUGYRD
DM5L6HI	MN	P-glycoprotein 1 (ABCB1)
DM5L6HI	MT	DTP
DM5L6HI	MA	Substrate
DM5L6HI	RN	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
DM5L6HI	RU	https://doi.org/10.1016/j.addr.2011.12.008

DMF28YC	DI	DMF28YC
DMF28YC	DN	Atorvastatin
DMF28YC	MI	DES5XRU
DMF28YC	MN	Cytochrome P450 2C8 (CYP2C8)
DMF28YC	MT	DME
DMF28YC	MA	Metabolism
DMF28YC	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DMF28YC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DMF28YC	DI	DMF28YC
DMF28YC	DN	Atorvastatin
DMF28YC	MI	DE4LYSA
DMF28YC	MN	Cytochrome P450 3A4 (CYP3A4)
DMF28YC	MT	DME
DMF28YC	MA	Metabolism
DMF28YC	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMF28YC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMF28YC	DI	DMF28YC
DMF28YC	DN	Atorvastatin
DMF28YC	MI	DEIBDNY
DMF28YC	MN	Cytochrome P450 3A5 (CYP3A5)
DMF28YC	MT	DME
DMF28YC	MA	Metabolism
DMF28YC	RN	Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm Res. 2006 Mar;23(3):506-12.
DMF28YC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16388406

DMF28YC	DI	DMF28YC
DMF28YC	DN	Atorvastatin
DMF28YC	MI	DERD86B
DMF28YC	MN	Cytochrome P450 3A7 (CYP3A7)
DMF28YC	MT	DME
DMF28YC	MA	Metabolism
DMF28YC	RN	Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers.
DMF28YC	RU	https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm

DMF28YC	DI	DMF28YC
DMF28YC	DN	Atorvastatin
DMF28YC	MI	TTPADOQ
DMF28YC	MN	HMG-CoA reductase (HMGCR)
DMF28YC	MT	DTT
DMF28YC	MA	Inhibitor
DMF28YC	RN	Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64.
DMF28YC	RU	https://pubmed.ncbi.nlm.nih.gov/11523064

DMF28YC	DI	DMF28YC
DMF28YC	DN	Atorvastatin
DMF28YC	MI	DT342ZG
DMF28YC	MN	Monocarboxylate transporter 1 (SLC16A1)
DMF28YC	MT	DTP
DMF28YC	MA	Substrate
DMF28YC	RN	H+-coupled nutrient, micronutrient and drug transporters in the mammalian small intestine. Exp Physiol. 2007 Jul;92(4):603-19.
DMF28YC	RU	https://doi.org/10.1113/expphysiol.2005.029959

DMF28YC	DI	DMF28YC
DMF28YC	DN	Atorvastatin
DMF28YC	MI	DTLT3UG
DMF28YC	MN	Monocarboxylate transporter 2 (SLC16A7)
DMF28YC	MT	DTP
DMF28YC	MA	Substrate
DMF28YC	RN	Monocarboxylate Transporters in Drug Disposition: Role in the Toxicokinetics and Toxicodynamics of the Drug of Abuse GHB.
DMF28YC	RU	https://www.njacs.org/wp-content/docs/2010-Spring-DrugMet-Marilyn_Morris.pdf

DMF28YC	DI	DMF28YC
DMF28YC	DN	Atorvastatin
DMF28YC	MI	DTE2B1D
DMF28YC	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMF28YC	MT	DTP
DMF28YC	MA	Substrate
DMF28YC	RN	Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol. 2010 Dec 1;80(11):1746-53.
DMF28YC	RU	http://www.ncbi.nlm.nih.gov/pubmed/20797388

DMF28YC	DI	DMF28YC
DMF28YC	DN	Atorvastatin
DMF28YC	MI	DT3D8F0
DMF28YC	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMF28YC	MT	DTP
DMF28YC	MA	Substrate
DMF28YC	RN	Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
DMF28YC	RU	http://www.ncbi.nlm.nih.gov/pubmed/19374892

DMF28YC	DI	DMF28YC
DMF28YC	DN	Atorvastatin
DMF28YC	MI	DT9C1TS
DMF28YC	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMF28YC	MT	DTP
DMF28YC	MA	Substrate
DMF28YC	RN	FDA Drug Development and Drug Interactions
DMF28YC	RU	https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2

DMF28YC	DI	DMF28YC
DMF28YC	DN	Atorvastatin
DMF28YC	MI	DTPFTEQ
DMF28YC	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DMF28YC	MT	DTP
DMF28YC	MA	Substrate
DMF28YC	RN	Human platelets express organic anion-transporting peptide 2B1, an uptake transporter for atorvastatin. Drug Metab Dispos. 2009 May;37(5):1129-37.
DMF28YC	RU	http://www.ncbi.nlm.nih.gov/pubmed/19237515

DMF28YC	DI	DMF28YC
DMF28YC	DN	Atorvastatin
DMF28YC	MI	DTUGYRD
DMF28YC	MN	P-glycoprotein 1 (ABCB1)
DMF28YC	MT	DTP
DMF28YC	MA	Substrate
DMF28YC	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DMF28YC	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DMF28YC	DI	DMF28YC
DMF28YC	DN	Atorvastatin
DMF28YC	MI	DEYGVN4
DMF28YC	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMF28YC	MT	DME
DMF28YC	MA	Metabolism
DMF28YC	RN	Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid. Drug Metab Dispos. 2007 Aug;35(8):1315-24.
DMF28YC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17470524

DMF28YC	DI	DMF28YC
DMF28YC	DN	Atorvastatin
DMF28YC	MI	DEF2WXN
DMF28YC	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMF28YC	MT	DME
DMF28YC	MA	Metabolism
DMF28YC	RN	UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone. Mol Diagn Ther. 2013 Aug;17(4):233-7.
DMF28YC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23580084

DMY4UMW	DI	DMY4UMW
DMY4UMW	DN	Atovaquone
DMY4UMW	MI	DE4LYSA
DMY4UMW	MN	Cytochrome P450 3A4 (CYP3A4)
DMY4UMW	MT	DME
DMY4UMW	MA	Metabolism
DMY4UMW	RN	Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis. Eur J Clin Pharmacol. 2002 Apr;58(1):19-27.
DMY4UMW	RU	https://www.ncbi.nlm.nih.gov/pubmed/11956669

DMY4UMW	DI	DMY4UMW
DMY4UMW	DN	Atovaquone
DMY4UMW	MI	TT3PQ2Y
DMY4UMW	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DMY4UMW	MT	DTT
DMY4UMW	MA	Inhibitor
DMY4UMW	RN	Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane-associated N-terminal domain. Protein Sci. 2004 Apr;13(4):1031-42.
DMY4UMW	RU	https://pubmed.ncbi.nlm.nih.gov/15044733

DM42HXN	DI	DM42HXN
DM42HXN	DN	Atracurium
DM42HXN	MI	TTJSZTB
DM42HXN	MN	Nicotinic acetylcholine receptor (nAChR)
DM42HXN	MT	DTT
DM42HXN	MA	Antagonist
DM42HXN	RN	Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52.
DM42HXN	RU	https://pubmed.ncbi.nlm.nih.gov/19417616

DMEN6X7	DI	DMEN6X7
DMEN6X7	DN	Atropine
DMEN6X7	MI	TTH18TF
DMEN6X7	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMEN6X7	MT	DTT
DMEN6X7	MA	Antagonist
DMEN6X7	RN	Additive protective effects of donepezil and nicotine against salsolinol-induced cytotoxicity in SH-SY5Y cells. Neurotox Res. 2009 Oct;16(3):194-204.
DMEN6X7	RU	https://pubmed.ncbi.nlm.nih.gov/19526284

DMEN6X7	DI	DMEN6X7
DMEN6X7	DN	Atropine
DMEN6X7	MI	DTT79CX
DMEN6X7	MN	Organic cation transporter 1 (SLC22A1)
DMEN6X7	MT	DTP
DMEN6X7	MA	Substrate
DMEN6X7	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMEN6X7	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DM79Y2T	DI	DM79Y2T
DM79Y2T	DN	ATryn antithrombin
DM79Y2T	MI	TT6L509
DM79Y2T	MN	Coagulation factor IIa (F2)
DM79Y2T	MT	DTT
DM79Y2T	MA	Modulator
DM79Y2T	RN	Antithrombin III Utilization in a Large Teaching Hospital. P T. 2013 December; 38(12): 764-767, 779.
DM79Y2T	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875262/

DMWE2N4	DI	DMWE2N4
DMWE2N4	DN	Auranofin
DMWE2N4	MI	DTZGT0P
DMWE2N4	MN	Multidrug and toxin extrusion protein 1 (SLC47A1)
DMWE2N4	MT	DTP
DMWE2N4	MA	Substrate
DMWE2N4	RN	Selection and characterization of a human ovarian cancer cell line resistant to auranofin. Oncotarget. 2017 Oct 9;8(56):96062-96078.
DMWE2N4	RU	http://www.ncbi.nlm.nih.gov/pubmed/29221187

DMWE2N4	DI	DMWE2N4
DMWE2N4	DN	Auranofin
DMWE2N4	MI	DTT79CX
DMWE2N4	MN	Organic cation transporter 1 (SLC22A1)
DMWE2N4	MT	DTP
DMWE2N4	MA	Substrate
DMWE2N4	RN	Selection and characterization of a human ovarian cancer cell line resistant to auranofin. Oncotarget. 2017 Oct 9;8(56):96062-96078.
DMWE2N4	RU	http://www.ncbi.nlm.nih.gov/pubmed/29221187

DMWE2N4	DI	DMWE2N4
DMWE2N4	DN	Auranofin
DMWE2N4	MI	TTP3UTW
DMWE2N4	MN	Steroid hormone receptor ERR (ESRR)
DMWE2N4	MT	DTT
DMWE2N4	MA	Modulator
DMWE2N4	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMWE2N4	RU	https://www.fda.gov/

DM75CXN	DI	DM75CXN
DM75CXN	DN	Avanafil
DM75CXN	MI	DE4LYSA
DM75CXN	MN	Cytochrome P450 3A4 (CYP3A4)
DM75CXN	MT	DME
DM75CXN	MA	Metabolism
DM75CXN	RN	An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors. Expert Opin Pharmacother. 2013 Jul;14(10):1333-44.
DM75CXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23675780

DM75CXN	DI	DM75CXN
DM75CXN	DN	Avanafil
DM75CXN	MI	TTJ0IQB
DM75CXN	MN	Phosphodiesterase 5A (PDE5A)
DM75CXN	MT	DTT
DM75CXN	MA	Modulator
DM75CXN	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DM75CXN	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMK2GZX	DI	DMK2GZX
DMK2GZX	DN	Avapritinib
DMK2GZX	MI	TT8FYO9
DMK2GZX	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMK2GZX	MT	DTT
DMK2GZX	MA	Inhibitor
DMK2GZX	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMK2GZX	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212608s000lbl.pdf

DMSZLJR	DI	DMSZLJR
DMSZLJR	DN	Avelumab
DMSZLJR	MI	TT8ZLTI
DMSZLJR	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMSZLJR	MT	DTT
DMSZLJR	RN	Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res. 2015 Oct;3(10):1148-57.
DMSZLJR	RU	https://pubmed.ncbi.nlm.nih.gov/26014098

DM1AEH4	DI	DM1AEH4
DM1AEH4	DN	Avibactam
DM1AEH4	MI	DE7IH52
DM1AEH4	MN	Beta-lactamase (blaB)
DM1AEH4	MT	DME
DM1AEH4	MA	Metabolism
DM1AEH4	RN	nan
DM1AEH4	RU	nan

DMYHN59	DI	DMYHN59
DMYHN59	DN	Axicabtagene ciloleucel
DMYHN59	MI	TTW640A
DMYHN59	MN	B-lymphocyte surface antigen B4 (CD19)
DMYHN59	MT	DTT
DMYHN59	MA	CAR-T-Cell-Therapy
DMYHN59	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services
DMYHN59	RU	https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/yescarta-axicabtagene-ciloleucel

DMGVH6N	DI	DMGVH6N
DMGVH6N	DN	Axitinib
DMGVH6N	MI	DEJGDUW
DMGVH6N	MN	Cytochrome P450 1A2 (CYP1A2)
DMGVH6N	MT	DME
DMGVH6N	MA	Metabolism
DMGVH6N	RN	Clinical pharmacology of axitinib. Clin Pharmacokinet. 2013 Sep;52(9):713-25.
DMGVH6N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23677771

DMGVH6N	DI	DMGVH6N
DMGVH6N	DN	Axitinib
DMGVH6N	MI	DE4LYSA
DMGVH6N	MN	Cytochrome P450 3A4 (CYP3A4)
DMGVH6N	MT	DME
DMGVH6N	MA	Metabolism
DMGVH6N	RN	Clinical pharmacology of axitinib. Clin Pharmacokinet. 2013 Sep;52(9):713-25.
DMGVH6N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23677771

DMGVH6N	DI	DMGVH6N
DMGVH6N	DN	Axitinib
DMGVH6N	MI	DEIBDNY
DMGVH6N	MN	Cytochrome P450 3A5 (CYP3A5)
DMGVH6N	MT	DME
DMGVH6N	MA	Metabolism
DMGVH6N	RN	Clinical pharmacology of axitinib. Clin Pharmacokinet. 2013 Sep;52(9):713-25.
DMGVH6N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23677771

DMGVH6N	DI	DMGVH6N
DMGVH6N	DN	Axitinib
DMGVH6N	MI	DEGTFWK
DMGVH6N	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMGVH6N	MT	DME
DMGVH6N	MA	Metabolism
DMGVH6N	RN	Clinical pharmacology of axitinib. Clin Pharmacokinet. 2013 Sep;52(9):713-25.
DMGVH6N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23677771

DMGVH6N	DI	DMGVH6N
DMGVH6N	DN	Axitinib
DMGVH6N	MI	DT3D8F0
DMGVH6N	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMGVH6N	MT	DTP
DMGVH6N	MA	Substrate
DMGVH6N	RN	Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics. Eur J Clin Pharmacol. 2012 May;68(5):645-55.
DMGVH6N	RU	http://www.ncbi.nlm.nih.gov/pubmed/22170007

DMGVH6N	DI	DMGVH6N
DMGVH6N	DN	Axitinib
DMGVH6N	MI	DTUGYRD
DMGVH6N	MN	P-glycoprotein 1 (ABCB1)
DMGVH6N	MT	DTP
DMGVH6N	MA	Substrate
DMGVH6N	RN	Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics. Eur J Clin Pharmacol. 2012 May;68(5):645-55.
DMGVH6N	RU	http://www.ncbi.nlm.nih.gov/pubmed/22170007

DMGVH6N	DI	DMGVH6N
DMGVH6N	DN	Axitinib
DMGVH6N	MI	DEYGVN4
DMGVH6N	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMGVH6N	MT	DME
DMGVH6N	MA	Metabolism
DMGVH6N	RN	Clinical pharmacology of axitinib. Clin Pharmacokinet. 2013 Sep;52(9):713-25.
DMGVH6N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23677771

DMGVH6N	DI	DMGVH6N
DMGVH6N	DN	Axitinib
DMGVH6N	MI	TTUTJGQ
DMGVH6N	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMGVH6N	MT	DTT
DMGVH6N	MA	Modulator
DMGVH6N	RN	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
DMGVH6N	RU	https://pubmed.ncbi.nlm.nih.gov/23370234

DMTA5OE	DI	DMTA5OE
DMTA5OE	DN	Azacitidine
DMTA5OE	MI	DEKEDRC
DMTA5OE	MN	Cytidine aminohydrolase (CDA)
DMTA5OE	MT	DME
DMTA5OE	MA	Metabolism
DMTA5OE	RN	A pilot pharmacokinetic study of oral azacitidine. Leukemia. 2008 Sep;22(9):1680-4.
DMTA5OE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18548103

DMTA5OE	DI	DMTA5OE
DMTA5OE	DN	Azacitidine
DMTA5OE	MI	DEYILK4
DMTA5OE	MN	Cytidine deaminase (cdd)
DMTA5OE	MT	DME
DMTA5OE	MA	Metabolism
DMTA5OE	RN	Mycoplasma hyorhinis-encoded cytidine deaminase efficiently inactivates cytosine-based anticancer drugs. FEBS Open Bio. 2015 Aug 3;5:634-9.
DMTA5OE	RU	https://pubmed.ncbi.nlm.nih.gov/26322268

DMTA5OE	DI	DMTA5OE
DMTA5OE	DN	Azacitidine
DMTA5OE	MI	TTHVCUP
DMTA5OE	MN	DNA [cytosine-5]-methyltransferase (DNMT)
DMTA5OE	MT	DTT
DMTA5OE	MA	Inhibitor
DMTA5OE	RN	The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid l... Leukemia. 2009 Jun;23(6):1019-28.
DMTA5OE	RU	https://pubmed.ncbi.nlm.nih.gov/19194470

DMZ80SB	DI	DMZ80SB
DMZ80SB	DN	Azatadine
DMZ80SB	MI	TTTIBOJ
DMZ80SB	MN	Histamine H1 receptor (H1R)
DMZ80SB	MT	DTT
DMZ80SB	MA	Antagonist
DMZ80SB	RN	Comparative effects of loratadine and azatadine in the treatment of seasonal allergic rhinitis. Asian Pac J Allergy Immunol. 1990 Dec;8(2):103-7.
DMZ80SB	RU	https://pubmed.ncbi.nlm.nih.gov/1982614

DMMZSXQ	DI	DMMZSXQ
DMMZSXQ	DN	Azathioprine
DMMZSXQ	MI	TTZFTY4
DMMZSXQ	MN	Amidophosphoribosyltransferase (PPAT)
DMMZSXQ	MT	DTT
DMMZSXQ	MA	Inhibitor
DMMZSXQ	RN	IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations. Br J Clin Pharmacol. 2008 Jan;65(1):69-77.
DMMZSXQ	RU	https://pubmed.ncbi.nlm.nih.gov/17662091

DMMZSXQ	DI	DMMZSXQ
DMMZSXQ	DN	Azathioprine
DMMZSXQ	MI	DEJGDUW
DMMZSXQ	MN	Cytochrome P450 1A2 (CYP1A2)
DMMZSXQ	MT	DME
DMMZSXQ	MA	Metabolism
DMMZSXQ	RN	Brassica vegetables increase and apiaceous vegetables decrease cytochrome P450 1A2 activity in humans: changes in caffeine metabolite ratios in response to controlled vegetable diets. Carcinogenesis. 2000 Jun;21(6):1157-62.
DMMZSXQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10837004

DMMZSXQ	DI	DMMZSXQ
DMMZSXQ	DN	Azathioprine
DMMZSXQ	MI	DEH49YS
DMMZSXQ	MN	Glutathione S-transferase alpha-2 (GSTA2)
DMMZSXQ	MT	DME
DMMZSXQ	MA	Metabolism
DMMZSXQ	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA2040)
DMMZSXQ	RU	https://www.pharmgkb.org/pathway/PA2040

DMMZSXQ	DI	DMMZSXQ
DMMZSXQ	DN	Azathioprine
DMMZSXQ	MI	DEYZEJA
DMMZSXQ	MN	Glutathione S-transferase mu-1 (GSTM1)
DMMZSXQ	MT	DME
DMMZSXQ	MA	Metabolism
DMMZSXQ	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA2040)
DMMZSXQ	RU	https://www.pharmgkb.org/pathway/PA2040

DMMZSXQ	DI	DMMZSXQ
DMMZSXQ	DN	Azathioprine
DMMZSXQ	MI	DTUGYRD
DMMZSXQ	MN	P-glycoprotein 1 (ABCB1)
DMMZSXQ	MT	DTP
DMMZSXQ	MA	Substrate
DMMZSXQ	RN	Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22.
DMMZSXQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/12954186

DMMZSXQ	DI	DMMZSXQ
DMMZSXQ	DN	Azathioprine
DMMZSXQ	MI	DEFQ8VO
DMMZSXQ	MN	Thiopurine methyltransferase (TPMT)
DMMZSXQ	MT	DME
DMMZSXQ	MA	Metabolism
DMMZSXQ	RN	Nodular regenerative liver hyperplasia as a complication of azathioprine-containing immunosuppressive treatment for Crohn's disease. Immunopharmacol Immunotoxicol. 2011 Jun;33(2):398-402.
DMMZSXQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20726808

DMHVL0J	DI	DMHVL0J
DMHVL0J	DN	Azelaic Acid
DMHVL0J	MI	TT2A0DR
DMHVL0J	MN	Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A)
DMHVL0J	MT	DTT
DMHVL0J	MA	Inhibitor
DMHVL0J	RN	Inhibition of 5 alpha-reductase activity in human skin by zinc and azelaic acid. Br J Dermatol. 1988 Nov;119(5):627-32.
DMHVL0J	RU	https://pubmed.ncbi.nlm.nih.gov/3207614

DMXTMBJ	DI	DMXTMBJ
DMXTMBJ	DN	Azelastine
DMXTMBJ	MI	DEJGDUW
DMXTMBJ	MN	Cytochrome P450 1A2 (CYP1A2)
DMXTMBJ	MT	DME
DMXTMBJ	MA	Metabolism
DMXTMBJ	RN	In vitro identification of the human cytochrome P-450 enzymes involved in the N-demethylation of azelastine. Drug Metab Dispos. 1999 Aug;27(8):942-6.
DMXTMBJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10421623

DMXTMBJ	DI	DMXTMBJ
DMXTMBJ	DN	Azelastine
DMXTMBJ	MI	DEJVYAZ
DMXTMBJ	MN	Cytochrome P450 2A6 (CYP2A6)
DMXTMBJ	MT	DME
DMXTMBJ	MA	Metabolism
DMXTMBJ	RN	Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab Dispos. 1999 Dec;27(12):1381-91.
DMXTMBJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10570018

DMXTMBJ	DI	DMXTMBJ
DMXTMBJ	DN	Azelastine
DMXTMBJ	MI	DES5XRU
DMXTMBJ	MN	Cytochrome P450 2C8 (CYP2C8)
DMXTMBJ	MT	DME
DMXTMBJ	MA	Metabolism
DMXTMBJ	RN	Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab Dispos. 1999 Dec;27(12):1381-91.
DMXTMBJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10570018

DMXTMBJ	DI	DMXTMBJ
DMXTMBJ	DN	Azelastine
DMXTMBJ	MI	DE5IED8
DMXTMBJ	MN	Cytochrome P450 2C9 (CYP2C9)
DMXTMBJ	MT	DME
DMXTMBJ	MA	Metabolism
DMXTMBJ	RN	Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab Dispos. 1999 Dec;27(12):1381-91.
DMXTMBJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10570018

DMXTMBJ	DI	DMXTMBJ
DMXTMBJ	DN	Azelastine
DMXTMBJ	MI	DECB0K3
DMXTMBJ	MN	Cytochrome P450 2D6 (CYP2D6)
DMXTMBJ	MT	DME
DMXTMBJ	MA	Metabolism
DMXTMBJ	RN	Inhibitory effects of azelastine and its metabolites on drug oxidation catalyzed by human cytochrome P-450 enzymes. Drug Metab Dispos. 1999 Jul;27(7):792-7.
DMXTMBJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10383922

DMXTMBJ	DI	DMXTMBJ
DMXTMBJ	DN	Azelastine
DMXTMBJ	MI	DE4LYSA
DMXTMBJ	MN	Cytochrome P450 3A4 (CYP3A4)
DMXTMBJ	MT	DME
DMXTMBJ	MA	Metabolism
DMXTMBJ	RN	In vitro identification of the human cytochrome P-450 enzymes involved in the N-demethylation of azelastine. Drug Metab Dispos. 1999 Aug;27(8):942-6.
DMXTMBJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10421623

DMXTMBJ	DI	DMXTMBJ
DMXTMBJ	DN	Azelastine
DMXTMBJ	MI	DEIBDNY
DMXTMBJ	MN	Cytochrome P450 3A5 (CYP3A5)
DMXTMBJ	MT	DME
DMXTMBJ	MA	Metabolism
DMXTMBJ	RN	Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab Dispos. 1999 Dec;27(12):1381-91.
DMXTMBJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10570018

DMXTMBJ	DI	DMXTMBJ
DMXTMBJ	DN	Azelastine
DMXTMBJ	MI	TTTIBOJ
DMXTMBJ	MN	Histamine H1 receptor (H1R)
DMXTMBJ	MT	DTT
DMXTMBJ	MA	Antagonist
DMXTMBJ	RN	Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79.
DMXTMBJ	RU	https://pubmed.ncbi.nlm.nih.gov/18446005

DMXTMBJ	DI	DMXTMBJ
DMXTMBJ	DN	Azelastine
DMXTMBJ	MI	DEGTFWK
DMXTMBJ	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMXTMBJ	MT	DME
DMXTMBJ	MA	Metabolism
DMXTMBJ	RN	In vitro identification of the human cytochrome P-450 enzymes involved in the N-demethylation of azelastine. Drug Metab Dispos. 1999 Aug;27(8):942-6.
DMXTMBJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10421623

DMOIX5S	DI	DMOIX5S
DMOIX5S	DN	Azilsartan
DMOIX5S	MI	TT8DBY3
DMOIX5S	MN	Angiotensin II receptor type-1 (AGTR1)
DMOIX5S	MT	DTT
DMOIX5S	MA	Modulator
DMOIX5S	RN	2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
DMOIX5S	RU	https://pubmed.ncbi.nlm.nih.gov/22293555

DMIR5QP	DI	DMIR5QP
DMIR5QP	DN	Azlocillin
DMIR5QP	MI	TTJP4SM
DMIR5QP	MN	Bacterial Penicillin binding protein (Bact PBP)
DMIR5QP	MT	DTT
DMIR5QP	MA	Binder
DMIR5QP	RN	Reactivation of peptidoglycan synthesis in ether-permeabilized Escherichia coli after inhibition by beta-lactam antibiotics. Antimicrob Agents Chemother. 1989 Dec;33(12):2101-8.
DMIR5QP	RU	https://pubmed.ncbi.nlm.nih.gov/2515794

DMDNJHG	DI	DMDNJHG
DMDNJHG	DN	Aztreonam
DMDNJHG	MI	TT85JMW
DMDNJHG	MN	Bacterial Penicillin binding protein 3 (Bact mrcA)
DMDNJHG	MT	DTT
DMDNJHG	MA	Binder
DMDNJHG	RN	Penicillin-binding protein PBP2 of Escherichia coli localizes preferentially in the lateral wall and at mid-cell in comparison with the old cell pole. Mol Microbiol. 2003 Jan;47(2):539-47.
DMDNJHG	RU	https://pubmed.ncbi.nlm.nih.gov/12519203

DMDNJHG	DI	DMDNJHG
DMDNJHG	DN	Aztreonam
DMDNJHG	MI	DEP0IWS
DMDNJHG	MN	Beta-lactamase (blaB)
DMDNJHG	MT	DME
DMDNJHG	MA	Metabolism
DMDNJHG	RN	Analysis of the drug-resistant characteristics of Klebsiella pneumoniae isolated from the respiratory tract and CTX-M ESBL genes. Genet Mol Res. 2015 Oct 5;14(4):12043-8.
DMDNJHG	RU	https://pubmed.ncbi.nlm.nih.gov/26505351

DMDNJHG	DI	DMDNJHG
DMDNJHG	DN	Aztreonam
DMDNJHG	MI	DEEAL81
DMDNJHG	MN	Beta-lactamase (blaB)
DMDNJHG	MT	DME
DMDNJHG	MA	Metabolism
DMDNJHG	RN	Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe. J Antimicrob Chemother. 1996 Sep;38(3):409-24.
DMDNJHG	RU	https://pubmed.ncbi.nlm.nih.gov/8889716

DMDNJHG	DI	DMDNJHG
DMDNJHG	DN	Aztreonam
DMDNJHG	MI	DE4LYSA
DMDNJHG	MN	Cytochrome P450 3A4 (CYP3A4)
DMDNJHG	MT	DME
DMDNJHG	MA	Metabolism
DMDNJHG	RN	Aztreonam decreases hepatic microsomal cytochrome P450 in cynomolgus monkeys. Pharmacology. 1994 Mar;48(3):137-42.
DMDNJHG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8153141

DMDNJHG	DI	DMDNJHG
DMDNJHG	DN	Aztreonam
DMDNJHG	MI	DEIBDNY
DMDNJHG	MN	Cytochrome P450 3A5 (CYP3A5)
DMDNJHG	MT	DME
DMDNJHG	MA	Metabolism
DMDNJHG	RN	Aztreonam decreases hepatic microsomal cytochrome P450 in cynomolgus monkeys. Pharmacology. 1994 Mar;48(3):137-42.
DMDNJHG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8153141

DMDNJHG	DI	DMDNJHG
DMDNJHG	DN	Aztreonam
DMDNJHG	MI	DERD86B
DMDNJHG	MN	Cytochrome P450 3A7 (CYP3A7)
DMDNJHG	MT	DME
DMDNJHG	MA	Metabolism
DMDNJHG	RN	Aztreonam decreases hepatic microsomal cytochrome P450 in cynomolgus monkeys. Pharmacology. 1994 Mar;48(3):137-42.
DMDNJHG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8153141

DMP54C7	DI	DMP54C7
DMP54C7	DN	Bacampicillin
DMP54C7	MI	TTJP4SM
DMP54C7	MN	Bacterial Penicillin binding protein (Bact PBP)
DMP54C7	MT	DTT
DMP54C7	MA	Binder
DMP54C7	RN	Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
DMP54C7	RU	https://pubmed.ncbi.nlm.nih.gov/17016423

DMD2871	DI	DMD2871
DMD2871	DN	Bacitracin
DMD2871	MI	DEK9LVM
DMD2871	MN	Endoglucanase A (EGA)
DMD2871	MT	DME
DMD2871	MA	Metabolism
DMD2871	RN	Expression of Clostridium thermocellum endoglucanase gene in Lactobacillus gasseri and Lactobacillus johnsonii and characterization of the genetically modified probiotic lactobacilli. Curr Microbiol. 2000 Apr;40(4):257-63.
DMD2871	RU	https://pubmed.ncbi.nlm.nih.gov/10688695

DMD2871	DI	DMD2871
DMD2871	DN	Bacitracin
DMD2871	MI	DE2M583
DMD2871	MN	Endoglucanase Y (EGY)
DMD2871	MT	DME
DMD2871	MA	Metabolism
DMD2871	RN	Expression of Clostridium thermocellum endoglucanase gene in Lactobacillus gasseri and Lactobacillus johnsonii and characterization of the genetically modified probiotic lactobacilli. Curr Microbiol. 2000 Apr;40(4):257-63.
DMD2871	RU	https://pubmed.ncbi.nlm.nih.gov/10688695

DM5OHYE	DI	DM5OHYE
DM5OHYE	DN	Bacitracin
DM5OHYE	MI	TT2EDHU
DM5OHYE	MN	Insulin-degrading enzyme (IDE)
DM5OHYE	MT	DTT
DM5OHYE	MA	Inhibitor
DM5OHYE	RN	Brain insulin impairs amyloid-beta(1-40) clearance from the brain. J Neurosci. 2004 Oct 27;24(43):9632-7.
DM5OHYE	RU	https://pubmed.ncbi.nlm.nih.gov/15509750

DM0QV1J	DI	DM0QV1J
DM0QV1J	DN	Baclofen
DM0QV1J	MI	TTDCVZW
DM0QV1J	MN	Gamma-aminobutyric acid B receptor (GABBR)
DM0QV1J	MT	DTT
DM0QV1J	MA	Modulator
DM0QV1J	RN	Synthesis and pharmacology of the baclofen homologues 5-amino-4-(4-chlorophenyl)pentanoic acid and the R- and S-enantiomers of 5-amino-3-(4-chlorop... J Med Chem. 1999 Jun 3;42(11):2053-9.
DM0QV1J	RU	https://pubmed.ncbi.nlm.nih.gov/10354414

DMPWNDB	DI	DMPWNDB
DMPWNDB	DN	Balofloxacin
DMPWNDB	MI	TTJP4SM
DMPWNDB	MN	Bacterial Penicillin binding protein (Bact PBP)
DMPWNDB	MT	DTT
DMPWNDB	MA	Inhibitor
DMPWNDB	RN	Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
DMPWNDB	RU	https://pubmed.ncbi.nlm.nih.gov/15934867

DM1UV7F	DI	DM1UV7F
DM1UV7F	DN	Baloxavir marboxil
DM1UV7F	MI	DE4LYSA
DM1UV7F	MN	Cytochrome P450 3A4 (CYP3A4)
DM1UV7F	MT	DME
DM1UV7F	MA	Metabolism
DM1UV7F	RN	FDA Label of Baloxavir marboxil. The 2020 official website of the U.S. Food and Drug Administration.
DM1UV7F	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210854s000lbl.pdf

DM1UV7F	DI	DM1UV7F
DM1UV7F	DN	Baloxavir marboxil
DM1UV7F	MI	TTWORX6
DM1UV7F	MN	Influenza Polymerase acidic endonuclease (Influ PA)
DM1UV7F	MT	DTT
DM1UV7F	MA	Inhibitor
DM1UV7F	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DM1UV7F	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMRJ9EN	DI	DMRJ9EN
DMRJ9EN	DN	Baloxavir marboxil
DMRJ9EN	MI	DTUGYRD
DMRJ9EN	MN	P-glycoprotein 1 (ABCB1)
DMRJ9EN	MT	DTP
DMRJ9EN	MA	Substrate
DMRJ9EN	RN	Baloxavir Marboxil FDA label
DMRJ9EN	RU	https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/078/original/Baloxavir_Marboxil_FDA_label.pdf?1543255968

DM1UV7F	DI	DM1UV7F
DM1UV7F	DN	Baloxavir marboxil
DM1UV7F	MI	DEF2WXN
DM1UV7F	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DM1UV7F	MT	DME
DM1UV7F	MA	Metabolism
DM1UV7F	RN	FDA Label of Baloxavir marboxil. The 2020 official website of the U.S. Food and Drug Administration.
DM1UV7F	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210854s000lbl.pdf

DM7I1T9	DI	DM7I1T9
DM7I1T9	DN	Balsalazide
DM7I1T9	MI	DEEHWOG
DM7I1T9	MN	Azoreductase (azoR)
DM7I1T9	MT	DME
DM7I1T9	MA	Metabolism
DM7I1T9	RN	Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide. Dig Dis Sci. 1983 Jul;28(7):609-15.
DM7I1T9	RU	https://pubmed.ncbi.nlm.nih.gov/6345112

DM7I1T9	DI	DM7I1T9
DM7I1T9	DN	Balsalazide
DM7I1T9	MI	DETQAEP
DM7I1T9	MN	FMN-dependent NADH-azoreductase (azoR1)
DM7I1T9	MT	DME
DM7I1T9	MA	Metabolism
DM7I1T9	RN	nan
DM7I1T9	RU	nan

DMO091F	DI	DMO091F
DMO091F	DN	Balsalazide
DMO091F	MI	TT8NGED
DMO091F	MN	Prostaglandin G/H synthase 1 (COX-1)
DMO091F	MT	DTT
DMO091F	MA	Inhibitor
DMO091F	RN	Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
DMO091F	RU	https://pubmed.ncbi.nlm.nih.gov/17016423

DMKLSHF	DI	DMKLSHF
DMKLSHF	DN	Bambuterol
DMKLSHF	MI	TT2CJVK
DMKLSHF	MN	Adrenergic receptor beta-2 (ADRB2)
DMKLSHF	MT	DTT
DMKLSHF	MA	Agonist
DMKLSHF	RN	Enantiomeric separation of beta2-agonists on macrocyclic antibiotic chiral stationary phases in high performance liquid chromatography. Pharmazie. 2007 Nov;62(11):836-40.
DMKLSHF	RU	https://pubmed.ncbi.nlm.nih.gov/18065099

DMXLHYN	DI	DMXLHYN
DMXLHYN	DN	Bamifylline
DMXLHYN	MI	DEJGDUW
DMXLHYN	MN	Cytochrome P450 1A2 (CYP1A2)
DMXLHYN	MT	DME
DMXLHYN	MA	Metabolism
DMXLHYN	RN	PharmGKB summary: caffeine pathway. Pharmacogenet Genomics. 2012 May;22(5):389-95.
DMXLHYN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22293536

DME1DJX	DI	DME1DJX
DME1DJX	DN	Baquting
DME1DJX	MI	TTWODQF
DME1DJX	MN	Fibrin (FG)
DME1DJX	MT	DTT
DME1DJX	MA	Modulator
DME1DJX	RN	Baquting, enable our sales and marketing team to effectively promote our principal products and help to stimulate the sales of our other pharmaceuticals.
DME1DJX	RU	http://www.sec.gov/Archives/edgar/data/1474952/000119312509239183/df1.htm

DMJ8NMC	DI	DMJ8NMC
DMJ8NMC	DN	Barbital
DMJ8NMC	MI	TT1MPAY
DMJ8NMC	MN	GABA(A) receptor alpha-1 (GABRA1)
DMJ8NMC	MT	DTT
DMJ8NMC	MA	Antagonist
DMJ8NMC	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DMJ8NMC	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DMJ8NMC	DI	DMJ8NMC
DMJ8NMC	DN	Barbital
DMJ8NMC	MI	DEGTFWK
DMJ8NMC	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMJ8NMC	MT	DME
DMJ8NMC	MA	Metabolism
DMJ8NMC	RN	Effects of cytochrome P450 (CYP)2C19 polymorphisms on pharmacokinetics of phenobarbital in neonates and infants with seizures. Arch Dis Child. 2012 Jun;97(6):569-72.
DMJ8NMC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22331680

DMJIA6T	DI	DMJIA6T
DMJIA6T	DN	Barbiturate
DMJIA6T	MI	TT1MPAY
DMJIA6T	MN	GABA(A) receptor alpha-1 (GABRA1)
DMJIA6T	MT	DTT
DMJIA6T	MA	Antagonist
DMJIA6T	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DMJIA6T	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DMJIA6T	DI	DMJIA6T
DMJIA6T	DN	Barbiturate
DMJIA6T	MI	TTAN6JD
DMJIA6T	MN	Glutamate receptor AMPA (GRIA)
DMJIA6T	MT	DTT
DMJIA6T	MA	Agonist
DMJIA6T	RN	Anaesthetic drugs: linking molecular actions to clinical effects. Curr Pharm Des. 2006;12(28):3665-79.
DMJIA6T	RU	https://pubmed.ncbi.nlm.nih.gov/17073666

DM4ONW5	DI	DM4ONW5
DM4ONW5	DN	Baricitinib
DM4ONW5	MI	DTI7UX6
DM4ONW5	MN	Breast cancer resistance protein (ABCG2)
DM4ONW5	MT	DTP
DM4ONW5	MA	Substrate
DM4ONW5	RN	Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran. Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01201-17.
DM4ONW5	RU	http://www.ncbi.nlm.nih.gov/pubmed/28848011

DM4ONW5	DI	DM4ONW5
DM4ONW5	DN	Baricitinib
DM4ONW5	MI	DE4LYSA
DM4ONW5	MN	Cytochrome P450 3A4 (CYP3A4)
DM4ONW5	MT	DME
DM4ONW5	MA	Metabolism
DM4ONW5	RN	FDA label of Baricitinib. The 2020 official website of the U.S. Food and Drug Administration.
DM4ONW5	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207924s000lbl.pdf

DM4ONW5	DI	DM4ONW5
DM4ONW5	DN	Baricitinib
DM4ONW5	MI	TT6DM01
DM4ONW5	MN	Janus kinase 1 (JAK-1)
DM4ONW5	MT	DTT
DM4ONW5	MA	Modulator
DM4ONW5	RN	Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.
DM4ONW5	RU	https://pubmed.ncbi.nlm.nih.gov/24818516

DM4ONW5	DI	DM4ONW5
DM4ONW5	DN	Baricitinib
DM4ONW5	MI	TTRMX3V
DM4ONW5	MN	Janus kinase 2 (JAK-2)
DM4ONW5	MT	DTT
DM4ONW5	MA	Modulator
DM4ONW5	RN	Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.
DM4ONW5	RU	https://pubmed.ncbi.nlm.nih.gov/24818516

DM4ONW5	DI	DM4ONW5
DM4ONW5	DN	Baricitinib
DM4ONW5	MI	DTUGYRD
DM4ONW5	MN	P-glycoprotein 1 (ABCB1)
DM4ONW5	MT	DTP
DM4ONW5	MA	Substrate
DM4ONW5	RN	Prediction of Transporter-Mediated Drug-Drug Interactions for Baricitinib. Clin Transl Sci. 2017 Nov;10(6):509-519.
DM4ONW5	RU	http://www.ncbi.nlm.nih.gov/pubmed/28749581

DM4ONW5	DI	DM4ONW5
DM4ONW5	DN	Baricitinib
DM4ONW5	MI	TTJSQEF
DM4ONW5	MN	Tyrosine-protein kinase (PTK)
DM4ONW5	MT	DTT
DM4ONW5	MA	Inhibitor
DM4ONW5	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DM4ONW5	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMWNRZT	DI	DMWNRZT
DMWNRZT	DN	Basiliximab
DMWNRZT	MI	TT10Y9E
DMWNRZT	MN	Interleukin 2 receptor alpha (IL2RA)
DMWNRZT	MT	DTT
DMWNRZT	MA	Modulator
DMWNRZT	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMWNRZT	RU	https://www.fda.gov/

DMU9C8F	DI	DMU9C8F
DMU9C8F	DN	Bavencio
DMU9C8F	MI	TT8ZLTI
DMU9C8F	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMU9C8F	MT	DTT
DMU9C8F	MA	Inhibitor
DMU9C8F	RN	ClinicalTrials.gov (NCT03403777) Avelumab in Refractory Testicular Germ Cell Cancer.. U.S. National Institutes of Health.
DMU9C8F	RU	https://clinicaltrials.gov/ct2/show/NCT03403777

DMLOS5R	DI	DMLOS5R
DMLOS5R	DN	Bay 80-6946
DMLOS5R	MI	DE6OQ3W
DMLOS5R	MN	Cytochrome P450 1A1 (CYP1A1)
DMLOS5R	MT	DME
DMLOS5R	MA	Metabolism
DMLOS5R	RN	FDA label of Copanlisib. The 2020 official website of the U.S. Food and Drug Administration.
DMLOS5R	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209936s000lbl.pdf

DMLOS5R	DI	DMLOS5R
DMLOS5R	DN	Bay 80-6946
DMLOS5R	MI	DE4LYSA
DMLOS5R	MN	Cytochrome P450 3A4 (CYP3A4)
DMLOS5R	MT	DME
DMLOS5R	MA	Metabolism
DMLOS5R	RN	FDA label of Copanlisib. The 2020 official website of the U.S. Food and Drug Administration.
DMLOS5R	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209936s000lbl.pdf

DMLOS5R	DI	DMLOS5R
DMLOS5R	DN	Bay 80-6946
DMLOS5R	MI	TTEUNMR
DMLOS5R	MN	PI3-kinase alpha (PIK3CA)
DMLOS5R	MT	DTT
DMLOS5R	MA	Inhibitor
DMLOS5R	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DMLOS5R	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DMLOS5R	DI	DMLOS5R
DMLOS5R	DN	Bay 80-6946
DMLOS5R	MI	TTGBPJE
DMLOS5R	MN	PI3-kinase delta (PIK3CD)
DMLOS5R	MT	DTT
DMLOS5R	MA	Inhibitor
DMLOS5R	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DMLOS5R	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DMLOS5R	DI	DMLOS5R
DMLOS5R	DN	Bay 80-6946
DMLOS5R	MI	TTHBTOP
DMLOS5R	MN	PI3-kinase gamma (PIK3CG)
DMLOS5R	MT	DTT
DMLOS5R	MA	Modulator
DMLOS5R	RN	BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110 and p110 activities in tumor cell lines and xenograft models.Mol Cancer Ther.2013 Nov;12(11):2319-30.
DMLOS5R	RU	https://www.ncbi.nlm.nih.gov/pubmed/24170767

DMY85QW	DI	DMY85QW
DMY85QW	DN	Bazedoxifene
DMY85QW	MI	DEWTCUK
DMY85QW	MN	Beta-glucuronidase (uidA)
DMY85QW	MT	DME
DMY85QW	MA	Metabolism
DMY85QW	RN	Long-term administration of conjugated estrogen and bazedoxifene decreased murine fecal beta-glucuronidase activity without impacting overall microbiome community. Sci Rep. 2018 May 25;8(1):8166.
DMY85QW	RU	https://pubmed.ncbi.nlm.nih.gov/29802368

DMY85QW	DI	DMY85QW
DMY85QW	DN	Bazedoxifene
DMY85QW	MI	TTZAYWL
DMY85QW	MN	Estrogen receptor (ESR)
DMY85QW	MT	DTT
DMY85QW	MA	Modulator
DMY85QW	RN	Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause. 2009 Nov-Dec;16(6):1109-15.
DMY85QW	RU	https://pubmed.ncbi.nlm.nih.gov/19543129

DMY85QW	DI	DMY85QW
DMY85QW	DN	Bazedoxifene
DMY85QW	MI	DEYGVN4
DMY85QW	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMY85QW	MT	DME
DMY85QW	MA	Metabolism
DMY85QW	RN	UGT1A1*28 polymorphism influences glucuronidation of bazedoxifene. Pharmazie. 2015 Feb;70(2):94-6.
DMY85QW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25997248

DMY85QW	DI	DMY85QW
DMY85QW	DN	Bazedoxifene
DMY85QW	MI	DEL5N6Y
DMY85QW	MN	UDP-glucuronosyltransferase 1A10 (UGT1A10)
DMY85QW	MT	DME
DMY85QW	MA	Metabolism
DMY85QW	RN	In vitro metabolism, permeability, and efflux of bazedoxifene in humans. Drug Metab Dispos. 2010 Sep;38(9):1471-9.
DMY85QW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20516255

DM1R5X4	DI	DM1R5X4
DM1R5X4	DN	Becaplermin
DM1R5X4	MI	TTI7421
DM1R5X4	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM1R5X4	MT	DTT
DM1R5X4	MA	Modulator
DM1R5X4	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM1R5X4	RU	https://www.fda.gov/

DMZPHIK	DI	DMZPHIK
DMZPHIK	DN	Beclomethasone
DMZPHIK	MI	DEDH7FP
DMZPHIK	MN	Corticosteroid 11-beta-dehydrogenase 2 (HSD11B2)
DMZPHIK	MT	DME
DMZPHIK	MA	Metabolism
DMZPHIK	RN	Metabolism of synthetic steroids by the human placenta. Placenta. 2007 Jan;28(1):39-46.
DMZPHIK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16549198

DMZPHIK	DI	DMZPHIK
DMZPHIK	DN	Beclomethasone
DMZPHIK	MI	DE4LYSA
DMZPHIK	MN	Cytochrome P450 3A4 (CYP3A4)
DMZPHIK	MT	DME
DMZPHIK	MA	Metabolism
DMZPHIK	RN	Metabolism of beclomethasone dipropionate by cytochrome P450 3A enzymes. J Pharmacol Exp Ther. 2013 May;345(2):308-16.
DMZPHIK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23512537

DMZPHIK	DI	DMZPHIK
DMZPHIK	DN	Beclomethasone
DMZPHIK	MI	DTUGYRD
DMZPHIK	MN	P-glycoprotein 1 (ABCB1)
DMZPHIK	MT	DTP
DMZPHIK	MA	Substrate
DMZPHIK	RN	Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux. Toxicol Appl Pharmacol. 2012 May 1;260(3):294-302.
DMZPHIK	RU	https://doi.org/10.1016/j.taap.2012.03.008

DMZPHIK	DI	DMZPHIK
DMZPHIK	DN	Beclomethasone
DMZPHIK	MI	TTP3UTW
DMZPHIK	MN	Steroid hormone receptor ERR (ESRR)
DMZPHIK	MT	DTT
DMZPHIK	MA	Modulator
DMZPHIK	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMZPHIK	RU	https://www.fda.gov/

DM3906J	DI	DM3906J
DM3906J	DN	Bedaquiline
DM3906J	MI	DE4LYSA
DM3906J	MN	Cytochrome P450 3A4 (CYP3A4)
DM3906J	MT	DME
DM3906J	MA	Metabolism
DM3906J	RN	Bedaquiline metabolism: enzymes and novel metabolites. Drug Metab Dispos. 2014 May;42(5):863-6.
DM3906J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24513655

DM3906J	DI	DM3906J
DM3906J	DN	Bedaquiline
DM3906J	MI	TT19K0L
DM3906J	MN	Mycobacterium Proton pump (MycB Prop)
DM3906J	MT	DTT
DM3906J	MA	Modulator
DM3906J	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DM3906J	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM8WCXM	DI	DM8WCXM
DM8WCXM	DN	Befunolol hci
DM8WCXM	MI	TTVIREA
DM8WCXM	MN	Adrenergic receptor (ADR)
DM8WCXM	MT	DTT
DM8WCXM	MA	Modulator
DM8WCXM	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DM8WCXM	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DMBT3AI	DI	DMBT3AI
DMBT3AI	DN	Belantamab mafodotin
DMBT3AI	MI	TTZ3P4W
DMBT3AI	MN	B-cell maturation protein (TNFRSF17)
DMBT3AI	MT	DTT
DMBT3AI	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMBT3AI	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761158s000lbl.pdf

DMXLYQF	DI	DMXLYQF
DMXLYQF	DN	Belatacept
DMXLYQF	MI	TTQ13FT
DMXLYQF	MN	T-cell-specific surface glycoprotein CD28 (CD28)
DMXLYQF	MT	DTT
DMXLYQF	MA	Inhibitor
DMXLYQF	RN	New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
DMXLYQF	RU	https://pubmed.ncbi.nlm.nih.gov/19265486

DM3OBQF	DI	DM3OBQF
DM3OBQF	DN	Belimumab
DM3OBQF	MI	TTWMIDN
DM3OBQF	MN	B-cell-activating factor (TNFSF13B)
DM3OBQF	MT	DTT
DM3OBQF	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DM3OBQF	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DM2RBWK	DI	DM2RBWK
DM2RBWK	DN	Belladonna
DM2RBWK	MI	TTH18TF
DM2RBWK	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DM2RBWK	MT	DTT
DM2RBWK	MA	Modulator
DM2RBWK	RN	Plasma level of atropine after accidental ingestion of Atropa belladonna. Clin Toxicol (Phila). 2009 Jul;47(6):602-4.
DM2RBWK	RU	https://pubmed.ncbi.nlm.nih.gov/19586361

DM3SRJZ	DI	DM3SRJZ
DM3SRJZ	DN	Belotecan hydrocholoride
DM3SRJZ	MI	TTGTQHC
DM3SRJZ	MN	DNA topoisomerase I (TOP1)
DM3SRJZ	MT	DTT
DM3SRJZ	MA	Modulator
DM3SRJZ	RN	Impact of natural products on developing new anti-cancer agents. Chem Rev. 2009 Jul;109(7):3012-43.
DM3SRJZ	RU	https://pubmed.ncbi.nlm.nih.gov/19422222

DM1CI9R	DI	DM1CI9R
DM1CI9R	DN	Bempedoic acid
DM1CI9R	MI	TT0Z6Y2
DM1CI9R	MN	ATP-citrate synthase (ACLY)
DM1CI9R	MT	DTT
DM1CI9R	MA	Inhibitor
DM1CI9R	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DM1CI9R	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211616s000lbl.pdf

DM1CI9R	DI	DM1CI9R
DM1CI9R	DN	Bempedoic acid
DM1CI9R	MI	TTRA79S
DM1CI9R	MN	Cholesterol synthesis (Chole synth)
DM1CI9R	MT	DTT
DM1CI9R	MA	Inhibitor
DM1CI9R	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DM1CI9R	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211616s000lbl.pdf

DMH1M9B	DI	DMH1M9B
DMH1M9B	DN	Benazepril
DMH1M9B	MI	TTL69WB
DMH1M9B	MN	Angiotensin-converting enzyme (ACE)
DMH1M9B	MT	DTT
DMH1M9B	MA	Inhibitor
DMH1M9B	RN	Efficacy of benazepril hydrochloride to delay the progression of occult dilated cardiomyopathy in Doberman Pinschers. J Vet Intern Med. 2009 Sep-Oct;23(5):977-83.
DMH1M9B	RU	https://pubmed.ncbi.nlm.nih.gov/19572914

DMH1M9B	DI	DMH1M9B
DMH1M9B	DN	Benazepril
DMH1M9B	MI	DEOXTPZ
DMH1M9B	MN	Methylenetetrahydrofolate reductase (MTHFR)
DMH1M9B	MT	DME
DMH1M9B	MA	Metabolism
DMH1M9B	RN	Effects of MTHFR and MS gene polymorphisms on baseline blood pressure and Benazepril effectiveness in Chinese hypertensive patients. J Hum Hypertens. 2011 Mar;25(3):172-7.
DMH1M9B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20445573

DMH1M9B	DI	DMH1M9B
DMH1M9B	DN	Benazepril
DMH1M9B	MI	DT9G7XN
DMH1M9B	MN	Peptide transporter 1 (SLC15A1)
DMH1M9B	MT	DTP
DMH1M9B	MA	Substrate
DMH1M9B	RN	Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41.
DMH1M9B	RU	http://www.ncbi.nlm.nih.gov/pubmed/18713951

DMH1M9B	DI	DMH1M9B
DMH1M9B	DN	Benazepril
DMH1M9B	MI	DT8QKNP
DMH1M9B	MN	Peptide transporter 2 (SLC15A2)
DMH1M9B	MT	DTP
DMH1M9B	MA	Substrate
DMH1M9B	RN	Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41.
DMH1M9B	RU	http://www.ncbi.nlm.nih.gov/pubmed/18713951

DMFH15Z	DI	DMFH15Z
DMFH15Z	DN	Bendamustine hydrochloride
DMFH15Z	MI	DEJGDUW
DMFH15Z	MN	Cytochrome P450 1A2 (CYP1A2)
DMFH15Z	MT	DME
DMFH15Z	MA	Metabolism
DMFH15Z	RN	Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites. Cancer Chemother Pharmacol. 2015 Jun;75(6):1143-54.
DMFH15Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25829094

DMFH15Z	DI	DMFH15Z
DMFH15Z	DN	Bendamustine hydrochloride
DMFH15Z	MI	TTUTN1I
DMFH15Z	MN	Human Deoxyribonucleic acid (hDNA)
DMFH15Z	MT	DTT
DMFH15Z	MA	Modulator
DMFH15Z	RN	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
DMFH15Z	RU	https://pubmed.ncbi.nlm.nih.gov/19180096

DM7EVLC	DI	DM7EVLC
DM7EVLC	DN	Bendroflumethiazide
DM7EVLC	MI	TTS087L
DM7EVLC	MN	Solute carrier family 12 member 1 (SLC12A1)
DM7EVLC	MT	DTT
DM7EVLC	MA	Blocker
DM7EVLC	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DM7EVLC	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DM7EVLC	DI	DM7EVLC
DM7EVLC	DN	Bendroflumethiazide
DM7EVLC	MI	TTP362L
DM7EVLC	MN	Solute carrier family 12 member 3 (SLC12A3)
DM7EVLC	MT	DTT
DM7EVLC	MA	Blocker
DM7EVLC	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DM7EVLC	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DM7P1J4	DI	DM7P1J4
DM7P1J4	DN	Benralizumab
DM7P1J4	MI	TTXH9AD
DM7P1J4	MN	Interleukin 5 receptor alpha (IL5RA)
DM7P1J4	MT	DTT
DM7P1J4	MA	Modulator
DM7P1J4	RN	Benralizumab--a humanized mAb to IL-5R with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma. Expert Opin Biol Ther. 2012 Jan;12(1):113-8. 
DM7P1J4	RU	https://www.ncbi.nlm.nih.gov/pubmed/22136436

DM7P1J4	DI	DM7P1J4
DM7P1J4	DN	Benralizumab
DM7P1J4	MI	TTPREZD
DM7P1J4	MN	Interleukin-5 (IL5)
DM7P1J4	MT	DTT
DM7P1J4	MA	Modulator
DM7P1J4	RN	Benralizumab a humanized mAb to IL-5R with enhanced antibody-dependent cell-mediated cytotoxicity a novel approach for the treatment of asthma
DM7P1J4	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3587289

DMRVBWU	DI	DMRVBWU
DMRVBWU	DN	Bentazepam
DMRVBWU	MI	TTEX6LM
DMRVBWU	MN	GABA(A) receptor gamma-3 (GABRG3)
DMRVBWU	MT	DTT
DMRVBWU	MA	Modulator
DMRVBWU	RN	Prodynorphin gene deletion increased anxiety-like behaviours, impaired the anxiolytic effect of bromazepam and altered GABAA receptor subunits gene expression in the amygdala. J Psychopharmacol. 2011Jan;25(1):87-96.
DMRVBWU	RU	https://pubmed.ncbi.nlm.nih.gov/20530587

DMF7EXL	DI	DMF7EXL
DMF7EXL	DN	Benzatropine
DMF7EXL	MI	DECB0K3
DMF7EXL	MN	Cytochrome P450 2D6 (CYP2D6)
DMF7EXL	MT	DME
DMF7EXL	MA	Metabolism
DMF7EXL	RN	Transport, metabolism, and in vivo population pharmacokinetics of the chloro benztropine analogs, a class of compounds extensively evaluated in animal models of drug abuse. J Pharmacol Exp Ther. 2007 Jan;320(1):344-53.
DMF7EXL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17003230

DMF7EXL	DI	DMF7EXL
DMF7EXL	DN	Benzatropine
DMF7EXL	MI	DEGTFWK
DMF7EXL	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMF7EXL	MT	DME
DMF7EXL	MA	Metabolism
DMF7EXL	RN	Transport, metabolism, and in vivo population pharmacokinetics of the chloro benztropine analogs, a class of compounds extensively evaluated in animal models of drug abuse. J Pharmacol Exp Ther. 2007 Jan;320(1):344-53.
DMF7EXL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17003230

DMC3YUA	DI	DMC3YUA
DMC3YUA	DN	Benzbromarone
DMC3YUA	MI	TTOJI4S
DMC3YUA	MN	Calcium-dependent chloride channel anoctamin (ANO)
DMC3YUA	MT	DTT
DMC3YUA	MA	Antagonist
DMC3YUA	RN	Anoctamin Channels in Human Myometrium: A Novel Target for Tocolysis.Reprod Sci. 2018 Nov;25(11):1589-1600.
DMC3YUA	RU	https://pubmed.ncbi.nlm.nih.gov/29471754

DMC3YUA	DI	DMC3YUA
DMC3YUA	DN	Benzbromarone
DMC3YUA	MI	DE5IED8
DMC3YUA	MN	Cytochrome P450 2C9 (CYP2C9)
DMC3YUA	MT	DME
DMC3YUA	MA	Metabolism
DMC3YUA	RN	Quantitative binding models for CYP2C9 based on benzbromarone analogues. Biochemistry. 2004 Jun 8;43(22):6948-58.
DMC3YUA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15170332

DMC3YUA	DI	DMC3YUA
DMC3YUA	DN	Benzbromarone
DMC3YUA	MI	TTOI92F
DMC3YUA	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMC3YUA	MT	DTT
DMC3YUA	MA	Stimulator
DMC3YUA	RN	Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transpo... Drug Metab Dispos. 2009 Jan;37(1):129-36.
DMC3YUA	RU	https://pubmed.ncbi.nlm.nih.gov/18845662

DMC3YUA	DI	DMC3YUA
DMC3YUA	DN	Benzbromarone
DMC3YUA	MI	DT582KR
DMC3YUA	MN	Multidrug resistance-associated protein 6 (ABCC6)
DMC3YUA	MT	DTP
DMC3YUA	MA	Substrate
DMC3YUA	RN	The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 3.A.1.208.10)
DMC3YUA	RU	http://www.tcdb.org/search/result.php?tc=3.A.1.208.10

DMI18HW	DI	DMI18HW
DMI18HW	DN	Benzocaine
DMI18HW	MI	TTRK8B9
DMI18HW	MN	Sodium channel unspecific (NaC)
DMI18HW	MT	DTT
DMI18HW	MA	Blocker
DMI18HW	RN	Electrostatic contributions of aromatic residues in the local anesthetic receptor of voltage-gated sodium channels. Circ Res. 2008 Jan 4;102(1):86-94.
DMI18HW	RU	https://pubmed.ncbi.nlm.nih.gov/17967784

DMKB9FI	DI	DMKB9FI
DMKB9FI	DN	Benzoic acid
DMKB9FI	MI	TT958S6
DMKB9FI	MN	Ras-related protein Rab-9A (RAB9A)
DMKB9FI	MT	DTT
DMKB9FI	MA	Inhibitor
DMKB9FI	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMKB9FI	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMKB9FI	DI	DMKB9FI
DMKB9FI	DN	Benzoic acid
DMKB9FI	MI	DTM301H
DMKB9FI	MN	Sodium-coupled monocarboxylate transporter 2 (SLC5A12)
DMKB9FI	MT	DTP
DMKB9FI	MA	Substrate
DMKB9FI	RN	Sodium-coupled monocarboxylate transporters in normal tissues and in cancer. AAPS J. 2008;10(1):193-9.
DMKB9FI	RU	http://www.ncbi.nlm.nih.gov/pubmed/18446519

DM9U4FO	DI	DM9U4FO
DM9U4FO	DN	Benzonatate
DM9U4FO	MI	TTZOVE0
DM9U4FO	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DM9U4FO	MT	DTT
DM9U4FO	MA	Blocker
DM9U4FO	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9U4FO	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMIJATC	DI	DMIJATC
DMIJATC	DN	Benzphetamine
DMIJATC	MI	DEPKLMQ
DMIJATC	MN	Cytochrome P450 2B6 (CYP2B6)
DMIJATC	MT	DME
DMIJATC	MA	Metabolism
DMIJATC	RN	Mechanistic analysis of the inactivation of cytochrome P450 2B6 by phencyclidine: effects on substrate binding, electron transfer, and uncoupling. Drug Metab Dispos. 2009 Apr;37(4):745-52.
DMIJATC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19144770

DMIJATC	DI	DMIJATC
DMIJATC	DN	Benzphetamine
DMIJATC	MI	DE4LYSA
DMIJATC	MN	Cytochrome P450 3A4 (CYP3A4)
DMIJATC	MT	DME
DMIJATC	MA	Metabolism
DMIJATC	RN	Identification of the human and animal hepatic cytochromes P450 involved in clonazepam metabolism. Fundam Clin Pharmacol. 1993;7(2):69-75.
DMIJATC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8486332

DMIJATC	DI	DMIJATC
DMIJATC	DN	Benzphetamine
DMIJATC	MI	DEIZLTN
DMIJATC	MN	Docosahexaenoic acid omega-hydroxylase (CYP4F11)
DMIJATC	MT	DME
DMIJATC	MA	Metabolism
DMIJATC	RN	Expression and characterization of human cytochrome P450 4F11: putative role in the metabolism of therapeutic drugs and eicosanoids. Toxicol Appl Pharmacol. 2004 Sep 15;199(3):295-304.
DMIJATC	RU	https://pubmed.ncbi.nlm.nih.gov/15364545

DMIJATC	DI	DMIJATC
DMIJATC	DN	Benzphetamine
DMIJATC	MI	DE3N2FM
DMIJATC	MN	NADPH-cytochrome P450 reductase (CPR)
DMIJATC	MT	DME
DMIJATC	MA	Metabolism
DMIJATC	RN	On the mechanism of the inactivation of the major phenobarbital-inducible isozyme of rat liver cytochrome P-450 by chloramphenicol. J Biol Chem. 1985 Jul 15;260(14):8397-403.
DMIJATC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=3924914

DMIJATC	DI	DMIJATC
DMIJATC	DN	Benzphetamine
DMIJATC	MI	TT9IK2Z
DMIJATC	MN	N-methyl-D-aspartate receptor (NMDAR)
DMIJATC	MT	DTT
DMIJATC	MA	Antagonist
DMIJATC	RN	Amphetamine inhibits the N-methyl-D-aspartate receptor-mediated responses by directly interacting with the receptor/channel complex. J Pharmacol Exp Ther. 2002 Mar;300(3):1008-16.
DMIJATC	RU	https://pubmed.ncbi.nlm.nih.gov/11861810

DMU4D5Y	DI	DMU4D5Y
DMU4D5Y	DN	Benzquinamide
DMU4D5Y	MI	TT0JLSD
DMU4D5Y	MN	Multidrug resistance protein (MDR)
DMU4D5Y	MT	DTT
DMU4D5Y	MA	Inhibitor
DMU4D5Y	RN	Benzquinamide inhibits P-glycoprotein mediated drug efflux and potentiates anticancer agent cytotoxicity in multidrug resistant cells. Oncol Res. 1992;4(8-9):359-65.
DMU4D5Y	RU	https://pubmed.ncbi.nlm.nih.gov/1362504

DMQWZ0H	DI	DMQWZ0H
DMQWZ0H	DN	Benzthiazide
DMQWZ0H	MI	TTANPDJ
DMQWZ0H	MN	Carbonic anhydrase II (CA-II)
DMQWZ0H	MT	DTT
DMQWZ0H	MA	Inhibitor
DMQWZ0H	RN	Nature of the inhibition of carbonic anhydrase by acetazolamide and benzthiazide. J Pharmacol Exp Ther. 1961 Mar;131:271-4.
DMQWZ0H	RU	https://pubmed.ncbi.nlm.nih.gov/13760527

DMGZOVN	DI	DMGZOVN
DMGZOVN	DN	Benztropine
DMGZOVN	MI	TTZ9SOR
DMGZOVN	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMGZOVN	MT	DTT
DMGZOVN	MA	Antagonist
DMGZOVN	RN	Formulation and biopharmaceutical evaluation of transdermal patch containing benztropine. Int J Pharm. 2008 Jun 5;357(1-2):55-60.
DMGZOVN	RU	https://pubmed.ncbi.nlm.nih.gov/18417307

DMGZOVN	DI	DMGZOVN
DMGZOVN	DN	Benztropine
DMGZOVN	MI	DT3BA8L
DMGZOVN	MN	Sodium-dependent dopamine transporter (SLC6A3)
DMGZOVN	MT	DTP
DMGZOVN	MA	Substrate
DMGZOVN	RN	Pharmacological characterization of a dopamine transporter ligand that functions as a cocaine antagonist. J Pharmacol Exp Ther. 2014 Jan;348(1):106-15.
DMGZOVN	RU	http://www.ncbi.nlm.nih.gov/pubmed/24194528

DMBVYDI	DI	DMBVYDI
DMBVYDI	DN	Benzyl alcohol
DMBVYDI	MI	DEWYTJB
DMBVYDI	MN	Aldehyde dehydrogenase 2 (ALDH2)
DMBVYDI	MT	DME
DMBVYDI	MA	Metabolism
DMBVYDI	RN	Effects of ALDH2, CYP1A1, and CYP2E1 genetic polymorphisms and smoking and drinking habits on toluene metabolism in humans. Toxicol Appl Pharmacol. 1995 Aug;133(2):295-304.
DMBVYDI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7645026

DMBVYDI	DI	DMBVYDI
DMBVYDI	DN	Benzyl alcohol
DMBVYDI	MI	DEJGDUW
DMBVYDI	MN	Cytochrome P450 1A2 (CYP1A2)
DMBVYDI	MT	DME
DMBVYDI	MA	Metabolism
DMBVYDI	RN	Cytochrome P450 isozymes responsible for the metabolism of toluene and styrene in human liver microsomes. Xenobiotica. 1997 Jul;27(7):657-65.
DMBVYDI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9253143

DMBVYDI	DI	DMBVYDI
DMBVYDI	DN	Benzyl alcohol
DMBVYDI	MI	DES5XRU
DMBVYDI	MN	Cytochrome P450 2C8 (CYP2C8)
DMBVYDI	MT	DME
DMBVYDI	MA	Metabolism
DMBVYDI	RN	Cytochrome P450 isozymes responsible for the metabolism of toluene and styrene in human liver microsomes. Xenobiotica. 1997 Jul;27(7):657-65.
DMBVYDI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9253143

DMBVYDI	DI	DMBVYDI
DMBVYDI	DN	Benzyl alcohol
DMBVYDI	MI	DECB0K3
DMBVYDI	MN	Cytochrome P450 2D6 (CYP2D6)
DMBVYDI	MT	DME
DMBVYDI	MA	Metabolism
DMBVYDI	RN	Mechanism of cytochrome P4503A4- and 2D6-catalyzed dehydrogenation of ezlopitant as probed with isotope effects using five deuterated analogs. Drug Metab Dispos. 2001 Dec;29(12):1599-607.
DMBVYDI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11717179

DMBVYDI	DI	DMBVYDI
DMBVYDI	DN	Benzyl alcohol
DMBVYDI	MI	DEVDYN7
DMBVYDI	MN	Cytochrome P450 2E1 (CYP2E1)
DMBVYDI	MT	DME
DMBVYDI	MA	Metabolism
DMBVYDI	RN	The metabolic rate constants and specific activity of human and rat hepatic cytochrome P-450 2E1 toward toluene and chloroform. J Toxicol Environ Health A. 2004 Apr 9;67(7):537-53.
DMBVYDI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15129551

DMBVYDI	DI	DMBVYDI
DMBVYDI	DN	Benzyl alcohol
DMBVYDI	MI	DEYWLRK
DMBVYDI	MN	Sulfotransferase 1A1 (SULT1A1)
DMBVYDI	MT	DME
DMBVYDI	MA	Metabolism
DMBVYDI	RN	Sulfation of benzyl alcohol by the human cytosolic sulfotransferases (SULTs): a systematic analysis. J Appl Toxicol. 2016 Sep;36(9):1090-4.
DMBVYDI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26663444

DMBVYDI	DI	DMBVYDI
DMBVYDI	DN	Benzyl alcohol
DMBVYDI	MI	DERUZL7
DMBVYDI	MN	Sulfotransferase 1A2 (SULT1A2)
DMBVYDI	MT	DME
DMBVYDI	MA	Metabolism
DMBVYDI	RN	Sulfation of benzyl alcohol by the human cytosolic sulfotransferases (SULTs): a systematic analysis. J Appl Toxicol. 2016 Sep;36(9):1090-4.
DMBVYDI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26663444

DMBVYDI	DI	DMBVYDI
DMBVYDI	DN	Benzyl alcohol
DMBVYDI	MI	DED5UR3
DMBVYDI	MN	Sulfotransferase 1B1 (SULT1B1)
DMBVYDI	MT	DME
DMBVYDI	MA	Metabolism
DMBVYDI	RN	Sulfation of benzyl alcohol by the human cytosolic sulfotransferases (SULTs): a systematic analysis. J Appl Toxicol. 2016 Sep;36(9):1090-4.
DMBVYDI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26663444

DMDPYI5	DI	DMDPYI5
DMDPYI5	DN	Benzyl benzoate
DMDPYI5	MI	TTLUQ8E
DMDPYI5	MN	Hormone sensitive lipase (LIPE)
DMDPYI5	MT	DTT
DMDPYI5	MA	Modulator
DMDPYI5	RN	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
DMDPYI5	RU	https://www.ncbi.nlm.nih.gov/pubmed/27899562

DMDPYI5	DI	DMDPYI5
DMDPYI5	DN	Benzyl benzoate
DMDPYI5	MI	DE4IY8S
DMDPYI5	MN	Peroxidase (katG)
DMDPYI5	MT	DME
DMDPYI5	MA	Metabolism
DMDPYI5	RN	Peroxidase activity in the sulfate-reducing bacterium Desulfotomaculum acetoxidans DSM 771. Pol J Microbiol. 2010;59(4):249-55.
DMDPYI5	RU	https://pubmed.ncbi.nlm.nih.gov/21466042

DMQHM2D	DI	DMQHM2D
DMQHM2D	DN	Benzylpenicilloyl Polylysine
DMQHM2D	MI	TTDGEC0
DMQHM2D	MN	Immunoglobulin epsilon Fc receptor gamma (FCERG)
DMQHM2D	MT	DTT
DMQHM2D	MA	Binder
DMQHM2D	RN	Penicillin allergy: anti-penicillin IgE antibodies and immediate hypersensitivity skin reactions employing major and minor determinants of penicillin. Arch Dis Child. 1980 Nov;55(11):857-60.
DMQHM2D	RU	https://pubmed.ncbi.nlm.nih.gov/7436456

DMXDZAQ	DI	DMXDZAQ
DMXDZAQ	DN	Bepotastine
DMXDZAQ	MI	TTTIBOJ
DMXDZAQ	MN	Histamine H1 receptor (H1R)
DMXDZAQ	MT	DTT
DMXDZAQ	MA	Antagonist
DMXDZAQ	RN	Mast cells play a critical role in the pathogenesis of viral myocarditis. Circulation. 2008 Jul 22;118(4):363-72.
DMXDZAQ	RU	https://pubmed.ncbi.nlm.nih.gov/18606918

DM0RKS4	DI	DM0RKS4
DM0RKS4	DN	Bepridil
DM0RKS4	MI	TT5HONZ
DM0RKS4	MN	Calcium channel unspecific (CaC)
DM0RKS4	MT	DTT
DM0RKS4	MA	Modulator
DM0RKS4	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM0RKS4	RU	https://www.fda.gov/

DM0RKS4	DI	DM0RKS4
DM0RKS4	DN	Bepridil
DM0RKS4	MI	DECB0K3
DM0RKS4	MN	Cytochrome P450 2D6 (CYP2D6)
DM0RKS4	MT	DME
DM0RKS4	MA	Metabolism
DM0RKS4	RN	Serum flecainide S/R ratio reflects the CYP2D6 genotype and changes in CYP2D6 activity. Drug Metab Pharmacokinet. 2015 Aug;30(4):257-62.
DM0RKS4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26195225

DM0RKS4	DI	DM0RKS4
DM0RKS4	DN	Bepridil
DM0RKS4	MI	DE4LYSA
DM0RKS4	MN	Cytochrome P450 3A4 (CYP3A4)
DM0RKS4	MT	DME
DM0RKS4	MA	Metabolism
DM0RKS4	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DM0RKS4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DM0RKS4	DI	DM0RKS4
DM0RKS4	DN	Bepridil
DM0RKS4	MI	DTUGYRD
DM0RKS4	MN	P-glycoprotein 1 (ABCB1)
DM0RKS4	MT	DTP
DM0RKS4	MA	Substrate
DM0RKS4	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM0RKS4	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMEBY2D	DI	DMEBY2D
DMEBY2D	DN	Beriplast-P
DMEBY2D	MI	TTWODQF
DMEBY2D	MN	Fibrin (FG)
DMEBY2D	MT	DTT
DMEBY2D	MA	Modulator
DMEBY2D	RN	Wound healing and degradation of the fibrin sealant Beriplast P following partial liver resection in rabbits. Wound Repair Regen. 2005 May-Jun;13(3):318-23.
DMEBY2D	RU	https://pubmed.ncbi.nlm.nih.gov/15953052

DMWA2DZ	DI	DMWA2DZ
DMWA2DZ	DN	Berotralstat
DMWA2DZ	MI	TTMF8H9
DMWA2DZ	MN	Plasma kallikrein (KLKB1)
DMWA2DZ	MT	DTT
DMWA2DZ	MA	Inhibitor
DMWA2DZ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMWA2DZ	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214094s000lbl.pdf

DMPHXMI	DI	DMPHXMI
DMPHXMI	DN	Besifloxacin
DMPHXMI	MI	TTN6J5F
DMPHXMI	MN	Bacterial DNA gyrase (Bact gyrase)
DMPHXMI	MT	DTT
DMPHXMI	MA	Modulator
DMPHXMI	RN	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
DMPHXMI	RU	https://pubmed.ncbi.nlm.nih.gov/20118952

DMPHXMI	DI	DMPHXMI
DMPHXMI	DN	Besifloxacin
DMPHXMI	MI	TTIXTO3
DMPHXMI	MN	Staphylococcus Topoisomerase IV (Stap-coc parC)
DMPHXMI	MT	DTT
DMPHXMI	MA	Modulator
DMPHXMI	RN	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
DMPHXMI	RU	https://pubmed.ncbi.nlm.nih.gov/20118952

DM8L9D4	DI	DM8L9D4
DM8L9D4	DN	Bestatin
DM8L9D4	MI	TTXZEAJ
DM8L9D4	MN	Leukotriene A-4 hydrolase (LTA4H)
DM8L9D4	MT	DTT
DM8L9D4	MA	Inhibitor
DM8L9D4	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DM8L9D4	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DM8L9D4	DI	DM8L9D4
DM8L9D4	DN	Bestatin
DM8L9D4	MI	DT9G7XN
DM8L9D4	MN	Peptide transporter 1 (SLC15A1)
DM8L9D4	MT	DTP
DM8L9D4	MA	Substrate
DM8L9D4	RN	Dipeptide transporters in apical and basolateral membranes of the human intestinal cell line Caco-2. Am J Physiol. 1993 Aug;265(2 Pt 1):G289-94.
DM8L9D4	RU	http://www.ncbi.nlm.nih.gov/pubmed/8396335

DM8L9D4	DI	DM8L9D4
DM8L9D4	DN	Bestatin
DM8L9D4	MI	DT8QKNP
DM8L9D4	MN	Peptide transporter 2 (SLC15A2)
DM8L9D4	MT	DTP
DM8L9D4	MA	Substrate
DM8L9D4	RN	Molecular mechanism of dipeptide and drug transport by the human renal H+/oligopeptide cotransporter hPEPT2. Am J Physiol Renal Physiol. 2008 Jun;294(6):F1422-32.
DM8L9D4	RU	http://www.ncbi.nlm.nih.gov/pubmed/18367661

DMI6GKT	DI	DMI6GKT
DMI6GKT	DN	Beta-acetyldigoxin
DMI6GKT	MI	DTUGYRD
DMI6GKT	MN	P-glycoprotein 1 (ABCB1)
DMI6GKT	MT	DTP
DMI6GKT	MA	Substrate
DMI6GKT	RN	P-glycoprotein-mediated transport of digitoxin, alpha-methyldigoxin and beta-acetyldigoxin. Naunyn Schmiedebergs Arch Pharmacol. 2001 Mar;363(3):337-43.
DMI6GKT	RU	https://doi.org/10.1007/s002100000354

DMI6GKT	DI	DMI6GKT
DMI6GKT	DN	Beta-acetyldigoxin
DMI6GKT	MI	TTYHPRQ
DMI6GKT	MN	Sodium pump (NaP)
DMI6GKT	MT	DTT
DMI6GKT	MA	Modulator
DMI6GKT	RN	Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81.
DMI6GKT	RU	https://pubmed.ncbi.nlm.nih.gov/3879679

DM0RXBT	DI	DM0RXBT
DM0RXBT	DN	Beta-carotene
DM0RXBT	MI	DE6BOK3
DM0RXBT	MN	Beta,beta-carotene 15,15'-dioxygenase (BCO1)
DM0RXBT	MT	DME
DM0RXBT	MA	Metabolism
DM0RXBT	RN	Substrate specificity of purified recombinant human beta-carotene 15,15'-oxygenase (BCO1). J Biol Chem. 2013 Dec 27;288(52):37094-103.
DM0RXBT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24187135

DM0RXBT	DI	DM0RXBT
DM0RXBT	DN	Beta-carotene
DM0RXBT	MI	DTUGYRD
DM0RXBT	MN	P-glycoprotein 1 (ABCB1)
DM0RXBT	MT	DTP
DM0RXBT	MA	Substrate
DM0RXBT	RN	Carotenoids reverse multidrug resistance in cancer cells by interfering with ABC-transporters. Phytomedicine. 2012 Aug 15;19(11):977-87.
DM0RXBT	RU	https://doi.org/10.1016/j.phymed.2012.05.010

DMGRZW2	DI	DMGRZW2
DMGRZW2	DN	Betaine
DMGRZW2	MI	DTBPTJF
DMGRZW2	MN	Na(+)/Cl(-) betaine/GABA transporter (SLC6A12)
DMGRZW2	MT	DTP
DMGRZW2	MA	Substrate
DMGRZW2	RN	Deletion of the betaine-GABA transporter (BGT1; slc6a12) gene does not affect seizure thresholds of adult mice. Epilepsy Res. 2011 Jun;95(1-2):70-81.
DMGRZW2	RU	http://www.ncbi.nlm.nih.gov/pubmed/21459558

DMAHJEF	DI	DMAHJEF
DMAHJEF	DN	Betamethasone
DMAHJEF	MI	TTYRL6O
DMAHJEF	MN	Glucocorticoid receptor (NR3C1)
DMAHJEF	MT	DTT
DMAHJEF	MA	Agonist
DMAHJEF	RN	The cannabinoid CB2 receptor inverse agonist JTE-907 suppresses spontaneous itch-associated responses of NC mice, a model of atopic dermatitis. Eur J Pharmacol. 2006 Aug 7;542(1-3):179-83.
DMAHJEF	RU	https://pubmed.ncbi.nlm.nih.gov/16824511

DMAHJEF	DI	DMAHJEF
DMAHJEF	DN	Betamethasone
DMAHJEF	MI	DTUGYRD
DMAHJEF	MN	P-glycoprotein 1 (ABCB1)
DMAHJEF	MT	DTP
DMAHJEF	MA	Substrate
DMAHJEF	RN	Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803.
DMAHJEF	RU	http://www.ncbi.nlm.nih.gov/pubmed/14661924

DMRMS1A	DI	DMRMS1A
DMRMS1A	DN	Betamethasone Benzoate
DMRMS1A	MI	TTYRL6O
DMRMS1A	MN	Glucocorticoid receptor (NR3C1)
DMRMS1A	MT	DTT
DMRMS1A	MA	Modulator
DMRMS1A	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMRMS1A	RU	https://www.fda.gov/

DMMIAXO	DI	DMMIAXO
DMMIAXO	DN	Betamethasone valerate
DMMIAXO	MI	DEDH7FP
DMMIAXO	MN	Corticosteroid 11-beta-dehydrogenase 2 (HSD11B2)
DMMIAXO	MT	DME
DMMIAXO	MA	Metabolism
DMMIAXO	RN	Metabolism of synthetic steroids by the human placenta. Placenta. 2007 Jan;28(1):39-46.
DMMIAXO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16549198

DMMIAXO	DI	DMMIAXO
DMMIAXO	DN	Betamethasone valerate
DMMIAXO	MI	DE4LYSA
DMMIAXO	MN	Cytochrome P450 3A4 (CYP3A4)
DMMIAXO	MT	DME
DMMIAXO	MA	Metabolism
DMMIAXO	RN	Studies on Drug Interactions between CYP3A4 Inhibitors and Glucocorticoids.
DMMIAXO	RU	https://pdfs.semanticscholar.org/dc99/4682bd504ab29f1c7075b9d769eb4ac4a9ce.pdf

DMMIAXO	DI	DMMIAXO
DMMIAXO	DN	Betamethasone valerate
DMMIAXO	MI	TTYRL6O
DMMIAXO	MN	Glucocorticoid receptor (NR3C1)
DMMIAXO	MT	DTT
DMMIAXO	MA	Modulator
DMMIAXO	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMMIAXO	RU	https://www.fda.gov/

DM6EUL5	DI	DM6EUL5
DM6EUL5	DN	Betaxolol
DM6EUL5	MI	TTR6W5O
DM6EUL5	MN	Adrenergic receptor beta-1 (ADRB1)
DM6EUL5	MT	DTT
DM6EUL5	MA	Antagonist
DM6EUL5	RN	beta-adrenergic enhancement of brain kynurenic acid production mediated via cAMP-related protein kinase A signaling. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):519-29.
DM6EUL5	RU	https://pubmed.ncbi.nlm.nih.gov/19439240

DM6EUL5	DI	DM6EUL5
DM6EUL5	DN	Betaxolol
DM6EUL5	MI	DEJGDUW
DM6EUL5	MN	Cytochrome P450 1A2 (CYP1A2)
DM6EUL5	MT	DME
DM6EUL5	MA	Metabolism
DM6EUL5	RN	Drugs that may have potential CYP1A2 interactions.
DM6EUL5	RU	https://drug-interactions.medicine.iu.edu/MainTable.aspx

DM6EUL5	DI	DM6EUL5
DM6EUL5	DN	Betaxolol
DM6EUL5	MI	DECB0K3
DM6EUL5	MN	Cytochrome P450 2D6 (CYP2D6)
DM6EUL5	MT	DME
DM6EUL5	MA	Metabolism
DM6EUL5	RN	Association of CYP2D6 and ADRB1 genes with hypotensive and antichronotropic action of betaxolol in patients with arterial hypertension. Fundam Clin Pharmacol. 2007 Aug;21(4):437-43.
DM6EUL5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17635183

DMUFGAY	DI	DMUFGAY
DMUFGAY	DN	Betazole
DMUFGAY	MI	TTQHJ1K
DMUFGAY	MN	Histamine H2 receptor (H2R)
DMUFGAY	MT	DTT
DMUFGAY	MA	Antagonist
DMUFGAY	RN	Effect of nizatidine and cimetidine on betazole-stimulated gastric secretion of normal subjects: comparison of effects on acid, water, and pepsin. Am J Gastroenterol. 1988 Jan;83(1):32-6.
DMUFGAY	RU	https://pubmed.ncbi.nlm.nih.gov/2892392

DMCLHO0	DI	DMCLHO0
DMCLHO0	DN	Bethanechol
DMCLHO0	MI	TTH18TF
DMCLHO0	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMCLHO0	MT	DTT
DMCLHO0	MA	Agonist
DMCLHO0	RN	Loss of Ca-mediated ion transport during colitis correlates with reduced ion transport responses to a Ca-activated K channel opener. Br J Pharmacol. 2009 Apr;156(7):1085-97.
DMCLHO0	RU	https://pubmed.ncbi.nlm.nih.gov/19298254

DM2C4RF	DI	DM2C4RF
DM2C4RF	DN	Betrixaban
DM2C4RF	MI	TTCIHJA
DM2C4RF	MN	Coagulation factor Xa (F10)
DM2C4RF	MT	DTT
DM2C4RF	MA	Modulator
DM2C4RF	RN	Company report (Portola)
DM2C4RF	RU	https://www.portola.com/clinical-development/betrixaban-fxa-inhibitor/

DM2C4RF	DI	DM2C4RF
DM2C4RF	DN	Betrixaban
DM2C4RF	MI	DTUGYRD
DM2C4RF	MN	P-glycoprotein 1 (ABCB1)
DM2C4RF	MT	DTP
DM2C4RF	MA	Substrate
DM2C4RF	RN	Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism. Vasc Health Risk Manag. 2015 Jun 26;11:343-51.
DM2C4RF	RU	http://www.ncbi.nlm.nih.gov/pubmed/26170684

DMSD1UN	DI	DMSD1UN
DMSD1UN	DN	Bevacizumab
DMSD1UN	MI	TTOHSBA
DMSD1UN	MN	Vascular endothelial growth factor A (VEGFA)
DMSD1UN	MT	DTT
DMSD1UN	MA	Inhibitor
DMSD1UN	RN	FDA Approved Drug Products from FDA Official Website. 2004. Application Number: (ANDA) 125085.
DMSD1UN	RU	https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125085

DMZFICR	DI	DMZFICR
DMZFICR	DN	Bevantolol
DMZFICR	MI	DECB0K3
DMZFICR	MN	Cytochrome P450 2D6 (CYP2D6)
DMZFICR	MT	DME
DMZFICR	MA	Metabolism
DMZFICR	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DMZFICR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DMZFICR	DI	DMZFICR
DMZFICR	DN	Bevantolol
DMZFICR	MI	TTEX248
DMZFICR	MN	Dopamine D2 receptor (D2R)
DMZFICR	MT	DTT
DMZFICR	MA	Antagonist
DMZFICR	RN	Determination of bevantolol in human plasma by high performance liquid chromatography using solid phase extraction technique. Arch Pharm Res. 2007 Jul;30(7):890-7.
DMZFICR	RU	https://pubmed.ncbi.nlm.nih.gov/17703743

DMOBIKY	DI	DMOBIKY
DMOBIKY	DN	Bexarotene
DMOBIKY	MI	DE5IED8
DMOBIKY	MN	Cytochrome P450 2C9 (CYP2C9)
DMOBIKY	MT	DME
DMOBIKY	MA	Metabolism
DMOBIKY	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMOBIKY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMOBIKY	DI	DMOBIKY
DMOBIKY	DN	Bexarotene
DMOBIKY	MI	DE4LYSA
DMOBIKY	MN	Cytochrome P450 3A4 (CYP3A4)
DMOBIKY	MT	DME
DMOBIKY	MA	Metabolism
DMOBIKY	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMOBIKY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMOBIKY	DI	DMOBIKY
DMOBIKY	DN	Bexarotene
DMOBIKY	MI	TT6PEUO
DMOBIKY	MN	Retinoic acid receptor RXR-alpha (RXRA)
DMOBIKY	MT	DTT
DMOBIKY	MA	Modulator
DMOBIKY	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMOBIKY	RU	https://www.fda.gov/

DMZDCS0	DI	DMZDCS0
DMZDCS0	DN	Bezafibrate
DMZDCS0	MI	DE4LYSA
DMZDCS0	MN	Cytochrome P450 3A4 (CYP3A4)
DMZDCS0	MT	DME
DMZDCS0	MA	Metabolism
DMZDCS0	RN	Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998 Feb;34(2):155-62.
DMZDCS0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9515185

DMZDCS0	DI	DMZDCS0
DMZDCS0	DN	Bezafibrate
DMZDCS0	MI	TTJ584C
DMZDCS0	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMZDCS0	MT	DTT
DMZDCS0	MA	Agonist
DMZDCS0	RN	Bezafibrate at clinically relevant doses decreases serum/liver triglycerides via down-regulation of sterol regulatory element-binding protein-1c in... Mol Pharmacol. 2009 Apr;75(4):782-92.
DMZDCS0	RU	https://pubmed.ncbi.nlm.nih.gov/19124612

DMTZC5G	DI	DMTZC5G
DMTZC5G	DN	Bezlotoxumab
DMTZC5G	MI	TTQH65V
DMTZC5G	MN	Clostridium difficile Toxin B (CD toxB)
DMTZC5G	MT	DTT
DMTZC5G	MA	Modulator
DMTZC5G	RN	2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. 
DMTZC5G	RU	https://www.ncbi.nlm.nih.gov/pubmed/28148938

DMTKD7Q	DI	DMTKD7Q
DMTKD7Q	DN	BIBW 2992
DMTKD7Q	MI	DTI7UX6
DMTKD7Q	MN	Breast cancer resistance protein (ABCG2)
DMTKD7Q	MT	DTP
DMTKD7Q	MA	Substrate
DMTKD7Q	RN	Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation. Pharmacol Res. 2017 Jun;120:43-50.
DMTKD7Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/28288939

DMTKD7Q	DI	DMTKD7Q
DMTKD7Q	DN	BIBW 2992
DMTKD7Q	MI	TTGKNB4
DMTKD7Q	MN	Epidermal growth factor receptor (EGFR)
DMTKD7Q	MT	DTT
DMTKD7Q	MA	Inhibitor
DMTKD7Q	RN	Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
DMTKD7Q	RU	http://www.boehringer-ingelheim.com/corporate/research/pipeline.asp

DMTKD7Q	DI	DMTKD7Q
DMTKD7Q	DN	BIBW 2992
DMTKD7Q	MI	TT6EO5L
DMTKD7Q	MN	Erbb2 tyrosine kinase receptor (HER2)
DMTKD7Q	MT	DTT
DMTKD7Q	MA	Inhibitor
DMTKD7Q	RN	Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
DMTKD7Q	RU	http://www.boehringer-ingelheim.com/corporate/research/pipeline.asp

DMTKD7Q	DI	DMTKD7Q
DMTKD7Q	DN	BIBW 2992
DMTKD7Q	MI	DTUGYRD
DMTKD7Q	MN	P-glycoprotein 1 (ABCB1)
DMTKD7Q	MT	DTP
DMTKD7Q	MA	Substrate
DMTKD7Q	RN	Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation. Pharmacol Res. 2017 Jun;120:43-50.
DMTKD7Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/28288939

DMZMSPF	DI	DMZMSPF
DMZMSPF	DN	Bicalutamide
DMZMSPF	MI	TTS64P2
DMZMSPF	MN	Androgen receptor (AR)
DMZMSPF	MT	DTT
DMZMSPF	MA	Antagonist
DMZMSPF	RN	Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010 May;121(1):1-11.
DMZMSPF	RU	https://pubmed.ncbi.nlm.nih.gov/19533338

DMZMSPF	DI	DMZMSPF
DMZMSPF	DN	Bicalutamide
DMZMSPF	MI	DTI7UX6
DMZMSPF	MN	Breast cancer resistance protein (ABCG2)
DMZMSPF	MT	DTP
DMZMSPF	MA	Substrate
DMZMSPF	RN	Effects of the ABCG2 and ABCB1 drug transporter polymorphisms on the pharmacokinetics of bicalutamide in humans. Clin Chim Acta. 2015 Jan 1;438:7-11.
DMZMSPF	RU	http://www.ncbi.nlm.nih.gov/pubmed/25124867

DMZMSPF	DI	DMZMSPF
DMZMSPF	DN	Bicalutamide
DMZMSPF	MI	DE4LYSA
DMZMSPF	MN	Cytochrome P450 3A4 (CYP3A4)
DMZMSPF	MT	DME
DMZMSPF	MA	Metabolism
DMZMSPF	RN	Bicalutamide: clinical pharmacokinetics and metabolism. Clin Pharmacokinet. 2004;43(13):855-78.
DMZMSPF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15509184

DMZMSPF	DI	DMZMSPF
DMZMSPF	DN	Bicalutamide
DMZMSPF	MI	DTUGYRD
DMZMSPF	MN	P-glycoprotein 1 (ABCB1)
DMZMSPF	MT	DTP
DMZMSPF	MA	Substrate
DMZMSPF	RN	Effects of the ABCG2 and ABCB1 drug transporter polymorphisms on the pharmacokinetics of bicalutamide in humans. Clin Chim Acta. 2015 Jan 1;438:7-11.
DMZMSPF	RU	http://www.ncbi.nlm.nih.gov/pubmed/25124867

DMG0H8K	DI	DMG0H8K
DMG0H8K	DN	Bictegravir, emtricitabine and tenofovir alafenamide
DMG0H8K	MI	TT5FH9Y
DMG0H8K	MN	Human immunodeficiency virus Integrase (HIV IN)
DMG0H8K	MT	DTT
DMG0H8K	MA	Inhibitor
DMG0H8K	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMG0H8K	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMG0H8K	DI	DMG0H8K
DMG0H8K	DN	Bictegravir, emtricitabine and tenofovir alafenamide
DMG0H8K	MI	TT84ETX
DMG0H8K	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMG0H8K	MT	DTT
DMG0H8K	MA	Inhibitor
DMG0H8K	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMG0H8K	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DM3KN7V	DI	DM3KN7V
DM3KN7V	DN	Bifonazole
DM3KN7V	MI	TTTSOUD
DM3KN7V	MN	Candida Cytochrome P450 51 (Candi ERG11)
DM3KN7V	MT	DTT
DM3KN7V	MA	Inhibitor
DM3KN7V	RN	Investigation of the role of cytochrome P450 2B4 active site residues in substrate metabolism based on crystal structures of the ligand-bound enzyme. Arch Biochem Biophys. 2006 Nov 1;455(1):61-7.
DM3KN7V	RU	https://pubmed.ncbi.nlm.nih.gov/17027909

DMX0E5B	DI	DMX0E5B
DMX0E5B	DN	Bimatoprost
DMX0E5B	MI	DE4LYSA
DMX0E5B	MN	Cytochrome P450 3A4 (CYP3A4)
DMX0E5B	MT	DME
DMX0E5B	MA	Metabolism
DMX0E5B	RN	Product monograph: LUMIGAN RC (Bimatoprost).
DMX0E5B	RU	https://allergan-web-cdn-prod.azureedge.net/allergancanadaspecialty/allergancanadaspecialty/media/actavis-canada-specialty/en/products/pms/lumigan-rc-pm-2016-05-11_e.pdf

DMX0E5B	DI	DMX0E5B
DMX0E5B	DN	Bimatoprost
DMX0E5B	MI	DEIBDNY
DMX0E5B	MN	Cytochrome P450 3A5 (CYP3A5)
DMX0E5B	MT	DME
DMX0E5B	MA	Metabolism
DMX0E5B	RN	Product monograph: LUMIGAN RC (Bimatoprost).
DMX0E5B	RU	https://allergan-web-cdn-prod.azureedge.net/allergancanadaspecialty/allergancanadaspecialty/media/actavis-canada-specialty/en/products/pms/lumigan-rc-pm-2016-05-11_e.pdf

DMX0E5B	DI	DMX0E5B
DMX0E5B	DN	Bimatoprost
DMX0E5B	MI	TT9B4N3
DMX0E5B	MN	Prostaglandin receptor (PTGR)
DMX0E5B	MT	DTT
DMX0E5B	MA	Modulator
DMX0E5B	RN	Bimatoprost-induced calcium signaling in human T-cells does not involve prostanoid FP or TP receptors. Curr Eye Res. 2009 Mar;34(3):184-95.
DMX0E5B	RU	https://pubmed.ncbi.nlm.nih.gov/19274525

DME78OA	DI	DME78OA
DME78OA	DN	Biperiden
DME78OA	MI	TTZ9SOR
DME78OA	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DME78OA	MT	DTT
DME78OA	MA	Antagonist
DME78OA	RN	Evaluation of in vivo binding properties of 3H-NMPB and 3H-QNB in mouse brain. J Neural Transm. 1999;106(7-8):583-92.
DME78OA	RU	https://pubmed.ncbi.nlm.nih.gov/10907719

DMTKU46	DI	DMTKU46
DMTKU46	DN	Bismuth
DMTKU46	MI	TTFNGC9
DMTKU46	MN	Serum albumin (ALB)
DMTKU46	MT	DTT
DMTKU46	MA	Binder
DMTKU46	RN	Competitive binding of bismuth to transferrin and albumin in aqueous solution and in blood plasma. J Biol Chem. 2001 Mar 23;276(12):8829-35.
DMTKU46	RU	https://pubmed.ncbi.nlm.nih.gov/11110794

DM3UZ95	DI	DM3UZ95
DM3UZ95	DN	Bisoprolol
DM3UZ95	MI	TTR6W5O
DM3UZ95	MN	Adrenergic receptor beta-1 (ADRB1)
DM3UZ95	MT	DTT
DM3UZ95	MA	Antagonist
DM3UZ95	RN	Antiarrhythmic effect of bisoprolol, a highly selective beta1-blocker, in patients with paroxysmal atrial fibrillation. Int Heart J. 2008 May;49(3):281-93.
DM3UZ95	RU	https://pubmed.ncbi.nlm.nih.gov/18612186

DM3UZ95	DI	DM3UZ95
DM3UZ95	DN	Bisoprolol
DM3UZ95	MI	DECB0K3
DM3UZ95	MN	Cytochrome P450 2D6 (CYP2D6)
DM3UZ95	MT	DME
DM3UZ95	MA	Metabolism
DM3UZ95	RN	Drug-drug interactions of beta-adrenoceptor blockers. Arzneimittelforschung. 2003;53(12):814-22.
DM3UZ95	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14732961

DM3UZ95	DI	DM3UZ95
DM3UZ95	DN	Bisoprolol
DM3UZ95	MI	DE4LYSA
DM3UZ95	MN	Cytochrome P450 3A4 (CYP3A4)
DM3UZ95	MT	DME
DM3UZ95	MA	Metabolism
DM3UZ95	RN	Stereoselective metabolism of bisoprolol enantiomers in dogs and humans. Life Sci. 1998;63(13):1097-108.
DM3UZ95	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9763205

DMK6XAV	DI	DMK6XAV
DMK6XAV	DN	Bitolterol
DMK6XAV	MI	TTMXGCW
DMK6XAV	MN	Adrenergic receptor beta-3 (ADRB3)
DMK6XAV	MT	DTT
DMK6XAV	MA	Modulator
DMK6XAV	RN	Bitolterol mesylate: a beta-adrenergic agent. Chemistry, pharmacokinetics, pharmacodynamics, adverse effects and clinical efficacy in asthma. Pharmacotherapy. 1985 May-Jun;5(3):127-37.
DMK6XAV	RU	https://pubmed.ncbi.nlm.nih.gov/3895171

DMECRX1	DI	DMECRX1
DMECRX1	DN	Bivalirudin
DMECRX1	MI	TT6L509
DMECRX1	MN	Coagulation factor IIa (F2)
DMECRX1	MT	DTT
DMECRX1	MA	Inhibitor
DMECRX1	RN	New anticoagulants. Am Heart J. 2001 Aug;142(2 Suppl):S3-8.
DMECRX1	RU	https://pubmed.ncbi.nlm.nih.gov/11479484

DMECRX1	DI	DMECRX1
DMECRX1	DN	Bivalirudin
DMECRX1	MI	TTRTKPV
DMECRX1	MN	Trypanosoma Trypanothione reductase (Trypano TPR)
DMECRX1	MT	DTT
DMECRX1	MA	Inhibitor
DMECRX1	RN	8-Methoxy-naphtho[2,3-b]thiophen-4,9-quinone, a non-competitive inhibitor of trypanothione reductase. Mem Inst Oswaldo Cruz. 2003 Jun;98(4):565-8.
DMECRX1	RU	https://pubmed.ncbi.nlm.nih.gov/12937775

DMR8YD6	DI	DMR8YD6
DMR8YD6	DN	B-Lactams
DMR8YD6	MI	TTPOI4B
DMR8YD6	MN	Acetyl-CoA:lyso-PAF acetyltransferase (PCAT)
DMR8YD6	MT	DTT
DMR8YD6	MA	Inhibitor
DMR8YD6	RN	Inhibition of lysoPAF acetyltransferase activity by flavonoids. Inflamm Res. 1996 Nov;45(11):546-9.
DMR8YD6	RU	https://pubmed.ncbi.nlm.nih.gov/8951505

DMR8YD6	DI	DMR8YD6
DMR8YD6	DN	B-Lactams
DMR8YD6	MI	TTLP6GN
DMR8YD6	MN	Bacterial DD-carboxypeptidase (Bact vanYB)
DMR8YD6	MT	DTT
DMR8YD6	MA	Inhibitor
DMR8YD6	RN	Has nature already identified all useful antibacterial targets Curr Opin Microbiol. 2008 Oct;11(5):387-92.
DMR8YD6	RU	https://pubmed.ncbi.nlm.nih.gov/18804175

DMR8YD6	DI	DMR8YD6
DMR8YD6	DN	B-Lactams
DMR8YD6	MI	TTGTQHC
DMR8YD6	MN	DNA topoisomerase I (TOP1)
DMR8YD6	MT	DTT
DMR8YD6	MA	Inhibitor
DMR8YD6	RN	Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I. Biochem J. 2002 Sep 1;366(Pt 2):653-61.
DMR8YD6	RU	https://pubmed.ncbi.nlm.nih.gov/12027807

DMNER5S	DI	DMNER5S
DMNER5S	DN	Bleomycin
DMNER5S	MI	DECH1VP
DMNER5S	MN	Bleomycin hydrolase (BLMH)
DMNER5S	MT	DME
DMNER5S	MA	Metabolism
DMNER5S	RN	The C-terminus of human bleomycin hydrolase is required for protection against bleomycin-induced chromosomal damage. Mutat Res. 1998 Oct 12;421(1):1-7.
DMNER5S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9748474

DMNER5S	DI	DMNER5S
DMNER5S	DN	Bleomycin
DMNER5S	MI	TTUTN1I
DMNER5S	MN	Human Deoxyribonucleic acid (hDNA)
DMNER5S	MT	DTT
DMNER5S	MA	Breaker
DMNER5S	RN	Bleomycin and talisomycin sequence-specific strand scission of DNA: a mechanism of double-strand cleavage. Cancer Res. 1982 Jul;42(7):2779-85.
DMNER5S	RU	https://pubmed.ncbi.nlm.nih.gov/6177398

DMGECIJ	DI	DMGECIJ
DMGECIJ	DN	Blinatumomab
DMGECIJ	MI	TTW640A
DMGECIJ	MN	B-lymphocyte surface antigen B4 (CD19)
DMGECIJ	MT	DTT
DMGECIJ	MA	Modulator
DMGECIJ	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMGECIJ	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMGECIJ	DI	DMGECIJ
DMGECIJ	DN	Blinatumomab
DMGECIJ	MI	TTUN7MC
DMGECIJ	MN	T-cell surface glycoprotein CD3 (CD3)
DMGECIJ	MT	DTT
DMGECIJ	MA	Modulator
DMGECIJ	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMGECIJ	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMQTAGO	DI	DMQTAGO
DMQTAGO	DN	BMS-201038
DMQTAGO	MI	TTUS1RD
DMQTAGO	MN	Microsomal triglyceride transfer protein (MTTP)
DMQTAGO	MT	DTT
DMQTAGO	MA	Inhibitor
DMQTAGO	RN	Dyslipidemia and cardiovascular diseases. Curr Opin Lipidol. 2009 Apr;20(2):157-8.
DMQTAGO	RU	https://pubmed.ncbi.nlm.nih.gov/19276898

DMBSHMF	DI	DMBSHMF
DMBSHMF	DN	Boceprevir
DMBSHMF	MI	DE4LYSA
DMBSHMF	MN	Cytochrome P450 3A4 (CYP3A4)
DMBSHMF	MT	DME
DMBSHMF	MA	Metabolism
DMBSHMF	RN	Pharmacokinetic evaluation of the interaction between hepatitis C virus protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatin. Antimicrob Agents Chemother. 2013 Jun;57(6):2582-8.
DMBSHMF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23529734

DMBSHMF	DI	DMBSHMF
DMBSHMF	DN	Boceprevir
DMBSHMF	MI	DEIBDNY
DMBSHMF	MN	Cytochrome P450 3A5 (CYP3A5)
DMBSHMF	MT	DME
DMBSHMF	MA	Metabolism
DMBSHMF	RN	Direct-acting antiviral agents for hepatitis C virus infection. Annu Rev Pharmacol Toxicol. 2013;53:427-49.
DMBSHMF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23140245

DMBSHMF	DI	DMBSHMF
DMBSHMF	DN	Boceprevir
DMBSHMF	MI	TTHC7JD
DMBSHMF	MN	Hepatitis C virus Serine protease NS3/4A (HCV NS3/4A)
DMBSHMF	MT	DTT
DMBSHMF	MA	Modulator
DMBSHMF	RN	2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
DMBSHMF	RU	https://pubmed.ncbi.nlm.nih.gov/22293555

DMBSHMF	DI	DMBSHMF
DMBSHMF	DN	Boceprevir
DMBSHMF	MI	DTUGYRD
DMBSHMF	MN	P-glycoprotein 1 (ABCB1)
DMBSHMF	MT	DTP
DMBSHMF	MA	Substrate
DMBSHMF	RN	Drug interactions and protease inhibitors used in the treatment of hepatitis C: how to manage? Eur J Clin Pharmacol. 2014 Jul;70(7):775-89.
DMBSHMF	RU	http://www.ncbi.nlm.nih.gov/pubmed/24817413

DM2EXC5	DI	DM2EXC5
DM2EXC5	DN	BOL-303259-X
DM2EXC5	MI	DTPFTEQ
DM2EXC5	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DM2EXC5	MT	DTP
DM2EXC5	MA	Substrate
DM2EXC5	RN	The prostaglandin transporter OATP2A1 is expressed in human ocular tissues and transports the antiglaucoma prostanoid latanoprost. Invest Ophthalmol Vis Sci. 2010 May;51(5):2504-11.
DM2EXC5	RU	http://www.ncbi.nlm.nih.gov/pubmed/20019365

DM2EXC5	DI	DM2EXC5
DM2EXC5	DN	BOL-303259-X
DM2EXC5	MI	TTT2ZAR
DM2EXC5	MN	Prostaglandin F2-alpha receptor (PTGFR)
DM2EXC5	MT	DTT
DM2EXC5	MA	Agonist
DM2EXC5	RN	Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2alpha agonist, in preclinical models. Exp Eye Res. 2011 Sep;93(3):250-5.
DM2EXC5	RU	https://pubmed.ncbi.nlm.nih.gov/21396362

DMIFYLX	DI	DMIFYLX
DMIFYLX	DN	Bopindolol
DMIFYLX	MI	TTMXGCW
DMIFYLX	MN	Adrenergic receptor beta-3 (ADRB3)
DMIFYLX	MT	DTT
DMIFYLX	MA	Modulator
DMIFYLX	RN	Effect of propranolol, alprenolol, pindolol, and bopindolol on beta 2-adrenoceptor density in human lymphocytes. J Cardiovasc Pharmacol. 1986;8 Suppl 6:S70-3.
DMIFYLX	RU	https://pubmed.ncbi.nlm.nih.gov/2439825

DMIFYLX	DI	DMIFYLX
DMIFYLX	DN	Bopindolol
DMIFYLX	MI	DECB0K3
DMIFYLX	MN	Cytochrome P450 2D6 (CYP2D6)
DMIFYLX	MT	DME
DMIFYLX	MA	Metabolism
DMIFYLX	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DMIFYLX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DMNO38U	DI	DMNO38U
DMNO38U	DN	Bortezomib
DMNO38U	MI	TT2WR1T
DMNO38U	MN	Cationic trypsinogen (PRSS1)
DMNO38U	MT	DTT
DMNO38U	MA	Inhibitor
DMNO38U	RN	Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin. J Med Chem. 1995 Apr 28;38(9):1511-22.
DMNO38U	RU	https://pubmed.ncbi.nlm.nih.gov/7739010

DMNO38U	DI	DMNO38U
DMNO38U	DN	Bortezomib
DMNO38U	MI	DEJGDUW
DMNO38U	MN	Cytochrome P450 1A2 (CYP1A2)
DMNO38U	MT	DME
DMNO38U	MA	Metabolism
DMNO38U	RN	Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites. Drug Metab Dispos. 2005 Jun;33(6):771-7.
DMNO38U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15764713

DMNO38U	DI	DMNO38U
DMNO38U	DN	Bortezomib
DMNO38U	MI	DE5IED8
DMNO38U	MN	Cytochrome P450 2C9 (CYP2C9)
DMNO38U	MT	DME
DMNO38U	MA	Metabolism
DMNO38U	RN	Investigation of drug-drug interaction potential of bortezomib in vivo in female Sprague-Dawley rats and in vitro in human liver microsomes. Drug Metab Dispos. 2006 Apr;34(4):702-8.
DMNO38U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16443666

DMNO38U	DI	DMNO38U
DMNO38U	DN	Bortezomib
DMNO38U	MI	DECB0K3
DMNO38U	MN	Cytochrome P450 2D6 (CYP2D6)
DMNO38U	MT	DME
DMNO38U	MA	Metabolism
DMNO38U	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMNO38U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMNO38U	DI	DMNO38U
DMNO38U	DN	Bortezomib
DMNO38U	MI	DE4LYSA
DMNO38U	MN	Cytochrome P450 3A4 (CYP3A4)
DMNO38U	MT	DME
DMNO38U	MA	Metabolism
DMNO38U	RN	Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Drug Metab Dispos. 2005 Nov;33(11):1723-8.
DMNO38U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16103134

DMNO38U	DI	DMNO38U
DMNO38U	DN	Bortezomib
DMNO38U	MI	TT5L2VC
DMNO38U	MN	Kallikrein-related peptidase (KLK)
DMNO38U	MT	DTT
DMNO38U	MA	Inhibitor
DMNO38U	RN	Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin. J Med Chem. 1995 Apr 28;38(9):1511-22.
DMNO38U	RU	https://pubmed.ncbi.nlm.nih.gov/7739010

DMNO38U	DI	DMNO38U
DMNO38U	DN	Bortezomib
DMNO38U	MI	DEGTFWK
DMNO38U	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMNO38U	MT	DME
DMNO38U	MA	Metabolism
DMNO38U	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMNO38U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMNO38U	DI	DMNO38U
DMNO38U	DN	Bortezomib
DMNO38U	MI	DTUGYRD
DMNO38U	MN	P-glycoprotein 1 (ABCB1)
DMNO38U	MT	DTP
DMNO38U	MA	Substrate
DMNO38U	RN	CNS uptake of bortezomib is enhanced by P-glycoprotein inhibition: implications for spinal muscular atrophy. Neurobiol Dis. 2016 Apr;88:118-24.
DMNO38U	RU	http://www.ncbi.nlm.nih.gov/pubmed/26792401

DMNO38U	DI	DMNO38U
DMNO38U	DN	Bortezomib
DMNO38U	MI	TTU7ZMG
DMNO38U	MN	Proteasome (PS)
DMNO38U	MT	DTT
DMNO38U	MA	Modulator
DMNO38U	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMNO38U	RU	https://www.fda.gov/

DMIOGBU	DI	DMIOGBU
DMIOGBU	DN	Bosentan
DMIOGBU	MI	DE5IED8
DMIOGBU	MN	Cytochrome P450 2C9 (CYP2C9)
DMIOGBU	MT	DME
DMIOGBU	MA	Metabolism
DMIOGBU	RN	Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. Clin Pharmacokinet. 2003;42(3):293-301.
DMIOGBU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12603176

DMIOGBU	DI	DMIOGBU
DMIOGBU	DN	Bosentan
DMIOGBU	MI	DE4LYSA
DMIOGBU	MN	Cytochrome P450 3A4 (CYP3A4)
DMIOGBU	MT	DME
DMIOGBU	MA	Metabolism
DMIOGBU	RN	Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007 Aug;35(8):1400-7.
DMIOGBU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17496208

DMIOGBU	DI	DMIOGBU
DMIOGBU	DN	Bosentan
DMIOGBU	MI	TTKRD0G
DMIOGBU	MN	Endothelin A receptor (EDNRA)
DMIOGBU	MT	DTT
DMIOGBU	MA	Modulator
DMIOGBU	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMIOGBU	RU	https://www.fda.gov/

DMIOGBU	DI	DMIOGBU
DMIOGBU	DN	Bosentan
DMIOGBU	MI	TT3ZTGU
DMIOGBU	MN	Endothelin B receptor (EDNRB)
DMIOGBU	MT	DTT
DMIOGBU	MA	Modulator
DMIOGBU	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMIOGBU	RU	https://www.fda.gov/

DMIOGBU	DI	DMIOGBU
DMIOGBU	DN	Bosentan
DMIOGBU	MI	DT3D8F0
DMIOGBU	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMIOGBU	MT	DTP
DMIOGBU	MA	Substrate
DMIOGBU	RN	Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007 Aug;35(8):1400-7.
DMIOGBU	RU	http://www.ncbi.nlm.nih.gov/pubmed/17496208

DMIOGBU	DI	DMIOGBU
DMIOGBU	DN	Bosentan
DMIOGBU	MI	DT9C1TS
DMIOGBU	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMIOGBU	MT	DTP
DMIOGBU	MA	Substrate
DMIOGBU	RN	Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007 Aug;35(8):1400-7.
DMIOGBU	RU	http://www.ncbi.nlm.nih.gov/pubmed/17496208

DMIOGBU	DI	DMIOGBU
DMIOGBU	DN	Bosentan
DMIOGBU	MI	DTPFTEQ
DMIOGBU	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DMIOGBU	MT	DTP
DMIOGBU	MA	Substrate
DMIOGBU	RN	Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007 Aug;35(8):1400-7.
DMIOGBU	RU	http://www.ncbi.nlm.nih.gov/pubmed/17496208

DMTI8YE	DI	DMTI8YE
DMTI8YE	DN	Bosutinib
DMTI8YE	MI	DE4LYSA
DMTI8YE	MN	Cytochrome P450 3A4 (CYP3A4)
DMTI8YE	MT	DME
DMTI8YE	MA	Metabolism
DMTI8YE	RN	In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors. Drug Metab Dispos. 2014 Jul;42(7):1202-9.
DMTI8YE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24713129

DMTI8YE	DI	DMTI8YE
DMTI8YE	DN	Bosutinib
DMTI8YE	MI	DTUGYRD
DMTI8YE	MN	P-glycoprotein 1 (ABCB1)
DMTI8YE	MT	DTP
DMTI8YE	MA	Substrate
DMTI8YE	RN	In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib. J Hematol Oncol. 2015 Jul 7;8:81.
DMTI8YE	RU	http://www.ncbi.nlm.nih.gov/pubmed/26149173

DMTI8YE	DI	DMTI8YE
DMTI8YE	DN	Bosutinib
DMTI8YE	MI	TT6PKBN
DMTI8YE	MN	Proto-oncogene c-Src (SRC)
DMTI8YE	MT	DTT
DMTI8YE	MA	Inhibitor
DMTI8YE	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMTI8YE	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMTI8YE	DI	DMTI8YE
DMTI8YE	DN	Bosutinib
DMTI8YE	MI	TT3PJMV
DMTI8YE	MN	Tyrosine-protein kinase ABL1 (ABL)
DMTI8YE	MT	DTT
DMTI8YE	MA	Inhibitor
DMTI8YE	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMTI8YE	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMW67MU	DI	DMW67MU
DMW67MU	DN	Botulinum Toxin Type A
DMW67MU	MI	TTYQWA0
DMW67MU	MN	Synaptosomal-associated protein 25 (SNAP25)
DMW67MU	MT	DTT
DMW67MU	MA	Inhibitor
DMW67MU	RN	Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct duration... J Biol Chem. 2003 Jan 10;278(2):1363-71.
DMW67MU	RU	https://pubmed.ncbi.nlm.nih.gov/12381720

DM58QS1	DI	DM58QS1
DM58QS1	DN	Botulinum Toxin Type B
DM58QS1	MI	TTG25NJ
DM58QS1	MN	Vesicle-associated membrane protein (VAMP)
DM58QS1	MT	DTT
DM58QS1	MA	Binder
DM58QS1	RN	Long-lasting benefits of botulinum toxin type B in Parkinson's disease-related drooling. J Neurol. 2009 Apr;256(4):563-7.
DM58QS1	RU	https://pubmed.ncbi.nlm.nih.gov/19401804

DM20LIM	DI	DM20LIM
DM20LIM	DN	Bremelanotide
DM20LIM	MI	TT0MV2T
DM20LIM	MN	Melanocortin receptor 1 (MC1R)
DM20LIM	MT	DTT
DM20LIM	MA	Agonist
DM20LIM	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DM20LIM	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf

DM20LIM	DI	DM20LIM
DM20LIM	DN	Bremelanotide
DM20LIM	MI	TTD0CIQ
DM20LIM	MN	Melanocortin receptor 4 (MC4R)
DM20LIM	MT	DTT
DM20LIM	MA	Agonist
DM20LIM	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DM20LIM	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf

DMWLC57	DI	DMWLC57
DMWLC57	DN	Brentuximab vedotin
DMWLC57	MI	DE4LYSA
DMWLC57	MN	Cytochrome P450 3A4 (CYP3A4)
DMWLC57	MT	DME
DMWLC57	MA	Metabolism
DMWLC57	RN	Brentuximab vedotin.
DMWLC57	RU	https://www.cancercareontario.ca/sites/ccocancercare/files/brentuximab%20vedotin.pdf

DMWLC57	DI	DMWLC57
DMWLC57	DN	Brentuximab vedotin
DMWLC57	MI	TT2GM5R
DMWLC57	MN	Lymphocyte activation antigen CD30 (TNFRSF8)
DMWLC57	MT	DTT
DMWLC57	MA	Modulator
DMWLC57	RN	2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
DMWLC57	RU	https://pubmed.ncbi.nlm.nih.gov/22293555

DM1FX74	DI	DM1FX74
DM1FX74	DN	Bretylium
DM1FX74	MI	TTR6W5O
DM1FX74	MN	Adrenergic receptor beta-1 (ADRB1)
DM1FX74	MT	DTT
DM1FX74	MA	Antagonist
DM1FX74	RN	Components of functional sympathetic control of heart rate in neonatal rats. Am J Physiol. 1985 May;248(5 Pt 2):R601-10.
DM1FX74	RU	https://pubmed.ncbi.nlm.nih.gov/2859811

DM1FX74	DI	DM1FX74
DM1FX74	DN	Bretylium
DM1FX74	MI	DT3BA8L
DM1FX74	MN	Sodium-dependent dopamine transporter (SLC6A3)
DM1FX74	MT	DTP
DM1FX74	MA	Substrate
DM1FX74	RN	Which form of dopamine is the substrate for the human dopamine transporter: the cationic or the uncharged species? J Biol Chem. 1999 Feb 19;274(8):4876-82.
DM1FX74	RU	http://www.ncbi.nlm.nih.gov/pubmed/9988729

DM7W94S	DI	DM7W94S
DM7W94S	DN	Brigatinib
DM7W94S	MI	TTPMQSO
DM7W94S	MN	ALK tyrosine kinase receptor (ALK)
DM7W94S	MT	DTT
DM7W94S	MA	Inhibitor
DM7W94S	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DM7W94S	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DM7W94S	DI	DM7W94S
DM7W94S	DN	Brigatinib
DM7W94S	MI	DTKVEXO
DM7W94S	MN	ATP-binding cassette sub-family B member 5 (ABCB5)
DM7W94S	MT	DTP
DM7W94S	MA	Substrate
DM7W94S	RN	NDA/BLA Multidisciplinary Review and Evaluation of ALUNBRIG (brigatinib) From FDA.
DM7W94S	RU	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208772Orig1s000MultidisciplineR.pdf

DM7W94S	DI	DM7W94S
DM7W94S	DN	Brigatinib
DM7W94S	MI	DTI7UX6
DM7W94S	MN	Breast cancer resistance protein (ABCG2)
DM7W94S	MT	DTP
DM7W94S	MA	Substrate
DM7W94S	RN	NDA/BLA Multidisciplinary Review and Evaluation of ALUNBRIG (brigatinib) From FDA.
DM7W94S	RU	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208772Orig1s000MultidisciplineR.pdf

DM7W94S	DI	DM7W94S
DM7W94S	DN	Brigatinib
DM7W94S	MI	DES5XRU
DM7W94S	MN	Cytochrome P450 2C8 (CYP2C8)
DM7W94S	MT	DME
DM7W94S	MA	Metabolism
DM7W94S	RN	Brigatinib: first global approval. Drugs. 2017 Jul;77(10):1131-1135.
DM7W94S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28597393

DMBR01X	DI	DMBR01X
DMBR01X	DN	Brilinta
DMBR01X	MI	DE4LYSA
DMBR01X	MN	Cytochrome P450 3A4 (CYP3A4)
DMBR01X	MT	DME
DMBR01X	MA	Metabolism
DMBR01X	RN	Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos. 2010 Sep;38(9):1514-21.
DMBR01X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20551239

DMBR01X	DI	DMBR01X
DMBR01X	DN	Brilinta
DMBR01X	MI	TTZ1DT0
DMBR01X	MN	P2Y purinoceptor 12 (P2RY12)
DMBR01X	MT	DTT
DMBR01X	MA	Antagonist
DMBR01X	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DMBR01X	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DMBR01X	DI	DMBR01X
DMBR01X	DN	Brilinta
DMBR01X	MI	DTUGYRD
DMBR01X	MN	P-glycoprotein 1 (ABCB1)
DMBR01X	MT	DTP
DMBR01X	MA	Substrate
DMBR01X	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
DMBR01X	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01665

DMQLT4N	DI	DMQLT4N
DMQLT4N	DN	Brimonidine
DMQLT4N	MI	TTQ8AFT
DMQLT4N	MN	Adrenergic receptor Alpha-2 (ADRA2)
DMQLT4N	MT	DTT
DMQLT4N	MA	Agonist
DMQLT4N	RN	Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum. 2000 Aug;43(8):1886-90.
DMQLT4N	RU	https://pubmed.ncbi.nlm.nih.gov/10943881

DMQLT4N	DI	DMQLT4N
DMQLT4N	DN	Brimonidine
DMQLT4N	MI	TT2NUT5
DMQLT4N	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMQLT4N	MT	DTT
DMQLT4N	MA	Modulator
DMQLT4N	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 520).
DMQLT4N	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=520

DMBAPFG	DI	DMBAPFG
DMBAPFG	DN	Brinzolamide
DMBAPFG	MI	TTZHA0O
DMBAPFG	MN	Carbonic anhydrase IV (CA-IV)
DMBAPFG	MT	DTT
DMBAPFG	MA	Modulator
DMBAPFG	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMBAPFG	RU	https://www.fda.gov/

DMBAPFG	DI	DMBAPFG
DMBAPFG	DN	Brinzolamide
DMBAPFG	MI	DE4LYSA
DMBAPFG	MN	Cytochrome P450 3A4 (CYP3A4)
DMBAPFG	MT	DME
DMBAPFG	MA	Metabolism
DMBAPFG	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMBAPFG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMSEPK8	DI	DMSEPK8
DMSEPK8	DN	Brivaracetam
DMSEPK8	MI	DEPKLMQ
DMSEPK8	MN	Cytochrome P450 2B6 (CYP2B6)
DMSEPK8	MT	DME
DMSEPK8	MA	Metabolism
DMSEPK8	RN	Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispos. 2008 Jan;36(1):36-45.
DMSEPK8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17908923

DMSEPK8	DI	DMSEPK8
DMSEPK8	DN	Brivaracetam
DMSEPK8	MI	DE5IED8
DMSEPK8	MN	Cytochrome P450 2C9 (CYP2C9)
DMSEPK8	MT	DME
DMSEPK8	MA	Metabolism
DMSEPK8	RN	Effect of gemfibrozil on the metabolism of brivaracetam in vitro and in human subjects. Drug Metab Dispos. 2012 Aug;40(8):1466-72.
DMSEPK8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22538270

DMSEPK8	DI	DMSEPK8
DMSEPK8	DN	Brivaracetam
DMSEPK8	MI	DEGTFWK
DMSEPK8	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMSEPK8	MT	DME
DMSEPK8	MA	Metabolism
DMSEPK8	RN	Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispos. 2008 Jan;36(1):36-45.
DMSEPK8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17908923

DMSEPK8	DI	DMSEPK8
DMSEPK8	DN	Brivaracetam
DMSEPK8	MI	TTT3P91
DMSEPK8	MN	Synaptic vesicle glycoprotein 2A (SV2A)
DMSEPK8	MT	DTT
DMSEPK8	MA	Inhibitor
DMSEPK8	RN	Pharmacological management of epilepsy: recent advances and future prospects. Drugs. 2008;68(14):1925-39.
DMSEPK8	RU	https://pubmed.ncbi.nlm.nih.gov/18778117

DMASDQ6	DI	DMASDQ6
DMASDQ6	DN	Brodalumab
DMASDQ6	MI	TT69OHW
DMASDQ6	MN	Interleukin 17 receptor (IL17R)
DMASDQ6	MT	DTT
DMASDQ6	MA	Antagonist
DMASDQ6	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DMASDQ6	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DMASDQ6	DI	DMASDQ6
DMASDQ6	DN	Brodalumab
DMASDQ6	MI	TTG0MT6
DMASDQ6	MN	Interleukin-17 (IL17)
DMASDQ6	MT	DTT
DMASDQ6	MA	Modulator
DMASDQ6	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMASDQ6	RU	https://www.fda.gov/

DMW8QNG	DI	DMW8QNG
DMW8QNG	DN	Brolucizumab
DMW8QNG	MI	TT9HKJA
DMW8QNG	MN	Vascular endothelial growth factor (VEGF)
DMW8QNG	MT	DTT
DMW8QNG	MA	Inhibitor
DMW8QNG	RN	Brolucizumab: First Approval. Drugs. 2019 Dec;79(18):1997-2000.
DMW8QNG	RU	https://pubmed.ncbi.nlm.nih.gov/31768932

DMW8QNG	DI	DMW8QNG
DMW8QNG	DN	Brolucizumab
DMW8QNG	MI	TTOHSBA
DMW8QNG	MN	Vascular endothelial growth factor A (VEGFA)
DMW8QNG	MT	DTT
DMW8QNG	MA	Inhibitor
DMW8QNG	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMW8QNG	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761125s000lbl.pdf

DMY9TCW	DI	DMY9TCW
DMY9TCW	DN	Bromazepam
DMY9TCW	MI	DEJGDUW
DMY9TCW	MN	Cytochrome P450 1A2 (CYP1A2)
DMY9TCW	MT	DME
DMY9TCW	MA	Metabolism
DMY9TCW	RN	Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clin Pharmacokinet. 1997 Dec;33(6):454-71.
DMY9TCW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9435993

DMY9TCW	DI	DMY9TCW
DMY9TCW	DN	Bromazepam
DMY9TCW	MI	TTAN6JD
DMY9TCW	MN	Glutamate receptor AMPA (GRIA)
DMY9TCW	MT	DTT
DMY9TCW	MA	Binder
DMY9TCW	RN	Glutamatergic and GABAergic modulations of ultrasonic vocalizations during maternal separation distress in mouse pups. Psychopharmacology (Berl). 2009 May;204(1):61-71.
DMY9TCW	RU	https://pubmed.ncbi.nlm.nih.gov/19099296

DMY9TCW	DI	DMY9TCW
DMY9TCW	DN	Bromazepam
DMY9TCW	MI	DEGTFWK
DMY9TCW	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMY9TCW	MT	DME
DMY9TCW	MA	Metabolism
DMY9TCW	RN	Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clin Pharmacokinet. 1997 Dec;33(6):454-71.
DMY9TCW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9435993

DMKB79O	DI	DMKB79O
DMKB79O	DN	Bromfenac
DMKB79O	MI	DES5XRU
DMKB79O	MN	Cytochrome P450 2C8 (CYP2C8)
DMKB79O	MT	DME
DMKB79O	MA	Metabolism
DMKB79O	RN	Metabolite profiling and reaction phenotyping for the in vitro assessment of the bioactivation of bromfenac. Chem Res Toxicol. 2020 Jan 21;33(1):249-257.
DMKB79O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31815452

DMKB79O	DI	DMKB79O
DMKB79O	DN	Bromfenac
DMKB79O	MI	DE5IED8
DMKB79O	MN	Cytochrome P450 2C9 (CYP2C9)
DMKB79O	MT	DME
DMKB79O	MA	Metabolism
DMKB79O	RN	Metabolite profiling and reaction phenotyping for the in vitro assessment of the bioactivation of bromfenac. Chem Res Toxicol. 2020 Jan 21;33(1):249-257.
DMKB79O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31815452

DMKB79O	DI	DMKB79O
DMKB79O	DN	Bromfenac
DMKB79O	MI	DEGTFWK
DMKB79O	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMKB79O	MT	DME
DMKB79O	MA	Metabolism
DMKB79O	RN	Metabolite profiling and reaction phenotyping for the in vitro assessment of the bioactivation of bromfenac. Chem Res Toxicol. 2020 Jan 21;33(1):249-257.
DMKB79O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31815452

DMKB79O	DI	DMKB79O
DMKB79O	DN	Bromfenac
DMKB79O	MI	DT3D8F0
DMKB79O	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMKB79O	MT	DTP
DMKB79O	MA	Substrate
DMKB79O	RN	Organic Anion Transporter 2-Mediated Hepatic Uptake Contributes to the Clearance of High-Permeability-Low-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs. J Pharmacol Exp Ther. 2018 Nov;367(2):322-334.
DMKB79O	RU	http://www.ncbi.nlm.nih.gov/pubmed/30135178

DMKB79O	DI	DMKB79O
DMKB79O	DN	Bromfenac
DMKB79O	MI	TT8NGED
DMKB79O	MN	Prostaglandin G/H synthase 1 (COX-1)
DMKB79O	MT	DTT
DMKB79O	MA	Inhibitor
DMKB79O	RN	Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40.
DMKB79O	RU	https://pubmed.ncbi.nlm.nih.gov/16846546

DMKB79O	DI	DMKB79O
DMKB79O	DN	Bromfenac
DMKB79O	MI	DEB3CV1
DMKB79O	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMKB79O	MT	DME
DMKB79O	MA	Metabolism
DMKB79O	RN	Metabolite profiling and reaction phenotyping for the in vitro assessment of the bioactivation of bromfenac. Chem Res Toxicol. 2020 Jan 21;33(1):249-257.
DMKB79O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31815452

DMVE3TK	DI	DMVE3TK
DMVE3TK	DN	Bromocriptine
DMVE3TK	MI	DE4LYSA
DMVE3TK	MN	Cytochrome P450 3A4 (CYP3A4)
DMVE3TK	MT	DME
DMVE3TK	MA	Metabolism
DMVE3TK	RN	Kinetics of dithionite-dependent reduction of cytochrome P450 3A4: heterogeneity of the enzyme caused by its oligomerization. Biochemistry. 2005 Oct 25;44(42):13902-13.
DMVE3TK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16229479

DMVE3TK	DI	DMVE3TK
DMVE3TK	DN	Bromocriptine
DMVE3TK	MI	TTEX248
DMVE3TK	MN	Dopamine D2 receptor (D2R)
DMVE3TK	MT	DTT
DMVE3TK	MA	Agonist
DMVE3TK	RN	Silymarin BIO-C, an extract from Silybum marianum fruits, induces hyperprolactinemia in intact female rats. Phytomedicine. 2009 Sep;16(9):839-44.
DMVE3TK	RU	https://pubmed.ncbi.nlm.nih.gov/19303749

DMVE3TK	DI	DMVE3TK
DMVE3TK	DN	Bromocriptine
DMVE3TK	MI	DTUGYRD
DMVE3TK	MN	P-glycoprotein 1 (ABCB1)
DMVE3TK	MT	DTP
DMVE3TK	MA	Substrate
DMVE3TK	RN	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
DMVE3TK	RU	https://doi.org/10.1016/j.addr.2011.12.008

DMNDJT5	DI	DMNDJT5
DMNDJT5	DN	Bromodiphenhydramine
DMNDJT5	MI	TTTIBOJ
DMNDJT5	MN	Histamine H1 receptor (H1R)
DMNDJT5	MT	DTT
DMNDJT5	MA	Antagonist
DMNDJT5	RN	Studies on synergism between penicillins and ambodryl (bromodiphenhydramine HCl), an antihistamine with antimicrobial property. Indian J Exp Biol. 1990 Mar;28(3):253-8.
DMNDJT5	RU	https://pubmed.ncbi.nlm.nih.gov/1973150

DM24XYQ	DI	DM24XYQ
DM24XYQ	DN	Bromperidol
DM24XYQ	MI	DE4LYSA
DM24XYQ	MN	Cytochrome P450 3A4 (CYP3A4)
DM24XYQ	MT	DME
DM24XYQ	MA	Metabolism
DM24XYQ	RN	CYP3A is responsible for N-dealkylation of haloperidol and bromperidol and oxidation of their reduced forms by human liver microsomes. Life Sci. 2000 Nov 3;67(24):2913-20.
DM24XYQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11133003

DMFOVSD	DI	DMFOVSD
DMFOVSD	DN	Brompheniramine
DMFOVSD	MI	TTTIBOJ
DMFOVSD	MN	Histamine H1 receptor (H1R)
DMFOVSD	MT	DTT
DMFOVSD	MA	Antagonist
DMFOVSD	RN	Histamine-induced venodilation in human beings involves both H1 and H2 receptor subtypes. J Allergy Clin Immunol. 1994 Mar;93(3):606-14.
DMFOVSD	RU	https://pubmed.ncbi.nlm.nih.gov/8151062

DMXKZT3	DI	DMXKZT3
DMXKZT3	DN	Buclizine
DMXKZT3	MI	TTTIBOJ
DMXKZT3	MN	Histamine H1 receptor (H1R)
DMXKZT3	MT	DTT
DMXKZT3	MA	Antagonist
DMXKZT3	RN	Toxicologic and clinical appraisal of buclizine, a new antihistaminic compound. J Allergy. 1956 Jan;27(1):63-7.
DMXKZT3	RU	https://pubmed.ncbi.nlm.nih.gov/13294975

DMJIBAW	DI	DMJIBAW
DMJIBAW	DN	Budesonide
DMJIBAW	MI	DE4LYSA
DMJIBAW	MN	Cytochrome P450 3A4 (CYP3A4)
DMJIBAW	MT	DME
DMJIBAW	MA	Metabolism
DMJIBAW	RN	No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis. Hepatology. 2005 Mar;41(3):595-602.
DMJIBAW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15726657

DMJIBAW	DI	DMJIBAW
DMJIBAW	DN	Budesonide
DMJIBAW	MI	TTYRL6O
DMJIBAW	MN	Glucocorticoid receptor (NR3C1)
DMJIBAW	MT	DTT
DMJIBAW	MA	Antagonist
DMJIBAW	RN	PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide. Eur J Pharm Sci. 2009 Mar 2;36(4-5):565-71.
DMJIBAW	RU	https://pubmed.ncbi.nlm.nih.gov/19138736

DMJIBAW	DI	DMJIBAW
DMJIBAW	DN	Budesonide
DMJIBAW	MI	DEYWLRK
DMJIBAW	MN	Sulfotransferase 1A1 (SULT1A1)
DMJIBAW	MT	DME
DMJIBAW	MA	Metabolism
DMJIBAW	RN	Sulfation of budesonide by human cytosolic sulfotransferase, dehydroepiandrosterone-sulfotransferase (DHEA-ST). Drug Metab Dispos. 2002 May;30(5):582-5.
DMJIBAW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11950791

DMODHQI	DI	DMODHQI
DMODHQI	DN	Budipine
DMODHQI	MI	TTGP7BY
DMODHQI	MN	Monoamine oxidase type B (MAO-B)
DMODHQI	MT	DTT
DMODHQI	MA	Modulator
DMODHQI	RN	Multiple mechanisms of action: the pharmacological profile of budipine. J Neural Transm Suppl. 1999;56:83-105.
DMODHQI	RU	https://pubmed.ncbi.nlm.nih.gov/10370904

DMG1OPF	DI	DMG1OPF
DMG1OPF	DN	Buflomedil
DMG1OPF	MI	DECB0K3
DMG1OPF	MN	Cytochrome P450 2D6 (CYP2D6)
DMG1OPF	MT	DME
DMG1OPF	MA	Metabolism
DMG1OPF	RN	DMW/ISSX 2000 Meeting. The Drug Metabolism Workshop/International Society for the Study of Xenobiotics. St. Andrews, Scotland, June 11-16, 2000. Abstracts. Drug Metab Rev. 2000;32 Suppl 1:1-136.
DMG1OPF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10909680

DMG1OPF	DI	DMG1OPF
DMG1OPF	DN	Buflomedil
DMG1OPF	MI	DEGTFWK
DMG1OPF	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMG1OPF	MT	DME
DMG1OPF	MA	Metabolism
DMG1OPF	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMG1OPF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMX82DO	DI	DMX82DO
DMX82DO	DN	Buformin
DMX82DO	MI	DTT79CX
DMX82DO	MN	Organic cation transporter 1 (SLC22A1)
DMX82DO	MT	DTP
DMX82DO	MA	Substrate
DMX82DO	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMX82DO	RU	https://doi.org/10.1007/s11095-012-0935-x

DMJUVE6	DI	DMJUVE6
DMJUVE6	DN	Bulevirtide
DMJUVE6	MI	TTWZRY5
DMJUVE6	MN	Sodium/bile acid cotransporter (SLC10A1)
DMJUVE6	MT	DTT
DMJUVE6	MA	Inhibitor
DMJUVE6	RN	Bulevirtide: First Approval. Drugs. 2020 Oct;80(15):1601-1605.
DMJUVE6	RU	https://pubmed.ncbi.nlm.nih.gov/32926353

DMRV7H0	DI	DMRV7H0
DMRV7H0	DN	Bumetanide
DMRV7H0	MI	DT3I124
DMRV7H0	MN	Monocarboxylate transporter 6 (SLC16A5)
DMRV7H0	MT	DTP
DMRV7H0	MA	Substrate
DMRV7H0	RN	Quercetin, Morin, Luteolin, and Phloretin Are Dietary Flavonoid Inhibitors of Monocarboxylate Transporter 6. Mol Pharm. 2017 Sep 5;14(9):2930-2936.
DMRV7H0	RU	http://www.ncbi.nlm.nih.gov/pubmed/28513167

DMRV7H0	DI	DMRV7H0
DMRV7H0	DN	Bumetanide
DMRV7H0	MI	DT0OC1Q
DMRV7H0	MN	Organic anion transporter 2 (SLC22A7)
DMRV7H0	MT	DTP
DMRV7H0	MA	Substrate
DMRV7H0	RN	Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8.
DMRV7H0	RU	http://www.ncbi.nlm.nih.gov/pubmed/15901346

DMRV7H0	DI	DMRV7H0
DMRV7H0	DN	Bumetanide
DMRV7H0	MI	DTVP67E
DMRV7H0	MN	Organic anion transporter 3 (SLC22A8)
DMRV7H0	MT	DTP
DMRV7H0	MA	Substrate
DMRV7H0	RN	Interactions of human organic anion transporters with diuretics. J Pharmacol Exp Ther. 2004 Mar;308(3):1021-9.
DMRV7H0	RU	http://www.ncbi.nlm.nih.gov/pubmed/14610216

DMRV7H0	DI	DMRV7H0
DMRV7H0	DN	Bumetanide
DMRV7H0	MI	DT06JWZ
DMRV7H0	MN	Organic anion transporter 4 (SLC22A11)
DMRV7H0	MT	DTP
DMRV7H0	MA	Substrate
DMRV7H0	RN	Interactions of human organic anion transporters with diuretics. J Pharmacol Exp Ther. 2004 Mar;308(3):1021-9.
DMRV7H0	RU	http://www.ncbi.nlm.nih.gov/pubmed/14610216

DMRV7H0	DI	DMRV7H0
DMRV7H0	DN	Bumetanide
DMRV7H0	MI	TTS087L
DMRV7H0	MN	Solute carrier family 12 member 1 (SLC12A1)
DMRV7H0	MT	DTT
DMRV7H0	MA	Blocker
DMRV7H0	RN	Nerve Terminal GABAA Receptors Activate Ca2+/Calmodulin-dependent Signaling to Inhibit Voltage-gated Ca2+ Influx and Glutamate Release. J Biol Chem. 2009 Mar 27;284(13):8726-37.
DMRV7H0	RU	https://pubmed.ncbi.nlm.nih.gov/19141616

DMRV7H0	DI	DMRV7H0
DMRV7H0	DN	Bumetanide
DMRV7H0	MI	DT6MDC9
DMRV7H0	MN	Thiazide-sensitive sodium-chloride cotransporter (SLC12A3)
DMRV7H0	MT	DTP
DMRV7H0	MA	Substrate
DMRV7H0	RN	Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. Clin Pharmacol Ther. 2007 Sep;82(3):300-9.
DMRV7H0	RU	http://www.ncbi.nlm.nih.gov/pubmed/17460608

DM4I8O7	DI	DM4I8O7
DM4I8O7	DN	Bunazosin
DM4I8O7	MI	TT34BHT
DM4I8O7	MN	Adrenergic receptor alpha-1D (ADRA1D)
DM4I8O7	MT	DTT
DM4I8O7	MA	Modulator
DM4I8O7	RN	Bunazosin, a selective alpha1-adrenoceptor antagonist, as an anti-glaucoma drug: effects on ocular circulation and retinal neuronal damage. Cardiovasc Drug Rev. 2005 Spring;23(1):43-56.
DM4I8O7	RU	https://pubmed.ncbi.nlm.nih.gov/15867947

DM4PRFC	DI	DM4PRFC
DM4PRFC	DN	Bupivacaine
DM4PRFC	MI	DECB0K3
DM4PRFC	MN	Cytochrome P450 2D6 (CYP2D6)
DM4PRFC	MT	DME
DM4PRFC	MA	Metabolism
DM4PRFC	RN	Oxidative metabolism of bupivacaine into pipecolylxylidine in humans is mainly catalyzed by CYP3A. Drug Metab Dispos. 2000 Apr;28(4):383-5.
DM4PRFC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10725304

DM4PRFC	DI	DM4PRFC
DM4PRFC	DN	Bupivacaine
DM4PRFC	MI	DE4LYSA
DM4PRFC	MN	Cytochrome P450 3A4 (CYP3A4)
DM4PRFC	MT	DME
DM4PRFC	MA	Metabolism
DM4PRFC	RN	Oxidative metabolism of bupivacaine into pipecolylxylidine in humans is mainly catalyzed by CYP3A. Drug Metab Dispos. 2000 Apr;28(4):383-5.
DM4PRFC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10725304

DM4PRFC	DI	DM4PRFC
DM4PRFC	DN	Bupivacaine
DM4PRFC	MI	DEGTFWK
DM4PRFC	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM4PRFC	MT	DME
DM4PRFC	MA	Metabolism
DM4PRFC	RN	Oxidative metabolism of bupivacaine into pipecolylxylidine in humans is mainly catalyzed by CYP3A. Drug Metab Dispos. 2000 Apr;28(4):383-5.
DM4PRFC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10725304

DM4PRFC	DI	DM4PRFC
DM4PRFC	DN	Bupivacaine
DM4PRFC	MI	TT90XZ8
DM4PRFC	MN	Voltage-gated sodium channel alpha Nav1.8 (SCN10A)
DM4PRFC	MT	DTT
DM4PRFC	MA	Modulator
DM4PRFC	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM4PRFC	RU	https://www.fda.gov/

DMPRI8G	DI	DMPRI8G
DMPRI8G	DN	Buprenorphine
DMPRI8G	MI	DEZMWRE
DMPRI8G	MN	Cytochrome P450 2C18 (CYP2C18)
DMPRI8G	MT	DME
DMPRI8G	MA	Metabolism
DMPRI8G	RN	In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab Dispos. 2005 May;33(5):689-95.
DMPRI8G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15743975

DMPRI8G	DI	DMPRI8G
DMPRI8G	DN	Buprenorphine
DMPRI8G	MI	DES5XRU
DMPRI8G	MN	Cytochrome P450 2C8 (CYP2C8)
DMPRI8G	MT	DME
DMPRI8G	MA	Metabolism
DMPRI8G	RN	Buprenorphine in cancer pain. Support Care Cancer. 2005 Nov;13(11):878-87.
DMPRI8G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16010532

DMPRI8G	DI	DMPRI8G
DMPRI8G	DN	Buprenorphine
DMPRI8G	MI	DE5IED8
DMPRI8G	MN	Cytochrome P450 2C9 (CYP2C9)
DMPRI8G	MT	DME
DMPRI8G	MA	Metabolism
DMPRI8G	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMPRI8G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMPRI8G	DI	DMPRI8G
DMPRI8G	DN	Buprenorphine
DMPRI8G	MI	DECB0K3
DMPRI8G	MN	Cytochrome P450 2D6 (CYP2D6)
DMPRI8G	MT	DME
DMPRI8G	MA	Metabolism
DMPRI8G	RN	Effect of nonspecific binding to microsomes and metabolic elimination of buprenorphine on the inhibition of cytochrome P4502D6. Biol Pharm Bull. 2005 Feb;28(2):212-6.
DMPRI8G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15684471

DMPRI8G	DI	DMPRI8G
DMPRI8G	DN	Buprenorphine
DMPRI8G	MI	DE4LYSA
DMPRI8G	MN	Cytochrome P450 3A4 (CYP3A4)
DMPRI8G	MT	DME
DMPRI8G	MA	Metabolism
DMPRI8G	RN	Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict. 2010 Jan-Feb;19(1):4-16.
DMPRI8G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20132117

DMPRI8G	DI	DMPRI8G
DMPRI8G	DN	Buprenorphine
DMPRI8G	MI	DEIBDNY
DMPRI8G	MN	Cytochrome P450 3A5 (CYP3A5)
DMPRI8G	MT	DME
DMPRI8G	MA	Metabolism
DMPRI8G	RN	Buprenorphine pharmacology review: update on transmucosal and long-acting formulations. J Addict Med. 2019 Mar/Apr;13(2):93-103.
DMPRI8G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30531584

DMPRI8G	DI	DMPRI8G
DMPRI8G	DN	Buprenorphine
DMPRI8G	MI	DERD86B
DMPRI8G	MN	Cytochrome P450 3A7 (CYP3A7)
DMPRI8G	MT	DME
DMPRI8G	MA	Metabolism
DMPRI8G	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMPRI8G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMPRI8G	DI	DMPRI8G
DMPRI8G	DN	Buprenorphine
DMPRI8G	MI	TTKWM86
DMPRI8G	MN	Opioid receptor mu (MOP)
DMPRI8G	MT	DTT
DMPRI8G	MA	Agonist
DMPRI8G	RN	Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization. J Neurosci. 2009 Jun 3;29(22):7341-8.
DMPRI8G	RU	https://pubmed.ncbi.nlm.nih.gov/19494155

DMPRI8G	DI	DMPRI8G
DMPRI8G	DN	Buprenorphine
DMPRI8G	MI	DEYGVN4
DMPRI8G	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMPRI8G	MT	DME
DMPRI8G	MA	Metabolism
DMPRI8G	RN	Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes. Drug Metab Dispos. 2010 Jan;38(1):40-5.
DMPRI8G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19841060

DMBQEGT	DI	DMBQEGT
DMBQEGT	DN	Buprenorphine + naloxone
DMBQEGT	MI	TTKWM86
DMBQEGT	MN	Opioid receptor mu (MOP)
DMBQEGT	MT	DTT
DMBQEGT	MA	Agonist
DMBQEGT	RN	Abstracts of Poster Presentations: CNS Summit 2013: November 14-17, 2013 Boca Raton, Florida. Innov Clin Neurosci. 2013 Nov-Dec; 10(11-12 Suppl B): 1-18.
DMBQEGT	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4051412/

DM5PCS7	DI	DM5PCS7
DM5PCS7	DN	Bupropion
DM5PCS7	MI	DTI7UX6
DM5PCS7	MN	Breast cancer resistance protein (ABCG2)
DM5PCS7	MT	DTP
DM5PCS7	MA	Substrate
DM5PCS7	RN	Role of transporter-mediated efflux in the placental biodisposition of bupropion and its metabolite, OH-bupropion. Biochem Pharmacol. 2010 Oct 1;80(7):1080-6.
DM5PCS7	RU	http://www.ncbi.nlm.nih.gov/pubmed/20599802

DM5PCS7	DI	DM5PCS7
DM5PCS7	DN	Bupropion
DM5PCS7	MI	DEPKLMQ
DM5PCS7	MN	Cytochrome P450 2B6 (CYP2B6)
DM5PCS7	MT	DME
DM5PCS7	MA	Metabolism
DM5PCS7	RN	Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. Basic Clin Pharmacol Toxicol. 2019 Aug;125(2):123-132.
DM5PCS7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30916845

DM5PCS7	DI	DM5PCS7
DM5PCS7	DN	Bupropion
DM5PCS7	MI	DE5IED8
DM5PCS7	MN	Cytochrome P450 2C9 (CYP2C9)
DM5PCS7	MT	DME
DM5PCS7	MA	Metabolism
DM5PCS7	RN	Product Monograph of Wellbutrin SR(Bupropion Hydrochloride).
DM5PCS7	RU	https://pdf.hres.ca/dpd_pm/00038603.PDF

DM5PCS7	DI	DM5PCS7
DM5PCS7	DN	Bupropion
DM5PCS7	MI	DECB0K3
DM5PCS7	MN	Cytochrome P450 2D6 (CYP2D6)
DM5PCS7	MT	DME
DM5PCS7	MA	Metabolism
DM5PCS7	RN	In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation. Biochem Pharmacol. 2017 Jan 1;123:85-96.
DM5PCS7	RU	https://www.ncbi.nlm.nih.gov/pubmed/27836670

DM5PCS7	DI	DM5PCS7
DM5PCS7	DN	Bupropion
DM5PCS7	MI	DEVDYN7
DM5PCS7	MN	Cytochrome P450 2E1 (CYP2E1)
DM5PCS7	MT	DME
DM5PCS7	MA	Metabolism
DM5PCS7	RN	Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos. 2000 Oct;28(10):1222-30.
DM5PCS7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10997944

DM5PCS7	DI	DM5PCS7
DM5PCS7	DN	Bupropion
DM5PCS7	MI	TTAWNKZ
DM5PCS7	MN	Norepinephrine transporter (NET)
DM5PCS7	MT	DTT
DM5PCS7	MA	Inhibitor
DM5PCS7	RN	Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
DM5PCS7	RU	https://pubmed.ncbi.nlm.nih.gov/19496045

DM5PCS7	DI	DM5PCS7
DM5PCS7	DN	Bupropion
DM5PCS7	MI	DTUGYRD
DM5PCS7	MN	P-glycoprotein 1 (ABCB1)
DM5PCS7	MT	DTP
DM5PCS7	MA	Substrate
DM5PCS7	RN	Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein. Biol Pharm Bull. 2008 Feb;31(2):231-4.
DM5PCS7	RU	https://doi.org/10.1248/bpb.31.231

DM5PCS7	DI	DM5PCS7
DM5PCS7	DN	Bupropion
DM5PCS7	MI	TT3ROYC
DM5PCS7	MN	Serotonin transporter (SERT)
DM5PCS7	MT	DTT
DM5PCS7	MA	Inhibitor
DM5PCS7	RN	Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
DM5PCS7	RU	https://pubmed.ncbi.nlm.nih.gov/19496045

DMKUOQV	DI	DMKUOQV
DMKUOQV	DN	Burosumab
DMKUOQV	MI	TT2IZ4K
DMKUOQV	MN	Fibroblast growth factor-23 (FGF23)
DMKUOQV	MT	DTT
DMKUOQV	MA	Modulator
DMKUOQV	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMKUOQV	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMBS632	DI	DMBS632
DMBS632	DN	Buspirone
DMBS632	MI	TTSQIFT
DMBS632	MN	5-HT 1A receptor (HTR1A)
DMBS632	MT	DTT
DMBS632	MA	Agonist
DMBS632	RN	Interactions between corticotropin-releasing hormone and serotonin: implications for the aetiology and treatment of anxiety disorders. Handb Exp Pharmacol. 2005;(169):181-204.
DMBS632	RU	https://pubmed.ncbi.nlm.nih.gov/16594259

DMBS632	DI	DMBS632
DMBS632	DN	Buspirone
DMBS632	MI	DE4OGUF
DMBS632	MN	Cytochrome P450 102A1 (cyp102)
DMBS632	MT	DME
DMBS632	MA	Metabolism
DMBS632	RN	The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities. Trends Biotechnol. 2007 Jul;25(7):289-98.
DMBS632	RU	https://pubmed.ncbi.nlm.nih.gov/17532492

DMBS632	DI	DMBS632
DMBS632	DN	Buspirone
DMBS632	MI	DECB0K3
DMBS632	MN	Cytochrome P450 2D6 (CYP2D6)
DMBS632	MT	DME
DMBS632	MA	Metabolism
DMBS632	RN	Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab Dispos. 2005 Apr;33(4):500-7.
DMBS632	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15640381

DMBS632	DI	DMBS632
DMBS632	DN	Buspirone
DMBS632	MI	DE4LYSA
DMBS632	MN	Cytochrome P450 3A4 (CYP3A4)
DMBS632	MT	DME
DMBS632	MA	Metabolism
DMBS632	RN	Effects of cytochrome P450 (CYP) 3A4 inhibitors on the anxiolytic action of tandospirone in rat contextual conditioned fear. Prog Neuropsychopharmacol Biol Psychiatry. 2007 May 9;31(4):926-31.
DMBS632	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17376576

DMBS632	DI	DMBS632
DMBS632	DN	Buspirone
DMBS632	MI	DEIBDNY
DMBS632	MN	Cytochrome P450 3A5 (CYP3A5)
DMBS632	MT	DME
DMBS632	MA	Metabolism
DMBS632	RN	Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab Dispos. 2005 Apr;33(4):500-7.
DMBS632	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15640381

DMBS632	DI	DMBS632
DMBS632	DN	Buspirone
DMBS632	MI	DERD86B
DMBS632	MN	Cytochrome P450 3A7 (CYP3A7)
DMBS632	MT	DME
DMBS632	MA	Metabolism
DMBS632	RN	Drug Interactions Flockhart Table
DMBS632	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMXYJ9C	DI	DMXYJ9C
DMXYJ9C	DN	Busulfan
DMXYJ9C	MI	DE4LYSA
DMXYJ9C	MN	Cytochrome P450 3A4 (CYP3A4)
DMXYJ9C	MT	DME
DMXYJ9C	MA	Metabolism
DMXYJ9C	RN	Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy. 1998 Jan-Feb;18(1):84-112.
DMXYJ9C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9469685

DMXYJ9C	DI	DMXYJ9C
DMXYJ9C	DN	Busulfan
DMXYJ9C	MI	DE4ZHS1
DMXYJ9C	MN	Glutathione S-transferase alpha-1 (GSTA1)
DMXYJ9C	MT	DME
DMXYJ9C	MA	Metabolism
DMXYJ9C	RN	Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood. 2004 Sep 1;104(5):1574-7.
DMXYJ9C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15142875

DMXYJ9C	DI	DMXYJ9C
DMXYJ9C	DN	Busulfan
DMXYJ9C	MI	DEH49YS
DMXYJ9C	MN	Glutathione S-transferase alpha-2 (GSTA2)
DMXYJ9C	MT	DME
DMXYJ9C	MA	Metabolism
DMXYJ9C	RN	Endothelial cells do not express GSTA1: potential relevance to busulfan-mediated endothelial damage during haematopoietic stem cell transplantation. Eur J Haematol. 2008 Apr;80(4):299-302.
DMXYJ9C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18194479

DMXYJ9C	DI	DMXYJ9C
DMXYJ9C	DN	Busulfan
DMXYJ9C	MI	DEYZEJA
DMXYJ9C	MN	Glutathione S-transferase mu-1 (GSTM1)
DMXYJ9C	MT	DME
DMXYJ9C	MA	Metabolism
DMXYJ9C	RN	Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. Drug Metab Dispos. 1996 Sep;24(9):1015-9.
DMXYJ9C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8886613

DMXYJ9C	DI	DMXYJ9C
DMXYJ9C	DN	Busulfan
DMXYJ9C	MI	DEK6079
DMXYJ9C	MN	Glutathione S-transferase pi (GSTP1)
DMXYJ9C	MT	DME
DMXYJ9C	MA	Metabolism
DMXYJ9C	RN	Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. Drug Metab Dispos. 1996 Sep;24(9):1015-9.
DMXYJ9C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8886613

DMXYJ9C	DI	DMXYJ9C
DMXYJ9C	DN	Busulfan
DMXYJ9C	MI	TTUTN1I
DMXYJ9C	MN	Human Deoxyribonucleic acid (hDNA)
DMXYJ9C	MT	DTT
DMXYJ9C	MA	Modulator
DMXYJ9C	RN	DNA intrastrand cross-link at the 5'-GA-3' sequence formed by busulfan and its role in the cytotoxic effect. Cancer Sci. 2004 May;95(5):454-8.
DMXYJ9C	RU	https://www.ncbi.nlm.nih.gov/pubmed/15132775

DMXYJ9C	DI	DMXYJ9C
DMXYJ9C	DN	Busulfan
DMXYJ9C	MI	DE31KMQ
DMXYJ9C	MN	Microsomal glutathione S-transferase 2 (MGST2)
DMXYJ9C	MT	DME
DMXYJ9C	MA	Metabolism
DMXYJ9C	RN	Overexpression of glutathione-S-transferase, MGSTII, confers resistance to busulfan and melphalan. Cancer Invest. 2005;23(1):19-25.
DMXYJ9C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15779864

DMC5AST	DI	DMC5AST
DMC5AST	DN	Butabarbital
DMC5AST	MI	TT1MPAY
DMC5AST	MN	GABA(A) receptor alpha-1 (GABRA1)
DMC5AST	MT	DTT
DMC5AST	MA	Antagonist
DMC5AST	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DMC5AST	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DM584TM	DI	DM584TM
DM584TM	DN	Butacaine
DM584TM	MI	TTRK8B9
DM584TM	MN	Sodium channel unspecific (NaC)
DM584TM	MT	DTT
DM584TM	MA	Modulator
DM584TM	RN	WO patent application no. 2008,0857,11, Synergy of sodium channel blockers and calcium channel blockers.
DM584TM	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20080717&CC=WO&NR=2008085711A1&KC=A1

DM9J04X	DI	DM9J04X
DM9J04X	DN	Butalbital
DM9J04X	MI	TT1MPAY
DM9J04X	MN	GABA(A) receptor alpha-1 (GABRA1)
DM9J04X	MT	DTT
DM9J04X	MA	Antagonist
DM9J04X	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DM9J04X	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DMOJ4ZI	DI	DMOJ4ZI
DMOJ4ZI	DN	Butenafine
DMOJ4ZI	MI	TTM9XSU
DMOJ4ZI	MN	Candida Squalene epoxidase (Candi ERG1)
DMOJ4ZI	MT	DTT
DMOJ4ZI	MA	Modulator
DMOJ4ZI	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMOJ4ZI	RU	https://www.fda.gov/

DM7JHX0	DI	DM7JHX0
DM7JHX0	DN	Butethal
DM7JHX0	MI	TT1MPAY
DM7JHX0	MN	GABA(A) receptor alpha-1 (GABRA1)
DM7JHX0	MT	DTT
DM7JHX0	MA	Antagonist
DM7JHX0	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DM7JHX0	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DM8SY60	DI	DM8SY60
DM8SY60	DN	Butoconazole
DM8SY60	MI	TTTSOUD
DM8SY60	MN	Candida Cytochrome P450 51 (Candi ERG11)
DM8SY60	MT	DTT
DM8SY60	MA	Inhibitor
DM8SY60	RN	Effects of terconazole and other azole antifungal agents on the sterol and carbohydrate composition of Candida albicans. Diagn Microbiol Infect Dis. 1990 Jan-Feb;13(1):31-5.
DM8SY60	RU	https://pubmed.ncbi.nlm.nih.gov/2184984

DM5KYPJ	DI	DM5KYPJ
DM5KYPJ	DN	Butorphanol
DM5KYPJ	MI	TT27RFC
DM5KYPJ	MN	Opioid receptor delta (OPRD1)
DM5KYPJ	MT	DTT
DM5KYPJ	MA	Agonist
DM5KYPJ	RN	Butorphanol: effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors. J Pharmacol Sci. 2005 Jun;98(2):109-16.
DM5KYPJ	RU	https://pubmed.ncbi.nlm.nih.gov/15942128

DMZKXB7	DI	DMZKXB7
DMZKXB7	DN	Butylscopolamine
DMZKXB7	MI	TTH18TF
DMZKXB7	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMZKXB7	MT	DTT
DMZKXB7	MA	Modulator
DMZKXB7	RN	Comparison of pharmacological effects of L- and DL-n-butyl-scopolamine in rat uterus. Yao Xue Xue Bao. 1994;29(1):24-7.
DMZKXB7	RU	https://pubmed.ncbi.nlm.nih.gov/8036897

DMPAZHC	DI	DMPAZHC
DMPAZHC	DN	Cabazitaxel
DMPAZHC	MI	DES5XRU
DMPAZHC	MN	Cytochrome P450 2C8 (CYP2C8)
DMPAZHC	MT	DME
DMPAZHC	MA	Metabolism
DMPAZHC	RN	DAILYMED.nlm.nih.gov: JEVTANA- cabazitaxel kit.
DMPAZHC	RU	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa

DMPAZHC	DI	DMPAZHC
DMPAZHC	DN	Cabazitaxel
DMPAZHC	MI	DE4LYSA
DMPAZHC	MN	Cytochrome P450 3A4 (CYP3A4)
DMPAZHC	MT	DME
DMPAZHC	MA	Metabolism
DMPAZHC	RN	DAILYMED.nlm.nih.gov: JEVTANA- cabazitaxel kit.
DMPAZHC	RU	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa

DMPAZHC	DI	DMPAZHC
DMPAZHC	DN	Cabazitaxel
DMPAZHC	MI	DEIBDNY
DMPAZHC	MN	Cytochrome P450 3A5 (CYP3A5)
DMPAZHC	MT	DME
DMPAZHC	MA	Metabolism
DMPAZHC	RN	DAILYMED.nlm.nih.gov: JEVTANA- cabazitaxel kit.
DMPAZHC	RU	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa

DMPAZHC	DI	DMPAZHC
DMPAZHC	DN	Cabazitaxel
DMPAZHC	MI	TTML2WA
DMPAZHC	MN	Tubulin (TUB)
DMPAZHC	MT	DTT
DMPAZHC	MA	Inhibitor
DMPAZHC	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DMPAZHC	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DMQ4HIN	DI	DMQ4HIN
DMQ4HIN	DN	Cabergoline
DMQ4HIN	MI	DE4LYSA
DMQ4HIN	MN	Cytochrome P450 3A4 (CYP3A4)
DMQ4HIN	MT	DME
DMQ4HIN	MA	Metabolism
DMQ4HIN	RN	Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67.
DMQ4HIN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18691132

DMQ4HIN	DI	DMQ4HIN
DMQ4HIN	DN	Cabergoline
DMQ4HIN	MI	TTEX248
DMQ4HIN	MN	Dopamine D2 receptor (D2R)
DMQ4HIN	MT	DTT
DMQ4HIN	MA	Agonist
DMQ4HIN	RN	Role of D1 and D2 receptors in the regulation of voluntary movements. Bull Exp Biol Med. 2008 Jul;146(1):14-7.
DMQ4HIN	RU	https://pubmed.ncbi.nlm.nih.gov/19145338

DMQ4HIN	DI	DMQ4HIN
DMQ4HIN	DN	Cabergoline
DMQ4HIN	MI	DTUGYRD
DMQ4HIN	MN	P-glycoprotein 1 (ABCB1)
DMQ4HIN	MT	DTP
DMQ4HIN	MA	Substrate
DMQ4HIN	RN	Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomas. Eur J Endocrinol. 2012 Sep;167(3):327-35.
DMQ4HIN	RU	http://www.ncbi.nlm.nih.gov/pubmed/22672924

DMIYDT4	DI	DMIYDT4
DMIYDT4	DN	Cabozantinib
DMIYDT4	MI	DE5IED8
DMIYDT4	MN	Cytochrome P450 2C9 (CYP2C9)
DMIYDT4	MT	DME
DMIYDT4	MA	Metabolism
DMIYDT4	RN	FDA Label of Cabozantinib. The 2020 official website of the U.S. Food and Drug Administration.
DMIYDT4	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208692s003lbl.pdf

DMIYDT4	DI	DMIYDT4
DMIYDT4	DN	Cabozantinib
DMIYDT4	MI	DE4LYSA
DMIYDT4	MN	Cytochrome P450 3A4 (CYP3A4)
DMIYDT4	MT	DME
DMIYDT4	MA	Metabolism
DMIYDT4	RN	Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma. Onco Targets Ther. 2017 Oct 19;10:5053-5064.
DMIYDT4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29089775

DMIYDT4	DI	DMIYDT4
DMIYDT4	DN	Cabozantinib
DMIYDT4	MI	TTNDSF4
DMIYDT4	MN	Proto-oncogene c-Met (MET)
DMIYDT4	MT	DTT
DMIYDT4	MA	Inhibitor
DMIYDT4	RN	Clinical pipeline report, company report or official report of Exelixis (2011).
DMIYDT4	RU	http://www.exelixis.com/pipeline

DMIYDT4	DI	DMIYDT4
DMIYDT4	DN	Cabozantinib
DMIYDT4	MI	TTUTJGQ
DMIYDT4	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMIYDT4	MT	DTT
DMIYDT4	MA	Inhibitor
DMIYDT4	RN	Clinical pipeline report, company report or official report of Exelixis (2011).
DMIYDT4	RU	http://www.exelixis.com/pipeline

DMKBJWP	DI	DMKBJWP
DMKBJWP	DN	Caffeine
DMKBJWP	MI	TTK25J1
DMKBJWP	MN	Adenosine A1 receptor (ADORA1)
DMKBJWP	MT	DTT
DMKBJWP	MA	Antagonist
DMKBJWP	RN	Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci. 2004 Apr;61(7-8):857-72.
DMKBJWP	RU	https://pubmed.ncbi.nlm.nih.gov/15095008

DMKBJWP	DI	DMKBJWP
DMKBJWP	DN	Caffeine
DMKBJWP	MI	TTM2AOE
DMKBJWP	MN	Adenosine A2a receptor (ADORA2A)
DMKBJWP	MT	DTT
DMKBJWP	MA	Antagonist
DMKBJWP	RN	Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci. 2004 Apr;61(7-8):857-72.
DMKBJWP	RU	https://pubmed.ncbi.nlm.nih.gov/15095008

DMKBJWP	DI	DMKBJWP
DMKBJWP	DN	Caffeine
DMKBJWP	MI	DEJGDUW
DMKBJWP	MN	Cytochrome P450 1A2 (CYP1A2)
DMKBJWP	MT	DME
DMKBJWP	MA	Metabolism
DMKBJWP	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMKBJWP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMKBJWP	DI	DMKBJWP
DMKBJWP	DN	Caffeine
DMKBJWP	MI	DE9QHP6
DMKBJWP	MN	Cytochrome P450 1B1 (CYP1B1)
DMKBJWP	MT	DME
DMKBJWP	MA	Metabolism
DMKBJWP	RN	Oxidation of xenobiotics by recombinant human cytochrome P450 1B1. Drug Metab Dispos. 1997 May;25(5):617-22.
DMKBJWP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9152602

DMKBJWP	DI	DMKBJWP
DMKBJWP	DN	Caffeine
DMKBJWP	MI	DES5XRU
DMKBJWP	MN	Cytochrome P450 2C8 (CYP2C8)
DMKBJWP	MT	DME
DMKBJWP	MA	Metabolism
DMKBJWP	RN	PharmGKB summary: caffeine pathway. Pharmacogenet Genomics. 2012 May;22(5):389-95.
DMKBJWP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22293536

DMKBJWP	DI	DMKBJWP
DMKBJWP	DN	Caffeine
DMKBJWP	MI	DE5IED8
DMKBJWP	MN	Cytochrome P450 2C9 (CYP2C9)
DMKBJWP	MT	DME
DMKBJWP	MA	Metabolism
DMKBJWP	RN	Monkey liver cytochrome P450 2C9 is involved in caffeine 7-N-demethylation to form theophylline. Xenobiotica. 2013 Dec;43(12):1037-42.
DMKBJWP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23679834

DMKBJWP	DI	DMKBJWP
DMKBJWP	DN	Caffeine
DMKBJWP	MI	DECB0K3
DMKBJWP	MN	Cytochrome P450 2D6 (CYP2D6)
DMKBJWP	MT	DME
DMKBJWP	MA	Metabolism
DMKBJWP	RN	Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo. J Clin Psychopharmacol. 1998 Jun;18(3):198-207.
DMKBJWP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9617978

DMKBJWP	DI	DMKBJWP
DMKBJWP	DN	Caffeine
DMKBJWP	MI	DEVDYN7
DMKBJWP	MN	Cytochrome P450 2E1 (CYP2E1)
DMKBJWP	MT	DME
DMKBJWP	MA	Metabolism
DMKBJWP	RN	CYP2E1 active site residues in substrate recognition sequence 5 identified by photoaffinity labeling and homology modeling. Arch Biochem Biophys. 2007 Mar 1;459(1):59-69.
DMKBJWP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17222385

DMKBJWP	DI	DMKBJWP
DMKBJWP	DN	Caffeine
DMKBJWP	MI	DE4LYSA
DMKBJWP	MN	Cytochrome P450 3A4 (CYP3A4)
DMKBJWP	MT	DME
DMKBJWP	MA	Metabolism
DMKBJWP	RN	Effect of cytochrome P450 (CYP) inducers on caffeine metabolism in the rat. Pharmacol Rep. 2007 May-Jun;59(3):296-305.
DMKBJWP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17652830

DMKBJWP	DI	DMKBJWP
DMKBJWP	DN	Caffeine
DMKBJWP	MI	DEZV4AP
DMKBJWP	MN	RNA cytidine acetyltransferase (hALP)
DMKBJWP	MT	DME
DMKBJWP	MA	Metabolism
DMKBJWP	RN	A population and family study of N-acetyltransferase using caffeine urinary metabolites. Clin Pharmacol Ther. 1993 Aug;54(2):134-41.
DMKBJWP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8354022

DMQZBXI	DI	DMQZBXI
DMQZBXI	DN	Calaspargase pegol
DMQZBXI	MI	TT4WT91
DMQZBXI	MN	Asparaginase (ASRGL1)
DMQZBXI	MT	DTT
DMQZBXI	MA	Inhibitor
DMQZBXI	RN	Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4. J Clin Oncol. 2014 Dec 1;32(34):3874-82.
DMQZBXI	RU	https://pubmed.ncbi.nlm.nih.gov/25348002

DMN4CV5	DI	DMN4CV5
DMN4CV5	DN	Calcidiol
DMN4CV5	MI	DE3FYEM
DMN4CV5	MN	Calcidiol 1-monooxygenase (CYP27B1)
DMN4CV5	MT	DME
DMN4CV5	MA	Metabolism
DMN4CV5	RN	Cytochromes P450 are essential players in the vitamin D signaling system. Biochim Biophys Acta. 2011 Jan;1814(1):186-99.
DMN4CV5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20619365

DMN4CV5	DI	DMN4CV5
DMN4CV5	DN	Calcidiol
DMN4CV5	MI	DEFI12S
DMN4CV5	MN	Vitamin D(3) 24-hydroxylase (CYP24A1)
DMN4CV5	MT	DME
DMN4CV5	MA	Metabolism
DMN4CV5	RN	Asthma families show transmission disequilibrium of gene variants in the vitamin D metabolism and signalling pathway. Respir Res. 2006 Apr 6;7:60.
DMN4CV5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16600026

DMN4CV5	DI	DMN4CV5
DMN4CV5	DN	Calcidiol
DMN4CV5	MI	TTK59TV
DMN4CV5	MN	Vitamin D3 receptor (VDR)
DMN4CV5	MT	DTT
DMN4CV5	MA	Antagonist
DMN4CV5	RN	Vitamin D in health and disease. Clin J Am Soc Nephrol. 2008 Sep;3(5):1535-41.
DMN4CV5	RU	https://pubmed.ncbi.nlm.nih.gov/18525006

DM03CP7	DI	DM03CP7
DM03CP7	DN	Calcipotriol
DM03CP7	MI	TTK59TV
DM03CP7	MN	Vitamin D3 receptor (VDR)
DM03CP7	MT	DTT
DM03CP7	MA	Antagonist
DM03CP7	RN	Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation. Curr Drug Targets. 2008 Apr;9(4):345-59.
DM03CP7	RU	https://pubmed.ncbi.nlm.nih.gov/18393827

DM0N9WA	DI	DM0N9WA
DM0N9WA	DN	Calcitonin Human
DM0N9WA	MI	TTLWS2O
DM0N9WA	MN	Calcitonin receptor (CALCR)
DM0N9WA	MT	DTT
DM0N9WA	MA	Modulator
DM0N9WA	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM0N9WA	RU	https://www.fda.gov/

DM8ZVJ7	DI	DM8ZVJ7
DM8ZVJ7	DN	Calcitriol
DM8ZVJ7	MI	DE4LYSA
DM8ZVJ7	MN	Cytochrome P450 3A4 (CYP3A4)
DM8ZVJ7	MT	DME
DM8ZVJ7	MA	Metabolism
DM8ZVJ7	RN	Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia. Mol Pharmacol. 2006 Jan;69(1):56-65.
DM8ZVJ7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16207822

DM8ZVJ7	DI	DM8ZVJ7
DM8ZVJ7	DN	Calcitriol
DM8ZVJ7	MI	DELOY3P
DM8ZVJ7	MN	UDP-glucuronosyltransferase 1A4 (UGT1A4)
DM8ZVJ7	MT	DME
DM8ZVJ7	MA	Metabolism
DM8ZVJ7	RN	Identification of human UDP-glucuronosyltransferases catalyzing hepatic 1alpha,25-dihydroxyvitamin D3 conjugation. Biochem Pharmacol. 2008 Mar 1;75(5):1240-50.
DM8ZVJ7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18177842

DM8ZVJ7	DI	DM8ZVJ7
DM8ZVJ7	DN	Calcitriol
DM8ZVJ7	MI	DEFI12S
DM8ZVJ7	MN	Vitamin D(3) 24-hydroxylase (CYP24A1)
DM8ZVJ7	MT	DME
DM8ZVJ7	MA	Metabolism
DM8ZVJ7	RN	The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer. 2014 May;14(5):342-57.
DM8ZVJ7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24705652

DM8ZVJ7	DI	DM8ZVJ7
DM8ZVJ7	DN	Calcitriol
DM8ZVJ7	MI	TTK59TV
DM8ZVJ7	MN	Vitamin D3 receptor (VDR)
DM8ZVJ7	MT	DTT
DM8ZVJ7	MA	Agonist
DM8ZVJ7	RN	Kaposi sarcoma is a therapeutic target for vitamin D(3) receptor agonist. Blood. 2000 Nov 1;96(9):3188-94.
DM8ZVJ7	RU	https://pubmed.ncbi.nlm.nih.gov/11050002

DM3W15N	DI	DM3W15N
DM3W15N	DN	Calcium carbimide
DM3W15N	MI	TTCTAOJ
DM3W15N	MN	Acetaldehyde dehydrogenase (ALDH)
DM3W15N	MT	DTT
DM3W15N	MA	Inhibitor
DM3W15N	RN	Disulfiram and calcium carbimide. Mode of action, adverse effects and clinical use. Tidsskr Nor Laegeforen. 1990 Apr 10;110(10):1224-8.
DM3W15N	RU	https://pubmed.ncbi.nlm.nih.gov/2185581

DM3W15N	DI	DM3W15N
DM3W15N	DN	Calcium carbimide
DM3W15N	MI	DE1XPGH
DM3W15N	MN	Catalase (CAT)
DM3W15N	MT	DME
DM3W15N	MA	Metabolism
DM3W15N	RN	Vasiliou V. and Petersen D. (2010). Comprehensive toxicology (2nd ed.). Elsevier.
DM3W15N	RU	https://www.elsevier.com/books/comprehensive-toxicology/mcqueen/978-0-08-100601-6

DMJ3CFY	DI	DMJ3CFY
DMJ3CFY	DN	Calcium phosphate dihydrate
DMJ3CFY	MI	DTKS517
DMJ3CFY	MN	Sodium-dependent phosphate transport protein 2C (SLC34A3)
DMJ3CFY	MT	DTP
DMJ3CFY	MA	Substrate
DMJ3CFY	RN	Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50.
DMJ3CFY	RU	http://www.ncbi.nlm.nih.gov/pubmed/23398154

DMWIO46	DI	DMWIO46
DMWIO46	DN	Camphor
DMWIO46	MI	DE9JBQK
DMWIO46	MN	Cytochrome P450 101D1 (cyp101)
DMWIO46	MT	DME
DMWIO46	MA	Metabolism
DMWIO46	RN	Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology. 2003 Nov;38(5):1250-7.
DMWIO46	RU	https://pubmed.ncbi.nlm.nih.gov/14578864

DMWIO46	DI	DMWIO46
DMWIO46	DN	Camphor
DMWIO46	MI	DE7HL3C
DMWIO46	MN	Cytochrome P450 101D2 (cyp101)
DMWIO46	MT	DME
DMWIO46	MA	Metabolism
DMWIO46	RN	Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology. 2003 Nov;38(5):1250-7.
DMWIO46	RU	https://pubmed.ncbi.nlm.nih.gov/14578864

DMWIO46	DI	DMWIO46
DMWIO46	DN	Camphor
DMWIO46	MI	DEJVYAZ
DMWIO46	MN	Cytochrome P450 2A6 (CYP2A6)
DMWIO46	MT	DME
DMWIO46	MA	Metabolism
DMWIO46	RN	In vitro metabolism of (-)-camphor using human liver microsomes and CYP2A6. Biol Pharm Bull. 2007 Feb;30(2):230-3.
DMWIO46	RU	https://pubmed.ncbi.nlm.nih.gov/17268056

DMFRM1I	DI	DMFRM1I
DMFRM1I	DN	Canagliflozin
DMFRM1I	MI	DTI7UX6
DMFRM1I	MN	Breast cancer resistance protein (ABCG2)
DMFRM1I	MT	DTP
DMFRM1I	MA	Substrate
DMFRM1I	RN	In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. Br J Clin Pharmacol. 2017 May;83(5):1082-1096.
DMFRM1I	RU	http://www.ncbi.nlm.nih.gov/pubmed/27862160

DMFRM1I	DI	DMFRM1I
DMFRM1I	DN	Canagliflozin
DMFRM1I	MI	DE4LYSA
DMFRM1I	MN	Cytochrome P450 3A4 (CYP3A4)
DMFRM1I	MT	DME
DMFRM1I	MA	Metabolism
DMFRM1I	RN	Sodium-glucose linked transporter 2 (SGLT2) inhibitors in the management of type-2 diabetes: a drug class overview. P T. 2015 Jul;40(7):451-62.
DMFRM1I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26185406

DMFRM1I	DI	DMFRM1I
DMFRM1I	DN	Canagliflozin
DMFRM1I	MI	DTUGYRD
DMFRM1I	MN	P-glycoprotein 1 (ABCB1)
DMFRM1I	MT	DTP
DMFRM1I	MA	Substrate
DMFRM1I	RN	In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. Br J Clin Pharmacol. 2017 May;83(5):1082-1096.
DMFRM1I	RU	http://www.ncbi.nlm.nih.gov/pubmed/27862160

DMFRM1I	DI	DMFRM1I
DMFRM1I	DN	Canagliflozin
DMFRM1I	MI	TTLWPVF
DMFRM1I	MN	Sodium/glucose cotransporter 2 (SGLT2)
DMFRM1I	MT	DTT
DMFRM1I	MA	Modulator
DMFRM1I	RN	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
DMFRM1I	RU	https://pubmed.ncbi.nlm.nih.gov/28919714

DMFRM1I	DI	DMFRM1I
DMFRM1I	DN	Canagliflozin
DMFRM1I	MI	DE85D2P
DMFRM1I	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMFRM1I	MT	DME
DMFRM1I	MA	Metabolism
DMFRM1I	RN	Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. Int J Clin Pharmacol Ther. 2015 Feb;53(2):115-28.
DMFRM1I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25407255

DMFRM1I	DI	DMFRM1I
DMFRM1I	DN	Canagliflozin
DMFRM1I	MI	DENUPDX
DMFRM1I	MN	UDP-glucuronosyltransferase 2B4 (UGT2B4)
DMFRM1I	MT	DME
DMFRM1I	MA	Metabolism
DMFRM1I	RN	Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. Int J Clin Pharmacol Ther. 2015 Feb;53(2):115-28.
DMFRM1I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25407255

DM8HLO5	DI	DM8HLO5
DM8HLO5	DN	Canakinumab
DM8HLO5	MI	TTRYK0X
DM8HLO5	MN	Interleukin-1 beta (IL1B)
DM8HLO5	MT	DTT
DM8HLO5	RN	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
DM8HLO5	RU	https://pubmed.ncbi.nlm.nih.gov/20118952

DMRK8OT	DI	DMRK8OT
DMRK8OT	DN	Candesartan
DMRK8OT	MI	TT8DBY3
DMRK8OT	MN	Angiotensin II receptor type-1 (AGTR1)
DMRK8OT	MT	DTT
DMRK8OT	MA	Antagonist
DMRK8OT	RN	Candesartan: widening indications for this angiotensin II receptor blocker Expert Opin Pharmacother. 2009 Aug;10(12):1995-2007.
DMRK8OT	RU	https://pubmed.ncbi.nlm.nih.gov/19563275

DMRK8OT	DI	DMRK8OT
DMRK8OT	DN	Candesartan
DMRK8OT	MI	DEB30C5
DMRK8OT	MN	Carboxylesterase 1 (CES1)
DMRK8OT	MT	DME
DMRK8OT	MA	Metabolism
DMRK8OT	RN	Different hydrolases involved in bioactivation of prodrug-type angiotensin receptor blockers: carboxymethylenebutenolidase and carboxylesterase 1. Drug Metab Dispos. 2013 Nov;41(11):1888-95.
DMRK8OT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23946449

DMRK8OT	DI	DMRK8OT
DMRK8OT	DN	Candesartan
DMRK8OT	MI	DE5IED8
DMRK8OT	MN	Cytochrome P450 2C9 (CYP2C9)
DMRK8OT	MT	DME
DMRK8OT	MA	Metabolism
DMRK8OT	RN	Product Monograph of Atacand.
DMRK8OT	RU	https://www.astrazeneca.ca/content/dam/az-ca/downloads/productinformation/ATACAND%20-%20Product-Monograph_001.pdf

DMRK8OT	DI	DMRK8OT
DMRK8OT	DN	Candesartan
DMRK8OT	MI	DE073H6
DMRK8OT	MN	Prostaglandin G/H synthase 1 (COX-1)
DMRK8OT	MT	DME
DMRK8OT	MA	Metabolism
DMRK8OT	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMRK8OT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMRK8OT	DI	DMRK8OT
DMRK8OT	DN	Candesartan
DMRK8OT	MI	DEYGVN4
DMRK8OT	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMRK8OT	MT	DME
DMRK8OT	MA	Metabolism
DMRK8OT	RN	The human UDP-glucuronosyltransferase UGT1A3 is highly selective towards N2 in the tetrazole ring of losartan, candesartan, and zolarsartan. Biochem Pharmacol. 2008 Sep 15;76(6):763-72.
DMRK8OT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18674515

DMRK8OT	DI	DMRK8OT
DMRK8OT	DN	Candesartan
DMRK8OT	MI	DEF2WXN
DMRK8OT	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMRK8OT	MT	DME
DMRK8OT	MA	Metabolism
DMRK8OT	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMRK8OT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMNZSC1	DI	DMNZSC1
DMNZSC1	DN	Candicidin
DMNZSC1	MI	TTQKWA4
DMNZSC1	MN	Fungal Cell membrane ergosterol (Fung CME)
DMNZSC1	MT	DTT
DMNZSC1	MA	Modulator
DMNZSC1	RN	Mode of Action of the Polyene Antibiotic Candicidin: Binding Factors in the Wall of Candida albicans
DMNZSC1	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC429577

DM8JRH0	DI	DM8JRH0
DM8JRH0	DN	Cangrelor
DM8JRH0	MI	TTZ1DT0
DM8JRH0	MN	P2Y purinoceptor 12 (P2RY12)
DM8JRH0	MT	DTT
DM8JRH0	MA	Antagonist
DM8JRH0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 328).
DM8JRH0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=328

DM0659E	DI	DM0659E
DM0659E	DN	Cannabidiol
DM0659E	MI	TT94IAG
DM0659E	MN	Cannabinoid receptor (CB)
DM0659E	MT	DTT
DM0659E	MA	Binder
DM0659E	RN	(-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. Eur J Pharmacol. 2002 Dec 5;456(1-3):99-106.
DM0659E	RU	https://pubmed.ncbi.nlm.nih.gov/12450575

DM0659E	DI	DM0659E
DM0659E	DN	Cannabidiol
DM0659E	MI	DE5IED8
DM0659E	MN	Cytochrome P450 2C9 (CYP2C9)
DM0659E	MT	DME
DM0659E	MA	Metabolism
DM0659E	RN	Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015 Oct;12(4):699-730.
DM0659E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26264914

DM0659E	DI	DM0659E
DM0659E	DN	Cannabidiol
DM0659E	MI	DECB0K3
DM0659E	MN	Cytochrome P450 2D6 (CYP2D6)
DM0659E	MT	DME
DM0659E	MA	Metabolism
DM0659E	RN	Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014 Feb;46(1):86-95.
DM0659E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24160757

DM0659E	DI	DM0659E
DM0659E	DN	Cannabidiol
DM0659E	MI	DE4LYSA
DM0659E	MN	Cytochrome P450 3A4 (CYP3A4)
DM0659E	MT	DME
DM0659E	MA	Metabolism
DM0659E	RN	Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015 Oct;12(4):699-730.
DM0659E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26264914

DM0659E	DI	DM0659E
DM0659E	DN	Cannabidiol
DM0659E	MI	DEIBDNY
DM0659E	MN	Cytochrome P450 3A5 (CYP3A5)
DM0659E	MT	DME
DM0659E	MA	Metabolism
DM0659E	RN	Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014 Feb;46(1):86-95.
DM0659E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24160757

DM0659E	DI	DM0659E
DM0659E	DN	Cannabidiol
DM0659E	MI	DEGTFWK
DM0659E	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM0659E	MT	DME
DM0659E	MA	Metabolism
DM0659E	RN	Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015 Oct;12(4):699-730.
DM0659E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26264914

DM0659E	DI	DM0659E
DM0659E	DN	Cannabidiol
DM0659E	MI	DTUGYRD
DM0659E	MN	P-glycoprotein 1 (ABCB1)
DM0659E	MT	DTP
DM0659E	MA	Substrate
DM0659E	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
DM0659E	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01665

DMBP5N3	DI	DMBP5N3
DMBP5N3	DN	Cantharidin
DMBP5N3	MI	TTFLH0E
DMBP5N3	MN	Serine/threonine PP1-alpha (PPP1CA)
DMBP5N3	MT	DTT
DMBP5N3	MA	Inhibitor
DMBP5N3	RN	Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies. J Med Chem. 2002 Mar 14;45(6):1151-75.
DMBP5N3	RU	https://pubmed.ncbi.nlm.nih.gov/11881984

DMTS85L	DI	DMTS85L
DMTS85L	DN	Capecitabine
DMTS85L	MI	TTU6BFZ
DMTS85L	MN	Candida Thymidylate synthase (Candi TMP1)
DMTS85L	MT	DTT
DMTS85L	MA	Inhibitor
DMTS85L	RN	UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res. 2005 Feb 1;11(3):1226-36.
DMTS85L	RU	https://pubmed.ncbi.nlm.nih.gov/15709193

DMTS85L	DI	DMTS85L
DMTS85L	DN	Capecitabine
DMTS85L	MI	DEKEDRC
DMTS85L	MN	Cytidine aminohydrolase (CDA)
DMTS85L	MT	DME
DMTS85L	MA	Metabolism
DMTS85L	RN	Augmentation of the antitumor activity of capecitabine by a tumor selective dihydropyrimidine dehydrogenase inhibitor, RO0094889. Int J Cancer. 2003 Sep 20;106(5):799-805.
DMTS85L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12866042

DMTS85L	DI	DMTS85L
DMTS85L	DN	Capecitabine
DMTS85L	MI	DE4HCYL
DMTS85L	MN	Thymidine phosphorylase (TYMP)
DMTS85L	MT	DME
DMTS85L	MA	Metabolism
DMTS85L	RN	Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation. Mol Cancer Ther. 2002 Oct;1(12):1139-45.
DMTS85L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12481438

DMPUKA7	DI	DMPUKA7
DMPUKA7	DN	Caplacizumab
DMPUKA7	MI	TT3SZBT
DMPUKA7	MN	von Willebrand factor (VWF)
DMPUKA7	MT	DTT
DMPUKA7	MA	Inhibitor
DMPUKA7	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMPUKA7	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761112s000lbl.pdf

DMYCXKL	DI	DMYCXKL
DMYCXKL	DN	Capmatinib
DMYCXKL	MI	TTNDSF4
DMYCXKL	MN	Proto-oncogene c-Met (MET)
DMYCXKL	MT	DTT
DMYCXKL	MA	Modulator
DMYCXKL	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMYCXKL	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf

DMNZBRY	DI	DMNZBRY
DMNZBRY	DN	Capreomycin
DMNZBRY	MI	TTIA0J5
DMNZBRY	MN	Bacterial 70S ribosomal RNA (Bact 70S rRNA)
DMNZBRY	MT	DTT
DMNZBRY	MA	Binder
DMNZBRY	RN	Interaction between the ribosomal subunits: 16S rRNA suppressors of the lethal DeltaA1916 mutation in the 23S rRNA of Escherichia coli. Mol Genet Genomics. 2007 Sep;278(3):307-15.
DMNZBRY	RU	https://pubmed.ncbi.nlm.nih.gov/17564727

DM346QI	DI	DM346QI
DM346QI	DN	Capreomycin Sulfate
DM346QI	MI	TTIA0J5
DM346QI	MN	Bacterial 70S ribosomal RNA (Bact 70S rRNA)
DM346QI	MT	DTT
DM346QI	MA	Modulator
DM346QI	RN	The structures of the anti-tuberculosis antibiotics viomycin and capreomycin bound to the 70S ribosome.Nat Struct Mol Biol.2010 Mar;17(3):289-93.
DM346QI	RU	https://www.ncbi.nlm.nih.gov/pubmed/20154709

DMHERIJ	DI	DMHERIJ
DMHERIJ	DN	Capromab
DMHERIJ	MI	TT9G4N0
DMHERIJ	MN	Glutamate carboxypeptidase II (GCPII)
DMHERIJ	MT	DTT
DMHERIJ	RN	Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. Semin Nucl Med. 2007 Jan;37(1):17-28.
DMHERIJ	RU	https://pubmed.ncbi.nlm.nih.gov/17161036

DMGMF6V	DI	DMGMF6V
DMGMF6V	DN	Capsaicin
DMGMF6V	MI	DE6OQ3W
DMGMF6V	MN	Cytochrome P450 1A1 (CYP1A1)
DMGMF6V	MT	DME
DMGMF6V	MA	Metabolism
DMGMF6V	RN	Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49.
DMGMF6V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12641434

DMGMF6V	DI	DMGMF6V
DMGMF6V	DN	Capsaicin
DMGMF6V	MI	DEJGDUW
DMGMF6V	MN	Cytochrome P450 1A2 (CYP1A2)
DMGMF6V	MT	DME
DMGMF6V	MA	Metabolism
DMGMF6V	RN	Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49.
DMGMF6V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12641434

DMGMF6V	DI	DMGMF6V
DMGMF6V	DN	Capsaicin
DMGMF6V	MI	DEPKLMQ
DMGMF6V	MN	Cytochrome P450 2B6 (CYP2B6)
DMGMF6V	MT	DME
DMGMF6V	MA	Metabolism
DMGMF6V	RN	Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49.
DMGMF6V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12641434

DMGMF6V	DI	DMGMF6V
DMGMF6V	DN	Capsaicin
DMGMF6V	MI	DES5XRU
DMGMF6V	MN	Cytochrome P450 2C8 (CYP2C8)
DMGMF6V	MT	DME
DMGMF6V	MA	Metabolism
DMGMF6V	RN	Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49.
DMGMF6V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12641434

DMGMF6V	DI	DMGMF6V
DMGMF6V	DN	Capsaicin
DMGMF6V	MI	DE5IED8
DMGMF6V	MN	Cytochrome P450 2C9 (CYP2C9)
DMGMF6V	MT	DME
DMGMF6V	MA	Metabolism
DMGMF6V	RN	Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49.
DMGMF6V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12641434

DMGMF6V	DI	DMGMF6V
DMGMF6V	DN	Capsaicin
DMGMF6V	MI	DECB0K3
DMGMF6V	MN	Cytochrome P450 2D6 (CYP2D6)
DMGMF6V	MT	DME
DMGMF6V	MA	Metabolism
DMGMF6V	RN	Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49.
DMGMF6V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12641434

DMGMF6V	DI	DMGMF6V
DMGMF6V	DN	Capsaicin
DMGMF6V	MI	DEVDYN7
DMGMF6V	MN	Cytochrome P450 2E1 (CYP2E1)
DMGMF6V	MT	DME
DMGMF6V	MA	Metabolism
DMGMF6V	RN	Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49.
DMGMF6V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12641434

DMGMF6V	DI	DMGMF6V
DMGMF6V	DN	Capsaicin
DMGMF6V	MI	DE4LYSA
DMGMF6V	MN	Cytochrome P450 3A4 (CYP3A4)
DMGMF6V	MT	DME
DMGMF6V	MA	Metabolism
DMGMF6V	RN	Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49.
DMGMF6V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12641434

DMGMF6V	DI	DMGMF6V
DMGMF6V	DN	Capsaicin
DMGMF6V	MI	DEGTFWK
DMGMF6V	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMGMF6V	MT	DME
DMGMF6V	MA	Metabolism
DMGMF6V	RN	Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49.
DMGMF6V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12641434

DMGMF6V	DI	DMGMF6V
DMGMF6V	DN	Capsaicin
DMGMF6V	MI	TTMI6F5
DMGMF6V	MN	Transient receptor potential cation channel V1 (TRPV1)
DMGMF6V	MT	DTT
DMGMF6V	MA	Agonist
DMGMF6V	RN	Capsaicin receptor: TRPV1 a promiscuous TRP channel. Handb Exp Pharmacol. 2007;(179):155-71.
DMGMF6V	RU	https://pubmed.ncbi.nlm.nih.gov/17217056

DM458UM	DI	DM458UM
DM458UM	DN	Captopril
DM458UM	MI	TTL69WB
DM458UM	MN	Angiotensin-converting enzyme (ACE)
DM458UM	MT	DTT
DM458UM	MA	Inhibitor
DM458UM	RN	Using ACE inhibitors appropriately. Am Fam Physician. 2002 Aug 1;66(3):461-8.
DM458UM	RU	https://pubmed.ncbi.nlm.nih.gov/12182524

DM458UM	DI	DM458UM
DM458UM	DN	Captopril
DM458UM	MI	DECB0K3
DM458UM	MN	Cytochrome P450 2D6 (CYP2D6)
DM458UM	MT	DME
DM458UM	MA	Metabolism
DM458UM	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM458UM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM458UM	DI	DM458UM
DM458UM	DN	Captopril
DM458UM	MI	DT9G7XN
DM458UM	MN	Peptide transporter 1 (SLC15A1)
DM458UM	MT	DTP
DM458UM	MA	Substrate
DM458UM	RN	Membrane transporters in drug development. Nat Rev Drug Discov. 2010 Mar;9(3):215-36.
DM458UM	RU	https://doi.org/10.1038/nrd3028

DM458UM	DI	DM458UM
DM458UM	DN	Captopril
DM458UM	MI	DEFQ8VO
DM458UM	MN	Thiopurine methyltransferase (TPMT)
DM458UM	MT	DME
DM458UM	MA	Metabolism
DM458UM	RN	S-methylation of captopril. Demonstration of captopril thiol methyltransferase activity in human erythrocytes and enzyme distribution in rat tissues. Biochem Pharmacol. 1983 May 15;32(10):1557-62.
DM458UM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=6344869

DMX9K8F	DI	DMX9K8F
DMX9K8F	DN	Carbachol
DMX9K8F	MI	TTF4E0J
DMX9K8F	MN	Neuronal acetylcholine receptor alpha-2 (CHRNA2)
DMX9K8F	MT	DTT
DMX9K8F	MA	Antagonist
DMX9K8F	RN	Synergy between pairs of competitive antagonists at adult human muscle acetylcholine receptors. Anesth Analg. 2008 Aug;107(2):525-33.
DMX9K8F	RU	https://pubmed.ncbi.nlm.nih.gov/18633030

DMZOLBI	DI	DMZOLBI
DMZOLBI	DN	Carbamazepine
DMZOLBI	MI	DEJGDUW
DMZOLBI	MN	Cytochrome P450 1A2 (CYP1A2)
DMZOLBI	MT	DME
DMZOLBI	MA	Metabolism
DMZOLBI	RN	Interactions between antiepileptics and second-generation antipsychotics. Expert Opin Drug Metab Toxicol. 2012 Mar;8(3):311-34.
DMZOLBI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22332980

DMZOLBI	DI	DMZOLBI
DMZOLBI	DN	Carbamazepine
DMZOLBI	MI	DEPKLMQ
DMZOLBI	MN	Cytochrome P450 2B6 (CYP2B6)
DMZOLBI	MT	DME
DMZOLBI	MA	Metabolism
DMZOLBI	RN	Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metab Dispos. 2004 Mar;32(3):348-58.
DMZOLBI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14977870

DMZOLBI	DI	DMZOLBI
DMZOLBI	DN	Carbamazepine
DMZOLBI	MI	DES5XRU
DMZOLBI	MN	Cytochrome P450 2C8 (CYP2C8)
DMZOLBI	MT	DME
DMZOLBI	MA	Metabolism
DMZOLBI	RN	Potential interaction between ritonavir and carbamazepine. Pharmacotherapy. 2000 Jul;20(7):851-4.
DMZOLBI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10907977

DMZOLBI	DI	DMZOLBI
DMZOLBI	DN	Carbamazepine
DMZOLBI	MI	DE4LYSA
DMZOLBI	MN	Cytochrome P450 3A4 (CYP3A4)
DMZOLBI	MT	DME
DMZOLBI	MA	Metabolism
DMZOLBI	RN	Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients. Epilepsy Res. 2004 Nov;62(1):1-11.
DMZOLBI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15519127

DMZOLBI	DI	DMZOLBI
DMZOLBI	DN	Carbamazepine
DMZOLBI	MI	DEIBDNY
DMZOLBI	MN	Cytochrome P450 3A5 (CYP3A5)
DMZOLBI	MT	DME
DMZOLBI	MA	Metabolism
DMZOLBI	RN	Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor. Biol Pharm Bull. 2003 Apr;26(4):510-7.
DMZOLBI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12673034

DMZOLBI	DI	DMZOLBI
DMZOLBI	DN	Carbamazepine
DMZOLBI	MI	DERD86B
DMZOLBI	MN	Cytochrome P450 3A7 (CYP3A7)
DMZOLBI	MT	DME
DMZOLBI	MA	Metabolism
DMZOLBI	RN	CYP3A4 and CYP3A7-mediated carbamazepine 10,11-epoxidation are activated by differential endogenous steroids. Drug Metab Dispos. 2003 Apr;31(4):432-8.
DMZOLBI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12642469

DMZOLBI	DI	DMZOLBI
DMZOLBI	DN	Carbamazepine
DMZOLBI	MI	DELB4KP
DMZOLBI	MN	Epoxide hydrolase 1 (EPHX1)
DMZOLBI	MT	DME
DMZOLBI	MA	Metabolism
DMZOLBI	RN	Haplotype structures of EPHX1 and their effects on the metabolism of carbamazepine-10,11-epoxide in Japanese epileptic patients. Eur J Clin Pharmacol. 2005 Mar;61(1):25-34.
DMZOLBI	RU	https://pubmed.ncbi.nlm.nih.gov/15692831

DMZOLBI	DI	DMZOLBI
DMZOLBI	DN	Carbamazepine
DMZOLBI	MI	DTFI42L
DMZOLBI	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMZOLBI	MT	DTP
DMZOLBI	MA	Substrate
DMZOLBI	RN	A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy. Pharmacogenet Genomics. 2010 Apr;20(4):249-56.
DMZOLBI	RU	http://www.ncbi.nlm.nih.gov/pubmed/20216337

DMZOLBI	DI	DMZOLBI
DMZOLBI	DN	Carbamazepine
DMZOLBI	MI	TTRK8B9
DMZOLBI	MN	Sodium channel unspecific (NaC)
DMZOLBI	MT	DTT
DMZOLBI	MA	Modulator
DMZOLBI	RN	Sidedness of carbamazepine accessibility to voltage-gated sodium channels. Mol Pharmacol. 2014 Feb;85(2):381-7.
DMZOLBI	RU	https://pubmed.ncbi.nlm.nih.gov/24319110

DMZOLBI	DI	DMZOLBI
DMZOLBI	DN	Carbamazepine
DMZOLBI	MI	DEB3CV1
DMZOLBI	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMZOLBI	MT	DME
DMZOLBI	MA	Metabolism
DMZOLBI	RN	Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy. Pharmacogenomics. 2013 Jan;14(1):35-45.
DMZOLBI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23252947

DMLEDNK	DI	DMLEDNK
DMLEDNK	DN	Carbenicillin
DMLEDNK	MI	TTJP4SM
DMLEDNK	MN	Bacterial Penicillin binding protein (Bact PBP)
DMLEDNK	MT	DTT
DMLEDNK	MA	Binder
DMLEDNK	RN	Resistance of Pseudomonas aeruginosa to cefsulodin: modification of penicillin-binding protein 3 and mapping of its chromosomal gene. J Antimicrob Chemother. 1990 Apr;25(4):513-23.
DMLEDNK	RU	https://pubmed.ncbi.nlm.nih.gov/2112536

DMLEDNK	DI	DMLEDNK
DMLEDNK	DN	Carbenicillin
DMLEDNK	MI	DEXB2A9
DMLEDNK	MN	Beta-lactamase (blaB)
DMLEDNK	MT	DME
DMLEDNK	MA	Metabolism
DMLEDNK	RN	Beta-lactamase expression in Plesiomonas shigelloides. J Antimicrob Chemother. 2000 Jun;45(6):877-80.
DMLEDNK	RU	https://pubmed.ncbi.nlm.nih.gov/10837443

DMLEDNK	DI	DMLEDNK
DMLEDNK	DN	Carbenicillin
DMLEDNK	MI	DEF01WC
DMLEDNK	MN	Beta-lactamase (blaB)
DMLEDNK	MT	DME
DMLEDNK	MA	Metabolism
DMLEDNK	RN	Beta-lactamase activity in Chromobacterium violaceum. J Infect Dis. 1976 Sep;134(3):290-3.
DMLEDNK	RU	https://pubmed.ncbi.nlm.nih.gov/977998

DMLEDNK	DI	DMLEDNK
DMLEDNK	DN	Carbenicillin
DMLEDNK	MI	DEIU0XN
DMLEDNK	MN	N-acylhomoserine lactone acylase (lacA)
DMLEDNK	MT	DME
DMLEDNK	MA	Metabolism
DMLEDNK	RN	A novel quorum-quenching N-acylhomoserine lactone acylase from Acidovorax sp. strain MR-S7 mediates antibiotic resistance. Appl Environ Microbiol. 2017 Jun 16;83(13). pii: e00080-17.
DMLEDNK	RU	https://pubmed.ncbi.nlm.nih.gov/28455333

DMLEDNK	DI	DMLEDNK
DMLEDNK	DN	Carbenicillin
DMLEDNK	MI	DE2ARDZ
DMLEDNK	MN	PenA beta-lactamase (penA1)
DMLEDNK	MT	DME
DMLEDNK	MA	Metabolism
DMLEDNK	RN	Characterization of the penA and penR genes of Burkholderia cepacia 249 which encode the chromosomal class A penicillinase and its LysR-type transcriptional regulator. Antimicrob Agents Chemother. 1997 Nov;41(11):2399-405.
DMLEDNK	RU	https://pubmed.ncbi.nlm.nih.gov/9371340

DME2XG3	DI	DME2XG3
DME2XG3	DN	Carbenicillin Indanyl Sodium
DME2XG3	MI	TTJP4SM
DME2XG3	MN	Bacterial Penicillin binding protein (Bact PBP)
DME2XG3	MT	DTT
DME2XG3	MA	Modulator
DME2XG3	RN	Carbenicillin resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1982 Aug;22(2):255-61.
DME2XG3	RU	https://www.ncbi.nlm.nih.gov/pubmed/6821456

DMUSLW3	DI	DMUSLW3
DMUSLW3	DN	Carbetocin
DMUSLW3	MI	TTSCIUP
DMUSLW3	MN	Oxytocin receptor (OTR)
DMUSLW3	MT	DTT
DMUSLW3	MA	Agonist
DMUSLW3	RN	Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog Brain Res. 2008;170:473-512.
DMUSLW3	RU	https://pubmed.ncbi.nlm.nih.gov/18655903

DMHRG8Q	DI	DMHRG8Q
DMHRG8Q	DN	Carbidopa
DMHRG8Q	MI	TTN451K
DMHRG8Q	MN	Aromatic-L-amino-acid decarboxylase (DDC)
DMHRG8Q	MT	DTT
DMHRG8Q	MA	Inhibitor
DMHRG8Q	RN	Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease. Semin Neurol. 2001;21(1):15-22.
DMHRG8Q	RU	https://pubmed.ncbi.nlm.nih.gov/11346021

DMULAI4	DI	DMULAI4
DMULAI4	DN	Carbimazole
DMULAI4	MI	TT52XDZ
DMULAI4	MN	Thyroid peroxidase (TPO)
DMULAI4	MT	DTT
DMULAI4	MA	Inhibitor
DMULAI4	RN	Diagnosis and treatment of thyrotoxicosis in childhood. A European questionnaire study. Eur J Endocrinol. 1994 Nov;131(5):467-73.
DMULAI4	RU	https://pubmed.ncbi.nlm.nih.gov/7952157

DMCT31R	DI	DMCT31R
DMCT31R	DN	Carbinoxamine
DMCT31R	MI	TTTIBOJ
DMCT31R	MN	Histamine H1 receptor (H1R)
DMCT31R	MT	DTT
DMCT31R	MA	Antagonist
DMCT31R	RN	Comparison of the effects of eleven histamine H1-receptor antagonists on monoamine turnover in the mouse brain. Naunyn Schmiedebergs Arch Pharmacol. 1994 Feb;349(2):140-4.
DMCT31R	RU	https://pubmed.ncbi.nlm.nih.gov/7513381

DMG281S	DI	DMG281S
DMG281S	DN	Carboplatin
DMG281S	MI	DEYZEJA
DMG281S	MN	Glutathione S-transferase mu-1 (GSTM1)
DMG281S	MT	DME
DMG281S	MA	Metabolism
DMG281S	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
DMG281S	RU	https://www.pharmgkb.org/pathway/PA150642262

DMG281S	DI	DMG281S
DMG281S	DN	Carboplatin
DMG281S	MI	DEK6079
DMG281S	MN	Glutathione S-transferase pi (GSTP1)
DMG281S	MT	DME
DMG281S	MA	Metabolism
DMG281S	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
DMG281S	RU	https://www.pharmgkb.org/pathway/PA150642262

DMG281S	DI	DMG281S
DMG281S	DN	Carboplatin
DMG281S	MI	DE3PKUG
DMG281S	MN	Glutathione S-transferase theta-1 (GSTT1)
DMG281S	MT	DME
DMG281S	MA	Metabolism
DMG281S	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
DMG281S	RU	https://www.pharmgkb.org/pathway/PA150642262

DMG281S	DI	DMG281S
DMG281S	DN	Carboplatin
DMG281S	MI	DTP8L4F
DMG281S	MN	High affinity copper uptake protein 1 (SLC31A1)
DMG281S	MT	DTP
DMG281S	MA	Substrate
DMG281S	RN	Overcoming platinum drug resistance with copper-lowering agents. Anticancer Res. 2013 Oct;33(10):4157-61.
DMG281S	RU	http://www.ncbi.nlm.nih.gov/pubmed/24122978

DMG281S	DI	DMG281S
DMG281S	DN	Carboplatin
DMG281S	MI	TTUTN1I
DMG281S	MN	Human Deoxyribonucleic acid (hDNA)
DMG281S	MT	DTT
DMG281S	MA	Modulator
DMG281S	RN	Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.Clin Cancer Res.2010 Oct 1;16(19):4899-905.
DMG281S	RU	https://www.ncbi.nlm.nih.gov/pubmed/20719935

DMG281S	DI	DMG281S
DMG281S	DN	Carboplatin
DMG281S	MI	DE5ME8A
DMG281S	MN	Metallothionein-1A (MT1A)
DMG281S	MT	DME
DMG281S	MA	Metabolism
DMG281S	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
DMG281S	RU	https://www.pharmgkb.org/pathway/PA150642262

DMG281S	DI	DMG281S
DMG281S	DN	Carboplatin
DMG281S	MI	DEFKGT7
DMG281S	MN	Metallothionein-2A (MT2A)
DMG281S	MT	DME
DMG281S	MA	Metabolism
DMG281S	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
DMG281S	RU	https://www.pharmgkb.org/pathway/PA150642262

DMG281S	DI	DMG281S
DMG281S	DN	Carboplatin
DMG281S	MI	DEA3U9Y
DMG281S	MN	Myeloperoxidase (MPO)
DMG281S	MT	DME
DMG281S	MA	Metabolism
DMG281S	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
DMG281S	RU	https://www.pharmgkb.org/pathway/PA150642262

DMG281S	DI	DMG281S
DMG281S	DN	Carboplatin
DMG281S	MI	DENP5RY
DMG281S	MN	Quinone reductase 1 (NQO1)
DMG281S	MT	DME
DMG281S	MA	Metabolism
DMG281S	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
DMG281S	RU	https://www.pharmgkb.org/pathway/PA150642262

DMS3508	DI	DMS3508
DMS3508	DN	Carboprost tromethamine
DMS3508	MI	TTT2ZAR
DMS3508	MN	Prostaglandin F2-alpha receptor (PTGFR)
DMS3508	MT	DTT
DMS3508	MA	Modulator
DMS3508	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMS3508	RU	https://www.fda.gov/

DM48K0X	DI	DM48K0X
DM48K0X	DN	Carfilzomib
DM48K0X	MI	DTUGYRD
DM48K0X	MN	P-glycoprotein 1 (ABCB1)
DM48K0X	MT	DTP
DM48K0X	MA	Substrate
DM48K0X	RN	Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1. Am J Hematol. 2013 Apr;88(4):265-72.
DM48K0X	RU	http://www.ncbi.nlm.nih.gov/pubmed/23475625

DM48K0X	DI	DM48K0X
DM48K0X	DN	Carfilzomib
DM48K0X	MI	TTU7ZMG
DM48K0X	MN	Proteasome (PS)
DM48K0X	MT	DTT
DM48K0X	MA	Modulator
DM48K0X	RN	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
DM48K0X	RU	https://pubmed.ncbi.nlm.nih.gov/23370234

DMCY0TI	DI	DMCY0TI
DMCY0TI	DN	Carglumic acid
DMCY0TI	MI	TT42M75
DMCY0TI	MN	Carbamoyl-phosphate synthetase I (CPS1)
DMCY0TI	MT	DTT
DMCY0TI	MA	Activator
DMCY0TI	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DMCY0TI	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DMJYDVK	DI	DMJYDVK
DMJYDVK	DN	Cariprazine
DMJYDVK	MI	DECB0K3
DMJYDVK	MN	Cytochrome P450 2D6 (CYP2D6)
DMJYDVK	MT	DME
DMJYDVK	MA	Metabolism
DMJYDVK	RN	Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol. 2013 Feb;9(2):193-206.
DMJYDVK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23320989

DMJYDVK	DI	DMJYDVK
DMJYDVK	DN	Cariprazine
DMJYDVK	MI	DE4LYSA
DMJYDVK	MN	Cytochrome P450 3A4 (CYP3A4)
DMJYDVK	MT	DME
DMJYDVK	MA	Metabolism
DMJYDVK	RN	Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol. 2013 Feb;9(2):193-206.
DMJYDVK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23320989

DMJYDVK	DI	DMJYDVK
DMJYDVK	DN	Cariprazine
DMJYDVK	MI	TTEX248
DMJYDVK	MN	Dopamine D2 receptor (D2R)
DMJYDVK	MT	DTT
DMJYDVK	MA	Modulator
DMJYDVK	RN	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
DMJYDVK	RU	https://pubmed.ncbi.nlm.nih.gov/28919714

DMJYDVK	DI	DMJYDVK
DMJYDVK	DN	Cariprazine
DMJYDVK	MI	TT4C8EA
DMJYDVK	MN	Dopamine D3 receptor (D3R)
DMJYDVK	MT	DTT
DMJYDVK	MA	Modulator
DMJYDVK	RN	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
DMJYDVK	RU	https://pubmed.ncbi.nlm.nih.gov/28919714

DMWR1JC	DI	DMWR1JC
DMWR1JC	DN	Carisoprodol
DMWR1JC	MI	DEGTFWK
DMWR1JC	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMWR1JC	MT	DME
DMWR1JC	MA	Metabolism
DMWR1JC	RN	Association between blood carisoprodol:meprobamate concentration ratios and CYP2C19 genotype in carisoprodol-drugged drivers: decreased metabolic capacity in heterozygous CYP2C19*1/CYP2C19*2 subjects? Pharmacogenetics. 2003 Jul;13(7):383-8.
DMWR1JC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12835613

DMHTB31	DI	DMHTB31
DMHTB31	DN	Carphenazine
DMHTB31	MI	TTEX248
DMHTB31	MN	Dopamine D2 receptor (D2R)
DMHTB31	MT	DTT
DMHTB31	MA	Antagonist
DMHTB31	RN	Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38.
DMHTB31	RU	https://pubmed.ncbi.nlm.nih.gov/11873706

DMHMP05	DI	DMHMP05
DMHMP05	DN	Carprofen
DMHMP05	MI	TTVKILB
DMHMP05	MN	Prostaglandin G/H synthase 2 (COX-2)
DMHMP05	MT	DTT
DMHMP05	MA	Inhibitor
DMHMP05	RN	Scaffold of the cyclooxygenase-2 (COX-2) inhibitor carprofen provides Alzheimer gamma-secretase modulators. J Med Chem. 2006 Dec 28;49(26):7588-91.
DMHMP05	RU	https://pubmed.ncbi.nlm.nih.gov/17181139

DMHMP05	DI	DMHMP05
DMHMP05	DN	Carprofen
DMHMP05	MI	DEB3CV1
DMHMP05	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMHMP05	MT	DME
DMHMP05	MA	Metabolism
DMHMP05	RN	Enantioselective inhibition of carprofen towards UDP-glucuronosyltransferase (UGT) 2B7. Chirality. 2015 Mar;27(3):189-93.
DMHMP05	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25502512

DMFMDOB	DI	DMFMDOB
DMFMDOB	DN	Carteolol
DMFMDOB	MI	TTR6W5O
DMFMDOB	MN	Adrenergic receptor beta-1 (ADRB1)
DMFMDOB	MT	DTT
DMFMDOB	MA	Agonist
DMFMDOB	RN	Partial agonistic effects of carteolol on atypical beta-adrenoceptors in the guinea pig gastric fundus. Jpn J Pharmacol. 2000 Nov;84(3):287-92.
DMFMDOB	RU	https://pubmed.ncbi.nlm.nih.gov/11138729

DMFMDOB	DI	DMFMDOB
DMFMDOB	DN	Carteolol
DMFMDOB	MI	DECB0K3
DMFMDOB	MN	Cytochrome P450 2D6 (CYP2D6)
DMFMDOB	MT	DME
DMFMDOB	MA	Metabolism
DMFMDOB	RN	Involvement of CYP2D1 in the metabolism of carteolol by male rat liver microsomes. Xenobiotica. 1997 Nov;27(11):1121-9.
DMFMDOB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9413916

DMHTEAO	DI	DMHTEAO
DMHTEAO	DN	Carvedilol
DMHTEAO	MI	TTG28O6
DMHTEAO	MN	Adrenergic receptor Alpha-1 (ADRA1)
DMHTEAO	MT	DTT
DMHTEAO	MA	Antagonist
DMHTEAO	RN	Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8.
DMHTEAO	RU	https://pubmed.ncbi.nlm.nih.gov/19491545

DMHTEAO	DI	DMHTEAO
DMHTEAO	DN	Carvedilol
DMHTEAO	MI	DEJGDUW
DMHTEAO	MN	Cytochrome P450 1A2 (CYP1A2)
DMHTEAO	MT	DME
DMHTEAO	MA	Metabolism
DMHTEAO	RN	Pharmacokinetic interactions study between carvedilol and some antidepressants in rat liver microsomes - a comparative study. Med Pharm Rep. 2019 Apr;92(2):158-164.
DMHTEAO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31086844

DMHTEAO	DI	DMHTEAO
DMHTEAO	DN	Carvedilol
DMHTEAO	MI	DE5IED8
DMHTEAO	MN	Cytochrome P450 2C9 (CYP2C9)
DMHTEAO	MT	DME
DMHTEAO	MA	Metabolism
DMHTEAO	RN	The role of CYP2C9 genetic polymorphism in carvedilol O-desmethylation in vitro. Eur J Drug Metab Pharmacokinet. 2016 Feb;41(1):79-86.
DMHTEAO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25476996

DMHTEAO	DI	DMHTEAO
DMHTEAO	DN	Carvedilol
DMHTEAO	MI	DECB0K3
DMHTEAO	MN	Cytochrome P450 2D6 (CYP2D6)
DMHTEAO	MT	DME
DMHTEAO	MA	Metabolism
DMHTEAO	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMHTEAO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMHTEAO	DI	DMHTEAO
DMHTEAO	DN	Carvedilol
DMHTEAO	MI	DEVDYN7
DMHTEAO	MN	Cytochrome P450 2E1 (CYP2E1)
DMHTEAO	MT	DME
DMHTEAO	MA	Metabolism
DMHTEAO	RN	In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol. Drug Metab Dispos. 1997 Aug;25(8):970-7.
DMHTEAO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9280405

DMHTEAO	DI	DMHTEAO
DMHTEAO	DN	Carvedilol
DMHTEAO	MI	DE4LYSA
DMHTEAO	MN	Cytochrome P450 3A4 (CYP3A4)
DMHTEAO	MT	DME
DMHTEAO	MA	Metabolism
DMHTEAO	RN	Role of cytochrome P450 2D6 genetic polymorphism in carvedilol hydroxylation in vitro. Drug Des Devel Ther. 2016 Jun 8;10:1909-16.
DMHTEAO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27354764

DMHTEAO	DI	DMHTEAO
DMHTEAO	DN	Carvedilol
DMHTEAO	MI	DTUGYRD
DMHTEAO	MN	P-glycoprotein 1 (ABCB1)
DMHTEAO	MT	DTP
DMHTEAO	MA	Substrate
DMHTEAO	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DMHTEAO	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DMHTEAO	DI	DMHTEAO
DMHTEAO	DN	Carvedilol
DMHTEAO	MI	DEYGVN4
DMHTEAO	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMHTEAO	MT	DME
DMHTEAO	MA	Metabolism
DMHTEAO	RN	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
DMHTEAO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429

DMHTEAO	DI	DMHTEAO
DMHTEAO	DN	Carvedilol
DMHTEAO	MI	DEB3CV1
DMHTEAO	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMHTEAO	MT	DME
DMHTEAO	MA	Metabolism
DMHTEAO	RN	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
DMHTEAO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429

DMZPXRC	DI	DMZPXRC
DMZPXRC	DN	Carzinophilin
DMZPXRC	MI	TTY1GPO
DMZPXRC	MN	Human Deoxyribonucleic acid major groove (hDNA maj)
DMZPXRC	MT	DTT
DMZPXRC	MA	Modulator
DMZPXRC	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMZPXRC	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DMGQIPT	DI	DMGQIPT
DMGQIPT	DN	Caspofungin
DMGQIPT	MI	TT0SFXH
DMGQIPT	MN	Fungal 1,3-beta-glucan synthase (Fung GSC2)
DMGQIPT	MT	DTT
DMGQIPT	MA	Modulator
DMGQIPT	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMGQIPT	RU	https://www.fda.gov/

DMGQIPT	DI	DMGQIPT
DMGQIPT	DN	Caspofungin
DMGQIPT	MI	DT3D8F0
DMGQIPT	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMGQIPT	MT	DTP
DMGQIPT	MA	Substrate
DMGQIPT	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DMGQIPT	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DMRSZA5	DI	DMRSZA5
DMRSZA5	DN	Cefacetrile
DMRSZA5	MI	TTJP4SM
DMRSZA5	MN	Bacterial Penicillin binding protein (Bact PBP)
DMRSZA5	MT	DTT
DMRSZA5	MA	Binder
DMRSZA5	RN	Single dose 1 g ceftriaxone for urogenital and pharyngeal infection caused by Neisseria gonorrhoeae. Int J Urol. 2008 Sep;15(9):837-42.
DMRSZA5	RU	https://pubmed.ncbi.nlm.nih.gov/18665871

DMJXDGC	DI	DMJXDGC
DMJXDGC	DN	Cefaclor
DMJXDGC	MI	TTJP4SM
DMJXDGC	MN	Bacterial Penicillin binding protein (Bact PBP)
DMJXDGC	MT	DTT
DMJXDGC	MA	Binder
DMJXDGC	RN	Antibacterial activity of oral cephems against various clinically isolated strains and evaluation of efficacy based on the pharmacokinetics/pharmacodynamics theory. Jpn J Antibiot. 2004 Dec;57(6):465-74.
DMJXDGC	RU	https://pubmed.ncbi.nlm.nih.gov/15747584

DMJXDGC	DI	DMJXDGC
DMJXDGC	DN	Cefaclor
DMJXDGC	MI	DTQ23VB
DMJXDGC	MN	Organic anion transporter 1 (SLC22A6)
DMJXDGC	MT	DTP
DMJXDGC	MA	Substrate
DMJXDGC	RN	FDA Drug Development and Drug Interactions
DMJXDGC	RU	https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2

DMJXDGC	DI	DMJXDGC
DMJXDGC	DN	Cefaclor
DMJXDGC	MI	DTVP67E
DMJXDGC	MN	Organic anion transporter 3 (SLC22A8)
DMJXDGC	MT	DTP
DMJXDGC	MA	Substrate
DMJXDGC	RN	Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. Biochem Pharmacol. 2005 Oct 1;70(7):1104-13.
DMJXDGC	RU	http://www.ncbi.nlm.nih.gov/pubmed/16098483

DMJXDGC	DI	DMJXDGC
DMJXDGC	DN	Cefaclor
DMJXDGC	MI	DT9G7XN
DMJXDGC	MN	Peptide transporter 1 (SLC15A1)
DMJXDGC	MT	DTP
DMJXDGC	MA	Substrate
DMJXDGC	RN	Protein hydrolysate-induced cholecystokinin secretion from enteroendocrine cells is indirectly mediated by the intestinal oligopeptide transporter PepT1. Am J Physiol Gastrointest Liver Physiol. 2011 May;300(5):G895-902.
DMJXDGC	RU	http://www.ncbi.nlm.nih.gov/pubmed/21311026

DMJXDGC	DI	DMJXDGC
DMJXDGC	DN	Cefaclor
DMJXDGC	MI	DT8QKNP
DMJXDGC	MN	Peptide transporter 2 (SLC15A2)
DMJXDGC	MT	DTP
DMJXDGC	MA	Substrate
DMJXDGC	RN	Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab Dispos. 2006 Apr;34(4):547-55.
DMJXDGC	RU	http://www.ncbi.nlm.nih.gov/pubmed/16434549

DMMC345	DI	DMMC345
DMMC345	DN	Cefadroxil
DMMC345	MI	TTJP4SM
DMMC345	MN	Bacterial Penicillin binding protein (Bact PBP)
DMMC345	MT	DTT
DMMC345	MA	Binder
DMMC345	RN	Penicillin-binding protein sensitive to cephalexin in sporulation of Bacillus cereus. Microbiol Res. 1997 Sep;152(3):227-32.
DMMC345	RU	https://pubmed.ncbi.nlm.nih.gov/9352657

DMMC345	DI	DMMC345
DMMC345	DN	Cefadroxil
DMMC345	MI	DTSYQGK
DMMC345	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMMC345	MT	DTP
DMMC345	MA	Substrate
DMMC345	RN	Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos. 2012 Mar;40(3):515-21.
DMMC345	RU	http://www.ncbi.nlm.nih.gov/pubmed/22166395

DMMC345	DI	DMMC345
DMMC345	DN	Cefadroxil
DMMC345	MI	DTFI42L
DMMC345	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMMC345	MT	DTP
DMMC345	MA	Substrate
DMMC345	RN	Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos. 2012 Mar;40(3):515-21.
DMMC345	RU	http://www.ncbi.nlm.nih.gov/pubmed/22166395

DMMC345	DI	DMMC345
DMMC345	DN	Cefadroxil
DMMC345	MI	DTQ3ZHF
DMMC345	MN	Multidrug resistance-associated protein 3 (ABCC3)
DMMC345	MT	DTP
DMMC345	MA	Substrate
DMMC345	RN	Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos. 2012 Mar;40(3):515-21.
DMMC345	RU	http://www.ncbi.nlm.nih.gov/pubmed/22166395

DMMC345	DI	DMMC345
DMMC345	DN	Cefadroxil
DMMC345	MI	DTCSGPB
DMMC345	MN	Multidrug resistance-associated protein 4 (ABCC4)
DMMC345	MT	DTP
DMMC345	MA	Substrate
DMMC345	RN	Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos. 2012 Mar;40(3):515-21.
DMMC345	RU	http://www.ncbi.nlm.nih.gov/pubmed/22166395

DMMC345	DI	DMMC345
DMMC345	DN	Cefadroxil
DMMC345	MI	DEIU0XN
DMMC345	MN	N-acylhomoserine lactone acylase (lacA)
DMMC345	MT	DME
DMMC345	MA	Metabolism
DMMC345	RN	A novel quorum-quenching N-acylhomoserine lactone acylase from Acidovorax sp. strain MR-S7 mediates antibiotic resistance. Appl Environ Microbiol. 2017 Jun 16;83(13). pii: e00080-17.
DMMC345	RU	https://pubmed.ncbi.nlm.nih.gov/28455333

DMMC345	DI	DMMC345
DMMC345	DN	Cefadroxil
DMMC345	MI	DT9G7XN
DMMC345	MN	Peptide transporter 1 (SLC15A1)
DMMC345	MT	DTP
DMMC345	MA	Substrate
DMMC345	RN	High-affinity interaction of sartans with H+/peptide transporters. Drug Metab Dispos. 2009 Jan;37(1):143-9.
DMMC345	RU	http://www.ncbi.nlm.nih.gov/pubmed/18824524

DMMC345	DI	DMMC345
DMMC345	DN	Cefadroxil
DMMC345	MI	DT8QKNP
DMMC345	MN	Peptide transporter 2 (SLC15A2)
DMMC345	MT	DTP
DMMC345	MA	Substrate
DMMC345	RN	Species Differences in Human and Rodent PEPT2-Mediated Transport of Glycylsarcosine and Cefadroxil in Pichia Pastoris Transformants. Drug Metab Dispos. 2017 Feb;45(2):130-136.
DMMC345	RU	http://www.ncbi.nlm.nih.gov/pubmed/27836942

DMVYSLE	DI	DMVYSLE
DMVYSLE	DN	Cefalotin
DMVYSLE	MI	DERI7LO
DMVYSLE	MN	AmpC beta-lactamase (ampC)
DMVYSLE	MT	DME
DMVYSLE	MA	Metabolism
DMVYSLE	RN	Characterization of the AmpC beta-Lactamase from Burkholderia multivorans. Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e01140-18.
DMVYSLE	RU	https://pubmed.ncbi.nlm.nih.gov/30012762

DMVYSLE	DI	DMVYSLE
DMVYSLE	DN	Cefalotin
DMVYSLE	MI	TTLP6GN
DMVYSLE	MN	Bacterial DD-carboxypeptidase (Bact vanYB)
DMVYSLE	MT	DTT
DMVYSLE	MA	Inhibitor
DMVYSLE	RN	Binding of cephalothin and cefotaxime to D-ala-D-ala-peptidase reveals a functional basis of a natural mutation in a low-affinity penicillin-binding protein and in extended-spectrum beta-lactamases. Biochemistry. 1995 Jul 25;34(29):9532-40.
DMVYSLE	RU	https://pubmed.ncbi.nlm.nih.gov/7626623

DMVYSLE	DI	DMVYSLE
DMVYSLE	DN	Cefalotin
DMVYSLE	MI	DET9I1W
DMVYSLE	MN	Beta-lactamase (blaB)
DMVYSLE	MT	DME
DMVYSLE	MA	Metabolism
DMVYSLE	RN	Purification and characterization of a new beta-lactamase from Bacteroides uniformis. Antimicrob Agents Chemother. 1995 Jul;39(7):1458-61.
DMVYSLE	RU	https://pubmed.ncbi.nlm.nih.gov/7492085

DMVYSLE	DI	DMVYSLE
DMVYSLE	DN	Cefalotin
DMVYSLE	MI	DENJ2SQ
DMVYSLE	MN	Beta-lactamase (blaB)
DMVYSLE	MT	DME
DMVYSLE	MA	Metabolism
DMVYSLE	RN	Antibacterial activity of cefoperazone against anaerobic bacteria (author's transl). Jpn J Antibiot. 1980 Nov;33(11):1171-82.
DMVYSLE	RU	https://pubmed.ncbi.nlm.nih.gov/6454011

DMNEXZF	DI	DMNEXZF
DMNEXZF	DN	Cefamandole
DMNEXZF	MI	TTJP4SM
DMNEXZF	MN	Bacterial Penicillin binding protein (Bact PBP)
DMNEXZF	MT	DTT
DMNEXZF	MA	Binder
DMNEXZF	RN	The impact of penicillinase on cefamandole treatment and prophylaxis of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. J Infect Dis. 1998 Jan;177(1):146-54.
DMNEXZF	RU	https://pubmed.ncbi.nlm.nih.gov/9419181

DMNEXZF	DI	DMNEXZF
DMNEXZF	DN	Cefamandole
DMNEXZF	MI	DT9G7XN
DMNEXZF	MN	Peptide transporter 1 (SLC15A1)
DMNEXZF	MT	DTP
DMNEXZF	MA	Substrate
DMNEXZF	RN	Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res. 1999 Jan;16(1):55-61.
DMNEXZF	RU	https://doi.org/10.1023/A:1018814627484

DMPDYFR	DI	DMPDYFR
DMPDYFR	DN	Cefazolin
DMPDYFR	MI	TTJP4SM
DMPDYFR	MN	Bacterial Penicillin binding protein (Bact PBP)
DMPDYFR	MT	DTT
DMPDYFR	MA	Binder
DMPDYFR	RN	Bacteriological characteristics of Staphylococcus aureus isolates from humans and bulk milk. J Dairy Sci. 2008 Feb;91(2):564-9.
DMPDYFR	RU	https://pubmed.ncbi.nlm.nih.gov/18218742

DMPDYFR	DI	DMPDYFR
DMPDYFR	DN	Cefazolin
DMPDYFR	MI	DEP0IWS
DMPDYFR	MN	Beta-lactamase (blaB)
DMPDYFR	MT	DME
DMPDYFR	MA	Metabolism
DMPDYFR	RN	Analysis of the drug-resistant characteristics of Klebsiella pneumoniae isolated from the respiratory tract and CTX-M ESBL genes. Genet Mol Res. 2015 Oct 5;14(4):12043-8.
DMPDYFR	RU	https://pubmed.ncbi.nlm.nih.gov/26505351

DMPDYFR	DI	DMPDYFR
DMPDYFR	DN	Cefazolin
DMPDYFR	MI	DE7IH52
DMPDYFR	MN	Beta-lactamase (blaB)
DMPDYFR	MT	DME
DMPDYFR	MA	Metabolism
DMPDYFR	RN	Citrobacter freundii bacteremia: Risk factors of mortality and prevalence of resistance genes. J Microbiol Immunol Infect. 2018 Aug;51(4):565-572.
DMPDYFR	RU	https://pubmed.ncbi.nlm.nih.gov/28711438

DMPDYFR	DI	DMPDYFR
DMPDYFR	DN	Cefazolin
DMPDYFR	MI	DENJ2SQ
DMPDYFR	MN	Beta-lactamase (blaB)
DMPDYFR	MT	DME
DMPDYFR	MA	Metabolism
DMPDYFR	RN	Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019 Sep;25(9):1156.e9-1156.e13.
DMPDYFR	RU	https://pubmed.ncbi.nlm.nih.gov/30802650

DMPDYFR	DI	DMPDYFR
DMPDYFR	DN	Cefazolin
DMPDYFR	MI	DTCSGPB
DMPDYFR	MN	Multidrug resistance-associated protein 4 (ABCC4)
DMPDYFR	MT	DTP
DMPDYFR	MA	Substrate
DMPDYFR	RN	Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos. 2012 Mar;40(3):515-21.
DMPDYFR	RU	http://www.ncbi.nlm.nih.gov/pubmed/22166395

DMPDYFR	DI	DMPDYFR
DMPDYFR	DN	Cefazolin
DMPDYFR	MI	DTQ23VB
DMPDYFR	MN	Organic anion transporter 1 (SLC22A6)
DMPDYFR	MT	DTP
DMPDYFR	MA	Substrate
DMPDYFR	RN	Expression levels of renal organic anion transporters (OATs) and their correlation with anionic drug excretion in patients with renal diseases. Pharm Res. 2004 Jan;21(1):61-7.
DMPDYFR	RU	http://www.ncbi.nlm.nih.gov/pubmed/14984259

DMPDYFR	DI	DMPDYFR
DMPDYFR	DN	Cefazolin
DMPDYFR	MI	DTVP67E
DMPDYFR	MN	Organic anion transporter 3 (SLC22A8)
DMPDYFR	MT	DTP
DMPDYFR	MA	Substrate
DMPDYFR	RN	Expression levels of renal organic anion transporters (OATs) and their correlation with anionic drug excretion in patients with renal diseases. Pharm Res. 2004 Jan;21(1):61-7.
DMPDYFR	RU	http://www.ncbi.nlm.nih.gov/pubmed/14984259

DMPDYFR	DI	DMPDYFR
DMPDYFR	DN	Cefazolin
DMPDYFR	MI	DT3D8F0
DMPDYFR	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMPDYFR	MT	DTP
DMPDYFR	MA	Substrate
DMPDYFR	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DMPDYFR	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DMPDYFR	DI	DMPDYFR
DMPDYFR	DN	Cefazolin
DMPDYFR	MI	DT9G7XN
DMPDYFR	MN	Peptide transporter 1 (SLC15A1)
DMPDYFR	MT	DTP
DMPDYFR	MA	Substrate
DMPDYFR	RN	Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. J Med Chem. 2005 Jun 30;48(13):4410-9.
DMPDYFR	RU	http://www.ncbi.nlm.nih.gov/pubmed/15974593

DMPDYFR	DI	DMPDYFR
DMPDYFR	DN	Cefazolin
DMPDYFR	MI	DEFQ8VO
DMPDYFR	MN	Thiopurine methyltransferase (TPMT)
DMPDYFR	MT	DME
DMPDYFR	MA	Metabolism
DMPDYFR	RN	Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in human tissue: possible relationship to hypoprothrombinemia. Drug Metab Dispos. 2002 Oct;30(10):1123-8.
DMPDYFR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12228189

DMJ7A0H	DI	DMJ7A0H
DMJ7A0H	DN	Cefdinir
DMJ7A0H	MI	TTJP4SM
DMJ7A0H	MN	Bacterial Penicillin binding protein (Bact PBP)
DMJ7A0H	MT	DTT
DMJ7A0H	MA	Binder
DMJ7A0H	RN	Decreased affinity of mosaic-structure recombinant penicillin-binding protein 2 for oral cephalosporins in Neisseria gonorrhoeae. J Antimicrob Chemother. 2007 Jul;60(1):54-60.
DMJ7A0H	RU	https://pubmed.ncbi.nlm.nih.gov/17540669

DMJ7A0H	DI	DMJ7A0H
DMJ7A0H	DN	Cefdinir
DMJ7A0H	MI	DTVP67E
DMJ7A0H	MN	Organic anion transporter 3 (SLC22A8)
DMJ7A0H	MT	DTP
DMJ7A0H	MA	Substrate
DMJ7A0H	RN	Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. Biochem Pharmacol. 2005 Oct 1;70(7):1104-13.
DMJ7A0H	RU	http://www.ncbi.nlm.nih.gov/pubmed/16098483

DMJ7A0H	DI	DMJ7A0H
DMJ7A0H	DN	Cefdinir
DMJ7A0H	MI	DT9G7XN
DMJ7A0H	MN	Peptide transporter 1 (SLC15A1)
DMJ7A0H	MT	DTP
DMJ7A0H	MA	Substrate
DMJ7A0H	RN	Transporter-mediated drug delivery: recent progress and experimental approaches. Drug Discov Today. 2004 Aug 15;9(16):712-20.
DMJ7A0H	RU	https://doi.org/10.1016/S1359-6446(04)03198-8

DMSUVM1	DI	DMSUVM1
DMSUVM1	DN	Cefditoren
DMSUVM1	MI	TTJP4SM
DMSUVM1	MN	Bacterial Penicillin binding protein (Bact PBP)
DMSUVM1	MT	DTT
DMSUVM1	MA	Binder
DMSUVM1	RN	Crystal structure of cefditoren complexed with Streptococcus pneumoniae penicillin-binding protein 2X: structural basis for its high antimicrobial ... Antimicrob Agents Chemother. 2007 Nov;51(11):3902-7.
DMSUVM1	RU	https://pubmed.ncbi.nlm.nih.gov/17724158

DMSUVM1	DI	DMSUVM1
DMSUVM1	DN	Cefditoren
DMSUVM1	MI	DT3D8F0
DMSUVM1	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMSUVM1	MT	DTP
DMSUVM1	MA	Substrate
DMSUVM1	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DMSUVM1	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DMHVWIK	DI	DMHVWIK
DMHVWIK	DN	Cefepime
DMHVWIK	MI	TTHWB7G
DMHVWIK	MN	Bacterial Penicillin binding protein 2 (Bact mrdA)
DMHVWIK	MT	DTT
DMHVWIK	MA	Modulator
DMHVWIK	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMHVWIK	RU	https://www.fda.gov/

DMY60I8	DI	DMY60I8
DMY60I8	DN	Cefixime
DMY60I8	MI	TTJP4SM
DMY60I8	MN	Bacterial Penicillin binding protein (Bact PBP)
DMY60I8	MT	DTT
DMY60I8	MA	Binder
DMY60I8	RN	Genetics of chromosomally mediated intermediate resistance to ceftriaxone and cefixime in Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2009 Sep;53(9):3744-51.
DMY60I8	RU	https://pubmed.ncbi.nlm.nih.gov/19528266

DMY60I8	DI	DMY60I8
DMY60I8	DN	Cefixime
DMY60I8	MI	DT9G7XN
DMY60I8	MN	Peptide transporter 1 (SLC15A1)
DMY60I8	MT	DTP
DMY60I8	MA	Substrate
DMY60I8	RN	Flavonoids with epidermal growth factor-receptor tyrosine kinase inhibitory activity stimulate PEPT1-mediated cefixime uptake into human intestinal epithelial cells. J Pharmacol Exp Ther. 2001 Oct;299(1):351-7.
DMY60I8	RU	http://www.ncbi.nlm.nih.gov/pubmed/11561098

DMY60I8	DI	DMY60I8
DMY60I8	DN	Cefixime
DMY60I8	MI	DT8QKNP
DMY60I8	MN	Peptide transporter 2 (SLC15A2)
DMY60I8	MT	DTP
DMY60I8	MA	Substrate
DMY60I8	RN	Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60.
DMY60I8	RU	http://www.ncbi.nlm.nih.gov/pubmed/16597710

DMPLY7B	DI	DMPLY7B
DMPLY7B	DN	Cefmenoxime
DMPLY7B	MI	TT85JMW
DMPLY7B	MN	Bacterial Penicillin binding protein 3 (Bact mrcA)
DMPLY7B	MT	DTT
DMPLY7B	MA	Binder
DMPLY7B	RN	In vitro evaluation of E1040, a new cephalosporin with potent antipseudomonal activity. Antimicrob Agents Chemother. 1988 May;32(5):693-701.
DMPLY7B	RU	https://pubmed.ncbi.nlm.nih.gov/3134847

DM42W1B	DI	DM42W1B
DM42W1B	DN	Cefmetazole
DM42W1B	MI	TT85JMW
DM42W1B	MN	Bacterial Penicillin binding protein 3 (Bact mrcA)
DM42W1B	MT	DTT
DM42W1B	MA	Binder
DM42W1B	RN	Clinical relevance of antibiotic-induced endotoxin release in patients undergoing hepatic resection. World J Surg. 1999 Jan;23(1):75-9.
DM42W1B	RU	https://pubmed.ncbi.nlm.nih.gov/9841767

DM42W1B	DI	DM42W1B
DM42W1B	DN	Cefmetazole
DM42W1B	MI	DT9C1TS
DM42W1B	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM42W1B	MT	DTP
DM42W1B	MA	Substrate
DM42W1B	RN	Screening of antibiotics that interact with organic anion-transporting polypeptides 1B1 and 1B3 using fluorescent probes. Biol Pharm Bull. 2011;34(3):389-95.
DM42W1B	RU	http://www.ncbi.nlm.nih.gov/pubmed/21372390

DM42W1B	DI	DM42W1B
DM42W1B	DN	Cefmetazole
DM42W1B	MI	DT9G7XN
DM42W1B	MN	Peptide transporter 1 (SLC15A1)
DM42W1B	MT	DTP
DM42W1B	MA	Substrate
DM42W1B	RN	Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res. 1999 Jan;16(1):55-61.
DM42W1B	RU	https://doi.org/10.1023/A:1018814627484

DMORSGU	DI	DMORSGU
DMORSGU	DN	Cefodizime
DMORSGU	MI	DTFI42L
DMORSGU	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMORSGU	MT	DTP
DMORSGU	MA	Substrate
DMORSGU	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMORSGU	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMTX2BH	DI	DMTX2BH
DMTX2BH	DN	Cefonicid
DMTX2BH	MI	TTJP4SM
DMTX2BH	MN	Bacterial Penicillin binding protein (Bact PBP)
DMTX2BH	MT	DTT
DMTX2BH	MA	Binder
DMTX2BH	RN	Affinity of cefonicid, a long-acting cephalosporin, for the penicillin-binding proteins of Escherichia coli K-12. J Antibiot (Tokyo). 1984 May;37(5):572-6.
DMTX2BH	RU	https://pubmed.ncbi.nlm.nih.gov/6376452

DM53PV8	DI	DM53PV8
DM53PV8	DN	Cefoperazone
DM53PV8	MI	TTJP4SM
DM53PV8	MN	Bacterial Penicillin binding protein (Bact PBP)
DM53PV8	MT	DTT
DM53PV8	MA	Binder
DM53PV8	RN	Clinical relevance of antibiotic-induced endotoxin release in patients undergoing hepatic resection. World J Surg. 1999 Jan;23(1):75-9.
DM53PV8	RU	https://pubmed.ncbi.nlm.nih.gov/9841767

DM53PV8	DI	DM53PV8
DM53PV8	DN	Cefoperazone
DM53PV8	MI	DT3D8F0
DM53PV8	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM53PV8	MT	DTP
DM53PV8	MA	Substrate
DM53PV8	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DM53PV8	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DM53PV8	DI	DM53PV8
DM53PV8	DN	Cefoperazone
DM53PV8	MI	DT9C1TS
DM53PV8	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM53PV8	MT	DTP
DM53PV8	MA	Substrate
DM53PV8	RN	Screening of antibiotics that interact with organic anion-transporting polypeptides 1B1 and 1B3 using fluorescent probes. Biol Pharm Bull. 2011;34(3):389-95.
DM53PV8	RU	http://www.ncbi.nlm.nih.gov/pubmed/21372390

DM53PV8	DI	DM53PV8
DM53PV8	DN	Cefoperazone
DM53PV8	MI	DTUGYRD
DM53PV8	MN	P-glycoprotein 1 (ABCB1)
DM53PV8	MT	DTP
DM53PV8	MA	Substrate
DM53PV8	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM53PV8	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMSQVD6	DI	DMSQVD6
DMSQVD6	DN	Ceforanide
DMSQVD6	MI	TTJP4SM
DMSQVD6	MN	Bacterial Penicillin binding protein (Bact PBP)
DMSQVD6	MT	DTT
DMSQVD6	MA	Binder
DMSQVD6	RN	The pharmacokinetics of the interstitial space in humans. BMC Clin Pharmacol. 2003 Jul 30;3:3.
DMSQVD6	RU	https://pubmed.ncbi.nlm.nih.gov/12890292

DMEB837	DI	DMEB837
DMEB837	DN	Cefotaxime
DMEB837	MI	DE0TCN3
DMEB837	MN	Ampc beta-lactamase (ampC)
DMEB837	MT	DME
DMEB837	MA	Metabolism
DMEB837	RN	Cell wall recycling-linked coregulation of AmpC and PenB beta-lactamases through ampD mutations in Burkholderia cenocepacia. Antimicrob Agents Chemother. 2015 Dec;59(12):7602-10.
DMEB837	RU	https://pubmed.ncbi.nlm.nih.gov/26416862

DMMKHBJ	DI	DMMKHBJ
DMMKHBJ	DN	Cefotaxime
DMMKHBJ	MI	TTLP6GN
DMMKHBJ	MN	Bacterial DD-carboxypeptidase (Bact vanYB)
DMMKHBJ	MT	DTT
DMMKHBJ	MA	Inhibitor
DMMKHBJ	RN	Extended-spectrum cephalosporinases: structure, detection and epidemiology. Future Microbiol. 2007 Jun;2:297-307.
DMMKHBJ	RU	https://pubmed.ncbi.nlm.nih.gov/17661704

DMEB837	DI	DMEB837
DMEB837	DN	Cefotaxime
DMEB837	MI	DEAYSTX
DMEB837	MN	Beta-lactamase (blaB)
DMEB837	MT	DME
DMEB837	MA	Metabolism
DMEB837	RN	ACI-1 beta-lactamase is widespread across human gut microbiomes in Negativicutes due to transposons harboured by tailed prophages. Environ Microbiol. 2018 Jun;20(6):2288-2300.
DMEB837	RU	https://pubmed.ncbi.nlm.nih.gov/30014616

DMEB837	DI	DMEB837
DMEB837	DN	Cefotaxime
DMEB837	MI	DEITMS0
DMEB837	MN	Beta-lactamase (blaB)
DMEB837	MT	DME
DMEB837	MA	Metabolism
DMEB837	RN	ACI-1 from Acidaminococcus fermentans: characterization of the first beta-lactamase in Anaerobic cocci. Antimicrob Agents Chemother. 2000 Nov;44(11):3144-9.
DMEB837	RU	https://pubmed.ncbi.nlm.nih.gov/11036038

DMEB837	DI	DMEB837
DMEB837	DN	Cefotaxime
DMEB837	MI	DEP0IWS
DMEB837	MN	Beta-lactamase (blaB)
DMEB837	MT	DME
DMEB837	MA	Metabolism
DMEB837	RN	Analysis of the drug-resistant characteristics of Klebsiella pneumoniae isolated from the respiratory tract and CTX-M ESBL genes. Genet Mol Res. 2015 Oct 5;14(4):12043-8.
DMEB837	RU	https://pubmed.ncbi.nlm.nih.gov/26505351

DMEB837	DI	DMEB837
DMEB837	DN	Cefotaxime
DMEB837	MI	DEEAL81
DMEB837	MN	Beta-lactamase (blaB)
DMEB837	MT	DME
DMEB837	MA	Metabolism
DMEB837	RN	nan
DMEB837	RU	nan

DMEB837	DI	DMEB837
DMEB837	DN	Cefotaxime
DMEB837	MI	DE7IH52
DMEB837	MN	Beta-lactamase (blaB)
DMEB837	MT	DME
DMEB837	MA	Metabolism
DMEB837	RN	nan
DMEB837	RU	nan

DMEB837	DI	DMEB837
DMEB837	DN	Cefotaxime
DMEB837	MI	DE5HV8P
DMEB837	MN	Beta-lactamase (blaB)
DMEB837	MT	DME
DMEB837	MA	Metabolism
DMEB837	RN	Presence of the cfxA gene in Bacteroides distasonis. Res Microbiol. 2003 Jun;154(5):369-74.
DMEB837	RU	https://pubmed.ncbi.nlm.nih.gov/12837513

DMEB837	DI	DMEB837
DMEB837	DN	Cefotaxime
DMEB837	MI	DE47ARF
DMEB837	MN	Beta-lactamase (blaB)
DMEB837	MT	DME
DMEB837	MA	Metabolism
DMEB837	RN	Presence of the cfxA gene in Bacteroides distasonis. Res Microbiol. 2003 Jun;154(5):369-74.
DMEB837	RU	https://pubmed.ncbi.nlm.nih.gov/12837513

DMEB837	DI	DMEB837
DMEB837	DN	Cefotaxime
DMEB837	MI	DEHJVX4
DMEB837	MN	Beta-lactamase (blaB)
DMEB837	MT	DME
DMEB837	MA	Metabolism
DMEB837	RN	Presence of the cfxA gene in Bacteroides distasonis. Res Microbiol. 2003 Jun;154(5):369-74.
DMEB837	RU	https://pubmed.ncbi.nlm.nih.gov/12837513

DMEB837	DI	DMEB837
DMEB837	DN	Cefotaxime
DMEB837	MI	DEG2PK9
DMEB837	MN	Beta-lactamase (blaB)
DMEB837	MT	DME
DMEB837	MA	Metabolism
DMEB837	RN	Presence of the cfxA gene in Bacteroides distasonis. Res Microbiol. 2003 Jun;154(5):369-74.
DMEB837	RU	https://pubmed.ncbi.nlm.nih.gov/12837513

DMEB837	DI	DMEB837
DMEB837	DN	Cefotaxime
DMEB837	MI	DEWHJ7A
DMEB837	MN	Beta-lactamase (blaB)
DMEB837	MT	DME
DMEB837	MA	Metabolism
DMEB837	RN	nan
DMEB837	RU	nan

DMEB837	DI	DMEB837
DMEB837	DN	Cefotaxime
DMEB837	MI	DEU1RXB
DMEB837	MN	Beta-lactamase (blaB)
DMEB837	MT	DME
DMEB837	MA	Metabolism
DMEB837	RN	Presence of the cfxA gene in Bacteroides distasonis. Res Microbiol. 2003 Jun;154(5):369-74.
DMEB837	RU	https://pubmed.ncbi.nlm.nih.gov/12837513

DMEB837	DI	DMEB837
DMEB837	DN	Cefotaxime
DMEB837	MI	DEMIUB2
DMEB837	MN	Beta-lactamase (blaB)
DMEB837	MT	DME
DMEB837	MA	Metabolism
DMEB837	RN	Oral streptococcal strains isolated from odontogenic infections and their susceptibility to antibiotics. Rev Med Chir Soc Med Nat Iasi. 2006 Oct-Dec;110(4):1012-5.
DMEB837	RU	https://pubmed.ncbi.nlm.nih.gov/17438917

DMEB837	DI	DMEB837
DMEB837	DN	Cefotaxime
DMEB837	MI	DEYIEO5
DMEB837	MN	Beta-lactamase (blaB)
DMEB837	MT	DME
DMEB837	MA	Metabolism
DMEB837	RN	Determination of the antibiotic resistance rates of Serratia marcescens isolates obtained from various clinical specimens. Niger J Clin Pract. 2019 Jan;22(1):125-130.
DMEB837	RU	https://pubmed.ncbi.nlm.nih.gov/30666031

DMEB837	DI	DMEB837
DMEB837	DN	Cefotaxime
DMEB837	MI	DEVHXAU
DMEB837	MN	Beta-lactamase (blaB)
DMEB837	MT	DME
DMEB837	MA	Metabolism
DMEB837	RN	Cephalosporinases associated with outer membrane vesicles released by Bacteroides spp. protect gut pathogens and commensals against beta-lactam antibiotics. J Antimicrob Chemother. 2015 Mar;70(3):701-9.
DMEB837	RU	https://pubmed.ncbi.nlm.nih.gov/25433011

DMEB837	DI	DMEB837
DMEB837	DN	Cefotaxime
DMEB837	MI	DEZLFV5
DMEB837	MN	Beta-lactamase (blaB)
DMEB837	MT	DME
DMEB837	MA	Metabolism
DMEB837	RN	Cell wall recycling-linked coregulation of AmpC and PenB beta-lactamases through ampD mutations in Burkholderia cenocepacia. Antimicrob Agents Chemother. 2015 Dec;59(12):7602-10.
DMEB837	RU	https://pubmed.ncbi.nlm.nih.gov/26416862

DMEB837	DI	DMEB837
DMEB837	DN	Cefotaxime
DMEB837	MI	DE5AHG6
DMEB837	MN	Beta-lactamase (blaB)
DMEB837	MT	DME
DMEB837	MA	Metabolism
DMEB837	RN	Novel TEM-type extended-spectrum beta-lactamase, TEM-134, in a Citrobacter koseri clinical isolate. Antimicrob Agents Chemother. 2005 Apr;49(4):1564-6.
DMEB837	RU	https://pubmed.ncbi.nlm.nih.gov/15793140

DMEB837	DI	DMEB837
DMEB837	DN	Cefotaxime
DMEB837	MI	DEKGVS4
DMEB837	MN	Beta-lactamase (blaB)
DMEB837	MT	DME
DMEB837	MA	Metabolism
DMEB837	RN	Overcoming an extremely drug resistant (XDR) pathogen: avibactam restores susceptibility to ceftazidime for Burkholderia cepacia complex isolates from cystic fibrosis patients. ACS Infect Dis. 2017 Jul 14;3(7):502-511.
DMEB837	RU	https://pubmed.ncbi.nlm.nih.gov/28264560

DMEB837	DI	DMEB837
DMEB837	DN	Cefotaxime
DMEB837	MI	DE2ARDZ
DMEB837	MN	PenA beta-lactamase (penA1)
DMEB837	MT	DME
DMEB837	MA	Metabolism
DMEB837	RN	Characterization of the penA and penR genes of Burkholderia cepacia 249 which encode the chromosomal class A penicillinase and its LysR-type transcriptional regulator. Antimicrob Agents Chemother. 1997 Nov;41(11):2399-405.
DMEB837	RU	https://pubmed.ncbi.nlm.nih.gov/9371340

DM07TX3	DI	DM07TX3
DM07TX3	DN	Cefotetan
DM07TX3	MI	TTJP4SM
DM07TX3	MN	Bacterial Penicillin binding protein (Bact PBP)
DM07TX3	MT	DTT
DM07TX3	MA	Binder
DM07TX3	RN	In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect. 2007 Jun;13 Suppl 2:17-24.
DM07TX3	RU	https://pubmed.ncbi.nlm.nih.gov/17488372

DM07TX3	DI	DM07TX3
DM07TX3	DN	Cefotetan
DM07TX3	MI	DTUGYRD
DM07TX3	MN	P-glycoprotein 1 (ABCB1)
DM07TX3	MT	DTP
DM07TX3	MA	Substrate
DM07TX3	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM07TX3	RU	https://doi.org/10.1007/s11095-012-0935-x

DMF5HU6	DI	DMF5HU6
DMF5HU6	DN	Cefotiam
DMF5HU6	MI	TT85JMW
DMF5HU6	MN	Bacterial Penicillin binding protein 3 (Bact mrcA)
DMF5HU6	MT	DTT
DMF5HU6	MA	Binder
DMF5HU6	RN	Genetic analyses of beta-lactamase negative ampicillin-resistant strains of Haemophilus influenzae isolated in Okinawa, Japan. Jpn J Infect Dis. 2006 Feb;59(1):36-41.
DMF5HU6	RU	https://pubmed.ncbi.nlm.nih.gov/16495632

DMF5HU6	DI	DMF5HU6
DMF5HU6	DN	Cefotiam
DMF5HU6	MI	DTVP67E
DMF5HU6	MN	Organic anion transporter 3 (SLC22A8)
DMF5HU6	MT	DTP
DMF5HU6	MA	Substrate
DMF5HU6	RN	Adaptive responses of renal organic anion transporter 3 (OAT3) during cholestasis. Am J Physiol Renal Physiol. 2008 Jul;295(1):F247-52.
DMF5HU6	RU	http://www.ncbi.nlm.nih.gov/pubmed/18480179

DMYTXVR	DI	DMYTXVR
DMYTXVR	DN	Cefoxitin
DMYTXVR	MI	TTJP4SM
DMYTXVR	MN	Bacterial Penicillin binding protein (Bact PBP)
DMYTXVR	MT	DTT
DMYTXVR	MA	Binder
DMYTXVR	RN	Staphylococcus aureus PBP4 is essential for beta-lactam resistance in community-acquired methicillin-resistant strains. Antimicrob Agents Chemother. 2008 Nov;52(11):3955-66.
DMYTXVR	RU	https://pubmed.ncbi.nlm.nih.gov/18725435

DMY8NC4	DI	DMY8NC4
DMY8NC4	DN	Cefoxitin
DMY8NC4	MI	DEP0IWS
DMY8NC4	MN	Beta-lactamase (blaB)
DMY8NC4	MT	DME
DMY8NC4	MA	Metabolism
DMY8NC4	RN	Analysis of the drug-resistant characteristics of Klebsiella pneumoniae isolated from the respiratory tract and CTX-M ESBL genes. Genet Mol Res. 2015 Oct 5;14(4):12043-8.
DMY8NC4	RU	https://pubmed.ncbi.nlm.nih.gov/26505351

DMY8NC4	DI	DMY8NC4
DMY8NC4	DN	Cefoxitin
DMY8NC4	MI	DEEAL81
DMY8NC4	MN	Beta-lactamase (blaB)
DMY8NC4	MT	DME
DMY8NC4	MA	Metabolism
DMY8NC4	RN	nan
DMY8NC4	RU	nan

DMY8NC4	DI	DMY8NC4
DMY8NC4	DN	Cefoxitin
DMY8NC4	MI	DE7IH52
DMY8NC4	MN	Beta-lactamase (blaB)
DMY8NC4	MT	DME
DMY8NC4	MA	Metabolism
DMY8NC4	RN	Citrobacter freundii bacteremia: Risk factors of mortality and prevalence of resistance genes. J Microbiol Immunol Infect. 2018 Aug;51(4):565-572.
DMY8NC4	RU	https://pubmed.ncbi.nlm.nih.gov/28711438

DMY8NC4	DI	DMY8NC4
DMY8NC4	DN	Cefoxitin
DMY8NC4	MI	DE5HV8P
DMY8NC4	MN	Beta-lactamase (blaB)
DMY8NC4	MT	DME
DMY8NC4	MA	Metabolism
DMY8NC4	RN	Presence of the cfxA gene in Bacteroides distasonis. Res Microbiol. 2003 Jun;154(5):369-74.
DMY8NC4	RU	https://pubmed.ncbi.nlm.nih.gov/12837513

DMY8NC4	DI	DMY8NC4
DMY8NC4	DN	Cefoxitin
DMY8NC4	MI	DE47ARF
DMY8NC4	MN	Beta-lactamase (blaB)
DMY8NC4	MT	DME
DMY8NC4	MA	Metabolism
DMY8NC4	RN	Presence of the cfxA gene in Bacteroides distasonis. Res Microbiol. 2003 Jun;154(5):369-74.
DMY8NC4	RU	https://pubmed.ncbi.nlm.nih.gov/12837513

DMY8NC4	DI	DMY8NC4
DMY8NC4	DN	Cefoxitin
DMY8NC4	MI	DEHJVX4
DMY8NC4	MN	Beta-lactamase (blaB)
DMY8NC4	MT	DME
DMY8NC4	MA	Metabolism
DMY8NC4	RN	Presence of the cfxA gene in Bacteroides distasonis. Res Microbiol. 2003 Jun;154(5):369-74.
DMY8NC4	RU	https://pubmed.ncbi.nlm.nih.gov/12837513

DMY8NC4	DI	DMY8NC4
DMY8NC4	DN	Cefoxitin
DMY8NC4	MI	DEG2PK9
DMY8NC4	MN	Beta-lactamase (blaB)
DMY8NC4	MT	DME
DMY8NC4	MA	Metabolism
DMY8NC4	RN	Presence of the cfxA gene in Bacteroides distasonis. Res Microbiol. 2003 Jun;154(5):369-74.
DMY8NC4	RU	https://pubmed.ncbi.nlm.nih.gov/12837513

DMY8NC4	DI	DMY8NC4
DMY8NC4	DN	Cefoxitin
DMY8NC4	MI	DEWHJ7A
DMY8NC4	MN	Beta-lactamase (blaB)
DMY8NC4	MT	DME
DMY8NC4	MA	Metabolism
DMY8NC4	RN	Presence of the cfxA gene in Bacteroides distasonis. Res Microbiol. 2003 Jun;154(5):369-74.
DMY8NC4	RU	https://pubmed.ncbi.nlm.nih.gov/12837513

DMY8NC4	DI	DMY8NC4
DMY8NC4	DN	Cefoxitin
DMY8NC4	MI	DEU1RXB
DMY8NC4	MN	Beta-lactamase (blaB)
DMY8NC4	MT	DME
DMY8NC4	MA	Metabolism
DMY8NC4	RN	Presence of the cfxA gene in Bacteroides distasonis. Res Microbiol. 2003 Jun;154(5):369-74.
DMY8NC4	RU	https://pubmed.ncbi.nlm.nih.gov/12837513

DMY8NC4	DI	DMY8NC4
DMY8NC4	DN	Cefoxitin
DMY8NC4	MI	DEMIUB2
DMY8NC4	MN	Beta-lactamase (blaB)
DMY8NC4	MT	DME
DMY8NC4	MA	Metabolism
DMY8NC4	RN	Oral streptococcal strains isolated from odontogenic infections and their susceptibility to antibiotics. Rev Med Chir Soc Med Nat Iasi. 2006 Oct-Dec;110(4):1012-5.
DMY8NC4	RU	https://pubmed.ncbi.nlm.nih.gov/17438917

DMY8NC4	DI	DMY8NC4
DMY8NC4	DN	Cefoxitin
DMY8NC4	MI	DEQAG48
DMY8NC4	MN	Beta-lactamase (blaB)
DMY8NC4	MT	DME
DMY8NC4	MA	Metabolism
DMY8NC4	RN	Citrobacter koseri and Citrobacter amalonaticus isolates carry highly divergent beta-lactamase genes despite having high levels of biochemical similarity and 16S rRNA sequence homology. J Antimicrob Chemother. 2004 Jun;53(6):1076-80.
DMY8NC4	RU	https://pubmed.ncbi.nlm.nih.gov/15128725

DMY8NC4	DI	DMY8NC4
DMY8NC4	DN	Cefoxitin
DMY8NC4	MI	DEF01WC
DMY8NC4	MN	Beta-lactamase (blaB)
DMY8NC4	MT	DME
DMY8NC4	MA	Metabolism
DMY8NC4	RN	Beta-lactamase activity in Chromobacterium violaceum. J Infect Dis. 1976 Sep;134(3):290-3.
DMY8NC4	RU	https://pubmed.ncbi.nlm.nih.gov/977998

DMY8NC4	DI	DMY8NC4
DMY8NC4	DN	Cefoxitin
DMY8NC4	MI	DE5AHG6
DMY8NC4	MN	Beta-lactamase (blaB)
DMY8NC4	MT	DME
DMY8NC4	MA	Metabolism
DMY8NC4	RN	Citrobacter koseri and Citrobacter amalonaticus isolates carry highly divergent beta-lactamase genes despite having high levels of biochemical similarity and 16S rRNA sequence homology. J Antimicrob Chemother. 2004 Jun;53(6):1076-80.
DMY8NC4	RU	https://pubmed.ncbi.nlm.nih.gov/15128725

DMYTXVR	DI	DMYTXVR
DMYTXVR	DN	Cefoxitin
DMYTXVR	MI	DT9G7XN
DMYTXVR	MN	Peptide transporter 1 (SLC15A1)
DMYTXVR	MT	DTP
DMYTXVR	MA	Substrate
DMYTXVR	RN	Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. J Med Chem. 2005 Jun 30;48(13):4410-9.
DMYTXVR	RU	http://www.ncbi.nlm.nih.gov/pubmed/15974593

DMKBTFG	DI	DMKBTFG
DMKBTFG	DN	Cefozopran
DMKBTFG	MI	TT4ILYC
DMKBTFG	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMKBTFG	MT	DTT
DMKBTFG	MA	Inhibitor
DMKBTFG	RN	Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
DMKBTFG	RU	https://pubmed.ncbi.nlm.nih.gov/15934867

DMZ2WL4	DI	DMZ2WL4
DMZ2WL4	DN	Cefpiramide
DMZ2WL4	MI	TTJP4SM
DMZ2WL4	MN	Bacterial Penicillin binding protein (Bact PBP)
DMZ2WL4	MT	DTT
DMZ2WL4	MA	Binder
DMZ2WL4	RN	Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
DMZ2WL4	RU	https://pubmed.ncbi.nlm.nih.gov/17016423

DMJUNY5	DI	DMJUNY5
DMJUNY5	DN	Cefpodoxime
DMJUNY5	MI	TTJP4SM
DMJUNY5	MN	Bacterial Penicillin binding protein (Bact PBP)
DMJUNY5	MT	DTT
DMJUNY5	MA	Binder
DMJUNY5	RN	Amino acid substitutions in mosaic penicillin-binding protein 2 associated with reduced susceptibility to cefixime in clinical isolates of Neisseri... Antimicrob Agents Chemother. 2006 Nov;50(11):3638-45.
DMJUNY5	RU	https://pubmed.ncbi.nlm.nih.gov/16940068

DMJUNY5	DI	DMJUNY5
DMJUNY5	DN	Cefpodoxime
DMJUNY5	MI	DEQAG48
DMJUNY5	MN	Beta-lactamase (blaB)
DMJUNY5	MT	DME
DMJUNY5	MA	Metabolism
DMJUNY5	RN	Low-virulence Citrobacter species encode resistance to multiple antimicrobials. Antimicrob Agents Chemother. 2002 Nov;46(11):3555-60.
DMJUNY5	RU	https://pubmed.ncbi.nlm.nih.gov/12384364

DMJUNY5	DI	DMJUNY5
DMJUNY5	DN	Cefpodoxime
DMJUNY5	MI	DEEQ3RW
DMJUNY5	MN	Beta-lactamase (blaB)
DMJUNY5	MT	DME
DMJUNY5	MA	Metabolism
DMJUNY5	RN	Low-virulence Citrobacter species encode resistance to multiple antimicrobials. Antimicrob Agents Chemother. 2002 Nov;46(11):3555-60.
DMJUNY5	RU	https://pubmed.ncbi.nlm.nih.gov/12384364

DMJUNY5	DI	DMJUNY5
DMJUNY5	DN	Cefpodoxime
DMJUNY5	MI	DT9G7XN
DMJUNY5	MN	Peptide transporter 1 (SLC15A1)
DMJUNY5	MT	DTP
DMJUNY5	MA	Substrate
DMJUNY5	RN	Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. J Med Chem. 2005 Jun 30;48(13):4410-9.
DMJUNY5	RU	http://www.ncbi.nlm.nih.gov/pubmed/15974593

DM7DSYP	DI	DM7DSYP
DM7DSYP	DN	Cefprozil
DM7DSYP	MI	TTJP4SM
DM7DSYP	MN	Bacterial Penicillin binding protein (Bact PBP)
DM7DSYP	MT	DTT
DM7DSYP	MA	Binder
DM7DSYP	RN	Microbiology and antimicrobial management of sinusitis. J Laryngol Otol. 2005 Apr;119(4):251-8.
DM7DSYP	RU	https://pubmed.ncbi.nlm.nih.gov/15949076

DMUNSWV	DI	DMUNSWV
DMUNSWV	DN	Cefradine
DMUNSWV	MI	TTJP4SM
DMUNSWV	MN	Bacterial Penicillin binding protein (Bact PBP)
DMUNSWV	MT	DTT
DMUNSWV	MA	Binder
DMUNSWV	RN	Staphylococcus aureus PBP4 is essential for beta-lactam resistance in community-acquired methicillin-resistant strains. Antimicrob Agents Chemother. 2008 Nov;52(11):3955-66.
DMUNSWV	RU	https://pubmed.ncbi.nlm.nih.gov/18725435

DMUNSWV	DI	DMUNSWV
DMUNSWV	DN	Cefradine
DMUNSWV	MI	DT9G7XN
DMUNSWV	MN	Peptide transporter 1 (SLC15A1)
DMUNSWV	MT	DTP
DMUNSWV	MA	Substrate
DMUNSWV	RN	Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells. Am J Physiol. 1997 Nov;273(5 Pt 2):F706-11.
DMUNSWV	RU	http://www.ncbi.nlm.nih.gov/pubmed/9374833

DMUNSWV	DI	DMUNSWV
DMUNSWV	DN	Cefradine
DMUNSWV	MI	DT8QKNP
DMUNSWV	MN	Peptide transporter 2 (SLC15A2)
DMUNSWV	MT	DTP
DMUNSWV	MA	Substrate
DMUNSWV	RN	Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60.
DMUNSWV	RU	http://www.ncbi.nlm.nih.gov/pubmed/16597710

DMQXLF3	DI	DMQXLF3
DMQXLF3	DN	Cefsulodin
DMQXLF3	MI	DT9G7XN
DMQXLF3	MN	Peptide transporter 1 (SLC15A1)
DMQXLF3	MT	DTP
DMQXLF3	MA	Substrate
DMQXLF3	RN	Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res. 1999 Jan;16(1):55-61.
DMQXLF3	RU	https://doi.org/10.1023/A:1018814627484

DM41GRA	DI	DM41GRA
DM41GRA	DN	Ceftazidime
DM41GRA	MI	TTJP4SM
DM41GRA	MN	Bacterial Penicillin binding protein (Bact PBP)
DM41GRA	MT	DTT
DM41GRA	MA	Binder
DM41GRA	RN	New and emerging treatment of Staphylococcus aureus infections in the hospital setting. Clin Microbiol Infect. 2008 Apr;14 Suppl 3:32-41.
DM41GRA	RU	https://pubmed.ncbi.nlm.nih.gov/18318877

DMWV2AG	DI	DMWV2AG
DMWV2AG	DN	Ceftibuten
DMWV2AG	MI	TTJP4SM
DMWV2AG	MN	Bacterial Penicillin binding protein (Bact PBP)
DMWV2AG	MT	DTT
DMWV2AG	MA	Binder
DMWV2AG	RN	Neisseria gonorrhoeae and emerging resistance to extended spectrum cephalosporins. Curr Opin Infect Dis. 2009 Feb;22(1):87-91.
DMWV2AG	RU	https://pubmed.ncbi.nlm.nih.gov/19532086

DMWV2AG	DI	DMWV2AG
DMWV2AG	DN	Ceftibuten
DMWV2AG	MI	DT9G7XN
DMWV2AG	MN	Peptide transporter 1 (SLC15A1)
DMWV2AG	MT	DTP
DMWV2AG	MA	Substrate
DMWV2AG	RN	Increased protein level of PEPT1 intestinal H+-peptide cotransporter upregulates absorption of glycylsarcosine and ceftibuten in 5/6 nephrectomized rats. Am J Physiol Gastrointest Liver Physiol. 2005 Apr;288(4):G664-70.
DMWV2AG	RU	http://www.ncbi.nlm.nih.gov/pubmed/15528259

DMWV2AG	DI	DMWV2AG
DMWV2AG	DN	Ceftibuten
DMWV2AG	MI	DT8QKNP
DMWV2AG	MN	Peptide transporter 2 (SLC15A2)
DMWV2AG	MT	DTP
DMWV2AG	MA	Substrate
DMWV2AG	RN	Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60.
DMWV2AG	RU	http://www.ncbi.nlm.nih.gov/pubmed/16597710

DMR2SOZ	DI	DMR2SOZ
DMR2SOZ	DN	Ceftiofur
DMR2SOZ	MI	DE3FVRW
DMR2SOZ	MN	Beta-lactamase (blaB)
DMR2SOZ	MT	DME
DMR2SOZ	MA	Metabolism
DMR2SOZ	RN	The bacterial degradation of chloramphenico. Lancet. 1967 Jun 10;1(7502):1259-60.
DMR2SOZ	RU	https://pubmed.ncbi.nlm.nih.gov/4165044

DMR2SOZ	DI	DMR2SOZ
DMR2SOZ	DN	Ceftiofur
DMR2SOZ	MI	DEYM2D3
DMR2SOZ	MN	Beta-lactamase (blaB)
DMR2SOZ	MT	DME
DMR2SOZ	MA	Metabolism
DMR2SOZ	RN	Bovine intestinal bacteria inactivate and degrade ceftiofur and ceftriaxone with multiple beta-lactamases. Antimicrob Agents Chemother. 2011 Nov;55(11):4990-8.
DMR2SOZ	RU	https://pubmed.ncbi.nlm.nih.gov/21876048

DMR2SOZ	DI	DMR2SOZ
DMR2SOZ	DN	Ceftiofur
DMR2SOZ	MI	DE9ZQ3L
DMR2SOZ	MN	Beta-lactamase (blaB)
DMR2SOZ	MT	DME
DMR2SOZ	MA	Metabolism
DMR2SOZ	RN	Bovine intestinal bacteria inactivate and degrade ceftiofur and ceftriaxone with multiple beta-lactamases. Antimicrob Agents Chemother. 2011 Nov;55(11):4990-8.
DMR2SOZ	RU	https://pubmed.ncbi.nlm.nih.gov/21876048

DMR2SOZ	DI	DMR2SOZ
DMR2SOZ	DN	Ceftiofur
DMR2SOZ	MI	DE69OXF
DMR2SOZ	MN	Beta-lactamase (blaB)
DMR2SOZ	MT	DME
DMR2SOZ	MA	Metabolism
DMR2SOZ	RN	Bovine intestinal bacteria inactivate and degrade ceftiofur and ceftriaxone with multiple beta-lactamases. Antimicrob Agents Chemother. 2011 Nov;55(11):4990-8.
DMR2SOZ	RU	https://pubmed.ncbi.nlm.nih.gov/21876048

DMR2SOZ	DI	DMR2SOZ
DMR2SOZ	DN	Ceftiofur
DMR2SOZ	MI	DEPYGS9
DMR2SOZ	MN	Beta-lactamase (blaB)
DMR2SOZ	MT	DME
DMR2SOZ	MA	Metabolism
DMR2SOZ	RN	Bovine intestinal bacteria inactivate and degrade ceftiofur and ceftriaxone with multiple beta-lactamases. Antimicrob Agents Chemother. 2011 Nov;55(11):4990-8.
DMR2SOZ	RU	https://pubmed.ncbi.nlm.nih.gov/21876048

DMR2SOZ	DI	DMR2SOZ
DMR2SOZ	DN	Ceftiofur
DMR2SOZ	MI	DEPGFHV
DMR2SOZ	MN	Beta-lactamase (blaB)
DMR2SOZ	MT	DME
DMR2SOZ	MA	Metabolism
DMR2SOZ	RN	Isolation of bacterial strains from bovine fecal microflora capable of degradation of ceftiofur. Vet Microbiol. 2009 Oct 20;139(1-2):89-96.
DMR2SOZ	RU	https://pubmed.ncbi.nlm.nih.gov/19428193

DMR2SOZ	DI	DMR2SOZ
DMR2SOZ	DN	Ceftiofur
DMR2SOZ	MI	DENZLGX
DMR2SOZ	MN	Beta-lactamase (blaB)
DMR2SOZ	MT	DME
DMR2SOZ	MA	Metabolism
DMR2SOZ	RN	Isolation of bacterial strains from bovine fecal microflora capable of degradation of ceftiofur. Vet Microbiol. 2009 Oct 20;139(1-2):89-96.
DMR2SOZ	RU	https://pubmed.ncbi.nlm.nih.gov/19428193

DMR2SOZ	DI	DMR2SOZ
DMR2SOZ	DN	Ceftiofur
DMR2SOZ	MI	DEZAQPD
DMR2SOZ	MN	Beta-lactamase (blaB)
DMR2SOZ	MT	DME
DMR2SOZ	MA	Metabolism
DMR2SOZ	RN	Isolation of bacterial strains from bovine fecal microflora capable of degradation of ceftiofur. Vet Microbiol. 2009 Oct 20;139(1-2):89-96.
DMR2SOZ	RU	https://pubmed.ncbi.nlm.nih.gov/19428193

DM3VOGS	DI	DM3VOGS
DM3VOGS	DN	Ceftizoxime
DM3VOGS	MI	TTJP4SM
DM3VOGS	MN	Bacterial Penicillin binding protein (Bact PBP)
DM3VOGS	MT	DTT
DM3VOGS	MA	Binder
DM3VOGS	RN	Role of penicillin-binding protein 2 (PBP2) in the antibiotic susceptibility and cell wall cross-linking of Staphylococcus aureus: evidence for the cooperative functioning of PBP2, PBP4, and PBP2A. JBacteriol. 2005 Mar;187(5):1815-24.
DM3VOGS	RU	https://pubmed.ncbi.nlm.nih.gov/15716453

DM3VOGS	DI	DM3VOGS
DM3VOGS	DN	Ceftizoxime
DM3VOGS	MI	DTCSGPB
DM3VOGS	MN	Multidrug resistance-associated protein 4 (ABCC4)
DM3VOGS	MT	DTP
DM3VOGS	MA	Substrate
DM3VOGS	RN	Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos. 2012 Mar;40(3):515-21.
DM3VOGS	RU	http://www.ncbi.nlm.nih.gov/pubmed/22166395

DM3VOGS	DI	DM3VOGS
DM3VOGS	DN	Ceftizoxime
DM3VOGS	MI	DTQ23VB
DM3VOGS	MN	Organic anion transporter 1 (SLC22A6)
DM3VOGS	MT	DTP
DM3VOGS	MA	Substrate
DM3VOGS	RN	FDA Drug Development and Drug Interactions
DM3VOGS	RU	https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2

DM3VOGS	DI	DM3VOGS
DM3VOGS	DN	Ceftizoxime
DM3VOGS	MI	DTVP67E
DM3VOGS	MN	Organic anion transporter 3 (SLC22A8)
DM3VOGS	MT	DTP
DM3VOGS	MA	Substrate
DM3VOGS	RN	Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. Biochem Pharmacol. 2005 Oct 1;70(7):1104-13.
DM3VOGS	RU	http://www.ncbi.nlm.nih.gov/pubmed/16098483

DM9QWAH	DI	DM9QWAH
DM9QWAH	DN	Ceftolozane/tazobactam
DM9QWAH	MI	TTHI19T
DM9QWAH	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DM9QWAH	MT	DTT
DM9QWAH	MA	Modulator
DM9QWAH	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DM9QWAH	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMCEW64	DI	DMCEW64
DMCEW64	DN	Ceftriaxone
DMCEW64	MI	TTJP4SM
DMCEW64	MN	Bacterial Penicillin binding protein (Bact PBP)
DMCEW64	MT	DTT
DMCEW64	MA	Modulator
DMCEW64	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMCEW64	RU	https://www.fda.gov/

DMCEW64	DI	DMCEW64
DMCEW64	DN	Ceftriaxone
DMCEW64	MI	DEEAL81
DMCEW64	MN	Beta-lactamase (blaB)
DMCEW64	MT	DME
DMCEW64	MA	Metabolism
DMCEW64	RN	Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe. J Antimicrob Chemother. 1996 Sep;38(3):409-24.
DMCEW64	RU	https://pubmed.ncbi.nlm.nih.gov/8889716

DMCEW64	DI	DMCEW64
DMCEW64	DN	Ceftriaxone
DMCEW64	MI	DEYIEO5
DMCEW64	MN	Beta-lactamase (blaB)
DMCEW64	MT	DME
DMCEW64	MA	Metabolism
DMCEW64	RN	Determination of the antibiotic resistance rates of Serratia marcescens isolates obtained from various clinical specimens. Niger J Clin Pract. 2019 Jan;22(1):125-130.
DMCEW64	RU	https://pubmed.ncbi.nlm.nih.gov/30666031

DMCEW64	DI	DMCEW64
DMCEW64	DN	Ceftriaxone
DMCEW64	MI	DEBKS91
DMCEW64	MN	Beta-lactamase (blaB)
DMCEW64	MT	DME
DMCEW64	MA	Metabolism
DMCEW64	RN	Drug-resistant genes carried by Acinetobacter baumanii isolated from patients with lower respiratory tract infection. Chin Med J (Engl). 2010 Sep;123(18):2571-5.
DMCEW64	RU	https://pubmed.ncbi.nlm.nih.gov/21034630

DMCEW64	DI	DMCEW64
DMCEW64	DN	Ceftriaxone
DMCEW64	MI	DTFI42L
DMCEW64	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMCEW64	MT	DTP
DMCEW64	MA	Substrate
DMCEW64	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMCEW64	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMCEW64	DI	DMCEW64
DMCEW64	DN	Ceftriaxone
DMCEW64	MI	DT9C1TS
DMCEW64	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMCEW64	MT	DTP
DMCEW64	MA	Substrate
DMCEW64	RN	Screening of antibiotics that interact with organic anion-transporting polypeptides 1B1 and 1B3 using fluorescent probes. Biol Pharm Bull. 2011;34(3):389-95.
DMCEW64	RU	http://www.ncbi.nlm.nih.gov/pubmed/21372390

DMCEW64	DI	DMCEW64
DMCEW64	DN	Ceftriaxone
DMCEW64	MI	DT9G7XN
DMCEW64	MN	Peptide transporter 1 (SLC15A1)
DMCEW64	MT	DTP
DMCEW64	MA	Substrate
DMCEW64	RN	Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res. 1999 Jan;16(1):55-61.
DMCEW64	RU	https://doi.org/10.1023/A:1018814627484

DMCEW64	DI	DMCEW64
DMCEW64	DN	Ceftriaxone
DMCEW64	MI	DTUGYRD
DMCEW64	MN	P-glycoprotein 1 (ABCB1)
DMCEW64	MT	DTP
DMCEW64	MA	Substrate
DMCEW64	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMCEW64	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMSIMD8	DI	DMSIMD8
DMSIMD8	DN	Cefuroxime
DMSIMD8	MI	TTJP4SM
DMSIMD8	MN	Bacterial Penicillin binding protein (Bact PBP)
DMSIMD8	MT	DTT
DMSIMD8	MA	Binder
DMSIMD8	RN	Cefuroxime resistance in non-beta-lactamase Haemophilus influenzae is linked to mutations in ftsI. J Antimicrob Chemother. 2003 Mar;51(3):523-30.
DMSIMD8	RU	https://pubmed.ncbi.nlm.nih.gov/12615852

DM4CHN0	DI	DM4CHN0
DM4CHN0	DN	Cefuroxime axetil
DM4CHN0	MI	DT9G7XN
DM4CHN0	MN	Peptide transporter 1 (SLC15A1)
DM4CHN0	MT	DTP
DM4CHN0	MA	Substrate
DM4CHN0	RN	Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res. 1999 Jan;16(1):55-61.
DM4CHN0	RU	https://doi.org/10.1023/A:1018814627484

DM6LOQU	DI	DM6LOQU
DM6LOQU	DN	Celecoxib
DM6LOQU	MI	DES5XRU
DM6LOQU	MN	Cytochrome P450 2C8 (CYP2C8)
DM6LOQU	MT	DME
DM6LOQU	MA	Metabolism
DM6LOQU	RN	Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics. 2009 Sep;10(9):1489-510.
DM6LOQU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19761371

DM6LOQU	DI	DM6LOQU
DM6LOQU	DN	Celecoxib
DM6LOQU	MI	DE5IED8
DM6LOQU	MN	Cytochrome P450 2C9 (CYP2C9)
DM6LOQU	MT	DME
DM6LOQU	MA	Metabolism
DM6LOQU	RN	Drug interactions in dentistry: the importance of knowing your CYPs. J Am Dent Assoc. 2004 Mar;135(3):298-311.
DM6LOQU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15058617

DM6LOQU	DI	DM6LOQU
DM6LOQU	DN	Celecoxib
DM6LOQU	MI	DECB0K3
DM6LOQU	MN	Cytochrome P450 2D6 (CYP2D6)
DM6LOQU	MT	DME
DM6LOQU	MA	Metabolism
DM6LOQU	RN	Celecoxib is a substrate of CYP2D6: impact on celecoxib metabolism in individuals with CYP2C9*3 variants. Drug Metab Pharmacokinet. 2018 Oct;33(5):219-227.
DM6LOQU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30219715

DM6LOQU	DI	DM6LOQU
DM6LOQU	DN	Celecoxib
DM6LOQU	MI	DE4LYSA
DM6LOQU	MN	Cytochrome P450 3A4 (CYP3A4)
DM6LOQU	MT	DME
DM6LOQU	MA	Metabolism
DM6LOQU	RN	Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. J Pharmacol Exp Ther. 2000 May;293(2):453-9.
DM6LOQU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10773015

DM6LOQU	DI	DM6LOQU
DM6LOQU	DN	Celecoxib
DM6LOQU	MI	TTVKILB
DM6LOQU	MN	Prostaglandin G/H synthase 2 (COX-2)
DM6LOQU	MT	DTT
DM6LOQU	MA	Inhibitor
DM6LOQU	RN	Pfizer. Product Development Pipeline. March 31 2009.
DM6LOQU	RU	http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf

DM6LOQU	DI	DM6LOQU
DM6LOQU	DN	Celecoxib
DM6LOQU	MI	DEYWLRK
DM6LOQU	MN	Sulfotransferase 1A1 (SULT1A1)
DM6LOQU	MT	DME
DM6LOQU	MA	Metabolism
DM6LOQU	RN	Sulfonation of 17beta-estradiol and inhibition of sulfotransferase activity by polychlorobiphenylols and celecoxib in channel catfish, Ictalurus punctatus. Aquat Toxicol. 2007 Mar 10;81(3):286-92.
DM6LOQU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17239972

DMD5LBX	DI	DMD5LBX
DMD5LBX	DN	Celiprolol HCL
DMD5LBX	MI	TTVIREA
DMD5LBX	MN	Adrenergic receptor (ADR)
DMD5LBX	MT	DTT
DMD5LBX	MA	Modulator
DMD5LBX	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMD5LBX	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DMD5LBX	DI	DMD5LBX
DMD5LBX	DN	Celiprolol HCL
DMD5LBX	MI	DTE2B1D
DMD5LBX	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMD5LBX	MT	DTP
DMD5LBX	MA	Substrate
DMD5LBX	RN	Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. J Pharm Sci. 2009 Jul;98(7):2529-39.
DMD5LBX	RU	http://www.ncbi.nlm.nih.gov/pubmed/19067419

DMD5LBX	DI	DMD5LBX
DMD5LBX	DN	Celiprolol HCL
DMD5LBX	MI	DTUGYRD
DMD5LBX	MN	P-glycoprotein 1 (ABCB1)
DMD5LBX	MT	DTP
DMD5LBX	MA	Substrate
DMD5LBX	RN	Relationship between urinary sodium excretion and pioglitazone-induced edema. J Diabetes Investig. 2010 Oct 19;1(5):208-11.
DMD5LBX	RU	https://doi.org/10.1111/j.2042-7158.1996.tb05904.x

DMYT2FP	DI	DMYT2FP
DMYT2FP	DN	Cellulose Sodium Phosphate
DMYT2FP	MI	TT8X5NO
DMYT2FP	MN	Calcium (Ca)
DMYT2FP	MT	DTT
DMYT2FP	MA	Modulator
DMYT2FP	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMYT2FP	RU	https://www.fda.gov/

DMTIUFA	DI	DMTIUFA
DMTIUFA	DN	Celtura
DMTIUFA	MI	TT3J5ZI
DMTIUFA	MN	Cell mediated immunity response (CMIR)
DMTIUFA	MT	DTT
DMTIUFA	RN	A prospective observational safety study on MF59( ) adjuvanted cell culture-derived vaccine, Celtura( ) during the A/H1N1 (2009) influenza pandemic. Vaccine. 2012 Oct 5;30(45):6436-43.
DMTIUFA	RU	https://pubmed.ncbi.nlm.nih.gov/22902681

DMKMJHE	DI	DMKMJHE
DMKMJHE	DN	Cemiplimab
DMKMJHE	MI	TTNBFWK
DMKMJHE	MN	Programmed cell death protein 1 (PD-1)
DMKMJHE	MT	DTT
DMKMJHE	MA	Modulator
DMKMJHE	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMKMJHE	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DM8Y2RU	DI	DM8Y2RU
DM8Y2RU	DN	Cenegermin
DM8Y2RU	MI	TTEDJN4
DM8Y2RU	MN	Low-affinity nerve growth factor receptor (NGFR)
DM8Y2RU	MT	DTT
DM8Y2RU	MA	Agonist
DM8Y2RU	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DM8Y2RU	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMXQS7K	DI	DMXQS7K
DMXQS7K	DN	Cenestin
DMXQS7K	MI	TTZAYWL
DMXQS7K	MN	Estrogen receptor (ESR)
DMXQS7K	MT	DTT
DMXQS7K	MA	Agonist
DMXQS7K	RN	Estrogen replacement therapy and cardioprotection: mechanisms and controversies. Braz J Med Biol Res. 2002 Mar;35(3):271-6.
DMXQS7K	RU	https://pubmed.ncbi.nlm.nih.gov/11887204

DM8KLU9	DI	DM8KLU9
DM8KLU9	DN	Cenobamate
DM8KLU9	MI	DEJVYAZ
DM8KLU9	MN	Cytochrome P450 2A6 (CYP2A6)
DM8KLU9	MT	DME
DM8KLU9	MA	Metabolism
DM8KLU9	RN	FDA label of Cenobamate. The 2020 official website of the U.S. Food and Drug Administration.
DM8KLU9	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf

DM8KLU9	DI	DM8KLU9
DM8KLU9	DN	Cenobamate
DM8KLU9	MI	DEPKLMQ
DM8KLU9	MN	Cytochrome P450 2B6 (CYP2B6)
DM8KLU9	MT	DME
DM8KLU9	MA	Metabolism
DM8KLU9	RN	FDA label of Cenobamate. The 2020 official website of the U.S. Food and Drug Administration.
DM8KLU9	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf

DM8KLU9	DI	DM8KLU9
DM8KLU9	DN	Cenobamate
DM8KLU9	MI	DEVDYN7
DM8KLU9	MN	Cytochrome P450 2E1 (CYP2E1)
DM8KLU9	MT	DME
DM8KLU9	MA	Metabolism
DM8KLU9	RN	FDA label of Cenobamate. The 2020 official website of the U.S. Food and Drug Administration.
DM8KLU9	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf

DM8KLU9	DI	DM8KLU9
DM8KLU9	DN	Cenobamate
DM8KLU9	MI	DE4LYSA
DM8KLU9	MN	Cytochrome P450 3A4 (CYP3A4)
DM8KLU9	MT	DME
DM8KLU9	MA	Metabolism
DM8KLU9	RN	FDA label of Cenobamate. The 2020 official website of the U.S. Food and Drug Administration.
DM8KLU9	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf

DM8KLU9	DI	DM8KLU9
DM8KLU9	DN	Cenobamate
DM8KLU9	MI	DEIBDNY
DM8KLU9	MN	Cytochrome P450 3A5 (CYP3A5)
DM8KLU9	MT	DME
DM8KLU9	MA	Metabolism
DM8KLU9	RN	FDA label of Cenobamate. The 2020 official website of the U.S. Food and Drug Administration.
DM8KLU9	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf

DM8KLU9	DI	DM8KLU9
DM8KLU9	DN	Cenobamate
DM8KLU9	MI	DEGTFWK
DM8KLU9	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM8KLU9	MT	DME
DM8KLU9	MA	Metabolism
DM8KLU9	RN	FDA label of Cenobamate. The 2020 official website of the U.S. Food and Drug Administration.
DM8KLU9	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf

DM8KLU9	DI	DM8KLU9
DM8KLU9	DN	Cenobamate
DM8KLU9	MI	DEB3CV1
DM8KLU9	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DM8KLU9	MT	DME
DM8KLU9	MA	Metabolism
DM8KLU9	RN	FDA label of Cenobamate. The 2020 official website of the U.S. Food and Drug Administration.
DM8KLU9	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf

DMGOVHA	DI	DMGOVHA
DMGOVHA	DN	Cenobamate
DMGOVHA	MI	TTIG65Q
DMGOVHA	MN	Voltage-gated sodium channel (Nav)
DMGOVHA	MT	DTT
DMGOVHA	MA	Inhibitor
DMGOVHA	RN	Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons. Eur J Pharmacol. 2019 Jul 15;855:175-182.
DMGOVHA	RU	https://pubmed.ncbi.nlm.nih.gov/31063770

DMD5JU8	DI	DMD5JU8
DMD5JU8	DN	Cephalexin
DMD5JU8	MI	TTJP4SM
DMD5JU8	MN	Bacterial Penicillin binding protein (Bact PBP)
DMD5JU8	MT	DTT
DMD5JU8	MA	Binder
DMD5JU8	RN	Relationship between penicillin-binding protein patterns and beta-lactamases in clinical isolates of Bacteroides fragilis with different susceptibility to beta-lactam antibiotics. J Med Microbiol. 2004 Mar;53(Pt 3):213-21.
DMD5JU8	RU	https://pubmed.ncbi.nlm.nih.gov/14970246

DMD5JU8	DI	DMD5JU8
DMD5JU8	DN	Cephalexin
DMD5JU8	MI	DECB0K3
DMD5JU8	MN	Cytochrome P450 2D6 (CYP2D6)
DMD5JU8	MT	DME
DMD5JU8	MA	Metabolism
DMD5JU8	RN	Population pharmacokinetic analysis of mirtazapine. Eur J Clin Pharmacol. 2004 Sep;60(7):473-80.
DMD5JU8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15289959

DMD5JU8	DI	DMD5JU8
DMD5JU8	DN	Cephalexin
DMD5JU8	MI	DE4LYSA
DMD5JU8	MN	Cytochrome P450 3A4 (CYP3A4)
DMD5JU8	MT	DME
DMD5JU8	MA	Metabolism
DMD5JU8	RN	Transport and metabolic characterization of Caco-2 cells expressing CYP3A4 and CYP3A4 plus oxidoreductase. Pharm Res. 1999 Sep;16(9):1352-9.
DMD5JU8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10496649

DMD5JU8	DI	DMD5JU8
DMD5JU8	DN	Cephalexin
DMD5JU8	MI	DTZGT0P
DMD5JU8	MN	Multidrug and toxin extrusion protein 1 (SLC47A1)
DMD5JU8	MT	DTP
DMD5JU8	MA	Substrate
DMD5JU8	RN	Reduced renal clearance of a zwitterionic substrate cephalexin in MATE1-deficient mice. J Pharmacol Exp Ther. 2010 Aug;334(2):651-6.
DMD5JU8	RU	http://www.ncbi.nlm.nih.gov/pubmed/20484555

DMD5JU8	DI	DMD5JU8
DMD5JU8	DN	Cephalexin
DMD5JU8	MI	DEIU0XN
DMD5JU8	MN	N-acylhomoserine lactone acylase (lacA)
DMD5JU8	MT	DME
DMD5JU8	MA	Metabolism
DMD5JU8	RN	A novel quorum-quenching N-acylhomoserine lactone acylase from Acidovorax sp. strain MR-S7 mediates antibiotic resistance. Appl Environ Microbiol. 2017 Jun 16;83(13). pii: e00080-17.
DMD5JU8	RU	https://pubmed.ncbi.nlm.nih.gov/28455333

DMD5JU8	DI	DMD5JU8
DMD5JU8	DN	Cephalexin
DMD5JU8	MI	DT9G7XN
DMD5JU8	MN	Peptide transporter 1 (SLC15A1)
DMD5JU8	MT	DTP
DMD5JU8	MA	Substrate
DMD5JU8	RN	Direct evidence for efficient transport and minimal metabolism of L-cephalexin by oligopeptide transporter 1 in budded baculovirus fraction. Biol Pharm Bull. 2009 Aug;32(8):1459-61.
DMD5JU8	RU	http://www.ncbi.nlm.nih.gov/pubmed/19652390

DMD5JU8	DI	DMD5JU8
DMD5JU8	DN	Cephalexin
DMD5JU8	MI	DT8QKNP
DMD5JU8	MN	Peptide transporter 2 (SLC15A2)
DMD5JU8	MT	DTP
DMD5JU8	MA	Substrate
DMD5JU8	RN	Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60.
DMD5JU8	RU	http://www.ncbi.nlm.nih.gov/pubmed/16597710

DMYZITL	DI	DMYZITL
DMYZITL	DN	Cephaloglycin
DMYZITL	MI	TTJP4SM
DMYZITL	MN	Bacterial Penicillin binding protein (Bact PBP)
DMYZITL	MT	DTT
DMYZITL	MA	Modulator
DMYZITL	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMYZITL	RU	https://www.fda.gov/

DMYZITL	DI	DMYZITL
DMYZITL	DN	Cephaloglycin
DMYZITL	MI	DT9G7XN
DMYZITL	MN	Peptide transporter 1 (SLC15A1)
DMYZITL	MT	DTP
DMYZITL	MA	Substrate
DMYZITL	RN	Pharmaceutical and pharmacological importance of peptide transporters. J Pharm Pharmacol. 2008 May;60(5):543-85.
DMYZITL	RU	https://doi.org/10.1211/jpp.60.5.0002

DM79XDW	DI	DM79XDW
DM79XDW	DN	Cephalosporin
DM79XDW	MI	TTLP6GN
DM79XDW	MN	Bacterial DD-carboxypeptidase (Bact vanYB)
DM79XDW	MT	DTT
DM79XDW	MA	Binder
DM79XDW	RN	A 1.2-A snapshot of the final step of bacterial cell wall biosynthesis. Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1427-31.
DM79XDW	RU	https://pubmed.ncbi.nlm.nih.gov/11171967

DM79XDW	DI	DM79XDW
DM79XDW	DN	Cephalosporin
DM79XDW	MI	DESIWFO
DM79XDW	MN	Beta-lactamase (blaB)
DM79XDW	MT	DME
DM79XDW	MA	Metabolism
DM79XDW	RN	EBR-1, a novel Ambler subclass B1 beta-lactamase from Empedobacter brevis. Antimicrob Agents Chemother. 2002 Oct;46(10):3223-7.
DM79XDW	RU	https://pubmed.ncbi.nlm.nih.gov/12234848

DM51Z9E	DI	DM51Z9E
DM51Z9E	DN	Cephalothin sodium
DM51Z9E	MI	TTJP4SM
DM51Z9E	MN	Bacterial Penicillin binding protein (Bact PBP)
DM51Z9E	MT	DTT
DM51Z9E	MA	Modulator
DM51Z9E	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM51Z9E	RU	https://www.fda.gov/

DM51Z9E	DI	DM51Z9E
DM51Z9E	DN	Cephalothin sodium
DM51Z9E	MI	DTI7UX6
DM51Z9E	MN	Breast cancer resistance protein (ABCG2)
DM51Z9E	MT	DTP
DM51Z9E	MA	Substrate
DM51Z9E	RN	Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). Biochem J. 2005 Jan 15;385(Pt 2):419-26.
DM51Z9E	RU	https://doi.org/10.1042/BJ20040791

DMV2JNY	DI	DMV2JNY
DMV2JNY	DN	Cephapirin
DMV2JNY	MI	TTJP4SM
DMV2JNY	MN	Bacterial Penicillin binding protein (Bact PBP)
DMV2JNY	MT	DTT
DMV2JNY	MA	Binder
DMV2JNY	RN	The formation of functional penicillin-binding proteins. J Biol Chem. 1975 Aug 25;250(16):6578-85.
DMV2JNY	RU	https://pubmed.ncbi.nlm.nih.gov/808545

DM9Y5JB	DI	DM9Y5JB
DM9Y5JB	DN	Cepharanthine
DM9Y5JB	MI	DTUGYRD
DM9Y5JB	MN	P-glycoprotein 1 (ABCB1)
DM9Y5JB	MT	DTP
DM9Y5JB	MA	Substrate
DM9Y5JB	RN	Cepharanthin, a multidrug resistant modifier, is a substrate for P-glycoprotein. J Pharmacol Exp Ther. 1995 Oct;275(1):73-8.
DM9Y5JB	RU	http://jpet.aspetjournals.org/content/275/1/73.long

DMB920Z	DI	DMB920Z
DMB920Z	DN	Ceritinib
DMB920Z	MI	TTPMQSO
DMB920Z	MN	ALK tyrosine kinase receptor (ALK)
DMB920Z	MT	DTT
DMB920Z	MA	Modulator
DMB920Z	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7397).
DMB920Z	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7397

DMB920Z	DI	DMB920Z
DMB920Z	DN	Ceritinib
DMB920Z	MI	DTUGYRD
DMB920Z	MN	P-glycoprotein 1 (ABCB1)
DMB920Z	MT	DTP
DMB920Z	MA	Substrate
DMB920Z	RN	P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer. EBioMedicine. 2015 Dec 12;3:54-66.
DMB920Z	RU	http://www.ncbi.nlm.nih.gov/pubmed/26870817

DMXCM7H	DI	DMXCM7H
DMXCM7H	DN	Cerivastatin
DMXCM7H	MI	DTI7UX6
DMXCM7H	MN	Breast cancer resistance protein (ABCG2)
DMXCM7H	MT	DTP
DMXCM7H	MA	Substrate
DMXCM7H	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMXCM7H	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMXCM7H	DI	DMXCM7H
DMXCM7H	DN	Cerivastatin
DMXCM7H	MI	DES5XRU
DMXCM7H	MN	Cytochrome P450 2C8 (CYP2C8)
DMXCM7H	MT	DME
DMXCM7H	MA	Metabolism
DMXCM7H	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DMXCM7H	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DMXCM7H	DI	DMXCM7H
DMXCM7H	DN	Cerivastatin
DMXCM7H	MI	DE4LYSA
DMXCM7H	MN	Cytochrome P450 3A4 (CYP3A4)
DMXCM7H	MT	DME
DMXCM7H	MA	Metabolism
DMXCM7H	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMXCM7H	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMXCM7H	DI	DMXCM7H
DMXCM7H	DN	Cerivastatin
DMXCM7H	MI	DEIBDNY
DMXCM7H	MN	Cytochrome P450 3A5 (CYP3A5)
DMXCM7H	MT	DME
DMXCM7H	MA	Metabolism
DMXCM7H	RN	Drug Interactions Flockhart Table
DMXCM7H	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMXCM7H	DI	DMXCM7H
DMXCM7H	DN	Cerivastatin
DMXCM7H	MI	DERD86B
DMXCM7H	MN	Cytochrome P450 3A7 (CYP3A7)
DMXCM7H	MT	DME
DMXCM7H	MA	Metabolism
DMXCM7H	RN	Drug Interactions Flockhart Table
DMXCM7H	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMXCM7H	DI	DMXCM7H
DMXCM7H	DN	Cerivastatin
DMXCM7H	MI	TTPADOQ
DMXCM7H	MN	HMG-CoA reductase (HMGCR)
DMXCM7H	MT	DTT
DMXCM7H	MA	Inhibitor
DMXCM7H	RN	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
DMXCM7H	RU	https://pubmed.ncbi.nlm.nih.gov/19249983

DMXCM7H	DI	DMXCM7H
DMXCM7H	DN	Cerivastatin
DMXCM7H	MI	DTFI42L
DMXCM7H	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMXCM7H	MT	DTP
DMXCM7H	MA	Substrate
DMXCM7H	RN	Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67.
DMXCM7H	RU	https://doi.org/10.1124/jpet.105.085589

DMXCM7H	DI	DMXCM7H
DMXCM7H	DN	Cerivastatin
DMXCM7H	MI	DT3D8F0
DMXCM7H	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMXCM7H	MT	DTP
DMXCM7H	MA	Substrate
DMXCM7H	RN	FDA Drug Development and Drug Interactions
DMXCM7H	RU	https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2

DMXCM7H	DI	DMXCM7H
DMXCM7H	DN	Cerivastatin
DMXCM7H	MI	DT9C1TS
DMXCM7H	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMXCM7H	MT	DTP
DMXCM7H	MA	Substrate
DMXCM7H	RN	FDA Drug Development and Drug Interactions
DMXCM7H	RU	https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2

DMXCM7H	DI	DMXCM7H
DMXCM7H	DN	Cerivastatin
DMXCM7H	MI	DTPFTEQ
DMXCM7H	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DMXCM7H	MT	DTP
DMXCM7H	MA	Substrate
DMXCM7H	RN	pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1. Mol Pharm. 2011 Aug 1;8(4):1303-13.
DMXCM7H	RU	https://doi.org/10.1021/mp200103h

DMXCM7H	DI	DMXCM7H
DMXCM7H	DN	Cerivastatin
DMXCM7H	MI	DTUGYRD
DMXCM7H	MN	P-glycoprotein 1 (ABCB1)
DMXCM7H	MT	DTP
DMXCM7H	MA	Substrate
DMXCM7H	RN	Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67.
DMXCM7H	RU	https://doi.org/10.1124/jpet.105.085589

DMXCM7H	DI	DMXCM7H
DMXCM7H	DN	Cerivastatin
DMXCM7H	MI	DT56EKP
DMXCM7H	MN	Sodium/taurocholate cotransporting polypeptide (SLC10A1)
DMXCM7H	MT	DTP
DMXCM7H	MA	Substrate
DMXCM7H	RN	Differential effect of genetic variants of Na(+)-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors. Xenobiotica. 2011 Jan;41(1):24-34.
DMXCM7H	RU	http://www.ncbi.nlm.nih.gov/pubmed/20946088

DMXCM7H	DI	DMXCM7H
DMXCM7H	DN	Cerivastatin
DMXCM7H	MI	DEYGVN4
DMXCM7H	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMXCM7H	MT	DME
DMXCM7H	MA	Metabolism
DMXCM7H	RN	Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011 May;21(5):280-8.
DMXCM7H	RU	https://www.ncbi.nlm.nih.gov/pubmed/21386754

DMXCM7H	DI	DMXCM7H
DMXCM7H	DN	Cerivastatin
DMXCM7H	MI	DEF2WXN
DMXCM7H	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMXCM7H	MT	DME
DMXCM7H	MA	Metabolism
DMXCM7H	RN	Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011 May;21(5):280-8.
DMXCM7H	RU	https://www.ncbi.nlm.nih.gov/pubmed/21386754

DM0HAC8	DI	DM0HAC8
DM0HAC8	DN	Cerliponase Alfa
DM0HAC8	MI	TTOVYPT
DM0HAC8	MN	Tripeptidyl-peptidase I (TPP1)
DM0HAC8	MT	DTT
DM0HAC8	MA	Modulator
DM0HAC8	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM0HAC8	RU	https://www.fda.gov/

DM5CL9Z	DI	DM5CL9Z
DM5CL9Z	DN	Certolizumab
DM5CL9Z	MI	TTF8CQI
DM5CL9Z	MN	Tumor necrosis factor (TNF)
DM5CL9Z	MT	DTT
DM5CL9Z	MA	Inhibitor
DM5CL9Z	RN	Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
DM5CL9Z	RU	https://pubmed.ncbi.nlm.nih.gov/18321156

DMUR94J	DI	DMUR94J
DMUR94J	DN	Certoparin sodium
DMUR94J	MI	TTCIHJA
DMUR94J	MN	Coagulation factor Xa (F10)
DMUR94J	MT	DTT
DMUR94J	MA	Modulator
DMUR94J	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMUR94J	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DM6N4PR	DI	DM6N4PR
DM6N4PR	DN	Cerulenin
DM6N4PR	MI	TT7AOUD
DM6N4PR	MN	Fatty acid synthase (FASN)
DM6N4PR	MT	DTT
DM6N4PR	MA	Inhibitor
DM6N4PR	RN	Inhibition of fatty acid biosynthesis prevents adipocyte lipotoxicity on human osteoblasts in vitro. J Cell Mol Med. 2010 Apr;14(4):982-91.
DM6N4PR	RU	https://pubmed.ncbi.nlm.nih.gov/19382912

DM2WE5K	DI	DM2WE5K
DM2WE5K	DN	Ceruletide
DM2WE5K	MI	TTVFO0U
DM2WE5K	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DM2WE5K	MT	DTT
DM2WE5K	MA	Agonist
DM2WE5K	RN	Comparison of postprandial and ceruletide serum bile acid stimulation in dogs. J Vet Intern Med. 2008 Jul-Aug;22(4):873-8.
DM2WE5K	RU	https://pubmed.ncbi.nlm.nih.gov/18537882

DMOMP9U	DI	DMOMP9U
DMOMP9U	DN	Cetirizine
DMOMP9U	MI	TTTIBOJ
DMOMP9U	MN	Histamine H1 receptor (H1R)
DMOMP9U	MT	DTT
DMOMP9U	MA	Antagonist
DMOMP9U	RN	Design, synthesis and histamine H1-receptor antagonistic activity of some novel 4-amino-2-(substituted)-5-(substituted) aryl-6-[(substituted aryl) amino] pyrimidines. Arzneimittelforschung. 2009;59(5):243-7.
DMOMP9U	RU	https://pubmed.ncbi.nlm.nih.gov/19537525

DMOMP9U	DI	DMOMP9U
DMOMP9U	DN	Cetirizine
DMOMP9U	MI	DTUGYRD
DMOMP9U	MN	P-glycoprotein 1 (ABCB1)
DMOMP9U	MT	DTP
DMOMP9U	MA	Substrate
DMOMP9U	RN	Stereoselective and multiple carrier-mediated transport of cetirizine across Caco-2 cell monolayers with potential drug interaction. Chirality. 2010 Jul;22(7):684-92.
DMOMP9U	RU	http://www.ncbi.nlm.nih.gov/pubmed/20014242

DMSP4JX	DI	DMSP4JX
DMSP4JX	DN	Cetraxate
DMSP4JX	MI	TT5L2VC
DMSP4JX	MN	Kallikrein-related peptidase (KLK)
DMSP4JX	MT	DTT
DMSP4JX	MA	Modulator
DMSP4JX	RN	A new broad spectrum inhibitor of esteroproteases, 4-(2-carboxyethyl) phenyl-trans-4-aminomethyl cyclohexane carboxylate hydrochloride (DV 1006). Tohoku J Exp Med. 1972 Mar;106(3):233-48.
DMSP4JX	RU	https://pubmed.ncbi.nlm.nih.gov/4261023

DMFD9Q6	DI	DMFD9Q6
DMFD9Q6	DN	Cetrorelix
DMFD9Q6	MI	TT8R70G
DMFD9Q6	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMFD9Q6	MT	DTT
DMFD9Q6	MA	Antagonist
DMFD9Q6	RN	Gonadotropin releasing hormone analogs induce apoptosis by extrinsic pathway involving p53 phosphorylation in primary cell cultures of human prostatic adenocarcinomas. Prostate. 2009 Jul 1;69(10):1025-33.
DMFD9Q6	RU	https://pubmed.ncbi.nlm.nih.gov/19301301

DMLNCE0	DI	DMLNCE0
DMLNCE0	DN	Cetuximab
DMLNCE0	MI	TTGKNB4
DMLNCE0	MN	Epidermal growth factor receptor (EGFR)
DMLNCE0	MT	DTT
DMLNCE0	RN	Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Mol Cancer Ther. 2002 May;1(7):507-14.
DMLNCE0	RU	https://pubmed.ncbi.nlm.nih.gov/12479268

DMWSMND	DI	DMWSMND
DMWSMND	DN	Cevimeline
DMWSMND	MI	DECB0K3
DMWSMND	MN	Cytochrome P450 2D6 (CYP2D6)
DMWSMND	MT	DME
DMWSMND	MA	Metabolism
DMWSMND	RN	Pharmacokinetics and metabolism of the novel muscarinic receptor agonist SNI-2011 in rats and dogs. Arzneimittelforschung. 2003;53(1):26-33.
DMWSMND	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12608011

DMWSMND	DI	DMWSMND
DMWSMND	DN	Cevimeline
DMWSMND	MI	DE4LYSA
DMWSMND	MN	Cytochrome P450 3A4 (CYP3A4)
DMWSMND	MT	DME
DMWSMND	MA	Metabolism
DMWSMND	RN	Pharmacokinetics and metabolism of the novel muscarinic receptor agonist SNI-2011 in rats and dogs. Arzneimittelforschung. 2003;53(1):26-33.
DMWSMND	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12608011

DMWSMND	DI	DMWSMND
DMWSMND	DN	Cevimeline
DMWSMND	MI	TTQ13Z5
DMWSMND	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMWSMND	MT	DTT
DMWSMND	MA	Agonist
DMWSMND	RN	Degradation of submandibular gland AQP5 by parasympathetic denervation of chorda tympani and its recovery by cevimeline, an M3 muscarinic receptor ... Am J Physiol Gastrointest Liver Physiol. 2008 Jul;295(1):G112-G123.
DMWSMND	RU	https://pubmed.ncbi.nlm.nih.gov/18450949

DMKN345	DI	DMKN345
DMKN345	DN	Charybdotoxin
DMKN345	MI	TTMNI76
DMKN345	MN	Calcium-activated potassium channel (KCN)
DMKN345	MT	DTT
DMKN345	MA	Blocker
DMKN345	RN	Reversible inhibition of the platelet procoagulant response through manipulation of the Gardos channel. Blood. 2006 Oct 1;108(7):2223-8.
DMKN345	RU	https://pubmed.ncbi.nlm.nih.gov/16741254

DMQ8JIK	DI	DMQ8JIK
DMQ8JIK	DN	Chenodiol
DMQ8JIK	MI	DE4LYSA
DMQ8JIK	MN	Cytochrome P450 3A4 (CYP3A4)
DMQ8JIK	MT	DME
DMQ8JIK	MA	Metabolism
DMQ8JIK	RN	Identification of human hepatic cytochrome p450 enzymes involved in the biotransformation of cholic and chenodeoxycholic acid. Drug Metab Dispos. 2008 Oct;36(10):1983-91.
DMQ8JIK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18583509

DMQ8JIK	DI	DMQ8JIK
DMQ8JIK	DN	Chenodiol
DMQ8JIK	MI	DETL4WB
DMQ8JIK	MN	Cytochrome P450 8B1 (CYP8B1)
DMQ8JIK	MT	DME
DMQ8JIK	MA	Metabolism
DMQ8JIK	RN	Conversion of chenodeoxycholic acid to cholic acid by human CYP8B1. Biol Chem. 2019 Apr 24;400(5):625-628.
DMQ8JIK	RU	https://pubmed.ncbi.nlm.nih.gov/30465713

DMQ8JIK	DI	DMQ8JIK
DMQ8JIK	DN	Chenodiol
DMQ8JIK	MI	TTS4UGC
DMQ8JIK	MN	Farnesoid X-activated receptor (FXR)
DMQ8JIK	MT	DTT
DMQ8JIK	MA	Modulator
DMQ8JIK	RN	Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity. J Biol Chem. 2002 Aug 30;277(35):31441-7.
DMQ8JIK	RU	https://pubmed.ncbi.nlm.nih.gov/12052824

DMQ8JIK	DI	DMQ8JIK
DMQ8JIK	DN	Chenodiol
DMQ8JIK	MI	DEYGVN4
DMQ8JIK	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMQ8JIK	MT	DME
DMQ8JIK	MA	Metabolism
DMQ8JIK	RN	Human UDP-glucuronosyltransferase (UGT)1A3 enzyme conjugates chenodeoxycholic acid in the liver. Hepatology. 2006 Nov;44(5):1158-70.
DMQ8JIK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17058234

DMXGJEI	DI	DMXGJEI
DMXGJEI	DN	Chlophedianol
DMXGJEI	MI	TTTIBOJ
DMXGJEI	MN	Histamine H1 receptor (H1R)
DMXGJEI	MT	DTT
DMXGJEI	MA	Antagonist
DMXGJEI	RN	Identification and differentiation of alkylamine antihistamines and their metabolites in urine by computerized gas chromatography-mass spectrometry. J Chromatogr. 1988 Aug 19;430(1):31-41.
DMXGJEI	RU	https://pubmed.ncbi.nlm.nih.gov/2905706

DMRKE63	DI	DMRKE63
DMRKE63	DN	Chlorambucil
DMRKE63	MI	TTABD5E
DMRKE63	MN	DNA replication (DNA repli)
DMRKE63	MT	DTT
DMRKE63	MA	Intercalator
DMRKE63	RN	Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A. Mol Cancer Ther. 2009 Jun;8(6):1714-23.
DMRKE63	RU	https://pubmed.ncbi.nlm.nih.gov/19509245

DMRKE63	DI	DMRKE63
DMRKE63	DN	Chlorambucil
DMRKE63	MI	DEK6079
DMRKE63	MN	Glutathione S-transferase pi (GSTP1)
DMRKE63	MT	DME
DMRKE63	MA	Metabolism
DMRKE63	RN	The anti-cancer drug chlorambucil as a substrate for the human polymorphic enzyme glutathione transferase P1-1: kinetic properties and crystallographic characterisation of allelic variants. J Mol Biol. 2008 Jun 27;380(1):131-44.
DMRKE63	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18511072

DMRKE63	DI	DMRKE63
DMRKE63	DN	Chlorambucil
DMRKE63	MI	DTE2B1D
DMRKE63	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMRKE63	MT	DTP
DMRKE63	MA	Substrate
DMRKE63	RN	Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol. 2004;44:137-66.
DMRKE63	RU	https://doi.org/10.1146/annurev.pharmtox.44.101802.121856

DMRKE63	DI	DMRKE63
DMRKE63	DN	Chlorambucil
DMRKE63	MI	DTUGYRD
DMRKE63	MN	P-glycoprotein 1 (ABCB1)
DMRKE63	MT	DTP
DMRKE63	MA	Substrate
DMRKE63	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMRKE63	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMFXEWT	DI	DMFXEWT
DMFXEWT	DN	Chloramphenicol
DMFXEWT	MI	TTLFGBV
DMFXEWT	MN	Bacterial 23S ribosomal RNA (Bact 23S rRNA)
DMFXEWT	MT	DTT
DMFXEWT	MA	Binder
DMFXEWT	RN	Inhibition of peptide bond formation by pleuromutilins: the structure of the 50S ribosomal subunit from Deinococcus radiodurans in complex with tiamulin. Mol Microbiol. 2004 Dec;54(5):1287-94.
DMFXEWT	RU	https://pubmed.ncbi.nlm.nih.gov/15554968

DMFXEWT	DI	DMFXEWT
DMFXEWT	DN	Chloramphenicol
DMFXEWT	MI	DE26V9J
DMFXEWT	MN	Chloramphenicolase (chlR)
DMFXEWT	MT	DME
DMFXEWT	MA	Metabolism
DMFXEWT	RN	The bacterial degradation of chloramphenico. Lancet. 1967 Jun 10;1(7502):1259-60.
DMFXEWT	RU	https://pubmed.ncbi.nlm.nih.gov/4165044

DMFXEWT	DI	DMFXEWT
DMFXEWT	DN	Chloramphenicol
DMFXEWT	MI	DEMUBWL
DMFXEWT	MN	Chloramphenicolase (chlR)
DMFXEWT	MT	DME
DMFXEWT	MA	Metabolism
DMFXEWT	RN	The bacterial degradation of chloramphenico. Lancet. 1967 Jun 10;1(7502):1259-60.
DMFXEWT	RU	https://pubmed.ncbi.nlm.nih.gov/4165044

DMFXEWT	DI	DMFXEWT
DMFXEWT	DN	Chloramphenicol
DMFXEWT	MI	DECMT89
DMFXEWT	MN	Chloramphenicolase (chlR)
DMFXEWT	MT	DME
DMFXEWT	MA	Metabolism
DMFXEWT	RN	The bacterial degradation of chloramphenico. Lancet. 1967 Jun 10;1(7502):1259-60.
DMFXEWT	RU	https://pubmed.ncbi.nlm.nih.gov/4165044

DMFXEWT	DI	DMFXEWT
DMFXEWT	DN	Chloramphenicol
DMFXEWT	MI	DEFVHQU
DMFXEWT	MN	Glycerol-3-phosphate dehydrogenase (gpsA)
DMFXEWT	MT	DME
DMFXEWT	MA	Metabolism
DMFXEWT	RN	Porcine beta-defensin 2 displays broad antimicrobial activity against pathogenic intestinal bacteria. Mol Immunol. 2008 Jan;45(2):386-94.
DMFXEWT	RU	http://www.ncbi.nlm.nih.gov/pubmed/17658606

DMFXEWT	DI	DMFXEWT
DMFXEWT	DN	Chloramphenicol
DMFXEWT	MI	DEGTFWK
DMFXEWT	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMFXEWT	MT	DME
DMFXEWT	MA	Metabolism
DMFXEWT	RN	Chloramphenicol is a potent inhibitor of cytochrome P450 isoforms CYP2C19 and CYP3A4 in human liver microsomes. Antimicrob Agents Chemother. 2003 Nov;47(11):3464-9.
DMFXEWT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14576103

DMFXEWT	DI	DMFXEWT
DMFXEWT	DN	Chloramphenicol
DMFXEWT	MI	DTUGYRD
DMFXEWT	MN	P-glycoprotein 1 (ABCB1)
DMFXEWT	MT	DTP
DMFXEWT	MA	Substrate
DMFXEWT	RN	Active Mediated Transport of Chloramphenicol and Thiamphenicol in a Calu-3 Lung Epithelial Cell Model. J Pharm Sci. 2018 Apr;107(4):1178-1184.
DMFXEWT	RU	http://www.ncbi.nlm.nih.gov/pubmed/29221992

DMTN5XI	DI	DMTN5XI
DMTN5XI	DN	Chlordiazepoxide
DMTN5XI	MI	TTPTXIN
DMTN5XI	MN	Translocator protein (TSPO)
DMTN5XI	MT	DTT
DMTN5XI	MA	Modulator
DMTN5XI	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMTN5XI	RU	https://www.fda.gov/

DMQ9MVG	DI	DMQ9MVG
DMQ9MVG	DN	Chlorhexidine
DMQ9MVG	MI	TT4ILYC
DMQ9MVG	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMQ9MVG	MT	DTT
DMQ9MVG	MA	Breaker
DMQ9MVG	RN	The mechanism of action of chlorhexidine. FEMS Microbiol Lett. 1992 Dec 15;79(1-3):211-5.
DMQ9MVG	RU	https://pubmed.ncbi.nlm.nih.gov/1335944

DMSF4PR	DI	DMSF4PR
DMSF4PR	DN	Chlormerodrin
DMSF4PR	MI	TTJUWVB
DMSF4PR	MN	Succinate-semialdehyde dehydrogenase (ALDH5A1)
DMSF4PR	MT	DTT
DMSF4PR	MA	Modulator
DMSF4PR	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMSF4PR	RU	https://www.fda.gov/

DMTWUXR	DI	DMTWUXR
DMTWUXR	DN	Chlormezanone
DMTWUXR	MI	TTPTXIN
DMTWUXR	MN	Translocator protein (TSPO)
DMTWUXR	MT	DTT
DMTWUXR	MA	Agonist
DMTWUXR	RN	Successful treatment of anxiety with a single night-time dose of chlormezanone: double-blind comparison with diazepam. Curr Med Res Opin. 1982;8(1):33-8.
DMTWUXR	RU	https://pubmed.ncbi.nlm.nih.gov/7105820

DMSOQK1	DI	DMSOQK1
DMSOQK1	DN	Chloroprocaine
DMSOQK1	MI	TTWK8D0
DMSOQK1	MN	Sodium pump subunit alpha-1 (ATP1A1)
DMSOQK1	MT	DTT
DMSOQK1	MA	Blocker
DMSOQK1	RN	Inhibition of the Na,K-ATPase of canine renal medulla by several local anesthetics. Pharmacol Res. 2001 Apr;43(4):399-403.
DMSOQK1	RU	https://pubmed.ncbi.nlm.nih.gov/11352545

DMSI5CB	DI	DMSI5CB
DMSI5CB	DN	Chloroquine
DMSI5CB	MI	DE6OQ3W
DMSI5CB	MN	Cytochrome P450 1A1 (CYP1A1)
DMSI5CB	MT	DME
DMSI5CB	MA	Metabolism
DMSI5CB	RN	In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab Dispos. 2003 Jun;31(6):748-54.
DMSI5CB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12756207

DMSI5CB	DI	DMSI5CB
DMSI5CB	DN	Chloroquine
DMSI5CB	MI	DES5XRU
DMSI5CB	MN	Cytochrome P450 2C8 (CYP2C8)
DMSI5CB	MT	DME
DMSI5CB	MA	Metabolism
DMSI5CB	RN	Short communication: high prevalence of the cytochrome P450 2C8*2 mutation in Northern Ghana. Trop Med Int Health. 2005 Dec;10(12):1271-3.
DMSI5CB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16359408

DMSI5CB	DI	DMSI5CB
DMSI5CB	DN	Chloroquine
DMSI5CB	MI	DECB0K3
DMSI5CB	MN	Cytochrome P450 2D6 (CYP2D6)
DMSI5CB	MT	DME
DMSI5CB	MA	Metabolism
DMSI5CB	RN	Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians. Br J Clin Pharmacol. 1998 Mar;45(3):315-7.
DMSI5CB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10896408

DMSI5CB	DI	DMSI5CB
DMSI5CB	DN	Chloroquine
DMSI5CB	MI	DE4LYSA
DMSI5CB	MN	Cytochrome P450 3A4 (CYP3A4)
DMSI5CB	MT	DME
DMSI5CB	MA	Metabolism
DMSI5CB	RN	Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes. Arch Pharm Res. 2003 Aug;26(8):631-7.
DMSI5CB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12967198

DMSI5CB	DI	DMSI5CB
DMSI5CB	DN	Chloroquine
DMSI5CB	MI	DEIBDNY
DMSI5CB	MN	Cytochrome P450 3A5 (CYP3A5)
DMSI5CB	MT	DME
DMSI5CB	MA	Metabolism
DMSI5CB	RN	Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes. Arch Pharm Res. 2003 Aug;26(8):631-7.
DMSI5CB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12967198

DMSI5CB	DI	DMSI5CB
DMSI5CB	DN	Chloroquine
DMSI5CB	MI	TTKY2NS
DMSI5CB	MN	Duffy antigen chemokine receptor (ACKR1)
DMSI5CB	MT	DTT
DMSI5CB	MA	Modulator
DMSI5CB	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMSI5CB	RU	https://www.fda.gov/

DMSI5CB	DI	DMSI5CB
DMSI5CB	DN	Chloroquine
DMSI5CB	MI	DTZGT0P
DMSI5CB	MN	Multidrug and toxin extrusion protein 1 (SLC47A1)
DMSI5CB	MT	DTP
DMSI5CB	MA	Substrate
DMSI5CB	RN	Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine. Antimicrob Agents Chemother. 2011 Jul;55(7):3091-8.
DMSI5CB	RU	http://www.ncbi.nlm.nih.gov/pubmed/21518836

DMSI5CB	DI	DMSI5CB
DMSI5CB	DN	Chloroquine
DMSI5CB	MI	DTUGYRD
DMSI5CB	MN	P-glycoprotein 1 (ABCB1)
DMSI5CB	MT	DTP
DMSI5CB	MA	Substrate
DMSI5CB	RN	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
DMSI5CB	RU	https://doi.org/10.1016/j.addr.2011.12.008

DMLHESP	DI	DMLHESP
DMLHESP	DN	Chlorothiazide
DMLHESP	MI	DTI7UX6
DMLHESP	MN	Breast cancer resistance protein (ABCG2)
DMLHESP	MT	DTP
DMLHESP	MA	Substrate
DMLHESP	RN	ABCG2 modulates chlorothiazide permeability--in vitro-characterization of its interactions. Drug Metab Pharmacokinet. 2012;27(3):349-53.
DMLHESP	RU	https://doi.org/10.2133/dmpk.DMPK-11-NT-068

DMLHESP	DI	DMLHESP
DMLHESP	DN	Chlorothiazide
DMLHESP	MI	TTANPDJ
DMLHESP	MN	Carbonic anhydrase II (CA-II)
DMLHESP	MT	DTT
DMLHESP	MA	Inhibitor
DMLHESP	RN	Localization of diuretic effects along the loop of Henle: an in vivo microperfusion study in rats. Clin Sci (Lond). 2000 Apr;98(4):481-8.
DMLHESP	RU	https://pubmed.ncbi.nlm.nih.gov/10731484

DMLHESP	DI	DMLHESP
DMLHESP	DN	Chlorothiazide
DMLHESP	MI	DTVP67E
DMLHESP	MN	Organic anion transporter 3 (SLC22A8)
DMLHESP	MT	DTP
DMLHESP	MA	Substrate
DMLHESP	RN	Overlapping in vitro and in vivo specificities of the organic anion transporters OAT1 and OAT3 for loop and thiazide diuretics. Am J Physiol Renal Physiol. 2008 Apr;294(4):F867-73.
DMLHESP	RU	http://www.ncbi.nlm.nih.gov/pubmed/18216144

DMFZBMQ	DI	DMFZBMQ
DMFZBMQ	DN	Chloroxine
DMFZBMQ	MI	TTQW87Y
DMFZBMQ	MN	Opioid receptor kappa (OPRK1)
DMFZBMQ	MT	DTT
DMFZBMQ	MA	Inhibitor
DMFZBMQ	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMFZBMQ	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DM5URA2	DI	DM5URA2
DM5URA2	DN	Chlorpheniramine
DM5URA2	MI	DECB0K3
DM5URA2	MN	Cytochrome P450 2D6 (CYP2D6)
DM5URA2	MT	DME
DM5URA2	MA	Metabolism
DM5URA2	RN	The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. Br J Clin Pharmacol. 2002 May;53(5):519-25.
DM5URA2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11994058

DM5URA2	DI	DM5URA2
DM5URA2	DN	Chlorpheniramine
DM5URA2	MI	DE4LYSA
DM5URA2	MN	Cytochrome P450 3A4 (CYP3A4)
DM5URA2	MT	DME
DM5URA2	MA	Metabolism
DM5URA2	RN	Drug Interactions Flockhart Table
DM5URA2	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM5URA2	DI	DM5URA2
DM5URA2	DN	Chlorpheniramine
DM5URA2	MI	DEIBDNY
DM5URA2	MN	Cytochrome P450 3A5 (CYP3A5)
DM5URA2	MT	DME
DM5URA2	MA	Metabolism
DM5URA2	RN	Drug Interactions Flockhart Table
DM5URA2	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM5URA2	DI	DM5URA2
DM5URA2	DN	Chlorpheniramine
DM5URA2	MI	DERD86B
DM5URA2	MN	Cytochrome P450 3A7 (CYP3A7)
DM5URA2	MT	DME
DM5URA2	MA	Metabolism
DM5URA2	RN	Drug Interactions Flockhart Table
DM5URA2	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM5URA2	DI	DM5URA2
DM5URA2	DN	Chlorpheniramine
DM5URA2	MI	TTTIBOJ
DM5URA2	MN	Histamine H1 receptor (H1R)
DM5URA2	MT	DTT
DM5URA2	MA	Antagonist
DM5URA2	RN	Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79.
DM5URA2	RU	https://pubmed.ncbi.nlm.nih.gov/18446005

DM5URA2	DI	DM5URA2
DM5URA2	DN	Chlorpheniramine
DM5URA2	MI	DTSYQGK
DM5URA2	MN	Multidrug resistance-associated protein 1 (ABCC1)
DM5URA2	MT	DTP
DM5URA2	MA	Substrate
DM5URA2	RN	Carrier mediated transport of chlorpheniramine and chlorcyclizine across bovine olfactory mucosa: implications on nose-to-brain transport. J Pharm Sci. 2005 Mar;94(3):613-24.
DM5URA2	RU	http://www.ncbi.nlm.nih.gov/pubmed/15666293

DMQRPOS	DI	DMQRPOS
DMQRPOS	DN	Chlorphentermine hydrochloride
DMQRPOS	MI	TT3ROYC
DMQRPOS	MN	Serotonin transporter (SERT)
DMQRPOS	MT	DTT
DMQRPOS	MA	Modulator
DMQRPOS	RN	Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates.Implications for primary pulmonary hypertension.Circulation.1999 Aug 24;100(8):869-75.
DMQRPOS	RU	https://www.ncbi.nlm.nih.gov/pubmed/10458725

DM1IFGT	DI	DM1IFGT
DM1IFGT	DN	Chlorproguanil
DM1IFGT	MI	TT9SL3Q
DM1IFGT	MN	Polypeptide deformylase (PDF)
DM1IFGT	MT	DTT
DM1IFGT	MA	Inhibitor
DM1IFGT	RN	The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
DM1IFGT	RU	https://pubmed.ncbi.nlm.nih.gov/18220771

DMBGZI3	DI	DMBGZI3
DMBGZI3	DN	Chlorpromazine
DMBGZI3	MI	DEJGDUW
DMBGZI3	MN	Cytochrome P450 1A2 (CYP1A2)
DMBGZI3	MT	DME
DMBGZI3	MA	Metabolism
DMBGZI3	RN	Functional polymorphisms of the cytochrome P450 1A2 (CYP1A2) gene and prolonged QTc interval in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Aug 15;31(6):1297-302.
DMBGZI3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17611010

DMBGZI3	DI	DMBGZI3
DMBGZI3	DN	Chlorpromazine
DMBGZI3	MI	DECB0K3
DMBGZI3	MN	Cytochrome P450 2D6 (CYP2D6)
DMBGZI3	MT	DME
DMBGZI3	MA	Metabolism
DMBGZI3	RN	Use of antidepressant drugs in schizophrenic patients with depression. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9.
DMBGZI3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16910628

DMBGZI3	DI	DMBGZI3
DMBGZI3	DN	Chlorpromazine
DMBGZI3	MI	DE4LYSA
DMBGZI3	MN	Cytochrome P450 3A4 (CYP3A4)
DMBGZI3	MT	DME
DMBGZI3	MA	Metabolism
DMBGZI3	RN	Effect of classic and atypical neuroleptics on cytochrome P450 3A (CYP3A) in rat liver. Pharmacol Rep. 2012;64(6):1411-8.
DMBGZI3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23406751

DMBGZI3	DI	DMBGZI3
DMBGZI3	DN	Chlorpromazine
DMBGZI3	MI	DEIZLTN
DMBGZI3	MN	Docosahexaenoic acid omega-hydroxylase (CYP4F11)
DMBGZI3	MT	DME
DMBGZI3	MA	Metabolism
DMBGZI3	RN	Expression and characterization of human cytochrome P450 4F11: putative role in the metabolism of therapeutic drugs and eicosanoids. Toxicol Appl Pharmacol. 2004 Sep 15;199(3):295-304.
DMBGZI3	RU	https://pubmed.ncbi.nlm.nih.gov/15364545

DMBGZI3	DI	DMBGZI3
DMBGZI3	DN	Chlorpromazine
DMBGZI3	MI	TTEX248
DMBGZI3	MN	Dopamine D2 receptor (D2R)
DMBGZI3	MT	DTT
DMBGZI3	MA	Antagonist
DMBGZI3	RN	Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
DMBGZI3	RU	https://pubmed.ncbi.nlm.nih.gov/19374860

DMBGZI3	DI	DMBGZI3
DMBGZI3	DN	Chlorpromazine
DMBGZI3	MI	DTUGYRD
DMBGZI3	MN	P-glycoprotein 1 (ABCB1)
DMBGZI3	MT	DTP
DMBGZI3	MA	Substrate
DMBGZI3	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMBGZI3	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMPHZQE	DI	DMPHZQE
DMPHZQE	DN	Chlorpropamide
DMPHZQE	MI	DE5IED8
DMPHZQE	MN	Cytochrome P450 2C9 (CYP2C9)
DMPHZQE	MT	DME
DMPHZQE	MA	Metabolism
DMPHZQE	RN	Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. Br J Clin Pharmacol. 2005 May;59(5):552-63.
DMPHZQE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15842554

DMPHZQE	DI	DMPHZQE
DMPHZQE	DN	Chlorpropamide
DMPHZQE	MI	TTG140O
DMPHZQE	MN	Inward rectifier potassium channel Kir1.2 (KCNJ10)
DMPHZQE	MT	DTT
DMPHZQE	MA	Blocker
DMPHZQE	RN	Effect of the chlorpropamide and fructose-1,6-bisphosphate of soluble TNF receptor II levels. Pharmacol Res. 2004 May;49(5):449-53.
DMPHZQE	RU	https://pubmed.ncbi.nlm.nih.gov/14998554

DMPHZQE	DI	DMPHZQE
DMPHZQE	DN	Chlorpropamide
DMPHZQE	MI	DEGTFWK
DMPHZQE	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMPHZQE	MT	DME
DMPHZQE	MA	Metabolism
DMPHZQE	RN	Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. Br J Clin Pharmacol. 2005 May;59(5):552-63.
DMPHZQE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15842554

DMY0KGJ	DI	DMY0KGJ
DMY0KGJ	DN	Chlorprothixene
DMY0KGJ	MI	TTEX248
DMY0KGJ	MN	Dopamine D2 receptor (D2R)
DMY0KGJ	MT	DTT
DMY0KGJ	MA	Antagonist
DMY0KGJ	RN	Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics. Bioorg Med Chem Lett. 2009 Jan 15;19(2):538-42.
DMY0KGJ	RU	https://pubmed.ncbi.nlm.nih.gov/19091563

DM4DMBT	DI	DM4DMBT
DM4DMBT	DN	Chlorthalidone
DM4DMBT	MI	TTS087L
DM4DMBT	MN	Solute carrier family 12 member 1 (SLC12A1)
DM4DMBT	MT	DTT
DM4DMBT	MA	Blocker
DM4DMBT	RN	The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol Cell Endocrinol. 2004 Mar 31;217(1-2):45-52.
DM4DMBT	RU	https://pubmed.ncbi.nlm.nih.gov/15134800

DMCYVDT	DI	DMCYVDT
DMCYVDT	DN	Chlorzoxazone
DMCYVDT	MI	TTMNI76
DMCYVDT	MN	Calcium-activated potassium channel (KCN)
DMCYVDT	MT	DTT
DMCYVDT	MA	Activator
DMCYVDT	RN	Chlorzoxazone inhibits contraction of rat thoracic aorta. Eur J Pharmacol. 2006 Sep 18;545(2-3):161-6.
DMCYVDT	RU	https://pubmed.ncbi.nlm.nih.gov/16859676

DMCYVDT	DI	DMCYVDT
DMCYVDT	DN	Chlorzoxazone
DMCYVDT	MI	DE4OGUF
DMCYVDT	MN	Cytochrome P450 102A1 (cyp102)
DMCYVDT	MT	DME
DMCYVDT	MA	Metabolism
DMCYVDT	RN	Wild-type CYP102A1 as a biocatalyst: turnover of drugs usually metabolised by human liver enzymes. J Biol Inorg Chem. 2007 Mar;12(3):313-23.
DMCYVDT	RU	https://pubmed.ncbi.nlm.nih.gov/17235582

DMCYVDT	DI	DMCYVDT
DMCYVDT	DN	Chlorzoxazone
DMCYVDT	MI	DEJGDUW
DMCYVDT	MN	Cytochrome P450 1A2 (CYP1A2)
DMCYVDT	MT	DME
DMCYVDT	MA	Metabolism
DMCYVDT	RN	Inhibitory monoclonal antibodies to human cytochrome P450 1A2: analysis of phenacetin O-deethylation in human liver. Pharmacogenetics. 1998 Oct;8(5):375-82.
DMCYVDT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9825829

DMCYVDT	DI	DMCYVDT
DMCYVDT	DN	Chlorzoxazone
DMCYVDT	MI	DEJVYAZ
DMCYVDT	MN	Cytochrome P450 2A6 (CYP2A6)
DMCYVDT	MT	DME
DMCYVDT	MA	Metabolism
DMCYVDT	RN	Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes. Drug Metab Dispos. 1999 Nov;27(11):1274-80.
DMCYVDT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10534312

DMCYVDT	DI	DMCYVDT
DMCYVDT	DN	Chlorzoxazone
DMCYVDT	MI	DECB0K3
DMCYVDT	MN	Cytochrome P450 2D6 (CYP2D6)
DMCYVDT	MT	DME
DMCYVDT	MA	Metabolism
DMCYVDT	RN	Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes. Drug Metab Dispos. 1999 Nov;27(11):1274-80.
DMCYVDT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10534312

DMCYVDT	DI	DMCYVDT
DMCYVDT	DN	Chlorzoxazone
DMCYVDT	MI	DEVDYN7
DMCYVDT	MN	Cytochrome P450 2E1 (CYP2E1)
DMCYVDT	MT	DME
DMCYVDT	MA	Metabolism
DMCYVDT	RN	Trimethadione metabolism by human liver cytochrome P450: evidence for the involvement of CYP2E1. Xenobiotica. 1998 Nov;28(11):1041-7.
DMCYVDT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9879636

DMCYVDT	DI	DMCYVDT
DMCYVDT	DN	Chlorzoxazone
DMCYVDT	MI	DE4LYSA
DMCYVDT	MN	Cytochrome P450 3A4 (CYP3A4)
DMCYVDT	MT	DME
DMCYVDT	MA	Metabolism
DMCYVDT	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMCYVDT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMGU74E	DI	DMGU74E
DMGU74E	DN	Cholecalciferol
DMGU74E	MI	TTK59TV
DMGU74E	MN	Vitamin D3 receptor (VDR)
DMGU74E	MT	DTT
DMGU74E	MA	Binder
DMGU74E	RN	[Vitamin D2 or vitamin D3]. Rev Med Interne. 2008 Oct;29(10):815-20.
DMGU74E	RU	https://pubmed.ncbi.nlm.nih.gov/18406498

DM7OKQV	DI	DM7OKQV
DM7OKQV	DN	Cholic acid
DM7OKQV	MI	DT7JELC
DM7OKQV	MN	Apical sodium-dependent bile acid transporter (SLC10A2)
DM7OKQV	MT	DTP
DM7OKQV	MA	Substrate
DM7OKQV	RN	Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter. Am J Physiol. 1998 Jan;274(1):G157-69.
DM7OKQV	RU	http://ajpgi.physiology.org/content/274/1/G157.long

DM7OKQV	DI	DM7OKQV
DM7OKQV	DN	Cholic acid
DM7OKQV	MI	DTI7UX6
DM7OKQV	MN	Breast cancer resistance protein (ABCG2)
DM7OKQV	MT	DTP
DM7OKQV	MA	Substrate
DM7OKQV	RN	Characterization of the role of ABCG2 as a bile acid transporter in liver and placenta. Mol Pharmacol. 2012 Feb;81(2):273-83.
DM7OKQV	RU	https://doi.org/10.1124/mol.111.075143

DM7OKQV	DI	DM7OKQV
DM7OKQV	DN	Cholic acid
DM7OKQV	MI	TTQ6VF4
DM7OKQV	MN	Ferrochelatase (FECH)
DM7OKQV	MT	DTT
DM7OKQV	MA	Inhibitor
DM7OKQV	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM7OKQV	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM7OKQV	DI	DM7OKQV
DM7OKQV	DN	Cholic acid
DM7OKQV	MI	TTMF541
DM7OKQV	MN	Liver carboxylesterase (CES1)
DM7OKQV	MT	DTT
DM7OKQV	MA	Inhibitor
DM7OKQV	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM7OKQV	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM7OKQV	DI	DM7OKQV
DM7OKQV	DN	Cholic acid
DM7OKQV	MI	DTFI42L
DM7OKQV	MN	Multidrug resistance-associated protein 2 (ABCC2)
DM7OKQV	MT	DTP
DM7OKQV	MA	Substrate
DM7OKQV	RN	Multiple pathways for fluoroquinolone secretion by human intestinal epithelial (Caco-2) cells. Br J Pharmacol. 2002 Mar;135(5):1263-75.
DM7OKQV	RU	https://doi.org/10.1038/sj.bjp.0704560

DM7OKQV	DI	DM7OKQV
DM7OKQV	DN	Cholic acid
DM7OKQV	MI	DTCSGPB
DM7OKQV	MN	Multidrug resistance-associated protein 4 (ABCC4)
DM7OKQV	MT	DTP
DM7OKQV	MA	Substrate
DM7OKQV	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM7OKQV	RU	https://doi.org/10.1007/s11095-012-0935-x

DM7OKQV	DI	DM7OKQV
DM7OKQV	DN	Cholic acid
DM7OKQV	MI	DTE2B1D
DM7OKQV	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DM7OKQV	MT	DTP
DM7OKQV	MA	Substrate
DM7OKQV	RN	Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology. 1995 Oct;109(4):1274-82.
DM7OKQV	RU	http://www.ncbi.nlm.nih.gov/pubmed/7557095

DM7OKQV	DI	DM7OKQV
DM7OKQV	DN	Cholic acid
DM7OKQV	MI	DT3D8F0
DM7OKQV	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM7OKQV	MT	DTP
DM7OKQV	MA	Substrate
DM7OKQV	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DM7OKQV	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DM7OKQV	DI	DM7OKQV
DM7OKQV	DN	Cholic acid
DM7OKQV	MI	TT9V5JH
DM7OKQV	MN	Phospholipase A2 (PLA2G1B)
DM7OKQV	MT	DTT
DM7OKQV	MA	Inhibitor
DM7OKQV	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM7OKQV	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM7OKQV	DI	DM7OKQV
DM7OKQV	DN	Cholic acid
DM7OKQV	MI	DEYWLRK
DM7OKQV	MN	Sulfotransferase 1A1 (SULT1A1)
DM7OKQV	MT	DME
DM7OKQV	MA	Metabolism
DM7OKQV	RN	Kinetic analysis of bile acid sulfation by stably expressed human sulfotransferase 2A1 (SULT2A1). Xenobiotica. 2010 Mar;40(3):184-94.
DM7OKQV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20102295

DMOI1ZF	DI	DMOI1ZF
DMOI1ZF	DN	Choline alfoscerate
DMOI1ZF	MI	TTH18TF
DMOI1ZF	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMOI1ZF	MT	DTT
DMOI1ZF	MA	Modulator
DMOI1ZF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 467).
DMOI1ZF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=467

DM8P137	DI	DM8P137
DM8P137	DN	Choline salicylate
DM8P137	MI	DEAHED0
DM8P137	MN	Choline dehydrogenase (CHDH)
DM8P137	MT	DME
DM8P137	MA	Metabolism
DM8P137	RN	Usual choline and betaine dietary intake and incident coronary heart disease: the atherosclerosis risk in communities (ARIC) study. BMC Cardiovasc Disord. 2007 Jul 13;7:20.
DM8P137	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17629908

DM8P137	DI	DM8P137
DM8P137	DN	Choline salicylate
DM8P137	MI	DE5NGOW
DM8P137	MN	Choline O-acetyltransferase (CHAT)
DM8P137	MT	DME
DM8P137	MA	Metabolism
DM8P137	RN	The effect of trichlorfon and methylazoxymethanol on the development of guinea pig cerebellum. Toxicol Appl Pharmacol. 2007 Mar;219(2-3):128-35.
DM8P137	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17150236

DM8P137	DI	DM8P137
DM8P137	DN	Choline salicylate
DM8P137	MI	DEL87ZT
DM8P137	MN	Choline/ethanolaminephosphotransferase 1 (CEPT1)
DM8P137	MT	DME
DM8P137	MA	Metabolism
DM8P137	RN	PC and PE synthesis: mixed micellar analysis of the cholinephosphotransferase and ethanolaminephosphotransferase activities of human choline/ethanolamine phosphotransferase 1 (CEPT1). Lipids. 2002 Jul;37(7):663-72.
DM8P137	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12216837

DMFMZ3G	DI	DMFMZ3G
DMFMZ3G	DN	Choriogonadotropin alfa
DMFMZ3G	MI	TT2O4W9
DMFMZ3G	MN	Luteinizing hormone receptor (LHCGR)
DMFMZ3G	MT	DTT
DMFMZ3G	MA	Modulator
DMFMZ3G	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMFMZ3G	RU	https://www.fda.gov/

DMFT73E	DI	DMFT73E
DMFT73E	DN	Chorionic Gonadotropin
DMFT73E	MI	TT2O4W9
DMFT73E	MN	Luteinizing hormone receptor (LHCGR)
DMFT73E	MT	DTT
DMFT73E	MA	Modulator
DMFT73E	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMFT73E	RU	https://www.fda.gov/

DM2NA4K	DI	DM2NA4K
DM2NA4K	DN	Ciclesonide
DM2NA4K	MI	TTJL8VG
DM2NA4K	MN	Corticosteroid-binding globulin (SERPINA6)
DM2NA4K	MT	DTT
DM2NA4K	MA	Binder
DM2NA4K	RN	Novel human corticosteroid-binding globulin variant with low cortisol-binding affinity. J Clin Endocrinol Metab. 2000 Jan;85(1):361-7.
DM2NA4K	RU	https://pubmed.ncbi.nlm.nih.gov/10634411

DM2NA4K	DI	DM2NA4K
DM2NA4K	DN	Ciclesonide
DM2NA4K	MI	DECB0K3
DM2NA4K	MN	Cytochrome P450 2D6 (CYP2D6)
DM2NA4K	MT	DME
DM2NA4K	MA	Metabolism
DM2NA4K	RN	Identification of enzymes involved in phase I metabolism of ciclesonide by human liver microsomes. Eur J Drug Metab Pharmacokinet. 2005 Oct-Dec;30(4):275-86.
DM2NA4K	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16435573

DM2NA4K	DI	DM2NA4K
DM2NA4K	DN	Ciclesonide
DM2NA4K	MI	DE4LYSA
DM2NA4K	MN	Cytochrome P450 3A4 (CYP3A4)
DM2NA4K	MT	DME
DM2NA4K	MA	Metabolism
DM2NA4K	RN	Identification of enzymes involved in phase I metabolism of ciclesonide by human liver microsomes. Eur J Drug Metab Pharmacokinet. 2005 Oct-Dec;30(4):275-86.
DM2NA4K	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16435573

DM2NA4K	DI	DM2NA4K
DM2NA4K	DN	Ciclesonide
DM2NA4K	MI	DTUGYRD
DM2NA4K	MN	P-glycoprotein 1 (ABCB1)
DM2NA4K	MT	DTP
DM2NA4K	MA	Substrate
DM2NA4K	RN	Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux. Toxicol Appl Pharmacol. 2012 May 1;260(3):294-302.
DM2NA4K	RU	https://doi.org/10.1016/j.taap.2012.03.008

DMN5T2A	DI	DMN5T2A
DMN5T2A	DN	Ciclopirox
DMN5T2A	MI	TTJQFBG
DMN5T2A	MN	HIF-prolyl hydroxylase (HPH)
DMN5T2A	MT	DTT
DMN5T2A	MA	Modulator
DMN5T2A	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMN5T2A	RU	https://www.fda.gov/

DMT2KRV	DI	DMT2KRV
DMT2KRV	DN	Ciclosporin
DMT2KRV	MI	DTI7UX6
DMT2KRV	MN	Breast cancer resistance protein (ABCG2)
DMT2KRV	MT	DTP
DMT2KRV	MA	Substrate
DMT2KRV	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMT2KRV	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMT2KRV	DI	DMT2KRV
DMT2KRV	DN	Ciclosporin
DMT2KRV	MI	TTA4LDE
DMT2KRV	MN	Calcineurin (PPP3CA)
DMT2KRV	MT	DTT
DMT2KRV	MA	Inhibitor
DMT2KRV	RN	Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis. Curr Opin Rheumatol. 2007 May;19(3):238-45.
DMT2KRV	RU	https://pubmed.ncbi.nlm.nih.gov/17414949

DMAZJFX	DI	DMAZJFX
DMAZJFX	DN	Ciclosporin
DMAZJFX	MI	DE4LYSA
DMAZJFX	MN	Cytochrome P450 3A4 (CYP3A4)
DMAZJFX	MT	DME
DMAZJFX	MA	Metabolism
DMAZJFX	RN	Dasatinib significantly reduced in vivo exposure to cyclosporine in a rat model: The possible involvement of CYP3A induction. Pharmacol Rep. 2019 Apr;71(2):201-205.
DMAZJFX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30785057

DMAZJFX	DI	DMAZJFX
DMAZJFX	DN	Ciclosporin
DMAZJFX	MI	DEIBDNY
DMAZJFX	MN	Cytochrome P450 3A5 (CYP3A5)
DMAZJFX	MT	DME
DMAZJFX	MA	Metabolism
DMAZJFX	RN	CYP3A4*18B and CYP3A5*3 polymorphisms contribute to pharmacokinetic variability of cyclosporine among healthy Chinese subjects. Eur J Pharm Sci. 2015 Aug 30;76:238-44.
DMAZJFX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25976223

DMAZJFX	DI	DMAZJFX
DMAZJFX	DN	Ciclosporin
DMAZJFX	MI	DERD86B
DMAZJFX	MN	Cytochrome P450 3A7 (CYP3A7)
DMAZJFX	MT	DME
DMAZJFX	MA	Metabolism
DMAZJFX	RN	CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients. Ther Drug Monit. 2008 Dec;30(6):689-99.
DMAZJFX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18978522

DMT2KRV	DI	DMT2KRV
DMT2KRV	DN	Ciclosporin
DMT2KRV	MI	DTFI42L
DMT2KRV	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMT2KRV	MT	DTP
DMT2KRV	MA	Substrate
DMT2KRV	RN	Is cyclosporine A transport inhibited by pravastatin via multidrug resistant protein 2? Eur J Clin Pharmacol. 2010 Feb;66(2):153-8.
DMT2KRV	RU	https://doi.org/10.1007/s00228-009-0740-6

DMT2KRV	DI	DMT2KRV
DMT2KRV	DN	Ciclosporin
DMT2KRV	MI	DTUGYRD
DMT2KRV	MN	P-glycoprotein 1 (ABCB1)
DMT2KRV	MT	DTP
DMT2KRV	MA	Substrate
DMT2KRV	RN	Contribution of down-regulation of intestinal and hepatic cytochrome P450 3A to increased absorption of cyclosporine A in a rat nephrosis model. J Pharmacol Exp Ther. 2008 Nov;327(2):592-9.
DMT2KRV	RU	http://www.ncbi.nlm.nih.gov/pubmed/18725544

DMA13GD	DI	DMA13GD
DMA13GD	DN	Cidofovir
DMA13GD	MI	TTIU7X1
DMA13GD	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMA13GD	MT	DTT
DMA13GD	MA	Modulator
DMA13GD	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMA13GD	RU	https://www.fda.gov/

DMA13GD	DI	DMA13GD
DMA13GD	DN	Cidofovir
DMA13GD	MI	DTFI42L
DMA13GD	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMA13GD	MT	DTP
DMA13GD	MA	Substrate
DMA13GD	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMA13GD	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMA13GD	DI	DMA13GD
DMA13GD	DN	Cidofovir
DMA13GD	MI	DTQ23VB
DMA13GD	MN	Organic anion transporter 1 (SLC22A6)
DMA13GD	MT	DTP
DMA13GD	MA	Substrate
DMA13GD	RN	Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm Res. 2007 Apr;24(4):811-5.
DMA13GD	RU	http://www.ncbi.nlm.nih.gov/pubmed/17372702

DMA13GD	DI	DMA13GD
DMA13GD	DN	Cidofovir
DMA13GD	MI	DTVP67E
DMA13GD	MN	Organic anion transporter 3 (SLC22A8)
DMA13GD	MT	DTP
DMA13GD	MA	Substrate
DMA13GD	RN	Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm Res. 2007 Apr;24(4):811-5.
DMA13GD	RU	http://www.ncbi.nlm.nih.gov/pubmed/17372702

DME2H5T	DI	DME2H5T
DME2H5T	DN	Cilastatin
DME2H5T	MI	TTYUENF
DME2H5T	MN	Dehydropeptidase I (DPEP1)
DME2H5T	MT	DTT
DME2H5T	MA	Inhibitor
DME2H5T	RN	Pharmacokinetic study of pleural fluid penetration of carbapenem antibiotic agents in chemical pleurisy. Respir Med. 2006 Feb;100(2):324-31.
DME2H5T	RU	https://pubmed.ncbi.nlm.nih.gov/16493791

DM4V6JA	DI	DM4V6JA
DM4V6JA	DN	Cilazapril
DM4V6JA	MI	TTL69WB
DM4V6JA	MN	Angiotensin-converting enzyme (ACE)
DM4V6JA	MT	DTT
DM4V6JA	MA	Inhibitor
DM4V6JA	RN	Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Am J Kidney Dis. 2008 Sep;52(3):486-93.
DM4V6JA	RU	https://pubmed.ncbi.nlm.nih.gov/18423812

DMZMSCT	DI	DMZMSCT
DMZMSCT	DN	Cilostazol
DMZMSCT	MI	DEJGDUW
DMZMSCT	MN	Cytochrome P450 1A2 (CYP1A2)
DMZMSCT	MT	DME
DMZMSCT	MA	Metabolism
DMZMSCT	RN	Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8.
DMZMSCT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10702888

DMZMSCT	DI	DMZMSCT
DMZMSCT	DN	Cilostazol
DMZMSCT	MI	DECB0K3
DMZMSCT	MN	Cytochrome P450 2D6 (CYP2D6)
DMZMSCT	MT	DME
DMZMSCT	MA	Metabolism
DMZMSCT	RN	Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8.
DMZMSCT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10702888

DMZMSCT	DI	DMZMSCT
DMZMSCT	DN	Cilostazol
DMZMSCT	MI	DE4LYSA
DMZMSCT	MN	Cytochrome P450 3A4 (CYP3A4)
DMZMSCT	MT	DME
DMZMSCT	MA	Metabolism
DMZMSCT	RN	Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8.
DMZMSCT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10702888

DMZMSCT	DI	DMZMSCT
DMZMSCT	DN	Cilostazol
DMZMSCT	MI	DEIBDNY
DMZMSCT	MN	Cytochrome P450 3A5 (CYP3A5)
DMZMSCT	MT	DME
DMZMSCT	MA	Metabolism
DMZMSCT	RN	Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8.
DMZMSCT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10702888

DMZMSCT	DI	DMZMSCT
DMZMSCT	DN	Cilostazol
DMZMSCT	MI	DERD86B
DMZMSCT	MN	Cytochrome P450 3A7 (CYP3A7)
DMZMSCT	MT	DME
DMZMSCT	MA	Metabolism
DMZMSCT	RN	Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8.
DMZMSCT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10702888

DMZMSCT	DI	DMZMSCT
DMZMSCT	DN	Cilostazol
DMZMSCT	MI	DEGTFWK
DMZMSCT	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMZMSCT	MT	DME
DMZMSCT	MA	Metabolism
DMZMSCT	RN	Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8.
DMZMSCT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10702888

DMZMSCT	DI	DMZMSCT
DMZMSCT	DN	Cilostazol
DMZMSCT	MI	DTVP67E
DMZMSCT	MN	Organic anion transporter 3 (SLC22A8)
DMZMSCT	MT	DTP
DMZMSCT	MA	Substrate
DMZMSCT	RN	Aspirin and probenecid inhibit organic anion transporter 3-mediated renal uptake of cilostazol and probenecid induces metabolism of cilostazol in the rat. Drug Metab Dispos. 2014 Jun;42(6):996-1007.
DMZMSCT	RU	http://www.ncbi.nlm.nih.gov/pubmed/24692216

DMZMSCT	DI	DMZMSCT
DMZMSCT	DN	Cilostazol
DMZMSCT	MI	DT3D8F0
DMZMSCT	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMZMSCT	MT	DTP
DMZMSCT	MA	Substrate
DMZMSCT	RN	Organic Anion-Transporting Polypeptide and Efflux Transporter-Mediated Hepatic Uptake and Biliary Excretion of Cilostazol and Its Metabolites in Rats and Humans. J Pharm Sci. 2017 Sep;106(9):2515-2523.
DMZMSCT	RU	http://www.ncbi.nlm.nih.gov/pubmed/28535976

DMZMSCT	DI	DMZMSCT
DMZMSCT	DN	Cilostazol
DMZMSCT	MI	DT9C1TS
DMZMSCT	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMZMSCT	MT	DTP
DMZMSCT	MA	Substrate
DMZMSCT	RN	Organic Anion-Transporting Polypeptide and Efflux Transporter-Mediated Hepatic Uptake and Biliary Excretion of Cilostazol and Its Metabolites in Rats and Humans. J Pharm Sci. 2017 Sep;106(9):2515-2523.
DMZMSCT	RU	http://www.ncbi.nlm.nih.gov/pubmed/28535976

DMZMSCT	DI	DMZMSCT
DMZMSCT	DN	Cilostazol
DMZMSCT	MI	TTZCG4L
DMZMSCT	MN	Phosphodiesterase 3 (PDE3)
DMZMSCT	MT	DTT
DMZMSCT	MA	Modulator
DMZMSCT	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMZMSCT	RU	https://www.fda.gov/

DMZMSCT	DI	DMZMSCT
DMZMSCT	DN	Cilostazol
DMZMSCT	MI	TT06AWU
DMZMSCT	MN	Phosphodiesterase 3A (PDE3A)
DMZMSCT	MT	DTT
DMZMSCT	MA	Inhibitor
DMZMSCT	RN	A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem. 1985 May;28(5):537-45.
DMZMSCT	RU	https://pubmed.ncbi.nlm.nih.gov/2985781

DMH61ZB	DI	DMH61ZB
DMH61ZB	DN	Cimetidine
DMH61ZB	MI	DTI7UX6
DMH61ZB	MN	Breast cancer resistance protein (ABCG2)
DMH61ZB	MT	DTP
DMH61ZB	MA	Substrate
DMH61ZB	RN	Progesterone acts via progesterone receptors A and B to regulate breast cancer resistance protein expression. Mol Pharmacol. 2008 Mar;73(3):613-5.
DMH61ZB	RU	http://www.ncbi.nlm.nih.gov/pubmed/18086804

DMH61ZB	DI	DMH61ZB
DMH61ZB	DN	Cimetidine
DMH61ZB	MI	TTQHJ1K
DMH61ZB	MN	Histamine H2 receptor (H2R)
DMH61ZB	MT	DTT
DMH61ZB	MA	Antagonist
DMH61ZB	RN	Histamine H1 and H2 receptor antagonists accelerate skin barrier repair and prevent epidermal hyperplasia induced by barrier disruption in a dry environment. J Invest Dermatol. 2001 Feb;116(2):261-5.
DMH61ZB	RU	https://pubmed.ncbi.nlm.nih.gov/11180002

DMH61ZB	DI	DMH61ZB
DMH61ZB	DN	Cimetidine
DMH61ZB	MI	DTZGT0P
DMH61ZB	MN	Multidrug and toxin extrusion protein 1 (SLC47A1)
DMH61ZB	MT	DTP
DMH61ZB	MA	Substrate
DMH61ZB	RN	Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
DMH61ZB	RU	http://www.ncbi.nlm.nih.gov/pubmed/17509534

DMH61ZB	DI	DMH61ZB
DMH61ZB	DN	Cimetidine
DMH61ZB	MI	DT3TX4H
DMH61ZB	MN	Multidrug and toxin extrusion protein 2 (SLC47A2)
DMH61ZB	MT	DTP
DMH61ZB	MA	Substrate
DMH61ZB	RN	Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
DMH61ZB	RU	http://www.ncbi.nlm.nih.gov/pubmed/17509534

DMH61ZB	DI	DMH61ZB
DMH61ZB	DN	Cimetidine
DMH61ZB	MI	DTVP67E
DMH61ZB	MN	Organic anion transporter 3 (SLC22A8)
DMH61ZB	MT	DTP
DMH61ZB	MA	Substrate
DMH61ZB	RN	Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther. 2007 May;321(2):673-83.
DMH61ZB	RU	http://www.ncbi.nlm.nih.gov/pubmed/17314201

DMH61ZB	DI	DMH61ZB
DMH61ZB	DN	Cimetidine
DMH61ZB	MI	DTT79CX
DMH61ZB	MN	Organic cation transporter 1 (SLC22A1)
DMH61ZB	MT	DTP
DMH61ZB	MA	Substrate
DMH61ZB	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMH61ZB	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DMH61ZB	DI	DMH61ZB
DMH61ZB	DN	Cimetidine
DMH61ZB	MI	DT9IDPW
DMH61ZB	MN	Organic cation transporter 2 (SLC22A2)
DMH61ZB	MT	DTP
DMH61ZB	MA	Substrate
DMH61ZB	RN	Elevated systemic elimination of cimetidine in rats with acute biliary obstruction: the role of renal organic cation transporter OCT2. Drug Metab Pharmacokinet. 2010;25(4):328-34.
DMH61ZB	RU	http://www.ncbi.nlm.nih.gov/pubmed/20814153

DMH61ZB	DI	DMH61ZB
DMH61ZB	DN	Cimetidine
DMH61ZB	MI	DTUGYRD
DMH61ZB	MN	P-glycoprotein 1 (ABCB1)
DMH61ZB	MT	DTP
DMH61ZB	MA	Substrate
DMH61ZB	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMH61ZB	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMZHPNE	DI	DMZHPNE
DMZHPNE	DN	Cimetropium bromide
DMZHPNE	MI	TTH18TF
DMZHPNE	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMZHPNE	MT	DTT
DMZHPNE	MA	Modulator
DMZHPNE	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMZHPNE	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DMCX0K3	DI	DMCX0K3
DMCX0K3	DN	Cinacalcet
DMCX0K3	MI	DEJGDUW
DMCX0K3	MN	Cytochrome P450 1A2 (CYP1A2)
DMCX0K3	MT	DME
DMCX0K3	MA	Metabolism
DMCX0K3	RN	Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8.
DMCX0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10702888

DMCX0K3	DI	DMCX0K3
DMCX0K3	DN	Cinacalcet
DMCX0K3	MI	DECB0K3
DMCX0K3	MN	Cytochrome P450 2D6 (CYP2D6)
DMCX0K3	MT	DME
DMCX0K3	MA	Metabolism
DMCX0K3	RN	Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. Clin Pharmacokinet. 2009;48(5):303-11.
DMCX0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19566113

DMCX0K3	DI	DMCX0K3
DMCX0K3	DN	Cinacalcet
DMCX0K3	MI	DE4LYSA
DMCX0K3	MN	Cytochrome P450 3A4 (CYP3A4)
DMCX0K3	MT	DME
DMCX0K3	MA	Metabolism
DMCX0K3	RN	Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. Clin Pharmacokinet. 2009;48(5):303-11.
DMCX0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19566113

DMCX0K3	DI	DMCX0K3
DMCX0K3	DN	Cinacalcet
DMCX0K3	MI	TTBUYHA
DMCX0K3	MN	Extracellular calcium-sensing receptor (CASR)
DMCX0K3	MT	DTT
DMCX0K3	MA	Agonist
DMCX0K3	RN	Clinical pipeline report, company report or official report of Amgen (2009).
DMCX0K3	RU	http://www.amgen.com/science/pipe.jsp

DMFIC0M	DI	DMFIC0M
DMFIC0M	DN	Cinalukast
DMFIC0M	MI	TTGKOY9
DMFIC0M	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DMFIC0M	MT	DTT
DMFIC0M	MA	Antagonist
DMFIC0M	RN	Prolonged protection against exercise-induced bronchoconstriction by the leukotriene D4-receptor antagonist cinalukast. J Allergy Clin Immunol. 1997 Feb;99(2):210-5.
DMFIC0M	RU	https://pubmed.ncbi.nlm.nih.gov/9042047

DM7U5QJ	DI	DM7U5QJ
DM7U5QJ	DN	Cinnarizine
DM7U5QJ	MI	DEJGDUW
DM7U5QJ	MN	Cytochrome P450 1A2 (CYP1A2)
DM7U5QJ	MT	DME
DM7U5QJ	MA	Metabolism
DM7U5QJ	RN	Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. AAPS J. 2009 Sep;11(3):481-94.
DM7U5QJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19590965

DM7U5QJ	DI	DM7U5QJ
DM7U5QJ	DN	Cinnarizine
DM7U5QJ	MI	DEJVYAZ
DM7U5QJ	MN	Cytochrome P450 2A6 (CYP2A6)
DM7U5QJ	MT	DME
DM7U5QJ	MA	Metabolism
DM7U5QJ	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM7U5QJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM7U5QJ	DI	DM7U5QJ
DM7U5QJ	DN	Cinnarizine
DM7U5QJ	MI	DEPKLMQ
DM7U5QJ	MN	Cytochrome P450 2B6 (CYP2B6)
DM7U5QJ	MT	DME
DM7U5QJ	MA	Metabolism
DM7U5QJ	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM7U5QJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM7U5QJ	DI	DM7U5QJ
DM7U5QJ	DN	Cinnarizine
DM7U5QJ	MI	DE5IED8
DM7U5QJ	MN	Cytochrome P450 2C9 (CYP2C9)
DM7U5QJ	MT	DME
DM7U5QJ	MA	Metabolism
DM7U5QJ	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM7U5QJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM7U5QJ	DI	DM7U5QJ
DM7U5QJ	DN	Cinnarizine
DM7U5QJ	MI	DECB0K3
DM7U5QJ	MN	Cytochrome P450 2D6 (CYP2D6)
DM7U5QJ	MT	DME
DM7U5QJ	MA	Metabolism
DM7U5QJ	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM7U5QJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM7U5QJ	DI	DM7U5QJ
DM7U5QJ	DN	Cinnarizine
DM7U5QJ	MI	DE4LYSA
DM7U5QJ	MN	Cytochrome P450 3A4 (CYP3A4)
DM7U5QJ	MT	DME
DM7U5QJ	MA	Metabolism
DM7U5QJ	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DM7U5QJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DM7U5QJ	DI	DM7U5QJ
DM7U5QJ	DN	Cinnarizine
DM7U5QJ	MI	TTTIBOJ
DM7U5QJ	MN	Histamine H1 receptor (H1R)
DM7U5QJ	MT	DTT
DM7U5QJ	MA	Antagonist
DM7U5QJ	RN	Central effects of cinnarizine: restricted use in aircrew. Aviat Space Environ Med. 2002 Jun;73(6):570-4.
DM7U5QJ	RU	https://pubmed.ncbi.nlm.nih.gov/12056673

DMDX1ZC	DI	DMDX1ZC
DMDX1ZC	DN	Cinolazepam
DMDX1ZC	MI	TTPTXIN
DMDX1ZC	MN	Translocator protein (TSPO)
DMDX1ZC	MT	DTT
DMDX1ZC	MA	Binder
DMDX1ZC	RN	Short-term sleep laboratory studies with cinolazepam in situational insomnia induced by traffic noise. Int J Clin Pharmacol Res. 1987;7(5):407-18.
DMDX1ZC	RU	https://pubmed.ncbi.nlm.nih.gov/2889679

DM4EWNS	DI	DM4EWNS
DM4EWNS	DN	Cinoxacin
DM4EWNS	MI	TT0IHXV
DM4EWNS	MN	DNA topoisomerase II (TOP2)
DM4EWNS	MT	DTT
DM4EWNS	MA	Inhibitor
DM4EWNS	RN	The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1. J Pharmacol Exp Ther. 1999 Aug;290(2):672-7.
DM4EWNS	RU	https://pubmed.ncbi.nlm.nih.gov/10411577

DMVIKJZ	DI	DMVIKJZ
DMVIKJZ	DN	Cinryze
DMVIKJZ	MI	TTVQ6R9
DMVIKJZ	MN	C1 esterase inhibitor (SERPING1)
DMVIKJZ	MT	DTT
DMVIKJZ	MA	Modulator
DMVIKJZ	RN	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
DMVIKJZ	RU	https://pubmed.ncbi.nlm.nih.gov/19180096

DMVIKJZ	DI	DMVIKJZ
DMVIKJZ	DN	Cinryze
DMVIKJZ	MI	TT7LRQH
DMVIKJZ	MN	Complement C1s component (C1S)
DMVIKJZ	MT	DTT
DMVIKJZ	MA	Modulator
DMVIKJZ	RN	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
DMVIKJZ	RU	https://pubmed.ncbi.nlm.nih.gov/19180096

DMGC5DB	DI	DMGC5DB
DMGC5DB	DN	Ciprofibrate
DMGC5DB	MI	DE4LYSA
DMGC5DB	MN	Cytochrome P450 3A4 (CYP3A4)
DMGC5DB	MT	DME
DMGC5DB	MA	Metabolism
DMGC5DB	RN	Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998 Feb;34(2):155-62.
DMGC5DB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9515185

DMGC5DB	DI	DMGC5DB
DMGC5DB	DN	Ciprofibrate
DMGC5DB	MI	TTJ584C
DMGC5DB	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMGC5DB	MT	DTT
DMGC5DB	MA	Agonist
DMGC5DB	RN	Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42.
DMGC5DB	RU	https://pubmed.ncbi.nlm.nih.gov/10828060

DM2NLS9	DI	DM2NLS9
DM2NLS9	DN	Ciprofloxacin XR
DM2NLS9	MI	TTN6J5F
DM2NLS9	MN	Bacterial DNA gyrase (Bact gyrase)
DM2NLS9	MT	DTT
DM2NLS9	MA	Modulator
DM2NLS9	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM2NLS9	RU	https://www.fda.gov/

DM2NLS9	DI	DM2NLS9
DM2NLS9	DN	Ciprofloxacin XR
DM2NLS9	MI	TTJP4SM
DM2NLS9	MN	Bacterial Penicillin binding protein (Bact PBP)
DM2NLS9	MT	DTT
DM2NLS9	MA	Inhibitor
DM2NLS9	RN	Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
DM2NLS9	RU	https://pubmed.ncbi.nlm.nih.gov/15934867

DM2NLS9	DI	DM2NLS9
DM2NLS9	DN	Ciprofloxacin XR
DM2NLS9	MI	DTI7UX6
DM2NLS9	MN	Breast cancer resistance protein (ABCG2)
DM2NLS9	MT	DTP
DM2NLS9	MA	Substrate
DM2NLS9	RN	Fluoroquinolone efflux mediated by ABC transporters. J Pharm Sci. 2008 Sep;97(9):3483-93.
DM2NLS9	RU	http://www.ncbi.nlm.nih.gov/pubmed/18200507

DM2NLS9	DI	DM2NLS9
DM2NLS9	DN	Ciprofloxacin XR
DM2NLS9	MI	TTU6BFZ
DM2NLS9	MN	Candida Thymidylate synthase (Candi TMP1)
DM2NLS9	MT	DTT
DM2NLS9	MA	Inhibitor
DM2NLS9	RN	Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer. 2003 Feb 20;103(5):587-99.
DM2NLS9	RU	https://pubmed.ncbi.nlm.nih.gov/12494465

DM2NLS9	DI	DM2NLS9
DM2NLS9	DN	Ciprofloxacin XR
DM2NLS9	MI	DTCSGPB
DM2NLS9	MN	Multidrug resistance-associated protein 4 (ABCC4)
DM2NLS9	MT	DTP
DM2NLS9	MA	Substrate
DM2NLS9	RN	Identification of the efflux transporter of the fluoroquinolone antibiotic ciprofloxacin in murine macrophages: studies with ciprofloxacin-resistant cells. Antimicrob Agents Chemother. 2009 Jun;53(6):2410-6.
DM2NLS9	RU	http://www.ncbi.nlm.nih.gov/pubmed/19307362

DM2NLS9	DI	DM2NLS9
DM2NLS9	DN	Ciprofloxacin XR
DM2NLS9	MI	DTVP67E
DM2NLS9	MN	Organic anion transporter 3 (SLC22A8)
DM2NLS9	MT	DTP
DM2NLS9	MA	Substrate
DM2NLS9	RN	Organic anion transporter 3 (oat3/slc22a8) interacts with carboxyfluoroquinolones, and deletion increases systemic exposure to ciprofloxacin. Mol Pharmacol. 2008 Jul;74(1):122-31.
DM2NLS9	RU	http://www.ncbi.nlm.nih.gov/pubmed/18381565

DM2NLS9	DI	DM2NLS9
DM2NLS9	DN	Ciprofloxacin XR
DM2NLS9	MI	DTE2B1D
DM2NLS9	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DM2NLS9	MT	DTP
DM2NLS9	MA	Substrate
DM2NLS9	RN	Fruit juice inhibition of uptake transport: a new type of food-drug interaction. Br J Clin Pharmacol. 2010 Nov;70(5):645-55.
DM2NLS9	RU	http://www.ncbi.nlm.nih.gov/pubmed/21039758

DM2NLS9	DI	DM2NLS9
DM2NLS9	DN	Ciprofloxacin XR
DM2NLS9	MI	TTIXTO3
DM2NLS9	MN	Staphylococcus Topoisomerase IV (Stap-coc parC)
DM2NLS9	MT	DTT
DM2NLS9	MA	Modulator
DM2NLS9	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM2NLS9	RU	https://www.fda.gov/

DMZR26N	DI	DMZR26N
DMZR26N	DN	Ciprofloxacin+dexamethasone
DMZR26N	MI	TT0IHXV
DMZR26N	MN	DNA topoisomerase II (TOP2)
DMZR26N	MT	DTT
DMZR26N	MA	Binder
DMZR26N	RN	Emerging therapies for the treatment and prevention of otitis media. Expert Opin Emerg Drugs. 2006 May;11(2):251-64.
DMZR26N	RU	https://pubmed.ncbi.nlm.nih.gov/16634700

DMY7PED	DI	DMY7PED
DMY7PED	DN	Cisapride
DMY7PED	MI	TT07C3Y
DMY7PED	MN	5-HT 4 receptor (HTR4)
DMY7PED	MT	DTT
DMY7PED	MA	Agonist
DMY7PED	RN	Metoclopramide stimulates catecholamine- and granin-derived peptide secretion from pheochromocytoma cells through activation of serotonin type 4 (5... Endocr Relat Cancer. 2009 Mar;16(1):281-90.
DMY7PED	RU	https://pubmed.ncbi.nlm.nih.gov/18948374

DMY7PED	DI	DMY7PED
DMY7PED	DN	Cisapride
DMY7PED	MI	DEJVYAZ
DMY7PED	MN	Cytochrome P450 2A6 (CYP2A6)
DMY7PED	MT	DME
DMY7PED	MA	Metabolism
DMY7PED	RN	Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co-medication interactions. Br J Pharmacol. 2000 Apr;129(8):1655-67.
DMY7PED	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10780971

DMY7PED	DI	DMY7PED
DMY7PED	DN	Cisapride
DMY7PED	MI	DEPKLMQ
DMY7PED	MN	Cytochrome P450 2B6 (CYP2B6)
DMY7PED	MT	DME
DMY7PED	MA	Metabolism
DMY7PED	RN	Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. Drug Metab Dispos. 2000 Jul;28(7):789-800.
DMY7PED	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10859153

DMY7PED	DI	DMY7PED
DMY7PED	DN	Cisapride
DMY7PED	MI	DES5XRU
DMY7PED	MN	Cytochrome P450 2C8 (CYP2C8)
DMY7PED	MT	DME
DMY7PED	MA	Metabolism
DMY7PED	RN	Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. Drug Metab Dispos. 2000 Jul;28(7):789-800.
DMY7PED	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10859153

DMY7PED	DI	DMY7PED
DMY7PED	DN	Cisapride
DMY7PED	MI	DE5IED8
DMY7PED	MN	Cytochrome P450 2C9 (CYP2C9)
DMY7PED	MT	DME
DMY7PED	MA	Metabolism
DMY7PED	RN	Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co-medication interactions. Br J Pharmacol. 2000 Apr;129(8):1655-67.
DMY7PED	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10780971

DMY7PED	DI	DMY7PED
DMY7PED	DN	Cisapride
DMY7PED	MI	DE4LYSA
DMY7PED	MN	Cytochrome P450 3A4 (CYP3A4)
DMY7PED	MT	DME
DMY7PED	MA	Metabolism
DMY7PED	RN	Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo. Clin Pharmacol Ther. 2003 Mar;73(3):209-22.
DMY7PED	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12621386

DMY7PED	DI	DMY7PED
DMY7PED	DN	Cisapride
DMY7PED	MI	DEIBDNY
DMY7PED	MN	Cytochrome P450 3A5 (CYP3A5)
DMY7PED	MT	DME
DMY7PED	MA	Metabolism
DMY7PED	RN	Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. Drug Metab Dispos. 2000 Jul;28(7):789-800.
DMY7PED	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10859153

DMY7PED	DI	DMY7PED
DMY7PED	DN	Cisapride
DMY7PED	MI	DERD86B
DMY7PED	MN	Cytochrome P450 3A7 (CYP3A7)
DMY7PED	MT	DME
DMY7PED	MA	Metabolism
DMY7PED	RN	Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. Drug Metab Dispos. 2000 Jul;28(7):789-800.
DMY7PED	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10859153

DMY7PED	DI	DMY7PED
DMY7PED	DN	Cisapride
DMY7PED	MI	DEGTFWK
DMY7PED	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMY7PED	MT	DME
DMY7PED	MA	Metabolism
DMY7PED	RN	Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. Drug Metab Dispos. 2000 Jul;28(7):789-800.
DMY7PED	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10859153

DMUZPJ5	DI	DMUZPJ5
DMUZPJ5	DN	Cisatracurium
DMUZPJ5	MI	TTUPDWN
DMUZPJ5	MN	Cholinergic receptor unspecific (CHR)
DMUZPJ5	MT	DTT
DMUZPJ5	MA	Antagonist
DMUZPJ5	RN	Bradycardia produced by pyridostigmine and physostigmine. Can J Anaesth. 1997 Dec;44(12):1286-92.
DMUZPJ5	RU	https://pubmed.ncbi.nlm.nih.gov/9429048

DMUZPJ5	DI	DMUZPJ5
DMUZPJ5	DN	Cisatracurium
DMUZPJ5	MI	TTF4E0J
DMUZPJ5	MN	Neuronal acetylcholine receptor alpha-2 (CHRNA2)
DMUZPJ5	MT	DTT
DMUZPJ5	MA	Antagonist
DMUZPJ5	RN	Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52.
DMUZPJ5	RU	https://pubmed.ncbi.nlm.nih.gov/19417616

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	DTI7UX6
DMRHGI9	MN	Breast cancer resistance protein (ABCG2)
DMRHGI9	MT	DTP
DMRHGI9	MA	Substrate
DMRHGI9	RN	Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
DMRHGI9	RU	https://doi.org/10.1016/j.bcp.2008.11.007

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	DT206GF
DMRHGI9	MN	Copper-transporting ATPase 2 (ATP7B)
DMRHGI9	MT	DTP
DMRHGI9	MA	Substrate
DMRHGI9	RN	Effect of cisplatin on the transport activity of PII-type ATPases. Metallomics. 2017 Jul 19;9(7):960-968.
DMRHGI9	RU	http://www.ncbi.nlm.nih.gov/pubmed/28636017

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	DEVDYN7
DMRHGI9	MN	Cytochrome P450 2E1 (CYP2E1)
DMRHGI9	MT	DME
DMRHGI9	MA	Metabolism
DMRHGI9	RN	Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
DMRHGI9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12675844

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	DE4ZHS1
DMRHGI9	MN	Glutathione S-transferase alpha-1 (GSTA1)
DMRHGI9	MT	DME
DMRHGI9	MA	Metabolism
DMRHGI9	RN	Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin. Mol Cancer Ther. 2008 Oct;7(10):3247-55.
DMRHGI9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18852128

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	DEH7XYP
DMRHGI9	MN	Glutathione S-transferase alpha-4 (GSTA4)
DMRHGI9	MT	DME
DMRHGI9	MA	Metabolism
DMRHGI9	RN	GSTA4 mediates reduction of cisplatin ototoxicity in female mice. Nat Commun. 2019 Sep 12;10(1):4150.
DMRHGI9	RU	https://pubmed.ncbi.nlm.nih.gov/31515474

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	DEYZEJA
DMRHGI9	MN	Glutathione S-transferase mu-1 (GSTM1)
DMRHGI9	MT	DME
DMRHGI9	MA	Metabolism
DMRHGI9	RN	Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs. 2000 Sep;11(8):639-43.
DMRHGI9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11081456

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	DEK6079
DMRHGI9	MN	Glutathione S-transferase pi (GSTP1)
DMRHGI9	MT	DME
DMRHGI9	MA	Metabolism
DMRHGI9	RN	Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs. 2000 Sep;11(8):639-43.
DMRHGI9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11081456

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	DE3PKUG
DMRHGI9	MN	Glutathione S-transferase theta-1 (GSTT1)
DMRHGI9	MT	DME
DMRHGI9	MA	Metabolism
DMRHGI9	RN	Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs. 2000 Sep;11(8):639-43.
DMRHGI9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11081456

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	DTP8L4F
DMRHGI9	MN	High affinity copper uptake protein 1 (SLC31A1)
DMRHGI9	MT	DTP
DMRHGI9	MA	Substrate
DMRHGI9	RN	Overcoming platinum drug resistance with copper-lowering agents. Anticancer Res. 2013 Oct;33(10):4157-61.
DMRHGI9	RU	http://www.ncbi.nlm.nih.gov/pubmed/24122978

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	TTUTN1I
DMRHGI9	MN	Human Deoxyribonucleic acid (hDNA)
DMRHGI9	MT	DTT
DMRHGI9	MA	Modulator
DMRHGI9	RN	Cisplatin and DNA repair in cancer chemotherapy.Trends Biochem Sci.1995 Oct;20(10):435-9.
DMRHGI9	RU	https://www.ncbi.nlm.nih.gov/pubmed/8533159

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	DE5ME8A
DMRHGI9	MN	Metallothionein-1A (MT1A)
DMRHGI9	MT	DME
DMRHGI9	MA	Metabolism
DMRHGI9	RN	Role of metallothionein in cisplatin sensitivity of germ-cell tumours. Int J Cancer. 2000 Mar 15;85(6):777-81.
DMRHGI9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10709094

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	DEFKGT7
DMRHGI9	MN	Metallothionein-2A (MT2A)
DMRHGI9	MT	DME
DMRHGI9	MA	Metabolism
DMRHGI9	RN	Role of metallothionein in cisplatin sensitivity of germ-cell tumours. Int J Cancer. 2000 Mar 15;85(6):777-81.
DMRHGI9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10709094

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	DTSYQGK
DMRHGI9	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMRHGI9	MT	DTP
DMRHGI9	MA	Substrate
DMRHGI9	RN	Hammerhead ribozyme against gamma-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins. Cancer Gene Ther. 2001 Oct;8(10):803-14.
DMRHGI9	RU	http://www.ncbi.nlm.nih.gov/pubmed/11687904

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	DTFI42L
DMRHGI9	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMRHGI9	MT	DTP
DMRHGI9	MA	Substrate
DMRHGI9	RN	Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
DMRHGI9	RU	http://www.ncbi.nlm.nih.gov/pubmed/18834541

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	DT582KR
DMRHGI9	MN	Multidrug resistance-associated protein 6 (ABCC6)
DMRHGI9	MT	DTP
DMRHGI9	MA	Substrate
DMRHGI9	RN	Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res. 2002 Nov 1;62(21):6172-7.
DMRHGI9	RU	http://www.ncbi.nlm.nih.gov/pubmed/12414644

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	DEA3U9Y
DMRHGI9	MN	Myeloperoxidase (MPO)
DMRHGI9	MT	DME
DMRHGI9	MA	Metabolism
DMRHGI9	RN	Cisplatin reduces Brucella melitensis-infected cell number by inducing apoptosis, oxidant and pro-inflammatory cytokine production. Res Vet Sci. 2010 Apr;88(2):218-26.
DMRHGI9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19818462

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	DTT79CX
DMRHGI9	MN	Organic cation transporter 1 (SLC22A1)
DMRHGI9	MT	DTP
DMRHGI9	MA	Substrate
DMRHGI9	RN	Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
DMRHGI9	RU	http://www.ncbi.nlm.nih.gov/pubmed/16914559

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	DT9IDPW
DMRHGI9	MN	Organic cation transporter 2 (SLC22A2)
DMRHGI9	MT	DTP
DMRHGI9	MA	Substrate
DMRHGI9	RN	Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol. 2005 Dec;167(6):1477-84.
DMRHGI9	RU	http://www.ncbi.nlm.nih.gov/pubmed/16314463

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	DTUGYRD
DMRHGI9	MN	P-glycoprotein 1 (ABCB1)
DMRHGI9	MT	DTP
DMRHGI9	MA	Substrate
DMRHGI9	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMRHGI9	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	DT8Q56F
DMRHGI9	MN	Probable low affinity copper uptake protein 2 (SLC31A2)
DMRHGI9	MT	DTP
DMRHGI9	MA	Substrate
DMRHGI9	RN	Copper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo. Mol Pharmacol. 2011 Jan;79(1):157-66.
DMRHGI9	RU	http://www.ncbi.nlm.nih.gov/pubmed/20930109

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	DENP5RY
DMRHGI9	MN	Quinone reductase 1 (NQO1)
DMRHGI9	MT	DME
DMRHGI9	MA	Metabolism
DMRHGI9	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
DMRHGI9	RU	https://www.pharmgkb.org/pathway/PA150642262

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	DEUTDON
DMRHGI9	MN	Superoxide dismutase 1 (SOD1)
DMRHGI9	MT	DME
DMRHGI9	MA	Metabolism
DMRHGI9	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
DMRHGI9	RU	https://www.pharmgkb.org/pathway/PA150642262

DM2G9AE	DI	DM2G9AE
DM2G9AE	DN	Citalopram
DM2G9AE	MI	DECB0K3
DM2G9AE	MN	Cytochrome P450 2D6 (CYP2D6)
DM2G9AE	MT	DME
DM2G9AE	MA	Metabolism
DM2G9AE	RN	Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69.
DM2G9AE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8968657

DM2G9AE	DI	DM2G9AE
DM2G9AE	DN	Citalopram
DM2G9AE	MI	DEVDYN7
DM2G9AE	MN	Cytochrome P450 2E1 (CYP2E1)
DM2G9AE	MT	DME
DM2G9AE	MA	Metabolism
DM2G9AE	RN	Antidepressant drugs in the elderly--role of the cytochrome P450 2D6. World J Biol Psychiatry. 2003 Apr;4(2):74-80.
DM2G9AE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12692778

DM2G9AE	DI	DM2G9AE
DM2G9AE	DN	Citalopram
DM2G9AE	MI	DE4LYSA
DM2G9AE	MN	Cytochrome P450 3A4 (CYP3A4)
DM2G9AE	MT	DME
DM2G9AE	MA	Metabolism
DM2G9AE	RN	PharmGKB summary: citalopram pharmacokinetics pathway. Pharmacogenet Genomics. 2011 Nov;21(11):769-72.
DM2G9AE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21546862

DM2G9AE	DI	DM2G9AE
DM2G9AE	DN	Citalopram
DM2G9AE	MI	DEGTFWK
DM2G9AE	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM2G9AE	MT	DME
DM2G9AE	MA	Metabolism
DM2G9AE	RN	Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects. Biol Psychiatry. 1999 Sep 15;46(6):839-49.
DM2G9AE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10494454

DM2G9AE	DI	DM2G9AE
DM2G9AE	DN	Citalopram
DM2G9AE	MI	DTSYQGK
DM2G9AE	MN	Multidrug resistance-associated protein 1 (ABCC1)
DM2G9AE	MT	DTP
DM2G9AE	MA	Substrate
DM2G9AE	RN	MRP1 polymorphisms associated with citalopram response in patients with major depression. J Clin Psychopharmacol. 2010 Apr;30(2):116-25.
DM2G9AE	RU	http://www.ncbi.nlm.nih.gov/pubmed/20520284

DM2G9AE	DI	DM2G9AE
DM2G9AE	DN	Citalopram
DM2G9AE	MI	DTT79CX
DM2G9AE	MN	Organic cation transporter 1 (SLC22A1)
DM2G9AE	MT	DTP
DM2G9AE	MA	Substrate
DM2G9AE	RN	Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
DM2G9AE	RU	https://doi.org/10.2133/dmpk.23.243

DM2G9AE	DI	DM2G9AE
DM2G9AE	DN	Citalopram
DM2G9AE	MI	DTUGYRD
DM2G9AE	MN	P-glycoprotein 1 (ABCB1)
DM2G9AE	MT	DTP
DM2G9AE	MA	Substrate
DM2G9AE	RN	ABCB1 gene polymorphisms are associated with fatal intoxications involving venlafaxine but not citalopram. Int J Legal Med. 2013 May;127(3):579-86.
DM2G9AE	RU	http://www.ncbi.nlm.nih.gov/pubmed/23515680

DM2G9AE	DI	DM2G9AE
DM2G9AE	DN	Citalopram
DM2G9AE	MI	TT3ROYC
DM2G9AE	MN	Serotonin transporter (SERT)
DM2G9AE	MT	DTT
DM2G9AE	MA	Modulator
DM2G9AE	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM2G9AE	RU	https://www.fda.gov/

DMI4XBM	DI	DMI4XBM
DMI4XBM	DN	Citicoline
DMI4XBM	MI	DEQJ8N3
DMI4XBM	MN	ASM-like phosphodiesterase 3a (SMPDL3A)
DMI4XBM	MT	DME
DMI4XBM	MA	Metabolism
DMI4XBM	RN	The structure and catalytic mechanism of human sphingomyelin phosphodiesterase like 3a--an acid sphingomyelinase homologue with a novel nucleotide hydrolase activity. FEBS J. 2016 Mar;283(6):1107-23.
DMI4XBM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26783088

DMI4XBM	DI	DMI4XBM
DMI4XBM	DN	Citicoline
DMI4XBM	MI	DEH6S1Q
DMI4XBM	MN	CDP-choline phosphohydrolase (ADPRM)
DMI4XBM	MT	DME
DMI4XBM	MA	Metabolism
DMI4XBM	RN	Molecular bases of catalysis and ADP-ribose preference of human Mn2+-dependent ADP-ribose/CDP-alcohol diphosphatase and conversion by mutagenesis to a preferential cyclic ADP-ribose phosphohydrolase. PLoS One. 2015 Feb 18;10(2):e0118680.
DMI4XBM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25692488

DMMEBWR	DI	DMMEBWR
DMMEBWR	DN	Citric acid, magnesium oxide, sodium picosulfate
DMMEBWR	MI	DEHYDG9
DMMEBWR	MN	Arylsulfate sulfotransferase (astA)
DMMEBWR	MT	DME
DMMEBWR	MA	Metabolism
DMMEBWR	RN	The role of intestinal bacteria in the transformation of sodium picosulfate. Jpn J Pharmacol. 1992 May;59(1):1-5.
DMMEBWR	RU	https://pubmed.ncbi.nlm.nih.gov/1507649

DM3JDRP	DI	DM3JDRP
DM3JDRP	DN	Cladribine
DM3JDRP	MI	TTLP57V
DM3JDRP	MN	Adenosine deaminase (ADA)
DM3JDRP	MT	DTT
DM3JDRP	MA	Inhibitor
DM3JDRP	RN	Cladribine: from the bench to the bedside--focus on hairy cell leukemia. Expert Rev Anticancer Ther. 2004 Oct;4(5):745-57.
DM3JDRP	RU	https://pubmed.ncbi.nlm.nih.gov/15485311

DM3JDRP	DI	DM3JDRP
DM3JDRP	DN	Cladribine
DM3JDRP	MI	DTI7UX6
DM3JDRP	MN	Breast cancer resistance protein (ABCG2)
DM3JDRP	MT	DTP
DM3JDRP	MA	Substrate
DM3JDRP	RN	Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides. Mol Cancer Ther. 2008 Sep;7(9):3092-102.
DM3JDRP	RU	http://www.ncbi.nlm.nih.gov/pubmed/18765824

DM3JDRP	DI	DM3JDRP
DM3JDRP	DN	Cladribine
DM3JDRP	MI	DE9FGNK
DM3JDRP	MN	Deoxycytidine kinase (DCK)
DM3JDRP	MT	DME
DM3JDRP	MA	Metabolism
DM3JDRP	RN	Potential mechanisms of action related to the efficacy and safety of cladribine. Mult Scler Relat Disord. 2019 May;30:176-186.
DM3JDRP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30785074

DM3JDRP	DI	DM3JDRP
DM3JDRP	DN	Cladribine
DM3JDRP	MI	DTZAWTH
DM3JDRP	MN	Equilibrative nucleoside transporter 3 (SLC29A3)
DM3JDRP	MT	DTP
DM3JDRP	MA	Substrate
DM3JDRP	RN	Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes. J Biol Chem. 2005 Apr 22;280(16):15880-7.
DM3JDRP	RU	http://www.ncbi.nlm.nih.gov/pubmed/15701636

DM3JDRP	DI	DM3JDRP
DM3JDRP	DN	Cladribine
DM3JDRP	MI	DTCSGPB
DM3JDRP	MN	Multidrug resistance-associated protein 4 (ABCC4)
DM3JDRP	MT	DTP
DM3JDRP	MA	Substrate
DM3JDRP	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM3JDRP	RU	https://doi.org/10.1007/s11095-012-0935-x

DM3JDRP	DI	DM3JDRP
DM3JDRP	DN	Cladribine
DM3JDRP	MI	DTT79CX
DM3JDRP	MN	Organic cation transporter 1 (SLC22A1)
DM3JDRP	MT	DTP
DM3JDRP	MA	Substrate
DM3JDRP	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM3JDRP	RU	https://doi.org/10.1007/s11095-012-0935-x

DM4M1SG	DI	DM4M1SG
DM4M1SG	DN	Clarithromycin
DM4M1SG	MI	TTUWYEA
DM4M1SG	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DM4M1SG	MT	DTT
DM4M1SG	MA	Binder
DM4M1SG	RN	Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001 Oct 25;413(6858):814-21.
DM4M1SG	RU	https://pubmed.ncbi.nlm.nih.gov/11677599

DM4M1SG	DI	DM4M1SG
DM4M1SG	DN	Clarithromycin
DM4M1SG	MI	DE4LYSA
DM4M1SG	MN	Cytochrome P450 3A4 (CYP3A4)
DM4M1SG	MT	DME
DM4M1SG	MA	Metabolism
DM4M1SG	RN	Pharmacokinetic variability of clarithromycin and differences in CYP3A4 activity in patients with cystic fibrosis. J Cyst Fibros. 2014 Mar;13(2):179-85.
DM4M1SG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24035278

DM4M1SG	DI	DM4M1SG
DM4M1SG	DN	Clarithromycin
DM4M1SG	MI	DEIBDNY
DM4M1SG	MN	Cytochrome P450 3A5 (CYP3A5)
DM4M1SG	MT	DME
DM4M1SG	MA	Metabolism
DM4M1SG	RN	Drug Interactions Flockhart Table
DM4M1SG	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM4M1SG	DI	DM4M1SG
DM4M1SG	DN	Clarithromycin
DM4M1SG	MI	DEGTFWK
DM4M1SG	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM4M1SG	MT	DME
DM4M1SG	MA	Metabolism
DM4M1SG	RN	Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection. Clin Gastroenterol Hepatol. 2005 Jun;3(6):564-73.
DM4M1SG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15952098

DM4M1SG	DI	DM4M1SG
DM4M1SG	DN	Clarithromycin
DM4M1SG	MI	DTUGYRD
DM4M1SG	MN	P-glycoprotein 1 (ABCB1)
DM4M1SG	MT	DTP
DM4M1SG	MA	Substrate
DM4M1SG	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM4M1SG	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMPGR1E	DI	DMPGR1E
DMPGR1E	DN	Clascoterone
DMPGR1E	MI	TTS64P2
DMPGR1E	MN	Androgen receptor (AR)
DMPGR1E	MT	DTT
DMPGR1E	MA	Antagonist
DMPGR1E	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMPGR1E	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213433s000lbl.pdf

DM2FGRT	DI	DM2FGRT
DM2FGRT	DN	Clavulanate
DM2FGRT	MI	TTHI19T
DM2FGRT	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DM2FGRT	MT	DTT
DM2FGRT	MA	Inhibitor
DM2FGRT	RN	A sensitive coupled HPLC/electrospray mass spectrometry assay for SPM-1 metallo-beta-lactamase inhibitors. Assay Drug Dev Technol. 2009 Apr;7(2):170-9.
DM2FGRT	RU	https://pubmed.ncbi.nlm.nih.gov/19505232

DMBZWQL	DI	DMBZWQL
DMBZWQL	DN	Clemastine
DMBZWQL	MI	TTTIBOJ
DMBZWQL	MN	Histamine H1 receptor (H1R)
DMBZWQL	MT	DTT
DMBZWQL	MA	Antagonist
DMBZWQL	RN	Histamine upregulates keratinocyte MMP-9 production via the histamine H1 receptor. J Invest Dermatol. 2008 Dec;128(12):2783-91.
DMBZWQL	RU	https://pubmed.ncbi.nlm.nih.gov/18548114

DMCKYZ5	DI	DMCKYZ5
DMCKYZ5	DN	Clenbuterol
DMCKYZ5	MI	TT2CJVK
DMCKYZ5	MN	Adrenergic receptor beta-2 (ADRB2)
DMCKYZ5	MT	DTT
DMCKYZ5	MA	Agonist
DMCKYZ5	RN	Postischemic brain injury is attenuated in mice lacking the beta2-adrenergic receptor. Anesth Analg. 2009 Jan;108(1):280-7.
DMCKYZ5	RU	https://pubmed.ncbi.nlm.nih.gov/19095863

DMCKYZ5	DI	DMCKYZ5
DMCKYZ5	DN	Clenbuterol
DMCKYZ5	MI	DE6OQ3W
DMCKYZ5	MN	Cytochrome P450 1A1 (CYP1A1)
DMCKYZ5	MT	DME
DMCKYZ5	MA	Metabolism
DMCKYZ5	RN	Beta-adrenergic receptor modulation of the LPS-mediated depression in CYP1A activity in astrocytes. Biochem Pharmacol. 2005 Mar 1;69(5):741-50.
DMCKYZ5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15710352

DMCKYZ5	DI	DMCKYZ5
DMCKYZ5	DN	Clenbuterol
DMCKYZ5	MI	DEJGDUW
DMCKYZ5	MN	Cytochrome P450 1A2 (CYP1A2)
DMCKYZ5	MT	DME
DMCKYZ5	MA	Metabolism
DMCKYZ5	RN	Beta-adrenergic receptor modulation of the LPS-mediated depression in CYP1A activity in astrocytes. Biochem Pharmacol. 2005 Mar 1;69(5):741-50.
DMCKYZ5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15710352

DMW4M97	DI	DMW4M97
DMW4M97	DN	Clevidipine butyrate
DMW4M97	MI	TT5HONZ
DMW4M97	MN	Calcium channel unspecific (CaC)
DMW4M97	MT	DTT
DMW4M97	MA	Modulator
DMW4M97	RN	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
DMW4M97	RU	https://pubmed.ncbi.nlm.nih.gov/19180096

DMW4M97	DI	DMW4M97
DMW4M97	DN	Clevidipine butyrate
DMW4M97	MI	DECB0K3
DMW4M97	MN	Cytochrome P450 2D6 (CYP2D6)
DMW4M97	MT	DME
DMW4M97	MA	Metabolism
DMW4M97	RN	Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7.
DMW4M97	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16501008

DMW4M97	DI	DMW4M97
DMW4M97	DN	Clevidipine butyrate
DMW4M97	MI	DEVDYN7
DMW4M97	MN	Cytochrome P450 2E1 (CYP2E1)
DMW4M97	MT	DME
DMW4M97	MA	Metabolism
DMW4M97	RN	Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7.
DMW4M97	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16501008

DMW4M97	DI	DMW4M97
DMW4M97	DN	Clevidipine butyrate
DMW4M97	MI	DE4LYSA
DMW4M97	MN	Cytochrome P450 3A4 (CYP3A4)
DMW4M97	MT	DME
DMW4M97	MA	Metabolism
DMW4M97	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DMW4M97	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DMW4M97	DI	DMW4M97
DMW4M97	DN	Clevidipine butyrate
DMW4M97	MI	TTXHYV6
DMW4M97	MN	Voltage-gated L-type calcium channel (L-CaC)
DMW4M97	MT	DTT
DMW4M97	MA	Inhibitor
DMW4M97	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMW4M97	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMUMQZ0	DI	DMUMQZ0
DMUMQZ0	DN	Clidinium
DMUMQZ0	MI	TTOXS3C
DMUMQZ0	MN	Muscarinic acetylcholine receptor (CHRM)
DMUMQZ0	MT	DTT
DMUMQZ0	MA	Antagonist
DMUMQZ0	RN	Pharmacological comparison of the cloned human and rat M2 muscarinic receptor genes expressed in the murine fibroblast (B82) cell line. J Pharmacol Exp Ther. 1998 Feb;284(2):500-7.
DMUMQZ0	RU	https://pubmed.ncbi.nlm.nih.gov/9454790

DMUMQZ0	DI	DMUMQZ0
DMUMQZ0	DN	Clidinium
DMUMQZ0	MI	TTZ9SOR
DMUMQZ0	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMUMQZ0	MT	DTT
DMUMQZ0	MA	Antagonist
DMUMQZ0	RN	Accidental acute clidinium toxicity. Emerg Med J. 2009 Jun;26(6):460.
DMUMQZ0	RU	https://pubmed.ncbi.nlm.nih.gov/19465630

DMUMQZ0	DI	DMUMQZ0
DMUMQZ0	DN	Clidinium
DMUMQZ0	MI	DTT79CX
DMUMQZ0	MN	Organic cation transporter 1 (SLC22A1)
DMUMQZ0	MT	DTP
DMUMQZ0	MA	Substrate
DMUMQZ0	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMUMQZ0	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DM15HL8	DI	DM15HL8
DM15HL8	DN	Clindamycin
DM15HL8	MI	TTUWYEA
DM15HL8	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DM15HL8	MT	DTT
DM15HL8	MA	Binder
DM15HL8	RN	Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001 Oct 25;413(6858):814-21.
DM15HL8	RU	https://pubmed.ncbi.nlm.nih.gov/11677599

DM15HL8	DI	DM15HL8
DM15HL8	DN	Clindamycin
DM15HL8	MI	DEMSNER
DM15HL8	MN	Beta-lactamase (blaB)
DM15HL8	MT	DME
DM15HL8	MA	Metabolism
DM15HL8	RN	Comparison of antimicrobial susceptibility, beta-lactamase production, plasmid analysis and serum bactericidal activity in Edwardsiella tarda, E. ictaluri and E. hoshinae. J Med Microbiol. 1993 Oct;39(4):273-81.
DM15HL8	RU	https://pubmed.ncbi.nlm.nih.gov/8411088

DM15HL8	DI	DM15HL8
DM15HL8	DN	Clindamycin
DM15HL8	MI	DE4LYSA
DM15HL8	MN	Cytochrome P450 3A4 (CYP3A4)
DM15HL8	MT	DME
DM15HL8	MA	Metabolism
DM15HL8	RN	In vitro metabolism of clindamycin in human liver and intestinal microsomes. Drug Metab Dispos. 2003 Jul;31(7):878-87.
DM15HL8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12814964

DMW1OQ0	DI	DMW1OQ0
DMW1OQ0	DN	Clobazam - Lundbeck
DMW1OQ0	MI	DEPKLMQ
DMW1OQ0	MN	Cytochrome P450 2B6 (CYP2B6)
DMW1OQ0	MT	DME
DMW1OQ0	MA	Metabolism
DMW1OQ0	RN	In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos. 2004 Nov;32(11):1279-86.
DMW1OQ0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15483195

DMW1OQ0	DI	DMW1OQ0
DMW1OQ0	DN	Clobazam - Lundbeck
DMW1OQ0	MI	DEZMWRE
DMW1OQ0	MN	Cytochrome P450 2C18 (CYP2C18)
DMW1OQ0	MT	DME
DMW1OQ0	MA	Metabolism
DMW1OQ0	RN	In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos. 2004 Nov;32(11):1279-86.
DMW1OQ0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15483195

DMW1OQ0	DI	DMW1OQ0
DMW1OQ0	DN	Clobazam - Lundbeck
DMW1OQ0	MI	DE4LYSA
DMW1OQ0	MN	Cytochrome P450 3A4 (CYP3A4)
DMW1OQ0	MT	DME
DMW1OQ0	MA	Metabolism
DMW1OQ0	RN	In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos. 2004 Nov;32(11):1279-86.
DMW1OQ0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15483195

DMW1OQ0	DI	DMW1OQ0
DMW1OQ0	DN	Clobazam - Lundbeck
DMW1OQ0	MI	TT1MPAY
DMW1OQ0	MN	GABA(A) receptor alpha-1 (GABRA1)
DMW1OQ0	MT	DTT
DMW1OQ0	MA	Antagonist
DMW1OQ0	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DMW1OQ0	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DMW1OQ0	DI	DMW1OQ0
DMW1OQ0	DN	Clobazam - Lundbeck
DMW1OQ0	MI	TTEX6LM
DMW1OQ0	MN	GABA(A) receptor gamma-3 (GABRG3)
DMW1OQ0	MT	DTT
DMW1OQ0	MA	Modulator
DMW1OQ0	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMW1OQ0	RU	https://www.fda.gov/

DMW1OQ0	DI	DMW1OQ0
DMW1OQ0	DN	Clobazam - Lundbeck
DMW1OQ0	MI	DEGTFWK
DMW1OQ0	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMW1OQ0	MT	DME
DMW1OQ0	MA	Metabolism
DMW1OQ0	RN	A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam. Brain Dev. 2004 Dec;26(8):530-4.
DMW1OQ0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15533655

DMW1OQ0	DI	DMW1OQ0
DMW1OQ0	DN	Clobazam - Lundbeck
DMW1OQ0	MI	DTUGYRD
DMW1OQ0	MN	P-glycoprotein 1 (ABCB1)
DMW1OQ0	MT	DTP
DMW1OQ0	MA	Substrate
DMW1OQ0	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DMW1OQ0	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DMUXP52	DI	DMUXP52
DMUXP52	DN	Clobetasol
DMUXP52	MI	TT9V5JH
DMUXP52	MN	Phospholipase A2 (PLA2G1B)
DMUXP52	MT	DTT
DMUXP52	MA	Inhibitor
DMUXP52	RN	Utilization of epidermal phospholipase A2 inhibition to monitor topical steroid action. Br J Dermatol. 1984 Jul;111 Suppl 27:195-203.
DMUXP52	RU	https://pubmed.ncbi.nlm.nih.gov/6743552

DM9ZMQH	DI	DM9ZMQH
DM9ZMQH	DN	Clocortolone
DM9ZMQH	MI	TT9V5JH
DM9ZMQH	MN	Phospholipase A2 (PLA2G1B)
DM9ZMQH	MT	DTT
DM9ZMQH	MA	Inducer
DM9ZMQH	RN	Clocortolone pivalate: a paired comparison clinical trial of a new topical steroid in eczema/atopic dermatitis. Cutis. 1980 Jan;25(1):96-8.
DM9ZMQH	RU	https://pubmed.ncbi.nlm.nih.gov/6986236

DM9Y6X7	DI	DM9Y6X7
DM9Y6X7	DN	Clodronate
DM9Y6X7	MI	TTU5A6Q
DM9Y6X7	MN	Adenine nucleotide translocator 1 (SLC25A4)
DM9Y6X7	MT	DTT
DM9Y6X7	MA	Inhibitor
DM9Y6X7	RN	Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol. 2002 May;61(5):1255-62.
DM9Y6X7	RU	https://pubmed.ncbi.nlm.nih.gov/11961144

DMCVJ86	DI	DMCVJ86
DMCVJ86	DN	Clofarabine
DMCVJ86	MI	TTJP4SM
DMCVJ86	MN	Bacterial Penicillin binding protein (Bact PBP)
DMCVJ86	MT	DTT
DMCVJ86	MA	Binder
DMCVJ86	RN	Clofarabine: past, present, and future. Leuk Lymphoma. 2007 Oct;48(10):1922-30.
DMCVJ86	RU	https://pubmed.ncbi.nlm.nih.gov/17852710

DMCVJ86	DI	DMCVJ86
DMCVJ86	DN	Clofarabine
DMCVJ86	MI	DTI7UX6
DMCVJ86	MN	Breast cancer resistance protein (ABCG2)
DMCVJ86	MT	DTP
DMCVJ86	MA	Substrate
DMCVJ86	RN	Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides. Mol Cancer Ther. 2008 Sep;7(9):3092-102.
DMCVJ86	RU	http://www.ncbi.nlm.nih.gov/pubmed/18765824

DMCVJ86	DI	DMCVJ86
DMCVJ86	DN	Clofarabine
DMCVJ86	MI	DT4YL5R
DMCVJ86	MN	Concentrative Na(+)-nucleoside cotransporter 3 (SLC28A3)
DMCVJ86	MT	DTP
DMCVJ86	MA	Substrate
DMCVJ86	RN	Cytarabine-resistant leukemia cells are moderately sensitive to clofarabine in vitro. Anticancer Res. 2014 Apr;34(4):1657-62.
DMCVJ86	RU	http://www.ncbi.nlm.nih.gov/pubmed/24692694

DMCVJ86	DI	DMCVJ86
DMCVJ86	DN	Clofarabine
DMCVJ86	MI	DE9FGNK
DMCVJ86	MN	Deoxycytidine kinase (DCK)
DMCVJ86	MT	DME
DMCVJ86	MA	Metabolism
DMCVJ86	RN	FDA label of Belinostat. The 2020 official website of the U.S. Food and Drug Administration.
DMCVJ86	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021673s024lbl.pdf

DMCVJ86	DI	DMCVJ86
DMCVJ86	DN	Clofarabine
DMCVJ86	MI	DTXD1TQ
DMCVJ86	MN	Equilibrative nucleoside transporter 1 (SLC29A1)
DMCVJ86	MT	DTP
DMCVJ86	MA	Substrate
DMCVJ86	RN	Cytarabine-resistant leukemia cells are moderately sensitive to clofarabine in vitro. Anticancer Res. 2014 Apr;34(4):1657-62.
DMCVJ86	RU	http://www.ncbi.nlm.nih.gov/pubmed/24692694

DMCVJ86	DI	DMCVJ86
DMCVJ86	DN	Clofarabine
DMCVJ86	MI	DTW78DQ
DMCVJ86	MN	Equilibrative nucleoside transporter 2 (SLC29A2)
DMCVJ86	MT	DTP
DMCVJ86	MA	Substrate
DMCVJ86	RN	Cytarabine-resistant leukemia cells are moderately sensitive to clofarabine in vitro. Anticancer Res. 2014 Apr;34(4):1657-62.
DMCVJ86	RU	http://www.ncbi.nlm.nih.gov/pubmed/24692694

DMCVJ86	DI	DMCVJ86
DMCVJ86	DN	Clofarabine
DMCVJ86	MI	TTX09M4
DMCVJ86	MN	Ribonucleotide reductase (RIR)
DMCVJ86	MT	DTT
DMCVJ86	MA	Inhibitor
DMCVJ86	RN	Clofarabine: past, present, and future. Leuk Lymphoma. 2007 Oct;48(10):1922-30.
DMCVJ86	RU	https://pubmed.ncbi.nlm.nih.gov/17852710

DMEBOFW	DI	DMEBOFW
DMEBOFW	DN	Clofazimine
DMEBOFW	MI	TTS1W4A
DMEBOFW	MN	Bacterial Deoxyribonucleic acid (Bact DNA)
DMEBOFW	MT	DTT
DMEBOFW	MA	Modulator
DMEBOFW	RN	The mode of action of clofazimine DNA binding studies. Int J Lepr Other Mycobact Dis. 1976 Jan-Jun;44(1-2):133-4.
DMEBOFW	RU	https://www.ncbi.nlm.nih.gov/pubmed/945233

DMEBOFW	DI	DMEBOFW
DMEBOFW	DN	Clofazimine
DMEBOFW	MI	DE4LYSA
DMEBOFW	MN	Cytochrome P450 3A4 (CYP3A4)
DMEBOFW	MT	DME
DMEBOFW	MA	Metabolism
DMEBOFW	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMEBOFW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMEBOFW	DI	DMEBOFW
DMEBOFW	DN	Clofazimine
DMEBOFW	MI	DTUGYRD
DMEBOFW	MN	P-glycoprotein 1 (ABCB1)
DMEBOFW	MT	DTP
DMEBOFW	MA	Substrate
DMEBOFW	RN	Efflux pump inhibitors: targeting mycobacterial efflux systems to enhance TB therapy. J Antimicrob Chemother. 2016 Jan;71(1):17-26.
DMEBOFW	RU	http://www.ncbi.nlm.nih.gov/pubmed/26472768

DMPC1J7	DI	DMPC1J7
DMPC1J7	DN	Clofibrate
DMPC1J7	MI	DE6OQ3W
DMPC1J7	MN	Cytochrome P450 1A1 (CYP1A1)
DMPC1J7	MT	DME
DMPC1J7	MA	Metabolism
DMPC1J7	RN	Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4.
DMPC1J7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8951176

DMPC1J7	DI	DMPC1J7
DMPC1J7	DN	Clofibrate
DMPC1J7	MI	DEJGDUW
DMPC1J7	MN	Cytochrome P450 1A2 (CYP1A2)
DMPC1J7	MT	DME
DMPC1J7	MA	Metabolism
DMPC1J7	RN	Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4.
DMPC1J7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8951176

DMPC1J7	DI	DMPC1J7
DMPC1J7	DN	Clofibrate
DMPC1J7	MI	DEJVYAZ
DMPC1J7	MN	Cytochrome P450 2A6 (CYP2A6)
DMPC1J7	MT	DME
DMPC1J7	MA	Metabolism
DMPC1J7	RN	Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4.
DMPC1J7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8951176

DMPC1J7	DI	DMPC1J7
DMPC1J7	DN	Clofibrate
DMPC1J7	MI	DEPKLMQ
DMPC1J7	MN	Cytochrome P450 2B6 (CYP2B6)
DMPC1J7	MT	DME
DMPC1J7	MA	Metabolism
DMPC1J7	RN	Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4.
DMPC1J7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8951176

DMPC1J7	DI	DMPC1J7
DMPC1J7	DN	Clofibrate
DMPC1J7	MI	DE5IED8
DMPC1J7	MN	Cytochrome P450 2C9 (CYP2C9)
DMPC1J7	MT	DME
DMPC1J7	MA	Metabolism
DMPC1J7	RN	Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4.
DMPC1J7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8951176

DMPC1J7	DI	DMPC1J7
DMPC1J7	DN	Clofibrate
DMPC1J7	MI	DECB0K3
DMPC1J7	MN	Cytochrome P450 2D6 (CYP2D6)
DMPC1J7	MT	DME
DMPC1J7	MA	Metabolism
DMPC1J7	RN	Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4.
DMPC1J7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8951176

DMPC1J7	DI	DMPC1J7
DMPC1J7	DN	Clofibrate
DMPC1J7	MI	DE4LYSA
DMPC1J7	MN	Cytochrome P450 3A4 (CYP3A4)
DMPC1J7	MT	DME
DMPC1J7	MA	Metabolism
DMPC1J7	RN	Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998 Feb;34(2):155-62.
DMPC1J7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9515185

DMPC1J7	DI	DMPC1J7
DMPC1J7	DN	Clofibrate
DMPC1J7	MI	DE4ZHS1
DMPC1J7	MN	Glutathione S-transferase alpha-1 (GSTA1)
DMPC1J7	MT	DME
DMPC1J7	MA	Metabolism
DMPC1J7	RN	Characterization and formation of the glutathione conjugate of clofibric acid. Drug Metab Dispos. 1995 Jan;23(1):119-23.
DMPC1J7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7720514

DMPC1J7	DI	DMPC1J7
DMPC1J7	DN	Clofibrate
DMPC1J7	MI	DE2XQGW
DMPC1J7	MN	Lauric acid omega-hydroxylase (CYP4A11)
DMPC1J7	MT	DME
DMPC1J7	MA	Metabolism
DMPC1J7	RN	Regulation of CYP2E1 by ethanol and palmitic acid and CYP4A11 by clofibrate in primary cultures of human hepatocytes. Toxicol Sci. 2004 Jun;79(2):233-41.
DMPC1J7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15056802

DMPC1J7	DI	DMPC1J7
DMPC1J7	DN	Clofibrate
DMPC1J7	MI	TTOF3WZ
DMPC1J7	MN	Lipoprotein lipase (LPL)
DMPC1J7	MT	DTT
DMPC1J7	MA	Activator
DMPC1J7	RN	Effects of clofibrate treatment in laying hens. Poult Sci. 2007 Jun;86(6):1187-95.
DMPC1J7	RU	https://pubmed.ncbi.nlm.nih.gov/17495091

DMKI7RB	DI	DMKI7RB
DMKI7RB	DN	Clomifene
DMKI7RB	MI	DECB0K3
DMKI7RB	MN	Cytochrome P450 2D6 (CYP2D6)
DMKI7RB	MT	DME
DMKI7RB	MA	Metabolism
DMKI7RB	RN	CYP2D6 is primarily responsible for the metabolism of clomiphene. Drug Metab Pharmacokinet. 2008;23(2):101-5.
DMKI7RB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18445989

DMKI7RB	DI	DMKI7RB
DMKI7RB	DN	Clomifene
DMKI7RB	MI	TTZAYWL
DMKI7RB	MN	Estrogen receptor (ESR)
DMKI7RB	MT	DTT
DMKI7RB	MA	Modulator
DMKI7RB	RN	The future of the new selective estrogen receptor modulators. Menopause Int. 2007 Mar;13(1):27-34.
DMKI7RB	RU	https://pubmed.ncbi.nlm.nih.gov/17448265

DMKI7RB	DI	DMKI7RB
DMKI7RB	DN	Clomifene
DMKI7RB	MI	DTUGYRD
DMKI7RB	MN	P-glycoprotein 1 (ABCB1)
DMKI7RB	MT	DTP
DMKI7RB	MA	Substrate
DMKI7RB	RN	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
DMKI7RB	RU	http://www.ncbi.nlm.nih.gov/pubmed/7914405

DMS51VC	DI	DMS51VC
DMS51VC	DN	Clomiphene citrate
DMS51VC	MI	TTZAYWL
DMS51VC	MN	Estrogen receptor (ESR)
DMS51VC	MT	DTT
DMS51VC	MA	Modulator
DMS51VC	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMS51VC	RU	https://www.fda.gov/

DMS51VC	DI	DMS51VC
DMS51VC	DN	Clomiphene citrate
DMS51VC	MI	DTUGYRD
DMS51VC	MN	P-glycoprotein 1 (ABCB1)
DMS51VC	MT	DTP
DMS51VC	MA	Substrate
DMS51VC	RN	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
DMS51VC	RU	http://www.ncbi.nlm.nih.gov/pubmed/7914405

DMINRKW	DI	DMINRKW
DMINRKW	DN	Clomipramine
DMINRKW	MI	DTUGYRD
DMINRKW	MN	P-glycoprotein 1 (ABCB1)
DMINRKW	MT	DTP
DMINRKW	MA	Substrate
DMINRKW	RN	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
DMINRKW	RU	https://doi.org/10.1016/j.addr.2011.12.008

DMINRKW	DI	DMINRKW
DMINRKW	DN	Clomipramine
DMINRKW	MI	TT3ROYC
DMINRKW	MN	Serotonin transporter (SERT)
DMINRKW	MT	DTT
DMINRKW	MA	Inhibitor
DMINRKW	RN	Efficacy of treatments for patients with obsessive-compulsive disorder: a systematic review. J Am Acad Nurse Pract. 2009 Apr;21(4):207-13.
DMINRKW	RU	https://pubmed.ncbi.nlm.nih.gov/19366379

DM0ZRMQ	DI	DM0ZRMQ
DM0ZRMQ	DN	Clomocycline
DM0ZRMQ	MI	TTQ8KVI
DM0ZRMQ	MN	Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)
DM0ZRMQ	MT	DTT
DM0ZRMQ	MA	Binder
DM0ZRMQ	RN	Molecular dynamics simulations of the 30S ribosomal subunit reveal a preferred tetracycline binding site. J Am Chem Soc. 2008 Jan 30;130(4):1114-5.
DM0ZRMQ	RU	https://pubmed.ncbi.nlm.nih.gov/18219717

DMTO13J	DI	DMTO13J
DMTO13J	DN	Clonazepam
DMTO13J	MI	DE4LYSA
DMTO13J	MN	Cytochrome P450 3A4 (CYP3A4)
DMTO13J	MT	DME
DMTO13J	MA	Metabolism
DMTO13J	RN	Identification of the human and animal hepatic cytochromes P450 involved in clonazepam metabolism. Fundam Clin Pharmacol. 1993;7(2):69-75.
DMTO13J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8486332

DMTO13J	DI	DMTO13J
DMTO13J	DN	Clonazepam
DMTO13J	MI	TTNJYV2
DMTO13J	MN	Gamma-aminobutyric acid receptor (GAR)
DMTO13J	MT	DTT
DMTO13J	MA	Agonist
DMTO13J	RN	Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
DMTO13J	RU	https://pubmed.ncbi.nlm.nih.gov/16377242

DMTO13J	DI	DMTO13J
DMTO13J	DN	Clonazepam
DMTO13J	MI	DE0QLUZ
DMTO13J	MN	Oxygen-insensitive NADPH nitroreductase B (nfsB)
DMTO13J	MT	DME
DMTO13J	MA	Metabolism
DMTO13J	RN	Characterization of Escherichia coli nitroreductase NfsB in the metabolism of nitrobenzodiazepines. Biochem Pharmacol. 2009 Jul 1;78(1):96-103.
DMTO13J	RU	https://pubmed.ncbi.nlm.nih.gov/19447228

DMTO13J	DI	DMTO13J
DMTO13J	DN	Clonazepam
DMTO13J	MI	DEZV4AP
DMTO13J	MN	RNA cytidine acetyltransferase (hALP)
DMTO13J	MT	DME
DMTO13J	MA	Metabolism
DMTO13J	RN	Effect of common NAT2 variant alleles in the acetylation of the major clonazepam metabolite, 7-aminoclonazepam. Drug Metab Lett. 2007 Jan;1(1):3-5.
DMTO13J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19356010

DM6RZ9Q	DI	DM6RZ9Q
DM6RZ9Q	DN	Clonidine
DM6RZ9Q	MI	TTQ8AFT
DM6RZ9Q	MN	Adrenergic receptor Alpha-2 (ADRA2)
DM6RZ9Q	MT	DTT
DM6RZ9Q	MA	Agonist
DM6RZ9Q	RN	Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats. Pharmacol Biochem Behav. 2000 Nov;67(3):397-403.
DM6RZ9Q	RU	https://pubmed.ncbi.nlm.nih.gov/11164065

DM6RZ9Q	DI	DM6RZ9Q
DM6RZ9Q	DN	Clonidine
DM6RZ9Q	MI	DEJGDUW
DM6RZ9Q	MN	Cytochrome P450 1A2 (CYP1A2)
DM6RZ9Q	MT	DME
DM6RZ9Q	MA	Metabolism
DM6RZ9Q	RN	CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6.
DM6RZ9Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20570945

DM6RZ9Q	DI	DM6RZ9Q
DM6RZ9Q	DN	Clonidine
DM6RZ9Q	MI	DECB0K3
DM6RZ9Q	MN	Cytochrome P450 2D6 (CYP2D6)
DM6RZ9Q	MT	DME
DM6RZ9Q	MA	Metabolism
DM6RZ9Q	RN	CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6.
DM6RZ9Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20570945

DM6RZ9Q	DI	DM6RZ9Q
DM6RZ9Q	DN	Clonidine
DM6RZ9Q	MI	DE4LYSA
DM6RZ9Q	MN	Cytochrome P450 3A4 (CYP3A4)
DM6RZ9Q	MT	DME
DM6RZ9Q	MA	Metabolism
DM6RZ9Q	RN	CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6.
DM6RZ9Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20570945

DM6RZ9Q	DI	DM6RZ9Q
DM6RZ9Q	DN	Clonidine
DM6RZ9Q	MI	DEIBDNY
DM6RZ9Q	MN	Cytochrome P450 3A5 (CYP3A5)
DM6RZ9Q	MT	DME
DM6RZ9Q	MA	Metabolism
DM6RZ9Q	RN	CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6.
DM6RZ9Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20570945

DM6RZ9Q	DI	DM6RZ9Q
DM6RZ9Q	DN	Clonidine
DM6RZ9Q	MI	TT7HC21
DM6RZ9Q	MN	Membrane copper amine oxidase (AOC3)
DM6RZ9Q	MT	DTT
DM6RZ9Q	MA	Inhibitor
DM6RZ9Q	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM6RZ9Q	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM6RZ9Q	DI	DM6RZ9Q
DM6RZ9Q	DN	Clonidine
DM6RZ9Q	MI	DTT79CX
DM6RZ9Q	MN	Organic cation transporter 1 (SLC22A1)
DM6RZ9Q	MT	DTP
DM6RZ9Q	MA	Substrate
DM6RZ9Q	RN	Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
DM6RZ9Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/28768994

DM6RZ9Q	DI	DM6RZ9Q
DM6RZ9Q	DN	Clonidine
DM6RZ9Q	MI	DT9IDPW
DM6RZ9Q	MN	Organic cation transporter 2 (SLC22A2)
DM6RZ9Q	MT	DTP
DM6RZ9Q	MA	Substrate
DM6RZ9Q	RN	Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
DM6RZ9Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/28768994

DM6RZ9Q	DI	DM6RZ9Q
DM6RZ9Q	DN	Clonidine
DM6RZ9Q	MI	DT6201N
DM6RZ9Q	MN	Organic cation transporter 3 (SLC22A3)
DM6RZ9Q	MT	DTP
DM6RZ9Q	MA	Substrate
DM6RZ9Q	RN	Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
DM6RZ9Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/28768994

DM6RZ9Q	DI	DM6RZ9Q
DM6RZ9Q	DN	Clonidine
DM6RZ9Q	MI	DTUGYRD
DM6RZ9Q	MN	P-glycoprotein 1 (ABCB1)
DM6RZ9Q	MT	DTP
DM6RZ9Q	MA	Substrate
DM6RZ9Q	RN	Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22.
DM6RZ9Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/12954186

DMOL54H	DI	DMOL54H
DMOL54H	DN	Clopidogrel
DMOL54H	MI	DEJGDUW
DMOL54H	MN	Cytochrome P450 1A2 (CYP1A2)
DMOL54H	MT	DME
DMOL54H	MA	Metabolism
DMOL54H	RN	Clinical pharmacokinetics and pharmacodynamics of clopidogrel. Clin Pharmacokinet. 2015 Feb;54(2):147-66.
DMOL54H	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25559342

DMOL54H	DI	DMOL54H
DMOL54H	DN	Clopidogrel
DMOL54H	MI	DEPKLMQ
DMOL54H	MN	Cytochrome P450 2B6 (CYP2B6)
DMOL54H	MT	DME
DMOL54H	MA	Metabolism
DMOL54H	RN	Clopidogrel pathway. Pharmacogenet Genomics. 2010 Jul;20(7):463-5.
DMOL54H	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20440227

DMOL54H	DI	DMOL54H
DMOL54H	DN	Clopidogrel
DMOL54H	MI	DE5IED8
DMOL54H	MN	Cytochrome P450 2C9 (CYP2C9)
DMOL54H	MT	DME
DMOL54H	MA	Metabolism
DMOL54H	RN	Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007 May;81(5):735-41.
DMOL54H	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17361128

DMOL54H	DI	DMOL54H
DMOL54H	DN	Clopidogrel
DMOL54H	MI	DE4LYSA
DMOL54H	MN	Cytochrome P450 3A4 (CYP3A4)
DMOL54H	MT	DME
DMOL54H	MA	Metabolism
DMOL54H	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMOL54H	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMOL54H	DI	DMOL54H
DMOL54H	DN	Clopidogrel
DMOL54H	MI	DEIBDNY
DMOL54H	MN	Cytochrome P450 3A5 (CYP3A5)
DMOL54H	MT	DME
DMOL54H	MA	Metabolism
DMOL54H	RN	Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007 May;81(5):735-41.
DMOL54H	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17361128

DMOL54H	DI	DMOL54H
DMOL54H	DN	Clopidogrel
DMOL54H	MI	DEGTFWK
DMOL54H	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMOL54H	MT	DME
DMOL54H	MA	Metabolism
DMOL54H	RN	Impact of the CYP2C19 gene polymorphism on clopidogrel personalized drug regimen and the clinical outcomes. Clin Lab. 2016 Sep 1;62(9):1773-1780.
DMOL54H	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28164572

DMOL54H	DI	DMOL54H
DMOL54H	DN	Clopidogrel
DMOL54H	MI	TTZ1DT0
DMOL54H	MN	P2Y purinoceptor 12 (P2RY12)
DMOL54H	MT	DTT
DMOL54H	MA	Antagonist
DMOL54H	RN	P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med. 2003 May;3(2):113-22.
DMOL54H	RU	https://pubmed.ncbi.nlm.nih.gov/15199474

DMOL54H	DI	DMOL54H
DMOL54H	DN	Clopidogrel
DMOL54H	MI	DTUGYRD
DMOL54H	MN	P-glycoprotein 1 (ABCB1)
DMOL54H	MT	DTP
DMOL54H	MA	Substrate
DMOL54H	RN	Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther. 2006 Nov;80(5):486-501.
DMOL54H	RU	http://www.ncbi.nlm.nih.gov/pubmed/17112805

DMC3JST	DI	DMC3JST
DMC3JST	DN	Clorazepate
DMC3JST	MI	DE4LYSA
DMC3JST	MN	Cytochrome P450 3A4 (CYP3A4)
DMC3JST	MT	DME
DMC3JST	MA	Metabolism
DMC3JST	RN	In vitro drug allergy detection system incorporating human liver microsomes in chlorazepate-induced skin rash: drug-specific proliferation associated with interleukin-5 secretion. Br J Dermatol. 2001 Feb;144(2):316-20.
DMC3JST	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11251565

DMC3JST	DI	DMC3JST
DMC3JST	DN	Clorazepate
DMC3JST	MI	TTPTXIN
DMC3JST	MN	Translocator protein (TSPO)
DMC3JST	MT	DTT
DMC3JST	MA	Modulator
DMC3JST	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMC3JST	RU	https://www.fda.gov/

DMCEUJD	DI	DMCEUJD
DMCEUJD	DN	Clorgyline
DMCEUJD	MI	TT32XQJ
DMCEUJD	MN	Monoamine oxidase (MAO)
DMCEUJD	MT	DTT
DMCEUJD	MA	Inhibitor
DMCEUJD	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMCEUJD	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMCEUJD	DI	DMCEUJD
DMCEUJD	DN	Clorgyline
DMCEUJD	MI	TT3WG5C
DMCEUJD	MN	Monoamine oxidase type A (MAO-A)
DMCEUJD	MT	DTT
DMCEUJD	MA	Inhibitor
DMCEUJD	RN	Further investigation into the mechanism of tachykinin NK(2) receptor-triggered serotonin release from guinea-pig proximal colon. J Pharmacol Sci. 2009 May;110(1):122-6.
DMCEUJD	RU	https://pubmed.ncbi.nlm.nih.gov/19423952

DM6K1OA	DI	DM6K1OA
DM6K1OA	DN	Clothiapine
DM6K1OA	MI	DERD86B
DM6K1OA	MN	Cytochrome P450 3A7 (CYP3A7)
DM6K1OA	MT	DME
DM6K1OA	MA	Metabolism
DM6K1OA	RN	Biotransformation of post-clozapine antipsychotics: pharmacological implications. Clin Pharmacokinet. 2000 May;38(5):393-414.
DM6K1OA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10843459

DM59AZT	DI	DM59AZT
DM59AZT	DN	Clotiazepam
DM59AZT	MI	DEPKLMQ
DM59AZT	MN	Cytochrome P450 2B6 (CYP2B6)
DM59AZT	MT	DME
DM59AZT	MA	Metabolism
DM59AZT	RN	Contribution of human hepatic cytochrome p450 isoforms to the metabolism of psychotropic drugs. Biol Pharm Bull. 2005 Sep;28(9):1711-6.
DM59AZT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16141545

DM59AZT	DI	DM59AZT
DM59AZT	DN	Clotiazepam
DM59AZT	MI	DEZMWRE
DM59AZT	MN	Cytochrome P450 2C18 (CYP2C18)
DM59AZT	MT	DME
DM59AZT	MA	Metabolism
DM59AZT	RN	Contribution of human hepatic cytochrome p450 isoforms to the metabolism of psychotropic drugs. Biol Pharm Bull. 2005 Sep;28(9):1711-6.
DM59AZT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16141545

DM59AZT	DI	DM59AZT
DM59AZT	DN	Clotiazepam
DM59AZT	MI	DE4LYSA
DM59AZT	MN	Cytochrome P450 3A4 (CYP3A4)
DM59AZT	MT	DME
DM59AZT	MA	Metabolism
DM59AZT	RN	Contribution of human hepatic cytochrome p450 isoforms to the metabolism of psychotropic drugs. Biol Pharm Bull. 2005 Sep;28(9):1711-6.
DM59AZT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16141545

DM59AZT	DI	DM59AZT
DM59AZT	DN	Clotiazepam
DM59AZT	MI	DEGTFWK
DM59AZT	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM59AZT	MT	DME
DM59AZT	MA	Metabolism
DM59AZT	RN	Contribution of human hepatic cytochrome p450 isoforms to the metabolism of psychotropic drugs. Biol Pharm Bull. 2005 Sep;28(9):1711-6.
DM59AZT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16141545

DM59AZT	DI	DM59AZT
DM59AZT	DN	Clotiazepam
DM59AZT	MI	TTPTXIN
DM59AZT	MN	Translocator protein (TSPO)
DM59AZT	MT	DTT
DM59AZT	MA	Agonist
DM59AZT	RN	Effects of benzodiazepines and non-benzodiazepine compounds on the GABA-induced response in frog isolated sensory neurones. Br J Pharmacol. 1989 Nov;98(3):735-40.
DM59AZT	RU	https://pubmed.ncbi.nlm.nih.gov/2574062

DMMFCIH	DI	DMMFCIH
DMMFCIH	DN	Clotrimazole
DMMFCIH	MI	TT30C9G
DMMFCIH	MN	C-X-C chemokine receptor type 2 (CXCR2)
DMMFCIH	MT	DTT
DMMFCIH	MA	Modulator
DMMFCIH	RN	Mode of action of clotrimazole: implications for therapy. Am J Obstet Gynecol. 1985 Aug 1;152(7 Pt 2):939-44.
DMMFCIH	RU	https://www.ncbi.nlm.nih.gov/pubmed/3895959

DMMFCIH	DI	DMMFCIH
DMMFCIH	DN	Clotrimazole
DMMFCIH	MI	DE4LYSA
DMMFCIH	MN	Cytochrome P450 3A4 (CYP3A4)
DMMFCIH	MT	DME
DMMFCIH	MA	Metabolism
DMMFCIH	RN	Tacrolimus interaction with clotrimazole: a concise case report and literature review. P T. 2010 Oct;35(10):568-9.
DMMFCIH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21037909

DMUTL7O	DI	DMUTL7O
DMUTL7O	DN	Cloxacillin
DMUTL7O	MI	TTJP4SM
DMUTL7O	MN	Bacterial Penicillin binding protein (Bact PBP)
DMUTL7O	MT	DTT
DMUTL7O	MA	Binder
DMUTL7O	RN	Development of a receptor-based microplate assay for the detection of beta-lactam antibiotics in different food matrices. Anal Chim Acta. 2007 Mar 14;586(1-2):296-303.
DMUTL7O	RU	https://pubmed.ncbi.nlm.nih.gov/17386727

DMFC71L	DI	DMFC71L
DMFC71L	DN	Clozapine
DMFC71L	MI	DEJGDUW
DMFC71L	MN	Cytochrome P450 1A2 (CYP1A2)
DMFC71L	MT	DME
DMFC71L	MA	Metabolism
DMFC71L	RN	Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007 Jan;100(1):4-22.
DMFC71L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17214606

DMFC71L	DI	DMFC71L
DMFC71L	DN	Clozapine
DMFC71L	MI	DEJVYAZ
DMFC71L	MN	Cytochrome P450 2A6 (CYP2A6)
DMFC71L	MT	DME
DMFC71L	MA	Metabolism
DMFC71L	RN	Characterization of human cytochrome P450s involved in the bioactivation of clozapine. Drug Metab Dispos. 2013 Mar;41(3):651-8.
DMFC71L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23297297

DMFC71L	DI	DMFC71L
DMFC71L	DN	Clozapine
DMFC71L	MI	DES5XRU
DMFC71L	MN	Cytochrome P450 2C8 (CYP2C8)
DMFC71L	MT	DME
DMFC71L	MA	Metabolism
DMFC71L	RN	Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine. Naunyn Schmiedebergs Arch Pharmacol. 1998 Nov;358(5):592-9.
DMFC71L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9840430

DMFC71L	DI	DMFC71L
DMFC71L	DN	Clozapine
DMFC71L	MI	DE5IED8
DMFC71L	MN	Cytochrome P450 2C9 (CYP2C9)
DMFC71L	MT	DME
DMFC71L	MA	Metabolism
DMFC71L	RN	Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine. Naunyn Schmiedebergs Arch Pharmacol. 1998 Nov;358(5):592-9.
DMFC71L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9840430

DMFC71L	DI	DMFC71L
DMFC71L	DN	Clozapine
DMFC71L	MI	DECB0K3
DMFC71L	MN	Cytochrome P450 2D6 (CYP2D6)
DMFC71L	MT	DME
DMFC71L	MA	Metabolism
DMFC71L	RN	Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos. 1999 Sep;27(9):1078-84.
DMFC71L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10460810

DMFC71L	DI	DMFC71L
DMFC71L	DN	Clozapine
DMFC71L	MI	DE4LYSA
DMFC71L	MN	Cytochrome P450 3A4 (CYP3A4)
DMFC71L	MT	DME
DMFC71L	MA	Metabolism
DMFC71L	RN	Drug metabolism and atypical antipsychotics. Eur Neuropsychopharmacol. 1999 Jun;9(4):301-9.
DMFC71L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10422890

DMFC71L	DI	DMFC71L
DMFC71L	DN	Clozapine
DMFC71L	MI	TTE0A2F
DMFC71L	MN	Dopamine D4 receptor (D4R)
DMFC71L	MT	DTT
DMFC71L	MA	Modulator
DMFC71L	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMFC71L	RU	https://www.fda.gov/

DMFC71L	DI	DMFC71L
DMFC71L	DN	Clozapine
DMFC71L	MI	DEGTFWK
DMFC71L	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMFC71L	MT	DME
DMFC71L	MA	Metabolism
DMFC71L	RN	Drug metabolism and atypical antipsychotics. Eur Neuropsychopharmacol. 1999 Jun;9(4):301-9.
DMFC71L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10422890

DMFC71L	DI	DMFC71L
DMFC71L	DN	Clozapine
DMFC71L	MI	DTUGYRD
DMFC71L	MN	P-glycoprotein 1 (ABCB1)
DMFC71L	MT	DTP
DMFC71L	MA	Substrate
DMFC71L	RN	Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
DMFC71L	RU	http://www.ncbi.nlm.nih.gov/pubmed/15285840

DMPC2QY	DI	DMPC2QY
DMPC2QY	DN	CNTO-1959
DMPC2QY	MI	TTC1GLB
DMPC2QY	MN	Interleukin-23 (IL23)
DMPC2QY	MT	DTT
DMPC2QY	RN	Interleukin-23 in the pathogenesis and treatment of psoriasis. Skin Therapy Lett. 2015 Mar-Apr;20(2):1-4.
DMPC2QY	RU	https://pubmed.ncbi.nlm.nih.gov/25807335

DM8HBJI	DI	DM8HBJI
DM8HBJI	DN	Coagulation Factor IX
DM8HBJI	MI	TTCIHJA
DM8HBJI	MN	Coagulation factor Xa (F10)
DM8HBJI	MT	DTT
DM8HBJI	MA	Activator
DM8HBJI	RN	Haemophilia B: Christmas disease. Expert Opin Pharmacother. 2005 Aug;6(9):1517-24.
DM8HBJI	RU	https://pubmed.ncbi.nlm.nih.gov/16086639

DM6L4H2	DI	DM6L4H2
DM6L4H2	DN	Cobicistat
DM6L4H2	MI	DECB0K3
DM6L4H2	MN	Cytochrome P450 2D6 (CYP2D6)
DM6L4H2	MT	DME
DM6L4H2	MA	Metabolism
DM6L4H2	RN	Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications. J Antimicrob Chemother. 2016 Jul;71(7):1755-8.
DM6L4H2	RU	https://academic.oup.com/jac/article/71/7/1755/1750409

DM6L4H2	DI	DM6L4H2
DM6L4H2	DN	Cobicistat
DM6L4H2	MI	TTIJQ3O
DM6L4H2	MN	Cytochrome P450 3A (CYP3A)
DM6L4H2	MT	DTT
DM6L4H2	MA	Modulator
DM6L4H2	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7535).
DM6L4H2	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7535

DM6L4H2	DI	DM6L4H2
DM6L4H2	DN	Cobicistat
DM6L4H2	MI	DE4LYSA
DM6L4H2	MN	Cytochrome P450 3A4 (CYP3A4)
DM6L4H2	MT	DME
DM6L4H2	MA	Metabolism
DM6L4H2	RN	Drug interactions between hormonal contraceptives and antiretrovirals. AIDS. 2017 Apr 24;31(7):917-952.
DM6L4H2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28060009

DM6L4H2	DI	DM6L4H2
DM6L4H2	DN	Cobicistat
DM6L4H2	MI	DEIBDNY
DM6L4H2	MN	Cytochrome P450 3A5 (CYP3A5)
DM6L4H2	MT	DME
DM6L4H2	MA	Metabolism
DM6L4H2	RN	Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther. 2010 Mar;87(3):322-9.
DM6L4H2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20043009

DM6L4H2	DI	DM6L4H2
DM6L4H2	DN	Cobicistat
DM6L4H2	MI	DERD86B
DM6L4H2	MN	Cytochrome P450 3A7 (CYP3A7)
DM6L4H2	MT	DME
DM6L4H2	MA	Metabolism
DM6L4H2	RN	Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther. 2010 Mar;87(3):322-9.
DM6L4H2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20043009

DMDKXTO	DI	DMDKXTO
DMDKXTO	DN	Cobicistat/darunavir
DMDKXTO	MI	TTIJQ3O
DMDKXTO	MN	Cytochrome P450 3A (CYP3A)
DMDKXTO	MT	DTT
DMDKXTO	MA	Modulator
DMDKXTO	RN	Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection. Drugs. 2014 Feb;74(2):195-206.
DMDKXTO	RU	https://pubmed.ncbi.nlm.nih.gov/24343782

DMSOX7I	DI	DMSOX7I
DMSOX7I	DN	Cocaine
DMSOX7I	MI	DEIHSMD
DMSOX7I	MN	Butyrylcholine esterase (BCHE)
DMSOX7I	MT	DME
DMSOX7I	MA	Metabolism
DMSOX7I	RN	An albumin-butyrylcholinesterase for cocaine toxicity and addiction: catalytic and pharmacokinetic properties. Chem Biol Interact. 2008 Sep 25;175(1-3):83-7.
DMSOX7I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18514640

DMSOX7I	DI	DMSOX7I
DMSOX7I	DN	Cocaine
DMSOX7I	MI	DECB0K3
DMSOX7I	MN	Cytochrome P450 2D6 (CYP2D6)
DMSOX7I	MT	DME
DMSOX7I	MA	Metabolism
DMSOX7I	RN	Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Mol Pharmacol. 1991 Jul;40(1):63-8.
DMSOX7I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1857341

DMSOX7I	DI	DMSOX7I
DMSOX7I	DN	Cocaine
DMSOX7I	MI	DE4LYSA
DMSOX7I	MN	Cytochrome P450 3A4 (CYP3A4)
DMSOX7I	MT	DME
DMSOX7I	MA	Metabolism
DMSOX7I	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMSOX7I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMSOX7I	DI	DMSOX7I
DMSOX7I	DN	Cocaine
DMSOX7I	MI	DEIBDNY
DMSOX7I	MN	Cytochrome P450 3A5 (CYP3A5)
DMSOX7I	MT	DME
DMSOX7I	MA	Metabolism
DMSOX7I	RN	Regenerative changes in hepatic morphology and enhanced expression of CYP2B10 and CYP3A during daily administration of cocaine. Hepatology. 1996 Mar;23(3):515-23.
DMSOX7I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8617431

DMSOX7I	DI	DMSOX7I
DMSOX7I	DN	Cocaine
DMSOX7I	MI	DERD86B
DMSOX7I	MN	Cytochrome P450 3A7 (CYP3A7)
DMSOX7I	MT	DME
DMSOX7I	MA	Metabolism
DMSOX7I	RN	Drug Interactions Flockhart Table
DMSOX7I	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMSOX7I	DI	DMSOX7I
DMSOX7I	DN	Cocaine
DMSOX7I	MI	TTVBI8W
DMSOX7I	MN	Dopamine transporter (DAT)
DMSOX7I	MT	DTT
DMSOX7I	MA	Inhibitor
DMSOX7I	RN	Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
DMSOX7I	RU	https://pubmed.ncbi.nlm.nih.gov/19376154

DMSOX7I	DI	DMSOX7I
DMSOX7I	DN	Cocaine
DMSOX7I	MI	TTAWNKZ
DMSOX7I	MN	Norepinephrine transporter (NET)
DMSOX7I	MT	DTT
DMSOX7I	MA	Inhibitor
DMSOX7I	RN	Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
DMSOX7I	RU	https://pubmed.ncbi.nlm.nih.gov/19376154

DMSOX7I	DI	DMSOX7I
DMSOX7I	DN	Cocaine
DMSOX7I	MI	TT3ROYC
DMSOX7I	MN	Serotonin transporter (SERT)
DMSOX7I	MT	DTT
DMSOX7I	MA	Inhibitor
DMSOX7I	RN	Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
DMSOX7I	RU	https://pubmed.ncbi.nlm.nih.gov/19376154

DMJX6ZG	DI	DMJX6ZG
DMJX6ZG	DN	Codeine
DMJX6ZG	MI	DECB0K3
DMJX6ZG	MN	Cytochrome P450 2D6 (CYP2D6)
DMJX6ZG	MT	DME
DMJX6ZG	MA	Metabolism
DMJX6ZG	RN	Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet. 2009;48(11):689-723.
DMJX6ZG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19817501

DMJX6ZG	DI	DMJX6ZG
DMJX6ZG	DN	Codeine
DMJX6ZG	MI	DE4LYSA
DMJX6ZG	MN	Cytochrome P450 3A4 (CYP3A4)
DMJX6ZG	MT	DME
DMJX6ZG	MA	Metabolism
DMJX6ZG	RN	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
DMJX6ZG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429

DMJX6ZG	DI	DMJX6ZG
DMJX6ZG	DN	Codeine
DMJX6ZG	MI	DERD86B
DMJX6ZG	MN	Cytochrome P450 3A7 (CYP3A7)
DMJX6ZG	MT	DME
DMJX6ZG	MA	Metabolism
DMJX6ZG	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMJX6ZG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMJX6ZG	DI	DMJX6ZG
DMJX6ZG	DN	Codeine
DMJX6ZG	MI	TT27RFC
DMJX6ZG	MN	Opioid receptor delta (OPRD1)
DMJX6ZG	MT	DTT
DMJX6ZG	MA	Agonist
DMJX6ZG	RN	Butorphanol: effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors. J Pharmacol Sci. 2005 Jun;98(2):109-16.
DMJX6ZG	RU	https://pubmed.ncbi.nlm.nih.gov/15942128

DMJX6ZG	DI	DMJX6ZG
DMJX6ZG	DN	Codeine
DMJX6ZG	MI	DTT79CX
DMJX6ZG	MN	Organic cation transporter 1 (SLC22A1)
DMJX6ZG	MT	DTP
DMJX6ZG	MA	Substrate
DMJX6ZG	RN	Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study. Diabetes. 2015 May;64(5):1786-93.
DMJX6ZG	RU	http://www.ncbi.nlm.nih.gov/pubmed/25510240

DMJX6ZG	DI	DMJX6ZG
DMJX6ZG	DN	Codeine
DMJX6ZG	MI	DEYGVN4
DMJX6ZG	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMJX6ZG	MT	DME
DMJX6ZG	MA	Metabolism
DMJX6ZG	RN	Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos. 2003 Sep;31(9):1125-33.
DMJX6ZG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920168

DMJX6ZG	DI	DMJX6ZG
DMJX6ZG	DN	Codeine
DMJX6ZG	MI	DENUPDX
DMJX6ZG	MN	UDP-glucuronosyltransferase 2B4 (UGT2B4)
DMJX6ZG	MT	DME
DMJX6ZG	MA	Metabolism
DMJX6ZG	RN	Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone- and buprenorphine-maintained subjects. Br J Clin Pharmacol. 2012 May;73(5):786-94.
DMJX6ZG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22092298

DMJX6ZG	DI	DMJX6ZG
DMJX6ZG	DN	Codeine
DMJX6ZG	MI	DEB3CV1
DMJX6ZG	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMJX6ZG	MT	DME
DMJX6ZG	MA	Metabolism
DMJX6ZG	RN	Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos. 1997 Jan;25(1):1-4.
DMJX6ZG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9010622

DM2POTE	DI	DM2POTE
DM2POTE	DN	Colchicine
DM2POTE	MI	DE4LYSA
DM2POTE	MN	Cytochrome P450 3A4 (CYP3A4)
DM2POTE	MT	DME
DM2POTE	MA	Metabolism
DM2POTE	RN	Colchicine down-regulates cytochrome P450 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation. Mol Pharmacol. 2003 Jul;64(1):160-9.
DM2POTE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12815172

DM2POTE	DI	DM2POTE
DM2POTE	DN	Colchicine
DM2POTE	MI	DTSYQGK
DM2POTE	MN	Multidrug resistance-associated protein 1 (ABCC1)
DM2POTE	MT	DTP
DM2POTE	MA	Substrate
DM2POTE	RN	Pharmacological characterization of the murine and human orthologs of multidrug-resistance protein in transfected human embryonic kidney cells. Mol Pharmacol. 1997 Sep;52(3):344-53.
DM2POTE	RU	http://molpharm.aspetjournals.org/content/52/3/344

DM2POTE	DI	DM2POTE
DM2POTE	DN	Colchicine
DM2POTE	MI	DTUGYRD
DM2POTE	MN	P-glycoprotein 1 (ABCB1)
DM2POTE	MT	DTP
DM2POTE	MA	Substrate
DM2POTE	RN	Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol. 2009 Jul 15;78(2):153-61.
DM2POTE	RU	http://www.ncbi.nlm.nih.gov/pubmed/19427995

DM2POTE	DI	DM2POTE
DM2POTE	DN	Colchicine
DM2POTE	MI	TTML2WA
DM2POTE	MN	Tubulin (TUB)
DM2POTE	MT	DTT
DM2POTE	MA	Binder
DM2POTE	RN	Vitamin K3 disrupts the microtubule networks by binding to tubulin: a novel mechanism of its antiproliferative activity. Biochemistry. 2009 Jul 28;48(29):6963-74.
DM2POTE	RU	https://pubmed.ncbi.nlm.nih.gov/19527023

DMJ01D8	DI	DMJ01D8
DMJ01D8	DN	Colforsin daropate hci
DMJ01D8	MI	TTULOB6
DMJ01D8	MN	Cathelicidin antimicrobial peptide (CAMP)
DMJ01D8	MT	DTT
DMJ01D8	MA	Modulator
DMJ01D8	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMJ01D8	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DMZ9BMU	DI	DMZ9BMU
DMZ9BMU	DN	Colistimethate
DMZ9BMU	MI	TT4ILYC
DMZ9BMU	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMZ9BMU	MT	DTT
DMZ9BMU	MA	Binder
DMZ9BMU	RN	Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother. 1999 Sep;33(9):960-7.
DMZ9BMU	RU	https://pubmed.ncbi.nlm.nih.gov/10492501

DMMD9QE	DI	DMMD9QE
DMMD9QE	DN	Colistin
DMMD9QE	MI	TT4ILYC
DMMD9QE	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMMD9QE	MT	DTT
DMMD9QE	MA	Binder
DMMD9QE	RN	Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother. 1999 Sep;33(9):960-7.
DMMD9QE	RU	https://pubmed.ncbi.nlm.nih.gov/10492501

DMMD9QE	DI	DMMD9QE
DMMD9QE	DN	Colistin
DMMD9QE	MI	DE2M583
DMMD9QE	MN	Endoglucanase Y (EGY)
DMMD9QE	MT	DME
DMMD9QE	MA	Metabolism
DMMD9QE	RN	Expression of Clostridium thermocellum endoglucanase gene in Lactobacillus gasseri and Lactobacillus johnsonii and characterization of the genetically modified probiotic lactobacilli. Curr Microbiol. 2000 Apr;40(4):257-63.
DMMD9QE	RU	https://pubmed.ncbi.nlm.nih.gov/10688695

DMMD9QE	DI	DMMD9QE
DMMD9QE	DN	Colistin
DMMD9QE	MI	DE2AZTG
DMMD9QE	MN	Endoglucanase Y (EGY)
DMMD9QE	MT	DME
DMMD9QE	MA	Metabolism
DMMD9QE	RN	Expression of Clostridium thermocellum endoglucanase gene in Lactobacillus gasseri and Lactobacillus johnsonii and characterization of the genetically modified probiotic lactobacilli. Curr Microbiol. 2000 Apr;40(4):257-63.
DMMD9QE	RU	https://pubmed.ncbi.nlm.nih.gov/10688695

DMFJ2OG	DI	DMFJ2OG
DMFJ2OG	DN	Collagenase
DMFJ2OG	MI	TTK982E
DMFJ2OG	MN	Collagen (CO)
DMFJ2OG	MT	DTT
DMFJ2OG	MA	Breaker
DMFJ2OG	RN	Contact dermatitis with clostridiopeptidase A contained in Noruxol ointment. Contact Dermatitis. 2007 Jun;56(6):361-2.
DMFJ2OG	RU	https://pubmed.ncbi.nlm.nih.gov/17577383

DM1V329	DI	DM1V329
DM1V329	DN	Conivaptan
DM1V329	MI	DE4LYSA
DM1V329	MN	Cytochrome P450 3A4 (CYP3A4)
DM1V329	MT	DME
DM1V329	MA	Metabolism
DM1V329	RN	Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected]. Cardiovasc Drug Rev. 2007 Fall;25(3):261-79.
DM1V329	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17919259

DM1V329	DI	DM1V329
DM1V329	DN	Conivaptan
DM1V329	MI	TT4TFGN
DM1V329	MN	Vasopressin V1a receptor (V1AR)
DM1V329	MT	DTT
DM1V329	MA	Modulator
DM1V329	RN	Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001 Nov 13;104(20):2417-23.
DM1V329	RU	https://pubmed.ncbi.nlm.nih.gov/11705818

DM1V329	DI	DM1V329
DM1V329	DN	Conivaptan
DM1V329	MI	TTK8R02
DM1V329	MN	Vasopressin V2 receptor (V2R)
DM1V329	MT	DTT
DM1V329	MA	Modulator
DM1V329	RN	Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001 Nov 13;104(20):2417-23.
DM1V329	RU	https://pubmed.ncbi.nlm.nih.gov/11705818

DMLT0E1	DI	DMLT0E1
DMLT0E1	DN	Conjugated estrogens
DMLT0E1	MI	DE9RA0I
DMLT0E1	MN	Beta-glucuronidase (uidA)
DMLT0E1	MT	DME
DMLT0E1	MA	Metabolism
DMLT0E1	RN	Long-term administration of conjugated estrogen and bazedoxifene decreased murine fecal beta-glucuronidase activity without impacting overall microbiome community. Sci Rep. 2018 May 25;8(1):8166.
DMLT0E1	RU	https://pubmed.ncbi.nlm.nih.gov/29802368

DMLT0E1	DI	DMLT0E1
DMLT0E1	DN	Conjugated estrogens
DMLT0E1	MI	DEJGDUW
DMLT0E1	MN	Cytochrome P450 1A2 (CYP1A2)
DMLT0E1	MT	DME
DMLT0E1	MA	Metabolism
DMLT0E1	RN	Effect of conjugated equine estrogens on oxidative metabolism in middle-aged and elderly postmenopausal women. J Clin Pharmacol. 2006 Nov;46(11):1299-307.
DMLT0E1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17050794

DMLT0E1	DI	DMLT0E1
DMLT0E1	DN	Conjugated estrogens
DMLT0E1	MI	DE4LYSA
DMLT0E1	MN	Cytochrome P450 3A4 (CYP3A4)
DMLT0E1	MT	DME
DMLT0E1	MA	Metabolism
DMLT0E1	RN	Conjugated oestrogens/bazedoxifene. Aust Prescr. 2017 Jun;40(3):114-115.
DMLT0E1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28798519

DMLT0E1	DI	DMLT0E1
DMLT0E1	DN	Conjugated estrogens
DMLT0E1	MI	TTOM3J0
DMLT0E1	MN	Estrogen receptor beta (ESR2)
DMLT0E1	MT	DTT
DMLT0E1	MA	Antagonist
DMLT0E1	RN	Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination. Mol Endocrinol. 2009 Jan;23(1):74-85.
DMLT0E1	RU	https://pubmed.ncbi.nlm.nih.gov/19036900

DMTPIZC	DI	DMTPIZC
DMTPIZC	DN	Conjugated estrogens a
DMTPIZC	MI	TTZAYWL
DMTPIZC	MN	Estrogen receptor (ESR)
DMTPIZC	MT	DTT
DMTPIZC	MA	Modulator
DMTPIZC	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMTPIZC	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DMU7SF8	DI	DMU7SF8
DMU7SF8	DN	Conjugated estrogens b
DMU7SF8	MI	TTZAYWL
DMU7SF8	MN	Estrogen receptor (ESR)
DMU7SF8	MT	DTT
DMU7SF8	MA	Modulator
DMU7SF8	RN	Effect of MK-486 alone on Parkinsonism; studies on the clinical symptoms and catecholamine concentrations in the blood, urine and cerebrospinal fluid. No To Shinkei. 1977 Feb;29(2):205-13.
DMU7SF8	RU	https://pubmed.ncbi.nlm.nih.gov/326277

DMF29Q5	DI	DMF29Q5
DMF29Q5	DN	Connexyn
DMF29Q5	MI	TTWG9A4
DMF29Q5	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMF29Q5	MT	DTT
DMF29Q5	MA	Agonist
DMF29Q5	RN	alpha2A-adrenergic receptors heterosynaptically regulate glutamatergic transmission in the bed nucleus of the stria terminalis. Neuroscience. 2009 Sep 29;163(1):339-51.
DMF29Q5	RU	https://pubmed.ncbi.nlm.nih.gov/19527774

DMF29Q5	DI	DMF29Q5
DMF29Q5	DN	Connexyn
DMF29Q5	MI	DE4LYSA
DMF29Q5	MN	Cytochrome P450 3A4 (CYP3A4)
DMF29Q5	MT	DME
DMF29Q5	MA	Metabolism
DMF29Q5	RN	Microsomal catalyzed N-hydroxylation of guanfacine and reduction of N-hydroxyguanfacine. Arch Pharm (Weinheim). 1997 Oct;330(9-10):303-6.
DMF29Q5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9396389

DM26KR1	DI	DM26KR1
DM26KR1	DN	Copper dotatate Cu-64
DM26KR1	MI	TTZ6T9E
DM26KR1	MN	Somatostatin receptor type 2 (SSTR2)
DM26KR1	MT	DTT
DM26KR1	MA	Binder
DM26KR1	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DM26KR1	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213227s000lbl.pdf

DMP9TWZ	DI	DMP9TWZ
DMP9TWZ	DN	Corticotropin
DMP9TWZ	MI	DE4LYSA
DMP9TWZ	MN	Cytochrome P450 3A4 (CYP3A4)
DMP9TWZ	MT	DME
DMP9TWZ	MA	Metabolism
DMP9TWZ	RN	Troglitazone induces CYP3A4 activity leading to falsely abnormal dexamethasone suppression test. J Clin Endocrinol Metab. 2003 Jul;88(7):3113-6.
DMP9TWZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12843151

DMU5QZX	DI	DMU5QZX
DMU5QZX	DN	Cortisone
DMU5QZX	MI	DTUGYRD
DMU5QZX	MN	P-glycoprotein 1 (ABCB1)
DMU5QZX	MT	DTP
DMU5QZX	MA	Substrate
DMU5QZX	RN	Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803.
DMU5QZX	RU	http://www.ncbi.nlm.nih.gov/pubmed/14661924

DMG8K57	DI	DMG8K57
DMG8K57	DN	Cortisone acetate
DMG8K57	MI	DEZDRQO
DMG8K57	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMG8K57	MT	DME
DMG8K57	MA	Metabolism
DMG8K57	RN	Comparative enzymology of 11beta-hydroxysteroid dehydrogenase type 1 from six species. J Mol Endocrinol. 2005 Aug;35(1):89-101.
DMG8K57	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16087724

DMG8K57	DI	DMG8K57
DMG8K57	DN	Cortisone acetate
DMG8K57	MI	DEDH7FP
DMG8K57	MN	Corticosteroid 11-beta-dehydrogenase 2 (HSD11B2)
DMG8K57	MT	DME
DMG8K57	MA	Metabolism
DMG8K57	RN	Comparative enzymology of 11beta-hydroxysteroid dehydrogenase type 1 from six species. J Mol Endocrinol. 2005 Aug;35(1):89-101.
DMG8K57	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16087724

DMG8K57	DI	DMG8K57
DMG8K57	DN	Cortisone acetate
DMG8K57	MI	DE4LYSA
DMG8K57	MN	Cytochrome P450 3A4 (CYP3A4)
DMG8K57	MT	DME
DMG8K57	MA	Metabolism
DMG8K57	RN	Prediction of tacrolimus metabolism and dosage requirements based on CYP3A4 phenotype and CYP3A5(*)3 genotype in Chinese renal transplant recipients. Acta Pharmacol Sin. 2016 Apr;37(4):555-60.
DMG8K57	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26924289

DMG8K57	DI	DMG8K57
DMG8K57	DN	Cortisone acetate
DMG8K57	MI	DEIBDNY
DMG8K57	MN	Cytochrome P450 3A5 (CYP3A5)
DMG8K57	MT	DME
DMG8K57	MA	Metabolism
DMG8K57	RN	Comparative pharmacokinetics and metabolism studies in lean and diet- induced obese mice: an animal efficacy model for 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors. Drug Metab Lett. 2011 Jan;5(1):55-63.
DMG8K57	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21198436

DMG8K57	DI	DMG8K57
DMG8K57	DN	Cortisone acetate
DMG8K57	MI	DERD86B
DMG8K57	MN	Cytochrome P450 3A7 (CYP3A7)
DMG8K57	MT	DME
DMG8K57	MA	Metabolism
DMG8K57	RN	Comparative pharmacokinetics and metabolism studies in lean and diet- induced obese mice: an animal efficacy model for 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors. Drug Metab Lett. 2011 Jan;5(1):55-63.
DMG8K57	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21198436

DMG8K57	DI	DMG8K57
DMG8K57	DN	Cortisone acetate
DMG8K57	MI	DEEXSKI
DMG8K57	MN	Short-chain dehydrogenase/reductase retSDR4 (DHRS7)
DMG8K57	MT	DME
DMG8K57	MA	Metabolism
DMG8K57	RN	Human DHRS7, promising enzyme in metabolism of steroids and retinoids? J Steroid Biochem Mol Biol. 2016 Jan;155(Pt A):112-9.
DMG8K57	RU	https://pubmed.ncbi.nlm.nih.gov/26466768

DMG8K57	DI	DMG8K57
DMG8K57	DN	Cortisone acetate
DMG8K57	MI	TTP3UTW
DMG8K57	MN	Steroid hormone receptor ERR (ESRR)
DMG8K57	MT	DTT
DMG8K57	MA	Modulator
DMG8K57	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMG8K57	RU	https://www.fda.gov/

DMUIASK	DI	DMUIASK
DMUIASK	DN	Cosyntropin
DMUIASK	MI	TTPWFDX
DMUIASK	MN	Melanocortin receptor 2 (MC2R)
DMUIASK	MT	DTT
DMUIASK	MA	Antagonist
DMUIASK	RN	Hypothalamic-pituitary-adrenal axis dysfunction in hospitalized neonatal foals. J Vet Intern Med. 2009 Jul-Aug;23(4):901-12.
DMUIASK	RU	https://pubmed.ncbi.nlm.nih.gov/19496914

DMCEZ1B	DI	DMCEZ1B
DMCEZ1B	DN	Cotinine
DMCEZ1B	MI	TTJSZTB
DMCEZ1B	MN	Nicotinic acetylcholine receptor (nAChR)
DMCEZ1B	MT	DTT
DMCEZ1B	MA	Modulator
DMCEZ1B	RN	Functional versus chemical diversity: is biodiversity important for drug discovery. Trends Pharmacol Sci. 2002 May;23(5):225-31.
DMCEZ1B	RU	https://pubmed.ncbi.nlm.nih.gov/12008000

DMCEZ1B	DI	DMCEZ1B
DMCEZ1B	DN	Cotinine
DMCEZ1B	MI	DEI8NGH
DMCEZ1B	MN	UDP-glucuronosyltransferase 2B10 (UGT2B10)
DMCEZ1B	MT	DME
DMCEZ1B	MA	Metabolism
DMCEZ1B	RN	Human UDP-glucuronosyltransferase (UGT) 2B10: validation of cotinine as a selective probe substrate, inhibition by UGT enzyme-selective inhibitors and antidepressant and antipsychotic drugs, and structural determinants of enzyme inhibition. Drug Metab Dispos. 2016 Mar;44(3):378-88.
DMCEZ1B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26669329

DMJ7IQX	DI	DMJ7IQX
DMJ7IQX	DN	Crestor/TriLipix
DMJ7IQX	MI	TTPADOQ
DMJ7IQX	MN	HMG-CoA reductase (HMGCR)
DMJ7IQX	MT	DTT
DMJ7IQX	MA	Inhibitor
DMJ7IQX	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DMJ7IQX	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DMNVKU6	DI	DMNVKU6
DMNVKU6	DN	Crisaborole
DMNVKU6	MI	TTV5CGO
DMNVKU6	MN	Phosphodiesterase 4 (PDE4)
DMNVKU6	MT	DTT
DMNVKU6	MA	Modulator
DMNVKU6	RN	2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. 
DMNVKU6	RU	https://www.ncbi.nlm.nih.gov/pubmed/28148938

DMAHOVJ	DI	DMAHOVJ
DMAHOVJ	DN	Crizanlizumab
DMAHOVJ	MI	TTE5VG0
DMAHOVJ	MN	P-selectin (SELP)
DMAHOVJ	MT	DTT
DMAHOVJ	MA	Inhibitor
DMAHOVJ	RN	Crizanlizumab: First Approval. Drugs. 2020 Jan;80(1):79-84.
DMAHOVJ	RU	https://pubmed.ncbi.nlm.nih.gov/31933169

DM4F29C	DI	DM4F29C
DM4F29C	DN	Crizotinib
DM4F29C	MI	TTPMQSO
DM4F29C	MN	ALK tyrosine kinase receptor (ALK)
DM4F29C	MT	DTT
DM4F29C	MA	Modulator
DM4F29C	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DM4F29C	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM4F29C	DI	DM4F29C
DM4F29C	DN	Crizotinib
DM4F29C	MI	DE4LYSA
DM4F29C	MN	Cytochrome P450 3A4 (CYP3A4)
DM4F29C	MT	DME
DM4F29C	MA	Metabolism
DM4F29C	RN	Crizotinib for the treatment of non-small-cell lung cancer. Am J Health Syst Pharm. 2013 Jun 1;70(11):943-7.
DM4F29C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23686600

DM4F29C	DI	DM4F29C
DM4F29C	DN	Crizotinib
DM4F29C	MI	DEIBDNY
DM4F29C	MN	Cytochrome P450 3A5 (CYP3A5)
DM4F29C	MT	DME
DM4F29C	MA	Metabolism
DM4F29C	RN	Crizotinib for the treatment of non-small-cell lung cancer. Am J Health Syst Pharm. 2013 Jun 1;70(11):943-7.
DM4F29C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23686600

DM4F29C	DI	DM4F29C
DM4F29C	DN	Crizotinib
DM4F29C	MI	TTKA5LP
DM4F29C	MN	HGF/Met signaling pathway (HGF/Met pathway)
DM4F29C	MT	DTT
DM4F29C	MA	Inhibitor
DM4F29C	RN	Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.Drug Des Devel Ther. 2015 Aug 26;9:4897-907.
DM4F29C	RU	https://pubmed.ncbi.nlm.nih.gov/26345996

DM4F29C	DI	DM4F29C
DM4F29C	DN	Crizotinib
DM4F29C	MI	DT3D8F0
DM4F29C	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM4F29C	MT	DTP
DM4F29C	MA	Substrate
DM4F29C	RN	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
DM4F29C	RU	http://www.ncbi.nlm.nih.gov/pubmed/23340295

DM4F29C	DI	DM4F29C
DM4F29C	DN	Crizotinib
DM4F29C	MI	DT9C1TS
DM4F29C	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM4F29C	MT	DTP
DM4F29C	MA	Substrate
DM4F29C	RN	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
DM4F29C	RU	http://www.ncbi.nlm.nih.gov/pubmed/23340295

DM4F29C	DI	DM4F29C
DM4F29C	DN	Crizotinib
DM4F29C	MI	DTUGYRD
DM4F29C	MN	P-glycoprotein 1 (ABCB1)
DM4F29C	MT	DTP
DM4F29C	MA	Substrate
DM4F29C	RN	Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int J Cancer. 2014 Mar 15;134(6):1484-94.
DM4F29C	RU	http://www.ncbi.nlm.nih.gov/pubmed/24037730

DM4F29C	DI	DM4F29C
DM4F29C	DN	Crizotinib
DM4F29C	MI	TTNDSF4
DM4F29C	MN	Proto-oncogene c-Met (MET)
DM4F29C	MT	DTT
DM4F29C	MA	Modulator
DM4F29C	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DM4F29C	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM4F29C	DI	DM4F29C
DM4F29C	DN	Crizotinib
DM4F29C	MI	TTSZ6Y3
DM4F29C	MN	Proto-oncogene c-Ros (ROS1)
DM4F29C	MT	DTT
DM4F29C	MA	Modulator
DM4F29C	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DM4F29C	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM4AMQZ	DI	DM4AMQZ
DM4AMQZ	DN	Crofelemer
DM4AMQZ	MI	TTOJI4S
DM4AMQZ	MN	Calcium-dependent chloride channel anoctamin (ANO)
DM4AMQZ	MT	DTT
DM4AMQZ	MA	Modulator
DM4AMQZ	RN	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
DM4AMQZ	RU	https://pubmed.ncbi.nlm.nih.gov/23370234

DM4AMQZ	DI	DM4AMQZ
DM4AMQZ	DN	Crofelemer
DM4AMQZ	MI	TTRLZHP
DM4AMQZ	MN	cAMP-dependent chloride channel (CFTR)
DM4AMQZ	MT	DTT
DM4AMQZ	MA	Modulator
DM4AMQZ	RN	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
DM4AMQZ	RU	https://pubmed.ncbi.nlm.nih.gov/23370234

DM74LZK	DI	DM74LZK
DM74LZK	DN	Cromoglicate
DM74LZK	MI	TT78R5H
DM74LZK	MN	Heat shock protein 90 alpha (HSP90A)
DM74LZK	MT	DTT
DM74LZK	MA	Inhibitor
DM74LZK	RN	Hsp90 is a direct target of the anti-allergic drugs disodium cromoglycate and amlexanox. Biochem J. 2003 Sep 1;374(Pt 2):433-41.
DM74LZK	RU	https://pubmed.ncbi.nlm.nih.gov/12803546

DMHCTAL	DI	DMHCTAL
DMHCTAL	DN	Cryptenamine Acetates
DMHCTAL	MI	TTH18TF
DMHCTAL	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMHCTAL	MT	DTT
DMHCTAL	MA	Modulator
DMHCTAL	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMHCTAL	RU	https://www.fda.gov/

DMB8PF3	DI	DMB8PF3
DMB8PF3	DN	CT-102
DMB8PF3	MI	TTI2WET
DMB8PF3	MN	Platelet-derived growth factor receptor (PDGFR)
DMB8PF3	MT	DTT
DMB8PF3	MA	Activator
DMB8PF3	RN	Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
DMB8PF3	RU	https://pubmed.ncbi.nlm.nih.gov/17064227

DMP0NFQ	DI	DMP0NFQ
DMP0NFQ	DN	Cupric Sulfate
DMP0NFQ	MI	DTP8L4F
DMP0NFQ	MN	High affinity copper uptake protein 1 (SLC31A1)
DMP0NFQ	MT	DTP
DMP0NFQ	MA	Substrate
DMP0NFQ	RN	Role of the copper transporter, CTR1, in platinum-induced ototoxicity. J Neurosci. 2010 Jul 14;30(28):9500-9.
DMP0NFQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/20631178

DMHSJB4	DI	DMHSJB4
DMHSJB4	DN	Cyclacillin
DMHSJB4	MI	TTJP4SM
DMHSJB4	MN	Bacterial Penicillin binding protein (Bact PBP)
DMHSJB4	MT	DTT
DMHSJB4	MA	Binder
DMHSJB4	RN	Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
DMHSJB4	RU	https://pubmed.ncbi.nlm.nih.gov/17016423

DMHSJB4	DI	DMHSJB4
DMHSJB4	DN	Cyclacillin
DMHSJB4	MI	DT9G7XN
DMHSJB4	MN	Peptide transporter 1 (SLC15A1)
DMHSJB4	MT	DTP
DMHSJB4	MA	Substrate
DMHSJB4	RN	Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60.
DMHSJB4	RU	http://www.ncbi.nlm.nih.gov/pubmed/16597710

DMHSJB4	DI	DMHSJB4
DMHSJB4	DN	Cyclacillin
DMHSJB4	MI	DT8QKNP
DMHSJB4	MN	Peptide transporter 2 (SLC15A2)
DMHSJB4	MT	DTP
DMHSJB4	MA	Substrate
DMHSJB4	RN	Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60.
DMHSJB4	RU	http://www.ncbi.nlm.nih.gov/pubmed/16597710

DMO0R76	DI	DMO0R76
DMO0R76	DN	Cyclandelate
DMO0R76	MI	DE4LYSA
DMO0R76	MN	Cytochrome P450 3A4 (CYP3A4)
DMO0R76	MT	DME
DMO0R76	MA	Metabolism
DMO0R76	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DMO0R76	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DM9G7BS	DI	DM9G7BS
DM9G7BS	DN	Cyclizine
DM9G7BS	MI	TTTIBOJ
DM9G7BS	MN	Histamine H1 receptor (H1R)
DM9G7BS	MT	DTT
DM9G7BS	MA	Antagonist
DM9G7BS	RN	Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol. Ther Drug Monit. 2003 Apr;25(2):192-6.
DM9G7BS	RU	https://pubmed.ncbi.nlm.nih.gov/12657913

DM1YBRM	DI	DM1YBRM
DM1YBRM	DN	Cyclobenzaprine
DM1YBRM	MI	TTYSN63
DM1YBRM	MN	5-HT 2 receptor (5HT2R)
DM1YBRM	MT	DTT
DM1YBRM	MA	Antagonist
DM1YBRM	RN	Torticollis under Cyclobenzaprine. Pharmacology. 2009 Jul 8;84(2):91-92.
DM1YBRM	RU	https://pubmed.ncbi.nlm.nih.gov/19590258

DM1YBRM	DI	DM1YBRM
DM1YBRM	DN	Cyclobenzaprine
DM1YBRM	MI	DEJGDUW
DM1YBRM	MN	Cytochrome P450 1A2 (CYP1A2)
DM1YBRM	MT	DME
DM1YBRM	MA	Metabolism
DM1YBRM	RN	Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine. Drug Metab Dispos. 1996 Jul;24(7):786-91.
DM1YBRM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8818577

DM1YBRM	DI	DM1YBRM
DM1YBRM	DN	Cyclobenzaprine
DM1YBRM	MI	DECB0K3
DM1YBRM	MN	Cytochrome P450 2D6 (CYP2D6)
DM1YBRM	MT	DME
DM1YBRM	MA	Metabolism
DM1YBRM	RN	Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine. Drug Metab Dispos. 1996 Jul;24(7):786-91.
DM1YBRM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8818577

DM1YBRM	DI	DM1YBRM
DM1YBRM	DN	Cyclobenzaprine
DM1YBRM	MI	DE4LYSA
DM1YBRM	MN	Cytochrome P450 3A4 (CYP3A4)
DM1YBRM	MT	DME
DM1YBRM	MA	Metabolism
DM1YBRM	RN	Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine. Drug Metab Dispos. 1996 Jul;24(7):786-91.
DM1YBRM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8818577

DMT5RMB	DI	DMT5RMB
DMT5RMB	DN	Cyclofenil
DMT5RMB	MI	TTZAYWL
DMT5RMB	MN	Estrogen receptor (ESR)
DMT5RMB	MT	DTT
DMT5RMB	MA	Modulator
DMT5RMB	RN	Fluorine-substituted cyclofenil derivatives as estrogen receptor ligands: synthesis and structure-affinity relationship study of potential positron emission tomography agents for imaging estrogen receptors in breast cancer. J Med Chem. 2006 Apr 20;49(8):2496-511.
DMT5RMB	RU	https://pubmed.ncbi.nlm.nih.gov/16610793

DMA8LM5	DI	DMA8LM5
DMA8LM5	DN	Cyclopentolate
DMA8LM5	MI	TTH18TF
DMA8LM5	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMA8LM5	MT	DTT
DMA8LM5	MA	Antagonist
DMA8LM5	RN	High spatial resolution studies of muscarinic neuroeffector junctions in mouse isolated vas deferens. Neuroscience. 2009 Sep 15;162(4):1366-76.
DMA8LM5	RU	https://pubmed.ncbi.nlm.nih.gov/19486927

DM4O2Z7	DI	DM4O2Z7
DM4O2Z7	DN	Cyclophosphamide
DM4O2Z7	MI	DEJVYAZ
DM4O2Z7	MN	Cytochrome P450 2A6 (CYP2A6)
DM4O2Z7	MT	DME
DM4O2Z7	MA	Metabolism
DM4O2Z7	RN	Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66.
DM4O2Z7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10348794

DM4O2Z7	DI	DM4O2Z7
DM4O2Z7	DN	Cyclophosphamide
DM4O2Z7	MI	DEPKLMQ
DM4O2Z7	MN	Cytochrome P450 2B6 (CYP2B6)
DM4O2Z7	MT	DME
DM4O2Z7	MA	Metabolism
DM4O2Z7	RN	The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes. Drug Metab Dispos. 2002 Jul;30(7):814-22.
DM4O2Z7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12065440

DM4O2Z7	DI	DM4O2Z7
DM4O2Z7	DN	Cyclophosphamide
DM4O2Z7	MI	DEZMWRE
DM4O2Z7	MN	Cytochrome P450 2C18 (CYP2C18)
DM4O2Z7	MT	DME
DM4O2Z7	MA	Metabolism
DM4O2Z7	RN	Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66.
DM4O2Z7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10348794

DM4O2Z7	DI	DM4O2Z7
DM4O2Z7	DN	Cyclophosphamide
DM4O2Z7	MI	DES5XRU
DM4O2Z7	MN	Cytochrome P450 2C8 (CYP2C8)
DM4O2Z7	MT	DME
DM4O2Z7	MA	Metabolism
DM4O2Z7	RN	Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res. 1997 May 15;57(10):1946-54.
DM4O2Z7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9157990

DM4O2Z7	DI	DM4O2Z7
DM4O2Z7	DN	Cyclophosphamide
DM4O2Z7	MI	DE5IED8
DM4O2Z7	MN	Cytochrome P450 2C9 (CYP2C9)
DM4O2Z7	MT	DME
DM4O2Z7	MA	Metabolism
DM4O2Z7	RN	CYP2C9 polymorphisms in human tumors. Anticancer Res. 2006 Jan-Feb;26(1A):299-305.
DM4O2Z7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16475710

DM4O2Z7	DI	DM4O2Z7
DM4O2Z7	DN	Cyclophosphamide
DM4O2Z7	MI	DE4LYSA
DM4O2Z7	MN	Cytochrome P450 3A4 (CYP3A4)
DM4O2Z7	MT	DME
DM4O2Z7	MA	Metabolism
DM4O2Z7	RN	Effects of ketoconazole on cyclophosphamide metabolism: evaluation of CYP3A4 inhibition effect using the in vitro and in vivo models. Exp Anim. 2018 Feb 9;67(1):71-82.
DM4O2Z7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29129847

DM4O2Z7	DI	DM4O2Z7
DM4O2Z7	DN	Cyclophosphamide
DM4O2Z7	MI	DERD86B
DM4O2Z7	MN	Cytochrome P450 3A7 (CYP3A7)
DM4O2Z7	MT	DME
DM4O2Z7	MA	Metabolism
DM4O2Z7	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM4O2Z7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM4O2Z7	DI	DM4O2Z7
DM4O2Z7	DN	Cyclophosphamide
DM4O2Z7	MI	TTUTN1I
DM4O2Z7	MN	Human Deoxyribonucleic acid (hDNA)
DM4O2Z7	MT	DTT
DM4O2Z7	MA	Modulator
DM4O2Z7	RN	O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts. Int J Cancer. 1998 Sep 11;77(6):919-22.
DM4O2Z7	RU	https://www.ncbi.nlm.nih.gov/pubmed/9714064

DM4O2Z7	DI	DM4O2Z7
DM4O2Z7	DN	Cyclophosphamide
DM4O2Z7	MI	DEGTFWK
DM4O2Z7	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM4O2Z7	MT	DME
DM4O2Z7	MA	Metabolism
DM4O2Z7	RN	Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
DM4O2Z7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16550168

DM4O2Z7	DI	DM4O2Z7
DM4O2Z7	DN	Cyclophosphamide
DM4O2Z7	MI	DTCSGPB
DM4O2Z7	MN	Multidrug resistance-associated protein 4 (ABCC4)
DM4O2Z7	MT	DTP
DM4O2Z7	MA	Substrate
DM4O2Z7	RN	Interaction of oxazaphosphorines with multidrug resistance-associated protein 4 (MRP4). AAPS J. 2010 Sep;12(3):300-8.
DM4O2Z7	RU	http://www.ncbi.nlm.nih.gov/pubmed/20405259

DMT1I52	DI	DMT1I52
DMT1I52	DN	Cycloserine
DMT1I52	MI	TTLD29N
DMT1I52	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMT1I52	MT	DTT
DMT1I52	MA	Inhibitor
DMT1I52	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMT1I52	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMT1I52	DI	DMT1I52
DMT1I52	DN	Cycloserine
DMT1I52	MI	TT6TMZU
DMT1I52	MN	Mycobacterium Biosynthetic alanine racemase (MycB alr)
DMT1I52	MT	DTT
DMT1I52	MA	Inhibitor
DMT1I52	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMT1I52	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMT1I52	DI	DMT1I52
DMT1I52	DN	Cycloserine
DMT1I52	MI	TTCS3P1
DMT1I52	MN	Mycobacterium D-alanine-D-alanine ligase A (MycB ddl)
DMT1I52	MT	DTT
DMT1I52	MA	Inhibitor
DMT1I52	RN	Self-protection mechanism in D-cycloserine-producing Streptomyces lavendulae. Gene cloning, characterization, and kinetics of its alanine racemase ... J Biol Chem. 2004 Oct 29;279(44):46143-52.
DMT1I52	RU	https://pubmed.ncbi.nlm.nih.gov/15302885

DMT1I52	DI	DMT1I52
DMT1I52	DN	Cycloserine
DMT1I52	MI	TT9IK2Z
DMT1I52	MN	N-methyl-D-aspartate receptor (NMDAR)
DMT1I52	MT	DTT
DMT1I52	MA	Agonist
DMT1I52	RN	How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
DMT1I52	RU	https://pubmed.ncbi.nlm.nih.gov/18621146

DMT1I52	DI	DMT1I52
DMT1I52	DN	Cycloserine
DMT1I52	MI	DT48WEM
DMT1I52	MN	Proton-coupled amino acid transporter 1 (SLC36A1)
DMT1I52	MT	DTP
DMT1I52	MA	Substrate
DMT1I52	RN	Indirect regulation of the intestinal H+-coupled amino acid transporter hPAT1 (SLC36A1). J Cell Physiol. 2005 Aug;204(2):604-13.
DMT1I52	RU	http://www.ncbi.nlm.nih.gov/pubmed/15754324

DMT1I52	DI	DMT1I52
DMT1I52	DN	Cycloserine
DMT1I52	MI	DTAOPTV
DMT1I52	MN	Proton-coupled amino acid transporter 2 (SLC36A2)
DMT1I52	MT	DTP
DMT1I52	MA	Substrate
DMT1I52	RN	Substrate specificity and functional characterisation of the H+/amino acid transporter rat PAT2 (Slc36a2). Br J Pharmacol. 2005 Jan;144(1):28-41.
DMT1I52	RU	http://www.ncbi.nlm.nih.gov/pubmed/15644866

DMJ4AWC	DI	DMJ4AWC
DMJ4AWC	DN	Cyclothiazide
DMJ4AWC	MI	TTANPDJ
DMJ4AWC	MN	Carbonic anhydrase II (CA-II)
DMJ4AWC	MT	DTT
DMJ4AWC	MA	Inhibitor
DMJ4AWC	RN	Selective effect of thiazides on the human osteoblast-like cell line MG-63. Kidney Int. 1996 Nov;50(5):1476-82.
DMJ4AWC	RU	https://pubmed.ncbi.nlm.nih.gov/8914012

DM8C43Q	DI	DM8C43Q
DM8C43Q	DN	Cycrimine
DM8C43Q	MI	TTZ9SOR
DM8C43Q	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DM8C43Q	MT	DTT
DM8C43Q	MA	Binder
DM8C43Q	RN	Capillary gas chromatography of trihexyphenidyl, procyclidine and cycrimine in biological fluids. J Chromatogr. 1989 Sep 29;494:135-42.
DM8C43Q	RU	https://pubmed.ncbi.nlm.nih.gov/2573609

DMUY2OR	DI	DMUY2OR
DMUY2OR	DN	Cynarin
DMUY2OR	MI	TTLOQ79
DMUY2OR	MN	Taste receptor (TASR)
DMUY2OR	MT	DTT
DMUY2OR	MA	Modulator
DMUY2OR	RN	Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81.
DMUY2OR	RU	https://pubmed.ncbi.nlm.nih.gov/3879679

DM92AH3	DI	DM92AH3
DM92AH3	DN	Cyproheptadine
DM92AH3	MI	TTTIBOJ
DM92AH3	MN	Histamine H1 receptor (H1R)
DM92AH3	MT	DTT
DM92AH3	MA	Antagonist
DM92AH3	RN	Cyproheptadine displays preclinical activity in myeloma and leukemia. Blood. 2008 Aug 1;112(3):760-9.
DM92AH3	RU	https://pubmed.ncbi.nlm.nih.gov/18502826

DM92AH3	DI	DM92AH3
DM92AH3	DN	Cyproheptadine
DM92AH3	MI	DEYGVN4
DM92AH3	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM92AH3	MT	DME
DM92AH3	MA	Metabolism
DM92AH3	RN	Effect of common exon variant (p.P364L) on drug glucuronidation by the human UDP-glucuronosyltransferase 1 family. Basic Clin Pharmacol Toxicol. 2011 Dec;109(6):486-93.
DM92AH3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21726413

DM92AH3	DI	DM92AH3
DM92AH3	DN	Cyproheptadine
DM92AH3	MI	DEF2WXN
DM92AH3	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DM92AH3	MT	DME
DM92AH3	MA	Metabolism
DM92AH3	RN	Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metab Dispos. 1998 Jun;26(6):507-12.
DM92AH3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9616184

DMQXLD2	DI	DMQXLD2
DMQXLD2	DN	Cyproterone
DMQXLD2	MI	TTS64P2
DMQXLD2	MN	Androgen receptor (AR)
DMQXLD2	MT	DTT
DMQXLD2	MA	Antagonist
DMQXLD2	RN	Coactivator selective regulation of androgen receptor activity. Steroids. 2009 Aug;74(8):669-74.
DMQXLD2	RU	https://pubmed.ncbi.nlm.nih.gov/19463689

DMSYFM8	DI	DMSYFM8
DMSYFM8	DN	Cysteamine
DMSYFM8	MI	DEA3U9Y
DMSYFM8	MN	Myeloperoxidase (MPO)
DMSYFM8	MT	DME
DMSYFM8	MA	Metabolism
DMSYFM8	RN	Thiols as peroxidase substrates. Free Radic Biol Med. 1993 Feb;14(2):167-75.
DMSYFM8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8381104

DMSYFM8	DI	DMSYFM8
DMSYFM8	DN	Cysteamine
DMSYFM8	MI	TTWF7UG
DMSYFM8	MN	Somatostatin (SST)
DMSYFM8	MT	DTT
DMSYFM8	MA	Binder
DMSYFM8	RN	Somatostatin, Alzheimer's disease and cognition: an old story coming of age Prog Neurobiol. 2009 Oct;89(2):153-61.
DMSYFM8	RU	https://pubmed.ncbi.nlm.nih.gov/19595735

DMZD5QR	DI	DMZD5QR
DMZD5QR	DN	Cytarabine
DMZD5QR	MI	DT0EQPW
DMZD5QR	MN	Concentrative nucleoside transporter 1 (SLC28A1)
DMZD5QR	MT	DTP
DMZD5QR	MA	Substrate
DMZD5QR	RN	FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia. Oncotarget. 2016 Aug 2;7(31):49786-49799.
DMZD5QR	RU	http://www.ncbi.nlm.nih.gov/pubmed/27391351

DMZD5QR	DI	DMZD5QR
DMZD5QR	DN	Cytarabine
DMZD5QR	MI	DEKEDRC
DMZD5QR	MN	Cytidine aminohydrolase (CDA)
DMZD5QR	MT	DME
DMZD5QR	MA	Metabolism
DMZD5QR	RN	Genetic factors influencing cytarabine therapy. Pharmacogenomics. 2009 Oct;10(10):1657-74.
DMZD5QR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19842938

DMZD5QR	DI	DMZD5QR
DMZD5QR	DN	Cytarabine
DMZD5QR	MI	DEYILK4
DMZD5QR	MN	Cytidine deaminase (cdd)
DMZD5QR	MT	DME
DMZD5QR	MA	Metabolism
DMZD5QR	RN	Mycoplasma hyorhinis-encoded cytidine deaminase efficiently inactivates cytosine-based anticancer drugs. FEBS Open Bio. 2015 Aug 3;5:634-9.
DMZD5QR	RU	https://pubmed.ncbi.nlm.nih.gov/26322268

DMZD5QR	DI	DMZD5QR
DMZD5QR	DN	Cytarabine
DMZD5QR	MI	DE4LYSA
DMZD5QR	MN	Cytochrome P450 3A4 (CYP3A4)
DMZD5QR	MT	DME
DMZD5QR	MA	Metabolism
DMZD5QR	RN	Synthesis and characterization of a novel liver-targeted prodrug of cytosine-1-beta-D-arabinofuranoside monophosphate for the treatment of hepatocellular carcinoma. J Med Chem. 2006 Dec 28;49(26):7711-20.
DMZD5QR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17181153

DMZD5QR	DI	DMZD5QR
DMZD5QR	DN	Cytarabine
DMZD5QR	MI	DEXL3P2
DMZD5QR	MN	Deoxycytidylate deaminase (DCTD)
DMZD5QR	MT	DME
DMZD5QR	MA	Metabolism
DMZD5QR	RN	Genetic factors influencing cytarabine therapy. Pharmacogenomics. 2009 Oct;10(10):1657-74.
DMZD5QR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19842938

DMZD5QR	DI	DMZD5QR
DMZD5QR	DN	Cytarabine
DMZD5QR	MI	DE3Z9HM
DMZD5QR	MN	Ecto-5'-nucleotidase (NT5E)
DMZD5QR	MT	DME
DMZD5QR	MA	Metabolism
DMZD5QR	RN	Genetic factors influencing cytarabine therapy. Pharmacogenomics. 2009 Oct;10(10):1657-74.
DMZD5QR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19842938

DMZD5QR	DI	DMZD5QR
DMZD5QR	DN	Cytarabine
DMZD5QR	MI	DTXD1TQ
DMZD5QR	MN	Equilibrative nucleoside transporter 1 (SLC29A1)
DMZD5QR	MT	DTP
DMZD5QR	MA	Substrate
DMZD5QR	RN	FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia. Oncotarget. 2016 Aug 2;7(31):49786-49799.
DMZD5QR	RU	http://www.ncbi.nlm.nih.gov/pubmed/27391351

DMZD5QR	DI	DMZD5QR
DMZD5QR	DN	Cytarabine
DMZD5QR	MI	DTW78DQ
DMZD5QR	MN	Equilibrative nucleoside transporter 2 (SLC29A2)
DMZD5QR	MT	DTP
DMZD5QR	MA	Substrate
DMZD5QR	RN	FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia. Oncotarget. 2016 Aug 2;7(31):49786-49799.
DMZD5QR	RU	http://www.ncbi.nlm.nih.gov/pubmed/27391351

DMZD5QR	DI	DMZD5QR
DMZD5QR	DN	Cytarabine
DMZD5QR	MI	TTIU7X1
DMZD5QR	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMZD5QR	MT	DTT
DMZD5QR	MA	Inhibitor
DMZD5QR	RN	Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage. Mol Cancer Ther. 2009 Apr;8(4):864-72.
DMZD5QR	RU	https://pubmed.ncbi.nlm.nih.gov/19372559

DMZD5QR	DI	DMZD5QR
DMZD5QR	DN	Cytarabine
DMZD5QR	MI	DTT79CX
DMZD5QR	MN	Organic cation transporter 1 (SLC22A1)
DMZD5QR	MT	DTP
DMZD5QR	MA	Substrate
DMZD5QR	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMZD5QR	RU	https://doi.org/10.1007/s11095-012-0935-x

DMZD5QR	DI	DMZD5QR
DMZD5QR	DN	Cytarabine
DMZD5QR	MI	DT2EG60
DMZD5QR	MN	Organic cation/carnitine transporter 1 (SLC22A4)
DMZD5QR	MT	DTP
DMZD5QR	MA	Substrate
DMZD5QR	RN	OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues. Cancer Res. 2017 Apr 15;77(8):2102-2111.
DMZD5QR	RU	http://www.ncbi.nlm.nih.gov/pubmed/28209616

DMZD5QR	DI	DMZD5QR
DMZD5QR	DN	Cytarabine
DMZD5QR	MI	DTUGYRD
DMZD5QR	MN	P-glycoprotein 1 (ABCB1)
DMZD5QR	MT	DTP
DMZD5QR	MA	Substrate
DMZD5QR	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMZD5QR	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMDI6R4	DI	DMDI6R4
DMDI6R4	DN	Dabigatran
DMDI6R4	MI	TT6L509
DMDI6R4	MN	Coagulation factor IIa (F2)
DMDI6R4	MT	DTT
DMDI6R4	MA	Inhibitor
DMDI6R4	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DMDI6R4	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DMDI6R4	DI	DMDI6R4
DMDI6R4	DN	Dabigatran
DMDI6R4	MI	DTUGYRD
DMDI6R4	MN	P-glycoprotein 1 (ABCB1)
DMDI6R4	MT	DTP
DMDI6R4	MA	Substrate
DMDI6R4	RN	Influence of ABCB11 and HNF4 genes on daclatasvir plasma concentration: preliminary pharmacogenetic data from the Kineti-C study. J Antimicrob Chemother. 2017 Oct 1;72(10):2846-2849.
DMDI6R4	RU	http://www.ncbi.nlm.nih.gov/pubmed/29091211

DMX6OE3	DI	DMX6OE3
DMX6OE3	DN	Dabrafenib
DMX6OE3	MI	DTI7UX6
DMX6OE3	MN	Breast cancer resistance protein (ABCG2)
DMX6OE3	MT	DTP
DMX6OE3	MA	Substrate
DMX6OE3	RN	Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J Pharmacol Exp Ther. 2013 Mar;344(3):655-64.
DMX6OE3	RU	http://www.ncbi.nlm.nih.gov/pubmed/23249624

DMX6OE3	DI	DMX6OE3
DMX6OE3	DN	Dabrafenib
DMX6OE3	MI	DES5XRU
DMX6OE3	MN	Cytochrome P450 2C8 (CYP2C8)
DMX6OE3	MT	DME
DMX6OE3	MA	Metabolism
DMX6OE3	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DMX6OE3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DMX6OE3	DI	DMX6OE3
DMX6OE3	DN	Dabrafenib
DMX6OE3	MI	DE4LYSA
DMX6OE3	MN	Cytochrome P450 3A4 (CYP3A4)
DMX6OE3	MT	DME
DMX6OE3	MA	Metabolism
DMX6OE3	RN	Physiologically based pharmacokinetic modeling to identify physiological and molecular characteristics driving variability in drug exposure. Clin Pharmacol Ther. 2018 Dec;104(6):1219-1228.
DMX6OE3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29574693

DMX6OE3	DI	DMX6OE3
DMX6OE3	DN	Dabrafenib
DMX6OE3	MI	DTUGYRD
DMX6OE3	MN	P-glycoprotein 1 (ABCB1)
DMX6OE3	MT	DTP
DMX6OE3	MA	Substrate
DMX6OE3	RN	Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J Pharmacol Exp Ther. 2013 Mar;344(3):655-64.
DMX6OE3	RU	http://www.ncbi.nlm.nih.gov/pubmed/23249624

DMX6OE3	DI	DMX6OE3
DMX6OE3	DN	Dabrafenib
DMX6OE3	MI	TTWCGQT
DMX6OE3	MN	Serine/threonine-protein kinase B-raf (BRAF)
DMX6OE3	MT	DTT
DMX6OE3	MA	Inhibitor
DMX6OE3	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2011).
DMX6OE3	RU	http://www.gsk.com/

DMNPZL4	DI	DMNPZL4
DMNPZL4	DN	Dacarbazine
DMNPZL4	MI	DE6OQ3W
DMNPZL4	MN	Cytochrome P450 1A1 (CYP1A1)
DMNPZL4	MT	DME
DMNPZL4	MA	Metabolism
DMNPZL4	RN	Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1. Clin Cancer Res. 1999 Aug;5(8):2192-7.
DMNPZL4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10473105

DMNPZL4	DI	DMNPZL4
DMNPZL4	DN	Dacarbazine
DMNPZL4	MI	DEJGDUW
DMNPZL4	MN	Cytochrome P450 1A2 (CYP1A2)
DMNPZL4	MT	DME
DMNPZL4	MA	Metabolism
DMNPZL4	RN	Study on mesenchymal stem cells mediated enzyme-prodrug gene CYP1A2 targeting anti-tumor effect. Zhonghua Xue Ye Xue Za Zhi. 2009 Oct;30(10):667-71.
DMNPZL4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19954661

DMNPZL4	DI	DMNPZL4
DMNPZL4	DN	Dacarbazine
DMNPZL4	MI	DEVDYN7
DMNPZL4	MN	Cytochrome P450 2E1 (CYP2E1)
DMNPZL4	MT	DME
DMNPZL4	MA	Metabolism
DMNPZL4	RN	Role of cytochrome P450 isoenzymes in metabolism of O(6)-benzylguanine: implications for dacarbazine activation. Clin Cancer Res. 2001 Dec;7(12):4239-44.
DMNPZL4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11751525

DMNPZL4	DI	DMNPZL4
DMNPZL4	DN	Dacarbazine
DMNPZL4	MI	TTUTN1I
DMNPZL4	MN	Human Deoxyribonucleic acid (hDNA)
DMNPZL4	MT	DTT
DMNPZL4	MA	Breaker
DMNPZL4	RN	Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mono... Melanoma Res. 2011 Dec;21(6):502-8.
DMNPZL4	RU	https://pubmed.ncbi.nlm.nih.gov/19561552

DMSFK9V	DI	DMSFK9V
DMSFK9V	DN	Daclatasvir
DMSFK9V	MI	DE4LYSA
DMSFK9V	MN	Cytochrome P450 3A4 (CYP3A4)
DMSFK9V	MT	DME
DMSFK9V	MA	Metabolism
DMSFK9V	RN	Daclatasvir: a NS5A replication complex inhibitor for hepatitis C infection. Ann Pharmacother. 2016 Jan;50(1):39-46.
DMSFK9V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26486762

DMSFK9V	DI	DMSFK9V
DMSFK9V	DN	Daclatasvir
DMSFK9V	MI	DEIBDNY
DMSFK9V	MN	Cytochrome P450 3A5 (CYP3A5)
DMSFK9V	MT	DME
DMSFK9V	MA	Metabolism
DMSFK9V	RN	Daclatasvir: a NS5A replication complex inhibitor for hepatitis C infection. Ann Pharmacother. 2016 Jan;50(1):39-46.
DMSFK9V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26486762

DMSFK9V	DI	DMSFK9V
DMSFK9V	DN	Daclatasvir
DMSFK9V	MI	DERD86B
DMSFK9V	MN	Cytochrome P450 3A7 (CYP3A7)
DMSFK9V	MT	DME
DMSFK9V	MA	Metabolism
DMSFK9V	RN	Daclatasvir: a NS5A replication complex inhibitor for hepatitis C infection. Ann Pharmacother. 2016 Jan;50(1):39-46.
DMSFK9V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26486762

DMSFK9V	DI	DMSFK9V
DMSFK9V	DN	Daclatasvir
DMSFK9V	MI	TTCJ2X8
DMSFK9V	MN	Hepatitis C virus Non-structural 5A (HCV NS5A)
DMSFK9V	MT	DTT
DMSFK9V	MA	Inhibitor
DMSFK9V	RN	2011 Pipeline of Bristol-Myers Squibb.
DMSFK9V	RU	http://www.bms.com/pages/default.aspx

DMSFK9V	DI	DMSFK9V
DMSFK9V	DN	Daclatasvir
DMSFK9V	MI	DTUGYRD
DMSFK9V	MN	P-glycoprotein 1 (ABCB1)
DMSFK9V	MT	DTP
DMSFK9V	MA	Substrate
DMSFK9V	RN	Influence of ABCB11 and HNF4 genes on daclatasvir plasma concentration: preliminary pharmacogenetic data from the Kineti-C study. J Antimicrob Chemother. 2017 Oct 1;72(10):2846-2849.
DMSFK9V	RU	http://www.ncbi.nlm.nih.gov/pubmed/29091211

DM6OZQV	DI	DM6OZQV
DM6OZQV	DN	Daclizumab
DM6OZQV	MI	TTF89GD
DM6OZQV	MN	Interleukin-2 (IL2)
DM6OZQV	MT	DTT
DM6OZQV	MA	Modulator
DM6OZQV	RN	2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. 
DM6OZQV	RU	https://www.ncbi.nlm.nih.gov/pubmed/28148938

DMOH8VY	DI	DMOH8VY
DMOH8VY	DN	Dacomitinib
DMOH8VY	MI	DE5IED8
DMOH8VY	MN	Cytochrome P450 2C9 (CYP2C9)
DMOH8VY	MT	DME
DMOH8VY	MA	Metabolism
DMOH8VY	RN	Phase 1 study to investigate the pharmacokinetic properties of dacomitinib in healthy adult Chinese subjects genotyped for CYP2D6. Xenobiotica. 2018 May;48(5):459-466.
DMOH8VY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28648122

DMOH8VY	DI	DMOH8VY
DMOH8VY	DN	Dacomitinib
DMOH8VY	MI	DECB0K3
DMOH8VY	MN	Cytochrome P450 2D6 (CYP2D6)
DMOH8VY	MT	DME
DMOH8VY	MA	Metabolism
DMOH8VY	RN	Phase 1 study to investigate the pharmacokinetic properties of dacomitinib in healthy adult Chinese subjects genotyped for CYP2D6. Xenobiotica. 2018 May;48(5):459-466.
DMOH8VY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28648122

DMOH8VY	DI	DMOH8VY
DMOH8VY	DN	Dacomitinib
DMOH8VY	MI	DE4LYSA
DMOH8VY	MN	Cytochrome P450 3A4 (CYP3A4)
DMOH8VY	MT	DME
DMOH8VY	MA	Metabolism
DMOH8VY	RN	Phase 1 study to investigate the pharmacokinetic properties of dacomitinib in healthy adult Chinese subjects genotyped for CYP2D6. Xenobiotica. 2018 May;48(5):459-466.
DMOH8VY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28648122

DMOH8VY	DI	DMOH8VY
DMOH8VY	DN	Dacomitinib
DMOH8VY	MI	TTGKNB4
DMOH8VY	MN	Epidermal growth factor receptor (EGFR)
DMOH8VY	MT	DTT
DMOH8VY	MA	Antagonist
DMOH8VY	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
DMOH8VY	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797

DMOH8VY	DI	DMOH8VY
DMOH8VY	DN	Dacomitinib
DMOH8VY	MI	TT6EO5L
DMOH8VY	MN	Erbb2 tyrosine kinase receptor (HER2)
DMOH8VY	MT	DTT
DMOH8VY	MA	Antagonist
DMOH8VY	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7422).
DMOH8VY	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7422

DMOH8VY	DI	DMOH8VY
DMOH8VY	DN	Dacomitinib
DMOH8VY	MI	TT0JESD
DMOH8VY	MN	Erbb4 tyrosine kinase receptor (Erbb-4)
DMOH8VY	MT	DTT
DMOH8VY	MA	Antagonist
DMOH8VY	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7422).
DMOH8VY	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7422

DM2YGNW	DI	DM2YGNW
DM2YGNW	DN	Dactinomycin
DM2YGNW	MI	DTI7UX6
DM2YGNW	MN	Breast cancer resistance protein (ABCG2)
DM2YGNW	MT	DTP
DM2YGNW	MA	Substrate
DM2YGNW	RN	Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol Pharmacol. 2003 Jan;63(1):65-72.
DM2YGNW	RU	https://doi.org/10.1124/mol.63.1.65

DM2YGNW	DI	DM2YGNW
DM2YGNW	DN	Dactinomycin
DM2YGNW	MI	TTUTN1I
DM2YGNW	MN	Human Deoxyribonucleic acid (hDNA)
DM2YGNW	MT	DTT
DM2YGNW	MA	Breaker
DM2YGNW	RN	Structural studies of atom-specific anticancer drugs acting on DNA. Pharmacol Ther. 1999 Sep;83(3):181-215.
DM2YGNW	RU	https://pubmed.ncbi.nlm.nih.gov/10576292

DM2YGNW	DI	DM2YGNW
DM2YGNW	DN	Dactinomycin
DM2YGNW	MI	DTSYQGK
DM2YGNW	MN	Multidrug resistance-associated protein 1 (ABCC1)
DM2YGNW	MT	DTP
DM2YGNW	MA	Substrate
DM2YGNW	RN	Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Res. 1995 Nov 15;55(22):5342-7.
DM2YGNW	RU	http://cancerres.aacrjournals.org/content/55/22/5342

DM2YGNW	DI	DM2YGNW
DM2YGNW	DN	Dactinomycin
DM2YGNW	MI	DTUGYRD
DM2YGNW	MN	P-glycoprotein 1 (ABCB1)
DM2YGNW	MT	DTP
DM2YGNW	MA	Substrate
DM2YGNW	RN	Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia. 2005 Feb;46(2):224-35.
DM2YGNW	RU	https://doi.org/10.1111/j.0013-9580.2005.31904.x

DMGMNH3	DI	DMGMNH3
DMGMNH3	DN	Dalbavancin
DMGMNH3	MI	TTXMY0J
DMGMNH3	MN	Pancreatic triacylglycerol lipase (PNLIP)
DMGMNH3	MT	DTT
DMGMNH3	MA	Inhibitor
DMGMNH3	RN	Pfizer. Product Development Pipeline. March 31 2009.
DMGMNH3	RU	http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf

DMM0PDO	DI	DMM0PDO
DMM0PDO	DN	Dalfampridine
DMM0PDO	MI	DEVDYN7
DMM0PDO	MN	Cytochrome P450 2E1 (CYP2E1)
DMM0PDO	MT	DME
DMM0PDO	MA	Metabolism
DMM0PDO	RN	Dalfampridine: a medication to improve walking in patients with multiple sclerosis. Ann Pharmacother. 2012 Jul-Aug;46(7-8):1010-5.
DMM0PDO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22764324

DMM0PDO	DI	DMM0PDO
DMM0PDO	DN	Dalfampridine
DMM0PDO	MI	TT1VOHK
DMM0PDO	MN	Potassium channel unspecific (KC)
DMM0PDO	MT	DTT
DMM0PDO	MA	Modulator
DMM0PDO	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DMM0PDO	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DM4LTKV	DI	DM4LTKV
DM4LTKV	DN	Dalfopristin
DM4LTKV	MI	TTUWYEA
DM4LTKV	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DM4LTKV	MT	DTT
DM4LTKV	MA	Binder
DM4LTKV	RN	The streptogramin antibiotics: update on their mechanism of action. Expert Opin Investig Drugs. 1998 Apr;7(4):591-9.
DM4LTKV	RU	https://pubmed.ncbi.nlm.nih.gov/15991995

DM6CLBN	DI	DM6CLBN
DM6CLBN	DN	Danaparoid
DM6CLBN	MI	TTCIHJA
DM6CLBN	MN	Coagulation factor Xa (F10)
DM6CLBN	MT	DTT
DM6CLBN	MA	Inhibitor
DM6CLBN	RN	Effect of factor X inhibition on coagulation activation and cytokine induction in human systemic inflammation. J Infect Dis. 2002 Nov 1;186(9):1270-6.
DM6CLBN	RU	https://pubmed.ncbi.nlm.nih.gov/12402196

DML8KTN	DI	DML8KTN
DML8KTN	DN	Danazol
DML8KTN	MI	TTZAYWL
DML8KTN	MN	Estrogen receptor (ESR)
DML8KTN	MT	DTT
DML8KTN	MA	Antagonist
DML8KTN	RN	Danazol suppression of luteinizing hormone in the rat: evidence for mediation by both androgen and estrogen receptors. Proc Soc Exp Biol Med. 1990 May;194(1):54-7.
DML8KTN	RU	https://pubmed.ncbi.nlm.nih.gov/2326286

DM1D8XY	DI	DM1D8XY
DM1D8XY	DN	Dantrolene
DM1D8XY	MI	DE4LYSA
DM1D8XY	MN	Cytochrome P450 3A4 (CYP3A4)
DM1D8XY	MT	DME
DM1D8XY	MA	Metabolism
DM1D8XY	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM1D8XY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM1D8XY	DI	DM1D8XY
DM1D8XY	DN	Dantrolene
DM1D8XY	MI	TT9YXM1
DM1D8XY	MN	Ryanodine receptor (RYR)
DM1D8XY	MT	DTT
DM1D8XY	MA	Modulator
DM1D8XY	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM1D8XY	RU	https://www.fda.gov/

DM28UJG	DI	DM28UJG
DM28UJG	DN	Dapagliflozin
DM28UJG	MI	DEJGDUW
DM28UJG	MN	Cytochrome P450 1A2 (CYP1A2)
DM28UJG	MT	DME
DM28UJG	MA	Metabolism
DM28UJG	RN	Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27.
DM28UJG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24105299

DM28UJG	DI	DM28UJG
DM28UJG	DN	Dapagliflozin
DM28UJG	MI	DEJVYAZ
DM28UJG	MN	Cytochrome P450 2A6 (CYP2A6)
DM28UJG	MT	DME
DM28UJG	MA	Metabolism
DM28UJG	RN	Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27.
DM28UJG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24105299

DM28UJG	DI	DM28UJG
DM28UJG	DN	Dapagliflozin
DM28UJG	MI	DE5IED8
DM28UJG	MN	Cytochrome P450 2C9 (CYP2C9)
DM28UJG	MT	DME
DM28UJG	MA	Metabolism
DM28UJG	RN	Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27.
DM28UJG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24105299

DM28UJG	DI	DM28UJG
DM28UJG	DN	Dapagliflozin
DM28UJG	MI	DECB0K3
DM28UJG	MN	Cytochrome P450 2D6 (CYP2D6)
DM28UJG	MT	DME
DM28UJG	MA	Metabolism
DM28UJG	RN	Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27.
DM28UJG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24105299

DM28UJG	DI	DM28UJG
DM28UJG	DN	Dapagliflozin
DM28UJG	MI	DE4LYSA
DM28UJG	MN	Cytochrome P450 3A4 (CYP3A4)
DM28UJG	MT	DME
DM28UJG	MA	Metabolism
DM28UJG	RN	Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27.
DM28UJG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24105299

DM28UJG	DI	DM28UJG
DM28UJG	DN	Dapagliflozin
DM28UJG	MI	TTLWPVF
DM28UJG	MN	Sodium/glucose cotransporter 2 (SGLT2)
DM28UJG	MT	DTT
DM28UJG	MA	Modulator
DM28UJG	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DM28UJG	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DM28UJG	DI	DM28UJG
DM28UJG	DN	Dapagliflozin
DM28UJG	MI	DE85D2P
DM28UJG	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DM28UJG	MT	DME
DM28UJG	MA	Metabolism
DM28UJG	RN	Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27.
DM28UJG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24105299

DM28UJG	DI	DM28UJG
DM28UJG	DN	Dapagliflozin
DM28UJG	MI	DEB3CV1
DM28UJG	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DM28UJG	MT	DME
DM28UJG	MA	Metabolism
DM28UJG	RN	Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27.
DM28UJG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24105299

DM34TXO	DI	DM34TXO
DM34TXO	DN	Dapagliflozin Propanediol; Saxagliptin Hydrochloride
DM34TXO	MI	TTDIGC1
DM34TXO	MN	Dipeptidyl peptidase 4 (DPP-4)
DM34TXO	MT	DTT
DM34TXO	MA	Modulator
DM34TXO	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM34TXO	RU	https://www.fda.gov/

DM34TXO	DI	DM34TXO
DM34TXO	DN	Dapagliflozin Propanediol; Saxagliptin Hydrochloride
DM34TXO	MI	TTLWPVF
DM34TXO	MN	Sodium/glucose cotransporter 2 (SGLT2)
DM34TXO	MT	DTT
DM34TXO	MA	Modulator
DM34TXO	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM34TXO	RU	https://www.fda.gov/

DMOXJKF	DI	DMOXJKF
DMOXJKF	DN	Dapiprazole
DMOXJKF	MI	TTEX248
DMOXJKF	MN	Dopamine D2 receptor (D2R)
DMOXJKF	MT	DTT
DMOXJKF	MA	Antagonist
DMOXJKF	RN	Effect of ibopamine on aqueous humor production in normotensive humans. Invest Ophthalmol Vis Sci. 2003 Nov;44(11):4853-8.
DMOXJKF	RU	https://pubmed.ncbi.nlm.nih.gov/14578408

DM4LT8A	DI	DM4LT8A
DM4LT8A	DN	Dapsone
DM4LT8A	MI	DEZMWRE
DM4LT8A	MN	Cytochrome P450 2C18 (CYP2C18)
DM4LT8A	MT	DME
DM4LT8A	MA	Metabolism
DM4LT8A	RN	CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8.
DM4LT8A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10901692

DM4LT8A	DI	DM4LT8A
DM4LT8A	DN	Dapsone
DM4LT8A	MI	DES5XRU
DM4LT8A	MN	Cytochrome P450 2C8 (CYP2C8)
DM4LT8A	MT	DME
DM4LT8A	MA	Metabolism
DM4LT8A	RN	CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8.
DM4LT8A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10901692

DM4LT8A	DI	DM4LT8A
DM4LT8A	DN	Dapsone
DM4LT8A	MI	DE5IED8
DM4LT8A	MN	Cytochrome P450 2C9 (CYP2C9)
DM4LT8A	MT	DME
DM4LT8A	MA	Metabolism
DM4LT8A	RN	Differential activation of CYP2C9 variants by dapsone. Biochem Pharmacol. 2004 May 15;67(10):1831-41.
DM4LT8A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15130760

DM4LT8A	DI	DM4LT8A
DM4LT8A	DN	Dapsone
DM4LT8A	MI	DEVDYN7
DM4LT8A	MN	Cytochrome P450 2E1 (CYP2E1)
DM4LT8A	MT	DME
DM4LT8A	MA	Metabolism
DM4LT8A	RN	CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8.
DM4LT8A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10901692

DM4LT8A	DI	DM4LT8A
DM4LT8A	DN	Dapsone
DM4LT8A	MI	DE4LYSA
DM4LT8A	MN	Cytochrome P450 3A4 (CYP3A4)
DM4LT8A	MT	DME
DM4LT8A	MA	Metabolism
DM4LT8A	RN	Metabolic interactions of putative cytochrome P4503A substrates with alternative pathways of dapsone metabolism in human liver microsomes. Drug Metab Dispos. 1996 Feb;24(2):164-171.
DM4LT8A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8742227

DM4LT8A	DI	DM4LT8A
DM4LT8A	DN	Dapsone
DM4LT8A	MI	DEIBDNY
DM4LT8A	MN	Cytochrome P450 3A5 (CYP3A5)
DM4LT8A	MT	DME
DM4LT8A	MA	Metabolism
DM4LT8A	RN	Drug Interactions Flockhart Table
DM4LT8A	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM4LT8A	DI	DM4LT8A
DM4LT8A	DN	Dapsone
DM4LT8A	MI	DERD86B
DM4LT8A	MN	Cytochrome P450 3A7 (CYP3A7)
DM4LT8A	MT	DME
DM4LT8A	MA	Metabolism
DM4LT8A	RN	Drug Interactions Flockhart Table
DM4LT8A	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM4LT8A	DI	DM4LT8A
DM4LT8A	DN	Dapsone
DM4LT8A	MI	DEGTFWK
DM4LT8A	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM4LT8A	MT	DME
DM4LT8A	MA	Metabolism
DM4LT8A	RN	CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8.
DM4LT8A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10901692

DM4LT8A	DI	DM4LT8A
DM4LT8A	DN	Dapsone
DM4LT8A	MI	DEA3U9Y
DM4LT8A	MN	Myeloperoxidase (MPO)
DM4LT8A	MT	DME
DM4LT8A	MA	Metabolism
DM4LT8A	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM4LT8A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM4LT8A	DI	DM4LT8A
DM4LT8A	DN	Dapsone
DM4LT8A	MI	TT6NHYC
DM4LT8A	MN	Pneumocystis carinii Dihydropteroate synthase (PC DHPS)
DM4LT8A	MT	DTT
DM4LT8A	MA	Modulator
DM4LT8A	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM4LT8A	RU	https://www.fda.gov/

DM4LT8A	DI	DM4LT8A
DM4LT8A	DN	Dapsone
DM4LT8A	MI	DE073H6
DM4LT8A	MN	Prostaglandin G/H synthase 1 (COX-1)
DM4LT8A	MT	DME
DM4LT8A	MA	Metabolism
DM4LT8A	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM4LT8A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM4LT8A	DI	DM4LT8A
DM4LT8A	DN	Dapsone
DM4LT8A	MI	DE492CE
DM4LT8A	MN	Prostaglandin G/H synthase 2 (COX-2)
DM4LT8A	MT	DME
DM4LT8A	MA	Metabolism
DM4LT8A	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM4LT8A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMKDU16	DI	DMKDU16
DMKDU16	DN	Daptomycin
DMKDU16	MI	TT4ILYC
DMKDU16	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMKDU16	MT	DTT
DMKDU16	MA	Binder
DMKDU16	RN	Structural transitions as determinants of the action of the calcium-dependent antibiotic daptomycin. Chem Biol. 2004 Jul;11(7):949-57.
DMKDU16	RU	https://pubmed.ncbi.nlm.nih.gov/15271353

DMFDQ3I	DI	DMFDQ3I
DMFDQ3I	DN	Daptomycin
DMFDQ3I	MI	DE49HWX
DMFDQ3I	MN	CDP-alcohol phosphatidyltransferase (pgsA)
DMFDQ3I	MT	DME
DMFDQ3I	MA	Metabolism
DMFDQ3I	RN	Mutations in cdsA and pgsA correlate with daptomycin resistance in Streptococcus mitis and S. oralis. Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01531-18.
DMFDQ3I	RU	https://pubmed.ncbi.nlm.nih.gov/30509945

DMFDQ3I	DI	DMFDQ3I
DMFDQ3I	DN	Daptomycin
DMFDQ3I	MI	DETMA7Z
DMFDQ3I	MN	CDP-alcohol phosphatidyltransferase (pgsA)
DMFDQ3I	MT	DME
DMFDQ3I	MA	Metabolism
DMFDQ3I	RN	Mutations in cdsA and pgsA correlate with daptomycin resistance in Streptococcus mitis and S. oralis. Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01531-18.
DMFDQ3I	RU	https://pubmed.ncbi.nlm.nih.gov/30509945

DMKCIUZ	DI	DMKCIUZ
DMKCIUZ	DN	Daratumumab
DMKCIUZ	MI	TTPURFN
DMKCIUZ	MN	Cyclic ADP-ribose hydrolase 1 (CD38)
DMKCIUZ	MT	DTT
DMKCIUZ	RN	Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med. 2015 Sep 24;373(13):1207-19.
DMKCIUZ	RU	https://pubmed.ncbi.nlm.nih.gov/26308596

DMMJTYW	DI	DMMJTYW
DMMJTYW	DN	Darbepoetin alfa
DMMJTYW	MI	TTAUX24
DMMJTYW	MN	Erythropoietin Receptor (EPOR)
DMMJTYW	MT	DTT
DMMJTYW	MA	Agonist
DMMJTYW	RN	A cytosolic domain of the erythropoietin receptor contributes to endoplasmic reticulum-associated degradation. Eur J Biochem. 1999 Jul;263(2):410-9.
DMMJTYW	RU	https://pubmed.ncbi.nlm.nih.gov/10406949

DMWXLYZ	DI	DMWXLYZ
DMWXLYZ	DN	Darifenacin
DMWXLYZ	MI	DECB0K3
DMWXLYZ	MN	Cytochrome P450 2D6 (CYP2D6)
DMWXLYZ	MT	DME
DMWXLYZ	MA	Metabolism
DMWXLYZ	RN	The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet. 2006;45(4):325-50.
DMWXLYZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16584282

DMWXLYZ	DI	DMWXLYZ
DMWXLYZ	DN	Darifenacin
DMWXLYZ	MI	DE4LYSA
DMWXLYZ	MN	Cytochrome P450 3A4 (CYP3A4)
DMWXLYZ	MT	DME
DMWXLYZ	MA	Metabolism
DMWXLYZ	RN	The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet. 2006;45(4):325-50.
DMWXLYZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16584282

DMWXLYZ	DI	DMWXLYZ
DMWXLYZ	DN	Darifenacin
DMWXLYZ	MI	TTOXS3C
DMWXLYZ	MN	Muscarinic acetylcholine receptor (CHRM)
DMWXLYZ	MT	DTT
DMWXLYZ	MA	Antagonist
DMWXLYZ	RN	Characterisation of [3H]-darifenacin as a novel radioligand for the study of muscarinic M3 receptors. J Recept Signal Transduct Res. 1997 Jan-May;17(1-3):177-84.
DMWXLYZ	RU	https://pubmed.ncbi.nlm.nih.gov/9029489

DMWXLYZ	DI	DMWXLYZ
DMWXLYZ	DN	Darifenacin
DMWXLYZ	MI	TTQ13Z5
DMWXLYZ	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMWXLYZ	MT	DTT
DMWXLYZ	MA	Antagonist
DMWXLYZ	RN	M(1) and M(3) muscarinic receptors are involved in the release of urinary bladder-derived relaxant factor. Pharmacol Res. 2009 May;59(5):300-5.
DMWXLYZ	RU	https://pubmed.ncbi.nlm.nih.gov/19416629

DMV7YFT	DI	DMV7YFT
DMV7YFT	DN	Darolutamide
DMV7YFT	MI	TTS64P2
DMV7YFT	MN	Androgen receptor (AR)
DMV7YFT	MT	DTT
DMV7YFT	MA	Antagonist
DMV7YFT	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMV7YFT	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf

DMV7YFT	DI	DMV7YFT
DMV7YFT	DN	Darolutamide
DMV7YFT	MI	DE4LYSA
DMV7YFT	MN	Cytochrome P450 3A4 (CYP3A4)
DMV7YFT	MT	DME
DMV7YFT	MA	Metabolism
DMV7YFT	RN	Drug-drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):747-759.
DMV7YFT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31571146

DMV7YFT	DI	DMV7YFT
DMV7YFT	DN	Darolutamide
DMV7YFT	MI	DEYGVN4
DMV7YFT	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMV7YFT	MT	DME
DMV7YFT	MA	Metabolism
DMV7YFT	RN	Drug-drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):747-759.
DMV7YFT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31571146

DMV7YFT	DI	DMV7YFT
DMV7YFT	DN	Darolutamide
DMV7YFT	MI	DEF2WXN
DMV7YFT	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMV7YFT	MT	DME
DMV7YFT	MA	Metabolism
DMV7YFT	RN	Drug-drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):747-759.
DMV7YFT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31571146

DMV7YFT	DI	DMV7YFT
DMV7YFT	DN	Darolutamide
DMV7YFT	MI	DE2GB8N
DMV7YFT	MN	UDP-glucuronosyltransferase 1A8 (UGT1A8)
DMV7YFT	MT	DME
DMV7YFT	MA	Metabolism
DMV7YFT	RN	Drug-drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):747-759.
DMV7YFT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31571146

DMV7YFT	DI	DMV7YFT
DMV7YFT	DN	Darolutamide
DMV7YFT	MI	DE85D2P
DMV7YFT	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMV7YFT	MT	DME
DMV7YFT	MA	Metabolism
DMV7YFT	RN	Drug-drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):747-759.
DMV7YFT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31571146

DMV7YFT	DI	DMV7YFT
DMV7YFT	DN	Darolutamide
DMV7YFT	MI	DEAZDL8
DMV7YFT	MN	UDP-glucuronosyltransferase 2B17 (UGT2B17)
DMV7YFT	MT	DME
DMV7YFT	MA	Metabolism
DMV7YFT	RN	Drug-drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):747-759.
DMV7YFT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31571146

DMN3GCH	DI	DMN3GCH
DMN3GCH	DN	Darunavir
DMN3GCH	MI	DE4LYSA
DMN3GCH	MN	Cytochrome P450 3A4 (CYP3A4)
DMN3GCH	MT	DME
DMN3GCH	MA	Metabolism
DMN3GCH	RN	Drug interactions with new and investigational antiretrovirals. Clin Pharmacokinet. 2009;48(4):211-41.
DMN3GCH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19492868

DMN3GCH	DI	DMN3GCH
DMN3GCH	DN	Darunavir
DMN3GCH	MI	TT5FNQT
DMN3GCH	MN	Human immunodeficiency virus Protease (HIV PR)
DMN3GCH	MT	DTT
DMN3GCH	MA	Modulator
DMN3GCH	RN	2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
DMN3GCH	RU	https://pubmed.ncbi.nlm.nih.gov/17342860

DMN3GCH	DI	DMN3GCH
DMN3GCH	DN	Darunavir
DMN3GCH	MI	DTE2B1D
DMN3GCH	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMN3GCH	MT	DTP
DMN3GCH	MA	Substrate
DMN3GCH	RN	P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines. Biol Pharm Bull. 2009 Sep;32(9):1588-93.
DMN3GCH	RU	https://doi.org/10.1248/bpb.32.1588

DMN3GCH	DI	DMN3GCH
DMN3GCH	DN	Darunavir
DMN3GCH	MI	DT3D8F0
DMN3GCH	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMN3GCH	MT	DTP
DMN3GCH	MA	Substrate
DMN3GCH	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DMN3GCH	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DMN3GCH	DI	DMN3GCH
DMN3GCH	DN	Darunavir
DMN3GCH	MI	DTUGYRD
DMN3GCH	MN	P-glycoprotein 1 (ABCB1)
DMN3GCH	MT	DTP
DMN3GCH	MA	Substrate
DMN3GCH	RN	Impact of drug transporters on cellular resistance towards saquinavir and darunavir. J Antimicrob Chemother. 2010 Nov;65(11):2319-28.
DMN3GCH	RU	https://doi.org/10.1093/jac/dkq324

DMJV2EK	DI	DMJV2EK
DMJV2EK	DN	Dasatinib
DMJV2EK	MI	DTI7UX6
DMJV2EK	MN	Breast cancer resistance protein (ABCG2)
DMJV2EK	MT	DTP
DMJV2EK	MA	Substrate
DMJV2EK	RN	Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64.
DMJV2EK	RU	http://www.ncbi.nlm.nih.gov/pubmed/19785662

DMJV2EK	DI	DMJV2EK
DMJV2EK	DN	Dasatinib
DMJV2EK	MI	DEJGDUW
DMJV2EK	MN	Cytochrome P450 1A2 (CYP1A2)
DMJV2EK	MT	DME
DMJV2EK	MA	Metabolism
DMJV2EK	RN	Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
DMJV2EK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19733976

DMJV2EK	DI	DMJV2EK
DMJV2EK	DN	Dasatinib
DMJV2EK	MI	DE4LYSA
DMJV2EK	MN	Cytochrome P450 3A4 (CYP3A4)
DMJV2EK	MT	DME
DMJV2EK	MA	Metabolism
DMJV2EK	RN	Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
DMJV2EK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19733976

DMJV2EK	DI	DMJV2EK
DMJV2EK	DN	Dasatinib
DMJV2EK	MI	DEIBDNY
DMJV2EK	MN	Cytochrome P450 3A5 (CYP3A5)
DMJV2EK	MT	DME
DMJV2EK	MA	Metabolism
DMJV2EK	RN	Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
DMJV2EK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19733976

DMJV2EK	DI	DMJV2EK
DMJV2EK	DN	Dasatinib
DMJV2EK	MI	DEP76YL
DMJV2EK	MN	Dimethylaniline oxidase 3 (FMO3)
DMJV2EK	MT	DME
DMJV2EK	MA	Metabolism
DMJV2EK	RN	Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos. 2008 Sep;36(9):1828-39.
DMJV2EK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18556438

DMJV2EK	DI	DMJV2EK
DMJV2EK	DN	Dasatinib
DMJV2EK	MI	TTS7G69
DMJV2EK	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMJV2EK	MT	DTT
DMJV2EK	MA	Inhibitor
DMJV2EK	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMJV2EK	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMJV2EK	DI	DMJV2EK
DMJV2EK	DN	Dasatinib
DMJV2EK	MI	TT2B9KF
DMJV2EK	MN	Fyn tyrosine protein kinase (FYN)
DMJV2EK	MT	DTT
DMJV2EK	MA	Inhibitor
DMJV2EK	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMJV2EK	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMJV2EK	DI	DMJV2EK
DMJV2EK	DN	Dasatinib
DMJV2EK	MI	TT860QF
DMJV2EK	MN	LCK tyrosine protein kinase (LCK)
DMJV2EK	MT	DTT
DMJV2EK	MA	Inhibitor
DMJV2EK	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMJV2EK	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMJV2EK	DI	DMJV2EK
DMJV2EK	DN	Dasatinib
DMJV2EK	MI	DT3D8F0
DMJV2EK	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMJV2EK	MT	DTP
DMJV2EK	MA	Substrate
DMJV2EK	RN	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
DMJV2EK	RU	http://www.ncbi.nlm.nih.gov/pubmed/23340295

DMJV2EK	DI	DMJV2EK
DMJV2EK	DN	Dasatinib
DMJV2EK	MI	DT9C1TS
DMJV2EK	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMJV2EK	MT	DTP
DMJV2EK	MA	Substrate
DMJV2EK	RN	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
DMJV2EK	RU	http://www.ncbi.nlm.nih.gov/pubmed/23340295

DMJV2EK	DI	DMJV2EK
DMJV2EK	DN	Dasatinib
DMJV2EK	MI	DTUGYRD
DMJV2EK	MN	P-glycoprotein 1 (ABCB1)
DMJV2EK	MT	DTP
DMJV2EK	MA	Substrate
DMJV2EK	RN	Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos. 2010 Aug;38(8):1371-80.
DMJV2EK	RU	http://www.ncbi.nlm.nih.gov/pubmed/20423956

DMJV2EK	DI	DMJV2EK
DMJV2EK	DN	Dasatinib
DMJV2EK	MI	TT6PKBN
DMJV2EK	MN	Proto-oncogene c-Src (SRC)
DMJV2EK	MT	DTT
DMJV2EK	MA	Inhibitor
DMJV2EK	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMJV2EK	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DM74SVE	DI	DM74SVE
DM74SVE	DN	Dasiglucagon
DM74SVE	MI	TT9O6WS
DM74SVE	MN	Glucagon receptor (GCGR)
DM74SVE	MT	DTT
DM74SVE	MA	Agonist
DM74SVE	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2021
DM74SVE	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214231s000lbl.pdf

DMLDQFV	DI	DMLDQFV
DMLDQFV	DN	Dasotraline
DMLDQFV	MI	TTVBI8W
DMLDQFV	MN	Dopamine transporter (DAT)
DMLDQFV	MT	DTT
DMLDQFV	MA	Inhibitor
DMLDQFV	RN	Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52.
DMLDQFV	RU	https://pubmed.ncbi.nlm.nih.gov/25948101

DMLDQFV	DI	DMLDQFV
DMLDQFV	DN	Dasotraline
DMLDQFV	MI	TTAWNKZ
DMLDQFV	MN	Norepinephrine transporter (NET)
DMLDQFV	MT	DTT
DMLDQFV	MA	Inhibitor
DMLDQFV	RN	Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52.
DMLDQFV	RU	https://pubmed.ncbi.nlm.nih.gov/25948101

DMLDQFV	DI	DMLDQFV
DMLDQFV	DN	Dasotraline
DMLDQFV	MI	TT3ROYC
DMLDQFV	MN	Serotonin transporter (SERT)
DMLDQFV	MT	DTT
DMLDQFV	MA	Inhibitor
DMLDQFV	RN	Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52.
DMLDQFV	RU	https://pubmed.ncbi.nlm.nih.gov/25948101

DMLDQFV	DI	DMLDQFV
DMLDQFV	DN	Dasotraline
DMLDQFV	MI	TT8G3Z7
DMLDQFV	MN	Serotoninnorepinephrinedopamine reuptake (SNDR)
DMLDQFV	MT	DTT
DMLDQFV	MA	Inhibitor
DMLDQFV	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMLDQFV	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMQUSBT	DI	DMQUSBT
DMQUSBT	DN	Daunorubicin
DMQUSBT	MI	DTI7UX6
DMQUSBT	MN	Breast cancer resistance protein (ABCG2)
DMQUSBT	MT	DTP
DMQUSBT	MA	Substrate
DMQUSBT	RN	Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun. 2001 Jul 6;285(1):111-7.
DMQUSBT	RU	http://www.ncbi.nlm.nih.gov/pubmed/11437380

DMQUSBT	DI	DMQUSBT
DMQUSBT	DN	Daunorubicin
DMQUSBT	MI	DE6OQ3W
DMQUSBT	MN	Cytochrome P450 1A1 (CYP1A1)
DMQUSBT	MT	DME
DMQUSBT	MA	Metabolism
DMQUSBT	RN	The effect of new lipophilic chelators on the activities of cytosolic reductases and P450 cytochromes involved in the metabolism of anthracycline antibiotics: studies in vitro. Physiol Res. 2004;53(6):683-91.
DMQUSBT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15588138

DMQUSBT	DI	DMQUSBT
DMQUSBT	DN	Daunorubicin
DMQUSBT	MI	DEJGDUW
DMQUSBT	MN	Cytochrome P450 1A2 (CYP1A2)
DMQUSBT	MT	DME
DMQUSBT	MA	Metabolism
DMQUSBT	RN	The effect of new lipophilic chelators on the activities of cytosolic reductases and P450 cytochromes involved in the metabolism of anthracycline antibiotics: studies in vitro. Physiol Res. 2004;53(6):683-91.
DMQUSBT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15588138

DMQUSBT	DI	DMQUSBT
DMQUSBT	DN	Daunorubicin
DMQUSBT	MI	DE4LYSA
DMQUSBT	MN	Cytochrome P450 3A4 (CYP3A4)
DMQUSBT	MT	DME
DMQUSBT	MA	Metabolism
DMQUSBT	RN	The effect of new lipophilic chelators on the activities of cytosolic reductases and P450 cytochromes involved in the metabolism of anthracycline antibiotics: studies in vitro. Physiol Res. 2004;53(6):683-91.
DMQUSBT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15588138

DMQUSBT	DI	DMQUSBT
DMQUSBT	DN	Daunorubicin
DMQUSBT	MI	TTABD5E
DMQUSBT	MN	DNA replication (DNA repli)
DMQUSBT	MT	DTT
DMQUSBT	MA	Modulator
DMQUSBT	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMQUSBT	RU	https://www.fda.gov/

DMQUSBT	DI	DMQUSBT
DMQUSBT	DN	Daunorubicin
DMQUSBT	MI	TTUTN1I
DMQUSBT	MN	Human Deoxyribonucleic acid (hDNA)
DMQUSBT	MT	DTT
DMQUSBT	MA	Intercalator
DMQUSBT	RN	31P NMR spectra of ethidium, quinacrine, and daunomycin complexes with poly(adenylic acid).poly(uridylic acid) RNA duplex and calf thymus DNA. Biochemistry. 1989 Apr 4;28(7):2804-12.
DMQUSBT	RU	https://pubmed.ncbi.nlm.nih.gov/2472832

DMQUSBT	DI	DMQUSBT
DMQUSBT	DN	Daunorubicin
DMQUSBT	MI	DTSYQGK
DMQUSBT	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMQUSBT	MT	DTP
DMQUSBT	MA	Substrate
DMQUSBT	RN	Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83.
DMQUSBT	RU	http://www.ncbi.nlm.nih.gov/pubmed/10917554

DMQUSBT	DI	DMQUSBT
DMQUSBT	DN	Daunorubicin
DMQUSBT	MI	DT582KR
DMQUSBT	MN	Multidrug resistance-associated protein 6 (ABCC6)
DMQUSBT	MT	DTP
DMQUSBT	MA	Substrate
DMQUSBT	RN	Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res. 2002 Nov 1;62(21):6172-7.
DMQUSBT	RU	http://www.ncbi.nlm.nih.gov/pubmed/12414644

DMQUSBT	DI	DMQUSBT
DMQUSBT	DN	Daunorubicin
DMQUSBT	MI	DE3N2FM
DMQUSBT	MN	NADPH-cytochrome P450 reductase (CPR)
DMQUSBT	MT	DME
DMQUSBT	MA	Metabolism
DMQUSBT	RN	Lack of mechanism-based inactivation of rat hepatic microsomal cytochromes P450 by doxorubicin. Can J Physiol Pharmacol. 1999 Aug;77(8):589-97.
DMQUSBT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10543722

DMQUSBT	DI	DMQUSBT
DMQUSBT	DN	Daunorubicin
DMQUSBT	MI	DE9JFMC
DMQUSBT	MN	NADPH-dependent carbonyl reductase 1 (CBR1)
DMQUSBT	MT	DME
DMQUSBT	MA	Metabolism
DMQUSBT	RN	Flavonoids as inhibitors of human carbonyl reductase 1. Chem Biol Interact. 2008 Jul 30;174(2):98-108.
DMQUSBT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18579125

DMQUSBT	DI	DMQUSBT
DMQUSBT	DN	Daunorubicin
DMQUSBT	MI	DEIVKZ8
DMQUSBT	MN	NADPH-dependent carbonyl reductase 3 (CBR3)
DMQUSBT	MT	DME
DMQUSBT	MA	Metabolism
DMQUSBT	RN	Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism. J Pharmacol Exp Ther. 2010 Mar;332(3):755-63.
DMQUSBT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20007405

DMQUSBT	DI	DMQUSBT
DMQUSBT	DN	Daunorubicin
DMQUSBT	MI	DTUGYRD
DMQUSBT	MN	P-glycoprotein 1 (ABCB1)
DMQUSBT	MT	DTP
DMQUSBT	MA	Substrate
DMQUSBT	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMQUSBT	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMC50ME	DI	DMC50ME
DMC50ME	DN	Debrisoquin
DMC50ME	MI	TTT04VN
DMC50ME	MN	Adrenergic neuron (AD neuro)
DMC50ME	MT	DTT
DMC50ME	MA	Blocker
DMC50ME	RN	Guanethidine and related agents. 3. Antagonism by drugs which inhibit the norepinephrine pump in man. J Clin Invest. 1970 Aug;49(8):1596-604.
DMC50ME	RU	https://pubmed.ncbi.nlm.nih.gov/5431666

DMC50ME	DI	DMC50ME
DMC50ME	DN	Debrisoquin
DMC50ME	MI	DE6OQ3W
DMC50ME	MN	Cytochrome P450 1A1 (CYP1A1)
DMC50ME	MT	DME
DMC50ME	MA	Metabolism
DMC50ME	RN	4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine. J Pharmacol Exp Ther. 2002 Jun;301(3):1025-32.
DMC50ME	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12023534

DMC50ME	DI	DMC50ME
DMC50ME	DN	Debrisoquin
DMC50ME	MI	DECB0K3
DMC50ME	MN	Cytochrome P450 2D6 (CYP2D6)
DMC50ME	MT	DME
DMC50ME	MA	Metabolism
DMC50ME	RN	Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution. Proteins. 2005 May 1;59(2):339-46.
DMC50ME	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15726636

DMC50ME	DI	DMC50ME
DMC50ME	DN	Debrisoquin
DMC50ME	MI	DTT79CX
DMC50ME	MN	Organic cation transporter 1 (SLC22A1)
DMC50ME	MT	DTP
DMC50ME	MA	Substrate
DMC50ME	RN	The prototypic pharmacogenetic drug debrisoquine is a substrate of the genetically polymorphic organic cation transporter OCT1. Biochem Pharmacol. 2012 May 15;83(10):1427-34.
DMC50ME	RU	https://doi.org/10.1016/j.bcp.2012.01.032

DMC50ME	DI	DMC50ME
DMC50ME	DN	Debrisoquin
DMC50ME	MI	DTUGYRD
DMC50ME	MN	P-glycoprotein 1 (ABCB1)
DMC50ME	MT	DTP
DMC50ME	MA	Substrate
DMC50ME	RN	Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999 Mar;16(3):408-14.
DMC50ME	RU	http://www.ncbi.nlm.nih.gov/pubmed/10213372

DMSBRUW	DI	DMSBRUW
DMSBRUW	DN	Decamethonium
DMSBRUW	MI	TT54JVQ
DMSBRUW	MN	Neuronal acetylcholine receptor alpha-1 (CHRNA1)
DMSBRUW	MT	DTT
DMSBRUW	MA	Modulator
DMSBRUW	RN	Potency of nondepolarizing muscle relaxants on muscle-type acetylcholine receptors in denervated mouse skeletal muscle.Acta Pharmacol Sin.2010 Dec;31(12):1541-6.
DMSBRUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/21102480

DMQL8XJ	DI	DMQL8XJ
DMQL8XJ	DN	Decitabine
DMQL8XJ	MI	DEKEDRC
DMQL8XJ	MN	Cytidine aminohydrolase (CDA)
DMQL8XJ	MT	DME
DMQL8XJ	MA	Metabolism
DMQL8XJ	RN	Tracking decitabine incorporation into malignant myeloid cell DNA in vitro and in vivo by LC-MS/MS with enzymatic digestion. Sci Rep. 2019 Mar 14;9(1):4558.
DMQL8XJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30872721

DMQL8XJ	DI	DMQL8XJ
DMQL8XJ	DN	Decitabine
DMQL8XJ	MI	DEYILK4
DMQL8XJ	MN	Cytidine deaminase (cdd)
DMQL8XJ	MT	DME
DMQL8XJ	MA	Metabolism
DMQL8XJ	RN	Mycoplasma hyorhinis-encoded cytidine deaminase efficiently inactivates cytosine-based anticancer drugs. FEBS Open Bio. 2015 Aug 3;5:634-9.
DMQL8XJ	RU	https://pubmed.ncbi.nlm.nih.gov/26322268

DMQL8XJ	DI	DMQL8XJ
DMQL8XJ	DN	Decitabine
DMQL8XJ	MI	TTUTN1I
DMQL8XJ	MN	Human Deoxyribonucleic acid (hDNA)
DMQL8XJ	MT	DTT
DMQL8XJ	MA	Modulator
DMQL8XJ	RN	2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
DMQL8XJ	RU	https://pubmed.ncbi.nlm.nih.gov/17342860

DM6ETS0	DI	DM6ETS0
DM6ETS0	DN	Deferasirox
DM6ETS0	MI	DEYGVN4
DM6ETS0	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM6ETS0	MT	DME
DM6ETS0	MA	Metabolism
DM6ETS0	RN	Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients. Pharmacogenomics. 2017 Apr;18(6):539-554.
DM6ETS0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28346059

DM6ETS0	DI	DM6ETS0
DM6ETS0	DN	Deferasirox
DM6ETS0	MI	DEF2WXN
DM6ETS0	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DM6ETS0	MT	DME
DM6ETS0	MA	Metabolism
DM6ETS0	RN	Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients. Pharmacogenomics. 2017 Apr;18(6):539-554.
DM6ETS0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28346059

DMS2M7O	DI	DMS2M7O
DMS2M7O	DN	Deferiprone
DMS2M7O	MI	TTUDR0C
DMS2M7O	MN	Iron (Fe)
DMS2M7O	MT	DTT
DMS2M7O	MA	Modulator
DMS2M7O	RN	2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
DMS2M7O	RU	https://pubmed.ncbi.nlm.nih.gov/22293555

DMS2M7O	DI	DMS2M7O
DMS2M7O	DN	Deferiprone
DMS2M7O	MI	DESD26P
DMS2M7O	MN	UDP-glucuronosyltransferase 1A6 (UGT1A6)
DMS2M7O	MT	DME
DMS2M7O	MA	Metabolism
DMS2M7O	RN	Deferiprone glucuronidation by human tissues and recombinant UDP glucuronosyltransferase 1A6: an in vitro investigation of genetic and splice variants. Drug Metab Dispos. 2009 Feb;37(2):322-9.
DMS2M7O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18971318

DMTUKZH	DI	DMTUKZH
DMTUKZH	DN	Deferoxamine mesylate
DMTUKZH	MI	TTUDR0C
DMTUKZH	MN	Iron (Fe)
DMTUKZH	MT	DTT
DMTUKZH	MA	Modulator
DMTUKZH	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMTUKZH	RU	https://www.fda.gov/

DMV0RNS	DI	DMV0RNS
DMV0RNS	DN	Deflazacort
DMV0RNS	MI	DE4LYSA
DMV0RNS	MN	Cytochrome P450 3A4 (CYP3A4)
DMV0RNS	MT	DME
DMV0RNS	MA	Metabolism
DMV0RNS	RN	Mechanisms and clinical significance of pharmacokinetic-based drug-drug interactions with drugs approved by the U.S. Food and Drug Administration in 2017. Drug Metab Dispos. 2019 Feb;47(2):135-144.
DMV0RNS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30442649

DMV0RNS	DI	DMV0RNS
DMV0RNS	DN	Deflazacort
DMV0RNS	MI	TTYRL6O
DMV0RNS	MN	Glucocorticoid receptor (NR3C1)
DMV0RNS	MT	DTT
DMV0RNS	MA	Modulator
DMV0RNS	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMV0RNS	RU	https://www.fda.gov/

DMV0RNS	DI	DMV0RNS
DMV0RNS	DN	Deflazacort
DMV0RNS	MI	DTUGYRD
DMV0RNS	MN	P-glycoprotein 1 (ABCB1)
DMV0RNS	MT	DTP
DMV0RNS	MA	Substrate
DMV0RNS	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
DMV0RNS	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01665

DM3O8QY	DI	DM3O8QY
DM3O8QY	DN	Degarelix
DM3O8QY	MI	TT8R70G
DM3O8QY	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DM3O8QY	MT	DTT
DM3O8QY	MA	Inhibitor
DM3O8QY	RN	Iterative approach to the discovery of novel degarelix analogues: substitutions at positions 3, 7, and 8. Part II. J Med Chem. 2005 Jul 28;48(15):4851-60.
DM3O8QY	RU	https://pubmed.ncbi.nlm.nih.gov/16033265

DM4Q80H	DI	DM4Q80H
DM4Q80H	DN	Dehydroepiandrosterone sulfate
DM4Q80H	MI	DTI7UX6
DM4Q80H	MN	Breast cancer resistance protein (ABCG2)
DM4Q80H	MT	DTP
DM4Q80H	MA	Substrate
DM4Q80H	RN	A prediction model of substrates and non-substrates of breast cancer resistance protein (BCRP) developed by GA-CG-SVM method. Comput Biol Med. 2011 Nov;41(11):1006-13.
DM4Q80H	RU	https://doi.org/10.1016/j.compbiomed.2011.08.009

DM4Q80H	DI	DM4Q80H
DM4Q80H	DN	Dehydroepiandrosterone sulfate
DM4Q80H	MI	DTSYQGK
DM4Q80H	MN	Multidrug resistance-associated protein 1 (ABCC1)
DM4Q80H	MT	DTP
DM4Q80H	MA	Substrate
DM4Q80H	RN	Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J. 2003 Apr 15;371(Pt 2):361-7.
DM4Q80H	RU	http://www.ncbi.nlm.nih.gov/pubmed/12523936

DM4Q80H	DI	DM4Q80H
DM4Q80H	DN	Dehydroepiandrosterone sulfate
DM4Q80H	MI	DTFI42L
DM4Q80H	MN	Multidrug resistance-associated protein 2 (ABCC2)
DM4Q80H	MT	DTP
DM4Q80H	MA	Substrate
DM4Q80H	RN	Directional trans-epithelial transport of organic anions in porcine LLC-PK1 cells that co-express human OATP1B1 (OATP-C) and MRP2. Biochem Pharmacol. 2005 Feb 1;69(3):415-23.
DM4Q80H	RU	http://www.ncbi.nlm.nih.gov/pubmed/15652233

DM4Q80H	DI	DM4Q80H
DM4Q80H	DN	Dehydroepiandrosterone sulfate
DM4Q80H	MI	DTQ3ZHF
DM4Q80H	MN	Multidrug resistance-associated protein 3 (ABCC3)
DM4Q80H	MT	DTP
DM4Q80H	MA	Substrate
DM4Q80H	RN	Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. Eur J Pharm Sci. 2006 Apr;27(5):447-86.
DM4Q80H	RU	https://doi.org/10.1016/j.ejps.2005.12.007

DM4Q80H	DI	DM4Q80H
DM4Q80H	DN	Dehydroepiandrosterone sulfate
DM4Q80H	MI	DTCSGPB
DM4Q80H	MN	Multidrug resistance-associated protein 4 (ABCC4)
DM4Q80H	MT	DTP
DM4Q80H	MA	Substrate
DM4Q80H	RN	Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J. 2003 Apr 15;371(Pt 2):361-7.
DM4Q80H	RU	http://www.ncbi.nlm.nih.gov/pubmed/12523936

DM4Q80H	DI	DM4Q80H
DM4Q80H	DN	Dehydroepiandrosterone sulfate
DM4Q80H	MI	DTE2B1D
DM4Q80H	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DM4Q80H	MT	DTP
DM4Q80H	MA	Substrate
DM4Q80H	RN	Membrane transporters in drug development. Nat Rev Drug Discov. 2010 Mar;9(3):215-36.
DM4Q80H	RU	https://doi.org/10.1038/nrd3028

DM4Q80H	DI	DM4Q80H
DM4Q80H	DN	Dehydroepiandrosterone sulfate
DM4Q80H	MI	DT3D8F0
DM4Q80H	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM4Q80H	MT	DTP
DM4Q80H	MA	Substrate
DM4Q80H	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DM4Q80H	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DM4Q80H	DI	DM4Q80H
DM4Q80H	DN	Dehydroepiandrosterone sulfate
DM4Q80H	MI	DT9C1TS
DM4Q80H	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM4Q80H	MT	DTP
DM4Q80H	MA	Substrate
DM4Q80H	RN	LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99.
DM4Q80H	RU	http://www.ncbi.nlm.nih.gov/pubmed/11375950

DM4Q80H	DI	DM4Q80H
DM4Q80H	DN	Dehydroepiandrosterone sulfate
DM4Q80H	MI	DTPFTEQ
DM4Q80H	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DM4Q80H	MT	DTP
DM4Q80H	MA	Substrate
DM4Q80H	RN	Expression of OATP family members in hormone-related cancers: potential markers of progression. PLoS One. 2011;6(5):e20372.
DM4Q80H	RU	https://doi.org/10.1371/journal.pone.0020372

DMVTU5Q	DI	DMVTU5Q
DMVTU5Q	DN	Delafloxacin Meglumine
DMVTU5Q	MI	TTZ82MR
DMVTU5Q	MN	Plasmodium DNA gyrase (Malaria gyrase)
DMVTU5Q	MT	DTT
DMVTU5Q	MA	Inhibitor
DMVTU5Q	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DMVTU5Q	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DMVTU5Q	DI	DMVTU5Q
DMVTU5Q	DN	Delafloxacin Meglumine
DMVTU5Q	MI	TTIXTO3
DMVTU5Q	MN	Staphylococcus Topoisomerase IV (Stap-coc parC)
DMVTU5Q	MT	DTT
DMVTU5Q	MA	Inhibitor
DMVTU5Q	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DMVTU5Q	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DMXE76K	DI	DMXE76K
DMXE76K	DN	Delamanid
DMXE76K	MI	TTXT4D5
DMXE76K	MN	Bacterial Cell membrane (Bact CM)
DMXE76K	MT	DTT
DMXE76K	MA	Inhibitor
DMXE76K	RN	Compassionate use of delamanid in adults and children for drug-resistant tuberculosis: 5-year update. Eur Respir J. 2021 May 20;57(5):2002483.
DMXE76K	RU	https://pubmed.ncbi.nlm.nih.gov/33243846

DMXE76K	DI	DMXE76K
DMXE76K	DN	Delamanid
DMXE76K	MI	DE4LYSA
DMXE76K	MN	Cytochrome P450 3A4 (CYP3A4)
DMXE76K	MT	DME
DMXE76K	MA	Metabolism
DMXE76K	RN	Pharmacokinetics and metabolism of delamanid, a novel anti-tuberculosis drug, in animals and humans: importance of albumin metabolism in vivo. Drug Metab Dispos. 2015 Aug;43(8):1267-76.
DMXE76K	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26055620

DM7EUK3	DI	DM7EUK3
DM7EUK3	DN	Delapril
DM7EUK3	MI	TTL69WB
DM7EUK3	MN	Angiotensin-converting enzyme (ACE)
DM7EUK3	MT	DTT
DM7EUK3	MA	Modulator
DM7EUK3	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DM7EUK3	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DM3NF5G	DI	DM3NF5G
DM3NF5G	DN	Delavirdine
DM3NF5G	MI	DTI7UX6
DM3NF5G	MN	Breast cancer resistance protein (ABCG2)
DM3NF5G	MT	DTP
DM3NF5G	MA	Substrate
DM3NF5G	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM3NF5G	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DM3NF5G	DI	DM3NF5G
DM3NF5G	DN	Delavirdine
DM3NF5G	MI	DECB0K3
DM3NF5G	MN	Cytochrome P450 2D6 (CYP2D6)
DM3NF5G	MT	DME
DM3NF5G	MA	Metabolism
DM3NF5G	RN	Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J Clin Pharmacol. 2001 Jan;41(1):85-91.
DM3NF5G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11225565

DM3NF5G	DI	DM3NF5G
DM3NF5G	DN	Delavirdine
DM3NF5G	MI	DE4LYSA
DM3NF5G	MN	Cytochrome P450 3A4 (CYP3A4)
DM3NF5G	MT	DME
DM3NF5G	MA	Metabolism
DM3NF5G	RN	Delavirdine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2001;40(3):207-26.
DM3NF5G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11327199

DM3NF5G	DI	DM3NF5G
DM3NF5G	DN	Delavirdine
DM3NF5G	MI	DEIBDNY
DM3NF5G	MN	Cytochrome P450 3A5 (CYP3A5)
DM3NF5G	MT	DME
DM3NF5G	MA	Metabolism
DM3NF5G	RN	Drug Interactions Flockhart Table
DM3NF5G	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM3NF5G	DI	DM3NF5G
DM3NF5G	DN	Delavirdine
DM3NF5G	MI	DERD86B
DM3NF5G	MN	Cytochrome P450 3A7 (CYP3A7)
DM3NF5G	MT	DME
DM3NF5G	MA	Metabolism
DM3NF5G	RN	Drug Interactions Flockhart Table
DM3NF5G	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM3NF5G	DI	DM3NF5G
DM3NF5G	DN	Delavirdine
DM3NF5G	MI	TT84ETX
DM3NF5G	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM3NF5G	MT	DTT
DM3NF5G	MA	Modulator
DM3NF5G	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM3NF5G	RU	https://www.fda.gov/

DM3NF5G	DI	DM3NF5G
DM3NF5G	DN	Delavirdine
DM3NF5G	MI	DTUGYRD
DM3NF5G	MN	P-glycoprotein 1 (ABCB1)
DM3NF5G	MT	DTP
DM3NF5G	MA	Substrate
DM3NF5G	RN	The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res. 2009 May;82(2):A99-109.
DM3NF5G	RU	https://doi.org/10.1016/j.antiviral.2008.12.013

DMAYEU1	DI	DMAYEU1
DMAYEU1	DN	Demecarium bromide
DMAYEU1	MI	TT1RS9F
DMAYEU1	MN	Acetylcholinesterase (AChE)
DMAYEU1	MT	DTT
DMAYEU1	MA	Inhibitor
DMAYEU1	RN	The effects of topical ocular application of 0.25% demecarium bromide on serum acetylcholinesterase levels in normal dogs. Vet Ophthalmol. 2003 Mar;6(1):23-5.
DMAYEU1	RU	https://pubmed.ncbi.nlm.nih.gov/12641839

DMZEPFJ	DI	DMZEPFJ
DMZEPFJ	DN	Demeclocycline
DMZEPFJ	MI	TTQ8KVI
DMZEPFJ	MN	Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)
DMZEPFJ	MT	DTT
DMZEPFJ	MA	Binder
DMZEPFJ	RN	Detection of tetracycline resistance genes by PCR methods. Methods Mol Biol. 2004;268:3-13.
DMZEPFJ	RU	https://pubmed.ncbi.nlm.nih.gov/15156014

DMCZQGK	DI	DMCZQGK
DMCZQGK	DN	Demecolcine
DMCZQGK	MI	TT1EDJZ
DMCZQGK	MN	Microtubule-associated protein (MAP)
DMCZQGK	MT	DTT
DMCZQGK	MA	Modulator
DMCZQGK	RN	Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81.
DMCZQGK	RU	https://pubmed.ncbi.nlm.nih.gov/3879679

DMMHR1U	DI	DMMHR1U
DMMHR1U	DN	Denileukin diftitox
DMMHR1U	MI	TTAJU0S
DMMHR1U	MN	Interleukin 2 receptor (IL2R)
DMMHR1U	MT	DTT
DMMHR1U	MA	Binder
DMMHR1U	RN	Optimizing denileukin diftitox (Ontak) therapy. Future Oncol. 2008 Aug;4(4):457-69.
DMMHR1U	RU	https://pubmed.ncbi.nlm.nih.gov/18684057

DM8C3GN	DI	DM8C3GN
DM8C3GN	DN	Denopamine
DM8C3GN	MI	TTEX248
DM8C3GN	MN	Dopamine D2 receptor (D2R)
DM8C3GN	MT	DTT
DM8C3GN	MA	Modulator
DM8C3GN	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DM8C3GN	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DM8C3GN	DI	DM8C3GN
DM8C3GN	DN	Denopamine
DM8C3GN	MI	DEAZDL8
DM8C3GN	MN	UDP-glucuronosyltransferase 2B17 (UGT2B17)
DM8C3GN	MT	DME
DM8C3GN	MA	Metabolism
DM8C3GN	RN	Regioselective glucuronidation of denopamine: marked species differences and identification of human udp-glucuronosyltransferase isoform. Drug Metab Dispos. 2005 Mar;33(3):403-12.
DM8C3GN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15608137

DMNI0KO	DI	DMNI0KO
DMNI0KO	DN	Denosumab
DMNI0KO	MI	TT9E8HR
DMNI0KO	MN	Osteoclast differentiation factor (ODF)
DMNI0KO	MT	DTT
DMNI0KO	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DMNI0KO	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DM3GYAL	DI	DM3GYAL
DM3GYAL	DN	Deoxycholic acid
DM3GYAL	MI	DT7JELC
DM3GYAL	MN	Apical sodium-dependent bile acid transporter (SLC10A2)
DM3GYAL	MT	DTP
DM3GYAL	MA	Substrate
DM3GYAL	RN	Functional nanoparticles exploit the bile acid pathway to overcome multiple barriers of the intestinal epithelium for oral insulin delivery. Biomaterials. 2018 Jan;151:13-23.
DM3GYAL	RU	http://www.ncbi.nlm.nih.gov/pubmed/29055774

DM3GYAL	DI	DM3GYAL
DM3GYAL	DN	Deoxycholic acid
DM3GYAL	MI	DTI7UX6
DM3GYAL	MN	Breast cancer resistance protein (ABCG2)
DM3GYAL	MT	DTP
DM3GYAL	MA	Substrate
DM3GYAL	RN	Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). Biochem J. 2005 Jan 15;385(Pt 2):419-26.
DM3GYAL	RU	https://doi.org/10.1042/BJ20040791

DMYE5LJ	DI	DMYE5LJ
DMYE5LJ	DN	DEOXYCYTIDINE
DMYE5LJ	MI	TTP3QRF
DMYE5LJ	MN	Thymidine kinase 1 (TK1)
DMYE5LJ	MT	DTT
DMYE5LJ	MA	Inhibitor
DMYE5LJ	RN	Species- or isozyme-specific enzyme inhibitors. 5. Differential effects of thymidine substituents on affinity for rat thymidine kinase isozymes. J Med Chem. 1982 Jun;25(6):644-9.
DMYE5LJ	RU	https://pubmed.ncbi.nlm.nih.gov/7097717

DMRH7CV	DI	DMRH7CV
DMRH7CV	DN	Deserpidine
DMRH7CV	MI	TTL69WB
DMRH7CV	MN	Angiotensin-converting enzyme (ACE)
DMRH7CV	MT	DTT
DMRH7CV	MA	Inhibitor
DMRH7CV	RN	Angiotensin II-induced modulation of endothelium-dependent relaxation in rabbit mesenteric resistance arteries. J Physiol. 2003 May 1;548(Pt 3):893-906.
DMRH7CV	RU	https://pubmed.ncbi.nlm.nih.gov/12651915

DM2TO9R	DI	DM2TO9R
DM2TO9R	DN	Desflurane
DM2TO9R	MI	TTAN6JD
DM2TO9R	MN	Glutamate receptor AMPA (GRIA)
DM2TO9R	MT	DTT
DM2TO9R	MA	Antagonist
DM2TO9R	RN	Modulation of NMDA receptor function by ketamine and magnesium. Part II: interactions with volatile anesthetics. Anesth Analg. 2001 May;92(5):1182-91.
DM2TO9R	RU	https://pubmed.ncbi.nlm.nih.gov/11323344

DMT2FDC	DI	DMT2FDC
DMT2FDC	DN	Desipramine
DMT2FDC	MI	DEJGDUW
DMT2FDC	MN	Cytochrome P450 1A2 (CYP1A2)
DMT2FDC	MT	DME
DMT2FDC	MA	Metabolism
DMT2FDC	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMT2FDC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMT2FDC	DI	DMT2FDC
DMT2FDC	DN	Desipramine
DMT2FDC	MI	DEPKLMQ
DMT2FDC	MN	Cytochrome P450 2B6 (CYP2B6)
DMT2FDC	MT	DME
DMT2FDC	MA	Metabolism
DMT2FDC	RN	Drugs that may have potential CYP2B6 interactions.
DMT2FDC	RU	https://drug-interactions.medicine.iu.edu/MainTable.aspx

DMT2FDC	DI	DMT2FDC
DMT2FDC	DN	Desipramine
DMT2FDC	MI	DECB0K3
DMT2FDC	MN	Cytochrome P450 2D6 (CYP2D6)
DMT2FDC	MT	DME
DMT2FDC	MA	Metabolism
DMT2FDC	RN	Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol. 1996;51(1):73-8.
DMT2FDC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8880055

DMT2FDC	DI	DMT2FDC
DMT2FDC	DN	Desipramine
DMT2FDC	MI	DE4LYSA
DMT2FDC	MN	Cytochrome P450 3A4 (CYP3A4)
DMT2FDC	MT	DME
DMT2FDC	MA	Metabolism
DMT2FDC	RN	Variability in metabolism of imipramine and desipramine using urinary excretion data. J Anal Toxicol. 2014 Jul-Aug;38(6):368-74.
DMT2FDC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24782142

DMT2FDC	DI	DMT2FDC
DMT2FDC	DN	Desipramine
DMT2FDC	MI	DEGTFWK
DMT2FDC	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMT2FDC	MT	DME
DMT2FDC	MA	Metabolism
DMT2FDC	RN	Eight inhibitory monoclonal antibodies define the role of individual P-450s in human liver microsomal diazepam, 7-ethoxycoumarin, and imipramine metabolism. Drug Metab Dispos. 1999 Jan;27(1):102-9.
DMT2FDC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9884317

DMT2FDC	DI	DMT2FDC
DMT2FDC	DN	Desipramine
DMT2FDC	MI	TTAWNKZ
DMT2FDC	MN	Norepinephrine transporter (NET)
DMT2FDC	MT	DTT
DMT2FDC	MA	Inhibitor
DMT2FDC	RN	Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
DMT2FDC	RU	https://pubmed.ncbi.nlm.nih.gov/19517098

DMT2FDC	DI	DMT2FDC
DMT2FDC	DN	Desipramine
DMT2FDC	MI	DTT79CX
DMT2FDC	MN	Organic cation transporter 1 (SLC22A1)
DMT2FDC	MT	DTP
DMT2FDC	MA	Substrate
DMT2FDC	RN	Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
DMT2FDC	RU	https://doi.org/10.1016/j.canlet.2005.06.051

DMT2FDC	DI	DMT2FDC
DMT2FDC	DN	Desipramine
DMT2FDC	MI	DTUGYRD
DMT2FDC	MN	P-glycoprotein 1 (ABCB1)
DMT2FDC	MT	DTP
DMT2FDC	MA	Substrate
DMT2FDC	RN	A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26.
DMT2FDC	RU	https://doi.org/10.1007/s00210-008-0345-0

DM2BTFN	DI	DM2BTFN
DM2BTFN	DN	Desirudin Recombinant
DM2BTFN	MI	TT6L509
DM2BTFN	MN	Coagulation factor IIa (F2)
DM2BTFN	MT	DTT
DM2BTFN	MA	Modulator
DM2BTFN	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM2BTFN	RU	https://www.fda.gov/

DMB3ZSK	DI	DMB3ZSK
DMB3ZSK	DN	Deslanoside
DMB3ZSK	MI	TTWK8D0
DMB3ZSK	MN	Sodium pump subunit alpha-1 (ATP1A1)
DMB3ZSK	MT	DTT
DMB3ZSK	MA	Binder
DMB3ZSK	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMB3ZSK	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM56YN7	DI	DM56YN7
DM56YN7	DN	Desloratadine
DM56YN7	MI	DES5XRU
DM56YN7	MN	Cytochrome P450 2C8 (CYP2C8)
DM56YN7	MT	DME
DM56YN7	MA	Metabolism
DM56YN7	RN	Further characterization of the metabolism of desloratadine and its cytochrome P450 and UDP-glucuronosyltransferase inhibition potential: identification of desloratadine as a relatively selective UGT2B10 inhibitor. Drug Metab Dispos. 2015 Sep;43(9):1294-302.
DM56YN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26135009

DM56YN7	DI	DM56YN7
DM56YN7	DN	Desloratadine
DM56YN7	MI	TTTIBOJ
DM56YN7	MN	Histamine H1 receptor (H1R)
DM56YN7	MT	DTT
DM56YN7	MA	Antagonist
DM56YN7	RN	Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in England. Drug Saf. 2009;32(2):169-79. 
DM56YN7	RU	https://pubmed.ncbi.nlm.nih.gov/19236123

DM56YN7	DI	DM56YN7
DM56YN7	DN	Desloratadine
DM56YN7	MI	DTUGYRD
DM56YN7	MN	P-glycoprotein 1 (ABCB1)
DM56YN7	MT	DTP
DM56YN7	MA	Substrate
DM56YN7	RN	P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos. 2003 Mar;31(3):312-8.
DM56YN7	RU	http://www.ncbi.nlm.nih.gov/pubmed/12584158

DM56YN7	DI	DM56YN7
DM56YN7	DN	Desloratadine
DM56YN7	MI	DEI8NGH
DM56YN7	MN	UDP-glucuronosyltransferase 2B10 (UGT2B10)
DM56YN7	MT	DME
DM56YN7	MA	Metabolism
DM56YN7	RN	Further characterization of the metabolism of desloratadine and its cytochrome P450 and UDP-glucuronosyltransferase inhibition potential: identification of desloratadine as a relatively selective UGT2B10 inhibitor. Drug Metab Dispos. 2015 Sep;43(9):1294-302.
DM56YN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26135009

DMS3GVE	DI	DMS3GVE
DMS3GVE	DN	Desmopressin
DMS3GVE	MI	TTSCIUP
DMS3GVE	MN	Oxytocin receptor (OTR)
DMS3GVE	MT	DTT
DMS3GVE	MA	Agonist
DMS3GVE	RN	Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem. 2004 Apr 22;47(9):2375-88.
DMS3GVE	RU	https://pubmed.ncbi.nlm.nih.gov/15084136

DMS3GVE	DI	DMS3GVE
DMS3GVE	DN	Desmopressin
DMS3GVE	MI	TTYCILE
DMS3GVE	MN	Vasopressin receptor (VR)
DMS3GVE	MT	DTT
DMS3GVE	MA	Modulator
DMS3GVE	RN	Vasopressin V2 (SR121463A) and V1a (SR49059) receptor antagonists both inhibit desmopressin vasorelaxing activity. Eur J Pharmacol. 1999 Nov 3;383(3):287-90.
DMS3GVE	RU	https://pubmed.ncbi.nlm.nih.gov/10594321

DMS3GVE	DI	DMS3GVE
DMS3GVE	DN	Desmopressin
DMS3GVE	MI	TT4TFGN
DMS3GVE	MN	Vasopressin V1a receptor (V1AR)
DMS3GVE	MT	DTT
DMS3GVE	MA	Agonist
DMS3GVE	RN	Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem. 2004 Apr 22;47(9):2375-88.
DMS3GVE	RU	https://pubmed.ncbi.nlm.nih.gov/15084136

DMS3GVE	DI	DMS3GVE
DMS3GVE	DN	Desmopressin
DMS3GVE	MI	TTL9MHW
DMS3GVE	MN	Vasopressin V1b receptor (V1BR)
DMS3GVE	MT	DTT
DMS3GVE	MA	Agonist
DMS3GVE	RN	Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem. 2004 Apr 22;47(9):2375-88.
DMS3GVE	RU	https://pubmed.ncbi.nlm.nih.gov/15084136

DMS3GVE	DI	DMS3GVE
DMS3GVE	DN	Desmopressin
DMS3GVE	MI	TTK8R02
DMS3GVE	MN	Vasopressin V2 receptor (V2R)
DMS3GVE	MT	DTT
DMS3GVE	MA	Agonist
DMS3GVE	RN	Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem. 2004 Apr 22;47(9):2375-88.
DMS3GVE	RU	https://pubmed.ncbi.nlm.nih.gov/15084136

DM27U4Y	DI	DM27U4Y
DM27U4Y	DN	Desogestrel
DM27U4Y	MI	DE5IED8
DM27U4Y	MN	Cytochrome P450 2C9 (CYP2C9)
DM27U4Y	MT	DME
DM27U4Y	MA	Metabolism
DM27U4Y	RN	The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel. J Pharmacol Exp Ther. 1998 Dec;287(3):975-82.
DM27U4Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9864282

DM27U4Y	DI	DM27U4Y
DM27U4Y	DN	Desogestrel
DM27U4Y	MI	DE4LYSA
DM27U4Y	MN	Cytochrome P450 3A4 (CYP3A4)
DM27U4Y	MT	DME
DM27U4Y	MA	Metabolism
DM27U4Y	RN	The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel. Br J Clin Pharmacol. 2005 Jul;60(1):69-75.
DM27U4Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15963096

DM27U4Y	DI	DM27U4Y
DM27U4Y	DN	Desogestrel
DM27U4Y	MI	DEGTFWK
DM27U4Y	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM27U4Y	MT	DME
DM27U4Y	MA	Metabolism
DM27U4Y	RN	The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel. J Pharmacol Exp Ther. 1998 Dec;287(3):975-82.
DM27U4Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9864282

DM27U4Y	DI	DM27U4Y
DM27U4Y	DN	Desogestrel
DM27U4Y	MI	TTUV8G9
DM27U4Y	MN	Progesterone receptor (PGR)
DM27U4Y	MT	DTT
DM27U4Y	MA	Modulator
DM27U4Y	RN	Preclinical experience with two selective progesterone receptor modulators on breast and endometrium. Steroids. 2000 Oct-Nov;65(10-11):733-40.
DM27U4Y	RU	https://pubmed.ncbi.nlm.nih.gov/11108884

DMTP2NJ	DI	DMTP2NJ
DMTP2NJ	DN	Desonide
DMTP2NJ	MI	DE4LYSA
DMTP2NJ	MN	Cytochrome P450 3A4 (CYP3A4)
DMTP2NJ	MT	DME
DMTP2NJ	MA	Metabolism
DMTP2NJ	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMTP2NJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMTP2NJ	DI	DMTP2NJ
DMTP2NJ	DN	Desonide
DMTP2NJ	MI	TTP3UTW
DMTP2NJ	MN	Steroid hormone receptor ERR (ESRR)
DMTP2NJ	MT	DTT
DMTP2NJ	MA	Modulator
DMTP2NJ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMTP2NJ	RU	https://www.fda.gov/

DM4PXF6	DI	DM4PXF6
DM4PXF6	DN	Desoximetasone
DM4PXF6	MI	TTP3UTW
DM4PXF6	MN	Steroid hormone receptor ERR (ESRR)
DM4PXF6	MT	DTT
DM4PXF6	MA	Modulator
DM4PXF6	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM4PXF6	RU	https://www.fda.gov/

DMS0AFE	DI	DMS0AFE
DMS0AFE	DN	Desoxycorticosterone acetate
DMS0AFE	MI	DE4LYSA
DMS0AFE	MN	Cytochrome P450 3A4 (CYP3A4)
DMS0AFE	MT	DME
DMS0AFE	MA	Metabolism
DMS0AFE	RN	Progress in Brain Research. Chapter 11 - Steroidogenic Enzymes in the Brain: Morphological Aspects. 2010, 181:193-207.
DMS0AFE	RU	https://www.sciencedirect.com/science/article/pii/S0079612308810114

DMS0AFE	DI	DMS0AFE
DMS0AFE	DN	Desoxycorticosterone acetate
DMS0AFE	MI	TT26PHO
DMS0AFE	MN	Mineralocorticoid receptor  (MR)
DMS0AFE	MT	DTT
DMS0AFE	MA	Modulator
DMS0AFE	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMS0AFE	RU	https://www.fda.gov/

DMSA4B3	DI	DMSA4B3
DMSA4B3	DN	Desoxycorticosterone pivalate
DMSA4B3	MI	DE4LYSA
DMSA4B3	MN	Cytochrome P450 3A4 (CYP3A4)
DMSA4B3	MT	DME
DMSA4B3	MA	Metabolism
DMSA4B3	RN	Progress in Brain Research. Chapter 11 - Steroidogenic Enzymes in the Brain: Morphological Aspects. 2010, 181:193-207.
DMSA4B3	RU	https://www.sciencedirect.com/science/article/pii/S0079612308810114

DMSA4B3	DI	DMSA4B3
DMSA4B3	DN	Desoxycorticosterone pivalate
DMSA4B3	MI	TT26PHO
DMSA4B3	MN	Mineralocorticoid receptor  (MR)
DMSA4B3	MT	DTT
DMSA4B3	MA	Binder
DMSA4B3	RN	Characterization of rat brain aldosterone receptors reveals high affinity for corticosterone. Endocrinology. 1983 Dec;113(6):2043-51.
DMSA4B3	RU	https://pubmed.ncbi.nlm.nih.gov/6227474

DMEZFXR	DI	DMEZFXR
DMEZFXR	DN	Desoxyribonuclease
DMEZFXR	MI	TT3C1VN
DMEZFXR	MN	Enzyme unspecific (Enz)
DMEZFXR	MT	DTT
DMEZFXR	MA	Modulator
DMEZFXR	RN	Preparation of the bifunctional enzyme ribonuclease-deoxyribonuclease by cross-linkage. Biochemistry. 1979 Oct 2;18(20):4449-52.
DMEZFXR	RU	https://pubmed.ncbi.nlm.nih.gov/486431

DMJE6KO	DI	DMJE6KO
DMJE6KO	DN	Desvenalfaxine succinate
DMJE6KO	MI	DECB0K3
DMJE6KO	MN	Cytochrome P450 2D6 (CYP2D6)
DMJE6KO	MT	DME
DMJE6KO	MA	Metabolism
DMJE6KO	RN	Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers. Br J Clin Pharmacol. 1999 Apr;47(4):450-3.
DMJE6KO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10233212

DMJE6KO	DI	DMJE6KO
DMJE6KO	DN	Desvenalfaxine succinate
DMJE6KO	MI	DE4LYSA
DMJE6KO	MN	Cytochrome P450 3A4 (CYP3A4)
DMJE6KO	MT	DME
DMJE6KO	MA	Metabolism
DMJE6KO	RN	Desvenlafaxine in the treatment of major depressive disorder. Expert Opin Pharmacother. 2011 Dec;12(18):2923-8.
DMJE6KO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22098230

DMJE6KO	DI	DMJE6KO
DMJE6KO	DN	Desvenalfaxine succinate
DMJE6KO	MI	TTAWNKZ
DMJE6KO	MN	Norepinephrine transporter (NET)
DMJE6KO	MT	DTT
DMJE6KO	MA	Inhibitor
DMJE6KO	RN	Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62.
DMJE6KO	RU	https://pubmed.ncbi.nlm.nih.gov/18321148

DMHD4PE	DI	DMHD4PE
DMHD4PE	DN	Desvenlafaxine
DMHD4PE	MI	TT3ROYC
DMHD4PE	MN	Serotonin transporter (SERT)
DMHD4PE	MT	DTT
DMHD4PE	MA	Modulator
DMHD4PE	RN	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
DMHD4PE	RU	https://pubmed.ncbi.nlm.nih.gov/19180096

DMUPFLI	DI	DMUPFLI
DMUPFLI	DN	Deutetrabenazine
DMUPFLI	MI	DEJGDUW
DMUPFLI	MN	Cytochrome P450 1A2 (CYP1A2)
DMUPFLI	MT	DME
DMUPFLI	MA	Metabolism
DMUPFLI	RN	FDA Label of Deutetrabenazine. The 2020 official website of the U.S. Food and Drug Administration.
DMUPFLI	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208082s000lbl.pdf

DMUPFLI	DI	DMUPFLI
DMUPFLI	DN	Deutetrabenazine
DMUPFLI	MI	DECB0K3
DMUPFLI	MN	Cytochrome P450 2D6 (CYP2D6)
DMUPFLI	MT	DME
DMUPFLI	MA	Metabolism
DMUPFLI	RN	FDA Label of Deutetrabenazine. The 2020 official website of the U.S. Food and Drug Administration.
DMUPFLI	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208082s000lbl.pdf

DMUPFLI	DI	DMUPFLI
DMUPFLI	DN	Deutetrabenazine
DMUPFLI	MI	TTNZRI3
DMUPFLI	MN	Synaptic vesicle amine transporter (SLC18A2)
DMUPFLI	MT	DTT
DMUPFLI	MA	Modulator
DMUPFLI	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMUPFLI	RU	https://www.fda.gov/

DMMWZET	DI	DMMWZET
DMMWZET	DN	Dexamethasone
DMMWZET	MI	DETHCPD
DMMWZET	MN	Carboxylesterase 2 (CES2)
DMMWZET	MT	DME
DMMWZET	MA	Metabolism
DMMWZET	RN	In vitro metabolism of dexamethasone cipecilate, a novel synthetic corticosteroid, in human liver and nasal mucosa. Xenobiotica. 2011 Oct;41(10):874-84.
DMMWZET	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21657966

DMMWZET	DI	DMMWZET
DMMWZET	DN	Dexamethasone
DMMWZET	MI	DEDH7FP
DMMWZET	MN	Corticosteroid 11-beta-dehydrogenase 2 (HSD11B2)
DMMWZET	MT	DME
DMMWZET	MA	Metabolism
DMMWZET	RN	Metabolism of synthetic steroids by the human placenta. Placenta. 2007 Jan;28(1):39-46.
DMMWZET	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16549198

DMMWZET	DI	DMMWZET
DMMWZET	DN	Dexamethasone
DMMWZET	MI	DE4LYSA
DMMWZET	MN	Cytochrome P450 3A4 (CYP3A4)
DMMWZET	MT	DME
DMMWZET	MA	Metabolism
DMMWZET	RN	Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. Br J Clin Pharmacol. 1996 Mar;41(3):187-90.
DMMWZET	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8866917

DMMWZET	DI	DMMWZET
DMMWZET	DN	Dexamethasone
DMMWZET	MI	DEIBDNY
DMMWZET	MN	Cytochrome P450 3A5 (CYP3A5)
DMMWZET	MT	DME
DMMWZET	MA	Metabolism
DMMWZET	RN	Regulation of CYP3A5 by glucocorticoids and cigarette smoke in human lung-derived cells. J Pharmacol Exp Ther. 2003 Feb;304(2):745-52.
DMMWZET	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12538830

DMMWZET	DI	DMMWZET
DMMWZET	DN	Dexamethasone
DMMWZET	MI	DERD86B
DMMWZET	MN	Cytochrome P450 3A7 (CYP3A7)
DMMWZET	MT	DME
DMMWZET	MA	Metabolism
DMMWZET	RN	Cytotoxicity of chloroacetanilide herbicide alachlor in HepG2 cells independent of CYP3A4 and CYP3A7. Food Chem Toxicol. 2007 May;45(5):871-7.
DMMWZET	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17207564

DMMWZET	DI	DMMWZET
DMMWZET	DN	Dexamethasone
DMMWZET	MI	TTYRL6O
DMMWZET	MN	Glucocorticoid receptor (NR3C1)
DMMWZET	MT	DTT
DMMWZET	MA	Agonist
DMMWZET	RN	Interaction between the glucocorticoid and erythropoietin receptors in human erythroid cells. Exp Hematol. 2009 May;37(5):559-72.
DMMWZET	RU	https://pubmed.ncbi.nlm.nih.gov/19375647

DMMWZET	DI	DMMWZET
DMMWZET	DN	Dexamethasone
DMMWZET	MI	DT9G7XN
DMMWZET	MN	Peptide transporter 1 (SLC15A1)
DMMWZET	MT	DTP
DMMWZET	MA	Substrate
DMMWZET	RN	Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells. Arch Pharm Res. 2007 Apr;30(4):507-18.
DMMWZET	RU	https://doi.org/10.1007/BF02980227

DMMWZET	DI	DMMWZET
DMMWZET	DN	Dexamethasone
DMMWZET	MI	DTUGYRD
DMMWZET	MN	P-glycoprotein 1 (ABCB1)
DMMWZET	MT	DTP
DMMWZET	MA	Substrate
DMMWZET	RN	Modulation of drug-stimulated ATPase activity of human MDR1/P-glycoprotein by cholesterol. Biochem J. 2007 Jan 15;401(2):597-605.
DMMWZET	RU	http://www.ncbi.nlm.nih.gov/pubmed/17029589

DMIG8DW	DI	DMIG8DW
DMIG8DW	DN	Dexamethasone sodium phosphate
DMIG8DW	MI	DE4LYSA
DMIG8DW	MN	Cytochrome P450 3A4 (CYP3A4)
DMIG8DW	MT	DME
DMIG8DW	MA	Metabolism
DMIG8DW	RN	Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. Br J Clin Pharmacol. 1996 Mar;41(3):187-90.
DMIG8DW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8866917

DMIG8DW	DI	DMIG8DW
DMIG8DW	DN	Dexamethasone sodium phosphate
DMIG8DW	MI	TTYRL6O
DMIG8DW	MN	Glucocorticoid receptor (NR3C1)
DMIG8DW	MT	DTT
DMIG8DW	MA	Agonist
DMIG8DW	RN	Dexamethasone rapidly increases GABA release in the dorsal motor nucleus of the vagus via retrograde messenger-mediated enhancement of TRPV1 activity. PLoS One. 2013 Jul 30;8(7):e70505.
DMIG8DW	RU	https://pubmed.ncbi.nlm.nih.gov/23936221

DMKVWGE	DI	DMKVWGE
DMKVWGE	DN	Dexbrompheniramine
DMKVWGE	MI	TTTIBOJ
DMKVWGE	MN	Histamine H1 receptor (H1R)
DMKVWGE	MT	DTT
DMKVWGE	MA	Antagonist
DMKVWGE	RN	H2 histaminergic control of inhibition of eating induced by intragastric NaCl in rats. Physiol Behav. 1998 Aug;65(1):105-13.
DMKVWGE	RU	https://pubmed.ncbi.nlm.nih.gov/9811372

DMA8DPN	DI	DMA8DPN
DMA8DPN	DN	Dexchlorpheniramine maleate
DMA8DPN	MI	DECB0K3
DMA8DPN	MN	Cytochrome P450 2D6 (CYP2D6)
DMA8DPN	MT	DME
DMA8DPN	MA	Metabolism
DMA8DPN	RN	The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. Br J Clin Pharmacol. 2002 May;53(5):519-25.
DMA8DPN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11994058

DMA8DPN	DI	DMA8DPN
DMA8DPN	DN	Dexchlorpheniramine maleate
DMA8DPN	MI	TTTIBOJ
DMA8DPN	MN	Histamine H1 receptor (H1R)
DMA8DPN	MT	DTT
DMA8DPN	MA	Modulator
DMA8DPN	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMA8DPN	RU	https://www.fda.gov/

DMFYBD0	DI	DMFYBD0
DMFYBD0	DN	Dexibuprofen
DMFYBD0	MI	DEGKWJB
DMFYBD0	MN	Alpha-methylacyl-CoA racemase (AMACR)
DMFYBD0	MT	DME
DMFYBD0	MA	Metabolism
DMFYBD0	RN	Alpha-Methylacyl-CoA racemase (AMACR): metabolic enzyme, drug metabolizer and cancer marker P504S. Prog Lipid Res. 2013 Apr;52(2):220-30.
DMFYBD0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23376124

DMFYBD0	DI	DMFYBD0
DMFYBD0	DN	Dexibuprofen
DMFYBD0	MI	DES5XRU
DMFYBD0	MN	Cytochrome P450 2C8 (CYP2C8)
DMFYBD0	MT	DME
DMFYBD0	MA	Metabolism
DMFYBD0	RN	Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos. 2013 Jul;34(5):278-87.
DMFYBD0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23536207

DMFYBD0	DI	DMFYBD0
DMFYBD0	DN	Dexibuprofen
DMFYBD0	MI	DE5IED8
DMFYBD0	MN	Cytochrome P450 2C9 (CYP2C9)
DMFYBD0	MT	DME
DMFYBD0	MA	Metabolism
DMFYBD0	RN	New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
DMFYBD0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20167001

DMFYBD0	DI	DMFYBD0
DMFYBD0	DN	Dexibuprofen
DMFYBD0	MI	DEGTFWK
DMFYBD0	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMFYBD0	MT	DME
DMFYBD0	MA	Metabolism
DMFYBD0	RN	PharmGKB summary: ibuprofen pathways. Pharmacogenet Genomics. 2015 Feb;25(2):96-106.
DMFYBD0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25502615

DMFYBD0	DI	DMFYBD0
DMFYBD0	DN	Dexibuprofen
DMFYBD0	MI	TTK0943
DMFYBD0	MN	Prostaglandin G/H synthase (COX)
DMFYBD0	MT	DTT
DMFYBD0	MA	Modulator
DMFYBD0	RN	Comparison of the efficacy and tolerability of dexibuprofen and celecoxib in the treatment of osteoarthritis of the hip. Int J Clin Pharmacol Ther. 2003 Apr;41(4):153-64.
DMFYBD0	RU	https://pubmed.ncbi.nlm.nih.gov/12708604

DMFYBD0	DI	DMFYBD0
DMFYBD0	DN	Dexibuprofen
DMFYBD0	MI	DEYGVN4
DMFYBD0	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMFYBD0	MT	DME
DMFYBD0	MA	Metabolism
DMFYBD0	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMFYBD0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMFYBD0	DI	DMFYBD0
DMFYBD0	DN	Dexibuprofen
DMFYBD0	MI	DEF2WXN
DMFYBD0	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMFYBD0	MT	DME
DMFYBD0	MA	Metabolism
DMFYBD0	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMFYBD0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMFYBD0	DI	DMFYBD0
DMFYBD0	DN	Dexibuprofen
DMFYBD0	MI	DE85D2P
DMFYBD0	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMFYBD0	MT	DME
DMFYBD0	MA	Metabolism
DMFYBD0	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMFYBD0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMFYBD0	DI	DMFYBD0
DMFYBD0	DN	Dexibuprofen
DMFYBD0	MI	DEB3CV1
DMFYBD0	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMFYBD0	MT	DME
DMFYBD0	MA	Metabolism
DMFYBD0	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMFYBD0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM1DBV5	DI	DM1DBV5
DM1DBV5	DN	Dexlansoprazole
DM1DBV5	MI	DE4LYSA
DM1DBV5	MN	Cytochrome P450 3A4 (CYP3A4)
DM1DBV5	MT	DME
DM1DBV5	MA	Metabolism
DM1DBV5	RN	Absorption, distribution, metabolism and excretion of [14C]dexlansoprazole in healthy male subjects. Clin Drug Investig. 2012 May 1;32(5):319-32.
DM1DBV5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22455762

DM1DBV5	DI	DM1DBV5
DM1DBV5	DN	Dexlansoprazole
DM1DBV5	MI	TTLOKXP
DM1DBV5	MN	Gastric H(+)/K(+) ATPase (Proton pump)
DM1DBV5	MT	DTT
DM1DBV5	MA	Modulator
DM1DBV5	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM1DBV5	RU	https://www.fda.gov/

DM1DBV5	DI	DM1DBV5
DM1DBV5	DN	Dexlansoprazole
DM1DBV5	MI	TTF1QVM
DM1DBV5	MN	Gastric H(+)/K(+) ATPase alpha (ATP4A)
DM1DBV5	MT	DTT
DM1DBV5	MA	Inhibitor
DM1DBV5	RN	Clinical pipeline report, company report or official report of Takeda (2009).
DM1DBV5	RU	http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf

DM1DBV5	DI	DM1DBV5
DM1DBV5	DN	Dexlansoprazole
DM1DBV5	MI	DEGTFWK
DM1DBV5	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM1DBV5	MT	DME
DM1DBV5	MA	Metabolism
DM1DBV5	RN	Pharmacological and safety profile of dexlansoprazole: a new proton pump inhibitor - implications for treatment of gastroesophageal reflux disease in the Asia Pacific region. J Neurogastroenterol Motil. 2016 Jul 30;22(3):355-66.
DM1DBV5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26932927

DM1DBV5	DI	DM1DBV5
DM1DBV5	DN	Dexlansoprazole
DM1DBV5	MI	DTUGYRD
DM1DBV5	MN	P-glycoprotein 1 (ABCB1)
DM1DBV5	MT	DTP
DM1DBV5	MA	Substrate
DM1DBV5	RN	A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26.
DM1DBV5	RU	https://doi.org/10.1007/s00210-008-0345-0

DM93L4X	DI	DM93L4X
DM93L4X	DN	Dexmedetomidine
DM93L4X	MI	TTQ8AFT
DM93L4X	MN	Adrenergic receptor Alpha-2 (ADRA2)
DM93L4X	MT	DTT
DM93L4X	MA	Agonist
DM93L4X	RN	Dexmedetomidine in intensive care unit: a study of hemodynamic changes. Middle East J Anesthesiol. 2002 Oct;16(6):587-95.
DM93L4X	RU	https://pubmed.ncbi.nlm.nih.gov/12503262

DM93L4X	DI	DM93L4X
DM93L4X	DN	Dexmedetomidine
DM93L4X	MI	DEJGDUW
DM93L4X	MN	Cytochrome P450 1A2 (CYP1A2)
DM93L4X	MT	DME
DM93L4X	MA	Metabolism
DM93L4X	RN	Predominant role of peripheral catecholamines in the stress-induced modulation of CYP1A2 inducibility by benzo(alpha)pyrene. Basic Clin Pharmacol Toxicol. 2008 Jan;102(1):35-44.
DM93L4X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17973897

DM93L4X	DI	DM93L4X
DM93L4X	DN	Dexmedetomidine
DM93L4X	MI	DEJVYAZ
DM93L4X	MN	Cytochrome P450 2A6 (CYP2A6)
DM93L4X	MT	DME
DM93L4X	MA	Metabolism
DM93L4X	RN	Impact of CYP2A6 gene polymorphism on the pharmacokinetics of dexmedetomidine for premedication. Expert Rev Clin Pharmacol. 2018 Sep;11(9):917-922.
DM93L4X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30092666

DM93L4X	DI	DM93L4X
DM93L4X	DN	Dexmedetomidine
DM93L4X	MI	DEVDYN7
DM93L4X	MN	Cytochrome P450 2E1 (CYP2E1)
DM93L4X	MT	DME
DM93L4X	MA	Metabolism
DM93L4X	RN	Metabolic stability and determination of cytochrome P450 isoenzymes' contribution to the metabolism of medetomidine in dog liver microsomes. Biomed Chromatogr. 2010 Aug;24(8):868-77.
DM93L4X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20020418

DMUQE2A	DI	DMUQE2A
DMUQE2A	DN	Dexmethylphenidate
DMUQE2A	MI	DEB30C5
DMUQE2A	MN	Carboxylesterase 1 (CES1)
DMUQE2A	MT	DME
DMUQE2A	MA	Metabolism
DMUQE2A	RN	Dexmethylphenidate hydrochloride in the treatment of attention deficit hyperactivity disorder. Neuropsychiatr Dis Treat. 2006 Dec;2(4):467-73.
DMUQE2A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19412495

DM8WBAH	DI	DM8WBAH
DM8WBAH	DN	Dexmethylphenidate hydrochloride
DM8WBAH	MI	TTVBI8W
DM8WBAH	MN	Dopamine transporter (DAT)
DM8WBAH	MT	DTT
DM8WBAH	MA	Inhibitor
DM8WBAH	RN	Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31.
DM8WBAH	RU	https://pubmed.ncbi.nlm.nih.gov/17489581

DMD7X1O	DI	DMD7X1O
DMD7X1O	DN	Dexrazoxane
DMD7X1O	MI	DE0EUXB
DMD7X1O	MN	Dihydropyrimidinase-related protein 1 (DRP1)
DMD7X1O	MT	DME
DMD7X1O	MA	Metabolism
DMD7X1O	RN	Metabolism of the cardioprotective drug dexrazoxane and one of its metabolites by isolated rat myocytes, hepatocytes, and blood. Drug Metab Dispos. 2005 Jun;33(6):719-25.
DMD7X1O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15764716

DMD7X1O	DI	DMD7X1O
DMD7X1O	DN	Dexrazoxane
DMD7X1O	MI	TT0IHXV
DMD7X1O	MN	DNA topoisomerase II (TOP2)
DMD7X1O	MT	DTT
DMD7X1O	MA	Modulator
DMD7X1O	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMD7X1O	RU	https://www.fda.gov/

DMD7X1O	DI	DMD7X1O
DMD7X1O	DN	Dexrazoxane
DMD7X1O	MI	TT4NVEM
DMD7X1O	MN	DNA topoisomerase II beta (TOP2B)
DMD7X1O	MT	DTT
DMD7X1O	MA	Inhibitor
DMD7X1O	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD7X1O	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMMIHVP	DI	DMMIHVP
DMMIHVP	DN	Dextroamphetamine
DMMIHVP	MI	DECB0K3
DMMIHVP	MN	Cytochrome P450 2D6 (CYP2D6)
DMMIHVP	MT	DME
DMMIHVP	MA	Metabolism
DMMIHVP	RN	Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives. Xenobiotica. 1999 Jul;29(7):719-32.
DMMIHVP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10456690

DMMIHVP	DI	DMMIHVP
DMMIHVP	DN	Dextroamphetamine
DMMIHVP	MI	TTIU98M
DMMIHVP	MN	Trace amine-associated receptor-1 (TAAR1)
DMMIHVP	MT	DTT
DMMIHVP	MA	Modulator
DMMIHVP	RN	Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes. Neuropharmacology. 2014 Oct;85:499-507.
DMMIHVP	RU	https://pubmed.ncbi.nlm.nih.gov/24950453

DMUDJZM	DI	DMUDJZM
DMUDJZM	DN	Dextromethorphan
DMUDJZM	MI	DEKP5HX
DMUDJZM	MN	Cholesterol 24-hydroxylase (CYP46A1)
DMUDJZM	MT	DME
DMUDJZM	MA	Metabolism
DMUDJZM	RN	Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain. Biochemistry. 2003 Dec 9;42(48):14284-92.
DMUDJZM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14640697

DMUDJZM	DI	DMUDJZM
DMUDJZM	DN	Dextromethorphan
DMUDJZM	MI	DE4OGUF
DMUDJZM	MN	Cytochrome P450 102A1 (cyp102)
DMUDJZM	MT	DME
DMUDJZM	MA	Metabolism
DMUDJZM	RN	The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities. Trends Biotechnol. 2007 Jul;25(7):289-98.
DMUDJZM	RU	https://pubmed.ncbi.nlm.nih.gov/17532492

DMUDJZM	DI	DMUDJZM
DMUDJZM	DN	Dextromethorphan
DMUDJZM	MI	DE6CQ0I
DMUDJZM	MN	Cytochrome P450 130A1 (cyp130)
DMUDJZM	MT	DME
DMUDJZM	MA	Metabolism
DMUDJZM	RN	Function, essentiality, and expression of cytochrome P450 enzymes and their cognate redox partners in Mycobacterium tuberculosis: are they drug targets? Appl Microbiol Biotechnol. 2019 May;103(9):3597-3614.
DMUDJZM	RU	https://pubmed.ncbi.nlm.nih.gov/30810776

DMUDJZM	DI	DMUDJZM
DMUDJZM	DN	Dextromethorphan
DMUDJZM	MI	DEPKLMQ
DMUDJZM	MN	Cytochrome P450 2B6 (CYP2B6)
DMUDJZM	MT	DME
DMUDJZM	MA	Metabolism
DMUDJZM	RN	Enzymes in addition to CYP3A4 and 3A5 mediate N-demethylation of dextromethorphan in human liver microsomes. Biopharm Drug Dispos. 1999 Oct;20(7):341-6.
DMUDJZM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10760842

DMUDJZM	DI	DMUDJZM
DMUDJZM	DN	Dextromethorphan
DMUDJZM	MI	DE5IED8
DMUDJZM	MN	Cytochrome P450 2C9 (CYP2C9)
DMUDJZM	MT	DME
DMUDJZM	MA	Metabolism
DMUDJZM	RN	Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. J Pharm Pharmacol. 1998 Sep;50(9):997-1004.
DMUDJZM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9811160

DMUDJZM	DI	DMUDJZM
DMUDJZM	DN	Dextromethorphan
DMUDJZM	MI	DECB0K3
DMUDJZM	MN	Cytochrome P450 2D6 (CYP2D6)
DMUDJZM	MT	DME
DMUDJZM	MA	Metabolism
DMUDJZM	RN	Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet. 2009;48(11):689-723.
DMUDJZM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19817501

DMUDJZM	DI	DMUDJZM
DMUDJZM	DN	Dextromethorphan
DMUDJZM	MI	DE4LYSA
DMUDJZM	MN	Cytochrome P450 3A4 (CYP3A4)
DMUDJZM	MT	DME
DMUDJZM	MA	Metabolism
DMUDJZM	RN	Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities? Drug Metab Dispos. 2001 Nov;29(11):1514-20.
DMUDJZM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11602530

DMUDJZM	DI	DMUDJZM
DMUDJZM	DN	Dextromethorphan
DMUDJZM	MI	DEIBDNY
DMUDJZM	MN	Cytochrome P450 3A5 (CYP3A5)
DMUDJZM	MT	DME
DMUDJZM	MA	Metabolism
DMUDJZM	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMUDJZM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMUDJZM	DI	DMUDJZM
DMUDJZM	DN	Dextromethorphan
DMUDJZM	MI	DERD86B
DMUDJZM	MN	Cytochrome P450 3A7 (CYP3A7)
DMUDJZM	MT	DME
DMUDJZM	MA	Metabolism
DMUDJZM	RN	Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol. 1994 Jul 5;48(1):173-82.
DMUDJZM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8043020

DMUDJZM	DI	DMUDJZM
DMUDJZM	DN	Dextromethorphan
DMUDJZM	MI	DEGTFWK
DMUDJZM	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMUDJZM	MT	DME
DMUDJZM	MA	Metabolism
DMUDJZM	RN	Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. J Pharm Pharmacol. 1998 Sep;50(9):997-1004.
DMUDJZM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9811160

DMUDJZM	DI	DMUDJZM
DMUDJZM	DN	Dextromethorphan
DMUDJZM	MI	TT5TPI6
DMUDJZM	MN	Opioid receptor sigma 1 (OPRS1)
DMUDJZM	MT	DTT
DMUDJZM	MA	Agonist
DMUDJZM	RN	Dextromethorphan/quinidine: AVP 923, dextromethorphan/cytochrome P450-2D6 inhibitor, quinidine/dextromethorphan. Drugs R D. 2005;6(3):174-7.
DMUDJZM	RU	https://pubmed.ncbi.nlm.nih.gov/15869321

DMEHCY5	DI	DMEHCY5
DMEHCY5	DN	Dextromethorphan polistirex
DMEHCY5	MI	TT5TPI6
DMEHCY5	MN	Opioid receptor sigma 1 (OPRS1)
DMEHCY5	MT	DTT
DMEHCY5	MA	Modulator
DMEHCY5	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMEHCY5	RU	https://www.fda.gov/

DMEHCY5	DI	DMEHCY5
DMEHCY5	DN	Dextromethorphan polistirex
DMEHCY5	MI	TT3ROYC
DMEHCY5	MN	Serotonin transporter (SERT)
DMEHCY5	MT	DTT
DMEHCY5	MA	Modulator
DMEHCY5	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMEHCY5	RU	https://www.fda.gov/

DM23HCX	DI	DM23HCX
DM23HCX	DN	Dextropropoxyphene
DM23HCX	MI	DECB0K3
DM23HCX	MN	Cytochrome P450 2D6 (CYP2D6)
DM23HCX	MT	DME
DM23HCX	MA	Metabolism
DM23HCX	RN	Different effects of inhibitors on the O- and N-demethylation of codeine in human liver microsomes. Eur J Clin Pharmacol. 1997;52(1):41-7.
DM23HCX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9143866

DM23HCX	DI	DM23HCX
DM23HCX	DN	Dextropropoxyphene
DM23HCX	MI	DE4LYSA
DM23HCX	MN	Cytochrome P450 3A4 (CYP3A4)
DM23HCX	MT	DME
DM23HCX	MA	Metabolism
DM23HCX	RN	CYP3A4 mediates dextropropoxyphene N-demethylation to nordextropropoxyphene: human in vitro and in vivo studies and lack of CYP2D6 involvement. Xenobiotica. 2004 Oct;34(10):875-87.
DM23HCX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15764408

DM23HCX	DI	DM23HCX
DM23HCX	DN	Dextropropoxyphene
DM23HCX	MI	TTN4QDT
DM23HCX	MN	Opioid receptor (OPR)
DM23HCX	MT	DTT
DM23HCX	MA	Agonist
DM23HCX	RN	Retrospective diagnosis of an adverse drug reaction in a breastfed neonate: liquid chromatography-tandem mass spectrometry quantification of dextropropoxyphene and norpropoxyphene in newborn and maternal hair. J Anal Toxicol. 2008 Nov-Dec;39(9):787-9.
DM23HCX	RU	https://pubmed.ncbi.nlm.nih.gov/19021937

DMBVEC7	DI	DMBVEC7
DMBVEC7	DN	Dextrothyroxine Sodium
DMBVEC7	MI	TTTSEPU
DMBVEC7	MN	Thyroid hormone receptor alpha (THRA)
DMBVEC7	MT	DTT
DMBVEC7	MA	Modulator
DMBVEC7	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMBVEC7	RU	https://www.fda.gov/

DMBVEC7	DI	DMBVEC7
DMBVEC7	DN	Dextrothyroxine Sodium
DMBVEC7	MI	TTGER3L
DMBVEC7	MN	Thyroid hormone receptor beta (THRB)
DMBVEC7	MT	DTT
DMBVEC7	MA	Modulator
DMBVEC7	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMBVEC7	RU	https://www.fda.gov/

DMJDB0Y	DI	DMJDB0Y
DMJDB0Y	DN	Dezocine
DMJDB0Y	MI	TTQW87Y
DMJDB0Y	MN	Opioid receptor kappa (OPRK1)
DMJDB0Y	MT	DTT
DMJDB0Y	MA	Antagonist
DMJDB0Y	RN	Pharmacological profiles of opioid ligands at kappa opioid receptors. BMC Pharmacol. 2006 Jan 25;6:3.
DMJDB0Y	RU	https://pubmed.ncbi.nlm.nih.gov/16433932

DMU3FGB	DI	DMU3FGB
DMU3FGB	DN	Dhaq diacetate
DMU3FGB	MI	TT0IHXV
DMU3FGB	MN	DNA topoisomerase II (TOP2)
DMU3FGB	MT	DTT
DMU3FGB	MA	Inhibitor
DMU3FGB	RN	The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone. Cancer Res. 2009 Feb 1;69(3):940-7.
DMU3FGB	RU	https://pubmed.ncbi.nlm.nih.gov/19176397

DM08E9O	DI	DM08E9O
DM08E9O	DN	Diazepam
DM08E9O	MI	DEJGDUW
DM08E9O	MN	Cytochrome P450 1A2 (CYP1A2)
DM08E9O	MT	DME
DM08E9O	MA	Metabolism
DM08E9O	RN	In vitro metabolism of zolmitriptan in rat cytochromes induced with beta-naphthoflavone and the interaction between six drugs and zolmitriptan. Chem Biol Interact. 2003 Dec 15;146(3):263-72.
DM08E9O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14642738

DM08E9O	DI	DM08E9O
DM08E9O	DN	Diazepam
DM08E9O	MI	DEPKLMQ
DM08E9O	MN	Cytochrome P450 2B6 (CYP2B6)
DM08E9O	MT	DME
DM08E9O	MA	Metabolism
DM08E9O	RN	Inhibitory monoclonal antibody to human cytochrome P450 2B6. Biochem Pharmacol. 1998 May 15;55(10):1633-40.
DM08E9O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9633999

DM08E9O	DI	DM08E9O
DM08E9O	DN	Diazepam
DM08E9O	MI	DEZMWRE
DM08E9O	MN	Cytochrome P450 2C18 (CYP2C18)
DM08E9O	MT	DME
DM08E9O	MA	Metabolism
DM08E9O	RN	Targeted antipeptide antibodies to cytochrome P450 2C18 based on epitope mapping of an inhibitory monoclonal antibody to P450 2C51. Arch Biochem Biophys. 1997 Feb 15;338(2):157-64.
DM08E9O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9028867

DM08E9O	DI	DM08E9O
DM08E9O	DN	Diazepam
DM08E9O	MI	DES5XRU
DM08E9O	MN	Cytochrome P450 2C8 (CYP2C8)
DM08E9O	MT	DME
DM08E9O	MA	Metabolism
DM08E9O	RN	Use of inhibitory monoclonal antibodies to assess the contribution of cytochromes P450 to human drug metabolism. Eur J Pharmacol. 2000 Apr 14;394(2-3):199-209.
DM08E9O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10771285

DM08E9O	DI	DM08E9O
DM08E9O	DN	Diazepam
DM08E9O	MI	DE5IED8
DM08E9O	MN	Cytochrome P450 2C9 (CYP2C9)
DM08E9O	MT	DME
DM08E9O	MA	Metabolism
DM08E9O	RN	Phenytoin-diazepam interaction. Ann Pharmacother. 2003 May;37(5):659-63.
DM08E9O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12708941

DM08E9O	DI	DM08E9O
DM08E9O	DN	Diazepam
DM08E9O	MI	DE4LYSA
DM08E9O	MN	Cytochrome P450 3A4 (CYP3A4)
DM08E9O	MT	DME
DM08E9O	MA	Metabolism
DM08E9O	RN	Comparative study of the metabolism of drug substrates by human cytochrome P450 3A4 expressed in bacterial, yeast and human lymphoblastoid cells. Xenobiotica. 2002 Nov;32(11):937-47.
DM08E9O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12487724

DM08E9O	DI	DM08E9O
DM08E9O	DN	Diazepam
DM08E9O	MI	DEIBDNY
DM08E9O	MN	Cytochrome P450 3A5 (CYP3A5)
DM08E9O	MT	DME
DM08E9O	MA	Metabolism
DM08E9O	RN	Eight inhibitory monoclonal antibodies define the role of individual P-450s in human liver microsomal diazepam, 7-ethoxycoumarin, and imipramine metabolism. Drug Metab Dispos. 1999 Jan;27(1):102-9.
DM08E9O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9884317

DM08E9O	DI	DM08E9O
DM08E9O	DN	Diazepam
DM08E9O	MI	DERD86B
DM08E9O	MN	Cytochrome P450 3A7 (CYP3A7)
DM08E9O	MT	DME
DM08E9O	MA	Metabolism
DM08E9O	RN	Drug Interactions Flockhart Table
DM08E9O	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM08E9O	DI	DM08E9O
DM08E9O	DN	Diazepam
DM08E9O	MI	DEGTFWK
DM08E9O	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM08E9O	MT	DME
DM08E9O	MA	Metabolism
DM08E9O	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM08E9O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM08E9O	DI	DM08E9O
DM08E9O	DN	Diazepam
DM08E9O	MI	DTUGYRD
DM08E9O	MN	P-glycoprotein 1 (ABCB1)
DM08E9O	MT	DTP
DM08E9O	MA	Substrate
DM08E9O	RN	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
DM08E9O	RU	http://www.ncbi.nlm.nih.gov/pubmed/11785684

DM08E9O	DI	DM08E9O
DM08E9O	DN	Diazepam
DM08E9O	MI	DE073H6
DM08E9O	MN	Prostaglandin G/H synthase 1 (COX-1)
DM08E9O	MT	DME
DM08E9O	MA	Metabolism
DM08E9O	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM08E9O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM08E9O	DI	DM08E9O
DM08E9O	DN	Diazepam
DM08E9O	MI	TTPTXIN
DM08E9O	MN	Translocator protein (TSPO)
DM08E9O	MT	DTT
DM08E9O	MA	Agonist
DM08E9O	RN	Translocator protein (18 kDa) mediates the pro-growth effects of diazepam on Ehrlich tumor cells in vivo. Eur J Pharmacol. 2010 Jan 25;626(2-3):131-8.
DM08E9O	RU	https://pubmed.ncbi.nlm.nih.gov/19782064

DML1538	DI	DML1538
DML1538	DN	Diazoxide
DML1538	MI	TT1VOHK
DML1538	MN	Potassium channel unspecific (KC)
DML1538	MT	DTT
DML1538	MA	Modulator
DML1538	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DML1538	RU	https://www.fda.gov/

DMF9G7L	DI	DMF9G7L
DMF9G7L	DN	Dibucaine
DMF9G7L	MI	TTZOVE0
DMF9G7L	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DMF9G7L	MT	DTT
DMF9G7L	MA	Blocker
DMF9G7L	RN	Halothane attenuates the cerebroprotective action of several Na+ and Ca2+ channel blockers via reversal of their ion channel blockade. Eur J Pharmacol. 2002 Oct 4;452(2):175-81.
DMF9G7L	RU	https://pubmed.ncbi.nlm.nih.gov/12354567

DMH7IDQ	DI	DMH7IDQ
DMH7IDQ	DN	Dichlorphenamide
DMH7IDQ	MI	TTHQPL7
DMH7IDQ	MN	Carbonic anhydrase I (CA-I)
DMH7IDQ	MT	DTT
DMH7IDQ	MA	Modulator
DMH7IDQ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMH7IDQ	RU	https://www.fda.gov/

DMH7IDQ	DI	DMH7IDQ
DMH7IDQ	DN	Dichlorphenamide
DMH7IDQ	MI	TTANPDJ
DMH7IDQ	MN	Carbonic anhydrase II (CA-II)
DMH7IDQ	MT	DTT
DMH7IDQ	MA	Inhibitor
DMH7IDQ	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMH7IDQ	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMPIHLS	DI	DMPIHLS
DMPIHLS	DN	Diclofenac
DMPIHLS	MI	DTI7UX6
DMPIHLS	MN	Breast cancer resistance protein (ABCG2)
DMPIHLS	MT	DTP
DMPIHLS	MA	Substrate
DMPIHLS	RN	Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone. Drug Metab Dispos. 2009 Jan;37(1):129-36.
DMPIHLS	RU	http://www.ncbi.nlm.nih.gov/pubmed/18845662

DMPIHLS	DI	DMPIHLS
DMPIHLS	DN	Diclofenac
DMPIHLS	MI	DEKP5HX
DMPIHLS	MN	Cholesterol 24-hydroxylase (CYP46A1)
DMPIHLS	MT	DME
DMPIHLS	MA	Metabolism
DMPIHLS	RN	Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain. Biochemistry. 2003 Dec 9;42(48):14284-92.
DMPIHLS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14640697

DMPIHLS	DI	DMPIHLS
DMPIHLS	DN	Diclofenac
DMPIHLS	MI	DE4OGUF
DMPIHLS	MN	Cytochrome P450 102A1 (cyp102)
DMPIHLS	MT	DME
DMPIHLS	MA	Metabolism
DMPIHLS	RN	Both reactivity and accessibility are important in cytochrome P450 metabolism: a combined DFT and MD study of fenamic acids in BM3 mutants. J Chem Inf Model. 2019 Feb 25;59(2):743-753.
DMPIHLS	RU	https://pubmed.ncbi.nlm.nih.gov/30758202

DMPIHLS	DI	DMPIHLS
DMPIHLS	DN	Diclofenac
DMPIHLS	MI	DECV2ME
DMPIHLS	MN	Cytochrome P450 105D7 (cyp105)
DMPIHLS	MT	DME
DMPIHLS	MA	Metabolism
DMPIHLS	RN	The metagenome of Caracolus marginella gut microbiome using culture independent approaches and shotgun sequencing. Data Brief. 2017 Nov 22;16:501-505.
DMPIHLS	RU	https://pubmed.ncbi.nlm.nih.gov/29270447

DMPIHLS	DI	DMPIHLS
DMPIHLS	DN	Diclofenac
DMPIHLS	MI	DE6OQ3W
DMPIHLS	MN	Cytochrome P450 1A1 (CYP1A1)
DMPIHLS	MT	DME
DMPIHLS	MA	Metabolism
DMPIHLS	RN	Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
DMPIHLS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10572000

DMPIHLS	DI	DMPIHLS
DMPIHLS	DN	Diclofenac
DMPIHLS	MI	DEJGDUW
DMPIHLS	MN	Cytochrome P450 1A2 (CYP1A2)
DMPIHLS	MT	DME
DMPIHLS	MA	Metabolism
DMPIHLS	RN	Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
DMPIHLS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27034690

DMPIHLS	DI	DMPIHLS
DMPIHLS	DN	Diclofenac
DMPIHLS	MI	DEPKLMQ
DMPIHLS	MN	Cytochrome P450 2B6 (CYP2B6)
DMPIHLS	MT	DME
DMPIHLS	MA	Metabolism
DMPIHLS	RN	Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
DMPIHLS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10449188

DMPIHLS	DI	DMPIHLS
DMPIHLS	DN	Diclofenac
DMPIHLS	MI	DEZMWRE
DMPIHLS	MN	Cytochrome P450 2C18 (CYP2C18)
DMPIHLS	MT	DME
DMPIHLS	MA	Metabolism
DMPIHLS	RN	Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
DMPIHLS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10572000

DMPIHLS	DI	DMPIHLS
DMPIHLS	DN	Diclofenac
DMPIHLS	MI	DES5XRU
DMPIHLS	MN	Cytochrome P450 2C8 (CYP2C8)
DMPIHLS	MT	DME
DMPIHLS	MA	Metabolism
DMPIHLS	RN	Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
DMPIHLS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15581350

DMPIHLS	DI	DMPIHLS
DMPIHLS	DN	Diclofenac
DMPIHLS	MI	DE5IED8
DMPIHLS	MN	Cytochrome P450 2C9 (CYP2C9)
DMPIHLS	MT	DME
DMPIHLS	MA	Metabolism
DMPIHLS	RN	New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
DMPIHLS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20167001

DMPIHLS	DI	DMPIHLS
DMPIHLS	DN	Diclofenac
DMPIHLS	MI	DE4LYSA
DMPIHLS	MN	Cytochrome P450 3A4 (CYP3A4)
DMPIHLS	MT	DME
DMPIHLS	MA	Metabolism
DMPIHLS	RN	Cytochrome P450 3A4-mediated interaction of diclofenac and quinidine. Drug Metab Dispos. 2000 Sep;28(9):1043-50.
DMPIHLS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10950847

DMPIHLS	DI	DMPIHLS
DMPIHLS	DN	Diclofenac
DMPIHLS	MI	DEGTFWK
DMPIHLS	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMPIHLS	MT	DME
DMPIHLS	MA	Metabolism
DMPIHLS	RN	Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
DMPIHLS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10572000

DMPIHLS	DI	DMPIHLS
DMPIHLS	DN	Diclofenac
DMPIHLS	MI	DT9C1TS
DMPIHLS	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMPIHLS	MT	DTP
DMPIHLS	MA	Substrate
DMPIHLS	RN	Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport. Drug Metab Dispos. 2011 Jun;39(6):1047-53.
DMPIHLS	RU	http://www.ncbi.nlm.nih.gov/pubmed/21389119

DMPIHLS	DI	DMPIHLS
DMPIHLS	DN	Diclofenac
DMPIHLS	MI	TTK0943
DMPIHLS	MN	Prostaglandin G/H synthase (COX)
DMPIHLS	MT	DTT
DMPIHLS	MA	Modulator
DMPIHLS	RN	Diclofenac and NS-398, a selective cyclooxygenase-2 inhibitor, decrease agonist-induced contractions of the pig isolated ureter. Urol Res. 2000 Dec;28(6):376-82.
DMPIHLS	RU	https://pubmed.ncbi.nlm.nih.gov/11221916

DMPIHLS	DI	DMPIHLS
DMPIHLS	DN	Diclofenac
DMPIHLS	MI	DEF2WXN
DMPIHLS	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMPIHLS	MT	DME
DMPIHLS	MA	Metabolism
DMPIHLS	RN	Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35.
DMPIHLS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15843492

DMPIHLS	DI	DMPIHLS
DMPIHLS	DN	Diclofenac
DMPIHLS	MI	DE85D2P
DMPIHLS	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMPIHLS	MT	DME
DMPIHLS	MA	Metabolism
DMPIHLS	RN	Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35.
DMPIHLS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15843492

DMPIHLS	DI	DMPIHLS
DMPIHLS	DN	Diclofenac
DMPIHLS	MI	DEB3CV1
DMPIHLS	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMPIHLS	MT	DME
DMPIHLS	MA	Metabolism
DMPIHLS	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMPIHLS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM8EU0Z	DI	DM8EU0Z
DM8EU0Z	DN	Dicloxacillin
DM8EU0Z	MI	TTJP4SM
DM8EU0Z	MN	Bacterial Penicillin binding protein (Bact PBP)
DM8EU0Z	MT	DTT
DM8EU0Z	MA	Binder
DM8EU0Z	RN	Mechanisms of resistance to beta-lactam antibiotics in Staphylococcus aureus. Scand J Infect Dis Suppl. 1984;42:64-71.
DM8EU0Z	RU	https://pubmed.ncbi.nlm.nih.gov/6335600

DM8EU0Z	DI	DM8EU0Z
DM8EU0Z	DN	Dicloxacillin
DM8EU0Z	MI	DT9G7XN
DM8EU0Z	MN	Peptide transporter 1 (SLC15A1)
DM8EU0Z	MT	DTP
DM8EU0Z	MA	Substrate
DM8EU0Z	RN	Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60.
DM8EU0Z	RU	http://www.ncbi.nlm.nih.gov/pubmed/16597710

DM8EU0Z	DI	DM8EU0Z
DM8EU0Z	DN	Dicloxacillin
DM8EU0Z	MI	DT8QKNP
DM8EU0Z	MN	Peptide transporter 2 (SLC15A2)
DM8EU0Z	MT	DTP
DM8EU0Z	MA	Substrate
DM8EU0Z	RN	Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60.
DM8EU0Z	RU	http://www.ncbi.nlm.nih.gov/pubmed/16597710

DM8EU0Z	DI	DM8EU0Z
DM8EU0Z	DN	Dicloxacillin
DM8EU0Z	MI	DTUGYRD
DM8EU0Z	MN	P-glycoprotein 1 (ABCB1)
DM8EU0Z	MT	DTP
DM8EU0Z	MA	Substrate
DM8EU0Z	RN	Can the enhanced renal clearance of antibiotics in cystic fibrosis patients be explained by P-glycoprotein transport? Pharm Res. 2002 Apr;19(4):457-62.
DM8EU0Z	RU	http://www.ncbi.nlm.nih.gov/pubmed/12033380

DMFQCB1	DI	DMFQCB1
DMFQCB1	DN	Dicumarol
DMFQCB1	MI	DE5IED8
DMFQCB1	MN	Cytochrome P450 2C9 (CYP2C9)
DMFQCB1	MT	DME
DMFQCB1	MA	Metabolism
DMFQCB1	RN	Pharmacogenetics aspects of oral anticoagulants therapy. J Med Life. 2015 Apr-Jun;8(2):171-5.
DMFQCB1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25866574

DMFQCB1	DI	DMFQCB1
DMFQCB1	DN	Dicumarol
DMFQCB1	MI	TTEUC8H
DMFQCB1	MN	Vitamin K epoxide reductase complex 1 (VKORC1)
DMFQCB1	MT	DTT
DMFQCB1	MA	Inhibitor
DMFQCB1	RN	Vitamin K antagonism of coumarin intoxication in the rat. Thromb Haemost. 1986 Apr 30;55(2):235-9.
DMFQCB1	RU	https://pubmed.ncbi.nlm.nih.gov/2424118

DMZSDGX	DI	DMZSDGX
DMZSDGX	DN	Dicyclomine
DMZSDGX	MI	TTZ9SOR
DMZSDGX	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMZSDGX	MT	DTT
DMZSDGX	MA	Antagonist
DMZSDGX	RN	[Characterization of muscarinic receptors in undifferentiated thyroid cells in Fisher rats]. Endocrinol Nutr. 2009 Mar;56(3):106-11.
DMZSDGX	RU	https://pubmed.ncbi.nlm.nih.gov/19627722

DMI2QPE	DI	DMI2QPE
DMI2QPE	DN	Didanosine
DMI2QPE	MI	DT82KPY
DMI2QPE	MN	Concentrative nucleoside transporter 2 (SLC28A2)
DMI2QPE	MT	DTP
DMI2QPE	MA	Substrate
DMI2QPE	RN	Clinical Nephrotoxins: Renal Injury from Drugs and Chemicals.
DMI2QPE	RU	https://books.google.co.jp/books?id=cYBGAAAAQBAJ&pg=PA59&lpg=PA59&dq=SLC15A1%09Didanosine&source=bl&ots=CeeUnMnW6Z&sig=ACfU3U10UhN6m18-AuKuLOfFeDKtUo5VYw&hl=zh-CN&sa=X&ved=2ahUKEwjh_IyK9KHiAhVIzbwKHZKiDoMQ6AEwAXoECAgQAQ#v=onepage&q=SLC15A1%09Didanosine&f=false

DMI2QPE	DI	DMI2QPE
DMI2QPE	DN	Didanosine
DMI2QPE	MI	TT84ETX
DMI2QPE	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMI2QPE	MT	DTT
DMI2QPE	MA	Inhibitor
DMI2QPE	RN	The effect of individual antiretroviral drugs on body composition in HIV-infected persons initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):298-304.
DMI2QPE	RU	https://pubmed.ncbi.nlm.nih.gov/19412117

DMBSXI0	DI	DMBSXI0
DMBSXI0	DN	Dienestrol
DMBSXI0	MI	TTZAYWL
DMBSXI0	MN	Estrogen receptor (ESR)
DMBSXI0	MT	DTT
DMBSXI0	MA	Agonist
DMBSXI0	RN	Potential use of an estrogen-glucocorticoid receptor chimera as a drug screen for tissue selective estrogenic activity. Bone. 2009 Jan;44(1):102-12.
DMBSXI0	RU	https://pubmed.ncbi.nlm.nih.gov/18976723

DM1TJ8F	DI	DM1TJ8F
DM1TJ8F	DN	Diethylcarbamazine
DM1TJ8F	MI	TT2J34L
DM1TJ8F	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM1TJ8F	MT	DTT
DM1TJ8F	MA	Inhibitor
DM1TJ8F	RN	Inhibition of leukotriene formation by diethylcarbamazine modifies the acid-base balance in the rabbits with blast injuries of the lungs. Vojnosanit Pregl. 1999 May-Jun;56(3):243-7.
DM1TJ8F	RU	https://pubmed.ncbi.nlm.nih.gov/10518442

DMN3UXQ	DI	DMN3UXQ
DMN3UXQ	DN	Diethylstilbestrol
DMN3UXQ	MI	DES5XRU
DMN3UXQ	MN	Cytochrome P450 2C8 (CYP2C8)
DMN3UXQ	MT	DME
DMN3UXQ	MA	Metabolism
DMN3UXQ	RN	Reversible inhibition of four important human liver cytochrome P450 enzymes by diethylstilbestrol. Pharmazie. 2011 Mar;66(3):216-21.
DMN3UXQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21553654

DMN3UXQ	DI	DMN3UXQ
DMN3UXQ	DN	Diethylstilbestrol
DMN3UXQ	MI	DE4LYSA
DMN3UXQ	MN	Cytochrome P450 3A4 (CYP3A4)
DMN3UXQ	MT	DME
DMN3UXQ	MA	Metabolism
DMN3UXQ	RN	Comparative analysis of human CYP3A4 and rat CYP3A1 induction and relevant gene expression by bisphenol A and diethylstilbestrol: implications for toxicity testing paradigms. Reprod Toxicol. 2013 Jun;37:24-30.
DMN3UXQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23384967

DMN3UXQ	DI	DMN3UXQ
DMN3UXQ	DN	Diethylstilbestrol
DMN3UXQ	MI	TTZAYWL
DMN3UXQ	MN	Estrogen receptor (ESR)
DMN3UXQ	MT	DTT
DMN3UXQ	MA	Agonist
DMN3UXQ	RN	Effects of diethylstilbestrol on programmed oocyte death and induction of polyovular follicles in neonatal mouse ovaries. Biol Reprod. 2009 Nov;81(5):1002-9.
DMN3UXQ	RU	https://pubmed.ncbi.nlm.nih.gov/19553606

DMN3UXQ	DI	DMN3UXQ
DMN3UXQ	DN	Diethylstilbestrol
DMN3UXQ	MI	DTUGYRD
DMN3UXQ	MN	P-glycoprotein 1 (ABCB1)
DMN3UXQ	MT	DTP
DMN3UXQ	MA	Substrate
DMN3UXQ	RN	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
DMN3UXQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/7914405

DMI9PRJ	DI	DMI9PRJ
DMI9PRJ	DN	Diflorasone
DMI9PRJ	MI	TT9V5JH
DMI9PRJ	MN	Phospholipase A2 (PLA2G1B)
DMI9PRJ	MT	DTT
DMI9PRJ	MA	Inhibitor
DMI9PRJ	RN	Structures from powders: diflorasone diacetate. Steroids. 2009 Jan;74(1):102-11.
DMI9PRJ	RU	https://pubmed.ncbi.nlm.nih.gov/19013475

DM7EN8I	DI	DM7EN8I
DM7EN8I	DN	Diflunisal
DM7EN8I	MI	TTVKILB
DM7EN8I	MN	Prostaglandin G/H synthase 2 (COX-2)
DM7EN8I	MT	DTT
DM7EN8I	MA	Inhibitor
DM7EN8I	RN	Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice. J Am Dent Assoc. 2001 Apr;132(4):451-6.
DM7EN8I	RU	https://pubmed.ncbi.nlm.nih.gov/11315375

DM7EN8I	DI	DM7EN8I
DM7EN8I	DN	Diflunisal
DM7EN8I	MI	DEYGVN4
DM7EN8I	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM7EN8I	MT	DME
DM7EN8I	MA	Metabolism
DM7EN8I	RN	Differential effects of phenobarbital on ester and ether glucuronidation of diflunisal in rats. J Pharmacol Exp Ther. 1987 Sep;242(3):1013-8.
DM7EN8I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=3656106

DMMFVB3	DI	DMMFVB3
DMMFVB3	DN	Difluprednate
DMMFVB3	MI	DE4LYSA
DMMFVB3	MN	Cytochrome P450 3A4 (CYP3A4)
DMMFVB3	MT	DME
DMMFVB3	MA	Metabolism
DMMFVB3	RN	Prevalence of non-cytochrome P450-mediated metabolism in food and drug administration-approved oral and intravenous drugs: 2006-2015. Drug Metab Dispos. 2016 Aug;44(8):1246-52.
DMMFVB3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27084892

DMMFVB3	DI	DMMFVB3
DMMFVB3	DN	Difluprednate
DMMFVB3	MI	TTUCK4B
DMMFVB3	MN	Phospholipase A2 inhibitory protein (PA2IP)
DMMFVB3	MT	DTT
DMMFVB3	MA	Agonist
DMMFVB3	RN	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
DMMFVB3	RU	https://pubmed.ncbi.nlm.nih.gov/19180096

DMWVIGP	DI	DMWVIGP
DMWVIGP	DN	Digitoxin
DMWVIGP	MI	DE4LYSA
DMWVIGP	MN	Cytochrome P450 3A4 (CYP3A4)
DMWVIGP	MT	DME
DMWVIGP	MA	Metabolism
DMWVIGP	RN	Species differences in the toxicity and cytochrome P450 IIIA-dependent metabolism of digitoxin. Mol Pharmacol. 1991 Nov;40(5):859-67.
DMWVIGP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1944247

DMWVIGP	DI	DMWVIGP
DMWVIGP	DN	Digitoxin
DMWVIGP	MI	DTUGYRD
DMWVIGP	MN	P-glycoprotein 1 (ABCB1)
DMWVIGP	MT	DTP
DMWVIGP	MA	Substrate
DMWVIGP	RN	The association of ABCB1 polymorphisms and elevated serum digitoxin concentrations in geriatric patients. Eur J Clin Pharmacol. 2008 Apr;64(4):367-72.
DMWVIGP	RU	http://www.ncbi.nlm.nih.gov/pubmed/18080812

DMWVIGP	DI	DMWVIGP
DMWVIGP	DN	Digitoxin
DMWVIGP	MI	TTQ38E9
DMWVIGP	MN	Sodium/potassium-transporting ATPase (SPT ATPase)
DMWVIGP	MT	DTT
DMWVIGP	MA	Inhibitor
DMWVIGP	RN	Treatment of congestive heart failure--current status of use of digitoxin. Eur J Clin Invest. 2001;31 Suppl 2:10-7.
DMWVIGP	RU	https://pubmed.ncbi.nlm.nih.gov/11525233

DMWVIGP	DI	DMWVIGP
DMWVIGP	DN	Digitoxin
DMWVIGP	MI	DEYWLRK
DMWVIGP	MN	Sulfotransferase 1A1 (SULT1A1)
DMWVIGP	MT	DME
DMWVIGP	MA	Metabolism
DMWVIGP	RN	Hydroxysteroid sulfotransferase and a specific UDP-glucuronosyltransferase are involved in the metabolism of digitoxin in man. Naunyn Schmiedebergs Arch Pharmacol. 1992 Aug;346(2):226-33.
DMWVIGP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1448185

DMWVIGP	DI	DMWVIGP
DMWVIGP	DN	Digitoxin
DMWVIGP	MI	DEYGVN4
DMWVIGP	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMWVIGP	MT	DME
DMWVIGP	MA	Metabolism
DMWVIGP	RN	Use of a human liver microsome bank in drug glucuronidation studies. Toxicol In Vitro. 1991;5(5-6):559-62.
DMWVIGP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20732077

DMQCTIH	DI	DMQCTIH
DMQCTIH	DN	Digoxin
DMQCTIH	MI	DE84PFW
DMQCTIH	MN	Cardiac glycoside reductase 1 (cgr1)
DMQCTIH	MT	DME
DMQCTIH	MA	Metabolism
DMQCTIH	RN	Mechanistic insight into digoxin inactivation by Eggerthella lenta augments our understanding of its pharmacokinetics. Gut Microbes. 2014 Mar-Apr;5(2):233-8.
DMQCTIH	RU	https://pubmed.ncbi.nlm.nih.gov/24637603

DMQCTIH	DI	DMQCTIH
DMQCTIH	DN	Digoxin
DMQCTIH	MI	DE9VSLW
DMQCTIH	MN	Cardiac glycoside reductase 2 (cgr2)
DMQCTIH	MT	DME
DMQCTIH	MA	Metabolism
DMQCTIH	RN	Mechanistic insight into digoxin inactivation by Eggerthella lenta augments our understanding of its pharmacokinetics. Gut Microbes. 2014 Mar-Apr;5(2):233-8.
DMQCTIH	RU	https://pubmed.ncbi.nlm.nih.gov/24637603

DMQCTIH	DI	DMQCTIH
DMQCTIH	DN	Digoxin
DMQCTIH	MI	DE4LYSA
DMQCTIH	MN	Cytochrome P450 3A4 (CYP3A4)
DMQCTIH	MT	DME
DMQCTIH	MA	Metabolism
DMQCTIH	RN	Omeprazole-associated digoxin toxicity. South Med J. 2007 Apr;100(4):400-2.
DMQCTIH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17458401

DMQCTIH	DI	DMQCTIH
DMQCTIH	DN	Digoxin
DMQCTIH	MI	DTZRMK5
DMQCTIH	MN	Multidrug resistance protein 3 (ABCB4)
DMQCTIH	MT	DTP
DMQCTIH	MA	Substrate
DMQCTIH	RN	MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem. 2000 Aug 4;275(31):23530-9.
DMQCTIH	RU	http://www.ncbi.nlm.nih.gov/pubmed/10918072

DMQCTIH	DI	DMQCTIH
DMQCTIH	DN	Digoxin
DMQCTIH	MI	TTACFNR
DMQCTIH	MN	Organic anion transporter M1 (SLCO4C1)
DMQCTIH	MT	DTT
DMQCTIH	MA	Modulator
DMQCTIH	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1227).
DMQCTIH	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1227

DMQCTIH	DI	DMQCTIH
DMQCTIH	DN	Digoxin
DMQCTIH	MI	DT9C1TS
DMQCTIH	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMQCTIH	MT	DTP
DMQCTIH	MA	Substrate
DMQCTIH	RN	Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
DMQCTIH	RU	http://www.ncbi.nlm.nih.gov/pubmed/11159893

DMQCTIH	DI	DMQCTIH
DMQCTIH	DN	Digoxin
DMQCTIH	MI	DTPFTEQ
DMQCTIH	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DMQCTIH	MT	DTP
DMQCTIH	MA	Substrate
DMQCTIH	RN	Drug Interactions in Infectious Diseases.
DMQCTIH	RU	http://www.springer.com/medicine/internal/book/978-1-61779-212-0

DMQCTIH	DI	DMQCTIH
DMQCTIH	DN	Digoxin
DMQCTIH	MI	DTY0QMU
DMQCTIH	MN	Organic anion transporting polypeptide 4C1 (SLCO4C1)
DMQCTIH	MT	DTP
DMQCTIH	MA	Substrate
DMQCTIH	RN	Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3569-74.
DMQCTIH	RU	http://www.ncbi.nlm.nih.gov/pubmed/14993604

DMQCTIH	DI	DMQCTIH
DMQCTIH	DN	Digoxin
DMQCTIH	MI	DTMEQ32
DMQCTIH	MN	Organic solute transporter subunit alpha (SLC51A)
DMQCTIH	MT	DTP
DMQCTIH	MA	Substrate
DMQCTIH	RN	Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem. 2003 Jul 25;278(30):27473-82.
DMQCTIH	RU	http://www.ncbi.nlm.nih.gov/pubmed/12719432

DMQCTIH	DI	DMQCTIH
DMQCTIH	DN	Digoxin
DMQCTIH	MI	DT1V9AJ
DMQCTIH	MN	Organic solute transporter subunit beta (SLC51B)
DMQCTIH	MT	DTP
DMQCTIH	MA	Substrate
DMQCTIH	RN	Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem. 2003 Jul 25;278(30):27473-82.
DMQCTIH	RU	http://www.ncbi.nlm.nih.gov/pubmed/12719432

DMQCTIH	DI	DMQCTIH
DMQCTIH	DN	Digoxin
DMQCTIH	MI	DTUGYRD
DMQCTIH	MN	P-glycoprotein 1 (ABCB1)
DMQCTIH	MT	DTP
DMQCTIH	MA	Substrate
DMQCTIH	RN	MDR1 function is sensitive to the phosphorylation state of myosin regulatory light chain. Biochem Biophys Res Commun. 2010 Jul 16;398(1):7-12.
DMQCTIH	RU	http://www.ncbi.nlm.nih.gov/pubmed/20510202

DMQCTIH	DI	DMQCTIH
DMQCTIH	DN	Digoxin
DMQCTIH	MI	TTQ38E9
DMQCTIH	MN	Sodium/potassium-transporting ATPase (SPT ATPase)
DMQCTIH	MT	DTT
DMQCTIH	MA	Inhibitor
DMQCTIH	RN	Fab antibody fragments: some applications in clinical toxicology. Drug Saf. 2004;27(14):1115-33.
DMQCTIH	RU	https://pubmed.ncbi.nlm.nih.gov/15554746

DMZIXU9	DI	DMZIXU9
DMZIXU9	DN	Dihydralazine
DMZIXU9	MI	DEJGDUW
DMZIXU9	MN	Cytochrome P450 1A2 (CYP1A2)
DMZIXU9	MT	DME
DMZIXU9	MA	Metabolism
DMZIXU9	RN	Mechanism-based inactivation of cytochrome P450s 1A2 and 3A4 by dihydralazine in human liver microsomes. Chem Res Toxicol. 1999 Oct;12(10):1028-32.
DMZIXU9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10525281

DMZIXU9	DI	DMZIXU9
DMZIXU9	DN	Dihydralazine
DMZIXU9	MI	DE4LYSA
DMZIXU9	MN	Cytochrome P450 3A4 (CYP3A4)
DMZIXU9	MT	DME
DMZIXU9	MA	Metabolism
DMZIXU9	RN	Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet. 2005;44(3):279-304.
DMZIXU9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15762770

DMZIXU9	DI	DMZIXU9
DMZIXU9	DN	Dihydralazine
DMZIXU9	MI	DEZV4AP
DMZIXU9	MN	RNA cytidine acetyltransferase (hALP)
DMZIXU9	MT	DME
DMZIXU9	MA	Metabolism
DMZIXU9	RN	The influence of the acetylator phenotype for the clinical use of dihydralazine. Int J Clin Pharmacol Ther Toxicol. 1985 Apr;23 Suppl 1:S74-8.
DMZIXU9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=3842694

DMBXVMZ	DI	DMBXVMZ
DMBXVMZ	DN	Dihydroartemisinin
DMBXVMZ	MI	TTZVSJ2
DMBXVMZ	MN	Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A)
DMBXVMZ	MT	DTT
DMBXVMZ	MA	Inhibitor
DMBXVMZ	RN	The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
DMBXVMZ	RU	https://pubmed.ncbi.nlm.nih.gov/18220771

DMBXVMZ	DI	DMBXVMZ
DMBXVMZ	DN	Dihydroartemisinin
DMBXVMZ	MI	DE85D2P
DMBXVMZ	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMBXVMZ	MT	DME
DMBXVMZ	MA	Metabolism
DMBXVMZ	RN	Eurartesim - European Medicines Agency
DMBXVMZ	RU	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001199/WC500118116.pdf

DMBXVMZ	DI	DMBXVMZ
DMBXVMZ	DN	Dihydroartemisinin
DMBXVMZ	MI	DEB3CV1
DMBXVMZ	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMBXVMZ	MT	DME
DMBXVMZ	MA	Metabolism
DMBXVMZ	RN	Eurartesim - European Medicines Agency
DMBXVMZ	RU	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001199/WC500118116.pdf

DM5SQ1G	DI	DM5SQ1G
DM5SQ1G	DN	Dihydroergocristine
DM5SQ1G	MI	TT2NUT5
DM5SQ1G	MN	Adrenergic receptor alpha-2C (ADRA2C)
DM5SQ1G	MT	DTT
DM5SQ1G	MA	Modulator
DM5SQ1G	RN	Effect of dihydroergocristine on blood pressure and activity at peripheral alpha-adrenoceptors in pithed rats. Eur J Pharmacol. 1984 Jan 13;97(1-2):21-7.
DM5SQ1G	RU	https://pubmed.ncbi.nlm.nih.gov/6321209

DM5SQ1G	DI	DM5SQ1G
DM5SQ1G	DN	Dihydroergocristine
DM5SQ1G	MI	DTUGYRD
DM5SQ1G	MN	P-glycoprotein 1 (ABCB1)
DM5SQ1G	MT	DTP
DM5SQ1G	MA	Substrate
DM5SQ1G	RN	Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther. 2002 Oct;303(1):323-32.
DM5SQ1G	RU	https://doi.org/10.1124/jpet.102.037549

DM5IKUF	DI	DM5IKUF
DM5IKUF	DN	Dihydroergotamine
DM5IKUF	MI	DE4LYSA
DM5IKUF	MN	Cytochrome P450 3A4 (CYP3A4)
DM5IKUF	MT	DME
DM5IKUF	MA	Metabolism
DM5IKUF	RN	CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol. 2004 Mar;57(3):287-97.
DM5IKUF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14998425

DM5IKUF	DI	DM5IKUF
DM5IKUF	DN	Dihydroergotamine
DM5IKUF	MI	TTEX248
DM5IKUF	MN	Dopamine D2 receptor (D2R)
DM5IKUF	MT	DTT
DM5IKUF	MA	Agonist
DM5IKUF	RN	Current and prospective pharmacological targets in relation to antimigraine action. Naunyn Schmiedebergs Arch Pharmacol. 2008 Oct;378(4):371-94.
DM5IKUF	RU	https://pubmed.ncbi.nlm.nih.gov/18626630

DM5D6WZ	DI	DM5D6WZ
DM5D6WZ	DN	Dihydroergotoxine
DM5D6WZ	MI	TTEX248
DM5D6WZ	MN	Dopamine D2 receptor (D2R)
DM5D6WZ	MT	DTT
DM5D6WZ	MA	Agonist
DM5D6WZ	RN	Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives. Ann Pharmacother. 1999 Feb;33(2):188-97.
DM5D6WZ	RU	https://pubmed.ncbi.nlm.nih.gov/10084415

DM5D6WZ	DI	DM5D6WZ
DM5D6WZ	DN	Dihydroergotoxine
DM5D6WZ	MI	TTAN6JD
DM5D6WZ	MN	Glutamate receptor AMPA (GRIA)
DM5D6WZ	MT	DTT
DM5D6WZ	MA	Agonist
DM5D6WZ	RN	Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives. Ann Pharmacother. 1999 Feb;33(2):188-97.
DM5D6WZ	RU	https://pubmed.ncbi.nlm.nih.gov/10084415

DMFB97P	DI	DMFB97P
DMFB97P	DN	Dihydrotachysterol
DMFB97P	MI	TTK59TV
DMFB97P	MN	Vitamin D3 receptor (VDR)
DMFB97P	MT	DTT
DMFB97P	MA	Antagonist
DMFB97P	RN	In vivo metabolism of the vitamin D analog, dihydrotachysterol. Evidence for formation of 1 alpha,25- and 1 beta,25-dihydroxy-dihydrotachysterol metabolites and studies of their biological activity. J Biol Chem. 1993 Jan 5;268(1):282-92.
DMFB97P	RU	https://pubmed.ncbi.nlm.nih.gov/8380156

DMM1LG2	DI	DMM1LG2
DMM1LG2	DN	Dihydroxyacetone
DMM1LG2	MI	DEX9ZJQ
DMM1LG2	MN	Triokinase/FMN cyclase (TKFC)
DMM1LG2	MT	DME
DMM1LG2	MA	Metabolism
DMM1LG2	RN	Bifunctional homodimeric triokinase/FMN cyclase: contribution of protein domains to the activities of the human enzyme and molecular dynamics simulation of domain movements. J Biol Chem. 2014 Apr 11;289(15):10620-36.
DMM1LG2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24569995

DM8YXKW	DI	DM8YXKW
DM8YXKW	DN	Dihydroxyaluminium
DM8YXKW	MI	TT8RDXP
DM8YXKW	MN	Troponin C (TN-C)
DM8YXKW	MT	DTT
DM8YXKW	MA	Stimulator
DM8YXKW	RN	A retrospective analysis of changes in inflammatory markers in patients treated with bacterial viruses. Clin Exp Med. 2009 Dec;9(4):303-12.
DM8YXKW	RU	https://pubmed.ncbi.nlm.nih.gov/19350363

DMAI7ZV	DI	DMAI7ZV
DMAI7ZV	DN	Diltiazem
DMAI7ZV	MI	DES5XRU
DMAI7ZV	MN	Cytochrome P450 2C8 (CYP2C8)
DMAI7ZV	MT	DME
DMAI7ZV	MA	Metabolism
DMAI7ZV	RN	Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites. J Pharmacol Exp Ther. 1997 Jul;282(1):294-300.
DMAI7ZV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9223567

DMAI7ZV	DI	DMAI7ZV
DMAI7ZV	DN	Diltiazem
DMAI7ZV	MI	DE5IED8
DMAI7ZV	MN	Cytochrome P450 2C9 (CYP2C9)
DMAI7ZV	MT	DME
DMAI7ZV	MA	Metabolism
DMAI7ZV	RN	Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
DMAI7ZV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10640508

DMAI7ZV	DI	DMAI7ZV
DMAI7ZV	DN	Diltiazem
DMAI7ZV	MI	DECB0K3
DMAI7ZV	MN	Cytochrome P450 2D6 (CYP2D6)
DMAI7ZV	MT	DME
DMAI7ZV	MA	Metabolism
DMAI7ZV	RN	Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
DMAI7ZV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10640508

DMAI7ZV	DI	DMAI7ZV
DMAI7ZV	DN	Diltiazem
DMAI7ZV	MI	DE4LYSA
DMAI7ZV	MN	Cytochrome P450 3A4 (CYP3A4)
DMAI7ZV	MT	DME
DMAI7ZV	MA	Metabolism
DMAI7ZV	RN	Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos. 2002 Aug;30(8):883-91.
DMAI7ZV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12124305

DMAI7ZV	DI	DMAI7ZV
DMAI7ZV	DN	Diltiazem
DMAI7ZV	MI	DEIBDNY
DMAI7ZV	MN	Cytochrome P450 3A5 (CYP3A5)
DMAI7ZV	MT	DME
DMAI7ZV	MA	Metabolism
DMAI7ZV	RN	Significant impacts of CYP3A4*1G and CYP3A5*3 genetic polymorphisms on the pharmacokinetics of diltiazem and its main metabolites in Chinese adult kidney transplant patients. J Clin Pharm Ther. 2016 Jun;41(3):341-7.
DMAI7ZV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27149910

DMAI7ZV	DI	DMAI7ZV
DMAI7ZV	DN	Diltiazem
DMAI7ZV	MI	DERD86B
DMAI7ZV	MN	Cytochrome P450 3A7 (CYP3A7)
DMAI7ZV	MT	DME
DMAI7ZV	MA	Metabolism
DMAI7ZV	RN	FDA Drug Development and Drug Interactions
DMAI7ZV	RU	https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2

DMAI7ZV	DI	DMAI7ZV
DMAI7ZV	DN	Diltiazem
DMAI7ZV	MI	DEGTFWK
DMAI7ZV	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMAI7ZV	MT	DME
DMAI7ZV	MA	Metabolism
DMAI7ZV	RN	Effects of CYP3A4 inhibition by diltiazem on pharmacokinetics and dynamics of diazepam in relation to CYP2C19 genotype status. Drug Metab Dispos. 2001 Oct;29(10):1284-9.
DMAI7ZV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11560871

DMAI7ZV	DI	DMAI7ZV
DMAI7ZV	DN	Diltiazem
DMAI7ZV	MI	DTUGYRD
DMAI7ZV	MN	P-glycoprotein 1 (ABCB1)
DMAI7ZV	MT	DTP
DMAI7ZV	MA	Substrate
DMAI7ZV	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMAI7ZV	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMAI7ZV	DI	DMAI7ZV
DMAI7ZV	DN	Diltiazem
DMAI7ZV	MI	TTFK1JQ
DMAI7ZV	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMAI7ZV	MT	DTT
DMAI7ZV	MA	Blocker
DMAI7ZV	RN	Egr-1, the potential target of calcium channel blockers in cardioprotection with ischemia/reperfusion injury in rats. Cell Physiol Biochem. 2009;24(1-2):17-24.
DMAI7ZV	RU	https://pubmed.ncbi.nlm.nih.gov/19590189

DM264B3	DI	DM264B3
DM264B3	DN	Dimenhydrinate
DM264B3	MI	TTTIBOJ
DM264B3	MN	Histamine H1 receptor (H1R)
DM264B3	MT	DTT
DM264B3	MA	Antagonist
DM264B3	RN	Histamine 1 receptor antagonist in symptomatic treatment of renal colic accompanied by nausea: two birds with one stone Urology. 2009 Jan;73(1):32-6.
DM264B3	RU	https://pubmed.ncbi.nlm.nih.gov/18849063

DM32YAI	DI	DM32YAI
DM32YAI	DN	Dimethindene
DM32YAI	MI	TTTIBOJ
DM32YAI	MN	Histamine H1 receptor (H1R)
DM32YAI	MT	DTT
DM32YAI	MA	Antagonist
DM32YAI	RN	Analytical method for simultaneously measuring ex vivo drug receptor occupancy and dissociation rate: application to (R)-dimethindene occupancy of central histamine H1 receptors. J Recept Signal Transduct Res. 2009;29(2):84-93.
DM32YAI	RU	https://pubmed.ncbi.nlm.nih.gov/19308787

DMXQKSL	DI	DMXQKSL
DMXQKSL	DN	Dinoprost Tromethamine
DMXQKSL	MI	TTOFYT1
DMXQKSL	MN	Prostacyclin receptor (PTGIR)
DMXQKSL	MT	DTT
DMXQKSL	MA	Antagonist
DMXQKSL	RN	Palmitoylation of the human prostacyclin receptor. Functional implications of palmitoylation and isoprenylation. J Biol Chem. 2003 Feb 28;278(9):6947-58.
DMXQKSL	RU	https://pubmed.ncbi.nlm.nih.gov/12488443

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	DEJGDUW
DMTYOPD	MN	Cytochrome P450 1A2 (CYP1A2)
DMTYOPD	MT	DME
DMTYOPD	MA	Metabolism
DMTYOPD	RN	Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
DMTYOPD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15224350

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	DE3GT9C
DMTYOPD	MN	Cytochrome P450 4F2 (CYP4F2)
DMTYOPD	MT	DME
DMTYOPD	MA	Metabolism
DMTYOPD	RN	Cloning and characterization of CYP4F21: a prostaglandin E2 20-hydroxylase of ram seminal vesicles. Arch Biochem Biophys. 2001 May 1;389(1):123-9.
DMTYOPD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11370662

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	DTFI42L
DMTYOPD	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMTYOPD	MT	DTP
DMTYOPD	MA	Substrate
DMTYOPD	RN	Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
DMTYOPD	RU	https://doi.org/10.1111/j.1478-3231.2005.01234.x

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	DTCSGPB
DMTYOPD	MN	Multidrug resistance-associated protein 4 (ABCC4)
DMTYOPD	MT	DTP
DMTYOPD	MA	Substrate
DMTYOPD	RN	The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9.
DMTYOPD	RU	http://www.ncbi.nlm.nih.gov/pubmed/12835412

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	DTQ23VB
DMTYOPD	MN	Organic anion transporter 1 (SLC22A6)
DMTYOPD	MT	DTP
DMTYOPD	MA	Substrate
DMTYOPD	RN	Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
DMTYOPD	RU	http://www.ncbi.nlm.nih.gov/pubmed/11907186

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	DT0OC1Q
DMTYOPD	MN	Organic anion transporter 2 (SLC22A7)
DMTYOPD	MT	DTP
DMTYOPD	MA	Substrate
DMTYOPD	RN	Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
DMTYOPD	RU	http://www.ncbi.nlm.nih.gov/pubmed/11907186

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	DTVP67E
DMTYOPD	MN	Organic anion transporter 3 (SLC22A8)
DMTYOPD	MT	DTP
DMTYOPD	MA	Substrate
DMTYOPD	RN	Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
DMTYOPD	RU	http://www.ncbi.nlm.nih.gov/pubmed/11907186

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	DT06JWZ
DMTYOPD	MN	Organic anion transporter 4 (SLC22A11)
DMTYOPD	MT	DTP
DMTYOPD	MA	Substrate
DMTYOPD	RN	Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
DMTYOPD	RU	http://www.ncbi.nlm.nih.gov/pubmed/11907186

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	DTE2B1D
DMTYOPD	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMTYOPD	MT	DTP
DMTYOPD	MA	Substrate
DMTYOPD	RN	Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflugers Arch. 2001 Nov;443(2):188-95.
DMTYOPD	RU	http://www.ncbi.nlm.nih.gov/pubmed/11713643

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	DT3D8F0
DMTYOPD	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMTYOPD	MT	DTP
DMTYOPD	MA	Substrate
DMTYOPD	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DMTYOPD	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	DTPYCQ4
DMTYOPD	MN	Organic anion transporting polypeptide 1C1 (SLCO1C1)
DMTYOPD	MT	DTP
DMTYOPD	MA	Substrate
DMTYOPD	RN	Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol Endocrinol. 2002 Oct;16(10):2283-96.
DMTYOPD	RU	http://www.ncbi.nlm.nih.gov/pubmed/12351693

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	DT021JD
DMTYOPD	MN	Organic anion transporting polypeptide 2A1 (SLCO2A1)
DMTYOPD	MT	DTP
DMTYOPD	MA	Substrate
DMTYOPD	RN	Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000 Jun 24;273(1):251-60.
DMTYOPD	RU	http://www.ncbi.nlm.nih.gov/pubmed/10873595

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	DTPFTEQ
DMTYOPD	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DMTYOPD	MT	DTP
DMTYOPD	MA	Substrate
DMTYOPD	RN	Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000 Jun 24;273(1):251-60.
DMTYOPD	RU	http://www.ncbi.nlm.nih.gov/pubmed/10873595

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	DTVNRXW
DMTYOPD	MN	Organic anion transporting polypeptide 3A1 (SLCO3A1)
DMTYOPD	MT	DTP
DMTYOPD	MA	Substrate
DMTYOPD	RN	Molecular characterization of human and rat organic anion transporter OATP-D. Am J Physiol Renal Physiol. 2003 Dec;285(6):F1188-97.
DMTYOPD	RU	http://www.ncbi.nlm.nih.gov/pubmed/14631946

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	DT8H2IC
DMTYOPD	MN	Organic anion transporting polypeptide 4A1 (SLCO4A1)
DMTYOPD	MT	DTP
DMTYOPD	MA	Substrate
DMTYOPD	RN	Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000 Jun 24;273(1):251-60.
DMTYOPD	RU	http://www.ncbi.nlm.nih.gov/pubmed/10873595

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	DTYVQ5M
DMTYOPD	MN	Organic anion transporting polypeptide 5A1 (SLCO5A1)
DMTYOPD	MT	DTP
DMTYOPD	MA	Substrate
DMTYOPD	RN	Expression and regulation of prostaglandin transporters, ATP-binding cassette, subfamily C, member 1 and 9, and solute carrier organic anion transporter family, member 2A1 and 5A1 in the uterine endometrium during the estrous cycle and pregnancy in pigs. Asian-Australas J Anim Sci. 2017 May;30(5):643-652.
DMTYOPD	RU	http://www.ncbi.nlm.nih.gov/pubmed/27764917

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	DTT79CX
DMTYOPD	MN	Organic cation transporter 1 (SLC22A1)
DMTYOPD	MT	DTP
DMTYOPD	MA	Substrate
DMTYOPD	RN	Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
DMTYOPD	RU	http://www.ncbi.nlm.nih.gov/pubmed/16211406

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	DT9IDPW
DMTYOPD	MN	Organic cation transporter 2 (SLC22A2)
DMTYOPD	MT	DTP
DMTYOPD	MA	Substrate
DMTYOPD	RN	Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
DMTYOPD	RU	http://www.ncbi.nlm.nih.gov/pubmed/16211406

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	DTMEQ32
DMTYOPD	MN	Organic solute transporter subunit alpha (SLC51A)
DMTYOPD	MT	DTP
DMTYOPD	MA	Substrate
DMTYOPD	RN	Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem. 2003 Jul 25;278(30):27473-82.
DMTYOPD	RU	http://www.ncbi.nlm.nih.gov/pubmed/12719432

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	DT1V9AJ
DMTYOPD	MN	Organic solute transporter subunit beta (SLC51B)
DMTYOPD	MT	DTP
DMTYOPD	MA	Substrate
DMTYOPD	RN	Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem. 2003 Jul 25;278(30):27473-82.
DMTYOPD	RU	http://www.ncbi.nlm.nih.gov/pubmed/12719432

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	TT1ZAVI
DMTYOPD	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DMTYOPD	MT	DTT
DMTYOPD	MA	Antagonist
DMTYOPD	RN	Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
DMTYOPD	RU	https://www.ncbi.nlm.nih.gov/pubmed/25772215

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	TTT2ZAR
DMTYOPD	MN	Prostaglandin F2-alpha receptor (PTGFR)
DMTYOPD	MT	DTT
DMTYOPD	MA	Antagonist
DMTYOPD	RN	Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
DMTYOPD	RU	https://www.ncbi.nlm.nih.gov/pubmed/25772215

DMXVU6D	DI	DMXVU6D
DMXVU6D	DN	Diphemanil Methylsulfate
DMXVU6D	MI	TTZ9SOR
DMXVU6D	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMXVU6D	MT	DTT
DMXVU6D	MA	Modulator
DMXVU6D	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMXVU6D	RU	https://www.fda.gov/

DMKQTBA	DI	DMKQTBA
DMKQTBA	DN	Diphenhydramine
DMKQTBA	MI	DE5IED8
DMKQTBA	MN	Cytochrome P450 2C9 (CYP2C9)
DMKQTBA	MT	DME
DMKQTBA	MA	Metabolism
DMKQTBA	RN	Pharmacogenomics in psychiatry: implications for practice. Recent Pat Biotechnol. 2014;8(2):152-9.
DMKQTBA	RU	https://www.ncbi.nlm.nih.gov/pubmed/25185985

DMKQTBA	DI	DMKQTBA
DMKQTBA	DN	Diphenhydramine
DMKQTBA	MI	DECB0K3
DMKQTBA	MN	Cytochrome P450 2D6 (CYP2D6)
DMKQTBA	MT	DME
DMKQTBA	MA	Metabolism
DMKQTBA	RN	Identification of human cytochrome p450 isozymes involved in diphenhydramine N-demethylation. Drug Metab Dispos. 2007 Jan;35(1):72-8.
DMKQTBA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17020955

DMKQTBA	DI	DMKQTBA
DMKQTBA	DN	Diphenhydramine
DMKQTBA	MI	TTTIBOJ
DMKQTBA	MN	Histamine H1 receptor (H1R)
DMKQTBA	MT	DTT
DMKQTBA	MA	Antagonist
DMKQTBA	RN	Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79.
DMKQTBA	RU	https://pubmed.ncbi.nlm.nih.gov/18446005

DMKQTBA	DI	DMKQTBA
DMKQTBA	DN	Diphenhydramine
DMKQTBA	MI	TT2B6EV
DMKQTBA	MN	Histamine N-methyltransferase (HNMT)
DMKQTBA	MT	DTT
DMKQTBA	MA	Inhibitor
DMKQTBA	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMKQTBA	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMKQTBA	DI	DMKQTBA
DMKQTBA	DN	Diphenhydramine
DMKQTBA	MI	DEGTFWK
DMKQTBA	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMKQTBA	MT	DME
DMKQTBA	MA	Metabolism
DMKQTBA	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMKQTBA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMKQTBA	DI	DMKQTBA
DMKQTBA	DN	Diphenhydramine
DMKQTBA	MI	DE073H6
DMKQTBA	MN	Prostaglandin G/H synthase 1 (COX-1)
DMKQTBA	MT	DME
DMKQTBA	MA	Metabolism
DMKQTBA	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMKQTBA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMHPWOM	DI	DMHPWOM
DMHPWOM	DN	Diphenidol
DMHPWOM	MI	TTQ3JTF
DMHPWOM	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DMHPWOM	MT	DTT
DMHPWOM	MA	Antagonist
DMHPWOM	RN	Diphenidol-related diamines as novel muscarinic M4 receptor antagonists. Bioorg Med Chem Lett. 2008 May 1;18(9):2972-6.
DMHPWOM	RU	https://pubmed.ncbi.nlm.nih.gov/18395442

DMO5SZX	DI	DMO5SZX
DMO5SZX	DN	Diphenoxylate
DMO5SZX	MI	TTKWM86
DMO5SZX	MN	Opioid receptor mu (MOP)
DMO5SZX	MT	DTT
DMO5SZX	MA	Agonist
DMO5SZX	RN	Loperamide: a pharmacological review. Rev Gastroenterol Disord. 2007;7 Suppl 3:S11-8.
DMO5SZX	RU	https://pubmed.ncbi.nlm.nih.gov/18192961

DMW4X37	DI	DMW4X37
DMW4X37	DN	Diphenylpyraline
DMW4X37	MI	TTTIBOJ
DMW4X37	MN	Histamine H1 receptor (H1R)
DMW4X37	MT	DTT
DMW4X37	MA	Antagonist
DMW4X37	RN	Transport mechanism of an H1-antagonist at the blood-brain barrier: transport mechanism of mepyramine using the carotid injection technique. Biol Pharm Bull. 1994 May;17(5):676-9.
DMW4X37	RU	https://pubmed.ncbi.nlm.nih.gov/7920432

DM0FSIM	DI	DM0FSIM
DM0FSIM	DN	Diphtheria-tetanus vaccine
DM0FSIM	MI	TTXT4D5
DM0FSIM	MN	Bacterial Cell membrane (Bact CM)
DM0FSIM	MT	DTT
DM0FSIM	RN	2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
DM0FSIM	RU	https://pubmed.ncbi.nlm.nih.gov/17342860

DMH5W0G	DI	DMH5W0G
DMH5W0G	DN	Dipivefrin
DMH5W0G	MI	TTR6W5O
DMH5W0G	MN	Adrenergic receptor beta-1 (ADRB1)
DMH5W0G	MT	DTT
DMH5W0G	MA	Antagonist
DMH5W0G	RN	Contractile response of the isolated trabecular meshwork and ciliary muscle to cholinergic and adrenergic agents. Ger J Ophthalmol. 1996 May;5(3):146-53.
DMH5W0G	RU	https://pubmed.ncbi.nlm.nih.gov/8803576

DMXY30O	DI	DMXY30O
DMXY30O	DN	Dipyridamole
DMXY30O	MI	DTI7UX6
DMXY30O	MN	Breast cancer resistance protein (ABCG2)
DMXY30O	MT	DTP
DMXY30O	MA	Substrate
DMXY30O	RN	ABCG2: a perspective. Adv Drug Deliv Rev. 2009 Jan 31;61(1):3-13.
DMXY30O	RU	https://doi.org/10.1016/j.addr.2008.11.003

DMXY30O	DI	DMXY30O
DMXY30O	DN	Dipyridamole
DMXY30O	MI	DTUGYRD
DMXY30O	MN	P-glycoprotein 1 (ABCB1)
DMXY30O	MT	DTP
DMXY30O	MA	Substrate
DMXY30O	RN	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
DMXY30O	RU	https://doi.org/10.1016/j.addr.2011.12.008

DMXY30O	DI	DMXY30O
DMXY30O	DN	Dipyridamole
DMXY30O	MI	TTJ0IQB
DMXY30O	MN	Phosphodiesterase 5A (PDE5A)
DMXY30O	MT	DTT
DMXY30O	MA	Modulator
DMXY30O	RN	Anti-platelet therapy: phosphodiesterase inhibitors.Br J Clin Pharmacol.2011 Oct;72(4):634-46.
DMXY30O	RU	https://www.ncbi.nlm.nih.gov/pubmed/21649691

DM0D9YJ	DI	DM0D9YJ
DM0D9YJ	DN	Dirithromycin
DM0D9YJ	MI	TTUWYEA
DM0D9YJ	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DM0D9YJ	MT	DTT
DM0D9YJ	MA	Binder
DM0D9YJ	RN	Review of macrolides and ketolides: focus on respiratory tract infections. Drugs. 2001;61(4):443-98.
DM0D9YJ	RU	https://pubmed.ncbi.nlm.nih.gov/11324679

DM0D9YJ	DI	DM0D9YJ
DM0D9YJ	DN	Dirithromycin
DM0D9YJ	MI	DTI7UX6
DM0D9YJ	MN	Breast cancer resistance protein (ABCG2)
DM0D9YJ	MT	DTP
DM0D9YJ	MA	Substrate
DM0D9YJ	RN	Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). Biochem J. 2005 Jan 15;385(Pt 2):419-26.
DM0D9YJ	RU	https://doi.org/10.1042/BJ20040791

DM0D9YJ	DI	DM0D9YJ
DM0D9YJ	DN	Dirithromycin
DM0D9YJ	MI	DE4LYSA
DM0D9YJ	MN	Cytochrome P450 3A4 (CYP3A4)
DM0D9YJ	MT	DME
DM0D9YJ	MA	Metabolism
DM0D9YJ	RN	Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet. 2000 Sep;39(3):203-14.
DM0D9YJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11020135

DM5SYZP	DI	DM5SYZP
DM5SYZP	DN	Disopyramide
DM5SYZP	MI	DEJGDUW
DM5SYZP	MN	Cytochrome P450 1A2 (CYP1A2)
DM5SYZP	MT	DME
DM5SYZP	MA	Metabolism
DM5SYZP	RN	Species difference in stereoselective involvement of CYP3A in the mono-N-dealkylation of disopyramide. Xenobiotica. 2001 Feb;31(2):73-83.
DM5SYZP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11407536

DM5SYZP	DI	DM5SYZP
DM5SYZP	DN	Disopyramide
DM5SYZP	MI	DE4LYSA
DM5SYZP	MN	Cytochrome P450 3A4 (CYP3A4)
DM5SYZP	MT	DME
DM5SYZP	MA	Metabolism
DM5SYZP	RN	Species difference in stereoselective involvement of CYP3A in the mono-N-dealkylation of disopyramide. Xenobiotica. 2001 Feb;31(2):73-83.
DM5SYZP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11407536

DM5SYZP	DI	DM5SYZP
DM5SYZP	DN	Disopyramide
DM5SYZP	MI	DTT79CX
DM5SYZP	MN	Organic cation transporter 1 (SLC22A1)
DM5SYZP	MT	DTP
DM5SYZP	MA	Substrate
DM5SYZP	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DM5SYZP	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DM5SYZP	DI	DM5SYZP
DM5SYZP	DN	Disopyramide
DM5SYZP	MI	TTZOVE0
DM5SYZP	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DM5SYZP	MT	DTT
DM5SYZP	MA	Blocker
DM5SYZP	RN	Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2000 Dec;11(12):1320-9.
DM5SYZP	RU	https://pubmed.ncbi.nlm.nih.gov/11196553

DMCL2OK	DI	DMCL2OK
DMCL2OK	DN	Disulfiram
DMCL2OK	MI	DEVDYN7
DMCL2OK	MN	Cytochrome P450 2E1 (CYP2E1)
DMCL2OK	MT	DME
DMCL2OK	MA	Metabolism
DMCL2OK	RN	Duration of cytochrome P-450 2E1 (CYP2E1) inhibition and estimation of functional CYP2E1 enzyme half-life after single-dose disulfiram administration in humans. J Pharmacol Exp Ther. 1999 Oct;291(1):213-9.
DMCL2OK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10490907

DMCL2OK	DI	DMCL2OK
DMCL2OK	DN	Disulfiram
DMCL2OK	MI	DE4LYSA
DMCL2OK	MN	Cytochrome P450 3A4 (CYP3A4)
DMCL2OK	MT	DME
DMCL2OK	MA	Metabolism
DMCL2OK	RN	Interaction of disulfiram with antiretroviral medications: efavirenz increases while atazanavir decreases disulfiram effect on enzymes of alcohol metabolism. Am J Addict. 2014 Mar-Apr;23(2):137-44.
DMCL2OK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24118434

DMCL2OK	DI	DMCL2OK
DMCL2OK	DN	Disulfiram
DMCL2OK	MI	DEIBDNY
DMCL2OK	MN	Cytochrome P450 3A5 (CYP3A5)
DMCL2OK	MT	DME
DMCL2OK	MA	Metabolism
DMCL2OK	RN	Identification of the human P-450 enzymes responsible for the sulfoxidation and thiono-oxidation of diethyldithiocarbamate methyl ester: role of P-450 enzymes in disulfiram bioactivation. Alcohol Clin Exp Res. 1998 Sep;22(6):1212-9.
DMCL2OK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9756035

DMCL2OK	DI	DMCL2OK
DMCL2OK	DN	Disulfiram
DMCL2OK	MI	TTB6UM0
DMCL2OK	MN	Fatty aldehyde dehydrogenase (ALDH3A2)
DMCL2OK	MT	DTT
DMCL2OK	MA	Inhibitor
DMCL2OK	RN	Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol Ther. 2006 Sep;111(3):855-76.
DMCL2OK	RU	https://pubmed.ncbi.nlm.nih.gov/16545872

DM4RK0G	DI	DM4RK0G
DM4RK0G	DN	Divalproex sodium
DM4RK0G	MI	TTT2LD9
DM4RK0G	MN	GABA transaminase (ABAT)
DM4RK0G	MT	DTT
DM4RK0G	MA	Inhibitor
DM4RK0G	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DM4RK0G	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DMD1B8Z	DI	DMD1B8Z
DMD1B8Z	DN	Dobutamine
DMD1B8Z	MI	TTR6W5O
DMD1B8Z	MN	Adrenergic receptor beta-1 (ADRB1)
DMD1B8Z	MT	DTT
DMD1B8Z	MA	Agonist
DMD1B8Z	RN	Beta-adrenoceptor alterations coupled with secretory response and experimental periodontitis in rat submandibular glands. Arch Oral Biol. 2008 Jun;53(6):509-16.
DMD1B8Z	RU	https://pubmed.ncbi.nlm.nih.gov/18275933

DMD1B8Z	DI	DMD1B8Z
DMD1B8Z	DN	Dobutamine
DMD1B8Z	MI	DEV3T4A
DMD1B8Z	MN	Catechol O-methyltransferase (COMT)
DMD1B8Z	MT	DME
DMD1B8Z	MA	Metabolism
DMD1B8Z	RN	Catechol-O-methyltransferase: substrate-specificity and stereoselectivity for beta-adrenoceptor agents. Xenobiotica. 1986 Jan;16(1):47-52.
DMD1B8Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=2868577

DMS5IEB	DI	DMS5IEB
DMS5IEB	DN	Docarpamine
DMS5IEB	MI	TTEX248
DMS5IEB	MN	Dopamine D2 receptor (D2R)
DMS5IEB	MT	DTT
DMS5IEB	MA	Modulator
DMS5IEB	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMS5IEB	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DMDI269	DI	DMDI269
DMDI269	DN	Docetaxel
DMDI269	MI	DTI7UX6
DMDI269	MN	Breast cancer resistance protein (ABCG2)
DMDI269	MT	DTP
DMDI269	MA	Substrate
DMDI269	RN	Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2011 May;337(2):423-32.
DMDI269	RU	http://www.ncbi.nlm.nih.gov/pubmed/21262849

DMDI269	DI	DMDI269
DMDI269	DN	Docetaxel
DMDI269	MI	DE4LYSA
DMDI269	MN	Cytochrome P450 3A4 (CYP3A4)
DMDI269	MT	DME
DMDI269	MA	Metabolism
DMDI269	RN	Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. J Clin Oncol. 2005 Feb 20;23(6):1061-9.
DMDI269	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15657405

DMDI269	DI	DMDI269
DMDI269	DN	Docetaxel
DMDI269	MI	DEIBDNY
DMDI269	MN	Cytochrome P450 3A5 (CYP3A5)
DMDI269	MT	DME
DMDI269	MA	Metabolism
DMDI269	RN	Drug Interactions Flockhart Table
DMDI269	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMDI269	DI	DMDI269
DMDI269	DN	Docetaxel
DMDI269	MI	DERD86B
DMDI269	MN	Cytochrome P450 3A7 (CYP3A7)
DMDI269	MT	DME
DMDI269	MA	Metabolism
DMDI269	RN	Drug Interactions Flockhart Table
DMDI269	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMDI269	DI	DMDI269
DMDI269	DN	Docetaxel
DMDI269	MI	DTSYQGK
DMDI269	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMDI269	MT	DTP
DMDI269	MA	Substrate
DMDI269	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMDI269	RU	https://doi.org/10.1007/s11095-012-0935-x

DMDI269	DI	DMDI269
DMDI269	DN	Docetaxel
DMDI269	MI	DTFI42L
DMDI269	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMDI269	MT	DTP
DMDI269	MA	Substrate
DMDI269	RN	Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone. Drug Metab Dispos. 2009 Jan;37(1):129-36.
DMDI269	RU	http://www.ncbi.nlm.nih.gov/pubmed/18845662

DMDI269	DI	DMDI269
DMDI269	DN	Docetaxel
DMDI269	MI	DTPS120
DMDI269	MN	Multidrug resistance-associated protein 7 (ABCC10)
DMDI269	MT	DTP
DMDI269	MA	Substrate
DMDI269	RN	Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7). Cancer Res. 2012 Dec 15;72(24):6457-67.
DMDI269	RU	http://www.ncbi.nlm.nih.gov/pubmed/23087055

DMDI269	DI	DMDI269
DMDI269	DN	Docetaxel
DMDI269	MI	DT3D8F0
DMDI269	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMDI269	MT	DTP
DMDI269	MA	Substrate
DMDI269	RN	FDA Drug Development and Drug Interactions
DMDI269	RU	https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2

DMDI269	DI	DMDI269
DMDI269	DN	Docetaxel
DMDI269	MI	DT9C1TS
DMDI269	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMDI269	MT	DTP
DMDI269	MA	Substrate
DMDI269	RN	Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes. Cancer Lett. 2008 Feb 18;260(1-2):163-9.
DMDI269	RU	http://www.ncbi.nlm.nih.gov/pubmed/18082941

DMDI269	DI	DMDI269
DMDI269	DN	Docetaxel
DMDI269	MI	DTUGYRD
DMDI269	MN	P-glycoprotein 1 (ABCB1)
DMDI269	MT	DTP
DMDI269	MA	Substrate
DMDI269	RN	Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients. Br J Cancer. 2010 Aug 10;103(4):560-6.
DMDI269	RU	http://www.ncbi.nlm.nih.gov/pubmed/20628376

DMDI269	DI	DMDI269
DMDI269	DN	Docetaxel
DMDI269	MI	DT68UV2
DMDI269	MN	TAP-like protein (ABCB9)
DMDI269	MT	DTP
DMDI269	MA	Substrate
DMDI269	RN	RNA-sequencing dissects the transcriptome of polyploid cancer cells that are resistant to combined treatments of cisplatin with paclitaxel and docetaxel. Mol Biosyst. 2017 Sep 26;13(10):2125-2134.
DMDI269	RU	http://www.ncbi.nlm.nih.gov/pubmed/28825433

DMDI269	DI	DMDI269
DMDI269	DN	Docetaxel
DMDI269	MI	TTML2WA
DMDI269	MN	Tubulin (TUB)
DMDI269	MT	DTT
DMDI269	MA	Inhibitor
DMDI269	RN	Docetaxel: a review of its use in metastatic breast cancer. Drugs. 2005;65(17):2513-31.
DMDI269	RU	https://pubmed.ncbi.nlm.nih.gov/16296875

DMOHK1E	DI	DMOHK1E
DMOHK1E	DN	Docosanol
DMOHK1E	MI	TT1JL7D
DMOHK1E	MN	Epstein-Barr virus Envelope glycoprotein gp340 (EBV BLLF1)
DMOHK1E	MT	DTT
DMOHK1E	MA	Modulator
DMOHK1E	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMOHK1E	RU	https://www.fda.gov/

DMPN1TW	DI	DMPN1TW
DMPN1TW	DN	Dofetilide
DMPN1TW	MI	DE4LYSA
DMPN1TW	MN	Cytochrome P450 3A4 (CYP3A4)
DMPN1TW	MT	DME
DMPN1TW	MA	Metabolism
DMPN1TW	RN	Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. In vitro studies and correlation with in vivo data. Drug Metab Dispos. 1996 Apr;24(4):447-55.
DMPN1TW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8801060

DMPN1TW	DI	DMPN1TW
DMPN1TW	DN	Dofetilide
DMPN1TW	MI	DTZGT0P
DMPN1TW	MN	Multidrug and toxin extrusion protein 1 (SLC47A1)
DMPN1TW	MT	DTP
DMPN1TW	MA	Substrate
DMPN1TW	RN	FDA Drug Development and Drug Interactions
DMPN1TW	RU	https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2

DMPN1TW	DI	DMPN1TW
DMPN1TW	DN	Dofetilide
DMPN1TW	MI	DT3TX4H
DMPN1TW	MN	Multidrug and toxin extrusion protein 2 (SLC47A2)
DMPN1TW	MT	DTP
DMPN1TW	MA	Substrate
DMPN1TW	RN	FDA Drug Development and Drug Interactions
DMPN1TW	RU	https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2

DMPN1TW	DI	DMPN1TW
DMPN1TW	DN	Dofetilide
DMPN1TW	MI	DT9IDPW
DMPN1TW	MN	Organic cation transporter 2 (SLC22A2)
DMPN1TW	MT	DTP
DMPN1TW	MA	Substrate
DMPN1TW	RN	FDA Drug Development and Drug Interactions
DMPN1TW	RU	https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2

DMPN1TW	DI	DMPN1TW
DMPN1TW	DN	Dofetilide
DMPN1TW	MI	TT1VOHK
DMPN1TW	MN	Potassium channel unspecific (KC)
DMPN1TW	MT	DTT
DMPN1TW	MA	Modulator
DMPN1TW	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMPN1TW	RU	https://www.fda.gov/

DMMG26Z	DI	DMMG26Z
DMMG26Z	DN	Dolasetron
DMMG26Z	MI	TTPC4TU
DMMG26Z	MN	5-HT 3A receptor (HTR3A)
DMMG26Z	MT	DTT
DMMG26Z	MA	Antagonist
DMMG26Z	RN	Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, do... Lancet Oncol. 2009 Feb;10(2):115-24.
DMMG26Z	RU	https://pubmed.ncbi.nlm.nih.gov/19135415

DMMG26Z	DI	DMMG26Z
DMMG26Z	DN	Dolasetron
DMMG26Z	MI	DE5IED8
DMMG26Z	MN	Cytochrome P450 2C9 (CYP2C9)
DMMG26Z	MT	DME
DMMG26Z	MA	Metabolism
DMMG26Z	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMMG26Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMMG26Z	DI	DMMG26Z
DMMG26Z	DN	Dolasetron
DMMG26Z	MI	DECB0K3
DMMG26Z	MN	Cytochrome P450 2D6 (CYP2D6)
DMMG26Z	MT	DME
DMMG26Z	MA	Metabolism
DMMG26Z	RN	Reappraisal of the role of dolasetron in prevention and treatment of nausea and vomiting associated with surgery or chemotherapy. Cancer Manag Res. 2012;4:67-73.
DMMG26Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22427733

DMMG26Z	DI	DMMG26Z
DMMG26Z	DN	Dolasetron
DMMG26Z	MI	DE4LYSA
DMMG26Z	MN	Cytochrome P450 3A4 (CYP3A4)
DMMG26Z	MT	DME
DMMG26Z	MA	Metabolism
DMMG26Z	RN	Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists. Drug Metab Dispos. 1996 May;24(5):602-9.
DMMG26Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8723743

DMCZGRE	DI	DMCZGRE
DMCZGRE	DN	Dolutegravir
DMCZGRE	MI	DE4LYSA
DMCZGRE	MN	Cytochrome P450 3A4 (CYP3A4)
DMCZGRE	MT	DME
DMCZGRE	MA	Metabolism
DMCZGRE	RN	Mechanisms of action, pharmacology and interactions of dolutegravir. Enferm Infecc Microbiol Clin. 2015 Mar;33 Suppl 1:2-8.
DMCZGRE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25858605

DMCZGRE	DI	DMCZGRE
DMCZGRE	DN	Dolutegravir
DMCZGRE	MI	TT5FH9Y
DMCZGRE	MN	Human immunodeficiency virus Integrase (HIV IN)
DMCZGRE	MT	DTT
DMCZGRE	MA	Modulator
DMCZGRE	RN	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
DMCZGRE	RU	https://pubmed.ncbi.nlm.nih.gov/28919714

DMCZGRE	DI	DMCZGRE
DMCZGRE	DN	Dolutegravir
DMCZGRE	MI	DTUGYRD
DMCZGRE	MN	P-glycoprotein 1 (ABCB1)
DMCZGRE	MT	DTP
DMCZGRE	MA	Substrate
DMCZGRE	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DMCZGRE	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DMCZGRE	DI	DMCZGRE
DMCZGRE	DN	Dolutegravir
DMCZGRE	MI	DEYGVN4
DMCZGRE	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMCZGRE	MT	DME
DMCZGRE	MA	Metabolism
DMCZGRE	RN	Mechanisms of action, pharmacology and interactions of dolutegravir. Enferm Infecc Microbiol Clin. 2015 Mar;33 Suppl 1:2-8.
DMCZGRE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25858605

DMBDPY0	DI	DMBDPY0
DMBDPY0	DN	Domperidone
DMBDPY0	MI	DEJGDUW
DMBDPY0	MN	Cytochrome P450 1A2 (CYP1A2)
DMBDPY0	MT	DME
DMBDPY0	MA	Metabolism
DMBDPY0	RN	Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol. 2004 Sep;58(3):277-87.
DMBDPY0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15327587

DMBDPY0	DI	DMBDPY0
DMBDPY0	DN	Domperidone
DMBDPY0	MI	DEPKLMQ
DMBDPY0	MN	Cytochrome P450 2B6 (CYP2B6)
DMBDPY0	MT	DME
DMBDPY0	MA	Metabolism
DMBDPY0	RN	Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol. 2004 Sep;58(3):277-87.
DMBDPY0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15327587

DMBDPY0	DI	DMBDPY0
DMBDPY0	DN	Domperidone
DMBDPY0	MI	DES5XRU
DMBDPY0	MN	Cytochrome P450 2C8 (CYP2C8)
DMBDPY0	MT	DME
DMBDPY0	MA	Metabolism
DMBDPY0	RN	Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol. 2004 Sep;58(3):277-87.
DMBDPY0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15327587

DMBDPY0	DI	DMBDPY0
DMBDPY0	DN	Domperidone
DMBDPY0	MI	DECB0K3
DMBDPY0	MN	Cytochrome P450 2D6 (CYP2D6)
DMBDPY0	MT	DME
DMBDPY0	MA	Metabolism
DMBDPY0	RN	Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol. 2004 Sep;58(3):277-87.
DMBDPY0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15327587

DMBDPY0	DI	DMBDPY0
DMBDPY0	DN	Domperidone
DMBDPY0	MI	DE4LYSA
DMBDPY0	MN	Cytochrome P450 3A4 (CYP3A4)
DMBDPY0	MT	DME
DMBDPY0	MA	Metabolism
DMBDPY0	RN	Characterization of CYP3A isozymes involved in the metabolism of domperidone: role of cytochrome b5 and inhibition by ketoconazole. Drug Metab Lett. 2010 Apr;4(2):95-103.
DMBDPY0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21281268

DMBDPY0	DI	DMBDPY0
DMBDPY0	DN	Domperidone
DMBDPY0	MI	DEIBDNY
DMBDPY0	MN	Cytochrome P450 3A5 (CYP3A5)
DMBDPY0	MT	DME
DMBDPY0	MA	Metabolism
DMBDPY0	RN	Drug Interactions Flockhart Table
DMBDPY0	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMBDPY0	DI	DMBDPY0
DMBDPY0	DN	Domperidone
DMBDPY0	MI	DERD86B
DMBDPY0	MN	Cytochrome P450 3A7 (CYP3A7)
DMBDPY0	MT	DME
DMBDPY0	MA	Metabolism
DMBDPY0	RN	Drug Interactions Flockhart Table
DMBDPY0	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMBDPY0	DI	DMBDPY0
DMBDPY0	DN	Domperidone
DMBDPY0	MI	TTEX248
DMBDPY0	MN	Dopamine D2 receptor (D2R)
DMBDPY0	MT	DTT
DMBDPY0	MA	Antagonist
DMBDPY0	RN	Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
DMBDPY0	RU	https://pubmed.ncbi.nlm.nih.gov/18970411

DMBDPY0	DI	DMBDPY0
DMBDPY0	DN	Domperidone
DMBDPY0	MI	DTUGYRD
DMBDPY0	MN	P-glycoprotein 1 (ABCB1)
DMBDPY0	MT	DTP
DMBDPY0	MA	Substrate
DMBDPY0	RN	Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
DMBDPY0	RU	http://www.ncbi.nlm.nih.gov/pubmed/15285840

DMIYG7Z	DI	DMIYG7Z
DMIYG7Z	DN	Donepezil
DMIYG7Z	MI	TT1RS9F
DMIYG7Z	MN	Acetylcholinesterase (AChE)
DMIYG7Z	MT	DTT
DMIYG7Z	MA	Modulator
DMIYG7Z	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2465).
DMIYG7Z	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2465

DMIYG7Z	DI	DMIYG7Z
DMIYG7Z	DN	Donepezil
DMIYG7Z	MI	DE5IED8
DMIYG7Z	MN	Cytochrome P450 2C9 (CYP2C9)
DMIYG7Z	MT	DME
DMIYG7Z	MA	Metabolism
DMIYG7Z	RN	Stereoselective metabolism of donepezil and steady-state plasma concentrations of S-donepezil based on CYP2D6 polymorphisms in the therapeutic responses of Han Chinese patients with Alzheimer's disease. J Pharmacol Sci. 2015 Nov;129(3):188-95.
DMIYG7Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26603528

DMIYG7Z	DI	DMIYG7Z
DMIYG7Z	DN	Donepezil
DMIYG7Z	MI	DECB0K3
DMIYG7Z	MN	Cytochrome P450 2D6 (CYP2D6)
DMIYG7Z	MT	DME
DMIYG7Z	MA	Metabolism
DMIYG7Z	RN	Donepezil plasma concentrations, CYP2D6 and CYP3A4 phenotypes, and cognitive outcome in Alzheimer's disease. Eur J Clin Pharmacol. 2016 Jun;72(6):711-7.
DMIYG7Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26952092

DMIYG7Z	DI	DMIYG7Z
DMIYG7Z	DN	Donepezil
DMIYG7Z	MI	DE4LYSA
DMIYG7Z	MN	Cytochrome P450 3A4 (CYP3A4)
DMIYG7Z	MT	DME
DMIYG7Z	MA	Metabolism
DMIYG7Z	RN	Donepezil plasma concentrations, CYP2D6 and CYP3A4 phenotypes, and cognitive outcome in Alzheimer's disease. Eur J Clin Pharmacol. 2016 Jun;72(6):711-7.
DMIYG7Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26952092

DMPGUCF	DI	DMPGUCF
DMPGUCF	DN	Dopamine
DMPGUCF	MI	DEV3T4A
DMPGUCF	MN	Catechol O-methyltransferase (COMT)
DMPGUCF	MT	DME
DMPGUCF	MA	Metabolism
DMPGUCF	RN	Association between polymorphisms in catechol-O-methyltransferase (COMT) and cocaine-induced paranoia in European-American and African-American populations. Am J Med Genet B Neuropsychiatr Genet. 2011 Sep;156B(6):651-60.
DMPGUCF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21656904

DMPGUCF	DI	DMPGUCF
DMPGUCF	DN	Dopamine
DMPGUCF	MI	DEJGDUW
DMPGUCF	MN	Cytochrome P450 1A2 (CYP1A2)
DMPGUCF	MT	DME
DMPGUCF	MA	Metabolism
DMPGUCF	RN	Modulation of CYP1A2 enzyme activity by indoleamines: inhibition by serotonin and tryptamine. Pharmacogenetics. 1998 Jun;8(3):251-8.
DMPGUCF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9682270

DMPGUCF	DI	DMPGUCF
DMPGUCF	DN	Dopamine
DMPGUCF	MI	DE5IED8
DMPGUCF	MN	Cytochrome P450 2C9 (CYP2C9)
DMPGUCF	MT	DME
DMPGUCF	MA	Metabolism
DMPGUCF	RN	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
DMPGUCF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10813809

DMPGUCF	DI	DMPGUCF
DMPGUCF	DN	Dopamine
DMPGUCF	MI	DECB0K3
DMPGUCF	MN	Cytochrome P450 2D6 (CYP2D6)
DMPGUCF	MT	DME
DMPGUCF	MA	Metabolism
DMPGUCF	RN	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
DMPGUCF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10813809

DMPGUCF	DI	DMPGUCF
DMPGUCF	DN	Dopamine
DMPGUCF	MI	TTEX248
DMPGUCF	MN	Dopamine D2 receptor (D2R)
DMPGUCF	MT	DTT
DMPGUCF	MA	Agonist
DMPGUCF	RN	The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
DMPGUCF	RU	https://pubmed.ncbi.nlm.nih.gov/17301410

DMPGUCF	DI	DMPGUCF
DMPGUCF	DN	Dopamine
DMPGUCF	MI	DEL0D64
DMPGUCF	MN	Dopamine dehydroxylase (dadH)
DMPGUCF	MT	DME
DMPGUCF	MA	Metabolism
DMPGUCF	RN	Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism. Science. 2019 Jun 14;364(6445). pii: eaau6323.
DMPGUCF	RU	https://pubmed.ncbi.nlm.nih.gov/31196984

DMPGUCF	DI	DMPGUCF
DMPGUCF	DN	Dopamine
DMPGUCF	MI	DEGTFWK
DMPGUCF	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMPGUCF	MT	DME
DMPGUCF	MA	Metabolism
DMPGUCF	RN	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
DMPGUCF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10813809

DMPGUCF	DI	DMPGUCF
DMPGUCF	DN	Dopamine
DMPGUCF	MI	DET2NXO
DMPGUCF	MN	Monoamine oxidase type B (MAO-B)
DMPGUCF	MT	DME
DMPGUCF	MA	Metabolism
DMPGUCF	RN	Monoamine oxidases (MAO) in the pathogenesis of heart failure and ischemia/reperfusion injury. Biochim Biophys Acta. 2011 Jul;1813(7):1323-32.
DMPGUCF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20869994

DMPGUCF	DI	DMPGUCF
DMPGUCF	DN	Dopamine
DMPGUCF	MI	DTT79CX
DMPGUCF	MN	Organic cation transporter 1 (SLC22A1)
DMPGUCF	MT	DTP
DMPGUCF	MA	Substrate
DMPGUCF	RN	Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
DMPGUCF	RU	https://doi.org/10.2133/dmpk.23.243

DMPGUCF	DI	DMPGUCF
DMPGUCF	DN	Dopamine
DMPGUCF	MI	DT9IDPW
DMPGUCF	MN	Organic cation transporter 2 (SLC22A2)
DMPGUCF	MT	DTP
DMPGUCF	MA	Substrate
DMPGUCF	RN	Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.
DMPGUCF	RU	http://www.ncbi.nlm.nih.gov/pubmed/16581093

DMPGUCF	DI	DMPGUCF
DMPGUCF	DN	Dopamine
DMPGUCF	MI	DT3BA8L
DMPGUCF	MN	Sodium-dependent dopamine transporter (SLC6A3)
DMPGUCF	MT	DTP
DMPGUCF	MA	Substrate
DMPGUCF	RN	Characterization of VNTRs Within the Entire Region of SLC6A3 and Its Association with Hypertension. DNA Cell Biol. 2017 Mar;36(3):227-236.
DMPGUCF	RU	http://www.ncbi.nlm.nih.gov/pubmed/28055236

DMPGUCF	DI	DMPGUCF
DMPGUCF	DN	Dopamine
DMPGUCF	MI	DED5UR3
DMPGUCF	MN	Sulfotransferase 1B1 (SULT1B1)
DMPGUCF	MT	DME
DMPGUCF	MA	Metabolism
DMPGUCF	RN	Molecular cloning, expression, and functional characterization of novel mouse sulfotransferases. Biochem Biophys Res Commun. 1998 Jun 29;247(3):681-6.
DMPGUCF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9647753

DMPGUCF	DI	DMPGUCF
DMPGUCF	DN	Dopamine
DMPGUCF	MI	DT7A9GF
DMPGUCF	MN	Synaptic vesicle glycoprotein 2C (SLC22B3)
DMPGUCF	MT	DTP
DMPGUCF	MA	Substrate
DMPGUCF	RN	Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson disease. Proc Natl Acad Sci U S A. 2017 Mar 14;114(11):E2253-E2262.
DMPGUCF	RU	http://www.ncbi.nlm.nih.gov/pubmed/28246328

DMPGUCF	DI	DMPGUCF
DMPGUCF	DN	Dopamine
DMPGUCF	MI	DTM953D
DMPGUCF	MN	Vesicular amine transporter 1 (SLC18A1)
DMPGUCF	MT	DTP
DMPGUCF	MA	Substrate
DMPGUCF	RN	SLC18: Vesicular neurotransmitter transporters for monoamines and acetylcholine. Mol Aspects Med. 2013 Apr-Jun;34(2-3):360-72.
DMPGUCF	RU	http://www.ncbi.nlm.nih.gov/pubmed/23506877

DMPGUCF	DI	DMPGUCF
DMPGUCF	DN	Dopamine
DMPGUCF	MI	DTT7VPB
DMPGUCF	MN	Vesicular amine transporter 2 (SLC18A2)
DMPGUCF	MT	DTP
DMPGUCF	MA	Substrate
DMPGUCF	RN	SLC18: Vesicular neurotransmitter transporters for monoamines and acetylcholine. Mol Aspects Med. 2013 Apr-Jun;34(2-3):360-72.
DMPGUCF	RU	http://www.ncbi.nlm.nih.gov/pubmed/23506877

DMSCIKZ	DI	DMSCIKZ
DMSCIKZ	DN	Dopexamine
DMSCIKZ	MI	TTEX248
DMSCIKZ	MN	Dopamine D2 receptor (D2R)
DMSCIKZ	MT	DTT
DMSCIKZ	MA	Modulator
DMSCIKZ	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMSCIKZ	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DM9UCJK	DI	DM9UCJK
DM9UCJK	DN	Doripenem
DM9UCJK	MI	TT4ILYC
DM9UCJK	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DM9UCJK	MT	DTT
DM9UCJK	MA	Inhibitor
DM9UCJK	RN	Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
DM9UCJK	RU	https://pubmed.ncbi.nlm.nih.gov/15934867

DM9UCJK	DI	DM9UCJK
DM9UCJK	DN	Doripenem
DM9UCJK	MI	DEC3G7M
DM9UCJK	MN	Beta-lactamase (blaB)
DM9UCJK	MT	DME
DM9UCJK	MA	Metabolism
DM9UCJK	RN	FRI-4 carbapenemase-producing Enterobacter cloacae complex isolated in Tokyo, Japan. J Antimicrob Chemother. 2018 Nov 1;73(11):2969-2972.
DM9UCJK	RU	https://pubmed.ncbi.nlm.nih.gov/30060114

DM9UCJK	DI	DM9UCJK
DM9UCJK	DN	Doripenem
DM9UCJK	MI	DEAMVR3
DM9UCJK	MN	Dehydropeptidase-I (DPEP1)
DM9UCJK	MT	DME
DM9UCJK	MA	Metabolism
DM9UCJK	RN	Disposition, metabolism, and excretion of [14C]doripenem after a single 500-milligram intravenous infusion in healthy men. Antimicrob Agents Chemother. 2008 Oct;52(10):3478-83.
DM9UCJK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18644951

DM3XU74	DI	DM3XU74
DM3XU74	DN	Dornase Alfa
DM3XU74	MI	TTUTN1I
DM3XU74	MN	Human Deoxyribonucleic acid (hDNA)
DM3XU74	MT	DTT
DM3XU74	MA	Breaker
DM3XU74	RN	Dornase alfa. BioDrugs. 1997 Dec;8(6):439-45.
DM3XU74	RU	https://pubmed.ncbi.nlm.nih.gov/18031106

DMA17D0	DI	DMA17D0
DMA17D0	DN	Dorzolamide
DMA17D0	MI	TTANPDJ
DMA17D0	MN	Carbonic anhydrase II (CA-II)
DMA17D0	MT	DTT
DMA17D0	MA	Inhibitor
DMA17D0	RN	Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorg Med Chem. 2009 Jul 15;17(14):5054-8.
DMA17D0	RU	https://pubmed.ncbi.nlm.nih.gov/19520577

DMA17D0	DI	DMA17D0
DMA17D0	DN	Dorzolamide
DMA17D0	MI	DE5IED8
DMA17D0	MN	Cytochrome P450 2C9 (CYP2C9)
DMA17D0	MT	DME
DMA17D0	MA	Metabolism
DMA17D0	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMA17D0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMA17D0	DI	DMA17D0
DMA17D0	DN	Dorzolamide
DMA17D0	MI	DEVDYN7
DMA17D0	MN	Cytochrome P450 2E1 (CYP2E1)
DMA17D0	MT	DME
DMA17D0	MA	Metabolism
DMA17D0	RN	In vitro metabolism of dorzolamide, a novel potent carbonic anhydrase inhibitor, in rat liver microsomes. Drug Metab Dispos. 1994 Nov-Dec;22(6):916-21.
DMA17D0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7895610

DMA17D0	DI	DMA17D0
DMA17D0	DN	Dorzolamide
DMA17D0	MI	DE4LYSA
DMA17D0	MN	Cytochrome P450 3A4 (CYP3A4)
DMA17D0	MT	DME
DMA17D0	MA	Metabolism
DMA17D0	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMA17D0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM78NWP	DI	DM78NWP
DM78NWP	DN	Dostarlimab
DM78NWP	MI	TTNBFWK
DM78NWP	MN	Programmed cell death protein 1 (PD-1)
DM78NWP	MT	DTT
DM78NWP	MA	Inhibitor
DM78NWP	RN	Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer. Future Oncol. 2021 Mar;17(8):877-892.
DM78NWP	RU	https://pubmed.ncbi.nlm.nih.gov/33251877

DMKE7L9	DI	DMKE7L9
DMKE7L9	DN	Doxacurium
DMKE7L9	MI	TTS5WZF
DMKE7L9	MN	Neuronal acetylcholine receptor alpha (NACHRA)
DMKE7L9	MT	DTT
DMKE7L9	MA	Antagonist
DMKE7L9	RN	Interaction of nondepolarizing muscle relaxants with M2 and M3 muscarinic receptors in guinea pig lung and heart. Anesthesiology. 1996 Jan;84(1):155-61.
DMKE7L9	RU	https://pubmed.ncbi.nlm.nih.gov/8572329

DMCYANK	DI	DMCYANK
DMCYANK	DN	Doxapram
DMCYANK	MI	DE4LYSA
DMCYANK	MN	Cytochrome P450 3A4 (CYP3A4)
DMCYANK	MT	DME
DMCYANK	MA	Metabolism
DMCYANK	RN	Population pharmacokinetics of doxapram in low-birth-weight Japanese infants with apnea. Eur J Pediatr. 2015 Apr;174(4):509-18.
DMCYANK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25248340

DMCYANK	DI	DMCYANK
DMCYANK	DN	Doxapram
DMCYANK	MI	DEIBDNY
DMCYANK	MN	Cytochrome P450 3A5 (CYP3A5)
DMCYANK	MT	DME
DMCYANK	MA	Metabolism
DMCYANK	RN	Population pharmacokinetics of doxapram in low-birth-weight Japanese infants with apnea. Eur J Pediatr. 2015 Apr;174(4):509-18.
DMCYANK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25248340

DMCYANK	DI	DMCYANK
DMCYANK	DN	Doxapram
DMCYANK	MI	TT6EYVN
DMCYANK	MN	Peripheral carotid chemoreceptor (PCC)
DMCYANK	MT	DTT
DMCYANK	MA	Stimulator
DMCYANK	RN	Ovalbumin sensitization alters the ventilatory responses to chemical challenges in guinea pigs. J Appl Physiol (1985). 2005 Nov;99(5):1782-8.
DMCYANK	RU	https://pubmed.ncbi.nlm.nih.gov/16024517

DM9PLRH	DI	DM9PLRH
DM9PLRH	DN	Doxazosin
DM9PLRH	MI	TT34BHT
DM9PLRH	MN	Adrenergic receptor alpha-1D (ADRA1D)
DM9PLRH	MT	DTT
DM9PLRH	MA	Antagonist
DM9PLRH	RN	The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43.
DM9PLRH	RU	https://pubmed.ncbi.nlm.nih.gov/19002123

DM9PLRH	DI	DM9PLRH
DM9PLRH	DN	Doxazosin
DM9PLRH	MI	DE5IED8
DM9PLRH	MN	Cytochrome P450 2C9 (CYP2C9)
DM9PLRH	MT	DME
DM9PLRH	MA	Metabolism
DM9PLRH	RN	Product monograph: CARDURA (Doxazosin mesylate).
DM9PLRH	RU	https://www.pfizer.ca/sites/g/files/g10050796/f/201710/CARDURA_PM_Eng_201486_4Apr2017.pdf

DM9PLRH	DI	DM9PLRH
DM9PLRH	DN	Doxazosin
DM9PLRH	MI	DECB0K3
DM9PLRH	MN	Cytochrome P450 2D6 (CYP2D6)
DM9PLRH	MT	DME
DM9PLRH	MA	Metabolism
DM9PLRH	RN	Priapism induced by boceprevir-CYP3A4 inhibition and alpha-adrenergic blockade: case report. Clin Infect Dis. 2014 Jan;58(1):e35-8.
DM9PLRH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24092799

DM9PLRH	DI	DM9PLRH
DM9PLRH	DN	Doxazosin
DM9PLRH	MI	DE4LYSA
DM9PLRH	MN	Cytochrome P450 3A4 (CYP3A4)
DM9PLRH	MT	DME
DM9PLRH	MA	Metabolism
DM9PLRH	RN	Priapism induced by boceprevir-CYP3A4 inhibition and alpha-adrenergic blockade: case report. Clin Infect Dis. 2014 Jan;58(1):e35-8.
DM9PLRH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24092799

DM9PLRH	DI	DM9PLRH
DM9PLRH	DN	Doxazosin
DM9PLRH	MI	DEGTFWK
DM9PLRH	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM9PLRH	MT	DME
DM9PLRH	MA	Metabolism
DM9PLRH	RN	Priapism induced by boceprevir-CYP3A4 inhibition and alpha-adrenergic blockade: case report. Clin Infect Dis. 2014 Jan;58(1):e35-8.
DM9PLRH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24092799

DMPI98T	DI	DMPI98T
DMPI98T	DN	Doxepin
DMPI98T	MI	DEJGDUW
DMPI98T	MN	Cytochrome P450 1A2 (CYP1A2)
DMPI98T	MT	DME
DMPI98T	MA	Metabolism
DMPI98T	RN	The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. Pharm Res. 2002 Jul;19(7):1034-7.
DMPI98T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12180536

DMPI98T	DI	DMPI98T
DMPI98T	DN	Doxepin
DMPI98T	MI	DE5IED8
DMPI98T	MN	Cytochrome P450 2C9 (CYP2C9)
DMPI98T	MT	DME
DMPI98T	MA	Metabolism
DMPI98T	RN	Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct;12(7):571-80.
DMPI98T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12360109

DMPI98T	DI	DMPI98T
DMPI98T	DN	Doxepin
DMPI98T	MI	DECB0K3
DMPI98T	MN	Cytochrome P450 2D6 (CYP2D6)
DMPI98T	MT	DME
DMPI98T	MA	Metabolism
DMPI98T	RN	Doxepin inhibits CYP2D6 activity in vivo. Pol J Pharmacol. 2004 Jul-Aug;56(4):491-4.
DMPI98T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15520506

DMPI98T	DI	DMPI98T
DMPI98T	DN	Doxepin
DMPI98T	MI	DE4LYSA
DMPI98T	MN	Cytochrome P450 3A4 (CYP3A4)
DMPI98T	MT	DME
DMPI98T	MA	Metabolism
DMPI98T	RN	The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. Pharm Res. 2002 Jul;19(7):1034-7.
DMPI98T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12180536

DMPI98T	DI	DMPI98T
DMPI98T	DN	Doxepin
DMPI98T	MI	TTTIBOJ
DMPI98T	MN	Histamine H1 receptor (H1R)
DMPI98T	MT	DTT
DMPI98T	MA	Inhibitor
DMPI98T	RN	Novel therapeutic usage of low-dose doxepin hydrochloride. Expert Opin Investig Drugs. 2007 Aug;16(8):1295-305.
DMPI98T	RU	https://pubmed.ncbi.nlm.nih.gov/17685877

DMPI98T	DI	DMPI98T
DMPI98T	DN	Doxepin
DMPI98T	MI	DEGTFWK
DMPI98T	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMPI98T	MT	DME
DMPI98T	MA	Metabolism
DMPI98T	RN	Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct;12(7):571-80.
DMPI98T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12360109

DM6FG1P	DI	DM6FG1P
DM6FG1P	DN	Doxercalciferol
DM6FG1P	MI	DEBS639
DM6FG1P	MN	Vitamin D(3) 25-hydroxylase (CYP27A1)
DM6FG1P	MT	DME
DM6FG1P	MA	Metabolism
DM6FG1P	RN	Efficacy and safety of oral doxercalciferol in the management of secondary hyperparathyroidism in chronic kidney disease stage 4. Indian J Nephrol. 2013 Jul;23(4):271-5.
DM6FG1P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23960343

DM6FG1P	DI	DM6FG1P
DM6FG1P	DN	Doxercalciferol
DM6FG1P	MI	TTK59TV
DM6FG1P	MN	Vitamin D3 receptor (VDR)
DM6FG1P	MT	DTT
DM6FG1P	MA	Antagonist
DM6FG1P	RN	Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
DM6FG1P	RU	https://pubmed.ncbi.nlm.nih.gov/19249988

DMEDKZH	DI	DMEDKZH
DMEDKZH	DN	Doxofylline
DMEDKZH	MI	DEJGDUW
DMEDKZH	MN	Cytochrome P450 1A2 (CYP1A2)
DMEDKZH	MT	DME
DMEDKZH	MA	Metabolism
DMEDKZH	RN	PharmGKB summary: caffeine pathway. Pharmacogenet Genomics. 2012 May;22(5):389-95.
DMEDKZH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22293536

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DED2FW3
DMVP5YE	MN	Aldo-keto reductase 1A1 (AKR1A1)
DMVP5YE	MT	DME
DMVP5YE	MA	Metabolism
DMVP5YE	RN	Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver. Drug Metab Dispos. 2008 Oct;36(10):2113-20.
DMVP5YE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18635746

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DEGQTXO
DMVP5YE	MN	Aldo-keto reductase 1C3 (AKR1C3)
DMVP5YE	MT	DME
DMVP5YE	MA	Metabolism
DMVP5YE	RN	Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3. Toxicol Lett. 2008 Sep;181(1):1-6.
DMVP5YE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18616992

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DTKVEXO
DMVP5YE	MN	ATP-binding cassette sub-family B member 5 (ABCB5)
DMVP5YE	MT	DTP
DMVP5YE	MA	Substrate
DMVP5YE	RN	ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res. 2005 May 15;65(10):4320-33.
DMVP5YE	RU	http://www.ncbi.nlm.nih.gov/pubmed/15899824

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DT0KQND
DMVP5YE	MN	ATP-binding cassette sub-family B member 8 (ABCB8)
DMVP5YE	MT	DTP
DMVP5YE	MA	Substrate
DMVP5YE	RN	ABCB8 mediates doxorubicin resistance in melanoma cells by protecting the mitochondrial genome. Mol Cancer Res. 2009 Jan;7(1):79-87.
DMVP5YE	RU	http://www.ncbi.nlm.nih.gov/pubmed/19147539

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DTI7UX6
DMVP5YE	MN	Breast cancer resistance protein (ABCG2)
DMVP5YE	MT	DTP
DMVP5YE	MA	Substrate
DMVP5YE	RN	Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
DMVP5YE	RU	http://www.ncbi.nlm.nih.gov/pubmed/17273774

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DECB0K3
DMVP5YE	MN	Cytochrome P450 2D6 (CYP2D6)
DMVP5YE	MT	DME
DMVP5YE	MA	Metabolism
DMVP5YE	RN	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
DMVP5YE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8258200

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DE4LYSA
DMVP5YE	MN	Cytochrome P450 3A4 (CYP3A4)
DMVP5YE	MT	DME
DMVP5YE	MA	Metabolism
DMVP5YE	RN	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
DMVP5YE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17279585

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DEIBDNY
DMVP5YE	MN	Cytochrome P450 3A5 (CYP3A5)
DMVP5YE	MT	DME
DMVP5YE	MA	Metabolism
DMVP5YE	RN	Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
DMVP5YE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18930278

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	TT0IHXV
DMVP5YE	MN	DNA topoisomerase II (TOP2)
DMVP5YE	MT	DTT
DMVP5YE	MA	Modulator
DMVP5YE	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMVP5YE	RU	https://www.fda.gov/

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DTPATLS
DMVP5YE	MN	Fly-like putative transporter 2 (SLC22A16)
DMVP5YE	MT	DTP
DMVP5YE	MA	Substrate
DMVP5YE	RN	Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer. 2010 Mar 16;102(6):1003-9.
DMVP5YE	RU	http://www.ncbi.nlm.nih.gov/pubmed/20179710

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DE6NIY9
DMVP5YE	MN	Methionine synthase reductase (MTRR)
DMVP5YE	MT	DME
DMVP5YE	MA	Metabolism
DMVP5YE	RN	Differences in the efficiency of reductive activation of methionine synthase and exogenous electron acceptors between the common polymorphic variants of human methionine synthase reductase. Biochemistry. 2002 Nov 12;41(45):13378-85.
DMVP5YE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12416982

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DEYSOD0
DMVP5YE	MN	Molybdopterin-dependent enzyme (molD)
DMVP5YE	MT	DME
DMVP5YE	MA	Metabolism
DMVP5YE	RN	Transformation of the anticancer drug doxorubicin in the human gut microbiome. ACS Infect Dis. 2018 Jan 12;4(1):68-76.
DMVP5YE	RU	https://pubmed.ncbi.nlm.nih.gov/29160065

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DE1QMDG
DMVP5YE	MN	Molybdopterin-dependent enzyme (molD)
DMVP5YE	MT	DME
DMVP5YE	MA	Metabolism
DMVP5YE	RN	Transformation of the anticancer drug doxorubicin in the human gut microbiome. ACS Infect Dis. 2018 Jan 12;4(1):68-76.
DMVP5YE	RU	https://pubmed.ncbi.nlm.nih.gov/29160065

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DEME01W
DMVP5YE	MN	Molybdopterin-dependent enzyme (molD)
DMVP5YE	MT	DME
DMVP5YE	MA	Metabolism
DMVP5YE	RN	Transformation of the anticancer drug doxorubicin in the human gut microbiome. ACS Infect Dis. 2018 Jan 12;4(1):68-76.
DMVP5YE	RU	https://pubmed.ncbi.nlm.nih.gov/29160065

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DT342ZG
DMVP5YE	MN	Monocarboxylate transporter 1 (SLC16A1)
DMVP5YE	MT	DTP
DMVP5YE	MA	Substrate
DMVP5YE	RN	Circadian rhythms in gene expression: Relationship to physiology, disease, drug disposition and drug action. Adv Drug Deliv Rev. 2010 Jul 31;62(9-10):904-17.
DMVP5YE	RU	https://doi.org/10.1016/j.addr.2010.05.009

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DTSYQGK
DMVP5YE	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMVP5YE	MT	DTP
DMVP5YE	MA	Substrate
DMVP5YE	RN	The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines. Br J Cancer. 2005 Jul 11;93(1):89-97.
DMVP5YE	RU	http://www.ncbi.nlm.nih.gov/pubmed/15942634

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DTFI42L
DMVP5YE	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMVP5YE	MT	DTP
DMVP5YE	MA	Substrate
DMVP5YE	RN	Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
DMVP5YE	RU	http://www.ncbi.nlm.nih.gov/pubmed/16377671

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DEAMEF2
DMVP5YE	MN	NADH dehydrogenase (nuoE)
DMVP5YE	MT	DME
DMVP5YE	MA	Metabolism
DMVP5YE	RN	Bacterial inactivation of the anticancer drug doxorubicin. Chem Biol. 2012 Oct 26;19(10):1255-64.
DMVP5YE	RU	https://pubmed.ncbi.nlm.nih.gov/23102220

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DEIW03B
DMVP5YE	MN	NADH-ubiquinone oxidoreductase 20 kDa (NDUFS7)
DMVP5YE	MT	DME
DMVP5YE	MA	Metabolism
DMVP5YE	RN	Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase. Oncol Res. 2003;13(5):245-52.
DMVP5YE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12688675

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DE741FI
DMVP5YE	MN	NADH-ubiquinone oxidoreductase 30 kDa (NDUFS3)
DMVP5YE	MT	DME
DMVP5YE	MA	Metabolism
DMVP5YE	RN	Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase. Oncol Res. 2003;13(5):245-52.
DMVP5YE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12688675

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DEKX5CD
DMVP5YE	MN	NADH-ubiquinone oxidoreductase 49 kDa (NDUFS2)
DMVP5YE	MT	DME
DMVP5YE	MA	Metabolism
DMVP5YE	RN	Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase. Oncol Res. 2003;13(5):245-52.
DMVP5YE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12688675

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DE3N2FM
DMVP5YE	MN	NADPH-cytochrome P450 reductase (CPR)
DMVP5YE	MT	DME
DMVP5YE	MA	Metabolism
DMVP5YE	RN	Kinetics of anthracycline antibiotic free radical formation and reductive glycosidase activity. Arch Biochem Biophys. 1983 May;223(1):68-75.
DMVP5YE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=6305277

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DEYEK78
DMVP5YE	MN	Nitric oxide synthase brain (NOS1)
DMVP5YE	MT	DME
DMVP5YE	MA	Metabolism
DMVP5YE	RN	The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. FASEB J. 2004 Apr;18(6):664-75.
DMVP5YE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15054088

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DE708H2
DMVP5YE	MN	Nitric oxide synthase endothelial (NOS3)
DMVP5YE	MT	DME
DMVP5YE	MA	Metabolism
DMVP5YE	RN	The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. FASEB J. 2004 Apr;18(6):664-75.
DMVP5YE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15054088

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DE3C1JY
DMVP5YE	MN	Nitric oxide synthase inducible (NOS2)
DMVP5YE	MT	DME
DMVP5YE	MA	Metabolism
DMVP5YE	RN	The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. FASEB J. 2004 Apr;18(6):664-75.
DMVP5YE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15054088

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DTUGYRD
DMVP5YE	MN	P-glycoprotein 1 (ABCB1)
DMVP5YE	MT	DTP
DMVP5YE	MA	Substrate
DMVP5YE	RN	MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
DMVP5YE	RU	http://www.ncbi.nlm.nih.gov/pubmed/19123050

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DENP5RY
DMVP5YE	MN	Quinone reductase 1 (NQO1)
DMVP5YE	MT	DME
DMVP5YE	MA	Metabolism
DMVP5YE	RN	Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase. Oncol Res. 2003;13(5):245-52.
DMVP5YE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12688675

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DE4G629
DMVP5YE	MN	Succinic semialdehyde reductase (AKR7A2)
DMVP5YE	MT	DME
DMVP5YE	MA	Metabolism
DMVP5YE	RN	Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin. J Pharmacol Exp Ther. 2010 Dec;335(3):533-45.
DMVP5YE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20837989

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	TTQY2EJ
DMVP5YE	MN	TERT messenger RNA (TERT mRNA)
DMVP5YE	MT	DTT
DMVP5YE	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DMVP5YE	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DECG04O
DMVP5YE	MN	Xanthine dehydrogenase/oxidase (XDH)
DMVP5YE	MT	DME
DMVP5YE	MA	Metabolism
DMVP5YE	RN	Xanthine oxidoreductase in drug metabolism: beyond a role as a detoxifying enzyme. Curr Med Chem. 2016;23(35):4027-4036.
DMVP5YE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27458036

DM7ICNU	DI	DM7ICNU
DM7ICNU	DN	Doxycycline
DM7ICNU	MI	TTOVFH2
DM7ICNU	MN	Bacterial 30S ribosomal RNA (Bact 30S rRNA)
DM7ICNU	MT	DTT
DM7ICNU	MA	Modulator
DM7ICNU	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM7ICNU	RU	https://www.fda.gov/

DM7ICNU	DI	DM7ICNU
DM7ICNU	DN	Doxycycline
DM7ICNU	MI	DE4LYSA
DM7ICNU	MN	Cytochrome P450 3A4 (CYP3A4)
DM7ICNU	MT	DME
DM7ICNU	MA	Metabolism
DM7ICNU	RN	A further interaction study of quinine with clinically important drugs by human liver microsomes: determinations of inhibition constant (Ki) and type of inhibition. Eur J Drug Metab Pharmacokinet. 1999 Jul-Sep;24(3):272-8.
DM7ICNU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10716067

DM7ICNU	DI	DM7ICNU
DM7ICNU	DN	Doxycycline
DM7ICNU	MI	DTUGYRD
DM7ICNU	MN	P-glycoprotein 1 (ABCB1)
DM7ICNU	MT	DTP
DM7ICNU	MA	Substrate
DM7ICNU	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM7ICNU	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMKOXFE	DI	DMKOXFE
DMKOXFE	DN	Doxylamine
DMKOXFE	MI	TTTIBOJ
DMKOXFE	MN	Histamine H1 receptor (H1R)
DMKOXFE	MT	DTT
DMKOXFE	MA	Antagonist
DMKOXFE	RN	First-generation H1 antihistamines found in pilot fatalities of civil aviation accidents, 1990-2005. Aviat Space Environ Med. 2007 May;78(5):514-22.
DMKOXFE	RU	https://pubmed.ncbi.nlm.nih.gov/17539447

DMGOXPQ	DI	DMGOXPQ
DMGOXPQ	DN	DP-VPA
DMGOXPQ	MI	TTNJYV2
DMGOXPQ	MN	Gamma-aminobutyric acid receptor (GAR)
DMGOXPQ	MT	DTT
DMGOXPQ	MA	Modulator
DMGOXPQ	RN	DP-VPA D-Pharm. Curr Opin Investig Drugs. 2002 Jun;3(6):921-3.
DMGOXPQ	RU	https://pubmed.ncbi.nlm.nih.gov/12137414

DMF2JDG	DI	DMF2JDG
DMF2JDG	DN	Dromostanolone
DMF2JDG	MI	TTS64P2
DMF2JDG	MN	Androgen receptor (AR)
DMF2JDG	MT	DTT
DMF2JDG	MA	Binder
DMF2JDG	RN	Endocrinological and pathological effects of anabolic-androgenic steroid in male rats. Endocr J. 2004 Aug;51(4):425-34.
DMF2JDG	RU	https://pubmed.ncbi.nlm.nih.gov/15351799

DMA8FS5	DI	DMA8FS5
DMA8FS5	DN	Dronedarone
DMA8FS5	MI	DECB0K3
DMA8FS5	MN	Cytochrome P450 2D6 (CYP2D6)
DMA8FS5	MT	DME
DMA8FS5	MA	Metabolism
DMA8FS5	RN	Effect of dronedarone on the pharmacokinetics of carvedilol following oral administration to rats. Eur J Pharm Sci. 2018 Jan 1;111:13-19.
DMA8FS5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28942006

DMA8FS5	DI	DMA8FS5
DMA8FS5	DN	Dronedarone
DMA8FS5	MI	DE4LYSA
DMA8FS5	MN	Cytochrome P450 3A4 (CYP3A4)
DMA8FS5	MT	DME
DMA8FS5	MA	Metabolism
DMA8FS5	RN	Drug safety evaluation of dronedarone in atrial fibrillation. Expert Opin Drug Saf. 2012 Nov;11(6):1023-45.
DMA8FS5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22971242

DMA8FS5	DI	DMA8FS5
DMA8FS5	DN	Dronedarone
DMA8FS5	MI	DEIBDNY
DMA8FS5	MN	Cytochrome P450 3A5 (CYP3A5)
DMA8FS5	MT	DME
DMA8FS5	MA	Metabolism
DMA8FS5	RN	Inactivation of human cytochrome P450 3A4 and 3A5 by dronedarone and N-desbutyl dronedarone. Mol Pharmacol. 2016 Jan;89(1):1-13.
DMA8FS5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26490246

DMA8FS5	DI	DMA8FS5
DMA8FS5	DN	Dronedarone
DMA8FS5	MI	TT1VOHK
DMA8FS5	MN	Potassium channel unspecific (KC)
DMA8FS5	MT	DTT
DMA8FS5	MA	Inhibitor
DMA8FS5	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMA8FS5	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMA8FS5	DI	DMA8FS5
DMA8FS5	DN	Dronedarone
DMA8FS5	MI	TTW0CMT
DMA8FS5	MN	Voltage-gated potassium channel Kv1.5 (KCNA5)
DMA8FS5	MT	DTT
DMA8FS5	MA	Blocker
DMA8FS5	RN	New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22.
DMA8FS5	RU	https://pubmed.ncbi.nlm.nih.gov/15934869

DM0DXA8	DI	DM0DXA8
DM0DXA8	DN	Droperidol
DM0DXA8	MI	TTEX248
DM0DXA8	MN	Dopamine D2 receptor (D2R)
DM0DXA8	MT	DTT
DM0DXA8	MA	Binder
DM0DXA8	RN	Alpha-adrenergic blockade: a possible mechanism of tocolytic action of certain benzodiazepines in a postpartum rat model in vivo. Life Sci. 2003 Jan 24;72(10):1093-102.
DM0DXA8	RU	https://pubmed.ncbi.nlm.nih.gov/12505540

DM1A9W3	DI	DM1A9W3
DM1A9W3	DN	Drospirenone
DM1A9W3	MI	DE4LYSA
DM1A9W3	MN	Cytochrome P450 3A4 (CYP3A4)
DM1A9W3	MT	DME
DM1A9W3	MA	Metabolism
DM1A9W3	RN	Role of CYP3A in oral contraceptives clearance. Clin Transl Sci. 2018 May;11(3):251-260.
DM1A9W3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28986954

DM1A9W3	DI	DM1A9W3
DM1A9W3	DN	Drospirenone
DM1A9W3	MI	TT26PHO
DM1A9W3	MN	Mineralocorticoid receptor  (MR)
DM1A9W3	MT	DTT
DM1A9W3	MA	Binder
DM1A9W3	RN	Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and ... Curr Top Med Chem. 2006;6(5):461-78.
DM1A9W3	RU	https://pubmed.ncbi.nlm.nih.gov/16719803

DM59JCN	DI	DM59JCN
DM59JCN	DN	Drotrecogin alfa
DM59JCN	MI	TT1O264
DM59JCN	MN	Coagulation factor Va (F5)
DM59JCN	MT	DTT
DM59JCN	MA	Inhibitor
DM59JCN	RN	Protein C in critical illness. Am J Health Syst Pharm. 2009 Jun 15;66(12):1089-96.
DM59JCN	RU	https://pubmed.ncbi.nlm.nih.gov/19498123

DM59JCN	DI	DM59JCN
DM59JCN	DN	Drotrecogin alfa
DM59JCN	MI	TT1290U
DM59JCN	MN	Coagulation factor VIII (F8)
DM59JCN	MT	DTT
DM59JCN	MA	Inhibitor
DM59JCN	RN	Protein C in critical illness. Am J Health Syst Pharm. 2009 Jun 15;66(12):1089-96.
DM59JCN	RU	https://pubmed.ncbi.nlm.nih.gov/19498123

DM5YF4M	DI	DM5YF4M
DM5YF4M	DN	Droxidopa
DM5YF4M	MI	DETK9CN
DM5YF4M	MN	DOPA decarboxylase (DDC)
DM5YF4M	MT	DME
DM5YF4M	MA	Metabolism
DM5YF4M	RN	L-Dihydroxyphenylserine (L-DOPS): a norepinephrine prodrug. Cardiovasc Drug Rev. 2006 Fall-Winter;24(3-4):189-203.
DM5YF4M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17214596

DMXZRW0	DI	DMXZRW0
DMXZRW0	DN	DTI-015
DMXZRW0	MI	DEJGDUW
DMXZRW0	MN	Cytochrome P450 1A2 (CYP1A2)
DMXZRW0	MT	DME
DMXZRW0	MA	Metabolism
DMXZRW0	RN	Principal drug-metabolizing enzyme systems in L1210 leukemia sensitive or resistant to BCNU in vivo. Leuk Res. 1994 Nov;18(11):829-35.
DMXZRW0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7967709

DMXZRW0	DI	DMXZRW0
DMXZRW0	DN	DTI-015
DMXZRW0	MI	DE4ZHS1
DMXZRW0	MN	Glutathione S-transferase alpha-1 (GSTA1)
DMXZRW0	MT	DME
DMXZRW0	MA	Metabolism
DMXZRW0	RN	Expression of glutathione S-transferase T1 (GSTT1) in human brain tumours. Histol Histopathol. 2006 Nov;21(11):1199-207.
DMXZRW0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16874663

DMXZRW0	DI	DMXZRW0
DMXZRW0	DN	DTI-015
DMXZRW0	MI	TTUTN1I
DMXZRW0	MN	Human Deoxyribonucleic acid (hDNA)
DMXZRW0	MT	DTT
DMXZRW0	MA	Binder
DMXZRW0	RN	Carmustine-induced toxicity, DNA crosslinking and O6-methylguanine-DNA methyltransferase activity in two human lung cancer cell lines. Eur J Cancer. 1991;27(12):1658-62.
DMXZRW0	RU	https://pubmed.ncbi.nlm.nih.gov/1664221

DMCIJBH	DI	DMCIJBH
DMCIJBH	DN	DU-176B
DMCIJBH	MI	TTCIHJA
DMCIJBH	MN	Coagulation factor Xa (F10)
DMCIJBH	MT	DTT
DMCIJBH	MA	Modulator
DMCIJBH	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2359).
DMCIJBH	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2359

DMCIJBH	DI	DMCIJBH
DMCIJBH	DN	DU-176B
DMCIJBH	MI	DE4LYSA
DMCIJBH	MN	Cytochrome P450 3A4 (CYP3A4)
DMCIJBH	MT	DME
DMCIJBH	MA	Metabolism
DMCIJBH	RN	Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine. Br J Clin Pharmacol. 2016 Dec;82(6):1591-1600.
DMCIJBH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27530188

DMCIJBH	DI	DMCIJBH
DMCIJBH	DN	DU-176B
DMCIJBH	MI	DTUGYRD
DMCIJBH	MN	P-glycoprotein 1 (ABCB1)
DMCIJBH	MT	DTP
DMCIJBH	MA	Substrate
DMCIJBH	RN	Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine. Br J Clin Pharmacol. 2016 Dec;82(6):1591-1600.
DMCIJBH	RU	http://www.ncbi.nlm.nih.gov/pubmed/27530188

DMYXBV3	DI	DMYXBV3
DMYXBV3	DN	Dulaglutide
DMYXBV3	MI	TTVIMDE
DMYXBV3	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMYXBV3	MT	DTT
DMYXBV3	MA	Agonist
DMYXBV3	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMYXBV3	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DM9BI7M	DI	DM9BI7M
DM9BI7M	DN	Duloxetine
DM9BI7M	MI	DEJGDUW
DM9BI7M	MN	Cytochrome P450 1A2 (CYP1A2)
DM9BI7M	MT	DME
DM9BI7M	MA	Metabolism
DM9BI7M	RN	Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011 May;50(5):281-94.
DM9BI7M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21366359

DM9BI7M	DI	DM9BI7M
DM9BI7M	DN	Duloxetine
DM9BI7M	MI	DE5IED8
DM9BI7M	MN	Cytochrome P450 2C9 (CYP2C9)
DM9BI7M	MT	DME
DM9BI7M	MA	Metabolism
DM9BI7M	RN	Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011 May;50(5):281-94.
DM9BI7M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21366359

DM9BI7M	DI	DM9BI7M
DM9BI7M	DN	Duloxetine
DM9BI7M	MI	DECB0K3
DM9BI7M	MN	Cytochrome P450 2D6 (CYP2D6)
DM9BI7M	MT	DME
DM9BI7M	MA	Metabolism
DM9BI7M	RN	Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011 May;50(5):281-94.
DM9BI7M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21366359

DM9BI7M	DI	DM9BI7M
DM9BI7M	DN	Duloxetine
DM9BI7M	MI	TTAWNKZ
DM9BI7M	MN	Norepinephrine transporter (NET)
DM9BI7M	MT	DTT
DM9BI7M	MA	Inhibitor
DM9BI7M	RN	Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.
DM9BI7M	RU	https://pubmed.ncbi.nlm.nih.gov/17198971

DM9BI7M	DI	DM9BI7M
DM9BI7M	DN	Duloxetine
DM9BI7M	MI	TT3ROYC
DM9BI7M	MN	Serotonin transporter (SERT)
DM9BI7M	MT	DTT
DM9BI7M	MA	Inhibitor
DM9BI7M	RN	Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.
DM9BI7M	RU	https://pubmed.ncbi.nlm.nih.gov/17198971

DMOAD2Y	DI	DMOAD2Y
DMOAD2Y	DN	Dupilumab
DMOAD2Y	MI	TTDWHC3
DMOAD2Y	MN	Interleukin 4 receptor alpha (IL4R)
DMOAD2Y	MT	DTT
DMOAD2Y	RN	Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013 Jun 27;368(26):2455-66.
DMOAD2Y	RU	https://pubmed.ncbi.nlm.nih.gov/23688323

DM4PVDY	DI	DM4PVDY
DM4PVDY	DN	Durvalumab
DM4PVDY	MI	TT8ZLTI
DM4PVDY	MN	Programmed cell death 1 ligand 1 (PD-L1)
DM4PVDY	MT	DTT
DM4PVDY	MA	Modulator
DM4PVDY	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM4PVDY	RU	https://www.fda.gov/

DMQ4TJK	DI	DMQ4TJK
DMQ4TJK	DN	Dutasteride
DMQ4TJK	MI	DECB0K3
DMQ4TJK	MN	Cytochrome P450 2D6 (CYP2D6)
DMQ4TJK	MT	DME
DMQ4TJK	MA	Metabolism
DMQ4TJK	RN	Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011 May;50(5):281-94.
DMQ4TJK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21366359

DMQ4TJK	DI	DMQ4TJK
DMQ4TJK	DN	Dutasteride
DMQ4TJK	MI	DEIBDNY
DMQ4TJK	MN	Cytochrome P450 3A5 (CYP3A5)
DMQ4TJK	MT	DME
DMQ4TJK	MA	Metabolism
DMQ4TJK	RN	Product monograph: Avodart (dutasteride capsules).
DMQ4TJK	RU	https://ca.gsk.com/media/588688/avodart.pdf

DMQ4TJK	DI	DMQ4TJK
DMQ4TJK	DN	Dutasteride
DMQ4TJK	MI	TT2A0DR
DMQ4TJK	MN	Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A)
DMQ4TJK	MT	DTT
DMQ4TJK	MA	Inhibitor
DMQ4TJK	RN	The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme Can Urol Assoc J. 2009 Jun;3(3 Suppl 2):S109-14.
DMQ4TJK	RU	https://pubmed.ncbi.nlm.nih.gov/19543428

DMU6OFP	DI	DMU6OFP
DMU6OFP	DN	Dyclonine
DMU6OFP	MI	TTZOVE0
DMU6OFP	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DMU6OFP	MT	DTT
DMU6OFP	MA	Blocker
DMU6OFP	RN	Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine. Pharmacol Biochem Behav. 1998 Feb;59(2):305-12.
DMU6OFP	RU	https://pubmed.ncbi.nlm.nih.gov/9476974

DMAKIDV	DI	DMAKIDV
DMAKIDV	DN	Dydrogesterone
DMAKIDV	MI	DE4LYSA
DMAKIDV	MN	Cytochrome P450 3A4 (CYP3A4)
DMAKIDV	MT	DME
DMAKIDV	MA	Metabolism
DMAKIDV	RN	Dydrogesterone metabolism in human liver by aldo-keto reductases and cytochrome P450 enzymes. Xenobiotica. 2016 Oct;46(10):868-74.
DMAKIDV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26796435

DMAKIDV	DI	DMAKIDV
DMAKIDV	DN	Dydrogesterone
DMAKIDV	MI	TTUV8G9
DMAKIDV	MN	Progesterone receptor (PGR)
DMAKIDV	MT	DTT
DMAKIDV	MA	Agonist
DMAKIDV	RN	Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharm... Steroids. 2008 Feb;73(2):222-31.
DMAKIDV	RU	https://pubmed.ncbi.nlm.nih.gov/18061638

DM8DZC1	DI	DM8DZC1
DM8DZC1	DN	Dyphylline
DM8DZC1	MI	TTZ97H5
DM8DZC1	MN	Phosphodiesterase 4A (PDE4A)
DM8DZC1	MT	DTT
DM8DZC1	MA	Inhibitor
DM8DZC1	RN	Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol. 1994 Jun 2;258(1-2):85-94.
DM8DZC1	RU	https://pubmed.ncbi.nlm.nih.gov/7925603

DMJDYNQ	DI	DMJDYNQ
DMJDYNQ	DN	E-2007
DMJDYNQ	MI	DEJGDUW
DMJDYNQ	MN	Cytochrome P450 1A2 (CYP1A2)
DMJDYNQ	MT	DME
DMJDYNQ	MA	Metabolism
DMJDYNQ	RN	Perampanel (Fycompa): a review of clinical efficacy and safety in epilepsy. P T. 2016 Nov;41(11):683-698.
DMJDYNQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27904300

DMJDYNQ	DI	DMJDYNQ
DMJDYNQ	DN	E-2007
DMJDYNQ	MI	DE4LYSA
DMJDYNQ	MN	Cytochrome P450 3A4 (CYP3A4)
DMJDYNQ	MT	DME
DMJDYNQ	MA	Metabolism
DMJDYNQ	RN	The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist. Epilepsia. 2015 Jan;56(1):12-27.
DMJDYNQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25495693

DMJDYNQ	DI	DMJDYNQ
DMJDYNQ	DN	E-2007
DMJDYNQ	MI	DEIBDNY
DMJDYNQ	MN	Cytochrome P450 3A5 (CYP3A5)
DMJDYNQ	MT	DME
DMJDYNQ	MA	Metabolism
DMJDYNQ	RN	FDA label of Perampanel. The 2020 official website of the U.S. Food and Drug Administration.
DMJDYNQ	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202834s011lbl.pdf

DMJDYNQ	DI	DMJDYNQ
DMJDYNQ	DN	E-2007
DMJDYNQ	MI	TTAN6JD
DMJDYNQ	MN	Glutamate receptor AMPA (GRIA)
DMJDYNQ	MT	DTT
DMJDYNQ	MA	Modulator
DMJDYNQ	RN	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
DMJDYNQ	RU	https://pubmed.ncbi.nlm.nih.gov/23370234

DMJDYNQ	DI	DMJDYNQ
DMJDYNQ	DN	E-2007
DMJDYNQ	MI	TTVPQTF
DMJDYNQ	MN	Glutamate receptor AMPA 1 (GRIA1)
DMJDYNQ	MT	DTT
DMJDYNQ	MA	Inhibitor
DMJDYNQ	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMJDYNQ	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMJDYNQ	DI	DMJDYNQ
DMJDYNQ	DN	E-2007
DMJDYNQ	MI	TT9HLZ0
DMJDYNQ	MN	Glutamate receptor AMPA 2 (GRIA2)
DMJDYNQ	MT	DTT
DMJDYNQ	MA	Inhibitor
DMJDYNQ	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMJDYNQ	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMJDYNQ	DI	DMJDYNQ
DMJDYNQ	DN	E-2007
DMJDYNQ	MI	TT82EZV
DMJDYNQ	MN	Glutamate receptor AMPA 3 (GRIA3)
DMJDYNQ	MT	DTT
DMJDYNQ	MA	Inhibitor
DMJDYNQ	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMJDYNQ	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMJDYNQ	DI	DMJDYNQ
DMJDYNQ	DN	E-2007
DMJDYNQ	MI	TTPJR0G
DMJDYNQ	MN	Glutamate receptor AMPA 4 (GRIA4)
DMJDYNQ	MT	DTT
DMJDYNQ	MA	Inhibitor
DMJDYNQ	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMJDYNQ	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMOF2C6	DI	DMOF2C6
DMOF2C6	DN	Ecallantide
DMOF2C6	MI	TT5L2VC
DMOF2C6	MN	Kallikrein-related peptidase (KLK)
DMOF2C6	MT	DTT
DMOF2C6	MA	Inhibitor
DMOF2C6	RN	Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery. Expert Opin Biol Ther. 2008 Aug;8(8):1187-99.
DMOF2C6	RU	https://pubmed.ncbi.nlm.nih.gov/18613770

DMOF2C6	DI	DMOF2C6
DMOF2C6	DN	Ecallantide
DMOF2C6	MI	TTMF8H9
DMOF2C6	MN	Plasma kallikrein (KLKB1)
DMOF2C6	MT	DTT
DMOF2C6	MA	Inhibitor
DMOF2C6	RN	Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery. Expert Opin Biol Ther. 2008 Aug;8(8):1187-99.
DMOF2C6	RU	https://pubmed.ncbi.nlm.nih.gov/18613770

DMSNVGB	DI	DMSNVGB
DMSNVGB	DN	Echothiophate Iodide
DMSNVGB	MI	TT1RS9F
DMSNVGB	MN	Acetylcholinesterase (AChE)
DMSNVGB	MT	DTT
DMSNVGB	MA	Modulator
DMSNVGB	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMSNVGB	RU	https://www.fda.gov/

DMFSWGH	DI	DMFSWGH
DMFSWGH	DN	Econazole
DMFSWGH	MI	TTTSOUD
DMFSWGH	MN	Candida Cytochrome P450 51 (Candi ERG11)
DMFSWGH	MT	DTT
DMFSWGH	MA	Inhibitor
DMFSWGH	RN	Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homolo... Antimicrob Agents Chemother. 2008 Oct;52(10):3597-603.
DMFSWGH	RU	https://pubmed.ncbi.nlm.nih.gov/18694951

DMCRQHB	DI	DMCRQHB
DMCRQHB	DN	Edrophonium
DMCRQHB	MI	TT1RS9F
DMCRQHB	MN	Acetylcholinesterase (AChE)
DMCRQHB	MT	DTT
DMCRQHB	MA	Inhibitor
DMCRQHB	RN	Screening of acetylcholinesterase inhibitors by CE after enzymatic reaction at capillary inlet. J Sep Sci. 2009 May;32(10):1748-56.
DMCRQHB	RU	https://pubmed.ncbi.nlm.nih.gov/19472276

DMCKL5V	DI	DMCKL5V
DMCKL5V	DN	Efalizumab
DMCKL5V	MI	TT48WR6
DMCKL5V	MN	Integrin alpha-L (ITGAL)
DMCKL5V	MT	DTT
DMCKL5V	RN	[Successful therapy of discoid lupus erythematosus with efalizumab]. Hautarzt. 2010 Mar;61(3):246-9.
DMCKL5V	RU	https://pubmed.ncbi.nlm.nih.gov/19436973

DMC0GSJ	DI	DMC0GSJ
DMC0GSJ	DN	Efavirenz
DMC0GSJ	MI	DEJGDUW
DMC0GSJ	MN	Cytochrome P450 1A2 (CYP1A2)
DMC0GSJ	MT	DME
DMC0GSJ	MA	Metabolism
DMC0GSJ	RN	CYP2B6 genotype-dependent inhibition of CYP1A2 and induction of CYP2A6 by the antiretroviral drug efavirenz in healthy volunteers. Clin Transl Sci. 2019 Nov;12(6):657-666.
DMC0GSJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31339646

DMC0GSJ	DI	DMC0GSJ
DMC0GSJ	DN	Efavirenz
DMC0GSJ	MI	DEPKLMQ
DMC0GSJ	MN	Cytochrome P450 2B6 (CYP2B6)
DMC0GSJ	MT	DME
DMC0GSJ	MA	Metabolism
DMC0GSJ	RN	Evaluation of CYP2B6 induction and prediction of clinical drug-drug interactions: considerations from the IQ consortium induction working group-an industry perspective. Drug Metab Dispos. 2016 Oct;44(10):1720-30.
DMC0GSJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27422672

DMC0GSJ	DI	DMC0GSJ
DMC0GSJ	DN	Efavirenz
DMC0GSJ	MI	DE4LYSA
DMC0GSJ	MN	Cytochrome P450 3A4 (CYP3A4)
DMC0GSJ	MT	DME
DMC0GSJ	MA	Metabolism
DMC0GSJ	RN	Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol. 2004 Nov;44(11):1273-81.
DMC0GSJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15496645

DMC0GSJ	DI	DMC0GSJ
DMC0GSJ	DN	Efavirenz
DMC0GSJ	MI	TT84ETX
DMC0GSJ	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMC0GSJ	MT	DTT
DMC0GSJ	MA	Modulator
DMC0GSJ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMC0GSJ	RU	https://www.fda.gov/

DMC0GSJ	DI	DMC0GSJ
DMC0GSJ	DN	Efavirenz
DMC0GSJ	MI	DTQ3ZHF
DMC0GSJ	MN	Multidrug resistance-associated protein 3 (ABCC3)
DMC0GSJ	MT	DTP
DMC0GSJ	MA	Substrate
DMC0GSJ	RN	Induction of multiple drug transporters by efavirenz. J Pharmacol Sci. 2009 Feb;109(2):242-50.
DMC0GSJ	RU	https://doi.org/10.1254/jphs.08209FP

DMC0GSJ	DI	DMC0GSJ
DMC0GSJ	DN	Efavirenz
DMC0GSJ	MI	DTUGYRD
DMC0GSJ	MN	P-glycoprotein 1 (ABCB1)
DMC0GSJ	MT	DTP
DMC0GSJ	MA	Substrate
DMC0GSJ	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMC0GSJ	RU	https://doi.org/10.1007/s11095-012-0935-x

DMFA9MV	DI	DMFA9MV
DMFA9MV	DN	Efinaconazole
DMFA9MV	MI	TTTSOUD
DMFA9MV	MN	Candida Cytochrome P450 51 (Candi ERG11)
DMFA9MV	MT	DTT
DMFA9MV	MA	Inhibitor
DMFA9MV	RN	Efinaconazole: Developmental and reproductive toxicity potential of a novel antifungal azole. Reprod Toxicol. 2015 Apr;52:18-25.
DMFA9MV	RU	https://pubmed.ncbi.nlm.nih.gov/25527861

DMJOQM3	DI	DMJOQM3
DMJOQM3	DN	Eflornithine
DMJOQM3	MI	TTUMGNO
DMJOQM3	MN	Ornithine decarboxylase (ODC1)
DMJOQM3	MT	DTT
DMJOQM3	MA	Inhibitor
DMJOQM3	RN	Plasmodium falciparum and Plasmodium berghei: effects of ornithine decarboxylase inhibitors on erythrocytic schizogony. Exp Parasitol. 1987 Oct;64(2):237-43.
DMJOQM3	RU	https://pubmed.ncbi.nlm.nih.gov/3115816

DMMUCG4	DI	DMMUCG4
DMMUCG4	DN	Eicosapentaenoic acid/docosa-hexaenoic acid
DMMUCG4	MI	DE5IED8
DMMUCG4	MN	Cytochrome P450 2C9 (CYP2C9)
DMMUCG4	MT	DME
DMMUCG4	MA	Metabolism
DMMUCG4	RN	CYP-eicosanoids--a new link between omega-3 fatty acids and cardiac disease? Prostaglandins Other Lipid Mediat. 2011 Nov;96(1-4):99-108.
DMMUCG4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21945326

DMMUCG4	DI	DMMUCG4
DMMUCG4	DN	Eicosapentaenoic acid/docosa-hexaenoic acid
DMMUCG4	MI	DT5G94L
DMMUCG4	MN	Major facilitator superfamily domain-containing protein 2A (SLC59A1)
DMMUCG4	MT	DTP
DMMUCG4	MA	Substrate
DMMUCG4	RN	Mfsd2a Is a Transporter for the Essential -3 Fatty Acid Docosahexaenoic Acid (DHA) in Eye and Is Important for Photoreceptor Cell Development. J Biol Chem. 2016 May 13;291(20):10501-14.
DMMUCG4	RU	http://www.ncbi.nlm.nih.gov/pubmed/27008858

DMMUCG4	DI	DMMUCG4
DMMUCG4	DN	Eicosapentaenoic acid/docosa-hexaenoic acid
DMMUCG4	MI	TT8NGED
DMMUCG4	MN	Prostaglandin G/H synthase 1 (COX-1)
DMMUCG4	MT	DTT
DMMUCG4	MA	Inhibitor
DMMUCG4	RN	Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
DMMUCG4	RU	https://pubmed.ncbi.nlm.nih.gov/11421736

DMMUCG4	DI	DMMUCG4
DMMUCG4	DN	Eicosapentaenoic acid/docosa-hexaenoic acid
DMMUCG4	MI	DE073H6
DMMUCG4	MN	Prostaglandin G/H synthase 1 (COX-1)
DMMUCG4	MT	DME
DMMUCG4	MA	Metabolism
DMMUCG4	RN	Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. FASEB J. 2006 Jun;20(8):1097-108.
DMMUCG4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16770009

DMMUCG4	DI	DMMUCG4
DMMUCG4	DN	Eicosapentaenoic acid/docosa-hexaenoic acid
DMMUCG4	MI	TTVKILB
DMMUCG4	MN	Prostaglandin G/H synthase 2 (COX-2)
DMMUCG4	MT	DTT
DMMUCG4	MA	Inhibitor
DMMUCG4	RN	Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
DMMUCG4	RU	https://pubmed.ncbi.nlm.nih.gov/11421736

DMMUCG4	DI	DMMUCG4
DMMUCG4	DN	Eicosapentaenoic acid/docosa-hexaenoic acid
DMMUCG4	MI	DE492CE
DMMUCG4	MN	Prostaglandin G/H synthase 2 (COX-2)
DMMUCG4	MT	DME
DMMUCG4	MA	Metabolism
DMMUCG4	RN	Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. FASEB J. 2006 Jun;20(8):1097-108.
DMMUCG4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16770009

DMRDUC0	DI	DMRDUC0
DMRDUC0	DN	Elagolix sodium
DMRDUC0	MI	TT8R70G
DMRDUC0	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMRDUC0	MT	DTT
DMRDUC0	MA	Antagonist
DMRDUC0	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMRDUC0	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMS7OU8	DI	DMS7OU8
DMS7OU8	DN	Elapegademase
DMS7OU8	MI	TTLP57V
DMS7OU8	MN	Adenosine deaminase (ADA)
DMS7OU8	MT	DTT
DMS7OU8	MA	Modulator
DMS7OU8	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMS7OU8	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMJLE18	DI	DMJLE18
DMJLE18	DN	Elbasvir
DMJLE18	MI	DE4LYSA
DMJLE18	MN	Cytochrome P450 3A4 (CYP3A4)
DMJLE18	MT	DME
DMJLE18	MA	Metabolism
DMJLE18	RN	Clinical pharmacokinetics and drug-drug interactions of Elbasvir/Grazoprevir. Eur J Drug Metab Pharmacokinet. 2018 Oct;43(5):509-531.
DMJLE18	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29557529

DMW649X	DI	DMW649X
DMW649X	DN	Eletriptan
DMW649X	MI	TTK8CXU
DMW649X	MN	5-HT 1B receptor (HTR1B)
DMW649X	MT	DTT
DMW649X	MA	Modulator
DMW649X	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMW649X	RU	https://www.fda.gov/

DMW649X	DI	DMW649X
DMW649X	DN	Eletriptan
DMW649X	MI	TT6MSOK
DMW649X	MN	5-HT 1D receptor (HTR1D)
DMW649X	MT	DTT
DMW649X	MA	Modulator
DMW649X	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMW649X	RU	https://www.fda.gov/

DMW649X	DI	DMW649X
DMW649X	DN	Eletriptan
DMW649X	MI	DE5IED8
DMW649X	MN	Cytochrome P450 2C9 (CYP2C9)
DMW649X	MT	DME
DMW649X	MA	Metabolism
DMW649X	RN	Eletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent response. Ther Adv Neurol Disord. 2016 Sep;9(5):414-23.
DMW649X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27582896

DMW649X	DI	DMW649X
DMW649X	DN	Eletriptan
DMW649X	MI	DECB0K3
DMW649X	MN	Cytochrome P450 2D6 (CYP2D6)
DMW649X	MT	DME
DMW649X	MA	Metabolism
DMW649X	RN	Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab Dispos. 2003 Jul;31(7):861-9.
DMW649X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12814962

DMW649X	DI	DMW649X
DMW649X	DN	Eletriptan
DMW649X	MI	DE4LYSA
DMW649X	MN	Cytochrome P450 3A4 (CYP3A4)
DMW649X	MT	DME
DMW649X	MA	Metabolism
DMW649X	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMW649X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMW649X	DI	DMW649X
DMW649X	DN	Eletriptan
DMW649X	MI	DTUGYRD
DMW649X	MN	P-glycoprotein 1 (ABCB1)
DMW649X	MT	DTP
DMW649X	MA	Substrate
DMW649X	RN	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
DMW649X	RU	https://doi.org/10.1016/j.addr.2011.12.008

DMW649X	DI	DMW649X
DMW649X	DN	Eletriptan
DMW649X	MI	DE073H6
DMW649X	MN	Prostaglandin G/H synthase 1 (COX-1)
DMW649X	MT	DME
DMW649X	MA	Metabolism
DMW649X	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMW649X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMSRZAO	DI	DMSRZAO
DMSRZAO	DN	Eliglustat tartrate
DMSRZAO	MI	TTPHEX3
DMSRZAO	MN	Ceramide glucosyltransferase (UGCG)
DMSRZAO	MT	DTT
DMSRZAO	MA	Modulator
DMSRZAO	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMSRZAO	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMSRZAO	DI	DMSRZAO
DMSRZAO	DN	Eliglustat tartrate
DMSRZAO	MI	DECB0K3
DMSRZAO	MN	Cytochrome P450 2D6 (CYP2D6)
DMSRZAO	MT	DME
DMSRZAO	MA	Metabolism
DMSRZAO	RN	Eliglustat: first global approval. Drugs. 2014 Oct;74(15):1829-36.
DMSRZAO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25239269

DMSRZAO	DI	DMSRZAO
DMSRZAO	DN	Eliglustat tartrate
DMSRZAO	MI	DE4LYSA
DMSRZAO	MN	Cytochrome P450 3A4 (CYP3A4)
DMSRZAO	MT	DME
DMSRZAO	MA	Metabolism
DMSRZAO	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMSRZAO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMSRZAO	DI	DMSRZAO
DMSRZAO	DN	Eliglustat tartrate
DMSRZAO	MI	DTUGYRD
DMSRZAO	MN	P-glycoprotein 1 (ABCB1)
DMSRZAO	MT	DTP
DMSRZAO	MA	Substrate
DMSRZAO	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
DMSRZAO	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01665

DMZC6GT	DI	DMZC6GT
DMZC6GT	DN	Elliptinium acetate
DMZC6GT	MI	TTABD5E
DMZC6GT	MN	DNA replication (DNA repli)
DMZC6GT	MT	DTT
DMZC6GT	MA	Modulator
DMZC6GT	RN	Stationary potential of the brain: Part II. Clinical studies. Neurol Med Chir (Tokyo). 1979 Jul;19(7):655-64.
DMZC6GT	RU	https://pubmed.ncbi.nlm.nih.gov/91123

DMRCX8K	DI	DMRCX8K
DMRCX8K	DN	Eloctate
DMRCX8K	MI	TT1290U
DMRCX8K	MN	Coagulation factor VIII (F8)
DMRCX8K	MT	DTT
DMRCX8K	MA	Modulator
DMRCX8K	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMRCX8K	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMA9REV	DI	DMA9REV
DMA9REV	DN	Elosulfase alfa
DMA9REV	MI	TTT9YPO
DMA9REV	MN	N-acetylgalactosamine 6 sulfatase (GALNS)
DMA9REV	MT	DTT
DMA9REV	MA	Modulator
DMA9REV	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMA9REV	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMEYHG9	DI	DMEYHG9
DMEYHG9	DN	Elotuzumab
DMEYHG9	MI	TT7ILZ1
DMEYHG9	MN	SLAM family member 7 SLAMF7 (CS1)
DMEYHG9	MT	DTT
DMEYHG9	RN	Market watch: Upcoming catalysts in Q2 2015. Nat Rev Drug Discov. 2015 Apr;14(4):228.
DMEYHG9	RU	https://pubmed.ncbi.nlm.nih.gov/25764988

DMOGFIX	DI	DMOGFIX
DMOGFIX	DN	Eltrombopag
DMOGFIX	MI	DTI7UX6
DMOGFIX	MN	Breast cancer resistance protein (ABCG2)
DMOGFIX	MT	DTP
DMOGFIX	MA	Substrate
DMOGFIX	RN	Assessment of the pharmacokinetic interaction between eltrombopag and lopinavir-ritonavir in healthy adult subjects. Antimicrob Agents Chemother. 2012 Jun;56(6):2846-51.
DMOGFIX	RU	https://doi.org/10.1128/AAC.05214-11

DMOGFIX	DI	DMOGFIX
DMOGFIX	DN	Eltrombopag
DMOGFIX	MI	DEJGDUW
DMOGFIX	MN	Cytochrome P450 1A2 (CYP1A2)
DMOGFIX	MT	DME
DMOGFIX	MA	Metabolism
DMOGFIX	RN	Eltrombopag for use in children with immune thrombocytopenia. Blood Adv. 2018 Feb 27;2(4):454-461.
DMOGFIX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29487060

DMOGFIX	DI	DMOGFIX
DMOGFIX	DN	Eltrombopag
DMOGFIX	MI	DES5XRU
DMOGFIX	MN	Cytochrome P450 2C8 (CYP2C8)
DMOGFIX	MT	DME
DMOGFIX	MA	Metabolism
DMOGFIX	RN	Eltrombopag-induced acute liver failure in a pediatric patient: a pharmacokinetic and pharmacogenetic analysis. Ther Drug Monit. 2018 Aug;40(4):386-388.
DMOGFIX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29683873

DMOGFIX	DI	DMOGFIX
DMOGFIX	DN	Eltrombopag
DMOGFIX	MI	DTPFTEQ
DMOGFIX	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DMOGFIX	MT	DTP
DMOGFIX	MA	Substrate
DMOGFIX	RN	Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent. Drug Metab Dispos. 2011 Jun;39(6):1088-96.
DMOGFIX	RU	http://www.ncbi.nlm.nih.gov/pubmed/21422191

DMOGFIX	DI	DMOGFIX
DMOGFIX	DN	Eltrombopag
DMOGFIX	MI	TTIHYA4
DMOGFIX	MN	Thrombopoietin receptor (MPL)
DMOGFIX	MT	DTT
DMOGFIX	MA	Agonist
DMOGFIX	RN	Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54.
DMOGFIX	RU	https://pubmed.ncbi.nlm.nih.gov/18537519

DMOGFIX	DI	DMOGFIX
DMOGFIX	DN	Eltrombopag
DMOGFIX	MI	DEYGVN4
DMOGFIX	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMOGFIX	MT	DME
DMOGFIX	MA	Metabolism
DMOGFIX	RN	Eltrombopag-induced acute liver failure in a pediatric patient: a pharmacokinetic and pharmacogenetic analysis. Ther Drug Monit. 2018 Aug;40(4):386-388.
DMOGFIX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29683873

DMYZ0P1	DI	DMYZ0P1
DMYZ0P1	DN	Eluxadoline
DMYZ0P1	MI	TT27RFC
DMYZ0P1	MN	Opioid receptor delta (OPRD1)
DMYZ0P1	MT	DTT
DMYZ0P1	MA	Modulator
DMYZ0P1	RN	Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.Biochem Pharmacol.2014 Dec 1;92(3):448-56.
DMYZ0P1	RU	https://www.ncbi.nlm.nih.gov/pubmed/25261794

DMYZ0P1	DI	DMYZ0P1
DMYZ0P1	DN	Eluxadoline
DMYZ0P1	MI	TTKWM86
DMYZ0P1	MN	Opioid receptor mu (MOP)
DMYZ0P1	MT	DTT
DMYZ0P1	MA	Modulator
DMYZ0P1	RN	Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.Biochem Pharmacol.2014 Dec 1;92(3):448-56.
DMYZ0P1	RU	https://www.ncbi.nlm.nih.gov/pubmed/25261794

DMYZ0P1	DI	DMYZ0P1
DMYZ0P1	DN	Eluxadoline
DMYZ0P1	MI	DT3D8F0
DMYZ0P1	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMYZ0P1	MT	DTP
DMYZ0P1	MA	Substrate
DMYZ0P1	RN	Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline. J Clin Pharmacol. 2015 May;55(5):534-42.
DMYZ0P1	RU	http://www.ncbi.nlm.nih.gov/pubmed/25491493

DMG9B1U	DI	DMG9B1U
DMG9B1U	DN	Elvitegravir
DMG9B1U	MI	DE4LYSA
DMG9B1U	MN	Cytochrome P450 3A4 (CYP3A4)
DMG9B1U	MT	DME
DMG9B1U	MA	Metabolism
DMG9B1U	RN	FDA Label of Elvitegravir. The 2020 official website of the U.S. Food and Drug Administration.
DMG9B1U	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203100s030lbl.pdf

DMG9B1U	DI	DMG9B1U
DMG9B1U	DN	Elvitegravir
DMG9B1U	MI	TT5FH9Y
DMG9B1U	MN	Human immunodeficiency virus Integrase (HIV IN)
DMG9B1U	MT	DTT
DMG9B1U	MA	Modulator
DMG9B1U	RN	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
DMG9B1U	RU	https://pubmed.ncbi.nlm.nih.gov/28919714

DMG9B1U	DI	DMG9B1U
DMG9B1U	DN	Elvitegravir
DMG9B1U	MI	DEYGVN4
DMG9B1U	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMG9B1U	MT	DME
DMG9B1U	MA	Metabolism
DMG9B1U	RN	Elvitegravir for the treatment of HIV infection. Drugs Today (Barc). 2014 Mar;50(3):209-17.
DMG9B1U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24696866

DMZG5WL	DI	DMZG5WL
DMZG5WL	DN	Emapalumab
DMZG5WL	MI	TT93WF5
DMZG5WL	MN	Interferon-gamma (IFNG)
DMZG5WL	MT	DTT
DMZG5WL	MA	Modulator
DMZG5WL	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMZG5WL	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DM36LAJ	DI	DM36LAJ
DM36LAJ	DN	Emedastine
DM36LAJ	MI	TTTIBOJ
DM36LAJ	MN	Histamine H1 receptor (H1R)
DM36LAJ	MT	DTT
DM36LAJ	MA	Antagonist
DM36LAJ	RN	Emedastine difumarate: a review of its potential ameliorating effect for tissue remodeling in allergic diseases. Expert Opin Pharmacother. 2009 Aug;10(11):1859-67.
DM36LAJ	RU	https://pubmed.ncbi.nlm.nih.gov/19558341

DMCOAVT	DI	DMCOAVT
DMCOAVT	DN	Emepronium
DMCOAVT	MI	TTH18TF
DMCOAVT	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMCOAVT	MT	DTT
DMCOAVT	MA	Modulator
DMCOAVT	RN	Classification of the presynaptic muscarinic receptor subtype that regulates 3H-acetylcholine secretion in the guinea pig urinary bladder in vitro. J Pharmacol Exp Ther. 1995 Jul;274(1):458-68.
DMCOAVT	RU	https://pubmed.ncbi.nlm.nih.gov/7616431

DMCT2YF	DI	DMCT2YF
DMCT2YF	DN	Emetine
DMCT2YF	MI	DECB0K3
DMCT2YF	MN	Cytochrome P450 2D6 (CYP2D6)
DMCT2YF	MT	DME
DMCT2YF	MA	Metabolism
DMCT2YF	RN	Metabolism of ipecac alkaloids cephaeline and emetine by human hepatic microsomal cytochrome P450s, and their inhibitory effects on P450 enzyme activities. Biol Pharm Bull. 2001 Jun;24(6):678-82.
DMCT2YF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11411558

DMCT2YF	DI	DMCT2YF
DMCT2YF	DN	Emetine
DMCT2YF	MI	DE4LYSA
DMCT2YF	MN	Cytochrome P450 3A4 (CYP3A4)
DMCT2YF	MT	DME
DMCT2YF	MA	Metabolism
DMCT2YF	RN	Metabolism of ipecac alkaloids cephaeline and emetine by human hepatic microsomal cytochrome P450s, and their inhibitory effects on P450 enzyme activities. Biol Pharm Bull. 2001 Jun;24(6):678-82.
DMCT2YF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11411558

DMCT2YF	DI	DMCT2YF
DMCT2YF	DN	Emetine
DMCT2YF	MI	DTUGYRD
DMCT2YF	MN	P-glycoprotein 1 (ABCB1)
DMCT2YF	MT	DTP
DMCT2YF	MA	Substrate
DMCT2YF	RN	Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia. 2005 Feb;46(2):224-35.
DMCT2YF	RU	https://doi.org/10.1111/j.0013-9580.2005.31904.x

DM0AQ83	DI	DM0AQ83
DM0AQ83	DN	Emicizumab
DM0AQ83	MI	TTFEZ5Q
DM0AQ83	MN	Coagulation factor IX (F9)
DM0AQ83	MT	DTT
DM0AQ83	MA	Modulator
DM0AQ83	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DM0AQ83	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DM0AQ83	DI	DM0AQ83
DM0AQ83	DN	Emicizumab
DM0AQ83	MI	TTCIHJA
DM0AQ83	MN	Coagulation factor Xa (F10)
DM0AQ83	MT	DTT
DM0AQ83	MA	Modulator
DM0AQ83	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DM0AQ83	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DMRF9YK	DI	DMRF9YK
DMRF9YK	DN	Empagliflozin
DMRF9YK	MI	DTI7UX6
DMRF9YK	MN	Breast cancer resistance protein (ABCG2)
DMRF9YK	MT	DTP
DMRF9YK	MA	Substrate
DMRF9YK	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01913)
DMRF9YK	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01913

DMRF9YK	DI	DMRF9YK
DMRF9YK	DN	Empagliflozin
DMRF9YK	MI	DTUGYRD
DMRF9YK	MN	P-glycoprotein 1 (ABCB1)
DMRF9YK	MT	DTP
DMRF9YK	MA	Substrate
DMRF9YK	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
DMRF9YK	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01665

DMRF9YK	DI	DMRF9YK
DMRF9YK	DN	Empagliflozin
DMRF9YK	MI	TTLWPVF
DMRF9YK	MN	Sodium/glucose cotransporter 2 (SGLT2)
DMRF9YK	MT	DTT
DMRF9YK	MA	Modulator
DMRF9YK	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMRF9YK	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMRF9YK	DI	DMRF9YK
DMRF9YK	DN	Empagliflozin
DMRF9YK	MI	DEF2WXN
DMRF9YK	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMRF9YK	MT	DME
DMRF9YK	MA	Metabolism
DMRF9YK	RN	Empagliflozin (Jardiance): a novel SGLT2 inhibitor for the treatment of type-2 diabetes. P T. 2015 Jun;40(6):364-8.
DMRF9YK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26045645

DMRF9YK	DI	DMRF9YK
DMRF9YK	DN	Empagliflozin
DMRF9YK	MI	DE2GB8N
DMRF9YK	MN	UDP-glucuronosyltransferase 1A8 (UGT1A8)
DMRF9YK	MT	DME
DMRF9YK	MA	Metabolism
DMRF9YK	RN	Empagliflozin (Jardiance): a novel SGLT2 inhibitor for the treatment of type-2 diabetes. P T. 2015 Jun;40(6):364-8.
DMRF9YK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26045645

DMRF9YK	DI	DMRF9YK
DMRF9YK	DN	Empagliflozin
DMRF9YK	MI	DE85D2P
DMRF9YK	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMRF9YK	MT	DME
DMRF9YK	MA	Metabolism
DMRF9YK	RN	Empagliflozin (Jardiance): a novel SGLT2 inhibitor for the treatment of type-2 diabetes. P T. 2015 Jun;40(6):364-8.
DMRF9YK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26045645

DMRF9YK	DI	DMRF9YK
DMRF9YK	DN	Empagliflozin
DMRF9YK	MI	DEB3CV1
DMRF9YK	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMRF9YK	MT	DME
DMRF9YK	MA	Metabolism
DMRF9YK	RN	Empagliflozin (Jardiance): a novel SGLT2 inhibitor for the treatment of type-2 diabetes. P T. 2015 Jun;40(6):364-8.
DMRF9YK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26045645

DMBMUWZ	DI	DMBMUWZ
DMBMUWZ	DN	Emtricitabine
DMBMUWZ	MI	TT84ETX
DMBMUWZ	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMBMUWZ	MT	DTT
DMBMUWZ	MA	Modulator
DMBMUWZ	RN	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
DMBMUWZ	RU	https://pubmed.ncbi.nlm.nih.gov/23370234

DMBMUWZ	DI	DMBMUWZ
DMBMUWZ	DN	Emtricitabine
DMBMUWZ	MI	DTZGT0P
DMBMUWZ	MN	Multidrug and toxin extrusion protein 1 (SLC47A1)
DMBMUWZ	MT	DTP
DMBMUWZ	MA	Substrate
DMBMUWZ	RN	Emtricitabine is a substrate of MATE1 but not of OCT1, OCT2, P-gp, BCRP or MRP2 transporters. Xenobiotica. 2017 Jan;47(1):77-85.
DMBMUWZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/27052107

DMNFUZR	DI	DMNFUZR
DMNFUZR	DN	Enalapril
DMNFUZR	MI	TTL69WB
DMNFUZR	MN	Angiotensin-converting enzyme (ACE)
DMNFUZR	MT	DTT
DMNFUZR	MA	Inhibitor
DMNFUZR	RN	Determination of bezafibrate, methotrexate, cyclophosphamide, orlistat and enalapril in waste and surface waters using on-line solid-phase extracti... J Environ Monit. 2009 Apr;11(4):830-8.
DMNFUZR	RU	https://pubmed.ncbi.nlm.nih.gov/19557238

DMNFUZR	DI	DMNFUZR
DMNFUZR	DN	Enalapril
DMNFUZR	MI	DEB30C5
DMNFUZR	MN	Carboxylesterase 1 (CES1)
DMNFUZR	MT	DME
DMNFUZR	MA	Metabolism
DMNFUZR	RN	Absorption and cleavage of enalapril, a carboxyl ester prodrug, in the rat intestine: in vitro, in situ intestinal perfusion and portal vein cannulation models. Biopharm Drug Dispos. 2015 Sep;36(6):385-397.
DMNFUZR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25832562

DMNFUZR	DI	DMNFUZR
DMNFUZR	DN	Enalapril
DMNFUZR	MI	DE4LYSA
DMNFUZR	MN	Cytochrome P450 3A4 (CYP3A4)
DMNFUZR	MT	DME
DMNFUZR	MA	Metabolism
DMNFUZR	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMNFUZR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMNFUZR	DI	DMNFUZR
DMNFUZR	DN	Enalapril
DMNFUZR	MI	DEQMBHW
DMNFUZR	MN	Dipeptidase (pepV)
DMNFUZR	MT	DME
DMNFUZR	MA	Metabolism
DMNFUZR	RN	Characterization and kinetic analysis of enzyme-substrate recognition by three recombinant lactococcal PepVs. Arch Biochem Biophys. 2006 Oct 15;454(2):137-45.
DMNFUZR	RU	https://pubmed.ncbi.nlm.nih.gov/16962986

DMNFUZR	DI	DMNFUZR
DMNFUZR	DN	Enalapril
DMNFUZR	MI	DTFI42L
DMNFUZR	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMNFUZR	MT	DTP
DMNFUZR	MA	Substrate
DMNFUZR	RN	Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers. J Pharmacol Exp Ther. 2006 Jul;318(1):395-402.
DMNFUZR	RU	http://www.ncbi.nlm.nih.gov/pubmed/16627748

DMNFUZR	DI	DMNFUZR
DMNFUZR	DN	Enalapril
DMNFUZR	MI	DTE2B1D
DMNFUZR	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMNFUZR	MT	DTP
DMNFUZR	MA	Substrate
DMNFUZR	RN	Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes. Drug Metab Dispos. 2000 Jul;28(7):801-6.
DMNFUZR	RU	http://www.ncbi.nlm.nih.gov/pubmed/10859154

DMNFUZR	DI	DMNFUZR
DMNFUZR	DN	Enalapril
DMNFUZR	MI	DT3D8F0
DMNFUZR	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMNFUZR	MT	DTP
DMNFUZR	MA	Substrate
DMNFUZR	RN	The modified dipeptide, enalapril, an angiotensin-converting enzyme inhibitor, is transported by the rat liver organic anion transport protein. Hepatology. 1998 Nov;28(5):1341-6.
DMNFUZR	RU	http://www.ncbi.nlm.nih.gov/pubmed/9794920

DMNFUZR	DI	DMNFUZR
DMNFUZR	DN	Enalapril
DMNFUZR	MI	DT9C1TS
DMNFUZR	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMNFUZR	MT	DTP
DMNFUZR	MA	Substrate
DMNFUZR	RN	Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers. J Pharmacol Exp Ther. 2006 Jul;318(1):395-402.
DMNFUZR	RU	http://www.ncbi.nlm.nih.gov/pubmed/16627748

DMNFUZR	DI	DMNFUZR
DMNFUZR	DN	Enalapril
DMNFUZR	MI	DT9G7XN
DMNFUZR	MN	Peptide transporter 1 (SLC15A1)
DMNFUZR	MT	DTP
DMNFUZR	MA	Substrate
DMNFUZR	RN	The intestinal H+/peptide symporter PEPT1: structure-affinity relationships. Eur J Pharm Sci. 2004 Jan;21(1):53-60.
DMNFUZR	RU	https://doi.org/10.1016/S0928-0987(03)00142-8

DMNFUZR	DI	DMNFUZR
DMNFUZR	DN	Enalapril
DMNFUZR	MI	DT8QKNP
DMNFUZR	MN	Peptide transporter 2 (SLC15A2)
DMNFUZR	MT	DTP
DMNFUZR	MA	Substrate
DMNFUZR	RN	Ethanol inhibits functional activity of the human intestinal dipeptide transporter hPepT1 expressed in Xenopus oocytes. Alcohol Clin Exp Res. 2008 May;32(5):777-84.
DMNFUZR	RU	http://www.ncbi.nlm.nih.gov/pubmed/18336632

DMPRBQV	DI	DMPRBQV
DMPRBQV	DN	Enalaprilat
DMPRBQV	MI	TTL69WB
DMPRBQV	MN	Angiotensin-converting enzyme (ACE)
DMPRBQV	MT	DTT
DMPRBQV	MA	Inhibitor
DMPRBQV	RN	Analysis of Vancomycin in the Hindlimb Vascular Bed of the Rat. Am J Ther. 1996 Oct;3(10):681-687.
DMPRBQV	RU	https://pubmed.ncbi.nlm.nih.gov/11862223

DMFYAM1	DI	DMFYAM1
DMFYAM1	DN	Enalaprilat
DMFYAM1	MI	DEQMBHW
DMFYAM1	MN	Dipeptidase (pepV)
DMFYAM1	MT	DME
DMFYAM1	MA	Metabolism
DMFYAM1	RN	Characterization and kinetic analysis of enzyme-substrate recognition by three recombinant lactococcal PepVs. Arch Biochem Biophys. 2006 Oct 15;454(2):137-45.
DMFYAM1	RU	https://pubmed.ncbi.nlm.nih.gov/16962986

DMPRBQV	DI	DMPRBQV
DMPRBQV	DN	Enalaprilat
DMPRBQV	MI	DT9G7XN
DMPRBQV	MN	Peptide transporter 1 (SLC15A1)
DMPRBQV	MT	DTP
DMPRBQV	MA	Substrate
DMPRBQV	RN	Transporter-mediated Drug Interactions. Drug Metab Pharmacokinet. 2002;17(4):253-74.
DMPRBQV	RU	https://doi.org/10.2133/dmpk.17.253

DM8QXOC	DI	DM8QXOC
DM8QXOC	DN	Enasidenib
DM8QXOC	MI	DEJGDUW
DM8QXOC	MN	Cytochrome P450 1A2 (CYP1A2)
DM8QXOC	MT	DME
DM8QXOC	MA	Metabolism
DM8QXOC	RN	FDA Label of Enasidenib. The 2020 official website of the U.S. Food and Drug Administration.
DM8QXOC	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf

DM8QXOC	DI	DM8QXOC
DM8QXOC	DN	Enasidenib
DM8QXOC	MI	DEPKLMQ
DM8QXOC	MN	Cytochrome P450 2B6 (CYP2B6)
DM8QXOC	MT	DME
DM8QXOC	MA	Metabolism
DM8QXOC	RN	FDA Label of Enasidenib. The 2020 official website of the U.S. Food and Drug Administration.
DM8QXOC	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf

DM8QXOC	DI	DM8QXOC
DM8QXOC	DN	Enasidenib
DM8QXOC	MI	DES5XRU
DM8QXOC	MN	Cytochrome P450 2C8 (CYP2C8)
DM8QXOC	MT	DME
DM8QXOC	MA	Metabolism
DM8QXOC	RN	FDA Label of Enasidenib. The 2020 official website of the U.S. Food and Drug Administration.
DM8QXOC	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf

DM8QXOC	DI	DM8QXOC
DM8QXOC	DN	Enasidenib
DM8QXOC	MI	DE5IED8
DM8QXOC	MN	Cytochrome P450 2C9 (CYP2C9)
DM8QXOC	MT	DME
DM8QXOC	MA	Metabolism
DM8QXOC	RN	FDA Label of Enasidenib. The 2020 official website of the U.S. Food and Drug Administration.
DM8QXOC	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf

DM8QXOC	DI	DM8QXOC
DM8QXOC	DN	Enasidenib
DM8QXOC	MI	DEGTFWK
DM8QXOC	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM8QXOC	MT	DME
DM8QXOC	MA	Metabolism
DM8QXOC	RN	Enasidenib for the treatment of acute myeloid leukemia. Expert Rev Clin Pharmacol. 2018 Aug;11(8):755-760.
DM8QXOC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29770715

DMPOU5H	DI	DMPOU5H
DMPOU5H	DN	ENASIDENIB MESYLATE
DMPOU5H	MI	TTDTWV0
DMPOU5H	MN	Isocitrate dehydrogenase (IDH)
DMPOU5H	MT	DTT
DMPOU5H	MA	Inhibitor
DMPOU5H	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DMPOU5H	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DM7RNP3	DI	DM7RNP3
DM7RNP3	DN	Enbrel
DM7RNP3	MI	TTF8CQI
DM7RNP3	MN	Tumor necrosis factor (TNF)
DM7RNP3	MT	DTT
DM7RNP3	MA	Modulator
DM7RNP3	RN	Oral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes : a potential treatment for aseptic loose... J Bone Joint Surg Am. 2001 Jul;83(7):1057-61.
DM7RNP3	RU	https://www.ncbi.nlm.nih.gov/pubmed/11451976

DM0YJSB	DI	DM0YJSB
DM0YJSB	DN	Enflurane
DM0YJSB	MI	DEVDYN7
DM0YJSB	MN	Cytochrome P450 2E1 (CYP2E1)
DM0YJSB	MT	DME
DM0YJSB	MA	Metabolism
DM0YJSB	RN	Stereoselective metabolism of enflurane by human liver cytochrome P450 2E1. Drug Metab Dispos. 1995 Dec;23(12):1426-30.
DM0YJSB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8689955

DM0YJSB	DI	DM0YJSB
DM0YJSB	DN	Enflurane
DM0YJSB	MI	DED5AT3
DM0YJSB	MN	Cytochrome P450 2F1 (CYP2F1)
DM0YJSB	MT	DME
DM0YJSB	MA	Metabolism
DM0YJSB	RN	Clinical enflurane metabolism by cytochrome P450 2E1. Clin Pharmacol Ther. 1994 Apr;55(4):434-40.
DM0YJSB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8162670

DM0YJSB	DI	DM0YJSB
DM0YJSB	DN	Enflurane
DM0YJSB	MI	TTAN6JD
DM0YJSB	MN	Glutamate receptor AMPA (GRIA)
DM0YJSB	MT	DTT
DM0YJSB	MA	Suppressor
DM0YJSB	RN	Enflurane directly depresses glutamate AMPA and NMDA currents in mouse spinal cord motor neurons independent of actions on GABAA or glycine receptors. Anesthesiology. 2000 Oct;93(4):1075-84.
DM0YJSB	RU	https://pubmed.ncbi.nlm.nih.gov/11020764

DMFS63G	DI	DMFS63G
DMFS63G	DN	Enfortumab
DMFS63G	MI	TTPO9EG
DMFS63G	MN	Nectin cell adhesion molecule 4 (NECTIN4)
DMFS63G	MT	DTT
DMFS63G	MA	Inhibitor
DMFS63G	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMFS63G	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761137s000lbl.pdf

DM7YPM1	DI	DM7YPM1
DM7YPM1	DN	Enfuvirtide
DM7YPM1	MI	DEVDYN7
DM7YPM1	MN	Cytochrome P450 2E1 (CYP2E1)
DM7YPM1	MT	DME
DM7YPM1	MA	Metabolism
DM7YPM1	RN	Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide. Clin Pharmacokinet. 2005;44(2):175-86.
DM7YPM1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15656696

DM7YPM1	DI	DM7YPM1
DM7YPM1	DN	Enfuvirtide
DM7YPM1	MI	TTG90S6
DM7YPM1	MN	Human immunodeficiency virus Glycoprotein 41 (HIV gp41)
DM7YPM1	MT	DTT
DM7YPM1	MA	Modulator
DM7YPM1	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM7YPM1	RU	https://www.fda.gov/

DM7YPM1	DI	DM7YPM1
DM7YPM1	DN	Enfuvirtide
DM7YPM1	MI	DEGTFWK
DM7YPM1	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM7YPM1	MT	DME
DM7YPM1	MA	Metabolism
DM7YPM1	RN	Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide. Clin Pharmacokinet. 2005;44(2):175-86.
DM7YPM1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15656696

DMYTE6L	DI	DMYTE6L
DMYTE6L	DN	Enoxacin
DMYTE6L	MI	TT0IHXV
DMYTE6L	MN	DNA topoisomerase II (TOP2)
DMYTE6L	MT	DTT
DMYTE6L	MA	Inhibitor
DMYTE6L	RN	Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96-121.
DMYTE6L	RU	https://pubmed.ncbi.nlm.nih.gov/3282749

DMYTE6L	DI	DMYTE6L
DMYTE6L	DN	Enoxacin
DMYTE6L	MI	DTZGT0P
DMYTE6L	MN	Multidrug and toxin extrusion protein 1 (SLC47A1)
DMYTE6L	MT	DTP
DMYTE6L	MA	Substrate
DMYTE6L	RN	Functional characterization of multidrug and toxin extrusion protein 1 as a facilitative transporter for fluoroquinolones. J Pharmacol Exp Ther. 2009 Feb;328(2):628-34.
DMYTE6L	RU	http://www.ncbi.nlm.nih.gov/pubmed/19004926

DMYTE6L	DI	DMYTE6L
DMYTE6L	DN	Enoxacin
DMYTE6L	MI	DTE2B1D
DMYTE6L	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMYTE6L	MT	DTP
DMYTE6L	MA	Substrate
DMYTE6L	RN	Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm. 2007 Jan-Feb;4(1):85-94.
DMYTE6L	RU	http://www.ncbi.nlm.nih.gov/pubmed/17274666

DMQVZJD	DI	DMQVZJD
DMQVZJD	DN	Enoximone
DMQVZJD	MI	TTZCG4L
DMQVZJD	MN	Phosphodiesterase 3 (PDE3)
DMQVZJD	MT	DTT
DMQVZJD	MA	Modulator
DMQVZJD	RN	In vitro and in vivo effects of the phosphodiesterase-III inhibitor enoximone on malignant hyperthermia-susceptible swine. Anesthesiology. 2003 Apr;98(4):944-9.
DMQVZJD	RU	https://www.ncbi.nlm.nih.gov/pubmed/12657857

DMQVZJD	DI	DMQVZJD
DMQVZJD	DN	Enoximone
DMQVZJD	MI	TT06AWU
DMQVZJD	MN	Phosphodiesterase 3A (PDE3A)
DMQVZJD	MT	DTT
DMQVZJD	MA	Inhibitor
DMQVZJD	RN	Inhibitors of cyclic AMP phosphodiesterase. 2. Structural variations of N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro- 2-oxoimidazo[2,1-b]quinazolin... J Med Chem. 1987 Feb;30(2):303-18.
DMQVZJD	RU	https://pubmed.ncbi.nlm.nih.gov/3027339

DMFYZKN	DI	DMFYZKN
DMFYZKN	DN	Enprofylline
DMFYZKN	MI	TTZ97H5
DMFYZKN	MN	Phosphodiesterase 4A (PDE4A)
DMFYZKN	MT	DTT
DMFYZKN	MA	Inhibitor
DMFYZKN	RN	Effects of enprofylline, a new xanthine derivate, on human pregnant myometrium. Am J Obstet Gynecol. 1987 Apr;156(4):958-62.
DMFYZKN	RU	https://pubmed.ncbi.nlm.nih.gov/3034059

DMLBVKQ	DI	DMLBVKQ
DMLBVKQ	DN	Entacapone
DMLBVKQ	MI	DTI7UX6
DMLBVKQ	MN	Breast cancer resistance protein (ABCG2)
DMLBVKQ	MT	DTP
DMLBVKQ	MA	Substrate
DMLBVKQ	RN	Elucidation of the Impact of P-glycoprotein and Breast Cancer Resistance Protein on the Brain Distribution of Catechol-O-Methyltransferase Inhibitors. Drug Metab Dispos. 2017 Dec;45(12):1282-1291.
DMLBVKQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/28916530

DMLBVKQ	DI	DMLBVKQ
DMLBVKQ	DN	Entacapone
DMLBVKQ	MI	TTKWFB8
DMLBVKQ	MN	Catechol-O-methyl-transferase (COMT)
DMLBVKQ	MT	DTT
DMLBVKQ	MA	Inhibitor
DMLBVKQ	RN	Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease. Clin Ther. 2001 Jun;23(6):802-32; discussion 771.
DMLBVKQ	RU	https://pubmed.ncbi.nlm.nih.gov/11440283

DMLBVKQ	DI	DMLBVKQ
DMLBVKQ	DN	Entacapone
DMLBVKQ	MI	DT3D8F0
DMLBVKQ	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMLBVKQ	MT	DTP
DMLBVKQ	MA	Substrate
DMLBVKQ	RN	Organic Anion Transporter 2-Mediated Hepatic Uptake Contributes to the Clearance of High-Permeability-Low-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs. J Pharmacol Exp Ther. 2018 Nov;367(2):322-334.
DMLBVKQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/30135178

DMLBVKQ	DI	DMLBVKQ
DMLBVKQ	DN	Entacapone
DMLBVKQ	MI	DE85D2P
DMLBVKQ	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMLBVKQ	MT	DME
DMLBVKQ	MA	Metabolism
DMLBVKQ	RN	Kinetic characterization of the 1A subfamily of recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos. 2005 Jul;33(7):1017-26.
DMLBVKQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15802387

DM7VTQO	DI	DM7VTQO
DM7VTQO	DN	Entecavir
DM7VTQO	MI	DTI7UX6
DM7VTQO	MN	Breast cancer resistance protein (ABCG2)
DM7VTQO	MT	DTP
DM7VTQO	MA	Substrate
DM7VTQO	RN	Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278.
DM7VTQO	RU	http://www.ncbi.nlm.nih.gov/pubmed/28062543

DM7VTQO	DI	DM7VTQO
DM7VTQO	DN	Entecavir
DM7VTQO	MI	DT4YL5R
DM7VTQO	MN	Concentrative Na(+)-nucleoside cotransporter 3 (SLC28A3)
DM7VTQO	MT	DTP
DM7VTQO	MA	Substrate
DM7VTQO	RN	Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278.
DM7VTQO	RU	http://www.ncbi.nlm.nih.gov/pubmed/28062543

DM7VTQO	DI	DM7VTQO
DM7VTQO	DN	Entecavir
DM7VTQO	MI	DT82KPY
DM7VTQO	MN	Concentrative nucleoside transporter 2 (SLC28A2)
DM7VTQO	MT	DTP
DM7VTQO	MA	Substrate
DM7VTQO	RN	Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278.
DM7VTQO	RU	http://www.ncbi.nlm.nih.gov/pubmed/28062543

DM7VTQO	DI	DM7VTQO
DM7VTQO	DN	Entecavir
DM7VTQO	MI	DTXD1TQ
DM7VTQO	MN	Equilibrative nucleoside transporter 1 (SLC29A1)
DM7VTQO	MT	DTP
DM7VTQO	MA	Substrate
DM7VTQO	RN	Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278.
DM7VTQO	RU	http://www.ncbi.nlm.nih.gov/pubmed/28062543

DM7VTQO	DI	DM7VTQO
DM7VTQO	DN	Entecavir
DM7VTQO	MI	DTW78DQ
DM7VTQO	MN	Equilibrative nucleoside transporter 2 (SLC29A2)
DM7VTQO	MT	DTP
DM7VTQO	MA	Substrate
DM7VTQO	RN	Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278.
DM7VTQO	RU	http://www.ncbi.nlm.nih.gov/pubmed/28062543

DM7VTQO	DI	DM7VTQO
DM7VTQO	DN	Entecavir
DM7VTQO	MI	TTS5K1M
DM7VTQO	MN	Hepatitis B virus Reverse transcriptase (HBV RT)
DM7VTQO	MT	DTT
DM7VTQO	MA	Modulator
DM7VTQO	RN	Effect of hepatitis B virus reverse transcriptase variations on entecavir treatment response. J Infect Dis. 2014 Sep 1;210(5):701-7.
DM7VTQO	RU	https://pubmed.ncbi.nlm.nih.gov/24610871

DM7VTQO	DI	DM7VTQO
DM7VTQO	DN	Entecavir
DM7VTQO	MI	DT0OC1Q
DM7VTQO	MN	Organic anion transporter 2 (SLC22A7)
DM7VTQO	MT	DTP
DM7VTQO	MA	Substrate
DM7VTQO	RN	Human organic anion transporter 2 is an entecavir, but not tenofovir, transporter. Drug Metab Pharmacokinet. 2017 Feb;32(1):116-119.
DM7VTQO	RU	http://www.ncbi.nlm.nih.gov/pubmed/27916488

DM7VTQO	DI	DM7VTQO
DM7VTQO	DN	Entecavir
DM7VTQO	MI	DT6201N
DM7VTQO	MN	Organic cation transporter 3 (SLC22A3)
DM7VTQO	MT	DTP
DM7VTQO	MA	Substrate
DM7VTQO	RN	Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278.
DM7VTQO	RU	http://www.ncbi.nlm.nih.gov/pubmed/28062543

DM7VTQO	DI	DM7VTQO
DM7VTQO	DN	Entecavir
DM7VTQO	MI	DT3HUVD
DM7VTQO	MN	Organic cation/carnitine transporter 2 (SLC22A5)
DM7VTQO	MT	DTP
DM7VTQO	MA	Substrate
DM7VTQO	RN	Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278.
DM7VTQO	RU	http://www.ncbi.nlm.nih.gov/pubmed/28062543

DM7VTQO	DI	DM7VTQO
DM7VTQO	DN	Entecavir
DM7VTQO	MI	DT8QKNP
DM7VTQO	MN	Peptide transporter 2 (SLC15A2)
DM7VTQO	MT	DTP
DM7VTQO	MA	Substrate
DM7VTQO	RN	The oligopeptide transporter 2-mediated reabsorption of entecavir in rat kidney. Eur J Pharm Sci. 2014 Feb 14;52:41-7.
DM7VTQO	RU	http://www.ncbi.nlm.nih.gov/pubmed/24184752

DMK659W	DI	DMK659W
DMK659W	DN	Enteric-coated mycophenolate sodium
DMK659W	MI	TTCAQMW
DMK659W	MN	Inosine-5'-monophosphate dehydrogenase (IMPDH)
DMK659W	MT	DTT
DMK659W	MA	Inhibitor
DMK659W	RN	Mycophenolate mofetil, an inhibitor of inosine monophosphate dehydrogenase, causes a paradoxical elevation of GTP in erythrocytes of renal transplant patients. Clin Sci (Lond). 2004 Jul;107(1):63-8.
DMK659W	RU	https://pubmed.ncbi.nlm.nih.gov/14723604

DMMPTLH	DI	DMMPTLH
DMMPTLH	DN	Entrectinib
DMMPTLH	MI	TTPMQSO
DMMPTLH	MN	ALK tyrosine kinase receptor (ALK)
DMMPTLH	MT	DTT
DMMPTLH	MA	Inhibitor
DMMPTLH	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMMPTLH	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf

DMMPTLH	DI	DMMPTLH
DMMPTLH	DN	Entrectinib
DMMPTLH	MI	TTKN7QR
DMMPTLH	MN	BDNF/NT-3 growth factors receptor (TrkB)
DMMPTLH	MT	DTT
DMMPTLH	MA	Inhibitor
DMMPTLH	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMMPTLH	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf

DMMPTLH	DI	DMMPTLH
DMMPTLH	DN	Entrectinib
DMMPTLH	MI	DE4LYSA
DMMPTLH	MN	Cytochrome P450 3A4 (CYP3A4)
DMMPTLH	MT	DME
DMMPTLH	MA	Metabolism
DMMPTLH	RN	Entrectinib: first global approval. Drugs. 2019 Sep;79(13):1477-1483.
DMMPTLH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31372957

DMMPTLH	DI	DMMPTLH
DMMPTLH	DN	Entrectinib
DMMPTLH	MI	TTXABCW
DMMPTLH	MN	NT-3 growth factor receptor (TrkC)
DMMPTLH	MT	DTT
DMMPTLH	MA	Inhibitor
DMMPTLH	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMMPTLH	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf

DMMPTLH	DI	DMMPTLH
DMMPTLH	DN	Entrectinib
DMMPTLH	MI	TTSZ6Y3
DMMPTLH	MN	Proto-oncogene c-Ros (ROS1)
DMMPTLH	MT	DTT
DMMPTLH	MA	Inhibitor
DMMPTLH	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMMPTLH	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf

DMMPTLH	DI	DMMPTLH
DMMPTLH	DN	Entrectinib
DMMPTLH	MI	TTTDVOJ
DMMPTLH	MN	Tropomyosin-related kinase A (TrkA)
DMMPTLH	MT	DTT
DMMPTLH	MA	Inhibitor
DMMPTLH	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMMPTLH	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf

DMGL19D	DI	DMGL19D
DMGL19D	DN	Enzalutamide
DMGL19D	MI	TTS64P2
DMGL19D	MN	Androgen receptor (AR)
DMGL19D	MT	DTT
DMGL19D	MA	Modulator
DMGL19D	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMGL19D	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM5OGK0	DI	DM5OGK0
DM5OGK0	DN	Epalrestat
DM5OGK0	MI	TTFBNVI
DM5OGK0	MN	Aldose reductase (AKR1B1)
DM5OGK0	MT	DTT
DM5OGK0	MA	Inhibitor
DM5OGK0	RN	Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients. J Diabetes Complications. 2001 Sep-Oct;15(5):241-4.
DM5OGK0	RU	https://pubmed.ncbi.nlm.nih.gov/11522497

DM5OGK0	DI	DM5OGK0
DM5OGK0	DN	Epalrestat
DM5OGK0	MI	TTXHYV6
DM5OGK0	MN	Voltage-gated L-type calcium channel (L-CaC)
DM5OGK0	MT	DTT
DM5OGK0	MA	Blocker
DM5OGK0	RN	Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95.
DM5OGK0	RU	https://pubmed.ncbi.nlm.nih.gov/19442208

DMHEAGL	DI	DMHEAGL
DMHEAGL	DN	Epanova
DMHEAGL	MI	DE87OZS
DMHEAGL	MN	Arachidonate 5-lipoxygenase (ALOX5)
DMHEAGL	MT	DME
DMHEAGL	MA	Metabolism
DMHEAGL	RN	Omega-3 fatty acids and inflammatory processes. Nutrients. 2010 Mar;2(3):355-74.
DMHEAGL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22254027

DMHEAGL	DI	DMHEAGL
DMHEAGL	DN	Epanova
DMHEAGL	MI	DEIPST6
DMHEAGL	MN	Cytochrome P450 147G1 (cyp147)
DMHEAGL	MT	DME
DMHEAGL	MA	Metabolism
DMHEAGL	RN	Selective Omega-1 oxidation of fatty acids by CYP147G1 from Mycobacterium marinum. Biochim Biophys Acta Gen Subj. 2019 Feb;1863(2):408-417.
DMHEAGL	RU	https://pubmed.ncbi.nlm.nih.gov/30476524

DMHEAGL	DI	DMHEAGL
DMHEAGL	DN	Epanova
DMHEAGL	MI	DE492CE
DMHEAGL	MN	Prostaglandin G/H synthase 2 (COX-2)
DMHEAGL	MT	DME
DMHEAGL	MA	Metabolism
DMHEAGL	RN	Structural basis of fatty acid substrate binding to cyclooxygenase-2. J Biol Chem. 2010 Jul 16;285(29):22152-63.
DMHEAGL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20463020

DMMV0KW	DI	DMMV0KW
DMMV0KW	DN	Ephedrine
DMMV0KW	MI	TTEX248
DMMV0KW	MN	Dopamine D2 receptor (D2R)
DMMV0KW	MT	DTT
DMMV0KW	MA	Agonist
DMMV0KW	RN	The effect of alpha-2 adrenergic agonists on memory and cognitive flexibility. Cogn Behav Neurol. 2006 Dec;19(4):204-7.
DMMV0KW	RU	https://pubmed.ncbi.nlm.nih.gov/17159617

DMMV0KW	DI	DMMV0KW
DMMV0KW	DN	Ephedrine
DMMV0KW	MI	DEYWLRK
DMMV0KW	MN	Sulfotransferase 1A1 (SULT1A1)
DMMV0KW	MT	DME
DMMV0KW	MA	Metabolism
DMMV0KW	RN	Benzylic alcohols as stereospecific substrates and inhibitors for aryl sulfotransferase. Chirality. 1991;3(2):104-11.
DMMV0KW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1863522

DMVONE6	DI	DMVONE6
DMVONE6	DN	Epidermal growth factor
DMVONE6	MI	DE1TNRG
DMVONE6	MN	Carboxypeptidase M (CPM)
DMVONE6	MT	DME
DMVONE6	MA	Metabolism
DMVONE6	RN	Extracellular conversion of epidermal growth factor (EGF) to des-Arg53-EGF by carboxypeptidase M. J Biol Chem. 1995 Jul 21;270(29):17154-8.
DMVONE6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7615511

DMVONE6	DI	DMVONE6
DMVONE6	DN	Epidermal growth factor
DMVONE6	MI	TTED8JB
DMVONE6	MN	Epidermal growth factor (EGF)
DMVONE6	MT	DTT
DMVONE6	MA	Modulator
DMVONE6	RN	Repurposing of the epidermal growth factor. Journal of Commercial Biotechnology (2011) 17, 45-52.
DMVONE6	RU	http://www.palgrave-journals.com/jcb/journal/v17/n1/full/jcb201028a.html

DMVONE6	DI	DMVONE6
DMVONE6	DN	Epidermal growth factor
DMVONE6	MI	TTGKNB4
DMVONE6	MN	Epidermal growth factor receptor (EGFR)
DMVONE6	MT	DTT
DMVONE6	MA	Modulator
DMVONE6	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
DMVONE6	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797

DMX0K3Q	DI	DMX0K3Q
DMX0K3Q	DN	Epinastine
DMX0K3Q	MI	DEPKLMQ
DMX0K3Q	MN	Cytochrome P450 2B6 (CYP2B6)
DMX0K3Q	MT	DME
DMX0K3Q	MA	Metabolism
DMX0K3Q	RN	Metabolism of epinastine, a histamine H1 receptor antagonist, in human liver microsomes in comparison with that of terfenadine. Res Commun Mol Pathol Pharmacol. 1997 Dec;98(3):273-92.
DMX0K3Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9485522

DMX0K3Q	DI	DMX0K3Q
DMX0K3Q	DN	Epinastine
DMX0K3Q	MI	DECB0K3
DMX0K3Q	MN	Cytochrome P450 2D6 (CYP2D6)
DMX0K3Q	MT	DME
DMX0K3Q	MA	Metabolism
DMX0K3Q	RN	Metabolism of epinastine, a histamine H1 receptor antagonist, in human liver microsomes in comparison with that of terfenadine. Res Commun Mol Pathol Pharmacol. 1997 Dec;98(3):273-92.
DMX0K3Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9485522

DMX0K3Q	DI	DMX0K3Q
DMX0K3Q	DN	Epinastine
DMX0K3Q	MI	DE4LYSA
DMX0K3Q	MN	Cytochrome P450 3A4 (CYP3A4)
DMX0K3Q	MT	DME
DMX0K3Q	MA	Metabolism
DMX0K3Q	RN	Metabolism of epinastine, a histamine H1 receptor antagonist, in human liver microsomes in comparison with that of terfenadine. Res Commun Mol Pathol Pharmacol. 1997 Dec;98(3):273-92.
DMX0K3Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9485522

DMX0K3Q	DI	DMX0K3Q
DMX0K3Q	DN	Epinastine
DMX0K3Q	MI	TTTIBOJ
DMX0K3Q	MN	Histamine H1 receptor (H1R)
DMX0K3Q	MT	DTT
DMX0K3Q	MA	Antagonist
DMX0K3Q	RN	Influence of epinastine hydrochloride, an H1-receptor antagonist, on the function of mite allergen-pulsed murine bone marrow-derived dendritic cell... Mediators Inflamm. 2009;2009:738038.
DMX0K3Q	RU	https://pubmed.ncbi.nlm.nih.gov/19381339

DMX0K3Q	DI	DMX0K3Q
DMX0K3Q	DN	Epinastine
DMX0K3Q	MI	DTUGYRD
DMX0K3Q	MN	P-glycoprotein 1 (ABCB1)
DMX0K3Q	MT	DTP
DMX0K3Q	MA	Substrate
DMX0K3Q	RN	Influx and efflux transport of H1-antagonist epinastine across the blood-brain barrier. Drug Metab Dispos. 2004 May;32(5):519-24.
DMX0K3Q	RU	https://doi.org/10.1124/dmd.32.5.519

DM3KJBC	DI	DM3KJBC
DM3KJBC	DN	Epinephrine
DM3KJBC	MI	TTR6W5O
DM3KJBC	MN	Adrenergic receptor beta-1 (ADRB1)
DM3KJBC	MT	DTT
DM3KJBC	MA	Agonist
DM3KJBC	RN	Adrenergic activation of electrogenic K+ secretion in guinea pig distal colonic epithelium: involvement of beta1- and beta2-adrenergic receptors. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G269-77.
DM3KJBC	RU	https://pubmed.ncbi.nlm.nih.gov/19460844

DM3KJBC	DI	DM3KJBC
DM3KJBC	DN	Epinephrine
DM3KJBC	MI	DEV3T4A
DM3KJBC	MN	Catechol O-methyltransferase (COMT)
DM3KJBC	MT	DME
DM3KJBC	MA	Metabolism
DM3KJBC	RN	Different metabolism of norepinephrine and epinephrine by catechol-O-methyltransferase and monoamine oxidase in rats. J Pharmacol Exp Ther. 1994 Mar;268(3):1242-51.
DM3KJBC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8138937

DM3KJBC	DI	DM3KJBC
DM3KJBC	DN	Epinephrine
DM3KJBC	MI	DERE4TU
DM3KJBC	MN	Monoamine oxidase type A (MAO-A)
DM3KJBC	MT	DME
DM3KJBC	MA	Metabolism
DM3KJBC	RN	Role of monoamine-oxidase-A-gene variation in the development of glioblastoma in males: a case control study. J Neurooncol. 2019 Nov;145(2):287-294.
DM3KJBC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31556016

DM3KJBC	DI	DM3KJBC
DM3KJBC	DN	Epinephrine
DM3KJBC	MI	DTT79CX
DM3KJBC	MN	Organic cation transporter 1 (SLC22A1)
DM3KJBC	MT	DTP
DM3KJBC	MA	Substrate
DM3KJBC	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM3KJBC	RU	https://doi.org/10.1007/s11095-012-0935-x

DM3KJBC	DI	DM3KJBC
DM3KJBC	DN	Epinephrine
DM3KJBC	MI	DT6201N
DM3KJBC	MN	Organic cation transporter 3 (SLC22A3)
DM3KJBC	MT	DTP
DM3KJBC	MA	Substrate
DM3KJBC	RN	Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.
DM3KJBC	RU	http://www.ncbi.nlm.nih.gov/pubmed/16581093

DM3KJBC	DI	DM3KJBC
DM3KJBC	DN	Epinephrine
DM3KJBC	MI	DEYWLRK
DM3KJBC	MN	Sulfotransferase 1A1 (SULT1A1)
DM3KJBC	MT	DME
DM3KJBC	MA	Metabolism
DM3KJBC	RN	Crystal structure of human sulfotransferase SULT1A3 in complex with dopamine and 3'-phosphoadenosine 5'-phosphate. Biochem Biophys Res Commun. 2005 Sep 23;335(2):417-23.
DM3KJBC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16083857

DM3KJBC	DI	DM3KJBC
DM3KJBC	DN	Epinephrine
DM3KJBC	MI	DEFQ8VO
DM3KJBC	MN	Thiopurine methyltransferase (TPMT)
DM3KJBC	MT	DME
DM3KJBC	MA	Metabolism
DM3KJBC	RN	Adrenal catecholamines and their metabolism in the vitamin A deficient rat. Ann Nutr Metab. 1983;27(3):220-7.
DM3KJBC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=6859813

DM3KJBC	DI	DM3KJBC
DM3KJBC	DN	Epinephrine
DM3KJBC	MI	DEYGVN4
DM3KJBC	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM3KJBC	MT	DME
DM3KJBC	MA	Metabolism
DM3KJBC	RN	Steroid glucuronides: human circulatory levels and formation by LNCaP cells. J Steroid Biochem Mol Biol. 1991;40(4-6):593-8.
DM3KJBC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1835648

DMPDW6T	DI	DMPDW6T
DMPDW6T	DN	Epirubicin
DMPDW6T	MI	DTI7UX6
DMPDW6T	MN	Breast cancer resistance protein (ABCG2)
DMPDW6T	MT	DTP
DMPDW6T	MA	Substrate
DMPDW6T	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMPDW6T	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMPDW6T	DI	DMPDW6T
DMPDW6T	DN	Epirubicin
DMPDW6T	MI	TT0IHXV
DMPDW6T	MN	DNA topoisomerase II (TOP2)
DMPDW6T	MT	DTT
DMPDW6T	MA	Modulator
DMPDW6T	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMPDW6T	RU	https://www.fda.gov/

DMPDW6T	DI	DMPDW6T
DMPDW6T	DN	Epirubicin
DMPDW6T	MI	DTSYQGK
DMPDW6T	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMPDW6T	MT	DTP
DMPDW6T	MA	Substrate
DMPDW6T	RN	Sulindac sulfide selectively increases sensitivity of ABCC1 expressing tumor cells to doxorubicin and glutathione depletion. J Biomed Res. 2016 Mar;30(2):120-133.
DMPDW6T	RU	http://www.ncbi.nlm.nih.gov/pubmed/28276667

DMPDW6T	DI	DMPDW6T
DMPDW6T	DN	Epirubicin
DMPDW6T	MI	DTFI42L
DMPDW6T	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMPDW6T	MT	DTP
DMPDW6T	MA	Substrate
DMPDW6T	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMPDW6T	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMPDW6T	DI	DMPDW6T
DMPDW6T	DN	Epirubicin
DMPDW6T	MI	DTUGYRD
DMPDW6T	MN	P-glycoprotein 1 (ABCB1)
DMPDW6T	MT	DTP
DMPDW6T	MA	Substrate
DMPDW6T	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMPDW6T	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMPDW6T	DI	DMPDW6T
DMPDW6T	DN	Epirubicin
DMPDW6T	MI	DEB3CV1
DMPDW6T	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMPDW6T	MT	DME
DMPDW6T	MA	Metabolism
DMPDW6T	RN	Epirubicin glucuronidation and UGT2B7 developmental expression. Drug Metab Dispos. 2006 Dec;34(12):2097-101.
DMPDW6T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16985101

DMF0NQR	DI	DMF0NQR
DMF0NQR	DN	Eplerenone
DMF0NQR	MI	DE4LYSA
DMF0NQR	MN	Cytochrome P450 3A4 (CYP3A4)
DMF0NQR	MT	DME
DMF0NQR	MA	Metabolism
DMF0NQR	RN	Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure. Heart Dis. 2003 Sep-Oct;5(5):354-63.
DMF0NQR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14503934

DMF0NQR	DI	DMF0NQR
DMF0NQR	DN	Eplerenone
DMF0NQR	MI	DEIBDNY
DMF0NQR	MN	Cytochrome P450 3A5 (CYP3A5)
DMF0NQR	MT	DME
DMF0NQR	MA	Metabolism
DMF0NQR	RN	The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
DMF0NQR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31408697

DMF0NQR	DI	DMF0NQR
DMF0NQR	DN	Eplerenone
DMF0NQR	MI	TT26PHO
DMF0NQR	MN	Mineralocorticoid receptor  (MR)
DMF0NQR	MT	DTT
DMF0NQR	MA	Modulator
DMF0NQR	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMF0NQR	RU	https://www.fda.gov/

DMKWB73	DI	DMKWB73
DMKWB73	DN	Epoetin alfa
DMKWB73	MI	TTAUX24
DMKWB73	MN	Erythropoietin Receptor (EPOR)
DMKWB73	MT	DTT
DMKWB73	MA	Agonist
DMKWB73	RN	2007 Standards, Options, and Recommendations: use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin beta, and darbepoetin) for the management of anemia in children with cancer. PediatrBlood Cancer. 2009 Jul;53(1):7-12.
DMKWB73	RU	https://pubmed.ncbi.nlm.nih.gov/19229970

DMUTYR2	DI	DMUTYR2
DMUTYR2	DN	Epoprostenol
DMUTYR2	MI	DE5IED8
DMUTYR2	MN	Cytochrome P450 2C9 (CYP2C9)
DMUTYR2	MT	DME
DMUTYR2	MA	Metabolism
DMUTYR2	RN	Cytochrome P4502C9-derived epoxyeicosatrienoic acids induce the expression of cyclooxygenase-2 in endothelial cells. Arterioscler Thromb Vasc Biol. 2005 Feb;25(2):321-6.
DMUTYR2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15569819

DMUTYR2	DI	DMUTYR2
DMUTYR2	DN	Epoprostenol
DMUTYR2	MI	TTOFYT1
DMUTYR2	MN	Prostacyclin receptor (PTGIR)
DMUTYR2	MT	DTT
DMUTYR2	MA	Agonist
DMUTYR2	RN	Novel signaling pathways promote a paracrine wave of prostacyclin-induced vascular smooth muscle differentiation. J Mol Cell Cardiol. 2009 May;46(5):682-94.
DMUTYR2	RU	https://pubmed.ncbi.nlm.nih.gov/19302827

DM07K2I	DI	DM07K2I
DM07K2I	DN	Eprosartan
DM07K2I	MI	TT8DBY3
DM07K2I	MN	Angiotensin II receptor type-1 (AGTR1)
DM07K2I	MT	DTT
DM07K2I	MA	Antagonist
DM07K2I	RN	Clinical profile of eprosartan: a different angiotensin II receptor blocker. Cardiovasc Hematol Agents Med Chem. 2008 Oct;6(4):253-7.
DM07K2I	RU	https://pubmed.ncbi.nlm.nih.gov/18855637

DM07K2I	DI	DM07K2I
DM07K2I	DN	Eprosartan
DM07K2I	MI	DT9G7XN
DM07K2I	MN	Peptide transporter 1 (SLC15A1)
DM07K2I	MT	DTP
DM07K2I	MA	Substrate
DM07K2I	RN	High-affinity interaction of sartans with H+/peptide transporters. Drug Metab Dispos. 2009 Jan;37(1):143-9.
DM07K2I	RU	http://www.ncbi.nlm.nih.gov/pubmed/18824524

DMQXTJS	DI	DMQXTJS
DMQXTJS	DN	Eptifibatide
DMQXTJS	MI	TT38RM1
DMQXTJS	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DMQXTJS	MT	DTT
DMQXTJS	MA	Modulator
DMQXTJS	RN	Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J Biol Chem. 1991 May 25;266(15):9359-62.
DMQXTJS	RU	https://pubmed.ncbi.nlm.nih.gov/2033037

DM5LJCI	DI	DM5LJCI
DM5LJCI	DN	Eptinezumab
DM5LJCI	MI	TTAFORY
DM5LJCI	MN	Calcitonin gene-related peptide (CALC)
DM5LJCI	MT	DTT
DM5LJCI	MA	Inhibitor
DM5LJCI	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DM5LJCI	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761119s000lbl.pdf

DMI782S	DI	DMI782S
DMI782S	DN	Erdafitinib
DMI782S	MI	DE5IED8
DMI782S	MN	Cytochrome P450 2C9 (CYP2C9)
DMI782S	MT	DME
DMI782S	MA	Metabolism
DMI782S	RN	FDA label of Erdafitinib. The 2020 official website of the U.S. Food and Drug Administration.
DMI782S	RU	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212018Orig1s000MultidisciplineR.pdf

DMI782S	DI	DMI782S
DMI782S	DN	Erdafitinib
DMI782S	MI	DE4LYSA
DMI782S	MN	Cytochrome P450 3A4 (CYP3A4)
DMI782S	MT	DME
DMI782S	MA	Metabolism
DMI782S	RN	FDA label of Erdafitinib. The 2020 official website of the U.S. Food and Drug Administration.
DMI782S	RU	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212018Orig1s000MultidisciplineR.pdf

DMI782S	DI	DMI782S
DMI782S	DN	Erdafitinib
DMI782S	MI	TT0LF7H
DMI782S	MN	Fibroblast growth factor receptor (FGFR)
DMI782S	MT	DTT
DMI782S	MA	Inhibitor
DMI782S	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMI782S	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf

DM6QFSV	DI	DM6QFSV
DM6QFSV	DN	Erdosteine
DM6QFSV	MI	TT3NKIB
DM6QFSV	MN	Pancreatic elastase 1 (CELA1)
DM6QFSV	MT	DTT
DM6QFSV	MA	Modulator
DM6QFSV	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DM6QFSV	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMWMCN0	DI	DMWMCN0
DMWMCN0	DN	Erenumab
DMWMCN0	MI	TTY6O0Q
DMWMCN0	MN	Calcitonin gene-related peptide receptor (CGRPR)
DMWMCN0	MT	DTT
DMWMCN0	MA	Modulator
DMWMCN0	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMWMCN0	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMHO0AR	DI	DMHO0AR
DMHO0AR	DN	Ergocalciferol
DMHO0AR	MI	DE98XPV
DMHO0AR	MN	Cholesterol desmolase (CYP11A1)
DMHO0AR	MT	DME
DMHO0AR	MA	Metabolism
DMHO0AR	RN	Vitamin D: mechanisms of action and clinical applications. Endocrinol Metab Clin North Am. 2017 Dec;46(4):xvii-xviii.
DMHO0AR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29080648

DMHO0AR	DI	DMHO0AR
DMHO0AR	DN	Ergocalciferol
DMHO0AR	MI	DERSX5P
DMHO0AR	MN	Cytochrome P450 2J2 (CYP2J2)
DMHO0AR	MT	DME
DMHO0AR	MA	Metabolism
DMHO0AR	RN	Characterization of rat and human CYP2J enzymes as Vitamin D 25-hydroxylases. Steroids. 2006 Oct;71(10):849-56.
DMHO0AR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16842832

DMHO0AR	DI	DMHO0AR
DMHO0AR	DN	Ergocalciferol
DMHO0AR	MI	DE4LYSA
DMHO0AR	MN	Cytochrome P450 3A4 (CYP3A4)
DMHO0AR	MT	DME
DMHO0AR	MA	Metabolism
DMHO0AR	RN	CYP3A4 is a human microsomal vitamin D 25-hydroxylase. J Bone Miner Res. 2004 Apr;19(4):680-8.
DMHO0AR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15005856

DMHO0AR	DI	DMHO0AR
DMHO0AR	DN	Ergocalciferol
DMHO0AR	MI	DEBIHM3
DMHO0AR	MN	Vitamin D 25-hydroxylase (CYP2R1)
DMHO0AR	MT	DME
DMHO0AR	MA	Metabolism
DMHO0AR	RN	CYP2R1 (vitamin D 25-hydroxylase) gene is associated with susceptibility to type 1 diabetes and vitamin D levels in Germans. Diabetes Metab Res Rev. 2007 Nov;23(8):631-6.
DMHO0AR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17607662

DMHO0AR	DI	DMHO0AR
DMHO0AR	DN	Ergocalciferol
DMHO0AR	MI	TTK59TV
DMHO0AR	MN	Vitamin D3 receptor (VDR)
DMHO0AR	MT	DTT
DMHO0AR	MA	Antagonist
DMHO0AR	RN	Vitamin D in health and disease. Clin J Am Soc Nephrol. 2008 Sep;3(5):1535-41.
DMHO0AR	RU	https://pubmed.ncbi.nlm.nih.gov/18525006

DMORPBA	DI	DMORPBA
DMORPBA	DN	Ergoloid mesylate
DMORPBA	MI	TT32XQJ
DMORPBA	MN	Monoamine oxidase (MAO)
DMORPBA	MT	DTT
DMORPBA	MA	Modulator
DMORPBA	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMORPBA	RU	https://www.fda.gov/

DM0VEC1	DI	DM0VEC1
DM0VEC1	DN	Ergonovine
DM0VEC1	MI	DE4LYSA
DM0VEC1	MN	Cytochrome P450 3A4 (CYP3A4)
DM0VEC1	MT	DME
DM0VEC1	MA	Metabolism
DM0VEC1	RN	Rational prescription of drugs within similar therapeutic or structural class for gastrointestinal disease treatment: drug metabolism and its related interactions. World J Gastroenterol. 2007 Nov 14;13(42):5618-28.
DM0VEC1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17948937

DM0VEC1	DI	DM0VEC1
DM0VEC1	DN	Ergonovine
DM0VEC1	MI	TTEX248
DM0VEC1	MN	Dopamine D2 receptor (D2R)
DM0VEC1	MT	DTT
DM0VEC1	MA	Agonist
DM0VEC1	RN	Agonist profile of ergometrine (ergonovine) on a population of postsynaptic alpha-adrenoceptors. J Pharm Pharmacol. 1988 Feb;40(2):137-9.
DM0VEC1	RU	https://pubmed.ncbi.nlm.nih.gov/2897449

DMKR3C5	DI	DMKR3C5
DMKR3C5	DN	Ergotamine
DMKR3C5	MI	TTG28O6
DMKR3C5	MN	Adrenergic receptor Alpha-1 (ADRA1)
DMKR3C5	MT	DTT
DMKR3C5	MA	Agonist
DMKR3C5	RN	Reversal of ergotamine-induced vasospasm following methylprednisolone. Clin Toxicol (Phila). 2008 Dec;46(10):1074-6.
DMKR3C5	RU	https://pubmed.ncbi.nlm.nih.gov/18763151

DMKR3C5	DI	DMKR3C5
DMKR3C5	DN	Ergotamine
DMKR3C5	MI	DEJGDUW
DMKR3C5	MN	Cytochrome P450 1A2 (CYP1A2)
DMKR3C5	MT	DME
DMKR3C5	MA	Metabolism
DMKR3C5	RN	Frovatriptan: a review of drug-drug interactions. Headache. 2002 Apr;42 Suppl 2:S63-73.
DMKR3C5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12028322

DMKR3C5	DI	DMKR3C5
DMKR3C5	DN	Ergotamine
DMKR3C5	MI	DE4LYSA
DMKR3C5	MN	Cytochrome P450 3A4 (CYP3A4)
DMKR3C5	MT	DME
DMKR3C5	MA	Metabolism
DMKR3C5	RN	Modulation of cytochrome P450 metabolism by ergonovine and dihydroergotamine. Vet Hum Toxicol. 2003 Feb;45(1):6-9.
DMKR3C5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12583687

DMKR3C5	DI	DMKR3C5
DMKR3C5	DN	Ergotamine
DMKR3C5	MI	DTUGYRD
DMKR3C5	MN	P-glycoprotein 1 (ABCB1)
DMKR3C5	MT	DTP
DMKR3C5	MA	Substrate
DMKR3C5	RN	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
DMKR3C5	RU	https://doi.org/10.1016/j.addr.2011.12.008

DM78IME	DI	DM78IME
DM78IME	DN	Ergotidine
DM78IME	MI	DETECWH
DM78IME	MN	Amiloride-sensitive amine oxidase (AOC1)
DM78IME	MT	DME
DM78IME	MA	Metabolism
DM78IME	RN	Human kidney diamine oxidase: heterologous expression, purification, and characterization. J Biol Inorg Chem. 2002 Jun;7(6):565-79.
DM78IME	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12072962

DM78IME	DI	DM78IME
DM78IME	DN	Ergotidine
DM78IME	MI	DE5IED8
DM78IME	MN	Cytochrome P450 2C9 (CYP2C9)
DM78IME	MT	DME
DM78IME	MA	Metabolism
DM78IME	RN	Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2004 Dec;24(12):1732-47.
DM78IME	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15585441

DM78IME	DI	DM78IME
DM78IME	DN	Ergotidine
DM78IME	MI	DE4LYSA
DM78IME	MN	Cytochrome P450 3A4 (CYP3A4)
DM78IME	MT	DME
DM78IME	MA	Metabolism
DM78IME	RN	Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2004 Dec;24(12):1732-47.
DM78IME	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15585441

DM78IME	DI	DM78IME
DM78IME	DN	Ergotidine
DM78IME	MI	DT3EAQP
DM78IME	MN	Equilibrative nucleoside transporter 4 (SLC29A4)
DM78IME	MT	DTP
DM78IME	MA	Substrate
DM78IME	RN	Histamine uptake mediated by plasma membrane monoamine transporter and organic cation transporters in rat mast cell lines. Eur J Pharmacol. 2019 Apr 15;849:75-83.
DM78IME	RU	http://www.ncbi.nlm.nih.gov/pubmed/30707958

DM78IME	DI	DM78IME
DM78IME	DN	Ergotidine
DM78IME	MI	TTTIBOJ
DM78IME	MN	Histamine H1 receptor (H1R)
DM78IME	MT	DTT
DM78IME	MA	Agonist
DM78IME	RN	Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol. 2001 Mar;59(3):420-6.
DM78IME	RU	https://pubmed.ncbi.nlm.nih.gov/11179434

DM78IME	DI	DM78IME
DM78IME	DN	Ergotidine
DM78IME	MI	DE3PZ0I
DM78IME	MN	Histamine N-methyltransferase (HNMT)
DM78IME	MT	DME
DM78IME	MA	Metabolism
DM78IME	RN	Histamine pharmacogenomics. Pharmacogenomics. 2009 May;10(5):867-83.
DM78IME	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19450133

DM78IME	DI	DM78IME
DM78IME	DN	Ergotidine
DM78IME	MI	DT9IDPW
DM78IME	MN	Organic cation transporter 2 (SLC22A2)
DM78IME	MT	DTP
DM78IME	MA	Substrate
DM78IME	RN	The organic cation transporters (OCT1, OCT2, EMT) and the plasma membrane monoamine transporter (PMAT) show differential distribution and cyclic expression pattern in human endometrium and early pregnancy decidua. Mol Reprod Dev. 2007 Oct;74(10):1303-11.
DM78IME	RU	http://www.ncbi.nlm.nih.gov/pubmed/17393420

DM78IME	DI	DM78IME
DM78IME	DN	Ergotidine
DM78IME	MI	DT6201N
DM78IME	MN	Organic cation transporter 3 (SLC22A3)
DM78IME	MT	DTP
DM78IME	MA	Substrate
DM78IME	RN	Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.
DM78IME	RU	http://www.ncbi.nlm.nih.gov/pubmed/16581093

DM78IME	DI	DM78IME
DM78IME	DN	Ergotidine
DM78IME	MI	DEFQ8VO
DM78IME	MN	Thiopurine methyltransferase (TPMT)
DM78IME	MT	DME
DM78IME	MA	Metabolism
DM78IME	RN	Histamine-N-methyl transferase polymorphism and risk for multiple sclerosis. Eur J Neurol. 2010 Feb;17(2):335-8.
DM78IME	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19538200

DM78IME	DI	DM78IME
DM78IME	DN	Ergotidine
DM78IME	MI	DTM953D
DM78IME	MN	Vesicular amine transporter 1 (SLC18A1)
DM78IME	MT	DTP
DM78IME	MA	Substrate
DM78IME	RN	Gastrin-producing endocrine cells: a novel source of histamine in the rat stomach. Endocrinology. 1998 Oct;139(10):4404-15.
DM78IME	RU	http://www.ncbi.nlm.nih.gov/pubmed/9751525

DM78IME	DI	DM78IME
DM78IME	DN	Ergotidine
DM78IME	MI	DTT7VPB
DM78IME	MN	Vesicular amine transporter 2 (SLC18A2)
DM78IME	MT	DTP
DM78IME	MA	Substrate
DM78IME	RN	The vesicular monoamine transporter 2: an underexplored pharmacological target. Neurochem Int. 2014 Jul;73:89-97.
DM78IME	RU	http://www.ncbi.nlm.nih.gov/pubmed/24398404

DM1DX4Q	DI	DM1DX4Q
DM1DX4Q	DN	Eribulin
DM1DX4Q	MI	DE4LYSA
DM1DX4Q	MN	Cytochrome P450 3A4 (CYP3A4)
DM1DX4Q	MT	DME
DM1DX4Q	MA	Metabolism
DM1DX4Q	RN	Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4. Cancer Chemother Pharmacol. 2008 Sep;62(4):707-16.
DM1DX4Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18431572

DM1DX4Q	DI	DM1DX4Q
DM1DX4Q	DN	Eribulin
DM1DX4Q	MI	TTML2WA
DM1DX4Q	MN	Tubulin (TUB)
DM1DX4Q	MT	DTT
DM1DX4Q	MA	Inhibitor
DM1DX4Q	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DM1DX4Q	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DMCMBHA	DI	DMCMBHA
DMCMBHA	DN	Erlotinib
DMCMBHA	MI	DTI7UX6
DMCMBHA	MN	Breast cancer resistance protein (ABCG2)
DMCMBHA	MT	DTP
DMCMBHA	MA	Substrate
DMCMBHA	RN	Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv Drug Deliv Rev. 2009 Jan 31;61(1):26-33.
DMCMBHA	RU	https://doi.org/10.1016/j.addr.2008.07.003

DMCMBHA	DI	DMCMBHA
DMCMBHA	DN	Erlotinib
DMCMBHA	MI	DEJGDUW
DMCMBHA	MN	Cytochrome P450 1A2 (CYP1A2)
DMCMBHA	MT	DME
DMCMBHA	MA	Metabolism
DMCMBHA	RN	Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
DMCMBHA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19733976

DMCMBHA	DI	DMCMBHA
DMCMBHA	DN	Erlotinib
DMCMBHA	MI	DECB0K3
DMCMBHA	MN	Cytochrome P450 2D6 (CYP2D6)
DMCMBHA	MT	DME
DMCMBHA	MA	Metabolism
DMCMBHA	RN	Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
DMCMBHA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19733976

DMCMBHA	DI	DMCMBHA
DMCMBHA	DN	Erlotinib
DMCMBHA	MI	DE4LYSA
DMCMBHA	MN	Cytochrome P450 3A4 (CYP3A4)
DMCMBHA	MT	DME
DMCMBHA	MA	Metabolism
DMCMBHA	RN	In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors. Drug Metab Dispos. 2014 Jul;42(7):1202-9.
DMCMBHA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24713129

DMCMBHA	DI	DMCMBHA
DMCMBHA	DN	Erlotinib
DMCMBHA	MI	DEIBDNY
DMCMBHA	MN	Cytochrome P450 3A5 (CYP3A5)
DMCMBHA	MT	DME
DMCMBHA	MA	Metabolism
DMCMBHA	RN	Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
DMCMBHA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19733976

DMCMBHA	DI	DMCMBHA
DMCMBHA	DN	Erlotinib
DMCMBHA	MI	TTGKNB4
DMCMBHA	MN	Epidermal growth factor receptor (EGFR)
DMCMBHA	MT	DTT
DMCMBHA	MA	Inhibitor
DMCMBHA	RN	Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
DMCMBHA	RU	https://pubmed.ncbi.nlm.nih.gov/19627157

DMCMBHA	DI	DMCMBHA
DMCMBHA	DN	Erlotinib
DMCMBHA	MI	DTUGYRD
DMCMBHA	MN	P-glycoprotein 1 (ABCB1)
DMCMBHA	MT	DTP
DMCMBHA	MA	Substrate
DMCMBHA	RN	Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol Cancer Ther. 2008 Aug;7(8):2280-7.
DMCMBHA	RU	https://doi.org/10.1158/1535-7163.MCT-07-2250

DM4S3O8	DI	DM4S3O8
DM4S3O8	DN	Ertapenem
DM4S3O8	MI	TTJP4SM
DM4S3O8	MN	Bacterial Penicillin binding protein (Bact PBP)
DM4S3O8	MT	DTT
DM4S3O8	MA	Binder
DM4S3O8	RN	Role of penicillin-binding protein 2 (PBP2) in the antibiotic susceptibility and cell wall cross-linking of Staphylococcus aureus: evidence for the cooperative functioning of PBP2, PBP4, and PBP2A. JBacteriol. 2005 Mar;187(5):1815-24.
DM4S3O8	RU	https://pubmed.ncbi.nlm.nih.gov/15716453

DM4S3O8	DI	DM4S3O8
DM4S3O8	DN	Ertapenem
DM4S3O8	MI	DEC3G7M
DM4S3O8	MN	Beta-lactamase (blaB)
DM4S3O8	MT	DME
DM4S3O8	MA	Metabolism
DM4S3O8	RN	FRI-4 carbapenemase-producing Enterobacter cloacae complex isolated in Tokyo, Japan. J Antimicrob Chemother. 2018 Nov 1;73(11):2969-2972.
DM4S3O8	RU	https://pubmed.ncbi.nlm.nih.gov/30060114

DM4S3O8	DI	DM4S3O8
DM4S3O8	DN	Ertapenem
DM4S3O8	MI	DEMIUB2
DM4S3O8	MN	Beta-lactamase (blaB)
DM4S3O8	MT	DME
DM4S3O8	MA	Metabolism
DM4S3O8	RN	War wound treatment complications due to transfer of an IncN plasmid harboring bla(OXA-181) from Morganella morganii to CTX-M-27-producing sequence type 131 Escherichia coli. Antimicrob Agents Chemother. 2015;59(6):3556-62.
DM4S3O8	RU	https://pubmed.ncbi.nlm.nih.gov/25870058

DM4S3O8	DI	DM4S3O8
DM4S3O8	DN	Ertapenem
DM4S3O8	MI	DECWSA9
DM4S3O8	MN	Beta-lactamase (blaB)
DM4S3O8	MT	DME
DM4S3O8	MA	Metabolism
DM4S3O8	RN	War wound treatment complications due to transfer of an IncN plasmid harboring bla(OXA-181) from Morganella morganii to CTX-M-27-producing sequence type 131 Escherichia coli. Antimicrob Agents Chemother. 2015;59(6):3556-62.
DM4S3O8	RU	https://pubmed.ncbi.nlm.nih.gov/25870058

DMFGQ2S	DI	DMFGQ2S
DMFGQ2S	DN	Erythrityl Tetranitrate
DMFGQ2S	MI	TT6HPVC
DMFGQ2S	MN	Guanylate cyclase (GC)
DMFGQ2S	MT	DTT
DMFGQ2S	MA	Stimulator
DMFGQ2S	RN	Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem. 2010 Jan;333(1-2):191-201.
DMFGQ2S	RU	https://pubmed.ncbi.nlm.nih.gov/19618122

DM4K7GQ	DI	DM4K7GQ
DM4K7GQ	DN	Erythromycin
DM4K7GQ	MI	TTUWYEA
DM4K7GQ	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DM4K7GQ	MT	DTT
DM4K7GQ	MA	Binder
DM4K7GQ	RN	A synthetic alanyl-initiator tRNA with initiator tRNA properties as determined by fluorescence measurements: comparison to a synthetic alanyl-elongator tRNA. Nucleic Acids Res. 1991 Oct 25;19(20):5749-54.
DM4K7GQ	RU	https://pubmed.ncbi.nlm.nih.gov/1945852

DM4K7GQ	DI	DM4K7GQ
DM4K7GQ	DN	Erythromycin
DM4K7GQ	MI	DE7IQ34
DM4K7GQ	MN	Beta-glucuronidase (uidA)
DM4K7GQ	MT	DME
DM4K7GQ	MA	Metabolism
DM4K7GQ	RN	Identification of Lactobacillus sakei genes induced during meat fermentation and their role in survival and growth. Appl Environ Microbiol. 2007 Apr;73(8):2522-31.
DM4K7GQ	RU	https://pubmed.ncbi.nlm.nih.gov/17308175

DM4K7GQ	DI	DM4K7GQ
DM4K7GQ	DN	Erythromycin
DM4K7GQ	MI	DTI7UX6
DM4K7GQ	MN	Breast cancer resistance protein (ABCG2)
DM4K7GQ	MT	DTP
DM4K7GQ	MA	Substrate
DM4K7GQ	RN	ABCG2: a perspective. Adv Drug Deliv Rev. 2009 Jan 31;61(1):3-13.
DM4K7GQ	RU	https://doi.org/10.1016/j.addr.2008.11.003

DM4K7GQ	DI	DM4K7GQ
DM4K7GQ	DN	Erythromycin
DM4K7GQ	MI	DE6OQ3W
DM4K7GQ	MN	Cytochrome P450 1A1 (CYP1A1)
DM4K7GQ	MT	DME
DM4K7GQ	MA	Metabolism
DM4K7GQ	RN	Cytochromes P450 in crustacea. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Nov;121(1-3):157-72.
DM4K7GQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9972457

DM4K7GQ	DI	DM4K7GQ
DM4K7GQ	DN	Erythromycin
DM4K7GQ	MI	DEJGDUW
DM4K7GQ	MN	Cytochrome P450 1A2 (CYP1A2)
DM4K7GQ	MT	DME
DM4K7GQ	MA	Metabolism
DM4K7GQ	RN	Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin. Drug Metab Dispos. 1998 Nov;26(11):1053-7.
DM4K7GQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9806945

DM4K7GQ	DI	DM4K7GQ
DM4K7GQ	DN	Erythromycin
DM4K7GQ	MI	DE9QHP6
DM4K7GQ	MN	Cytochrome P450 1B1 (CYP1B1)
DM4K7GQ	MT	DME
DM4K7GQ	MA	Metabolism
DM4K7GQ	RN	Cytochromes P450 in crustacea. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Nov;121(1-3):157-72.
DM4K7GQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9972457

DM4K7GQ	DI	DM4K7GQ
DM4K7GQ	DN	Erythromycin
DM4K7GQ	MI	DE4LYSA
DM4K7GQ	MN	Cytochrome P450 3A4 (CYP3A4)
DM4K7GQ	MT	DME
DM4K7GQ	MA	Metabolism
DM4K7GQ	RN	Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function. Br J Clin Pharmacol. 2003 Jan;55(1):86-93.
DM4K7GQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12534644

DM4K7GQ	DI	DM4K7GQ
DM4K7GQ	DN	Erythromycin
DM4K7GQ	MI	DEIBDNY
DM4K7GQ	MN	Cytochrome P450 3A5 (CYP3A5)
DM4K7GQ	MT	DME
DM4K7GQ	MA	Metabolism
DM4K7GQ	RN	Differential regulation of CYP3A4 and CYP3A5 and its implication in drug discovery. Curr Drug Metab. 2017;18(12):1095-1105.
DM4K7GQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28558634

DM4K7GQ	DI	DM4K7GQ
DM4K7GQ	DN	Erythromycin
DM4K7GQ	MI	DERD86B
DM4K7GQ	MN	Cytochrome P450 3A7 (CYP3A7)
DM4K7GQ	MT	DME
DM4K7GQ	MA	Metabolism
DM4K7GQ	RN	Helices F-G are important for the substrate specificities of CYP3A7. Drug Metab Dispos. 2007 Mar;35(3):484-92.
DM4K7GQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17178770

DM4K7GQ	DI	DM4K7GQ
DM4K7GQ	DN	Erythromycin
DM4K7GQ	MI	DEIZLTN
DM4K7GQ	MN	Docosahexaenoic acid omega-hydroxylase (CYP4F11)
DM4K7GQ	MT	DME
DM4K7GQ	MA	Metabolism
DM4K7GQ	RN	Expression and characterization of human cytochrome P450 4F11: putative role in the metabolism of therapeutic drugs and eicosanoids. Toxicol Appl Pharmacol. 2004 Sep 15;199(3):295-304.
DM4K7GQ	RU	https://pubmed.ncbi.nlm.nih.gov/15364545

DM4K7GQ	DI	DM4K7GQ
DM4K7GQ	DN	Erythromycin
DM4K7GQ	MI	DTFI42L
DM4K7GQ	MN	Multidrug resistance-associated protein 2 (ABCC2)
DM4K7GQ	MT	DTP
DM4K7GQ	MA	Substrate
DM4K7GQ	RN	Effect of ABCC2 (MRP2) transport function on erythromycin metabolism. Clin Pharmacol Ther. 2011 May;89(5):693-701.
DM4K7GQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/21451505

DM4K7GQ	DI	DM4K7GQ
DM4K7GQ	DN	Erythromycin
DM4K7GQ	MI	DT0OC1Q
DM4K7GQ	MN	Organic anion transporter 2 (SLC22A7)
DM4K7GQ	MT	DTP
DM4K7GQ	MA	Substrate
DM4K7GQ	RN	Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver. Drug Metab Dispos. 2005 May;33(5):619-22.
DM4K7GQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/15708966

DM4K7GQ	DI	DM4K7GQ
DM4K7GQ	DN	Erythromycin
DM4K7GQ	MI	DT9C1TS
DM4K7GQ	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM4K7GQ	MT	DTP
DM4K7GQ	MA	Substrate
DM4K7GQ	RN	Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705.
DM4K7GQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/19785645

DM4K7GQ	DI	DM4K7GQ
DM4K7GQ	DN	Erythromycin
DM4K7GQ	MI	DTUGYRD
DM4K7GQ	MN	P-glycoprotein 1 (ABCB1)
DM4K7GQ	MT	DTP
DM4K7GQ	MA	Substrate
DM4K7GQ	RN	Enhanced corneal absorption of erythromycin by modulating P-glycoprotein and MRP mediated efflux with corticosteroids. Pharm Res. 2009 May;26(5):1270-82.
DM4K7GQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/18958406

DMFK9HG	DI	DMFK9HG
DMFK9HG	DN	Escitalopram
DMFK9HG	MI	DECB0K3
DMFK9HG	MN	Cytochrome P450 2D6 (CYP2D6)
DMFK9HG	MT	DME
DMFK9HG	MA	Metabolism
DMFK9HG	RN	CYP2D6 P34S Polymorphism and Outcomes of Escitalopram Treatment in Koreans with Major Depression. Psychiatry Investig. 2013 Sep;10(3):286-93.
DMFK9HG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24302953

DMFK9HG	DI	DMFK9HG
DMFK9HG	DN	Escitalopram
DMFK9HG	MI	DE4LYSA
DMFK9HG	MN	Cytochrome P450 3A4 (CYP3A4)
DMFK9HG	MT	DME
DMFK9HG	MA	Metabolism
DMFK9HG	RN	PharmGKB summary: citalopram pharmacokinetics pathway. Pharmacogenet Genomics. 2011 Nov;21(11):769-72.
DMFK9HG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21546862

DMFK9HG	DI	DMFK9HG
DMFK9HG	DN	Escitalopram
DMFK9HG	MI	DEGTFWK
DMFK9HG	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMFK9HG	MT	DME
DMFK9HG	MA	Metabolism
DMFK9HG	RN	Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder. Pharmacogenet Genomics. 2015 Nov;25(11):548-54.
DMFK9HG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26313485

DMFK9HG	DI	DMFK9HG
DMFK9HG	DN	Escitalopram
DMFK9HG	MI	TT3ROYC
DMFK9HG	MN	Serotonin transporter (SERT)
DMFK9HG	MT	DTT
DMFK9HG	MA	Inhibitor
DMFK9HG	RN	Antidepressants and sleep: a review. Perspect Psychiatr Care. 2009 Jul;45(3):191-7.
DMFK9HG	RU	https://pubmed.ncbi.nlm.nih.gov/19566691

DMZREFQ	DI	DMZREFQ
DMZREFQ	DN	Eslicarbazepine
DMZREFQ	MI	TTRK8B9
DMZREFQ	MN	Sodium channel unspecific (NaC)
DMZREFQ	MT	DTT
DMZREFQ	MA	Blocker
DMZREFQ	RN	Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
DMZREFQ	RU	https://pubmed.ncbi.nlm.nih.gov/19008076

DMZREFQ	DI	DMZREFQ
DMZREFQ	DN	Eslicarbazepine
DMZREFQ	MI	DEYGVN4
DMZREFQ	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMZREFQ	MT	DME
DMZREFQ	MA	Metabolism
DMZREFQ	RN	Hepatic UDP-glucuronosyltransferase is responsible for eslicarbazepine glucuronidation. Drug Metab Dispos. 2011 Sep;39(9):1486-94.
DMZREFQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21673130

DMZREFQ	DI	DMZREFQ
DMZREFQ	DN	Eslicarbazepine
DMZREFQ	MI	TTIG65Q
DMZREFQ	MN	Voltage-gated sodium channel (Nav)
DMZREFQ	MT	DTT
DMZREFQ	MA	Inhibitor
DMZREFQ	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMZREFQ	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMZREFQ	DI	DMZREFQ
DMZREFQ	DN	Eslicarbazepine
DMZREFQ	MI	TTN9VTF
DMZREFQ	MN	Voltage-gated sodium channel alpha Nav1.9 (SCN11A)
DMZREFQ	MT	DTT
DMZREFQ	MA	Inhibitor
DMZREFQ	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMZREFQ	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMREUZV	DI	DMREUZV
DMREUZV	DN	Eslicarbazepine acetate
DMREUZV	MI	DTUGYRD
DMREUZV	MN	P-glycoprotein 1 (ABCB1)
DMREUZV	MT	DTP
DMREUZV	MA	Substrate
DMREUZV	RN	In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein. Epilepsia. 2011 Oct;52(10):1894-904.
DMREUZV	RU	https://doi.org/10.1111/j.1528-1167.2011.03140.x

DM51TYR	DI	DM51TYR
DM51TYR	DN	Esmolol
DM51TYR	MI	TTR6W5O
DM51TYR	MN	Adrenergic receptor beta-1 (ADRB1)
DM51TYR	MT	DTT
DM51TYR	MA	Antagonist
DM51TYR	RN	Beta-1 selective adrenergic antagonist landiolol and esmolol can be safely used in patients with airway hyperreactivity. Heart Lung. 2009 Jan-Feb;38(1):48-55.
DM51TYR	RU	https://pubmed.ncbi.nlm.nih.gov/19150530

DM51TYR	DI	DM51TYR
DM51TYR	DN	Esmolol
DM51TYR	MI	DECB0K3
DM51TYR	MN	Cytochrome P450 2D6 (CYP2D6)
DM51TYR	MT	DME
DM51TYR	MA	Metabolism
DM51TYR	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DM51TYR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DM7BN0X	DI	DM7BN0X
DM7BN0X	DN	Esomeprazole
DM7BN0X	MI	TTLOKXP
DM7BN0X	MN	Gastric H(+)/K(+) ATPase (Proton pump)
DM7BN0X	MT	DTT
DM7BN0X	MA	Modulator
DM7BN0X	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM7BN0X	RU	https://www.fda.gov/

DM7BN0X	DI	DM7BN0X
DM7BN0X	DN	Esomeprazole
DM7BN0X	MI	DEGTFWK
DM7BN0X	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM7BN0X	MT	DME
DM7BN0X	MA	Metabolism
DM7BN0X	RN	Predictive performance of physiologically based pharmacokinetic (PBPK) modeling of drugs extensively metabolized by major cytochrome P450s in children. Clin Pharmacol Ther. 2018 Jul;104(1):188-200.
DM7BN0X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29027194

DMZGXUM	DI	DMZGXUM
DMZGXUM	DN	Estazolam
DMZGXUM	MI	DE4LYSA
DMZGXUM	MN	Cytochrome P450 3A4 (CYP3A4)
DMZGXUM	MT	DME
DMZGXUM	MA	Metabolism
DMZGXUM	RN	Identification of human cytochrome P450 enzymes involved in the formation of 4-hydroxyestazolam from estazolam. Xenobiotica. 2005 May;35(5):455-65.
DMZGXUM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16012077

DMZGXUM	DI	DMZGXUM
DMZGXUM	DN	Estazolam
DMZGXUM	MI	TTPTXIN
DMZGXUM	MN	Translocator protein (TSPO)
DMZGXUM	MT	DTT
DMZGXUM	MA	Agonist
DMZGXUM	RN	Design and synthesis of new 2-substituted-5-(2-benzylthiophenyl)-1,3,4-oxadiazoles as benzodiazepine receptor agonists. Bioorg Med Chem Lett. 2005 Jun 15;15(12):3126-9.
DMZGXUM	RU	https://pubmed.ncbi.nlm.nih.gov/15876530

DM9KZDO	DI	DM9KZDO
DM9KZDO	DN	Esterified estrogens
DM9KZDO	MI	TTZAYWL
DM9KZDO	MN	Estrogen receptor (ESR)
DM9KZDO	MT	DTT
DM9KZDO	MA	Modulator
DM9KZDO	RN	Safety and efficacy of low-dose esterified estrogens and methyltestosterone, alone or combined, for the treatment of hot flashes in menopausal women: a randomized, double-blind, placebo-controlled study. Fertil Steril. 2011 Jan;95(1):366-8.
DM9KZDO	RU	https://pubmed.ncbi.nlm.nih.gov/20850731

DMUNTE3	DI	DMUNTE3
DMUNTE3	DN	Estradiol
DMUNTE3	MI	DTI7UX6
DMUNTE3	MN	Breast cancer resistance protein (ABCG2)
DMUNTE3	MT	DTP
DMUNTE3	MA	Substrate
DMUNTE3	RN	Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
DMUNTE3	RU	http://www.ncbi.nlm.nih.gov/pubmed/12668685

DMUNTE3	DI	DMUNTE3
DMUNTE3	DN	Estradiol
DMUNTE3	MI	DE6OQ3W
DMUNTE3	MN	Cytochrome P450 1A1 (CYP1A1)
DMUNTE3	MT	DME
DMUNTE3	MA	Metabolism
DMUNTE3	RN	Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA. Metabolism. 2007 Jul;56(7):887-94.
DMUNTE3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17570247

DMUNTE3	DI	DMUNTE3
DMUNTE3	DN	Estradiol
DMUNTE3	MI	DEJGDUW
DMUNTE3	MN	Cytochrome P450 1A2 (CYP1A2)
DMUNTE3	MT	DME
DMUNTE3	MA	Metabolism
DMUNTE3	RN	Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
DMUNTE3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15217502

DMUNTE3	DI	DMUNTE3
DMUNTE3	DN	Estradiol
DMUNTE3	MI	DE9QHP6
DMUNTE3	MN	Cytochrome P450 1B1 (CYP1B1)
DMUNTE3	MT	DME
DMUNTE3	MA	Metabolism
DMUNTE3	RN	Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA. Metabolism. 2007 Jul;56(7):887-94.
DMUNTE3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17570247

DMUNTE3	DI	DMUNTE3
DMUNTE3	DN	Estradiol
DMUNTE3	MI	DES5XRU
DMUNTE3	MN	Cytochrome P450 2C8 (CYP2C8)
DMUNTE3	MT	DME
DMUNTE3	MA	Metabolism
DMUNTE3	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DMUNTE3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DMUNTE3	DI	DMUNTE3
DMUNTE3	DN	Estradiol
DMUNTE3	MI	DE5IED8
DMUNTE3	MN	Cytochrome P450 2C9 (CYP2C9)
DMUNTE3	MT	DME
DMUNTE3	MA	Metabolism
DMUNTE3	RN	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
DMUNTE3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12865317

DMUNTE3	DI	DMUNTE3
DMUNTE3	DN	Estradiol
DMUNTE3	MI	DE4LYSA
DMUNTE3	MN	Cytochrome P450 3A4 (CYP3A4)
DMUNTE3	MT	DME
DMUNTE3	MA	Metabolism
DMUNTE3	RN	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
DMUNTE3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22837389

DMUNTE3	DI	DMUNTE3
DMUNTE3	DN	Estradiol
DMUNTE3	MI	DEIBDNY
DMUNTE3	MN	Cytochrome P450 3A5 (CYP3A5)
DMUNTE3	MT	DME
DMUNTE3	MA	Metabolism
DMUNTE3	RN	Drug Interactions Flockhart Table
DMUNTE3	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMUNTE3	DI	DMUNTE3
DMUNTE3	DN	Estradiol
DMUNTE3	MI	DERD86B
DMUNTE3	MN	Cytochrome P450 3A7 (CYP3A7)
DMUNTE3	MT	DME
DMUNTE3	MA	Metabolism
DMUNTE3	RN	Drug Interactions Flockhart Table
DMUNTE3	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMUNTE3	DI	DMUNTE3
DMUNTE3	DN	Estradiol
DMUNTE3	MI	DEGTB1K
DMUNTE3	MN	Dehydrogenase/reductase retSDR3 (HSD17B14)
DMUNTE3	MT	DME
DMUNTE3	MA	Metabolism
DMUNTE3	RN	Expression patterns of 17beta-hydroxysteroid dehydrogenase 14 in human tissues. Horm Metab Res. 2012 Dec;44(13):949-56.
DMUNTE3	RU	https://pubmed.ncbi.nlm.nih.gov/22864907

DMUNTE3	DI	DMUNTE3
DMUNTE3	DN	Estradiol
DMUNTE3	MI	TTZAYWL
DMUNTE3	MN	Estrogen receptor (ESR)
DMUNTE3	MT	DTT
DMUNTE3	MA	Agonist
DMUNTE3	RN	Reprint of Are all estrogens the same Maturitas. 2008 Sep-Oct;61(1-2):195-201.
DMUNTE3	RU	https://pubmed.ncbi.nlm.nih.gov/19434891

DMUNTE3	DI	DMUNTE3
DMUNTE3	DN	Estradiol
DMUNTE3	MI	DER0XCH
DMUNTE3	MN	Farnesol dehydrogenase (AKR1B15)
DMUNTE3	MT	DME
DMUNTE3	MA	Metabolism
DMUNTE3	RN	Aldo-keto Reductase 1B15 (AKR1B15): a mitochondrial human aldo-keto reductase with activity toward steroids and 3-keto-acyl-CoA conjugates. J Biol Chem. 2015 Mar 6;290(10):6531-45.
DMUNTE3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25577493

DMUNTE3	DI	DMUNTE3
DMUNTE3	DN	Estradiol
DMUNTE3	MI	DEHX1DZ
DMUNTE3	MN	Lactoperoxidase (LPO)
DMUNTE3	MT	DME
DMUNTE3	MA	Metabolism
DMUNTE3	RN	The metabolism of 17 beta-estradiol by lactoperoxidase: a possible source of oxidative stress in breast cancer. Carcinogenesis. 1994 Nov;15(11):2637-43.
DMUNTE3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7955118

DMUNTE3	DI	DMUNTE3
DMUNTE3	DN	Estradiol
DMUNTE3	MI	DEGTFWK
DMUNTE3	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMUNTE3	MT	DME
DMUNTE3	MA	Metabolism
DMUNTE3	RN	CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
DMUNTE3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18521743

DMUNTE3	DI	DMUNTE3
DMUNTE3	DN	Estradiol
DMUNTE3	MI	DTUGYRD
DMUNTE3	MN	P-glycoprotein 1 (ABCB1)
DMUNTE3	MT	DTP
DMUNTE3	MA	Substrate
DMUNTE3	RN	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
DMUNTE3	RU	http://www.ncbi.nlm.nih.gov/pubmed/7914405

DMUNTE3	DI	DMUNTE3
DMUNTE3	DN	Estradiol
DMUNTE3	MI	DEYWLRK
DMUNTE3	MN	Sulfotransferase 1A1 (SULT1A1)
DMUNTE3	MT	DME
DMUNTE3	MA	Metabolism
DMUNTE3	RN	Proposed role of the sulfotransferase/sulfatase pathway in modulating yolk steroid effects. Integr Comp Biol. 2008 Sep;48(3):419-27.
DMUNTE3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21669803

DMUNTE3	DI	DMUNTE3
DMUNTE3	DN	Estradiol
DMUNTE3	MI	DEFQ8VO
DMUNTE3	MN	Thiopurine methyltransferase (TPMT)
DMUNTE3	MT	DME
DMUNTE3	MA	Metabolism
DMUNTE3	RN	Influence of estradiol-17 beta and progesterone on catechol-O-methyltransferase and monoamine oxidase activities in uterine artery and myometrium of ovariectomized pigs. Arch Vet Pol. 1993;33(1-2):29-37.
DMUNTE3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8055052

DMUNTE3	DI	DMUNTE3
DMUNTE3	DN	Estradiol
DMUNTE3	MI	DEYGVN4
DMUNTE3	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMUNTE3	MT	DME
DMUNTE3	MA	Metabolism
DMUNTE3	RN	Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
DMUNTE3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20620155

DMUNTE3	DI	DMUNTE3
DMUNTE3	DN	Estradiol
DMUNTE3	MI	DEB7I4M
DMUNTE3	MN	UDP-glucuronosyltransferase 2B28 (UGT2B28)
DMUNTE3	MT	DME
DMUNTE3	MA	Metabolism
DMUNTE3	RN	Isolation and characterization of the UGT2B28 cDNA encoding a novel human steroid conjugating UDP-glucuronosyltransferase. Biochemistry. 2001 Apr 3;40(13):3869-81.
DMUNTE3	RU	https://pubmed.ncbi.nlm.nih.gov/11300766

DM07U2A	DI	DM07U2A
DM07U2A	DN	Estradiol acetate
DM07U2A	MI	DEJGDUW
DM07U2A	MN	Cytochrome P450 1A2 (CYP1A2)
DM07U2A	MT	DME
DM07U2A	MA	Metabolism
DM07U2A	RN	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
DM07U2A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12865317

DM07U2A	DI	DM07U2A
DM07U2A	DN	Estradiol acetate
DM07U2A	MI	DES5XRU
DM07U2A	MN	Cytochrome P450 2C8 (CYP2C8)
DM07U2A	MT	DME
DM07U2A	MA	Metabolism
DM07U2A	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DM07U2A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DM07U2A	DI	DM07U2A
DM07U2A	DN	Estradiol acetate
DM07U2A	MI	DE5IED8
DM07U2A	MN	Cytochrome P450 2C9 (CYP2C9)
DM07U2A	MT	DME
DM07U2A	MA	Metabolism
DM07U2A	RN	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
DM07U2A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14703066

DM07U2A	DI	DM07U2A
DM07U2A	DN	Estradiol acetate
DM07U2A	MI	DE4LYSA
DM07U2A	MN	Cytochrome P450 3A4 (CYP3A4)
DM07U2A	MT	DME
DM07U2A	MA	Metabolism
DM07U2A	RN	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
DM07U2A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14703066

DM07U2A	DI	DM07U2A
DM07U2A	DN	Estradiol acetate
DM07U2A	MI	DEIBDNY
DM07U2A	MN	Cytochrome P450 3A5 (CYP3A5)
DM07U2A	MT	DME
DM07U2A	MA	Metabolism
DM07U2A	RN	Drug Interactions Flockhart Table
DM07U2A	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM07U2A	DI	DM07U2A
DM07U2A	DN	Estradiol acetate
DM07U2A	MI	DERD86B
DM07U2A	MN	Cytochrome P450 3A7 (CYP3A7)
DM07U2A	MT	DME
DM07U2A	MA	Metabolism
DM07U2A	RN	Drug Interactions Flockhart Table
DM07U2A	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM07U2A	DI	DM07U2A
DM07U2A	DN	Estradiol acetate
DM07U2A	MI	TTZAYWL
DM07U2A	MN	Estrogen receptor (ESR)
DM07U2A	MT	DTT
DM07U2A	MA	Modulator
DM07U2A	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM07U2A	RU	https://www.fda.gov/

DM07U2A	DI	DM07U2A
DM07U2A	DN	Estradiol acetate
DM07U2A	MI	DEGTFWK
DM07U2A	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM07U2A	MT	DME
DM07U2A	MA	Metabolism
DM07U2A	RN	Role of cytochrome P450 in estradiol metabolism in vitro. Acta Pharmacol Sin. 2001 Feb;22(2):148-54.
DM07U2A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11741520

DM07U2A	DI	DM07U2A
DM07U2A	DN	Estradiol acetate
DM07U2A	MI	DEYGVN4
DM07U2A	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM07U2A	MT	DME
DM07U2A	MA	Metabolism
DM07U2A	RN	Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
DM07U2A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20620155

DM27Z5T	DI	DM27Z5T
DM27Z5T	DN	Estradiol cypionate
DM27Z5T	MI	DEJGDUW
DM27Z5T	MN	Cytochrome P450 1A2 (CYP1A2)
DM27Z5T	MT	DME
DM27Z5T	MA	Metabolism
DM27Z5T	RN	Inhibition of the human liver microsomal and human cytochrome P450 1A2 and 3A4 metabolism of estradiol by deployment-related and other chemicals. Drug Metab Dispos. 2006 Sep;34(9):1606-14.
DM27Z5T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16790556

DM27Z5T	DI	DM27Z5T
DM27Z5T	DN	Estradiol cypionate
DM27Z5T	MI	DES5XRU
DM27Z5T	MN	Cytochrome P450 2C8 (CYP2C8)
DM27Z5T	MT	DME
DM27Z5T	MA	Metabolism
DM27Z5T	RN	Role of cytochrome P450 in estradiol metabolism in vitro. Acta Pharmacol Sin. 2001 Feb;22(2):148-54.
DM27Z5T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11741520

DM27Z5T	DI	DM27Z5T
DM27Z5T	DN	Estradiol cypionate
DM27Z5T	MI	DE5IED8
DM27Z5T	MN	Cytochrome P450 2C9 (CYP2C9)
DM27Z5T	MT	DME
DM27Z5T	MA	Metabolism
DM27Z5T	RN	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
DM27Z5T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14703066

DM27Z5T	DI	DM27Z5T
DM27Z5T	DN	Estradiol cypionate
DM27Z5T	MI	DE4LYSA
DM27Z5T	MN	Cytochrome P450 3A4 (CYP3A4)
DM27Z5T	MT	DME
DM27Z5T	MA	Metabolism
DM27Z5T	RN	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
DM27Z5T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14703066

DM27Z5T	DI	DM27Z5T
DM27Z5T	DN	Estradiol cypionate
DM27Z5T	MI	DEIBDNY
DM27Z5T	MN	Cytochrome P450 3A5 (CYP3A5)
DM27Z5T	MT	DME
DM27Z5T	MA	Metabolism
DM27Z5T	RN	Drug Interactions Flockhart Table
DM27Z5T	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM27Z5T	DI	DM27Z5T
DM27Z5T	DN	Estradiol cypionate
DM27Z5T	MI	DERD86B
DM27Z5T	MN	Cytochrome P450 3A7 (CYP3A7)
DM27Z5T	MT	DME
DM27Z5T	MA	Metabolism
DM27Z5T	RN	Drug Interactions Flockhart Table
DM27Z5T	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM27Z5T	DI	DM27Z5T
DM27Z5T	DN	Estradiol cypionate
DM27Z5T	MI	TTZAYWL
DM27Z5T	MN	Estrogen receptor (ESR)
DM27Z5T	MT	DTT
DM27Z5T	MA	Modulator
DM27Z5T	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM27Z5T	RU	https://www.fda.gov/

DM27Z5T	DI	DM27Z5T
DM27Z5T	DN	Estradiol cypionate
DM27Z5T	MI	DEGTFWK
DM27Z5T	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM27Z5T	MT	DME
DM27Z5T	MA	Metabolism
DM27Z5T	RN	Role of cytochrome P450 in estradiol metabolism in vitro. Acta Pharmacol Sin. 2001 Feb;22(2):148-54.
DM27Z5T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11741520

DM27Z5T	DI	DM27Z5T
DM27Z5T	DN	Estradiol cypionate
DM27Z5T	MI	DEYGVN4
DM27Z5T	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM27Z5T	MT	DME
DM27Z5T	MA	Metabolism
DM27Z5T	RN	Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
DM27Z5T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20620155

DM8MC6O	DI	DM8MC6O
DM8MC6O	DN	Estradiol valerate
DM8MC6O	MI	DEJGDUW
DM8MC6O	MN	Cytochrome P450 1A2 (CYP1A2)
DM8MC6O	MT	DME
DM8MC6O	MA	Metabolism
DM8MC6O	RN	Inhibition of the human liver microsomal and human cytochrome P450 1A2 and 3A4 metabolism of estradiol by deployment-related and other chemicals. Drug Metab Dispos. 2006 Sep;34(9):1606-14.
DM8MC6O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16790556

DM8MC6O	DI	DM8MC6O
DM8MC6O	DN	Estradiol valerate
DM8MC6O	MI	DES5XRU
DM8MC6O	MN	Cytochrome P450 2C8 (CYP2C8)
DM8MC6O	MT	DME
DM8MC6O	MA	Metabolism
DM8MC6O	RN	Role of cytochrome P450 in estradiol metabolism in vitro. Acta Pharmacol Sin. 2001 Feb;22(2):148-54.
DM8MC6O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11741520

DM8MC6O	DI	DM8MC6O
DM8MC6O	DN	Estradiol valerate
DM8MC6O	MI	DE5IED8
DM8MC6O	MN	Cytochrome P450 2C9 (CYP2C9)
DM8MC6O	MT	DME
DM8MC6O	MA	Metabolism
DM8MC6O	RN	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
DM8MC6O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14703066

DM8MC6O	DI	DM8MC6O
DM8MC6O	DN	Estradiol valerate
DM8MC6O	MI	DE4LYSA
DM8MC6O	MN	Cytochrome P450 3A4 (CYP3A4)
DM8MC6O	MT	DME
DM8MC6O	MA	Metabolism
DM8MC6O	RN	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
DM8MC6O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14703066

DM8MC6O	DI	DM8MC6O
DM8MC6O	DN	Estradiol valerate
DM8MC6O	MI	DEIBDNY
DM8MC6O	MN	Cytochrome P450 3A5 (CYP3A5)
DM8MC6O	MT	DME
DM8MC6O	MA	Metabolism
DM8MC6O	RN	Drug Interactions Flockhart Table
DM8MC6O	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM8MC6O	DI	DM8MC6O
DM8MC6O	DN	Estradiol valerate
DM8MC6O	MI	DERD86B
DM8MC6O	MN	Cytochrome P450 3A7 (CYP3A7)
DM8MC6O	MT	DME
DM8MC6O	MA	Metabolism
DM8MC6O	RN	Drug Interactions Flockhart Table
DM8MC6O	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM8MC6O	DI	DM8MC6O
DM8MC6O	DN	Estradiol valerate
DM8MC6O	MI	TTZAYWL
DM8MC6O	MN	Estrogen receptor (ESR)
DM8MC6O	MT	DTT
DM8MC6O	MA	Modulator
DM8MC6O	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM8MC6O	RU	https://www.fda.gov/

DM8MC6O	DI	DM8MC6O
DM8MC6O	DN	Estradiol valerate
DM8MC6O	MI	DEGTFWK
DM8MC6O	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM8MC6O	MT	DME
DM8MC6O	MA	Metabolism
DM8MC6O	RN	Role of cytochrome P450 in estradiol metabolism in vitro. Acta Pharmacol Sin. 2001 Feb;22(2):148-54.
DM8MC6O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11741520

DM8MC6O	DI	DM8MC6O
DM8MC6O	DN	Estradiol valerate
DM8MC6O	MI	DEYGVN4
DM8MC6O	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM8MC6O	MT	DME
DM8MC6O	MA	Metabolism
DM8MC6O	RN	Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
DM8MC6O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20620155

DMLNMEA	DI	DMLNMEA
DMLNMEA	DN	Estradiol valerate/dienogest
DMLNMEA	MI	TTUV8G9
DMLNMEA	MN	Progesterone receptor (PGR)
DMLNMEA	MT	DTT
DMLNMEA	MA	Modulator
DMLNMEA	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DMLNMEA	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DMWTAOI	DI	DMWTAOI
DMWTAOI	DN	Estramustine
DMWTAOI	MI	DE4LYSA
DMWTAOI	MN	Cytochrome P450 3A4 (CYP3A4)
DMWTAOI	MT	DME
DMWTAOI	MA	Metabolism
DMWTAOI	RN	Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts. J Urol. 2003 May;169(5):1729-34.
DMWTAOI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12686819

DMWTAOI	DI	DMWTAOI
DMWTAOI	DN	Estramustine
DMWTAOI	MI	TTSBFYK
DMWTAOI	MN	Estramustine binding protein (EMBP)
DMWTAOI	MT	DTT
DMWTAOI	MA	Binder
DMWTAOI	RN	Estramustine binding protein in primary tumours and metastases of malignant melanoma. Melanoma Res. 1994 Dec;4(6):401-5.
DMWTAOI	RU	https://pubmed.ncbi.nlm.nih.gov/7703721

DMOEM2I	DI	DMOEM2I
DMOEM2I	DN	Estriol
DMOEM2I	MI	DERD86B
DMOEM2I	MN	Cytochrome P450 3A7 (CYP3A7)
DMOEM2I	MT	DME
DMOEM2I	MA	Metabolism
DMOEM2I	RN	Expression and cyclic variability of CYP3A4 and CYP3A7 isoforms in human endometrium and cervix during the menstrual cycle. Drug Metab Dispos. 2003 Jan;31(1):1-6.
DMOEM2I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12485945

DMOEM2I	DI	DMOEM2I
DMOEM2I	DN	Estriol
DMOEM2I	MI	TTZAYWL
DMOEM2I	MN	Estrogen receptor (ESR)
DMOEM2I	MT	DTT
DMOEM2I	MA	Agonist
DMOEM2I	RN	Reprint of Are all estrogens the same Maturitas. 2008 Sep-Oct;61(1-2):195-201.
DMOEM2I	RU	https://pubmed.ncbi.nlm.nih.gov/19434891

DMOEM2I	DI	DMOEM2I
DMOEM2I	DN	Estriol
DMOEM2I	MI	DTUGYRD
DMOEM2I	MN	P-glycoprotein 1 (ABCB1)
DMOEM2I	MT	DTP
DMOEM2I	MA	Substrate
DMOEM2I	RN	P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004 Jul;21(7):1284-93.
DMOEM2I	RU	http://www.ncbi.nlm.nih.gov/pubmed/15290871

DMOEM2I	DI	DMOEM2I
DMOEM2I	DN	Estriol
DMOEM2I	MI	DEYGVN4
DMOEM2I	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMOEM2I	MT	DME
DMOEM2I	MA	Metabolism
DMOEM2I	RN	Stimulation of microsomal uridine diphosphate glucuronyltransferase by glucuronic acid derivatives. Biochem J. 1974 Apr;139(1):243-9.
DMOEM2I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=4219139

DMGY0UT	DI	DMGY0UT
DMGY0UT	DN	Estrogen
DMGY0UT	MI	TTZAYWL
DMGY0UT	MN	Estrogen receptor (ESR)
DMGY0UT	MT	DTT
DMGY0UT	MA	Agonist
DMGY0UT	RN	Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med. 2002 Mar 28;346(13):967-74.
DMGY0UT	RU	https://pubmed.ncbi.nlm.nih.gov/11919305

DMGY0UT	DI	DMGY0UT
DMGY0UT	DN	Estrogen
DMGY0UT	MI	TTOM3J0
DMGY0UT	MN	Estrogen receptor beta (ESR2)
DMGY0UT	MT	DTT
DMGY0UT	MA	Agonist
DMGY0UT	RN	Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient female mice. Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15133-6.
DMGY0UT	RU	https://pubmed.ncbi.nlm.nih.gov/10611350

DM5T6US	DI	DM5T6US
DM5T6US	DN	Estrone
DM5T6US	MI	DE6OQ3W
DM5T6US	MN	Cytochrome P450 1A1 (CYP1A1)
DM5T6US	MT	DME
DM5T6US	MA	Metabolism
DM5T6US	RN	A common CYP1B1 polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio. Clin Chem Lab Med. 2005;43(7):702-6.
DM5T6US	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16207128

DM5T6US	DI	DM5T6US
DM5T6US	DN	Estrone
DM5T6US	MI	DEJGDUW
DM5T6US	MN	Cytochrome P450 1A2 (CYP1A2)
DM5T6US	MT	DME
DM5T6US	MA	Metabolism
DM5T6US	RN	A transgenic mouse expressing human CYP1A2 in the pancreas. Biochem Pharmacol. 2000 Sep 15;60(6):857-63.
DM5T6US	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10930541

DM5T6US	DI	DM5T6US
DM5T6US	DN	Estrone
DM5T6US	MI	DE9QHP6
DM5T6US	MN	Cytochrome P450 1B1 (CYP1B1)
DM5T6US	MT	DME
DM5T6US	MA	Metabolism
DM5T6US	RN	A common CYP1B1 polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio. Clin Chem Lab Med. 2005;43(7):702-6.
DM5T6US	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16207128

DM5T6US	DI	DM5T6US
DM5T6US	DN	Estrone
DM5T6US	MI	DEPKLMQ
DM5T6US	MN	Cytochrome P450 2B6 (CYP2B6)
DM5T6US	MT	DME
DM5T6US	MA	Metabolism
DM5T6US	RN	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
DM5T6US	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12865317

DM5T6US	DI	DM5T6US
DM5T6US	DN	Estrone
DM5T6US	MI	DE5IED8
DM5T6US	MN	Cytochrome P450 2C9 (CYP2C9)
DM5T6US	MT	DME
DM5T6US	MA	Metabolism
DM5T6US	RN	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
DM5T6US	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14703066

DM5T6US	DI	DM5T6US
DM5T6US	DN	Estrone
DM5T6US	MI	DEVDYN7
DM5T6US	MN	Cytochrome P450 2E1 (CYP2E1)
DM5T6US	MT	DME
DM5T6US	MA	Metabolism
DM5T6US	RN	Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2.
DM5T6US	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10640505

DM5T6US	DI	DM5T6US
DM5T6US	DN	Estrone
DM5T6US	MI	DE4LYSA
DM5T6US	MN	Cytochrome P450 3A4 (CYP3A4)
DM5T6US	MT	DME
DM5T6US	MA	Metabolism
DM5T6US	RN	Regioselective hydroxylation of steroid hormones by human cytochromes P450. Drug Metab Rev. 2015 May;47(2):89-110.
DM5T6US	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25678418

DM5T6US	DI	DM5T6US
DM5T6US	DN	Estrone
DM5T6US	MI	DEIBDNY
DM5T6US	MN	Cytochrome P450 3A5 (CYP3A5)
DM5T6US	MT	DME
DM5T6US	MA	Metabolism
DM5T6US	RN	16Alpha-hydroxylation of estrone by human cytochrome P4503A4/5. Carcinogenesis. 1998 May;19(5):867-72.
DM5T6US	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9635876

DM5T6US	DI	DM5T6US
DM5T6US	DN	Estrone
DM5T6US	MI	DEBMFZ8
DM5T6US	MN	Estradiol 17-beta-dehydrogenase 2 (HSD17B2)
DM5T6US	MT	DME
DM5T6US	MA	Metabolism
DM5T6US	RN	Steroid signalling in the ovarian surface epithelium. Trends Endocrinol Metab. 2005 Sep;16(7):327-33.
DM5T6US	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16054388

DM5T6US	DI	DM5T6US
DM5T6US	DN	Estrone
DM5T6US	MI	TTZAYWL
DM5T6US	MN	Estrogen receptor (ESR)
DM5T6US	MT	DTT
DM5T6US	MA	Agonist
DM5T6US	RN	Reprint of Are all estrogens the same Maturitas. 2008 Sep-Oct;61(1-2):195-201.
DM5T6US	RU	https://pubmed.ncbi.nlm.nih.gov/19434891

DM5T6US	DI	DM5T6US
DM5T6US	DN	Estrone
DM5T6US	MI	DER0XCH
DM5T6US	MN	Farnesol dehydrogenase (AKR1B15)
DM5T6US	MT	DME
DM5T6US	MA	Metabolism
DM5T6US	RN	Aldo-keto Reductase 1B15 (AKR1B15): a mitochondrial human aldo-keto reductase with activity toward steroids and 3-keto-acyl-CoA conjugates. J Biol Chem. 2015 Mar 6;290(10):6531-45.
DM5T6US	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25577493

DM5T6US	DI	DM5T6US
DM5T6US	DN	Estrone
DM5T6US	MI	DE915QP
DM5T6US	MN	Ketoacyl-CoA reductase (HSD17B12)
DM5T6US	MT	DME
DM5T6US	MA	Metabolism
DM5T6US	RN	Characterization of type 12 17beta-hydroxysteroid dehydrogenase, an isoform of type 3 17beta-hydroxysteroid dehydrogenase responsible for estradiol formation in women. Mol Endocrinol. 2006 Feb;20(2):437-43.
DM5T6US	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16166196

DM5T6US	DI	DM5T6US
DM5T6US	DN	Estrone
DM5T6US	MI	DEDMWFX
DM5T6US	MN	Keto-steroid reductase (HSD17B7)
DM5T6US	MT	DME
DM5T6US	MA	Metabolism
DM5T6US	RN	Steroid signalling in the ovarian surface epithelium. Trends Endocrinol Metab. 2005 Sep;16(7):327-33.
DM5T6US	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16054388

DM5T6US	DI	DM5T6US
DM5T6US	DN	Estrone
DM5T6US	MI	DE2XQGW
DM5T6US	MN	Lauric acid omega-hydroxylase (CYP4A11)
DM5T6US	MT	DME
DM5T6US	MA	Metabolism
DM5T6US	RN	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
DM5T6US	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12865317

DM5T6US	DI	DM5T6US
DM5T6US	DN	Estrone
DM5T6US	MI	DEJHG19
DM5T6US	MN	Peroxisomal multifunctional enzyme 2 (HSD17B4)
DM5T6US	MT	DME
DM5T6US	MA	Metabolism
DM5T6US	RN	Steroid signalling in the ovarian surface epithelium. Trends Endocrinol Metab. 2005 Sep;16(7):327-33.
DM5T6US	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16054388

DM5T6US	DI	DM5T6US
DM5T6US	DN	Estrone
DM5T6US	MI	DTUGYRD
DM5T6US	MN	P-glycoprotein 1 (ABCB1)
DM5T6US	MT	DTP
DM5T6US	MA	Substrate
DM5T6US	RN	P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004 Jul;21(7):1284-93.
DM5T6US	RU	http://www.ncbi.nlm.nih.gov/pubmed/15290871

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DT9NXMV
DMVBIZL	MN	ATP-binding cassette sub-family A member 8 (ABCA8)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	Functional analysis of ABCA8, a new drug transporter. Biochem Biophys Res Commun. 2002 Oct 18;298(1):41-5.
DMVBIZL	RU	http://www.ncbi.nlm.nih.gov/pubmed/12379217

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DTI7UX6
DMVBIZL	MN	Breast cancer resistance protein (ABCG2)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem. 2003 Jun 20;278(25):22644-9.
DMVBIZL	RU	http://www.ncbi.nlm.nih.gov/pubmed/12682043

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DTI7UX6
DMVBIZL	MN	Breast cancer resistance protein (ABCG2)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2. J Pharm Sci. 2012 May;101(5):1888-97.
DMVBIZL	RU	https://doi.org/10.1002/jps.23069

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DTZGT0P
DMVBIZL	MN	Multidrug and toxin extrusion protein 1 (SLC47A1)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
DMVBIZL	RU	http://www.ncbi.nlm.nih.gov/pubmed/17509534

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DT3TX4H
DMVBIZL	MN	Multidrug and toxin extrusion protein 2 (SLC47A2)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
DMVBIZL	RU	http://www.ncbi.nlm.nih.gov/pubmed/17509534

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DTSYQGK
DMVBIZL	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	Molecular cloning and pharmacological characterization of rat multidrug resistance protein 1 (mrp1). Drug Metab Dispos. 2003 Aug;31(8):1016-26.
DMVBIZL	RU	http://www.ncbi.nlm.nih.gov/pubmed/12867490

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DTFI42L
DMVBIZL	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol Pharmacol. 2005 Oct;68(4):1031-8.
DMVBIZL	RU	http://www.ncbi.nlm.nih.gov/pubmed/16046661

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DTVP67E
DMVBIZL	MN	Organic anion transporter 3 (SLC22A8)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	Involvement of tyrosine kinase and PI3K in the regulation of OAT3-mediated estrone sulfate transport in isolated rabbit renal proximal tubules. Am J Physiol Renal Physiol. 2005 Nov;289(5):F1057-64.
DMVBIZL	RU	http://www.ncbi.nlm.nih.gov/pubmed/15956776

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DT06JWZ
DMVBIZL	MN	Organic anion transporter 4 (SLC22A11)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	Inhibitory effects of angiotensin II receptor antagonists and leukotriene receptor antagonists on the transport of human organic anion transporter 4. J Pharm Pharmacol. 2006 Nov;58(11):1499-505.
DMVBIZL	RU	http://www.ncbi.nlm.nih.gov/pubmed/17132213

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DTT3IKQ
DMVBIZL	MN	Organic anion transporter 6 (SLC22A20)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	Transport of estrone sulfate by the novel organic anion transporter Oat6 (Slc22a20). Am J Physiol Renal Physiol. 2006 Aug;291(2):F314-21.
DMVBIZL	RU	http://www.ncbi.nlm.nih.gov/pubmed/16478971

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DTE2B1D
DMVBIZL	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	Determination of OATP-, NTCP- and OCT-mediated substrate uptake activities in individual and pooled batches of cryopreserved human hepatocytes. Eur J Pharm Sci. 2011 Jul 17;43(4):297-307.
DMVBIZL	RU	http://www.ncbi.nlm.nih.gov/pubmed/21605667

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DT3D8F0
DMVBIZL	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	Role of transmembrane domain 10 for the function of organic anion transporting polypeptide 1B1. Protein Sci. 2009 Nov;18(11):2298-306.
DMVBIZL	RU	http://www.ncbi.nlm.nih.gov/pubmed/19760661

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DT9C1TS
DMVBIZL	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65.
DMVBIZL	RU	http://www.ncbi.nlm.nih.gov/pubmed/18321482

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DTPFTEQ
DMVBIZL	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos. 2007 Aug;35(8):1308-14.
DMVBIZL	RU	http://www.ncbi.nlm.nih.gov/pubmed/17470528

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DTVNRXW
DMVBIZL	MN	Organic anion transporting polypeptide 3A1 (SLCO3A1)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000 Jun 24;273(1):251-60.
DMVBIZL	RU	http://www.ncbi.nlm.nih.gov/pubmed/10873595

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DT8H2IC
DMVBIZL	MN	Organic anion transporting polypeptide 4A1 (SLCO4A1)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	Involvement of estrone-3-sulfate transporters in proliferation of hormone-dependent breast cancer cells. J Pharmacol Exp Ther. 2004 Dec;311(3):1032-7.
DMVBIZL	RU	http://www.ncbi.nlm.nih.gov/pubmed/15328376

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DTY0QMU
DMVBIZL	MN	Organic anion transporting polypeptide 4C1 (SLCO4C1)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	Transport of estrone 3-sulfate mediated by organic anion transporter OATP4C1: estrone 3-sulfate binds to the different recognition site for digoxin in OATP4C1. Drug Metab Pharmacokinet. 2010;25(3):314-7.
DMVBIZL	RU	http://www.ncbi.nlm.nih.gov/pubmed/20610891

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DTMEQ32
DMVBIZL	MN	Organic solute transporter subunit alpha (SLC51A)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem. 2003 Jul 25;278(30):27473-82.
DMVBIZL	RU	http://www.ncbi.nlm.nih.gov/pubmed/12719432

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DT1V9AJ
DMVBIZL	MN	Organic solute transporter subunit beta (SLC51B)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem. 2003 Jul 25;278(30):27473-82.
DMVBIZL	RU	http://www.ncbi.nlm.nih.gov/pubmed/12719432

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DT1V9AJ
DMVBIZL	MN	Organic solute transporter subunit beta (SLC51B)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem. 2003 Jul 25;278(30):27473-82.
DMVBIZL	RU	http://www.ncbi.nlm.nih.gov/pubmed/12719432

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DTUGYRD
DMVBIZL	MN	P-glycoprotein 1 (ABCB1)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67.
DMVBIZL	RU	https://doi.org/10.1124/jpet.105.085589

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DT56EKP
DMVBIZL	MN	Sodium/taurocholate cotransporting polypeptide (SLC10A1)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	Ethnicity-dependent polymorphism in Na+-taurocholate cotransporting polypeptide (SLC10A1) reveals a domain critical for bile acid substrate recognition. J Biol Chem. 2004 Feb 20;279(8):7213-22.
DMVBIZL	RU	http://www.ncbi.nlm.nih.gov/pubmed/14660639

DMRMDWA	DI	DMRMDWA
DMRMDWA	DN	Estropipate
DMRMDWA	MI	DE4LYSA
DMRMDWA	MN	Cytochrome P450 3A4 (CYP3A4)
DMRMDWA	MT	DME
DMRMDWA	MA	Metabolism
DMRMDWA	RN	Estrogen regulation of the cytochrome P450 3A subfamily in humans. J Pharmacol Exp Ther. 2004 Nov;311(2):728-35.
DMRMDWA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15282264

DMRMDWA	DI	DMRMDWA
DMRMDWA	DN	Estropipate
DMRMDWA	MI	TTZAYWL
DMRMDWA	MN	Estrogen receptor (ESR)
DMRMDWA	MT	DTT
DMRMDWA	MA	Modulator
DMRMDWA	RN	US patent application no. 5,004,651, Stabilizing system for solid dosage forms.
DMRMDWA	RU	http://www.google.com/patents/US5004651

DM8RZ9H	DI	DM8RZ9H
DM8RZ9H	DN	Eszopiclone
DM8RZ9H	MI	DES5XRU
DM8RZ9H	MN	Cytochrome P450 2C8 (CYP2C8)
DM8RZ9H	MT	DME
DM8RZ9H	MA	Metabolism
DM8RZ9H	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM8RZ9H	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM8RZ9H	DI	DM8RZ9H
DM8RZ9H	DN	Eszopiclone
DM8RZ9H	MI	DEVDYN7
DM8RZ9H	MN	Cytochrome P450 2E1 (CYP2E1)
DM8RZ9H	MT	DME
DM8RZ9H	MA	Metabolism
DM8RZ9H	RN	Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia. Clin Ther. 2006 Apr;28(4):491-516.
DM8RZ9H	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16750462

DM8RZ9H	DI	DM8RZ9H
DM8RZ9H	DN	Eszopiclone
DM8RZ9H	MI	DE4LYSA
DM8RZ9H	MN	Cytochrome P450 3A4 (CYP3A4)
DM8RZ9H	MT	DME
DM8RZ9H	MA	Metabolism
DM8RZ9H	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM8RZ9H	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM8RZ9H	DI	DM8RZ9H
DM8RZ9H	DN	Eszopiclone
DM8RZ9H	MI	TTPTXIN
DM8RZ9H	MN	Translocator protein (TSPO)
DM8RZ9H	MT	DTT
DM8RZ9H	MA	Agonist
DM8RZ9H	RN	New hypnotics: perspectives from sleep physiology. Vertex. 2007 Jul-Aug;18(74):294-9.
DM8RZ9H	RU	https://pubmed.ncbi.nlm.nih.gov/18265473

DMCV109	DI	DMCV109
DMCV109	DN	Etanercept
DMCV109	MI	TTF8CQI
DMCV109	MN	Tumor necrosis factor (TNF)
DMCV109	MT	DTT
DMCV109	MA	Modulator
DMCV109	RN	The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. 
DMCV109	RU	https://www.ncbi.nlm.nih.gov/pubmed/23197041

DMHP9BL	DI	DMHP9BL
DMHP9BL	DN	Etelcalcetide
DMHP9BL	MI	TTBUYHA
DMHP9BL	MN	Extracellular calcium-sensing receptor (CASR)
DMHP9BL	MT	DTT
DMHP9BL	MA	Modulator
DMHP9BL	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMHP9BL	RU	https://www.fda.gov/

DM2QBHP	DI	DM2QBHP
DM2QBHP	DN	Eteplirsen
DM2QBHP	MI	TTWLFXU
DM2QBHP	MN	Dystrophin messenger RNA (DMD mRNA)
DM2QBHP	MT	DTT
DM2QBHP	MA	Modulator
DM2QBHP	RN	2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. 
DM2QBHP	RU	https://www.ncbi.nlm.nih.gov/pubmed/28148938

DM5M4NT	DI	DM5M4NT
DM5M4NT	DN	Ethacrynate sodium
DM5M4NT	MI	TTS087L
DM5M4NT	MN	Solute carrier family 12 member 1 (SLC12A1)
DM5M4NT	MT	DTT
DM5M4NT	MA	Modulator
DM5M4NT	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM5M4NT	RU	https://www.fda.gov/

DM60QMR	DI	DM60QMR
DM60QMR	DN	Ethacrynic acid
DM60QMR	MI	DE6OQ3W
DM60QMR	MN	Cytochrome P450 1A1 (CYP1A1)
DM60QMR	MT	DME
DM60QMR	MA	Metabolism
DM60QMR	RN	Xenobiotic metabolizing and antioxidant enzymes in normal and neoplastic human breast tissue. Eur J Drug Metab Pharmacokinet. 1998 Oct-Dec;23(4):497-500.
DM60QMR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10323333

DM60QMR	DI	DM60QMR
DM60QMR	DN	Ethacrynic acid
DM60QMR	MI	DE4ZHS1
DM60QMR	MN	Glutathione S-transferase alpha-1 (GSTA1)
DM60QMR	MT	DME
DM60QMR	MA	Metabolism
DM60QMR	RN	Purification and biochemical properties of glutathione S-transferase from Lactuca sativa. J Biochem Mol Biol. 2005 Mar 31;38(2):232-7.
DM60QMR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15826502

DM60QMR	DI	DM60QMR
DM60QMR	DN	Ethacrynic acid
DM60QMR	MI	DTSYQGK
DM60QMR	MN	Multidrug resistance-associated protein 1 (ABCC1)
DM60QMR	MT	DTP
DM60QMR	MA	Substrate
DM60QMR	RN	Inhibition of the multidrug resistance protein 1 (MRP1) by peptidomimetic glutathione-conjugate analogs. Mol Pharmacol. 2002 Nov;62(5):1160-6.
DM60QMR	RU	http://www.ncbi.nlm.nih.gov/pubmed/12391280

DM60QMR	DI	DM60QMR
DM60QMR	DN	Ethacrynic acid
DM60QMR	MI	TTS087L
DM60QMR	MN	Solute carrier family 12 member 1 (SLC12A1)
DM60QMR	MT	DTT
DM60QMR	MA	Blocker
DM60QMR	RN	Na-K-Cl cotransport regulates intracellular volume and monolayer permeability of trabecular meshwork cells. Am J Physiol. 1995 Apr;268(4 Pt 1):C1067-74.
DM60QMR	RU	https://pubmed.ncbi.nlm.nih.gov/7733229

DMR87LC	DI	DMR87LC
DMR87LC	DN	Ethambutol
DMR87LC	MI	TT1Q8GP
DMR87LC	MN	Mycobacterium Arabinosyltransferase C (MycB embC)
DMR87LC	MT	DTT
DMR87LC	MA	Inhibitor
DMR87LC	RN	The arabinosyltransferase EmbC is inhibited by ethambutol in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2009 Oct;53(10):4138-46.
DMR87LC	RU	https://pubmed.ncbi.nlm.nih.gov/19596878

DMDRQZU	DI	DMDRQZU
DMDRQZU	DN	Ethanol
DMDRQZU	MI	DEG8NJD
DMDRQZU	MN	Alcohol dehydrogenase (ADH)
DMDRQZU	MT	DME
DMDRQZU	MA	Metabolism
DMDRQZU	RN	Functional profiles of coronal and dentin caries in children. J Oral Microbiol. 2018 Jul 16;10(1):1495976.
DMDRQZU	RU	https://pubmed.ncbi.nlm.nih.gov/30034639

DMDRQZU	DI	DMDRQZU
DMDRQZU	DN	Ethanol
DMDRQZU	MI	DEE5M8O
DMDRQZU	MN	Alcohol dehydrogenase class-I alpha (ADH1A)
DMDRQZU	MT	DME
DMDRQZU	MA	Metabolism
DMDRQZU	RN	Natural alcohol exposure: is ethanol the main substrate for alcohol dehydrogenases in animals? Chem Biol Interact. 2011 May 30;191(1-3):14-25.
DMDRQZU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21329681

DMDRQZU	DI	DMDRQZU
DMDRQZU	DN	Ethanol
DMDRQZU	MI	DEEN9RD
DMDRQZU	MN	Alcohol dehydrogenase class-I beta (ADH1B)
DMDRQZU	MT	DME
DMDRQZU	MA	Metabolism
DMDRQZU	RN	Natural alcohol exposure: is ethanol the main substrate for alcohol dehydrogenases in animals? Chem Biol Interact. 2011 May 30;191(1-3):14-25.
DMDRQZU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21329681

DMDRQZU	DI	DMDRQZU
DMDRQZU	DN	Ethanol
DMDRQZU	MI	DEM1HNL
DMDRQZU	MN	Alcohol dehydrogenase class-I gamma (ADH1C)
DMDRQZU	MT	DME
DMDRQZU	MA	Metabolism
DMDRQZU	RN	Natural alcohol exposure: is ethanol the main substrate for alcohol dehydrogenases in animals? Chem Biol Interact. 2011 May 30;191(1-3):14-25.
DMDRQZU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21329681

DMDRQZU	DI	DMDRQZU
DMDRQZU	DN	Ethanol
DMDRQZU	MI	DEOCWU3
DMDRQZU	MN	Alcohol dehydrogenase class-II (ADH4)
DMDRQZU	MT	DME
DMDRQZU	MA	Metabolism
DMDRQZU	RN	Oxidation of alcohols and reduction of aldehydes derived from methyl- and dimethylpyrenes by cDNA-expressed human alcohol dehydrogenases. Toxicology. 2008 Mar 12;245(1-2):65-75.
DMDRQZU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18242813

DMDRQZU	DI	DMDRQZU
DMDRQZU	DN	Ethanol
DMDRQZU	MI	DEIOH6A
DMDRQZU	MN	Alcohol dehydrogenase class-III (ADH5)
DMDRQZU	MT	DME
DMDRQZU	MA	Metabolism
DMDRQZU	RN	Functional assessment of human alcohol dehydrogenase family in ethanol metabolism: significance of first-pass metabolism. Alcohol Clin Exp Res. 2006 Jul;30(7):1132-42.
DMDRQZU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16792560

DMDRQZU	DI	DMDRQZU
DMDRQZU	DN	Ethanol
DMDRQZU	MI	DE017IC
DMDRQZU	MN	Alcohol dehydrogenase class-V (ADH6)
DMDRQZU	MT	DME
DMDRQZU	MA	Metabolism
DMDRQZU	RN	Functional assessment of human alcohol dehydrogenase family in ethanol metabolism: significance of first-pass metabolism. Alcohol Clin Exp Res. 2006 Jul;30(7):1132-42.
DMDRQZU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16792560

DMDRQZU	DI	DMDRQZU
DMDRQZU	DN	Ethanol
DMDRQZU	MI	DED2FW3
DMDRQZU	MN	Aldo-keto reductase 1A1 (AKR1A1)
DMDRQZU	MT	DME
DMDRQZU	MA	Metabolism
DMDRQZU	RN	Functional assessment of human alcohol dehydrogenase family in ethanol metabolism: significance of first-pass metabolism. Alcohol Clin Exp Res. 2006 Jul;30(7):1132-42.
DMDRQZU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16792560

DMDRQZU	DI	DMDRQZU
DMDRQZU	DN	Ethanol
DMDRQZU	MI	DEJGDUW
DMDRQZU	MN	Cytochrome P450 1A2 (CYP1A2)
DMDRQZU	MT	DME
DMDRQZU	MA	Metabolism
DMDRQZU	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMDRQZU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMDRQZU	DI	DMDRQZU
DMDRQZU	DN	Ethanol
DMDRQZU	MI	DEVDYN7
DMDRQZU	MN	Cytochrome P450 2E1 (CYP2E1)
DMDRQZU	MT	DME
DMDRQZU	MA	Metabolism
DMDRQZU	RN	CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9.
DMDRQZU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12707490

DMDRQZU	DI	DMDRQZU
DMDRQZU	DN	Ethanol
DMDRQZU	MI	DE4LYSA
DMDRQZU	MN	Cytochrome P450 3A4 (CYP3A4)
DMDRQZU	MT	DME
DMDRQZU	MA	Metabolism
DMDRQZU	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMDRQZU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMDRQZU	DI	DMDRQZU
DMDRQZU	DN	Ethanol
DMDRQZU	MI	TT1MPAY
DMDRQZU	MN	GABA(A) receptor alpha-1 (GABRA1)
DMDRQZU	MT	DTT
DMDRQZU	MA	Antagonist
DMDRQZU	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DMDRQZU	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DMDRQZU	DI	DMDRQZU
DMDRQZU	DN	Ethanol
DMDRQZU	MI	DEZMAHX
DMDRQZU	MN	Gastric alcohol dehydrogenase (ADH7)
DMDRQZU	MT	DME
DMDRQZU	MA	Metabolism
DMDRQZU	RN	Functional assessment of human alcohol dehydrogenase family in ethanol metabolism: significance of first-pass metabolism. Alcohol Clin Exp Res. 2006 Jul;30(7):1132-42.
DMDRQZU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16792560

DMDRQZU	DI	DMDRQZU
DMDRQZU	DN	Ethanol
DMDRQZU	MI	DEYGVN4
DMDRQZU	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMDRQZU	MT	DME
DMDRQZU	MA	Metabolism
DMDRQZU	RN	Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
DMDRQZU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24553666

DM3B654	DI	DM3B654
DM3B654	DN	Ethanolamine oleate
DM3B654	MI	DEVDYN7
DM3B654	MN	Cytochrome P450 2E1 (CYP2E1)
DM3B654	MT	DME
DM3B654	MA	Metabolism
DM3B654	RN	CYP2E1--biochemical and toxicological aspects and role in alcohol-induced liver injury. Mt Sinai J Med. 2006 Jul;73(4):657-72.
DM3B654	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16878272

DM53IP1	DI	DM53IP1
DM53IP1	DN	Ethchlorvynol
DM53IP1	MI	DE4LYSA
DM53IP1	MN	Cytochrome P450 3A4 (CYP3A4)
DM53IP1	MT	DME
DM53IP1	MA	Metabolism
DM53IP1	RN	Alkylation of the prosthetic heme in cytochrome P-450 during oxidative metabolism of the sedative-hypnotic ethchlorvynol. J Med Chem. 1982 Oct;25(10):1174-9.
DM53IP1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7143353

DM53IP1	DI	DM53IP1
DM53IP1	DN	Ethchlorvynol
DM53IP1	MI	TT1MPAY
DM53IP1	MN	GABA(A) receptor alpha-1 (GABRA1)
DM53IP1	MT	DTT
DM53IP1	MA	Antagonist
DM53IP1	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DM53IP1	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DM53IP1	DI	DM53IP1
DM53IP1	DN	Ethchlorvynol
DM53IP1	MI	TTZA1NY
DM53IP1	MN	GABA(A) receptor beta-2 (GABRB2)
DM53IP1	MT	DTT
DM53IP1	MA	Antagonist
DM53IP1	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DM53IP1	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DMK57GB	DI	DMK57GB
DMK57GB	DN	Ethinamate
DMK57GB	MI	TTANPDJ
DMK57GB	MN	Carbonic anhydrase II (CA-II)
DMK57GB	MT	DTT
DMK57GB	MA	Inhibitor
DMK57GB	RN	Inhibition of carbonic anhydrases I and II by N-unsubstituted carbamate esters. J Biol Chem. 1992 Dec 15;267(35):25044-50.
DMK57GB	RU	https://pubmed.ncbi.nlm.nih.gov/1460006

DMODJ40	DI	DMODJ40
DMODJ40	DN	Ethinyl estradiol
DMODJ40	MI	DE6OQ3W
DMODJ40	MN	Cytochrome P450 1A1 (CYP1A1)
DMODJ40	MT	DME
DMODJ40	MA	Metabolism
DMODJ40	RN	The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos. 2004 Nov;32(11):1209-12.
DMODJ40	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304426

DMODJ40	DI	DMODJ40
DMODJ40	DN	Ethinyl estradiol
DMODJ40	MI	DES5XRU
DMODJ40	MN	Cytochrome P450 2C8 (CYP2C8)
DMODJ40	MT	DME
DMODJ40	MA	Metabolism
DMODJ40	RN	Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78.
DMODJ40	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15601807

DMODJ40	DI	DMODJ40
DMODJ40	DN	Ethinyl estradiol
DMODJ40	MI	DE5IED8
DMODJ40	MN	Cytochrome P450 2C9 (CYP2C9)
DMODJ40	MT	DME
DMODJ40	MA	Metabolism
DMODJ40	RN	The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos. 2004 Nov;32(11):1209-12.
DMODJ40	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304426

DMODJ40	DI	DMODJ40
DMODJ40	DN	Ethinyl estradiol
DMODJ40	MI	DE4LYSA
DMODJ40	MN	Cytochrome P450 3A4 (CYP3A4)
DMODJ40	MT	DME
DMODJ40	MA	Metabolism
DMODJ40	RN	Rifampicin, a keystone inducer of drug metabolism: from Herbert Remmer's pioneering ideas to modern concepts. Drug Metab Rev. 2004 Oct;36(3-4):497-509.
DMODJ40	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15554232

DMODJ40	DI	DMODJ40
DMODJ40	DN	Ethinyl estradiol
DMODJ40	MI	TTZAYWL
DMODJ40	MN	Estrogen receptor (ESR)
DMODJ40	MT	DTT
DMODJ40	MA	Agonist
DMODJ40	RN	17alpha-Ethinylestradiol hinders nucleotide excision repair in zebrafish liver cells. Aquat Toxicol. 2009 Dec 13;95(4):273-8.
DMODJ40	RU	https://pubmed.ncbi.nlm.nih.gov/19237207

DMODJ40	DI	DMODJ40
DMODJ40	DN	Ethinyl estradiol
DMODJ40	MI	DEGTFWK
DMODJ40	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMODJ40	MT	DME
DMODJ40	MA	Metabolism
DMODJ40	RN	The effect of ethinyloestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects. Br J Clin Pharmacol. 2003 Aug;56(2):232-7.
DMODJ40	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12895199

DMODJ40	DI	DMODJ40
DMODJ40	DN	Ethinyl estradiol
DMODJ40	MI	DTUGYRD
DMODJ40	MN	P-glycoprotein 1 (ABCB1)
DMODJ40	MT	DTP
DMODJ40	MA	Substrate
DMODJ40	RN	P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004 Jul;21(7):1284-93.
DMODJ40	RU	http://www.ncbi.nlm.nih.gov/pubmed/15290871

DMODJ40	DI	DMODJ40
DMODJ40	DN	Ethinyl estradiol
DMODJ40	MI	DEYGVN4
DMODJ40	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMODJ40	MT	DME
DMODJ40	MA	Metabolism
DMODJ40	RN	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
DMODJ40	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429

DM8K3EI	DI	DM8K3EI
DM8K3EI	DN	Ethionamide
DM8K3EI	MI	TTVTX4N
DM8K3EI	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DM8K3EI	MT	DTT
DM8K3EI	MA	Inhibitor
DM8K3EI	RN	Mechanism of thioamide drug action against tuberculosis and leprosy. J Exp Med. 2007 Jan 22;204(1):73-8.
DM8K3EI	RU	https://pubmed.ncbi.nlm.nih.gov/17227913

DM8K3EI	DI	DM8K3EI
DM8K3EI	DN	Ethionamide
DM8K3EI	MI	DEIASEZ
DM8K3EI	MN	Dimethylaniline oxidase 2 (FMO2)
DM8K3EI	MT	DME
DM8K3EI	MA	Metabolism
DM8K3EI	RN	Drug metabolism by flavin-containing monooxygenases of human and mouse. Expert Opin Drug Metab Toxicol. 2017 Feb;13(2):167-181.
DM8K3EI	RU	https://pubmed.ncbi.nlm.nih.gov/27678284

DM8K3EI	DI	DM8K3EI
DM8K3EI	DN	Ethionamide
DM8K3EI	MI	DEP76YL
DM8K3EI	MN	Dimethylaniline oxidase 3 (FMO3)
DM8K3EI	MT	DME
DM8K3EI	MA	Metabolism
DM8K3EI	RN	Physiologically based pharmacokinetic modeling approach to predict drug-drug interactions with ethionamide involving impact of genetic polymorphism on FMO3. J Clin Pharmacol. 2019 Jun;59(6):880-889.
DM8K3EI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30690726

DM0N3L7	DI	DM0N3L7
DM0N3L7	DN	Ethopropazine
DM0N3L7	MI	TTTIBOJ
DM0N3L7	MN	Histamine H1 receptor (H1R)
DM0N3L7	MT	DTT
DM0N3L7	MA	Modulator
DM0N3L7	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM0N3L7	RU	https://www.fda.gov/

DMDZ9LT	DI	DMDZ9LT
DMDZ9LT	DN	Ethosuximide
DMDZ9LT	MI	DEVDYN7
DMDZ9LT	MN	Cytochrome P450 2E1 (CYP2E1)
DMDZ9LT	MT	DME
DMDZ9LT	MA	Metabolism
DMDZ9LT	RN	Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of ethosuximide by human hepatic microsomal enzymes. Xenobiotica. 2003 Mar;33(3):265-76.
DMDZ9LT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12637244

DMDZ9LT	DI	DMDZ9LT
DMDZ9LT	DN	Ethosuximide
DMDZ9LT	MI	DE4LYSA
DMDZ9LT	MN	Cytochrome P450 3A4 (CYP3A4)
DMDZ9LT	MT	DME
DMDZ9LT	MA	Metabolism
DMDZ9LT	RN	Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of ethosuximide by human hepatic microsomal enzymes. Xenobiotica. 2003 Mar;33(3):265-76.
DMDZ9LT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12637244

DMDZ9LT	DI	DMDZ9LT
DMDZ9LT	DN	Ethosuximide
DMDZ9LT	MI	DEO1IE3
DMDZ9LT	MN	Cytochrome P450 3A43 (CYP3A43)
DMDZ9LT	MT	DME
DMDZ9LT	MA	Metabolism
DMDZ9LT	RN	Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of ethosuximide by human hepatic microsomal enzymes. Xenobiotica. 2003 Mar;33(3):265-76.
DMDZ9LT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12637244

DMDZ9LT	DI	DMDZ9LT
DMDZ9LT	DN	Ethosuximide
DMDZ9LT	MI	DEIBDNY
DMDZ9LT	MN	Cytochrome P450 3A5 (CYP3A5)
DMDZ9LT	MT	DME
DMDZ9LT	MA	Metabolism
DMDZ9LT	RN	Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of ethosuximide by human hepatic microsomal enzymes. Xenobiotica. 2003 Mar;33(3):265-76.
DMDZ9LT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12637244

DMDZ9LT	DI	DMDZ9LT
DMDZ9LT	DN	Ethosuximide
DMDZ9LT	MI	DERD86B
DMDZ9LT	MN	Cytochrome P450 3A7 (CYP3A7)
DMDZ9LT	MT	DME
DMDZ9LT	MA	Metabolism
DMDZ9LT	RN	Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of ethosuximide by human hepatic microsomal enzymes. Xenobiotica. 2003 Mar;33(3):265-76.
DMDZ9LT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12637244

DMDZ9LT	DI	DMDZ9LT
DMDZ9LT	DN	Ethosuximide
DMDZ9LT	MI	TT729IR
DMDZ9LT	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DMDZ9LT	MT	DTT
DMDZ9LT	MA	Blocker
DMDZ9LT	RN	Maladaptive homeostatic plasticity in a rodent model of central pain syndrome: thalamic hyperexcitability after spinothalamic tract lesions. J Neurosci. 2008 Nov 12;28(46):11959-69.
DMDZ9LT	RU	https://pubmed.ncbi.nlm.nih.gov/19005061

DMXWOCP	DI	DMXWOCP
DMXWOCP	DN	Ethotoin
DMXWOCP	MI	TTZOVE0
DMXWOCP	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DMXWOCP	MT	DTT
DMXWOCP	MA	Blocker
DMXWOCP	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMXWOCP	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMVO4ED	DI	DMVO4ED
DMVO4ED	DN	Ethoxzolamide
DMVO4ED	MI	TTHQPL7
DMVO4ED	MN	Carbonic anhydrase I (CA-I)
DMVO4ED	MT	DTT
DMVO4ED	MA	Modulator
DMVO4ED	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMVO4ED	RU	https://www.fda.gov/

DMVO4ED	DI	DMVO4ED
DMVO4ED	DN	Ethoxzolamide
DMVO4ED	MI	TTANPDJ
DMVO4ED	MN	Carbonic anhydrase II (CA-II)
DMVO4ED	MT	DTT
DMVO4ED	MA	Inhibitor
DMVO4ED	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMVO4ED	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM20VMW	DI	DM20VMW
DM20VMW	DN	Ethylestrenol
DM20VMW	MI	TTS64P2
DM20VMW	MN	Androgen receptor (AR)
DM20VMW	MT	DTT
DM20VMW	MA	Modulator
DM20VMW	RN	Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscle and in prostate, ... Endocrinology. 1984 Jun;114(6):2100-6.
DM20VMW	RU	https://www.ncbi.nlm.nih.gov/pubmed/6539197

DMZM84R	DI	DMZM84R
DMZM84R	DN	Ethynodiol diacetate
DMZM84R	MI	DE4LYSA
DMZM84R	MN	Cytochrome P450 3A4 (CYP3A4)
DMZM84R	MT	DME
DMZM84R	MA	Metabolism
DMZM84R	RN	News and information in drug research: Ethynodiol diacetate.
DMZM84R	RU	http://genelabs.com/drugsdb/details/ethynodiol-diacetate/

DMZM84R	DI	DMZM84R
DMZM84R	DN	Ethynodiol diacetate
DMZM84R	MI	TTUV8G9
DMZM84R	MN	Progesterone receptor (PGR)
DMZM84R	MT	DTT
DMZM84R	MA	Binder
DMZM84R	RN	Contribution of functional groups of 19-nor-progestogens to binding to progesterone and estradiol-17beta receptors in rabbit uterus. Endocrinology. 1977 Jun;100(6):1579-84.
DMZM84R	RU	https://pubmed.ncbi.nlm.nih.gov/858280

DMBIYNH	DI	DMBIYNH
DMBIYNH	DN	ETI-204
DMBIYNH	MI	TTRLPUB
DMBIYNH	MN	Bacillus anthracis Protective antigen (Anthrax PA)
DMBIYNH	MT	DTT
DMBIYNH	RN	Efficacy of ETI-204 monoclonal antibody as an adjunct therapy in a New Zealand white rabbit partial survival model for inhalational anthrax. Antimicrob Agents Chemother. 2015 Apr;59(4):2206-14.
DMBIYNH	RU	https://pubmed.ncbi.nlm.nih.gov/25645849

DMAWJIN	DI	DMAWJIN
DMAWJIN	DN	Etidronate Disodium
DMAWJIN	MI	TT8X5NO
DMAWJIN	MN	Calcium (Ca)
DMAWJIN	MT	DTT
DMAWJIN	MA	Modulator
DMAWJIN	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMAWJIN	RU	https://www.fda.gov/

DMAWJIN	DI	DMAWJIN
DMAWJIN	DN	Etidronate Disodium
DMAWJIN	MI	TTUDR0C
DMAWJIN	MN	Iron (Fe)
DMAWJIN	MT	DTT
DMAWJIN	MA	Modulator
DMAWJIN	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMAWJIN	RU	https://www.fda.gov/

DM1XHYJ	DI	DM1XHYJ
DM1XHYJ	DN	Etidronic acid
DM1XHYJ	MI	TTCWXFA
DM1XHYJ	MN	Protein-tyrosine phosphatase sigma (R-PTP-sigma)
DM1XHYJ	MT	DTT
DM1XHYJ	MA	Inhibitor
DM1XHYJ	RN	Human protein tyrosine phosphatase-sigma: alternative splicing and inhibition by bisphosphonates. J Bone Miner Res. 1996 Apr;11(4):535-43.
DM1XHYJ	RU	https://pubmed.ncbi.nlm.nih.gov/8992885

DM6WJO9	DI	DM6WJO9
DM6WJO9	DN	Etodolac
DM6WJO9	MI	DE5IED8
DM6WJO9	MN	Cytochrome P450 2C9 (CYP2C9)
DM6WJO9	MT	DME
DM6WJO9	MA	Metabolism
DM6WJO9	RN	Stereoselective glucuronidation and hydroxylation of etodolac by UGT1A9 and CYP2C9 in man. Xenobiotica. 2004 May;34(5):449-61.
DM6WJO9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15370961

DM6WJO9	DI	DM6WJO9
DM6WJO9	DN	Etodolac
DM6WJO9	MI	TTVKILB
DM6WJO9	MN	Prostaglandin G/H synthase 2 (COX-2)
DM6WJO9	MT	DTT
DM6WJO9	MA	Inhibitor
DM6WJO9	RN	Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. Intern Med. 2007;46(13):1055-8.
DM6WJO9	RU	https://pubmed.ncbi.nlm.nih.gov/17603251

DM6WJO9	DI	DM6WJO9
DM6WJO9	DN	Etodolac
DM6WJO9	MI	DEYGVN4
DM6WJO9	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM6WJO9	MT	DME
DM6WJO9	MA	Metabolism
DM6WJO9	RN	Stereoselective glucuronidation and hydroxylation of etodolac by UGT1A9 and CYP2C9 in man. Xenobiotica. 2004 May;34(5):449-61.
DM6WJO9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15370961

DM6WJO9	DI	DM6WJO9
DM6WJO9	DN	Etodolac
DM6WJO9	MI	DEL5N6Y
DM6WJO9	MN	UDP-glucuronosyltransferase 1A10 (UGT1A10)
DM6WJO9	MT	DME
DM6WJO9	MA	Metabolism
DM6WJO9	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM6WJO9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM6WJO9	DI	DM6WJO9
DM6WJO9	DN	Etodolac
DM6WJO9	MI	DEF2WXN
DM6WJO9	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DM6WJO9	MT	DME
DM6WJO9	MA	Metabolism
DM6WJO9	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM6WJO9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM6WJO9	DI	DM6WJO9
DM6WJO9	DN	Etodolac
DM6WJO9	MI	DE85D2P
DM6WJO9	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DM6WJO9	MT	DME
DM6WJO9	MA	Metabolism
DM6WJO9	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM6WJO9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM6WJO9	DI	DM6WJO9
DM6WJO9	DN	Etodolac
DM6WJO9	MI	DEB3CV1
DM6WJO9	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DM6WJO9	MT	DME
DM6WJO9	MA	Metabolism
DM6WJO9	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM6WJO9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMZI3WO	DI	DMZI3WO
DMZI3WO	DN	Etomidate
DMZI3WO	MI	TTEX6LM
DMZI3WO	MN	GABA(A) receptor gamma-3 (GABRG3)
DMZI3WO	MT	DTT
DMZI3WO	MA	Modulator
DMZI3WO	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMZI3WO	RU	https://www.fda.gov/

DMKA8J4	DI	DMKA8J4
DMKA8J4	DN	Etonogestrel
DMKA8J4	MI	DE4LYSA
DMKA8J4	MN	Cytochrome P450 3A4 (CYP3A4)
DMKA8J4	MT	DME
DMKA8J4	MA	Metabolism
DMKA8J4	RN	The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel. Br J Clin Pharmacol. 2005 Jul;60(1):69-75.
DMKA8J4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15963096

DMKA8J4	DI	DMKA8J4
DMKA8J4	DN	Etonogestrel
DMKA8J4	MI	TTUV8G9
DMKA8J4	MN	Progesterone receptor (PGR)
DMKA8J4	MT	DTT
DMKA8J4	MA	Binder
DMKA8J4	RN	Pharmacological profile of progestins. Maturitas. 2008 Sep-Oct;61(1-2):151-7.
DMKA8J4	RU	https://pubmed.ncbi.nlm.nih.gov/19434887

DMNH3PG	DI	DMNH3PG
DMNH3PG	DN	Etoposide
DMNH3PG	MI	DTI7UX6
DMNH3PG	MN	Breast cancer resistance protein (ABCG2)
DMNH3PG	MT	DTP
DMNH3PG	MA	Substrate
DMNH3PG	RN	Characterization of 3-methoxy flavones for their interaction with ABCG2 as suggested by ATPase activity. Biochim Biophys Acta. 2014 Nov;1838(11):2929-38.
DMNH3PG	RU	http://www.ncbi.nlm.nih.gov/pubmed/25128152

DMNH3PG	DI	DMNH3PG
DMNH3PG	DN	Etoposide
DMNH3PG	MI	DEJGDUW
DMNH3PG	MN	Cytochrome P450 1A2 (CYP1A2)
DMNH3PG	MT	DME
DMNH3PG	MA	Metabolism
DMNH3PG	RN	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
DMNH3PG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17315145

DMNH3PG	DI	DMNH3PG
DMNH3PG	DN	Etoposide
DMNH3PG	MI	DEVDYN7
DMNH3PG	MN	Cytochrome P450 2E1 (CYP2E1)
DMNH3PG	MT	DME
DMNH3PG	MA	Metabolism
DMNH3PG	RN	A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
DMNH3PG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9732391

DMNH3PG	DI	DMNH3PG
DMNH3PG	DN	Etoposide
DMNH3PG	MI	DE4LYSA
DMNH3PG	MN	Cytochrome P450 3A4 (CYP3A4)
DMNH3PG	MT	DME
DMNH3PG	MA	Metabolism
DMNH3PG	RN	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
DMNH3PG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17315145

DMNH3PG	DI	DMNH3PG
DMNH3PG	DN	Etoposide
DMNH3PG	MI	DEIBDNY
DMNH3PG	MN	Cytochrome P450 3A5 (CYP3A5)
DMNH3PG	MT	DME
DMNH3PG	MA	Metabolism
DMNH3PG	RN	Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
DMNH3PG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15319341

DMNH3PG	DI	DMNH3PG
DMNH3PG	DN	Etoposide
DMNH3PG	MI	TT0IHXV
DMNH3PG	MN	DNA topoisomerase II (TOP2)
DMNH3PG	MT	DTT
DMNH3PG	MA	Modulator
DMNH3PG	RN	Etoposide, topoisomerase II and cancer.Curr Med Chem Anticancer Agents.2005 Jul;5(4):363-72.
DMNH3PG	RU	https://www.ncbi.nlm.nih.gov/pubmed/16101488

DMNH3PG	DI	DMNH3PG
DMNH3PG	DN	Etoposide
DMNH3PG	MI	DEK6079
DMNH3PG	MN	Glutathione S-transferase pi (GSTP1)
DMNH3PG	MT	DME
DMNH3PG	MA	Metabolism
DMNH3PG	RN	Reactions of glutathione with the catechol, the ortho-quinone and the semi-quinone free radical of etoposide. Consequences for DNA inactivation. Biochem Pharmacol. 1992 Apr 15;43(8):1761-8.
DMNH3PG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1315544

DMNH3PG	DI	DMNH3PG
DMNH3PG	DN	Etoposide
DMNH3PG	MI	DE3PKUG
DMNH3PG	MN	Glutathione S-transferase theta-1 (GSTT1)
DMNH3PG	MT	DME
DMNH3PG	MA	Metabolism
DMNH3PG	RN	Reactions of glutathione with the catechol, the ortho-quinone and the semi-quinone free radical of etoposide. Consequences for DNA inactivation. Biochem Pharmacol. 1992 Apr 15;43(8):1761-8.
DMNH3PG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1315544

DMNH3PG	DI	DMNH3PG
DMNH3PG	DN	Etoposide
DMNH3PG	MI	DTSYQGK
DMNH3PG	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMNH3PG	MT	DTP
DMNH3PG	MA	Substrate
DMNH3PG	RN	Multidrug resistance-associated protein-1 functional activity in Calu-3 cells. J Pharmacol Exp Ther. 2001 Sep;298(3):1199-205.
DMNH3PG	RU	http://www.ncbi.nlm.nih.gov/pubmed/11504821

DMNH3PG	DI	DMNH3PG
DMNH3PG	DN	Etoposide
DMNH3PG	MI	DTFI42L
DMNH3PG	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMNH3PG	MT	DTP
DMNH3PG	MA	Substrate
DMNH3PG	RN	Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
DMNH3PG	RU	http://www.ncbi.nlm.nih.gov/pubmed/11901101

DMNH3PG	DI	DMNH3PG
DMNH3PG	DN	Etoposide
DMNH3PG	MI	DTQ3ZHF
DMNH3PG	MN	Multidrug resistance-associated protein 3 (ABCC3)
DMNH3PG	MT	DTP
DMNH3PG	MA	Substrate
DMNH3PG	RN	Functional reconstitution of human ABCC3 into proteoliposomes reveals a transport mechanism with positive cooperativity. Biochemistry. 2009 May 26;48(20):4423-30.
DMNH3PG	RU	http://www.ncbi.nlm.nih.gov/pubmed/19334674

DMNH3PG	DI	DMNH3PG
DMNH3PG	DN	Etoposide
DMNH3PG	MI	DT3D8F0
DMNH3PG	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMNH3PG	MT	DTP
DMNH3PG	MA	Substrate
DMNH3PG	RN	Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
DMNH3PG	RU	https://doi.org/10.1111/j.1476-5381.2011.01672.x

DMNH3PG	DI	DMNH3PG
DMNH3PG	DN	Etoposide
DMNH3PG	MI	DT9C1TS
DMNH3PG	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMNH3PG	MT	DTP
DMNH3PG	MA	Substrate
DMNH3PG	RN	Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65.
DMNH3PG	RU	http://www.ncbi.nlm.nih.gov/pubmed/18321482

DMNH3PG	DI	DMNH3PG
DMNH3PG	DN	Etoposide
DMNH3PG	MI	DTPFTEQ
DMNH3PG	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DMNH3PG	MT	DTP
DMNH3PG	MA	Substrate
DMNH3PG	RN	Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
DMNH3PG	RU	https://doi.org/10.1111/j.1476-5381.2011.01672.x

DMNH3PG	DI	DMNH3PG
DMNH3PG	DN	Etoposide
DMNH3PG	MI	DTUGYRD
DMNH3PG	MN	P-glycoprotein 1 (ABCB1)
DMNH3PG	MT	DTP
DMNH3PG	MA	Substrate
DMNH3PG	RN	Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm Res. 2003 Aug;20(8):1200-9.
DMNH3PG	RU	http://www.ncbi.nlm.nih.gov/pubmed/12948018

DMNH3PG	DI	DMNH3PG
DMNH3PG	DN	Etoposide
DMNH3PG	MI	DE073H6
DMNH3PG	MN	Prostaglandin G/H synthase 1 (COX-1)
DMNH3PG	MT	DME
DMNH3PG	MA	Metabolism
DMNH3PG	RN	Peroxidative free radical formation and O-demethylation of etoposide(VP-16) and teniposide(VM-26). Biochem Biophys Res Commun. 1986 Feb 26;135(1):215-20.
DMNH3PG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=3006680

DMNH3PG	DI	DMNH3PG
DMNH3PG	DN	Etoposide
DMNH3PG	MI	DE492CE
DMNH3PG	MN	Prostaglandin G/H synthase 2 (COX-2)
DMNH3PG	MT	DME
DMNH3PG	MA	Metabolism
DMNH3PG	RN	Peroxidative free radical formation and O-demethylation of etoposide(VP-16) and teniposide(VM-26). Biochem Biophys Res Commun. 1986 Feb 26;135(1):215-20.
DMNH3PG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=3006680

DMNH3PG	DI	DMNH3PG
DMNH3PG	DN	Etoposide
DMNH3PG	MI	DEYGVN4
DMNH3PG	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMNH3PG	MT	DME
DMNH3PG	MA	Metabolism
DMNH3PG	RN	UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
DMNH3PG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17151191

DM6A4NW	DI	DM6A4NW
DM6A4NW	DN	Etoricoxib
DM6A4NW	MI	DEJGDUW
DM6A4NW	MN	Cytochrome P450 1A2 (CYP1A2)
DM6A4NW	MT	DME
DM6A4NW	MA	Metabolism
DM6A4NW	RN	Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor. Drug Metab Dispos. 2001 Jun;29(6):813-20.
DM6A4NW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11353749

DM6A4NW	DI	DM6A4NW
DM6A4NW	DN	Etoricoxib
DM6A4NW	MI	DE5IED8
DM6A4NW	MN	Cytochrome P450 2C9 (CYP2C9)
DM6A4NW	MT	DME
DM6A4NW	MA	Metabolism
DM6A4NW	RN	Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor. Drug Metab Dispos. 2001 Jun;29(6):813-20.
DM6A4NW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11353749

DM6A4NW	DI	DM6A4NW
DM6A4NW	DN	Etoricoxib
DM6A4NW	MI	DE4LYSA
DM6A4NW	MN	Cytochrome P450 3A4 (CYP3A4)
DM6A4NW	MT	DME
DM6A4NW	MA	Metabolism
DM6A4NW	RN	Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor. Drug Metab Dispos. 2001 Jun;29(6):813-20.
DM6A4NW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11353749

DM6A4NW	DI	DM6A4NW
DM6A4NW	DN	Etoricoxib
DM6A4NW	MI	TTVKILB
DM6A4NW	MN	Prostaglandin G/H synthase 2 (COX-2)
DM6A4NW	MT	DTT
DM6A4NW	MA	Inhibitor
DM6A4NW	RN	The effect of newer anti-rheumatic drugs on osteogenic cell proliferation: an in-vitro study. J Orthop Surg Res. 2009 May 26;4:17.
DM6A4NW	RU	https://pubmed.ncbi.nlm.nih.gov/19470170

DMGV8QU	DI	DMGV8QU
DMGV8QU	DN	Etravirine
DMGV8QU	MI	DE5IED8
DMGV8QU	MN	Cytochrome P450 2C9 (CYP2C9)
DMGV8QU	MT	DME
DMGV8QU	MA	Metabolism
DMGV8QU	RN	Pharmacokinetic interactions between etravirine and non-antiretroviral drugs. Clin Pharmacokinet. 2011 Jan;50(1):25-39.
DMGV8QU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21142266

DMGV8QU	DI	DMGV8QU
DMGV8QU	DN	Etravirine
DMGV8QU	MI	DE4LYSA
DMGV8QU	MN	Cytochrome P450 3A4 (CYP3A4)
DMGV8QU	MT	DME
DMGV8QU	MA	Metabolism
DMGV8QU	RN	Pharmacokinetic interactions between etravirine and non-antiretroviral drugs. Clin Pharmacokinet. 2011 Jan;50(1):25-39.
DMGV8QU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21142266

DMGV8QU	DI	DMGV8QU
DMGV8QU	DN	Etravirine
DMGV8QU	MI	TT84ETX
DMGV8QU	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMGV8QU	MT	DTT
DMGV8QU	MA	Modulator
DMGV8QU	RN	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
DMGV8QU	RU	https://pubmed.ncbi.nlm.nih.gov/19180096

DMGV8QU	DI	DMGV8QU
DMGV8QU	DN	Etravirine
DMGV8QU	MI	DEGTFWK
DMGV8QU	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMGV8QU	MT	DME
DMGV8QU	MA	Metabolism
DMGV8QU	RN	Biotransformation of the antiretroviral drug etravirine: metabolite identification, reaction phenotyping, and characterization of autoinduction of cytochrome P450-dependent metabolism. Drug Metab Dispos. 2012 Apr;40(4):803-14.
DMGV8QU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22269145

DMGV8QU	DI	DMGV8QU
DMGV8QU	DN	Etravirine
DMGV8QU	MI	DTQ3ZHF
DMGV8QU	MN	Multidrug resistance-associated protein 3 (ABCC3)
DMGV8QU	MT	DTP
DMGV8QU	MA	Substrate
DMGV8QU	RN	Interaction potential of etravirine with drug transporters assessed in vitro. Antimicrob Agents Chemother. 2011 Mar;55(3):1282-4.
DMGV8QU	RU	http://www.ncbi.nlm.nih.gov/pubmed/21189339

DM2CZFA	DI	DM2CZFA
DM2CZFA	DN	Etretinate
DM2CZFA	MI	DEZT8FM
DM2CZFA	MN	Retinoic acid 4-hydroxylase 26B1 (CYP26B1)
DM2CZFA	MT	DME
DM2CZFA	MA	Metabolism
DM2CZFA	RN	Lipopolysaccharide opposes the induction of CYP26A1 and CYP26B1 gene expression by retinoic acid in the rat liver in vivo. Am J Physiol Gastrointest Liver Physiol. 2007 Apr;292(4):G1029-36.
DM2CZFA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17185629

DM5GT1M	DI	DM5GT1M
DM5GT1M	DN	EVANS BLUE
DM5GT1M	MI	TTFNGC9
DM5GT1M	MN	Serum albumin (ALB)
DM5GT1M	MT	DTT
DM5GT1M	MA	Modulator
DM5GT1M	RN	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
DM5GT1M	RU	https://www.ncbi.nlm.nih.gov/pubmed/27899562

DM8X2EH	DI	DM8X2EH
DM8X2EH	DN	Everolimus
DM8X2EH	MI	DE4LYSA
DM8X2EH	MN	Cytochrome P450 3A4 (CYP3A4)
DM8X2EH	MT	DME
DM8X2EH	MA	Metabolism
DM8X2EH	RN	The evolving experience using everolimus in clinical transplantation. Transplant Proc. 2004 Mar;36(2 Suppl):495S-499S.
DM8X2EH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15041395

DM8X2EH	DI	DM8X2EH
DM8X2EH	DN	Everolimus
DM8X2EH	MI	DTUGYRD
DM8X2EH	MN	P-glycoprotein 1 (ABCB1)
DM8X2EH	MT	DTP
DM8X2EH	MA	Substrate
DM8X2EH	RN	Closer to the Site of Action: Everolimus Concentrations in Peripheral Blood Mononuclear Cells Correlate Well With Whole Blood Concentrations. Ther Drug Monit. 2015 Oct;37(5):675-80.
DM8X2EH	RU	http://www.ncbi.nlm.nih.gov/pubmed/25565673

DM8X2EH	DI	DM8X2EH
DM8X2EH	DN	Everolimus
DM8X2EH	MI	TTCJG29
DM8X2EH	MN	Serine/threonine-protein kinase mTOR (mTOR)
DM8X2EH	MT	DTT
DM8X2EH	MA	Inhibitor
DM8X2EH	RN	Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma. Gan To Kagaku Ryoho. 2009 Jul;36(7):1076-9.
DM8X2EH	RU	https://pubmed.ncbi.nlm.nih.gov/19620795

DMBLX7U	DI	DMBLX7U
DMBLX7U	DN	Evinacumab
DMBLX7U	MI	TTUO98L
DMBLX7U	MN	Angiopoietin-related protein 3 (ANGPTL3)
DMBLX7U	MT	DTT
DMBLX7U	MA	Inhibitor
DMBLX7U	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2021
DMBLX7U	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761181s000lbl.pdf

DM9HPW3	DI	DM9HPW3
DM9HPW3	DN	Exemestane
DM9HPW3	MI	TTSZLWK
DM9HPW3	MN	Aromatase (CYP19A1)
DM9HPW3	MT	DTT
DM9HPW3	MA	Inhibitor
DM9HPW3	RN	Aromatase inhibitors--theoretical concept and present experiences in the treatment of endometriosis. Zentralbl Gynakol. 2003 Jul-Aug;125(7-8):247-51.
DM9HPW3	RU	https://pubmed.ncbi.nlm.nih.gov/14505258

DM9HPW3	DI	DM9HPW3
DM9HPW3	DN	Exemestane
DM9HPW3	MI	DE4LYSA
DM9HPW3	MN	Cytochrome P450 3A4 (CYP3A4)
DM9HPW3	MT	DME
DM9HPW3	MA	Metabolism
DM9HPW3	RN	In vitro metabolism of exemestane by hepatic cytochrome P450s: impact of nonsynonymous polymorphisms on formation of the active metabolite 17beta-dihydroexemestane. Pharmacol Res Perspect. 2017 Apr 27;5(3):e00314.
DM9HPW3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28603633

DMYHBKN	DI	DMYHBKN
DMYHBKN	DN	Exenatide
DMYHBKN	MI	DEKZQY6
DMYHBKN	MN	Dipeptidyl peptidase IV (DPP4)
DMYHBKN	MT	DME
DMYHBKN	MA	Metabolism
DMYHBKN	RN	In vitro metabolic stability of exendin-4: pharmacokinetics and identification of cleavage products. PLoS One. 2015 Feb 27;10(2):e0116805.
DMYHBKN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25723538

DMYHBKN	DI	DMYHBKN
DMYHBKN	DN	Exenatide
DMYHBKN	MI	TTVIMDE
DMYHBKN	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMYHBKN	MT	DTT
DMYHBKN	MA	Binder
DMYHBKN	RN	Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting. Diabetes TechnolTher. 2009 Jun;11(6):353-9.
DMYHBKN	RU	https://pubmed.ncbi.nlm.nih.gov/19459763

DMHPRWG	DI	DMHPRWG
DMHPRWG	DN	Exjade
DMHPRWG	MI	TTUDR0C
DMHPRWG	MN	Iron (Fe)
DMHPRWG	MT	DTT
DMHPRWG	MA	Modulator
DMHPRWG	RN	Deferasirox : a review of its use in the management of transfusional chronic iron overload. Drugs. 2007;67(15):2211-30.
DMHPRWG	RU	https://pubmed.ncbi.nlm.nih.gov/17927285

DM7A8TW	DI	DM7A8TW
DM7A8TW	DN	Ezetimibe
DM7A8TW	MI	DTJ0EW4
DM7A8TW	MN	Bile salt export pump (ABCB11)
DM7A8TW	MT	DTP
DM7A8TW	MA	Substrate
DM7A8TW	RN	Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
DM7A8TW	RU	http://www.ncbi.nlm.nih.gov/pubmed/24014644

DM7A8TW	DI	DM7A8TW
DM7A8TW	DN	Ezetimibe
DM7A8TW	MI	DTI7UX6
DM7A8TW	MN	Breast cancer resistance protein (ABCG2)
DM7A8TW	MT	DTP
DM7A8TW	MA	Substrate
DM7A8TW	RN	Complex pharmacokinetic behavior of ezetimibe depends on abcc2, abcc3, and abcg2. Drug Metab Dispos. 2009 Aug;37(8):1698-702.
DM7A8TW	RU	http://www.ncbi.nlm.nih.gov/pubmed/19443695

DM7A8TW	DI	DM7A8TW
DM7A8TW	DN	Ezetimibe
DM7A8TW	MI	DE4LYSA
DM7A8TW	MN	Cytochrome P450 3A4 (CYP3A4)
DM7A8TW	MT	DME
DM7A8TW	MA	Metabolism
DM7A8TW	RN	Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
DM7A8TW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15871634

DM7A8TW	DI	DM7A8TW
DM7A8TW	DN	Ezetimibe
DM7A8TW	MI	DTFI42L
DM7A8TW	MN	Multidrug resistance-associated protein 2 (ABCC2)
DM7A8TW	MT	DTP
DM7A8TW	MA	Substrate
DM7A8TW	RN	Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. Clin Pharmacol Ther. 2006 Mar;79(3):206-17.
DM7A8TW	RU	http://www.ncbi.nlm.nih.gov/pubmed/16513445

DM7A8TW	DI	DM7A8TW
DM7A8TW	DN	Ezetimibe
DM7A8TW	MI	DTQ3ZHF
DM7A8TW	MN	Multidrug resistance-associated protein 3 (ABCC3)
DM7A8TW	MT	DTP
DM7A8TW	MA	Substrate
DM7A8TW	RN	Complex pharmacokinetic behavior of ezetimibe depends on abcc2, abcc3, and abcg2. Drug Metab Dispos. 2009 Aug;37(8):1698-702.
DM7A8TW	RU	http://www.ncbi.nlm.nih.gov/pubmed/19443695

DM7A8TW	DI	DM7A8TW
DM7A8TW	DN	Ezetimibe
DM7A8TW	MI	TTPD1CN
DM7A8TW	MN	Niemann-Pick C1-like protein 1 (NPC1L1)
DM7A8TW	MT	DTT
DM7A8TW	MA	Inhibitor
DM7A8TW	RN	Update on patented cholesterol absorption inhibitors. Expert Opin Ther Pat. 2009 Aug;19(8):1083-107.
DM7A8TW	RU	https://pubmed.ncbi.nlm.nih.gov/19552506

DM7A8TW	DI	DM7A8TW
DM7A8TW	DN	Ezetimibe
DM7A8TW	MI	DT3D8F0
DM7A8TW	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM7A8TW	MT	DTP
DM7A8TW	MA	Substrate
DM7A8TW	RN	A LC-MS/MS method to quantify the novel cholesterol lowering drug ezetimibe in human serum, urine and feces in healthy subjects genotyped for SLCO1B1. J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Jan 2;830(1):143-50.
DM7A8TW	RU	http://www.ncbi.nlm.nih.gov/pubmed/16280261

DM7A8TW	DI	DM7A8TW
DM7A8TW	DN	Ezetimibe
DM7A8TW	MI	DTUGYRD
DM7A8TW	MN	P-glycoprotein 1 (ABCB1)
DM7A8TW	MT	DTP
DM7A8TW	MA	Substrate
DM7A8TW	RN	Pharmacokinetic and pharmacodynamic interactions between the immunosuppressant sirolimus and the lipid-lowering drug ezetimibe in healthy volunteers. Clin Pharmacol Ther. 2010 Jun;87(6):663-7.
DM7A8TW	RU	http://www.ncbi.nlm.nih.gov/pubmed/20220747

DM7A8TW	DI	DM7A8TW
DM7A8TW	DN	Ezetimibe
DM7A8TW	MI	DEYGVN4
DM7A8TW	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM7A8TW	MT	DME
DM7A8TW	MA	Metabolism
DM7A8TW	RN	Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
DM7A8TW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15871634

DM7A8TW	DI	DM7A8TW
DM7A8TW	DN	Ezetimibe
DM7A8TW	MI	DEF2WXN
DM7A8TW	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DM7A8TW	MT	DME
DM7A8TW	MA	Metabolism
DM7A8TW	RN	Drug interactions between the immunosuppressant tacrolimus and the cholesterol absorption inhibitor ezetimibe in healthy volunteers. Clin Pharmacol Ther. 2011 Apr;89(4):524-8.
DM7A8TW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21368751

DM7A8TW	DI	DM7A8TW
DM7A8TW	DN	Ezetimibe
DM7A8TW	MI	DENZ6B1
DM7A8TW	MN	UDP-glucuronosyltransferase 2B15 (UGT2B15)
DM7A8TW	MT	DME
DM7A8TW	MA	Metabolism
DM7A8TW	RN	Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
DM7A8TW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15871634

DM7A8TW	DI	DM7A8TW
DM7A8TW	DN	Ezetimibe
DM7A8TW	MI	DEB3CV1
DM7A8TW	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DM7A8TW	MT	DME
DM7A8TW	MA	Metabolism
DM7A8TW	RN	Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
DM7A8TW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15871634

DMAB6PM	DI	DMAB6PM
DMAB6PM	DN	Factor 8
DMAB6PM	MI	TT1290U
DMAB6PM	MN	Coagulation factor VIII (F8)
DMAB6PM	MT	DTT
DMAB6PM	MA	Modulator
DMAB6PM	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2607).
DMAB6PM	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2607

DMZUW6P	DI	DMZUW6P
DMZUW6P	DN	Factor viia
DMZUW6P	MI	TTF0EGX
DMZUW6P	MN	Coagulation factor VII (F7)
DMZUW6P	MT	DTT
DMZUW6P	MA	Modulator
DMZUW6P	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2363).
DMZUW6P	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2363

DM3C5GZ	DI	DM3C5GZ
DM3C5GZ	DN	FADROZOLE
DM3C5GZ	MI	TTSZLWK
DM3C5GZ	MN	Aromatase (CYP19A1)
DM3C5GZ	MT	DTT
DM3C5GZ	MA	Inhibitor
DM3C5GZ	RN	Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach. J Med Chem. 2005 Nov 17;48(23):7282-9.
DM3C5GZ	RU	https://pubmed.ncbi.nlm.nih.gov/16279787

DM3C5GZ	DI	DM3C5GZ
DM3C5GZ	DN	FADROZOLE
DM3C5GZ	MI	TTIQUX7
DM3C5GZ	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM3C5GZ	MT	DTT
DM3C5GZ	MA	Inhibitor
DM3C5GZ	RN	Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25.
DM3C5GZ	RU	https://pubmed.ncbi.nlm.nih.gov/20121113

DMBI9ZJ	DI	DMBI9ZJ
DMBI9ZJ	DN	Falecalcitrol
DMBI9ZJ	MI	TTK59TV
DMBI9ZJ	MN	Vitamin D3 receptor (VDR)
DMBI9ZJ	MT	DTT
DMBI9ZJ	MA	Agonist
DMBI9ZJ	RN	Synthesis and biological evaluations of A-ring isomers of 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3. Bioorg Med Chem. 2000 Aug;8(8):2157-66.
DMBI9ZJ	RU	https://pubmed.ncbi.nlm.nih.gov/11003160

DMJHLSD	DI	DMJHLSD
DMJHLSD	DN	Famciclovir
DMJHLSD	MI	DE4LYSA
DMJHLSD	MN	Cytochrome P450 3A4 (CYP3A4)
DMJHLSD	MT	DME
DMJHLSD	MA	Metabolism
DMJHLSD	RN	Evidence that famciclovir (BRL 42810) and its associated metabolites do not inhibit the 6 beta-hydroxylation of testosterone in human liver microsomes. Drug Metab Dispos. 1993 Jan-Feb;21(1):18-23.
DMJHLSD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8095215

DMJHLSD	DI	DMJHLSD
DMJHLSD	DN	Famciclovir
DMJHLSD	MI	TTIU7X1
DMJHLSD	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMJHLSD	MT	DTT
DMJHLSD	MA	Inhibitor
DMJHLSD	RN	Penciclovir cream--improved topical treatment for herpes simplex infections. Skin Pharmacol Physiol. 2004 Sep-Oct;17(5):214-8.
DMJHLSD	RU	https://pubmed.ncbi.nlm.nih.gov/15452407

DMJHLSD	DI	DMJHLSD
DMJHLSD	DN	Famciclovir
DMJHLSD	MI	DTUGYRD
DMJHLSD	MN	P-glycoprotein 1 (ABCB1)
DMJHLSD	MT	DTP
DMJHLSD	MA	Substrate
DMJHLSD	RN	Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.
DMJHLSD	RU	http://www.ncbi.nlm.nih.gov/pubmed/12438524

DMRL3AB	DI	DMRL3AB
DMRL3AB	DN	Famotidine
DMRL3AB	MI	TTQHJ1K
DMRL3AB	MN	Histamine H2 receptor (H2R)
DMRL3AB	MT	DTT
DMRL3AB	MA	Antagonist
DMRL3AB	RN	Histamine H1 and H2 receptor antagonists accelerate skin barrier repair and prevent epidermal hyperplasia induced by barrier disruption in a dry environment. J Invest Dermatol. 2001 Feb;116(2):261-5.
DMRL3AB	RU	https://pubmed.ncbi.nlm.nih.gov/11180002

DMRL3AB	DI	DMRL3AB
DMRL3AB	DN	Famotidine
DMRL3AB	MI	DEGTFWK
DMRL3AB	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMRL3AB	MT	DME
DMRL3AB	MA	Metabolism
DMRL3AB	RN	Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther. 2006 Nov;80(5):539-48.
DMRL3AB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17112810

DMRL3AB	DI	DMRL3AB
DMRL3AB	DN	Famotidine
DMRL3AB	MI	DTQ23VB
DMRL3AB	MN	Organic anion transporter 1 (SLC22A6)
DMRL3AB	MT	DTP
DMRL3AB	MA	Substrate
DMRL3AB	RN	Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). Eur J Pharmacol. 2004 Oct 25;503(1-3):25-30.
DMRL3AB	RU	http://www.ncbi.nlm.nih.gov/pubmed/15496291

DMRL3AB	DI	DMRL3AB
DMRL3AB	DN	Famotidine
DMRL3AB	MI	DTVP67E
DMRL3AB	MN	Organic anion transporter 3 (SLC22A8)
DMRL3AB	MT	DTP
DMRL3AB	MA	Substrate
DMRL3AB	RN	A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
DMRL3AB	RU	http://www.ncbi.nlm.nih.gov/pubmed/16006492

DMRL3AB	DI	DMRL3AB
DMRL3AB	DN	Famotidine
DMRL3AB	MI	DT9IDPW
DMRL3AB	MN	Organic cation transporter 2 (SLC22A2)
DMRL3AB	MT	DTP
DMRL3AB	MA	Substrate
DMRL3AB	RN	A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
DMRL3AB	RU	http://www.ncbi.nlm.nih.gov/pubmed/16006492

DMX7A5V	DI	DMX7A5V
DMX7A5V	DN	Faropenem
DMX7A5V	MI	TT4ILYC
DMX7A5V	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMX7A5V	MT	DTT
DMX7A5V	MA	Inhibitor
DMX7A5V	RN	Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
DMX7A5V	RU	https://pubmed.ncbi.nlm.nih.gov/15934867

DMDEXQ0	DI	DMDEXQ0
DMDEXQ0	DN	Febuxostat
DMDEXQ0	MI	DEYGVN4
DMDEXQ0	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMDEXQ0	MT	DME
DMDEXQ0	MA	Metabolism
DMDEXQ0	RN	In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition. Xenobiotica. 2008 May;38(5):496-510.
DMDEXQ0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18421623

DMDEXQ0	DI	DMDEXQ0
DMDEXQ0	DN	Febuxostat
DMDEXQ0	MI	TT7RJY8
DMDEXQ0	MN	Xanthine dehydrogenase/oxidase (XDH)
DMDEXQ0	MT	DTT
DMDEXQ0	MA	Inhibitor
DMDEXQ0	RN	Clinical pipeline report, company report or official report of Takeda (2009).
DMDEXQ0	RU	http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf

DM4ZBK6	DI	DM4ZBK6
DM4ZBK6	DN	Fedratinib
DM4ZBK6	MI	TTRMX3V
DM4ZBK6	MN	Janus kinase 2 (JAK-2)
DM4ZBK6	MT	DTT
DM4ZBK6	MA	Inhibitor
DM4ZBK6	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DM4ZBK6	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf

DML2DCR	DI	DML2DCR
DML2DCR	DN	Fedratinib hydrochloride
DML2DCR	MI	DE4LYSA
DML2DCR	MN	Cytochrome P450 3A4 (CYP3A4)
DML2DCR	MT	DME
DML2DCR	MA	Metabolism
DML2DCR	RN	FDA label of Fedratinib. The 2020 official website of the U.S. Food and Drug Administration.
DML2DCR	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf

DML2DCR	DI	DML2DCR
DML2DCR	DN	Fedratinib hydrochloride
DML2DCR	MI	DEP76YL
DML2DCR	MN	Dimethylaniline oxidase 3 (FMO3)
DML2DCR	MT	DME
DML2DCR	MA	Metabolism
DML2DCR	RN	FDA label of Fedratinib. The 2020 official website of the U.S. Food and Drug Administration.
DML2DCR	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf

DML2DCR	DI	DML2DCR
DML2DCR	DN	Fedratinib hydrochloride
DML2DCR	MI	DEGTFWK
DML2DCR	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DML2DCR	MT	DME
DML2DCR	MA	Metabolism
DML2DCR	RN	FDA label of Fedratinib. The 2020 official website of the U.S. Food and Drug Administration.
DML2DCR	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf

DM1V5ZS	DI	DM1V5ZS
DM1V5ZS	DN	Felbamate
DM1V5ZS	MI	DEVDYN7
DM1V5ZS	MN	Cytochrome P450 2E1 (CYP2E1)
DM1V5ZS	MT	DME
DM1V5ZS	MA	Metabolism
DM1V5ZS	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM1V5ZS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM1V5ZS	DI	DM1V5ZS
DM1V5ZS	DN	Felbamate
DM1V5ZS	MI	DE4LYSA
DM1V5ZS	MN	Cytochrome P450 3A4 (CYP3A4)
DM1V5ZS	MT	DME
DM1V5ZS	MA	Metabolism
DM1V5ZS	RN	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
DM1V5ZS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9606477

DM1V5ZS	DI	DM1V5ZS
DM1V5ZS	DN	Felbamate
DM1V5ZS	MI	TT9IK2Z
DM1V5ZS	MN	N-methyl-D-aspartate receptor (NMDAR)
DM1V5ZS	MT	DTT
DM1V5ZS	MA	Antagonist
DM1V5ZS	RN	Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor. J Med Chem. 2008 Mar 27;51(6):1534-45.
DM1V5ZS	RU	https://pubmed.ncbi.nlm.nih.gov/18311896

DMKZEIB	DI	DMKZEIB
DMKZEIB	DN	Felbinac
DMKZEIB	MI	TTK0943
DMKZEIB	MN	Prostaglandin G/H synthase (COX)
DMKZEIB	MT	DTT
DMKZEIB	MA	Modulator
DMKZEIB	RN	A review of the effects of fenbufen and a metabolite, biphenylacetic acid, on platelet biochemistry and function. Arzneimittelforschung. 1980;30(4A):702-7.
DMKZEIB	RU	https://pubmed.ncbi.nlm.nih.gov/6254545

DMOSW35	DI	DMOSW35
DMOSW35	DN	Felodipine
DMOSW35	MI	TT5HONZ
DMOSW35	MN	Calcium channel unspecific (CaC)
DMOSW35	MT	DTT
DMOSW35	MA	Blocker
DMOSW35	RN	Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7.
DMOSW35	RU	https://pubmed.ncbi.nlm.nih.gov/18974361

DMOSW35	DI	DMOSW35
DMOSW35	DN	Felodipine
DMOSW35	MI	DE4LYSA
DMOSW35	MN	Cytochrome P450 3A4 (CYP3A4)
DMOSW35	MT	DME
DMOSW35	MA	Metabolism
DMOSW35	RN	Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
DMOSW35	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10640508

DMOSW35	DI	DMOSW35
DMOSW35	DN	Felodipine
DMOSW35	MI	DEIBDNY
DMOSW35	MN	Cytochrome P450 3A5 (CYP3A5)
DMOSW35	MT	DME
DMOSW35	MA	Metabolism
DMOSW35	RN	Drug Interactions Flockhart Table
DMOSW35	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMOSW35	DI	DMOSW35
DMOSW35	DN	Felodipine
DMOSW35	MI	DERD86B
DMOSW35	MN	Cytochrome P450 3A7 (CYP3A7)
DMOSW35	MT	DME
DMOSW35	MA	Metabolism
DMOSW35	RN	Drug Interactions Flockhart Table
DMOSW35	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMOSW35	DI	DMOSW35
DMOSW35	DN	Felodipine
DMOSW35	MI	DTUGYRD
DMOSW35	MN	P-glycoprotein 1 (ABCB1)
DMOSW35	MT	DTP
DMOSW35	MA	Substrate
DMOSW35	RN	The influence of CYP3A5*3 and BCRPC421A genetic polymorphisms on the pharmacokinetics of felodipine in healthy Chinese volunteers. J Clin Pharm Ther. 2017 Jun;42(3):345-349.
DMOSW35	RU	http://www.ncbi.nlm.nih.gov/pubmed/28244604

DMHLP9C	DI	DMHLP9C
DMHLP9C	DN	Felypressin
DMHLP9C	MI	TT4TFGN
DMHLP9C	MN	Vasopressin V1a receptor (V1AR)
DMHLP9C	MT	DTT
DMHLP9C	MA	Agonist
DMHLP9C	RN	Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog Brain Res. 2008;170:473-512.
DMHLP9C	RU	https://pubmed.ncbi.nlm.nih.gov/18655903

DMXGDFK	DI	DMXGDFK
DMXGDFK	DN	Fenbufen
DMXGDFK	MI	TT8NGED
DMXGDFK	MN	Prostaglandin G/H synthase 1 (COX-1)
DMXGDFK	MT	DTT
DMXGDFK	MA	Inhibitor
DMXGDFK	RN	Fenbufen based 3-[5-(substituted aryl)-1,3,4-oxadiazol-2-yl]-1-(biphenyl-4-yl)propan-1-ones as safer antiinflammatory and analgesic agents. Eur J Med Chem. 2009 Sep;44(9):3798-804.
DMXGDFK	RU	https://pubmed.ncbi.nlm.nih.gov/19457595

DMXGDFK	DI	DMXGDFK
DMXGDFK	DN	Fenbufen
DMXGDFK	MI	TTVKILB
DMXGDFK	MN	Prostaglandin G/H synthase 2 (COX-2)
DMXGDFK	MT	DTT
DMXGDFK	MA	Inhibitor
DMXGDFK	RN	Fenbufen based 3-[5-(substituted aryl)-1,3,4-oxadiazol-2-yl]-1-(biphenyl-4-yl)propan-1-ones as safer antiinflammatory and analgesic agents. Eur J Med Chem. 2009 Sep;44(9):3798-804.
DMXGDFK	RU	https://pubmed.ncbi.nlm.nih.gov/19457595

DM0LRU9	DI	DM0LRU9
DM0LRU9	DN	Fendrix
DM0LRU9	MI	TT3J5ZI
DM0LRU9	MN	Cell mediated immunity response (CMIR)
DM0LRU9	MT	DTT
DM0LRU9	RN	Revaccination with Fendrix or HBVaxPro results in better response rates than does revaccination with three doses of Engerix-B in previous non-responders. Vaccine. 2012 Nov 6;30(48):6734-7.
DM0LRU9	RU	https://pubmed.ncbi.nlm.nih.gov/22981848

DMFKXDY	DI	DMFKXDY
DMFKXDY	DN	Fenofibrate
DMFKXDY	MI	DE4LYSA
DMFKXDY	MN	Cytochrome P450 3A4 (CYP3A4)
DMFKXDY	MT	DME
DMFKXDY	MA	Metabolism
DMFKXDY	RN	Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998 Feb;34(2):155-62.
DMFKXDY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9515185

DMFKXDY	DI	DMFKXDY
DMFKXDY	DN	Fenofibrate
DMFKXDY	MI	TTJ584C
DMFKXDY	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMFKXDY	MT	DTT
DMFKXDY	MA	Agonist
DMFKXDY	RN	Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42.
DMFKXDY	RU	https://pubmed.ncbi.nlm.nih.gov/10828060

DMFKXDY	DI	DMFKXDY
DMFKXDY	DN	Fenofibrate
DMFKXDY	MI	DE85D2P
DMFKXDY	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMFKXDY	MT	DME
DMFKXDY	MA	Metabolism
DMFKXDY	RN	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
DMFKXDY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429

DMGO2MC	DI	DMGO2MC
DMGO2MC	DN	Fenofibric acid
DMGO2MC	MI	DE7WS3H
DMGO2MC	MN	Aldo-keto reductase 1B1 (AKR1B1)
DMGO2MC	MT	DME
DMGO2MC	MA	Metabolism
DMGO2MC	RN	In vitro metabolism of fenofibric acid by carbonyl reducing enzymes. Chem Biol Interact. 2016 Oct 25;258:153-8.
DMGO2MC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27599626

DMGO2MC	DI	DMGO2MC
DMGO2MC	DN	Fenofibric acid
DMGO2MC	MI	DE7P2FB
DMGO2MC	MN	Aldo-keto reductase 1C1 (AKR1C1)
DMGO2MC	MT	DME
DMGO2MC	MA	Metabolism
DMGO2MC	RN	In vitro metabolism of fenofibric acid by carbonyl reducing enzymes. Chem Biol Interact. 2016 Oct 25;258:153-8.
DMGO2MC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27599626

DMGO2MC	DI	DMGO2MC
DMGO2MC	DN	Fenofibric acid
DMGO2MC	MI	DEOY5ZM
DMGO2MC	MN	Aldo-keto reductase 1C2 (AKR1C2)
DMGO2MC	MT	DME
DMGO2MC	MA	Metabolism
DMGO2MC	RN	In vitro metabolism of fenofibric acid by carbonyl reducing enzymes. Chem Biol Interact. 2016 Oct 25;258:153-8.
DMGO2MC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27599626

DMGO2MC	DI	DMGO2MC
DMGO2MC	DN	Fenofibric acid
DMGO2MC	MI	DEGQTXO
DMGO2MC	MN	Aldo-keto reductase 1C3 (AKR1C3)
DMGO2MC	MT	DME
DMGO2MC	MA	Metabolism
DMGO2MC	RN	In vitro metabolism of fenofibric acid by carbonyl reducing enzymes. Chem Biol Interact. 2016 Oct 25;258:153-8.
DMGO2MC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27599626

DMGO2MC	DI	DMGO2MC
DMGO2MC	DN	Fenofibric acid
DMGO2MC	MI	DT61TWI
DMGO2MC	MN	ATP-binding cassette sub-family A member 1 (ABCA1)
DMGO2MC	MT	DTP
DMGO2MC	MA	Substrate
DMGO2MC	RN	Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner. Arterioscler Thromb Vasc Biol. 2005 Jun;25(6):1193-7.
DMGO2MC	RU	http://www.ncbi.nlm.nih.gov/pubmed/15790930

DMGO2MC	DI	DMGO2MC
DMGO2MC	DN	Fenofibric acid
DMGO2MC	MI	TTIV96N
DMGO2MC	MN	Fatty acid-binding protein 1 (FABP1)
DMGO2MC	MT	DTT
DMGO2MC	MA	Inhibitor
DMGO2MC	RN	Characterization of the drug binding specificity of rat liver fatty acid binding protein. J Med Chem. 2008 Jul 10;51(13):3755-64.
DMGO2MC	RU	https://pubmed.ncbi.nlm.nih.gov/18533710

DMGO2MC	DI	DMGO2MC
DMGO2MC	DN	Fenofibric acid
DMGO2MC	MI	DE9JFMC
DMGO2MC	MN	NADPH-dependent carbonyl reductase 1 (CBR1)
DMGO2MC	MT	DME
DMGO2MC	MA	Metabolism
DMGO2MC	RN	In vitro metabolism of fenofibric acid by carbonyl reducing enzymes. Chem Biol Interact. 2016 Oct 25;258:153-8.
DMGO2MC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27599626

DMFAOKP	DI	DMFAOKP
DMFAOKP	DN	Fenoldopam
DMFAOKP	MI	TTZFYLI
DMFAOKP	MN	Dopamine D1 receptor (D1R)
DMFAOKP	MT	DTT
DMFAOKP	MA	Agonist
DMFAOKP	RN	Etiology of iodinated radiocontrast nephrotoxicity and its attenuation by beraprost. Yakugaku Zasshi. 2008 Jul;128(7):1023-9.
DMFAOKP	RU	https://pubmed.ncbi.nlm.nih.gov/18591870

DML5VQ0	DI	DML5VQ0
DML5VQ0	DN	Fenoprofen
DML5VQ0	MI	TTK0943
DML5VQ0	MN	Prostaglandin G/H synthase (COX)
DML5VQ0	MT	DTT
DML5VQ0	MA	Inhibitor
DML5VQ0	RN	The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells. Cancer Res. 2007 Apr 1;67(7):3254-62.
DML5VQ0	RU	https://pubmed.ncbi.nlm.nih.gov/17409433

DMIP3ZV	DI	DMIP3ZV
DMIP3ZV	DN	Fenoterol
DMIP3ZV	MI	TT2CJVK
DMIP3ZV	MN	Adrenergic receptor beta-2 (ADRB2)
DMIP3ZV	MT	DTT
DMIP3ZV	MA	Agonist
DMIP3ZV	RN	Functional alpha1- and beta2-adrenergic receptors in human osteoblasts. J Cell Physiol. 2009 Jul;220(1):267-75.
DMIP3ZV	RU	https://pubmed.ncbi.nlm.nih.gov/19334040

DMIP3ZV	DI	DMIP3ZV
DMIP3ZV	DN	Fenoterol
DMIP3ZV	MI	DTT79CX
DMIP3ZV	MN	Organic cation transporter 1 (SLC22A1)
DMIP3ZV	MT	DTP
DMIP3ZV	MA	Substrate
DMIP3ZV	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMIP3ZV	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DM8WAHT	DI	DM8WAHT
DM8WAHT	DN	Fentanyl
DM8WAHT	MI	DE4LYSA
DM8WAHT	MN	Cytochrome P450 3A4 (CYP3A4)
DM8WAHT	MT	DME
DM8WAHT	MA	Metabolism
DM8WAHT	RN	Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33.
DM8WAHT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10490933

DM8WAHT	DI	DM8WAHT
DM8WAHT	DN	Fentanyl
DM8WAHT	MI	DEIBDNY
DM8WAHT	MN	Cytochrome P450 3A5 (CYP3A5)
DM8WAHT	MT	DME
DM8WAHT	MA	Metabolism
DM8WAHT	RN	Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases. J Anal Toxicol. 2005 Oct;29(7):590-8.
DM8WAHT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16419387

DM8WAHT	DI	DM8WAHT
DM8WAHT	DN	Fentanyl
DM8WAHT	MI	DERD86B
DM8WAHT	MN	Cytochrome P450 3A7 (CYP3A7)
DM8WAHT	MT	DME
DM8WAHT	MA	Metabolism
DM8WAHT	RN	Drug Interactions Flockhart Table
DM8WAHT	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM8WAHT	DI	DM8WAHT
DM8WAHT	DN	Fentanyl
DM8WAHT	MI	TTKWM86
DM8WAHT	MN	Opioid receptor mu (MOP)
DM8WAHT	MT	DTT
DM8WAHT	MA	Modulator
DM8WAHT	RN	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
DM8WAHT	RU	https://www.ncbi.nlm.nih.gov/pubmed/27899562

DM8WAHT	DI	DM8WAHT
DM8WAHT	DN	Fentanyl
DM8WAHT	MI	DTUGYRD
DM8WAHT	MN	P-glycoprotein 1 (ABCB1)
DM8WAHT	MT	DTP
DM8WAHT	MA	Substrate
DM8WAHT	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM8WAHT	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DM13495	DI	DM13495
DM13495	DN	Fesoterodine fumarate
DM13495	MI	DECB0K3
DM13495	MN	Cytochrome P450 2D6 (CYP2D6)
DM13495	MT	DME
DM13495	MA	Metabolism
DM13495	RN	Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects. Br J Clin Pharmacol. 2011 Aug;72(2):263-9.
DM13495	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21545485

DM13495	DI	DM13495
DM13495	DN	Fesoterodine fumarate
DM13495	MI	DE4LYSA
DM13495	MN	Cytochrome P450 3A4 (CYP3A4)
DM13495	MT	DME
DM13495	MA	Metabolism
DM13495	RN	Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects. Br J Clin Pharmacol. 2011 Aug;72(2):263-9.
DM13495	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21545485

DM13495	DI	DM13495
DM13495	DN	Fesoterodine fumarate
DM13495	MI	TTZ9SOR
DM13495	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DM13495	MT	DTT
DM13495	MA	Modulator
DM13495	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DM13495	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM13495	DI	DM13495
DM13495	DN	Fesoterodine fumarate
DM13495	MI	DTUGYRD
DM13495	MN	P-glycoprotein 1 (ABCB1)
DM13495	MT	DTP
DM13495	MA	Substrate
DM13495	RN	Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder. Drugs Aging. 2012 Apr 1;29(4):259-73.
DM13495	RU	http://www.ncbi.nlm.nih.gov/pubmed/22390261

DM17ONX	DI	DM17ONX
DM17ONX	DN	Fexofenadine
DM17ONX	MI	TTTIBOJ
DM17ONX	MN	Histamine H1 receptor (H1R)
DM17ONX	MT	DTT
DM17ONX	MA	Antagonist
DM17ONX	RN	Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy. Curr Allergy Asthma Rep. 2009 Mar;9(2):140-8.
DM17ONX	RU	https://pubmed.ncbi.nlm.nih.gov/19210904

DM17ONX	DI	DM17ONX
DM17ONX	DN	Fexofenadine
DM17ONX	MI	DTQ3ZHF
DM17ONX	MN	Multidrug resistance-associated protein 3 (ABCC3)
DM17ONX	MT	DTP
DM17ONX	MA	Substrate
DM17ONX	RN	Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. Mol Pharmacol. 2008 May;73(5):1474-83.
DM17ONX	RU	http://www.ncbi.nlm.nih.gov/pubmed/18245269

DM17ONX	DI	DM17ONX
DM17ONX	DN	Fexofenadine
DM17ONX	MI	DTE2B1D
DM17ONX	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DM17ONX	MT	DTP
DM17ONX	MA	Substrate
DM17ONX	RN	Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol. 2010 Dec 1;80(11):1746-53.
DM17ONX	RU	http://www.ncbi.nlm.nih.gov/pubmed/20797388

DM17ONX	DI	DM17ONX
DM17ONX	DN	Fexofenadine
DM17ONX	MI	DT9C1TS
DM17ONX	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM17ONX	MT	DTP
DM17ONX	MA	Substrate
DM17ONX	RN	Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab Dispos. 2005 Oct;33(10):1477-81.
DM17ONX	RU	http://www.ncbi.nlm.nih.gov/pubmed/16014768

DM17ONX	DI	DM17ONX
DM17ONX	DN	Fexofenadine
DM17ONX	MI	DTPFTEQ
DM17ONX	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DM17ONX	MT	DTP
DM17ONX	MA	Substrate
DM17ONX	RN	The effects of the SLCO2B1 c.1457C>T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans. Pharmacogenet Genomics. 2011 Feb;21(2):84-93.
DM17ONX	RU	http://www.ncbi.nlm.nih.gov/pubmed/21280267

DM17ONX	DI	DM17ONX
DM17ONX	DN	Fexofenadine
DM17ONX	MI	DTT79CX
DM17ONX	MN	Organic cation transporter 1 (SLC22A1)
DM17ONX	MT	DTP
DM17ONX	MA	Substrate
DM17ONX	RN	Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther. 2007 Mar;81(3):362-70.
DM17ONX	RU	https://doi.org/10.1038/sj.clpt.6100056

DM17ONX	DI	DM17ONX
DM17ONX	DN	Fexofenadine
DM17ONX	MI	DTUGYRD
DM17ONX	MN	P-glycoprotein 1 (ABCB1)
DM17ONX	MT	DTP
DM17ONX	MA	Substrate
DM17ONX	RN	Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. Clin Pharmacol Ther. 2005 Aug;78(2):191-201.
DM17ONX	RU	http://www.ncbi.nlm.nih.gov/pubmed/16084853

DM9Q8SO	DI	DM9Q8SO
DM9Q8SO	DN	Fibrinolysin
DM9Q8SO	MI	TTWODQF
DM9Q8SO	MN	Fibrin (FG)
DM9Q8SO	MT	DTT
DM9Q8SO	MA	Modulator
DM9Q8SO	RN	FIBRINOLYSIN, FIBRIN AND HYALINE MEMBRANES. Pediatrics. 1963 Nov;32:940-2.
DM9Q8SO	RU	https://pubmed.ncbi.nlm.nih.gov/14075642

DMFP6MV	DI	DMFP6MV
DMFP6MV	DN	Fidaxomicin
DMFP6MV	MI	TTIJ5EB
DMFP6MV	MN	Bacterial RNA polymerase switch region (Bact RNAP-SR)
DMFP6MV	MT	DTT
DMFP6MV	MA	Modulator
DMFP6MV	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMFP6MV	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMZEONG	DI	DMZEONG
DMZEONG	DN	Finafloxacin
DMZEONG	MI	TTN6J5F
DMZEONG	MN	Bacterial DNA gyrase (Bact gyrase)
DMZEONG	MT	DTT
DMZEONG	MA	Modulator
DMZEONG	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMZEONG	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMZEONG	DI	DMZEONG
DMZEONG	DN	Finafloxacin
DMZEONG	MI	TTIXTO3
DMZEONG	MN	Staphylococcus Topoisomerase IV (Stap-coc parC)
DMZEONG	MT	DTT
DMZEONG	MA	Modulator
DMZEONG	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMZEONG	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMWV3TZ	DI	DMWV3TZ
DMWV3TZ	DN	Finasteride
DMWV3TZ	MI	DE4LYSA
DMWV3TZ	MN	Cytochrome P450 3A4 (CYP3A4)
DMWV3TZ	MT	DME
DMWV3TZ	MA	Metabolism
DMWV3TZ	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMWV3TZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMWV3TZ	DI	DMWV3TZ
DMWV3TZ	DN	Finasteride
DMWV3TZ	MI	DEIBDNY
DMWV3TZ	MN	Cytochrome P450 3A5 (CYP3A5)
DMWV3TZ	MT	DME
DMWV3TZ	MA	Metabolism
DMWV3TZ	RN	Drug Interactions Flockhart Table
DMWV3TZ	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMWV3TZ	DI	DMWV3TZ
DMWV3TZ	DN	Finasteride
DMWV3TZ	MI	DERD86B
DMWV3TZ	MN	Cytochrome P450 3A7 (CYP3A7)
DMWV3TZ	MT	DME
DMWV3TZ	MA	Metabolism
DMWV3TZ	RN	Drug Interactions Flockhart Table
DMWV3TZ	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMWV3TZ	DI	DMWV3TZ
DMWV3TZ	DN	Finasteride
DMWV3TZ	MI	TT2A0DR
DMWV3TZ	MN	Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A)
DMWV3TZ	MT	DTT
DMWV3TZ	MA	Inhibitor
DMWV3TZ	RN	The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme Can Urol Assoc J. 2009 Jun;3(3 Suppl 2):S109-14.
DMWV3TZ	RU	https://pubmed.ncbi.nlm.nih.gov/19543428

DMWV3TZ	DI	DMWV3TZ
DMWV3TZ	DN	Finasteride
DMWV3TZ	MI	TTT02K8
DMWV3TZ	MN	Steroid 5-alpha-reductase 2 (SRD5A2)
DMWV3TZ	MT	DTT
DMWV3TZ	MA	Inhibitor
DMWV3TZ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMWV3TZ	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM5JVAN	DI	DM5JVAN
DM5JVAN	DN	Fingolimod
DM5JVAN	MI	DED26GV
DM5JVAN	MN	Cytochrome P450 4F12 (CYP4F12)
DM5JVAN	MT	DME
DM5JVAN	MA	Metabolism
DM5JVAN	RN	CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis. Drug Metab Dispos. 2011 Feb;39(2):191-8.
DM5JVAN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21045201

DM5JVAN	DI	DM5JVAN
DM5JVAN	DN	Fingolimod
DM5JVAN	MI	DE3GT9C
DM5JVAN	MN	Cytochrome P450 4F2 (CYP4F2)
DM5JVAN	MT	DME
DM5JVAN	MA	Metabolism
DM5JVAN	RN	CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis. Drug Metab Dispos. 2011 Feb;39(2):191-8.
DM5JVAN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21045201

DM5JVAN	DI	DM5JVAN
DM5JVAN	DN	Fingolimod
DM5JVAN	MI	TT9JZCK
DM5JVAN	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DM5JVAN	MT	DTT
DM5JVAN	MA	Modulator
DM5JVAN	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DM5JVAN	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DMKV4NL	DI	DMKV4NL
DMKV4NL	DN	Flavoxate
DMKV4NL	MI	TTH18TF
DMKV4NL	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMKV4NL	MT	DTT
DMKV4NL	MA	Antagonist
DMKV4NL	RN	Brain pertussis toxin-sensitive G proteins are involved in the flavoxate hydrochloride-induced suppression of the micturition reflex in rats. Brain Res. 1996 Jul 15;727(1-2):91-8.
DMKV4NL	RU	https://pubmed.ncbi.nlm.nih.gov/8842386

DMSQDLE	DI	DMSQDLE
DMSQDLE	DN	Flecainide
DMSQDLE	MI	DEJGDUW
DMSQDLE	MN	Cytochrome P450 1A2 (CYP1A2)
DMSQDLE	MT	DME
DMSQDLE	MA	Metabolism
DMSQDLE	RN	Flecainide: current status and perspectives in arrhythmia management. World J Cardiol. 2015 Feb 26;7(2):76-85.
DMSQDLE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25717355

DMSQDLE	DI	DMSQDLE
DMSQDLE	DN	Flecainide
DMSQDLE	MI	DECB0K3
DMSQDLE	MN	Cytochrome P450 2D6 (CYP2D6)
DMSQDLE	MT	DME
DMSQDLE	MA	Metabolism
DMSQDLE	RN	Flecainide: current status and perspectives in arrhythmia management. World J Cardiol. 2015 Feb 26;7(2):76-85.
DMSQDLE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25717355

DMSQDLE	DI	DMSQDLE
DMSQDLE	DN	Flecainide
DMSQDLE	MI	TT05DLS
DMSQDLE	MN	E3 ubiquitin-protein ligase COP1 (RFWD2)
DMSQDLE	MT	DTT
DMSQDLE	MA	Modulator
DMSQDLE	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMSQDLE	RU	https://www.fda.gov/

DMSQDLE	DI	DMSQDLE
DMSQDLE	DN	Flecainide
DMSQDLE	MI	TTN9VTF
DMSQDLE	MN	Voltage-gated sodium channel alpha Nav1.9 (SCN11A)
DMSQDLE	MT	DTT
DMSQDLE	MA	Blocker
DMSQDLE	RN	New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22.
DMSQDLE	RU	https://pubmed.ncbi.nlm.nih.gov/15934869

DMXGQYZ	DI	DMXGQYZ
DMXGQYZ	DN	Fleroxacin
DMXGQYZ	MI	TT0IHXV
DMXGQYZ	MN	DNA topoisomerase II (TOP2)
DMXGQYZ	MT	DTT
DMXGQYZ	MA	Inhibitor
DMXGQYZ	RN	Fleroxacin overview. Chemotherapy. 1996 Mar;42 Suppl 1:1-9.
DMXGQYZ	RU	https://pubmed.ncbi.nlm.nih.gov/8861529

DM70DTN	DI	DM70DTN
DM70DTN	DN	Flibanserin
DM70DTN	MI	TTSQIFT
DM70DTN	MN	5-HT 1A receptor (HTR1A)
DM70DTN	MT	DTT
DM70DTN	MA	Modulator
DM70DTN	RN	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
DM70DTN	RU	https://pubmed.ncbi.nlm.nih.gov/28919714

DM70DTN	DI	DM70DTN
DM70DTN	DN	Flibanserin
DM70DTN	MI	TTJQOD7
DM70DTN	MN	5-HT 2A receptor (HTR2A)
DM70DTN	MT	DTT
DM70DTN	MA	Modulator
DM70DTN	RN	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
DM70DTN	RU	https://pubmed.ncbi.nlm.nih.gov/28919714

DM70DTN	DI	DM70DTN
DM70DTN	DN	Flibanserin
DM70DTN	MI	DE4LYSA
DM70DTN	MN	Cytochrome P450 3A4 (CYP3A4)
DM70DTN	MT	DME
DM70DTN	MA	Metabolism
DM70DTN	RN	Flibanserin: first global approval. Drugs. 2015 Oct;75(15):1815-22.
DM70DTN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26412054

DM70DTN	DI	DM70DTN
DM70DTN	DN	Flibanserin
DM70DTN	MI	DEGTFWK
DM70DTN	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM70DTN	MT	DME
DM70DTN	MA	Metabolism
DM70DTN	RN	Flibanserin therapy and CYP2C19 genotype.
DM70DTN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31550099

DMJ8A3Z	DI	DMJ8A3Z
DMJ8A3Z	DN	Florbetapir F-18
DMJ8A3Z	MI	TTE4KHA
DMJ8A3Z	MN	Amyloid beta A4 protein (APP)
DMJ8A3Z	MT	DTT
DMJ8A3Z	MA	Modulator
DMJ8A3Z	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMJ8A3Z	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM04LR2	DI	DM04LR2
DM04LR2	DN	Floxuridine
DM04LR2	MI	TTU6BFZ
DM04LR2	MN	Candida Thymidylate synthase (Candi TMP1)
DM04LR2	MT	DTT
DM04LR2	MA	Inhibitor
DM04LR2	RN	Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells. Br J Pharmacol. 1999 Aug;127(8):1777-86.
DM04LR2	RU	https://pubmed.ncbi.nlm.nih.gov/10482907

DM04LR2	DI	DM04LR2
DM04LR2	DN	Floxuridine
DM04LR2	MI	DE4HCYL
DM04LR2	MN	Thymidine phosphorylase (TYMP)
DM04LR2	MT	DME
DM04LR2	MA	Metabolism
DM04LR2	RN	Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability. Mol Pharm. 2008 Sep-Oct;5(5):717-27.
DM04LR2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18652477

DMNUWST	DI	DMNUWST
DMNUWST	DN	Flucloxacillin
DMNUWST	MI	TTJP4SM
DMNUWST	MN	Bacterial Penicillin binding protein (Bact PBP)
DMNUWST	MT	DTT
DMNUWST	MA	Binder
DMNUWST	RN	Mechanisms of resistance to beta-lactam antibiotics in Staphylococcus aureus. Scand J Infect Dis Suppl. 1984;42:64-71.
DMNUWST	RU	https://pubmed.ncbi.nlm.nih.gov/6335600

DMNUWST	DI	DMNUWST
DMNUWST	DN	Flucloxacillin
DMNUWST	MI	DE4LYSA
DMNUWST	MN	Cytochrome P450 3A4 (CYP3A4)
DMNUWST	MT	DME
DMNUWST	MA	Metabolism
DMNUWST	RN	Characterization of kinetics of human cytochrome P450s involved in bioactivation of flucloxacillin: inhibition of CYP3A-catalysed hydroxylation by sulfaphenazole. Br J Pharmacol. 2019 Feb;176(3):466-477.
DMNUWST	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30447161

DMNUWST	DI	DMNUWST
DMNUWST	DN	Flucloxacillin
DMNUWST	MI	DT9G7XN
DMNUWST	MN	Peptide transporter 1 (SLC15A1)
DMNUWST	MT	DTP
DMNUWST	MA	Substrate
DMNUWST	RN	Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. J Med Chem. 2005 Jun 30;48(13):4410-9.
DMNUWST	RU	http://www.ncbi.nlm.nih.gov/pubmed/15974593

DMOWZ6B	DI	DMOWZ6B
DMOWZ6B	DN	Fluconazole
DMOWZ6B	MI	TTTSOUD
DMOWZ6B	MN	Candida Cytochrome P450 51 (Candi ERG11)
DMOWZ6B	MT	DTT
DMOWZ6B	MA	Modulator
DMOWZ6B	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMOWZ6B	RU	https://www.fda.gov/

DMOWZ6B	DI	DMOWZ6B
DMOWZ6B	DN	Fluconazole
DMOWZ6B	MI	DE5IED8
DMOWZ6B	MN	Cytochrome P450 2C9 (CYP2C9)
DMOWZ6B	MT	DME
DMOWZ6B	MA	Metabolism
DMOWZ6B	RN	Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol. 2000 Jun;56(3):225-9.
DMOWZ6B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10952477

DM13VTW	DI	DM13VTW
DM13VTW	DN	Flucytosine
DM13VTW	MI	TTU6BFZ
DM13VTW	MN	Candida Thymidylate synthase (Candi TMP1)
DM13VTW	MT	DTT
DM13VTW	MA	Inhibitor
DM13VTW	RN	Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter. 2006 Jun;19(2):130-9.
DM13VTW	RU	https://pubmed.ncbi.nlm.nih.gov/16964330

DMVRLT7	DI	DMVRLT7
DMVRLT7	DN	Fludarabine
DMVRLT7	MI	TTLP57V
DMVRLT7	MN	Adenosine deaminase (ADA)
DMVRLT7	MT	DTT
DMVRLT7	MA	Inhibitor
DMVRLT7	RN	Purine nucleoside analogs in indolent non-Hodgkin's lymphoma. Oncology (Williston Park). 2000 Jun;14(6 Suppl 2):13-5.
DMVRLT7	RU	https://pubmed.ncbi.nlm.nih.gov/10887639

DMD2K4I	DI	DMD2K4I
DMD2K4I	DN	Fludiazepam
DMD2K4I	MI	TTPTXIN
DMD2K4I	MN	Translocator protein (TSPO)
DMD2K4I	MT	DTT
DMD2K4I	MA	Agonist
DMD2K4I	RN	Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9.
DMD2K4I	RU	https://pubmed.ncbi.nlm.nih.gov/2857046

DMUDIR8	DI	DMUDIR8
DMUDIR8	DN	Fludrocortisone
DMUDIR8	MI	TTS64P2
DMUDIR8	MN	Androgen receptor (AR)
DMUDIR8	MT	DTT
DMUDIR8	MA	Inhibitor
DMUDIR8	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMUDIR8	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMUDIR8	DI	DMUDIR8
DMUDIR8	DN	Fludrocortisone
DMUDIR8	MI	DE4LYSA
DMUDIR8	MN	Cytochrome P450 3A4 (CYP3A4)
DMUDIR8	MT	DME
DMUDIR8	MA	Metabolism
DMUDIR8	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMUDIR8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMUDIR8	DI	DMUDIR8
DMUDIR8	DN	Fludrocortisone
DMUDIR8	MI	TT26PHO
DMUDIR8	MN	Mineralocorticoid receptor  (MR)
DMUDIR8	MT	DTT
DMUDIR8	MA	Agonist
DMUDIR8	RN	Mineralocorticoid receptor-mediated inhibition of the hypothalamic-pituitary-adrenal axis in aged humans. J Gerontol A Biol Sci Med Sci. 2003 Oct;58(10):B900-5.
DMUDIR8	RU	https://pubmed.ncbi.nlm.nih.gov/14570856

DMC8VNH	DI	DMC8VNH
DMC8VNH	DN	Flufenamic Acid
DMC8VNH	MI	TTS64P2
DMC8VNH	MN	Androgen receptor (AR)
DMC8VNH	MT	DTT
DMC8VNH	MA	Inhibitor
DMC8VNH	RN	Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
DMC8VNH	RU	https://pubmed.ncbi.nlm.nih.gov/7864817

DMC8VNH	DI	DMC8VNH
DMC8VNH	DN	Flufenamic Acid
DMC8VNH	MI	TT5ZWB6
DMC8VNH	MN	Dihydrodiol dehydrogenase type I (AKR1C3)
DMC8VNH	MT	DTT
DMC8VNH	MA	Inhibitor
DMC8VNH	RN	Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
DMC8VNH	RU	https://pubmed.ncbi.nlm.nih.gov/7864817

DMC8VNH	DI	DMC8VNH
DMC8VNH	DN	Flufenamic Acid
DMC8VNH	MI	TT8NGED
DMC8VNH	MN	Prostaglandin G/H synthase 1 (COX-1)
DMC8VNH	MT	DTT
DMC8VNH	MA	Inhibitor
DMC8VNH	RN	Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
DMC8VNH	RU	https://pubmed.ncbi.nlm.nih.gov/7864817

DMC8VNH	DI	DMC8VNH
DMC8VNH	DN	Flufenamic Acid
DMC8VNH	MI	TTVKILB
DMC8VNH	MN	Prostaglandin G/H synthase 2 (COX-2)
DMC8VNH	MT	DTT
DMC8VNH	MA	Inhibitor
DMC8VNH	RN	Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
DMC8VNH	RU	https://pubmed.ncbi.nlm.nih.gov/7864817

DMPCG2L	DI	DMPCG2L
DMPCG2L	DN	Flumazenil
DMPCG2L	MI	TTBMV1G
DMPCG2L	MN	GABA(A) receptor alpha-2 (GABRA2)
DMPCG2L	MT	DTT
DMPCG2L	MA	Modulator (allosteric modulator)
DMPCG2L	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 405).
DMPCG2L	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=405

DMPCG2L	DI	DMPCG2L
DMPCG2L	DN	Flumazenil
DMPCG2L	MI	TT37EDJ
DMPCG2L	MN	GABA(A) receptor alpha-3 (GABRA3)
DMPCG2L	MT	DTT
DMPCG2L	MA	Modulator (allosteric modulator)
DMPCG2L	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 406).
DMPCG2L	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=406

DMPCG2L	DI	DMPCG2L
DMPCG2L	DN	Flumazenil
DMPCG2L	MI	TTNZPQ1
DMPCG2L	MN	GABA(A) receptor alpha-5 (GABRA5)
DMPCG2L	MT	DTT
DMPCG2L	MA	Modulator (allosteric modulator)
DMPCG2L	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 408).
DMPCG2L	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=408

DMPCG2L	DI	DMPCG2L
DMPCG2L	DN	Flumazenil
DMPCG2L	MI	TTEX6LM
DMPCG2L	MN	GABA(A) receptor gamma-3 (GABRG3)
DMPCG2L	MT	DTT
DMPCG2L	MA	Modulator (allosteric modulator)
DMPCG2L	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415).
DMPCG2L	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415

DMPCG2L	DI	DMPCG2L
DMPCG2L	DN	Flumazenil
DMPCG2L	MI	TTPTXIN
DMPCG2L	MN	Translocator protein (TSPO)
DMPCG2L	MT	DTT
DMPCG2L	MA	Antagonist
DMPCG2L	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2879).
DMPCG2L	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2879

DMUNG4A	DI	DMUNG4A
DMUNG4A	DN	Flumethasone
DMUNG4A	MI	DE4LYSA
DMUNG4A	MN	Cytochrome P450 3A4 (CYP3A4)
DMUNG4A	MT	DME
DMUNG4A	MA	Metabolism
DMUNG4A	RN	Prediction of cytochrome P450 isoform responsible for metabolizing a drug molecule. BMC Pharmacol. 2010 Jul 16;10:8.
DMUNG4A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20637097

DMU0YP6	DI	DMU0YP6
DMU0YP6	DN	Flumethasone Pivalate
DMU0YP6	MI	TTP3UTW
DMU0YP6	MN	Steroid hormone receptor ERR (ESRR)
DMU0YP6	MT	DTT
DMU0YP6	MA	Modulator
DMU0YP6	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMU0YP6	RU	https://www.fda.gov/

DMZU5JP	DI	DMZU5JP
DMZU5JP	DN	Flunarizine
DMZU5JP	MI	DE6OQ3W
DMZU5JP	MN	Cytochrome P450 1A1 (CYP1A1)
DMZU5JP	MT	DME
DMZU5JP	MA	Metabolism
DMZU5JP	RN	Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4.
DMZU5JP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8951176

DMZU5JP	DI	DMZU5JP
DMZU5JP	DN	Flunarizine
DMZU5JP	MI	DEJGDUW
DMZU5JP	MN	Cytochrome P450 1A2 (CYP1A2)
DMZU5JP	MT	DME
DMZU5JP	MA	Metabolism
DMZU5JP	RN	Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4.
DMZU5JP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8951176

DMZU5JP	DI	DMZU5JP
DMZU5JP	DN	Flunarizine
DMZU5JP	MI	DEJVYAZ
DMZU5JP	MN	Cytochrome P450 2A6 (CYP2A6)
DMZU5JP	MT	DME
DMZU5JP	MA	Metabolism
DMZU5JP	RN	Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4.
DMZU5JP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8951176

DMZU5JP	DI	DMZU5JP
DMZU5JP	DN	Flunarizine
DMZU5JP	MI	DE5IED8
DMZU5JP	MN	Cytochrome P450 2C9 (CYP2C9)
DMZU5JP	MT	DME
DMZU5JP	MA	Metabolism
DMZU5JP	RN	Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4.
DMZU5JP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8951176

DMZU5JP	DI	DMZU5JP
DMZU5JP	DN	Flunarizine
DMZU5JP	MI	DECB0K3
DMZU5JP	MN	Cytochrome P450 2D6 (CYP2D6)
DMZU5JP	MT	DME
DMZU5JP	MA	Metabolism
DMZU5JP	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMZU5JP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMZU5JP	DI	DMZU5JP
DMZU5JP	DN	Flunarizine
DMZU5JP	MI	TTX4QDJ
DMZU5JP	MN	Voltage-gated calcium channel alpha Cav2.1 (CACNA1A)
DMZU5JP	MT	DTT
DMZU5JP	MA	Inhibitor
DMZU5JP	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMZU5JP	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMZU5JP	DI	DMZU5JP
DMZU5JP	DN	Flunarizine
DMZU5JP	MI	TTZPWGN
DMZU5JP	MN	Voltage-gated calcium channel alpha Cav3.2 (CACNA1H)
DMZU5JP	MT	DTT
DMZU5JP	MA	Blocker
DMZU5JP	RN	Positive allosteric interaction of structurally diverse T-type calcium channel antagonists. Cell Biochem Biophys. 2009;55(2):81-93.
DMZU5JP	RU	https://pubmed.ncbi.nlm.nih.gov/19582593

DMZSWQC	DI	DMZSWQC
DMZSWQC	DN	Flunisolide
DMZSWQC	MI	DE4LYSA
DMZSWQC	MN	Cytochrome P450 3A4 (CYP3A4)
DMZSWQC	MT	DME
DMZSWQC	MA	Metabolism
DMZSWQC	RN	Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes. Drug Metab Dispos. 2013 Feb;41(2):379-89.
DMZSWQC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23143891

DMZSWQC	DI	DMZSWQC
DMZSWQC	DN	Flunisolide
DMZSWQC	MI	TTYRL6O
DMZSWQC	MN	Glucocorticoid receptor (NR3C1)
DMZSWQC	MT	DTT
DMZSWQC	MA	Agonist
DMZSWQC	RN	The glucocorticoid receptor heterocomplex gene STIP1 is associated with improved lung function in asthmatic subjects treated with inhaled corticost... J Allergy Clin Immunol. 2009 Jun;123(6):1376-83.e7.
DMZSWQC	RU	https://pubmed.ncbi.nlm.nih.gov/19254810

DMGR5Z3	DI	DMGR5Z3
DMGR5Z3	DN	Flunitrazepam
DMGR5Z3	MI	DEJGDUW
DMGR5Z3	MN	Cytochrome P450 1A2 (CYP1A2)
DMGR5Z3	MT	DME
DMGR5Z3	MA	Metabolism
DMGR5Z3	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMGR5Z3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMGR5Z3	DI	DMGR5Z3
DMGR5Z3	DN	Flunitrazepam
DMGR5Z3	MI	DEJVYAZ
DMGR5Z3	MN	Cytochrome P450 2A6 (CYP2A6)
DMGR5Z3	MT	DME
DMGR5Z3	MA	Metabolism
DMGR5Z3	RN	CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam. Drug Metab Dispos. 2001 Feb;29(2):133-40.
DMGR5Z3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11159802

DMGR5Z3	DI	DMGR5Z3
DMGR5Z3	DN	Flunitrazepam
DMGR5Z3	MI	DEPKLMQ
DMGR5Z3	MN	Cytochrome P450 2B6 (CYP2B6)
DMGR5Z3	MT	DME
DMGR5Z3	MA	Metabolism
DMGR5Z3	RN	CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam. Drug Metab Dispos. 2001 Feb;29(2):133-40.
DMGR5Z3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11159802

DMGR5Z3	DI	DMGR5Z3
DMGR5Z3	DN	Flunitrazepam
DMGR5Z3	MI	DE5IED8
DMGR5Z3	MN	Cytochrome P450 2C9 (CYP2C9)
DMGR5Z3	MT	DME
DMGR5Z3	MA	Metabolism
DMGR5Z3	RN	CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam. Drug Metab Dispos. 2001 Feb;29(2):133-40.
DMGR5Z3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11159802

DMGR5Z3	DI	DMGR5Z3
DMGR5Z3	DN	Flunitrazepam
DMGR5Z3	MI	DE4LYSA
DMGR5Z3	MN	Cytochrome P450 3A4 (CYP3A4)
DMGR5Z3	MT	DME
DMGR5Z3	MA	Metabolism
DMGR5Z3	RN	Cytochrome P450 3A4 and benzodiazepines. Seishin Shinkeigaku Zasshi. 2003;105(5):631-42.
DMGR5Z3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12875231

DMGR5Z3	DI	DMGR5Z3
DMGR5Z3	DN	Flunitrazepam
DMGR5Z3	MI	DEGTFWK
DMGR5Z3	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMGR5Z3	MT	DME
DMGR5Z3	MA	Metabolism
DMGR5Z3	RN	The role of cytochrome P450 2C19 activity in flunitrazepam metabolism in vivo. J Clin Psychopharmacol. 2003 Apr;23(2):169-75.
DMGR5Z3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12640218

DMGR5Z3	DI	DMGR5Z3
DMGR5Z3	DN	Flunitrazepam
DMGR5Z3	MI	DE0QLUZ
DMGR5Z3	MN	Oxygen-insensitive NADPH nitroreductase B (nfsB)
DMGR5Z3	MT	DME
DMGR5Z3	MA	Metabolism
DMGR5Z3	RN	Structure-based development of bacterial nitroreductase against nitrobenzodiazepine-induced hypnosis. Biochem Pharmacol. 2012 Jun 15;83(12):1690-9.
DMGR5Z3	RU	https://pubmed.ncbi.nlm.nih.gov/22445794

DMGR5Z3	DI	DMGR5Z3
DMGR5Z3	DN	Flunitrazepam
DMGR5Z3	MI	TTPTXIN
DMGR5Z3	MN	Translocator protein (TSPO)
DMGR5Z3	MT	DTT
DMGR5Z3	MA	Agonist
DMGR5Z3	RN	Comparison of five benzodiazepine-receptor agonists on buprenorphine-induced mu-opioid receptor regulation. J Pharmacol Sci. 2009 May;110(1):36-46.
DMGR5Z3	RU	https://pubmed.ncbi.nlm.nih.gov/19443999

DMG2KI4	DI	DMG2KI4
DMG2KI4	DN	Fluocinolone acetonide
DMG2KI4	MI	DE4LYSA
DMG2KI4	MN	Cytochrome P450 3A4 (CYP3A4)
DMG2KI4	MT	DME
DMG2KI4	MA	Metabolism
DMG2KI4	RN	Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes. Drug Metab Dispos. 2013 Feb;41(2):379-89.
DMG2KI4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23143891

DMG2KI4	DI	DMG2KI4
DMG2KI4	DN	Fluocinolone acetonide
DMG2KI4	MI	TTYRL6O
DMG2KI4	MN	Glucocorticoid receptor (NR3C1)
DMG2KI4	MT	DTT
DMG2KI4	MA	Modulator
DMG2KI4	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMG2KI4	RU	https://www.fda.gov/

DM65KL8	DI	DM65KL8
DM65KL8	DN	Fluocinonide
DM65KL8	MI	DE4LYSA
DM65KL8	MN	Cytochrome P450 3A4 (CYP3A4)
DM65KL8	MT	DME
DM65KL8	MA	Metabolism
DM65KL8	RN	Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes. Drug Metab Dispos. 2013 Feb;41(2):379-89.
DM65KL8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23143891

DM65KL8	DI	DM65KL8
DM65KL8	DN	Fluocinonide
DM65KL8	MI	TTP3UTW
DM65KL8	MN	Steroid hormone receptor ERR (ESRR)
DM65KL8	MT	DTT
DM65KL8	MA	Modulator
DM65KL8	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM65KL8	RU	https://www.fda.gov/

DMQTFAO	DI	DMQTFAO
DMQTFAO	DN	Fluorescein
DMQTFAO	MI	TTHQZV7
DMQTFAO	MN	Mothers against decapentaplegic homolog 3 (SMAD3)
DMQTFAO	MT	DTT
DMQTFAO	MA	Inhibitor
DMQTFAO	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMQTFAO	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMQTFAO	DI	DMQTFAO
DMQTFAO	DN	Fluorescein
DMQTFAO	MI	DTSYQGK
DMQTFAO	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMQTFAO	MT	DTP
DMQTFAO	MA	Substrate
DMQTFAO	RN	Transport of fluorescein in MDCKII-MRP1 transfected cells and mrp1-knockout mice. Biochem Biophys Res Commun. 2001 Jun 22;284(4):863-9.
DMQTFAO	RU	http://www.ncbi.nlm.nih.gov/pubmed/11409873

DMQTFAO	DI	DMQTFAO
DMQTFAO	DN	Fluorescein
DMQTFAO	MI	DTFI42L
DMQTFAO	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMQTFAO	MT	DTP
DMQTFAO	MA	Substrate
DMQTFAO	RN	Phosphoinositide 3-kinase/protein kinase B signaling pathway is involved in estradiol 17-D-glucuronide-induced cholestasis: complementarity with classical protein kinase C. Hepatology. 2010 Oct;52(4):1465-76.
DMQTFAO	RU	http://www.ncbi.nlm.nih.gov/pubmed/20815017

DMQTFAO	DI	DMQTFAO
DMQTFAO	DN	Fluorescein
DMQTFAO	MI	DTYVM24
DMQTFAO	MN	Multidrug resistance-associated protein 5 (ABCC5)
DMQTFAO	MT	DTP
DMQTFAO	MA	Substrate
DMQTFAO	RN	Hyaluronan export by the ABC transporter MRP5 and its modulation by intracellular cGMP. J Biol Chem. 2007 Jul 20;282(29):20999-1004.
DMQTFAO	RU	http://www.ncbi.nlm.nih.gov/pubmed/17540771

DMQTFAO	DI	DMQTFAO
DMQTFAO	DN	Fluorescein
DMQTFAO	MI	DTQ23VB
DMQTFAO	MN	Organic anion transporter 1 (SLC22A6)
DMQTFAO	MT	DTP
DMQTFAO	MA	Substrate
DMQTFAO	RN	Apical expression or expression in a non polarized cell of hOAT1 inverses regulation by epidermal growth factor (EGF) as compared to basolateral hOAT1. Cell Physiol Biochem. 2004;14(3):177-86.
DMQTFAO	RU	http://www.ncbi.nlm.nih.gov/pubmed/15107594

DMQTFAO	DI	DMQTFAO
DMQTFAO	DN	Fluorescein
DMQTFAO	MI	DT3D8F0
DMQTFAO	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMQTFAO	MT	DTP
DMQTFAO	MA	Substrate
DMQTFAO	RN	Organic Anion Transporter 2-Mediated Hepatic Uptake Contributes to the Clearance of High-Permeability-Low-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs. J Pharmacol Exp Ther. 2018 Nov;367(2):322-334.
DMQTFAO	RU	http://www.ncbi.nlm.nih.gov/pubmed/30135178

DMQTFAO	DI	DMQTFAO
DMQTFAO	DN	Fluorescein
DMQTFAO	MI	DT9C1TS
DMQTFAO	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMQTFAO	MT	DTP
DMQTFAO	MA	Substrate
DMQTFAO	RN	Development of a cell-based high-throughput assay to screen for inhibitors of organic anion transporting polypeptides 1B1 and 1B3. Curr Chem Genomics. 2010 Mar 1;4:1-8.
DMQTFAO	RU	http://www.ncbi.nlm.nih.gov/pubmed/20448812

DMQTFAO	DI	DMQTFAO
DMQTFAO	DN	Fluorescein
DMQTFAO	MI	TTTQR47
DMQTFAO	MN	Solute carrier family 22 member 8 (SLC22A8)
DMQTFAO	MT	DTT
DMQTFAO	MA	Inhibitor
DMQTFAO	RN	Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members. J Biol Chem. 2007 Aug 17;282(33):23841-53.
DMQTFAO	RU	https://pubmed.ncbi.nlm.nih.gov/17553798

DM2HKC4	DI	DM2HKC4
DM2HKC4	DN	Fluorometholone
DM2HKC4	MI	DE4LYSA
DM2HKC4	MN	Cytochrome P450 3A4 (CYP3A4)
DM2HKC4	MT	DME
DM2HKC4	MA	Metabolism
DM2HKC4	RN	Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35.
DM2HKC4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20482443

DM2HKC4	DI	DM2HKC4
DM2HKC4	DN	Fluorometholone
DM2HKC4	MI	TTYRL6O
DM2HKC4	MN	Glucocorticoid receptor (NR3C1)
DM2HKC4	MT	DTT
DM2HKC4	MA	Binder
DM2HKC4	RN	Loteprednol etabonate: a soft steroid for the treatment of allergic diseases of the airways. Drugs Today (Barc). 2000 May;36(5):313-20.
DM2HKC4	RU	https://pubmed.ncbi.nlm.nih.gov/12861354

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	DEMJ7R2
DMUM7HZ	MN	Amidophosphoribosyltransferase (GPAT)
DMUM7HZ	MT	DME
DMUM7HZ	MA	Metabolism
DMUM7HZ	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150653776)
DMUM7HZ	RU	https://www.pharmgkb.org/pathway/PA150653776

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	DTI7UX6
DMUM7HZ	MN	Breast cancer resistance protein (ABCG2)
DMUM7HZ	MT	DTP
DMUM7HZ	MA	Substrate
DMUM7HZ	RN	Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
DMUM7HZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/18820913

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	TTU6BFZ
DMUM7HZ	MN	Candida Thymidylate synthase (Candi TMP1)
DMUM7HZ	MT	DTT
DMUM7HZ	MA	Inhibitor
DMUM7HZ	RN	The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. Cancer Chemother Pharmacol. 2004 Apr;53(4):296-304.
DMUM7HZ	RU	https://pubmed.ncbi.nlm.nih.gov/14689231

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	DEJGDUW
DMUM7HZ	MN	Cytochrome P450 1A2 (CYP1A2)
DMUM7HZ	MT	DME
DMUM7HZ	MA	Metabolism
DMUM7HZ	RN	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
DMUM7HZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11095583

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	DEJVYAZ
DMUM7HZ	MN	Cytochrome P450 2A6 (CYP2A6)
DMUM7HZ	MT	DME
DMUM7HZ	MA	Metabolism
DMUM7HZ	RN	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
DMUM7HZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11095583

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	DES5XRU
DMUM7HZ	MN	Cytochrome P450 2C8 (CYP2C8)
DMUM7HZ	MT	DME
DMUM7HZ	MA	Metabolism
DMUM7HZ	RN	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
DMUM7HZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11095583

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	TTZPS91
DMUM7HZ	MN	Dihydrothymine dehydrogenase (DPYD)
DMUM7HZ	MT	DTT
DMUM7HZ	MA	Inhibitor
DMUM7HZ	RN	Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. Eur J Cancer. 2002 Jun;38(9):1271-7.
DMUM7HZ	RU	https://pubmed.ncbi.nlm.nih.gov/12044515

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	DESOEW1
DMUM7HZ	MN	Dihydrothymine dehydrogenase (DPYD)
DMUM7HZ	MT	DME
DMUM7HZ	MA	Metabolism
DMUM7HZ	RN	5-Fluorouracil toxicity-attributable IVS14 + 1G > A mutation of the dihydropyrimidine dehydrogenase gene in Polish colorectal cancer patients. Pharmacol Rep. 2008 Mar-Apr;60(2):238-42.
DMUM7HZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18443386

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	DTXD1TQ
DMUM7HZ	MN	Equilibrative nucleoside transporter 1 (SLC29A1)
DMUM7HZ	MT	DTP
DMUM7HZ	MA	Substrate
DMUM7HZ	RN	Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer. Anticancer Res. 2007 Jul-Aug;27(4B):2241-9.
DMUM7HZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/17695509

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	DEOXTPZ
DMUM7HZ	MN	Methylenetetrahydrofolate reductase (MTHFR)
DMUM7HZ	MT	DME
DMUM7HZ	MA	Metabolism
DMUM7HZ	RN	5-Fluorouracil pharmacogenomics: still rocking after all these years? Pharmacogenomics. 2011 Feb;12(2):251-65.
DMUM7HZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21332317

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	DTFI42L
DMUM7HZ	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMUM7HZ	MT	DTP
DMUM7HZ	MA	Substrate
DMUM7HZ	RN	Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
DMUM7HZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/27602148

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	DTQ3ZHF
DMUM7HZ	MN	Multidrug resistance-associated protein 3 (ABCC3)
DMUM7HZ	MT	DTP
DMUM7HZ	MA	Substrate
DMUM7HZ	RN	ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology. 2009;9(1-2):136-44.
DMUM7HZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/19077464

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	DTCSGPB
DMUM7HZ	MN	Multidrug resistance-associated protein 4 (ABCC4)
DMUM7HZ	MT	DTP
DMUM7HZ	MA	Substrate
DMUM7HZ	RN	ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology. 2009;9(1-2):136-44.
DMUM7HZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/19077464

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	DTYVM24
DMUM7HZ	MN	Multidrug resistance-associated protein 5 (ABCC5)
DMUM7HZ	MT	DTP
DMUM7HZ	MA	Substrate
DMUM7HZ	RN	ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology. 2009;9(1-2):136-44.
DMUM7HZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/19077464

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	DT0OC1Q
DMUM7HZ	MN	Organic anion transporter 2 (SLC22A7)
DMUM7HZ	MT	DTP
DMUM7HZ	MA	Substrate
DMUM7HZ	RN	Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8.
DMUM7HZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/15901346

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	DTUGYRD
DMUM7HZ	MN	P-glycoprotein 1 (ABCB1)
DMUM7HZ	MT	DTP
DMUM7HZ	MA	Substrate
DMUM7HZ	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMUM7HZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	TTQY2EJ
DMUM7HZ	MN	TERT messenger RNA (TERT mRNA)
DMUM7HZ	MT	DTT
DMUM7HZ	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DMUM7HZ	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	DE4HCYL
DMUM7HZ	MN	Thymidine phosphorylase (TYMP)
DMUM7HZ	MT	DME
DMUM7HZ	MA	Metabolism
DMUM7HZ	RN	5-Fluorouracil pharmacogenomics: still rocking after all these years? Pharmacogenomics. 2011 Feb;12(2):251-65.
DMUM7HZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21332317

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	DEASG0Q
DMUM7HZ	MN	Thymidylate synthase (TYMS)
DMUM7HZ	MT	DME
DMUM7HZ	MA	Metabolism
DMUM7HZ	RN	5-Fluorouracil pharmacogenomics: still rocking after all these years? Pharmacogenomics. 2011 Feb;12(2):251-65.
DMUM7HZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21332317

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	TTP1UKZ
DMUM7HZ	MN	Thymidylate synthase messenger RNA (TYMS mRNA)
DMUM7HZ	MT	DTT
DMUM7HZ	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DMUM7HZ	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	DE20ETR
DMUM7HZ	MN	Uracil phosphoribosyltransferase (UPRT)
DMUM7HZ	MT	DME
DMUM7HZ	MA	Metabolism
DMUM7HZ	RN	Combined suicide gene therapy for human colon cancer cells using adenovirus-mediated transfer of escherichia coli cytosine deaminase gene and Escherichia coli uracil phosphoribosyltransferase gene with 5-fluorocytosine. Cancer Gene Ther. 2000 Jul;7(7):1015-22.
DMUM7HZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10917204

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	DEWJYTE
DMUM7HZ	MN	Uridine 5'-monophosphate synthase (UMPS)
DMUM7HZ	MT	DME
DMUM7HZ	MA	Metabolism
DMUM7HZ	RN	Orotate phosphoribosyltransferase is overexpressed in malignant pleural mesothelioma: Dramatically responds one case in high OPRT expression. Rare Dis. 2016 Apr 5;4(1):e1165909.
DMUM7HZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27274438

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	DEFZWAX
DMUM7HZ	MN	Uridine phosphorylase 1 (UPP1)
DMUM7HZ	MT	DME
DMUM7HZ	MA	Metabolism
DMUM7HZ	RN	Uridine phosphorylase in breast cancer: a new prognostic factor? Front Biosci. 2006 Sep 1;11:2759-66.
DMUM7HZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16720348

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	DEBQ2WU
DMUM7HZ	MN	Uridine phosphorylase 2 (UPP2)
DMUM7HZ	MT	DME
DMUM7HZ	MA	Metabolism
DMUM7HZ	RN	Uridine phosphorylase in breast cancer: a new prognostic factor? Front Biosci. 2006 Sep 1;11:2759-66.
DMUM7HZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16720348

DM3PD2C	DI	DM3PD2C
DM3PD2C	DN	Fluoxetine
DM3PD2C	MI	DEJGDUW
DM3PD2C	MN	Cytochrome P450 1A2 (CYP1A2)
DM3PD2C	MT	DME
DM3PD2C	MA	Metabolism
DM3PD2C	RN	Clinically significant psychotropic drug-drug interactions in the primary care setting. Curr Psychiatry Rep. 2012 Aug;14(4):376-90.
DM3PD2C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22707017

DM3PD2C	DI	DM3PD2C
DM3PD2C	DN	Fluoxetine
DM3PD2C	MI	DEPKLMQ
DM3PD2C	MN	Cytochrome P450 2B6 (CYP2B6)
DM3PD2C	MT	DME
DM3PD2C	MA	Metabolism
DM3PD2C	RN	Molecular characterization of CYP2B6 substrates. Curr Drug Metab. 2008 Jun;9(5):363-73.
DM3PD2C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18537573

DM3PD2C	DI	DM3PD2C
DM3PD2C	DN	Fluoxetine
DM3PD2C	MI	DE5IED8
DM3PD2C	MN	Cytochrome P450 2C9 (CYP2C9)
DM3PD2C	MT	DME
DM3PD2C	MA	Metabolism
DM3PD2C	RN	Binding of CYP2C9 with diverse drugs and its implications for metabolic mechanism. Med Chem. 2009 May;5(3):263-70.
DM3PD2C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19442216

DM3PD2C	DI	DM3PD2C
DM3PD2C	DN	Fluoxetine
DM3PD2C	MI	DECB0K3
DM3PD2C	MN	Cytochrome P450 2D6 (CYP2D6)
DM3PD2C	MT	DME
DM3PD2C	MA	Metabolism
DM3PD2C	RN	(R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos. 2000 Oct;28(10):1187-91.
DM3PD2C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10997938

DM3PD2C	DI	DM3PD2C
DM3PD2C	DN	Fluoxetine
DM3PD2C	MI	DEVDYN7
DM3PD2C	MN	Cytochrome P450 2E1 (CYP2E1)
DM3PD2C	MT	DME
DM3PD2C	MA	Metabolism
DM3PD2C	RN	Antidepressant drugs in the elderly--role of the cytochrome P450 2D6. World J Biol Psychiatry. 2003 Apr;4(2):74-80.
DM3PD2C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12692778

DM3PD2C	DI	DM3PD2C
DM3PD2C	DN	Fluoxetine
DM3PD2C	MI	DE4LYSA
DM3PD2C	MN	Cytochrome P450 3A4 (CYP3A4)
DM3PD2C	MT	DME
DM3PD2C	MA	Metabolism
DM3PD2C	RN	O-Dealkylation of fluoxetine in relation to CYP2C19 gene dose and involvement of CYP3A4 in human liver microsomes. J Pharmacol Exp Ther. 2002 Jan;300(1):105-11.
DM3PD2C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11752104

DM3PD2C	DI	DM3PD2C
DM3PD2C	DN	Fluoxetine
DM3PD2C	MI	DEIBDNY
DM3PD2C	MN	Cytochrome P450 3A5 (CYP3A5)
DM3PD2C	MT	DME
DM3PD2C	MA	Metabolism
DM3PD2C	RN	(R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos. 2000 Oct;28(10):1187-91.
DM3PD2C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10997938

DM3PD2C	DI	DM3PD2C
DM3PD2C	DN	Fluoxetine
DM3PD2C	MI	DEGTFWK
DM3PD2C	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM3PD2C	MT	DME
DM3PD2C	MA	Metabolism
DM3PD2C	RN	Effects of CYP2C19 genotype and CYP2C9 on fluoxetine N-demethylation in human liver microsomes. Acta Pharmacol Sin. 2001 Jan;22(1):85-90.
DM3PD2C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11730569

DM3PD2C	DI	DM3PD2C
DM3PD2C	DN	Fluoxetine
DM3PD2C	MI	DTUGYRD
DM3PD2C	MN	P-glycoprotein 1 (ABCB1)
DM3PD2C	MT	DTP
DM3PD2C	MA	Substrate
DM3PD2C	RN	Fluoxetine and reversal of multidrug resistance. Cancer Lett. 2006 Jun 18;237(2):180-7.
DM3PD2C	RU	https://doi.org/10.1016/j.canlet.2005.06.003

DM3PD2C	DI	DM3PD2C
DM3PD2C	DN	Fluoxetine
DM3PD2C	MI	TT3ROYC
DM3PD2C	MN	Serotonin transporter (SERT)
DM3PD2C	MT	DTT
DM3PD2C	MA	Modulator
DM3PD2C	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM3PD2C	RU	https://www.fda.gov/

DMUHCF1	DI	DMUHCF1
DMUHCF1	DN	Fluoxymesterone
DMUHCF1	MI	TTS64P2
DMUHCF1	MN	Androgen receptor (AR)
DMUHCF1	MT	DTT
DMUHCF1	MA	Agonist
DMUHCF1	RN	An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology. 2007 Jan;148(1):363-73.
DMUHCF1	RU	https://pubmed.ncbi.nlm.nih.gov/17023534

DMUHCF1	DI	DMUHCF1
DMUHCF1	DN	Fluoxymesterone
DMUHCF1	MI	DE4LYSA
DMUHCF1	MN	Cytochrome P450 3A4 (CYP3A4)
DMUHCF1	MT	DME
DMUHCF1	MA	Metabolism
DMUHCF1	RN	Effect of dexamethasone on cytochrome P-450 mediated metabolism of 2-acetylaminofluorene in cultured rat hepatocytes. Biochem Pharmacol. 1987 Jan 15;36(2):237-43.
DMUHCF1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=2880590

DM0DJ9O	DI	DM0DJ9O
DM0DJ9O	DN	Flupentixol
DM0DJ9O	MI	DTUGYRD
DM0DJ9O	MN	P-glycoprotein 1 (ABCB1)
DM0DJ9O	MT	DTP
DM0DJ9O	MA	Substrate
DM0DJ9O	RN	Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
DM0DJ9O	RU	http://www.ncbi.nlm.nih.gov/pubmed/15285840

DMIT8LX	DI	DMIT8LX
DMIT8LX	DN	Fluphenazine
DMIT8LX	MI	TTK8CXU
DMIT8LX	MN	5-HT 1B receptor (HTR1B)
DMIT8LX	MT	DTT
DMIT8LX	MA	Modulator
DMIT8LX	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMIT8LX	RU	https://www.fda.gov/

DMIT8LX	DI	DMIT8LX
DMIT8LX	DN	Fluphenazine
DMIT8LX	MI	DECB0K3
DMIT8LX	MN	Cytochrome P450 2D6 (CYP2D6)
DMIT8LX	MT	DME
DMIT8LX	MA	Metabolism
DMIT8LX	RN	Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos. 1999 Sep;27(9):1078-84.
DMIT8LX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10460810

DMIT8LX	DI	DMIT8LX
DMIT8LX	DN	Fluphenazine
DMIT8LX	MI	DTUGYRD
DMIT8LX	MN	P-glycoprotein 1 (ABCB1)
DMIT8LX	MT	DTP
DMIT8LX	MA	Substrate
DMIT8LX	RN	Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
DMIT8LX	RU	http://www.ncbi.nlm.nih.gov/pubmed/15285840

DMZWBKG	DI	DMZWBKG
DMZWBKG	DN	Fluprednisolone
DMZWBKG	MI	DE4LYSA
DMZWBKG	MN	Cytochrome P450 3A4 (CYP3A4)
DMZWBKG	MT	DME
DMZWBKG	MA	Metabolism
DMZWBKG	RN	NCIthesaurus: Fluprednisolone
DMZWBKG	RU	https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=18.06d&code=C65730&ns=ncit&type=relationship&key=null&b=1&n=0&vse=null

DMHCI9S	DI	DMHCI9S
DMHCI9S	DN	Flurandrenolide
DMHCI9S	MI	DE4LYSA
DMHCI9S	MN	Cytochrome P450 3A4 (CYP3A4)
DMHCI9S	MT	DME
DMHCI9S	MA	Metabolism
DMHCI9S	RN	Prediction of cytochrome P450 isoform responsible for metabolizing a drug molecule. BMC Pharmacol. 2010 Jul 16;10:8.
DMHCI9S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20637097

DMHCI9S	DI	DMHCI9S
DMHCI9S	DN	Flurandrenolide
DMHCI9S	MI	TTP3UTW
DMHCI9S	MN	Steroid hormone receptor ERR (ESRR)
DMHCI9S	MT	DTT
DMHCI9S	MA	Modulator
DMHCI9S	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMHCI9S	RU	https://www.fda.gov/

DMAL4G0	DI	DMAL4G0
DMAL4G0	DN	Flurazepam
DMAL4G0	MI	DEJVYAZ
DMAL4G0	MN	Cytochrome P450 2A6 (CYP2A6)
DMAL4G0	MT	DME
DMAL4G0	MA	Metabolism
DMAL4G0	RN	Is 1-aminobenzotriazole an appropriate in vitro tool as a nonspecific cytochrome P450 inactivator? Drug Metab Dispos. 2009 Jan;37(1):10-3.
DMAL4G0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18936109

DMAL4G0	DI	DMAL4G0
DMAL4G0	DN	Flurazepam
DMAL4G0	MI	DE4LYSA
DMAL4G0	MN	Cytochrome P450 3A4 (CYP3A4)
DMAL4G0	MT	DME
DMAL4G0	MA	Metabolism
DMAL4G0	RN	Is 1-aminobenzotriazole an appropriate in vitro tool as a nonspecific cytochrome P450 inactivator? Drug Metab Dispos. 2009 Jan;37(1):10-3.
DMAL4G0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18936109

DMAL4G0	DI	DMAL4G0
DMAL4G0	DN	Flurazepam
DMAL4G0	MI	TTPTXIN
DMAL4G0	MN	Translocator protein (TSPO)
DMAL4G0	MT	DTT
DMAL4G0	MA	Modulator
DMAL4G0	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMAL4G0	RU	https://www.fda.gov/

DMGN4BY	DI	DMGN4BY
DMGN4BY	DN	Flurbiprofen
DMGN4BY	MI	DE5IED8
DMGN4BY	MN	Cytochrome P450 2C9 (CYP2C9)
DMGN4BY	MT	DME
DMGN4BY	MA	Metabolism
DMGN4BY	RN	Effect of CYP2C9 genetic polymorphism on the metabolism of flurbiprofen in vitro. Drug Dev Ind Pharm. 2015;41(8):1363-7.
DMGN4BY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25144335

DMGN4BY	DI	DMGN4BY
DMGN4BY	DN	Flurbiprofen
DMGN4BY	MI	TTVKILB
DMGN4BY	MN	Prostaglandin G/H synthase 2 (COX-2)
DMGN4BY	MT	DTT
DMGN4BY	MA	Modulator
DMGN4BY	RN	Flurbiprofen, a cyclooxygenase inhibitor, protects mice from hepatic ischemia/reperfusion injury by inhibiting GSK-3 signaling and mitochondrial permeability transition.Mol Med.2012 Sep 25;18:1128-35.
DMGN4BY	RU	https://www.ncbi.nlm.nih.gov/pubmed/22714712

DMGN4BY	DI	DMGN4BY
DMGN4BY	DN	Flurbiprofen
DMGN4BY	MI	DEYGVN4
DMGN4BY	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMGN4BY	MT	DME
DMGN4BY	MA	Metabolism
DMGN4BY	RN	Predominant contribution of UDP-glucuronosyltransferase 2B7 in the glucuronidation of racemic flurbiprofen in the human liver. Drug Metab Dispos. 2007 Jul;35(7):1182-7.
DMGN4BY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17446261

DMGN4BY	DI	DMGN4BY
DMGN4BY	DN	Flurbiprofen
DMGN4BY	MI	DEF2WXN
DMGN4BY	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMGN4BY	MT	DME
DMGN4BY	MA	Metabolism
DMGN4BY	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMGN4BY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMGN4BY	DI	DMGN4BY
DMGN4BY	DN	Flurbiprofen
DMGN4BY	MI	DE85D2P
DMGN4BY	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMGN4BY	MT	DME
DMGN4BY	MA	Metabolism
DMGN4BY	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMGN4BY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMGN4BY	DI	DMGN4BY
DMGN4BY	DN	Flurbiprofen
DMGN4BY	MI	DEB3CV1
DMGN4BY	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMGN4BY	MT	DME
DMGN4BY	MA	Metabolism
DMGN4BY	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMGN4BY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMFO843	DI	DMFO843
DMFO843	DN	Fluspirilene
DMFO843	MI	DE4LYSA
DMFO843	MN	Cytochrome P450 3A4 (CYP3A4)
DMFO843	MT	DME
DMFO843	MA	Metabolism
DMFO843	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DMFO843	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DMFO843	DI	DMFO843
DMFO843	DN	Fluspirilene
DMFO843	MI	TTEX248
DMFO843	MN	Dopamine D2 receptor (D2R)
DMFO843	MT	DTT
DMFO843	MA	Antagonist
DMFO843	RN	Inhibition of glutamate release by fluspirilene in cerebrocortical nerve terminals (synaptosomes). Synapse. 2002 Apr;44(1):36-41.
DMFO843	RU	https://pubmed.ncbi.nlm.nih.gov/11842444

DMK0O7U	DI	DMK0O7U
DMK0O7U	DN	Flutamide
DMK0O7U	MI	TTS64P2
DMK0O7U	MN	Androgen receptor (AR)
DMK0O7U	MT	DTT
DMK0O7U	MA	Antagonist
DMK0O7U	RN	Androgen receptor as a target in androgen-independent prostate cancer. Urology. 2002 Sep;60(3 Suppl 1):132-8; discussion 138-9.
DMK0O7U	RU	https://pubmed.ncbi.nlm.nih.gov/12231070

DMK0O7U	DI	DMK0O7U
DMK0O7U	DN	Flutamide
DMK0O7U	MI	DE6OQ3W
DMK0O7U	MN	Cytochrome P450 1A1 (CYP1A1)
DMK0O7U	MT	DME
DMK0O7U	MA	Metabolism
DMK0O7U	RN	Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther. 2001 Feb;296(2):537-41.
DMK0O7U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11160641

DMK0O7U	DI	DMK0O7U
DMK0O7U	DN	Flutamide
DMK0O7U	MI	DEJGDUW
DMK0O7U	MN	Cytochrome P450 1A2 (CYP1A2)
DMK0O7U	MT	DME
DMK0O7U	MA	Metabolism
DMK0O7U	RN	Metabolism of the antiandrogenic drug (Flutamide) by human CYP1A2. Drug Metab Dispos. 1997 Nov;25(11):1298-303.
DMK0O7U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9351907

DMK0O7U	DI	DMK0O7U
DMK0O7U	DN	Flutamide
DMK0O7U	MI	DE9QHP6
DMK0O7U	MN	Cytochrome P450 1B1 (CYP1B1)
DMK0O7U	MT	DME
DMK0O7U	MA	Metabolism
DMK0O7U	RN	Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther. 2001 Feb;296(2):537-41.
DMK0O7U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11160641

DMK0O7U	DI	DMK0O7U
DMK0O7U	DN	Flutamide
DMK0O7U	MI	DE4LYSA
DMK0O7U	MN	Cytochrome P450 3A4 (CYP3A4)
DMK0O7U	MT	DME
DMK0O7U	MA	Metabolism
DMK0O7U	RN	Identification of a novel glutathione conjugate of flutamide in incubations with human liver microsomes. Drug Metab Dispos. 2007 Jul;35(7):1081-8.
DMK0O7U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17403914

DMK0O7U	DI	DMK0O7U
DMK0O7U	DN	Flutamide
DMK0O7U	MI	DEIBDNY
DMK0O7U	MN	Cytochrome P450 3A5 (CYP3A5)
DMK0O7U	MT	DME
DMK0O7U	MA	Metabolism
DMK0O7U	RN	Identification of a novel glutathione conjugate of flutamide in incubations with human liver microsomes. Drug Metab Dispos. 2007 Jul;35(7):1081-8.
DMK0O7U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17403914

DMK0O7U	DI	DMK0O7U
DMK0O7U	DN	Flutamide
DMK0O7U	MI	DEGTFWK
DMK0O7U	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMK0O7U	MT	DME
DMK0O7U	MA	Metabolism
DMK0O7U	RN	Identification of a novel glutathione conjugate of flutamide in incubations with human liver microsomes. Drug Metab Dispos. 2007 Jul;35(7):1081-8.
DMK0O7U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17403914

DMK0O7U	DI	DMK0O7U
DMK0O7U	DN	Flutamide
DMK0O7U	MI	DTSYQGK
DMK0O7U	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMK0O7U	MT	DTP
DMK0O7U	MA	Substrate
DMK0O7U	RN	The multidrug resistance-associated protein 1 transports methoxychlor and protects the seminiferous epithelium from injury. Toxicol Lett. 2003 Apr 30;142(1-2):61-70.
DMK0O7U	RU	https://doi.org/10.1016/S0378-4274(02)00485-X

DMGCSVF	DI	DMGCSVF
DMGCSVF	DN	Fluticasone
DMGCSVF	MI	DE4LYSA
DMGCSVF	MN	Cytochrome P450 3A4 (CYP3A4)
DMGCSVF	MT	DME
DMGCSVF	MA	Metabolism
DMGCSVF	RN	Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35.
DMGCSVF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20482443

DMGCSVF	DI	DMGCSVF
DMGCSVF	DN	Fluticasone
DMGCSVF	MI	DEIBDNY
DMGCSVF	MN	Cytochrome P450 3A5 (CYP3A5)
DMGCSVF	MT	DME
DMGCSVF	MA	Metabolism
DMGCSVF	RN	Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35.
DMGCSVF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20482443

DMGCSVF	DI	DMGCSVF
DMGCSVF	DN	Fluticasone
DMGCSVF	MI	DERD86B
DMGCSVF	MN	Cytochrome P450 3A7 (CYP3A7)
DMGCSVF	MT	DME
DMGCSVF	MA	Metabolism
DMGCSVF	RN	Biotransformation of fluticasone: in vitro characterization. Drug Metab Dispos. 2006 Jun;34(6):1035-40.
DMGCSVF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16565171

DMGCSVF	DI	DMGCSVF
DMGCSVF	DN	Fluticasone
DMGCSVF	MI	TTYRL6O
DMGCSVF	MN	Glucocorticoid receptor (NR3C1)
DMGCSVF	MT	DTT
DMGCSVF	MA	Antagonist
DMGCSVF	RN	Fluticasone furoate nasal spray in allergic rhinitis. Drugs Today (Barc). 2008 Apr;44(4):251-60.
DMGCSVF	RU	https://pubmed.ncbi.nlm.nih.gov/18536783

DMRWLB2	DI	DMRWLB2
DMRWLB2	DN	Fluticasone propionate
DMRWLB2	MI	DTUGYRD
DMRWLB2	MN	P-glycoprotein 1 (ABCB1)
DMRWLB2	MT	DTP
DMRWLB2	MA	Substrate
DMRWLB2	RN	Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux. Toxicol Appl Pharmacol. 2012 May 1;260(3):294-302.
DMRWLB2	RU	https://doi.org/10.1016/j.taap.2012.03.008

DMU54C3	DI	DMU54C3
DMU54C3	DN	Flutropium bromide
DMU54C3	MI	TTH18TF
DMU54C3	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMU54C3	MT	DTT
DMU54C3	MA	Modulator
DMU54C3	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMU54C3	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DM4MDJY	DI	DM4MDJY
DM4MDJY	DN	Fluvastatin
DM4MDJY	MI	DTI7UX6
DM4MDJY	MN	Breast cancer resistance protein (ABCG2)
DM4MDJY	MT	DTP
DM4MDJY	MA	Substrate
DM4MDJY	RN	Evaluation of the usefulness of breast cancer resistance protein (BCRP) knockout mice and BCRP inhibitor-treated monkeys to estimate the clinical impact of BCRP modulation on the pharmacokinetics of BCRP substrates. Pharm Res. 2015 May;32(5):1634-47.
DM4MDJY	RU	http://www.ncbi.nlm.nih.gov/pubmed/25380981

DM4MDJY	DI	DM4MDJY
DM4MDJY	DN	Fluvastatin
DM4MDJY	MI	DE6OQ3W
DM4MDJY	MN	Cytochrome P450 1A1 (CYP1A1)
DM4MDJY	MT	DME
DM4MDJY	MA	Metabolism
DM4MDJY	RN	Regulation of cytochrome P450 expression by inhibitors of hydroxymethylglutaryl-coenzyme A reductase in primary cultured rat hepatocytes and in rat liver. Drug Metab Dispos. 1996 Nov;24(11):1197-204.
DM4MDJY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8937853

DM4MDJY	DI	DM4MDJY
DM4MDJY	DN	Fluvastatin
DM4MDJY	MI	DES5XRU
DM4MDJY	MN	Cytochrome P450 2C8 (CYP2C8)
DM4MDJY	MT	DME
DM4MDJY	MA	Metabolism
DM4MDJY	RN	Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8. Basic Clin Pharmacol Toxicol. 2005 Aug;97(2):104-8.
DM4MDJY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15998357

DM4MDJY	DI	DM4MDJY
DM4MDJY	DN	Fluvastatin
DM4MDJY	MI	DE5IED8
DM4MDJY	MN	Cytochrome P450 2C9 (CYP2C9)
DM4MDJY	MT	DME
DM4MDJY	MA	Metabolism
DM4MDJY	RN	Limitations of S-warfarin truncated area under the concentration-time curve to predict cytochrome P450 2c9 activity. Drug Metab Lett. 2012 Jun 1;6(2):94-101.
DM4MDJY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22594566

DM4MDJY	DI	DM4MDJY
DM4MDJY	DN	Fluvastatin
DM4MDJY	MI	DECB0K3
DM4MDJY	MN	Cytochrome P450 2D6 (CYP2D6)
DM4MDJY	MT	DME
DM4MDJY	MA	Metabolism
DM4MDJY	RN	Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet. 2001;40(4):263-81.
DM4MDJY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11368292

DM4MDJY	DI	DM4MDJY
DM4MDJY	DN	Fluvastatin
DM4MDJY	MI	DE4LYSA
DM4MDJY	MN	Cytochrome P450 3A4 (CYP3A4)
DM4MDJY	MT	DME
DM4MDJY	MA	Metabolism
DM4MDJY	RN	Effects of fluvastatin on the pharmacokinetics of eepaglinide: possible role of CYP3A4 and P-glycoprotein inhibition by fluvastatin. Korean J Physiol Pharmacol. 2013 Jun;17(3):245-51.
DM4MDJY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23776402

DM4MDJY	DI	DM4MDJY
DM4MDJY	DN	Fluvastatin
DM4MDJY	MI	DEIBDNY
DM4MDJY	MN	Cytochrome P450 3A5 (CYP3A5)
DM4MDJY	MT	DME
DM4MDJY	MA	Metabolism
DM4MDJY	RN	Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics. 2004 Aug;14(8):523-5.
DM4MDJY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15284534

DM4MDJY	DI	DM4MDJY
DM4MDJY	DN	Fluvastatin
DM4MDJY	MI	TTPADOQ
DM4MDJY	MN	HMG-CoA reductase (HMGCR)
DM4MDJY	MT	DTT
DM4MDJY	MA	Inhibitor
DM4MDJY	RN	Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64.
DM4MDJY	RU	https://pubmed.ncbi.nlm.nih.gov/11523064

DM4MDJY	DI	DM4MDJY
DM4MDJY	DN	Fluvastatin
DM4MDJY	MI	DT3D8F0
DM4MDJY	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM4MDJY	MT	DTP
DM4MDJY	MA	Substrate
DM4MDJY	RN	SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther. 2006 Oct;80(4):356-66.
DM4MDJY	RU	http://www.ncbi.nlm.nih.gov/pubmed/17015053

DM4MDJY	DI	DM4MDJY
DM4MDJY	DN	Fluvastatin
DM4MDJY	MI	DT9C1TS
DM4MDJY	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM4MDJY	MT	DTP
DM4MDJY	MA	Substrate
DM4MDJY	RN	Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos. 2007 Aug;35(8):1308-14.
DM4MDJY	RU	http://www.ncbi.nlm.nih.gov/pubmed/17470528

DM4MDJY	DI	DM4MDJY
DM4MDJY	DN	Fluvastatin
DM4MDJY	MI	DTPFTEQ
DM4MDJY	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DM4MDJY	MT	DTP
DM4MDJY	MA	Substrate
DM4MDJY	RN	Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos. 2007 Aug;35(8):1308-14.
DM4MDJY	RU	http://www.ncbi.nlm.nih.gov/pubmed/17470528

DM4MDJY	DI	DM4MDJY
DM4MDJY	DN	Fluvastatin
DM4MDJY	MI	DTUGYRD
DM4MDJY	MN	P-glycoprotein 1 (ABCB1)
DM4MDJY	MT	DTP
DM4MDJY	MA	Substrate
DM4MDJY	RN	A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26.
DM4MDJY	RU	https://doi.org/10.1007/s00210-008-0345-0

DMQTJSX	DI	DMQTJSX
DMQTJSX	DN	Fluvoxamine
DMQTJSX	MI	DTUGYRD
DMQTJSX	MN	P-glycoprotein 1 (ABCB1)
DMQTJSX	MT	DTP
DMQTJSX	MA	Substrate
DMQTJSX	RN	Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
DMQTJSX	RU	http://www.ncbi.nlm.nih.gov/pubmed/15285840

DMQTJSX	DI	DMQTJSX
DMQTJSX	DN	Fluvoxamine
DMQTJSX	MI	TT3ROYC
DMQTJSX	MN	Serotonin transporter (SERT)
DMQTJSX	MT	DTT
DMQTJSX	MA	Inhibitor
DMQTJSX	RN	Changes of functional MRI findings in a patient whose pathological gambling improved with fluvoxamine. Yonsei Med J. 2009 Jun 30;50(3):441-4.
DMQTJSX	RU	https://pubmed.ncbi.nlm.nih.gov/19568609

DM2PSBE	DI	DM2PSBE
DM2PSBE	DN	Focetria A(H1N1)
DM2PSBE	MI	TT3J5ZI
DM2PSBE	MN	Cell mediated immunity response (CMIR)
DM2PSBE	MT	DTT
DM2PSBE	RN	Influenza A/H1N1 MF59 adjuvanted vaccine in pregnant women and adverse perinatal outcomes: multicentre study. BMJ. 2013 Feb 4;346:f393.
DM2PSBE	RU	https://pubmed.ncbi.nlm.nih.gov/23381200

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DTI7UX6
DMEMBJC	MN	Breast cancer resistance protein (ABCG2)
DMEMBJC	MT	DTP
DMEMBJC	MA	Substrate
DMEMBJC	RN	The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
DMEMBJC	RU	http://www.ncbi.nlm.nih.gov/pubmed/17032904

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DEVDYN7
DMEMBJC	MN	Cytochrome P450 2E1 (CYP2E1)
DMEMBJC	MT	DME
DMEMBJC	MA	Metabolism
DMEMBJC	RN	Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G54-63.
DMEMBJC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15705656

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DE4EGMZ
DMEMBJC	MN	Dihydrofolate reductase (DHFR)
DMEMBJC	MT	DME
DMEMBJC	MA	Metabolism
DMEMBJC	RN	The dihydrofolate reductase 19 bp polymorphism is not associated with biomarkers of folate status in healthy young adults, irrespective of folic acid intake. J Nutr. 2015 Oct;145(10):2207-11.
DMEMBJC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26269242

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DERGIEC
DMEMBJC	MN	Dihydrofolate reductase (folA)
DMEMBJC	MT	DME
DMEMBJC	MA	Metabolism
DMEMBJC	RN	Measurement of the uptake of radioactive para-aminobenzoic acid monitors folate biosynthesis in Escherichia coli K-12. Anal Biochem. 1994 Feb 1;216(2):427-30.
DMEMBJC	RU	https://pubmed.ncbi.nlm.nih.gov/8179200

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DEEBFXM
DMEMBJC	MN	Dihydrofolate reductase (folA)
DMEMBJC	MT	DME
DMEMBJC	MA	Metabolism
DMEMBJC	RN	Molecular cloning of the gene for dihydrofolate reductase from Lactobacillus casei. Gene. 1982 Feb;17(2):229-33.
DMEMBJC	RU	https://pubmed.ncbi.nlm.nih.gov/6282715

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DE1GYMX
DMEMBJC	MN	Dihydrofolate reductase (folA)
DMEMBJC	MT	DME
DMEMBJC	MA	Metabolism
DMEMBJC	RN	Biophysical principles predict fitness landscapes of drug resistance. Proc Natl Acad Sci U S A. 2016 Mar 15;113(11):E1470-8.
DMEMBJC	RU	https://pubmed.ncbi.nlm.nih.gov/26929328

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	TTQOD3G
DMEMBJC	MN	Folate receptor (FOLR)
DMEMBJC	MT	DTT
DMEMBJC	MA	Binder
DMEMBJC	RN	Gamma-glutamyl hydrolase and drug resistance. Clin Chim Acta. 2006 Dec;374(1-2):25-32.
DMEMBJC	RU	https://pubmed.ncbi.nlm.nih.gov/16859665

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DTOSN46
DMEMBJC	MN	Folate transporter 1 (SLC19A1)
DMEMBJC	MT	DTP
DMEMBJC	MA	Substrate
DMEMBJC	RN	Biology of the major facilitative folate transporters SLC19A1 and SLC46A1. Curr Top Membr. 2014;73:175-204.
DMEMBJC	RU	http://www.ncbi.nlm.nih.gov/pubmed/24745983

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DEW0GI5
DMEMBJC	MN	Folylpolyglutamate synthetase (fpgS)
DMEMBJC	MT	DME
DMEMBJC	MA	Metabolism
DMEMBJC	RN	Mutagenesis of folylpolyglutamate synthetase indicates that dihydropteroate and tetrahydrofolate bind to the same site. Biochemistry. 2008 Feb 26;47(8):2388-96.
DMEMBJC	RU	https://pubmed.ncbi.nlm.nih.gov/18232714

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DEU7MWJ
DMEMBJC	MN	Gamma-Glu-X carboxypeptidase (GGH)
DMEMBJC	MT	DME
DMEMBJC	MA	Metabolism
DMEMBJC	RN	Optimization of the trienzyme extraction for the microbiological assay of folate in vegetables. J Agric Food Chem. 2007 May 16;55(10):3884-8.
DMEMBJC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17439143

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DE6NIY9
DMEMBJC	MN	Methionine synthase reductase (MTRR)
DMEMBJC	MT	DME
DMEMBJC	MA	Metabolism
DMEMBJC	RN	Polymorphisms in genes involved in folate metabolism as maternal risk factors for Down syndrome in China. J Zhejiang Univ Sci B. 2008 Feb;9(2):93-9.
DMEMBJC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18257130

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DEOXTPZ
DMEMBJC	MN	Methylenetetrahydrofolate reductase (MTHFR)
DMEMBJC	MT	DME
DMEMBJC	MA	Metabolism
DMEMBJC	RN	Genetic variation: impact on folate (and choline) bioefficacy. Int J Vitam Nutr Res. 2010 Oct;80(4-5):319-29.
DMEMBJC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21462116

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DTM8E7H
DMEMBJC	MN	Mitochondrial folate transporter/carrier (SLC25A32)
DMEMBJC	MT	DTP
DMEMBJC	MA	Substrate
DMEMBJC	RN	Polymorphism of SLC25A32, the folate transporter gene, is associated with plasma folate levels and bone fractures in Japanese postmenopausal women. Geriatr Gerontol Int. 2014 Oct;14(4):942-6.
DMEMBJC	RU	http://www.ncbi.nlm.nih.gov/pubmed/24354357

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DTSYQGK
DMEMBJC	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMEMBJC	MT	DTP
DMEMBJC	MA	Substrate
DMEMBJC	RN	Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1). Biochem Pharmacol. 2004 Apr 15;67(8):1541-8.
DMEMBJC	RU	http://www.ncbi.nlm.nih.gov/pubmed/15041471

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DTFI42L
DMEMBJC	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMEMBJC	MT	DTP
DMEMBJC	MA	Substrate
DMEMBJC	RN	Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
DMEMBJC	RU	https://doi.org/10.1042/bse0500179

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DTQ3ZHF
DMEMBJC	MN	Multidrug resistance-associated protein 3 (ABCC3)
DMEMBJC	MT	DTP
DMEMBJC	MA	Substrate
DMEMBJC	RN	Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.
DMEMBJC	RU	http://www.ncbi.nlm.nih.gov/pubmed/11585759

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DTCSGPB
DMEMBJC	MN	Multidrug resistance-associated protein 4 (ABCC4)
DMEMBJC	MT	DTP
DMEMBJC	MA	Substrate
DMEMBJC	RN	Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 2002 Jun 1;62(11):3144-50.
DMEMBJC	RU	http://www.ncbi.nlm.nih.gov/pubmed/12036927

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DTYVM24
DMEMBJC	MN	Multidrug resistance-associated protein 5 (ABCC5)
DMEMBJC	MT	DTP
DMEMBJC	MA	Substrate
DMEMBJC	RN	The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Res. 2005 May 15;65(10):4425-30.
DMEMBJC	RU	http://www.ncbi.nlm.nih.gov/pubmed/15899835

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DTUGYRD
DMEMBJC	MN	P-glycoprotein 1 (ABCB1)
DMEMBJC	MT	DTP
DMEMBJC	MA	Substrate
DMEMBJC	RN	Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
DMEMBJC	RU	http://www.ncbi.nlm.nih.gov/pubmed/26105097

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	TTY8Z2E
DMEMBJC	MN	Proton-coupled folate transporter (SLC46A1)
DMEMBJC	MT	DTT
DMEMBJC	MA	Modulator
DMEMBJC	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1213).
DMEMBJC	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1213

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DTDJEMI
DMEMBJC	MN	Proton-coupled folate transporter (SLC46A1)
DMEMBJC	MT	DTP
DMEMBJC	MA	Substrate
DMEMBJC	RN	Characterization of uptake of folates by rat and human blood-brain barrier endothelial cells. Biofactors. 2010 May-Jun;36(3):201-9.
DMEMBJC	RU	http://www.ncbi.nlm.nih.gov/pubmed/20232349

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DEZV4AP
DMEMBJC	MN	RNA cytidine acetyltransferase (hALP)
DMEMBJC	MT	DME
DMEMBJC	MA	Metabolism
DMEMBJC	RN	Arylamine N-acetyltransferase in human red blood cells. Biochem Pharmacol. 1992 Sep 25;44(6):1099-104.
DMEMBJC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1329759

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DTKWJH3
DMEMBJC	MN	Sodium-coupled neutral amino acid transporter 3 (SLC38A3)
DMEMBJC	MT	DTP
DMEMBJC	MA	Substrate
DMEMBJC	RN	Purification of recombinant human N-acetyltransferase type 1 (NAT1) expressed in E. coli and characterization of its potential role in folate metabolism. Biochem Pharmacol. 1995 Jun 16;49(12):1759-67.
DMEMBJC	RU	http://www.ncbi.nlm.nih.gov/pubmed/7598738

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	TT09I7D
DMEMBJC	MN	Solute carrier family 19 member 1 (SLC19A1)
DMEMBJC	MT	DTT
DMEMBJC	MA	Modulator
DMEMBJC	RN	Increased activity of a novel low pH folate transporter associated with lipophilic antifolate resistance in chinese hamster ovary cells. J Biol Chem. 1998 Apr 3;273(14):8106-11.
DMEMBJC	RU	https://pubmed.ncbi.nlm.nih.gov/9525913

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DEWSHL5
DMEMBJC	MN	Vitamin B12 methionine synthase (MTR)
DMEMBJC	MT	DME
DMEMBJC	MA	Metabolism
DMEMBJC	RN	Metabolic derangement of methionine and folate metabolism in mice deficient in methionine synthase reductase. Mol Genet Metab. 2007 May;91(1):85-97.
DMEMBJC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17369066

DM2JTS5	DI	DM2JTS5
DM2JTS5	DN	Follitropin beta
DM2JTS5	MI	TTZFDBT
DM2JTS5	MN	Follicle-stimulating hormone receptor (FSHR)
DM2JTS5	MT	DTT
DM2JTS5	MA	Binder
DM2JTS5	RN	Follitropin-alpha (Gonal-F) versus follitropin-beta (Puregon) in controlled ovarian hyperstimulation for in vitro fertilization: is there any diffe... Fertil Steril. 2009 Apr;91(4 Suppl):1522-5.
DM2JTS5	RU	https://pubmed.ncbi.nlm.nih.gov/18851846

DM6VOWQ	DI	DM6VOWQ
DM6VOWQ	DN	Fomepizole
DM6VOWQ	MI	TT5AHZ0
DM6VOWQ	MN	Alcohol dehydrogenase 1A (ADH1A)
DM6VOWQ	MT	DTT
DM6VOWQ	MA	Modulator
DM6VOWQ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM6VOWQ	RU	https://www.fda.gov/

DM6VOWQ	DI	DM6VOWQ
DM6VOWQ	DN	Fomepizole
DM6VOWQ	MI	DEVDYN7
DM6VOWQ	MN	Cytochrome P450 2E1 (CYP2E1)
DM6VOWQ	MT	DME
DM6VOWQ	MA	Metabolism
DM6VOWQ	RN	Treatment of patients with ethylene glycol or methanol poisoning: focus on fomepizole. Open Access Emerg Med. 2010 Aug 24;2:67-75.
DM6VOWQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27147840

DMBEP7G	DI	DMBEP7G
DMBEP7G	DN	Fomivirsen sodium
DMBEP7G	MI	TT4SCBE
DMBEP7G	MN	Cytomegalovirus IE2 region messenger RNA (CMV IE2 mRNA)
DMBEP7G	MT	DTT
DMBEP7G	MA	Modulator
DMBEP7G	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMBEP7G	RU	https://www.fda.gov/

DMWS3FH	DI	DMWS3FH
DMWS3FH	DN	Fondaparinux sodium
DMWS3FH	MI	TTCIHJA
DMWS3FH	MN	Coagulation factor Xa (F10)
DMWS3FH	MT	DTT
DMWS3FH	MA	Inhibitor
DMWS3FH	RN	Biochemistry and clinical pharmacology of new anticoagulant agents. Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):218-24.
DMWS3FH	RU	https://pubmed.ncbi.nlm.nih.gov/13679646

DMRBJNZ	DI	DMRBJNZ
DMRBJNZ	DN	Forasartan
DMRBJNZ	MI	TT8DBY3
DMRBJNZ	MN	Angiotensin II receptor type-1 (AGTR1)
DMRBJNZ	MT	DTT
DMRBJNZ	MA	Antagonist
DMRBJNZ	RN	Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification. J Med Chem. 2003 Feb 27;46(5):716-26.
DMRBJNZ	RU	https://pubmed.ncbi.nlm.nih.gov/12593652

DMSOURV	DI	DMSOURV
DMSOURV	DN	Formoterol
DMSOURV	MI	TT2CJVK
DMSOURV	MN	Adrenergic receptor beta-2 (ADRB2)
DMSOURV	MT	DTT
DMSOURV	MA	Agonist
DMSOURV	RN	Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation. Cochrane Database Syst Rev. 2002;(3):CD001104.
DMSOURV	RU	https://pubmed.ncbi.nlm.nih.gov/12137617

DMSOURV	DI	DMSOURV
DMSOURV	DN	Formoterol
DMSOURV	MI	DE5IED8
DMSOURV	MN	Cytochrome P450 2C9 (CYP2C9)
DMSOURV	MT	DME
DMSOURV	MA	Metabolism
DMSOURV	RN	FDA Label of Formoterol. The 2020 official website of the U.S. Food and Drug Administration.
DMSOURV	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020831s028lbl.pdf

DMSOURV	DI	DMSOURV
DMSOURV	DN	Formoterol
DMSOURV	MI	DECB0K3
DMSOURV	MN	Cytochrome P450 2D6 (CYP2D6)
DMSOURV	MT	DME
DMSOURV	MA	Metabolism
DMSOURV	RN	A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes. Drug Metab Dispos. 2007 Oct;35(10):1797-805.
DMSOURV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17627976

DMSOURV	DI	DMSOURV
DMSOURV	DN	Formoterol
DMSOURV	MI	DEGTFWK
DMSOURV	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMSOURV	MT	DME
DMSOURV	MA	Metabolism
DMSOURV	RN	A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes. Drug Metab Dispos. 2007 Oct;35(10):1797-805.
DMSOURV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17627976

DMSOURV	DI	DMSOURV
DMSOURV	DN	Formoterol
DMSOURV	MI	DTT79CX
DMSOURV	MN	Organic cation transporter 1 (SLC22A1)
DMSOURV	MT	DTP
DMSOURV	MA	Substrate
DMSOURV	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMSOURV	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DM4W9B3	DI	DM4W9B3
DM4W9B3	DN	Fosamprenavir
DM4W9B3	MI	DE4LYSA
DM4W9B3	MN	Cytochrome P450 3A4 (CYP3A4)
DM4W9B3	MT	DME
DM4W9B3	MA	Metabolism
DM4W9B3	RN	Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin Pharmacokinet. 2006;45(2):137-68.
DM4W9B3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16485915

DM4W9B3	DI	DM4W9B3
DM4W9B3	DN	Fosamprenavir
DM4W9B3	MI	TT5FNQT
DM4W9B3	MN	Human immunodeficiency virus Protease (HIV PR)
DM4W9B3	MT	DTT
DM4W9B3	MA	Inhibitor
DM4W9B3	RN	Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in ... J Antimicrob Chemother. 2009 Aug;64(2):398-410.
DM4W9B3	RU	https://pubmed.ncbi.nlm.nih.gov/19515730

DM4W9B3	DI	DM4W9B3
DM4W9B3	DN	Fosamprenavir
DM4W9B3	MI	DTUGYRD
DM4W9B3	MN	P-glycoprotein 1 (ABCB1)
DM4W9B3	MT	DTP
DM4W9B3	MA	Substrate
DM4W9B3	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DM4W9B3	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DM9KJLZ	DI	DM9KJLZ
DM9KJLZ	DN	Foscavir
DM9KJLZ	MI	TTIU7X1
DM9KJLZ	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DM9KJLZ	MT	DTT
DM9KJLZ	MA	Inhibitor
DM9KJLZ	RN	Drug targets in cytomegalovirus infection. Infect Disord Drug Targets. 2009 Apr;9(2):201-22.
DM9KJLZ	RU	https://pubmed.ncbi.nlm.nih.gov/19275707

DMR0TYK	DI	DMR0TYK
DMR0TYK	DN	Fosdenopterin
DMR0TYK	MI	TT7RJY8
DMR0TYK	MN	Xanthine dehydrogenase/oxidase (XDH)
DMR0TYK	MT	DTT
DMR0TYK	MA	Cofactor
DMR0TYK	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2021
DMR0TYK	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214018s000lbl.pdf

DMD072M	DI	DMD072M
DMD072M	DN	Fosfestrol
DMD072M	MI	TTZAYWL
DMD072M	MN	Estrogen receptor (ESR)
DMD072M	MT	DTT
DMD072M	MA	Modulator
DMD072M	RN	Impact of natural products on developing new anti-cancer agents. Chem Rev. 2009 Jul;109(7):3012-43.
DMD072M	RU	https://pubmed.ncbi.nlm.nih.gov/19422222

DMVGPMX	DI	DMVGPMX
DMVGPMX	DN	Fosfomycin
DMVGPMX	MI	TTICX3S
DMVGPMX	MN	Bacterial UDP-N-acetylglucosamine carboxyvinyltransferase (Bact murA)
DMVGPMX	MT	DTT
DMVGPMX	MA	Inhibitor
DMVGPMX	RN	Evidence that the fosfomycin target Cys115 in UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) is essential for product release. J Biol Chem. 2005 Feb 4;280(5):3757-63.
DMVGPMX	RU	https://pubmed.ncbi.nlm.nih.gov/15531591

DMVGPMX	DI	DMVGPMX
DMVGPMX	DN	Fosfomycin
DMVGPMX	MI	DE4ZHS1
DMVGPMX	MN	Glutathione S-transferase alpha-1 (GSTA1)
DMVGPMX	MT	DME
DMVGPMX	MA	Metabolism
DMVGPMX	RN	Formation of an adduct between fosfomycin and glutathione: a new mechanism of antibiotic resistance in bacteria. Antimicrob Agents Chemother. 1988 Oct;32(10):1552-6.
DMVGPMX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=3056239

DMDIC39	DI	DMDIC39
DMDIC39	DN	Fosfosal
DMDIC39	MI	TTK0943
DMDIC39	MN	Prostaglandin G/H synthase (COX)
DMDIC39	MT	DTT
DMDIC39	MA	Modulator
DMDIC39	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMDIC39	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DM9NJ52	DI	DM9NJ52
DM9NJ52	DN	Fosinopril
DM9NJ52	MI	TTL69WB
DM9NJ52	MN	Angiotensin-converting enzyme (ACE)
DM9NJ52	MT	DTT
DM9NJ52	MA	Inhibitor
DM9NJ52	RN	Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. Am Heart J. 2009 Feb;157(2):334.e1-8.
DM9NJ52	RU	https://pubmed.ncbi.nlm.nih.gov/19185642

DM9NJ52	DI	DM9NJ52
DM9NJ52	DN	Fosinopril
DM9NJ52	MI	DT9G7XN
DM9NJ52	MN	Peptide transporter 1 (SLC15A1)
DM9NJ52	MT	DTP
DM9NJ52	MA	Substrate
DM9NJ52	RN	Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41.
DM9NJ52	RU	http://www.ncbi.nlm.nih.gov/pubmed/18713951

DM9NJ52	DI	DM9NJ52
DM9NJ52	DN	Fosinopril
DM9NJ52	MI	DT8QKNP
DM9NJ52	MN	Peptide transporter 2 (SLC15A2)
DM9NJ52	MT	DTP
DM9NJ52	MA	Substrate
DM9NJ52	RN	Mechanism of intestinal absorption and renal reabsorption of an orally active ace inhibitor: uptake and transport of fosinopril in cell cultures. Drug Metab Dispos. 2001 Oct;29(10):1307-15.
DM9NJ52	RU	http://www.ncbi.nlm.nih.gov/pubmed/11560874

DM7G0EP	DI	DM7G0EP
DM7G0EP	DN	Fosmidomycin
DM7G0EP	MI	TTLH4J3
DM7G0EP	MN	Plasmodium DOXP reductoisomerase (Malaria DXR)
DM7G0EP	MT	DTT
DM7G0EP	MA	Binder
DM7G0EP	RN	Structural basis of fosmidomycin action revealed by the complex with 2-C-methyl-D-erythritol 4-phosphate synthase (IspC). Implications for the cata... J Biol Chem. 2003 May 16;278(20):18401-7.
DM7G0EP	RU	https://pubmed.ncbi.nlm.nih.gov/12621040

DMOX3LB	DI	DMOX3LB
DMOX3LB	DN	Fosphenytoin
DMOX3LB	MI	DE5IED8
DMOX3LB	MN	Cytochrome P450 2C9 (CYP2C9)
DMOX3LB	MT	DME
DMOX3LB	MA	Metabolism
DMOX3LB	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMOX3LB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMOX3LB	DI	DMOX3LB
DMOX3LB	DN	Fosphenytoin
DMOX3LB	MI	DE4LYSA
DMOX3LB	MN	Cytochrome P450 3A4 (CYP3A4)
DMOX3LB	MT	DME
DMOX3LB	MA	Metabolism
DMOX3LB	RN	Basic review of the cytochrome p450 system. J Adv Pract Oncol. 2013 Jul;4(4):263-8.
DMOX3LB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25032007

DMOX3LB	DI	DMOX3LB
DMOX3LB	DN	Fosphenytoin
DMOX3LB	MI	DEGTFWK
DMOX3LB	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMOX3LB	MT	DME
DMOX3LB	MA	Metabolism
DMOX3LB	RN	CYP2C9, CYP2C19, and ABCB1 genotype and hospitalization for phenytoin toxicity. J Clin Pharmacol. 2009 Dec;49(12):1483-7.
DMOX3LB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19617466

DMOX3LB	DI	DMOX3LB
DMOX3LB	DN	Fosphenytoin
DMOX3LB	MI	TTZOVE0
DMOX3LB	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DMOX3LB	MT	DTT
DMOX3LB	MA	Blocker
DMOX3LB	RN	Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68. 
DMOX3LB	RU	https://pubmed.ncbi.nlm.nih.gov/19552484

DM8J5XT	DI	DM8J5XT
DM8J5XT	DN	Fospropofol
DM8J5XT	MI	DEVEFKM
DM8J5XT	MN	Alkaline phosphatase (ALPL)
DM8J5XT	MT	DME
DM8J5XT	MA	Metabolism
DM8J5XT	RN	A double-blind, randomized, multicenter, dose-ranging study to evaluate the safety and efficacy of fospropofol disodium as an intravenous sedative for colonoscopy in high-risk populations. Am J Ther. 2013 Mar-Apr;20(2):163-71.
DM8J5XT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22820718

DMKLJRD	DI	DMKLJRD
DMKLJRD	DN	Fospropofol disodium
DMKLJRD	MI	TTAN6JD
DMKLJRD	MN	Glutamate receptor AMPA (GRIA)
DMKLJRD	MT	DTT
DMKLJRD	MA	Modulator
DMKLJRD	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMKLJRD	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM6AUHV	DI	DM6AUHV
DM6AUHV	DN	Fostamatinib
DM6AUHV	MI	DTKVEXO
DM6AUHV	MN	ATP-binding cassette sub-family B member 5 (ABCB5)
DM6AUHV	MT	DTP
DM6AUHV	MA	Substrate
DM6AUHV	RN	DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB12010)
DM6AUHV	RU	https://www.drugbank.ca/drugs/DB12010

DM6AUHV	DI	DM6AUHV
DM6AUHV	DN	Fostamatinib
DM6AUHV	MI	DE4LYSA
DM6AUHV	MN	Cytochrome P450 3A4 (CYP3A4)
DM6AUHV	MT	DME
DM6AUHV	MA	Metabolism
DM6AUHV	RN	Effects of CYP3A4 inhibitors ketoconazole and verapamil and the CYP3A4 inducer rifampicin on the pharmacokinetic parameters of fostamatinib: results from In vitro and phase I clinical studies. Drugs R D. 2016 Mar;16(1):81-92.
DM6AUHV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26739683

DM6AUHV	DI	DM6AUHV
DM6AUHV	DN	Fostamatinib
DM6AUHV	MI	TTOU65C
DM6AUHV	MN	Tyrosine-protein kinase SYK (SYK)
DM6AUHV	MT	DTT
DM6AUHV	MA	Modulator
DM6AUHV	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2230).
DM6AUHV	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2230

DM50ILT	DI	DM50ILT
DM50ILT	DN	Fostemsavir
DM50ILT	MI	TTBYP1X
DM50ILT	MN	Human immunodeficiency virus Envelope glycoprotein gp120 (HIV gp120)
DM50ILT	MT	DTT
DM50ILT	MA	Inhibitor
DM50ILT	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2020
DM50ILT	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf

DMV62ED	DI	DMV62ED
DMV62ED	DN	Fotemustine
DMV62ED	MI	TTR7UJ3
DMV62ED	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMV62ED	MT	DTT
DMV62ED	MA	Inhibitor
DMV62ED	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMV62ED	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMF8DNE	DI	DMF8DNE
DMF8DNE	DN	Framycetin
DMF8DNE	MI	DEJADS9
DMF8DNE	MN	Aminoglycoside N-acetyltransferase (aacC2)
DMF8DNE	MT	DME
DMF8DNE	MA	Metabolism
DMF8DNE	RN	Relationship between antimicrobial resistance and aminoglycoside-modifying enzyme gene expressions in Acinetobacter baumannii. Chin Med J (Engl). 2005 Jan 20;118(2):141-5.
DMF8DNE	RU	https://pubmed.ncbi.nlm.nih.gov/15667800

DMF8DNE	DI	DMF8DNE
DMF8DNE	DN	Framycetin
DMF8DNE	MI	DEWPAJD
DMF8DNE	MN	Aminoglycoside O-phosphotransferase (aphA6)
DMF8DNE	MT	DME
DMF8DNE	MA	Metabolism
DMF8DNE	RN	Relationship between antimicrobial resistance and aminoglycoside-modifying enzyme gene expressions in Acinetobacter baumannii. Chin Med J (Engl). 2005 Jan 20;118(2):141-5.
DMF8DNE	RU	https://pubmed.ncbi.nlm.nih.gov/15667800

DMF8DNE	DI	DMF8DNE
DMF8DNE	DN	Framycetin
DMF8DNE	MI	TT38DW5
DMF8DNE	MN	Bacterial 16S ribosomal RNA (Bact 16S rRNA)
DMF8DNE	MT	DTT
DMF8DNE	MA	Binder
DMF8DNE	RN	Antistaphylococcal activity of gentamicin. Minerva Med. 1975 Dec 8;66(84):4505-26.
DMF8DNE	RU	https://pubmed.ncbi.nlm.nih.gov/1105242

DMF8DNE	DI	DMF8DNE
DMF8DNE	DN	Framycetin
DMF8DNE	MI	TTQ8KVI
DMF8DNE	MN	Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)
DMF8DNE	MT	DTT
DMF8DNE	MA	Binder
DMF8DNE	RN	Characterization of a 30S ribosomal subunit assembly intermediate found in Escherichia coli cells growing with neomycin or paromomycin. Arch Microbiol. 2008 May;189(5):441-9.
DMF8DNE	RU	https://pubmed.ncbi.nlm.nih.gov/18060665

DMDZY54	DI	DMDZY54
DMDZY54	DN	Fremanezumab
DMDZY54	MI	TTY6O0Q
DMDZY54	MN	Calcitonin gene-related peptide receptor (CGRPR)
DMDZY54	MT	DTT
DMDZY54	MA	Modulator
DMDZY54	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMDZY54	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DM7RE8P	DI	DM7RE8P
DM7RE8P	DN	Frovatriptan
DM7RE8P	MI	TTK8CXU
DM7RE8P	MN	5-HT 1B receptor (HTR1B)
DM7RE8P	MT	DTT
DM7RE8P	MA	Modulator
DM7RE8P	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM7RE8P	RU	https://www.fda.gov/

DM7RE8P	DI	DM7RE8P
DM7RE8P	DN	Frovatriptan
DM7RE8P	MI	TT6MSOK
DM7RE8P	MN	5-HT 1D receptor (HTR1D)
DM7RE8P	MT	DTT
DM7RE8P	MA	Modulator
DM7RE8P	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM7RE8P	RU	https://www.fda.gov/

DM7RE8P	DI	DM7RE8P
DM7RE8P	DN	Frovatriptan
DM7RE8P	MI	DEJGDUW
DM7RE8P	MN	Cytochrome P450 1A2 (CYP1A2)
DM7RE8P	MT	DME
DM7RE8P	MA	Metabolism
DM7RE8P	RN	Frovatriptan: a review of drug-drug interactions. Headache. 2002 Apr;42 Suppl 2:S63-73.
DM7RE8P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12028322

DM43AN2	DI	DM43AN2
DM43AN2	DN	Fructose
DM43AN2	MI	TTMS54D
DM43AN2	MN	Fragile histidine triad protein (FHIT)
DM43AN2	MT	DTT
DM43AN2	MA	Inhibitor
DM43AN2	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM43AN2	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM43AN2	DI	DM43AN2
DM43AN2	DN	Fructose
DM43AN2	MI	DTOR02F
DM43AN2	MN	Glucose transporter type 5, small intestine (SLC2A5)
DM43AN2	MT	DTP
DM43AN2	MA	Substrate
DM43AN2	RN	Dexamethasone sensitizes the neonatal intestine to fructose induction of intestinal fructose transporter (Slc2A5) function. Endocrinology. 2008 Jan;149(1):409-23.
DM43AN2	RU	http://www.ncbi.nlm.nih.gov/pubmed/17947353

DM43AN2	DI	DM43AN2
DM43AN2	DN	Fructose
DM43AN2	MI	DT8SQBG
DM43AN2	MN	Glucose transporter type 7 (SLC2A7)
DM43AN2	MT	DTP
DM43AN2	MA	Substrate
DM43AN2	RN	Functional Properties and Genomics of Glucose Transporters. Curr Genomics. 2007 Apr; 8(2): 113128.
DM43AN2	RU	http://www.ncbi.nlm.nih.gov/pubmed/18660845

DM43AN2	DI	DM43AN2
DM43AN2	DN	Fructose
DM43AN2	MI	DT1CP40
DM43AN2	MN	Sodium/glucose cotransporter 4 (SLC5A9)
DM43AN2	MT	DTP
DM43AN2	MA	Substrate
DM43AN2	RN	SLC5A9/SGLT4, a new Na+-dependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-D-glucitol, and fructose. Life Sci. 2005 Jan 14;76(9):1039-50.
DM43AN2	RU	http://www.ncbi.nlm.nih.gov/pubmed/15607332

DM43AN2	DI	DM43AN2
DM43AN2	DN	Fructose
DM43AN2	MI	DEWU03P
DM43AN2	MN	Sorbitol dehydrogenase (SORD)
DM43AN2	MT	DME
DM43AN2	MA	Metabolism
DM43AN2	RN	Isolation, characterization and evaluation of the Pichia pastoris sorbitol dehydrogenase promoter for expression of heterologous proteins. Protein Expr Purif. 2013 Nov;92(1):128-33.
DM43AN2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24075932

DM0YZC6	DI	DM0YZC6
DM0YZC6	DN	Fulvestrant
DM0YZC6	MI	DE4LYSA
DM0YZC6	MN	Cytochrome P450 3A4 (CYP3A4)
DM0YZC6	MT	DME
DM0YZC6	MA	Metabolism
DM0YZC6	RN	Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer. Ann Pharmacother. 2006 Sep;40(9):1572-83.
DM0YZC6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16912252

DM0YZC6	DI	DM0YZC6
DM0YZC6	DN	Fulvestrant
DM0YZC6	MI	TTZAYWL
DM0YZC6	MN	Estrogen receptor (ESR)
DM0YZC6	MT	DTT
DM0YZC6	MA	Antagonist
DM0YZC6	RN	Beta3-tubulin is induced by estradiol in human breast carcinoma cells through an estrogen-receptor dependent pathway. Cell Motil Cytoskeleton. 2009 Jul;66(7):378-88.
DM0YZC6	RU	https://pubmed.ncbi.nlm.nih.gov/19466750

DM0YZC6	DI	DM0YZC6
DM0YZC6	DN	Fulvestrant
DM0YZC6	MI	DEYGVN4
DM0YZC6	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM0YZC6	MT	DME
DM0YZC6	MA	Metabolism
DM0YZC6	RN	Inactivation of the pure antiestrogen fulvestrant and other synthetic estrogen molecules by UDP-glucuronosyltransferase 1A enzymes expressed in breast tissue. Mol Pharmacol. 2006 Mar;69(3):908-20.
DM0YZC6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16339389

DM3P6V7	DI	DM3P6V7
DM3P6V7	DN	Furazolidone
DM3P6V7	MI	TTS1W4A
DM3P6V7	MN	Bacterial Deoxyribonucleic acid (Bact DNA)
DM3P6V7	MT	DTT
DM3P6V7	MA	Modulator
DM3P6V7	RN	Interaction of furazolidone with DNA. Biochim Biophys Acta. 1975 Aug 21;402(2):161-5.
DM3P6V7	RU	https://www.ncbi.nlm.nih.gov/pubmed/1174533

DMMQ8ZG	DI	DMMQ8ZG
DMMQ8ZG	DN	Furosemide
DMMQ8ZG	MI	DEVDYN7
DMMQ8ZG	MN	Cytochrome P450 2E1 (CYP2E1)
DMMQ8ZG	MT	DME
DMMQ8ZG	MA	Metabolism
DMMQ8ZG	RN	Effects of cytochrome P450 inducers and inhibitors on the pharmacokinetics of intravenous furosemide in rats: involvement of CYP2C11, 2E1, 3A1 and 3A2 in furosemide metabolism. J Pharm Pharmacol. 2009 Jan;61(1):47-54.
DMMQ8ZG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19126296

DMMQ8ZG	DI	DMMQ8ZG
DMMQ8ZG	DN	Furosemide
DMMQ8ZG	MI	DTQ23VB
DMMQ8ZG	MN	Organic anion transporter 1 (SLC22A6)
DMMQ8ZG	MT	DTP
DMMQ8ZG	MA	Substrate
DMMQ8ZG	RN	Interactions of human organic anion transporters with diuretics. J Pharmacol Exp Ther. 2004 Mar;308(3):1021-9.
DMMQ8ZG	RU	http://www.ncbi.nlm.nih.gov/pubmed/14610216

DMMQ8ZG	DI	DMMQ8ZG
DMMQ8ZG	DN	Furosemide
DMMQ8ZG	MI	DTVP67E
DMMQ8ZG	MN	Organic anion transporter 3 (SLC22A8)
DMMQ8ZG	MT	DTP
DMMQ8ZG	MA	Substrate
DMMQ8ZG	RN	Interactions of human organic anion transporters with diuretics. J Pharmacol Exp Ther. 2004 Mar;308(3):1021-9.
DMMQ8ZG	RU	http://www.ncbi.nlm.nih.gov/pubmed/14610216

DMMQ8ZG	DI	DMMQ8ZG
DMMQ8ZG	DN	Furosemide
DMMQ8ZG	MI	DT9G7XN
DMMQ8ZG	MN	Peptide transporter 1 (SLC15A1)
DMMQ8ZG	MT	DTP
DMMQ8ZG	MA	Substrate
DMMQ8ZG	RN	Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells. Arch Pharm Res. 2007 Apr;30(4):507-18.
DMMQ8ZG	RU	https://doi.org/10.1007/BF02980227

DMMQ8ZG	DI	DMMQ8ZG
DMMQ8ZG	DN	Furosemide
DMMQ8ZG	MI	TTS087L
DMMQ8ZG	MN	Solute carrier family 12 member 1 (SLC12A1)
DMMQ8ZG	MT	DTT
DMMQ8ZG	MA	Blocker
DMMQ8ZG	RN	Update of diuretics in the treatment of hypertension. Am J Ther. 2007 Mar-Apr;14(2):154-60.
DMMQ8ZG	RU	https://pubmed.ncbi.nlm.nih.gov/17414583

DMMQ8ZG	DI	DMMQ8ZG
DMMQ8ZG	DN	Furosemide
DMMQ8ZG	MI	DEYGVN4
DMMQ8ZG	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMMQ8ZG	MT	DME
DMMQ8ZG	MA	Metabolism
DMMQ8ZG	RN	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
DMMQ8ZG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429

DMWVCF3	DI	DMWVCF3
DMWVCF3	DN	Fusidic acid
DMWVCF3	MI	DECB0K3
DMWVCF3	MN	Cytochrome P450 2D6 (CYP2D6)
DMWVCF3	MT	DME
DMWVCF3	MA	Metabolism
DMWVCF3	RN	The potent mechanism-based inactivation of CYP2D6 and CYP3A4 with fusidic acid in in vivo bioaccumulation. Xenobiotica. 2018 Oct;48(10):999-1005.
DMWVCF3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29027845

DMWVCF3	DI	DMWVCF3
DMWVCF3	DN	Fusidic acid
DMWVCF3	MI	TT6HP1T
DMWVCF3	MN	Streptococcus Elongation factor G (Stre-coc fusA)
DMWVCF3	MT	DTT
DMWVCF3	MA	Inhibitor
DMWVCF3	RN	Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus. Antimicrob Agents Chemother. 2009 May;53(5):2059-65.
DMWVCF3	RU	https://pubmed.ncbi.nlm.nih.gov/19289529

DMWVCF3	DI	DMWVCF3
DMWVCF3	DN	Fusidic acid
DMWVCF3	MI	DEYGVN4
DMWVCF3	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMWVCF3	MT	DME
DMWVCF3	MA	Metabolism
DMWVCF3	RN	Fusidic acid inhibits hepatic transporters and metabolic enzymes: potential cause of clinical drug-drug interaction observed with statin coadministration. Antimicrob Agents Chemother. 2016 Sep 23;60(10):5986-94.
DMWVCF3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27458210

DMZ0P95	DI	DMZ0P95
DMZ0P95	DN	Ga-68-DOTATOC
DMZ0P95	MI	TTZ6T9E
DMZ0P95	MN	Somatostatin receptor type 2 (SSTR2)
DMZ0P95	MT	DTT
DMZ0P95	MA	Binder
DMZ0P95	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMZ0P95	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210828s000lbl.pdf

DM6T924	DI	DM6T924
DM6T924	DN	Gabapentin
DM6T924	MI	TTDCVZW
DM6T924	MN	Gamma-aminobutyric acid B receptor (GABBR)
DM6T924	MT	DTT
DM6T924	MA	Antagonist
DM6T924	RN	Gabapentin increases a tonic inhibitory conductance in hippocampal pyramidal neurons. Anesthesiology. 2006 Aug;105(2):325-33.
DM6T924	RU	https://pubmed.ncbi.nlm.nih.gov/16871066

DM6T924	DI	DM6T924
DM6T924	DN	Gabapentin
DM6T924	MI	DT48T0N
DM6T924	MN	L-type amino acid transporter 1 (SLC7A5)
DM6T924	MT	DTP
DM6T924	MA	Substrate
DM6T924	RN	Transport of gabapentin by LAT1 (SLC7A5). Biochem Pharmacol. 2013 Jun 1;85(11):1672-83.
DM6T924	RU	http://www.ncbi.nlm.nih.gov/pubmed/23567998

DM6T924	DI	DM6T924
DM6T924	DN	Gabapentin
DM6T924	MI	DT9IDPW
DM6T924	MN	Organic cation transporter 2 (SLC22A2)
DM6T924	MT	DTP
DM6T924	MA	Substrate
DM6T924	RN	Clinical pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported prodrug of gabapentin, with naproxen and cimetidine. Br J Clin Pharmacol. 2010 May;69(5):498-507.
DM6T924	RU	http://www.ncbi.nlm.nih.gov/pubmed/20573085

DM6T924	DI	DM6T924
DM6T924	DN	Gabapentin
DM6T924	MI	DT2EG60
DM6T924	MN	Organic cation/carnitine transporter 1 (SLC22A4)
DM6T924	MT	DTP
DM6T924	MA	Substrate
DM6T924	RN	Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. Clin Pharmacol Ther. 2008 Mar;83(3):416-21.
DM6T924	RU	http://www.ncbi.nlm.nih.gov/pubmed/17609685

DMU9D2F	DI	DMU9D2F
DMU9D2F	DN	Gabexate
DMU9D2F	MI	TTEMV5X
DMU9D2F	MN	Serine protease unspecific (SP)
DMU9D2F	MT	DTT
DMU9D2F	MA	Inhibitor
DMU9D2F	RN	Tryptase-positive mast cells correlate with angiogenesis in early breast cancer patients. Int J Oncol. 2009 Jul;35(1):115-20.
DMU9D2F	RU	https://pubmed.ncbi.nlm.nih.gov/19513558

DMI53FU	DI	DMI53FU
DMI53FU	DN	Gaboxadol
DMI53FU	MI	TTGXH6N
DMI53FU	MN	GABA(A) receptor delta (GABRD)
DMI53FU	MT	DTT
DMI53FU	MA	Modulator
DMI53FU	RN	Gaboxadol--a new awakening in sleep.Curr Opin Pharmacol.2006 Feb;6(1):30-6.
DMI53FU	RU	https://www.ncbi.nlm.nih.gov/pubmed/16368265

DMI53FU	DI	DMI53FU
DMI53FU	DN	Gaboxadol
DMI53FU	MI	DT48WEM
DMI53FU	MN	Proton-coupled amino acid transporter 1 (SLC36A1)
DMI53FU	MT	DTP
DMI53FU	MA	Substrate
DMI53FU	RN	Intestinal gaboxadol absorption via PAT1 (SLC36A1): modified absorption in vivo following co-administration of L-tryptophan. Br J Pharmacol. 2009 Aug;157(8):1380-9.
DMI53FU	RU	http://www.ncbi.nlm.nih.gov/pubmed/19594759

DM4VAOG	DI	DM4VAOG
DM4VAOG	DN	Gadobenate dimeglumine
DM4VAOG	MI	DTFI42L
DM4VAOG	MN	Multidrug resistance-associated protein 2 (ABCC2)
DM4VAOG	MT	DTP
DM4VAOG	MA	Substrate
DM4VAOG	RN	Liver Perfusion Modifies Gd-DTPA and Gd-BOPTA Hepatocyte Concentrations Through Transfer Clearances Across Sinusoidal Membranes. Eur J Drug Metab Pharmacokinet. 2017 Aug;42(4):657-667.
DM4VAOG	RU	http://www.ncbi.nlm.nih.gov/pubmed/27778300

DM4VAOG	DI	DM4VAOG
DM4VAOG	DN	Gadobenate dimeglumine
DM4VAOG	MI	DT3D8F0
DM4VAOG	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM4VAOG	MT	DTP
DM4VAOG	MA	Substrate
DM4VAOG	RN	Liver Perfusion Modifies Gd-DTPA and Gd-BOPTA Hepatocyte Concentrations Through Transfer Clearances Across Sinusoidal Membranes. Eur J Drug Metab Pharmacokinet. 2017 Aug;42(4):657-667.
DM4VAOG	RU	http://www.ncbi.nlm.nih.gov/pubmed/27778300

DM4VAOG	DI	DM4VAOG
DM4VAOG	DN	Gadobenate dimeglumine
DM4VAOG	MI	DT9C1TS
DM4VAOG	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM4VAOG	MT	DTP
DM4VAOG	MA	Substrate
DM4VAOG	RN	Liver Perfusion Modifies Gd-DTPA and Gd-BOPTA Hepatocyte Concentrations Through Transfer Clearances Across Sinusoidal Membranes. Eur J Drug Metab Pharmacokinet. 2017 Aug;42(4):657-667.
DM4VAOG	RU	http://www.ncbi.nlm.nih.gov/pubmed/27778300

DM4VAOG	DI	DM4VAOG
DM4VAOG	DN	Gadobenate dimeglumine
DM4VAOG	MI	TTFNGC9
DM4VAOG	MN	Serum albumin (ALB)
DM4VAOG	MT	DTT
DM4VAOG	MA	Binder
DM4VAOG	RN	Protocol design for high relaxivity contrast agents in MR imaging of the CNS. Eur Radiol. 2006 Nov;16 Suppl 7:M3-7.
DM4VAOG	RU	https://pubmed.ncbi.nlm.nih.gov/18655261

DM5V9U1	DI	DM5V9U1
DM5V9U1	DN	Gadofosveset
DM5V9U1	MI	TTFNGC9
DM5V9U1	MN	Serum albumin (ALB)
DM5V9U1	MT	DTT
DM5V9U1	MA	Modulator
DM5V9U1	RN	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
DM5V9U1	RU	https://pubmed.ncbi.nlm.nih.gov/19180096

DMEO794	DI	DMEO794
DMEO794	DN	Galantamine
DMEO794	MI	TT1RS9F
DMEO794	MN	Acetylcholinesterase (AChE)
DMEO794	MT	DTT
DMEO794	MA	Inhibitor
DMEO794	RN	[From symptomatic to disease modifying therapy Recent developments in the pharmacotherapy of Alzheimer's disease]. Fortschr Neurol Psychiatr. 2009 Jun;77(6):326-33.
DMEO794	RU	https://pubmed.ncbi.nlm.nih.gov/19504422

DMEO794	DI	DMEO794
DMEO794	DN	Galantamine
DMEO794	MI	DECB0K3
DMEO794	MN	Cytochrome P450 2D6 (CYP2D6)
DMEO794	MT	DME
DMEO794	MA	Metabolism
DMEO794	RN	Clinical pharmacokinetics of galantamine. Clin Pharmacokinet. 2003;42(15):1383-92.
DMEO794	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14674789

DMEO794	DI	DMEO794
DMEO794	DN	Galantamine
DMEO794	MI	DE4LYSA
DMEO794	MN	Cytochrome P450 3A4 (CYP3A4)
DMEO794	MT	DME
DMEO794	MA	Metabolism
DMEO794	RN	Clinical pharmacokinetics of galantamine. Clin Pharmacokinet. 2003;42(15):1383-92.
DMEO794	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14674789

DMIZ1E8	DI	DMIZ1E8
DMIZ1E8	DN	Galcanezumab
DMIZ1E8	MI	TTY6O0Q
DMIZ1E8	MN	Calcitonin gene-related peptide receptor (CGRPR)
DMIZ1E8	MT	DTT
DMIZ1E8	MA	Modulator
DMIZ1E8	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMIZ1E8	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMPO0MS	DI	DMPO0MS
DMPO0MS	DN	Gallamine Triethiodide
DMPO0MS	MI	TTYEG6Q
DMPO0MS	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMPO0MS	MT	DTT
DMPO0MS	MA	Antagonist
DMPO0MS	RN	Cholinergic regulation of the corpora allata in adult male loreyi leafworm Mythimna loreyi. Arch Insect Biochem Physiol. 2002 Apr;49(4):215-24.
DMPO0MS	RU	https://pubmed.ncbi.nlm.nih.gov/11921079

DMF9O6B	DI	DMF9O6B
DMF9O6B	DN	Gallium nitrate
DMF9O6B	MI	TTRYK0X
DMF9O6B	MN	Interleukin-1 beta (IL1B)
DMF9O6B	MT	DTT
DMF9O6B	MA	Inhibitor
DMF9O6B	RN	Elimination of arthritis pain and inflammation for over 2 years with a single 90 min, topical 14% gallium nitrate treatment: case reports and revie... Med Hypotheses. 2005;65(6):1136-41.
DMF9O6B	RU	https://pubmed.ncbi.nlm.nih.gov/16122880

DMER9YA	DI	DMER9YA
DMER9YA	DN	Galsulfase
DMER9YA	MI	TTESQTG
DMER9YA	MN	N-acetylgalactosamine-4-sulfatase (G4S)
DMER9YA	MT	DTT
DMER9YA	MA	Modulator
DMER9YA	RN	Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme ) therapy. J Inherit Metab Dis. 2013 Mar;36(2):385-94.
DMER9YA	RU	https://pubmed.ncbi.nlm.nih.gov/22669363

DMGBKVD	DI	DMGBKVD
DMGBKVD	DN	Gamma hydroxybutyric acid
DMGBKVD	MI	TTDCVZW
DMGBKVD	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMGBKVD	MT	DTT
DMGBKVD	MA	Modulator
DMGBKVD	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMGBKVD	RU	https://www.fda.gov/

DMGBKVD	DI	DMGBKVD
DMGBKVD	DN	Gamma hydroxybutyric acid
DMGBKVD	MI	DT342ZG
DMGBKVD	MN	Monocarboxylate transporter 1 (SLC16A1)
DMGBKVD	MT	DTP
DMGBKVD	MA	Substrate
DMGBKVD	RN	Flavonoids modulate monocarboxylate transporter-1-mediated transport of gamma-hydroxybutyrate in vitro and in vivo. Drug Metab Dispos. 2007 Feb;35(2):201-8.
DMGBKVD	RU	http://www.ncbi.nlm.nih.gov/pubmed/17108059

DMGBKVD	DI	DMGBKVD
DMGBKVD	DN	Gamma hydroxybutyric acid
DMGBKVD	MI	DTM301H
DMGBKVD	MN	Sodium-coupled monocarboxylate transporter 2 (SLC5A12)
DMGBKVD	MT	DTP
DMGBKVD	MA	Substrate
DMGBKVD	RN	Sodium-coupled monocarboxylate transporters in normal tissues and in cancer. AAPS J. 2008;10(1):193-9.
DMGBKVD	RU	http://www.ncbi.nlm.nih.gov/pubmed/18446519

DMSXKYG	DI	DMSXKYG
DMSXKYG	DN	Gamma-homolinolenic acid
DMSXKYG	MI	TT8NGED
DMSXKYG	MN	Prostaglandin G/H synthase 1 (COX-1)
DMSXKYG	MT	DTT
DMSXKYG	MA	Inhibitor
DMSXKYG	RN	Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2. Biochem J. 2002 Jul 15;365(Pt 2):489-96.
DMSXKYG	RU	https://pubmed.ncbi.nlm.nih.gov/11939906

DMSXKYG	DI	DMSXKYG
DMSXKYG	DN	Gamma-homolinolenic acid
DMSXKYG	MI	DE073H6
DMSXKYG	MN	Prostaglandin G/H synthase 1 (COX-1)
DMSXKYG	MT	DME
DMSXKYG	MA	Metabolism
DMSXKYG	RN	Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. FASEB J. 2006 Jun;20(8):1097-108.
DMSXKYG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16770009

DMSXKYG	DI	DMSXKYG
DMSXKYG	DN	Gamma-homolinolenic acid
DMSXKYG	MI	DE492CE
DMSXKYG	MN	Prostaglandin G/H synthase 2 (COX-2)
DMSXKYG	MT	DME
DMSXKYG	MA	Metabolism
DMSXKYG	RN	Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. FASEB J. 2006 Jun;20(8):1097-108.
DMSXKYG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16770009

DMQN30Z	DI	DMQN30Z
DMQN30Z	DN	Gamolenic acid
DMQN30Z	MI	DE073H6
DMQN30Z	MN	Prostaglandin G/H synthase 1 (COX-1)
DMQN30Z	MT	DME
DMQN30Z	MA	Metabolism
DMQN30Z	RN	Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. FASEB J. 2006 Jun;20(8):1097-108.
DMQN30Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16770009

DMQN30Z	DI	DMQN30Z
DMQN30Z	DN	Gamolenic acid
DMQN30Z	MI	DE492CE
DMQN30Z	MN	Prostaglandin G/H synthase 2 (COX-2)
DMQN30Z	MT	DME
DMQN30Z	MA	Metabolism
DMQN30Z	RN	Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. FASEB J. 2006 Jun;20(8):1097-108.
DMQN30Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16770009

DM1MBYQ	DI	DM1MBYQ
DM1MBYQ	DN	Ganciclovir
DM1MBYQ	MI	DTW7AE3
DM1MBYQ	MN	Alanine/serine/cysteine/threonine transporter 2 (SLC1A5)
DM1MBYQ	MT	DTP
DM1MBYQ	MA	Substrate
DM1MBYQ	RN	Amino Acid Transporter ATB0,+ as a delivery system for drugs and prodrugs. Curr Drug Targets Immune Endocr Metabol Disord. 2005 Dec;5(4):357-64.
DM1MBYQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/16375689

DM1MBYQ	DI	DM1MBYQ
DM1MBYQ	DN	Ganciclovir
DM1MBYQ	MI	DTI7UX6
DM1MBYQ	MN	Breast cancer resistance protein (ABCG2)
DM1MBYQ	MT	DTP
DM1MBYQ	MA	Substrate
DM1MBYQ	RN	Side populations of glioblastoma cells are less sensitive to HSV-TK/GCV suicide gene therapy system than the non-side population. In Vitro Cell Dev Biol Anim. 2010 Jun;46(6):497-501.
DM1MBYQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/20135358

DM1MBYQ	DI	DM1MBYQ
DM1MBYQ	DN	Ganciclovir
DM1MBYQ	MI	TTIU7X1
DM1MBYQ	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DM1MBYQ	MT	DTT
DM1MBYQ	MA	Inhibitor
DM1MBYQ	RN	Application of real time polymerase chain reaction to the diagnosis and treatment of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Zhonghua Xue Ye Xue Za Zhi. 2009 Feb;30(2):77-81.
DM1MBYQ	RU	https://pubmed.ncbi.nlm.nih.gov/19563015

DM1MBYQ	DI	DM1MBYQ
DM1MBYQ	DN	Ganciclovir
DM1MBYQ	MI	DTZGT0P
DM1MBYQ	MN	Multidrug and toxin extrusion protein 1 (SLC47A1)
DM1MBYQ	MT	DTP
DM1MBYQ	MA	Substrate
DM1MBYQ	RN	Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
DM1MBYQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/17509534

DM1MBYQ	DI	DM1MBYQ
DM1MBYQ	DN	Ganciclovir
DM1MBYQ	MI	DT3TX4H
DM1MBYQ	MN	Multidrug and toxin extrusion protein 2 (SLC47A2)
DM1MBYQ	MT	DTP
DM1MBYQ	MA	Substrate
DM1MBYQ	RN	Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
DM1MBYQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/17509534

DM1MBYQ	DI	DM1MBYQ
DM1MBYQ	DN	Ganciclovir
DM1MBYQ	MI	DTCSGPB
DM1MBYQ	MN	Multidrug resistance-associated protein 4 (ABCC4)
DM1MBYQ	MT	DTP
DM1MBYQ	MA	Substrate
DM1MBYQ	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM1MBYQ	RU	https://doi.org/10.1007/s11095-012-0935-x

DM1MBYQ	DI	DM1MBYQ
DM1MBYQ	DN	Ganciclovir
DM1MBYQ	MI	DTYVM24
DM1MBYQ	MN	Multidrug resistance-associated protein 5 (ABCC5)
DM1MBYQ	MT	DTP
DM1MBYQ	MA	Substrate
DM1MBYQ	RN	Cellular export of drugs and signaling molecules by the ATP-binding cassette transporters MRP4 (ABCC4) and MRP5 (ABCC5). Drug Metab Rev. 2005;37(1):253-78.
DM1MBYQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/15747503

DM1MBYQ	DI	DM1MBYQ
DM1MBYQ	DN	Ganciclovir
DM1MBYQ	MI	DTQ23VB
DM1MBYQ	MN	Organic anion transporter 1 (SLC22A6)
DM1MBYQ	MT	DTP
DM1MBYQ	MA	Substrate
DM1MBYQ	RN	Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
DM1MBYQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/11861798

DM1MBYQ	DI	DM1MBYQ
DM1MBYQ	DN	Ganciclovir
DM1MBYQ	MI	DTVP67E
DM1MBYQ	MN	Organic anion transporter 3 (SLC22A8)
DM1MBYQ	MT	DTP
DM1MBYQ	MA	Substrate
DM1MBYQ	RN	FDA Drug Development and Drug Interactions
DM1MBYQ	RU	https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2

DM1MBYQ	DI	DM1MBYQ
DM1MBYQ	DN	Ganciclovir
DM1MBYQ	MI	DTT79CX
DM1MBYQ	MN	Organic cation transporter 1 (SLC22A1)
DM1MBYQ	MT	DTP
DM1MBYQ	MA	Substrate
DM1MBYQ	RN	Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
DM1MBYQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/11861798

DMGMB30	DI	DMGMB30
DMGMB30	DN	Ganirelix
DMGMB30	MI	TT8R70G
DMGMB30	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMGMB30	MT	DTT
DMGMB30	MA	Antagonist
DMGMB30	RN	Age attenuates testosterone secretion driven by amplitude-varying pulses of recombinant human luteinizing hormone during acute gonadotrope inhibiti... J Clin Endocrinol Metab. 2007 Sep;92(9):3626-32.
DMGMB30	RU	https://pubmed.ncbi.nlm.nih.gov/17579202

DMSL679	DI	DMSL679
DMSL679	DN	Gatifloxacin
DMSL679	MI	TTN6J5F
DMSL679	MN	Bacterial DNA gyrase (Bact gyrase)
DMSL679	MT	DTT
DMSL679	MA	Modulator
DMSL679	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMSL679	RU	https://www.fda.gov/

DMSL679	DI	DMSL679
DMSL679	DN	Gatifloxacin
DMSL679	MI	DTFI42L
DMSL679	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMSL679	MT	DTP
DMSL679	MA	Substrate
DMSL679	RN	Uptake and intracellular release kinetics of liposome formulations in glioma cells. Int J Pharm. 2010 Aug 16;395(1-2):251-9.
DMSL679	RU	http://www.ncbi.nlm.nih.gov/pubmed/20573571

DMSL679	DI	DMSL679
DMSL679	DN	Gatifloxacin
DMSL679	MI	DTE2B1D
DMSL679	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMSL679	MT	DTP
DMSL679	MA	Substrate
DMSL679	RN	Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm. 2007 Jan-Feb;4(1):85-94.
DMSL679	RU	http://www.ncbi.nlm.nih.gov/pubmed/17274666

DMSL679	DI	DMSL679
DMSL679	DN	Gatifloxacin
DMSL679	MI	DTUGYRD
DMSL679	MN	P-glycoprotein 1 (ABCB1)
DMSL679	MT	DTP
DMSL679	MA	Substrate
DMSL679	RN	Interaction of gatifloxacin with efflux transporters: a possible mechanism for drug resistance. Int J Pharm. 2010 Aug 16;395(1-2):114-21.
DMSL679	RU	http://www.ncbi.nlm.nih.gov/pubmed/20573570

DMSL679	DI	DMSL679
DMSL679	DN	Gatifloxacin
DMSL679	MI	TTIXTO3
DMSL679	MN	Staphylococcus Topoisomerase IV (Stap-coc parC)
DMSL679	MT	DTT
DMSL679	MA	Modulator
DMSL679	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMSL679	RU	https://www.fda.gov/

DMH0QKA	DI	DMH0QKA
DMH0QKA	DN	GDC-0199
DMH0QKA	MI	TTJGNVC
DMH0QKA	MN	Apoptosis regulator Bcl-2 (BCL-2)
DMH0QKA	MT	DTT
DMH0QKA	MA	Modulator
DMH0QKA	RN	ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013 Feb;19(2):202-8.
DMH0QKA	RU	https://pubmed.ncbi.nlm.nih.gov/23291630

DM15F0X	DI	DM15F0X
DM15F0X	DN	Gefitinib
DM15F0X	MI	DTI7UX6
DM15F0X	MN	Breast cancer resistance protein (ABCG2)
DM15F0X	MT	DTP
DM15F0X	MA	Substrate
DM15F0X	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM15F0X	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DM15F0X	DI	DM15F0X
DM15F0X	DN	Gefitinib
DM15F0X	MI	DECB0K3
DM15F0X	MN	Cytochrome P450 2D6 (CYP2D6)
DM15F0X	MT	DME
DM15F0X	MA	Metabolism
DM15F0X	RN	Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet. 2005;44(10):1067-81.
DM15F0X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16176119

DM15F0X	DI	DM15F0X
DM15F0X	DN	Gefitinib
DM15F0X	MI	DE4LYSA
DM15F0X	MN	Cytochrome P450 3A4 (CYP3A4)
DM15F0X	MT	DME
DM15F0X	MA	Metabolism
DM15F0X	RN	Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res. 2007 Jun 15;13(12):3731-7.
DM15F0X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17575239

DM15F0X	DI	DM15F0X
DM15F0X	DN	Gefitinib
DM15F0X	MI	DEIBDNY
DM15F0X	MN	Cytochrome P450 3A5 (CYP3A5)
DM15F0X	MT	DME
DM15F0X	MA	Metabolism
DM15F0X	RN	Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res. 2007 Jun 15;13(12):3731-7.
DM15F0X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17575239

DM15F0X	DI	DM15F0X
DM15F0X	DN	Gefitinib
DM15F0X	MI	TTGKNB4
DM15F0X	MN	Epidermal growth factor receptor (EGFR)
DM15F0X	MT	DTT
DM15F0X	MA	Inhibitor
DM15F0X	RN	Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
DM15F0X	RU	https://pubmed.ncbi.nlm.nih.gov/14760365

DM15F0X	DI	DM15F0X
DM15F0X	DN	Gefitinib
DM15F0X	MI	DT3D8F0
DM15F0X	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM15F0X	MT	DTP
DM15F0X	MA	Substrate
DM15F0X	RN	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
DM15F0X	RU	http://www.ncbi.nlm.nih.gov/pubmed/23340295

DM15F0X	DI	DM15F0X
DM15F0X	DN	Gefitinib
DM15F0X	MI	DT9C1TS
DM15F0X	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM15F0X	MT	DTP
DM15F0X	MA	Substrate
DM15F0X	RN	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
DM15F0X	RU	http://www.ncbi.nlm.nih.gov/pubmed/23340295

DM15F0X	DI	DM15F0X
DM15F0X	DN	Gefitinib
DM15F0X	MI	DTUGYRD
DM15F0X	MN	P-glycoprotein 1 (ABCB1)
DM15F0X	MT	DTP
DM15F0X	MA	Substrate
DM15F0X	RN	Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers. Br J Clin Pharmacol. 2009 Aug;68(2):226-37.
DM15F0X	RU	http://www.ncbi.nlm.nih.gov/pubmed/19694743

DMSE3I7	DI	DMSE3I7
DMSE3I7	DN	Gemcitabine
DMSE3I7	MI	DT0EQPW
DMSE3I7	MN	Concentrative nucleoside transporter 1 (SLC28A1)
DMSE3I7	MT	DTP
DMSE3I7	MA	Substrate
DMSE3I7	RN	Pancreatic Cancer Chemoresistance to Gemcitabine. Cancers (Basel). 2017 Nov 16;9(11).
DMSE3I7	RU	http://www.ncbi.nlm.nih.gov/pubmed/29144412

DMSE3I7	DI	DMSE3I7
DMSE3I7	DN	Gemcitabine
DMSE3I7	MI	DEKEDRC
DMSE3I7	MN	Cytidine aminohydrolase (CDA)
DMSE3I7	MT	DME
DMSE3I7	MA	Metabolism
DMSE3I7	RN	Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours. Br J Clin Pharmacol. 2011 Mar;71(3):437-44.
DMSE3I7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21284703

DMSE3I7	DI	DMSE3I7
DMSE3I7	DN	Gemcitabine
DMSE3I7	MI	DETX3A5
DMSE3I7	MN	Cytidine deaminase (cdd)
DMSE3I7	MT	DME
DMSE3I7	MA	Metabolism
DMSE3I7	RN	Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science. 2017 Sep 15;357(6356):1156-1160.
DMSE3I7	RU	https://pubmed.ncbi.nlm.nih.gov/28912244

DMSE3I7	DI	DMSE3I7
DMSE3I7	DN	Gemcitabine
DMSE3I7	MI	DEFVABT
DMSE3I7	MN	Cytidine deaminase (cdd)
DMSE3I7	MT	DME
DMSE3I7	MA	Metabolism
DMSE3I7	RN	Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science. 2017 Sep 15;357(6356):1156-1160.
DMSE3I7	RU	https://pubmed.ncbi.nlm.nih.gov/28912244

DMSE3I7	DI	DMSE3I7
DMSE3I7	DN	Gemcitabine
DMSE3I7	MI	DEYILK4
DMSE3I7	MN	Cytidine deaminase (cdd)
DMSE3I7	MT	DME
DMSE3I7	MA	Metabolism
DMSE3I7	RN	Mycoplasma hyorhinis-encoded cytidine deaminase efficiently inactivates cytosine-based anticancer drugs. FEBS Open Bio. 2015 Aug 3;5:634-9.
DMSE3I7	RU	https://pubmed.ncbi.nlm.nih.gov/26322268

DMSE3I7	DI	DMSE3I7
DMSE3I7	DN	Gemcitabine
DMSE3I7	MI	DTYVM24
DMSE3I7	MN	Multidrug resistance-associated protein 5 (ABCC5)
DMSE3I7	MT	DTP
DMSE3I7	MA	Substrate
DMSE3I7	RN	Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells. Neoplasia. 2010 Sep;12(9):740-7.
DMSE3I7	RU	http://www.ncbi.nlm.nih.gov/pubmed/20824050

DMSE3I7	DI	DMSE3I7
DMSE3I7	DN	Gemcitabine
DMSE3I7	MI	DTUGYRD
DMSE3I7	MN	P-glycoprotein 1 (ABCB1)
DMSE3I7	MT	DTP
DMSE3I7	MA	Substrate
DMSE3I7	RN	Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br J Cancer. 2003 Jun 16;88(12):1963-70.
DMSE3I7	RU	https://doi.org/10.1038/sj.bjc.6601011

DMSE3I7	DI	DMSE3I7
DMSE3I7	DN	Gemcitabine
DMSE3I7	MI	TTBWDI0
DMSE3I7	MN	Ribonucleoside-diphosphate reductase M2 (RRM2)
DMSE3I7	MT	DTT
DMSE3I7	MA	Modulator
DMSE3I7	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMSE3I7	RU	https://www.fda.gov/

DMSE3I7	DI	DMSE3I7
DMSE3I7	DN	Gemcitabine
DMSE3I7	MI	DEMPH4I
DMSE3I7	MN	Uridine/cytidine monophosphate kinase (UMPK)
DMSE3I7	MT	DME
DMSE3I7	MA	Metabolism
DMSE3I7	RN	Gemcitabine pharmacogenomics: deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics. Drug Metab Dispos. 2008 Sep;36(9):1951-9.
DMSE3I7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18556440

DMD8Q3J	DI	DMD8Q3J
DMD8Q3J	DN	Gemfibrozil
DMD8Q3J	MI	DEFKSVZ
DMD8Q3J	MN	Catechol-2,3-dioxygenase (caD)
DMD8Q3J	MT	DME
DMD8Q3J	MA	Metabolism
DMD8Q3J	RN	Genomic, proteomic, and metabolite characterization of gemfibrozil-degrading organism Bacillus sp. GeD10. Environ Sci Technol. 2016 Jan 19;50(2):744-55.
DMD8Q3J	RU	https://pubmed.ncbi.nlm.nih.gov/26683816

DMD8Q3J	DI	DMD8Q3J
DMD8Q3J	DN	Gemfibrozil
DMD8Q3J	MI	DE4LYSA
DMD8Q3J	MN	Cytochrome P450 3A4 (CYP3A4)
DMD8Q3J	MT	DME
DMD8Q3J	MA	Metabolism
DMD8Q3J	RN	Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998 Feb;34(2):155-62.
DMD8Q3J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9515185

DMD8Q3J	DI	DMD8Q3J
DMD8Q3J	DN	Gemfibrozil
DMD8Q3J	MI	TTOF3WZ
DMD8Q3J	MN	Lipoprotein lipase (LPL)
DMD8Q3J	MT	DTT
DMD8Q3J	MA	Activator
DMD8Q3J	RN	Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today (Barc). 2006 Jan;42(1):39-64.
DMD8Q3J	RU	https://pubmed.ncbi.nlm.nih.gov/16511610

DMD8Q3J	DI	DMD8Q3J
DMD8Q3J	DN	Gemfibrozil
DMD8Q3J	MI	DEYGVN4
DMD8Q3J	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMD8Q3J	MT	DME
DMD8Q3J	MA	Metabolism
DMD8Q3J	RN	The UDP-glucuronosyltransferase 2B7 isozyme is responsible for gemfibrozil glucuronidation in the human liver. Drug Metab Dispos. 2007 Nov;35(11):2040-4.
DMD8Q3J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17670842

DMD8Q3J	DI	DMD8Q3J
DMD8Q3J	DN	Gemfibrozil
DMD8Q3J	MI	DEF2WXN
DMD8Q3J	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMD8Q3J	MT	DME
DMD8Q3J	MA	Metabolism
DMD8Q3J	RN	Comprehensive pharmacogenomic study reveals an important role of UGT1A3 in montelukast pharmacokinetics. Clin Pharmacol Ther. 2018 Jul;104(1):158-168.
DMD8Q3J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28940478

DMD8Q3J	DI	DMD8Q3J
DMD8Q3J	DN	Gemfibrozil
DMD8Q3J	MI	DE85D2P
DMD8Q3J	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMD8Q3J	MT	DME
DMD8Q3J	MA	Metabolism
DMD8Q3J	RN	The UDP-glucuronosyltransferase 2B7 isozyme is responsible for gemfibrozil glucuronidation in the human liver. Drug Metab Dispos. 2007 Nov;35(11):2040-4.
DMD8Q3J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17670842

DMD8Q3J	DI	DMD8Q3J
DMD8Q3J	DN	Gemfibrozil
DMD8Q3J	MI	DEB3CV1
DMD8Q3J	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMD8Q3J	MT	DME
DMD8Q3J	MA	Metabolism
DMD8Q3J	RN	The UDP-glucuronosyltransferase 2B7 isozyme is responsible for gemfibrozil glucuronidation in the human liver. Drug Metab Dispos. 2007 Nov;35(11):2040-4.
DMD8Q3J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17670842

DMHT34O	DI	DMHT34O
DMHT34O	DN	Gemifloxacin
DMHT34O	MI	TTN6J5F
DMHT34O	MN	Bacterial DNA gyrase (Bact gyrase)
DMHT34O	MT	DTT
DMHT34O	MA	Modulator
DMHT34O	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMHT34O	RU	https://www.fda.gov/

DMHT34O	DI	DMHT34O
DMHT34O	DN	Gemifloxacin
DMHT34O	MI	DTFI42L
DMHT34O	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMHT34O	MT	DTP
DMHT34O	MA	Substrate
DMHT34O	RN	Differential effect of P-gp and MRP2 on cellular translocation of gemifloxacin. Int J Pharm. 2011 Nov 25;420(1):26-33.
DMHT34O	RU	http://www.ncbi.nlm.nih.gov/pubmed/21864659

DMHT34O	DI	DMHT34O
DMHT34O	DN	Gemifloxacin
DMHT34O	MI	TTIXTO3
DMHT34O	MN	Staphylococcus Topoisomerase IV (Stap-coc parC)
DMHT34O	MT	DTT
DMHT34O	MA	Modulator
DMHT34O	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMHT34O	RU	https://www.fda.gov/

DMJ2O7B	DI	DMJ2O7B
DMJ2O7B	DN	Gemtuzumab ozogamicin
DMJ2O7B	MI	DE4LYSA
DMJ2O7B	MN	Cytochrome P450 3A4 (CYP3A4)
DMJ2O7B	MT	DME
DMJ2O7B	MA	Metabolism
DMJ2O7B	RN	Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998 Feb;34(2):155-62.
DMJ2O7B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9515185

DMJ2O7B	DI	DMJ2O7B
DMJ2O7B	DN	Gemtuzumab ozogamicin
DMJ2O7B	MI	TTJVYO3
DMJ2O7B	MN	Myeloid cell surface antigen CD33 (CD33)
DMJ2O7B	MT	DTT
DMJ2O7B	RN	Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin. Clin Interv Aging. 2009;4:197-205.
DMJ2O7B	RU	https://pubmed.ncbi.nlm.nih.gov/19503782

DMKINJO	DI	DMKINJO
DMKINJO	DN	Gentamicin
DMKINJO	MI	DE48UAX
DMKINJO	MN	Aminoglycoside 6'-N-acetyltransferase (aacA)
DMKINJO	MT	DME
DMKINJO	MA	Metabolism
DMKINJO	RN	Detection of multidrug-resistant Enterobacteriaceae isolated from river waters flowing to the Guanabara Bay and from clinical samples of hospitals in Rio de Janeiro, Brazil. Biomedica. 2019 May 1;39(s1):135-149.
DMKINJO	RU	https://pubmed.ncbi.nlm.nih.gov/31529856

DMKINJO	DI	DMKINJO
DMKINJO	DN	Gentamicin
DMKINJO	MI	DEWPAJD
DMKINJO	MN	Aminoglycoside O-phosphotransferase (aphA6)
DMKINJO	MT	DME
DMKINJO	MA	Metabolism
DMKINJO	RN	Relationship between antimicrobial resistance and aminoglycoside-modifying enzyme gene expressions in Acinetobacter baumannii. Chin Med J (Engl). 2005 Jan 20;118(2):141-5.
DMKINJO	RU	https://pubmed.ncbi.nlm.nih.gov/15667800

DMKINJO	DI	DMKINJO
DMKINJO	DN	Gentamicin
DMKINJO	MI	DE5WGIM
DMKINJO	MN	Aminoglycoside phosphotransferase (aph-Ib)
DMKINJO	MT	DME
DMKINJO	MA	Metabolism
DMKINJO	RN	Cloning and expression of novel aminoglycoside phosphotransferase genes from Campylobacter and their role in the resistance to six aminoglycosides. Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01682-17.
DMKINJO	RU	https://pubmed.ncbi.nlm.nih.gov/29109167

DMKINJO	DI	DMKINJO
DMKINJO	DN	Gentamicin
DMKINJO	MI	TTOVFH2
DMKINJO	MN	Bacterial 30S ribosomal RNA (Bact 30S rRNA)
DMKINJO	MT	DTT
DMKINJO	MA	Modulator
DMKINJO	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMKINJO	RU	https://www.fda.gov/

DMKINJO	DI	DMKINJO
DMKINJO	DN	Gentamicin
DMKINJO	MI	DE2M583
DMKINJO	MN	Endoglucanase Y (EGY)
DMKINJO	MT	DME
DMKINJO	MA	Metabolism
DMKINJO	RN	Expression of Clostridium thermocellum endoglucanase gene in Lactobacillus gasseri and Lactobacillus johnsonii and characterization of the genetically modified probiotic lactobacilli. Curr Microbiol. 2000 Apr;40(4):257-63.
DMKINJO	RU	https://pubmed.ncbi.nlm.nih.gov/10688695

DMKINJO	DI	DMKINJO
DMKINJO	DN	Gentamicin
DMKINJO	MI	DE2AZTG
DMKINJO	MN	Endoglucanase Y (EGY)
DMKINJO	MT	DME
DMKINJO	MA	Metabolism
DMKINJO	RN	Expression of Clostridium thermocellum endoglucanase gene in Lactobacillus gasseri and Lactobacillus johnsonii and characterization of the genetically modified probiotic lactobacilli. Curr Microbiol. 2000 Apr;40(4):257-63.
DMKINJO	RU	https://pubmed.ncbi.nlm.nih.gov/10688695

DMKINJO	DI	DMKINJO
DMKINJO	DN	Gentamicin
DMKINJO	MI	DECXWN8
DMKINJO	MN	Kanamycin/gentamycin-resistance enzyme (aacA)
DMKINJO	MT	DME
DMKINJO	MA	Metabolism
DMKINJO	RN	Cloning and expression of novel aminoglycoside phosphotransferase genes from Campylobacter and their role in the resistance to six aminoglycosides. Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01682-17.
DMKINJO	RU	https://pubmed.ncbi.nlm.nih.gov/29109167

DMBT7MI	DI	DMBT7MI
DMBT7MI	DN	Gentamicine sulfate
DMBT7MI	MI	TTUWYEA
DMBT7MI	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DMBT7MI	MT	DTT
DMBT7MI	MA	Binder
DMBT7MI	RN	The protein synthesis inhibitors, oxazolidinones and chloramphenicol, cause extensive translational inaccuracy in vivo. J Mol Biol. 2002 Sep 13;322(2):273-9.
DMBT7MI	RU	https://pubmed.ncbi.nlm.nih.gov/12217690

DMP0OVQ	DI	DMP0OVQ
DMP0OVQ	DN	Gestrinone
DMP0OVQ	MI	DE4LYSA
DMP0OVQ	MN	Cytochrome P450 3A4 (CYP3A4)
DMP0OVQ	MT	DME
DMP0OVQ	MA	Metabolism
DMP0OVQ	RN	Adverse drug interactions: a handbook for prescribers. Taylor and Francis group.2010.
DMP0OVQ	RU	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040554/

DMP0OVQ	DI	DMP0OVQ
DMP0OVQ	DN	Gestrinone
DMP0OVQ	MI	TTZAYWL
DMP0OVQ	MN	Estrogen receptor (ESR)
DMP0OVQ	MT	DTT
DMP0OVQ	MA	Modulator
DMP0OVQ	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMP0OVQ	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DMKGH0R	DI	DMKGH0R
DMKGH0R	DN	GHRP-2
DMKGH0R	MI	TTWDC17
DMKGH0R	MN	Growth hormone secretagogue receptor 1 (GHSR)
DMKGH0R	MT	DTT
DMKGH0R	MA	Agonist
DMKGH0R	RN	GH-releasing peptide-2 increases fat mass in mice lacking NPY: indication for a crucial mediating role of hypothalamic agouti-related protein. Endocrinology. 2002 Feb;143(2):558-68.
DMKGH0R	RU	https://pubmed.ncbi.nlm.nih.gov/11796511

DMKGH0R	DI	DMKGH0R
DMKGH0R	DN	GHRP-2
DMKGH0R	MI	TTZ3IFB
DMKGH0R	MN	Phosphogluconate dehydrogenase (PGD)
DMKGH0R	MT	DTT
DMKGH0R	MA	Inhibitor
DMKGH0R	RN	Synthesis and biological evaluation of substrate-based inhibitors of 6-phosphogluconate dehydrogenase as potential drugs against African trypanosomiasis. Bioorg Med Chem. 2003 Jul 17;11(14):3205-14.
DMKGH0R	RU	https://pubmed.ncbi.nlm.nih.gov/12818683

DMWQ4MZ	DI	DMWQ4MZ
DMWQ4MZ	DN	Gilteritinib
DMWQ4MZ	MI	DE4LYSA
DMWQ4MZ	MN	Cytochrome P450 3A4 (CYP3A4)
DMWQ4MZ	MT	DME
DMWQ4MZ	MA	Metabolism
DMWQ4MZ	RN	ClinicalTrials.gov (NCT02456883) Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors.
DMWQ4MZ	RU	https://clinicaltrials.gov/ct2/show/NCT02456883

DMWQ4MZ	DI	DMWQ4MZ
DMWQ4MZ	DN	Gilteritinib
DMWQ4MZ	MI	TTGJCWZ
DMWQ4MZ	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMWQ4MZ	MT	DTT
DMWQ4MZ	MA	Inhibitor
DMWQ4MZ	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMWQ4MZ	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMTI0ZO	DI	DMTI0ZO
DMTI0ZO	DN	Gilteritinib
DMTI0ZO	MI	DTUGYRD
DMTI0ZO	MN	P-glycoprotein 1 (ABCB1)
DMTI0ZO	MT	DTP
DMTI0ZO	MA	Substrate
DMTI0ZO	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
DMTI0ZO	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01665

DMWQ4MZ	DI	DMWQ4MZ
DMWQ4MZ	DN	Gilteritinib
DMWQ4MZ	MI	TTZPY6J
DMWQ4MZ	MN	Tyrosine-protein kinase UFO (AXL)
DMWQ4MZ	MT	DTT
DMWQ4MZ	MA	Inhibitor
DMWQ4MZ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMWQ4MZ	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM5PFIJ	DI	DM5PFIJ
DM5PFIJ	DN	Givosiran
DM5PFIJ	MI	TTG1FXO
DM5PFIJ	MN	ALAS1 messenger RNA (ALAS1 mRNA)
DM5PFIJ	MT	DTT
DM5PFIJ	MA	Inhibitor
DM5PFIJ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DM5PFIJ	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/0212194s000lbl.pdf

DM83MOK	DI	DM83MOK
DM83MOK	DN	Glassia
DM83MOK	MI	TTA7UJC
DM83MOK	MN	Alpha-1-antitrypsin (SERPINA1)
DM83MOK	MT	DTT
DM83MOK	MA	Inhibitor
DM83MOK	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DM83MOK	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DMAPV1B	DI	DMAPV1B
DMAPV1B	DN	Glatiramer acetate
DMAPV1B	MI	TTLCMWF
DMAPV1B	MN	MHC class II antigen DRB1*1 (HLA-DRB1)
DMAPV1B	MT	DTT
DMAPV1B	MA	Binder
DMAPV1B	RN	Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14593-8.
DMAPV1B	RU	https://pubmed.ncbi.nlm.nih.gov/15371592

DM31YVO	DI	DM31YVO
DM31YVO	DN	Glecaprevir
DM31YVO	MI	DE4LYSA
DM31YVO	MN	Cytochrome P450 3A4 (CYP3A4)
DM31YVO	MT	DME
DM31YVO	MA	Metabolism
DM31YVO	RN	The pharmacological interactions between direct-acting antivirals for the treatment of chronic hepatitis c and psychotropic drugs. Expert Rev Clin Pharmacol. 2018 Oct;11(10):999-1030.
DM31YVO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30199279

DMF6Z5T	DI	DMF6Z5T
DMF6Z5T	DN	Glecaprevir; pibrentasvir
DMF6Z5T	MI	TTCJ2X8
DMF6Z5T	MN	Hepatitis C virus Non-structural 5A (HCV NS5A)
DMF6Z5T	MT	DTT
DMF6Z5T	MA	Inhibitor
DMF6Z5T	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DMF6Z5T	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DMF6Z5T	DI	DMF6Z5T
DMF6Z5T	DN	Glecaprevir; pibrentasvir
DMF6Z5T	MI	TTHC7JD
DMF6Z5T	MN	Hepatitis C virus Serine protease NS3/4A (HCV NS3/4A)
DMF6Z5T	MT	DTT
DMF6Z5T	MA	Inhibitor
DMF6Z5T	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DMF6Z5T	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DM8JXPZ	DI	DM8JXPZ
DM8JXPZ	DN	Glibenclamide
DM8JXPZ	MI	TTP835K
DM8JXPZ	MN	ATP-binding cassette transporter C8 (ABCC8)
DM8JXPZ	MT	DTT
DM8JXPZ	MA	Modulator
DM8JXPZ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM8JXPZ	RU	https://www.fda.gov/

DM8JXPZ	DI	DM8JXPZ
DM8JXPZ	DN	Glibenclamide
DM8JXPZ	MI	DTI7UX6
DM8JXPZ	MN	Breast cancer resistance protein (ABCG2)
DM8JXPZ	MT	DTP
DM8JXPZ	MA	Substrate
DM8JXPZ	RN	Glyburide transport across the human placenta. Obstet Gynecol. 2015 Mar;125(3):583-8.
DM8JXPZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/25730219

DM8JXPZ	DI	DM8JXPZ
DM8JXPZ	DN	Glibenclamide
DM8JXPZ	MI	DE5IED8
DM8JXPZ	MN	Cytochrome P450 2C9 (CYP2C9)
DM8JXPZ	MT	DME
DM8JXPZ	MA	Metabolism
DM8JXPZ	RN	Contributions of human cytochrome P450 enzymes to glyburide metabolism. Biopharm Drug Dispos. 2010 May;31(4):228-42.
DM8JXPZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20437462

DM8JXPZ	DI	DM8JXPZ
DM8JXPZ	DN	Glibenclamide
DM8JXPZ	MI	DE4LYSA
DM8JXPZ	MN	Cytochrome P450 3A4 (CYP3A4)
DM8JXPZ	MT	DME
DM8JXPZ	MA	Metabolism
DM8JXPZ	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM8JXPZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM8JXPZ	DI	DM8JXPZ
DM8JXPZ	DN	Glibenclamide
DM8JXPZ	MI	DEIBDNY
DM8JXPZ	MN	Cytochrome P450 3A5 (CYP3A5)
DM8JXPZ	MT	DME
DM8JXPZ	MA	Metabolism
DM8JXPZ	RN	Identification of CYP3A7 for glyburide metabolism in human fetal livers. Biochem Pharmacol. 2014 Dec 15;92(4):690-700.
DM8JXPZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25450675

DM8JXPZ	DI	DM8JXPZ
DM8JXPZ	DN	Glibenclamide
DM8JXPZ	MI	DERD86B
DM8JXPZ	MN	Cytochrome P450 3A7 (CYP3A7)
DM8JXPZ	MT	DME
DM8JXPZ	MA	Metabolism
DM8JXPZ	RN	Identification of CYP3A7 for glyburide metabolism in human fetal livers. Biochem Pharmacol. 2014 Dec 15;92(4):690-700.
DM8JXPZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25450675

DM8JXPZ	DI	DM8JXPZ
DM8JXPZ	DN	Glibenclamide
DM8JXPZ	MI	DEGTFWK
DM8JXPZ	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM8JXPZ	MT	DME
DM8JXPZ	MA	Metabolism
DM8JXPZ	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM8JXPZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM8JXPZ	DI	DM8JXPZ
DM8JXPZ	DN	Glibenclamide
DM8JXPZ	MI	DTQ3ZHF
DM8JXPZ	MN	Multidrug resistance-associated protein 3 (ABCC3)
DM8JXPZ	MT	DTP
DM8JXPZ	MA	Substrate
DM8JXPZ	RN	Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta. 2006 Nov-Dec;27(11-12):1096-102.
DM8JXPZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/16460798

DM8JXPZ	DI	DM8JXPZ
DM8JXPZ	DN	Glibenclamide
DM8JXPZ	MI	DTPFTEQ
DM8JXPZ	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DM8JXPZ	MT	DTP
DM8JXPZ	MA	Substrate
DM8JXPZ	RN	Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos. 2005 Apr;33(4):518-23.
DM8JXPZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/15640378

DM8JXPZ	DI	DM8JXPZ
DM8JXPZ	DN	Glibenclamide
DM8JXPZ	MI	DEYGVN4
DM8JXPZ	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM8JXPZ	MT	DME
DM8JXPZ	MA	Metabolism
DM8JXPZ	RN	Contribution of UDP-glucuronosyltransferases 1A9 and 2B7 to the glucuronidation of indomethacin in the human liver. Eur J Clin Pharmacol. 2007 Mar;63(3):289-96.
DM8JXPZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17245571

DMN6QO5	DI	DMN6QO5
DMN6QO5	DN	Gliclazide
DMN6QO5	MI	TTP835K
DMN6QO5	MN	ATP-binding cassette transporter C8 (ABCC8)
DMN6QO5	MT	DTT
DMN6QO5	MA	Blocker
DMN6QO5	RN	Structural basis for the interference between nicorandil and sulfonylurea action. Diabetes. 2001 Oct;50(10):2253-9.
DMN6QO5	RU	https://pubmed.ncbi.nlm.nih.gov/11574406

DMN6QO5	DI	DMN6QO5
DMN6QO5	DN	Gliclazide
DMN6QO5	MI	DE5IED8
DMN6QO5	MN	Cytochrome P450 2C9 (CYP2C9)
DMN6QO5	MT	DME
DMN6QO5	MA	Metabolism
DMN6QO5	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMN6QO5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMN6QO5	DI	DMN6QO5
DMN6QO5	DN	Gliclazide
DMN6QO5	MI	DEGTFWK
DMN6QO5	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMN6QO5	MT	DME
DMN6QO5	MA	Metabolism
DMN6QO5	RN	The metabolism of CYP2C9 and CYP2C19 for gliclazide by homology modeling and docking study. Eur J Med Chem. 2009 Feb;44(2):854-61.
DMN6QO5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18541345

DM5FSJA	DI	DM5FSJA
DM5FSJA	DN	Glimepiride
DM5FSJA	MI	TTP835K
DM5FSJA	MN	ATP-binding cassette transporter C8 (ABCC8)
DM5FSJA	MT	DTT
DM5FSJA	MA	Blocker
DM5FSJA	RN	Mechanism of disopyramide-induced hypoglycaemia in a patient with Type 2 diabetes. Diabet Med. 2009 Jan;26(1):76-8.
DM5FSJA	RU	https://pubmed.ncbi.nlm.nih.gov/19125764

DM5FSJA	DI	DM5FSJA
DM5FSJA	DN	Glimepiride
DM5FSJA	MI	TTEF5MJ
DM5FSJA	MN	ATP-binding cassette transporter C9 (ABCC9)
DM5FSJA	MT	DTT
DM5FSJA	MA	Blocker
DM5FSJA	RN	Mechanism of disopyramide-induced hypoglycaemia in a patient with Type 2 diabetes. Diabet Med. 2009 Jan;26(1):76-8.
DM5FSJA	RU	https://pubmed.ncbi.nlm.nih.gov/19125764

DM5FSJA	DI	DM5FSJA
DM5FSJA	DN	Glimepiride
DM5FSJA	MI	DTJ0EW4
DM5FSJA	MN	Bile salt export pump (ABCB11)
DM5FSJA	MT	DTP
DM5FSJA	MA	Substrate
DM5FSJA	RN	Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
DM5FSJA	RU	http://www.ncbi.nlm.nih.gov/pubmed/24014644

DM5FSJA	DI	DM5FSJA
DM5FSJA	DN	Glimepiride
DM5FSJA	MI	DE5IED8
DM5FSJA	MN	Cytochrome P450 2C9 (CYP2C9)
DM5FSJA	MT	DME
DM5FSJA	MA	Metabolism
DM5FSJA	RN	Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. Diabetes Res Clin Pract. 2006 May;72(2):148-54.
DM5FSJA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16325295

DMZA5PQ	DI	DMZA5PQ
DMZA5PQ	DN	Glipizide
DMZA5PQ	MI	DTJ0EW4
DMZA5PQ	MN	Bile salt export pump (ABCB11)
DMZA5PQ	MT	DTP
DMZA5PQ	MA	Substrate
DMZA5PQ	RN	Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
DMZA5PQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/24014644

DMZA5PQ	DI	DMZA5PQ
DMZA5PQ	DN	Glipizide
DMZA5PQ	MI	DE5IED8
DMZA5PQ	MN	Cytochrome P450 2C9 (CYP2C9)
DMZA5PQ	MT	DME
DMZA5PQ	MA	Metabolism
DMZA5PQ	RN	Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther. 2005 Jan;77(1):1-16.
DMZA5PQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15637526

DMZA5PQ	DI	DMZA5PQ
DMZA5PQ	DN	Glipizide
DMZA5PQ	MI	DE4LYSA
DMZA5PQ	MN	Cytochrome P450 3A4 (CYP3A4)
DMZA5PQ	MT	DME
DMZA5PQ	MA	Metabolism
DMZA5PQ	RN	Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. Pharmacoeconomics. 2004;22(6):389-411.
DMZA5PQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15099124

DMZA5PQ	DI	DMZA5PQ
DMZA5PQ	DN	Glipizide
DMZA5PQ	MI	TTG140O
DMZA5PQ	MN	Inward rectifier potassium channel Kir1.2 (KCNJ10)
DMZA5PQ	MT	DTT
DMZA5PQ	MA	Blocker
DMZA5PQ	RN	Triggering and amplification of insulin secretion by dimethyl alpha-ketoglutarate, a membrane permeable alpha-ketoglutarate analogue. Eur J Pharmacol. 2009 Apr 1;607(1-3):41-6.
DMZA5PQ	RU	https://pubmed.ncbi.nlm.nih.gov/19233162

DMZA5PQ	DI	DMZA5PQ
DMZA5PQ	DN	Glipizide
DMZA5PQ	MI	DEGTFWK
DMZA5PQ	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMZA5PQ	MT	DME
DMZA5PQ	MA	Metabolism
DMZA5PQ	RN	Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics. 1999 Feb;9(1):71-80.
DMZA5PQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10208645

DMZA5PQ	DI	DMZA5PQ
DMZA5PQ	DN	Glipizide
DMZA5PQ	MI	DEYGVN4
DMZA5PQ	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMZA5PQ	MT	DME
DMZA5PQ	MA	Metabolism
DMZA5PQ	RN	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
DMZA5PQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429

DMB0EUX	DI	DMB0EUX
DMB0EUX	DN	Gliquidone
DMB0EUX	MI	DE5IED8
DMB0EUX	MN	Cytochrome P450 2C9 (CYP2C9)
DMB0EUX	MT	DME
DMB0EUX	MA	Metabolism
DMB0EUX	RN	Clinically and pharmacologically relevant interactions of antidiabetic drugs. Ther Adv Endocrinol Metab. 2016 Apr;7(2):69-83.
DMB0EUX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27092232

DMB0EUX	DI	DMB0EUX
DMB0EUX	DN	Gliquidone
DMB0EUX	MI	TTG140O
DMB0EUX	MN	Inward rectifier potassium channel Kir1.2 (KCNJ10)
DMB0EUX	MT	DTT
DMB0EUX	MA	Binder
DMB0EUX	RN	Hydroxyl-substituted sulfonylureas as potent inhibitors of specific [3H]glyburide binding to rat brain synaptosomes. Bioorg Med Chem. 2003 May 1;11(9):2099-113.
DMB0EUX	RU	https://pubmed.ncbi.nlm.nih.gov/12670661

DMJPR2B	DI	DMJPR2B
DMJPR2B	DN	Glisoxepide
DMJPR2B	MI	DE5IED8
DMJPR2B	MN	Cytochrome P450 2C9 (CYP2C9)
DMJPR2B	MT	DME
DMJPR2B	MA	Metabolism
DMJPR2B	RN	Clinically and pharmacologically relevant interactions of antidiabetic drugs. Ther Adv Endocrinol Metab. 2016 Apr;7(2):69-83.
DMJPR2B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27092232

DMJPR2B	DI	DMJPR2B
DMJPR2B	DN	Glisoxepide
DMJPR2B	MI	TTG140O
DMJPR2B	MN	Inward rectifier potassium channel Kir1.2 (KCNJ10)
DMJPR2B	MT	DTT
DMJPR2B	MA	Blocker
DMJPR2B	RN	Bepridil, an antiarrhythmic drug, opens mitochondrial KATP channels, blocks sarcolemmal KATP channels, and confers cardioprotection. J Pharmacol Exp Ther. 2006 Jan;316(1):182-8.
DMJPR2B	RU	https://pubmed.ncbi.nlm.nih.gov/16174795

DMFLUTR	DI	DMFLUTR
DMFLUTR	DN	Glucagon recombinant
DMFLUTR	MI	TT9O6WS
DMFLUTR	MN	Glucagon receptor (GCGR)
DMFLUTR	MT	DTT
DMFLUTR	MA	Binder
DMFLUTR	RN	Glucagon receptor expression and glucagon stimulation of ghrelin secretion in rat stomach. Biochem Biophys Res Commun. 2007 Jun 15;357(4):865-70.
DMFLUTR	RU	https://pubmed.ncbi.nlm.nih.gov/17462598

DM6EL5Q	DI	DM6EL5Q
DM6EL5Q	DN	Glucarpidase
DM6EL5Q	MI	TTX81QL
DM6EL5Q	MN	Toxic methotrexate (TM)
DM6EL5Q	MT	DTT
DM6EL5Q	MA	Modulator
DM6EL5Q	RN	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
DM6EL5Q	RU	https://pubmed.ncbi.nlm.nih.gov/23370234

DM4ZLFD	DI	DM4ZLFD
DM4ZLFD	DN	Glucosamine
DM4ZLFD	MI	DEVDYN7
DM4ZLFD	MN	Cytochrome P450 2E1 (CYP2E1)
DM4ZLFD	MT	DME
DM4ZLFD	MA	Metabolism
DM4ZLFD	RN	Characterization of moclobemide N-oxidation in human liver microsomes. Xenobiotica. 2001 Jul;31(7):387-97.
DM4ZLFD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11531003

DM4ZLFD	DI	DM4ZLFD
DM4ZLFD	DN	Glucosamine
DM4ZLFD	MI	TTRYK0X
DM4ZLFD	MN	Interleukin-1 beta (IL1B)
DM4ZLFD	MT	DTT
DM4ZLFD	MA	Inhibitor
DM4ZLFD	RN	Glucosamine inhibits IL-1beta-mediated IL-8 production in prostate cancer cells by MAPK attenuation. J Cell Biochem. 2009 Oct 1;108(2):489-98.
DM4ZLFD	RU	https://pubmed.ncbi.nlm.nih.gov/19626664

DM4ZLFD	DI	DM4ZLFD
DM4ZLFD	DN	Glucosamine
DM4ZLFD	MI	DEGTFWK
DM4ZLFD	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM4ZLFD	MT	DME
DM4ZLFD	MA	Metabolism
DM4ZLFD	RN	Characterization of moclobemide N-oxidation in human liver microsomes. Xenobiotica. 2001 Jul;31(7):387-97.
DM4ZLFD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11531003

DMAHMT9	DI	DMAHMT9
DMAHMT9	DN	Glutathione
DMAHMT9	MI	DTI7UX6
DMAHMT9	MN	Breast cancer resistance protein (ABCG2)
DMAHMT9	MT	DTP
DMAHMT9	MA	Substrate
DMAHMT9	RN	Glutathione transport is a unique function of the ATP-binding cassette protein ABCG2. J Biol Chem. 2010 May 28;285(22):16582-7.
DMAHMT9	RU	http://www.ncbi.nlm.nih.gov/pubmed/20332504

DMAHMT9	DI	DMAHMT9
DMAHMT9	DN	Glutathione
DMAHMT9	MI	TT3C1VN
DMAHMT9	MN	Enzyme unspecific (Enz)
DMAHMT9	MT	DTT
DMAHMT9	MA	Modulator
DMAHMT9	RN	Methionine and cysteine affect glutathione level, glutathione-related enzyme activities and the expression of glutathione S-transferase isozymes in rat hepatocytes. J Nutr. 1997 Nov;127(11):2135-41.
DMAHMT9	RU	https://pubmed.ncbi.nlm.nih.gov/9372907

DMAHMT9	DI	DMAHMT9
DMAHMT9	DN	Glutathione
DMAHMT9	MI	DEKW6PB
DMAHMT9	MN	Gamma-glutamylcyclotransferase (GGCT)
DMAHMT9	MT	DME
DMAHMT9	MA	Metabolism
DMAHMT9	RN	Characterization of the mechanism of thioredoxin-dependent activation of gamma-glutamylcyclotransferase, RipAY, from Ralstonia solanacearum. Biochem Biophys Res Commun. 2020 Mar 12;523(3):759-765.
DMAHMT9	RU	https://pubmed.ncbi.nlm.nih.gov/31948763

DMAHMT9	DI	DMAHMT9
DMAHMT9	DN	Glutathione
DMAHMT9	MI	DEB4JZV
DMAHMT9	MN	Gamma-glutamylcyclotransferase 2 (CHAC2)
DMAHMT9	MT	DME
DMAHMT9	MA	Metabolism
DMAHMT9	RN	ChaC2, an enzyme for slow turnover of cytosolic glutathione. J Biol Chem. 2017 Jan 13;292(2):638-651.
DMAHMT9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27913623

DMAHMT9	DI	DMAHMT9
DMAHMT9	DN	Glutathione
DMAHMT9	MI	DEH6CAO
DMAHMT9	MN	Gamma-glutamyltranspeptidase 5 (GGT5)
DMAHMT9	MT	DME
DMAHMT9	MA	Metabolism
DMAHMT9	RN	Gamma-glutamyl compounds: substrate specificity of gamma-glutamyl transpeptidase enzymes. Anal Biochem. 2011 Jul 15;414(2):208-14.
DMAHMT9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21447318

DMAHMT9	DI	DMAHMT9
DMAHMT9	DN	Glutathione
DMAHMT9	MI	DEOS3FD
DMAHMT9	MN	Glutathione peroxidase 6 (GPX6)
DMAHMT9	MT	DME
DMAHMT9	MA	Metabolism
DMAHMT9	RN	Metabolomics reveals a role for the chromatin-binding protein HMGN5 in glutathione metabolism. PLoS One. 2014 Jan 2;9(1):e84583.
DMAHMT9	RU	https://pubmed.ncbi.nlm.nih.gov/24392144

DMAHMT9	DI	DMAHMT9
DMAHMT9	DN	Glutathione
DMAHMT9	MI	DEZSNJD
DMAHMT9	MN	Glutathione S-transferase omega-1 (GSTO1)
DMAHMT9	MT	DME
DMAHMT9	MA	Metabolism
DMAHMT9	RN	Structural insights into the dehydroascorbate reductase activity of human omega-class glutathione transferases. J Mol Biol. 2012 Jul 13;420(3):190-203.
DMAHMT9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22522127

DMAHMT9	DI	DMAHMT9
DMAHMT9	DN	Glutathione
DMAHMT9	MI	DEHMPZR
DMAHMT9	MN	Glutathione S-transferase omega-2 (GSTO2)
DMAHMT9	MT	DME
DMAHMT9	MA	Metabolism
DMAHMT9	RN	Structural insights into the dehydroascorbate reductase activity of human omega-class glutathione transferases. J Mol Biol. 2012 Jul 13;420(3):190-203.
DMAHMT9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22522127

DMAHMT9	DI	DMAHMT9
DMAHMT9	DN	Glutathione
DMAHMT9	MI	DTSYQGK
DMAHMT9	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMAHMT9	MT	DTP
DMAHMT9	MA	Substrate
DMAHMT9	RN	Structural determinants of substrate specificity differences between human multidrug resistance protein (MRP) 1 (ABCC1) and MRP3 (ABCC3). Drug Metab Dispos. 2008 Dec;36(12):2571-81.
DMAHMT9	RU	http://www.ncbi.nlm.nih.gov/pubmed/18775981

DMAHMT9	DI	DMAHMT9
DMAHMT9	DN	Glutathione
DMAHMT9	MI	DTFI42L
DMAHMT9	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMAHMT9	MT	DTP
DMAHMT9	MA	Substrate
DMAHMT9	RN	Oxidative and electrophilic stress induces multidrug resistance-associated protein transporters via the nuclear factor-E2-related factor-2 transcriptional pathway. Hepatology. 2007 Nov;46(5):1597-610.
DMAHMT9	RU	http://www.ncbi.nlm.nih.gov/pubmed/17668877

DMAHMT9	DI	DMAHMT9
DMAHMT9	DN	Glutathione
DMAHMT9	MI	DTCSGPB
DMAHMT9	MN	Multidrug resistance-associated protein 4 (ABCC4)
DMAHMT9	MT	DTP
DMAHMT9	MA	Substrate
DMAHMT9	RN	Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues. Biochem J. 2002 Feb 1;361(Pt 3):497-503.
DMAHMT9	RU	https://doi.org/10.1042/0264-6021:3610497

DMAHMT9	DI	DMAHMT9
DMAHMT9	DN	Glutathione
DMAHMT9	MI	DT9C1TS
DMAHMT9	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMAHMT9	MT	DTP
DMAHMT9	MA	Substrate
DMAHMT9	RN	Regulation of Organic Anion Transporting Polypeptides (OATP) 1B1- and OATP1B3-Mediated Transport: An Updated Review in the Context of OATP-Mediated Drug-Drug Interactions. Int J Mol Sci. 2018 Mar 14;19(3). pii: E855.
DMAHMT9	RU	http://www.ncbi.nlm.nih.gov/pubmed/29538325

DMAHMT9	DI	DMAHMT9
DMAHMT9	DN	Glutathione
DMAHMT9	MI	DTUGYRD
DMAHMT9	MN	P-glycoprotein 1 (ABCB1)
DMAHMT9	MT	DTP
DMAHMT9	MA	Substrate
DMAHMT9	RN	Upregulation of cellular glutathione levels in human ABCB5- and murine Abcb5-transfected cells. BMC Pharmacol Toxicol. 2015 Dec 15;16:37.
DMAHMT9	RU	http://www.ncbi.nlm.nih.gov/pubmed/26666373

DMGE0CW	DI	DMGE0CW
DMGE0CW	DN	Glutethimide
DMGE0CW	MI	TTVG215
DMGE0CW	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DMGE0CW	MT	DTT
DMGE0CW	MA	Inducer
DMGE0CW	RN	A study of the effects of large doses of glutethimide that were used for self-poisoning during pregnancy on human fetuses. Toxicol Ind Health. 2008 Feb-Mar;24(1-2):69-78.
DMGE0CW	RU	https://pubmed.ncbi.nlm.nih.gov/18818183

DMGE0CW	DI	DMGE0CW
DMGE0CW	DN	Glutethimide
DMGE0CW	MI	DEA3U9Y
DMGE0CW	MN	Myeloperoxidase (MPO)
DMGE0CW	MT	DME
DMGE0CW	MA	Metabolism
DMGE0CW	RN	Proteomic profile of aminoglutethimide-induced apoptosis in HL-60 cells: role of myeloperoxidase and arylamine free radicals. Chem Biol Interact. 2015 Sep 5;239:129-38.
DMGE0CW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26102013

DMDGRQO	DI	DMDGRQO
DMDGRQO	DN	Glycerol phenylbutyrate
DMDGRQO	MI	DEVOTU4
DMDGRQO	MN	Aquaporin adipose (AQP7)
DMDGRQO	MT	DME
DMDGRQO	MA	Metabolism
DMDGRQO	RN	Aquaporins in the human testis and spermatozoa - identification, involvement in sperm volume regulation and clinical relevance. Int J Androl. 2010 Aug 1;33(4):629-41.
DMDGRQO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19840149

DMDGRQO	DI	DMDGRQO
DMDGRQO	DN	Glycerol phenylbutyrate
DMDGRQO	MI	DEDI8VX
DMDGRQO	MN	Propanediol dehydrogenase (dhaT)
DMDGRQO	MT	DME
DMDGRQO	MA	Metabolism
DMDGRQO	RN	Expression and characterization of a novel 1,3-propanediol dehydrogenase from Lactobacillus brevis. Appl Biochem Biotechnol. 2016 Jul;179(6):959-72.
DMDGRQO	RU	https://pubmed.ncbi.nlm.nih.gov/26961082

DMIOZ29	DI	DMIOZ29
DMIOZ29	DN	Glycine
DMIOZ29	MI	DTW7AE3
DMIOZ29	MN	Alanine/serine/cysteine/threonine transporter 2 (SLC1A5)
DMIOZ29	MT	DTP
DMIOZ29	MA	Substrate
DMIOZ29	RN	Transport of butyryl-L-carnitine, a potential prodrug, via the carnitine transporter OCTN2 and the amino acid transporter ATB(0,+). Am J Physiol Gastrointest Liver Physiol. 2007 Nov;293(5):G1046-53.
DMIOZ29	RU	http://www.ncbi.nlm.nih.gov/pubmed/17855766

DMIOZ29	DI	DMIOZ29
DMIOZ29	DN	Glycine
DMIOZ29	MI	DERA3OF
DMIOZ29	MN	Bile acid-CoA thioesterase (BAAT)
DMIOZ29	MT	DME
DMIOZ29	MA	Metabolism
DMIOZ29	RN	Bile acid coenzyme A: amino acid N-acyltransferase in the amino acid conjugation of bile acids. Methods Enzymol. 2005;400:374-94.
DMIOZ29	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16399361

DMIOZ29	DI	DMIOZ29
DMIOZ29	DN	Glycine
DMIOZ29	MI	DE437BY
DMIOZ29	MN	Delta-aminolevulinate synthase 2 (ALAS2)
DMIOZ29	MT	DME
DMIOZ29	MA	Metabolism
DMIOZ29	RN	Molecular expression and characterization of erythroid-specific 5-aminolevulinate synthase gain-of-function mutations causing X-linked protoporphyria. Mol Med. 2013 Mar 5;19:18-25.
DMIOZ29	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23348515

DMIOZ29	DI	DMIOZ29
DMIOZ29	DN	Glycine
DMIOZ29	MI	TTKJEMQ
DMIOZ29	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMIOZ29	MT	DTT
DMIOZ29	MA	Antagonist
DMIOZ29	RN	Glycine transport inhibitors for the treatment of schizophrenia: Symptom and disease modification. Curr Opin Drug Discov Devel. 2009 Jul;12(4):468-78.
DMIOZ29	RU	https://pubmed.ncbi.nlm.nih.gov/19562643

DMIOZ29	DI	DMIOZ29
DMIOZ29	DN	Glycine
DMIOZ29	MI	DTJF3DX
DMIOZ29	MN	L-type amino acid transporter 2 (SLC7A8)
DMIOZ29	MT	DTP
DMIOZ29	MA	Substrate
DMIOZ29	RN	The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.3.8.20)
DMIOZ29	RU	http://www.tcdb.org/search/result.php?tc=2.A.3.8.20

DMIOZ29	DI	DMIOZ29
DMIOZ29	DN	Glycine
DMIOZ29	MI	DTBPTJF
DMIOZ29	MN	Na(+)/Cl(-) betaine/GABA transporter (SLC6A12)
DMIOZ29	MT	DTP
DMIOZ29	MA	Substrate
DMIOZ29	RN	Interpreting metabolomic profiles using unbiased pathway models. PLoS Comput Biol. 2010 Feb 26;6(2):e1000692.
DMIOZ29	RU	http://www.ncbi.nlm.nih.gov/pubmed/20195502

DMIOZ29	DI	DMIOZ29
DMIOZ29	DN	Glycine
DMIOZ29	MI	DT48WEM
DMIOZ29	MN	Proton-coupled amino acid transporter 1 (SLC36A1)
DMIOZ29	MT	DTP
DMIOZ29	MA	Substrate
DMIOZ29	RN	Transport of amino acids and GABA analogues via the human proton-coupled amino acid transporter, hPAT1: characterization of conditions for affinity and transport experiments in Caco-2 cells. Eur J Pharm Sci. 2008 Sep 2;35(1-2):86-95.
DMIOZ29	RU	http://www.ncbi.nlm.nih.gov/pubmed/18621125

DMIOZ29	DI	DMIOZ29
DMIOZ29	DN	Glycine
DMIOZ29	MI	DT2CFQ5
DMIOZ29	MN	Sodium- and chloride-dependent glycine transporter 1 (SLC6A9)
DMIOZ29	MT	DTP
DMIOZ29	MA	Substrate
DMIOZ29	RN	Mutation in SLC6A9 encoding a glycine transporter causes a novel form of non-ketotic hyperglycinemia in humans. Hum Genet. 2016 Nov;135(11):1263-1268.
DMIOZ29	RU	http://www.ncbi.nlm.nih.gov/pubmed/27481395

DMIOZ29	DI	DMIOZ29
DMIOZ29	DN	Glycine
DMIOZ29	MI	DTE8R17
DMIOZ29	MN	Sodium- and chloride-dependent glycine transporter 2 (SLC6A5)
DMIOZ29	MT	DTP
DMIOZ29	MA	Substrate
DMIOZ29	RN	Mutations in the GlyT2 gene (SLC6A5) are a second major cause of startle disease. J Biol Chem. 2012 Aug 17;287(34):28975-85.
DMIOZ29	RU	http://www.ncbi.nlm.nih.gov/pubmed/22700964

DM1WL9O	DI	DM1WL9O
DM1WL9O	DN	Glycodiazine
DM1WL9O	MI	TTG140O
DM1WL9O	MN	Inward rectifier potassium channel Kir1.2 (KCNJ10)
DM1WL9O	MT	DTT
DM1WL9O	MA	Binder
DM1WL9O	RN	Coupling between proximal tubular transport processes. Studies with ouabain, SITS and HCO3-free solutions. Pflugers Arch. 1977 Apr 25;368(3):245-52.
DM1WL9O	RU	https://pubmed.ncbi.nlm.nih.gov/141035

DM2M3ZA	DI	DM2M3ZA
DM2M3ZA	DN	Glycopyrrolate
DM2M3ZA	MI	TTZ9SOR
DM2M3ZA	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DM2M3ZA	MT	DTT
DM2M3ZA	MA	Antagonist
DM2M3ZA	RN	Autonomic cardiovascular control during a novel pharmacologic alternative to ganglionic blockade. Clin Pharmacol Ther. 2008 May;83(5):692-701.
DM2M3ZA	RU	https://pubmed.ncbi.nlm.nih.gov/17687267

DM2M3ZA	DI	DM2M3ZA
DM2M3ZA	DN	Glycopyrrolate
DM2M3ZA	MI	DTT79CX
DM2M3ZA	MN	Organic cation transporter 1 (SLC22A1)
DM2M3ZA	MT	DTP
DM2M3ZA	MA	Substrate
DM2M3ZA	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DM2M3ZA	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DMGVJLB	DI	DMGVJLB
DMGVJLB	DN	GMA-161
DMGVJLB	MI	TT7KTSR
DMGVJLB	MN	Immunoglobulin gamma Fc receptor III (FCGR3)
DMGVJLB	MT	DTT
DMGVJLB	MA	Antagonist
DMGVJLB	RN	Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54.
DMGVJLB	RU	https://pubmed.ncbi.nlm.nih.gov/18537519

DMHZV7X	DI	DMHZV7X
DMHZV7X	DN	Golimumab
DMHZV7X	MI	TTF8CQI
DMHZV7X	MN	Tumor necrosis factor (TNF)
DMHZV7X	MT	DTT
DMHZV7X	RN	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
DMHZV7X	RU	https://pubmed.ncbi.nlm.nih.gov/20118952

DMAQ469	DI	DMAQ469
DMAQ469	DN	Gonadorelin
DMAQ469	MI	TT8R70G
DMAQ469	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMAQ469	MT	DTT
DMAQ469	MA	Agonist
DMAQ469	RN	Use of cognitive behavior therapy for functional hypothalamic amenorrhea. Ann N Y Acad Sci. 2006 Dec;1092:114-29.
DMAQ469	RU	https://pubmed.ncbi.nlm.nih.gov/17308138

DMAQ469	DI	DMAQ469
DMAQ469	DN	Gonadorelin
DMAQ469	MI	DEYCUQ2
DMAQ469	MN	Metallo-endopeptidase-like 1 (MMEL1)
DMAQ469	MT	DME
DMAQ469	MA	Metabolism
DMAQ469	RN	Cell-specific activity of neprilysin 2 isoforms and enzymic specificity compared with neprilysin. Biochem J. 2002 May 1;363(Pt 3):697-705.
DMAQ469	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11964170

DMAQ469	DI	DMAQ469
DMAQ469	DN	Gonadorelin
DMAQ469	MI	DEVSCNZ
DMAQ469	MN	Prolyl endopeptidase (PREP)
DMAQ469	MT	DME
DMAQ469	MA	Metabolism
DMAQ469	RN	Ion-exchange chromatography: basic principles and application to the partial purification of soluble mammalian prolyl oligopeptidase. Methods Mol Biol. 2011;681:215-28.
DMAQ469	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20978968

DMAQ469	DI	DMAQ469
DMAQ469	DN	Gonadorelin
DMAQ469	MI	DE95LJC
DMAQ469	MN	Thimet oligopeptidase (THOP1)
DMAQ469	MT	DME
DMAQ469	MA	Metabolism
DMAQ469	RN	Sleep deprivation changes thimet oligopeptidase (THOP1) expression and activity in rat brain. Heliyon. 2019 Nov 26;5(11):e02896.
DMAQ469	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31828230

DMAT8CG	DI	DMAT8CG
DMAT8CG	DN	Goserelin
DMAT8CG	MI	TT0ID4A
DMAT8CG	MN	Leutinizing-hormone-releasing hormone (GNRH1)
DMAT8CG	MT	DTT
DMAT8CG	MA	Activator
DMAT8CG	RN	Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):341-9.
DMAT8CG	RU	https://pubmed.ncbi.nlm.nih.gov/19244174

DMPT74U	DI	DMPT74U
DMPT74U	DN	Gramicidin D
DMPT74U	MI	TT4ILYC
DMPT74U	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMPT74U	MT	DTT
DMPT74U	MA	Binder
DMPT74U	RN	Structures of gramicidins A, B, and C incorporated into sodium dodecyl sulfate micelles. Biochemistry. 2001 Oct 2;40(39):11676-86.
DMPT74U	RU	https://pubmed.ncbi.nlm.nih.gov/11570868

DMPT74U	DI	DMPT74U
DMPT74U	DN	Gramicidin D
DMPT74U	MI	DTUGYRD
DMPT74U	MN	P-glycoprotein 1 (ABCB1)
DMPT74U	MT	DTP
DMPT74U	MA	Substrate
DMPT74U	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMPT74U	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMIUW25	DI	DMIUW25
DMIUW25	DN	Granisetron
DMIUW25	MI	TTNXLKE
DMIUW25	MN	5-HT 3 receptor (5HT3R)
DMIUW25	MT	DTT
DMIUW25	MA	Antagonist
DMIUW25	RN	New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigations. Cancer J. 2006 Sep-Oct;12(5):341-7.
DMIUW25	RU	https://pubmed.ncbi.nlm.nih.gov/17034670

DMIUW25	DI	DMIUW25
DMIUW25	DN	Granisetron
DMIUW25	MI	DE6OQ3W
DMIUW25	MN	Cytochrome P450 1A1 (CYP1A1)
DMIUW25	MT	DME
DMIUW25	MA	Metabolism
DMIUW25	RN	CYP1A1 is a major enzyme responsible for the metabolism of granisetron in human liver microsomes. Curr Drug Metab. 2005 Oct;6(5):469-80.
DMIUW25	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16248838

DMIUW25	DI	DMIUW25
DMIUW25	DN	Granisetron
DMIUW25	MI	DEJGDUW
DMIUW25	MN	Cytochrome P450 1A2 (CYP1A2)
DMIUW25	MT	DME
DMIUW25	MA	Metabolism
DMIUW25	RN	Heterogeneity in systemic availability of ondansetron and granisetron following oral administration. Drug Metab Dispos. 1999 Jan;27(1):110-2.
DMIUW25	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9884318

DMIUW25	DI	DMIUW25
DMIUW25	DN	Granisetron
DMIUW25	MI	DECB0K3
DMIUW25	MN	Cytochrome P450 2D6 (CYP2D6)
DMIUW25	MT	DME
DMIUW25	MA	Metabolism
DMIUW25	RN	Granisetron: new insights into its use for the treatment of chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother. 2003 Sep;4(9):1563-71.
DMIUW25	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12943486

DMIUW25	DI	DMIUW25
DMIUW25	DN	Granisetron
DMIUW25	MI	DE4LYSA
DMIUW25	MN	Cytochrome P450 3A4 (CYP3A4)
DMIUW25	MT	DME
DMIUW25	MA	Metabolism
DMIUW25	RN	CYP1A1 is a major enzyme responsible for the metabolism of granisetron in human liver microsomes. Curr Drug Metab. 2005 Oct;6(5):469-80.
DMIUW25	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16248838

DMIUW25	DI	DMIUW25
DMIUW25	DN	Granisetron
DMIUW25	MI	DEIBDNY
DMIUW25	MN	Cytochrome P450 3A5 (CYP3A5)
DMIUW25	MT	DME
DMIUW25	MA	Metabolism
DMIUW25	RN	Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron. Br J Clin Pharmacol. 1994 Dec;38(6):557-66.
DMIUW25	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7888294

DMGLX0T	DI	DMGLX0T
DMGLX0T	DN	Grepafloxacin
DMGLX0T	MI	TTN6J5F
DMGLX0T	MN	Bacterial DNA gyrase (Bact gyrase)
DMGLX0T	MT	DTT
DMGLX0T	MA	Modulator
DMGLX0T	RN	Grepafloxacin, a dimethyl derivative of ciprofloxacin, acts preferentially through gyrase in Streptococcus pneumoniae: role of the C-5 group in tar... Antimicrob Agents Chemother. 2002 Feb;46(2):582-5.
DMGLX0T	RU	https://www.ncbi.nlm.nih.gov/pubmed/11796384

DMGLX0T	DI	DMGLX0T
DMGLX0T	DN	Grepafloxacin
DMGLX0T	MI	DTI7UX6
DMGLX0T	MN	Breast cancer resistance protein (ABCG2)
DMGLX0T	MT	DTP
DMGLX0T	MA	Substrate
DMGLX0T	RN	Involvement of breast cancer resistance protein (ABCG2) in the biliary excretion mechanism of fluoroquinolones. Drug Metab Dispos. 2007 Oct;35(10):1873-9.
DMGLX0T	RU	http://www.ncbi.nlm.nih.gov/pubmed/17639028

DMGLX0T	DI	DMGLX0T
DMGLX0T	DN	Grepafloxacin
DMGLX0T	MI	DEJGDUW
DMGLX0T	MN	Cytochrome P450 1A2 (CYP1A2)
DMGLX0T	MT	DME
DMGLX0T	MA	Metabolism
DMGLX0T	RN	Quantitative prediction of drug interactions caused by CYP1A2 inhibitors and inducers. Clin Pharmacokinet. 2016 Aug;55(8):977-90.
DMGLX0T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26936044

DMGLX0T	DI	DMGLX0T
DMGLX0T	DN	Grepafloxacin
DMGLX0T	MI	DE4LYSA
DMGLX0T	MN	Cytochrome P450 3A4 (CYP3A4)
DMGLX0T	MT	DME
DMGLX0T	MA	Metabolism
DMGLX0T	RN	MDR- and CYP3A4-mediated drug-drug interactions. J Neuroimmune Pharmacol. 2006 Sep;1(3):323-39.
DMGLX0T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18040809

DMGLX0T	DI	DMGLX0T
DMGLX0T	DN	Grepafloxacin
DMGLX0T	MI	DTSYQGK
DMGLX0T	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMGLX0T	MT	DTP
DMGLX0T	MA	Substrate
DMGLX0T	RN	Limited distribution of new quinolone antibacterial agents into brain caused by multiple efflux transporters at the blood-brain barrier. J Pharmacol Exp Ther. 2000 Oct;295(1):146-52.
DMGLX0T	RU	http://jpet.aspetjournals.org/content/295/1/146.long

DMGLX0T	DI	DMGLX0T
DMGLX0T	DN	Grepafloxacin
DMGLX0T	MI	DTFI42L
DMGLX0T	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMGLX0T	MT	DTP
DMGLX0T	MA	Substrate
DMGLX0T	RN	Fluoroquinolone efflux mediated by ABC transporters. J Pharm Sci. 2008 Sep;97(9):3483-93.
DMGLX0T	RU	http://www.ncbi.nlm.nih.gov/pubmed/18200507

DMGLX0T	DI	DMGLX0T
DMGLX0T	DN	Grepafloxacin
DMGLX0T	MI	DTE2B1D
DMGLX0T	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMGLX0T	MT	DTP
DMGLX0T	MA	Substrate
DMGLX0T	RN	Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm. 2007 Jan-Feb;4(1):85-94.
DMGLX0T	RU	http://www.ncbi.nlm.nih.gov/pubmed/17274666

DMGLX0T	DI	DMGLX0T
DMGLX0T	DN	Grepafloxacin
DMGLX0T	MI	DTUGYRD
DMGLX0T	MN	P-glycoprotein 1 (ABCB1)
DMGLX0T	MT	DTP
DMGLX0T	MA	Substrate
DMGLX0T	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMGLX0T	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMK54YG	DI	DMK54YG
DMK54YG	DN	Griseofulvin
DMK54YG	MI	DEJGDUW
DMK54YG	MN	Cytochrome P450 1A2 (CYP1A2)
DMK54YG	MT	DME
DMK54YG	MA	Metabolism
DMK54YG	RN	Kinetic mechanism of the activation of human plasminogen by streptokinase. Biochemistry. 1975 Oct 7;14(20):4459-65.
DMK54YG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=126078

DMK54YG	DI	DMK54YG
DMK54YG	DN	Griseofulvin
DMK54YG	MI	TT7PBUD
DMK54YG	MN	Fungal Microtubule (Fung MicroTU)
DMK54YG	MT	DTT
DMK54YG	MA	Inducer
DMK54YG	RN	Dermatophyte infections. Am Fam Physician. 2003 Jan 1;67(1):101-8.
DMK54YG	RU	https://pubmed.ncbi.nlm.nih.gov/12537173

DM1ECNJ	DI	DM1ECNJ
DM1ECNJ	DN	GS-7340
DM1ECNJ	MI	TT84ETX
DM1ECNJ	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM1ECNJ	MT	DTT
DM1ECNJ	MA	Inhibitor
DM1ECNJ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2020
DM1ECNJ	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208464s008lbl.pdf

DM8QB0T	DI	DM8QB0T
DM8QB0T	DN	GSK2592984A
DM8QB0T	MI	TT3J5ZI
DM8QB0T	MN	Cell mediated immunity response (CMIR)
DM8QB0T	MT	DTT
DM8QB0T	RN	Anti-influenza agents from Traditional Chinese Medicine. Nat Prod Rep. 2010 Jan;27(12):1758-80.
DM8QB0T	RU	https://pubmed.ncbi.nlm.nih.gov/20941447

DM5QWEL	DI	DM5QWEL
DM5QWEL	DN	Guanabenz
DM5QWEL	MI	TTQ8AFT
DM5QWEL	MN	Adrenergic receptor Alpha-2 (ADRA2)
DM5QWEL	MT	DTT
DM5QWEL	MA	Agonist
DM5QWEL	RN	Centrally acting sympathetic inhibitors for therapy of patients with hypertension. Nippon Rinsho. 1997 Aug;55(8):2081-5.
DM5QWEL	RU	https://pubmed.ncbi.nlm.nih.gov/9284427

DM5QWEL	DI	DM5QWEL
DM5QWEL	DN	Guanabenz
DM5QWEL	MI	DEJGDUW
DM5QWEL	MN	Cytochrome P450 1A2 (CYP1A2)
DM5QWEL	MT	DME
DM5QWEL	MA	Metabolism
DM5QWEL	RN	Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
DM5QWEL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19754423

DM5QWEL	DI	DM5QWEL
DM5QWEL	DN	Guanabenz
DM5QWEL	MI	DTUGYRD
DM5QWEL	MN	P-glycoprotein 1 (ABCB1)
DM5QWEL	MT	DTP
DM5QWEL	MA	Substrate
DM5QWEL	RN	A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26.
DM5QWEL	RU	https://doi.org/10.1007/s00210-008-0345-0

DM6S157	DI	DM6S157
DM6S157	DN	Guanadrel Sulfate
DM6S157	MI	TTVIREA
DM6S157	MN	Adrenergic receptor (ADR)
DM6S157	MT	DTT
DM6S157	MA	Modulator
DM6S157	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM6S157	RU	https://www.fda.gov/

DM9NSWT	DI	DM9NSWT
DM9NSWT	DN	Guanethidine
DM9NSWT	MI	TTT04VN
DM9NSWT	MN	Adrenergic neuron (AD neuro)
DM9NSWT	MT	DTT
DM9NSWT	MA	Blocker
DM9NSWT	RN	Characterization of bradykinin-induced endothelium-independent contraction in equine basilar artery. J Vet Pharmacol Ther. 2009 Jun;32(3):264-70.
DM9NSWT	RU	https://pubmed.ncbi.nlm.nih.gov/19646091

DMB1CZ8	DI	DMB1CZ8
DMB1CZ8	DN	Guanfacine extended release
DMB1CZ8	MI	TTQ8AFT
DMB1CZ8	MN	Adrenergic receptor Alpha-2 (ADRA2)
DMB1CZ8	MT	DTT
DMB1CZ8	MA	Agonist
DMB1CZ8	RN	Emerging drugs for attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs. 2007 Sep;12(3):423-34.
DMB1CZ8	RU	https://pubmed.ncbi.nlm.nih.gov/17874970

DMB1CZ8	DI	DMB1CZ8
DMB1CZ8	DN	Guanfacine extended release
DMB1CZ8	MI	TTMSFAW
DMB1CZ8	MN	Cannabinoid receptor 2 (CB2)
DMB1CZ8	MT	DTT
DMB1CZ8	MA	Agonist
DMB1CZ8	RN	Posttraining activation of CB1 cannabinoid receptors in the CA1 region of the dorsal hippocampus impairs object recognition long-term memory. Neurobiol Learn Mem. 2008 Sep;90(2):374-81.
DMB1CZ8	RU	https://pubmed.ncbi.nlm.nih.gov/18524639

DMB1CZ8	DI	DMB1CZ8
DMB1CZ8	DN	Guanfacine extended release
DMB1CZ8	MI	TT7QNVC
DMB1CZ8	MN	Glucose-dependent insulinotropic receptor (GPR119)
DMB1CZ8	MT	DTT
DMB1CZ8	MA	Agonist
DMB1CZ8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 126).
DMB1CZ8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=126

DMB1CZ8	DI	DMB1CZ8
DMB1CZ8	DN	Guanfacine extended release
DMB1CZ8	MI	TTNET8J
DMB1CZ8	MN	G-protein coupled receptor 55 (GPR55)
DMB1CZ8	MT	DTT
DMB1CZ8	MA	Agonist
DMB1CZ8	RN	The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007 Dec;152(7):1092-101.
DMB1CZ8	RU	https://pubmed.ncbi.nlm.nih.gov/17876302

DM0P63W	DI	DM0P63W
DM0P63W	DN	Guanidine Hydrochloride
DM0P63W	MI	TTQ8AFT
DM0P63W	MN	Adrenergic receptor Alpha-2 (ADRA2)
DM0P63W	MT	DTT
DM0P63W	MA	Modulator
DM0P63W	RN	Guanidine-based 2-adrenoceptor ligands: Towards selective antagonist activity.Eur J Med Chem.2014 Jul 23;82:242-54.
DM0P63W	RU	https://www.ncbi.nlm.nih.gov/pubmed/24908653

DMP7LK1	DI	DMP7LK1
DMP7LK1	DN	Guggulsterone
DMP7LK1	MI	TTS4UGC
DMP7LK1	MN	Farnesoid X-activated receptor (FXR)
DMP7LK1	MT	DTT
DMP7LK1	MA	Antagonist
DMP7LK1	RN	Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia. J Nat Prod. 2009 Jan;72(1):24-8.
DMP7LK1	RU	https://pubmed.ncbi.nlm.nih.gov/19102680

DMP7LK1	DI	DMP7LK1
DMP7LK1	DN	Guggulsterone
DMP7LK1	MI	DTUGYRD
DMP7LK1	MN	P-glycoprotein 1 (ABCB1)
DMP7LK1	MT	DTP
DMP7LK1	MA	Substrate
DMP7LK1	RN	Effects of plant sterols on human multidrug transporters ABCB1 and ABCC1. Biochem Biophys Res Commun. 2008 May 2;369(2):363-8.
DMP7LK1	RU	https://doi.org/10.1016/j.bbrc.2008.02.026

DMV4KOA	DI	DMV4KOA
DMV4KOA	DN	GW642444
DMV4KOA	MI	TT2CJVK
DMV4KOA	MN	Adrenergic receptor beta-2 (ADRB2)
DMV4KOA	MT	DTT
DMV4KOA	MA	Agonist
DMV4KOA	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMV4KOA	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DML72VJ	DI	DML72VJ
DML72VJ	DN	GW685698X
DML72VJ	MI	TTYRL6O
DML72VJ	MN	Glucocorticoid receptor (NR3C1)
DML72VJ	MT	DTT
DML72VJ	MA	Agonist
DML72VJ	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DML72VJ	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMFUAXT	DI	DMFUAXT
DMFUAXT	DN	H1N1 pandemic influenza A vaccine
DMFUAXT	MI	TT3J5ZI
DMFUAXT	MN	Cell mediated immunity response (CMIR)
DMFUAXT	MT	DTT
DMFUAXT	RN	How Influenza (Flu) Vaccines Are Made. FLU.gov. 2014.
DMFUAXT	RU	http://www.flu.gov/about_the_flu/h1n1/

DMMHYLB	DI	DMMHYLB
DMMHYLB	DN	H5N1 influenza vaccine
DMMHYLB	MI	TT3J5ZI
DMMHYLB	MN	Cell mediated immunity response (CMIR)
DMMHYLB	MT	DTT
DMMHYLB	RN	Comparative clinical trial of vaccines against avian influenza. Zh Mikrobiol Epidemiol Immunobiol. 2007 May-Jun;(3):10-6.
DMMHYLB	RU	https://pubmed.ncbi.nlm.nih.gov/17672124

DM7JNTV	DI	DM7JNTV
DM7JNTV	DN	Halaven
DM7JNTV	MI	DE4LYSA
DM7JNTV	MN	Cytochrome P450 3A4 (CYP3A4)
DM7JNTV	MT	DME
DM7JNTV	MA	Metabolism
DM7JNTV	RN	Eribulin, a microtubule inhibitor for metastatic breast cancer. Oncology (Williston Park). 2011 Feb;25(2 Suppl Nurse Ed):46-8.
DM7JNTV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25373284

DMPFWO6	DI	DMPFWO6
DMPFWO6	DN	Halazepam
DMPFWO6	MI	TTPTXIN
DMPFWO6	MN	Translocator protein (TSPO)
DMPFWO6	MT	DTT
DMPFWO6	MA	Modulator
DMPFWO6	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMPFWO6	RU	https://www.fda.gov/

DMGLAX1	DI	DMGLAX1
DMGLAX1	DN	Halcinonide
DMGLAX1	MI	DE4LYSA
DMGLAX1	MN	Cytochrome P450 3A4 (CYP3A4)
DMGLAX1	MT	DME
DMGLAX1	MA	Metabolism
DMGLAX1	RN	NCIthesaurus: Halcinonide
DMGLAX1	RU	https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=18.06d&code=C47552&ns=ncit&type=relationship&key=null&b=1&n=0&vse=null

DMGLAX1	DI	DMGLAX1
DMGLAX1	DN	Halcinonide
DMGLAX1	MI	TTP3UTW
DMGLAX1	MN	Steroid hormone receptor ERR (ESRR)
DMGLAX1	MT	DTT
DMGLAX1	MA	Modulator
DMGLAX1	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMGLAX1	RU	https://www.fda.gov/

DM3GB6S	DI	DM3GB6S
DM3GB6S	DN	Halobetasol propionate
DM3GB6S	MI	TTP3UTW
DM3GB6S	MN	Steroid hormone receptor ERR (ESRR)
DM3GB6S	MT	DTT
DM3GB6S	MA	Modulator
DM3GB6S	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM3GB6S	RU	https://www.fda.gov/

DMOMK1V	DI	DMOMK1V
DMOMK1V	DN	Halofantrine
DMOMK1V	MI	TTV3NH6
DMOMK1V	MN	Calmodulin (CALM)
DMOMK1V	MT	DTT
DMOMK1V	MA	Modulator
DMOMK1V	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMOMK1V	RU	https://www.fda.gov/

DMOMK1V	DI	DMOMK1V
DMOMK1V	DN	Halofantrine
DMOMK1V	MI	DES5XRU
DMOMK1V	MN	Cytochrome P450 2C8 (CYP2C8)
DMOMK1V	MT	DME
DMOMK1V	MA	Metabolism
DMOMK1V	RN	Halofantrine metabolism in microsomes in man: major role of CYP 3A4 and CYP 3A5. J Pharm Pharmacol. 1999 Apr;51(4):419-26.
DMOMK1V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10385214

DMOMK1V	DI	DMOMK1V
DMOMK1V	DN	Halofantrine
DMOMK1V	MI	DECB0K3
DMOMK1V	MN	Cytochrome P450 2D6 (CYP2D6)
DMOMK1V	MT	DME
DMOMK1V	MA	Metabolism
DMOMK1V	RN	Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians. Br J Clin Pharmacol. 1998 Mar;45(3):315-7.
DMOMK1V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10896408

DMOMK1V	DI	DMOMK1V
DMOMK1V	DN	Halofantrine
DMOMK1V	MI	DE4LYSA
DMOMK1V	MN	Cytochrome P450 3A4 (CYP3A4)
DMOMK1V	MT	DME
DMOMK1V	MA	Metabolism
DMOMK1V	RN	Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine. Clin Pharmacol Ther. 2002 Nov;72(5):514-23.
DMOMK1V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12426515

DMOMK1V	DI	DMOMK1V
DMOMK1V	DN	Halofantrine
DMOMK1V	MI	DEIBDNY
DMOMK1V	MN	Cytochrome P450 3A5 (CYP3A5)
DMOMK1V	MT	DME
DMOMK1V	MA	Metabolism
DMOMK1V	RN	Halofantrine metabolism in microsomes in man: major role of CYP 3A4 and CYP 3A5. J Pharm Pharmacol. 1999 Apr;51(4):419-26.
DMOMK1V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10385214

DM96SE0	DI	DM96SE0
DM96SE0	DN	Haloperidol
DM96SE0	MI	DE6OQ3W
DM96SE0	MN	Cytochrome P450 1A1 (CYP1A1)
DM96SE0	MT	DME
DM96SE0	MA	Metabolism
DM96SE0	RN	In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes. Drug Metab Dispos. 2001 Dec;29(12):1638-43.
DM96SE0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11717183

DM96SE0	DI	DM96SE0
DM96SE0	DN	Haloperidol
DM96SE0	MI	DEJGDUW
DM96SE0	MN	Cytochrome P450 1A2 (CYP1A2)
DM96SE0	MT	DME
DM96SE0	MA	Metabolism
DM96SE0	RN	In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes. Drug Metab Dispos. 2001 Dec;29(12):1638-43.
DM96SE0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11717183

DM96SE0	DI	DM96SE0
DM96SE0	DN	Haloperidol
DM96SE0	MI	DE5IED8
DM96SE0	MN	Cytochrome P450 2C9 (CYP2C9)
DM96SE0	MT	DME
DM96SE0	MA	Metabolism
DM96SE0	RN	In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes. Drug Metab Dispos. 2001 Dec;29(12):1638-43.
DM96SE0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11717183

DM96SE0	DI	DM96SE0
DM96SE0	DN	Haloperidol
DM96SE0	MI	DECB0K3
DM96SE0	MN	Cytochrome P450 2D6 (CYP2D6)
DM96SE0	MT	DME
DM96SE0	MA	Metabolism
DM96SE0	RN	Use of antidepressant drugs in schizophrenic patients with depression. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9.
DM96SE0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16910628

DM96SE0	DI	DM96SE0
DM96SE0	DN	Haloperidol
DM96SE0	MI	DE4LYSA
DM96SE0	MN	Cytochrome P450 3A4 (CYP3A4)
DM96SE0	MT	DME
DM96SE0	MA	Metabolism
DM96SE0	RN	Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway. Drug Metab Dispos. 2003 Mar;31(3):243-9.
DM96SE0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12584149

DM96SE0	DI	DM96SE0
DM96SE0	DN	Haloperidol
DM96SE0	MI	DEIBDNY
DM96SE0	MN	Cytochrome P450 3A5 (CYP3A5)
DM96SE0	MT	DME
DM96SE0	MA	Metabolism
DM96SE0	RN	Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway. Drug Metab Dispos. 2003 Mar;31(3):243-9.
DM96SE0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12584149

DM96SE0	DI	DM96SE0
DM96SE0	DN	Haloperidol
DM96SE0	MI	DERD86B
DM96SE0	MN	Cytochrome P450 3A7 (CYP3A7)
DM96SE0	MT	DME
DM96SE0	MA	Metabolism
DM96SE0	RN	Drug Interactions Flockhart Table
DM96SE0	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM96SE0	DI	DM96SE0
DM96SE0	DN	Haloperidol
DM96SE0	MI	TTEX248
DM96SE0	MN	Dopamine D2 receptor (D2R)
DM96SE0	MT	DTT
DM96SE0	MA	Antagonist
DM96SE0	RN	Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
DM96SE0	RU	https://pubmed.ncbi.nlm.nih.gov/12112400

DM96SE0	DI	DM96SE0
DM96SE0	DN	Haloperidol
DM96SE0	MI	DEGTFWK
DM96SE0	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM96SE0	MT	DME
DM96SE0	MA	Metabolism
DM96SE0	RN	In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes. Drug Metab Dispos. 2001 Dec;29(12):1638-43.
DM96SE0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11717183

DM96SE0	DI	DM96SE0
DM96SE0	DN	Haloperidol
DM96SE0	MI	DTUGYRD
DM96SE0	MN	P-glycoprotein 1 (ABCB1)
DM96SE0	MT	DTP
DM96SE0	MA	Substrate
DM96SE0	RN	Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
DM96SE0	RU	http://www.ncbi.nlm.nih.gov/pubmed/15285840

DM96SE0	DI	DM96SE0
DM96SE0	DN	Haloperidol
DM96SE0	MI	DE85D2P
DM96SE0	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DM96SE0	MT	DME
DM96SE0	MA	Metabolism
DM96SE0	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM96SE0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMH4IVU	DI	DMH4IVU
DMH4IVU	DN	Haloprogin
DMH4IVU	MI	TTAH0B3
DMH4IVU	MN	Fungal Cell membrane (Fung CM)
DMH4IVU	MT	DTT
DMH4IVU	MA	Binder
DMH4IVU	RN	Haloprogin: mode of action studies in Candida albicans. Can J Microbiol. 1974 Sep;20(9):1241-5.
DMH4IVU	RU	https://pubmed.ncbi.nlm.nih.gov/4608935

DM80OZ5	DI	DM80OZ5
DM80OZ5	DN	Halothane
DM80OZ5	MI	DEJVYAZ
DM80OZ5	MN	Cytochrome P450 2A6 (CYP2A6)
DM80OZ5	MT	DME
DM80OZ5	MA	Metabolism
DM80OZ5	RN	Halothane-dependent lipid peroxidation in human liver microsomes is catalyzed by cytochrome P4502A6 (CYP2A6). Anesthesiology. 2001 Aug;95(2):509-14.
DM80OZ5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11506127

DM80OZ5	DI	DM80OZ5
DM80OZ5	DN	Halothane
DM80OZ5	MI	DEPKLMQ
DM80OZ5	MN	Cytochrome P450 2B6 (CYP2B6)
DM80OZ5	MT	DME
DM80OZ5	MA	Metabolism
DM80OZ5	RN	Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics. 2003 Oct;13(10):619-26.
DM80OZ5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14515060

DM80OZ5	DI	DM80OZ5
DM80OZ5	DN	Halothane
DM80OZ5	MI	DE5IED8
DM80OZ5	MN	Cytochrome P450 2C9 (CYP2C9)
DM80OZ5	MT	DME
DM80OZ5	MA	Metabolism
DM80OZ5	RN	Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4. Drug Metab Dispos. 1996 Sep;24(9):976-83.
DM80OZ5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8886607

DM80OZ5	DI	DM80OZ5
DM80OZ5	DN	Halothane
DM80OZ5	MI	DECB0K3
DM80OZ5	MN	Cytochrome P450 2D6 (CYP2D6)
DM80OZ5	MT	DME
DM80OZ5	MA	Metabolism
DM80OZ5	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM80OZ5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM80OZ5	DI	DM80OZ5
DM80OZ5	DN	Halothane
DM80OZ5	MI	DEVDYN7
DM80OZ5	MN	Cytochrome P450 2E1 (CYP2E1)
DM80OZ5	MT	DME
DM80OZ5	MA	Metabolism
DM80OZ5	RN	Concordance between trifluoroacetic acid and hepatic protein trifluoroacetylation after disulfiram inhibition of halothane metabolism in rats. Acta Anaesthesiol Scand. 2003 Jul;47(6):765-70.
DM80OZ5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12803597

DM80OZ5	DI	DM80OZ5
DM80OZ5	DN	Halothane
DM80OZ5	MI	DE4LYSA
DM80OZ5	MN	Cytochrome P450 3A4 (CYP3A4)
DM80OZ5	MT	DME
DM80OZ5	MA	Metabolism
DM80OZ5	RN	Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4. Drug Metab Dispos. 1996 Sep;24(9):976-83.
DM80OZ5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8886607

DM80OZ5	DI	DM80OZ5
DM80OZ5	DN	Halothane
DM80OZ5	MI	TTAN6JD
DM80OZ5	MN	Glutamate receptor AMPA (GRIA)
DM80OZ5	MT	DTT
DM80OZ5	MA	Antagonist
DM80OZ5	RN	Reduced inhibition of cortical glutamate and GABA release by halothane in mice lacking the K+ channel, TREK-1. Br J Pharmacol. 2007 Nov;152(6):939-45.
DM80OZ5	RU	https://pubmed.ncbi.nlm.nih.gov/17828284

DM80OZ5	DI	DM80OZ5
DM80OZ5	DN	Halothane
DM80OZ5	MI	DE9A2LB
DM80OZ5	MN	Microsomal cytochrome MCB5 (CYB5A)
DM80OZ5	MT	DME
DM80OZ5	MA	Metabolism
DM80OZ5	RN	Modulation of the reductive metabolism of halothane by microsomal cytochrome b5 in rat liver. Biochim Biophys Acta. 1987 Dec 7;926(3):231-8.
DM80OZ5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=3689822

DMN0S1G	DI	DMN0S1G
DMN0S1G	DN	HEGF
DMN0S1G	MI	TTGKNB4
DMN0S1G	MN	Epidermal growth factor receptor (EGFR)
DMN0S1G	MT	DTT
DMN0S1G	MA	Activator
DMN0S1G	RN	Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
DMN0S1G	RU	https://pubmed.ncbi.nlm.nih.gov/17064227

DMEVXY6	DI	DMEVXY6
DMEVXY6	DN	Heparin Calcium
DMEVXY6	MI	TT4QPUL
DMEVXY6	MN	Antithrombin-III (ATIII)
DMEVXY6	MT	DTT
DMEVXY6	MA	Modulator
DMEVXY6	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMEVXY6	RU	https://www.fda.gov/

DM9KHZL	DI	DM9KHZL
DM9KHZL	DN	Heparin Sodium
DM9KHZL	MI	TT4QPUL
DM9KHZL	MN	Antithrombin-III (ATIII)
DM9KHZL	MT	DTT
DM9KHZL	MA	Modulator
DM9KHZL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2632).
DM9KHZL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2632

DMOB2F3	DI	DMOB2F3
DMOB2F3	DN	Heptabarbital
DMOB2F3	MI	TTAN6JD
DMOB2F3	MN	Glutamate receptor AMPA (GRIA)
DMOB2F3	MT	DTT
DMOB2F3	MA	Antagonist
DMOB2F3	RN	A computer program using disposition decomposition analysis in pharmacodynamics. Biopharm Drug Dispos. 1997 Jan;18(1):9-15.
DMOB2F3	RU	https://pubmed.ncbi.nlm.nih.gov/9008265

DM6YWBF	DI	DM6YWBF
DM6YWBF	DN	Herbimycin A
DM6YWBF	MI	TT6PKBN
DM6YWBF	MN	Proto-oncogene c-Src (SRC)
DM6YWBF	MT	DTT
DM6YWBF	MA	Inhibitor
DM6YWBF	RN	In vivo antitumor activity of herbimycin A, a tyrosine kinase inhibitor, targeted against BCR/ABL oncoprotein in mice bearing BCR/ABL-transfected cells. Leuk Res. 1994 Nov;18(11):867-73.
DM6YWBF	RU	https://pubmed.ncbi.nlm.nih.gov/7967714

DMDBWHY	DI	DMDBWHY
DMDBWHY	DN	Heroin diacetylmorphine
DMDBWHY	MI	DEQ2BAJ
DMDBWHY	MN	Acetylcholinesterase (ACHE)
DMDBWHY	MT	DME
DMDBWHY	MA	Metabolism
DMDBWHY	RN	Kinetic characterization of cholinesterases and a therapeutically valuable cocaine hydrolase for their catalytic activities against heroin and its metabolite 6-monoacetylmorphine. Chem Biol Interact. 2018 Sep 25;293:107-114.
DMDBWHY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30080993

DMKER83	DI	DMKER83
DMKER83	DN	Hesperetin
DMKER83	MI	DTI7UX6
DMKER83	MN	Breast cancer resistance protein (ABCG2)
DMKER83	MT	DTP
DMKER83	MA	Substrate
DMKER83	RN	Interaction of the breast cancer resistance protein with plant polyphenols. Biochem Biophys Res Commun. 2004 Apr 23;317(1):269-75.
DMKER83	RU	https://doi.org/10.1016/j.bbrc.2004.03.040

DMKER83	DI	DMKER83
DMKER83	DN	Hesperetin
DMKER83	MI	DEJGDUW
DMKER83	MN	Cytochrome P450 1A2 (CYP1A2)
DMKER83	MT	DME
DMKER83	MA	Metabolism
DMKER83	RN	In vitro investigation of cytochrome P450-mediated metabolism of dietary flavonoids. Food Chem Toxicol. 2002 May;40(5):609-16.
DMKER83	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11955666

DMKER83	DI	DMKER83
DMKER83	DN	Hesperetin
DMKER83	MI	TTF8P9I
DMKER83	MN	Diacylglycerol acyltransferase 1 (DGAT1)
DMKER83	MT	DTT
DMKER83	MA	Inhibitor
DMKER83	RN	In vitro inhibition of diacylglycerol acyltransferase by prenylflavonoids from Sophora flavescens. Planta Med. 2004 Mar;70(3):258-60.
DMKER83	RU	https://pubmed.ncbi.nlm.nih.gov/15114505

DMI5DW1	DI	DMI5DW1
DMI5DW1	DN	Hesperidin
DMI5DW1	MI	TT4FDG6
DMI5DW1	MN	Voltage-gated calcium channel alpha Cav2.2 (CACNA1B)
DMI5DW1	MT	DTT
DMI5DW1	MA	Inhibitor
DMI5DW1	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMI5DW1	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMPXITB	DI	DMPXITB
DMPXITB	DN	Hetacillin
DMPXITB	MI	TTJP4SM
DMPXITB	MN	Bacterial Penicillin binding protein (Bact PBP)
DMPXITB	MT	DTT
DMPXITB	MA	Modulator
DMPXITB	RN	JBioWH: an open-source Java framework for bioinformatics data integration.Database (Oxford).2013 Jul 11;2013:bat051.
DMPXITB	RU	https://www.ncbi.nlm.nih.gov/pubmed/23846595

DMGUC9T	DI	DMGUC9T
DMGUC9T	DN	HEV-239
DMGUC9T	MI	TT3J5ZI
DMGUC9T	MN	Cell mediated immunity response (CMIR)
DMGUC9T	MT	DTT
DMGUC9T	RN	The development of a recombinant hepatitis E vaccine HEV 239. Hum Vaccin Immunother. 2015;11(4):908-14.
DMGUC9T	RU	https://pubmed.ncbi.nlm.nih.gov/25714510

DMLKSE0	DI	DMLKSE0
DMLKSE0	DN	Hexachlorophene
DMLKSE0	MI	TTAO7YK
DMLKSE0	MN	Plasmodium Glutamate dehydrogenase (Malaria gdh)
DMLKSE0	MT	DTT
DMLKSE0	MA	Inhibitor
DMLKSE0	RN	Novel inhibitors complexed with glutamate dehydrogenase: allosteric regulation by control of protein dynamics. J Biol Chem. 2009 Aug 21;284(34):22988-3000.
DMLKSE0	RU	https://pubmed.ncbi.nlm.nih.gov/19531491

DMFY307	DI	DMFY307
DMFY307	DN	Hexafluronium bromide
DMFY307	MI	TTEB0GD
DMFY307	MN	Cholinesterase (BCHE)
DMFY307	MT	DTT
DMFY307	MA	Inhibitor
DMFY307	RN	Synergistic effect of acidosis and succinylcholine-induced hyperkalemia in spinal cord transected rats. Acta Anaesthesiol Scand. 1984 Feb;28(1):87-90.
DMFY307	RU	https://pubmed.ncbi.nlm.nih.gov/6711267

DMQ314B	DI	DMQ314B
DMQ314B	DN	Hexobarbital
DMQ314B	MI	DEJGDUW
DMQ314B	MN	Cytochrome P450 1A2 (CYP1A2)
DMQ314B	MT	DME
DMQ314B	MA	Metabolism
DMQ314B	RN	Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug Metab Dispos. 1994 Nov-Dec;22(6):909-15.
DMQ314B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7895609

DMQ314B	DI	DMQ314B
DMQ314B	DN	Hexobarbital
DMQ314B	MI	DE5IED8
DMQ314B	MN	Cytochrome P450 2C9 (CYP2C9)
DMQ314B	MT	DME
DMQ314B	MA	Metabolism
DMQ314B	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMQ314B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMQ314B	DI	DMQ314B
DMQ314B	DN	Hexobarbital
DMQ314B	MI	DE4LYSA
DMQ314B	MN	Cytochrome P450 3A4 (CYP3A4)
DMQ314B	MT	DME
DMQ314B	MA	Metabolism
DMQ314B	RN	Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug Metab Dispos. 1994 Nov-Dec;22(6):909-15.
DMQ314B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7895609

DMQ314B	DI	DMQ314B
DMQ314B	DN	Hexobarbital
DMQ314B	MI	TT1MPAY
DMQ314B	MN	GABA(A) receptor alpha-1 (GABRA1)
DMQ314B	MT	DTT
DMQ314B	MA	Antagonist
DMQ314B	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DMQ314B	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DMQ314B	DI	DMQ314B
DMQ314B	DN	Hexobarbital
DMQ314B	MI	DEGTFWK
DMQ314B	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMQ314B	MT	DME
DMQ314B	MA	Metabolism
DMQ314B	RN	Stereoselective hexobarbital 3'-hydroxylation by CYP2C19 expressed in yeast cells and the roles of amino acid residues at positions 300 and 476. Chirality. 2007 Jul;19(7):550-8.
DMQ314B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17487889

DMQ314B	DI	DMQ314B
DMQ314B	DN	Hexobarbital
DMQ314B	MI	DE073H6
DMQ314B	MN	Prostaglandin G/H synthase 1 (COX-1)
DMQ314B	MT	DME
DMQ314B	MA	Metabolism
DMQ314B	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMQ314B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMEADRK	DI	DMEADRK
DMEADRK	DN	Hexylcaine
DMEADRK	MI	TTZOVE0
DMEADRK	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DMEADRK	MT	DTT
DMEADRK	MA	Blocker
DMEADRK	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMEADRK	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMV7IM6	DI	DMV7IM6
DMV7IM6	DN	Histamine Phosphate
DMV7IM6	MI	TT7CXIM
DMV7IM6	MN	Histamine receptor (HR)
DMV7IM6	MT	DTT
DMV7IM6	MA	Modulator
DMV7IM6	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMV7IM6	RU	https://www.fda.gov/

DMGBPSH	DI	DMGBPSH
DMGBPSH	DN	Homatropine Methylbromide
DMGBPSH	MI	TTH18TF
DMGBPSH	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMGBPSH	MT	DTT
DMGBPSH	MA	Antagonist
DMGBPSH	RN	Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
DMGBPSH	RU	https://pubmed.ncbi.nlm.nih.gov/17016423

DM78G6F	DI	DM78G6F
DM78G6F	DN	HTF 919
DM78G6F	MI	TT07C3Y
DM78G6F	MN	5-HT 4 receptor (HTR4)
DM78G6F	MT	DTT
DM78G6F	MA	Agonist
DM78G6F	RN	5-Hydroxytryptamine mediated contractions in isolated preparations of equine ileum and pelvic flexure: pharmacological characterization of a new 5-HT(4) agonist. J Vet Pharmacol Ther. 2002 Feb;25(1):49-58.
DM78G6F	RU	https://pubmed.ncbi.nlm.nih.gov/11874527

DMA5OBU	DI	DMA5OBU
DMA5OBU	DN	Human neutral insulin
DMA5OBU	MI	TTCBFJO
DMA5OBU	MN	Insulin receptor (INSR)
DMA5OBU	MT	DTT
DMA5OBU	MA	Binder
DMA5OBU	RN	Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
DMA5OBU	RU	https://pubmed.ncbi.nlm.nih.gov/12509758

DMPHVQ1	DI	DMPHVQ1
DMPHVQ1	DN	Human prothrombin complex concentrate
DMPHVQ1	MI	TT6L509
DMPHVQ1	MN	Coagulation factor IIa (F2)
DMPHVQ1	MT	DTT
DMPHVQ1	MA	Modulator
DMPHVQ1	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362).
DMPHVQ1	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2362

DMMAWLU	DI	DMMAWLU
DMMAWLU	DN	Huperzine A
DMMAWLU	MI	TT1RS9F
DMMAWLU	MN	Acetylcholinesterase (AChE)
DMMAWLU	MT	DTT
DMMAWLU	MA	Inhibitor
DMMAWLU	RN	Huperzine A attenuates cognitive deficits and brain injury in neonatal rats after hypoxia-ischemia. Brain Res. 2002 Sep 13;949(1-2):162-70.
DMMAWLU	RU	https://pubmed.ncbi.nlm.nih.gov/12213312

DMMAWLU	DI	DMMAWLU
DMMAWLU	DN	Huperzine A
DMMAWLU	MI	TT9IK2Z
DMMAWLU	MN	N-methyl-D-aspartate receptor (NMDAR)
DMMAWLU	MT	DTT
DMMAWLU	MA	Antagonist
DMMAWLU	RN	Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
DMMAWLU	RU	https://pubmed.ncbi.nlm.nih.gov/19008076

DMX8M26	DI	DMX8M26
DMX8M26	DN	Hyaluronate sodium
DMX8M26	MI	DEH31BC
DMX8M26	MN	Hyaluronate lyase (hyaL)
DMX8M26	MT	DME
DMX8M26	MA	Metabolism
DMX8M26	RN	A bacterial ABC transporter enables import of mammalian host glycosaminoglycans. Sci Rep. 2017 Apr 21;7(1):1069.
DMX8M26	RU	https://pubmed.ncbi.nlm.nih.gov/28432302

DMX8M26	DI	DMX8M26
DMX8M26	DN	Hyaluronate sodium
DMX8M26	MI	TTG8DNU
DMX8M26	MN	Hyaluronic acid receptor (LYVE1)
DMX8M26	MT	DTT
DMX8M26	MA	Modulator
DMX8M26	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4954).
DMX8M26	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4954

DMX8M26	DI	DMX8M26
DMX8M26	DN	Hyaluronate sodium
DMX8M26	MI	DEWP153
DMX8M26	MN	Hyaluronidase (hyl)
DMX8M26	MT	DME
DMX8M26	MA	Metabolism
DMX8M26	RN	A novel hyaluronidase produced by Bacillus sp. A50. PLoS One. 2014 Apr 15;9(4):e94156.
DMX8M26	RU	https://pubmed.ncbi.nlm.nih.gov/24736576

DMETWAU	DI	DMETWAU
DMETWAU	DN	Hyaluronidase (ovine)
DMETWAU	MI	TTYTVXF
DMETWAU	MN	Hyaluronic acid (HA)
DMETWAU	MT	DTT
DMETWAU	MA	Modulator
DMETWAU	RN	Safety results of two phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J Ophthalmol. 2005 Oct;140(4):585-97.
DMETWAU	RU	https://pubmed.ncbi.nlm.nih.gov/16226510

DMU8JGH	DI	DMU8JGH
DMU8JGH	DN	Hydralazine
DMU8JGH	MI	TT7HC21
DMU8JGH	MN	Membrane copper amine oxidase (AOC3)
DMU8JGH	MT	DTT
DMU8JGH	MA	Modulator
DMU8JGH	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMU8JGH	RU	https://www.fda.gov/

DMU8JGH	DI	DMU8JGH
DMU8JGH	DN	Hydralazine
DMU8JGH	MI	DE7OAB3
DMU8JGH	MN	N-acetyltransferase 1 (NAT1)
DMU8JGH	MT	DME
DMU8JGH	MA	Metabolism
DMU8JGH	RN	N-acetyltransferase 2 genotype-dependent N-acetylation of hydralazine in human hepatocytes. Drug Metab Dispos. 2017 Dec;45(12):1276-1281.
DMU8JGH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29018032

DMU8JGH	DI	DMU8JGH
DMU8JGH	DN	Hydralazine
DMU8JGH	MI	DER7TA0
DMU8JGH	MN	N-acetyltransferase 2 (NAT2)
DMU8JGH	MT	DME
DMU8JGH	MA	Metabolism
DMU8JGH	RN	N-acetyltransferase 2 genotype-dependent N-acetylation of hydralazine in human hepatocytes. Drug Metab Dispos. 2017 Dec;45(12):1276-1281.
DMU8JGH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29018032

DMU8JGH	DI	DMU8JGH
DMU8JGH	DN	Hydralazine
DMU8JGH	MI	DEZV4AP
DMU8JGH	MN	RNA cytidine acetyltransferase (hALP)
DMU8JGH	MT	DME
DMU8JGH	MA	Metabolism
DMU8JGH	RN	Prizidilol, an antihypertensive with precapillary vasodilator and beta-adrenoceptor blocking actions, in primary hypertension. Clin Pharmacol Ther. 1981 May;29(5):588-93.
DMU8JGH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=6111409

DMUSZHD	DI	DMUSZHD
DMUSZHD	DN	Hydrochlorothiazide
DMUSZHD	MI	TTL69WB
DMUSZHD	MN	Angiotensin-converting enzyme (ACE)
DMUSZHD	MT	DTT
DMUSZHD	MA	Modulator
DMUSZHD	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMUSZHD	RU	https://www.fda.gov/

DMQ2JO5	DI	DMQ2JO5
DMQ2JO5	DN	Hydrocodone
DMQ2JO5	MI	TTKWM86
DMQ2JO5	MN	Opioid receptor mu (MOP)
DMQ2JO5	MT	DTT
DMQ2JO5	MA	Modulator
DMQ2JO5	RN	Clinical pipeline report, company report or official report of kempharm.
DMQ2JO5	RU	http://www.kempharm.com/pages/pipeline/pain.php

DMIAPBE	DI	DMIAPBE
DMIAPBE	DN	Hydrocodone bitartrate
DMIAPBE	MI	DEPKLMQ
DMIAPBE	MN	Cytochrome P450 2B6 (CYP2B6)
DMIAPBE	MT	DME
DMIAPBE	MA	Metabolism
DMIAPBE	RN	FDA label of Hydrocodone bitartrate. The 2020 official website of the U.S. Food and Drug Administration.
DMIAPBE	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206627s007s008lbl.pdf

DMIAPBE	DI	DMIAPBE
DMIAPBE	DN	Hydrocodone bitartrate
DMIAPBE	MI	DECB0K3
DMIAPBE	MN	Cytochrome P450 2D6 (CYP2D6)
DMIAPBE	MT	DME
DMIAPBE	MA	Metabolism
DMIAPBE	RN	The effect of CYP2D6 drug-drug interactions on hydrocodone effectiveness. Acad Emerg Med. 2014 Aug;21(8):879-85.
DMIAPBE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25156930

DMIAPBE	DI	DMIAPBE
DMIAPBE	DN	Hydrocodone bitartrate
DMIAPBE	MI	DE4LYSA
DMIAPBE	MN	Cytochrome P450 3A4 (CYP3A4)
DMIAPBE	MT	DME
DMIAPBE	MA	Metabolism
DMIAPBE	RN	The effect of CYP2D6 drug-drug interactions on hydrocodone effectiveness. Acad Emerg Med. 2014 Aug;21(8):879-85.
DMIAPBE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25156930

DMIAPBE	DI	DMIAPBE
DMIAPBE	DN	Hydrocodone bitartrate
DMIAPBE	MI	DEYGVN4
DMIAPBE	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMIAPBE	MT	DME
DMIAPBE	MA	Metabolism
DMIAPBE	RN	Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, Part II. Psychosomatics. 2003 Nov-Dec;44(6):515-20.
DMIAPBE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14597688

DM8K1XO	DI	DM8K1XO
DM8K1XO	DN	Hydrocortamate
DM8K1XO	MI	TTYRL6O
DM8K1XO	MN	Glucocorticoid receptor (NR3C1)
DM8K1XO	MT	DTT
DM8K1XO	MA	Modulator
DM8K1XO	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM8K1XO	RU	https://www.fda.gov/

DMGEMB7	DI	DMGEMB7
DMGEMB7	DN	Hydrocortisone
DMGEMB7	MI	DE6TYUK
DMGEMB7	MN	Aldosterone synthase (CYP11B2)
DMGEMB7	MT	DME
DMGEMB7	MA	Metabolism
DMGEMB7	RN	Studies on the origin of circulating 18-hydroxycortisol and 18-oxocortisol in normal human subjects. J Clin Endocrinol Metab. 2004 Sep;89(9):4628-33.
DMGEMB7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15356073

DMGEMB7	DI	DMGEMB7
DMGEMB7	DN	Hydrocortisone
DMGEMB7	MI	DE4LYSA
DMGEMB7	MN	Cytochrome P450 3A4 (CYP3A4)
DMGEMB7	MT	DME
DMGEMB7	MA	Metabolism
DMGEMB7	RN	Regulation of the CYP3A4 gene by hydrocortisone and xenobiotics: role of the glucocorticoid and pregnane X receptors. Drug Metab Dispos. 2000 May;28(5):493-6.
DMGEMB7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10772626

DMGEMB7	DI	DMGEMB7
DMGEMB7	DN	Hydrocortisone
DMGEMB7	MI	DEIBDNY
DMGEMB7	MN	Cytochrome P450 3A5 (CYP3A5)
DMGEMB7	MT	DME
DMGEMB7	MA	Metabolism
DMGEMB7	RN	CYP3A5 genotype is associated with elevated blood pressure. Pharmacogenet Genomics. 2005 Oct;15(10):737-41.
DMGEMB7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16141800

DMGEMB7	DI	DMGEMB7
DMGEMB7	DN	Hydrocortisone
DMGEMB7	MI	DERD86B
DMGEMB7	MN	Cytochrome P450 3A7 (CYP3A7)
DMGEMB7	MT	DME
DMGEMB7	MA	Metabolism
DMGEMB7	RN	Steroid hydroxylation by human fetal CYP3A7 and human NADPH-cytochrome P450 reductase coexpressed in insect cells using baculovirus. Res Commun Mol Pathol Pharmacol. 1998 Apr;100(1):15-28.
DMGEMB7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9644715

DMGEMB7	DI	DMGEMB7
DMGEMB7	DN	Hydrocortisone
DMGEMB7	MI	TTYRL6O
DMGEMB7	MN	Glucocorticoid receptor (NR3C1)
DMGEMB7	MT	DTT
DMGEMB7	MA	Modulator
DMGEMB7	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMGEMB7	RU	https://www.fda.gov/

DMGEMB7	DI	DMGEMB7
DMGEMB7	DN	Hydrocortisone
DMGEMB7	MI	DTUGYRD
DMGEMB7	MN	P-glycoprotein 1 (ABCB1)
DMGEMB7	MT	DTP
DMGEMB7	MA	Substrate
DMGEMB7	RN	Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux. Toxicol Appl Pharmacol. 2012 May 1;260(3):294-302.
DMGEMB7	RU	https://doi.org/10.1016/j.taap.2012.03.008

DMGEMB7	DI	DMGEMB7
DMGEMB7	DN	Hydrocortisone
DMGEMB7	MI	DEPE0RD
DMGEMB7	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMGEMB7	MT	DME
DMGEMB7	MA	Metabolism
DMGEMB7	RN	Studies on the origin of circulating 18-hydroxycortisol and 18-oxocortisol in normal human subjects. J Clin Endocrinol Metab. 2004 Sep;89(9):4628-33.
DMGEMB7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15356073

DMVPUQI	DI	DMVPUQI
DMVPUQI	DN	Hydroflumethiazide
DMVPUQI	MI	TTS087L
DMVPUQI	MN	Solute carrier family 12 member 1 (SLC12A1)
DMVPUQI	MT	DTT
DMVPUQI	MA	Blocker
DMVPUQI	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DMVPUQI	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DM1NG5W	DI	DM1NG5W
DM1NG5W	DN	Hydrogen peroxide
DM1NG5W	MI	DE1XPGH
DM1NG5W	MN	Catalase (CAT)
DM1NG5W	MT	DME
DM1NG5W	MA	Metabolism
DM1NG5W	RN	Catalase and glutathione peroxidase are equally active in detoxification of hydrogen peroxide in human erythrocytes. Blood. 1989 Jan;73(1):334-9.
DM1NG5W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=2491951

DM1NG5W	DI	DM1NG5W
DM1NG5W	DN	Hydrogen peroxide
DM1NG5W	MI	DESZ5G9
DM1NG5W	MN	Cellular glutathione peroxidase (GPX1)
DM1NG5W	MT	DME
DM1NG5W	MA	Metabolism
DM1NG5W	RN	Catalase and glutathione peroxidase are equally active in detoxification of hydrogen peroxide in human erythrocytes. Blood. 1989 Jan;73(1):334-9.
DM1NG5W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=2491951

DM1NG5W	DI	DM1NG5W
DM1NG5W	DN	Hydrogen peroxide
DM1NG5W	MI	DE9QHP6
DM1NG5W	MN	Cytochrome P450 1B1 (CYP1B1)
DM1NG5W	MT	DME
DM1NG5W	MA	Metabolism
DM1NG5W	RN	NADPH- and hydroperoxide-supported 17beta-estradiol hydroxylation catalyzed by a variant form (432L, 453S) of human cytochrome P450 1B1. J Steroid Biochem Mol Biol. 2000 Sep;74(1-2):11-8.
DM1NG5W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11074351

DM1NG5W	DI	DM1NG5W
DM1NG5W	DN	Hydrogen peroxide
DM1NG5W	MI	DECB0K3
DM1NG5W	MN	Cytochrome P450 2D6 (CYP2D6)
DM1NG5W	MT	DME
DM1NG5W	MA	Metabolism
DM1NG5W	RN	Engineering of cytochrome P450 3A4 for enhanced peroxide-mediated substrate oxidation using directed evolution and site-directed mutagenesis. Drug Metab Dispos. 2006 Dec;34(12):1958-65.
DM1NG5W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16987939

DM1NG5W	DI	DM1NG5W
DM1NG5W	DN	Hydrogen peroxide
DM1NG5W	MI	TTELIN2
DM1NG5W	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DM1NG5W	MT	DTT
DM1NG5W	MA	Inhibitor
DM1NG5W	RN	Periodinates: a new class of protein tyrosine phosphatase inhibitors. Bioorg Med Chem Lett. 1999 Feb 8;9(3):353-6.
DM1NG5W	RU	https://pubmed.ncbi.nlm.nih.gov/10091683

DMHP21E	DI	DMHP21E
DMHP21E	DN	Hydromorphone
DMHP21E	MI	DE5IED8
DMHP21E	MN	Cytochrome P450 2C9 (CYP2C9)
DMHP21E	MT	DME
DMHP21E	MA	Metabolism
DMHP21E	RN	Role of individual human cytochrome P450 enzymes in the in vitro metabolism of hydromorphone. Xenobiotica. 2004 Apr;34(4):335-44.;
DMHP21E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15268978

DMHP21E	DI	DMHP21E
DMHP21E	DN	Hydromorphone
DMHP21E	MI	DECB0K3
DMHP21E	MN	Cytochrome P450 2D6 (CYP2D6)
DMHP21E	MT	DME
DMHP21E	MA	Metabolism
DMHP21E	RN	Effect of cytochrome P450 2D1 inhibition on hydrocodone metabolism and its behavioral consequences in rats. J Pharmacol Exp Ther. 1997 Mar;280(3):1374-82.
DMHP21E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9067326

DMHP21E	DI	DMHP21E
DMHP21E	DN	Hydromorphone
DMHP21E	MI	DE4LYSA
DMHP21E	MN	Cytochrome P450 3A4 (CYP3A4)
DMHP21E	MT	DME
DMHP21E	MA	Metabolism
DMHP21E	RN	Capillary electrophoresis contributions to the hydromorphone metabolism in man. Electrophoresis. 2006 Jun;27(12):2444-57.
DMHP21E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16718649

DMHP21E	DI	DMHP21E
DMHP21E	DN	Hydromorphone
DMHP21E	MI	TT27RFC
DMHP21E	MN	Opioid receptor delta (OPRD1)
DMHP21E	MT	DTT
DMHP21E	MA	Binder
DMHP21E	RN	Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone]. J Med Chem. 2004 Mar 11;47(6):1400-12.
DMHP21E	RU	https://pubmed.ncbi.nlm.nih.gov/14998329

DMHP21E	DI	DMHP21E
DMHP21E	DN	Hydromorphone
DMHP21E	MI	TTKWM86
DMHP21E	MN	Opioid receptor mu (MOP)
DMHP21E	MT	DTT
DMHP21E	MA	Inhibitor
DMHP21E	RN	Clinical pipeline report, company report or official report of signaturerx.
DMHP21E	RU	http://www.signaturerx.com/view.cfm/59/Abuse-Resistant-Opioids

DMHP21E	DI	DMHP21E
DMHP21E	DN	Hydromorphone
DMHP21E	MI	DEYGVN4
DMHP21E	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMHP21E	MT	DME
DMHP21E	MA	Metabolism
DMHP21E	RN	Is maternal opioid use hazardous to breast-fed infants? Clin Toxicol (Phila). 2012 Jan;50(1):1-14.
DMHP21E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22148986

DMHP21E	DI	DMHP21E
DMHP21E	DN	Hydromorphone
DMHP21E	MI	DEF2WXN
DMHP21E	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMHP21E	MT	DME
DMHP21E	MA	Metabolism
DMHP21E	RN	Opioid therapies and cytochrome p450 interactions. J Pain Symptom Manage. 2012 Dec;44(6 Suppl):S4-14.
DMHP21E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23218233

DMHP21E	DI	DMHP21E
DMHP21E	DN	Hydromorphone
DMHP21E	MI	DEB3CV1
DMHP21E	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMHP21E	MT	DME
DMHP21E	MA	Metabolism
DMHP21E	RN	Opioid therapies and cytochrome p450 interactions. J Pain Symptom Manage. 2012 Dec;44(6 Suppl):S4-14.
DMHP21E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23218233

DM6AVR4	DI	DM6AVR4
DM6AVR4	DN	Hydroquinone
DM6AVR4	MI	DE4LYSA
DM6AVR4	MN	Cytochrome P450 3A4 (CYP3A4)
DM6AVR4	MT	DME
DM6AVR4	MA	Metabolism
DM6AVR4	RN	Metabolism of (S)-5,6-difluoro-4-cyclopropylethynyl-4-trifluoromethyl-3, 4-dihydro-2(1H)-quinazolinone, a non-nucleoside reverse transcriptase inhibitor, in human liver microsomes. Metabolic activation and enzyme kinetics. Drug Metab Dispos. 2003 Jan;31(1):122-32.
DM6AVR4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12485961

DM6AVR4	DI	DM6AVR4
DM6AVR4	DN	Hydroquinone
DM6AVR4	MI	DEQUXZ5
DM6AVR4	MN	Fumarate reductase flavoprotein (frdA)
DM6AVR4	MT	DME
DM6AVR4	MA	Metabolism
DM6AVR4	RN	Wolinella succinogenes quinol:fumarate reductase and its comparison to E. coli succinate:quinone reductase. FEBS Lett. 2003 Nov 27;555(1):21-8.
DM6AVR4	RU	https://pubmed.ncbi.nlm.nih.gov/14630313

DM6AVR4	DI	DM6AVR4
DM6AVR4	DN	Hydroquinone
DM6AVR4	MI	TT38RM1
DM6AVR4	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DM6AVR4	MT	DTT
DM6AVR4	MA	Antagonist
DM6AVR4	RN	Accutin, a new disintegrin, inhibits angiogenesis in vitro and in vivo by acting as integrin alphavbeta3 antagonist and inducing apoptosis. Blood. 1998 Nov 1;92(9):3268-76.
DM6AVR4	RU	https://pubmed.ncbi.nlm.nih.gov/9787163

DM6AVR4	DI	DM6AVR4
DM6AVR4	DN	Hydroquinone
DM6AVR4	MI	TTULVH8
DM6AVR4	MN	Tyrosinase (TYR)
DM6AVR4	MT	DTT
DM6AVR4	MA	Inhibitor
DM6AVR4	RN	Identification of an Alkylhydroquinone from Rhus succedanea as an Inhibitor of Tyrosinase and Melanogenesis. J Agric Food Chem. 2009 Mar 25;57(6):2200-5.
DM6AVR4	RU	https://pubmed.ncbi.nlm.nih.gov/19159217

DMGKV9D	DI	DMGKV9D
DMGKV9D	DN	Hydroxocobalamin
DMGKV9D	MI	TTCQ21Y
DMGKV9D	MN	Methylmalonyl-CoA mutase (MMUT)
DMGKV9D	MT	DTT
DMGKV9D	MA	Cofactor
DMGKV9D	RN	Vitamin B12. Nippon Rinsho. 1999 Oct;57(10):2205-10.
DMGKV9D	RU	https://pubmed.ncbi.nlm.nih.gov/10540863

DMJAS3O	DI	DMJAS3O
DMJAS3O	DN	Hydroxyamphetamine
DMJAS3O	MI	DE4LYSA
DMJAS3O	MN	Cytochrome P450 3A4 (CYP3A4)
DMJAS3O	MT	DME
DMJAS3O	MA	Metabolism
DMJAS3O	RN	Stereoselective method development and validation for determination of concentrations of amphetamine-type stimulants and metabolites in human urine using a simultaneous extraction-chiral derivatization approach. J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Jan 1;879(1):8-16.
DMJAS3O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21147046

DMQSGM0	DI	DMQSGM0
DMQSGM0	DN	Hydroxyamphetamine Hydrobromide
DMQSGM0	MI	TTIU98M
DMQSGM0	MN	Trace amine-associated receptor-1 (TAAR1)
DMQSGM0	MT	DTT
DMQSGM0	MA	Modulator
DMQSGM0	RN	Diagnostic pharmacology of the pupil.Clin Neuropharmacol.1985;8(1):27-37.
DMQSGM0	RU	https://www.ncbi.nlm.nih.gov/pubmed/3884149

DMSIVND	DI	DMSIVND
DMSIVND	DN	Hydroxychloroquine
DMSIVND	MI	DTI7UX6
DMSIVND	MN	Breast cancer resistance protein (ABCG2)
DMSIVND	MT	DTP
DMSIVND	MA	Substrate
DMSIVND	RN	MDR-ABC transporters: biomarkers in rheumatoid arthritis. Clin Exp Rheumatol. 2013 Sep-Oct;31(5):779-87.
DMSIVND	RU	http://www.ncbi.nlm.nih.gov/pubmed/23711386

DMSIVND	DI	DMSIVND
DMSIVND	DN	Hydroxychloroquine
DMSIVND	MI	DE4LYSA
DMSIVND	MN	Cytochrome P450 3A4 (CYP3A4)
DMSIVND	MT	DME
DMSIVND	MA	Metabolism
DMSIVND	RN	Hydroxychloroquine: a physiologically-based pharmacokinetic model in the context of cancer-related autophagy modulation. J Pharmacol Exp Ther. 2018 Jun;365(3):447-459.
DMSIVND	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29438998

DMSIVND	DI	DMSIVND
DMSIVND	DN	Hydroxychloroquine
DMSIVND	MI	TTRJ1K4
DMSIVND	MN	Toll-like receptor 7 (TLR7)
DMSIVND	MT	DTT
DMSIVND	MA	Antagonist
DMSIVND	RN	TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets. 2007 Dec;6(4):223-35.
DMSIVND	RU	https://pubmed.ncbi.nlm.nih.gov/18220957

DMGIZF5	DI	DMGIZF5
DMGIZF5	DN	Hydroxyflutamide
DMGIZF5	MI	TTS64P2
DMGIZF5	MN	Androgen receptor (AR)
DMGIZF5	MT	DTT
DMGIZF5	MA	Antagonist
DMGIZF5	RN	Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol. 2007 Apr;4(4):236-44.
DMGIZF5	RU	https://pubmed.ncbi.nlm.nih.gov/17392714

DMIKQH5	DI	DMIKQH5
DMIKQH5	DN	Hydroxyprogesterone
DMIKQH5	MI	DE4LYSA
DMIKQH5	MN	Cytochrome P450 3A4 (CYP3A4)
DMIKQH5	MT	DME
DMIKQH5	MA	Metabolism
DMIKQH5	RN	Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations. Semin Perinatol. 2014 Dec;38(8):516-22.
DMIKQH5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25256193

DMIKQH5	DI	DMIKQH5
DMIKQH5	DN	Hydroxyprogesterone
DMIKQH5	MI	DEIBDNY
DMIKQH5	MN	Cytochrome P450 3A5 (CYP3A5)
DMIKQH5	MT	DME
DMIKQH5	MA	Metabolism
DMIKQH5	RN	Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations. Semin Perinatol. 2014 Dec;38(8):516-22.
DMIKQH5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25256193

DMIKQH5	DI	DMIKQH5
DMIKQH5	DN	Hydroxyprogesterone
DMIKQH5	MI	DE0JMZ5
DMIKQH5	MN	Steroid 21-hydroxylase (CYP21A2)
DMIKQH5	MT	DME
DMIKQH5	MA	Metabolism
DMIKQH5	RN	Functional characterization of two novel point mutations in the CYP21 gene causing simple virilizing forms of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2005 Jan;90(1):445-54.
DMIKQH5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15483094

DMIKQH5	DI	DMIKQH5
DMIKQH5	DN	Hydroxyprogesterone
DMIKQH5	MI	DEYGVN4
DMIKQH5	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMIKQH5	MT	DME
DMIKQH5	MA	Metabolism
DMIKQH5	RN	The glucuronidation of Delta4-3-Keto C19- and C21-hydroxysteroids by human liver microsomal and recombinant UDP-glucuronosyltransferases (UGTs): 6alpha- and 21-hydroxyprogesterone are selective substrates for UGT2B7. Drug Metab Dispos. 2007 Mar;35(3):363-70.
DMIKQH5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17151189

DMR5QS6	DI	DMR5QS6
DMR5QS6	DN	Hydroxystilbamidine Isethionate
DMR5QS6	MI	TTS1W4A
DMR5QS6	MN	Bacterial Deoxyribonucleic acid (Bact DNA)
DMR5QS6	MT	DTT
DMR5QS6	MA	Modulator
DMR5QS6	RN	Interaction between hydroxystilbamidine and DNA. I. Binding isotherms and thermodynamics of the association. Biochim Biophys Acta. 1975 Sep 12;407(1):24-42.
DMR5QS6	RU	https://www.ncbi.nlm.nih.gov/pubmed/1242363

DMOQVU9	DI	DMOQVU9
DMOQVU9	DN	Hydroxyurea
DMOQVU9	MI	DTE2B1D
DMOQVU9	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMOQVU9	MT	DTP
DMOQVU9	MA	Substrate
DMOQVU9	RN	Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. Exp Hematol. 2011 Apr;39(4):446-56.
DMOQVU9	RU	http://www.ncbi.nlm.nih.gov/pubmed/21256917

DMOQVU9	DI	DMOQVU9
DMOQVU9	DN	Hydroxyurea
DMOQVU9	MI	DT3D8F0
DMOQVU9	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMOQVU9	MT	DTP
DMOQVU9	MA	Substrate
DMOQVU9	RN	Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. Exp Hematol. 2011 Apr;39(4):446-56.
DMOQVU9	RU	http://www.ncbi.nlm.nih.gov/pubmed/21256917

DMOQVU9	DI	DMOQVU9
DMOQVU9	DN	Hydroxyurea
DMOQVU9	MI	DT9C1TS
DMOQVU9	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMOQVU9	MT	DTP
DMOQVU9	MA	Substrate
DMOQVU9	RN	Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. Exp Hematol. 2011 Apr;39(4):446-56.
DMOQVU9	RU	http://www.ncbi.nlm.nih.gov/pubmed/21256917

DMOQVU9	DI	DMOQVU9
DMOQVU9	DN	Hydroxyurea
DMOQVU9	MI	DTUGYRD
DMOQVU9	MN	P-glycoprotein 1 (ABCB1)
DMOQVU9	MT	DTP
DMOQVU9	MA	Substrate
DMOQVU9	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMOQVU9	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMOQVU9	DI	DMOQVU9
DMOQVU9	DN	Hydroxyurea
DMOQVU9	MI	TTBWDI0
DMOQVU9	MN	Ribonucleoside-diphosphate reductase M2 (RRM2)
DMOQVU9	MT	DTT
DMOQVU9	MA	Modulator
DMOQVU9	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMOQVU9	RU	https://www.fda.gov/

DMF8Y74	DI	DMF8Y74
DMF8Y74	DN	Hydroxyzine
DMF8Y74	MI	DE4LYSA
DMF8Y74	MN	Cytochrome P450 3A4 (CYP3A4)
DMF8Y74	MT	DME
DMF8Y74	MA	Metabolism
DMF8Y74	RN	Product characteristics of HYDROXYZINE (Hydroxyzine Hydrochloride Capsules).
DMF8Y74	RU	https://www.aapharma.ca/downloads/en/PIL/2018/Hydroxyzine-Pr_Info_Mono-ENG-Jul_09_2018.pdf

DMF8Y74	DI	DMF8Y74
DMF8Y74	DN	Hydroxyzine
DMF8Y74	MI	DEIBDNY
DMF8Y74	MN	Cytochrome P450 3A5 (CYP3A5)
DMF8Y74	MT	DME
DMF8Y74	MA	Metabolism
DMF8Y74	RN	Product characteristics of HYDROXYZINE (Hydroxyzine Hydrochloride Capsules).
DMF8Y74	RU	https://www.aapharma.ca/downloads/en/PIL/2018/Hydroxyzine-Pr_Info_Mono-ENG-Jul_09_2018.pdf

DMF8Y74	DI	DMF8Y74
DMF8Y74	DN	Hydroxyzine
DMF8Y74	MI	TTTIBOJ
DMF8Y74	MN	Histamine H1 receptor (H1R)
DMF8Y74	MT	DTT
DMF8Y74	MA	Antagonist
DMF8Y74	RN	Hydroxyzine, a first generation H(1)-receptor antagonist, inhibits human ether-a-go-go-related gene (HERG) current and causes syncope in a patient ... J Pharmacol Sci. 2008 Dec;108(4):462-71.
DMF8Y74	RU	https://pubmed.ncbi.nlm.nih.gov/19057127

DMVAIH4	DI	DMVAIH4
DMVAIH4	DN	Hylenex
DMVAIH4	MI	TTYTVXF
DMVAIH4	MN	Hyaluronic acid (HA)
DMVAIH4	MT	DTT
DMVAIH4	MA	Modulator
DMVAIH4	RN	Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look. Cancer Discov. 2011 September; 1(4): 291-296.
DMVAIH4	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3204883/

DM804UR	DI	DM804UR
DM804UR	DN	Hyoscyamine
DM804UR	MI	TTH18TF
DM804UR	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DM804UR	MT	DTT
DM804UR	MA	Antagonist
DM804UR	RN	Reconstitution of the purified porcine atrial muscarinic acetylcholine receptor with purified porcine atrial inhibitory guanine nucleotide binding protein. Biochemistry. 1987 Dec 15;26(25):8175-82.
DM804UR	RU	https://pubmed.ncbi.nlm.nih.gov/3126798

DM0RXF5	DI	DM0RXF5
DM0RXF5	DN	Hyqvia
DM0RXF5	MI	TTXFI1K
DM0RXF5	MN	Hyaluronidase (HYAL)
DM0RXF5	MT	DTT
DM0RXF5	MA	Modulator
DM0RXF5	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DM0RXF5	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMV67QO	DI	DMV67QO
DMV67QO	DN	Ibalizumab 
DMV67QO	MI	TTN2JFW
DMV67QO	MN	T-cell surface glycoprotein CD4 (CD4)
DMV67QO	MT	DTT
DMV67QO	MA	Modulator
DMV67QO	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMV67QO	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DM0QZBN	DI	DM0QZBN
DM0QZBN	DN	Ibandronate
DM0QZBN	MI	TTIKWV4
DM0QZBN	MN	Geranyltranstransferase (FDPS)
DM0QZBN	MT	DTT
DM0QZBN	MA	Modulator
DM0QZBN	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM0QZBN	RU	https://www.fda.gov/

DMGUX67	DI	DMGUX67
DMGUX67	DN	Ibopamine hci
DMGUX67	MI	TTEX248
DMGUX67	MN	Dopamine D2 receptor (D2R)
DMGUX67	MT	DTT
DMGUX67	MA	Modulator
DMGUX67	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMGUX67	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DMG594T	DI	DMG594T
DMG594T	DN	Ibritumomab
DMG594T	MI	TTUE541
DMG594T	MN	Leukocyte surface antigen Leu-16 (CD20)
DMG594T	MT	DTT
DMG594T	RN	Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol. 2009 Jul;46(11-12):2419-23.
DMG594T	RU	https://pubmed.ncbi.nlm.nih.gov/19427037

DMHZCPO	DI	DMHZCPO
DMHZCPO	DN	Ibrutinib
DMHZCPO	MI	DECB0K3
DMHZCPO	MN	Cytochrome P450 2D6 (CYP2D6)
DMHZCPO	MT	DME
DMHZCPO	MA	Metabolism
DMHZCPO	RN	Absorption, metabolism, and excretion of oral 14C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab Dispos. 2015 Feb;43(2):289-97.
DMHZCPO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25488930

DMHZCPO	DI	DMHZCPO
DMHZCPO	DN	Ibrutinib
DMHZCPO	MI	DE4LYSA
DMHZCPO	MN	Cytochrome P450 3A4 (CYP3A4)
DMHZCPO	MT	DME
DMHZCPO	MA	Metabolism
DMHZCPO	RN	Absorption, metabolism, and excretion of oral 14C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab Dispos. 2015 Feb;43(2):289-97.
DMHZCPO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25488930

DMHZCPO	DI	DMHZCPO
DMHZCPO	DN	Ibrutinib
DMHZCPO	MI	DEIBDNY
DMHZCPO	MN	Cytochrome P450 3A5 (CYP3A5)
DMHZCPO	MT	DME
DMHZCPO	MA	Metabolism
DMHZCPO	RN	Absorption, metabolism, and excretion of oral 14C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab Dispos. 2015 Feb;43(2):289-97.
DMHZCPO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25488930

DMHZCPO	DI	DMHZCPO
DMHZCPO	DN	Ibrutinib
DMHZCPO	MI	DTUGYRD
DMHZCPO	MN	P-glycoprotein 1 (ABCB1)
DMHZCPO	MT	DTP
DMHZCPO	MA	Substrate
DMHZCPO	RN	P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability. Mol Pharm. 2018 Nov 5;15(11):5124-5134.
DMHZCPO	RU	http://www.ncbi.nlm.nih.gov/pubmed/30247919

DMHZCPO	DI	DMHZCPO
DMHZCPO	DN	Ibrutinib
DMHZCPO	MI	TTGM6VW
DMHZCPO	MN	Tyrosine-protein kinase BTK (ATK)
DMHZCPO	MT	DTT
DMHZCPO	MA	Inhibitor
DMHZCPO	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1948).
DMHZCPO	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1948

DM4LSPN	DI	DM4LSPN
DM4LSPN	DN	Ibudilast
DM4LSPN	MI	TTZCG4L
DM4LSPN	MN	Phosphodiesterase 3 (PDE3)
DM4LSPN	MT	DTT
DM4LSPN	MA	Inhibitor
DM4LSPN	RN	Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond. Nat Rev Drug Discov. 2019 Oct;18(10):770-796.
DM4LSPN	RU	https://pubmed.ncbi.nlm.nih.gov/31388135

DM4LSPN	DI	DM4LSPN
DM4LSPN	DN	Ibudilast
DM4LSPN	MI	TTV5CGO
DM4LSPN	MN	Phosphodiesterase 4 (PDE4)
DM4LSPN	MT	DTT
DM4LSPN	MA	Inhibitor
DM4LSPN	RN	Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond. Nat Rev Drug Discov. 2019 Oct;18(10):770-796.
DM4LSPN	RU	https://pubmed.ncbi.nlm.nih.gov/31388135

DM8VCBE	DI	DM8VCBE
DM8VCBE	DN	Ibuprofen
DM8VCBE	MI	DEMEPVJ
DM8VCBE	MN	Acyl-CoA thioesterase 2 (ACOT2)
DM8VCBE	MT	DME
DM8VCBE	MA	Metabolism
DM8VCBE	RN	A study on the chiral inversion of mandelic acid in humans. Org Biomol Chem. 2014 Sep 14;12(34):6737-44.
DM8VCBE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25050409

DM8VCBE	DI	DM8VCBE
DM8VCBE	DN	Ibuprofen
DM8VCBE	MI	DEGKWJB
DM8VCBE	MN	Alpha-methylacyl-CoA racemase (AMACR)
DM8VCBE	MT	DME
DM8VCBE	MA	Metabolism
DM8VCBE	RN	Ibuprofen: pharmacology, efficacy and safety. Inflammopharmacology. 2009 Dec;17(6):275-342.
DM8VCBE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19949916

DM8VCBE	DI	DM8VCBE
DM8VCBE	DN	Ibuprofen
DM8VCBE	MI	TTMWT8Z
DM8VCBE	MN	C-X-C chemokine receptor type 1 (CXCR1)
DM8VCBE	MT	DTT
DM8VCBE	MA	Inhibitor
DM8VCBE	RN	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
DM8VCBE	RU	https://pubmed.ncbi.nlm.nih.gov/15974585

DM8VCBE	DI	DM8VCBE
DM8VCBE	DN	Ibuprofen
DM8VCBE	MI	TT30C9G
DM8VCBE	MN	C-X-C chemokine receptor type 2 (CXCR2)
DM8VCBE	MT	DTT
DM8VCBE	MA	Inhibitor
DM8VCBE	RN	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
DM8VCBE	RU	https://pubmed.ncbi.nlm.nih.gov/15974585

DM8VCBE	DI	DM8VCBE
DM8VCBE	DN	Ibuprofen
DM8VCBE	MI	DES5XRU
DM8VCBE	MN	Cytochrome P450 2C8 (CYP2C8)
DM8VCBE	MT	DME
DM8VCBE	MA	Metabolism
DM8VCBE	RN	Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos. 2013 Jul;34(5):278-87.
DM8VCBE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23536207

DM8VCBE	DI	DM8VCBE
DM8VCBE	DN	Ibuprofen
DM8VCBE	MI	DE5IED8
DM8VCBE	MN	Cytochrome P450 2C9 (CYP2C9)
DM8VCBE	MT	DME
DM8VCBE	MA	Metabolism
DM8VCBE	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM8VCBE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM8VCBE	DI	DM8VCBE
DM8VCBE	DN	Ibuprofen
DM8VCBE	MI	DE4LYSA
DM8VCBE	MN	Cytochrome P450 3A4 (CYP3A4)
DM8VCBE	MT	DME
DM8VCBE	MA	Metabolism
DM8VCBE	RN	PharmGKB summary: ibuprofen pathways. Pharmacogenet Genomics. 2015 Feb;25(2):96-106.
DM8VCBE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25502615

DM8VCBE	DI	DM8VCBE
DM8VCBE	DN	Ibuprofen
DM8VCBE	MI	TTCTE1G
DM8VCBE	MN	Interleukin-8 (IL8)
DM8VCBE	MT	DTT
DM8VCBE	MA	Inhibitor
DM8VCBE	RN	Structure-Activity Relationship of novel phenylacetic CXCR1 inhibitors. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4026-30.
DM8VCBE	RU	https://pubmed.ncbi.nlm.nih.gov/19560921

DM8VCBE	DI	DM8VCBE
DM8VCBE	DN	Ibuprofen
DM8VCBE	MI	DEGTFWK
DM8VCBE	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM8VCBE	MT	DME
DM8VCBE	MA	Metabolism
DM8VCBE	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM8VCBE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM8VCBE	DI	DM8VCBE
DM8VCBE	DN	Ibuprofen
DM8VCBE	MI	DTLT3UG
DM8VCBE	MN	Monocarboxylate transporter 2 (SLC16A7)
DM8VCBE	MT	DTP
DM8VCBE	MA	Substrate
DM8VCBE	RN	Monocarboxylate Transporters in Drug Disposition: Role in the Toxicokinetics and Toxicodynamics of the Drug of Abuse GHB.
DM8VCBE	RU	https://www.njacs.org/wp-content/docs/2010-Spring-DrugMet-Marilyn_Morris.pdf

DM8VCBE	DI	DM8VCBE
DM8VCBE	DN	Ibuprofen
DM8VCBE	MI	DTHE530
DM8VCBE	MN	Probable small intestine urate exporter (SLC17A4)
DM8VCBE	MT	DTP
DM8VCBE	MA	Substrate
DM8VCBE	RN	A Na+-phosphate cotransporter homologue (SLC17A4 protein) is an intestinal organic anion exporter. Am J Physiol Cell Physiol. 2012 Jun 1;302(11):C1652-60.
DM8VCBE	RU	http://www.ncbi.nlm.nih.gov/pubmed/22460716

DM8VCBE	DI	DM8VCBE
DM8VCBE	DN	Ibuprofen
DM8VCBE	MI	TTVKILB
DM8VCBE	MN	Prostaglandin G/H synthase 2 (COX-2)
DM8VCBE	MT	DTT
DM8VCBE	MA	Inhibitor
DM8VCBE	RN	Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44.
DM8VCBE	RU	https://pubmed.ncbi.nlm.nih.gov/19379806

DM8VCBE	DI	DM8VCBE
DM8VCBE	DN	Ibuprofen
DM8VCBE	MI	DEF2WXN
DM8VCBE	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DM8VCBE	MT	DME
DM8VCBE	MA	Metabolism
DM8VCBE	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM8VCBE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM8VCBE	DI	DM8VCBE
DM8VCBE	DN	Ibuprofen
DM8VCBE	MI	DE85D2P
DM8VCBE	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DM8VCBE	MT	DME
DM8VCBE	MA	Metabolism
DM8VCBE	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM8VCBE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM8VCBE	DI	DM8VCBE
DM8VCBE	DN	Ibuprofen
DM8VCBE	MI	DEB3CV1
DM8VCBE	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DM8VCBE	MT	DME
DM8VCBE	MA	Metabolism
DM8VCBE	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM8VCBE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMFJ8LT	DI	DMFJ8LT
DMFJ8LT	DN	Ibutamoren
DMFJ8LT	MI	TTWDC17
DMFJ8LT	MN	Growth hormone secretagogue receptor 1 (GHSR)
DMFJ8LT	MT	DTT
DMFJ8LT	MA	Modulator
DMFJ8LT	RN	Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):7001-5.
DMFJ8LT	RU	https://www.ncbi.nlm.nih.gov/pubmed/7624358

DMKXY2R	DI	DMKXY2R
DMKXY2R	DN	Ibutilide
DMKXY2R	MI	TT1VOHK
DMKXY2R	MN	Potassium channel unspecific (KC)
DMKXY2R	MT	DTT
DMKXY2R	MA	Modulator
DMKXY2R	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMKXY2R	RU	https://www.fda.gov/

DMQPTOZ	DI	DMQPTOZ
DMQPTOZ	DN	Icatibant
DMQPTOZ	MI	TTGY8IW
DMQPTOZ	MN	B2 bradykinin receptor (BDKRB2)
DMQPTOZ	MT	DTT
DMQPTOZ	MA	Antagonist
DMQPTOZ	RN	Bradykinin receptor antagonists--a review of the patent literature 2005-2008. Expert Opin Ther Pat. 2009 Jul;19(7):919-41.
DMQPTOZ	RU	https://pubmed.ncbi.nlm.nih.gov/19552510

DM648X9	DI	DM648X9
DM648X9	DN	Icodextrin
DM648X9	MI	DET64RG
DM648X9	MN	Pancreatic alpha-amylase (AMY2A)
DM648X9	MT	DME
DM648X9	MA	Metabolism
DM648X9	RN	Analytical interferences in point-of-care testing glucometers by icodextrin and its metabolites: an overview. Perit Dial Int. 2009 Jul-Aug;29(4):377-83.
DM648X9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19602602

DMJHN0A	DI	DMJHN0A
DMJHN0A	DN	Icosapent
DMJHN0A	MI	TTK0943
DMJHN0A	MN	Prostaglandin G/H synthase (COX)
DMJHN0A	MT	DTT
DMJHN0A	MA	Binder
DMJHN0A	RN	Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids. J Lipid Res. 2003 Mar;44(3):479-86.
DMJHN0A	RU	https://pubmed.ncbi.nlm.nih.gov/12562875

DMM0XGL	DI	DMM0XGL
DMM0XGL	DN	Idarubicin
DMM0XGL	MI	DTI7UX6
DMM0XGL	MN	Breast cancer resistance protein (ABCG2)
DMM0XGL	MT	DTP
DMM0XGL	MA	Substrate
DMM0XGL	RN	Amonafide L-malate is not a substrate for multidrug resistance proteins in secondary acute myeloid leukemia. Leukemia. 2008 Nov;22(11):2110-5.
DMM0XGL	RU	https://doi.org/10.1038/leu.2008.87

DMM0XGL	DI	DMM0XGL
DMM0XGL	DN	Idarubicin
DMM0XGL	MI	DE5IED8
DMM0XGL	MN	Cytochrome P450 2C9 (CYP2C9)
DMM0XGL	MT	DME
DMM0XGL	MA	Metabolism
DMM0XGL	RN	In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin. Hematology. 2004 Jun;9(3):217-21.
DMM0XGL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15204103

DMM0XGL	DI	DMM0XGL
DMM0XGL	DN	Idarubicin
DMM0XGL	MI	DECB0K3
DMM0XGL	MN	Cytochrome P450 2D6 (CYP2D6)
DMM0XGL	MT	DME
DMM0XGL	MA	Metabolism
DMM0XGL	RN	In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin. Hematology. 2004 Jun;9(3):217-21.
DMM0XGL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15204103

DMM0XGL	DI	DMM0XGL
DMM0XGL	DN	Idarubicin
DMM0XGL	MI	TT0IHXV
DMM0XGL	MN	DNA topoisomerase II (TOP2)
DMM0XGL	MT	DTT
DMM0XGL	MA	Modulator
DMM0XGL	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMM0XGL	RU	https://www.fda.gov/

DMM0XGL	DI	DMM0XGL
DMM0XGL	DN	Idarubicin
DMM0XGL	MI	DTSYQGK
DMM0XGL	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMM0XGL	MT	DTP
DMM0XGL	MA	Substrate
DMM0XGL	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMM0XGL	RU	https://doi.org/10.1007/s11095-012-0935-x

DMM0XGL	DI	DMM0XGL
DMM0XGL	DN	Idarubicin
DMM0XGL	MI	DTUGYRD
DMM0XGL	MN	P-glycoprotein 1 (ABCB1)
DMM0XGL	MT	DTP
DMM0XGL	MA	Substrate
DMM0XGL	RN	Amonafide L-malate is not a substrate for multidrug resistance proteins in secondary acute myeloid leukemia. Leukemia. 2008 Nov;22(11):2110-5.
DMM0XGL	RU	https://doi.org/10.1038/leu.2008.87

DMXEACF	DI	DMXEACF
DMXEACF	DN	Idarucizumab
DMXEACF	MI	TTFDXCO
DMXEACF	MN	Dabigatran (Dabi)
DMXEACF	MT	DTT
DMXEACF	MA	Binder
DMXEACF	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2015
DMXEACF	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761025lbl.pdf

DMQFDRC	DI	DMQFDRC
DMQFDRC	DN	Idebenone
DMQFDRC	MI	DEJGDUW
DMQFDRC	MN	Cytochrome P450 1A2 (CYP1A2)
DMQFDRC	MT	DME
DMQFDRC	MA	Metabolism
DMQFDRC	RN	Pharmacokinetic evaluation of idebenone. Expert Opin Drug Metab Toxicol. 2010 Nov;6(11):1437-44.
DMQFDRC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20955109

DMP1QTS	DI	DMP1QTS
DMP1QTS	DN	Idecabtagene vicleucel
DMP1QTS	MI	TTZ3P4W
DMP1QTS	MN	B-cell maturation protein (TNFRSF17)
DMP1QTS	MT	DTT
DMP1QTS	MA	CAR-T-Cell-Therapy
DMP1QTS	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services.
DMP1QTS	RU	https://www.fda.gov/vaccines-blood-biologics/abecma-idecabtagene-vicleucel

DM602WT	DI	DM602WT
DM602WT	DN	Idelalisib
DM602WT	MI	DTI7UX6
DM602WT	MN	Breast cancer resistance protein (ABCG2)
DM602WT	MT	DTP
DM602WT	MA	Substrate
DM602WT	RN	DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB09054)
DM602WT	RU	https://www.drugbank.ca/drugs/DB09054

DM602WT	DI	DM602WT
DM602WT	DN	Idelalisib
DM602WT	MI	DE4LYSA
DM602WT	MN	Cytochrome P450 3A4 (CYP3A4)
DM602WT	MT	DME
DM602WT	MA	Metabolism
DM602WT	RN	FDA label of Idelalisib. The 2020 official website of the U.S. Food and Drug Administration.
DM602WT	RU	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206545Orig1s000ClinPharmR.pdf

DM602WT	DI	DM602WT
DM602WT	DN	Idelalisib
DM602WT	MI	TTGBPJE
DM602WT	MN	PI3-kinase delta (PIK3CD)
DM602WT	MT	DTT
DM602WT	MA	Inhibitor
DM602WT	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DM602WT	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMDRT0E	DI	DMDRT0E
DMDRT0E	DN	Idoxuridine
DMDRT0E	MI	TT4823K
DMDRT0E	MN	Virus Deoxyribonucleic acid (Viru DNA)
DMDRT0E	MT	DTT
DMDRT0E	MA	Binder
DMDRT0E	RN	Radiopharmaceuticals (Strontium 89) and radiosensitizers (idoxuridine). J Intraven Nurs. 1998 Nov-Dec;21(6):335-7.
DMDRT0E	RU	https://pubmed.ncbi.nlm.nih.gov/10392098

DM30SXV	DI	DM30SXV
DM30SXV	DN	Idursulfase
DM30SXV	MI	TTNY2AP
DM30SXV	MN	Iduronate 2-sulfatase (IDS)
DM30SXV	MT	DTT
DM30SXV	MA	Modulator
DM30SXV	RN	2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
DM30SXV	RU	https://pubmed.ncbi.nlm.nih.gov/17342860

DMCT3I8	DI	DMCT3I8
DMCT3I8	DN	Ifosfamide
DMCT3I8	MI	DEJVYAZ
DMCT3I8	MN	Cytochrome P450 2A6 (CYP2A6)
DMCT3I8	MT	DME
DMCT3I8	MA	Metabolism
DMCT3I8	RN	Measurement of 4-hydroxylation of ifosfamide in human liver microsomes using the estimation of free and protein-bound acrolein and codetermination of keto- and carboxyifosfamide. J Cancer Res Clin Oncol. 2002 Jul;128(7):385-92.
DMCT3I8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12136253

DMCT3I8	DI	DMCT3I8
DMCT3I8	DN	Ifosfamide
DMCT3I8	MI	DEPKLMQ
DMCT3I8	MN	Cytochrome P450 2B6 (CYP2B6)
DMCT3I8	MT	DME
DMCT3I8	MA	Metabolism
DMCT3I8	RN	A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression. J Biol Chem. 2003 Apr 18;278(16):14146-52.
DMCT3I8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12571232

DMCT3I8	DI	DMCT3I8
DMCT3I8	DN	Ifosfamide
DMCT3I8	MI	DEZMWRE
DMCT3I8	MN	Cytochrome P450 2C18 (CYP2C18)
DMCT3I8	MT	DME
DMCT3I8	MA	Metabolism
DMCT3I8	RN	Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66.
DMCT3I8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10348794

DMCT3I8	DI	DMCT3I8
DMCT3I8	DN	Ifosfamide
DMCT3I8	MI	DES5XRU
DMCT3I8	MN	Cytochrome P450 2C8 (CYP2C8)
DMCT3I8	MT	DME
DMCT3I8	MA	Metabolism
DMCT3I8	RN	Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res. 1997 May 15;57(10):1946-54.
DMCT3I8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9157990

DMCT3I8	DI	DMCT3I8
DMCT3I8	DN	Ifosfamide
DMCT3I8	MI	DE5IED8
DMCT3I8	MN	Cytochrome P450 2C9 (CYP2C9)
DMCT3I8	MT	DME
DMCT3I8	MA	Metabolism
DMCT3I8	RN	CYP2C9 polymorphisms in human tumors. Anticancer Res. 2006 Jan-Feb;26(1A):299-305.
DMCT3I8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16475710

DMCT3I8	DI	DMCT3I8
DMCT3I8	DN	Ifosfamide
DMCT3I8	MI	DE4LYSA
DMCT3I8	MN	Cytochrome P450 3A4 (CYP3A4)
DMCT3I8	MT	DME
DMCT3I8	MA	Metabolism
DMCT3I8	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMCT3I8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMCT3I8	DI	DMCT3I8
DMCT3I8	DN	Ifosfamide
DMCT3I8	MI	DEIBDNY
DMCT3I8	MN	Cytochrome P450 3A5 (CYP3A5)
DMCT3I8	MT	DME
DMCT3I8	MA	Metabolism
DMCT3I8	RN	Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res. 1997 May 15;57(10):1946-54.
DMCT3I8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9157990

DMCT3I8	DI	DMCT3I8
DMCT3I8	DN	Ifosfamide
DMCT3I8	MI	DERD86B
DMCT3I8	MN	Cytochrome P450 3A7 (CYP3A7)
DMCT3I8	MT	DME
DMCT3I8	MA	Metabolism
DMCT3I8	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMCT3I8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMCT3I8	DI	DMCT3I8
DMCT3I8	DN	Ifosfamide
DMCT3I8	MI	TTUTN1I
DMCT3I8	MN	Human Deoxyribonucleic acid (hDNA)
DMCT3I8	MT	DTT
DMCT3I8	MA	Modulator
DMCT3I8	RN	Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. Br J Cancer. 2005 May 9;92(9):1626-35.
DMCT3I8	RU	https://www.ncbi.nlm.nih.gov/pubmed/15827549

DMCT3I8	DI	DMCT3I8
DMCT3I8	DN	Ifosfamide
DMCT3I8	MI	DEGTFWK
DMCT3I8	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMCT3I8	MT	DME
DMCT3I8	MA	Metabolism
DMCT3I8	RN	Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66.
DMCT3I8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10348794

DMCT3I8	DI	DMCT3I8
DMCT3I8	DN	Ifosfamide
DMCT3I8	MI	DE073H6
DMCT3I8	MN	Prostaglandin G/H synthase 1 (COX-1)
DMCT3I8	MT	DME
DMCT3I8	MA	Metabolism
DMCT3I8	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMCT3I8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM6AUFY	DI	DM6AUFY
DM6AUFY	DN	Iloperidone
DM6AUFY	MI	TTJQOD7
DM6AUFY	MN	5-HT 2A receptor (HTR2A)
DM6AUFY	MT	DTT
DM6AUFY	MA	Antagonist
DM6AUFY	RN	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
DM6AUFY	RU	https://pubmed.ncbi.nlm.nih.gov/20118952

DM6AUFY	DI	DM6AUFY
DM6AUFY	DN	Iloperidone
DM6AUFY	MI	DECB0K3
DM6AUFY	MN	Cytochrome P450 2D6 (CYP2D6)
DM6AUFY	MT	DME
DM6AUFY	MA	Metabolism
DM6AUFY	RN	Influences of CYP2D6*10 polymorphisms on the pharmacokinetics of iloperidone and its metabolites in Chinese patients with schizophrenia: a population pharmacokinetic analysis. Acta Pharmacol Sin. 2016 Nov;37(11):1499-1508.
DM6AUFY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27665849

DM6AUFY	DI	DM6AUFY
DM6AUFY	DN	Iloperidone
DM6AUFY	MI	DE4LYSA
DM6AUFY	MN	Cytochrome P450 3A4 (CYP3A4)
DM6AUFY	MT	DME
DM6AUFY	MA	Metabolism
DM6AUFY	RN	Influences of CYP2D6*10 polymorphisms on the pharmacokinetics of iloperidone and its metabolites in Chinese patients with schizophrenia: a population pharmacokinetic analysis. Acta Pharmacol Sin. 2016 Nov;37(11):1499-1508.
DM6AUFY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27665849

DM6AUFY	DI	DM6AUFY
DM6AUFY	DN	Iloperidone
DM6AUFY	MI	DEIBDNY
DM6AUFY	MN	Cytochrome P450 3A5 (CYP3A5)
DM6AUFY	MT	DME
DM6AUFY	MA	Metabolism
DM6AUFY	RN	Application of liquid chromatography/mass spectrometry in accelerating the identification of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone. J Pharmacol Exp Ther. 1998 Sep;286(3):1285-93.
DM6AUFY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9732390

DM6AUFY	DI	DM6AUFY
DM6AUFY	DN	Iloperidone
DM6AUFY	MI	DERD86B
DM6AUFY	MN	Cytochrome P450 3A7 (CYP3A7)
DM6AUFY	MT	DME
DM6AUFY	MA	Metabolism
DM6AUFY	RN	Application of liquid chromatography/mass spectrometry in accelerating the identification of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone. J Pharmacol Exp Ther. 1998 Sep;286(3):1285-93.
DM6AUFY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9732390

DM6AUFY	DI	DM6AUFY
DM6AUFY	DN	Iloperidone
DM6AUFY	MI	TTEX248
DM6AUFY	MN	Dopamine D2 receptor (D2R)
DM6AUFY	MT	DTT
DM6AUFY	MA	Antagonist
DM6AUFY	RN	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
DM6AUFY	RU	https://pubmed.ncbi.nlm.nih.gov/20118952

DMVPZBE	DI	DMVPZBE
DMVPZBE	DN	Iloprost
DMVPZBE	MI	DT021JD
DMVPZBE	MN	Organic anion transporting polypeptide 2A1 (SLCO2A1)
DMVPZBE	MT	DTP
DMVPZBE	MA	Substrate
DMVPZBE	RN	Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT). J Clin Invest. 1996 Sep 1;98(5):1142-9.
DMVPZBE	RU	http://www.ncbi.nlm.nih.gov/pubmed/8787677

DMVPZBE	DI	DMVPZBE
DMVPZBE	DN	Iloprost
DMVPZBE	MI	DTVNRXW
DMVPZBE	MN	Organic anion transporting polypeptide 3A1 (SLCO3A1)
DMVPZBE	MT	DTP
DMVPZBE	MA	Substrate
DMVPZBE	RN	Molecular characterization of human and rat organic anion transporter OATP-D. Am J Physiol Renal Physiol. 2003 Dec;285(6):F1188-97.
DMVPZBE	RU	http://www.ncbi.nlm.nih.gov/pubmed/14631946

DMVPZBE	DI	DMVPZBE
DMVPZBE	DN	Iloprost
DMVPZBE	MI	TT1ZAVI
DMVPZBE	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DMVPZBE	MT	DTT
DMVPZBE	MA	Agonist
DMVPZBE	RN	Exploration of prostanoid receptor subtype regulating estradiol and prostaglandin E2 induction of spinophilin in developing preoptic area neurons. Neuroscience. 2007 May 25;146(3):1117-27.
DMVPZBE	RU	https://pubmed.ncbi.nlm.nih.gov/17408863

DM7RJXL	DI	DM7RJXL
DM7RJXL	DN	Imatinib
DM7RJXL	MI	DTI7UX6
DM7RJXL	MN	Breast cancer resistance protein (ABCG2)
DM7RJXL	MT	DTP
DM7RJXL	MA	Substrate
DM7RJXL	RN	Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
DM7RJXL	RU	http://www.ncbi.nlm.nih.gov/pubmed/15251980

DM7RJXL	DI	DM7RJXL
DM7RJXL	DN	Imatinib
DM7RJXL	MI	DEJGDUW
DM7RJXL	MN	Cytochrome P450 1A2 (CYP1A2)
DM7RJXL	MT	DME
DM7RJXL	MA	Metabolism
DM7RJXL	RN	The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
DM7RJXL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24369535

DM7RJXL	DI	DM7RJXL
DM7RJXL	DN	Imatinib
DM7RJXL	MI	DES5XRU
DM7RJXL	MN	Cytochrome P450 2C8 (CYP2C8)
DM7RJXL	MT	DME
DM7RJXL	MA	Metabolism
DM7RJXL	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DM7RJXL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DM7RJXL	DI	DM7RJXL
DM7RJXL	DN	Imatinib
DM7RJXL	MI	DE5IED8
DM7RJXL	MN	Cytochrome P450 2C9 (CYP2C9)
DM7RJXL	MT	DME
DM7RJXL	MA	Metabolism
DM7RJXL	RN	Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
DM7RJXL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27749579

DM7RJXL	DI	DM7RJXL
DM7RJXL	DN	Imatinib
DM7RJXL	MI	DECB0K3
DM7RJXL	MN	Cytochrome P450 2D6 (CYP2D6)
DM7RJXL	MT	DME
DM7RJXL	MA	Metabolism
DM7RJXL	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM7RJXL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM7RJXL	DI	DM7RJXL
DM7RJXL	DN	Imatinib
DM7RJXL	MI	DE4LYSA
DM7RJXL	MN	Cytochrome P450 3A4 (CYP3A4)
DM7RJXL	MT	DME
DM7RJXL	MA	Metabolism
DM7RJXL	RN	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
DM7RJXL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22014153

DM7RJXL	DI	DM7RJXL
DM7RJXL	DN	Imatinib
DM7RJXL	MI	DEIBDNY
DM7RJXL	MN	Cytochrome P450 3A5 (CYP3A5)
DM7RJXL	MT	DME
DM7RJXL	MA	Metabolism
DM7RJXL	RN	Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
DM7RJXL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16122278

DM7RJXL	DI	DM7RJXL
DM7RJXL	DN	Imatinib
DM7RJXL	MI	DERD86B
DM7RJXL	MN	Cytochrome P450 3A7 (CYP3A7)
DM7RJXL	MT	DME
DM7RJXL	MA	Metabolism
DM7RJXL	RN	Drug Interactions Flockhart Table
DM7RJXL	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM7RJXL	DI	DM7RJXL
DM7RJXL	DN	Imatinib
DM7RJXL	MI	TTS7G69
DM7RJXL	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DM7RJXL	MT	DTT
DM7RJXL	MA	Inhibitor
DM7RJXL	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DM7RJXL	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DM7RJXL	DI	DM7RJXL
DM7RJXL	DN	Imatinib
DM7RJXL	MI	TTN6ORK
DM7RJXL	MN	Mcl-1 messenger RNA (MCL-1 mRNA)
DM7RJXL	MT	DTT
DM7RJXL	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DM7RJXL	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DM7RJXL	DI	DM7RJXL
DM7RJXL	DN	Imatinib
DM7RJXL	MI	DTE2B1D
DM7RJXL	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DM7RJXL	MT	DTP
DM7RJXL	MA	Substrate
DM7RJXL	RN	Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther. 2011 Jun;89(6):816-20.
DM7RJXL	RU	http://www.ncbi.nlm.nih.gov/pubmed/21508937

DM7RJXL	DI	DM7RJXL
DM7RJXL	DN	Imatinib
DM7RJXL	MI	DT3D8F0
DM7RJXL	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM7RJXL	MT	DTP
DM7RJXL	MA	Substrate
DM7RJXL	RN	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
DM7RJXL	RU	http://www.ncbi.nlm.nih.gov/pubmed/23340295

DM7RJXL	DI	DM7RJXL
DM7RJXL	DN	Imatinib
DM7RJXL	MI	DT9C1TS
DM7RJXL	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM7RJXL	MT	DTP
DM7RJXL	MA	Substrate
DM7RJXL	RN	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
DM7RJXL	RU	http://www.ncbi.nlm.nih.gov/pubmed/23340295

DM7RJXL	DI	DM7RJXL
DM7RJXL	DN	Imatinib
DM7RJXL	MI	DTT79CX
DM7RJXL	MN	Organic cation transporter 1 (SLC22A1)
DM7RJXL	MT	DTP
DM7RJXL	MA	Substrate
DM7RJXL	RN	Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
DM7RJXL	RU	http://www.ncbi.nlm.nih.gov/pubmed/18398725

DM7RJXL	DI	DM7RJXL
DM7RJXL	DN	Imatinib
DM7RJXL	MI	DTUGYRD
DM7RJXL	MN	P-glycoprotein 1 (ABCB1)
DM7RJXL	MT	DTP
DM7RJXL	MA	Substrate
DM7RJXL	RN	Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
DM7RJXL	RU	http://www.ncbi.nlm.nih.gov/pubmed/21311410

DM7RJXL	DI	DM7RJXL
DM7RJXL	DN	Imatinib
DM7RJXL	MI	TTI2WET
DM7RJXL	MN	Platelet-derived growth factor receptor (PDGFR)
DM7RJXL	MT	DTT
DM7RJXL	MA	Inhibitor
DM7RJXL	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DM7RJXL	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DM7RJXL	DI	DM7RJXL
DM7RJXL	DN	Imatinib
DM7RJXL	MI	DE073H6
DM7RJXL	MN	Prostaglandin G/H synthase 1 (COX-1)
DM7RJXL	MT	DME
DM7RJXL	MA	Metabolism
DM7RJXL	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM7RJXL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM7RJXL	DI	DM7RJXL
DM7RJXL	DN	Imatinib
DM7RJXL	MI	TTX41N9
DM7RJXL	MN	Tyrosine-protein kinase Kit (KIT)
DM7RJXL	MT	DTT
DM7RJXL	MA	Inhibitor
DM7RJXL	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DM7RJXL	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMUL7T1	DI	DMUL7T1
DMUL7T1	DN	Imidapril
DMUL7T1	MI	TTL69WB
DMUL7T1	MN	Angiotensin-converting enzyme (ACE)
DMUL7T1	MT	DTT
DMUL7T1	MA	Modulator
DMUL7T1	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMUL7T1	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DM3VS7Z	DI	DM3VS7Z
DM3VS7Z	DN	Imidazole salicylate
DM3VS7Z	MI	TTTEJMY
DM3VS7Z	MN	Tromboxane A2 synthesis (TA2 synth)
DM3VS7Z	MT	DTT
DM3VS7Z	MA	Modulator
DM3VS7Z	RN	Tolerability of imidazole salycilate in aspirin-sensitive patients. Allergy Proc. 1995 Sep-Oct;16(5):251-4.
DM3VS7Z	RU	https://pubmed.ncbi.nlm.nih.gov/8566739

DMI9FBP	DI	DMI9FBP
DMI9FBP	DN	Imipenem
DMI9FBP	MI	DERI7LO
DMI9FBP	MN	AmpC beta-lactamase (ampC)
DMI9FBP	MT	DME
DMI9FBP	MA	Metabolism
DMI9FBP	RN	Characterization of the AmpC beta-Lactamase from Burkholderia multivorans. Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e01140-18.
DMI9FBP	RU	https://pubmed.ncbi.nlm.nih.gov/30012762

DMI9FBP	DI	DMI9FBP
DMI9FBP	DN	Imipenem
DMI9FBP	MI	TTHWB7G
DMI9FBP	MN	Bacterial Penicillin binding protein 2 (Bact mrdA)
DMI9FBP	MT	DTT
DMI9FBP	MA	Binder
DMI9FBP	RN	A comparative trial of imipenem versus ceftazidime in the release of endotoxin and cytokine generation in patients with gram-negative urosepsis. Urosepsis Study Group. J Endotoxin Res. 2000;6(1):25-31.
DMI9FBP	RU	https://pubmed.ncbi.nlm.nih.gov/11061029

DMI9FBP	DI	DMI9FBP
DMI9FBP	DN	Imipenem
DMI9FBP	MI	DEC3G7M
DMI9FBP	MN	Beta-lactamase (blaB)
DMI9FBP	MT	DME
DMI9FBP	MA	Metabolism
DMI9FBP	RN	FRI-4 carbapenemase-producing Enterobacter cloacae complex isolated in Tokyo, Japan. J Antimicrob Chemother. 2018 Nov 1;73(11):2969-2972.
DMI9FBP	RU	https://pubmed.ncbi.nlm.nih.gov/30060114

DMI9FBP	DI	DMI9FBP
DMI9FBP	DN	Imipenem
DMI9FBP	MI	DE7IH52
DMI9FBP	MN	Beta-lactamase (blaB)
DMI9FBP	MT	DME
DMI9FBP	MA	Metabolism
DMI9FBP	RN	Antibiotic therapy for inducible AmpC beta-lactamase-producing Gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides? Int J Antimicrob Agents. 2012 Oct;40(4):297-305.
DMI9FBP	RU	https://pubmed.ncbi.nlm.nih.gov/22824371

DMI9FBP	DI	DMI9FBP
DMI9FBP	DN	Imipenem
DMI9FBP	MI	DEYIEO5
DMI9FBP	MN	Beta-lactamase (blaB)
DMI9FBP	MT	DME
DMI9FBP	MA	Metabolism
DMI9FBP	RN	Antibiotic therapy for inducible AmpC beta-lactamase-producing Gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides? Int J Antimicrob Agents. 2012 Oct;40(4):297-305.
DMI9FBP	RU	https://pubmed.ncbi.nlm.nih.gov/22824371

DMI9FBP	DI	DMI9FBP
DMI9FBP	DN	Imipenem
DMI9FBP	MI	DEBKS91
DMI9FBP	MN	Beta-lactamase (blaB)
DMI9FBP	MT	DME
DMI9FBP	MA	Metabolism
DMI9FBP	RN	A high mortality rate associated with multidrug-resistant Acinetobacter baumannii ST79 and ST25 carrying OXA-23 in a Brazilian intensive care unit. PLoS One. 2018 Dec 28;13(12):e0209367.
DMI9FBP	RU	https://pubmed.ncbi.nlm.nih.gov/30592758

DMI9FBP	DI	DMI9FBP
DMI9FBP	DN	Imipenem
DMI9FBP	MI	DEUHIQS
DMI9FBP	MN	Beta-lactamase (blaB)
DMI9FBP	MT	DME
DMI9FBP	MA	Metabolism
DMI9FBP	RN	AmpC beta-lactamase-producing Enterobacterales: what a clinician should know. Infection. 2019 Jun;47(3):363-375.
DMI9FBP	RU	https://pubmed.ncbi.nlm.nih.gov/30840201

DMI9FBP	DI	DMI9FBP
DMI9FBP	DN	Imipenem
DMI9FBP	MI	DECWSA9
DMI9FBP	MN	Beta-lactamase (blaB)
DMI9FBP	MT	DME
DMI9FBP	MA	Metabolism
DMI9FBP	RN	Molecular investigation of extended-spectrum beta-lactamase genes and potential drug resistance in clinical isolates of Morganella morganii. Ann Saudi Med. 2016 May-Jun;36(3):223-8.
DMI9FBP	RU	https://pubmed.ncbi.nlm.nih.gov/27236395

DMI9FBP	DI	DMI9FBP
DMI9FBP	DN	Imipenem
DMI9FBP	MI	DECB2MX
DMI9FBP	MN	Beta-lactamase (blaB)
DMI9FBP	MT	DME
DMI9FBP	MA	Metabolism
DMI9FBP	RN	Whole-genome sequence of Chryseobacterium oranimense, a colistin-resistant bacterium isolated from a cystic fibrosis patient in France. Antimicrob Agents Chemother. 2015 Mar;59(3):1696-706.
DMI9FBP	RU	https://pubmed.ncbi.nlm.nih.gov/25583710

DMI9FBP	DI	DMI9FBP
DMI9FBP	DN	Imipenem
DMI9FBP	MI	DEEQ3RW
DMI9FBP	MN	Beta-lactamase (blaB)
DMI9FBP	MT	DME
DMI9FBP	MA	Metabolism
DMI9FBP	RN	Hospital sewage water: a reservoir for variants of New Delhi metallo-beta-lactamase (NDM)- and extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae. Int J Antimicrob Agents. 2018 Jan;51(1):82-88.
DMI9FBP	RU	https://pubmed.ncbi.nlm.nih.gov/28887202

DMI9FBP	DI	DMI9FBP
DMI9FBP	DN	Imipenem
DMI9FBP	MI	DEQ0K5J
DMI9FBP	MN	Beta-lactamase (blaB)
DMI9FBP	MT	DME
DMI9FBP	MA	Metabolism
DMI9FBP	RN	Hospital sewage water: a reservoir for variants of New Delhi metallo-beta-lactamase (NDM)- and extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae. Int J Antimicrob Agents. 2018 Jan;51(1):82-88.
DMI9FBP	RU	https://pubmed.ncbi.nlm.nih.gov/28887202

DMI9FBP	DI	DMI9FBP
DMI9FBP	DN	Imipenem
DMI9FBP	MI	DE7MYGB
DMI9FBP	MN	Beta-lactamase (blaB)
DMI9FBP	MT	DME
DMI9FBP	MA	Metabolism
DMI9FBP	RN	Antibiotic therapy for inducible AmpC beta-lactamase-producing Gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides? Int J Antimicrob Agents. 2012 Oct;40(4):297-305.
DMI9FBP	RU	https://pubmed.ncbi.nlm.nih.gov/22824371

DMI9FBP	DI	DMI9FBP
DMI9FBP	DN	Imipenem
DMI9FBP	MI	DEL6894
DMI9FBP	MN	Beta-lactamase (blaB)
DMI9FBP	MT	DME
DMI9FBP	MA	Metabolism
DMI9FBP	RN	Hospital sewage water: a reservoir for variants of New Delhi metallo-beta-lactamase (NDM)- and extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae. Int J Antimicrob Agents. 2018 Jan;51(1):82-88.
DMI9FBP	RU	https://pubmed.ncbi.nlm.nih.gov/28887202

DMI9FBP	DI	DMI9FBP
DMI9FBP	DN	Imipenem
DMI9FBP	MI	DE8KH4C
DMI9FBP	MN	Beta-lactamase (blaB)
DMI9FBP	MT	DME
DMI9FBP	MA	Metabolism
DMI9FBP	RN	Carbapenemase VCC-1-producing Vibrio cholerae in coastal waters of Germany. Emerg Infect Dis. 2017 Oct;23(10):1735-1737.
DMI9FBP	RU	https://pubmed.ncbi.nlm.nih.gov/28930017

DMI9FBP	DI	DMI9FBP
DMI9FBP	DN	Imipenem
DMI9FBP	MI	DEB90AL
DMI9FBP	MN	Carbapenemase (cphA)
DMI9FBP	MT	DME
DMI9FBP	MA	Metabolism
DMI9FBP	RN	A carbapenem-resistant clinical isolate of Aeromonas hydrophila in Japan harbouring an acquired gene encoding GES-24 beta-lactamase. J Med Microbiol. 2018 Nov;67(11):1535-1537.
DMI9FBP	RU	https://pubmed.ncbi.nlm.nih.gov/30289383

DMI9FBP	DI	DMI9FBP
DMI9FBP	DN	Imipenem
DMI9FBP	MI	DETRKSD
DMI9FBP	MN	Carbapenemase (cphA)
DMI9FBP	MT	DME
DMI9FBP	MA	Metabolism
DMI9FBP	RN	Proteomic identification of Axc, a novel beta-lactamase with carbapenemase activity in a meropenem-resistant clinical isolate of Achromobacter xylosoxidans. Sci Rep. 2018 May 25;8(1):8181.
DMI9FBP	RU	https://pubmed.ncbi.nlm.nih.gov/29802257

DMI9FBP	DI	DMI9FBP
DMI9FBP	DN	Imipenem
DMI9FBP	MI	DEQ4LIN
DMI9FBP	MN	Carbapenemase (cphA)
DMI9FBP	MT	DME
DMI9FBP	MA	Metabolism
DMI9FBP	RN	Occurrence of a new metallo-beta-lactamase IMP-4 carried on a conjugative plasmid in Citrobacter youngae from the People's Republic of China. FEMS Microbiol Lett. 2001 Jan 1;194(1):53-7.
DMI9FBP	RU	https://pubmed.ncbi.nlm.nih.gov/11150665

DMI9FBP	DI	DMI9FBP
DMI9FBP	DN	Imipenem
DMI9FBP	MI	DE9QNXV
DMI9FBP	MN	Carbapenemase (cphA)
DMI9FBP	MT	DME
DMI9FBP	MA	Metabolism
DMI9FBP	RN	Pseudocitrobacter gen. nov., a novel genus of the Enterobacteriaceae with two new species Pseudocitrobacter faecalis sp. nov., and Pseudocitrobacter anthropi sp. nov, isolated from fecal samples from hospitalized patients in Pakistan. Syst Appl Microbiol. 2014 Feb;37(1):17-22.
DMI9FBP	RU	https://pubmed.ncbi.nlm.nih.gov/24182752

DM2NUH3	DI	DM2NUH3
DM2NUH3	DN	Imipramine
DM2NUH3	MI	DEJGDUW
DM2NUH3	MN	Cytochrome P450 1A2 (CYP1A2)
DM2NUH3	MT	DME
DM2NUH3	MA	Metabolism
DM2NUH3	RN	Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther. 1997 Jun;281(3):1199-210.
DM2NUH3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9190854

DM2NUH3	DI	DM2NUH3
DM2NUH3	DN	Imipramine
DM2NUH3	MI	DEPKLMQ
DM2NUH3	MN	Cytochrome P450 2B6 (CYP2B6)
DM2NUH3	MT	DME
DM2NUH3	MA	Metabolism
DM2NUH3	RN	Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther. 1997 Jun;281(3):1199-210.
DM2NUH3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9190854

DM2NUH3	DI	DM2NUH3
DM2NUH3	DN	Imipramine
DM2NUH3	MI	DEZMWRE
DM2NUH3	MN	Cytochrome P450 2C18 (CYP2C18)
DM2NUH3	MT	DME
DM2NUH3	MA	Metabolism
DM2NUH3	RN	Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther. 1997 Jun;281(3):1199-210.
DM2NUH3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9190854

DM2NUH3	DI	DM2NUH3
DM2NUH3	DN	Imipramine
DM2NUH3	MI	DECB0K3
DM2NUH3	MN	Cytochrome P450 2D6 (CYP2D6)
DM2NUH3	MT	DME
DM2NUH3	MA	Metabolism
DM2NUH3	RN	QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine. Ann Pharmacother. 2005 Mar;39(3):543-6.
DM2NUH3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15687478

DM2NUH3	DI	DM2NUH3
DM2NUH3	DN	Imipramine
DM2NUH3	MI	DE4LYSA
DM2NUH3	MN	Cytochrome P450 3A4 (CYP3A4)
DM2NUH3	MT	DME
DM2NUH3	MA	Metabolism
DM2NUH3	RN	Variability in metabolism of imipramine and desipramine using urinary excretion data. J Anal Toxicol. 2014 Jul-Aug;38(6):368-74.
DM2NUH3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24782142

DM2NUH3	DI	DM2NUH3
DM2NUH3	DN	Imipramine
DM2NUH3	MI	DERD86B
DM2NUH3	MN	Cytochrome P450 3A7 (CYP3A7)
DM2NUH3	MT	DME
DM2NUH3	MA	Metabolism
DM2NUH3	RN	Catalysis of drug oxidation during embryogenesis in human hepatic tissues using imipramine as a model substrate. Drug Metab Dispos. 1999 Nov;27(11):1306-8.
DM2NUH3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10534316

DM2NUH3	DI	DM2NUH3
DM2NUH3	DN	Imipramine
DM2NUH3	MI	DEIZLTN
DM2NUH3	MN	Docosahexaenoic acid omega-hydroxylase (CYP4F11)
DM2NUH3	MT	DME
DM2NUH3	MA	Metabolism
DM2NUH3	RN	Expression and characterization of human cytochrome P450 4F11: putative role in the metabolism of therapeutic drugs and eicosanoids. Toxicol Appl Pharmacol. 2004 Sep 15;199(3):295-304.
DM2NUH3	RU	https://pubmed.ncbi.nlm.nih.gov/15364545

DM2NUH3	DI	DM2NUH3
DM2NUH3	DN	Imipramine
DM2NUH3	MI	DEGTFWK
DM2NUH3	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM2NUH3	MT	DME
DM2NUH3	MA	Metabolism
DM2NUH3	RN	Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin. Drug Metab Dispos. 2002 Oct;30(10):1102-7.
DM2NUH3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12228186

DM2NUH3	DI	DM2NUH3
DM2NUH3	DN	Imipramine
DM2NUH3	MI	TTAWNKZ
DM2NUH3	MN	Norepinephrine transporter (NET)
DM2NUH3	MT	DTT
DM2NUH3	MA	Inhibitor
DM2NUH3	RN	Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8.
DM2NUH3	RU	https://pubmed.ncbi.nlm.nih.gov/19059298

DM2NUH3	DI	DM2NUH3
DM2NUH3	DN	Imipramine
DM2NUH3	MI	DTUGYRD
DM2NUH3	MN	P-glycoprotein 1 (ABCB1)
DM2NUH3	MT	DTP
DM2NUH3	MA	Substrate
DM2NUH3	RN	Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22.
DM2NUH3	RU	http://www.ncbi.nlm.nih.gov/pubmed/12954186

DM2NUH3	DI	DM2NUH3
DM2NUH3	DN	Imipramine
DM2NUH3	MI	DEYGVN4
DM2NUH3	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM2NUH3	MT	DME
DM2NUH3	MA	Metabolism
DM2NUH3	RN	Liquid chromatography-tandem mass spectrometry method for measurement of nicotine N-glucuronide: a marker for human UGT2B10 inhibition. J Pharm Biomed Anal. 2011 Jul 15;55(5):964-71.
DM2NUH3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21497036

DM1TMA3	DI	DM1TMA3
DM1TMA3	DN	Imiquimod
DM1TMA3	MI	DEJGDUW
DM1TMA3	MN	Cytochrome P450 1A2 (CYP1A2)
DM1TMA3	MT	DME
DM1TMA3	MA	Metabolism
DM1TMA3	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM1TMA3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM1TMA3	DI	DM1TMA3
DM1TMA3	DN	Imiquimod
DM1TMA3	MI	DE4LYSA
DM1TMA3	MN	Cytochrome P450 3A4 (CYP3A4)
DM1TMA3	MT	DME
DM1TMA3	MA	Metabolism
DM1TMA3	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM1TMA3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM1TMA3	DI	DM1TMA3
DM1TMA3	DN	Imiquimod
DM1TMA3	MI	TTRJ1K4
DM1TMA3	MN	Toll-like receptor 7 (TLR7)
DM1TMA3	MT	DTT
DM1TMA3	MA	Agonist
DM1TMA3	RN	Imiquimod enhances IFN-gamma production and effector function of T cells infiltrating human squamous cell carcinomas of the skin. J Invest Dermatol. 2009 Nov;129(11):2676-85.
DM1TMA3	RU	https://pubmed.ncbi.nlm.nih.gov/19516264

DMRMFP4	DI	DMRMFP4
DMRMFP4	DN	Inamrinone Lactate
DMRMFP4	MI	TTZCG4L
DMRMFP4	MN	Phosphodiesterase 3 (PDE3)
DMRMFP4	MT	DTT
DMRMFP4	MA	Inhibitor
DMRMFP4	RN	Effects of amrinone on hepatic ischemia-reperfusion injury in rats. J Hepatol. 2002 Jul;37(1):31-8.
DMRMFP4	RU	https://pubmed.ncbi.nlm.nih.gov/12076859

DM3DSVJ	DI	DM3DSVJ
DM3DSVJ	DN	Incadronate
DM3DSVJ	MI	TTIKWV4
DM3DSVJ	MN	Geranyltranstransferase (FDPS)
DM3DSVJ	MT	DTT
DM3DSVJ	MA	Inhibitor
DM3DSVJ	RN	Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001 Feb;296(2):235-42.
DM3DSVJ	RU	https://pubmed.ncbi.nlm.nih.gov/11160603

DMKE6YT	DI	DMKE6YT
DMKE6YT	DN	Incobotulinum toxin A
DMKE6YT	MI	TTZJD1B
DMKE6YT	MN	Acetylcholine release (Ach rele)
DMKE6YT	MT	DTT
DMKE6YT	MA	Modulator
DMKE6YT	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DMKE6YT	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DM32GSJ	DI	DM32GSJ
DM32GSJ	DN	Incruse ellipta
DM32GSJ	MI	DECB0K3
DM32GSJ	MN	Cytochrome P450 2D6 (CYP2D6)
DM32GSJ	MT	DME
DM32GSJ	MA	Metabolism
DM32GSJ	RN	The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects. Ther Adv Respir Dis. 2013 Dec;7(6):311-9.
DM32GSJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24004659

DM32GSJ	DI	DM32GSJ
DM32GSJ	DN	Incruse ellipta
DM32GSJ	MI	TTOXS3C
DM32GSJ	MN	Muscarinic acetylcholine receptor (CHRM)
DM32GSJ	MT	DTT
DM32GSJ	MA	Antagonist
DM32GSJ	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline.
DM32GSJ	RU	http://www.gsk.ca/english/html/media-centre/2014-04-17.html

DMQJHR7	DI	DMQJHR7
DMQJHR7	DN	Indacaterol
DMQJHR7	MI	TT2CJVK
DMQJHR7	MN	Adrenergic receptor beta-2 (ADRB2)
DMQJHR7	MT	DTT
DMQJHR7	MA	Agonist
DMQJHR7	RN	Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94.
DMQJHR7	RU	https://pubmed.ncbi.nlm.nih.gov/19265487

DMQJHR7	DI	DMQJHR7
DMQJHR7	DN	Indacaterol
DMQJHR7	MI	DE4LYSA
DMQJHR7	MN	Cytochrome P450 3A4 (CYP3A4)
DMQJHR7	MT	DME
DMQJHR7	MA	Metabolism
DMQJHR7	RN	Use of indacaterol for the treatment of COPD: a pharmacokinetic evaluation. Expert Opin Drug Metab Toxicol. 2014 Jan;10(1):129-37.
DMQJHR7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24295085

DMQJHR7	DI	DMQJHR7
DMQJHR7	DN	Indacaterol
DMQJHR7	MI	DTT79CX
DMQJHR7	MN	Organic cation transporter 1 (SLC22A1)
DMQJHR7	MT	DTP
DMQJHR7	MA	Substrate
DMQJHR7	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMQJHR7	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DMQJHR7	DI	DMQJHR7
DMQJHR7	DN	Indacaterol
DMQJHR7	MI	DTUGYRD
DMQJHR7	MN	P-glycoprotein 1 (ABCB1)
DMQJHR7	MT	DTP
DMQJHR7	MA	Substrate
DMQJHR7	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
DMQJHR7	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01665

DMQJHR7	DI	DMQJHR7
DMQJHR7	DN	Indacaterol
DMQJHR7	MI	DEYGVN4
DMQJHR7	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMQJHR7	MT	DME
DMQJHR7	MA	Metabolism
DMQJHR7	RN	Use of indacaterol for the treatment of COPD: a pharmacokinetic evaluation. Expert Opin Drug Metab Toxicol. 2014 Jan;10(1):129-37.
DMQJHR7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24295085

DMGN1PW	DI	DMGN1PW
DMGN1PW	DN	Indapamide
DMGN1PW	MI	DE4LYSA
DMGN1PW	MN	Cytochrome P450 3A4 (CYP3A4)
DMGN1PW	MT	DME
DMGN1PW	MA	Metabolism
DMGN1PW	RN	Dehydrogenation of the indoline-containing drug 4-chloro-N-(2-methyl-1-indolinyl)-3-sulfamoylbenzamide (indapamide) by CYP3A4: correlation with in silico predictions. Drug Metab Dispos. 2009 Mar;37(3):672-84.
DMGN1PW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19074530

DMGN1PW	DI	DMGN1PW
DMGN1PW	DN	Indapamide
DMGN1PW	MI	TT846HF
DMGN1PW	MN	Voltage-gated potassium channel Kv7.1 (KCNQ1)
DMGN1PW	MT	DTT
DMGN1PW	MA	Blocker
DMGN1PW	RN	Indapamide induces apoptosis of GH3 pituitary cells independently of its inhibition of voltage-dependent K+ currents. Eur J Pharmacol. 2006 Apr 24;536(1-2):78-84.
DMGN1PW	RU	https://pubmed.ncbi.nlm.nih.gov/16556441

DMUV8OR	DI	DMUV8OR
DMUV8OR	DN	Indecainide
DMUV8OR	MI	TTZOVE0
DMUV8OR	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DMUV8OR	MT	DTT
DMUV8OR	MA	Blocker
DMUV8OR	RN	Electrophysiological studies of indecainide hydrochloride, a new antiarrhythmic agent, in canine cardiac tissues. J Cardiovasc Pharmacol. 1984 Jul-Aug;6(4):614-21.
DMUV8OR	RU	https://pubmed.ncbi.nlm.nih.gov/6206315

DMWO3N6	DI	DMWO3N6
DMWO3N6	DN	Indeloxazine
DMWO3N6	MI	TTGP7BY
DMWO3N6	MN	Monoamine oxidase type B (MAO-B)
DMWO3N6	MT	DTT
DMWO3N6	MA	Modulator
DMWO3N6	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMWO3N6	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM0T3YH	DI	DM0T3YH
DM0T3YH	DN	Indinavir
DM0T3YH	MI	DECB0K3
DM0T3YH	MN	Cytochrome P450 2D6 (CYP2D6)
DM0T3YH	MT	DME
DM0T3YH	MA	Metabolism
DM0T3YH	RN	Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. J Pharm Sci. 1998 Oct;87(10):1184-9.
DM0T3YH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9758674

DM0T3YH	DI	DM0T3YH
DM0T3YH	DN	Indinavir
DM0T3YH	MI	DE4LYSA
DM0T3YH	MN	Cytochrome P450 3A4 (CYP3A4)
DM0T3YH	MT	DME
DM0T3YH	MA	Metabolism
DM0T3YH	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM0T3YH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM0T3YH	DI	DM0T3YH
DM0T3YH	DN	Indinavir
DM0T3YH	MI	DEIBDNY
DM0T3YH	MN	Cytochrome P450 3A5 (CYP3A5)
DM0T3YH	MT	DME
DM0T3YH	MA	Metabolism
DM0T3YH	RN	Enzymes in addition to CYP3A4 and 3A5 mediate N-demethylation of dextromethorphan in human liver microsomes. Biopharm Drug Dispos. 1999 Oct;20(7):341-6.
DM0T3YH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10760842

DM0T3YH	DI	DM0T3YH
DM0T3YH	DN	Indinavir
DM0T3YH	MI	DERD86B
DM0T3YH	MN	Cytochrome P450 3A7 (CYP3A7)
DM0T3YH	MT	DME
DM0T3YH	MA	Metabolism
DM0T3YH	RN	Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):79-85.
DM0T3YH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16433896

DM0T3YH	DI	DM0T3YH
DM0T3YH	DN	Indinavir
DM0T3YH	MI	TT5FNQT
DM0T3YH	MN	Human immunodeficiency virus Protease (HIV PR)
DM0T3YH	MT	DTT
DM0T3YH	MA	Inhibitor
DM0T3YH	RN	Quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cell lysate using liq... J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Feb 15;877(5-6):575-80.
DM0T3YH	RU	https://pubmed.ncbi.nlm.nih.gov/19168402

DM0T3YH	DI	DM0T3YH
DM0T3YH	DN	Indinavir
DM0T3YH	MI	DTSYQGK
DM0T3YH	MN	Multidrug resistance-associated protein 1 (ABCC1)
DM0T3YH	MT	DTP
DM0T3YH	MA	Substrate
DM0T3YH	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM0T3YH	RU	https://doi.org/10.1007/s11095-012-0935-x

DM0T3YH	DI	DM0T3YH
DM0T3YH	DN	Indinavir
DM0T3YH	MI	DTFI42L
DM0T3YH	MN	Multidrug resistance-associated protein 2 (ABCC2)
DM0T3YH	MT	DTP
DM0T3YH	MA	Substrate
DM0T3YH	RN	Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes. Biopharm Drug Dispos. 2010 Mar;31(2-3):178-88.
DM0T3YH	RU	http://www.ncbi.nlm.nih.gov/pubmed/20238377

DM0T3YH	DI	DM0T3YH
DM0T3YH	DN	Indinavir
DM0T3YH	MI	DTUGYRD
DM0T3YH	MN	P-glycoprotein 1 (ABCB1)
DM0T3YH	MT	DTP
DM0T3YH	MA	Substrate
DM0T3YH	RN	HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry. 1998 Mar 17;37(11):3594-601.
DM0T3YH	RU	http://www.ncbi.nlm.nih.gov/pubmed/9530286

DM0T3YH	DI	DM0T3YH
DM0T3YH	DN	Indinavir
DM0T3YH	MI	DEYGVN4
DM0T3YH	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM0T3YH	MT	DME
DM0T3YH	MA	Metabolism
DM0T3YH	RN	Inhibition of bilirubin metabolism induces moderate hyperbilirubinemia and attenuates ANG II-dependent hypertension in mice. Am J Physiol Regul Integr Comp Physiol. 2009 Sep;297(3):R738-43.
DM0T3YH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19571206

DMOPGHQ	DI	DMOPGHQ
DMOPGHQ	DN	Indiplon
DMOPGHQ	MI	TT1MPAY
DMOPGHQ	MN	GABA(A) receptor alpha-1 (GABRA1)
DMOPGHQ	MT	DTT
DMOPGHQ	MA	Agonist
DMOPGHQ	RN	Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62.
DMOPGHQ	RU	https://pubmed.ncbi.nlm.nih.gov/18321148

DM2NQUY	DI	DM2NQUY
DM2NQUY	DN	Indocyanine green
DM2NQUY	MI	DT9C1TS
DM2NQUY	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM2NQUY	MT	DTP
DM2NQUY	MA	Substrate
DM2NQUY	RN	Primovist, Eovist: what to expect? J Hepatol. 2012 Aug;57(2):421-9.
DM2NQUY	RU	https://doi.org/10.1016/j.jhep.2012.01.031

DMSC4A7	DI	DMSC4A7
DMSC4A7	DN	Indomethacin
DMSC4A7	MI	DE5IED8
DMSC4A7	MN	Cytochrome P450 2C9 (CYP2C9)
DMSC4A7	MT	DME
DMSC4A7	MA	Metabolism
DMSC4A7	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMSC4A7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMSC4A7	DI	DMSC4A7
DMSC4A7	DN	Indomethacin
DMSC4A7	MI	DEGTFWK
DMSC4A7	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMSC4A7	MT	DME
DMSC4A7	MA	Metabolism
DMSC4A7	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMSC4A7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMSC4A7	DI	DMSC4A7
DMSC4A7	DN	Indomethacin
DMSC4A7	MI	DTUGYRD
DMSC4A7	MN	P-glycoprotein 1 (ABCB1)
DMSC4A7	MT	DTP
DMSC4A7	MA	Substrate
DMSC4A7	RN	Indomethacin induces apoptosis via a MRP1-dependent mechanism in doxorubicin-resistant small-cell lung cancer cells overexpressing MRP1. Br J Cancer. 2007 Oct 22;97(8):1077-83.
DMSC4A7	RU	http://www.ncbi.nlm.nih.gov/pubmed/17940500

DMSC4A7	DI	DMSC4A7
DMSC4A7	DN	Indomethacin
DMSC4A7	MI	TTVKILB
DMSC4A7	MN	Prostaglandin G/H synthase 2 (COX-2)
DMSC4A7	MT	DTT
DMSC4A7	MA	Modulator
DMSC4A7	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMSC4A7	RU	https://www.fda.gov/

DMSC4A7	DI	DMSC4A7
DMSC4A7	DN	Indomethacin
DMSC4A7	MI	DEYGVN4
DMSC4A7	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMSC4A7	MT	DME
DMSC4A7	MA	Metabolism
DMSC4A7	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMSC4A7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMSC4A7	DI	DMSC4A7
DMSC4A7	DN	Indomethacin
DMSC4A7	MI	DE85D2P
DMSC4A7	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMSC4A7	MT	DME
DMSC4A7	MA	Metabolism
DMSC4A7	RN	Contribution of UDP-glucuronosyltransferases 1A9 and 2B7 to the glucuronidation of indomethacin in the human liver. Eur J Clin Pharmacol. 2007 Mar;63(3):289-96.
DMSC4A7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17245571

DMSC4A7	DI	DMSC4A7
DMSC4A7	DN	Indomethacin
DMSC4A7	MI	DEB3CV1
DMSC4A7	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMSC4A7	MT	DME
DMSC4A7	MA	Metabolism
DMSC4A7	RN	Contribution of UDP-glucuronosyltransferases 1A9 and 2B7 to the glucuronidation of indomethacin in the human liver. Eur J Clin Pharmacol. 2007 Mar;63(3):289-96.
DMSC4A7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17245571

DMI0RHA	DI	DMI0RHA
DMI0RHA	DN	Inebilizumab
DMI0RHA	MI	TTW640A
DMI0RHA	MN	B-lymphocyte surface antigen B4 (CD19)
DMI0RHA	MT	DTT
DMI0RHA	MA	Inhibitor
DMI0RHA	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMI0RHA	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761142s000lbl.pdf

DMH7OIA	DI	DMH7OIA
DMH7OIA	DN	Infliximab
DMH7OIA	MI	TTF8CQI
DMH7OIA	MN	Tumor necrosis factor (TNF)
DMH7OIA	MT	DTT
DMH7OIA	RN	Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2008 Jun;4(6):300-9.
DMH7OIA	RU	https://pubmed.ncbi.nlm.nih.gov/18414459

DMK1CZJ	DI	DMK1CZJ
DMK1CZJ	DN	Ingenol mebutate
DMK1CZJ	MI	DTUGYRD
DMK1CZJ	MN	P-glycoprotein 1 (ABCB1)
DMK1CZJ	MT	DTP
DMK1CZJ	MA	Substrate
DMK1CZJ	RN	The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature. Cancer Res. 2010 Jun 1;70(11):4509-19.
DMK1CZJ	RU	https://doi.org/10.1158/0008-5472.CAN-09-4303

DMJ93CT	DI	DMJ93CT
DMJ93CT	DN	Inotersen
DMJ93CT	MI	TTC1I86
DMJ93CT	MN	Transthyretin (TTR)
DMJ93CT	MT	DTT
DMJ93CT	MA	Antisense 
DMJ93CT	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMJ93CT	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMAC130	DI	DMAC130
DMAC130	DN	Inotuzumab ozogamicin
DMAC130	MI	TTM6QSK
DMAC130	MN	B-cell receptor CD22 (CD22)
DMAC130	MT	DTT
DMAC130	RN	Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013 Aug 1;119(15):2728-36.
DMAC130	RU	https://pubmed.ncbi.nlm.nih.gov/23633004

DMB7CE0	DI	DMB7CE0
DMB7CE0	DN	Insulin
DMB7CE0	MI	DE9OSW8
DMB7CE0	MN	Insulin-degrading enzyme (IDE)
DMB7CE0	MT	DME
DMB7CE0	MA	Metabolism
DMB7CE0	RN	Alternative splicing of human insulin-degrading enzyme yields a novel isoform with a decreased ability to degrade insulin and amyloid beta-protein. Biochemistry. 2005 May 3;44(17):6513-25.
DMB7CE0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15850385

DMB7CE0	DI	DMB7CE0
DMB7CE0	DN	Insulin
DMB7CE0	MI	DE0QGHP
DMB7CE0	MN	Insulin-degrading enzyme (ide)
DMB7CE0	MT	DME
DMB7CE0	MA	Metabolism
DMB7CE0	RN	Vibrio vulnificus secretes an insulin-degrading enzyme that promotes bacterial proliferation in vivo. J Biol Chem. 2015 Jul 24;290(30):18708-20.
DMB7CE0	RU	https://pubmed.ncbi.nlm.nih.gov/26041774

DMPL395	DI	DMPL395
DMPL395	DN	Insulin degludec
DMPL395	MI	TTZOPHG
DMPL395	MN	Insulin (INS)
DMPL395	MT	DTT
DMPL395	MA	Modulator
DMPL395	RN	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
DMPL395	RU	https://pubmed.ncbi.nlm.nih.gov/28919714

DM79NZ5	DI	DM79NZ5
DM79NZ5	DN	Insulin determir
DM79NZ5	MI	TTZOPHG
DM79NZ5	MN	Insulin (INS)
DM79NZ5	MT	DTT
DM79NZ5	MA	Modulator
DM79NZ5	RN	2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006).
DM79NZ5	RU	http://www.nature.com/nrd/journal/v11/n1/full/nrd3645.html

DM5XHVR	DI	DM5XHVR
DM5XHVR	DN	Insulin Lyspro recombinant
DM5XHVR	MI	TTCBFJO
DM5XHVR	MN	Insulin receptor (INSR)
DM5XHVR	MT	DTT
DM5XHVR	MA	Binder
DM5XHVR	RN	Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
DM5XHVR	RU	https://pubmed.ncbi.nlm.nih.gov/12509758

DMYVP5G	DI	DMYVP5G
DMYVP5G	DN	Insulin recombinant
DMYVP5G	MI	TTCBFJO
DMYVP5G	MN	Insulin receptor (INSR)
DMYVP5G	MT	DTT
DMYVP5G	MA	Binder
DMYVP5G	RN	Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
DMYVP5G	RU	https://pubmed.ncbi.nlm.nih.gov/12509758

DMW8KI7	DI	DMW8KI7
DMW8KI7	DN	Insulin Susp Isophane Recombinant Human
DMW8KI7	MI	TTZOPHG
DMW8KI7	MN	Insulin (INS)
DMW8KI7	MT	DTT
DMW8KI7	MA	Modulator
DMW8KI7	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMW8KI7	RU	https://www.fda.gov/

DM0NATE	DI	DM0NATE
DM0NATE	DN	Insulin Susp Protamine Zinc Beef/Pork
DM0NATE	MI	TTZOPHG
DM0NATE	MN	Insulin (INS)
DM0NATE	MT	DTT
DM0NATE	MA	Modulator
DM0NATE	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM0NATE	RU	https://www.fda.gov/

DM6MO9X	DI	DM6MO9X
DM6MO9X	DN	Insulin Zinc Susp Recombinant Human
DM6MO9X	MI	TTZOPHG
DM6MO9X	MN	Insulin (INS)
DM6MO9X	MT	DTT
DM6MO9X	MA	Modulator
DM6MO9X	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM6MO9X	RU	https://www.fda.gov/

DMO95XI	DI	DMO95XI
DMO95XI	DN	Insulin, porcine
DMO95XI	MI	TTCBFJO
DMO95XI	MN	Insulin receptor (INSR)
DMO95XI	MT	DTT
DMO95XI	MA	Binder
DMO95XI	RN	Acidic residues on the N-terminus of proinsulin C-Peptide are important for the folding of insulin precursor. J Biochem. 2002 Jun;131(6):855-9.
DMO95XI	RU	https://pubmed.ncbi.nlm.nih.gov/12038982

DMX7V28	DI	DMX7V28
DMX7V28	DN	Insulin-aspart
DMX7V28	MI	TTZOPHG
DMX7V28	MN	Insulin (INS)
DMX7V28	MT	DTT
DMX7V28	MA	Modulator
DMX7V28	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMX7V28	RU	https://www.fda.gov/

DMOA4VW	DI	DMOA4VW
DMOA4VW	DN	Insulin-detemir
DMOA4VW	MI	TTZOPHG
DMOA4VW	MN	Insulin (INS)
DMOA4VW	MT	DTT
DMOA4VW	MA	Modulator
DMOA4VW	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMOA4VW	RU	https://www.fda.gov/

DMR4HIW	DI	DMR4HIW
DMR4HIW	DN	Insulin-glargine
DMR4HIW	MI	TTZOPHG
DMR4HIW	MN	Insulin (INS)
DMR4HIW	MT	DTT
DMR4HIW	MA	Modulator
DMR4HIW	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMR4HIW	RU	https://www.fda.gov/

DMQI0FU	DI	DMQI0FU
DMQI0FU	DN	Insulin-glulisine
DMQI0FU	MI	TTCBFJO
DMQI0FU	MN	Insulin receptor (INSR)
DMQI0FU	MT	DTT
DMQI0FU	MA	Binder
DMQI0FU	RN	Insulin glulisine: a review of its use in the management of diabetes mellitus. Drugs. 2009;69(8):1035-57. 
DMQI0FU	RU	https://pubmed.ncbi.nlm.nih.gov/19496630

DM4O90W	DI	DM4O90W
DM4O90W	DN	Insulin-lispro
DM4O90W	MI	TTCBFJO
DM4O90W	MN	Insulin receptor (INSR)
DM4O90W	MT	DTT
DM4O90W	MA	Binder
DM4O90W	RN	Hope for insulin mimetic oral antidiabetic drugs. Eur J Endocrinol. 1999 Dec;141(6):561-2.
DM4O90W	RU	https://pubmed.ncbi.nlm.nih.gov/10601956

DMSTA36	DI	DMSTA36
DMSTA36	DN	Intedanib
DMSTA36	MI	TTRLW2X
DMSTA36	MN	Fibroblast growth factor receptor 1 (FGFR1)
DMSTA36	MT	DTT
DMSTA36	MA	Modulator
DMSTA36	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMSTA36	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMSTA36	DI	DMSTA36
DMSTA36	DN	Intedanib
DMSTA36	MI	TTGJCWZ
DMSTA36	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMSTA36	MT	DTT
DMSTA36	MA	Inhibitor
DMSTA36	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMSTA36	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMSTA36	DI	DMSTA36
DMSTA36	DN	Intedanib
DMSTA36	MI	DTUGYRD
DMSTA36	MN	P-glycoprotein 1 (ABCB1)
DMSTA36	MT	DTP
DMSTA36	MA	Substrate
DMSTA36	RN	Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Nintedanib in Healthy Subjects. Eur J Drug Metab Pharmacokinet. 2018 Oct;43(5):533-541.
DMSTA36	RU	http://www.ncbi.nlm.nih.gov/pubmed/29500603

DMSTA36	DI	DMSTA36
DMSTA36	DN	Intedanib
DMSTA36	MI	TTI2WET
DMSTA36	MN	Platelet-derived growth factor receptor (PDGFR)
DMSTA36	MT	DTT
DMSTA36	MA	Modulator
DMSTA36	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMSTA36	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMSTA36	DI	DMSTA36
DMSTA36	DN	Intedanib
DMSTA36	MI	TTVJ1D8
DMSTA36	MN	Vascular endothelial growth factor receptor (VEGFR)
DMSTA36	MT	DTT
DMSTA36	MA	Modulator
DMSTA36	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMSTA36	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMUTZ8S	DI	DMUTZ8S
DMUTZ8S	DN	Interferon Alfa-2a, Recombinant
DMUTZ8S	MI	TTGJVQM
DMUTZ8S	MN	Fibroblast growth factor receptor 2 (FGFR2)
DMUTZ8S	MT	DTT
DMUTZ8S	MA	Binder
DMUTZ8S	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DMUTZ8S	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DMWCQP4	DI	DMWCQP4
DMWCQP4	DN	Interferon alfa-2B
DMWCQP4	MI	TTSIUJ9
DMWCQP4	MN	Interferon-alpha 2 (IFNA2)
DMWCQP4	MT	DTT
DMWCQP4	MA	Modulator
DMWCQP4	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMWCQP4	RU	https://www.fda.gov/

DM3TPY8	DI	DM3TPY8
DM3TPY8	DN	Interferon Alfa-2b, Recombinant
DM3TPY8	MI	TTMQB37
DM3TPY8	MN	Interferon alpha/beta receptor 2 (IFNAR2)
DM3TPY8	MT	DTT
DM3TPY8	MA	Binder
DM3TPY8	RN	Successful treatment of relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia with T315I mutation after haplo-identical hematopoie... Leuk Res. 2009 Aug;33(8):e111-3.
DM3TPY8	RU	https://pubmed.ncbi.nlm.nih.gov/19362369

DM90WJH	DI	DM90WJH
DM90WJH	DN	Interferon alfacon-1
DM90WJH	MI	TTMQB37
DM90WJH	MN	Interferon alpha/beta receptor 2 (IFNAR2)
DM90WJH	MT	DTT
DM90WJH	MA	Binder
DM90WJH	RN	Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology. 2009 Jun;49(6):1838-46.
DM90WJH	RU	https://pubmed.ncbi.nlm.nih.gov/19291790

DM4AK0Q	DI	DM4AK0Q
DM4AK0Q	DN	Interferon alfa-n1
DM4AK0Q	MI	TTMQB37
DM4AK0Q	MN	Interferon alpha/beta receptor 2 (IFNAR2)
DM4AK0Q	MT	DTT
DM4AK0Q	MA	Binder
DM4AK0Q	RN	Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study. Hepatology. 1998 Apr;27(4):1121-7.
DM4AK0Q	RU	https://pubmed.ncbi.nlm.nih.gov/9537453

DMTZNQ9	DI	DMTZNQ9
DMTZNQ9	DN	Interferon alfa-n3
DMTZNQ9	MI	TT95SOA
DMTZNQ9	MN	Interferon alpha (IFNA)
DMTZNQ9	MT	DTT
DMTZNQ9	MA	Modulator
DMTZNQ9	RN	Clinical pipeline report, company report or official report of Hemispherx Biopharma.
DMTZNQ9	RU	http://www.hemispherx.net/content/rnd/

DM1A6RV	DI	DM1A6RV
DM1A6RV	DN	Interferon beta-1a
DM1A6RV	MI	TT4TZ8J
DM1A6RV	MN	Interferon-beta (IFNB1)
DM1A6RV	MT	DTT
DM1A6RV	MA	Modulator
DM1A6RV	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM1A6RV	RU	https://www.fda.gov/

DMCN61Z	DI	DMCN61Z
DMCN61Z	DN	Interferon beta-1b
DMCN61Z	MI	TTMQB37
DMCN61Z	MN	Interferon alpha/beta receptor 2 (IFNAR2)
DMCN61Z	MT	DTT
DMCN61Z	MA	Binder
DMCN61Z	RN	Interferon-beta(1b) Treatment in Neuromyelitis Optica. Eur Neurol. 2009 Jul 7;62(3):167-170.
DMCN61Z	RU	https://pubmed.ncbi.nlm.nih.gov/19590215

DMWUMRL	DI	DMWUMRL
DMWUMRL	DN	Interferon gamma-1b
DMWUMRL	MI	TT13TL0
DMWUMRL	MN	Interferon gamma receptor (IFNGR2)
DMWUMRL	MT	DTT
DMWUMRL	MA	Binder
DMWUMRL	RN	Genetic polymorphisms in the promoter of the interferon gamma receptor 1 gene are associated with atopic cataracts. Invest Ophthalmol Vis Sci. 2007 Feb;48(2):583-9.
DMWUMRL	RU	https://pubmed.ncbi.nlm.nih.gov/17251453

DM1Y69Q	DI	DM1Y69Q
DM1Y69Q	DN	Interleukin-3
DM1Y69Q	MI	TT5TQ2W
DM1Y69Q	MN	Granulocyte colony-stimulating factor (CSF3)
DM1Y69Q	MT	DTT
DM1Y69Q	MA	Modulator
DM1Y69Q	RN	Interleukin 3: from colony-stimulating factor to pluripotent immunoregulatory cytokine. Int J Immunopharmacol. 1992 Apr;14(3):421-30.
DM1Y69Q	RU	https://pubmed.ncbi.nlm.nih.gov/1618595

DMS6ZI0	DI	DMS6ZI0
DMS6ZI0	DN	Inulin
DMS6ZI0	MI	DE4EX78
DMS6ZI0	MN	Beta-fructofuranosidase (BFRU)
DMS6ZI0	MT	DME
DMS6ZI0	MA	Metabolism
DMS6ZI0	RN	Substrate-driven gene expression in Roseburia inulinivorans: importance of inducible enzymes in the utilization of inulin and starch. Proc Natl Acad Sci U S A. 2011 Mar 15;108 Suppl 1:4672-9.
DMS6ZI0	RU	https://pubmed.ncbi.nlm.nih.gov/20679207

DM1Y2JH	DI	DM1Y2JH
DM1Y2JH	DN	Inulin
DM1Y2JH	MI	TTZOPHG
DM1Y2JH	MN	Insulin (INS)
DM1Y2JH	MT	DTT
DM1Y2JH	MA	Modulator
DM1Y2JH	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM1Y2JH	RU	https://www.fda.gov/

DM80OEZ	DI	DM80OEZ
DM80OEZ	DN	Iobenguane I-123
DM80OEZ	MI	TTAWNKZ
DM80OEZ	MN	Norepinephrine transporter (NET)
DM80OEZ	MT	DTT
DM80OEZ	MA	Inhibitor
DM80OEZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 926).
DM80OEZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=926

DMXIQYS	DI	DMXIQYS
DMXIQYS	DN	Iodipamide
DMXIQYS	MI	TTFNGC9
DMXIQYS	MN	Serum albumin (ALB)
DMXIQYS	MT	DTT
DMXIQYS	MA	Binder
DMXIQYS	RN	Determining binding sites of drugs on human serum albumin using FIA-QCM. Biosens Bioelectron. 2008 Sep 15;24(1):48-54.
DMXIQYS	RU	https://pubmed.ncbi.nlm.nih.gov/18436441

DMNARJT	DI	DMNARJT
DMNARJT	DN	Ioflupane I-123
DMNARJT	MI	TTVBI8W
DMNARJT	MN	Dopamine transporter (DAT)
DMNARJT	MT	DTT
DMNARJT	MA	Modulator
DMNARJT	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMNARJT	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMLZTP9	DI	DMLZTP9
DMLZTP9	DN	Ipecac
DMLZTP9	MI	DECB0K3
DMLZTP9	MN	Cytochrome P450 2D6 (CYP2D6)
DMLZTP9	MT	DME
DMLZTP9	MA	Metabolism
DMLZTP9	RN	Medical Toxicology of Drug Abuse: Synthesized Chemicals and Psychoactive Plants. doi: 10.1002/9781118105955.ch13
DMLZTP9	RU	https://onlinelibrary.wiley.com/doi/abs/10.1002/9781118105955.ch13

DMWA24P	DI	DMWA24P
DMWA24P	DN	IPI-145
DMWA24P	MI	TTGBPJE
DMWA24P	MN	PI3-kinase delta (PIK3CD)
DMWA24P	MT	DTT
DMWA24P	MA	Modulator
DMWA24P	RN	PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013 Nov 21;20(11):1364-74.
DMWA24P	RU	https://pubmed.ncbi.nlm.nih.gov/24211136

DMWA24P	DI	DMWA24P
DMWA24P	DN	IPI-145
DMWA24P	MI	TTHBTOP
DMWA24P	MN	PI3-kinase gamma (PIK3CG)
DMWA24P	MT	DTT
DMWA24P	MA	Modulator
DMWA24P	RN	PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013 Nov 21;20(11):1364-74.
DMWA24P	RU	https://pubmed.ncbi.nlm.nih.gov/24211136

DMJTIYK	DI	DMJTIYK
DMJTIYK	DN	Ipilimumab
DMJTIYK	MI	TTI2S1D
DMJTIYK	MN	Cytotoxic T-lymphocyte protein 4 (CTLA-4)
DMJTIYK	MT	DTT
DMJTIYK	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DMJTIYK	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DMFQ320	DI	DMFQ320
DMFQ320	DN	Ipratropium
DMFQ320	MI	TTQ13Z5
DMFQ320	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMFQ320	MT	DTT
DMFQ320	MA	Modulator
DMFQ320	RN	Role of parasympathetic nerves and muscarinic receptors in allergy and asthma.Chem Immunol Allergy.2012;98:48-69.
DMFQ320	RU	https://www.ncbi.nlm.nih.gov/pubmed/22767057

DMFQ320	DI	DMFQ320
DMFQ320	DN	Ipratropium
DMFQ320	MI	DTT79CX
DMFQ320	MN	Organic cation transporter 1 (SLC22A1)
DMFQ320	MT	DTP
DMFQ320	MA	Substrate
DMFQ320	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMFQ320	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DMFQ320	DI	DMFQ320
DMFQ320	DN	Ipratropium
DMFQ320	MI	DT2EG60
DMFQ320	MN	Organic cation/carnitine transporter 1 (SLC22A4)
DMFQ320	MT	DTP
DMFQ320	MA	Substrate
DMFQ320	RN	Transport of ipratropium, an anti-chronic obstructive pulmonary disease drug, is mediated by organic cation/carnitine transporters in human bronchial epithelial cells: implications for carrier-mediated pulmonary absorption. Mol Pharm. 2010 Feb 1;7(1):187-95.
DMFQ320	RU	http://www.ncbi.nlm.nih.gov/pubmed/20020740

DMFQ320	DI	DMFQ320
DMFQ320	DN	Ipratropium
DMFQ320	MI	DT3HUVD
DMFQ320	MN	Organic cation/carnitine transporter 2 (SLC22A5)
DMFQ320	MT	DTP
DMFQ320	MA	Substrate
DMFQ320	RN	Transport of ipratropium, an anti-chronic obstructive pulmonary disease drug, is mediated by organic cation/carnitine transporters in human bronchial epithelial cells: implications for carrier-mediated pulmonary absorption. Mol Pharm. 2010 Feb 1;7(1):187-95.
DMFQ320	RU	http://www.ncbi.nlm.nih.gov/pubmed/20020740

DM0IO13	DI	DM0IO13
DM0IO13	DN	Ipriflavone
DM0IO13	MI	DE6OQ3W
DM0IO13	MN	Cytochrome P450 1A1 (CYP1A1)
DM0IO13	MT	DME
DM0IO13	MA	Metabolism
DM0IO13	RN	Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous ipriflavone in rats. J Pharm Pharmacol. 2006 Apr;58(4):449-57.
DM0IO13	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16597362

DM0IO13	DI	DM0IO13
DM0IO13	DN	Ipriflavone
DM0IO13	MI	DEJGDUW
DM0IO13	MN	Cytochrome P450 1A2 (CYP1A2)
DM0IO13	MT	DME
DM0IO13	MA	Metabolism
DM0IO13	RN	Characterization of cytochrome P450s mediating ipriflavone metabolism in human liver microsomes. Xenobiotica. 2007 Mar;37(3):246-59.
DM0IO13	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17624023

DM0IO13	DI	DM0IO13
DM0IO13	DN	Ipriflavone
DM0IO13	MI	DE4LYSA
DM0IO13	MN	Cytochrome P450 3A4 (CYP3A4)
DM0IO13	MT	DME
DM0IO13	MA	Metabolism
DM0IO13	RN	Pharmacokinetics of ipriflavone and metabolites after oral administration of a corn-oil suspension relative to the Osteofix tablet. Am J Ther. 1997 Jul-Aug;4(7-8):229-38.
DM0IO13	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10423615

DMTP1DC	DI	DMTP1DC
DMTP1DC	DN	Irbesartan
DMTP1DC	MI	TT8DBY3
DMTP1DC	MN	Angiotensin II receptor type-1 (AGTR1)
DMTP1DC	MT	DTT
DMTP1DC	MA	Antagonist
DMTP1DC	RN	Radioligand binding assays: application of [(125)I]angiotensin II receptor binding. Methods Mol Biol. 2009;552:131-41.
DMTP1DC	RU	https://pubmed.ncbi.nlm.nih.gov/19513646

DMTP1DC	DI	DMTP1DC
DMTP1DC	DN	Irbesartan
DMTP1DC	MI	DES5XRU
DMTP1DC	MN	Cytochrome P450 2C8 (CYP2C8)
DMTP1DC	MT	DME
DMTP1DC	MA	Metabolism
DMTP1DC	RN	Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78.
DMTP1DC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15601807

DMTP1DC	DI	DMTP1DC
DMTP1DC	DN	Irbesartan
DMTP1DC	MI	DE5IED8
DMTP1DC	MN	Cytochrome P450 2C9 (CYP2C9)
DMTP1DC	MT	DME
DMTP1DC	MA	Metabolism
DMTP1DC	RN	Rapid detection of the known SNPs of CYP2C9 using oligonucleotide microarray. World J Gastroenterol. 2003 Jun;9(6):1342-6.
DMTP1DC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12800253

DMTP1DC	DI	DMTP1DC
DMTP1DC	DN	Irbesartan
DMTP1DC	MI	DE4LYSA
DMTP1DC	MN	Cytochrome P450 3A4 (CYP3A4)
DMTP1DC	MT	DME
DMTP1DC	MA	Metabolism
DMTP1DC	RN	Drug interactions with irbesartan. Clin Pharmacokinet. 2001;40(8):605-14.
DMTP1DC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11523726

DMTP1DC	DI	DMTP1DC
DMTP1DC	DN	Irbesartan
DMTP1DC	MI	DT9G7XN
DMTP1DC	MN	Peptide transporter 1 (SLC15A1)
DMTP1DC	MT	DTP
DMTP1DC	MA	Substrate
DMTP1DC	RN	High-affinity interaction of sartans with H+/peptide transporters. Drug Metab Dispos. 2009 Jan;37(1):143-9.
DMTP1DC	RU	http://www.ncbi.nlm.nih.gov/pubmed/18824524

DMTP1DC	DI	DMTP1DC
DMTP1DC	DN	Irbesartan
DMTP1DC	MI	DE073H6
DMTP1DC	MN	Prostaglandin G/H synthase 1 (COX-1)
DMTP1DC	MT	DME
DMTP1DC	MA	Metabolism
DMTP1DC	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMTP1DC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMTP1DC	DI	DMTP1DC
DMTP1DC	DN	Irbesartan
DMTP1DC	MI	DEF2WXN
DMTP1DC	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMTP1DC	MT	DME
DMTP1DC	MA	Metabolism
DMTP1DC	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMTP1DC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMP6SC2	DI	DMP6SC2
DMP6SC2	DN	Irinotecan
DMP6SC2	MI	DE9RA0I
DMP6SC2	MN	Beta-glucuronidase (uidA)
DMP6SC2	MT	DME
DMP6SC2	MA	Metabolism
DMP6SC2	RN	Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res. 1996 Aug 15;56(16):3752-7.
DMP6SC2	RU	https://pubmed.ncbi.nlm.nih.gov/8706020

DMP6SC2	DI	DMP6SC2
DMP6SC2	DN	Irinotecan
DMP6SC2	MI	DTI7UX6
DMP6SC2	MN	Breast cancer resistance protein (ABCG2)
DMP6SC2	MT	DTP
DMP6SC2	MA	Substrate
DMP6SC2	RN	Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Cancer Chemother Pharmacol. 2006 Sep;58(3):374-83.
DMP6SC2	RU	http://www.ncbi.nlm.nih.gov/pubmed/16404634

DMP6SC2	DI	DMP6SC2
DMP6SC2	DN	Irinotecan
DMP6SC2	MI	DEB30C5
DMP6SC2	MN	Carboxylesterase 1 (CES1)
DMP6SC2	MT	DME
DMP6SC2	MA	Metabolism
DMP6SC2	RN	Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed Chromatogr. 2010 Jan;24(1):104-23.
DMP6SC2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19852077

DMP6SC2	DI	DMP6SC2
DMP6SC2	DN	Irinotecan
DMP6SC2	MI	DETHCPD
DMP6SC2	MN	Carboxylesterase 2 (CES2)
DMP6SC2	MT	DME
DMP6SC2	MA	Metabolism
DMP6SC2	RN	Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3. Drug Metab Dispos. 2004 May;32(5):505-11.
DMP6SC2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15100172

DMP6SC2	DI	DMP6SC2
DMP6SC2	DN	Irinotecan
DMP6SC2	MI	DEMI4VE
DMP6SC2	MN	Carboxylesterase 3 (CES3)
DMP6SC2	MT	DME
DMP6SC2	MA	Metabolism
DMP6SC2	RN	Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3. Drug Metab Dispos. 2004 May;32(5):505-11.
DMP6SC2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15100172

DMP6SC2	DI	DMP6SC2
DMP6SC2	DN	Irinotecan
DMP6SC2	MI	DEPKLMQ
DMP6SC2	MN	Cytochrome P450 2B6 (CYP2B6)
DMP6SC2	MT	DME
DMP6SC2	MA	Metabolism
DMP6SC2	RN	Drugs that may have potential CYP2B6 interactions.
DMP6SC2	RU	https://drug-interactions.medicine.iu.edu/MainTable.aspx

DMP6SC2	DI	DMP6SC2
DMP6SC2	DN	Irinotecan
DMP6SC2	MI	DE4LYSA
DMP6SC2	MN	Cytochrome P450 3A4 (CYP3A4)
DMP6SC2	MT	DME
DMP6SC2	MA	Metabolism
DMP6SC2	RN	Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed Chromatogr. 2010 Jan;24(1):104-23.
DMP6SC2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19852077

DMP6SC2	DI	DMP6SC2
DMP6SC2	DN	Irinotecan
DMP6SC2	MI	DEIBDNY
DMP6SC2	MN	Cytochrome P450 3A5 (CYP3A5)
DMP6SC2	MT	DME
DMP6SC2	MA	Metabolism
DMP6SC2	RN	Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro. 2006 Mar;20(2):163-75.
DMP6SC2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16271446

DMP6SC2	DI	DMP6SC2
DMP6SC2	DN	Irinotecan
DMP6SC2	MI	DERD86B
DMP6SC2	MN	Cytochrome P450 3A7 (CYP3A7)
DMP6SC2	MT	DME
DMP6SC2	MA	Metabolism
DMP6SC2	RN	Drug Interactions Flockhart Table
DMP6SC2	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMP6SC2	DI	DMP6SC2
DMP6SC2	DN	Irinotecan
DMP6SC2	MI	TTGTQHC
DMP6SC2	MN	DNA topoisomerase I (TOP1)
DMP6SC2	MT	DTT
DMP6SC2	MA	Modulator
DMP6SC2	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMP6SC2	RU	https://www.fda.gov/

DMP6SC2	DI	DMP6SC2
DMP6SC2	DN	Irinotecan
DMP6SC2	MI	DTSYQGK
DMP6SC2	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMP6SC2	MT	DTP
DMP6SC2	MA	Substrate
DMP6SC2	RN	ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol. 1999 May;55(5):921-8.
DMP6SC2	RU	http://molpharm.aspetjournals.org/content/55/5/921

DMP6SC2	DI	DMP6SC2
DMP6SC2	DN	Irinotecan
DMP6SC2	MI	DTFI42L
DMP6SC2	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMP6SC2	MT	DTP
DMP6SC2	MA	Substrate
DMP6SC2	RN	Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1. Drug Metab Dispos. 2002 Jul;30(7):763-70.
DMP6SC2	RU	http://www.ncbi.nlm.nih.gov/pubmed/12065434

DMP6SC2	DI	DMP6SC2
DMP6SC2	DN	Irinotecan
DMP6SC2	MI	DTCSGPB
DMP6SC2	MN	Multidrug resistance-associated protein 4 (ABCC4)
DMP6SC2	MT	DTP
DMP6SC2	MA	Substrate
DMP6SC2	RN	P-glycoprotein, but not multidrug resistance protein 4, plays a role in the systemic clearance of irinotecan and SN-38 in mice. Drug Metab Lett. 2010 Dec;4(4):195-201.
DMP6SC2	RU	http://www.ncbi.nlm.nih.gov/pubmed/20583968

DMP6SC2	DI	DMP6SC2
DMP6SC2	DN	Irinotecan
DMP6SC2	MI	DTYVM24
DMP6SC2	MN	Multidrug resistance-associated protein 5 (ABCC5)
DMP6SC2	MT	DTP
DMP6SC2	MA	Substrate
DMP6SC2	RN	Celecoxib upregulates multidrug resistance proteins in colon cancer: lack of synergy with standard chemotherapy. Curr Cancer Drug Targets. 2008 Aug;8(5):414-20.
DMP6SC2	RU	http://www.ncbi.nlm.nih.gov/pubmed/18690847

DMP6SC2	DI	DMP6SC2
DMP6SC2	DN	Irinotecan
DMP6SC2	MI	DTUGYRD
DMP6SC2	MN	P-glycoprotein 1 (ABCB1)
DMP6SC2	MT	DTP
DMP6SC2	MA	Substrate
DMP6SC2	RN	Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1. Drug Metab Dispos. 2002 Jul;30(7):763-70.
DMP6SC2	RU	http://www.ncbi.nlm.nih.gov/pubmed/12065434

DMAP8MV	DI	DMAP8MV
DMAP8MV	DN	Iron
DMAP8MV	MI	DEXVHDB
DMAP8MV	MN	Friedreich ataxia protein (FXN)
DMAP8MV	MT	DME
DMAP8MV	MA	Metabolism
DMAP8MV	RN	Iron dysregulation in Friedreich ataxia. Semin Pediatr Neurol. 2006 Sep;13(3):166-75.
DMAP8MV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17101455

DMAP8MV	DI	DMAP8MV
DMAP8MV	DN	Iron
DMAP8MV	MI	TTQO71U
DMAP8MV	MN	Hemoglobin (HB)
DMAP8MV	MT	DTT
DMAP8MV	MA	Activator
DMAP8MV	RN	Efficacy and safety of total dose infusion of low molecular weight iron dextran in the treatment of iron deficiency anemia during pregnancy. J Coll Physicians Surg Pak. 2008 Jul;18(7):424-7.
DMAP8MV	RU	https://pubmed.ncbi.nlm.nih.gov/18760066

DMAP8MV	DI	DMAP8MV
DMAP8MV	DN	Iron
DMAP8MV	MI	DTVKMHD
DMAP8MV	MN	Natural resistance-associated macrophage protein 2 (SLC11A2)
DMAP8MV	MT	DTP
DMAP8MV	MA	Substrate
DMAP8MV	RN	Transmembrane topology of the mammalian Slc11a2 iron transporter. Biochemistry. 2009 Sep 8;48(35):8422-34.
DMAP8MV	RU	http://www.ncbi.nlm.nih.gov/pubmed/19621945

DMAP8MV	DI	DMAP8MV
DMAP8MV	DN	Iron
DMAP8MV	MI	DTG1RJO
DMAP8MV	MN	Sodium/bile acid cotransporter 7 (SLC10A7)
DMAP8MV	MT	DTP
DMAP8MV	MA	Substrate
DMAP8MV	RN	Modulation of macrophage iron transport by Nramp1 (Slc11a1). Immunobiology. 2007;212(9-10):751-7.
DMAP8MV	RU	http://www.ncbi.nlm.nih.gov/pubmed/18086376

DM5OY70	DI	DM5OY70
DM5OY70	DN	Iron Dextran
DM5OY70	MI	TTQO71U
DM5OY70	MN	Hemoglobin (HB)
DM5OY70	MT	DTT
DM5OY70	MA	Activator
DM5OY70	RN	Efficacy and safety of total dose infusion of low molecular weight iron dextran in the treatment of iron deficiency anemia during pregnancy. J Coll Physicians Surg Pak. 2008 Jul;18(7):424-7.
DM5OY70	RU	https://pubmed.ncbi.nlm.nih.gov/18760066

DMD45S9	DI	DMD45S9
DMD45S9	DN	Isavuconazonium
DMD45S9	MI	DE4LYSA
DMD45S9	MN	Cytochrome P450 3A4 (CYP3A4)
DMD45S9	MT	DME
DMD45S9	MA	Metabolism
DMD45S9	RN	Isavuconazole: pharmacology, pharmacodynamics, and current clinical experience with a new triazole antifungal agent. Pharmacotherapy. 2015 Nov;35(11):1037-51.
DMD45S9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26598096

DMJ9G23	DI	DMJ9G23
DMJ9G23	DN	ISIS 1570
DMJ9G23	MI	TTA1L39
DMJ9G23	MN	ICAM1 messenger RNA (ICAM1 mRNA)
DMJ9G23	MT	DTT
DMJ9G23	RN	US patent application no. 6,300,491, Oligonucleotide inhibition of cell adhesion.
DMJ9G23	RU	http://www.patentbuddy.com/Patent/6300491?ft=true&sr=true

DMAF1NB	DI	DMAF1NB
DMAF1NB	DN	Isocarboxazid
DMAF1NB	MI	TT3WG5C
DMAF1NB	MN	Monoamine oxidase type A (MAO-A)
DMAF1NB	MT	DTT
DMAF1NB	MA	Inhibitor
DMAF1NB	RN	MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995 May;12(3):185-219.
DMAF1NB	RU	https://pubmed.ncbi.nlm.nih.gov/7612154

DMITSEH	DI	DMITSEH
DMITSEH	DN	Isoetharine
DMITSEH	MI	TT2CJVK
DMITSEH	MN	Adrenergic receptor beta-2 (ADRB2)
DMITSEH	MT	DTT
DMITSEH	MA	Modulator
DMITSEH	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMITSEH	RU	https://www.fda.gov/

DMY6T31	DI	DMY6T31
DMY6T31	DN	Isoflurane
DMY6T31	MI	DEPKLMQ
DMY6T31	MN	Cytochrome P450 2B6 (CYP2B6)
DMY6T31	MT	DME
DMY6T31	MA	Metabolism
DMY6T31	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMY6T31	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMY6T31	DI	DMY6T31
DMY6T31	DN	Isoflurane
DMY6T31	MI	DEVDYN7
DMY6T31	MN	Cytochrome P450 2E1 (CYP2E1)
DMY6T31	MT	DME
DMY6T31	MA	Metabolism
DMY6T31	RN	Clinical isoflurane metabolism by cytochrome P450 2E1. Anesthesiology. 1999 Mar;90(3):766-71.
DMY6T31	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10078678

DMY6T31	DI	DMY6T31
DMY6T31	DN	Isoflurane
DMY6T31	MI	TTAN6JD
DMY6T31	MN	Glutamate receptor AMPA (GRIA)
DMY6T31	MT	DTT
DMY6T31	MA	Agonist
DMY6T31	RN	Transmembrane residues define the action of isoflurane at the GABAA receptor alpha-3 subunit. Brain Res. 2005 Jan 25;1032(1-2):30-5.
DMY6T31	RU	https://pubmed.ncbi.nlm.nih.gov/15680938

DMBSK7X	DI	DMBSK7X
DMBSK7X	DN	Isoflurophate
DMBSK7X	MI	TT1RS9F
DMBSK7X	MN	Acetylcholinesterase (AChE)
DMBSK7X	MT	DTT
DMBSK7X	MA	Inhibitor
DMBSK7X	RN	Rational design of alkylene-linked bis-pyridiniumaldoximes as improved acetylcholinesterase reactivators. Chem Biol. 2003 Jun;10(6):491-502.
DMBSK7X	RU	https://pubmed.ncbi.nlm.nih.gov/12837382

DM5JVS3	DI	DM5JVS3
DM5JVS3	DN	Isoniazid
DM5JVS3	MI	DEXCQTM
DM5JVS3	MN	Arylamine N-acetyltransferase (NAT)
DM5JVS3	MT	DME
DM5JVS3	MA	Metabolism
DM5JVS3	RN	The actinobacterium Tsukamurella paurometabola has a functionally divergent arylamine N-acetyltransferase (NAT) homolog. World J Microbiol Biotechnol. 2019 Oct 31;35(11):174.
DM5JVS3	RU	https://pubmed.ncbi.nlm.nih.gov/31673919

DM5JVS3	DI	DM5JVS3
DM5JVS3	DN	Isoniazid
DM5JVS3	MI	TTVTX4N
DM5JVS3	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DM5JVS3	MT	DTT
DM5JVS3	MA	Inhibitor
DM5JVS3	RN	Diversity in enoyl-acyl carrier protein reductases. Cell Mol Life Sci. 2009 May;66(9):1507-17.
DM5JVS3	RU	https://pubmed.ncbi.nlm.nih.gov/19151923

DM5JVS3	DI	DM5JVS3
DM5JVS3	DN	Isoniazid
DM5JVS3	MI	DEAGY5M
DM5JVS3	MN	Catalase-peroxidase (katG)
DM5JVS3	MT	DME
DM5JVS3	MA	Metabolism
DM5JVS3	RN	Crystal structure of the catalase-peroxidase KatG W78F mutant from Synechococcus elongatus PCC7942 in complex with the antitubercular pro-drug isoniazid. FEBS Lett. 2015 Jan 2;589(1):131-7.
DM5JVS3	RU	https://pubmed.ncbi.nlm.nih.gov/25479089

DM5JVS3	DI	DM5JVS3
DM5JVS3	DN	Isoniazid
DM5JVS3	MI	DEVDYN7
DM5JVS3	MN	Cytochrome P450 2E1 (CYP2E1)
DM5JVS3	MT	DME
DM5JVS3	MA	Metabolism
DM5JVS3	RN	Inhibition of CYP2E1 catalytic activity in vitro by S-adenosyl-L-methionine. Biochem Pharmacol. 2005 Apr 1;69(7):1081-93.
DM5JVS3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15763544

DMQYV60	DI	DMQYV60
DMQYV60	DN	Isopropamide iodide
DMQYV60	MI	TTOXS3C
DMQYV60	MN	Muscarinic acetylcholine receptor (CHRM)
DMQYV60	MT	DTT
DMQYV60	MA	Modulator
DMQYV60	RN	Competitive and non-competitive antagonism exhibited by 'selective' antagonists at atrial and ileal muscarinic receptor subtypes. Br J Pharmacol. 1987 Apr;90(4):701-7.
DMQYV60	RU	https://pubmed.ncbi.nlm.nih.gov/3580704

DMK7MEY	DI	DMK7MEY
DMK7MEY	DN	Isoproterenol
DMK7MEY	MI	TTR6W5O
DMK7MEY	MN	Adrenergic receptor beta-1 (ADRB1)
DMK7MEY	MT	DTT
DMK7MEY	MA	Agonist
DMK7MEY	RN	Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404.
DMK7MEY	RU	https://pubmed.ncbi.nlm.nih.gov/9551698

DMK7MEY	DI	DMK7MEY
DMK7MEY	DN	Isoproterenol
DMK7MEY	MI	TT2CJVK
DMK7MEY	MN	Adrenergic receptor beta-2 (ADRB2)
DMK7MEY	MT	DTT
DMK7MEY	MA	Modulator
DMK7MEY	RN	Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404.
DMK7MEY	RU	https://pubmed.ncbi.nlm.nih.gov/9551698

DMK7MEY	DI	DMK7MEY
DMK7MEY	DN	Isoproterenol
DMK7MEY	MI	TTGW72V
DMK7MEY	MN	Interleukin-12 beta (IL12B)
DMK7MEY	MT	DTT
DMK7MEY	MA	Modulator
DMK7MEY	RN	A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma. Clin Cancer Res. 2011 Apr 1;17(7):1998-2005.
DMK7MEY	RU	https://pubmed.ncbi.nlm.nih.gov/21447719

DMK7MEY	DI	DMK7MEY
DMK7MEY	DN	Isoproterenol
DMK7MEY	MI	DEFQ8VO
DMK7MEY	MN	Thiopurine methyltransferase (TPMT)
DMK7MEY	MT	DME
DMK7MEY	MA	Metabolism
DMK7MEY	RN	Identification, characterization, and ontogenic study of a catechol O-methyltransferase from zebrafish. Aquat Toxicol. 2011 Mar;102(1-2):18-23.
DMK7MEY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21371608

DMBI4JG	DI	DMBI4JG
DMBI4JG	DN	Isosorbide dinitrate
DMBI4JG	MI	DE4LYSA
DMBI4JG	MN	Cytochrome P450 3A4 (CYP3A4)
DMBI4JG	MT	DME
DMBI4JG	MA	Metabolism
DMBI4JG	RN	Isoforms of cytochrome P450 on organic nitrate-derived nitric oxide release in human heart vessels. FEBS Lett. 1999 Jun 11;452(3):165-9.
DMBI4JG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10386583

DMBI4JG	DI	DMBI4JG
DMBI4JG	DN	Isosorbide dinitrate
DMBI4JG	MI	DE4ZHS1
DMBI4JG	MN	Glutathione S-transferase alpha-1 (GSTA1)
DMBI4JG	MT	DME
DMBI4JG	MA	Metabolism
DMBI4JG	RN	Nitroglycerin and isosorbide dinitrate stimulation of glutathione disulfide efflux from perfused rat liver. Biochem Pharmacol. 1989 Nov 1;38(21):3807-10.
DMBI4JG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=2512927

DMBI4JG	DI	DMBI4JG
DMBI4JG	DN	Isosorbide dinitrate
DMBI4JG	MI	TT6HPVC
DMBI4JG	MN	Guanylate cyclase (GC)
DMBI4JG	MT	DTT
DMBI4JG	MA	Stimulator
DMBI4JG	RN	Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem. 2010 Jan;333(1-2):191-201.
DMBI4JG	RU	https://pubmed.ncbi.nlm.nih.gov/19618122

DMYLMU0	DI	DMYLMU0
DMYLMU0	DN	Isosorbide mononitrate
DMYLMU0	MI	DE4LYSA
DMYLMU0	MN	Cytochrome P450 3A4 (CYP3A4)
DMYLMU0	MT	DME
DMYLMU0	MA	Metabolism
DMYLMU0	RN	Isoforms of cytochrome P450 on organic nitrate-derived nitric oxide release in human heart vessels. FEBS Lett. 1999 Jun 11;452(3):165-9.
DMYLMU0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10386583

DMYLMU0	DI	DMYLMU0
DMYLMU0	DN	Isosorbide mononitrate
DMYLMU0	MI	TT6HPVC
DMYLMU0	MN	Guanylate cyclase (GC)
DMYLMU0	MT	DTT
DMYLMU0	MA	Stimulator
DMYLMU0	RN	Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem. 2010 Jan;333(1-2):191-201.
DMYLMU0	RU	https://pubmed.ncbi.nlm.nih.gov/19618122

DM4QTBN	DI	DM4QTBN
DM4QTBN	DN	Isotretinoin
DM4QTBN	MI	DE4LYSA
DM4QTBN	MN	Cytochrome P450 3A4 (CYP3A4)
DM4QTBN	MT	DME
DM4QTBN	MA	Metabolism
DM4QTBN	RN	The effect of isotretinoin on the pharmacokinetics and pharmacodynamics of ethinyl estradiol and norethindrone. Clin Pharmacol Ther. 2004 May;75(5):464-75.
DM4QTBN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15116059

DM4QTBN	DI	DM4QTBN
DM4QTBN	DN	Isotretinoin
DM4QTBN	MI	TTOD7B3
DM4QTBN	MN	Retinoic acid receptor (RAR)
DM4QTBN	MT	DTT
DM4QTBN	MA	Agonist
DM4QTBN	RN	Retinoid agonist isotretinoin ameliorates obstructive renal injury. J Urol. 2003 Oct;170(4 Pt 1):1398-402.
DM4QTBN	RU	https://pubmed.ncbi.nlm.nih.gov/14501777

DMX7LKS	DI	DMX7LKS
DMX7LKS	DN	Isovanillin
DMX7LKS	MI	TT3MOS2
DMX7LKS	MN	Aldehyde oxidase (AOX1)
DMX7LKS	MT	DTT
DMX7LKS	MA	Inhibitor
DMX7LKS	RN	Contribution of aldehyde oxidizing enzymes on the metabolism of 3,4-dimethoxy-2-phenylethylamine to 3,4-dimethoxyphenylacetic acid by guinea pig li... Cell Physiol Biochem. 2006;17(1-2):47-56.
DMX7LKS	RU	https://pubmed.ncbi.nlm.nih.gov/16543721

DMJL10P	DI	DMJL10P
DMJL10P	DN	Isoxyl
DMJL10P	MI	TT6RIOV
DMJL10P	MN	Acyl-CoA desaturase (SCD)
DMJL10P	MT	DTT
DMJL10P	MA	Binder
DMJL10P	RN	Has nature already identified all useful antibacterial targets Curr Opin Microbiol. 2008 Oct;11(5):387-92.
DMJL10P	RU	https://pubmed.ncbi.nlm.nih.gov/18804175

DMWCRN1	DI	DMWCRN1
DMWCRN1	DN	Ispaghula
DMWCRN1	MI	TTH18TF
DMWCRN1	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMWCRN1	MT	DTT
DMWCRN1	MA	Antagonist
DMWCRN1	RN	Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
DMWCRN1	RU	https://pubmed.ncbi.nlm.nih.gov/16634703

DMA5XGH	DI	DMA5XGH
DMA5XGH	DN	Isradipine
DMA5XGH	MI	TT5HONZ
DMA5XGH	MN	Calcium channel unspecific (CaC)
DMA5XGH	MT	DTT
DMA5XGH	MA	Modulator
DMA5XGH	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMA5XGH	RU	https://www.fda.gov/

DM20VSK	DI	DM20VSK
DM20VSK	DN	Istradefylline
DM20VSK	MI	TTM2AOE
DM20VSK	MN	Adenosine A2a receptor (ADORA2A)
DM20VSK	MT	DTT
DM20VSK	MA	Modulator
DM20VSK	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DM20VSK	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022075s000lbl.pdf

DM20VSK	DI	DM20VSK
DM20VSK	DN	Istradefylline
DM20VSK	MI	DEJGDUW
DM20VSK	MN	Cytochrome P450 1A2 (CYP1A2)
DM20VSK	MT	DME
DM20VSK	MA	Metabolism
DM20VSK	RN	Effects of rifampin on the pharmacokinetics of a single dose of istradefylline in healthy subjects. J Clin Pharmacol. 2018 Feb;58(2):193-201.
DM20VSK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28881378

DM20VSK	DI	DM20VSK
DM20VSK	DN	Istradefylline
DM20VSK	MI	DEPKLMQ
DM20VSK	MN	Cytochrome P450 2B6 (CYP2B6)
DM20VSK	MT	DME
DM20VSK	MA	Metabolism
DM20VSK	RN	Effects of rifampin on the pharmacokinetics of a single dose of istradefylline in healthy subjects. J Clin Pharmacol. 2018 Feb;58(2):193-201.
DM20VSK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28881378

DM20VSK	DI	DM20VSK
DM20VSK	DN	Istradefylline
DM20VSK	MI	DEZMWRE
DM20VSK	MN	Cytochrome P450 2C18 (CYP2C18)
DM20VSK	MT	DME
DM20VSK	MA	Metabolism
DM20VSK	RN	Effects of rifampin on the pharmacokinetics of a single dose of istradefylline in healthy subjects. J Clin Pharmacol. 2018 Feb;58(2):193-201.
DM20VSK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28881378

DM20VSK	DI	DM20VSK
DM20VSK	DN	Istradefylline
DM20VSK	MI	DES5XRU
DM20VSK	MN	Cytochrome P450 2C8 (CYP2C8)
DM20VSK	MT	DME
DM20VSK	MA	Metabolism
DM20VSK	RN	Effects of rifampin on the pharmacokinetics of a single dose of istradefylline in healthy subjects. J Clin Pharmacol. 2018 Feb;58(2):193-201.
DM20VSK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28881378

DM20VSK	DI	DM20VSK
DM20VSK	DN	Istradefylline
DM20VSK	MI	DE5IED8
DM20VSK	MN	Cytochrome P450 2C9 (CYP2C9)
DM20VSK	MT	DME
DM20VSK	MA	Metabolism
DM20VSK	RN	Effects of rifampin on the pharmacokinetics of a single dose of istradefylline in healthy subjects. J Clin Pharmacol. 2018 Feb;58(2):193-201.
DM20VSK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28881378

DM20VSK	DI	DM20VSK
DM20VSK	DN	Istradefylline
DM20VSK	MI	DECB0K3
DM20VSK	MN	Cytochrome P450 2D6 (CYP2D6)
DM20VSK	MT	DME
DM20VSK	MA	Metabolism
DM20VSK	RN	Effects of rifampin on the pharmacokinetics of a single dose of istradefylline in healthy subjects. J Clin Pharmacol. 2018 Feb;58(2):193-201.
DM20VSK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28881378

DM20VSK	DI	DM20VSK
DM20VSK	DN	Istradefylline
DM20VSK	MI	DE4LYSA
DM20VSK	MN	Cytochrome P450 3A4 (CYP3A4)
DM20VSK	MT	DME
DM20VSK	MA	Metabolism
DM20VSK	RN	Effects of rifampin on the pharmacokinetics of a single dose of istradefylline in healthy subjects. J Clin Pharmacol. 2018 Feb;58(2):193-201.
DM20VSK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28881378

DM20VSK	DI	DM20VSK
DM20VSK	DN	Istradefylline
DM20VSK	MI	DEIBDNY
DM20VSK	MN	Cytochrome P450 3A5 (CYP3A5)
DM20VSK	MT	DME
DM20VSK	MA	Metabolism
DM20VSK	RN	Effects of rifampin on the pharmacokinetics of a single dose of istradefylline in healthy subjects. J Clin Pharmacol. 2018 Feb;58(2):193-201.
DM20VSK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28881378

DMCR1MV	DI	DMCR1MV
DMCR1MV	DN	Itraconazole
DMCR1MV	MI	TTTSOUD
DMCR1MV	MN	Candida Cytochrome P450 51 (Candi ERG11)
DMCR1MV	MT	DTT
DMCR1MV	MA	Modulator
DMCR1MV	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMCR1MV	RU	https://www.fda.gov/

DMCR1MV	DI	DMCR1MV
DMCR1MV	DN	Itraconazole
DMCR1MV	MI	DE4LYSA
DMCR1MV	MN	Cytochrome P450 3A4 (CYP3A4)
DMCR1MV	MT	DME
DMCR1MV	MA	Metabolism
DMCR1MV	RN	Effects of itraconazole and tandospirone on the pharmacokinetics of perospirone. Ther Drug Monit. 2006 Feb;28(1):73-5.
DMCR1MV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16418697

DMCR1MV	DI	DMCR1MV
DMCR1MV	DN	Itraconazole
DMCR1MV	MI	TT4LXBC
DMCR1MV	MN	Hedgehog signaling pathway (HS pathway)
DMCR1MV	MT	DTT
DMCR1MV	MA	Inhibitor
DMCR1MV	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMCR1MV	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMCR1MV	DI	DMCR1MV
DMCR1MV	DN	Itraconazole
DMCR1MV	MI	DTUGYRD
DMCR1MV	MN	P-glycoprotein 1 (ABCB1)
DMCR1MV	MT	DTP
DMCR1MV	MA	Substrate
DMCR1MV	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMCR1MV	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMCR1MV	DI	DMCR1MV
DMCR1MV	DN	Itraconazole
DMCR1MV	MI	DEYGVN4
DMCR1MV	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMCR1MV	MT	DME
DMCR1MV	MA	Metabolism
DMCR1MV	RN	Investigation into UDP-glucuronosyltransferase (UGT) enzyme kinetics of imidazole- and triazole-containing antifungal drugs in human liver microsomes and recombinant UGT enzymes. Drug Metab Dispos. 2010 Jun;38(6):923-9.
DMCR1MV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20304965

DM0L594	DI	DM0L594
DM0L594	DN	Ivabradine
DM0L594	MI	DE4LYSA
DM0L594	MN	Cytochrome P450 3A4 (CYP3A4)
DM0L594	MT	DME
DM0L594	MA	Metabolism
DM0L594	RN	Ivabradine: new drug. Best avoided in stable angina. Prescrire Int. 2007 Apr;16(88):53-6.
DM0L594	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17458043

DM0L594	DI	DM0L594
DM0L594	DN	Ivabradine
DM0L594	MI	TTKLW9S
DM0L594	MN	Hyperpolarization cyclic nucleotide-gated channel (HCN)
DM0L594	MT	DTT
DM0L594	MA	Inhibitor
DM0L594	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DM0L594	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DM0L594	DI	DM0L594
DM0L594	DN	Ivabradine
DM0L594	MI	TTFCQYU
DM0L594	MN	Sinus node I(f) channel (SA node IfC)
DM0L594	MT	DTT
DM0L594	MA	Modulator
DM0L594	RN	Ivabradine - the first selective sinus node If channel inhibitor in the treatment of stable angina. Int J Clin Pract. 2006 February; 60(2): 222-228.
DM0L594	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1448693/

DMZC1HS	DI	DMZC1HS
DMZC1HS	DN	Ivacaftor
DMZC1HS	MI	TTRLZHP
DMZC1HS	MN	cAMP-dependent chloride channel (CFTR)
DMZC1HS	MT	DTT
DMZC1HS	MA	Modulator
DMZC1HS	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMZC1HS	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMZC1HS	DI	DMZC1HS
DMZC1HS	DN	Ivacaftor
DMZC1HS	MI	DE4LYSA
DMZC1HS	MN	Cytochrome P450 3A4 (CYP3A4)
DMZC1HS	MT	DME
DMZC1HS	MA	Metabolism
DMZC1HS	RN	Sensitivity of ivacaftor to drug-drug interactions with rifampin, a cytochrome P450 3A4 inducer. Pediatr Pulmonol. 2018 May;53(5):E6-E8.
DMZC1HS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29488691

DMZC1HS	DI	DMZC1HS
DMZC1HS	DN	Ivacaftor
DMZC1HS	MI	DEIBDNY
DMZC1HS	MN	Cytochrome P450 3A5 (CYP3A5)
DMZC1HS	MT	DME
DMZC1HS	MA	Metabolism
DMZC1HS	RN	Sensitivity of ivacaftor to drug-drug interactions with rifampin, a cytochrome P450 3A4 inducer. Pediatr Pulmonol. 2018 May;53(5):E6-E8.
DMZC1HS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29488691

DMZC1HS	DI	DMZC1HS
DMZC1HS	DN	Ivacaftor
DMZC1HS	MI	DTUGYRD
DMZC1HS	MN	P-glycoprotein 1 (ABCB1)
DMZC1HS	MT	DTP
DMZC1HS	MA	Substrate
DMZC1HS	RN	Investigation of the effects of the CFTR potentiator ivacaftor on human P-glycoprotein (ABCB1). Sci Rep. 2017 Dec 13;7(1):17481.
DMZC1HS	RU	http://www.ncbi.nlm.nih.gov/pubmed/29235532

DMDBX5F	DI	DMDBX5F
DMDBX5F	DN	Ivermectin
DMDBX5F	MI	DE4LYSA
DMDBX5F	MN	Cytochrome P450 3A4 (CYP3A4)
DMDBX5F	MT	DME
DMDBX5F	MA	Metabolism
DMDBX5F	RN	Identification of cytochrome P4503A4 as the major enzyme responsible for the metabolism of ivermectin by human liver microsomes. Xenobiotica. 1998 Mar;28(3):313-21.
DMDBX5F	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9574819

DMDBX5F	DI	DMDBX5F
DMDBX5F	DN	Ivermectin
DMDBX5F	MI	DTSYQGK
DMDBX5F	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMDBX5F	MT	DTP
DMDBX5F	MA	Substrate
DMDBX5F	RN	Interaction of ivermectin with multidrug resistance proteins (MRP1, 2 and 3). Chem Biol Interact. 2006 Feb 25;159(3):169-79.
DMDBX5F	RU	http://www.ncbi.nlm.nih.gov/pubmed/16384552

DMDBX5F	DI	DMDBX5F
DMDBX5F	DN	Ivermectin
DMDBX5F	MI	TTSNVHO
DMDBX5F	MN	Onchocerca Glutamate-gated chloride channel (Onchoc GluCl)
DMDBX5F	MT	DTT
DMDBX5F	MA	Activator
DMDBX5F	RN	Inhibitory neurotransmission and olfactory memory in honeybees. Neurobiol Learn Mem. 2008 Nov;90(4):589-95.
DMDBX5F	RU	https://pubmed.ncbi.nlm.nih.gov/18755283

DMDBX5F	DI	DMDBX5F
DMDBX5F	DN	Ivermectin
DMDBX5F	MI	DTUGYRD
DMDBX5F	MN	P-glycoprotein 1 (ABCB1)
DMDBX5F	MT	DTP
DMDBX5F	MA	Substrate
DMDBX5F	RN	MDR1-deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin. Eur J Pharmacol. 2003 Jan 24;460(2-3):85-91.
DMDBX5F	RU	http://www.ncbi.nlm.nih.gov/pubmed/12559367

DM8S6T7	DI	DM8S6T7
DM8S6T7	DN	Ivosidenib
DM8S6T7	MI	TTV2A1R
DM8S6T7	MN	Oxalosuccinate decarboxylase (IDH1)
DM8S6T7	MT	DTT
DM8S6T7	MA	Inhibitor
DM8S6T7	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DM8S6T7	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMRVITQ	DI	DMRVITQ
DMRVITQ	DN	Ivosidenib
DMRVITQ	MI	DTUGYRD
DMRVITQ	MN	P-glycoprotein 1 (ABCB1)
DMRVITQ	MT	DTP
DMRVITQ	MA	Substrate
DMRVITQ	RN	DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB14568)
DMRVITQ	RU	https://www.drugbank.ca/drugs/DB14568

DM2OZ3G	DI	DM2OZ3G
DM2OZ3G	DN	Ixabepilone
DM2OZ3G	MI	DE4LYSA
DM2OZ3G	MN	Cytochrome P450 3A4 (CYP3A4)
DM2OZ3G	MT	DME
DM2OZ3G	MA	Metabolism
DM2OZ3G	RN	The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development. Clin Cancer Res. 2008 May 1;14(9):2701-9.
DM2OZ3G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18451235

DM2OZ3G	DI	DM2OZ3G
DM2OZ3G	DN	Ixabepilone
DM2OZ3G	MI	DTUGYRD
DM2OZ3G	MN	P-glycoprotein 1 (ABCB1)
DM2OZ3G	MT	DTP
DM2OZ3G	MA	Substrate
DM2OZ3G	RN	Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2011 May;337(2):423-32.
DM2OZ3G	RU	http://www.ncbi.nlm.nih.gov/pubmed/21262849

DM2OZ3G	DI	DM2OZ3G
DM2OZ3G	DN	Ixabepilone
DM2OZ3G	MI	TTML2WA
DM2OZ3G	MN	Tubulin (TUB)
DM2OZ3G	MT	DTT
DM2OZ3G	MA	Stablizer
DM2OZ3G	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DM2OZ3G	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DMXW92T	DI	DMXW92T
DMXW92T	DN	Ixekizumab
DMXW92T	MI	TTG0MT6
DMXW92T	MN	Interleukin-17 (IL17)
DMXW92T	MT	DTT
DMXW92T	MA	Modulator
DMXW92T	RN	Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal. Br J Dermatol. 2012 Oct;167(4):710-3; discussion 714-5.
DMXW92T	RU	https://pubmed.ncbi.nlm.nih.gov/23013312

DMKJ8LB	DI	DMKJ8LB
DMKJ8LB	DN	Josamycin
DMKJ8LB	MI	TTUWYEA
DMKJ8LB	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DMKJ8LB	MT	DTT
DMKJ8LB	MA	Binder
DMKJ8LB	RN	The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome. J Mol Biol. 2003 Jul 25;330(5):1005-14.
DMKJ8LB	RU	https://pubmed.ncbi.nlm.nih.gov/12860123

DMITFB8	DI	DMITFB8
DMITFB8	DN	Kanamycin
DMITFB8	MI	DEWPAJD
DMITFB8	MN	Aminoglycoside O-phosphotransferase (aphA6)
DMITFB8	MT	DME
DMITFB8	MA	Metabolism
DMITFB8	RN	Relationship between antimicrobial resistance and aminoglycoside-modifying enzyme gene expressions in Acinetobacter baumannii. Chin Med J (Engl). 2005 Jan 20;118(2):141-5.
DMITFB8	RU	https://pubmed.ncbi.nlm.nih.gov/15667800

DMITFB8	DI	DMITFB8
DMITFB8	DN	Kanamycin
DMITFB8	MI	DE5WGIM
DMITFB8	MN	Aminoglycoside phosphotransferase (aph-Ib)
DMITFB8	MT	DME
DMITFB8	MA	Metabolism
DMITFB8	RN	Cloning and expression of novel aminoglycoside phosphotransferase genes from Campylobacter and their role in the resistance to six aminoglycosides. Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01682-17.
DMITFB8	RU	https://pubmed.ncbi.nlm.nih.gov/29109167

DMITFB8	DI	DMITFB8
DMITFB8	DN	Kanamycin
DMITFB8	MI	DE2M583
DMITFB8	MN	Endoglucanase Y (EGY)
DMITFB8	MT	DME
DMITFB8	MA	Metabolism
DMITFB8	RN	Expression of Clostridium thermocellum endoglucanase gene in Lactobacillus gasseri and Lactobacillus johnsonii and characterization of the genetically modified probiotic lactobacilli. Curr Microbiol. 2000 Apr;40(4):257-63.
DMITFB8	RU	https://pubmed.ncbi.nlm.nih.gov/10688695

DMITFB8	DI	DMITFB8
DMITFB8	DN	Kanamycin
DMITFB8	MI	DE2AZTG
DMITFB8	MN	Endoglucanase Y (EGY)
DMITFB8	MT	DME
DMITFB8	MA	Metabolism
DMITFB8	RN	Expression of Clostridium thermocellum endoglucanase gene in Lactobacillus gasseri and Lactobacillus johnsonii and characterization of the genetically modified probiotic lactobacilli. Curr Microbiol. 2000 Apr;40(4):257-63.
DMITFB8	RU	https://pubmed.ncbi.nlm.nih.gov/10688695

DMITFB8	DI	DMITFB8
DMITFB8	DN	Kanamycin
DMITFB8	MI	DECXWN8
DMITFB8	MN	Kanamycin/gentamycin-resistance enzyme (aacA)
DMITFB8	MT	DME
DMITFB8	MA	Metabolism
DMITFB8	RN	Cloning and expression of novel aminoglycoside phosphotransferase genes from Campylobacter and their role in the resistance to six aminoglycosides. Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01682-17.
DMITFB8	RU	https://pubmed.ncbi.nlm.nih.gov/29109167

DM2DMPO	DI	DM2DMPO
DM2DMPO	DN	Kanamycin
DM2DMPO	MI	TTQ8KVI
DM2DMPO	MN	Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)
DM2DMPO	MT	DTT
DM2DMPO	MA	Binder
DM2DMPO	RN	SsrA-mediated protein tagging in the presence of miscoding drugs and its physiological role in Escherichia coli. Genes Cells. 2002 Jul;7(7):629-38.
DM2DMPO	RU	https://pubmed.ncbi.nlm.nih.gov/12081641

DMT5HA4	DI	DMT5HA4
DMT5HA4	DN	Ketamine
DMT5HA4	MI	DEPKLMQ
DMT5HA4	MN	Cytochrome P450 2B6 (CYP2B6)
DMT5HA4	MT	DME
DMT5HA4	MA	Metabolism
DMT5HA4	RN	Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos. 2002 Jul;30(7):853-8.
DMT5HA4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12065445

DMT5HA4	DI	DMT5HA4
DMT5HA4	DN	Ketamine
DMT5HA4	MI	DE5IED8
DMT5HA4	MN	Cytochrome P450 2C9 (CYP2C9)
DMT5HA4	MT	DME
DMT5HA4	MA	Metabolism
DMT5HA4	RN	Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos. 2002 Jul;30(7):853-8.
DMT5HA4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12065445

DMT5HA4	DI	DMT5HA4
DMT5HA4	DN	Ketamine
DMT5HA4	MI	DE4LYSA
DMT5HA4	MN	Cytochrome P450 3A4 (CYP3A4)
DMT5HA4	MT	DME
DMT5HA4	MA	Metabolism
DMT5HA4	RN	Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos. 2002 Jul;30(7):853-8.
DMT5HA4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12065445

DMT5HA4	DI	DMT5HA4
DMT5HA4	DN	Ketamine
DMT5HA4	MI	TT9IK2Z
DMT5HA4	MN	N-methyl-D-aspartate receptor (NMDAR)
DMT5HA4	MT	DTT
DMT5HA4	MA	Antagonist
DMT5HA4	RN	Ketamine modulates theta and gamma oscillations. J Cogn Neurosci. 2010 Jul;22(7):1452-64.
DMT5HA4	RU	https://pubmed.ncbi.nlm.nih.gov/19583475

DMVLMW6	DI	DMVLMW6
DMVLMW6	DN	Ketanserin
DMVLMW6	MI	TTYSN63
DMVLMW6	MN	5-HT 2 receptor (5HT2R)
DMVLMW6	MT	DTT
DMVLMW6	MA	Antagonist
DMVLMW6	RN	Nordexfenfluramine causes more severe pulmonary vasoconstriction than dexfenfluramine. Am J Physiol Lung Cell Mol Physiol. 2004 Mar;286(3):L531-8.
DMVLMW6	RU	https://pubmed.ncbi.nlm.nih.gov/14607779

DMM3L6Z	DI	DMM3L6Z
DMM3L6Z	DN	Ketobemidone
DMM3L6Z	MI	DEPKLMQ
DMM3L6Z	MN	Cytochrome P450 2B6 (CYP2B6)
DMM3L6Z	MT	DME
DMM3L6Z	MA	Metabolism
DMM3L6Z	RN	Ketobemidone is a substrate for cytochrome P4502C9 and 3A4, but not for P-glycoprotein. Xenobiotica. 2005 Aug;35(8):785-96.
DMM3L6Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16278191

DMM3L6Z	DI	DMM3L6Z
DMM3L6Z	DN	Ketobemidone
DMM3L6Z	MI	DES5XRU
DMM3L6Z	MN	Cytochrome P450 2C8 (CYP2C8)
DMM3L6Z	MT	DME
DMM3L6Z	MA	Metabolism
DMM3L6Z	RN	Ketobemidone is a substrate for cytochrome P4502C9 and 3A4, but not for P-glycoprotein. Xenobiotica. 2005 Aug;35(8):785-96.
DMM3L6Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16278191

DMM3L6Z	DI	DMM3L6Z
DMM3L6Z	DN	Ketobemidone
DMM3L6Z	MI	DE5IED8
DMM3L6Z	MN	Cytochrome P450 2C9 (CYP2C9)
DMM3L6Z	MT	DME
DMM3L6Z	MA	Metabolism
DMM3L6Z	RN	Ketobemidone is a substrate for cytochrome P4502C9 and 3A4, but not for P-glycoprotein. Xenobiotica. 2005 Aug;35(8):785-96.
DMM3L6Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16278191

DMM3L6Z	DI	DMM3L6Z
DMM3L6Z	DN	Ketobemidone
DMM3L6Z	MI	DE4LYSA
DMM3L6Z	MN	Cytochrome P450 3A4 (CYP3A4)
DMM3L6Z	MT	DME
DMM3L6Z	MA	Metabolism
DMM3L6Z	RN	Ketobemidone is a substrate for cytochrome P4502C9 and 3A4, but not for P-glycoprotein. Xenobiotica. 2005 Aug;35(8):785-96.
DMM3L6Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16278191

DMM3L6Z	DI	DMM3L6Z
DMM3L6Z	DN	Ketobemidone
DMM3L6Z	MI	DEGTFWK
DMM3L6Z	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMM3L6Z	MT	DME
DMM3L6Z	MA	Metabolism
DMM3L6Z	RN	Ketobemidone is a substrate for cytochrome P4502C9 and 3A4, but not for P-glycoprotein. Xenobiotica. 2005 Aug;35(8):785-96.
DMM3L6Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16278191

DMM3L6Z	DI	DMM3L6Z
DMM3L6Z	DN	Ketobemidone
DMM3L6Z	MI	TTN4QDT
DMM3L6Z	MN	Opioid receptor (OPR)
DMM3L6Z	MT	DTT
DMM3L6Z	MA	Modulator
DMM3L6Z	RN	The mu1 and mu2 opioid receptor binding of ketobemidone, norketobemidone and 3-dimethylamino-1,1-diphenylbutene. Pharmacol Toxicol. 1996 Aug;79(2):103-4.
DMM3L6Z	RU	https://pubmed.ncbi.nlm.nih.gov/8878254

DMM3L6Z	DI	DMM3L6Z
DMM3L6Z	DN	Ketobemidone
DMM3L6Z	MI	DE073H6
DMM3L6Z	MN	Prostaglandin G/H synthase 1 (COX-1)
DMM3L6Z	MT	DME
DMM3L6Z	MA	Metabolism
DMM3L6Z	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMM3L6Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMM3L6Z	DI	DMM3L6Z
DMM3L6Z	DN	Ketobemidone
DMM3L6Z	MI	DE85D2P
DMM3L6Z	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMM3L6Z	MT	DME
DMM3L6Z	MA	Metabolism
DMM3L6Z	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMM3L6Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMPZI3Q	DI	DMPZI3Q
DMPZI3Q	DN	Ketoconazole
DMPZI3Q	MI	TTTSOUD
DMPZI3Q	MN	Candida Cytochrome P450 51 (Candi ERG11)
DMPZI3Q	MT	DTT
DMPZI3Q	MA	Inhibitor
DMPZI3Q	RN	Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet. 2009;48(5):281-302. 
DMPZI3Q	RU	https://pubmed.ncbi.nlm.nih.gov/19566112

DMPZI3Q	DI	DMPZI3Q
DMPZI3Q	DN	Ketoconazole
DMPZI3Q	MI	DE4LYSA
DMPZI3Q	MN	Cytochrome P450 3A4 (CYP3A4)
DMPZI3Q	MT	DME
DMPZI3Q	MA	Metabolism
DMPZI3Q	RN	The metabolism of amiodarone by various CYP isoenzymes of human and rat, and the inhibitory influence of ketoconazole. J Pharm Pharm Sci. 2008;11(1):147-59.
DMPZI3Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18445370

DMPZI3Q	DI	DMPZI3Q
DMPZI3Q	DN	Ketoconazole
DMPZI3Q	MI	DTUGYRD
DMPZI3Q	MN	P-glycoprotein 1 (ABCB1)
DMPZI3Q	MT	DTP
DMPZI3Q	MA	Substrate
DMPZI3Q	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMPZI3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMRKXPT	DI	DMRKXPT
DMRKXPT	DN	Ketoprofen
DMRKXPT	MI	DE5IED8
DMRKXPT	MN	Cytochrome P450 2C9 (CYP2C9)
DMRKXPT	MT	DME
DMRKXPT	MA	Metabolism
DMRKXPT	RN	Clinical pharmacokinetics of ketoprofen enantiomers in wild type of Cyp 2c8 and Cyp 2c9 patients with rheumatoid arthritis. Eur J Drug Metab Pharmacokinet. 2011 Sep;36(3):167-73.
DMRKXPT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21516380

DMRKXPT	DI	DMRKXPT
DMRKXPT	DN	Ketoprofen
DMRKXPT	MI	TTVKILB
DMRKXPT	MN	Prostaglandin G/H synthase 2 (COX-2)
DMRKXPT	MT	DTT
DMRKXPT	MA	Inhibitor
DMRKXPT	RN	Probing the skin permeation of fish oil/EPA and ketoprofen-3. Effects on epidermal COX-2 and LOX. Prostaglandins Leukot Essent Fatty Acids. 2007 Jun;76(6):357-62.
DMRKXPT	RU	https://pubmed.ncbi.nlm.nih.gov/17588732

DMRKXPT	DI	DMRKXPT
DMRKXPT	DN	Ketoprofen
DMRKXPT	MI	DEYGVN4
DMRKXPT	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMRKXPT	MT	DME
DMRKXPT	MA	Metabolism
DMRKXPT	RN	Association between the UGT1A1*28 allele and hyperbilirubinemia in HIV-positive patients receiving atazanavir: a meta-analysis. Biosci Rep. 2019 May 2;39(5). pii: BSR20182105.
DMRKXPT	RU	https://www.ncbi.nlm.nih.gov/pubmed/30962262

DMI4EL5	DI	DMI4EL5
DMI4EL5	DN	Ketorolac
DMI4EL5	MI	DES5XRU
DMI4EL5	MN	Cytochrome P450 2C8 (CYP2C8)
DMI4EL5	MT	DME
DMI4EL5	MA	Metabolism
DMI4EL5	RN	Body weight, gender and pregnancy affect enantiomer-specific ketorolac pharmacokinetics. Br J Clin Pharmacol. 2017 Sep;83(9):1966-1975.
DMI4EL5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28429492

DMI4EL5	DI	DMI4EL5
DMI4EL5	DN	Ketorolac
DMI4EL5	MI	TTK0943
DMI4EL5	MN	Prostaglandin G/H synthase (COX)
DMI4EL5	MT	DTT
DMI4EL5	MA	Inhibitor
DMI4EL5	RN	Cyclooxygenase and nitric oxide synthase dependence of cutaneous reactive hyperemia in humans. Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H425-32.
DMI4EL5	RU	https://pubmed.ncbi.nlm.nih.gov/17369458

DMI4EL5	DI	DMI4EL5
DMI4EL5	DN	Ketorolac
DMI4EL5	MI	DEB3CV1
DMI4EL5	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMI4EL5	MT	DME
DMI4EL5	MA	Metabolism
DMI4EL5	RN	Body weight, gender and pregnancy affect enantiomer-specific ketorolac pharmacokinetics. Br J Clin Pharmacol. 2017 Sep;83(9):1966-1975.
DMI4EL5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28429492

DMOVY05	DI	DMOVY05
DMOVY05	DN	Ketotifen
DMOVY05	MI	TTTIBOJ
DMOVY05	MN	Histamine H1 receptor (H1R)
DMOVY05	MT	DTT
DMOVY05	MA	Antagonist
DMOVY05	RN	Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79.
DMOVY05	RU	https://pubmed.ncbi.nlm.nih.gov/18446005

DM74XKS	DI	DM74XKS
DM74XKS	DN	Ketotifen
DM74XKS	MI	DE1LZID
DM74XKS	MN	Short-chain dehydrogenase/reductase SDR19C1 (DHRS1)
DM74XKS	MT	DME
DM74XKS	MA	Metabolism
DM74XKS	RN	Initial characterization of human DHRS1 (SDR19C1), a member of the short-chain dehydrogenase/reductase superfamily. J Steroid Biochem Mol Biol. 2019 Jan;185:80-89.
DM74XKS	RU	https://pubmed.ncbi.nlm.nih.gov/30031147

DM0KAE6	DI	DM0KAE6
DM0KAE6	DN	Kombiglyze XR/Komboglyze FDC
DM0KAE6	MI	TTDIGC1
DM0KAE6	MN	Dipeptidyl peptidase 4 (DPP-4)
DM0KAE6	MT	DTT
DM0KAE6	MA	Modulator
DM0KAE6	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1612).
DM0KAE6	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1612

DMSA4HZ	DI	DMSA4HZ
DMSA4HZ	DN	KU-0058948
DMSA4HZ	MI	TTVDSZ0
DMSA4HZ	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMSA4HZ	MT	DTT
DMSA4HZ	MA	Inhibitor
DMSA4HZ	RN	Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3. J Med Chem. 2009 May 14;52(9):3108-11.
DMSA4HZ	RU	https://pubmed.ncbi.nlm.nih.gov/19354255

DMK8U72	DI	DMK8U72
DMK8U72	DN	Labetalol
DMK8U72	MI	TTG28O6
DMK8U72	MN	Adrenergic receptor Alpha-1 (ADRA1)
DMK8U72	MT	DTT
DMK8U72	MA	Antagonist
DMK8U72	RN	Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8.
DMK8U72	RU	https://pubmed.ncbi.nlm.nih.gov/19491545

DMK8U72	DI	DMK8U72
DMK8U72	DN	Labetalol
DMK8U72	MI	DECB0K3
DMK8U72	MN	Cytochrome P450 2D6 (CYP2D6)
DMK8U72	MT	DME
DMK8U72	MA	Metabolism
DMK8U72	RN	Comparison of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imipramine. J Clin Pharmacol. 1992 Feb;32(2):176-83.
DMK8U72	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1613128

DMK8U72	DI	DMK8U72
DMK8U72	DN	Labetalol
DMK8U72	MI	DEGTFWK
DMK8U72	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMK8U72	MT	DME
DMK8U72	MA	Metabolism
DMK8U72	RN	Drug Interactions Flockhart Table
DMK8U72	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMK8U72	DI	DMK8U72
DMK8U72	DN	Labetalol
DMK8U72	MI	DTE2B1D
DMK8U72	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMK8U72	MT	DTP
DMK8U72	MA	Substrate
DMK8U72	RN	Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. J Pharm Sci. 2009 Jul;98(7):2529-39.
DMK8U72	RU	http://www.ncbi.nlm.nih.gov/pubmed/19067419

DMK8U72	DI	DMK8U72
DMK8U72	DN	Labetalol
DMK8U72	MI	DTUGYRD
DMK8U72	MN	P-glycoprotein 1 (ABCB1)
DMK8U72	MT	DTP
DMK8U72	MA	Substrate
DMK8U72	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMK8U72	RU	https://doi.org/10.1007/s11095-012-0935-x

DMK8U72	DI	DMK8U72
DMK8U72	DN	Labetalol
DMK8U72	MI	DEYGVN4
DMK8U72	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMK8U72	MT	DME
DMK8U72	MA	Metabolism
DMK8U72	RN	Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination. Xenobiotica. 2008 Jan;38(1):62-75.
DMK8U72	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18098064

DMK8U72	DI	DMK8U72
DMK8U72	DN	Labetalol
DMK8U72	MI	DE85D2P
DMK8U72	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMK8U72	MT	DME
DMK8U72	MA	Metabolism
DMK8U72	RN	Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination. Xenobiotica. 2008 Jan;38(1):62-75.
DMK8U72	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18098064

DMK8U72	DI	DMK8U72
DMK8U72	DN	Labetalol
DMK8U72	MI	DENUPDX
DMK8U72	MN	UDP-glucuronosyltransferase 2B4 (UGT2B4)
DMK8U72	MT	DME
DMK8U72	MA	Metabolism
DMK8U72	RN	Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination. Xenobiotica. 2008 Jan;38(1):62-75.
DMK8U72	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18098064

DMK8U72	DI	DMK8U72
DMK8U72	DN	Labetalol
DMK8U72	MI	DEB3CV1
DMK8U72	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMK8U72	MT	DME
DMK8U72	MA	Metabolism
DMK8U72	RN	Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination. Xenobiotica. 2008 Jan;38(1):62-75.
DMK8U72	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18098064

DMVM6QR	DI	DMVM6QR
DMVM6QR	DN	Lacosamide
DMVM6QR	MI	DE5IED8
DMVM6QR	MN	Cytochrome P450 2C9 (CYP2C9)
DMVM6QR	MT	DME
DMVM6QR	MA	Metabolism
DMVM6QR	RN	Lacosamide: what can be expected from the next new antiepileptic drug? Epilepsy Curr. 2009 Sep-Oct;9(5):133-4.
DMVM6QR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19826503

DMVM6QR	DI	DMVM6QR
DMVM6QR	DN	Lacosamide
DMVM6QR	MI	TTZCW3T
DMVM6QR	MN	Dihydropyrimidinase related protein 2 (DPYSL2)
DMVM6QR	MT	DTT
DMVM6QR	MA	Modulator
DMVM6QR	RN	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
DMVM6QR	RU	https://pubmed.ncbi.nlm.nih.gov/19180096

DMVM6QR	DI	DMVM6QR
DMVM6QR	DN	Lacosamide
DMVM6QR	MI	DEGTFWK
DMVM6QR	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMVM6QR	MT	DME
DMVM6QR	MA	Metabolism
DMVM6QR	RN	Lacosamide therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. Ther Drug Monit. 2013 Dec;35(6):849-52.
DMVM6QR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23942540

DMVM6QR	DI	DMVM6QR
DMVM6QR	DN	Lacosamide
DMVM6QR	MI	TTIG65Q
DMVM6QR	MN	Voltage-gated sodium channel (Nav)
DMVM6QR	MT	DTT
DMVM6QR	MA	Inhibitor
DMVM6QR	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMVM6QR	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMVM6QR	DI	DMVM6QR
DMVM6QR	DN	Lacosamide
DMVM6QR	MI	TTN9VTF
DMVM6QR	MN	Voltage-gated sodium channel alpha Nav1.9 (SCN11A)
DMVM6QR	MT	DTT
DMVM6QR	MA	Inhibitor
DMVM6QR	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMVM6QR	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMA7QTC	DI	DMA7QTC
DMA7QTC	DN	Lactoferrin
DMA7QTC	MI	TTM1TDX
DMA7QTC	MN	Tryptase alpha/beta-1 (Tryptase)
DMA7QTC	MT	DTT
DMA7QTC	MA	Inhibitor
DMA7QTC	RN	Inhibitors of tryptase for the treatment of mast cell-mediated diseases. Curr Pharm Des. 1998 Oct;4(5):381-96.
DMA7QTC	RU	https://pubmed.ncbi.nlm.nih.gov/10197050

DMV7OPN	DI	DMV7OPN
DMV7OPN	DN	Lactulose
DMV7OPN	MI	DEIEY19
DMV7OPN	MN	Beta-galactosidase (bgaB)
DMV7OPN	MT	DME
DMV7OPN	MA	Metabolism
DMV7OPN	RN	In vitro fermentation of lactulose by human gut bacteria. J Agric Food Chem. 2014 Nov 12;62(45):10970-7.
DMV7OPN	RU	https://pubmed.ncbi.nlm.nih.gov/25340538

DMV7OPN	DI	DMV7OPN
DMV7OPN	DN	Lactulose
DMV7OPN	MI	DE235K6
DMV7OPN	MN	Beta-glucosidase (bglA)
DMV7OPN	MT	DME
DMV7OPN	MA	Metabolism
DMV7OPN	RN	In vitro fermentation of lactulose by human gut bacteria. J Agric Food Chem. 2014 Nov 12;62(45):10970-7.
DMV7OPN	RU	https://pubmed.ncbi.nlm.nih.gov/25340538

DMV7OPN	DI	DMV7OPN
DMV7OPN	DN	Lactulose
DMV7OPN	MI	DEPB9C2
DMV7OPN	MN	Glycosyl hydrolase (glyH)
DMV7OPN	MT	DME
DMV7OPN	MA	Metabolism
DMV7OPN	RN	In vitro fermentation of lactulose by human gut bacteria. J Agric Food Chem. 2014 Nov 12;62(45):10970-7.
DMV7OPN	RU	https://pubmed.ncbi.nlm.nih.gov/25340538

DMZDN4W	DI	DMZDN4W
DMZDN4W	DN	L-alanine
DMZDN4W	MI	DTC54PX
DMZDN4W	MN	Alanine/serine/cysteine/threonine transporter 1 (SLC1A4)
DMZDN4W	MT	DTP
DMZDN4W	MA	Substrate
DMZDN4W	RN	D-Serine Is a Substrate for Neutral Amino Acid Transporters ASCT1/SLC1A4 and ASCT2/SLC1A5, and Is Transported by Both Subtypes in Rat Hippocampal Astrocyte Cultures. PLoS One. 2016 Jun 7;11(6):e0156551.
DMZDN4W	RU	http://www.ncbi.nlm.nih.gov/pubmed/27272177

DMZDN4W	DI	DMZDN4W
DMZDN4W	DN	L-alanine
DMZDN4W	MI	TTT2LD9
DMZDN4W	MN	GABA transaminase (ABAT)
DMZDN4W	MT	DTT
DMZDN4W	MA	Inhibitor
DMZDN4W	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DMZDN4W	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DMZDN4W	DI	DMZDN4W
DMZDN4W	DN	L-alanine
DMZDN4W	MI	DTJF3DX
DMZDN4W	MN	L-type amino acid transporter 2 (SLC7A8)
DMZDN4W	MT	DTP
DMZDN4W	MA	Substrate
DMZDN4W	RN	The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.3.8.20)
DMZDN4W	RU	http://www.tcdb.org/search/result.php?tc=2.A.3.8.20

DMZDN4W	DI	DMZDN4W
DMZDN4W	DN	L-alanine
DMZDN4W	MI	DTD815L
DMZDN4W	MN	Sodium-coupled neutral amino acid transporter 1 (SLC38A1)
DMZDN4W	MT	DTP
DMZDN4W	MA	Substrate
DMZDN4W	RN	Identification of SLC38A7 (SNAT7) protein as a glutamine transporter expressed in neurons. J Biol Chem. 2011 Jun 10;286(23):20500-11.
DMZDN4W	RU	http://www.ncbi.nlm.nih.gov/pubmed/21511949

DMZDN4W	DI	DMZDN4W
DMZDN4W	DN	L-alanine
DMZDN4W	MI	DTTWL58
DMZDN4W	MN	Sodium-coupled neutral amino acid transporter 2 (SLC38A2)
DMZDN4W	MT	DTP
DMZDN4W	MA	Substrate
DMZDN4W	RN	Identification of SLC38A7 (SNAT7) protein as a glutamine transporter expressed in neurons. J Biol Chem. 2011 Jun 10;286(23):20500-11.
DMZDN4W	RU	http://www.ncbi.nlm.nih.gov/pubmed/21511949

DMZDN4W	DI	DMZDN4W
DMZDN4W	DN	L-alanine
DMZDN4W	MI	DTKWJH3
DMZDN4W	MN	Sodium-coupled neutral amino acid transporter 3 (SLC38A3)
DMZDN4W	MT	DTP
DMZDN4W	MA	Substrate
DMZDN4W	RN	Identification of SLC38A7 (SNAT7) protein as a glutamine transporter expressed in neurons. J Biol Chem. 2011 Jun 10;286(23):20500-11.
DMZDN4W	RU	http://www.ncbi.nlm.nih.gov/pubmed/21511949

DMZDN4W	DI	DMZDN4W
DMZDN4W	DN	L-alanine
DMZDN4W	MI	DTPJBD5
DMZDN4W	MN	Sodium-coupled neutral amino acid transporter 4 (SLC38A4)
DMZDN4W	MT	DTP
DMZDN4W	MA	Substrate
DMZDN4W	RN	Identification of SLC38A7 (SNAT7) protein as a glutamine transporter expressed in neurons. J Biol Chem. 2011 Jun 10;286(23):20500-11.
DMZDN4W	RU	http://www.ncbi.nlm.nih.gov/pubmed/21511949

DMZDN4W	DI	DMZDN4W
DMZDN4W	DN	L-alanine
DMZDN4W	MI	DTLX28N
DMZDN4W	MN	Sodium-coupled neutral amino acid transporter 5 (SLC38A5)
DMZDN4W	MT	DTP
DMZDN4W	MA	Substrate
DMZDN4W	RN	Identification of SLC38A7 (SNAT7) protein as a glutamine transporter expressed in neurons. J Biol Chem. 2011 Jun 10;286(23):20500-11.
DMZDN4W	RU	http://www.ncbi.nlm.nih.gov/pubmed/21511949

DMANBR7	DI	DMANBR7
DMANBR7	DN	L-alanyl-l-glutamine
DMANBR7	MI	TTI7S12
DMANBR7	MN	Glutamine receptor (GluR)
DMANBR7	MT	DTT
DMANBR7	MA	Modulator
DMANBR7	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMANBR7	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DMI347A	DI	DMI347A
DMI347A	DN	Lamivudine
DMI347A	MI	DTI7UX6
DMI347A	MN	Breast cancer resistance protein (ABCG2)
DMI347A	MT	DTP
DMI347A	MA	Substrate
DMI347A	RN	The effect of ABCG2 V12M, Q141K and Q126X, known functional variants in vitro, on the disposition of lamivudine. Br J Clin Pharmacol. 2007 Nov;64(5):645-54.
DMI347A	RU	http://www.ncbi.nlm.nih.gov/pubmed/17509035

DMI347A	DI	DMI347A
DMI347A	DN	Lamivudine
DMI347A	MI	DE4E31Z
DMI347A	MN	Deoxy-5'-nucleotidase 1 (NT5C)
DMI347A	MT	DME
DMI347A	MA	Metabolism
DMI347A	RN	Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. Antiviral Res. 2010 Jan;85(1):39-58.
DMI347A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19887088

DMI347A	DI	DMI347A
DMI347A	DN	Lamivudine
DMI347A	MI	TT84ETX
DMI347A	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMI347A	MT	DTT
DMI347A	MA	Modulator
DMI347A	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMI347A	RU	https://www.fda.gov/

DMI347A	DI	DMI347A
DMI347A	DN	Lamivudine
DMI347A	MI	DTT79CX
DMI347A	MN	Organic cation transporter 1 (SLC22A1)
DMI347A	MT	DTP
DMI347A	MA	Substrate
DMI347A	RN	Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection. Drug Metab Dispos. 2008 Aug;36(8):1616-23.
DMI347A	RU	http://www.ncbi.nlm.nih.gov/pubmed/18490433

DMI347A	DI	DMI347A
DMI347A	DN	Lamivudine
DMI347A	MI	DT9IDPW
DMI347A	MN	Organic cation transporter 2 (SLC22A2)
DMI347A	MT	DTP
DMI347A	MA	Substrate
DMI347A	RN	Genetic variants of organic cation transporter 1 (OCT1) and OCT2 significantly reduce lamivudine uptake. Biopharm Drug Dispos. 2012 Apr;33(3):170-8.
DMI347A	RU	http://www.ncbi.nlm.nih.gov/pubmed/22415520

DMI347A	DI	DMI347A
DMI347A	DN	Lamivudine
DMI347A	MI	DEQYXD4
DMI347A	MN	Phosphorylcholine transferase A (PCYT1A)
DMI347A	MT	DME
DMI347A	MA	Metabolism
DMI347A	RN	Model for intracellular Lamivudine metabolism in peripheral blood mononuclear cells ex vivo and in human immunodeficiency virus type 1-infected adolescents. Antimicrob Agents Chemother. 2006 Aug;50(8):2686-94.
DMI347A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16870759

DMI347A	DI	DMI347A
DMI347A	DN	Lamivudine
DMI347A	MI	DEIX1PO
DMI347A	MN	Phosphorylethanolamine transferase (PCYT2)
DMI347A	MT	DME
DMI347A	MA	Metabolism
DMI347A	RN	Model for intracellular Lamivudine metabolism in peripheral blood mononuclear cells ex vivo and in human immunodeficiency virus type 1-infected adolescents. Antimicrob Agents Chemother. 2006 Aug;50(8):2686-94.
DMI347A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16870759

DM8SXYG	DI	DM8SXYG
DM8SXYG	DN	Lamotrigine
DM8SXYG	MI	DTT79CX
DM8SXYG	MN	Organic cation transporter 1 (SLC22A1)
DM8SXYG	MT	DTP
DM8SXYG	MA	Substrate
DM8SXYG	RN	Lamotrigine is a substrate for OCT1 in brain endothelial cells. Biochem Pharmacol. 2012 Mar 15;83(6):805-14.
DM8SXYG	RU	https://doi.org/10.1016/j.bcp.2011.12.032

DM8SXYG	DI	DM8SXYG
DM8SXYG	DN	Lamotrigine
DM8SXYG	MI	DTUGYRD
DM8SXYG	MN	P-glycoprotein 1 (ABCB1)
DM8SXYG	MT	DTP
DM8SXYG	MA	Substrate
DM8SXYG	RN	Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology. 2008 Dec;55(8):1364-75.
DM8SXYG	RU	http://www.ncbi.nlm.nih.gov/pubmed/18824002

DM8SXYG	DI	DM8SXYG
DM8SXYG	DN	Lamotrigine
DM8SXYG	MI	DEYGVN4
DM8SXYG	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM8SXYG	MT	DME
DM8SXYG	MA	Metabolism
DM8SXYG	RN	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
DM8SXYG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429

DM8SXYG	DI	DM8SXYG
DM8SXYG	DN	Lamotrigine
DM8SXYG	MI	DEF2WXN
DM8SXYG	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DM8SXYG	MT	DME
DM8SXYG	MA	Metabolism
DM8SXYG	RN	Variation in glucuronidation of lamotrigine in human liver microsomes. Xenobiotica. 2009 May;39(5):355-63.
DM8SXYG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19387891

DM8SXYG	DI	DM8SXYG
DM8SXYG	DN	Lamotrigine
DM8SXYG	MI	DELOY3P
DM8SXYG	MN	UDP-glucuronosyltransferase 1A4 (UGT1A4)
DM8SXYG	MT	DME
DM8SXYG	MA	Metabolism
DM8SXYG	RN	Studies on induction of lamotrigine metabolism in transgenic UGT1 mice. Xenobiotica. 2009 Nov;39(11):826-35.
DM8SXYG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19845433

DM8SXYG	DI	DM8SXYG
DM8SXYG	DN	Lamotrigine
DM8SXYG	MI	TTN9VTF
DM8SXYG	MN	Voltage-gated sodium channel alpha Nav1.9 (SCN11A)
DM8SXYG	MT	DTT
DM8SXYG	MA	Blocker
DM8SXYG	RN	The effects of lamotrigine on the acquisition and expression of morphine-induced place preference in mice. Pak J Biol Sci. 2009 Jan 1;12(1):33-9.
DM8SXYG	RU	https://pubmed.ncbi.nlm.nih.gov/19579915

DMEH7YU	DI	DMEH7YU
DMEH7YU	DN	Lanadelumab
DMEH7YU	MI	TTMF8H9
DMEH7YU	MN	Plasma kallikrein (KLKB1)
DMEH7YU	MT	DTT
DMEH7YU	MA	Modulator
DMEH7YU	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMEH7YU	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMG6ZU4	DI	DMG6ZU4
DMG6ZU4	DN	Lanreotide acetate
DMG6ZU4	MI	TTZ6T9E
DMG6ZU4	MN	Somatostatin receptor type 2 (SSTR2)
DMG6ZU4	MT	DTT
DMG6ZU4	MA	Modulator
DMG6ZU4	RN	Treatment strategies for acromegaly. Expert Opin Emerg Drugs. 2005 Nov;10(4):875-90.
DMG6ZU4	RU	https://pubmed.ncbi.nlm.nih.gov/16262568

DMXYLQ3	DI	DMXYLQ3
DMXYLQ3	DN	Lansoprazole
DMXYLQ3	MI	DEZMWRE
DMXYLQ3	MN	Cytochrome P450 2C18 (CYP2C18)
DMXYLQ3	MT	DME
DMXYLQ3	MA	Metabolism
DMXYLQ3	RN	Oxidative metabolism of lansoprazole by human liver cytochromes P450. Mol Pharmacol. 1995 Feb;47(2):410-8.
DMXYLQ3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7870052

DMXYLQ3	DI	DMXYLQ3
DMXYLQ3	DN	Lansoprazole
DMXYLQ3	MI	DES5XRU
DMXYLQ3	MN	Cytochrome P450 2C8 (CYP2C8)
DMXYLQ3	MT	DME
DMXYLQ3	MA	Metabolism
DMXYLQ3	RN	Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther. 1996 May;277(2):805-16.
DMXYLQ3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8627562

DMXYLQ3	DI	DMXYLQ3
DMXYLQ3	DN	Lansoprazole
DMXYLQ3	MI	DE5IED8
DMXYLQ3	MN	Cytochrome P450 2C9 (CYP2C9)
DMXYLQ3	MT	DME
DMXYLQ3	MA	Metabolism
DMXYLQ3	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMXYLQ3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMXYLQ3	DI	DMXYLQ3
DMXYLQ3	DN	Lansoprazole
DMXYLQ3	MI	DE4LYSA
DMXYLQ3	MN	Cytochrome P450 3A4 (CYP3A4)
DMXYLQ3	MT	DME
DMXYLQ3	MA	Metabolism
DMXYLQ3	RN	An evaluation of the cytochrome P450 induction potential of pantoprazole in primary human hepatocytes. Chem Biol Interact. 1998 Jul 3;114(1-2):1-13.
DMXYLQ3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9744552

DMXYLQ3	DI	DMXYLQ3
DMXYLQ3	DN	Lansoprazole
DMXYLQ3	MI	DEGTFWK
DMXYLQ3	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMXYLQ3	MT	DME
DMXYLQ3	MA	Metabolism
DMXYLQ3	RN	Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. Br J Clin Pharmacol. 2005 Mar;59(3):302-9.
DMXYLQ3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15752376

DMMJQSH	DI	DMMJQSH
DMMJQSH	DN	Lanthanum carbonate
DMMJQSH	MI	TTHOTF6
DMMJQSH	MN	Phosphate (PHO)
DMMJQSH	MT	DTT
DMMJQSH	MA	Modulator
DMMJQSH	RN	2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4.
DMMJQSH	RU	https://pubmed.ncbi.nlm.nih.gov/15756752

DM3BH1Y	DI	DM3BH1Y
DM3BH1Y	DN	Lapatinib
DM3BH1Y	MI	DTI7UX6
DM3BH1Y	MN	Breast cancer resistance protein (ABCG2)
DM3BH1Y	MT	DTP
DM3BH1Y	MA	Substrate
DM3BH1Y	RN	The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos. 2008 Apr;36(4):695-701.
DM3BH1Y	RU	https://doi.org/10.1124/dmd.107.018374

DM3BH1Y	DI	DM3BH1Y
DM3BH1Y	DN	Lapatinib
DM3BH1Y	MI	DES5XRU
DM3BH1Y	MN	Cytochrome P450 2C8 (CYP2C8)
DM3BH1Y	MT	DME
DM3BH1Y	MA	Metabolism
DM3BH1Y	RN	Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. Mol Pharmacol. 2010 Oct;78(4):693-703.
DM3BH1Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20624855

DM3BH1Y	DI	DM3BH1Y
DM3BH1Y	DN	Lapatinib
DM3BH1Y	MI	DE4LYSA
DM3BH1Y	MN	Cytochrome P450 3A4 (CYP3A4)
DM3BH1Y	MT	DME
DM3BH1Y	MA	Metabolism
DM3BH1Y	RN	Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. Mol Pharmacol. 2010 Oct;78(4):693-703.
DM3BH1Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20624855

DM3BH1Y	DI	DM3BH1Y
DM3BH1Y	DN	Lapatinib
DM3BH1Y	MI	DEIBDNY
DM3BH1Y	MN	Cytochrome P450 3A5 (CYP3A5)
DM3BH1Y	MT	DME
DM3BH1Y	MA	Metabolism
DM3BH1Y	RN	Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
DM3BH1Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19733976

DM3BH1Y	DI	DM3BH1Y
DM3BH1Y	DN	Lapatinib
DM3BH1Y	MI	TTGKNB4
DM3BH1Y	MN	Epidermal growth factor receptor (EGFR)
DM3BH1Y	MT	DTT
DM3BH1Y	MA	Inhibitor
DM3BH1Y	RN	Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
DM3BH1Y	RU	https://pubmed.ncbi.nlm.nih.gov/19365520

DM3BH1Y	DI	DM3BH1Y
DM3BH1Y	DN	Lapatinib
DM3BH1Y	MI	TT6EO5L
DM3BH1Y	MN	Erbb2 tyrosine kinase receptor (HER2)
DM3BH1Y	MT	DTT
DM3BH1Y	MA	Inhibitor
DM3BH1Y	RN	Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
DM3BH1Y	RU	https://pubmed.ncbi.nlm.nih.gov/19365520

DM3BH1Y	DI	DM3BH1Y
DM3BH1Y	DN	Lapatinib
DM3BH1Y	MI	TT1QFLA
DM3BH1Y	MN	Eukaryotic elongation factor 2 kinase (eEF-2K)
DM3BH1Y	MT	DTT
DM3BH1Y	MA	Inhibitor
DM3BH1Y	RN	Inhibition of eEF-2 kinase sensitizes human nasopharyngeal carcinoma cells to lapatinib-induced apoptosis through the Src and Erk pathways.BMC Cancer. 2016 Oct 19;16(1):813.
DM3BH1Y	RU	https://pubmed.ncbi.nlm.nih.gov/27756261

DM3BH1Y	DI	DM3BH1Y
DM3BH1Y	DN	Lapatinib
DM3BH1Y	MI	DEGTFWK
DM3BH1Y	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM3BH1Y	MT	DME
DM3BH1Y	MA	Metabolism
DM3BH1Y	RN	Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
DM3BH1Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19733976

DM3BH1Y	DI	DM3BH1Y
DM3BH1Y	DN	Lapatinib
DM3BH1Y	MI	DTUGYRD
DM3BH1Y	MN	P-glycoprotein 1 (ABCB1)
DM3BH1Y	MT	DTP
DM3BH1Y	MA	Substrate
DM3BH1Y	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DM3BH1Y	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DM26CQR	DI	DM26CQR
DM26CQR	DN	Larotrectinib
DM26CQR	MI	TTKN7QR
DM26CQR	MN	BDNF/NT-3 growth factors receptor (TrkB)
DM26CQR	MT	DTT
DM26CQR	MA	Inhibitor
DM26CQR	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DM26CQR	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DM26CQR	DI	DM26CQR
DM26CQR	DN	Larotrectinib
DM26CQR	MI	TTXABCW
DM26CQR	MN	NT-3 growth factor receptor (TrkC)
DM26CQR	MT	DTT
DM26CQR	MA	Inhibitor
DM26CQR	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DM26CQR	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DM26CQR	DI	DM26CQR
DM26CQR	DN	Larotrectinib
DM26CQR	MI	TTTDVOJ
DM26CQR	MN	Tropomyosin-related kinase A (TrkA)
DM26CQR	MT	DTT
DM26CQR	MA	Inhibitor
DM26CQR	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DM26CQR	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMSQ1JV	DI	DMSQ1JV
DMSQ1JV	DN	LAS-34273
DMSQ1JV	MI	TTQ13Z5
DMSQ1JV	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMSQ1JV	MT	DTT
DMSQ1JV	MA	Antagonist
DMSQ1JV	RN	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
DMSQ1JV	RU	https://pubmed.ncbi.nlm.nih.gov/16634702

DMXLVDT	DI	DMXLVDT
DMXLVDT	DN	Lasmiditan
DMXLVDT	MI	TT0MI3F
DMXLVDT	MN	5-HT 1F receptor (HTR1F)
DMXLVDT	MT	DTT
DMXLVDT	MA	Agonist
DMXLVDT	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMXLVDT	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf

DMHA18P	DI	DMHA18P
DMHA18P	DN	Lasofoxifene
DMHA18P	MI	TTZAYWL
DMHA18P	MN	Estrogen receptor (ESR)
DMHA18P	MT	DTT
DMHA18P	MA	Modulator
DMHA18P	RN	Pfizer. Product Development Pipeline. March 31 2009.
DMHA18P	RU	http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf

DMHA18P	DI	DMHA18P
DMHA18P	DN	Lasofoxifene
DMHA18P	MI	TT57ID8
DMHA18P	MN	Respiratory syncytial virus protein F (RSV F)
DMHA18P	MT	DTT
DMHA18P	MA	Modulator
DMHA18P	RN	Prospects for the development of fusion inhibitors to treat human respiratory syncytial virus infection. Curr Opin Drug Discov Devel. 2009 Jul;12(4):479-87.
DMHA18P	RU	https://pubmed.ncbi.nlm.nih.gov/19562644

DMANL0D	DI	DMANL0D
DMANL0D	DN	Latamoxef
DMANL0D	MI	TT85JMW
DMANL0D	MN	Bacterial Penicillin binding protein 3 (Bact mrcA)
DMANL0D	MT	DTT
DMANL0D	MA	Binder
DMANL0D	RN	Clinical relevance of antibiotic-induced endotoxin release in patients undergoing hepatic resection. World J Surg. 1999 Jan;23(1):75-9.
DMANL0D	RU	https://pubmed.ncbi.nlm.nih.gov/9841767

DMANL0D	DI	DMANL0D
DMANL0D	DN	Latamoxef
DMANL0D	MI	DT8QKNP
DMANL0D	MN	Peptide transporter 2 (SLC15A2)
DMANL0D	MT	DTP
DMANL0D	MA	Substrate
DMANL0D	RN	Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60.
DMANL0D	RU	http://www.ncbi.nlm.nih.gov/pubmed/16597710

DMI5OXG	DI	DMI5OXG
DMI5OXG	DN	Latanoprost
DMI5OXG	MI	DT021JD
DMI5OXG	MN	Organic anion transporting polypeptide 2A1 (SLCO2A1)
DMI5OXG	MT	DTP
DMI5OXG	MA	Substrate
DMI5OXG	RN	The prostaglandin transporter OATP2A1 is expressed in human ocular tissues and transports the antiglaucoma prostanoid latanoprost. Invest Ophthalmol Vis Sci. 2010 May;51(5):2504-11.
DMI5OXG	RU	http://www.ncbi.nlm.nih.gov/pubmed/20019365

DMI5OXG	DI	DMI5OXG
DMI5OXG	DN	Latanoprost
DMI5OXG	MI	DTPFTEQ
DMI5OXG	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DMI5OXG	MT	DTP
DMI5OXG	MA	Substrate
DMI5OXG	RN	The prostaglandin transporter OATP2A1 is expressed in human ocular tissues and transports the antiglaucoma prostanoid latanoprost. Invest Ophthalmol Vis Sci. 2010 May;51(5):2504-11.
DMI5OXG	RU	http://www.ncbi.nlm.nih.gov/pubmed/20019365

DMI5OXG	DI	DMI5OXG
DMI5OXG	DN	Latanoprost
DMI5OXG	MI	TTT2ZAR
DMI5OXG	MN	Prostaglandin F2-alpha receptor (PTGFR)
DMI5OXG	MT	DTT
DMI5OXG	MA	Agonist
DMI5OXG	RN	PGF(2alpha) FP receptor contributes to brain damage following transient focal brain ischemia. Neurotox Res. 2009 Jan;15(1):62-70.
DMI5OXG	RU	https://pubmed.ncbi.nlm.nih.gov/19384589

DMLFX7K	DI	DMLFX7K
DMLFX7K	DN	LCZ696
DMLFX7K	MI	TT5TKPM
DMLFX7K	MN	Neutral endopeptidase (MME)
DMLFX7K	MT	DTT
DMLFX7K	MA	Modulator
DMLFX7K	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMLFX7K	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DME6G97	DI	DME6G97
DME6G97	DN	Lefamulin
DME6G97	MI	TTLFGBV
DME6G97	MN	Bacterial 23S ribosomal RNA (Bact 23S rRNA)
DME6G97	MT	DTT
DME6G97	MA	Inhibitor
DME6G97	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DME6G97	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211672s000,211673s000lbl.pdf

DME6G97	DI	DME6G97
DME6G97	DN	Lefamulin
DME6G97	MI	DE4LYSA
DME6G97	MN	Cytochrome P450 3A4 (CYP3A4)
DME6G97	MT	DME
DME6G97	MA	Metabolism
DME6G97	RN	Lefamulin: review of a promising novel pleuromutilin antibiotic. Pharmacotherapy. 2018 Sep;38(9):935-946.
DME6G97	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30019769

DMR8ONJ	DI	DMR8ONJ
DMR8ONJ	DN	Leflunomide
DMR8ONJ	MI	DTI7UX6
DMR8ONJ	MN	Breast cancer resistance protein (ABCG2)
DMR8ONJ	MT	DTP
DMR8ONJ	MA	Substrate
DMR8ONJ	RN	Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance. Ann Rheum Dis. 2009 Jul;68(7):1201-7.
DMR8ONJ	RU	http://www.ncbi.nlm.nih.gov/pubmed/18397960

DMR8ONJ	DI	DMR8ONJ
DMR8ONJ	DN	Leflunomide
DMR8ONJ	MI	DEJGDUW
DMR8ONJ	MN	Cytochrome P450 1A2 (CYP1A2)
DMR8ONJ	MT	DME
DMR8ONJ	MA	Metabolism
DMR8ONJ	RN	Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
DMR8ONJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19754423

DMR8ONJ	DI	DMR8ONJ
DMR8ONJ	DN	Leflunomide
DMR8ONJ	MI	DE5IED8
DMR8ONJ	MN	Cytochrome P450 2C9 (CYP2C9)
DMR8ONJ	MT	DME
DMR8ONJ	MA	Metabolism
DMR8ONJ	RN	Leflunomide-induced acute hepatitis. Dig Liver Dis. 2004 Jan;36(1):82-4.
DMR8ONJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14971821

DMR8ONJ	DI	DMR8ONJ
DMR8ONJ	DN	Leflunomide
DMR8ONJ	MI	DE4LYSA
DMR8ONJ	MN	Cytochrome P450 3A4 (CYP3A4)
DMR8ONJ	MT	DME
DMR8ONJ	MA	Metabolism
DMR8ONJ	RN	Prediction of drug-induced liver injury in HepG2 cells cultured with human liver microsomes. Chem Res Toxicol. 2015 May 18;28(5):872-85.
DMR8ONJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25860621

DMR8ONJ	DI	DMR8ONJ
DMR8ONJ	DN	Leflunomide
DMR8ONJ	MI	TT3PQ2Y
DMR8ONJ	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DMR8ONJ	MT	DTT
DMR8ONJ	MA	Inhibitor
DMR8ONJ	RN	Identification and characterization of potential new therapeutic targets in inflammatory and autoimmune diseases. Eur J Biochem. 1999 Dec;266(3):1184-91.
DMR8ONJ	RU	https://pubmed.ncbi.nlm.nih.gov/10583416

DM6Q7U4	DI	DM6Q7U4
DM6Q7U4	DN	Lenalidomide
DM6Q7U4	MI	DTUGYRD
DM6Q7U4	MN	P-glycoprotein 1 (ABCB1)
DM6Q7U4	MT	DTP
DM6Q7U4	MA	Substrate
DM6Q7U4	RN	DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB00480)
DM6Q7U4	RU	https://www.drugbank.ca/drugs/DB00480

DM6Q7U4	DI	DM6Q7U4
DM6Q7U4	DN	Lenalidomide
DM6Q7U4	MI	TTF8CQI
DM6Q7U4	MN	Tumor necrosis factor (TNF)
DM6Q7U4	MT	DTT
DM6Q7U4	MA	Inhibitor
DM6Q7U4	RN	Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007351.
DM6Q7U4	RU	https://pubmed.ncbi.nlm.nih.gov/19370685

DMB1IU4	DI	DMB1IU4
DMB1IU4	DN	Lenvatinib
DMB1IU4	MI	DTUGYRD
DMB1IU4	MN	P-glycoprotein 1 (ABCB1)
DMB1IU4	MT	DTP
DMB1IU4	MA	Substrate
DMB1IU4	RN	Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer. Sci Rep. 2019 Apr 1;9(1):5404.
DMB1IU4	RU	http://www.ncbi.nlm.nih.gov/pubmed/30931962

DMB1IU4	DI	DMB1IU4
DMB1IU4	DN	Lenvatinib
DMB1IU4	MI	TTUTJGQ
DMB1IU4	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMB1IU4	MT	DTT
DMB1IU4	MA	Inhibitor
DMB1IU4	RN	Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.
DMB1IU4	RU	https://pubmed.ncbi.nlm.nih.gov/18764727

DM1I3D5	DI	DM1I3D5
DM1I3D5	DN	Lepirudin
DM1I3D5	MI	TT6L509
DM1I3D5	MN	Coagulation factor IIa (F2)
DM1I3D5	MT	DTT
DM1I3D5	MA	Inhibitor
DM1I3D5	RN	Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis. Kidney Int Suppl. 1999 Nov;(72):S46-50.
DM1I3D5	RU	https://pubmed.ncbi.nlm.nih.gov/10560805

DMPWSEM	DI	DMPWSEM
DMPWSEM	DN	Lercanidipine
DMPWSEM	MI	DE4LYSA
DMPWSEM	MN	Cytochrome P450 3A4 (CYP3A4)
DMPWSEM	MT	DME
DMPWSEM	MA	Metabolism
DMPWSEM	RN	Lercanidipine in hypertension. Vasc Health Risk Manag. 2005;1(3):173-82.
DMPWSEM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17319103

DMPWSEM	DI	DMPWSEM
DMPWSEM	DN	Lercanidipine
DMPWSEM	MI	DEIBDNY
DMPWSEM	MN	Cytochrome P450 3A5 (CYP3A5)
DMPWSEM	MT	DME
DMPWSEM	MA	Metabolism
DMPWSEM	RN	Drug Interactions Flockhart Table
DMPWSEM	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMPWSEM	DI	DMPWSEM
DMPWSEM	DN	Lercanidipine
DMPWSEM	MI	DERD86B
DMPWSEM	MN	Cytochrome P450 3A7 (CYP3A7)
DMPWSEM	MT	DME
DMPWSEM	MA	Metabolism
DMPWSEM	RN	Drug Interactions Flockhart Table
DMPWSEM	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMPWSEM	DI	DMPWSEM
DMPWSEM	DN	Lercanidipine
DMPWSEM	MI	TTFK1JQ
DMPWSEM	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMPWSEM	MT	DTT
DMPWSEM	MA	Blocker
DMPWSEM	RN	Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine Expert Opin Drug Metab Toxicol. 2009 Aug;5(8):981-7.
DMPWSEM	RU	https://pubmed.ncbi.nlm.nih.gov/19619074

DMUR64T	DI	DMUR64T
DMUR64T	DN	Lesinurad
DMUR64T	MI	DE5IED8
DMUR64T	MN	Cytochrome P450 2C9 (CYP2C9)
DMUR64T	MT	DME
DMUR64T	MA	Metabolism
DMUR64T	RN	FDA Label of Lesinurad. The 2020 official website of the U.S. Food and Drug Administration.
DMUR64T	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207988lbl.pdf

DMUR64T	DI	DMUR64T
DMUR64T	DN	Lesinurad
DMUR64T	MI	TTA592U
DMUR64T	MN	Urate anion exchanger 1 (URAT1)
DMUR64T	MT	DTT
DMUR64T	MA	Modulator
DMUR64T	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1031).
DMUR64T	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1031

DMQ2AIJ	DI	DMQ2AIJ
DMQ2AIJ	DN	Lestaurtinib
DMQ2AIJ	MI	TTGJCWZ
DMQ2AIJ	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMQ2AIJ	MT	DTT
DMQ2AIJ	MA	Modulator
DMQ2AIJ	RN	Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with ... Blood. 2008 Jun 15;111(12):5663-71.
DMQ2AIJ	RU	https://pubmed.ncbi.nlm.nih.gov/17984313

DMH07Y3	DI	DMH07Y3
DMH07Y3	DN	Letrozole
DMH07Y3	MI	TTSZLWK
DMH07Y3	MN	Aromatase (CYP19A1)
DMH07Y3	MT	DTT
DMH07Y3	MA	Inhibitor
DMH07Y3	RN	Aromatase inhibitors--theoretical concept and present experiences in the treatment of endometriosis. Zentralbl Gynakol. 2003 Jul-Aug;125(7-8):247-51.
DMH07Y3	RU	https://pubmed.ncbi.nlm.nih.gov/14505258

DMH07Y3	DI	DMH07Y3
DMH07Y3	DN	Letrozole
DMH07Y3	MI	DEQX145
DMH07Y3	MN	Aromatase (CYP19A1)
DMH07Y3	MT	DME
DMH07Y3	MA	Metabolism
DMH07Y3	RN	Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients. Eur J Cancer. 1999 Feb;35(2):208-13.
DMH07Y3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10448261

DMH07Y3	DI	DMH07Y3
DMH07Y3	DN	Letrozole
DMH07Y3	MI	DEJVYAZ
DMH07Y3	MN	Cytochrome P450 2A6 (CYP2A6)
DMH07Y3	MT	DME
DMH07Y3	MA	Metabolism
DMH07Y3	RN	Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer. Breast Cancer Res Treat. 2018 Nov;172(2):371-379.
DMH07Y3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30094551

DMH07Y3	DI	DMH07Y3
DMH07Y3	DN	Letrozole
DMH07Y3	MI	DE4LYSA
DMH07Y3	MN	Cytochrome P450 3A4 (CYP3A4)
DMH07Y3	MT	DME
DMH07Y3	MA	Metabolism
DMH07Y3	RN	Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4'-methanol-bisbenzonitrile in vitro. Cancer Chemother Pharmacol. 2009 Oct;64(5):867-75.
DMH07Y3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19198839

DMUAZWG	DI	DMUAZWG
DMUAZWG	DN	Leucovorin
DMUAZWG	MI	DTFI42L
DMUAZWG	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMUAZWG	MT	DTP
DMUAZWG	MA	Substrate
DMUAZWG	RN	Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res. 2003 Jul 15;63(14):4048-54.
DMUAZWG	RU	http://www.ncbi.nlm.nih.gov/pubmed/12874005

DMUAZWG	DI	DMUAZWG
DMUAZWG	DN	Leucovorin
DMUAZWG	MI	DTQ3ZHF
DMUAZWG	MN	Multidrug resistance-associated protein 3 (ABCC3)
DMUAZWG	MT	DTP
DMUAZWG	MA	Substrate
DMUAZWG	RN	Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.
DMUAZWG	RU	http://www.ncbi.nlm.nih.gov/pubmed/11585759

DMUAZWG	DI	DMUAZWG
DMUAZWG	DN	Leucovorin
DMUAZWG	MI	DTCSGPB
DMUAZWG	MN	Multidrug resistance-associated protein 4 (ABCC4)
DMUAZWG	MT	DTP
DMUAZWG	MA	Substrate
DMUAZWG	RN	Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 2002 Jun 1;62(11):3144-50.
DMUAZWG	RU	http://www.ncbi.nlm.nih.gov/pubmed/12036927

DMNWZJG	DI	DMNWZJG
DMNWZJG	DN	Leucovorin Calcium
DMNWZJG	MI	TTYZVDJ
DMNWZJG	MN	Dihydrofolate reductase (DHFR)
DMNWZJG	MT	DTT
DMNWZJG	MA	Modulator
DMNWZJG	RN	Biochemical factors in the selectivity of leucovorin rescue: selective inhibition of leucovorin reactivation of dihydrofolate reductase and leucovorin utilization in purine and pyrimidine biosynthesis by methotrexate and dihydrofolate polyglutamates.NCI Monogr.1987;(5):17-26.
DMNWZJG	RU	https://www.ncbi.nlm.nih.gov/pubmed/2448654

DMZT4N7	DI	DMZT4N7
DMZT4N7	DN	Leucovorin/5-fluorouracil
DMZT4N7	MI	TTU6BFZ
DMZT4N7	MN	Candida Thymidylate synthase (Candi TMP1)
DMZT4N7	MT	DTT
DMZT4N7	MA	Inhibitor
DMZT4N7	RN	Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance. Mol Cancer Ther. 2009 May;8(5):1037-44.
DMZT4N7	RU	https://pubmed.ncbi.nlm.nih.gov/19383847

DM5XPIJ	DI	DM5XPIJ
DM5XPIJ	DN	Leuprolide
DM5XPIJ	MI	TT0ID4A
DM5XPIJ	MN	Leutinizing-hormone-releasing hormone (GNRH1)
DM5XPIJ	MT	DTT
DM5XPIJ	MA	Activator
DM5XPIJ	RN	Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer. Pharmacotherapy. 2008 Dec;28(12):1511-22.
DM5XPIJ	RU	https://pubmed.ncbi.nlm.nih.gov/19025432

DM15HAT	DI	DM15HAT
DM15HAT	DN	Leuprorelin acetate
DM15HAT	MI	TT8R70G
DM15HAT	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DM15HAT	MT	DTT
DM15HAT	MA	Agonist
DM15HAT	RN	Clinical pipeline report, company report or official report of Takeda (2009).
DM15HAT	RU	http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf

DMJBOCR	DI	DMJBOCR
DMJBOCR	DN	Levacecarnine HCL
DMJBOCR	MI	DTW7AE3
DMJBOCR	MN	Alanine/serine/cysteine/threonine transporter 2 (SLC1A5)
DMJBOCR	MT	DTP
DMJBOCR	MA	Substrate
DMJBOCR	RN	A polarized localization of amino acid/carnitine transporter B(0,+) (ATB(0,+)) in the blood-brain barrier. Biochem Biophys Res Commun. 2008 Nov 14;376(2):267-70.
DMJBOCR	RU	http://www.ncbi.nlm.nih.gov/pubmed/18771654

DMJBOCR	DI	DMJBOCR
DMJBOCR	DN	Levacecarnine HCL
DMJBOCR	MI	DEIGQCY
DMJBOCR	MN	Carnitine O-acetyltransferase (CRAT)
DMJBOCR	MT	DME
DMJBOCR	MA	Metabolism
DMJBOCR	RN	Structural and mutational characterization of L-carnitine binding to human carnitine acetyltransferase. J Struct Biol. 2004 Jun;146(3):416-24.
DMJBOCR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15099582

DMJBOCR	DI	DMJBOCR
DMJBOCR	DN	Levacecarnine HCL
DMJBOCR	MI	TTDL0NY
DMJBOCR	MN	Carnitine O-palmitoyltransferase I (CPT1B)
DMJBOCR	MT	DTT
DMJBOCR	MA	Activator
DMJBOCR	RN	Central ghrelin regulates peripheral lipid metabolism in a growth hormone-independent fashion. Endocrinology. 2009 Oct;150(10):4562-74.
DMJBOCR	RU	https://pubmed.ncbi.nlm.nih.gov/19608647

DMJBOCR	DI	DMJBOCR
DMJBOCR	DN	Levacecarnine HCL
DMJBOCR	MI	DTQOUM4
DMJBOCR	MN	Carnitine/acylcarnitine translocase (SLC25A20)
DMJBOCR	MT	DTP
DMJBOCR	MA	Substrate
DMJBOCR	RN	Molecular and functional analysis of SLC25A20 mutations causing carnitine-acylcarnitine translocase deficiency. Hum Mutat. 2004 Oct;24(4):312-20.
DMJBOCR	RU	http://www.ncbi.nlm.nih.gov/pubmed/15365988

DMJBOCR	DI	DMJBOCR
DMJBOCR	DN	Levacecarnine HCL
DMJBOCR	MI	DEVDYN7
DMJBOCR	MN	Cytochrome P450 2E1 (CYP2E1)
DMJBOCR	MT	DME
DMJBOCR	MA	Metabolism
DMJBOCR	RN	Modulation of ethanol-mediated CYP2E1 induction by clofibrate and L-carnitine in rat liver. Biol Pharm Bull. 1993 Dec;16(12):1240-3.
DMJBOCR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8130774

DMJBOCR	DI	DMJBOCR
DMJBOCR	DN	Levacecarnine HCL
DMJBOCR	MI	DTPATLS
DMJBOCR	MN	Fly-like putative transporter 2 (SLC22A16)
DMJBOCR	MT	DTP
DMJBOCR	MA	Substrate
DMJBOCR	RN	The human carnitine transporter SLC22A16 mediates high affinity uptake of the anticancer polyamine analogue bleomycin-A5. J Biol Chem. 2010 Feb 26;285(9):6275-84.
DMJBOCR	RU	http://www.ncbi.nlm.nih.gov/pubmed/20037140

DMJBOCR	DI	DMJBOCR
DMJBOCR	DN	Levacecarnine HCL
DMJBOCR	MI	DTQK5O9
DMJBOCR	MN	Monocarboxylate transporter 9 (SLC16A9)
DMJBOCR	MT	DTP
DMJBOCR	MA	Substrate
DMJBOCR	RN	Histological characterization of orphan transporter MCT14 (SLC16A14) shows abundant expression in mouse CNS and kidney. BMC Neurosci. 2016 Jul 1;17(1):43.
DMJBOCR	RU	http://www.ncbi.nlm.nih.gov/pubmed/27364523

DMJBOCR	DI	DMJBOCR
DMJBOCR	DN	Levacecarnine HCL
DMJBOCR	MI	DT2EG60
DMJBOCR	MN	Organic cation/carnitine transporter 1 (SLC22A4)
DMJBOCR	MT	DTP
DMJBOCR	MA	Substrate
DMJBOCR	RN	Spontaneous development of intestinal and colonic atrophy and inflammation in the carnitine-deficient jvs (OCTN2(-/-)) mice. Mol Genet Metab. 2007 Dec;92(4):315-24.
DMJBOCR	RU	http://www.ncbi.nlm.nih.gov/pubmed/17884651

DMJBOCR	DI	DMJBOCR
DMJBOCR	DN	Levacecarnine HCL
DMJBOCR	MI	DT3HUVD
DMJBOCR	MN	Organic cation/carnitine transporter 2 (SLC22A5)
DMJBOCR	MT	DTP
DMJBOCR	MA	Substrate
DMJBOCR	RN	Colistin is substrate of the carnitine/organic cation transporter 2 (OCTN2, SLC22A5). Drug Metab Dispos. 2017 Dec;45(12):1240-1244.
DMJBOCR	RU	http://www.ncbi.nlm.nih.gov/pubmed/28986476

DM5YBO1	DI	DM5YBO1
DM5YBO1	DN	Levalbuterol
DM5YBO1	MI	TT2CJVK
DM5YBO1	MN	Adrenergic receptor beta-2 (ADRB2)
DM5YBO1	MT	DTT
DM5YBO1	MA	Antagonist
DM5YBO1	RN	Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8.
DM5YBO1	RU	https://pubmed.ncbi.nlm.nih.gov/19491545

DMCOLUP	DI	DMCOLUP
DMCOLUP	DN	Levallorphan
DMCOLUP	MI	TTF4E0J
DMCOLUP	MN	Neuronal acetylcholine receptor alpha-2 (CHRNA2)
DMCOLUP	MT	DTT
DMCOLUP	MA	Antagonist
DMCOLUP	RN	Synergy between pairs of competitive antagonists at adult human muscle acetylcholine receptors. Anesth Analg. 2008 Aug;107(2):525-33.
DMCOLUP	RU	https://pubmed.ncbi.nlm.nih.gov/18633030

DM5EN79	DI	DM5EN79
DM5EN79	DN	Levamisole
DM5EN79	MI	TTMR5UV
DM5EN79	MN	Alkaline phosphatase tissue-nonspecific (ALPL)
DM5EN79	MT	DTT
DM5EN79	MA	Inhibitor
DM5EN79	RN	Characterization of rat heart alkaline phosphatase isoenzymes and modulation of activity. Braz J Med Biol Res. 2008 Jul;41(7):600-9.
DM5EN79	RU	https://pubmed.ncbi.nlm.nih.gov/18719742

DMTGDN8	DI	DMTGDN8
DMTGDN8	DN	Levetiracetam
DMTGDN8	MI	TTPC4TU
DMTGDN8	MN	5-HT 3A receptor (HTR3A)
DMTGDN8	MT	DTT
DMTGDN8	MA	Antagonist
DMTGDN8	RN	Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62.
DMTGDN8	RU	https://pubmed.ncbi.nlm.nih.gov/18321148

DMTGDN8	DI	DMTGDN8
DMTGDN8	DN	Levetiracetam
DMTGDN8	MI	DTUGYRD
DMTGDN8	MN	P-glycoprotein 1 (ABCB1)
DMTGDN8	MT	DTP
DMTGDN8	MA	Substrate
DMTGDN8	RN	Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2007 Feb;52(2):333-46.
DMTGDN8	RU	http://www.ncbi.nlm.nih.gov/pubmed/17045309

DMTGDN8	DI	DMTGDN8
DMTGDN8	DN	Levetiracetam
DMTGDN8	MI	TTT3P91
DMTGDN8	MN	Synaptic vesicle glycoprotein 2A (SV2A)
DMTGDN8	MT	DTT
DMTGDN8	MA	Modulator
DMTGDN8	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMTGDN8	RU	https://www.fda.gov/

DMSREPX	DI	DMSREPX
DMSREPX	DN	Levobetaxolol
DMSREPX	MI	TTR6W5O
DMSREPX	MN	Adrenergic receptor beta-1 (ADRB1)
DMSREPX	MT	DTT
DMSREPX	MA	Antagonist
DMSREPX	RN	Binding affinities of ocular hypotensive beta-blockers levobetaxolol, levobunolol, and timolol at endogenous guinea pig beta-adrenoceptors. J Ocul Pharmacol Ther. 2004 Apr;20(2):93-9.
DMSREPX	RU	https://pubmed.ncbi.nlm.nih.gov/15117564

DMSREPX	DI	DMSREPX
DMSREPX	DN	Levobetaxolol
DMSREPX	MI	DECB0K3
DMSREPX	MN	Cytochrome P450 2D6 (CYP2D6)
DMSREPX	MT	DME
DMSREPX	MA	Metabolism
DMSREPX	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DMSREPX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DMTNFCQ	DI	DMTNFCQ
DMTNFCQ	DN	Levobunolol
DMTNFCQ	MI	TTR6W5O
DMTNFCQ	MN	Adrenergic receptor beta-1 (ADRB1)
DMTNFCQ	MT	DTT
DMTNFCQ	MA	Antagonist
DMTNFCQ	RN	Binding of beta-adrenoceptor antagonists to rat and rabbit lung: special reference to levobunolol. Arzneimittelforschung. 1984;34(5):579-84.
DMTNFCQ	RU	https://pubmed.ncbi.nlm.nih.gov/6147147

DMTNFCQ	DI	DMTNFCQ
DMTNFCQ	DN	Levobunolol
DMTNFCQ	MI	DECB0K3
DMTNFCQ	MN	Cytochrome P450 2D6 (CYP2D6)
DMTNFCQ	MT	DME
DMTNFCQ	MA	Metabolism
DMTNFCQ	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DMTNFCQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DM783CH	DI	DM783CH
DM783CH	DN	Levobupivacaine
DM783CH	MI	DEJGDUW
DM783CH	MN	Cytochrome P450 1A2 (CYP1A2)
DM783CH	MT	DME
DM783CH	MA	Metabolism
DM783CH	RN	Pharmacokinetics of levobupivacaine after caudal epidural administration in infants less than 3 months of age. Br J Anaesth. 2005 Oct;95(4):524-9.
DM783CH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16100236

DM783CH	DI	DM783CH
DM783CH	DN	Levobupivacaine
DM783CH	MI	DE4LYSA
DM783CH	MN	Cytochrome P450 3A4 (CYP3A4)
DM783CH	MT	DME
DM783CH	MA	Metabolism
DM783CH	RN	Clinical profile of levobupivacaine in regional anesthesia: A systematic review. J Anaesthesiol Clin Pharmacol. 2013 Oct;29(4):530-9.
DM783CH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24249993

DM783CH	DI	DM783CH
DM783CH	DN	Levobupivacaine
DM783CH	MI	TTRK8B9
DM783CH	MN	Sodium channel unspecific (NaC)
DM783CH	MT	DTT
DM783CH	MA	Blocker
DM783CH	RN	Block of neuronal tetrodotoxin-resistant Na+ currents by stereoisomers of piperidine local anesthetics. Anesth Analg. 2000 Dec;91(6):1499-505.
DM783CH	RU	https://pubmed.ncbi.nlm.nih.gov/11094008

DMMZPWT	DI	DMMZPWT
DMMZPWT	DN	Levocabastine
DMMZPWT	MI	TTTIBOJ
DMMZPWT	MN	Histamine H1 receptor (H1R)
DMMZPWT	MT	DTT
DMMZPWT	MA	Antagonist
DMMZPWT	RN	Contribution of alpha4beta1 integrin to the antiallergic effect of levocabastine. Biochem Pharmacol. 2008 Sep 15;76(6):751-62.
DMMZPWT	RU	https://pubmed.ncbi.nlm.nih.gov/18680729

DMQYLGP	DI	DMQYLGP
DMQYLGP	DN	Levocetirizine
DMQYLGP	MI	DT06JWZ
DMQYLGP	MN	Organic anion transporter 4 (SLC22A11)
DMQYLGP	MT	DTP
DMQYLGP	MA	Substrate
DMQYLGP	RN	Cellular Uptake of Levocetirizine by Organic Anion Transporter 4. J Pharm Sci. 2017 Sep;106(9):2895-2898.
DMQYLGP	RU	http://www.ncbi.nlm.nih.gov/pubmed/28385546

DMW6ZJI	DI	DMW6ZJI
DMW6ZJI	DN	Levocetirizine dihydrochloride
DMW6ZJI	MI	DE4LYSA
DMW6ZJI	MN	Cytochrome P450 3A4 (CYP3A4)
DMW6ZJI	MT	DME
DMW6ZJI	MA	Metabolism
DMW6ZJI	RN	FDA label of Levocetirizine dihydrochloride. The 2020 official website of the U.S. Food and Drug Administration.
DMW6ZJI	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022064s038,022157s020lbl.pdf

DMW6ZJI	DI	DMW6ZJI
DMW6ZJI	DN	Levocetirizine dihydrochloride
DMW6ZJI	MI	TTTIBOJ
DMW6ZJI	MN	Histamine H1 receptor (H1R)
DMW6ZJI	MT	DTT
DMW6ZJI	MA	Antagonist
DMW6ZJI	RN	Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy. Curr Allergy Asthma Rep. 2009 Mar;9(2):140-8.
DMW6ZJI	RU	https://pubmed.ncbi.nlm.nih.gov/19210904

DMN3E57	DI	DMN3E57
DMN3E57	DN	Levodopa
DMN3E57	MI	DECB0K3
DMN3E57	MN	Cytochrome P450 2D6 (CYP2D6)
DMN3E57	MT	DME
DMN3E57	MA	Metabolism
DMN3E57	RN	Multiple cytochrome P450 enzymes responsible for the oxidative metabolism of the substituted (S)-3-phenylpiperidine, (S,S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride, in human liver microsomes. Drug Metab Dispos. 2002 Dec;30(12):1372-7.
DMN3E57	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12433806

DMN3E57	DI	DMN3E57
DMN3E57	DN	Levodopa
DMN3E57	MI	DETK9CN
DMN3E57	MN	DOPA decarboxylase (DDC)
DMN3E57	MT	DME
DMN3E57	MA	Metabolism
DMN3E57	RN	Complexity of dopamine metabolism. Cell Commun Signal. 2013 May 17;11(1):34.
DMN3E57	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23683503

DMN3E57	DI	DMN3E57
DMN3E57	DN	Levodopa
DMN3E57	MI	TTEX248
DMN3E57	MN	Dopamine D2 receptor (D2R)
DMN3E57	MT	DTT
DMN3E57	MA	Modulator
DMN3E57	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
DMN3E57	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3639

DMN3E57	DI	DMN3E57
DMN3E57	DN	Levodopa
DMN3E57	MI	DT48T0N
DMN3E57	MN	L-type amino acid transporter 1 (SLC7A5)
DMN3E57	MT	DTP
DMN3E57	MA	Substrate
DMN3E57	RN	Modulation of LAT1 (SLC7A5) transporter activity and stability by membrane cholesterol. Sci Rep. 2017 Mar 8;7:43580.
DMN3E57	RU	http://www.ncbi.nlm.nih.gov/pubmed/28272458

DMN3E57	DI	DMN3E57
DMN3E57	DN	Levodopa
DMN3E57	MI	DTUGYRD
DMN3E57	MN	P-glycoprotein 1 (ABCB1)
DMN3E57	MT	DTP
DMN3E57	MA	Substrate
DMN3E57	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMN3E57	RU	https://doi.org/10.1007/s11095-012-0935-x

DMN3E57	DI	DMN3E57
DMN3E57	DN	Levodopa
DMN3E57	MI	DEFQ8VO
DMN3E57	MN	Thiopurine methyltransferase (TPMT)
DMN3E57	MT	DME
DMN3E57	MA	Metabolism
DMN3E57	RN	Reduced 3-O-methyl-dopa levels in OCD patients and their unaffected parents is associated with the low activity M158 COMT allele. Am J Med Genet B Neuropsychiatr Genet. 2010 Mar 5;153B(2):542-548.
DMN3E57	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19676096

DMN3E57	DI	DMN3E57
DMN3E57	DN	Levodopa
DMN3E57	MI	DE3HL9N
DMN3E57	MN	Tyrosine decarboxylase (tdc)
DMN3E57	MT	DME
DMN3E57	MA	Metabolism
DMN3E57	RN	Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism. Science. 2019 Jun 14;364(6445). pii: eaau6323.
DMN3E57	RU	https://pubmed.ncbi.nlm.nih.gov/31196984

DMN3E57	DI	DMN3E57
DMN3E57	DN	Levodopa
DMN3E57	MI	DEX2ZLF
DMN3E57	MN	Tyrosine decarboxylase (tdc)
DMN3E57	MT	DME
DMN3E57	MA	Metabolism
DMN3E57	RN	Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson's disease. Nat Commun. 2019 Jan 18;10(1):310.
DMN3E57	RU	https://pubmed.ncbi.nlm.nih.gov/30659181

DMS60RB	DI	DMS60RB
DMS60RB	DN	Levofloxacin
DMS60RB	MI	TTN6J5F
DMS60RB	MN	Bacterial DNA gyrase (Bact gyrase)
DMS60RB	MT	DTT
DMS60RB	MA	Modulator
DMS60RB	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMS60RB	RU	https://www.fda.gov/

DMS60RB	DI	DMS60RB
DMS60RB	DN	Levofloxacin
DMS60RB	MI	DEP0IWS
DMS60RB	MN	Beta-lactamase (blaB)
DMS60RB	MT	DME
DMS60RB	MA	Metabolism
DMS60RB	RN	Analysis of the drug-resistant characteristics of Klebsiella pneumoniae isolated from the respiratory tract and CTX-M ESBL genes. Genet Mol Res. 2015 Oct 5;14(4):12043-8.
DMS60RB	RU	https://pubmed.ncbi.nlm.nih.gov/26505351

DMS60RB	DI	DMS60RB
DMS60RB	DN	Levofloxacin
DMS60RB	MI	DTE2B1D
DMS60RB	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMS60RB	MT	DTP
DMS60RB	MA	Substrate
DMS60RB	RN	Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm. 2007 Jan-Feb;4(1):85-94.
DMS60RB	RU	http://www.ncbi.nlm.nih.gov/pubmed/17274666

DMS60RB	DI	DMS60RB
DMS60RB	DN	Levofloxacin
DMS60RB	MI	DTUGYRD
DMS60RB	MN	P-glycoprotein 1 (ABCB1)
DMS60RB	MT	DTP
DMS60RB	MA	Substrate
DMS60RB	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMS60RB	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMS60RB	DI	DMS60RB
DMS60RB	DN	Levofloxacin
DMS60RB	MI	TTIXTO3
DMS60RB	MN	Staphylococcus Topoisomerase IV (Stap-coc parC)
DMS60RB	MT	DTT
DMS60RB	MA	Modulator
DMS60RB	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMS60RB	RU	https://www.fda.gov/

DMUV5JB	DI	DMUV5JB
DMUV5JB	DN	Levomefolic acid
DMUV5JB	MI	DEWSHL5
DMUV5JB	MN	Vitamin B12 methionine synthase (MTR)
DMUV5JB	MT	DME
DMUV5JB	MA	Metabolism
DMUV5JB	RN	Folic acid and L-5-methyltetrahydrofolate: comparison of clinical pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2010 Aug;49(8):535-48.
DMUV5JB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20608755

DMIKFEL	DI	DMIKFEL
DMIKFEL	DN	Levomepromazine
DMIKFEL	MI	DECB0K3
DMIKFEL	MN	Cytochrome P450 2D6 (CYP2D6)
DMIKFEL	MT	DME
DMIKFEL	MA	Metabolism
DMIKFEL	RN	Influence of the CYP2D6 isoenzyme in patients treated with venlafaxine for major depressive disorder: clinical and economic consequences. PLoS One. 2014 Nov 4;9(11):e90453.
DMIKFEL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25369508

DMIKFEL	DI	DMIKFEL
DMIKFEL	DN	Levomepromazine
DMIKFEL	MI	TTEX248
DMIKFEL	MN	Dopamine D2 receptor (D2R)
DMIKFEL	MT	DTT
DMIKFEL	MA	Modulator
DMIKFEL	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMIKFEL	RU	https://www.fda.gov/

DMIKFEL	DI	DMIKFEL
DMIKFEL	DN	Levomepromazine
DMIKFEL	MI	DTUGYRD
DMIKFEL	MN	P-glycoprotein 1 (ABCB1)
DMIKFEL	MT	DTP
DMIKFEL	MA	Substrate
DMIKFEL	RN	Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
DMIKFEL	RU	http://www.ncbi.nlm.nih.gov/pubmed/15285840

DM06HG5	DI	DM06HG5
DM06HG5	DN	Levomethadyl Acetate
DM06HG5	MI	TTKWM86
DM06HG5	MN	Opioid receptor mu (MOP)
DM06HG5	MT	DTT
DM06HG5	MA	Agonist
DM06HG5	RN	Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann N Y Acad Sci. 2000;909:186-216.
DM06HG5	RU	https://pubmed.ncbi.nlm.nih.gov/10911931

DM429AE	DI	DM429AE
DM429AE	DN	Levomethadyl acetate hydrochloride
DM429AE	MI	DEQX145
DM429AE	MN	Aromatase (CYP19A1)
DM429AE	MT	DME
DM429AE	MA	Metabolism
DM429AE	RN	N-demethylation of levo-alpha-acetylmethadol by human placental aromatase. Biochem Pharmacol. 2004 Mar 1;67(5):885-92.
DM429AE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15104241

DM429AE	DI	DM429AE
DM429AE	DN	Levomethadyl acetate hydrochloride
DM429AE	MI	DE4LYSA
DM429AE	MN	Cytochrome P450 3A4 (CYP3A4)
DM429AE	MT	DME
DM429AE	MA	Metabolism
DM429AE	RN	Paradoxical role of cytochrome P450 3A in the bioactivation and clinical effects of levo-alpha-acetylmethadol: importance of clinical investigations to validate in vitro drug metabolism studies. Clin Pharmacokinet. 2005;44(7):731-51.
DM429AE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15966756

DM429AE	DI	DM429AE
DM429AE	DN	Levomethadyl acetate hydrochloride
DM429AE	MI	DEIBDNY
DM429AE	MN	Cytochrome P450 3A5 (CYP3A5)
DM429AE	MT	DME
DM429AE	MA	Metabolism
DM429AE	RN	Drug Interactions Flockhart Table
DM429AE	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM429AE	DI	DM429AE
DM429AE	DN	Levomethadyl acetate hydrochloride
DM429AE	MI	DERD86B
DM429AE	MN	Cytochrome P450 3A7 (CYP3A7)
DM429AE	MT	DME
DM429AE	MA	Metabolism
DM429AE	RN	Drug Interactions Flockhart Table
DM429AE	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMV26S8	DI	DMV26S8
DMV26S8	DN	Levomilnacipran
DMV26S8	MI	DES5XRU
DMV26S8	MN	Cytochrome P450 2C8 (CYP2C8)
DMV26S8	MT	DME
DMV26S8	MA	Metabolism
DMV26S8	RN	The role of levomilnacipran in the management of major depressive disorder: a comprehensive review. Curr Neuropharmacol. 2016;14(2):191-9.
DMV26S8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26572745

DMV26S8	DI	DMV26S8
DMV26S8	DN	Levomilnacipran
DMV26S8	MI	TTAWNKZ
DMV26S8	MN	Norepinephrine transporter (NET)
DMV26S8	MT	DTT
DMV26S8	MA	Modulator
DMV26S8	RN	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
DMV26S8	RU	https://pubmed.ncbi.nlm.nih.gov/20118952

DMV26S8	DI	DMV26S8
DMV26S8	DN	Levomilnacipran
DMV26S8	MI	DTUGYRD
DMV26S8	MN	P-glycoprotein 1 (ABCB1)
DMV26S8	MT	DTP
DMV26S8	MA	Substrate
DMV26S8	RN	P-glycoprotein differentially affects escitalopram, levomilnacipran, vilazodone and vortioxetine transport at the mouse blood-brain barrier inivo. Neuropharmacology. 2016 Apr;103:104-11.
DMV26S8	RU	http://www.ncbi.nlm.nih.gov/pubmed/26700248

DMV26S8	DI	DMV26S8
DMV26S8	DN	Levomilnacipran
DMV26S8	MI	TT3ROYC
DMV26S8	MN	Serotonin transporter (SERT)
DMV26S8	MT	DTT
DMV26S8	MA	Modulator
DMV26S8	RN	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
DMV26S8	RU	https://pubmed.ncbi.nlm.nih.gov/20118952

DM1DP7T	DI	DM1DP7T
DM1DP7T	DN	Levonorgestrel
DM1DP7T	MI	TTUV8G9
DM1DP7T	MN	Progesterone receptor (PGR)
DM1DP7T	MT	DTT
DM1DP7T	MA	Binder
DM1DP7T	RN	Met909 plays a key role in the activation of the progesterone receptor and also in the high potency of 13-ethyl progestins. Mol Pharmacol. 2009 Jun;75(6):1317-24.
DM1DP7T	RU	https://pubmed.ncbi.nlm.nih.gov/19289570

DMECB4H	DI	DMECB4H
DMECB4H	DN	Levopropoxyphene Napsylate Anhydrous
DMECB4H	MI	TT35UGH
DMECB4H	MN	Neuronal acetylcholine receptor alpha-3/beta-4 (CHRNA3/B4)
DMECB4H	MT	DTT
DMECB4H	MA	Modulator
DMECB4H	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMECB4H	RU	https://www.fda.gov/

DMECB4H	DI	DMECB4H
DMECB4H	DN	Levopropoxyphene Napsylate Anhydrous
DMECB4H	MI	TTKWM86
DMECB4H	MN	Opioid receptor mu (MOP)
DMECB4H	MT	DTT
DMECB4H	MA	Modulator
DMECB4H	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMECB4H	RU	https://www.fda.gov/

DM2XVNI	DI	DM2XVNI
DM2XVNI	DN	Levormeloxifene
DM2XVNI	MI	TTZAYWL
DM2XVNI	MN	Estrogen receptor (ESR)
DM2XVNI	MT	DTT
DM2XVNI	MA	Modulator
DM2XVNI	RN	Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormone-related clinical disorders. Med Res Rev. 2001 Jul;21(4):302-47.
DM2XVNI	RU	https://pubmed.ncbi.nlm.nih.gov/11410933

DMGS80V	DI	DMGS80V
DMGS80V	DN	Levorphanol
DMGS80V	MI	TT9IK2Z
DMGS80V	MN	N-methyl-D-aspartate receptor (NMDAR)
DMGS80V	MT	DTT
DMGS80V	MA	Antagonist
DMGS80V	RN	Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2003 Jan;3(1):9-20.
DMGS80V	RU	https://pubmed.ncbi.nlm.nih.gov/12507405

DMGS80V	DI	DMGS80V
DMGS80V	DN	Levorphanol
DMGS80V	MI	TTN4QDT
DMGS80V	MN	Opioid receptor (OPR)
DMGS80V	MT	DTT
DMGS80V	MA	Agonist
DMGS80V	RN	Comparison of the effects of dextromethorphan, dextrorphan, and levorphanol on the hypothalamo-pituitary-adrenal axis. J Pharmacol Exp Ther. 2004 May;309(2):515-22.
DMGS80V	RU	https://pubmed.ncbi.nlm.nih.gov/14742749

DMKBOS2	DI	DMKBOS2
DMKBOS2	DN	Levosimendan
DMKBOS2	MI	TT8RDXP
DMKBOS2	MN	Troponin C (TN-C)
DMKBOS2	MT	DTT
DMKBOS2	MA	Stimulator
DMKBOS2	RN	Timing of levosimendan in cardiac surgery. Anadolu Kardiyol Derg. 2009 Jun;9(3):223-30.
DMKBOS2	RU	https://pubmed.ncbi.nlm.nih.gov/19520657

DMHN027	DI	DMHN027
DMHN027	DN	Levothyroxine
DMHN027	MI	DE4LYSA
DMHN027	MN	Cytochrome P450 3A4 (CYP3A4)
DMHN027	MT	DME
DMHN027	MA	Metabolism
DMHN027	RN	[Metabolic interaction between psychopharmaceuticals. Probable cause of exacerbation of hypothyroidism according to a case report]. Lakartidningen. 2002 Jun 20;99(25):2854-6.
DMHN027	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12143142

DMHN027	DI	DMHN027
DMHN027	DN	Levothyroxine
DMHN027	MI	DTE2B1D
DMHN027	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMHN027	MT	DTP
DMHN027	MA	Substrate
DMHN027	RN	Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology. 2001 May;142(5):2005-12.
DMHN027	RU	http://www.ncbi.nlm.nih.gov/pubmed/11316767

DMHN027	DI	DMHN027
DMHN027	DN	Levothyroxine
DMHN027	MI	DT3D8F0
DMHN027	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMHN027	MT	DTP
DMHN027	MA	Substrate
DMHN027	RN	Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem. 1999 Jun 11;274(24):17159-63.
DMHN027	RU	http://www.ncbi.nlm.nih.gov/pubmed/10358072

DMHN027	DI	DMHN027
DMHN027	DN	Levothyroxine
DMHN027	MI	DTPYCQ4
DMHN027	MN	Organic anion transporting polypeptide 1C1 (SLCO1C1)
DMHN027	MT	DTP
DMHN027	MA	Substrate
DMHN027	RN	Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol Endocrinol. 2002 Oct;16(10):2283-96.
DMHN027	RU	http://www.ncbi.nlm.nih.gov/pubmed/12351693

DMHN027	DI	DMHN027
DMHN027	DN	Levothyroxine
DMHN027	MI	TTTSEPU
DMHN027	MN	Thyroid hormone receptor alpha (THRA)
DMHN027	MT	DTT
DMHN027	MA	Antagonist
DMHN027	RN	Thyroid hormone resistance and pituitary enlargement after thyroid ablation in a woman on levothyroxine treatment. Thyroid. 2008 Oct;18(10):1119-23.
DMHN027	RU	https://pubmed.ncbi.nlm.nih.gov/18816177

DMHN027	DI	DMHN027
DMHN027	DN	Levothyroxine
DMHN027	MI	DEYGVN4
DMHN027	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMHN027	MT	DME
DMHN027	MA	Metabolism
DMHN027	RN	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
DMHN027	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429

DM4PUDW	DI	DM4PUDW
DM4PUDW	DN	L-glutamic acid
DM4PUDW	MI	DT85HYR
DM4PUDW	MN	Calcium-binding mitochondrial carrier protein Aralar1 (SLC25A12)
DM4PUDW	MT	DTP
DM4PUDW	MA	Substrate
DM4PUDW	RN	Mitochondrial Aspartate/Glutamate Carrier SLC25A12 and Autism Spectrum Disorder: a Meta-Analysis. Mol Neurobiol. 2016 Apr;53(3):1579-1588.
DM4PUDW	RU	http://www.ncbi.nlm.nih.gov/pubmed/25663199

DM4PUDW	DI	DM4PUDW
DM4PUDW	DN	L-glutamic acid
DM4PUDW	MI	DTDSYAQ
DM4PUDW	MN	Calcium-binding mitochondrial carrier protein Aralar2 (SLC25A13)
DM4PUDW	MT	DTP
DM4PUDW	MA	Substrate
DM4PUDW	RN	Epigenetic upregulation and functional role of the mitochondrial aspartate/glutamate carrier isoform 1 in hepatocellular carcinoma. Biochim Biophys Acta Mol Basis Dis. 2019 Jan;1865(1):38-47.
DM4PUDW	RU	http://www.ncbi.nlm.nih.gov/pubmed/30321589

DM4PUDW	DI	DM4PUDW
DM4PUDW	DN	L-glutamic acid
DM4PUDW	MI	DTKLMH6
DM4PUDW	MN	Cystine/glutamate transporter (SLC7A11)
DM4PUDW	MT	DTP
DM4PUDW	MA	Substrate
DM4PUDW	RN	The glutamate/cystine antiporter SLC7A11/xCT enhances cancer cell dependency on glucose by exporting glutamate. J Biol Chem. 2017 Aug 25;292(34):14240-14249.
DM4PUDW	RU	http://www.ncbi.nlm.nih.gov/pubmed/28630042

DM4PUDW	DI	DM4PUDW
DM4PUDW	DN	L-glutamic acid
DM4PUDW	MI	DT9U216
DM4PUDW	MN	Excitatory amino acid transporter 1 (SLC1A3)
DM4PUDW	MT	DTP
DM4PUDW	MA	Substrate
DM4PUDW	RN	The SLC1 high-affinity glutamate and neutral amino acid transporter family. Mol Aspects Med. 2013 Apr-Jun;34(2-3):108-20.
DM4PUDW	RU	http://www.ncbi.nlm.nih.gov/pubmed/23506861

DM4PUDW	DI	DM4PUDW
DM4PUDW	DN	L-glutamic acid
DM4PUDW	MI	DT0VAI5
DM4PUDW	MN	Excitatory amino acid transporter 2 (SLC1A2)
DM4PUDW	MT	DTP
DM4PUDW	MA	Substrate
DM4PUDW	RN	EAAT2 (GLT-1; slc1a2) glutamate transporters reconstituted in liposomes argues against heteroexchange being substantially faster than net uptake. J Neurosci. 2014 Oct 1;34(40):13472-85.
DM4PUDW	RU	http://www.ncbi.nlm.nih.gov/pubmed/25274824

DM4PUDW	DI	DM4PUDW
DM4PUDW	DN	L-glutamic acid
DM4PUDW	MI	DTJIRMD
DM4PUDW	MN	Excitatory amino acid transporter 3 (SLC1A1)
DM4PUDW	MT	DTP
DM4PUDW	MA	Substrate
DM4PUDW	RN	Loss-of-function mutations in the glutamate transporter SLC1A1 cause human dicarboxylic aminoaciduria. J Clin Invest. 2011 Jan;121(1):446-53.
DM4PUDW	RU	http://www.ncbi.nlm.nih.gov/pubmed/21123949

DM4PUDW	DI	DM4PUDW
DM4PUDW	DN	L-glutamic acid
DM4PUDW	MI	DTV2AOB
DM4PUDW	MN	Excitatory amino acid transporter 4 (SLC1A6)
DM4PUDW	MT	DTP
DM4PUDW	MA	Substrate
DM4PUDW	RN	The SLC1 high-affinity glutamate and neutral amino acid transporter family. Mol Aspects Med. 2013 Apr-Jun;34(2-3):108-20.
DM4PUDW	RU	http://www.ncbi.nlm.nih.gov/pubmed/23506861

DM4PUDW	DI	DM4PUDW
DM4PUDW	DN	L-glutamic acid
DM4PUDW	MI	DTBGZ8H
DM4PUDW	MN	Excitatory amino acid transporter 5 (SLC1A7)
DM4PUDW	MT	DTP
DM4PUDW	MA	Substrate
DM4PUDW	RN	The SLC1 high-affinity glutamate and neutral amino acid transporter family. Mol Aspects Med. 2013 Apr-Jun;34(2-3):108-20.
DM4PUDW	RU	http://www.ncbi.nlm.nih.gov/pubmed/23506861

DM4PUDW	DI	DM4PUDW
DM4PUDW	DN	L-glutamic acid
DM4PUDW	MI	DTJCWP8
DM4PUDW	MN	Mitochondrial glutamate carrier 1 (SLC25A22)
DM4PUDW	MT	DTP
DM4PUDW	MA	Substrate
DM4PUDW	RN	Impaired mitochondrial glutamate transport in autosomal recessive neonatal myoclonic epilepsy. Am J Hum Genet. 2005 Feb;76(2):334-9.
DM4PUDW	RU	http://www.ncbi.nlm.nih.gov/pubmed/15592994

DM4PUDW	DI	DM4PUDW
DM4PUDW	DN	L-glutamic acid
DM4PUDW	MI	DT3VZJO
DM4PUDW	MN	Mitochondrial glutamate carrier 2 (SLC25A18)
DM4PUDW	MT	DTP
DM4PUDW	MA	Substrate
DM4PUDW	RN	The ABCs of membrane transporters in health and disease (SLC series): Introduction. Molecular Aspects of Medicine, 2013, 34(2-3):95-107. (GeneName=SLC25A18)
DM4PUDW	RU	http://slc.bioparadigms.org/protein?GeneName=SLC25A18

DM4PUDW	DI	DM4PUDW
DM4PUDW	DN	L-glutamic acid
DM4PUDW	MI	TT9IK2Z
DM4PUDW	MN	N-methyl-D-aspartate receptor (NMDAR)
DM4PUDW	MT	DTT
DM4PUDW	MA	Antagonist
DM4PUDW	RN	Altered expression of genes involved in GABAergic transmission and neuromodulation of granule cell activity in the cerebellum of schizophrenia pati... Am J Psychiatry. 2008 Dec;165(12):1594-603.
DM4PUDW	RU	https://pubmed.ncbi.nlm.nih.gov/18923069

DM4PUDW	DI	DM4PUDW
DM4PUDW	DN	L-glutamic acid
DM4PUDW	MI	DT06JWZ
DM4PUDW	MN	Organic anion transporter 4 (SLC22A11)
DM4PUDW	MT	DTP
DM4PUDW	MA	Substrate
DM4PUDW	RN	The role of the intracellular glutamate gradient in driving organic anion transporter function.
DM4PUDW	RU	http://www.physoc.org/proceedings/abstract/Proc%20Physiol%20Soc%2034C12

DM4PUDW	DI	DM4PUDW
DM4PUDW	DN	L-glutamic acid
DM4PUDW	MI	DTPFTEQ
DM4PUDW	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DM4PUDW	MT	DTP
DM4PUDW	MA	Substrate
DM4PUDW	RN	The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.60.1.20)
DM4PUDW	RU	http://www.tcdb.org/search/result.php?tc=2.A.60.1.20

DM4PUDW	DI	DM4PUDW
DM4PUDW	DN	L-glutamic acid
DM4PUDW	MI	DT38SZL
DM4PUDW	MN	Organic cation transporter-like 3 (SLC22A13)
DM4PUDW	MT	DTP
DM4PUDW	MA	Substrate
DM4PUDW	RN	SLC22A13 catalyses unidirectional efflux of aspartate and glutamate at the basolateral membrane of type A intercalated cells in the renal collecting duct. Biochem J. 2014 Jan 15;457(2):243-51.
DM4PUDW	RU	http://www.ncbi.nlm.nih.gov/pubmed/24147638

DM4PUDW	DI	DM4PUDW
DM4PUDW	DN	L-glutamic acid
DM4PUDW	MI	DT2LGOY
DM4PUDW	MN	Putative sodium-coupled neutral amino acid transporter 10 (SLC38A10)
DM4PUDW	MT	DTP
DM4PUDW	MA	Substrate
DM4PUDW	RN	The neuronal and astrocytic protein SLC38A10 transports glutamine, glutamate, and aspartate, suggesting a role in neurotransmission. FEBS Open Bio. 2017 Apr 26;7(6):730-746.
DM4PUDW	RU	http://www.ncbi.nlm.nih.gov/pubmed/28593130

DM4PUDW	DI	DM4PUDW
DM4PUDW	DN	L-glutamic acid
DM4PUDW	MI	DT0UQDA
DM4PUDW	MN	Putative sodium-coupled neutral amino acid transporter 8 (SLC38A8)
DM4PUDW	MT	DTP
DM4PUDW	MA	Substrate
DM4PUDW	RN	Structural modeling of a novel SLC38A8 mutation that causes foveal hypoplasia. Mol Genet Genomic Med. 2017 Feb 26;5(3):202-209.
DM4PUDW	RU	http://www.ncbi.nlm.nih.gov/pubmed/28546991

DM4PUDW	DI	DM4PUDW
DM4PUDW	DN	L-glutamic acid
DM4PUDW	MI	DTMWE5P
DM4PUDW	MN	Sodium-independent aspartate/glutamate transporter 1 (SLC7A13)
DM4PUDW	MT	DTP
DM4PUDW	MA	Substrate
DM4PUDW	RN	Novel cystine transporter in renal proximal tubule identified as a missing partner of cystinuria-related plasma membrane protein rBAT/SLC3A1. Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):775-80.
DM4PUDW	RU	http://www.ncbi.nlm.nih.gov/pubmed/26739563

DM4PUDW	DI	DM4PUDW
DM4PUDW	DN	L-glutamic acid
DM4PUDW	MI	DTNK0FR
DM4PUDW	MN	Vesicular glutamate transporter 1 (SLC17A7)
DM4PUDW	MT	DTP
DM4PUDW	MA	Substrate
DM4PUDW	RN	Molecular pharmacology of glutamate transporters, EAATs and VGLUTs. Brain Res Brain Res Rev. 2004 Jul;45(3):250-65.
DM4PUDW	RU	http://www.ncbi.nlm.nih.gov/pubmed/15210307

DM4PUDW	DI	DM4PUDW
DM4PUDW	DN	L-glutamic acid
DM4PUDW	MI	DT5LHCR
DM4PUDW	MN	Vesicular glutamate transporter 2 (SLC17A6)
DM4PUDW	MT	DTP
DM4PUDW	MA	Substrate
DM4PUDW	RN	Molecular pharmacology of glutamate transporters, EAATs and VGLUTs. Brain Res Brain Res Rev. 2004 Jul;45(3):250-65.
DM4PUDW	RU	http://www.ncbi.nlm.nih.gov/pubmed/15210307

DM4PUDW	DI	DM4PUDW
DM4PUDW	DN	L-glutamic acid
DM4PUDW	MI	DTAGDH7
DM4PUDW	MN	Vesicular glutamate transporter 3 (SLC17A8)
DM4PUDW	MT	DTP
DM4PUDW	MA	Substrate
DM4PUDW	RN	Molecular pharmacology of glutamate transporters, EAATs and VGLUTs. Brain Res Brain Res Rev. 2004 Jul;45(3):250-65.
DM4PUDW	RU	http://www.ncbi.nlm.nih.gov/pubmed/15210307

DM69G8X	DI	DM69G8X
DM69G8X	DN	L-glutamine
DM69G8X	MI	DTW7AE3
DM69G8X	MN	Alanine/serine/cysteine/threonine transporter 2 (SLC1A5)
DM69G8X	MT	DTP
DM69G8X	MA	Substrate
DM69G8X	RN	High-affinity glutamate transporter GLAST/EAAT1 regulates cell surface expression of glutamine/neutral amino acid transporter ASCT2 in human fetal astrocytes. Neurochem Int. 2006 May-Jun;48(6-7):611-5.
DM69G8X	RU	http://www.ncbi.nlm.nih.gov/pubmed/16516348

DM69G8X	DI	DM69G8X
DM69G8X	DN	L-glutamine
DM69G8X	MI	DT48T0N
DM69G8X	MN	L-type amino acid transporter 1 (SLC7A5)
DM69G8X	MT	DTP
DM69G8X	MA	Substrate
DM69G8X	RN	Bidirectional transport of amino acids regulates mTOR and autophagy. Cell. 2009 Feb 6;136(3):521-34.
DM69G8X	RU	http://www.ncbi.nlm.nih.gov/pubmed/19203585

DM69G8X	DI	DM69G8X
DM69G8X	DN	L-glutamine
DM69G8X	MI	DT2EGUN
DM69G8X	MN	Putative sodium-coupled neutral amino acid transporter 7 (SLC38A7)
DM69G8X	MT	DTP
DM69G8X	MA	Substrate
DM69G8X	RN	Identification of SLC38A7 (SNAT7) protein as a glutamine transporter expressed in neurons. J Biol Chem. 2011 Jun 10;286(23):20500-11.
DM69G8X	RU	http://www.ncbi.nlm.nih.gov/pubmed/21511949

DM69G8X	DI	DM69G8X
DM69G8X	DN	L-glutamine
DM69G8X	MI	DTD815L
DM69G8X	MN	Sodium-coupled neutral amino acid transporter 1 (SLC38A1)
DM69G8X	MT	DTP
DM69G8X	MA	Substrate
DM69G8X	RN	Identification of SLC38A7 (SNAT7) protein as a glutamine transporter expressed in neurons. J Biol Chem. 2011 Jun 10;286(23):20500-11.
DM69G8X	RU	http://www.ncbi.nlm.nih.gov/pubmed/21511949

DM69G8X	DI	DM69G8X
DM69G8X	DN	L-glutamine
DM69G8X	MI	DTTWL58
DM69G8X	MN	Sodium-coupled neutral amino acid transporter 2 (SLC38A2)
DM69G8X	MT	DTP
DM69G8X	MA	Substrate
DM69G8X	RN	Identification of SLC38A7 (SNAT7) protein as a glutamine transporter expressed in neurons. J Biol Chem. 2011 Jun 10;286(23):20500-11.
DM69G8X	RU	http://www.ncbi.nlm.nih.gov/pubmed/21511949

DM69G8X	DI	DM69G8X
DM69G8X	DN	L-glutamine
DM69G8X	MI	DTKWJH3
DM69G8X	MN	Sodium-coupled neutral amino acid transporter 3 (SLC38A3)
DM69G8X	MT	DTP
DM69G8X	MA	Substrate
DM69G8X	RN	Identification of SLC38A7 (SNAT7) protein as a glutamine transporter expressed in neurons. J Biol Chem. 2011 Jun 10;286(23):20500-11.
DM69G8X	RU	http://www.ncbi.nlm.nih.gov/pubmed/21511949

DM69G8X	DI	DM69G8X
DM69G8X	DN	L-glutamine
DM69G8X	MI	DTPJBD5
DM69G8X	MN	Sodium-coupled neutral amino acid transporter 4 (SLC38A4)
DM69G8X	MT	DTP
DM69G8X	MA	Substrate
DM69G8X	RN	Identification of SLC38A7 (SNAT7) protein as a glutamine transporter expressed in neurons. J Biol Chem. 2011 Jun 10;286(23):20500-11.
DM69G8X	RU	http://www.ncbi.nlm.nih.gov/pubmed/21511949

DM69G8X	DI	DM69G8X
DM69G8X	DN	L-glutamine
DM69G8X	MI	DTLX28N
DM69G8X	MN	Sodium-coupled neutral amino acid transporter 5 (SLC38A5)
DM69G8X	MT	DTP
DM69G8X	MA	Substrate
DM69G8X	RN	Identification of SLC38A7 (SNAT7) protein as a glutamine transporter expressed in neurons. J Biol Chem. 2011 Jun 10;286(23):20500-11.
DM69G8X	RU	http://www.ncbi.nlm.nih.gov/pubmed/21511949

DMNQXV8	DI	DMNQXV8
DMNQXV8	DN	LGX818
DMNQXV8	MI	DE4LYSA
DMNQXV8	MN	Cytochrome P450 3A4 (CYP3A4)
DMNQXV8	MT	DME
DMNQXV8	MA	Metabolism
DMNQXV8	RN	Development of encorafenib for BRAF-mutated advanced melanoma. Curr Opin Oncol. 2018 Mar;30(2):125-133.
DMNQXV8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29356698

DMNQXV8	DI	DMNQXV8
DMNQXV8	DN	LGX818
DMNQXV8	MI	DEGTFWK
DMNQXV8	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMNQXV8	MT	DME
DMNQXV8	MA	Metabolism
DMNQXV8	RN	Development of encorafenib for BRAF-mutated advanced melanoma. Curr Opin Oncol. 2018 Mar;30(2):125-133.
DMNQXV8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29356698

DMNQXV8	DI	DMNQXV8
DMNQXV8	DN	LGX818
DMNQXV8	MI	TTWCGQT
DMNQXV8	MN	Serine/threonine-protein kinase B-raf (BRAF)
DMNQXV8	MT	DTT
DMNQXV8	MA	Modulator
DMNQXV8	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMNQXV8	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DML4ZOT	DI	DML4ZOT
DML4ZOT	DN	Lidocaine
DML4ZOT	MI	DEJGDUW
DML4ZOT	MN	Cytochrome P450 1A2 (CYP1A2)
DML4ZOT	MT	DME
DML4ZOT	MA	Metabolism
DML4ZOT	RN	Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
DML4ZOT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19754423

DML4ZOT	DI	DML4ZOT
DML4ZOT	DN	Lidocaine
DML4ZOT	MI	DEJVYAZ
DML4ZOT	MN	Cytochrome P450 2A6 (CYP2A6)
DML4ZOT	MT	DME
DML4ZOT	MA	Metabolism
DML4ZOT	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DML4ZOT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DML4ZOT	DI	DML4ZOT
DML4ZOT	DN	Lidocaine
DML4ZOT	MI	DEPKLMQ
DML4ZOT	MN	Cytochrome P450 2B6 (CYP2B6)
DML4ZOT	MT	DME
DML4ZOT	MA	Metabolism
DML4ZOT	RN	Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
DML4ZOT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27709010

DML4ZOT	DI	DML4ZOT
DML4ZOT	DN	Lidocaine
DML4ZOT	MI	DEZMWRE
DML4ZOT	MN	Cytochrome P450 2C18 (CYP2C18)
DML4ZOT	MT	DME
DML4ZOT	MA	Metabolism
DML4ZOT	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DML4ZOT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DML4ZOT	DI	DML4ZOT
DML4ZOT	DN	Lidocaine
DML4ZOT	MI	DES5XRU
DML4ZOT	MN	Cytochrome P450 2C8 (CYP2C8)
DML4ZOT	MT	DME
DML4ZOT	MA	Metabolism
DML4ZOT	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DML4ZOT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DML4ZOT	DI	DML4ZOT
DML4ZOT	DN	Lidocaine
DML4ZOT	MI	DE5IED8
DML4ZOT	MN	Cytochrome P450 2C9 (CYP2C9)
DML4ZOT	MT	DME
DML4ZOT	MA	Metabolism
DML4ZOT	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DML4ZOT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DML4ZOT	DI	DML4ZOT
DML4ZOT	DN	Lidocaine
DML4ZOT	MI	DECB0K3
DML4ZOT	MN	Cytochrome P450 2D6 (CYP2D6)
DML4ZOT	MT	DME
DML4ZOT	MA	Metabolism
DML4ZOT	RN	Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans. Drug Metab Dispos. 2000 Aug;28(8):959-65.
DML4ZOT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10901707

DML4ZOT	DI	DML4ZOT
DML4ZOT	DN	Lidocaine
DML4ZOT	MI	DE4LYSA
DML4ZOT	MN	Cytochrome P450 3A4 (CYP3A4)
DML4ZOT	MT	DME
DML4ZOT	MA	Metabolism
DML4ZOT	RN	Pharmacokinetics of lidocaine hydrochloride metabolized by CYP3A4 in Chinese Han volunteers living at low altitude and in native Han and Tibetan Chinese volunteers living at high altitude. Pharmacology. 2016;97(3-4):107-13.
DML4ZOT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26730802

DML4ZOT	DI	DML4ZOT
DML4ZOT	DN	Lidocaine
DML4ZOT	MI	DEIBDNY
DML4ZOT	MN	Cytochrome P450 3A5 (CYP3A5)
DML4ZOT	MT	DME
DML4ZOT	MA	Metabolism
DML4ZOT	RN	Drug Interactions Flockhart Table
DML4ZOT	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DML4ZOT	DI	DML4ZOT
DML4ZOT	DN	Lidocaine
DML4ZOT	MI	DERD86B
DML4ZOT	MN	Cytochrome P450 3A7 (CYP3A7)
DML4ZOT	MT	DME
DML4ZOT	MA	Metabolism
DML4ZOT	RN	Drug Interactions Flockhart Table
DML4ZOT	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DML4ZOT	DI	DML4ZOT
DML4ZOT	DN	Lidocaine
DML4ZOT	MI	DTUGYRD
DML4ZOT	MN	P-glycoprotein 1 (ABCB1)
DML4ZOT	MT	DTP
DML4ZOT	MA	Substrate
DML4ZOT	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DML4ZOT	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DML4ZOT	DI	DML4ZOT
DML4ZOT	DN	Lidocaine
DML4ZOT	MI	TTN9VTF
DML4ZOT	MN	Voltage-gated sodium channel alpha Nav1.9 (SCN11A)
DML4ZOT	MT	DTT
DML4ZOT	MA	Blocker
DML4ZOT	RN	Mechanisms of analgesia of intravenous lidocaine. Rev Bras Anestesiol. 2008 May-Jun;58(3):280-6.
DML4ZOT	RU	https://pubmed.ncbi.nlm.nih.gov/19378524

DMV23GL	DI	DMV23GL
DMV23GL	DN	Lidoflazine
DMV23GL	MI	DE4LYSA
DMV23GL	MN	Cytochrome P450 3A4 (CYP3A4)
DMV23GL	MT	DME
DMV23GL	MA	Metabolism
DMV23GL	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DMV23GL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DMV23GL	DI	DMV23GL
DMV23GL	DN	Lidoflazine
DMV23GL	MI	TTRK8B9
DMV23GL	MN	Sodium channel unspecific (NaC)
DMV23GL	MT	DTT
DMV23GL	MA	Inhibitor
DMV23GL	RN	Synthesis and pharmacological evaluation of phenylacetamides as sodium-channel blockers. J Med Chem. 1994 Jan 21;37(2):268-74.
DMV23GL	RU	https://pubmed.ncbi.nlm.nih.gov/8295214

DMV23GL	DI	DMV23GL
DMV23GL	DN	Lidoflazine
DMV23GL	MI	TTLXAKE
DMV23GL	MN	Solute carrier family 29 member 1 (SLC29A1)
DMV23GL	MT	DTT
DMV23GL	MA	Inhibitor
DMV23GL	RN	Synthesis, flow cytometric evaluation, and identification of highly potent dipyridamole analogues as equilibrative nucleoside transporter 1 inhibit... J Med Chem. 2007 Aug 9;50(16):3906-20.
DMV23GL	RU	https://pubmed.ncbi.nlm.nih.gov/17636949

DMV23GL	DI	DMV23GL
DMV23GL	DN	Lidoflazine
DMV23GL	MI	TTAXZ0K
DMV23GL	MN	Voltage-gated sodium channel alpha Nav1.3 (SCN3A)
DMV23GL	MT	DTT
DMV23GL	MA	Inhibitor
DMV23GL	RN	Synthesis and pharmacological evaluation of phenylacetamides as sodium-channel blockers. J Med Chem. 1994 Jan 21;37(2):268-74.
DMV23GL	RU	https://pubmed.ncbi.nlm.nih.gov/8295214

DM4WVC5	DI	DM4WVC5
DM4WVC5	DN	Lifitegrast
DM4WVC5	MI	TT48WR6
DM4WVC5	MN	Integrin alpha-L (ITGAL)
DM4WVC5	MT	DTT
DM4WVC5	MA	Modulator
DM4WVC5	RN	Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118). J Ocul Pharmacol Ther. 2013 May;29(4):395-402.
DM4WVC5	RU	https://pubmed.ncbi.nlm.nih.gov/23215542

DM4WVC5	DI	DM4WVC5
DM4WVC5	DN	Lifitegrast
DM4WVC5	MI	TTCT6F7
DM4WVC5	MN	Intercellular adhesion molecule ICAM-1 (ICAM1)
DM4WVC5	MT	DTT
DM4WVC5	MA	Inhibitor
DM4WVC5	RN	Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye. ACS Med Chem Lett. 2012 Jan 31;3(3):203-6.
DM4WVC5	RU	https://pubmed.ncbi.nlm.nih.gov/24900456

DM4WVC5	DI	DM4WVC5
DM4WVC5	DN	Lifitegrast
DM4WVC5	MI	DTE2B1D
DM4WVC5	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DM4WVC5	MT	DTP
DM4WVC5	MA	Substrate
DM4WVC5	RN	Clinical Pharmacology and Biopharmaceutics review(s)
DM4WVC5	RU	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208073Orig1s000ClinPharmR.pdf

DM4WVC5	DI	DM4WVC5
DM4WVC5	DN	Lifitegrast
DM4WVC5	MI	DTPFTEQ
DM4WVC5	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DM4WVC5	MT	DTP
DM4WVC5	MA	Substrate
DM4WVC5	RN	Clinical Pharmacology and Biopharmaceutics review(s)
DM4WVC5	RU	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208073Orig1s000ClinPharmR.pdf

DM4EGV0	DI	DM4EGV0
DM4EGV0	DN	Linaclotide
DM4EGV0	MI	TTLDPRG
DM4EGV0	MN	Guanylyl cyclase C (GUCY2C)
DM4EGV0	MT	DTT
DM4EGV0	MA	Activator
DM4EGV0	RN	Emerging drugs for postoperative ileus. Expert Opin Emerg Drugs. 2007 Nov;12(4):619-26.
DM4EGV0	RU	https://pubmed.ncbi.nlm.nih.gov/17979603

DMWFJTR	DI	DMWFJTR
DMWFJTR	DN	Linagliptin
DMWFJTR	MI	TTDIGC1
DMWFJTR	MN	Dipeptidyl peptidase 4 (DPP-4)
DMWFJTR	MT	DTT
DMWFJTR	MA	Inhibitor
DMWFJTR	RN	Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
DMWFJTR	RU	http://www.boehringer-ingelheim.com/corporate/research/pipeline.asp

DMWFJTR	DI	DMWFJTR
DMWFJTR	DN	Linagliptin
DMWFJTR	MI	DTUGYRD
DMWFJTR	MN	P-glycoprotein 1 (ABCB1)
DMWFJTR	MT	DTP
DMWFJTR	MA	Substrate
DMWFJTR	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DMWFJTR	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DMVTHER	DI	DMVTHER
DMVTHER	DN	Lincomycin
DMVTHER	MI	TTUWYEA
DMVTHER	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DMVTHER	MT	DTT
DMVTHER	MA	Inhibitor
DMVTHER	RN	Specific inhibition of 50S ribosomal subunit formation in Staphylococcus aureus cells by 16-membered macrolide, lincosamide, and streptogramin B antibiotics. Curr Microbiol. 2000 Aug;41(2):126-35.
DMVTHER	RU	https://pubmed.ncbi.nlm.nih.gov/10856379

DMB8CNL	DI	DMB8CNL
DMB8CNL	DN	Lindane
DMB8CNL	MI	TTAN6JD
DMB8CNL	MN	Glutamate receptor AMPA (GRIA)
DMB8CNL	MT	DTT
DMB8CNL	MA	Antagonist
DMB8CNL	RN	NMDA-induced seizure intensity is enhanced in COX-2 deficient mice. Neurotoxicology. 2008 Nov;29(6):1114-20.
DMB8CNL	RU	https://pubmed.ncbi.nlm.nih.gov/18834901

DMGFPU2	DI	DMGFPU2
DMGFPU2	DN	Linezolid
DMGFPU2	MI	TTLFGBV
DMGFPU2	MN	Bacterial 23S ribosomal RNA (Bact 23S rRNA)
DMGFPU2	MT	DTT
DMGFPU2	MA	Binder
DMGFPU2	RN	Genome sequencing of linezolid-resistant Streptococcus pneumoniae mutants reveals novel mechanisms of resistance. Genome Res. 2009 Jul;19(7):1214-23.
DMGFPU2	RU	https://pubmed.ncbi.nlm.nih.gov/19351617

DM6IR3P	DI	DM6IR3P
DM6IR3P	DN	Liothyronine
DM6IR3P	MI	DTE2B1D
DM6IR3P	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DM6IR3P	MT	DTP
DM6IR3P	MA	Substrate
DM6IR3P	RN	Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology. 2001 May;142(5):2005-12.
DM6IR3P	RU	http://www.ncbi.nlm.nih.gov/pubmed/11316767

DM6IR3P	DI	DM6IR3P
DM6IR3P	DN	Liothyronine
DM6IR3P	MI	DT3D8F0
DM6IR3P	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM6IR3P	MT	DTP
DM6IR3P	MA	Substrate
DM6IR3P	RN	Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem. 1999 Jun 11;274(24):17159-63.
DM6IR3P	RU	http://www.ncbi.nlm.nih.gov/pubmed/10358072

DM6IR3P	DI	DM6IR3P
DM6IR3P	DN	Liothyronine
DM6IR3P	MI	DT9C1TS
DM6IR3P	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM6IR3P	MT	DTP
DM6IR3P	MA	Substrate
DM6IR3P	RN	LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99.
DM6IR3P	RU	http://www.ncbi.nlm.nih.gov/pubmed/11375950

DM6IR3P	DI	DM6IR3P
DM6IR3P	DN	Liothyronine
DM6IR3P	MI	DTPYCQ4
DM6IR3P	MN	Organic anion transporting polypeptide 1C1 (SLCO1C1)
DM6IR3P	MT	DTP
DM6IR3P	MA	Substrate
DM6IR3P	RN	Involvement of multispecific organic anion transporter, Oatp14 (Slc21a14), in the transport of thyroxine across the blood-brain barrier. Endocrinology. 2004 Sep;145(9):4384-91.
DM6IR3P	RU	http://www.ncbi.nlm.nih.gov/pubmed/15166123

DM6IR3P	DI	DM6IR3P
DM6IR3P	DN	Liothyronine
DM6IR3P	MI	DT8H2IC
DM6IR3P	MN	Organic anion transporting polypeptide 4A1 (SLCO4A1)
DM6IR3P	MT	DTP
DM6IR3P	MA	Substrate
DM6IR3P	RN	Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3569-74.
DM6IR3P	RU	http://www.ncbi.nlm.nih.gov/pubmed/14993604

DM6IR3P	DI	DM6IR3P
DM6IR3P	DN	Liothyronine
DM6IR3P	MI	DTY0QMU
DM6IR3P	MN	Organic anion transporting polypeptide 4C1 (SLCO4C1)
DM6IR3P	MT	DTP
DM6IR3P	MA	Substrate
DM6IR3P	RN	Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3569-74.
DM6IR3P	RU	http://www.ncbi.nlm.nih.gov/pubmed/14993604

DM6IR3P	DI	DM6IR3P
DM6IR3P	DN	Liothyronine
DM6IR3P	MI	DT56EKP
DM6IR3P	MN	Sodium/taurocholate cotransporting polypeptide (SLC10A1)
DM6IR3P	MT	DTP
DM6IR3P	MA	Substrate
DM6IR3P	RN	Identification of thyroid hormone transporters. Biochem Biophys Res Commun. 1999 Jan 19;254(2):497-501.
DM6IR3P	RU	http://www.ncbi.nlm.nih.gov/pubmed/9918867

DM6IR3P	DI	DM6IR3P
DM6IR3P	DN	Liothyronine
DM6IR3P	MI	DEYWLRK
DM6IR3P	MN	Sulfotransferase 1A1 (SULT1A1)
DM6IR3P	MT	DME
DM6IR3P	MA	Metabolism
DM6IR3P	RN	Characterization of human liver thermostable phenol sulfotransferase (SULT1A1) allozymes with 3,3',5-triiodothyronine as the substrate. J Endocrinol. 2001 Dec;171(3):525-32.
DM6IR3P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11739018

DM6IR3P	DI	DM6IR3P
DM6IR3P	DN	Liothyronine
DM6IR3P	MI	TTTSEPU
DM6IR3P	MN	Thyroid hormone receptor alpha (THRA)
DM6IR3P	MT	DTT
DM6IR3P	MA	Antagonist
DM6IR3P	RN	Evaluation of thyroid hormone action in a case of generalized resistance to thyroid hormone with chronic thyroiditis: discovery of a novel heterozy... Endocr J. 2007 Dec;54(5):727-32.
DM6IR3P	RU	https://pubmed.ncbi.nlm.nih.gov/17827792

DM6IR3P	DI	DM6IR3P
DM6IR3P	DN	Liothyronine
DM6IR3P	MI	DEYGVN4
DM6IR3P	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM6IR3P	MT	DME
DM6IR3P	MA	Metabolism
DM6IR3P	RN	FDA Label of Liothyronine sodium. The 2020 official website of the U.S. Food and Drug Administration.
DM6IR3P	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/010379s054lbl.pdf

DMSTXWR	DI	DMSTXWR
DMSTXWR	DN	Liotrix
DMSTXWR	MI	DE4LYSA
DMSTXWR	MN	Cytochrome P450 3A4 (CYP3A4)
DMSTXWR	MT	DME
DMSTXWR	MA	Metabolism
DMSTXWR	RN	A basic conceptual and practical overview of interactions with highly prescribed drugs. Can J Clin Pharmacol. 2002 Winter;9(4):191-8.
DMSTXWR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12584577

DM3FXPS	DI	DM3FXPS
DM3FXPS	DN	Liraglutide
DM3FXPS	MI	DEKZQY6
DM3FXPS	MN	Dipeptidyl peptidase IV (DPP4)
DM3FXPS	MT	DME
DM3FXPS	MA	Metabolism
DM3FXPS	RN	Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos. 2010 Nov;38(11):1944-53.
DM3FXPS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20709939

DM3FXPS	DI	DM3FXPS
DM3FXPS	DN	Liraglutide
DM3FXPS	MI	TTVIMDE
DM3FXPS	MN	Glucagon-like peptide 1 receptor (GLP1R)
DM3FXPS	MT	DTT
DM3FXPS	MA	Agonist
DM3FXPS	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DM3FXPS	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DM3FXPS	DI	DM3FXPS
DM3FXPS	DN	Liraglutide
DM3FXPS	MI	DEVN830
DM3FXPS	MN	Neprilysin (MME)
DM3FXPS	MT	DME
DM3FXPS	MA	Metabolism
DM3FXPS	RN	Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos. 2010 Nov;38(11):1944-53.
DM3FXPS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20709939

DM6W8V5	DI	DM6W8V5
DM6W8V5	DN	Lisdexamfetamine
DM6W8V5	MI	DECB0K3
DM6W8V5	MN	Cytochrome P450 2D6 (CYP2D6)
DM6W8V5	MT	DME
DM6W8V5	MA	Metabolism
DM6W8V5	RN	Preclinical pharmacokinetics, pharmacology and toxicology of lisdexamfetamine: a novel d-amphetamine pro-drug. Neuropharmacology. 2014 Dec;87:41-50.
DM6W8V5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24594478

DM6W8V5	DI	DM6W8V5
DM6W8V5	DN	Lisdexamfetamine
DM6W8V5	MI	DT9G7XN
DM6W8V5	MN	Peptide transporter 1 (SLC15A1)
DM6W8V5	MT	DTP
DM6W8V5	MA	Substrate
DM6W8V5	RN	Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat. 2010 Jun 24;6:317-27.
DM6W8V5	RU	http://www.ncbi.nlm.nih.gov/pubmed/20628632

DM6W8V5	DI	DM6W8V5
DM6W8V5	DN	Lisdexamfetamine
DM6W8V5	MI	TTIU98M
DM6W8V5	MN	Trace amine-associated receptor-1 (TAAR1)
DM6W8V5	MT	DTT
DM6W8V5	MA	Modulator
DM6W8V5	RN	2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
DM6W8V5	RU	https://pubmed.ncbi.nlm.nih.gov/18246607

DMUOK4C	DI	DMUOK4C
DMUOK4C	DN	Lisinopril
DMUOK4C	MI	TTL69WB
DMUOK4C	MN	Angiotensin-converting enzyme (ACE)
DMUOK4C	MT	DTT
DMUOK4C	MA	Inhibitor
DMUOK4C	RN	Involvement of vascular angiotensin II-forming enzymes in the progression of aortic abdominal aneurysms in angiotensin II- infused ApoE-deficient m... J Atheroscler Thromb. 2009 Jun;16(3):164-71.
DMUOK4C	RU	https://pubmed.ncbi.nlm.nih.gov/19556720

DMUOK4C	DI	DMUOK4C
DMUOK4C	DN	Lisinopril
DMUOK4C	MI	DT9G7XN
DMUOK4C	MN	Peptide transporter 1 (SLC15A1)
DMUOK4C	MT	DTP
DMUOK4C	MA	Substrate
DMUOK4C	RN	Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells. Arch Pharm Res. 2007 Apr;30(4):507-18.
DMUOK4C	RU	https://doi.org/10.1007/BF02980227

DMP45ME	DI	DMP45ME
DMP45ME	DN	Lisocabtagene maraleucel
DMP45ME	MI	TTW640A
DMP45ME	MN	B-lymphocyte surface antigen B4 (CD19)
DMP45ME	MT	DTT
DMP45ME	MA	CAR-T-Cell-Therapy
DMP45ME	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services.
DMP45ME	RU	https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/breyanzi-lisocabtagene-maraleucel

DMCME17	DI	DMCME17
DMCME17	DN	Lisuride
DMCME17	MI	DECB0K3
DMCME17	MN	Cytochrome P450 2D6 (CYP2D6)
DMCME17	MT	DME
DMCME17	MA	Metabolism
DMCME17	RN	Stable expression of human cytochrome P450 3A4 in V79 cells and its application for metabolic profiling of ergot derivatives. Eur J Pharmacol. 1995 Oct 6;293(3):183-90.
DMCME17	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8666035

DMCME17	DI	DMCME17
DMCME17	DN	Lisuride
DMCME17	MI	DE4LYSA
DMCME17	MN	Cytochrome P450 3A4 (CYP3A4)
DMCME17	MT	DME
DMCME17	MA	Metabolism
DMCME17	RN	Stable expression of human cytochrome P450 3A4 in V79 cells and its application for metabolic profiling of ergot derivatives. Eur J Pharmacol. 1995 Oct 6;293(3):183-90.
DMCME17	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8666035

DMCME17	DI	DMCME17
DMCME17	DN	Lisuride
DMCME17	MI	TTEX248
DMCME17	MN	Dopamine D2 receptor (D2R)
DMCME17	MT	DTT
DMCME17	MA	Agonist
DMCME17	RN	Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol. 2007 Sep;6(9):826-9.
DMCME17	RU	https://pubmed.ncbi.nlm.nih.gov/17706566

DMX9PIA	DI	DMX9PIA
DMX9PIA	DN	Live attenuated influenza vaccine
DMX9PIA	MI	TT3J5ZI
DMX9PIA	MN	Cell mediated immunity response (CMIR)
DMX9PIA	MT	DTT
DMX9PIA	RN	Flu myths: dispelling the myths associated with live attenuated influenza vaccine. Mayo Clin Proc. 2008 Jan;83(1):77-84.
DMX9PIA	RU	https://pubmed.ncbi.nlm.nih.gov/18174020

DM0QJDC	DI	DM0QJDC
DM0QJDC	DN	Lixisenatide
DM0QJDC	MI	TTVIMDE
DM0QJDC	MN	Glucagon-like peptide 1 receptor (GLP1R)
DM0QJDC	MT	DTT
DM0QJDC	MA	Modulator
DM0QJDC	RN	GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.Nat Rev Endocrinol.2012 Dec;8(12):728-42.
DM0QJDC	RU	https://www.ncbi.nlm.nih.gov/pubmed/22945360

DMJPD06	DI	DMJPD06
DMJPD06	DN	Lmw heparin
DMJPD06	MI	TTCIHJA
DMJPD06	MN	Coagulation factor Xa (F10)
DMJPD06	MT	DTT
DMJPD06	MA	Modulator
DMJPD06	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMJPD06	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DMHY3IP	DI	DMHY3IP
DMHY3IP	DN	Lobeglitazone
DMHY3IP	MI	DES5XRU
DMHY3IP	MN	Cytochrome P450 2C8 (CYP2C8)
DMHY3IP	MT	DME
DMHY3IP	MA	Metabolism
DMHY3IP	RN	Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther. 2005 May;77(5):404-14.
DMHY3IP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15900286

DMHY3IP	DI	DMHY3IP
DMHY3IP	DN	Lobeglitazone
DMHY3IP	MI	DE4LYSA
DMHY3IP	MN	Cytochrome P450 3A4 (CYP3A4)
DMHY3IP	MT	DME
DMHY3IP	MA	Metabolism
DMHY3IP	RN	Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on the pharmacokinetics and pharmacodynamics of warfarin. Drug Des Devel Ther. 2015 Mar 2;9:737-43.
DMHY3IP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25767371

DMHY3IP	DI	DMHY3IP
DMHY3IP	DN	Lobeglitazone
DMHY3IP	MI	TTJ584C
DMHY3IP	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMHY3IP	MT	DTT
DMHY3IP	MA	Agonist
DMHY3IP	RN	Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, after a single oral administration in healthy female subjects. Clin Drug Investig. 2014 Jul;34(7):467-74.
DMHY3IP	RU	https://pubmed.ncbi.nlm.nih.gov/24802657

DMHY3IP	DI	DMHY3IP
DMHY3IP	DN	Lobeglitazone
DMHY3IP	MI	TTZMAO3
DMHY3IP	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMHY3IP	MT	DTT
DMHY3IP	MA	Agonist
DMHY3IP	RN	Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, after a single oral administration in healthy female subjects. Clin Drug Investig. 2014 Jul;34(7):467-74.
DMHY3IP	RU	https://pubmed.ncbi.nlm.nih.gov/24802657

DM1WXA6	DI	DM1WXA6
DM1WXA6	DN	Lofexidine
DM1WXA6	MI	TTQ8AFT
DM1WXA6	MN	Adrenergic receptor Alpha-2 (ADRA2)
DM1WXA6	MT	DTT
DM1WXA6	MA	Agonist
DM1WXA6	RN	Clinical pharmacokinetics of lofexidine, the alpha 2-adrenergic receptor agonist, in opiate addicts plasma using a highly sensitive liquid chromatography tandem mass spectrometric analysis. Am J DrugAlcohol Abuse. 2008;34(5):611-6.
DM1WXA6	RU	https://pubmed.ncbi.nlm.nih.gov/18821454

DM1WXA6	DI	DM1WXA6
DM1WXA6	DN	Lofexidine
DM1WXA6	MI	TTWG9A4
DM1WXA6	MN	Adrenergic receptor alpha-2A (ADRA2A)
DM1WXA6	MT	DTT
DM1WXA6	MA	Agonist
DM1WXA6	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DM1WXA6	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DM1WXA6	DI	DM1WXA6
DM1WXA6	DN	Lofexidine
DM1WXA6	MI	DEJGDUW
DM1WXA6	MN	Cytochrome P450 1A2 (CYP1A2)
DM1WXA6	MT	DME
DM1WXA6	MA	Metabolism
DM1WXA6	RN	The Drugs.com International Drug Name Database: Lofexidine
DM1WXA6	RU	https://www.drugs.com/ppa/lofexidine.html

DM1WXA6	DI	DM1WXA6
DM1WXA6	DN	Lofexidine
DM1WXA6	MI	DECB0K3
DM1WXA6	MN	Cytochrome P450 2D6 (CYP2D6)
DM1WXA6	MT	DME
DM1WXA6	MA	Metabolism
DM1WXA6	RN	Advisory committee lofexidine hydrochloride (lucemyratm) briefing document.
DM1WXA6	RU	https://www.fda.gov/media/111903/download

DM1WXA6	DI	DM1WXA6
DM1WXA6	DN	Lofexidine
DM1WXA6	MI	DEGTFWK
DM1WXA6	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM1WXA6	MT	DME
DM1WXA6	MA	Metabolism
DM1WXA6	RN	Advisory committee lofexidine hydrochloride (lucemyratm) briefing document.
DM1WXA6	RU	https://www.fda.gov/media/111903/download

DMVRH9C	DI	DMVRH9C
DMVRH9C	DN	Lomefloxacin
DMVRH9C	MI	DEJGDUW
DMVRH9C	MN	Cytochrome P450 1A2 (CYP1A2)
DMVRH9C	MT	DME
DMVRH9C	MA	Metabolism
DMVRH9C	RN	Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro. Antimicrob Agents Chemother. 1992 May;36(5):942-8.
DMVRH9C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1510417

DMVRH9C	DI	DMVRH9C
DMVRH9C	DN	Lomefloxacin
DMVRH9C	MI	TT0IHXV
DMVRH9C	MN	DNA topoisomerase II (TOP2)
DMVRH9C	MT	DTT
DMVRH9C	MA	Inhibitor
DMVRH9C	RN	Inhibition of human topoisomerase IIalpha by fluoroquinolones and ultraviolet A irradiation. Toxicol Sci. 2002 Sep;69(1):16-22.
DMVRH9C	RU	https://pubmed.ncbi.nlm.nih.gov/12215656

DMVRH9C	DI	DMVRH9C
DMVRH9C	DN	Lomefloxacin
DMVRH9C	MI	DTE2B1D
DMVRH9C	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMVRH9C	MT	DTP
DMVRH9C	MA	Substrate
DMVRH9C	RN	Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm. 2007 Jan-Feb;4(1):85-94.
DMVRH9C	RU	http://www.ncbi.nlm.nih.gov/pubmed/17274666

DME0TC8	DI	DME0TC8
DME0TC8	DN	Lomerizine
DME0TC8	MI	DE4LYSA
DME0TC8	MN	Cytochrome P450 3A4 (CYP3A4)
DME0TC8	MT	DME
DME0TC8	MA	Metabolism
DME0TC8	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DME0TC8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DME0TC8	DI	DME0TC8
DME0TC8	DN	Lomerizine
DME0TC8	MI	TTRK8B9
DME0TC8	MN	Sodium channel unspecific (NaC)
DME0TC8	MT	DTT
DME0TC8	MA	Inhibitor
DME0TC8	RN	Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37.
DME0TC8	RU	https://pubmed.ncbi.nlm.nih.gov/11170622

DME0TC8	DI	DME0TC8
DME0TC8	DN	Lomerizine
DME0TC8	MI	TT4FDG6
DME0TC8	MN	Voltage-gated calcium channel alpha Cav2.2 (CACNA1B)
DME0TC8	MT	DTT
DME0TC8	MA	Inhibitor
DME0TC8	RN	Synthesis and SAR of novel 2-arylthiazolidinones as selective analgesic N-type calcium channel blockers. Bioorg Med Chem Lett. 2007 Feb 1;17(3):662-7.
DME0TC8	RU	https://pubmed.ncbi.nlm.nih.gov/17134896

DME0TC8	DI	DME0TC8
DME0TC8	DN	Lomerizine
DME0TC8	MI	TTZOVE0
DME0TC8	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DME0TC8	MT	DTT
DME0TC8	MA	Inhibitor
DME0TC8	RN	Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37.
DME0TC8	RU	https://pubmed.ncbi.nlm.nih.gov/11170622

DMLB4PE	DI	DMLB4PE
DMLB4PE	DN	Lomitapide mesylate
DMLB4PE	MI	DE4LYSA
DMLB4PE	MN	Cytochrome P450 3A4 (CYP3A4)
DMLB4PE	MT	DME
DMLB4PE	MA	Metabolism
DMLB4PE	RN	Evaluation of the effects of the weak CYP3A inhibitors atorvastatin and ethinyl estradiol/norgestimate on lomitapide pharmacokinetics in healthy subjects. J Clin Pharmacol. 2016 Jan;56(1):47-55.
DMLB4PE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26120010

DMMWSUL	DI	DMMWSUL
DMMWSUL	DN	Lomustine
DMMWSUL	MI	TTUTN1I
DMMWSUL	MN	Human Deoxyribonucleic acid (hDNA)
DMMWSUL	MT	DTT
DMMWSUL	MA	Inhibitor
DMMWSUL	RN	Synthesis and evaluation of ethylnitrosoureas of substituted naphthalimides as anticancer compounds. Acta Pol Pharm. 2007 Jan-Feb;64(1):27-33.
DMMWSUL	RU	https://pubmed.ncbi.nlm.nih.gov/17665847

DMGM2Z6	DI	DMGM2Z6
DMGM2Z6	DN	Lonafarnib
DMGM2Z6	MI	DE4LYSA
DMGM2Z6	MN	Cytochrome P450 3A4 (CYP3A4)
DMGM2Z6	MT	DME
DMGM2Z6	MA	Metabolism
DMGM2Z6	RN	Identification of human liver cytochrome P450 enzymes responsible for the metabolism of lonafarnib (Sarasar). Drug Metab Dispos. 2006 Apr;34(4):628-35.
DMGM2Z6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16443667

DMGM2Z6	DI	DMGM2Z6
DMGM2Z6	DN	Lonafarnib
DMGM2Z6	MI	DEIBDNY
DMGM2Z6	MN	Cytochrome P450 3A5 (CYP3A5)
DMGM2Z6	MT	DME
DMGM2Z6	MA	Metabolism
DMGM2Z6	RN	Identification of human liver cytochrome P450 enzymes responsible for the metabolism of lonafarnib (Sarasar). Drug Metab Dispos. 2006 Apr;34(4):628-35.
DMGM2Z6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16443667

DMGM2Z6	DI	DMGM2Z6
DMGM2Z6	DN	Lonafarnib
DMGM2Z6	MI	TTXQKM3
DMGM2Z6	MN	Farnesyl protein transferase (Ftase)
DMGM2Z6	MT	DTT
DMGM2Z6	MA	Modulator
DMGM2Z6	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMGM2Z6	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213969s000lbl.pdf

DMXSVGI	DI	DMXSVGI
DMXSVGI	DN	Loncastuximab tesirine
DMXSVGI	MI	TTW640A
DMXSVGI	MN	B-lymphocyte surface antigen B4 (CD19)
DMXSVGI	MT	DTT
DMXSVGI	MA	Inhibitor
DMXSVGI	RN	Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021 May 13;137(19):2634-2645.
DMXSVGI	RU	https://pubmed.ncbi.nlm.nih.gov/33211842

DMOJZQ9	DI	DMOJZQ9
DMOJZQ9	DN	Loperamide
DMOJZQ9	MI	DEPKLMQ
DMOJZQ9	MN	Cytochrome P450 2B6 (CYP2B6)
DMOJZQ9	MT	DME
DMOJZQ9	MA	Metabolism
DMOJZQ9	RN	Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur J Clin Pharmacol. 2004 Oct;60(8):575-81.
DMOJZQ9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15365656

DMOJZQ9	DI	DMOJZQ9
DMOJZQ9	DN	Loperamide
DMOJZQ9	MI	DES5XRU
DMOJZQ9	MN	Cytochrome P450 2C8 (CYP2C8)
DMOJZQ9	MT	DME
DMOJZQ9	MA	Metabolism
DMOJZQ9	RN	Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur J Clin Pharmacol. 2004 Oct;60(8):575-81.
DMOJZQ9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15365656

DMOJZQ9	DI	DMOJZQ9
DMOJZQ9	DN	Loperamide
DMOJZQ9	MI	DECB0K3
DMOJZQ9	MN	Cytochrome P450 2D6 (CYP2D6)
DMOJZQ9	MT	DME
DMOJZQ9	MA	Metabolism
DMOJZQ9	RN	Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur J Clin Pharmacol. 2004 Oct;60(8):575-81.
DMOJZQ9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15365656

DMOJZQ9	DI	DMOJZQ9
DMOJZQ9	DN	Loperamide
DMOJZQ9	MI	DE4LYSA
DMOJZQ9	MN	Cytochrome P450 3A4 (CYP3A4)
DMOJZQ9	MT	DME
DMOJZQ9	MA	Metabolism
DMOJZQ9	RN	Loperamide: a pharmacological review. Rev Gastroenterol Disord. 2007;7 Suppl 3:S11-8.
DMOJZQ9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18192961

DMOJZQ9	DI	DMOJZQ9
DMOJZQ9	DN	Loperamide
DMOJZQ9	MI	TT27RFC
DMOJZQ9	MN	Opioid receptor delta (OPRD1)
DMOJZQ9	MT	DTT
DMOJZQ9	MA	Binder
DMOJZQ9	RN	Loperamide: evidence of interaction with mu and delta opioid receptors. Life Sci. 1983;33 Suppl 1:315-8.
DMOJZQ9	RU	https://pubmed.ncbi.nlm.nih.gov/6319884

DMOJZQ9	DI	DMOJZQ9
DMOJZQ9	DN	Loperamide
DMOJZQ9	MI	DEDPI65
DMOJZQ9	MN	Oxygen-insensitive NADPH nitroreductase A (nfsA)
DMOJZQ9	MT	DME
DMOJZQ9	MA	Metabolism
DMOJZQ9	RN	Reduction of the prodrug loperamide oxide to its active drug loperamide in the gut of rats, dogs, and humans. Drug Metab Dispos. 1995 Mar;23(3):354-62.
DMOJZQ9	RU	https://pubmed.ncbi.nlm.nih.gov/7628301

DMOJZQ9	DI	DMOJZQ9
DMOJZQ9	DN	Loperamide
DMOJZQ9	MI	DTUGYRD
DMOJZQ9	MN	P-glycoprotein 1 (ABCB1)
DMOJZQ9	MT	DTP
DMOJZQ9	MA	Substrate
DMOJZQ9	RN	In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab Dispos. 2008 Feb;36(2):268-75.
DMOJZQ9	RU	http://www.ncbi.nlm.nih.gov/pubmed/17962372

DMITQS0	DI	DMITQS0
DMITQS0	DN	Lopinavir
DMITQS0	MI	TTLFGBV
DMITQS0	MN	Bacterial 23S ribosomal RNA (Bact 23S rRNA)
DMITQS0	MT	DTT
DMITQS0	MA	Modulator
DMITQS0	RN	Company report (JMI Laboratories)
DMITQS0	RU	http://www.jmilabs.com/data/posters/ICAAC2013%5CE-144.pdf

DMITQS0	DI	DMITQS0
DMITQS0	DN	Lopinavir
DMITQS0	MI	DTI7UX6
DMITQS0	MN	Breast cancer resistance protein (ABCG2)
DMITQS0	MT	DTP
DMITQS0	MA	Substrate
DMITQS0	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMITQS0	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMITQS0	DI	DMITQS0
DMITQS0	DN	Lopinavir
DMITQS0	MI	DE4LYSA
DMITQS0	MN	Cytochrome P450 3A4 (CYP3A4)
DMITQS0	MT	DME
DMITQS0	MA	Metabolism
DMITQS0	RN	Synthesis and antiviral activities of the major metabolites of the HIV protease inhibitor ABT-378 (Lopinavir). Bioorg Med Chem Lett. 2001 Jun 4;11(11):1351-3.
DMITQS0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11378352

DMITQS0	DI	DMITQS0
DMITQS0	DN	Lopinavir
DMITQS0	MI	DTSYQGK
DMITQS0	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMITQS0	MT	DTP
DMITQS0	MA	Substrate
DMITQS0	RN	Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother. 2007 Nov;60(5):987-93.
DMITQS0	RU	http://www.ncbi.nlm.nih.gov/pubmed/17890284

DMITQS0	DI	DMITQS0
DMITQS0	DN	Lopinavir
DMITQS0	MI	DTFI42L
DMITQS0	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMITQS0	MT	DTP
DMITQS0	MA	Substrate
DMITQS0	RN	Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir. Br J Pharmacol. 2010 Jul;160(5):1224-33.
DMITQS0	RU	http://www.ncbi.nlm.nih.gov/pubmed/20590614

DMITQS0	DI	DMITQS0
DMITQS0	DN	Lopinavir
DMITQS0	MI	DT3D8F0
DMITQS0	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMITQS0	MT	DTP
DMITQS0	MA	Substrate
DMITQS0	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DMITQS0	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DMITQS0	DI	DMITQS0
DMITQS0	DN	Lopinavir
DMITQS0	MI	DTUGYRD
DMITQS0	MN	P-glycoprotein 1 (ABCB1)
DMITQS0	MT	DTP
DMITQS0	MA	Substrate
DMITQS0	RN	Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir. Br J Pharmacol. 2010 Jul;160(5):1224-33.
DMITQS0	RU	http://www.ncbi.nlm.nih.gov/pubmed/20590614

DM4L8H3	DI	DM4L8H3
DM4L8H3	DN	Loracarbef
DM4L8H3	MI	TTJP4SM
DM4L8H3	MN	Bacterial Penicillin binding protein (Bact PBP)
DM4L8H3	MT	DTT
DM4L8H3	MA	Binder
DM4L8H3	RN	Amino acid substitutions in mosaic penicillin-binding protein 2 associated with reduced susceptibility to cefixime in clinical isolates of Neisseri... Antimicrob Agents Chemother. 2006 Nov;50(11):3638-45.
DM4L8H3	RU	https://pubmed.ncbi.nlm.nih.gov/16940068

DMF3AN7	DI	DMF3AN7
DMF3AN7	DN	Loratadine
DMF3AN7	MI	DEJGDUW
DMF3AN7	MN	Cytochrome P450 1A2 (CYP1A2)
DMF3AN7	MT	DME
DMF3AN7	MA	Metabolism
DMF3AN7	RN	Metabolism of loratadine and further characterization of its in vitro metabolites. Drug Metab Lett. 2009 Aug;3(3):162-70.
DMF3AN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19702548

DMF3AN7	DI	DMF3AN7
DMF3AN7	DN	Loratadine
DMF3AN7	MI	DEPKLMQ
DMF3AN7	MN	Cytochrome P450 2B6 (CYP2B6)
DMF3AN7	MT	DME
DMF3AN7	MA	Metabolism
DMF3AN7	RN	Metabolism of loratadine and further characterization of its in vitro metabolites. Drug Metab Lett. 2009 Aug;3(3):162-70.
DMF3AN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19702548

DMF3AN7	DI	DMF3AN7
DMF3AN7	DN	Loratadine
DMF3AN7	MI	DES5XRU
DMF3AN7	MN	Cytochrome P450 2C8 (CYP2C8)
DMF3AN7	MT	DME
DMF3AN7	MA	Metabolism
DMF3AN7	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DMF3AN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DMF3AN7	DI	DMF3AN7
DMF3AN7	DN	Loratadine
DMF3AN7	MI	DE5IED8
DMF3AN7	MN	Cytochrome P450 2C9 (CYP2C9)
DMF3AN7	MT	DME
DMF3AN7	MA	Metabolism
DMF3AN7	RN	In vitro inhibition of human liver drug metabolizing enzymes by second generation antihistamines. Chem Biol Interact. 1999 Nov 15;123(1):63-79.
DMF3AN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10597902

DMF3AN7	DI	DMF3AN7
DMF3AN7	DN	Loratadine
DMF3AN7	MI	DECB0K3
DMF3AN7	MN	Cytochrome P450 2D6 (CYP2D6)
DMF3AN7	MT	DME
DMF3AN7	MA	Metabolism
DMF3AN7	RN	In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. Drug Metab Dispos. 2001 Sep;29(9):1173-5.
DMF3AN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11502723

DMF3AN7	DI	DMF3AN7
DMF3AN7	DN	Loratadine
DMF3AN7	MI	DE4LYSA
DMF3AN7	MN	Cytochrome P450 3A4 (CYP3A4)
DMF3AN7	MT	DME
DMF3AN7	MA	Metabolism
DMF3AN7	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMF3AN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMF3AN7	DI	DMF3AN7
DMF3AN7	DN	Loratadine
DMF3AN7	MI	DEIBDNY
DMF3AN7	MN	Cytochrome P450 3A5 (CYP3A5)
DMF3AN7	MT	DME
DMF3AN7	MA	Metabolism
DMF3AN7	RN	Metabolism of loratadine and further characterization of its in vitro metabolites. Drug Metab Lett. 2009 Aug;3(3):162-70.
DMF3AN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19702548

DMF3AN7	DI	DMF3AN7
DMF3AN7	DN	Loratadine
DMF3AN7	MI	TTTIBOJ
DMF3AN7	MN	Histamine H1 receptor (H1R)
DMF3AN7	MT	DTT
DMF3AN7	MA	Antagonist
DMF3AN7	RN	Clinical research of Ibudilast on treating the steroid resistant allergic rhinitis. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009 Jan;23(2):63-6.
DMF3AN7	RU	https://pubmed.ncbi.nlm.nih.gov/19452709

DMF3AN7	DI	DMF3AN7
DMF3AN7	DN	Loratadine
DMF3AN7	MI	DEGTFWK
DMF3AN7	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMF3AN7	MT	DME
DMF3AN7	MA	Metabolism
DMF3AN7	RN	Advances in high-resolution MS and hepatocyte models solve a long-standing metabolism challenge: the loratadine story. Bioanalysis. 2016 Aug;8(16):1645-62.
DMF3AN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27460981

DMF3AN7	DI	DMF3AN7
DMF3AN7	DN	Loratadine
DMF3AN7	MI	DTUGYRD
DMF3AN7	MN	P-glycoprotein 1 (ABCB1)
DMF3AN7	MT	DTP
DMF3AN7	MA	Substrate
DMF3AN7	RN	P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos. 2003 Mar;31(3):312-8.
DMF3AN7	RU	http://www.ncbi.nlm.nih.gov/pubmed/12584158

DM84ZXF	DI	DM84ZXF
DM84ZXF	DN	Lorazepam
DM84ZXF	MI	TTPTXIN
DM84ZXF	MN	Translocator protein (TSPO)
DM84ZXF	MT	DTT
DM84ZXF	MA	Modulator
DM84ZXF	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM84ZXF	RU	https://www.fda.gov/

DM84ZXF	DI	DM84ZXF
DM84ZXF	DN	Lorazepam
DM84ZXF	MI	DENZ6B1
DM84ZXF	MN	UDP-glucuronosyltransferase 2B15 (UGT2B15)
DM84ZXF	MT	DME
DM84ZXF	MA	Metabolism
DM84ZXF	RN	Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers. Clin Pharmacol Ther. 2005 Jun;77(6):486-94.
DM84ZXF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15961980

DM84ZXF	DI	DM84ZXF
DM84ZXF	DN	Lorazepam
DM84ZXF	MI	DEB3CV1
DM84ZXF	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DM84ZXF	MT	DME
DM84ZXF	MA	Metabolism
DM84ZXF	RN	Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2008 Apr;83(4):595-600.
DM84ZXF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17687269

DMG6OYJ	DI	DMG6OYJ
DMG6OYJ	DN	Lorcaserin
DMG6OYJ	MI	TTWJBZ5
DMG6OYJ	MN	5-HT 2C receptor (HTR2C)
DMG6OYJ	MT	DTT
DMG6OYJ	MA	Agonist
DMG6OYJ	RN	Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
DMG6OYJ	RU	https://pubmed.ncbi.nlm.nih.gov/18473708

DMG6OYJ	DI	DMG6OYJ
DMG6OYJ	DN	Lorcaserin
DMG6OYJ	MI	DEJGDUW
DMG6OYJ	MN	Cytochrome P450 1A2 (CYP1A2)
DMG6OYJ	MT	DME
DMG6OYJ	MA	Metabolism
DMG6OYJ	RN	Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos. 2012 Apr;40(4):761-71.
DMG6OYJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22266842

DMG6OYJ	DI	DMG6OYJ
DMG6OYJ	DN	Lorcaserin
DMG6OYJ	MI	DEJVYAZ
DMG6OYJ	MN	Cytochrome P450 2A6 (CYP2A6)
DMG6OYJ	MT	DME
DMG6OYJ	MA	Metabolism
DMG6OYJ	RN	Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos. 2012 Apr;40(4):761-71.
DMG6OYJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22266842

DMG6OYJ	DI	DMG6OYJ
DMG6OYJ	DN	Lorcaserin
DMG6OYJ	MI	DEPKLMQ
DMG6OYJ	MN	Cytochrome P450 2B6 (CYP2B6)
DMG6OYJ	MT	DME
DMG6OYJ	MA	Metabolism
DMG6OYJ	RN	Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos. 2012 Apr;40(4):761-71.
DMG6OYJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22266842

DMG6OYJ	DI	DMG6OYJ
DMG6OYJ	DN	Lorcaserin
DMG6OYJ	MI	DECB0K3
DMG6OYJ	MN	Cytochrome P450 2D6 (CYP2D6)
DMG6OYJ	MT	DME
DMG6OYJ	MA	Metabolism
DMG6OYJ	RN	Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos. 2012 Apr;40(4):761-71.
DMG6OYJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22266842

DMG6OYJ	DI	DMG6OYJ
DMG6OYJ	DN	Lorcaserin
DMG6OYJ	MI	DE4LYSA
DMG6OYJ	MN	Cytochrome P450 3A4 (CYP3A4)
DMG6OYJ	MT	DME
DMG6OYJ	MA	Metabolism
DMG6OYJ	RN	Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos. 2012 Apr;40(4):761-71.
DMG6OYJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22266842

DMG6OYJ	DI	DMG6OYJ
DMG6OYJ	DN	Lorcaserin
DMG6OYJ	MI	DEGTFWK
DMG6OYJ	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMG6OYJ	MT	DME
DMG6OYJ	MA	Metabolism
DMG6OYJ	RN	Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos. 2012 Apr;40(4):761-71.
DMG6OYJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22266842

DMICDLV	DI	DMICDLV
DMICDLV	DN	Lorlatinib
DMICDLV	MI	TTPMQSO
DMICDLV	MN	ALK tyrosine kinase receptor (ALK)
DMICDLV	MT	DTT
DMICDLV	MA	Inhibitor
DMICDLV	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMICDLV	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMICDLV	DI	DMICDLV
DMICDLV	DN	Lorlatinib
DMICDLV	MI	DES5XRU
DMICDLV	MN	Cytochrome P450 2C8 (CYP2C8)
DMICDLV	MT	DME
DMICDLV	MA	Metabolism
DMICDLV	RN	FDA label of Lorlatinib. The 2020 official website of the U.S. Food and Drug Administration.
DMICDLV	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf

DMICDLV	DI	DMICDLV
DMICDLV	DN	Lorlatinib
DMICDLV	MI	DE4LYSA
DMICDLV	MN	Cytochrome P450 3A4 (CYP3A4)
DMICDLV	MT	DME
DMICDLV	MA	Metabolism
DMICDLV	RN	FDA label of Lorlatinib. The 2020 official website of the U.S. Food and Drug Administration.
DMICDLV	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf

DMICDLV	DI	DMICDLV
DMICDLV	DN	Lorlatinib
DMICDLV	MI	DEIBDNY
DMICDLV	MN	Cytochrome P450 3A5 (CYP3A5)
DMICDLV	MT	DME
DMICDLV	MA	Metabolism
DMICDLV	RN	FDA label of Lorlatinib. The 2020 official website of the U.S. Food and Drug Administration.
DMICDLV	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf

DMICDLV	DI	DMICDLV
DMICDLV	DN	Lorlatinib
DMICDLV	MI	DERD86B
DMICDLV	MN	Cytochrome P450 3A7 (CYP3A7)
DMICDLV	MT	DME
DMICDLV	MA	Metabolism
DMICDLV	RN	Product characteristics of Lorviqua.
DMICDLV	RU	https://www.ema.europa.eu/en/documents/product-information/lorviqua-epar-product-information_en.pdf

DMICDLV	DI	DMICDLV
DMICDLV	DN	Lorlatinib
DMICDLV	MI	DEGTFWK
DMICDLV	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMICDLV	MT	DME
DMICDLV	MA	Metabolism
DMICDLV	RN	FDA label of Lorlatinib. The 2020 official website of the U.S. Food and Drug Administration.
DMICDLV	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf

DMICDLV	DI	DMICDLV
DMICDLV	DN	Lorlatinib
DMICDLV	MI	TTSZ6Y3
DMICDLV	MN	Proto-oncogene c-Ros (ROS1)
DMICDLV	MT	DTT
DMICDLV	MA	Inhibitor
DMICDLV	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMICDLV	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMICDLV	DI	DMICDLV
DMICDLV	DN	Lorlatinib
DMICDLV	MI	DEF2WXN
DMICDLV	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMICDLV	MT	DME
DMICDLV	MA	Metabolism
DMICDLV	RN	FDA label of Lorlatinib. The 2020 official website of the U.S. Food and Drug Administration.
DMICDLV	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf

DMICDLV	DI	DMICDLV
DMICDLV	DN	Lorlatinib
DMICDLV	MI	DELOY3P
DMICDLV	MN	UDP-glucuronosyltransferase 1A4 (UGT1A4)
DMICDLV	MT	DME
DMICDLV	MA	Metabolism
DMICDLV	RN	FDA label of Lorlatinib. The 2020 official website of the U.S. Food and Drug Administration.
DMICDLV	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf

DMYZFXN	DI	DMYZFXN
DMYZFXN	DN	Lornoxicam
DMYZFXN	MI	DE5IED8
DMYZFXN	MN	Cytochrome P450 2C9 (CYP2C9)
DMYZFXN	MT	DME
DMYZFXN	MA	Metabolism
DMYZFXN	RN	Prediction of pharmacokinetic drug/drug interactions from In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants. Drug Metab Dispos. 2000 Feb;28(2):161-8.
DMYZFXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10640513

DMYZFXN	DI	DMYZFXN
DMYZFXN	DN	Lornoxicam
DMYZFXN	MI	TTK0943
DMYZFXN	MN	Prostaglandin G/H synthase (COX)
DMYZFXN	MT	DTT
DMYZFXN	MA	Modulator
DMYZFXN	RN	The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res. 1999 Jul;48(7):369-79.
DMYZFXN	RU	https://pubmed.ncbi.nlm.nih.gov/10450786

DM72JXH	DI	DM72JXH
DM72JXH	DN	Losartan
DM72JXH	MI	TT8DBY3
DM72JXH	MN	Angiotensin II receptor type-1 (AGTR1)
DM72JXH	MT	DTT
DM72JXH	MA	Antagonist
DM72JXH	RN	Radioligand binding assays: application of [(125)I]angiotensin II receptor binding. Methods Mol Biol. 2009;552:131-41.
DM72JXH	RU	https://pubmed.ncbi.nlm.nih.gov/19513646

DM72JXH	DI	DM72JXH
DM72JXH	DN	Losartan
DM72JXH	MI	DES5XRU
DM72JXH	MN	Cytochrome P450 2C8 (CYP2C8)
DM72JXH	MT	DME
DM72JXH	MA	Metabolism
DM72JXH	RN	Drug-drug interaction between losartan and paclitaxel in human liver microsomes with different CYP2C8 genotypes. Basic Clin Pharmacol Toxicol. 2015 Jun;116(6):493-8.
DM72JXH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25424246

DM72JXH	DI	DM72JXH
DM72JXH	DN	Losartan
DM72JXH	MI	DE5IED8
DM72JXH	MN	Cytochrome P450 2C9 (CYP2C9)
DM72JXH	MT	DME
DM72JXH	MA	Metabolism
DM72JXH	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM72JXH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM72JXH	DI	DM72JXH
DM72JXH	DN	Losartan
DM72JXH	MI	DE4LYSA
DM72JXH	MN	Cytochrome P450 3A4 (CYP3A4)
DM72JXH	MT	DME
DM72JXH	MA	Metabolism
DM72JXH	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM72JXH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM72JXH	DI	DM72JXH
DM72JXH	DN	Losartan
DM72JXH	MI	DEIBDNY
DM72JXH	MN	Cytochrome P450 3A5 (CYP3A5)
DM72JXH	MT	DME
DM72JXH	MA	Metabolism
DM72JXH	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM72JXH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM72JXH	DI	DM72JXH
DM72JXH	DN	Losartan
DM72JXH	MI	DT9G7XN
DM72JXH	MN	Peptide transporter 1 (SLC15A1)
DM72JXH	MT	DTP
DM72JXH	MA	Substrate
DM72JXH	RN	High-affinity interaction of sartans with H+/peptide transporters. Drug Metab Dispos. 2009 Jan;37(1):143-9.
DM72JXH	RU	http://www.ncbi.nlm.nih.gov/pubmed/18824524

DM72JXH	DI	DM72JXH
DM72JXH	DN	Losartan
DM72JXH	MI	DTUGYRD
DM72JXH	MN	P-glycoprotein 1 (ABCB1)
DM72JXH	MT	DTP
DM72JXH	MA	Substrate
DM72JXH	RN	Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers. Br J Pharmacol. 2000 Mar;129(6):1235-43.
DM72JXH	RU	http://www.ncbi.nlm.nih.gov/pubmed/10725273

DM72JXH	DI	DM72JXH
DM72JXH	DN	Losartan
DM72JXH	MI	DEYGVN4
DM72JXH	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM72JXH	MT	DME
DM72JXH	MA	Metabolism
DM72JXH	RN	The human UDP-glucuronosyltransferase UGT1A3 is highly selective towards N2 in the tetrazole ring of losartan, candesartan, and zolarsartan. Biochem Pharmacol. 2008 Sep 15;76(6):763-72.
DM72JXH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18674515

DM72JXH	DI	DM72JXH
DM72JXH	DN	Losartan
DM72JXH	MI	DEL5N6Y
DM72JXH	MN	UDP-glucuronosyltransferase 1A10 (UGT1A10)
DM72JXH	MT	DME
DM72JXH	MA	Metabolism
DM72JXH	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM72JXH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM72JXH	DI	DM72JXH
DM72JXH	DN	Losartan
DM72JXH	MI	DEF2WXN
DM72JXH	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DM72JXH	MT	DME
DM72JXH	MA	Metabolism
DM72JXH	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM72JXH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM72JXH	DI	DM72JXH
DM72JXH	DN	Losartan
DM72JXH	MI	DEB3CV1
DM72JXH	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DM72JXH	MT	DME
DM72JXH	MA	Metabolism
DM72JXH	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM72JXH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM8QTJI	DI	DM8QTJI
DM8QTJI	DN	Loteprednol etabonate
DM8QTJI	MI	DE4LYSA
DM8QTJI	MN	Cytochrome P450 3A4 (CYP3A4)
DM8QTJI	MT	DME
DM8QTJI	MA	Metabolism
DM8QTJI	RN	EMC: Lotemax 0.5% w/v Eye Drops, Suspension.
DM8QTJI	RU	https://www.medicines.org.uk/emc/product/6212

DM8QTJI	DI	DM8QTJI
DM8QTJI	DN	Loteprednol etabonate
DM8QTJI	MI	DESDN74
DM8QTJI	MN	Serum paraoxonase/arylesterase 1 (PON1)
DM8QTJI	MT	DME
DM8QTJI	MA	Metabolism
DM8QTJI	RN	Identification of esterase involved in the metabolism of two corticosteroid soft drugs. Biochem Pharmacol. 2017 Mar 1;127:82-89.
DM8QTJI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28017774

DM8QTJI	DI	DM8QTJI
DM8QTJI	DN	Loteprednol etabonate
DM8QTJI	MI	TTP3UTW
DM8QTJI	MN	Steroid hormone receptor ERR (ESRR)
DM8QTJI	MT	DTT
DM8QTJI	MA	Modulator
DM8QTJI	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM8QTJI	RU	https://www.fda.gov/

DM9OZWQ	DI	DM9OZWQ
DM9OZWQ	DN	Lovastatin
DM9OZWQ	MI	DES5XRU
DM9OZWQ	MN	Cytochrome P450 2C8 (CYP2C8)
DM9OZWQ	MT	DME
DM9OZWQ	MA	Metabolism
DM9OZWQ	RN	Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
DM9OZWQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27757045

DM9OZWQ	DI	DM9OZWQ
DM9OZWQ	DN	Lovastatin
DM9OZWQ	MI	DE4LYSA
DM9OZWQ	MN	Cytochrome P450 3A4 (CYP3A4)
DM9OZWQ	MT	DME
DM9OZWQ	MA	Metabolism
DM9OZWQ	RN	Metabolic interactions with statins. Tidsskr Nor Laegeforen. 2001 Jan 20;121(2):189-93.
DM9OZWQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11475198

DM9OZWQ	DI	DM9OZWQ
DM9OZWQ	DN	Lovastatin
DM9OZWQ	MI	TTPADOQ
DM9OZWQ	MN	HMG-CoA reductase (HMGCR)
DM9OZWQ	MT	DTT
DM9OZWQ	MA	Inhibitor
DM9OZWQ	RN	Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. Neoplasia. 2002 Jul-Aug;4(4):337-46.
DM9OZWQ	RU	https://pubmed.ncbi.nlm.nih.gov/12082550

DM9OZWQ	DI	DM9OZWQ
DM9OZWQ	DN	Lovastatin
DM9OZWQ	MI	DEGTFWK
DM9OZWQ	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM9OZWQ	MT	DME
DM9OZWQ	MA	Metabolism
DM9OZWQ	RN	Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
DM9OZWQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27757045

DM9OZWQ	DI	DM9OZWQ
DM9OZWQ	DN	Lovastatin
DM9OZWQ	MI	DT3D8F0
DM9OZWQ	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM9OZWQ	MT	DTP
DM9OZWQ	MA	Substrate
DM9OZWQ	RN	A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999 Dec 24;274(52):37161-8.
DM9OZWQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/10601278

DM9OZWQ	DI	DM9OZWQ
DM9OZWQ	DN	Lovastatin
DM9OZWQ	MI	DTUGYRD
DM9OZWQ	MN	P-glycoprotein 1 (ABCB1)
DM9OZWQ	MT	DTP
DM9OZWQ	MA	Substrate
DM9OZWQ	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM9OZWQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DM9OZWQ	DI	DM9OZWQ
DM9OZWQ	DN	Lovastatin
DM9OZWQ	MI	DETXQZ1
DM9OZWQ	MN	Serum paraoxonase/lactonase 3 (PON3)
DM9OZWQ	MT	DME
DM9OZWQ	MA	Metabolism
DM9OZWQ	RN	Paraoxonases-1, -2 and -3: what are their functions? Chem Biol Interact. 2016 Nov 25;259(Pt B):51-62.
DM9OZWQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27238723

DM9OZWQ	DI	DM9OZWQ
DM9OZWQ	DN	Lovastatin
DM9OZWQ	MI	DEYGVN4
DM9OZWQ	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM9OZWQ	MT	DME
DM9OZWQ	MA	Metabolism
DM9OZWQ	RN	Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
DM9OZWQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27757045

DM9OZWQ	DI	DM9OZWQ
DM9OZWQ	DN	Lovastatin
DM9OZWQ	MI	DEF2WXN
DM9OZWQ	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DM9OZWQ	MT	DME
DM9OZWQ	MA	Metabolism
DM9OZWQ	RN	Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
DM9OZWQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27757045

DM9OZWQ	DI	DM9OZWQ
DM9OZWQ	DN	Lovastatin
DM9OZWQ	MI	DEB3CV1
DM9OZWQ	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DM9OZWQ	MT	DME
DM9OZWQ	MA	Metabolism
DM9OZWQ	RN	Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
DM9OZWQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27757045

DMGCQ4E	DI	DMGCQ4E
DMGCQ4E	DN	Lovastatin acid
DMGCQ4E	MI	DTUGYRD
DMGCQ4E	MN	P-glycoprotein 1 (ABCB1)
DMGCQ4E	MT	DTP
DMGCQ4E	MA	Substrate
DMGCQ4E	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMGCQ4E	RU	https://doi.org/10.1007/s11095-012-0935-x

DM8AI9U	DI	DM8AI9U
DM8AI9U	DN	Loxapine
DM8AI9U	MI	DEJGDUW
DM8AI9U	MN	Cytochrome P450 1A2 (CYP1A2)
DM8AI9U	MT	DME
DM8AI9U	MA	Metabolism
DM8AI9U	RN	In vitro identification of the human cytochrome p450 enzymes involved in the oxidative metabolism of loxapine. Biopharm Drug Dispos. 2011 Oct;32(7):398-407.
DM8AI9U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21826677

DM8AI9U	DI	DM8AI9U
DM8AI9U	DN	Loxapine
DM8AI9U	MI	DECB0K3
DM8AI9U	MN	Cytochrome P450 2D6 (CYP2D6)
DM8AI9U	MT	DME
DM8AI9U	MA	Metabolism
DM8AI9U	RN	In vitro identification of the human cytochrome p450 enzymes involved in the oxidative metabolism of loxapine. Biopharm Drug Dispos. 2011 Oct;32(7):398-407.
DM8AI9U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21826677

DM8AI9U	DI	DM8AI9U
DM8AI9U	DN	Loxapine
DM8AI9U	MI	DE4LYSA
DM8AI9U	MN	Cytochrome P450 3A4 (CYP3A4)
DM8AI9U	MT	DME
DM8AI9U	MA	Metabolism
DM8AI9U	RN	In vitro identification of the human cytochrome p450 enzymes involved in the oxidative metabolism of loxapine. Biopharm Drug Dispos. 2011 Oct;32(7):398-407.
DM8AI9U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21826677

DM8AI9U	DI	DM8AI9U
DM8AI9U	DN	Loxapine
DM8AI9U	MI	TTEX248
DM8AI9U	MN	Dopamine D2 receptor (D2R)
DM8AI9U	MT	DTT
DM8AI9U	MA	Antagonist
DM8AI9U	RN	Remoxipride in Parkinson's disease: differential response in patients with dyskinesias fluctuations versus psychosis. Clin Neuropharmacol. 1995 Feb;18(1):39-45.
DM8AI9U	RU	https://pubmed.ncbi.nlm.nih.gov/8665533

DMQMGXV	DI	DMQMGXV
DMQMGXV	DN	Loxoprofen gel
DMQMGXV	MI	TTK0943
DMQMGXV	MN	Prostaglandin G/H synthase (COX)
DMQMGXV	MT	DTT
DMQMGXV	MA	Inhibitor
DMQMGXV	RN	Comparative study of the clinical efficacy of the selective cyclooxygenase-2 inhibitor celecoxib compared with loxoprofen in patients with frozen shoulder. Mod Rheumatol. 2014 Jan;24(1):144-9.
DMQMGXV	RU	https://pubmed.ncbi.nlm.nih.gov/24261771

DMQXI9F	DI	DMQXI9F
DMQXI9F	DN	L-Phenylalanine
DMQXI9F	MI	DTJF3DX
DMQXI9F	MN	L-type amino acid transporter 2 (SLC7A8)
DMQXI9F	MT	DTP
DMQXI9F	MA	Substrate
DMQXI9F	RN	Quantifying the relative contributions of different solute carriers to aggregate substrate transport. Sci Rep. 2017 Jan 16;7:40628.
DMQXI9F	RU	http://www.ncbi.nlm.nih.gov/pubmed/28091567

DMQXI9F	DI	DMQXI9F
DMQXI9F	DN	L-Phenylalanine
DMQXI9F	MI	DTBMSWG
DMQXI9F	MN	L-type amino acid transporter 3 (SLC43A1)
DMQXI9F	MT	DTP
DMQXI9F	MA	Substrate
DMQXI9F	RN	Identification of a novel system L amino acid transporter structurally distinct from heterodimeric amino acid transporters. J Biol Chem. 2003 Oct 31;278(44):43838-45.
DMQXI9F	RU	http://www.ncbi.nlm.nih.gov/pubmed/12930836

DMQXI9F	DI	DMQXI9F
DMQXI9F	DN	L-Phenylalanine
DMQXI9F	MI	DTK02I1
DMQXI9F	MN	L-type amino acid transporter 4 (SLC43A2)
DMQXI9F	MT	DTP
DMQXI9F	MA	Substrate
DMQXI9F	RN	Anticipation of food intake induces phosphorylation switch to regulate basolateral amino acid transporter LAT4 (SLC43A2) function. J Physiol. 2019 Jan;597(2):521-542.
DMQXI9F	RU	http://www.ncbi.nlm.nih.gov/pubmed/30379325

DMQXI9F	DI	DMQXI9F
DMQXI9F	DN	L-Phenylalanine
DMQXI9F	MI	DE0WGR8
DMQXI9F	MN	Phenylalanine--tRNA ligase mitochondrial (FARS2)
DMQXI9F	MT	DME
DMQXI9F	MA	Metabolism
DMQXI9F	RN	Expression and characterization of a human mitochondrial phenylalanyl-tRNA synthetase. J Mol Biol. 1999 May 14;288(4):567-77.
DMQXI9F	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10329163

DMQXI9F	DI	DMQXI9F
DMQXI9F	DN	L-Phenylalanine
DMQXI9F	MI	TTUHP71
DMQXI9F	MN	Tyrosine 3-monooxygenase (TH)
DMQXI9F	MT	DTT
DMQXI9F	MA	Binder
DMQXI9F	RN	Selectivity and affinity determinants for ligand binding to the aromatic amino acid hydroxylases. Curr Med Chem. 2007;14(4):455-67.
DMQXI9F	RU	https://pubmed.ncbi.nlm.nih.gov/17305546

DMKSTWR	DI	DMKSTWR
DMKSTWR	DN	L-Proline
DMKSTWR	MI	DTJF3DX
DMKSTWR	MN	L-type amino acid transporter 2 (SLC7A8)
DMKSTWR	MT	DTP
DMKSTWR	MA	Substrate
DMKSTWR	RN	The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.3.8.20)
DMKSTWR	RU	http://www.tcdb.org/search/result.php?tc=2.A.3.8.20

DMKSTWR	DI	DMKSTWR
DMKSTWR	DN	L-Proline
DMKSTWR	MI	DTBPTJF
DMKSTWR	MN	Na(+)/Cl(-) betaine/GABA transporter (SLC6A12)
DMKSTWR	MT	DTP
DMKSTWR	MA	Substrate
DMKSTWR	RN	Interpreting metabolomic profiles using unbiased pathway models. PLoS Comput Biol. 2010 Feb 26;6(2):e1000692.
DMKSTWR	RU	http://www.ncbi.nlm.nih.gov/pubmed/20195502

DMKSTWR	DI	DMKSTWR
DMKSTWR	DN	L-Proline
DMKSTWR	MI	DT48WEM
DMKSTWR	MN	Proton-coupled amino acid transporter 1 (SLC36A1)
DMKSTWR	MT	DTP
DMKSTWR	MA	Substrate
DMKSTWR	RN	PAT1 (SLC36A1) shows nuclear localization and affects growth of smooth muscle cells from rats. Am J Physiol Endocrinol Metab. 2014 Jan 1;306(1):E65-74.
DMKSTWR	RU	http://www.ncbi.nlm.nih.gov/pubmed/24222668

DMKSTWR	DI	DMKSTWR
DMKSTWR	DN	L-Proline
DMKSTWR	MI	DTBS49U
DMKSTWR	MN	Proton-coupled amino acid transporter 4 (SLC36A4)
DMKSTWR	MT	DTP
DMKSTWR	MA	Substrate
DMKSTWR	RN	SLC36A4 (hPAT4) is a high affinity amino acid transporter when expressed in Xenopus laevis oocytes. J Biol Chem. 2011 Jan 28;286(4):2455-60.
DMKSTWR	RU	http://www.ncbi.nlm.nih.gov/pubmed/21097500

DMKSTWR	DI	DMKSTWR
DMKSTWR	DN	L-Proline
DMKSTWR	MI	TTL2ADK
DMKSTWR	MN	Rotamase A (PPIA)
DMKSTWR	MT	DTT
DMKSTWR	MA	Binder
DMKSTWR	RN	Mechanistic insight into the role of transition-state stabilization in cyclophilin A. J Am Chem Soc. 2009 Jan 14;131(1):147-52.
DMKSTWR	RU	https://pubmed.ncbi.nlm.nih.gov/19128175

DMKSTWR	DI	DMKSTWR
DMKSTWR	DN	L-Proline
DMKSTWR	MI	TT6ZFQ4
DMKSTWR	MN	Rotamase B (PPIB)
DMKSTWR	MT	DTT
DMKSTWR	MA	Binder
DMKSTWR	RN	Escherichia coli cyclophilin B binds a highly distorted form of trans-prolyl peptide isomer. Eur J Biochem. 2004 Sep;271(18):3794-803.
DMKSTWR	RU	https://pubmed.ncbi.nlm.nih.gov/15355356

DMKSTWR	DI	DMKSTWR
DMKSTWR	DN	L-Proline
DMKSTWR	MI	DTH1GEL
DMKSTWR	MN	Sodium-dependent proline transporter (SLC6A7)
DMKSTWR	MT	DTP
DMKSTWR	MA	Substrate
DMKSTWR	RN	A new association between polymorphisms of the SLC6A7 gene in the chromosome 5q31-32 region and asthma. J Hum Genet. 2010 Jun;55(6):358-65.
DMKSTWR	RU	http://www.ncbi.nlm.nih.gov/pubmed/20431603

DMIBH7M	DI	DMIBH7M
DMIBH7M	DN	L-tryptophan
DMIBH7M	MI	DETK9CN
DMIBH7M	MN	DOPA decarboxylase (DDC)
DMIBH7M	MT	DME
DMIBH7M	MA	Metabolism
DMIBH7M	RN	Origin and metabolism of serotonin. J Cardiovasc Pharmacol. 1990;16 Suppl 3:S1-7.
DMIBH7M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1369709

DMIBH7M	DI	DMIBH7M
DMIBH7M	DN	L-tryptophan
DMIBH7M	MI	TTZJYKH
DMIBH7M	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMIBH7M	MT	DTT
DMIBH7M	MA	Binder
DMIBH7M	RN	Interactions between nitric oxide and indoleamine 2,3-dioxygenase. Biochemistry. 2006 Jul 18;45(28):8527-38.
DMIBH7M	RU	https://pubmed.ncbi.nlm.nih.gov/16834326

DMIBH7M	DI	DMIBH7M
DMIBH7M	DN	L-tryptophan
DMIBH7M	MI	DE43MW5
DMIBH7M	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMIBH7M	MT	DME
DMIBH7M	MA	Metabolism
DMIBH7M	RN	Kynurenine pathway metabolites and enzymes involved in redox reactions. Neuropharmacology. 2017 Jan;112(Pt B):331-345.
DMIBH7M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26970015

DMIBH7M	DI	DMIBH7M
DMIBH7M	DN	L-tryptophan
DMIBH7M	MI	DE8BVKA
DMIBH7M	MN	Indoleamine 2,3-dioxygenase 2 (IDO2)
DMIBH7M	MT	DME
DMIBH7M	MA	Metabolism
DMIBH7M	RN	Kynurenine pathway metabolites and enzymes involved in redox reactions. Neuropharmacology. 2017 Jan;112(Pt B):331-345.
DMIBH7M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26970015

DMIBH7M	DI	DMIBH7M
DMIBH7M	DN	L-tryptophan
DMIBH7M	MI	DTJF3DX
DMIBH7M	MN	L-type amino acid transporter 2 (SLC7A8)
DMIBH7M	MT	DTP
DMIBH7M	MA	Substrate
DMIBH7M	RN	The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.3.8.20)
DMIBH7M	RU	http://www.tcdb.org/search/result.php?tc=2.A.3.8.20

DMIBH7M	DI	DMIBH7M
DMIBH7M	DN	L-tryptophan
DMIBH7M	MI	DTPAQJO
DMIBH7M	MN	Monocarboxylate transporter 10 (SLC16A10)
DMIBH7M	MT	DTP
DMIBH7M	MA	Substrate
DMIBH7M	RN	Phosphatidylserine synthesis required for the maximal tryptophan transport activity in Saccharomyces cerevisiae. Biosci Biotechnol Biochem. 2000 Jan;64(1):167-72.
DMIBH7M	RU	http://www.ncbi.nlm.nih.gov/pubmed/10705462

DMIBH7M	DI	DMIBH7M
DMIBH7M	DN	L-tryptophan
DMIBH7M	MI	DTVP67E
DMIBH7M	MN	Organic anion transporter 3 (SLC22A8)
DMIBH7M	MT	DTP
DMIBH7M	MA	Substrate
DMIBH7M	RN	Murine renal organic anion transporters mOAT1 and mOAT3 facilitate the transport of neuroactive tryptophan metabolites. Am J Physiol Cell Physiol. 2005 Nov;289(5):C1075-84.
DMIBH7M	RU	http://www.ncbi.nlm.nih.gov/pubmed/15944205

DMIBH7M	DI	DMIBH7M
DMIBH7M	DN	L-tryptophan
DMIBH7M	MI	DTUGYRD
DMIBH7M	MN	P-glycoprotein 1 (ABCB1)
DMIBH7M	MT	DTP
DMIBH7M	MA	Substrate
DMIBH7M	RN	Pharmacogenetics of antidepressants. Front Pharmacol. 2011 Feb 16;2:6.
DMIBH7M	RU	http://www.ncbi.nlm.nih.gov/pubmed/21687501

DMIBH7M	DI	DMIBH7M
DMIBH7M	DN	L-tryptophan
DMIBH7M	MI	DTBS49U
DMIBH7M	MN	Proton-coupled amino acid transporter 4 (SLC36A4)
DMIBH7M	MT	DTP
DMIBH7M	MA	Substrate
DMIBH7M	RN	SLC36A4 (hPAT4) is a high affinity amino acid transporter when expressed in Xenopus laevis oocytes. J Biol Chem. 2011 Jan 28;286(4):2455-60.
DMIBH7M	RU	http://www.ncbi.nlm.nih.gov/pubmed/21097500

DMIBH7M	DI	DMIBH7M
DMIBH7M	DN	L-tryptophan
DMIBH7M	MI	DEP5BDK
DMIBH7M	MN	Tryptophan 5-hydroxylase 1 (TPH1)
DMIBH7M	MT	DME
DMIBH7M	MA	Metabolism
DMIBH7M	RN	Developmental role of tryptophan hydroxylase in the nervous system. Mol Neurobiol. 2007 Feb;35(1):45-54.
DMIBH7M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17519505

DMIBH7M	DI	DMIBH7M
DMIBH7M	DN	L-tryptophan
DMIBH7M	MI	DER6XYF
DMIBH7M	MN	Tryptophan 5-hydroxylase 2 (TPH2)
DMIBH7M	MT	DME
DMIBH7M	MA	Metabolism
DMIBH7M	RN	Strain differences in basal and post-citalopram extracellular 5-HT in the mouse medial prefrontal cortex and dorsal hippocampus: relation with tryptophan hydroxylase-2 activity. J Neurochem. 2007 Nov;103(3):1111-20.
DMIBH7M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17666043

DMIBH7M	DI	DMIBH7M
DMIBH7M	DN	L-tryptophan
DMIBH7M	MI	DEGH1QU
DMIBH7M	MN	Tryptophan oxygenase (TRPO)
DMIBH7M	MT	DME
DMIBH7M	MA	Metabolism
DMIBH7M	RN	Reaction pathway of tryptophanase-catalyzed L-tryptophan synthesis from D-serine. J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Nov 1;879(29):3289-95.
DMIBH7M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21601540

DMIBH7M	DI	DMIBH7M
DMIBH7M	DN	L-tryptophan
DMIBH7M	MI	DEPVE0M
DMIBH7M	MN	Tryptophanyl-tRNA synthetase cytoplasmic (WARS1)
DMIBH7M	MT	DME
DMIBH7M	MA	Metabolism
DMIBH7M	RN	IFN-gamma-induced IDO and WRS expression in microglia is differentially regulated by IL-4. Glia. 2007 Oct;55(13):1385-96.
DMIBH7M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17661345

DMIBH7M	DI	DMIBH7M
DMIBH7M	DN	L-tryptophan
DMIBH7M	MI	DEPTKBQ
DMIBH7M	MN	Tryptophanyl-tRNA synthetase mitochondrial (WARS2)
DMIBH7M	MT	DME
DMIBH7M	MA	Metabolism
DMIBH7M	RN	Crystal structure of tryptophanyl-tRNA synthetase complexed with adenosine-5' tetraphosphate: evidence for distributed use of catalytic binding energy in amino acid activation by class I aminoacyl-tRNA synthetases. J Mol Biol. 2007 May 25;369(1):108-28.
DMIBH7M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17428498

DM9O8DT	DI	DM9O8DT
DM9O8DT	DN	L-tyrosine
DM9O8DT	MI	DTJF3DX
DM9O8DT	MN	L-type amino acid transporter 2 (SLC7A8)
DM9O8DT	MT	DTP
DM9O8DT	MA	Substrate
DM9O8DT	RN	The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.3.8.20)
DM9O8DT	RU	http://www.tcdb.org/search/result.php?tc=2.A.3.8.20

DM9O8DT	DI	DM9O8DT
DM9O8DT	DN	L-tyrosine
DM9O8DT	MI	TTUHP71
DM9O8DT	MN	Tyrosine 3-monooxygenase (TH)
DM9O8DT	MT	DTT
DM9O8DT	MA	Binder
DM9O8DT	RN	Effect of metals and phenylalanine on the activity of human tryptophan hydroxylase-2: comparison with that on tyrosine hydroxylase activity. Neurosci Lett. 2006 Jul 3;401(3):261-5.
DM9O8DT	RU	https://pubmed.ncbi.nlm.nih.gov/16581181

DM9O8DT	DI	DM9O8DT
DM9O8DT	DN	L-tyrosine
DM9O8DT	MI	DEX2ZLF
DM9O8DT	MN	Tyrosine decarboxylase (tdc)
DM9O8DT	MT	DME
DM9O8DT	MA	Metabolism
DM9O8DT	RN	Tyrosine decarboxylase from Lactobacillus brevis: soluble expression and characterization. Protein Expr Purif. 2014 Feb;94:33-9.
DM9O8DT	RU	https://pubmed.ncbi.nlm.nih.gov/24211777

DMMJVXZ	DI	DMMJVXZ
DMMJVXZ	DN	LU302146
DMMJVXZ	MI	TTKRD0G
DMMJVXZ	MN	Endothelin A receptor (EDNRA)
DMMJVXZ	MT	DTT
DMMJVXZ	MA	Antagonist
DMMJVXZ	RN	Influence of endothelin receptor antagonists on myocardial protein kinase C isoforms in uraemic cardiomyopathy. Clin Sci (Lond). 2002 Aug;103 Suppl 48:276S-279S.
DMMJVXZ	RU	https://pubmed.ncbi.nlm.nih.gov/12193103

DMJTEMW	DI	DMJTEMW
DMJTEMW	DN	Lubiprostone
DMJTEMW	MI	TT30NW6
DMJTEMW	MN	Chloride channel protein 2 (CLC-2)
DMJTEMW	MT	DTT
DMJTEMW	MA	Activator
DMJTEMW	RN	Lubiprostone stimulates secretion from tracheal submucosal glands of sheep, pigs, and humans. Am J Physiol Lung Cell Mol Physiol. 2009 May;296(5):L811-24.
DMJTEMW	RU	https://pubmed.ncbi.nlm.nih.gov/19233902

DMZLBUO	DI	DMZLBUO
DMZLBUO	DN	Lucanthone
DMZLBUO	MI	TT0IHXV
DMZLBUO	MN	DNA topoisomerase II (TOP2)
DMZLBUO	MT	DTT
DMZLBUO	MA	Inhibitor
DMZLBUO	RN	Clonogenicity of human leukemic cells protected from cell-lethal agents by heat shock protein 70. Cell Stress Chaperones. 2005 Spring;10(1):37-45.
DMZLBUO	RU	https://pubmed.ncbi.nlm.nih.gov/15832946

DMT73J8	DI	DMT73J8
DMT73J8	DN	Luliconazole
DMT73J8	MI	TTTSOUD
DMT73J8	MN	Candida Cytochrome P450 51 (Candi ERG11)
DMT73J8	MT	DTT
DMT73J8	MA	Inhibitor
DMT73J8	RN	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
DMT73J8	RU	https://pubmed.ncbi.nlm.nih.gov/28919714

DMUPOGR	DI	DMUPOGR
DMUPOGR	DN	Lumacaftor + Ivacaftor
DMUPOGR	MI	TTRLZHP
DMUPOGR	MN	cAMP-dependent chloride channel (CFTR)
DMUPOGR	MT	DTT
DMUPOGR	MA	Enhancer
DMUPOGR	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMUPOGR	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMUPOGR	DI	DMUPOGR
DMUPOGR	DN	Lumacaftor + Ivacaftor
DMUPOGR	MI	TTFPKRB
DMUPOGR	MN	cAMP-dependent chloride channel F508 deletion (CFTR del F508)
DMUPOGR	MT	DTT
DMUPOGR	MA	Enhancer
DMUPOGR	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMUPOGR	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMEBQAO	DI	DMEBQAO
DMEBQAO	DN	Lumasiran
DMEBQAO	MI	TTS58YO
DMEBQAO	MN	HAO1 messenger RNA (HAO1 mRNA)
DMEBQAO	MT	DTT
DMEBQAO	MA	Inhibitor
DMEBQAO	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMEBQAO	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214103lbl.pdf

DMQ8HOJ	DI	DMQ8HOJ
DMQ8HOJ	DN	lumateperone tosylate
DMQ8HOJ	MI	TTJQOD7
DMQ8HOJ	MN	5-HT 2A receptor (HTR2A)
DMQ8HOJ	MT	DTT
DMQ8HOJ	MA	Antagonist
DMQ8HOJ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMQ8HOJ	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209500s000lbl.pdf

DMQ8HOJ	DI	DMQ8HOJ
DMQ8HOJ	DN	lumateperone tosylate
DMQ8HOJ	MI	TTEX248
DMQ8HOJ	MN	Dopamine D2 receptor (D2R)
DMQ8HOJ	MT	DTT
DMQ8HOJ	MA	Antagonist
DMQ8HOJ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMQ8HOJ	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209500s000lbl.pdf

DM29GAD	DI	DM29GAD
DM29GAD	DN	Lumefantrine
DM29GAD	MI	DE4LYSA
DM29GAD	MN	Cytochrome P450 3A4 (CYP3A4)
DM29GAD	MT	DME
DM29GAD	MA	Metabolism
DM29GAD	RN	Development of a paediatric physiologically based pharmacokinetic model to assess the impact of drug-drug interactions in tuberculosis co-infected malaria subjects: A case study with artemether-lumefantrine and the CYP3A4-inducer rifampicin. Eur J Pharm Sci. 2017 Aug 30;106:20-33.
DM29GAD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28546104

DM29GAD	DI	DM29GAD
DM29GAD	DN	Lumefantrine
DM29GAD	MI	TTWK8D0
DM29GAD	MN	Sodium pump subunit alpha-1 (ATP1A1)
DM29GAD	MT	DTT
DM29GAD	MA	Binder
DM29GAD	RN	The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
DM29GAD	RU	https://pubmed.ncbi.nlm.nih.gov/18220771

DM1S4AG	DI	DM1S4AG
DM1S4AG	DN	Lumiracoxib
DM1S4AG	MI	DEJGDUW
DM1S4AG	MN	Cytochrome P450 1A2 (CYP1A2)
DM1S4AG	MT	DME
DM1S4AG	MA	Metabolism
DM1S4AG	RN	Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet. 2005;44(12):1247-66.
DM1S4AG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16372823

DM1S4AG	DI	DM1S4AG
DM1S4AG	DN	Lumiracoxib
DM1S4AG	MI	DE5IED8
DM1S4AG	MN	Cytochrome P450 2C9 (CYP2C9)
DM1S4AG	MT	DME
DM1S4AG	MA	Metabolism
DM1S4AG	RN	Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet. 2005;44(12):1247-66.
DM1S4AG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16372823

DM1S4AG	DI	DM1S4AG
DM1S4AG	DN	Lumiracoxib
DM1S4AG	MI	DEGTFWK
DM1S4AG	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM1S4AG	MT	DME
DM1S4AG	MA	Metabolism
DM1S4AG	RN	Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet. 2005;44(12):1247-66.
DM1S4AG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16372823

DM1S4AG	DI	DM1S4AG
DM1S4AG	DN	Lumiracoxib
DM1S4AG	MI	TTVKILB
DM1S4AG	MN	Prostaglandin G/H synthase 2 (COX-2)
DM1S4AG	MT	DTT
DM1S4AG	MA	Inhibitor
DM1S4AG	RN	Dissociation of airway inflammation and hyperresponsiveness by cyclooxygenase inhibition in allergen challenged mice. Eur Respir J. 2009 Jul;34(1):200-8.
DM1S4AG	RU	https://pubmed.ncbi.nlm.nih.gov/19251789

DM1S4AG	DI	DM1S4AG
DM1S4AG	DN	Lumiracoxib
DM1S4AG	MI	DE85D2P
DM1S4AG	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DM1S4AG	MT	DME
DM1S4AG	MA	Metabolism
DM1S4AG	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM1S4AG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMCVPXO	DI	DMCVPXO
DMCVPXO	DN	Lurasidone hydrochloride
DMCVPXO	MI	TTJQOD7
DMCVPXO	MN	5-HT 2A receptor (HTR2A)
DMCVPXO	MT	DTT
DMCVPXO	MA	Modulator
DMCVPXO	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DMCVPXO	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DMCVPXO	DI	DMCVPXO
DMCVPXO	DN	Lurasidone hydrochloride
DMCVPXO	MI	DE4LYSA
DMCVPXO	MN	Cytochrome P450 3A4 (CYP3A4)
DMCVPXO	MT	DME
DMCVPXO	MA	Metabolism
DMCVPXO	RN	Pharmacokinetics and pharmacodynamics of lurasidone hydrochloride, a second-generation antipsychotic: a systematic review of the published literature. Clin Pharmacokinet. 2017 May;56(5):493-503.
DMCVPXO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27722855

DMCVPXO	DI	DMCVPXO
DMCVPXO	DN	Lurasidone hydrochloride
DMCVPXO	MI	TTEX248
DMCVPXO	MN	Dopamine D2 receptor (D2R)
DMCVPXO	MT	DTT
DMCVPXO	MA	Modulator
DMCVPXO	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DMCVPXO	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DMEFRTZ	DI	DMEFRTZ
DMEFRTZ	DN	Lurbinectedin
DMEFRTZ	MI	TTUTN1I
DMEFRTZ	MN	Human Deoxyribonucleic acid (hDNA)
DMEFRTZ	MT	DTT
DMEFRTZ	MA	Inhibitor
DMEFRTZ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMEFRTZ	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf

DMEFRTZ	DI	DMEFRTZ
DMEFRTZ	DN	Lurbinectedin
DMEFRTZ	MI	TTOVXHF
DMEFRTZ	MN	Human Deoxyribonucleic acid minor groove (hDNA min)
DMEFRTZ	MT	DTT
DMEFRTZ	MA	Inhibitor
DMEFRTZ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMEFRTZ	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf

DMH6IKO	DI	DMH6IKO
DMH6IKO	DN	Lusutrombopag
DMH6IKO	MI	TTIHYA4
DMH6IKO	MN	Thrombopoietin receptor (MPL)
DMH6IKO	MT	DTT
DMH6IKO	MA	Agonist
DMH6IKO	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMH6IKO	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMN1XVC	DI	DMN1XVC
DMN1XVC	DN	Lutetium Lu 177 dotatate
DMN1XVC	MI	TTIND6G
DMN1XVC	MN	Somatostatin receptor type 1 (SSTR1)
DMN1XVC	MT	DTT
DMN1XVC	MA	Antagonist
DMN1XVC	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMN1XVC	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DM7K5GD	DI	DM7K5GD
DM7K5GD	DN	Lutropin alfa
DM7K5GD	MI	TT2O4W9
DM7K5GD	MN	Luteinizing hormone receptor (LHCGR)
DM7K5GD	MT	DTT
DM7K5GD	MA	Binder
DM7K5GD	RN	Lutropin alfa. Drugs. 2008;68(11):1529-40.
DM7K5GD	RU	https://pubmed.ncbi.nlm.nih.gov/18627209

DMJKROX	DI	DMJKROX
DMJKROX	DN	Luvox
DMJKROX	MI	DEJGDUW
DMJKROX	MN	Cytochrome P450 1A2 (CYP1A2)
DMJKROX	MT	DME
DMJKROX	MA	Metabolism
DMJKROX	RN	Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide. Clin Pharmacokinet. 2007;46(7):613-22.
DMJKROX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17596106

DMJKROX	DI	DMJKROX
DMJKROX	DN	Luvox
DMJKROX	MI	DECB0K3
DMJKROX	MN	Cytochrome P450 2D6 (CYP2D6)
DMJKROX	MT	DME
DMJKROX	MA	Metabolism
DMJKROX	RN	Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit. 2000 Apr;22(2):143-54.
DMJKROX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10774624

DMJKROX	DI	DMJKROX
DMJKROX	DN	Luvox
DMJKROX	MI	DEVDYN7
DMJKROX	MN	Cytochrome P450 2E1 (CYP2E1)
DMJKROX	MT	DME
DMJKROX	MA	Metabolism
DMJKROX	RN	Antidepressant drugs in the elderly--role of the cytochrome P450 2D6. World J Biol Psychiatry. 2003 Apr;4(2):74-80.
DMJKROX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12692778

DMJKROX	DI	DMJKROX
DMJKROX	DN	Luvox
DMJKROX	MI	TT3ROYC
DMJKROX	MN	Serotonin transporter (SERT)
DMJKROX	MT	DTT
DMJKROX	MA	Modulator
DMJKROX	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMJKROX	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM93VBZ	DI	DM93VBZ
DM93VBZ	DN	LY2835219
DM93VBZ	MI	TT0PG8F
DM93VBZ	MN	Cyclin-dependent kinase 4 (CDK4)
DM93VBZ	MT	DTT
DM93VBZ	MA	Modulator
DM93VBZ	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM93VBZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM93VBZ	DI	DM93VBZ
DM93VBZ	DN	LY2835219
DM93VBZ	MI	TTO0FDJ
DM93VBZ	MN	Cyclin-dependent kinase 6 (CDK6)
DM93VBZ	MT	DTT
DM93VBZ	MA	Modulator
DM93VBZ	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM93VBZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM93VBZ	DI	DM93VBZ
DM93VBZ	DN	LY2835219
DM93VBZ	MI	DE4LYSA
DM93VBZ	MN	Cytochrome P450 3A4 (CYP3A4)
DM93VBZ	MT	DME
DM93VBZ	MA	Metabolism
DM93VBZ	RN	LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]-Abemaciclib.
DM93VBZ	RU	https://www.ncbi.nlm.nih.gov/books/NBK548807/

DM93VBZ	DI	DM93VBZ
DM93VBZ	DN	LY2835219
DM93VBZ	MI	DTZGT0P
DM93VBZ	MN	Multidrug and toxin extrusion protein 1 (SLC47A1)
DM93VBZ	MT	DTP
DM93VBZ	MA	Substrate
DM93VBZ	RN	Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate. Clin Pharmacol Ther. 2019 May;105(5):1187-1195.
DM93VBZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/30449032

DM93VBZ	DI	DM93VBZ
DM93VBZ	DN	LY2835219
DM93VBZ	MI	DT3TX4H
DM93VBZ	MN	Multidrug and toxin extrusion protein 2 (SLC47A2)
DM93VBZ	MT	DTP
DM93VBZ	MA	Substrate
DM93VBZ	RN	Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate. Clin Pharmacol Ther. 2019 May;105(5):1187-1195.
DM93VBZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/30449032

DM93VBZ	DI	DM93VBZ
DM93VBZ	DN	LY2835219
DM93VBZ	MI	DT9IDPW
DM93VBZ	MN	Organic cation transporter 2 (SLC22A2)
DM93VBZ	MT	DTP
DM93VBZ	MA	Substrate
DM93VBZ	RN	Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate. Clin Pharmacol Ther. 2019 May;105(5):1187-1195.
DM93VBZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/30449032

DMOMLHJ	DI	DMOMLHJ
DMOMLHJ	DN	Lymecycline
DMOMLHJ	MI	TTQ8KVI
DMOMLHJ	MN	Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)
DMOMLHJ	MT	DTT
DMOMLHJ	MA	Binder
DMOMLHJ	RN	Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
DMOMLHJ	RU	https://pubmed.ncbi.nlm.nih.gov/17016423

DM154EB	DI	DM154EB
DM154EB	DN	Lypressin
DM154EB	MI	TTPFZJ1
DM154EB	MN	Vasopressin V1 receptor (V1R)
DM154EB	MT	DTT
DM154EB	MA	Modulator
DM154EB	RN	Human pain thresholds after the application of lypressin, a vasopressin analogue. Pharmacol Toxicol. 1987 Jul;61(1):16-9.
DM154EB	RU	https://pubmed.ncbi.nlm.nih.gov/3628176

DMQYJIR	DI	DMQYJIR
DMQYJIR	DN	Macimorelin
DMQYJIR	MI	TTWDC17
DMQYJIR	MN	Growth hormone secretagogue receptor 1 (GHSR)
DMQYJIR	MT	DTT
DMQYJIR	MA	Agonist
DMQYJIR	RN	National Cancer Institute Drug Dictionary (drug id 735530).
DMQYJIR	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=735530

DMP79A1	DI	DMP79A1
DMP79A1	DN	Macitentan
DMP79A1	MI	DE4LYSA
DMP79A1	MN	Cytochrome P450 3A4 (CYP3A4)
DMP79A1	MT	DME
DMP79A1	MA	Metabolism
DMP79A1	RN	Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects. Clin Pharmacokinet. 2013 Aug;52(8):685-92.
DMP79A1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23568224

DMP79A1	DI	DMP79A1
DMP79A1	DN	Macitentan
DMP79A1	MI	TTKRD0G
DMP79A1	MN	Endothelin A receptor (EDNRA)
DMP79A1	MT	DTT
DMP79A1	MA	Modulator
DMP79A1	RN	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
DMP79A1	RU	https://pubmed.ncbi.nlm.nih.gov/28919714

DMP79A1	DI	DMP79A1
DMP79A1	DN	Macitentan
DMP79A1	MI	TT3ZTGU
DMP79A1	MN	Endothelin B receptor (EDNRB)
DMP79A1	MT	DTT
DMP79A1	MA	Modulator
DMP79A1	RN	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
DMP79A1	RU	https://pubmed.ncbi.nlm.nih.gov/28919714

DMP79A1	DI	DMP79A1
DMP79A1	DN	Macitentan
DMP79A1	MI	DEGTFWK
DMP79A1	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMP79A1	MT	DME
DMP79A1	MA	Metabolism
DMP79A1	RN	Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects. Clin Pharmacokinet. 2013 Aug;52(8):685-92.
DMP79A1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23568224

DM3BS97	DI	DM3BS97
DM3BS97	DN	Macrolides
DM3BS97	MI	TTLFGBV
DM3BS97	MN	Bacterial 23S ribosomal RNA (Bact 23S rRNA)
DM3BS97	MT	DTT
DM3BS97	MA	Binder
DM3BS97	RN	Has nature already identified all useful antibacterial targets Curr Opin Microbiol. 2008 Oct;11(5):387-92.
DM3BS97	RU	https://pubmed.ncbi.nlm.nih.gov/18804175

DMU4ORS	DI	DMU4ORS
DMU4ORS	DN	Magnesium
DMU4ORS	MI	TT9IK2Z
DMU4ORS	MN	N-methyl-D-aspartate receptor (NMDAR)
DMU4ORS	MT	DTT
DMU4ORS	MA	Antagonist
DMU4ORS	RN	Emerging drugs for acute ischemic stroke. Expert Opin Emerg Drugs. 2009 Mar;14(1):33-42.
DMU4ORS	RU	https://pubmed.ncbi.nlm.nih.gov/19249986

DMVEK07	DI	DMVEK07
DMVEK07	DN	Magnesium Sulfate
DMVEK07	MI	TT9IK2Z
DMVEK07	MN	N-methyl-D-aspartate receptor (NMDAR)
DMVEK07	MT	DTT
DMVEK07	MA	Antagonist
DMVEK07	RN	Magnesium sulfate diminishes the effects of amide local anesthetics in rat sciatic-nerve block. Reg Anesth Pain Med. 2007 Jul-Aug;32(4):288-95.
DMVEK07	RU	https://pubmed.ncbi.nlm.nih.gov/17720112

DMXZ84M	DI	DMXZ84M
DMXZ84M	DN	Malathion
DMXZ84M	MI	TT1RS9F
DMXZ84M	MN	Acetylcholinesterase (AChE)
DMXZ84M	MT	DTT
DMXZ84M	MA	Inhibitor
DMXZ84M	RN	Acetylcholinesterase activity in Corbicula fluminea Mull., as a biomarker of organophosphate pesticide pollution in Pinacanauan River, Philippines. Environ Monit Assess. 2010 Jun;165(1-4):331-40.
DMXZ84M	RU	https://pubmed.ncbi.nlm.nih.gov/19444631

DMXZ84M	DI	DMXZ84M
DMXZ84M	DN	Malathion
DMXZ84M	MI	DEJGDUW
DMXZ84M	MN	Cytochrome P450 1A2 (CYP1A2)
DMXZ84M	MT	DME
DMXZ84M	MA	Metabolism
DMXZ84M	RN	Malathion bioactivation in the human liver: the contribution of different cytochrome p450 isoforms. Drug Metab Dispos. 2005 Mar;33(3):295-302.
DMXZ84M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15557345

DMXZ84M	DI	DMXZ84M
DMXZ84M	DN	Malathion
DMXZ84M	MI	DEPKLMQ
DMXZ84M	MN	Cytochrome P450 2B6 (CYP2B6)
DMXZ84M	MT	DME
DMXZ84M	MA	Metabolism
DMXZ84M	RN	Malathion bioactivation in the human liver: the contribution of different cytochrome p450 isoforms. Drug Metab Dispos. 2005 Mar;33(3):295-302.
DMXZ84M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15557345

DMSCDY9	DI	DMSCDY9
DMSCDY9	DN	Mannitol
DMSCDY9	MI	TTTX5M8
DMSCDY9	MN	Aspergillus Mannitol 2-dehydrogenase (Asperg M2DH)
DMSCDY9	MT	DTT
DMSCDY9	MA	Activator
DMSCDY9	RN	Polyol-specific long-chain dehydrogenases/reductases of mannitol metabolism in Aspergillus fumigatus: biochemical characterization and pH studies o... Chem Biol Interact. 2009 Mar 16;178(1-3):274-82.
DMSCDY9	RU	https://pubmed.ncbi.nlm.nih.gov/18983992

DMSCDY9	DI	DMSCDY9
DMSCDY9	DN	Mannitol
DMSCDY9	MI	TTV0PE2
DMSCDY9	MN	Aspergillus Mannitol-1-phosphate 5-dehydrogenase (Asperg mpdA)
DMSCDY9	MT	DTT
DMSCDY9	MA	Activator
DMSCDY9	RN	Polyol-specific long-chain dehydrogenases/reductases of mannitol metabolism in Aspergillus fumigatus: biochemical characterization and pH studies o... Chem Biol Interact. 2009 Mar 16;178(1-3):274-82.
DMSCDY9	RU	https://pubmed.ncbi.nlm.nih.gov/18983992

DMPWB7T	DI	DMPWB7T
DMPWB7T	DN	Maprotiline
DMPWB7T	MI	DEJGDUW
DMPWB7T	MN	Cytochrome P450 1A2 (CYP1A2)
DMPWB7T	MT	DME
DMPWB7T	MA	Metabolism
DMPWB7T	RN	Cytochrome P450 enzymes contributing to demethylation of maprotiline in man. Pharmacol Toxicol. 2002 Mar;90(3):144-9.
DMPWB7T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12071336

DMPWB7T	DI	DMPWB7T
DMPWB7T	DN	Maprotiline
DMPWB7T	MI	DECB0K3
DMPWB7T	MN	Cytochrome P450 2D6 (CYP2D6)
DMPWB7T	MT	DME
DMPWB7T	MA	Metabolism
DMPWB7T	RN	Cytochrome P450 enzymes contributing to demethylation of maprotiline in man. Pharmacol Toxicol. 2002 Mar;90(3):144-9.
DMPWB7T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12071336

DMPWB7T	DI	DMPWB7T
DMPWB7T	DN	Maprotiline
DMPWB7T	MI	TTAWNKZ
DMPWB7T	MN	Norepinephrine transporter (NET)
DMPWB7T	MT	DTT
DMPWB7T	MA	Inhibitor
DMPWB7T	RN	Effect of pharmacologically selective antidepressants on serotonin uptake in rat platelets. Gen Physiol Biophys. 2005 Mar;24(1):113-28.
DMPWB7T	RU	https://pubmed.ncbi.nlm.nih.gov/15900091

DMTL94F	DI	DMTL94F
DMTL94F	DN	Maraviroc
DMTL94F	MI	TT2CEJG
DMTL94F	MN	C-C chemokine receptor type 5 (CCR5)
DMTL94F	MT	DTT
DMTL94F	MA	Antagonist
DMTL94F	RN	Rapamycin enhances aplaviroc anti-HIV activity: implications for the clinical development of novel CCR5 antagonists. Antiviral Res. 2009 Jul;83(1):86-9.
DMTL94F	RU	https://pubmed.ncbi.nlm.nih.gov/19501260

DMTL94F	DI	DMTL94F
DMTL94F	DN	Maraviroc
DMTL94F	MI	TTJIH8Q
DMTL94F	MN	CCR5 messenger RNA (CCR5 mRNA)
DMTL94F	MT	DTT
DMTL94F	MA	Antagonist
DMTL94F	RN	Molecular cloning and radioligand binding characterization of the chemokine receptor CCR5 from rhesus macaque and human. Biochem Pharmacol. 2005 Dec 19;71(1-2):163-72.
DMTL94F	RU	https://pubmed.ncbi.nlm.nih.gov/16298345

DMTL94F	DI	DMTL94F
DMTL94F	DN	Maraviroc
DMTL94F	MI	DTUGYRD
DMTL94F	MN	P-glycoprotein 1 (ABCB1)
DMTL94F	MT	DTP
DMTL94F	MA	Substrate
DMTL94F	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DMTL94F	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DMKEY6S	DI	DMKEY6S
DMKEY6S	DN	Margetuximab
DMKEY6S	MI	TT6EO5L
DMKEY6S	MN	Erbb2 tyrosine kinase receptor (HER2)
DMKEY6S	MT	DTT
DMKEY6S	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMKEY6S	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf

DM70IK5	DI	DM70IK5
DM70IK5	DN	Marinol
DM70IK5	MI	TT6OEDT
DM70IK5	MN	Cannabinoid receptor 1 (CB1)
DM70IK5	MT	DTT
DM70IK5	MA	Agonist
DM70IK5	RN	Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol. 2009 Feb;156(3):397-411.
DM70IK5	RU	https://pubmed.ncbi.nlm.nih.gov/19226257

DM70IK5	DI	DM70IK5
DM70IK5	DN	Marinol
DM70IK5	MI	DE6OQ3W
DM70IK5	MN	Cytochrome P450 1A1 (CYP1A1)
DM70IK5	MT	DME
DM70IK5	MA	Metabolism
DM70IK5	RN	Increasing the intracellular availability of all-trans retinoic acid in neuroblastoma cells. Br J Cancer. 2005 Feb 28;92(4):696-704.
DM70IK5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15714209

DM70IK5	DI	DM70IK5
DM70IK5	DN	Marinol
DM70IK5	MI	DEJVYAZ
DM70IK5	MN	Cytochrome P450 2A6 (CYP2A6)
DM70IK5	MT	DME
DM70IK5	MA	Metabolism
DM70IK5	RN	Health control over the feeding of troops on the Western and 3d Belorussian Fronts during the Great Patriotic War years. Voen Med Zh. 1975 Jun;(6):86-8.
DM70IK5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1103455

DM70IK5	DI	DM70IK5
DM70IK5	DN	Marinol
DM70IK5	MI	DE5IED8
DM70IK5	MN	Cytochrome P450 2C9 (CYP2C9)
DM70IK5	MT	DME
DM70IK5	MA	Metabolism
DM70IK5	RN	CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin. Biochem Pharmacol. 2005 Oct 1;70(7):1096-103.
DM70IK5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16112652

DM70IK5	DI	DM70IK5
DM70IK5	DN	Marinol
DM70IK5	MI	DE4LYSA
DM70IK5	MN	Cytochrome P450 3A4 (CYP3A4)
DM70IK5	MT	DME
DM70IK5	MA	Metabolism
DM70IK5	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM70IK5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM70IK5	DI	DM70IK5
DM70IK5	DN	Marinol
DM70IK5	MI	DEGTFWK
DM70IK5	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM70IK5	MT	DME
DM70IK5	MA	Metabolism
DM70IK5	RN	Inhibition of cyclosporine and tetrahydrocannabinol metabolism by cannabidiol in mouse and human microsomes. Xenobiotica. 1996 Mar;26(3):275-84.
DM70IK5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8730919

DM70IK5	DI	DM70IK5
DM70IK5	DN	Marinol
DM70IK5	MI	DE073H6
DM70IK5	MN	Prostaglandin G/H synthase 1 (COX-1)
DM70IK5	MT	DME
DM70IK5	MA	Metabolism
DM70IK5	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM70IK5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMMVNZ0	DI	DMMVNZ0
DMMVNZ0	DN	Masoprocol
DMMVNZ0	MI	TT6EO5L
DMMVNZ0	MN	Erbb2 tyrosine kinase receptor (HER2)
DMMVNZ0	MT	DTT
DMMVNZ0	MA	Modulator
DMMVNZ0	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMMVNZ0	RU	https://www.fda.gov/

DMZ36RN	DI	DMZ36RN
DMZ36RN	DN	Mazindol
DMZ36RN	MI	TTAWNKZ
DMZ36RN	MN	Norepinephrine transporter (NET)
DMZ36RN	MT	DTT
DMZ36RN	MA	Modulator
DMZ36RN	RN	Binding of [3H]mazindol to cardiac norepinephrine transporters: kinetic and equilibrium studies. Naunyn Schmiedebergs Arch Pharmacol. 2004 Jul;370(1):9-16.
DMZ36RN	RU	https://pubmed.ncbi.nlm.nih.gov/15300361

DM0R4Z5	DI	DM0R4Z5
DM0R4Z5	DN	MCB-3837
DM0R4Z5	MI	TT9SL3Q
DM0R4Z5	MN	Polypeptide deformylase (PDF)
DM0R4Z5	MT	DTT
DM0R4Z5	MA	Inhibitor
DM0R4Z5	RN	The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
DM0R4Z5	RU	https://pubmed.ncbi.nlm.nih.gov/18220771

DM8ZHP1	DI	DM8ZHP1
DM8ZHP1	DN	MCI-186
DM8ZHP1	MI	TTJGNVC
DM8ZHP1	MN	Apoptosis regulator Bcl-2 (BCL-2)
DM8ZHP1	MT	DTT
DM8ZHP1	MA	Regulator (upregulator)
DM8ZHP1	RN	Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
DM8ZHP1	RU	https://pubmed.ncbi.nlm.nih.gov/17604499

DM8ZHP1	DI	DM8ZHP1
DM8ZHP1	DN	MCI-186
DM8ZHP1	MI	DTQ23VB
DM8ZHP1	MN	Organic anion transporter 1 (SLC22A6)
DM8ZHP1	MT	DTP
DM8ZHP1	MA	Substrate
DM8ZHP1	RN	Human organic anion transporters 1 (hOAT1/SLC22A6) and 3 (hOAT3/SLC22A8) transport edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one) and its sulfate conjugate. Drug Metab Dispos. 2007 Aug;35(8):1429-34.
DM8ZHP1	RU	http://www.ncbi.nlm.nih.gov/pubmed/17502342

DM8ZHP1	DI	DM8ZHP1
DM8ZHP1	DN	MCI-186
DM8ZHP1	MI	DTVP67E
DM8ZHP1	MN	Organic anion transporter 3 (SLC22A8)
DM8ZHP1	MT	DTP
DM8ZHP1	MA	Substrate
DM8ZHP1	RN	Human organic anion transporters 1 (hOAT1/SLC22A6) and 3 (hOAT3/SLC22A8) transport edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one) and its sulfate conjugate. Drug Metab Dispos. 2007 Aug;35(8):1429-34.
DM8ZHP1	RU	http://www.ncbi.nlm.nih.gov/pubmed/17502342

DM8ZHP1	DI	DM8ZHP1
DM8ZHP1	DN	MCI-186
DM8ZHP1	MI	DEYGVN4
DM8ZHP1	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM8ZHP1	MT	DME
DM8ZHP1	MA	Metabolism
DM8ZHP1	RN	A novel administration route for edaravone: I. Effects of metabolic inhibitors on skin permeability of edaravone. Int J Pharm. 2009 May 8;372(1-2):33-8.
DM8ZHP1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19166920

DM4IAKR	DI	DM4IAKR
DM4IAKR	DN	MD-1100
DM4IAKR	MI	TTLDPRG
DM4IAKR	MN	Guanylyl cyclase C (GUCY2C)
DM4IAKR	MT	DTT
DM4IAKR	MA	Activator
DM4IAKR	RN	Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
DM4IAKR	RU	https://pubmed.ncbi.nlm.nih.gov/16634703

DMO14SG	DI	DMO14SG
DMO14SG	DN	Mebendazole
DMO14SG	MI	DE4LYSA
DMO14SG	MN	Cytochrome P450 3A4 (CYP3A4)
DMO14SG	MT	DME
DMO14SG	MA	Metabolism
DMO14SG	RN	Alveolar echinococcosis of the liver in an adult with human immunodeficiency virus type-1 infection. Infection. 2004 Oct;32(5):299-302.
DMO14SG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15624896

DMO14SG	DI	DMO14SG
DMO14SG	DN	Mebendazole
DMO14SG	MI	TTYFKSZ
DMO14SG	MN	Tubulin beta (TUBB)
DMO14SG	MT	DTT
DMO14SG	MA	Binder
DMO14SG	RN	Flubendazole interferes with a wide spectrum of cell homeostatic mechanisms in Echinococcus granulosus protoscoleces. Parasitol Int. 2009 Sep;58(3):270-7.
DMO14SG	RU	https://pubmed.ncbi.nlm.nih.gov/19336257

DMNOBFQ	DI	DMNOBFQ
DMNOBFQ	DN	Mebeverine
DMNOBFQ	MI	TTH18TF
DMNOBFQ	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMNOBFQ	MT	DTT
DMNOBFQ	MA	Antagonist
DMNOBFQ	RN	Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
DMNOBFQ	RU	https://pubmed.ncbi.nlm.nih.gov/16634703

DM0KYI4	DI	DM0KYI4
DM0KYI4	DN	Mebutamate
DM0KYI4	MI	TTEX6LM
DM0KYI4	MN	GABA(A) receptor gamma-3 (GABRG3)
DM0KYI4	MT	DTT
DM0KYI4	MA	Modulator
DM0KYI4	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM0KYI4	RU	https://www.fda.gov/

DMGQFYB	DI	DMGQFYB
DMGQFYB	DN	Mecamylamine
DMGQFYB	MI	TTJSZTB
DMGQFYB	MN	Nicotinic acetylcholine receptor (nAChR)
DMGQFYB	MT	DTT
DMGQFYB	MA	Antagonist
DMGQFYB	RN	Mecamylamine (Inversine): an old antihypertensive with new research directions. J Hum Hypertens. 2002 Jul;16(7):453-7.
DMGQFYB	RU	https://pubmed.ncbi.nlm.nih.gov/12080428

DM1O3BY	DI	DM1O3BY
DM1O3BY	DN	Mecasermin
DM1O3BY	MI	TTHRID2
DM1O3BY	MN	Insulin-like growth factor I receptor (IGF1R)
DM1O3BY	MT	DTT
DM1O3BY	MA	Inhibitor
DM1O3BY	RN	IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer. Virchows Arch. 2003 Aug;443(2):139-45.
DM1O3BY	RU	https://pubmed.ncbi.nlm.nih.gov/12845531

DM0CVXA	DI	DM0CVXA
DM0CVXA	DN	Mechlorethamine
DM0CVXA	MI	TTUTN1I
DM0CVXA	MN	Human Deoxyribonucleic acid (hDNA)
DM0CVXA	MT	DTT
DM0CVXA	MA	Intercalator
DM0CVXA	RN	Proteomic analysis of DNA-protein cross-linking by antitumor nitrogen mustards. Chem Res Toxicol. 2009 Jun;22(6):1151-62.
DM0CVXA	RU	https://pubmed.ncbi.nlm.nih.gov/19480393

DMS7T13	DI	DMS7T13
DMS7T13	DN	Meclizine
DMS7T13	MI	DECB0K3
DMS7T13	MN	Cytochrome P450 2D6 (CYP2D6)
DMS7T13	MT	DME
DMS7T13	MA	Metabolism
DMS7T13	RN	Meclizine metabolism and pharmacokinetics: formulation on its absorption. J Clin Pharmacol. 2012 Sep;52(9):1343-9.
DMS7T13	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21903894

DMS7T13	DI	DMS7T13
DMS7T13	DN	Meclizine
DMS7T13	MI	TTRANFM
DMS7T13	MN	Orphan nuclear receptor NR1I3 (NR1I3)
DMS7T13	MT	DTT
DMS7T13	MA	Modulator
DMS7T13	RN	Synthetic drugs and natural products as modulators of constitutive androstane receptor (CAR) and pregnane X receptor (PXR). Drug Metab Rev. 2006;38(1-2):51-73.
DMS7T13	RU	https://pubmed.ncbi.nlm.nih.gov/16684648

DMSFQ8I	DI	DMSFQ8I
DMSFQ8I	DN	Meclocycline
DMSFQ8I	MI	TTQ8KVI
DMSFQ8I	MN	Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)
DMSFQ8I	MT	DTT
DMSFQ8I	MA	Binder
DMSFQ8I	RN	Detection of tetracycline resistance genes by PCR methods. Methods Mol Biol. 2004;268:3-13.
DMSFQ8I	RU	https://pubmed.ncbi.nlm.nih.gov/15156014

DMNL98G	DI	DMNL98G
DMNL98G	DN	Meclofenamate sodium
DMNL98G	MI	TT8NGED
DMNL98G	MN	Prostaglandin G/H synthase 1 (COX-1)
DMNL98G	MT	DTT
DMNL98G	MA	Modulator
DMNL98G	RN	Role of COX-2-derived metabolites in regulation of the renal hemodynamic response to norepinephrine. Am J Physiol Renal Physiol. 2001 Nov;281(5):F975-82.
DMNL98G	RU	https://www.ncbi.nlm.nih.gov/pubmed/11592955

DMNL98G	DI	DMNL98G
DMNL98G	DN	Meclofenamate sodium
DMNL98G	MI	TTVKILB
DMNL98G	MN	Prostaglandin G/H synthase 2 (COX-2)
DMNL98G	MT	DTT
DMNL98G	MA	Modulator
DMNL98G	RN	Role of COX-2-derived metabolites in regulation of the renal hemodynamic response to norepinephrine. Am J Physiol Renal Physiol. 2001 Nov;281(5):F975-82.
DMNL98G	RU	https://www.ncbi.nlm.nih.gov/pubmed/11592955

DM05FXR	DI	DM05FXR
DM05FXR	DN	Meclofenamic acid
DM05FXR	MI	DE4OGUF
DM05FXR	MN	Cytochrome P450 102A1 (cyp102)
DM05FXR	MT	DME
DM05FXR	MA	Metabolism
DM05FXR	RN	Both reactivity and accessibility are important in cytochrome P450 metabolism: a combined DFT and MD study of fenamic acids in BM3 mutants. J Chem Inf Model. 2019 Feb 25;59(2):743-753.
DM05FXR	RU	https://pubmed.ncbi.nlm.nih.gov/30758202

DM05FXR	DI	DM05FXR
DM05FXR	DN	Meclofenamic acid
DM05FXR	MI	TTK0943
DM05FXR	MN	Prostaglandin G/H synthase (COX)
DM05FXR	MT	DTT
DM05FXR	MA	Inhibitor
DM05FXR	RN	Interactions of PGH synthase isozymes-1 and -2 with NSAIDs. Ann N Y Acad Sci. 1994 Nov 15;744:50-7.
DM05FXR	RU	https://pubmed.ncbi.nlm.nih.gov/7825862

DMBGWPH	DI	DMBGWPH
DMBGWPH	DN	Medroxyprogesterone
DMBGWPH	MI	DE4LYSA
DMBGWPH	MN	Cytochrome P450 3A4 (CYP3A4)
DMBGWPH	MT	DME
DMBGWPH	MA	Metabolism
DMBGWPH	RN	Metabolic profiling and cytochrome P450 reaction phenotyping of medroxyprogesterone acetate. Drug Metab Dispos. 2008 Nov;36(11):2292-8.
DMBGWPH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18725509

DMBGWPH	DI	DMBGWPH
DMBGWPH	DN	Medroxyprogesterone
DMBGWPH	MI	TTUV8G9
DMBGWPH	MN	Progesterone receptor (PGR)
DMBGWPH	MT	DTT
DMBGWPH	MA	Agonist
DMBGWPH	RN	Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharm... Steroids. 2008 Feb;73(2):222-31.
DMBGWPH	RU	https://pubmed.ncbi.nlm.nih.gov/18061638

DMJ90O5	DI	DMJ90O5
DMJ90O5	DN	Medrysone
DMJ90O5	MI	DE4LYSA
DMJ90O5	MN	Cytochrome P450 3A4 (CYP3A4)
DMJ90O5	MT	DME
DMJ90O5	MA	Metabolism
DMJ90O5	RN	Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35.
DMJ90O5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20482443

DMJ90O5	DI	DMJ90O5
DMJ90O5	DN	Medrysone
DMJ90O5	MI	TTP3UTW
DMJ90O5	MN	Steroid hormone receptor ERR (ESRR)
DMJ90O5	MT	DTT
DMJ90O5	MA	Modulator
DMJ90O5	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMJ90O5	RU	https://www.fda.gov/

DMK7HFI	DI	DMK7HFI
DMK7HFI	DN	Mefenamic acid
DMK7HFI	MI	DE4OGUF
DMK7HFI	MN	Cytochrome P450 102A1 (cyp102)
DMK7HFI	MT	DME
DMK7HFI	MA	Metabolism
DMK7HFI	RN	Both reactivity and accessibility are important in cytochrome P450 metabolism: a combined DFT and MD study of fenamic acids in BM3 mutants. J Chem Inf Model. 2019 Feb 25;59(2):743-753.
DMK7HFI	RU	https://pubmed.ncbi.nlm.nih.gov/30758202

DMK7HFI	DI	DMK7HFI
DMK7HFI	DN	Mefenamic acid
DMK7HFI	MI	DES5XRU
DMK7HFI	MN	Cytochrome P450 2C8 (CYP2C8)
DMK7HFI	MT	DME
DMK7HFI	MA	Metabolism
DMK7HFI	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DMK7HFI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DMK7HFI	DI	DMK7HFI
DMK7HFI	DN	Mefenamic acid
DMK7HFI	MI	DE5IED8
DMK7HFI	MN	Cytochrome P450 2C9 (CYP2C9)
DMK7HFI	MT	DME
DMK7HFI	MA	Metabolism
DMK7HFI	RN	Cytochrome P450-mediated bioactivation of mefenamic acid to quinoneimine intermediates and inactivation by human glutathione S-transferases. Chem Res Toxicol. 2014 Dec 15;27(12):2071-81.
DMK7HFI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25372302

DMK7HFI	DI	DMK7HFI
DMK7HFI	DN	Mefenamic acid
DMK7HFI	MI	TTVKILB
DMK7HFI	MN	Prostaglandin G/H synthase 2 (COX-2)
DMK7HFI	MT	DTT
DMK7HFI	MA	Inhibitor
DMK7HFI	RN	Systematic pharmacological approach to the characterization of NSAIDs. Prostaglandins Leukot Essent Fatty Acids. 1998 Jul;59(1):55-62.
DMK7HFI	RU	https://pubmed.ncbi.nlm.nih.gov/9758208

DMWT905	DI	DMWT905
DMWT905	DN	Mefloquine
DMWT905	MI	DE4LYSA
DMWT905	MN	Cytochrome P450 3A4 (CYP3A4)
DMWT905	MT	DME
DMWT905	MA	Metabolism
DMWT905	RN	Effect of rifampin on plasma concentrations of mefloquine in healthy volunteers. J Pharm Pharmacol. 2000 Oct;52(10):1265-9.
DMWT905	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11092571

DMWT905	DI	DMWT905
DMWT905	DN	Mefloquine
DMWT905	MI	DTUGYRD
DMWT905	MN	P-glycoprotein 1 (ABCB1)
DMWT905	MT	DTP
DMWT905	MA	Substrate
DMWT905	RN	Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004 Jan;75(1):13-33.
DMWT905	RU	https://doi.org/10.1016/j.clpt.2003.09.012

DMWT905	DI	DMWT905
DMWT905	DN	Mefloquine
DMWT905	MI	TTT28H3
DMWT905	MN	Plasmodium 80S ribosome (Malaria 80S)
DMWT905	MT	DTT
DMWT905	MA	Binder
DMWT905	RN	An ultrastructural study of the effects of mefloquine on malaria parasites. Am J Trop Med Hyg. 1987 Jan;36(1):9-14.
DMWT905	RU	https://pubmed.ncbi.nlm.nih.gov/3544894

DMDH9KX	DI	DMDH9KX
DMDH9KX	DN	Megestrol
DMDH9KX	MI	DE4LYSA
DMDH9KX	MN	Cytochrome P450 3A4 (CYP3A4)
DMDH9KX	MT	DME
DMDH9KX	MA	Metabolism
DMDH9KX	RN	Metabolism of megestrol acetate in vitro and the role of oxidative metabolites. Xenobiotica. 2018 Oct;48(10):973-983.
DMDH9KX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29050522

DMDH9KX	DI	DMDH9KX
DMDH9KX	DN	Megestrol
DMDH9KX	MI	TTUV8G9
DMDH9KX	MN	Progesterone receptor (PGR)
DMDH9KX	MT	DTT
DMDH9KX	MA	Binder
DMDH9KX	RN	Focus on anastrozole and breast cancer. Curr Med Res Opin. 2003;19(8):683-8.
DMDH9KX	RU	https://pubmed.ncbi.nlm.nih.gov/14687437

DM1OFHN	DI	DM1OFHN
DM1OFHN	DN	Meglitinides
DM1OFHN	MI	TTEX248
DM1OFHN	MN	Dopamine D2 receptor (D2R)
DM1OFHN	MT	DTT
DM1OFHN	MA	Antagonist
DM1OFHN	RN	Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. Biochem Pharmacol. 1985 Jul 1;34(13):2251-9.
DM1OFHN	RU	https://pubmed.ncbi.nlm.nih.gov/4015674

DM1OFHN	DI	DM1OFHN
DM1OFHN	DN	Meglitinides
DM1OFHN	MI	TTCBFJO
DM1OFHN	MN	Insulin receptor (INSR)
DM1OFHN	MT	DTT
DM1OFHN	MA	Stimulator
DM1OFHN	RN	New drugs for type 2 diabetes mellitus: what is their place in therapy Drugs. 2008;68(15):2131-62.
DM1OFHN	RU	https://pubmed.ncbi.nlm.nih.gov/18840004

DMGUZ0W	DI	DMGUZ0W
DMGUZ0W	DN	MELARSOPROL
DMGUZ0W	MI	TT2SUAQ
DMGUZ0W	MN	Cysteine protease (CYP)
DMGUZ0W	MT	DTT
DMGUZ0W	MA	Inhibitor
DMGUZ0W	RN	On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide s... J Med Chem. 2009 Sep 24;52(18):5662-72.
DMGUZ0W	RU	https://pubmed.ncbi.nlm.nih.gov/19715342

DMKWFBT	DI	DMKWFBT
DMKWFBT	DN	Melatonin
DMKWFBT	MI	DE6OQ3W
DMKWFBT	MN	Cytochrome P450 1A1 (CYP1A1)
DMKWFBT	MT	DME
DMKWFBT	MA	Metabolism
DMKWFBT	RN	Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. 2005 Apr;33(4):489-94.
DMKWFBT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15616152

DMKWFBT	DI	DMKWFBT
DMKWFBT	DN	Melatonin
DMKWFBT	MI	DEJGDUW
DMKWFBT	MN	Cytochrome P450 1A2 (CYP1A2)
DMKWFBT	MT	DME
DMKWFBT	MA	Metabolism
DMKWFBT	RN	Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay. Eur J Pharm Sci. 2005 Jan;24(1):123-32.
DMKWFBT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15626586

DMKWFBT	DI	DMKWFBT
DMKWFBT	DN	Melatonin
DMKWFBT	MI	DE9QHP6
DMKWFBT	MN	Cytochrome P450 1B1 (CYP1B1)
DMKWFBT	MT	DME
DMKWFBT	MA	Metabolism
DMKWFBT	RN	Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. 2005 Apr;33(4):489-94.
DMKWFBT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15616152

DMKWFBT	DI	DMKWFBT
DMKWFBT	DN	Melatonin
DMKWFBT	MI	DE5IED8
DMKWFBT	MN	Cytochrome P450 2C9 (CYP2C9)
DMKWFBT	MT	DME
DMKWFBT	MA	Metabolism
DMKWFBT	RN	New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
DMKWFBT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20167001

DMKWFBT	DI	DMKWFBT
DMKWFBT	DN	Melatonin
DMKWFBT	MI	DEHGR57
DMKWFBT	MN	Hydroxyindole O-methyltransferase (ASMT)
DMKWFBT	MT	DME
DMKWFBT	MA	Metabolism
DMKWFBT	RN	The pharmacology of the pineal gland. Annu Rev Pharmacol Toxicol. 1976;16:33-51.
DMKWFBT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=180879

DMKWFBT	DI	DMKWFBT
DMKWFBT	DN	Melatonin
DMKWFBT	MI	DE43MW5
DMKWFBT	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMKWFBT	MT	DME
DMKWFBT	MA	Metabolism
DMKWFBT	RN	Molecular evidence that melatonin is enzymatically oxidized in a different manner than tryptophan: investigations with both indoleamine 2,3-dioxygenase and myeloperoxidase. Biochem J. 2005 May 15;388(Pt 1):205-15.
DMKWFBT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15636586

DMKWFBT	DI	DMKWFBT
DMKWFBT	DN	Melatonin
DMKWFBT	MI	TT0WAIE
DMKWFBT	MN	Melatonin receptor type 1A (MTNR1A)
DMKWFBT	MT	DTT
DMKWFBT	MA	Binder
DMKWFBT	RN	The human MT1 melatonin receptor stimulates cAMP production in the human neuroblastoma cell line SH-SY5Y cells via a calcium-calmodulin signal transduction pathway. J Neuroendocrinol. 2005 Mar;17(3):170-8.
DMKWFBT	RU	https://pubmed.ncbi.nlm.nih.gov/15796769

DMKWFBT	DI	DMKWFBT
DMKWFBT	DN	Melatonin
DMKWFBT	MI	DEGTFWK
DMKWFBT	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMKWFBT	MT	DME
DMKWFBT	MA	Metabolism
DMKWFBT	RN	The effect of CYP2C19 substrate on the metabolism of melatonin in the elderly: a randomized, double-blind, placebo-controlled study. Methods Find Exp Clin Pharmacol. 2006 Sep;28(7):447-50.
DMKWFBT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17003850

DMKWFBT	DI	DMKWFBT
DMKWFBT	DN	Melatonin
DMKWFBT	MI	TTJLP0R
DMKWFBT	MN	Quinone reductase 2 (NQO2)
DMKWFBT	MT	DTT
DMKWFBT	MA	Inhibitor
DMKWFBT	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMKWFBT	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM2AR7L	DI	DM2AR7L
DM2AR7L	DN	Meloxicam
DM2AR7L	MI	DES5XRU
DM2AR7L	MN	Cytochrome P450 2C8 (CYP2C8)
DM2AR7L	MT	DME
DM2AR7L	MA	Metabolism
DM2AR7L	RN	Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):607-20.
DM2AR7L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19422321

DM2AR7L	DI	DM2AR7L
DM2AR7L	DN	Meloxicam
DM2AR7L	MI	DE5IED8
DM2AR7L	MN	Cytochrome P450 2C9 (CYP2C9)
DM2AR7L	MT	DME
DM2AR7L	MA	Metabolism
DM2AR7L	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM2AR7L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM2AR7L	DI	DM2AR7L
DM2AR7L	DN	Meloxicam
DM2AR7L	MI	DE4LYSA
DM2AR7L	MN	Cytochrome P450 3A4 (CYP3A4)
DM2AR7L	MT	DME
DM2AR7L	MA	Metabolism
DM2AR7L	RN	Activation of human cytochrome P-450 3A4-catalyzed meloxicam 5'-methylhydroxylation by quinidine and hydroquinidine in vitro. J Pharmacol Exp Ther. 1999 Jul;290(1):1-8.
DM2AR7L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10381752

DM2AR7L	DI	DM2AR7L
DM2AR7L	DN	Meloxicam
DM2AR7L	MI	TTVKILB
DM2AR7L	MN	Prostaglandin G/H synthase 2 (COX-2)
DM2AR7L	MT	DTT
DM2AR7L	MA	Inhibitor
DM2AR7L	RN	Meloxicam: selective COX-2 inhibition in clinical practice. Semin Arthritis Rheum. 1997 Jun;26(6 Suppl 1):21-7.
DM2AR7L	RU	https://pubmed.ncbi.nlm.nih.gov/9219316

DMOLNHF	DI	DMOLNHF
DMOLNHF	DN	Melphalan
DMOLNHF	MI	DE4ZHS1
DMOLNHF	MN	Glutathione S-transferase alpha-1 (GSTA1)
DMOLNHF	MT	DME
DMOLNHF	MA	Metabolism
DMOLNHF	RN	Metabolism of melphalan by rat liver microsomal glutathione S-transferase. Chem Biol Interact. 2005 Apr 15;152(2-3):101-6.
DMOLNHF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15840383

DMOLNHF	DI	DMOLNHF
DMOLNHF	DN	Melphalan
DMOLNHF	MI	TTUTN1I
DMOLNHF	MN	Human Deoxyribonucleic acid (hDNA)
DMOLNHF	MT	DTT
DMOLNHF	MA	Modulator
DMOLNHF	RN	Alkylation of DNA by melphalan in relation to immunoassay of melphalan-DNA adducts: characterization of mono-alkylated and cross-linked products fr... Chem Biol Interact. 1990;73(2-3):183-94.
DMOLNHF	RU	https://www.ncbi.nlm.nih.gov/pubmed/2155711

DMOLNHF	DI	DMOLNHF
DMOLNHF	DN	Melphalan
DMOLNHF	MI	DTUGYRD
DMOLNHF	MN	P-glycoprotein 1 (ABCB1)
DMOLNHF	MT	DTP
DMOLNHF	MA	Substrate
DMOLNHF	RN	Multidrug resistance protein-mediated transport of chlorambucil and melphalan conjugated to glutathione. Br J Cancer. 1998;77(2):201-9.
DMOLNHF	RU	http://www.ncbi.nlm.nih.gov/pubmed/9460989

DMWF5R4	DI	DMWF5R4
DMWF5R4	DN	Melphalan flufenamide
DMWF5R4	MI	TTUTN1I
DMWF5R4	MN	Human Deoxyribonucleic acid (hDNA)
DMWF5R4	MT	DTT
DMWF5R4	MA	Binder
DMWF5R4	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2021
DMWF5R4	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214383s000lbl.pdf

DMD9WSC	DI	DMD9WSC
DMD9WSC	DN	Memantine
DMD9WSC	MI	TT9IK2Z
DMD9WSC	MN	N-methyl-D-aspartate receptor (NMDAR)
DMD9WSC	MT	DTT
DMD9WSC	MA	Modulator
DMD9WSC	RN	The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry. 2003 Sep;18(Suppl 1):S23-32.
DMD9WSC	RU	https://pubmed.ncbi.nlm.nih.gov/12973747

DMD9WSC	DI	DMD9WSC
DMD9WSC	DN	Memantine
DMD9WSC	MI	DT9IDPW
DMD9WSC	MN	Organic cation transporter 2 (SLC22A2)
DMD9WSC	MT	DTP
DMD9WSC	MA	Substrate
DMD9WSC	RN	Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol Pharmacol. 1998 Aug;54(2):342-52.
DMD9WSC	RU	http://www.ncbi.nlm.nih.gov/pubmed/9687576

DMP9N85	DI	DMP9N85
DMP9N85	DN	Menadiol sodium diphosphate
DMP9N85	MI	DE3N2FM
DMP9N85	MN	NADPH-cytochrome P450 reductase (CPR)
DMP9N85	MT	DME
DMP9N85	MA	Metabolism
DMP9N85	RN	Creatinine sulfate/esculoside/hesperidin methyl chalcone/menadiol sodium phosphate/tranexamic acid actions.
DMP9N85	RU	https://www.ndrugs.com/?s=creatinine%20sulfate/esculoside/hesperidin%20methyl%20chalcone/menadiol%20sodium%20phosphate/tranexamic%20acid&t=actions#doctor_pharmacology

DMP9N85	DI	DMP9N85
DMP9N85	DN	Menadiol sodium diphosphate
DMP9N85	MI	DEVRYQN
DMP9N85	MN	Vitamin K1 2,3-epoxide reductase 1 (VKOR)
DMP9N85	MT	DME
DMP9N85	MA	Metabolism
DMP9N85	RN	SMPDB database: Vitamin K Metabolism
DMP9N85	RU	http://smpdb.ca/view/SMP00464

DMSJDTY	DI	DMSJDTY
DMSJDTY	DN	Menadione
DMSJDTY	MI	TT3MOS2
DMSJDTY	MN	Aldehyde oxidase (AOX1)
DMSJDTY	MT	DTT
DMSJDTY	MA	Inhibitor
DMSJDTY	RN	Inhibition by SKF-525A of the aldehyde oxidase-mediated metabolism of the experimental antitumour agent acridine carboxamide. Biochem Pharmacol. 1993 May 25;45(10):2159-62.
DMSJDTY	RU	https://pubmed.ncbi.nlm.nih.gov/8512597

DMSJDTY	DI	DMSJDTY
DMSJDTY	DN	Menadione
DMSJDTY	MI	DTI7UX6
DMSJDTY	MN	Breast cancer resistance protein (ABCG2)
DMSJDTY	MT	DTP
DMSJDTY	MA	Substrate
DMSJDTY	RN	The naphthoquinones, vitamin K3 and its structural analogue plumbagin, are substrates of the multidrug resistance linked ATP binding cassette drug transporter ABCG2. Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3279-86.
DMSJDTY	RU	http://www.ncbi.nlm.nih.gov/pubmed/18065489

DMSJDTY	DI	DMSJDTY
DMSJDTY	DN	Menadione
DMSJDTY	MI	DE6OQ3W
DMSJDTY	MN	Cytochrome P450 1A1 (CYP1A1)
DMSJDTY	MT	DME
DMSJDTY	MA	Metabolism
DMSJDTY	RN	Rat hepatic CYP1A1 and CYP1A2 induction by menadione. Toxicol Lett. 2005 Feb 15;155(2):253-8.
DMSJDTY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15603920

DMSJDTY	DI	DMSJDTY
DMSJDTY	DN	Menadione
DMSJDTY	MI	DEJGDUW
DMSJDTY	MN	Cytochrome P450 1A2 (CYP1A2)
DMSJDTY	MT	DME
DMSJDTY	MA	Metabolism
DMSJDTY	RN	Rat hepatic CYP1A1 and CYP1A2 induction by menadione. Toxicol Lett. 2005 Feb 15;155(2):253-8.
DMSJDTY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15603920

DMSJDTY	DI	DMSJDTY
DMSJDTY	DN	Menadione
DMSJDTY	MI	DEVDYN7
DMSJDTY	MN	Cytochrome P450 2E1 (CYP2E1)
DMSJDTY	MT	DME
DMSJDTY	MA	Metabolism
DMSJDTY	RN	CYP2E1 overexpression alters hepatocyte death from menadione and fatty acids by activation of ERK1/2 signaling. Hepatology. 2004 Feb;39(2):444-55.
DMSJDTY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14767997

DMSJDTY	DI	DMSJDTY
DMSJDTY	DN	Menadione
DMSJDTY	MI	DE6NIY9
DMSJDTY	MN	Methionine synthase reductase (MTRR)
DMSJDTY	MT	DME
DMSJDTY	MA	Metabolism
DMSJDTY	RN	Differences in the efficiency of reductive activation of methionine synthase and exogenous electron acceptors between the common polymorphic variants of human methionine synthase reductase. Biochemistry. 2002 Nov 12;41(45):13378-85.
DMSJDTY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12416982

DMSJDTY	DI	DMSJDTY
DMSJDTY	DN	Menadione
DMSJDTY	MI	DEOXTPZ
DMSJDTY	MN	Methylenetetrahydrofolate reductase (MTHFR)
DMSJDTY	MT	DME
DMSJDTY	MA	Metabolism
DMSJDTY	RN	Purification and properties of 5,10-methylenetetrahydrofolate reductase, an iron-sulfur flavoprotein from Clostridium formicoaceticum. J Biol Chem. 1984 Sep 10;259(17):10845-9.
DMSJDTY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=6381490

DMSJDTY	DI	DMSJDTY
DMSJDTY	DN	Menadione
DMSJDTY	MI	DE8RYV5
DMSJDTY	MN	NADPH:quinone reductase (CRYZ)
DMSJDTY	MT	DME
DMSJDTY	MA	Metabolism
DMSJDTY	RN	Role of glutathione reductase during menadione-induced NADPH oxidation in isolated rat hepatocytes. Biochem Pharmacol. 1987 Nov 15;36(22):3879-84.
DMSJDTY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=3689427

DMSJDTY	DI	DMSJDTY
DMSJDTY	DN	Menadione
DMSJDTY	MI	DE9JFMC
DMSJDTY	MN	NADPH-dependent carbonyl reductase 1 (CBR1)
DMSJDTY	MT	DME
DMSJDTY	MA	Metabolism
DMSJDTY	RN	Polycyclic aromatic hydrocarbon quinones and glutathione thioethers as substrates and inhibitors of the human placental NADP-linked 15-hydroxyprostaglandin dehydrogenase. J Biol Chem. 1987 Sep 15;262(26):12448-51.
DMSJDTY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=3624267

DMSJDTY	DI	DMSJDTY
DMSJDTY	DN	Menadione
DMSJDTY	MI	DEIVKZ8
DMSJDTY	MN	NADPH-dependent carbonyl reductase 3 (CBR3)
DMSJDTY	MT	DME
DMSJDTY	MA	Metabolism
DMSJDTY	RN	Different functions between human monomeric carbonyl reductase 3 and carbonyl reductase 1. Mol Cell Biochem. 2008 Aug;315(1-2):113-21.
DMSJDTY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18493841

DMSJDTY	DI	DMSJDTY
DMSJDTY	DN	Menadione
DMSJDTY	MI	DEPG9C0
DMSJDTY	MN	Nitroreductase (NTR)
DMSJDTY	MT	DME
DMSJDTY	MA	Metabolism
DMSJDTY	RN	Purification and characterization of wild-type and mutant "classical" nitroreductases of Salmonella typhimurium. L33R mutation greatly diminishes binding of FMN to the nitroreductase of S. typhimurium. J Biol Chem. 1998 Sep 11;273(37):23922-8.
DMSJDTY	RU	https://pubmed.ncbi.nlm.nih.gov/9727006

DMSJDTY	DI	DMSJDTY
DMSJDTY	DN	Menadione
DMSJDTY	MI	DEJVDAT
DMSJDTY	MN	Sepiapterin reductase (SPR)
DMSJDTY	MT	DME
DMSJDTY	MA	Metabolism
DMSJDTY	RN	Sepiapterin reductase mediates chemical redox cycling in lung epithelial cells. J Biol Chem. 2013 Jun 28;288(26):19221-37.
DMSJDTY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23640889

DMSJDTY	DI	DMSJDTY
DMSJDTY	DN	Menadione
DMSJDTY	MI	TTPFZJ1
DMSJDTY	MN	Vasopressin V1 receptor (V1R)
DMSJDTY	MT	DTT
DMSJDTY	MA	Agonist
DMSJDTY	RN	Evidence in hyponatremia related to inappropriate secretion of ADH that V1 receptor stimulation contributes to the increase in renal uric acid clearance. J Am Soc Nephrol. 1996 May;7(5):805-10.
DMSJDTY	RU	https://pubmed.ncbi.nlm.nih.gov/8738818

DM2SR1J	DI	DM2SR1J
DM2SR1J	DN	Meningococcal groups A, C, Y and W-135 conjugate vaccine
DM2SR1J	MI	TTY4IQ9
DM2SR1J	MN	Corynebacterium Mutated CRM197 (Cory mTOX)
DM2SR1J	MT	DTT
DM2SR1J	MA	Binder
DM2SR1J	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DM2SR1J	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DM4CF18	DI	DM4CF18
DM4CF18	DN	Menotropins
DM4CF18	MI	TTZFDBT
DM4CF18	MN	Follicle-stimulating hormone receptor (FSHR)
DM4CF18	MT	DTT
DM4CF18	MA	Binder
DM4CF18	RN	The role of gonadotropins in ovulation induction. Am J Obstet Gynecol. 1995 Feb;172(2 Pt 2):759-65.
DM4CF18	RU	https://pubmed.ncbi.nlm.nih.gov/7872378

DMG2KW7	DI	DMG2KW7
DMG2KW7	DN	Menthol
DMG2KW7	MI	TTXDKTO
DMG2KW7	MN	Long transient receptor potential channel 8 (TRPM8)
DMG2KW7	MT	DTT
DMG2KW7	MA	Activator
DMG2KW7	RN	TRPV1-mediated itch in seasonal allergic rhinitis. Allergy. 2009 May;64(5):807-10.
DMG2KW7	RU	https://pubmed.ncbi.nlm.nih.gov/19220220

DMG2KW7	DI	DMG2KW7
DMG2KW7	DN	Menthol
DMG2KW7	MI	TTELV3W
DMG2KW7	MN	Transformation-sensitive protein p120 (TRPA1)
DMG2KW7	MT	DTT
DMG2KW7	MA	Activator
DMG2KW7	RN	TRPV1-mediated itch in seasonal allergic rhinitis. Allergy. 2009 May;64(5):807-10.
DMG2KW7	RU	https://pubmed.ncbi.nlm.nih.gov/19220220

DM8YU2F	DI	DM8YU2F
DM8YU2F	DN	Mepenzolate
DM8YU2F	MI	TTH18TF
DM8YU2F	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DM8YU2F	MT	DTT
DM8YU2F	MA	Antagonist
DM8YU2F	RN	Isolation of cholinergic active ingredients in aqueous extracts of Mareya micrantha using the longitudinal muscle of isolated guinea-pig ileum as a pharmacological activity marker. J Ethnopharmacol. 1995 Mar;45(3):215-22.
DM8YU2F	RU	https://pubmed.ncbi.nlm.nih.gov/7623487

DMX4GND	DI	DMX4GND
DMX4GND	DN	Meperidine
DMX4GND	MI	TTQ8AFT
DMX4GND	MN	Adrenergic receptor Alpha-2 (ADRA2)
DMX4GND	MT	DTT
DMX4GND	MA	Agonist
DMX4GND	RN	Meperidine, remifentanil and tramadol but not sufentanil interact with alpha(2)-adrenoceptors in alpha(2A)-, alpha(2B)- and alpha(2C)-adrenoceptor ... Eur J Pharmacol. 2008 Mar 17;582(1-3):70-7.
DMX4GND	RU	https://pubmed.ncbi.nlm.nih.gov/18234187

DMX4GND	DI	DMX4GND
DMX4GND	DN	Meperidine
DMX4GND	MI	DEPKLMQ
DMX4GND	MN	Cytochrome P450 2B6 (CYP2B6)
DMX4GND	MT	DME
DMX4GND	MA	Metabolism
DMX4GND	RN	Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
DMX4GND	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27709010

DMX4GND	DI	DMX4GND
DMX4GND	DN	Meperidine
DMX4GND	MI	DECB0K3
DMX4GND	MN	Cytochrome P450 2D6 (CYP2D6)
DMX4GND	MT	DME
DMX4GND	MA	Metabolism
DMX4GND	RN	CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab Dispos. 2004 Sep;32(9):930-6.
DMX4GND	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15319333

DMX4GND	DI	DMX4GND
DMX4GND	DN	Meperidine
DMX4GND	MI	DE4LYSA
DMX4GND	MN	Cytochrome P450 3A4 (CYP3A4)
DMX4GND	MT	DME
DMX4GND	MA	Metabolism
DMX4GND	RN	Is meperidine the drug that just won't die? J Pediatr Pharmacol Ther. 2011 Jul;16(3):167-9.
DMX4GND	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22479158

DMX4GND	DI	DMX4GND
DMX4GND	DN	Meperidine
DMX4GND	MI	DEGTFWK
DMX4GND	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMX4GND	MT	DME
DMX4GND	MA	Metabolism
DMX4GND	RN	Impact of cytochrome P450 variation on meperidine N-demethylation to the neurotoxic metabolite normeperidine. Xenobiotica. 2020 Feb;50(2):209-222.
DMX4GND	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30902024

DMX4GND	DI	DMX4GND
DMX4GND	DN	Meperidine
DMX4GND	MI	DTUGYRD
DMX4GND	MN	P-glycoprotein 1 (ABCB1)
DMX4GND	MT	DTP
DMX4GND	MA	Substrate
DMX4GND	RN	Opioids and efflux transporters. Part 3: P-glycoprotein substrate activity of 3-hydroxyl addition to meperidine analogs. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3638-40.
DMX4GND	RU	http://www.ncbi.nlm.nih.gov/pubmed/18499452

DMFJH5Q	DI	DMFJH5Q
DMFJH5Q	DN	Mephentermine
DMFJH5Q	MI	TTEX248
DMFJH5Q	MN	Dopamine D2 receptor (D2R)
DMFJH5Q	MT	DTT
DMFJH5Q	MA	Agonist
DMFJH5Q	RN	Present state of alpha- and beta-adrenergic drugs I. The adrenergic receptor. Am Heart J. 1976 Nov;92(5):661-4.
DMFJH5Q	RU	https://pubmed.ncbi.nlm.nih.gov/10722

DM5UGDK	DI	DM5UGDK
DM5UGDK	DN	Mephenytoin
DM5UGDK	MI	DEJGDUW
DM5UGDK	MN	Cytochrome P450 1A2 (CYP1A2)
DM5UGDK	MT	DME
DM5UGDK	MA	Metabolism
DM5UGDK	RN	Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms. Br J Clin Pharmacol. 1999 Aug;48(2):158-67.
DM5UGDK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10417492

DM5UGDK	DI	DM5UGDK
DM5UGDK	DN	Mephenytoin
DM5UGDK	MI	DEPKLMQ
DM5UGDK	MN	Cytochrome P450 2B6 (CYP2B6)
DM5UGDK	MT	DME
DM5UGDK	MA	Metabolism
DM5UGDK	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM5UGDK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM5UGDK	DI	DM5UGDK
DM5UGDK	DN	Mephenytoin
DM5UGDK	MI	DEZMWRE
DM5UGDK	MN	Cytochrome P450 2C18 (CYP2C18)
DM5UGDK	MT	DME
DM5UGDK	MA	Metabolism
DM5UGDK	RN	Cytochrome P450 metabolic dealkylation of nine N-nitrosodialkylamines by human liver microsomes. Carcinogenesis. 1996 Sep;17(9):2029-34.
DM5UGDK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8824531

DM5UGDK	DI	DM5UGDK
DM5UGDK	DN	Mephenytoin
DM5UGDK	MI	DES5XRU
DM5UGDK	MN	Cytochrome P450 2C8 (CYP2C8)
DM5UGDK	MT	DME
DM5UGDK	MA	Metabolism
DM5UGDK	RN	Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans. Biochemistry. 1994 Feb 22;33(7):1743-52.
DM5UGDK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8110777

DM5UGDK	DI	DM5UGDK
DM5UGDK	DN	Mephenytoin
DM5UGDK	MI	DE5IED8
DM5UGDK	MN	Cytochrome P450 2C9 (CYP2C9)
DM5UGDK	MT	DME
DM5UGDK	MA	Metabolism
DM5UGDK	RN	Cytochrome P450 metabolic dealkylation of nine N-nitrosodialkylamines by human liver microsomes. Carcinogenesis. 1996 Sep;17(9):2029-34.
DM5UGDK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8824531

DM5UGDK	DI	DM5UGDK
DM5UGDK	DN	Mephenytoin
DM5UGDK	MI	DECB0K3
DM5UGDK	MN	Cytochrome P450 2D6 (CYP2D6)
DM5UGDK	MT	DME
DM5UGDK	MA	Metabolism
DM5UGDK	RN	Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab Pharmacokinet. 2004 Apr;19(2):83-95.
DM5UGDK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15499174

DM5UGDK	DI	DM5UGDK
DM5UGDK	DN	Mephenytoin
DM5UGDK	MI	DE4LYSA
DM5UGDK	MN	Cytochrome P450 3A4 (CYP3A4)
DM5UGDK	MT	DME
DM5UGDK	MA	Metabolism
DM5UGDK	RN	Species differences in stereoselective metabolism of mephenytoin by cytochrome P450 (CYP2C and CYP3A). J Pharmacol Exp Ther. 1993 Jan;264(1):89-94.
DM5UGDK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8423554

DM5UGDK	DI	DM5UGDK
DM5UGDK	DN	Mephenytoin
DM5UGDK	MI	DEIBDNY
DM5UGDK	MN	Cytochrome P450 3A5 (CYP3A5)
DM5UGDK	MT	DME
DM5UGDK	MA	Metabolism
DM5UGDK	RN	Species differences in stereoselective metabolism of mephenytoin by cytochrome P450 (CYP2C and CYP3A). J Pharmacol Exp Ther. 1993 Jan;264(1):89-94.
DM5UGDK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8423554

DM5UGDK	DI	DM5UGDK
DM5UGDK	DN	Mephenytoin
DM5UGDK	MI	DEGTFWK
DM5UGDK	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM5UGDK	MT	DME
DM5UGDK	MA	Metabolism
DM5UGDK	RN	Cytochromes P450 mediating the N-demethylation of amitriptyline. Br J Clin Pharmacol. 1997 Feb;43(2):137-44.
DM5UGDK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9131945

DM5UGDK	DI	DM5UGDK
DM5UGDK	DN	Mephenytoin
DM5UGDK	MI	TTZOVE0
DM5UGDK	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DM5UGDK	MT	DTT
DM5UGDK	MA	Blocker
DM5UGDK	RN	Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68. 
DM5UGDK	RU	https://pubmed.ncbi.nlm.nih.gov/19552484

DMUDWP9	DI	DMUDWP9
DMUDWP9	DN	Mepindolol
DMUDWP9	MI	TTMXGCW
DMUDWP9	MN	Adrenergic receptor beta-3 (ADRB3)
DMUDWP9	MT	DTT
DMUDWP9	MA	Modulator
DMUDWP9	RN	Pharmacological studies on the intrinsic sympathomimetic activity of the beta-adrenoceptor antagonist mepindolol. Arzneimittelforschung. 1986 May;36(5):811-3.
DMUDWP9	RU	https://pubmed.ncbi.nlm.nih.gov/2873820

DMUDWP9	DI	DMUDWP9
DMUDWP9	DN	Mepindolol
DMUDWP9	MI	DECB0K3
DMUDWP9	MN	Cytochrome P450 2D6 (CYP2D6)
DMUDWP9	MT	DME
DMUDWP9	MA	Metabolism
DMUDWP9	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DMUDWP9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DMH2NMY	DI	DMH2NMY
DMH2NMY	DN	Mepivacaine
DMH2NMY	MI	TTRK8B9
DMH2NMY	MN	Sodium channel unspecific (NaC)
DMH2NMY	MT	DTT
DMH2NMY	MA	Blocker
DMH2NMY	RN	Block of neuronal tetrodotoxin-resistant Na+ currents by stereoisomers of piperidine local anesthetics. Anesth Analg. 2000 Dec;91(6):1499-505.
DMH2NMY	RU	https://pubmed.ncbi.nlm.nih.gov/11094008

DMW2GEJ	DI	DMW2GEJ
DMW2GEJ	DN	Mepolizumab
DMW2GEJ	MI	TTPREZD
DMW2GEJ	MN	Interleukin-5 (IL5)
DMW2GEJ	MT	DTT
DMW2GEJ	MA	Modulator
DMW2GEJ	RN	Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563. Drugs R D. 2008;9(2):125-30.
DMW2GEJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/18298130

DMTL9IP	DI	DMTL9IP
DMTL9IP	DN	Meprednisone
DMTL9IP	MI	DE4LYSA
DMTL9IP	MN	Cytochrome P450 3A4 (CYP3A4)
DMTL9IP	MT	DME
DMTL9IP	MA	Metabolism
DMTL9IP	RN	Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35.
DMTL9IP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20482443

DMTL9IP	DI	DMTL9IP
DMTL9IP	DN	Meprednisone
DMTL9IP	MI	TTYRL6O
DMTL9IP	MN	Glucocorticoid receptor (NR3C1)
DMTL9IP	MT	DTT
DMTL9IP	MA	Modulator
DMTL9IP	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMTL9IP	RU	https://www.fda.gov/

DMHM93Y	DI	DMHM93Y
DMHM93Y	DN	Meprobamate
DMHM93Y	MI	DEVDYN7
DMHM93Y	MN	Cytochrome P450 2E1 (CYP2E1)
DMHM93Y	MT	DME
DMHM93Y	MA	Metabolism
DMHM93Y	RN	Mechanisms of circadian rhythmicity of carbon tetrachloride hepatotoxicity. J Pharmacol Exp Ther. 2002 Jan;300(1):273-81.
DMHM93Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11752126

DMHM93Y	DI	DMHM93Y
DMHM93Y	DN	Meprobamate
DMHM93Y	MI	TT1MPAY
DMHM93Y	MN	GABA(A) receptor alpha-1 (GABRA1)
DMHM93Y	MT	DTT
DMHM93Y	MA	Antagonist
DMHM93Y	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DMHM93Y	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DMHM93Y	DI	DMHM93Y
DMHM93Y	DN	Meprobamate
DMHM93Y	MI	DEGTFWK
DMHM93Y	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMHM93Y	MT	DME
DMHM93Y	MA	Metabolism
DMHM93Y	RN	Association between blood carisoprodol:meprobamate concentration ratios and CYP2C19 genotype in carisoprodol-drugged drivers: decreased metabolic capacity in heterozygous CYP2C19*1/CYP2C19*2 subjects? Pharmacogenetics. 2003 Jul;13(7):383-8.
DMHM93Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12835613

DMHM93Y	DI	DMHM93Y
DMHM93Y	DN	Meprobamate
DMHM93Y	MI	TT9SL3Q
DMHM93Y	MN	Polypeptide deformylase (PDF)
DMHM93Y	MT	DTT
DMHM93Y	MA	Inhibitor
DMHM93Y	RN	The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
DMHM93Y	RU	https://pubmed.ncbi.nlm.nih.gov/18220771

DMHM93Y	DI	DMHM93Y
DMHM93Y	DN	Meprobamate
DMHM93Y	MI	TTBZ7OD
DMHM93Y	MN	Protein kinase C epsilon (PRKCE)
DMHM93Y	MT	DTT
DMHM93Y	MA	Stimulator
DMHM93Y	RN	Protein kinase C, an elusive therapeutic target . Nat Rev Drug Discov. 2012 December; 11(12): 937-957.
DMHM93Y	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3760692/

DMHM93Y	DI	DMHM93Y
DMHM93Y	DN	Meprobamate
DMHM93Y	MI	DEYGVN4
DMHM93Y	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMHM93Y	MT	DME
DMHM93Y	MA	Metabolism
DMHM93Y	RN	Solid-phase synthesis of drug glucuronides by immobilized glucuronosyltransferase. J Med Chem. 1976 May;19(5):679-83.
DMHM93Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=818382

DMPSB8F	DI	DMPSB8F
DMPSB8F	DN	MEPTAZINOL
DMPSB8F	MI	TTEB0GD
DMPSB8F	MN	Cholinesterase (BCHE)
DMPSB8F	MT	DTT
DMPSB8F	MA	Inhibitor
DMPSB8F	RN	Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36.
DMPSB8F	RU	https://pubmed.ncbi.nlm.nih.gov/18333606

DMB4SFH	DI	DMB4SFH
DMB4SFH	DN	Mepyramine
DMB4SFH	MI	TTTIBOJ
DMB4SFH	MN	Histamine H1 receptor (H1R)
DMB4SFH	MT	DTT
DMB4SFH	MA	Antagonist
DMB4SFH	RN	Antinociception induced by central administration of histamine in the formalin test in rats. Indian J Physiol Pharmacol. 2008 Jul-Sep;52(3):249-54.
DMB4SFH	RU	https://pubmed.ncbi.nlm.nih.gov/19552055

DMB4SFH	DI	DMB4SFH
DMB4SFH	DN	Mepyramine
DMB4SFH	MI	DT3HUVD
DMB4SFH	MN	Organic cation/carnitine transporter 2 (SLC22A5)
DMB4SFH	MT	DTP
DMB4SFH	MA	Substrate
DMB4SFH	RN	Genetic deficiency of carnitine/organic cation transporter 2 (slc22a5) is associated with altered tissue distribution of its substrate pyrilamine in mice. Biopharm Drug Dispos. 2009 Dec;30(9):495-507.
DMB4SFH	RU	http://www.ncbi.nlm.nih.gov/pubmed/19821448

DM7F5OW	DI	DM7F5OW
DM7F5OW	DN	Mepyramine maleate
DM7F5OW	MI	TTTIBOJ
DM7F5OW	MN	Histamine H1 receptor (H1R)
DM7F5OW	MT	DTT
DM7F5OW	MA	Antagonist
DM7F5OW	RN	Antinociception induced by central administration of histamine in the formalin test in rats. Indian J Physiol Pharmacol. 2008 Jul-Sep;52(3):249-54.
DM7F5OW	RU	https://pubmed.ncbi.nlm.nih.gov/19552055

DMAFBCY	DI	DMAFBCY
DMAFBCY	DN	Mequitazine
DMAFBCY	MI	DECB0K3
DMAFBCY	MN	Cytochrome P450 2D6 (CYP2D6)
DMAFBCY	MT	DME
DMAFBCY	MA	Metabolism
DMAFBCY	RN	Oxidation of histamine H1 antagonist mequitazine is catalyzed by cytochrome P450 2D6 in human liver microsomes. J Pharmacol Exp Ther. 1998 Feb;284(2):437-42.
DMAFBCY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9454781

DMAFBCY	DI	DMAFBCY
DMAFBCY	DN	Mequitazine
DMAFBCY	MI	TTTIBOJ
DMAFBCY	MN	Histamine H1 receptor (H1R)
DMAFBCY	MT	DTT
DMAFBCY	MA	Antagonist
DMAFBCY	RN	Efficiency of mequitazine in the treatment of allergic rhinitis and chronic urticaria in children. A bibliographic systematic review. Rev Alerg Mex. 2008 Jan-Feb;55(1):3-9.
DMAFBCY	RU	https://pubmed.ncbi.nlm.nih.gov/18697448

DMAFBCY	DI	DMAFBCY
DMAFBCY	DN	Mequitazine
DMAFBCY	MI	DTUGYRD
DMAFBCY	MN	P-glycoprotein 1 (ABCB1)
DMAFBCY	MT	DTP
DMAFBCY	MA	Substrate
DMAFBCY	RN	Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.
DMAFBCY	RU	http://www.ncbi.nlm.nih.gov/pubmed/12438524

DMTM2IK	DI	DMTM2IK
DMTM2IK	DN	Mercaptopurine
DMTM2IK	MI	TTZFTY4
DMTM2IK	MN	Amidophosphoribosyltransferase (PPAT)
DMTM2IK	MT	DTT
DMTM2IK	MA	Breaker
DMTM2IK	RN	6-mercaptopurine (6-MP) induces p53-mediated apoptosis of neural progenitor cells in the developing fetal rodent brain. Neurotoxicol Teratol. 2009 Jul-Aug;31(4):198-202.
DMTM2IK	RU	https://pubmed.ncbi.nlm.nih.gov/19281843

DMTM2IK	DI	DMTM2IK
DMTM2IK	DN	Mercaptopurine
DMTM2IK	MI	DTI7UX6
DMTM2IK	MN	Breast cancer resistance protein (ABCG2)
DMTM2IK	MT	DTP
DMTM2IK	MA	Substrate
DMTM2IK	RN	ABC transporters and their role in nucleoside and nucleotide drug resistance. Biochem Pharmacol. 2012 Apr 15;83(8):1073-83.
DMTM2IK	RU	https://doi.org/10.1016/j.bcp.2011.12.042

DMTM2IK	DI	DMTM2IK
DMTM2IK	DN	Mercaptopurine
DMTM2IK	MI	DT4YL5R
DMTM2IK	MN	Concentrative Na(+)-nucleoside cotransporter 3 (SLC28A3)
DMTM2IK	MT	DTP
DMTM2IK	MA	Substrate
DMTM2IK	RN	Involvement of the concentrative nucleoside transporter 3 and equilibrative nucleoside transporter 2 in the resistance of T-lymphoblastic cell lines to thiopurines. Biochem Biophys Res Commun. 2006 Apr 28;343(1):208-15.
DMTM2IK	RU	http://www.ncbi.nlm.nih.gov/pubmed/16530731

DMTM2IK	DI	DMTM2IK
DMTM2IK	DN	Mercaptopurine
DMTM2IK	MI	DT82KPY
DMTM2IK	MN	Concentrative nucleoside transporter 2 (SLC28A2)
DMTM2IK	MT	DTP
DMTM2IK	MA	Substrate
DMTM2IK	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA2040)
DMTM2IK	RU	https://www.pharmgkb.org/pathway/PA2040

DMTM2IK	DI	DMTM2IK
DMTM2IK	DN	Mercaptopurine
DMTM2IK	MI	DE6OQ3W
DMTM2IK	MN	Cytochrome P450 1A1 (CYP1A1)
DMTM2IK	MT	DME
DMTM2IK	MA	Metabolism
DMTM2IK	RN	Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr Drug Metab. 2007 Aug;8(6):554-62.
DMTM2IK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17691917

DMTM2IK	DI	DMTM2IK
DMTM2IK	DN	Mercaptopurine
DMTM2IK	MI	DTGBPR5
DMTM2IK	MN	Equilibrative nucleobase transporter 1 (SLC43A3)
DMTM2IK	MT	DTP
DMTM2IK	MA	Substrate
DMTM2IK	RN	Characterization of 6-Mercaptopurine Transport by the SLC43A3-Encoded Nucleobase Transporter. Mol Pharmacol. 2019 Jun;95(6):584-596.
DMTM2IK	RU	http://www.ncbi.nlm.nih.gov/pubmed/30910793

DMTM2IK	DI	DMTM2IK
DMTM2IK	DN	Mercaptopurine
DMTM2IK	MI	DTXD1TQ
DMTM2IK	MN	Equilibrative nucleoside transporter 1 (SLC29A1)
DMTM2IK	MT	DTP
DMTM2IK	MA	Substrate
DMTM2IK	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA2040)
DMTM2IK	RU	https://www.pharmgkb.org/pathway/PA2040

DMTM2IK	DI	DMTM2IK
DMTM2IK	DN	Mercaptopurine
DMTM2IK	MI	DTW78DQ
DMTM2IK	MN	Equilibrative nucleoside transporter 2 (SLC29A2)
DMTM2IK	MT	DTP
DMTM2IK	MA	Substrate
DMTM2IK	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA2040)
DMTM2IK	RU	https://www.pharmgkb.org/pathway/PA2040

DMTM2IK	DI	DMTM2IK
DMTM2IK	DN	Mercaptopurine
DMTM2IK	MI	TTL7C8Q
DMTM2IK	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMTM2IK	MT	DTT
DMTM2IK	MA	Inhibitor
DMTM2IK	RN	Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol. 2008 Aug;64(8):753-67.
DMTM2IK	RU	https://pubmed.ncbi.nlm.nih.gov/18506437

DMTM2IK	DI	DMTM2IK
DMTM2IK	DN	Mercaptopurine
DMTM2IK	MI	DTCSGPB
DMTM2IK	MN	Multidrug resistance-associated protein 4 (ABCC4)
DMTM2IK	MT	DTP
DMTM2IK	MA	Substrate
DMTM2IK	RN	Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. Blood. 2009 Aug 13;114(7):1383-6.
DMTM2IK	RU	http://www.ncbi.nlm.nih.gov/pubmed/19515727

DMTM2IK	DI	DMTM2IK
DMTM2IK	DN	Mercaptopurine
DMTM2IK	MI	DTYVM24
DMTM2IK	MN	Multidrug resistance-associated protein 5 (ABCC5)
DMTM2IK	MT	DTP
DMTM2IK	MA	Substrate
DMTM2IK	RN	Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine. Springerplus. 2014 Dec 13;3:732.
DMTM2IK	RU	http://www.ncbi.nlm.nih.gov/pubmed/25674464

DMTM2IK	DI	DMTM2IK
DMTM2IK	DN	Mercaptopurine
DMTM2IK	MI	DTVP67E
DMTM2IK	MN	Organic anion transporter 3 (SLC22A8)
DMTM2IK	MT	DTP
DMTM2IK	MA	Substrate
DMTM2IK	RN	Organic anion transporter 3 is involved in the brain-to-blood efflux transport of thiopurine nucleobase analogs. J Neurochem. 2004 Aug;90(4):931-41.
DMTM2IK	RU	http://www.ncbi.nlm.nih.gov/pubmed/15287899

DMTM2IK	DI	DMTM2IK
DMTM2IK	DN	Mercaptopurine
DMTM2IK	MI	DEFQ8VO
DMTM2IK	MN	Thiopurine methyltransferase (TPMT)
DMTM2IK	MT	DME
DMTM2IK	MA	Metabolism
DMTM2IK	RN	The degree of myelosuppression during maintenance therapy of adolescents with B-lineage intermediate risk acute lymphoblastic leukemia predicts risk of relapse. Leukemia. 2010 Apr;24(4):715-20.
DMTM2IK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20130603

DMTM2IK	DI	DMTM2IK
DMTM2IK	DN	Mercaptopurine
DMTM2IK	MI	DEYGVN4
DMTM2IK	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMTM2IK	MT	DME
DMTM2IK	MA	Metabolism
DMTM2IK	RN	Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr Drug Metab. 2007 Aug;8(6):554-62.
DMTM2IK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17691917

DM0HS92	DI	DM0HS92
DM0HS92	DN	Merimepodib
DM0HS92	MI	TTGKNB4
DM0HS92	MN	Epidermal growth factor receptor (EGFR)
DM0HS92	MT	DTT
DM0HS92	MA	Inhibitor
DM0HS92	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DM0HS92	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DM0HS92	DI	DM0HS92
DM0HS92	DN	Merimepodib
DM0HS92	MI	TT6EO5L
DM0HS92	MN	Erbb2 tyrosine kinase receptor (HER2)
DM0HS92	MT	DTT
DM0HS92	MA	Inhibitor
DM0HS92	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DM0HS92	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DM0HS92	DI	DM0HS92
DM0HS92	DN	Merimepodib
DM0HS92	MI	TTL7C8Q
DM0HS92	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DM0HS92	MT	DTT
DM0HS92	MA	Inhibitor
DM0HS92	RN	VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent. J Pharm Sci. 2001 May;90(5):625-37.
DM0HS92	RU	https://pubmed.ncbi.nlm.nih.gov/11288107

DM62UHC	DI	DM62UHC
DM62UHC	DN	Meropenem
DM62UHC	MI	TTJP4SM
DM62UHC	MN	Bacterial Penicillin binding protein (Bact PBP)
DM62UHC	MT	DTT
DM62UHC	MA	Modulator
DM62UHC	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM62UHC	RU	https://www.fda.gov/

DM62UHC	DI	DM62UHC
DM62UHC	DN	Meropenem
DM62UHC	MI	DEC3G7M
DM62UHC	MN	Beta-lactamase (blaB)
DM62UHC	MT	DME
DM62UHC	MA	Metabolism
DM62UHC	RN	FRI-4 carbapenemase-producing Enterobacter cloacae complex isolated in Tokyo, Japan. J Antimicrob Chemother. 2018 Nov 1;73(11):2969-2972.
DM62UHC	RU	https://pubmed.ncbi.nlm.nih.gov/30060114

DM62UHC	DI	DM62UHC
DM62UHC	DN	Meropenem
DM62UHC	MI	DENJ2SQ
DM62UHC	MN	Beta-lactamase (blaB)
DM62UHC	MT	DME
DM62UHC	MA	Metabolism
DM62UHC	RN	Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019 Sep;25(9):1156.e9-1156.e13.
DM62UHC	RU	https://pubmed.ncbi.nlm.nih.gov/30802650

DM62UHC	DI	DM62UHC
DM62UHC	DN	Meropenem
DM62UHC	MI	DEBKS91
DM62UHC	MN	Beta-lactamase (blaB)
DM62UHC	MT	DME
DM62UHC	MA	Metabolism
DM62UHC	RN	A high mortality rate associated with multidrug-resistant Acinetobacter baumannii ST79 and ST25 carrying OXA-23 in a Brazilian intensive care unit. PLoS One. 2018 Dec 28;13(12):e0209367.
DM62UHC	RU	https://pubmed.ncbi.nlm.nih.gov/30592758

DM62UHC	DI	DM62UHC
DM62UHC	DN	Meropenem
DM62UHC	MI	DECWSA9
DM62UHC	MN	Beta-lactamase (blaB)
DM62UHC	MT	DME
DM62UHC	MA	Metabolism
DM62UHC	RN	Molecular investigation of extended-spectrum beta-lactamase genes and potential drug resistance in clinical isolates of Morganella morganii. Ann Saudi Med. 2016 May-Jun;36(3):223-8.
DM62UHC	RU	https://pubmed.ncbi.nlm.nih.gov/27236395

DM62UHC	DI	DM62UHC
DM62UHC	DN	Meropenem
DM62UHC	MI	DEB90AL
DM62UHC	MN	Carbapenemase (cphA)
DM62UHC	MT	DME
DM62UHC	MA	Metabolism
DM62UHC	RN	A carbapenem-resistant clinical isolate of Aeromonas hydrophila in Japan harbouring an acquired gene encoding GES-24 beta-lactamase. J Med Microbiol. 2018 Nov;67(11):1535-1537.
DM62UHC	RU	https://pubmed.ncbi.nlm.nih.gov/30289383

DM62UHC	DI	DM62UHC
DM62UHC	DN	Meropenem
DM62UHC	MI	DEBGCYQ
DM62UHC	MN	New delhi metallo-beta-lactamase NDM-1 (blaNDM)
DM62UHC	MT	DME
DM62UHC	MA	Metabolism
DM62UHC	RN	Genomic characterization of an extensively-drug resistance Salmonella enterica serotype Indiana strain harboring bla NDM-1 gene isolated from a chicken carcass in China. Microbiol Res. 2017 Nov;204:48-54.
DM62UHC	RU	https://pubmed.ncbi.nlm.nih.gov/28870291

DM62UHC	DI	DM62UHC
DM62UHC	DN	Meropenem
DM62UHC	MI	DTQ23VB
DM62UHC	MN	Organic anion transporter 1 (SLC22A6)
DM62UHC	MT	DTP
DM62UHC	MA	Substrate
DM62UHC	RN	Characterization of CS-023 (RO4908463), a novel parenteral carbapenem antibiotic, and meropenem as substrates of human renal transporters. Drug Metab Pharmacokinet. 2007 Feb 25;22(1):41-7.
DM62UHC	RU	http://www.ncbi.nlm.nih.gov/pubmed/17329910

DMOVAIX	DI	DMOVAIX
DMOVAIX	DN	Meropenem + vaborbactam
DMOVAIX	MI	TTHI19T
DMOVAIX	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMOVAIX	MT	DTT
DMOVAIX	MA	Inhibitor
DMOVAIX	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DMOVAIX	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DMOL5IU	DI	DMOL5IU
DMOL5IU	DN	Mesalazine
DMOL5IU	MI	DTFI42L
DMOL5IU	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMOL5IU	MT	DTP
DMOL5IU	MA	Substrate
DMOL5IU	RN	Transport studies with 5-aminosalicylate. Eur J Clin Pharmacol. 2006 Oct;62(10):871-5.
DMOL5IU	RU	http://www.ncbi.nlm.nih.gov/pubmed/16944117

DMOL5IU	DI	DMOL5IU
DMOL5IU	DN	Mesalazine
DMOL5IU	MI	DT3D8F0
DMOL5IU	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMOL5IU	MT	DTP
DMOL5IU	MA	Substrate
DMOL5IU	RN	Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake. Drug Metab Dispos. 2011 Jun;39(6):1097-102.
DMOL5IU	RU	http://www.ncbi.nlm.nih.gov/pubmed/21430235

DMOL5IU	DI	DMOL5IU
DMOL5IU	DN	Mesalazine
DMOL5IU	MI	DT9C1TS
DMOL5IU	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMOL5IU	MT	DTP
DMOL5IU	MA	Substrate
DMOL5IU	RN	Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake. Drug Metab Dispos. 2011 Jun;39(6):1097-102.
DMOL5IU	RU	http://www.ncbi.nlm.nih.gov/pubmed/21430235

DMOL5IU	DI	DMOL5IU
DMOL5IU	DN	Mesalazine
DMOL5IU	MI	DTPFTEQ
DMOL5IU	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DMOL5IU	MT	DTP
DMOL5IU	MA	Substrate
DMOL5IU	RN	Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake. Drug Metab Dispos. 2011 Jun;39(6):1097-102.
DMOL5IU	RU	http://www.ncbi.nlm.nih.gov/pubmed/21430235

DMOL5IU	DI	DMOL5IU
DMOL5IU	DN	Mesalazine
DMOL5IU	MI	TT8NGED
DMOL5IU	MN	Prostaglandin G/H synthase 1 (COX-1)
DMOL5IU	MT	DTT
DMOL5IU	MA	Inhibitor
DMOL5IU	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMOL5IU	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMOL5IU	DI	DMOL5IU
DMOL5IU	DN	Mesalazine
DMOL5IU	MI	DEZV4AP
DMOL5IU	MN	RNA cytidine acetyltransferase (hALP)
DMOL5IU	MT	DME
DMOL5IU	MA	Metabolism
DMOL5IU	RN	NAT1 genotypes do not predict response to mesalamine in patients with ulcerative colitis. Z Gastroenterol. 2008 Mar;46(3):259-65.
DMOL5IU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18322880

DM2ZGAN	DI	DM2ZGAN
DM2ZGAN	DN	Mesoridazine
DM2ZGAN	MI	DECB0K3
DM2ZGAN	MN	Cytochrome P450 2D6 (CYP2D6)
DM2ZGAN	MT	DME
DM2ZGAN	MA	Metabolism
DM2ZGAN	RN	Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Eur J Clin Pharmacol. 2003 May;59(1):45-50.
DM2ZGAN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12682803

DM2ZGAN	DI	DM2ZGAN
DM2ZGAN	DN	Mesoridazine
DM2ZGAN	MI	TTEX248
DM2ZGAN	MN	Dopamine D2 receptor (D2R)
DM2ZGAN	MT	DTT
DM2ZGAN	MA	Agonist
DM2ZGAN	RN	Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as... J Pharmacol Exp Ther. 2005 Dec;315(3):1278-87.
DM2ZGAN	RU	https://pubmed.ncbi.nlm.nih.gov/16135699

DMG3F94	DI	DMG3F94
DMG3F94	DN	Mestranol
DMG3F94	MI	DES5XRU
DMG3F94	MN	Cytochrome P450 2C8 (CYP2C8)
DMG3F94	MT	DME
DMG3F94	MA	Metabolism
DMG3F94	RN	Loss of orally administered drugs in GI tract. Saudi Pharm J. 2012 Oct;20(4):331-44.
DMG3F94	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23960808

DMG3F94	DI	DMG3F94
DMG3F94	DN	Mestranol
DMG3F94	MI	DE5IED8
DMG3F94	MN	Cytochrome P450 2C9 (CYP2C9)
DMG3F94	MT	DME
DMG3F94	MA	Metabolism
DMG3F94	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMG3F94	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMG3F94	DI	DMG3F94
DMG3F94	DN	Mestranol
DMG3F94	MI	DE4LYSA
DMG3F94	MN	Cytochrome P450 3A4 (CYP3A4)
DMG3F94	MT	DME
DMG3F94	MA	Metabolism
DMG3F94	RN	Prescribrt's digital referenve - Ethinyl estradiol/norethindrone; mestranol/norethindrone - Drug Summary
DMG3F94	RU	http://www.pdr.net/drug-summary/Necon-ethinyl-estradiol-norethindrone----mestranol-norethindrone-2049

DMG3F94	DI	DMG3F94
DMG3F94	DN	Mestranol
DMG3F94	MI	TTZAYWL
DMG3F94	MN	Estrogen receptor (ESR)
DMG3F94	MT	DTT
DMG3F94	MA	Agonist
DMG3F94	RN	Short-term effects of environmentally relevant concentrations of EDC mixtures on Mytilus galloprovincialis digestive gland. Aquat Toxicol. 2008 May 30;87(4):272-9.
DMG3F94	RU	https://pubmed.ncbi.nlm.nih.gov/18374427

DMM4QOJ	DI	DMM4QOJ
DMM4QOJ	DN	Metadoxine
DMM4QOJ	MI	TTPRKM0
DMM4QOJ	MN	GABA transporter GAT-1 (SLC6A1)
DMM4QOJ	MT	DTT
DMM4QOJ	MA	Modulator
DMM4QOJ	RN	Company report (Alcobra pharma)
DMM4QOJ	RU	http://www.alcobra-pharma.com/products.cfm?productID=163127

DMTQS9A	DI	DMTQS9A
DMTQS9A	DN	Metaproterenol sulfate
DMTQS9A	MI	TT2CJVK
DMTQS9A	MN	Adrenergic receptor beta-2 (ADRB2)
DMTQS9A	MT	DTT
DMTQS9A	MA	Modulator
DMTQS9A	RN	Male--female differences in the impact of beta-adrenoceptor stimulation on resistance to experimental metastasis: exploring the effects of age and ... J Neuroimmunol. 2008 Jan;193(1-2):113-9.
DMTQS9A	RU	https://pubmed.ncbi.nlm.nih.gov/18037507

DMWIX23	DI	DMWIX23
DMWIX23	DN	Metaraminol
DMWIX23	MI	TTEX248
DMWIX23	MN	Dopamine D2 receptor (D2R)
DMWIX23	MT	DTT
DMWIX23	MA	Agonist
DMWIX23	RN	Alpha1-adrenoceptor stimulation enhances experimental gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats. Int J Cancer. 1998 Jul 29;77(3):467-9.
DMWIX23	RU	https://pubmed.ncbi.nlm.nih.gov/9663612

DMJFP6G	DI	DMJFP6G
DMJFP6G	DN	Metergolin
DMJFP6G	MI	TTK8CXU
DMJFP6G	MN	5-HT 1B receptor (HTR1B)
DMJFP6G	MT	DTT
DMJFP6G	MA	Antagonist
DMJFP6G	RN	Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors. J Neurochem. 1996 Nov;67(5):2096-103.
DMJFP6G	RU	https://pubmed.ncbi.nlm.nih.gov/8863519

DMJFP6G	DI	DMJFP6G
DMJFP6G	DN	Metergolin
DMJFP6G	MI	TT6MSOK
DMJFP6G	MN	5-HT 1D receptor (HTR1D)
DMJFP6G	MT	DTT
DMJFP6G	MA	Antagonist
DMJFP6G	RN	Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143-8.
DMJFP6G	RU	https://pubmed.ncbi.nlm.nih.gov/1652050

DMJFP6G	DI	DMJFP6G
DMJFP6G	DN	Metergolin
DMJFP6G	MI	TTCPG9S
DMJFP6G	MN	5-HT 1E receptor (HTR1E)
DMJFP6G	MT	DTT
DMJFP6G	MA	Antagonist
DMJFP6G	RN	Molecular cloning and pharmacological characterization of the guinea pig 5-HT1E receptor. Eur J Pharmacol. 2004 Jan 26;484(2-3):127-39.
DMJFP6G	RU	https://pubmed.ncbi.nlm.nih.gov/14744596

DMJFP6G	DI	DMJFP6G
DMJFP6G	DN	Metergolin
DMJFP6G	MI	TT0MI3F
DMJFP6G	MN	5-HT 1F receptor (HTR1F)
DMJFP6G	MT	DTT
DMJFP6G	MA	Antagonist
DMJFP6G	RN	Cloning and characterization of the guinea pig 5-HT1F receptor subtype: a comparison of the pharmacological profile to the human species homolog. Neuropharmacology. 1997 Apr-May;36(4-5):569-76.
DMJFP6G	RU	https://pubmed.ncbi.nlm.nih.gov/9225282

DMJFP6G	DI	DMJFP6G
DMJFP6G	DN	Metergolin
DMJFP6G	MI	TTJQOD7
DMJFP6G	MN	5-HT 2A receptor (HTR2A)
DMJFP6G	MT	DTT
DMJFP6G	MA	Antagonist
DMJFP6G	RN	Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
DMJFP6G	RU	https://pubmed.ncbi.nlm.nih.gov/15322733

DMJFP6G	DI	DMJFP6G
DMJFP6G	DN	Metergolin
DMJFP6G	MI	TT0K1SC
DMJFP6G	MN	5-HT 2B receptor (HTR2B)
DMJFP6G	MT	DTT
DMJFP6G	MA	Antagonist
DMJFP6G	RN	Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
DMJFP6G	RU	https://pubmed.ncbi.nlm.nih.gov/15322733

DMJFP6G	DI	DMJFP6G
DMJFP6G	DN	Metergolin
DMJFP6G	MI	TTWJBZ5
DMJFP6G	MN	5-HT 2C receptor (HTR2C)
DMJFP6G	MT	DTT
DMJFP6G	MA	Antagonist
DMJFP6G	RN	Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
DMJFP6G	RU	https://pubmed.ncbi.nlm.nih.gov/15322733

DMJFP6G	DI	DMJFP6G
DMJFP6G	DN	Metergolin
DMJFP6G	MI	TTRUFDT
DMJFP6G	MN	5-HT 5A receptor (HTR5A)
DMJFP6G	MT	DTT
DMJFP6G	MA	Antagonist
DMJFP6G	RN	Cloning and characterisation of the human 5-HT5A serotonin receptor. FEBS Lett. 1994 Dec 5;355(3):242-6.
DMJFP6G	RU	https://pubmed.ncbi.nlm.nih.gov/7988681

DMJFP6G	DI	DMJFP6G
DMJFP6G	DN	Metergolin
DMJFP6G	MI	TT85JO3
DMJFP6G	MN	5-HT receptor (5HTR)
DMJFP6G	MT	DTT
DMJFP6G	MA	Modulator
DMJFP6G	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMJFP6G	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DM89QE1	DI	DM89QE1
DM89QE1	DN	Metformin
DM89QE1	MI	TTY84UG
DM89QE1	MN	Acetyl-CoA carboxylase 2 (ACACB)
DM89QE1	MT	DTT
DM89QE1	MA	Activator
DM89QE1	RN	AMP-activated protein kinase-dependent and -independent mechanisms underlying in vitro antiglioma action of compound C. Biochem Pharmacol. 2009 Jun 1;77(11):1684-93.
DM89QE1	RU	https://pubmed.ncbi.nlm.nih.gov/19428322

DM89QE1	DI	DM89QE1
DM89QE1	DN	Metformin
DM89QE1	MI	DTI7UX6
DM89QE1	MN	Breast cancer resistance protein (ABCG2)
DM89QE1	MT	DTP
DM89QE1	MA	Substrate
DM89QE1	RN	Role of human placental apical membrane transporters in the efflux of glyburide, rosiglitazone, and metformin. Am J Obstet Gynecol. 2010 Apr;202(4):383.e1-7.
DM89QE1	RU	http://www.ncbi.nlm.nih.gov/pubmed/20350646

DM89QE1	DI	DM89QE1
DM89QE1	DN	Metformin
DM89QE1	MI	DT3EAQP
DM89QE1	MN	Equilibrative nucleoside transporter 4 (SLC29A4)
DM89QE1	MT	DTP
DM89QE1	MA	Substrate
DM89QE1	RN	Metformin: from mechanisms of action to therapies. Cell Metab. 2014 Dec 2;20(6):953-66.
DM89QE1	RU	http://www.ncbi.nlm.nih.gov/pubmed/25456737

DM89QE1	DI	DM89QE1
DM89QE1	DN	Metformin
DM89QE1	MI	DTZGT0P
DM89QE1	MN	Multidrug and toxin extrusion protein 1 (SLC47A1)
DM89QE1	MT	DTP
DM89QE1	MA	Substrate
DM89QE1	RN	Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol. 2010 Apr;298(4):F997-F1005.
DM89QE1	RU	http://www.ncbi.nlm.nih.gov/pubmed/20053795

DM89QE1	DI	DM89QE1
DM89QE1	DN	Metformin
DM89QE1	MI	DT3TX4H
DM89QE1	MN	Multidrug and toxin extrusion protein 2 (SLC47A2)
DM89QE1	MT	DTP
DM89QE1	MA	Substrate
DM89QE1	RN	Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
DM89QE1	RU	http://www.ncbi.nlm.nih.gov/pubmed/17509534

DM89QE1	DI	DM89QE1
DM89QE1	DN	Metformin
DM89QE1	MI	DTT79CX
DM89QE1	MN	Organic cation transporter 1 (SLC22A1)
DM89QE1	MT	DTP
DM89QE1	MA	Substrate
DM89QE1	RN	Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet. 2005 Oct;20(5):379-86.
DM89QE1	RU	http://www.ncbi.nlm.nih.gov/pubmed/16272756

DM89QE1	DI	DM89QE1
DM89QE1	DN	Metformin
DM89QE1	MI	DT9IDPW
DM89QE1	MN	Organic cation transporter 2 (SLC22A2)
DM89QE1	MT	DTP
DM89QE1	MA	Substrate
DM89QE1	RN	Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet. 2005 Oct;20(5):379-86.
DM89QE1	RU	http://www.ncbi.nlm.nih.gov/pubmed/16272756

DM89QE1	DI	DM89QE1
DM89QE1	DN	Metformin
DM89QE1	MI	DT6201N
DM89QE1	MN	Organic cation transporter 3 (SLC22A3)
DM89QE1	MT	DTP
DM89QE1	MA	Substrate
DM89QE1	RN	Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology. 2009 Oct;50(4):1227-40.
DM89QE1	RU	http://www.ncbi.nlm.nih.gov/pubmed/19591196

DM89QE1	DI	DM89QE1
DM89QE1	DN	Metformin
DM89QE1	MI	TTMHCGA
DM89QE1	MN	Solute carrier family 47 member 1 (SLC47A1)
DM89QE1	MT	DTT
DM89QE1	MA	Modulator
DM89QE1	RN	Molecular cloning, functional characterization and tissue distribution of rat H+/organic cation antiporter MATE1. Pharm Res. 2006 Aug;23(8):1696-701.
DM89QE1	RU	https://pubmed.ncbi.nlm.nih.gov/16850272

DM89QE1	DI	DM89QE1
DM89QE1	DN	Metformin
DM89QE1	MI	DTLA4Q2
DM89QE1	MN	Thiamine transporter 1 (SLC19A2)
DM89QE1	MT	DTP
DM89QE1	MA	Substrate
DM89QE1	RN	Metformin Is a Substrate and Inhibitor of the Human Thiamine Transporter, THTR-2 (SLC19A3). Mol Pharm. 2015 Dec 7;12(12):4301-10.
DM89QE1	RU	http://www.ncbi.nlm.nih.gov/pubmed/26528626

DM89QE1	DI	DM89QE1
DM89QE1	DN	Metformin
DM89QE1	MI	DT39CEA
DM89QE1	MN	Thiamine transporter 2 (SLC19A3)
DM89QE1	MT	DTP
DM89QE1	MA	Substrate
DM89QE1	RN	Metformin Is a Substrate and Inhibitor of the Human Thiamine Transporter, THTR-2 (SLC19A3). Mol Pharm. 2015 Dec 7;12(12):4301-10.
DM89QE1	RU	http://www.ncbi.nlm.nih.gov/pubmed/26528626

DMTPAM3	DI	DMTPAM3
DMTPAM3	DN	Metformin arginine-hemisuccinimide
DMTPAM3	MI	TTCBFJO
DMTPAM3	MN	Insulin receptor (INSR)
DMTPAM3	MT	DTT
DMTPAM3	MA	Inhibitor
DMTPAM3	RN	Metformin (Glucophage) inhibits tyrosine phosphatase activity to stimulate the insulin receptor tyrosine kinase. Biochem Pharmacol. 2004 Jun 1;67(11):2081-91.
DMTPAM3	RU	https://pubmed.ncbi.nlm.nih.gov/15135305

DMGS4QH	DI	DMGS4QH
DMGS4QH	DN	Methacholine Chloride
DMGS4QH	MI	TTYEG6Q
DMGS4QH	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMGS4QH	MT	DTT
DMGS4QH	MA	Inhibitor
DMGS4QH	RN	6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors. J Med Chem. 1998 Jun 4;41(12):2047-55.
DMGS4QH	RU	https://pubmed.ncbi.nlm.nih.gov/9622546

DMGS4QH	DI	DMGS4QH
DMGS4QH	DN	Methacholine Chloride
DMGS4QH	MI	TTQ13Z5
DMGS4QH	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMGS4QH	MT	DTT
DMGS4QH	MA	Modulator
DMGS4QH	RN	Muscarinic M3-receptors mediate cholinergic synergism of mitogenesis in airway smooth muscle. Am J Respir Cell Mol Biol. 2003 Feb;28(2):257-62.
DMGS4QH	RU	https://pubmed.ncbi.nlm.nih.gov/12540494

DMGS4QH	DI	DMGS4QH
DMGS4QH	DN	Methacholine Chloride
DMGS4QH	MI	TTQ3JTF
DMGS4QH	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DMGS4QH	MT	DTT
DMGS4QH	MA	Inhibitor
DMGS4QH	RN	6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors. J Med Chem. 1998 Jun 4;41(12):2047-55.
DMGS4QH	RU	https://pubmed.ncbi.nlm.nih.gov/9622546

DMAY96V	DI	DMAY96V
DMAY96V	DN	Methacycline
DMAY96V	MI	TTQ8KVI
DMAY96V	MN	Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)
DMAY96V	MT	DTT
DMAY96V	MA	Binder
DMAY96V	RN	Tetracyclines and pulmonary inflammation. Endocr Metab Immune Disord Drug Targets. 2007 Dec;7(4):232-6.
DMAY96V	RU	https://pubmed.ncbi.nlm.nih.gov/18220943

DMTW6IU	DI	DMTW6IU
DMTW6IU	DN	Methadone
DMTW6IU	MI	DEQX145
DMTW6IU	MN	Aromatase (CYP19A1)
DMTW6IU	MT	DME
DMTW6IU	MA	Metabolism
DMTW6IU	RN	Bidirectional transfer of methadone across human placenta. Biochem Pharmacol. 2005 Jan 1;69(1):187-97.
DMTW6IU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15588727

DMTW6IU	DI	DMTW6IU
DMTW6IU	DN	Methadone
DMTW6IU	MI	DEJGDUW
DMTW6IU	MN	Cytochrome P450 1A2 (CYP1A2)
DMTW6IU	MT	DME
DMTW6IU	MA	Metabolism
DMTW6IU	RN	Methadone--metabolism, pharmacokinetics and interactions. Pharmacol Res. 2004 Dec;50(6):551-9.
DMTW6IU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15501692

DMTW6IU	DI	DMTW6IU
DMTW6IU	DN	Methadone
DMTW6IU	MI	DEPKLMQ
DMTW6IU	MN	Cytochrome P450 2B6 (CYP2B6)
DMTW6IU	MT	DME
DMTW6IU	MA	Metabolism
DMTW6IU	RN	Methadone metabolism and drug-drug interactions: in vitro and in vivo literature review. J Pharm Sci. 2018 Dec;107(12):2983-2991.
DMTW6IU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30205091

DMTW6IU	DI	DMTW6IU
DMTW6IU	DN	Methadone
DMTW6IU	MI	DEZMWRE
DMTW6IU	MN	Cytochrome P450 2C18 (CYP2C18)
DMTW6IU	MT	DME
DMTW6IU	MA	Metabolism
DMTW6IU	RN	Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol. 1996 Mar;9(2):365-73.
DMTW6IU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8839037

DMTW6IU	DI	DMTW6IU
DMTW6IU	DN	Methadone
DMTW6IU	MI	DES5XRU
DMTW6IU	MN	Cytochrome P450 2C8 (CYP2C8)
DMTW6IU	MT	DME
DMTW6IU	MA	Metabolism
DMTW6IU	RN	Methadone metabolism and drug-drug interactions: in vitro and in vivo literature review. J Pharm Sci. 2018 Dec;107(12):2983-2991.
DMTW6IU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30205091

DMTW6IU	DI	DMTW6IU
DMTW6IU	DN	Methadone
DMTW6IU	MI	DE5IED8
DMTW6IU	MN	Cytochrome P450 2C9 (CYP2C9)
DMTW6IU	MT	DME
DMTW6IU	MA	Metabolism
DMTW6IU	RN	Methadone metabolism and drug-drug interactions: in vitro and in vivo literature review. J Pharm Sci. 2018 Dec;107(12):2983-2991.
DMTW6IU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30205091

DMTW6IU	DI	DMTW6IU
DMTW6IU	DN	Methadone
DMTW6IU	MI	DECB0K3
DMTW6IU	MN	Cytochrome P450 2D6 (CYP2D6)
DMTW6IU	MT	DME
DMTW6IU	MA	Metabolism
DMTW6IU	RN	Methadone metabolism and drug-drug interactions: in vitro and in vivo literature review. J Pharm Sci. 2018 Dec;107(12):2983-2991.
DMTW6IU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30205091

DMTW6IU	DI	DMTW6IU
DMTW6IU	DN	Methadone
DMTW6IU	MI	DE4LYSA
DMTW6IU	MN	Cytochrome P450 3A4 (CYP3A4)
DMTW6IU	MT	DME
DMTW6IU	MA	Metabolism
DMTW6IU	RN	Methadone metabolism and drug-drug interactions: in vitro and in vivo literature review. J Pharm Sci. 2018 Dec;107(12):2983-2991.
DMTW6IU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30205091

DMTW6IU	DI	DMTW6IU
DMTW6IU	DN	Methadone
DMTW6IU	MI	DERD86B
DMTW6IU	MN	Cytochrome P450 3A7 (CYP3A7)
DMTW6IU	MT	DME
DMTW6IU	MA	Metabolism
DMTW6IU	RN	Methadone metabolism and drug-drug interactions: in vitro and in vivo literature review. J Pharm Sci. 2018 Dec;107(12):2983-2991.
DMTW6IU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30205091

DMTW6IU	DI	DMTW6IU
DMTW6IU	DN	Methadone
DMTW6IU	MI	DEGTFWK
DMTW6IU	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMTW6IU	MT	DME
DMTW6IU	MA	Metabolism
DMTW6IU	RN	Methadone metabolism and drug-drug interactions: in vitro and in vivo literature review. J Pharm Sci. 2018 Dec;107(12):2983-2991.
DMTW6IU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30205091

DMTW6IU	DI	DMTW6IU
DMTW6IU	DN	Methadone
DMTW6IU	MI	TTN4QDT
DMTW6IU	MN	Opioid receptor (OPR)
DMTW6IU	MT	DTT
DMTW6IU	MA	Agonist
DMTW6IU	RN	Methadone treatment and its dangers. Medicina (Kaunas). 2009;45(5):419-25.
DMTW6IU	RU	https://pubmed.ncbi.nlm.nih.gov/19535889

DMTW6IU	DI	DMTW6IU
DMTW6IU	DN	Methadone
DMTW6IU	MI	DTUGYRD
DMTW6IU	MN	P-glycoprotein 1 (ABCB1)
DMTW6IU	MT	DTP
DMTW6IU	MA	Substrate
DMTW6IU	RN	In vitro P-glycoprotein-mediated transport of (R)-, (S)-, (R,S)-methadone, LAAM and their main metabolites. Pharmacology. 2007;80(4):304-11.
DMTW6IU	RU	http://www.ncbi.nlm.nih.gov/pubmed/17690563

DMIRMVB	DI	DMIRMVB
DMIRMVB	DN	Methadyl Acetate
DMIRMVB	MI	TTKWM86
DMIRMVB	MN	Opioid receptor mu (MOP)
DMIRMVB	MT	DTT
DMIRMVB	MA	Agonist
DMIRMVB	RN	Acetylmethadol metabolites influence opiate receptors and adenylate cyclase in amygdala. Eur J Pharmacol. 1981 Jul 10;72(4):343-9.
DMIRMVB	RU	https://pubmed.ncbi.nlm.nih.gov/6268422

DMPM4SK	DI	DMPM4SK
DMPM4SK	DN	Methamphetamine
DMPM4SK	MI	TTBRKXS
DMPM4SK	MN	Adrenergic receptor alpha-1B (ADRA1B)
DMPM4SK	MT	DTT
DMPM4SK	MA	Antagonist
DMPM4SK	RN	Mirtazapine treatment after conditioning with methamphetamine alters subsequent expression of place preference. Drug Alcohol Depend. 2009 Jan 1;99(1-3):231-9.
DMPM4SK	RU	https://pubmed.ncbi.nlm.nih.gov/18945553

DMPM4SK	DI	DMPM4SK
DMPM4SK	DN	Methamphetamine
DMPM4SK	MI	DECB0K3
DMPM4SK	MN	Cytochrome P450 2D6 (CYP2D6)
DMPM4SK	MT	DME
DMPM4SK	MA	Metabolism
DMPM4SK	RN	Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. Pharmacogenetics. 2001 Aug;11(6):477-87.
DMPM4SK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11505218

DMPM4SK	DI	DMPM4SK
DMPM4SK	DN	Methamphetamine
DMPM4SK	MI	TTEX248
DMPM4SK	MN	Dopamine D2 receptor (D2R)
DMPM4SK	MT	DTT
DMPM4SK	MA	Agonist
DMPM4SK	RN	Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418.
DMPM4SK	RU	https://pubmed.ncbi.nlm.nih.gov/15977970

DMPM4SK	DI	DMPM4SK
DMPM4SK	DN	Methamphetamine
DMPM4SK	MI	DTT7VPB
DMPM4SK	MN	Vesicular amine transporter 2 (SLC18A2)
DMPM4SK	MT	DTP
DMPM4SK	MA	Substrate
DMPM4SK	RN	Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter. J Med Chem. 2018 Oct 25;61(20):9121-9131.
DMPM4SK	RU	http://www.ncbi.nlm.nih.gov/pubmed/30240563

DMO2JBC	DI	DMO2JBC
DMO2JBC	DN	Methamphetamine hydrochloride
DMO2JBC	MI	DECB0K3
DMO2JBC	MN	Cytochrome P450 2D6 (CYP2D6)
DMO2JBC	MT	DME
DMO2JBC	MA	Metabolism
DMO2JBC	RN	Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. Pharmacogenetics. 2001 Aug;11(6):477-87.
DMO2JBC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11505218

DM8X4A1	DI	DM8X4A1
DM8X4A1	DN	Methantheline
DM8X4A1	MI	TTH18TF
DM8X4A1	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DM8X4A1	MT	DTT
DM8X4A1	MA	Antagonist
DM8X4A1	RN	Anticholinergics for urinary symptoms in multiple sclerosis. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD004193.
DM8X4A1	RU	https://pubmed.ncbi.nlm.nih.gov/19160231

DM5A38V	DI	DM5A38V
DM5A38V	DN	Metharbital
DM5A38V	MI	TTEX6LM
DM5A38V	MN	GABA(A) receptor gamma-3 (GABRG3)
DM5A38V	MT	DTT
DM5A38V	MA	Modulator
DM5A38V	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM5A38V	RU	https://www.fda.gov/

DM7J2TA	DI	DM7J2TA
DM7J2TA	DN	Methazolamide
DM7J2TA	MI	TTHQPL7
DM7J2TA	MN	Carbonic anhydrase I (CA-I)
DM7J2TA	MT	DTT
DM7J2TA	MA	Modulator
DM7J2TA	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2597).
DM7J2TA	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2597

DMAUHQX	DI	DMAUHQX
DMAUHQX	DN	Methdilazine
DMAUHQX	MI	TTTIBOJ
DMAUHQX	MN	Histamine H1 receptor (H1R)
DMAUHQX	MT	DTT
DMAUHQX	MA	Antagonist
DMAUHQX	RN	Effect of H1 blockers alone and in combination with morphine to produce antinociception in mice. Neuropharmacology. 1985 Jan;24(1):1-4.
DMAUHQX	RU	https://pubmed.ncbi.nlm.nih.gov/2858829

DM3Z217	DI	DM3Z217
DM3Z217	DN	Methimazole
DM3Z217	MI	DEIASEZ
DM3Z217	MN	Dimethylaniline oxidase 2 (FMO2)
DM3Z217	MT	DME
DM3Z217	MA	Metabolism
DM3Z217	RN	Drug metabolism by flavin-containing monooxygenases of human and mouse. Expert Opin Drug Metab Toxicol. 2017 Feb;13(2):167-181.
DM3Z217	RU	https://pubmed.ncbi.nlm.nih.gov/27678284

DM25FL8	DI	DM25FL8
DM25FL8	DN	Methimazole
DM25FL8	MI	TT52XDZ
DM25FL8	MN	Thyroid peroxidase (TPO)
DM25FL8	MT	DTT
DM25FL8	MA	Inhibitor
DM25FL8	RN	Diagnosis and treatment of thyrotoxicosis in childhood. A European questionnaire study. Eur J Endocrinol. 1994 Nov;131(5):467-73.
DM25FL8	RU	https://pubmed.ncbi.nlm.nih.gov/7952157

DM7YMIT	DI	DM7YMIT
DM7YMIT	DN	Methohexital
DM7YMIT	MI	TT1MPAY
DM7YMIT	MN	GABA(A) receptor alpha-1 (GABRA1)
DM7YMIT	MT	DTT
DM7YMIT	MA	Antagonist
DM7YMIT	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DM7YMIT	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DTI7UX6
DM2TEOL	MN	Breast cancer resistance protein (ABCG2)
DM2TEOL	MT	DTP
DM2TEOL	MA	Substrate
DM2TEOL	RN	Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
DM2TEOL	RU	http://www.ncbi.nlm.nih.gov/pubmed/14500392

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DE4EGMZ
DM2TEOL	MN	Dihydrofolate reductase (DHFR)
DM2TEOL	MT	DME
DM2TEOL	MA	Metabolism
DM2TEOL	RN	The pharmacogenetics of methotrexate. Rheumatology (Oxford). 2007 Oct;46(10):1520-4.
DM2TEOL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17586865

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DTOSN46
DM2TEOL	MN	Folate transporter 1 (SLC19A1)
DM2TEOL	MT	DTP
DM2TEOL	MA	Substrate
DM2TEOL	RN	Biology of the major facilitative folate transporters SLC19A1 and SLC46A1. Curr Top Membr. 2014;73:175-204.
DM2TEOL	RU	http://www.ncbi.nlm.nih.gov/pubmed/24745983

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DECWT2V
DM2TEOL	MN	Folylpolyglutamate synthase (FPGS)
DM2TEOL	MT	DME
DM2TEOL	MA	Metabolism
DM2TEOL	RN	The pharmacogenetics of methotrexate. Rheumatology (Oxford). 2007 Oct;46(10):1520-4.
DM2TEOL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17586865

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DEU7MWJ
DM2TEOL	MN	Gamma-Glu-X carboxypeptidase (GGH)
DM2TEOL	MT	DME
DM2TEOL	MA	Metabolism
DM2TEOL	RN	The pharmacogenetics of methotrexate. Rheumatology (Oxford). 2007 Oct;46(10):1520-4.
DM2TEOL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17586865

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DEN8V7Z
DM2TEOL	MN	Glutamate carboxypeptidase II (FOLH1)
DM2TEOL	MT	DME
DM2TEOL	MA	Metabolism
DM2TEOL	RN	Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006 Jun;11(6):694-703.
DM2TEOL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16794248

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DEOXTPZ
DM2TEOL	MN	Methylenetetrahydrofolate reductase (MTHFR)
DM2TEOL	MT	DME
DM2TEOL	MA	Metabolism
DM2TEOL	RN	The pharmacogenetics of methotrexate. Rheumatology (Oxford). 2007 Oct;46(10):1520-4.
DM2TEOL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17586865

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DTSYQGK
DM2TEOL	MN	Multidrug resistance-associated protein 1 (ABCC1)
DM2TEOL	MT	DTP
DM2TEOL	MA	Substrate
DM2TEOL	RN	Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.
DM2TEOL	RU	http://www.ncbi.nlm.nih.gov/pubmed/11585759

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DTFI42L
DM2TEOL	MN	Multidrug resistance-associated protein 2 (ABCC2)
DM2TEOL	MT	DTP
DM2TEOL	MA	Substrate
DM2TEOL	RN	Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
DM2TEOL	RU	http://www.ncbi.nlm.nih.gov/pubmed/21841039

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DTQ3ZHF
DM2TEOL	MN	Multidrug resistance-associated protein 3 (ABCC3)
DM2TEOL	MT	DTP
DM2TEOL	MA	Substrate
DM2TEOL	RN	Multidrug resistance protein (MRP) 1 and MRP3 attenuate cytotoxic and transactivating effects of the cyclopentenone prostaglandin, 15-deoxy-Delta(12,14)prostaglandin J2 in MCF7 breast cancer cells. Biochemistry. 2003 May 13;42(18):5429-37.
DM2TEOL	RU	http://www.ncbi.nlm.nih.gov/pubmed/12731885

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DTCSGPB
DM2TEOL	MN	Multidrug resistance-associated protein 4 (ABCC4)
DM2TEOL	MT	DTP
DM2TEOL	MA	Substrate
DM2TEOL	RN	Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther. 2007 Jan;320(1):229-35.
DM2TEOL	RU	http://www.ncbi.nlm.nih.gov/pubmed/17005917

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DTYVM24
DM2TEOL	MN	Multidrug resistance-associated protein 5 (ABCC5)
DM2TEOL	MT	DTP
DM2TEOL	MA	Substrate
DM2TEOL	RN	The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Res. 2005 May 15;65(10):4425-30.
DM2TEOL	RU	http://www.ncbi.nlm.nih.gov/pubmed/15899835

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DTWN7FC
DM2TEOL	MN	Multidrug resistance-associated protein 8 (ABCC11)
DM2TEOL	MT	DTP
DM2TEOL	MA	Substrate
DM2TEOL	RN	ABCC11/MRP8 confers pemetrexed resistance in lung cancer. Cancer Sci. 2010 Nov;101(11):2404-10.
DM2TEOL	RU	http://www.ncbi.nlm.nih.gov/pubmed/20718756

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DTQ23VB
DM2TEOL	MN	Organic anion transporter 1 (SLC22A6)
DM2TEOL	MT	DTP
DM2TEOL	MA	Substrate
DM2TEOL	RN	Transport of aminopterin by human organic anion transporters hOAT1 and hOAT3: Comparison with methotrexate. Drug Metab Pharmacokinet. 2010;25(2):163-9.
DM2TEOL	RU	http://www.ncbi.nlm.nih.gov/pubmed/20460822

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DT0OC1Q
DM2TEOL	MN	Organic anion transporter 2 (SLC22A7)
DM2TEOL	MT	DTP
DM2TEOL	MA	Substrate
DM2TEOL	RN	Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev Physiol Biochem Pharmacol. 2003;146:95-158.
DM2TEOL	RU	http://www.ncbi.nlm.nih.gov/pubmed/12605306

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DTVP67E
DM2TEOL	MN	Organic anion transporter 3 (SLC22A8)
DM2TEOL	MT	DTP
DM2TEOL	MA	Substrate
DM2TEOL	RN	Methotrexate-loxoprofen interaction: involvement of human organic anion transporters hOAT1 and hOAT3. Drug Metab Pharmacokinet. 2004 Oct;19(5):369-74.
DM2TEOL	RU	http://www.ncbi.nlm.nih.gov/pubmed/15548848

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DT06JWZ
DM2TEOL	MN	Organic anion transporter 4 (SLC22A11)
DM2TEOL	MT	DTP
DM2TEOL	MA	Substrate
DM2TEOL	RN	Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71.
DM2TEOL	RU	http://www.ncbi.nlm.nih.gov/pubmed/12130730

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DTE2B1D
DM2TEOL	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DM2TEOL	MT	DTP
DM2TEOL	MA	Substrate
DM2TEOL	RN	Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther. 2006 Aug;318(2):521-9.
DM2TEOL	RU	http://www.ncbi.nlm.nih.gov/pubmed/16702441

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DT3D8F0
DM2TEOL	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM2TEOL	MT	DTP
DM2TEOL	MA	Substrate
DM2TEOL	RN	Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo. Mol Pharm. 2015 Dec 7;12(12):4259-69.
DM2TEOL	RU	http://www.ncbi.nlm.nih.gov/pubmed/26474710

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DT9C1TS
DM2TEOL	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM2TEOL	MT	DTP
DM2TEOL	MA	Substrate
DM2TEOL	RN	LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99.
DM2TEOL	RU	http://www.ncbi.nlm.nih.gov/pubmed/11375950

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DTUGYRD
DM2TEOL	MN	P-glycoprotein 1 (ABCB1)
DM2TEOL	MT	DTP
DM2TEOL	MA	Substrate
DM2TEOL	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM2TEOL	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	TTY8Z2E
DM2TEOL	MN	Proton-coupled folate transporter (SLC46A1)
DM2TEOL	MT	DTT
DM2TEOL	MA	Modulator
DM2TEOL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1213).
DM2TEOL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1213

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DTDJEMI
DM2TEOL	MN	Proton-coupled folate transporter (SLC46A1)
DM2TEOL	MT	DTP
DM2TEOL	MA	Substrate
DM2TEOL	RN	Site-specific contribution of proton-coupled folate transporter/haem carrier protein 1 in the intestinal absorption of methotrexate in rats. J Pharm Pharmacol. 2009 Jul;61(7):911-8.
DM2TEOL	RU	http://www.ncbi.nlm.nih.gov/pubmed/19589233

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	TT09I7D
DM2TEOL	MN	Solute carrier family 19 member 1 (SLC19A1)
DM2TEOL	MT	DTT
DM2TEOL	MA	Modulator
DM2TEOL	RN	Increased activity of a novel low pH folate transporter associated with lipophilic antifolate resistance in chinese hamster ovary cells. J Biol Chem. 1998 Apr 3;273(14):8106-11.
DM2TEOL	RU	https://pubmed.ncbi.nlm.nih.gov/9525913

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DEFQ8VO
DM2TEOL	MN	Thiopurine methyltransferase (TPMT)
DM2TEOL	MT	DME
DM2TEOL	MA	Metabolism
DM2TEOL	RN	Genetics of rheumatoid arthritis. Mayo Clin Proc. 2006 Jan;81(1):94-101.
DM2TEOL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16438485

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DEASG0Q
DM2TEOL	MN	Thymidylate synthase (TYMS)
DM2TEOL	MT	DME
DM2TEOL	MA	Metabolism
DM2TEOL	RN	The pharmacogenetics of methotrexate. Rheumatology (Oxford). 2007 Oct;46(10):1520-4.
DM2TEOL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17586865

DM5XH2C	DI	DM5XH2C
DM5XH2C	DN	Methotrexate Sodium
DM5XH2C	MI	TTYZVDJ
DM5XH2C	MN	Dihydrofolate reductase (DHFR)
DM5XH2C	MT	DTT
DM5XH2C	MA	Modulator
DM5XH2C	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM5XH2C	RU	https://www.fda.gov/

DMF5XQH	DI	DMF5XQH
DMF5XQH	DN	Methoxamine
DMF5XQH	MI	TTBRKXS
DMF5XQH	MN	Adrenergic receptor alpha-1B (ADRA1B)
DMF5XQH	MT	DTT
DMF5XQH	MA	Stimulator
DMF5XQH	RN	Activation of alpha1-adrenoceptors inhibits growth hormone secretion in humans. Exp Clin Endocrinol Diabetes. 2009 Oct;117(9):460-2.
DMF5XQH	RU	https://pubmed.ncbi.nlm.nih.gov/19373756

DME8FZ9	DI	DME8FZ9
DME8FZ9	DN	Methoxsalen
DME8FZ9	MI	TTAQ6ZW
DME8FZ9	MN	Cytochrome P450 2A6 (CYP2A6)
DME8FZ9	MT	DTT
DME8FZ9	MA	Binder
DME8FZ9	RN	Mutagenicity and carcinogenicity of methoxsalen plus UV-A. Arch Dermatol. 1984 May;120(5):662-9.
DME8FZ9	RU	https://pubmed.ncbi.nlm.nih.gov/6372701

DME8FZ9	DI	DME8FZ9
DME8FZ9	DN	Methoxsalen
DME8FZ9	MI	DEJVYAZ
DME8FZ9	MN	Cytochrome P450 2A6 (CYP2A6)
DME8FZ9	MT	DME
DME8FZ9	MA	Metabolism
DME8FZ9	RN	Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin. Br J Clin Pharmacol. 1999 Oct;48(4):528-35.
DME8FZ9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10583023

DME8FZ9	DI	DME8FZ9
DME8FZ9	DN	Methoxsalen
DME8FZ9	MI	DE4LYSA
DME8FZ9	MN	Cytochrome P450 3A4 (CYP3A4)
DME8FZ9	MT	DME
DME8FZ9	MA	Metabolism
DME8FZ9	RN	Photochemotherapeutic agent 8-methoxypsoralen induces cytochrome P450 3A4 and carboxylesterase HCE2: evidence on an involvement of the pregnane X receptor. Toxicol Sci. 2007 Jan;95(1):13-22.
DME8FZ9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17003103

DMK1LZD	DI	DMK1LZD
DMK1LZD	DN	Methoxy polyethylene glycol-epoetin beta
DMK1LZD	MI	TTAUX24
DMK1LZD	MN	Erythropoietin Receptor (EPOR)
DMK1LZD	MT	DTT
DMK1LZD	MA	Activator
DMK1LZD	RN	2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
DMK1LZD	RU	https://pubmed.ncbi.nlm.nih.gov/18246607

DML0RAE	DI	DML0RAE
DML0RAE	DN	Methoxyflurane
DML0RAE	MI	DEJGDUW
DML0RAE	MN	Cytochrome P450 1A2 (CYP1A2)
DML0RAE	MT	DME
DML0RAE	MA	Metabolism
DML0RAE	RN	Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology. 1993 Oct;79(4):795-807.
DML0RAE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8214760

DML0RAE	DI	DML0RAE
DML0RAE	DN	Methoxyflurane
DML0RAE	MI	DEJVYAZ
DML0RAE	MN	Cytochrome P450 2A6 (CYP2A6)
DML0RAE	MT	DME
DML0RAE	MA	Metabolism
DML0RAE	RN	Human kidney methoxyflurane and sevoflurane metabolism. Intrarenal fluoride production as a possible mechanism of methoxyflurane nephrotoxicity. Anesthesiology. 1995 Mar;82(3):689-99.
DML0RAE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7879937

DML0RAE	DI	DML0RAE
DML0RAE	DN	Methoxyflurane
DML0RAE	MI	DEPKLMQ
DML0RAE	MN	Cytochrome P450 2B6 (CYP2B6)
DML0RAE	MT	DME
DML0RAE	MA	Metabolism
DML0RAE	RN	Human kidney methoxyflurane and sevoflurane metabolism. Intrarenal fluoride production as a possible mechanism of methoxyflurane nephrotoxicity. Anesthesiology. 1995 Mar;82(3):689-99.
DML0RAE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7879937

DML0RAE	DI	DML0RAE
DML0RAE	DN	Methoxyflurane
DML0RAE	MI	DE5IED8
DML0RAE	MN	Cytochrome P450 2C9 (CYP2C9)
DML0RAE	MT	DME
DML0RAE	MA	Metabolism
DML0RAE	RN	Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology. 1993 Oct;79(4):795-807.
DML0RAE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8214760

DML0RAE	DI	DML0RAE
DML0RAE	DN	Methoxyflurane
DML0RAE	MI	DECB0K3
DML0RAE	MN	Cytochrome P450 2D6 (CYP2D6)
DML0RAE	MT	DME
DML0RAE	MA	Metabolism
DML0RAE	RN	Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology. 1993 Oct;79(4):795-807.
DML0RAE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8214760

DML0RAE	DI	DML0RAE
DML0RAE	DN	Methoxyflurane
DML0RAE	MI	DEVDYN7
DML0RAE	MN	Cytochrome P450 2E1 (CYP2E1)
DML0RAE	MT	DME
DML0RAE	MA	Metabolism
DML0RAE	RN	Construction and assessment of models of CYP2E1: predictions of metabolism from docking, molecular dynamics, and density functional theoretical calculations. J Med Chem. 2003 Apr 24;46(9):1645-60.
DML0RAE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12699383

DML0RAE	DI	DML0RAE
DML0RAE	DN	Methoxyflurane
DML0RAE	MI	DE4LYSA
DML0RAE	MN	Cytochrome P450 3A4 (CYP3A4)
DML0RAE	MT	DME
DML0RAE	MA	Metabolism
DML0RAE	RN	Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology. 1993 Oct;79(4):795-807.
DML0RAE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8214760

DML0RAE	DI	DML0RAE
DML0RAE	DN	Methoxyflurane
DML0RAE	MI	TT1MPAY
DML0RAE	MN	GABA(A) receptor alpha-1 (GABRA1)
DML0RAE	MT	DTT
DML0RAE	MA	Antagonist
DML0RAE	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DML0RAE	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DMHP8FI	DI	DMHP8FI
DMHP8FI	DN	Methscopolamine bromide
DMHP8FI	MI	TTQ13Z5
DMHP8FI	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMHP8FI	MT	DTT
DMHP8FI	MA	Modulator
DMHP8FI	RN	Agonist-regulated alteration of the affinity of pancreatic muscarinic cholinergic receptors. J Biol Chem. 1993 Oct 25;268(30):22436-43.
DMHP8FI	RU	https://www.ncbi.nlm.nih.gov/pubmed/7693670

DM6L5VO	DI	DM6L5VO
DM6L5VO	DN	Methsuximide
DM6L5VO	MI	DEGTFWK
DM6L5VO	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM6L5VO	MT	DME
DM6L5VO	MA	Metabolism
DM6L5VO	RN	The role of S-mephenytoin hydroxylase (CYP2C19) in the metabolism of the antimalarial biguanides. Br J Clin Pharmacol. 1995 Apr;39(4):441-4.
DM6L5VO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7640152

DM6L5VO	DI	DM6L5VO
DM6L5VO	DN	Methsuximide
DM6L5VO	MI	TT729IR
DM6L5VO	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DM6L5VO	MT	DTT
DM6L5VO	MA	Blocker
DM6L5VO	RN	Block of cloned human T-type calcium channels by succinimide antiepileptic drugs. Mol Pharmacol. 2001 Nov;60(5):1121-32.
DM6L5VO	RU	https://pubmed.ncbi.nlm.nih.gov/11641441

DMN7SDE	DI	DMN7SDE
DMN7SDE	DN	Methyclothiazide
DMN7SDE	MI	TTS087L
DMN7SDE	MN	Solute carrier family 12 member 1 (SLC12A1)
DMN7SDE	MT	DTT
DMN7SDE	MA	Blocker
DMN7SDE	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DMN7SDE	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DMIUX3D	DI	DMIUX3D
DMIUX3D	DN	Methyl aminolevulinate
DMIUX3D	MI	TTQ6VF4
DMIUX3D	MN	Ferrochelatase (FECH)
DMIUX3D	MT	DTT
DMIUX3D	MA	Activator
DMIUX3D	RN	Low-dose methotrexate enhances aminolevulinate-based photodynamic therapy in skin carcinoma cells in vitro and in vivo. Clin Cancer Res. 2009 May 15;15(10):3333-43.
DMIUX3D	RU	https://pubmed.ncbi.nlm.nih.gov/19447864

DM5I621	DI	DM5I621
DM5I621	DN	Methyldopa
DM5I621	MI	DEJGDUW
DM5I621	MN	Cytochrome P450 1A2 (CYP1A2)
DM5I621	MT	DME
DM5I621	MA	Metabolism
DM5I621	RN	Lack of interaction between amiodarone and mexiletine in cardiac arrhythmia patients. J Clin Pharmacol. 2002 Mar;42(3):342-6.
DM5I621	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11865972

DM5I621	DI	DM5I621
DM5I621	DN	Methyldopa
DM5I621	MI	DECB0K3
DM5I621	MN	Cytochrome P450 2D6 (CYP2D6)
DM5I621	MT	DME
DM5I621	MA	Metabolism
DM5I621	RN	Lack of interaction between amiodarone and mexiletine in cardiac arrhythmia patients. J Clin Pharmacol. 2002 Mar;42(3):342-6.
DM5I621	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11865972

DM5I621	DI	DM5I621
DM5I621	DN	Methyldopa
DM5I621	MI	TTEX248
DM5I621	MN	Dopamine D2 receptor (D2R)
DM5I621	MT	DTT
DM5I621	MA	Agonist
DM5I621	RN	Centrally acting antihypertensive agents: an update. J Clin Hypertens (Greenwich). 2007 May;9(5):399-405.
DM5I621	RU	https://pubmed.ncbi.nlm.nih.gov/17485976

DM5I621	DI	DM5I621
DM5I621	DN	Methyldopa
DM5I621	MI	DEYWLRK
DM5I621	MN	Sulfotransferase 1A1 (SULT1A1)
DM5I621	MT	DME
DM5I621	MA	Metabolism
DM5I621	RN	Platelet phenol sulfotransferase and erythrocyte catechol-O-methyltransferase activities: correlation with methyldopa metabolism. Clin Pharmacol Ther. 1984 Jan;35(1):55-63.
DM5I621	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=6580988

DM5I621	DI	DM5I621
DM5I621	DN	Methyldopa
DM5I621	MI	DEFQ8VO
DM5I621	MN	Thiopurine methyltransferase (TPMT)
DM5I621	MT	DME
DM5I621	MA	Metabolism
DM5I621	RN	Identification, characterization, and ontogenic study of a catechol O-methyltransferase from zebrafish. Aquat Toxicol. 2011 Mar;102(1-2):18-23.
DM5I621	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21371608

DM8XI09	DI	DM8XI09
DM8XI09	DN	Methyldopate Hydrochloride
DM8XI09	MI	TTQ8AFT
DM8XI09	MN	Adrenergic receptor Alpha-2 (ADRA2)
DM8XI09	MT	DTT
DM8XI09	MA	Modulator
DM8XI09	RN	Effect of Antihypertensive Therapy with Alpha Methyldopa on Levels of Angiogenic Factors in Pregnancies with Hypertensive Disorders
DM8XI09	RU	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2447877

DMJAPE7	DI	DMJAPE7
DMJAPE7	DN	Methylene blue
DMJAPE7	MI	TT6HPVC
DMJAPE7	MN	Guanylate cyclase (GC)
DMJAPE7	MT	DTT
DMJAPE7	MA	Inhibitor
DMJAPE7	RN	Curcumin ameliorates high glucose-induced acute vascular endothelial dysfunction in rat thoracic aorta. Clin Exp Pharmacol Physiol. 2009 Dec;36(12):1177-82.
DMJAPE7	RU	https://pubmed.ncbi.nlm.nih.gov/19473193

DMJAPE7	DI	DMJAPE7
DMJAPE7	DN	Methylene blue
DMJAPE7	MI	TT32XQJ
DMJAPE7	MN	Monoamine oxidase (MAO)
DMJAPE7	MT	DTT
DMJAPE7	RN	Photoluminescence of CdTe nanocrystals modulated by methylene blue and DNA. A label-free luminescent signaling nanohybrid platform. Phys Chem Chem Phys. 2009 Jul 7;11(25):5062-9.
DMJAPE7	RU	https://pubmed.ncbi.nlm.nih.gov/19562136

DMBEX4O	DI	DMBEX4O
DMBEX4O	DN	Methylergonovine
DMBEX4O	MI	DE4LYSA
DMBEX4O	MN	Cytochrome P450 3A4 (CYP3A4)
DMBEX4O	MT	DME
DMBEX4O	MA	Metabolism
DMBEX4O	RN	Modulation of cytochrome P450 metabolism by ergonovine and dihydroergotamine. Vet Hum Toxicol. 2003 Feb;45(1):6-9.
DMBEX4O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12583687

DMBEX4O	DI	DMBEX4O
DMBEX4O	DN	Methylergonovine
DMBEX4O	MI	TTZFYLI
DMBEX4O	MN	Dopamine D1 receptor (D1R)
DMBEX4O	MT	DTT
DMBEX4O	MA	Antagonist
DMBEX4O	RN	Reinforcement in an in vitro analog of appetitive classical conditioning of feeding behavior in Aplysia: blockade by a dopamine antagonist. Learn Mem. 2005 May-Jun;12(3):216-20.
DMBEX4O	RU	https://pubmed.ncbi.nlm.nih.gov/15930499

DMZTGN2	DI	DMZTGN2
DMZTGN2	DN	Methylnaltrexone bromide
DMZTGN2	MI	TTD0CIQ
DMZTGN2	MN	Melanocortin receptor 4 (MC4R)
DMZTGN2	MT	DTT
DMZTGN2	MA	Agonist
DMZTGN2	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DMZTGN2	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMZTGN2	DI	DMZTGN2
DMZTGN2	DN	Methylnaltrexone bromide
DMZTGN2	MI	TTKWM86
DMZTGN2	MN	Opioid receptor mu (MOP)
DMZTGN2	MT	DTT
DMZTGN2	MA	Modulator
DMZTGN2	RN	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
DMZTGN2	RU	https://pubmed.ncbi.nlm.nih.gov/19180096

DM7SJD6	DI	DM7SJD6
DM7SJD6	DN	Methylphenidate
DM7SJD6	MI	DEB30C5
DM7SJD6	MN	Carboxylesterase 1 (CES1)
DM7SJD6	MT	DME
DM7SJD6	MA	Metabolism
DM7SJD6	RN	Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1. J Pharmacol Exp Ther. 2004 Aug;310(2):469-76.
DM7SJD6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15082749

DM7SJD6	DI	DM7SJD6
DM7SJD6	DN	Methylphenidate
DM7SJD6	MI	TTVBI8W
DM7SJD6	MN	Dopamine transporter (DAT)
DM7SJD6	MT	DTT
DM7SJD6	MA	Blocker
DM7SJD6	RN	Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005 Jun 1;57(11):1410-5.
DM7SJD6	RU	https://pubmed.ncbi.nlm.nih.gov/15950015

DM7SJD6	DI	DM7SJD6
DM7SJD6	DN	Methylphenidate
DM7SJD6	MI	DTE8R17
DM7SJD6	MN	Sodium- and chloride-dependent glycine transporter 2 (SLC6A5)
DM7SJD6	MT	DTP
DM7SJD6	MA	Substrate
DM7SJD6	RN	SLC6 transporters: structure, function, regulation, disease association and therapeutics. Mol Aspects Med. 2013 Apr-Jun;34(2-3):197-219.
DM7SJD6	RU	http://www.ncbi.nlm.nih.gov/pubmed/23506866

DMDSWAG	DI	DMDSWAG
DMDSWAG	DN	Methylphenobarbital
DMDSWAG	MI	DEPKLMQ
DMDSWAG	MN	Cytochrome P450 2B6 (CYP2B6)
DMDSWAG	MT	DME
DMDSWAG	MA	Metabolism
DMDSWAG	RN	Pharmacogenetic roles of CYP2C19 and CYP2B6 in the metabolism of R- and S-mephobarbital in humans. Pharmacogenetics. 2004 Aug;14(8):549-56.
DMDSWAG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15284537

DMDSWAG	DI	DMDSWAG
DMDSWAG	DN	Methylphenobarbital
DMDSWAG	MI	TT1MPAY
DMDSWAG	MN	GABA(A) receptor alpha-1 (GABRA1)
DMDSWAG	MT	DTT
DMDSWAG	MA	Antagonist
DMDSWAG	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DMDSWAG	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DMDSWAG	DI	DMDSWAG
DMDSWAG	DN	Methylphenobarbital
DMDSWAG	MI	DEGTFWK
DMDSWAG	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMDSWAG	MT	DME
DMDSWAG	MA	Metabolism
DMDSWAG	RN	A novel single nucleotide polymorphism (SNP) of the CYP2C19 gene in a Japanese subject with lowered capacity of mephobarbital 4'-hydroxylation. Drug Metab Pharmacokinet. 2004 Jun;19(3):236-8.
DMDSWAG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15499191

DM4BDON	DI	DM4BDON
DM4BDON	DN	Methylprednisolone
DM4BDON	MI	DE4LYSA
DM4BDON	MN	Cytochrome P450 3A4 (CYP3A4)
DM4BDON	MT	DME
DM4BDON	MA	Metabolism
DM4BDON	RN	Cytochrome P450 enzyme regulation by glucocorticoids and consequences in terms of drug interaction. Expert Opin Drug Metab Toxicol. 2014 Mar;10(3):425-35.
DM4BDON	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24451000

DM4BDON	DI	DM4BDON
DM4BDON	DN	Methylprednisolone
DM4BDON	MI	TTYRL6O
DM4BDON	MN	Glucocorticoid receptor (NR3C1)
DM4BDON	MT	DTT
DM4BDON	MA	Modulator
DM4BDON	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM4BDON	RU	https://www.fda.gov/

DM4BDON	DI	DM4BDON
DM4BDON	DN	Methylprednisolone
DM4BDON	MI	DTUGYRD
DM4BDON	MN	P-glycoprotein 1 (ABCB1)
DM4BDON	MT	DTP
DM4BDON	MA	Substrate
DM4BDON	RN	Secretory transport of methylprednisolone possibly mediated by P-glycoprotein in Caco-2 cells. Biol Pharm Bull. 2002 Mar;25(3):393-6.
DM4BDON	RU	http://www.ncbi.nlm.nih.gov/pubmed/11913542

DM5VWOB	DI	DM5VWOB
DM5VWOB	DN	Methylscopolamine
DM5VWOB	MI	TTOXS3C
DM5VWOB	MN	Muscarinic acetylcholine receptor (CHRM)
DM5VWOB	MT	DTT
DM5VWOB	MA	Antagonist
DM5VWOB	RN	Lithocholylcholine, a bile acid/acetylcholine hybrid, is a muscarinic receptor antagonist. J Pharmacol Exp Ther. 2002 Oct;303(1):29-35.
DM5VWOB	RU	https://pubmed.ncbi.nlm.nih.gov/12235229

DM5VWOB	DI	DM5VWOB
DM5VWOB	DN	Methylscopolamine
DM5VWOB	MI	TTYEG6Q
DM5VWOB	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DM5VWOB	MT	DTT
DM5VWOB	MA	Antagonist
DM5VWOB	RN	Methylacridinium and its cholinergic properties. Neurotox Res. 2009 Nov;16(4):372-7.
DM5VWOB	RU	https://pubmed.ncbi.nlm.nih.gov/19565307

DM5VWOB	DI	DM5VWOB
DM5VWOB	DN	Methylscopolamine
DM5VWOB	MI	TTQ13Z5
DM5VWOB	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DM5VWOB	MT	DTT
DM5VWOB	MA	Antagonist
DM5VWOB	RN	Interaction of neuromuscular blocking drugs with recombinant human m1-m5 muscarinic receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1998 Nov;125(5):1088-94.
DM5VWOB	RU	https://pubmed.ncbi.nlm.nih.gov/9846649

DMWLFGO	DI	DMWLFGO
DMWLFGO	DN	Methyltestosterone
DMWLFGO	MI	DEPKLMQ
DMWLFGO	MN	Cytochrome P450 2B6 (CYP2B6)
DMWLFGO	MT	DME
DMWLFGO	MA	Metabolism
DMWLFGO	RN	Metabolism of anabolic steroids by recombinant human cytochrome P450 enzymes. Gas chromatographic-mass spectrometric determination of metabolites. J Chromatogr B Biomed Sci Appl. 1999 Nov 26;735(1):73-83.
DMWLFGO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10630892

DMWLFGO	DI	DMWLFGO
DMWLFGO	DN	Methyltestosterone
DMWLFGO	MI	DE4LYSA
DMWLFGO	MN	Cytochrome P450 3A4 (CYP3A4)
DMWLFGO	MT	DME
DMWLFGO	MA	Metabolism
DMWLFGO	RN	Metabolism of anabolic steroids by recombinant human cytochrome P450 enzymes. Gas chromatographic-mass spectrometric determination of metabolites. J Chromatogr B Biomed Sci Appl. 1999 Nov 26;735(1):73-83.
DMWLFGO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10630892

DMWLFGO	DI	DMWLFGO
DMWLFGO	DN	Methyltestosterone
DMWLFGO	MI	DEGKRXT
DMWLFGO	MN	UDP-glucuronosyltransferase 2A1 (UGT2A1)
DMWLFGO	MT	DME
DMWLFGO	MA	Metabolism
DMWLFGO	RN	Hepatic expression patterns of aryl hydrocarbon receptor, pregnane X receptor, two cytochrome P450s and five phase II metabolism genes responsive to 17alpha-methyltestosterone in rare minnow Gobiocypris rarus. Environ Toxicol Pharmacol. 2014 May;37(3):1157-68.
DMWLFGO	RU	https://pubmed.ncbi.nlm.nih.gov/24814259

DMBW7VH	DI	DMBW7VH
DMBW7VH	DN	Methyprylon
DMBW7VH	MI	DECB0K3
DMBW7VH	MN	Cytochrome P450 2D6 (CYP2D6)
DMBW7VH	MT	DME
DMBW7VH	MA	Metabolism
DMBW7VH	RN	Drugs and steatohepatitis. Semin Liver Dis. 2002;22(2):185-94.
DMBW7VH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12016549

DMBW7VH	DI	DMBW7VH
DMBW7VH	DN	Methyprylon
DMBW7VH	MI	TT1MPAY
DMBW7VH	MN	GABA(A) receptor alpha-1 (GABRA1)
DMBW7VH	MT	DTT
DMBW7VH	MA	Antagonist
DMBW7VH	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DMBW7VH	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DM1EF73	DI	DM1EF73
DM1EF73	DN	Methysergide
DM1EF73	MI	TTWJBZ5
DM1EF73	MN	5-HT 2C receptor (HTR2C)
DM1EF73	MT	DTT
DM1EF73	MA	Antagonist
DM1EF73	RN	Spinal serotonin receptor activation modulates the exercise ventilatory response with increased dead space in goats. Respir Physiol Neurobiol. 2008 May 31;161(3):230-8.
DM1EF73	RU	https://pubmed.ncbi.nlm.nih.gov/18396470

DM1EF73	DI	DM1EF73
DM1EF73	DN	Methysergide
DM1EF73	MI	DTUGYRD
DM1EF73	MN	P-glycoprotein 1 (ABCB1)
DM1EF73	MT	DTP
DM1EF73	MA	Substrate
DM1EF73	RN	Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.
DM1EF73	RU	http://www.ncbi.nlm.nih.gov/pubmed/12438524

DMIKHN0	DI	DMIKHN0
DMIKHN0	DN	Meticillin
DMIKHN0	MI	TTJP4SM
DMIKHN0	MN	Bacterial Penicillin binding protein (Bact PBP)
DMIKHN0	MT	DTT
DMIKHN0	MA	Binder
DMIKHN0	RN	A link in transcription between the native pbpB and the acquired mecA gene in a strain of Staphylococcus aureus. Microbiology. 2006 Sep;152(Pt 9):2549-58.
DMIKHN0	RU	https://pubmed.ncbi.nlm.nih.gov/16946250

DMJMVKI	DI	DMJMVKI
DMJMVKI	DN	Metipranolol
DMJMVKI	MI	TTR6W5O
DMJMVKI	MN	Adrenergic receptor beta-1 (ADRB1)
DMJMVKI	MT	DTT
DMJMVKI	MA	Antagonist
DMJMVKI	RN	Invited review: Neuroprotective properties of certain beta-adrenoceptor antagonists used for the treatment of glaucoma. J Ocul Pharmacol Ther. 2005 Jun;21(3):175-81.
DMJMVKI	RU	https://pubmed.ncbi.nlm.nih.gov/15969634

DMJMVKI	DI	DMJMVKI
DMJMVKI	DN	Metipranolol
DMJMVKI	MI	DECB0K3
DMJMVKI	MN	Cytochrome P450 2D6 (CYP2D6)
DMJMVKI	MT	DME
DMJMVKI	MA	Metabolism
DMJMVKI	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DMJMVKI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DM0JE6N	DI	DM0JE6N
DM0JE6N	DN	Metixene
DM0JE6N	MI	TTZ9SOR
DM0JE6N	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DM0JE6N	MT	DTT
DM0JE6N	MA	Modulator
DM0JE6N	RN	Roles of the M1 muscarinic acetylcholine receptor subtype in the regulation of basal ganglia function and implications for the treatment of Parkinson's disease.J Pharmacol Exp Ther.2012 Mar;340(3):595-603.
DM0JE6N	RU	https://www.ncbi.nlm.nih.gov/pubmed/22135383

DMFA5MY	DI	DMFA5MY
DMFA5MY	DN	Metoclopramide
DMFA5MY	MI	DEJGDUW
DMFA5MY	MN	Cytochrome P450 1A2 (CYP1A2)
DMFA5MY	MT	DME
DMFA5MY	MA	Metabolism
DMFA5MY	RN	Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6. Xenobiotica. 2014 Apr;44(4):309-319.
DMFA5MY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24010633

DMFA5MY	DI	DMFA5MY
DMFA5MY	DN	Metoclopramide
DMFA5MY	MI	DECB0K3
DMFA5MY	MN	Cytochrome P450 2D6 (CYP2D6)
DMFA5MY	MT	DME
DMFA5MY	MA	Metabolism
DMFA5MY	RN	Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6. Xenobiotica. 2014 Apr;44(4):309-319.
DMFA5MY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24010633

DMFA5MY	DI	DMFA5MY
DMFA5MY	DN	Metoclopramide
DMFA5MY	MI	DE4LYSA
DMFA5MY	MN	Cytochrome P450 3A4 (CYP3A4)
DMFA5MY	MT	DME
DMFA5MY	MA	Metabolism
DMFA5MY	RN	Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6. Xenobiotica. 2014 Apr;44(4):309-319.
DMFA5MY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24010633

DMFA5MY	DI	DMFA5MY
DMFA5MY	DN	Metoclopramide
DMFA5MY	MI	TTEX248
DMFA5MY	MN	Dopamine D2 receptor (D2R)
DMFA5MY	MT	DTT
DMFA5MY	MA	Antagonist
DMFA5MY	RN	Mechanisms for metoclopramide-mediated sensitization and haloperidol-induced catalepsy in rats. Eur J Pharmacol. 2008 Jun 10;587(1-3):181-6.
DMFA5MY	RU	https://pubmed.ncbi.nlm.nih.gov/18457824

DMFA5MY	DI	DMFA5MY
DMFA5MY	DN	Metoclopramide
DMFA5MY	MI	DTT79CX
DMFA5MY	MN	Organic cation transporter 1 (SLC22A1)
DMFA5MY	MT	DTP
DMFA5MY	MA	Substrate
DMFA5MY	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMFA5MY	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DMZJYBW	DI	DMZJYBW
DMZJYBW	DN	Metocurine Iodide
DMZJYBW	MI	TTL1ATN
DMZJYBW	MN	Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2)
DMZJYBW	MT	DTT
DMZJYBW	MA	Modulator
DMZJYBW	RN	NMR study of general anesthetic interaction with nAChR beta2 subunit.Biophys J.2008 Mar 1;94(5):1681-8.
DMZJYBW	RU	https://www.ncbi.nlm.nih.gov/pubmed/17993502

DMB39LO	DI	DMB39LO
DMB39LO	DN	Metolazone
DMB39LO	MI	TTP362L
DMB39LO	MN	Solute carrier family 12 member 3 (SLC12A3)
DMB39LO	MT	DTT
DMB39LO	MA	Blocker
DMB39LO	RN	The renal thiazide-sensitive Na-Cl cotransporter as mediator of the aldosterone-escape phenomenon. J Clin Invest. 2001 Jul;108(2):215-22.
DMB39LO	RU	https://pubmed.ncbi.nlm.nih.gov/11457874

DMB39LO	DI	DMB39LO
DMB39LO	DN	Metolazone
DMB39LO	MI	DT6MDC9
DMB39LO	MN	Thiazide-sensitive sodium-chloride cotransporter (SLC12A3)
DMB39LO	MT	DTP
DMB39LO	MA	Substrate
DMB39LO	RN	Inhibition of binding of [3H]metolazone to rat kidney membrane by stilbene disulfonates. Biochem Pharmacol. 1991 Jun 1;41(11):1745-50.
DMB39LO	RU	http://www.ncbi.nlm.nih.gov/pubmed/2043163

DMOJ0V6	DI	DMOJ0V6
DMOJ0V6	DN	Metoprolol
DMOJ0V6	MI	TTR6W5O
DMOJ0V6	MN	Adrenergic receptor beta-1 (ADRB1)
DMOJ0V6	MT	DTT
DMOJ0V6	MA	Antagonist
DMOJ0V6	RN	Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6.
DMOJ0V6	RU	https://pubmed.ncbi.nlm.nih.gov/16268148

DMOJ0V6	DI	DMOJ0V6
DMOJ0V6	DN	Metoprolol
DMOJ0V6	MI	DECB0K3
DMOJ0V6	MN	Cytochrome P450 2D6 (CYP2D6)
DMOJ0V6	MT	DME
DMOJ0V6	MA	Metabolism
DMOJ0V6	RN	The impact of CYP2D6 mediated drug-drug interaction: a systematic review on a combination of metoprolol and paroxetine/fluoxetine. Br J Clin Pharmacol. 2018 Dec;84(12):2704-2715.
DMOJ0V6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30248178

DMOJ0V6	DI	DMOJ0V6
DMOJ0V6	DN	Metoprolol
DMOJ0V6	MI	DE4LYSA
DMOJ0V6	MN	Cytochrome P450 3A4 (CYP3A4)
DMOJ0V6	MT	DME
DMOJ0V6	MA	Metabolism
DMOJ0V6	RN	Chemical stability-indicating HPLC study of fixed-dosage combination containing metoprolol tartrate and hydrochlorothiazide.
DMOJ0V6	RU	https://www.researchgate.net/publication/257614687_Chemical_stability-indicating_HPLC_study_of_fixed-dosage_combination_containing_metoprolol_tartrate_and_hydrochlorothiazide

DMOJ0V6	DI	DMOJ0V6
DMOJ0V6	DN	Metoprolol
DMOJ0V6	MI	DEGTFWK
DMOJ0V6	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMOJ0V6	MT	DME
DMOJ0V6	MA	Metabolism
DMOJ0V6	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMOJ0V6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMOJ0V6	DI	DMOJ0V6
DMOJ0V6	DN	Metoprolol
DMOJ0V6	MI	DT9G7XN
DMOJ0V6	MN	Peptide transporter 1 (SLC15A1)
DMOJ0V6	MT	DTP
DMOJ0V6	MA	Substrate
DMOJ0V6	RN	Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells. Arch Pharm Res. 2007 Apr;30(4):507-18.
DMOJ0V6	RU	https://doi.org/10.1007/BF02980227

DM1NOEK	DI	DM1NOEK
DM1NOEK	DN	Metreleptin
DM1NOEK	MI	TT0HD6V
DM1NOEK	MN	Leptin receptor (LEPR)
DM1NOEK	MT	DTT
DM1NOEK	MA	Modulator
DM1NOEK	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DM1NOEK	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMTIVEN	DI	DMTIVEN
DMTIVEN	DN	Metronidazole
DMTIVEN	MI	TTS1W4A
DMTIVEN	MN	Bacterial Deoxyribonucleic acid (Bact DNA)
DMTIVEN	MT	DTT
DMTIVEN	MA	Modulator
DMTIVEN	RN	DNA breakage due to metronidazole treatment. Mutat Res. 2001 Jul 1;478(1-2):153-8.
DMTIVEN	RU	https://www.ncbi.nlm.nih.gov/pubmed/11406179

DMTIVEN	DI	DMTIVEN
DMTIVEN	DN	Metronidazole
DMTIVEN	MI	DEJVYAZ
DMTIVEN	MN	Cytochrome P450 2A6 (CYP2A6)
DMTIVEN	MT	DME
DMTIVEN	MA	Metabolism
DMTIVEN	RN	The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
DMTIVEN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23813797

DMTIVEN	DI	DMTIVEN
DMTIVEN	DN	Metronidazole
DMTIVEN	MI	DE5IED8
DMTIVEN	MN	Cytochrome P450 2C9 (CYP2C9)
DMTIVEN	MT	DME
DMTIVEN	MA	Metabolism
DMTIVEN	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMTIVEN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMTIVEN	DI	DMTIVEN
DMTIVEN	DN	Metronidazole
DMTIVEN	MI	DE4LYSA
DMTIVEN	MN	Cytochrome P450 3A4 (CYP3A4)
DMTIVEN	MT	DME
DMTIVEN	MA	Metabolism
DMTIVEN	RN	Does metronidazole interact with CYP3A substrates by inhibiting their metabolism through this metabolic pathway? Or should other mechanisms be considered? Ann Pharmacother. 2007 Apr;41(4):653-8.
DMTIVEN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17374625

DMTIVEN	DI	DMTIVEN
DMTIVEN	DN	Metronidazole
DMTIVEN	MI	DEIBDNY
DMTIVEN	MN	Cytochrome P450 3A5 (CYP3A5)
DMTIVEN	MT	DME
DMTIVEN	MA	Metabolism
DMTIVEN	RN	The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
DMTIVEN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23813797

DMTIVEN	DI	DMTIVEN
DMTIVEN	DN	Metronidazole
DMTIVEN	MI	DERD86B
DMTIVEN	MN	Cytochrome P450 3A7 (CYP3A7)
DMTIVEN	MT	DME
DMTIVEN	MA	Metabolism
DMTIVEN	RN	The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
DMTIVEN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23813797

DMTIVEN	DI	DMTIVEN
DMTIVEN	DN	Metronidazole
DMTIVEN	MI	DE8R7QY
DMTIVEN	MN	Nitroreductase (NTR)
DMTIVEN	MT	DME
DMTIVEN	MA	Metabolism
DMTIVEN	RN	Giardia, Entamoeba, and Trichomonas enzymes activate metronidazole (nitroreductases) and inactivate metronidazole (nitroimidazole reductases). Antimicrob Agents Chemother. 2009 Feb;53(2):458-64.
DMTIVEN	RU	https://pubmed.ncbi.nlm.nih.gov/19015349

DMTIVEN	DI	DMTIVEN
DMTIVEN	DN	Metronidazole
DMTIVEN	MI	DE2VSMT
DMTIVEN	MN	Nitroreductase (NTR)
DMTIVEN	MT	DME
DMTIVEN	MA	Metabolism
DMTIVEN	RN	Giardia, Entamoeba, and Trichomonas enzymes activate metronidazole (nitroreductases) and inactivate metronidazole (nitroimidazole reductases). Antimicrob Agents Chemother. 2009 Feb;53(2):458-64.
DMTIVEN	RU	https://pubmed.ncbi.nlm.nih.gov/19015349

DMTIVEN	DI	DMTIVEN
DMTIVEN	DN	Metronidazole
DMTIVEN	MI	DEQGIMN
DMTIVEN	MN	Nitroreductase (NTR)
DMTIVEN	MT	DME
DMTIVEN	MA	Metabolism
DMTIVEN	RN	Giardia, Entamoeba, and Trichomonas enzymes activate metronidazole (nitroreductases) and inactivate metronidazole (nitroimidazole reductases). Antimicrob Agents Chemother. 2009 Feb;53(2):458-64.
DMTIVEN	RU	https://pubmed.ncbi.nlm.nih.gov/19015349

DMTIVEN	DI	DMTIVEN
DMTIVEN	DN	Metronidazole
DMTIVEN	MI	DEP7ECA
DMTIVEN	MN	Nitroreductase (NTR)
DMTIVEN	MT	DME
DMTIVEN	MA	Metabolism
DMTIVEN	RN	Acetamide--a metabolite of metronidazole formed by the intestinal flora. Biochem Pharmacol. 1979 Dec 15;28(24):3611-5.
DMTIVEN	RU	https://pubmed.ncbi.nlm.nih.gov/231450

DMTIVEN	DI	DMTIVEN
DMTIVEN	DN	Metronidazole
DMTIVEN	MI	DEAN5EW
DMTIVEN	MN	Nitroreductase (NTR)
DMTIVEN	MT	DME
DMTIVEN	MA	Metabolism
DMTIVEN	RN	Overexpression, isotopic labeling, and spectral characterization of Enterobacter cloacae nitroreductase. Protein Expr Purif. 1998 Jun;13(1):53-60.
DMTIVEN	RU	https://pubmed.ncbi.nlm.nih.gov/9631515

DMTIVEN	DI	DMTIVEN
DMTIVEN	DN	Metronidazole
DMTIVEN	MI	DE3U2Y6
DMTIVEN	MN	Nitroreductase (NTR)
DMTIVEN	MT	DME
DMTIVEN	MA	Metabolism
DMTIVEN	RN	Mechanism of metronidazole-resistance by isolates of nitroreductase-producing Enterococcus gallinarum and Enterococcus casseliflavus from the human intestinal tract. FEMS Microbiol Lett. 2003 Aug 29;225(2):195-200.
DMTIVEN	RU	https://pubmed.ncbi.nlm.nih.gov/12951241

DMTIVEN	DI	DMTIVEN
DMTIVEN	DN	Metronidazole
DMTIVEN	MI	DEUW4J0
DMTIVEN	MN	Nitroreductase (NTR)
DMTIVEN	MT	DME
DMTIVEN	MA	Metabolism
DMTIVEN	RN	Mechanism of metronidazole-resistance by isolates of nitroreductase-producing Enterococcus gallinarum and Enterococcus casseliflavus from the human intestinal tract. FEMS Microbiol Lett. 2003 Aug 29;225(2):195-200.
DMTIVEN	RU	https://pubmed.ncbi.nlm.nih.gov/12951241

DMTIVEN	DI	DMTIVEN
DMTIVEN	DN	Metronidazole
DMTIVEN	MI	DELAPDY
DMTIVEN	MN	Nitroreductase (NTR)
DMTIVEN	MT	DME
DMTIVEN	MA	Metabolism
DMTIVEN	RN	Isolation of metronidazole-resistant Bacteroides fragilis carrying the nimA nitroreductase gene from a patient in Washington State. J Clin Microbiol. 2004 Sep;42(9):4127-9. Case Reports
DMTIVEN	RU	https://pubmed.ncbi.nlm.nih.gov/15364999

DMTIVEN	DI	DMTIVEN
DMTIVEN	DN	Metronidazole
DMTIVEN	MI	DEYGVN4
DMTIVEN	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMTIVEN	MT	DME
DMTIVEN	MA	Metabolism
DMTIVEN	RN	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
DMTIVEN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429

DMI7FVQ	DI	DMI7FVQ
DMI7FVQ	DN	Metyrapone
DMI7FVQ	MI	TTIQUX7
DMI7FVQ	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMI7FVQ	MT	DTT
DMI7FVQ	MA	Inhibitor
DMI7FVQ	RN	Effects of 3-MeSO2-DDE and some CYP inhibitors on glucocorticoid steroidogenesis in the H295R human adrenocortical carcinoma cell line. Toxicol In Vitro. 2002 Apr;16(2):113-21.
DMI7FVQ	RU	https://pubmed.ncbi.nlm.nih.gov/11869873

DMBYCU0	DI	DMBYCU0
DMBYCU0	DN	Metyrosine
DMBYCU0	MI	TTUHP71
DMBYCU0	MN	Tyrosine 3-monooxygenase (TH)
DMBYCU0	MT	DTT
DMBYCU0	MA	Binder
DMBYCU0	RN	Dopamine beta-hydroxylase deficiency. A genetic disorder of cardiovascular regulation. Hypertension. 1991 Jul;18(1):1-8.
DMBYCU0	RU	https://pubmed.ncbi.nlm.nih.gov/1677640

DMCTE9R	DI	DMCTE9R
DMCTE9R	DN	Mexiletine
DMCTE9R	MI	DEJGDUW
DMCTE9R	MN	Cytochrome P450 1A2 (CYP1A2)
DMCTE9R	MT	DME
DMCTE9R	MA	Metabolism
DMCTE9R	RN	Inhibition of human liver cytochrome P-450 1A2 by the class IB antiarrhythmics mexiletine, lidocaine, and tocainide. J Pharmacol Exp Ther. 1999 May;289(2):853-8.
DMCTE9R	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10215663

DMCTE9R	DI	DMCTE9R
DMCTE9R	DN	Mexiletine
DMCTE9R	MI	DEPKLMQ
DMCTE9R	MN	Cytochrome P450 2B6 (CYP2B6)
DMCTE9R	MT	DME
DMCTE9R	MA	Metabolism
DMCTE9R	RN	Role of specific cytochrome P450 enzymes in the N-oxidation of the antiarrhythmic agent mexiletine. Xenobiotica. 2003 Jan;33(1):13-25.
DMCTE9R	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12519691

DMCTE9R	DI	DMCTE9R
DMCTE9R	DN	Mexiletine
DMCTE9R	MI	DECB0K3
DMCTE9R	MN	Cytochrome P450 2D6 (CYP2D6)
DMCTE9R	MT	DME
DMCTE9R	MA	Metabolism
DMCTE9R	RN	Impact of CYP2D6*10 on mexiletine pharmacokinetics in healthy adult volunteers. Eur J Clin Pharmacol. 2003 Sep;59(5-6):395-9.
DMCTE9R	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12937870

DMCTE9R	DI	DMCTE9R
DMCTE9R	DN	Mexiletine
DMCTE9R	MI	DEVDYN7
DMCTE9R	MN	Cytochrome P450 2E1 (CYP2E1)
DMCTE9R	MT	DME
DMCTE9R	MA	Metabolism
DMCTE9R	RN	Role of specific cytochrome P450 enzymes in the N-oxidation of the antiarrhythmic agent mexiletine. Xenobiotica. 2003 Jan;33(1):13-25.
DMCTE9R	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12519691

DMCTE9R	DI	DMCTE9R
DMCTE9R	DN	Mexiletine
DMCTE9R	MI	DE4LYSA
DMCTE9R	MN	Cytochrome P450 3A4 (CYP3A4)
DMCTE9R	MT	DME
DMCTE9R	MA	Metabolism
DMCTE9R	RN	Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings. Clin Pharmacol Ther. 2000 Jul;68(1):44-57.
DMCTE9R	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10945315

DMCTE9R	DI	DMCTE9R
DMCTE9R	DN	Mexiletine
DMCTE9R	MI	TTZOVE0
DMCTE9R	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DMCTE9R	MT	DTT
DMCTE9R	MA	Blocker
DMCTE9R	RN	Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2000 Dec;11(12):1320-9.
DMCTE9R	RU	https://pubmed.ncbi.nlm.nih.gov/11196553

DMY5JEP	DI	DMY5JEP
DMY5JEP	DN	Mezlocillin
DMY5JEP	MI	TT85JMW
DMY5JEP	MN	Bacterial Penicillin binding protein 3 (Bact mrcA)
DMY5JEP	MT	DTT
DMY5JEP	MA	Binder
DMY5JEP	RN	Bactericidal effect of piperacillin alone and combined. Presse Med. 1986 Dec 20;15(46):2297-302.
DMY5JEP	RU	https://pubmed.ncbi.nlm.nih.gov/2949271

DMVKA4O	DI	DMVKA4O
DMVKA4O	DN	Mianserin
DMVKA4O	MI	TTYSN63
DMVKA4O	MN	5-HT 2 receptor (5HT2R)
DMVKA4O	MT	DTT
DMVKA4O	MA	Antagonist
DMVKA4O	RN	5-HT reuptake and 5-HT2 receptors modulate capsaicin-evoked hypothermia in rats. Neurosci Lett. 2008 Jan 17;430(3):191-6.
DMVKA4O	RU	https://pubmed.ncbi.nlm.nih.gov/18155835

DMVKA4O	DI	DMVKA4O
DMVKA4O	DN	Mianserin
DMVKA4O	MI	DEJGDUW
DMVKA4O	MN	Cytochrome P450 1A2 (CYP1A2)
DMVKA4O	MT	DME
DMVKA4O	MA	Metabolism
DMVKA4O	RN	Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers. J Pharmacol Exp Ther. 1996 Jul;278(1):21-30.
DMVKA4O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8764331

DMVKA4O	DI	DMVKA4O
DMVKA4O	DN	Mianserin
DMVKA4O	MI	DEPKLMQ
DMVKA4O	MN	Cytochrome P450 2B6 (CYP2B6)
DMVKA4O	MT	DME
DMVKA4O	MA	Metabolism
DMVKA4O	RN	Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics. 2003 Oct;13(10):619-26.
DMVKA4O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14515060

DMVKA4O	DI	DMVKA4O
DMVKA4O	DN	Mianserin
DMVKA4O	MI	DECB0K3
DMVKA4O	MN	Cytochrome P450 2D6 (CYP2D6)
DMVKA4O	MT	DME
DMVKA4O	MA	Metabolism
DMVKA4O	RN	Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy. Psychiatr Pol. 2004 Nov-Dec;38(6):1093-104.
DMVKA4O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15779673

DMVKA4O	DI	DMVKA4O
DMVKA4O	DN	Mianserin
DMVKA4O	MI	DE4LYSA
DMVKA4O	MN	Cytochrome P450 3A4 (CYP3A4)
DMVKA4O	MT	DME
DMVKA4O	MA	Metabolism
DMVKA4O	RN	[Metabolic interaction between psychopharmaceuticals. Probable cause of exacerbation of hypothyroidism according to a case report]. Lakartidningen. 2002 Jun 20;99(25):2854-6.
DMVKA4O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12143142

DM6Y3AN	DI	DM6Y3AN
DM6Y3AN	DN	Micafungin
DM6Y3AN	MI	DEJ6FSR
DM6Y3AN	MN	Arylsulfatase A (ARSA)
DM6Y3AN	MT	DME
DM6Y3AN	MA	Metabolism
DM6Y3AN	RN	The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety. Expert Opin Pharmacother. 2007 Jun;8(8):1155-66.
DM6Y3AN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17516879

DM6Y3AN	DI	DM6Y3AN
DM6Y3AN	DN	Micafungin
DM6Y3AN	MI	TT0SFXH
DM6Y3AN	MN	Fungal 1,3-beta-glucan synthase (Fung GSC2)
DM6Y3AN	MT	DTT
DM6Y3AN	MA	Modulator
DM6Y3AN	RN	An immunomodulatory activity of micafungin in preclinical aspergillosis. J Antimicrob Chemother. 2014 Apr;69(4):1065-74.
DM6Y3AN	RU	https://pubmed.ncbi.nlm.nih.gov/24265229

DM3O6CY	DI	DM3O6CY
DM3O6CY	DN	Micardis telmisartan
DM3O6CY	MI	TT8DBY3
DM3O6CY	MN	Angiotensin II receptor type-1 (AGTR1)
DM3O6CY	MT	DTT
DM3O6CY	MA	Antagonist
DM3O6CY	RN	The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial. J Hypertens. 2005 Nov;23(11):2055-61.
DM3O6CY	RU	https://pubmed.ncbi.nlm.nih.gov/16208149

DMPMYE8	DI	DMPMYE8
DMPMYE8	DN	Miconazole
DMPMYE8	MI	TTTSOUD
DMPMYE8	MN	Candida Cytochrome P450 51 (Candi ERG11)
DMPMYE8	MT	DTT
DMPMYE8	MA	Modulator
DMPMYE8	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMPMYE8	RU	https://www.fda.gov/

DMPMYE8	DI	DMPMYE8
DMPMYE8	DN	Miconazole
DMPMYE8	MI	DE4LYSA
DMPMYE8	MN	Cytochrome P450 3A4 (CYP3A4)
DMPMYE8	MT	DME
DMPMYE8	MA	Metabolism
DMPMYE8	RN	Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chem Biol Interact. 2004 Apr 15;147(3):331-40.
DMPMYE8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15135088

DMXOELT	DI	DMXOELT
DMXOELT	DN	Midazolam
DMXOELT	MI	DEPKLMQ
DMXOELT	MN	Cytochrome P450 2B6 (CYP2B6)
DMXOELT	MT	DME
DMXOELT	MA	Metabolism
DMXOELT	RN	Further characterization of the expression in liver and catalytic activity of CYP2B6. J Pharmacol Exp Ther. 1998 Sep;286(3):1253-9.
DMXOELT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9732386

DMXOELT	DI	DMXOELT
DMXOELT	DN	Midazolam
DMXOELT	MI	DE4LYSA
DMXOELT	MN	Cytochrome P450 3A4 (CYP3A4)
DMXOELT	MT	DME
DMXOELT	MA	Metabolism
DMXOELT	RN	Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation. Drug Metab Dispos. 2010 Jun;38(6):981-7.
DMXOELT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20203109

DMXOELT	DI	DMXOELT
DMXOELT	DN	Midazolam
DMXOELT	MI	DEIBDNY
DMXOELT	MN	Cytochrome P450 3A5 (CYP3A5)
DMXOELT	MT	DME
DMXOELT	MA	Metabolism
DMXOELT	RN	In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos. 2003 Jul;31(7):938-44.
DMXOELT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12814972

DMXOELT	DI	DMXOELT
DMXOELT	DN	Midazolam
DMXOELT	MI	DERD86B
DMXOELT	MN	Cytochrome P450 3A7 (CYP3A7)
DMXOELT	MT	DME
DMXOELT	MA	Metabolism
DMXOELT	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMXOELT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMXOELT	DI	DMXOELT
DMXOELT	DN	Midazolam
DMXOELT	MI	DEMF740
DMXOELT	MN	Cytochrome P450 4B1 (CYP4B1)
DMXOELT	MT	DME
DMXOELT	MA	Metabolism
DMXOELT	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMXOELT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMXOELT	DI	DMXOELT
DMXOELT	DN	Midazolam
DMXOELT	MI	DTUGYRD
DMXOELT	MN	P-glycoprotein 1 (ABCB1)
DMXOELT	MT	DTP
DMXOELT	MA	Substrate
DMXOELT	RN	A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26.
DMXOELT	RU	https://doi.org/10.1007/s00210-008-0345-0

DMXOELT	DI	DMXOELT
DMXOELT	DN	Midazolam
DMXOELT	MI	TTPTXIN
DMXOELT	MN	Translocator protein (TSPO)
DMXOELT	MT	DTT
DMXOELT	MA	Modulator
DMXOELT	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMXOELT	RU	https://www.fda.gov/

DME2PY5	DI	DME2PY5
DME2PY5	DN	Midodrine
DME2PY5	MI	TTG28O6
DME2PY5	MN	Adrenergic receptor Alpha-1 (ADRA1)
DME2PY5	MT	DTT
DME2PY5	MA	Agonist
DME2PY5	RN	Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management. Drugs Aging. 2001;18(7):495-505.
DME2PY5	RU	https://pubmed.ncbi.nlm.nih.gov/11482743

DME2PY5	DI	DME2PY5
DME2PY5	DN	Midodrine
DME2PY5	MI	DECB0K3
DME2PY5	MN	Cytochrome P450 2D6 (CYP2D6)
DME2PY5	MT	DME
DME2PY5	MA	Metabolism
DME2PY5	RN	Akathisia with combined use of midodrine and promethazine. JAMA. 2006 May 3;295(17):2000-1. Letter
DME2PY5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16670408

DME2PY5	DI	DME2PY5
DME2PY5	DN	Midodrine
DME2PY5	MI	DT9G7XN
DME2PY5	MN	Peptide transporter 1 (SLC15A1)
DME2PY5	MT	DTP
DME2PY5	MA	Substrate
DME2PY5	RN	Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60.
DME2PY5	RU	http://www.ncbi.nlm.nih.gov/pubmed/16597710

DMI6E0R	DI	DMI6E0R
DMI6E0R	DN	Midostaurin
DMI6E0R	MI	DE4LYSA
DMI6E0R	MN	Cytochrome P450 3A4 (CYP3A4)
DMI6E0R	MT	DME
DMI6E0R	MA	Metabolism
DMI6E0R	RN	Midostaurin, a novel protein kinase inhibitor for the treatment of acute myelogenous leukemia: insights from human absorption, metabolism, and excretion studies of a BDDCS II drug. Drug Metab Dispos. 2017 May;45(5):540-555.
DMI6E0R	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28270565

DMI6E0R	DI	DMI6E0R
DMI6E0R	DN	Midostaurin
DMI6E0R	MI	TTGJCWZ
DMI6E0R	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMI6E0R	MT	DTT
DMI6E0R	MA	Inhibitor
DMI6E0R	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMI6E0R	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMI6E0R	DI	DMI6E0R
DMI6E0R	DN	Midostaurin
DMI6E0R	MI	DTUGYRD
DMI6E0R	MN	P-glycoprotein 1 (ABCB1)
DMI6E0R	MT	DTP
DMI6E0R	MA	Substrate
DMI6E0R	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMI6E0R	RU	https://doi.org/10.1007/s11095-012-0935-x

DMI6E0R	DI	DMI6E0R
DMI6E0R	DN	Midostaurin
DMI6E0R	MI	TTRFOXJ
DMI6E0R	MN	Protein kinase C gamma (PRKCG)
DMI6E0R	MT	DTT
DMI6E0R	MA	Inhibitor
DMI6E0R	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMI6E0R	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMGZQEF	DI	DMGZQEF
DMGZQEF	DN	Mifepristone
DMGZQEF	MI	DE4LYSA
DMGZQEF	MN	Cytochrome P450 3A4 (CYP3A4)
DMGZQEF	MT	DME
DMGZQEF	MA	Metabolism
DMGZQEF	RN	Evaluation of strategies for the assessment of drug-drug interactions involving cytochrome P450 enzymes. Eur J Drug Metab Pharmacokinet. 2018 Dec;43(6):737-750.
DMGZQEF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29785610

DMGZQEF	DI	DMGZQEF
DMGZQEF	DN	Mifepristone
DMGZQEF	MI	DEIBDNY
DMGZQEF	MN	Cytochrome P450 3A5 (CYP3A5)
DMGZQEF	MT	DME
DMGZQEF	MA	Metabolism
DMGZQEF	RN	Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5. Xenobiotica. 2006 Apr;36(4):287-99.
DMGZQEF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16684709

DMGZQEF	DI	DMGZQEF
DMGZQEF	DN	Mifepristone
DMGZQEF	MI	TTYRL6O
DMGZQEF	MN	Glucocorticoid receptor (NR3C1)
DMGZQEF	MT	DTT
DMGZQEF	MA	Modulator
DMGZQEF	RN	The glucocorticoid agonist activities of mifepristone (RU486) and progesterone are dependent on glucocorticoid receptor levels but not on EC50 values. Steroids. 2007 Jun;72(6-7):600-8.
DMGZQEF	RU	https://pubmed.ncbi.nlm.nih.gov/17509631

DMFIQ2H	DI	DMFIQ2H
DMFIQ2H	DN	Migalastat
DMFIQ2H	MI	TTIS03D
DMFIQ2H	MN	Alpha-galactosidase A (GLA)
DMFIQ2H	MT	DTT
DMFIQ2H	MA	Modulator
DMFIQ2H	RN	AT-1001: a high-affinity alpha3beta4 nAChR ligand with novel nicotine-suppressive pharmacology. Br J Pharmacol. 2015 Apr;172(7):1834-45.
DMFIQ2H	RU	https://pubmed.ncbi.nlm.nih.gov/25440006

DMXBQAM	DI	DMXBQAM
DMXBQAM	DN	Miglitol
DMXBQAM	MI	TTXWASR
DMXBQAM	MN	Intestinal maltase-glucoamylase (MGAM)
DMXBQAM	MT	DTT
DMXBQAM	MA	Inhibitor
DMXBQAM	RN	Drug therapy of postprandial hyperglycaemia. Drugs. 1999 Jan;57(1):19-29.
DMXBQAM	RU	https://pubmed.ncbi.nlm.nih.gov/9951949

DM5J64S	DI	DM5J64S
DM5J64S	DN	Miglustat
DM5J64S	MI	TTPHEX3
DM5J64S	MN	Ceramide glucosyltransferase (UGCG)
DM5J64S	MT	DTT
DM5J64S	MA	Inhibitor
DM5J64S	RN	Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies. Clin Ther. 2007 Aug;29(8):1645-54.
DM5J64S	RU	https://pubmed.ncbi.nlm.nih.gov/17919546

DMBFE74	DI	DMBFE74
DMBFE74	DN	Milnacipran
DMBFE74	MI	TTAWNKZ
DMBFE74	MN	Norepinephrine transporter (NET)
DMBFE74	MT	DTT
DMBFE74	MA	Inhibitor
DMBFE74	RN	Milnacipran: beyond a role of antidepressant. Clin Neuropharmacol. 2009 Nov-Dec;32(6):355-63.
DMBFE74	RU	https://pubmed.ncbi.nlm.nih.gov/19620845

DM8TUPF	DI	DM8TUPF
DM8TUPF	DN	Milrinone
DM8TUPF	MI	TTZCG4L
DM8TUPF	MN	Phosphodiesterase 3 (PDE3)
DM8TUPF	MT	DTT
DM8TUPF	MA	Modulator
DM8TUPF	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM8TUPF	RU	https://www.fda.gov/

DMND304	DI	DMND304
DMND304	DN	Miltefosine
DMND304	MI	DEB2ZMT
DMND304	MN	Choline phosphatase 1 (PLD1)
DMND304	MT	DME
DMND304	MA	Metabolism
DMND304	RN	Development of miltefosine as an oral treatment for leishmaniasis. Trans R Soc Trop Med Hyg. 2006 Dec;100 Suppl 1:S17-20.
DMND304	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16730362

DMND304	DI	DMND304
DMND304	DN	Miltefosine
DMND304	MI	TT9V5JH
DMND304	MN	Phospholipase A2 (PLA2G1B)
DMND304	MT	DTT
DMND304	MA	Inhibitor
DMND304	RN	Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22.
DMND304	RU	https://pubmed.ncbi.nlm.nih.gov/19463273

DM0EP7M	DI	DM0EP7M
DM0EP7M	DN	Minaprine
DM0EP7M	MI	TT0K1SC
DM0EP7M	MN	5-HT 2B receptor (HTR2B)
DM0EP7M	MT	DTT
DM0EP7M	MA	Antagonist
DM0EP7M	RN	Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
DM0EP7M	RU	https://pubmed.ncbi.nlm.nih.gov/18045214

DM0EP7M	DI	DM0EP7M
DM0EP7M	DN	Minaprine
DM0EP7M	MI	DECB0K3
DM0EP7M	MN	Cytochrome P450 2D6 (CYP2D6)
DM0EP7M	MT	DME
DM0EP7M	MA	Metabolism
DM0EP7M	RN	Comparative molecular field analysis and QSAR on substrates binding to cytochrome p450 2D6. Bioorg Med Chem. 2003 Dec 1;11(24):5545-54.
DM0EP7M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14642599

DMVN5OH	DI	DMVN5OH
DMVN5OH	DN	Minocycline
DMVN5OH	MI	TTQ8KVI
DMVN5OH	MN	Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)
DMVN5OH	MT	DTT
DMVN5OH	MA	Binder
DMVN5OH	RN	Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother. 2006 Jun;50(6):2156-66.
DMVN5OH	RU	https://pubmed.ncbi.nlm.nih.gov/16723578

DM50PMY	DI	DM50PMY
DM50PMY	DN	Minodronate
DM50PMY	MI	TTIKWV4
DM50PMY	MN	Geranyltranstransferase (FDPS)
DM50PMY	MT	DTT
DM50PMY	MA	Inhibitor
DM50PMY	RN	Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid. J Med Chem. 2010 May 13;53(9):3454-64.
DM50PMY	RU	https://pubmed.ncbi.nlm.nih.gov/20394422

DMA2Z4F	DI	DMA2Z4F
DMA2Z4F	DN	Minoxidil
DMA2Z4F	MI	TT1VOHK
DMA2Z4F	MN	Potassium channel unspecific (KC)
DMA2Z4F	MT	DTT
DMA2Z4F	MA	Modulator
DMA2Z4F	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMA2Z4F	RU	https://www.fda.gov/

DMA2Z4F	DI	DMA2Z4F
DMA2Z4F	DN	Minoxidil
DMA2Z4F	MI	DEYWLRK
DMA2Z4F	MN	Sulfotransferase 1A1 (SULT1A1)
DMA2Z4F	MT	DME
DMA2Z4F	MA	Metabolism
DMA2Z4F	RN	Sulfation of minoxidil by multiple human cytosolic sulfotransferases. Chem Biol Interact. 1998 Feb 20;109(1-3):53-67.
DMA2Z4F	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9566733

DMA2Z4F	DI	DMA2Z4F
DMA2Z4F	DN	Minoxidil
DMA2Z4F	MI	DEYGVN4
DMA2Z4F	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMA2Z4F	MT	DME
DMA2Z4F	MA	Metabolism
DMA2Z4F	RN	Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Dispos. 2004 Apr;32(4):413-23.
DMA2Z4F	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15039294

DMGSRN1	DI	DMGSRN1
DMGSRN1	DN	Mipomersen
DMGSRN1	MI	TTN1IE2
DMGSRN1	MN	APOB messenger RNA (APOB mRNA)
DMGSRN1	MT	DTT
DMGSRN1	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DMGSRN1	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DMS1GYT	DI	DMS1GYT
DMS1GYT	DN	Mirabegron
DMS1GYT	MI	TTMXGCW
DMS1GYT	MN	Adrenergic receptor beta-3 (ADRB3)
DMS1GYT	MT	DTT
DMS1GYT	MA	Modulator
DMS1GYT	RN	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
DMS1GYT	RU	https://pubmed.ncbi.nlm.nih.gov/23370234

DMS1GYT	DI	DMS1GYT
DMS1GYT	DN	Mirabegron
DMS1GYT	MI	DECB0K3
DMS1GYT	MN	Cytochrome P450 2D6 (CYP2D6)
DMS1GYT	MT	DME
DMS1GYT	MA	Metabolism
DMS1GYT	RN	Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a beta-3-adrenoceptor agonist. Clin Drug Investig. 2013 Jun;33(6):429-40.
DMS1GYT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23625188

DMS1GYT	DI	DMS1GYT
DMS1GYT	DN	Mirabegron
DMS1GYT	MI	DE4LYSA
DMS1GYT	MN	Cytochrome P450 3A4 (CYP3A4)
DMS1GYT	MT	DME
DMS1GYT	MA	Metabolism
DMS1GYT	RN	Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a beta-3-adrenoceptor agonist. Clin Drug Investig. 2013 Jun;33(6):429-40.
DMS1GYT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23625188

DML53ZJ	DI	DML53ZJ
DML53ZJ	DN	Mirtazapine
DML53ZJ	MI	TTWJBZ5
DML53ZJ	MN	5-HT 2C receptor (HTR2C)
DML53ZJ	MT	DTT
DML53ZJ	MA	Antagonist
DML53ZJ	RN	Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulatio... Mol Pharmacol. 2008 Mar;73(3):748-57.
DML53ZJ	RU	https://pubmed.ncbi.nlm.nih.gov/18083778

DML53ZJ	DI	DML53ZJ
DML53ZJ	DN	Mirtazapine
DML53ZJ	MI	DEJGDUW
DML53ZJ	MN	Cytochrome P450 1A2 (CYP1A2)
DML53ZJ	MT	DME
DML53ZJ	MA	Metabolism
DML53ZJ	RN	Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. J Clin Psychopharmacol. 2004 Dec;24(6):647-52.
DML53ZJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15538128

DML53ZJ	DI	DML53ZJ
DML53ZJ	DN	Mirtazapine
DML53ZJ	MI	DES5XRU
DML53ZJ	MN	Cytochrome P450 2C8 (CYP2C8)
DML53ZJ	MT	DME
DML53ZJ	MA	Metabolism
DML53ZJ	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DML53ZJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DML53ZJ	DI	DML53ZJ
DML53ZJ	DN	Mirtazapine
DML53ZJ	MI	DE5IED8
DML53ZJ	MN	Cytochrome P450 2C9 (CYP2C9)
DML53ZJ	MT	DME
DML53ZJ	MA	Metabolism
DML53ZJ	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DML53ZJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DML53ZJ	DI	DML53ZJ
DML53ZJ	DN	Mirtazapine
DML53ZJ	MI	DECB0K3
DML53ZJ	MN	Cytochrome P450 2D6 (CYP2D6)
DML53ZJ	MT	DME
DML53ZJ	MA	Metabolism
DML53ZJ	RN	A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64.
DML53ZJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11607047

DML53ZJ	DI	DML53ZJ
DML53ZJ	DN	Mirtazapine
DML53ZJ	MI	DE4LYSA
DML53ZJ	MN	Cytochrome P450 3A4 (CYP3A4)
DML53ZJ	MT	DME
DML53ZJ	MA	Metabolism
DML53ZJ	RN	A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64.
DML53ZJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11607047

DMHVJFK	DI	DMHVJFK
DMHVJFK	DN	Misoprostol
DMHVJFK	MI	TTOFYT1
DMHVJFK	MN	Prostacyclin receptor (PTGIR)
DMHVJFK	MT	DTT
DMHVJFK	MA	Antagonist
DMHVJFK	RN	Palmitoylation of the human prostacyclin receptor. Functional implications of palmitoylation and isoprenylation. J Biol Chem. 2003 Feb 28;278(9):6947-58.
DMHVJFK	RU	https://pubmed.ncbi.nlm.nih.gov/12488443

DMP8HEL	DI	DMP8HEL
DMP8HEL	DN	Mitiglinide
DMP8HEL	MI	TTG140O
DMP8HEL	MN	Inward rectifier potassium channel Kir1.2 (KCNJ10)
DMP8HEL	MT	DTT
DMP8HEL	MA	Blocker
DMP8HEL	RN	Carboxyl-glucuronidation of mitiglinide by human UDP-glucuronosyltransferases. Biochem Pharmacol. 2007 Jun 1;73(11):1842-51.
DMP8HEL	RU	https://pubmed.ncbi.nlm.nih.gov/17359941

DMP8HEL	DI	DMP8HEL
DMP8HEL	DN	Mitiglinide
DMP8HEL	MI	DEF2WXN
DMP8HEL	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMP8HEL	MT	DME
DMP8HEL	MA	Metabolism
DMP8HEL	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMP8HEL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMH0ZJE	DI	DMH0ZJE
DMH0ZJE	DN	Mitomycin
DMH0ZJE	MI	TTUTN1I
DMH0ZJE	MN	Human Deoxyribonucleic acid (hDNA)
DMH0ZJE	MT	DTT
DMH0ZJE	MA	Binder
DMH0ZJE	RN	Assessment of cell viability, lipid peroxidation and quantification of DNA fragmentation after the treatment of anticancerous drug mitomycin C and ... Exp Toxicol Pathol. 2010 Sep;62(5):503-8.
DMH0ZJE	RU	https://pubmed.ncbi.nlm.nih.gov/19608391

DMH0ZJE	DI	DMH0ZJE
DMH0ZJE	DN	Mitomycin
DMH0ZJE	MI	DTUGYRD
DMH0ZJE	MN	P-glycoprotein 1 (ABCB1)
DMH0ZJE	MT	DTP
DMH0ZJE	MA	Substrate
DMH0ZJE	RN	In vivo expansion of MDR1-transduced cells accompanied by a post-transplantation chemotherapy regimen with mitomycin C and methotrexate. J Gene Med. 2010 Jul;12(7):596-603.
DMH0ZJE	RU	http://www.ncbi.nlm.nih.gov/pubmed/20533531

DM4PF81	DI	DM4PF81
DM4PF81	DN	Mitomycin A
DM4PF81	MI	TTUTN1I
DM4PF81	MN	Human Deoxyribonucleic acid (hDNA)
DM4PF81	MT	DTT
DM4PF81	RN	Selective activation of mitomycin A by thiols to form DNA cross-links and monoadducts: biochemical basis for the modulation of mitomycin cytotoxicity by the quinone redox potential. J Med Chem. 2001 Aug 16;44(17):2834-42.
DM4PF81	RU	https://pubmed.ncbi.nlm.nih.gov/11495594

DMU1GX0	DI	DMU1GX0
DMU1GX0	DN	Mitotane
DMU1GX0	MI	TTZAYWL
DMU1GX0	MN	Estrogen receptor (ESR)
DMU1GX0	MT	DTT
DMU1GX0	MA	Binder
DMU1GX0	RN	Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs. 2005 Apr;6(4):386-94.
DMU1GX0	RU	https://pubmed.ncbi.nlm.nih.gov/15898346

DMM39BF	DI	DMM39BF
DMM39BF	DN	Mitoxantrone
DMM39BF	MI	DT2T6VQ
DMM39BF	MN	ATP-binding cassette sub-family A member 3 (ABCA3)
DMM39BF	MT	DTP
DMM39BF	MA	Substrate
DMM39BF	RN	A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33.
DMM39BF	RU	http://www.ncbi.nlm.nih.gov/pubmed/15381773

DMM39BF	DI	DMM39BF
DMM39BF	DN	Mitoxantrone
DMM39BF	MI	DTI7UX6
DMM39BF	MN	Breast cancer resistance protein (ABCG2)
DMM39BF	MT	DTP
DMM39BF	MA	Substrate
DMM39BF	RN	Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun. 2001 Jul 6;285(1):111-7.
DMM39BF	RU	http://www.ncbi.nlm.nih.gov/pubmed/11437380

DMM39BF	DI	DMM39BF
DMM39BF	DN	Mitoxantrone
DMM39BF	MI	DEVDYN7
DMM39BF	MN	Cytochrome P450 2E1 (CYP2E1)
DMM39BF	MT	DME
DMM39BF	MA	Metabolism
DMM39BF	RN	FDA label of Mitoxantrone. The 2020 official website of the U.S. Food and Drug Administration.
DMM39BF	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019297s035lbl.pdf

DMM39BF	DI	DMM39BF
DMM39BF	DN	Mitoxantrone
DMM39BF	MI	TT0IHXV
DMM39BF	MN	DNA topoisomerase II (TOP2)
DMM39BF	MT	DTT
DMM39BF	MA	Modulator
DMM39BF	RN	Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6.
DMM39BF	RU	https://pubmed.ncbi.nlm.nih.gov/9450803

DMM39BF	DI	DMM39BF
DMM39BF	DN	Mitoxantrone
DMM39BF	MI	DTSYQGK
DMM39BF	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMM39BF	MT	DTP
DMM39BF	MA	Substrate
DMM39BF	RN	Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux. Mol Pharmacol. 2006 Apr;69(4):1499-505.
DMM39BF	RU	https://doi.org/10.1124/mol.105.017988

DMM39BF	DI	DMM39BF
DMM39BF	DN	Mitoxantrone
DMM39BF	MI	DTFI42L
DMM39BF	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMM39BF	MT	DTP
DMM39BF	MA	Substrate
DMM39BF	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMM39BF	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMM39BF	DI	DMM39BF
DMM39BF	DN	Mitoxantrone
DMM39BF	MI	DTUGYRD
DMM39BF	MN	P-glycoprotein 1 (ABCB1)
DMM39BF	MT	DTP
DMM39BF	MA	Substrate
DMM39BF	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMM39BF	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DM473VD	DI	DM473VD
DM473VD	DN	Mivacurium
DM473VD	MI	TTF4E0J
DM473VD	MN	Neuronal acetylcholine receptor alpha-2 (CHRNA2)
DM473VD	MT	DTT
DM473VD	MA	Antagonist
DM473VD	RN	Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52.
DM473VD	RU	https://pubmed.ncbi.nlm.nih.gov/19417616

DM1FDN8	DI	DM1FDN8
DM1FDN8	DN	Mizolastine
DM1FDN8	MI	TTTIBOJ
DM1FDN8	MN	Histamine H1 receptor (H1R)
DM1FDN8	MT	DTT
DM1FDN8	MA	Antagonist
DM1FDN8	RN	Histamine H1-receptor antagonists inhibit nuclear factor-kappaB and activator protein-1 activities via H1-receptor-dependent and -independent mechanisms. Clin Exp Allergy. 2008 Jun;38(6):947-56.
DM1FDN8	RU	https://pubmed.ncbi.nlm.nih.gov/18498541

DMW6F0S	DI	DMW6F0S
DMW6F0S	DN	Mizoribine
DMW6F0S	MI	TTL7C8Q
DMW6F0S	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMW6F0S	MT	DTT
DMW6F0S	MA	Inhibitor
DMW6F0S	RN	VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent. J Pharm Sci. 2001 May;90(5):625-37.
DMW6F0S	RU	https://pubmed.ncbi.nlm.nih.gov/11288107

DM215WE	DI	DM215WE
DM215WE	DN	MK-1439
DM215WE	MI	DE4LYSA
DM215WE	MN	Cytochrome P450 3A4 (CYP3A4)
DM215WE	MT	DME
DM215WE	MA	Metabolism
DM215WE	RN	Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans. Xenobiotica. 2019 Apr;49(4):422-432.
DM215WE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29557716

DM215WE	DI	DM215WE
DM215WE	DN	MK-1439
DM215WE	MI	DEIBDNY
DM215WE	MN	Cytochrome P450 3A5 (CYP3A5)
DM215WE	MT	DME
DM215WE	MA	Metabolism
DM215WE	RN	Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans. Xenobiotica. 2019 Apr;49(4):422-432.
DM215WE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29557716

DM215WE	DI	DM215WE
DM215WE	DN	MK-1439
DM215WE	MI	TT84ETX
DM215WE	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM215WE	MT	DTT
DM215WE	MA	Inhibitor
DM215WE	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DM215WE	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMBYNW0	DI	DMBYNW0
DMBYNW0	DN	MK-3475
DMBYNW0	MI	TTNBFWK
DMBYNW0	MN	Programmed cell death protein 1 (PD-1)
DMBYNW0	MT	DTT
DMBYNW0	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMBYNW0	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMOB58Q	DI	DMOB58Q
DMOB58Q	DN	MK-8228
DMOB58Q	MI	TTZHSBO
DMOB58Q	MN	Cytomegalovirus Terminase (CMV TRM)
DMOB58Q	MT	DTT
DMOB58Q	MA	Inhibitor
DMOB58Q	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DMOB58Q	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DMOB58Q	DI	DMOB58Q
DMOB58Q	DN	MK-8228
DMOB58Q	MI	TTOGPL1
DMOB58Q	MN	Cytomegalovirus Terminase UL56 (CMV TRM1)
DMOB58Q	MT	DTT
DMOB58Q	MA	Inhibitor
DMOB58Q	RN	The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol. 2011 Oct;85(20):10884-93.
DMOB58Q	RU	https://pubmed.ncbi.nlm.nih.gov/21752907

DMOB58Q	DI	DMOB58Q
DMOB58Q	DN	MK-8228
DMOB58Q	MI	DEYGVN4
DMOB58Q	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMOB58Q	MT	DME
DMOB58Q	MA	Metabolism
DMOB58Q	RN	Pharmacogenetic analysis of OATP1B1, UGT1A1, and BCRP variants in relation to the pharmacokinetics of letermovir in previously conducted clinical studies. J Clin Pharmacol. 2019 Sep;59(9):1236-1243.
DMOB58Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31022310

DMP2LZ8	DI	DMP2LZ8
DMP2LZ8	DN	MLN0002
DMP2LZ8	MI	TT7ZMI1
DMP2LZ8	MN	Integrin alpha-4/beta-7 (ITGA4/B7)
DMP2LZ8	MT	DTT
DMP2LZ8	MA	Modulator
DMP2LZ8	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMP2LZ8	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMCMETN	DI	DMCMETN
DMCMETN	DN	MLN9708
DMCMETN	MI	DEJGDUW
DMCMETN	MN	Cytochrome P450 1A2 (CYP1A2)
DMCMETN	MT	DME
DMCMETN	MA	Metabolism
DMCMETN	RN	Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J. 2018 Jul 30;8(8):70.
DMCMETN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30061664

DMCMETN	DI	DMCMETN
DMCMETN	DN	MLN9708
DMCMETN	MI	DEPKLMQ
DMCMETN	MN	Cytochrome P450 2B6 (CYP2B6)
DMCMETN	MT	DME
DMCMETN	MA	Metabolism
DMCMETN	RN	NINLARO- European Medicines Agency - European Union
DMCMETN	RU	https://www.ema.europa.eu/en/documents/product-information/ninlaro-epar-product-information_en.pdf

DMCMETN	DI	DMCMETN
DMCMETN	DN	MLN9708
DMCMETN	MI	DES5XRU
DMCMETN	MN	Cytochrome P450 2C8 (CYP2C8)
DMCMETN	MT	DME
DMCMETN	MA	Metabolism
DMCMETN	RN	Ninlaro- European Medicines Agency - European Union
DMCMETN	RU	https://www.ema.europa.eu/en/documents/product-information/ninlaro-epar-product-information_en.pdf

DMCMETN	DI	DMCMETN
DMCMETN	DN	MLN9708
DMCMETN	MI	TTU7ZMG
DMCMETN	MN	Proteasome (PS)
DMCMETN	MT	DTT
DMCMETN	MA	Modulator
DMCMETN	RN	Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 2010 Mar 1;70(5):1970-80.
DMCMETN	RU	https://pubmed.ncbi.nlm.nih.gov/20160034

DMNZWL7	DI	DMNZWL7
DMNZWL7	DN	Moclobemide
DMNZWL7	MI	DE5IED8
DMNZWL7	MN	Cytochrome P450 2C9 (CYP2C9)
DMNZWL7	MT	DME
DMNZWL7	MA	Metabolism
DMNZWL7	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMNZWL7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMNZWL7	DI	DMNZWL7
DMNZWL7	DN	Moclobemide
DMNZWL7	MI	DECB0K3
DMNZWL7	MN	Cytochrome P450 2D6 (CYP2D6)
DMNZWL7	MT	DME
DMNZWL7	MA	Metabolism
DMNZWL7	RN	Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin Pharmacol Ther. 1995 Jun;57(6):670-7.
DMNZWL7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7781267

DMNZWL7	DI	DMNZWL7
DMNZWL7	DN	Moclobemide
DMNZWL7	MI	DEGTFWK
DMNZWL7	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMNZWL7	MT	DME
DMNZWL7	MA	Metabolism
DMNZWL7	RN	Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19. Clin Pharmacol Ther. 2001 Apr;69(4):266-73.
DMNZWL7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11309556

DMNZWL7	DI	DMNZWL7
DMNZWL7	DN	Moclobemide
DMNZWL7	MI	TT32XQJ
DMNZWL7	MN	Monoamine oxidase (MAO)
DMNZWL7	MT	DTT
DMNZWL7	MA	Inhibitor
DMNZWL7	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMNZWL7	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMNZWL7	DI	DMNZWL7
DMNZWL7	DN	Moclobemide
DMNZWL7	MI	TT3WG5C
DMNZWL7	MN	Monoamine oxidase type A (MAO-A)
DMNZWL7	MT	DTT
DMNZWL7	MA	Inhibitor
DMNZWL7	RN	Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. Hum Psychopharmacol. 2002 Dec;17(8):401-5.
DMNZWL7	RU	https://pubmed.ncbi.nlm.nih.gov/12457375

DMYILBE	DI	DMYILBE
DMYILBE	DN	Modafinil
DMYILBE	MI	DE4LYSA
DMYILBE	MN	Cytochrome P450 3A4 (CYP3A4)
DMYILBE	MT	DME
DMYILBE	MA	Metabolism
DMYILBE	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMYILBE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMYILBE	DI	DMYILBE
DMYILBE	DN	Modafinil
DMYILBE	MI	TTVBI8W
DMYILBE	MN	Dopamine transporter (DAT)
DMYILBE	MT	DTT
DMYILBE	MA	Modulator
DMYILBE	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMYILBE	RU	https://www.fda.gov/

DM26E4B	DI	DM26E4B
DM26E4B	DN	Moexipril
DM26E4B	MI	TTL69WB
DM26E4B	MN	Angiotensin-converting enzyme (ACE)
DM26E4B	MT	DTT
DM26E4B	MA	Inhibitor
DM26E4B	RN	Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. Dig Dis Sci. 2010 Feb;55(2):476-83.
DM26E4B	RU	https://pubmed.ncbi.nlm.nih.gov/19255851

DM26E4B	DI	DM26E4B
DM26E4B	DN	Moexipril
DM26E4B	MI	DT9G7XN
DM26E4B	MN	Peptide transporter 1 (SLC15A1)
DM26E4B	MT	DTP
DM26E4B	MA	Substrate
DM26E4B	RN	Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41.
DM26E4B	RU	http://www.ncbi.nlm.nih.gov/pubmed/18713951

DM26E4B	DI	DM26E4B
DM26E4B	DN	Moexipril
DM26E4B	MI	DT8QKNP
DM26E4B	MN	Peptide transporter 2 (SLC15A2)
DM26E4B	MT	DTP
DM26E4B	MA	Substrate
DM26E4B	RN	Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41.
DM26E4B	RU	http://www.ncbi.nlm.nih.gov/pubmed/18713951

DMISH0Z	DI	DMISH0Z
DMISH0Z	DN	Mogamulizumab
DMISH0Z	MI	TT7HQD0
DMISH0Z	MN	C-C chemokine receptor type 4 (CCR4)
DMISH0Z	MT	DTT
DMISH0Z	MA	Inhibitor
DMISH0Z	RN	Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma. Curr Opin Mol Ther. 2010 Dec;12(6):770-9.
DMISH0Z	RU	https://pubmed.ncbi.nlm.nih.gov/21154168

DMAH70G	DI	DMAH70G
DMAH70G	DN	Molindone
DMAH70G	MI	TTEX248
DMAH70G	MN	Dopamine D2 receptor (D2R)
DMAH70G	MT	DTT
DMAH70G	MA	Binder
DMAH70G	RN	Molindone for schizophrenia and severe mental illness. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD002083.
DMAH70G	RU	https://pubmed.ncbi.nlm.nih.gov/17253473

DM9MA8O	DI	DM9MA8O
DM9MA8O	DN	Molsidomine
DM9MA8O	MI	DE37ABY
DM9MA8O	MN	Phosphodiesterase 5A (PDE5A)
DM9MA8O	MT	DME
DM9MA8O	MA	Metabolism
DM9MA8O	RN	DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (id: DB09282)
DM9MA8O	RU	https://www.drugbank.ca/drugs/DB09282

DM45OJN	DI	DM45OJN
DM45OJN	DN	Mometasone
DM45OJN	MI	DE4LYSA
DM45OJN	MN	Cytochrome P450 3A4 (CYP3A4)
DM45OJN	MT	DME
DM45OJN	MA	Metabolism
DM45OJN	RN	Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35.
DM45OJN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20482443

DM45OJN	DI	DM45OJN
DM45OJN	DN	Mometasone
DM45OJN	MI	TTYRL6O
DM45OJN	MN	Glucocorticoid receptor (NR3C1)
DM45OJN	MT	DTT
DM45OJN	MA	Agonist
DM45OJN	RN	Mometasone furoate is a less specific glucocorticoid than fluticasone propionate. Eur Respir J. 2002 Dec;20(6):1386-92.
DM45OJN	RU	https://pubmed.ncbi.nlm.nih.gov/12503693

DMVJS2K	DI	DMVJS2K
DMVJS2K	DN	Monobenzone
DMVJS2K	MI	TTULVH8
DMVJS2K	MN	Tyrosinase (TYR)
DMVJS2K	MT	DTT
DMVJS2K	MA	Inhibitor
DMVJS2K	RN	Identification of an Alkylhydroquinone from Rhus succedanea as an Inhibitor of Tyrosinase and Melanogenesis. J Agric Food Chem. 2009 Mar 25;57(6):2200-5.
DMVJS2K	RU	https://pubmed.ncbi.nlm.nih.gov/19159217

DMD157S	DI	DMD157S
DMD157S	DN	Montelukast
DMD157S	MI	DEJVYAZ
DMD157S	MN	Cytochrome P450 2A6 (CYP2A6)
DMD157S	MT	DME
DMD157S	MA	Metabolism
DMD157S	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMD157S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMD157S	DI	DMD157S
DMD157S	DN	Montelukast
DMD157S	MI	DES5XRU
DMD157S	MN	Cytochrome P450 2C8 (CYP2C8)
DMD157S	MT	DME
DMD157S	MA	Metabolism
DMD157S	RN	Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid. J Biol Chem. 2008 Jun 20;283(25):17227-37.
DMD157S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18413310

DMD157S	DI	DMD157S
DMD157S	DN	Montelukast
DMD157S	MI	DE5IED8
DMD157S	MN	Cytochrome P450 2C9 (CYP2C9)
DMD157S	MT	DME
DMD157S	MA	Metabolism
DMD157S	RN	In vitro metabolism of montelukast by cytochrome P450s and UDP-glucuronosyltransferases. Drug Metab Dispos. 2015 Dec;43(12):1905-16.
DMD157S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26374173

DMD157S	DI	DMD157S
DMD157S	DN	Montelukast
DMD157S	MI	DE4LYSA
DMD157S	MN	Cytochrome P450 3A4 (CYP3A4)
DMD157S	MT	DME
DMD157S	MA	Metabolism
DMD157S	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMD157S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMD157S	DI	DMD157S
DMD157S	DN	Montelukast
DMD157S	MI	TTGKOY9
DMD157S	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DMD157S	MT	DTT
DMD157S	MA	Antagonist
DMD157S	RN	Protective potential of montelukast against hepatic ischemia/reperfusion injury in rats. J Surg Res. 2010 Mar;159(1):588-94.
DMD157S	RU	https://pubmed.ncbi.nlm.nih.gov/19515388

DMD157S	DI	DMD157S
DMD157S	DN	Montelukast
DMD157S	MI	DTE2B1D
DMD157S	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMD157S	MT	DTP
DMD157S	MA	Substrate
DMD157S	RN	Effect of citrus juice and SLCO2B1 genotype on the pharmacokinetics of montelukast. J Clin Pharmacol. 2011 May;51(5):751-60.
DMD157S	RU	http://www.ncbi.nlm.nih.gov/pubmed/20974993

DMD157S	DI	DMD157S
DMD157S	DN	Montelukast
DMD157S	MI	DTPFTEQ
DMD157S	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DMD157S	MT	DTP
DMD157S	MA	Substrate
DMD157S	RN	Effects of polymorphisms of the SLCO2B1 transporter gene on the pharmacokinetics of montelukast in humans. J Clin Pharmacol. 2013 Nov;53(11):1186-93.
DMD157S	RU	http://www.ncbi.nlm.nih.gov/pubmed/23970434

DM560Y3	DI	DM560Y3
DM560Y3	DN	Morantel tartrate
DM560Y3	MI	TTHDSE2
DM560Y3	MN	Bacterial Fumarate reductase flavoprotein (Bact frdA)
DM560Y3	MT	DTT
DM560Y3	MA	Inhibitor
DM560Y3	RN	Fumarate reductase is essential for Helicobacter pylori colonization of the mouse stomach. Microb Pathog. 2000 Nov;29(5):279-87.
DM560Y3	RU	https://pubmed.ncbi.nlm.nih.gov/11031122

DMOMBJW	DI	DMOMBJW
DMOMBJW	DN	Moricizine
DMOMBJW	MI	TTZOVE0
DMOMBJW	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DMOMBJW	MT	DTT
DMOMBJW	MA	Blocker
DMOMBJW	RN	From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials. Am J Cardiol. 1996 Aug 29;78(4A):28-33.
DMOMBJW	RU	https://pubmed.ncbi.nlm.nih.gov/8780326

DM9UTDE	DI	DM9UTDE
DM9UTDE	DN	Morniflumate
DM9UTDE	MI	TTK0943
DM9UTDE	MN	Prostaglandin G/H synthase (COX)
DM9UTDE	MT	DTT
DM9UTDE	MA	Modulator
DM9UTDE	RN	Modulation of arachidonic acid metabolism by orally administered morniflumate in man. Agents Actions. 1991 Jul;33(3-4):233-9.
DM9UTDE	RU	https://pubmed.ncbi.nlm.nih.gov/1659152

DMRMS0L	DI	DMRMS0L
DMRMS0L	DN	Morphine
DMRMS0L	MI	DES5XRU
DMRMS0L	MN	Cytochrome P450 2C8 (CYP2C8)
DMRMS0L	MT	DME
DMRMS0L	MA	Metabolism
DMRMS0L	RN	In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab Dispos. 2005 May;33(5):689-95.
DMRMS0L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15743975

DMRMS0L	DI	DMRMS0L
DMRMS0L	DN	Morphine
DMRMS0L	MI	DECB0K3
DMRMS0L	MN	Cytochrome P450 2D6 (CYP2D6)
DMRMS0L	MT	DME
DMRMS0L	MA	Metabolism
DMRMS0L	RN	Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors. J Pharmacol Exp Ther. 2004 Feb;308(2):547-54.
DMRMS0L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14600248

DMRMS0L	DI	DMRMS0L
DMRMS0L	DN	Morphine
DMRMS0L	MI	DE4LYSA
DMRMS0L	MN	Cytochrome P450 3A4 (CYP3A4)
DMRMS0L	MT	DME
DMRMS0L	MA	Metabolism
DMRMS0L	RN	Modulation of UDP-glucuronosyltransferase 2B7 function by cytochrome P450s in vitro: differential effects of CYP1A2, CYP2C9 and CYP3A4. Biol Pharm Bull. 2005 Oct;28(10):2026-7.
DMRMS0L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16204972

DMRMS0L	DI	DMRMS0L
DMRMS0L	DN	Morphine
DMRMS0L	MI	DTQ3ZHF
DMRMS0L	MN	Multidrug resistance-associated protein 3 (ABCC3)
DMRMS0L	MT	DTP
DMRMS0L	MA	Substrate
DMRMS0L	RN	Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch. 2007 Feb;453(5):661-73.
DMRMS0L	RU	http://www.ncbi.nlm.nih.gov/pubmed/16586096

DMRMS0L	DI	DMRMS0L
DMRMS0L	DN	Morphine
DMRMS0L	MI	TTKWM86
DMRMS0L	MN	Opioid receptor mu (MOP)
DMRMS0L	MT	DTT
DMRMS0L	MA	Modulator
DMRMS0L	RN	Antianalgesia: stereoselective action of dextro-morphine over levo-morphine on glia in the mouse spinal cord.J Pharmacol Exp Ther.2005 Sep;314(3):1101-8.
DMRMS0L	RU	https://www.ncbi.nlm.nih.gov/pubmed/15901793

DMRMS0L	DI	DMRMS0L
DMRMS0L	DN	Morphine
DMRMS0L	MI	DTUGYRD
DMRMS0L	MN	P-glycoprotein 1 (ABCB1)
DMRMS0L	MT	DTP
DMRMS0L	MA	Substrate
DMRMS0L	RN	Genetic variability and clinical efficacy of morphine. Acta Anaesthesiol Scand. 2005 Aug;49(7):902-8.
DMRMS0L	RU	http://www.ncbi.nlm.nih.gov/pubmed/16045647

DMRMS0L	DI	DMRMS0L
DMRMS0L	DN	Morphine
DMRMS0L	MI	DEYGVN4
DMRMS0L	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMRMS0L	MT	DME
DMRMS0L	MA	Metabolism
DMRMS0L	RN	Contribution of UDP-glucuronosyltransferase 1A1 and 1A8 to morphine-6-glucuronidation and its kinetic properties. Drug Metab Dispos. 2008 Apr;36(4):688-94.
DMRMS0L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18187562

DMRMS0L	DI	DMRMS0L
DMRMS0L	DN	Morphine
DMRMS0L	MI	DEF2WXN
DMRMS0L	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMRMS0L	MT	DME
DMRMS0L	MA	Metabolism
DMRMS0L	RN	Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metab Dispos. 1998 Jun;26(6):507-12.
DMRMS0L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9616184

DMRMS0L	DI	DMRMS0L
DMRMS0L	DN	Morphine
DMRMS0L	MI	DEB3CV1
DMRMS0L	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMRMS0L	MT	DME
DMRMS0L	MA	Metabolism
DMRMS0L	RN	Molecular cloning of the baboon UDP-glucuronosyltransferase 2B gene family and their activity in conjugating morphine. Drug Metab Dispos. 2010 Apr;38(4):545-53.
DMRMS0L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20071451

DMEJKRF	DI	DMEJKRF
DMEJKRF	DN	Motexafin gadolinium
DMEJKRF	MI	TTLPJWH
DMEJKRF	MN	Thioredoxin reductase (PRDX5)
DMEJKRF	MT	DTT
DMEJKRF	MA	Modulator
DMEJKRF	RN	Mechanism of inhibition of ribonucleotide reductase with motexafin gadolinium (MGd). Biochem Biophys Res Commun. 2009 Feb 13;379(3):775-9.
DMEJKRF	RU	https://pubmed.ncbi.nlm.nih.gov/19121624

DMYKUNR	DI	DMYKUNR
DMYKUNR	DN	Moxalactam Disodium
DMYKUNR	MI	TT85JMW
DMYKUNR	MN	Bacterial Penicillin binding protein 3 (Bact mrcA)
DMYKUNR	MT	DTT
DMYKUNR	MA	Modulator
DMYKUNR	RN	Moxalactam (6059-S), a new 1-oxa-beta-lactam: binding affinity for penicillin-binding proteins of Escherichia coli K-12.
DMYKUNR	RU	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC283783 

DMN63DZ	DI	DMN63DZ
DMN63DZ	DN	Moxetumomab pasudotox
DMN63DZ	MI	TTM6QSK
DMN63DZ	MN	B-cell receptor CD22 (CD22)
DMN63DZ	MT	DTT
DMN63DZ	MA	Modulator
DMN63DZ	RN	Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res. 2011 Oct 15;17(20):6398-405.
DMN63DZ	RU	https://pubmed.ncbi.nlm.nih.gov/22003067

DMYGHX5	DI	DMYGHX5
DMYGHX5	DN	Moxidectin 
DMYGHX5	MI	TTNJYV2
DMYGHX5	MN	Gamma-aminobutyric acid receptor (GAR)
DMYGHX5	MT	DTT
DMYGHX5	MA	Modulator
DMYGHX5	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMYGHX5	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMYGHX5	DI	DMYGHX5
DMYGHX5	DN	Moxidectin 
DMYGHX5	MI	TTSNVHO
DMYGHX5	MN	Onchocerca Glutamate-gated chloride channel (Onchoc GluCl)
DMYGHX5	MT	DTT
DMYGHX5	MA	Modulator
DMYGHX5	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMYGHX5	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMU8V4S	DI	DMU8V4S
DMU8V4S	DN	Moxifloxacin
DMU8V4S	MI	TTN6J5F
DMU8V4S	MN	Bacterial DNA gyrase (Bact gyrase)
DMU8V4S	MT	DTT
DMU8V4S	MA	Modulator
DMU8V4S	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMU8V4S	RU	https://www.fda.gov/

DMU8V4S	DI	DMU8V4S
DMU8V4S	DN	Moxifloxacin
DMU8V4S	MI	TTIXTO3
DMU8V4S	MN	Staphylococcus Topoisomerase IV (Stap-coc parC)
DMU8V4S	MT	DTT
DMU8V4S	MA	Modulator
DMU8V4S	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMU8V4S	RU	https://www.fda.gov/

DMFCLYW	DI	DMFCLYW
DMFCLYW	DN	Moxisylyte
DMFCLYW	MI	TT34BHT
DMFCLYW	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMFCLYW	MT	DTT
DMFCLYW	MA	Modulator
DMFCLYW	RN	Pharmacokinetics of moxisylyte in healthy volunteers after intracavernous injection of increasing doses. Eur J Clin Pharmacol. 1996;49(5):411-5.
DMFCLYW	RU	https://pubmed.ncbi.nlm.nih.gov/8866639

DMGFB0E	DI	DMGFB0E
DMGFB0E	DN	MOXONIDINE
DMGFB0E	MI	TTWG9A4
DMGFB0E	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMGFB0E	MT	DTT
DMGFB0E	MA	Inhibitor
DMGFB0E	RN	Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996 Mar 15;39(6):1193-5.
DMGFB0E	RU	https://pubmed.ncbi.nlm.nih.gov/8632424

DMGFB0E	DI	DMGFB0E
DMGFB0E	DN	MOXONIDINE
DMGFB0E	MI	TTWM4TY
DMGFB0E	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMGFB0E	MT	DTT
DMGFB0E	MA	Inhibitor
DMGFB0E	RN	Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996 Mar 15;39(6):1193-5.
DMGFB0E	RU	https://pubmed.ncbi.nlm.nih.gov/8632424

DMGFB0E	DI	DMGFB0E
DMGFB0E	DN	MOXONIDINE
DMGFB0E	MI	TT2NUT5
DMGFB0E	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMGFB0E	MT	DTT
DMGFB0E	MA	Inhibitor
DMGFB0E	RN	Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996 Mar 15;39(6):1193-5.
DMGFB0E	RU	https://pubmed.ncbi.nlm.nih.gov/8632424

DMZ905C	DI	DMZ905C
DMZ905C	DN	Mozavaptan
DMZ905C	MI	TTPFZJ1
DMZ905C	MN	Vasopressin V1 receptor (V1R)
DMZ905C	MT	DTT
DMZ905C	MA	Antagonist
DMZ905C	RN	Vasopressin (ADH). Nippon Rinsho. 1992 Dec;50(12):2893-900.
DMZ905C	RU	https://pubmed.ncbi.nlm.nih.gov/1337114

DMZ905C	DI	DMZ905C
DMZ905C	DN	Mozavaptan
DMZ905C	MI	TT4TFGN
DMZ905C	MN	Vasopressin V1a receptor (V1AR)
DMZ905C	MT	DTT
DMZ905C	MA	Inhibitor
DMZ905C	RN	Nonpeptide vasopressin antagonists: a new group of hormone blockers entering the scene. Exp Clin Endocrinol Diabetes. 1999;107(3):157-65.
DMZ905C	RU	https://pubmed.ncbi.nlm.nih.gov/10376439

DMZ905C	DI	DMZ905C
DMZ905C	DN	Mozavaptan
DMZ905C	MI	TTL9MHW
DMZ905C	MN	Vasopressin V1b receptor (V1BR)
DMZ905C	MT	DTT
DMZ905C	MA	Inhibitor
DMZ905C	RN	New analgesic drugs derived from phencyclidine. J Med Chem. 1981 May;24(5):496-9.
DMZ905C	RU	https://pubmed.ncbi.nlm.nih.gov/7241506

DMZ905C	DI	DMZ905C
DMZ905C	DN	Mozavaptan
DMZ905C	MI	TTK8R02
DMZ905C	MN	Vasopressin V2 receptor (V2R)
DMZ905C	MT	DTT
DMZ905C	MA	Inhibitor
DMZ905C	RN	Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res. 2002;139:197-210.
DMZ905C	RU	https://pubmed.ncbi.nlm.nih.gov/12436936

DMWX683	DI	DMWX683
DMWX683	DN	Mupirocin
DMWX683	MI	TT6KYJ5
DMWX683	MN	Bacterial Isoleucyl-tRNA synthetase (Bact ileS)
DMWX683	MT	DTT
DMWX683	MA	Modulator
DMWX683	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMWX683	RU	https://www.fda.gov/

DM8ANCF	DI	DM8ANCF
DM8ANCF	DN	Muromonab
DM8ANCF	MI	TTZAT79
DM8ANCF	MN	T-cell surface glycoprotein CD3 epsilon (CD3E)
DM8ANCF	MT	DTT
DM8ANCF	MA	Binder
DM8ANCF	RN	Basiliximab: a review of its use as induction therapy in renal transplantation. Drugs. 2003;63(24):2803-35.
DM8ANCF	RU	https://pubmed.ncbi.nlm.nih.gov/14664658

DMPQAGE	DI	DMPQAGE
DMPQAGE	DN	Mycophenolate mofetil
DMPQAGE	MI	DTI7UX6
DMPQAGE	MN	Breast cancer resistance protein (ABCG2)
DMPQAGE	MT	DTP
DMPQAGE	MA	Substrate
DMPQAGE	RN	Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther Drug Monit. 2008 Oct;30(5):559-64.
DMPQAGE	RU	http://www.ncbi.nlm.nih.gov/pubmed/18695635

DMPQAGE	DI	DMPQAGE
DMPQAGE	DN	Mycophenolate mofetil
DMPQAGE	MI	DES5XRU
DMPQAGE	MN	Cytochrome P450 2C8 (CYP2C8)
DMPQAGE	MT	DME
DMPQAGE	MA	Metabolism
DMPQAGE	RN	PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
DMPQAGE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24220207

DMPQAGE	DI	DMPQAGE
DMPQAGE	DN	Mycophenolate mofetil
DMPQAGE	MI	DE4LYSA
DMPQAGE	MN	Cytochrome P450 3A4 (CYP3A4)
DMPQAGE	MT	DME
DMPQAGE	MA	Metabolism
DMPQAGE	RN	PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
DMPQAGE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24220207

DMPQAGE	DI	DMPQAGE
DMPQAGE	DN	Mycophenolate mofetil
DMPQAGE	MI	DEIBDNY
DMPQAGE	MN	Cytochrome P450 3A5 (CYP3A5)
DMPQAGE	MT	DME
DMPQAGE	MA	Metabolism
DMPQAGE	RN	PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
DMPQAGE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24220207

DMPQAGE	DI	DMPQAGE
DMPQAGE	DN	Mycophenolate mofetil
DMPQAGE	MI	TTTB4UP
DMPQAGE	MN	Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2)
DMPQAGE	MT	DTT
DMPQAGE	MA	Inhibitor
DMPQAGE	RN	Clinical pipeline report, company report or official report of Roche (2009).
DMPQAGE	RU	http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm

DMPQAGE	DI	DMPQAGE
DMPQAGE	DN	Mycophenolate mofetil
DMPQAGE	MI	DTFI42L
DMPQAGE	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMPQAGE	MT	DTP
DMPQAGE	MA	Substrate
DMPQAGE	RN	Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
DMPQAGE	RU	http://www.ncbi.nlm.nih.gov/pubmed/17906856

DMPQAGE	DI	DMPQAGE
DMPQAGE	DN	Mycophenolate mofetil
DMPQAGE	MI	DT3D8F0
DMPQAGE	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMPQAGE	MT	DTP
DMPQAGE	MA	Substrate
DMPQAGE	RN	Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
DMPQAGE	RU	http://www.ncbi.nlm.nih.gov/pubmed/17906856

DMPQAGE	DI	DMPQAGE
DMPQAGE	DN	Mycophenolate mofetil
DMPQAGE	MI	DT9C1TS
DMPQAGE	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMPQAGE	MT	DTP
DMPQAGE	MA	Substrate
DMPQAGE	RN	Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
DMPQAGE	RU	http://www.ncbi.nlm.nih.gov/pubmed/17906856

DMPQAGE	DI	DMPQAGE
DMPQAGE	DN	Mycophenolate mofetil
DMPQAGE	MI	DTUGYRD
DMPQAGE	MN	P-glycoprotein 1 (ABCB1)
DMPQAGE	MT	DTP
DMPQAGE	MA	Substrate
DMPQAGE	RN	Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther Drug Monit. 2008 Oct;30(5):559-64.
DMPQAGE	RU	http://www.ncbi.nlm.nih.gov/pubmed/18695635

DMPQAGE	DI	DMPQAGE
DMPQAGE	DN	Mycophenolate mofetil
DMPQAGE	MI	TT1ZAVI
DMPQAGE	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DMPQAGE	MT	DTT
DMPQAGE	MA	Modulator
DMPQAGE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 341).
DMPQAGE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=341

DMPQAGE	DI	DMPQAGE
DMPQAGE	DN	Mycophenolate mofetil
DMPQAGE	MI	DEYGVN4
DMPQAGE	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMPQAGE	MT	DME
DMPQAGE	MA	Metabolism
DMPQAGE	RN	Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
DMPQAGE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16790558

DMPQAGE	DI	DMPQAGE
DMPQAGE	DN	Mycophenolate mofetil
DMPQAGE	MI	DEL5N6Y
DMPQAGE	MN	UDP-glucuronosyltransferase 1A10 (UGT1A10)
DMPQAGE	MT	DME
DMPQAGE	MA	Metabolism
DMPQAGE	RN	[Pharmacology of mycophenolate mofetil: recent data and clinical consequences]. Nephrologie. 2001;22(7):331-7.
DMPQAGE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11817210

DMPQAGE	DI	DMPQAGE
DMPQAGE	DN	Mycophenolate mofetil
DMPQAGE	MI	DESD26P
DMPQAGE	MN	UDP-glucuronosyltransferase 1A6 (UGT1A6)
DMPQAGE	MT	DME
DMPQAGE	MA	Metabolism
DMPQAGE	RN	Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
DMPQAGE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16790558

DMPQAGE	DI	DMPQAGE
DMPQAGE	DN	Mycophenolate mofetil
DMPQAGE	MI	DE85D2P
DMPQAGE	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMPQAGE	MT	DME
DMPQAGE	MA	Metabolism
DMPQAGE	RN	The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011 Jan;50(1):1-24.
DMPQAGE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21142265

DMPQAGE	DI	DMPQAGE
DMPQAGE	DN	Mycophenolate mofetil
DMPQAGE	MI	DEB3CV1
DMPQAGE	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMPQAGE	MT	DME
DMPQAGE	MA	Metabolism
DMPQAGE	RN	PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
DMPQAGE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24220207

DMYTN18	DI	DMYTN18
DMYTN18	DN	Mycophenolic acid
DMYTN18	MI	DTFI42L
DMYTN18	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMYTN18	MT	DTP
DMYTN18	MA	Substrate
DMYTN18	RN	C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics. 2007 Sep;8(9):1127-41.
DMYTN18	RU	http://www.ncbi.nlm.nih.gov/pubmed/17924828

DMYTN18	DI	DMYTN18
DMYTN18	DN	Mycophenolic acid
DMYTN18	MI	DTQ23VB
DMYTN18	MN	Organic anion transporter 1 (SLC22A6)
DMYTN18	MT	DTP
DMYTN18	MA	Substrate
DMYTN18	RN	Interaction and transport characteristics of mycophenolic acid and its glucuronide via human organic anion transporters hOAT1 and hOAT3. Biochem Pharmacol. 2007 Jun 30;74(1):161-8.
DMYTN18	RU	http://www.ncbi.nlm.nih.gov/pubmed/17462604

DMRBMAU	DI	DMRBMAU
DMRBMAU	DN	Mycophenolic acid
DMRBMAU	MI	DE85D2P
DMRBMAU	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMRBMAU	MT	DME
DMRBMAU	MA	Metabolism
DMRBMAU	RN	Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite. Drug Metab Dispos. 2011 Mar;39(3):448-55.
DMRBMAU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21123165

DMRBMAU	DI	DMRBMAU
DMRBMAU	DN	Mycophenolic acid
DMRBMAU	MI	DEB3CV1
DMRBMAU	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMRBMAU	MT	DME
DMRBMAU	MA	Metabolism
DMRBMAU	RN	Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite. Drug Metab Dispos. 2011 Mar;39(3):448-55.
DMRBMAU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21123165

DMSOAJ2	DI	DMSOAJ2
DMSOAJ2	DN	N-0923
DMSOAJ2	MI	TTEX248
DMSOAJ2	MN	Dopamine D2 receptor (D2R)
DMSOAJ2	MT	DTT
DMSOAJ2	MA	Agonist
DMSOAJ2	RN	Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42.
DMSOAJ2	RU	https://pubmed.ncbi.nlm.nih.gov/18991661

DMHJVOL	DI	DMHJVOL
DMHJVOL	DN	Nabi-HB
DMHJVOL	MI	TT6KSF7
DMHJVOL	MN	Hepatitis B virus Large envelope protein (HBV S)
DMHJVOL	MT	DTT
DMHJVOL	MA	Modulator
DMHJVOL	RN	Hepatitis B Immune Globulin (Human) Nabi-HB . US Food and Drug Administration report.
DMHJVOL	RU	http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm117658.pdf

DMVRYT2	DI	DMVRYT2
DMVRYT2	DN	Nabilone
DMVRYT2	MI	TT6OEDT
DMVRYT2	MN	Cannabinoid receptor 1 (CB1)
DMVRYT2	MT	DTT
DMVRYT2	MA	Inhibitor
DMVRYT2	RN	Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010.
DMVRYT2	RU	https://pubmed.ncbi.nlm.nih.gov/20925434

DMVRYT2	DI	DMVRYT2
DMVRYT2	DN	Nabilone
DMVRYT2	MI	TTMSFAW
DMVRYT2	MN	Cannabinoid receptor 2 (CB2)
DMVRYT2	MT	DTT
DMVRYT2	MA	Inhibitor
DMVRYT2	RN	Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010.
DMVRYT2	RU	https://pubmed.ncbi.nlm.nih.gov/20925434

DMAT2XH	DI	DMAT2XH
DMAT2XH	DN	Nabumetone
DMAT2XH	MI	DE7P2FB
DMAT2XH	MN	Aldo-keto reductase 1C1 (AKR1C1)
DMAT2XH	MT	DME
DMAT2XH	MA	Metabolism
DMAT2XH	RN	Reductive metabolism of nabumetone by human liver microsomal and cytosolic fractions: exploratory prediction using inhibitors and substrates as marker probes. Eur J Drug Metab Pharmacokinet. 2015 Jun;40(2):127-35.
DMAT2XH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24659525

DMAT2XH	DI	DMAT2XH
DMAT2XH	DN	Nabumetone
DMAT2XH	MI	DEAJN47
DMAT2XH	MN	Aldo-keto reductase 1C4 (AKR1C4)
DMAT2XH	MT	DME
DMAT2XH	MA	Metabolism
DMAT2XH	RN	Reductive metabolism of nabumetone by human liver microsomal and cytosolic fractions: exploratory prediction using inhibitors and substrates as marker probes. Eur J Drug Metab Pharmacokinet. 2015 Jun;40(2):127-35.
DMAT2XH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24659525

DMAT2XH	DI	DMAT2XH
DMAT2XH	DN	Nabumetone
DMAT2XH	MI	DEZDRQO
DMAT2XH	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMAT2XH	MT	DME
DMAT2XH	MA	Metabolism
DMAT2XH	RN	Reductive metabolism of nabumetone by human liver microsomal and cytosolic fractions: exploratory prediction using inhibitors and substrates as marker probes. Eur J Drug Metab Pharmacokinet. 2015 Jun;40(2):127-35.
DMAT2XH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24659525

DMAT2XH	DI	DMAT2XH
DMAT2XH	DN	Nabumetone
DMAT2XH	MI	DEJGDUW
DMAT2XH	MN	Cytochrome P450 1A2 (CYP1A2)
DMAT2XH	MT	DME
DMAT2XH	MA	Metabolism
DMAT2XH	RN	A predominate role of CYP1A2 for the metabolism of nabumetone to the active metabolite, 6-methoxy-2-naphthylacetic acid, in human liver microsomes. Drug Metab Dispos. 2009 May;37(5):1017-24.
DMAT2XH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19204080

DMAT2XH	DI	DMAT2XH
DMAT2XH	DN	Nabumetone
DMAT2XH	MI	DE5IED8
DMAT2XH	MN	Cytochrome P450 2C9 (CYP2C9)
DMAT2XH	MT	DME
DMAT2XH	MA	Metabolism
DMAT2XH	RN	In vitro characterization of the cytochrome P450 isoforms involved in the metabolism of 6-methoxy-2-napthylacetic acid, an active metabolite of the prodrug nabumetone. Biol Pharm Bull. 2011;34(5):734-9.
DMAT2XH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21532165

DMAT2XH	DI	DMAT2XH
DMAT2XH	DN	Nabumetone
DMAT2XH	MI	TTVKILB
DMAT2XH	MN	Prostaglandin G/H synthase 2 (COX-2)
DMAT2XH	MT	DTT
DMAT2XH	MA	Inhibitor
DMAT2XH	RN	Renal effects of nabumetone, a COX-2 antagonist: impairment of function in isolated perfused rat kidneys contrasts with preserved renal function in vivo. Exp Nephrol. 2001;9(6):387-96.
DMAT2XH	RU	https://pubmed.ncbi.nlm.nih.gov/11701998

DM1XBWR	DI	DM1XBWR
DM1XBWR	DN	N-acetyl-D-glucosamine
DM1XBWR	MI	TTDM6HZ
DM1XBWR	MN	Alpha-N-acetylglucosaminidase (NAGLU)
DM1XBWR	MT	DTT
DM1XBWR	MA	Activator
DM1XBWR	RN	Development of bFGF-Chitosan Matrices and Their Interactions with Human Dermal Fibroblast Cells. J Biomater Sci Polym Ed. 2009;20(10):1335-51.
DM1XBWR	RU	https://pubmed.ncbi.nlm.nih.gov/19622275

DM1XBWR	DI	DM1XBWR
DM1XBWR	DN	N-acetyl-D-glucosamine
DM1XBWR	MI	DEROYHE
DM1XBWR	MN	N-acetyl-D-glucosamine 2-epimerase (AGE)
DM1XBWR	MT	DME
DM1XBWR	MA	Metabolism
DM1XBWR	RN	Production of N-acetyl-d-neuraminic acid by whole cells expressing Bacteroides thetaiotaomicron N-acetyl-d-glucosamine 2-epimerase and Escherichia coli N-acetyl-d-neuraminic acid aldolase. J Agric Food Chem. 2019 Jun 5;67(22):6285-6291.
DM1XBWR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31117501

DM5NM6E	DI	DM5NM6E
DM5NM6E	DN	NADH
DM5NM6E	MI	DEE5M8O
DM5NM6E	MN	Alcohol dehydrogenase class-I alpha (ADH1A)
DM5NM6E	MT	DME
DM5NM6E	MA	Metabolism
DM5NM6E	RN	Conformational changes and catalysis by alcohol dehydrogenase. Arch Biochem Biophys. 2010 Jan 1;493(1):3-12.
DM5NM6E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19583966

DM5NM6E	DI	DM5NM6E
DM5NM6E	DN	NADH
DM5NM6E	MI	DEEN9RD
DM5NM6E	MN	Alcohol dehydrogenase class-I beta (ADH1B)
DM5NM6E	MT	DME
DM5NM6E	MA	Metabolism
DM5NM6E	RN	Conformational changes and catalysis by alcohol dehydrogenase. Arch Biochem Biophys. 2010 Jan 1;493(1):3-12.
DM5NM6E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19583966

DM5NM6E	DI	DM5NM6E
DM5NM6E	DN	NADH
DM5NM6E	MI	DEIOH6A
DM5NM6E	MN	Alcohol dehydrogenase class-III (ADH5)
DM5NM6E	MT	DME
DM5NM6E	MA	Metabolism
DM5NM6E	RN	Conformational changes and catalysis by alcohol dehydrogenase. Arch Biochem Biophys. 2010 Jan 1;493(1):3-12.
DM5NM6E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19583966

DM5NM6E	DI	DM5NM6E
DM5NM6E	DN	NADH
DM5NM6E	MI	DE017IC
DM5NM6E	MN	Alcohol dehydrogenase class-V (ADH6)
DM5NM6E	MT	DME
DM5NM6E	MA	Metabolism
DM5NM6E	RN	Conformational changes and catalysis by alcohol dehydrogenase. Arch Biochem Biophys. 2010 Jan 1;493(1):3-12.
DM5NM6E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19583966

DM5NM6E	DI	DM5NM6E
DM5NM6E	DN	NADH
DM5NM6E	MI	DED2FW3
DM5NM6E	MN	Aldo-keto reductase 1A1 (AKR1A1)
DM5NM6E	MT	DME
DM5NM6E	MA	Metabolism
DM5NM6E	RN	Conformational changes and catalysis by alcohol dehydrogenase. Arch Biochem Biophys. 2010 Jan 1;493(1):3-12.
DM5NM6E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19583966

DM5NM6E	DI	DM5NM6E
DM5NM6E	DN	NADH
DM5NM6E	MI	DE4A3BL
DM5NM6E	MN	Diaphorase-1 (CYB5R3)
DM5NM6E	MT	DME
DM5NM6E	MA	Metabolism
DM5NM6E	RN	Expression of a novel P275L variant of NADH:cytochrome b5 reductase gives functional insight into the conserved motif important for pyridine nucleotide binding. Arch Biochem Biophys. 2006 Mar 1;447(1):59-67.
DM5NM6E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16469290

DM5NM6E	DI	DM5NM6E
DM5NM6E	DN	NADH
DM5NM6E	MI	DEZMAHX
DM5NM6E	MN	Gastric alcohol dehydrogenase (ADH7)
DM5NM6E	MT	DME
DM5NM6E	MA	Metabolism
DM5NM6E	RN	Conformational changes and catalysis by alcohol dehydrogenase. Arch Biochem Biophys. 2010 Jan 1;493(1):3-12.
DM5NM6E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19583966

DM5NM6E	DI	DM5NM6E
DM5NM6E	DN	NADH
DM5NM6E	MI	DEGSPC9
DM5NM6E	MN	Hydroxyacyl-CoA dehydrogenase 2 (HSD17B10)
DM5NM6E	MT	DME
DM5NM6E	MA	Metabolism
DM5NM6E	RN	A human brain L-3-hydroxyacyl-coenzyme A dehydrogenase is identical to an amyloid beta-peptide-binding protein involved in Alzheimer's disease. J Biol Chem. 1998 Apr 24;273(17):10741-6.
DM5NM6E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9553139

DM5NM6E	DI	DM5NM6E
DM5NM6E	DN	NADH
DM5NM6E	MI	TTTJF7V
DM5NM6E	MN	NADH dehydrogenase (MT-ND3)
DM5NM6E	MT	DTT
DM5NM6E	MA	Binder
DM5NM6E	RN	Mechanism of cadmium-decreased glucuronidation in the rat. Biochem Pharmacol. 1992 Dec 1;44(11):2139-47.
DM5NM6E	RU	https://pubmed.ncbi.nlm.nih.gov/1472079

DM5NM6E	DI	DM5NM6E
DM5NM6E	DN	NADH
DM5NM6E	MI	DESICUZ
DM5NM6E	MN	Retinol dehydrogenase 13 (RDH13)
DM5NM6E	MT	DME
DM5NM6E	MA	Metabolism
DM5NM6E	RN	Human retinol dehydrogenase 13 (RDH13) is a mitochondrial short-chain dehydrogenase/reductase with a retinaldehyde reductase activity. FEBS J. 2008 Jan;275(1):138-47.
DM5NM6E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18039331

DM5NM6E	DI	DM5NM6E
DM5NM6E	DN	NADH
DM5NM6E	MI	DEWDJU4
DM5NM6E	MN	Retinol dehydrogenase 14 (RDH14)
DM5NM6E	MT	DME
DM5NM6E	MA	Metabolism
DM5NM6E	RN	Human pancreas protein 2 (PAN2) has a retinal reductase activity and is ubiquitously expressed in human tissues. FEBS Lett. 2002 Nov 20;531(3):489-93.
DM5NM6E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12435598

DMW6GVL	DI	DMW6GVL
DMW6GVL	DN	Nadolol
DMW6GVL	MI	TTR6W5O
DMW6GVL	MN	Adrenergic receptor beta-1 (ADRB1)
DMW6GVL	MT	DTT
DMW6GVL	MA	Modulator
DMW6GVL	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMW6GVL	RU	https://www.fda.gov/

DMW6GVL	DI	DMW6GVL
DMW6GVL	DN	Nadolol
DMW6GVL	MI	DTE2B1D
DMW6GVL	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMW6GVL	MT	DTP
DMW6GVL	MA	Substrate
DMW6GVL	RN	Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. J Pharm Sci. 2009 Jul;98(7):2529-39.
DMW6GVL	RU	http://www.ncbi.nlm.nih.gov/pubmed/19067419

DMW6GVL	DI	DMW6GVL
DMW6GVL	DN	Nadolol
DMW6GVL	MI	DTUGYRD
DMW6GVL	MN	P-glycoprotein 1 (ABCB1)
DMW6GVL	MT	DTP
DMW6GVL	MA	Substrate
DMW6GVL	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DMW6GVL	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DMBNKST	DI	DMBNKST
DMBNKST	DN	Nadroparin calcium
DMBNKST	MI	TTCIHJA
DMBNKST	MN	Coagulation factor Xa (F10)
DMBNKST	MT	DTT
DMBNKST	MA	Modulator
DMBNKST	RN	Serum zinc concentrations: contamination from laboratory equipment. JPEN J Parenter Enteral Nutr. 1979 May-Jun;3(3):179-81.
DMBNKST	RU	https://pubmed.ncbi.nlm.nih.gov/113585

DMU1XOD	DI	DMU1XOD
DMU1XOD	DN	Nafamostat
DMU1XOD	MI	TTEMV5X
DMU1XOD	MN	Serine protease unspecific (SP)
DMU1XOD	MT	DTT
DMU1XOD	MA	Inhibitor
DMU1XOD	RN	Tryptase-positive mast cells correlate with angiogenesis in early breast cancer patients. Int J Oncol. 2009 Jul;35(1):115-20.
DMU1XOD	RU	https://pubmed.ncbi.nlm.nih.gov/19513558

DMU1XOD	DI	DMU1XOD
DMU1XOD	DN	Nafamostat
DMU1XOD	MI	TTF8CQI
DMU1XOD	MN	Tumor necrosis factor (TNF)
DMU1XOD	MT	DTT
DMU1XOD	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DMU1XOD	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DMAHEFY	DI	DMAHEFY
DMAHEFY	DN	Nafarelin
DMAHEFY	MI	TT8R70G
DMAHEFY	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMAHEFY	MT	DTT
DMAHEFY	MA	Agonist
DMAHEFY	RN	Reversible downregulation of endocrine and germinative testicular function (hormonal castration) in the dog with the GnRH-agonist azagly-nafarelin ... Theriogenology. 2009 Apr 15;71(7):1037-45.
DMAHEFY	RU	https://pubmed.ncbi.nlm.nih.gov/19233456

DMN9RPO	DI	DMN9RPO
DMN9RPO	DN	Nafcillin
DMN9RPO	MI	TTJP4SM
DMN9RPO	MN	Bacterial Penicillin binding protein (Bact PBP)
DMN9RPO	MT	DTT
DMN9RPO	MA	Binder
DMN9RPO	RN	Binding affinity for penicillin-binding protein 2a correlates with in vivo activity of beta-lactam antibiotics against methicillin-resistant Staphylococcus aureus. J Infect Dis. 1990 Sep;162(3):705-10.
DMN9RPO	RU	https://pubmed.ncbi.nlm.nih.gov/2387996

DMN9RPO	DI	DMN9RPO
DMN9RPO	DN	Nafcillin
DMN9RPO	MI	DT3D8F0
DMN9RPO	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMN9RPO	MT	DTP
DMN9RPO	MA	Substrate
DMN9RPO	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DMN9RPO	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DMVMQ1L	DI	DMVMQ1L
DMVMQ1L	DN	Nafronyl
DMVMQ1L	MI	TT85JO3
DMVMQ1L	MN	5-HT receptor (5HTR)
DMVMQ1L	MT	DTT
DMVMQ1L	MA	Modulator
DMVMQ1L	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMVMQ1L	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMHVBG1	DI	DMHVBG1
DMHVBG1	DN	Naftifine
DMHVBG1	MI	TTE14XG
DMHVBG1	MN	Squalene monooxygenase (SQLE)
DMHVBG1	MT	DTT
DMHVBG1	MA	Inhibitor
DMHVBG1	RN	Characterization of squalene epoxidase activity from the dermatophyte Trichophyton rubrum and its inhibition by terbinafine and other antimycotic agents. Antimicrob Agents Chemother. 1996 Feb;40(2):443-7.
DMHVBG1	RU	https://pubmed.ncbi.nlm.nih.gov/8834895

DMQ8R4E	DI	DMQ8R4E
DMQ8R4E	DN	Naftopidil
DMQ8R4E	MI	TTNGILX
DMQ8R4E	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMQ8R4E	MT	DTT
DMQ8R4E	MA	Inhibitor
DMQ8R4E	RN	Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
DMQ8R4E	RU	https://pubmed.ncbi.nlm.nih.gov/15664832

DMQ8R4E	DI	DMQ8R4E
DMQ8R4E	DN	Naftopidil
DMQ8R4E	MI	DE5IED8
DMQ8R4E	MN	Cytochrome P450 2C9 (CYP2C9)
DMQ8R4E	MT	DME
DMQ8R4E	MA	Metabolism
DMQ8R4E	RN	Identification of human cytochrome P450 isozymes involved in the metabolism of naftopidil enantiomers in vitro. J Pharm Pharmacol. 2014 Nov;66(11):1534-51.
DMQ8R4E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24944083

DMQ8R4E	DI	DMQ8R4E
DMQ8R4E	DN	Naftopidil
DMQ8R4E	MI	DEGTFWK
DMQ8R4E	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMQ8R4E	MT	DME
DMQ8R4E	MA	Metabolism
DMQ8R4E	RN	Identification of human cytochrome P450 isozymes involved in the metabolism of naftopidil enantiomers in vitro. J Pharm Pharmacol. 2014 Nov;66(11):1534-51.
DMQ8R4E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24944083

DMOSQGU	DI	DMOSQGU
DMOSQGU	DN	Nalbuphine
DMOSQGU	MI	TTQW87Y
DMOSQGU	MN	Opioid receptor kappa (OPRK1)
DMOSQGU	MT	DTT
DMOSQGU	MA	Modulator
DMOSQGU	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMOSQGU	RU	https://www.fda.gov/

DMOSQGU	DI	DMOSQGU
DMOSQGU	DN	Nalbuphine
DMOSQGU	MI	DTUGYRD
DMOSQGU	MN	P-glycoprotein 1 (ABCB1)
DMOSQGU	MT	DTP
DMOSQGU	MA	Substrate
DMOSQGU	RN	Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.
DMOSQGU	RU	http://www.ncbi.nlm.nih.gov/pubmed/12438524

DMGD3YH	DI	DMGD3YH
DMGD3YH	DN	Naldemedine Tosylate
DMGD3YH	MI	TTKWM86
DMGD3YH	MN	Opioid receptor mu (MOP)
DMGD3YH	MT	DTT
DMGD3YH	MA	Antagonist
DMGD3YH	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DMGD3YH	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DMA9DHW	DI	DMA9DHW
DMA9DHW	DN	Nalfurafine hcl
DMA9DHW	MI	TTQW87Y
DMA9DHW	MN	Opioid receptor kappa (OPRK1)
DMA9DHW	MT	DTT
DMA9DHW	MA	Inhibitor
DMA9DHW	RN	Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4.
DMA9DHW	RU	https://pubmed.ncbi.nlm.nih.gov/19962305

DMA9DHW	DI	DMA9DHW
DMA9DHW	DN	Nalfurafine hcl
DMA9DHW	MI	TTKWM86
DMA9DHW	MN	Opioid receptor mu (MOP)
DMA9DHW	MT	DTT
DMA9DHW	MA	Inhibitor
DMA9DHW	RN	Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4.
DMA9DHW	RU	https://pubmed.ncbi.nlm.nih.gov/19962305

DMRM0JV	DI	DMRM0JV
DMRM0JV	DN	Nalidixic acid
DMRM0JV	MI	TT0IHXV
DMRM0JV	MN	DNA topoisomerase II (TOP2)
DMRM0JV	MT	DTT
DMRM0JV	MA	Inhibitor
DMRM0JV	RN	Activity of fluoroquinolone antibiotics against Plasmodium falciparum in vitro. Antimicrob Agents Chemother. 1988 Aug;32(8):1182-6.
DMRM0JV	RU	https://pubmed.ncbi.nlm.nih.gov/2847647

DM4YWCZ	DI	DM4YWCZ
DM4YWCZ	DN	Nalmefene
DM4YWCZ	MI	TTN4QDT
DM4YWCZ	MN	Opioid receptor (OPR)
DM4YWCZ	MT	DTT
DM4YWCZ	MA	Antagonist
DM4YWCZ	RN	Unconditioned behavioral effects of the powerful kappa-opioid hallucinogen salvinorin A in nonhuman primates: fast onset and entry into cerebrospin... J Pharmacol Exp Ther. 2009 Feb;328(2):588-97.
DM4YWCZ	RU	https://pubmed.ncbi.nlm.nih.gov/19001155

DML0B41	DI	DML0B41
DML0B41	DN	Naloxegol
DML0B41	MI	DE4LYSA
DML0B41	MN	Cytochrome P450 3A4 (CYP3A4)
DML0B41	MT	DME
DML0B41	MA	Metabolism
DML0B41	RN	Naloxegol: treatment for opioid-induced constipation in chronic non-cancer pain. Ann Pharmacother. 2015 Mar;49(3):360-5.
DML0B41	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25471070

DML0B41	DI	DML0B41
DML0B41	DN	Naloxegol
DML0B41	MI	TTKWM86
DML0B41	MN	Opioid receptor mu (MOP)
DML0B41	MT	DTT
DML0B41	MA	Modulator
DML0B41	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DML0B41	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DML0B41	DI	DML0B41
DML0B41	DN	Naloxegol
DML0B41	MI	DTUGYRD
DML0B41	MN	P-glycoprotein 1 (ABCB1)
DML0B41	MT	DTP
DML0B41	MA	Substrate
DML0B41	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DML0B41	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DM3FXMA	DI	DM3FXMA
DM3FXMA	DN	Naloxone
DM3FXMA	MI	TTKWM86
DM3FXMA	MN	Opioid receptor mu (MOP)
DM3FXMA	MT	DTT
DM3FXMA	MA	Antagonist
DM3FXMA	RN	OxyContin abuse and overdose. Postgrad Med. 2009 Mar;121(2):163-7.
DM3FXMA	RU	https://pubmed.ncbi.nlm.nih.gov/19332974

DMUL45H	DI	DMUL45H
DMUL45H	DN	Naltrexone
DMUL45H	MI	TTN4QDT
DMUL45H	MN	Opioid receptor (OPR)
DMUL45H	MT	DTT
DMUL45H	MA	Antagonist
DMUL45H	RN	An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry. 2008 Feb;65(2):135-44.
DMUL45H	RU	https://pubmed.ncbi.nlm.nih.gov/18250251

DMUL45H	DI	DMUL45H
DMUL45H	DN	Naltrexone
DMUL45H	MI	DEYGVN4
DMUL45H	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMUL45H	MT	DME
DMUL45H	MA	Metabolism
DMUL45H	RN	In vivo chronic exposure to heroin or naltrexone selectively inhibits liver microsome formation of estradiol-3-glucuronide in the rat. Biochem Pharmacol. 2008 Sep 1;76(5):672-9.
DMUL45H	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18639530

DMFWKG1	DI	DMFWKG1
DMFWKG1	DN	Nandrolone
DMFWKG1	MI	TTS64P2
DMFWKG1	MN	Androgen receptor (AR)
DMFWKG1	MT	DTT
DMFWKG1	MA	Agonist
DMFWKG1	RN	Expression of androgen receptor on fibroblast and hepatocyte of rats after deep second-degree burn caused by scalding. Sichuan Da Xue Xue Bao Yi Xue Ban. 2005 May;36(3):362-4.
DMFWKG1	RU	https://pubmed.ncbi.nlm.nih.gov/15931869

DMFWKG1	DI	DMFWKG1
DMFWKG1	DN	Nandrolone
DMFWKG1	MI	DEQX145
DMFWKG1	MN	Aromatase (CYP19A1)
DMFWKG1	MT	DME
DMFWKG1	MA	Metabolism
DMFWKG1	RN	Aromatization of testosterone and 19-nortestosterone by a single enzyme from equine testicular microsomes. Differences from human placental aromatase. J Steroid Biochem. 1988 Jan;29(1):119-25.
DMFWKG1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=3347045

DMJFZDL	DI	DMJFZDL
DMJFZDL	DN	Naphazoline
DMJFZDL	MI	TTEX248
DMJFZDL	MN	Dopamine D2 receptor (D2R)
DMJFZDL	MT	DTT
DMJFZDL	MA	Agonist
DMJFZDL	RN	Decongestants in treatment of nasal obstruction. Otolaryngol Pol. 1999;53(3):347-52.
DMJFZDL	RU	https://pubmed.ncbi.nlm.nih.gov/10481510

DMZ5RGV	DI	DMZ5RGV
DMZ5RGV	DN	Naproxen
DMZ5RGV	MI	DEJGDUW
DMZ5RGV	MN	Cytochrome P450 1A2 (CYP1A2)
DMZ5RGV	MT	DME
DMZ5RGV	MA	Metabolism
DMZ5RGV	RN	Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation. Eur J Clin Pharmacol. 1997;52(4):293-8.
DMZ5RGV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9248768

DMZ5RGV	DI	DMZ5RGV
DMZ5RGV	DN	Naproxen
DMZ5RGV	MI	DES5XRU
DMZ5RGV	MN	Cytochrome P450 2C8 (CYP2C8)
DMZ5RGV	MT	DME
DMZ5RGV	MA	Metabolism
DMZ5RGV	RN	Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation. Eur J Clin Pharmacol. 1997;52(4):293-8.
DMZ5RGV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9248768

DMZ5RGV	DI	DMZ5RGV
DMZ5RGV	DN	Naproxen
DMZ5RGV	MI	DE5IED8
DMZ5RGV	MN	Cytochrome P450 2C9 (CYP2C9)
DMZ5RGV	MT	DME
DMZ5RGV	MA	Metabolism
DMZ5RGV	RN	Drug interactions in dentistry: the importance of knowing your CYPs. J Am Dent Assoc. 2004 Mar;135(3):298-311.
DMZ5RGV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15058617

DMZ5RGV	DI	DMZ5RGV
DMZ5RGV	DN	Naproxen
DMZ5RGV	MI	TT8NGED
DMZ5RGV	MN	Prostaglandin G/H synthase 1 (COX-1)
DMZ5RGV	MT	DTT
DMZ5RGV	MA	Inhibitor
DMZ5RGV	RN	Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
DMZ5RGV	RU	https://pubmed.ncbi.nlm.nih.gov/11028250

DMZ5RGV	DI	DMZ5RGV
DMZ5RGV	DN	Naproxen
DMZ5RGV	MI	TTVKILB
DMZ5RGV	MN	Prostaglandin G/H synthase 2 (COX-2)
DMZ5RGV	MT	DTT
DMZ5RGV	MA	Inhibitor
DMZ5RGV	RN	Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
DMZ5RGV	RU	https://pubmed.ncbi.nlm.nih.gov/11028250

DMZ5RGV	DI	DMZ5RGV
DMZ5RGV	DN	Naproxen
DMZ5RGV	MI	DEYGVN4
DMZ5RGV	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMZ5RGV	MT	DME
DMZ5RGV	MA	Metabolism
DMZ5RGV	RN	Influence of mutations associated with Gilbert and Crigler-Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates. Pharmacogenet Genomics. 2007 Dec;17(12):1017-29.
DMZ5RGV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18004206

DMZ5RGV	DI	DMZ5RGV
DMZ5RGV	DN	Naproxen
DMZ5RGV	MI	DEL5N6Y
DMZ5RGV	MN	UDP-glucuronosyltransferase 1A10 (UGT1A10)
DMZ5RGV	MT	DME
DMZ5RGV	MA	Metabolism
DMZ5RGV	RN	S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol. 2005 Oct;60(4):423-33.
DMZ5RGV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16187975

DMZ5RGV	DI	DMZ5RGV
DMZ5RGV	DN	Naproxen
DMZ5RGV	MI	DEF2WXN
DMZ5RGV	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMZ5RGV	MT	DME
DMZ5RGV	MA	Metabolism
DMZ5RGV	RN	S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol. 2005 Oct;60(4):423-33.
DMZ5RGV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16187975

DMZ5RGV	DI	DMZ5RGV
DMZ5RGV	DN	Naproxen
DMZ5RGV	MI	DESD26P
DMZ5RGV	MN	UDP-glucuronosyltransferase 1A6 (UGT1A6)
DMZ5RGV	MT	DME
DMZ5RGV	MA	Metabolism
DMZ5RGV	RN	S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol. 2005 Oct;60(4):423-33.
DMZ5RGV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16187975

DMZ5RGV	DI	DMZ5RGV
DMZ5RGV	DN	Naproxen
DMZ5RGV	MI	DE85D2P
DMZ5RGV	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMZ5RGV	MT	DME
DMZ5RGV	MA	Metabolism
DMZ5RGV	RN	S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol. 2005 Oct;60(4):423-33.
DMZ5RGV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16187975

DMZ5RGV	DI	DMZ5RGV
DMZ5RGV	DN	Naproxen
DMZ5RGV	MI	DEB3CV1
DMZ5RGV	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMZ5RGV	MT	DME
DMZ5RGV	MA	Metabolism
DMZ5RGV	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMZ5RGV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMO50U2	DI	DMO50U2
DMO50U2	DN	Naratriptan
DMO50U2	MI	TTK8CXU
DMO50U2	MN	5-HT 1B receptor (HTR1B)
DMO50U2	MT	DTT
DMO50U2	MA	Agonist
DMO50U2	RN	Triptans in pregnancy. Ther Drug Monit. 2008 Feb;30(1):5-9.
DMO50U2	RU	https://pubmed.ncbi.nlm.nih.gov/18223456

DMO50U2	DI	DMO50U2
DMO50U2	DN	Naratriptan
DMO50U2	MI	DERE4TU
DMO50U2	MN	Monoamine oxidase type A (MAO-A)
DMO50U2	MT	DME
DMO50U2	MA	Metabolism
DMO50U2	RN	Migraine pharmacotherapy with oral triptans: a rational approach to clinical management. Expert Opin Pharmacother. 2000 Mar;1(3):391-404.
DMO50U2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11249525

DMO50U2	DI	DMO50U2
DMO50U2	DN	Naratriptan
DMO50U2	MI	DTT79CX
DMO50U2	MN	Organic cation transporter 1 (SLC22A1)
DMO50U2	MT	DTP
DMO50U2	MA	Substrate
DMO50U2	RN	OCT1 mediates hepatic uptake of sumatriptan and loss-of-function OCT1 polymorphisms affect sumatriptan pharmacokinetics. Clin Pharmacol Ther. 2016 Jun;99(6):633-41.
DMO50U2	RU	http://www.ncbi.nlm.nih.gov/pubmed/26659468

DMFEHXD	DI	DMFEHXD
DMFEHXD	DN	Natamycin
DMFEHXD	MI	TTAH0B3
DMFEHXD	MN	Fungal Cell membrane (Fung CM)
DMFEHXD	MT	DTT
DMFEHXD	MA	Binder
DMFEHXD	RN	Natamycin blocks fungal growth by binding specifically to ergosterol without permeabilizing the membrane. J Biol Chem. 2008 Mar 7;283(10):6393-401.
DMFEHXD	RU	https://pubmed.ncbi.nlm.nih.gov/18165687

DMLK2QH	DI	DMLK2QH
DMLK2QH	DN	Nateglinide
DMLK2QH	MI	DE5IED8
DMLK2QH	MN	Cytochrome P450 2C9 (CYP2C9)
DMLK2QH	MT	DME
DMLK2QH	MA	Metabolism
DMLK2QH	RN	Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet. 2007;46(2):93-108.
DMLK2QH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17253883

DMLK2QH	DI	DMLK2QH
DMLK2QH	DN	Nateglinide
DMLK2QH	MI	DECB0K3
DMLK2QH	MN	Cytochrome P450 2D6 (CYP2D6)
DMLK2QH	MT	DME
DMLK2QH	MA	Metabolism
DMLK2QH	RN	Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. Clin Pharmacokinet. 2004;43(4):267-78.
DMLK2QH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15005635

DMLK2QH	DI	DMLK2QH
DMLK2QH	DN	Nateglinide
DMLK2QH	MI	DE4LYSA
DMLK2QH	MN	Cytochrome P450 3A4 (CYP3A4)
DMLK2QH	MT	DME
DMLK2QH	MA	Metabolism
DMLK2QH	RN	Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet. 2007;46(2):93-108.
DMLK2QH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17253883

DMLK2QH	DI	DMLK2QH
DMLK2QH	DN	Nateglinide
DMLK2QH	MI	DEIBDNY
DMLK2QH	MN	Cytochrome P450 3A5 (CYP3A5)
DMLK2QH	MT	DME
DMLK2QH	MA	Metabolism
DMLK2QH	RN	Drug Interactions Flockhart Table
DMLK2QH	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMLK2QH	DI	DMLK2QH
DMLK2QH	DN	Nateglinide
DMLK2QH	MI	DERD86B
DMLK2QH	MN	Cytochrome P450 3A7 (CYP3A7)
DMLK2QH	MT	DME
DMLK2QH	MA	Metabolism
DMLK2QH	RN	Drug Interactions Flockhart Table
DMLK2QH	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMLK2QH	DI	DMLK2QH
DMLK2QH	DN	Nateglinide
DMLK2QH	MI	DT3I124
DMLK2QH	MN	Monocarboxylate transporter 6 (SLC16A5)
DMLK2QH	MT	DTP
DMLK2QH	MA	Substrate
DMLK2QH	RN	Quercetin, Morin, Luteolin, and Phloretin Are Dietary Flavonoid Inhibitors of Monocarboxylate Transporter 6. Mol Pharm. 2017 Sep 5;14(9):2930-2936.
DMLK2QH	RU	http://www.ncbi.nlm.nih.gov/pubmed/28513167

DMLK2QH	DI	DMLK2QH
DMLK2QH	DN	Nateglinide
DMLK2QH	MI	DT3D8F0
DMLK2QH	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMLK2QH	MT	DTP
DMLK2QH	MA	Substrate
DMLK2QH	RN	Organic Anion Transporter 2-Mediated Hepatic Uptake Contributes to the Clearance of High-Permeability-Low-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs. J Pharmacol Exp Ther. 2018 Nov;367(2):322-334.
DMLK2QH	RU	http://www.ncbi.nlm.nih.gov/pubmed/30135178

DMLK2QH	DI	DMLK2QH
DMLK2QH	DN	Nateglinide
DMLK2QH	MI	DT9C1TS
DMLK2QH	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMLK2QH	MT	DTP
DMLK2QH	MA	Substrate
DMLK2QH	RN	FDA Drug Development and Drug Interactions
DMLK2QH	RU	https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2

DMLK2QH	DI	DMLK2QH
DMLK2QH	DN	Nateglinide
DMLK2QH	MI	TT1VOHK
DMLK2QH	MN	Potassium channel unspecific (KC)
DMLK2QH	MT	DTT
DMLK2QH	MA	Modulator
DMLK2QH	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMLK2QH	RU	https://www.fda.gov/

DMLK2QH	DI	DMLK2QH
DMLK2QH	DN	Nateglinide
DMLK2QH	MI	DE073H6
DMLK2QH	MN	Prostaglandin G/H synthase 1 (COX-1)
DMLK2QH	MT	DME
DMLK2QH	MA	Metabolism
DMLK2QH	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMLK2QH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMLK2QH	DI	DMLK2QH
DMLK2QH	DN	Nateglinide
DMLK2QH	MI	DE85D2P
DMLK2QH	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMLK2QH	MT	DME
DMLK2QH	MA	Metabolism
DMLK2QH	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMLK2QH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM7F1PA	DI	DM7F1PA
DM7F1PA	DN	Nebivolol
DM7F1PA	MI	TTR6W5O
DM7F1PA	MN	Adrenergic receptor beta-1 (ADRB1)
DM7F1PA	MT	DTT
DM7F1PA	MA	Antagonist
DM7F1PA	RN	Nitric oxide mechanisms of nebivolol. Ther Adv Cardiovasc Dis. 2009 Aug;3(4):317-27.
DM7F1PA	RU	https://pubmed.ncbi.nlm.nih.gov/19443516

DM7F1PA	DI	DM7F1PA
DM7F1PA	DN	Nebivolol
DM7F1PA	MI	DECB0K3
DM7F1PA	MN	Cytochrome P450 2D6 (CYP2D6)
DM7F1PA	MT	DME
DM7F1PA	MA	Metabolism
DM7F1PA	RN	Nebivolol: a review of its clinical and pharmacological characteristics. Int J Clin Pharmacol Ther. 2006 Aug;44(8):344-57.
DM7F1PA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16961165

DM7F1PA	DI	DM7F1PA
DM7F1PA	DN	Nebivolol
DM7F1PA	MI	DEGTFWK
DM7F1PA	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM7F1PA	MT	DME
DM7F1PA	MA	Metabolism
DM7F1PA	RN	Evaluation of 24 CYP2D6 variants on the metabolism of nebivolol in vitro. Drug Metab Dispos. 2016 Nov;44(11):1828-1831.
DM7F1PA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27538917

DMKOJSN	DI	DMKOJSN
DMKOJSN	DN	Necitumumab
DMKOJSN	MI	TTGKNB4
DMKOJSN	MN	Epidermal growth factor receptor (EGFR)
DMKOJSN	MT	DTT
DMKOJSN	MA	Modulator
DMKOJSN	RN	Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme. Curr Opin Mol Ther. 2010 Dec;12(6):741-54.
DMKOJSN	RU	https://pubmed.ncbi.nlm.nih.gov/21154166

DM4ZS8M	DI	DM4ZS8M
DM4ZS8M	DN	Nefazodone
DM4ZS8M	MI	TTWJBZ5
DM4ZS8M	MN	5-HT 2C receptor (HTR2C)
DM4ZS8M	MT	DTT
DM4ZS8M	MA	Antagonist
DM4ZS8M	RN	Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie. 2005 Sep-Oct;60(5):441-60.
DM4ZS8M	RU	https://pubmed.ncbi.nlm.nih.gov/16433010

DM4ZS8M	DI	DM4ZS8M
DM4ZS8M	DN	Nefazodone
DM4ZS8M	MI	DECB0K3
DM4ZS8M	MN	Cytochrome P450 2D6 (CYP2D6)
DM4ZS8M	MT	DME
DM4ZS8M	MA	Metabolism
DM4ZS8M	RN	Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions. Psychopharmacology (Berl). 1999 Jul;145(1):113-22.
DM4ZS8M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10445380

DM4ZS8M	DI	DM4ZS8M
DM4ZS8M	DN	Nefazodone
DM4ZS8M	MI	DE4LYSA
DM4ZS8M	MN	Cytochrome P450 3A4 (CYP3A4)
DM4ZS8M	MT	DME
DM4ZS8M	MA	Metabolism
DM4ZS8M	RN	Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions. Psychopharmacology (Berl). 1999 Jul;145(1):113-22.
DM4ZS8M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10445380

DMB6VEG	DI	DMB6VEG
DMB6VEG	DN	Nelarabine
DMB6VEG	MI	DEDQHBV
DMB6VEG	MN	Adenosine aminohydrolase (ADA)
DMB6VEG	MT	DME
DMB6VEG	MA	Metabolism
DMB6VEG	RN	Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia. Onco Targets Ther. 2009 Feb 18;2:219-28.
DMB6VEG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20616909

DMB6VEG	DI	DMB6VEG
DMB6VEG	DN	Nelarabine
DMB6VEG	MI	TTUBNVO
DMB6VEG	MN	DNA synthesis (DNA synth)
DMB6VEG	MT	DTT
DMB6VEG	MA	Binder
DMB6VEG	RN	Nelarabine. Drugs. 2008;68(4):439-47.
DMB6VEG	RU	https://pubmed.ncbi.nlm.nih.gov/18318562

DMFX6G8	DI	DMFX6G8
DMFX6G8	DN	Nelfinavir mesylate
DMFX6G8	MI	DE4LYSA
DMFX6G8	MN	Cytochrome P450 3A4 (CYP3A4)
DMFX6G8	MT	DME
DMFX6G8	MA	Metabolism
DMFX6G8	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMFX6G8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMFX6G8	DI	DMFX6G8
DMFX6G8	DN	Nelfinavir mesylate
DMFX6G8	MI	DEIBDNY
DMFX6G8	MN	Cytochrome P450 3A5 (CYP3A5)
DMFX6G8	MT	DME
DMFX6G8	MA	Metabolism
DMFX6G8	RN	Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):79-85.
DMFX6G8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16433896

DMFX6G8	DI	DMFX6G8
DMFX6G8	DN	Nelfinavir mesylate
DMFX6G8	MI	DERD86B
DMFX6G8	MN	Cytochrome P450 3A7 (CYP3A7)
DMFX6G8	MT	DME
DMFX6G8	MA	Metabolism
DMFX6G8	RN	Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):79-85.
DMFX6G8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16433896

DMFX6G8	DI	DMFX6G8
DMFX6G8	DN	Nelfinavir mesylate
DMFX6G8	MI	DEGTFWK
DMFX6G8	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMFX6G8	MT	DME
DMFX6G8	MA	Metabolism
DMFX6G8	RN	Impact of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir in patients with pancreatic cancer. Br J Clin Pharmacol. 2015 Aug;80(2):267-75.
DMFX6G8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25752914

DMY0EKH	DI	DMY0EKH
DMY0EKH	DN	Nemonapride
DMY0EKH	MI	TTEX248
DMY0EKH	MN	Dopamine D2 receptor (D2R)
DMY0EKH	MT	DTT
DMY0EKH	MA	Agonist
DMY0EKH	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMY0EKH	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DM0S9Z1	DI	DM0S9Z1
DM0S9Z1	DN	Nemonoxacin
DM0S9Z1	MI	TTN6J5F
DM0S9Z1	MN	Bacterial DNA gyrase (Bact gyrase)
DM0S9Z1	MT	DTT
DM0S9Z1	MA	Inhibitor
DM0S9Z1	RN	Nemonoxacin: first global approval. Drugs. 2014 Aug;74(12):1445-53.
DM0S9Z1	RU	https://pubmed.ncbi.nlm.nih.gov/25079302

DMPWCTH	DI	DMPWCTH
DMPWCTH	DN	Neocarzinostatin
DMPWCTH	MI	TTUTN1I
DMPWCTH	MN	Human Deoxyribonucleic acid (hDNA)
DMPWCTH	MT	DTT
DMPWCTH	MA	Modulator
DMPWCTH	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMPWCTH	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DM6T2J3	DI	DM6T2J3
DM6T2J3	DN	Neostigmine
DM6T2J3	MI	TT1RS9F
DM6T2J3	MN	Acetylcholinesterase (AChE)
DM6T2J3	MT	DTT
DM6T2J3	MA	Inhibitor
DM6T2J3	RN	Screening of acetylcholinesterase inhibitors by CE after enzymatic reaction at capillary inlet. J Sep Sci. 2009 May;32(10):1748-56.
DM6T2J3	RU	https://pubmed.ncbi.nlm.nih.gov/19472276

DM6T2J3	DI	DM6T2J3
DM6T2J3	DN	Neostigmine
DM6T2J3	MI	DTUGYRD
DM6T2J3	MN	P-glycoprotein 1 (ABCB1)
DM6T2J3	MT	DTP
DM6T2J3	MA	Substrate
DM6T2J3	RN	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
DM6T2J3	RU	https://doi.org/10.1016/j.addr.2011.12.008

DMYK490	DI	DMYK490
DMYK490	DN	Nepafenac
DMYK490	MI	TTK0943
DMYK490	MN	Prostaglandin G/H synthase (COX)
DMYK490	MT	DTT
DMYK490	MA	Inhibitor
DMYK490	RN	Topical nepafenac inhibits ocular neovascularization. Invest Ophthalmol Vis Sci. 2003 Jan;44(1):409-15.
DMYK490	RU	https://pubmed.ncbi.nlm.nih.gov/12506103

DMEDU7B	DI	DMEDU7B
DMEDU7B	DN	NERATINIB MALEATE
DMEDU7B	MI	TTGKNB4
DMEDU7B	MN	Epidermal growth factor receptor (EGFR)
DMEDU7B	MT	DTT
DMEDU7B	MA	Antagonist
DMEDU7B	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DMEDU7B	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DMEDU7B	DI	DMEDU7B
DMEDU7B	DN	NERATINIB MALEATE
DMEDU7B	MI	TT6EO5L
DMEDU7B	MN	Erbb2 tyrosine kinase receptor (HER2)
DMEDU7B	MT	DTT
DMEDU7B	MA	Antagonist
DMEDU7B	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DMEDU7B	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DMMPG5V	DI	DMMPG5V
DMMPG5V	DN	NERIDRONIC ACID
DMMPG5V	MI	TTIKWV4
DMMPG5V	MN	Geranyltranstransferase (FDPS)
DMMPG5V	MT	DTT
DMMPG5V	MA	Inhibitor
DMMPG5V	RN	Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of hu... J Med Chem. 2008 Apr 10;51(7):2187-95.
DMMPG5V	RU	https://pubmed.ncbi.nlm.nih.gov/18327899

DMFOIA8	DI	DMFOIA8
DMFOIA8	DN	Nesiritide
DMFOIA8	MI	TTJME02
DMFOIA8	MN	Atrial natriuretic peptide receptor A (NPR1)
DMFOIA8	MT	DTT
DMFOIA8	MA	Binder
DMFOIA8	RN	The efficacy and safety of B-type natriuretic peptide (nesiritide) in patients with renal insufficiency and acutely decompensated congestive heart failure. Nephrol Dial Transplant. 2004 Feb;19(2):391-9.
DMFOIA8	RU	https://pubmed.ncbi.nlm.nih.gov/14736964

DM0LPI9	DI	DM0LPI9
DM0LPI9	DN	Netarsudil
DM0LPI9	MI	TTAWNKZ
DM0LPI9	MN	Norepinephrine transporter (NET)
DM0LPI9	MT	DTT
DM0LPI9	MA	Modulator
DM0LPI9	RN	Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma. 2015 Jan;24(1):51-4.
DM0LPI9	RU	https://pubmed.ncbi.nlm.nih.gov/25535688

DM0LPI9	DI	DM0LPI9
DM0LPI9	DN	Netarsudil
DM0LPI9	MI	TTMQO60
DM0LPI9	MN	Rho-associated protein kinase (ROCK)
DM0LPI9	MT	DTT
DM0LPI9	MA	Modulator
DM0LPI9	RN	Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma. 2015 Jan;24(1):51-4.
DM0LPI9	RU	https://pubmed.ncbi.nlm.nih.gov/25535688

DM0LPI9	DI	DM0LPI9
DM0LPI9	DN	Netarsudil
DM0LPI9	MI	TTZN7RP
DM0LPI9	MN	Rho-associated protein kinase 1 (ROCK1)
DM0LPI9	MT	DTT
DM0LPI9	MA	Inhibitor
DM0LPI9	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DM0LPI9	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DMRD1QK	DI	DMRD1QK
DMRD1QK	DN	Netilmicin
DMRD1QK	MI	DEJADS9
DMRD1QK	MN	Aminoglycoside N-acetyltransferase (aacC2)
DMRD1QK	MT	DME
DMRD1QK	MA	Metabolism
DMRD1QK	RN	Relationship between antimicrobial resistance and aminoglycoside-modifying enzyme gene expressions in Acinetobacter baumannii. Chin Med J (Engl). 2005 Jan 20;118(2):141-5.
DMRD1QK	RU	https://pubmed.ncbi.nlm.nih.gov/15667800

DMRD1QK	DI	DMRD1QK
DMRD1QK	DN	Netilmicin
DMRD1QK	MI	DEWPAJD
DMRD1QK	MN	Aminoglycoside O-phosphotransferase (aphA6)
DMRD1QK	MT	DME
DMRD1QK	MA	Metabolism
DMRD1QK	RN	Relationship between antimicrobial resistance and aminoglycoside-modifying enzyme gene expressions in Acinetobacter baumannii. Chin Med J (Engl). 2005 Jan 20;118(2):141-5.
DMRD1QK	RU	https://pubmed.ncbi.nlm.nih.gov/15667800

DMRD1QK	DI	DMRD1QK
DMRD1QK	DN	Netilmicin
DMRD1QK	MI	DEZV4AP
DMRD1QK	MN	RNA cytidine acetyltransferase (hALP)
DMRD1QK	MT	DME
DMRD1QK	MA	Metabolism
DMRD1QK	RN	Aminoglycoside resistance resulting from tight drug binding to an altered aminoglycoside acetyltransferase. Antimicrob Agents Chemother. 2003 May;47(5):1577-83.
DMRD1QK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12709325

DMRD1QK	DI	DMRD1QK
DMRD1QK	DN	Netilmicin
DMRD1QK	MI	TTQ8KVI
DMRD1QK	MN	Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)
DMRD1QK	MT	DTT
DMRD1QK	MA	Binder
DMRD1QK	RN	Ribosomal resistance in the gentamicin producer organism Micromonospora purpurea. Antimicrob Agents Chemother. 1982 Aug;22(2):231-6.
DMRD1QK	RU	https://pubmed.ncbi.nlm.nih.gov/6927285

DM6HX9B	DI	DM6HX9B
DM6HX9B	DN	Nevirapine
DM6HX9B	MI	DEJVYAZ
DM6HX9B	MN	Cytochrome P450 2A6 (CYP2A6)
DM6HX9B	MT	DME
DM6HX9B	MA	Metabolism
DM6HX9B	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM6HX9B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM6HX9B	DI	DM6HX9B
DM6HX9B	DN	Nevirapine
DM6HX9B	MI	DEPKLMQ
DM6HX9B	MN	Cytochrome P450 2B6 (CYP2B6)
DM6HX9B	MT	DME
DM6HX9B	MA	Metabolism
DM6HX9B	RN	RAT CYP3A and CYP2B1/2 were not associated with nevirapine-induced hepatotoxicity. Methods Find Exp Clin Pharmacol. 2006 Sep;28(7):423-31.
DM6HX9B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17003847

DM6HX9B	DI	DM6HX9B
DM6HX9B	DN	Nevirapine
DM6HX9B	MI	DE5IED8
DM6HX9B	MN	Cytochrome P450 2C9 (CYP2C9)
DM6HX9B	MT	DME
DM6HX9B	MA	Metabolism
DM6HX9B	RN	Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J Clin Pharmacol. 2001 Jan;41(1):85-91.
DM6HX9B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11225565

DM6HX9B	DI	DM6HX9B
DM6HX9B	DN	Nevirapine
DM6HX9B	MI	DECB0K3
DM6HX9B	MN	Cytochrome P450 2D6 (CYP2D6)
DM6HX9B	MT	DME
DM6HX9B	MA	Metabolism
DM6HX9B	RN	Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos. 1999 Dec;27(12):1488-95.
DM6HX9B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10570031

DM6HX9B	DI	DM6HX9B
DM6HX9B	DN	Nevirapine
DM6HX9B	MI	DE4LYSA
DM6HX9B	MN	Cytochrome P450 3A4 (CYP3A4)
DM6HX9B	MT	DME
DM6HX9B	MA	Metabolism
DM6HX9B	RN	Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos. 1999 Dec;27(12):1488-95.
DM6HX9B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10570031

DM6HX9B	DI	DM6HX9B
DM6HX9B	DN	Nevirapine
DM6HX9B	MI	DEIBDNY
DM6HX9B	MN	Cytochrome P450 3A5 (CYP3A5)
DM6HX9B	MT	DME
DM6HX9B	MA	Metabolism
DM6HX9B	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM6HX9B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM6HX9B	DI	DM6HX9B
DM6HX9B	DN	Nevirapine
DM6HX9B	MI	DERD86B
DM6HX9B	MN	Cytochrome P450 3A7 (CYP3A7)
DM6HX9B	MT	DME
DM6HX9B	MA	Metabolism
DM6HX9B	RN	Helices F-G are important for the substrate specificities of CYP3A7. Drug Metab Dispos. 2007 Mar;35(3):484-92.
DM6HX9B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17178770

DM6HX9B	DI	DM6HX9B
DM6HX9B	DN	Nevirapine
DM6HX9B	MI	TT84ETX
DM6HX9B	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM6HX9B	MT	DTT
DM6HX9B	MA	Modulator
DM6HX9B	RN	HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism.Nat Struct Mol Biol.2012 Jan 22;19(2):253-9.
DM6HX9B	RU	https://www.ncbi.nlm.nih.gov/pubmed/22266819

DM6HX9B	DI	DM6HX9B
DM6HX9B	DN	Nevirapine
DM6HX9B	MI	DTUGYRD
DM6HX9B	MN	P-glycoprotein 1 (ABCB1)
DM6HX9B	MT	DTP
DM6HX9B	MA	Substrate
DM6HX9B	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM6HX9B	RU	https://doi.org/10.1007/s11095-012-0935-x

DMCDYW7	DI	DMCDYW7
DMCDYW7	DN	Nicardipine
DMCDYW7	MI	DTI7UX6
DMCDYW7	MN	Breast cancer resistance protein (ABCG2)
DMCDYW7	MT	DTP
DMCDYW7	MA	Substrate
DMCDYW7	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMCDYW7	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMCDYW7	DI	DMCDYW7
DMCDYW7	DN	Nicardipine
DMCDYW7	MI	TT5HONZ
DMCDYW7	MN	Calcium channel unspecific (CaC)
DMCDYW7	MT	DTT
DMCDYW7	MA	Blocker
DMCDYW7	RN	Effect of intracoronary nicardipine on cardiac enzymes after elective percutaneous coronary intervention. Clin Cardiol. 2009 Jun;32(6):315-20.
DMCDYW7	RU	https://pubmed.ncbi.nlm.nih.gov/19569065

DMCDYW7	DI	DMCDYW7
DMCDYW7	DN	Nicardipine
DMCDYW7	MI	DES5XRU
DMCDYW7	MN	Cytochrome P450 2C8 (CYP2C8)
DMCDYW7	MT	DME
DMCDYW7	MA	Metabolism
DMCDYW7	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMCDYW7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMCDYW7	DI	DMCDYW7
DMCDYW7	DN	Nicardipine
DMCDYW7	MI	DECB0K3
DMCDYW7	MN	Cytochrome P450 2D6 (CYP2D6)
DMCDYW7	MT	DME
DMCDYW7	MA	Metabolism
DMCDYW7	RN	Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes. Biol Pharm Bull. 2005 May;28(5):882-5.
DMCDYW7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15863898

DMCDYW7	DI	DMCDYW7
DMCDYW7	DN	Nicardipine
DMCDYW7	MI	DEVDYN7
DMCDYW7	MN	Cytochrome P450 2E1 (CYP2E1)
DMCDYW7	MT	DME
DMCDYW7	MA	Metabolism
DMCDYW7	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMCDYW7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMCDYW7	DI	DMCDYW7
DMCDYW7	DN	Nicardipine
DMCDYW7	MI	DE4LYSA
DMCDYW7	MN	Cytochrome P450 3A4 (CYP3A4)
DMCDYW7	MT	DME
DMCDYW7	MA	Metabolism
DMCDYW7	RN	Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes. Biol Pharm Bull. 2005 May;28(5):882-5.
DMCDYW7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15863898

DMCDYW7	DI	DMCDYW7
DMCDYW7	DN	Nicardipine
DMCDYW7	MI	DTUGYRD
DMCDYW7	MN	P-glycoprotein 1 (ABCB1)
DMCDYW7	MT	DTP
DMCDYW7	MA	Substrate
DMCDYW7	RN	Modulation of drug-stimulated ATPase activity of human MDR1/P-glycoprotein by cholesterol. Biochem J. 2007 Jan 15;401(2):597-605.
DMCDYW7	RU	http://www.ncbi.nlm.nih.gov/pubmed/17029589

DMBCM8L	DI	DMBCM8L
DMBCM8L	DN	Nicergoline
DMBCM8L	MI	TTQ8AFT
DMBCM8L	MN	Adrenergic receptor Alpha-2 (ADRA2)
DMBCM8L	MT	DTT
DMBCM8L	MA	Antagonist
DMBCM8L	RN	Effect of non-selective alpha-adrenergic receptor antagonist nicergoline on the activity of neurons in the ventral lateral thalamic nucleus. Fiziol Zh. 2005;51(4):29-35.
DMBCM8L	RU	https://pubmed.ncbi.nlm.nih.gov/16201147

DMBCM8L	DI	DMBCM8L
DMBCM8L	DN	Nicergoline
DMBCM8L	MI	DECB0K3
DMBCM8L	MN	Cytochrome P450 2D6 (CYP2D6)
DMBCM8L	MT	DME
DMBCM8L	MA	Metabolism
DMBCM8L	RN	Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans. Br J Clin Pharmacol. 1996 Dec;42(6):707-11.
DMBCM8L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8971425

DMJAGXQ	DI	DMJAGXQ
DMJAGXQ	DN	Niclosamide
DMJAGXQ	MI	DE5IED8
DMJAGXQ	MN	Cytochrome P450 2C9 (CYP2C9)
DMJAGXQ	MT	DME
DMJAGXQ	MA	Metabolism
DMJAGXQ	RN	Generation and evaluation of a CYP2C9 heteroactivation pharmacophore. J Pharmacol Exp Ther. 2003 Dec;307(3):878-87.
DMJAGXQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14557374

DMJAGXQ	DI	DMJAGXQ
DMJAGXQ	DN	Niclosamide
DMJAGXQ	MI	DE0K82S
DMJAGXQ	MN	Nitroreductase (NTR)
DMJAGXQ	MT	DME
DMJAGXQ	MA	Metabolism
DMJAGXQ	RN	CYP1A1 and Cnr nitroreductase bioactivated niclosamide in vitro. Mutagenesis. 2013 Nov;28(6):645-51.
DMJAGXQ	RU	https://pubmed.ncbi.nlm.nih.gov/23956140

DMIYJFV	DI	DMIYJFV
DMIYJFV	DN	Nicorandil
DMIYJFV	MI	TTEF5MJ
DMIYJFV	MN	ATP-binding cassette transporter C9 (ABCC9)
DMIYJFV	MT	DTT
DMIYJFV	MA	Activator
DMIYJFV	RN	A functional role of the C-terminal 42 amino acids of SUR2A and SUR2B in the physiology and pharmacology of cardiovascular ATP-sensitive K(+) chann... J Mol Cell Cardiol. 2005 Jul;39(1):1-6.
DMIYJFV	RU	https://pubmed.ncbi.nlm.nih.gov/15978900

DMUPE07	DI	DMUPE07
DMUPE07	DN	Nicotinamide
DMUPE07	MI	DEVDYN7
DMUPE07	MN	Cytochrome P450 2E1 (CYP2E1)
DMUPE07	MT	DME
DMUPE07	MA	Metabolism
DMUPE07	RN	Nicotinamide N-oxidation by CYP2E1 in human liver microsomes. Drug Metab Dispos. 2013 Mar;41(3):550-3.
DMUPE07	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23418369

DMUPE07	DI	DMUPE07
DMUPE07	DN	Nicotinamide
DMUPE07	MI	TTVDSZ0
DMUPE07	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMUPE07	MT	DTT
DMUPE07	MA	Binder
DMUPE07	RN	beta-1,2,3-Triazolyl-nucleosides as nicotinamide riboside mimics. Nucleosides Nucleotides Nucleic Acids. 2009 Mar;28(3):238-59.
DMUPE07	RU	https://pubmed.ncbi.nlm.nih.gov/19333861

DMWX5CO	DI	DMWX5CO
DMWX5CO	DN	Nicotine
DMWX5CO	MI	DE6OQ3W
DMWX5CO	MN	Cytochrome P450 1A1 (CYP1A1)
DMWX5CO	MT	DME
DMWX5CO	MA	Metabolism
DMWX5CO	RN	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
DMWX5CO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10350185

DMWX5CO	DI	DMWX5CO
DMWX5CO	DN	Nicotine
DMWX5CO	MI	DEJGDUW
DMWX5CO	MN	Cytochrome P450 1A2 (CYP1A2)
DMWX5CO	MT	DME
DMWX5CO	MA	Metabolism
DMWX5CO	RN	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
DMWX5CO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10350185

DMWX5CO	DI	DMWX5CO
DMWX5CO	DN	Nicotine
DMWX5CO	MI	DEXZA9U
DMWX5CO	MN	Cytochrome P450 2A13 (CYP2A13)
DMWX5CO	MT	DME
DMWX5CO	MA	Metabolism
DMWX5CO	RN	Inactivation of CYP2A6 and CYP2A13 during nicotine metabolism. J Pharmacol Exp Ther. 2006 Jan;316(1):295-303.
DMWX5CO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16188955

DMWX5CO	DI	DMWX5CO
DMWX5CO	DN	Nicotine
DMWX5CO	MI	DEJVYAZ
DMWX5CO	MN	Cytochrome P450 2A6 (CYP2A6)
DMWX5CO	MT	DME
DMWX5CO	MA	Metabolism
DMWX5CO	RN	CYP2A6- and CYP2A13-catalyzed metabolism of the nicotine delta-5'(1')iminium ion. J Pharmacol Exp Ther. 2012 Nov;343(2):307-15.
DMWX5CO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22869927

DMWX5CO	DI	DMWX5CO
DMWX5CO	DN	Nicotine
DMWX5CO	MI	DEPKLMQ
DMWX5CO	MN	Cytochrome P450 2B6 (CYP2B6)
DMWX5CO	MT	DME
DMWX5CO	MA	Metabolism
DMWX5CO	RN	Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
DMWX5CO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16174803

DMWX5CO	DI	DMWX5CO
DMWX5CO	DN	Nicotine
DMWX5CO	MI	DES5XRU
DMWX5CO	MN	Cytochrome P450 2C8 (CYP2C8)
DMWX5CO	MT	DME
DMWX5CO	MA	Metabolism
DMWX5CO	RN	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
DMWX5CO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10350185

DMWX5CO	DI	DMWX5CO
DMWX5CO	DN	Nicotine
DMWX5CO	MI	DE5IED8
DMWX5CO	MN	Cytochrome P450 2C9 (CYP2C9)
DMWX5CO	MT	DME
DMWX5CO	MA	Metabolism
DMWX5CO	RN	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
DMWX5CO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10350185

DMWX5CO	DI	DMWX5CO
DMWX5CO	DN	Nicotine
DMWX5CO	MI	DECB0K3
DMWX5CO	MN	Cytochrome P450 2D6 (CYP2D6)
DMWX5CO	MT	DME
DMWX5CO	MA	Metabolism
DMWX5CO	RN	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
DMWX5CO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10350185

DMWX5CO	DI	DMWX5CO
DMWX5CO	DN	Nicotine
DMWX5CO	MI	DEVDYN7
DMWX5CO	MN	Cytochrome P450 2E1 (CYP2E1)
DMWX5CO	MT	DME
DMWX5CO	MA	Metabolism
DMWX5CO	RN	Effects of nicotine on cytochrome P450 2A6 and 2E1 activities. Br J Clin Pharmacol. 2010 Feb;69(2):152-9.
DMWX5CO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20233178

DMWX5CO	DI	DMWX5CO
DMWX5CO	DN	Nicotine
DMWX5CO	MI	DE4LYSA
DMWX5CO	MN	Cytochrome P450 3A4 (CYP3A4)
DMWX5CO	MT	DME
DMWX5CO	MA	Metabolism
DMWX5CO	RN	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
DMWX5CO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10350185

DMWX5CO	DI	DMWX5CO
DMWX5CO	DN	Nicotine
DMWX5CO	MI	DEGTFWK
DMWX5CO	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMWX5CO	MT	DME
DMWX5CO	MA	Metabolism
DMWX5CO	RN	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
DMWX5CO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10350185

DMWX5CO	DI	DMWX5CO
DMWX5CO	DN	Nicotine
DMWX5CO	MI	DE4AMLP
DMWX5CO	MN	Nicotinate dehydrogenase (nicA)
DMWX5CO	MT	DME
DMWX5CO	MA	Metabolism
DMWX5CO	RN	Optimization of a nicotine degrading enzyme for potential use in treatment of nicotine addiction. BMC Biotechnol. 2019 Aug 2;19(1):56.
DMWX5CO	RU	https://pubmed.ncbi.nlm.nih.gov/31375100

DMWX5CO	DI	DMWX5CO
DMWX5CO	DN	Nicotine
DMWX5CO	MI	TTJSZTB
DMWX5CO	MN	Nicotinic acetylcholine receptor (nAChR)
DMWX5CO	MT	DTT
DMWX5CO	MA	Antagonist
DMWX5CO	RN	Atypical antipsychotics as noncompetitive inhibitors of alpha4beta2 and alpha7 neuronal nicotinic receptors. Neuropharmacology. 2009 Aug;57(2):183-91.
DMWX5CO	RU	https://pubmed.ncbi.nlm.nih.gov/19481556

DMWX5CO	DI	DMWX5CO
DMWX5CO	DN	Nicotine
DMWX5CO	MI	DEYGVN4
DMWX5CO	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMWX5CO	MT	DME
DMWX5CO	MA	Metabolism
DMWX5CO	RN	Liquid chromatography-tandem mass spectrometry method for measurement of nicotine N-glucuronide: a marker for human UGT2B10 inhibition. J Pharm Biomed Anal. 2011 Jul 15;55(5):964-71.
DMWX5CO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21497036

DMSVOZT	DI	DMSVOZT
DMSVOZT	DN	Nifedipine
DMSVOZT	MI	DE4OGUF
DMSVOZT	MN	Cytochrome P450 102A1 (cyp102)
DMSVOZT	MT	DME
DMSVOZT	MA	Metabolism
DMSVOZT	RN	Wild-type CYP102A1 as a biocatalyst: turnover of drugs usually metabolised by human liver enzymes. J Biol Inorg Chem. 2007 Mar;12(3):313-23.
DMSVOZT	RU	https://pubmed.ncbi.nlm.nih.gov/17235582

DMSVOZT	DI	DMSVOZT
DMSVOZT	DN	Nifedipine
DMSVOZT	MI	DEJGDUW
DMSVOZT	MN	Cytochrome P450 1A2 (CYP1A2)
DMSVOZT	MT	DME
DMSVOZT	MA	Metabolism
DMSVOZT	RN	Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
DMSVOZT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10805063

DMSVOZT	DI	DMSVOZT
DMSVOZT	DN	Nifedipine
DMSVOZT	MI	DECB0K3
DMSVOZT	MN	Cytochrome P450 2D6 (CYP2D6)
DMSVOZT	MT	DME
DMSVOZT	MA	Metabolism
DMSVOZT	RN	Molecular basis of polymorphic drug metabolism. J Mol Med (Berl). 1995 Nov;73(11):539-53.
DMSVOZT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8751138

DMSVOZT	DI	DMSVOZT
DMSVOZT	DN	Nifedipine
DMSVOZT	MI	DE4LYSA
DMSVOZT	MN	Cytochrome P450 3A4 (CYP3A4)
DMSVOZT	MT	DME
DMSVOZT	MA	Metabolism
DMSVOZT	RN	Metabolic interactions of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes. Br J Clin Pharmacol. 1997 Nov;44(5):505-11.
DMSVOZT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9384469

DMSVOZT	DI	DMSVOZT
DMSVOZT	DN	Nifedipine
DMSVOZT	MI	DEIBDNY
DMSVOZT	MN	Cytochrome P450 3A5 (CYP3A5)
DMSVOZT	MT	DME
DMSVOZT	MA	Metabolism
DMSVOZT	RN	In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos. 2003 Jul;31(7):938-44.
DMSVOZT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12814972

DMSVOZT	DI	DMSVOZT
DMSVOZT	DN	Nifedipine
DMSVOZT	MI	DTUGYRD
DMSVOZT	MN	P-glycoprotein 1 (ABCB1)
DMSVOZT	MT	DTP
DMSVOZT	MA	Substrate
DMSVOZT	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMSVOZT	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMSVOZT	DI	DMSVOZT
DMSVOZT	DN	Nifedipine
DMSVOZT	MI	TTXHYV6
DMSVOZT	MN	Voltage-gated L-type calcium channel (L-CaC)
DMSVOZT	MT	DTT
DMSVOZT	MA	Modulator
DMSVOZT	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMSVOZT	RU	https://www.fda.gov/

DMJ3I1Q	DI	DMJ3I1Q
DMJ3I1Q	DN	Niflumic acid
DMJ3I1Q	MI	TTVKILB
DMJ3I1Q	MN	Prostaglandin G/H synthase 2 (COX-2)
DMJ3I1Q	MT	DTT
DMJ3I1Q	MA	Inhibitor
DMJ3I1Q	RN	Rat ovulation, implantation and decidualization are severely compromised by COX-2 inhibitors. Front Biosci. 2007 May 1;12:3333-42.
DMJ3I1Q	RU	https://pubmed.ncbi.nlm.nih.gov/17485303

DMJ3I1Q	DI	DMJ3I1Q
DMJ3I1Q	DN	Niflumic acid
DMJ3I1Q	MI	DEYGVN4
DMJ3I1Q	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMJ3I1Q	MT	DME
DMJ3I1Q	MA	Metabolism
DMJ3I1Q	RN	Identification of human UDP-glucuronosyltransferase responsible for the glucuronidation of niflumic acid in human liver. Pharm Res. 2006 Jul;23(7):1502-8.
DMJ3I1Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16783480

DMSQLZJ	DI	DMSQLZJ
DMSQLZJ	DN	Nifurtimox
DMSQLZJ	MI	DTI7UX6
DMSQLZJ	MN	Breast cancer resistance protein (ABCG2)
DMSQLZJ	MT	DTP
DMSQLZJ	MA	Substrate
DMSQLZJ	RN	The transport of nifurtimox, an anti-trypanosomal drug, in an in vitro model of the human blood-brain barrier: evidence for involvement of breast cancer resistance protein. Brain Res. 2012 Feb 3;1436:111-21.
DMSQLZJ	RU	https://doi.org/10.1016/j.brainres.2011.11.053

DM7HXWT	DI	DM7HXWT
DM7HXWT	DN	Nilotinib
DM7HXWT	MI	DTI7UX6
DM7HXWT	MN	Breast cancer resistance protein (ABCG2)
DM7HXWT	MT	DTP
DM7HXWT	MA	Substrate
DM7HXWT	RN	Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64.
DM7HXWT	RU	http://www.ncbi.nlm.nih.gov/pubmed/19785662

DM7HXWT	DI	DM7HXWT
DM7HXWT	DN	Nilotinib
DM7HXWT	MI	DES5XRU
DM7HXWT	MN	Cytochrome P450 2C8 (CYP2C8)
DM7HXWT	MT	DME
DM7HXWT	MA	Metabolism
DM7HXWT	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DM7HXWT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DM7HXWT	DI	DM7HXWT
DM7HXWT	DN	Nilotinib
DM7HXWT	MI	DE4LYSA
DM7HXWT	MN	Cytochrome P450 3A4 (CYP3A4)
DM7HXWT	MT	DME
DM7HXWT	MA	Metabolism
DM7HXWT	RN	Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011 Feb 24;117(8):e75-87.
DM7HXWT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20810928

DM7HXWT	DI	DM7HXWT
DM7HXWT	DN	Nilotinib
DM7HXWT	MI	TTS7G69
DM7HXWT	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DM7HXWT	MT	DTT
DM7HXWT	MA	Modulator
DM7HXWT	RN	2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
DM7HXWT	RU	https://pubmed.ncbi.nlm.nih.gov/18246607

DM7HXWT	DI	DM7HXWT
DM7HXWT	DN	Nilotinib
DM7HXWT	MI	DTFI42L
DM7HXWT	MN	Multidrug resistance-associated protein 2 (ABCC2)
DM7HXWT	MT	DTP
DM7HXWT	MA	Substrate
DM7HXWT	RN	Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64.
DM7HXWT	RU	http://www.ncbi.nlm.nih.gov/pubmed/19785662

DM7HXWT	DI	DM7HXWT
DM7HXWT	DN	Nilotinib
DM7HXWT	MI	DT3D8F0
DM7HXWT	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM7HXWT	MT	DTP
DM7HXWT	MA	Substrate
DM7HXWT	RN	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
DM7HXWT	RU	http://www.ncbi.nlm.nih.gov/pubmed/23340295

DM7HXWT	DI	DM7HXWT
DM7HXWT	DN	Nilotinib
DM7HXWT	MI	DT9C1TS
DM7HXWT	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM7HXWT	MT	DTP
DM7HXWT	MA	Substrate
DM7HXWT	RN	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
DM7HXWT	RU	http://www.ncbi.nlm.nih.gov/pubmed/23340295

DM7HXWT	DI	DM7HXWT
DM7HXWT	DN	Nilotinib
DM7HXWT	MI	DTUGYRD
DM7HXWT	MN	P-glycoprotein 1 (ABCB1)
DM7HXWT	MT	DTP
DM7HXWT	MA	Substrate
DM7HXWT	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
DM7HXWT	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01665

DMFN07X	DI	DMFN07X
DMFN07X	DN	Nilutamide
DMFN07X	MI	TTS64P2
DMFN07X	MN	Androgen receptor (AR)
DMFN07X	MT	DTT
DMFN07X	MA	Antagonist
DMFN07X	RN	CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism. Cancer Res. 2008 Mar 15;68(6):1715-22.
DMFN07X	RU	https://pubmed.ncbi.nlm.nih.gov/18339851

DMFN07X	DI	DMFN07X
DMFN07X	DN	Nilutamide
DMFN07X	MI	DEGTFWK
DMFN07X	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMFN07X	MT	DME
DMFN07X	MA	Metabolism
DMFN07X	RN	Nilutamide inhibits mephenytoin 4-hydroxylation in untreated male rats and in human liver microsomes. Xenobiotica. 1991 Dec;21(12):1559-70.
DMFN07X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1785203

DMFN07X	DI	DMFN07X
DMFN07X	DN	Nilutamide
DMFN07X	MI	DE3N2FM
DMFN07X	MN	NADPH-cytochrome P450 reductase (CPR)
DMFN07X	MT	DME
DMFN07X	MA	Metabolism
DMFN07X	RN	Generation of free radicals during the reductive metabolism of nilutamide by lung microsomes: possible role in the development of lung lesions in patients treated with this anti-androgen. Biochem Pharmacol. 1992 Feb 4;43(3):654-7.
DMFN07X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1311586

DMQ0RKZ	DI	DMQ0RKZ
DMQ0RKZ	DN	Nimodipine
DMQ0RKZ	MI	TT5HONZ
DMQ0RKZ	MN	Calcium channel unspecific (CaC)
DMQ0RKZ	MT	DTT
DMQ0RKZ	MA	Blocker
DMQ0RKZ	RN	Influence of bupropion and calcium channel antagonists on the nicotine-induced memory-related response of mice in the elevated plus maze. Pharmacol Rep. 2009 Mar-Apr;61(2):236-44.
DMQ0RKZ	RU	https://pubmed.ncbi.nlm.nih.gov/19443934

DMQ0RKZ	DI	DMQ0RKZ
DMQ0RKZ	DN	Nimodipine
DMQ0RKZ	MI	DE4LYSA
DMQ0RKZ	MN	Cytochrome P450 3A4 (CYP3A4)
DMQ0RKZ	MT	DME
DMQ0RKZ	MA	Metabolism
DMQ0RKZ	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMQ0RKZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMQ0RKZ	DI	DMQ0RKZ
DMQ0RKZ	DN	Nimodipine
DMQ0RKZ	MI	DEIBDNY
DMQ0RKZ	MN	Cytochrome P450 3A5 (CYP3A5)
DMQ0RKZ	MT	DME
DMQ0RKZ	MA	Metabolism
DMQ0RKZ	RN	Enzyme kinetics and inhibition of nimodipine metabolism in human liver microsomes. Acta Pharmacol Sin. 2000 Aug;21(8):690-4.
DMQ0RKZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11501176

DMQ0RKZ	DI	DMQ0RKZ
DMQ0RKZ	DN	Nimodipine
DMQ0RKZ	MI	DTUGYRD
DMQ0RKZ	MN	P-glycoprotein 1 (ABCB1)
DMQ0RKZ	MT	DTP
DMQ0RKZ	MA	Substrate
DMQ0RKZ	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMQ0RKZ	RU	https://doi.org/10.1007/s11095-012-0935-x

DMA65ER	DI	DMA65ER
DMA65ER	DN	Nipradilol
DMA65ER	MI	TTMXGCW
DMA65ER	MN	Adrenergic receptor beta-3 (ADRB3)
DMA65ER	MT	DTT
DMA65ER	MA	Modulator
DMA65ER	RN	Actions of nipradilol (K-351), a new alpha- and beta-adrenoceptor blocker, on the rabbit portal vein. Jpn J Pharmacol. 1984 Aug;35(4):359-69.
DMA65ER	RU	https://pubmed.ncbi.nlm.nih.gov/6150128

DMLPSWQ	DI	DMLPSWQ
DMLPSWQ	DN	Niraparib Tosylate
DMLPSWQ	MI	TTVDSZ0
DMLPSWQ	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMLPSWQ	MT	DTT
DMLPSWQ	MA	Modulator
DMLPSWQ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMLPSWQ	RU	https://www.fda.gov/

DM7ISKJ	DI	DM7ISKJ
DM7ISKJ	DN	Nisoldipine
DM7ISKJ	MI	TT5HONZ
DM7ISKJ	MN	Calcium channel unspecific (CaC)
DM7ISKJ	MT	DTT
DM7ISKJ	MA	Blocker
DM7ISKJ	RN	RT-PCR and pharmacological analysis of L-and T-type calcium channels in rat carotid body. Adv Exp Med Biol. 2009;648:105-12.
DM7ISKJ	RU	https://pubmed.ncbi.nlm.nih.gov/19536471

DM7ISKJ	DI	DM7ISKJ
DM7ISKJ	DN	Nisoldipine
DM7ISKJ	MI	DE4LYSA
DM7ISKJ	MN	Cytochrome P450 3A4 (CYP3A4)
DM7ISKJ	MT	DME
DM7ISKJ	MA	Metabolism
DM7ISKJ	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM7ISKJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM7ISKJ	DI	DM7ISKJ
DM7ISKJ	DN	Nisoldipine
DM7ISKJ	MI	DEIBDNY
DM7ISKJ	MN	Cytochrome P450 3A5 (CYP3A5)
DM7ISKJ	MT	DME
DM7ISKJ	MA	Metabolism
DM7ISKJ	RN	Drug Interactions Flockhart Table
DM7ISKJ	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM7ISKJ	DI	DM7ISKJ
DM7ISKJ	DN	Nisoldipine
DM7ISKJ	MI	DERD86B
DM7ISKJ	MN	Cytochrome P450 3A7 (CYP3A7)
DM7ISKJ	MT	DME
DM7ISKJ	MA	Metabolism
DM7ISKJ	RN	Drug Interactions Flockhart Table
DM7ISKJ	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM7ISKJ	DI	DM7ISKJ
DM7ISKJ	DN	Nisoldipine
DM7ISKJ	MI	DTUGYRD
DM7ISKJ	MN	P-glycoprotein 1 (ABCB1)
DM7ISKJ	MT	DTP
DM7ISKJ	MA	Substrate
DM7ISKJ	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM7ISKJ	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMOWLVG	DI	DMOWLVG
DMOWLVG	DN	Nitazoxanide
DMOWLVG	MI	TT0F5P8
DMOWLVG	MN	Cryptosporidium Pyruvate:ferredoxin oxidoreductase (Crypto CpPNO)
DMOWLVG	MT	DTT
DMOWLVG	MA	Modulator
DMOWLVG	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMOWLVG	RU	https://www.fda.gov/

DMVS9WQ	DI	DMVS9WQ
DMVS9WQ	DN	Nitisinone
DMVS9WQ	MI	TT8DSFC
DMVS9WQ	MN	Hydroxyphenylpyruvate dioxygenase (HPD)
DMVS9WQ	MT	DTT
DMVS9WQ	MA	Inhibitor
DMVS9WQ	RN	Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1. Expert Opin Pharmacother. 2008 May;9(7):1229-36.
DMVS9WQ	RU	https://pubmed.ncbi.nlm.nih.gov/18422479

DMEGIQ6	DI	DMEGIQ6
DMEGIQ6	DN	Nitrazepam
DMEGIQ6	MI	DE4LYSA
DMEGIQ6	MN	Cytochrome P450 3A4 (CYP3A4)
DMEGIQ6	MT	DME
DMEGIQ6	MA	Metabolism
DMEGIQ6	RN	Prediction of metabolic clearance using fresh human hepatocytes: comparison with cryopreserved hepatocytes and hepatic microsomes for five benzodiazepines. Xenobiotica. 2008 Apr;38(4):353-67.
DMEGIQ6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18340561

DMEGIQ6	DI	DMEGIQ6
DMEGIQ6	DN	Nitrazepam
DMEGIQ6	MI	TT1MPAY
DMEGIQ6	MN	GABA(A) receptor alpha-1 (GABRA1)
DMEGIQ6	MT	DTT
DMEGIQ6	MA	Antagonist
DMEGIQ6	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DMEGIQ6	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DMEGIQ6	DI	DMEGIQ6
DMEGIQ6	DN	Nitrazepam
DMEGIQ6	MI	DEAVXGM
DMEGIQ6	MN	Nitroreductase (NTR)
DMEGIQ6	MT	DME
DMEGIQ6	MA	Metabolism
DMEGIQ6	RN	Reduction of nitrazepam by Clostridium leptum, a nitroreductase-producing bacterium isolated from the human intestinal tract. Clin Infect Dis. 1997 Sep;25 Suppl 2:S121-2.
DMEGIQ6	RU	https://pubmed.ncbi.nlm.nih.gov/9310649

DMEGIQ6	DI	DMEGIQ6
DMEGIQ6	DN	Nitrazepam
DMEGIQ6	MI	DEGV7K0
DMEGIQ6	MN	Nitroreductase (NTR)
DMEGIQ6	MT	DME
DMEGIQ6	MA	Metabolism
DMEGIQ6	RN	Distinct genetic and functional traits of human intestinal Prevotella copri strains are associated with different habitual diets. Cell Host Microbe. 2019 Mar 13;25(3):444-453.e3.
DMEGIQ6	RU	https://pubmed.ncbi.nlm.nih.gov/30799264

DMEGIQ6	DI	DMEGIQ6
DMEGIQ6	DN	Nitrazepam
DMEGIQ6	MI	DE0K82S
DMEGIQ6	MN	Nitroreductase (NTR)
DMEGIQ6	MT	DME
DMEGIQ6	MA	Metabolism
DMEGIQ6	RN	Purification and characterization of wild-type and mutant "classical" nitroreductases of Salmonella typhimurium. L33R mutation greatly diminishes binding of FMN to the nitroreductase of S. typhimurium. J Biol Chem. 1998 Sep 11;273(37):23922-8.
DMEGIQ6	RU	https://pubmed.ncbi.nlm.nih.gov/9727006

DMEGIQ6	DI	DMEGIQ6
DMEGIQ6	DN	Nitrazepam
DMEGIQ6	MI	DEDPI65
DMEGIQ6	MN	Oxygen-insensitive NADPH nitroreductase A (nfsA)
DMEGIQ6	MT	DME
DMEGIQ6	MA	Metabolism
DMEGIQ6	RN	Biochemical characterization of NfsA, the Escherichia coli major nitroreductase exhibiting a high amino acid sequence homology to Frp, a Vibrio harveyi flavin oxidoreductase. J Bacteriol. 1996 Aug;178(15):4508-14.
DMEGIQ6	RU	https://pubmed.ncbi.nlm.nih.gov/8755878

DMEGIQ6	DI	DMEGIQ6
DMEGIQ6	DN	Nitrazepam
DMEGIQ6	MI	DEX5D46
DMEGIQ6	MN	Oxygen-insensitive NADPH nitroreductase A (nfsA)
DMEGIQ6	MT	DME
DMEGIQ6	MA	Metabolism
DMEGIQ6	RN	Identification and characterization of SnrA, an inducible oxygen-insensitive nitroreductase in Salmonella enterica serovar Typhimurium TA1535. Mutat Res. 2002 Oct 31;508(1-2):59-70.
DMEGIQ6	RU	https://pubmed.ncbi.nlm.nih.gov/12379462

DMEGIQ6	DI	DMEGIQ6
DMEGIQ6	DN	Nitrazepam
DMEGIQ6	MI	DE0QLUZ
DMEGIQ6	MN	Oxygen-insensitive NADPH nitroreductase B (nfsB)
DMEGIQ6	MT	DME
DMEGIQ6	MA	Metabolism
DMEGIQ6	RN	Conversion of NfsB, a minor Escherichia coli nitroreductase, to a flavin reductase similar in biochemical properties to FRase I, the major flavin reductase in Vibrio fischeri, by a single amino acid substitution. J Bacteriol. 1996 Aug;178(15):4731-3.
DMEGIQ6	RU	https://pubmed.ncbi.nlm.nih.gov/8755909

DM21C09	DI	DM21C09
DM21C09	DN	Nitrendipine
DM21C09	MI	DE4LYSA
DM21C09	MN	Cytochrome P450 3A4 (CYP3A4)
DM21C09	MT	DME
DM21C09	MA	Metabolism
DM21C09	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM21C09	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM21C09	DI	DM21C09
DM21C09	DN	Nitrendipine
DM21C09	MI	DEIBDNY
DM21C09	MN	Cytochrome P450 3A5 (CYP3A5)
DM21C09	MT	DME
DM21C09	MA	Metabolism
DM21C09	RN	Drug Interactions Flockhart Table
DM21C09	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM21C09	DI	DM21C09
DM21C09	DN	Nitrendipine
DM21C09	MI	DERD86B
DM21C09	MN	Cytochrome P450 3A7 (CYP3A7)
DM21C09	MT	DME
DM21C09	MA	Metabolism
DM21C09	RN	Drug Interactions Flockhart Table
DM21C09	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM21C09	DI	DM21C09
DM21C09	DN	Nitrendipine
DM21C09	MI	DTUGYRD
DM21C09	MN	P-glycoprotein 1 (ABCB1)
DM21C09	MT	DTP
DM21C09	MA	Substrate
DM21C09	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM21C09	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DM21C09	DI	DM21C09
DM21C09	DN	Nitrendipine
DM21C09	MI	TTFK1JQ
DM21C09	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DM21C09	MT	DTT
DM21C09	MA	Blocker
DM21C09	RN	Sulfobutyl ether-alkyl ether mixed cyclodextrin derivatives with enhanced inclusion ability. J Pharm Sci. 2009 Dec;98(12):4769-80.
DM21C09	RU	https://pubmed.ncbi.nlm.nih.gov/19408308

DM1RBYG	DI	DM1RBYG
DM1RBYG	DN	Nitric Oxide
DM1RBYG	MI	DTW7AE3
DM1RBYG	MN	Alanine/serine/cysteine/threonine transporter 2 (SLC1A5)
DM1RBYG	MT	DTP
DM1RBYG	MA	Substrate
DM1RBYG	RN	Functional regulation of Na+-dependent neutral amino acid transporter ASCT2 by S-nitrosothiols and nitric oxide in Caco-2 cells. FEBS Lett. 2005 Apr 25;579(11):2499-506.
DM1RBYG	RU	http://www.ncbi.nlm.nih.gov/pubmed/15848195

DM1RBYG	DI	DM1RBYG
DM1RBYG	DN	Nitric Oxide
DM1RBYG	MI	TT6HPVC
DM1RBYG	MN	Guanylate cyclase (GC)
DM1RBYG	MT	DTT
DM1RBYG	MA	Stimulator
DM1RBYG	RN	Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem. 2010 Jan;333(1-2):191-201.
DM1RBYG	RU	https://pubmed.ncbi.nlm.nih.gov/19618122

DM1RBYG	DI	DM1RBYG
DM1RBYG	DN	Nitric Oxide
DM1RBYG	MI	TT23PYC
DM1RBYG	MN	Soluble guanylate cyclase (GCS)
DM1RBYG	MT	DTT
DM1RBYG	MA	Stimulator
DM1RBYG	RN	Nitric oxide and nitrovasodilators: similarities, differences, and interactions. Am J Cardiol. 1996 May 30;77(13):2C-7C.
DM1RBYG	RU	https://pubmed.ncbi.nlm.nih.gov/8638522

DM7PQIK	DI	DM7PQIK
DM7PQIK	DN	Nitrofurantoin
DM7PQIK	MI	TTS1W4A
DM7PQIK	MN	Bacterial Deoxyribonucleic acid (Bact DNA)
DM7PQIK	MT	DTT
DM7PQIK	MA	Breaker
DM7PQIK	RN	On the nature of the adaptive response induced by mitomycin C in Vibrio cholerae OGAWA 154 cells. Biochem Biophys Res Commun. 1996 Mar 27;220(3):509-14.
DM7PQIK	RU	https://pubmed.ncbi.nlm.nih.gov/8607796

DM7PQIK	DI	DM7PQIK
DM7PQIK	DN	Nitrofurantoin
DM7PQIK	MI	DTI7UX6
DM7PQIK	MN	Breast cancer resistance protein (ABCG2)
DM7PQIK	MT	DTP
DM7PQIK	MA	Substrate
DM7PQIK	RN	The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin. Mol Pharmacol. 2005 May;67(5):1758-64.
DM7PQIK	RU	http://www.ncbi.nlm.nih.gov/pubmed/15709111

DM7PQIK	DI	DM7PQIK
DM7PQIK	DN	Nitrofurantoin
DM7PQIK	MI	DE3N2FM
DM7PQIK	MN	NADPH-cytochrome P450 reductase (CPR)
DM7PQIK	MT	DME
DM7PQIK	MA	Metabolism
DM7PQIK	RN	Role of cytochrome P450 reductase in nitrofurantoin-induced redox cycling and cytotoxicity. Free Radic Biol Med. 2008 Mar 15;44(6):1169-79.
DM7PQIK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18206659

DM7PQIK	DI	DM7PQIK
DM7PQIK	DN	Nitrofurantoin
DM7PQIK	MI	DE21PLI
DM7PQIK	MN	NADPH-dependent nitroreductase (nfrA1)
DM7PQIK	MT	DME
DM7PQIK	MA	Metabolism
DM7PQIK	RN	Conversion of NfsA, the major Escherichia coli nitroreductase, to a flavin reductase with an activity similar to that of Frp, a flavin reductase in Vibrio harveyi, by a single amino acid substitution. J Bacteriol. 1998 Jan;180(2):422-5.
DM7PQIK	RU	https://pubmed.ncbi.nlm.nih.gov/9440535

DM7PQIK	DI	DM7PQIK
DM7PQIK	DN	Nitrofurantoin
DM7PQIK	MI	DE82GV7
DM7PQIK	MN	NADPH-dependent oxidoreductase (nfrA)
DM7PQIK	MT	DME
DM7PQIK	MA	Metabolism
DM7PQIK	RN	Reduction of polynitroaromatic compounds: the bacterial nitroreductases. FEMS Microbiol Rev. 2008 May;32(3):474-500.
DM7PQIK	RU	https://pubmed.ncbi.nlm.nih.gov/18355273

DM7PQIK	DI	DM7PQIK
DM7PQIK	DN	Nitrofurantoin
DM7PQIK	MI	DEAVXGM
DM7PQIK	MN	Nitroreductase (NTR)
DM7PQIK	MT	DME
DM7PQIK	MA	Metabolism
DM7PQIK	RN	Isolation of nitrofurantoin-resistant mutants of nitroreductase-producing Clostridium sp. strains from the human intestinal tract. Antimicrob Agents Chemother. 1998 May;42(5):1121-6.
DM7PQIK	RU	https://pubmed.ncbi.nlm.nih.gov/9593138

DM7PQIK	DI	DM7PQIK
DM7PQIK	DN	Nitrofurantoin
DM7PQIK	MI	DE7XBKW
DM7PQIK	MN	Nitroreductase (NTR)
DM7PQIK	MT	DME
DM7PQIK	MA	Metabolism
DM7PQIK	RN	Isolation of nitrofurantoin-resistant mutants of nitroreductase-producing Clostridium sp. strains from the human intestinal tract. Antimicrob Agents Chemother. 1998 May;42(5):1121-6.
DM7PQIK	RU	https://pubmed.ncbi.nlm.nih.gov/9593138

DM7PQIK	DI	DM7PQIK
DM7PQIK	DN	Nitrofurantoin
DM7PQIK	MI	DEP7ECA
DM7PQIK	MN	Nitroreductase (NTR)
DM7PQIK	MT	DME
DM7PQIK	MA	Metabolism
DM7PQIK	RN	Isolation of nitrofurantoin-resistant mutants of nitroreductase-producing Clostridium sp. strains from the human intestinal tract. Antimicrob Agents Chemother. 1998 May;42(5):1121-6.
DM7PQIK	RU	https://pubmed.ncbi.nlm.nih.gov/9593138

DM7PQIK	DI	DM7PQIK
DM7PQIK	DN	Nitrofurantoin
DM7PQIK	MI	DEH3ABM
DM7PQIK	MN	Nitroreductase (NTR)
DM7PQIK	MT	DME
DM7PQIK	MA	Metabolism
DM7PQIK	RN	Isolation of nitrofurantoin-resistant mutants of nitroreductase-producing Clostridium sp. strains from the human intestinal tract. Antimicrob Agents Chemother. 1998 May;42(5):1121-6.
DM7PQIK	RU	https://pubmed.ncbi.nlm.nih.gov/9593138

DM7PQIK	DI	DM7PQIK
DM7PQIK	DN	Nitrofurantoin
DM7PQIK	MI	DE3U2Y6
DM7PQIK	MN	Nitroreductase (NTR)
DM7PQIK	MT	DME
DM7PQIK	MA	Metabolism
DM7PQIK	RN	Mechanism of metronidazole-resistance by isolates of nitroreductase-producing Enterococcus gallinarum and Enterococcus casseliflavus from the human intestinal tract. FEMS Microbiol Lett. 2003 Aug 29;225(2):195-200.
DM7PQIK	RU	https://pubmed.ncbi.nlm.nih.gov/12951241

DM7PQIK	DI	DM7PQIK
DM7PQIK	DN	Nitrofurantoin
DM7PQIK	MI	DEUW4J0
DM7PQIK	MN	Nitroreductase (NTR)
DM7PQIK	MT	DME
DM7PQIK	MA	Metabolism
DM7PQIK	RN	Mechanism of metronidazole-resistance by isolates of nitroreductase-producing Enterococcus gallinarum and Enterococcus casseliflavus from the human intestinal tract. FEMS Microbiol Lett. 2003 Aug 29;225(2):195-200.
DM7PQIK	RU	https://pubmed.ncbi.nlm.nih.gov/12951241

DM7PQIK	DI	DM7PQIK
DM7PQIK	DN	Nitrofurantoin
DM7PQIK	MI	DE5LYXF
DM7PQIK	MN	Nitroreductase (NTR)
DM7PQIK	MT	DME
DM7PQIK	MA	Metabolism
DM7PQIK	RN	Biotransformation of 1-nitropyrene in intestinal anaerobic bacteria. Microbiol Immunol. 1982;26(11):993-1005.
DM7PQIK	RU	https://pubmed.ncbi.nlm.nih.gov/7167066

DMSM2KE	DI	DMSM2KE
DMSM2KE	DN	Nitrofurazone
DMSM2KE	MI	TTOVFH2
DMSM2KE	MN	Bacterial 30S ribosomal RNA (Bact 30S rRNA)
DMSM2KE	MT	DTT
DMSM2KE	MA	Inhibitor
DMSM2KE	RN	The antibiotic Furvina targets the P-site of 30S ribosomal subunits and inhibits translation initiation displaying start codon bias. Nucleic Acids Res. 2012 Nov 1;40(20):10366-74.
DMSM2KE	RU	https://pubmed.ncbi.nlm.nih.gov/22941660

DMSM2KE	DI	DMSM2KE
DMSM2KE	DN	Nitrofurazone
DMSM2KE	MI	DECB0K3
DMSM2KE	MN	Cytochrome P450 2D6 (CYP2D6)
DMSM2KE	MT	DME
DMSM2KE	MA	Metabolism
DMSM2KE	RN	Nefazodone pharmacokinetics in depressed children and adolescents. J Am Acad Child Adolesc Psychiatry. 2000 Aug;39(8):1008-16.
DMSM2KE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10939229

DMSM2KE	DI	DMSM2KE
DMSM2KE	DN	Nitrofurazone
DMSM2KE	MI	DE21PLI
DMSM2KE	MN	NADPH-dependent nitroreductase (nfrA1)
DMSM2KE	MT	DME
DMSM2KE	MA	Metabolism
DMSM2KE	RN	Conversion of NfsA, the major Escherichia coli nitroreductase, to a flavin reductase with an activity similar to that of Frp, a flavin reductase in Vibrio harveyi, by a single amino acid substitution. J Bacteriol. 1998 Jan;180(2):422-5.
DMSM2KE	RU	https://pubmed.ncbi.nlm.nih.gov/9440535

DMSM2KE	DI	DMSM2KE
DMSM2KE	DN	Nitrofurazone
DMSM2KE	MI	DE82GV7
DMSM2KE	MN	NADPH-dependent oxidoreductase (nfrA)
DMSM2KE	MT	DME
DMSM2KE	MA	Metabolism
DMSM2KE	RN	Reduction of polynitroaromatic compounds: the bacterial nitroreductases. FEMS Microbiol Rev. 2008 May;32(3):474-500.
DMSM2KE	RU	https://pubmed.ncbi.nlm.nih.gov/18355273

DMSM2KE	DI	DMSM2KE
DMSM2KE	DN	Nitrofurazone
DMSM2KE	MI	DE3U2Y6
DMSM2KE	MN	Nitroreductase (NTR)
DMSM2KE	MT	DME
DMSM2KE	MA	Metabolism
DMSM2KE	RN	Mechanism of metronidazole-resistance by isolates of nitroreductase-producing Enterococcus gallinarum and Enterococcus casseliflavus from the human intestinal tract. FEMS Microbiol Lett. 2003 Aug 29;225(2):195-200.
DMSM2KE	RU	https://pubmed.ncbi.nlm.nih.gov/12951241

DMSM2KE	DI	DMSM2KE
DMSM2KE	DN	Nitrofurazone
DMSM2KE	MI	DEUW4J0
DMSM2KE	MN	Nitroreductase (NTR)
DMSM2KE	MT	DME
DMSM2KE	MA	Metabolism
DMSM2KE	RN	Mechanism of metronidazole-resistance by isolates of nitroreductase-producing Enterococcus gallinarum and Enterococcus casseliflavus from the human intestinal tract. FEMS Microbiol Lett. 2003 Aug 29;225(2):195-200.
DMSM2KE	RU	https://pubmed.ncbi.nlm.nih.gov/12951241

DMSM2KE	DI	DMSM2KE
DMSM2KE	DN	Nitrofurazone
DMSM2KE	MI	DEDPI65
DMSM2KE	MN	Oxygen-insensitive NADPH nitroreductase A (nfsA)
DMSM2KE	MT	DME
DMSM2KE	MA	Metabolism
DMSM2KE	RN	Biochemical characterization of NfsA, the Escherichia coli major nitroreductase exhibiting a high amino acid sequence homology to Frp, a Vibrio harveyi flavin oxidoreductase. J Bacteriol. 1996 Aug;178(15):4508-14.
DMSM2KE	RU	https://pubmed.ncbi.nlm.nih.gov/8755878

DMSM2KE	DI	DMSM2KE
DMSM2KE	DN	Nitrofurazone
DMSM2KE	MI	DE0QLUZ
DMSM2KE	MN	Oxygen-insensitive NADPH nitroreductase B (nfsB)
DMSM2KE	MT	DME
DMSM2KE	MA	Metabolism
DMSM2KE	RN	Conversion of NfsB, a minor Escherichia coli nitroreductase, to a flavin reductase similar in biochemical properties to FRase I, the major flavin reductase in Vibrio fischeri, by a single amino acid substitution. J Bacteriol. 1996 Aug;178(15):4731-3.
DMSM2KE	RU	https://pubmed.ncbi.nlm.nih.gov/8755909

DMQ2491	DI	DMQ2491
DMQ2491	DN	Nitroglycerin
DMQ2491	MI	TTGKNB4
DMQ2491	MN	Epidermal growth factor receptor (EGFR)
DMQ2491	MT	DTT
DMQ2491	MA	Activator
DMQ2491	RN	Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
DMQ2491	RU	https://pubmed.ncbi.nlm.nih.gov/17064227

DMQ2491	DI	DMQ2491
DMQ2491	DN	Nitroglycerin
DMQ2491	MI	TT23PYC
DMQ2491	MN	Soluble guanylate cyclase (GCS)
DMQ2491	MT	DTT
DMQ2491	MA	Modulator
DMQ2491	RN	Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction. Int J Impot Res. 2002 Feb;14(1):8-14.
DMQ2491	RU	https://pubmed.ncbi.nlm.nih.gov/11896472

DMM765C	DI	DMM765C
DMM765C	DN	Nitroprusside
DMM765C	MI	TTC9IZL
DMM765C	MN	Inositol 1,4,5-trisphosphate receptor (ITPR)
DMM765C	MT	DTT
DMM765C	MA	Antagonist
DMM765C	RN	Prostacyclin and sodium nitroprusside inhibit the activity of the platelet inositol 1,4,5-trisphosphate receptor and promote its phosphorylation. J Biol Chem. 1996 Mar 8;271(10):5545-51.
DMM765C	RU	https://pubmed.ncbi.nlm.nih.gov/8621413

DMLUA2J	DI	DMLUA2J
DMLUA2J	DN	Nitroprusside
DMLUA2J	MI	DEAH3PE
DMLUA2J	MN	S-(hydroxymethyl)glutathione dehydrogenase (adh)
DMLUA2J	MT	DME
DMLUA2J	MA	Metabolism
DMLUA2J	RN	Nitrosative stress response in Vibrio cholerae: role of S-nitrosoglutathione reductase. Appl Biochem Biotechnol. 2017 Jul;182(3):871-884.
DMLUA2J	RU	https://pubmed.ncbi.nlm.nih.gov/28000045

DMTHWBI	DI	DMTHWBI
DMTHWBI	DN	Nitrous oxide
DMTHWBI	MI	TT9IK2Z
DMTHWBI	MN	N-methyl-D-aspartate receptor (NMDAR)
DMTHWBI	MT	DTT
DMTHWBI	MA	Antagonist
DMTHWBI	RN	Anaesthetic drugs: linking molecular actions to clinical effects. Curr Pharm Des. 2006;12(28):3665-79.
DMTHWBI	RU	https://pubmed.ncbi.nlm.nih.gov/17073666

DMAB9QE	DI	DMAB9QE
DMAB9QE	DN	Nivolumab
DMAB9QE	MI	TTNBFWK
DMAB9QE	MN	Programmed cell death protein 1 (PD-1)
DMAB9QE	MT	DTT
DMAB9QE	MA	Modulator
DMAB9QE	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMAB9QE	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMGFV3Z	DI	DMGFV3Z
DMGFV3Z	DN	Nizatidine
DMGFV3Z	MI	TTQHJ1K
DMGFV3Z	MN	Histamine H2 receptor (H2R)
DMGFV3Z	MT	DTT
DMGFV3Z	MA	Antagonist
DMGFV3Z	RN	Does the use of nizatidine, as a pro-kinetic agent, improve gastric emptying in patients post-oesophagectomy J Gastrointest Surg. 2009 Mar;13(3):432-7.
DMGFV3Z	RU	https://pubmed.ncbi.nlm.nih.gov/18979143

DMGFV3Z	DI	DMGFV3Z
DMGFV3Z	DN	Nizatidine
DMGFV3Z	MI	DTT79CX
DMGFV3Z	MN	Organic cation transporter 1 (SLC22A1)
DMGFV3Z	MT	DTP
DMGFV3Z	MA	Substrate
DMGFV3Z	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMGFV3Z	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DMGFV3Z	DI	DMGFV3Z
DMGFV3Z	DN	Nizatidine
DMGFV3Z	MI	DTUGYRD
DMGFV3Z	MN	P-glycoprotein 1 (ABCB1)
DMGFV3Z	MT	DTP
DMGFV3Z	MA	Substrate
DMGFV3Z	RN	DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB00585)
DMGFV3Z	RU	https://www.drugbank.ca/drugs/DB00585

DMRJ7D1	DI	DMRJ7D1
DMRJ7D1	DN	Nomegestrol acetate
DMRJ7D1	MI	TTZAYWL
DMRJ7D1	MN	Estrogen receptor (ESR)
DMRJ7D1	MT	DTT
DMRJ7D1	MA	Modulator
DMRJ7D1	RN	Regulation of rat uterine steroid receptors by nomegestrol acetate, a new 19-nor-progesterone derivative. J Pharmacol Exp Ther. 1989 Feb;248(2):758-61.
DMRJ7D1	RU	https://pubmed.ncbi.nlm.nih.gov/2918478

DMOUC09	DI	DMOUC09
DMOUC09	DN	Norepinephrine
DMOUC09	MI	TTR6W5O
DMOUC09	MN	Adrenergic receptor beta-1 (ADRB1)
DMOUC09	MT	DTT
DMOUC09	MA	Stimulator
DMOUC09	RN	Impact of exogenous beta-adrenergic receptor stimulation on hepatosplanchnic oxygen kinetics and metabolic activity in septic shock. Crit Care Med. 1999 Feb;27(2):325-31.
DMOUC09	RU	https://pubmed.ncbi.nlm.nih.gov/10075057

DMOUC09	DI	DMOUC09
DMOUC09	DN	Norepinephrine
DMOUC09	MI	DTT79CX
DMOUC09	MN	Organic cation transporter 1 (SLC22A1)
DMOUC09	MT	DTP
DMOUC09	MA	Substrate
DMOUC09	RN	Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
DMOUC09	RU	https://doi.org/10.2133/dmpk.23.243

DMOUC09	DI	DMOUC09
DMOUC09	DN	Norepinephrine
DMOUC09	MI	DT9IDPW
DMOUC09	MN	Organic cation transporter 2 (SLC22A2)
DMOUC09	MT	DTP
DMOUC09	MA	Substrate
DMOUC09	RN	Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.
DMOUC09	RU	http://www.ncbi.nlm.nih.gov/pubmed/16581093

DMOUC09	DI	DMOUC09
DMOUC09	DN	Norepinephrine
DMOUC09	MI	DT6201N
DMOUC09	MN	Organic cation transporter 3 (SLC22A3)
DMOUC09	MT	DTP
DMOUC09	MA	Substrate
DMOUC09	RN	Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.
DMOUC09	RU	http://www.ncbi.nlm.nih.gov/pubmed/16581093

DMOUC09	DI	DMOUC09
DMOUC09	DN	Norepinephrine
DMOUC09	MI	DTE8R17
DMOUC09	MN	Sodium- and chloride-dependent glycine transporter 2 (SLC6A5)
DMOUC09	MT	DTP
DMOUC09	MA	Substrate
DMOUC09	RN	SLC6A2 Gene (Protein Coding).
DMOUC09	RU	https://www.genecards.org/cgi-bin/carddisp.pl?gene=SLC6A2

DMOUC09	DI	DMOUC09
DMOUC09	DN	Norepinephrine
DMOUC09	MI	DT9JBVI
DMOUC09	MN	Sodium-dependent noradrenaline transporter (SLC6A2)
DMOUC09	MT	DTP
DMOUC09	MA	Substrate
DMOUC09	RN	Chronic depolarization stimulates norepinephrine transporter expression via catecholamines. J Neurochem. 2006 May;97(4):1044-51.
DMOUC09	RU	http://www.ncbi.nlm.nih.gov/pubmed/16573647

DMOUC09	DI	DMOUC09
DMOUC09	DN	Norepinephrine
DMOUC09	MI	DTM953D
DMOUC09	MN	Vesicular amine transporter 1 (SLC18A1)
DMOUC09	MT	DTP
DMOUC09	MA	Substrate
DMOUC09	RN	SLC18: Vesicular neurotransmitter transporters for monoamines and acetylcholine. Mol Aspects Med. 2013 Apr-Jun;34(2-3):360-72.
DMOUC09	RU	http://www.ncbi.nlm.nih.gov/pubmed/23506877

DMOUC09	DI	DMOUC09
DMOUC09	DN	Norepinephrine
DMOUC09	MI	DTT7VPB
DMOUC09	MN	Vesicular amine transporter 2 (SLC18A2)
DMOUC09	MT	DTP
DMOUC09	MA	Substrate
DMOUC09	RN	SLC18: Vesicular neurotransmitter transporters for monoamines and acetylcholine. Mol Aspects Med. 2013 Apr-Jun;34(2-3):360-72.
DMOUC09	RU	http://www.ncbi.nlm.nih.gov/pubmed/23506877

DMTY169	DI	DMTY169
DMTY169	DN	Norethindrone
DMTY169	MI	TTUV8G9
DMTY169	MN	Progesterone receptor (PGR)
DMTY169	MT	DTT
DMTY169	MA	Agonist
DMTY169	RN	Progesterone receptor ligand binding pocket flexibility: crystal structures of the norethindrone and mometasone furoate complexes. J Med Chem. 2004 Jun 17;47(13):3381-7.
DMTY169	RU	https://pubmed.ncbi.nlm.nih.gov/15189034

DMDGCQP	DI	DMDGCQP
DMDGCQP	DN	Norethindrone acetate
DMDGCQP	MI	DEAJN47
DMDGCQP	MN	Aldo-keto reductase 1C4 (AKR1C4)
DMDGCQP	MT	DME
DMDGCQP	MA	Metabolism
DMDGCQP	RN	Hormonal properties of norethisterone, 7alpha-methyl-norethisterone and their derivatives. J Steroid Biochem Mol Biol. 2000 Nov 15;74(4):213-22.
DMDGCQP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11162927

DMDGCQP	DI	DMDGCQP
DMDGCQP	DN	Norethindrone acetate
DMDGCQP	MI	DEVON3M
DMDGCQP	MN	Aldo-keto reductase 1D1 (AKR1D1)
DMDGCQP	MT	DME
DMDGCQP	MA	Metabolism
DMDGCQP	RN	Hormonal properties of norethisterone, 7alpha-methyl-norethisterone and their derivatives. J Steroid Biochem Mol Biol. 2000 Nov 15;74(4):213-22.
DMDGCQP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11162927

DMDGCQP	DI	DMDGCQP
DMDGCQP	DN	Norethindrone acetate
DMDGCQP	MI	DEN0GVQ
DMDGCQP	MN	Beta-HSD adrenal and gonadal type (HSD3B2)
DMDGCQP	MT	DME
DMDGCQP	MA	Metabolism
DMDGCQP	RN	Hormonal properties of norethisterone, 7alpha-methyl-norethisterone and their derivatives. J Steroid Biochem Mol Biol. 2000 Nov 15;74(4):213-22.
DMDGCQP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11162927

DMDGCQP	DI	DMDGCQP
DMDGCQP	DN	Norethindrone acetate
DMDGCQP	MI	DEJGDUW
DMDGCQP	MN	Cytochrome P450 1A2 (CYP1A2)
DMDGCQP	MT	DME
DMDGCQP	MA	Metabolism
DMDGCQP	RN	Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone. J Steroid Biochem Mol Biol. 2008 May;110(1-2):56-66.
DMDGCQP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18356043

DMDGCQP	DI	DMDGCQP
DMDGCQP	DN	Norethindrone acetate
DMDGCQP	MI	DEJVYAZ
DMDGCQP	MN	Cytochrome P450 2A6 (CYP2A6)
DMDGCQP	MT	DME
DMDGCQP	MA	Metabolism
DMDGCQP	RN	Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone. J Steroid Biochem Mol Biol. 2008 May;110(1-2):56-66.
DMDGCQP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18356043

DMDGCQP	DI	DMDGCQP
DMDGCQP	DN	Norethindrone acetate
DMDGCQP	MI	DE4LYSA
DMDGCQP	MN	Cytochrome P450 3A4 (CYP3A4)
DMDGCQP	MT	DME
DMDGCQP	MA	Metabolism
DMDGCQP	RN	Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone. J Steroid Biochem Mol Biol. 2008 May;110(1-2):56-66.
DMDGCQP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18356043

DMDGCQP	DI	DMDGCQP
DMDGCQP	DN	Norethindrone acetate
DMDGCQP	MI	DEIBDNY
DMDGCQP	MN	Cytochrome P450 3A5 (CYP3A5)
DMDGCQP	MT	DME
DMDGCQP	MA	Metabolism
DMDGCQP	RN	The interaction between St John's wort and an oral contraceptive. Clin Pharmacol Ther. 2003 Dec;74(6):525-35.
DMDGCQP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14663455

DMDGCQP	DI	DMDGCQP
DMDGCQP	DN	Norethindrone acetate
DMDGCQP	MI	DERD86B
DMDGCQP	MN	Cytochrome P450 3A7 (CYP3A7)
DMDGCQP	MT	DME
DMDGCQP	MA	Metabolism
DMDGCQP	RN	The interaction between St John's wort and an oral contraceptive. Clin Pharmacol Ther. 2003 Dec;74(6):525-35.
DMDGCQP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14663455

DMDGCQP	DI	DMDGCQP
DMDGCQP	DN	Norethindrone acetate
DMDGCQP	MI	DEGTFWK
DMDGCQP	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMDGCQP	MT	DME
DMDGCQP	MA	Metabolism
DMDGCQP	RN	Drug Interactions Flockhart Table
DMDGCQP	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMIZ6W2	DI	DMIZ6W2
DMIZ6W2	DN	Norfloxacin
DMIZ6W2	MI	TTN6J5F
DMIZ6W2	MN	Bacterial DNA gyrase (Bact gyrase)
DMIZ6W2	MT	DTT
DMIZ6W2	MA	Modulator
DMIZ6W2	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMIZ6W2	RU	https://www.fda.gov/

DMIZ6W2	DI	DMIZ6W2
DMIZ6W2	DN	Norfloxacin
DMIZ6W2	MI	DTI7UX6
DMIZ6W2	MN	Breast cancer resistance protein (ABCG2)
DMIZ6W2	MT	DTP
DMIZ6W2	MA	Substrate
DMIZ6W2	RN	Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. Drug Metab Dispos. 2006 Apr;34(4):690-5.
DMIZ6W2	RU	http://www.ncbi.nlm.nih.gov/pubmed/16434544

DMIZ6W2	DI	DMIZ6W2
DMIZ6W2	DN	Norfloxacin
DMIZ6W2	MI	DEJGDUW
DMIZ6W2	MN	Cytochrome P450 1A2 (CYP1A2)
DMIZ6W2	MT	DME
DMIZ6W2	MA	Metabolism
DMIZ6W2	RN	Clinically significant psychotropic drug-drug interactions in the primary care setting. Curr Psychiatry Rep. 2012 Aug;14(4):376-90.
DMIZ6W2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22707017

DMIZ6W2	DI	DMIZ6W2
DMIZ6W2	DN	Norfloxacin
DMIZ6W2	MI	DTE2B1D
DMIZ6W2	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMIZ6W2	MT	DTP
DMIZ6W2	MA	Substrate
DMIZ6W2	RN	Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm. 2007 Jan-Feb;4(1):85-94.
DMIZ6W2	RU	http://www.ncbi.nlm.nih.gov/pubmed/17274666

DMIZ6W2	DI	DMIZ6W2
DMIZ6W2	DN	Norfloxacin
DMIZ6W2	MI	DTUGYRD
DMIZ6W2	MN	P-glycoprotein 1 (ABCB1)
DMIZ6W2	MT	DTP
DMIZ6W2	MA	Substrate
DMIZ6W2	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMIZ6W2	RU	https://doi.org/10.1007/s11095-012-0935-x

DMYP4XC	DI	DMYP4XC
DMYP4XC	DN	Norgestimate
DMYP4XC	MI	DE4LYSA
DMYP4XC	MN	Cytochrome P450 3A4 (CYP3A4)
DMYP4XC	MT	DME
DMYP4XC	MA	Metabolism
DMYP4XC	RN	Metabolite identification, reaction phenotyping, and retrospective drug-drug interaction predictions of 17-deacetylnorgestimate, the active component of the oral contraceptive norgestimate. Drug Metab Dispos. 2017 Jun;45(6):676-685.
DMYP4XC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28283499

DMYP4XC	DI	DMYP4XC
DMYP4XC	DN	Norgestimate
DMYP4XC	MI	TTUV8G9
DMYP4XC	MN	Progesterone receptor (PGR)
DMYP4XC	MT	DTT
DMYP4XC	MA	Agonist
DMYP4XC	RN	Pharmacological profile of progestins. Maturitas. 2008 Sep-Oct;61(1-2):151-7.
DMYP4XC	RU	https://pubmed.ncbi.nlm.nih.gov/19434887

DM4KDYJ	DI	DM4KDYJ
DM4KDYJ	DN	Nortriptyline
DM4KDYJ	MI	DEJGDUW
DM4KDYJ	MN	Cytochrome P450 1A2 (CYP1A2)
DM4KDYJ	MT	DME
DM4KDYJ	MA	Metabolism
DM4KDYJ	RN	Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes. Drug Metab Dispos. 1997 Jun;25(6):740-4.
DM4KDYJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9193876

DM4KDYJ	DI	DM4KDYJ
DM4KDYJ	DN	Nortriptyline
DM4KDYJ	MI	DECB0K3
DM4KDYJ	MN	Cytochrome P450 2D6 (CYP2D6)
DM4KDYJ	MT	DME
DM4KDYJ	MA	Metabolism
DM4KDYJ	RN	A study on CYP2C19 and CYP2D6 polymorphic effects on pharmacokinetics and pharmacodynamics of amitriptyline in healthy Koreans. Clin Transl Sci. 2017 Mar;10(2):93-101.
DM4KDYJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28296334

DM4KDYJ	DI	DM4KDYJ
DM4KDYJ	DN	Nortriptyline
DM4KDYJ	MI	DE4LYSA
DM4KDYJ	MN	Cytochrome P450 3A4 (CYP3A4)
DM4KDYJ	MT	DME
DM4KDYJ	MA	Metabolism
DM4KDYJ	RN	Cytochrome P-450 activities in human and rat brain microsomes. Brain Res. 2000 Feb 14;855(2):235-43.
DM4KDYJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10677595

DM4KDYJ	DI	DM4KDYJ
DM4KDYJ	DN	Nortriptyline
DM4KDYJ	MI	DEIBDNY
DM4KDYJ	MN	Cytochrome P450 3A5 (CYP3A5)
DM4KDYJ	MT	DME
DM4KDYJ	MA	Metabolism
DM4KDYJ	RN	Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67.
DM4KDYJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18359012

DM4KDYJ	DI	DM4KDYJ
DM4KDYJ	DN	Nortriptyline
DM4KDYJ	MI	DEGTFWK
DM4KDYJ	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM4KDYJ	MT	DME
DM4KDYJ	MA	Metabolism
DM4KDYJ	RN	In vivo age-related changes in hepatic drug-oxidizing capacity in humans. J Clin Pharm Ther. 1998 Aug;23(4):247-55.
DM4KDYJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9867310

DM4KDYJ	DI	DM4KDYJ
DM4KDYJ	DN	Nortriptyline
DM4KDYJ	MI	DE073H6
DM4KDYJ	MN	Prostaglandin G/H synthase 1 (COX-1)
DM4KDYJ	MT	DME
DM4KDYJ	MA	Metabolism
DM4KDYJ	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM4KDYJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM4KDYJ	DI	DM4KDYJ
DM4KDYJ	DN	Nortriptyline
DM4KDYJ	MI	TT3ROYC
DM4KDYJ	MN	Serotonin transporter (SERT)
DM4KDYJ	MT	DTT
DM4KDYJ	MA	Modulator
DM4KDYJ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM4KDYJ	RU	https://www.fda.gov/

DMRFWGK	DI	DMRFWGK
DMRFWGK	DN	Novobiocin
DMRFWGK	MI	TT0IHXV
DMRFWGK	MN	DNA topoisomerase II (TOP2)
DMRFWGK	MT	DTT
DMRFWGK	MA	Inhibitor
DMRFWGK	RN	Transcriptional responses of Bacillus subtillis and thuringiensis to antibiotics and anti-tumour drugs. Int J Mol Med. 2009 Jan;23(1):33-9.
DMRFWGK	RU	https://pubmed.ncbi.nlm.nih.gov/19082504

DM6ZPLQ	DI	DM6ZPLQ
DM6ZPLQ	DN	Novolimus
DM6ZPLQ	MI	TTCJG29
DM6ZPLQ	MN	Serine/threonine-protein kinase mTOR (mTOR)
DM6ZPLQ	MT	DTT
DM6ZPLQ	MA	Inhibitor
DM6ZPLQ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
DM6ZPLQ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109

DMRSX53	DI	DMRSX53
DMRSX53	DN	nusinersen
DMRSX53	MI	TTSVGQ5
DMRSX53	MN	SMN1 messenger RNA (SMN1 mRNA)
DMRSX53	MT	DTT
DMRSX53	MA	Modulator
DMRSX53	RN	2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. 
DMRSX53	RU	https://www.ncbi.nlm.nih.gov/pubmed/28148938

DM63QS9	DI	DM63QS9
DM63QS9	DN	Nystatin
DM63QS9	MI	TTQKWA4
DM63QS9	MN	Fungal Cell membrane ergosterol (Fung CME)
DM63QS9	MT	DTT
DM63QS9	MA	Modulator
DM63QS9	RN	Cholesterol and Ergosterol Influence Nystatin Surface Aggregation: Relation to Pore Formation
DM63QS9	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1304795

DM3Q1SM	DI	DM3Q1SM
DM3Q1SM	DN	Obeticholic acid
DM3Q1SM	MI	DERA3OF
DM3Q1SM	MN	Bile acid-CoA thioesterase (BAAT)
DM3Q1SM	MT	DME
DM3Q1SM	MA	Metabolism
DM3Q1SM	RN	Glycine and taurine conjugation of bile acids by a single enzyme. Molecular cloning and expression of human liver bile acid CoA:amino acid N-acyltransferase. J Biol Chem. 1994 Jul 29;269(30):19375-9.
DM3Q1SM	RU	http://www.jbc.org/content/269/30/19375.full.pdf

DM3Q1SM	DI	DM3Q1SM
DM3Q1SM	DN	Obeticholic acid
DM3Q1SM	MI	TTS4UGC
DM3Q1SM	MN	Farnesoid X-activated receptor (FXR)
DM3Q1SM	MT	DTT
DM3Q1SM	MA	Modulator
DM3Q1SM	RN	2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. 
DM3Q1SM	RU	https://www.ncbi.nlm.nih.gov/pubmed/28148938

DM3BVAE	DI	DM3BVAE
DM3BVAE	DN	Obinutuzumab
DM3BVAE	MI	TTUE541
DM3BVAE	MN	Leukocyte surface antigen Leu-16 (CD20)
DM3BVAE	MT	DTT
DM3BVAE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628).
DM3BVAE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2628

DMEZ2KH	DI	DMEZ2KH
DMEZ2KH	DN	Ocrelizumab
DMEZ2KH	MI	TTUE541
DMEZ2KH	MN	Leukocyte surface antigen Leu-16 (CD20)
DMEZ2KH	MT	DTT
DMEZ2KH	RN	Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
DMEZ2KH	RU	https://pubmed.ncbi.nlm.nih.gov/18321156

DM7AVGW	DI	DM7AVGW
DM7AVGW	DN	Ocriplasmin
DM7AVGW	MI	TTPJ921
DM7AVGW	MN	Fibronectin (FN1)
DM7AVGW	MT	DTT
DM7AVGW	MA	Inhibitor
DM7AVGW	RN	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
DM7AVGW	RU	https://pubmed.ncbi.nlm.nih.gov/23370234

DMHIDCJ	DI	DMHIDCJ
DMHIDCJ	DN	Octreotide
DMHIDCJ	MI	DTFI42L
DMHIDCJ	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMHIDCJ	MT	DTP
DMHIDCJ	MA	Substrate
DMHIDCJ	RN	P-glycoprotein- and mrp2-mediated octreotide transport in renal proximal tubule. Br J Pharmacol. 2000 Jan;129(2):251-6.
DMHIDCJ	RU	http://www.ncbi.nlm.nih.gov/pubmed/10694230

DMHIDCJ	DI	DMHIDCJ
DMHIDCJ	DN	Octreotide
DMHIDCJ	MI	TTZ6T9E
DMHIDCJ	MN	Somatostatin receptor type 2 (SSTR2)
DMHIDCJ	MT	DTT
DMHIDCJ	MA	Binder
DMHIDCJ	RN	Versatile conjugation of octreotide to dendrimers by cycloaddition ("click") chemistry to yield high-affinity multivalent cyclic Peptide dendrimers. Bioconjug Chem. 2009 Jul;20(7):1323-31.
DMHIDCJ	RU	https://pubmed.ncbi.nlm.nih.gov/19537708

DMZK0FQ	DI	DMZK0FQ
DMZK0FQ	DN	Oestradiol valerate and dienogest
DMZK0FQ	MI	DE4LYSA
DMZK0FQ	MN	Cytochrome P450 3A4 (CYP3A4)
DMZK0FQ	MT	DME
DMZK0FQ	MA	Metabolism
DMZK0FQ	RN	Progestogens in menopausal hormone therapy. Prz Menopauzalny. 2015 Jun;14(2):134-43.
DMZK0FQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26327902

DM295PR	DI	DM295PR
DM295PR	DN	Ofatumumab
DM295PR	MI	TTUE541
DM295PR	MN	Leukocyte surface antigen Leu-16 (CD20)
DM295PR	MT	DTT
DM295PR	RN	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
DM295PR	RU	https://pubmed.ncbi.nlm.nih.gov/20118952

DM0VQN3	DI	DM0VQN3
DM0VQN3	DN	Ofloxacin
DM0VQN3	MI	TTN6J5F
DM0VQN3	MN	Bacterial DNA gyrase (Bact gyrase)
DM0VQN3	MT	DTT
DM0VQN3	MA	Modulator
DM0VQN3	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM0VQN3	RU	https://www.fda.gov/

DM0VQN3	DI	DM0VQN3
DM0VQN3	DN	Ofloxacin
DM0VQN3	MI	DTI7UX6
DM0VQN3	MN	Breast cancer resistance protein (ABCG2)
DM0VQN3	MT	DTP
DM0VQN3	MA	Substrate
DM0VQN3	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM0VQN3	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMQ4PKA	DI	DMQ4PKA
DMQ4PKA	DN	Olamufloxacin
DMQ4PKA	MI	DTFI42L
DMQ4PKA	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMQ4PKA	MT	DTP
DMQ4PKA	MA	Substrate
DMQ4PKA	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMQ4PKA	RU	https://doi.org/10.1007/s11095-012-0935-x

DMPFN6Y	DI	DMPFN6Y
DMPFN6Y	DN	Olanzapine
DMPFN6Y	MI	DEJGDUW
DMPFN6Y	MN	Cytochrome P450 1A2 (CYP1A2)
DMPFN6Y	MT	DME
DMPFN6Y	MA	Metabolism
DMPFN6Y	RN	Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci. 2003 Mar;28(2):99-112.
DMPFN6Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12670127

DMPFN6Y	DI	DMPFN6Y
DMPFN6Y	DN	Olanzapine
DMPFN6Y	MI	DECB0K3
DMPFN6Y	MN	Cytochrome P450 2D6 (CYP2D6)
DMPFN6Y	MT	DME
DMPFN6Y	MA	Metabolism
DMPFN6Y	RN	[Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring]. Fortschr Neurol Psychiatr. 2001 Nov;69(11):510-7.
DMPFN6Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11704898

DMPFN6Y	DI	DMPFN6Y
DMPFN6Y	DN	Olanzapine
DMPFN6Y	MI	TTEX248
DMPFN6Y	MN	Dopamine D2 receptor (D2R)
DMPFN6Y	MT	DTT
DMPFN6Y	MA	Agonist
DMPFN6Y	RN	Olanzapine: an updated review of its use in the management of schizophrenia. Drugs. 2001;61(1):111-61.
DMPFN6Y	RU	https://pubmed.ncbi.nlm.nih.gov/11217867

DMPFN6Y	DI	DMPFN6Y
DMPFN6Y	DN	Olanzapine
DMPFN6Y	MI	DTUGYRD
DMPFN6Y	MN	P-glycoprotein 1 (ABCB1)
DMPFN6Y	MT	DTP
DMPFN6Y	MA	Substrate
DMPFN6Y	RN	Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
DMPFN6Y	RU	http://www.ncbi.nlm.nih.gov/pubmed/15285840

DM0Y49P	DI	DM0Y49P
DM0Y49P	DN	Olanzapine/fluoxetine combination
DM0Y49P	MI	TT8G3Z7
DM0Y49P	MN	Serotoninnorepinephrinedopamine reuptake (SNDR)
DM0Y49P	MT	DTT
DM0Y49P	MA	Antagonist
DM0Y49P	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DM0Y49P	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM8QB1D	DI	DM8QB1D
DM8QB1D	DN	Olaparib
DM8QB1D	MI	DE4LYSA
DM8QB1D	MN	Cytochrome P450 3A4 (CYP3A4)
DM8QB1D	MT	DME
DM8QB1D	MA	Metabolism
DM8QB1D	RN	Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells. Radiother Oncol. 2015 Sep;116(3):358-65.
DM8QB1D	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25981132

DM8QB1D	DI	DM8QB1D
DM8QB1D	DN	Olaparib
DM8QB1D	MI	DTUGYRD
DM8QB1D	MN	P-glycoprotein 1 (ABCB1)
DM8QB1D	MT	DTP
DM8QB1D	MA	Substrate
DM8QB1D	RN	Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer. Transl Oncol. 2019 May 7;12(7):871-878.
DM8QB1D	RU	http://www.ncbi.nlm.nih.gov/pubmed/31075528

DM8QB1D	DI	DM8QB1D
DM8QB1D	DN	Olaparib
DM8QB1D	MI	TTEBCY8
DM8QB1D	MN	Poly [ADP-ribose] polymerase (PARP)
DM8QB1D	MT	DTT
DM8QB1D	MA	Modulator
DM8QB1D	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DM8QB1D	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMNYOIX	DI	DMNYOIX
DMNYOIX	DN	Olaratumab
DMNYOIX	MI	TT8FYO9
DMNYOIX	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMNYOIX	MT	DTT
DMNYOIX	MA	Modulator
DMNYOIX	RN	A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRalpha) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Mar;73(3):595-604.
DMNYOIX	RU	https://pubmed.ncbi.nlm.nih.gov/24452395

DM6MDCF	DI	DM6MDCF
DM6MDCF	DN	Oliceridine
DM6MDCF	MI	DECB0K3
DM6MDCF	MN	Cytochrome P450 2D6 (CYP2D6)
DM6MDCF	MT	DME
DM6MDCF	MA	Metabolism
DM6MDCF	RN	First clinical experience with TRV130: pharmacokinetics and pharmacodynamics in healthy volunteers. J Clin Pharmacol. 2014 Mar;54(3):351-7.
DM6MDCF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24122908

DMWBHRY	DI	DMWBHRY
DMWBHRY	DN	Olmesartan medoxomil
DMWBHRY	MI	TT8DBY3
DMWBHRY	MN	Angiotensin II receptor type-1 (AGTR1)
DMWBHRY	MT	DTT
DMWBHRY	MA	Antagonist
DMWBHRY	RN	Mechanism of diastolic stiffening of the failing myocardium and its prevention by angiotensin receptor and calcium channel blockers. J Cardiovasc Pharmacol. 2009 Jul;54(1):47-56.
DMWBHRY	RU	https://pubmed.ncbi.nlm.nih.gov/19528815

DMWBHRY	DI	DMWBHRY
DMWBHRY	DN	Olmesartan medoxomil
DMWBHRY	MI	DTI7UX6
DMWBHRY	MN	Breast cancer resistance protein (ABCG2)
DMWBHRY	MT	DTP
DMWBHRY	MA	Substrate
DMWBHRY	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01913)
DMWBHRY	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01913

DMWBHRY	DI	DMWBHRY
DMWBHRY	DN	Olmesartan medoxomil
DMWBHRY	MI	DTFI42L
DMWBHRY	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMWBHRY	MT	DTP
DMWBHRY	MA	Substrate
DMWBHRY	RN	Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos. 2007 Dec;35(12):2166-76.
DMWBHRY	RU	http://www.ncbi.nlm.nih.gov/pubmed/17823233

DMWBHRY	DI	DMWBHRY
DMWBHRY	DN	Olmesartan medoxomil
DMWBHRY	MI	DTCSGPB
DMWBHRY	MN	Multidrug resistance-associated protein 4 (ABCC4)
DMWBHRY	MT	DTP
DMWBHRY	MA	Substrate
DMWBHRY	RN	Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos. 2007 Dec;35(12):2166-76.
DMWBHRY	RU	http://www.ncbi.nlm.nih.gov/pubmed/17823233

DMWBHRY	DI	DMWBHRY
DMWBHRY	DN	Olmesartan medoxomil
DMWBHRY	MI	DTQ23VB
DMWBHRY	MN	Organic anion transporter 1 (SLC22A6)
DMWBHRY	MT	DTP
DMWBHRY	MA	Substrate
DMWBHRY	RN	Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos. 2007 Dec;35(12):2166-76.
DMWBHRY	RU	http://www.ncbi.nlm.nih.gov/pubmed/17823233

DMWBHRY	DI	DMWBHRY
DMWBHRY	DN	Olmesartan medoxomil
DMWBHRY	MI	DTVP67E
DMWBHRY	MN	Organic anion transporter 3 (SLC22A8)
DMWBHRY	MT	DTP
DMWBHRY	MA	Substrate
DMWBHRY	RN	Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos. 2007 Dec;35(12):2166-76.
DMWBHRY	RU	http://www.ncbi.nlm.nih.gov/pubmed/17823233

DMWBHRY	DI	DMWBHRY
DMWBHRY	DN	Olmesartan medoxomil
DMWBHRY	MI	DT3D8F0
DMWBHRY	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMWBHRY	MT	DTP
DMWBHRY	MA	Substrate
DMWBHRY	RN	OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker. Drug Metab Dispos. 2006 May;34(5):862-9.
DMWBHRY	RU	http://www.ncbi.nlm.nih.gov/pubmed/16501004

DMWBHRY	DI	DMWBHRY
DMWBHRY	DN	Olmesartan medoxomil
DMWBHRY	MI	DT9C1TS
DMWBHRY	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMWBHRY	MT	DTP
DMWBHRY	MA	Substrate
DMWBHRY	RN	Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos. 2007 Dec;35(12):2166-76.
DMWBHRY	RU	http://www.ncbi.nlm.nih.gov/pubmed/17823233

DMWBHRY	DI	DMWBHRY
DMWBHRY	DN	Olmesartan medoxomil
DMWBHRY	MI	DTUGYRD
DMWBHRY	MN	P-glycoprotein 1 (ABCB1)
DMWBHRY	MT	DTP
DMWBHRY	MA	Substrate
DMWBHRY	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
DMWBHRY	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01665

DM62B78	DI	DM62B78
DM62B78	DN	Olodaterol
DM62B78	MI	TT2CJVK
DM62B78	MN	Adrenergic receptor beta-2 (ADRB2)
DM62B78	MT	DTT
DM62B78	MA	Modulator
DM62B78	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DM62B78	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DM62B78	DI	DM62B78
DM62B78	DN	Olodaterol
DM62B78	MI	DE5IED8
DM62B78	MN	Cytochrome P450 2C9 (CYP2C9)
DM62B78	MT	DME
DM62B78	MA	Metabolism
DM62B78	RN	FDA Label of Olodaterol. The 2020 official website of the U.S. Food and Drug Administration.
DM62B78	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/203108s006lbl.pdf

DMKMWQG	DI	DMKMWQG
DMKMWQG	DN	Olopatadine
DMKMWQG	MI	DE4LYSA
DMKMWQG	MN	Cytochrome P450 3A4 (CYP3A4)
DMKMWQG	MT	DME
DMKMWQG	MA	Metabolism
DMKMWQG	RN	Effects of olopatadine, a new antiallergic agent, on human liver microsomal cytochrome P450 activities. Drug Metab Dispos. 2002 Dec;30(12):1504-11.
DMKMWQG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12433826

DMKMWQG	DI	DMKMWQG
DMKMWQG	DN	Olopatadine
DMKMWQG	MI	TTTIBOJ
DMKMWQG	MN	Histamine H1 receptor (H1R)
DMKMWQG	MT	DTT
DMKMWQG	MA	Antagonist
DMKMWQG	RN	Emerging drugs for ocular allergy. Expert Opin Emerg Drugs. 2005 Aug;10(3):505-20.
DMKMWQG	RU	https://pubmed.ncbi.nlm.nih.gov/16083326

DMKMWQG	DI	DMKMWQG
DMKMWQG	DN	Olopatadine
DMKMWQG	MI	DTUGYRD
DMKMWQG	MN	P-glycoprotein 1 (ABCB1)
DMKMWQG	MT	DTP
DMKMWQG	MA	Substrate
DMKMWQG	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMKMWQG	RU	https://doi.org/10.1007/s11095-012-0935-x

DMWBQKU	DI	DMWBQKU
DMWBQKU	DN	Olprinone
DMWBQKU	MI	TTZCG4L
DMWBQKU	MN	Phosphodiesterase 3 (PDE3)
DMWBQKU	MT	DTT
DMWBQKU	MA	Inhibitor
DMWBQKU	RN	Olprinone: a phosphodiesterase III inhibitor with positive inotropic and vasodilator effects. Cardiovasc Drug Rev. 2002 Fall;20(3):163-74.
DMWBQKU	RU	https://pubmed.ncbi.nlm.nih.gov/12397365

DMZW9HA	DI	DMZW9HA
DMZW9HA	DN	Olsalazine
DMZW9HA	MI	TTPZ7AG
DMZW9HA	MN	Oxidoreductase unspecific (OR)
DMZW9HA	MT	DTT
DMZW9HA	MA	Modulator
DMZW9HA	RN	Reaction mechanism of azoreductases suggests convergent evolution with quinone oxidoreductases. Protein Cell. 2010 Aug;1(8):780-90.
DMZW9HA	RU	https://pubmed.ncbi.nlm.nih.gov/21203919

DMPU2WX	DI	DMPU2WX
DMPU2WX	DN	Omacetaxine mepesuccinate
DMPU2WX	MI	TTA4FIU
DMPU2WX	MN	Ribosome A (hRA)
DMPU2WX	MT	DTT
DMPU2WX	MA	Modulator
DMPU2WX	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMPU2WX	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMR2J95	DI	DMR2J95
DMR2J95	DN	Omadacycline
DMR2J95	MI	TTOVFH2
DMR2J95	MN	Bacterial 30S ribosomal RNA (Bact 30S rRNA)
DMR2J95	MT	DTT
DMR2J95	MA	Inhibitor
DMR2J95	RN	Omadacycline Enters the Ring: A New Antimicrobial Contender.Pharmacotherapy. 2018 Dec;38(12):1194-1204. 
DMR2J95	RU	https://pubmed.ncbi.nlm.nih.gov/30290000

DMU5G01	DI	DMU5G01
DMU5G01	DN	Omadacycline
DMU5G01	MI	DTUGYRD
DMU5G01	MN	P-glycoprotein 1 (ABCB1)
DMU5G01	MT	DTP
DMU5G01	MA	Substrate
DMU5G01	RN	DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB12455)
DMU5G01	RU	https://www.drugbank.ca/drugs/DB12455

DMETVFJ	DI	DMETVFJ
DMETVFJ	DN	Omalizumab
DMETVFJ	MI	TTDGEC0
DMETVFJ	MN	Immunoglobulin epsilon Fc receptor gamma (FCERG)
DMETVFJ	MT	DTT
DMETVFJ	MA	Modulator
DMETVFJ	RN	The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. 
DMETVFJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/23197041

DML9TI0	DI	DML9TI0
DML9TI0	DN	Ombitasvir + paritaprevir + ritonavir
DML9TI0	MI	TTWXB3E
DML9TI0	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DML9TI0	MT	DTT
DML9TI0	MA	Modulator
DML9TI0	RN	HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy
DML9TI0	RU	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4632384

DM471KJ	DI	DM471KJ
DM471KJ	DN	Omeprazole
DM471KJ	MI	DEZMWRE
DM471KJ	MN	Cytochrome P450 2C18 (CYP2C18)
DM471KJ	MT	DME
DM471KJ	MA	Metabolism
DM471KJ	RN	Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metab Dispos. 1996 Oct;24(10):1081-7.
DM471KJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8894508

DM471KJ	DI	DM471KJ
DM471KJ	DN	Omeprazole
DM471KJ	MI	DES5XRU
DM471KJ	MN	Cytochrome P450 2C8 (CYP2C8)
DM471KJ	MT	DME
DM471KJ	MA	Metabolism
DM471KJ	RN	Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metab Dispos. 1996 Oct;24(10):1081-7.
DM471KJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8894508

DM471KJ	DI	DM471KJ
DM471KJ	DN	Omeprazole
DM471KJ	MI	DE5IED8
DM471KJ	MN	Cytochrome P450 2C9 (CYP2C9)
DM471KJ	MT	DME
DM471KJ	MA	Metabolism
DM471KJ	RN	Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32(8):821-7.
DM471KJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15258107

DM471KJ	DI	DM471KJ
DM471KJ	DN	Omeprazole
DM471KJ	MI	DE4LYSA
DM471KJ	MN	Cytochrome P450 3A4 (CYP3A4)
DM471KJ	MT	DME
DM471KJ	MA	Metabolism
DM471KJ	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM471KJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM471KJ	DI	DM471KJ
DM471KJ	DN	Omeprazole
DM471KJ	MI	DEIBDNY
DM471KJ	MN	Cytochrome P450 3A5 (CYP3A5)
DM471KJ	MT	DME
DM471KJ	MA	Metabolism
DM471KJ	RN	Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patients. Drug Metab Dispos. 2009 Apr;37(4):821-6.
DM471KJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19139162

DM471KJ	DI	DM471KJ
DM471KJ	DN	Omeprazole
DM471KJ	MI	TTLOKXP
DM471KJ	MN	Gastric H(+)/K(+) ATPase (Proton pump)
DM471KJ	MT	DTT
DM471KJ	MA	Modulator
DM471KJ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM471KJ	RU	https://www.fda.gov/

DM471KJ	DI	DM471KJ
DM471KJ	DN	Omeprazole
DM471KJ	MI	DEGTFWK
DM471KJ	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM471KJ	MT	DME
DM471KJ	MA	Metabolism
DM471KJ	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM471KJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM471KJ	DI	DM471KJ
DM471KJ	DN	Omeprazole
DM471KJ	MI	DTUGYRD
DM471KJ	MN	P-glycoprotein 1 (ABCB1)
DM471KJ	MT	DTP
DM471KJ	MA	Substrate
DM471KJ	RN	A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26.
DM471KJ	RU	https://doi.org/10.1007/s00210-008-0345-0

DMOTQ1I	DI	DMOTQ1I
DMOTQ1I	DN	Ondansetron
DMOTQ1I	MI	TTNXLKE
DMOTQ1I	MN	5-HT 3 receptor (5HT3R)
DMOTQ1I	MT	DTT
DMOTQ1I	MA	Agonist
DMOTQ1I	RN	Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol. 1998 Oct;10(10):865-70.
DMOTQ1I	RU	https://pubmed.ncbi.nlm.nih.gov/9831410

DMOTQ1I	DI	DMOTQ1I
DMOTQ1I	DN	Ondansetron
DMOTQ1I	MI	DEJGDUW
DMOTQ1I	MN	Cytochrome P450 1A2 (CYP1A2)
DMOTQ1I	MT	DME
DMOTQ1I	MA	Metabolism
DMOTQ1I	RN	Effects of serotonin-3 receptor antagonists on cytochrome P450 activities in human liver microsomes. Biol Pharm Bull. 2006 Sep;29(9):1931-5.
DMOTQ1I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16946512

DMOTQ1I	DI	DMOTQ1I
DMOTQ1I	DN	Ondansetron
DMOTQ1I	MI	DE5IED8
DMOTQ1I	MN	Cytochrome P450 2C9 (CYP2C9)
DMOTQ1I	MT	DME
DMOTQ1I	MA	Metabolism
DMOTQ1I	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMOTQ1I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMOTQ1I	DI	DMOTQ1I
DMOTQ1I	DN	Ondansetron
DMOTQ1I	MI	DECB0K3
DMOTQ1I	MN	Cytochrome P450 2D6 (CYP2D6)
DMOTQ1I	MT	DME
DMOTQ1I	MA	Metabolism
DMOTQ1I	RN	Cytochrome P450 2D6 metabolism and 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Med Sci Monit. 2005 Oct;11(10):RA322-8.
DMOTQ1I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16192915

DMOTQ1I	DI	DMOTQ1I
DMOTQ1I	DN	Ondansetron
DMOTQ1I	MI	DEVDYN7
DMOTQ1I	MN	Cytochrome P450 2E1 (CYP2E1)
DMOTQ1I	MT	DME
DMOTQ1I	MA	Metabolism
DMOTQ1I	RN	Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists. Drug Metab Dispos. 1996 May;24(5):602-9.
DMOTQ1I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8723743

DMOTQ1I	DI	DMOTQ1I
DMOTQ1I	DN	Ondansetron
DMOTQ1I	MI	DE4LYSA
DMOTQ1I	MN	Cytochrome P450 3A4 (CYP3A4)
DMOTQ1I	MT	DME
DMOTQ1I	MA	Metabolism
DMOTQ1I	RN	The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron. Clin Pharmacol Ther. 1999 Apr;65(4):377-81.
DMOTQ1I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10223773

DMOTQ1I	DI	DMOTQ1I
DMOTQ1I	DN	Ondansetron
DMOTQ1I	MI	DEIBDNY
DMOTQ1I	MN	Cytochrome P450 3A5 (CYP3A5)
DMOTQ1I	MT	DME
DMOTQ1I	MA	Metabolism
DMOTQ1I	RN	Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos. 1995 Nov;23(11):1225-30.
DMOTQ1I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8591723

DMOTQ1I	DI	DMOTQ1I
DMOTQ1I	DN	Ondansetron
DMOTQ1I	MI	DERD86B
DMOTQ1I	MN	Cytochrome P450 3A7 (CYP3A7)
DMOTQ1I	MT	DME
DMOTQ1I	MA	Metabolism
DMOTQ1I	RN	Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos. 1995 Nov;23(11):1225-30.
DMOTQ1I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8591723

DMOTQ1I	DI	DMOTQ1I
DMOTQ1I	DN	Ondansetron
DMOTQ1I	MI	DTUGYRD
DMOTQ1I	MN	P-glycoprotein 1 (ABCB1)
DMOTQ1I	MT	DTP
DMOTQ1I	MA	Substrate
DMOTQ1I	RN	Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004 Jan;75(1):13-33.
DMOTQ1I	RU	https://doi.org/10.1016/j.clpt.2003.09.012

DMHG57U	DI	DMHG57U
DMHG57U	DN	OPC-34712
DMHG57U	MI	TTSQIFT
DMHG57U	MN	5-HT 1A receptor (HTR1A)
DMHG57U	MT	DTT
DMHG57U	MA	Modulator
DMHG57U	RN	Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9.
DMHG57U	RU	https://www.ncbi.nlm.nih.gov/pubmed/24955861

DMHG57U	DI	DMHG57U
DMHG57U	DN	OPC-34712
DMHG57U	MI	DECB0K3
DMHG57U	MN	Cytochrome P450 2D6 (CYP2D6)
DMHG57U	MT	DME
DMHG57U	MA	Metabolism
DMHG57U	RN	Brexpiprazole: first global approval. Drugs. 2015 Sep;75(14):1687-97.
DMHG57U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26310190

DMHG57U	DI	DMHG57U
DMHG57U	DN	OPC-34712
DMHG57U	MI	DE4LYSA
DMHG57U	MN	Cytochrome P450 3A4 (CYP3A4)
DMHG57U	MT	DME
DMHG57U	MA	Metabolism
DMHG57U	RN	Brexpiprazole: first global approval. Drugs. 2015 Sep;75(14):1687-97.
DMHG57U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26310190

DMHG57U	DI	DMHG57U
DMHG57U	DN	OPC-34712
DMHG57U	MI	TTEX248
DMHG57U	MN	Dopamine D2 receptor (D2R)
DMHG57U	MT	DTT
DMHG57U	MA	Modulator
DMHG57U	RN	Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9.
DMHG57U	RU	https://www.ncbi.nlm.nih.gov/pubmed/24955861

DMHG57U	DI	DMHG57U
DMHG57U	DN	OPC-34712
DMHG57U	MI	DT3BA8L
DMHG57U	MN	Sodium-dependent dopamine transporter (SLC6A3)
DMHG57U	MT	DTP
DMHG57U	MA	Substrate
DMHG57U	RN	Brexpiprazole reduces hyperactivity, impulsivity, and risk-preference behavior in mice with dopamine transporter knockdown-a model of mania. Psychopharmacology (Berl). 2017 Mar;234(6):1017-1028.
DMHG57U	RU	http://www.ncbi.nlm.nih.gov/pubmed/28160035

DM1BKA6	DI	DM1BKA6
DM1BKA6	DN	Opicapone
DM1BKA6	MI	TTKWFB8
DM1BKA6	MN	Catechol-O-methyl-transferase (COMT)
DM1BKA6	MT	DTT
DM1BKA6	MA	Inhibitor
DM1BKA6	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DM1BKA6	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212489s000lbl.pdf

DMPUOXF	DI	DMPUOXF
DMPUOXF	DN	Opipramol
DMPUOXF	MI	DECB0K3
DMPUOXF	MN	Cytochrome P450 2D6 (CYP2D6)
DMPUOXF	MT	DME
DMPUOXF	MA	Metabolism
DMPUOXF	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMPUOXF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMTSRI6	DI	DMTSRI6
DMTSRI6	DN	Oprelvekin
DMTSRI6	MI	TTZPLJS
DMTSRI6	MN	Interleukin 11 receptor alpha (IL11RA)
DMTSRI6	MT	DTT
DMTSRI6	MA	Binder
DMTSRI6	RN	Oprelvekin: a review of its pharmacology and therapeutic potential in chemotherapy-induced thrombocytopenia. BioDrugs. 1998 Aug;10(2):159-71.
DMTSRI6	RU	https://pubmed.ncbi.nlm.nih.gov/18020592

DM28D05	DI	DM28D05
DM28D05	DN	Oritavancin
DM28D05	MI	TT4ILYC
DM28D05	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DM28D05	MT	DTT
DM28D05	MA	Inhibitor
DM28D05	RN	Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
DM28D05	RU	https://pubmed.ncbi.nlm.nih.gov/15934867

DMRJSP8	DI	DMRJSP8
DMRJSP8	DN	Orlistat
DMRJSP8	MI	TT6OEDT
DMRJSP8	MN	Cannabinoid receptor 1 (CB1)
DMRJSP8	MT	DTT
DMRJSP8	MA	Inhibitor
DMRJSP8	RN	Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. J Med Chem. 2008 Nov 13;51(21):6970-9.
DMRJSP8	RU	https://pubmed.ncbi.nlm.nih.gov/18831576

DMRJSP8	DI	DMRJSP8
DMRJSP8	DN	Orlistat
DMRJSP8	MI	TTXMY0J
DMRJSP8	MN	Pancreatic triacylglycerol lipase (PNLIP)
DMRJSP8	MT	DTT
DMRJSP8	MA	Modulator
DMRJSP8	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMRJSP8	RU	https://www.fda.gov/

DM6QHDJ	DI	DM6QHDJ
DM6QHDJ	DN	Ornidazole
DM6QHDJ	MI	DE4LYSA
DM6QHDJ	MN	Cytochrome P450 3A4 (CYP3A4)
DM6QHDJ	MT	DME
DM6QHDJ	MA	Metabolism
DM6QHDJ	RN	Effect of ketoconazole on the pharmacokinetics of ornidazole--a possible role of p-glycoprotein and CYP3A. Drug Metabol Drug Interact. 2006;22(1):67-77.
DM6QHDJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17152348

DM6QHDJ	DI	DM6QHDJ
DM6QHDJ	DN	Ornidazole
DM6QHDJ	MI	DEIBDNY
DM6QHDJ	MN	Cytochrome P450 3A5 (CYP3A5)
DM6QHDJ	MT	DME
DM6QHDJ	MA	Metabolism
DM6QHDJ	RN	Effect of ketoconazole on the pharmacokinetics of ornidazole--a possible role of p-glycoprotein and CYP3A. Drug Metabol Drug Interact. 2006;22(1):67-77.
DM6QHDJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17152348

DM6QHDJ	DI	DM6QHDJ
DM6QHDJ	DN	Ornidazole
DM6QHDJ	MI	DERD86B
DM6QHDJ	MN	Cytochrome P450 3A7 (CYP3A7)
DM6QHDJ	MT	DME
DM6QHDJ	MA	Metabolism
DM6QHDJ	RN	Effect of ketoconazole on the pharmacokinetics of ornidazole--a possible role of p-glycoprotein and CYP3A. Drug Metabol Drug Interact. 2006;22(1):67-77.
DM6QHDJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17152348

DM6QHDJ	DI	DM6QHDJ
DM6QHDJ	DN	Ornidazole
DM6QHDJ	MI	DE90ZBW
DM6QHDJ	MN	Flavin adenine dinucleotide dehydrogenase (fadd)
DM6QHDJ	MT	DME
DM6QHDJ	MA	Metabolism
DM6QHDJ	RN	Reduction of azo dyes and nitroaromatic compounds by bacterial enzymes from the human intestinal tract. Environ Health Perspect. 1995 Jun;103 Suppl 5:17-9.
DM6QHDJ	RU	https://pubmed.ncbi.nlm.nih.gov/8565901

DM6QHDJ	DI	DM6QHDJ
DM6QHDJ	DN	Ornidazole
DM6QHDJ	MI	DEXG57F
DM6QHDJ	MN	Flavin adenine dinucleotide dehydrogenase (fadd)
DM6QHDJ	MT	DME
DM6QHDJ	MA	Metabolism
DM6QHDJ	RN	Reduction of azo dyes and nitroaromatic compounds by bacterial enzymes from the human intestinal tract. Environ Health Perspect. 1995 Jun;103 Suppl 5:17-9.
DM6QHDJ	RU	https://pubmed.ncbi.nlm.nih.gov/8565901

DM6QHDJ	DI	DM6QHDJ
DM6QHDJ	DN	Ornidazole
DM6QHDJ	MI	DE5CJFM
DM6QHDJ	MN	Flavin adenine dinucleotide dehydrogenase (fadd)
DM6QHDJ	MT	DME
DM6QHDJ	MA	Metabolism
DM6QHDJ	RN	Reduction of azo dyes and nitroaromatic compounds by bacterial enzymes from the human intestinal tract. Environ Health Perspect. 1995 Jun;103 Suppl 5:17-9.
DM6QHDJ	RU	https://pubmed.ncbi.nlm.nih.gov/8565901

DM6QHDJ	DI	DM6QHDJ
DM6QHDJ	DN	Ornidazole
DM6QHDJ	MI	DE9WXYE
DM6QHDJ	MN	Flavin adenine dinucleotide dehydrogenase (fadd)
DM6QHDJ	MT	DME
DM6QHDJ	MA	Metabolism
DM6QHDJ	RN	Reduction of azo dyes and nitroaromatic compounds by bacterial enzymes from the human intestinal tract. Environ Health Perspect. 1995 Jun;103 Suppl 5:17-9.
DM6QHDJ	RU	https://pubmed.ncbi.nlm.nih.gov/8565901

DM6QHDJ	DI	DM6QHDJ
DM6QHDJ	DN	Ornidazole
DM6QHDJ	MI	DEX5D46
DM6QHDJ	MN	Oxygen-insensitive NADPH nitroreductase A (nfsA)
DM6QHDJ	MT	DME
DM6QHDJ	MA	Metabolism
DM6QHDJ	RN	Identification and characterization of SnrA, an inducible oxygen-insensitive nitroreductase in Salmonella enterica serovar Typhimurium TA1535. Mutat Res. 2002 Oct 31;508(1-2):59-70.
DM6QHDJ	RU	https://pubmed.ncbi.nlm.nih.gov/12379462

DMW542E	DI	DMW542E
DMW542E	DN	Orphenadrine
DMW542E	MI	TT9IK2Z
DMW542E	MN	N-methyl-D-aspartate receptor (NMDAR)
DMW542E	MT	DTT
DMW542E	MA	Antagonist
DMW542E	RN	Involvement of voltage-gated sodium channels blockade in the analgesic effects of orphenadrine. Pain. 2009 Apr;142(3):225-35.
DMW542E	RU	https://pubmed.ncbi.nlm.nih.gov/19217209

DMFIQ20	DI	DMFIQ20
DMFIQ20	DN	Orphenadrine citrate
DMFIQ20	MI	DE4LYSA
DMFIQ20	MN	Cytochrome P450 3A4 (CYP3A4)
DMFIQ20	MT	DME
DMFIQ20	MA	Metabolism
DMFIQ20	RN	Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes. Drug Metab Dispos. 1997 Mar;25(3):390-3.
DMFIQ20	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9172960

DMGO72P	DI	DMGO72P
DMGO72P	DN	Oseltamivir
DMGO72P	MI	TT50QJ3
DMGO72P	MN	Influenza Neuraminidase (Influ NA)
DMGO72P	MT	DTT
DMGO72P	MA	Inhibitor
DMGO72P	RN	Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res. 2008 Apr;78(1):91-102.
DMGO72P	RU	https://pubmed.ncbi.nlm.nih.gov/18328578

DMGO72P	DI	DMGO72P
DMGO72P	DN	Oseltamivir
DMGO72P	MI	DTCSGPB
DMGO72P	MN	Multidrug resistance-associated protein 4 (ABCC4)
DMGO72P	MT	DTP
DMGO72P	MA	Substrate
DMGO72P	RN	Limited brain distribution of [3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), a pharmacologically active form of oseltamivir, by active efflux across the blood-brain barrier mediated by organic anion transporter 3 (Oat3/Slc22a8) and multidrug resistance-associated protein 4 (Mrp4/Abcc4). Drug Metab Dispos. 2009 Feb;37(2):315-21.
DMGO72P	RU	http://www.ncbi.nlm.nih.gov/pubmed/19029202

DMGO72P	DI	DMGO72P
DMGO72P	DN	Oseltamivir
DMGO72P	MI	DTQ23VB
DMGO72P	MN	Organic anion transporter 1 (SLC22A6)
DMGO72P	MT	DTP
DMGO72P	MA	Substrate
DMGO72P	RN	FDA Drug Development and Drug Interactions
DMGO72P	RU	https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2

DMGO72P	DI	DMGO72P
DMGO72P	DN	Oseltamivir
DMGO72P	MI	DTVP67E
DMGO72P	MN	Organic anion transporter 3 (SLC22A8)
DMGO72P	MT	DTP
DMGO72P	MA	Substrate
DMGO72P	RN	FDA Drug Development and Drug Interactions
DMGO72P	RU	https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2

DMGO72P	DI	DMGO72P
DMGO72P	DN	Oseltamivir
DMGO72P	MI	DT9G7XN
DMGO72P	MN	Peptide transporter 1 (SLC15A1)
DMGO72P	MT	DTP
DMGO72P	MA	Substrate
DMGO72P	RN	Oseltamivir (tamiflu) is a substrate of peptide transporter 1. Drug Metab Dispos. 2009 Aug;37(8):1676-81.
DMGO72P	RU	http://www.ncbi.nlm.nih.gov/pubmed/19439487

DMGO72P	DI	DMGO72P
DMGO72P	DN	Oseltamivir
DMGO72P	MI	DTUGYRD
DMGO72P	MN	P-glycoprotein 1 (ABCB1)
DMGO72P	MT	DTP
DMGO72P	MA	Substrate
DMGO72P	RN	Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. Antimicrob Agents Chemother. 2009 Nov;53(11):4753-61.
DMGO72P	RU	http://www.ncbi.nlm.nih.gov/pubmed/19721074

DMIJC9X	DI	DMIJC9X
DMIJC9X	DN	Osilodrostat
DMIJC9X	MI	TTIQUX7
DMIJC9X	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMIJC9X	MT	DTT
DMIJC9X	MA	Modulator
DMIJC9X	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMIJC9X	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212801s000lbl.pdf

DMRJLAT	DI	DMRJLAT
DMRJLAT	DN	Osimertinib
DMRJLAT	MI	TTGKNB4
DMRJLAT	MN	Epidermal growth factor receptor (EGFR)
DMRJLAT	MT	DTT
DMRJLAT	MA	Inhibitor
DMRJLAT	RN	AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014 Sep;4(9):1046-61.
DMRJLAT	RU	https://pubmed.ncbi.nlm.nih.gov/24893891

DMF5ZB3	DI	DMF5ZB3
DMF5ZB3	DN	OspA lipoprotein
DMF5ZB3	MI	TTM6QSK
DMF5ZB3	MN	B-cell receptor CD22 (CD22)
DMF5ZB3	MT	DTT
DMF5ZB3	MA	Binder
DMF5ZB3	RN	Safety and immunogenicity of recombinant Bacille Calmette-Gu |rin (rBCG) expressing Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: a candidate Lyme disease vaccine. Vaccine. 1999 Feb 26;17(7-8):904-14.
DMF5ZB3	RU	https://pubmed.ncbi.nlm.nih.gov/10067697

DMC4GEI	DI	DMC4GEI
DMC4GEI	DN	Ospemifene
DMC4GEI	MI	DEPKLMQ
DMC4GEI	MN	Cytochrome P450 2B6 (CYP2B6)
DMC4GEI	MT	DME
DMC4GEI	MA	Metabolism
DMC4GEI	RN	Ospemifene metabolism in humans in vitro and in vivo: metabolite identification, quantitation, and CYP assignment of major hydroxylations. Drug Metabol Drug Interact. 2013;28(3):153-61.
DMC4GEI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23729558

DMC4GEI	DI	DMC4GEI
DMC4GEI	DN	Ospemifene
DMC4GEI	MI	DE5IED8
DMC4GEI	MN	Cytochrome P450 2C9 (CYP2C9)
DMC4GEI	MT	DME
DMC4GEI	MA	Metabolism
DMC4GEI	RN	Ospemifene metabolism in humans in vitro and in vivo: metabolite identification, quantitation, and CYP assignment of major hydroxylations. Drug Metabol Drug Interact. 2013;28(3):153-61.
DMC4GEI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23729558

DMC4GEI	DI	DMC4GEI
DMC4GEI	DN	Ospemifene
DMC4GEI	MI	DE4LYSA
DMC4GEI	MN	Cytochrome P450 3A4 (CYP3A4)
DMC4GEI	MT	DME
DMC4GEI	MA	Metabolism
DMC4GEI	RN	Ospemifene metabolism in humans in vitro and in vivo: metabolite identification, quantitation, and CYP assignment of major hydroxylations. Drug Metabol Drug Interact. 2013;28(3):153-61.
DMC4GEI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23729558

DMC4GEI	DI	DMC4GEI
DMC4GEI	DN	Ospemifene
DMC4GEI	MI	TTZAYWL
DMC4GEI	MN	Estrogen receptor (ESR)
DMC4GEI	MT	DTT
DMC4GEI	MA	Modulator
DMC4GEI	RN	Clinical pipeline report, company report or official report of Shionogi (2011).
DMC4GEI	RU	http://www.shionogi.co.jp/index_e.html

DMC4GEI	DI	DMC4GEI
DMC4GEI	DN	Ospemifene
DMC4GEI	MI	DEGTFWK
DMC4GEI	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMC4GEI	MT	DME
DMC4GEI	MA	Metabolism
DMC4GEI	RN	Ospemifene metabolism in humans in vitro and in vivo: metabolite identification, quantitation, and CYP assignment of major hydroxylations. Drug Metabol Drug Interact. 2013;28(3):153-61.
DMC4GEI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23729558

DM05968	DI	DM05968
DM05968	DN	Otilonium bromide
DM05968	MI	TTXHYV6
DM05968	MN	Voltage-gated L-type calcium channel (L-CaC)
DM05968	MT	DTT
DM05968	MA	Blocker
DM05968	RN	Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
DM05968	RU	https://pubmed.ncbi.nlm.nih.gov/16634703

DMQNI7O	DI	DMQNI7O
DMQNI7O	DN	OTL-200
DMQNI7O	MI	TTYQANR
DMQNI7O	MN	Cerebroside-sulfatase (ARSA)
DMQNI7O	MT	DTT
DMQNI7O	MA	Replacement
DMQNI7O	RN	Clinical pipeline report, company report or official report of Orchard Therapeutics.
DMQNI7O	RU	https://www.orchard-tx.com/approach/pipeline/

DME0F98	DI	DME0F98
DME0F98	DN	Ovine corticotropin-releasing hormone
DME0F98	MI	TTVIREA
DME0F98	MN	Adrenergic receptor (ADR)
DME0F98	MT	DTT
DME0F98	MA	Modulator
DME0F98	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DME0F98	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMTAFY4	DI	DMTAFY4
DMTAFY4	DN	Oxacillin
DMTAFY4	MI	TTJP4SM
DMTAFY4	MN	Bacterial Penicillin binding protein (Bact PBP)
DMTAFY4	MT	DTT
DMTAFY4	MA	Binder
DMTAFY4	RN	Novel anion liposome-encapsulated antisense oligonucleotide restores susceptibility of methicillin-resistant Staphylococcus aureus and rescues mice... Antimicrob Agents Chemother. 2009 Jul;53(7):2871-8.
DMTAFY4	RU	https://pubmed.ncbi.nlm.nih.gov/19433567

DMTAFY4	DI	DMTAFY4
DMTAFY4	DN	Oxacillin
DMTAFY4	MI	DE2ARDZ
DMTAFY4	MN	PenA beta-lactamase (penA1)
DMTAFY4	MT	DME
DMTAFY4	MA	Metabolism
DMTAFY4	RN	Characterization of the penA and penR genes of Burkholderia cepacia 249 which encode the chromosomal class A penicillinase and its LysR-type transcriptional regulator. Antimicrob Agents Chemother. 1997 Nov;41(11):2399-405.
DMTAFY4	RU	https://pubmed.ncbi.nlm.nih.gov/9371340

DMQNWRD	DI	DMQNWRD
DMQNWRD	DN	Oxaliplatin
DMQNWRD	MI	DTI7UX6
DMQNWRD	MN	Breast cancer resistance protein (ABCG2)
DMQNWRD	MT	DTP
DMQNWRD	MA	Substrate
DMQNWRD	RN	Effect of ABCG2 on cytotoxicity of platinum drugs: interference of EGFP. Toxicol In Vitro. 2008 Dec;22(8):1846-52.
DMQNWRD	RU	https://doi.org/10.1016/j.tiv.2008.09.001

DMQNWRD	DI	DMQNWRD
DMQNWRD	DN	Oxaliplatin
DMQNWRD	MI	DE6OQ3W
DMQNWRD	MN	Cytochrome P450 1A1 (CYP1A1)
DMQNWRD	MT	DME
DMQNWRD	MA	Metabolism
DMQNWRD	RN	The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
DMQNWRD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17498780

DMQNWRD	DI	DMQNWRD
DMQNWRD	DN	Oxaliplatin
DMQNWRD	MI	DEJGDUW
DMQNWRD	MN	Cytochrome P450 1A2 (CYP1A2)
DMQNWRD	MT	DME
DMQNWRD	MA	Metabolism
DMQNWRD	RN	The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
DMQNWRD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17498780

DMQNWRD	DI	DMQNWRD
DMQNWRD	DN	Oxaliplatin
DMQNWRD	MI	DE9QHP6
DMQNWRD	MN	Cytochrome P450 1B1 (CYP1B1)
DMQNWRD	MT	DME
DMQNWRD	MA	Metabolism
DMQNWRD	RN	The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
DMQNWRD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17498780

DMQNWRD	DI	DMQNWRD
DMQNWRD	DN	Oxaliplatin
DMQNWRD	MI	DEVDYN7
DMQNWRD	MN	Cytochrome P450 2E1 (CYP2E1)
DMQNWRD	MT	DME
DMQNWRD	MA	Metabolism
DMQNWRD	RN	The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
DMQNWRD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17498780

DMQNWRD	DI	DMQNWRD
DMQNWRD	DN	Oxaliplatin
DMQNWRD	MI	DEYZEJA
DMQNWRD	MN	Glutathione S-transferase mu-1 (GSTM1)
DMQNWRD	MT	DME
DMQNWRD	MA	Metabolism
DMQNWRD	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
DMQNWRD	RU	https://www.pharmgkb.org/pathway/PA150642262

DMQNWRD	DI	DMQNWRD
DMQNWRD	DN	Oxaliplatin
DMQNWRD	MI	DEK6079
DMQNWRD	MN	Glutathione S-transferase pi (GSTP1)
DMQNWRD	MT	DME
DMQNWRD	MA	Metabolism
DMQNWRD	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
DMQNWRD	RU	https://www.pharmgkb.org/pathway/PA150642262

DMQNWRD	DI	DMQNWRD
DMQNWRD	DN	Oxaliplatin
DMQNWRD	MI	DE3PKUG
DMQNWRD	MN	Glutathione S-transferase theta-1 (GSTT1)
DMQNWRD	MT	DME
DMQNWRD	MA	Metabolism
DMQNWRD	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
DMQNWRD	RU	https://www.pharmgkb.org/pathway/PA150642262

DMQNWRD	DI	DMQNWRD
DMQNWRD	DN	Oxaliplatin
DMQNWRD	MI	DTP8L4F
DMQNWRD	MN	High affinity copper uptake protein 1 (SLC31A1)
DMQNWRD	MT	DTP
DMQNWRD	MA	Substrate
DMQNWRD	RN	Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol. 2005 Jan;53(1):13-23.
DMQNWRD	RU	http://www.ncbi.nlm.nih.gov/pubmed/15607932

DMQNWRD	DI	DMQNWRD
DMQNWRD	DN	Oxaliplatin
DMQNWRD	MI	TTUTN1I
DMQNWRD	MN	Human Deoxyribonucleic acid (hDNA)
DMQNWRD	MT	DTT
DMQNWRD	MA	Modulator
DMQNWRD	RN	Structures of oxaliplatin-oligonucleotide adducts from DNA.J Mass Spectrom.2012 Oct;47(10):1282-93.
DMQNWRD	RU	https://www.ncbi.nlm.nih.gov/pubmed/23019159

DMQNWRD	DI	DMQNWRD
DMQNWRD	DN	Oxaliplatin
DMQNWRD	MI	DE5ME8A
DMQNWRD	MN	Metallothionein-1A (MT1A)
DMQNWRD	MT	DME
DMQNWRD	MA	Metabolism
DMQNWRD	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
DMQNWRD	RU	https://www.pharmgkb.org/pathway/PA150642262

DMQNWRD	DI	DMQNWRD
DMQNWRD	DN	Oxaliplatin
DMQNWRD	MI	DEFKGT7
DMQNWRD	MN	Metallothionein-2A (MT2A)
DMQNWRD	MT	DME
DMQNWRD	MA	Metabolism
DMQNWRD	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
DMQNWRD	RU	https://www.pharmgkb.org/pathway/PA150642262

DMQNWRD	DI	DMQNWRD
DMQNWRD	DN	Oxaliplatin
DMQNWRD	MI	DTFI42L
DMQNWRD	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMQNWRD	MT	DTP
DMQNWRD	MA	Substrate
DMQNWRD	RN	Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
DMQNWRD	RU	http://www.ncbi.nlm.nih.gov/pubmed/26131551

DMQNWRD	DI	DMQNWRD
DMQNWRD	DN	Oxaliplatin
DMQNWRD	MI	DEA3U9Y
DMQNWRD	MN	Myeloperoxidase (MPO)
DMQNWRD	MT	DME
DMQNWRD	MA	Metabolism
DMQNWRD	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
DMQNWRD	RU	https://www.pharmgkb.org/pathway/PA150642262

DMQNWRD	DI	DMQNWRD
DMQNWRD	DN	Oxaliplatin
DMQNWRD	MI	DTT79CX
DMQNWRD	MN	Organic cation transporter 1 (SLC22A1)
DMQNWRD	MT	DTP
DMQNWRD	MA	Substrate
DMQNWRD	RN	Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
DMQNWRD	RU	http://www.ncbi.nlm.nih.gov/pubmed/16951202

DMQNWRD	DI	DMQNWRD
DMQNWRD	DN	Oxaliplatin
DMQNWRD	MI	DT9IDPW
DMQNWRD	MN	Organic cation transporter 2 (SLC22A2)
DMQNWRD	MT	DTP
DMQNWRD	MA	Substrate
DMQNWRD	RN	Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells. Metallomics. 2018 Mar 1;10(3):414-425.
DMQNWRD	RU	http://www.ncbi.nlm.nih.gov/pubmed/29417972

DMQNWRD	DI	DMQNWRD
DMQNWRD	DN	Oxaliplatin
DMQNWRD	MI	DENP5RY
DMQNWRD	MN	Quinone reductase 1 (NQO1)
DMQNWRD	MT	DME
DMQNWRD	MA	Metabolism
DMQNWRD	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
DMQNWRD	RU	https://www.pharmgkb.org/pathway/PA150642262

DMQNWRD	DI	DMQNWRD
DMQNWRD	DN	Oxaliplatin
DMQNWRD	MI	DEUTDON
DMQNWRD	MN	Superoxide dismutase 1 (SOD1)
DMQNWRD	MT	DME
DMQNWRD	MA	Metabolism
DMQNWRD	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
DMQNWRD	RU	https://www.pharmgkb.org/pathway/PA150642262

DM2QDX1	DI	DM2QDX1
DM2QDX1	DN	Oxamniquine
DM2QDX1	MI	DECB0K3
DM2QDX1	MN	Cytochrome P450 2D6 (CYP2D6)
DM2QDX1	MT	DME
DM2QDX1	MA	Metabolism
DM2QDX1	RN	Inhibitory effects of antiparasitic drugs on cytochrome P450 2D6. Eur J Clin Pharmacol. 1995;48(1):35-8.
DM2QDX1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7621845

DM2QDX1	DI	DM2QDX1
DM2QDX1	DN	Oxamniquine
DM2QDX1	MI	TTB1TZG
DM2QDX1	MN	Schistosoma Deoxyribonucleic acid (Schist DNA)
DM2QDX1	MT	DTT
DM2QDX1	MA	Modulator
DM2QDX1	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM2QDX1	RU	https://www.fda.gov/

DMU9MYJ	DI	DMU9MYJ
DMU9MYJ	DN	Oxandrolone
DMU9MYJ	MI	TTS64P2
DMU9MYJ	MN	Androgen receptor (AR)
DMU9MYJ	MT	DTT
DMU9MYJ	MA	Agonist
DMU9MYJ	RN	The effect of oxandrolone treatment on human osteoblastic cells. J Burns Wounds. 2007 Mar 7;6:e4.
DMU9MYJ	RU	https://pubmed.ncbi.nlm.nih.gov/17364004

DMZ30JT	DI	DMZ30JT
DMZ30JT	DN	Oxantel pamoate
DMZ30JT	MI	TTHDSE2
DMZ30JT	MN	Bacterial Fumarate reductase flavoprotein (Bact frdA)
DMZ30JT	MT	DTT
DMZ30JT	MA	Inhibitor
DMZ30JT	RN	Fumarate reductase is essential for Helicobacter pylori colonization of the mouse stomach. Microb Pathog. 2000 Nov;29(5):279-87.
DMZ30JT	RU	https://pubmed.ncbi.nlm.nih.gov/11031122

DM9UB0P	DI	DM9UB0P
DM9UB0P	DN	Oxaprozin
DM9UB0P	MI	DE5IED8
DM9UB0P	MN	Cytochrome P450 2C9 (CYP2C9)
DM9UB0P	MT	DME
DM9UB0P	MA	Metabolism
DM9UB0P	RN	Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics. J Clin Pharmacol. 1997 Apr;37(4):267-78.
DM9UB0P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9115051

DM9UB0P	DI	DM9UB0P
DM9UB0P	DN	Oxaprozin
DM9UB0P	MI	TTK0943
DM9UB0P	MN	Prostaglandin G/H synthase (COX)
DM9UB0P	MT	DTT
DM9UB0P	MA	Inhibitor
DM9UB0P	RN	The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells. Cancer Res. 2007 Apr 1;67(7):3254-62.
DM9UB0P	RU	https://pubmed.ncbi.nlm.nih.gov/17409433

DM1F42Z	DI	DM1F42Z
DM1F42Z	DN	Oxatomide
DM1F42Z	MI	DECB0K3
DM1F42Z	MN	Cytochrome P450 2D6 (CYP2D6)
DM1F42Z	MT	DME
DM1F42Z	MA	Metabolism
DM1F42Z	RN	Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants. Biol Pharm Bull. 2005 Feb;28(2):328-34.
DM1F42Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15684493

DM1F42Z	DI	DM1F42Z
DM1F42Z	DN	Oxatomide
DM1F42Z	MI	DE4LYSA
DM1F42Z	MN	Cytochrome P450 3A4 (CYP3A4)
DM1F42Z	MT	DME
DM1F42Z	MA	Metabolism
DM1F42Z	RN	Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants. Biol Pharm Bull. 2005 Feb;28(2):328-34.
DM1F42Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15684493

DM1F42Z	DI	DM1F42Z
DM1F42Z	DN	Oxatomide
DM1F42Z	MI	TTTIBOJ
DM1F42Z	MN	Histamine H1 receptor (H1R)
DM1F42Z	MT	DTT
DM1F42Z	MA	Antagonist
DM1F42Z	RN	Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79.
DM1F42Z	RU	https://pubmed.ncbi.nlm.nih.gov/18446005

DMXNZM4	DI	DMXNZM4
DMXNZM4	DN	Oxazepam
DMXNZM4	MI	DE4LYSA
DMXNZM4	MN	Cytochrome P450 3A4 (CYP3A4)
DMXNZM4	MT	DME
DMXNZM4	MA	Metabolism
DMXNZM4	RN	Bioreactor systems in drug metabolism: synthesis of cytochrome P450-generated metabolites. Metab Eng. 2000 Apr;2(2):115-25.
DMXNZM4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10935727

DMXNZM4	DI	DMXNZM4
DMXNZM4	DN	Oxazepam
DMXNZM4	MI	DEO1IE3
DMXNZM4	MN	Cytochrome P450 3A43 (CYP3A43)
DMXNZM4	MT	DME
DMXNZM4	MA	Metabolism
DMXNZM4	RN	Cytochrome P450 enzyme activity and protein expression in primary porcine enterocyte and hepatocyte cultures. Xenobiotica. 2000 Jan;30(1):27-46.
DMXNZM4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10659949

DMXNZM4	DI	DMXNZM4
DMXNZM4	DN	Oxazepam
DMXNZM4	MI	DEIBDNY
DMXNZM4	MN	Cytochrome P450 3A5 (CYP3A5)
DMXNZM4	MT	DME
DMXNZM4	MA	Metabolism
DMXNZM4	RN	Cytochrome P450 enzyme activity and protein expression in primary porcine enterocyte and hepatocyte cultures. Xenobiotica. 2000 Jan;30(1):27-46.
DMXNZM4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10659949

DMXNZM4	DI	DMXNZM4
DMXNZM4	DN	Oxazepam
DMXNZM4	MI	DERD86B
DMXNZM4	MN	Cytochrome P450 3A7 (CYP3A7)
DMXNZM4	MT	DME
DMXNZM4	MA	Metabolism
DMXNZM4	RN	Cytochrome P450 enzyme activity and protein expression in primary porcine enterocyte and hepatocyte cultures. Xenobiotica. 2000 Jan;30(1):27-46.
DMXNZM4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10659949

DMXNZM4	DI	DMXNZM4
DMXNZM4	DN	Oxazepam
DMXNZM4	MI	TTPTXIN
DMXNZM4	MN	Translocator protein (TSPO)
DMXNZM4	MT	DTT
DMXNZM4	MA	Agonist
DMXNZM4	RN	Effects of the combination of metyrapone and oxazepam on cocaine and food self-administration in rats. Pharmacol Biochem Behav. 2008 Nov;91(1):181-9.
DMXNZM4	RU	https://pubmed.ncbi.nlm.nih.gov/18692521

DMXNZM4	DI	DMXNZM4
DMXNZM4	DN	Oxazepam
DMXNZM4	MI	DEYGVN4
DMXNZM4	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMXNZM4	MT	DME
DMXNZM4	MA	Metabolism
DMXNZM4	RN	Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion. Br J Clin Pharmacol. 2009 Nov;68(5):721-30.
DMXNZM4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19916996

DMXNZM4	DI	DMXNZM4
DMXNZM4	DN	Oxazepam
DMXNZM4	MI	DEB3CV1
DMXNZM4	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMXNZM4	MT	DME
DMXNZM4	MA	Metabolism
DMXNZM4	RN	Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. Drug Metab Dispos. 2002 Nov;30(11):1257-65.
DMXNZM4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12386133

DM5PU6O	DI	DM5PU6O
DM5PU6O	DN	Oxcarbazepine
DM5PU6O	MI	DTUGYRD
DM5PU6O	MN	P-glycoprotein 1 (ABCB1)
DM5PU6O	MT	DTP
DM5PU6O	MA	Substrate
DM5PU6O	RN	The transport of antiepileptic drugs by P-glycoprotein. Adv Drug Deliv Rev. 2012 Jul;64(10):930-42.
DM5PU6O	RU	https://doi.org/10.1016/j.addr.2011.12.003

DM5PU6O	DI	DM5PU6O
DM5PU6O	DN	Oxcarbazepine
DM5PU6O	MI	TTN9VTF
DM5PU6O	MN	Voltage-gated sodium channel alpha Nav1.9 (SCN11A)
DM5PU6O	MT	DTT
DM5PU6O	MA	Blocker
DM5PU6O	RN	Debate: Does genetic information in humans help us treat patients PRO--genetic information in humans helps us treat patients. CON--genetic information does not help at all. Epilepsia. 2008 Dec;49 Suppl 9:13-24.
DM5PU6O	RU	https://pubmed.ncbi.nlm.nih.gov/19087113

DME7KRM	DI	DME7KRM
DME7KRM	DN	Oxiconazole
DME7KRM	MI	TTTSOUD
DME7KRM	MN	Candida Cytochrome P450 51 (Candi ERG11)
DME7KRM	MT	DTT
DME7KRM	MA	Inhibitor
DME7KRM	RN	Antifungal agents: mechanisms of action. Trends Microbiol. 2003 Jun;11(6):272-9.
DME7KRM	RU	https://pubmed.ncbi.nlm.nih.gov/12823944

DME7KRM	DI	DME7KRM
DME7KRM	DN	Oxiconazole
DME7KRM	MI	DEGTFWK
DME7KRM	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DME7KRM	MT	DME
DME7KRM	MA	Metabolism
DME7KRM	RN	In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. Drug Metab Dispos. 2011 Apr;39(4):693-702.
DME7KRM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21177487

DM9EQC0	DI	DM9EQC0
DM9EQC0	DN	Oxidized glutathione
DM9EQC0	MI	TTEP6RV
DM9EQC0	MN	Glutathione reductase (GR)
DM9EQC0	MT	DTT
DM9EQC0	MA	Inhibitor
DM9EQC0	RN	The purification and properties of glutathione reductase from the cestode Moniezia expansa. Int J Biochem Cell Biol. 1995 Apr;27(4):393-401.
DM9EQC0	RU	https://pubmed.ncbi.nlm.nih.gov/7788561

DMRKOS1	DI	DMRKOS1
DMRKOS1	DN	Oxilofrine
DMRKOS1	MI	TTVIREA
DMRKOS1	MN	Adrenergic receptor (ADR)
DMRKOS1	MT	DTT
DMRKOS1	MA	Modulator
DMRKOS1	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMRKOS1	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM9FKSR	DI	DM9FKSR
DM9FKSR	DN	Oxitropium bromide
DM9FKSR	MI	TTH18TF
DM9FKSR	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DM9FKSR	MT	DTT
DM9FKSR	MA	Modulator
DM9FKSR	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DM9FKSR	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DM51OQW	DI	DM51OQW
DM51OQW	DN	Oxprenolol
DM51OQW	MI	TTR6W5O
DM51OQW	MN	Adrenergic receptor beta-1 (ADRB1)
DM51OQW	MT	DTT
DM51OQW	MA	Antagonist
DM51OQW	RN	Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6.
DM51OQW	RU	https://pubmed.ncbi.nlm.nih.gov/16268148

DM51OQW	DI	DM51OQW
DM51OQW	DN	Oxprenolol
DM51OQW	MI	DECB0K3
DM51OQW	MN	Cytochrome P450 2D6 (CYP2D6)
DM51OQW	MT	DME
DM51OQW	MA	Metabolism
DM51OQW	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DM51OQW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DMLHSE3	DI	DMLHSE3
DMLHSE3	DN	Oxtriphylline
DMLHSE3	MI	DEJGDUW
DMLHSE3	MN	Cytochrome P450 1A2 (CYP1A2)
DMLHSE3	MT	DME
DMLHSE3	MA	Metabolism
DMLHSE3	RN	PharmGKB summary: very important pharmacogene information for CYP1A2. Pharmacogenet Genomics. 2012 Jan;22(1):73-7.
DMLHSE3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21989077

DMLHSE3	DI	DMLHSE3
DMLHSE3	DN	Oxtriphylline
DMLHSE3	MI	TTZCG4L
DMLHSE3	MN	Phosphodiesterase 3 (PDE3)
DMLHSE3	MT	DTT
DMLHSE3	MA	Modulator
DMLHSE3	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMLHSE3	RU	https://www.fda.gov/

DMLHSE3	DI	DMLHSE3
DMLHSE3	DN	Oxtriphylline
DMLHSE3	MI	TTV5CGO
DMLHSE3	MN	Phosphodiesterase 4 (PDE4)
DMLHSE3	MT	DTT
DMLHSE3	MA	Modulator
DMLHSE3	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMLHSE3	RU	https://www.fda.gov/

DMI0GDH	DI	DMI0GDH
DMI0GDH	DN	Oxybuprocaine
DMI0GDH	MI	TTRK8B9
DMI0GDH	MN	Sodium channel unspecific (NaC)
DMI0GDH	MT	DTT
DMI0GDH	MA	Blocker
DMI0GDH	RN	Intrathecal oxybuprocaine and proxymetacaine produced potent and long-lasting spinal anesthesia in rats. Neurosci Lett. 2009 May 1;454(3):249-53.
DMI0GDH	RU	https://pubmed.ncbi.nlm.nih.gov/19429093

DMF2KLU	DI	DMF2KLU
DMF2KLU	DN	Oxybutynin hydrochloride
DMF2KLU	MI	DE4LYSA
DMF2KLU	MN	Cytochrome P450 3A4 (CYP3A4)
DMF2KLU	MT	DME
DMF2KLU	MA	Metabolism
DMF2KLU	RN	A comparative review of oxybutynin chloride formulations: pharmacokinetics and therapeutic efficacy in overactive bladder. Rev Urol. 2010 Winter;12(1):12-9.
DMF2KLU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20428289

DMF2KLU	DI	DMF2KLU
DMF2KLU	DN	Oxybutynin hydrochloride
DMF2KLU	MI	DEIBDNY
DMF2KLU	MN	Cytochrome P450 3A5 (CYP3A5)
DMF2KLU	MT	DME
DMF2KLU	MA	Metabolism
DMF2KLU	RN	Stereoselective pharmacokinetics of oxybutynin and N-desethyloxybutynin in vitro and in vivo. Xenobiotica. 2007 Jan;37(1):59-73.
DMF2KLU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17178634

DMF2KLU	DI	DMF2KLU
DMF2KLU	DN	Oxybutynin hydrochloride
DMF2KLU	MI	TTOXS3C
DMF2KLU	MN	Muscarinic acetylcholine receptor (CHRM)
DMF2KLU	MT	DTT
DMF2KLU	MA	Modulator
DMF2KLU	RN	Effects of propiverine hydrochloride (propiverine) on the muscarinic receptor binding affinity in guinea pig tissues and on salivation in conscious dogs. Nihon Yakurigaku Zasshi. 1999 Mar;113(3):157-66.
DMF2KLU	RU	https://pubmed.ncbi.nlm.nih.gov/10347840

DMXLKHV	DI	DMXLKHV
DMXLKHV	DN	Oxycodone
DMXLKHV	MI	TT27RFC
DMXLKHV	MN	Opioid receptor delta (OPRD1)
DMXLKHV	MT	DTT
DMXLKHV	MA	Agonist
DMXLKHV	RN	Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007 May;9(5):298-307.
DMXLKHV	RU	https://pubmed.ncbi.nlm.nih.gov/17525040

DMXLKHV	DI	DMXLKHV
DMXLKHV	DN	Oxycodone
DMXLKHV	MI	TTKWM86
DMXLKHV	MN	Opioid receptor mu (MOP)
DMXLKHV	MT	DTT
DMXLKHV	MA	Modulator
DMXLKHV	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
DMXLKHV	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319

DM8ZXT6	DI	DM8ZXT6
DM8ZXT6	DN	Oxymetazoline
DM8ZXT6	MI	TTQ8AFT
DM8ZXT6	MN	Adrenergic receptor Alpha-2 (ADRA2)
DM8ZXT6	MT	DTT
DM8ZXT6	MA	Agonist
DM8ZXT6	RN	Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries. Invest Ophthalmol Vis Sci. 2001 Aug;42(9):2049-55.
DM8ZXT6	RU	https://pubmed.ncbi.nlm.nih.gov/11481271

DM8ZXT6	DI	DM8ZXT6
DM8ZXT6	DN	Oxymetazoline
DM8ZXT6	MI	DEYGVN4
DM8ZXT6	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM8ZXT6	MT	DME
DM8ZXT6	MA	Metabolism
DM8ZXT6	RN	Identification and characterization of oxymetazoline glucuronidation in human liver microsomes: evidence for the involvement of UGT1A9. J Pharm Sci. 2011 Feb;100(2):784-93.
DM8ZXT6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20669329

DMFXUT8	DI	DMFXUT8
DMFXUT8	DN	Oxymetholone
DMFXUT8	MI	DEOG15F
DMFXUT8	MN	Steroid 5-alpha-reductase 1 (SRD5A1)
DMFXUT8	MT	DME
DMFXUT8	MA	Metabolism
DMFXUT8	RN	Androgen physiology. Semin Reprod Med. 2006 Apr;24(2):71-7.
DMFXUT8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16633980

DM65AGJ	DI	DM65AGJ
DM65AGJ	DN	Oxymorphone
DM65AGJ	MI	DECB0K3
DM65AGJ	MN	Cytochrome P450 2D6 (CYP2D6)
DM65AGJ	MT	DME
DM65AGJ	MA	Metabolism
DM65AGJ	RN	Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. Br J Clin Pharmacol. 2010 Jul;70(1):78-87.
DM65AGJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20642550

DM65AGJ	DI	DM65AGJ
DM65AGJ	DN	Oxymorphone
DM65AGJ	MI	DE4LYSA
DM65AGJ	MN	Cytochrome P450 3A4 (CYP3A4)
DM65AGJ	MT	DME
DM65AGJ	MA	Metabolism
DM65AGJ	RN	Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. Br J Clin Pharmacol. 2010 Jul;70(1):78-87.
DM65AGJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20642550

DM65AGJ	DI	DM65AGJ
DM65AGJ	DN	Oxymorphone
DM65AGJ	MI	TTN4QDT
DM65AGJ	MN	Opioid receptor (OPR)
DM65AGJ	MT	DTT
DM65AGJ	MA	Modulator
DM65AGJ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7094).
DM65AGJ	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7094

DMPZS7U	DI	DMPZS7U
DMPZS7U	DN	Oxyphenbutazone
DMPZS7U	MI	TTFNGC9
DMPZS7U	MN	Serum albumin (ALB)
DMPZS7U	MT	DTT
DMPZS7U	MA	Modulator
DMPZS7U	RN	Effect of albumin conformation on binding of phenylbutazone and oxyphenbutazone to human serum albumin. J Pharm Sci. 1982 Feb;71(2):241-4.
DMPZS7U	RU	https://www.ncbi.nlm.nih.gov/pubmed/7062254

DM3TABW	DI	DM3TABW
DM3TABW	DN	Oxyphencyclimine
DM3TABW	MI	TTH18TF
DM3TABW	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DM3TABW	MT	DTT
DM3TABW	MA	Binder
DM3TABW	RN	Stereoselective interaction of procyclidine, hexahydro-difenidol, hexbutinol and oxyphencyclimine, and of related antagonists, with four muscarinic receptors. Eur J Pharmacol. 1992 Sep 1;227(1):33-42.
DM3TABW	RU	https://pubmed.ncbi.nlm.nih.gov/1426023

DMMQHOZ	DI	DMMQHOZ
DMMQHOZ	DN	Oxyphenonium
DMMQHOZ	MI	TTZ9SOR
DMMQHOZ	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMMQHOZ	MT	DTT
DMMQHOZ	MA	Antagonist
DMMQHOZ	RN	Ultraviolet spectroscopic estimation of microenvironments and bitter tastes of oxyphenonium bromide in cyclodextrin solutions. J Pharm Sci. 1999 Aug;88(8):759-62.
DMMQHOZ	RU	https://pubmed.ncbi.nlm.nih.gov/10430538

DMMQHOZ	DI	DMMQHOZ
DMMQHOZ	DN	Oxyphenonium
DMMQHOZ	MI	DTT79CX
DMMQHOZ	MN	Organic cation transporter 1 (SLC22A1)
DMMQHOZ	MT	DTP
DMMQHOZ	MA	Substrate
DMMQHOZ	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMMQHOZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DMOVH1M	DI	DMOVH1M
DMOVH1M	DN	Oxytetracycline
DMOVH1M	MI	TTQ8KVI
DMOVH1M	MN	Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)
DMOVH1M	MT	DTT
DMOVH1M	MA	Binder
DMOVH1M	RN	Detection of tetracycline resistance genes by PCR methods. Methods Mol Biol. 2004;268:3-13.
DMOVH1M	RU	https://pubmed.ncbi.nlm.nih.gov/15156014

DMDL27I	DI	DMDL27I
DMDL27I	DN	Oxytocin
DMDL27I	MI	TTSCIUP
DMDL27I	MN	Oxytocin receptor (OTR)
DMDL27I	MT	DTT
DMDL27I	MA	Modulator
DMDL27I	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 369).
DMDL27I	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=369

DMDL27I	DI	DMDL27I
DMDL27I	DN	Oxytocin
DMDL27I	MI	TT4TFGN
DMDL27I	MN	Vasopressin V1a receptor (V1AR)
DMDL27I	MT	DTT
DMDL27I	MA	Agonist
DMDL27I	RN	Mapping peptide-binding domains of the human V1a vasopressin receptor with a photoactivatable linear peptide antagonist. J Biol Chem. 1997 Oct 17;272(42):26536-44.
DMDL27I	RU	https://pubmed.ncbi.nlm.nih.gov/9334232

DMDL27I	DI	DMDL27I
DMDL27I	DN	Oxytocin
DMDL27I	MI	TTL9MHW
DMDL27I	MN	Vasopressin V1b receptor (V1BR)
DMDL27I	MT	DTT
DMDL27I	MA	Agonist
DMDL27I	RN	The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways. Endocrinology. 1997 Oct;138(10):4109-22.
DMDL27I	RU	https://pubmed.ncbi.nlm.nih.gov/9322919

DMDL27I	DI	DMDL27I
DMDL27I	DN	Oxytocin
DMDL27I	MI	TTK8R02
DMDL27I	MN	Vasopressin V2 receptor (V2R)
DMDL27I	MT	DTT
DMDL27I	MA	Agonist
DMDL27I	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 368).
DMDL27I	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=368

DM1YB0R	DI	DM1YB0R
DM1YB0R	DN	OZ277
DM1YB0R	MI	TTZVSJ2
DM1YB0R	MN	Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A)
DM1YB0R	MT	DTT
DM1YB0R	MA	Inhibitor
DM1YB0R	RN	The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
DM1YB0R	RU	https://pubmed.ncbi.nlm.nih.gov/18220771

DMT6AM2	DI	DMT6AM2
DMT6AM2	DN	Ozanimod
DMT6AM2	MI	TT9JZCK
DMT6AM2	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMT6AM2	MT	DTT
DMT6AM2	MA	Agonist
DMT6AM2	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMT6AM2	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209899s000lbl.pdf

DM6KZMG	DI	DM6KZMG
DM6KZMG	DN	Ozenoxacin
DM6KZMG	MI	TTN6J5F
DM6KZMG	MN	Bacterial DNA gyrase (Bact gyrase)
DM6KZMG	MT	DTT
DM6KZMG	MA	Modulator
DM6KZMG	RN	In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother. 2002 Mar;49(3):455-65.
DM6KZMG	RU	https://www.ncbi.nlm.nih.gov/pubmed/11864945

DM6KZMG	DI	DM6KZMG
DM6KZMG	DN	Ozenoxacin
DM6KZMG	MI	TTABD5E
DM6KZMG	MN	DNA replication (DNA repli)
DM6KZMG	MT	DTT
DM6KZMG	MA	Inhibitor
DM6KZMG	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DM6KZMG	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DM6KZMG	DI	DM6KZMG
DM6KZMG	DN	Ozenoxacin
DM6KZMG	MI	TTRVWAT
DM6KZMG	MN	Staphylococcus DNA gyrase A (Stap-coc gyrA)
DM6KZMG	MT	DTT
DM6KZMG	MA	Inhibitor
DM6KZMG	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DM6KZMG	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DM6KZMG	DI	DM6KZMG
DM6KZMG	DN	Ozenoxacin
DM6KZMG	MI	TTIXTO3
DM6KZMG	MN	Staphylococcus Topoisomerase IV (Stap-coc parC)
DM6KZMG	MT	DTT
DM6KZMG	MA	Modulator
DM6KZMG	RN	In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother. 2002 Mar;49(3):455-65.
DM6KZMG	RU	https://www.ncbi.nlm.nih.gov/pubmed/11864945

DMNKT8Z	DI	DMNKT8Z
DMNKT8Z	DN	Pachycarpine
DMNKT8Z	MI	TTRK8B9
DMNKT8Z	MN	Sodium channel unspecific (NaC)
DMNKT8Z	MT	DTT
DMNKT8Z	MA	Modulator
DMNKT8Z	RN	Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81.
DMNKT8Z	RU	https://pubmed.ncbi.nlm.nih.gov/3879679

DMLB81S	DI	DMLB81S
DMLB81S	DN	Paclitaxel
DMLB81S	MI	DTI7UX6
DMLB81S	MN	Breast cancer resistance protein (ABCG2)
DMLB81S	MT	DTP
DMLB81S	MA	Substrate
DMLB81S	RN	Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2011 May;337(2):423-32.
DMLB81S	RU	http://www.ncbi.nlm.nih.gov/pubmed/21262849

DMLB81S	DI	DMLB81S
DMLB81S	DN	Paclitaxel
DMLB81S	MI	DTZRMK5
DMLB81S	MN	Multidrug resistance protein 3 (ABCB4)
DMLB81S	MT	DTP
DMLB81S	MA	Substrate
DMLB81S	RN	MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem. 2000 Aug 4;275(31):23530-9.
DMLB81S	RU	http://www.ncbi.nlm.nih.gov/pubmed/10918072

DMLB81S	DI	DMLB81S
DMLB81S	DN	Paclitaxel
DMLB81S	MI	DTSYQGK
DMLB81S	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMLB81S	MT	DTP
DMLB81S	MA	Substrate
DMLB81S	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMLB81S	RU	https://doi.org/10.1007/s11095-012-0935-x

DMLB81S	DI	DMLB81S
DMLB81S	DN	Paclitaxel
DMLB81S	MI	DTFI42L
DMLB81S	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMLB81S	MT	DTP
DMLB81S	MA	Substrate
DMLB81S	RN	Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6125-32.
DMLB81S	RU	http://www.ncbi.nlm.nih.gov/pubmed/17062689

DMLB81S	DI	DMLB81S
DMLB81S	DN	Paclitaxel
DMLB81S	MI	DTQ3ZHF
DMLB81S	MN	Multidrug resistance-associated protein 3 (ABCC3)
DMLB81S	MT	DTP
DMLB81S	MA	Substrate
DMLB81S	RN	Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer. Cancer Res. 2008 Jul 1;68(13):5380-9.
DMLB81S	RU	https://doi.org/10.1158/0008-5472.CAN-08-0234

DMLB81S	DI	DMLB81S
DMLB81S	DN	Paclitaxel
DMLB81S	MI	DTPS120
DMLB81S	MN	Multidrug resistance-associated protein 7 (ABCC10)
DMLB81S	MT	DTP
DMLB81S	MA	Substrate
DMLB81S	RN	Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7). Cancer Res. 2012 Dec 15;72(24):6457-67.
DMLB81S	RU	http://www.ncbi.nlm.nih.gov/pubmed/23087055

DMLB81S	DI	DMLB81S
DMLB81S	DN	Paclitaxel
DMLB81S	MI	DT0OC1Q
DMLB81S	MN	Organic anion transporter 2 (SLC22A7)
DMLB81S	MT	DTP
DMLB81S	MA	Substrate
DMLB81S	RN	Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8.
DMLB81S	RU	http://www.ncbi.nlm.nih.gov/pubmed/15901346

DMLB81S	DI	DMLB81S
DMLB81S	DN	Paclitaxel
DMLB81S	MI	DT3D8F0
DMLB81S	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMLB81S	MT	DTP
DMLB81S	MA	Substrate
DMLB81S	RN	Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds. Eur J Med Chem. 2015 Mar 6;92:723-31.
DMLB81S	RU	http://www.ncbi.nlm.nih.gov/pubmed/25618019

DMLB81S	DI	DMLB81S
DMLB81S	DN	Paclitaxel
DMLB81S	MI	DT9C1TS
DMLB81S	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMLB81S	MT	DTP
DMLB81S	MA	Substrate
DMLB81S	RN	Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther. 2005 Aug;4(8):815-8.
DMLB81S	RU	http://www.ncbi.nlm.nih.gov/pubmed/16210916

DMLB81S	DI	DMLB81S
DMLB81S	DN	Paclitaxel
DMLB81S	MI	DTUGYRD
DMLB81S	MN	P-glycoprotein 1 (ABCB1)
DMLB81S	MT	DTP
DMLB81S	MA	Substrate
DMLB81S	RN	Kinetics of P-glycoprotein-mediated efflux of paclitaxel. J Pharmacol Exp Ther. 2001 Sep;298(3):1236-42.
DMLB81S	RU	http://www.ncbi.nlm.nih.gov/pubmed/11504826

DMLB81S	DI	DMLB81S
DMLB81S	DN	Paclitaxel
DMLB81S	MI	DT68UV2
DMLB81S	MN	TAP-like protein (ABCB9)
DMLB81S	MT	DTP
DMLB81S	MA	Substrate
DMLB81S	RN	Overexpression of microRNA-24 increases the sensitivity to paclitaxel in drug-resistant breast carcinoma cell lines via targeting ABCB9. Oncol Lett. 2016 Nov;12(5):3905-3911.
DMLB81S	RU	http://www.ncbi.nlm.nih.gov/pubmed/27895747

DMD7L94	DI	DMD7L94
DMD7L94	DN	Palbociclib
DMD7L94	MI	DTI7UX6
DMD7L94	MN	Breast cancer resistance protein (ABCG2)
DMD7L94	MT	DTP
DMD7L94	MA	Substrate
DMD7L94	RN	Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model. J Pharmacol Exp Ther. 2015 Nov;355(2):264-71.
DMD7L94	RU	http://www.ncbi.nlm.nih.gov/pubmed/26354993

DMD7L94	DI	DMD7L94
DMD7L94	DN	Palbociclib
DMD7L94	MI	TT0PG8F
DMD7L94	MN	Cyclin-dependent kinase 4 (CDK4)
DMD7L94	MT	DTT
DMD7L94	MA	Modulator
DMD7L94	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2017
DMD7L94	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207103s004lbl.pdf

DMD7L94	DI	DMD7L94
DMD7L94	DN	Palbociclib
DMD7L94	MI	TTO0FDJ
DMD7L94	MN	Cyclin-dependent kinase 6 (CDK6)
DMD7L94	MT	DTT
DMD7L94	MA	Modulator
DMD7L94	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2017
DMD7L94	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207103s004lbl.pdf

DMD7L94	DI	DMD7L94
DMD7L94	DN	Palbociclib
DMD7L94	MI	DE4LYSA
DMD7L94	MN	Cytochrome P450 3A4 (CYP3A4)
DMD7L94	MT	DME
DMD7L94	MA	Metabolism
DMD7L94	RN	Progress with palbociclib in breast cancer: latest evidence and clinical considerations. Ther Adv Med Oncol. 2017 Feb;9(2):83-105.
DMD7L94	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28203301

DMD7L94	DI	DMD7L94
DMD7L94	DN	Palbociclib
DMD7L94	MI	DTUGYRD
DMD7L94	MN	P-glycoprotein 1 (ABCB1)
DMD7L94	MT	DTP
DMD7L94	MA	Substrate
DMD7L94	RN	Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model. J Pharmacol Exp Ther. 2015 Nov;355(2):264-71.
DMD7L94	RU	http://www.ncbi.nlm.nih.gov/pubmed/26354993

DM9JOYP	DI	DM9JOYP
DM9JOYP	DN	Palifermin
DM9JOYP	MI	TTGJVQM
DM9JOYP	MN	Fibroblast growth factor receptor 2 (FGFR2)
DM9JOYP	MT	DTT
DM9JOYP	MA	Binder
DM9JOYP	RN	Keratinocyte growth factor. Expert Opin Biol Ther. 2009 Jun;9(6):779-87.
DM9JOYP	RU	https://pubmed.ncbi.nlm.nih.gov/19456212

DM7NPJS	DI	DM7NPJS
DM7NPJS	DN	Paliperidone
DM7NPJS	MI	TT85JO3
DM7NPJS	MN	5-HT receptor (5HTR)
DM7NPJS	MT	DTT
DM7NPJS	MA	Antagonist
DM7NPJS	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DM7NPJS	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM7NPJS	DI	DM7NPJS
DM7NPJS	DN	Paliperidone
DM7NPJS	MI	DECB0K3
DM7NPJS	MN	Cytochrome P450 2D6 (CYP2D6)
DM7NPJS	MT	DME
DM7NPJS	MA	Metabolism
DM7NPJS	RN	Interpreting serum risperidone concentrations. Pharmacotherapy. 2005 Feb;25(2):299-302.
DM7NPJS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15767244

DM7NPJS	DI	DM7NPJS
DM7NPJS	DN	Paliperidone
DM7NPJS	MI	DE4LYSA
DM7NPJS	MN	Cytochrome P450 3A4 (CYP3A4)
DM7NPJS	MT	DME
DM7NPJS	MA	Metabolism
DM7NPJS	RN	ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety. Ther Drug Monit. 2008 Oct;30(5):628-33.
DM7NPJS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18708991

DM7NPJS	DI	DM7NPJS
DM7NPJS	DN	Paliperidone
DM7NPJS	MI	DEIBDNY
DM7NPJS	MN	Cytochrome P450 3A5 (CYP3A5)
DM7NPJS	MT	DME
DM7NPJS	MA	Metabolism
DM7NPJS	RN	Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos. 2001 Oct;29(10):1263-8.
DM7NPJS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11560868

DM7NPJS	DI	DM7NPJS
DM7NPJS	DN	Paliperidone
DM7NPJS	MI	DTUGYRD
DM7NPJS	MN	P-glycoprotein 1 (ABCB1)
DM7NPJS	MT	DTP
DM7NPJS	MA	Substrate
DM7NPJS	RN	Invega (paliperidone) extended release tablets FDA Label
DM7NPJS	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021999s018lbl.pdf

DMQM9S0	DI	DMQM9S0
DMQM9S0	DN	Palivizumab
DMQM9S0	MI	TT57ID8
DMQM9S0	MN	Respiratory syncytial virus protein F (RSV F)
DMQM9S0	MT	DTT
DMQM9S0	MA	Modulator
DMQM9S0	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMQM9S0	RU	https://www.fda.gov/

DMBHMOX	DI	DMBHMOX
DMBHMOX	DN	Palonosetron
DMBHMOX	MI	TTPC4TU
DMBHMOX	MN	5-HT 3A receptor (HTR3A)
DMBHMOX	MT	DTT
DMBHMOX	MA	Antagonist
DMBHMOX	RN	Management of postoperative nausea and vomiting: focus on palonosetron. Ther Clin Risk Manag. 2009 Feb;5(1):21-34.
DMBHMOX	RU	https://pubmed.ncbi.nlm.nih.gov/19436621

DMBHMOX	DI	DMBHMOX
DMBHMOX	DN	Palonosetron
DMBHMOX	MI	DECB0K3
DMBHMOX	MN	Cytochrome P450 2D6 (CYP2D6)
DMBHMOX	MT	DME
DMBHMOX	MA	Metabolism
DMBHMOX	RN	Cytochrome P450 2D6 metabolism and 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Med Sci Monit. 2005 Oct;11(10):RA322-8.
DMBHMOX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16192915

DMBHMOX	DI	DMBHMOX
DMBHMOX	DN	Palonosetron
DMBHMOX	MI	DE4LYSA
DMBHMOX	MN	Cytochrome P450 3A4 (CYP3A4)
DMBHMOX	MT	DME
DMBHMOX	MA	Metabolism
DMBHMOX	RN	Pharmacokinetics, metabolism and excretion of intravenous [l4C]-palonosetron in healthy human volunteers. Biopharm Drug Dispos. 2004 Nov;25(8):329-37.
DMBHMOX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15378559

DMK2PBD	DI	DMK2PBD
DMK2PBD	DN	Palonosetron + fosnetupitant
DMK2PBD	MI	TTPC4TU
DMK2PBD	MN	5-HT 3A receptor (HTR3A)
DMK2PBD	MT	DTT
DMK2PBD	MA	Antagonist
DMK2PBD	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMK2PBD	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMK2PBD	DI	DMK2PBD
DMK2PBD	DN	Palonosetron + fosnetupitant
DMK2PBD	MI	TTZPO1L
DMK2PBD	MN	Substance-P receptor (TACR1)
DMK2PBD	MT	DTT
DMK2PBD	MA	Antagonist
DMK2PBD	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMK2PBD	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMB4AVP	DI	DMB4AVP
DMB4AVP	DN	Pamidronate
DMB4AVP	MI	TTIKWV4
DMB4AVP	MN	Geranyltranstransferase (FDPS)
DMB4AVP	MT	DTT
DMB4AVP	MA	Inhibitor
DMB4AVP	RN	Detection of nonsterol isoprenoids by HPLC-MS/MS. Anal Biochem. 2008 Dec 1;383(1):18-24.
DMB4AVP	RU	https://pubmed.ncbi.nlm.nih.gov/18782552

DMB0VY8	DI	DMB0VY8
DMB0VY8	DN	Pancuronium
DMB0VY8	MI	TTJSZTB
DMB0VY8	MN	Nicotinic acetylcholine receptor (nAChR)
DMB0VY8	MT	DTT
DMB0VY8	MA	Antagonist
DMB0VY8	RN	Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52.
DMB0VY8	RU	https://pubmed.ncbi.nlm.nih.gov/19417616

DMQPD1F	DI	DMQPD1F
DMQPD1F	DN	Panitumumab
DMQPD1F	MI	TTGKNB4
DMQPD1F	MN	Epidermal growth factor receptor (EGFR)
DMQPD1F	MT	DTT
DMQPD1F	MA	Suppressor
DMQPD1F	RN	Integration of panitumumab into the treatment of colorectal cancer. Crit Rev Oncol Hematol. 2010 Apr;74(1):16-26.
DMQPD1F	RU	https://pubmed.ncbi.nlm.nih.gov/19616446

DM58WKG	DI	DM58WKG
DM58WKG	DN	Panobinostat
DM58WKG	MI	DE4LYSA
DM58WKG	MN	Cytochrome P450 3A4 (CYP3A4)
DM58WKG	MT	DME
DM58WKG	MA	Metabolism
DM58WKG	RN	Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes. Expert Rev Clin Pharmacol. 2016;9(1):35-48.
DM58WKG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26503877

DM58WKG	DI	DM58WKG
DM58WKG	DN	Panobinostat
DM58WKG	MI	TT6R7JZ
DM58WKG	MN	Histone deacetylase 1 (HDAC1)
DM58WKG	MT	DTT
DM58WKG	MA	Inhibitor
DM58WKG	RN	Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32.
DM58WKG	RU	https://pubmed.ncbi.nlm.nih.gov/19721445

DM58WKG	DI	DM58WKG
DM58WKG	DN	Panobinostat
DM58WKG	MI	DTUGYRD
DM58WKG	MN	P-glycoprotein 1 (ABCB1)
DM58WKG	MT	DTP
DM58WKG	MA	Substrate
DM58WKG	RN	Panobinostat for the treatment of multiple myeloma: the evidence to date. J Blood Med. 2015 Oct 8;6:269-76.
DM58WKG	RU	http://www.ncbi.nlm.nih.gov/pubmed/26504410

DMSVOCZ	DI	DMSVOCZ
DMSVOCZ	DN	Pantoprazole
DMSVOCZ	MI	DTI7UX6
DMSVOCZ	MN	Breast cancer resistance protein (ABCG2)
DMSVOCZ	MT	DTP
DMSVOCZ	MA	Substrate
DMSVOCZ	RN	Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res. 2004 Aug 15;64(16):5804-11.
DMSVOCZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/15313923

DMSVOCZ	DI	DMSVOCZ
DMSVOCZ	DN	Pantoprazole
DMSVOCZ	MI	DEJGDUW
DMSVOCZ	MN	Cytochrome P450 1A2 (CYP1A2)
DMSVOCZ	MT	DME
DMSVOCZ	MA	Metabolism
DMSVOCZ	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMSVOCZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMSVOCZ	DI	DMSVOCZ
DMSVOCZ	DN	Pantoprazole
DMSVOCZ	MI	DE4LYSA
DMSVOCZ	MN	Cytochrome P450 3A4 (CYP3A4)
DMSVOCZ	MT	DME
DMSVOCZ	MA	Metabolism
DMSVOCZ	RN	Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions. Yale J Biol Med. 1996 May-Jun;69(3):203-9.
DMSVOCZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9165689

DMSVOCZ	DI	DMSVOCZ
DMSVOCZ	DN	Pantoprazole
DMSVOCZ	MI	TTLOKXP
DMSVOCZ	MN	Gastric H(+)/K(+) ATPase (Proton pump)
DMSVOCZ	MT	DTT
DMSVOCZ	MA	Modulator
DMSVOCZ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMSVOCZ	RU	https://www.fda.gov/

DMSVOCZ	DI	DMSVOCZ
DMSVOCZ	DN	Pantoprazole
DMSVOCZ	MI	DEGTFWK
DMSVOCZ	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMSVOCZ	MT	DME
DMSVOCZ	MA	Metabolism
DMSVOCZ	RN	Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin Drug Metab Toxicol. 2018 Apr;14(4):447-460.
DMSVOCZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29620484

DMSVOCZ	DI	DMSVOCZ
DMSVOCZ	DN	Pantoprazole
DMSVOCZ	MI	DTUGYRD
DMSVOCZ	MN	P-glycoprotein 1 (ABCB1)
DMSVOCZ	MT	DTP
DMSVOCZ	MA	Substrate
DMSVOCZ	RN	A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26.
DMSVOCZ	RU	https://doi.org/10.1007/s00210-008-0345-0

DMSVOCZ	DI	DMSVOCZ
DMSVOCZ	DN	Pantoprazole
DMSVOCZ	MI	DEYWLRK
DMSVOCZ	MN	Sulfotransferase 1A1 (SULT1A1)
DMSVOCZ	MT	DME
DMSVOCZ	MA	Metabolism
DMSVOCZ	RN	Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions. Yale J Biol Med. 1996 May-Jun;69(3):203-9.
DMSVOCZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9165689

DM091H2	DI	DM091H2
DM091H2	DN	Pantothenic acid
DM091H2	MI	DENRZXT
DM091H2	MN	Pantothenate kinase 3 (PANK3)
DM091H2	MT	DME
DM091H2	MA	Metabolism
DM091H2	RN	Modulation of pantothenate kinase 3 activity by small molecules that interact with the substrate/allosteric regulatory domain. Chem Biol. 2010 Aug 27;17(8):892-902.
DM091H2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20797618

DMCA9QP	DI	DMCA9QP
DMCA9QP	DN	Papaverine
DMCA9QP	MI	TTSKMI8
DMCA9QP	MN	Phosphodiesterase 4D (PDE4D)
DMCA9QP	MT	DTT
DMCA9QP	MA	Inhibitor
DMCA9QP	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMCA9QP	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMCA9QP	DI	DMCA9QP
DMCA9QP	DN	Papaverine
DMCA9QP	MI	TTJ0IQB
DMCA9QP	MN	Phosphodiesterase 5A (PDE5A)
DMCA9QP	MT	DTT
DMCA9QP	MA	Inhibitor
DMCA9QP	RN	Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities. Asian J Androl. 2003 Mar;5(1):15-8.
DMCA9QP	RU	https://pubmed.ncbi.nlm.nih.gov/12646997

DMOC1BX	DI	DMOC1BX
DMOC1BX	DN	Paraldehyde
DMOC1BX	MI	DEWYTJB
DMOC1BX	MN	Aldehyde dehydrogenase 2 (ALDH2)
DMOC1BX	MT	DME
DMOC1BX	MA	Metabolism
DMOC1BX	RN	Paraldehyde. J Appl Toxicol. 1991 Oct;11(5):379-81.
DMOC1BX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1783744

DMR5ZUP	DI	DMR5ZUP
DMR5ZUP	DN	Paramethadione
DMR5ZUP	MI	DE5IED8
DMR5ZUP	MN	Cytochrome P450 2C9 (CYP2C9)
DMR5ZUP	MT	DME
DMR5ZUP	MA	Metabolism
DMR5ZUP	RN	Involvement of cytochrome P450 2C9, 2E1 and 3A4 in trimethadione N-demethylation in human microsomes. J Clin Pharm Ther. 2003 Dec;28(6):493-6.
DMR5ZUP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14651673

DMR5ZUP	DI	DMR5ZUP
DMR5ZUP	DN	Paramethadione
DMR5ZUP	MI	DEVDYN7
DMR5ZUP	MN	Cytochrome P450 2E1 (CYP2E1)
DMR5ZUP	MT	DME
DMR5ZUP	MA	Metabolism
DMR5ZUP	RN	Cytochrome P450 2E1: its clinical and toxicological role. J Clin Pharm Ther. 2000 Jun;25(3):165-75.
DMR5ZUP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10886461

DMR5ZUP	DI	DMR5ZUP
DMR5ZUP	DN	Paramethadione
DMR5ZUP	MI	DE4LYSA
DMR5ZUP	MN	Cytochrome P450 3A4 (CYP3A4)
DMR5ZUP	MT	DME
DMR5ZUP	MA	Metabolism
DMR5ZUP	RN	Involvement of cytochrome P450 2C9, 2E1 and 3A4 in trimethadione N-demethylation in human microsomes. J Clin Pharm Ther. 2003 Dec;28(6):493-6.
DMR5ZUP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14651673

DMR5ZUP	DI	DMR5ZUP
DMR5ZUP	DN	Paramethadione
DMR5ZUP	MI	TT729IR
DMR5ZUP	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DMR5ZUP	MT	DTT
DMR5ZUP	MA	Blocker
DMR5ZUP	RN	Prophylactic and therapeutic functions of T-type calcium blockers against noise-induced hearing loss. Hear Res. 2007 Apr;226(1-2):52-60.
DMR5ZUP	RU	https://pubmed.ncbi.nlm.nih.gov/17291698

DM6PR40	DI	DM6PR40
DM6PR40	DN	Paramethasone
DM6PR40	MI	TTJL8VG
DM6PR40	MN	Corticosteroid-binding globulin (SERPINA6)
DM6PR40	MT	DTT
DM6PR40	MA	Binder
DM6PR40	RN	Novel human corticosteroid-binding globulin variant with low cortisol-binding affinity. J Clin Endocrinol Metab. 2000 Jan;85(1):361-7.
DM6PR40	RU	https://pubmed.ncbi.nlm.nih.gov/10634411

DM6PR40	DI	DM6PR40
DM6PR40	DN	Paramethasone
DM6PR40	MI	DE4LYSA
DM6PR40	MN	Cytochrome P450 3A4 (CYP3A4)
DM6PR40	MT	DME
DM6PR40	MA	Metabolism
DM6PR40	RN	Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35.
DM6PR40	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20482443

DMM0HR1	DI	DMM0HR1
DMM0HR1	DN	Pargyline
DMM0HR1	MI	TT32XQJ
DMM0HR1	MN	Monoamine oxidase (MAO)
DMM0HR1	MT	DTT
DMM0HR1	MA	Inhibitor
DMM0HR1	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMM0HR1	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMM0HR1	DI	DMM0HR1
DMM0HR1	DN	Pargyline
DMM0HR1	MI	TTGP7BY
DMM0HR1	MN	Monoamine oxidase type B (MAO-B)
DMM0HR1	MT	DTT
DMM0HR1	MA	Inhibitor
DMM0HR1	RN	Dose-dependent activation of distinct hypertrophic pathways by serotonin in cardiac cells. Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H821-8.
DMM0HR1	RU	https://pubmed.ncbi.nlm.nih.gov/19542488

DMYBV3G	DI	DMYBV3G
DMYBV3G	DN	Paricalcitol
DMYBV3G	MI	TTK59TV
DMYBV3G	MN	Vitamin D3 receptor (VDR)
DMYBV3G	MT	DTT
DMYBV3G	MA	Agonist
DMYBV3G	RN	New acquisitions in therapy of secondary hyperparathyroidism in chronic kidney disease and peritoneal dialysis patients: role of vitamin D receptor... Contrib Nephrol. 2009;163:219-226.
DMYBV3G	RU	https://pubmed.ncbi.nlm.nih.gov/19494617

DM1AGXN	DI	DM1AGXN
DM1AGXN	DN	Paromomycin
DM1AGXN	MI	TTQ8KVI
DM1AGXN	MN	Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)
DM1AGXN	MT	DTT
DM1AGXN	MA	Binder
DM1AGXN	RN	Aminoglycoside association pathways with the 30S ribosomal subunit. J Phys Chem B. 2009 May 21;113(20):7322-30.
DM1AGXN	RU	https://pubmed.ncbi.nlm.nih.gov/19438282

DM5PVQE	DI	DM5PVQE
DM5PVQE	DN	Paroxetine
DM5PVQE	MI	DEJGDUW
DM5PVQE	MN	Cytochrome P450 1A2 (CYP1A2)
DM5PVQE	MT	DME
DM5PVQE	MA	Metabolism
DM5PVQE	RN	CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine. Pharmacogenomics. 2010 Nov;11(11):1535-43.
DM5PVQE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21121774

DM5PVQE	DI	DM5PVQE
DM5PVQE	DN	Paroxetine
DM5PVQE	MI	DECB0K3
DM5PVQE	MN	Cytochrome P450 2D6 (CYP2D6)
DM5PVQE	MT	DME
DM5PVQE	MA	Metabolism
DM5PVQE	RN	Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015 Aug;98(2):127-34.
DM5PVQE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25974703

DM5PVQE	DI	DM5PVQE
DM5PVQE	DN	Paroxetine
DM5PVQE	MI	DE4LYSA
DM5PVQE	MN	Cytochrome P450 3A4 (CYP3A4)
DM5PVQE	MT	DME
DM5PVQE	MA	Metabolism
DM5PVQE	RN	New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients. Ther Clin Risk Manag. 2014 Jun 13;10:423-36.
DM5PVQE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24966680

DM5PVQE	DI	DM5PVQE
DM5PVQE	DN	Paroxetine
DM5PVQE	MI	DEGTFWK
DM5PVQE	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM5PVQE	MT	DME
DM5PVQE	MA	Metabolism
DM5PVQE	RN	Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator. Drug Metab Dispos. 2010 Mar;38(3):376-85.
DM5PVQE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20007670

DM5PVQE	DI	DM5PVQE
DM5PVQE	DN	Paroxetine
DM5PVQE	MI	DTUGYRD
DM5PVQE	MN	P-glycoprotein 1 (ABCB1)
DM5PVQE	MT	DTP
DM5PVQE	MA	Substrate
DM5PVQE	RN	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
DM5PVQE	RU	https://doi.org/10.1016/j.addr.2011.12.008

DM5PVQE	DI	DM5PVQE
DM5PVQE	DN	Paroxetine
DM5PVQE	MI	TT3ROYC
DM5PVQE	MN	Serotonin transporter (SERT)
DM5PVQE	MT	DTT
DM5PVQE	MA	Modulator
DM5PVQE	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM5PVQE	RU	https://www.fda.gov/

DMHM7JS	DI	DMHM7JS
DMHM7JS	DN	Pasireotide
DMHM7JS	MI	TTIND6G
DMHM7JS	MN	Somatostatin receptor type 1 (SSTR1)
DMHM7JS	MT	DTT
DMHM7JS	MA	Inhibitor
DMHM7JS	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 355).
DMHM7JS	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=355

DMHM7JS	DI	DMHM7JS
DMHM7JS	DN	Pasireotide
DMHM7JS	MI	TTZ6T9E
DMHM7JS	MN	Somatostatin receptor type 2 (SSTR2)
DMHM7JS	MT	DTT
DMHM7JS	MA	Inhibitor
DMHM7JS	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 356).
DMHM7JS	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=356

DMHM7JS	DI	DMHM7JS
DMHM7JS	DN	Pasireotide
DMHM7JS	MI	TTJX3UE
DMHM7JS	MN	Somatostatin receptor type 3 (SSTR3)
DMHM7JS	MT	DTT
DMHM7JS	MA	Inhibitor
DMHM7JS	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 357).
DMHM7JS	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=357

DMHM7JS	DI	DMHM7JS
DMHM7JS	DN	Pasireotide
DMHM7JS	MI	TT2BC4G
DMHM7JS	MN	Somatostatin receptor type 5 (SSTR5)
DMHM7JS	MT	DTT
DMHM7JS	MA	Inhibitor
DMHM7JS	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 359).
DMHM7JS	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=359

DMMIQ20	DI	DMMIQ20
DMMIQ20	DN	Patiromer calcium
DMMIQ20	MI	TTB0SC6
DMMIQ20	MN	Potassium (K)
DMMIQ20	MT	DTT
DMMIQ20	MA	Binder
DMMIQ20	RN	Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J. 2011 Apr;32(7):820-8.
DMMIQ20	RU	https://pubmed.ncbi.nlm.nih.gov/21208974

DMWSA0V	DI	DMWSA0V
DMWSA0V	DN	Patisiran
DMWSA0V	MI	TTPOYU7
DMWSA0V	MN	Transthyretin messenger RNA (TTR mRNA)
DMWSA0V	MT	DTT
DMWSA0V	RN	Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc.
DMWSA0V	RU	http://www.alnylam.com/product-pipeline/ttr-amyloidosis-fac/

DMF57DM	DI	DMF57DM
DMF57DM	DN	Pazopanib
DMF57DM	MI	DEJGDUW
DMF57DM	MN	Cytochrome P450 1A2 (CYP1A2)
DMF57DM	MT	DME
DMF57DM	MA	Metabolism
DMF57DM	RN	Pazopanib, a new therapy for metastatic soft tissue sarcoma. Expert Opin Pharmacother. 2013 May;14(7):929-35.
DMF57DM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23488774

DMF57DM	DI	DMF57DM
DMF57DM	DN	Pazopanib
DMF57DM	MI	DES5XRU
DMF57DM	MN	Cytochrome P450 2C8 (CYP2C8)
DMF57DM	MT	DME
DMF57DM	MA	Metabolism
DMF57DM	RN	Pazopanib, a new therapy for metastatic soft tissue sarcoma. Expert Opin Pharmacother. 2013 May;14(7):929-35.
DMF57DM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23488774

DMF57DM	DI	DMF57DM
DMF57DM	DN	Pazopanib
DMF57DM	MI	DECB0K3
DMF57DM	MN	Cytochrome P450 2D6 (CYP2D6)
DMF57DM	MT	DME
DMF57DM	MA	Metabolism
DMF57DM	RN	Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs. 2011 Mar 5;71(4):443-54.
DMF57DM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21395357

DMF57DM	DI	DMF57DM
DMF57DM	DN	Pazopanib
DMF57DM	MI	DE4LYSA
DMF57DM	MN	Cytochrome P450 3A4 (CYP3A4)
DMF57DM	MT	DME
DMF57DM	MA	Metabolism
DMF57DM	RN	Pazopanib, a new therapy for metastatic soft tissue sarcoma. Expert Opin Pharmacother. 2013 May;14(7):929-35.
DMF57DM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23488774

DM6U9CQ	DI	DM6U9CQ
DM6U9CQ	DN	Pazopanib HCl
DM6U9CQ	MI	DTI7UX6
DM6U9CQ	MN	Breast cancer resistance protein (ABCG2)
DM6U9CQ	MT	DTP
DM6U9CQ	MA	Substrate
DM6U9CQ	RN	Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. Xenobiotica. 2013 May;43(5):443-53.
DM6U9CQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/23548165

DM6U9CQ	DI	DM6U9CQ
DM6U9CQ	DN	Pazopanib HCl
DM6U9CQ	MI	DT3D8F0
DM6U9CQ	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM6U9CQ	MT	DTP
DM6U9CQ	MA	Substrate
DM6U9CQ	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DM6U9CQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DM6U9CQ	DI	DM6U9CQ
DM6U9CQ	DN	Pazopanib HCl
DM6U9CQ	MI	DTUGYRD
DM6U9CQ	MN	P-glycoprotein 1 (ABCB1)
DM6U9CQ	MT	DTP
DM6U9CQ	MA	Substrate
DM6U9CQ	RN	Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. Xenobiotica. 2013 May;43(5):443-53.
DM6U9CQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/23548165

DM6U9CQ	DI	DM6U9CQ
DM6U9CQ	DN	Pazopanib HCl
DM6U9CQ	MI	TTI2WET
DM6U9CQ	MN	Platelet-derived growth factor receptor (PDGFR)
DM6U9CQ	MT	DTT
DM6U9CQ	MA	Inhibitor
DM6U9CQ	RN	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
DM6U9CQ	RU	https://pubmed.ncbi.nlm.nih.gov/20118952

DM6U9CQ	DI	DM6U9CQ
DM6U9CQ	DN	Pazopanib HCl
DM6U9CQ	MI	TTX41N9
DM6U9CQ	MN	Tyrosine-protein kinase Kit (KIT)
DM6U9CQ	MT	DTT
DM6U9CQ	MA	Inhibitor
DM6U9CQ	RN	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
DM6U9CQ	RU	https://pubmed.ncbi.nlm.nih.gov/20118952

DM6U9CQ	DI	DM6U9CQ
DM6U9CQ	DN	Pazopanib HCl
DM6U9CQ	MI	TTUTJGQ
DM6U9CQ	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM6U9CQ	MT	DTT
DM6U9CQ	MA	Inhibitor
DM6U9CQ	RN	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
DM6U9CQ	RU	https://pubmed.ncbi.nlm.nih.gov/20118952

DM49IGF	DI	DM49IGF
DM49IGF	DN	Pefloxacin
DM49IGF	MI	TT0IHXV
DM49IGF	MN	DNA topoisomerase II (TOP2)
DM49IGF	MT	DTT
DM49IGF	MA	Inhibitor
DM49IGF	RN	Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96-121.
DM49IGF	RU	https://pubmed.ncbi.nlm.nih.gov/3282749

DMOWEBU	DI	DMOWEBU
DMOWEBU	DN	Pegaptanib
DMOWEBU	MI	TTIPJCB
DMOWEBU	MN	Neuropilin-1 (NRP1)
DMOWEBU	MT	DTT
DMOWEBU	RN	Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov. 2006 Feb;5(2):123-32.
DMOWEBU	RU	https://pubmed.ncbi.nlm.nih.gov/16518379

DM7UP8X	DI	DM7UP8X
DM7UP8X	DN	Pegfilgrastim
DM7UP8X	MI	TTC70AJ
DM7UP8X	MN	Granulocyte colony-stimulating factor receptor (G-CSF-R)
DM7UP8X	MT	DTT
DM7UP8X	MA	Binder
DM7UP8X	RN	Evidence that the granulocyte colony-stimulating factor (G-CSF) receptor plays a role in the pharmacokinetics of G-CSF and PegG-CSF using a G-CSF-R KO model. Pharmacol Res. 2004 Jul;50(1):55-8.
DM7UP8X	RU	https://pubmed.ncbi.nlm.nih.gov/15082029

DMJI3BA	DI	DMJI3BA
DMJI3BA	DN	Peginterferon alfa-2a
DMJI3BA	MI	TTSIUJ9
DMJI3BA	MN	Interferon-alpha 2 (IFNA2)
DMJI3BA	MT	DTT
DMJI3BA	MA	Modulator
DMJI3BA	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMJI3BA	RU	https://www.fda.gov/

DMAP58Y	DI	DMAP58Y
DMAP58Y	DN	Peginterferon alfa-2b
DMAP58Y	MI	TTSIUJ9
DMAP58Y	MN	Interferon-alpha 2 (IFNA2)
DMAP58Y	MT	DTT
DMAP58Y	MA	Modulator
DMAP58Y	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMAP58Y	RU	https://www.fda.gov/

DMCLR6G	DI	DMCLR6G
DMCLR6G	DN	Pegloticase
DMCLR6G	MI	TTZ1SWF
DMCLR6G	MN	Uric acid (URA)
DMCLR6G	MT	DTT
DMCLR6G	MA	Modulator
DMCLR6G	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DMCLR6G	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DM6NZ2P	DI	DM6NZ2P
DM6NZ2P	DN	Pegvaliase
DM6NZ2P	MI	TTGSVH2
DM6NZ2P	MN	Phenylalanine hydroxylase (PAH)
DM6NZ2P	MT	DTT
DM6NZ2P	MA	Modulator
DM6NZ2P	RN	Induction, titration, and maintenance dosing regimen in a phase 2 study of pegvaliase for control of blood phenylalanine in adults with phenylketonuria.Mol Genet Metab. 2018 Nov;125(3):217-227. 
DM6NZ2P	RU	https://pubmed.ncbi.nlm.nih.gov/30146451

DMDEZI3	DI	DMDEZI3
DMDEZI3	DN	Pegvisomant
DMDEZI3	MI	TTKMAZ6
DMDEZI3	MN	Growth hormone receptor (GHR)
DMDEZI3	MT	DTT
DMDEZI3	MA	Antagonist
DMDEZI3	RN	Growth hormone receptor antagonist treatment reduces exercise performance in young males. J Clin Endocrinol Metab. 2009 Sep;94(9):3265-72.
DMDEZI3	RU	https://pubmed.ncbi.nlm.nih.gov/19549743

DMRH0D5	DI	DMRH0D5
DMRH0D5	DN	PEGylated IFN beta 1-a
DMRH0D5	MI	TT4TZ8J
DMRH0D5	MN	Interferon-beta (IFNB1)
DMRH0D5	MT	DTT
DMRH0D5	MA	Modulator
DMRH0D5	RN	Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014 Jul;13(7):657-65.
DMRH0D5	RU	https://pubmed.ncbi.nlm.nih.gov/24794721

DM8DQV9	DI	DM8DQV9
DM8DQV9	DN	Pelubiprofen
DM8DQV9	MI	TTK0943
DM8DQV9	MN	Prostaglandin G/H synthase (COX)
DM8DQV9	MT	DTT
DM8DQV9	MA	Modulator
DM8DQV9	RN	Anti-inflammatory effect of pelubiprofen, 2-[4-(oxocyclohexylidenemethyl)-phenyl]propionic acid, mediated by dual suppression of COX activity and LPS-induced inflammatory gene expression via NF- B inactivation. J Cell Biochem. 2011 Dec;112(12):3594-603.
DM8DQV9	RU	https://pubmed.ncbi.nlm.nih.gov/21809372

DMD1VZL	DI	DMD1VZL
DMD1VZL	DN	Pemafibrate
DMD1VZL	MI	TTJ584C
DMD1VZL	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMD1VZL	MT	DTT
DMD1VZL	MA	Agonist
DMD1VZL	RN	Pemafibrate: First Global Approval. Drugs. 2017 Oct;77(16):1805-1810.
DMD1VZL	RU	https://pubmed.ncbi.nlm.nih.gov/28929345

DMFQEA6	DI	DMFQEA6
DMFQEA6	DN	Pembrolizumab
DMFQEA6	MI	TTNBFWK
DMFQEA6	MN	Programmed cell death protein 1 (PD-1)
DMFQEA6	MT	DTT
DMFQEA6	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMFQEA6	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMMX2E6	DI	DMMX2E6
DMMX2E6	DN	Pemetrexed
DMMX2E6	MI	DTI7UX6
DMMX2E6	MN	Breast cancer resistance protein (ABCG2)
DMMX2E6	MT	DTP
DMMX2E6	MA	Substrate
DMMX2E6	RN	pH-Dependent transport of pemetrexed by breast cancer resistance protein. Drug Metab Dispos. 2011 Sep;39(9):1478-85.
DMMX2E6	RU	https://doi.org/10.1124/dmd.111.039370

DMMX2E6	DI	DMMX2E6
DMMX2E6	DN	Pemetrexed
DMMX2E6	MI	TTU6BFZ
DMMX2E6	MN	Candida Thymidylate synthase (Candi TMP1)
DMMX2E6	MT	DTT
DMMX2E6	MA	Inhibitor
DMMX2E6	RN	Updated clinical information on multitargeted antifolates in lung cancer. Clin Lung Cancer. 2009 Mar;10 Suppl 1:S35-40.
DMMX2E6	RU	https://pubmed.ncbi.nlm.nih.gov/19362945

DMMX2E6	DI	DMMX2E6
DMMX2E6	DN	Pemetrexed
DMMX2E6	MI	DTOSN46
DMMX2E6	MN	Folate transporter 1 (SLC19A1)
DMMX2E6	MT	DTP
DMMX2E6	MA	Substrate
DMMX2E6	RN	Biology of the major facilitative folate transporters SLC19A1 and SLC46A1. Curr Top Membr. 2014;73:175-204.
DMMX2E6	RU	http://www.ncbi.nlm.nih.gov/pubmed/24745983

DMMX2E6	DI	DMMX2E6
DMMX2E6	DN	Pemetrexed
DMMX2E6	MI	DTFI42L
DMMX2E6	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMMX2E6	MT	DTP
DMMX2E6	MA	Substrate
DMMX2E6	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMMX2E6	RU	https://doi.org/10.1007/s11095-012-0935-x

DMMX2E6	DI	DMMX2E6
DMMX2E6	DN	Pemetrexed
DMMX2E6	MI	DTYVM24
DMMX2E6	MN	Multidrug resistance-associated protein 5 (ABCC5)
DMMX2E6	MT	DTP
DMMX2E6	MA	Substrate
DMMX2E6	RN	Kinetic validation of the use of carboxydichlorofluorescein as a drug surrogate for MRP5-mediated transport. Eur J Pharm Sci. 2006 Apr;27(5):524-32.
DMMX2E6	RU	http://www.ncbi.nlm.nih.gov/pubmed/16337112

DMMX2E6	DI	DMMX2E6
DMMX2E6	DN	Pemetrexed
DMMX2E6	MI	DTPFTEQ
DMMX2E6	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DMMX2E6	MT	DTP
DMMX2E6	MA	Substrate
DMMX2E6	RN	Substrate- and pH-specific antifolate transport mediated by organic anion-transporting polypeptide 2B1 (OATP2B1-SLCO2B1). Mol Pharmacol. 2012 Feb;81(2):134-42.
DMMX2E6	RU	https://doi.org/10.1124/mol.111.074823

DMMX2E6	DI	DMMX2E6
DMMX2E6	DN	Pemetrexed
DMMX2E6	MI	DTDJEMI
DMMX2E6	MN	Proton-coupled folate transporter (SLC46A1)
DMMX2E6	MT	DTP
DMMX2E6	MA	Substrate
DMMX2E6	RN	The proton-coupled folate transporter: impact on pemetrexed transport and on antifolates activities compared with the reduced folate carrier. Mol Pharmacol. 2008 Sep;74(3):854-62.
DMMX2E6	RU	http://www.ncbi.nlm.nih.gov/pubmed/18524888

DM819JF	DI	DM819JF
DM819JF	DN	Pemigatinib
DM819JF	MI	TTRLW2X
DM819JF	MN	Fibroblast growth factor receptor 1 (FGFR1)
DM819JF	MT	DTT
DM819JF	MA	Inhibitor
DM819JF	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DM819JF	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf

DM819JF	DI	DM819JF
DM819JF	DN	Pemigatinib
DM819JF	MI	TTGJVQM
DM819JF	MN	Fibroblast growth factor receptor 2 (FGFR2)
DM819JF	MT	DTT
DM819JF	MA	Inhibitor
DM819JF	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DM819JF	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf

DM819JF	DI	DM819JF
DM819JF	DN	Pemigatinib
DM819JF	MI	TTST7KB
DM819JF	MN	Fibroblast growth factor receptor 3 (FGFR3)
DM819JF	MT	DTT
DM819JF	MA	Inhibitor
DM819JF	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DM819JF	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf

DML97WV	DI	DML97WV
DML97WV	DN	Pemirolast
DML97WV	MI	TTTIBOJ
DML97WV	MN	Histamine H1 receptor (H1R)
DML97WV	MT	DTT
DML97WV	MA	Antagonist
DML97WV	RN	The effect of a combined therapy with a histamine H1 antagonist and a chemical mediator release inhibitor on allergic conjunctivitis. Ophthalmologica. 2008;222(4):232-9.
DML97WV	RU	https://pubmed.ncbi.nlm.nih.gov/18463425

DML97WV	DI	DML97WV
DML97WV	DN	Pemirolast
DML97WV	MI	DTFI42L
DML97WV	MN	Multidrug resistance-associated protein 2 (ABCC2)
DML97WV	MT	DTP
DML97WV	MA	Substrate
DML97WV	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DML97WV	RU	https://doi.org/10.1007/s11095-012-0935-x

DML97WV	DI	DML97WV
DML97WV	DN	Pemirolast
DML97WV	MI	DTUGYRD
DML97WV	MN	P-glycoprotein 1 (ABCB1)
DML97WV	MT	DTP
DML97WV	MA	Substrate
DML97WV	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DML97WV	RU	https://doi.org/10.1007/s11095-012-0935-x

DM4ES8F	DI	DM4ES8F
DM4ES8F	DN	Penbutolol
DM4ES8F	MI	TTR6W5O
DM4ES8F	MN	Adrenergic receptor beta-1 (ADRB1)
DM4ES8F	MT	DTT
DM4ES8F	MA	Antagonist
DM4ES8F	RN	beta-Adrenergic receptor blockers--a group of chiral drugs: different effects of each enantiomer. Ceska Slov Farm. 2002 May;51(3):121-8.
DM4ES8F	RU	https://pubmed.ncbi.nlm.nih.gov/12058352

DM4ES8F	DI	DM4ES8F
DM4ES8F	DN	Penbutolol
DM4ES8F	MI	DECB0K3
DM4ES8F	MN	Cytochrome P450 2D6 (CYP2D6)
DM4ES8F	MT	DME
DM4ES8F	MA	Metabolism
DM4ES8F	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DM4ES8F	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DMOUMDV	DI	DMOUMDV
DMOUMDV	DN	Penciclovir
DMOUMDV	MI	TTIU7X1
DMOUMDV	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMOUMDV	MT	DTT
DMOUMDV	MA	Inhibitor
DMOUMDV	RN	Antimicrobial strategies: inhibition of viral polymerases by 3'-hydroxyl nucleosides. Drugs. 2009;69(2):151-66. 
DMOUMDV	RU	https://pubmed.ncbi.nlm.nih.gov/19228073

DMOUMDV	DI	DMOUMDV
DMOUMDV	DN	Penciclovir
DMOUMDV	MI	DT0OC1Q
DMOUMDV	MN	Organic anion transporter 2 (SLC22A7)
DMOUMDV	MT	DTP
DMOUMDV	MA	Substrate
DMOUMDV	RN	In vitro studies with two human organic anion transporters: OAT2 and OAT7. Xenobiotica. 2018 Oct;48(10):1037-1049.
DMOUMDV	RU	http://www.ncbi.nlm.nih.gov/pubmed/28945155

DMOUMDV	DI	DMOUMDV
DMOUMDV	DN	Penciclovir
DMOUMDV	MI	TTP3QRF
DMOUMDV	MN	Thymidine kinase 1 (TK1)
DMOUMDV	MT	DTT
DMOUMDV	MA	Inhibitor
DMOUMDV	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMOUMDV	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMG1DTE	DI	DMG1DTE
DMG1DTE	DN	Penfluridol
DMG1DTE	MI	TT729IR
DMG1DTE	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DMG1DTE	MT	DTT
DMG1DTE	MA	Blocker
DMG1DTE	RN	Differential inhibition of T-type calcium channels by neuroleptics. J Neurosci. 2002 Jan 15;22(2):396-403.
DMG1DTE	RU	https://pubmed.ncbi.nlm.nih.gov/11784784

DM40EF6	DI	DM40EF6
DM40EF6	DN	Penicillamine
DM40EF6	MI	TTT3ZC9
DM40EF6	MN	Human immunodeficiency virus Tat protein (HIV tat)
DM40EF6	MT	DTT
DM40EF6	MA	Inhibitor
DM40EF6	RN	Docking studies reveal a selective binding of D-penicillamine to the transactivator protein of human immunodeficiency virus type 1. FEBS Lett. 2002 Apr 10;516(1-3):43-6.
DM40EF6	RU	https://pubmed.ncbi.nlm.nih.gov/11959100

DMNMHBV	DI	DMNMHBV
DMNMHBV	DN	Penicillin
DMNMHBV	MI	TTJP4SM
DMNMHBV	MN	Bacterial Penicillin binding protein (Bact PBP)
DMNMHBV	MT	DTT
DMNMHBV	MA	Modulator
DMNMHBV	RN	Bacterial Resistance to Penicillin G by Decreased Affinity of Penicillin-Binding Proteins: A Mathematical Model
DMNMHBV	RU	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957969 

DM49VEW	DI	DM49VEW
DM49VEW	DN	Penicillin G Benzathine
DM49VEW	MI	TTJP4SM
DM49VEW	MN	Bacterial Penicillin binding protein (Bact PBP)
DM49VEW	MT	DTT
DM49VEW	MA	Modulator
DM49VEW	RN	Bacterial Resistance to Penicillin G by Decreased Affinity of Penicillin-Binding Proteins: A Mathematical Model
DM49VEW	RU	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957969 

DMU4JLB	DI	DMU4JLB
DMU4JLB	DN	Penicillin G Procaine
DMU4JLB	MI	TTJP4SM
DMU4JLB	MN	Bacterial Penicillin binding protein (Bact PBP)
DMU4JLB	MT	DTT
DMU4JLB	MA	Modulator
DMU4JLB	RN	Bacterial Resistance to Penicillin G by Decreased Affinity of Penicillin-Binding Proteins: A Mathematical Model
DMU4JLB	RU	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957969 

DMY18XK	DI	DMY18XK
DMY18XK	DN	Penicillin G Sodium
DMY18XK	MI	TTJP4SM
DMY18XK	MN	Bacterial Penicillin binding protein (Bact PBP)
DMY18XK	MT	DTT
DMY18XK	MA	Modulator
DMY18XK	RN	Bacterial Resistance to Penicillin G by Decreased Affinity of Penicillin-Binding Proteins: A Mathematical Model
DMY18XK	RU	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957969 

DMKVOYF	DI	DMKVOYF
DMKVOYF	DN	Penicillin V
DMKVOYF	MI	TTJP4SM
DMKVOYF	MN	Bacterial Penicillin binding protein (Bact PBP)
DMKVOYF	MT	DTT
DMKVOYF	MA	Binder
DMKVOYF	RN	Localization of penicillin-binding proteins to the splitting system of Staphylococcus aureus septa by using a mercury-penicillin V derivative. J Bacteriol. 1995 Jul;177(13):3631-40.
DMKVOYF	RU	https://pubmed.ncbi.nlm.nih.gov/7541399

DM8LX76	DI	DM8LX76
DM8LX76	DN	Penicillin V Potassium
DM8LX76	MI	TTJP4SM
DM8LX76	MN	Bacterial Penicillin binding protein (Bact PBP)
DM8LX76	MT	DTT
DM8LX76	MA	Modulator
DM8LX76	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM8LX76	RU	https://www.fda.gov/

DMZ9MO5	DI	DMZ9MO5
DMZ9MO5	DN	Pentaerythritol tetranitrate
DMZ9MO5	MI	DEWYTJB
DMZ9MO5	MN	Aldehyde dehydrogenase 2 (ALDH2)
DMZ9MO5	MT	DME
DMZ9MO5	MA	Metabolism
DMZ9MO5	RN	OSHA Occupational Chemical Database: drug information.
DMZ9MO5	RU	https://www.osha.gov/dts/chemicalsampling/data/CH_260110.html

DMRCLZB	DI	DMRCLZB
DMRCLZB	DN	Pentagastrin
DMRCLZB	MI	TTVFO0U
DMRCLZB	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMRCLZB	MT	DTT
DMRCLZB	MA	Agonist
DMRCLZB	RN	Functional interactions between endocannabinoid and CCK neurotransmitter systems may be critical for extinction learning. Neuropsychopharmacology. 2009 Jan;34(2):509-21.
DMRCLZB	RU	https://pubmed.ncbi.nlm.nih.gov/18580872

DMHZJCG	DI	DMHZJCG
DMHZJCG	DN	Pentamidine
DMHZJCG	MI	DEJGDUW
DMHZJCG	MN	Cytochrome P450 1A2 (CYP1A2)
DMHZJCG	MT	DME
DMHZJCG	MA	Metabolism
DMHZJCG	RN	Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
DMHZJCG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920490

DMHZJCG	DI	DMHZJCG
DMHZJCG	DN	Pentamidine
DMHZJCG	MI	DES5XRU
DMHZJCG	MN	Cytochrome P450 2C8 (CYP2C8)
DMHZJCG	MT	DME
DMHZJCG	MA	Metabolism
DMHZJCG	RN	Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
DMHZJCG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920490

DMHZJCG	DI	DMHZJCG
DMHZJCG	DN	Pentamidine
DMHZJCG	MI	DECB0K3
DMHZJCG	MN	Cytochrome P450 2D6 (CYP2D6)
DMHZJCG	MT	DME
DMHZJCG	MA	Metabolism
DMHZJCG	RN	Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
DMHZJCG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920490

DMHZJCG	DI	DMHZJCG
DMHZJCG	DN	Pentamidine
DMHZJCG	MI	DE4LYSA
DMHZJCG	MN	Cytochrome P450 3A4 (CYP3A4)
DMHZJCG	MT	DME
DMHZJCG	MA	Metabolism
DMHZJCG	RN	Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
DMHZJCG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920490

DMHZJCG	DI	DMHZJCG
DMHZJCG	DN	Pentamidine
DMHZJCG	MI	DEIBDNY
DMHZJCG	MN	Cytochrome P450 3A5 (CYP3A5)
DMHZJCG	MT	DME
DMHZJCG	MA	Metabolism
DMHZJCG	RN	Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
DMHZJCG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920490

DMHZJCG	DI	DMHZJCG
DMHZJCG	DN	Pentamidine
DMHZJCG	MI	DEGTFWK
DMHZJCG	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMHZJCG	MT	DME
DMHZJCG	MA	Metabolism
DMHZJCG	RN	Value of preemptive CYP2C19 genotyping in allogeneic stem cell transplant patients considered for pentamidine administration. Clin Transplant. 2011 May-Jun;25(3):E271-5.
DMHZJCG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21299635

DMHZJCG	DI	DMHZJCG
DMHZJCG	DN	Pentamidine
DMHZJCG	MI	DTT79CX
DMHZJCG	MN	Organic cation transporter 1 (SLC22A1)
DMHZJCG	MT	DTP
DMHZJCG	MA	Substrate
DMHZJCG	RN	Transport of dicationic drugs pentamidine and furamidine by human organic cation transporters. Drug Metab Dispos. 2009 Feb;37(2):424-30.
DMHZJCG	RU	http://www.ncbi.nlm.nih.gov/pubmed/18971316

DMHZJCG	DI	DMHZJCG
DMHZJCG	DN	Pentamidine
DMHZJCG	MI	TTM1TDX
DMHZJCG	MN	Tryptase alpha/beta-1 (Tryptase)
DMHZJCG	MT	DTT
DMHZJCG	MA	Inhibitor
DMHZJCG	RN	Inhibitors of tryptase for the treatment of mast cell-mediated diseases. Curr Pharm Des. 1998 Oct;4(5):381-96.
DMHZJCG	RU	https://pubmed.ncbi.nlm.nih.gov/10197050

DM1XBHS	DI	DM1XBHS
DM1XBHS	DN	Pentazocine
DM1XBHS	MI	TTN4QDT
DM1XBHS	MN	Opioid receptor (OPR)
DM1XBHS	MT	DTT
DM1XBHS	MA	Antagonist
DM1XBHS	RN	Functional characterization of a sigma receptor and its gene expression by haloperidol. Nippon Yakurigaku Zasshi. 1999 Jul;114(1):61-8.
DM1XBHS	RU	https://pubmed.ncbi.nlm.nih.gov/10562966

DM1XBHS	DI	DM1XBHS
DM1XBHS	DN	Pentazocine
DM1XBHS	MI	DTUGYRD
DM1XBHS	MN	P-glycoprotein 1 (ABCB1)
DM1XBHS	MT	DTP
DM1XBHS	MA	Substrate
DM1XBHS	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM1XBHS	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMFNH7L	DI	DMFNH7L
DMFNH7L	DN	Pentobarbital
DMFNH7L	MI	TT1MPAY
DMFNH7L	MN	GABA(A) receptor alpha-1 (GABRA1)
DMFNH7L	MT	DTT
DMFNH7L	MA	Antagonist
DMFNH7L	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DMFNH7L	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DMFNH7L	DI	DMFNH7L
DMFNH7L	DN	Pentobarbital
DMFNH7L	MI	DEGTFWK
DMFNH7L	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMFNH7L	MT	DME
DMFNH7L	MA	Metabolism
DMFNH7L	RN	CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):821-5.
DMFNH7L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10805060

DM38VYQ	DI	DM38VYQ
DM38VYQ	DN	Pentolinium
DM38VYQ	MI	TT4H1MQ
DM38VYQ	MN	Neuronal acetylcholine receptor alpha-4 (CHRNA4)
DM38VYQ	MT	DTT
DM38VYQ	MA	Antagonist
DM38VYQ	RN	Nicotinic and nonnicotinic receptor-mediated actions of vinblastine. Proc Soc Exp Biol Med. 1993 Jul;203(3):372-6.
DM38VYQ	RU	https://pubmed.ncbi.nlm.nih.gov/8516349

DM2HRKE	DI	DM2HRKE
DM2HRKE	DN	Pentosan polysulfate
DM2HRKE	MI	TTCEKVZ
DM2HRKE	MN	Fibroblast growth factor-4 (FGF4)
DM2HRKE	MT	DTT
DM2HRKE	MA	Modulator
DM2HRKE	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM2HRKE	RU	https://www.fda.gov/

DM0HXDS	DI	DM0HXDS
DM0HXDS	DN	Pentostatin
DM0HXDS	MI	TTLP57V
DM0HXDS	MN	Adenosine deaminase (ADA)
DM0HXDS	MT	DTT
DM0HXDS	MA	Inhibitor
DM0HXDS	RN	Purine nucleoside analogs in indolent non-Hodgkin's lymphoma. Oncology (Williston Park). 2000 Jun;14(6 Suppl 2):13-5.
DM0HXDS	RU	https://pubmed.ncbi.nlm.nih.gov/10887639

DMU3DNC	DI	DMU3DNC
DMU3DNC	DN	Pentoxifylline
DMU3DNC	MI	DEJGDUW
DMU3DNC	MN	Cytochrome P450 1A2 (CYP1A2)
DMU3DNC	MT	DME
DMU3DNC	MA	Metabolism
DMU3DNC	RN	Cytochrome P450 isozymes involved in lisofylline metabolism to pentoxifylline in human liver microsomes. Drug Metab Dispos. 1997 Dec;25(12):1354-8.
DMU3DNC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9394024

DMU3DNC	DI	DMU3DNC
DMU3DNC	DN	Pentoxifylline
DMU3DNC	MI	TTF8CQI
DMU3DNC	MN	Tumor necrosis factor (TNF)
DMU3DNC	MT	DTT
DMU3DNC	RN	Targeted therapies in myelodysplastic syndromes: ASH 2003 review. Semin Hematol. 2004 Apr;41(2 Suppl 4):13-20.
DMU3DNC	RU	https://pubmed.ncbi.nlm.nih.gov/15190511

DMNXY5K	DI	DMNXY5K
DMNXY5K	DN	Peramivir
DMNXY5K	MI	TT50QJ3
DMNXY5K	MN	Influenza Neuraminidase (Influ NA)
DMNXY5K	MT	DTT
DMNXY5K	MA	Inhibitor
DMNXY5K	RN	Developing new antiviral agents for influenza treatment: what does the future hold Clin Infect Dis. 2009 Jan 1;48 Suppl 1:S3-13.
DMNXY5K	RU	https://pubmed.ncbi.nlm.nih.gov/19067613

DM2AOTZ	DI	DM2AOTZ
DM2AOTZ	DN	Perazine
DM2AOTZ	MI	DE6OQ3W
DM2AOTZ	MN	Cytochrome P450 1A1 (CYP1A1)
DM2AOTZ	MT	DME
DM2AOTZ	MA	Metabolism
DM2AOTZ	RN	The metabolism of the piperazine-type phenothiazine neuroleptic perazine by the human cytochrome P-450 isoenzymes. Eur Neuropsychopharmacol. 2004 May;14(3):199-208.
DM2AOTZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15056479

DM2AOTZ	DI	DM2AOTZ
DM2AOTZ	DN	Perazine
DM2AOTZ	MI	DEJGDUW
DM2AOTZ	MN	Cytochrome P450 1A2 (CYP1A2)
DM2AOTZ	MT	DME
DM2AOTZ	MA	Metabolism
DM2AOTZ	RN	Perazine as a potent inhibitor of human CYP1A2 but not CYP3A4. Pol J Pharmacol. 2002 Jul-Aug;54(4):407-10.
DM2AOTZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12523495

DM2AOTZ	DI	DM2AOTZ
DM2AOTZ	DN	Perazine
DM2AOTZ	MI	DEJVYAZ
DM2AOTZ	MN	Cytochrome P450 2A6 (CYP2A6)
DM2AOTZ	MT	DME
DM2AOTZ	MA	Metabolism
DM2AOTZ	RN	The metabolism of the piperazine-type phenothiazine neuroleptic perazine by the human cytochrome P-450 isoenzymes. Eur Neuropsychopharmacol. 2004 May;14(3):199-208.
DM2AOTZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15056479

DM2AOTZ	DI	DM2AOTZ
DM2AOTZ	DN	Perazine
DM2AOTZ	MI	DE5IED8
DM2AOTZ	MN	Cytochrome P450 2C9 (CYP2C9)
DM2AOTZ	MT	DME
DM2AOTZ	MA	Metabolism
DM2AOTZ	RN	Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro. Psychopharmacology (Berl). 2000 Sep;151(4):312-20.
DM2AOTZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11026737

DM2AOTZ	DI	DM2AOTZ
DM2AOTZ	DN	Perazine
DM2AOTZ	MI	DECB0K3
DM2AOTZ	MN	Cytochrome P450 2D6 (CYP2D6)
DM2AOTZ	MT	DME
DM2AOTZ	MA	Metabolism
DM2AOTZ	RN	Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro. Psychopharmacology (Berl). 2000 Sep;151(4):312-20.
DM2AOTZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11026737

DM2AOTZ	DI	DM2AOTZ
DM2AOTZ	DN	Perazine
DM2AOTZ	MI	DEVDYN7
DM2AOTZ	MN	Cytochrome P450 2E1 (CYP2E1)
DM2AOTZ	MT	DME
DM2AOTZ	MA	Metabolism
DM2AOTZ	RN	Effects of phenothiazine neuroleptics on the rate of caffeine demethylation and hydroxylation in the rat liver. Pol J Pharmacol. 2001 Nov-Dec;53(6):615-21.
DM2AOTZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11985335

DM2AOTZ	DI	DM2AOTZ
DM2AOTZ	DN	Perazine
DM2AOTZ	MI	DE4LYSA
DM2AOTZ	MN	Cytochrome P450 3A4 (CYP3A4)
DM2AOTZ	MT	DME
DM2AOTZ	MA	Metabolism
DM2AOTZ	RN	The metabolism of the piperazine-type phenothiazine neuroleptic perazine by the human cytochrome P-450 isoenzymes. Eur Neuropsychopharmacol. 2004 May;14(3):199-208.
DM2AOTZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15056479

DM2AOTZ	DI	DM2AOTZ
DM2AOTZ	DN	Perazine
DM2AOTZ	MI	TTEX248
DM2AOTZ	MN	Dopamine D2 receptor (D2R)
DM2AOTZ	MT	DTT
DM2AOTZ	MA	Modulator
DM2AOTZ	RN	Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
DM2AOTZ	RU	https://pubmed.ncbi.nlm.nih.gov/15582454

DM2AOTZ	DI	DM2AOTZ
DM2AOTZ	DN	Perazine
DM2AOTZ	MI	DEGTFWK
DM2AOTZ	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM2AOTZ	MT	DME
DM2AOTZ	MA	Metabolism
DM2AOTZ	RN	Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro. Psychopharmacology (Berl). 2000 Sep;151(4):312-20.
DM2AOTZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11026737

DM2AOTZ	DI	DM2AOTZ
DM2AOTZ	DN	Perazine
DM2AOTZ	MI	DTUGYRD
DM2AOTZ	MN	P-glycoprotein 1 (ABCB1)
DM2AOTZ	MT	DTP
DM2AOTZ	MA	Substrate
DM2AOTZ	RN	Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
DM2AOTZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/15285840

DM14MAE	DI	DM14MAE
DM14MAE	DN	Pergolide
DM14MAE	MI	TTZFYLI
DM14MAE	MN	Dopamine D1 receptor (D1R)
DM14MAE	MT	DTT
DM14MAE	MA	Modulator
DM14MAE	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM14MAE	RU	https://www.fda.gov/

DM14MAE	DI	DM14MAE
DM14MAE	DN	Pergolide
DM14MAE	MI	TTEX248
DM14MAE	MN	Dopamine D2 receptor (D2R)
DM14MAE	MT	DTT
DM14MAE	MA	Modulator
DM14MAE	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM14MAE	RU	https://www.fda.gov/

DM5GKOV	DI	DM5GKOV
DM5GKOV	DN	Pergolide mesylate
DM5GKOV	MI	DE4LYSA
DM5GKOV	MN	Cytochrome P450 3A4 (CYP3A4)
DM5GKOV	MT	DME
DM5GKOV	MA	Metabolism
DM5GKOV	RN	Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67.
DM5GKOV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18691132

DMINO7Z	DI	DMINO7Z
DMINO7Z	DN	Perhexiline
DMINO7Z	MI	TTDL0NY
DMINO7Z	MN	Carnitine O-palmitoyltransferase I (CPT1B)
DMINO7Z	MT	DTT
DMINO7Z	MA	Inhibitor
DMINO7Z	RN	Perhexiline. Cardiovasc Drug Rev. 2007 Spring;25(1):76-97.
DMINO7Z	RU	https://pubmed.ncbi.nlm.nih.gov/17445089

DMINO7Z	DI	DMINO7Z
DMINO7Z	DN	Perhexiline
DMINO7Z	MI	DEPKLMQ
DMINO7Z	MN	Cytochrome P450 2B6 (CYP2B6)
DMINO7Z	MT	DME
DMINO7Z	MA	Metabolism
DMINO7Z	RN	CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes. Drug Metab Dispos. 2007 Jan;35(1):128-38.
DMINO7Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17050648

DMINO7Z	DI	DMINO7Z
DMINO7Z	DN	Perhexiline
DMINO7Z	MI	DECB0K3
DMINO7Z	MN	Cytochrome P450 2D6 (CYP2D6)
DMINO7Z	MT	DME
DMINO7Z	MA	Metabolism
DMINO7Z	RN	CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes. Drug Metab Dispos. 2007 Jan;35(1):128-38.
DMINO7Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17050648

DMINO7Z	DI	DMINO7Z
DMINO7Z	DN	Perhexiline
DMINO7Z	MI	DE4LYSA
DMINO7Z	MN	Cytochrome P450 3A4 (CYP3A4)
DMINO7Z	MT	DME
DMINO7Z	MA	Metabolism
DMINO7Z	RN	CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes. Drug Metab Dispos. 2007 Jan;35(1):128-38.
DMINO7Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17050648

DMOPZDT	DI	DMOPZDT
DMOPZDT	DN	Perindopril
DMOPZDT	MI	TTL69WB
DMOPZDT	MN	Angiotensin-converting enzyme (ACE)
DMOPZDT	MT	DTT
DMOPZDT	MA	Inhibitor
DMOPZDT	RN	Fixed combination perindopril-amlodipine (Coveram) in the treatment of hypertension and coronary heart disease. Rev Med Liege. 2009 Apr;64(4):223-7.
DMOPZDT	RU	https://pubmed.ncbi.nlm.nih.gov/19514543

DMOPZDT	DI	DMOPZDT
DMOPZDT	DN	Perindopril
DMOPZDT	MI	DT9G7XN
DMOPZDT	MN	Peptide transporter 1 (SLC15A1)
DMOPZDT	MT	DTP
DMOPZDT	MA	Substrate
DMOPZDT	RN	Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41.
DMOPZDT	RU	http://www.ncbi.nlm.nih.gov/pubmed/18713951

DMOPZDT	DI	DMOPZDT
DMOPZDT	DN	Perindopril
DMOPZDT	MI	DT8QKNP
DMOPZDT	MN	Peptide transporter 2 (SLC15A2)
DMOPZDT	MT	DTP
DMOPZDT	MA	Substrate
DMOPZDT	RN	Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41.
DMOPZDT	RU	http://www.ncbi.nlm.nih.gov/pubmed/18713951

DMZ0Q1G	DI	DMZ0Q1G
DMZ0Q1G	DN	Permethrin
DMZ0Q1G	MI	DEPKLMQ
DMZ0Q1G	MN	Cytochrome P450 2B6 (CYP2B6)
DMZ0Q1G	MT	DME
DMZ0Q1G	MA	Metabolism
DMZ0Q1G	RN	Human metabolic interactions of environmental chemicals. J Biochem Mol Toxicol. 2007;21(4):182-6.
DMZ0Q1G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17936932

DMZ0Q1G	DI	DMZ0Q1G
DMZ0Q1G	DN	Permethrin
DMZ0Q1G	MI	DE4LYSA
DMZ0Q1G	MN	Cytochrome P450 3A4 (CYP3A4)
DMZ0Q1G	MT	DME
DMZ0Q1G	MA	Metabolism
DMZ0Q1G	RN	Human metabolic interactions of environmental chemicals. J Biochem Mol Toxicol. 2007;21(4):182-6.
DMZ0Q1G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17936932

DMZ0Q1G	DI	DMZ0Q1G
DMZ0Q1G	DN	Permethrin
DMZ0Q1G	MI	TTRK8B9
DMZ0Q1G	MN	Sodium channel unspecific (NaC)
DMZ0Q1G	MT	DTT
DMZ0Q1G	MA	Blocker
DMZ0Q1G	RN	In vitro assays for repellents and deterrents for ticks: differing effects of products when tested with attractant or arrestment stimuli. Med Vet Entomol. 2003 Dec;17(4):370-8.
DMZ0Q1G	RU	https://pubmed.ncbi.nlm.nih.gov/14651650

DMVHJLX	DI	DMVHJLX
DMVHJLX	DN	Perospirone
DMVHJLX	MI	TTYSN63
DMVHJLX	MN	5-HT 2 receptor (5HT2R)
DMVHJLX	MT	DTT
DMVHJLX	MA	Modulator
DMVHJLX	RN	Pharmacological effects of zotepine and other antipsychotics on the central 5-HT2 receptors. Pharmacopsychiatry. 1993 Mar;26(2):53-8.
DMVHJLX	RU	https://pubmed.ncbi.nlm.nih.gov/7690975

DMVHJLX	DI	DMVHJLX
DMVHJLX	DN	Perospirone
DMVHJLX	MI	DES5XRU
DMVHJLX	MN	Cytochrome P450 2C8 (CYP2C8)
DMVHJLX	MT	DME
DMVHJLX	MA	Metabolism
DMVHJLX	RN	Steady-state pharmacokinetics of a new antipsychotic agent perospirone and its active metabolite, and its relationship with prolactin response. Ther Drug Monit. 2004 Aug;26(4):361-5.
DMVHJLX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15257064

DMVHJLX	DI	DMVHJLX
DMVHJLX	DN	Perospirone
DMVHJLX	MI	DECB0K3
DMVHJLX	MN	Cytochrome P450 2D6 (CYP2D6)
DMVHJLX	MT	DME
DMVHJLX	MA	Metabolism
DMVHJLX	RN	Steady-state pharmacokinetics of a new antipsychotic agent perospirone and its active metabolite, and its relationship with prolactin response. Ther Drug Monit. 2004 Aug;26(4):361-5.
DMVHJLX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15257064

DMA4MRX	DI	DMA4MRX
DMA4MRX	DN	Perphenazine
DMA4MRX	MI	DEJGDUW
DMA4MRX	MN	Cytochrome P450 1A2 (CYP1A2)
DMA4MRX	MT	DME
DMA4MRX	MA	Metabolism
DMA4MRX	RN	Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos. 1999 Sep;27(9):1078-84.
DMA4MRX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10460810

DMA4MRX	DI	DMA4MRX
DMA4MRX	DN	Perphenazine
DMA4MRX	MI	DEZMWRE
DMA4MRX	MN	Cytochrome P450 2C18 (CYP2C18)
DMA4MRX	MT	DME
DMA4MRX	MA	Metabolism
DMA4MRX	RN	Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. Br J Clin Pharmacol. 2000 Dec;50(6):563-71.
DMA4MRX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11136295

DMA4MRX	DI	DMA4MRX
DMA4MRX	DN	Perphenazine
DMA4MRX	MI	DES5XRU
DMA4MRX	MN	Cytochrome P450 2C8 (CYP2C8)
DMA4MRX	MT	DME
DMA4MRX	MA	Metabolism
DMA4MRX	RN	Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. Br J Clin Pharmacol. 2000 Dec;50(6):563-71.
DMA4MRX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11136295

DMA4MRX	DI	DMA4MRX
DMA4MRX	DN	Perphenazine
DMA4MRX	MI	DE5IED8
DMA4MRX	MN	Cytochrome P450 2C9 (CYP2C9)
DMA4MRX	MT	DME
DMA4MRX	MA	Metabolism
DMA4MRX	RN	Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. Br J Clin Pharmacol. 2000 Dec;50(6):563-71.
DMA4MRX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11136295

DMA4MRX	DI	DMA4MRX
DMA4MRX	DN	Perphenazine
DMA4MRX	MI	DECB0K3
DMA4MRX	MN	Cytochrome P450 2D6 (CYP2D6)
DMA4MRX	MT	DME
DMA4MRX	MA	Metabolism
DMA4MRX	RN	Use of antidepressant drugs in schizophrenic patients with depression. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9.
DMA4MRX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16910628

DMA4MRX	DI	DMA4MRX
DMA4MRX	DN	Perphenazine
DMA4MRX	MI	DE4LYSA
DMA4MRX	MN	Cytochrome P450 3A4 (CYP3A4)
DMA4MRX	MT	DME
DMA4MRX	MA	Metabolism
DMA4MRX	RN	Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. Br J Clin Pharmacol. 2000 Dec;50(6):563-71.
DMA4MRX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11136295

DMA4MRX	DI	DMA4MRX
DMA4MRX	DN	Perphenazine
DMA4MRX	MI	TTEX248
DMA4MRX	MN	Dopamine D2 receptor (D2R)
DMA4MRX	MT	DTT
DMA4MRX	MA	Antagonist
DMA4MRX	RN	CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
DMA4MRX	RU	https://pubmed.ncbi.nlm.nih.gov/18075468

DMA4MRX	DI	DMA4MRX
DMA4MRX	DN	Perphenazine
DMA4MRX	MI	DEGTFWK
DMA4MRX	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMA4MRX	MT	DME
DMA4MRX	MA	Metabolism
DMA4MRX	RN	Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. Br J Clin Pharmacol. 2000 Dec;50(6):563-71.
DMA4MRX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11136295

DMA4MRX	DI	DMA4MRX
DMA4MRX	DN	Perphenazine
DMA4MRX	MI	DTT79CX
DMA4MRX	MN	Organic cation transporter 1 (SLC22A1)
DMA4MRX	MT	DTP
DMA4MRX	MA	Substrate
DMA4MRX	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMA4MRX	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DMA4MRX	DI	DMA4MRX
DMA4MRX	DN	Perphenazine
DMA4MRX	MI	DTUGYRD
DMA4MRX	MN	P-glycoprotein 1 (ABCB1)
DMA4MRX	MT	DTP
DMA4MRX	MA	Substrate
DMA4MRX	RN	Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
DMA4MRX	RU	http://www.ncbi.nlm.nih.gov/pubmed/15285840

DMHJV0X	DI	DMHJV0X
DMHJV0X	DN	Pertuzumab
DMHJV0X	MI	TT6EO5L
DMHJV0X	MN	Erbb2 tyrosine kinase receptor (HER2)
DMHJV0X	MT	DTT
DMHJV0X	MA	Inhibitor
DMHJV0X	RN	Clinical pipeline report, company report or official report of Roche (2009).
DMHJV0X	RU	http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm

DMS2J0Z	DI	DMS2J0Z
DMS2J0Z	DN	Pexidartinib
DMS2J0Z	MI	TTGJCWZ
DMS2J0Z	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMS2J0Z	MT	DTT
DMS2J0Z	MA	Inhibitor
DMS2J0Z	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMS2J0Z	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211810s000lbl.pdf

DMS2J0Z	DI	DMS2J0Z
DMS2J0Z	DN	Pexidartinib
DMS2J0Z	MI	TT7MRDV
DMS2J0Z	MN	Macrophage colony-stimulating factor 1 receptor (CSF1R)
DMS2J0Z	MT	DTT
DMS2J0Z	MA	Inhibitor
DMS2J0Z	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMS2J0Z	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211810s000lbl.pdf

DMS2J0Z	DI	DMS2J0Z
DMS2J0Z	DN	Pexidartinib
DMS2J0Z	MI	TTX41N9
DMS2J0Z	MN	Tyrosine-protein kinase Kit (KIT)
DMS2J0Z	MT	DTT
DMS2J0Z	MA	Inhibitor
DMS2J0Z	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMS2J0Z	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211810s000lbl.pdf

DMSB068	DI	DMSB068
DMSB068	DN	PF-04449913
DMSB068	MI	DES5XRU
DMSB068	MN	Cytochrome P450 2C8 (CYP2C8)
DMSB068	MT	DME
DMSB068	MA	Metabolism
DMSB068	RN	Metabolism, excretion and pharmacokinetics of [14C]glasdegib (PF-04449913) in healthy volunteers following oral administration. Xenobiotica. 2017 Dec;47(12):1064-1076.
DMSB068	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27866461

DMSB068	DI	DMSB068
DMSB068	DN	PF-04449913
DMSB068	MI	TT4LXBC
DMSB068	MN	Hedgehog signaling pathway (HS pathway)
DMSB068	MT	DTT
DMSB068	MA	Inhibitor
DMSB068	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMSB068	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMSB068	DI	DMSB068
DMSB068	DN	PF-04449913
DMSB068	MI	TTCJG29
DMSB068	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMSB068	MT	DTT
DMSB068	MA	Inhibitor
DMSB068	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMSB068	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMSB068	DI	DMSB068
DMSB068	DN	PF-04449913
DMSB068	MI	TT8J1S3
DMSB068	MN	Smoothened homolog (SMO)
DMSB068	MT	DTT
DMSB068	MA	Modulator
DMSB068	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMSB068	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMSB068	DI	DMSB068
DMSB068	DN	PF-04449913
DMSB068	MI	DE85D2P
DMSB068	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMSB068	MT	DME
DMSB068	MA	Metabolism
DMSB068	RN	Metabolism, excretion and pharmacokinetics of [14C]glasdegib (PF-04449913) in healthy volunteers following oral administration. Xenobiotica. 2017 Dec;47(12):1064-1076.
DMSB068	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27866461

DM79VXT	DI	DM79VXT
DM79VXT	DN	PF-04971729
DM79VXT	MI	TTLWPVF
DM79VXT	MN	Sodium/glucose cotransporter 2 (SGLT2)
DM79VXT	MT	DTT
DM79VXT	MA	Modulator
DM79VXT	RN	Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin.Diabetes Obes Metab.2015 Jun;17(6):591-8.
DM79VXT	RU	https://www.ncbi.nlm.nih.gov/pubmed/25754396

DM79VXT	DI	DM79VXT
DM79VXT	DN	PF-04971729
DM79VXT	MI	DE85D2P
DM79VXT	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DM79VXT	MT	DME
DM79VXT	MA	Metabolism
DM79VXT	RN	The effect of renal impairment on the pharmacokinetics and pharmacodynamics of ertugliflozin in subjects with type 2 diabetes mellitus. J Clin Pharmacol. 2017 Nov;57(11):1432-1443.
DM79VXT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28703316

DM79VXT	DI	DM79VXT
DM79VXT	DN	PF-04971729
DM79VXT	MI	DEB3CV1
DM79VXT	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DM79VXT	MT	DME
DM79VXT	MA	Metabolism
DM79VXT	RN	The effect of renal impairment on the pharmacokinetics and pharmacodynamics of ertugliflozin in subjects with type 2 diabetes mellitus. J Clin Pharmacol. 2017 Nov;57(11):1432-1443.
DM79VXT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28703316

DMOHS9P	DI	DMOHS9P
DMOHS9P	DN	Phenacemide
DMOHS9P	MI	TTRK8B9
DMOHS9P	MN	Sodium channel unspecific (NaC)
DMOHS9P	MT	DTT
DMOHS9P	MA	Blocker
DMOHS9P	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMOHS9P	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM6TS1N	DI	DM6TS1N
DM6TS1N	DN	Phendimetrazine
DM6TS1N	MI	TTBRKXS
DM6TS1N	MN	Adrenergic receptor alpha-1B (ADRA1B)
DM6TS1N	MT	DTT
DM6TS1N	MA	Antagonist
DM6TS1N	RN	Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
DM6TS1N	RU	https://pubmed.ncbi.nlm.nih.gov/17016423

DMHIDUE	DI	DMHIDUE
DMHIDUE	DN	Phenelzine
DMHIDUE	MI	DE4LYSA
DMHIDUE	MN	Cytochrome P450 3A4 (CYP3A4)
DMHIDUE	MT	DME
DMHIDUE	MA	Metabolism
DMHIDUE	RN	An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. Br J Clin Pharmacol. 2006 May;61(5):570-84.
DMHIDUE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16669850

DMHIDUE	DI	DMHIDUE
DMHIDUE	DN	Phenelzine
DMHIDUE	MI	DEIBDNY
DMHIDUE	MN	Cytochrome P450 3A5 (CYP3A5)
DMHIDUE	MT	DME
DMHIDUE	MA	Metabolism
DMHIDUE	RN	An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. Br J Clin Pharmacol. 2006 May;61(5):570-84.
DMHIDUE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16669850

DMHIDUE	DI	DMHIDUE
DMHIDUE	DN	Phenelzine
DMHIDUE	MI	DEGTFWK
DMHIDUE	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMHIDUE	MT	DME
DMHIDUE	MA	Metabolism
DMHIDUE	RN	An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. Br J Clin Pharmacol. 2006 May;61(5):570-84.
DMHIDUE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16669850

DMHIDUE	DI	DMHIDUE
DMHIDUE	DN	Phenelzine
DMHIDUE	MI	TT32XQJ
DMHIDUE	MN	Monoamine oxidase (MAO)
DMHIDUE	MT	DTT
DMHIDUE	MA	Inhibitor
DMHIDUE	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMHIDUE	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMHIDUE	DI	DMHIDUE
DMHIDUE	DN	Phenelzine
DMHIDUE	MI	TTGP7BY
DMHIDUE	MN	Monoamine oxidase type B (MAO-B)
DMHIDUE	MT	DTT
DMHIDUE	MA	Inhibitor
DMHIDUE	RN	Limitation of adipose tissue enlargement in rats chronically treated with semicarbazide-sensitive amine oxidase and monoamine oxidase inhibitors. Pharmacol Res. 2008 Jun;57(6):426-34.
DMHIDUE	RU	https://pubmed.ncbi.nlm.nih.gov/18539478

DMDTC7R	DI	DMDTC7R
DMDTC7R	DN	Phenindamine
DMDTC7R	MI	TTTIBOJ
DMDTC7R	MN	Histamine H1 receptor (H1R)
DMDTC7R	MT	DTT
DMDTC7R	MA	Antagonist
DMDTC7R	RN	The histamine H1-receptor antagonist binding site. A stereoselective pharmacophoric model based upon (semi-)rigid H1-antagonists and including a known interaction site on the receptor. J Med Chem. 1995 Aug 18;38(17):3351-60.
DMDTC7R	RU	https://pubmed.ncbi.nlm.nih.gov/7650688

DM2PYNR	DI	DM2PYNR
DM2PYNR	DN	Phenindione
DM2PYNR	MI	TTEUC8H
DM2PYNR	MN	Vitamin K epoxide reductase complex 1 (VKORC1)
DM2PYNR	MT	DTT
DM2PYNR	MA	Inhibitor
DM2PYNR	RN	[Oral anticoagulation and pharmacogenetics: importance in the clinical setting]. Rev Med Suisse. 2007 Sep 12;3(124):2030, 2033-4, 2036.
DM2PYNR	RU	https://pubmed.ncbi.nlm.nih.gov/17955831

DMCH7RU	DI	DMCH7RU
DMCH7RU	DN	Pheniramine
DMCH7RU	MI	TTTIBOJ
DMCH7RU	MN	Histamine H1 receptor (H1R)
DMCH7RU	MT	DTT
DMCH7RU	MA	Antagonist
DMCH7RU	RN	Role of central histaminergic system in lorazepam withdrawal syndrome in rats. Pharmacol Biochem Behav. 2001 Apr;68(4):777-82.
DMCH7RU	RU	https://pubmed.ncbi.nlm.nih.gov/11526976

DMXYTN9	DI	DMXYTN9
DMXYTN9	DN	Phenmetrazine
DMXYTN9	MI	TTVBI8W
DMXYTN9	MN	Dopamine transporter (DAT)
DMXYTN9	MT	DTT
DMXYTN9	MA	Inhibitor
DMXYTN9	RN	Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol. 2002 Jun 28;447(1):51-7.
DMXYTN9	RU	https://pubmed.ncbi.nlm.nih.gov/12106802

DMXYTN9	DI	DMXYTN9
DMXYTN9	DN	Phenmetrazine
DMXYTN9	MI	TTAWNKZ
DMXYTN9	MN	Norepinephrine transporter (NET)
DMXYTN9	MT	DTT
DMXYTN9	MA	Inhibitor
DMXYTN9	RN	Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol. 2002 Jun 28;447(1):51-7.
DMXYTN9	RU	https://pubmed.ncbi.nlm.nih.gov/12106802

DMXZOCG	DI	DMXZOCG
DMXZOCG	DN	Phenobarbital
DMXZOCG	MI	DEPKLMQ
DMXZOCG	MN	Cytochrome P450 2B6 (CYP2B6)
DMXZOCG	MT	DME
DMXZOCG	MA	Metabolism
DMXZOCG	RN	Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metab Dispos. 2004 Mar;32(3):348-58.
DMXZOCG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14977870

DMXZOCG	DI	DMXZOCG
DMXZOCG	DN	Phenobarbital
DMXZOCG	MI	DEZMWRE
DMXZOCG	MN	Cytochrome P450 2C18 (CYP2C18)
DMXZOCG	MT	DME
DMXZOCG	MA	Metabolism
DMXZOCG	RN	Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos. 2001 Mar;29(3):242-51.
DMXZOCG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11181490

DMXZOCG	DI	DMXZOCG
DMXZOCG	DN	Phenobarbital
DMXZOCG	MI	DES5XRU
DMXZOCG	MN	Cytochrome P450 2C8 (CYP2C8)
DMXZOCG	MT	DME
DMXZOCG	MA	Metabolism
DMXZOCG	RN	Colchicine down-regulates cytochrome P450 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation. Mol Pharmacol. 2003 Jul;64(1):160-9.
DMXZOCG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12815172

DMXZOCG	DI	DMXZOCG
DMXZOCG	DN	Phenobarbital
DMXZOCG	MI	DE5IED8
DMXZOCG	MN	Cytochrome P450 2C9 (CYP2C9)
DMXZOCG	MT	DME
DMXZOCG	MA	Metabolism
DMXZOCG	RN	Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. J Pharmacol Exp Ther. 2004 Feb;308(2):495-501.
DMXZOCG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14600250

DMXZOCG	DI	DMXZOCG
DMXZOCG	DN	Phenobarbital
DMXZOCG	MI	DEVDYN7
DMXZOCG	MN	Cytochrome P450 2E1 (CYP2E1)
DMXZOCG	MT	DME
DMXZOCG	MA	Metabolism
DMXZOCG	RN	Phenobarbital induces monkey brain CYP2E1 protein but not hepatic CYP2E1, in vitro or in vivo chlorzoxazone metabolism. Eur J Pharmacol. 2006 Dec 15;552(1-3):151-8.
DMXZOCG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17049344

DMXZOCG	DI	DMXZOCG
DMXZOCG	DN	Phenobarbital
DMXZOCG	MI	DE4LYSA
DMXZOCG	MN	Cytochrome P450 3A4 (CYP3A4)
DMXZOCG	MT	DME
DMXZOCG	MA	Metabolism
DMXZOCG	RN	Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit. 2007 Dec;29(6):687-710.
DMXZOCG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18043468

DMXZOCG	DI	DMXZOCG
DMXZOCG	DN	Phenobarbital
DMXZOCG	MI	DEIBDNY
DMXZOCG	MN	Cytochrome P450 3A5 (CYP3A5)
DMXZOCG	MT	DME
DMXZOCG	MA	Metabolism
DMXZOCG	RN	Induction and regulation of xenobiotic-metabolizing cytochrome P450s in the human A549 lung adenocarcinoma cell line. Am J Respir Cell Mol Biol. 2000 Mar;22(3):360-6.
DMXZOCG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10696073

DMXZOCG	DI	DMXZOCG
DMXZOCG	DN	Phenobarbital
DMXZOCG	MI	DERD86B
DMXZOCG	MN	Cytochrome P450 3A7 (CYP3A7)
DMXZOCG	MT	DME
DMXZOCG	MA	Metabolism
DMXZOCG	RN	Regulation of human liver cytochromes P-450 in family 3A in primary and continuous culture of human hepatocytes. Hepatology. 1993 Nov;18(5):1254-62.
DMXZOCG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8225233

DMXZOCG	DI	DMXZOCG
DMXZOCG	DN	Phenobarbital
DMXZOCG	MI	TTNJYV2
DMXZOCG	MN	Gamma-aminobutyric acid receptor (GAR)
DMXZOCG	MT	DTT
DMXZOCG	MA	Antagonist
DMXZOCG	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DMXZOCG	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DMXZOCG	DI	DMXZOCG
DMXZOCG	DN	Phenobarbital
DMXZOCG	MI	DEGTFWK
DMXZOCG	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMXZOCG	MT	DME
DMXZOCG	MA	Metabolism
DMXZOCG	RN	Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos. 2003 Apr;31(4):421-31.
DMXZOCG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12642468

DMXZOCG	DI	DMXZOCG
DMXZOCG	DN	Phenobarbital
DMXZOCG	MI	DTFI42L
DMXZOCG	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMXZOCG	MT	DTP
DMXZOCG	MA	Substrate
DMXZOCG	RN	Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem. 2002 Jan 25;277(4):2908-15.
DMXZOCG	RU	http://www.ncbi.nlm.nih.gov/pubmed/11706036

DMXZOCG	DI	DMXZOCG
DMXZOCG	DN	Phenobarbital
DMXZOCG	MI	DTUGYRD
DMXZOCG	MN	P-glycoprotein 1 (ABCB1)
DMXZOCG	MT	DTP
DMXZOCG	MA	Substrate
DMXZOCG	RN	The transport of antiepileptic drugs by P-glycoprotein. Adv Drug Deliv Rev. 2012 Jul;64(10):930-42.
DMXZOCG	RU	https://doi.org/10.1016/j.addr.2011.12.003

DM8KSQH	DI	DM8KSQH
DM8KSQH	DN	Phenoxybenzamine
DM8KSQH	MI	TTEX248
DM8KSQH	MN	Dopamine D2 receptor (D2R)
DM8KSQH	MT	DTT
DM8KSQH	MA	Antagonist
DM8KSQH	RN	Catecholamine-secreting neuroblastoma in a 4-month-old infant: perioperative management. J Clin Anesth. 2009 Feb;21(1):54-6.
DM8KSQH	RU	https://pubmed.ncbi.nlm.nih.gov/19232942

DM8KSQH	DI	DM8KSQH
DM8KSQH	DN	Phenoxybenzamine
DM8KSQH	MI	DTT79CX
DM8KSQH	MN	Organic cation transporter 1 (SLC22A1)
DM8KSQH	MT	DTP
DM8KSQH	MA	Substrate
DM8KSQH	RN	Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
DM8KSQH	RU	https://doi.org/10.1016/j.canlet.2005.06.051

DMDO279	DI	DMDO279
DMDO279	DN	Phenprocoumon
DMDO279	MI	DES5XRU
DMDO279	MN	Cytochrome P450 2C8 (CYP2C8)
DMDO279	MT	DME
DMDO279	MA	Metabolism
DMDO279	RN	Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro. Eur J Clin Pharmacol. 2004 May;60(3):173-82.
DMDO279	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15054565

DMDO279	DI	DMDO279
DMDO279	DN	Phenprocoumon
DMDO279	MI	DE5IED8
DMDO279	MN	Cytochrome P450 2C9 (CYP2C9)
DMDO279	MT	DME
DMDO279	MA	Metabolism
DMDO279	RN	Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo. Xenobiotica. 2004 Sep;34(9):847-59.
DMDO279	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15742978

DMDO279	DI	DMDO279
DMDO279	DN	Phenprocoumon
DMDO279	MI	DE4LYSA
DMDO279	MN	Cytochrome P450 3A4 (CYP3A4)
DMDO279	MT	DME
DMDO279	MA	Metabolism
DMDO279	RN	Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro. Eur J Clin Pharmacol. 2004 May;60(3):173-82.
DMDO279	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15054565

DMDO279	DI	DMDO279
DMDO279	DN	Phenprocoumon
DMDO279	MI	DTUGYRD
DMDO279	MN	P-glycoprotein 1 (ABCB1)
DMDO279	MT	DTP
DMDO279	MA	Substrate
DMDO279	RN	Role of P-glycoprotein in the uptake/efflux transport of oral vitamin K antagonists and rivaroxaban through the Caco-2 cell model. Basic Clin Pharmacol Toxicol. 2013 Oct;113(4):259-65.
DMDO279	RU	http://www.ncbi.nlm.nih.gov/pubmed/23663291

DMDO279	DI	DMDO279
DMDO279	DN	Phenprocoumon
DMDO279	MI	TTEUC8H
DMDO279	MN	Vitamin K epoxide reductase complex 1 (VKORC1)
DMDO279	MT	DTT
DMDO279	MA	Inhibitor
DMDO279	RN	[Oral anticoagulation and pharmacogenetics: importance in the clinical setting]. Rev Med Suisse. 2007 Sep 12;3(124):2030, 2033-4, 2036.
DMDO279	RU	https://pubmed.ncbi.nlm.nih.gov/17955831

DMG60XN	DI	DMG60XN
DMG60XN	DN	Phentermine
DMG60XN	MI	DE4LYSA
DMG60XN	MN	Cytochrome P450 3A4 (CYP3A4)
DMG60XN	MT	DME
DMG60XN	MA	Metabolism
DMG60XN	RN	FDA Label of Qsymia. The 2020 official website of the U.S. Food and Drug Administration.
DMG60XN	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022580s000lbl.pdf

DMG60XN	DI	DMG60XN
DMG60XN	DN	Phentermine
DMG60XN	MI	TTAWNKZ
DMG60XN	MN	Norepinephrine transporter (NET)
DMG60XN	MT	DTT
DMG60XN	MA	Inhibitor
DMG60XN	RN	Novel anti-obesity drugs. Expert Opin Investig Drugs. 2000 Jun;9(6):1317-26.
DMG60XN	RU	https://pubmed.ncbi.nlm.nih.gov/11060745

DMXYJOB	DI	DMXYJOB
DMXYJOB	DN	Phentolamine
DMXYJOB	MI	TTEX248
DMXYJOB	MN	Dopamine D2 receptor (D2R)
DMXYJOB	MT	DTT
DMXYJOB	MA	Antagonist
DMXYJOB	RN	Nesfatin-1 exerts cardiovascular actions in brain: possible interaction with the central melanocortin system. Am J Physiol Regul Integr Comp Physiol. 2009 Aug;297(2):R330-6.
DMXYJOB	RU	https://pubmed.ncbi.nlm.nih.gov/19474390

DMQ95GE	DI	DMQ95GE
DMQ95GE	DN	Phenylacetic acid
DMQ95GE	MI	DT39AOM
DMQ95GE	MN	Monocarboxylate transporter 3 (SLC16A8)
DMQ95GE	MT	DTP
DMQ95GE	MA	Substrate
DMQ95GE	RN	Immunohistochemical and functional characterization of peptide, organic cation, neutral and basic amino acid, and monocarboxylate drug transporters in human ocular tissues. Drug Metab Dispos. 2013 Feb;41(2):466-74.
DMQ95GE	RU	http://www.ncbi.nlm.nih.gov/pubmed/23169611

DMAYL0T	DI	DMAYL0T
DMAYL0T	DN	Phenylbutazone
DMAYL0T	MI	DE5IED8
DMAYL0T	MN	Cytochrome P450 2C9 (CYP2C9)
DMAYL0T	MT	DME
DMAYL0T	MA	Metabolism
DMAYL0T	RN	Metabolism of sulfinpyrazone sulfide and sulfinpyrazone by human liver microsomes and cDNA-expressed cytochrome P450s. Drug Metab Dispos. 2001 May;29(5):701-11.
DMAYL0T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11302937

DMAYL0T	DI	DMAYL0T
DMAYL0T	DN	Phenylbutazone
DMAYL0T	MI	TTVKILB
DMAYL0T	MN	Prostaglandin G/H synthase 2 (COX-2)
DMAYL0T	MT	DTT
DMAYL0T	MA	Inhibitor
DMAYL0T	RN	COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis. Pharmacol Res. 2005 Oct;52(4):302-6.
DMAYL0T	RU	https://pubmed.ncbi.nlm.nih.gov/15939622

DMAYL0T	DI	DMAYL0T
DMAYL0T	DN	Phenylbutazone
DMAYL0T	MI	DEYGVN4
DMAYL0T	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMAYL0T	MT	DME
DMAYL0T	MA	Metabolism
DMAYL0T	RN	Identification of human UDP-glucuronosyltransferase isoform(s) responsible for the C-glucuronidation of phenylbutazone. Arch Biochem Biophys. 2006 Oct 1;454(1):72-9.
DMAYL0T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16949544

DMZHUO5	DI	DMZHUO5
DMZHUO5	DN	Phenylephrine
DMZHUO5	MI	TTEX248
DMZHUO5	MN	Dopamine D2 receptor (D2R)
DMZHUO5	MT	DTT
DMZHUO5	MA	Agonist
DMZHUO5	RN	MMP-2 induced vein relaxation via inhibition of [Ca2+]e-dependent mechanisms of venous smooth muscle contraction. Role of RGD peptides. J Surg Res. 2010 Apr;159(2):755-64.
DMZHUO5	RU	https://pubmed.ncbi.nlm.nih.gov/19482300

DMKAEQW	DI	DMKAEQW
DMKAEQW	DN	Phenyltoloxamine
DMKAEQW	MI	TTZFYLI
DMKAEQW	MN	Dopamine D1 receptor (D1R)
DMKAEQW	MT	DTT
DMKAEQW	MA	Inhibitor
DMKAEQW	RN	Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
DMKAEQW	RU	https://pubmed.ncbi.nlm.nih.gov/15293986

DMKAEQW	DI	DMKAEQW
DMKAEQW	DN	Phenyltoloxamine
DMKAEQW	MI	TTEX248
DMKAEQW	MN	Dopamine D2 receptor (D2R)
DMKAEQW	MT	DTT
DMKAEQW	MA	Inhibitor
DMKAEQW	RN	Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
DMKAEQW	RU	https://pubmed.ncbi.nlm.nih.gov/15293986

DMKAEQW	DI	DMKAEQW
DMKAEQW	DN	Phenyltoloxamine
DMKAEQW	MI	TTE0A2F
DMKAEQW	MN	Dopamine D4 receptor (D4R)
DMKAEQW	MT	DTT
DMKAEQW	MA	Inhibitor
DMKAEQW	RN	Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
DMKAEQW	RU	https://pubmed.ncbi.nlm.nih.gov/15293986

DMKAEQW	DI	DMKAEQW
DMKAEQW	DN	Phenyltoloxamine
DMKAEQW	MI	TTS2PH3
DMKAEQW	MN	Dopamine D5 receptor (D5R)
DMKAEQW	MT	DTT
DMKAEQW	MA	Inhibitor
DMKAEQW	RN	Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
DMKAEQW	RU	https://pubmed.ncbi.nlm.nih.gov/15293986

DMNOKBV	DI	DMNOKBV
DMNOKBV	DN	Phenytoin
DMNOKBV	MI	DEPKLMQ
DMNOKBV	MN	Cytochrome P450 2B6 (CYP2B6)
DMNOKBV	MT	DME
DMNOKBV	MA	Metabolism
DMNOKBV	RN	PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
DMNOKBV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22569204

DMNOKBV	DI	DMNOKBV
DMNOKBV	DN	Phenytoin
DMNOKBV	MI	DEZMWRE
DMNOKBV	MN	Cytochrome P450 2C18 (CYP2C18)
DMNOKBV	MT	DME
DMNOKBV	MA	Metabolism
DMNOKBV	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMNOKBV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMNOKBV	DI	DMNOKBV
DMNOKBV	DN	Phenytoin
DMNOKBV	MI	DES5XRU
DMNOKBV	MN	Cytochrome P450 2C8 (CYP2C8)
DMNOKBV	MT	DME
DMNOKBV	MA	Metabolism
DMNOKBV	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMNOKBV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMNOKBV	DI	DMNOKBV
DMNOKBV	DN	Phenytoin
DMNOKBV	MI	DE5IED8
DMNOKBV	MN	Cytochrome P450 2C9 (CYP2C9)
DMNOKBV	MT	DME
DMNOKBV	MA	Metabolism
DMNOKBV	RN	Antiepileptic drug interactions - principles and clinical implications. Curr Neuropharmacol. 2010 Sep;8(3):254-67.
DMNOKBV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21358975

DMNOKBV	DI	DMNOKBV
DMNOKBV	DN	Phenytoin
DMNOKBV	MI	DE4LYSA
DMNOKBV	MN	Cytochrome P450 3A4 (CYP3A4)
DMNOKBV	MT	DME
DMNOKBV	MA	Metabolism
DMNOKBV	RN	Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1034-40.
DMNOKBV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15247556

DMNOKBV	DI	DMNOKBV
DMNOKBV	DN	Phenytoin
DMNOKBV	MI	DEIBDNY
DMNOKBV	MN	Cytochrome P450 3A5 (CYP3A5)
DMNOKBV	MT	DME
DMNOKBV	MA	Metabolism
DMNOKBV	RN	PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
DMNOKBV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22569204

DMNOKBV	DI	DMNOKBV
DMNOKBV	DN	Phenytoin
DMNOKBV	MI	DERD86B
DMNOKBV	MN	Cytochrome P450 3A7 (CYP3A7)
DMNOKBV	MT	DME
DMNOKBV	MA	Metabolism
DMNOKBV	RN	PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
DMNOKBV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22569204

DMNOKBV	DI	DMNOKBV
DMNOKBV	DN	Phenytoin
DMNOKBV	MI	DE4ZHS1
DMNOKBV	MN	Glutathione S-transferase alpha-1 (GSTA1)
DMNOKBV	MT	DME
DMNOKBV	MA	Metabolism
DMNOKBV	RN	Comparison of basal glutathione S-transferase activities and of the influence of phenobarbital, butylated hydroxy-anisole or 5,5'-diphenylhydantoin on enzyme activity in male rodents. Comp Biochem Physiol C. 1987;88(1):91-3.
DMNOKBV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=2890493

DMNOKBV	DI	DMNOKBV
DMNOKBV	DN	Phenytoin
DMNOKBV	MI	DEGTFWK
DMNOKBV	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMNOKBV	MT	DME
DMNOKBV	MA	Metabolism
DMNOKBV	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMNOKBV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMNOKBV	DI	DMNOKBV
DMNOKBV	DN	Phenytoin
DMNOKBV	MI	DTSYQGK
DMNOKBV	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMNOKBV	MT	DTP
DMNOKBV	MA	Substrate
DMNOKBV	RN	Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. Neuropharmacology. 2010 Jun;58(7):1019-32.
DMNOKBV	RU	http://www.ncbi.nlm.nih.gov/pubmed/20080116

DMNOKBV	DI	DMNOKBV
DMNOKBV	DN	Phenytoin
DMNOKBV	MI	DTFI42L
DMNOKBV	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMNOKBV	MT	DTP
DMNOKBV	MA	Substrate
DMNOKBV	RN	Upregulation of brain expression of P-glycoprotein in MRP2-deficient TR(-) rats resembles seizure-induced up-regulation of this drug efflux transporter in normal rats. Epilepsia. 2007 Apr;48(4):631-45.
DMNOKBV	RU	http://www.ncbi.nlm.nih.gov/pubmed/17437408

DMNOKBV	DI	DMNOKBV
DMNOKBV	DN	Phenytoin
DMNOKBV	MI	DTUGYRD
DMNOKBV	MN	P-glycoprotein 1 (ABCB1)
DMNOKBV	MT	DTP
DMNOKBV	MA	Substrate
DMNOKBV	RN	The transport of antiepileptic drugs by P-glycoprotein. Adv Drug Deliv Rev. 2012 Jul;64(10):930-42.
DMNOKBV	RU	https://doi.org/10.1016/j.addr.2011.12.003

DMNOKBV	DI	DMNOKBV
DMNOKBV	DN	Phenytoin
DMNOKBV	MI	TTRK8B9
DMNOKBV	MN	Sodium channel unspecific (NaC)
DMNOKBV	MT	DTT
DMNOKBV	MA	Blocker
DMNOKBV	RN	Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68. 
DMNOKBV	RU	https://pubmed.ncbi.nlm.nih.gov/19552484

DMUKMC8	DI	DMUKMC8
DMUKMC8	DN	Phloroglucinol
DMUKMC8	MI	DE69WKO
DMUKMC8	MN	Phloroglucinol reductase (PHGR)
DMUKMC8	MT	DME
DMUKMC8	MA	Metabolism
DMUKMC8	RN	Purification and properties of phloroglucinol reductase from Eubacterium oxidoreducens G-41. J Biol Chem. 1989 Mar 15;264(8):4423-7.
DMUKMC8	RU	https://pubmed.ncbi.nlm.nih.gov/2925649

DMUXQG7	DI	DMUXQG7
DMUXQG7	DN	Phosphate
DMUXQG7	MI	DTVAEDK
DMUXQG7	MN	Calcium-binding mitochondrial carrier protein SCaMC-1 (SLC25A24)
DMUXQG7	MT	DTP
DMUXQG7	MA	Substrate
DMUXQG7	RN	De Novo Mutations in SLC25A24 Cause a Disorder Characterized by Early Aging, Bone Dysplasia, Characteristic Face, and Early Demise. Am J Hum Genet. 2017 Nov 2;101(5):844-855.
DMUXQG7	RU	http://www.ncbi.nlm.nih.gov/pubmed/29100094

DMUXQG7	DI	DMUXQG7
DMUXQG7	DN	Phosphate
DMUXQG7	MI	DTN7X5J
DMUXQG7	MN	Calcium-binding mitochondrial carrier protein SCaMC-2 (SLC25A25)
DMUXQG7	MT	DTP
DMUXQG7	MA	Substrate
DMUXQG7	RN	Ketogenic diet induces expression of the muscle circadian gene Slc25a25 via neural pathway that might be involved in muscle thermogenesis. Sci Rep. 2017 Jun 6;7(1):2885.
DMUXQG7	RU	http://www.ncbi.nlm.nih.gov/pubmed/28588221

DMUXQG7	DI	DMUXQG7
DMUXQG7	DN	Phosphate
DMUXQG7	MI	DTLQ0EZ
DMUXQG7	MN	Calcium-binding mitochondrial carrier protein SCaMC-3 (SLC25A23)
DMUXQG7	MT	DTP
DMUXQG7	MA	Substrate
DMUXQG7	RN	Cellular expression and alternative splicing of SLC25A23, a member of the mitochondrial Ca2+-dependent solute carrier gene family. Gene. 2005 Jan 31;345(2):173-82.
DMUXQG7	RU	http://www.ncbi.nlm.nih.gov/pubmed/15716113

DMUXQG7	DI	DMUXQG7
DMUXQG7	DN	Phosphate
DMUXQG7	MI	DE9P5K7
DMUXQG7	MN	GDP-D-glucose phosphorylase 1 (GDPGP1)
DMUXQG7	MT	DME
DMUXQG7	MA	Metabolism
DMUXQG7	RN	A novel GDP-D-glucose phosphorylase involved in quality control of the nucleoside diphosphate sugar pool in Caenorhabditis elegans and mammals. J Biol Chem. 2011 Jun 17;286(24):21511-23.
DMUXQG7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21507950

DMUXQG7	DI	DMUXQG7
DMUXQG7	DN	Phosphate
DMUXQG7	MI	DTH9SQJ
DMUXQG7	MN	Glycerol-3-phosphate permease (SLC37A1)
DMUXQG7	MT	DTP
DMUXQG7	MA	Substrate
DMUXQG7	RN	SLC37A1 and SLC37A2 are phosphate-linked, glucose-6-phosphate antiporters. PLoS One. 2011;6(9):e23157.
DMUXQG7	RU	http://www.ncbi.nlm.nih.gov/pubmed/21949678

DMUXQG7	DI	DMUXQG7
DMUXQG7	DN	Phosphate
DMUXQG7	MI	DTJYKDQ
DMUXQG7	MN	Mitochondrial dicarboxylate carrier (SLC25A10)
DMUXQG7	MT	DTP
DMUXQG7	MA	Substrate
DMUXQG7	RN	SLC25A10 biallelic mutations in intractable epileptic encephalopathy with complex I deficiency. Hum Mol Genet. 2018 Feb 1;27(3):499-504.
DMUXQG7	RU	http://www.ncbi.nlm.nih.gov/pubmed/29211846

DMUXQG7	DI	DMUXQG7
DMUXQG7	DN	Phosphate
DMUXQG7	MI	DTCRIWV
DMUXQG7	MN	Phosphate carrier protein (SLC25A3)
DMUXQG7	MT	DTP
DMUXQG7	MA	Substrate
DMUXQG7	RN	The mammalian phosphate carrier SLC25A3 is a mitochondrial copper transporter required for cytochrome c oxidase biogenesis. J Biol Chem. 2018 Feb 9;293(6):1887-1896.
DMUXQG7	RU	http://www.ncbi.nlm.nih.gov/pubmed/29237729

DMUXQG7	DI	DMUXQG7
DMUXQG7	DN	Phosphate
DMUXQG7	MI	DTHE530
DMUXQG7	MN	Probable small intestine urate exporter (SLC17A4)
DMUXQG7	MT	DTP
DMUXQG7	MA	Substrate
DMUXQG7	RN	A Na+-phosphate cotransporter homologue (SLC17A4 protein) is an intestinal organic anion exporter. Am J Physiol Cell Physiol. 2012 Jun 1;302(11):C1652-60.
DMUXQG7	RU	http://www.ncbi.nlm.nih.gov/pubmed/22460716

DMUXQG7	DI	DMUXQG7
DMUXQG7	DN	Phosphate
DMUXQG7	MI	DT8ARWJ
DMUXQG7	MN	Sodium-dependent phosphate transport protein 1 (SLC17A1)
DMUXQG7	MT	DTP
DMUXQG7	MA	Substrate
DMUXQG7	RN	Type 1 sodium-dependent phosphate transporter (SLC17A1 Protein) is a Cl(-)-dependent urate exporter. J Biol Chem. 2010 Aug 20;285(34):26107-13.
DMUXQG7	RU	http://www.ncbi.nlm.nih.gov/pubmed/20566650

DMUXQG7	DI	DMUXQG7
DMUXQG7	DN	Phosphate
DMUXQG7	MI	DTFOJL7
DMUXQG7	MN	Sodium-dependent phosphate transport protein 4 (SLC17A3)
DMUXQG7	MT	DTP
DMUXQG7	MA	Substrate
DMUXQG7	RN	Human sodium phosphate transporter 4 (hNPT4/SLC17A3) as a common renal secretory pathway for drugs and urate. J Biol Chem. 2010 Nov 5;285(45):35123-32.
DMUXQG7	RU	http://www.ncbi.nlm.nih.gov/pubmed/20810651

DMUXQG7	DI	DMUXQG7
DMUXQG7	DN	Phosphate
DMUXQG7	MI	DTMULXV
DMUXQG7	MN	Sodium-dependent phosphate transporter 1 (SLC20A1)
DMUXQG7	MT	DTP
DMUXQG7	MA	Substrate
DMUXQG7	RN	Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50.
DMUXQG7	RU	http://www.ncbi.nlm.nih.gov/pubmed/23398154

DMUXQG7	DI	DMUXQG7
DMUXQG7	DN	Phosphate
DMUXQG7	MI	DTFD4VB
DMUXQG7	MN	Sodium-dependent phosphate transporter 2 (SLC20A2)
DMUXQG7	MT	DTP
DMUXQG7	MA	Substrate
DMUXQG7	RN	Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50.
DMUXQG7	RU	http://www.ncbi.nlm.nih.gov/pubmed/23398154

DMUXQG7	DI	DMUXQG7
DMUXQG7	DN	Phosphate
DMUXQG7	MI	DTNK0FR
DMUXQG7	MN	Vesicular glutamate transporter 1 (SLC17A7)
DMUXQG7	MT	DTP
DMUXQG7	MA	Substrate
DMUXQG7	RN	SLC17: a functionally diverse family of organic anion transporters. Mol Aspects Med. 2013 Apr-Jun;34(2-3):350-9.
DMUXQG7	RU	http://www.ncbi.nlm.nih.gov/pubmed/23506876

DMUXQG7	DI	DMUXQG7
DMUXQG7	DN	Phosphate
DMUXQG7	MI	DT5LHCR
DMUXQG7	MN	Vesicular glutamate transporter 2 (SLC17A6)
DMUXQG7	MT	DTP
DMUXQG7	MA	Substrate
DMUXQG7	RN	Type 1 sodium-dependent phosphate transporter (SLC17A1 Protein) is a Cl(-)-dependent urate exporter. J Biol Chem. 2010 Aug 20;285(34):26107-13.
DMUXQG7	RU	http://www.ncbi.nlm.nih.gov/pubmed/20566650

DM8HDOL	DI	DM8HDOL
DM8HDOL	DN	Phytonadione
DM8HDOL	MI	TT76OLR
DM8HDOL	MN	Vitamin K-dependent gamma-carboxylase (GGCX)
DM8HDOL	MT	DTT
DM8HDOL	MA	Cofactor
DM8HDOL	RN	Quinone oxidoreductases and vitamin K metabolism. Vitam Horm. 2008;78:85-101.
DM8HDOL	RU	https://pubmed.ncbi.nlm.nih.gov/18374191

DM27BL1	DI	DM27BL1
DM27BL1	DN	Pibrentasvir
DM27BL1	MI	DTUGYRD
DM27BL1	MN	P-glycoprotein 1 (ABCB1)
DM27BL1	MT	DTP
DM27BL1	MA	Substrate
DM27BL1	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DM27BL1	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DMIBNG2	DI	DMIBNG2
DMIBNG2	DN	Picrotoxin
DMIBNG2	MI	TT1MPAY
DMIBNG2	MN	GABA(A) receptor alpha-1 (GABRA1)
DMIBNG2	MT	DTT
DMIBNG2	MA	Antagonist
DMIBNG2	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DMIBNG2	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DMV9ADG	DI	DMV9ADG
DMV9ADG	DN	Pilocarpine
DMV9ADG	MI	DEJVYAZ
DMV9ADG	MN	Cytochrome P450 2A6 (CYP2A6)
DMV9ADG	MT	DME
DMV9ADG	MA	Metabolism
DMV9ADG	RN	Structural comparison of cytochromes P450 2A6, 2A13, and 2E1 with pilocarpine. FEBS J. 2012 May;279(9):1621-31.
DMV9ADG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22051186

DMV9ADG	DI	DMV9ADG
DMV9ADG	DN	Pilocarpine
DMV9ADG	MI	DE4LYSA
DMV9ADG	MN	Cytochrome P450 3A4 (CYP3A4)
DMV9ADG	MT	DME
DMV9ADG	MA	Metabolism
DMV9ADG	RN	The inhibition of CYP enzymes in mouse and human liver by pilocarpine. Br J Pharmacol. 1995 Feb;114(4):832-6.
DMV9ADG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7773543

DMV9ADG	DI	DMV9ADG
DMV9ADG	DN	Pilocarpine
DMV9ADG	MI	TTH18TF
DMV9ADG	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMV9ADG	MT	DTT
DMV9ADG	MA	Agonist
DMV9ADG	RN	Retinoic acid prevents virus-induced airway hyperreactivity and M2 receptor dysfunction via anti-inflammatory and antiviral effects. Am J Physiol Lung Cell Mol Physiol. 2009 Aug;297(2):L340-6.
DMV9ADG	RU	https://pubmed.ncbi.nlm.nih.gov/19465517

DMZ65K8	DI	DMZ65K8
DMZ65K8	DN	Pilsicainide
DMZ65K8	MI	TTRK8B9
DMZ65K8	MN	Sodium channel unspecific (NaC)
DMZ65K8	MT	DTT
DMZ65K8	MA	Modulator
DMZ65K8	RN	A sodium channel blocker, pilsicainide, produces atrial post-repolarization refractoriness through the reduction of sodium channel availability. Tohoku J Exp Med. 2011;225(1):35-42.
DMZ65K8	RU	https://pubmed.ncbi.nlm.nih.gov/21869589

DMR7IVC	DI	DMR7IVC
DMR7IVC	DN	Pimavanserin
DMR7IVC	MI	TTJQOD7
DMR7IVC	MN	5-HT 2A receptor (HTR2A)
DMR7IVC	MT	DTT
DMR7IVC	MA	Modulator
DMR7IVC	RN	Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52.
DMR7IVC	RU	https://www.ncbi.nlm.nih.gov/pubmed/22954754

DMZLGRB	DI	DMZLGRB
DMZLGRB	DN	Pimecrolimus
DMZLGRB	MI	TTA4LDE
DMZLGRB	MN	Calcineurin (PPP3CA)
DMZLGRB	MT	DTT
DMZLGRB	MA	Inhibitor
DMZLGRB	RN	Treatment of chronic blepharokeratoconjunctivitis with local calcineurin inhibitors. Ophthalmologe. 2009 Jul;106(7):635-8.
DMZLGRB	RU	https://pubmed.ncbi.nlm.nih.gov/19499228

DMZLGRB	DI	DMZLGRB
DMZLGRB	DN	Pimecrolimus
DMZLGRB	MI	DE4LYSA
DMZLGRB	MN	Cytochrome P450 3A4 (CYP3A4)
DMZLGRB	MT	DME
DMZLGRB	MA	Metabolism
DMZLGRB	RN	Pimecrolimus: absorption, distribution, metabolism, and excretion in healthy volunteers after a single oral dose and supplementary investigations in vitro. Drug Metab Dispos. 2006 May;34(5):765-74.
DMZLGRB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16467136

DMW83TP	DI	DMW83TP
DMW83TP	DN	Pimozide
DMW83TP	MI	DEJGDUW
DMW83TP	MN	Cytochrome P450 1A2 (CYP1A2)
DMW83TP	MT	DME
DMW83TP	MA	Metabolism
DMW83TP	RN	Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. J Pharmacol Exp Ther. 1998 May;285(2):428-37.
DMW83TP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9580580

DMW83TP	DI	DMW83TP
DMW83TP	DN	Pimozide
DMW83TP	MI	DECB0K3
DMW83TP	MN	Cytochrome P450 2D6 (CYP2D6)
DMW83TP	MT	DME
DMW83TP	MA	Metabolism
DMW83TP	RN	The influence of the CYP3A4*22 polymorphism and CYP2D6 polymorphisms on serum concentrations of aripiprazole, haloperidol, pimozide, and risperidone in psychiatric patients. J Clin Psychopharmacol. 2015 Jun;35(3):228-36.
DMW83TP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25868121

DMW83TP	DI	DMW83TP
DMW83TP	DN	Pimozide
DMW83TP	MI	DE4LYSA
DMW83TP	MN	Cytochrome P450 3A4 (CYP3A4)
DMW83TP	MT	DME
DMW83TP	MA	Metabolism
DMW83TP	RN	Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. J Pharmacol Exp Ther. 1998 May;285(2):428-37.
DMW83TP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9580580

DMW83TP	DI	DMW83TP
DMW83TP	DN	Pimozide
DMW83TP	MI	DEIBDNY
DMW83TP	MN	Cytochrome P450 3A5 (CYP3A5)
DMW83TP	MT	DME
DMW83TP	MA	Metabolism
DMW83TP	RN	Drug Interactions Flockhart Table
DMW83TP	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMW83TP	DI	DMW83TP
DMW83TP	DN	Pimozide
DMW83TP	MI	DERD86B
DMW83TP	MN	Cytochrome P450 3A7 (CYP3A7)
DMW83TP	MT	DME
DMW83TP	MA	Metabolism
DMW83TP	RN	Drug Interactions Flockhart Table
DMW83TP	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMW83TP	DI	DMW83TP
DMW83TP	DN	Pimozide
DMW83TP	MI	TTEX248
DMW83TP	MN	Dopamine D2 receptor (D2R)
DMW83TP	MT	DTT
DMW83TP	MA	Antagonist
DMW83TP	RN	[The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
DMW83TP	RU	https://pubmed.ncbi.nlm.nih.gov/16924461

DMW83TP	DI	DMW83TP
DMW83TP	DN	Pimozide
DMW83TP	MI	DTUGYRD
DMW83TP	MN	P-glycoprotein 1 (ABCB1)
DMW83TP	MT	DTP
DMW83TP	MA	Substrate
DMW83TP	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMW83TP	RU	https://doi.org/10.1007/s11095-012-0935-x

DMRADYL	DI	DMRADYL
DMRADYL	DN	Pinacidil
DMRADYL	MI	DE4LYSA
DMRADYL	MN	Cytochrome P450 3A4 (CYP3A4)
DMRADYL	MT	DME
DMRADYL	MA	Metabolism
DMRADYL	RN	Cytochrome P450 3A4-mediated oxidative conversion of a cyano to an amide group in the metabolism of pinacidil. Biochemistry. 2002 Feb 26;41(8):2712-8.
DMRADYL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11851418

DMRADYL	DI	DMRADYL
DMRADYL	DN	Pinacidil
DMRADYL	MI	TT1VOHK
DMRADYL	MN	Potassium channel unspecific (KC)
DMRADYL	MT	DTT
DMRADYL	MA	Modulator
DMRADYL	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMRADYL	RU	https://www.fda.gov/

DMD2NV7	DI	DMD2NV7
DMD2NV7	DN	Pindolol
DMD2NV7	MI	TTR6W5O
DMD2NV7	MN	Adrenergic receptor beta-1 (ADRB1)
DMD2NV7	MT	DTT
DMD2NV7	MA	Antagonist
DMD2NV7	RN	Are we misunderstanding beta-blockers. Int J Cardiol. 2007 Aug 9;120(1):10-27.
DMD2NV7	RU	https://pubmed.ncbi.nlm.nih.gov/17433471

DMKJ485	DI	DMKJ485
DMKJ485	DN	Pioglitazone
DMKJ485	MI	DES5XRU
DMKJ485	MN	Cytochrome P450 2C8 (CYP2C8)
DMKJ485	MT	DME
DMKJ485	MA	Metabolism
DMKJ485	RN	The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro. Basic Clin Pharmacol Toxicol. 2009 Dec;105(6):374-9.
DMKJ485	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19614891

DMKJ485	DI	DMKJ485
DMKJ485	DN	Pioglitazone
DMKJ485	MI	DE5IED8
DMKJ485	MN	Cytochrome P450 2C9 (CYP2C9)
DMKJ485	MT	DME
DMKJ485	MA	Metabolism
DMKJ485	RN	Current clinical evidence on pioglitazone pharmacogenomics. Front Pharmacol. 2013 Nov 26;4:147.
DMKJ485	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24324437

DMKJ485	DI	DMKJ485
DMKJ485	DN	Pioglitazone
DMKJ485	MI	DE4LYSA
DMKJ485	MN	Cytochrome P450 3A4 (CYP3A4)
DMKJ485	MT	DME
DMKJ485	MA	Metabolism
DMKJ485	RN	Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol. 2006 Jul;99(1):44-51.
DMKJ485	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16867170

DMKJ485	DI	DMKJ485
DMKJ485	DN	Pioglitazone
DMKJ485	MI	TTZMAO3
DMKJ485	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMKJ485	MT	DTT
DMKJ485	MA	Agonist
DMKJ485	RN	Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med. 2002 Nov;8(11):1281-7.
DMKJ485	RU	https://pubmed.ncbi.nlm.nih.gov/12379847

DMKJ485	DI	DMKJ485
DMKJ485	DN	Pioglitazone
DMKJ485	MI	DE073H6
DMKJ485	MN	Prostaglandin G/H synthase 1 (COX-1)
DMKJ485	MT	DME
DMKJ485	MA	Metabolism
DMKJ485	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMKJ485	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM5F84A	DI	DM5F84A
DM5F84A	DN	Pipecuronium
DM5F84A	MI	TTF4E0J
DM5F84A	MN	Neuronal acetylcholine receptor alpha-2 (CHRNA2)
DM5F84A	MT	DTT
DM5F84A	MA	Antagonist
DM5F84A	RN	Synergy between pairs of competitive antagonists at adult human muscle acetylcholine receptors. Anesth Analg. 2008 Aug;107(2):525-33.
DM5F84A	RU	https://pubmed.ncbi.nlm.nih.gov/18633030

DMGQU0Y	DI	DMGQU0Y
DMGQU0Y	DN	Piperacetazine
DMGQU0Y	MI	TTEX248
DMGQU0Y	MN	Dopamine D2 receptor (D2R)
DMGQU0Y	MT	DTT
DMGQU0Y	MA	Modulator
DMGQU0Y	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMGQU0Y	RU	https://www.fda.gov/

DMTBKF3	DI	DMTBKF3
DMTBKF3	DN	Piperacillin
DMTBKF3	MI	TTJP4SM
DMTBKF3	MN	Bacterial Penicillin binding protein (Bact PBP)
DMTBKF3	MT	DTT
DMTBKF3	MA	Binder
DMTBKF3	RN	In vitro antienterococcal activity explains associations between exposures to antimicrobial agents and risk of colonization by multiresistant enter... J Infect Dis. 2004 Dec 15;190(12):2162-6.
DMTBKF3	RU	https://pubmed.ncbi.nlm.nih.gov/15551215

DMTBKF3	DI	DMTBKF3
DMTBKF3	DN	Piperacillin
DMTBKF3	MI	DET9I1W
DMTBKF3	MN	Beta-lactamase (blaB)
DMTBKF3	MT	DME
DMTBKF3	MA	Metabolism
DMTBKF3	RN	Purification and characterization of a new beta-lactamase from Bacteroides uniformis. Antimicrob Agents Chemother. 1995 Jul;39(7):1458-61.
DMTBKF3	RU	https://pubmed.ncbi.nlm.nih.gov/7492085

DMTBKF3	DI	DMTBKF3
DMTBKF3	DN	Piperacillin
DMTBKF3	MI	DEEZ5CV
DMTBKF3	MN	Beta-lactamase (blaB)
DMTBKF3	MT	DME
DMTBKF3	MA	Metabolism
DMTBKF3	RN	Characterization of piperacillin/tazobactam-resistant klebsiella oxytoca recovered from a nosocomial outbreak. PLoS One. 2015 Nov 5;10(11):e0142366.
DMTBKF3	RU	https://pubmed.ncbi.nlm.nih.gov/26539828

DMTBKF3	DI	DMTBKF3
DMTBKF3	DN	Piperacillin
DMTBKF3	MI	DEYIEO5
DMTBKF3	MN	Beta-lactamase (blaB)
DMTBKF3	MT	DME
DMTBKF3	MA	Metabolism
DMTBKF3	RN	Determination of the antibiotic resistance rates of Serratia marcescens isolates obtained from various clinical specimens. Niger J Clin Pract. 2019 Jan;22(1):125-130.
DMTBKF3	RU	https://pubmed.ncbi.nlm.nih.gov/30666031

DMTBKF3	DI	DMTBKF3
DMTBKF3	DN	Piperacillin
DMTBKF3	MI	DT9G7XN
DMTBKF3	MN	Peptide transporter 1 (SLC15A1)
DMTBKF3	MT	DTP
DMTBKF3	MA	Substrate
DMTBKF3	RN	Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. J Med Chem. 2005 Jun 30;48(13):4410-9.
DMTBKF3	RU	http://www.ncbi.nlm.nih.gov/pubmed/15974593

DMT70RC	DI	DMT70RC
DMT70RC	DN	Piperaquine
DMT70RC	MI	DE5IED8
DMT70RC	MN	Cytochrome P450 2C9 (CYP2C9)
DMT70RC	MT	DME
DMT70RC	MA	Metabolism
DMT70RC	RN	Eurartesim - European Medicines Agency
DMT70RC	RU	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001199/WC500118116.pdf

DMT70RC	DI	DMT70RC
DMT70RC	DN	Piperaquine
DMT70RC	MI	DEGTFWK
DMT70RC	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMT70RC	MT	DME
DMT70RC	MA	Metabolism
DMT70RC	RN	Open-label crossover study of primaquine and dihydroartemisinin-piperaquine pharmacokinetics in healthy adult thai subjects. Antimicrob Agents Chemother. 2014 Dec;58(12):7340-6.
DMT70RC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25267661

DMT70RC	DI	DMT70RC
DMT70RC	DN	Piperaquine
DMT70RC	MI	TTZVSJ2
DMT70RC	MN	Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A)
DMT70RC	MT	DTT
DMT70RC	MA	Inhibitor
DMT70RC	RN	The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
DMT70RC	RU	https://pubmed.ncbi.nlm.nih.gov/18220771

DMTY9LU	DI	DMTY9LU
DMTY9LU	DN	Piperazine
DMTY9LU	MI	DECB0K3
DMTY9LU	MN	Cytochrome P450 2D6 (CYP2D6)
DMTY9LU	MT	DME
DMTY9LU	MA	Metabolism
DMTY9LU	RN	Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis. Ther Drug Monit. 2004 Apr;26(2):127-31.
DMTY9LU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15228152

DMTY9LU	DI	DMTY9LU
DMTY9LU	DN	Piperazine
DMTY9LU	MI	TTNJYV2
DMTY9LU	MN	Gamma-aminobutyric acid receptor (GAR)
DMTY9LU	MT	DTT
DMTY9LU	MA	Antagonist
DMTY9LU	RN	Cyclooctadepsipeptides--an anthelmintically active class of compounds exhibiting a novel mode of action. Int J Antimicrob Agents. 2003 Sep;22(3):318-31.
DMTY9LU	RU	https://pubmed.ncbi.nlm.nih.gov/13678839

DMNL0E6	DI	DMNL0E6
DMNL0E6	DN	Pipobroman
DMNL0E6	MI	TTUTN1I
DMNL0E6	MN	Human Deoxyribonucleic acid (hDNA)
DMNL0E6	MT	DTT
DMNL0E6	MA	Binder
DMNL0E6	RN	Effects of piposulfan (Ancyte) on protein and DNA synthesis in Ehrlich ascites carcinoma. Life Sci II. 1971 Jun 8;10(11):605-12.
DMNL0E6	RU	https://pubmed.ncbi.nlm.nih.gov/5556760

DMC68DF	DI	DMC68DF
DMC68DF	DN	Pipotiazine
DMC68DF	MI	DECB0K3
DMC68DF	MN	Cytochrome P450 2D6 (CYP2D6)
DMC68DF	MT	DME
DMC68DF	MA	Metabolism
DMC68DF	RN	Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet. 2009;48(12):761-804.
DMC68DF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19902987

DMC68DF	DI	DMC68DF
DMC68DF	DN	Pipotiazine
DMC68DF	MI	DE4LYSA
DMC68DF	MN	Cytochrome P450 3A4 (CYP3A4)
DMC68DF	MT	DME
DMC68DF	MA	Metabolism
DMC68DF	RN	Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver--A comparison with other phenothiazines. Biochem Pharmacol. 2010 Oct 15;80(8):1252-9.
DMC68DF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20615392

DMC68DF	DI	DMC68DF
DMC68DF	DN	Pipotiazine
DMC68DF	MI	DEGTFWK
DMC68DF	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMC68DF	MT	DME
DMC68DF	MA	Metabolism
DMC68DF	RN	Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver--A comparison with other phenothiazines. Biochem Pharmacol. 2010 Oct 15;80(8):1252-9.
DMC68DF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20615392

DMGTW1I	DI	DMGTW1I
DMGTW1I	DN	Pirarubicin
DMGTW1I	MI	DTI7UX6
DMGTW1I	MN	Breast cancer resistance protein (ABCG2)
DMGTW1I	MT	DTP
DMGTW1I	MA	Substrate
DMGTW1I	RN	Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
DMGTW1I	RU	http://www.ncbi.nlm.nih.gov/pubmed/18820913

DMGTW1I	DI	DMGTW1I
DMGTW1I	DN	Pirarubicin
DMGTW1I	MI	TTUTN1I
DMGTW1I	MN	Human Deoxyribonucleic acid (hDNA)
DMGTW1I	MT	DTT
DMGTW1I	MA	Modulator
DMGTW1I	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMGTW1I	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DMGTW1I	DI	DMGTW1I
DMGTW1I	DN	Pirarubicin
DMGTW1I	MI	DTUGYRD
DMGTW1I	MN	P-glycoprotein 1 (ABCB1)
DMGTW1I	MT	DTP
DMGTW1I	MA	Substrate
DMGTW1I	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMGTW1I	RU	https://doi.org/10.1007/s11095-012-0935-x

DMI5678	DI	DMI5678
DMI5678	DN	Pirbuterol
DMI5678	MI	TT2CJVK
DMI5678	MN	Adrenergic receptor beta-2 (ADRB2)
DMI5678	MT	DTT
DMI5678	MA	Agonist
DMI5678	RN	Inhaled beta agonists. Respir Care. 2007 Jul;52(7):820-32.
DMI5678	RU	https://pubmed.ncbi.nlm.nih.gov/17594727

DMP6M1N	DI	DMP6M1N
DMP6M1N	DN	Pirenzepine
DMP6M1N	MI	TTZ9SOR
DMP6M1N	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMP6M1N	MT	DTT
DMP6M1N	MA	Antagonist
DMP6M1N	RN	Negative crosstalk between M1 and M2 muscarinic autoreceptors involves endogenous adenosine activating A1 receptors at the rat motor endplate. Neurosci Lett. 2009 Aug 14;459(3):127-31.
DMP6M1N	RU	https://pubmed.ncbi.nlm.nih.gov/19427366

DMP6M1N	DI	DMP6M1N
DMP6M1N	DN	Pirenzepine
DMP6M1N	MI	DTUGYRD
DMP6M1N	MN	P-glycoprotein 1 (ABCB1)
DMP6M1N	MT	DTP
DMP6M1N	MA	Substrate
DMP6M1N	RN	Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.
DMP6M1N	RU	http://www.ncbi.nlm.nih.gov/pubmed/12438524

DM6VZFQ	DI	DM6VZFQ
DM6VZFQ	DN	Pirfenidone
DM6VZFQ	MI	DEJGDUW
DM6VZFQ	MN	Cytochrome P450 1A2 (CYP1A2)
DM6VZFQ	MT	DME
DM6VZFQ	MA	Metabolism
DM6VZFQ	RN	Risk of clinically relevant pharmacokinetic-based drug-drug interactions with drugs approved by the U.S. Food and Drug Administration between 2013 and 2016. Drug Metab Dispos. 2018 Jun;46(6):835-845.
DM6VZFQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29572333

DM6VZFQ	DI	DM6VZFQ
DM6VZFQ	DN	Pirfenidone
DM6VZFQ	MI	TTR9XHZ
DM6VZFQ	MN	Transforming growth factor beta 1 (TGFB1)
DM6VZFQ	MT	DTT
DM6VZFQ	MA	Modulator
DM6VZFQ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM6VZFQ	RU	https://www.fda.gov/

DMBCYF5	DI	DMBCYF5
DMBCYF5	DN	Pirmenol
DMBCYF5	MI	TTRK8B9
DMBCYF5	MN	Sodium channel unspecific (NaC)
DMBCYF5	MT	DTT
DMBCYF5	MA	Modulator
DMBCYF5	RN	Pirmenol, a new antiarrhythmic drug with potassium- and sodium-channel blocking activity; a voltage-clamp study in rabbit Purkinje fibres. Naunyn Schmiedebergs Arch Pharmacol. 1990 May;341(5):462-71.
DMBCYF5	RU	https://pubmed.ncbi.nlm.nih.gov/2164163

DMTK234	DI	DMTK234
DMTK234	DN	Piroxicam
DMTK234	MI	DES5XRU
DMTK234	MN	Cytochrome P450 2C8 (CYP2C8)
DMTK234	MT	DME
DMTK234	MA	Metabolism
DMTK234	RN	Efficacy of piroxicam for postoperative pain after lower third molar surgery associated with CYP2C8*3 and CYP2C9 J Pain Res. 2017 Jul 6;10:1581-1589.
DMTK234	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28740425

DMTK234	DI	DMTK234
DMTK234	DN	Piroxicam
DMTK234	MI	DE5IED8
DMTK234	MN	Cytochrome P450 2C9 (CYP2C9)
DMTK234	MT	DME
DMTK234	MA	Metabolism
DMTK234	RN	Functional characterization of human CYP2C9 allelic variants in COS-7 cells. Front Pharmacol. 2016 Apr 25;7:98.
DMTK234	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27199745

DMTK234	DI	DMTK234
DMTK234	DN	Piroxicam
DMTK234	MI	TT8NGED
DMTK234	MN	Prostaglandin G/H synthase 1 (COX-1)
DMTK234	MT	DTT
DMTK234	MA	Modulator
DMTK234	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMTK234	RU	https://www.fda.gov/

DMMOFHT	DI	DMMOFHT
DMMOFHT	DN	Pirprofen
DMMOFHT	MI	DEYGVN4
DMMOFHT	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMMOFHT	MT	DME
DMMOFHT	MA	Metabolism
DMMOFHT	RN	Glucuronidation of 2-arylpropionic acids pirprofen, flurbiprofen, and ibuprofen by liver microsomes. Drug Metab Dispos. 1990 Sep-Oct;18(5):692-7.
DMMOFHT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1981722

DMJH792	DI	DMJH792
DMJH792	DN	Pitavastatin
DMJH792	MI	DTI7UX6
DMJH792	MN	Breast cancer resistance protein (ABCG2)
DMJH792	MT	DTP
DMJH792	MA	Substrate
DMJH792	RN	ABCG2: a perspective. Adv Drug Deliv Rev. 2009 Jan 31;61(1):3-13.
DMJH792	RU	https://doi.org/10.1016/j.addr.2008.11.003

DMJH792	DI	DMJH792
DMJH792	DN	Pitavastatin
DMJH792	MI	DTFI42L
DMJH792	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMJH792	MT	DTP
DMJH792	MA	Substrate
DMJH792	RN	Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol. 2005 Sep;68(3):800-7.
DMJH792	RU	http://www.ncbi.nlm.nih.gov/pubmed/15955871

DMJH792	DI	DMJH792
DMJH792	DN	Pitavastatin
DMJH792	MI	DTE2B1D
DMJH792	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMJH792	MT	DTP
DMJH792	MA	Substrate
DMJH792	RN	Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
DMJH792	RU	http://www.ncbi.nlm.nih.gov/pubmed/16259759

DMJH792	DI	DMJH792
DMJH792	DN	Pitavastatin
DMJH792	MI	DT3D8F0
DMJH792	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMJH792	MT	DTP
DMJH792	MA	Substrate
DMJH792	RN	Prediction of the in vivo OATP1B1-mediated drug-drug interaction potential of an investigational drug against a range of statins. Eur J Pharm Sci. 2012 Aug 30;47(1):244-55.
DMJH792	RU	http://www.ncbi.nlm.nih.gov/pubmed/22538052

DMJH792	DI	DMJH792
DMJH792	DN	Pitavastatin
DMJH792	MI	DT9C1TS
DMJH792	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMJH792	MT	DTP
DMJH792	MA	Substrate
DMJH792	RN	Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705.
DMJH792	RU	http://www.ncbi.nlm.nih.gov/pubmed/19785645

DMJH792	DI	DMJH792
DMJH792	DN	Pitavastatin
DMJH792	MI	DTPFTEQ
DMJH792	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DMJH792	MT	DTP
DMJH792	MA	Substrate
DMJH792	RN	Intestinal absorption of HMG-CoA reductase inhibitor pitavastatin mediated by organic anion transporting polypeptide and P-glycoprotein/multidrug resistance 1. Drug Metab Pharmacokinet. 2011;26(2):171-9.
DMJH792	RU	https://doi.org/10.2133/dmpk.DMPK-10-RG-073

DM1UJO0	DI	DM1UJO0
DM1UJO0	DN	Pitavastatin calcium
DM1UJO0	MI	DTI7UX6
DM1UJO0	MN	Breast cancer resistance protein (ABCG2)
DM1UJO0	MT	DTP
DM1UJO0	MA	Substrate
DM1UJO0	RN	Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol. 2005 Sep;68(3):800-7.
DM1UJO0	RU	http://www.ncbi.nlm.nih.gov/pubmed/15955871

DM1UJO0	DI	DM1UJO0
DM1UJO0	DN	Pitavastatin calcium
DM1UJO0	MI	DES5XRU
DM1UJO0	MN	Cytochrome P450 2C8 (CYP2C8)
DM1UJO0	MT	DME
DM1UJO0	MA	Metabolism
DM1UJO0	RN	Comparison of the safety, tolerability, and pharmacokinetic profile of a single oral dose of pitavastatin 4 mg in adult subjects with severe renal impairment not on hemodialysis versus healthy adult subjects. J Cardiovasc Pharmacol. 2012 Jul;60(1):42-8.
DM1UJO0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22472908

DM1UJO0	DI	DM1UJO0
DM1UJO0	DN	Pitavastatin calcium
DM1UJO0	MI	DE5IED8
DM1UJO0	MN	Cytochrome P450 2C9 (CYP2C9)
DM1UJO0	MT	DME
DM1UJO0	MA	Metabolism
DM1UJO0	RN	Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168.
DM1UJO0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28130659

DM1UJO0	DI	DM1UJO0
DM1UJO0	DN	Pitavastatin calcium
DM1UJO0	MI	TTPADOQ
DM1UJO0	MN	HMG-CoA reductase (HMGCR)
DM1UJO0	MT	DTT
DM1UJO0	MA	Inhibitor
DM1UJO0	RN	Cholesterol-lowering effect of NK-104, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, in guinea pig model of hyperlipidemia. Arzneimittelforschung. 2001;51(3):197-203.
DM1UJO0	RU	https://pubmed.ncbi.nlm.nih.gov/11304935

DM1UJO0	DI	DM1UJO0
DM1UJO0	DN	Pitavastatin calcium
DM1UJO0	MI	DTFI42L
DM1UJO0	MN	Multidrug resistance-associated protein 2 (ABCC2)
DM1UJO0	MT	DTP
DM1UJO0	MA	Substrate
DM1UJO0	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM1UJO0	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DM1UJO0	DI	DM1UJO0
DM1UJO0	DN	Pitavastatin calcium
DM1UJO0	MI	DTVP67E
DM1UJO0	MN	Organic anion transporter 3 (SLC22A8)
DM1UJO0	MT	DTP
DM1UJO0	MA	Substrate
DM1UJO0	RN	Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
DM1UJO0	RU	http://www.ncbi.nlm.nih.gov/pubmed/16259759

DM1UJO0	DI	DM1UJO0
DM1UJO0	DN	Pitavastatin calcium
DM1UJO0	MI	DTE2B1D
DM1UJO0	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DM1UJO0	MT	DTP
DM1UJO0	MA	Substrate
DM1UJO0	RN	Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
DM1UJO0	RU	http://www.ncbi.nlm.nih.gov/pubmed/16259759

DM1UJO0	DI	DM1UJO0
DM1UJO0	DN	Pitavastatin calcium
DM1UJO0	MI	DT3D8F0
DM1UJO0	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM1UJO0	MT	DTP
DM1UJO0	MA	Substrate
DM1UJO0	RN	The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008 May;18(5):424-33.
DM1UJO0	RU	http://www.ncbi.nlm.nih.gov/pubmed/18408565

DM1UJO0	DI	DM1UJO0
DM1UJO0	DN	Pitavastatin calcium
DM1UJO0	MI	DT9C1TS
DM1UJO0	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM1UJO0	MT	DTP
DM1UJO0	MA	Substrate
DM1UJO0	RN	Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther. 2004 Oct;311(1):139-46.
DM1UJO0	RU	http://www.ncbi.nlm.nih.gov/pubmed/15159445

DM1UJO0	DI	DM1UJO0
DM1UJO0	DN	Pitavastatin calcium
DM1UJO0	MI	DTPFTEQ
DM1UJO0	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DM1UJO0	MT	DTP
DM1UJO0	MA	Substrate
DM1UJO0	RN	Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos. 2006 Jul;34(7):1229-36.
DM1UJO0	RU	http://www.ncbi.nlm.nih.gov/pubmed/16595711

DM1UJO0	DI	DM1UJO0
DM1UJO0	DN	Pitavastatin calcium
DM1UJO0	MI	DT56EKP
DM1UJO0	MN	Sodium/taurocholate cotransporting polypeptide (SLC10A1)
DM1UJO0	MT	DTP
DM1UJO0	MA	Substrate
DM1UJO0	RN	Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
DM1UJO0	RU	http://www.ncbi.nlm.nih.gov/pubmed/16259759

DM1UJO0	DI	DM1UJO0
DM1UJO0	DN	Pitavastatin calcium
DM1UJO0	MI	DEYGVN4
DM1UJO0	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM1UJO0	MT	DME
DM1UJO0	MA	Metabolism
DM1UJO0	RN	Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization. Xenobiotica. 2003 Jan;33(1):27-41.
DM1UJO0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12519692

DM1UJO0	DI	DM1UJO0
DM1UJO0	DN	Pitavastatin calcium
DM1UJO0	MI	DEF2WXN
DM1UJO0	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DM1UJO0	MT	DME
DM1UJO0	MA	Metabolism
DM1UJO0	RN	Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168.
DM1UJO0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28130659

DM1UJO0	DI	DM1UJO0
DM1UJO0	DN	Pitavastatin calcium
DM1UJO0	MI	DEB3CV1
DM1UJO0	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DM1UJO0	MT	DME
DM1UJO0	MA	Metabolism
DM1UJO0	RN	Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168.
DM1UJO0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28130659

DM8RFNJ	DI	DM8RFNJ
DM8RFNJ	DN	Pitolisant
DM8RFNJ	MI	TT9JNIC
DM8RFNJ	MN	Histamine H3 receptor (H3R)
DM8RFNJ	MT	DTT
DM8RFNJ	MA	Agonist
DM8RFNJ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DM8RFNJ	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211150s000lbl.pdf

DMX8CVY	DI	DMX8CVY
DMX8CVY	DN	Pivampicillin
DMX8CVY	MI	TTJP4SM
DMX8CVY	MN	Bacterial Penicillin binding protein (Bact PBP)
DMX8CVY	MT	DTT
DMX8CVY	MA	Binder
DMX8CVY	RN	Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
DMX8CVY	RU	https://pubmed.ncbi.nlm.nih.gov/17016423

DMDU0BV	DI	DMDU0BV
DMDU0BV	DN	Pivmecillinam
DMDU0BV	MI	TTJP4SM
DMDU0BV	MN	Bacterial Penicillin binding protein (Bact PBP)
DMDU0BV	MT	DTT
DMDU0BV	MA	Binder
DMDU0BV	RN	Association between antimicrobial consumption and resistance in Escherichia coli. Antimicrob Agents Chemother. 2009 Mar;53(3):912-7.
DMDU0BV	RU	https://pubmed.ncbi.nlm.nih.gov/19104012

DMV74ZH	DI	DMV74ZH
DMV74ZH	DN	Pizotyline
DMV74ZH	MI	TT85JO3
DMV74ZH	MN	5-HT receptor (5HTR)
DMV74ZH	MT	DTT
DMV74ZH	MA	Modulator
DMV74ZH	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMV74ZH	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMV74ZH	DI	DMV74ZH
DMV74ZH	DN	Pizotyline
DMV74ZH	MI	DEI8NGH
DMV74ZH	MN	UDP-glucuronosyltransferase 2B10 (UGT2B10)
DMV74ZH	MT	DME
DMV74ZH	MA	Metabolism
DMV74ZH	RN	Human UDP-glucuronosyltransferase (UGT) 2B10 in drug N-glucuronidation: substrate screening and comparison with UGT1A3 and UGT1A4. Drug Metab Dispos. 2013 Jul;41(7):1389-97.
DMV74ZH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23611809

DMKMBES	DI	DMKMBES
DMKMBES	DN	Plazomicin
DMKMBES	MI	DE69QHT
DMKMBES	MN	Aminoglycoside acetyltransferase (aac)
DMKMBES	MT	DME
DMKMBES	MA	Metabolism
DMKMBES	RN	Plazomicin retains antibiotic activity against most aminoglycoside modifying enzymes. ACS Infect Dis. 2018 Jun 8;4(6):980-987.
DMKMBES	RU	https://pubmed.ncbi.nlm.nih.gov/29634241

DMKMBES	DI	DMKMBES
DMKMBES	DN	Plazomicin
DMKMBES	MI	DESGYWE
DMKMBES	MN	Aminoglycoside O-phosphotransferase (aphA6)
DMKMBES	MT	DME
DMKMBES	MA	Metabolism
DMKMBES	RN	Plazomicin retains antibiotic activity against most aminoglycoside modifying enzymes. ACS Infect Dis. 2018 Jun 8;4(6):980-987.
DMKMBES	RU	https://pubmed.ncbi.nlm.nih.gov/29634241

DMKMBES	DI	DMKMBES
DMKMBES	DN	Plazomicin
DMKMBES	MI	TTUQ7WN
DMKMBES	MN	Mitochondrial rRNA methyltransferase 2 (MRM2)
DMKMBES	MT	DTT
DMKMBES	MA	Inhibitor
DMKMBES	RN	In vitro activity of plazomicin against -lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE).J Antimicrob Chemother. 2017 Oct 1;72(10):2792-2795. 
DMKMBES	RU	https://pubmed.ncbi.nlm.nih.gov/29091224

DMKEX7O	DI	DMKEX7O
DMKEX7O	DN	Plecanatide
DMKEX7O	MI	TTLDPRG
DMKEX7O	MN	Guanylyl cyclase C (GUCY2C)
DMKEX7O	MT	DTT
DMKEX7O	MA	Modulator
DMKEX7O	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMKEX7O	RU	https://www.fda.gov/

DMAKXW9	DI	DMAKXW9
DMAKXW9	DN	PLEGRIDY
DMAKXW9	MI	TT4TZ8J
DMAKXW9	MN	Interferon-beta (IFNB1)
DMAKXW9	MT	DTT
DMAKXW9	MA	Modulator
DMAKXW9	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMAKXW9	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMCJN1P	DI	DMCJN1P
DMCJN1P	DN	Plerixafor
DMCJN1P	MI	TTBID49
DMCJN1P	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMCJN1P	MT	DTT
DMCJN1P	MA	Antagonist
DMCJN1P	RN	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
DMCJN1P	RU	https://pubmed.ncbi.nlm.nih.gov/19249983

DM7C8YV	DI	DM7C8YV
DM7C8YV	DN	Plicamycin
DM7C8YV	MI	TTX2AYW
DM7C8YV	MN	RNA synthesis (hRNA synth)
DM7C8YV	MT	DTT
DM7C8YV	MA	Modulator
DM7C8YV	RN	Role of magnesium ion in mithramycin-DNA interaction: binding of mithramycin-Mg2+ complexes with DNA. Biochemistry. 1995 Jan 31;34(4):1376-85.
DM7C8YV	RU	https://pubmed.ncbi.nlm.nih.gov/7827085

DMG8MLJ	DI	DMG8MLJ
DMG8MLJ	DN	Pneumococcal 13-valent conjugate vaccine
DMG8MLJ	MI	TTY4IQ9
DMG8MLJ	MN	Corynebacterium Mutated CRM197 (Cory mTOX)
DMG8MLJ	MT	DTT
DMG8MLJ	MA	Binder
DMG8MLJ	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DMG8MLJ	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DMT2EJP	DI	DMT2EJP
DMT2EJP	DN	Podofilox
DMT2EJP	MI	DE4LYSA
DMT2EJP	MN	Cytochrome P450 3A4 (CYP3A4)
DMT2EJP	MT	DME
DMT2EJP	MA	Metabolism
DMT2EJP	RN	Characterization of in vitro metabolites of deoxypodophyllotoxin in human and rat liver microsomes using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2008;22(1):52-8.
DMT2EJP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18050240

DMT2EJP	DI	DMT2EJP
DMT2EJP	DN	Podofilox
DMT2EJP	MI	TT0IHXV
DMT2EJP	MN	DNA topoisomerase II (TOP2)
DMT2EJP	MT	DTT
DMT2EJP	MA	Modulator
DMT2EJP	RN	Antitumor properties of podophyllotoxin and related compounds. Curr Pharm Des. 2000 Dec;6(18):1811-39.
DMT2EJP	RU	https://pubmed.ncbi.nlm.nih.gov/11102564

DMT2EJP	DI	DMT2EJP
DMT2EJP	DN	Podofilox
DMT2EJP	MI	DEGTFWK
DMT2EJP	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMT2EJP	MT	DME
DMT2EJP	MA	Metabolism
DMT2EJP	RN	Characterization of in vitro metabolites of deoxypodophyllotoxin in human and rat liver microsomes using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2008;22(1):52-8.
DMT2EJP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18050240

DMF6Y0L	DI	DMF6Y0L
DMF6Y0L	DN	Polatuzumab vedotin
DMF6Y0L	MI	TTBN5I7
DMF6Y0L	MN	B-cell-specific glycoprotein B29 (CD79B)
DMF6Y0L	MT	DTT
DMF6Y0L	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMF6Y0L	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761121s000lbl.pdf

DMF6Y0L	DI	DMF6Y0L
DMF6Y0L	DN	Polatuzumab vedotin
DMF6Y0L	MI	DE4LYSA
DMF6Y0L	MN	Cytochrome P450 3A4 (CYP3A4)
DMF6Y0L	MT	DME
DMF6Y0L	MA	Metabolism
DMF6Y0L	RN	FDA label of Polatuzumab vedotin-piiq. The 2020 official website of the U.S. Food and Drug Administration.
DMF6Y0L	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761121s000lbl.pdf

DMH1KMT	DI	DMH1KMT
DMH1KMT	DN	Polidocanol
DMH1KMT	MI	TTT6K3S
DMH1KMT	MN	Endothelium of blood vessels (Endothelium)
DMH1KMT	MT	DTT
DMH1KMT	MA	Modulator
DMH1KMT	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMH1KMT	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMUCWEX	DI	DMUCWEX
DMUCWEX	DN	Polidocanol - BioForm Medical/Chemische Fabrik Kreussler & Co
DMUCWEX	MI	TT42M75
DMUCWEX	MN	Carbamoyl-phosphate synthetase I (CPS1)
DMUCWEX	MT	DTT
DMUCWEX	MA	Modulator
DMUCWEX	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DMUCWEX	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DM0PMGJ	DI	DM0PMGJ
DM0PMGJ	DN	Polyestradiol Phosphate
DM0PMGJ	MI	TT2A0DR
DM0PMGJ	MN	Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A)
DM0PMGJ	MT	DTT
DM0PMGJ	MA	Modulator
DM0PMGJ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM0PMGJ	RU	https://www.fda.gov/

DM4I1JP	DI	DM4I1JP
DM4I1JP	DN	Polyethylene glycol
DM4I1JP	MI	DEIOH6A
DM4I1JP	MN	Alcohol dehydrogenase class-III (ADH5)
DM4I1JP	MT	DME
DM4I1JP	MA	Metabolism
DM4I1JP	RN	PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies. Drug Metab Dispos. 2007 Jan;35(1):9-16.
DM4I1JP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17020954

DMN0LP8	DI	DMN0LP8
DMN0LP8	DN	Polymyxin B Sulfate
DMN0LP8	MI	TT4ILYC
DMN0LP8	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMN0LP8	MT	DTT
DMN0LP8	MA	Binder
DMN0LP8	RN	Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother. 1999 Sep;33(9):960-7.
DMN0LP8	RU	https://pubmed.ncbi.nlm.nih.gov/10492501

DMJAOT1	DI	DMJAOT1
DMJAOT1	DN	Polyoxidonium
DMJAOT1	MI	TT3J5ZI
DMJAOT1	MN	Cell mediated immunity response (CMIR)
DMJAOT1	MT	DTT
DMJAOT1	MA	Modulator
DMJAOT1	RN	Effect of polyoxidonium on the phagocytic activity of human peripheral blood leukocytes. Russ J Immunol. 2003 Apr;8(1):53-60.
DMJAOT1	RU	https://pubmed.ncbi.nlm.nih.gov/12717555

DMCH80F	DI	DMCH80F
DMCH80F	DN	Polythiazide
DMCH80F	MI	TTP362L
DMCH80F	MN	Solute carrier family 12 member 3 (SLC12A3)
DMCH80F	MT	DTT
DMCH80F	MA	Blocker
DMCH80F	RN	The renal thiazide-sensitive Na-Cl cotransporter as mediator of the aldosterone-escape phenomenon. J Clin Invest. 2001 Jul;108(2):215-22.
DMCH80F	RU	https://pubmed.ncbi.nlm.nih.gov/11457874

DMTGBAX	DI	DMTGBAX
DMTGBAX	DN	Pomalidomide
DMTGBAX	MI	TTDIBYJ
DMTGBAX	MN	Angiogenesis/myeloma cell growth (AMCG)
DMTGBAX	MT	DTT
DMTGBAX	MA	Modulator
DMTGBAX	RN	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
DMTGBAX	RU	https://pubmed.ncbi.nlm.nih.gov/28919714

DMTGBAX	DI	DMTGBAX
DMTGBAX	DN	Pomalidomide
DMTGBAX	MI	DEJGDUW
DMTGBAX	MN	Cytochrome P450 1A2 (CYP1A2)
DMTGBAX	MT	DME
DMTGBAX	MA	Metabolism
DMTGBAX	RN	Population pharmacokinetics of pomalidomide. J Clin Pharmacol. 2015 May;55(5):563-72.
DMTGBAX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25556560

DMTGBAX	DI	DMTGBAX
DMTGBAX	DN	Pomalidomide
DMTGBAX	MI	DE4LYSA
DMTGBAX	MN	Cytochrome P450 3A4 (CYP3A4)
DMTGBAX	MT	DME
DMTGBAX	MA	Metabolism
DMTGBAX	RN	Pomalidomide: evaluation of cytochrome P450 and transporter-mediated drug-drug interaction potential in vitro and in healthy subjects. J Clin Pharmacol. 2015 Feb;55(2):168-78.
DMTGBAX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25159194

DMTGBAX	DI	DMTGBAX
DMTGBAX	DN	Pomalidomide
DMTGBAX	MI	DTUGYRD
DMTGBAX	MN	P-glycoprotein 1 (ABCB1)
DMTGBAX	MT	DTP
DMTGBAX	MA	Substrate
DMTGBAX	RN	DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB08910)
DMTGBAX	RU	https://www.drugbank.ca/drugs/DB08910

DMYGJQO	DI	DMYGJQO
DMYGJQO	DN	Ponatinib
DMYGJQO	MI	DTI7UX6
DMYGJQO	MN	Breast cancer resistance protein (ABCG2)
DMYGJQO	MT	DTP
DMYGJQO	MA	Substrate
DMYGJQO	RN	DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB08901)
DMYGJQO	RU	https://www.drugbank.ca/drugs/DB08901

DMYGJQO	DI	DMYGJQO
DMYGJQO	DN	Ponatinib
DMYGJQO	MI	DECB0K3
DMYGJQO	MN	Cytochrome P450 2D6 (CYP2D6)
DMYGJQO	MT	DME
DMYGJQO	MA	Metabolism
DMYGJQO	RN	Novel pathways of ponatinib disposition catalyzed by CYP1A1 involving generation of potentially toxic metabolites. J Pharmacol Exp Ther. 2017 Oct;363(1):12-19.
DMYGJQO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28882992

DMYGJQO	DI	DMYGJQO
DMYGJQO	DN	Ponatinib
DMYGJQO	MI	DE4LYSA
DMYGJQO	MN	Cytochrome P450 3A4 (CYP3A4)
DMYGJQO	MT	DME
DMYGJQO	MA	Metabolism
DMYGJQO	RN	Evaluation of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects. Clin Pharmacol Drug Dev. 2015 Sep;4(5):354-60.
DMYGJQO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27137144

DMYGJQO	DI	DMYGJQO
DMYGJQO	DN	Ponatinib
DMYGJQO	MI	DEIBDNY
DMYGJQO	MN	Cytochrome P450 3A5 (CYP3A5)
DMYGJQO	MT	DME
DMYGJQO	MA	Metabolism
DMYGJQO	RN	Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia. Onco Targets Ther. 2013 Aug 20;6:1111-8.
DMYGJQO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23986642

DMYGJQO	DI	DMYGJQO
DMYGJQO	DN	Ponatinib
DMYGJQO	MI	TTGJCWZ
DMYGJQO	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMYGJQO	MT	DTT
DMYGJQO	MA	Modulator
DMYGJQO	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMYGJQO	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMYGJQO	DI	DMYGJQO
DMYGJQO	DN	Ponatinib
DMYGJQO	MI	DTUGYRD
DMYGJQO	MN	P-glycoprotein 1 (ABCB1)
DMYGJQO	MT	DTP
DMYGJQO	MA	Substrate
DMYGJQO	RN	DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB08901)
DMYGJQO	RU	https://www.drugbank.ca/drugs/DB08901

DMYGJQO	DI	DMYGJQO
DMYGJQO	DN	Ponatinib
DMYGJQO	MI	TT4DXQT
DMYGJQO	MN	Proto-oncogene c-Ret (RET)
DMYGJQO	MT	DTT
DMYGJQO	MA	Modulator
DMYGJQO	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMYGJQO	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMYGJQO	DI	DMYGJQO
DMYGJQO	DN	Ponatinib
DMYGJQO	MI	TT3PJMV
DMYGJQO	MN	Tyrosine-protein kinase ABL1 (ABL)
DMYGJQO	MT	DTT
DMYGJQO	MA	Modulator
DMYGJQO	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMYGJQO	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMYGJQO	DI	DMYGJQO
DMYGJQO	DN	Ponatinib
DMYGJQO	MI	TTX41N9
DMYGJQO	MN	Tyrosine-protein kinase Kit (KIT)
DMYGJQO	MT	DTT
DMYGJQO	MA	Modulator
DMYGJQO	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMYGJQO	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMEAOYJ	DI	DMEAOYJ
DMEAOYJ	DN	Ponesimod
DMEAOYJ	MI	TT9JZCK
DMEAOYJ	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMEAOYJ	MT	DTT
DMEAOYJ	MA	Agonist
DMEAOYJ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2021
DMEAOYJ	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213498s000lbl.pdf

DM7ZWNY	DI	DM7ZWNY
DM7ZWNY	DN	Porfimer Sodium
DM7ZWNY	MI	TTH0DUS
DM7ZWNY	MN	Low-density lipoprotein receptor (LDL-R)
DM7ZWNY	MT	DTT
DM7ZWNY	MA	Modulator
DM7ZWNY	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM7ZWNY	RU	https://www.fda.gov/

DMUL5EW	DI	DMUL5EW
DMUL5EW	DN	Posaconazole
DMUL5EW	MI	TTTSOUD
DMUL5EW	MN	Candida Cytochrome P450 51 (Candi ERG11)
DMUL5EW	MT	DTT
DMUL5EW	MA	Inhibitor
DMUL5EW	RN	A new, broad-spectrum azole antifungal: posaconazole--mechanisms of action and resistance, spectrum of activity. Mycoses. 2006;49 Suppl 1:2-6.
DMUL5EW	RU	https://pubmed.ncbi.nlm.nih.gov/16961575

DMUL5EW	DI	DMUL5EW
DMUL5EW	DN	Posaconazole
DMUL5EW	MI	DE4LYSA
DMUL5EW	MN	Cytochrome P450 3A4 (CYP3A4)
DMUL5EW	MT	DME
DMUL5EW	MA	Metabolism
DMUL5EW	RN	Survey of computed tomography doses and establishment of national diagnostic reference levels in the Republic of Belarus. Radiat Prot Dosimetry. 2010 Apr-May;139(1-3):367-70.
DMUL5EW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20181649

DMUL5EW	DI	DMUL5EW
DMUL5EW	DN	Posaconazole
DMUL5EW	MI	DTUGYRD
DMUL5EW	MN	P-glycoprotein 1 (ABCB1)
DMUL5EW	MT	DTP
DMUL5EW	MA	Substrate
DMUL5EW	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
DMUL5EW	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01665

DMUL5EW	DI	DMUL5EW
DMUL5EW	DN	Posaconazole
DMUL5EW	MI	DEYGVN4
DMUL5EW	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMUL5EW	MT	DME
DMUL5EW	MA	Metabolism
DMUL5EW	RN	Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Drug Metab Dispos. 2004 Feb;32(2):267-71.
DMUL5EW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14744950

DMMTAJC	DI	DMMTAJC
DMMTAJC	DN	Potassium chloride
DMMTAJC	MI	DTHKL3Q
DMMTAJC	MN	Basolateral Na-K-Cl symporter (SLC12A2)
DMMTAJC	MT	DTP
DMMTAJC	MA	Substrate
DMMTAJC	RN	Expression of the sodium potassium chloride cotransporter (NKCC1) and sodium chloride cotransporter (NCC) and their effects on rat lens transparency. Mol Vis. 2010 May 4;16:800-12.
DMMTAJC	RU	http://www.ncbi.nlm.nih.gov/pubmed/20458365

DMMTAJC	DI	DMMTAJC
DMMTAJC	DN	Potassium chloride
DMMTAJC	MI	DTO1UQY
DMMTAJC	MN	Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 2 (SLC12A1)
DMMTAJC	MT	DTP
DMMTAJC	MA	Substrate
DMMTAJC	RN	Rare mutations in renal sodium and potassium transporter genes exhibit impaired transport function. Curr Opin Nephrol Hypertens. 2014 Jan;23(1):1-8.
DMMTAJC	RU	http://www.ncbi.nlm.nih.gov/pubmed/24253496 

DMMTAJC	DI	DMMTAJC
DMMTAJC	DN	Potassium chloride
DMMTAJC	MI	DTY25IU
DMMTAJC	MN	Electroneutral potassium-chloride cotransporter 1 (SLC12A4)
DMMTAJC	MT	DTP
DMMTAJC	MA	Substrate
DMMTAJC	RN	Human potassium chloride cotransporter 1 (SLC12A4) promoter is regulated by AP-2 and contains a functional downstream promoter element. Blood. 2004 Jun 1;103(11):4302-9.
DMMTAJC	RU	http://www.ncbi.nlm.nih.gov/pubmed/14976052

DMMTAJC	DI	DMMTAJC
DMMTAJC	DN	Potassium chloride
DMMTAJC	MI	DTD62VB
DMMTAJC	MN	Electroneutral potassium-chloride cotransporter 2 (SLC12A5)
DMMTAJC	MT	DTP
DMMTAJC	MA	Substrate
DMMTAJC	RN	Tyrosine phosphorylation regulates the membrane trafficking of the potassium chloride co-transporter KCC2. Mol Cell Neurosci. 2010 Oct;45(2):173-9.
DMMTAJC	RU	http://www.ncbi.nlm.nih.gov/pubmed/20600929

DMMTAJC	DI	DMMTAJC
DMMTAJC	DN	Potassium chloride
DMMTAJC	MI	DTMA4FJ
DMMTAJC	MN	Electroneutral potassium-chloride cotransporter 3 (SLC12A6)
DMMTAJC	MT	DTP
DMMTAJC	MA	Substrate
DMMTAJC	RN	Functional analysis of a potassium-chloride co-transporter 3 (SLC12A6) promoter polymorphism leading to an additional DNA methylation site. Neuropsychopharmacology. 2009 Jan;34(2):458-67.
DMMTAJC	RU	http://www.ncbi.nlm.nih.gov/pubmed/18536702

DMMTAJC	DI	DMMTAJC
DMMTAJC	DN	Potassium chloride
DMMTAJC	MI	DT3HUVD
DMMTAJC	MN	Organic cation/carnitine transporter 2 (SLC22A5)
DMMTAJC	MT	DTP
DMMTAJC	MA	Substrate
DMMTAJC	RN	Mutations affecting GABAergic signaling in seizures and epilepsy. Pflugers Arch. 2010 Jul;460(2):505-23.
DMMTAJC	RU	http://www.ncbi.nlm.nih.gov/pubmed/20352446

DMMTAJC	DI	DMMTAJC
DMMTAJC	DN	Potassium chloride
DMMTAJC	MI	TTS087L
DMMTAJC	MN	Solute carrier family 12 member 1 (SLC12A1)
DMMTAJC	MT	DTT
DMMTAJC	MA	Modulator
DMMTAJC	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMMTAJC	RU	https://www.fda.gov/

DMGLZ26	DI	DMGLZ26
DMGLZ26	DN	Practolol
DMGLZ26	MI	TTR6W5O
DMGLZ26	MN	Adrenergic receptor beta-1 (ADRB1)
DMGLZ26	MT	DTT
DMGLZ26	MA	Antagonist
DMGLZ26	RN	Prostaglandin E2 synthesis elicited by adrenergic stimuli in guinea pig trachea is mediated primarily via activation of beta 2 adrenergic receptors. Prostaglandins. 1992 Nov;44(5):399-412.
DMGLZ26	RU	https://pubmed.ncbi.nlm.nih.gov/1335153

DMGLZ26	DI	DMGLZ26
DMGLZ26	DN	Practolol
DMGLZ26	MI	DECB0K3
DMGLZ26	MN	Cytochrome P450 2D6 (CYP2D6)
DMGLZ26	MT	DME
DMGLZ26	MA	Metabolism
DMGLZ26	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DMGLZ26	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DMAO80I	DI	DMAO80I
DMAO80I	DN	Pralatrexate
DMAO80I	MI	DTOSN46
DMAO80I	MN	Folate transporter 1 (SLC19A1)
DMAO80I	MT	DTP
DMAO80I	MA	Substrate
DMAO80I	RN	Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist Updat. 2012 Aug;15(4):183-210.
DMAO80I	RU	http://www.ncbi.nlm.nih.gov/pubmed/22921318

DMAO80I	DI	DMAO80I
DMAO80I	DN	Pralatrexate
DMAO80I	MI	DECWT2V
DMAO80I	MN	Folylpolyglutamate synthase (FPGS)
DMAO80I	MT	DME
DMAO80I	MA	Metabolism
DMAO80I	RN	Pralatrexate : evaluation of clinical efficacy and toxicity in T-cell lymphoma. Expert Opin Pharmacother. 2013 Mar;14(4):515-23.
DMAO80I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23409799

DMAO80I	DI	DMAO80I
DMAO80I	DN	Pralatrexate
DMAO80I	MI	TT9SL3Q
DMAO80I	MN	Polypeptide deformylase (PDF)
DMAO80I	MT	DTT
DMAO80I	MA	Inhibitor
DMAO80I	RN	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
DMAO80I	RU	https://pubmed.ncbi.nlm.nih.gov/20118952

DMAO80I	DI	DMAO80I
DMAO80I	DN	Pralatrexate
DMAO80I	MI	DTDJEMI
DMAO80I	MN	Proton-coupled folate transporter (SLC46A1)
DMAO80I	MT	DTP
DMAO80I	MA	Substrate
DMAO80I	RN	Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist Updat. 2012 Aug;15(4):183-210.
DMAO80I	RU	http://www.ncbi.nlm.nih.gov/pubmed/22921318

DMGQ0ZI	DI	DMGQ0ZI
DMGQ0ZI	DN	Pralidoxime chloride
DMGQ0ZI	MI	TT1RS9F
DMGQ0ZI	MN	Acetylcholinesterase (AChE)
DMGQ0ZI	MT	DTT
DMGQ0ZI	MA	Modulator
DMGQ0ZI	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMGQ0ZI	RU	https://www.fda.gov/

DMWU0I2	DI	DMWU0I2
DMWU0I2	DN	Pralsetinib
DMWU0I2	MI	TT4DXQT
DMWU0I2	MN	Proto-oncogene c-Ret (RET)
DMWU0I2	MT	DTT
DMWU0I2	MA	Inhibitor
DMWU0I2	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMWU0I2	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213721s000lbl.pdf

DMNMW9R	DI	DMNMW9R
DMNMW9R	DN	Pramipexole
DMNMW9R	MI	TTEX248
DMNMW9R	MN	Dopamine D2 receptor (D2R)
DMNMW9R	MT	DTT
DMNMW9R	MA	Modulator
DMNMW9R	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMNMW9R	RU	https://www.fda.gov/

DMNMW9R	DI	DMNMW9R
DMNMW9R	DN	Pramipexole
DMNMW9R	MI	TT4C8EA
DMNMW9R	MN	Dopamine D3 receptor (D3R)
DMNMW9R	MT	DTT
DMNMW9R	MA	Modulator
DMNMW9R	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMNMW9R	RU	https://www.fda.gov/

DMNMW9R	DI	DMNMW9R
DMNMW9R	DN	Pramipexole
DMNMW9R	MI	DTT79CX
DMNMW9R	MN	Organic cation transporter 1 (SLC22A1)
DMNMW9R	MT	DTP
DMNMW9R	MA	Substrate
DMNMW9R	RN	OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users. Neurogenetics. 2011 Feb;12(1):79-82.
DMNMW9R	RU	http://www.ncbi.nlm.nih.gov/pubmed/20680652

DMNMW9R	DI	DMNMW9R
DMNMW9R	DN	Pramipexole
DMNMW9R	MI	DT9IDPW
DMNMW9R	MN	Organic cation transporter 2 (SLC22A2)
DMNMW9R	MT	DTP
DMNMW9R	MA	Substrate
DMNMW9R	RN	Uptake of pramipexole by human organic cation transporters. Mol Pharm. 2010 Aug 2;7(4):1342-7.
DMNMW9R	RU	http://www.ncbi.nlm.nih.gov/pubmed/20496886

DM2FHG3	DI	DM2FHG3
DM2FHG3	DN	Pramiracetam
DM2FHG3	MI	TTH18TF
DM2FHG3	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DM2FHG3	MT	DTT
DM2FHG3	MA	Modulator
DM2FHG3	RN	Some neurochemical properties of pramiracetam (CI-879), a new cognition-enhancing agent. Article first published online: 5 OCT 2004.
DM2FHG3	RU	http://onlinelibrary.wiley.com/doi/10.1002/ddr.430030503/abstract

DM0EZ9Q	DI	DM0EZ9Q
DM0EZ9Q	DN	Pramlintide
DM0EZ9Q	MI	TTVIMDE
DM0EZ9Q	MN	Glucagon-like peptide 1 receptor (GLP1R)
DM0EZ9Q	MT	DTT
DM0EZ9Q	MA	Agonist
DM0EZ9Q	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DM0EZ9Q	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMYHDCA	DI	DMYHDCA
DMYHDCA	DN	Pranlukast
DMYHDCA	MI	DE4LYSA
DMYHDCA	MN	Cytochrome P450 3A4 (CYP3A4)
DMYHDCA	MT	DME
DMYHDCA	MA	Metabolism
DMYHDCA	RN	Effect of clarithromycin on the pharmacokinetics of pranlukast in healthy volunteers. Drug Metab Pharmacokinet. 2008;23(6):428-33.;
DMYHDCA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19122337

DMYHDCA	DI	DMYHDCA
DMYHDCA	DN	Pranlukast
DMYHDCA	MI	TTGKOY9
DMYHDCA	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DMYHDCA	MT	DTT
DMYHDCA	MA	Antagonist
DMYHDCA	RN	Beneficial effects of leukotriene receptor antagonists in the prevention of cedar pollinosis in a community setting. J Investig Allergol Clin Immunol. 2009;19(3):195-203.
DMYHDCA	RU	https://pubmed.ncbi.nlm.nih.gov/19610262

DM67VKL	DI	DM67VKL
DM67VKL	DN	Prasterone
DM67VKL	MI	TTS64P2
DM67VKL	MN	Androgen receptor (AR)
DM67VKL	MT	DTT
DM67VKL	MA	Antagonist
DM67VKL	RN	Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res Rev. 2004 Apr;3(2):171-87.
DM67VKL	RU	https://pubmed.ncbi.nlm.nih.gov/15177053

DM67VKL	DI	DM67VKL
DM67VKL	DN	Prasterone
DM67VKL	MI	DEQX145
DM67VKL	MN	Aromatase (CYP19A1)
DM67VKL	MT	DME
DM67VKL	MA	Metabolism
DM67VKL	RN	Urinary and serum octopamine in patients with portal-systemic encephalopathy. Lancet. 1975 Nov 15;2(7942):943-6.
DM67VKL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=53430

DM67VKL	DI	DM67VKL
DM67VKL	DN	Prasterone
DM67VKL	MI	DEN0GVQ
DM67VKL	MN	Beta-HSD adrenal and gonadal type (HSD3B2)
DM67VKL	MT	DME
DM67VKL	MA	Metabolism
DM67VKL	RN	Selective inhibition of human 3beta-hydroxysteroid dehydrogenase type 1 as a potential treatment for breast cancer. J Steroid Biochem Mol Biol. 2011 May;125(1-2):57-65.
DM67VKL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20736065

DM67VKL	DI	DM67VKL
DM67VKL	DN	Prasterone
DM67VKL	MI	DTI7UX6
DM67VKL	MN	Breast cancer resistance protein (ABCG2)
DM67VKL	MT	DTP
DM67VKL	MA	Substrate
DM67VKL	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM67VKL	RU	https://doi.org/10.1007/s11095-012-0935-x

DM67VKL	DI	DM67VKL
DM67VKL	DN	Prasterone
DM67VKL	MI	DE4LYSA
DM67VKL	MN	Cytochrome P450 3A4 (CYP3A4)
DM67VKL	MT	DME
DM67VKL	MA	Metabolism
DM67VKL	RN	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
DM67VKL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9667077

DM67VKL	DI	DM67VKL
DM67VKL	DN	Prasterone
DM67VKL	MI	DERD86B
DM67VKL	MN	Cytochrome P450 3A7 (CYP3A7)
DM67VKL	MT	DME
DM67VKL	MA	Metabolism
DM67VKL	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM67VKL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM67VKL	DI	DM67VKL
DM67VKL	DN	Prasterone
DM67VKL	MI	DE36TMY
DM67VKL	MN	Cytochrome P450 7B1 (CYP7B1)
DM67VKL	MT	DME
DM67VKL	MA	Metabolism
DM67VKL	RN	CYP7B1-mediated metabolism of dehydroepiandrosterone and 5alpha-androstane-3beta,17beta-diol--potential role(s) for estrogen signaling. FEBS J. 2008 Apr;275(8):1778-89.
DM67VKL	RU	https://pubmed.ncbi.nlm.nih.gov/18331353

DM67VKL	DI	DM67VKL
DM67VKL	DN	Prasterone
DM67VKL	MI	DERDQWN
DM67VKL	MN	Dihydrotestosterone oxidoreductase (HSD3B1)
DM67VKL	MT	DME
DM67VKL	MA	Metabolism
DM67VKL	RN	Selective inhibition of human 3beta-hydroxysteroid dehydrogenase type 1 as a potential treatment for breast cancer. J Steroid Biochem Mol Biol. 2011 May;125(1-2):57-65.
DM67VKL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20736065

DM67VKL	DI	DM67VKL
DM67VKL	DN	Prasterone
DM67VKL	MI	DEZS5YK
DM67VKL	MN	Estradiol 17-beta-dehydrogenase 1 (HSD17B1)
DM67VKL	MT	DME
DM67VKL	MA	Metabolism
DM67VKL	RN	Steroid signalling in the ovarian surface epithelium. Trends Endocrinol Metab. 2005 Sep;16(7):327-33.
DM67VKL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16054388

DM67VKL	DI	DM67VKL
DM67VKL	DN	Prasterone
DM67VKL	MI	DEBMFZ8
DM67VKL	MN	Estradiol 17-beta-dehydrogenase 2 (HSD17B2)
DM67VKL	MT	DME
DM67VKL	MA	Metabolism
DM67VKL	RN	Steroid signalling in the ovarian surface epithelium. Trends Endocrinol Metab. 2005 Sep;16(7):327-33.
DM67VKL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16054388

DM67VKL	DI	DM67VKL
DM67VKL	DN	Prasterone
DM67VKL	MI	TTKN8W0
DM67VKL	MN	Glucose-6-phosphate dehydrogenase (G6PD)
DM67VKL	MT	DTT
DM67VKL	MA	Inhibitor
DM67VKL	RN	Glucose utilization and activity of glucose-6-phosphate dehydrogenase, isocitrate dehydrogenase and malate dehydrogenase in rat erythrocytes after treatment with tuberculostatic agents. Vopr Med Khim. 1986 Sep-Oct;32(5):32-5.
DM67VKL	RU	https://pubmed.ncbi.nlm.nih.gov/3776114

DM67VKL	DI	DM67VKL
DM67VKL	DN	Prasterone
DM67VKL	MI	DTCSGPB
DM67VKL	MN	Multidrug resistance-associated protein 4 (ABCC4)
DM67VKL	MT	DTP
DM67VKL	MA	Substrate
DM67VKL	RN	Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J. 2003 Apr 15;371(Pt 2):361-7.
DM67VKL	RU	http://www.ncbi.nlm.nih.gov/pubmed/12523936

DM67VKL	DI	DM67VKL
DM67VKL	DN	Prasterone
DM67VKL	MI	DTWN7FC
DM67VKL	MN	Multidrug resistance-associated protein 8 (ABCC11)
DM67VKL	MT	DTP
DM67VKL	MA	Substrate
DM67VKL	RN	Human multidrug resistance protein 8 (MRP8/ABCC11), an apical efflux pump for steroid sulfates, is an axonal protein of the CNS and peripheral nervous system. Neuroscience. 2006;137(4):1247-57.
DM67VKL	RU	http://www.ncbi.nlm.nih.gov/pubmed/16359813

DM67VKL	DI	DM67VKL
DM67VKL	DN	Prasterone
DM67VKL	MI	DTVP67E
DM67VKL	MN	Organic anion transporter 3 (SLC22A8)
DM67VKL	MT	DTP
DM67VKL	MA	Substrate
DM67VKL	RN	Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86.
DM67VKL	RU	http://www.ncbi.nlm.nih.gov/pubmed/11306713

DM67VKL	DI	DM67VKL
DM67VKL	DN	Prasterone
DM67VKL	MI	DEJHG19
DM67VKL	MN	Peroxisomal multifunctional enzyme 2 (HSD17B4)
DM67VKL	MT	DME
DM67VKL	MA	Metabolism
DM67VKL	RN	Steroid signalling in the ovarian surface epithelium. Trends Endocrinol Metab. 2005 Sep;16(7):327-33.
DM67VKL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16054388

DM67VKL	DI	DM67VKL
DM67VKL	DN	Prasterone
DM67VKL	MI	DE0P6LK
DM67VKL	MN	Sulfotransferase 2A1 (SULT2A1)
DM67VKL	MT	DME
DM67VKL	MA	Metabolism
DM67VKL	RN	Sulfation of environmental estrogens by cytosolic human sulfotransferases. Drug Metab Pharmacokinet. 2002;17(3):221-8.
DM67VKL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15618673

DM67VKL	DI	DM67VKL
DM67VKL	DN	Prasterone
DM67VKL	MI	DEZBN53
DM67VKL	MN	Sulfotransferase 2B1 (SULT2B1)
DM67VKL	MT	DME
DM67VKL	MA	Metabolism
DM67VKL	RN	Expression and characterization of the human 3 beta-hydroxysteroid sulfotransferases (SULT2B1a and SULT2B1b). J Steroid Biochem Mol Biol. 2001 Jun;77(4-5):261-9.
DM67VKL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11457664

DM7MT6E	DI	DM7MT6E
DM7MT6E	DN	Prasugrel
DM7MT6E	MI	DEPKLMQ
DM7MT6E	MN	Cytochrome P450 2B6 (CYP2B6)
DM7MT6E	MT	DME
DM7MT6E	MA	Metabolism
DM7MT6E	RN	The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs. 2012 Nov 12;72(16):2087-116.
DM7MT6E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23083110

DM7MT6E	DI	DM7MT6E
DM7MT6E	DN	Prasugrel
DM7MT6E	MI	DE5IED8
DM7MT6E	MN	Cytochrome P450 2C9 (CYP2C9)
DM7MT6E	MT	DME
DM7MT6E	MA	Metabolism
DM7MT6E	RN	The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs. 2012 Nov 12;72(16):2087-116.
DM7MT6E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23083110

DM7MT6E	DI	DM7MT6E
DM7MT6E	DN	Prasugrel
DM7MT6E	MI	DE4LYSA
DM7MT6E	MN	Cytochrome P450 3A4 (CYP3A4)
DM7MT6E	MT	DME
DM7MT6E	MA	Metabolism
DM7MT6E	RN	The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs. 2012 Nov 12;72(16):2087-116.
DM7MT6E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23083110

DM7MT6E	DI	DM7MT6E
DM7MT6E	DN	Prasugrel
DM7MT6E	MI	DEGTFWK
DM7MT6E	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM7MT6E	MT	DME
DM7MT6E	MA	Metabolism
DM7MT6E	RN	The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs. 2012 Nov 12;72(16):2087-116.
DM7MT6E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23083110

DM7MT6E	DI	DM7MT6E
DM7MT6E	DN	Prasugrel
DM7MT6E	MI	TTZ1DT0
DM7MT6E	MN	P2Y purinoceptor 12 (P2RY12)
DM7MT6E	MT	DTT
DM7MT6E	MA	Inhibitor
DM7MT6E	RN	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
DM7MT6E	RU	https://pubmed.ncbi.nlm.nih.gov/20118952

DM6A0X7	DI	DM6A0X7
DM6A0X7	DN	Pravastatin
DM6A0X7	MI	DTJ0EW4
DM6A0X7	MN	Bile salt export pump (ABCB11)
DM6A0X7	MT	DTP
DM6A0X7	MA	Substrate
DM6A0X7	RN	Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin. J Pharmacol Exp Ther. 2005 Aug;314(2):876-82.
DM6A0X7	RU	http://www.ncbi.nlm.nih.gov/pubmed/15901796

DM6A0X7	DI	DM6A0X7
DM6A0X7	DN	Pravastatin
DM6A0X7	MI	DTI7UX6
DM6A0X7	MN	Breast cancer resistance protein (ABCG2)
DM6A0X7	MT	DTP
DM6A0X7	MA	Substrate
DM6A0X7	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM6A0X7	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DM6A0X7	DI	DM6A0X7
DM6A0X7	DN	Pravastatin
DM6A0X7	MI	DE5IED8
DM6A0X7	MN	Cytochrome P450 2C9 (CYP2C9)
DM6A0X7	MT	DME
DM6A0X7	MA	Metabolism
DM6A0X7	RN	In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol. 1996;50(3):209-15.
DM6A0X7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8737761

DM6A0X7	DI	DM6A0X7
DM6A0X7	DN	Pravastatin
DM6A0X7	MI	DE4LYSA
DM6A0X7	MN	Cytochrome P450 3A4 (CYP3A4)
DM6A0X7	MT	DME
DM6A0X7	MA	Metabolism
DM6A0X7	RN	Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clin Pharmacokinet. 2000 Dec;39(6):397-412.
DM6A0X7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11192473

DM6A0X7	DI	DM6A0X7
DM6A0X7	DN	Pravastatin
DM6A0X7	MI	DEIBDNY
DM6A0X7	MN	Cytochrome P450 3A5 (CYP3A5)
DM6A0X7	MT	DME
DM6A0X7	MA	Metabolism
DM6A0X7	RN	Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab Dispos. 1999 Feb;27(2):173-9.
DM6A0X7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9929499

DM6A0X7	DI	DM6A0X7
DM6A0X7	DN	Pravastatin
DM6A0X7	MI	TTPADOQ
DM6A0X7	MN	HMG-CoA reductase (HMGCR)
DM6A0X7	MT	DTT
DM6A0X7	MA	Inhibitor
DM6A0X7	RN	A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis. 2002 Jun;162(2):373-9.
DM6A0X7	RU	https://pubmed.ncbi.nlm.nih.gov/11996957

DM6A0X7	DI	DM6A0X7
DM6A0X7	DN	Pravastatin
DM6A0X7	MI	DTFI42L
DM6A0X7	MN	Multidrug resistance-associated protein 2 (ABCC2)
DM6A0X7	MT	DTP
DM6A0X7	MA	Substrate
DM6A0X7	RN	Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney. J Control Release. 2002 Jan 17;78(1-3):43-54.
DM6A0X7	RU	http://www.ncbi.nlm.nih.gov/pubmed/11772448

DM6A0X7	DI	DM6A0X7
DM6A0X7	DN	Pravastatin
DM6A0X7	MI	DTVP67E
DM6A0X7	MN	Organic anion transporter 3 (SLC22A8)
DM6A0X7	MT	DTP
DM6A0X7	MA	Substrate
DM6A0X7	RN	Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab Dispos. 2011 Jun;39(6):1031-8.
DM6A0X7	RU	http://www.ncbi.nlm.nih.gov/pubmed/21383204

DM6A0X7	DI	DM6A0X7
DM6A0X7	DN	Pravastatin
DM6A0X7	MI	DT06JWZ
DM6A0X7	MN	Organic anion transporter 4 (SLC22A11)
DM6A0X7	MT	DTP
DM6A0X7	MA	Substrate
DM6A0X7	RN	Inhibition of human organic anion transporter 3 mediated pravastatin transport by gemfibrozil and the metabolites in humans. Xenobiotica. 2007 Apr;37(4):416-26.
DM6A0X7	RU	http://www.ncbi.nlm.nih.gov/pubmed/17455113

DM6A0X7	DI	DM6A0X7
DM6A0X7	DN	Pravastatin
DM6A0X7	MI	DTDI5S3
DM6A0X7	MN	Organic anion transporter 7 (SLC22A9)
DM6A0X7	MT	DTP
DM6A0X7	MA	Substrate
DM6A0X7	RN	Variability in hepatic expression of organic anion transporter 7/SLC22A9, a novel pravastatin uptake transporter: impact of genetic and regulatory factors. Pharmacogenomics J. 2016 Aug;16(4):341-51.
DM6A0X7	RU	http://www.ncbi.nlm.nih.gov/pubmed/26239079

DM6A0X7	DI	DM6A0X7
DM6A0X7	DN	Pravastatin
DM6A0X7	MI	DT3D8F0
DM6A0X7	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM6A0X7	MT	DTP
DM6A0X7	MA	Substrate
DM6A0X7	RN	The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008 May;18(5):424-33.
DM6A0X7	RU	http://www.ncbi.nlm.nih.gov/pubmed/18408565

DM6A0X7	DI	DM6A0X7
DM6A0X7	DN	Pravastatin
DM6A0X7	MI	DT9C1TS
DM6A0X7	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM6A0X7	MT	DTP
DM6A0X7	MA	Substrate
DM6A0X7	RN	Relevance of conserved lysine and arginine residues in transmembrane helices for the transport activity of organic anion transporting polypeptide 1B3. Br J Pharmacol. 2010 Feb 1;159(3):698-708.
DM6A0X7	RU	http://www.ncbi.nlm.nih.gov/pubmed/20100277

DM6A0X7	DI	DM6A0X7
DM6A0X7	DN	Pravastatin
DM6A0X7	MI	DTPFTEQ
DM6A0X7	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DM6A0X7	MT	DTP
DM6A0X7	MA	Substrate
DM6A0X7	RN	Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther. 2004 Feb;308(2):438-45.
DM6A0X7	RU	http://www.ncbi.nlm.nih.gov/pubmed/14610227

DM6A0X7	DI	DM6A0X7
DM6A0X7	DN	Pravastatin
DM6A0X7	MI	DTUGYRD
DM6A0X7	MN	P-glycoprotein 1 (ABCB1)
DM6A0X7	MT	DTP
DM6A0X7	MA	Substrate
DM6A0X7	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DM6A0X7	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DM6A0X7	DI	DM6A0X7
DM6A0X7	DN	Pravastatin
DM6A0X7	MI	DTHE530
DM6A0X7	MN	Probable small intestine urate exporter (SLC17A4)
DM6A0X7	MT	DTP
DM6A0X7	MA	Substrate
DM6A0X7	RN	A Na+-phosphate cotransporter homologue (SLC17A4 protein) is an intestinal organic anion exporter. Am J Physiol Cell Physiol. 2012 Jun 1;302(11):C1652-60.
DM6A0X7	RU	http://www.ncbi.nlm.nih.gov/pubmed/22460716

DMEWC7N	DI	DMEWC7N
DMEWC7N	DN	Prazepam
DMEWC7N	MI	DE4LYSA
DMEWC7N	MN	Cytochrome P450 3A4 (CYP3A4)
DMEWC7N	MT	DME
DMEWC7N	MA	Metabolism
DMEWC7N	RN	Metabolic profile of oxazepam and related benzodiazepines: clinical and forensic aspects. Drug Metab Rev. 2017 Nov;49(4):451-463.
DMEWC7N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28903606

DMEWC7N	DI	DMEWC7N
DMEWC7N	DN	Prazepam
DMEWC7N	MI	TTPTXIN
DMEWC7N	MN	Translocator protein (TSPO)
DMEWC7N	MT	DTT
DMEWC7N	MA	Modulator
DMEWC7N	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMEWC7N	RU	https://www.fda.gov/

DMOU1PK	DI	DMOU1PK
DMOU1PK	DN	Praziquantel
DMOU1PK	MI	DEJGDUW
DMOU1PK	MN	Cytochrome P450 1A2 (CYP1A2)
DMOU1PK	MT	DME
DMOU1PK	MA	Metabolism
DMOU1PK	RN	Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
DMOU1PK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920490

DMOU1PK	DI	DMOU1PK
DMOU1PK	DN	Praziquantel
DMOU1PK	MI	DE4LYSA
DMOU1PK	MN	Cytochrome P450 3A4 (CYP3A4)
DMOU1PK	MT	DME
DMOU1PK	MA	Metabolism
DMOU1PK	RN	Biotransformation of praziquantel by human cytochrome p450 3A4 (CYP 3A4). Acta Pol Pharm. 2006 Sep-Oct;63(5):381-5.
DMOU1PK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17357589

DMOU1PK	DI	DMOU1PK
DMOU1PK	DN	Praziquantel
DMOU1PK	MI	DEO1IE3
DMOU1PK	MN	Cytochrome P450 3A43 (CYP3A43)
DMOU1PK	MT	DME
DMOU1PK	MA	Metabolism
DMOU1PK	RN	Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers. Clin Pharmacol Ther. 2002 Nov;72(5):505-13.
DMOU1PK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12426514

DMOU1PK	DI	DMOU1PK
DMOU1PK	DN	Praziquantel
DMOU1PK	MI	DEIBDNY
DMOU1PK	MN	Cytochrome P450 3A5 (CYP3A5)
DMOU1PK	MT	DME
DMOU1PK	MA	Metabolism
DMOU1PK	RN	Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers. Clin Pharmacol Ther. 2002 Nov;72(5):505-13.
DMOU1PK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12426514

DMOU1PK	DI	DMOU1PK
DMOU1PK	DN	Praziquantel
DMOU1PK	MI	DERD86B
DMOU1PK	MN	Cytochrome P450 3A7 (CYP3A7)
DMOU1PK	MT	DME
DMOU1PK	MA	Metabolism
DMOU1PK	RN	Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers. Clin Pharmacol Ther. 2002 Nov;72(5):505-13.
DMOU1PK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12426514

DMOU1PK	DI	DMOU1PK
DMOU1PK	DN	Praziquantel
DMOU1PK	MI	TTCYE56
DMOU1PK	MN	Glutathione-dependent PGD synthase (HPGDS)
DMOU1PK	MT	DTT
DMOU1PK	MA	Inhibitor
DMOU1PK	RN	X-ray structure of glutathione S-transferase from Schistosoma japonicum in a new crystal form reveals flexibility of the substrate-binding site. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2005 Mar 1;61(Pt 3):263-5.
DMOU1PK	RU	https://pubmed.ncbi.nlm.nih.gov/16511012

DMOU1PK	DI	DMOU1PK
DMOU1PK	DN	Praziquantel
DMOU1PK	MI	DEGTFWK
DMOU1PK	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMOU1PK	MT	DME
DMOU1PK	MA	Metabolism
DMOU1PK	RN	Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
DMOU1PK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920490

DMCD9YG	DI	DMCD9YG
DMCD9YG	DN	Prazosin
DMCD9YG	MI	TTG28O6
DMCD9YG	MN	Adrenergic receptor Alpha-1 (ADRA1)
DMCD9YG	MT	DTT
DMCD9YG	MA	Antagonist
DMCD9YG	RN	Adventitia removal does not modify the alphaID-adrenoceptors response in aorta during hypertension and ageing. Auton Autacoid Pharmacol. 2009 Jul;29(3):117-33.
DMCD9YG	RU	https://pubmed.ncbi.nlm.nih.gov/19566752

DMCD9YG	DI	DMCD9YG
DMCD9YG	DN	Prazosin
DMCD9YG	MI	DTI7UX6
DMCD9YG	MN	Breast cancer resistance protein (ABCG2)
DMCD9YG	MT	DTP
DMCD9YG	MA	Substrate
DMCD9YG	RN	P-glycoprotein and breast cancer resistance protein expression and function at the blood-brain barrier and blood-cerebrospinal fluid barrier (choroid plexus) in streptozotocin-induced diabetes in rats. Brain Res. 2011 Jan 25;1370:238-45.
DMCD9YG	RU	http://www.ncbi.nlm.nih.gov/pubmed/21075088

DMCD9YG	DI	DMCD9YG
DMCD9YG	DN	Prazosin
DMCD9YG	MI	DE6OQ3W
DMCD9YG	MN	Cytochrome P450 1A1 (CYP1A1)
DMCD9YG	MT	DME
DMCD9YG	MA	Metabolism
DMCD9YG	RN	Role of adrenoceptor-linked signaling pathways in the regulation of CYP1A1 gene expression. Biochem Pharmacol. 2005 Jan 15;69(2):277-87.
DMCD9YG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15627480

DMCD9YG	DI	DMCD9YG
DMCD9YG	DN	Prazosin
DMCD9YG	MI	DTT79CX
DMCD9YG	MN	Organic cation transporter 1 (SLC22A1)
DMCD9YG	MT	DTP
DMCD9YG	MA	Substrate
DMCD9YG	RN	Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
DMCD9YG	RU	https://doi.org/10.1016/j.canlet.2005.06.051

DMCD9YG	DI	DMCD9YG
DMCD9YG	DN	Prazosin
DMCD9YG	MI	DTUGYRD
DMCD9YG	MN	P-glycoprotein 1 (ABCB1)
DMCD9YG	MT	DTP
DMCD9YG	MA	Substrate
DMCD9YG	RN	Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10594-9.
DMCD9YG	RU	http://www.ncbi.nlm.nih.gov/pubmed/9380680

DMBUNVW	DI	DMBUNVW
DMBUNVW	DN	Prednicarbate
DMBUNVW	MI	DE4LYSA
DMBUNVW	MN	Cytochrome P450 3A4 (CYP3A4)
DMBUNVW	MT	DME
DMBUNVW	MA	Metabolism
DMBUNVW	RN	HEP Drug interaction: daclatasvir and abacavir.
DMBUNVW	RU	https://hep-druginteractions.org/interactions/1205/all

DMBUNVW	DI	DMBUNVW
DMBUNVW	DN	Prednicarbate
DMBUNVW	MI	TTP3UTW
DMBUNVW	MN	Steroid hormone receptor ERR (ESRR)
DMBUNVW	MT	DTT
DMBUNVW	MA	Modulator
DMBUNVW	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMBUNVW	RU	https://www.fda.gov/

DMQ8FR2	DI	DMQ8FR2
DMQ8FR2	DN	Prednisolone
DMQ8FR2	MI	DE4LYSA
DMQ8FR2	MN	Cytochrome P450 3A4 (CYP3A4)
DMQ8FR2	MT	DME
DMQ8FR2	MA	Metabolism
DMQ8FR2	RN	Inter-individual difference determinant of prednisolone pharmacokinetics for Japanese renal transplant recipients in the maintenance stage. Xenobiotica. 2009 Dec;39(12):939-45.
DMQ8FR2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19795924

DMQ8FR2	DI	DMQ8FR2
DMQ8FR2	DN	Prednisolone
DMQ8FR2	MI	DEIBDNY
DMQ8FR2	MN	Cytochrome P450 3A5 (CYP3A5)
DMQ8FR2	MT	DME
DMQ8FR2	MA	Metabolism
DMQ8FR2	RN	Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats. J Pharmacokinet Biopharm. 1999 Feb;27(1):1-21.
DMQ8FR2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10533695

DMQ8FR2	DI	DMQ8FR2
DMQ8FR2	DN	Prednisolone
DMQ8FR2	MI	TTYRL6O
DMQ8FR2	MN	Glucocorticoid receptor (NR3C1)
DMQ8FR2	MT	DTT
DMQ8FR2	MA	Modulator
DMQ8FR2	RN	Aldosterone (mineralocorticoid) equivalent to prednisolone (glucocorticoid) in reversing hearing loss in MRL/MpJ-Fas1pr autoimmune mice. Laryngoscope. 2000 Nov;110(11):1902-6.
DMQ8FR2	RU	https://pubmed.ncbi.nlm.nih.gov/11081607

DMQ8FR2	DI	DMQ8FR2
DMQ8FR2	DN	Prednisolone
DMQ8FR2	MI	DTUGYRD
DMQ8FR2	MN	P-glycoprotein 1 (ABCB1)
DMQ8FR2	MT	DTP
DMQ8FR2	MA	Substrate
DMQ8FR2	RN	The role of the efflux transporter P-glycoprotein in brain penetration of prednisolone. J Endocrinol. 2002 Oct;175(1):251-60.
DMQ8FR2	RU	http://www.ncbi.nlm.nih.gov/pubmed/12379510

DM2HG4X	DI	DM2HG4X
DM2HG4X	DN	Prednisone
DM2HG4X	MI	DE4LYSA
DM2HG4X	MN	Cytochrome P450 3A4 (CYP3A4)
DM2HG4X	MT	DME
DM2HG4X	MA	Metabolism
DM2HG4X	RN	Cytochrome P450 enzyme regulation by glucocorticoids and consequences in terms of drug interaction. Expert Opin Drug Metab Toxicol. 2014 Mar;10(3):425-35.
DM2HG4X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24451000

DM2HG4X	DI	DM2HG4X
DM2HG4X	DN	Prednisone
DM2HG4X	MI	TTYRL6O
DM2HG4X	MN	Glucocorticoid receptor (NR3C1)
DM2HG4X	MT	DTT
DM2HG4X	MA	Agonist
DM2HG4X	RN	Cytochromes P450 (CYP) in the Poeciliopsis lucida hepatocellular carcinoma cell line (PLHC-1): dose- and time-dependent glucocorticoid potentiation of CYP1A induction without induction of CYP3A. ArchBiochem Biophys. 1996 May 1;329(1):113-22.
DM2HG4X	RU	https://pubmed.ncbi.nlm.nih.gov/8619627

DM2HG4X	DI	DM2HG4X
DM2HG4X	DN	Prednisone
DM2HG4X	MI	DTUGYRD
DM2HG4X	MN	P-glycoprotein 1 (ABCB1)
DM2HG4X	MT	DTP
DM2HG4X	MA	Substrate
DM2HG4X	RN	Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803.
DM2HG4X	RU	http://www.ncbi.nlm.nih.gov/pubmed/14661924

DMDVP3B	DI	DMDVP3B
DMDVP3B	DN	Pregabalin
DMDVP3B	MI	DT48T0N
DMDVP3B	MN	L-type amino acid transporter 1 (SLC7A5)
DMDVP3B	MT	DTP
DMDVP3B	MA	Substrate
DMDVP3B	RN	Transport of Pregabalin Via L-Type Amino Acid Transporter 1 (SLC7A5) in Human Brain Capillary Endothelial Cell Line. Pharm Res. 2018 Oct 29;35(12):246.
DMDVP3B	RU	http://www.ncbi.nlm.nih.gov/pubmed/30374619

DMDVP3B	DI	DMDVP3B
DMDVP3B	DN	Pregabalin
DMDVP3B	MI	TTFK1JQ
DMDVP3B	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMDVP3B	MT	DTT
DMDVP3B	MA	Modulator
DMDVP3B	RN	Pregabalin reduces the release of synaptic vesicles from cultured hippocampal neurons. Mol Pharmacol. 2006 Aug;70(2):467-76.
DMDVP3B	RU	https://pubmed.ncbi.nlm.nih.gov/16641316

DMYQVGN	DI	DMYQVGN
DMYQVGN	DN	Premarin/Trimegestone
DMYQVGN	MI	TTZAYWL
DMYQVGN	MN	Estrogen receptor (ESR)
DMYQVGN	MT	DTT
DMYQVGN	MA	Modulator
DMYQVGN	RN	The Haunting of Medical Journals: How Ghostwriting Sold RT PLoS Med. 2010 September; 7(9): e1000335.
DMYQVGN	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2935455/

DMDYA31	DI	DMDYA31
DMDYA31	DN	Pretomanid
DMDYA31	MI	DE4LYSA
DMDYA31	MN	Cytochrome P450 3A4 (CYP3A4)
DMDYA31	MT	DME
DMDYA31	MA	Metabolism
DMDYA31	RN	FDA briefing document - pretomanid tablet, 200 mg meeting of the antimicrobial drugs advisory committee (AMDAC).
DMDYA31	RU	https://www.fda.gov/media/127592/download

DMDYA31	DI	DMDYA31
DMDYA31	DN	Pretomanid
DMDYA31	MI	TT08ESN
DMDYA31	MN	Mycobacterium Mycolic acid synthase (MycB cma)
DMDYA31	MT	DTT
DMDYA31	MA	Inhibitor
DMDYA31	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMDYA31	RU	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212862Orig1s000Lbl.pdf

DMQ0C2Z	DI	DMQ0C2Z
DMQ0C2Z	DN	Prevnar
DMQ0C2Z	MI	TT9GOIR
DMQ0C2Z	MN	Streptococcus Diphtheria protein (Stre DIPP)
DMQ0C2Z	MT	DTT
DMQ0C2Z	RN	Patent WO2013131983 A1.
DMQ0C2Z	RU	http://www.google.com/patents/WO2013131983A1?cl=en

DMMZB0K	DI	DMMZB0K
DMMZB0K	DN	Prifinium
DMMZB0K	MI	TTH18TF
DMMZB0K	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMMZB0K	MT	DTT
DMMZB0K	MA	Modulator
DMMZB0K	RN	Ligand binding properties of muscarinic acetylcholine receptor subtypes (m1-m5) expressed in baculovirus-infected insect cells. J Pharmacol Exp Ther. 1995 Jul;274(1):378-84.
DMMZB0K	RU	https://pubmed.ncbi.nlm.nih.gov/7616422

DMI7DZ2	DI	DMI7DZ2
DMI7DZ2	DN	Prilocaine
DMI7DZ2	MI	TTZOVE0
DMI7DZ2	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DMI7DZ2	MT	DTT
DMI7DZ2	MA	Blocker
DMI7DZ2	RN	Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine. Pharmacol Biochem Behav. 1998 Feb;59(2):305-12.
DMI7DZ2	RU	https://pubmed.ncbi.nlm.nih.gov/9476974

DMWQ16I	DI	DMWQ16I
DMWQ16I	DN	Primaquine
DMWQ16I	MI	DEJGDUW
DMWQ16I	MN	Cytochrome P450 1A2 (CYP1A2)
DMWQ16I	MT	DME
DMWQ16I	MA	Metabolism
DMWQ16I	RN	Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
DMWQ16I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920490

DMWQ16I	DI	DMWQ16I
DMWQ16I	DN	Primaquine
DMWQ16I	MI	DE4LYSA
DMWQ16I	MN	Cytochrome P450 3A4 (CYP3A4)
DMWQ16I	MT	DME
DMWQ16I	MA	Metabolism
DMWQ16I	RN	Primaquine metabolism by human liver microsomes: effect of other antimalarial drugs. Biochem Pharmacol. 1992 Aug 4;44(3):587-90.
DMWQ16I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1510705

DMWQ16I	DI	DMWQ16I
DMWQ16I	DN	Primaquine
DMWQ16I	MI	TT698WO
DMWQ16I	MN	Plasmodium Deoxyribonucleic acid (Malaria DNA)
DMWQ16I	MT	DTT
DMWQ16I	RN	Primaquine-induced differential gene expression analysis in mice liver using DNA microarrays. Toxicology. 2007 Sep 24;239(1-2):96-107.
DMWQ16I	RU	https://pubmed.ncbi.nlm.nih.gov/17686563

DM0WX6I	DI	DM0WX6I
DM0WX6I	DN	Primidone
DM0WX6I	MI	DE5IED8
DM0WX6I	MN	Cytochrome P450 2C9 (CYP2C9)
DM0WX6I	MT	DME
DM0WX6I	MA	Metabolism
DM0WX6I	RN	Prescribrt's digital referenve - Primidone - Drug Summary.
DM0WX6I	RU	https://www.pdr.net/drug-summary/Mysoline-primidone-775

DM0WX6I	DI	DM0WX6I
DM0WX6I	DN	Primidone
DM0WX6I	MI	TT1MPAY
DM0WX6I	MN	GABA(A) receptor alpha-1 (GABRA1)
DM0WX6I	MT	DTT
DM0WX6I	MA	Antagonist
DM0WX6I	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DM0WX6I	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DM0WX6I	DI	DM0WX6I
DM0WX6I	DN	Primidone
DM0WX6I	MI	DEGTFWK
DM0WX6I	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM0WX6I	MT	DME
DM0WX6I	MA	Metabolism
DM0WX6I	RN	Clinically significant pharmacokinetic drug interactions between antiepileptic drugs. J Clin Pharm Ther. 1999 Apr;24(2):87-92.
DM0WX6I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10380060

DM9HOKG	DI	DM9HOKG
DM9HOKG	DN	Prinomastat
DM9HOKG	MI	TTMX39J
DM9HOKG	MN	Matrix metalloproteinase-1 (MMP-1)
DM9HOKG	MT	DTT
DM9HOKG	MA	Inhibitor
DM9HOKG	RN	AG-3340 (Agouron Pharmaceuticals Inc). IDrugs. 2000 Mar;3(3):336-45.
DM9HOKG	RU	https://pubmed.ncbi.nlm.nih.gov/16103944

DM9HOKG	DI	DM9HOKG
DM9HOKG	DN	Prinomastat
DM9HOKG	MI	TTLM12X
DM9HOKG	MN	Matrix metalloproteinase-2 (MMP-2)
DM9HOKG	MT	DTT
DM9HOKG	MA	Inhibitor
DM9HOKG	RN	AG-3340 (Agouron Pharmaceuticals Inc). IDrugs. 2000 Mar;3(3):336-45.
DM9HOKG	RU	https://pubmed.ncbi.nlm.nih.gov/16103944

DM9HOKG	DI	DM9HOKG
DM9HOKG	DN	Prinomastat
DM9HOKG	MI	TTMTWOS
DM9HOKG	MN	Matrix metalloproteinase-7 (MMP-7)
DM9HOKG	MT	DTT
DM9HOKG	MA	Inhibitor
DM9HOKG	RN	AG-3340 (Agouron Pharmaceuticals Inc). IDrugs. 2000 Mar;3(3):336-45.
DM9HOKG	RU	https://pubmed.ncbi.nlm.nih.gov/16103944

DMMFWOJ	DI	DMMFWOJ
DMMFWOJ	DN	Probenecid
DMMFWOJ	MI	DT3I124
DMMFWOJ	MN	Monocarboxylate transporter 6 (SLC16A5)
DMMFWOJ	MT	DTP
DMMFWOJ	MA	Substrate
DMMFWOJ	RN	Quercetin, Morin, Luteolin, and Phloretin Are Dietary Flavonoid Inhibitors of Monocarboxylate Transporter 6. Mol Pharm. 2017 Sep 5;14(9):2930-2936.
DMMFWOJ	RU	http://www.ncbi.nlm.nih.gov/pubmed/28513167

DMMFWOJ	DI	DMMFWOJ
DMMFWOJ	DN	Probenecid
DMMFWOJ	MI	DTFI42L
DMMFWOJ	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMMFWOJ	MT	DTP
DMMFWOJ	MA	Substrate
DMMFWOJ	RN	MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer. 2005 Sep 20;116(5):824-9.
DMMFWOJ	RU	https://doi.org/10.1002/ijc.21013

DMMFWOJ	DI	DMMFWOJ
DMMFWOJ	DN	Probenecid
DMMFWOJ	MI	DTE2B1D
DMMFWOJ	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMMFWOJ	MT	DTP
DMMFWOJ	MA	Substrate
DMMFWOJ	RN	Characterization of the efflux transport of 17beta-estradiol-D-17beta-glucuronide from the brain across the blood-brain barrier. J Pharmacol Exp Ther. 2001 Jul;298(1):316-22.
DMMFWOJ	RU	http://www.ncbi.nlm.nih.gov/pubmed/11408557

DMMFWOJ	DI	DMMFWOJ
DMMFWOJ	DN	Probenecid
DMMFWOJ	MI	TTTQR47
DMMFWOJ	MN	Solute carrier family 22 member 8 (SLC22A8)
DMMFWOJ	MT	DTT
DMMFWOJ	MA	Blocker
DMMFWOJ	RN	Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev Physiol Biochem Pharmacol. 2003;146:95-158.
DMMFWOJ	RU	https://pubmed.ncbi.nlm.nih.gov/12605306

DMMFWOJ	DI	DMMFWOJ
DMMFWOJ	DN	Probenecid
DMMFWOJ	MI	DEYGVN4
DMMFWOJ	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMMFWOJ	MT	DME
DMMFWOJ	MA	Metabolism
DMMFWOJ	RN	Modulation of 3'-azido-3'-deoxythymidine catabolism by probenecid and acetaminophen in freshly isolated rat hepatocytes. Biochem Pharmacol. 1991 Sep 12;42(7):1475-80.
DMMFWOJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1930271

DMVZQ2M	DI	DMVZQ2M
DMVZQ2M	DN	Probucol
DMVZQ2M	MI	TTJW1GN
DMVZQ2M	MN	ATP-binding cassette transporter A1 (ABCA1)
DMVZQ2M	MT	DTT
DMVZQ2M	MA	Modulator
DMVZQ2M	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMVZQ2M	RU	https://www.fda.gov/

DMNMXR8	DI	DMNMXR8
DMNMXR8	DN	Procainamide
DMNMXR8	MI	DECB0K3
DMNMXR8	MN	Cytochrome P450 2D6 (CYP2D6)
DMNMXR8	MT	DME
DMNMXR8	MA	Metabolism
DMNMXR8	RN	Involvement of CYP2D6 activity in the N-oxidation of procainamide in man. Pharmacogenetics. 1999 Dec;9(6):683-96.
DMNMXR8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10634131

DMNMXR8	DI	DMNMXR8
DMNMXR8	DN	Procainamide
DMNMXR8	MI	TT05DLS
DMNMXR8	MN	E3 ubiquitin-protein ligase COP1 (RFWD2)
DMNMXR8	MT	DTT
DMNMXR8	MA	Modulator
DMNMXR8	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMNMXR8	RU	https://www.fda.gov/

DMNMXR8	DI	DMNMXR8
DMNMXR8	DN	Procainamide
DMNMXR8	MI	DTZGT0P
DMNMXR8	MN	Multidrug and toxin extrusion protein 1 (SLC47A1)
DMNMXR8	MT	DTP
DMNMXR8	MA	Substrate
DMNMXR8	RN	Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
DMNMXR8	RU	http://www.ncbi.nlm.nih.gov/pubmed/17509534

DMNMXR8	DI	DMNMXR8
DMNMXR8	DN	Procainamide
DMNMXR8	MI	DT3TX4H
DMNMXR8	MN	Multidrug and toxin extrusion protein 2 (SLC47A2)
DMNMXR8	MT	DTP
DMNMXR8	MA	Substrate
DMNMXR8	RN	Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
DMNMXR8	RU	http://www.ncbi.nlm.nih.gov/pubmed/17509534

DMNMXR8	DI	DMNMXR8
DMNMXR8	DN	Procainamide
DMNMXR8	MI	DE7OAB3
DMNMXR8	MN	N-acetyltransferase 1 (NAT1)
DMNMXR8	MT	DME
DMNMXR8	MA	Metabolism
DMNMXR8	RN	Longitudinal distribution of arylamine N-acetyltransferases in the intestine of the hamster, mouse, and rat. Evidence for multiplicity of N-acetyltransferases in the intestine. Biochem Pharmacol. 1996 Nov 22;52(10):1613-20.
DMNMXR8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8937477

DMNMXR8	DI	DMNMXR8
DMNMXR8	DN	Procainamide
DMNMXR8	MI	DER7TA0
DMNMXR8	MN	N-acetyltransferase 2 (NAT2)
DMNMXR8	MT	DME
DMNMXR8	MA	Metabolism
DMNMXR8	RN	Substrate-dependent regulation of human arylamine N-acetyltransferase-1 in cultured cells. Mol Pharmacol. 2000 Mar;57(3):468-73.
DMNMXR8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10692486

DMNMXR8	DI	DMNMXR8
DMNMXR8	DN	Procainamide
DMNMXR8	MI	DTT79CX
DMNMXR8	MN	Organic cation transporter 1 (SLC22A1)
DMNMXR8	MT	DTP
DMNMXR8	MA	Substrate
DMNMXR8	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMNMXR8	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DMNMXR8	DI	DMNMXR8
DMNMXR8	DN	Procainamide
DMNMXR8	MI	DEZV4AP
DMNMXR8	MN	RNA cytidine acetyltransferase (hALP)
DMNMXR8	MT	DME
DMNMXR8	MA	Metabolism
DMNMXR8	RN	Effect of H2-receptor antagonists on rat liver cytosolic acetyl CoA:arylamine N-acetyltransferase activity. Drug Metab Dispos. 1992 Jan-Feb;20(1):74-8.
DMNMXR8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1371435

DM4LSNE	DI	DM4LSNE
DM4LSNE	DN	Procaine
DM4LSNE	MI	TTPC4TU
DM4LSNE	MN	5-HT 3A receptor (HTR3A)
DM4LSNE	MT	DTT
DM4LSNE	MA	Antagonist
DM4LSNE	RN	Local anesthetics have different mechanisms and sites of action at recombinant 5-HT3 receptors. Reg Anesth Pain Med. 2007 Nov-Dec;32(6):462-70.
DM4LSNE	RU	https://pubmed.ncbi.nlm.nih.gov/18035290

DMIK367	DI	DMIK367
DMIK367	DN	Procarbazine
DMIK367	MI	DE6OQ3W
DMIK367	MN	Cytochrome P450 1A1 (CYP1A1)
DMIK367	MT	DME
DMIK367	MA	Metabolism
DMIK367	RN	In vitro and in vivo evidence for the formation of methyl radical from procarbazine: a spin-trapping study. Carcinogenesis. 1992 May;13(5):799-805.
DMIK367	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1316811

DMIK367	DI	DMIK367
DMIK367	DN	Procarbazine
DMIK367	MI	DEJGDUW
DMIK367	MN	Cytochrome P450 1A2 (CYP1A2)
DMIK367	MT	DME
DMIK367	MA	Metabolism
DMIK367	RN	In vitro and in vivo evidence for the formation of methyl radical from procarbazine: a spin-trapping study. Carcinogenesis. 1992 May;13(5):799-805.
DMIK367	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1316811

DMIK367	DI	DMIK367
DMIK367	DN	Procarbazine
DMIK367	MI	DE9QHP6
DMIK367	MN	Cytochrome P450 1B1 (CYP1B1)
DMIK367	MT	DME
DMIK367	MA	Metabolism
DMIK367	RN	Tumour cytochrome P450 and drug activation. Curr Pharm Des. 2002;8(15):1335-47.
DMIK367	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12052211

DMIK367	DI	DMIK367
DMIK367	DN	Procarbazine
DMIK367	MI	TTUTN1I
DMIK367	MN	Human Deoxyribonucleic acid (hDNA)
DMIK367	MT	DTT
DMIK367	RN	Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations... DNA Repair (Amst). 2009 Jan 1;8(1):72-86.
DMIK367	RU	https://pubmed.ncbi.nlm.nih.gov/18840549

DM1M0Q4	DI	DM1M0Q4
DM1M0Q4	DN	Procaterol
DM1M0Q4	MI	TT2CJVK
DM1M0Q4	MN	Adrenergic receptor beta-2 (ADRB2)
DM1M0Q4	MT	DTT
DM1M0Q4	MA	Agonist
DM1M0Q4	RN	Inhalation and incubation with procaterol increases diaphragm muscle contractility in mice. Allergol Int. 2007 Sep;56(3):285-91.
DM1M0Q4	RU	https://pubmed.ncbi.nlm.nih.gov/17646734

DM1M0Q4	DI	DM1M0Q4
DM1M0Q4	DN	Procaterol
DM1M0Q4	MI	DTT79CX
DM1M0Q4	MN	Organic cation transporter 1 (SLC22A1)
DM1M0Q4	MT	DTP
DM1M0Q4	MA	Substrate
DM1M0Q4	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DM1M0Q4	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DM53SRA	DI	DM53SRA
DM53SRA	DN	Prochlorperazine
DM53SRA	MI	DECB0K3
DM53SRA	MN	Cytochrome P450 2D6 (CYP2D6)
DM53SRA	MT	DME
DM53SRA	MA	Metabolism
DM53SRA	RN	Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards. Br J Clin Pharmacol. 2004 Apr;57(4):464-72.
DM53SRA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15025745

DM53SRA	DI	DM53SRA
DM53SRA	DN	Prochlorperazine
DM53SRA	MI	TTEX248
DM53SRA	MN	Dopamine D2 receptor (D2R)
DM53SRA	MT	DTT
DM53SRA	MA	Antagonist
DM53SRA	RN	In vitro and in vivo characteristics of prochlorperazine oral disintegrating film. Int J Pharm. 2009 Feb 23;368(1-2):98-102.
DM53SRA	RU	https://pubmed.ncbi.nlm.nih.gov/18992311

DMHFJDT	DI	DMHFJDT
DMHFJDT	DN	Procyclidine
DMHFJDT	MI	TTH18TF
DMHFJDT	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMHFJDT	MT	DTT
DMHFJDT	MA	Antagonist
DMHFJDT	RN	Protection against soman-induced seizures in rats: relationship among doses of prophylactics, soman, and adjuncts. Toxicol Appl Pharmacol. 2004 May 1;196(3):327-36.
DMHFJDT	RU	https://pubmed.ncbi.nlm.nih.gov/15094303

DMF1X5P	DI	DMF1X5P
DMF1X5P	DN	Proflavine
DMF1X5P	MI	TTS1W4A
DMF1X5P	MN	Bacterial Deoxyribonucleic acid (Bact DNA)
DMF1X5P	MT	DTT
DMF1X5P	MA	Binder
DMF1X5P	RN	Interaction of small molecules with double-stranded RNA: spectroscopic, viscometric, and calorimetric study of hoechst and proflavine binding to PolyCG structures. DNA Cell Biol. 2009 Apr;28(4):209-19.
DMF1X5P	RU	https://pubmed.ncbi.nlm.nih.gov/19364280

DM671NG	DI	DM671NG
DM671NG	DN	Progabide
DM671NG	MI	TTDCVZW
DM671NG	MN	Gamma-aminobutyric acid B receptor (GABBR)
DM671NG	MT	DTT
DM671NG	MA	Agonist
DM671NG	RN	Interactions between dopamine and GABA in the control of ambulatory activity and neophobia in the mouse. Pharmacol Biochem Behav. 1998 Jan;59(1):239-47.
DM671NG	RU	https://pubmed.ncbi.nlm.nih.gov/9443561

DMUY35B	DI	DMUY35B
DMUY35B	DN	Progesterone
DMUY35B	MI	DE7P2FB
DMUY35B	MN	Aldo-keto reductase 1C1 (AKR1C1)
DMUY35B	MT	DME
DMUY35B	MA	Metabolism
DMUY35B	RN	Human 3-alpha hydroxysteroid dehydrogenase type 3 (3alpha-HSD3): the V54L mutation restricting the steroid alternative binding and enhancing the 20alpha-HSD activity. J Steroid Biochem Mol Biol. 2014 May;141:135-43.
DMUY35B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24434280

DMUY35B	DI	DMUY35B
DMUY35B	DN	Progesterone
DMUY35B	MI	DTI7UX6
DMUY35B	MN	Breast cancer resistance protein (ABCG2)
DMUY35B	MT	DTP
DMUY35B	MA	Substrate
DMUY35B	RN	Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
DMUY35B	RU	http://www.ncbi.nlm.nih.gov/pubmed/12668685

DMUY35B	DI	DMUY35B
DMUY35B	DN	Progesterone
DMUY35B	MI	DEKP5HX
DMUY35B	MN	Cholesterol 24-hydroxylase (CYP46A1)
DMUY35B	MT	DME
DMUY35B	MA	Metabolism
DMUY35B	RN	Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain. Biochemistry. 2003 Dec 9;42(48):14284-92.
DMUY35B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14640697

DMUY35B	DI	DMUY35B
DMUY35B	DN	Progesterone
DMUY35B	MI	DE6OQ3W
DMUY35B	MN	Cytochrome P450 1A1 (CYP1A1)
DMUY35B	MT	DME
DMUY35B	MA	Metabolism
DMUY35B	RN	Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics. 2000 Aug;10(6):519-30.
DMUY35B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10975606

DMUY35B	DI	DMUY35B
DMUY35B	DN	Progesterone
DMUY35B	MI	DE9QHP6
DMUY35B	MN	Cytochrome P450 1B1 (CYP1B1)
DMUY35B	MT	DME
DMUY35B	MA	Metabolism
DMUY35B	RN	Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis. 1999 Aug;20(8):1607-13.
DMUY35B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10426814

DMUY35B	DI	DMUY35B
DMUY35B	DN	Progesterone
DMUY35B	MI	DEBY951
DMUY35B	MN	Cytochrome P450 21A2 (cyp21)
DMUY35B	MT	DME
DMUY35B	MA	Metabolism
DMUY35B	RN	acillus megaterium SF185 spores exert protective effects against oxidative stress in vivo and in vitro. Sci Rep. 2019 Aug 19;9(1):12082.
DMUY35B	RU	https://pubmed.ncbi.nlm.nih.gov/31427655

DMUY35B	DI	DMUY35B
DMUY35B	DN	Progesterone
DMUY35B	MI	DEJVYAZ
DMUY35B	MN	Cytochrome P450 2A6 (CYP2A6)
DMUY35B	MT	DME
DMUY35B	MA	Metabolism
DMUY35B	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMUY35B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMUY35B	DI	DMUY35B
DMUY35B	DN	Progesterone
DMUY35B	MI	DE5IED8
DMUY35B	MN	Cytochrome P450 2C9 (CYP2C9)
DMUY35B	MT	DME
DMUY35B	MA	Metabolism
DMUY35B	RN	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
DMUY35B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9328296

DMUY35B	DI	DMUY35B
DMUY35B	DN	Progesterone
DMUY35B	MI	DECB0K3
DMUY35B	MN	Cytochrome P450 2D6 (CYP2D6)
DMUY35B	MT	DME
DMUY35B	MA	Metabolism
DMUY35B	RN	Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
DMUY35B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15469888

DMUY35B	DI	DMUY35B
DMUY35B	DN	Progesterone
DMUY35B	MI	DE4LYSA
DMUY35B	MN	Cytochrome P450 3A4 (CYP3A4)
DMUY35B	MT	DME
DMUY35B	MA	Metabolism
DMUY35B	RN	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
DMUY35B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9667077

DMUY35B	DI	DMUY35B
DMUY35B	DN	Progesterone
DMUY35B	MI	DEIBDNY
DMUY35B	MN	Cytochrome P450 3A5 (CYP3A5)
DMUY35B	MT	DME
DMUY35B	MA	Metabolism
DMUY35B	RN	Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
DMUY35B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10403825

DMUY35B	DI	DMUY35B
DMUY35B	DN	Progesterone
DMUY35B	MI	DERD86B
DMUY35B	MN	Cytochrome P450 3A7 (CYP3A7)
DMUY35B	MT	DME
DMUY35B	MA	Metabolism
DMUY35B	RN	The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
DMUY35B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8424894

DMUY35B	DI	DMUY35B
DMUY35B	DN	Progesterone
DMUY35B	MI	DEMF740
DMUY35B	MN	Cytochrome P450 4B1 (CYP4B1)
DMUY35B	MT	DME
DMUY35B	MA	Metabolism
DMUY35B	RN	Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch Biochem Biophys. 1991 Oct;290(1):160-6.
DMUY35B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1898086

DMUY35B	DI	DMUY35B
DMUY35B	DN	Progesterone
DMUY35B	MI	DEZ1H4L
DMUY35B	MN	Cytochrome P450 MEG (cyp106)
DMUY35B	MT	DME
DMUY35B	MA	Metabolism
DMUY35B	RN	Engineering of CYP106A2 for steroid 9alpha- and 6beta-hydroxylation. Steroids. 2017 Apr;120:41-48.
DMUY35B	RU	https://pubmed.ncbi.nlm.nih.gov/28163026

DMUY35B	DI	DMUY35B
DMUY35B	DN	Progesterone
DMUY35B	MI	DE4ZHS1
DMUY35B	MN	Glutathione S-transferase alpha-1 (GSTA1)
DMUY35B	MT	DME
DMUY35B	MA	Metabolism
DMUY35B	RN	Human glutathione transferase A3-3, a highly efficient catalyst of double-bond isomerization in the biosynthetic pathway of steroid hormones. J Biol Chem. 2001 Aug 31;276(35):33061-5.
DMUY35B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11418619

DMUY35B	DI	DMUY35B
DMUY35B	DN	Progesterone
DMUY35B	MI	DEGTFWK
DMUY35B	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMUY35B	MT	DME
DMUY35B	MA	Metabolism
DMUY35B	RN	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
DMUY35B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9328296

DMUY35B	DI	DMUY35B
DMUY35B	DN	Progesterone
DMUY35B	MI	DTUGYRD
DMUY35B	MN	P-glycoprotein 1 (ABCB1)
DMUY35B	MT	DTP
DMUY35B	MA	Substrate
DMUY35B	RN	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
DMUY35B	RU	http://www.ncbi.nlm.nih.gov/pubmed/11785684

DMUY35B	DI	DMUY35B
DMUY35B	DN	Progesterone
DMUY35B	MI	TTUV8G9
DMUY35B	MN	Progesterone receptor (PGR)
DMUY35B	MT	DTT
DMUY35B	MA	Agonist
DMUY35B	RN	Clinical pipeline report, company report or official report of lipocine.
DMUY35B	RU	http://www.lipocine.com/pipeline/lpcn-1107/

DMUY35B	DI	DMUY35B
DMUY35B	DN	Progesterone
DMUY35B	MI	DE0JMZ5
DMUY35B	MN	Steroid 21-hydroxylase (CYP21A2)
DMUY35B	MT	DME
DMUY35B	MA	Metabolism
DMUY35B	RN	Human cytochrome P450 21A2, the major steroid 21-hydroxylase: structure of the enzyme progesterone substrate complex and rate-limiting C-H bond cleavage. J Biol Chem. 2015 May 22;290(21):13128-43.
DMUY35B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25855791

DMUY35B	DI	DMUY35B
DMUY35B	DN	Progesterone
DMUY35B	MI	DEYWLRK
DMUY35B	MN	Sulfotransferase 1A1 (SULT1A1)
DMUY35B	MT	DME
DMUY35B	MA	Metabolism
DMUY35B	RN	Progestagenic effects of tibolone are target gene-specific in human endometrial cells. J Soc Gynecol Investig. 2006 Sep;13(6):459-65.
DMUY35B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16879988

DMBL79I	DI	DMBL79I
DMBL79I	DN	Proguanil
DMBL79I	MI	DEJGDUW
DMBL79I	MN	Cytochrome P450 1A2 (CYP1A2)
DMBL79I	MT	DME
DMBL79I	MA	Metabolism
DMBL79I	RN	Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms. Br J Clin Pharmacol. 1999 Aug;48(2):158-67.
DMBL79I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10417492

DMBL79I	DI	DMBL79I
DMBL79I	DN	Proguanil
DMBL79I	MI	DE5IED8
DMBL79I	MN	Cytochrome P450 2C9 (CYP2C9)
DMBL79I	MT	DME
DMBL79I	MA	Metabolism
DMBL79I	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMBL79I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMBL79I	DI	DMBL79I
DMBL79I	DN	Proguanil
DMBL79I	MI	DEVDYN7
DMBL79I	MN	Cytochrome P450 2E1 (CYP2E1)
DMBL79I	MT	DME
DMBL79I	MA	Metabolism
DMBL79I	RN	Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms. Br J Clin Pharmacol. 1999 Aug;48(2):158-67.
DMBL79I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10417492

DMBL79I	DI	DMBL79I
DMBL79I	DN	Proguanil
DMBL79I	MI	DE4LYSA
DMBL79I	MN	Cytochrome P450 3A4 (CYP3A4)
DMBL79I	MT	DME
DMBL79I	MA	Metabolism
DMBL79I	RN	In vitro proguanil activation to cycloguanil is mediated by CYP2C19 and CYP3A4 in adult Chinese liver microsomes. Acta Pharmacol Sin. 2000 Aug;21(8):747-52.
DMBL79I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11501186

DMBL79I	DI	DMBL79I
DMBL79I	DN	Proguanil
DMBL79I	MI	DEGTFWK
DMBL79I	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMBL79I	MT	DME
DMBL79I	MA	Metabolism
DMBL79I	RN	Polymorphic oxidative metabolism of proguanil in a Nigerian population. Eur J Clin Pharmacol. 2002 Nov;58(8):543-5.
DMBL79I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12451432

DMBL79I	DI	DMBL79I
DMBL79I	DN	Proguanil
DMBL79I	MI	TT9SL3Q
DMBL79I	MN	Polypeptide deformylase (PDF)
DMBL79I	MT	DTT
DMBL79I	MA	Inhibitor
DMBL79I	RN	Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10931-6.
DMBL79I	RU	https://pubmed.ncbi.nlm.nih.gov/9380737

DMYSCIL	DI	DMYSCIL
DMYSCIL	DN	Prolastin
DMYSCIL	MI	TTZBFA0
DMYSCIL	MN	Protease unspecific (PRO)
DMYSCIL	MT	DTT
DMYSCIL	MA	Inhibitor
DMYSCIL	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMYSCIL	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMMJ1IS	DI	DMMJ1IS
DMMJ1IS	DN	Prolixin decanoate
DMMJ1IS	MI	TTK8CXU
DMMJ1IS	MN	5-HT 1B receptor (HTR1B)
DMMJ1IS	MT	DTT
DMMJ1IS	MA	Modulator
DMMJ1IS	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMMJ1IS	RU	https://www.fda.gov/

DMMJ1IS	DI	DMMJ1IS
DMMJ1IS	DN	Prolixin decanoate
DMMJ1IS	MI	DECB0K3
DMMJ1IS	MN	Cytochrome P450 2D6 (CYP2D6)
DMMJ1IS	MT	DME
DMMJ1IS	MA	Metabolism
DMMJ1IS	RN	Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos. 1999 Sep;27(9):1078-84.
DMMJ1IS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10460810

DMZAL7W	DI	DMZAL7W
DMZAL7W	DN	Promazine
DMZAL7W	MI	DEJGDUW
DMZAL7W	MN	Cytochrome P450 1A2 (CYP1A2)
DMZAL7W	MT	DME
DMZAL7W	MA	Metabolism
DMZAL7W	RN	Contribution of human cytochrome p-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine. Br J Pharmacol. 2003 Apr;138(8):1465-74.
DMZAL7W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12721102

DMZAL7W	DI	DMZAL7W
DMZAL7W	DN	Promazine
DMZAL7W	MI	DE5IED8
DMZAL7W	MN	Cytochrome P450 2C9 (CYP2C9)
DMZAL7W	MT	DME
DMZAL7W	MA	Metabolism
DMZAL7W	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMZAL7W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMZAL7W	DI	DMZAL7W
DMZAL7W	DN	Promazine
DMZAL7W	MI	DE4LYSA
DMZAL7W	MN	Cytochrome P450 3A4 (CYP3A4)
DMZAL7W	MT	DME
DMZAL7W	MA	Metabolism
DMZAL7W	RN	Contribution of human cytochrome p-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine. Br J Pharmacol. 2003 Apr;138(8):1465-74.
DMZAL7W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12721102

DMZAL7W	DI	DMZAL7W
DMZAL7W	DN	Promazine
DMZAL7W	MI	DEGTFWK
DMZAL7W	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMZAL7W	MT	DME
DMZAL7W	MA	Metabolism
DMZAL7W	RN	Contribution of human cytochrome p-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine. Br J Pharmacol. 2003 Apr;138(8):1465-74.
DMZAL7W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12721102

DMZAL7W	DI	DMZAL7W
DMZAL7W	DN	Promazine
DMZAL7W	MI	TTH18TF
DMZAL7W	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMZAL7W	MT	DTT
DMZAL7W	MA	Binder
DMZAL7W	RN	Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12.
DMZAL7W	RU	https://pubmed.ncbi.nlm.nih.gov/2899826

DMK4S8I	DI	DMK4S8I
DMK4S8I	DN	Promegestone
DMK4S8I	MI	DE4LYSA
DMK4S8I	MN	Cytochrome P450 3A4 (CYP3A4)
DMK4S8I	MT	DME
DMK4S8I	MA	Metabolism
DMK4S8I	RN	Progestogens in menopausal hormone therapy. Prz Menopauzalny. 2015 Jun;14(2):134-43.
DMK4S8I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26327902

DMU92F8	DI	DMU92F8
DMU92F8	DN	Promestriene
DMU92F8	MI	TTZAYWL
DMU92F8	MN	Estrogen receptor (ESR)
DMU92F8	MT	DTT
DMU92F8	MA	Modulator
DMU92F8	RN	Promestriene, a specific topic estrogen. Review of 40 years of vaginal atrophy treatment: is it safe even in cancer patients. Anticancer Drugs. 2013 Nov;24(10):989-98.
DMU92F8	RU	https://pubmed.ncbi.nlm.nih.gov/24080714

DM6I5GR	DI	DM6I5GR
DM6I5GR	DN	Promethazine
DM6I5GR	MI	DEPKLMQ
DM6I5GR	MN	Cytochrome P450 2B6 (CYP2B6)
DM6I5GR	MT	DME
DM6I5GR	MA	Metabolism
DM6I5GR	RN	Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics. 2003 Oct;13(10):619-26.
DM6I5GR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14515060

DM6I5GR	DI	DM6I5GR
DM6I5GR	DN	Promethazine
DM6I5GR	MI	DECB0K3
DM6I5GR	MN	Cytochrome P450 2D6 (CYP2D6)
DM6I5GR	MT	DME
DM6I5GR	MA	Metabolism
DM6I5GR	RN	Akathisia with combined use of midodrine and promethazine. JAMA. 2006 May 3;295(17):2000-1. Letter
DM6I5GR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16670408

DM6I5GR	DI	DM6I5GR
DM6I5GR	DN	Promethazine
DM6I5GR	MI	TTTIBOJ
DM6I5GR	MN	Histamine H1 receptor (H1R)
DM6I5GR	MT	DTT
DM6I5GR	MA	Antagonist
DM6I5GR	RN	Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79.
DM6I5GR	RU	https://pubmed.ncbi.nlm.nih.gov/18446005

DMPIBJK	DI	DMPIBJK
DMPIBJK	DN	Propafenone
DMPIBJK	MI	DEJGDUW
DMPIBJK	MN	Cytochrome P450 1A2 (CYP1A2)
DMPIBJK	MT	DME
DMPIBJK	MA	Metabolism
DMPIBJK	RN	Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2. Br J Clin Pharmacol. 1998 Apr;45(4):361-8.
DMPIBJK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9578183

DMPIBJK	DI	DMPIBJK
DMPIBJK	DN	Propafenone
DMPIBJK	MI	DECB0K3
DMPIBJK	MN	Cytochrome P450 2D6 (CYP2D6)
DMPIBJK	MT	DME
DMPIBJK	MA	Metabolism
DMPIBJK	RN	Effect of selective serotonin reuptake inhibitors on the oxidative metabolism of propafenone: in vitro studies using human liver microsomes. J Clin Psychopharmacol. 2000 Aug;20(4):428-34.
DMPIBJK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10917404

DMPIBJK	DI	DMPIBJK
DMPIBJK	DN	Propafenone
DMPIBJK	MI	DE4LYSA
DMPIBJK	MN	Cytochrome P450 3A4 (CYP3A4)
DMPIBJK	MT	DME
DMPIBJK	MA	Metabolism
DMPIBJK	RN	Effect of selective serotonin reuptake inhibitors on the oxidative metabolism of propafenone: in vitro studies using human liver microsomes. J Clin Psychopharmacol. 2000 Aug;20(4):428-34.
DMPIBJK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10917404

DMPIBJK	DI	DMPIBJK
DMPIBJK	DN	Propafenone
DMPIBJK	MI	TT05DLS
DMPIBJK	MN	E3 ubiquitin-protein ligase COP1 (RFWD2)
DMPIBJK	MT	DTT
DMPIBJK	MA	Modulator
DMPIBJK	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMPIBJK	RU	https://www.fda.gov/

DMPIBJK	DI	DMPIBJK
DMPIBJK	DN	Propafenone
DMPIBJK	MI	DTUGYRD
DMPIBJK	MN	P-glycoprotein 1 (ABCB1)
DMPIBJK	MT	DTP
DMPIBJK	MA	Substrate
DMPIBJK	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMPIBJK	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DM2EN6G	DI	DM2EN6G
DM2EN6G	DN	Propantheline
DM2EN6G	MI	TTZ9SOR
DM2EN6G	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DM2EN6G	MT	DTT
DM2EN6G	MA	Antagonist
DM2EN6G	RN	Involvement of the peripheral cholinergic muscarinic system in the compensatory ovarian hypertrophy in the rat. Exp Biol Med (Maywood). 2004 Sep;229(8):793-805.
DM2EN6G	RU	https://pubmed.ncbi.nlm.nih.gov/15337834

DMLS39E	DI	DMLS39E
DMLS39E	DN	Proparacaine
DMLS39E	MI	TT90XZ8
DMLS39E	MN	Voltage-gated sodium channel alpha Nav1.8 (SCN10A)
DMLS39E	MT	DTT
DMLS39E	MA	Modulator
DMLS39E	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMLS39E	RU	https://www.fda.gov/

DM6JQ2I	DI	DM6JQ2I
DM6JQ2I	DN	Propentofylline propionate
DM6JQ2I	MI	DEJGDUW
DM6JQ2I	MN	Cytochrome P450 1A2 (CYP1A2)
DM6JQ2I	MT	DME
DM6JQ2I	MA	Metabolism
DM6JQ2I	RN	PharmGKB summary: caffeine pathway. Pharmacogenet Genomics. 2012 May;22(5):389-95.
DM6JQ2I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22293536

DME9JNL	DI	DME9JNL
DME9JNL	DN	Propericiazine
DME9JNL	MI	TTBRKXS
DME9JNL	MN	Adrenergic receptor alpha-1B (ADRA1B)
DME9JNL	MT	DTT
DME9JNL	MA	Binder
DME9JNL	RN	Interaction of neuroleptics and antidepressants with rat brain alpha 2-receptors: a possible relationship between alpha 2-receptor antagonism and antidepressant action. Biol Psychiatry. 1984 Sep;19(9):1283-91.
DME9JNL	RU	https://pubmed.ncbi.nlm.nih.gov/6149771

DMWDHUZ	DI	DMWDHUZ
DMWDHUZ	DN	Propicillin
DMWDHUZ	MI	DTLT3UG
DMWDHUZ	MN	Monocarboxylate transporter 2 (SLC16A7)
DMWDHUZ	MT	DTP
DMWDHUZ	MA	Substrate
DMWDHUZ	RN	Monocarboxylate Transporters in Drug Disposition: Role in the Toxicokinetics and Toxicodynamics of the Drug of Abuse GHB.
DMWDHUZ	RU	https://www.njacs.org/wp-content/docs/2010-Spring-DrugMet-Marilyn_Morris.pdf

DMKY8V1	DI	DMKY8V1
DMKY8V1	DN	Propiomazine
DMKY8V1	MI	TTTIBOJ
DMKY8V1	MN	Histamine H1 receptor (H1R)
DMKY8V1	MT	DTT
DMKY8V1	MA	Antagonist
DMKY8V1	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMKY8V1	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMUWBIJ	DI	DMUWBIJ
DMUWBIJ	DN	Propiverine
DMUWBIJ	MI	DE4LYSA
DMUWBIJ	MN	Cytochrome P450 3A4 (CYP3A4)
DMUWBIJ	MT	DME
DMUWBIJ	MA	Metabolism
DMUWBIJ	RN	Product monograph: Mictoryl (Propiverine hydrochloride modified-release capsules).
DMUWBIJ	RU	https://www.duchesnay.com/files/pdf/mictoryl-monograph.pdf

DMUWBIJ	DI	DMUWBIJ
DMUWBIJ	DN	Propiverine
DMUWBIJ	MI	TTH18TF
DMUWBIJ	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMUWBIJ	MT	DTT
DMUWBIJ	MA	Antagonist
DMUWBIJ	RN	Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci. 1999;64(25):2351-8.
DMUWBIJ	RU	https://pubmed.ncbi.nlm.nih.gov/10374898

DMB4OLE	DI	DMB4OLE
DMB4OLE	DN	Propofol
DMB4OLE	MI	DEJGDUW
DMB4OLE	MN	Cytochrome P450 1A2 (CYP1A2)
DMB4OLE	MT	DME
DMB4OLE	MA	Metabolism
DMB4OLE	RN	Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
DMB4OLE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12234619

DMB4OLE	DI	DMB4OLE
DMB4OLE	DN	Propofol
DMB4OLE	MI	DEJVYAZ
DMB4OLE	MN	Cytochrome P450 2A6 (CYP2A6)
DMB4OLE	MT	DME
DMB4OLE	MA	Metabolism
DMB4OLE	RN	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
DMB4OLE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9771309

DMB4OLE	DI	DMB4OLE
DMB4OLE	DN	Propofol
DMB4OLE	MI	DEPKLMQ
DMB4OLE	MN	Cytochrome P450 2B6 (CYP2B6)
DMB4OLE	MT	DME
DMB4OLE	MA	Metabolism
DMB4OLE	RN	Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
DMB4OLE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17620218

DMB4OLE	DI	DMB4OLE
DMB4OLE	DN	Propofol
DMB4OLE	MI	DEZMWRE
DMB4OLE	MN	Cytochrome P450 2C18 (CYP2C18)
DMB4OLE	MT	DME
DMB4OLE	MA	Metabolism
DMB4OLE	RN	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
DMB4OLE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9771309

DMB4OLE	DI	DMB4OLE
DMB4OLE	DN	Propofol
DMB4OLE	MI	DES5XRU
DMB4OLE	MN	Cytochrome P450 2C8 (CYP2C8)
DMB4OLE	MT	DME
DMB4OLE	MA	Metabolism
DMB4OLE	RN	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
DMB4OLE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9771309

DMB4OLE	DI	DMB4OLE
DMB4OLE	DN	Propofol
DMB4OLE	MI	DE5IED8
DMB4OLE	MN	Cytochrome P450 2C9 (CYP2C9)
DMB4OLE	MT	DME
DMB4OLE	MA	Metabolism
DMB4OLE	RN	Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. Anesthesiology. 2001 Jan;94(1):110-9.
DMB4OLE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11135730

DMB4OLE	DI	DMB4OLE
DMB4OLE	DN	Propofol
DMB4OLE	MI	DECB0K3
DMB4OLE	MN	Cytochrome P450 2D6 (CYP2D6)
DMB4OLE	MT	DME
DMB4OLE	MA	Metabolism
DMB4OLE	RN	Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
DMB4OLE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9764927

DMB4OLE	DI	DMB4OLE
DMB4OLE	DN	Propofol
DMB4OLE	MI	DEVDYN7
DMB4OLE	MN	Cytochrome P450 2E1 (CYP2E1)
DMB4OLE	MT	DME
DMB4OLE	MA	Metabolism
DMB4OLE	RN	Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
DMB4OLE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12234619

DMB4OLE	DI	DMB4OLE
DMB4OLE	DN	Propofol
DMB4OLE	MI	DE4LYSA
DMB4OLE	MN	Cytochrome P450 3A4 (CYP3A4)
DMB4OLE	MT	DME
DMB4OLE	MA	Metabolism
DMB4OLE	RN	Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. Anesthesiology. 2001 Jan;94(1):110-9.
DMB4OLE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11135730

DMB4OLE	DI	DMB4OLE
DMB4OLE	DN	Propofol
DMB4OLE	MI	TTDP1UC
DMB4OLE	MN	Fatty acid amide hydrolase (FAAH)
DMB4OLE	MT	DTT
DMB4OLE	MA	Inhibitor
DMB4OLE	RN	Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
DMB4OLE	RU	https://pubmed.ncbi.nlm.nih.gov/16377242

DMB4OLE	DI	DMB4OLE
DMB4OLE	DN	Propofol
DMB4OLE	MI	DEGTFWK
DMB4OLE	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMB4OLE	MT	DME
DMB4OLE	MA	Metabolism
DMB4OLE	RN	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
DMB4OLE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9771309

DMB4OLE	DI	DMB4OLE
DMB4OLE	DN	Propofol
DMB4OLE	MI	DEUM1EX
DMB4OLE	MN	Oleamide hydrolase 1 (FAAH)
DMB4OLE	MT	DME
DMB4OLE	MA	Metabolism
DMB4OLE	RN	Update of TTD: therapeutic target database. Nucleic Acids Res. 2010 Jan;38(Database issue):D787-91.
DMB4OLE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19933260

DMB4OLE	DI	DMB4OLE
DMB4OLE	DN	Propofol
DMB4OLE	MI	DEYGVN4
DMB4OLE	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMB4OLE	MT	DME
DMB4OLE	MA	Metabolism
DMB4OLE	RN	Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
DMB4OLE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17697043

DMB4OLE	DI	DMB4OLE
DMB4OLE	DN	Propofol
DMB4OLE	MI	DESD26P
DMB4OLE	MN	UDP-glucuronosyltransferase 1A6 (UGT1A6)
DMB4OLE	MT	DME
DMB4OLE	MA	Metabolism
DMB4OLE	RN	Pharmacokinetics of propofol and extrahepatic UGT1A6 gene expression in anhepatic rats. Pharmacology. 2009;84(4):219-26.
DMB4OLE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19752585

DMB4OLE	DI	DMB4OLE
DMB4OLE	DN	Propofol
DMB4OLE	MI	DE85D2P
DMB4OLE	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMB4OLE	MT	DME
DMB4OLE	MA	Metabolism
DMB4OLE	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMB4OLE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMMSOLA	DI	DMMSOLA
DMMSOLA	DN	Propoxyphene Hydrochloride
DMMSOLA	MI	TTKWM86
DMMSOLA	MN	Opioid receptor mu (MOP)
DMMSOLA	MT	DTT
DMMSOLA	MA	Modulator
DMMSOLA	RN	Norpropoxyphene-induced cardiotoxicity is associated with changes in ion-selectivity and gating of HERG currents. Cardiovasc Res. 1999 Dec;44(3):568-78.
DMMSOLA	RU	https://www.ncbi.nlm.nih.gov/pubmed/10690289

DM79NTF	DI	DM79NTF
DM79NTF	DN	Propranolol
DM79NTF	MI	TTR6W5O
DM79NTF	MN	Adrenergic receptor beta-1 (ADRB1)
DM79NTF	MT	DTT
DM79NTF	MA	Antagonist
DM79NTF	RN	Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8.
DM79NTF	RU	https://pubmed.ncbi.nlm.nih.gov/19491545

DM79NTF	DI	DM79NTF
DM79NTF	DN	Propranolol
DM79NTF	MI	DE4OGUF
DM79NTF	MN	Cytochrome P450 102A1 (cyp102)
DM79NTF	MT	DME
DM79NTF	MA	Metabolism
DM79NTF	RN	acillus megaterium SF185 spores exert protective effects against oxidative stress in vivo and in vitro. Sci Rep. 2019 Aug 19;9(1):12082.
DM79NTF	RU	https://pubmed.ncbi.nlm.nih.gov/31427655

DM79NTF	DI	DM79NTF
DM79NTF	DN	Propranolol
DM79NTF	MI	DEJGDUW
DM79NTF	MN	Cytochrome P450 1A2 (CYP1A2)
DM79NTF	MT	DME
DM79NTF	MA	Metabolism
DM79NTF	RN	Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
DM79NTF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19754423

DM79NTF	DI	DM79NTF
DM79NTF	DN	Propranolol
DM79NTF	MI	DECB0K3
DM79NTF	MN	Cytochrome P450 2D6 (CYP2D6)
DM79NTF	MT	DME
DM79NTF	MA	Metabolism
DM79NTF	RN	Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
DM79NTF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996013

DM79NTF	DI	DM79NTF
DM79NTF	DN	Propranolol
DM79NTF	MI	DE4LYSA
DM79NTF	MN	Cytochrome P450 3A4 (CYP3A4)
DM79NTF	MT	DME
DM79NTF	MA	Metabolism
DM79NTF	RN	Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug Metab Dispos. 1994 Nov-Dec;22(6):909-15.
DM79NTF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7895609

DM79NTF	DI	DM79NTF
DM79NTF	DN	Propranolol
DM79NTF	MI	DEIBDNY
DM79NTF	MN	Cytochrome P450 3A5 (CYP3A5)
DM79NTF	MT	DME
DM79NTF	MA	Metabolism
DM79NTF	RN	The influence of diltiazem versus cimetidine on propranolol metabolism. J Clin Pharmacol. 1992 Dec;32(12):1099-104.
DM79NTF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1487547

DM79NTF	DI	DM79NTF
DM79NTF	DN	Propranolol
DM79NTF	MI	DERD86B
DM79NTF	MN	Cytochrome P450 3A7 (CYP3A7)
DM79NTF	MT	DME
DM79NTF	MA	Metabolism
DM79NTF	RN	The influence of diltiazem versus cimetidine on propranolol metabolism. J Clin Pharmacol. 1992 Dec;32(12):1099-104.
DM79NTF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1487547

DM79NTF	DI	DM79NTF
DM79NTF	DN	Propranolol
DM79NTF	MI	DEIASEZ
DM79NTF	MN	Dimethylaniline oxidase 2 (FMO2)
DM79NTF	MT	DME
DM79NTF	MA	Metabolism
DM79NTF	RN	Human FMO2-based microbial whole-cell catalysts for drug metabolite synthesis. Microb Cell Fact. 2015 Jun 12;14:82.
DM79NTF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26062974

DM79NTF	DI	DM79NTF
DM79NTF	DN	Propranolol
DM79NTF	MI	DEGTFWK
DM79NTF	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM79NTF	MT	DME
DM79NTF	MA	Metabolism
DM79NTF	RN	Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol. 2001 Oct;52(4):349-55.
DM79NTF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11678778

DM79NTF	DI	DM79NTF
DM79NTF	DN	Propranolol
DM79NTF	MI	DTT79CX
DM79NTF	MN	Organic cation transporter 1 (SLC22A1)
DM79NTF	MT	DTP
DM79NTF	MA	Substrate
DM79NTF	RN	Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
DM79NTF	RU	http://www.ncbi.nlm.nih.gov/pubmed/28768994

DM79NTF	DI	DM79NTF
DM79NTF	DN	Propranolol
DM79NTF	MI	DT9IDPW
DM79NTF	MN	Organic cation transporter 2 (SLC22A2)
DM79NTF	MT	DTP
DM79NTF	MA	Substrate
DM79NTF	RN	Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
DM79NTF	RU	http://www.ncbi.nlm.nih.gov/pubmed/28768994

DM79NTF	DI	DM79NTF
DM79NTF	DN	Propranolol
DM79NTF	MI	DT6201N
DM79NTF	MN	Organic cation transporter 3 (SLC22A3)
DM79NTF	MT	DTP
DM79NTF	MA	Substrate
DM79NTF	RN	Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
DM79NTF	RU	http://www.ncbi.nlm.nih.gov/pubmed/28768994

DM79NTF	DI	DM79NTF
DM79NTF	DN	Propranolol
DM79NTF	MI	DTUGYRD
DM79NTF	MN	P-glycoprotein 1 (ABCB1)
DM79NTF	MT	DTP
DM79NTF	MA	Substrate
DM79NTF	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DM79NTF	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DMTBW2O	DI	DMTBW2O
DMTBW2O	DN	Propylhexedrine
DMTBW2O	MI	TT2NUT5
DMTBW2O	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMTBW2O	MT	DTT
DMTBW2O	MA	Modulator
DMTBW2O	RN	Airway compromise and delayed death following attempted central vein injection of propylhexedrine. J Emerg Med. 1994 Nov-Dec;12(6):795-7.
DMTBW2O	RU	https://pubmed.ncbi.nlm.nih.gov/7533806

DM6D7N8	DI	DM6D7N8
DM6D7N8	DN	Propylthiouracil
DM6D7N8	MI	TTU3X26
DM6D7N8	MN	Iodothyronine deiodinase type I (DIO1)
DM6D7N8	MT	DTT
DM6D7N8	MA	Inhibitor
DM6D7N8	RN	Type 1 iodothyronine deiodinase is the major source of circulating T3 in hyperthyroidism: implications for therapy. Nat Clin Pract Endocrinol Metab. 2007 Nov;3(11):740-1.
DM6D7N8	RU	https://pubmed.ncbi.nlm.nih.gov/17712320

DM6D7N8	DI	DM6D7N8
DM6D7N8	DN	Propylthiouracil
DM6D7N8	MI	TT52XDZ
DM6D7N8	MN	Thyroid peroxidase (TPO)
DM6D7N8	MT	DTT
DM6D7N8	MA	Inhibitor
DM6D7N8	RN	Bioinorganic chemistry in thyroid gland: effect of antithyroid drugs on peroxidase-catalyzed oxidation and iodination reactions. Bioinorg Chem Appl. 2006:23214.
DM6D7N8	RU	https://pubmed.ncbi.nlm.nih.gov/17497002

DMX0EZJ	DI	DMX0EZJ
DMX0EZJ	DN	Prothionamide
DMX0EZJ	MI	TTVTX4N
DMX0EZJ	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DMX0EZJ	MT	DTT
DMX0EZJ	MA	Inhibitor
DMX0EZJ	RN	Mechanism of thioamide drug action against tuberculosis and leprosy. J Exp Med. 2007 Jan 22;204(1):73-8.
DMX0EZJ	RU	https://pubmed.ncbi.nlm.nih.gov/17227913

DMGN5QD	DI	DMGN5QD
DMGN5QD	DN	Protirelin
DMGN5QD	MI	DEVDR46
DMGN5QD	MN	Pyrrolidone-carboxylate peptidase (PGPI)
DMGN5QD	MT	DME
DMGN5QD	MA	Metabolism
DMGN5QD	RN	Marginal involvement of pyroglutamyl aminopeptidase I in metabolism of thyrotropin-releasing hormone in rat brain. Biol Pharm Bull. 2004 Aug;27(8):1197-201.
DMGN5QD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15305021

DMGN5QD	DI	DMGN5QD
DMGN5QD	DN	Protirelin
DMGN5QD	MI	TT4J8MF
DMGN5QD	MN	Thyrotropin-releasing hormone receptor (TRHR)
DMGN5QD	MT	DTT
DMGN5QD	MA	Modulator
DMGN5QD	RN	Company report (takeda)
DMGN5QD	RU	https://www.takeda.com/csr/reports/pdf/index/ar2010_04_en.pdf

DMAHZKR	DI	DMAHZKR
DMAHZKR	DN	Protokylol Hydrochloride
DMAHZKR	MI	TTR6W5O
DMAHZKR	MN	Adrenergic receptor beta-1 (ADRB1)
DMAHZKR	MT	DTT
DMAHZKR	MA	Modulator
DMAHZKR	RN	N-Aralkyl substitution increases the affinity of adrenergic drugs for the alpha-adrenoceptor in rat liver.
DMAHZKR	RU	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1668481

DMNHTZI	DI	DMNHTZI
DMNHTZI	DN	Protriptyline
DMNHTZI	MI	TTAWNKZ
DMNHTZI	MN	Norepinephrine transporter (NET)
DMNHTZI	MT	DTT
DMNHTZI	MA	Inhibitor
DMNHTZI	RN	Analgesic properties of intrathecally administered heterocyclic antidepressants. Pain. 1987 Mar;28(3):343-55.
DMNHTZI	RU	https://pubmed.ncbi.nlm.nih.gov/3494977

DMNHTZI	DI	DMNHTZI
DMNHTZI	DN	Protriptyline
DMNHTZI	MI	DTUGYRD
DMNHTZI	MN	P-glycoprotein 1 (ABCB1)
DMNHTZI	MT	DTP
DMNHTZI	MA	Substrate
DMNHTZI	RN	Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.
DMNHTZI	RU	http://www.ncbi.nlm.nih.gov/pubmed/12438524

DMGKT2L	DI	DMGKT2L
DMGKT2L	DN	Pro-urokinase
DMGKT2L	MI	TTGY7WI
DMGKT2L	MN	Urokinase-type plasminogen activator (PLAU)
DMGKT2L	MT	DTT
DMGKT2L	MA	Modulator
DMGKT2L	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2393).
DMGKT2L	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2393

DMOK965	DI	DMOK965
DMOK965	DN	Prulifloxacin
DMOK965	MI	TTN6J5F
DMOK965	MN	Bacterial DNA gyrase (Bact gyrase)
DMOK965	MT	DTT
DMOK965	MA	Inhibitor
DMOK965	RN	Prulifloxacin: a new antibacterial fluoroquinolone. Expert Rev Anti Infect Ther. 2006 Feb;4(1):27-41.
DMOK965	RU	https://pubmed.ncbi.nlm.nih.gov/16441207

DMOK965	DI	DMOK965
DMOK965	DN	Prulifloxacin
DMOK965	MI	TTFK8YB
DMOK965	MN	Bacterial DNA topoisomerase 4A (Bact parC)
DMOK965	MT	DTT
DMOK965	MA	Inhibitor
DMOK965	RN	Prulifloxacin: a new antibacterial fluoroquinolone. Expert Rev Anti Infect Ther. 2006 Feb;4(1):27-41.
DMOK965	RU	https://pubmed.ncbi.nlm.nih.gov/16441207

DMIVJ0D	DI	DMIVJ0D
DMIVJ0D	DN	Pseudoephedrine
DMIVJ0D	MI	TTEX248
DMIVJ0D	MN	Dopamine D2 receptor (D2R)
DMIVJ0D	MT	DTT
DMIVJ0D	MA	Stimulator
DMIVJ0D	RN	Cetirizine/pseudoephedrine. Drugs. 2001;61(15):2231-40; discussion 2241-2.
DMIVJ0D	RU	https://pubmed.ncbi.nlm.nih.gov/11772135

DMIVJ0D	DI	DMIVJ0D
DMIVJ0D	DN	Pseudoephedrine
DMIVJ0D	MI	DEYWLRK
DMIVJ0D	MN	Sulfotransferase 1A1 (SULT1A1)
DMIVJ0D	MT	DME
DMIVJ0D	MA	Metabolism
DMIVJ0D	RN	Benzylic alcohols as stereospecific substrates and inhibitors for aryl sulfotransferase. Chirality. 1991;3(2):104-11.
DMIVJ0D	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1863522

DMLSUWZ	DI	DMLSUWZ
DMLSUWZ	DN	PSI-7977
DMLSUWZ	MI	DEWJATF
DMLSUWZ	MN	Adenosine 5'-monophosphoramidase (HINT1)
DMLSUWZ	MT	DME
DMLSUWZ	MA	Metabolism
DMLSUWZ	RN	Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem. 2010 Nov 5;285(45):34337-47.
DMLSUWZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20801890

DMLSUWZ	DI	DMLSUWZ
DMLSUWZ	DN	PSI-7977
DMLSUWZ	MI	DEB30C5
DMLSUWZ	MN	Carboxylesterase 1 (CES1)
DMLSUWZ	MT	DME
DMLSUWZ	MA	Metabolism
DMLSUWZ	RN	Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem. 2010 Nov 5;285(45):34337-47.
DMLSUWZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20801890

DMLSUWZ	DI	DMLSUWZ
DMLSUWZ	DN	PSI-7977
DMLSUWZ	MI	TTMVBWH
DMLSUWZ	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMLSUWZ	MT	DTT
DMLSUWZ	MA	Modulator
DMLSUWZ	RN	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
DMLSUWZ	RU	https://pubmed.ncbi.nlm.nih.gov/28919714

DMWLTU2	DI	DMWLTU2
DMWLTU2	DN	PSMA-11 Ga-68
DMWLTU2	MI	TT9G4N0
DMWLTU2	MN	Glutamate carboxypeptidase II (GCPII)
DMWLTU2	MT	DTT
DMWLTU2	MA	Binder
DMWLTU2	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMWLTU2	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212642s000lbl.pdf

DMG2X3E	DI	DMG2X3E
DMG2X3E	DN	Pyrantel
DMG2X3E	MI	DECB0K3
DMG2X3E	MN	Cytochrome P450 2D6 (CYP2D6)
DMG2X3E	MT	DME
DMG2X3E	MA	Metabolism
DMG2X3E	RN	Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
DMG2X3E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920490

DM4IF32	DI	DM4IF32
DM4IF32	DN	Pyrazinamide
DM4IF32	MI	TTVTX4N
DM4IF32	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DM4IF32	MT	DTT
DM4IF32	MA	Inhibitor
DM4IF32	RN	Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat Med. 2000 Sep;6(9):1043-7.
DM4IF32	RU	https://pubmed.ncbi.nlm.nih.gov/10973326

DM4IF32	DI	DM4IF32
DM4IF32	DN	Pyrazinamide
DM4IF32	MI	DEJGDUW
DM4IF32	MN	Cytochrome P450 1A2 (CYP1A2)
DM4IF32	MT	DME
DM4IF32	MA	Metabolism
DM4IF32	RN	The metabolism of pyrazoloacridine (NSC 366140) by cytochromes p450 and flavin monooxygenase in human liver microsomes. Clin Cancer Res. 2004 Feb 15;10(4):1471-80.
DM4IF32	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14977851

DM4IF32	DI	DM4IF32
DM4IF32	DN	Pyrazinamide
DM4IF32	MI	DE4LYSA
DM4IF32	MN	Cytochrome P450 3A4 (CYP3A4)
DM4IF32	MT	DME
DM4IF32	MA	Metabolism
DM4IF32	RN	The metabolism of pyrazoloacridine (NSC 366140) by cytochromes p450 and flavin monooxygenase in human liver microsomes. Clin Cancer Res. 2004 Feb 15;10(4):1471-80.
DM4IF32	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14977851

DM4IF32	DI	DM4IF32
DM4IF32	DN	Pyrazinamide
DM4IF32	MI	DERQS6E
DM4IF32	MN	Nicotinamidase (pncA)
DM4IF32	MT	DME
DM4IF32	MA	Metabolism
DM4IF32	RN	Specificity and mechanism of Acinetobacter baumanii nicotinamidase: implications for activation of the front-line tuberculosis drug pyrazinamide. Angew Chem Int Ed Engl. 2009;48(48):9176-9.
DM4IF32	RU	https://pubmed.ncbi.nlm.nih.gov/19859929

DM8HO1L	DI	DM8HO1L
DM8HO1L	DN	Pyridostigmine
DM8HO1L	MI	TT1RS9F
DM8HO1L	MN	Acetylcholinesterase (AChE)
DM8HO1L	MT	DTT
DM8HO1L	MA	Inhibitor
DM8HO1L	RN	Neuromuscular blockade, reversal agent use, and operating room time: retrospective analysis of US inpatient surgeries. Curr Med Res Opin. 2009 Apr;25(4):943-50.
DM8HO1L	RU	https://pubmed.ncbi.nlm.nih.gov/19257799

DMO2K0J	DI	DMO2K0J
DMO2K0J	DN	Pyridoxal Phosphate
DMO2K0J	MI	TT6L509
DMO2K0J	MN	Coagulation factor IIa (F2)
DMO2K0J	MT	DTT
DMO2K0J	MA	Inhibitor
DMO2K0J	RN	New antithrombotic drugs (excluding plasminogen activators. Arch Mal Coeur Vaiss. 2001 Nov;94(11 Suppl):1225-32.
DMO2K0J	RU	https://pubmed.ncbi.nlm.nih.gov/11794963

DMO2K0J	DI	DMO2K0J
DMO2K0J	DN	Pyridoxal Phosphate
DMO2K0J	MI	TTT2LD9
DMO2K0J	MN	GABA transaminase (ABAT)
DMO2K0J	MT	DTT
DMO2K0J	MA	Inhibitor
DMO2K0J	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DMO2K0J	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DM5X7VY	DI	DM5X7VY
DM5X7VY	DN	Pyrimethamine
DM5X7VY	MI	DTI7UX6
DM5X7VY	MN	Breast cancer resistance protein (ABCG2)
DM5X7VY	MT	DTP
DM5X7VY	MA	Substrate
DM5X7VY	RN	Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34.
DM5X7VY	RU	https://doi.org/10.1007/s00280-006-0230-9

DM5X7VY	DI	DM5X7VY
DM5X7VY	DN	Pyrimethamine
DM5X7VY	MI	TTVC37M
DM5X7VY	MN	Folate receptor alpha (FOLR1)
DM5X7VY	MT	DTT
DM5X7VY	MA	Modulator
DM5X7VY	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM5X7VY	RU	https://www.fda.gov/

DM5X7VY	DI	DM5X7VY
DM5X7VY	DN	Pyrimethamine
DM5X7VY	MI	DTZGT0P
DM5X7VY	MN	Multidrug and toxin extrusion protein 1 (SLC47A1)
DM5X7VY	MT	DTP
DM5X7VY	MA	Substrate
DM5X7VY	RN	Expression of Organic Anion Transporter 1 or 3 in Human Kidney Proximal Tubule Cells Reduces Cisplatin Sensitivity. Drug Metab Dispos. 2018 May;46(5):592-599.
DM5X7VY	RU	http://www.ncbi.nlm.nih.gov/pubmed/29514829

DMNA8HM	DI	DMNA8HM
DMNA8HM	DN	Pyrithione Zinc
DMNA8HM	MI	TTG5TOX
DMNA8HM	MN	Fungal Proton pump (FPPCM)
DMNA8HM	MT	DTT
DMNA8HM	MA	Modulator
DMNA8HM	RN	Mechanism of the antimicrobial action of pyrithione: effects on membrane transport, ATP levels, and protein synthesis. Antimicrob Agents Chemother. 1978 Jul;14(1):60-8.
DMNA8HM	RU	https://www.ncbi.nlm.nih.gov/pubmed/28693

DMUWAM2	DI	DMUWAM2
DMUWAM2	DN	Pyronaridine
DMUWAM2	MI	TTZVSJ2
DMUWAM2	MN	Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A)
DMUWAM2	MT	DTT
DMUWAM2	MA	Inhibitor
DMUWAM2	RN	The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
DMUWAM2	RU	https://pubmed.ncbi.nlm.nih.gov/18220771

DM7Q41G	DI	DM7Q41G
DM7Q41G	DN	Pyruvic acid
DM7Q41G	MI	TTT2LD9
DM7Q41G	MN	GABA transaminase (ABAT)
DM7Q41G	MT	DTT
DM7Q41G	MA	Inhibitor
DM7Q41G	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DM7Q41G	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DM7Q41G	DI	DM7Q41G
DM7Q41G	DN	Pyruvic acid
DM7Q41G	MI	DT342ZG
DM7Q41G	MN	Monocarboxylate transporter 1 (SLC16A1)
DM7Q41G	MT	DTP
DM7Q41G	MA	Substrate
DM7Q41G	RN	AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7-10. Biochem J. 2010 Jan 15;425(3):523-30.
DM7Q41G	RU	https://doi.org/10.1042/BJ20091515

DMGAZHU	DI	DMGAZHU
DMGAZHU	DN	Quattvaxem
DMGAZHU	MI	TT3J5ZI
DMGAZHU	MN	Cell mediated immunity response (CMIR)
DMGAZHU	MT	DTT
DMGAZHU	RN	Double-blind study comparing the immunogenicity of a licensed DTwPHib-CRM197 conjugate vaccine (Quattvaxem) with three investigational, liquid formulations using lower doses of Hib-CRM197 conjugate. Vaccine. 2005 Feb 25;23(14):1715-9.
DMGAZHU	RU	https://pubmed.ncbi.nlm.nih.gov/15705477

DMY4D87	DI	DMY4D87
DMY4D87	DN	Quazepam
DMY4D87	MI	DE5IED8
DMY4D87	MN	Cytochrome P450 2C9 (CYP2C9)
DMY4D87	MT	DME
DMY4D87	MA	Metabolism
DMY4D87	RN	Interaction between grapefruit juice and hypnotic drugs: comparison of triazolam and quazepam. Eur J Clin Pharmacol. 2006 Mar;62(3):209-15.
DMY4D87	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16416305

DMY4D87	DI	DMY4D87
DMY4D87	DN	Quazepam
DMY4D87	MI	DE4LYSA
DMY4D87	MN	Cytochrome P450 3A4 (CYP3A4)
DMY4D87	MT	DME
DMY4D87	MA	Metabolism
DMY4D87	RN	Interaction between grapefruit juice and hypnotic drugs: comparison of triazolam and quazepam. Eur J Clin Pharmacol. 2006 Mar;62(3):209-15.
DMY4D87	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16416305

DMY4D87	DI	DMY4D87
DMY4D87	DN	Quazepam
DMY4D87	MI	DEGTFWK
DMY4D87	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMY4D87	MT	DME
DMY4D87	MA	Metabolism
DMY4D87	RN	In vitro metabolism of quazepam in human liver and intestine and assessment of drug interactions. Xenobiotica. 2004 Nov-Dec;34(11-12):1001-11.
DMY4D87	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15801544

DMY4D87	DI	DMY4D87
DMY4D87	DN	Quazepam
DMY4D87	MI	TTPTXIN
DMY4D87	MN	Translocator protein (TSPO)
DMY4D87	MT	DTT
DMY4D87	MA	Modulator
DMY4D87	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMY4D87	RU	https://www.fda.gov/

DM3NC4M	DI	DM3NC4M
DM3NC4M	DN	Quercetin
DM3NC4M	MI	TTPOI4B
DM3NC4M	MN	Acetyl-CoA:lyso-PAF acetyltransferase (PCAT)
DM3NC4M	MT	DTT
DM3NC4M	MA	Inhibitor
DM3NC4M	RN	Modulation by flavonoids of PAF and related phospholipids in endothelial cells during oxidative stress. J Lipid Res. 2003 Feb;44(2):380-7.
DM3NC4M	RU	https://pubmed.ncbi.nlm.nih.gov/12576520

DM3NC4M	DI	DM3NC4M
DM3NC4M	DN	Quercetin
DM3NC4M	MI	DTI7UX6
DM3NC4M	MN	Breast cancer resistance protein (ABCG2)
DM3NC4M	MT	DTP
DM3NC4M	MA	Substrate
DM3NC4M	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM3NC4M	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DM3NC4M	DI	DM3NC4M
DM3NC4M	DN	Quercetin
DM3NC4M	MI	DTH6X7Q
DM3NC4M	MN	Feline leukemia virus subgroup C receptor-related protein 1 (SLC49A1)
DM3NC4M	MT	DTP
DM3NC4M	MA	Substrate
DM3NC4M	RN	The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.1.28.1)
DM3NC4M	RU	http://www.tcdb.org/search/result.php?tc=2.A.1.28.1

DM3NC4M	DI	DM3NC4M
DM3NC4M	DN	Quercetin
DM3NC4M	MI	DTG3T6X
DM3NC4M	MN	Glucose transporter type 1, erythrocyte/brain (SLC2A1)
DM3NC4M	MT	DTP
DM3NC4M	MA	Substrate
DM3NC4M	RN	Oral Bioavailability and Disposition of Phytochemicals
DM3NC4M	RU	http://cdn.intechweb.org/pdfs/25496.pdf

DM3NC4M	DI	DM3NC4M
DM3NC4M	DN	Quercetin
DM3NC4M	MI	DTLT3UG
DM3NC4M	MN	Monocarboxylate transporter 2 (SLC16A7)
DM3NC4M	MT	DTP
DM3NC4M	MA	Substrate
DM3NC4M	RN	Monocarboxylate Transporters in Drug Disposition: Role in the Toxicokinetics and Toxicodynamics of the Drug of Abuse GHB.
DM3NC4M	RU	https://www.njacs.org/wp-content/docs/2010-Spring-DrugMet-Marilyn_Morris.pdf

DM3NC4M	DI	DM3NC4M
DM3NC4M	DN	Quercetin
DM3NC4M	MI	DTSYQGK
DM3NC4M	MN	Multidrug resistance-associated protein 1 (ABCC1)
DM3NC4M	MT	DTP
DM3NC4M	MA	Substrate
DM3NC4M	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM3NC4M	RU	https://doi.org/10.1007/s11095-012-0935-x

DM3NC4M	DI	DM3NC4M
DM3NC4M	DN	Quercetin
DM3NC4M	MI	DTCSGPB
DM3NC4M	MN	Multidrug resistance-associated protein 4 (ABCC4)
DM3NC4M	MT	DTP
DM3NC4M	MA	Substrate
DM3NC4M	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM3NC4M	RU	https://doi.org/10.1007/s11095-012-0935-x

DM3NC4M	DI	DM3NC4M
DM3NC4M	DN	Quercetin
DM3NC4M	MI	DTUGYRD
DM3NC4M	MN	P-glycoprotein 1 (ABCB1)
DM3NC4M	MT	DTP
DM3NC4M	MA	Substrate
DM3NC4M	RN	Flavonoid permeability across an in situ model of the blood-brain barrier. Free Radic Biol Med. 2004 Mar 1;36(5):592-604.
DM3NC4M	RU	https://doi.org/10.1016/j.freeradbiomed.2003.11.023

DM1N62C	DI	DM1N62C
DM1N62C	DN	Quetiapine
DM1N62C	MI	DECB0K3
DM1N62C	MN	Cytochrome P450 2D6 (CYP2D6)
DM1N62C	MT	DME
DM1N62C	MA	Metabolism
DM1N62C	RN	A liquid chromatographic-electrospray-tandem mass spectrometric method for quantitation of quetiapine in human plasma and liver microsomes: application to study in vitro metabolism. J Anal Toxicol. 2004 Sep;28(6):443-8.
DM1N62C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15516294

DM1N62C	DI	DM1N62C
DM1N62C	DN	Quetiapine
DM1N62C	MI	DE4LYSA
DM1N62C	MN	Cytochrome P450 3A4 (CYP3A4)
DM1N62C	MT	DME
DM1N62C	MA	Metabolism
DM1N62C	RN	Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro. Drug Metab Dispos. 2012 Sep;40(9):1778-84.
DM1N62C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22688609

DM1N62C	DI	DM1N62C
DM1N62C	DN	Quetiapine
DM1N62C	MI	DEIBDNY
DM1N62C	MN	Cytochrome P450 3A5 (CYP3A5)
DM1N62C	MT	DME
DM1N62C	MA	Metabolism
DM1N62C	RN	Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteers. Pharmacogenet Genomics. 2014 Jan;24(1):35-42.
DM1N62C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24240480

DM1N62C	DI	DM1N62C
DM1N62C	DN	Quetiapine
DM1N62C	MI	DERD86B
DM1N62C	MN	Cytochrome P450 3A7 (CYP3A7)
DM1N62C	MT	DME
DM1N62C	MA	Metabolism
DM1N62C	RN	A liquid chromatographic-electrospray-tandem mass spectrometric method for quantitation of quetiapine in human plasma and liver microsomes: application to study in vitro metabolism. J Anal Toxicol. 2004 Sep;28(6):443-8.
DM1N62C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15516294

DM1N62C	DI	DM1N62C
DM1N62C	DN	Quetiapine
DM1N62C	MI	TTEX248
DM1N62C	MN	Dopamine D2 receptor (D2R)
DM1N62C	MT	DTT
DM1N62C	MA	Agonist
DM1N62C	RN	Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
DM1N62C	RU	https://pubmed.ncbi.nlm.nih.gov/19217900

DM1N62C	DI	DM1N62C
DM1N62C	DN	Quetiapine
DM1N62C	MI	DEGTFWK
DM1N62C	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM1N62C	MT	DME
DM1N62C	MA	Metabolism
DM1N62C	RN	A liquid chromatographic-electrospray-tandem mass spectrometric method for quantitation of quetiapine in human plasma and liver microsomes: application to study in vitro metabolism. J Anal Toxicol. 2004 Sep;28(6):443-8.
DM1N62C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15516294

DM1N62C	DI	DM1N62C
DM1N62C	DN	Quetiapine
DM1N62C	MI	DTUGYRD
DM1N62C	MN	P-glycoprotein 1 (ABCB1)
DM1N62C	MT	DTP
DM1N62C	MA	Substrate
DM1N62C	RN	Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
DM1N62C	RU	http://www.ncbi.nlm.nih.gov/pubmed/15285840

DM1N62C	DI	DM1N62C
DM1N62C	DN	Quetiapine
DM1N62C	MI	DTMJK12
DM1N62C	MN	Solute carrier family 22 member 23 (SLC22A23)
DM1N62C	MT	DTP
DM1N62C	MA	Substrate
DM1N62C	RN	Genome-wide association study of antipsychotic-induced QTc interval prolongation. Pharmacogenomics J. 2012 Apr;12(2):165-72.
DM1N62C	RU	http://www.ncbi.nlm.nih.gov/pubmed/20921969

DM7WI4Q	DI	DM7WI4Q
DM7WI4Q	DN	Quinagolide
DM7WI4Q	MI	TTEX248
DM7WI4Q	MN	Dopamine D2 receptor (D2R)
DM7WI4Q	MT	DTT
DM7WI4Q	MA	Agonist
DM7WI4Q	RN	Effect of dopamine receptor agonists on sensory nerve activity: possible therapeutic targets for the treatment of asthma and COPD. Br J Pharmacol. 2002 Jun;136(4):620-8.
DM7WI4Q	RU	https://pubmed.ncbi.nlm.nih.gov/12055141

DMR8H31	DI	DMR8H31
DMR8H31	DN	Quinapril
DMR8H31	MI	TTL69WB
DMR8H31	MN	Angiotensin-converting enzyme (ACE)
DMR8H31	MT	DTT
DMR8H31	MA	Inhibitor
DMR8H31	RN	An experimental model of encapsulating peritoneal sclerosis. Perit Dial Int. 2009 Feb;29 Suppl 2:S49-50.
DMR8H31	RU	https://pubmed.ncbi.nlm.nih.gov/19270231

DMJ6H1Z	DI	DMJ6H1Z
DMJ6H1Z	DN	Quinestrol
DMJ6H1Z	MI	TTZAYWL
DMJ6H1Z	MN	Estrogen receptor (ESR)
DMJ6H1Z	MT	DTT
DMJ6H1Z	MA	Modulator
DMJ6H1Z	RN	The antioxidant effect of estrogen and Selective Estrogen Receptor Modulators in the inhibition of osteocyte apoptosis in vitro. Bone. 2007 Mar;40(3):674-84.
DMJ6H1Z	RU	https://pubmed.ncbi.nlm.nih.gov/17174166

DMWCOSR	DI	DMWCOSR
DMWCOSR	DN	Quinethazone
DMWCOSR	MI	TTUNARX
DMWCOSR	MN	Carbonic anhydrase (CA)
DMWCOSR	MT	DTT
DMWCOSR	MA	Inhibitor
DMWCOSR	RN	Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for th... Bioorg Med Chem Lett. 2008 Apr 15;18(8):2567-73.
DMWCOSR	RU	https://pubmed.ncbi.nlm.nih.gov/18374572

DMLPICK	DI	DMLPICK
DMLPICK	DN	Quinidine
DMLPICK	MI	DES5XRU
DMLPICK	MN	Cytochrome P450 2C8 (CYP2C8)
DMLPICK	MT	DME
DMLPICK	MA	Metabolism
DMLPICK	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DMLPICK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DMLPICK	DI	DMLPICK
DMLPICK	DN	Quinidine
DMLPICK	MI	DE5IED8
DMLPICK	MN	Cytochrome P450 2C9 (CYP2C9)
DMLPICK	MT	DME
DMLPICK	MA	Metabolism
DMLPICK	RN	Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. Br J Clin Pharmacol. 1999 Dec;48(6):829-38.
DMLPICK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10594487

DMLPICK	DI	DMLPICK
DMLPICK	DN	Quinidine
DMLPICK	MI	DECB0K3
DMLPICK	MN	Cytochrome P450 2D6 (CYP2D6)
DMLPICK	MT	DME
DMLPICK	MA	Metabolism
DMLPICK	RN	Binding of quinidine radically increases the stability and decreases the flexibility of the cytochrome P450 2D6 active site. J Inorg Biochem. 2012 May;110:46-50.
DMLPICK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22459173

DMLPICK	DI	DMLPICK
DMLPICK	DN	Quinidine
DMLPICK	MI	DEVDYN7
DMLPICK	MN	Cytochrome P450 2E1 (CYP2E1)
DMLPICK	MT	DME
DMLPICK	MA	Metabolism
DMLPICK	RN	In vitro metabolism of quinidine: the (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P-4503A4 activity in human liver microsomes. J Pharmacol Exp Ther. 1999 Apr;289(1):31-7.
DMLPICK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10086984

DMLPICK	DI	DMLPICK
DMLPICK	DN	Quinidine
DMLPICK	MI	DE4LYSA
DMLPICK	MN	Cytochrome P450 3A4 (CYP3A4)
DMLPICK	MT	DME
DMLPICK	MA	Metabolism
DMLPICK	RN	10th North American ISSX meeting. October 24-28, 2000. Indianapolis, Indiana, USA. Abstracts. Drug Metab Rev. 2000;32 Suppl 2:137-340.
DMLPICK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11057336

DMLPICK	DI	DMLPICK
DMLPICK	DN	Quinidine
DMLPICK	MI	DERD86B
DMLPICK	MN	Cytochrome P450 3A7 (CYP3A7)
DMLPICK	MT	DME
DMLPICK	MA	Metabolism
DMLPICK	RN	Drug Interactions Flockhart Table
DMLPICK	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMSWYF5	DI	DMSWYF5
DMSWYF5	DN	Quinine
DMSWYF5	MI	DEJGDUW
DMSWYF5	MN	Cytochrome P450 1A2 (CYP1A2)
DMSWYF5	MT	DME
DMSWYF5	MA	Metabolism
DMSWYF5	RN	The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. Clin Pharmacol Ther. 1999 Nov;66(5):454-60.
DMSWYF5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10579472

DMSWYF5	DI	DMSWYF5
DMSWYF5	DN	Quinine
DMSWYF5	MI	DES5XRU
DMSWYF5	MN	Cytochrome P450 2C8 (CYP2C8)
DMSWYF5	MT	DME
DMSWYF5	MA	Metabolism
DMSWYF5	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DMSWYF5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DMSWYF5	DI	DMSWYF5
DMSWYF5	DN	Quinine
DMSWYF5	MI	DE5IED8
DMSWYF5	MN	Cytochrome P450 2C9 (CYP2C9)
DMSWYF5	MT	DME
DMSWYF5	MA	Metabolism
DMSWYF5	RN	Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human live microsomes and nine recombinant human cytochromes P450. J Pharmacol Exp Ther. 1996 Dec;279(3):1327-34.
DMSWYF5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8968357

DMSWYF5	DI	DMSWYF5
DMSWYF5	DN	Quinine
DMSWYF5	MI	DECB0K3
DMSWYF5	MN	Cytochrome P450 2D6 (CYP2D6)
DMSWYF5	MT	DME
DMSWYF5	MA	Metabolism
DMSWYF5	RN	Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
DMSWYF5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12703961

DMSWYF5	DI	DMSWYF5
DMSWYF5	DN	Quinine
DMSWYF5	MI	DE4LYSA
DMSWYF5	MN	Cytochrome P450 3A4 (CYP3A4)
DMSWYF5	MT	DME
DMSWYF5	MA	Metabolism
DMSWYF5	RN	Quinine induced simvastatin toxicity through cytochrome inhibition - a case report. BMC Geriatr. 2016 Oct 1;16(1):168.
DMSWYF5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27716084

DMSWYF5	DI	DMSWYF5
DMSWYF5	DN	Quinine
DMSWYF5	MI	DEIBDNY
DMSWYF5	MN	Cytochrome P450 3A5 (CYP3A5)
DMSWYF5	MT	DME
DMSWYF5	MA	Metabolism
DMSWYF5	RN	Drug Interactions Flockhart Table
DMSWYF5	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMSWYF5	DI	DMSWYF5
DMSWYF5	DN	Quinine
DMSWYF5	MI	DERD86B
DMSWYF5	MN	Cytochrome P450 3A7 (CYP3A7)
DMSWYF5	MT	DME
DMSWYF5	MA	Metabolism
DMSWYF5	RN	Drug Interactions Flockhart Table
DMSWYF5	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMSWYF5	DI	DMSWYF5
DMSWYF5	DN	Quinine
DMSWYF5	MI	TT05DLS
DMSWYF5	MN	E3 ubiquitin-protein ligase COP1 (RFWD2)
DMSWYF5	MT	DTT
DMSWYF5	MA	Modulator
DMSWYF5	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMSWYF5	RU	https://www.fda.gov/

DMSWYF5	DI	DMSWYF5
DMSWYF5	DN	Quinine
DMSWYF5	MI	DEGTFWK
DMSWYF5	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMSWYF5	MT	DME
DMSWYF5	MA	Metabolism
DMSWYF5	RN	Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
DMSWYF5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11159893

DMSWYF5	DI	DMSWYF5
DMSWYF5	DN	Quinine
DMSWYF5	MI	DTBPTJF
DMSWYF5	MN	Na(+)/Cl(-) betaine/GABA transporter (SLC6A12)
DMSWYF5	MT	DTP
DMSWYF5	MA	Substrate
DMSWYF5	RN	The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.22.3.1)
DMSWYF5	RU	http://www.tcdb.org/search/result.php?tc=2.A.22.3.1

DMSWYF5	DI	DMSWYF5
DMSWYF5	DN	Quinine
DMSWYF5	MI	DTT79CX
DMSWYF5	MN	Organic cation transporter 1 (SLC22A1)
DMSWYF5	MT	DTP
DMSWYF5	MA	Substrate
DMSWYF5	RN	Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
DMSWYF5	RU	http://www.ncbi.nlm.nih.gov/pubmed/11408531

DMSWYF5	DI	DMSWYF5
DMSWYF5	DN	Quinine
DMSWYF5	MI	DT9IDPW
DMSWYF5	MN	Organic cation transporter 2 (SLC22A2)
DMSWYF5	MT	DTP
DMSWYF5	MA	Substrate
DMSWYF5	RN	Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997 Jul;16(7):871-81.
DMSWYF5	RU	http://www.ncbi.nlm.nih.gov/pubmed/9260930

DMSWYF5	DI	DMSWYF5
DMSWYF5	DN	Quinine
DMSWYF5	MI	DT2EG60
DMSWYF5	MN	Organic cation/carnitine transporter 1 (SLC22A4)
DMSWYF5	MT	DTP
DMSWYF5	MA	Substrate
DMSWYF5	RN	Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther. 1999 May;289(2):768-73.
DMSWYF5	RU	http://www.ncbi.nlm.nih.gov/pubmed/10215651

DMSWYF5	DI	DMSWYF5
DMSWYF5	DN	Quinine
DMSWYF5	MI	DT3HUVD
DMSWYF5	MN	Organic cation/carnitine transporter 2 (SLC22A5)
DMSWYF5	MT	DTP
DMSWYF5	MA	Substrate
DMSWYF5	RN	Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84.
DMSWYF5	RU	http://www.ncbi.nlm.nih.gov/pubmed/10525100

DMSWYF5	DI	DMSWYF5
DMSWYF5	DN	Quinine
DMSWYF5	MI	DTUGYRD
DMSWYF5	MN	P-glycoprotein 1 (ABCB1)
DMSWYF5	MT	DTP
DMSWYF5	MA	Substrate
DMSWYF5	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMSWYF5	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DM5GVHU	DI	DM5GVHU
DM5GVHU	DN	Quinolones
DM5GVHU	MI	TT0IHXV
DM5GVHU	MN	DNA topoisomerase II (TOP2)
DM5GVHU	MT	DTT
DM5GVHU	MA	Inhibitor
DM5GVHU	RN	The magic bullets and tuberculosis drug targets. Annu Rev Pharmacol Toxicol. 2005;45:529-64.
DM5GVHU	RU	https://pubmed.ncbi.nlm.nih.gov/15822188

DM5GVHU	DI	DM5GVHU
DM5GVHU	DN	Quinolones
DM5GVHU	MI	DTE2B1D
DM5GVHU	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DM5GVHU	MT	DTP
DM5GVHU	MA	Substrate
DM5GVHU	RN	The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.60.1.14)
DM5GVHU	RU	http://www.tcdb.org/search/result.php?tc=2.A.60.1.14

DMLKFC4	DI	DMLKFC4
DMLKFC4	DN	Quinupristin
DMLKFC4	MI	TTIB7O8
DMLKFC4	MN	Bacterial Integral membrane LmrP (Bact lmrP)
DMLKFC4	MT	DTT
DMLKFC4	MA	Modulator
DMLKFC4	RN	The lactococcal secondary multidrug transporter LmrP confers resistance to lincosamides, macrolides, streptogramins and tetracyclines. Microbiology. 2001 Oct;147(Pt 10):2873-80.
DMLKFC4	RU	https://pubmed.ncbi.nlm.nih.gov/11577166

DMM4U9G	DI	DMM4U9G
DMM4U9G	DN	R0-93877
DMM4U9G	MI	TT07C3Y
DMM4U9G	MN	5-HT 4 receptor (HTR4)
DMM4U9G	MT	DTT
DMM4U9G	MA	Agonist
DMM4U9G	RN	Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
DMM4U9G	RU	https://pubmed.ncbi.nlm.nih.gov/11293643

DMM4U9G	DI	DMM4U9G
DMM4U9G	DN	R0-93877
DMM4U9G	MI	DTUGYRD
DMM4U9G	MN	P-glycoprotein 1 (ABCB1)
DMM4U9G	MT	DTP
DMM4U9G	MA	Substrate
DMM4U9G	RN	Resolor, INN-prucalopride
DMM4U9G	RU	https://www.ema.europa.eu/documents/product-information/resolor-epar-product-information_en.pdf

DMMZXIW	DI	DMMZXIW
DMMZXIW	DN	Rabeprazole
DMMZXIW	MI	DTI7UX6
DMMZXIW	MN	Breast cancer resistance protein (ABCG2)
DMMZXIW	MT	DTP
DMMZXIW	MA	Substrate
DMMZXIW	RN	Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009 Jan;67(1):44-9.
DMMZXIW	RU	http://www.ncbi.nlm.nih.gov/pubmed/19076159

DMMZXIW	DI	DMMZXIW
DMMZXIW	DN	Rabeprazole
DMMZXIW	MI	DE4LYSA
DMMZXIW	MN	Cytochrome P450 3A4 (CYP3A4)
DMMZXIW	MT	DME
DMMZXIW	MA	Metabolism
DMMZXIW	RN	Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. Eur J Clin Pharmacol. 2006 Aug;62(8):597-603.
DMMZXIW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16783561

DMMZXIW	DI	DMMZXIW
DMMZXIW	DN	Rabeprazole
DMMZXIW	MI	TTF1QVM
DMMZXIW	MN	Gastric H(+)/K(+) ATPase alpha (ATP4A)
DMMZXIW	MT	DTT
DMMZXIW	MA	Inhibitor
DMMZXIW	RN	Review article: rabeprazole's tolerability profile in clinical trials. Aliment Pharmacol Ther. 1999 Oct;13 Suppl 5:17-23.
DMMZXIW	RU	https://pubmed.ncbi.nlm.nih.gov/10555605

DMMZXIW	DI	DMMZXIW
DMMZXIW	DN	Rabeprazole
DMMZXIW	MI	DEGTFWK
DMMZXIW	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMMZXIW	MT	DME
DMMZXIW	MA	Metabolism
DMMZXIW	RN	Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. Eur J Clin Pharmacol. 2006 Aug;62(8):597-603.
DMMZXIW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16783561

DMFOTZ7	DI	DMFOTZ7
DMFOTZ7	DN	Racecadotril
DMFOTZ7	MI	TT8CYO4
DMFOTZ7	MN	Endopeptidase (ENP)
DMFOTZ7	MT	DTT
DMFOTZ7	MA	Modulator
DMFOTZ7	RN	A comprehensive review of the pharmacodynamics, pharmacokinetics, and clinical effects of the neutral endopeptidase inhibitor racecadotril. Front Pharmacol. 2012 May 30;3:93.
DMFOTZ7	RU	https://pubmed.ncbi.nlm.nih.gov/22661949

DMXTCVF	DI	DMXTCVF
DMXTCVF	DN	Radium-223-Dichloride
DMXTCVF	MI	TTUTN1I
DMXTCVF	MN	Human Deoxyribonucleic acid (hDNA)
DMXTCVF	MT	DTT
DMXTCVF	MA	Modulator
DMXTCVF	RN	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
DMXTCVF	RU	https://pubmed.ncbi.nlm.nih.gov/28919714

DMDKF3M	DI	DMDKF3M
DMDKF3M	DN	Raloxifene
DMDKF3M	MI	DE4LYSA
DMDKF3M	MN	Cytochrome P450 3A4 (CYP3A4)
DMDKF3M	MT	DME
DMDKF3M	MA	Metabolism
DMDKF3M	RN	The role of P-glycoprotein in the bioactivation of raloxifene. Drug Metab Dispos. 2006 Dec;34(12):2073-8.
DMDKF3M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16959878

DMDKF3M	DI	DMDKF3M
DMDKF3M	DN	Raloxifene
DMDKF3M	MI	TTZAYWL
DMDKF3M	MN	Estrogen receptor (ESR)
DMDKF3M	MT	DTT
DMDKF3M	MA	Modulator
DMDKF3M	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620).
DMDKF3M	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=620

DMDKF3M	DI	DMDKF3M
DMDKF3M	DN	Raloxifene
DMDKF3M	MI	DTUGYRD
DMDKF3M	MN	P-glycoprotein 1 (ABCB1)
DMDKF3M	MT	DTP
DMDKF3M	MA	Substrate
DMDKF3M	RN	Influence of hepatic and intestinal efflux transporters and their genetic variants on the pharmacokinetics and pharmacodynamics of raloxifene in osteoporosis treatment. Transl Res. 2012 Oct;160(4):298-308.
DMDKF3M	RU	https://doi.org/10.1016/j.trsl.2012.03.002

DMDKF3M	DI	DMDKF3M
DMDKF3M	DN	Raloxifene
DMDKF3M	MI	DEYGVN4
DMDKF3M	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMDKF3M	MT	DME
DMDKF3M	MA	Metabolism
DMDKF3M	RN	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
DMDKF3M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429

DMDKF3M	DI	DMDKF3M
DMDKF3M	DN	Raloxifene
DMDKF3M	MI	DEL5N6Y
DMDKF3M	MN	UDP-glucuronosyltransferase 1A10 (UGT1A10)
DMDKF3M	MT	DME
DMDKF3M	MA	Metabolism
DMDKF3M	RN	Characterization of raloxifene glucuronidation: potential role of UGT1A8 genotype on raloxifene metabolism in vivo. Cancer Prev Res (Phila). 2013 Jul;6(7):719-30.
DMDKF3M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23682072

DMYURI6	DI	DMYURI6
DMYURI6	DN	Raltegravir
DMYURI6	MI	DE6OQ3W
DMYURI6	MN	Cytochrome P450 1A1 (CYP1A1)
DMYURI6	MT	DME
DMYURI6	MA	Metabolism
DMYURI6	RN	Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients. Ther Drug Monit. 2010 Dec;32(6):782-6.
DMYURI6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20926993

DMYURI6	DI	DMYURI6
DMYURI6	DN	Raltegravir
DMYURI6	MI	TT5FH9Y
DMYURI6	MN	Human immunodeficiency virus Integrase (HIV IN)
DMYURI6	MT	DTT
DMYURI6	MA	Modulator
DMYURI6	RN	2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
DMYURI6	RU	https://pubmed.ncbi.nlm.nih.gov/18246607

DMYURI6	DI	DMYURI6
DMYURI6	DN	Raltegravir
DMYURI6	MI	DEYGVN4
DMYURI6	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMYURI6	MT	DME
DMYURI6	MA	Metabolism
DMYURI6	RN	Successful tacrolimus treatment following renal transplant in a HIV-infected patient with raltegravir previously treated with a protease inhibitor based regimen. Drug Metabol Drug Interact. 2011;26(3):139-41.
DMYURI6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21980965

DMT9K8G	DI	DMT9K8G
DMT9K8G	DN	Raltitrexed
DMT9K8G	MI	DTI7UX6
DMT9K8G	MN	Breast cancer resistance protein (ABCG2)
DMT9K8G	MT	DTP
DMT9K8G	MA	Substrate
DMT9K8G	RN	Pharmacogenomic importance of ABCG2. Pharmacogenomics. 2008 Aug;9(8):1005-9.
DMT9K8G	RU	https://doi.org/10.2217/14622416.9.8.1005

DMT9K8G	DI	DMT9K8G
DMT9K8G	DN	Raltitrexed
DMT9K8G	MI	TTU6BFZ
DMT9K8G	MN	Candida Thymidylate synthase (Candi TMP1)
DMT9K8G	MT	DTT
DMT9K8G	MA	Inhibitor
DMT9K8G	RN	DNA damage and homologous recombination signaling induced by thymidylate deprivation. Biochem Pharmacol. 2008 Oct 15;76(8):987-96.
DMT9K8G	RU	https://pubmed.ncbi.nlm.nih.gov/18773878

DMT9K8G	DI	DMT9K8G
DMT9K8G	DN	Raltitrexed
DMT9K8G	MI	DTFI42L
DMT9K8G	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMT9K8G	MT	DTP
DMT9K8G	MA	Substrate
DMT9K8G	RN	Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 1999 Jun 1;59(11):2532-5.
DMT9K8G	RU	http://cancerres.aacrjournals.org/content/59/11/2532

DM7IW9J	DI	DM7IW9J
DM7IW9J	DN	Ramelteon
DM7IW9J	MI	DEJGDUW
DM7IW9J	MN	Cytochrome P450 1A2 (CYP1A2)
DM7IW9J	MT	DME
DM7IW9J	MA	Metabolism
DM7IW9J	RN	Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokinetics. Drug Metab Dispos. 2010 Aug;38(8):1381-91.
DM7IW9J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20478852

DM7IW9J	DI	DM7IW9J
DM7IW9J	DN	Ramelteon
DM7IW9J	MI	DE4LYSA
DM7IW9J	MN	Cytochrome P450 3A4 (CYP3A4)
DM7IW9J	MT	DME
DM7IW9J	MA	Metabolism
DM7IW9J	RN	Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokinetics. Drug Metab Dispos. 2010 Aug;38(8):1381-91.
DM7IW9J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20478852

DM7IW9J	DI	DM7IW9J
DM7IW9J	DN	Ramelteon
DM7IW9J	MI	TT0WAIE
DM7IW9J	MN	Melatonin receptor type 1A (MTNR1A)
DM7IW9J	MT	DTT
DM7IW9J	MA	Modulator
DM7IW9J	RN	MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential. J Med Chem. 2014 Apr 24;57(8):3161-85.
DM7IW9J	RU	https://pubmed.ncbi.nlm.nih.gov/24228714

DM7IW9J	DI	DM7IW9J
DM7IW9J	DN	Ramelteon
DM7IW9J	MI	TT32JK8
DM7IW9J	MN	Melatonin receptor type 1B (MTNR1B)
DM7IW9J	MT	DTT
DM7IW9J	MA	Modulator
DM7IW9J	RN	MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential. J Med Chem. 2014 Apr 24;57(8):3161-85.
DM7IW9J	RU	https://pubmed.ncbi.nlm.nih.gov/24228714

DM7IW9J	DI	DM7IW9J
DM7IW9J	DN	Ramelteon
DM7IW9J	MI	DEGTFWK
DM7IW9J	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM7IW9J	MT	DME
DM7IW9J	MA	Metabolism
DM7IW9J	RN	Pharmacotherapy of insomnia with ramelteon: safety, efficacy and clinical applications. J Cent Nerv Syst Dis. 2011 Apr 12;3:51-65.
DM7IW9J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23861638

DM2R68E	DI	DM2R68E
DM2R68E	DN	Ramipril
DM2R68E	MI	TTL69WB
DM2R68E	MN	Angiotensin-converting enzyme (ACE)
DM2R68E	MT	DTT
DM2R68E	MA	Inhibitor
DM2R68E	RN	Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
DM2R68E	RU	https://pubmed.ncbi.nlm.nih.gov/12509758

DM2R68E	DI	DM2R68E
DM2R68E	DN	Ramipril
DM2R68E	MI	DT9G7XN
DM2R68E	MN	Peptide transporter 1 (SLC15A1)
DM2R68E	MT	DTP
DM2R68E	MA	Substrate
DM2R68E	RN	Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41.
DM2R68E	RU	http://www.ncbi.nlm.nih.gov/pubmed/18713951

DM2R68E	DI	DM2R68E
DM2R68E	DN	Ramipril
DM2R68E	MI	DT8QKNP
DM2R68E	MN	Peptide transporter 2 (SLC15A2)
DM2R68E	MT	DTP
DM2R68E	MA	Substrate
DM2R68E	RN	Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41.
DM2R68E	RU	http://www.ncbi.nlm.nih.gov/pubmed/18713951

DMH7GN8	DI	DMH7GN8
DMH7GN8	DN	Ramosetron
DMH7GN8	MI	TTNXLKE
DMH7GN8	MN	5-HT 3 receptor (5HT3R)
DMH7GN8	MT	DTT
DMH7GN8	MA	Modulator
DMH7GN8	RN	Inhibitory effect of YM060 on 5-HT3 receptor-mediated depolarization in colonic myenteric neurons of the guinea pig. Eur J Pharmacol. 1995 Sep 5;283(1-3):107-12.
DMH7GN8	RU	https://pubmed.ncbi.nlm.nih.gov/7498299

DMH7GN8	DI	DMH7GN8
DMH7GN8	DN	Ramosetron
DMH7GN8	MI	TT85JO3
DMH7GN8	MN	5-HT receptor (5HTR)
DMH7GN8	MT	DTT
DMH7GN8	MA	Modulator
DMH7GN8	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMH7GN8	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DMH7GN8	DI	DMH7GN8
DMH7GN8	DN	Ramosetron
DMH7GN8	MI	DEJGDUW
DMH7GN8	MN	Cytochrome P450 1A2 (CYP1A2)
DMH7GN8	MT	DME
DMH7GN8	MA	Metabolism
DMH7GN8	RN	Ondansetron, ramosetron, or palonosetron: which is a better choice of antiemetic to prevent postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy? Anesth Essays Res. 2011 Jul-Dec;5(2):182-6.
DMH7GN8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25885385

DMH7GN8	DI	DMH7GN8
DMH7GN8	DN	Ramosetron
DMH7GN8	MI	DTUGYRD
DMH7GN8	MN	P-glycoprotein 1 (ABCB1)
DMH7GN8	MT	DTP
DMH7GN8	MA	Substrate
DMH7GN8	RN	Contribution of P-glycoprotein to efflux of ramosetron, a 5-HT3 receptor antagonist, across the blood-brain barrier. J Pharm Pharmacol. 2002 Aug;54(8):1055-63.
DMH7GN8	RU	https://doi.org/10.1211/002235702320266208

DMWUFQ4	DI	DMWUFQ4
DMWUFQ4	DN	Ramucirumab
DMWUFQ4	MI	TTUTJGQ
DMWUFQ4	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMWUFQ4	MT	DTT
DMWUFQ4	MA	Modulator
DMWUFQ4	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMWUFQ4	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMSYPNW	DI	DMSYPNW
DMSYPNW	DN	Ranibizumab
DMSYPNW	MI	TTOHSBA
DMSYPNW	MN	Vascular endothelial growth factor A (VEGFA)
DMSYPNW	MT	DTT
DMSYPNW	RN	Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006 Oct;26(8):859-70.
DMSYPNW	RU	https://pubmed.ncbi.nlm.nih.gov/17031284

DM0GUSX	DI	DM0GUSX
DM0GUSX	DN	Ranitidine
DM0GUSX	MI	DEJGDUW
DM0GUSX	MN	Cytochrome P450 1A2 (CYP1A2)
DM0GUSX	MT	DME
DM0GUSX	MA	Metabolism
DM0GUSX	RN	Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. Clin Pharmacol Ther. 1999 Apr;65(4):369-76.
DM0GUSX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10223772

DM0GUSX	DI	DM0GUSX
DM0GUSX	DN	Ranitidine
DM0GUSX	MI	DECB0K3
DM0GUSX	MN	Cytochrome P450 2D6 (CYP2D6)
DM0GUSX	MT	DME
DM0GUSX	MA	Metabolism
DM0GUSX	RN	Oxidation of ranitidine by isozymes of flavin-containing monooxygenase and cytochrome P450. Jpn J Pharmacol. 2000 Oct;84(2):213-20.
DM0GUSX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11128045

DM0GUSX	DI	DM0GUSX
DM0GUSX	DN	Ranitidine
DM0GUSX	MI	DEBMX7C
DM0GUSX	MN	Dimethylaniline oxidase 5 (FMO5)
DM0GUSX	MT	DME
DM0GUSX	MA	Metabolism
DM0GUSX	RN	Drug metabolism by flavin-containing monooxygenases of human and mouse. Expert Opin Drug Metab Toxicol. 2017 Feb;13(2):167-181.
DM0GUSX	RU	https://pubmed.ncbi.nlm.nih.gov/27678284

DM0GUSX	DI	DM0GUSX
DM0GUSX	DN	Ranitidine
DM0GUSX	MI	TTQHJ1K
DM0GUSX	MN	Histamine H2 receptor (H2R)
DM0GUSX	MT	DTT
DM0GUSX	MA	Antagonist
DM0GUSX	RN	Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
DM0GUSX	RU	https://pubmed.ncbi.nlm.nih.gov/12509758

DM0GUSX	DI	DM0GUSX
DM0GUSX	DN	Ranitidine
DM0GUSX	MI	DEGTFWK
DM0GUSX	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM0GUSX	MT	DME
DM0GUSX	MA	Metabolism
DM0GUSX	RN	Oxidation of ranitidine by isozymes of flavin-containing monooxygenase and cytochrome P450. Jpn J Pharmacol. 2000 Oct;84(2):213-20.
DM0GUSX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11128045

DM0GUSX	DI	DM0GUSX
DM0GUSX	DN	Ranitidine
DM0GUSX	MI	DT0OC1Q
DM0GUSX	MN	Organic anion transporter 2 (SLC22A7)
DM0GUSX	MT	DTP
DM0GUSX	MA	Substrate
DM0GUSX	RN	A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
DM0GUSX	RU	http://www.ncbi.nlm.nih.gov/pubmed/16006492

DM0GUSX	DI	DM0GUSX
DM0GUSX	DN	Ranitidine
DM0GUSX	MI	DTVP67E
DM0GUSX	MN	Organic anion transporter 3 (SLC22A8)
DM0GUSX	MT	DTP
DM0GUSX	MA	Substrate
DM0GUSX	RN	A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
DM0GUSX	RU	http://www.ncbi.nlm.nih.gov/pubmed/16006492

DM0GUSX	DI	DM0GUSX
DM0GUSX	DN	Ranitidine
DM0GUSX	MI	DTT79CX
DM0GUSX	MN	Organic cation transporter 1 (SLC22A1)
DM0GUSX	MT	DTP
DM0GUSX	MA	Substrate
DM0GUSX	RN	Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J Pharmacol Exp Ther. 2005 Dec;315(3):1288-97.
DM0GUSX	RU	http://www.ncbi.nlm.nih.gov/pubmed/16141367

DM0GUSX	DI	DM0GUSX
DM0GUSX	DN	Ranitidine
DM0GUSX	MI	DT9IDPW
DM0GUSX	MN	Organic cation transporter 2 (SLC22A2)
DM0GUSX	MT	DTP
DM0GUSX	MA	Substrate
DM0GUSX	RN	A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
DM0GUSX	RU	http://www.ncbi.nlm.nih.gov/pubmed/16006492

DM0GUSX	DI	DM0GUSX
DM0GUSX	DN	Ranitidine
DM0GUSX	MI	DTUGYRD
DM0GUSX	MN	P-glycoprotein 1 (ABCB1)
DM0GUSX	MT	DTP
DM0GUSX	MA	Substrate
DM0GUSX	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM0GUSX	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DM0C9IL	DI	DM0C9IL
DM0C9IL	DN	Ranolazine
DM0C9IL	MI	DECB0K3
DM0C9IL	MN	Cytochrome P450 2D6 (CYP2D6)
DM0C9IL	MT	DME
DM0C9IL	MA	Metabolism
DM0C9IL	RN	Ranolazine: a contemporary review. J Am Heart Assoc. 2016 Mar 15;5(3):e003196.
DM0C9IL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26979079

DM0C9IL	DI	DM0C9IL
DM0C9IL	DN	Ranolazine
DM0C9IL	MI	DE4LYSA
DM0C9IL	MN	Cytochrome P450 3A4 (CYP3A4)
DM0C9IL	MT	DME
DM0C9IL	MA	Metabolism
DM0C9IL	RN	Ranolazine: a contemporary review. J Am Heart Assoc. 2016 Mar 15;5(3):e003196.
DM0C9IL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26979079

DM0C9IL	DI	DM0C9IL
DM0C9IL	DN	Ranolazine
DM0C9IL	MI	DTUGYRD
DM0C9IL	MN	P-glycoprotein 1 (ABCB1)
DM0C9IL	MT	DTP
DM0C9IL	MA	Substrate
DM0C9IL	RN	Ranolazine-tacrolimus interaction. Ann Pharmacother. 2010 Nov;44(11):1844-9.
DM0C9IL	RU	http://www.ncbi.nlm.nih.gov/pubmed/20876828

DM0C9IL	DI	DM0C9IL
DM0C9IL	DN	Ranolazine
DM0C9IL	MI	TTP86E2
DM0C9IL	MN	Plasminogen (PLG)
DM0C9IL	MT	DTT
DM0C9IL	MA	Modulator
DM0C9IL	RN	Tranexamic acid in trauma: how should we use it. J Trauma Acute Care Surg. 2013 Jun;74(6):1575-86.
DM0C9IL	RU	https://pubmed.ncbi.nlm.nih.gov/23694890

DM3WKQ4	DI	DM3WKQ4
DM3WKQ4	DN	Rasagiline
DM3WKQ4	MI	DEJGDUW
DM3WKQ4	MN	Cytochrome P450 1A2 (CYP1A2)
DM3WKQ4	MT	DME
DM3WKQ4	MA	Metabolism
DM3WKQ4	RN	Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease. Am J Geriatr Pharmacother. 2006 Dec;4(4):330-46.
DM3WKQ4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17296539

DM3WKQ4	DI	DM3WKQ4
DM3WKQ4	DN	Rasagiline
DM3WKQ4	MI	TTGP7BY
DM3WKQ4	MN	Monoamine oxidase type B (MAO-B)
DM3WKQ4	MT	DTT
DM3WKQ4	MA	Inhibitor
DM3WKQ4	RN	Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox Res. 2009 Aug;16(2):148-59.
DM3WKQ4	RU	https://pubmed.ncbi.nlm.nih.gov/19526291

DMWTVAN	DI	DMWTVAN
DMWTVAN	DN	Rauwolfia serpentina root
DMWTVAN	MI	TTZIFHC
DMWTVAN	MN	Voltage-gated calcium channel alpha Cav1.2 (CACNA1C)
DMWTVAN	MT	DTT
DMWTVAN	MA	Inhibitor
DMWTVAN	RN	Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
DMWTVAN	RU	https://pubmed.ncbi.nlm.nih.gov/7562902

DMSWNJF	DI	DMSWNJF
DMSWNJF	DN	Ravulizumab
DMSWNJF	MI	TTKANGO
DMSWNJF	MN	Complement C5 (CO5)
DMSWNJF	MT	DTT
DMSWNJF	MA	Inhibitor
DMSWNJF	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMSWNJF	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DM7QG0M	DI	DM7QG0M
DM7QG0M	DN	Raxibacumab
DM7QG0M	MI	TT3YGCD
DM7QG0M	MN	Bacterial Protective antigen (Bact pagA)
DM7QG0M	MT	DTT
DM7QG0M	MA	Modulator
DM7QG0M	RN	Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011 Apr 1;186(7):4234-43.
DM7QG0M	RU	https://pubmed.ncbi.nlm.nih.gov/21383241

DM26PRD	DI	DM26PRD
DM26PRD	DN	Reboxetine
DM26PRD	MI	DE4LYSA
DM26PRD	MN	Cytochrome P450 3A4 (CYP3A4)
DM26PRD	MT	DME
DM26PRD	MA	Metabolism
DM26PRD	RN	Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. Clin Pharmacokinet. 2000 Dec;39(6):413-27.
DM26PRD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11192474

DM26PRD	DI	DM26PRD
DM26PRD	DN	Reboxetine
DM26PRD	MI	TTAWNKZ
DM26PRD	MN	Norepinephrine transporter (NET)
DM26PRD	MT	DTT
DM26PRD	MA	Inhibitor
DM26PRD	RN	Reboxetine: the first selective noradrenaline re-uptake inhibitor. Expert Opin Pharmacother. 2000 May;1(4):771-82.
DM26PRD	RU	https://pubmed.ncbi.nlm.nih.gov/11249515

DMY7ESM	DI	DMY7ESM
DMY7ESM	DN	Recombinant Factor IX
DMY7ESM	MI	TTFEZ5Q
DMY7ESM	MN	Coagulation factor IX (F9)
DMY7ESM	MT	DTT
DMY7ESM	MA	Modulator
DMY7ESM	RN	BAX326 (RIXUBIS): a novel recombinant factor IX for the control and prevention of bleeding episodes in adults and children with hemophilia B. Ther Adv Hematol. 2014 Oct;5(5):168-80.
DMY7ESM	RU	https://pubmed.ncbi.nlm.nih.gov/25324957

DMMPCFX	DI	DMMPCFX
DMMPCFX	DN	Recombinant human endostatin
DMMPCFX	MI	TTRPKQG
DMMPCFX	MN	Beta-catenin (CTNNB1)
DMMPCFX	MT	DTT
DMMPCFX	MA	Modulator
DMMPCFX	RN	Endostar, a modified recombinant human endostatin, suppresses angiogenesis through inhibition of Wnt/beta-catenin signaling pathway. PLoS One. 2014 Sep 18;9(9):e107463.
DMMPCFX	RU	https://pubmed.ncbi.nlm.nih.gov/25232946

DM76VHG	DI	DM76VHG
DM76VHG	DN	Regadenoson
DM76VHG	MI	TTM2AOE
DM76VHG	MN	Adenosine A2a receptor (ADORA2A)
DM76VHG	MT	DTT
DM76VHG	MA	Modulator
DM76VHG	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DM76VHG	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM87XSN	DI	DM87XSN
DM87XSN	DN	REGN-727
DM87XSN	MI	TTBRG7E
DM87XSN	MN	Proprotein convertase subtilisin/kexin type 9 (PCSK9)
DM87XSN	MT	DTT
DM87XSN	RN	Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012 Jul 7;380(9836):29-36.
DM87XSN	RU	https://pubmed.ncbi.nlm.nih.gov/22633824

DMHSY1I	DI	DMHSY1I
DMHSY1I	DN	Regorafenib
DMHSY1I	MI	DTI7UX6
DMHSY1I	MN	Breast cancer resistance protein (ABCG2)
DMHSY1I	MT	DTP
DMHSY1I	MA	Substrate
DMHSY1I	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01913)
DMHSY1I	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01913

DMHSY1I	DI	DMHSY1I
DMHSY1I	DN	Regorafenib
DMHSY1I	MI	DE4LYSA
DMHSY1I	MN	Cytochrome P450 3A4 (CYP3A4)
DMHSY1I	MT	DME
DMHSY1I	MA	Metabolism
DMHSY1I	RN	FDA Label of Regorafenib. The 2020 official website of the U.S. Food and Drug Administration.
DMHSY1I	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf

DMHSY1I	DI	DMHSY1I
DMHSY1I	DN	Regorafenib
DMHSY1I	MI	DTFI42L
DMHSY1I	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMHSY1I	MT	DTP
DMHSY1I	MA	Substrate
DMHSY1I	RN	Regorafenib is transported by the organic anion transporter 1B1 and the multidrug resistance protein 2. Biol Pharm Bull. 2015;38(4):582-6.
DMHSY1I	RU	http://www.ncbi.nlm.nih.gov/pubmed/25739790

DMHSY1I	DI	DMHSY1I
DMHSY1I	DN	Regorafenib
DMHSY1I	MI	DT3D8F0
DMHSY1I	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMHSY1I	MT	DTP
DMHSY1I	MA	Substrate
DMHSY1I	RN	Regorafenib is transported by the organic anion transporter 1B1 and the multidrug resistance protein 2. Biol Pharm Bull. 2015;38(4):582-6.
DMHSY1I	RU	http://www.ncbi.nlm.nih.gov/pubmed/25739790

DMHSY1I	DI	DMHSY1I
DMHSY1I	DN	Regorafenib
DMHSY1I	MI	DTUGYRD
DMHSY1I	MN	P-glycoprotein 1 (ABCB1)
DMHSY1I	MT	DTP
DMHSY1I	MA	Substrate
DMHSY1I	RN	Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1). Pharm Res. 2015 Jul;32(7):2205-16.
DMHSY1I	RU	http://www.ncbi.nlm.nih.gov/pubmed/25563977

DMHSY1I	DI	DMHSY1I
DMHSY1I	DN	Regorafenib
DMHSY1I	MI	TT4DXQT
DMHSY1I	MN	Proto-oncogene c-Ret (RET)
DMHSY1I	MT	DTT
DMHSY1I	MA	Modulator
DMHSY1I	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMHSY1I	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMHSY1I	DI	DMHSY1I
DMHSY1I	DN	Regorafenib
DMHSY1I	MI	TTX41N9
DMHSY1I	MN	Tyrosine-protein kinase Kit (KIT)
DMHSY1I	MT	DTT
DMHSY1I	MA	Modulator
DMHSY1I	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMHSY1I	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMHSY1I	DI	DMHSY1I
DMHSY1I	DN	Regorafenib
DMHSY1I	MI	DE85D2P
DMHSY1I	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMHSY1I	MT	DME
DMHSY1I	MA	Metabolism
DMHSY1I	RN	FDA Label of Regorafenib. The 2020 official website of the U.S. Food and Drug Administration.
DMHSY1I	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf

DMHSY1I	DI	DMHSY1I
DMHSY1I	DN	Regorafenib
DMHSY1I	MI	TTUTJGQ
DMHSY1I	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMHSY1I	MT	DTT
DMHSY1I	MA	Modulator
DMHSY1I	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMHSY1I	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMK7IWL	DI	DMK7IWL
DMK7IWL	DN	Relugolix
DMK7IWL	MI	TT8R70G
DMK7IWL	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMK7IWL	MT	DTT
DMK7IWL	MA	Antagonist
DMK7IWL	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMK7IWL	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214621s000lbl.pdf

DMK7IWL	DI	DMK7IWL
DMK7IWL	DN	Relugolix
DMK7IWL	MI	DTUGYRD
DMK7IWL	MN	P-glycoprotein 1 (ABCB1)
DMK7IWL	MT	DTP
DMK7IWL	MA	Substrate
DMK7IWL	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
DMK7IWL	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01665

DMBFZ6L	DI	DMBFZ6L
DMBFZ6L	DN	Remdesivir
DMBFZ6L	MI	TTV1095
DMBFZ6L	MN	COVID-19 RNA-directed RNA polymerase (RdRp)
DMBFZ6L	MT	DTT
DMBFZ6L	MA	Inhibitor
DMBFZ6L	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMBFZ6L	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214787Orig1s000lbl.pdf

DMZTXCH	DI	DMZTXCH
DMZTXCH	DN	Remifentanil
DMZTXCH	MI	TTKWM86
DMZTXCH	MN	Opioid receptor mu (MOP)
DMZTXCH	MT	DTT
DMZTXCH	MA	Agonist
DMZTXCH	RN	The pro-nociceptive effects of remifentanil or surgical injury in mice are associated with a decrease in delta-opioid receptor mRNA levels: Prevent... Pain. 2009 Jan;141(1-2):88-96.
DMZTXCH	RU	https://pubmed.ncbi.nlm.nih.gov/19058913

DMNAKLY	DI	DMNAKLY
DMNAKLY	DN	Remikiren
DMNAKLY	MI	TTB2MXP
DMNAKLY	MN	Angiotensinogenase renin (REN)
DMNAKLY	MT	DTT
DMNAKLY	MA	Inhibitor
DMNAKLY	RN	Functional expression of the renin-angiotensin system in human podocytes. Am J Physiol Renal Physiol. 2006 Mar;290(3):F710-9.
DMNAKLY	RU	https://pubmed.ncbi.nlm.nih.gov/16189286

DMLVSYX	DI	DMLVSYX
DMLVSYX	DN	Remimazolam
DMLVSYX	MI	TTEX6LM
DMLVSYX	MN	GABA(A) receptor gamma-3 (GABRG3)
DMLVSYX	MT	DTT
DMLVSYX	MA	Agonist
DMLVSYX	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMLVSYX	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212295s000lbl.pdf

DM5SXUV	DI	DM5SXUV
DM5SXUV	DN	Repaglinide
DM5SXUV	MI	TTP835K
DM5SXUV	MN	ATP-binding cassette transporter C8 (ABCC8)
DM5SXUV	MT	DTT
DM5SXUV	MA	Blocker
DM5SXUV	RN	Metformin/Repaglinide (PrandiMet) for type 2 diabetes. Med Lett Drugs Ther. 2009 Jun 1;51(1313):41-3.
DM5SXUV	RU	https://pubmed.ncbi.nlm.nih.gov/19478691

DM5SXUV	DI	DM5SXUV
DM5SXUV	DN	Repaglinide
DM5SXUV	MI	TTEF5MJ
DM5SXUV	MN	ATP-binding cassette transporter C9 (ABCC9)
DM5SXUV	MT	DTT
DM5SXUV	MA	Blocker
DM5SXUV	RN	Metformin/Repaglinide (PrandiMet) for type 2 diabetes. Med Lett Drugs Ther. 2009 Jun 1;51(1313):41-3.
DM5SXUV	RU	https://pubmed.ncbi.nlm.nih.gov/19478691

DM5SXUV	DI	DM5SXUV
DM5SXUV	DN	Repaglinide
DM5SXUV	MI	DES5XRU
DM5SXUV	MN	Cytochrome P450 2C8 (CYP2C8)
DM5SXUV	MT	DME
DM5SXUV	MA	Metabolism
DM5SXUV	RN	Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet. 2007;46(2):93-108.
DM5SXUV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17253883

DM5SXUV	DI	DM5SXUV
DM5SXUV	DN	Repaglinide
DM5SXUV	MI	DE4LYSA
DM5SXUV	MN	Cytochrome P450 3A4 (CYP3A4)
DM5SXUV	MT	DME
DM5SXUV	MA	Metabolism
DM5SXUV	RN	Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet. 2007;46(2):93-108.
DM5SXUV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17253883

DM5SXUV	DI	DM5SXUV
DM5SXUV	DN	Repaglinide
DM5SXUV	MI	DT3D8F0
DM5SXUV	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM5SXUV	MT	DTP
DM5SXUV	MA	Substrate
DM5SXUV	RN	Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium. Clin Pharmacol Ther. 2018 Nov;104(5):900-915.
DM5SXUV	RU	http://www.ncbi.nlm.nih.gov/pubmed/29756222

DM5SXUV	DI	DM5SXUV
DM5SXUV	DN	Repaglinide
DM5SXUV	MI	DEYGVN4
DM5SXUV	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM5SXUV	MT	DME
DM5SXUV	MA	Metabolism
DM5SXUV	RN	Repaglinide-gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanism. Br J Clin Pharmacol. 2010 Dec;70(6):870-80.
DM5SXUV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21175442

DM6KI0D	DI	DM6KI0D
DM6KI0D	DN	Repirinast
DM6KI0D	MI	TT7CXIM
DM6KI0D	MN	Histamine receptor (HR)
DM6KI0D	MT	DTT
DM6KI0D	MA	Modulator
DM6KI0D	RN	Mechanism of action of MY-1250, an active metabolite of Repirinast, in inhibiting histamine release from rat mast cells. Br J Pharmacol. 1992 Mar;105(3):587-90.
DM6KI0D	RU	https://pubmed.ncbi.nlm.nih.gov/1378339

DMG7SQK	DI	DMG7SQK
DMG7SQK	DN	Rescinnamine
DMG7SQK	MI	TTL69WB
DMG7SQK	MN	Angiotensin-converting enzyme (ACE)
DMG7SQK	MT	DTT
DMG7SQK	MA	Inhibitor
DMG7SQK	RN	Colorimetric determination of indolic drugs. Pak J Pharm Sci. 2005 Apr;18(2):48-51.
DMG7SQK	RU	https://pubmed.ncbi.nlm.nih.gov/16431399

DM6VM38	DI	DM6VM38
DM6VM38	DN	Reserpine
DM6VM38	MI	DTI7UX6
DM6VM38	MN	Breast cancer resistance protein (ABCG2)
DM6VM38	MT	DTP
DM6VM38	MA	Substrate
DM6VM38	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM6VM38	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DM6VM38	DI	DM6VM38
DM6VM38	DN	Reserpine
DM6VM38	MI	DTUGYRD
DM6VM38	MN	P-glycoprotein 1 (ABCB1)
DM6VM38	MT	DTP
DM6VM38	MA	Substrate
DM6VM38	RN	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
DM6VM38	RU	https://doi.org/10.1016/j.addr.2011.12.008

DM6VM38	DI	DM6VM38
DM6VM38	DN	Reserpine
DM6VM38	MI	TTNZRI3
DM6VM38	MN	Synaptic vesicle amine transporter (SLC18A2)
DM6VM38	MT	DTT
DM6VM38	MA	Blocker
DM6VM38	RN	Dopamine signaling is required for depolarization-induced slow current in cerebellar Purkinje cells. J Neurosci. 2009 Jul 1;29(26):8530-8.
DM6VM38	RU	https://pubmed.ncbi.nlm.nih.gov/19571144

DM0AUCH	DI	DM0AUCH
DM0AUCH	DN	Reslizumab
DM0AUCH	MI	TTPREZD
DM0AUCH	MN	Interleukin-5 (IL5)
DM0AUCH	MT	DTT
DM0AUCH	MA	Modulator
DM0AUCH	RN	The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. 
DM0AUCH	RU	https://www.ncbi.nlm.nih.gov/pubmed/23197041

DM9JXB7	DI	DM9JXB7
DM9JXB7	DN	Retapamulin
DM9JXB7	MI	TTUWYEA
DM9JXB7	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DM9JXB7	MT	DTT
DM9JXB7	MA	Inhibitor
DM9JXB7	RN	Retapamulin inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells. Antimicrob Agents Chemother. 2007 Sep;51(9):3385-7.
DM9JXB7	RU	https://pubmed.ncbi.nlm.nih.gov/17562806

DML0D1P	DI	DML0D1P
DML0D1P	DN	Reteplase
DML0D1P	MI	TTP86E2
DML0D1P	MN	Plasminogen (PLG)
DML0D1P	MT	DTT
DML0D1P	MA	Activator
DML0D1P	RN	Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23.
DML0D1P	RU	https://pubmed.ncbi.nlm.nih.gov/18673235

DMGNYIH	DI	DMGNYIH
DMGNYIH	DN	Retigabine
DMGNYIH	MI	DE6OQ3W
DMGNYIH	MN	Cytochrome P450 1A1 (CYP1A1)
DMGNYIH	MT	DME
DMGNYIH	MA	Metabolism
DMGNYIH	RN	Retigabine N-glucuronidation and its potential role in enterohepatic circulation. Drug Metab Dispos. 1999 May;27(5):605-12.
DMGNYIH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10220490

DMGNYIH	DI	DMGNYIH
DMGNYIH	DN	Retigabine
DMGNYIH	MI	DEYGVN4
DMGNYIH	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMGNYIH	MT	DME
DMGNYIH	MA	Metabolism
DMGNYIH	RN	N-Glucuronidation of the antiepileptic drug retigabine: results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler-Najjar type II. Metabolism. 2006 Jun;55(6):711-21.
DMGNYIH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16713428

DMGNYIH	DI	DMGNYIH
DMGNYIH	DN	Retigabine
DMGNYIH	MI	DEF2WXN
DMGNYIH	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMGNYIH	MT	DME
DMGNYIH	MA	Metabolism
DMGNYIH	RN	Retigabine N-glucuronidation and its potential role in enterohepatic circulation. Drug Metab Dispos. 1999 May;27(5):605-12.
DMGNYIH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10220490

DMGNYIH	DI	DMGNYIH
DMGNYIH	DN	Retigabine
DMGNYIH	MI	DE85D2P
DMGNYIH	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMGNYIH	MT	DME
DMGNYIH	MA	Metabolism
DMGNYIH	RN	Retigabine N-glucuronidation and its potential role in enterohepatic circulation. Drug Metab Dispos. 1999 May;27(5):605-12.
DMGNYIH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10220490

DMGNYIH	DI	DMGNYIH
DMGNYIH	DN	Retigabine
DMGNYIH	MI	TTQ29KF
DMGNYIH	MN	Voltage-gated potassium channel Kv7 (KCNQ)
DMGNYIH	MT	DTT
DMGNYIH	MA	Activator
DMGNYIH	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMGNYIH	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMGNYIH	DI	DMGNYIH
DMGNYIH	DN	Retigabine
DMGNYIH	MI	TTIVDM3
DMGNYIH	MN	Voltage-gated potassium channel Kv7.3 (KCNQ3)
DMGNYIH	MT	DTT
DMGNYIH	MA	Modulator
DMGNYIH	RN	The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (K(v)7) potassium channels. Epilepsia. 2012 Apr;53(4):606-12.
DMGNYIH	RU	https://pubmed.ncbi.nlm.nih.gov/22428574

DMMP5SI	DI	DMMP5SI
DMMP5SI	DN	Revefenacin
DMMP5SI	MI	DECB0K3
DMMP5SI	MN	Cytochrome P450 2D6 (CYP2D6)
DMMP5SI	MT	DME
DMMP5SI	MA	Metabolism
DMMP5SI	RN	A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease. Respir Res. 2017 Nov 2;18(1):182.
DMMP5SI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29096627

DMMP5SI	DI	DMMP5SI
DMMP5SI	DN	Revefenacin
DMMP5SI	MI	TTOXS3C
DMMP5SI	MN	Muscarinic acetylcholine receptor (CHRM)
DMMP5SI	MT	DTT
DMMP5SI	MA	Antagonist
DMMP5SI	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMMP5SI	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DM8LRU2	DI	DM8LRU2
DM8LRU2	DN	Revolade/Promacta
DM8LRU2	MI	TTIHYA4
DM8LRU2	MN	Thrombopoietin receptor (MPL)
DM8LRU2	MT	DTT
DM8LRU2	MA	Agonist
DM8LRU2	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DM8LRU2	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DM69XMQ	DI	DM69XMQ
DM69XMQ	DN	RG-7446
DM69XMQ	MI	TT8ZLTI
DM69XMQ	MN	Programmed cell death 1 ligand 1 (PD-L1)
DM69XMQ	MT	DTT
DM69XMQ	RN	PD-1 as a potential target in cancer therapy. Cancer Med. 2013 October; 2(5): 662-673.
DM69XMQ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3892798/

DMNF0G8	DI	DMNF0G8
DMNF0G8	DN	Rh-alphaglucosidase
DMNF0G8	MI	TTXWASR
DMNF0G8	MN	Intestinal maltase-glucoamylase (MGAM)
DMNF0G8	MT	DTT
DMNF0G8	MA	Modulator
DMNF0G8	RN	2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
DMNF0G8	RU	https://pubmed.ncbi.nlm.nih.gov/17342860

DM3ADGP	DI	DM3ADGP
DM3ADGP	DN	Rhucin
DM3ADGP	MI	TTVQ6R9
DM3ADGP	MN	C1 esterase inhibitor (SERPING1)
DM3ADGP	MT	DTT
DM3ADGP	MA	Modulator
DM3ADGP	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DM3ADGP	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DM3ADGP	DI	DM3ADGP
DM3ADGP	DN	Rhucin
DM3ADGP	MI	TTJ0IQB
DM3ADGP	MN	Phosphodiesterase 5A (PDE5A)
DM3ADGP	MT	DTT
DM3ADGP	MA	Inhibitor
DM3ADGP	RN	cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium. J Pharmacol Exp Ther. 2009 Sep;330(3):884-91.
DM3ADGP	RU	https://pubmed.ncbi.nlm.nih.gov/19546307

DMALNG0	DI	DMALNG0
DMALNG0	DN	RHuEPO
DMALNG0	MI	TTAUX24
DMALNG0	MN	Erythropoietin Receptor (EPOR)
DMALNG0	MT	DTT
DMALNG0	MA	Stimulator
DMALNG0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1718).
DMALNG0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1718

DMEYLH9	DI	DMEYLH9
DMEYLH9	DN	Ribavirin
DMEYLH9	MI	DT4YL5R
DMEYLH9	MN	Concentrative Na(+)-nucleoside cotransporter 3 (SLC28A3)
DMEYLH9	MT	DTP
DMEYLH9	MA	Substrate
DMEYLH9	RN	Kinetic study of anti-viral ribavirin uptake mediated by hCNT3 and hENT1 in Xenopus laevis oocytes. Biophys Chem. 2010 Mar;147(1-2):59-65.
DMEYLH9	RU	http://www.ncbi.nlm.nih.gov/pubmed/20096989

DMEYLH9	DI	DMEYLH9
DMEYLH9	DN	Ribavirin
DMEYLH9	MI	DT82KPY
DMEYLH9	MN	Concentrative nucleoside transporter 2 (SLC28A2)
DMEYLH9	MT	DTP
DMEYLH9	MA	Substrate
DMEYLH9	RN	Identification and functional analysis of variants in the human concentrative nucleoside transporter 2, hCNT2 (SLC28A2) in Chinese, Malays and Indians. Pharmacogenet Genomics. 2007 Sep;17(9):783-6.
DMEYLH9	RU	http://www.ncbi.nlm.nih.gov/pubmed/17700367

DMEYLH9	DI	DMEYLH9
DMEYLH9	DN	Ribavirin
DMEYLH9	MI	DE1DOKJ
DMEYLH9	MN	Cytosolic 5'-nucleotidase II (NT5C2)
DMEYLH9	MT	DME
DMEYLH9	MA	Metabolism
DMEYLH9	RN	Phosphorylation of ribavirin and viramidine by adenosine kinase and cytosolic 5'-nucleotidase II: Implications for ribavirin metabolism in erythrocytes. Antimicrob Agents Chemother. 2005 Jun;49(6):2164-71.
DMEYLH9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15917509

DMEYLH9	DI	DMEYLH9
DMEYLH9	DN	Ribavirin
DMEYLH9	MI	DTXD1TQ
DMEYLH9	MN	Equilibrative nucleoside transporter 1 (SLC29A1)
DMEYLH9	MT	DTP
DMEYLH9	MA	Substrate
DMEYLH9	RN	Effects of dipyridamole coadministration on the pharmacokinetics of ribavirin in healthy volunteers. Drug Metab Pharmacokinet. 2013;28(5):406-10.
DMEYLH9	RU	http://www.ncbi.nlm.nih.gov/pubmed/23459628

DMEYLH9	DI	DMEYLH9
DMEYLH9	DN	Ribavirin
DMEYLH9	MI	TTL7C8Q
DMEYLH9	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMEYLH9	MT	DTT
DMEYLH9	MA	Inhibitor
DMEYLH9	RN	Treating HCV with ribavirin analogues and ribavirin-like molecules. J Antimicrob Chemother. 2006 Jan;57(1):8-13.
DMEYLH9	RU	https://pubmed.ncbi.nlm.nih.gov/16293677

DMEYLH9	DI	DMEYLH9
DMEYLH9	DN	Ribavirin
DMEYLH9	MI	DT9G7XN
DMEYLH9	MN	Peptide transporter 1 (SLC15A1)
DMEYLH9	MT	DTP
DMEYLH9	MA	Substrate
DMEYLH9	RN	Transport of levovirin prodrugs in the human intestinal Caco-2 cell line. J Pharm Sci. 2006 Jun;95(6):1318-25.
DMEYLH9	RU	https://doi.org/10.1002/jps.20434

DMEYLH9	DI	DMEYLH9
DMEYLH9	DN	Ribavirin
DMEYLH9	MI	DE2WSAL
DMEYLH9	MN	Purine nucleoside phosphorylase (PNP)
DMEYLH9	MT	DME
DMEYLH9	MA	Metabolism
DMEYLH9	RN	Functional analysis of purine nucleoside phosphorylase as a key enzyme in ribavirin metabolism. Drug Metab Pharmacokinet. 2014;29(2):211-4.
DMEYLH9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24107682

DM9CIUW	DI	DM9CIUW
DM9CIUW	DN	Ribociclib succinate
DM9CIUW	MI	TT0PG8F
DM9CIUW	MN	Cyclin-dependent kinase 4 (CDK4)
DM9CIUW	MT	DTT
DM9CIUW	MA	Modulator
DM9CIUW	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM9CIUW	RU	https://www.fda.gov/

DM9CIUW	DI	DM9CIUW
DM9CIUW	DN	Ribociclib succinate
DM9CIUW	MI	TTO0FDJ
DM9CIUW	MN	Cyclin-dependent kinase 6 (CDK6)
DM9CIUW	MT	DTT
DM9CIUW	MA	Modulator
DM9CIUW	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM9CIUW	RU	https://www.fda.gov/

DM9CIUW	DI	DM9CIUW
DM9CIUW	DN	Ribociclib succinate
DM9CIUW	MI	DE4LYSA
DM9CIUW	MN	Cytochrome P450 3A4 (CYP3A4)
DM9CIUW	MT	DME
DM9CIUW	MA	Metabolism
DM9CIUW	RN	P-glycoprotein limits ribociclib brain exposure and CYP3A4 restricts its oral bioavailability. Mol Pharm. 2019 Sep 3;16(9):3842-3852.
DM9CIUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31329454

DM8YMWE	DI	DM8YMWE
DM8YMWE	DN	Riboflavin
DM8YMWE	MI	DER6BCE
DM8YMWE	MN	Acid phosphatase-like protein 1 (ACP6)
DM8YMWE	MT	DME
DM8YMWE	MA	Metabolism
DM8YMWE	RN	An atlas of human metabolism. Sci Signal. 2020 Mar 24;13(624). pii: eaaz1482. (Reaction HMR_6507)
DM8YMWE	RU	https://www.metabolicatlas.org/explore/gem-browser/human1/reaction/HMR_6507

DM8YMWE	DI	DM8YMWE
DM8YMWE	DN	Riboflavin
DM8YMWE	MI	DTI7UX6
DM8YMWE	MN	Breast cancer resistance protein (ABCG2)
DM8YMWE	MT	DTP
DM8YMWE	MA	Substrate
DM8YMWE	RN	Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk. Mol Cell Biol. 2007 Feb;27(4):1247-53.
DM8YMWE	RU	http://www.ncbi.nlm.nih.gov/pubmed/17145775

DM8YMWE	DI	DM8YMWE
DM8YMWE	DN	Riboflavin
DM8YMWE	MI	DE6OQ3W
DM8YMWE	MN	Cytochrome P450 1A1 (CYP1A1)
DM8YMWE	MT	DME
DM8YMWE	MA	Metabolism
DM8YMWE	RN	Disruption of endogenous regulator homeostasis underlies the mechanism of rat CYP1A1 mRNA induction by metyrapone. Biochem J. 1998 Apr 1;331 ( Pt 1):273-81.
DM8YMWE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9512490

DM8YMWE	DI	DM8YMWE
DM8YMWE	DN	Riboflavin
DM8YMWE	MI	DETE84Z
DM8YMWE	MN	Eosinophil peroxidase (EPX)
DM8YMWE	MT	DME
DM8YMWE	MA	Metabolism
DM8YMWE	RN	An atlas of human metabolism. Sci Signal. 2020 Mar 24;13(624). pii: eaaz1482. (Reaction HMR_6507)
DM8YMWE	RU	https://www.metabolicatlas.org/explore/gem-browser/human1/reaction/HMR_6507

DM8YMWE	DI	DM8YMWE
DM8YMWE	DN	Riboflavin
DM8YMWE	MI	DE21PLI
DM8YMWE	MN	NADPH-dependent nitroreductase (nfrA1)
DM8YMWE	MT	DME
DM8YMWE	MA	Metabolism
DM8YMWE	RN	Conversion of NfsA, the major Escherichia coli nitroreductase, to a flavin reductase with an activity similar to that of Frp, a flavin reductase in Vibrio harveyi, by a single amino acid substitution. J Bacteriol. 1998 Jan;180(2):422-5.
DM8YMWE	RU	https://pubmed.ncbi.nlm.nih.gov/9440535

DM8YMWE	DI	DM8YMWE
DM8YMWE	DN	Riboflavin
DM8YMWE	MI	DE82GV7
DM8YMWE	MN	NADPH-dependent oxidoreductase (nfrA)
DM8YMWE	MT	DME
DM8YMWE	MA	Metabolism
DM8YMWE	RN	Reduction of polynitroaromatic compounds: the bacterial nitroreductases. FEMS Microbiol Rev. 2008 May;32(3):474-500.
DM8YMWE	RU	https://pubmed.ncbi.nlm.nih.gov/18355273

DM8YMWE	DI	DM8YMWE
DM8YMWE	DN	Riboflavin
DM8YMWE	MI	DE0K82S
DM8YMWE	MN	Nitroreductase (NTR)
DM8YMWE	MT	DME
DM8YMWE	MA	Metabolism
DM8YMWE	RN	Purification and characterization of wild-type and mutant "classical" nitroreductases of Salmonella typhimurium. L33R mutation greatly diminishes binding of FMN to the nitroreductase of S. typhimurium. J Biol Chem. 1998 Sep 11;273(37):23922-8.
DM8YMWE	RU	https://pubmed.ncbi.nlm.nih.gov/9727006

DM8YMWE	DI	DM8YMWE
DM8YMWE	DN	Riboflavin
DM8YMWE	MI	DEDW5H6
DM8YMWE	MN	Prostatic acid phosphatase (ACP3)
DM8YMWE	MT	DME
DM8YMWE	MA	Metabolism
DM8YMWE	RN	An atlas of human metabolism. Sci Signal. 2020 Mar 24;13(624). pii: eaaz1482. (Reaction HMR_6507)
DM8YMWE	RU	https://www.metabolicatlas.org/explore/gem-browser/human1/reaction/HMR_6507

DM8YMWE	DI	DM8YMWE
DM8YMWE	DN	Riboflavin
DM8YMWE	MI	DT7NOKR
DM8YMWE	MN	Riboflavin transporter 1 (SLC52A1)
DM8YMWE	MT	DTP
DM8YMWE	MA	Substrate
DM8YMWE	RN	An intronic variation in SLC52A1 causes exon skipping and transient riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency. Mol Genet Metab. 2017 Dec;122(4):182-188.
DM8YMWE	RU	http://www.ncbi.nlm.nih.gov/pubmed/29122468

DM8YMWE	DI	DM8YMWE
DM8YMWE	DN	Riboflavin
DM8YMWE	MI	DTBVQIO
DM8YMWE	MN	Riboflavin transporter 2 (SLC52A3)
DM8YMWE	MT	DTP
DM8YMWE	MA	Substrate
DM8YMWE	RN	An intronic variation in SLC52A1 causes exon skipping and transient riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency. Mol Genet Metab. 2017 Dec;122(4):182-188.
DM8YMWE	RU	http://www.ncbi.nlm.nih.gov/pubmed/29122468

DM8YMWE	DI	DM8YMWE
DM8YMWE	DN	Riboflavin
DM8YMWE	MI	DTAVOS6
DM8YMWE	MN	Riboflavin transporter 3 (SLC52A2)
DM8YMWE	MT	DTP
DM8YMWE	MA	Substrate
DM8YMWE	RN	An intronic variation in SLC52A1 causes exon skipping and transient riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency. Mol Genet Metab. 2017 Dec;122(4):182-188.
DM8YMWE	RU	http://www.ncbi.nlm.nih.gov/pubmed/29122468

DM8YMWE	DI	DM8YMWE
DM8YMWE	DN	Riboflavin
DM8YMWE	MI	DESITDW
DM8YMWE	MN	Tartrate-resistant acid ATPase (ACP5)
DM8YMWE	MT	DME
DM8YMWE	MA	Metabolism
DM8YMWE	RN	An atlas of human metabolism. Sci Signal. 2020 Mar 24;13(624). pii: eaaz1482. (Reaction HMR_6507)
DM8YMWE	RU	https://www.metabolicatlas.org/explore/gem-browser/human1/reaction/HMR_6507

DM8YMWE	DI	DM8YMWE
DM8YMWE	DN	Riboflavin
DM8YMWE	MI	DE3OZT4
DM8YMWE	MN	Testicular acid phosphatase (ACP4)
DM8YMWE	MT	DME
DM8YMWE	MA	Metabolism
DM8YMWE	RN	An atlas of human metabolism. Sci Signal. 2020 Mar 24;13(624). pii: eaaz1482. (Reaction HMR_6507)
DM8YMWE	RU	https://www.metabolicatlas.org/explore/gem-browser/human1/reaction/HMR_6507

DM8YMWE	DI	DM8YMWE
DM8YMWE	DN	Riboflavin
DM8YMWE	MI	DEGSUI0
DM8YMWE	MN	Xylosyl phosphatase (PXYLP1)
DM8YMWE	MT	DME
DM8YMWE	MA	Metabolism
DM8YMWE	RN	An atlas of human metabolism. Sci Signal. 2020 Mar 24;13(624). pii: eaaz1482. (Reaction HMR_6507)
DM8YMWE	RU	https://www.metabolicatlas.org/explore/gem-browser/human1/reaction/HMR_6507

DMWH9CN	DI	DMWH9CN
DMWH9CN	DN	Ridogrel
DMWH9CN	MI	TT2O84V
DMWH9CN	MN	Thromboxane A2 receptor (TBXA2R)
DMWH9CN	MT	DTT
DMWH9CN	MA	Binder
DMWH9CN	RN	Chronic ouabain treatment exacerbates blood pressure elevation in spontaneously hypertensive rats: the role of vascular mechanisms. J Hypertens. 2009 Jun;27(6):1233-42.
DMWH9CN	RU	https://pubmed.ncbi.nlm.nih.gov/19337130

DM1YBHK	DI	DM1YBHK
DM1YBHK	DN	Rifabutin
DM1YBHK	MI	DE4LYSA
DM1YBHK	MN	Cytochrome P450 3A4 (CYP3A4)
DM1YBHK	MT	DME
DM1YBHK	MA	Metabolism
DM1YBHK	RN	The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Clin Pharmacol Ther. 1998 Apr;63(4):414-21.
DM1YBHK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9585795

DM1YBHK	DI	DM1YBHK
DM1YBHK	DN	Rifabutin
DM1YBHK	MI	TTHKJLN
DM1YBHK	MN	DNA-directed RNA polymerase (RNAP)
DM1YBHK	MT	DTT
DM1YBHK	MA	Modulator
DM1YBHK	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM1YBHK	RU	https://www.fda.gov/

DM5DSFZ	DI	DM5DSFZ
DM5DSFZ	DN	Rifampicin
DM5DSFZ	MI	DEJGDUW
DM5DSFZ	MN	Cytochrome P450 1A2 (CYP1A2)
DM5DSFZ	MT	DME
DM5DSFZ	MA	Metabolism
DM5DSFZ	RN	Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos. 2003 Apr;31(4):421-31.
DM5DSFZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12642468

DM5DSFZ	DI	DM5DSFZ
DM5DSFZ	DN	Rifampicin
DM5DSFZ	MI	DEPKLMQ
DM5DSFZ	MN	Cytochrome P450 2B6 (CYP2B6)
DM5DSFZ	MT	DME
DM5DSFZ	MA	Metabolism
DM5DSFZ	RN	Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. Clin Pharmacol Ther. 2006 Jul;80(1):75-84.
DM5DSFZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16815319

DM5DSFZ	DI	DM5DSFZ
DM5DSFZ	DN	Rifampicin
DM5DSFZ	MI	DE5IED8
DM5DSFZ	MN	Cytochrome P450 2C9 (CYP2C9)
DM5DSFZ	MT	DME
DM5DSFZ	MA	Metabolism
DM5DSFZ	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM5DSFZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM5DSFZ	DI	DM5DSFZ
DM5DSFZ	DN	Rifampicin
DM5DSFZ	MI	DECB0K3
DM5DSFZ	MN	Cytochrome P450 2D6 (CYP2D6)
DM5DSFZ	MT	DME
DM5DSFZ	MA	Metabolism
DM5DSFZ	RN	Xenobiotic-metabolizing cytochromes p450 in human white adipose tissue: expression and induction. Drug Metab Dispos. 2010 Apr;38(4):679-86.
DM5DSFZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20035023

DM5DSFZ	DI	DM5DSFZ
DM5DSFZ	DN	Rifampicin
DM5DSFZ	MI	DEVDYN7
DM5DSFZ	MN	Cytochrome P450 2E1 (CYP2E1)
DM5DSFZ	MT	DME
DM5DSFZ	MA	Metabolism
DM5DSFZ	RN	Protective effect of rifampicin against acute liver injury induced by carbon tetrachloride in mice. Jpn J Pharmacol. 1995 Dec;69(4):325-34.
DM5DSFZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8786635

DM5DSFZ	DI	DM5DSFZ
DM5DSFZ	DN	Rifampicin
DM5DSFZ	MI	DE4LYSA
DM5DSFZ	MN	Cytochrome P450 3A4 (CYP3A4)
DM5DSFZ	MT	DME
DM5DSFZ	MA	Metabolism
DM5DSFZ	RN	Ketoconazole and rifampin significantly affect the pharmacokinetics, but not the safety or QTc interval, of casopitant, a neurokinin-1 receptor antagonist. J Clin Pharmacol. 2010 Aug;50(8):951-9.
DM5DSFZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20124517

DM5DSFZ	DI	DM5DSFZ
DM5DSFZ	DN	Rifampicin
DM5DSFZ	MI	DEGTFWK
DM5DSFZ	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM5DSFZ	MT	DME
DM5DSFZ	MA	Metabolism
DM5DSFZ	RN	Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers. Clin Pharmacol Ther. 2002 Nov;72(5):505-13.
DM5DSFZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12426514

DM5DSFZ	DI	DM5DSFZ
DM5DSFZ	DN	Rifampicin
DM5DSFZ	MI	DE6PKFB
DM5DSFZ	MN	Rifampicin monooxygenase (rox)
DM5DSFZ	MT	DME
DM5DSFZ	MA	Metabolism
DM5DSFZ	RN	Mechanism of rifampicin inactivation in Nocardia farcinica. PLoS One. 2016 Oct 5;11(10):e0162578.
DM5DSFZ	RU	https://pubmed.ncbi.nlm.nih.gov/27706151

DMA8J1G	DI	DMA8J1G
DMA8J1G	DN	Rifampin
DMA8J1G	MI	TTIJ5EB
DMA8J1G	MN	Bacterial RNA polymerase switch region (Bact RNAP-SR)
DMA8J1G	MT	DTT
DMA8J1G	MA	Inhibitor
DMA8J1G	RN	Bacillus subtilis tolerance of moderate concentrations of rifampin involves the sigma(B)-dependent general and multiple stress response. J Bacteriol. 2002 Jan;184(2):459-67.
DMA8J1G	RU	https://pubmed.ncbi.nlm.nih.gov/11751823

DMA8J1G	DI	DMA8J1G
DMA8J1G	DN	Rifampin
DMA8J1G	MI	DTI7UX6
DMA8J1G	MN	Breast cancer resistance protein (ABCG2)
DMA8J1G	MT	DTP
DMA8J1G	MA	Substrate
DMA8J1G	RN	Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). Biochem J. 2005 Jan 15;385(Pt 2):419-26.
DMA8J1G	RU	https://doi.org/10.1042/BJ20040791

DMA8J1G	DI	DMA8J1G
DMA8J1G	DN	Rifampin
DMA8J1G	MI	DTFI42L
DMA8J1G	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMA8J1G	MT	DTP
DMA8J1G	MA	Substrate
DMA8J1G	RN	Expression and distribution of CYP3A genes, CYP2B22, and MDR1, MRP1, MRP2, LRP efflux transporters in brain of control and rifampicin-treated pigs. Mol Cell Biochem. 2010 Apr;337(1-2):133-43.
DMA8J1G	RU	http://www.ncbi.nlm.nih.gov/pubmed/19844775

DMA8J1G	DI	DMA8J1G
DMA8J1G	DN	Rifampin
DMA8J1G	MI	DT3D8F0
DMA8J1G	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMA8J1G	MT	DTP
DMA8J1G	MA	Substrate
DMA8J1G	RN	Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther. 2003 Jan;304(1):223-8.
DMA8J1G	RU	http://www.ncbi.nlm.nih.gov/pubmed/12490595

DMA8J1G	DI	DMA8J1G
DMA8J1G	DN	Rifampin
DMA8J1G	MI	DT9C1TS
DMA8J1G	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMA8J1G	MT	DTP
DMA8J1G	MA	Substrate
DMA8J1G	RN	Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology. 2002 Jul;36(1):164-72.
DMA8J1G	RU	http://www.ncbi.nlm.nih.gov/pubmed/12085361

DMA8J1G	DI	DMA8J1G
DMA8J1G	DN	Rifampin
DMA8J1G	MI	DTUGYRD
DMA8J1G	MN	P-glycoprotein 1 (ABCB1)
DMA8J1G	MT	DTP
DMA8J1G	MA	Substrate
DMA8J1G	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMA8J1G	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMEH3O7	DI	DMEH3O7
DMEH3O7	DN	Rifamycin
DMEH3O7	MI	TTR6YA2
DMEH3O7	MN	Bacterial RNA polymerase sigma factor SigA (Bact sigA)
DMEH3O7	MT	DTT
DMEH3O7	MA	Modulator
DMEH3O7	RN	NCBI report
DMEH3O7	RU	http://www.ncbi.nlm.nih.gov/Structure/mmdb/mmdbsrv.cgi?uid=4OIR

DMEH3O7	DI	DMEH3O7
DMEH3O7	DN	Rifamycin
DMEH3O7	MI	TT79JGK
DMEH3O7	MN	Mycobacterium RNA polymerase (MycB RNAP)
DMEH3O7	MT	DTT
DMEH3O7	MA	Inhibitor
DMEH3O7	RN	Rifamycin action on RNA polymerase in antibiotic-tolerant Mycobacterium tuberculosis results in differentially detectable populations.Proc Natl Acad Sci U S A. 2017 Jun 13;114(24):E4832-E4840. 
DMEH3O7	RU	https://pubmed.ncbi.nlm.nih.gov/28559332

DMEH3O7	DI	DMEH3O7
DMEH3O7	DN	Rifamycin
DMEH3O7	MI	TTS31JH
DMEH3O7	MN	Staphylococcus Plastid RNA polymerase beta (Stap-coc rpoB)
DMEH3O7	MT	DTT
DMEH3O7	MA	Modulator
DMEH3O7	RN	NCBI report
DMEH3O7	RU	http://www.ncbi.nlm.nih.gov/Structure/mmdb/mmdbsrv.cgi?uid=4OIR

DMCHV4I	DI	DMCHV4I
DMCHV4I	DN	Rifapentine
DMCHV4I	MI	DE4LYSA
DMCHV4I	MN	Cytochrome P450 3A4 (CYP3A4)
DMCHV4I	MT	DME
DMCHV4I	MA	Metabolism
DMCHV4I	RN	Inhibitory potential of twenty five anti-tuberculosis drugs on CYP activities in human liver microsomes. Biol Pharm Bull. 2015;38(9):1425-9.
DMCHV4I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26094899

DMCHV4I	DI	DMCHV4I
DMCHV4I	DN	Rifapentine
DMCHV4I	MI	TTHKJLN
DMCHV4I	MN	DNA-directed RNA polymerase (RNAP)
DMCHV4I	MT	DTT
DMCHV4I	MA	Binder
DMCHV4I	RN	Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1998 Jul;42(7):1853-7.
DMCHV4I	RU	https://pubmed.ncbi.nlm.nih.gov/9661035

DMW1TV2	DI	DMW1TV2
DMW1TV2	DN	Rifaximin
DMW1TV2	MI	DE4LYSA
DMW1TV2	MN	Cytochrome P450 3A4 (CYP3A4)
DMW1TV2	MT	DME
DMW1TV2	MA	Metabolism
DMW1TV2	RN	Probable interaction between warfarin and rifaximin in a patient treated for small intestine bacterial overgrowth. Ann Pharmacother. 2011 May;45(5):e25.
DMW1TV2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21505109

DMW1TV2	DI	DMW1TV2
DMW1TV2	DN	Rifaximin
DMW1TV2	MI	DTUGYRD
DMW1TV2	MN	P-glycoprotein 1 (ABCB1)
DMW1TV2	MT	DTP
DMW1TV2	MA	Substrate
DMW1TV2	RN	Advantageous Solubility-Permeability Interplay When Using Amorphous Solid Dispersion (ASD) Formulation for the BCS Class IV P-gp Substrate Rifaximin: Simultaneous Increase of Both the Solubility and the Permeability. AAPS J. 2017 May;19(3):806-813.
DMW1TV2	RU	http://www.ncbi.nlm.nih.gov/pubmed/28204967

DM13PQW	DI	DM13PQW
DM13PQW	DN	Rilmenidine
DM13PQW	MI	TT2NUT5
DM13PQW	MN	Adrenergic receptor alpha-2C (ADRA2C)
DM13PQW	MT	DTT
DM13PQW	MA	Modulator
DM13PQW	RN	Rilmenidine-induced ocular hypotension: role of imidazoline1 and alpha 2 receptors. Curr Eye Res. 1996 Sep;15(9):943-50.
DM13PQW	RU	https://pubmed.ncbi.nlm.nih.gov/8921215

DMGLUQS	DI	DMGLUQS
DMGLUQS	DN	Rilonacept
DMGLUQS	MI	TTRYK0X
DMGLUQS	MN	Interleukin-1 beta (IL1B)
DMGLUQS	MT	DTT
DMGLUQS	MA	Modulator
DMGLUQS	RN	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
DMGLUQS	RU	https://pubmed.ncbi.nlm.nih.gov/19180096

DMJ0QOW	DI	DMJ0QOW
DMJ0QOW	DN	Rilpivirine
DMJ0QOW	MI	DE4LYSA
DMJ0QOW	MN	Cytochrome P450 3A4 (CYP3A4)
DMJ0QOW	MT	DME
DMJ0QOW	MA	Metabolism
DMJ0QOW	RN	Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro. Int J Antimicrob Agents. 2013 May;41(5):484-7.
DMJ0QOW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23428312

DMJ0QOW	DI	DMJ0QOW
DMJ0QOW	DN	Rilpivirine
DMJ0QOW	MI	TT84ETX
DMJ0QOW	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMJ0QOW	MT	DTT
DMJ0QOW	MA	Inhibitor
DMJ0QOW	RN	Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416.
DMJ0QOW	RU	https://pubmed.ncbi.nlm.nih.gov/18764719

DMJ0QOW	DI	DMJ0QOW
DMJ0QOW	DN	Rilpivirine
DMJ0QOW	MI	DEGTFWK
DMJ0QOW	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMJ0QOW	MT	DME
DMJ0QOW	MA	Metabolism
DMJ0QOW	RN	Population pharmacokinetics and pharmacogenetics analysis of rilpivirine in HIV-1-infected individuals. Antimicrob Agents Chemother. 2016 Dec 27;61(1).
DMJ0QOW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27799217

DMJ0QOW	DI	DMJ0QOW
DMJ0QOW	DN	Rilpivirine
DMJ0QOW	MI	DEYGVN4
DMJ0QOW	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMJ0QOW	MT	DME
DMJ0QOW	MA	Metabolism
DMJ0QOW	RN	Human biotransformation of the nonnucleoside reverse transcriptase inhibitor rilpivirine and a cross-species metabolism comparison. Antimicrob Agents Chemother. 2013 Oct;57(10):5067-79.
DMJ0QOW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23917319

DMJ0QOW	DI	DMJ0QOW
DMJ0QOW	DN	Rilpivirine
DMJ0QOW	MI	DELOY3P
DMJ0QOW	MN	UDP-glucuronosyltransferase 1A4 (UGT1A4)
DMJ0QOW	MT	DME
DMJ0QOW	MA	Metabolism
DMJ0QOW	RN	Human biotransformation of the nonnucleoside reverse transcriptase inhibitor rilpivirine and a cross-species metabolism comparison. Antimicrob Agents Chemother. 2013 Oct;57(10):5067-79.
DMJ0QOW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23917319

DMJ0QOW	DI	DMJ0QOW
DMJ0QOW	DN	Rilpivirine
DMJ0QOW	MI	TT90XZ8
DMJ0QOW	MN	Voltage-gated sodium channel alpha Nav1.8 (SCN10A)
DMJ0QOW	MT	DTT
DMJ0QOW	MA	Inhibitor
DMJ0QOW	RN	Structures of muO-conotoxins from Conus marmoreus. I nhibitors of tetrodotoxin (TTX)-sensitive and TTX-resistant sodium channels in mammalian senso... J Biol Chem. 2004 Jun 11;279(24):25774-82.
DMJ0QOW	RU	https://pubmed.ncbi.nlm.nih.gov/15044438

DMECBWN	DI	DMECBWN
DMECBWN	DN	Riluzole
DMECBWN	MI	DTI7UX6
DMECBWN	MN	Breast cancer resistance protein (ABCG2)
DMECBWN	MT	DTP
DMECBWN	MA	Substrate
DMECBWN	RN	Interactions between riluzole and ABCG2/BCRP transporter. Neurosci Lett. 2009 Mar 6;452(1):12-6.
DMECBWN	RU	http://www.ncbi.nlm.nih.gov/pubmed/19146924

DMECBWN	DI	DMECBWN
DMECBWN	DN	Riluzole
DMECBWN	MI	DE6OQ3W
DMECBWN	MN	Cytochrome P450 1A1 (CYP1A1)
DMECBWN	MT	DME
DMECBWN	MA	Metabolism
DMECBWN	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMECBWN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMECBWN	DI	DMECBWN
DMECBWN	DN	Riluzole
DMECBWN	MI	DEJGDUW
DMECBWN	MN	Cytochrome P450 1A2 (CYP1A2)
DMECBWN	MT	DME
DMECBWN	MA	Metabolism
DMECBWN	RN	Association between CYP1A2 activity and riluzole clearance in patients with amyotrophic lateral sclerosis. Br J Clin Pharmacol. 2005 Mar;59(3):310-3.
DMECBWN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15752377

DMECBWN	DI	DMECBWN
DMECBWN	DN	Riluzole
DMECBWN	MI	DEYGVN4
DMECBWN	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMECBWN	MT	DME
DMECBWN	MA	Metabolism
DMECBWN	RN	Involvement of human CYP1A isoenzymes in the metabolism and drug interactions of riluzole in vitro. J Pharmacol Exp Ther. 1997 Sep;282(3):1465-72.
DMECBWN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9316860

DMECBWN	DI	DMECBWN
DMECBWN	DN	Riluzole
DMECBWN	MI	TTN9VTF
DMECBWN	MN	Voltage-gated sodium channel alpha Nav1.9 (SCN11A)
DMECBWN	MT	DTT
DMECBWN	MA	Blocker
DMECBWN	RN	Secondary injury mechanisms of spinal cord trauma: a novel therapeutic approach for the management of secondary pathophysiology with the sodium channel blocker riluzole. Prog Brain Res. 2002;137:177-90.
DMECBWN	RU	https://pubmed.ncbi.nlm.nih.gov/12440368

DM5DWMU	DI	DM5DWMU
DM5DWMU	DN	Rimantadine
DM5DWMU	MI	TTXT3PU
DM5DWMU	MN	Influenza M2 protein (Influ M)
DM5DWMU	MT	DTT
DM5DWMU	MA	Inhibitor
DM5DWMU	RN	Antiviral resistance of influenza A (H3N2) strains isolated in northern Greece between 2004 and 2007. Euro Surveill. 2009 Jan 29;14(4). pii: 19104.
DM5DWMU	RU	https://pubmed.ncbi.nlm.nih.gov/19215710

DMHOAUG	DI	DMHOAUG
DMHOAUG	DN	Rimegepant
DMHOAUG	MI	TTY6O0Q
DMHOAUG	MN	Calcitonin gene-related peptide receptor (CGRPR)
DMHOAUG	MT	DTT
DMHOAUG	MA	Antagonist
DMHOAUG	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMHOAUG	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212728s000lbl.pdf

DMTAREC	DI	DMTAREC
DMTAREC	DN	Rimexolone
DMTAREC	MI	DE4LYSA
DMTAREC	MN	Cytochrome P450 3A4 (CYP3A4)
DMTAREC	MT	DME
DMTAREC	MA	Metabolism
DMTAREC	RN	Identification of clinically used drugs that activate pregnane X receptors. Drug Metab Dispos. 2011 Jan;39(1):151-9.
DMTAREC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20966043

DMTAREC	DI	DMTAREC
DMTAREC	DN	Rimexolone
DMTAREC	MI	TTPNQAC
DMTAREC	MN	Estrogen-related receptor-alpha (ESRRA)
DMTAREC	MT	DTT
DMTAREC	MA	Modulator
DMTAREC	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 622).
DMTAREC	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=622

DMA47C6	DI	DMA47C6
DMA47C6	DN	Rimiterol
DMA47C6	MI	TTMXGCW
DMA47C6	MN	Adrenergic receptor beta-3 (ADRB3)
DMA47C6	MT	DTT
DMA47C6	MA	Modulator
DMA47C6	RN	Comparison of the beta2-adrenoceptor selectivity of rimiterol, salbutamol and isoprenaline by the intravenous route in man. Br J Clin Pharmacol. 1975 Feb;2(1):41-8.
DMA47C6	RU	https://pubmed.ncbi.nlm.nih.gov/10940

DMXBLMP	DI	DMXBLMP
DMXBLMP	DN	Riociguat
DMXBLMP	MI	DTI7UX6
DMXBLMP	MN	Breast cancer resistance protein (ABCG2)
DMXBLMP	MT	DTP
DMXBLMP	MA	Substrate
DMXBLMP	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01913)
DMXBLMP	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01913

DMXBLMP	DI	DMXBLMP
DMXBLMP	DN	Riociguat
DMXBLMP	MI	DE6OQ3W
DMXBLMP	MN	Cytochrome P450 1A1 (CYP1A1)
DMXBLMP	MT	DME
DMXBLMP	MA	Metabolism
DMXBLMP	RN	Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. P T. 2014 Nov;39(11):749-58.
DMXBLMP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25395817

DMXBLMP	DI	DMXBLMP
DMXBLMP	DN	Riociguat
DMXBLMP	MI	DES5XRU
DMXBLMP	MN	Cytochrome P450 2C8 (CYP2C8)
DMXBLMP	MT	DME
DMXBLMP	MA	Metabolism
DMXBLMP	RN	Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. P T. 2014 Nov;39(11):749-58.
DMXBLMP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25395817

DMXBLMP	DI	DMXBLMP
DMXBLMP	DN	Riociguat
DMXBLMP	MI	DERSX5P
DMXBLMP	MN	Cytochrome P450 2J2 (CYP2J2)
DMXBLMP	MT	DME
DMXBLMP	MA	Metabolism
DMXBLMP	RN	Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. P T. 2014 Nov;39(11):749-58.
DMXBLMP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25395817

DMXBLMP	DI	DMXBLMP
DMXBLMP	DN	Riociguat
DMXBLMP	MI	DE4LYSA
DMXBLMP	MN	Cytochrome P450 3A4 (CYP3A4)
DMXBLMP	MT	DME
DMXBLMP	MA	Metabolism
DMXBLMP	RN	Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. P T. 2014 Nov;39(11):749-58.
DMXBLMP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25395817

DMXBLMP	DI	DMXBLMP
DMXBLMP	DN	Riociguat
DMXBLMP	MI	DTUGYRD
DMXBLMP	MN	P-glycoprotein 1 (ABCB1)
DMXBLMP	MT	DTP
DMXBLMP	MA	Substrate
DMXBLMP	RN	Pharmacokinetic interaction profile of riociguat, a new soluble guanylate cyclase stimulator, initro. Pulm Pharmacol Ther. 2014 Aug;28(2):130-7.
DMXBLMP	RU	http://www.ncbi.nlm.nih.gov/pubmed/24657506

DMXBLMP	DI	DMXBLMP
DMXBLMP	DN	Riociguat
DMXBLMP	MI	TTWNFC2
DMXBLMP	MN	Soluble guanylyl cyclase (GUCY2D)
DMXBLMP	MT	DTT
DMXBLMP	MA	Modulator
DMXBLMP	RN	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
DMXBLMP	RU	https://pubmed.ncbi.nlm.nih.gov/28919714

DM958QB	DI	DM958QB
DM958QB	DN	Ripretinib
DM958QB	MI	TT8FYO9
DM958QB	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DM958QB	MT	DTT
DM958QB	MA	Inhibitor
DM958QB	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DM958QB	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf

DM958QB	DI	DM958QB
DM958QB	DN	Ripretinib
DM958QB	MI	TTX41N9
DM958QB	MN	Tyrosine-protein kinase Kit (KIT)
DM958QB	MT	DTT
DM958QB	MA	Inhibitor
DM958QB	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DM958QB	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf

DMM32GT	DI	DMM32GT
DMM32GT	DN	Risankizumab
DMM32GT	MI	TTC1GLB
DMM32GT	MN	Interleukin-23 (IL23)
DMM32GT	MT	DTT
DMM32GT	MA	Inhibitor
DMM32GT	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMM32GT	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761105s000lbl.pdf

DMIMF8J	DI	DMIMF8J
DMIMF8J	DN	Risdiplam
DMIMF8J	MI	DE4LYSA
DMIMF8J	MN	Cytochrome P450 3A4 (CYP3A4)
DMIMF8J	MT	DME
DMIMF8J	MA	Metabolism
DMIMF8J	RN	A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier. Br J Clin Pharmacol. 2019 Jan;85(1):181-193.
DMIMF8J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30302786

DM5FLTY	DI	DM5FLTY
DM5FLTY	DN	Risedronate
DM5FLTY	MI	TTIKWV4
DM5FLTY	MN	Geranyltranstransferase (FDPS)
DM5FLTY	MT	DTT
DM5FLTY	MA	Inhibitor
DM5FLTY	RN	Activity of bisphosphonates against Trypanosoma brucei rhodesiense. J Med Chem. 2002 Jul 4;45(14):2904-14.
DM5FLTY	RU	https://pubmed.ncbi.nlm.nih.gov/12086478

DMN6DXL	DI	DMN6DXL
DMN6DXL	DN	Risperidone
DMN6DXL	MI	DECB0K3
DMN6DXL	MN	Cytochrome P450 2D6 (CYP2D6)
DMN6DXL	MT	DME
DMN6DXL	MA	Metabolism
DMN6DXL	RN	Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients. Clin Pharmacol Ther. 2005 Nov;78(5):520-8.
DMN6DXL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16321618

DMN6DXL	DI	DMN6DXL
DMN6DXL	DN	Risperidone
DMN6DXL	MI	DE4LYSA
DMN6DXL	MN	Cytochrome P450 3A4 (CYP3A4)
DMN6DXL	MT	DME
DMN6DXL	MA	Metabolism
DMN6DXL	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMN6DXL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMN6DXL	DI	DMN6DXL
DMN6DXL	DN	Risperidone
DMN6DXL	MI	DEIBDNY
DMN6DXL	MN	Cytochrome P450 3A5 (CYP3A5)
DMN6DXL	MT	DME
DMN6DXL	MA	Metabolism
DMN6DXL	RN	Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos. 2001 Oct;29(10):1263-8.
DMN6DXL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11560868

DMN6DXL	DI	DMN6DXL
DMN6DXL	DN	Risperidone
DMN6DXL	MI	TTEX248
DMN6DXL	MN	Dopamine D2 receptor (D2R)
DMN6DXL	MT	DTT
DMN6DXL	MA	Antagonist
DMN6DXL	RN	Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study. Psychiatry Clin Neurosci. 2009 Jun;63(3):322-8.
DMN6DXL	RU	https://pubmed.ncbi.nlm.nih.gov/19566763

DMN6DXL	DI	DMN6DXL
DMN6DXL	DN	Risperidone
DMN6DXL	MI	DTUGYRD
DMN6DXL	MN	P-glycoprotein 1 (ABCB1)
DMN6DXL	MT	DTP
DMN6DXL	MA	Substrate
DMN6DXL	RN	Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition. Clin Pharmacol Ther. 2005 Jul;78(1):43-51.
DMN6DXL	RU	http://www.ncbi.nlm.nih.gov/pubmed/16003291

DM4V6RL	DI	DM4V6RL
DM4V6RL	DN	Ritodrine
DM4V6RL	MI	TT2CJVK
DM4V6RL	MN	Adrenergic receptor beta-2 (ADRB2)
DM4V6RL	MT	DTT
DM4V6RL	MA	Modulator
DM4V6RL	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM4V6RL	RU	https://www.fda.gov/

DM4V6RL	DI	DM4V6RL
DM4V6RL	DN	Ritodrine
DM4V6RL	MI	DEYWLRK
DM4V6RL	MN	Sulfotransferase 1A1 (SULT1A1)
DM4V6RL	MT	DME
DM4V6RL	MA	Metabolism
DM4V6RL	RN	Inhibitory effects of various beverages on ritodrine sulfation by recombinant human sulfotransferase isoforms SULT1A1 and SULT1A3. Pharm Res. 2005 Aug;22(8):1406-10.
DM4V6RL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16078151

DMU764S	DI	DMU764S
DMU764S	DN	Ritonavir
DMU764S	MI	DEPKLMQ
DMU764S	MN	Cytochrome P450 2B6 (CYP2B6)
DMU764S	MT	DME
DMU764S	MA	Metabolism
DMU764S	RN	Evaluation of CYP2B6 induction and prediction of clinical drug-drug interactions: considerations from the IQ consortium induction working group-an industry perspective. Drug Metab Dispos. 2016 Oct;44(10):1720-30.
DMU764S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27422672

DMU764S	DI	DMU764S
DMU764S	DN	Ritonavir
DMU764S	MI	DECB0K3
DMU764S	MN	Cytochrome P450 2D6 (CYP2D6)
DMU764S	MT	DME
DMU764S	MA	Metabolism
DMU764S	RN	Reversible coma caused by risperidone-ritonavir interaction. Clin Neuropharmacol. 2002 Sep-Oct;25(5):251-3.
DMU764S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12410055

DMU764S	DI	DMU764S
DMU764S	DN	Ritonavir
DMU764S	MI	DE4LYSA
DMU764S	MN	Cytochrome P450 3A4 (CYP3A4)
DMU764S	MT	DME
DMU764S	MA	Metabolism
DMU764S	RN	Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir. Clin Pharmacol Ther. 2006 Mar;79(3):243-54.
DMU764S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16513448

DMU764S	DI	DMU764S
DMU764S	DN	Ritonavir
DMU764S	MI	DEIBDNY
DMU764S	MN	Cytochrome P450 3A5 (CYP3A5)
DMU764S	MT	DME
DMU764S	MA	Metabolism
DMU764S	RN	Drug Interactions Flockhart Table
DMU764S	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMU764S	DI	DMU764S
DMU764S	DN	Ritonavir
DMU764S	MI	DERD86B
DMU764S	MN	Cytochrome P450 3A7 (CYP3A7)
DMU764S	MT	DME
DMU764S	MA	Metabolism
DMU764S	RN	Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir. Clin Pharmacol Ther. 2006 Mar;79(3):243-54.
DMU764S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16513448

DMU764S	DI	DMU764S
DMU764S	DN	Ritonavir
DMU764S	MI	TT5FNQT
DMU764S	MN	Human immunodeficiency virus Protease (HIV PR)
DMU764S	MT	DTT
DMU764S	MA	Inhibitor
DMU764S	RN	Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents. 2009 Apr;33(4):307-20.
DMU764S	RU	https://pubmed.ncbi.nlm.nih.gov/19108994

DMU764S	DI	DMU764S
DMU764S	DN	Ritonavir
DMU764S	MI	DTFI42L
DMU764S	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMU764S	MT	DTP
DMU764S	MA	Substrate
DMU764S	RN	Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes. Biopharm Drug Dispos. 2010 Mar;31(2-3):178-88.
DMU764S	RU	http://www.ncbi.nlm.nih.gov/pubmed/20238377

DMU764S	DI	DMU764S
DMU764S	DN	Ritonavir
DMU764S	MI	DTPFTEQ
DMU764S	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DMU764S	MT	DTP
DMU764S	MA	Substrate
DMU764S	RN	pH dependence of organic anion-transporting polypeptide 2B1 in Caco-2 cells: potential role in antiretroviral drug oral bioavailability and drug-drug interactions. J Pharmacol Exp Ther. 2010 Sep 1;334(3):1009-22.
DMU764S	RU	http://www.ncbi.nlm.nih.gov/pubmed/20507927

DMU764S	DI	DMU764S
DMU764S	DN	Ritonavir
DMU764S	MI	DTUGYRD
DMU764S	MN	P-glycoprotein 1 (ABCB1)
DMU764S	MT	DTP
DMU764S	MA	Substrate
DMU764S	RN	MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells. AIDS. 2005 Oct 14;19(15):1617-25.
DMU764S	RU	http://www.ncbi.nlm.nih.gov/pubmed/16184031

DMBUH26	DI	DMBUH26
DMBUH26	DN	Rituximab
DMBUH26	MI	TTUE541
DMBUH26	MN	Leukocyte surface antigen Leu-16 (CD20)
DMBUH26	MT	DTT
DMBUH26	RN	[Contribution of radioimmunotherapy to the treatment of lymphoma]. Ann Pharm Fr. 2008 Nov-Dec;66(5-6):300-8.
DMBUH26	RU	https://pubmed.ncbi.nlm.nih.gov/19061730

DM1YVZT	DI	DM1YVZT
DM1YVZT	DN	Rituximab
DM1YVZT	MI	TTUE541
DM1YVZT	MN	Leukocyte surface antigen Leu-16 (CD20)
DM1YVZT	MT	DTT
DM1YVZT	RN	Clinical pipeline report, company report or official report of Genentech (2009).
DM1YVZT	RU	http://www.gene.com/gene/pipeline/status/

DMQMBZ1	DI	DMQMBZ1
DMQMBZ1	DN	Rivaroxaban
DMQMBZ1	MI	DTI7UX6
DMQMBZ1	MN	Breast cancer resistance protein (ABCG2)
DMQMBZ1	MT	DTP
DMQMBZ1	MA	Substrate
DMQMBZ1	RN	Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entry. Basic Clin Pharmacol Toxicol. 2013 Mar;112(3):164-70.
DMQMBZ1	RU	http://www.ncbi.nlm.nih.gov/pubmed/22958812

DMQMBZ1	DI	DMQMBZ1
DMQMBZ1	DN	Rivaroxaban
DMQMBZ1	MI	TTCIHJA
DMQMBZ1	MN	Coagulation factor Xa (F10)
DMQMBZ1	MT	DTT
DMQMBZ1	MA	Modulator
DMQMBZ1	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMQMBZ1	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMQMBZ1	DI	DMQMBZ1
DMQMBZ1	DN	Rivaroxaban
DMQMBZ1	MI	DERSX5P
DMQMBZ1	MN	Cytochrome P450 2J2 (CYP2J2)
DMQMBZ1	MT	DME
DMQMBZ1	MA	Metabolism
DMQMBZ1	RN	Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost. 2010 Mar;103(3):572-85.
DMQMBZ1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20135071

DMQMBZ1	DI	DMQMBZ1
DMQMBZ1	DN	Rivaroxaban
DMQMBZ1	MI	DE4LYSA
DMQMBZ1	MN	Cytochrome P450 3A4 (CYP3A4)
DMQMBZ1	MT	DME
DMQMBZ1	MA	Metabolism
DMQMBZ1	RN	Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost. 2010 Mar;103(3):572-85.
DMQMBZ1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20135071

DMQMBZ1	DI	DMQMBZ1
DMQMBZ1	DN	Rivaroxaban
DMQMBZ1	MI	DEIBDNY
DMQMBZ1	MN	Cytochrome P450 3A5 (CYP3A5)
DMQMBZ1	MT	DME
DMQMBZ1	MA	Metabolism
DMQMBZ1	RN	Pharmacology of the new target-specific oral anticoagulants. J Thromb Thrombolysis. 2013 Aug;36(2):133-40.
DMQMBZ1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23645472

DMQMBZ1	DI	DMQMBZ1
DMQMBZ1	DN	Rivaroxaban
DMQMBZ1	MI	DTUGYRD
DMQMBZ1	MN	P-glycoprotein 1 (ABCB1)
DMQMBZ1	MT	DTP
DMQMBZ1	MA	Substrate
DMQMBZ1	RN	Downregulation of ABCB1 gene in patients with total hip or knee arthroplasty influences pharmacokinetics of rivaroxaban: a population pharmacokinetic-pharmacodynamic study. Eur J Clin Pharmacol. 2019 Feb 6.
DMQMBZ1	RU	http://www.ncbi.nlm.nih.gov/pubmed/30725221

DMG629M	DI	DMG629M
DMG629M	DN	Rivastigmine
DMG629M	MI	TT1RS9F
DMG629M	MN	Acetylcholinesterase (AChE)
DMG629M	MT	DTT
DMG629M	MA	Modulator
DMG629M	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2465).
DMG629M	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2465

DMDJMA3	DI	DMDJMA3
DMDJMA3	DN	Rizatriptan
DMDJMA3	MI	TT6MSOK
DMDJMA3	MN	5-HT 1D receptor (HTR1D)
DMDJMA3	MT	DTT
DMDJMA3	MA	Agonist
DMDJMA3	RN	An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210.
DMDJMA3	RU	https://pubmed.ncbi.nlm.nih.gov/12434581

DMDJMA3	DI	DMDJMA3
DMDJMA3	DN	Rizatriptan
DMDJMA3	MI	DTT79CX
DMDJMA3	MN	Organic cation transporter 1 (SLC22A1)
DMDJMA3	MT	DTP
DMDJMA3	MA	Substrate
DMDJMA3	RN	OCT1 mediates hepatic uptake of sumatriptan and loss-of-function OCT1 polymorphisms affect sumatriptan pharmacokinetics. Clin Pharmacol Ther. 2016 Jun;99(6):633-41.
DMDJMA3	RU	http://www.ncbi.nlm.nih.gov/pubmed/26659468

DMY9BMK	DI	DMY9BMK
DMY9BMK	DN	Rocuronium
DMY9BMK	MI	TTF4E0J
DMY9BMK	MN	Neuronal acetylcholine receptor alpha-2 (CHRNA2)
DMY9BMK	MT	DTT
DMY9BMK	MA	Antagonist
DMY9BMK	RN	Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52.
DMY9BMK	RU	https://pubmed.ncbi.nlm.nih.gov/19417616

DMY9BMK	DI	DMY9BMK
DMY9BMK	DN	Rocuronium
DMY9BMK	MI	DTE2B1D
DMY9BMK	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMY9BMK	MT	DTP
DMY9BMK	MA	Substrate
DMY9BMK	RN	Polyspecific organic anion transporting polypeptides mediate hepatic uptake of amphipathic type II organic cations. J Pharmacol Exp Ther. 1999 Oct;291(1):147-52.
DMY9BMK	RU	http://jpet.aspetjournals.org/content/291/1/147.long

DMY9BMK	DI	DMY9BMK
DMY9BMK	DN	Rocuronium
DMY9BMK	MI	DTPFTEQ
DMY9BMK	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DMY9BMK	MT	DTP
DMY9BMK	MA	Substrate
DMY9BMK	RN	Drug Interactions in Infectious Diseases.
DMY9BMK	RU	http://www.springer.com/medicine/internal/book/978-1-61779-212-0

DM3P5DA	DI	DM3P5DA
DM3P5DA	DN	Rofecoxib
DM3P5DA	MI	DEJGDUW
DM3P5DA	MN	Cytochrome P450 1A2 (CYP1A2)
DM3P5DA	MT	DME
DM3P5DA	MA	Metabolism
DM3P5DA	RN	Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects. Br J Clin Pharmacol. 2006 Sep;62(3):345-57.
DM3P5DA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16934051

DM3P5DA	DI	DM3P5DA
DM3P5DA	DN	Rofecoxib
DM3P5DA	MI	DES5XRU
DM3P5DA	MN	Cytochrome P450 2C8 (CYP2C8)
DM3P5DA	MT	DME
DM3P5DA	MA	Metabolism
DM3P5DA	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DM3P5DA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DM3P5DA	DI	DM3P5DA
DM3P5DA	DN	Rofecoxib
DM3P5DA	MI	DE5IED8
DM3P5DA	MN	Cytochrome P450 2C9 (CYP2C9)
DM3P5DA	MT	DME
DM3P5DA	MA	Metabolism
DM3P5DA	RN	Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? Drug Metab Dispos. 2005 Nov;33(11):1567-75.
DM3P5DA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16118328

DM3P5DA	DI	DM3P5DA
DM3P5DA	DN	Rofecoxib
DM3P5DA	MI	DE4LYSA
DM3P5DA	MN	Cytochrome P450 3A4 (CYP3A4)
DM3P5DA	MT	DME
DM3P5DA	MA	Metabolism
DM3P5DA	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM3P5DA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM3P5DA	DI	DM3P5DA
DM3P5DA	DN	Rofecoxib
DM3P5DA	MI	DE073H6
DM3P5DA	MN	Prostaglandin G/H synthase 1 (COX-1)
DM3P5DA	MT	DME
DM3P5DA	MA	Metabolism
DM3P5DA	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM3P5DA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM3P5DA	DI	DM3P5DA
DM3P5DA	DN	Rofecoxib
DM3P5DA	MI	TTVKILB
DM3P5DA	MN	Prostaglandin G/H synthase 2 (COX-2)
DM3P5DA	MT	DTT
DM3P5DA	MA	Inhibitor
DM3P5DA	RN	Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
DM3P5DA	RU	https://pubmed.ncbi.nlm.nih.gov/18045214

DMPGHY8	DI	DMPGHY8
DMPGHY8	DN	Roflumilast
DMPGHY8	MI	DEJGDUW
DMPGHY8	MN	Cytochrome P450 1A2 (CYP1A2)
DMPGHY8	MT	DME
DMPGHY8	MA	Metabolism
DMPGHY8	RN	Effect of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide. J Clin Pharmacol. 2011 Apr;51(4):586-93.
DMPGHY8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20466871

DMPGHY8	DI	DMPGHY8
DMPGHY8	DN	Roflumilast
DMPGHY8	MI	DE4LYSA
DMPGHY8	MN	Cytochrome P450 3A4 (CYP3A4)
DMPGHY8	MT	DME
DMPGHY8	MA	Metabolism
DMPGHY8	RN	Effect of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide. J Clin Pharmacol. 2011 Apr;51(4):586-93.
DMPGHY8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20466871

DMPGHY8	DI	DMPGHY8
DMPGHY8	DN	Roflumilast
DMPGHY8	MI	TTV5CGO
DMPGHY8	MN	Phosphodiesterase 4 (PDE4)
DMPGHY8	MT	DTT
DMPGHY8	MA	Modulator
DMPGHY8	RN	2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
DMPGHY8	RU	https://pubmed.ncbi.nlm.nih.gov/22293555

DMCZWOK	DI	DMCZWOK
DMCZWOK	DN	Rokitamycin
DMCZWOK	MI	DE4LYSA
DMCZWOK	MN	Cytochrome P450 3A4 (CYP3A4)
DMCZWOK	MT	DME
DMCZWOK	MA	Metabolism
DMCZWOK	RN	An in vitro study on the metabolism and possible drug interactions of rokitamycin, a macrolide antibiotic, using human liver microsomes. Drug Metab Dispos. 1999 Jul;27(7):776-85.
DMCZWOK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10383920

DM8XP26	DI	DM8XP26
DM8XP26	DN	Rolapitant
DM8XP26	MI	DE4LYSA
DM8XP26	MN	Cytochrome P450 3A4 (CYP3A4)
DM8XP26	MT	DME
DM8XP26	MA	Metabolism
DM8XP26	RN	Pharmacokinetic interactions of rolapitant with cytochrome P450 3A substrates in healthy subjects. J Clin Pharmacol. 2019 Apr;59(4):488-499.
DM8XP26	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30422319

DM8XP26	DI	DM8XP26
DM8XP26	DN	Rolapitant
DM8XP26	MI	TTZPO1L
DM8XP26	MN	Substance-P receptor (TACR1)
DM8XP26	MT	DTT
DM8XP26	MA	Antagonist
DM8XP26	RN	Netupitant and palonosetron trigger NK1 receptor internalization in NG108-15 cells. Exp Brain Res. 2014 Aug;232(8):2637-44.
DM8XP26	RU	https://pubmed.ncbi.nlm.nih.gov/24969614

DMBR5Q7	DI	DMBR5Q7
DMBR5Q7	DN	Rolitetracycline
DMBR5Q7	MI	TTQ8KVI
DMBR5Q7	MN	Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)
DMBR5Q7	MT	DTT
DMBR5Q7	MA	Binder
DMBR5Q7	RN	Reversed-phase high-performance liquid chromatography coupled to ultraviolet and electrospray time-of-flight mass spectrometry on-line detection fo... J Chromatogr A. 2008 Jun 27;1195(1-2):107-16.
DMBR5Q7	RU	https://pubmed.ncbi.nlm.nih.gov/18501371

DMT5GNL	DI	DMT5GNL
DMT5GNL	DN	Romidepsin
DMT5GNL	MI	DEPKLMQ
DMT5GNL	MN	Cytochrome P450 2B6 (CYP2B6)
DMT5GNL	MT	DME
DMT5GNL	MA	Metabolism
DMT5GNL	RN	FDA Label of Romidepsin. The 2020 official website of the U.S. Food and Drug Administration.
DMT5GNL	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022393lbl.pdf

DMT5GNL	DI	DMT5GNL
DMT5GNL	DN	Romidepsin
DMT5GNL	MI	DE4LYSA
DMT5GNL	MN	Cytochrome P450 3A4 (CYP3A4)
DMT5GNL	MT	DME
DMT5GNL	MA	Metabolism
DMT5GNL	RN	A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neuro Oncol. 2011 May;13(5):509-16.
DMT5GNL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21377994

DMT5GNL	DI	DMT5GNL
DMT5GNL	DN	Romidepsin
DMT5GNL	MI	DEIBDNY
DMT5GNL	MN	Cytochrome P450 3A5 (CYP3A5)
DMT5GNL	MT	DME
DMT5GNL	MA	Metabolism
DMT5GNL	RN	Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res. 2009 Feb 15;15(4):1496-503.
DMT5GNL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19228751

DMT5GNL	DI	DMT5GNL
DMT5GNL	DN	Romidepsin
DMT5GNL	MI	TT6R7JZ
DMT5GNL	MN	Histone deacetylase 1 (HDAC1)
DMT5GNL	MT	DTT
DMT5GNL	MA	Inhibitor
DMT5GNL	RN	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
DMT5GNL	RU	https://pubmed.ncbi.nlm.nih.gov/20118952

DMT5GNL	DI	DMT5GNL
DMT5GNL	DN	Romidepsin
DMT5GNL	MI	DT9C1TS
DMT5GNL	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMT5GNL	MT	DTP
DMT5GNL	MA	Substrate
DMT5GNL	RN	Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res. 2009 Feb 15;15(4):1496-503.
DMT5GNL	RU	http://www.ncbi.nlm.nih.gov/pubmed/19228751

DMT5GNL	DI	DMT5GNL
DMT5GNL	DN	Romidepsin
DMT5GNL	MI	DTUGYRD
DMT5GNL	MN	P-glycoprotein 1 (ABCB1)
DMT5GNL	MT	DTP
DMT5GNL	MA	Substrate
DMT5GNL	RN	Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res. 2009 Feb 15;15(4):1496-503.
DMT5GNL	RU	http://www.ncbi.nlm.nih.gov/pubmed/19228751

DM3U7SZ	DI	DM3U7SZ
DM3U7SZ	DN	Romiplostim
DM3U7SZ	MI	TT037IE
DM3U7SZ	MN	Aryl hydrocarbon receptor (AHR)
DM3U7SZ	MT	DTT
DM3U7SZ	MA	Modulator
DM3U7SZ	RN	A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points. Br J Cancer. 2005 Oct 17;93(8):876-83.
DM3U7SZ	RU	https://pubmed.ncbi.nlm.nih.gov/16222321

DM3U7SZ	DI	DM3U7SZ
DM3U7SZ	DN	Romiplostim
DM3U7SZ	MI	TTRLW2X
DM3U7SZ	MN	Fibroblast growth factor receptor 1 (FGFR1)
DM3U7SZ	MT	DTT
DM3U7SZ	MA	Inhibitor
DM3U7SZ	RN	Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93.
DM3U7SZ	RU	https://pubmed.ncbi.nlm.nih.gov/12477352

DM3U7SZ	DI	DM3U7SZ
DM3U7SZ	DN	Romiplostim
DM3U7SZ	MI	TT8FYO9
DM3U7SZ	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DM3U7SZ	MT	DTT
DM3U7SZ	MA	Inhibitor
DM3U7SZ	RN	Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9.
DM3U7SZ	RU	https://pubmed.ncbi.nlm.nih.gov/12646019

DM3U7SZ	DI	DM3U7SZ
DM3U7SZ	DN	Romiplostim
DM3U7SZ	MI	TTI7421
DM3U7SZ	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM3U7SZ	MT	DTT
DM3U7SZ	MA	Inhibitor
DM3U7SZ	RN	Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9.
DM3U7SZ	RU	https://pubmed.ncbi.nlm.nih.gov/12646019

DM3U7SZ	DI	DM3U7SZ
DM3U7SZ	DN	Romiplostim
DM3U7SZ	MI	TT4DXQT
DM3U7SZ	MN	Proto-oncogene c-Ret (RET)
DM3U7SZ	MT	DTT
DM3U7SZ	MA	Inhibitor
DM3U7SZ	RN	Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1482-96.
DM3U7SZ	RU	https://pubmed.ncbi.nlm.nih.gov/20117004

DM3U7SZ	DI	DM3U7SZ
DM3U7SZ	DN	Romiplostim
DM3U7SZ	MI	TTIHYA4
DM3U7SZ	MN	Thrombopoietin receptor (MPL)
DM3U7SZ	MT	DTT
DM3U7SZ	MA	Modulator
DM3U7SZ	RN	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
DM3U7SZ	RU	https://pubmed.ncbi.nlm.nih.gov/19180096

DM3U7SZ	DI	DM3U7SZ
DM3U7SZ	DN	Romiplostim
DM3U7SZ	MI	TTX41N9
DM3U7SZ	MN	Tyrosine-protein kinase Kit (KIT)
DM3U7SZ	MT	DTT
DM3U7SZ	MA	Inhibitor
DM3U7SZ	RN	New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven a... J Med Chem. 2000 Jun 15;43(12):2310-23.
DM3U7SZ	RU	https://pubmed.ncbi.nlm.nih.gov/10882357

DM3U7SZ	DI	DM3U7SZ
DM3U7SZ	DN	Romiplostim
DM3U7SZ	MI	TTUTJGQ
DM3U7SZ	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM3U7SZ	MT	DTT
DM3U7SZ	MA	Inhibitor
DM3U7SZ	RN	Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93.
DM3U7SZ	RU	https://pubmed.ncbi.nlm.nih.gov/12477352

DM3U7SZ	DI	DM3U7SZ
DM3U7SZ	DN	Romiplostim
DM3U7SZ	MI	TT1VAUK
DM3U7SZ	MN	VEGFR1 messenger RNA (VEGFR1 mRNA)
DM3U7SZ	MT	DTT
DM3U7SZ	MA	Inhibitor
DM3U7SZ	RN	New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven a... J Med Chem. 2000 Jun 15;43(12):2310-23.
DM3U7SZ	RU	https://pubmed.ncbi.nlm.nih.gov/10882357

DMFJZN0	DI	DMFJZN0
DMFJZN0	DN	Romosozumab
DMFJZN0	MI	TTYRO4F
DMFJZN0	MN	Sclerostin (SOST)
DMFJZN0	MT	DTT
DMFJZN0	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMFJZN0	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761062s000lbl.pdf

DMA6S1D	DI	DMA6S1D
DMA6S1D	DN	Ropinirole
DMA6S1D	MI	DEJGDUW
DMA6S1D	MN	Cytochrome P450 1A2 (CYP1A2)
DMA6S1D	MT	DME
DMA6S1D	MA	Metabolism
DMA6S1D	RN	Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67.
DMA6S1D	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18691132

DMA6S1D	DI	DMA6S1D
DMA6S1D	DN	Ropinirole
DMA6S1D	MI	DE4LYSA
DMA6S1D	MN	Cytochrome P450 3A4 (CYP3A4)
DMA6S1D	MT	DME
DMA6S1D	MA	Metabolism
DMA6S1D	RN	In vitro identification of the P450 enzymes responsible for the metabolism of ropinirole. Drug Metab Dispos. 1997 Jul;25(7):840-4.
DMA6S1D	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9224778

DMA6S1D	DI	DMA6S1D
DMA6S1D	DN	Ropinirole
DMA6S1D	MI	TTEX248
DMA6S1D	MN	Dopamine D2 receptor (D2R)
DMA6S1D	MT	DTT
DMA6S1D	MA	Modulator
DMA6S1D	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMA6S1D	RU	https://www.fda.gov/

DMA6S1D	DI	DMA6S1D
DMA6S1D	DN	Ropinirole
DMA6S1D	MI	TT4C8EA
DMA6S1D	MN	Dopamine D3 receptor (D3R)
DMA6S1D	MT	DTT
DMA6S1D	MA	Modulator
DMA6S1D	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMA6S1D	RU	https://www.fda.gov/

DMSPJG2	DI	DMSPJG2
DMSPJG2	DN	Ropivacaine
DMSPJG2	MI	DEJGDUW
DMSPJG2	MN	Cytochrome P450 1A2 (CYP1A2)
DMSPJG2	MT	DME
DMSPJG2	MA	Metabolism
DMSPJG2	RN	Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors. Clin Pharmacol Ther. 1998 Nov;64(5):484-91.
DMSPJG2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9834040

DMSPJG2	DI	DMSPJG2
DMSPJG2	DN	Ropivacaine
DMSPJG2	MI	DEPKLMQ
DMSPJG2	MN	Cytochrome P450 2B6 (CYP2B6)
DMSPJG2	MT	DME
DMSPJG2	MA	Metabolism
DMSPJG2	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMSPJG2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMSPJG2	DI	DMSPJG2
DMSPJG2	DN	Ropivacaine
DMSPJG2	MI	DECB0K3
DMSPJG2	MN	Cytochrome P450 2D6 (CYP2D6)
DMSPJG2	MT	DME
DMSPJG2	MA	Metabolism
DMSPJG2	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMSPJG2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMSPJG2	DI	DMSPJG2
DMSPJG2	DN	Ropivacaine
DMSPJG2	MI	DE4LYSA
DMSPJG2	MN	Cytochrome P450 3A4 (CYP3A4)
DMSPJG2	MT	DME
DMSPJG2	MA	Metabolism
DMSPJG2	RN	Metabolism of a new local anesthetic, ropivacaine, by human hepatic cytochrome P450. Anesthesiology. 1995 Jan;82(1):214-20.
DMSPJG2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7832304

DMSPJG2	DI	DMSPJG2
DMSPJG2	DN	Ropivacaine
DMSPJG2	MI	TT90XZ8
DMSPJG2	MN	Voltage-gated sodium channel alpha Nav1.8 (SCN10A)
DMSPJG2	MT	DTT
DMSPJG2	MA	Modulator
DMSPJG2	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMSPJG2	RU	https://www.fda.gov/

DMILWZR	DI	DMILWZR
DMILWZR	DN	Rosiglitazone
DMILWZR	MI	DTI7UX6
DMILWZR	MN	Breast cancer resistance protein (ABCG2)
DMILWZR	MT	DTP
DMILWZR	MA	Substrate
DMILWZR	RN	ATP-binding cassette transporters in human heart failure. Naunyn Schmiedebergs Arch Pharmacol. 2008 May;377(3):231-43.
DMILWZR	RU	http://www.ncbi.nlm.nih.gov/pubmed/18392808

DMY6EAO	DI	DMY6EAO
DMY6EAO	DN	Rosiglitazone
DMY6EAO	MI	DES5XRU
DMY6EAO	MN	Cytochrome P450 2C8 (CYP2C8)
DMY6EAO	MT	DME
DMY6EAO	MA	Metabolism
DMY6EAO	RN	Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol. 1999 Sep;48(3):424-32.
DMY6EAO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10510156

DMY6EAO	DI	DMY6EAO
DMY6EAO	DN	Rosiglitazone
DMY6EAO	MI	DE5IED8
DMY6EAO	MN	Cytochrome P450 2C9 (CYP2C9)
DMY6EAO	MT	DME
DMY6EAO	MA	Metabolism
DMY6EAO	RN	Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol. 1999 Sep;48(3):424-32.
DMY6EAO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10510156

DMY6EAO	DI	DMY6EAO
DMY6EAO	DN	Rosiglitazone
DMY6EAO	MI	DE4LYSA
DMY6EAO	MN	Cytochrome P450 3A4 (CYP3A4)
DMY6EAO	MT	DME
DMY6EAO	MA	Metabolism
DMY6EAO	RN	Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther. 2005 May;77(5):404-14.
DMY6EAO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15900286

DMY6EAO	DI	DMY6EAO
DMY6EAO	DN	Rosiglitazone
DMY6EAO	MI	DE073H6
DMY6EAO	MN	Prostaglandin G/H synthase 1 (COX-1)
DMY6EAO	MT	DME
DMY6EAO	MA	Metabolism
DMY6EAO	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMY6EAO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMT45MU	DI	DMT45MU
DMT45MU	DN	Rosiglitazone XR
DMT45MU	MI	TTZMAO3
DMT45MU	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMT45MU	MT	DTT
DMT45MU	MA	Agonist
DMT45MU	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMT45MU	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMVOIK1	DI	DMVOIK1
DMVOIK1	DN	Rosoxacin
DMVOIK1	MI	TT0IHXV
DMVOIK1	MN	DNA topoisomerase II (TOP2)
DMVOIK1	MT	DTT
DMVOIK1	MA	Inhibitor
DMVOIK1	RN	Inhibition of Micrococcus luteus DNA gyrase by norfloxacin and 10 other quinolone carboxylic acids. Antimicrob Agents Chemother. 1986 Apr;29(4):598-601.
DMVOIK1	RU	https://pubmed.ncbi.nlm.nih.gov/3010848

DMMIQ7G	DI	DMMIQ7G
DMMIQ7G	DN	Rosuvastatin
DMMIQ7G	MI	DTI7UX6
DMMIQ7G	MN	Breast cancer resistance protein (ABCG2)
DMMIQ7G	MT	DTP
DMMIQ7G	MA	Substrate
DMMIQ7G	RN	Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 Oct;36(10):2014-23.
DMMIQ7G	RU	http://www.ncbi.nlm.nih.gov/pubmed/18617601

DMMIQ7G	DI	DMMIQ7G
DMMIQ7G	DN	Rosuvastatin
DMMIQ7G	MI	DE9QHP6
DMMIQ7G	MN	Cytochrome P450 1B1 (CYP1B1)
DMMIQ7G	MT	DME
DMMIQ7G	MA	Metabolism
DMMIQ7G	RN	Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. Clin Ther. 2008 Jul;30(7):1283-9.
DMMIQ7G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18691987

DMMIQ7G	DI	DMMIQ7G
DMMIQ7G	DN	Rosuvastatin
DMMIQ7G	MI	DE5IED8
DMMIQ7G	MN	Cytochrome P450 2C9 (CYP2C9)
DMMIQ7G	MT	DME
DMMIQ7G	MA	Metabolism
DMMIQ7G	RN	Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm Res. 2006 Mar;23(3):506-12.
DMMIQ7G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16388406

DMMIQ7G	DI	DMMIQ7G
DMMIQ7G	DN	Rosuvastatin
DMMIQ7G	MI	DE4LYSA
DMMIQ7G	MN	Cytochrome P450 3A4 (CYP3A4)
DMMIQ7G	MT	DME
DMMIQ7G	MA	Metabolism
DMMIQ7G	RN	Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm Res. 2006 Mar;23(3):506-12.
DMMIQ7G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16388406

DMMIQ7G	DI	DMMIQ7G
DMMIQ7G	DN	Rosuvastatin
DMMIQ7G	MI	TTPADOQ
DMMIQ7G	MN	HMG-CoA reductase (HMGCR)
DMMIQ7G	MT	DTT
DMMIQ7G	MA	Inhibitor
DMMIQ7G	RN	New dimension of statin action on ApoB atherogenicity. Clin Cardiol. 2003 Jan;26(1 Suppl 1):I7-10.
DMMIQ7G	RU	https://pubmed.ncbi.nlm.nih.gov/12539816

DMMIQ7G	DI	DMMIQ7G
DMMIQ7G	DN	Rosuvastatin
DMMIQ7G	MI	DTFI42L
DMMIQ7G	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMMIQ7G	MT	DTP
DMMIQ7G	MA	Substrate
DMMIQ7G	RN	Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 Oct;36(10):2014-23.
DMMIQ7G	RU	http://www.ncbi.nlm.nih.gov/pubmed/18617601

DMMIQ7G	DI	DMMIQ7G
DMMIQ7G	DN	Rosuvastatin
DMMIQ7G	MI	DTVP67E
DMMIQ7G	MN	Organic anion transporter 3 (SLC22A8)
DMMIQ7G	MT	DTP
DMMIQ7G	MA	Substrate
DMMIQ7G	RN	The contribution of organic anion transporters OAT1 and OAT3 to the renal uptake of rosuvastatin. J Pharmacol Exp Ther. 2007 Sep;322(3):1221-7.
DMMIQ7G	RU	http://www.ncbi.nlm.nih.gov/pubmed/17585018

DMMIQ7G	DI	DMMIQ7G
DMMIQ7G	DN	Rosuvastatin
DMMIQ7G	MI	DTE2B1D
DMMIQ7G	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMMIQ7G	MT	DTP
DMMIQ7G	MA	Substrate
DMMIQ7G	RN	Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.
DMMIQ7G	RU	http://www.ncbi.nlm.nih.gov/pubmed/16697742

DMMIQ7G	DI	DMMIQ7G
DMMIQ7G	DN	Rosuvastatin
DMMIQ7G	MI	DT3D8F0
DMMIQ7G	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMMIQ7G	MT	DTP
DMMIQ7G	MA	Substrate
DMMIQ7G	RN	Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 Oct;36(10):2014-23.
DMMIQ7G	RU	http://www.ncbi.nlm.nih.gov/pubmed/18617601

DMMIQ7G	DI	DMMIQ7G
DMMIQ7G	DN	Rosuvastatin
DMMIQ7G	MI	DT9C1TS
DMMIQ7G	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMMIQ7G	MT	DTP
DMMIQ7G	MA	Substrate
DMMIQ7G	RN	Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 Oct;36(10):2014-23.
DMMIQ7G	RU	http://www.ncbi.nlm.nih.gov/pubmed/18617601

DMMIQ7G	DI	DMMIQ7G
DMMIQ7G	DN	Rosuvastatin
DMMIQ7G	MI	DTPFTEQ
DMMIQ7G	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DMMIQ7G	MT	DTP
DMMIQ7G	MA	Substrate
DMMIQ7G	RN	Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 Oct;36(10):2014-23.
DMMIQ7G	RU	http://www.ncbi.nlm.nih.gov/pubmed/18617601

DMMIQ7G	DI	DMMIQ7G
DMMIQ7G	DN	Rosuvastatin
DMMIQ7G	MI	DTUGYRD
DMMIQ7G	MN	P-glycoprotein 1 (ABCB1)
DMMIQ7G	MT	DTP
DMMIQ7G	MA	Substrate
DMMIQ7G	RN	Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 Oct;36(10):2014-23.
DMMIQ7G	RU	http://www.ncbi.nlm.nih.gov/pubmed/18617601

DMMIQ7G	DI	DMMIQ7G
DMMIQ7G	DN	Rosuvastatin
DMMIQ7G	MI	DT56EKP
DMMIQ7G	MN	Sodium/taurocholate cotransporting polypeptide (SLC10A1)
DMMIQ7G	MT	DTP
DMMIQ7G	MA	Substrate
DMMIQ7G	RN	Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.
DMMIQ7G	RU	http://www.ncbi.nlm.nih.gov/pubmed/16697742

DMP7X6Q	DI	DMP7X6Q
DMP7X6Q	DN	Rotigotine
DMP7X6Q	MI	DE4LYSA
DMP7X6Q	MN	Cytochrome P450 3A4 (CYP3A4)
DMP7X6Q	MT	DME
DMP7X6Q	MA	Metabolism
DMP7X6Q	RN	Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67.
DMP7X6Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18691132

DMP7X6Q	DI	DMP7X6Q
DMP7X6Q	DN	Rotigotine
DMP7X6Q	MI	DEYWLRK
DMP7X6Q	MN	Sulfotransferase 1A1 (SULT1A1)
DMP7X6Q	MT	DME
DMP7X6Q	MA	Metabolism
DMP7X6Q	RN	Identification of the human SULT enzymes involved in the metabolism of rotigotine. J Clin Pharmacol. 2016 Jun;56(6):754-60.
DMP7X6Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26465778

DMP7X6Q	DI	DMP7X6Q
DMP7X6Q	DN	Rotigotine
DMP7X6Q	MI	DERUZL7
DMP7X6Q	MN	Sulfotransferase 1A2 (SULT1A2)
DMP7X6Q	MT	DME
DMP7X6Q	MA	Metabolism
DMP7X6Q	RN	Identification of the human SULT enzymes involved in the metabolism of rotigotine. J Clin Pharmacol. 2016 Jun;56(6):754-60.
DMP7X6Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26465778

DMP7X6Q	DI	DMP7X6Q
DMP7X6Q	DN	Rotigotine
DMP7X6Q	MI	DEP7E8X
DMP7X6Q	MN	Sulfotransferase 1A3 (SULT1A3)
DMP7X6Q	MT	DME
DMP7X6Q	MA	Metabolism
DMP7X6Q	RN	Identification of the human SULT enzymes involved in the metabolism of rotigotine. J Clin Pharmacol. 2016 Jun;56(6):754-60.
DMP7X6Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26465778

DMP7X6Q	DI	DMP7X6Q
DMP7X6Q	DN	Rotigotine
DMP7X6Q	MI	DED5UR3
DMP7X6Q	MN	Sulfotransferase 1B1 (SULT1B1)
DMP7X6Q	MT	DME
DMP7X6Q	MA	Metabolism
DMP7X6Q	RN	Identification of the human SULT enzymes involved in the metabolism of rotigotine. J Clin Pharmacol. 2016 Jun;56(6):754-60.
DMP7X6Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26465778

DMP7X6Q	DI	DMP7X6Q
DMP7X6Q	DN	Rotigotine
DMP7X6Q	MI	DEU3DHN
DMP7X6Q	MN	Sulfotransferase 1C4 (SULT1C4)
DMP7X6Q	MT	DME
DMP7X6Q	MA	Metabolism
DMP7X6Q	RN	Identification of the human SULT enzymes involved in the metabolism of rotigotine. J Clin Pharmacol. 2016 Jun;56(6):754-60.
DMP7X6Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26465778

DMP7X6Q	DI	DMP7X6Q
DMP7X6Q	DN	Rotigotine
DMP7X6Q	MI	DESTKG6
DMP7X6Q	MN	Sulfotransferase 1E1 (SULT1E1)
DMP7X6Q	MT	DME
DMP7X6Q	MA	Metabolism
DMP7X6Q	RN	Identification of the human SULT enzymes involved in the metabolism of rotigotine. J Clin Pharmacol. 2016 Jun;56(6):754-60.
DMP7X6Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26465778

DM9PVX8	DI	DM9PVX8
DM9PVX8	DN	Rucaparib
DM9PVX8	MI	DEJGDUW
DM9PVX8	MN	Cytochrome P450 1A2 (CYP1A2)
DM9PVX8	MT	DME
DM9PVX8	MA	Metabolism
DM9PVX8	RN	Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer. Onco Targets Ther. 2017 Jun 19;10:3029-3037.
DM9PVX8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28790837

DM9PVX8	DI	DM9PVX8
DM9PVX8	DN	Rucaparib
DM9PVX8	MI	TTEBCY8
DM9PVX8	MN	Poly [ADP-ribose] polymerase (PARP)
DM9PVX8	MT	DTT
DM9PVX8	MA	Modulator
DM9PVX8	RN	2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. 
DM9PVX8	RU	https://www.ncbi.nlm.nih.gov/pubmed/28148938

DMWE60C	DI	DMWE60C
DMWE60C	DN	Rufinamide
DMWE60C	MI	DEB30C5
DMWE60C	MN	Carboxylesterase 1 (CES1)
DMWE60C	MT	DME
DMWE60C	MA	Metabolism
DMWE60C	RN	Investigation of the metabolism of rufinamide and its interaction with valproate. Drug Metab Lett. 2011 Dec;5(4):280-9.
DMWE60C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22022867

DMWE60C	DI	DMWE60C
DMWE60C	DN	Rufinamide
DMWE60C	MI	DETHCPD
DMWE60C	MN	Carboxylesterase 2 (CES2)
DMWE60C	MT	DME
DMWE60C	MA	Metabolism
DMWE60C	RN	Investigation of the metabolism of rufinamide and its interaction with valproate. Drug Metab Lett. 2011 Dec;5(4):280-9.
DMWE60C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22022867

DMWE60C	DI	DMWE60C
DMWE60C	DN	Rufinamide
DMWE60C	MI	TTRK8B9
DMWE60C	MN	Sodium channel unspecific (NaC)
DMWE60C	MT	DTT
DMWE60C	MA	Blocker
DMWE60C	RN	Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.
DMWE60C	RU	https://pubmed.ncbi.nlm.nih.gov/17874969

DM7Q98D	DI	DM7Q98D
DM7Q98D	DN	Ruxolitinib
DM7Q98D	MI	TT6DM01
DM7Q98D	MN	Janus kinase 1 (JAK-1)
DM7Q98D	MT	DTT
DM7Q98D	MA	Modulator
DM7Q98D	RN	2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
DM7Q98D	RU	https://pubmed.ncbi.nlm.nih.gov/22293555

DM7Q98D	DI	DM7Q98D
DM7Q98D	DN	Ruxolitinib
DM7Q98D	MI	TTRMX3V
DM7Q98D	MN	Janus kinase 2 (JAK-2)
DM7Q98D	MT	DTT
DM7Q98D	MA	Modulator
DM7Q98D	RN	2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
DM7Q98D	RU	https://pubmed.ncbi.nlm.nih.gov/22293555

DM7Q98D	DI	DM7Q98D
DM7Q98D	DN	Ruxolitinib
DM7Q98D	MI	TTPRL03
DM7Q98D	MN	Urokinase plasminogen activator surface receptor (PLAUR)
DM7Q98D	MT	DTT
DM7Q98D	MA	Inhibitor
DM7Q98D	RN	Urokinase-type plasminogen activator receptor signaling is critical in nasopharyngeal carcinoma cell growth and metastasis.Cell Cycle. 2014;13(12):1958-69.
DM7Q98D	RU	https://pubmed.ncbi.nlm.nih.gov/24763226

DMOFP18	DI	DMOFP18
DMOFP18	DN	Ryzodeq
DMOFP18	MI	TTCBFJO
DMOFP18	MN	Insulin receptor (INSR)
DMOFP18	MT	DTT
DMOFP18	MA	Modulator
DMOFP18	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800).
DMOFP18	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800

DM0YWJC	DI	DM0YWJC
DM0YWJC	DN	Safinamide
DM0YWJC	MI	TTGP7BY
DM0YWJC	MN	Monoamine oxidase type B (MAO-B)
DM0YWJC	MT	DTT
DM0YWJC	MA	Inhibitor
DM0YWJC	RN	Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.
DM0YWJC	RU	https://pubmed.ncbi.nlm.nih.gov/17874969

DM0J2ZT	DI	DM0J2ZT
DM0J2ZT	DN	Safinamide mesylate
DM0J2ZT	MI	DE4LYSA
DM0J2ZT	MN	Cytochrome P450 3A4 (CYP3A4)
DM0J2ZT	MT	DME
DM0J2ZT	MA	Metabolism
DM0J2ZT	RN	Disposition and metabolism of safinamide, a novel drug for Parkinson's disease, in healthy male volunteers. Pharmacology. 2013;92(3-4):207-16.
DM0J2ZT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24136086

DM0J2ZT	DI	DM0J2ZT
DM0J2ZT	DN	Safinamide mesylate
DM0J2ZT	MI	DERE4TU
DM0J2ZT	MN	Monoamine oxidase type A (MAO-A)
DM0J2ZT	MT	DME
DM0J2ZT	MA	Metabolism
DM0J2ZT	RN	Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoamine oxidase. J Med Chem. 2007 Oct 4;50(20):4909-16.
DM0J2ZT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17824599

DM0J2ZT	DI	DM0J2ZT
DM0J2ZT	DN	Safinamide mesylate
DM0J2ZT	MI	TTGP7BY
DM0J2ZT	MN	Monoamine oxidase type B (MAO-B)
DM0J2ZT	MT	DTT
DM0J2ZT	MA	Inhibitor
DM0J2ZT	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DM0J2ZT	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DMN9CWF	DI	DMN9CWF
DMN9CWF	DN	Salbutamol
DMN9CWF	MI	TT2CJVK
DMN9CWF	MN	Adrenergic receptor beta-2 (ADRB2)
DMN9CWF	MT	DTT
DMN9CWF	MA	Agonist
DMN9CWF	RN	Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol). CNS Drugs. 2002;16(1):1-8.
DMN9CWF	RU	https://pubmed.ncbi.nlm.nih.gov/11772115

DMN9CWF	DI	DMN9CWF
DMN9CWF	DN	Salbutamol
DMN9CWF	MI	DEB30C5
DMN9CWF	MN	Carboxylesterase 1 (CES1)
DMN9CWF	MT	DME
DMN9CWF	MA	Metabolism
DMN9CWF	RN	Effect of carboxylesterase 1 c.428G>A single nucleotide variation on the pharmacokinetics of quinapril and enalapril. Br J Clin Pharmacol. 2015 Nov;80(5):1131-8.
DMN9CWF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25919042

DMN9CWF	DI	DMN9CWF
DMN9CWF	DN	Salbutamol
DMN9CWF	MI	DE4LYSA
DMN9CWF	MN	Cytochrome P450 3A4 (CYP3A4)
DMN9CWF	MT	DME
DMN9CWF	MA	Metabolism
DMN9CWF	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMN9CWF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMN9CWF	DI	DMN9CWF
DMN9CWF	DN	Salbutamol
DMN9CWF	MI	DTT79CX
DMN9CWF	MN	Organic cation transporter 1 (SLC22A1)
DMN9CWF	MT	DTP
DMN9CWF	MA	Substrate
DMN9CWF	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMN9CWF	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DMN9CWF	DI	DMN9CWF
DMN9CWF	DN	Salbutamol
DMN9CWF	MI	DEP7E8X
DMN9CWF	MN	Sulfotransferase 1A3 (SULT1A3)
DMN9CWF	MT	DME
DMN9CWF	MA	Metabolism
DMN9CWF	RN	SULT 1A3 single-nucleotide polymorphism and the single dose pharmacokinetics of inhaled salbutamol enantiomers: are some athletes at risk of higher urine levels? Drug Test Anal. 2015 Feb;7(2):109-13.
DMN9CWF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24692077

DM1T2LS	DI	DM1T2LS
DM1T2LS	DN	Salicin
DM1T2LS	MI	DEFKVZD
DM1T2LS	MN	Phospho-beta-glucosidase (LBA1706)
DM1T2LS	MT	DME
DM1T2LS	MA	Metabolism
DM1T2LS	RN	Microbial unmasking of plant glycosides. mBio. 2018 Jan 30;9(1). pii: e02433-17.
DM1T2LS	RU	https://pubmed.ncbi.nlm.nih.gov/29382739

DM2F8XZ	DI	DM2F8XZ
DM2F8XZ	DN	Salicyclic acid
DM2F8XZ	MI	TTUNARX
DM2F8XZ	MN	Carbonic anhydrase (CA)
DM2F8XZ	MT	DTT
DM2F8XZ	MA	Inhibitor
DM2F8XZ	RN	Carbonic anhydrase inhibitors: Inhibition of the new membrane-associated isoform XV with phenols. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3593-6.
DM2F8XZ	RU	https://pubmed.ncbi.nlm.nih.gov/18501600

DM2F8XZ	DI	DM2F8XZ
DM2F8XZ	DN	Salicyclic acid
DM2F8XZ	MI	TTHQPL7
DM2F8XZ	MN	Carbonic anhydrase I (CA-I)
DM2F8XZ	MT	DTT
DM2F8XZ	MA	Inhibitor
DM2F8XZ	RN	Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8.
DM2F8XZ	RU	https://pubmed.ncbi.nlm.nih.gov/18579385

DM2F8XZ	DI	DM2F8XZ
DM2F8XZ	DN	Salicyclic acid
DM2F8XZ	MI	TTANPDJ
DM2F8XZ	MN	Carbonic anhydrase II (CA-II)
DM2F8XZ	MT	DTT
DM2F8XZ	MA	Inhibitor
DM2F8XZ	RN	Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8.
DM2F8XZ	RU	https://pubmed.ncbi.nlm.nih.gov/18579385

DM2F8XZ	DI	DM2F8XZ
DM2F8XZ	DN	Salicyclic acid
DM2F8XZ	MI	TTZHA0O
DM2F8XZ	MN	Carbonic anhydrase IV (CA-IV)
DM2F8XZ	MT	DTT
DM2F8XZ	MA	Inhibitor
DM2F8XZ	RN	Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8.
DM2F8XZ	RU	https://pubmed.ncbi.nlm.nih.gov/18579385

DM2F8XZ	DI	DM2F8XZ
DM2F8XZ	DN	Salicyclic acid
DM2F8XZ	MI	TTCFSPE
DM2F8XZ	MN	Carbonic anhydrase VI (CA-VI)
DM2F8XZ	MT	DTT
DM2F8XZ	MA	Inhibitor
DM2F8XZ	RN	Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8.
DM2F8XZ	RU	https://pubmed.ncbi.nlm.nih.gov/18579385

DM2F8XZ	DI	DM2F8XZ
DM2F8XZ	DN	Salicyclic acid
DM2F8XZ	MI	TTSYM0R
DM2F8XZ	MN	Carbonic anhydrase XII (CA-XII)
DM2F8XZ	MT	DTT
DM2F8XZ	MA	Inhibitor
DM2F8XZ	RN	Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8.
DM2F8XZ	RU	https://pubmed.ncbi.nlm.nih.gov/18579385

DM2F8XZ	DI	DM2F8XZ
DM2F8XZ	DN	Salicyclic acid
DM2F8XZ	MI	DE5IED8
DM2F8XZ	MN	Cytochrome P450 2C9 (CYP2C9)
DM2F8XZ	MT	DME
DM2F8XZ	MA	Metabolism
DM2F8XZ	RN	Aromatic hydroxylation of salicylic acid and aspirin by human cytochromes P450. Eur J Pharm Sci. 2015 Jun 20;73:49-56.
DM2F8XZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25840124

DM2F8XZ	DI	DM2F8XZ
DM2F8XZ	DN	Salicyclic acid
DM2F8XZ	MI	DT342ZG
DM2F8XZ	MN	Monocarboxylate transporter 1 (SLC16A1)
DM2F8XZ	MT	DTP
DM2F8XZ	MA	Substrate
DM2F8XZ	RN	H+-coupled nutrient, micronutrient and drug transporters in the mammalian small intestine. Exp Physiol. 2007 Jul;92(4):603-19.
DM2F8XZ	RU	https://doi.org/10.1113/expphysiol.2005.029959

DM2F8XZ	DI	DM2F8XZ
DM2F8XZ	DN	Salicyclic acid
DM2F8XZ	MI	DTLT3UG
DM2F8XZ	MN	Monocarboxylate transporter 2 (SLC16A7)
DM2F8XZ	MT	DTP
DM2F8XZ	MA	Substrate
DM2F8XZ	RN	Clinical and Functional Relevance of the Monocarboxylate Transporter Family in Disease Pathophysiology and Drug Therapy. Clin Transl Sci. 2018 Jul;11(4):352-364.
DM2F8XZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/29660777

DM2F8XZ	DI	DM2F8XZ
DM2F8XZ	DN	Salicyclic acid
DM2F8XZ	MI	DTHE530
DM2F8XZ	MN	Probable small intestine urate exporter (SLC17A4)
DM2F8XZ	MT	DTP
DM2F8XZ	MA	Substrate
DM2F8XZ	RN	A Na+-phosphate cotransporter homologue (SLC17A4 protein) is an intestinal organic anion exporter. Am J Physiol Cell Physiol. 2012 Jun 1;302(11):C1652-60.
DM2F8XZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/22460716

DM2F8XZ	DI	DM2F8XZ
DM2F8XZ	DN	Salicyclic acid
DM2F8XZ	MI	TT8NGED
DM2F8XZ	MN	Prostaglandin G/H synthase 1 (COX-1)
DM2F8XZ	MT	DTT
DM2F8XZ	MA	Inhibitor
DM2F8XZ	RN	The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb Haemost. 2008 Jul;100(1):70-5.
DM2F8XZ	RU	https://pubmed.ncbi.nlm.nih.gov/18612540

DM2F8XZ	DI	DM2F8XZ
DM2F8XZ	DN	Salicyclic acid
DM2F8XZ	MI	DTM301H
DM2F8XZ	MN	Sodium-coupled monocarboxylate transporter 2 (SLC5A12)
DM2F8XZ	MT	DTP
DM2F8XZ	MA	Substrate
DM2F8XZ	RN	Sodium-coupled monocarboxylate transporters in normal tissues and in cancer. AAPS J. 2008;10(1):193-9.
DM2F8XZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/18446519

DMIEU69	DI	DMIEU69
DMIEU69	DN	Salmeterol
DMIEU69	MI	TT2CJVK
DMIEU69	MN	Adrenergic receptor beta-2 (ADRB2)
DMIEU69	MT	DTT
DMIEU69	MA	Agonist
DMIEU69	RN	Pharmacogenetic tests in asthma therapy. Clin Lab Med. 2008 Dec;28(4):645-65.
DMIEU69	RU	https://pubmed.ncbi.nlm.nih.gov/19059068

DMIEU69	DI	DMIEU69
DMIEU69	DN	Salmeterol
DMIEU69	MI	DE4LYSA
DMIEU69	MN	Cytochrome P450 3A4 (CYP3A4)
DMIEU69	MT	DME
DMIEU69	MA	Metabolism
DMIEU69	RN	Clinical pharmacokinetics of salmeterol. Clin Pharmacokinet. 2002;41(1):19-30.
DMIEU69	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11825095

DMIEU69	DI	DMIEU69
DMIEU69	DN	Salmeterol
DMIEU69	MI	DEIBDNY
DMIEU69	MN	Cytochrome P450 3A5 (CYP3A5)
DMIEU69	MT	DME
DMIEU69	MA	Metabolism
DMIEU69	RN	Drug Interactions Flockhart Table
DMIEU69	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMIEU69	DI	DMIEU69
DMIEU69	DN	Salmeterol
DMIEU69	MI	DERD86B
DMIEU69	MN	Cytochrome P450 3A7 (CYP3A7)
DMIEU69	MT	DME
DMIEU69	MA	Metabolism
DMIEU69	RN	Drug Interactions Flockhart Table
DMIEU69	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMEWUPF	DI	DMEWUPF
DMEWUPF	DN	Salmon Calcitonin
DMEWUPF	MI	TTLWS2O
DMEWUPF	MN	Calcitonin receptor (CALCR)
DMEWUPF	MT	DTT
DMEWUPF	MA	Binder
DMEWUPF	RN	Improved absorption of salmon calcitonin by ultraflexible liposomes through intranasal delivery. Peptides. 2009 Jul;30(7):1288-95.
DMEWUPF	RU	https://pubmed.ncbi.nlm.nih.gov/19540427

DM13P4C	DI	DM13P4C
DM13P4C	DN	Salsalate
DM13P4C	MI	TT8NGED
DM13P4C	MN	Prostaglandin G/H synthase 1 (COX-1)
DM13P4C	MT	DTT
DM13P4C	MA	Inhibitor
DM13P4C	RN	New non-steroidal anti-rheumatic drugs: selective inhibitors of inducible cyclooxygenase. Med Klin (Munich). 1998 Jul 15;93(7):407-15.
DM13P4C	RU	https://pubmed.ncbi.nlm.nih.gov/9711054

DM62MUZ	DI	DM62MUZ
DM62MUZ	DN	Samarium Sm-153 Lexidronam Pentasodium
DM62MUZ	MI	TTGXKP7
DM62MUZ	MN	Samarium (SAM)
DM62MUZ	MT	DTT
DM62MUZ	MA	Modulator
DM62MUZ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM62MUZ	RU	https://www.fda.gov/

DMDINFS	DI	DMDINFS
DMDINFS	DN	Sanguinarine
DMDINFS	MI	TTQ38E9
DMDINFS	MN	Sodium/potassium-transporting ATPase (SPT ATPase)
DMDINFS	MT	DTT
DMDINFS	MA	Modulator
DMDINFS	RN	Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81.
DMDINFS	RU	https://pubmed.ncbi.nlm.nih.gov/3879679

DM5VP0F	DI	DM5VP0F
DM5VP0F	DN	Saphris
DM5VP0F	MI	DTUGYRD
DM5VP0F	MN	P-glycoprotein 1 (ABCB1)
DM5VP0F	MT	DTP
DM5VP0F	MA	Substrate
DM5VP0F	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM5VP0F	RU	https://doi.org/10.1007/s11095-012-0935-x

DM4087K	DI	DM4087K
DM4087K	DN	Saprisartan
DM4087K	MI	TT8DBY3
DM4087K	MN	Angiotensin II receptor type-1 (AGTR1)
DM4087K	MT	DTT
DM4087K	MA	Antagonist
DM4087K	RN	Pharmacological properties of angiotensin II receptor antagonists. Can J Cardiol. 1999 Nov;15 Suppl F:26F-8F.
DM4087K	RU	https://pubmed.ncbi.nlm.nih.gov/10579749

DM90TJP	DI	DM90TJP
DM90TJP	DN	Sapropterin hydrochloride
DM90TJP	MI	TTGSVH2
DM90TJP	MN	Phenylalanine hydroxylase (PAH)
DM90TJP	MT	DTT
DM90TJP	MA	Modulator
DM90TJP	RN	2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
DM90TJP	RU	https://pubmed.ncbi.nlm.nih.gov/18246607

DMG814N	DI	DMG814N
DMG814N	DN	Saquinavir
DMG814N	MI	DTI7UX6
DMG814N	MN	Breast cancer resistance protein (ABCG2)
DMG814N	MT	DTP
DMG814N	MA	Substrate
DMG814N	RN	Nicotine and cotinine increases the brain penetration of saquinavir in rat. J Neurochem. 2010 Dec;115(6):1495-507.
DMG814N	RU	http://www.ncbi.nlm.nih.gov/pubmed/20950334

DMG814N	DI	DMG814N
DMG814N	DN	Saquinavir
DMG814N	MI	DECB0K3
DMG814N	MN	Cytochrome P450 2D6 (CYP2D6)
DMG814N	MT	DME
DMG814N	MA	Metabolism
DMG814N	RN	Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. J Pharm Sci. 1998 Oct;87(10):1184-9.
DMG814N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9758674

DMG814N	DI	DMG814N
DMG814N	DN	Saquinavir
DMG814N	MI	DE4LYSA
DMG814N	MN	Cytochrome P450 3A4 (CYP3A4)
DMG814N	MT	DME
DMG814N	MA	Metabolism
DMG814N	RN	Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe. Pharmacotherapy. 2009 Oct;29(10):1175-81.
DMG814N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19792991

DMG814N	DI	DMG814N
DMG814N	DN	Saquinavir
DMG814N	MI	DEIBDNY
DMG814N	MN	Cytochrome P450 3A5 (CYP3A5)
DMG814N	MT	DME
DMG814N	MA	Metabolism
DMG814N	RN	Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):79-85.
DMG814N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16433896

DMG814N	DI	DMG814N
DMG814N	DN	Saquinavir
DMG814N	MI	DERD86B
DMG814N	MN	Cytochrome P450 3A7 (CYP3A7)
DMG814N	MT	DME
DMG814N	MA	Metabolism
DMG814N	RN	Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):79-85.
DMG814N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16433896

DMG814N	DI	DMG814N
DMG814N	DN	Saquinavir
DMG814N	MI	TT5FNQT
DMG814N	MN	Human immunodeficiency virus Protease (HIV PR)
DMG814N	MT	DTT
DMG814N	MA	Inhibitor
DMG814N	RN	PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study. J Med Virol. 2008 Dec;80(12):2053-63.
DMG814N	RU	https://pubmed.ncbi.nlm.nih.gov/19040279

DMG814N	DI	DMG814N
DMG814N	DN	Saquinavir
DMG814N	MI	DTSYQGK
DMG814N	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMG814N	MT	DTP
DMG814N	MA	Substrate
DMG814N	RN	Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2). Antimicrob Agents Chemother. 2002 Nov;46(11):3456-62.
DMG814N	RU	http://www.ncbi.nlm.nih.gov/pubmed/12384350

DMG814N	DI	DMG814N
DMG814N	DN	Saquinavir
DMG814N	MI	DTFI42L
DMG814N	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMG814N	MT	DTP
DMG814N	MA	Substrate
DMG814N	RN	Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). J Biol Chem. 2003 Jun 27;278(26):23538-44.
DMG814N	RU	http://www.ncbi.nlm.nih.gov/pubmed/12702717

DMG814N	DI	DMG814N
DMG814N	DN	Saquinavir
DMG814N	MI	DTE2B1D
DMG814N	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMG814N	MT	DTP
DMG814N	MA	Substrate
DMG814N	RN	Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm. 2004 Jan 12;1(1):49-56.
DMG814N	RU	http://www.ncbi.nlm.nih.gov/pubmed/15832500

DMG814N	DI	DMG814N
DMG814N	DN	Saquinavir
DMG814N	MI	DT3D8F0
DMG814N	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMG814N	MT	DTP
DMG814N	MA	Substrate
DMG814N	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DMG814N	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DMG814N	DI	DMG814N
DMG814N	DN	Saquinavir
DMG814N	MI	DTUGYRD
DMG814N	MN	P-glycoprotein 1 (ABCB1)
DMG814N	MT	DTP
DMG814N	MA	Substrate
DMG814N	RN	Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo. Pharm Res. 2004 May;21(5):819-26.
DMG814N	RU	http://www.ncbi.nlm.nih.gov/pubmed/15180340

DMKS1DV	DI	DMKS1DV
DMKS1DV	DN	SARALASIN
DMKS1DV	MI	TT8DBY3
DMKS1DV	MN	Angiotensin II receptor type-1 (AGTR1)
DMKS1DV	MT	DTT
DMKS1DV	MA	Inhibitor
DMKS1DV	RN	Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69.
DMKS1DV	RU	https://pubmed.ncbi.nlm.nih.gov/18588282

DMKS1DV	DI	DMKS1DV
DMKS1DV	DN	SARALASIN
DMKS1DV	MI	TTQVOEI
DMKS1DV	MN	Angiotensin II receptor type-2 (AGTR2)
DMKS1DV	MT	DTT
DMKS1DV	MA	Inhibitor
DMKS1DV	RN	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
DMKS1DV	RU	https://pubmed.ncbi.nlm.nih.gov/18983139

DMKZROL	DI	DMKZROL
DMKZROL	DN	Saralasin Acetate
DMKZROL	MI	TT8DBY3
DMKZROL	MN	Angiotensin II receptor type-1 (AGTR1)
DMKZROL	MT	DTT
DMKZROL	MA	Modulator
DMKZROL	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMKZROL	RU	https://www.fda.gov/

DMLZNIQ	DI	DMLZNIQ
DMLZNIQ	DN	Sarecycline 
DMLZNIQ	MI	TTOVFH2
DMLZNIQ	MN	Bacterial 30S ribosomal RNA (Bact 30S rRNA)
DMLZNIQ	MT	DTT
DMLZNIQ	MA	Inhibitor
DMLZNIQ	RN	Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris.Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01297-18. 
DMLZNIQ	RU	https://pubmed.ncbi.nlm.nih.gov/30397052

DMY0M8J	DI	DMY0M8J
DMY0M8J	DN	Sargramostim
DMY0M8J	MI	TT6MP2Z
DMY0M8J	MN	GMCSFR-alpha (CSF2RA)
DMY0M8J	MT	DTT
DMY0M8J	MA	Binder
DMY0M8J	RN	Stem cell transplantation and hematopoietic growth factors. Curr Hematol Rep. 2002 Nov;1(2):103-9.
DMY0M8J	RU	https://pubmed.ncbi.nlm.nih.gov/12901131

DMOGNXY	DI	DMOGNXY
DMOGNXY	DN	Sarilumab
DMOGNXY	MI	TT0E5SK
DMOGNXY	MN	Interleukin 6 receptor (IL6R)
DMOGNXY	MT	DTT
DMOGNXY	MA	Modulator
DMOGNXY	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMOGNXY	RU	https://www.fda.gov/

DMGLP6S	DI	DMGLP6S
DMGLP6S	DN	Sarpogrelate
DMGLP6S	MI	TTJQOD7
DMGLP6S	MN	5-HT 2A receptor (HTR2A)
DMGLP6S	MT	DTT
DMGLP6S	MA	Antagonist
DMGLP6S	RN	Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30.
DMGLP6S	RU	https://pubmed.ncbi.nlm.nih.gov/19557588

DMRSKMZ	DI	DMRSKMZ
DMRSKMZ	DN	Satumomab Pendetide
DMRSKMZ	MI	TTX35ZM
DMRSKMZ	MN	Tumor-associated glycoprotein 72 (TAG-72)
DMRSKMZ	MT	DTT
DMRSKMZ	MA	Binder
DMRSKMZ	RN	Indium-111 satumomab pendetide: the first FDA-approved monoclonal antibody for tumor imaging. J Nucl Med Technol. 1998 Sep;26(3):155-63; quiz 170-1.
DMRSKMZ	RU	https://pubmed.ncbi.nlm.nih.gov/9755434

DMGXENV	DI	DMGXENV
DMGXENV	DN	Saxagliptin
DMGXENV	MI	DE4LYSA
DMGXENV	MN	Cytochrome P450 3A4 (CYP3A4)
DMGXENV	MT	DME
DMGXENV	MA	Metabolism
DMGXENV	RN	Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects. Br J Clin Pharmacol. 2011 Jul;72(1):92-102.
DMGXENV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21651615

DMGXENV	DI	DMGXENV
DMGXENV	DN	Saxagliptin
DMGXENV	MI	DEIBDNY
DMGXENV	MN	Cytochrome P450 3A5 (CYP3A5)
DMGXENV	MT	DME
DMGXENV	MA	Metabolism
DMGXENV	RN	Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects. Br J Clin Pharmacol. 2011 Jul;72(1):92-102.
DMGXENV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21651615

DMGXENV	DI	DMGXENV
DMGXENV	DN	Saxagliptin
DMGXENV	MI	TTDIGC1
DMGXENV	MN	Dipeptidyl peptidase 4 (DPP-4)
DMGXENV	MT	DTT
DMGXENV	MA	Inhibitor
DMGXENV	RN	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
DMGXENV	RU	https://pubmed.ncbi.nlm.nih.gov/20118952

DMGXENV	DI	DMGXENV
DMGXENV	DN	Saxagliptin
DMGXENV	MI	DTSYQGK
DMGXENV	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMGXENV	MT	DTP
DMGXENV	MA	Substrate
DMGXENV	RN	Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet. 2010 Sep;49(9):573-88.
DMGXENV	RU	http://www.ncbi.nlm.nih.gov/pubmed/20690781

DMGXENV	DI	DMGXENV
DMGXENV	DN	Saxagliptin
DMGXENV	MI	DTVP67E
DMGXENV	MN	Organic anion transporter 3 (SLC22A8)
DMGXENV	MT	DTP
DMGXENV	MA	Substrate
DMGXENV	RN	Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 2012 Aug 1;51(8):501-14.
DMGXENV	RU	http://www.ncbi.nlm.nih.gov/pubmed/22686547

DMGXENV	DI	DMGXENV
DMGXENV	DN	Saxagliptin
DMGXENV	MI	DTY0QMU
DMGXENV	MN	Organic anion transporting polypeptide 4C1 (SLCO4C1)
DMGXENV	MT	DTP
DMGXENV	MA	Substrate
DMGXENV	RN	Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 2012 Aug 1;51(8):501-14.
DMGXENV	RU	http://www.ncbi.nlm.nih.gov/pubmed/22686547

DMGXENV	DI	DMGXENV
DMGXENV	DN	Saxagliptin
DMGXENV	MI	DTUGYRD
DMGXENV	MN	P-glycoprotein 1 (ABCB1)
DMGXENV	MT	DTP
DMGXENV	MA	Substrate
DMGXENV	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DMGXENV	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DMDK7T9	DI	DMDK7T9
DMDK7T9	DN	SBC-102
DMDK7T9	MI	TTS8T1M
DMDK7T9	MN	Lysosomal acid lipase (LIPA)
DMDK7T9	MT	DTT
DMDK7T9	MA	Modulator
DMDK7T9	RN	A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency. N Engl J Med. 2015 Sep 10;373(11):1010-20.
DMDK7T9	RU	https://pubmed.ncbi.nlm.nih.gov/26352813

DMOM8AL	DI	DMOM8AL
DMOM8AL	DN	Scopolamine
DMOM8AL	MI	TTOXS3C
DMOM8AL	MN	Muscarinic acetylcholine receptor (CHRM)
DMOM8AL	MT	DTT
DMOM8AL	MA	Antagonist
DMOM8AL	RN	The amygdala modulates morphine-induced state-dependent memory retrieval via muscarinic acetylcholine receptors. Neuroscience. 2009 May 5;160(2):255-63.
DMOM8AL	RU	https://pubmed.ncbi.nlm.nih.gov/19272427

DMJ18YL	DI	DMJ18YL
DMJ18YL	DN	Secnidazole
DMJ18YL	MI	DEAN5EW
DMJ18YL	MN	Nitroreductase (NTR)
DMJ18YL	MT	DME
DMJ18YL	MA	Metabolism
DMJ18YL	RN	Overexpression, isotopic labeling, and spectral characterization of Enterobacter cloacae nitroreductase. Protein Expr Purif. 1998 Jun;13(1):53-60.
DMJ18YL	RU	https://pubmed.ncbi.nlm.nih.gov/9631515

DM14RF5	DI	DM14RF5
DM14RF5	DN	Secobarbital
DM14RF5	MI	TT1MPAY
DM14RF5	MN	GABA(A) receptor alpha-1 (GABRA1)
DM14RF5	MT	DTT
DM14RF5	MA	Antagonist
DM14RF5	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DM14RF5	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DMDKE4N	DI	DMDKE4N
DMDKE4N	DN	Secretin
DMDKE4N	MI	TTOBVIN
DMDKE4N	MN	Secretin receptor (SCT)
DMDKE4N	MT	DTT
DMDKE4N	MA	Binder
DMDKE4N	RN	False-positive secretin stimulation test for gastrinoma associated with the use of proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2009 May;7(5):600-2.
DMDKE4N	RU	https://pubmed.ncbi.nlm.nih.gov/19245850

DMFEGB0	DI	DMFEGB0
DMFEGB0	DN	Segesterone acetate; ethinyl estradiol
DMFEGB0	MI	TTDSB34
DMFEGB0	MN	G-protein coupled estrogen receptor 1 (GPER1)
DMFEGB0	MT	DTT
DMFEGB0	MA	Modulator
DMFEGB0	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMFEGB0	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMFEGB0	DI	DMFEGB0
DMFEGB0	DN	Segesterone acetate; ethinyl estradiol
DMFEGB0	MI	TTUV8G9
DMFEGB0	MN	Progesterone receptor (PGR)
DMFEGB0	MT	DTT
DMFEGB0	MA	Modulator
DMFEGB0	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMFEGB0	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DM6034S	DI	DM6034S
DM6034S	DN	Selegiline
DM6034S	MI	TT32XQJ
DM6034S	MN	Monoamine oxidase (MAO)
DM6034S	MT	DTT
DM6034S	MA	Inhibitor
DM6034S	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DM6034S	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DM6034S	DI	DM6034S
DM6034S	DN	Selegiline
DM6034S	MI	TTGP7BY
DM6034S	MN	Monoamine oxidase type B (MAO-B)
DM6034S	MT	DTT
DM6034S	MA	Inhibitor
DM6034S	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2490).
DM6034S	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2490

DM6034S	DI	DM6034S
DM6034S	DN	Selegiline
DM6034S	MI	TTZPO1L
DM6034S	MN	Substance-P receptor (TACR1)
DM6034S	MT	DTT
DM6034S	MA	Antagonist
DM6034S	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DM6034S	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DM3VR1L	DI	DM3VR1L
DM3VR1L	DN	Selegiline hydrochloride
DM3VR1L	MI	DEJGDUW
DM3VR1L	MN	Cytochrome P450 1A2 (CYP1A2)
DM3VR1L	MT	DME
DM3VR1L	MA	Metabolism
DM3VR1L	RN	Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. Drug Metab Dispos. 2003 Sep;31(9):1093-102.
DM3VR1L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920164

DM3VR1L	DI	DM3VR1L
DM3VR1L	DN	Selegiline hydrochloride
DM3VR1L	MI	DEJVYAZ
DM3VR1L	MN	Cytochrome P450 2A6 (CYP2A6)
DM3VR1L	MT	DME
DM3VR1L	MA	Metabolism
DM3VR1L	RN	Variation in CYP2A6 activity and personalized medicine. J Pers Med. 2017 Dec 1;7(4). pii: E18.
DM3VR1L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29194389

DM3VR1L	DI	DM3VR1L
DM3VR1L	DN	Selegiline hydrochloride
DM3VR1L	MI	DEPKLMQ
DM3VR1L	MN	Cytochrome P450 2B6 (CYP2B6)
DM3VR1L	MT	DME
DM3VR1L	MA	Metabolism
DM3VR1L	RN	Evaluation of metabolism dependent inhibition of CYP2B6 mediated bupropion hydroxylation in human liver microsomes by monoamine oxidase inhibitors and prediction of potential as perpetrators of drug interaction. Chem Biol Interact. 2015 Mar 25;230:9-20.
DM3VR1L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25656918

DM3VR1L	DI	DM3VR1L
DM3VR1L	DN	Selegiline hydrochloride
DM3VR1L	MI	DES5XRU
DM3VR1L	MN	Cytochrome P450 2C8 (CYP2C8)
DM3VR1L	MT	DME
DM3VR1L	MA	Metabolism
DM3VR1L	RN	Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. Drug Metab Dispos. 2003 Sep;31(9):1093-102.
DM3VR1L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920164

DM3VR1L	DI	DM3VR1L
DM3VR1L	DN	Selegiline hydrochloride
DM3VR1L	MI	DE5IED8
DM3VR1L	MN	Cytochrome P450 2C9 (CYP2C9)
DM3VR1L	MT	DME
DM3VR1L	MA	Metabolism
DM3VR1L	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM3VR1L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM3VR1L	DI	DM3VR1L
DM3VR1L	DN	Selegiline hydrochloride
DM3VR1L	MI	DECB0K3
DM3VR1L	MN	Cytochrome P450 2D6 (CYP2D6)
DM3VR1L	MT	DME
DM3VR1L	MA	Metabolism
DM3VR1L	RN	Inter- and intraindividual pharmacokinetic variations in the treatment of Parkinson's disease. Rinsho Shinkeigaku. 2005 Nov;45(11):895-8.
DM3VR1L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16447756

DM3VR1L	DI	DM3VR1L
DM3VR1L	DN	Selegiline hydrochloride
DM3VR1L	MI	DE4LYSA
DM3VR1L	MN	Cytochrome P450 3A4 (CYP3A4)
DM3VR1L	MT	DME
DM3VR1L	MA	Metabolism
DM3VR1L	RN	P450 phenotyping of the metabolism of selegiline to desmethylselegiline and methamphetamine. Drug Metab Pharmacokinet. 2007 Apr;22(2):78-87.
DM3VR1L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17495414

DM3VR1L	DI	DM3VR1L
DM3VR1L	DN	Selegiline hydrochloride
DM3VR1L	MI	DEGTFWK
DM3VR1L	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM3VR1L	MT	DME
DM3VR1L	MA	Metabolism
DM3VR1L	RN	Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. Drug Metab Dispos. 2003 Sep;31(9):1093-102.
DM3VR1L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920164

DM3VR1L	DI	DM3VR1L
DM3VR1L	DN	Selegiline hydrochloride
DM3VR1L	MI	TTGP7BY
DM3VR1L	MN	Monoamine oxidase type B (MAO-B)
DM3VR1L	MT	DTT
DM3VR1L	MA	Modulator
DM3VR1L	RN	Emerging drugs for Parkinson's disease. Expert Opin Emerg Drugs. 2006 Sep;11(3):403-17.
DM3VR1L	RU	https://pubmed.ncbi.nlm.nih.gov/16939381

DM25CGV	DI	DM25CGV
DM25CGV	DN	Selenium
DM25CGV	MI	DEGDPL2
DM25CGV	MN	Glutathione reductase (GSR)
DM25CGV	MT	DME
DM25CGV	MA	Metabolism
DM25CGV	RN	Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase. Carcinogenesis. 1999 Sep;20(9):1657-66.
DM25CGV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10469608

DM25CGV	DI	DM25CGV
DM25CGV	DN	Selenium
DM25CGV	MI	DEH4TD6
DM25CGV	MN	Selenocysteine lyase (SCLY)
DM25CGV	MT	DME
DM25CGV	MA	Metabolism
DM25CGV	RN	Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase. Carcinogenesis. 1999 Sep;20(9):1657-66.
DM25CGV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10469608

DM25CGV	DI	DM25CGV
DM25CGV	DN	Selenium
DM25CGV	MI	DEUP4DA
DM25CGV	MN	Thioredoxin reductase TR1 (TXNRD1)
DM25CGV	MT	DME
DM25CGV	MA	Metabolism
DM25CGV	RN	Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase. Carcinogenesis. 1999 Sep;20(9):1657-66.
DM25CGV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10469608

DMAHSU0	DI	DMAHSU0
DMAHSU0	DN	Selexipag
DMAHSU0	MI	DES5XRU
DMAHSU0	MN	Cytochrome P450 2C8 (CYP2C8)
DMAHSU0	MT	DME
DMAHSU0	MA	Metabolism
DMAHSU0	RN	FDA Label of Uptravi. The 2020 official website of the U.S. Food and Drug Administration.
DMAHSU0	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207947s005lbl.pdf

DMAHSU0	DI	DMAHSU0
DMAHSU0	DN	Selexipag
DMAHSU0	MI	TTOFYT1
DMAHSU0	MN	Prostacyclin receptor (PTGIR)
DMAHSU0	MT	DTT
DMAHSU0	MA	Agonist
DMAHSU0	RN	Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J. 2012 Oct;40(4):874-80.
DMAHSU0	RU	https://pubmed.ncbi.nlm.nih.gov/22362844

DMZR15V	DI	DMZR15V
DMZR15V	DN	Selpercatinib
DMZR15V	MI	TT4DXQT
DMZR15V	MN	Proto-oncogene c-Ret (RET)
DMZR15V	MT	DTT
DMZR15V	MA	Inhibitor
DMZR15V	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMZR15V	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf

DMAGFOD	DI	DMAGFOD
DMAGFOD	DN	Semaglutide
DMAGFOD	MI	DEKZQY6
DMAGFOD	MN	Dipeptidyl peptidase IV (DPP4)
DMAGFOD	MT	DME
DMAGFOD	MA	Metabolism
DMAGFOD	RN	Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species. Eur J Pharm Sci. 2017 Jun 15;104:31-41.
DMAGFOD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28323117

DMAGFOD	DI	DMAGFOD
DMAGFOD	DN	Semaglutide
DMAGFOD	MI	TTVIMDE
DMAGFOD	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMAGFOD	MT	DTT
DMAGFOD	MA	Agonist
DMAGFOD	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249).
DMAGFOD	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=249

DMAGFOD	DI	DMAGFOD
DMAGFOD	DN	Semaglutide
DMAGFOD	MI	DEVN830
DMAGFOD	MN	Neprilysin (MME)
DMAGFOD	MT	DME
DMAGFOD	MA	Metabolism
DMAGFOD	RN	Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species. Eur J Pharm Sci. 2017 Jun 15;104:31-41.
DMAGFOD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28323117

DM25HP1	DI	DM25HP1
DM25HP1	DN	Sermorelin
DM25HP1	MI	TTG4R8V
DM25HP1	MN	Growth hormone-releasing hormone receptor (GHRHR)
DM25HP1	MT	DTT
DM25HP1	MA	Binder
DM25HP1	RN	Sermorelin: a better approach to management of adult-onset growth hormone insufficiency Clin Interv Aging. 2006;1(4):307-8.
DM25HP1	RU	https://pubmed.ncbi.nlm.nih.gov/18046908

DM1A9XO	DI	DM1A9XO
DM1A9XO	DN	Sertaconazole
DM1A9XO	MI	TTTSOUD
DM1A9XO	MN	Candida Cytochrome P450 51 (Candi ERG11)
DM1A9XO	MT	DTT
DM1A9XO	MA	Inhibitor
DM1A9XO	RN	Sertaconazole: a review of its use in the management of superficial mycoses in dermatology and gynaecology. Drugs. 2009;69(3):339-59. 
DM1A9XO	RU	https://pubmed.ncbi.nlm.nih.gov/19275277

DM0FB1J	DI	DM0FB1J
DM0FB1J	DN	Sertraline
DM0FB1J	MI	DEJGDUW
DM0FB1J	MN	Cytochrome P450 1A2 (CYP1A2)
DM0FB1J	MT	DME
DM0FB1J	MA	Metabolism
DM0FB1J	RN	The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders. CNS Drug Rev. 2001 Spring;7(1):1-24.
DM0FB1J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11420570

DM0FB1J	DI	DM0FB1J
DM0FB1J	DN	Sertraline
DM0FB1J	MI	DEPKLMQ
DM0FB1J	MN	Cytochrome P450 2B6 (CYP2B6)
DM0FB1J	MT	DME
DM0FB1J	MA	Metabolism
DM0FB1J	RN	Influence of CYP2B6 and CYP2C19 polymorphisms on sertraline metabolism in major depression patients. Int J Clin Pharm. 2016 Apr;38(2):388-94.
DM0FB1J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26830411

DM0FB1J	DI	DM0FB1J
DM0FB1J	DN	Sertraline
DM0FB1J	MI	DE5IED8
DM0FB1J	MN	Cytochrome P450 2C9 (CYP2C9)
DM0FB1J	MT	DME
DM0FB1J	MA	Metabolism
DM0FB1J	RN	Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos. 2005 Feb;33(2):262-70.
DM0FB1J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15547048

DM0FB1J	DI	DM0FB1J
DM0FB1J	DN	Sertraline
DM0FB1J	MI	DECB0K3
DM0FB1J	MN	Cytochrome P450 2D6 (CYP2D6)
DM0FB1J	MT	DME
DM0FB1J	MA	Metabolism
DM0FB1J	RN	Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapie. 2004 Jan-Feb;59(1):5-12.
DM0FB1J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15199661

DM0FB1J	DI	DM0FB1J
DM0FB1J	DN	Sertraline
DM0FB1J	MI	DEVDYN7
DM0FB1J	MN	Cytochrome P450 2E1 (CYP2E1)
DM0FB1J	MT	DME
DM0FB1J	MA	Metabolism
DM0FB1J	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA166181117)
DM0FB1J	RU	https://www.pharmgkb.org/pathway/PA166181117

DM0FB1J	DI	DM0FB1J
DM0FB1J	DN	Sertraline
DM0FB1J	MI	DE4LYSA
DM0FB1J	MN	Cytochrome P450 3A4 (CYP3A4)
DM0FB1J	MT	DME
DM0FB1J	MA	Metabolism
DM0FB1J	RN	New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients. Ther Clin Risk Manag. 2014 Jun 13;10:423-36.
DM0FB1J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24966680

DM0FB1J	DI	DM0FB1J
DM0FB1J	DN	Sertraline
DM0FB1J	MI	DEGTFWK
DM0FB1J	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM0FB1J	MT	DME
DM0FB1J	MA	Metabolism
DM0FB1J	RN	Influence of CYP2B6 and CYP2C19 polymorphisms on sertraline metabolism in major depression patients. Int J Clin Pharm. 2016 Apr;38(2):388-94.
DM0FB1J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26830411

DM0FB1J	DI	DM0FB1J
DM0FB1J	DN	Sertraline
DM0FB1J	MI	DTUGYRD
DM0FB1J	MN	P-glycoprotein 1 (ABCB1)
DM0FB1J	MT	DTP
DM0FB1J	MA	Substrate
DM0FB1J	RN	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
DM0FB1J	RU	https://doi.org/10.1016/j.addr.2011.12.008

DM0FB1J	DI	DM0FB1J
DM0FB1J	DN	Sertraline
DM0FB1J	MI	TT3ROYC
DM0FB1J	MN	Serotonin transporter (SERT)
DM0FB1J	MT	DTT
DM0FB1J	MA	Inhibitor
DM0FB1J	RN	Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6.
DM0FB1J	RU	https://pubmed.ncbi.nlm.nih.gov/17877739

DMPVRN9	DI	DMPVRN9
DMPVRN9	DN	Setmelanotide
DMPVRN9	MI	TTD0CIQ
DMPVRN9	MN	Melanocortin receptor 4 (MC4R)
DMPVRN9	MT	DTT
DMPVRN9	MA	Agonist
DMPVRN9	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMPVRN9	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213793s000lbl.pdf

DMC9O43	DI	DMC9O43
DMC9O43	DN	Sevoflurane
DMC9O43	MI	DEJVYAZ
DMC9O43	MN	Cytochrome P450 2A6 (CYP2A6)
DMC9O43	MT	DME
DMC9O43	MA	Metabolism
DMC9O43	RN	Human kidney methoxyflurane and sevoflurane metabolism. Intrarenal fluoride production as a possible mechanism of methoxyflurane nephrotoxicity. Anesthesiology. 1995 Mar;82(3):689-99.
DMC9O43	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7879937

DMC9O43	DI	DMC9O43
DMC9O43	DN	Sevoflurane
DMC9O43	MI	DEPKLMQ
DMC9O43	MN	Cytochrome P450 2B6 (CYP2B6)
DMC9O43	MT	DME
DMC9O43	MA	Metabolism
DMC9O43	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMC9O43	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMC9O43	DI	DMC9O43
DMC9O43	DN	Sevoflurane
DMC9O43	MI	DEVDYN7
DMC9O43	MN	Cytochrome P450 2E1 (CYP2E1)
DMC9O43	MT	DME
DMC9O43	MA	Metabolism
DMC9O43	RN	Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
DMC9O43	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12234619

DMC9O43	DI	DMC9O43
DMC9O43	DN	Sevoflurane
DMC9O43	MI	DE4LYSA
DMC9O43	MN	Cytochrome P450 3A4 (CYP3A4)
DMC9O43	MT	DME
DMC9O43	MA	Metabolism
DMC9O43	RN	Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology. 1993 Oct;79(4):795-807.
DMC9O43	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8214760

DMC9O43	DI	DMC9O43
DMC9O43	DN	Sevoflurane
DMC9O43	MI	TTAN6JD
DMC9O43	MN	Glutamate receptor AMPA (GRIA)
DMC9O43	MT	DTT
DMC9O43	MA	Antagonist
DMC9O43	RN	Effects of sevoflurane on carrageenan- and fentanyl-induced pain hypersensitivity in Sprague-Dawley rats. Can J Anaesth. 2009 Feb;56(2):126-35.
DMC9O43	RU	https://pubmed.ncbi.nlm.nih.gov/19247760

DMFJTDI	DI	DMFJTDI
DMFJTDI	DN	Sibutramine
DMFJTDI	MI	DE4LYSA
DMFJTDI	MN	Cytochrome P450 3A4 (CYP3A4)
DMFJTDI	MT	DME
DMFJTDI	MA	Metabolism
DMFJTDI	RN	Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity. Ann Pharmacother. 1999 Sep;33(9):968-78.
DMFJTDI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10492502

DMFJTDI	DI	DMFJTDI
DMFJTDI	DN	Sibutramine
DMFJTDI	MI	TTAWNKZ
DMFJTDI	MN	Norepinephrine transporter (NET)
DMFJTDI	MT	DTT
DMFJTDI	MA	Modulator
DMFJTDI	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMFJTDI	RU	https://www.fda.gov/

DMFJTDI	DI	DMFJTDI
DMFJTDI	DN	Sibutramine
DMFJTDI	MI	TT3ROYC
DMFJTDI	MN	Serotonin transporter (SERT)
DMFJTDI	MT	DTT
DMFJTDI	MA	Modulator
DMFJTDI	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMFJTDI	RU	https://www.fda.gov/

DM1BS03	DI	DM1BS03
DM1BS03	DN	Sifalimumab
DM1BS03	MI	TTMQB37
DM1BS03	MN	Interferon alpha/beta receptor 2 (IFNAR2)
DM1BS03	MT	DTT
DM1BS03	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DM1BS03	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DMSWJ5X	DI	DMSWJ5X
DMSWJ5X	DN	Sildenafil citrate
DMSWJ5X	MI	DE5IED8
DMSWJ5X	MN	Cytochrome P450 2C9 (CYP2C9)
DMSWJ5X	MT	DME
DMSWJ5X	MA	Metabolism
DMSWJ5X	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMSWJ5X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMSWJ5X	DI	DMSWJ5X
DMSWJ5X	DN	Sildenafil citrate
DMSWJ5X	MI	DECB0K3
DMSWJ5X	MN	Cytochrome P450 2D6 (CYP2D6)
DMSWJ5X	MT	DME
DMSWJ5X	MA	Metabolism
DMSWJ5X	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMSWJ5X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMSWJ5X	DI	DMSWJ5X
DMSWJ5X	DN	Sildenafil citrate
DMSWJ5X	MI	DEVDYN7
DMSWJ5X	MN	Cytochrome P450 2E1 (CYP2E1)
DMSWJ5X	MT	DME
DMSWJ5X	MA	Metabolism
DMSWJ5X	RN	Erectile dysfunction drugs changed the protein expressions and activities of drug-metabolising enzymes in the liver of male rats. Oxid Med Cell Longev. 2016;2016:4970906.
DMSWJ5X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27800121

DMSWJ5X	DI	DMSWJ5X
DMSWJ5X	DN	Sildenafil citrate
DMSWJ5X	MI	DE4LYSA
DMSWJ5X	MN	Cytochrome P450 3A4 (CYP3A4)
DMSWJ5X	MT	DME
DMSWJ5X	MA	Metabolism
DMSWJ5X	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMSWJ5X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMSWJ5X	DI	DMSWJ5X
DMSWJ5X	DN	Sildenafil citrate
DMSWJ5X	MI	DEIBDNY
DMSWJ5X	MN	Cytochrome P450 3A5 (CYP3A5)
DMSWJ5X	MT	DME
DMSWJ5X	MA	Metabolism
DMSWJ5X	RN	The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil. Drug Metab Dispos. 2008 Jun;36(6):986-90.
DMSWJ5X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18308836

DMSWJ5X	DI	DMSWJ5X
DMSWJ5X	DN	Sildenafil citrate
DMSWJ5X	MI	DERD86B
DMSWJ5X	MN	Cytochrome P450 3A7 (CYP3A7)
DMSWJ5X	MT	DME
DMSWJ5X	MA	Metabolism
DMSWJ5X	RN	Drug Interactions Flockhart Table
DMSWJ5X	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMSWJ5X	DI	DMSWJ5X
DMSWJ5X	DN	Sildenafil citrate
DMSWJ5X	MI	DEGTFWK
DMSWJ5X	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMSWJ5X	MT	DME
DMSWJ5X	MA	Metabolism
DMSWJ5X	RN	Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. Br J Clin Pharmacol. 2001 Mar;51(3):239-48.
DMSWJ5X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11298070

DMJSBT6	DI	DMJSBT6
DMJSBT6	DN	Silodosin
DMJSBT6	MI	TTNGILX
DMJSBT6	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMJSBT6	MT	DTT
DMJSBT6	MA	Inhibitor
DMJSBT6	RN	Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
DMJSBT6	RU	https://pubmed.ncbi.nlm.nih.gov/15664832

DMJSBT6	DI	DMJSBT6
DMJSBT6	DN	Silodosin
DMJSBT6	MI	DEE5M8O
DMJSBT6	MN	Alcohol dehydrogenase class-I alpha (ADH1A)
DMJSBT6	MT	DME
DMJSBT6	MA	Metabolism
DMJSBT6	RN	Pharmacokinetics and disposition of silodosin (KMD-3213). Yakugaku Zasshi. 2006 Mar;126 Spec no.:237-45.
DMJSBT6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16518089

DMJSBT6	DI	DMJSBT6
DMJSBT6	DN	Silodosin
DMJSBT6	MI	DEWYTJB
DMJSBT6	MN	Aldehyde dehydrogenase 2 (ALDH2)
DMJSBT6	MT	DME
DMJSBT6	MA	Metabolism
DMJSBT6	RN	Pharmacokinetics and disposition of silodosin (KMD-3213). Yakugaku Zasshi. 2006 Mar;126 Spec no.:237-45.
DMJSBT6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16518089

DMJSBT6	DI	DMJSBT6
DMJSBT6	DN	Silodosin
DMJSBT6	MI	DE4LYSA
DMJSBT6	MN	Cytochrome P450 3A4 (CYP3A4)
DMJSBT6	MT	DME
DMJSBT6	MA	Metabolism
DMJSBT6	RN	Silodosin for benign prostatic hyperplasia. Ann Pharmacother. 2010 Feb;44(2):302-10.
DMJSBT6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20071497

DMJSBT6	DI	DMJSBT6
DMJSBT6	DN	Silodosin
DMJSBT6	MI	DTZRMK5
DMJSBT6	MN	Multidrug resistance protein 3 (ABCB4)
DMJSBT6	MT	DTP
DMJSBT6	MA	Substrate
DMJSBT6	RN	Pharmacokinetics and disposition of silodosin (KMD-3213)]. Yakugaku Zasshi. 2006 Mar;126 Spec no.:237-45.
DMJSBT6	RU	http://www.ncbi.nlm.nih.gov/pubmed/16518089

DMJSBT6	DI	DMJSBT6
DMJSBT6	DN	Silodosin
DMJSBT6	MI	DTUGYRD
DMJSBT6	MN	P-glycoprotein 1 (ABCB1)
DMJSBT6	MT	DTP
DMJSBT6	MA	Substrate
DMJSBT6	RN	The influence of UGT2B7, UGT1A8, MDR1, ALDH, ADH, CYP3A4 and CYP3A5 genetic polymorphisms on the pharmacokinetics of silodosin in healthy Chinese volunteers. Drug Metab Pharmacokinet. 2013;28(3):239-43.
DMJSBT6	RU	http://www.ncbi.nlm.nih.gov/pubmed/23257391

DMJSBT6	DI	DMJSBT6
DMJSBT6	DN	Silodosin
DMJSBT6	MI	DEB3CV1
DMJSBT6	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMJSBT6	MT	DME
DMJSBT6	MA	Metabolism
DMJSBT6	RN	Pharmacokinetics and disposition of silodosin (KMD-3213). Yakugaku Zasshi. 2006 Mar;126 Spec no.:237-45.
DMJSBT6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16518089

DMGEATB	DI	DMGEATB
DMGEATB	DN	Siltuximab
DMGEATB	MI	TTT1V78
DMGEATB	MN	Interleukin-6 (IL6)
DMGEATB	MT	DTT
DMGEATB	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMGEATB	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMVTHWQ	DI	DMVTHWQ
DMVTHWQ	DN	Silver sulfadiazine
DMVTHWQ	MI	TT4ILYC
DMVTHWQ	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMVTHWQ	MT	DTT
DMVTHWQ	MA	Binder
DMVTHWQ	RN	Comparative evaluation of transdermal formulations of norfloxacin with silver sulfadiazine cream, USP, for burn wound healing property. J Burns Wounds. 2006 Jun 7;5:e4.
DMVTHWQ	RU	https://pubmed.ncbi.nlm.nih.gov/16921417

DMLUA9D	DI	DMLUA9D
DMLUA9D	DN	Simeprevir
DMLUA9D	MI	DE4LYSA
DMLUA9D	MN	Cytochrome P450 3A4 (CYP3A4)
DMLUA9D	MT	DME
DMLUA9D	MA	Metabolism
DMLUA9D	RN	Hepatitis C virus direct-acting antiviral drug interactions and use in renal and hepatic impairment. Top Antivir Med. 2015 May-Jun;23(2):92-6.
DMLUA9D	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26200709

DMLUA9D	DI	DMLUA9D
DMLUA9D	DN	Simeprevir
DMLUA9D	MI	TTHC7JD
DMLUA9D	MN	Hepatitis C virus Serine protease NS3/4A (HCV NS3/4A)
DMLUA9D	MT	DTT
DMLUA9D	MA	Modulator
DMLUA9D	RN	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
DMLUA9D	RU	https://pubmed.ncbi.nlm.nih.gov/28919714

DMLUA9D	DI	DMLUA9D
DMLUA9D	DN	Simeprevir
DMLUA9D	MI	DT3D8F0
DMLUA9D	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMLUA9D	MT	DTP
DMLUA9D	MA	Substrate
DMLUA9D	RN	Drug-Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir. Clin Pharmacokinet. 2016 Feb;55(2):197-208.
DMLUA9D	RU	http://www.ncbi.nlm.nih.gov/pubmed/26353895

DMLUA9D	DI	DMLUA9D
DMLUA9D	DN	Simeprevir
DMLUA9D	MI	DTUGYRD
DMLUA9D	MN	P-glycoprotein 1 (ABCB1)
DMLUA9D	MT	DTP
DMLUA9D	MA	Substrate
DMLUA9D	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
DMLUA9D	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01665

DM30SGU	DI	DM30SGU
DM30SGU	DN	Simvastatin
DM30SGU	MI	DTI7UX6
DM30SGU	MN	Breast cancer resistance protein (ABCG2)
DM30SGU	MT	DTP
DM30SGU	MA	Substrate
DM30SGU	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM30SGU	RU	https://doi.org/10.1007/s11095-012-0935-x

DM30SGU	DI	DM30SGU
DM30SGU	DN	Simvastatin
DM30SGU	MI	DES5XRU
DM30SGU	MN	Cytochrome P450 2C8 (CYP2C8)
DM30SGU	MT	DME
DM30SGU	MA	Metabolism
DM30SGU	RN	Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006 Dec;80(6):565-81.
DM30SGU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17178259

DM30SGU	DI	DM30SGU
DM30SGU	DN	Simvastatin
DM30SGU	MI	DECB0K3
DM30SGU	MN	Cytochrome P450 2D6 (CYP2D6)
DM30SGU	MT	DME
DM30SGU	MA	Metabolism
DM30SGU	RN	Genetic polymorphisms in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors. Am J Cardiovasc Drugs. 2004;4(4):247-55.
DM30SGU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15285699

DM30SGU	DI	DM30SGU
DM30SGU	DN	Simvastatin
DM30SGU	MI	DE4LYSA
DM30SGU	MN	Cytochrome P450 3A4 (CYP3A4)
DM30SGU	MT	DME
DM30SGU	MA	Metabolism
DM30SGU	RN	A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. Drug Metab Dispos. 2001 Mar;29(3):282-8.
DM30SGU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11181496

DM30SGU	DI	DM30SGU
DM30SGU	DN	Simvastatin
DM30SGU	MI	DEIBDNY
DM30SGU	MN	Cytochrome P450 3A5 (CYP3A5)
DM30SGU	MT	DME
DM30SGU	MA	Metabolism
DM30SGU	RN	In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos. 1997 Oct;25(10):1191-9.
DM30SGU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9321523

DM30SGU	DI	DM30SGU
DM30SGU	DN	Simvastatin
DM30SGU	MI	TTPADOQ
DM30SGU	MN	HMG-CoA reductase (HMGCR)
DM30SGU	MT	DTT
DM30SGU	MA	Inhibitor
DM30SGU	RN	Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64.
DM30SGU	RU	https://pubmed.ncbi.nlm.nih.gov/11523064

DM30SGU	DI	DM30SGU
DM30SGU	DN	Simvastatin
DM30SGU	MI	DEGTFWK
DM30SGU	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM30SGU	MT	DME
DM30SGU	MA	Metabolism
DM30SGU	RN	Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
DM30SGU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27757045

DM30SGU	DI	DM30SGU
DM30SGU	DN	Simvastatin
DM30SGU	MI	DT3D8F0
DM30SGU	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM30SGU	MT	DTP
DM30SGU	MA	Substrate
DM30SGU	RN	Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705.
DM30SGU	RU	http://www.ncbi.nlm.nih.gov/pubmed/19785645

DM30SGU	DI	DM30SGU
DM30SGU	DN	Simvastatin
DM30SGU	MI	DTUGYRD
DM30SGU	MN	P-glycoprotein 1 (ABCB1)
DM30SGU	MT	DTP
DM30SGU	MA	Substrate
DM30SGU	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM30SGU	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DM30SGU	DI	DM30SGU
DM30SGU	DN	Simvastatin
DM30SGU	MI	DEYGVN4
DM30SGU	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM30SGU	MT	DME
DM30SGU	MA	Metabolism
DM30SGU	RN	Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
DM30SGU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27757045

DM30SGU	DI	DM30SGU
DM30SGU	DN	Simvastatin
DM30SGU	MI	DEF2WXN
DM30SGU	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DM30SGU	MT	DME
DM30SGU	MA	Metabolism
DM30SGU	RN	Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
DM30SGU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27757045

DM30SGU	DI	DM30SGU
DM30SGU	DN	Simvastatin
DM30SGU	MI	DEB3CV1
DM30SGU	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DM30SGU	MT	DME
DM30SGU	MA	Metabolism
DM30SGU	RN	Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
DM30SGU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27757045

DMGWR0C	DI	DMGWR0C
DMGWR0C	DN	Sintilimab
DMGWR0C	MI	TTNBFWK
DMGWR0C	MN	Programmed cell death protein 1 (PD-1)
DMGWR0C	MT	DTT
DMGWR0C	MA	Inhibitor
DMGWR0C	RN	Sintilimab: First Global Approval. Drugs. 2019 Feb;79(3):341-346.
DMGWR0C	RU	https://pubmed.ncbi.nlm.nih.gov/30742278

DM2R86O	DI	DM2R86O
DM2R86O	DN	Siponimod
DM2R86O	MI	DE5IED8
DM2R86O	MN	Cytochrome P450 2C9 (CYP2C9)
DM2R86O	MT	DME
DM2R86O	MA	Metabolism
DM2R86O	RN	Metabolism and disposition of siponimod, a novel selective S1P1/S1P5 agonist, in healthy volunteers and in vitro identification of human cytochrome P450 enzymes involved in its oxidative metabolism. Drug Metab Dispos. 2018 Jul;46(7):1001-1013.
DM2R86O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29735753

DMVCMUJ	DI	DMVCMUJ
DMVCMUJ	DN	Siponimod
DMVCMUJ	MI	DE5IED8
DMVCMUJ	MN	Cytochrome P450 2C9 (CYP2C9)
DMVCMUJ	MT	DME
DMVCMUJ	MA	Metabolism
DMVCMUJ	RN	Metabolism and disposition of siponimod, a novel selective S1P1/S1P5 agonist, in healthy volunteers and in vitro identification of human cytochrome P450 enzymes involved in its oxidative metabolism. Drug Metab Dispos. 2018 Jul;46(7):1001-1013.
DMVCMUJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29735753

DM2R86O	DI	DM2R86O
DM2R86O	DN	Siponimod
DM2R86O	MI	DE4LYSA
DM2R86O	MN	Cytochrome P450 3A4 (CYP3A4)
DM2R86O	MT	DME
DM2R86O	MA	Metabolism
DM2R86O	RN	Metabolism and disposition of siponimod, a novel selective S1P1/S1P5 agonist, in healthy volunteers and in vitro identification of human cytochrome P450 enzymes involved in its oxidative metabolism. Drug Metab Dispos. 2018 Jul;46(7):1001-1013.
DM2R86O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29735753

DMVCMUJ	DI	DMVCMUJ
DMVCMUJ	DN	Siponimod
DMVCMUJ	MI	DE4LYSA
DMVCMUJ	MN	Cytochrome P450 3A4 (CYP3A4)
DMVCMUJ	MT	DME
DMVCMUJ	MA	Metabolism
DMVCMUJ	RN	Metabolism and disposition of siponimod, a novel selective S1P1/S1P5 agonist, in healthy volunteers and in vitro identification of human cytochrome P450 enzymes involved in its oxidative metabolism. Drug Metab Dispos. 2018 Jul;46(7):1001-1013.
DMVCMUJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29735753

DM2R86O	DI	DM2R86O
DM2R86O	DN	Siponimod
DM2R86O	MI	TT7BQRM
DM2R86O	MN	Sphingosine-1 phosphate receptor (S1PR)
DM2R86O	MT	DTT
DM2R86O	MA	Modulator
DM2R86O	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DM2R86O	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209884s000lbl.pdf

DM2R86O	DI	DM2R86O
DM2R86O	DN	Siponimod
DM2R86O	MI	TT9JZCK
DM2R86O	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DM2R86O	MT	DTT
DM2R86O	MA	Modulator
DM2R86O	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DM2R86O	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209884s000lbl.pdf

DMGW1ID	DI	DMGW1ID
DMGW1ID	DN	Sirolimus
DMGW1ID	MI	DE4LYSA
DMGW1ID	MN	Cytochrome P450 3A4 (CYP3A4)
DMGW1ID	MT	DME
DMGW1ID	MA	Metabolism
DMGW1ID	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMGW1ID	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMGW1ID	DI	DMGW1ID
DMGW1ID	DN	Sirolimus
DMGW1ID	MI	DEIBDNY
DMGW1ID	MN	Cytochrome P450 3A5 (CYP3A5)
DMGW1ID	MT	DME
DMGW1ID	MA	Metabolism
DMGW1ID	RN	Drug Interactions Flockhart Table
DMGW1ID	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMGW1ID	DI	DMGW1ID
DMGW1ID	DN	Sirolimus
DMGW1ID	MI	DERD86B
DMGW1ID	MN	Cytochrome P450 3A7 (CYP3A7)
DMGW1ID	MT	DME
DMGW1ID	MA	Metabolism
DMGW1ID	RN	Drug Interactions Flockhart Table
DMGW1ID	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMGW1ID	DI	DMGW1ID
DMGW1ID	DN	Sirolimus
DMGW1ID	MI	DT3D8F0
DMGW1ID	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMGW1ID	MT	DTP
DMGW1ID	MA	Substrate
DMGW1ID	RN	Pharmacokinetic and pharmacodynamic interactions between the immunosuppressant sirolimus and the lipid-lowering drug ezetimibe in healthy volunteers. Clin Pharmacol Ther. 2010 Jun;87(6):663-7.
DMGW1ID	RU	http://www.ncbi.nlm.nih.gov/pubmed/20220747

DMGW1ID	DI	DMGW1ID
DMGW1ID	DN	Sirolimus
DMGW1ID	MI	DTUGYRD
DMGW1ID	MN	P-glycoprotein 1 (ABCB1)
DMGW1ID	MT	DTP
DMGW1ID	MA	Substrate
DMGW1ID	RN	Pharmacogenetics of tacrolimus and sirolimus in renal transplant patients: from retrospective analyses to prospective studies. Transplant Proc. 2007 Sep;39(7):2142-4.
DMGW1ID	RU	http://www.ncbi.nlm.nih.gov/pubmed/17889118

DMGW1ID	DI	DMGW1ID
DMGW1ID	DN	Sirolimus
DMGW1ID	MI	TTGQUFK
DMGW1ID	MN	PI3K/AKT/mTOR pathway (PAm pathway)
DMGW1ID	MT	DTT
DMGW1ID	MA	Inhibitor
DMGW1ID	RN	The genomic landscape of nasopharyngeal carcinoma.Nat Genet. 2014 Aug;46(8):866-71.
DMGW1ID	RU	https://pubmed.ncbi.nlm.nih.gov/24952746

DMGW1ID	DI	DMGW1ID
DMGW1ID	DN	Sirolimus
DMGW1ID	MI	TTCJG29
DMGW1ID	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMGW1ID	MT	DTT
DMGW1ID	MA	Inhibitor
DMGW1ID	RN	Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
DMGW1ID	RU	https://pubmed.ncbi.nlm.nih.gov/12509758

DM92P0F	DI	DM92P0F
DM92P0F	DN	Sisomicin
DM92P0F	MI	DE5WGIM
DM92P0F	MN	Aminoglycoside phosphotransferase (aph-Ib)
DM92P0F	MT	DME
DM92P0F	MA	Metabolism
DM92P0F	RN	Novel aminoglycoside 2''-phosphotransferase identified in a gram-negative pathogen. Antimicrob Agents Chemother. 2013 Jan;57(1):452-7.
DM92P0F	RU	https://pubmed.ncbi.nlm.nih.gov/23129050

DMGDKXN	DI	DMGDKXN
DMGDKXN	DN	Sitagliptin
DMGDKXN	MI	DES5XRU
DMGDKXN	MN	Cytochrome P450 2C8 (CYP2C8)
DMGDKXN	MT	DME
DMGDKXN	MA	Metabolism
DMGDKXN	RN	Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010 Aug;12(8):648-58.
DMGDKXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20590741

DMGDKXN	DI	DMGDKXN
DMGDKXN	DN	Sitagliptin
DMGDKXN	MI	DE4LYSA
DMGDKXN	MN	Cytochrome P450 3A4 (CYP3A4)
DMGDKXN	MT	DME
DMGDKXN	MA	Metabolism
DMGDKXN	RN	Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010 Aug;12(8):648-58.
DMGDKXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20590741

DMGDKXN	DI	DMGDKXN
DMGDKXN	DN	Sitagliptin
DMGDKXN	MI	TTDIGC1
DMGDKXN	MN	Dipeptidyl peptidase 4 (DPP-4)
DMGDKXN	MT	DTT
DMGDKXN	MA	Inhibitor
DMGDKXN	RN	Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther. 2009 Oct;124(1):113-38.
DMGDKXN	RU	https://pubmed.ncbi.nlm.nih.gov/19545590

DMGDKXN	DI	DMGDKXN
DMGDKXN	DN	Sitagliptin
DMGDKXN	MI	DTVP67E
DMGDKXN	MN	Organic anion transporter 3 (SLC22A8)
DMGDKXN	MT	DTP
DMGDKXN	MA	Substrate
DMGDKXN	RN	Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther. 2007 May;321(2):673-83.
DMGDKXN	RU	http://www.ncbi.nlm.nih.gov/pubmed/17314201

DMGDKXN	DI	DMGDKXN
DMGDKXN	DN	Sitagliptin
DMGDKXN	MI	DTT79CX
DMGDKXN	MN	Organic cation transporter 1 (SLC22A1)
DMGDKXN	MT	DTP
DMGDKXN	MA	Substrate
DMGDKXN	RN	265 effect of dietary cholesterol on gallbladder bile lithogenicity and gene expression in the enterohepatic axis of non-obese gallstone and control women. Journal of Hepatology, 2009, 50(09):S105-S106.
DMGDKXN	RU	https://doi.org/10.1016/S0168-8278(09)60267-1

DMGDKXN	DI	DMGDKXN
DMGDKXN	DN	Sitagliptin
DMGDKXN	MI	DTUGYRD
DMGDKXN	MN	P-glycoprotein 1 (ABCB1)
DMGDKXN	MT	DTP
DMGDKXN	MA	Substrate
DMGDKXN	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DMGDKXN	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DMQ8E9R	DI	DMQ8E9R
DMQ8E9R	DN	SKI-758
DMQ8E9R	MI	TTGKNB4
DMQ8E9R	MN	Epidermal growth factor receptor (EGFR)
DMQ8E9R	MT	DTT
DMQ8E9R	MA	Inhibitor
DMQ8E9R	RN	Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
DMQ8E9R	RU	https://pubmed.ncbi.nlm.nih.gov/17181170

DMQ8E9R	DI	DMQ8E9R
DMQ8E9R	DN	SKI-758
DMQ8E9R	MI	TT6PKBN
DMQ8E9R	MN	Proto-oncogene c-Src (SRC)
DMQ8E9R	MT	DTT
DMQ8E9R	MA	Inhibitor
DMQ8E9R	RN	Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
DMQ8E9R	RU	https://pubmed.ncbi.nlm.nih.gov/17181170

DMQ8E9R	DI	DMQ8E9R
DMQ8E9R	DN	SKI-758
DMQ8E9R	MI	TT3PJMV
DMQ8E9R	MN	Tyrosine-protein kinase ABL1 (ABL)
DMQ8E9R	MT	DTT
DMQ8E9R	MA	Inhibitor
DMQ8E9R	RN	Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
DMQ8E9R	RU	https://pubmed.ncbi.nlm.nih.gov/17181170

DMDIZCS	DI	DMDIZCS
DMDIZCS	DN	S-licarbazepine
DMDIZCS	MI	DTUGYRD
DMDIZCS	MN	P-glycoprotein 1 (ABCB1)
DMDIZCS	MT	DTP
DMDIZCS	MA	Substrate
DMDIZCS	RN	In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein. Epilepsia. 2011 Oct;52(10):1894-904.
DMDIZCS	RU	https://doi.org/10.1111/j.1528-1167.2011.03140.x

DMFX9O6	DI	DMFX9O6
DMFX9O6	DN	SM-101
DMFX9O6	MI	TTXT21W
DMFX9O6	MN	Immunoglobulin gamma Fc receptor IIA (FCGR2A)
DMFX9O6	MT	DTT
DMFX9O6	MA	Antagonist
DMFX9O6	RN	Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54.
DMFX9O6	RU	https://pubmed.ncbi.nlm.nih.gov/18537519

DMFX9O6	DI	DMFX9O6
DMFX9O6	DN	SM-101
DMFX9O6	MI	TTYT93M
DMFX9O6	MN	MAP kinase p38 (MAPK12)
DMFX9O6	MT	DTT
DMFX9O6	MA	Inhibitor
DMFX9O6	RN	Agents in development for the treatment of diabetic nephropathy. Expert Opin Emerg Drugs. 2008 Sep;13(3):447-63.
DMFX9O6	RU	https://pubmed.ncbi.nlm.nih.gov/18764722

DM1I93C	DI	DM1I93C
DM1I93C	DN	SMT-D002
DM1I93C	MI	TTZ9SOR
DM1I93C	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DM1I93C	MT	DTT
DM1I93C	MA	Agonist
DM1I93C	RN	Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J Urol. 2004 Nov;172(5 Pt 1):2059-64.
DM1I93C	RU	https://pubmed.ncbi.nlm.nih.gov/15540789

DM1I93C	DI	DM1I93C
DM1I93C	DN	SMT-D002
DM1I93C	MI	TTYEG6Q
DM1I93C	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DM1I93C	MT	DTT
DM1I93C	MA	Agonist
DM1I93C	RN	Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J Urol. 2004 Nov;172(5 Pt 1):2059-64.
DM1I93C	RU	https://pubmed.ncbi.nlm.nih.gov/15540789

DM1I93C	DI	DM1I93C
DM1I93C	DN	SMT-D002
DM1I93C	MI	TTQ13Z5
DM1I93C	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DM1I93C	MT	DTT
DM1I93C	MA	Agonist
DM1I93C	RN	Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J Urol. 2004 Nov;172(5 Pt 1):2059-64.
DM1I93C	RU	https://pubmed.ncbi.nlm.nih.gov/15540789

DMH21E0	DI	DMH21E0
DMH21E0	DN	Sodium acetate anhydrous
DMH21E0	MI	DEE76VW
DMH21E0	MN	Acetyl-CoA synthetase (ACSS2)
DMH21E0	MT	DME
DMH21E0	MA	Metabolism
DMH21E0	RN	Sodium acetate induces a metabolic alkalosis but not the increase in fatty acid oxidation observed following bicarbonate ingestion in humans. J Nutr. 2007 Jul;137(7):1750-6.
DMH21E0	RU	http://jn.nutrition.org/content/137/7/1750.full

DMMU6BJ	DI	DMMU6BJ
DMMU6BJ	DN	Sodium bicarbonate
DMMU6BJ	MI	DTSQY0W
DMMU6BJ	MN	Anion exchange protein 4 (SLC4A9)
DMMU6BJ	MT	DTP
DMMU6BJ	MA	Substrate
DMMU6BJ	RN	A novel sodium bicarbonate cotransporter-like gene in an ancient duplicated region: SLC4A9 at 5q31. Genome Biol. 2001;2(4):RESEARCH0011.
DMMU6BJ	RU	http://www.ncbi.nlm.nih.gov/pubmed/11305939

DMMU6BJ	DI	DMMU6BJ
DMMU6BJ	DN	Sodium bicarbonate
DMMU6BJ	MI	DTWDEIL
DMMU6BJ	MN	Electrogenic sodium bicarbonate cotransporter 1 (SLC4A4)
DMMU6BJ	MT	DTP
DMMU6BJ	MA	Substrate
DMMU6BJ	RN	The sodium bicarbonate cotransporter (NBCe1) is essential for normal development of mouse dentition. J Biol Chem. 2010 Aug 6;285(32):24432-8.
DMMU6BJ	RU	http://www.ncbi.nlm.nih.gov/pubmed/20529845

DMMU6BJ	DI	DMMU6BJ
DMMU6BJ	DN	Sodium bicarbonate
DMMU6BJ	MI	DTCL4P8
DMMU6BJ	MN	Electrogenic sodium bicarbonate cotransporter 4 (SLC4A5)
DMMU6BJ	MT	DTP
DMMU6BJ	MA	Substrate
DMMU6BJ	RN	The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60.
DMMU6BJ	RU	http://www.ncbi.nlm.nih.gov/pubmed/17071329

DMMU6BJ	DI	DMMU6BJ
DMMU6BJ	DN	Sodium bicarbonate
DMMU6BJ	MI	DTW40Z7
DMMU6BJ	MN	Electroneutral sodium bicarbonate exchanger 1 (SLC4A8)
DMMU6BJ	MT	DTP
DMMU6BJ	MA	Substrate
DMMU6BJ	RN	The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60.
DMMU6BJ	RU	http://www.ncbi.nlm.nih.gov/pubmed/17071329

DMMU6BJ	DI	DMMU6BJ
DMMU6BJ	DN	Sodium bicarbonate
DMMU6BJ	MI	DT03V27
DMMU6BJ	MN	Sodium bicarbonate cotransporter 3 (SLC4A7)
DMMU6BJ	MT	DTP
DMMU6BJ	MA	Substrate
DMMU6BJ	RN	The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60.
DMMU6BJ	RU	http://www.ncbi.nlm.nih.gov/pubmed/17071329

DMMU6BJ	DI	DMMU6BJ
DMMU6BJ	DN	Sodium bicarbonate
DMMU6BJ	MI	DT7RYVF
DMMU6BJ	MN	Sodium-driven chloride bicarbonate exchanger (SLC4A10)
DMMU6BJ	MT	DTP
DMMU6BJ	MA	Substrate
DMMU6BJ	RN	Molecular mechanisms of electrogenic sodium bicarbonate cotransport: structural and equilibrium thermodynamic considerations. J Membr Biol. 2004 Jan 15;197(2):77-90.
DMMU6BJ	RU	http://www.ncbi.nlm.nih.gov/pubmed/15014910

DMMU6BJ	DI	DMMU6BJ
DMMU6BJ	DN	Sodium bicarbonate
DMMU6BJ	MI	TTZPWGN
DMMU6BJ	MN	Voltage-gated calcium channel alpha Cav3.2 (CACNA1H)
DMMU6BJ	MT	DTT
DMMU6BJ	MA	Blocker
DMMU6BJ	RN	Acute renal failure. Clin Evid (Online). 2008 Sep 3;2008. pii: 2001.
DMMU6BJ	RU	https://pubmed.ncbi.nlm.nih.gov/19445797

DMMU6BJ	DI	DMMU6BJ
DMMU6BJ	DN	Sodium bicarbonate
DMMU6BJ	MI	TTPLQO0
DMMU6BJ	MN	Voltage-gated potassium channel Kv4.3 (KCND3)
DMMU6BJ	MT	DTT
DMMU6BJ	MA	Blocker
DMMU6BJ	RN	Management of cocaine-induced cardiac arrhythmias due to cardiac ion channel dysfunction. Clin Toxicol (Phila). 2009 Jan;47(1):14-23.
DMMU6BJ	RU	https://pubmed.ncbi.nlm.nih.gov/18815938

DMM3950	DI	DMM3950
DMM3950	DN	Sodium chloride
DMM3950	MI	TTQ8AFT
DMM3950	MN	Adrenergic receptor Alpha-2 (ADRA2)
DMM3950	MT	DTT
DMM3950	MA	Agonist
DMM3950	RN	Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats. Pharmacol Biochem Behav. 2000 Nov;67(3):397-403.
DMM3950	RU	https://pubmed.ncbi.nlm.nih.gov/11164065

DMM3950	DI	DMM3950
DMM3950	DN	Sodium chloride
DMM3950	MI	DTHKL3Q
DMM3950	MN	Basolateral Na-K-Cl symporter (SLC12A2)
DMM3950	MT	DTP
DMM3950	MA	Substrate
DMM3950	RN	Expression of the sodium potassium chloride cotransporter (NKCC1) and sodium chloride cotransporter (NCC) and their effects on rat lens transparency. Mol Vis. 2010 May 4;16:800-12.
DMM3950	RU	http://www.ncbi.nlm.nih.gov/pubmed/20458365

DMM3950	DI	DMM3950
DMM3950	DN	Sodium chloride
DMM3950	MI	DTO1UQY
DMM3950	MN	Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 2 (SLC12A1)
DMM3950	MT	DTP
DMM3950	MA	Substrate
DMM3950	RN	Upregulation of renal sodium transporters in D5 dopamine receptor-deficient mice. Hypertension. 2010 Jun;55(6):1431-7.
DMM3950	RU	http://www.ncbi.nlm.nih.gov/pubmed/20404220

DMM3950	DI	DMM3950
DMM3950	DN	Sodium chloride
DMM3950	MI	DT6201N
DMM3950	MN	Organic cation transporter 3 (SLC22A3)
DMM3950	MT	DTP
DMM3950	MA	Substrate
DMM3950	RN	Organic cation transporter 3 (Slc22a3) is implicated in salt-intake regulation. J Neurosci. 2004 Mar 17;24(11):2846-51.
DMM3950	RU	http://www.ncbi.nlm.nih.gov/pubmed/15028779

DMLJ634	DI	DMLJ634
DMLJ634	DN	Sodium lauryl sulfate
DMLJ634	MI	TTFNGC9
DMLJ634	MN	Serum albumin (ALB)
DMLJ634	MT	DTT
DMLJ634	MA	Binder
DMLJ634	RN	Some properties of the interaction between 2,2'-diselenadibenzoic acid and serum albumins. J Pharm Biomed Anal. 2005 Sep 1;39(1-2):263-7.
DMLJ634	RU	https://pubmed.ncbi.nlm.nih.gov/16085141

DMGA9X0	DI	DMGA9X0
DMGA9X0	DN	Sodium nitroprusside
DMGA9X0	MI	TT23PYC
DMGA9X0	MN	Soluble guanylate cyclase (GCS)
DMGA9X0	MT	DTT
DMGA9X0	MA	Modulator
DMGA9X0	RN	Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications.Crit Care Res Pract.2012;2012:290805.
DMGA9X0	RU	https://www.ncbi.nlm.nih.gov/pubmed/22482042

DMCIWZL	DI	DMCIWZL
DMCIWZL	DN	Sodium oxybate
DMCIWZL	MI	DE8RJ3F
DMCIWZL	MN	Hydroxyacid-oxoacid transhydrogenase (ADHFE1)
DMCIWZL	MT	DME
DMCIWZL	MA	Metabolism
DMCIWZL	RN	Kinetic characterization of human hydroxyacid-oxoacid transhydrogenase: relevance to D-2-hydroxyglutaric and gamma-hydroxybutyric acidurias. J Inherit Metab Dis. 2005;28(6):921-30.
DMCIWZL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16435184

DMCIWZL	DI	DMCIWZL
DMCIWZL	DN	Sodium oxybate
DMCIWZL	MI	DE5KEWZ
DMCIWZL	MN	Succinate-semialdehyde dehydrogenase (ALDH5A1)
DMCIWZL	MT	DME
DMCIWZL	MA	Metabolism
DMCIWZL	RN	Redox-switch modulation of human SSADH by dynamic catalytic loop. EMBO J. 2009 Apr 8;28(7):959-68.
DMCIWZL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19300440

DMXLBCQ	DI	DMXLBCQ
DMXLBCQ	DN	Sodium phenylbutyrate
DMXLBCQ	MI	TTBH0VX
DMXLBCQ	MN	Histone deacetylase (HDAC)
DMXLBCQ	MT	DTT
DMXLBCQ	MA	Inhibitor
DMXLBCQ	RN	Histone Deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases. Curr Drug Targets. 2010 Nov;11(11):1430-8.
DMXLBCQ	RU	https://pubmed.ncbi.nlm.nih.gov/20583972

DMXLBCQ	DI	DMXLBCQ
DMXLBCQ	DN	Sodium phenylbutyrate
DMXLBCQ	MI	TTFJ8Q1
DMXLBCQ	MN	Protein kinase C alpha (PRKCA)
DMXLBCQ	MT	DTT
DMXLBCQ	MA	Modulator
DMXLBCQ	RN	Polo-like kinase inhibitor Ro5203280 has potent antitumor activity in nasopharyngeal carcinoma.Mol Cancer Ther. 2013 Aug;12(8):1393-401.
DMXLBCQ	RU	https://pubmed.ncbi.nlm.nih.gov/23686835

DMKY27B	DI	DMKY27B
DMKY27B	DN	Sodium phosphate dibasic/sodium phosphate monobasic
DMKY27B	MI	DTWFOPY
DMKY27B	MN	Sodium-dependent phosphate transport protein 2B (SLC34A2)
DMKY27B	MT	DTP
DMKY27B	MA	Substrate
DMKY27B	RN	Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50.
DMKY27B	RU	http://www.ncbi.nlm.nih.gov/pubmed/23398154

DM4QFXJ	DI	DM4QFXJ
DM4QFXJ	DN	Sodium Tetradecyl Sulfate
DM4QFXJ	MI	TTZUXYS
DM4QFXJ	MN	Vitamin K-dependent protein C (PROC)
DM4QFXJ	MT	DTT
DM4QFXJ	MA	Inhibitor
DM4QFXJ	RN	Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
DM4QFXJ	RU	https://pubmed.ncbi.nlm.nih.gov/17016423

DMCSLZ4	DI	DMCSLZ4
DMCSLZ4	DN	Sodium zirconium cyclosilicate
DMCSLZ4	MI	TTB0SC6
DMCSLZ4	MN	Potassium (K)
DMCSLZ4	MT	DTT
DMCSLZ4	MA	Binder
DMCSLZ4	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMCSLZ4	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMQI86A	DI	DMQI86A
DMQI86A	DN	Sofosbuvir
DMQI86A	MI	DTI7UX6
DMQI86A	MN	Breast cancer resistance protein (ABCG2)
DMQI86A	MT	DTP
DMQI86A	MA	Substrate
DMQI86A	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01913)
DMQI86A	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01913

DMQI86A	DI	DMQI86A
DMQI86A	DN	Sofosbuvir
DMQI86A	MI	DTUGYRD
DMQI86A	MN	P-glycoprotein 1 (ABCB1)
DMQI86A	MT	DTP
DMQI86A	MA	Substrate
DMQI86A	RN	Cytochrome P450 3A Induction Predicts P-glycoprotein Induction; Part 2: Prediction of Decreased Substrate Exposure After Rifabutin or Carbamazepine. Clin Pharmacol Ther. 2018 Dec;104(6):1191-1198.
DMQI86A	RU	http://www.ncbi.nlm.nih.gov/pubmed/29569712

DM5F47O	DI	DM5F47O
DM5F47O	DN	Sofosbuvir + velpatasvir + voxilaprevir
DM5F47O	MI	TTCJ2X8
DM5F47O	MN	Hepatitis C virus Non-structural 5A (HCV NS5A)
DM5F47O	MT	DTT
DM5F47O	MA	Inhibitor
DM5F47O	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DM5F47O	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DM5F47O	DI	DM5F47O
DM5F47O	DN	Sofosbuvir + velpatasvir + voxilaprevir
DM5F47O	MI	TTMVBWH
DM5F47O	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DM5F47O	MT	DTT
DM5F47O	MA	Inhibitor
DM5F47O	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DM5F47O	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DM5F47O	DI	DM5F47O
DM5F47O	DN	Sofosbuvir + velpatasvir + voxilaprevir
DM5F47O	MI	TTHC7JD
DM5F47O	MN	Hepatitis C virus Serine protease NS3/4A (HCV NS3/4A)
DM5F47O	MT	DTT
DM5F47O	MA	Inhibitor
DM5F47O	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DM5F47O	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DMG592Q	DI	DMG592Q
DMG592Q	DN	Solifenacin
DMG592Q	MI	DECB0K3
DMG592Q	MN	Cytochrome P450 2D6 (CYP2D6)
DMG592Q	MT	DME
DMG592Q	MA	Metabolism
DMG592Q	RN	Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet. 2009;48(5):281-302.
DMG592Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19566112

DMG592Q	DI	DMG592Q
DMG592Q	DN	Solifenacin
DMG592Q	MI	DE4LYSA
DMG592Q	MN	Cytochrome P450 3A4 (CYP3A4)
DMG592Q	MT	DME
DMG592Q	MA	Metabolism
DMG592Q	RN	Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet. 2009;48(5):281-302.
DMG592Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19566112

DMG592Q	DI	DMG592Q
DMG592Q	DN	Solifenacin
DMG592Q	MI	TTQ13Z5
DMG592Q	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMG592Q	MT	DTT
DMG592Q	MA	Antagonist
DMG592Q	RN	Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout ... Eur J Pharmacol. 2009 Aug 1;615(1-3):201-6.
DMG592Q	RU	https://pubmed.ncbi.nlm.nih.gov/19446545

DMZ9FAO	DI	DMZ9FAO
DMZ9FAO	DN	Somatomedin-1
DMZ9FAO	MI	TTHRID2
DMZ9FAO	MN	Insulin-like growth factor I receptor (IGF1R)
DMZ9FAO	MT	DTT
DMZ9FAO	MA	Modulator
DMZ9FAO	RN	2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006).
DMZ9FAO	RU	http://www.nature.com/nrd/journal/v11/n1/full/nrd3645.html

DMF3GM2	DI	DMF3GM2
DMF3GM2	DN	Somatropin recombinant
DMF3GM2	MI	TTKMAZ6
DMF3GM2	MN	Growth hormone receptor (GHR)
DMF3GM2	MT	DTT
DMF3GM2	MA	Binder
DMF3GM2	RN	Cost-utility of somatropin (rDNA origin) in the treatment of growth hormone deficiency in children. Curr Med Res Opin. 2006 Feb;22(2):351-7.
DMF3GM2	RU	https://pubmed.ncbi.nlm.nih.gov/16466607

DM72409	DI	DM72409
DM72409	DN	Sonidegib phosphate
DM72409	MI	DE4LYSA
DM72409	MN	Cytochrome P450 3A4 (CYP3A4)
DM72409	MT	DME
DM72409	MA	Metabolism
DM72409	RN	Sonidegib: first global approval. Drugs. 2015 Sep;75(13):1559-66.
DM72409	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26323341

DMS8IFC	DI	DMS8IFC
DMS8IFC	DN	Sorafenib
DMS8IFC	MI	DTI7UX6
DMS8IFC	MN	Breast cancer resistance protein (ABCG2)
DMS8IFC	MT	DTP
DMS8IFC	MA	Substrate
DMS8IFC	RN	Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. Mol Pharm. 2011 Apr 4;8(2):571-82.
DMS8IFC	RU	https://doi.org/10.1021/mp1003898

DMS8IFC	DI	DMS8IFC
DMS8IFC	DN	Sorafenib
DMS8IFC	MI	DEJGDUW
DMS8IFC	MN	Cytochrome P450 1A2 (CYP1A2)
DMS8IFC	MT	DME
DMS8IFC	MA	Metabolism
DMS8IFC	RN	Ontogeny and sorafenib metabolism. Clin Cancer Res. 2012 Oct 15;18(20):5788-95.
DMS8IFC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22927483

DMS8IFC	DI	DMS8IFC
DMS8IFC	DN	Sorafenib
DMS8IFC	MI	DES5XRU
DMS8IFC	MN	Cytochrome P450 2C8 (CYP2C8)
DMS8IFC	MT	DME
DMS8IFC	MA	Metabolism
DMS8IFC	RN	Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
DMS8IFC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21350850

DMS8IFC	DI	DMS8IFC
DMS8IFC	DN	Sorafenib
DMS8IFC	MI	DE4LYSA
DMS8IFC	MN	Cytochrome P450 3A4 (CYP3A4)
DMS8IFC	MT	DME
DMS8IFC	MA	Metabolism
DMS8IFC	RN	Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
DMS8IFC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21350850

DMS8IFC	DI	DMS8IFC
DMS8IFC	DN	Sorafenib
DMS8IFC	MI	DEIBDNY
DMS8IFC	MN	Cytochrome P450 3A5 (CYP3A5)
DMS8IFC	MT	DME
DMS8IFC	MA	Metabolism
DMS8IFC	RN	Drug Interactions Flockhart Table
DMS8IFC	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMS8IFC	DI	DMS8IFC
DMS8IFC	DN	Sorafenib
DMS8IFC	MI	DERD86B
DMS8IFC	MN	Cytochrome P450 3A7 (CYP3A7)
DMS8IFC	MT	DME
DMS8IFC	MA	Metabolism
DMS8IFC	RN	Drug Interactions Flockhart Table
DMS8IFC	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMS8IFC	DI	DMS8IFC
DMS8IFC	DN	Sorafenib
DMS8IFC	MI	TTGKNB4
DMS8IFC	MN	Epidermal growth factor receptor (EGFR)
DMS8IFC	MT	DTT
DMS8IFC	MA	Inhibitor
DMS8IFC	RN	Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
DMS8IFC	RU	http://journalofnasopharyngealcarcinoma.org/JNPC/article/view/30/227

DMS8IFC	DI	DMS8IFC
DMS8IFC	DN	Sorafenib
DMS8IFC	MI	DTFI42L
DMS8IFC	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMS8IFC	MT	DTP
DMS8IFC	MA	Substrate
DMS8IFC	RN	Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib. Biol Pharm Bull. 2011;34(3):433-5.
DMS8IFC	RU	https://doi.org/10.1248/bpb.34.433

DMS8IFC	DI	DMS8IFC
DMS8IFC	DN	Sorafenib
DMS8IFC	MI	DT3D8F0
DMS8IFC	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMS8IFC	MT	DTP
DMS8IFC	MA	Substrate
DMS8IFC	RN	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
DMS8IFC	RU	http://www.ncbi.nlm.nih.gov/pubmed/23340295

DMS8IFC	DI	DMS8IFC
DMS8IFC	DN	Sorafenib
DMS8IFC	MI	DT9C1TS
DMS8IFC	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMS8IFC	MT	DTP
DMS8IFC	MA	Substrate
DMS8IFC	RN	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
DMS8IFC	RU	http://www.ncbi.nlm.nih.gov/pubmed/23340295

DMS8IFC	DI	DMS8IFC
DMS8IFC	DN	Sorafenib
DMS8IFC	MI	DTT79CX
DMS8IFC	MN	Organic cation transporter 1 (SLC22A1)
DMS8IFC	MT	DTP
DMS8IFC	MA	Substrate
DMS8IFC	RN	nan
DMS8IFC	RU	nan

DMS8IFC	DI	DMS8IFC
DMS8IFC	DN	Sorafenib
DMS8IFC	MI	DTUGYRD
DMS8IFC	MN	P-glycoprotein 1 (ABCB1)
DMS8IFC	MT	DTP
DMS8IFC	MA	Substrate
DMS8IFC	RN	Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol Cancer Ther. 2010 Feb;9(2):319-26.
DMS8IFC	RU	http://www.ncbi.nlm.nih.gov/pubmed/20103600

DMS8IFC	DI	DMS8IFC
DMS8IFC	DN	Sorafenib
DMS8IFC	MI	TTI7421
DMS8IFC	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMS8IFC	MT	DTT
DMS8IFC	MA	Modulator
DMS8IFC	RN	Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
DMS8IFC	RU	https://www.ncbi.nlm.nih.gov/pubmed/18852116

DMS8IFC	DI	DMS8IFC
DMS8IFC	DN	Sorafenib
DMS8IFC	MI	DTYEM9B
DMS8IFC	MN	RalBP1-associated Eps domain-containing protein 2 (RALBP1)
DMS8IFC	MT	DTP
DMS8IFC	MA	Substrate
DMS8IFC	RN	Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer. Int J Cancer. 2010 Mar 15;126(6):1327-38.
DMS8IFC	RU	http://www.ncbi.nlm.nih.gov/pubmed/19626587

DMS8IFC	DI	DMS8IFC
DMS8IFC	DN	Sorafenib
DMS8IFC	MI	TTX41N9
DMS8IFC	MN	Tyrosine-protein kinase Kit (KIT)
DMS8IFC	MT	DTT
DMS8IFC	MA	Modulator
DMS8IFC	RN	Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
DMS8IFC	RU	https://www.ncbi.nlm.nih.gov/pubmed/18852116

DMS8IFC	DI	DMS8IFC
DMS8IFC	DN	Sorafenib
DMS8IFC	MI	DE85D2P
DMS8IFC	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMS8IFC	MT	DME
DMS8IFC	MA	Metabolism
DMS8IFC	RN	Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011 Dec;29(6):1511-4.
DMS8IFC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20706860

DMS8IFC	DI	DMS8IFC
DMS8IFC	DN	Sorafenib
DMS8IFC	MI	TTUTJGQ
DMS8IFC	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMS8IFC	MT	DTT
DMS8IFC	MA	Modulator
DMS8IFC	RN	Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
DMS8IFC	RU	https://www.ncbi.nlm.nih.gov/pubmed/18852116

DMAN0DE	DI	DMAN0DE
DMAN0DE	DN	Sorbitol
DMAN0DE	MI	DEWU03P
DMAN0DE	MN	Sorbitol dehydrogenase (SORD)
DMAN0DE	MT	DME
DMAN0DE	MA	Metabolism
DMAN0DE	RN	Plasma concentration of iditol dehydrogenase (sorbitol dehydrogenase) in ponies treated with aflatoxin B1. Am J Vet Res. 1980 Jun;41(6):925-7.
DMAN0DE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7436081

DMUJGR1	DI	DMUJGR1
DMUJGR1	DN	Sorivudine
DMUJGR1	MI	TT84ETX
DMUJGR1	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMUJGR1	MT	DTT
DMUJGR1	MA	Modulator
DMUJGR1	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMUJGR1	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DML60TN	DI	DML60TN
DML60TN	DN	Sotalol
DML60TN	MI	TTR6W5O
DML60TN	MN	Adrenergic receptor beta-1 (ADRB1)
DML60TN	MT	DTT
DML60TN	MA	Antagonist
DML60TN	RN	beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann Neurol. 2009 Feb;65(2):218-25.
DML60TN	RU	https://pubmed.ncbi.nlm.nih.gov/19259968

DML60TN	DI	DML60TN
DML60TN	DN	Sotalol
DML60TN	MI	DECB0K3
DML60TN	MN	Cytochrome P450 2D6 (CYP2D6)
DML60TN	MT	DME
DML60TN	MA	Metabolism
DML60TN	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DML60TN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DML60TN	DI	DML60TN
DML60TN	DN	Sotalol
DML60TN	MI	DTE2B1D
DML60TN	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DML60TN	MT	DTP
DML60TN	MA	Substrate
DML60TN	RN	Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. J Pharm Sci. 2009 Jul;98(7):2529-39.
DML60TN	RU	http://www.ncbi.nlm.nih.gov/pubmed/19067419

DMB4HCT	DI	DMB4HCT
DMB4HCT	DN	Sparfloxacin
DMB4HCT	MI	TTN6J5F
DMB4HCT	MN	Bacterial DNA gyrase (Bact gyrase)
DMB4HCT	MT	DTT
DMB4HCT	MA	Modulator
DMB4HCT	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMB4HCT	RU	https://www.fda.gov/

DMB4HCT	DI	DMB4HCT
DMB4HCT	DN	Sparfloxacin
DMB4HCT	MI	DTUGYRD
DMB4HCT	MN	P-glycoprotein 1 (ABCB1)
DMB4HCT	MT	DTP
DMB4HCT	MA	Substrate
DMB4HCT	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMB4HCT	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMB4HCT	DI	DMB4HCT
DMB4HCT	DN	Sparfloxacin
DMB4HCT	MI	TTIXTO3
DMB4HCT	MN	Staphylococcus Topoisomerase IV (Stap-coc parC)
DMB4HCT	MT	DTT
DMB4HCT	MA	Modulator
DMB4HCT	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMB4HCT	RU	https://www.fda.gov/

DM6CMJD	DI	DM6CMJD
DM6CMJD	DN	Spectinomycin
DM6CMJD	MI	DEYWTIQ
DM6CMJD	MN	Aminoglycoside adenylyltransferase (aadA1a)
DM6CMJD	MT	DME
DM6CMJD	MA	Metabolism
DM6CMJD	RN	Structural mechanism of AadA, a dual-specificity aminoglycoside adenylyltransferase from Salmonella enterica. J Biol Chem. 2018 Jul 20;293(29):11481-11490.
DM6CMJD	RU	https://pubmed.ncbi.nlm.nih.gov/29871922

DM0MQ35	DI	DM0MQ35
DM0MQ35	DN	Spectinomycin
DM0MQ35	MI	TTQ8KVI
DM0MQ35	MN	Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)
DM0MQ35	MT	DTT
DM0MQ35	MA	Binder
DM0MQ35	RN	Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature. 2000 Sep 21;407(6802):340-8.
DM0MQ35	RU	https://pubmed.ncbi.nlm.nih.gov/11014183

DM6XFHS	DI	DM6XFHS
DM6XFHS	DN	SPI-1005
DM6XFHS	MI	TTFNGC9
DM6XFHS	MN	Serum albumin (ALB)
DM6XFHS	MT	DTT
DM6XFHS	MA	Binder
DM6XFHS	RN	Transport of ebselen in plasma and its transfer to binding sites in the hepatocyte. Biochem Pharmacol. 1994 Sep 15;48(6):1137-44.
DM6XFHS	RU	https://pubmed.ncbi.nlm.nih.gov/7945407

DM0BQRS	DI	DM0BQRS
DM0BQRS	DN	Spinosad
DM0BQRS	MI	TT9JZPU
DM0BQRS	MN	Pediculus humanus Nicotinic acetylcholine receptor (Pedhc nAChR)
DM0BQRS	MT	DTT
DM0BQRS	MA	Modulator
DM0BQRS	RN	2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
DM0BQRS	RU	https://pubmed.ncbi.nlm.nih.gov/22293555

DM20R5F	DI	DM20R5F
DM20R5F	DN	Spiramycin
DM20R5F	MI	TTLFGBV
DM20R5F	MN	Bacterial 23S ribosomal RNA (Bact 23S rRNA)
DM20R5F	MT	DTT
DM20R5F	MA	Binder
DM20R5F	RN	The apicoplast as an antimalarial drug target. Drug Resist Updat. 2001 Jun;4(3):145-51.
DM20R5F	RU	https://pubmed.ncbi.nlm.nih.gov/11768328

DM5XLTY	DI	DM5XLTY
DM5XLTY	DN	Spirapril
DM5XLTY	MI	TTL69WB
DM5XLTY	MN	Angiotensin-converting enzyme (ACE)
DM5XLTY	MT	DTT
DM5XLTY	MA	Inhibitor
DM5XLTY	RN	Central angiotensin II controls alcohol consumption via its AT1 receptor. FASEB J. 2005 Sep;19(11):1474-81.
DM5XLTY	RU	https://pubmed.ncbi.nlm.nih.gov/16126915

DM5XLTY	DI	DM5XLTY
DM5XLTY	DN	Spirapril
DM5XLTY	MI	DEQMBHW
DM5XLTY	MN	Dipeptidase (pepV)
DM5XLTY	MT	DME
DM5XLTY	MA	Metabolism
DM5XLTY	RN	Characterization and kinetic analysis of enzyme-substrate recognition by three recombinant lactococcal PepVs. Arch Biochem Biophys. 2006 Oct 15;454(2):137-45.
DM5XLTY	RU	https://pubmed.ncbi.nlm.nih.gov/16962986

DM5XLTY	DI	DM5XLTY
DM5XLTY	DN	Spirapril
DM5XLTY	MI	DT9G7XN
DM5XLTY	MN	Peptide transporter 1 (SLC15A1)
DM5XLTY	MT	DTP
DM5XLTY	MA	Substrate
DM5XLTY	RN	Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41.
DM5XLTY	RU	http://www.ncbi.nlm.nih.gov/pubmed/18713951

DM5XLTY	DI	DM5XLTY
DM5XLTY	DN	Spirapril
DM5XLTY	MI	DT8QKNP
DM5XLTY	MN	Peptide transporter 2 (SLC15A2)
DM5XLTY	MT	DTP
DM5XLTY	MA	Substrate
DM5XLTY	RN	Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41.
DM5XLTY	RU	http://www.ncbi.nlm.nih.gov/pubmed/18713951

DM2AQ5N	DI	DM2AQ5N
DM2AQ5N	DN	Spironolactone
DM2AQ5N	MI	TT26PHO
DM2AQ5N	MN	Mineralocorticoid receptor  (MR)
DM2AQ5N	MT	DTT
DM2AQ5N	MA	Modulator
DM2AQ5N	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM2AQ5N	RU	https://www.fda.gov/

DMCO5JZ	DI	DMCO5JZ
DMCO5JZ	DN	SR141716A
DMCO5JZ	MI	TT6OEDT
DMCO5JZ	MN	Cannabinoid receptor 1 (CB1)
DMCO5JZ	MT	DTT
DMCO5JZ	MA	Antagonist
DMCO5JZ	RN	Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
DMCO5JZ	RU	https://pubmed.ncbi.nlm.nih.gov/18473708

DM6DEK9	DI	DM6DEK9
DM6DEK9	DN	Stavudine
DM6DEK9	MI	TT84ETX
DM6DEK9	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM6DEK9	MT	DTT
DM6DEK9	MA	Inhibitor
DM6DEK9	RN	Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs). Int J Biochem Cell Biol. 2004 Sep;36(9):1687-705.
DM6DEK9	RU	https://pubmed.ncbi.nlm.nih.gov/15183338

DMMSDOY	DI	DMMSDOY
DMMSDOY	DN	Stiripentol
DMMSDOY	MI	DEJGDUW
DMMSDOY	MN	Cytochrome P450 1A2 (CYP1A2)
DMMSDOY	MT	DME
DMMSDOY	MA	Metabolism
DMMSDOY	RN	Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
DMMSDOY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16022579

DMMSDOY	DI	DMMSDOY
DMMSDOY	DN	Stiripentol
DMMSDOY	MI	DE4LYSA
DMMSDOY	MN	Cytochrome P450 3A4 (CYP3A4)
DMMSDOY	MT	DME
DMMSDOY	MA	Metabolism
DMMSDOY	RN	Product characteristics of Diacomit.
DMMSDOY	RU	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000664/WC500036518.pdf

DMMSDOY	DI	DMMSDOY
DMMSDOY	DN	Stiripentol
DMMSDOY	MI	TTEX6LM
DMMSDOY	MN	GABA(A) receptor gamma-3 (GABRG3)
DMMSDOY	MT	DTT
DMMSDOY	MA	Modulator
DMMSDOY	RN	Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA-A receptor channels. Epilepsia. 2006 Apr;47(4):704-16.
DMMSDOY	RU	https://pubmed.ncbi.nlm.nih.gov/16650136

DMMSDOY	DI	DMMSDOY
DMMSDOY	DN	Stiripentol
DMMSDOY	MI	DEGTFWK
DMMSDOY	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMMSDOY	MT	DME
DMMSDOY	MA	Metabolism
DMMSDOY	RN	FDA Label of Diacomit. The 2020 official website of the U.S. Food and Drug Administration.
DMMSDOY	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf

DM5JQ0D	DI	DM5JQ0D
DM5JQ0D	DN	Streptokinase
DM5JQ0D	MI	TTP86E2
DM5JQ0D	MN	Plasminogen (PLG)
DM5JQ0D	MT	DTT
DM5JQ0D	MA	Activator
DM5JQ0D	RN	Acute anuric renal failure with streptokinase therapy in a patient with acute venous thromboembolic disease and the review of renal side effects of streptokinase. Tuberk Toraks. 2008;56(4):456-61.
DM5JQ0D	RU	https://pubmed.ncbi.nlm.nih.gov/19123085

DMSRXVM	DI	DMSRXVM
DMSRXVM	DN	Streptomycin
DMSRXVM	MI	DEYWTIQ
DMSRXVM	MN	Aminoglycoside adenylyltransferase (aadA1a)
DMSRXVM	MT	DME
DMSRXVM	MA	Metabolism
DMSRXVM	RN	Structural mechanism of AadA, a dual-specificity aminoglycoside adenylyltransferase from Salmonella enterica. J Biol Chem. 2018 Jul 20;293(29):11481-11490.
DMSRXVM	RU	https://pubmed.ncbi.nlm.nih.gov/29871922

DMSRXVM	DI	DMSRXVM
DMSRXVM	DN	Streptomycin
DMSRXVM	MI	DEWPAJD
DMSRXVM	MN	Aminoglycoside O-phosphotransferase (aphA6)
DMSRXVM	MT	DME
DMSRXVM	MA	Metabolism
DMSRXVM	RN	Relationship between antimicrobial resistance and aminoglycoside-modifying enzyme gene expressions in Acinetobacter baumannii. Chin Med J (Engl). 2005 Jan 20;118(2):141-5.
DMSRXVM	RU	https://pubmed.ncbi.nlm.nih.gov/15667800

DMSRXVM	DI	DMSRXVM
DMSRXVM	DN	Streptomycin
DMSRXVM	MI	DE2M583
DMSRXVM	MN	Endoglucanase Y (EGY)
DMSRXVM	MT	DME
DMSRXVM	MA	Metabolism
DMSRXVM	RN	Expression of Clostridium thermocellum endoglucanase gene in Lactobacillus gasseri and Lactobacillus johnsonii and characterization of the genetically modified probiotic lactobacilli. Curr Microbiol. 2000 Apr;40(4):257-63.
DMSRXVM	RU	https://pubmed.ncbi.nlm.nih.gov/10688695

DMSRXVM	DI	DMSRXVM
DMSRXVM	DN	Streptomycin
DMSRXVM	MI	DE2AZTG
DMSRXVM	MN	Endoglucanase Y (EGY)
DMSRXVM	MT	DME
DMSRXVM	MA	Metabolism
DMSRXVM	RN	Expression of Clostridium thermocellum endoglucanase gene in Lactobacillus gasseri and Lactobacillus johnsonii and characterization of the genetically modified probiotic lactobacilli. Curr Microbiol. 2000 Apr;40(4):257-63.
DMSRXVM	RU	https://pubmed.ncbi.nlm.nih.gov/10688695

DMSRXVM	DI	DMSRXVM
DMSRXVM	DN	Streptomycin
DMSRXVM	MI	DEMVXEA
DMSRXVM	MN	Phosphotransferase enzyme strA (strA)
DMSRXVM	MT	DME
DMSRXVM	MA	Metabolism
DMSRXVM	RN	Genetic analysis of streptomycin-resistant (Sm(R)) strains of Erwinia amylovora suggests that dissemination of two genotypes is responsible for the current distribution of Sm(R) E. amylovora in Michigan. Phytopathology. 2011 Feb;101(2):182-91.
DMSRXVM	RU	https://pubmed.ncbi.nlm.nih.gov/20923367

DMSRXVM	DI	DMSRXVM
DMSRXVM	DN	Streptomycin
DMSRXVM	MI	DEXCHR2
DMSRXVM	MN	Phosphotransferase enzyme strB (strB)
DMSRXVM	MT	DME
DMSRXVM	MA	Metabolism
DMSRXVM	RN	Genetic analysis of streptomycin-resistant (Sm(R)) strains of Erwinia amylovora suggests that dissemination of two genotypes is responsible for the current distribution of Sm(R) E. amylovora in Michigan. Phytopathology. 2011 Feb;101(2):182-91.
DMSRXVM	RU	https://pubmed.ncbi.nlm.nih.gov/20923367

DME1LQN	DI	DME1LQN
DME1LQN	DN	Streptomycin
DME1LQN	MI	TTQ8KVI
DME1LQN	MN	Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)
DME1LQN	MT	DTT
DME1LQN	MA	Binder
DME1LQN	RN	Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature. 2000 Sep 21;407(6802):340-8.
DME1LQN	RU	https://pubmed.ncbi.nlm.nih.gov/11014183

DMOF7AT	DI	DMOF7AT
DMOF7AT	DN	Streptozocin
DMOF7AT	MI	TTUTN1I
DMOF7AT	MN	Human Deoxyribonucleic acid (hDNA)
DMOF7AT	MT	DTT
DMOF7AT	MA	Breaker
DMOF7AT	RN	Hydrodynamics-based transfection of pancreatic duodenal homeobox 1 DNA improves hyperglycemia and is associated with limited complications in diabe... Endocr J. 2009;56(6):783-90.
DMOF7AT	RU	https://pubmed.ncbi.nlm.nih.gov/19561381

DME81IY	DI	DME81IY
DME81IY	DN	Succimer
DME81IY	MI	DTFI42L
DME81IY	MN	Multidrug resistance-associated protein 2 (ABCC2)
DME81IY	MT	DTP
DME81IY	MA	Substrate
DME81IY	RN	MRP2 involvement in renal proximal tubular elimination of methylmercury mediated by DMPS or DMSA. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):10-7.
DME81IY	RU	http://www.ncbi.nlm.nih.gov/pubmed/19063911

DMDWICP	DI	DMDWICP
DMDWICP	DN	Succinic acid
DMDWICP	MI	TTJUWVB
DMDWICP	MN	Succinate-semialdehyde dehydrogenase (ALDH5A1)
DMDWICP	MT	DTT
DMDWICP	MA	Inhibitor
DMDWICP	RN	Redox-switch modulation of human SSADH by dynamic catalytic loop. EMBO J. 2009 Apr 8;28(7):959-68.
DMDWICP	RU	https://pubmed.ncbi.nlm.nih.gov/19300440

DM2ET1M	DI	DM2ET1M
DM2ET1M	DN	Succinylcholine
DM2ET1M	MI	TTQ13Z5
DM2ET1M	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DM2ET1M	MT	DTT
DM2ET1M	MA	Antagonist
DM2ET1M	RN	The involvement of histaminic and muscarinic receptors in the bronchoconstriction induced by myorelaxant administration in sensitized rabbits. Anesth Analg. 2008 Dec;107(6):1899-906.
DM2ET1M	RU	https://pubmed.ncbi.nlm.nih.gov/19020136

DMP9HBO	DI	DMP9HBO
DMP9HBO	DN	Sucralfate
DMP9HBO	MI	TTGKIED
DMP9HBO	MN	Fibroblast growth factor-2 (FGF2)
DMP9HBO	MT	DTT
DMP9HBO	MA	Modulator
DMP9HBO	RN	Assessment of sucralfate coating by sequential scintigraphic imaging in radiation-induced esophageal lesions. Gastrointest Endosc. 1995 Feb;41(2):109-14.
DMP9HBO	RU	https://pubmed.ncbi.nlm.nih.gov/7720996

DMU7YEL	DI	DMU7YEL
DMU7YEL	DN	Sufentanil
DMU7YEL	MI	DE4LYSA
DMU7YEL	MN	Cytochrome P450 3A4 (CYP3A4)
DMU7YEL	MT	DME
DMU7YEL	MA	Metabolism
DMU7YEL	RN	Possible involvement of multiple cytochrome P450S in fentanyl and sufentanil metabolism as opposed to alfentanil. Biochem Pharmacol. 1997 Jun 1;53(11):1613-9.
DMU7YEL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9264313

DMU7YEL	DI	DMU7YEL
DMU7YEL	DN	Sufentanil
DMU7YEL	MI	TTN4QDT
DMU7YEL	MN	Opioid receptor (OPR)
DMU7YEL	MT	DTT
DMU7YEL	MA	Antagonist
DMU7YEL	RN	mu-opioid receptor-stimulated synthesis of reactive oxygen species is mediated via phospholipase D2. J Neurochem. 2009 Aug;110(4):1288-96.
DMU7YEL	RU	https://pubmed.ncbi.nlm.nih.gov/19519662

DMZ6VEY	DI	DMZ6VEY
DMZ6VEY	DN	Sulfacetamide
DMZ6VEY	MI	TT915ZD
DMZ6VEY	MN	Candida Mannose-6-phosphate isomerase (Candi PMI1)
DMZ6VEY	MT	DTT
DMZ6VEY	MA	Inhibitor
DMZ6VEY	RN	Antifungal Activity of Ag(I) and Zn(II) Complexes of Sulfacetamide Derivatives. Met Based Drugs. 2000;7(1):49-54.
DMZ6VEY	RU	https://pubmed.ncbi.nlm.nih.gov/18475922

DMKI2XC	DI	DMKI2XC
DMKI2XC	DN	Sulfacytine
DMKI2XC	MI	TT4ILYC
DMKI2XC	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMKI2XC	MT	DTT
DMKI2XC	MA	Inhibitor
DMKI2XC	RN	Sulfacytine in uncomplicated urinary tract infections. Double-blind comparison with sulfisoxazole. Urology. 1976 Mar;7(3):267-71.
DMKI2XC	RU	https://pubmed.ncbi.nlm.nih.gov/769287

DMTW3R8	DI	DMTW3R8
DMTW3R8	DN	Sulfadiazine
DMTW3R8	MI	TT4ILYC
DMTW3R8	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMTW3R8	MT	DTT
DMTW3R8	MA	Inhibitor
DMTW3R8	RN	Sulfadiazine/hydroxypropyl-beta-cyclodextrin host-guest system: Characterization, phase-solubility and molecular modeling. Bioorg Med Chem. 2008 May 15;16(10):5788-94.
DMTW3R8	RU	https://pubmed.ncbi.nlm.nih.gov/18434167

DMTW3R8	DI	DMTW3R8
DMTW3R8	DN	Sulfadiazine
DMTW3R8	MI	DES5XRU
DMTW3R8	MN	Cytochrome P450 2C8 (CYP2C8)
DMTW3R8	MT	DME
DMTW3R8	MA	Metabolism
DMTW3R8	RN	Reduction of sulfamethoxazole and dapsone hydroxylamines by a microsomal enzyme system purified from pig liver and pig and human liver microsomes. Life Sci. 2005 May 27;77(2):205-19.
DMTW3R8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15862605

DMTW3R8	DI	DMTW3R8
DMTW3R8	DN	Sulfadiazine
DMTW3R8	MI	DE5IED8
DMTW3R8	MN	Cytochrome P450 2C9 (CYP2C9)
DMTW3R8	MT	DME
DMTW3R8	MA	Metabolism
DMTW3R8	RN	Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments. Drug Metab Dispos. 2000 Apr;28(4):475-81.
DMTW3R8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10725317

DMTW3R8	DI	DMTW3R8
DMTW3R8	DN	Sulfadiazine
DMTW3R8	MI	DEVDYN7
DMTW3R8	MN	Cytochrome P450 2E1 (CYP2E1)
DMTW3R8	MT	DME
DMTW3R8	MA	Metabolism
DMTW3R8	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMTW3R8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMTW3R8	DI	DMTW3R8
DMTW3R8	DN	Sulfadiazine
DMTW3R8	MI	DE4LYSA
DMTW3R8	MN	Cytochrome P450 3A4 (CYP3A4)
DMTW3R8	MT	DME
DMTW3R8	MA	Metabolism
DMTW3R8	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMTW3R8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMTW3R8	DI	DMTW3R8
DMTW3R8	DN	Sulfadiazine
DMTW3R8	MI	DEZV4AP
DMTW3R8	MN	RNA cytidine acetyltransferase (hALP)
DMTW3R8	MT	DME
DMTW3R8	MA	Metabolism
DMTW3R8	RN	Identification of cytochrome P450 and arylamine N-acetyltransferase isoforms involved in sulfadiazine metabolism. Drug Metab Dispos. 2005 Jul;33(7):969-76.
DMTW3R8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15843491

DMKM3SX	DI	DMKM3SX
DMKM3SX	DN	Sulfamerazine
DMKM3SX	MI	TT4ILYC
DMKM3SX	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMKM3SX	MT	DTT
DMKM3SX	MA	Inhibitor
DMKM3SX	RN	A confirmatory method for the simultaneous extraction, separation, identification and quantification of Tetracycline, Sulphonamide, Trimethoprim an... J Chromatogr A. 2009 Nov 13;1216(46):8110-6.
DMKM3SX	RU	https://pubmed.ncbi.nlm.nih.gov/19586630

DMRGZ16	DI	DMRGZ16
DMRGZ16	DN	Sulfamethazine
DMRGZ16	MI	TT4ILYC
DMRGZ16	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMRGZ16	MT	DTT
DMRGZ16	MA	Inhibitor
DMRGZ16	RN	A new and simple method to determine trace levels of sulfonamides in honey by high performance liquid chromatography with fluorescence detection. J Chromatogr A. 2009 Oct 23;1216(43):7275-80.
DMRGZ16	RU	https://pubmed.ncbi.nlm.nih.gov/19505691

DMGCHDS	DI	DMGCHDS
DMGCHDS	DN	Sulfamethizole
DMGCHDS	MI	TT4ILYC
DMGCHDS	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMGCHDS	MT	DTT
DMGCHDS	MA	Inhibitor
DMGCHDS	RN	Inhibition of bioluminescence in Photobacterium phosphoreum by sulfamethizole and its stimulation by thymine. Biochim Biophys Acta. 1990 Jun 26;1017(3):229-34.
DMGCHDS	RU	https://pubmed.ncbi.nlm.nih.gov/2372557

DMB08GE	DI	DMB08GE
DMB08GE	DN	Sulfamethoxazole
DMB08GE	MI	TT4ILYC
DMB08GE	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMB08GE	MT	DTT
DMB08GE	MA	Inhibitor
DMB08GE	RN	In vitro activities of novel antifolate drug combinations against Plasmodium falciparum and human granulocyte CFUs. Antimicrob Agents Chemother. 1995 Apr;39(4):948-52.
DMB08GE	RU	https://pubmed.ncbi.nlm.nih.gov/7786001

DMB08GE	DI	DMB08GE
DMB08GE	DN	Sulfamethoxazole
DMB08GE	MI	DES5XRU
DMB08GE	MN	Cytochrome P450 2C8 (CYP2C8)
DMB08GE	MT	DME
DMB08GE	MA	Metabolism
DMB08GE	RN	Sulfamethoxazole and its metabolite nitroso sulfamethoxazole stimulate dendritic cell costimulatory signaling. J Immunol. 2007 May 1;178(9):5533-42.
DMB08GE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17442935

DMB08GE	DI	DMB08GE
DMB08GE	DN	Sulfamethoxazole
DMB08GE	MI	DE5IED8
DMB08GE	MN	Cytochrome P450 2C9 (CYP2C9)
DMB08GE	MT	DME
DMB08GE	MA	Metabolism
DMB08GE	RN	Reduction of sulfamethoxazole and dapsone hydroxylamines by a microsomal enzyme system purified from pig liver and pig and human liver microsomes. Life Sci. 2005 May 27;77(2):205-19.
DMB08GE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15862605

DMB08GE	DI	DMB08GE
DMB08GE	DN	Sulfamethoxazole
DMB08GE	MI	DE4LYSA
DMB08GE	MN	Cytochrome P450 3A4 (CYP3A4)
DMB08GE	MT	DME
DMB08GE	MA	Metabolism
DMB08GE	RN	The effect of cimetidine on the formation of sulfamethoxazole hydroxylamine in patients with human immunodeficiency virus. J Clin Pharmacol. 1998 May;38(5):463-6.
DMB08GE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9602961

DMB08GE	DI	DMB08GE
DMB08GE	DN	Sulfamethoxazole
DMB08GE	MI	DE073H6
DMB08GE	MN	Prostaglandin G/H synthase 1 (COX-1)
DMB08GE	MT	DME
DMB08GE	MA	Metabolism
DMB08GE	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMB08GE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMB08GE	DI	DMB08GE
DMB08GE	DN	Sulfamethoxazole
DMB08GE	MI	DEZV4AP
DMB08GE	MN	RNA cytidine acetyltransferase (hALP)
DMB08GE	MT	DME
DMB08GE	MA	Metabolism
DMB08GE	RN	Crystallization and preliminary X-ray characterization of arylamine N-acetyltransferase C (BanatC) from Bacillus anthracis. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007 Oct 1;63(Pt 10):862-4.
DMB08GE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17909290

DMB08GE	DI	DMB08GE
DMB08GE	DN	Sulfamethoxazole
DMB08GE	MI	DE85D2P
DMB08GE	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMB08GE	MT	DME
DMB08GE	MA	Metabolism
DMB08GE	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMB08GE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMIO1K0	DI	DMIO1K0
DMIO1K0	DN	Sulfamylon
DMIO1K0	MI	TTUNARX
DMIO1K0	MN	Carbonic anhydrase (CA)
DMIO1K0	MT	DTT
DMIO1K0	MA	Inhibitor
DMIO1K0	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DMIO1K0	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DMIO1K0	DI	DMIO1K0
DMIO1K0	DN	Sulfamylon
DMIO1K0	MI	TTANPDJ
DMIO1K0	MN	Carbonic anhydrase II (CA-II)
DMIO1K0	MT	DTT
DMIO1K0	MA	Inhibitor
DMIO1K0	RN	Sulfonamide linked neoglycoconjugates--a new class of inhibitors for cancer-associated carbonic anhydrases. J Med Chem. 2010 Apr 8;53(7):2913-26.
DMIO1K0	RU	https://pubmed.ncbi.nlm.nih.gov/20201556

DMIO1K0	DI	DMIO1K0
DMIO1K0	DN	Sulfamylon
DMIO1K0	MI	TTZHA0O
DMIO1K0	MN	Carbonic anhydrase IV (CA-IV)
DMIO1K0	MT	DTT
DMIO1K0	MA	Inhibitor
DMIO1K0	RN	Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1149-54.
DMIO1K0	RU	https://pubmed.ncbi.nlm.nih.gov/15686931

DMIO1K0	DI	DMIO1K0
DMIO1K0	DN	Sulfamylon
DMIO1K0	MI	TTCFSPE
DMIO1K0	MN	Carbonic anhydrase VI (CA-VI)
DMIO1K0	MT	DTT
DMIO1K0	MA	Inhibitor
DMIO1K0	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DMIO1K0	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DMIO1K0	DI	DMIO1K0
DMIO1K0	DN	Sulfamylon
DMIO1K0	MI	TTSYM0R
DMIO1K0	MN	Carbonic anhydrase XII (CA-XII)
DMIO1K0	MT	DTT
DMIO1K0	MA	Inhibitor
DMIO1K0	RN	Sulfonamide linked neoglycoconjugates--a new class of inhibitors for cancer-associated carbonic anhydrases. J Med Chem. 2010 Apr 8;53(7):2913-26.
DMIO1K0	RU	https://pubmed.ncbi.nlm.nih.gov/20201556

DMIO1K0	DI	DMIO1K0
DMIO1K0	DN	Sulfamylon
DMIO1K0	MI	TTEYTKG
DMIO1K0	MN	Carbonic anhydrase XIV (CA-XIV)
DMIO1K0	MT	DTT
DMIO1K0	MA	Inhibitor
DMIO1K0	RN	Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33.
DMIO1K0	RU	https://pubmed.ncbi.nlm.nih.gov/16039848

DMABVE9	DI	DMABVE9
DMABVE9	DN	Sulfanilamide
DMABVE9	MI	TT4ILYC
DMABVE9	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMABVE9	MT	DTT
DMABVE9	MA	Modulator
DMABVE9	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMABVE9	RU	https://www.fda.gov/

DMFNAEM	DI	DMFNAEM
DMFNAEM	DN	Sulfaphenazole
DMFNAEM	MI	TTR40YJ
DMFNAEM	MN	S-mephenytoin 4-hydroxylase (CYP2C9)
DMFNAEM	MT	DTT
DMFNAEM	MA	Modulator
DMFNAEM	RN	Identification of amino acid substitutions that confer a high affinity for sulfaphenazole binding and a high catalytic efficiency for warfarin meta... Biochemistry. 1998 Nov 17;37(46):16270-9.
DMFNAEM	RU	https://www.ncbi.nlm.nih.gov/pubmed/9819219

DMIUYFH	DI	DMIUYFH
DMIUYFH	DN	Sulfapyridine
DMIUYFH	MI	TT4ILYC
DMIUYFH	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMIUYFH	MT	DTT
DMIUYFH	MA	Inhibitor
DMIUYFH	RN	A confirmatory method for the simultaneous extraction, separation, identification and quantification of Tetracycline, Sulphonamide, Trimethoprim an... J Chromatogr A. 2009 Nov 13;1216(46):8110-6.
DMIUYFH	RU	https://pubmed.ncbi.nlm.nih.gov/19586630

DMIUYFH	DI	DMIUYFH
DMIUYFH	DN	Sulfapyridine
DMIUYFH	MI	DEZV4AP
DMIUYFH	MN	RNA cytidine acetyltransferase (hALP)
DMIUYFH	MT	DME
DMIUYFH	MA	Metabolism
DMIUYFH	RN	Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population. Clin Chim Acta. 2009 Sep;407(1-2):30-5.
DMIUYFH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19560446

DMICA9H	DI	DMICA9H
DMICA9H	DN	Sulfasalazine
DMICA9H	MI	TTIMJ02
DMICA9H	MN	ATP-binding cassette transporter G2 (ABCG2)
DMICA9H	MT	DTT
DMICA9H	MA	Inhibitor
DMICA9H	RN	The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol. 1996 Mar 1;156(5):1937-41.
DMICA9H	RU	https://pubmed.ncbi.nlm.nih.gov/8596047

DMICA9H	DI	DMICA9H
DMICA9H	DN	Sulfasalazine
DMICA9H	MI	DE5CAX1
DMICA9H	MN	Azoreductase (azoR)
DMICA9H	MT	DME
DMICA9H	MA	Metabolism
DMICA9H	RN	The influence of probiotic treatment on sulfasalazine metabolism in rat. Xenobiotica. 2012 Aug;42(8):791-7.
DMICA9H	RU	https://pubmed.ncbi.nlm.nih.gov/22348441

DMICA9H	DI	DMICA9H
DMICA9H	DN	Sulfasalazine
DMICA9H	MI	DEGTKHL
DMICA9H	MN	Azoreductase (azoR)
DMICA9H	MT	DME
DMICA9H	MA	Metabolism
DMICA9H	RN	The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther. 1972 Jun;181(3):555-62.
DMICA9H	RU	https://pubmed.ncbi.nlm.nih.gov/4402374

DMICA9H	DI	DMICA9H
DMICA9H	DN	Sulfasalazine
DMICA9H	MI	DE3UF6Z
DMICA9H	MN	Azoreductase (azoR)
DMICA9H	MT	DME
DMICA9H	MA	Metabolism
DMICA9H	RN	The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther. 1972 Jun;181(3):555-62.
DMICA9H	RU	https://pubmed.ncbi.nlm.nih.gov/4402374

DMICA9H	DI	DMICA9H
DMICA9H	DN	Sulfasalazine
DMICA9H	MI	DE6GHJ5
DMICA9H	MN	Azoreductase (azoR)
DMICA9H	MT	DME
DMICA9H	MA	Metabolism
DMICA9H	RN	The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther. 1972 Jun;181(3):555-62.
DMICA9H	RU	https://pubmed.ncbi.nlm.nih.gov/4402374

DMICA9H	DI	DMICA9H
DMICA9H	DN	Sulfasalazine
DMICA9H	MI	DEEISQ2
DMICA9H	MN	Azoreductase (azoR)
DMICA9H	MT	DME
DMICA9H	MA	Metabolism
DMICA9H	RN	The influence of probiotic treatment on sulfasalazine metabolism in rat. Xenobiotica. 2012 Aug;42(8):791-7.
DMICA9H	RU	https://pubmed.ncbi.nlm.nih.gov/22348441

DMICA9H	DI	DMICA9H
DMICA9H	DN	Sulfasalazine
DMICA9H	MI	DEI2PC5
DMICA9H	MN	Azoreductase (azoR)
DMICA9H	MT	DME
DMICA9H	MA	Metabolism
DMICA9H	RN	The influence of probiotic treatment on sulfasalazine metabolism in rat. Xenobiotica. 2012 Aug;42(8):791-7.
DMICA9H	RU	https://pubmed.ncbi.nlm.nih.gov/22348441

DMICA9H	DI	DMICA9H
DMICA9H	DN	Sulfasalazine
DMICA9H	MI	DETEMAH
DMICA9H	MN	Azoreductase (azoR)
DMICA9H	MT	DME
DMICA9H	MA	Metabolism
DMICA9H	RN	The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther. 1972 Jun;181(3):555-62.
DMICA9H	RU	https://pubmed.ncbi.nlm.nih.gov/4402374

DMICA9H	DI	DMICA9H
DMICA9H	DN	Sulfasalazine
DMICA9H	MI	DEM1BHT
DMICA9H	MN	Azoreductase (azoR)
DMICA9H	MT	DME
DMICA9H	MA	Metabolism
DMICA9H	RN	The influence of probiotic treatment on sulfasalazine metabolism in rat. Xenobiotica. 2012 Aug;42(8):791-7.
DMICA9H	RU	https://pubmed.ncbi.nlm.nih.gov/22348441

DMICA9H	DI	DMICA9H
DMICA9H	DN	Sulfasalazine
DMICA9H	MI	DEIKZOU
DMICA9H	MN	Azoreductase (azoR)
DMICA9H	MT	DME
DMICA9H	MA	Metabolism
DMICA9H	RN	Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467.
DMICA9H	RU	https://pubmed.ncbi.nlm.nih.gov/31158845

DMICA9H	DI	DMICA9H
DMICA9H	DN	Sulfasalazine
DMICA9H	MI	DENLBG3
DMICA9H	MN	Azoreductase (azoR)
DMICA9H	MT	DME
DMICA9H	MA	Metabolism
DMICA9H	RN	The influence of probiotic treatment on sulfasalazine metabolism in rat. Xenobiotica. 2012 Aug;42(8):791-7.
DMICA9H	RU	https://pubmed.ncbi.nlm.nih.gov/22348441

DMICA9H	DI	DMICA9H
DMICA9H	DN	Sulfasalazine
DMICA9H	MI	DEIHK8V
DMICA9H	MN	Azoreductase (azoR)
DMICA9H	MT	DME
DMICA9H	MA	Metabolism
DMICA9H	RN	The influence of probiotic treatment on sulfasalazine metabolism in rat. Xenobiotica. 2012 Aug;42(8):791-7.
DMICA9H	RU	https://pubmed.ncbi.nlm.nih.gov/22348441

DMICA9H	DI	DMICA9H
DMICA9H	DN	Sulfasalazine
DMICA9H	MI	DTI7UX6
DMICA9H	MN	Breast cancer resistance protein (ABCG2)
DMICA9H	MT	DTP
DMICA9H	MA	Substrate
DMICA9H	RN	Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
DMICA9H	RU	http://www.ncbi.nlm.nih.gov/pubmed/18841445

DMICA9H	DI	DMICA9H
DMICA9H	DN	Sulfasalazine
DMICA9H	MI	DEIBDNY
DMICA9H	MN	Cytochrome P450 3A5 (CYP3A5)
DMICA9H	MT	DME
DMICA9H	MA	Metabolism
DMICA9H	RN	Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
DMICA9H	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9117175

DMICA9H	DI	DMICA9H
DMICA9H	DN	Sulfasalazine
DMICA9H	MI	DTFI42L
DMICA9H	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMICA9H	MT	DTP
DMICA9H	MA	Substrate
DMICA9H	RN	Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
DMICA9H	RU	http://www.ncbi.nlm.nih.gov/pubmed/19541926

DMICA9H	DI	DMICA9H
DMICA9H	DN	Sulfasalazine
DMICA9H	MI	TTSXVID
DMICA9H	MN	Nuclear factor NF-kappa-B (NFKB)
DMICA9H	MT	DTT
DMICA9H	MA	Activator
DMICA9H	RN	Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
DMICA9H	RU	https://pubmed.ncbi.nlm.nih.gov/18321156

DMICA9H	DI	DMICA9H
DMICA9H	DN	Sulfasalazine
DMICA9H	MI	DTPFTEQ
DMICA9H	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DMICA9H	MT	DTP
DMICA9H	MA	Substrate
DMICA9H	RN	Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP. J Pharm Sci. 2017 Sep;106(9):2688-2694.
DMICA9H	RU	http://www.ncbi.nlm.nih.gov/pubmed/28322941

DMICA9H	DI	DMICA9H
DMICA9H	DN	Sulfasalazine
DMICA9H	MI	DT9G7XN
DMICA9H	MN	Peptide transporter 1 (SLC15A1)
DMICA9H	MT	DTP
DMICA9H	MA	Substrate
DMICA9H	RN	Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells. Arch Pharm Res. 2007 Apr;30(4):507-18.
DMICA9H	RU	https://doi.org/10.1007/BF02980227

DMEV954	DI	DMEV954
DMEV954	DN	Sulfinpyrazone
DMEV954	MI	DES5XRU
DMEV954	MN	Cytochrome P450 2C8 (CYP2C8)
DMEV954	MT	DME
DMEV954	MA	Metabolism
DMEV954	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMEV954	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMEV954	DI	DMEV954
DMEV954	DN	Sulfinpyrazone
DMEV954	MI	DE4LYSA
DMEV954	MN	Cytochrome P450 3A4 (CYP3A4)
DMEV954	MT	DME
DMEV954	MA	Metabolism
DMEV954	RN	CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos. 2002 Jul;30(7):795-804.
DMEV954	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12065438

DMEV954	DI	DMEV954
DMEV954	DN	Sulfinpyrazone
DMEV954	MI	TTOI92F
DMEV954	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMEV954	MT	DTT
DMEV954	MA	Modulator
DMEV954	RN	Species-dependent transport and modulation properties of human and mouse multidrug resistance protein 2 (MRP2/Mrp2, ABCC2/Abcc2). Drug Metab Dispos. 2008 Apr;36(4):631-40.
DMEV954	RU	https://pubmed.ncbi.nlm.nih.gov/18180270

DMEV954	DI	DMEV954
DMEV954	DN	Sulfinpyrazone
DMEV954	MI	DTFI42L
DMEV954	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMEV954	MT	DTP
DMEV954	MA	Substrate
DMEV954	RN	Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83.
DMEV954	RU	http://www.ncbi.nlm.nih.gov/pubmed/10917554

DMXLT8C	DI	DMXLT8C
DMXLT8C	DN	Sulfisoxazole
DMXLT8C	MI	TT4ILYC
DMXLT8C	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMXLT8C	MT	DTT
DMXLT8C	MA	Inhibitor
DMXLT8C	RN	Inhibition of recombinant Pneumocystis carinii dihydropteroate synthetase by sulfa drugs. Antimicrob Agents Chemother. 1995 Aug;39(8):1756-63.
DMXLT8C	RU	https://pubmed.ncbi.nlm.nih.gov/7486915

DMXLT8C	DI	DMXLT8C
DMXLT8C	DN	Sulfisoxazole
DMXLT8C	MI	DE5IED8
DMXLT8C	MN	Cytochrome P450 2C9 (CYP2C9)
DMXLT8C	MT	DME
DMXLT8C	MA	Metabolism
DMXLT8C	RN	Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments. Drug Metab Dispos. 2000 Apr;28(4):475-81.
DMXLT8C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10725317

DM1YA7M	DI	DM1YA7M
DM1YA7M	DN	Sulfonamides
DM1YA7M	MI	TT4ILYC
DM1YA7M	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DM1YA7M	MT	DTT
DM1YA7M	MA	Binder
DM1YA7M	RN	Has nature already identified all useful antibacterial targets Curr Opin Microbiol. 2008 Oct;11(5):387-92.
DM1YA7M	RU	https://pubmed.ncbi.nlm.nih.gov/18804175

DMAYX6P	DI	DMAYX6P
DMAYX6P	DN	Sulfoxone
DMAYX6P	MI	TT915ZD
DMAYX6P	MN	Candida Mannose-6-phosphate isomerase (Candi PMI1)
DMAYX6P	MT	DTT
DMAYX6P	MA	Inhibitor
DMAYX6P	RN	Antifungal Activity of Ag(I) and Zn(II) Complexes of Sulfacetamide Derivatives. Met Based Drugs. 2000;7(1):49-54.
DMAYX6P	RU	https://pubmed.ncbi.nlm.nih.gov/18475922

DM2QHZU	DI	DM2QHZU
DM2QHZU	DN	Sulindac
DM2QHZU	MI	TTFBNVI
DM2QHZU	MN	Aldose reductase (AKR1B1)
DM2QHZU	MT	DTT
DM2QHZU	MA	Inhibitor
DM2QHZU	RN	Inhibition of human lens aldose reductase by flavonoids, sulindac and indomethacin. Biochem Pharmacol. 1983 Jul 1;32(13):1995-8.
DM2QHZU	RU	https://pubmed.ncbi.nlm.nih.gov/6409111

DM2QHZU	DI	DM2QHZU
DM2QHZU	DN	Sulindac
DM2QHZU	MI	DTCSGPB
DM2QHZU	MN	Multidrug resistance-associated protein 4 (ABCC4)
DM2QHZU	MT	DTP
DM2QHZU	MA	Substrate
DM2QHZU	RN	Fluo-cAMP is transported by multidrug resistance-associated protein isoform 4 in rat choroid plexus. J Neurochem. 2010 Oct;115(1):200-8.
DM2QHZU	RU	http://www.ncbi.nlm.nih.gov/pubmed/20649844

DMNUC42	DI	DMNUC42
DMNUC42	DN	Sulodexide
DMNUC42	MI	TT4QPUL
DMNUC42	MN	Antithrombin-III (ATIII)
DMNUC42	MT	DTT
DMNUC42	MA	Activator
DMNUC42	RN	Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide. Med Res Rev. 1998 Jan;18(1):1-20.
DMNUC42	RU	https://pubmed.ncbi.nlm.nih.gov/9436179

DMZI2UF	DI	DMZI2UF
DMZI2UF	DN	Sulphadoxine
DMZI2UF	MI	TT4ILYC
DMZI2UF	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMZI2UF	MT	DTT
DMZI2UF	MA	Binder
DMZI2UF	RN	The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
DMZI2UF	RU	https://pubmed.ncbi.nlm.nih.gov/18220771

DMZI2UF	DI	DMZI2UF
DMZI2UF	DN	Sulphadoxine
DMZI2UF	MI	TTGP7BY
DMZI2UF	MN	Monoamine oxidase type B (MAO-B)
DMZI2UF	MT	DTT
DMZI2UF	MA	Inhibitor
DMZI2UF	RN	Novel monoamine oxidase inhibitors, 3-(2-aminoethoxy)-1,2-benzisoxazole derivatives, and their differential reversibility. Jpn J Pharmacol. 2002 Feb;88(2):174-82.
DMZI2UF	RU	https://pubmed.ncbi.nlm.nih.gov/11928718

DMF54ZG	DI	DMF54ZG
DMF54ZG	DN	Sulpiride
DMF54ZG	MI	TTEX248
DMF54ZG	MN	Dopamine D2 receptor (D2R)
DMF54ZG	MT	DTT
DMF54ZG	MA	Antagonist
DMF54ZG	RN	The treatment of Tourette's syndrome: current opinions. Expert Opin Pharmacother. 2002 Jul;3(7):899-914.
DMF54ZG	RU	https://pubmed.ncbi.nlm.nih.gov/12083990

DMF54ZG	DI	DMF54ZG
DMF54ZG	DN	Sulpiride
DMF54ZG	MI	DT9G7XN
DMF54ZG	MN	Peptide transporter 1 (SLC15A1)
DMF54ZG	MT	DTP
DMF54ZG	MA	Substrate
DMF54ZG	RN	Studies on intestinal absorption of sulpiride (2): transepithelial transport of sulpiride across the human intestinal cell line Caco-2. Biol Pharm Bull. 2002 Oct;25(10):1345-50.
DMF54ZG	RU	http://www.ncbi.nlm.nih.gov/pubmed/12392092

DMVYXR8	DI	DMVYXR8
DMVYXR8	DN	Sumatriptan
DMVYXR8	MI	TT6MSOK
DMVYXR8	MN	5-HT 1D receptor (HTR1D)
DMVYXR8	MT	DTT
DMVYXR8	MA	Agonist
DMVYXR8	RN	Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
DMVYXR8	RU	https://pubmed.ncbi.nlm.nih.gov/11293643

DMVYXR8	DI	DMVYXR8
DMVYXR8	DN	Sumatriptan
DMVYXR8	MI	DTT79CX
DMVYXR8	MN	Organic cation transporter 1 (SLC22A1)
DMVYXR8	MT	DTP
DMVYXR8	MA	Substrate
DMVYXR8	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMVYXR8	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DMVYXR8	DI	DMVYXR8
DMVYXR8	DN	Sumatriptan
DMVYXR8	MI	DTUGYRD
DMVYXR8	MN	P-glycoprotein 1 (ABCB1)
DMVYXR8	MT	DTP
DMVYXR8	MA	Substrate
DMVYXR8	RN	HT29-MTX and Caco-2/TC7 monolayers as predictive models for human intestinal absorption: role of the mucus layer. J Pharm Sci. 2001 Oct;90(10):1608-19. Comparative Study
DMVYXR8	RU	http://www.ncbi.nlm.nih.gov/pubmed/11745719

DMCBJSR	DI	DMCBJSR
DMCBJSR	DN	Sunitinib
DMCBJSR	MI	DTI7UX6
DMCBJSR	MN	Breast cancer resistance protein (ABCG2)
DMCBJSR	MT	DTP
DMCBJSR	MA	Substrate
DMCBJSR	RN	Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. Mol Pharm. 2011 Apr 4;8(2):571-82.
DMCBJSR	RU	https://doi.org/10.1021/mp1003898

DMCBJSR	DI	DMCBJSR
DMCBJSR	DN	Sunitinib
DMCBJSR	MI	DE4LYSA
DMCBJSR	MN	Cytochrome P450 3A4 (CYP3A4)
DMCBJSR	MT	DME
DMCBJSR	MA	Metabolism
DMCBJSR	RN	In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors. Drug Metab Dispos. 2014 Jul;42(7):1202-9.
DMCBJSR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24713129

DMCBJSR	DI	DMCBJSR
DMCBJSR	DN	Sunitinib
DMCBJSR	MI	DEIBDNY
DMCBJSR	MN	Cytochrome P450 3A5 (CYP3A5)
DMCBJSR	MT	DME
DMCBJSR	MA	Metabolism
DMCBJSR	RN	Drug Interactions Flockhart Table
DMCBJSR	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMCBJSR	DI	DMCBJSR
DMCBJSR	DN	Sunitinib
DMCBJSR	MI	DERD86B
DMCBJSR	MN	Cytochrome P450 3A7 (CYP3A7)
DMCBJSR	MT	DME
DMCBJSR	MA	Metabolism
DMCBJSR	RN	Drug Interactions Flockhart Table
DMCBJSR	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMCBJSR	DI	DMCBJSR
DMCBJSR	DN	Sunitinib
DMCBJSR	MI	DT3D8F0
DMCBJSR	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMCBJSR	MT	DTP
DMCBJSR	MA	Substrate
DMCBJSR	RN	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
DMCBJSR	RU	http://www.ncbi.nlm.nih.gov/pubmed/23340295

DMCBJSR	DI	DMCBJSR
DMCBJSR	DN	Sunitinib
DMCBJSR	MI	DT9C1TS
DMCBJSR	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMCBJSR	MT	DTP
DMCBJSR	MA	Substrate
DMCBJSR	RN	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
DMCBJSR	RU	http://www.ncbi.nlm.nih.gov/pubmed/23340295

DMCBJSR	DI	DMCBJSR
DMCBJSR	DN	Sunitinib
DMCBJSR	MI	DTUGYRD
DMCBJSR	MN	P-glycoprotein 1 (ABCB1)
DMCBJSR	MT	DTP
DMCBJSR	MA	Substrate
DMCBJSR	RN	Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res. 2009 Oct 1;15(19):6062-9.
DMCBJSR	RU	http://www.ncbi.nlm.nih.gov/pubmed/19773380

DMCBJSR	DI	DMCBJSR
DMCBJSR	DN	Sunitinib
DMCBJSR	MI	DTYEM9B
DMCBJSR	MN	RalBP1-associated Eps domain-containing protein 2 (RALBP1)
DMCBJSR	MT	DTP
DMCBJSR	MA	Substrate
DMCBJSR	RN	Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer. Int J Cancer. 2010 Mar 15;126(6):1327-38.
DMCBJSR	RU	http://www.ncbi.nlm.nih.gov/pubmed/19626587

DMCBJSR	DI	DMCBJSR
DMCBJSR	DN	Sunitinib
DMCBJSR	MI	TTUTJGQ
DMCBJSR	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMCBJSR	MT	DTT
DMCBJSR	MA	Modulator
DMCBJSR	RN	2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
DMCBJSR	RU	https://pubmed.ncbi.nlm.nih.gov/17342860

DMN8E5D	DI	DMN8E5D
DMN8E5D	DN	Sunitinib malate
DMN8E5D	MI	DTUGYRD
DMN8E5D	MN	P-glycoprotein 1 (ABCB1)
DMN8E5D	MT	DTP
DMN8E5D	MA	Substrate
DMN8E5D	RN	JNK-AKT-NF-kB controls P-glycoprotein expression to attenuate the cytotoxicity of deoxynivalenol in mammalian cells. Biochem Pharmacol. 2018 Oct;156:120-134.
DMN8E5D	RU	http://www.ncbi.nlm.nih.gov/pubmed/30121250

DMOGREH	DI	DMOGREH
DMOGREH	DN	Suplatast tosilate
DMOGREH	MI	TTGPK5Y
DMOGREH	MN	T(H2) cytokine production (TH2 produ)
DMOGREH	MT	DTT
DMOGREH	MA	Modulator
DMOGREH	RN	Suplatast tosilate inhibits goblet-cell metaplasia of airway epithelium in sensitized mice. J Allergy Clin Immunol. 2000 Apr;105(4):739-45.
DMOGREH	RU	https://pubmed.ncbi.nlm.nih.gov/10756224

DMKXJZ7	DI	DMKXJZ7
DMKXJZ7	DN	Suprofen
DMKXJZ7	MI	DE5IED8
DMKXJZ7	MN	Cytochrome P450 2C9 (CYP2C9)
DMKXJZ7	MT	DME
DMKXJZ7	MA	Metabolism
DMKXJZ7	RN	Mechanism-based inactivation of human recombinant P450 2C9 by the nonsteroidal anti-inflammatory drug suprofen. Drug Metab Dispos. 2003 Nov;31(11):1369-77.
DMKXJZ7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14570769

DMKXJZ7	DI	DMKXJZ7
DMKXJZ7	DN	Suprofen
DMKXJZ7	MI	TT8NGED
DMKXJZ7	MN	Prostaglandin G/H synthase 1 (COX-1)
DMKXJZ7	MT	DTT
DMKXJZ7	MA	Inhibitor
DMKXJZ7	RN	Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model. 2002 Mar;20(5):359-71.
DMKXJZ7	RU	https://pubmed.ncbi.nlm.nih.gov/11885959

DMKXJZ7	DI	DMKXJZ7
DMKXJZ7	DN	Suprofen
DMKXJZ7	MI	DEYGVN4
DMKXJZ7	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMKXJZ7	MT	DME
DMKXJZ7	MA	Metabolism
DMKXJZ7	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMKXJZ7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM0E6S3	DI	DM0E6S3
DM0E6S3	DN	Suvorexant
DM0E6S3	MI	DE4LYSA
DM0E6S3	MN	Cytochrome P450 3A4 (CYP3A4)
DM0E6S3	MT	DME
DM0E6S3	MA	Metabolism
DM0E6S3	RN	Suvorexant: a promising, novel treatment for insomnia. Neuropsychiatr Dis Treat. 2016 Feb 25;12:491-5.
DM0E6S3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26955275

DM0E6S3	DI	DM0E6S3
DM0E6S3	DN	Suvorexant
DM0E6S3	MI	TT9N02I
DM0E6S3	MN	Orexin receptor type 2 (HCRTR2)
DM0E6S3	MT	DTT
DM0E6S3	MA	Modulator
DM0E6S3	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DM0E6S3	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DM6S0HB	DI	DM6S0HB
DM6S0HB	DN	TachoComb
DM6S0HB	MI	TTWODQF
DM6S0HB	MN	Fibrin (FG)
DM6S0HB	MT	DTT
DM6S0HB	MA	Modulator
DM6S0HB	RN	Pancreaticojejunostomy using a fibrin adhesive sealant (TachoComb) for the prevention of pancreatic fistula after pancreaticoduodenectomy. Hepatogastroenterology. 2011 Jan-Feb;58(105):187-91.
DM6S0HB	RU	https://pubmed.ncbi.nlm.nih.gov/21510312

DM51FY6	DI	DM51FY6
DM51FY6	DN	Tacrine
DM51FY6	MI	TT1RS9F
DM51FY6	MN	Acetylcholinesterase (AChE)
DM51FY6	MT	DTT
DM51FY6	MA	Inhibitor
DM51FY6	RN	Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract Suppl. 2002 Jun;(127):6-19.
DM51FY6	RU	https://pubmed.ncbi.nlm.nih.gov/12139368

DM51FY6	DI	DM51FY6
DM51FY6	DN	Tacrine
DM51FY6	MI	DEJGDUW
DM51FY6	MN	Cytochrome P450 1A2 (CYP1A2)
DM51FY6	MT	DME
DM51FY6	MA	Metabolism
DM51FY6	RN	Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
DM51FY6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19754423

DM51FY6	DI	DM51FY6
DM51FY6	DN	Tacrine
DM51FY6	MI	DE4ZHS1
DM51FY6	MN	Glutathione S-transferase alpha-1 (GSTA1)
DM51FY6	MT	DME
DM51FY6	MA	Metabolism
DM51FY6	RN	Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. Clin Pharmacol Ther. 2000 Apr;67(4):432-7.
DM51FY6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10801254

DM51FY6	DI	DM51FY6
DM51FY6	DN	Tacrine
DM51FY6	MI	DTUGYRD
DM51FY6	MN	P-glycoprotein 1 (ABCB1)
DM51FY6	MT	DTP
DM51FY6	MA	Substrate
DM51FY6	RN	Tacrine sinusoidal uptake and biliary excretion in sandwich-cultured primary rat hepatocytes. J Pharm Pharm Sci. 2014;17(3):427-38.
DM51FY6	RU	http://www.ncbi.nlm.nih.gov/pubmed/25224352

DMZ7XNQ	DI	DMZ7XNQ
DMZ7XNQ	DN	Tacrolimus
DMZ7XNQ	MI	TTA4LDE
DMZ7XNQ	MN	Calcineurin (PPP3CA)
DMZ7XNQ	MT	DTT
DMZ7XNQ	MA	Inhibitor
DMZ7XNQ	RN	Emerging drugs for ocular allergy. Expert Opin Emerg Drugs. 2005 Aug;10(3):505-20.
DMZ7XNQ	RU	https://pubmed.ncbi.nlm.nih.gov/16083326

DMZ7XNQ	DI	DMZ7XNQ
DMZ7XNQ	DN	Tacrolimus
DMZ7XNQ	MI	DE4LYSA
DMZ7XNQ	MN	Cytochrome P450 3A4 (CYP3A4)
DMZ7XNQ	MT	DME
DMZ7XNQ	MA	Metabolism
DMZ7XNQ	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMZ7XNQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMZ7XNQ	DI	DMZ7XNQ
DMZ7XNQ	DN	Tacrolimus
DMZ7XNQ	MI	DEIBDNY
DMZ7XNQ	MN	Cytochrome P450 3A5 (CYP3A5)
DMZ7XNQ	MT	DME
DMZ7XNQ	MA	Metabolism
DMZ7XNQ	RN	Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms. Fundam Clin Pharmacol. 2007 Aug;21(4):427-35.
DMZ7XNQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17635182

DMZ7XNQ	DI	DMZ7XNQ
DMZ7XNQ	DN	Tacrolimus
DMZ7XNQ	MI	DE3N2FM
DMZ7XNQ	MN	NADPH-cytochrome P450 reductase (CPR)
DMZ7XNQ	MT	DME
DMZ7XNQ	MA	Metabolism
DMZ7XNQ	RN	Polymorphisms in cytochrome P450 oxidoreductase and its effect on drug metabolism and efficacy. Pharmacogenet Genomics. 2017 Sep;27(9):337-346.
DMZ7XNQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28731962

DMZ7XNQ	DI	DMZ7XNQ
DMZ7XNQ	DN	Tacrolimus
DMZ7XNQ	MI	DTUGYRD
DMZ7XNQ	MN	P-glycoprotein 1 (ABCB1)
DMZ7XNQ	MT	DTP
DMZ7XNQ	MA	Substrate
DMZ7XNQ	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMZ7XNQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMZ7XNQ	DI	DMZ7XNQ
DMZ7XNQ	DN	Tacrolimus
DMZ7XNQ	MI	DEW6V07
DMZ7XNQ	MN	Ribosomal 23S RNA methyltransferase Erm (erm)
DMZ7XNQ	MT	DME
DMZ7XNQ	MA	Metabolism
DMZ7XNQ	RN	High frequency of macrolide resistance mechanisms in clinical isolates of Corynebacterium species. Microb Drug Resist. 2010 Dec;16(4):273-7.
DMZ7XNQ	RU	https://pubmed.ncbi.nlm.nih.gov/20624090

DMZ7XNQ	DI	DMZ7XNQ
DMZ7XNQ	DN	Tacrolimus
DMZ7XNQ	MI	DEA65D8
DMZ7XNQ	MN	Ribosomal 23S RNA methyltransferase Erm (erm)
DMZ7XNQ	MT	DME
DMZ7XNQ	MA	Metabolism
DMZ7XNQ	RN	High frequency of macrolide resistance mechanisms in clinical isolates of Corynebacterium species. Microb Drug Resist. 2010 Dec;16(4):273-7.
DMZ7XNQ	RU	https://pubmed.ncbi.nlm.nih.gov/20624090

DMJZHT1	DI	DMJZHT1
DMJZHT1	DN	Tadalafil
DMJZHT1	MI	DE4LYSA
DMJZHT1	MN	Cytochrome P450 3A4 (CYP3A4)
DMJZHT1	MT	DME
DMJZHT1	MA	Metabolism
DMJZHT1	RN	Contribution of CYP3A isoforms to dealkylation of PDE5 inhibitors: a comparison between sildenafil N-demethylation and tadalafil demethylenation. Biol Pharm Bull. 2015;38(1):58-65.
DMJZHT1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25744459

DMJZHT1	DI	DMJZHT1
DMJZHT1	DN	Tadalafil
DMJZHT1	MI	DEIBDNY
DMJZHT1	MN	Cytochrome P450 3A5 (CYP3A5)
DMJZHT1	MT	DME
DMJZHT1	MA	Metabolism
DMJZHT1	RN	Contribution of CYP3A isoforms to dealkylation of PDE5 inhibitors: a comparison between sildenafil N-demethylation and tadalafil demethylenation. Biol Pharm Bull. 2015;38(1):58-65.
DMJZHT1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25744459

DMJZHT1	DI	DMJZHT1
DMJZHT1	DN	Tadalafil
DMJZHT1	MI	DTUGYRD
DMJZHT1	MN	P-glycoprotein 1 (ABCB1)
DMJZHT1	MT	DTP
DMJZHT1	MA	Substrate
DMJZHT1	RN	In Vitro P-Glycoprotein-Mediated Transport of Tadalafil: A Comparison with Sildenafil. Biol Pharm Bull. 2017;40(8):1314-1319.
DMJZHT1	RU	http://www.ncbi.nlm.nih.gov/pubmed/28769012

DMJZHT1	DI	DMJZHT1
DMJZHT1	DN	Tadalafil
DMJZHT1	MI	TTJ0IQB
DMJZHT1	MN	Phosphodiesterase 5A (PDE5A)
DMJZHT1	MT	DTT
DMJZHT1	MA	Inhibitor
DMJZHT1	RN	Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology (Oxford). 2009 Jun;48 Suppl 3:iii25-31.
DMJZHT1	RU	https://pubmed.ncbi.nlm.nih.gov/19487219

DM1XT4N	DI	DM1XT4N
DM1XT4N	DN	Tafenoquine
DM1XT4N	MI	DECB0K3
DM1XT4N	MN	Cytochrome P450 2D6 (CYP2D6)
DM1XT4N	MT	DME
DM1XT4N	MA	Metabolism
DM1XT4N	RN	Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date. Drug Des Devel Ther. 2016 Jul 26;10:2387-99.
DM1XT4N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27528800

DM1XT4N	DI	DM1XT4N
DM1XT4N	DN	Tafenoquine
DM1XT4N	MI	TTB8JQ7
DM1XT4N	MN	Electron transport complex III (Complex III)
DM1XT4N	MT	DTT
DM1XT4N	MA	Inhibitor
DM1XT4N	RN	Tafenoquine: First Global Approval.Drugs. 2018 Sep;78(14):1517-1523. 
DM1XT4N	RU	https://pubmed.ncbi.nlm.nih.gov/30229442

DM1XT4N	DI	DM1XT4N
DM1XT4N	DN	Tafenoquine
DM1XT4N	MI	TTULV0X
DM1XT4N	MN	Reactive oxygen species (ROS)
DM1XT4N	MT	DTT
DM1XT4N	MA	Modulator
DM1XT4N	RN	Tafenoquine: First Global Approval.Drugs. 2018 Sep;78(14):1517-1523. 
DM1XT4N	RU	https://pubmed.ncbi.nlm.nih.gov/30229442

DMFC41K	DI	DMFC41K
DMFC41K	DN	Tafluprost
DMFC41K	MI	TTT2ZAR
DMFC41K	MN	Prostaglandin F2-alpha receptor (PTGFR)
DMFC41K	MT	DTT
DMFC41K	MA	Modulator
DMFC41K	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMFC41K	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM9HQ5U	DI	DM9HQ5U
DM9HQ5U	DN	Tagraxofusp
DM9HQ5U	MI	TTENHJ0
DM9HQ5U	MN	Interleukin 3 receptor alpha (IL3RA)
DM9HQ5U	MT	DTT
DM9HQ5U	MA	Modulator
DM9HQ5U	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DM9HQ5U	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DM2M3OC	DI	DM2M3OC
DM2M3OC	DN	Talazoparib
DM2M3OC	MI	DTI7UX6
DM2M3OC	MN	Breast cancer resistance protein (ABCG2)
DM2M3OC	MT	DTP
DM2M3OC	MA	Substrate
DM2M3OC	RN	DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB11760)
DM2M3OC	RU	https://www.drugbank.ca/drugs/DB11760

DM2M3OC	DI	DM2M3OC
DM2M3OC	DN	Talazoparib
DM2M3OC	MI	DTUGYRD
DM2M3OC	MN	P-glycoprotein 1 (ABCB1)
DM2M3OC	MT	DTP
DM2M3OC	MA	Substrate
DM2M3OC	RN	DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB11760)
DM2M3OC	RU	https://www.drugbank.ca/drugs/DB11760

DM1KS78	DI	DM1KS78
DM1KS78	DN	Talazoparib
DM1KS78	MI	TTEBCY8
DM1KS78	MN	Poly [ADP-ribose] polymerase (PARP)
DM1KS78	MT	DTT
DM1KS78	MA	Inhibitor
DM1KS78	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DM1KS78	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DM214Q8	DI	DM214Q8
DM214Q8	DN	Talbutal
DM214Q8	MI	TTEX6LM
DM214Q8	MN	GABA(A) receptor gamma-3 (GABRG3)
DM214Q8	MT	DTT
DM214Q8	MA	Modulator
DM214Q8	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM214Q8	RU	https://www.fda.gov/

DM3PZXN	DI	DM3PZXN
DM3PZXN	DN	Taliglucerase alfa
DM3PZXN	MI	TT1B5PU
DM3PZXN	MN	Glucosylceramidase (GBA)
DM3PZXN	MT	DTT
DM3PZXN	MA	Modulator
DM3PZXN	RN	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
DM3PZXN	RU	https://pubmed.ncbi.nlm.nih.gov/23370234

DMKBW5C	DI	DMKBW5C
DMKBW5C	DN	Talimogene Laherparepvec
DMKBW5C	MI	TTNYZG2
DMKBW5C	MN	Granulocyte-macrophage colony-stimulating factor (CSF2)
DMKBW5C	MT	DTT
DMKBW5C	MA	Modulator
DMKBW5C	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMKBW5C	RU	https://www.fda.gov/

DMLB0EZ	DI	DMLB0EZ
DMLB0EZ	DN	Tamoxifen
DMLB0EZ	MI	DTI7UX6
DMLB0EZ	MN	Breast cancer resistance protein (ABCG2)
DMLB0EZ	MT	DTP
DMLB0EZ	MA	Substrate
DMLB0EZ	RN	The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
DMLB0EZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/27033456

DMLB0EZ	DI	DMLB0EZ
DMLB0EZ	DN	Tamoxifen
DMLB0EZ	MI	DE6OQ3W
DMLB0EZ	MN	Cytochrome P450 1A1 (CYP1A1)
DMLB0EZ	MT	DME
DMLB0EZ	MA	Metabolism
DMLB0EZ	RN	Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002 Aug;30(8):869-74.
DMLB0EZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12124303

DMLB0EZ	DI	DMLB0EZ
DMLB0EZ	DN	Tamoxifen
DMLB0EZ	MI	DEJGDUW
DMLB0EZ	MN	Cytochrome P450 1A2 (CYP1A2)
DMLB0EZ	MT	DME
DMLB0EZ	MA	Metabolism
DMLB0EZ	RN	Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
DMLB0EZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25157097

DMLB0EZ	DI	DMLB0EZ
DMLB0EZ	DN	Tamoxifen
DMLB0EZ	MI	DEJVYAZ
DMLB0EZ	MN	Cytochrome P450 2A6 (CYP2A6)
DMLB0EZ	MT	DME
DMLB0EZ	MA	Metabolism
DMLB0EZ	RN	Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
DMLB0EZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8293548

DMLB0EZ	DI	DMLB0EZ
DMLB0EZ	DN	Tamoxifen
DMLB0EZ	MI	DEPKLMQ
DMLB0EZ	MN	Cytochrome P450 2B6 (CYP2B6)
DMLB0EZ	MT	DME
DMLB0EZ	MA	Metabolism
DMLB0EZ	RN	Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
DMLB0EZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12023523

DMLB0EZ	DI	DMLB0EZ
DMLB0EZ	DN	Tamoxifen
DMLB0EZ	MI	DE5IED8
DMLB0EZ	MN	Cytochrome P450 2C9 (CYP2C9)
DMLB0EZ	MT	DME
DMLB0EZ	MA	Metabolism
DMLB0EZ	RN	Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
DMLB0EZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17024799

DMLB0EZ	DI	DMLB0EZ
DMLB0EZ	DN	Tamoxifen
DMLB0EZ	MI	DECB0K3
DMLB0EZ	MN	Cytochrome P450 2D6 (CYP2D6)
DMLB0EZ	MT	DME
DMLB0EZ	MA	Metabolism
DMLB0EZ	RN	CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
DMLB0EZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20425602

DMLB0EZ	DI	DMLB0EZ
DMLB0EZ	DN	Tamoxifen
DMLB0EZ	MI	DEVDYN7
DMLB0EZ	MN	Cytochrome P450 2E1 (CYP2E1)
DMLB0EZ	MT	DME
DMLB0EZ	MA	Metabolism
DMLB0EZ	RN	Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
DMLB0EZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8293548

DMLB0EZ	DI	DMLB0EZ
DMLB0EZ	DN	Tamoxifen
DMLB0EZ	MI	DE4LYSA
DMLB0EZ	MN	Cytochrome P450 3A4 (CYP3A4)
DMLB0EZ	MT	DME
DMLB0EZ	MA	Metabolism
DMLB0EZ	RN	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
DMLB0EZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15159443

DMLB0EZ	DI	DMLB0EZ
DMLB0EZ	DN	Tamoxifen
DMLB0EZ	MI	DEIBDNY
DMLB0EZ	MN	Cytochrome P450 3A5 (CYP3A5)
DMLB0EZ	MT	DME
DMLB0EZ	MA	Metabolism
DMLB0EZ	RN	Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
DMLB0EZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15596297

DMLB0EZ	DI	DMLB0EZ
DMLB0EZ	DN	Tamoxifen
DMLB0EZ	MI	DERD86B
DMLB0EZ	MN	Cytochrome P450 3A7 (CYP3A7)
DMLB0EZ	MT	DME
DMLB0EZ	MA	Metabolism
DMLB0EZ	RN	Drug Interactions Flockhart Table
DMLB0EZ	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMLB0EZ	DI	DMLB0EZ
DMLB0EZ	DN	Tamoxifen
DMLB0EZ	MI	TTZAYWL
DMLB0EZ	MN	Estrogen receptor (ESR)
DMLB0EZ	MT	DTT
DMLB0EZ	MA	Antagonist
DMLB0EZ	RN	Modulators of vascular sex hormone receptors and their effects in estrogen-deficiency states associated with menopause. Recent Pat Cardiovasc Drug Discov. 2008 Nov;3(3):165-86.
DMLB0EZ	RU	https://pubmed.ncbi.nlm.nih.gov/18991792

DMLB0EZ	DI	DMLB0EZ
DMLB0EZ	DN	Tamoxifen
DMLB0EZ	MI	DEGTFWK
DMLB0EZ	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMLB0EZ	MT	DME
DMLB0EZ	MA	Metabolism
DMLB0EZ	RN	Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
DMLB0EZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16550168

DMLB0EZ	DI	DMLB0EZ
DMLB0EZ	DN	Tamoxifen
DMLB0EZ	MI	DTPS120
DMLB0EZ	MN	Multidrug resistance-associated protein 7 (ABCC10)
DMLB0EZ	MT	DTP
DMLB0EZ	MA	Substrate
DMLB0EZ	RN	Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7). Cancer Res. 2012 Dec 15;72(24):6457-67.
DMLB0EZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/23087055

DMLB0EZ	DI	DMLB0EZ
DMLB0EZ	DN	Tamoxifen
DMLB0EZ	MI	DTUGYRD
DMLB0EZ	MN	P-glycoprotein 1 (ABCB1)
DMLB0EZ	MT	DTP
DMLB0EZ	MA	Substrate
DMLB0EZ	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMLB0EZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMLB0EZ	DI	DMLB0EZ
DMLB0EZ	DN	Tamoxifen
DMLB0EZ	MI	DEYWLRK
DMLB0EZ	MN	Sulfotransferase 1A1 (SULT1A1)
DMLB0EZ	MT	DME
DMLB0EZ	MA	Metabolism
DMLB0EZ	RN	Tamoxifen-induced adduct formation and cell stress in human endometrial glands. Drug Metab Dispos. 2010 Jan;38(1):200-7.
DMLB0EZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19812351

DMLB0EZ	DI	DMLB0EZ
DMLB0EZ	DN	Tamoxifen
DMLB0EZ	MI	DEFQ8VO
DMLB0EZ	MN	Thiopurine methyltransferase (TPMT)
DMLB0EZ	MT	DME
DMLB0EZ	MA	Metabolism
DMLB0EZ	RN	Polymorphism of estrogen metabolism genes and cataract. Med Hypotheses. 2004;63(3):494-7.
DMLB0EZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15288375

DMLB0EZ	DI	DMLB0EZ
DMLB0EZ	DN	Tamoxifen
DMLB0EZ	MI	DEYGVN4
DMLB0EZ	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMLB0EZ	MT	DME
DMLB0EZ	MA	Metabolism
DMLB0EZ	RN	Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
DMLB0EZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19244109

DMLB0EZ	DI	DMLB0EZ
DMLB0EZ	DN	Tamoxifen
DMLB0EZ	MI	DEL5N6Y
DMLB0EZ	MN	UDP-glucuronosyltransferase 1A10 (UGT1A10)
DMLB0EZ	MT	DME
DMLB0EZ	MA	Metabolism
DMLB0EZ	RN	Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos. 2007 Nov;35(11):2006-14.
DMLB0EZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17664247

DMLB0EZ	DI	DMLB0EZ
DMLB0EZ	DN	Tamoxifen
DMLB0EZ	MI	DEB3CV1
DMLB0EZ	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMLB0EZ	MT	DME
DMLB0EZ	MA	Metabolism
DMLB0EZ	RN	Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol. 2014 Jan;10(1):107-22.
DMLB0EZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24328412

DM5QF9V	DI	DM5QF9V
DM5QF9V	DN	Tamsulosin
DM5QF9V	MI	TTNGILX
DM5QF9V	MN	Adrenergic receptor alpha-1A (ADRA1A)
DM5QF9V	MT	DTT
DM5QF9V	MA	Modulator
DM5QF9V	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM5QF9V	RU	https://www.fda.gov/

DM5QF9V	DI	DM5QF9V
DM5QF9V	DN	Tamsulosin
DM5QF9V	MI	DECB0K3
DM5QF9V	MN	Cytochrome P450 2D6 (CYP2D6)
DM5QF9V	MT	DME
DM5QF9V	MA	Metabolism
DM5QF9V	RN	Identification of cytochrome P450 isozymes involved in metabolism of the alpha1-adrenoceptor blocker tamsulosin in human liver microsomes. Xenobiotica. 1998 Oct;28(10):909-22.
DM5QF9V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9849639

DM5QF9V	DI	DM5QF9V
DM5QF9V	DN	Tamsulosin
DM5QF9V	MI	DE4LYSA
DM5QF9V	MN	Cytochrome P450 3A4 (CYP3A4)
DM5QF9V	MT	DME
DM5QF9V	MA	Metabolism
DM5QF9V	RN	Identification of cytochrome P450 isozymes involved in metabolism of the alpha1-adrenoceptor blocker tamsulosin in human liver microsomes. Xenobiotica. 1998 Oct;28(10):909-22.
DM5QF9V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9849639

DMPHWU6	DI	DMPHWU6
DMPHWU6	DN	Tandospirone
DMPHWU6	MI	TT85JO3
DMPHWU6	MN	5-HT receptor (5HTR)
DMPHWU6	MT	DTT
DMPHWU6	MA	Modulator
DMPHWU6	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMPHWU6	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DMXLSH3	DI	DMXLSH3
DMXLSH3	DN	Tapentadol hydrochloride
DMXLSH3	MI	DE5IED8
DMXLSH3	MN	Cytochrome P450 2C9 (CYP2C9)
DMXLSH3	MT	DME
DMXLSH3	MA	Metabolism
DMXLSH3	RN	Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett. 2008 Jan;2(1):67-75.
DMXLSH3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19356073

DMXLSH3	DI	DMXLSH3
DMXLSH3	DN	Tapentadol hydrochloride
DMXLSH3	MI	DECB0K3
DMXLSH3	MN	Cytochrome P450 2D6 (CYP2D6)
DMXLSH3	MT	DME
DMXLSH3	MA	Metabolism
DMXLSH3	RN	Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett. 2008 Jan;2(1):67-75.
DMXLSH3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19356073

DMXLSH3	DI	DMXLSH3
DMXLSH3	DN	Tapentadol hydrochloride
DMXLSH3	MI	TTAWNKZ
DMXLSH3	MN	Norepinephrine transporter (NET)
DMXLSH3	MT	DTT
DMXLSH3	MA	Modulator
DMXLSH3	RN	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
DMXLSH3	RU	https://pubmed.ncbi.nlm.nih.gov/19180096

DMXLSH3	DI	DMXLSH3
DMXLSH3	DN	Tapentadol hydrochloride
DMXLSH3	MI	TTKWM86
DMXLSH3	MN	Opioid receptor mu (MOP)
DMXLSH3	MT	DTT
DMXLSH3	MA	Modulator
DMXLSH3	RN	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
DMXLSH3	RU	https://pubmed.ncbi.nlm.nih.gov/19180096

DMXLSH3	DI	DMXLSH3
DMXLSH3	DN	Tapentadol hydrochloride
DMXLSH3	MI	DE85D2P
DMXLSH3	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMXLSH3	MT	DME
DMXLSH3	MA	Metabolism
DMXLSH3	RN	Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett. 2008 Jan;2(1):67-75.
DMXLSH3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19356073

DMXLSH3	DI	DMXLSH3
DMXLSH3	DN	Tapentadol hydrochloride
DMXLSH3	MI	DEB3CV1
DMXLSH3	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMXLSH3	MT	DME
DMXLSH3	MA	Metabolism
DMXLSH3	RN	Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett. 2008 Jan;2(1):67-75.
DMXLSH3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19356073

DMLOQ1V	DI	DMLOQ1V
DMLOQ1V	DN	Tasimelteon
DMLOQ1V	MI	DEJGDUW
DMLOQ1V	MN	Cytochrome P450 1A2 (CYP1A2)
DMLOQ1V	MT	DME
DMLOQ1V	MA	Metabolism
DMLOQ1V	RN	Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist. J Clin Pharmacol. 2015 Sep;55(9):1004-11.
DMLOQ1V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25851638

DMLOQ1V	DI	DMLOQ1V
DMLOQ1V	DN	Tasimelteon
DMLOQ1V	MI	DE4LYSA
DMLOQ1V	MN	Cytochrome P450 3A4 (CYP3A4)
DMLOQ1V	MT	DME
DMLOQ1V	MA	Metabolism
DMLOQ1V	RN	Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist. J Clin Pharmacol. 2015 Sep;55(9):1004-11.
DMLOQ1V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25851638

DMLOQ1V	DI	DMLOQ1V
DMLOQ1V	DN	Tasimelteon
DMLOQ1V	MI	TT0WAIE
DMLOQ1V	MN	Melatonin receptor type 1A (MTNR1A)
DMLOQ1V	MT	DTT
DMLOQ1V	MA	Agonist
DMLOQ1V	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7393).
DMLOQ1V	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7393

DMLOQ1V	DI	DMLOQ1V
DMLOQ1V	DN	Tasimelteon
DMLOQ1V	MI	TT32JK8
DMLOQ1V	MN	Melatonin receptor type 1B (MTNR1B)
DMLOQ1V	MT	DTT
DMLOQ1V	MA	Agonist
DMLOQ1V	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7393).
DMLOQ1V	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7393

DMM13DI	DI	DMM13DI
DMM13DI	DN	Tasosartan
DMM13DI	MI	TT8DBY3
DMM13DI	MN	Angiotensin II receptor type-1 (AGTR1)
DMM13DI	MT	DTT
DMM13DI	MA	Antagonist
DMM13DI	RN	Tasosartan, enoltasosartan, and angiotensin II receptor blockade: the confounding role of protein binding. J Pharmacol Exp Ther. 2000 Nov;295(2):649-54.
DMM13DI	RU	https://pubmed.ncbi.nlm.nih.gov/11046101

DMM13DI	DI	DMM13DI
DMM13DI	DN	Tasosartan
DMM13DI	MI	DE4LYSA
DMM13DI	MN	Cytochrome P450 3A4 (CYP3A4)
DMM13DI	MT	DME
DMM13DI	MA	Metabolism
DMM13DI	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMM13DI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM3ED1A	DI	DM3ED1A
DM3ED1A	DN	Tavaborole
DM3ED1A	MI	TT37GL6
DM3ED1A	MN	Staphylococcus Leucyl-tRNA synthetase (Stap-coc leuS)
DM3ED1A	MT	DTT
DM3ED1A	MA	Inhibitor
DM3ED1A	RN	An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science. 2007 Jun 22;316(5832):1759-61.
DM3ED1A	RU	https://pubmed.ncbi.nlm.nih.gov/17588934

DMUOT9V	DI	DMUOT9V
DMUOT9V	DN	Taxol
DMUOT9V	MI	TTJGNVC
DMUOT9V	MN	Apoptosis regulator Bcl-2 (BCL-2)
DMUOT9V	MT	DTT
DMUOT9V	MA	Modulator
DMUOT9V	RN	Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
DMUOT9V	RU	https://pubmed.ncbi.nlm.nih.gov/19671798

DMUOT9V	DI	DMUOT9V
DMUOT9V	DN	Taxol
DMUOT9V	MI	TTYFKSZ
DMUOT9V	MN	Tubulin beta (TUBB)
DMUOT9V	MT	DTT
DMUOT9V	MA	Modulator
DMUOT9V	RN	Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
DMUOT9V	RU	https://pubmed.ncbi.nlm.nih.gov/19671798

DM8SMD1	DI	DM8SMD1
DM8SMD1	DN	Tazarotene
DM8SMD1	MI	DES5XRU
DM8SMD1	MN	Cytochrome P450 2C8 (CYP2C8)
DM8SMD1	MT	DME
DM8SMD1	MA	Metabolism
DM8SMD1	RN	Cytochrome P450 2C8 and flavin-containing monooxygenases are involved in the metabolism of tazarotenic acid in humans. Drug Metab Dispos. 2003 Apr;31(4):476-81.
DM8SMD1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12642475

DM8SMD1	DI	DM8SMD1
DM8SMD1	DN	Tazarotene
DM8SMD1	MI	TT1Q3IE
DM8SMD1	MN	Retinoic acid receptor gamma (RARG)
DM8SMD1	MT	DTT
DM8SMD1	MA	Binder
DM8SMD1	RN	Recent developments in receptor-selective retinoids. Curr Pharm Des. 2000 Jun;6(9):919-31.
DM8SMD1	RU	https://pubmed.ncbi.nlm.nih.gov/10828316

DMWP1BH	DI	DMWP1BH
DMWP1BH	DN	Tazemetostat
DMWP1BH	MI	TT9MZCQ
DMWP1BH	MN	Enhancer of zeste homolog 2 (EZH2)
DMWP1BH	MT	DTT
DMWP1BH	MA	Inhibitor
DMWP1BH	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMWP1BH	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf

DM3XNUI	DI	DM3XNUI
DM3XNUI	DN	Tazobactam
DM3XNUI	MI	DEEZ5CV
DM3XNUI	MN	Beta-lactamase (blaB)
DM3XNUI	MT	DME
DM3XNUI	MA	Metabolism
DM3XNUI	RN	Characterization of piperacillin/tazobactam-resistant klebsiella oxytoca recovered from a nosocomial outbreak. PLoS One. 2015 Nov 5;10(11):e0142366.
DM3XNUI	RU	https://pubmed.ncbi.nlm.nih.gov/26539828

DM3XNUI	DI	DM3XNUI
DM3XNUI	DN	Tazobactam
DM3XNUI	MI	DEYIEO5
DM3XNUI	MN	Beta-lactamase (blaB)
DM3XNUI	MT	DME
DM3XNUI	MA	Metabolism
DM3XNUI	RN	Determination of the antibiotic resistance rates of Serratia marcescens isolates obtained from various clinical specimens. Niger J Clin Pract. 2019 Jan;22(1):125-130.
DM3XNUI	RU	https://pubmed.ncbi.nlm.nih.gov/30666031

DM3XNUI	DI	DM3XNUI
DM3XNUI	DN	Tazobactam
DM3XNUI	MI	TTHI19T
DM3XNUI	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DM3XNUI	MT	DTT
DM3XNUI	MA	Inhibitor
DM3XNUI	RN	Selection of TNF-alpha binding affibody molecules using a beta-lactamase protein fragment complementation assay. N Biotechnol. 2009 Nov 30;26(5):251-9.
DM3XNUI	RU	https://pubmed.ncbi.nlm.nih.gov/19576305

DML6OE7	DI	DML6OE7
DML6OE7	DN	Tbo-Filgrastim
DML6OE7	MI	TTC70AJ
DML6OE7	MN	Granulocyte colony-stimulating factor receptor (G-CSF-R)
DML6OE7	MT	DTT
DML6OE7	MA	Modulator
DML6OE7	RN	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
DML6OE7	RU	https://pubmed.ncbi.nlm.nih.gov/23370234

DMQ5S6C	DI	DMQ5S6C
DMQ5S6C	DN	Tebipenem pivoxil
DMQ5S6C	MI	TTJP4SM
DMQ5S6C	MN	Bacterial Penicillin binding protein (Bact PBP)
DMQ5S6C	MT	DTT
DMQ5S6C	MA	Binder
DMQ5S6C	RN	In Vitro Activity of Tebipenem (SPR859) against Penicillin-Binding Proteins of Gram-Negative and Gram-Positive Bacteria. Antimicrob Agents Chemother. 2019 Mar 27;63(4):e02181-18.
DMQ5S6C	RU	https://pubmed.ncbi.nlm.nih.gov/30718255

DMYQCWT	DI	DMYQCWT
DMYQCWT	DN	Tecartus
DMYQCWT	MI	TTW640A
DMYQCWT	MN	B-lymphocyte surface antigen B4 (CD19)
DMYQCWT	MT	DTT
DMYQCWT	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services.
DMYQCWT	RU	https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/tecartus-brexucabtagene-autoleucel

DM2OVDT	DI	DM2OVDT
DM2OVDT	DN	Tecfidera
DM2OVDT	MI	TTK3Q4W
DM2OVDT	MN	NFE2-related factor 2 pathway (Nrf2 pathway)
DM2OVDT	MT	DTT
DM2OVDT	MA	Inhibitor
DM2OVDT	RN	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
DM2OVDT	RU	https://pubmed.ncbi.nlm.nih.gov/28919714

DMUEWM3	DI	DMUEWM3
DMUEWM3	DN	Technetium (99MTC) mebrofenin
DMUEWM3	MI	DTFI42L
DMUEWM3	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMUEWM3	MT	DTP
DMUEWM3	MA	Substrate
DMUEWM3	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMUEWM3	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMUEWM3	DI	DMUEWM3
DMUEWM3	DN	Technetium (99MTC) mebrofenin
DMUEWM3	MI	DTQ3ZHF
DMUEWM3	MN	Multidrug resistance-associated protein 3 (ABCC3)
DMUEWM3	MT	DTP
DMUEWM3	MA	Substrate
DMUEWM3	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMUEWM3	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMUEWM3	DI	DMUEWM3
DMUEWM3	DN	Technetium (99MTC) mebrofenin
DMUEWM3	MI	DT3D8F0
DMUEWM3	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMUEWM3	MT	DTP
DMUEWM3	MA	Substrate
DMUEWM3	RN	Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium. Clin Pharmacol Ther. 2018 Nov;104(5):900-915.
DMUEWM3	RU	http://www.ncbi.nlm.nih.gov/pubmed/29756222

DMUEWM3	DI	DMUEWM3
DMUEWM3	DN	Technetium (99MTC) mebrofenin
DMUEWM3	MI	DT9C1TS
DMUEWM3	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMUEWM3	MT	DTP
DMUEWM3	MA	Substrate
DMUEWM3	RN	Transporters involved in the hepatic uptake of (99m)Tc-mebrofenin and indocyanine green. J Hepatol. 2011 Apr;54(4):738-45.
DMUEWM3	RU	http://www.ncbi.nlm.nih.gov/pubmed/21163547

DMW5ML9	DI	DMW5ML9
DMW5ML9	DN	Tecovirimat 
DMW5ML9	MI	TTG7UOF
DMW5ML9	MN	Variola virus Envelope phospholipase F13 (VARV p37)
DMW5ML9	MT	DTT
DMW5ML9	MA	Inhibitor
DMW5ML9	RN	Tecovirimat, a p37 envelope protein inhibitor for the treatment of smallpox infection.IDrugs. 2010 Mar;13(3):181-91. Review
DMW5ML9	RU	https://pubmed.ncbi.nlm.nih.gov/20191435

DMG2SKR	DI	DMG2SKR
DMG2SKR	DN	Tedizolid
DMG2SKR	MI	TTUWYEA
DMG2SKR	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DMG2SKR	MT	DTT
DMG2SKR	MA	Modulator
DMG2SKR	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMG2SKR	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMYOAKS	DI	DMYOAKS
DMYOAKS	DN	Teduglutide
DMYOAKS	MI	TT1YWO5
DMYOAKS	MN	Glucagon-like peptide 2 receptor (GLP2R)
DMYOAKS	MT	DTT
DMYOAKS	MA	Modulator
DMYOAKS	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMYOAKS	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM31ZQM	DI	DM31ZQM
DM31ZQM	DN	Tegafur
DM31ZQM	MI	DEJGDUW
DM31ZQM	MN	Cytochrome P450 1A2 (CYP1A2)
DM31ZQM	MT	DME
DM31ZQM	MA	Metabolism
DM31ZQM	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM31ZQM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM31ZQM	DI	DM31ZQM
DM31ZQM	DN	Tegafur
DM31ZQM	MI	DEJVYAZ
DM31ZQM	MN	Cytochrome P450 2A6 (CYP2A6)
DM31ZQM	MT	DME
DM31ZQM	MA	Metabolism
DM31ZQM	RN	Rapid development of S-1 in the west for therapy of advanced gastric carcinoma. Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:117-20.
DM31ZQM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16897985

DM31ZQM	DI	DM31ZQM
DM31ZQM	DN	Tegafur
DM31ZQM	MI	DES5XRU
DM31ZQM	MN	Cytochrome P450 2C8 (CYP2C8)
DM31ZQM	MT	DME
DM31ZQM	MA	Metabolism
DM31ZQM	RN	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
DM31ZQM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11095583

DM31ZQM	DI	DM31ZQM
DM31ZQM	DN	Tegafur
DM31ZQM	MI	DEVDYN7
DM31ZQM	MN	Cytochrome P450 2E1 (CYP2E1)
DM31ZQM	MT	DME
DM31ZQM	MA	Metabolism
DM31ZQM	RN	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
DM31ZQM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11095583

DM31ZQM	DI	DM31ZQM
DM31ZQM	DN	Tegafur
DM31ZQM	MI	DEIBDNY
DM31ZQM	MN	Cytochrome P450 3A5 (CYP3A5)
DM31ZQM	MT	DME
DM31ZQM	MA	Metabolism
DM31ZQM	RN	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
DM31ZQM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11095583

DM3XYD1	DI	DM3XYD1
DM3XYD1	DN	Tegaserod
DM3XYD1	MI	TT07C3Y
DM3XYD1	MN	5-HT 4 receptor (HTR4)
DM3XYD1	MT	DTT
DM3XYD1	MA	Agonist
DM3XYD1	RN	Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
DM3XYD1	RU	https://pubmed.ncbi.nlm.nih.gov/16634703

DM3XYD1	DI	DM3XYD1
DM3XYD1	DN	Tegaserod
DM3XYD1	MI	DECB0K3
DM3XYD1	MN	Cytochrome P450 2D6 (CYP2D6)
DM3XYD1	MT	DME
DM3XYD1	MA	Metabolism
DM3XYD1	RN	In vitro metabolism of tegaserod in human liver and intestine: assessment of drug interactions. Drug Metab Dispos. 2001 Oct;29(10):1269-76.
DM3XYD1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11560869

DMAQ2LK	DI	DMAQ2LK
DMAQ2LK	DN	Teicoplanin
DMAQ2LK	MI	TTXT4D5
DMAQ2LK	MN	Bacterial Cell membrane (Bact CM)
DMAQ2LK	MT	DTT
DMAQ2LK	MA	Inhibitor
DMAQ2LK	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMAQ2LK	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMAQ2LK	DI	DMAQ2LK
DMAQ2LK	DN	Teicoplanin
DMAQ2LK	MI	DEYWLRK
DMAQ2LK	MN	Sulfotransferase 1A1 (SULT1A1)
DMAQ2LK	MT	DME
DMAQ2LK	MA	Metabolism
DMAQ2LK	RN	The 2.7 A resolution structure of the glycopeptide sulfotransferase Teg14. Acta Crystallogr D Biol Crystallogr. 2010 Dec;66(Pt 12):1278-86.
DMAQ2LK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21123867

DMAQ2LK	DI	DMAQ2LK
DMAQ2LK	DN	Teicoplanin
DMAQ2LK	MI	DEOFMQ7
DMAQ2LK	MN	VanA ligase (vanA)
DMAQ2LK	MT	DME
DMAQ2LK	MA	Metabolism
DMAQ2LK	RN	Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother. 1993 Aug;37(8):1563-71.
DMAQ2LK	RU	https://pubmed.ncbi.nlm.nih.gov/8215264

DMAQ2LK	DI	DMAQ2LK
DMAQ2LK	DN	Teicoplanin
DMAQ2LK	MI	DEO97D6
DMAQ2LK	MN	VanA ligase (vanA)
DMAQ2LK	MT	DME
DMAQ2LK	MA	Metabolism
DMAQ2LK	RN	Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother. 1993 Aug;37(8):1563-71.
DMAQ2LK	RU	https://pubmed.ncbi.nlm.nih.gov/8215264

DMAQ2LK	DI	DMAQ2LK
DMAQ2LK	DN	Teicoplanin
DMAQ2LK	MI	DEO8E75
DMAQ2LK	MN	VanA ligase (vanA)
DMAQ2LK	MT	DME
DMAQ2LK	MA	Metabolism
DMAQ2LK	RN	Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother. 1993 Aug;37(8):1563-71.
DMAQ2LK	RU	https://pubmed.ncbi.nlm.nih.gov/8215264

DMAQ2LK	DI	DMAQ2LK
DMAQ2LK	DN	Teicoplanin
DMAQ2LK	MI	DEN6VO0
DMAQ2LK	MN	VanA ligase (vanA)
DMAQ2LK	MT	DME
DMAQ2LK	MA	Metabolism
DMAQ2LK	RN	Emergence of high-level resistance to glycopeptides in Enterococcus gallinarum and Enterococcus casseliflavus. Antimicrob Agents Chemother. 1994 Jul;38(7):1675-7.
DMAQ2LK	RU	https://pubmed.ncbi.nlm.nih.gov/7979308

DMAQ2LK	DI	DMAQ2LK
DMAQ2LK	DN	Teicoplanin
DMAQ2LK	MI	DESOXHP
DMAQ2LK	MN	VanA ligase (vanA)
DMAQ2LK	MT	DME
DMAQ2LK	MA	Metabolism
DMAQ2LK	RN	vanA in Enterococcus faecium, Enterococcus faecalis, and Enterococcus casseliflavus detected in French cattle. Foodborne Pathog Dis. 2009 Nov;6(9):1107-11.
DMAQ2LK	RU	https://pubmed.ncbi.nlm.nih.gov/19694552

DMMRV29	DI	DMMRV29
DMMRV29	DN	Telaprevir
DMMRV29	MI	DE4LYSA
DMMRV29	MN	Cytochrome P450 3A4 (CYP3A4)
DMMRV29	MT	DME
DMMRV29	MA	Metabolism
DMMRV29	RN	Managing drug-drug interactions with boceprevir and telaprevir. Clin Liver Dis (Hoboken). 2012 Apr 26;1(2):36-40.
DMMRV29	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31186844

DMMRV29	DI	DMMRV29
DMMRV29	DN	Telaprevir
DMMRV29	MI	TTHC7JD
DMMRV29	MN	Hepatitis C virus Serine protease NS3/4A (HCV NS3/4A)
DMMRV29	MT	DTT
DMMRV29	MA	Modulator
DMMRV29	RN	2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
DMMRV29	RU	https://pubmed.ncbi.nlm.nih.gov/22293555

DMMRV29	DI	DMMRV29
DMMRV29	DN	Telaprevir
DMMRV29	MI	DTUGYRD
DMMRV29	MN	P-glycoprotein 1 (ABCB1)
DMMRV29	MT	DTP
DMMRV29	MA	Substrate
DMMRV29	RN	Drug interactions and protease inhibitors used in the treatment of hepatitis C: how to manage? Eur J Clin Pharmacol. 2014 Jul;70(7):775-89.
DMMRV29	RU	http://www.ncbi.nlm.nih.gov/pubmed/24817413

DM58VQX	DI	DM58VQX
DM58VQX	DN	Telavancin
DM58VQX	MI	TT7EFHR
DM58VQX	MN	Corticotropin-releasing factor receptor 1 (CRHR1)
DM58VQX	MT	DTT
DM58VQX	MA	Antagonist
DM58VQX	RN	A review of drug options in age-related macular degeneration therapy and potential new agents. Expert Opin Pharmacother. 2006 Dec;7(17):2355-68.
DM58VQX	RU	https://pubmed.ncbi.nlm.nih.gov/17109611

DMSWUGE	DI	DMSWUGE
DMSWUGE	DN	Telbivudine
DMSWUGE	MI	TTT4SY6
DMSWUGE	MN	Hepatitis B virus Polymerase (HBV P)
DMSWUGE	MT	DTT
DMSWUGE	MA	Inhibitor
DMSWUGE	RN	Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success. Best Pract Res Clin Gastroenterol. 2008;22(6):1081-92.
DMSWUGE	RU	https://pubmed.ncbi.nlm.nih.gov/19187868

DMZ4P3A	DI	DMZ4P3A
DMZ4P3A	DN	Telithromycin
DMZ4P3A	MI	TTUWYEA
DMZ4P3A	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DMZ4P3A	MT	DTT
DMZ4P3A	MA	Binder
DMZ4P3A	RN	An examination of the differential sensitivity to ketolide antibiotics in ermB strains of Streptococcus pyogenes and Streptococcus pneumoniae. Curr Microbiol. 2004 Oct;49(4):239-47.
DMZ4P3A	RU	https://pubmed.ncbi.nlm.nih.gov/15386111

DMZ4P3A	DI	DMZ4P3A
DMZ4P3A	DN	Telithromycin
DMZ4P3A	MI	DE4LYSA
DMZ4P3A	MN	Cytochrome P450 3A4 (CYP3A4)
DMZ4P3A	MT	DME
DMZ4P3A	MA	Metabolism
DMZ4P3A	RN	Drug interactions during therapy with three major groups of antimicrobial agents. Expert Opin Pharmacother. 2006 Apr;7(6):639-51.
DMZ4P3A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16556082

DMZ4P3A	DI	DMZ4P3A
DMZ4P3A	DN	Telithromycin
DMZ4P3A	MI	DEIBDNY
DMZ4P3A	MN	Cytochrome P450 3A5 (CYP3A5)
DMZ4P3A	MT	DME
DMZ4P3A	MA	Metabolism
DMZ4P3A	RN	Verapamil toxicity resulting from a probable interaction with telithromycin. Ann Pharmacother. 2005 Feb;39(2):357-60.
DMZ4P3A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15598962

DMZ4P3A	DI	DMZ4P3A
DMZ4P3A	DN	Telithromycin
DMZ4P3A	MI	DTFI42L
DMZ4P3A	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMZ4P3A	MT	DTP
DMZ4P3A	MA	Substrate
DMZ4P3A	RN	Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
DMZ4P3A	RU	http://www.ncbi.nlm.nih.gov/pubmed/16377671

DMZ4P3A	DI	DMZ4P3A
DMZ4P3A	DN	Telithromycin
DMZ4P3A	MI	DTUGYRD
DMZ4P3A	MN	P-glycoprotein 1 (ABCB1)
DMZ4P3A	MT	DTP
DMZ4P3A	MA	Substrate
DMZ4P3A	RN	Differences in assessment of macrolide interaction with human MDR1 (ABCB1, P-gp) using rhodamine-123 efflux, ATPase activity and cellular accumulation assays. Eur J Pharm Sci. 2010 Sep 11;41(1):86-95.
DMZ4P3A	RU	https://doi.org/10.1016/j.ejps.2010.05.016

DMS3GX2	DI	DMS3GX2
DMS3GX2	DN	Telmisartan
DMS3GX2	MI	TT8DBY3
DMS3GX2	MN	Angiotensin II receptor type-1 (AGTR1)
DMS3GX2	MT	DTT
DMS3GX2	MA	Antagonist
DMS3GX2	RN	Deletion of angiotensin II type I receptor reduces hepatic steatosis. J Hepatol. 2009 Jun;50(6):1226-35.
DMS3GX2	RU	https://pubmed.ncbi.nlm.nih.gov/19395110

DMS3GX2	DI	DMS3GX2
DMS3GX2	DN	Telmisartan
DMS3GX2	MI	DTE2B1D
DMS3GX2	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMS3GX2	MT	DTP
DMS3GX2	MA	Substrate
DMS3GX2	RN	Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab Dispos. 2006 Jul;34(7):1109-15.
DMS3GX2	RU	http://www.ncbi.nlm.nih.gov/pubmed/16611857

DMS3GX2	DI	DMS3GX2
DMS3GX2	DN	Telmisartan
DMS3GX2	MI	DT9C1TS
DMS3GX2	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMS3GX2	MT	DTP
DMS3GX2	MA	Substrate
DMS3GX2	RN	Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab Dispos. 2006 Jul;34(7):1109-15.
DMS3GX2	RU	http://www.ncbi.nlm.nih.gov/pubmed/16611857

DMS3GX2	DI	DMS3GX2
DMS3GX2	DN	Telmisartan
DMS3GX2	MI	DTPFTEQ
DMS3GX2	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DMS3GX2	MT	DTP
DMS3GX2	MA	Substrate
DMS3GX2	RN	Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide. Drug Metab Dispos. 2008 Apr;36(4):796-805.
DMS3GX2	RU	http://www.ncbi.nlm.nih.gov/pubmed/18180273

DMS3GX2	DI	DMS3GX2
DMS3GX2	DN	Telmisartan
DMS3GX2	MI	DEYGVN4
DMS3GX2	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMS3GX2	MT	DME
DMS3GX2	MA	Metabolism
DMS3GX2	RN	The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers. Pharmacogenet Genomics. 2011 Sep;21(9):523-30.
DMS3GX2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21829131

DMS3GX2	DI	DMS3GX2
DMS3GX2	DN	Telmisartan
DMS3GX2	MI	DEF2WXN
DMS3GX2	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMS3GX2	MT	DME
DMS3GX2	MA	Metabolism
DMS3GX2	RN	Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin. Drug Metab Dispos. 2012 Apr;40(4):825-35.
DMS3GX2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22275465

DMDIYFZ	DI	DMDIYFZ
DMDIYFZ	DN	Telotristat ethyl
DMDIYFZ	MI	TTDJBV3
DMDIYFZ	MN	Tryptophan hydroxylase (TPH)
DMDIYFZ	MT	DTT
DMDIYFZ	MA	Modulator
DMDIYFZ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMDIYFZ	RU	https://www.fda.gov/

DM02A65	DI	DM02A65
DM02A65	DN	Temazepam
DM02A65	MI	DEPKLMQ
DM02A65	MN	Cytochrome P450 2B6 (CYP2B6)
DM02A65	MT	DME
DM02A65	MA	Metabolism
DM02A65	RN	Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica. 1996 Nov;26(11):1155-66.
DM02A65	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8948091

DM02A65	DI	DM02A65
DM02A65	DN	Temazepam
DM02A65	MI	DES5XRU
DM02A65	MN	Cytochrome P450 2C8 (CYP2C8)
DM02A65	MT	DME
DM02A65	MA	Metabolism
DM02A65	RN	Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica. 1996 Nov;26(11):1155-66.
DM02A65	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8948091

DM02A65	DI	DM02A65
DM02A65	DN	Temazepam
DM02A65	MI	DE5IED8
DM02A65	MN	Cytochrome P450 2C9 (CYP2C9)
DM02A65	MT	DME
DM02A65	MA	Metabolism
DM02A65	RN	Role of cDNA-expressed human cytochromes P450 in the metabolism of diazepam. Biochem Pharmacol. 1998 Mar 15;55(6):889-96.
DM02A65	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9586962

DM02A65	DI	DM02A65
DM02A65	DN	Temazepam
DM02A65	MI	DE4LYSA
DM02A65	MN	Cytochrome P450 3A4 (CYP3A4)
DM02A65	MT	DME
DM02A65	MA	Metabolism
DM02A65	RN	Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica. 1996 Nov;26(11):1155-66.
DM02A65	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8948091

DM02A65	DI	DM02A65
DM02A65	DN	Temazepam
DM02A65	MI	DEGTFWK
DM02A65	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM02A65	MT	DME
DM02A65	MA	Metabolism
DM02A65	RN	Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica. 1996 Nov;26(11):1155-66.
DM02A65	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8948091

DM02A65	DI	DM02A65
DM02A65	DN	Temazepam
DM02A65	MI	TTPTXIN
DM02A65	MN	Translocator protein (TSPO)
DM02A65	MT	DTT
DM02A65	MA	Modulator
DM02A65	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM02A65	RU	https://www.fda.gov/

DM1A79H	DI	DM1A79H
DM1A79H	DN	Temocapril
DM1A79H	MI	DT3D8F0
DM1A79H	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM1A79H	MT	DTP
DM1A79H	MA	Substrate
DM1A79H	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DM1A79H	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DM1A79H	DI	DM1A79H
DM1A79H	DN	Temocapril
DM1A79H	MI	DT9G7XN
DM1A79H	MN	Peptide transporter 1 (SLC15A1)
DM1A79H	MT	DTP
DM1A79H	MA	Substrate
DM1A79H	RN	The role of transporters in drug interactions. Eur J Pharm Sci. 2006 Apr;27(5):501-17.
DM1A79H	RU	https://doi.org/10.1016/j.ejps.2005.11.002

DM0JXFL	DI	DM0JXFL
DM0JXFL	DN	Temocapril hydrochloride
DM0JXFL	MI	TTL69WB
DM0JXFL	MN	Angiotensin-converting enzyme (ACE)
DM0JXFL	MT	DTT
DM0JXFL	MA	Modulator
DM0JXFL	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DM0JXFL	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DMNX2QI	DI	DMNX2QI
DMNX2QI	DN	Temocaprilate
DMNX2QI	MI	DTFI42L
DMNX2QI	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMNX2QI	MT	DTP
DMNX2QI	MA	Substrate
DMNX2QI	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMNX2QI	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMNX2QI	DI	DMNX2QI
DMNX2QI	DN	Temocaprilate
DMNX2QI	MI	DTFI42L
DMNX2QI	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMNX2QI	MT	DTP
DMNX2QI	MA	Substrate
DMNX2QI	RN	Pharmacogenetics of membrane transporters: an update on current approaches. Mol Biotechnol. 2010 Feb;44(2):152-67.
DMNX2QI	RU	https://doi.org/10.1007/s12033-009-9220-6

DMNX2QI	DI	DMNX2QI
DMNX2QI	DN	Temocaprilate
DMNX2QI	MI	DT9G7XN
DMNX2QI	MN	Peptide transporter 1 (SLC15A1)
DMNX2QI	MT	DTP
DMNX2QI	MA	Substrate
DMNX2QI	RN	Transporter-mediated Drug Interactions. Drug Metab Pharmacokinet. 2002;17(4):253-74.
DMNX2QI	RU	https://doi.org/10.2133/dmpk.17.253

DMKECZD	DI	DMKECZD
DMKECZD	DN	Temozolomide
DMKECZD	MI	TTUTN1I
DMKECZD	MN	Human Deoxyribonucleic acid (hDNA)
DMKECZD	MT	DTT
DMKECZD	MA	Modulator
DMKECZD	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMKECZD	RU	https://www.fda.gov/

DMS104F	DI	DMS104F
DMS104F	DN	Temsirolimus
DMS104F	MI	DE4LYSA
DMS104F	MN	Cytochrome P450 3A4 (CYP3A4)
DMS104F	MT	DME
DMS104F	MA	Metabolism
DMS104F	RN	Drug Interactions Flockhart Table
DMS104F	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMS104F	DI	DMS104F
DMS104F	DN	Temsirolimus
DMS104F	MI	DEIBDNY
DMS104F	MN	Cytochrome P450 3A5 (CYP3A5)
DMS104F	MT	DME
DMS104F	MA	Metabolism
DMS104F	RN	Drug Interactions Flockhart Table
DMS104F	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMS104F	DI	DMS104F
DMS104F	DN	Temsirolimus
DMS104F	MI	DERD86B
DMS104F	MN	Cytochrome P450 3A7 (CYP3A7)
DMS104F	MT	DME
DMS104F	MA	Metabolism
DMS104F	RN	Drug Interactions Flockhart Table
DMS104F	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMS104F	DI	DMS104F
DMS104F	DN	Temsirolimus
DMS104F	MI	DTUGYRD
DMS104F	MN	P-glycoprotein 1 (ABCB1)
DMS104F	MT	DTP
DMS104F	MA	Substrate
DMS104F	RN	Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer. Cancer Chemother Pharmacol. 2017 Sep;80(3):653-659.
DMS104F	RU	http://www.ncbi.nlm.nih.gov/pubmed/28676933

DMS104F	DI	DMS104F
DMS104F	DN	Temsirolimus
DMS104F	MI	TTCJG29
DMS104F	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMS104F	MT	DTT
DMS104F	MA	Inhibitor
DMS104F	RN	Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol Sci. 2014 Nov;35(11):604-20.
DMS104F	RU	https://pubmed.ncbi.nlm.nih.gov/25312588

DMCOZJY	DI	DMCOZJY
DMCOZJY	DN	Tenapanor
DMCOZJY	MI	DE4LYSA
DMCOZJY	MN	Cytochrome P450 3A4 (CYP3A4)
DMCOZJY	MT	DME
DMCOZJY	MA	Metabolism
DMCOZJY	RN	FDA label of Tenapanor. The 2020 official website of the U.S. Food and Drug Administration.
DMCOZJY	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211801s000lbl.pdf

DMCOZJY	DI	DMCOZJY
DMCOZJY	DN	Tenapanor
DMCOZJY	MI	DEIBDNY
DMCOZJY	MN	Cytochrome P450 3A5 (CYP3A5)
DMCOZJY	MT	DME
DMCOZJY	MA	Metabolism
DMCOZJY	RN	FDA label of Tenapanor. The 2020 official website of the U.S. Food and Drug Administration.
DMCOZJY	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211801s000lbl.pdf

DMCOZJY	DI	DMCOZJY
DMCOZJY	DN	Tenapanor
DMCOZJY	MI	TTFZVPO
DMCOZJY	MN	Sodium/hydrogen exchanger 3 (SLC9A3)
DMCOZJY	MT	DTT
DMCOZJY	MA	Modulator
DMCOZJY	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMCOZJY	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211801s000lbl.pdf

DMJYN25	DI	DMJYN25
DMJYN25	DN	Tenecteplase
DMJYN25	MI	TTP86E2
DMJYN25	MN	Plasminogen (PLG)
DMJYN25	MT	DTT
DMJYN25	MA	Activator
DMJYN25	RN	Thrombolytic therapies: the current state of affairs. J Endovasc Ther. 2005 Apr;12(2):224-32.
DMJYN25	RU	https://pubmed.ncbi.nlm.nih.gov/15823070

DMLW57T	DI	DMLW57T
DMLW57T	DN	Teniposide
DMLW57T	MI	DTI7UX6
DMLW57T	MN	Breast cancer resistance protein (ABCG2)
DMLW57T	MT	DTP
DMLW57T	MA	Substrate
DMLW57T	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMLW57T	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMLW57T	DI	DMLW57T
DMLW57T	DN	Teniposide
DMLW57T	MI	DE4LYSA
DMLW57T	MN	Cytochrome P450 3A4 (CYP3A4)
DMLW57T	MT	DME
DMLW57T	MA	Metabolism
DMLW57T	RN	Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes. Int J Clin Pharmacol Ther. 2001 Dec;39(12):517-28.
DMLW57T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11770832

DMLW57T	DI	DMLW57T
DMLW57T	DN	Teniposide
DMLW57T	MI	DEIBDNY
DMLW57T	MN	Cytochrome P450 3A5 (CYP3A5)
DMLW57T	MT	DME
DMLW57T	MA	Metabolism
DMLW57T	RN	O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol. 1994 Feb;45(2):352-8.
DMLW57T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8114683

DMLW57T	DI	DMLW57T
DMLW57T	DN	Teniposide
DMLW57T	MI	TT0IHXV
DMLW57T	MN	DNA topoisomerase II (TOP2)
DMLW57T	MT	DTT
DMLW57T	MA	Modulator
DMLW57T	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMLW57T	RU	https://www.fda.gov/

DMLW57T	DI	DMLW57T
DMLW57T	DN	Teniposide
DMLW57T	MI	DEGTFWK
DMLW57T	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMLW57T	MT	DME
DMLW57T	MA	Metabolism
DMLW57T	RN	Drug Interactions Flockhart Table
DMLW57T	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMLW57T	DI	DMLW57T
DMLW57T	DN	Teniposide
DMLW57T	MI	DTQ3ZHF
DMLW57T	MN	Multidrug resistance-associated protein 3 (ABCC3)
DMLW57T	MT	DTP
DMLW57T	MA	Substrate
DMLW57T	RN	Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem. 2001 Dec 7;276(49):46400-7.
DMLW57T	RU	http://www.ncbi.nlm.nih.gov/pubmed/11581266

DMLW57T	DI	DMLW57T
DMLW57T	DN	Teniposide
DMLW57T	MI	DTUGYRD
DMLW57T	MN	P-glycoprotein 1 (ABCB1)
DMLW57T	MT	DTP
DMLW57T	MA	Substrate
DMLW57T	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMLW57T	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DM1IS6U	DI	DM1IS6U
DM1IS6U	DN	Tenofovir
DM1IS6U	MI	DTI7UX6
DM1IS6U	MN	Breast cancer resistance protein (ABCG2)
DM1IS6U	MT	DTP
DM1IS6U	MA	Substrate
DM1IS6U	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01913)
DM1IS6U	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01913

DM1IS6U	DI	DM1IS6U
DM1IS6U	DN	Tenofovir
DM1IS6U	MI	TT84ETX
DM1IS6U	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM1IS6U	MT	DTT
DM1IS6U	MA	Inhibitor
DM1IS6U	RN	Antiviral drugs in current clinical use. J Clin Virol. 2004 Jun;30(2):115-33.
DM1IS6U	RU	https://pubmed.ncbi.nlm.nih.gov/15125867

DM1IS6U	DI	DM1IS6U
DM1IS6U	DN	Tenofovir
DM1IS6U	MI	DTCSGPB
DM1IS6U	MN	Multidrug resistance-associated protein 4 (ABCC4)
DM1IS6U	MT	DTP
DM1IS6U	MA	Substrate
DM1IS6U	RN	Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol. 2007 Feb;71(2):619-27.
DM1IS6U	RU	http://www.ncbi.nlm.nih.gov/pubmed/17110501

DM1IS6U	DI	DM1IS6U
DM1IS6U	DN	Tenofovir
DM1IS6U	MI	DTPS120
DM1IS6U	MN	Multidrug resistance-associated protein 7 (ABCC10)
DM1IS6U	MT	DTP
DM1IS6U	MA	Substrate
DM1IS6U	RN	Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. J Infect Dis. 2011 Jul 1;204(1):145-53.
DM1IS6U	RU	http://www.ncbi.nlm.nih.gov/pubmed/21628669

DM1IS6U	DI	DM1IS6U
DM1IS6U	DN	Tenofovir
DM1IS6U	MI	DTWN7FC
DM1IS6U	MN	Multidrug resistance-associated protein 8 (ABCC11)
DM1IS6U	MT	DTP
DM1IS6U	MA	Substrate
DM1IS6U	RN	Tenofovir Disoproxil Fumarate Is a New Substrate of ATP-Binding Cassette Subfamily C Member 11. Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e01725-16.
DM1IS6U	RU	http://www.ncbi.nlm.nih.gov/pubmed/28167562

DM1IS6U	DI	DM1IS6U
DM1IS6U	DN	Tenofovir
DM1IS6U	MI	DTQ23VB
DM1IS6U	MN	Organic anion transporter 1 (SLC22A6)
DM1IS6U	MT	DTP
DM1IS6U	MA	Substrate
DM1IS6U	RN	Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids. 2001 Apr-Jul;20(4-7):641-8.
DM1IS6U	RU	http://www.ncbi.nlm.nih.gov/pubmed/11563082

DM1IS6U	DI	DM1IS6U
DM1IS6U	DN	Tenofovir
DM1IS6U	MI	DTVP67E
DM1IS6U	MN	Organic anion transporter 3 (SLC22A8)
DM1IS6U	MT	DTP
DM1IS6U	MA	Substrate
DM1IS6U	RN	Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity. Antivir Ther. 2014;19(7):687-92.
DM1IS6U	RU	http://www.ncbi.nlm.nih.gov/pubmed/24699134

DM1IS6U	DI	DM1IS6U
DM1IS6U	DN	Tenofovir
DM1IS6U	MI	DTUGYRD
DM1IS6U	MN	P-glycoprotein 1 (ABCB1)
DM1IS6U	MT	DTP
DM1IS6U	MA	Substrate
DM1IS6U	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
DM1IS6U	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01665

DMTQF4A	DI	DMTQF4A
DMTQF4A	DN	Tenofovir alafenamide
DMTQF4A	MI	DE14JZK
DMTQF4A	MN	Cathepsin A (CTSA)
DMTQF4A	MT	DME
DMTQF4A	MA	Metabolism
DMTQF4A	RN	Bictegravir/Emtricitabine/Tenofovir Alafenamide: a review in HIV-1 infection. Drugs. 2018 Nov;78(17):1817-1828.
DMTQF4A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30460547

DMTQF4A	DI	DMTQF4A
DMTQF4A	DN	Tenofovir alafenamide
DMTQF4A	MI	DE4LYSA
DMTQF4A	MN	Cytochrome P450 3A4 (CYP3A4)
DMTQF4A	MT	DME
DMTQF4A	MA	Metabolism
DMTQF4A	RN	FDA label of Bictegravir, emtricitabine, and tenofovir alafenamide. The 2020 official website of the U.S. Food and Drug Administration.
DMTQF4A	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210251s000lbl.pdf

DMSY4ZG	DI	DMSY4ZG
DMSY4ZG	DN	Tenofovir disoproxil fumarate
DMSY4ZG	MI	DE4LYSA
DMSY4ZG	MN	Cytochrome P450 3A4 (CYP3A4)
DMSY4ZG	MT	DME
DMSY4ZG	MA	Metabolism
DMSY4ZG	RN	FDA label of Bictegravir, emtricitabine, and tenofovir alafenamide. The 2020 official website of the U.S. Food and Drug Administration.
DMSY4ZG	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210251s000lbl.pdf

DMSY4ZG	DI	DMSY4ZG
DMSY4ZG	DN	Tenofovir disoproxil fumarate
DMSY4ZG	MI	TT84ETX
DMSY4ZG	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMSY4ZG	MT	DTT
DMSY4ZG	MA	Modulator
DMSY4ZG	RN	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
DMSY4ZG	RU	https://pubmed.ncbi.nlm.nih.gov/23370234

DMVAZP9	DI	DMVAZP9
DMVAZP9	DN	Tenoxicam
DMVAZP9	MI	DE5IED8
DMVAZP9	MN	Cytochrome P450 2C9 (CYP2C9)
DMVAZP9	MT	DME
DMVAZP9	MA	Metabolism
DMVAZP9	RN	CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. Clin Pharmacol Ther. 2004 Jul;76(1):18-26.
DMVAZP9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15229460

DMVAZP9	DI	DMVAZP9
DMVAZP9	DN	Tenoxicam
DMVAZP9	MI	DTUGYRD
DMVAZP9	MN	P-glycoprotein 1 (ABCB1)
DMVAZP9	MT	DTP
DMVAZP9	MA	Substrate
DMVAZP9	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMVAZP9	RU	https://doi.org/10.1007/s11095-012-0935-x

DMVAZP9	DI	DMVAZP9
DMVAZP9	DN	Tenoxicam
DMVAZP9	MI	TTVKILB
DMVAZP9	MN	Prostaglandin G/H synthase 2 (COX-2)
DMVAZP9	MT	DTT
DMVAZP9	MA	Inhibitor
DMVAZP9	RN	The use and safety profile of non-steroidal antiinflammatory drugs among Turkish patients with osteoarthritis. Turk J Gastroenterol. 2005 Sep;16(3):138-42.
DMVAZP9	RU	https://pubmed.ncbi.nlm.nih.gov/16245223

DMUQ0E8	DI	DMUQ0E8
DMUQ0E8	DN	Tepotinib
DMUQ0E8	MI	TTNDSF4
DMUQ0E8	MN	Proto-oncogene c-Met (MET)
DMUQ0E8	MT	DTT
DMUQ0E8	MA	Modulator
DMUQ0E8	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2021
DMUQ0E8	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214096s000lbl.pdf

DM4L59B	DI	DM4L59B
DM4L59B	DN	Teprotumumab
DM4L59B	MI	TTHRID2
DM4L59B	MN	Insulin-like growth factor I receptor (IGF1R)
DM4L59B	MT	DTT
DM4L59B	MA	Antagonist
DM4L59B	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DM4L59B	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761143s000lbl.pdf

DM3JCVS	DI	DM3JCVS
DM3JCVS	DN	Terazosin
DM3JCVS	MI	TT34BHT
DM3JCVS	MN	Adrenergic receptor alpha-1D (ADRA1D)
DM3JCVS	MT	DTT
DM3JCVS	MA	Antagonist
DM3JCVS	RN	Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component. Prostate Cancer Prostatic Dis. 2002;5(2):88-95.
DM3JCVS	RU	https://pubmed.ncbi.nlm.nih.gov/12496995

DMI6HUW	DI	DMI6HUW
DMI6HUW	DN	Terbinafine
DMI6HUW	MI	TTM9XSU
DMI6HUW	MN	Candida Squalene epoxidase (Candi ERG1)
DMI6HUW	MT	DTT
DMI6HUW	MA	Modulator
DMI6HUW	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMI6HUW	RU	https://www.fda.gov/

DMI6HUW	DI	DMI6HUW
DMI6HUW	DN	Terbinafine
DMI6HUW	MI	DEJGDUW
DMI6HUW	MN	Cytochrome P450 1A2 (CYP1A2)
DMI6HUW	MT	DME
DMI6HUW	MA	Metabolism
DMI6HUW	RN	Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. Drug Metab Dispos. 1999 Sep;27(9):1029-38.
DMI6HUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10460803

DMI6HUW	DI	DMI6HUW
DMI6HUW	DN	Terbinafine
DMI6HUW	MI	DES5XRU
DMI6HUW	MN	Cytochrome P450 2C8 (CYP2C8)
DMI6HUW	MT	DME
DMI6HUW	MA	Metabolism
DMI6HUW	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMI6HUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMI6HUW	DI	DMI6HUW
DMI6HUW	DN	Terbinafine
DMI6HUW	MI	DE5IED8
DMI6HUW	MN	Cytochrome P450 2C9 (CYP2C9)
DMI6HUW	MT	DME
DMI6HUW	MA	Metabolism
DMI6HUW	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMI6HUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMI6HUW	DI	DMI6HUW
DMI6HUW	DN	Terbinafine
DMI6HUW	MI	DE4LYSA
DMI6HUW	MN	Cytochrome P450 3A4 (CYP3A4)
DMI6HUW	MT	DME
DMI6HUW	MA	Metabolism
DMI6HUW	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMI6HUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMI6HUW	DI	DMI6HUW
DMI6HUW	DN	Terbinafine
DMI6HUW	MI	DEGTFWK
DMI6HUW	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMI6HUW	MT	DME
DMI6HUW	MA	Metabolism
DMI6HUW	RN	Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. Drug Metab Dispos. 1999 Sep;27(9):1029-38.
DMI6HUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10460803

DMI6HUW	DI	DMI6HUW
DMI6HUW	DN	Terbinafine
DMI6HUW	MI	DE073H6
DMI6HUW	MN	Prostaglandin G/H synthase 1 (COX-1)
DMI6HUW	MT	DME
DMI6HUW	MA	Metabolism
DMI6HUW	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMI6HUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMD4381	DI	DMD4381
DMD4381	DN	Terbutaline
DMD4381	MI	TT2CJVK
DMD4381	MN	Adrenergic receptor beta-2 (ADRB2)
DMD4381	MT	DTT
DMD4381	MA	Agonist
DMD4381	RN	Evaluation of a new oral beta2-adrenoceptor stimulant bronchodilator, terbutaline. Pharmacology. 1975;13(3):201-11.
DMD4381	RU	https://pubmed.ncbi.nlm.nih.gov/239414

DMD4381	DI	DMD4381
DMD4381	DN	Terbutaline
DMD4381	MI	DTT79CX
DMD4381	MN	Organic cation transporter 1 (SLC22A1)
DMD4381	MT	DTP
DMD4381	MA	Substrate
DMD4381	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMD4381	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DMVPWLZ	DI	DMVPWLZ
DMVPWLZ	DN	Terbutyline
DMVPWLZ	MI	TTVIREA
DMVPWLZ	MN	Adrenergic receptor (ADR)
DMVPWLZ	MT	DTT
DMVPWLZ	MA	Modulator
DMVPWLZ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMVPWLZ	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMJ13KI	DI	DMJ13KI
DMJ13KI	DN	Terconazole
DMJ13KI	MI	TTTSOUD
DMJ13KI	MN	Candida Cytochrome P450 51 (Candi ERG11)
DMJ13KI	MT	DTT
DMJ13KI	MA	Inhibitor
DMJ13KI	RN	Mode of action of anti-Candida drugs: focus on terconazole and other ergosterol biosynthesis inhibitors. Am J Obstet Gynecol. 1991 Oct;165(4 Pt 2):1193-9.
DMJ13KI	RU	https://pubmed.ncbi.nlm.nih.gov/1951574

DMQ2FKJ	DI	DMQ2FKJ
DMQ2FKJ	DN	Teriflunomide
DMQ2FKJ	MI	DTI7UX6
DMQ2FKJ	MN	Breast cancer resistance protein (ABCG2)
DMQ2FKJ	MT	DTP
DMQ2FKJ	MA	Substrate
DMQ2FKJ	RN	MDR-ABC transporters: biomarkers in rheumatoid arthritis. Clin Exp Rheumatol. 2013 Sep-Oct;31(5):779-87.
DMQ2FKJ	RU	http://www.ncbi.nlm.nih.gov/pubmed/23711386

DMQ2FKJ	DI	DMQ2FKJ
DMQ2FKJ	DN	Teriflunomide
DMQ2FKJ	MI	TTLVP78
DMQ2FKJ	MN	Dihydroorotate dehydrogenase (DHODH)
DMQ2FKJ	MT	DTT
DMQ2FKJ	MA	Modulator
DMQ2FKJ	RN	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
DMQ2FKJ	RU	https://pubmed.ncbi.nlm.nih.gov/23370234

DMQ2FKJ	DI	DMQ2FKJ
DMQ2FKJ	DN	Teriflunomide
DMQ2FKJ	MI	TTPADOQ
DMQ2FKJ	MN	HMG-CoA reductase (HMGCR)
DMQ2FKJ	MT	DTT
DMQ2FKJ	MA	Inhibitor
DMQ2FKJ	RN	Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
DMQ2FKJ	RU	https://pubmed.ncbi.nlm.nih.gov/16503827

DMQ2FKJ	DI	DMQ2FKJ
DMQ2FKJ	DN	Teriflunomide
DMQ2FKJ	MI	TT3PQ2Y
DMQ2FKJ	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DMQ2FKJ	MT	DTT
DMQ2FKJ	MA	Inhibitor
DMQ2FKJ	RN	Expression and characterization of E. coli-produced soluble, functional human dihydroorotate dehydrogenase: a potential target for immunosuppression. J Mol Microbiol Biotechnol. 1999 Aug;1(1):183-8.
DMQ2FKJ	RU	https://pubmed.ncbi.nlm.nih.gov/10941801

DMMC45B	DI	DMMC45B
DMMC45B	DN	Teriparatide
DMMC45B	MI	TT6F7GZ
DMMC45B	MN	Parathyroid hormone (PTH)
DMMC45B	MT	DTT
DMMC45B	MA	Modulator
DMMC45B	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMMC45B	RU	https://www.fda.gov/

DMT9FH3	DI	DMT9FH3
DMT9FH3	DN	Terlipressin
DMT9FH3	MI	TT4TFGN
DMT9FH3	MN	Vasopressin V1a receptor (V1AR)
DMT9FH3	MT	DTT
DMT9FH3	MA	Stimulator
DMT9FH3	RN	Investigational vasopressin receptor modulators in the pipeline. Expert Opin Investig Drugs. 2009 Aug;18(8):1119-31.
DMT9FH3	RU	https://pubmed.ncbi.nlm.nih.gov/19589090

DM2L3D5	DI	DM2L3D5
DM2L3D5	DN	Tertatolol
DM2L3D5	MI	TTSQIFT
DM2L3D5	MN	5-HT 1A receptor (HTR1A)
DM2L3D5	MT	DTT
DM2L3D5	MA	Inhibitor
DM2L3D5	RN	Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993).
DM2L3D5	RU	http://www.sciencedirect.com/science/article/pii/S0960894X0181009X

DM2L3D5	DI	DM2L3D5
DM2L3D5	DN	Tertatolol
DM2L3D5	MI	DECB0K3
DM2L3D5	MN	Cytochrome P450 2D6 (CYP2D6)
DM2L3D5	MT	DME
DM2L3D5	MA	Metabolism
DM2L3D5	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DM2L3D5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DM9GP85	DI	DM9GP85
DM9GP85	DN	Tesamorelin
DM9GP85	MI	TTG4R8V
DM9GP85	MN	Growth hormone-releasing hormone receptor (GHRHR)
DM9GP85	MT	DTT
DM9GP85	MA	Binder
DM9GP85	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DM9GP85	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DMVY4GN	DI	DMVY4GN
DMVY4GN	DN	Testolactone
DMVY4GN	MI	TTSZLWK
DMVY4GN	MN	Aromatase (CYP19A1)
DMVY4GN	MT	DTT
DMVY4GN	MA	Inhibitor
DMVY4GN	RN	Aromatase inhibitors for male infertility. J Urol. 2002 Feb;167(2 Pt 1):624-9.
DMVY4GN	RU	https://pubmed.ncbi.nlm.nih.gov/11792932

DM7HUNW	DI	DM7HUNW
DM7HUNW	DN	Testosterone
DM7HUNW	MI	TTS64P2
DM7HUNW	MN	Androgen receptor (AR)
DM7HUNW	MT	DTT
DM7HUNW	MA	Agonist
DM7HUNW	RN	Molecular mechanism of androgen action. Trends Endocrinol Metab. 1998 Oct 1;9(8):317-24.
DM7HUNW	RU	https://pubmed.ncbi.nlm.nih.gov/18406296

DM7HUNW	DI	DM7HUNW
DM7HUNW	DN	Testosterone
DM7HUNW	MI	DTI7UX6
DM7HUNW	MN	Breast cancer resistance protein (ABCG2)
DM7HUNW	MT	DTP
DM7HUNW	MA	Substrate
DM7HUNW	RN	Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival. BJU Int. 2008 Dec;102(11):1694-9.
DM7HUNW	RU	http://www.ncbi.nlm.nih.gov/pubmed/18710444

DM7HUNW	DI	DM7HUNW
DM7HUNW	DN	Testosterone
DM7HUNW	MI	DT9C1TS
DM7HUNW	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM7HUNW	MT	DTP
DM7HUNW	MA	Substrate
DM7HUNW	RN	Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res. 2008 Jun 1;14(11):3312-8.
DM7HUNW	RU	http://www.ncbi.nlm.nih.gov/pubmed/18519758

DM7HUNW	DI	DM7HUNW
DM7HUNW	DN	Testosterone
DM7HUNW	MI	DTUGYRD
DM7HUNW	MN	P-glycoprotein 1 (ABCB1)
DM7HUNW	MT	DTP
DM7HUNW	MA	Substrate
DM7HUNW	RN	A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26.
DM7HUNW	RU	https://doi.org/10.1007/s00210-008-0345-0

DMC1TEV	DI	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	MI	DEQX145
DMC1TEV	MN	Aromatase (CYP19A1)
DMC1TEV	MT	DME
DMC1TEV	MA	Metabolism
DMC1TEV	RN	Loss of aromatase cytochrome P450 function as a risk factor for Parkinson's disease? Brain Res Rev. 2008 Mar;57(2):431-43.
DMC1TEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18063054

DMC1TEV	DI	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	MI	DEKP5HX
DMC1TEV	MN	Cholesterol 24-hydroxylase (CYP46A1)
DMC1TEV	MT	DME
DMC1TEV	MA	Metabolism
DMC1TEV	RN	Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain. Biochemistry. 2003 Dec 9;42(48):14284-92.
DMC1TEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14640697

DMC1TEV	DI	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	MI	DEHDW40
DMC1TEV	MN	Cytochrome P450 154C2 (cyp154)
DMC1TEV	MT	DME
DMC1TEV	MA	Metabolism
DMC1TEV	RN	nan
DMC1TEV	RU	nan

DMC1TEV	DI	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	MI	DE6OQ3W
DMC1TEV	MN	Cytochrome P450 1A1 (CYP1A1)
DMC1TEV	MT	DME
DMC1TEV	MA	Metabolism
DMC1TEV	RN	Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics. 2000 Aug;10(6):519-30.
DMC1TEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10975606

DMC1TEV	DI	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	MI	DE9QHP6
DMC1TEV	MN	Cytochrome P450 1B1 (CYP1B1)
DMC1TEV	MT	DME
DMC1TEV	MA	Metabolism
DMC1TEV	RN	Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis. 1999 Aug;20(8):1607-13.
DMC1TEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10426814

DMC1TEV	DI	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	MI	DEXZA9U
DMC1TEV	MN	Cytochrome P450 2A13 (CYP2A13)
DMC1TEV	MT	DME
DMC1TEV	MA	Metabolism
DMC1TEV	RN	Effects of 8-methoxypsoralen on cytochrome P450 2A13. Carcinogenesis. 2005 Mar;26(3):621-9.
DMC1TEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15579482

DMC1TEV	DI	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	MI	DEPKLMQ
DMC1TEV	MN	Cytochrome P450 2B6 (CYP2B6)
DMC1TEV	MT	DME
DMC1TEV	MA	Metabolism
DMC1TEV	RN	Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
DMC1TEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27709010

DMC1TEV	DI	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	MI	DES5XRU
DMC1TEV	MN	Cytochrome P450 2C8 (CYP2C8)
DMC1TEV	MT	DME
DMC1TEV	MA	Metabolism
DMC1TEV	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DMC1TEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DMC1TEV	DI	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	MI	DE5IED8
DMC1TEV	MN	Cytochrome P450 2C9 (CYP2C9)
DMC1TEV	MT	DME
DMC1TEV	MA	Metabolism
DMC1TEV	RN	Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7.
DMC1TEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16501008

DMC1TEV	DI	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	MI	DE4LYSA
DMC1TEV	MN	Cytochrome P450 3A4 (CYP3A4)
DMC1TEV	MT	DME
DMC1TEV	MA	Metabolism
DMC1TEV	RN	Digging deeper into CYP3A testosterone metabolism: kinetic, regioselectivity, and stereoselectivity differences between CYP3A4/5 and CYP3A7. Drug Metab Dispos. 2017 Dec;45(12):1266-1275.
DMC1TEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28986474

DMC1TEV	DI	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	MI	DEO1IE3
DMC1TEV	MN	Cytochrome P450 3A43 (CYP3A43)
DMC1TEV	MT	DME
DMC1TEV	MA	Metabolism
DMC1TEV	RN	cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol Pharmacol. 2001 Feb;59(2):386-92.
DMC1TEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11160876

DMC1TEV	DI	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	MI	DEIBDNY
DMC1TEV	MN	Cytochrome P450 3A5 (CYP3A5)
DMC1TEV	MT	DME
DMC1TEV	MA	Metabolism
DMC1TEV	RN	In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos. 2003 Jul;31(7):938-44.
DMC1TEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12814972

DMC1TEV	DI	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	MI	DERD86B
DMC1TEV	MN	Cytochrome P450 3A7 (CYP3A7)
DMC1TEV	MT	DME
DMC1TEV	MA	Metabolism
DMC1TEV	RN	Steroid hydroxylation by human fetal CYP3A7 and human NADPH-cytochrome P450 reductase coexpressed in insect cells using baculovirus. Res Commun Mol Pathol Pharmacol. 1998 Apr;100(1):15-28.
DMC1TEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9644715

DMC1TEV	DI	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	MI	DEMF740
DMC1TEV	MN	Cytochrome P450 4B1 (CYP4B1)
DMC1TEV	MT	DME
DMC1TEV	MA	Metabolism
DMC1TEV	RN	Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch Biochem Biophys. 1991 Oct;290(1):160-6.
DMC1TEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1898086

DMC1TEV	DI	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	MI	DEZ1H4L
DMC1TEV	MN	Cytochrome P450 MEG (cyp106)
DMC1TEV	MT	DME
DMC1TEV	MA	Metabolism
DMC1TEV	RN	nan
DMC1TEV	RU	nan

DMC1TEV	DI	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	MI	DEGTB1K
DMC1TEV	MN	Dehydrogenase/reductase retSDR3 (HSD17B14)
DMC1TEV	MT	DME
DMC1TEV	MA	Metabolism
DMC1TEV	RN	Expression patterns of 17beta-hydroxysteroid dehydrogenase 14 in human tissues. Horm Metab Res. 2012 Dec;44(13):949-56.
DMC1TEV	RU	https://pubmed.ncbi.nlm.nih.gov/22864907

DMC1TEV	DI	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	MI	DER0XCH
DMC1TEV	MN	Farnesol dehydrogenase (AKR1B15)
DMC1TEV	MT	DME
DMC1TEV	MA	Metabolism
DMC1TEV	RN	Aldo-keto Reductase 1B15 (AKR1B15): a mitochondrial human aldo-keto reductase with activity toward steroids and 3-keto-acyl-CoA conjugates. J Biol Chem. 2015 Mar 6;290(10):6531-45.
DMC1TEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25577493

DMC1TEV	DI	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	MI	DEGTFWK
DMC1TEV	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMC1TEV	MT	DME
DMC1TEV	MA	Metabolism
DMC1TEV	RN	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
DMC1TEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9328296

DMC1TEV	DI	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	MI	DEOG15F
DMC1TEV	MN	Steroid 5-alpha-reductase 1 (SRD5A1)
DMC1TEV	MT	DME
DMC1TEV	MA	Metabolism
DMC1TEV	RN	Molecular analysis of the SRD5A1 and SRD5A2 genes in patients with benign prostatic hyperplasia with regard to metabolic parameters and selected hormone levels. Int J Environ Res Public Health. 2017 Oct 30;14(11).
DMC1TEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/29084161

DMC1TEV	DI	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	MI	DEPTJ3D
DMC1TEV	MN	Steroid 5-alpha-reductase 2 (SRD5A2)
DMC1TEV	MT	DME
DMC1TEV	MA	Metabolism
DMC1TEV	RN	Molecular analysis of the SRD5A1 and SRD5A2 genes in patients with benign prostatic hyperplasia with regard to metabolic parameters and selected hormone levels. Int J Environ Res Public Health. 2017 Oct 30;14(11).
DMC1TEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/29084161

DMC1TEV	DI	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	MI	DEZGVDW
DMC1TEV	MN	Steroid 5-alpha-reductase 3 (SRD5A3)
DMC1TEV	MT	DME
DMC1TEV	MA	Metabolism
DMC1TEV	RN	Molecular analysis of the SRD5A1 and SRD5A2 genes in patients with benign prostatic hyperplasia with regard to metabolic parameters and selected hormone levels. Int J Environ Res Public Health. 2017 Oct 30;14(11).
DMC1TEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/29084161

DMB6871	DI	DMB6871
DMB6871	DN	Testosterone enanthate
DMB6871	MI	DEPKLMQ
DMB6871	MN	Cytochrome P450 2B6 (CYP2B6)
DMB6871	MT	DME
DMB6871	MA	Metabolism
DMB6871	RN	Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
DMB6871	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27709010

DMB6871	DI	DMB6871
DMB6871	DN	Testosterone enanthate
DMB6871	MI	DES5XRU
DMB6871	MN	Cytochrome P450 2C8 (CYP2C8)
DMB6871	MT	DME
DMB6871	MA	Metabolism
DMB6871	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DMB6871	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DMB6871	DI	DMB6871
DMB6871	DN	Testosterone enanthate
DMB6871	MI	DE5IED8
DMB6871	MN	Cytochrome P450 2C9 (CYP2C9)
DMB6871	MT	DME
DMB6871	MA	Metabolism
DMB6871	RN	Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7.
DMB6871	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16501008

DMB6871	DI	DMB6871
DMB6871	DN	Testosterone enanthate
DMB6871	MI	DEIBDNY
DMB6871	MN	Cytochrome P450 3A5 (CYP3A5)
DMB6871	MT	DME
DMB6871	MA	Metabolism
DMB6871	RN	In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos. 2003 Jul;31(7):938-44.
DMB6871	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12814972

DMB6871	DI	DMB6871
DMB6871	DN	Testosterone enanthate
DMB6871	MI	DERD86B
DMB6871	MN	Cytochrome P450 3A7 (CYP3A7)
DMB6871	MT	DME
DMB6871	MA	Metabolism
DMB6871	RN	Steroid hydroxylation by human fetal CYP3A7 and human NADPH-cytochrome P450 reductase coexpressed in insect cells using baculovirus. Res Commun Mol Pathol Pharmacol. 1998 Apr;100(1):15-28.
DMB6871	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9644715

DMB6871	DI	DMB6871
DMB6871	DN	Testosterone enanthate
DMB6871	MI	DEGTFWK
DMB6871	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMB6871	MT	DME
DMB6871	MA	Metabolism
DMB6871	RN	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
DMB6871	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9328296

DMB6871	DI	DMB6871
DMB6871	DN	Testosterone enanthate
DMB6871	MI	DEON3ED
DMB6871	MN	Phosphodiesterase 7B (PDE7B)
DMB6871	MT	DME
DMB6871	MA	Metabolism
DMB6871	RN	PDE7B is involved in nandrolone decanoate hydrolysis in liver cytosol and its transcription is up-regulated by androgens in HepG2. Front Pharmacol. 2014 May 30;5:132.
DMB6871	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24910615

DMB6871	DI	DMB6871
DMB6871	DN	Testosterone enanthate
DMB6871	MI	DEOG15F
DMB6871	MN	Steroid 5-alpha-reductase 1 (SRD5A1)
DMB6871	MT	DME
DMB6871	MA	Metabolism
DMB6871	RN	Molecular analysis of the SRD5A1 and SRD5A2 genes in patients with benign prostatic hyperplasia with regard to metabolic parameters and selected hormone levels. Int J Environ Res Public Health. 2017 Oct 30;14(11).
DMB6871	RU	https://www.ncbi.nlm.nih.gov/pubmed/29084161

DMB6871	DI	DMB6871
DMB6871	DN	Testosterone enanthate
DMB6871	MI	DEPTJ3D
DMB6871	MN	Steroid 5-alpha-reductase 2 (SRD5A2)
DMB6871	MT	DME
DMB6871	MA	Metabolism
DMB6871	RN	Molecular analysis of the SRD5A1 and SRD5A2 genes in patients with benign prostatic hyperplasia with regard to metabolic parameters and selected hormone levels. Int J Environ Res Public Health. 2017 Oct 30;14(11).
DMB6871	RU	https://www.ncbi.nlm.nih.gov/pubmed/29084161

DMB6871	DI	DMB6871
DMB6871	DN	Testosterone enanthate
DMB6871	MI	DEZGVDW
DMB6871	MN	Steroid 5-alpha-reductase 3 (SRD5A3)
DMB6871	MT	DME
DMB6871	MA	Metabolism
DMB6871	RN	Molecular analysis of the SRD5A1 and SRD5A2 genes in patients with benign prostatic hyperplasia with regard to metabolic parameters and selected hormone levels. Int J Environ Res Public Health. 2017 Oct 30;14(11).
DMB6871	RU	https://www.ncbi.nlm.nih.gov/pubmed/29084161

DMZO10Y	DI	DMZO10Y
DMZO10Y	DN	Testosterone Undecanoate
DMZO10Y	MI	DEPKLMQ
DMZO10Y	MN	Cytochrome P450 2B6 (CYP2B6)
DMZO10Y	MT	DME
DMZO10Y	MA	Metabolism
DMZO10Y	RN	Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
DMZO10Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27709010

DMZO10Y	DI	DMZO10Y
DMZO10Y	DN	Testosterone Undecanoate
DMZO10Y	MI	DES5XRU
DMZO10Y	MN	Cytochrome P450 2C8 (CYP2C8)
DMZO10Y	MT	DME
DMZO10Y	MA	Metabolism
DMZO10Y	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DMZO10Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DMZO10Y	DI	DMZO10Y
DMZO10Y	DN	Testosterone Undecanoate
DMZO10Y	MI	DE5IED8
DMZO10Y	MN	Cytochrome P450 2C9 (CYP2C9)
DMZO10Y	MT	DME
DMZO10Y	MA	Metabolism
DMZO10Y	RN	Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7.
DMZO10Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16501008

DMZO10Y	DI	DMZO10Y
DMZO10Y	DN	Testosterone Undecanoate
DMZO10Y	MI	DEIBDNY
DMZO10Y	MN	Cytochrome P450 3A5 (CYP3A5)
DMZO10Y	MT	DME
DMZO10Y	MA	Metabolism
DMZO10Y	RN	In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos. 2003 Jul;31(7):938-44.
DMZO10Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12814972

DMZO10Y	DI	DMZO10Y
DMZO10Y	DN	Testosterone Undecanoate
DMZO10Y	MI	DERD86B
DMZO10Y	MN	Cytochrome P450 3A7 (CYP3A7)
DMZO10Y	MT	DME
DMZO10Y	MA	Metabolism
DMZO10Y	RN	Steroid hydroxylation by human fetal CYP3A7 and human NADPH-cytochrome P450 reductase coexpressed in insect cells using baculovirus. Res Commun Mol Pathol Pharmacol. 1998 Apr;100(1):15-28.
DMZO10Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9644715

DMZO10Y	DI	DMZO10Y
DMZO10Y	DN	Testosterone Undecanoate
DMZO10Y	MI	DEGTFWK
DMZO10Y	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMZO10Y	MT	DME
DMZO10Y	MA	Metabolism
DMZO10Y	RN	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
DMZO10Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9328296

DMYWQ0O	DI	DMYWQ0O
DMYWQ0O	DN	Tetrabenazine
DMYWQ0O	MI	DECB0K3
DMYWQ0O	MN	Cytochrome P450 2D6 (CYP2D6)
DMYWQ0O	MT	DME
DMYWQ0O	MA	Metabolism
DMYWQ0O	RN	Role of tetrabenazine for Huntington's disease-associated chorea. Ann Pharmacother. 2010 Jun;44(6):1080-9.
DMYWQ0O	RU	http://www.ncbi.nlm.nih.gov/pubmed/20442355

DMYWQ0O	DI	DMYWQ0O
DMYWQ0O	DN	Tetrabenazine
DMYWQ0O	MI	TTNZRI3
DMYWQ0O	MN	Synaptic vesicle amine transporter (SLC18A2)
DMYWQ0O	MT	DTT
DMYWQ0O	MA	Blocker
DMYWQ0O	RN	Dopamine signaling is required for depolarization-induced slow current in cerebellar Purkinje cells. J Neurosci. 2009 Jul 1;29(26):8530-8.
DMYWQ0O	RU	https://pubmed.ncbi.nlm.nih.gov/19571144

DM9J6C2	DI	DM9J6C2
DM9J6C2	DN	Tetracaine
DM9J6C2	MI	TT90XZ8
DM9J6C2	MN	Voltage-gated sodium channel alpha Nav1.8 (SCN10A)
DM9J6C2	MT	DTT
DM9J6C2	MA	Inhibitor
DM9J6C2	RN	Heterologous expression and functional analysis of rat Nav1.8 (SNS) voltage-gated sodium channels in the dorsal root ganglion neuroblastoma cell line ND7-23. Neuropharmacology. 2004 Mar;46(3):425-38.
DM9J6C2	RU	https://pubmed.ncbi.nlm.nih.gov/14975698

DMZA017	DI	DMZA017
DMZA017	DN	Tetracycline
DMZA017	MI	DTI7UX6
DMZA017	MN	Breast cancer resistance protein (ABCG2)
DMZA017	MT	DTP
DMZA017	MA	Substrate
DMZA017	RN	Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). Biochem J. 2005 Jan 15;385(Pt 2):419-26.
DMZA017	RU	https://doi.org/10.1042/BJ20040791

DMZA017	DI	DMZA017
DMZA017	DN	Tetracycline
DMZA017	MI	DT0OC1Q
DMZA017	MN	Organic anion transporter 2 (SLC22A7)
DMZA017	MT	DTP
DMZA017	MA	Substrate
DMZA017	RN	Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76.
DMZA017	RU	http://www.ncbi.nlm.nih.gov/pubmed/11855680

DMZA017	DI	DMZA017
DMZA017	DN	Tetracycline
DMZA017	MI	DTVP67E
DMZA017	MN	Organic anion transporter 3 (SLC22A8)
DMZA017	MT	DTP
DMZA017	MA	Substrate
DMZA017	RN	Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76.
DMZA017	RU	http://www.ncbi.nlm.nih.gov/pubmed/11855680

DMZA017	DI	DMZA017
DMZA017	DN	Tetracycline
DMZA017	MI	DT06JWZ
DMZA017	MN	Organic anion transporter 4 (SLC22A11)
DMZA017	MT	DTP
DMZA017	MA	Substrate
DMZA017	RN	Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76.
DMZA017	RU	http://www.ncbi.nlm.nih.gov/pubmed/11855680

DMZA017	DI	DMZA017
DMZA017	DN	Tetracycline
DMZA017	MI	DTUGYRD
DMZA017	MN	P-glycoprotein 1 (ABCB1)
DMZA017	MT	DTP
DMZA017	MA	Substrate
DMZA017	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMZA017	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMZA017	DI	DMZA017
DMZA017	DN	Tetracycline
DMZA017	MI	TTQ8KVI
DMZA017	MN	Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)
DMZA017	MT	DTT
DMZA017	MA	Binder
DMZA017	RN	The glycylcyclines: a comparative review with the tetracyclines. Drugs. 2004;64(1):63-88.
DMZA017	RU	https://pubmed.ncbi.nlm.nih.gov/14723559

DMINZ4W	DI	DMINZ4W
DMINZ4W	DN	Tetrahydrobiopterin
DMINZ4W	MI	DER6XYF
DMINZ4W	MN	Tryptophan 5-hydroxylase 2 (TPH2)
DMINZ4W	MT	DME
DMINZ4W	MA	Metabolism
DMINZ4W	RN	Characterization of wild-type and mutant forms of human tryptophan hydroxylase 2. J Neurochem. 2007 Mar;100(6):1648-57.
DMINZ4W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17181551

DMINZ4W	DI	DMINZ4W
DMINZ4W	DN	Tetrahydrobiopterin
DMINZ4W	MI	TTUHP71
DMINZ4W	MN	Tyrosine 3-monooxygenase (TH)
DMINZ4W	MT	DTT
DMINZ4W	MA	Cofactor
DMINZ4W	RN	Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects. J Neural Transm Suppl. 2007;(72):113-20.
DMINZ4W	RU	https://pubmed.ncbi.nlm.nih.gov/17982884

DMH15UV	DI	DMH15UV
DMH15UV	DN	Tetrahydrofolic acid
DMH15UV	MI	TTQOD3G
DMH15UV	MN	Folate receptor (FOLR)
DMH15UV	MT	DTT
DMH15UV	MA	Binder
DMH15UV	RN	Common mutations at the homocysteine metabolism pathway and pediatric stroke. Thromb Res. 2001 Apr 15;102(2):115-20.
DMH15UV	RU	https://pubmed.ncbi.nlm.nih.gov/11323021

DMT57WC	DI	DMT57WC
DMT57WC	DN	Tetrahydrozoline
DMT57WC	MI	TT2NUT5
DMT57WC	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMT57WC	MT	DTT
DMT57WC	MA	Modulator
DMT57WC	RN	Prolonged cardiovascular effects after unintentional ingestion of tetrahydrozoline. Clin Toxicol (Phila). 2008 Feb;46(2):171-2.
DMT57WC	RU	https://pubmed.ncbi.nlm.nih.gov/18259967

DMWMPRG	DI	DMWMPRG
DMWMPRG	DN	Tetrodotoxin
DMWMPRG	MI	TTRK8B9
DMWMPRG	MN	Sodium channel unspecific (NaC)
DMWMPRG	MT	DTT
DMWMPRG	MA	Antagonist
DMWMPRG	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMWMPRG	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMWMPRG	DI	DMWMPRG
DMWMPRG	DN	Tetrodotoxin
DMWMPRG	MI	TTIG65Q
DMWMPRG	MN	Voltage-gated sodium channel (Nav)
DMWMPRG	MT	DTT
DMWMPRG	MA	Inhibitor
DMWMPRG	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMWMPRG	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMWMPRG	DI	DMWMPRG
DMWMPRG	DN	Tetrodotoxin
DMWMPRG	MI	TTZOVE0
DMWMPRG	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DMWMPRG	MT	DTT
DMWMPRG	MA	Blocker
DMWMPRG	RN	Halothane attenuates the cerebroprotective action of several Na+ and Ca2+ channel blockers via reversal of their ion channel blockade. Eur J Pharmacol. 2002 Oct 4;452(2):175-81.
DMWMPRG	RU	https://pubmed.ncbi.nlm.nih.gov/12354567

DMY62FC	DI	DMY62FC
DMY62FC	DN	Tezacaftor And Ivacaftor
DMY62FC	MI	TTRLZHP
DMY62FC	MN	cAMP-dependent chloride channel (CFTR)
DMY62FC	MT	DTT
DMY62FC	MA	Binder
DMY62FC	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMY62FC	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DM70BU5	DI	DM70BU5
DM70BU5	DN	Thalidomide
DM70BU5	MI	DEJVYAZ
DM70BU5	MN	Cytochrome P450 2A6 (CYP2A6)
DM70BU5	MT	DME
DM70BU5	MA	Metabolism
DM70BU5	RN	Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients. J Biochem Mol Toxicol. 2000;14(3):140-7.
DM70BU5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10711629

DM70BU5	DI	DM70BU5
DM70BU5	DN	Thalidomide
DM70BU5	MI	DEPKLMQ
DM70BU5	MN	Cytochrome P450 2B6 (CYP2B6)
DM70BU5	MT	DME
DM70BU5	MA	Metabolism
DM70BU5	RN	Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients. J Biochem Mol Toxicol. 2000;14(3):140-7.
DM70BU5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10711629

DM70BU5	DI	DM70BU5
DM70BU5	DN	Thalidomide
DM70BU5	MI	DEZMWRE
DM70BU5	MN	Cytochrome P450 2C18 (CYP2C18)
DM70BU5	MT	DME
DM70BU5	MA	Metabolism
DM70BU5	RN	Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res. 2002 Jun;8(6):1964-73.
DM70BU5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12060642

DM70BU5	DI	DM70BU5
DM70BU5	DN	Thalidomide
DM70BU5	MI	DES5XRU
DM70BU5	MN	Cytochrome P450 2C8 (CYP2C8)
DM70BU5	MT	DME
DM70BU5	MA	Metabolism
DM70BU5	RN	Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res. 2002 Jun;8(6):1964-73.
DM70BU5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12060642

DM70BU5	DI	DM70BU5
DM70BU5	DN	Thalidomide
DM70BU5	MI	DE5IED8
DM70BU5	MN	Cytochrome P450 2C9 (CYP2C9)
DM70BU5	MT	DME
DM70BU5	MA	Metabolism
DM70BU5	RN	Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res. 2002 Jun;8(6):1964-73.
DM70BU5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12060642

DM70BU5	DI	DM70BU5
DM70BU5	DN	Thalidomide
DM70BU5	MI	DEVDYN7
DM70BU5	MN	Cytochrome P450 2E1 (CYP2E1)
DM70BU5	MT	DME
DM70BU5	MA	Metabolism
DM70BU5	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM70BU5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM70BU5	DI	DM70BU5
DM70BU5	DN	Thalidomide
DM70BU5	MI	DEIBDNY
DM70BU5	MN	Cytochrome P450 3A5 (CYP3A5)
DM70BU5	MT	DME
DM70BU5	MA	Metabolism
DM70BU5	RN	Human liver microsomal cytochrome P450 3A enzymes involved in thalidomide 5-hydroxylation and formation of a glutathione conjugate. Chem Res Toxicol. 2010 Jun 21;23(6):1018-24.
DM70BU5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20443640

DM70BU5	DI	DM70BU5
DM70BU5	DN	Thalidomide
DM70BU5	MI	DEGTFWK
DM70BU5	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM70BU5	MT	DME
DM70BU5	MA	Metabolism
DM70BU5	RN	Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide. Cancer Biol Ther. 2002 Nov-Dec;1(6):669-73.
DM70BU5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12642692

DM70BU5	DI	DM70BU5
DM70BU5	DN	Thalidomide
DM70BU5	MI	DE073H6
DM70BU5	MN	Prostaglandin G/H synthase 1 (COX-1)
DM70BU5	MT	DME
DM70BU5	MA	Metabolism
DM70BU5	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM70BU5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM70BU5	DI	DM70BU5
DM70BU5	DN	Thalidomide
DM70BU5	MI	TTF8CQI
DM70BU5	MN	Tumor necrosis factor (TNF)
DM70BU5	MT	DTT
DM70BU5	MA	Inhibitor
DM70BU5	RN	Efficacy of different thalidomide regimens for patients with multiple myeloma and its relationship with TNF-alpha level. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Dec;16(6):1312-5.
DM70BU5	RU	https://pubmed.ncbi.nlm.nih.gov/19099634

DMM8D3F	DI	DMM8D3F
DMM8D3F	DN	Theobromine
DMM8D3F	MI	DEJGDUW
DMM8D3F	MN	Cytochrome P450 1A2 (CYP1A2)
DMM8D3F	MT	DME
DMM8D3F	MA	Metabolism
DMM8D3F	RN	Cytochrome P450 isoform selectivity in human hepatic theobromine metabolism. Br J Clin Pharmacol. 1999 Mar;47(3):299-305.
DMM8D3F	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10215755

DMM8D3F	DI	DMM8D3F
DMM8D3F	DN	Theobromine
DMM8D3F	MI	DEVDYN7
DMM8D3F	MN	Cytochrome P450 2E1 (CYP2E1)
DMM8D3F	MT	DME
DMM8D3F	MA	Metabolism
DMM8D3F	RN	Cytochrome P450 isoform selectivity in human hepatic theobromine metabolism. Br J Clin Pharmacol. 1999 Mar;47(3):299-305.
DMM8D3F	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10215755

DMRJFN9	DI	DMRJFN9
DMRJFN9	DN	Theophylline
DMRJFN9	MI	TTSLI08
DMRJFN9	MN	Adenosine receptor (ADOR)
DMRJFN9	MT	DTT
DMRJFN9	MA	Antagonist
DMRJFN9	RN	Emerging adenosine receptor agonists. Expert Opin Emerg Drugs. 2007 Sep;12(3):479-92.
DMRJFN9	RU	https://pubmed.ncbi.nlm.nih.gov/17874974

DMRJFN9	DI	DMRJFN9
DMRJFN9	DN	Theophylline
DMRJFN9	MI	DE6OQ3W
DMRJFN9	MN	Cytochrome P450 1A1 (CYP1A1)
DMRJFN9	MT	DME
DMRJFN9	MA	Metabolism
DMRJFN9	RN	Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther. 1993 Apr;265(1):401-7.
DMRJFN9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8474022

DMRJFN9	DI	DMRJFN9
DMRJFN9	DN	Theophylline
DMRJFN9	MI	DEJGDUW
DMRJFN9	MN	Cytochrome P450 1A2 (CYP1A2)
DMRJFN9	MT	DME
DMRJFN9	MA	Metabolism
DMRJFN9	RN	Association between common CYP1A2 polymorphisms and theophylline metabolism in non-smoking healthy volunteers. Basic Clin Pharmacol Toxicol. 2013 Apr;112(4):257-63.
DMRJFN9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23167834

DMRJFN9	DI	DMRJFN9
DMRJFN9	DN	Theophylline
DMRJFN9	MI	DE9QHP6
DMRJFN9	MN	Cytochrome P450 1B1 (CYP1B1)
DMRJFN9	MT	DME
DMRJFN9	MA	Metabolism
DMRJFN9	RN	Oxidation of xenobiotics by recombinant human cytochrome P450 1B1. Drug Metab Dispos. 1997 May;25(5):617-22.
DMRJFN9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9152602

DMRJFN9	DI	DMRJFN9
DMRJFN9	DN	Theophylline
DMRJFN9	MI	DECB0K3
DMRJFN9	MN	Cytochrome P450 2D6 (CYP2D6)
DMRJFN9	MT	DME
DMRJFN9	MA	Metabolism
DMRJFN9	RN	Characterization of human cytochromes P450 involved in theophylline 8-hydroxylation. Biochem Pharmacol. 1995 Jul 17;50(2):205-11.
DMRJFN9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7632164

DMRJFN9	DI	DMRJFN9
DMRJFN9	DN	Theophylline
DMRJFN9	MI	DEVDYN7
DMRJFN9	MN	Cytochrome P450 2E1 (CYP2E1)
DMRJFN9	MT	DME
DMRJFN9	MA	Metabolism
DMRJFN9	RN	Construction and assessment of models of CYP2E1: predictions of metabolism from docking, molecular dynamics, and density functional theoretical calculations. J Med Chem. 2003 Apr 24;46(9):1645-60.
DMRJFN9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12699383

DMRJFN9	DI	DMRJFN9
DMRJFN9	DN	Theophylline
DMRJFN9	MI	DE4LYSA
DMRJFN9	MN	Cytochrome P450 3A4 (CYP3A4)
DMRJFN9	MT	DME
DMRJFN9	MA	Metabolism
DMRJFN9	RN	Characterization of human cytochromes P450 involved in theophylline 8-hydroxylation. Biochem Pharmacol. 1995 Jul 17;50(2):205-11.
DMRJFN9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7632164

DMRJFN9	DI	DMRJFN9
DMRJFN9	DN	Theophylline
DMRJFN9	MI	DT0OC1Q
DMRJFN9	MN	Organic anion transporter 2 (SLC22A7)
DMRJFN9	MT	DTP
DMRJFN9	MA	Substrate
DMRJFN9	RN	Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver. Drug Metab Dispos. 2005 May;33(5):619-22.
DMRJFN9	RU	http://www.ncbi.nlm.nih.gov/pubmed/15708966

DM7YCK3	DI	DM7YCK3
DM7YCK3	DN	Thiabendazole
DM7YCK3	MI	TTHDSE2
DM7YCK3	MN	Bacterial Fumarate reductase flavoprotein (Bact frdA)
DM7YCK3	MT	DTT
DM7YCK3	MA	Inhibitor
DM7YCK3	RN	Fumarate reductase is essential for Helicobacter pylori colonization of the mouse stomach. Microb Pathog. 2000 Nov;29(5):279-87.
DM7YCK3	RU	https://pubmed.ncbi.nlm.nih.gov/11031122

DM7YCK3	DI	DM7YCK3
DM7YCK3	DN	Thiabendazole
DM7YCK3	MI	DEJGDUW
DM7YCK3	MN	Cytochrome P450 1A2 (CYP1A2)
DM7YCK3	MT	DME
DM7YCK3	MA	Metabolism
DM7YCK3	RN	Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
DM7YCK3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19754423

DMDRKH2	DI	DMDRKH2
DMDRKH2	DN	Thiamphenicol
DMDRKH2	MI	TTLFGBV
DMDRKH2	MN	Bacterial 23S ribosomal RNA (Bact 23S rRNA)
DMDRKH2	MT	DTT
DMDRKH2	MA	Modulator
DMDRKH2	RN	The fused TrpEG from Streptomyces venezuelae is an anthranilate synthase, not a 2-amino-2-deoxyisochorismate [corrected] (ADIC) synthase. Ethn Dis. 2008 Spring;18(2 Suppl 2):S2-9-13.
DMDRKH2	RU	https://pubmed.ncbi.nlm.nih.gov/18646313

DMDRKH2	DI	DMDRKH2
DMDRKH2	DN	Thiamphenicol
DMDRKH2	MI	DTUGYRD
DMDRKH2	MN	P-glycoprotein 1 (ABCB1)
DMDRKH2	MT	DTP
DMDRKH2	MA	Substrate
DMDRKH2	RN	Active Mediated Transport of Chloramphenicol and Thiamphenicol in a Calu-3 Lung Epithelial Cell Model. J Pharm Sci. 2018 Apr;107(4):1178-1184.
DMDRKH2	RU	http://www.ncbi.nlm.nih.gov/pubmed/29221992

DMHDF7B	DI	DMHDF7B
DMHDF7B	DN	Thiamylal
DMHDF7B	MI	DE5IED8
DMHDF7B	MN	Cytochrome P450 2C9 (CYP2C9)
DMHDF7B	MT	DME
DMHDF7B	MA	Metabolism
DMHDF7B	RN	Protein binding and the metabolism of thiamylal enantiomers in vitro. Anesth Analg. 2000 Sep;91(3):736-40.
DMHDF7B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10960410

DMHDF7B	DI	DMHDF7B
DMHDF7B	DN	Thiamylal
DMHDF7B	MI	DEVDYN7
DMHDF7B	MN	Cytochrome P450 2E1 (CYP2E1)
DMHDF7B	MT	DME
DMHDF7B	MA	Metabolism
DMHDF7B	RN	Effects of premedication medicines on the formation of the CYP3A4-dependent metabolite of ropivacaine, 2', 6'-Pipecoloxylidide, on human liver microsomes in vitro. Basic Clin Pharmacol Toxicol. 2006 Feb;98(2):181-3.
DMHDF7B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16445592

DMHDF7B	DI	DMHDF7B
DMHDF7B	DN	Thiamylal
DMHDF7B	MI	DE4LYSA
DMHDF7B	MN	Cytochrome P450 3A4 (CYP3A4)
DMHDF7B	MT	DME
DMHDF7B	MA	Metabolism
DMHDF7B	RN	Protein binding and the metabolism of thiamylal enantiomers in vitro. Anesth Analg. 2000 Sep;91(3):736-40.
DMHDF7B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10960410

DMHDF7B	DI	DMHDF7B
DMHDF7B	DN	Thiamylal
DMHDF7B	MI	TTEX6LM
DMHDF7B	MN	GABA(A) receptor gamma-3 (GABRG3)
DMHDF7B	MT	DTT
DMHDF7B	MA	Modulator
DMHDF7B	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMHDF7B	RU	https://www.fda.gov/

DMC1NBW	DI	DMC1NBW
DMC1NBW	DN	Thiazolidinedione
DMC1NBW	MI	TTZMAO3
DMC1NBW	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMC1NBW	MT	DTT
DMC1NBW	MA	Agonist
DMC1NBW	RN	Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med. 2002 Nov;8(11):1281-7.
DMC1NBW	RU	https://pubmed.ncbi.nlm.nih.gov/12379847

DMU3IET	DI	DMU3IET
DMU3IET	DN	Thiethylperazine
DMU3IET	MI	TTEX248
DMU3IET	MN	Dopamine D2 receptor (D2R)
DMU3IET	MT	DTT
DMU3IET	MA	Antagonist
DMU3IET	RN	Antiemetic specificity of dopamine antagonists. Psychopharmacology (Berl). 1982;78(3):210-3.
DMU3IET	RU	https://pubmed.ncbi.nlm.nih.gov/6130555

DMEPWYA	DI	DMEPWYA
DMEPWYA	DN	THIOCOLCHICOSIDE
DMEPWYA	MI	TT1MPAY
DMEPWYA	MN	GABA(A) receptor alpha-1 (GABRA1)
DMEPWYA	MT	DTT
DMEPWYA	MA	Inhibitor
DMEPWYA	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DMEPWYA	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DMEPWYA	DI	DMEPWYA
DMEPWYA	DN	THIOCOLCHICOSIDE
DMEPWYA	MI	TTZA1NY
DMEPWYA	MN	GABA(A) receptor beta-2 (GABRB2)
DMEPWYA	MT	DTT
DMEPWYA	MA	Inhibitor
DMEPWYA	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DMEPWYA	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DMEPWYA	DI	DMEPWYA
DMEPWYA	DN	THIOCOLCHICOSIDE
DMEPWYA	MI	TT06RH5
DMEPWYA	MN	GABA(A) receptor gamma-2 (GABRG2)
DMEPWYA	MT	DTT
DMEPWYA	MA	Inhibitor
DMEPWYA	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DMEPWYA	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DMEPWYA	DI	DMEPWYA
DMEPWYA	DN	THIOCOLCHICOSIDE
DMEPWYA	MI	TTNJYV2
DMEPWYA	MN	Gamma-aminobutyric acid receptor (GAR)
DMEPWYA	MT	DTT
DMEPWYA	MA	Inhibitor
DMEPWYA	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DMEPWYA	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DMEPWYA	DI	DMEPWYA
DMEPWYA	DN	THIOCOLCHICOSIDE
DMEPWYA	MI	TTZ8EM9
DMEPWYA	MN	Glycine receptor (GlyR)
DMEPWYA	MT	DTT
DMEPWYA	MA	Inhibitor
DMEPWYA	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DMEPWYA	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DMEPWYA	DI	DMEPWYA
DMEPWYA	DN	THIOCOLCHICOSIDE
DMEPWYA	MI	TTF45NW
DMEPWYA	MN	Strychnine-binding glycine receptor (GLRA1)
DMEPWYA	MT	DTT
DMEPWYA	MA	Inhibitor
DMEPWYA	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DMEPWYA	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DM7NKEV	DI	DM7NKEV
DM7NKEV	DN	Thioguanine
DM7NKEV	MI	DTI7UX6
DM7NKEV	MN	Breast cancer resistance protein (ABCG2)
DM7NKEV	MT	DTP
DM7NKEV	MA	Substrate
DM7NKEV	RN	ABC transporters and their role in nucleoside and nucleotide drug resistance. Biochem Pharmacol. 2012 Apr 15;83(8):1073-83.
DM7NKEV	RU	https://doi.org/10.1016/j.bcp.2011.12.042

DM7NKEV	DI	DM7NKEV
DM7NKEV	DN	Thioguanine
DM7NKEV	MI	DT4YL5R
DM7NKEV	MN	Concentrative Na(+)-nucleoside cotransporter 3 (SLC28A3)
DM7NKEV	MT	DTP
DM7NKEV	MA	Substrate
DM7NKEV	RN	Involvement of the concentrative nucleoside transporter 3 and equilibrative nucleoside transporter 2 in the resistance of T-lymphoblastic cell lines to thiopurines. Biochem Biophys Res Commun. 2006 Apr 28;343(1):208-15.
DM7NKEV	RU	http://www.ncbi.nlm.nih.gov/pubmed/16530731

DM7NKEV	DI	DM7NKEV
DM7NKEV	DN	Thioguanine
DM7NKEV	MI	DEVXTP5
DM7NKEV	MN	Hypoxanthine phosphoribosyltransferase (HPRT1)
DM7NKEV	MT	DME
DM7NKEV	MA	Metabolism
DM7NKEV	RN	Qualitative and quantitative difference in mutation induction between carbon- and neon-ion beams in normal human cells. Biol Sci Space. 2003 Dec;17(4):302-6.
DM7NKEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15136753

DM7NKEV	DI	DM7NKEV
DM7NKEV	DN	Thioguanine
DM7NKEV	MI	TTCAQMW
DM7NKEV	MN	Inosine-5'-monophosphate dehydrogenase (IMPDH)
DM7NKEV	MT	DTT
DM7NKEV	MA	Intercalator
DM7NKEV	RN	Immune effector cells produce lethal DNA damage in cells treated with a thiopurine. Cancer Res. 2009 Mar 15;69(6):2393-9.
DM7NKEV	RU	https://pubmed.ncbi.nlm.nih.gov/19244103

DM7NKEV	DI	DM7NKEV
DM7NKEV	DN	Thioguanine
DM7NKEV	MI	DTCSGPB
DM7NKEV	MN	Multidrug resistance-associated protein 4 (ABCC4)
DM7NKEV	MT	DTP
DM7NKEV	MA	Substrate
DM7NKEV	RN	Multidrug resistance protein 4 (MRP4/ABCC4) mediates efflux of bimane-glutathione. Int J Biochem Cell Biol. 2004 Feb;36(2):247-57.
DM7NKEV	RU	http://www.ncbi.nlm.nih.gov/pubmed/14643890

DM7NKEV	DI	DM7NKEV
DM7NKEV	DN	Thioguanine
DM7NKEV	MI	DEFQ8VO
DM7NKEV	MN	Thiopurine methyltransferase (TPMT)
DM7NKEV	MT	DME
DM7NKEV	MA	Metabolism
DM7NKEV	RN	Usefulness of thiopurine methyltransferase and thiopurine metabolite analysis in clinical practice in patients with inflammatory bowel diseases. Acta Gastroenterol Belg. 2010 Jul-Sep;73(3):331-5.
DM7NKEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21086934

DMGP8AX	DI	DMGP8AX
DMGP8AX	DN	Thiopental
DMGP8AX	MI	TTDP1UC
DMGP8AX	MN	Fatty acid amide hydrolase (FAAH)
DMGP8AX	MT	DTT
DMGP8AX	MA	Inhibitor
DMGP8AX	RN	The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase. Br J Pharmacol. 2003 Jul;139(5):1005-13.
DMGP8AX	RU	https://pubmed.ncbi.nlm.nih.gov/12839875

DMGP8AX	DI	DMGP8AX
DMGP8AX	DN	Thiopental
DMGP8AX	MI	DEGTFWK
DMGP8AX	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMGP8AX	MT	DME
DMGP8AX	MA	Metabolism
DMGP8AX	RN	Lerman J. (2014). Neonatal Anesthesia. Springer.
DMGP8AX	RU	https://link.springer.com/book/10.1007%2F978-1-4419-6041-2

DM35M8J	DI	DM35M8J
DM35M8J	DN	Thioridazine
DM35M8J	MI	DECB0K3
DM35M8J	MN	Cytochrome P450 2D6 (CYP2D6)
DM35M8J	MT	DME
DM35M8J	MA	Metabolism
DM35M8J	RN	Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Eur J Clin Pharmacol. 2003 May;59(1):45-50.
DM35M8J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12682803

DM35M8J	DI	DM35M8J
DM35M8J	DN	Thioridazine
DM35M8J	MI	TTEX248
DM35M8J	MN	Dopamine D2 receptor (D2R)
DM35M8J	MT	DTT
DM35M8J	MA	Antagonist
DM35M8J	RN	Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat. Eur Neuropsychopharmacol. 2005 Mar;15(2):231-4.
DM35M8J	RU	https://pubmed.ncbi.nlm.nih.gov/15695070

DM35M8J	DI	DM35M8J
DM35M8J	DN	Thioridazine
DM35M8J	MI	DEGTFWK
DM35M8J	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM35M8J	MT	DME
DM35M8J	MA	Metabolism
DM35M8J	RN	CYP2J2 and CYP2C19 are the major enzymes responsible for metabolism of albendazole and fenbendazole in human liver microsomes and recombinant P450 assay systems. Antimicrob Agents Chemother. 2013 Nov;57(11):5448-56.
DM35M8J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23959307

DM35M8J	DI	DM35M8J
DM35M8J	DN	Thioridazine
DM35M8J	MI	DTUGYRD
DM35M8J	MN	P-glycoprotein 1 (ABCB1)
DM35M8J	MT	DTP
DM35M8J	MA	Substrate
DM35M8J	RN	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
DM35M8J	RU	https://doi.org/10.1016/j.addr.2011.12.008

DMIZKOP	DI	DMIZKOP
DMIZKOP	DN	Thiotepa
DMIZKOP	MI	DE4LYSA
DMIZKOP	MN	Cytochrome P450 3A4 (CYP3A4)
DMIZKOP	MT	DME
DMIZKOP	MA	Metabolism
DMIZKOP	RN	Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA. Cancer Chemother Pharmacol. 2002 Jun;49(6):461-7.
DMIZKOP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12107550

DMIZKOP	DI	DMIZKOP
DMIZKOP	DN	Thiotepa
DMIZKOP	MI	DE4ZHS1
DMIZKOP	MN	Glutathione S-transferase alpha-1 (GSTA1)
DMIZKOP	MT	DME
DMIZKOP	MA	Metabolism
DMIZKOP	RN	Differential catalytic efficiency of allelic variants of human glutathione S-transferase Pi in catalyzing the glutathione conjugation of thiotepa. Arch Biochem Biophys. 1999 Jun 1;366(1):89-94.
DMIZKOP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10334868

DMDINC4	DI	DMDINC4
DMDINC4	DN	Thiothixene
DMDINC4	MI	DEJGDUW
DMDINC4	MN	Cytochrome P450 1A2 (CYP1A2)
DMDINC4	MT	DME
DMDINC4	MA	Metabolism
DMDINC4	RN	In vitro analysis of factors influencing CYP1A2 expression as potential determinants of interindividual variation. Pharmacol Res Perspect. 2017 Mar 2;5(2):e00299.
DMDINC4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28357125

DMDINC4	DI	DMDINC4
DMDINC4	DN	Thiothixene
DMDINC4	MI	TTEX248
DMDINC4	MN	Dopamine D2 receptor (D2R)
DMDINC4	MT	DTT
DMDINC4	MA	Antagonist
DMDINC4	RN	Dopaminergic stimulation of cAMP accumulation in cultured rat mesangial cells. Am J Physiol. 1987 Aug;253(2 Pt 2):H358-64.
DMDINC4	RU	https://pubmed.ncbi.nlm.nih.gov/3039860

DM2P6VD	DI	DM2P6VD
DM2P6VD	DN	Thrombin/fibrinogen matrix patch
DM2P6VD	MI	TTWODQF
DM2P6VD	MN	Fibrin (FG)
DM2P6VD	MT	DTT
DM2P6VD	MA	Modulator
DM2P6VD	RN	Fibrin sealant patch for repair of acute type a aortic dissection. J Card Surg. 2013 Nov;28(6):736-41.
DM2P6VD	RU	https://pubmed.ncbi.nlm.nih.gov/23957708

DMJ47QC	DI	DMJ47QC
DMJ47QC	DN	Thyrotropin
DMJ47QC	MI	TT6NYJA
DMJ47QC	MN	Thyrotropin receptor (TSHR)
DMJ47QC	MT	DTT
DMJ47QC	MA	Modulator
DMJ47QC	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMJ47QC	RU	https://www.fda.gov/

DMMYLTI	DI	DMMYLTI
DMMYLTI	DN	Thyrotropin Alfa
DMMYLTI	MI	TT6NYJA
DMMYLTI	MN	Thyrotropin receptor (TSHR)
DMMYLTI	MT	DTT
DMMYLTI	MA	Binder
DMMYLTI	RN	Pharmacological profiles and clinical effects of recombinant human thyrotropin alfa (Thyrogen) Intramuscular Injection 0.9 mg). Nippon Yakurigaku Zasshi. 2009 Jul;134(1):28-34.
DMMYLTI	RU	https://pubmed.ncbi.nlm.nih.gov/19602784

DMKSQG0	DI	DMKSQG0
DMKSQG0	DN	Tiagabine
DMKSQG0	MI	DE4LYSA
DMKSQG0	MN	Cytochrome P450 3A4 (CYP3A4)
DMKSQG0	MT	DME
DMKSQG0	MA	Metabolism
DMKSQG0	RN	Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. Fundam Clin Pharmacol. 2000 Jul-Aug;14(4):301-19.
DMKSQG0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11030437

DMKSQG0	DI	DMKSQG0
DMKSQG0	DN	Tiagabine
DMKSQG0	MI	TTPRKM0
DMKSQG0	MN	GABA transporter GAT-1 (SLC6A1)
DMKSQG0	MT	DTT
DMKSQG0	MA	Inhibitor
DMKSQG0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 929).
DMKSQG0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=929

DMKSQG0	DI	DMKSQG0
DMKSQG0	DN	Tiagabine
DMKSQG0	MI	TTV9MQG
DMKSQG0	MN	Gamma-aminobutyric acid uptake (GABAU)
DMKSQG0	MT	DTT
DMKSQG0	MA	Inhibitor
DMKSQG0	RN	Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
DMKSQG0	RU	https://pubmed.ncbi.nlm.nih.gov/16377242

DMKSQG0	DI	DMKSQG0
DMKSQG0	DN	Tiagabine
DMKSQG0	MI	DEYGVN4
DMKSQG0	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMKSQG0	MT	DME
DMKSQG0	MA	Metabolism
DMKSQG0	RN	Actual and Predicted Pharmacokinetic Interactions Between Anticonvulsants and Antiretrovirals.
DMKSQG0	RU	https://hivclinic.ca/archive/main/drugs_interact_files/anticonvulsant-int.pdf

DMYN8MA	DI	DMYN8MA
DMYN8MA	DN	Tianeptine
DMYN8MA	MI	DE4LYSA
DMYN8MA	MN	Cytochrome P450 3A4 (CYP3A4)
DMYN8MA	MT	DME
DMYN8MA	MA	Metabolism
DMYN8MA	RN	Tianeptine: a facilitator of the reuptake of serotonin and norepinephrine as an antidepressant? J Psychiatr Pract. 2004 Sep;10(5):323-30.
DMYN8MA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15361747

DMYN8MA	DI	DMYN8MA
DMYN8MA	DN	Tianeptine
DMYN8MA	MI	TT3ROYC
DMYN8MA	MN	Serotonin transporter (SERT)
DMYN8MA	MT	DTT
DMYN8MA	MA	Inhibitor
DMYN8MA	RN	Emerging treatments for depression. Expert Opin Pharmacother. 2006 Dec;7(17):2323-39.
DMYN8MA	RU	https://pubmed.ncbi.nlm.nih.gov/17109609

DMN6CAG	DI	DMN6CAG
DMN6CAG	DN	Tiapride
DMN6CAG	MI	TTEX248
DMN6CAG	MN	Dopamine D2 receptor (D2R)
DMN6CAG	MT	DTT
DMN6CAG	MA	Antagonist
DMN6CAG	RN	The treatment of Tourette's syndrome: current opinions. Expert Opin Pharmacother. 2002 Jul;3(7):899-914.
DMN6CAG	RU	https://pubmed.ncbi.nlm.nih.gov/12083990

DMN6CAG	DI	DMN6CAG
DMN6CAG	DN	Tiapride
DMN6CAG	MI	TT90XZ8
DMN6CAG	MN	Voltage-gated sodium channel alpha Nav1.8 (SCN10A)
DMN6CAG	MT	DTT
DMN6CAG	MA	Inhibitor
DMN6CAG	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DMN6CAG	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DM23D7J	DI	DM23D7J
DM23D7J	DN	Tiaprofenic acid
DM23D7J	MI	TTVKILB
DM23D7J	MN	Prostaglandin G/H synthase 2 (COX-2)
DM23D7J	MT	DTT
DM23D7J	MA	Inhibitor
DM23D7J	RN	Effects of tiaprofenic acid on the concentration and metabolism of proteoglycans in normal and degenerating canine articular cartilage. J Clin Pharmacol. 1990 Sep;30(9):808-14.
DM23D7J	RU	https://pubmed.ncbi.nlm.nih.gov/2277128

DM5JWV9	DI	DM5JWV9
DM5JWV9	DN	Tiazofurin
DM5JWV9	MI	TTL7C8Q
DM5JWV9	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DM5JWV9	MT	DTT
DM5JWV9	MA	Inhibitor
DM5JWV9	RN	In vitro and in vivo antiproliferative activity of IPCAR, a new pyrazole nucleoside analog. Anticancer Res. 1998 Jul-Aug;18(4A):2623-30.
DM5JWV9	RU	https://pubmed.ncbi.nlm.nih.gov/9703919

DM5JWV9	DI	DM5JWV9
DM5JWV9	DN	Tiazofurin
DM5JWV9	MI	DENV24I
DM5JWV9	MN	Nicotinamide riboside kinase 1 (NRK1)
DM5JWV9	MT	DME
DM5JWV9	MA	Metabolism
DM5JWV9	RN	Nicotinamide riboside kinase structures reveal new pathways to NAD+. PLoS Biol. 2007 Oct 2;5(10):e263.
DM5JWV9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17914902

DM5JWV9	DI	DM5JWV9
DM5JWV9	DN	Tiazofurin
DM5JWV9	MI	DE8DJ3N
DM5JWV9	MN	Nicotinamide riboside kinase 2 (NRK2)
DM5JWV9	MT	DME
DM5JWV9	MA	Metabolism
DM5JWV9	RN	Nicotinamide riboside kinase structures reveal new pathways to NAD+. PLoS Biol. 2007 Oct 2;5(10):e263.
DM5JWV9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17914902

DM78XFG	DI	DM78XFG
DM78XFG	DN	Tibolone
DM78XFG	MI	DEN0GVQ
DM78XFG	MN	Beta-HSD adrenal and gonadal type (HSD3B2)
DM78XFG	MT	DME
DM78XFG	MA	Metabolism
DM78XFG	RN	Tibolone: a unique version of hormone replacement therapy. Ann Pharmacother. 2004 May;38(5):874-81.
DM78XFG	RU	http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.919.2384&rep=rep1&type=pdf

DM78XFG	DI	DM78XFG
DM78XFG	DN	Tibolone
DM78XFG	MI	DERDQWN
DM78XFG	MN	Dihydrotestosterone oxidoreductase (HSD3B1)
DM78XFG	MT	DME
DM78XFG	MA	Metabolism
DM78XFG	RN	Tibolone: a unique version of hormone replacement therapy. Ann Pharmacother. 2004 May;38(5):874-81.
DM78XFG	RU	http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.919.2384&rep=rep1&type=pdf

DM78XFG	DI	DM78XFG
DM78XFG	DN	Tibolone
DM78XFG	MI	DEYWLRK
DM78XFG	MN	Sulfotransferase 1A1 (SULT1A1)
DM78XFG	MT	DME
DM78XFG	MA	Metabolism
DM78XFG	RN	Sulfation of tibolone metabolites by human postmenopausal liver and small intestinal sulfotransferases (SULTs). Steroids. 2006 May;71(5):343-51.
DM78XFG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16360722

DM4ME02	DI	DM4ME02
DM4ME02	DN	Ticarcillin
DM4ME02	MI	TTJP4SM
DM4ME02	MN	Bacterial Penicillin binding protein (Bact PBP)
DM4ME02	MT	DTT
DM4ME02	MA	Binder
DM4ME02	RN	Activities of antibiotics against methicillin-resistant Staphylococcus aureus with particular reference to synergetic effect between ticarcillin and fosfomycin on penicillinase non-producing methicillin-resistant S. aureus. Jpn J Antibiot. 1993 Jun;46(6):421-7.
DM4ME02	RU	https://pubmed.ncbi.nlm.nih.gov/8360977

DM4ME02	DI	DM4ME02
DM4ME02	DN	Ticarcillin
DM4ME02	MI	DED0TBR
DM4ME02	MN	Beta-lactamase (blaB)
DM4ME02	MT	DME
DM4ME02	MA	Metabolism
DM4ME02	RN	Effect of CO2 on susceptibilities of anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin. Antimicrob Agents Chemother. 1994 Feb;38(2):211-6.
DM4ME02	RU	https://pubmed.ncbi.nlm.nih.gov/8192445

DM4ME02	DI	DM4ME02
DM4ME02	DN	Ticarcillin
DM4ME02	MI	DERGEVU
DM4ME02	MN	Beta-lactamase (blaB)
DM4ME02	MT	DME
DM4ME02	MA	Metabolism
DM4ME02	RN	Effect of CO2 on susceptibilities of anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin. Antimicrob Agents Chemother. 1994 Feb;38(2):211-6.
DM4ME02	RU	https://pubmed.ncbi.nlm.nih.gov/8192445

DM4ME02	DI	DM4ME02
DM4ME02	DN	Ticarcillin
DM4ME02	MI	DEQMISO
DM4ME02	MN	Beta-lactamase (blaB)
DM4ME02	MT	DME
DM4ME02	MA	Metabolism
DM4ME02	RN	Effect of CO2 on susceptibilities of anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin. Antimicrob Agents Chemother. 1994 Feb;38(2):211-6.
DM4ME02	RU	https://pubmed.ncbi.nlm.nih.gov/8192445

DM4ME02	DI	DM4ME02
DM4ME02	DN	Ticarcillin
DM4ME02	MI	DEHFJ4G
DM4ME02	MN	Beta-lactamase (blaB)
DM4ME02	MT	DME
DM4ME02	MA	Metabolism
DM4ME02	RN	Effect of CO2 on susceptibilities of anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin. Antimicrob Agents Chemother. 1994 Feb;38(2):211-6.
DM4ME02	RU	https://pubmed.ncbi.nlm.nih.gov/8192445

DM4ME02	DI	DM4ME02
DM4ME02	DN	Ticarcillin
DM4ME02	MI	DEHPJRC
DM4ME02	MN	Beta-lactamase (blaB)
DM4ME02	MT	DME
DM4ME02	MA	Metabolism
DM4ME02	RN	Effect of CO2 on susceptibilities of anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin. Antimicrob Agents Chemother. 1994 Feb;38(2):211-6.
DM4ME02	RU	https://pubmed.ncbi.nlm.nih.gov/8192445

DM4ME02	DI	DM4ME02
DM4ME02	DN	Ticarcillin
DM4ME02	MI	DE37FJH
DM4ME02	MN	Beta-lactamase (blaB)
DM4ME02	MT	DME
DM4ME02	MA	Metabolism
DM4ME02	RN	Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers. Antimicrob Agents Chemother. 1990 Aug;34(8):1546-50.
DM4ME02	RU	https://pubmed.ncbi.nlm.nih.gov/2221864

DM4ME02	DI	DM4ME02
DM4ME02	DN	Ticarcillin
DM4ME02	MI	DEF01WC
DM4ME02	MN	Beta-lactamase (blaB)
DM4ME02	MT	DME
DM4ME02	MA	Metabolism
DM4ME02	RN	Beta-lactamase activity in Chromobacterium violaceum. J Infect Dis. 1976 Sep;134(3):290-3.
DM4ME02	RU	https://pubmed.ncbi.nlm.nih.gov/977998

DMO946V	DI	DMO946V
DMO946V	DN	Ticlopidine
DMO946V	MI	DECB0K3
DMO946V	MN	Cytochrome P450 2D6 (CYP2D6)
DMO946V	MT	DME
DMO946V	MA	Metabolism
DMO946V	RN	Effect of health foods on cytochrome P450-mediated drug metabolism. J Pharm Health Care Sci. 2017 May 10;3:14.
DMO946V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28496987

DMO946V	DI	DMO946V
DMO946V	DN	Ticlopidine
DMO946V	MI	DEGTFWK
DMO946V	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMO946V	MT	DME
DMO946V	MA	Metabolism
DMO946V	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMO946V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMO946V	DI	DMO946V
DMO946V	DN	Ticlopidine
DMO946V	MI	DEA3U9Y
DMO946V	MN	Myeloperoxidase (MPO)
DMO946V	MT	DME
DMO946V	MA	Metabolism
DMO946V	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMO946V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMO946V	DI	DMO946V
DMO946V	DN	Ticlopidine
DMO946V	MI	TTQL5VC
DMO946V	MN	Platelet-activating factor receptor (PTAFR)
DMO946V	MT	DTT
DMO946V	MA	Modulator
DMO946V	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMO946V	RU	https://www.fda.gov/

DMLE7IO	DI	DMLE7IO
DMLE7IO	DN	Tigecycline
DMLE7IO	MI	TTQ8KVI
DMLE7IO	MN	Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)
DMLE7IO	MT	DTT
DMLE7IO	MA	Binder
DMLE7IO	RN	Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy. 2006 Aug;26(8):1099-110.
DMLE7IO	RU	https://pubmed.ncbi.nlm.nih.gov/16863487

DMLW9HG	DI	DMLW9HG
DMLW9HG	DN	Tildrakizumab
DMLW9HG	MI	TTC1GLB
DMLW9HG	MN	Interleukin-23 (IL23)
DMLW9HG	MT	DTT
DMLW9HG	MA	Modulator
DMLW9HG	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMLW9HG	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMLW9HG	DI	DMLW9HG
DMLW9HG	DN	Tildrakizumab
DMLW9HG	MI	TTQTX98
DMLW9HG	MN	Interleukin-37 (IL37)
DMLW9HG	MT	DTT
DMLW9HG	MA	Inhibitor
DMLW9HG	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMLW9HG	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMJW0VS	DI	DMJW0VS
DMJW0VS	DN	Tilidine
DMJW0VS	MI	TTN4QDT
DMJW0VS	MN	Opioid receptor (OPR)
DMJW0VS	MT	DTT
DMJW0VS	MA	Modulator
DMJW0VS	RN	Actions of tilidine and nortilidine on cloned opioid receptors. Eur J Pharmacol. 2005 Jan 4;506(3):205-8.
DMJW0VS	RU	https://pubmed.ncbi.nlm.nih.gov/15627429

DM3NXRU	DI	DM3NXRU
DM3NXRU	DN	Timolol
DM3NXRU	MI	TTR6W5O
DM3NXRU	MN	Adrenergic receptor beta-1 (ADRB1)
DM3NXRU	MT	DTT
DM3NXRU	MA	Antagonist
DM3NXRU	RN	Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension. Drugs Aging. 2006;23(12):977-95.
DM3NXRU	RU	https://pubmed.ncbi.nlm.nih.gov/17154662

DM3NXRU	DI	DM3NXRU
DM3NXRU	DN	Timolol
DM3NXRU	MI	DECB0K3
DM3NXRU	MN	Cytochrome P450 2D6 (CYP2D6)
DM3NXRU	MT	DME
DM3NXRU	MA	Metabolism
DM3NXRU	RN	Cardiac safety of ophthalmic timolol. Expert Opin Drug Saf. 2016 Nov;15(11):1549-1561.
DM3NXRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27534869

DM3NXRU	DI	DM3NXRU
DM3NXRU	DN	Timolol
DM3NXRU	MI	DEGTFWK
DM3NXRU	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM3NXRU	MT	DME
DM3NXRU	MA	Metabolism
DM3NXRU	RN	Metabolism of ophthalmic timolol: new aspects of an old drug. Basic Clin Pharmacol Toxicol. 2011 May;108(5):297-303.
DM3NXRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21385322

DM3NXRU	DI	DM3NXRU
DM3NXRU	DN	Timolol
DM3NXRU	MI	DTUGYRD
DM3NXRU	MN	P-glycoprotein 1 (ABCB1)
DM3NXRU	MT	DTP
DM3NXRU	MA	Substrate
DM3NXRU	RN	Relationship between urinary sodium excretion and pioglitazone-induced edema. J Diabetes Investig. 2010 Oct 19;1(5):208-11.
DM3NXRU	RU	https://doi.org/10.1111/j.2042-7158.1996.tb05904.x

DM3OWT4	DI	DM3OWT4
DM3OWT4	DN	Tindamax
DM3OWT4	MI	DE4LYSA
DM3OWT4	MN	Cytochrome P450 3A4 (CYP3A4)
DM3OWT4	MT	DME
DM3OWT4	MA	Metabolism
DM3OWT4	RN	FDA label of Tinidazole. The 2020 official website of the U.S. Food and Drug Administration.
DM3OWT4	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021618s003lbl.pdf

DM3OWT4	DI	DM3OWT4
DM3OWT4	DN	Tindamax
DM3OWT4	MI	DEAN5EW
DM3OWT4	MN	Nitroreductase (NTR)
DM3OWT4	MT	DME
DM3OWT4	MA	Metabolism
DM3OWT4	RN	Overexpression, isotopic labeling, and spectral characterization of Enterobacter cloacae nitroreductase. Protein Expr Purif. 1998 Jun;13(1):53-60.
DM3OWT4	RU	https://pubmed.ncbi.nlm.nih.gov/9631515

DMNYPGS	DI	DMNYPGS
DMNYPGS	DN	Tioconazole
DMNYPGS	MI	TTTSOUD
DMNYPGS	MN	Candida Cytochrome P450 51 (Candi ERG11)
DMNYPGS	MT	DTT
DMNYPGS	MA	Inhibitor
DMNYPGS	RN	Biological spectra analysis: Linking biological activity profiles to molecular structure. Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):261-6.
DMNYPGS	RU	https://pubmed.ncbi.nlm.nih.gov/15625110

DMFDC0Q	DI	DMFDC0Q
DMFDC0Q	DN	Tiotropium
DMFDC0Q	MI	TTOXS3C
DMFDC0Q	MN	Muscarinic acetylcholine receptor (CHRM)
DMFDC0Q	MT	DTT
DMFDC0Q	MA	Antagonist
DMFDC0Q	RN	Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J Pharmacol Exp Ther. 2013 May;345(2):260-70.
DMFDC0Q	RU	https://pubmed.ncbi.nlm.nih.gov/23435542

DMFDC0Q	DI	DMFDC0Q
DMFDC0Q	DN	Tiotropium
DMFDC0Q	MI	TTQ13Z5
DMFDC0Q	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMFDC0Q	MT	DTT
DMFDC0Q	MA	Antagonist
DMFDC0Q	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DMFDC0Q	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DMFDC0Q	DI	DMFDC0Q
DMFDC0Q	DN	Tiotropium
DMFDC0Q	MI	DTT79CX
DMFDC0Q	MN	Organic cation transporter 1 (SLC22A1)
DMFDC0Q	MT	DTP
DMFDC0Q	MA	Substrate
DMFDC0Q	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMFDC0Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DMFDC0Q	DI	DMFDC0Q
DMFDC0Q	DN	Tiotropium
DMFDC0Q	MI	DT3HUVD
DMFDC0Q	MN	Organic cation/carnitine transporter 2 (SLC22A5)
DMFDC0Q	MT	DTP
DMFDC0Q	MA	Substrate
DMFDC0Q	RN	Transport of ipratropium, an anti-chronic obstructive pulmonary disease drug, is mediated by organic cation/carnitine transporters in human bronchial epithelial cells: implications for carrier-mediated pulmonary absorption. Mol Pharm. 2010 Feb 1;7(1):187-95.
DMFDC0Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/20020740

DM8HJX6	DI	DM8HJX6
DM8HJX6	DN	Tipranavir
DM8HJX6	MI	DECB0K3
DM8HJX6	MN	Cytochrome P450 2D6 (CYP2D6)
DM8HJX6	MT	DME
DM8HJX6	MA	Metabolism
DM8HJX6	RN	A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther. 2010 Jun;87(6):735-42.
DM8HJX6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20147896

DM8HJX6	DI	DM8HJX6
DM8HJX6	DN	Tipranavir
DM8HJX6	MI	DE4LYSA
DM8HJX6	MN	Cytochrome P450 3A4 (CYP3A4)
DM8HJX6	MT	DME
DM8HJX6	MA	Metabolism
DM8HJX6	RN	A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther. 2010 Jun;87(6):735-42.
DM8HJX6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20147896

DM8HJX6	DI	DM8HJX6
DM8HJX6	DN	Tipranavir
DM8HJX6	MI	TT5FNQT
DM8HJX6	MN	Human immunodeficiency virus Protease (HIV PR)
DM8HJX6	MT	DTT
DM8HJX6	MA	Modulator
DM8HJX6	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM8HJX6	RU	https://www.fda.gov/

DM8HJX6	DI	DM8HJX6
DM8HJX6	DN	Tipranavir
DM8HJX6	MI	DEGTFWK
DM8HJX6	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM8HJX6	MT	DME
DM8HJX6	MA	Metabolism
DM8HJX6	RN	A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther. 2010 Jun;87(6):735-42.
DM8HJX6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20147896

DMJNV4O	DI	DMJNV4O
DMJNV4O	DN	Tirbanibulin
DMJNV4O	MI	TTHVQ4N
DMJNV4O	MN	Tubulin polymerization (TubP)
DMJNV4O	MT	DTT
DMJNV4O	MA	Inhibitor
DMJNV4O	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMJNV4O	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213189s000lbl.pdf

DMQG17S	DI	DMQG17S
DMQG17S	DN	Tirofiban
DMQG17S	MI	TT38RM1
DMQG17S	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DMQG17S	MT	DTT
DMQG17S	MA	Modulator
DMQG17S	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMQG17S	RU	https://www.fda.gov/

DMM9BJD	DI	DMM9BJD
DMM9BJD	DN	Tisagenlecleucel
DMM9BJD	MI	TTW640A
DMM9BJD	MN	B-lymphocyte surface antigen B4 (CD19)
DMM9BJD	MT	DTT
DMM9BJD	MA	Immunostimulant
DMM9BJD	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DMM9BJD	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DMM9BJD	DI	DMM9BJD
DMM9BJD	DN	Tisagenlecleucel
DMM9BJD	MI	TTUE541
DMM9BJD	MN	Leukocyte surface antigen Leu-16 (CD20)
DMM9BJD	MT	DTT
DMM9BJD	MA	Immunostimulant
DMM9BJD	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMM9BJD	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMGVUO5	DI	DMGVUO5
DMGVUO5	DN	Tislelizumab
DMGVUO5	MI	TTNBFWK
DMGVUO5	MN	Programmed cell death protein 1 (PD-1)
DMGVUO5	MT	DTT
DMGVUO5	RN	Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC). Expert Opin Investig Drugs. 2020 Dec;29(12):1355-1364.
DMGVUO5	RU	https://pubmed.ncbi.nlm.nih.gov/33044117

DMUKC5L	DI	DMUKC5L
DMUKC5L	DN	Tivozanib
DMUKC5L	MI	TT2Q6G1
DMUKC5L	MN	Vascular endothelial growth factor receptor 1 (FLT-1)
DMUKC5L	MT	DTT
DMUKC5L	MA	Inhibitor
DMUKC5L	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services
DMUKC5L	RU	https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-tivozanib-relapsed-or-refractory-advanced-renal-cell-carcinoma

DMUKC5L	DI	DMUKC5L
DMUKC5L	DN	Tivozanib
DMUKC5L	MI	TTUTJGQ
DMUKC5L	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMUKC5L	MT	DTT
DMUKC5L	MA	Modulator
DMUKC5L	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services
DMUKC5L	RU	https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-tivozanib-relapsed-or-refractory-advanced-renal-cell-carcinoma

DMUKC5L	DI	DMUKC5L
DMUKC5L	DN	Tivozanib
DMUKC5L	MI	TTDCBX5
DMUKC5L	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DMUKC5L	MT	DTT
DMUKC5L	MA	Modulator
DMUKC5L	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services
DMUKC5L	RU	https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-tivozanib-relapsed-or-refractory-advanced-renal-cell-carcinoma

DMR2IQ4	DI	DMR2IQ4
DMR2IQ4	DN	Tizanidine
DMR2IQ4	MI	TTQ8AFT
DMR2IQ4	MN	Adrenergic receptor Alpha-2 (ADRA2)
DMR2IQ4	MT	DTT
DMR2IQ4	MA	Agonist
DMR2IQ4	RN	Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs. 1997 Mar;53(3):435-52.
DMR2IQ4	RU	https://pubmed.ncbi.nlm.nih.gov/9074844

DMR2IQ4	DI	DMR2IQ4
DMR2IQ4	DN	Tizanidine
DMR2IQ4	MI	DEJGDUW
DMR2IQ4	MN	Cytochrome P450 1A2 (CYP1A2)
DMR2IQ4	MT	DME
DMR2IQ4	MA	Metabolism
DMR2IQ4	RN	Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
DMR2IQ4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19754423

DMUI0CH	DI	DMUI0CH
DMUI0CH	DN	Tobramycin
DMUI0CH	MI	DEJADS9
DMUI0CH	MN	Aminoglycoside N-acetyltransferase (aacC2)
DMUI0CH	MT	DME
DMUI0CH	MA	Metabolism
DMUI0CH	RN	Relationship between antimicrobial resistance and aminoglycoside-modifying enzyme gene expressions in Acinetobacter baumannii. Chin Med J (Engl). 2005 Jan 20;118(2):141-5.
DMUI0CH	RU	https://pubmed.ncbi.nlm.nih.gov/15667800

DMUI0CH	DI	DMUI0CH
DMUI0CH	DN	Tobramycin
DMUI0CH	MI	DEWPAJD
DMUI0CH	MN	Aminoglycoside O-phosphotransferase (aphA6)
DMUI0CH	MT	DME
DMUI0CH	MA	Metabolism
DMUI0CH	RN	Relationship between antimicrobial resistance and aminoglycoside-modifying enzyme gene expressions in Acinetobacter baumannii. Chin Med J (Engl). 2005 Jan 20;118(2):141-5.
DMUI0CH	RU	https://pubmed.ncbi.nlm.nih.gov/15667800

DMUI0CH	DI	DMUI0CH
DMUI0CH	DN	Tobramycin
DMUI0CH	MI	DE5WGIM
DMUI0CH	MN	Aminoglycoside phosphotransferase (aph-Ib)
DMUI0CH	MT	DME
DMUI0CH	MA	Metabolism
DMUI0CH	RN	Cloning and expression of novel aminoglycoside phosphotransferase genes from Campylobacter and their role in the resistance to six aminoglycosides. Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01682-17.
DMUI0CH	RU	https://pubmed.ncbi.nlm.nih.gov/29109167

DMUI0CH	DI	DMUI0CH
DMUI0CH	DN	Tobramycin
DMUI0CH	MI	TTOVFH2
DMUI0CH	MN	Bacterial 30S ribosomal RNA (Bact 30S rRNA)
DMUI0CH	MT	DTT
DMUI0CH	MA	Modulator
DMUI0CH	RN	Mechanism of action of aminoglycoside antibiotics.Binding studies of tobramycin and its 6'-N-acetyl derivative to the bacterial ribosome and its subunits.Eur J Biochem.1979 Dec;102(1):73-81.
DMUI0CH	RU	https://www.ncbi.nlm.nih.gov/pubmed/391568

DMUI0CH	DI	DMUI0CH
DMUI0CH	DN	Tobramycin
DMUI0CH	MI	DECXWN8
DMUI0CH	MN	Kanamycin/gentamycin-resistance enzyme (aacA)
DMUI0CH	MT	DME
DMUI0CH	MA	Metabolism
DMUI0CH	RN	Cloning and expression of novel aminoglycoside phosphotransferase genes from Campylobacter and their role in the resistance to six aminoglycosides. Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01682-17.
DMUI0CH	RU	https://pubmed.ncbi.nlm.nih.gov/29109167

DMUI0CH	DI	DMUI0CH
DMUI0CH	DN	Tobramycin
DMUI0CH	MI	DEZV4AP
DMUI0CH	MN	RNA cytidine acetyltransferase (hALP)
DMUI0CH	MT	DME
DMUI0CH	MA	Metabolism
DMUI0CH	RN	Genetic analysis of bacterial acetyltransferases: identification of amino acids determining the specificities of the aminoglycoside 6'-N-acetyltransferase Ib and IIa proteins. J Bacteriol. 1992 May;174(10):3196-203.
DMUI0CH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1577689

DMYNMDP	DI	DMYNMDP
DMYNMDP	DN	Tocainide
DMYNMDP	MI	DEJGDUW
DMYNMDP	MN	Cytochrome P450 1A2 (CYP1A2)
DMYNMDP	MT	DME
DMYNMDP	MA	Metabolism
DMYNMDP	RN	The effect of tocainide on theophylline metabolism. Br J Clin Pharmacol. 1993 Apr;35(4):437-40.
DMYNMDP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8485025

DMYNMDP	DI	DMYNMDP
DMYNMDP	DN	Tocainide
DMYNMDP	MI	TT05DLS
DMYNMDP	MN	E3 ubiquitin-protein ligase COP1 (RFWD2)
DMYNMDP	MT	DTT
DMYNMDP	MA	Modulator
DMYNMDP	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMYNMDP	RU	https://www.fda.gov/

DM7J6OR	DI	DM7J6OR
DM7J6OR	DN	Tocilizumab
DM7J6OR	MI	TT0E5SK
DM7J6OR	MN	Interleukin 6 receptor (IL6R)
DM7J6OR	MT	DTT
DM7J6OR	MA	Modulator
DM7J6OR	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DM7J6OR	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DM1UE67	DI	DM1UE67
DM1UE67	DN	TOCOTRIENOL
DM1UE67	MI	TTPADOQ
DM1UE67	MN	HMG-CoA reductase (HMGCR)
DM1UE67	MT	DTT
DM1UE67	MA	Inhibitor
DM1UE67	RN	Inhibitory effect of delta-tocotrienol, a HMG CoA reductase inhibitor, on monocyte-endothelial cell adhesion. J Nutr Sci Vitaminol (Tokyo). 2002 Oct;48(5):332-7.
DM1UE67	RU	https://pubmed.ncbi.nlm.nih.gov/12656204

DMBS370	DI	DMBS370
DMBS370	DN	Tofacitinib
DMBS370	MI	DE4LYSA
DMBS370	MN	Cytochrome P450 3A4 (CYP3A4)
DMBS370	MT	DME
DMBS370	MA	Metabolism
DMBS370	RN	The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans. Drug Metab Dispos. 2014 Apr;42(4):759-73.
DMBS370	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24464803

DMBS370	DI	DMBS370
DMBS370	DN	Tofacitinib
DMBS370	MI	TTT7PJU
DMBS370	MN	Janus kinase 3 (JAK-3)
DMBS370	MT	DTT
DMBS370	MA	Modulator
DMBS370	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMBS370	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMBS370	DI	DMBS370
DMBS370	DN	Tofacitinib
DMBS370	MI	DEGTFWK
DMBS370	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMBS370	MT	DME
DMBS370	MA	Metabolism
DMBS370	RN	The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans. Drug Metab Dispos. 2014 Apr;42(4):759-73.
DMBS370	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24464803

DMIHRNA	DI	DMIHRNA
DMIHRNA	DN	Tolazamide
DMIHRNA	MI	DE5IED8
DMIHRNA	MN	Cytochrome P450 2C9 (CYP2C9)
DMIHRNA	MT	DME
DMIHRNA	MA	Metabolism
DMIHRNA	RN	Clinically and pharmacologically relevant interactions of antidiabetic drugs. Ther Adv Endocrinol Metab. 2016 Apr;7(2):69-83.
DMIHRNA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27092232

DMIHRNA	DI	DMIHRNA
DMIHRNA	DN	Tolazamide
DMIHRNA	MI	TTG140O
DMIHRNA	MN	Inward rectifier potassium channel Kir1.2 (KCNJ10)
DMIHRNA	MT	DTT
DMIHRNA	MA	Blocker
DMIHRNA	RN	Inhibition of ATP-activated potassium channels exerts pressor effects and improves survival in a rat model of severe hemorrhagic shock. Shock. 1996 Jun;5(6):391-4.
DMIHRNA	RU	https://pubmed.ncbi.nlm.nih.gov/8799949

DMI40NL	DI	DMI40NL
DMI40NL	DN	Tolazoline
DMI40NL	MI	TTEX248
DMI40NL	MN	Dopamine D2 receptor (D2R)
DMI40NL	MT	DTT
DMI40NL	MA	Antagonist
DMI40NL	RN	Comparative effects of tolazoline and nitroprusside on human isolated radial artery. Ann Thorac Surg. 2006 Jan;81(1):125-31.
DMI40NL	RU	https://pubmed.ncbi.nlm.nih.gov/16368348

DM02AWV	DI	DM02AWV
DM02AWV	DN	Tolbutamide
DM02AWV	MI	TTP835K
DM02AWV	MN	ATP-binding cassette transporter C8 (ABCC8)
DM02AWV	MT	DTT
DM02AWV	MA	Blocker
DM02AWV	RN	Expression of an activating mutation in the gene encoding the KATP channel subunit Kir6.2 in mouse pancreatic beta cells recapitulates neonatal diabetes. J Clin Invest. 2009 Jan;119(1):80-90. 
DM02AWV	RU	https://pubmed.ncbi.nlm.nih.gov/19065048

DM02AWV	DI	DM02AWV
DM02AWV	DN	Tolbutamide
DM02AWV	MI	TTEF5MJ
DM02AWV	MN	ATP-binding cassette transporter C9 (ABCC9)
DM02AWV	MT	DTT
DM02AWV	MA	Blocker
DM02AWV	RN	Expression of an activating mutation in the gene encoding the KATP channel subunit Kir6.2 in mouse pancreatic beta cells recapitulates neonatal diabetes. J Clin Invest. 2009 Jan;119(1):80-90. 
DM02AWV	RU	https://pubmed.ncbi.nlm.nih.gov/19065048

DM02AWV	DI	DM02AWV
DM02AWV	DN	Tolbutamide
DM02AWV	MI	DEZMWRE
DM02AWV	MN	Cytochrome P450 2C18 (CYP2C18)
DM02AWV	MT	DME
DM02AWV	MA	Metabolism
DM02AWV	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM02AWV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM02AWV	DI	DM02AWV
DM02AWV	DN	Tolbutamide
DM02AWV	MI	DES5XRU
DM02AWV	MN	Cytochrome P450 2C8 (CYP2C8)
DM02AWV	MT	DME
DM02AWV	MA	Metabolism
DM02AWV	RN	Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments. Drug Metab Dispos. 2000 Apr;28(4):475-81.
DM02AWV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10725317

DM02AWV	DI	DM02AWV
DM02AWV	DN	Tolbutamide
DM02AWV	MI	DE5IED8
DM02AWV	MN	Cytochrome P450 2C9 (CYP2C9)
DM02AWV	MT	DME
DM02AWV	MA	Metabolism
DM02AWV	RN	Effects of organic solvents on the activities of cytochrome P450 isoforms, UDP-dependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes. Drug Metab Dispos. 2001 Feb;29(2):141-4.
DM02AWV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11159803

DM02AWV	DI	DM02AWV
DM02AWV	DN	Tolbutamide
DM02AWV	MI	DEGTFWK
DM02AWV	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM02AWV	MT	DME
DM02AWV	MA	Metabolism
DM02AWV	RN	CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes. Drug Metab Dispos. 2000 Mar;28(3):354-9.
DM02AWV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10681382

DM02AWV	DI	DM02AWV
DM02AWV	DN	Tolbutamide
DM02AWV	MI	DTI58LU
DM02AWV	MN	Sulfonylurea receptor 1 (ABCC8)
DM02AWV	MT	DTP
DM02AWV	MA	Substrate
DM02AWV	RN	ABCC8 and ABCC9: ABC transporters that regulate K+ channels. Pflugers Arch. 2007 Feb;453(5):703-18.
DM02AWV	RU	http://www.ncbi.nlm.nih.gov/pubmed/16897043

DM02AWV	DI	DM02AWV
DM02AWV	DN	Tolbutamide
DM02AWV	MI	DT3JCE6
DM02AWV	MN	Sulfonylurea receptor 2 (ABCC9)
DM02AWV	MT	DTP
DM02AWV	MA	Substrate
DM02AWV	RN	ABCC8 and ABCC9: ABC transporters that regulate K+ channels. Pflugers Arch. 2007 Feb;453(5):703-18.
DM02AWV	RU	http://www.ncbi.nlm.nih.gov/pubmed/16897043

DM8MNVO	DI	DM8MNVO
DM8MNVO	DN	Tolcapone
DM8MNVO	MI	TTKWFB8
DM8MNVO	MN	Catechol-O-methyl-transferase (COMT)
DM8MNVO	MT	DTT
DM8MNVO	MA	Inhibitor
DM8MNVO	RN	Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease. Semin Neurol. 2001;21(1):15-22.
DM8MNVO	RU	https://pubmed.ncbi.nlm.nih.gov/11346021

DMWUIJE	DI	DMWUIJE
DMWUIJE	DN	Tolmetin
DMWUIJE	MI	TTVKILB
DMWUIJE	MN	Prostaglandin G/H synthase 2 (COX-2)
DMWUIJE	MT	DTT
DMWUIJE	MA	Inhibitor
DMWUIJE	RN	Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44.
DMWUIJE	RU	https://pubmed.ncbi.nlm.nih.gov/19379806

DM28MU7	DI	DM28MU7
DM28MU7	DN	Tolnaftate
DM28MU7	MI	TTE14XG
DM28MU7	MN	Squalene monooxygenase (SQLE)
DM28MU7	MT	DTT
DM28MU7	MA	Inhibitor
DM28MU7	RN	Effects of squalene epoxidase inhibitors on Candida albicans. Antimicrob Agents Chemother. 1992 Aug;36(8):1779-81.
DM28MU7	RU	https://pubmed.ncbi.nlm.nih.gov/1416865

DMA2GHJ	DI	DMA2GHJ
DMA2GHJ	DN	Tolperisone
DMA2GHJ	MI	DEJGDUW
DMA2GHJ	MN	Cytochrome P450 1A2 (CYP1A2)
DMA2GHJ	MT	DME
DMA2GHJ	MA	Metabolism
DMA2GHJ	RN	Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes. Drug Metab Dispos. 2003 May;31(5):631-6.
DMA2GHJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12695352

DMA2GHJ	DI	DMA2GHJ
DMA2GHJ	DN	Tolperisone
DMA2GHJ	MI	DECB0K3
DMA2GHJ	MN	Cytochrome P450 2D6 (CYP2D6)
DMA2GHJ	MT	DME
DMA2GHJ	MA	Metabolism
DMA2GHJ	RN	Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes. Drug Metab Dispos. 2003 May;31(5):631-6.
DMA2GHJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12695352

DMA2GHJ	DI	DMA2GHJ
DMA2GHJ	DN	Tolperisone
DMA2GHJ	MI	DEGTFWK
DMA2GHJ	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMA2GHJ	MT	DME
DMA2GHJ	MA	Metabolism
DMA2GHJ	RN	Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes. Drug Metab Dispos. 2003 May;31(5):631-6.
DMA2GHJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12695352

DMA2GHJ	DI	DMA2GHJ
DMA2GHJ	DN	Tolperisone
DMA2GHJ	MI	TTCRJKY
DMA2GHJ	MN	Voltage-gated calcium channel (Cav)
DMA2GHJ	MT	DTT
DMA2GHJ	MA	Modulator
DMA2GHJ	RN	Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec;315(3):1237-46.
DMA2GHJ	RU	https://pubmed.ncbi.nlm.nih.gov/16126840

DMA2GHJ	DI	DMA2GHJ
DMA2GHJ	DN	Tolperisone
DMA2GHJ	MI	TTN9VTF
DMA2GHJ	MN	Voltage-gated sodium channel alpha Nav1.9 (SCN11A)
DMA2GHJ	MT	DTT
DMA2GHJ	MA	Modulator
DMA2GHJ	RN	Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec;315(3):1237-46.
DMA2GHJ	RU	https://pubmed.ncbi.nlm.nih.gov/16126840

DMSHPW8	DI	DMSHPW8
DMSHPW8	DN	Tolterodine
DMSHPW8	MI	DE5IED8
DMSHPW8	MN	Cytochrome P450 2C9 (CYP2C9)
DMSHPW8	MT	DME
DMSHPW8	MA	Metabolism
DMSHPW8	RN	Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab Dispos. 1998 Apr;26(4):289-93.
DMSHPW8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9531513

DMSHPW8	DI	DMSHPW8
DMSHPW8	DN	Tolterodine
DMSHPW8	MI	DECB0K3
DMSHPW8	MN	Cytochrome P450 2D6 (CYP2D6)
DMSHPW8	MT	DME
DMSHPW8	MA	Metabolism
DMSHPW8	RN	Effect of the CYP2D6*10 genotype on tolterodine pharmacokinetics. Drug Metab Dispos. 2010 Sep;38(9):1456-63.
DMSHPW8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20530222

DMSHPW8	DI	DMSHPW8
DMSHPW8	DN	Tolterodine
DMSHPW8	MI	DE4LYSA
DMSHPW8	MN	Cytochrome P450 3A4 (CYP3A4)
DMSHPW8	MT	DME
DMSHPW8	MA	Metabolism
DMSHPW8	RN	Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab Dispos. 1998 Apr;26(4):289-93.
DMSHPW8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9531513

DMSHPW8	DI	DMSHPW8
DMSHPW8	DN	Tolterodine
DMSHPW8	MI	DEGTFWK
DMSHPW8	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMSHPW8	MT	DME
DMSHPW8	MA	Metabolism
DMSHPW8	RN	Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab Dispos. 1998 Apr;26(4):289-93.
DMSHPW8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9531513

DMSHPW8	DI	DMSHPW8
DMSHPW8	DN	Tolterodine
DMSHPW8	MI	TTQ13Z5
DMSHPW8	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMSHPW8	MT	DTT
DMSHPW8	MA	Antagonist
DMSHPW8	RN	Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther. 2004 Jun;309(3):1148-53.
DMSHPW8	RU	https://pubmed.ncbi.nlm.nih.gov/14769832

DMIWFRL	DI	DMIWFRL
DMIWFRL	DN	Tolvaptan
DMIWFRL	MI	DE4LYSA
DMIWFRL	MN	Cytochrome P450 3A4 (CYP3A4)
DMIWFRL	MT	DME
DMIWFRL	MA	Metabolism
DMIWFRL	RN	Tolvaptan: a new therapeutic agent. Rev Recent Clin Trials. 2011 May;6(2):177-88.
DMIWFRL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20868352

DMIWFRL	DI	DMIWFRL
DMIWFRL	DN	Tolvaptan
DMIWFRL	MI	DTUGYRD
DMIWFRL	MN	P-glycoprotein 1 (ABCB1)
DMIWFRL	MT	DTP
DMIWFRL	MA	Substrate
DMIWFRL	RN	In vitro P-glycoprotein interactions and steady-state pharmacokinetic interactions between tolvaptan and digoxin in healthy subjects. J Clin Pharmacol. 2011 May;51(5):761-9.
DMIWFRL	RU	http://www.ncbi.nlm.nih.gov/pubmed/20679500

DMIWFRL	DI	DMIWFRL
DMIWFRL	DN	Tolvaptan
DMIWFRL	MI	TTK8R02
DMIWFRL	MN	Vasopressin V2 receptor (V2R)
DMIWFRL	MT	DTT
DMIWFRL	MA	Antagonist
DMIWFRL	RN	Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor. Biochem J. 2009 May 1;419(3):577-84.
DMIWFRL	RU	https://pubmed.ncbi.nlm.nih.gov/19196236

DMAE6LK	DI	DMAE6LK
DMAE6LK	DN	Topetecan
DMAE6LK	MI	TTGTQHC
DMAE6LK	MN	DNA topoisomerase I (TOP1)
DMAE6LK	MT	DTT
DMAE6LK	MA	Inhibitor
DMAE6LK	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMAE6LK	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DM82Z30	DI	DM82Z30
DM82Z30	DN	Topiramate
DM82Z30	MI	DE4LYSA
DM82Z30	MN	Cytochrome P450 3A4 (CYP3A4)
DM82Z30	MT	DME
DM82Z30	MA	Metabolism
DM82Z30	RN	Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate. Epilepsia. 2003 Dec;44(12):1521-8.
DM82Z30	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14636322

DM82Z30	DI	DM82Z30
DM82Z30	DN	Topiramate
DM82Z30	MI	TT0MYE2
DM82Z30	MN	Glutamate receptor ionotropic kainate 1 (GRIK1)
DM82Z30	MT	DTT
DM82Z30	MA	Antagonist
DM82Z30	RN	Development of medications for alcohol use disorders: recent advances and ongoing challenges. Expert Opin Emerg Drugs. 2005 May;10(2):323-43.
DM82Z30	RU	https://pubmed.ncbi.nlm.nih.gov/15934870

DM82Z30	DI	DM82Z30
DM82Z30	DN	Topiramate
DM82Z30	MI	DTUGYRD
DM82Z30	MN	P-glycoprotein 1 (ABCB1)
DM82Z30	MT	DTP
DM82Z30	MA	Substrate
DM82Z30	RN	The antiepileptic drug topiramate is a substrate for human P-glycoprotein but not multidrug resistance proteins. Pharm Res. 2009 Nov;26(11):2464-70.
DM82Z30	RU	https://doi.org/10.1007/s11095-009-9961-8

DMP6G8T	DI	DMP6G8T
DMP6G8T	DN	Topotecan
DMP6G8T	MI	DTI7UX6
DMP6G8T	MN	Breast cancer resistance protein (ABCG2)
DMP6G8T	MT	DTP
DMP6G8T	MA	Substrate
DMP6G8T	RN	Differential inhibition of murine Bcrp1/Abcg2 and human BCRP/ABCG2 by the mycotoxin fumitremorgin C. Eur J Pharmacol. 2010 Oct 10;644(1-3):41-8.
DMP6G8T	RU	http://www.ncbi.nlm.nih.gov/pubmed/20655304

DMP6G8T	DI	DMP6G8T
DMP6G8T	DN	Topotecan
DMP6G8T	MI	TTGTQHC
DMP6G8T	MN	DNA topoisomerase I (TOP1)
DMP6G8T	MT	DTT
DMP6G8T	MA	Modulator
DMP6G8T	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMP6G8T	RU	https://www.fda.gov/

DMP6G8T	DI	DMP6G8T
DMP6G8T	DN	Topotecan
DMP6G8T	MI	DTZGT0P
DMP6G8T	MN	Multidrug and toxin extrusion protein 1 (SLC47A1)
DMP6G8T	MT	DTP
DMP6G8T	MA	Substrate
DMP6G8T	RN	Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
DMP6G8T	RU	http://www.ncbi.nlm.nih.gov/pubmed/17509534

DMP6G8T	DI	DMP6G8T
DMP6G8T	DN	Topotecan
DMP6G8T	MI	DT3TX4H
DMP6G8T	MN	Multidrug and toxin extrusion protein 2 (SLC47A2)
DMP6G8T	MT	DTP
DMP6G8T	MA	Substrate
DMP6G8T	RN	Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
DMP6G8T	RU	http://www.ncbi.nlm.nih.gov/pubmed/17509534

DMP6G8T	DI	DMP6G8T
DMP6G8T	DN	Topotecan
DMP6G8T	MI	DTSYQGK
DMP6G8T	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMP6G8T	MT	DTP
DMP6G8T	MA	Substrate
DMP6G8T	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMP6G8T	RU	https://doi.org/10.1007/s11095-012-0935-x

DMP6G8T	DI	DMP6G8T
DMP6G8T	DN	Topotecan
DMP6G8T	MI	DTCSGPB
DMP6G8T	MN	Multidrug resistance-associated protein 4 (ABCC4)
DMP6G8T	MT	DTP
DMP6G8T	MA	Substrate
DMP6G8T	RN	Topotecan is a substrate for multidrug resistance associated protein 4. Curr Drug Metab. 2006 Jan;7(1):105-18.
DMP6G8T	RU	http://www.ncbi.nlm.nih.gov/pubmed/16454695

DMP6G8T	DI	DMP6G8T
DMP6G8T	DN	Topotecan
DMP6G8T	MI	DTUGYRD
DMP6G8T	MN	P-glycoprotein 1 (ABCB1)
DMP6G8T	MT	DTP
DMP6G8T	MA	Substrate
DMP6G8T	RN	Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells. Pharm Res. 2008 Nov;25(11):2601-12.
DMP6G8T	RU	http://www.ncbi.nlm.nih.gov/pubmed/18654741

DMXKJ6C	DI	DMXKJ6C
DMXKJ6C	DN	Torasemide
DMXKJ6C	MI	DES5XRU
DMXKJ6C	MN	Cytochrome P450 2C8 (CYP2C8)
DMXKJ6C	MT	DME
DMXKJ6C	MA	Metabolism
DMXKJ6C	RN	Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro. J Pharmacol Exp Ther. 2004 Dec;311(3):996-1007.
DMXKJ6C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304522

DMXKJ6C	DI	DMXKJ6C
DMXKJ6C	DN	Torasemide
DMXKJ6C	MI	DE5IED8
DMXKJ6C	MN	Cytochrome P450 2C9 (CYP2C9)
DMXKJ6C	MT	DME
DMXKJ6C	MA	Metabolism
DMXKJ6C	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMXKJ6C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMXKJ6C	DI	DMXKJ6C
DMXKJ6C	DN	Torasemide
DMXKJ6C	MI	DT3D8F0
DMXKJ6C	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMXKJ6C	MT	DTP
DMXKJ6C	MA	Substrate
DMXKJ6C	RN	Coleman J., Cox A. and Cowley N. (2011). Side Effects of Drugs Annual. Elsevier.
DMXKJ6C	RU	http://www.doc88.com/p-7415211358030.html

DMXKJ6C	DI	DMXKJ6C
DMXKJ6C	DN	Torasemide
DMXKJ6C	MI	TTS087L
DMXKJ6C	MN	Solute carrier family 12 member 1 (SLC12A1)
DMXKJ6C	MT	DTT
DMXKJ6C	MA	Blocker
DMXKJ6C	RN	Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. Clin Pharmacol Ther. 2007 Sep;82(3):300-9.
DMXKJ6C	RU	https://pubmed.ncbi.nlm.nih.gov/17460608

DMQYUWG	DI	DMQYUWG
DMQYUWG	DN	Toremifene
DMQYUWG	MI	DE6OQ3W
DMQYUWG	MN	Cytochrome P450 1A1 (CYP1A1)
DMQYUWG	MT	DME
DMQYUWG	MA	Metabolism
DMQYUWG	RN	Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes. Biochem Pharmacol. 1994 May 18;47(10):1883-95.
DMQYUWG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8204106

DMQYUWG	DI	DMQYUWG
DMQYUWG	DN	Toremifene
DMQYUWG	MI	DE4LYSA
DMQYUWG	MN	Cytochrome P450 3A4 (CYP3A4)
DMQYUWG	MT	DME
DMQYUWG	MA	Metabolism
DMQYUWG	RN	Drug interaction potential of toremifene and N-desmethyltoremifene with multiple cytochrome P450 isoforms. Xenobiotica. 2011 Oct;41(10):851-62.
DMQYUWG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21726172

DMQYUWG	DI	DMQYUWG
DMQYUWG	DN	Toremifene
DMQYUWG	MI	TTZAYWL
DMQYUWG	MN	Estrogen receptor (ESR)
DMQYUWG	MT	DTT
DMQYUWG	MA	Modulator
DMQYUWG	RN	Effect of selective estrogen receptor modulators on cell proliferation and estrogen receptor activities in normal human prostate stromal and epithe... Prostate Cancer Prostatic Dis. 2009;12(4):375-81.
DMQYUWG	RU	https://pubmed.ncbi.nlm.nih.gov/19468285

DMQYUWG	DI	DMQYUWG
DMQYUWG	DN	Toremifene
DMQYUWG	MI	DTUGYRD
DMQYUWG	MN	P-glycoprotein 1 (ABCB1)
DMQYUWG	MT	DTP
DMQYUWG	MA	Substrate
DMQYUWG	RN	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
DMQYUWG	RU	http://www.ncbi.nlm.nih.gov/pubmed/7914405

DMMYZ3D	DI	DMMYZ3D
DMMYZ3D	DN	Tositumomab
DMMYZ3D	MI	TTUE541
DMMYZ3D	MN	Leukocyte surface antigen Leu-16 (CD20)
DMMYZ3D	MT	DTT
DMMYZ3D	RN	Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol. 2009 Jul;46(11-12):2419-23.
DMMYZ3D	RU	https://pubmed.ncbi.nlm.nih.gov/19427037

DM5A31S	DI	DM5A31S
DM5A31S	DN	TP-434
DM5A31S	MI	TTOVFH2
DM5A31S	MN	Bacterial 30S ribosomal RNA (Bact 30S rRNA)
DM5A31S	MT	DTT
DM5A31S	MA	Inhibitor
DM5A31S	RN	The antibiotic arms race: current and emerging therapy for Klebsiella pneumoniae carbapenemase (KPC) - producing bacteria.Expert Opin Pharmacother. 2018 Oct 22:1-13. 
DM5A31S	RU	https://pubmed.ncbi.nlm.nih.gov/30346216

DM5A31S	DI	DM5A31S
DM5A31S	DN	TP-434
DM5A31S	MI	TTND3XS
DM5A31S	MN	Bacterial Ribosome (Bact RIBS)
DM5A31S	MT	DTT
DM5A31S	MA	Modulator
DM5A31S	RN	Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob Agents Chemother. 2012 May;56(5):2559-64.
DM5A31S	RU	https://pubmed.ncbi.nlm.nih.gov/22354310

DM5A31S	DI	DM5A31S
DM5A31S	DN	TP-434
DM5A31S	MI	DE4LYSA
DM5A31S	MN	Cytochrome P450 3A4 (CYP3A4)
DM5A31S	MT	DME
DM5A31S	MA	Metabolism
DM5A31S	RN	Mass balance and drug interaction potential of intravenous eravacycline administered to healthy subjects. Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e01810-18.
DM5A31S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30559132

DMG3Y89	DI	DMG3Y89
DMG3Y89	DN	Trabectedin
DMG3Y89	MI	DE5IED8
DMG3Y89	MN	Cytochrome P450 2C9 (CYP2C9)
DMG3Y89	MT	DME
DMG3Y89	MA	Metabolism
DMG3Y89	RN	In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug. Invest New Drugs. 2006 Jan;24(1):3-14.
DMG3Y89	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16379042

DMG3Y89	DI	DMG3Y89
DMG3Y89	DN	Trabectedin
DMG3Y89	MI	DECB0K3
DMG3Y89	MN	Cytochrome P450 2D6 (CYP2D6)
DMG3Y89	MT	DME
DMG3Y89	MA	Metabolism
DMG3Y89	RN	In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug. Invest New Drugs. 2006 Jan;24(1):3-14.
DMG3Y89	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16379042

DMG3Y89	DI	DMG3Y89
DMG3Y89	DN	Trabectedin
DMG3Y89	MI	DEVDYN7
DMG3Y89	MN	Cytochrome P450 2E1 (CYP2E1)
DMG3Y89	MT	DME
DMG3Y89	MA	Metabolism
DMG3Y89	RN	In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug. Invest New Drugs. 2006 Jan;24(1):3-14.
DMG3Y89	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16379042

DMG3Y89	DI	DMG3Y89
DMG3Y89	DN	Trabectedin
DMG3Y89	MI	DE4LYSA
DMG3Y89	MN	Cytochrome P450 3A4 (CYP3A4)
DMG3Y89	MT	DME
DMG3Y89	MA	Metabolism
DMG3Y89	RN	In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug. Invest New Drugs. 2006 Jan;24(1):3-14.
DMG3Y89	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16379042

DMG3Y89	DI	DMG3Y89
DMG3Y89	DN	Trabectedin
DMG3Y89	MI	DE4ZHS1
DMG3Y89	MN	Glutathione S-transferase alpha-1 (GSTA1)
DMG3Y89	MT	DME
DMG3Y89	MA	Metabolism
DMG3Y89	RN	In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug. Invest New Drugs. 2006 Jan;24(1):3-14.
DMG3Y89	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16379042

DMG3Y89	DI	DMG3Y89
DMG3Y89	DN	Trabectedin
DMG3Y89	MI	DEGTFWK
DMG3Y89	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMG3Y89	MT	DME
DMG3Y89	MA	Metabolism
DMG3Y89	RN	In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug. Invest New Drugs. 2006 Jan;24(1):3-14.
DMG3Y89	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16379042

DMG3Y89	DI	DMG3Y89
DMG3Y89	DN	Trabectedin
DMG3Y89	MI	DE073H6
DMG3Y89	MN	Prostaglandin G/H synthase 1 (COX-1)
DMG3Y89	MT	DME
DMG3Y89	MA	Metabolism
DMG3Y89	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMG3Y89	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMRQD04	DI	DMRQD04
DMRQD04	DN	Tramadol
DMRQD04	MI	TTWJBZ5
DMRQD04	MN	5-HT 2C receptor (HTR2C)
DMRQD04	MT	DTT
DMRQD04	MA	Modulator
DMRQD04	RN	The inhibitory effects of tramadol on 5-hydroxytryptamine type 2C receptors expressed in Xenopus oocytes. Anesth Analg. 2004 May;98(5):1401-6, table of contents.
DMRQD04	RU	https://pubmed.ncbi.nlm.nih.gov/15105221

DMRQD04	DI	DMRQD04
DMRQD04	DN	Tramadol
DMRQD04	MI	DEPKLMQ
DMRQD04	MN	Cytochrome P450 2B6 (CYP2B6)
DMRQD04	MT	DME
DMRQD04	MA	Metabolism
DMRQD04	RN	Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923.
DMRQD04	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15509185

DMRQD04	DI	DMRQD04
DMRQD04	DN	Tramadol
DMRQD04	MI	DECB0K3
DMRQD04	MN	Cytochrome P450 2D6 (CYP2D6)
DMRQD04	MT	DME
DMRQD04	MA	Metabolism
DMRQD04	RN	Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923.
DMRQD04	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15509185

DMRQD04	DI	DMRQD04
DMRQD04	DN	Tramadol
DMRQD04	MI	DE4LYSA
DMRQD04	MN	Cytochrome P450 3A4 (CYP3A4)
DMRQD04	MT	DME
DMRQD04	MA	Metabolism
DMRQD04	RN	Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923.
DMRQD04	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15509185

DMRQD04	DI	DMRQD04
DMRQD04	DN	Tramadol
DMRQD04	MI	DTUGYRD
DMRQD04	MN	P-glycoprotein 1 (ABCB1)
DMRQD04	MT	DTP
DMRQD04	MA	Substrate
DMRQD04	RN	Tramadol hydrochloride: pharmacokinetics, pharmacodynamics, adverse side effects, co-administration of drugs and new drug delivery systems. Biomed Pharmacother. 2015 Mar;70:234-8.
DMRQD04	RU	http://www.ncbi.nlm.nih.gov/pubmed/25776506

DMRQD04	DI	DMRQD04
DMRQD04	DN	Tramadol
DMRQD04	MI	DEYGVN4
DMRQD04	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMRQD04	MT	DME
DMRQD04	MA	Metabolism
DMRQD04	RN	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
DMRQD04	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429

DM2JGQ3	DI	DM2JGQ3
DM2JGQ3	DN	Trametinib
DM2JGQ3	MI	TTROQ37
DM2JGQ3	MN	MAPK/ERK kinase kinase (MAP3K)
DM2JGQ3	MT	DTT
DM2JGQ3	MA	Modulator
DM2JGQ3	RN	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
DM2JGQ3	RU	https://pubmed.ncbi.nlm.nih.gov/28919714

DM4L6EU	DI	DM4L6EU
DM4L6EU	DN	Trandolapril
DM4L6EU	MI	TTL69WB
DM4L6EU	MN	Angiotensin-converting enzyme (ACE)
DM4L6EU	MT	DTT
DM4L6EU	MA	Inhibitor
DM4L6EU	RN	Selective reduction of central pulse pressure under angiotensin blockage in SHR: role of the fibronectin-alpha5beta1 integrin complex. Am J Hypertens. 2009 Jul;22(7):711-7.
DM4L6EU	RU	https://pubmed.ncbi.nlm.nih.gov/19424161

DM4L6EU	DI	DM4L6EU
DM4L6EU	DN	Trandolapril
DM4L6EU	MI	DT9G7XN
DM4L6EU	MN	Peptide transporter 1 (SLC15A1)
DM4L6EU	MT	DTP
DM4L6EU	MA	Substrate
DM4L6EU	RN	Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41.
DM4L6EU	RU	http://www.ncbi.nlm.nih.gov/pubmed/18713951

DM4L6EU	DI	DM4L6EU
DM4L6EU	DN	Trandolapril
DM4L6EU	MI	DT8QKNP
DM4L6EU	MN	Peptide transporter 2 (SLC15A2)
DM4L6EU	MT	DTP
DM4L6EU	MA	Substrate
DM4L6EU	RN	Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41.
DM4L6EU	RU	http://www.ncbi.nlm.nih.gov/pubmed/18713951

DMFI8A7	DI	DMFI8A7
DMFI8A7	DN	Tranexamic acid
DMFI8A7	MI	TTP86E2
DMFI8A7	MN	Plasminogen (PLG)
DMFI8A7	MT	DTT
DMFI8A7	MA	Inhibitor
DMFI8A7	RN	Evaluation of aprotinin and tranexamic acid in different in vitro and in vivo models of fibrinolysis, coagulation and thrombus formation. J Thromb Haemost. 2007 Oct;5(10):2113-8.
DMFI8A7	RU	https://pubmed.ncbi.nlm.nih.gov/17666018

DME5Y64	DI	DME5Y64
DME5Y64	DN	Tranilast
DME5Y64	MI	DE5IED8
DME5Y64	MN	Cytochrome P450 2C9 (CYP2C9)
DME5Y64	MT	DME
DME5Y64	MA	Metabolism
DME5Y64	RN	Glucuronidation of antiallergic drug, Tranilast: identification of human UDP-glucuronosyltransferase isoforms and effect of its phase I metabolite. Drug Metab Dispos. 2007 Apr;35(4):583-9.
DME5Y64	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17220234

DME5Y64	DI	DME5Y64
DME5Y64	DN	Tranilast
DME5Y64	MI	DE4LYSA
DME5Y64	MN	Cytochrome P450 3A4 (CYP3A4)
DME5Y64	MT	DME
DME5Y64	MA	Metabolism
DME5Y64	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DME5Y64	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DME5Y64	DI	DME5Y64
DME5Y64	DN	Tranilast
DME5Y64	MI	TTTIBOJ
DME5Y64	MN	Histamine H1 receptor (H1R)
DME5Y64	MT	DTT
DME5Y64	MA	Antagonist
DME5Y64	RN	Emerging drugs for ocular allergy. Expert Opin Emerg Drugs. 2005 Aug;10(3):505-20.
DME5Y64	RU	https://pubmed.ncbi.nlm.nih.gov/16083326

DME5Y64	DI	DME5Y64
DME5Y64	DN	Tranilast
DME5Y64	MI	TTHM0R1
DME5Y64	MN	Steryl-sulfatase (STS)
DME5Y64	MT	DTT
DME5Y64	MA	Inhibitor
DME5Y64	RN	Review of estrone sulfatase and its inhibitors--an important new target against hormone dependent breast cancer. Curr Med Chem. 2002 Jan;9(2):263-73.
DME5Y64	RU	https://pubmed.ncbi.nlm.nih.gov/11860358

DMGB5RE	DI	DMGB5RE
DMGB5RE	DN	Tranylcypromine
DMGB5RE	MI	TT32XQJ
DMGB5RE	MN	Monoamine oxidase (MAO)
DMGB5RE	MT	DTT
DMGB5RE	MA	Inhibitor
DMGB5RE	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMGB5RE	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMGB5RE	DI	DMGB5RE
DMGB5RE	DN	Tranylcypromine
DMGB5RE	MI	TT3WG5C
DMGB5RE	MN	Monoamine oxidase type A (MAO-A)
DMGB5RE	MT	DTT
DMGB5RE	MA	Inhibitor
DMGB5RE	RN	Tramadol and another atypical opioid meperidine have exaggerated serotonin syndrome behavioural effects, but decreased analgesic effects, in genetically deficient serotonin transporter (SERT) mice. Int J Neuropsychopharmacol. 2009 Mar 11:1-11.
DMGB5RE	RU	https://pubmed.ncbi.nlm.nih.gov/19275775

DMGB5RE	DI	DMGB5RE
DMGB5RE	DN	Tranylcypromine
DMGB5RE	MI	TTGP7BY
DMGB5RE	MN	Monoamine oxidase type B (MAO-B)
DMGB5RE	MT	DTT
DMGB5RE	MA	Inhibitor
DMGB5RE	RN	Tranylcypromine: new perspectives on an "old" drug. Eur Arch Psychiatry Clin Neurosci. 2006 Aug;256(5):268-73.
DMGB5RE	RU	https://pubmed.ncbi.nlm.nih.gov/16927039

DMZQOUX	DI	DMZQOUX
DMZQOUX	DN	Trastuzumab
DMZQOUX	MI	TT6EO5L
DMZQOUX	MN	Erbb2 tyrosine kinase receptor (HER2)
DMZQOUX	MT	DTT
DMZQOUX	RN	Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study. Melanoma Res. 2004 Jun;14(3):207-10.
DMZQOUX	RU	https://pubmed.ncbi.nlm.nih.gov/15179190

DM20K91	DI	DM20K91
DM20K91	DN	Travoprost
DM20K91	MI	TTT2ZAR
DM20K91	MN	Prostaglandin F2-alpha receptor (PTGFR)
DM20K91	MT	DTT
DM20K91	MA	Agonist
DM20K91	RN	Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeys. J Ocul Pharmacol Ther. 2009 Feb;25(1):1-8.
DM20K91	RU	https://pubmed.ncbi.nlm.nih.gov/19232013

DMK1GBJ	DI	DMK1GBJ
DMK1GBJ	DN	Trazodone
DMK1GBJ	MI	TTSQIFT
DMK1GBJ	MN	5-HT 1A receptor (HTR1A)
DMK1GBJ	MT	DTT
DMK1GBJ	MA	Modulator
DMK1GBJ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMK1GBJ	RU	https://www.fda.gov/

DMK1GBJ	DI	DMK1GBJ
DMK1GBJ	DN	Trazodone
DMK1GBJ	MI	DECB0K3
DMK1GBJ	MN	Cytochrome P450 2D6 (CYP2D6)
DMK1GBJ	MT	DME
DMK1GBJ	MA	Metabolism
DMK1GBJ	RN	Evaluating the role of drug metabolism and reactive intermediates in trazodone-induced cytotoxicity toward freshly-isolated rat hepatocytes. Drug Res (Stuttg). 2016 Nov;66(11):592-596.
DMK1GBJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27643409

DMK1GBJ	DI	DMK1GBJ
DMK1GBJ	DN	Trazodone
DMK1GBJ	MI	DE4LYSA
DMK1GBJ	MN	Cytochrome P450 3A4 (CYP3A4)
DMK1GBJ	MT	DME
DMK1GBJ	MA	Metabolism
DMK1GBJ	RN	Metabolic activation of the nontricyclic antidepressant trazodone to electrophilic quinone-imine and epoxide intermediates in human liver microsomes and recombinant P4503A4. Chem Biol Interact. 2005 Jun 30;155(1-2):10-20.
DMK1GBJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15978881

DMK1GBJ	DI	DMK1GBJ
DMK1GBJ	DN	Trazodone
DMK1GBJ	MI	DEIBDNY
DMK1GBJ	MN	Cytochrome P450 3A5 (CYP3A5)
DMK1GBJ	MT	DME
DMK1GBJ	MA	Metabolism
DMK1GBJ	RN	Drug Interactions Flockhart Table
DMK1GBJ	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMK1GBJ	DI	DMK1GBJ
DMK1GBJ	DN	Trazodone
DMK1GBJ	MI	DERD86B
DMK1GBJ	MN	Cytochrome P450 3A7 (CYP3A7)
DMK1GBJ	MT	DME
DMK1GBJ	MA	Metabolism
DMK1GBJ	RN	Drug Interactions Flockhart Table
DMK1GBJ	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMK1GBJ	DI	DMK1GBJ
DMK1GBJ	DN	Trazodone
DMK1GBJ	MI	TT3ROYC
DMK1GBJ	MN	Serotonin transporter (SERT)
DMK1GBJ	MT	DTT
DMK1GBJ	MA	Modulator
DMK1GBJ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMK1GBJ	RU	https://www.fda.gov/

DMTIQF3	DI	DMTIQF3
DMTIQF3	DN	Treprostinil
DMTIQF3	MI	DES5XRU
DMTIQF3	MN	Cytochrome P450 2C8 (CYP2C8)
DMTIQF3	MT	DME
DMTIQF3	MA	Metabolism
DMTIQF3	RN	FDA label of Treprostinil. The 2020 official website of the U.S. Food and Drug Administration.
DMTIQF3	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021272s026lbl.pdf

DMTIQF3	DI	DMTIQF3
DMTIQF3	DN	Treprostinil
DMTIQF3	MI	DE5IED8
DMTIQF3	MN	Cytochrome P450 2C9 (CYP2C9)
DMTIQF3	MT	DME
DMTIQF3	MA	Metabolism
DMTIQF3	RN	Lack of a pharmacokinetic interaction between oral treprostinil and bosentan in healthy adult volunteers. J Clin Pharmacol. 2010 Jul;50(7):829-34.
DMTIQF3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20133511

DMTIQF3	DI	DMTIQF3
DMTIQF3	DN	Treprostinil
DMTIQF3	MI	TTOFYT1
DMTIQF3	MN	Prostacyclin receptor (PTGIR)
DMTIQF3	MT	DTT
DMTIQF3	MA	Agonist
DMTIQF3	RN	Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review. Am Heart J. 2009 Apr;157(4):625-35.
DMTIQF3	RU	https://pubmed.ncbi.nlm.nih.gov/19332188

DM49DUI	DI	DM49DUI
DM49DUI	DN	Tretinoin
DM49DUI	MI	DEXNDR0
DM49DUI	MN	Cytochrome P450 26C1 (CYP26C1)
DM49DUI	MT	DME
DM49DUI	MA	Metabolism
DM49DUI	RN	CYP26C1 is a hydroxylase of multiple active retinoids and interacts with cellular retinoic acid binding proteins. Mol Pharmacol. 2018 May;93(5):489-503.
DM49DUI	RU	https://pubmed.ncbi.nlm.nih.gov/29476041

DM49DUI	DI	DM49DUI
DM49DUI	DN	Tretinoin
DM49DUI	MI	DEJVYAZ
DM49DUI	MN	Cytochrome P450 2A6 (CYP2A6)
DM49DUI	MT	DME
DM49DUI	MA	Metabolism
DM49DUI	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM49DUI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM49DUI	DI	DM49DUI
DM49DUI	DN	Tretinoin
DM49DUI	MI	DEPKLMQ
DM49DUI	MN	Cytochrome P450 2B6 (CYP2B6)
DM49DUI	MT	DME
DM49DUI	MA	Metabolism
DM49DUI	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM49DUI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM49DUI	DI	DM49DUI
DM49DUI	DN	Tretinoin
DM49DUI	MI	DEZMWRE
DM49DUI	MN	Cytochrome P450 2C18 (CYP2C18)
DM49DUI	MT	DME
DM49DUI	MA	Metabolism
DM49DUI	RN	Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol. 2000 Dec;58(6):1341-8.
DM49DUI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11093772

DM49DUI	DI	DM49DUI
DM49DUI	DN	Tretinoin
DM49DUI	MI	DES5XRU
DM49DUI	MN	Cytochrome P450 2C8 (CYP2C8)
DM49DUI	MT	DME
DM49DUI	MA	Metabolism
DM49DUI	RN	Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol. 2000 Dec;58(6):1341-8.
DM49DUI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11093772

DM49DUI	DI	DM49DUI
DM49DUI	DN	Tretinoin
DM49DUI	MI	DE5IED8
DM49DUI	MN	Cytochrome P450 2C9 (CYP2C9)
DM49DUI	MT	DME
DM49DUI	MA	Metabolism
DM49DUI	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM49DUI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM49DUI	DI	DM49DUI
DM49DUI	DN	Tretinoin
DM49DUI	MI	DE4LYSA
DM49DUI	MN	Cytochrome P450 3A4 (CYP3A4)
DM49DUI	MT	DME
DM49DUI	MA	Metabolism
DM49DUI	RN	Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol. 2000 Dec;58(6):1341-8.
DM49DUI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11093772

DM49DUI	DI	DM49DUI
DM49DUI	DN	Tretinoin
DM49DUI	MI	DEIBDNY
DM49DUI	MN	Cytochrome P450 3A5 (CYP3A5)
DM49DUI	MT	DME
DM49DUI	MA	Metabolism
DM49DUI	RN	Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol. 2000 Dec;58(6):1341-8.
DM49DUI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11093772

DM49DUI	DI	DM49DUI
DM49DUI	DN	Tretinoin
DM49DUI	MI	DERD86B
DM49DUI	MN	Cytochrome P450 3A7 (CYP3A7)
DM49DUI	MT	DME
DM49DUI	MA	Metabolism
DM49DUI	RN	Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol. 2000 Dec;58(6):1341-8.
DM49DUI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11093772

DM49DUI	DI	DM49DUI
DM49DUI	DN	Tretinoin
DM49DUI	MI	DTUGYRD
DM49DUI	MN	P-glycoprotein 1 (ABCB1)
DM49DUI	MT	DTP
DM49DUI	MA	Substrate
DM49DUI	RN	Carotenoids reverse multidrug resistance in cancer cells by interfering with ABC-transporters. Phytomedicine. 2012 Aug 15;19(11):977-87.
DM49DUI	RU	https://doi.org/10.1016/j.phymed.2012.05.010

DM49DUI	DI	DM49DUI
DM49DUI	DN	Tretinoin
DM49DUI	MI	TTOD7B3
DM49DUI	MN	Retinoic acid receptor (RAR)
DM49DUI	MT	DTT
DM49DUI	MA	Binder
DM49DUI	RN	Retinoids--which dermatological indications will benefit in the near future Skin Pharmacol Appl Skin Physiol. 2001 Sep-Oct;14(5):303-15.
DM49DUI	RU	https://pubmed.ncbi.nlm.nih.gov/11586072

DM49DUI	DI	DM49DUI
DM49DUI	DN	Tretinoin
DM49DUI	MI	TT1Q3IE
DM49DUI	MN	Retinoic acid receptor gamma (RARG)
DM49DUI	MT	DTT
DM49DUI	MA	Agonist
DM49DUI	RN	Targacept active conformation search: a new method for predicting the conformation of a ligand bound to its protein target. J Med Chem. 2004 Dec 30;47(27):6831-9.
DM49DUI	RU	https://pubmed.ncbi.nlm.nih.gov/15615532

DMU54QB	DI	DMU54QB
DMU54QB	DN	Treximet
DMU54QB	MI	TTSQIFT
DMU54QB	MN	5-HT 1A receptor (HTR1A)
DMU54QB	MT	DTT
DMU54QB	MA	Antagonist
DMU54QB	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMU54QB	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DM0AEPG	DI	DM0AEPG
DM0AEPG	DN	Triacetin
DM0AEPG	MI	DEQU4N2
DM0AEPG	MN	Carboxyl ester lipase (CEL)
DM0AEPG	MT	DME
DM0AEPG	MA	Metabolism
DM0AEPG	RN	Lipoamidase activity in normal and mutagenized pancreatic cholesterol esterase (bile salt-stimulated lipase). Biochem J. 1993 Apr 1;291 ( Pt 1):65-9.
DM0AEPG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8471055

DM98IXF	DI	DM98IXF
DM98IXF	DN	Triamcinolone
DM98IXF	MI	TTYRL6O
DM98IXF	MN	Glucocorticoid receptor (NR3C1)
DM98IXF	MT	DTT
DM98IXF	MA	Modulator
DM98IXF	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM98IXF	RU	https://www.fda.gov/

DM7LRKD	DI	DM7LRKD
DM7LRKD	DN	Triamcinolone diacetate
DM7LRKD	MI	DE4LYSA
DM7LRKD	MN	Cytochrome P450 3A4 (CYP3A4)
DM7LRKD	MT	DME
DM7LRKD	MA	Metabolism
DM7LRKD	RN	Triamcinolone acetonide induced secondary adrenal insufficiency related to impaired CYP3A4 metabolism by coadministration of nefazodone. Pain Med. 2010 Jul;11(7):1132-5.
DM7LRKD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20456080

DM7LRKD	DI	DM7LRKD
DM7LRKD	DN	Triamcinolone diacetate
DM7LRKD	MI	DEIBDNY
DM7LRKD	MN	Cytochrome P450 3A5 (CYP3A5)
DM7LRKD	MT	DME
DM7LRKD	MA	Metabolism
DM7LRKD	RN	Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes. Drug Metab Dispos. 2013 Feb;41(2):379-89.
DM7LRKD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23143891

DM7LRKD	DI	DM7LRKD
DM7LRKD	DN	Triamcinolone diacetate
DM7LRKD	MI	DERD86B
DM7LRKD	MN	Cytochrome P450 3A7 (CYP3A7)
DM7LRKD	MT	DME
DM7LRKD	MA	Metabolism
DM7LRKD	RN	Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes. Drug Metab Dispos. 2013 Feb;41(2):379-89.
DM7LRKD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23143891

DM2HU9I	DI	DM2HU9I
DM2HU9I	DN	Triamterene
DM2HU9I	MI	TTQM7TE
DM2HU9I	MN	Amiloride-sensitive sodium channel (ENaC)
DM2HU9I	MT	DTT
DM2HU9I	MA	Blocker
DM2HU9I	RN	Effects of the serine/threonine kinase SGK1 on the epithelial Na(+) channel (ENaC) and CFTR: implications for cystic fibrosis. Cell Physiol Biochem. 2001;11(4):209-18.
DM2HU9I	RU	https://pubmed.ncbi.nlm.nih.gov/11509829

DM2HU9I	DI	DM2HU9I
DM2HU9I	DN	Triamterene
DM2HU9I	MI	DEJGDUW
DM2HU9I	MN	Cytochrome P450 1A2 (CYP1A2)
DM2HU9I	MT	DME
DM2HU9I	MA	Metabolism
DM2HU9I	RN	Rate-limiting biotransformation of triamterene is mediated by CYP1A2. Int J Clin Pharmacol Ther. 2005 Jul;43(7):327-34.
DM2HU9I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16035375

DM2HU9I	DI	DM2HU9I
DM2HU9I	DN	Triamterene
DM2HU9I	MI	DTT79CX
DM2HU9I	MN	Organic cation transporter 1 (SLC22A1)
DM2HU9I	MT	DTP
DM2HU9I	MA	Substrate
DM2HU9I	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DM2HU9I	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DMETYK5	DI	DMETYK5
DMETYK5	DN	Triazolam
DMETYK5	MI	DE4LYSA
DMETYK5	MN	Cytochrome P450 3A4 (CYP3A4)
DMETYK5	MT	DME
DMETYK5	MA	Metabolism
DMETYK5	RN	In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos. 2003 Jul;31(7):938-44.
DMETYK5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12814972

DMETYK5	DI	DMETYK5
DMETYK5	DN	Triazolam
DMETYK5	MI	DEIBDNY
DMETYK5	MN	Cytochrome P450 3A5 (CYP3A5)
DMETYK5	MT	DME
DMETYK5	MA	Metabolism
DMETYK5	RN	In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos. 2003 Jul;31(7):938-44.
DMETYK5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12814972

DMETYK5	DI	DMETYK5
DMETYK5	DN	Triazolam
DMETYK5	MI	DERD86B
DMETYK5	MN	Cytochrome P450 3A7 (CYP3A7)
DMETYK5	MT	DME
DMETYK5	MA	Metabolism
DMETYK5	RN	Drug Interactions Flockhart Table
DMETYK5	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMETYK5	DI	DMETYK5
DMETYK5	DN	Triazolam
DMETYK5	MI	TTPTXIN
DMETYK5	MN	Translocator protein (TSPO)
DMETYK5	MT	DTT
DMETYK5	MA	Modulator
DMETYK5	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMETYK5	RU	https://www.fda.gov/

DMHAQCO	DI	DMHAQCO
DMHAQCO	DN	Trichlormethiazide
DMHAQCO	MI	DTVP67E
DMHAQCO	MN	Organic anion transporter 3 (SLC22A8)
DMHAQCO	MT	DTP
DMHAQCO	MA	Substrate
DMHAQCO	RN	Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab Dispos. 2011 Jun;39(6):1031-8.
DMHAQCO	RU	http://www.ncbi.nlm.nih.gov/pubmed/21383204

DMHAQCO	DI	DMHAQCO
DMHAQCO	DN	Trichlormethiazide
DMHAQCO	MI	TTS087L
DMHAQCO	MN	Solute carrier family 12 member 1 (SLC12A1)
DMHAQCO	MT	DTT
DMHAQCO	MA	Blocker
DMHAQCO	RN	Function and regulation of epithelial sodium transporters in the kidney of a salt-sensitive hypertensive rat model. J Hypertens. 2007 May;25(5):1065-72.
DMHAQCO	RU	https://pubmed.ncbi.nlm.nih.gov/17414671

DMPWGBR	DI	DMPWGBR
DMPWGBR	DN	Triclabendazole
DMPWGBR	MI	DEJGDUW
DMPWGBR	MN	Cytochrome P450 1A2 (CYP1A2)
DMPWGBR	MT	DME
DMPWGBR	MA	Metabolism
DMPWGBR	RN	In vitro drug-drug interaction potential of sulfoxide and/or sulfone metabolites of albendazole, triclabendazole, aldicarb, methiocarb, montelukast and ziprasidone. Drug Metab Lett. 2018;12(2):101-116.
DMPWGBR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30117405

DMPWGBR	DI	DMPWGBR
DMPWGBR	DN	Triclabendazole
DMPWGBR	MI	DE5IED8
DMPWGBR	MN	Cytochrome P450 2C9 (CYP2C9)
DMPWGBR	MT	DME
DMPWGBR	MA	Metabolism
DMPWGBR	RN	In vitro drug-drug interaction potential of sulfoxide and/or sulfone metabolites of albendazole, triclabendazole, aldicarb, methiocarb, montelukast and ziprasidone. Drug Metab Lett. 2018;12(2):101-116.
DMPWGBR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30117405

DMPWGBR	DI	DMPWGBR
DMPWGBR	DN	Triclabendazole
DMPWGBR	MI	DECB0K3
DMPWGBR	MN	Cytochrome P450 2D6 (CYP2D6)
DMPWGBR	MT	DME
DMPWGBR	MA	Metabolism
DMPWGBR	RN	FDA Label of Egaten. The 2020 official website of the U.S. Food and Drug Administration.
DMPWGBR	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf

DMPWGBR	DI	DMPWGBR
DMPWGBR	DN	Triclabendazole
DMPWGBR	MI	DE4LYSA
DMPWGBR	MN	Cytochrome P450 3A4 (CYP3A4)
DMPWGBR	MT	DME
DMPWGBR	MA	Metabolism
DMPWGBR	RN	In vitro drug-drug interaction potential of sulfoxide and/or sulfone metabolites of albendazole, triclabendazole, aldicarb, methiocarb, montelukast and ziprasidone. Drug Metab Lett. 2018;12(2):101-116.
DMPWGBR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30117405

DMPWGBR	DI	DMPWGBR
DMPWGBR	DN	Triclabendazole
DMPWGBR	MI	DEGTFWK
DMPWGBR	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMPWGBR	MT	DME
DMPWGBR	MA	Metabolism
DMPWGBR	RN	In vitro drug-drug interaction potential of sulfoxide and/or sulfone metabolites of albendazole, triclabendazole, aldicarb, methiocarb, montelukast and ziprasidone. Drug Metab Lett. 2018;12(2):101-116.
DMPWGBR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30117405

DMPWGBR	DI	DMPWGBR
DMPWGBR	DN	Triclabendazole
DMPWGBR	MI	TTEAID7
DMPWGBR	MN	Trypanosoma Cruzipain (Trypano CYSP)
DMPWGBR	MT	DTT
DMPWGBR	MA	Inhibitor
DMPWGBR	RN	Colloid formation by drugs in simulated intestinal fluid. J Med Chem. 2010 May 27;53(10):4259-65.
DMPWGBR	RU	https://pubmed.ncbi.nlm.nih.gov/20426472

DMZUR4N	DI	DMZUR4N
DMZUR4N	DN	Triclosan
DMZUR4N	MI	TTNX2CS
DMZUR4N	MN	Plasmodium Enoyl-ACP reductase (Malaria fabI)
DMZUR4N	MT	DTT
DMZUR4N	MA	Binder
DMZUR4N	RN	Novel molecular targets for antimalarial drug development. Chem Biol Drug Des. 2008 Apr;71(4):287-97.
DMZUR4N	RU	https://pubmed.ncbi.nlm.nih.gov/18298458

DMVLHNI	DI	DMVLHNI
DMVLHNI	DN	Tridihexethyl
DMVLHNI	MI	TTH18TF
DMVLHNI	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMVLHNI	MT	DTT
DMVLHNI	MA	Binder
DMVLHNI	RN	Effect of anticholinergic agents upon acquired nystagmus: a double-blind study of trihexyphenidyl and tridihexethyl chloride. Neurology. 1991 Nov;41(11):1737-41.
DMVLHNI	RU	https://pubmed.ncbi.nlm.nih.gov/1944902

DMD2WPG	DI	DMD2WPG
DMD2WPG	DN	Trientine
DMD2WPG	MI	TTEYTKG
DMD2WPG	MN	Carbonic anhydrase XIV (CA-XIV)
DMD2WPG	MT	DTT
DMD2WPG	MA	Inhibitor
DMD2WPG	RN	Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22.
DMD2WPG	RU	https://pubmed.ncbi.nlm.nih.gov/20590092

DMOL793	DI	DMOL793
DMOL793	DN	Trifarotene
DMOL793	MI	DEPKLMQ
DMOL793	MN	Cytochrome P450 2B6 (CYP2B6)
DMOL793	MT	DME
DMOL793	MA	Metabolism
DMOL793	RN	FDA label of Trifarotene. The 2020 official website of the U.S. Food and Drug Administration.
DMOL793	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf

DMOL793	DI	DMOL793
DMOL793	DN	Trifarotene
DMOL793	MI	DES5XRU
DMOL793	MN	Cytochrome P450 2C8 (CYP2C8)
DMOL793	MT	DME
DMOL793	MA	Metabolism
DMOL793	RN	FDA label of Trifarotene. The 2020 official website of the U.S. Food and Drug Administration.
DMOL793	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf

DMOL793	DI	DMOL793
DMOL793	DN	Trifarotene
DMOL793	MI	DE5IED8
DMOL793	MN	Cytochrome P450 2C9 (CYP2C9)
DMOL793	MT	DME
DMOL793	MA	Metabolism
DMOL793	RN	FDA label of Trifarotene. The 2020 official website of the U.S. Food and Drug Administration.
DMOL793	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf

DMOL793	DI	DMOL793
DMOL793	DN	Trifarotene
DMOL793	MI	DE4LYSA
DMOL793	MN	Cytochrome P450 3A4 (CYP3A4)
DMOL793	MT	DME
DMOL793	MA	Metabolism
DMOL793	RN	FDA label of Trifarotene. The 2020 official website of the U.S. Food and Drug Administration.
DMOL793	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf

DMOL793	DI	DMOL793
DMOL793	DN	Trifarotene
DMOL793	MI	TT1Q3IE
DMOL793	MN	Retinoic acid receptor gamma (RARG)
DMOL793	MT	DTT
DMOL793	MA	Agonist
DMOL793	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMOL793	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf

DMKBYWI	DI	DMKBYWI
DMKBYWI	DN	Trifluoperazine
DMKBYWI	MI	TTV3NH6
DMKBYWI	MN	Calmodulin (CALM)
DMKBYWI	MT	DTT
DMKBYWI	MA	Inhibitor
DMKBYWI	RN	Inhibitory effect of jujuboside A on glutamate-mediated excitatory signal pathway in hippocampus. Planta Med. 2003 Aug;69(8):692-5.
DMKBYWI	RU	https://pubmed.ncbi.nlm.nih.gov/14531016

DMKBYWI	DI	DMKBYWI
DMKBYWI	DN	Trifluoperazine
DMKBYWI	MI	DEJGDUW
DMKBYWI	MN	Cytochrome P450 1A2 (CYP1A2)
DMKBYWI	MT	DME
DMKBYWI	MA	Metabolism
DMKBYWI	RN	Psychotropic Medications Metabolized by Cytochromes P450 (CYP) 1A2 Enzyme and Relevant Drug Interactions: Review of Articles
DMKBYWI	RU	https://austinpublishinggroup.com/pharmacology-therapeutics/fulltext/ajpt-v4-id1085.php

DMKBYWI	DI	DMKBYWI
DMKBYWI	DN	Trifluoperazine
DMKBYWI	MI	DEIASEZ
DMKBYWI	MN	Dimethylaniline oxidase 2 (FMO2)
DMKBYWI	MT	DME
DMKBYWI	MA	Metabolism
DMKBYWI	RN	Human FMO2-based microbial whole-cell catalysts for drug metabolite synthesis. Microb Cell Fact. 2015 Jun 12;14:82.
DMKBYWI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26062974

DMKBYWI	DI	DMKBYWI
DMKBYWI	DN	Trifluoperazine
DMKBYWI	MI	DTUGYRD
DMKBYWI	MN	P-glycoprotein 1 (ABCB1)
DMKBYWI	MT	DTP
DMKBYWI	MA	Substrate
DMKBYWI	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMKBYWI	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMKFQJP	DI	DMKFQJP
DMKFQJP	DN	Triflupromazine
DMKFQJP	MI	TT0K1SC
DMKFQJP	MN	5-HT 2B receptor (HTR2B)
DMKFQJP	MT	DTT
DMKFQJP	MA	Antagonist
DMKFQJP	RN	Some properties of 5-hydroxytryptamine receptors in the hindquarters of the rat. Br J Pharmacol. 1979 Sep;67(1):79-85.
DMKFQJP	RU	https://pubmed.ncbi.nlm.nih.gov/497523

DMKFQJP	DI	DMKFQJP
DMKFQJP	DN	Triflupromazine
DMKFQJP	MI	DTUGYRD
DMKFQJP	MN	P-glycoprotein 1 (ABCB1)
DMKFQJP	MT	DTP
DMKFQJP	MA	Substrate
DMKFQJP	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMKFQJP	RU	https://doi.org/10.1007/s11095-012-0935-x

DMG2YBD	DI	DMG2YBD
DMG2YBD	DN	Trifluridine
DMG2YBD	MI	TTU6BFZ
DMG2YBD	MN	Candida Thymidylate synthase (Candi TMP1)
DMG2YBD	MT	DTT
DMG2YBD	MA	Inhibitor
DMG2YBD	RN	Trifluorothymidine induces cell death independently of p53. Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):699-703.
DMG2YBD	RU	https://pubmed.ncbi.nlm.nih.gov/18600528

DMG2YBD	DI	DMG2YBD
DMG2YBD	DN	Trifluridine
DMG2YBD	MI	DT0EQPW
DMG2YBD	MN	Concentrative nucleoside transporter 1 (SLC28A1)
DMG2YBD	MT	DTP
DMG2YBD	MA	Substrate
DMG2YBD	RN	Lonsurf, INN-trifluridine/tipiracil.
DMG2YBD	RU	https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/649/original/WC500206246.pdf?1531845997

DMG2YBD	DI	DMG2YBD
DMG2YBD	DN	Trifluridine
DMG2YBD	MI	DTXD1TQ
DMG2YBD	MN	Equilibrative nucleoside transporter 1 (SLC29A1)
DMG2YBD	MT	DTP
DMG2YBD	MA	Substrate
DMG2YBD	RN	Lonsurf, INN-trifluridine/tipiracil.
DMG2YBD	RU	https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/649/original/WC500206246.pdf?1531845997

DMG2YBD	DI	DMG2YBD
DMG2YBD	DN	Trifluridine
DMG2YBD	MI	DTW78DQ
DMG2YBD	MN	Equilibrative nucleoside transporter 2 (SLC29A2)
DMG2YBD	MT	DTP
DMG2YBD	MA	Substrate
DMG2YBD	RN	Lonsurf, INN-trifluridine/tipiracil.
DMG2YBD	RU	https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/649/original/WC500206246.pdf?1531845997

DMG2YBD	DI	DMG2YBD
DMG2YBD	DN	Trifluridine
DMG2YBD	MI	DTQ23VB
DMG2YBD	MN	Organic anion transporter 1 (SLC22A6)
DMG2YBD	MT	DTP
DMG2YBD	MA	Substrate
DMG2YBD	RN	Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs. J Pharmacol Exp Ther. 2000 Sep;294(3):844-9.
DMG2YBD	RU	http://www.ncbi.nlm.nih.gov/pubmed/10945832

DMG2YBD	DI	DMG2YBD
DMG2YBD	DN	Trifluridine
DMG2YBD	MI	DE4HCYL
DMG2YBD	MN	Thymidine phosphorylase (TYMP)
DMG2YBD	MT	DME
DMG2YBD	MA	Metabolism
DMG2YBD	RN	Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest. 2008 Oct;26(8):794-9.
DMG2YBD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18798063

DMB19L8	DI	DMB19L8
DMB19L8	DN	Trihexyphenidyl
DMB19L8	MI	TTMXGCW
DMB19L8	MN	Adrenergic receptor beta-3 (ADRB3)
DMB19L8	MT	DTT
DMB19L8	MA	Agonist
DMB19L8	RN	Obesity: pathophysiology and clinical management. Curr Med Chem. 2009;16(4):506-21.
DMB19L8	RU	https://pubmed.ncbi.nlm.nih.gov/19199918

DMB19L8	DI	DMB19L8
DMB19L8	DN	Trihexyphenidyl
DMB19L8	MI	TTZ9SOR
DMB19L8	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMB19L8	MT	DTT
DMB19L8	MA	Antagonist
DMB19L8	RN	The role of M1 muscarinic cholinergic receptors in the discriminative stimulus properties of N-desmethylclozapine and the atypical antipsychotic dr... Psychopharmacology (Berl). 2009 Apr;203(2):295-301.
DMB19L8	RU	https://pubmed.ncbi.nlm.nih.gov/18685832

DMP5A4T	DI	DMP5A4T
DMP5A4T	DN	Trilaciclib
DMP5A4T	MI	TT0PG8F
DMP5A4T	MN	Cyclin-dependent kinase 4 (CDK4)
DMP5A4T	MT	DTT
DMP5A4T	MA	Inhibitor
DMP5A4T	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2021
DMP5A4T	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214200s000lbl.pdf

DMP5A4T	DI	DMP5A4T
DMP5A4T	DN	Trilaciclib
DMP5A4T	MI	TTO0FDJ
DMP5A4T	MN	Cyclin-dependent kinase 6 (CDK6)
DMP5A4T	MT	DTT
DMP5A4T	MA	Inhibitor
DMP5A4T	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2021
DMP5A4T	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214200s000lbl.pdf

DMQZ9GF	DI	DMQZ9GF
DMQZ9GF	DN	Trilostane
DMQZ9GF	MI	DE4LYSA
DMQZ9GF	MN	Cytochrome P450 3A4 (CYP3A4)
DMQZ9GF	MT	DME
DMQZ9GF	MA	Metabolism
DMQZ9GF	RN	Long-term low-dose ketoconazole treatment in bilateral macronodular adrenal hyperplasia. Endocrinol Diabetes Metab Case Rep. 2014;2014:140083.
DMQZ9GF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25535576

DMQZ9GF	DI	DMQZ9GF
DMQZ9GF	DN	Trilostane
DMQZ9GF	MI	TTOM3J0
DMQZ9GF	MN	Estrogen receptor beta (ESR2)
DMQZ9GF	MT	DTT
DMQZ9GF	MA	Modulator
DMQZ9GF	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMQZ9GF	RU	https://www.fda.gov/

DM1QLST	DI	DM1QLST
DM1QLST	DN	Trimazosin
DM1QLST	MI	TT34BHT
DM1QLST	MN	Adrenergic receptor alpha-1D (ADRA1D)
DM1QLST	MT	DTT
DM1QLST	MA	Modulator
DM1QLST	RN	The hypotensive effect of trimazosin is not caused solely by alpha 1-adrenoceptor blockade. J Cardiovasc Pharmacol. 1984 Jan-Feb;6(1):142-50.
DM1QLST	RU	https://pubmed.ncbi.nlm.nih.gov/6199597

DMPYQ7B	DI	DMPYQ7B
DMPYQ7B	DN	Trimebutine
DMPYQ7B	MI	DE4LYSA
DMPYQ7B	MN	Cytochrome P450 3A4 (CYP3A4)
DMPYQ7B	MT	DME
DMPYQ7B	MA	Metabolism
DMPYQ7B	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DMPYQ7B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DMEMV9D	DI	DMEMV9D
DMEMV9D	DN	Trimeprazine
DMEMV9D	MI	TTTIBOJ
DMEMV9D	MN	Histamine H1 receptor (H1R)
DMEMV9D	MT	DTT
DMEMV9D	MA	Antagonist
DMEMV9D	RN	Effectiveness of alimemazine in controlling retching after Nissen fundoplication. J Pediatr Surg. 2005 Nov;40(11):1737-40.
DMEMV9D	RU	https://pubmed.ncbi.nlm.nih.gov/16291162

DM0Q8MZ	DI	DM0Q8MZ
DM0Q8MZ	DN	Trimethadione
DM0Q8MZ	MI	DES5XRU
DM0Q8MZ	MN	Cytochrome P450 2C8 (CYP2C8)
DM0Q8MZ	MT	DME
DM0Q8MZ	MA	Metabolism
DM0Q8MZ	RN	Trimethadione metabolism by human liver cytochrome P450: evidence for the involvement of CYP2E1. Xenobiotica. 1998 Nov;28(11):1041-7.
DM0Q8MZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9879636

DM0Q8MZ	DI	DM0Q8MZ
DM0Q8MZ	DN	Trimethadione
DM0Q8MZ	MI	DE5IED8
DM0Q8MZ	MN	Cytochrome P450 2C9 (CYP2C9)
DM0Q8MZ	MT	DME
DM0Q8MZ	MA	Metabolism
DM0Q8MZ	RN	Involvement of cytochrome P450 2C9, 2E1 and 3A4 in trimethadione N-demethylation in human microsomes. J Clin Pharm Ther. 2003 Dec;28(6):493-6.
DM0Q8MZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14651673

DM0Q8MZ	DI	DM0Q8MZ
DM0Q8MZ	DN	Trimethadione
DM0Q8MZ	MI	DEVDYN7
DM0Q8MZ	MN	Cytochrome P450 2E1 (CYP2E1)
DM0Q8MZ	MT	DME
DM0Q8MZ	MA	Metabolism
DM0Q8MZ	RN	Involvement of cytochrome P450 2C9, 2E1 and 3A4 in trimethadione N-demethylation in human microsomes. J Clin Pharm Ther. 2003 Dec;28(6):493-6.
DM0Q8MZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14651673

DM0Q8MZ	DI	DM0Q8MZ
DM0Q8MZ	DN	Trimethadione
DM0Q8MZ	MI	DE4LYSA
DM0Q8MZ	MN	Cytochrome P450 3A4 (CYP3A4)
DM0Q8MZ	MT	DME
DM0Q8MZ	MA	Metabolism
DM0Q8MZ	RN	Involvement of cytochrome P450 2C9, 2E1 and 3A4 in trimethadione N-demethylation in human microsomes. J Clin Pharm Ther. 2003 Dec;28(6):493-6.
DM0Q8MZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14651673

DM0Q8MZ	DI	DM0Q8MZ
DM0Q8MZ	DN	Trimethadione
DM0Q8MZ	MI	DEGTFWK
DM0Q8MZ	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM0Q8MZ	MT	DME
DM0Q8MZ	MA	Metabolism
DM0Q8MZ	RN	Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol Sci. 2002 Apr;66(2):185-200.
DM0Q8MZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11896285

DM0Q8MZ	DI	DM0Q8MZ
DM0Q8MZ	DN	Trimethadione
DM0Q8MZ	MI	TT729IR
DM0Q8MZ	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DM0Q8MZ	MT	DTT
DM0Q8MZ	MA	Blocker
DM0Q8MZ	RN	Prophylactic and therapeutic functions of T-type calcium blockers against noise-induced hearing loss. Hear Res. 2007 Apr;226(1-2):52-60.
DM0Q8MZ	RU	https://pubmed.ncbi.nlm.nih.gov/17291698

DMHF4IQ	DI	DMHF4IQ
DMHF4IQ	DN	Trimethaphan
DMHF4IQ	MI	TT4H1MQ
DMHF4IQ	MN	Neuronal acetylcholine receptor alpha-4 (CHRNA4)
DMHF4IQ	MT	DTT
DMHF4IQ	MA	Antagonist
DMHF4IQ	RN	Mechanism of long-lasting block of ganglion nicotinic receptors by mono-ammonium compounds with long aliphatic chain. J Auton Nerv Syst. 1994 Aug;48(3):231-40.
DMHF4IQ	RU	https://pubmed.ncbi.nlm.nih.gov/7963258

DMM7CHK	DI	DMM7CHK
DMM7CHK	DN	Trimethoprim
DMM7CHK	MI	DES5XRU
DMM7CHK	MN	Cytochrome P450 2C8 (CYP2C8)
DMM7CHK	MT	DME
DMM7CHK	MA	Metabolism
DMM7CHK	RN	Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol. 2006 Jul;99(1):44-51.
DMM7CHK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16867170

DMM7CHK	DI	DMM7CHK
DMM7CHK	DN	Trimethoprim
DMM7CHK	MI	DE5IED8
DMM7CHK	MN	Cytochrome P450 2C9 (CYP2C9)
DMM7CHK	MT	DME
DMM7CHK	MA	Metabolism
DMM7CHK	RN	Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug Metab Dispos. 2002 Jun;30(6):631-5.
DMM7CHK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12019187

DMM7CHK	DI	DMM7CHK
DMM7CHK	DN	Trimethoprim
DMM7CHK	MI	DE4LYSA
DMM7CHK	MN	Cytochrome P450 3A4 (CYP3A4)
DMM7CHK	MT	DME
DMM7CHK	MA	Metabolism
DMM7CHK	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMM7CHK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMM7CHK	DI	DMM7CHK
DMM7CHK	DN	Trimethoprim
DMM7CHK	MI	TTYZVDJ
DMM7CHK	MN	Dihydrofolate reductase (DHFR)
DMM7CHK	MT	DTT
DMM7CHK	MA	Modulator
DMM7CHK	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMM7CHK	RU	https://www.fda.gov/

DMM7CHK	DI	DMM7CHK
DMM7CHK	DN	Trimethoprim
DMM7CHK	MI	DTT79CX
DMM7CHK	MN	Organic cation transporter 1 (SLC22A1)
DMM7CHK	MT	DTP
DMM7CHK	MA	Substrate
DMM7CHK	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMM7CHK	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DMM7CHK	DI	DMM7CHK
DMM7CHK	DN	Trimethoprim
DMM7CHK	MI	DTUGYRD
DMM7CHK	MN	P-glycoprotein 1 (ABCB1)
DMM7CHK	MT	DTP
DMM7CHK	MA	Substrate
DMM7CHK	RN	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
DMM7CHK	RU	https://doi.org/10.1016/j.addr.2011.12.008

DMDEA85	DI	DMDEA85
DMDEA85	DN	Trimetrexate
DMDEA85	MI	DTI7UX6
DMDEA85	MN	Breast cancer resistance protein (ABCG2)
DMDEA85	MT	DTP
DMDEA85	MA	Substrate
DMDEA85	RN	Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34.
DMDEA85	RU	https://doi.org/10.1007/s00280-006-0230-9

DMDEA85	DI	DMDEA85
DMDEA85	DN	Trimetrexate
DMDEA85	MI	TT9SL3Q
DMDEA85	MN	Polypeptide deformylase (PDF)
DMDEA85	MT	DTT
DMDEA85	MA	Inhibitor
DMDEA85	RN	Expression and characterization of recombinant human-derived Pneumocystis carinii dihydrofolate reductase. Antimicrob Agents Chemother. 2000 Nov;44(11):3092-6.
DMDEA85	RU	https://pubmed.ncbi.nlm.nih.gov/11036028

DM1SC8M	DI	DM1SC8M
DM1SC8M	DN	Trimipramine
DM1SC8M	MI	DE5IED8
DM1SC8M	MN	Cytochrome P450 2C9 (CYP2C9)
DM1SC8M	MT	DME
DM1SC8M	MA	Metabolism
DM1SC8M	RN	Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics. J Clin Psychopharmacol. 2003 Oct;23(5):459-66.
DM1SC8M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14520122

DM1SC8M	DI	DM1SC8M
DM1SC8M	DN	Trimipramine
DM1SC8M	MI	DECB0K3
DM1SC8M	MN	Cytochrome P450 2D6 (CYP2D6)
DM1SC8M	MT	DME
DM1SC8M	MA	Metabolism
DM1SC8M	RN	Galactorrhea during treatment with trimipramine. A case report. Pharmacopsychiatry. 2005 Nov;38(6):326-7.
DM1SC8M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16342006

DM1SC8M	DI	DM1SC8M
DM1SC8M	DN	Trimipramine
DM1SC8M	MI	DEGTFWK
DM1SC8M	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM1SC8M	MT	DME
DM1SC8M	MA	Metabolism
DM1SC8M	RN	Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics. J Clin Psychopharmacol. 2003 Oct;23(5):459-66.
DM1SC8M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14520122

DM1SC8M	DI	DM1SC8M
DM1SC8M	DN	Trimipramine
DM1SC8M	MI	TTAWNKZ
DM1SC8M	MN	Norepinephrine transporter (NET)
DM1SC8M	MT	DTT
DM1SC8M	MA	Inhibitor
DM1SC8M	RN	Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90.
DM1SC8M	RU	https://pubmed.ncbi.nlm.nih.gov/16388933

DM1SC8M	DI	DM1SC8M
DM1SC8M	DN	Trimipramine
DM1SC8M	MI	DEYGVN4
DM1SC8M	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM1SC8M	MT	DME
DM1SC8M	MA	Metabolism
DM1SC8M	RN	Role of human UGT2B10 in N-glucuronidation of tricyclic antidepressants, amitriptyline, imipramine, clomipramine, and trimipramine. Drug Metab Dispos. 2010 May;38(5):863-70.
DM1SC8M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20133892

DMZBU15	DI	DMZBU15
DMZBU15	DN	Tripelennamine
DMZBU15	MI	TTTIBOJ
DMZBU15	MN	Histamine H1 receptor (H1R)
DMZBU15	MT	DTT
DMZBU15	MA	Antagonist
DMZBU15	RN	Involvement of histamine H1 and H2 receptors in the regulation of STAT-1 phosphorylation: inverse agonism exhibited by the receptor antagonists. Int Immunopharmacol. 2005 Jul;5(7-8):1299-309.
DMZBU15	RU	https://pubmed.ncbi.nlm.nih.gov/15914334

DM7SWIA	DI	DM7SWIA
DM7SWIA	DN	Triprolidine
DM7SWIA	MI	TTTIBOJ
DM7SWIA	MN	Histamine H1 receptor (H1R)
DM7SWIA	MT	DTT
DM7SWIA	MA	Antagonist
DM7SWIA	RN	Histamine excites rat lateral vestibular nuclear neurons through activation of post-synaptic H2 receptors. Neurosci Lett. 2008 Dec 19;448(1):15-9.
DM7SWIA	RU	https://pubmed.ncbi.nlm.nih.gov/18938221

DM7SWIA	DI	DM7SWIA
DM7SWIA	DN	Triprolidine
DM7SWIA	MI	DTUGYRD
DM7SWIA	MN	P-glycoprotein 1 (ABCB1)
DM7SWIA	MT	DTP
DM7SWIA	MA	Substrate
DM7SWIA	RN	Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures. Drug Metab Dispos. 2007 Aug;35(8):1341-9.
DM7SWIA	RU	https://doi.org/10.1124/dmd.106.013953

DMTK4LS	DI	DMTK4LS
DMTK4LS	DN	Triptorelin
DMTK4LS	MI	TT8R70G
DMTK4LS	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMTK4LS	MT	DTT
DMTK4LS	MA	Modulator
DMTK4LS	RN	Regulation of GnRH I receptor gene expression by the GnRH agonist triptorelin, estradiol, and progesterone in the gonadotroph-derived cell line alphaT3-1. Endocrine. 2006 Aug;30(1):139-44.
DMTK4LS	RU	https://pubmed.ncbi.nlm.nih.gov/17185802

DMHB2C3	DI	DMHB2C3
DMHB2C3	DN	Trofosfamide
DMHB2C3	MI	DEPKLMQ
DMHB2C3	MN	Cytochrome P450 2B6 (CYP2B6)
DMHB2C3	MT	DME
DMHB2C3	MA	Metabolism
DMHB2C3	RN	Investigation of the major human hepatic cytochrome P450 involved in 4-hydroxylation and N-dechloroethylation of trofosfamide. Cancer Chemother Pharmacol. 1999;44(4):327-34.
DMHB2C3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10447581

DMHB2C3	DI	DMHB2C3
DMHB2C3	DN	Trofosfamide
DMHB2C3	MI	DE4LYSA
DMHB2C3	MN	Cytochrome P450 3A4 (CYP3A4)
DMHB2C3	MT	DME
DMHB2C3	MA	Metabolism
DMHB2C3	RN	Investigation of the major human hepatic cytochrome P450 involved in 4-hydroxylation and N-dechloroethylation of trofosfamide. Cancer Chemother Pharmacol. 1999;44(4):327-34.
DMHB2C3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10447581

DM3VFPD	DI	DM3VFPD
DM3VFPD	DN	Troglitazone
DM3VFPD	MI	DE6OQ3W
DM3VFPD	MN	Cytochrome P450 1A1 (CYP1A1)
DM3VFPD	MT	DME
DM3VFPD	MA	Metabolism
DM3VFPD	RN	Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. Drug Metab Dispos. 1999 Nov;27(11):1260-6.
DM3VFPD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10534310

DM3VFPD	DI	DM3VFPD
DM3VFPD	DN	Troglitazone
DM3VFPD	MI	DES5XRU
DM3VFPD	MN	Cytochrome P450 2C8 (CYP2C8)
DM3VFPD	MT	DME
DM3VFPD	MA	Metabolism
DM3VFPD	RN	Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet. 2005;44(12):1209-25.
DM3VFPD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16372821

DM3VFPD	DI	DM3VFPD
DM3VFPD	DN	Troglitazone
DM3VFPD	MI	DE5IED8
DM3VFPD	MN	Cytochrome P450 2C9 (CYP2C9)
DM3VFPD	MT	DME
DM3VFPD	MA	Metabolism
DM3VFPD	RN	In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone. Xenobiotica. 2000 Jan;30(1):61-70.
DM3VFPD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10659951

DM3VFPD	DI	DM3VFPD
DM3VFPD	DN	Troglitazone
DM3VFPD	MI	DE4LYSA
DM3VFPD	MN	Cytochrome P450 3A4 (CYP3A4)
DM3VFPD	MT	DME
DM3VFPD	MA	Metabolism
DM3VFPD	RN	Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet. 2005;44(12):1209-25.
DM3VFPD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16372821

DM3VFPD	DI	DM3VFPD
DM3VFPD	DN	Troglitazone
DM3VFPD	MI	DEGTFWK
DM3VFPD	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM3VFPD	MT	DME
DM3VFPD	MA	Metabolism
DM3VFPD	RN	In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone. Xenobiotica. 2000 Jan;30(1):61-70.
DM3VFPD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10659951

DM3VFPD	DI	DM3VFPD
DM3VFPD	DN	Troglitazone
DM3VFPD	MI	TTZMAO3
DM3VFPD	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DM3VFPD	MT	DTT
DM3VFPD	MA	Agonist
DM3VFPD	RN	Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer. 2003 May 1;104(5):597-602.
DM3VFPD	RU	https://pubmed.ncbi.nlm.nih.gov/12594814

DM3VFPD	DI	DM3VFPD
DM3VFPD	DN	Troglitazone
DM3VFPD	MI	DEYGVN4
DM3VFPD	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM3VFPD	MT	DME
DM3VFPD	MA	Metabolism
DM3VFPD	RN	Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
DM3VFPD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12433820

DM3VFPD	DI	DM3VFPD
DM3VFPD	DN	Troglitazone
DM3VFPD	MI	DEL5N6Y
DM3VFPD	MN	UDP-glucuronosyltransferase 1A10 (UGT1A10)
DM3VFPD	MT	DME
DM3VFPD	MA	Metabolism
DM3VFPD	RN	Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
DM3VFPD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12433820

DM3VFPD	DI	DM3VFPD
DM3VFPD	DN	Troglitazone
DM3VFPD	MI	DEF2WXN
DM3VFPD	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DM3VFPD	MT	DME
DM3VFPD	MA	Metabolism
DM3VFPD	RN	Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
DM3VFPD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12433820

DM3VFPD	DI	DM3VFPD
DM3VFPD	DN	Troglitazone
DM3VFPD	MI	DESD26P
DM3VFPD	MN	UDP-glucuronosyltransferase 1A6 (UGT1A6)
DM3VFPD	MT	DME
DM3VFPD	MA	Metabolism
DM3VFPD	RN	Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
DM3VFPD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12433820

DM3VFPD	DI	DM3VFPD
DM3VFPD	DN	Troglitazone
DM3VFPD	MI	DE85D2P
DM3VFPD	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DM3VFPD	MT	DME
DM3VFPD	MA	Metabolism
DM3VFPD	RN	The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J Biol Chem. 2003 Apr 18;278(16):13975-83.
DM3VFPD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12582161

DM3VFPD	DI	DM3VFPD
DM3VFPD	DN	Troglitazone
DM3VFPD	MI	DEB3CV1
DM3VFPD	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DM3VFPD	MT	DME
DM3VFPD	MA	Metabolism
DM3VFPD	RN	Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
DM3VFPD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12433820

DMUZNIG	DI	DMUZNIG
DMUZNIG	DN	Troleandomycin
DMUZNIG	MI	TTUWYEA
DMUZNIG	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DMUZNIG	MT	DTT
DMUZNIG	MA	Binder
DMUZNIG	RN	Depression of colony formation by human thymus-derived lymphocytes with rifampin and other antimicrobial agents. J Infect Dis. 1981 Jun;143(6):832-5.
DMUZNIG	RU	https://pubmed.ncbi.nlm.nih.gov/6972981

DMUZNIG	DI	DMUZNIG
DMUZNIG	DN	Troleandomycin
DMUZNIG	MI	DE4LYSA
DMUZNIG	MN	Cytochrome P450 3A4 (CYP3A4)
DMUZNIG	MT	DME
DMUZNIG	MA	Metabolism
DMUZNIG	RN	Effects of roxithromycin, erythromycin and troleandomycin on their N-demethylation by rat and human cytochrome P450 enzymes. Xenobiotica. 1996 Nov;26(11):1143-53.
DMUZNIG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8948090

DMOBLGK	DI	DMOBLGK
DMOBLGK	DN	Tromethamine
DMOBLGK	MI	TTBFROQ
DMOBLGK	MN	S-adenosylmethionine decarboxylase proenzyme (AMD1)
DMOBLGK	MT	DTT
DMOBLGK	MA	Inhibitor
DMOBLGK	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMOBLGK	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM1D90W	DI	DM1D90W
DM1D90W	DN	Tropicamide
DM1D90W	MI	TTQ3JTF
DM1D90W	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DM1D90W	MT	DTT
DM1D90W	MA	Antagonist
DM1D90W	RN	The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 rec... Psychopharmacology (Berl). 2007 Oct;194(3):347-59.
DM1D90W	RU	https://pubmed.ncbi.nlm.nih.gov/17594079

DMNSJ7V	DI	DMNSJ7V
DMNSJ7V	DN	Tropisetron
DMNSJ7V	MI	TTPC4TU
DMNSJ7V	MN	5-HT 3A receptor (HTR3A)
DMNSJ7V	MT	DTT
DMNSJ7V	MA	Antagonist
DMNSJ7V	RN	Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62.
DMNSJ7V	RU	https://pubmed.ncbi.nlm.nih.gov/18321148

DMNSJ7V	DI	DMNSJ7V
DMNSJ7V	DN	Tropisetron
DMNSJ7V	MI	DE5IED8
DMNSJ7V	MN	Cytochrome P450 2C9 (CYP2C9)
DMNSJ7V	MT	DME
DMNSJ7V	MA	Metabolism
DMNSJ7V	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMNSJ7V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMNSJ7V	DI	DMNSJ7V
DMNSJ7V	DN	Tropisetron
DMNSJ7V	MI	DECB0K3
DMNSJ7V	MN	Cytochrome P450 2D6 (CYP2D6)
DMNSJ7V	MT	DME
DMNSJ7V	MA	Metabolism
DMNSJ7V	RN	Cytochrome P450 2D6 metabolism and 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Med Sci Monit. 2005 Oct;11(10):RA322-8.
DMNSJ7V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16192915

DMNSJ7V	DI	DMNSJ7V
DMNSJ7V	DN	Tropisetron
DMNSJ7V	MI	DE4LYSA
DMNSJ7V	MN	Cytochrome P450 3A4 (CYP3A4)
DMNSJ7V	MT	DME
DMNSJ7V	MA	Metabolism
DMNSJ7V	RN	Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists. Drug Metab Dispos. 1996 May;24(5):602-9.
DMNSJ7V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8723743

DMX6RTG	DI	DMX6RTG
DMX6RTG	DN	Trospium
DMX6RTG	MI	TTH18TF
DMX6RTG	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMX6RTG	MT	DTT
DMX6RTG	MA	Antagonist
DMX6RTG	RN	Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
DMX6RTG	RU	https://pubmed.ncbi.nlm.nih.gov/17016423

DM32XZT	DI	DM32XZT
DM32XZT	DN	Trospium chloride
DM32XZT	MI	DTE2B1D
DM32XZT	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DM32XZT	MT	DTP
DM32XZT	MA	Substrate
DM32XZT	RN	Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. Mol Pharm. 2015 Jan 5;12(1):171-8.
DM32XZT	RU	http://www.ncbi.nlm.nih.gov/pubmed/25466967

DM32XZT	DI	DM32XZT
DM32XZT	DN	Trospium chloride
DM32XZT	MI	DTT79CX
DM32XZT	MN	Organic cation transporter 1 (SLC22A1)
DM32XZT	MT	DTP
DM32XZT	MA	Substrate
DM32XZT	RN	Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. Mol Pharm. 2015 Jan 5;12(1):171-8.
DM32XZT	RU	http://www.ncbi.nlm.nih.gov/pubmed/25466967

DM32XZT	DI	DM32XZT
DM32XZT	DN	Trospium chloride
DM32XZT	MI	DTUGYRD
DM32XZT	MN	P-glycoprotein 1 (ABCB1)
DM32XZT	MT	DTP
DM32XZT	MA	Substrate
DM32XZT	RN	Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. Mol Pharm. 2015 Jan 5;12(1):171-8.
DM32XZT	RU	http://www.ncbi.nlm.nih.gov/pubmed/25466967

DM6AN32	DI	DM6AN32
DM6AN32	DN	Trovafloxacin
DM6AN32	MI	TTN6J5F
DM6AN32	MN	Bacterial DNA gyrase (Bact gyrase)
DM6AN32	MT	DTT
DM6AN32	MA	Modulator
DM6AN32	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM6AN32	RU	https://www.fda.gov/

DMDHCK9	DI	DMDHCK9
DMDHCK9	DN	Trumenba
DMDHCK9	MI	TTUW6OP
DMDHCK9	MN	Complement factor H (CFH)
DMDHCK9	MT	DTT
DMDHCK9	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMDHCK9	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DM4NTMO	DI	DM4NTMO
DM4NTMO	DN	TRYPAN BLUE
DM4NTMO	MI	TTELIN2
DM4NTMO	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DM4NTMO	MT	DTT
DM4NTMO	MA	Inhibitor
DM4NTMO	RN	Evans Blue and other dyes as protein tyrosine phosphatase inhibitors. Bioorg Med Chem Lett. 2004 Apr 19;14(8):1923-6.
DM4NTMO	RU	https://pubmed.ncbi.nlm.nih.gov/15050628

DMBZIVP	DI	DMBZIVP
DMBZIVP	DN	Tubocurarine
DMBZIVP	MI	TTF4E0J
DMBZIVP	MN	Neuronal acetylcholine receptor alpha-2 (CHRNA2)
DMBZIVP	MT	DTT
DMBZIVP	MA	Antagonist
DMBZIVP	RN	Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52.
DMBZIVP	RU	https://pubmed.ncbi.nlm.nih.gov/19417616

DMBZIVP	DI	DMBZIVP
DMBZIVP	DN	Tubocurarine
DMBZIVP	MI	DTT79CX
DMBZIVP	MN	Organic cation transporter 1 (SLC22A1)
DMBZIVP	MT	DTP
DMBZIVP	MA	Substrate
DMBZIVP	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMBZIVP	RU	https://doi.org/10.1007/s11095-012-0935-x

DMBESUA	DI	DMBESUA
DMBESUA	DN	Tucatinib
DMBESUA	MI	TT6EO5L
DMBESUA	MN	Erbb2 tyrosine kinase receptor (HER2)
DMBESUA	MT	DTT
DMBESUA	MA	Inhibitor
DMBESUA	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMBESUA	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213411s000lbl.pdf

DM749I3	DI	DM749I3
DM749I3	DN	Ubrogepant
DM749I3	MI	TTY6O0Q
DM749I3	MN	Calcitonin gene-related peptide receptor (CGRPR)
DM749I3	MT	DTT
DM749I3	MA	Antagonist
DM749I3	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DM749I3	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211765s000lbl.pdf

DM1IQRP	DI	DM1IQRP
DM1IQRP	DN	Udenafil
DM1IQRP	MI	DE4LYSA
DM1IQRP	MN	Cytochrome P450 3A4 (CYP3A4)
DM1IQRP	MT	DME
DM1IQRP	MA	Metabolism
DM1IQRP	RN	The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil. Drug Metab Dispos. 2008 Jun;36(6):986-90.
DM1IQRP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18308836

DM1IQRP	DI	DM1IQRP
DM1IQRP	DN	Udenafil
DM1IQRP	MI	DEIBDNY
DM1IQRP	MN	Cytochrome P450 3A5 (CYP3A5)
DM1IQRP	MT	DME
DM1IQRP	MA	Metabolism
DM1IQRP	RN	The disposition of three phosphodiesterase type 5 inhibitors, vardenafil, sildenafil, and udenafil, is differently influenced by the CYP3A5 genotype. Pharmacogenet Genomics. 2011 Dec;21(12):820-8.
DM1IQRP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21934637

DM1IQRP	DI	DM1IQRP
DM1IQRP	DN	Udenafil
DM1IQRP	MI	TTJ0IQB
DM1IQRP	MN	Phosphodiesterase 5A (PDE5A)
DM1IQRP	MT	DTT
DM1IQRP	MA	Inhibitor
DM1IQRP	RN	Increased expression of the nitric oxide synthase gene and protein in corpus cavernosum by repeated dosing of udenafil in a rat model of chemical d... Asian J Androl. 2009 Jul;11(4):435-42.
DM1IQRP	RU	https://pubmed.ncbi.nlm.nih.gov/19465935

DMX3O0D	DI	DMX3O0D
DMX3O0D	DN	UFT
DMX3O0D	MI	DEJVYAZ
DMX3O0D	MN	Cytochrome P450 2A6 (CYP2A6)
DMX3O0D	MT	DME
DMX3O0D	MA	Metabolism
DMX3O0D	RN	UFT Capsules (uracil-tegafur).
DMX3O0D	RU	https://hemonc.org/docs/packageinsert/uraciltegafur.pdf

DMBNI20	DI	DMBNI20
DMBNI20	DN	Ulipristal
DMBNI20	MI	DEJGDUW
DMBNI20	MN	Cytochrome P450 1A2 (CYP1A2)
DMBNI20	MT	DME
DMBNI20	MA	Metabolism
DMBNI20	RN	The clinical pharmacology and pharmacokinetics of ulipristal acetate for the treatment of uterine fibroids. Reprod Sci. 2015 Apr;22(4):476-83.
DMBNI20	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25228633

DMBNI20	DI	DMBNI20
DMBNI20	DN	Ulipristal
DMBNI20	MI	DE4LYSA
DMBNI20	MN	Cytochrome P450 3A4 (CYP3A4)
DMBNI20	MT	DME
DMBNI20	MA	Metabolism
DMBNI20	RN	Emergency contraception. Gynecol Endocrinol. 2013 Mar;29 Suppl 1:1-14.
DMBNI20	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23437846

DMBNI20	DI	DMBNI20
DMBNI20	DN	Ulipristal
DMBNI20	MI	TTUV8G9
DMBNI20	MN	Progesterone receptor (PGR)
DMBNI20	MT	DTT
DMBNI20	MA	Modulator
DMBNI20	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DMBNI20	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DMYRBO1	DI	DMYRBO1
DMYRBO1	DN	Umbralisib
DMYRBO1	MI	TTA8PLI
DMYRBO1	MN	Casein kinase I epsilon (CSNK1E)
DMYRBO1	MT	DTT
DMYRBO1	MA	Inhibitor
DMYRBO1	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2021
DMYRBO1	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213176s000lbl.pdf

DMYRBO1	DI	DMYRBO1
DMYRBO1	DN	Umbralisib
DMYRBO1	MI	TTGBPJE
DMYRBO1	MN	PI3-kinase delta (PIK3CD)
DMYRBO1	MT	DTT
DMYRBO1	MA	Inhibitor
DMYRBO1	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2021
DMYRBO1	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213176s000lbl.pdf

DM4E8O9	DI	DM4E8O9
DM4E8O9	DN	Umeclidinium
DM4E8O9	MI	TTH18TF
DM4E8O9	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DM4E8O9	MT	DTT
DM4E8O9	MA	Modulator
DM4E8O9	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7354).
DM4E8O9	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7354

DMXNR04	DI	DMXNR04
DMXNR04	DN	Unoprostone
DMXNR04	MI	TT9B4N3
DMXNR04	MN	Prostaglandin receptor (PTGR)
DMXNR04	MT	DTT
DMXNR04	MA	Modulator
DMXNR04	RN	Comparison of the vasoactive effects of the docosanoid unoprostone and selected prostanoids on isolated perfused retinal arterioles. Invest Ophthalmol Vis Sci. 2001 Jun;42(7):1499-504.
DMXNR04	RU	https://pubmed.ncbi.nlm.nih.gov/11381053

DM8T2OI	DI	DM8T2OI
DM8T2OI	DN	Upadacitinib
DM8T2OI	MI	DECB0K3
DM8T2OI	MN	Cytochrome P450 2D6 (CYP2D6)
DM8T2OI	MT	DME
DM8T2OI	MA	Metabolism
DM8T2OI	RN	Population pharmacokinetics of upadacitinib using the immediate-release and extended-release formulations in healthy subjects and subjects with rheumatoid arthritis: analyses of phase I-III clinical trials. Clin Pharmacokinet. 2019 Aug;58(8):1045-1058.
DM8T2OI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30945116

DM8T2OI	DI	DM8T2OI
DM8T2OI	DN	Upadacitinib
DM8T2OI	MI	DE4LYSA
DM8T2OI	MN	Cytochrome P450 3A4 (CYP3A4)
DM8T2OI	MT	DME
DM8T2OI	MA	Metabolism
DM8T2OI	RN	Population pharmacokinetics of upadacitinib using the immediate-release and extended-release formulations in healthy subjects and subjects with rheumatoid arthritis: analyses of phase I-III clinical trials. Clin Pharmacokinet. 2019 Aug;58(8):1045-1058.
DM8T2OI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30945116

DM32B5U	DI	DM32B5U
DM32B5U	DN	Upadacitinib
DM32B5U	MI	TT6DM01
DM32B5U	MN	Janus kinase 1 (JAK-1)
DM32B5U	MT	DTT
DM32B5U	MA	Modulator
DM32B5U	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DM32B5U	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211675s000lbl.pdf

DMHL7OB	DI	DMHL7OB
DMHL7OB	DN	Uracil mustard
DMHL7OB	MI	TTUTN1I
DMHL7OB	MN	Human Deoxyribonucleic acid (hDNA)
DMHL7OB	MT	DTT
DMHL7OB	MA	Modulator
DMHL7OB	RN	Excision of DNA adducts of nitrogen mustards by bacterial and mammalian 3-methyladenine-DNA glycosylases. Carcinogenesis. 1996 Apr;17(4):643-8.
DMHL7OB	RU	https://pubmed.ncbi.nlm.nih.gov/8625472

DMD59GI	DI	DMD59GI
DMD59GI	DN	Urapidil
DMD59GI	MI	TTSQIFT
DMD59GI	MN	5-HT 1A receptor (HTR1A)
DMD59GI	MT	DTT
DMD59GI	MA	Agonist
DMD59GI	RN	Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55.
DMD59GI	RU	https://pubmed.ncbi.nlm.nih.gov/9829161

DMD59GI	DI	DMD59GI
DMD59GI	DN	Urapidil
DMD59GI	MI	TTG28O6
DMD59GI	MN	Adrenergic receptor Alpha-1 (ADRA1)
DMD59GI	MT	DTT
DMD59GI	MA	Antagonist
DMD59GI	RN	Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55.
DMD59GI	RU	https://pubmed.ncbi.nlm.nih.gov/9829161

DMUK75B	DI	DMUK75B
DMUK75B	DN	Urea
DMUK75B	MI	DTE2B1D
DMUK75B	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMUK75B	MT	DTP
DMUK75B	MA	Substrate
DMUK75B	RN	Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. Exp Hematol. 2011 Apr;39(4):446-56.
DMUK75B	RU	http://www.ncbi.nlm.nih.gov/pubmed/21256917

DMQTREB	DI	DMQTREB
DMQTREB	DN	Uridine
DMQTREB	MI	DT0EQPW
DMQTREB	MN	Concentrative nucleoside transporter 1 (SLC28A1)
DMQTREB	MT	DTP
DMQTREB	MA	Substrate
DMQTREB	RN	Electrophysiological recordings of CNT1 (SLC28A1) activity on Nanions SURFE2R N1.
DMQTREB	RU	https://www.nanion.de/images/phocadownloadpap/Application_Notes/Nanion_APP_Note_SURFE2R_CNT1_09003.pdf

DMQTREB	DI	DMQTREB
DMQTREB	DN	Uridine
DMQTREB	MI	DT82KPY
DMQTREB	MN	Concentrative nucleoside transporter 2 (SLC28A2)
DMQTREB	MT	DTP
DMQTREB	MA	Substrate
DMQTREB	RN	Transport of ribavirin across the rat and human placental barrier: Roles of nucleoside and ATP-binding cassette drug efflux transporters. Biochem Pharmacol. 2019 May;163:60-70.
DMQTREB	RU	http://www.ncbi.nlm.nih.gov/pubmed/30716294

DMQTREB	DI	DMQTREB
DMQTREB	DN	Uridine
DMQTREB	MI	DENV24I
DMQTREB	MN	Nicotinamide riboside kinase 1 (NRK1)
DMQTREB	MT	DME
DMQTREB	MA	Metabolism
DMQTREB	RN	Nicotinamide riboside kinase structures reveal new pathways to NAD+. PLoS Biol. 2007 Oct 2;5(10):e263.
DMQTREB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17914902

DMQTREB	DI	DMQTREB
DMQTREB	DN	Uridine
DMQTREB	MI	DE8DJ3N
DMQTREB	MN	Nicotinamide riboside kinase 2 (NRK2)
DMQTREB	MT	DME
DMQTREB	MA	Metabolism
DMQTREB	RN	Nicotinamide riboside kinase structures reveal new pathways to NAD+. PLoS Biol. 2007 Oct 2;5(10):e263.
DMQTREB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17914902

DMQTREB	DI	DMQTREB
DMQTREB	DN	Uridine
DMQTREB	MI	TTO0IB8
DMQTREB	MN	Thymidine phosphorylase (TYMP)
DMQTREB	MT	DTT
DMQTREB	MA	Inhibitor
DMQTREB	RN	Enzymatic activities of uridine and thymidine phosphorylase in normal and cancerous uterine cervical tissues. Hum Cell. 2007 Nov;20(4):107-10.
DMQTREB	RU	https://pubmed.ncbi.nlm.nih.gov/17949350

DMQTREB	DI	DMQTREB
DMQTREB	DN	Uridine
DMQTREB	MI	DE478BP
DMQTREB	MN	Uridine-cytidine kinase 1 (UCK1)
DMQTREB	MT	DME
DMQTREB	MA	Metabolism
DMQTREB	RN	Phosphorylation of uridine and cytidine nucleoside analogs by two human uridine-cytidine kinases. Mol Pharmacol. 2001 May;59(5):1181-6.
DMQTREB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11306702

DMQTREB	DI	DMQTREB
DMQTREB	DN	Uridine
DMQTREB	MI	DETN1O0
DMQTREB	MN	Uridine-cytidine kinase 2 (UCK2)
DMQTREB	MT	DME
DMQTREB	MA	Metabolism
DMQTREB	RN	Phosphorylation of uridine and cytidine nucleoside analogs by two human uridine-cytidine kinases. Mol Pharmacol. 2001 May;59(5):1181-6.
DMQTREB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11306702

DMG9HIA	DI	DMG9HIA
DMG9HIA	DN	Urofollitropin
DMG9HIA	MI	TTZFDBT
DMG9HIA	MN	Follicle-stimulating hormone receptor (FSHR)
DMG9HIA	MT	DTT
DMG9HIA	MA	Binder
DMG9HIA	RN	Follicle-stimulating hormone in clinical practice: an update. Treat Endocrinol. 2004;3(3):161-71.
DMG9HIA	RU	https://pubmed.ncbi.nlm.nih.gov/16026112

DM0GOUD	DI	DM0GOUD
DM0GOUD	DN	Urokinase
DM0GOUD	MI	TTGY7WI
DM0GOUD	MN	Urokinase-type plasminogen activator (PLAU)
DM0GOUD	MT	DTT
DM0GOUD	MA	Modulator
DM0GOUD	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM0GOUD	RU	https://www.fda.gov/

DMCUT21	DI	DMCUT21
DMCUT21	DN	Ursodeoxycholic acid
DMCUT21	MI	DEOMLHG
DMCUT21	MN	Beta-hydroxysteroid dehydrogenase (hdhB)
DMCUT21	MT	DME
DMCUT21	MA	Metabolism
DMCUT21	RN	Identification, cloning, heterologous expression, and characterization of a NADPH-dependent 7beta-hydroxysteroid dehydrogenase from Collinsella aerofaciens. Appl Microbiol Biotechnol. 2011 Apr;90(1):127-35.
DMCUT21	RU	https://pubmed.ncbi.nlm.nih.gov/21181147

DMCUT21	DI	DMCUT21
DMCUT21	DN	Ursodeoxycholic acid
DMCUT21	MI	TTJBPN3
DMCUT21	MN	Biliverdin reductase A (BLVRA)
DMCUT21	MT	DTT
DMCUT21	MA	Activator
DMCUT21	RN	Role of vitamin C transporters and biliverdin reductase in the dual pro-oxidant and anti-oxidant effect of biliary compounds on the placental-fetal... Toxicol Appl Pharmacol. 2008 Oct 15;232(2):327-36.
DMCUT21	RU	https://pubmed.ncbi.nlm.nih.gov/18706437

DMCUT21	DI	DMCUT21
DMCUT21	DN	Ursodeoxycholic acid
DMCUT21	MI	DT3D8F0
DMCUT21	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMCUT21	MT	DTP
DMCUT21	MA	Substrate
DMCUT21	RN	Transport of fluorescent chenodeoxycholic acid via the human organic anion transporters OATP1B1 and OATP1B3. J Lipid Res. 2006 Jun;47(6):1196-202.
DMCUT21	RU	http://www.ncbi.nlm.nih.gov/pubmed/16534140

DMCUT21	DI	DMCUT21
DMCUT21	DN	Ursodeoxycholic acid
DMCUT21	MI	TTOP832
DMCUT21	MN	Solute carrier family 23 member 2 (SLC23A2)
DMCUT21	MT	DTT
DMCUT21	MA	Activator
DMCUT21	RN	Role of vitamin C transporters and biliverdin reductase in the dual pro-oxidant and anti-oxidant effect of biliary compounds on the placental-fetal... Toxicol Appl Pharmacol. 2008 Oct 15;232(2):327-36.
DMCUT21	RU	https://pubmed.ncbi.nlm.nih.gov/18706437

DMHTYK3	DI	DMHTYK3
DMHTYK3	DN	Ustekinumab
DMHTYK3	MI	TTRTK6Y
DMHTYK3	MN	Interleukin-12 alpha (IL12A)
DMHTYK3	MT	DTT
DMHTYK3	RN	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
DMHTYK3	RU	https://pubmed.ncbi.nlm.nih.gov/20118952

DMHTYK3	DI	DMHTYK3
DMHTYK3	DN	Ustekinumab
DMHTYK3	MI	TTC1GLB
DMHTYK3	MN	Interleukin-23 (IL23)
DMHTYK3	MT	DTT
DMHTYK3	RN	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
DMHTYK3	RU	https://pubmed.ncbi.nlm.nih.gov/20118952

DMHTYK3	DI	DMHTYK3
DMHTYK3	DN	Ustekinumab
DMHTYK3	MI	TT9SL3Q
DMHTYK3	MN	Polypeptide deformylase (PDF)
DMHTYK3	MT	DTT
DMHTYK3	MA	Inhibitor
DMHTYK3	RN	Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase. Antimicrob Agents Chemother. 2002 Nov;46(11):3362-9.
DMHTYK3	RU	https://pubmed.ncbi.nlm.nih.gov/12384337

DMA630M	DI	DMA630M
DMA630M	DN	Vaccinia immune globulin
DMA630M	MI	TTOP3CH
DMA630M	MN	Immunoglobulin unspecific (Ig)
DMA630M	MT	DTT
DMA630M	MA	Modulator
DMA630M	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMA630M	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMHKS94	DI	DMHKS94
DMHKS94	DN	Valaciclovir
DMHKS94	MI	DTW7AE3
DMHKS94	MN	Alanine/serine/cysteine/threonine transporter 2 (SLC1A5)
DMHKS94	MT	DTP
DMHKS94	MA	Substrate
DMHKS94	RN	Transport of amino acid-based prodrugs by the Na+- and Cl(-) -coupled amino acid transporter ATB0,+ and expression of the transporter in tissues amenable for drug delivery. J Pharmacol Exp Ther. 2004 Mar;308(3):1138-47.
DMHKS94	RU	http://www.ncbi.nlm.nih.gov/pubmed/14617696

DMHKS94	DI	DMHKS94
DMHKS94	DN	Valaciclovir
DMHKS94	MI	TTIU7X1
DMHKS94	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMHKS94	MT	DTT
DMHKS94	MA	Inhibitor
DMHKS94	RN	Extensive oral shedding of human herpesvirus 8 in a renal allograft recipient. Oral Microbiol Immunol. 2009 Apr;24(2):109-15.
DMHKS94	RU	https://pubmed.ncbi.nlm.nih.gov/19239637

DMHKS94	DI	DMHKS94
DMHKS94	DN	Valaciclovir
DMHKS94	MI	DTVP67E
DMHKS94	MN	Organic anion transporter 3 (SLC22A8)
DMHKS94	MT	DTP
DMHKS94	MA	Substrate
DMHKS94	RN	Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
DMHKS94	RU	http://www.ncbi.nlm.nih.gov/pubmed/11861798

DMHKS94	DI	DMHKS94
DMHKS94	DN	Valaciclovir
DMHKS94	MI	DT9G7XN
DMHKS94	MN	Peptide transporter 1 (SLC15A1)
DMHKS94	MT	DTP
DMHKS94	MA	Substrate
DMHKS94	RN	Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem Biophys Res Commun. 1998 May 19;246(2):470-5.
DMHKS94	RU	http://www.ncbi.nlm.nih.gov/pubmed/9610386

DMHKS94	DI	DMHKS94
DMHKS94	DN	Valaciclovir
DMHKS94	MI	DT8QKNP
DMHKS94	MN	Peptide transporter 2 (SLC15A2)
DMHKS94	MT	DTP
DMHKS94	MA	Substrate
DMHKS94	RN	Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem Biophys Res Commun. 1998 May 19;246(2):470-5.
DMHKS94	RU	http://www.ncbi.nlm.nih.gov/pubmed/9610386

DM5I1CE	DI	DM5I1CE
DM5I1CE	DN	Valacyclovir Hydrochloride
DM5I1CE	MI	TTIU7X1
DM5I1CE	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DM5I1CE	MT	DTT
DM5I1CE	MA	Modulator
DM5I1CE	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM5I1CE	RU	https://www.fda.gov/

DMQSA2V	DI	DMQSA2V
DMQSA2V	DN	Valbenazine tosylate
DMQSA2V	MI	TTNZRI3
DMQSA2V	MN	Synaptic vesicle amine transporter (SLC18A2)
DMQSA2V	MT	DTT
DMQSA2V	MA	Modulator
DMQSA2V	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMQSA2V	RU	https://www.fda.gov/

DMAY7H4	DI	DMAY7H4
DMAY7H4	DN	Valdecoxib
DMAY7H4	MI	DE5IED8
DMAY7H4	MN	Cytochrome P450 2C9 (CYP2C9)
DMAY7H4	MT	DME
DMAY7H4	MA	Metabolism
DMAY7H4	RN	Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):607-20.
DMAY7H4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19422321

DMAY7H4	DI	DMAY7H4
DMAY7H4	DN	Valdecoxib
DMAY7H4	MI	DE4LYSA
DMAY7H4	MN	Cytochrome P450 3A4 (CYP3A4)
DMAY7H4	MT	DME
DMAY7H4	MA	Metabolism
DMAY7H4	RN	Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. Anesthesiology. 2003 Apr;98(4):853-61.
DMAY7H4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12657846

DMAY7H4	DI	DMAY7H4
DMAY7H4	DN	Valdecoxib
DMAY7H4	MI	TTVKILB
DMAY7H4	MN	Prostaglandin G/H synthase 2 (COX-2)
DMAY7H4	MT	DTT
DMAY7H4	MA	Inhibitor
DMAY7H4	RN	Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and ... Curr Top Med Chem. 2006;6(5):461-78.
DMAY7H4	RU	https://pubmed.ncbi.nlm.nih.gov/16719803

DMAY7H4	DI	DMAY7H4
DMAY7H4	DN	Valdecoxib
DMAY7H4	MI	DE85D2P
DMAY7H4	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMAY7H4	MT	DME
DMAY7H4	MA	Metabolism
DMAY7H4	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMAY7H4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMS2IUH	DI	DMS2IUH
DMS2IUH	DN	Valganciclovir
DMS2IUH	MI	DTW7AE3
DMS2IUH	MN	Alanine/serine/cysteine/threonine transporter 2 (SLC1A5)
DMS2IUH	MT	DTP
DMS2IUH	MA	Substrate
DMS2IUH	RN	Transport of amino acid esters and the amino-acid-based prodrug valganciclovir by the amino acid transporter ATB(0,+). Pharm Res. 2004 Jul;21(7):1303-10.
DMS2IUH	RU	http://www.ncbi.nlm.nih.gov/pubmed/15290873

DMS2IUH	DI	DMS2IUH
DMS2IUH	DN	Valganciclovir
DMS2IUH	MI	TTIU7X1
DMS2IUH	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMS2IUH	MT	DTT
DMS2IUH	MA	Inhibitor
DMS2IUH	RN	Drug targets in cytomegalovirus infection. Infect Disord Drug Targets. 2009 Apr;9(2):201-22.
DMS2IUH	RU	https://pubmed.ncbi.nlm.nih.gov/19275707

DMS2IUH	DI	DMS2IUH
DMS2IUH	DN	Valganciclovir
DMS2IUH	MI	DT9G7XN
DMS2IUH	MN	Peptide transporter 1 (SLC15A1)
DMS2IUH	MT	DTP
DMS2IUH	MA	Substrate
DMS2IUH	RN	Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J Pharm Sci. 2000 Jun;89(6):781-9.
DMS2IUH	RU	http://www.ncbi.nlm.nih.gov/pubmed/10824137

DMCFE9I	DI	DMCFE9I
DMCFE9I	DN	Valproate
DMCFE9I	MI	DEJVYAZ
DMCFE9I	MN	Cytochrome P450 2A6 (CYP2A6)
DMCFE9I	MT	DME
DMCFE9I	MA	Metabolism
DMCFE9I	RN	Psychotropic drug interactions with valproate. Clin Neuropharmacol. 2005 Mar-Apr;28(2):96-101.
DMCFE9I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15795555

DMCFE9I	DI	DMCFE9I
DMCFE9I	DN	Valproate
DMCFE9I	MI	DEPKLMQ
DMCFE9I	MN	Cytochrome P450 2B6 (CYP2B6)
DMCFE9I	MT	DME
DMCFE9I	MA	Metabolism
DMCFE9I	RN	Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
DMCFE9I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27709010

DMCFE9I	DI	DMCFE9I
DMCFE9I	DN	Valproate
DMCFE9I	MI	DE5IED8
DMCFE9I	MN	Cytochrome P450 2C9 (CYP2C9)
DMCFE9I	MT	DME
DMCFE9I	MA	Metabolism
DMCFE9I	RN	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
DMCFE9I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9606477

DMCFE9I	DI	DMCFE9I
DMCFE9I	DN	Valproate
DMCFE9I	MI	DEIBDNY
DMCFE9I	MN	Cytochrome P450 3A5 (CYP3A5)
DMCFE9I	MT	DME
DMCFE9I	MA	Metabolism
DMCFE9I	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMCFE9I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMCFE9I	DI	DMCFE9I
DMCFE9I	DN	Valproate
DMCFE9I	MI	TTRZQE3
DMCFE9I	MN	Glycogen synthase kinase-3 alpha (GSK-3A)
DMCFE9I	MT	DTT
DMCFE9I	MA	Inhibitor
DMCFE9I	RN	Challenges and new opportunities in the investigation of new drug therapies to treat frontotemporal dementia. Expert Opin Ther Targets. 2008 Nov;12(11):1367-76.
DMCFE9I	RU	https://pubmed.ncbi.nlm.nih.gov/18851693

DMCFE9I	DI	DMCFE9I
DMCFE9I	DN	Valproate
DMCFE9I	MI	TTBH0VX
DMCFE9I	MN	Histone deacetylase (HDAC)
DMCFE9I	MT	DTT
DMCFE9I	MA	Inhibitor
DMCFE9I	RN	Transcription-independent heritability of induced histone modifications in the mouse preimplantation embryo. PLoS One. 2009 Jun 30;4(6):e6086.
DMCFE9I	RU	https://pubmed.ncbi.nlm.nih.gov/19564914

DMCFE9I	DI	DMCFE9I
DMCFE9I	DN	Valproate
DMCFE9I	MI	DEGTFWK
DMCFE9I	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMCFE9I	MT	DME
DMCFE9I	MA	Metabolism
DMCFE9I	RN	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
DMCFE9I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9606477

DMCFE9I	DI	DMCFE9I
DMCFE9I	DN	Valproate
DMCFE9I	MI	DTLT3UG
DMCFE9I	MN	Monocarboxylate transporter 2 (SLC16A7)
DMCFE9I	MT	DTP
DMCFE9I	MA	Substrate
DMCFE9I	RN	Monocarboxylate Transporters in Drug Disposition: Role in the Toxicokinetics and Toxicodynamics of the Drug of Abuse GHB.
DMCFE9I	RU	https://www.njacs.org/wp-content/docs/2010-Spring-DrugMet-Marilyn_Morris.pdf

DMCFE9I	DI	DMCFE9I
DMCFE9I	DN	Valproate
DMCFE9I	MI	DTFI42L
DMCFE9I	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMCFE9I	MT	DTP
DMCFE9I	MA	Substrate
DMCFE9I	RN	Pharmacogenetics of membrane transporters: an update on current approaches. Mol Biotechnol. 2010 Feb;44(2):152-67.
DMCFE9I	RU	https://doi.org/10.1007/s12033-009-9220-6

DMCFE9I	DI	DMCFE9I
DMCFE9I	DN	Valproate
DMCFE9I	MI	DE073H6
DMCFE9I	MN	Prostaglandin G/H synthase 1 (COX-1)
DMCFE9I	MT	DME
DMCFE9I	MA	Metabolism
DMCFE9I	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMCFE9I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMCFE9I	DI	DMCFE9I
DMCFE9I	DN	Valproate
DMCFE9I	MI	DEYGVN4
DMCFE9I	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMCFE9I	MT	DME
DMCFE9I	MA	Metabolism
DMCFE9I	RN	Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
DMCFE9I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18838507

DMCFE9I	DI	DMCFE9I
DMCFE9I	DN	Valproate
DMCFE9I	MI	DEL5N6Y
DMCFE9I	MN	UDP-glucuronosyltransferase 1A10 (UGT1A10)
DMCFE9I	MT	DME
DMCFE9I	MA	Metabolism
DMCFE9I	RN	UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J Pharmacol Exp Ther. 2005 Jun;313(3):1340-6.
DMCFE9I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15761113

DMCFE9I	DI	DMCFE9I
DMCFE9I	DN	Valproate
DMCFE9I	MI	DEF2WXN
DMCFE9I	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMCFE9I	MT	DME
DMCFE9I	MA	Metabolism
DMCFE9I	RN	Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
DMCFE9I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18838507

DMCFE9I	DI	DMCFE9I
DMCFE9I	DN	Valproate
DMCFE9I	MI	DESD26P
DMCFE9I	MN	UDP-glucuronosyltransferase 1A6 (UGT1A6)
DMCFE9I	MT	DME
DMCFE9I	MA	Metabolism
DMCFE9I	RN	UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J Pharmacol Exp Ther. 2005 Jun;313(3):1340-6.
DMCFE9I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15761113

DMCFE9I	DI	DMCFE9I
DMCFE9I	DN	Valproate
DMCFE9I	MI	DE85D2P
DMCFE9I	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMCFE9I	MT	DME
DMCFE9I	MA	Metabolism
DMCFE9I	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMCFE9I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMCFE9I	DI	DMCFE9I
DMCFE9I	DN	Valproate
DMCFE9I	MI	DEB3CV1
DMCFE9I	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMCFE9I	MT	DME
DMCFE9I	MA	Metabolism
DMCFE9I	RN	Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2008 Apr;83(4):595-600.
DMCFE9I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17687269

DMOYJFK	DI	DMOYJFK
DMOYJFK	DN	Valrubicin
DMOYJFK	MI	TT0IHXV
DMOYJFK	MN	DNA topoisomerase II (TOP2)
DMOYJFK	MT	DTT
DMOYJFK	MA	Inhibitor
DMOYJFK	RN	Metabolic activation of N-acylanthracyclines precedes their interaction with DNA topoisomerase II. NCI Monogr. 1987;(4):111-5.
DMOYJFK	RU	https://pubmed.ncbi.nlm.nih.gov/3041237

DMREUQ6	DI	DMREUQ6
DMREUQ6	DN	Valsartan
DMREUQ6	MI	TT8DBY3
DMREUQ6	MN	Angiotensin II receptor type-1 (AGTR1)
DMREUQ6	MT	DTT
DMREUQ6	MA	Antagonist
DMREUQ6	RN	Radioligand binding assays: application of [(125)I]angiotensin II receptor binding. Methods Mol Biol. 2009;552:131-41.
DMREUQ6	RU	https://pubmed.ncbi.nlm.nih.gov/19513646

DMREUQ6	DI	DMREUQ6
DMREUQ6	DN	Valsartan
DMREUQ6	MI	DE5IED8
DMREUQ6	MN	Cytochrome P450 2C9 (CYP2C9)
DMREUQ6	MT	DME
DMREUQ6	MA	Metabolism
DMREUQ6	RN	In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists. Eur J Clin Pharmacol. 2000 May;56(2):135-40.
DMREUQ6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10877007

DMREUQ6	DI	DMREUQ6
DMREUQ6	DN	Valsartan
DMREUQ6	MI	DTFI42L
DMREUQ6	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMREUQ6	MT	DTP
DMREUQ6	MA	Substrate
DMREUQ6	RN	Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos. 2006 Jul;34(7):1247-54.
DMREUQ6	RU	http://www.ncbi.nlm.nih.gov/pubmed/16624871

DMREUQ6	DI	DMREUQ6
DMREUQ6	DN	Valsartan
DMREUQ6	MI	DTVP67E
DMREUQ6	MN	Organic anion transporter 3 (SLC22A8)
DMREUQ6	MT	DTP
DMREUQ6	MA	Substrate
DMREUQ6	RN	Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab Dispos. 2011 Jun;39(6):1031-8.
DMREUQ6	RU	http://www.ncbi.nlm.nih.gov/pubmed/21383204

DMREUQ6	DI	DMREUQ6
DMREUQ6	DN	Valsartan
DMREUQ6	MI	DT3D8F0
DMREUQ6	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMREUQ6	MT	DTP
DMREUQ6	MA	Substrate
DMREUQ6	RN	Regulation of Organic Anion Transporting Polypeptides (OATP) 1B1- and OATP1B3-Mediated Transport: An Updated Review in the Context of OATP-Mediated Drug-Drug Interactions. Int J Mol Sci. 2018 Mar 14;19(3). pii: E855.
DMREUQ6	RU	http://www.ncbi.nlm.nih.gov/pubmed/29538325

DMREUQ6	DI	DMREUQ6
DMREUQ6	DN	Valsartan
DMREUQ6	MI	DT9C1TS
DMREUQ6	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMREUQ6	MT	DTP
DMREUQ6	MA	Substrate
DMREUQ6	RN	Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos. 2006 Jul;34(7):1247-54.
DMREUQ6	RU	http://www.ncbi.nlm.nih.gov/pubmed/16624871

DMREUQ6	DI	DMREUQ6
DMREUQ6	DN	Valsartan
DMREUQ6	MI	DT9G7XN
DMREUQ6	MN	Peptide transporter 1 (SLC15A1)
DMREUQ6	MT	DTP
DMREUQ6	MA	Substrate
DMREUQ6	RN	High-affinity interaction of sartans with H+/peptide transporters. Drug Metab Dispos. 2009 Jan;37(1):143-9.
DMREUQ6	RU	http://www.ncbi.nlm.nih.gov/pubmed/18824524

DMK7T1Q	DI	DMK7T1Q
DMK7T1Q	DN	Vancomycin
DMK7T1Q	MI	DE035GU
DMK7T1Q	MN	D-alanylalanine synthetase (ddl)
DMK7T1Q	MT	DME
DMK7T1Q	MA	Metabolism
DMK7T1Q	RN	vanG element insertions within a conserved chromosomal site conferring vancomycin resistance to Streptococcus agalactiae and Streptococcus anginosus. mBio. 2014 Jul 22;5(4):e01386-14.
DMK7T1Q	RU	https://pubmed.ncbi.nlm.nih.gov/25053786

DMK7T1Q	DI	DMK7T1Q
DMK7T1Q	DN	Vancomycin
DMK7T1Q	MI	DEOFMQ7
DMK7T1Q	MN	VanA ligase (vanA)
DMK7T1Q	MT	DME
DMK7T1Q	MA	Metabolism
DMK7T1Q	RN	Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother. 1993 Aug;37(8):1563-71.
DMK7T1Q	RU	https://pubmed.ncbi.nlm.nih.gov/8215264

DMK7T1Q	DI	DMK7T1Q
DMK7T1Q	DN	Vancomycin
DMK7T1Q	MI	DEO97D6
DMK7T1Q	MN	VanA ligase (vanA)
DMK7T1Q	MT	DME
DMK7T1Q	MA	Metabolism
DMK7T1Q	RN	Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother. 1993 Aug;37(8):1563-71.
DMK7T1Q	RU	https://pubmed.ncbi.nlm.nih.gov/8215264

DMK7T1Q	DI	DMK7T1Q
DMK7T1Q	DN	Vancomycin
DMK7T1Q	MI	DEO8E75
DMK7T1Q	MN	VanA ligase (vanA)
DMK7T1Q	MT	DME
DMK7T1Q	MA	Metabolism
DMK7T1Q	RN	Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother. 1993 Aug;37(8):1563-71.
DMK7T1Q	RU	https://pubmed.ncbi.nlm.nih.gov/8215264

DMK7T1Q	DI	DMK7T1Q
DMK7T1Q	DN	Vancomycin
DMK7T1Q	MI	DEN6VO0
DMK7T1Q	MN	VanA ligase (vanA)
DMK7T1Q	MT	DME
DMK7T1Q	MA	Metabolism
DMK7T1Q	RN	Emergence of high-level resistance to glycopeptides in Enterococcus gallinarum and Enterococcus casseliflavus. Antimicrob Agents Chemother. 1994 Jul;38(7):1675-7.
DMK7T1Q	RU	https://pubmed.ncbi.nlm.nih.gov/7979308

DMK7T1Q	DI	DMK7T1Q
DMK7T1Q	DN	Vancomycin
DMK7T1Q	MI	DESOXHP
DMK7T1Q	MN	VanA ligase (vanA)
DMK7T1Q	MT	DME
DMK7T1Q	MA	Metabolism
DMK7T1Q	RN	nan
DMK7T1Q	RU	nan

DMK7T1Q	DI	DMK7T1Q
DMK7T1Q	DN	Vancomycin
DMK7T1Q	MI	DE27YVU
DMK7T1Q	MN	VanB ligase (vanB)
DMK7T1Q	MT	DME
DMK7T1Q	MA	Metabolism
DMK7T1Q	RN	Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother. 1993 Aug;37(8):1563-71.
DMK7T1Q	RU	https://pubmed.ncbi.nlm.nih.gov/8215264

DMK7T1Q	DI	DMK7T1Q
DMK7T1Q	DN	Vancomycin
DMK7T1Q	MI	DER7KFQ
DMK7T1Q	MN	VanB ligase (vanB)
DMK7T1Q	MT	DME
DMK7T1Q	MA	Metabolism
DMK7T1Q	RN	Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother. 1993 Aug;37(8):1563-71.
DMK7T1Q	RU	https://pubmed.ncbi.nlm.nih.gov/8215264

DMK7T1Q	DI	DMK7T1Q
DMK7T1Q	DN	Vancomycin
DMK7T1Q	MI	DEMDEJ8
DMK7T1Q	MN	VanB ligase (vanB)
DMK7T1Q	MT	DME
DMK7T1Q	MA	Metabolism
DMK7T1Q	RN	vanI: a novel D-Ala-D-Lac vancomycin resistance gene cluster found in Desulfitobacterium hafniense. Microb Biotechnol. 2014 Sep;7(5):456-66.
DMK7T1Q	RU	https://pubmed.ncbi.nlm.nih.gov/25042042

DMK7T1Q	DI	DMK7T1Q
DMK7T1Q	DN	Vancomycin
DMK7T1Q	MI	DE2GMEK
DMK7T1Q	MN	VanB ligase (vanB)
DMK7T1Q	MT	DME
DMK7T1Q	MA	Metabolism
DMK7T1Q	RN	vanI: a novel D-Ala-D-Lac vancomycin resistance gene cluster found in Desulfitobacterium hafniense. Microb Biotechnol. 2014 Sep;7(5):456-66.
DMK7T1Q	RU	https://pubmed.ncbi.nlm.nih.gov/25042042

DMK7T1Q	DI	DMK7T1Q
DMK7T1Q	DN	Vancomycin
DMK7T1Q	MI	DEIF4P9
DMK7T1Q	MN	VanC2 ligase (vanC)
DMK7T1Q	MT	DME
DMK7T1Q	MA	Metabolism
DMK7T1Q	RN	Sequence of the vanC gene of Enterococcus gallinarum BM4174 encoding a D-alanine:D-alanine ligase-related protein necessary for vancomycin resistance. Gene. 1992 Mar 1;112(1):53-8.
DMK7T1Q	RU	https://pubmed.ncbi.nlm.nih.gov/1551598

DMK7T1Q	DI	DMK7T1Q
DMK7T1Q	DN	Vancomycin
DMK7T1Q	MI	DEH73ZC
DMK7T1Q	MN	VanC2 ligase (vanC)
DMK7T1Q	MT	DME
DMK7T1Q	MA	Metabolism
DMK7T1Q	RN	Bacterial resistance to vancomycin: overproduction, purification, and characterization of VanC2 from Enterococcus casseliflavus as a D-Ala-D-Ser ligase. Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10040-4.
DMK7T1Q	RU	https://pubmed.ncbi.nlm.nih.gov/9294159

DMK7T1Q	DI	DMK7T1Q
DMK7T1Q	DN	Vancomycin
DMK7T1Q	MI	DEPH3S7
DMK7T1Q	MN	VanG ligase (vanG)
DMK7T1Q	MT	DME
DMK7T1Q	MA	Metabolism
DMK7T1Q	RN	vanG element insertions within a conserved chromosomal site conferring vancomycin resistance to Streptococcus agalactiae and Streptococcus anginosus. mBio. 2014 Jul 22;5(4):e01386-14.
DMK7T1Q	RU	https://pubmed.ncbi.nlm.nih.gov/25053786

DMK7T1Q	DI	DMK7T1Q
DMK7T1Q	DN	Vancomycin
DMK7T1Q	MI	DEPN8F9
DMK7T1Q	MN	VanG ligase (vanG)
DMK7T1Q	MT	DME
DMK7T1Q	MA	Metabolism
DMK7T1Q	RN	vanG element insertions within a conserved chromosomal site conferring vancomycin resistance to Streptococcus agalactiae and Streptococcus anginosus. mBio. 2014 Jul 22;5(4):e01386-14.
DMK7T1Q	RU	https://pubmed.ncbi.nlm.nih.gov/25053786

DMRICNP	DI	DMRICNP
DMRICNP	DN	Vandetanib
DMRICNP	MI	DTI7UX6
DMRICNP	MN	Breast cancer resistance protein (ABCG2)
DMRICNP	MT	DTP
DMRICNP	MA	Substrate
DMRICNP	RN	Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences. Cancer Chemother Pharmacol. 2010 Jan;65(2):335-46.
DMRICNP	RU	https://doi.org/10.1007/s00280-009-1039-0

DMRICNP	DI	DMRICNP
DMRICNP	DN	Vandetanib
DMRICNP	MI	DE4LYSA
DMRICNP	MN	Cytochrome P450 3A4 (CYP3A4)
DMRICNP	MT	DME
DMRICNP	MA	Metabolism
DMRICNP	RN	FDA label of Vandetanib. The 2020 official website of the U.S. Food and Drug Administration.
DMRICNP	RU	http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d2a87691-c9ad-4753-97a1-311fccfe6515

DMRICNP	DI	DMRICNP
DMRICNP	DN	Vandetanib
DMRICNP	MI	TTGKNB4
DMRICNP	MN	Epidermal growth factor receptor (EGFR)
DMRICNP	MT	DTT
DMRICNP	MA	Inhibitor
DMRICNP	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMRICNP	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMRICNP	DI	DMRICNP
DMRICNP	DN	Vandetanib
DMRICNP	MI	DT3D8F0
DMRICNP	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMRICNP	MT	DTP
DMRICNP	MA	Substrate
DMRICNP	RN	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
DMRICNP	RU	http://www.ncbi.nlm.nih.gov/pubmed/23340295

DMRICNP	DI	DMRICNP
DMRICNP	DN	Vandetanib
DMRICNP	MI	DT9C1TS
DMRICNP	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMRICNP	MT	DTP
DMRICNP	MA	Substrate
DMRICNP	RN	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
DMRICNP	RU	http://www.ncbi.nlm.nih.gov/pubmed/23340295

DMRICNP	DI	DMRICNP
DMRICNP	DN	Vandetanib
DMRICNP	MI	TT4DXQT
DMRICNP	MN	Proto-oncogene c-Ret (RET)
DMRICNP	MT	DTT
DMRICNP	MA	Inhibitor
DMRICNP	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMRICNP	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMRICNP	DI	DMRICNP
DMRICNP	DN	Vandetanib
DMRICNP	MI	TTUTJGQ
DMRICNP	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMRICNP	MT	DTT
DMRICNP	MA	Inhibitor
DMRICNP	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMRICNP	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMTBGW8	DI	DMTBGW8
DMTBGW8	DN	Vardenafil
DMTBGW8	MI	DE4LYSA
DMTBGW8	MN	Cytochrome P450 3A4 (CYP3A4)
DMTBGW8	MT	DME
DMTBGW8	MA	Metabolism
DMTBGW8	RN	Erectile dysfunction drugs changed the protein expressions and activities of drug-metabolising enzymes in the liver of male rats. Oxid Med Cell Longev. 2016;2016:4970906.
DMTBGW8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27800121

DMTBGW8	DI	DMTBGW8
DMTBGW8	DN	Vardenafil
DMTBGW8	MI	DEIBDNY
DMTBGW8	MN	Cytochrome P450 3A5 (CYP3A5)
DMTBGW8	MT	DME
DMTBGW8	MA	Metabolism
DMTBGW8	RN	The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil. Drug Metab Dispos. 2008 Jun;36(6):986-90.
DMTBGW8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18308836

DMTBGW8	DI	DMTBGW8
DMTBGW8	DN	Vardenafil
DMTBGW8	MI	TTJ0IQB
DMTBGW8	MN	Phosphodiesterase 5A (PDE5A)
DMTBGW8	MT	DTT
DMTBGW8	MA	Binder
DMTBGW8	RN	The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol. 2002 Dec 4;40(11):2006-12.
DMTBGW8	RU	https://pubmed.ncbi.nlm.nih.gov/12475462

DMMUOLJ	DI	DMMUOLJ
DMMUOLJ	DN	Varenicline
DMMUOLJ	MI	TTL1ATN
DMMUOLJ	MN	Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2)
DMMUOLJ	MT	DTT
DMMUOLJ	MA	Modulator
DMMUOLJ	RN	2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
DMMUOLJ	RU	https://pubmed.ncbi.nlm.nih.gov/17342860

DMMUOLJ	DI	DMMUOLJ
DMMUOLJ	DN	Varenicline
DMMUOLJ	MI	DTT79CX
DMMUOLJ	MN	Organic cation transporter 1 (SLC22A1)
DMMUOLJ	MT	DTP
DMMUOLJ	MA	Substrate
DMMUOLJ	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMMUOLJ	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DMMUOLJ	DI	DMMUOLJ
DMMUOLJ	DN	Varenicline
DMMUOLJ	MI	DT9IDPW
DMMUOLJ	MN	Organic cation transporter 2 (SLC22A2)
DMMUOLJ	MT	DTP
DMMUOLJ	MA	Substrate
DMMUOLJ	RN	Effect of human renal cationic transporter inhibition on the pharmacokinetics of varenicline, a new therapy for smoking cessation: an in vitro-in vivo study. Clin Pharmacol Ther. 2008 Apr;83(4):567-76.
DMMUOLJ	RU	http://www.ncbi.nlm.nih.gov/pubmed/17971819

DMQ2FPC	DI	DMQ2FPC
DMQ2FPC	DN	Vasopressin
DMQ2FPC	MI	DTFI42L
DMQ2FPC	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMQ2FPC	MT	DTP
DMQ2FPC	MA	Substrate
DMQ2FPC	RN	Transport function and hepatocellular localization of mrp6 in rat liver. Mol Pharmacol. 2000 Mar;57(3):634-41.
DMQ2FPC	RU	http://www.ncbi.nlm.nih.gov/pubmed/10692506

DMQ2FPC	DI	DMQ2FPC
DMQ2FPC	DN	Vasopressin
DMQ2FPC	MI	TTK8R02
DMQ2FPC	MN	Vasopressin V2 receptor (V2R)
DMQ2FPC	MT	DTT
DMQ2FPC	MA	Agonist
DMQ2FPC	RN	Vasopressin receptors: structure/function relationships and signal transduction in target cells. J Soc Biol. 2005;199(4):351-9.
DMQ2FPC	RU	https://pubmed.ncbi.nlm.nih.gov/16738530

DMP0UK2	DI	DMP0UK2
DMP0UK2	DN	Vecuronium
DMP0UK2	MI	TTF4E0J
DMP0UK2	MN	Neuronal acetylcholine receptor alpha-2 (CHRNA2)
DMP0UK2	MT	DTT
DMP0UK2	MA	Antagonist
DMP0UK2	RN	Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52.
DMP0UK2	RU	https://pubmed.ncbi.nlm.nih.gov/19417616

DMP0UK2	DI	DMP0UK2
DMP0UK2	DN	Vecuronium
DMP0UK2	MI	DTUGYRD
DMP0UK2	MN	P-glycoprotein 1 (ABCB1)
DMP0UK2	MT	DTP
DMP0UK2	MA	Substrate
DMP0UK2	RN	Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004 Jan;75(1):13-33.
DMP0UK2	RU	https://doi.org/10.1016/j.clpt.2003.09.012

DMV3YMX	DI	DMV3YMX
DMV3YMX	DN	Vedolizmab
DMV3YMX	MI	TT4BT06
DMV3YMX	MN	Integrin alpha-4 (ITGA4)
DMV3YMX	MT	DTT
DMV3YMX	MA	Antagonist
DMV3YMX	RN	Clinical pipeline report, company report or official report of Takeda (2009).
DMV3YMX	RU	http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf

DMV3YMX	DI	DMV3YMX
DMV3YMX	DN	Vedolizmab
DMV3YMX	MI	TTLT9XQ
DMV3YMX	MN	Integrin beta-7 (ITGB7)
DMV3YMX	MT	DTT
DMV3YMX	MA	Antagonist
DMV3YMX	RN	Clinical pipeline report, company report or official report of Takeda (2009).
DMV3YMX	RU	http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf

DM4BOAS	DI	DM4BOAS
DM4BOAS	DN	Velaglucerase alfa
DM4BOAS	MI	TT1B5PU
DM4BOAS	MN	Glucosylceramidase (GBA)
DM4BOAS	MT	DTT
DM4BOAS	MA	Modulator
DM4BOAS	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DM4BOAS	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DMGF8ZQ	DI	DMGF8ZQ
DMGF8ZQ	DN	Velpatasvir
DMGF8ZQ	MI	DEPKLMQ
DMGF8ZQ	MN	Cytochrome P450 2B6 (CYP2B6)
DMGF8ZQ	MT	DME
DMGF8ZQ	MA	Metabolism
DMGF8ZQ	RN	Epclusa- European Medicines Agency - European Union
DMGF8ZQ	RU	https://www.ema.europa.eu/en/documents/product-information/epclusa-epar-product-information_de.pdf

DMGF8ZQ	DI	DMGF8ZQ
DMGF8ZQ	DN	Velpatasvir
DMGF8ZQ	MI	DES5XRU
DMGF8ZQ	MN	Cytochrome P450 2C8 (CYP2C8)
DMGF8ZQ	MT	DME
DMGF8ZQ	MA	Metabolism
DMGF8ZQ	RN	FDA Label of Vosevi. The 2020 official website of the U.S. Food and Drug Administration.
DMGF8ZQ	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209195s000lbl.pdf

DMGF8ZQ	DI	DMGF8ZQ
DMGF8ZQ	DN	Velpatasvir
DMGF8ZQ	MI	DE4LYSA
DMGF8ZQ	MN	Cytochrome P450 3A4 (CYP3A4)
DMGF8ZQ	MT	DME
DMGF8ZQ	MA	Metabolism
DMGF8ZQ	RN	Product characteristics of Epclusa.
DMGF8ZQ	RU	https://www.ema.europa.eu/en/documents/product-information/epclusa-epar-product-information_en.pdf

DM62UG5	DI	DM62UG5
DM62UG5	DN	Vemurafenib
DM62UG5	MI	DE4LYSA
DM62UG5	MN	Cytochrome P450 3A4 (CYP3A4)
DM62UG5	MT	DME
DM62UG5	MA	Metabolism
DM62UG5	RN	Vemurafenib for the treatment of melanoma. Expert Opin Pharmacother. 2012 Dec;13(17):2533-43.
DM62UG5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23094782

DM62UG5	DI	DM62UG5
DM62UG5	DN	Vemurafenib
DM62UG5	MI	DT3D8F0
DM62UG5	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM62UG5	MT	DTP
DM62UG5	MA	Substrate
DM62UG5	RN	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
DM62UG5	RU	http://www.ncbi.nlm.nih.gov/pubmed/23340295

DM62UG5	DI	DM62UG5
DM62UG5	DN	Vemurafenib
DM62UG5	MI	DT9C1TS
DM62UG5	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM62UG5	MT	DTP
DM62UG5	MA	Substrate
DM62UG5	RN	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
DM62UG5	RU	http://www.ncbi.nlm.nih.gov/pubmed/23340295

DM62UG5	DI	DM62UG5
DM62UG5	DN	Vemurafenib
DM62UG5	MI	DTUGYRD
DM62UG5	MN	P-glycoprotein 1 (ABCB1)
DM62UG5	MT	DTP
DM62UG5	MA	Substrate
DM62UG5	RN	Differential effects of the oncogenic BRAF inhibitor PLX4032 (vemurafenib) and its progenitor PLX4720 on ABCB1 function. J Pharm Pharm Sci. 2014;17(1):154-68.
DM62UG5	RU	http://www.ncbi.nlm.nih.gov/pubmed/24735766

DM62UG5	DI	DM62UG5
DM62UG5	DN	Vemurafenib
DM62UG5	MI	TTWCGQT
DM62UG5	MN	Serine/threonine-protein kinase B-raf (BRAF)
DM62UG5	MT	DTT
DM62UG5	MA	Modulator
DM62UG5	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DM62UG5	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM8I94Y	DI	DM8I94Y
DM8I94Y	DN	Venetoclax
DM8I94Y	MI	DTUGYRD
DM8I94Y	MN	P-glycoprotein 1 (ABCB1)
DM8I94Y	MT	DTP
DM8I94Y	MA	Substrate
DM8I94Y	RN	Venclexta FDA label
DM8I94Y	RU	https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/127/original/Venclexta_FDA_label.pdf?1543869212

DMR6QH0	DI	DMR6QH0
DMR6QH0	DN	Venlafaxine
DMR6QH0	MI	DE5IED8
DMR6QH0	MN	Cytochrome P450 2C9 (CYP2C9)
DMR6QH0	MT	DME
DMR6QH0	MA	Metabolism
DMR6QH0	RN	O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology. 1999 May;20(5):480-90.
DMR6QH0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10192828

DMR6QH0	DI	DMR6QH0
DMR6QH0	DN	Venlafaxine
DMR6QH0	MI	DECB0K3
DMR6QH0	MN	Cytochrome P450 2D6 (CYP2D6)
DMR6QH0	MT	DME
DMR6QH0	MA	Metabolism
DMR6QH0	RN	The associations between CYP2D6 metabolizer status and pharmacokinetics and clinical outcomes of venlafaxine: a systematic review and meta-analysis. Pharmacopsychiatry. 2019 Sep;52(5):222-231.
DMR6QH0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30485867

DMR6QH0	DI	DMR6QH0
DMR6QH0	DN	Venlafaxine
DMR6QH0	MI	DE4LYSA
DMR6QH0	MN	Cytochrome P450 3A4 (CYP3A4)
DMR6QH0	MT	DME
DMR6QH0	MA	Metabolism
DMR6QH0	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMR6QH0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMR6QH0	DI	DMR6QH0
DMR6QH0	DN	Venlafaxine
DMR6QH0	MI	DEGTFWK
DMR6QH0	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMR6QH0	MT	DME
DMR6QH0	MA	Metabolism
DMR6QH0	RN	O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology. 1999 May;20(5):480-90.
DMR6QH0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10192828

DMR6QH0	DI	DMR6QH0
DMR6QH0	DN	Venlafaxine
DMR6QH0	MI	TTAWNKZ
DMR6QH0	MN	Norepinephrine transporter (NET)
DMR6QH0	MT	DTT
DMR6QH0	MA	Inhibitor
DMR6QH0	RN	Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
DMR6QH0	RU	https://pubmed.ncbi.nlm.nih.gov/19496045

DMR6QH0	DI	DMR6QH0
DMR6QH0	DN	Venlafaxine
DMR6QH0	MI	TT3ROYC
DMR6QH0	MN	Serotonin transporter (SERT)
DMR6QH0	MT	DTT
DMR6QH0	MA	Inhibitor
DMR6QH0	RN	Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
DMR6QH0	RU	https://pubmed.ncbi.nlm.nih.gov/19496045

DMA7PEW	DI	DMA7PEW
DMA7PEW	DN	Verapamil
DMA7PEW	MI	DEJGDUW
DMA7PEW	MN	Cytochrome P450 1A2 (CYP1A2)
DMA7PEW	MT	DME
DMA7PEW	MA	Metabolism
DMA7PEW	RN	Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
DMA7PEW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8232610

DMA7PEW	DI	DMA7PEW
DMA7PEW	DN	Verapamil
DMA7PEW	MI	DEPKLMQ
DMA7PEW	MN	Cytochrome P450 2B6 (CYP2B6)
DMA7PEW	MT	DME
DMA7PEW	MA	Metabolism
DMA7PEW	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMA7PEW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMA7PEW	DI	DMA7PEW
DMA7PEW	DN	Verapamil
DMA7PEW	MI	DEZMWRE
DMA7PEW	MN	Cytochrome P450 2C18 (CYP2C18)
DMA7PEW	MT	DME
DMA7PEW	MA	Metabolism
DMA7PEW	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMA7PEW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMA7PEW	DI	DMA7PEW
DMA7PEW	DN	Verapamil
DMA7PEW	MI	DES5XRU
DMA7PEW	MN	Cytochrome P450 2C8 (CYP2C8)
DMA7PEW	MT	DME
DMA7PEW	MA	Metabolism
DMA7PEW	RN	Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
DMA7PEW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12972955

DMA7PEW	DI	DMA7PEW
DMA7PEW	DN	Verapamil
DMA7PEW	MI	DE5IED8
DMA7PEW	MN	Cytochrome P450 2C9 (CYP2C9)
DMA7PEW	MT	DME
DMA7PEW	MA	Metabolism
DMA7PEW	RN	Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
DMA7PEW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10640508

DMA7PEW	DI	DMA7PEW
DMA7PEW	DN	Verapamil
DMA7PEW	MI	DEVDYN7
DMA7PEW	MN	Cytochrome P450 2E1 (CYP2E1)
DMA7PEW	MT	DME
DMA7PEW	MA	Metabolism
DMA7PEW	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMA7PEW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMA7PEW	DI	DMA7PEW
DMA7PEW	DN	Verapamil
DMA7PEW	MI	DE4LYSA
DMA7PEW	MN	Cytochrome P450 3A4 (CYP3A4)
DMA7PEW	MT	DME
DMA7PEW	MA	Metabolism
DMA7PEW	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMA7PEW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMA7PEW	DI	DMA7PEW
DMA7PEW	DN	Verapamil
DMA7PEW	MI	DEIBDNY
DMA7PEW	MN	Cytochrome P450 3A5 (CYP3A5)
DMA7PEW	MT	DME
DMA7PEW	MA	Metabolism
DMA7PEW	RN	Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
DMA7PEW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15689501

DMA7PEW	DI	DMA7PEW
DMA7PEW	DN	Verapamil
DMA7PEW	MI	DERD86B
DMA7PEW	MN	Cytochrome P450 3A7 (CYP3A7)
DMA7PEW	MT	DME
DMA7PEW	MA	Metabolism
DMA7PEW	RN	Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
DMA7PEW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14744949

DMA7PEW	DI	DMA7PEW
DMA7PEW	DN	Verapamil
DMA7PEW	MI	DEGTFWK
DMA7PEW	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMA7PEW	MT	DME
DMA7PEW	MA	Metabolism
DMA7PEW	RN	Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
DMA7PEW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8750925

DMA7PEW	DI	DMA7PEW
DMA7PEW	DN	Verapamil
DMA7PEW	MI	DTZRMK5
DMA7PEW	MN	Multidrug resistance protein 3 (ABCB4)
DMA7PEW	MT	DTP
DMA7PEW	MA	Substrate
DMA7PEW	RN	MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem. 2000 Aug 4;275(31):23530-9.
DMA7PEW	RU	http://www.ncbi.nlm.nih.gov/pubmed/10918072

DMA7PEW	DI	DMA7PEW
DMA7PEW	DN	Verapamil
DMA7PEW	MI	DTSYQGK
DMA7PEW	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMA7PEW	MT	DTP
DMA7PEW	MA	Substrate
DMA7PEW	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMA7PEW	RU	https://doi.org/10.1007/s11095-012-0935-x

DMA7PEW	DI	DMA7PEW
DMA7PEW	DN	Verapamil
DMA7PEW	MI	DTT79CX
DMA7PEW	MN	Organic cation transporter 1 (SLC22A1)
DMA7PEW	MT	DTP
DMA7PEW	MA	Substrate
DMA7PEW	RN	Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
DMA7PEW	RU	https://doi.org/10.1016/j.canlet.2005.06.051

DMA7PEW	DI	DMA7PEW
DMA7PEW	DN	Verapamil
DMA7PEW	MI	DT2EG60
DMA7PEW	MN	Organic cation/carnitine transporter 1 (SLC22A4)
DMA7PEW	MT	DTP
DMA7PEW	MA	Substrate
DMA7PEW	RN	Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther. 1999 May;289(2):768-73.
DMA7PEW	RU	http://www.ncbi.nlm.nih.gov/pubmed/10215651

DMA7PEW	DI	DMA7PEW
DMA7PEW	DN	Verapamil
DMA7PEW	MI	DT3HUVD
DMA7PEW	MN	Organic cation/carnitine transporter 2 (SLC22A5)
DMA7PEW	MT	DTP
DMA7PEW	MA	Substrate
DMA7PEW	RN	Genetic variations of the SLC22A5 gene in the Chinese and Indian populations of Singapore. Drug Metab Pharmacokinet. 2010;25(1):112-9.
DMA7PEW	RU	http://www.ncbi.nlm.nih.gov/pubmed/20208395

DMA7PEW	DI	DMA7PEW
DMA7PEW	DN	Verapamil
DMA7PEW	MI	DTUGYRD
DMA7PEW	MN	P-glycoprotein 1 (ABCB1)
DMA7PEW	MT	DTP
DMA7PEW	MA	Substrate
DMA7PEW	RN	Improved expression and purification of human multidrug resistance protein MDR1 from baculovirus-infected insect cells. Protein Expr Purif. 2009 Jul;66(1):7-14.
DMA7PEW	RU	http://www.ncbi.nlm.nih.gov/pubmed/19233288

DMA7PEW	DI	DMA7PEW
DMA7PEW	DN	Verapamil
DMA7PEW	MI	TT729IR
DMA7PEW	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DMA7PEW	MT	DTT
DMA7PEW	MA	Blocker
DMA7PEW	RN	Mechanism of tissue-selective drug action in the cardiovascular system. Mol Interv. 2005 Apr;5(2):84-93.
DMA7PEW	RU	https://pubmed.ncbi.nlm.nih.gov/15821157

DM7MDBE	DI	DM7MDBE
DM7MDBE	DN	Vericiguat
DM7MDBE	MI	TTWNFC2
DM7MDBE	MN	Soluble guanylyl cyclase (GUCY2D)
DM7MDBE	MT	DTT
DM7MDBE	MA	Modulator
DM7MDBE	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2021
DM7MDBE	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214377s000lbl.pdf

DMIY6DB	DI	DMIY6DB
DMIY6DB	DN	Verteporfin
DMIY6DB	MI	DTF9Y2V
DMIY6DB	MN	ATP-binding cassette sub-family B member 6 (ABCB6)
DMIY6DB	MT	DTP
DMIY6DB	MA	Substrate
DMIY6DB	RN	Efficient purification and reconstitution of ATP binding cassette transporter B6 (ABCB6) for functional and structural studies. J Biol Chem. 2013 Aug 2;288(31):22658-69.
DMIY6DB	RU	http://www.ncbi.nlm.nih.gov/pubmed/23792964

DMIY6DB	DI	DMIY6DB
DMIY6DB	DN	Verteporfin
DMIY6DB	MI	DTI7UX6
DMIY6DB	MN	Breast cancer resistance protein (ABCG2)
DMIY6DB	MT	DTP
DMIY6DB	MA	Substrate
DMIY6DB	RN	The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2. Clin Cancer Res. 2007 Apr 15;13(8):2463-70.
DMIY6DB	RU	https://doi.org/10.1158/1078-0432.CCR-06-1599

DMBKX3C	DI	DMBKX3C
DMBKX3C	DN	VESNARINONE
DMBKX3C	MI	TT06AWU
DMBKX3C	MN	Phosphodiesterase 3A (PDE3A)
DMBKX3C	MT	DTT
DMBKX3C	MA	Inhibitor
DMBKX3C	RN	Design, synthesis and biological evaluation of 6-(benzyloxy)-4-methylquinolin-2(1H)-one derivatives as PDE3 inhibitors. Bioorg Med Chem. 2010 Jan 15;18(2):855-62.
DMBKX3C	RU	https://pubmed.ncbi.nlm.nih.gov/20005117

DMBKX3C	DI	DMBKX3C
DMBKX3C	DN	VESNARINONE
DMBKX3C	MI	TTQ6VDM
DMBKX3C	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMBKX3C	MT	DTT
DMBKX3C	MA	Inhibitor
DMBKX3C	RN	Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. Bioorg Med Chem Lett. 2003 Aug 18;13(16):2773-5.
DMBKX3C	RU	https://pubmed.ncbi.nlm.nih.gov/12873512

DM4UHZF	DI	DM4UHZF
DM4UHZF	DN	Vestronidase alfa
DM4UHZF	MI	TTHS7CM
DM4UHZF	MN	Beta-glucuronidase (GUSB)
DM4UHZF	MT	DTT
DM4UHZF	MA	Modulator
DM4UHZF	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DM4UHZF	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DMFR201	DI	DMFR201
DMFR201	DN	Vibegron
DMFR201	MI	TTMXGCW
DMFR201	MN	Adrenergic receptor beta-3 (ADRB3)
DMFR201	MT	DTT
DMFR201	MA	Agonist
DMFR201	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMFR201	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213006s000lbl.pdf

DM0N85H	DI	DM0N85H
DM0N85H	DN	Vidarabine
DM0N85H	MI	TTNE7KG
DM0N85H	MN	Adenosine A2b receptor (ADORA2B)
DM0N85H	MT	DTT
DM0N85H	MA	Modulator
DM0N85H	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM0N85H	RU	https://www.fda.gov/

DMYT0OG	DI	DMYT0OG
DMYT0OG	DN	Vigabatrin
DMYT0OG	MI	TTT2LD9
DMYT0OG	MN	GABA transaminase (ABAT)
DMYT0OG	MT	DTT
DMYT0OG	MA	Inhibitor
DMYT0OG	RN	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
DMYT0OG	RU	https://pubmed.ncbi.nlm.nih.gov/20118952

DMYT0OG	DI	DMYT0OG
DMYT0OG	DN	Vigabatrin
DMYT0OG	MI	DT48WEM
DMYT0OG	MN	Proton-coupled amino acid transporter 1 (SLC36A1)
DMYT0OG	MT	DTP
DMYT0OG	MA	Substrate
DMYT0OG	RN	Rectal absorption of vigabatrin, a substrate of the proton coupled amino acid transporter (PAT1, Slc36a1), in rats. Pharm Res. 2012 Apr;29(4):1134-42.
DMYT0OG	RU	http://www.ncbi.nlm.nih.gov/pubmed/22234618

DMF5EK1	DI	DMF5EK1
DMF5EK1	DN	Vilanterol
DMF5EK1	MI	TT2CJVK
DMF5EK1	MN	Adrenergic receptor beta-2 (ADRB2)
DMF5EK1	MT	DTT
DMF5EK1	MA	Modulator
DMF5EK1	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7353).
DMF5EK1	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7353

DMF5EK1	DI	DMF5EK1
DMF5EK1	DN	Vilanterol
DMF5EK1	MI	DE4LYSA
DMF5EK1	MN	Cytochrome P450 3A4 (CYP3A4)
DMF5EK1	MT	DME
DMF5EK1	MA	Metabolism
DMF5EK1	RN	The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of inhaled fluticasone furoate and vilanterol trifenatate in healthy subjects. Br J Clin Pharmacol. 2013 Jun;75(6):1478-87.
DMF5EK1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23116485

DM4LECQ	DI	DM4LECQ
DM4LECQ	DN	Vilazodone
DM4LECQ	MI	TTSQIFT
DM4LECQ	MN	5-HT 1A receptor (HTR1A)
DM4LECQ	MT	DTT
DM4LECQ	MA	Modulator
DM4LECQ	RN	2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
DM4LECQ	RU	https://pubmed.ncbi.nlm.nih.gov/22293555

DM4LECQ	DI	DM4LECQ
DM4LECQ	DN	Vilazodone
DM4LECQ	MI	DECB0K3
DM4LECQ	MN	Cytochrome P450 2D6 (CYP2D6)
DM4LECQ	MT	DME
DM4LECQ	MA	Metabolism
DM4LECQ	RN	Vilazodone HCl (Viibryd): A Serotonin Partial Agonist and Reuptake Inhibitor For the Treatment of Major Depressive Disorder. P T. 2012 Jan;37(1):28-31.
DM4LECQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22346333

DM4LECQ	DI	DM4LECQ
DM4LECQ	DN	Vilazodone
DM4LECQ	MI	DE4LYSA
DM4LECQ	MN	Cytochrome P450 3A4 (CYP3A4)
DM4LECQ	MT	DME
DM4LECQ	MA	Metabolism
DM4LECQ	RN	Vilazodone HCl (Viibryd): A Serotonin Partial Agonist and Reuptake Inhibitor For the Treatment of Major Depressive Disorder. P T. 2012 Jan;37(1):28-31.
DM4LECQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22346333

DM4LECQ	DI	DM4LECQ
DM4LECQ	DN	Vilazodone
DM4LECQ	MI	DEGTFWK
DM4LECQ	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM4LECQ	MT	DME
DM4LECQ	MA	Metabolism
DM4LECQ	RN	Vilazodone HCl (Viibryd): A Serotonin Partial Agonist and Reuptake Inhibitor For the Treatment of Major Depressive Disorder. P T. 2012 Jan;37(1):28-31.
DM4LECQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22346333

DM4LECQ	DI	DM4LECQ
DM4LECQ	DN	Vilazodone
DM4LECQ	MI	TT3ROYC
DM4LECQ	MN	Serotonin transporter (SERT)
DM4LECQ	MT	DTT
DM4LECQ	MA	Modulator
DM4LECQ	RN	2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
DM4LECQ	RU	https://pubmed.ncbi.nlm.nih.gov/22293555

DMYN59P	DI	DMYN59P
DMYN59P	DN	Vildagliptin
DMYN59P	MI	TTDIGC1
DMYN59P	MN	Dipeptidyl peptidase 4 (DPP-4)
DMYN59P	MT	DTT
DMYN59P	MA	Inhibitor
DMYN59P	RN	Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87.
DMYN59P	RU	https://pubmed.ncbi.nlm.nih.gov/19149538

DMYN59P	DI	DMYN59P
DMYN59P	DN	Vildagliptin
DMYN59P	MI	DTUGYRD
DMYN59P	MN	P-glycoprotein 1 (ABCB1)
DMYN59P	MT	DTP
DMYN59P	MA	Substrate
DMYN59P	RN	Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010 Aug;12(8):648-58.
DMYN59P	RU	https://doi.org/10.1111/j.1463-1326.2010.01212.x

DM5TVS3	DI	DM5TVS3
DM5TVS3	DN	Vinblastine
DM5TVS3	MI	DTI7UX6
DM5TVS3	MN	Breast cancer resistance protein (ABCG2)
DM5TVS3	MT	DTP
DM5TVS3	MA	Substrate
DM5TVS3	RN	Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2011 May;337(2):423-32.
DM5TVS3	RU	http://www.ncbi.nlm.nih.gov/pubmed/21262849

DM5TVS3	DI	DM5TVS3
DM5TVS3	DN	Vinblastine
DM5TVS3	MI	DECB0K3
DM5TVS3	MN	Cytochrome P450 2D6 (CYP2D6)
DM5TVS3	MT	DME
DM5TVS3	MA	Metabolism
DM5TVS3	RN	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
DM5TVS3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8258200

DM5TVS3	DI	DM5TVS3
DM5TVS3	DN	Vinblastine
DM5TVS3	MI	DE4LYSA
DM5TVS3	MN	Cytochrome P450 3A4 (CYP3A4)
DM5TVS3	MT	DME
DM5TVS3	MA	Metabolism
DM5TVS3	RN	Induction of CYP3A4 by vinblastine: role of the nuclear receptor NR1I2. Ann Pharmacother. 2010 Nov;44(11):1709-17.
DM5TVS3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20959500

DM5TVS3	DI	DM5TVS3
DM5TVS3	DN	Vinblastine
DM5TVS3	MI	DEIBDNY
DM5TVS3	MN	Cytochrome P450 3A5 (CYP3A5)
DM5TVS3	MT	DME
DM5TVS3	MA	Metabolism
DM5TVS3	RN	Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
DM5TVS3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18930278

DM5TVS3	DI	DM5TVS3
DM5TVS3	DN	Vinblastine
DM5TVS3	MI	DTZRMK5
DM5TVS3	MN	Multidrug resistance protein 3 (ABCB4)
DM5TVS3	MT	DTP
DM5TVS3	MA	Substrate
DM5TVS3	RN	MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem. 2000 Aug 4;275(31):23530-9.
DM5TVS3	RU	http://www.ncbi.nlm.nih.gov/pubmed/10918072

DM5TVS3	DI	DM5TVS3
DM5TVS3	DN	Vinblastine
DM5TVS3	MI	DTSYQGK
DM5TVS3	MN	Multidrug resistance-associated protein 1 (ABCC1)
DM5TVS3	MT	DTP
DM5TVS3	MA	Substrate
DM5TVS3	RN	Development and characterization of a recombinant Madin-Darby canine kidney cell line that expresses rat multidrug resistance-associated protein 1 (rMRP1). AAPS PharmSci. 2004 Mar 9;6(1):E8.
DM5TVS3	RU	http://www.ncbi.nlm.nih.gov/pubmed/15198509

DM5TVS3	DI	DM5TVS3
DM5TVS3	DN	Vinblastine
DM5TVS3	MI	DTFI42L
DM5TVS3	MN	Multidrug resistance-associated protein 2 (ABCC2)
DM5TVS3	MT	DTP
DM5TVS3	MA	Substrate
DM5TVS3	RN	Severe hypokalemia due to a possible drug-drug interaction between vinblastine and antiretrovirals in a HIV-infected patient with Hodgkin's lymphoma. Int J STD AIDS. 2017 Oct;28(12):1259-1262.
DM5TVS3	RU	http://www.ncbi.nlm.nih.gov/pubmed/28403692

DM5TVS3	DI	DM5TVS3
DM5TVS3	DN	Vinblastine
DM5TVS3	MI	DTUGYRD
DM5TVS3	MN	P-glycoprotein 1 (ABCB1)
DM5TVS3	MT	DTP
DM5TVS3	MA	Substrate
DM5TVS3	RN	Xenopus laevis oocytes expressing human P-glycoprotein: probing trans- and cis-inhibitory effects on [3H]vinblastine and [3H]digoxin efflux. Pharmacol Res. 2010 Jan;61(1):76-84.
DM5TVS3	RU	http://www.ncbi.nlm.nih.gov/pubmed/19631272

DM5TVS3	DI	DM5TVS3
DM5TVS3	DN	Vinblastine
DM5TVS3	MI	TTJ2PTI
DM5TVS3	MN	Tubulin beta-2 chain (TUBB2)
DM5TVS3	MT	DTT
DM5TVS3	MA	Inhibitor
DM5TVS3	RN	Effect of the antitumor drug vinblastine on nuclear betaII-tubulin in cultured rat kidney mesangial cells. Invest New Drugs. 2003 Feb;21(1):15-20.
DM5TVS3	RU	https://pubmed.ncbi.nlm.nih.gov/12795526

DMK1ZOR	DI	DMK1ZOR
DMK1ZOR	DN	Vincamine
DMK1ZOR	MI	DEJGDUW
DMK1ZOR	MN	Cytochrome P450 1A2 (CYP1A2)
DMK1ZOR	MT	DME
DMK1ZOR	MA	Metabolism
DMK1ZOR	RN	Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine. Fundam Clin Pharmacol. 2005 Oct;19(5):545-53.
DMK1ZOR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16176333

DMK1ZOR	DI	DMK1ZOR
DMK1ZOR	DN	Vincamine
DMK1ZOR	MI	DECB0K3
DMK1ZOR	MN	Cytochrome P450 2D6 (CYP2D6)
DMK1ZOR	MT	DME
DMK1ZOR	MA	Metabolism
DMK1ZOR	RN	Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine. Fundam Clin Pharmacol. 2005 Oct;19(5):545-53.
DMK1ZOR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16176333

DMK1ZOR	DI	DMK1ZOR
DMK1ZOR	DN	Vincamine
DMK1ZOR	MI	DEVDYN7
DMK1ZOR	MN	Cytochrome P450 2E1 (CYP2E1)
DMK1ZOR	MT	DME
DMK1ZOR	MA	Metabolism
DMK1ZOR	RN	Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine. Fundam Clin Pharmacol. 2005 Oct;19(5):545-53.
DMK1ZOR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16176333

DMK1ZOR	DI	DMK1ZOR
DMK1ZOR	DN	Vincamine
DMK1ZOR	MI	DE4LYSA
DMK1ZOR	MN	Cytochrome P450 3A4 (CYP3A4)
DMK1ZOR	MT	DME
DMK1ZOR	MA	Metabolism
DMK1ZOR	RN	Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine. Fundam Clin Pharmacol. 2005 Oct;19(5):545-53.
DMK1ZOR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16176333

DMINOX3	DI	DMINOX3
DMINOX3	DN	Vincristine
DMINOX3	MI	DTI7UX6
DMINOX3	MN	Breast cancer resistance protein (ABCG2)
DMINOX3	MT	DTP
DMINOX3	MA	Substrate
DMINOX3	RN	Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34.
DMINOX3	RU	https://doi.org/10.1007/s00280-006-0230-9

DMINOX3	DI	DMINOX3
DMINOX3	DN	Vincristine
DMINOX3	MI	DE4LYSA
DMINOX3	MN	Cytochrome P450 3A4 (CYP3A4)
DMINOX3	MT	DME
DMINOX3	MA	Metabolism
DMINOX3	RN	Association of CYP3A5 expression and vincristine neurotoxicity in pediatric malignancies in Turkish population. J Pediatr Hematol Oncol. 2017 Aug;39(6):458-462.
DMINOX3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28697165

DMINOX3	DI	DMINOX3
DMINOX3	DN	Vincristine
DMINOX3	MI	DEIBDNY
DMINOX3	MN	Cytochrome P450 3A5 (CYP3A5)
DMINOX3	MT	DME
DMINOX3	MA	Metabolism
DMINOX3	RN	Association of CYP3A5 expression and vincristine neurotoxicity in pediatric malignancies in Turkish population. J Pediatr Hematol Oncol. 2017 Aug;39(6):458-462.
DMINOX3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28697165

DMINOX3	DI	DMINOX3
DMINOX3	DN	Vincristine
DMINOX3	MI	DERD86B
DMINOX3	MN	Cytochrome P450 3A7 (CYP3A7)
DMINOX3	MT	DME
DMINOX3	MA	Metabolism
DMINOX3	RN	Drug Interactions Flockhart Table
DMINOX3	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMINOX3	DI	DMINOX3
DMINOX3	DN	Vincristine
DMINOX3	MI	DTSYQGK
DMINOX3	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMINOX3	MT	DTP
DMINOX3	MA	Substrate
DMINOX3	RN	Interaction of plant cannabinoids with the multidrug transporter ABCC1 (MRP1). Eur J Pharmacol. 2008 Sep 4;591(1-3):128-31.
DMINOX3	RU	http://www.ncbi.nlm.nih.gov/pubmed/18619955

DMINOX3	DI	DMINOX3
DMINOX3	DN	Vincristine
DMINOX3	MI	DTFI42L
DMINOX3	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMINOX3	MT	DTP
DMINOX3	MA	Substrate
DMINOX3	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMINOX3	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMINOX3	DI	DMINOX3
DMINOX3	DN	Vincristine
DMINOX3	MI	DTUGYRD
DMINOX3	MN	P-glycoprotein 1 (ABCB1)
DMINOX3	MT	DTP
DMINOX3	MA	Substrate
DMINOX3	RN	L-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1 expression in human lung cancer cell lines. Toxicol Lett. 2010 Feb 15;192(3):408-18.
DMINOX3	RU	http://www.ncbi.nlm.nih.gov/pubmed/19944135

DMINOX3	DI	DMINOX3
DMINOX3	DN	Vincristine
DMINOX3	MI	TTYFKSZ
DMINOX3	MN	Tubulin beta (TUBB)
DMINOX3	MT	DTT
DMINOX3	MA	Modulator
DMINOX3	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMINOX3	RU	https://www.fda.gov/

DMVR628	DI	DMVR628
DMVR628	DN	Vindesine
DMVR628	MI	DE4LYSA
DMVR628	MN	Cytochrome P450 3A4 (CYP3A4)
DMVR628	MT	DME
DMVR628	MA	Metabolism
DMVR628	RN	Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions. Biochem Pharmacol. 1993 Feb 24;45(4):853-61.
DMVR628	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8452560

DMVR628	DI	DMVR628
DMVR628	DN	Vindesine
DMVR628	MI	DEIBDNY
DMVR628	MN	Cytochrome P450 3A5 (CYP3A5)
DMVR628	MT	DME
DMVR628	MA	Metabolism
DMVR628	RN	Structural perspectives of the CYP3A family and their small molecule modulators in drug metabolism. 2019, 3(3), 132-142.
DMVR628	RU	https://www.sciencedirect.com/science/article/pii/S2542568419300431

DMVR628	DI	DMVR628
DMVR628	DN	Vindesine
DMVR628	MI	DERD86B
DMVR628	MN	Cytochrome P450 3A7 (CYP3A7)
DMVR628	MT	DME
DMVR628	MA	Metabolism
DMVR628	RN	Structural perspectives of the CYP3A family and their small molecule modulators in drug metabolism. 2019, 3(3), 132-142.
DMVR628	RU	https://www.sciencedirect.com/science/article/pii/S2542568419300431

DMVR628	DI	DMVR628
DMVR628	DN	Vindesine
DMVR628	MI	DTUGYRD
DMVR628	MN	P-glycoprotein 1 (ABCB1)
DMVR628	MT	DTP
DMVR628	MA	Substrate
DMVR628	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMVR628	RU	https://doi.org/10.1007/s11095-012-0935-x

DMVR628	DI	DMVR628
DMVR628	DN	Vindesine
DMVR628	MI	TTYFKSZ
DMVR628	MN	Tubulin beta (TUBB)
DMVR628	MT	DTT
DMVR628	MA	Binder
DMVR628	RN	Antiproliferating activity of the mitotic inhibitor pironetin against vindesine- and paclitaxel-resistant human small cell lung cancer H69 cells. Anticancer Res. 2007 Mar-Apr;27(2):729-36.
DMVR628	RU	https://pubmed.ncbi.nlm.nih.gov/17465195

DMVXFYE	DI	DMVXFYE
DMVXFYE	DN	Vinorelbine
DMVXFYE	MI	DECB0K3
DMVXFYE	MN	Cytochrome P450 2D6 (CYP2D6)
DMVXFYE	MT	DME
DMVXFYE	MA	Metabolism
DMVXFYE	RN	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
DMVXFYE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8258200

DMVXFYE	DI	DMVXFYE
DMVXFYE	DN	Vinorelbine
DMVXFYE	MI	DE4LYSA
DMVXFYE	MN	Cytochrome P450 3A4 (CYP3A4)
DMVXFYE	MT	DME
DMVXFYE	MA	Metabolism
DMVXFYE	RN	Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine. Fundam Clin Pharmacol. 2005 Oct;19(5):545-53.
DMVXFYE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16176333

DMVXFYE	DI	DMVXFYE
DMVXFYE	DN	Vinorelbine
DMVXFYE	MI	DTUGYRD
DMVXFYE	MN	P-glycoprotein 1 (ABCB1)
DMVXFYE	MT	DTP
DMVXFYE	MA	Substrate
DMVXFYE	RN	Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8.
DMVXFYE	RU	http://www.ncbi.nlm.nih.gov/pubmed/11602674

DMVXFYE	DI	DMVXFYE
DMVXFYE	DN	Vinorelbine
DMVXFYE	MI	TTML2WA
DMVXFYE	MN	Tubulin (TUB)
DMVXFYE	MT	DTT
DMVXFYE	MA	Inhibitor
DMVXFYE	RN	Vinca alkaloid and MDR1. Gan To Kagaku Ryoho. 2008 Jul;35(7):1086-9.
DMVXFYE	RU	https://pubmed.ncbi.nlm.nih.gov/18633246

DMVN2E6	DI	DMVN2E6
DMVN2E6	DN	Vinpocetine
DMVN2E6	MI	DE4LYSA
DMVN2E6	MN	Cytochrome P450 3A4 (CYP3A4)
DMVN2E6	MT	DME
DMVN2E6	MA	Metabolism
DMVN2E6	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DMVN2E6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DMVN2E6	DI	DMVN2E6
DMVN2E6	DN	Vinpocetine
DMVN2E6	MI	TTHQENC
DMVN2E6	MN	Phosphodiesterase 1 (PDE1)
DMVN2E6	MT	DTT
DMVN2E6	MA	Inhibitor
DMVN2E6	RN	Effects of phosphodiesterase inhibitors on contraction induced by endothelin-1 of isolated human prostatic tissue. Urology. 2009 Jun;73(6):1397-401.
DMVN2E6	RU	https://pubmed.ncbi.nlm.nih.gov/19285714

DMZYLFC	DI	DMZYLFC
DMZYLFC	DN	Viomycin sulfate
DMZYLFC	MI	TTIA0J5
DMZYLFC	MN	Bacterial 70S ribosomal RNA (Bact 70S rRNA)
DMZYLFC	MT	DTT
DMZYLFC	MA	Modulator
DMZYLFC	RN	The antibiotic viomycin traps the ribosome in an intermediate state of translocation.Nat Struct Mol Biol.2007 Jun;14(6):493-7.
DMZYLFC	RU	https://www.ncbi.nlm.nih.gov/pubmed/17515906

DM0REZS	DI	DM0REZS
DM0REZS	DN	Virulizin
DM0REZS	MI	TTD2MLN
DM0REZS	MN	Natural killer cell activation (NKA)
DM0REZS	MT	DTT
DM0REZS	MA	Modulator
DM0REZS	RN	Virulizin, a novel immunotherapy agent, activates NK cells through induction of IL-12 expression in macrophages. Cancer Immunol Immunother. 2005 Nov;54(11):1115-26.
DM0REZS	RU	https://pubmed.ncbi.nlm.nih.gov/15891881

DM5IXKQ	DI	DM5IXKQ
DM5IXKQ	DN	Vismodegib
DM5IXKQ	MI	DE5IED8
DM5IXKQ	MN	Cytochrome P450 2C9 (CYP2C9)
DM5IXKQ	MT	DME
DM5IXKQ	MA	Metabolism
DM5IXKQ	RN	The dawn of hedgehog inhibitors: Vismodegib. J Pharmacol Pharmacother. 2013 Jan;4(1):4-7.
DM5IXKQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23662017

DM5IXKQ	DI	DM5IXKQ
DM5IXKQ	DN	Vismodegib
DM5IXKQ	MI	DE4LYSA
DM5IXKQ	MN	Cytochrome P450 3A4 (CYP3A4)
DM5IXKQ	MT	DME
DM5IXKQ	MA	Metabolism
DM5IXKQ	RN	The dawn of hedgehog inhibitors: Vismodegib. J Pharmacol Pharmacother. 2013 Jan;4(1):4-7.
DM5IXKQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23662017

DM5IXKQ	DI	DM5IXKQ
DM5IXKQ	DN	Vismodegib
DM5IXKQ	MI	TT8J1S3
DM5IXKQ	MN	Smoothened homolog (SMO)
DM5IXKQ	MT	DTT
DM5IXKQ	MA	Modulator
DM5IXKQ	RN	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
DM5IXKQ	RU	https://pubmed.ncbi.nlm.nih.gov/23370234

DMJ2AH4	DI	DMJ2AH4
DMJ2AH4	DN	Vitamin A
DMJ2AH4	MI	DEJGDUW
DMJ2AH4	MN	Cytochrome P450 1A2 (CYP1A2)
DMJ2AH4	MT	DME
DMJ2AH4	MA	Metabolism
DMJ2AH4	RN	Carotenoids as regulators for inter-species difference in cytochrome P450 1A expression and activity in ungulates and rats. Food Chem Toxicol. 2010 Nov;48(11):3201-8.
DMJ2AH4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20797421

DMJ2AH4	DI	DMJ2AH4
DMJ2AH4	DN	Vitamin A
DMJ2AH4	MI	DE9QHP6
DMJ2AH4	MN	Cytochrome P450 1B1 (CYP1B1)
DMJ2AH4	MT	DME
DMJ2AH4	MA	Metabolism
DMJ2AH4	RN	Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos. 2004 Aug;32(8):840-7.
DMJ2AH4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15258110

DMJ2AH4	DI	DMJ2AH4
DMJ2AH4	DN	Vitamin A
DMJ2AH4	MI	DES5XRU
DMJ2AH4	MN	Cytochrome P450 2C8 (CYP2C8)
DMJ2AH4	MT	DME
DMJ2AH4	MA	Metabolism
DMJ2AH4	RN	Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by human cytochrome P450 enzymes. Xenobiotica. 1999 Mar;29(3):231-41.
DMJ2AH4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10219964

DMJ2AH4	DI	DMJ2AH4
DMJ2AH4	DN	Vitamin A
DMJ2AH4	MI	DEVDYN7
DMJ2AH4	MN	Cytochrome P450 2E1 (CYP2E1)
DMJ2AH4	MT	DME
DMJ2AH4	MA	Metabolism
DMJ2AH4	RN	The role of inflammatory cells and cytochrome P450 in the potentiation of CCl4-induced liver injury by a single dose of retinol. Toxicol Appl Pharmacol. 1996 Dec;141(2):507-19.
DMJ2AH4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8975775

DMJ2AH4	DI	DMJ2AH4
DMJ2AH4	DN	Vitamin A
DMJ2AH4	MI	DE6NMGO
DMJ2AH4	MN	Cytochrome P450 2S1 (CYP2S1)
DMJ2AH4	MT	DME
DMJ2AH4	MA	Metabolism
DMJ2AH4	RN	The involvement of cytochrome p450 (CYP) 26 in the retinoic acid metabolism of human epidermal keratinocytes. Biochim Biophys Acta. 2009 Mar;1791(3):220-8.
DMJ2AH4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19171200

DMJ2AH4	DI	DMJ2AH4
DMJ2AH4	DN	Vitamin A
DMJ2AH4	MI	DE4LYSA
DMJ2AH4	MN	Cytochrome P450 3A4 (CYP3A4)
DMJ2AH4	MT	DME
DMJ2AH4	MA	Metabolism
DMJ2AH4	RN	Biosynthesis of all-trans-retinoic acid from all-trans-retinol: catalysis of all-trans-retinol oxidation by human P-450 cytochromes. Drug Metab Dispos. 2000 Mar;28(3):315-22.
DMJ2AH4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10681376

DMJ2AH4	DI	DMJ2AH4
DMJ2AH4	DN	Vitamin A
DMJ2AH4	MI	DEKN1H4
DMJ2AH4	MN	Retinal dehydrogenase 2 (ALDH1A2)
DMJ2AH4	MT	DME
DMJ2AH4	MA	Metabolism
DMJ2AH4	RN	Vitamin A metabolism by dendritic cells triggers an antimicrobial response against Mycobacterium tuberculosis. mSphere. 2019 Jun 5;4(3). pii: e00327-19.
DMJ2AH4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31167948

DMJ2AH4	DI	DMJ2AH4
DMJ2AH4	DN	Vitamin A
DMJ2AH4	MI	DEOVJF2
DMJ2AH4	MN	Retinoic acid 4-hydroxylase 26A1 (CYP26A1)
DMJ2AH4	MT	DME
DMJ2AH4	MA	Metabolism
DMJ2AH4	RN	Induction of CYP26A1 by metabolites of retinoic acid: evidence that CYP26A1 is an important enzyme in the elimination of active retinoids. Mol Pharmacol. 2015;87(3):430-41.
DMJ2AH4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25492813

DMJ2AH4	DI	DMJ2AH4
DMJ2AH4	DN	Vitamin A
DMJ2AH4	MI	TTOD7B3
DMJ2AH4	MN	Retinoic acid receptor (RAR)
DMJ2AH4	MT	DTT
DMJ2AH4	MA	Binder
DMJ2AH4	RN	Vitamins and cofactors: highlights of ESBOC 2009. Nat Chem Biol. 2009 Aug;5(8):530-3.
DMJ2AH4	RU	https://pubmed.ncbi.nlm.nih.gov/19620989

DMJ2AH4	DI	DMJ2AH4
DMJ2AH4	DN	Vitamin A
DMJ2AH4	MI	TTH029C
DMJ2AH4	MN	Retinoic acid receptor RXR-gamma (RXRG)
DMJ2AH4	MT	DTT
DMJ2AH4	MA	Binder
DMJ2AH4	RN	Vitamins and cofactors: highlights of ESBOC 2009. Nat Chem Biol. 2009 Aug;5(8):530-3.
DMJ2AH4	RU	https://pubmed.ncbi.nlm.nih.gov/19620989

DMJ2AH4	DI	DMJ2AH4
DMJ2AH4	DN	Vitamin A
DMJ2AH4	MI	DESI4OK
DMJ2AH4	MN	Retinol dehydrogenase 5 (RDH5)
DMJ2AH4	MT	DME
DMJ2AH4	MA	Metabolism
DMJ2AH4	RN	Generation of retinaldehyde for retinoic acid biosynthesis. Biomolecules. 2019 Dec 18;10(1). pii: E5.
DMJ2AH4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31861321

DMJ2AH4	DI	DMJ2AH4
DMJ2AH4	DN	Vitamin A
DMJ2AH4	MI	DEGTU5I
DMJ2AH4	MN	Short-chain dehydrogenase/reductase retSDR8 (DHRS9)
DMJ2AH4	MT	DME
DMJ2AH4	MA	Metabolism
DMJ2AH4	RN	Vitamin A metabolism by dendritic cells triggers an antimicrobial response against Mycobacterium tuberculosis. mSphere. 2019 Jun 5;4(3). pii: e00327-19.
DMJ2AH4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31167948

DMJ2AH4	DI	DMJ2AH4
DMJ2AH4	DN	Vitamin A
DMJ2AH4	MI	TTRTKPV
DMJ2AH4	MN	Trypanosoma Trypanothione reductase (Trypano TPR)
DMJ2AH4	MT	DTT
DMJ2AH4	MA	Binder
DMJ2AH4	RN	Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40.
DMJ2AH4	RU	https://pubmed.ncbi.nlm.nih.gov/16138106

DMZ1WXJ	DI	DMZ1WXJ
DMZ1WXJ	DN	Vitamin B1
DMZ1WXJ	MI	TT8RHGB
DMZ1WXJ	MN	Bacterial Pyruvate decarboxylase (Bact aceE)
DMZ1WXJ	MT	DTT
DMZ1WXJ	MA	Cofactor
DMZ1WXJ	RN	Vitamins and cofactors: highlights of ESBOC 2009. Nat Chem Biol. 2009 Aug;5(8):530-3.
DMZ1WXJ	RU	https://pubmed.ncbi.nlm.nih.gov/19620989

DMZ1WXJ	DI	DMZ1WXJ
DMZ1WXJ	DN	Vitamin B1
DMZ1WXJ	MI	DT8KXR9
DMZ1WXJ	MN	Choline transporter-like protein 4 (SLC44A4)
DMZ1WXJ	MT	DTP
DMZ1WXJ	MA	Substrate
DMZ1WXJ	RN	Molecular identification and functional characterization of the human colonic thiamine pyrophosphate transporter. J Biol Chem. 2017 Oct 6;292(40):16526.
DMZ1WXJ	RU	http://www.ncbi.nlm.nih.gov/pubmed/28986434

DMZ1WXJ	DI	DMZ1WXJ
DMZ1WXJ	DN	Vitamin B1
DMZ1WXJ	MI	DTEHSG0
DMZ1WXJ	MN	Putative thiamine transporter SLC35F3 (SLC35F3)
DMZ1WXJ	MT	DTP
DMZ1WXJ	MA	Substrate
DMZ1WXJ	RN	Genetic implication of a novel thiamine transporter in human hypertension. J Am Coll Cardiol. 2014 Apr 22;63(15):1542-55.
DMZ1WXJ	RU	http://www.ncbi.nlm.nih.gov/pubmed/24509276

DMZ1WXJ	DI	DMZ1WXJ
DMZ1WXJ	DN	Vitamin B1
DMZ1WXJ	MI	DT39CEA
DMZ1WXJ	MN	Thiamine transporter 2 (SLC19A3)
DMZ1WXJ	MT	DTP
DMZ1WXJ	MA	Substrate
DMZ1WXJ	RN	Folate and thiamine transporters mediated by facilitative carriers (SLC19A1-3 and SLC46A1) and folate receptors. Mol Aspects Med. 2013 Apr-Jun;34(2-3):373-85.
DMZ1WXJ	RU	http://www.ncbi.nlm.nih.gov/pubmed/23506878

DMQVRZH	DI	DMQVRZH
DMQVRZH	DN	Vitamin B3
DMQVRZH	MI	DEGF70S
DMQVRZH	MN	Cyclic ADP-ribose hydrolase 1 (CD38)
DMQVRZH	MT	DME
DMQVRZH	MA	Metabolism
DMQVRZH	RN	ADP-ribosyl cyclase and CD38 catalyze the synthesis of a calcium-mobilizing metabolite from NADP. J Biol Chem. 1995 Dec 22;270(51):30327-33.
DMQVRZH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8530456

DMQVRZH	DI	DMQVRZH
DMQVRZH	DN	Vitamin B3
DMQVRZH	MI	TTRHEQ4
DMQVRZH	MN	Diacylglycerol O-acyltransferase 2 (DGAT2)
DMQVRZH	MT	DTT
DMQVRZH	MA	Inhibitor
DMQVRZH	RN	Hakozaki T, Minwalla L, Zhuang J, Chhoa M, Matsubara A, Miyamoto K, Greatens A, Hillebrand GG, Bissett DL, Boissy RE: The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002 Jul;147(1):20-31.
DMQVRZH	RU	https://pubmed.ncbi.nlm.nih.gov/12100180

DMQVRZH	DI	DMQVRZH
DMQVRZH	DN	Vitamin B3
DMQVRZH	MI	TTWNV8U
DMQVRZH	MN	Nicotinic acid receptor (HCAR2)
DMQVRZH	MT	DTT
DMQVRZH	MA	Agonist
DMQVRZH	RN	Hakozaki T, Minwalla L, Zhuang J, Chhoa M, Matsubara A, Miyamoto K, Greatens A, Hillebrand GG, Bissett DL, Boissy RE: The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002 Jul;147(1):20-31.
DMQVRZH	RU	https://pubmed.ncbi.nlm.nih.gov/12100180

DMDBZMV	DI	DMDBZMV
DMDBZMV	DN	Vitamin B6
DMDBZMV	MI	TTN451K
DMDBZMV	MN	Aromatic-L-amino-acid decarboxylase (DDC)
DMDBZMV	MT	DTT
DMDBZMV	MA	Cofactor
DMDBZMV	RN	Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet. 2005 Aug 5;137B(1):1-4.
DMDBZMV	RU	https://pubmed.ncbi.nlm.nih.gov/15965967

DMDBZMV	DI	DMDBZMV
DMDBZMV	DN	Vitamin B6
DMDBZMV	MI	DE2UNSW
DMDBZMV	MN	Pyridoxal phosphate phosphatase (PDXP)
DMDBZMV	MT	DME
DMDBZMV	MA	Metabolism
DMDBZMV	RN	Purification and characterization of vitamin B6-phosphate phosphatase from human erythrocytes. J Biol Chem. 1992 Aug 5;267(22):15978-83.
DMDBZMV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1322411

DMXJ7O8	DI	DMXJ7O8
DMXJ7O8	DN	Vitamin C
DMXJ7O8	MI	TTK982E
DMXJ7O8	MN	Collagen (CO)
DMXJ7O8	MT	DTT
DMXJ7O8	MA	Activator
DMXJ7O8	RN	Effects of vitamin C on dark circles of the lower eyelids: quantitative evaluation using image analysis and echogram. Skin Res Technol. 2009 May;15(2):214-7.
DMXJ7O8	RU	https://pubmed.ncbi.nlm.nih.gov/19626722

DMXJ7O8	DI	DMXJ7O8
DMXJ7O8	DN	Vitamin C
DMXJ7O8	MI	DEWO724
DMXJ7O8	MN	HIF-prolyl hydroxylase 2 (EGLN1)
DMXJ7O8	MT	DME
DMXJ7O8	MA	Metabolism
DMXJ7O8	RN	Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J Biol Chem. 2003 Aug 15;278(33):30772-80.
DMXJ7O8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12788921

DMXJ7O8	DI	DMXJ7O8
DMXJ7O8	DN	Vitamin C
DMXJ7O8	MI	DESO5ZY
DMXJ7O8	MN	Prolyl 4-hydroxylase alpha-1 (P4HA1)
DMXJ7O8	MT	DME
DMXJ7O8	MA	Metabolism
DMXJ7O8	RN	Prolyl 4-hydroxylases, the key enzymes of collagen biosynthesis. Matrix Biol. 2003 Mar;22(1):15-24.
DMXJ7O8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12714038

DMXJ7O8	DI	DMXJ7O8
DMXJ7O8	DN	Vitamin C
DMXJ7O8	MI	DE5EGK0
DMXJ7O8	MN	Prolyl 4-hydroxylase alpha-2 (P4HA2)
DMXJ7O8	MT	DME
DMXJ7O8	MA	Metabolism
DMXJ7O8	RN	Prolyl 4-hydroxylases, the key enzymes of collagen biosynthesis. Matrix Biol. 2003 Mar;22(1):15-24.
DMXJ7O8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12714038

DMXJ7O8	DI	DMXJ7O8
DMXJ7O8	DN	Vitamin C
DMXJ7O8	MI	DE2L4RX
DMXJ7O8	MN	Prolyl 4-hydroxylase alpha-3 (P4HA3)
DMXJ7O8	MT	DME
DMXJ7O8	MA	Metabolism
DMXJ7O8	RN	Identification and characterization of a third human, rat, and mouse collagen prolyl 4-hydroxylase isoenzyme. J Biol Chem. 2003 Nov 28;278(48):47685-93.
DMXJ7O8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14500733

DMXJ7O8	DI	DMXJ7O8
DMXJ7O8	DN	Vitamin C
DMXJ7O8	MI	DT3KH2X
DMXJ7O8	MN	Sodium-dependent vitamin C transporter 1 (SLC23A1)
DMXJ7O8	MT	DTP
DMXJ7O8	MA	Substrate
DMXJ7O8	RN	A family of mammalian Na+-dependent L-ascorbic acid transporters. Nature. 1999 May 6;399(6731):70-5.
DMXJ7O8	RU	http://www.ncbi.nlm.nih.gov/pubmed/10331392

DMXJ7O8	DI	DMXJ7O8
DMXJ7O8	DN	Vitamin C
DMXJ7O8	MI	DTVY9PJ
DMXJ7O8	MN	Sodium-dependent vitamin C transporter 2 (SLC23A2)
DMXJ7O8	MT	DTP
DMXJ7O8	MA	Substrate
DMXJ7O8	RN	Molecular characterization and transcriptional regulation of the sodium-dependent vitamin C transporter genes (slc23a1 and slc23a2) in a teleost fish, the Senegalese sole (Solea senegalensis). Comp Biochem Physiol B Biochem Mol Biol. 2012 Mar;161(3):208-18.
DMXJ7O8	RU	http://www.ncbi.nlm.nih.gov/pubmed/22142801

DMXJ7O8	DI	DMXJ7O8
DMXJ7O8	DN	Vitamin C
DMXJ7O8	MI	TT6XAGK
DMXJ7O8	MN	Solute carrier family 23 member 1 (SLC23A1)
DMXJ7O8	MT	DTT
DMXJ7O8	MA	Modulator
DMXJ7O8	RN	Decreased expression of the vitamin C transporter SVCT1 by ascorbic acid in a human intestinal epithelial cell line. Br J Nutr. 2002 Feb;87(2):97-100.
DMXJ7O8	RU	https://pubmed.ncbi.nlm.nih.gov/11895172

DMXJ7O8	DI	DMXJ7O8
DMXJ7O8	DN	Vitamin C
DMXJ7O8	MI	TTOP832
DMXJ7O8	MN	Solute carrier family 23 member 2 (SLC23A2)
DMXJ7O8	MT	DTT
DMXJ7O8	MA	Modulator
DMXJ7O8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1042).
DMXJ7O8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1042

DMXJ7O8	DI	DMXJ7O8
DMXJ7O8	DN	Vitamin C
DMXJ7O8	MI	DEFQ8VO
DMXJ7O8	MN	Thiopurine methyltransferase (TPMT)
DMXJ7O8	MT	DME
DMXJ7O8	MA	Metabolism
DMXJ7O8	RN	Ascorbic acid inhibits spinal meningeal catechol-o-methyl transferase in vitro, markedly increasing epinephrine bioavailability. Anesthesiology. 1997 Feb;86(2):405-9.
DMXJ7O8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9054258

DMWQUC9	DI	DMWQUC9
DMWQUC9	DN	Vitamin D
DMWQUC9	MI	DE98XPV
DMWQUC9	MN	Cholesterol desmolase (CYP11A1)
DMWQUC9	MT	DME
DMWQUC9	MA	Metabolism
DMWQUC9	RN	Metabolism of 1alpha-hydroxyvitamin D3 by cytochrome P450scc to biologically active 1alpha,20-dihydroxyvitamin D3. J Steroid Biochem Mol Biol. 2008 Dec;112(4-5):213-9.
DMWQUC9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19000766

DMWQUC9	DI	DMWQUC9
DMWQUC9	DN	Vitamin D
DMWQUC9	MI	DE28NZ9
DMWQUC9	MN	Cytochrome P450 124 (cyp124)
DMWQUC9	MT	DME
DMWQUC9	MA	Metabolism
DMWQUC9	RN	Identification of Mycobacterium tuberculosis enzyme involved in vitamin D and 7-dehydrocholesterol metabolism. J Steroid Biochem Mol Biol. 2017 May;169:202-209.
DMWQUC9	RU	https://pubmed.ncbi.nlm.nih.gov/27289046

DMWQUC9	DI	DMWQUC9
DMWQUC9	DN	Vitamin D
DMWQUC9	MI	DERSX5P
DMWQUC9	MN	Cytochrome P450 2J2 (CYP2J2)
DMWQUC9	MT	DME
DMWQUC9	MA	Metabolism
DMWQUC9	RN	Characterization of rat and human CYP2J enzymes as Vitamin D 25-hydroxylases. Steroids. 2006 Oct;71(10):849-56.
DMWQUC9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16842832

DMWQUC9	DI	DMWQUC9
DMWQUC9	DN	Vitamin D
DMWQUC9	MI	DE4LYSA
DMWQUC9	MN	Cytochrome P450 3A4 (CYP3A4)
DMWQUC9	MT	DME
DMWQUC9	MA	Metabolism
DMWQUC9	RN	Interplay between vitamin D and the drug metabolizing enzyme CYP3A4. J Steroid Biochem Mol Biol. 2013 Jul;136:54-8.
DMWQUC9	RU	https://www.ncbi.nlm.nih.gov/pubmed/22985909

DMWQUC9	DI	DMWQUC9
DMWQUC9	DN	Vitamin D
DMWQUC9	MI	DEBIHM3
DMWQUC9	MN	Vitamin D 25-hydroxylase (CYP2R1)
DMWQUC9	MT	DME
DMWQUC9	MA	Metabolism
DMWQUC9	RN	Placental vitamin D metabolism and its associations with circulating vitamin D metabolites in pregnant women. Am J Clin Nutr. 2017 Dec;106(6):1439-1448.
DMWQUC9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29021285

DMWQUC9	DI	DMWQUC9
DMWQUC9	DN	Vitamin D
DMWQUC9	MI	DEBS639
DMWQUC9	MN	Vitamin D(3) 25-hydroxylase (CYP27A1)
DMWQUC9	MT	DME
DMWQUC9	MA	Metabolism
DMWQUC9	RN	Chemoprevention of prostate cancer by cholecalciferol (vitamin D3): 25-hydroxylase (CYP27A1) in human prostate epithelial cells. Clin Exp Metastasis. 2005;22(3):265-73.
DMWQUC9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16158254

DMZC90K	DI	DMZC90K
DMZC90K	DN	Vitamin E
DMZC90K	MI	DE4LYSA
DMZC90K	MN	Cytochrome P450 3A4 (CYP3A4)
DMZC90K	MT	DME
DMZC90K	MA	Metabolism
DMZC90K	RN	Adverse effects of vitamin E by induction of drug metabolism. Genes Nutr. 2007 Dec;2(3):249-56.
DMZC90K	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18850180

DMWIJTN	DI	DMWIJTN
DMWIJTN	DN	Voclosporin
DMWIJTN	MI	TTA4LDE
DMWIJTN	MN	Calcineurin (PPP3CA)
DMWIJTN	MT	DTT
DMWIJTN	MA	Inhibitor
DMWIJTN	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2021
DMWIJTN	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213716s000lbl.pdf

DMUBP9O	DI	DMUBP9O
DMUBP9O	DN	Voglibose
DMUBP9O	MI	TTXWASR
DMUBP9O	MN	Intestinal maltase-glucoamylase (MGAM)
DMUBP9O	MT	DTT
DMUBP9O	MA	Inhibitor
DMUBP9O	RN	Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients. Adv Ther. 2009 Jun;26(6):660-6.
DMUBP9O	RU	https://pubmed.ncbi.nlm.nih.gov/19568704

DM1YEPS	DI	DM1YEPS
DM1YEPS	DN	Volanesorsen
DM1YEPS	MI	TTXOZQ1
DM1YEPS	MN	ApoC-III messenger RNA (APOC3 mRNA)
DM1YEPS	MT	DTT
DM1YEPS	MA	Inhibitor
DM1YEPS	RN	Metabolism and Disposition of Volanesorsen, a 2'- O-(2 methoxyethyl) Antisense Oligonucleotide, Across Species. Drug Metab Dispos. 2019 Oct;47(10):1164-1173.
DM1YEPS	RU	https://pubmed.ncbi.nlm.nih.gov/31350288

DMO6315	DI	DMO6315
DMO6315	DN	Vonoprazan
DMO6315	MI	TTLOKXP
DMO6315	MN	Gastric H(+)/K(+) ATPase (Proton pump)
DMO6315	MT	DTT
DMO6315	MA	Modulator
DMO6315	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2008
DMO6315	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020973s022lbl.pdf

DMI783H	DI	DMI783H
DMI783H	DN	Vonvendi
DMI783H	MI	TT3SZBT
DMI783H	MN	von Willebrand factor (VWF)
DMI783H	MT	DTT
DMI783H	MA	Replacement
DMI783H	RN	Clinical pipeline report, company report or official report of Vonvendi.
DMI783H	RU	https://www.vonvendi.com/

DMA16BR	DI	DMA16BR
DMA16BR	DN	Vorapaxar
DMA16BR	MI	DERSX5P
DMA16BR	MN	Cytochrome P450 2J2 (CYP2J2)
DMA16BR	MT	DME
DMA16BR	MA	Metabolism
DMA16BR	RN	Vorapaxar: the missing link in antiplatelet therapy! J Anaesthesiol Clin Pharmacol. 2017 Apr-Jun;33(2):269-270.
DMA16BR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28781465

DMA16BR	DI	DMA16BR
DMA16BR	DN	Vorapaxar
DMA16BR	MI	DE4LYSA
DMA16BR	MN	Cytochrome P450 3A4 (CYP3A4)
DMA16BR	MT	DME
DMA16BR	MA	Metabolism
DMA16BR	RN	Vorapaxar: the missing link in antiplatelet therapy! J Anaesthesiol Clin Pharmacol. 2017 Apr-Jun;33(2):269-270.
DMA16BR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28781465

DMA16BR	DI	DMA16BR
DMA16BR	DN	Vorapaxar
DMA16BR	MI	TTL935N
DMA16BR	MN	Proteinase activated receptor 1 (F2R)
DMA16BR	MT	DTT
DMA16BR	MA	Antagonist
DMA16BR	RN	In Process Citation. Pharm Unserer Zeit. 2009;38(4):320-8.
DMA16BR	RU	https://pubmed.ncbi.nlm.nih.gov/19572350

DMAOL2S	DI	DMAOL2S
DMAOL2S	DN	Voriconazole
DMAOL2S	MI	TTTSOUD
DMAOL2S	MN	Candida Cytochrome P450 51 (Candi ERG11)
DMAOL2S	MT	DTT
DMAOL2S	MA	Modulator
DMAOL2S	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMAOL2S	RU	https://www.fda.gov/

DMAOL2S	DI	DMAOL2S
DMAOL2S	DN	Voriconazole
DMAOL2S	MI	DE5IED8
DMAOL2S	MN	Cytochrome P450 2C9 (CYP2C9)
DMAOL2S	MT	DME
DMAOL2S	MA	Metabolism
DMAOL2S	RN	Effect of voriconazole on the pharmacokinetics of diclofenac. Fundam Clin Pharmacol. 2007 Dec;21(6):651-6.
DMAOL2S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18034666

DMAOL2S	DI	DMAOL2S
DMAOL2S	DN	Voriconazole
DMAOL2S	MI	DE4LYSA
DMAOL2S	MN	Cytochrome P450 3A4 (CYP3A4)
DMAOL2S	MT	DME
DMAOL2S	MA	Metabolism
DMAOL2S	RN	Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. Biochem Pharmacol. 2007 Jun 15;73(12):2020-6.
DMAOL2S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17433262

DMAOL2S	DI	DMAOL2S
DMAOL2S	DN	Voriconazole
DMAOL2S	MI	DEGTFWK
DMAOL2S	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMAOL2S	MT	DME
DMAOL2S	MA	Metabolism
DMAOL2S	RN	Effect of voriconazole on the pharmacokinetics of diclofenac. Fundam Clin Pharmacol. 2007 Dec;21(6):651-6.
DMAOL2S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18034666

DMAOL2S	DI	DMAOL2S
DMAOL2S	DN	Voriconazole
DMAOL2S	MI	DE073H6
DMAOL2S	MN	Prostaglandin G/H synthase 1 (COX-1)
DMAOL2S	MT	DME
DMAOL2S	MA	Metabolism
DMAOL2S	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMAOL2S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMWMPD4	DI	DMWMPD4
DMWMPD4	DN	Vorinostat
DMWMPD4	MI	TT6R7JZ
DMWMPD4	MN	Histone deacetylase 1 (HDAC1)
DMWMPD4	MT	DTT
DMWMPD4	MA	Inhibitor
DMWMPD4	RN	Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32.
DMWMPD4	RU	https://pubmed.ncbi.nlm.nih.gov/19721445

DMWMPD4	DI	DMWMPD4
DMWMPD4	DN	Vorinostat
DMWMPD4	MI	DEYGVN4
DMWMPD4	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMWMPD4	MT	DME
DMWMPD4	MA	Metabolism
DMWMPD4	RN	A pharmacogenetic study of vorinostat glucuronidation. Pharmacogenet Genomics. 2010 Oct;20(10):638-41.
DMWMPD4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20729791

DMWMPD4	DI	DMWMPD4
DMWMPD4	DN	Vorinostat
DMWMPD4	MI	DEF2WXN
DMWMPD4	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMWMPD4	MT	DME
DMWMPD4	MA	Metabolism
DMWMPD4	RN	Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy. Future Oncol. 2010 Apr;6(4):563-85.
DMWMPD4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20373870

DMWMPD4	DI	DMWMPD4
DMWMPD4	DN	Vorinostat
DMWMPD4	MI	DEZO4N3
DMWMPD4	MN	UDP-glucuronosyltransferase 1A7 (UGT1A7)
DMWMPD4	MT	DME
DMWMPD4	MA	Metabolism
DMWMPD4	RN	Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy. Future Oncol. 2010 Apr;6(4):563-85.
DMWMPD4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20373870

DMWMPD4	DI	DMWMPD4
DMWMPD4	DN	Vorinostat
DMWMPD4	MI	DE2GB8N
DMWMPD4	MN	UDP-glucuronosyltransferase 1A8 (UGT1A8)
DMWMPD4	MT	DME
DMWMPD4	MA	Metabolism
DMWMPD4	RN	Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy. Future Oncol. 2010 Apr;6(4):563-85.
DMWMPD4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20373870

DMWMPD4	DI	DMWMPD4
DMWMPD4	DN	Vorinostat
DMWMPD4	MI	DE85D2P
DMWMPD4	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMWMPD4	MT	DME
DMWMPD4	MA	Metabolism
DMWMPD4	RN	Age-dependent hepatic UDP-glucuronosyltransferase gene expression and activity in children. Front Pharmacol. 2016 Nov 16;7:437.
DMWMPD4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27899892

DMWMPD4	DI	DMWMPD4
DMWMPD4	DN	Vorinostat
DMWMPD4	MI	DEAZDL8
DMWMPD4	MN	UDP-glucuronosyltransferase 2B17 (UGT2B17)
DMWMPD4	MT	DME
DMWMPD4	MA	Metabolism
DMWMPD4	RN	Age-dependent hepatic UDP-glucuronosyltransferase gene expression and activity in children. Front Pharmacol. 2016 Nov 16;7:437.
DMWMPD4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27899892

DMWMPD4	DI	DMWMPD4
DMWMPD4	DN	Vorinostat
DMWMPD4	MI	DEB3CV1
DMWMPD4	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMWMPD4	MT	DME
DMWMPD4	MA	Metabolism
DMWMPD4	RN	Age-dependent hepatic UDP-glucuronosyltransferase gene expression and activity in children. Front Pharmacol. 2016 Nov 16;7:437.
DMWMPD4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27899892

DM6F1PU	DI	DM6F1PU
DM6F1PU	DN	Vortioxetine
DM6F1PU	MI	DEJVYAZ
DM6F1PU	MN	Cytochrome P450 2A6 (CYP2A6)
DM6F1PU	MT	DME
DM6F1PU	MA	Metabolism
DM6F1PU	RN	Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65.
DM6F1PU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22496396

DM6F1PU	DI	DM6F1PU
DM6F1PU	DN	Vortioxetine
DM6F1PU	MI	DEPKLMQ
DM6F1PU	MN	Cytochrome P450 2B6 (CYP2B6)
DM6F1PU	MT	DME
DM6F1PU	MA	Metabolism
DM6F1PU	RN	Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65.
DM6F1PU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22496396

DM6F1PU	DI	DM6F1PU
DM6F1PU	DN	Vortioxetine
DM6F1PU	MI	DES5XRU
DM6F1PU	MN	Cytochrome P450 2C8 (CYP2C8)
DM6F1PU	MT	DME
DM6F1PU	MA	Metabolism
DM6F1PU	RN	Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65.
DM6F1PU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22496396

DM6F1PU	DI	DM6F1PU
DM6F1PU	DN	Vortioxetine
DM6F1PU	MI	DE5IED8
DM6F1PU	MN	Cytochrome P450 2C9 (CYP2C9)
DM6F1PU	MT	DME
DM6F1PU	MA	Metabolism
DM6F1PU	RN	Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65.
DM6F1PU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22496396

DM6F1PU	DI	DM6F1PU
DM6F1PU	DN	Vortioxetine
DM6F1PU	MI	DECB0K3
DM6F1PU	MN	Cytochrome P450 2D6 (CYP2D6)
DM6F1PU	MT	DME
DM6F1PU	MA	Metabolism
DM6F1PU	RN	Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65.
DM6F1PU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22496396

DM6F1PU	DI	DM6F1PU
DM6F1PU	DN	Vortioxetine
DM6F1PU	MI	DE4LYSA
DM6F1PU	MN	Cytochrome P450 3A4 (CYP3A4)
DM6F1PU	MT	DME
DM6F1PU	MA	Metabolism
DM6F1PU	RN	Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65.
DM6F1PU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22496396

DM6F1PU	DI	DM6F1PU
DM6F1PU	DN	Vortioxetine
DM6F1PU	MI	DEIBDNY
DM6F1PU	MN	Cytochrome P450 3A5 (CYP3A5)
DM6F1PU	MT	DME
DM6F1PU	MA	Metabolism
DM6F1PU	RN	Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65.
DM6F1PU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22496396

DM6F1PU	DI	DM6F1PU
DM6F1PU	DN	Vortioxetine
DM6F1PU	MI	DEGTFWK
DM6F1PU	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM6F1PU	MT	DME
DM6F1PU	MA	Metabolism
DM6F1PU	RN	Vortioxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2018 Jun;57(6):673-686.
DM6F1PU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29189941

DM6F1PU	DI	DM6F1PU
DM6F1PU	DN	Vortioxetine
DM6F1PU	MI	TT3ROYC
DM6F1PU	MN	Serotonin transporter (SERT)
DM6F1PU	MT	DTT
DM6F1PU	MA	Inhibitor
DM6F1PU	RN	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
DM6F1PU	RU	https://pubmed.ncbi.nlm.nih.gov/28919714

DMCS6M5	DI	DMCS6M5
DMCS6M5	DN	Voxelotor
DMCS6M5	MI	DEPKLMQ
DMCS6M5	MN	Cytochrome P450 2B6 (CYP2B6)
DMCS6M5	MT	DME
DMCS6M5	MA	Metabolism
DMCS6M5	RN	FDA label of Fedratinib. The 2020 official website of the U.S. Food and Drug Administration.
DMCS6M5	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf

DMCS6M5	DI	DMCS6M5
DMCS6M5	DN	Voxelotor
DMCS6M5	MI	DE5IED8
DMCS6M5	MN	Cytochrome P450 2C9 (CYP2C9)
DMCS6M5	MT	DME
DMCS6M5	MA	Metabolism
DMCS6M5	RN	FDA label of Fedratinib. The 2020 official website of the U.S. Food and Drug Administration.
DMCS6M5	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf

DMCS6M5	DI	DMCS6M5
DMCS6M5	DN	Voxelotor
DMCS6M5	MI	DE4LYSA
DMCS6M5	MN	Cytochrome P450 3A4 (CYP3A4)
DMCS6M5	MT	DME
DMCS6M5	MA	Metabolism
DMCS6M5	RN	FDA label of Fedratinib. The 2020 official website of the U.S. Food and Drug Administration.
DMCS6M5	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf

DMCS6M5	DI	DMCS6M5
DMCS6M5	DN	Voxelotor
DMCS6M5	MI	TTQO71U
DMCS6M5	MN	Hemoglobin (HB)
DMCS6M5	MT	DTT
DMCS6M5	MA	Modulator
DMCS6M5	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMCS6M5	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213137s000lbl.pdf

DMCS6M5	DI	DMCS6M5
DMCS6M5	DN	Voxelotor
DMCS6M5	MI	DEGTFWK
DMCS6M5	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMCS6M5	MT	DME
DMCS6M5	MA	Metabolism
DMCS6M5	RN	FDA label of Fedratinib. The 2020 official website of the U.S. Food and Drug Administration.
DMCS6M5	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf

DMAI83D	DI	DMAI83D
DMAI83D	DN	Voxilaprevir
DMAI83D	MI	DEJGDUW
DMAI83D	MN	Cytochrome P450 1A2 (CYP1A2)
DMAI83D	MT	DME
DMAI83D	MA	Metabolism
DMAI83D	RN	Management of Unique Populations with HCV Infection
DMAI83D	RU	https://www.hcvguidelines.org/unique-populations

DMAI83D	DI	DMAI83D
DMAI83D	DN	Voxilaprevir
DMAI83D	MI	DES5XRU
DMAI83D	MN	Cytochrome P450 2C8 (CYP2C8)
DMAI83D	MT	DME
DMAI83D	MA	Metabolism
DMAI83D	RN	FDA Label of Vosevi. The 2020 official website of the U.S. Food and Drug Administration.
DMAI83D	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209195s000lbl.pdf

DMIO4V5	DI	DMIO4V5
DMIO4V5	DN	VRX496
DMIO4V5	MI	DTI7UX6
DMIO4V5	MN	Breast cancer resistance protein (ABCG2)
DMIO4V5	MT	DTP
DMIO4V5	MA	Substrate
DMIO4V5	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMIO4V5	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMIO4V5	DI	DMIO4V5
DMIO4V5	DN	VRX496
DMIO4V5	MI	TTXVOJ5
DMIO4V5	MN	Human immunodeficiency virus Envelope messenger RNA (HIV env mRNA)
DMIO4V5	MT	DTT
DMIO4V5	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DMIO4V5	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DMIO4V5	DI	DMIO4V5
DMIO4V5	DN	VRX496
DMIO4V5	MI	DTFI42L
DMIO4V5	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMIO4V5	MT	DTP
DMIO4V5	MA	Substrate
DMIO4V5	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMIO4V5	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMIO4V5	DI	DMIO4V5
DMIO4V5	DN	VRX496
DMIO4V5	MI	DTUGYRD
DMIO4V5	MN	P-glycoprotein 1 (ABCB1)
DMIO4V5	MT	DTP
DMIO4V5	MA	Substrate
DMIO4V5	RN	Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis. 2005 Dec 1;192(11):1931-42.
DMIO4V5	RU	http://www.ncbi.nlm.nih.gov/pubmed/16267764

DMJYCVW	DI	DMJYCVW
DMJYCVW	DN	Warfarin
DMJYCVW	MI	DEJGDUW
DMJYCVW	MN	Cytochrome P450 1A2 (CYP1A2)
DMJYCVW	MT	DME
DMJYCVW	MA	Metabolism
DMJYCVW	RN	Metabolism of R- and S-warfarin by CYP2C19 into four hydroxywarfarins. Drug Metab Lett. 2012 Sep 1;6(3):157-64.
DMJYCVW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23331088

DMJYCVW	DI	DMJYCVW
DMJYCVW	DN	Warfarin
DMJYCVW	MI	DEZMWRE
DMJYCVW	MN	Cytochrome P450 2C18 (CYP2C18)
DMJYCVW	MT	DME
DMJYCVW	MA	Metabolism
DMJYCVW	RN	Human P450 metabolism of warfarin. Pharmacol Ther. 1997;73(1):67-74.
DMJYCVW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9014207

DMJYCVW	DI	DMJYCVW
DMJYCVW	DN	Warfarin
DMJYCVW	MI	DES5XRU
DMJYCVW	MN	Cytochrome P450 2C8 (CYP2C8)
DMJYCVW	MT	DME
DMJYCVW	MA	Metabolism
DMJYCVW	RN	Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation. Eur J Clin Pharmacol. 1997;52(4):293-8.
DMJYCVW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9248768

DMJYCVW	DI	DMJYCVW
DMJYCVW	DN	Warfarin
DMJYCVW	MI	DE5IED8
DMJYCVW	MN	Cytochrome P450 2C9 (CYP2C9)
DMJYCVW	MT	DME
DMJYCVW	MA	Metabolism
DMJYCVW	RN	Pharmacogenomics of CYP2C9: functional and clinical considerations. J Pers Med. 2017 Dec 28;8(1).
DMJYCVW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29283396

DMJYCVW	DI	DMJYCVW
DMJYCVW	DN	Warfarin
DMJYCVW	MI	DE4LYSA
DMJYCVW	MN	Cytochrome P450 3A4 (CYP3A4)
DMJYCVW	MT	DME
DMJYCVW	MA	Metabolism
DMJYCVW	RN	Contribution of three CYP3A isoforms to metabolism of R- and S-warfarin. Drug Metab Lett. 2010 Dec;4(4):213-9.
DMJYCVW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20615193

DMJYCVW	DI	DMJYCVW
DMJYCVW	DN	Warfarin
DMJYCVW	MI	DEGTFWK
DMJYCVW	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMJYCVW	MT	DME
DMJYCVW	MA	Metabolism
DMJYCVW	RN	Metabolism of R- and S-warfarin by CYP2C19 into four hydroxywarfarins. Drug Metab Lett. 2012 Sep 1;6(3):157-64.
DMJYCVW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23331088

DMJYCVW	DI	DMJYCVW
DMJYCVW	DN	Warfarin
DMJYCVW	MI	DT9C1TS
DMJYCVW	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMJYCVW	MT	DTP
DMJYCVW	MA	Substrate
DMJYCVW	RN	Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007 Aug;35(8):1400-7.
DMJYCVW	RU	http://www.ncbi.nlm.nih.gov/pubmed/17496208

DMJYCVW	DI	DMJYCVW
DMJYCVW	DN	Warfarin
DMJYCVW	MI	DEYWLRK
DMJYCVW	MN	Sulfotransferase 1A1 (SULT1A1)
DMJYCVW	MT	DME
DMJYCVW	MA	Metabolism
DMJYCVW	RN	Natural products isolated from Mexican medicinal plants: novel inhibitors of sulfotransferases, SULT1A1 and SULT2A1. Phytomedicine. 2001 Nov;8(6):481-8.
DMJYCVW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11824526

DMJYCVW	DI	DMJYCVW
DMJYCVW	DN	Warfarin
DMJYCVW	MI	DEYGVN4
DMJYCVW	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMJYCVW	MT	DME
DMJYCVW	MA	Metabolism
DMJYCVW	RN	Assessing cytochrome P450 and UDP-glucuronosyltransferase contributions to warfarin metabolism in humans. Chem Res Toxicol. 2009 Jul;22(7):1239-45.
DMJYCVW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19408964

DMJYCVW	DI	DMJYCVW
DMJYCVW	DN	Warfarin
DMJYCVW	MI	TTEUC8H
DMJYCVW	MN	Vitamin K epoxide reductase complex 1 (VKORC1)
DMJYCVW	MT	DTT
DMJYCVW	MA	Inhibitor
DMJYCVW	RN	[Oral anticoagulation and pharmacogenetics: importance in the clinical setting]. Rev Med Suisse. 2007 Sep 12;3(124):2030, 2033-4, 2036.
DMJYCVW	RU	https://pubmed.ncbi.nlm.nih.gov/17955831

DMLHOA0	DI	DMLHOA0
DMLHOA0	DN	Xatral
DMLHOA0	MI	TTNGILX
DMLHOA0	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMLHOA0	MT	DTT
DMLHOA0	MA	Antagonist
DMLHOA0	RN	Pharma & Vaccines. Product Development Pipeline. April 29 2009.
DMLHOA0	RU	http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf

DMLHOA0	DI	DMLHOA0
DMLHOA0	DN	Xatral
DMLHOA0	MI	DE4LYSA
DMLHOA0	MN	Cytochrome P450 3A4 (CYP3A4)
DMLHOA0	MT	DME
DMLHOA0	MA	Metabolism
DMLHOA0	RN	Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia. Am J Geriatr Pharmacother. 2004 Mar;2(1):14-23.
DMLHOA0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15555475

DMU8ANS	DI	DMU8ANS
DMU8ANS	DN	Ximelegatran
DMU8ANS	MI	TT6L509
DMU8ANS	MN	Coagulation factor IIa (F2)
DMU8ANS	MT	DTT
DMU8ANS	MA	Inhibitor
DMU8ANS	RN	Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
DMU8ANS	RU	https://pubmed.ncbi.nlm.nih.gov/16503827

DMU8ANS	DI	DMU8ANS
DMU8ANS	DN	Ximelegatran
DMU8ANS	MI	TTMQO60
DMU8ANS	MN	Rho-associated protein kinase (ROCK)
DMU8ANS	MT	DTT
DMU8ANS	MA	Modulator
DMU8ANS	RN	Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol. 2000 May;57(5):976-83.
DMU8ANS	RU	https://www.ncbi.nlm.nih.gov/pubmed/10779382

DMAR467	DI	DMAR467
DMAR467	DN	Xylose
DMAR467	MI	DE86CHA
DMAR467	MN	Xylose isomerase (xylA)
DMAR467	MT	DME
DMAR467	MA	Metabolism
DMAR467	RN	Purification and characterization of D-xylose isomerase from Bifidobacterium adolescentis. Biosci Biotechnol Biochem. 1994 Apr;58(4):691-4.
DMAR467	RU	https://pubmed.ncbi.nlm.nih.gov/7764860

DMAR467	DI	DMAR467
DMAR467	DN	Xylose
DMAR467	MI	DEMZ1HA
DMAR467	MN	Xylose isomerase (xylA)
DMAR467	MT	DME
DMAR467	MA	Metabolism
DMAR467	RN	Bacterial xylose isomerases from the mammal gut Bacteroidetes cluster function in Saccharomyces cerevisiae for effective xylose fermentation. Microb Cell Fact. 2015 May 17;14:70.
DMAR467	RU	https://pubmed.ncbi.nlm.nih.gov/25981595

DMDPM7R	DI	DMDPM7R
DMDPM7R	DN	Y-25130
DMDPM7R	MI	TTNXLKE
DMDPM7R	MN	5-HT 3 receptor (5HT3R)
DMDPM7R	MT	DTT
DMDPM7R	MA	Antagonist
DMDPM7R	RN	The antiemetic profile of Y-25130, a new selective 5-HT3 receptor antagonist. Eur J Pharmacol. 1991 Apr 24;196(3):299-305.
DMDPM7R	RU	https://pubmed.ncbi.nlm.nih.gov/1654255

DMDPM7R	DI	DMDPM7R
DMDPM7R	DN	Y-25130
DMDPM7R	MI	DTUGYRD
DMDPM7R	MN	P-glycoprotein 1 (ABCB1)
DMDPM7R	MT	DTP
DMDPM7R	MA	Substrate
DMDPM7R	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMDPM7R	RU	https://doi.org/10.1007/s11095-012-0935-x

DMNZCI1	DI	DMNZCI1
DMNZCI1	DN	YM443
DMNZCI1	MI	TT1RS9F
DMNZCI1	MN	Acetylcholinesterase (AChE)
DMNZCI1	MT	DTT
DMNZCI1	MA	Modulator
DMNZCI1	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMNZCI1	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMMP3Y2	DI	DMMP3Y2
DMMP3Y2	DN	Yn-968D1
DMMP3Y2	MI	DTI7UX6
DMMP3Y2	MN	Breast cancer resistance protein (ABCG2)
DMMP3Y2	MT	DTP
DMMP3Y2	MA	Substrate
DMMP3Y2	RN	Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res. 2010 Oct 15;70(20):7981-91.
DMMP3Y2	RU	https://doi.org/10.1158/0008-5472.CAN-10-0111

DMMP3Y2	DI	DMMP3Y2
DMMP3Y2	DN	Yn-968D1
DMMP3Y2	MI	TTUTJGQ
DMMP3Y2	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMMP3Y2	MT	DTT
DMMP3Y2	MA	Inhibitor
DMMP3Y2	RN	YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 2011 Jul;102(7):1374-80.
DMMP3Y2	RU	https://pubmed.ncbi.nlm.nih.gov/21443688

DMJCP1Y	DI	DMJCP1Y
DMJCP1Y	DN	Yohimbine
DMJCP1Y	MI	TTQ8AFT
DMJCP1Y	MN	Adrenergic receptor Alpha-2 (ADRA2)
DMJCP1Y	MT	DTT
DMJCP1Y	MA	Antagonist
DMJCP1Y	RN	Acute neurotoxicity after yohimbine ingestion by a body builder. Clin Toxicol (Phila). 2009 Sep;47(8):827-9.
DMJCP1Y	RU	https://pubmed.ncbi.nlm.nih.gov/19640235

DMJCP1Y	DI	DMJCP1Y
DMJCP1Y	DN	Yohimbine
DMJCP1Y	MI	DECB0K3
DMJCP1Y	MN	Cytochrome P450 2D6 (CYP2D6)
DMJCP1Y	MT	DME
DMJCP1Y	MA	Metabolism
DMJCP1Y	RN	Relationship of cytochrome P450 pharmacogenetics to the effects of yohimbine on gastrointestinal transit and catecholamines in healthy subjects. Neurogastroenterol Motil. 2008 Aug;20(8):891-9.
DMJCP1Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18433425

DMJCP1Y	DI	DMJCP1Y
DMJCP1Y	DN	Yohimbine
DMJCP1Y	MI	DE4LYSA
DMJCP1Y	MN	Cytochrome P450 3A4 (CYP3A4)
DMJCP1Y	MT	DME
DMJCP1Y	MA	Metabolism
DMJCP1Y	RN	Human sympathetic activation by alpha2-adrenergic blockade with yohimbine: bimodal, epistatic influence of cytochrome P450-mediated drug metabolism. Clin Pharmacol Ther. 2004 Aug;76(2):139-53.
DMJCP1Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15289791

DMHNQOG	DI	DMHNQOG
DMHNQOG	DN	Zafirlukast
DMHNQOG	MI	DES5XRU
DMHNQOG	MN	Cytochrome P450 2C8 (CYP2C8)
DMHNQOG	MT	DME
DMHNQOG	MA	Metabolism
DMHNQOG	RN	Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol. 2006 Jul;99(1):44-51.
DMHNQOG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16867170

DMHNQOG	DI	DMHNQOG
DMHNQOG	DN	Zafirlukast
DMHNQOG	MI	DE5IED8
DMHNQOG	MN	Cytochrome P450 2C9 (CYP2C9)
DMHNQOG	MT	DME
DMHNQOG	MA	Metabolism
DMHNQOG	RN	Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. Xenobiotica. 2004 May;34(5):429-38.
DMHNQOG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15370959

DMHNQOG	DI	DMHNQOG
DMHNQOG	DN	Zafirlukast
DMHNQOG	MI	DE4LYSA
DMHNQOG	MN	Cytochrome P450 3A4 (CYP3A4)
DMHNQOG	MT	DME
DMHNQOG	MA	Metabolism
DMHNQOG	RN	Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations. Eur J Clin Pharmacol. 2012 May;68(5):681-8.
DMHNQOG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22108774

DMHNQOG	DI	DMHNQOG
DMHNQOG	DN	Zafirlukast
DMHNQOG	MI	TTGKOY9
DMHNQOG	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DMHNQOG	MT	DTT
DMHNQOG	MA	Antagonist
DMHNQOG	RN	Inhibitory effects of zafirlukast on respiratory bursts of human neutrophils. Drugs Exp Clin Res. 2002;28(4):133-45.
DMHNQOG	RU	https://pubmed.ncbi.nlm.nih.gov/12512231

DMHNQOG	DI	DMHNQOG
DMHNQOG	DN	Zafirlukast
DMHNQOG	MI	DE073H6
DMHNQOG	MN	Prostaglandin G/H synthase 1 (COX-1)
DMHNQOG	MT	DME
DMHNQOG	MA	Metabolism
DMHNQOG	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMHNQOG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMH7MUV	DI	DMH7MUV
DMH7MUV	DN	Zalcitabine
DMH7MUV	MI	DE5IED8
DMH7MUV	MN	Cytochrome P450 2C9 (CYP2C9)
DMH7MUV	MT	DME
DMH7MUV	MA	Metabolism
DMH7MUV	RN	Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet. 1997 Mar;32(3):194-209.
DMH7MUV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9084959

DMH7MUV	DI	DMH7MUV
DMH7MUV	DN	Zalcitabine
DMH7MUV	MI	DECB0K3
DMH7MUV	MN	Cytochrome P450 2D6 (CYP2D6)
DMH7MUV	MT	DME
DMH7MUV	MA	Metabolism
DMH7MUV	RN	Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet. 1997 Mar;32(3):194-209.
DMH7MUV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9084959

DMH7MUV	DI	DMH7MUV
DMH7MUV	DN	Zalcitabine
DMH7MUV	MI	DE4LYSA
DMH7MUV	MN	Cytochrome P450 3A4 (CYP3A4)
DMH7MUV	MT	DME
DMH7MUV	MA	Metabolism
DMH7MUV	RN	Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet. 1997 Mar;32(3):194-209.
DMH7MUV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9084959

DMH7MUV	DI	DMH7MUV
DMH7MUV	DN	Zalcitabine
DMH7MUV	MI	DEO1IE3
DMH7MUV	MN	Cytochrome P450 3A43 (CYP3A43)
DMH7MUV	MT	DME
DMH7MUV	MA	Metabolism
DMH7MUV	RN	Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet. 1997 Mar;32(3):194-209.
DMH7MUV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9084959

DMH7MUV	DI	DMH7MUV
DMH7MUV	DN	Zalcitabine
DMH7MUV	MI	DEIBDNY
DMH7MUV	MN	Cytochrome P450 3A5 (CYP3A5)
DMH7MUV	MT	DME
DMH7MUV	MA	Metabolism
DMH7MUV	RN	Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet. 1997 Mar;32(3):194-209.
DMH7MUV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9084959

DMH7MUV	DI	DMH7MUV
DMH7MUV	DN	Zalcitabine
DMH7MUV	MI	DERD86B
DMH7MUV	MN	Cytochrome P450 3A7 (CYP3A7)
DMH7MUV	MT	DME
DMH7MUV	MA	Metabolism
DMH7MUV	RN	Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet. 1997 Mar;32(3):194-209.
DMH7MUV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9084959

DMH7MUV	DI	DMH7MUV
DMH7MUV	DN	Zalcitabine
DMH7MUV	MI	TT84ETX
DMH7MUV	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMH7MUV	MT	DTT
DMH7MUV	MA	Inhibitor
DMH7MUV	RN	A peptide inhibitor of HIV-1 reverse transcriptase using alpha,beta-dehydro residues: a structure-based computer model. J Biomol Struct Dyn. 1998 Oct;16(2):347-54.
DMH7MUV	RU	https://pubmed.ncbi.nlm.nih.gov/9833673

DMH7MUV	DI	DMH7MUV
DMH7MUV	DN	Zalcitabine
DMH7MUV	MI	DTWN7FC
DMH7MUV	MN	Multidrug resistance-associated protein 8 (ABCC11)
DMH7MUV	MT	DTP
DMH7MUV	MA	Substrate
DMH7MUV	RN	MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2',3'-dideoxycytidine and 9'-(2'-phosphonylmethoxyethyl)adenine. J Biol Chem. 2003 Aug 8;278(32):29509-14.
DMH7MUV	RU	http://www.ncbi.nlm.nih.gov/pubmed/12764137

DMH7MUV	DI	DMH7MUV
DMH7MUV	DN	Zalcitabine
DMH7MUV	MI	DTQ23VB
DMH7MUV	MN	Organic anion transporter 1 (SLC22A6)
DMH7MUV	MT	DTP
DMH7MUV	MA	Substrate
DMH7MUV	RN	Interaction of zalcitabine with human organic anion transporter 1. Pharmazie. 2006 May;61(5):491-2.
DMH7MUV	RU	http://www.ncbi.nlm.nih.gov/pubmed/16724555

DMGFWSM	DI	DMGFWSM
DMGFWSM	DN	Zaleplon
DMGFWSM	MI	DEAWHS8
DMGFWSM	MN	Aldehyde oxidase (AOX1)
DMGFWSM	MT	DME
DMGFWSM	MA	Metabolism
DMGFWSM	RN	Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes. Drug Metab Dispos. 2012 Feb;40(2):267-75.
DMGFWSM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22031625

DMGFWSM	DI	DMGFWSM
DMGFWSM	DN	Zaleplon
DMGFWSM	MI	DE4LYSA
DMGFWSM	MN	Cytochrome P450 3A4 (CYP3A4)
DMGFWSM	MT	DME
DMGFWSM	MA	Metabolism
DMGFWSM	RN	Metabolism of zaleplon by human liver: evidence for involvement of aldehyde oxidase. Xenobiotica. 2002 Oct;32(10):835-47.
DMGFWSM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12419014

DMGFWSM	DI	DMGFWSM
DMGFWSM	DN	Zaleplon
DMGFWSM	MI	DEIBDNY
DMGFWSM	MN	Cytochrome P450 3A5 (CYP3A5)
DMGFWSM	MT	DME
DMGFWSM	MA	Metabolism
DMGFWSM	RN	Drug Interactions Flockhart Table
DMGFWSM	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMGFWSM	DI	DMGFWSM
DMGFWSM	DN	Zaleplon
DMGFWSM	MI	DERD86B
DMGFWSM	MN	Cytochrome P450 3A7 (CYP3A7)
DMGFWSM	MT	DME
DMGFWSM	MA	Metabolism
DMGFWSM	RN	Drug Interactions Flockhart Table
DMGFWSM	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMGFWSM	DI	DMGFWSM
DMGFWSM	DN	Zaleplon
DMGFWSM	MI	TT1MPAY
DMGFWSM	MN	GABA(A) receptor alpha-1 (GABRA1)
DMGFWSM	MT	DTT
DMGFWSM	MA	Modulator
DMGFWSM	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMGFWSM	RU	https://www.fda.gov/

DMFMBZ4	DI	DMFMBZ4
DMFMBZ4	DN	Zanamivir
DMFMBZ4	MI	TT50QJ3
DMFMBZ4	MN	Influenza Neuraminidase (Influ NA)
DMFMBZ4	MT	DTT
DMFMBZ4	MA	Inhibitor
DMFMBZ4	RN	Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res. 2008 Apr;78(1):91-102.
DMFMBZ4	RU	https://pubmed.ncbi.nlm.nih.gov/18328578

DMUR5NG	DI	DMUR5NG
DMUR5NG	DN	Zanubrutinib
DMUR5NG	MI	DE4LYSA
DMUR5NG	MN	Cytochrome P450 3A4 (CYP3A4)
DMUR5NG	MT	DME
DMUR5NG	MA	Metabolism
DMUR5NG	RN	FDA label of Zanubrutinib. The 2020 official website of the U.S. Food and Drug Administration.
DMUR5NG	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213217s000lbl.pdf

DMJWRQP	DI	DMJWRQP
DMJWRQP	DN	Zanubrutinib
DMJWRQP	MI	TTGM6VW
DMJWRQP	MN	Tyrosine-protein kinase BTK (ATK)
DMJWRQP	MT	DTT
DMJWRQP	MA	Inhibitor
DMJWRQP	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMJWRQP	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213217s000lbl.pdf

DMA5QPM	DI	DMA5QPM
DMA5QPM	DN	Zemaira
DMA5QPM	MI	TTA7UJC
DMA5QPM	MN	Alpha-1-antitrypsin (SERPINA1)
DMA5QPM	MT	DTT
DMA5QPM	MA	Inhibitor
DMA5QPM	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services.
DMA5QPM	RU	https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/zemaira

DMSLJP4	DI	DMSLJP4
DMSLJP4	DN	Ziconotide
DMSLJP4	MI	DE4LYSA
DMSLJP4	MN	Cytochrome P450 3A4 (CYP3A4)
DMSLJP4	MT	DME
DMSLJP4	MA	Metabolism
DMSLJP4	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DMSLJP4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DMSLJP4	DI	DMSLJP4
DMSLJP4	DN	Ziconotide
DMSLJP4	MI	TT4FDG6
DMSLJP4	MN	Voltage-gated calcium channel alpha Cav2.2 (CACNA1B)
DMSLJP4	MT	DTT
DMSLJP4	MA	Blocker
DMSLJP4	RN	Emerging treatments for traumatic brain injury. Expert Opin Emerg Drugs. 2009 Mar;14(1):67-84.
DMSLJP4	RU	https://pubmed.ncbi.nlm.nih.gov/19249984

DM4KI7O	DI	DM4KI7O
DM4KI7O	DN	Zidovudine
DM4KI7O	MI	DTI7UX6
DM4KI7O	MN	Breast cancer resistance protein (ABCG2)
DM4KI7O	MT	DTP
DM4KI7O	MA	Substrate
DM4KI7O	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM4KI7O	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DM4KI7O	DI	DM4KI7O
DM4KI7O	DN	Zidovudine
DM4KI7O	MI	DEJVYAZ
DM4KI7O	MN	Cytochrome P450 2A6 (CYP2A6)
DM4KI7O	MT	DME
DM4KI7O	MA	Metabolism
DM4KI7O	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM4KI7O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM4KI7O	DI	DM4KI7O
DM4KI7O	DN	Zidovudine
DM4KI7O	MI	DES5XRU
DM4KI7O	MN	Cytochrome P450 2C8 (CYP2C8)
DM4KI7O	MT	DME
DM4KI7O	MA	Metabolism
DM4KI7O	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM4KI7O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM4KI7O	DI	DM4KI7O
DM4KI7O	DN	Zidovudine
DM4KI7O	MI	DE5IED8
DM4KI7O	MN	Cytochrome P450 2C9 (CYP2C9)
DM4KI7O	MT	DME
DM4KI7O	MA	Metabolism
DM4KI7O	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM4KI7O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM4KI7O	DI	DM4KI7O
DM4KI7O	DN	Zidovudine
DM4KI7O	MI	DE4LYSA
DM4KI7O	MN	Cytochrome P450 3A4 (CYP3A4)
DM4KI7O	MT	DME
DM4KI7O	MA	Metabolism
DM4KI7O	RN	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
DM4KI7O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8053924

DM4KI7O	DI	DM4KI7O
DM4KI7O	DN	Zidovudine
DM4KI7O	MI	TTGJCWZ
DM4KI7O	MN	Fms-like tyrosine kinase 3 (FLT-3)
DM4KI7O	MT	DTT
DM4KI7O	MA	Binder
DM4KI7O	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1807).
DM4KI7O	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1807

DM4KI7O	DI	DM4KI7O
DM4KI7O	DN	Zidovudine
DM4KI7O	MI	TT84ETX
DM4KI7O	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM4KI7O	MT	DTT
DM4KI7O	MA	Inhibitor
DM4KI7O	RN	Antiviral drugs in current clinical use. J Clin Virol. 2004 Jun;30(2):115-33.
DM4KI7O	RU	https://pubmed.ncbi.nlm.nih.gov/15125867

DM4KI7O	DI	DM4KI7O
DM4KI7O	DN	Zidovudine
DM4KI7O	MI	DEGTFWK
DM4KI7O	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM4KI7O	MT	DME
DM4KI7O	MA	Metabolism
DM4KI7O	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM4KI7O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM4KI7O	DI	DM4KI7O
DM4KI7O	DN	Zidovudine
DM4KI7O	MI	DTCSGPB
DM4KI7O	MN	Multidrug resistance-associated protein 4 (ABCC4)
DM4KI7O	MT	DTP
DM4KI7O	MA	Substrate
DM4KI7O	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM4KI7O	RU	https://doi.org/10.1007/s11095-012-0935-x

DM4KI7O	DI	DM4KI7O
DM4KI7O	DN	Zidovudine
DM4KI7O	MI	DTQ23VB
DM4KI7O	MN	Organic anion transporter 1 (SLC22A6)
DM4KI7O	MT	DTP
DM4KI7O	MA	Substrate
DM4KI7O	RN	Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
DM4KI7O	RU	http://www.ncbi.nlm.nih.gov/pubmed/11861798

DM4KI7O	DI	DM4KI7O
DM4KI7O	DN	Zidovudine
DM4KI7O	MI	DT0OC1Q
DM4KI7O	MN	Organic anion transporter 2 (SLC22A7)
DM4KI7O	MT	DTP
DM4KI7O	MA	Substrate
DM4KI7O	RN	Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
DM4KI7O	RU	http://www.ncbi.nlm.nih.gov/pubmed/11861798

DM4KI7O	DI	DM4KI7O
DM4KI7O	DN	Zidovudine
DM4KI7O	MI	DTVP67E
DM4KI7O	MN	Organic anion transporter 3 (SLC22A8)
DM4KI7O	MT	DTP
DM4KI7O	MA	Substrate
DM4KI7O	RN	Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
DM4KI7O	RU	http://www.ncbi.nlm.nih.gov/pubmed/11861798

DM4KI7O	DI	DM4KI7O
DM4KI7O	DN	Zidovudine
DM4KI7O	MI	DT06JWZ
DM4KI7O	MN	Organic anion transporter 4 (SLC22A11)
DM4KI7O	MT	DTP
DM4KI7O	MA	Substrate
DM4KI7O	RN	Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
DM4KI7O	RU	http://www.ncbi.nlm.nih.gov/pubmed/11861798

DM4KI7O	DI	DM4KI7O
DM4KI7O	DN	Zidovudine
DM4KI7O	MI	DTT79CX
DM4KI7O	MN	Organic cation transporter 1 (SLC22A1)
DM4KI7O	MT	DTP
DM4KI7O	MA	Substrate
DM4KI7O	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM4KI7O	RU	https://doi.org/10.1007/s11095-012-0935-x

DM4KI7O	DI	DM4KI7O
DM4KI7O	DN	Zidovudine
DM4KI7O	MI	DTUGYRD
DM4KI7O	MN	P-glycoprotein 1 (ABCB1)
DM4KI7O	MT	DTP
DM4KI7O	MA	Substrate
DM4KI7O	RN	The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res. 2009 May;82(2):A99-109.
DM4KI7O	RU	https://doi.org/10.1016/j.antiviral.2008.12.013

DM4KI7O	DI	DM4KI7O
DM4KI7O	DN	Zidovudine
DM4KI7O	MI	DEYGVN4
DM4KI7O	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM4KI7O	MT	DME
DM4KI7O	MA	Metabolism
DM4KI7O	RN	Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
DM4KI7O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19628728

DM4KI7O	DI	DM4KI7O
DM4KI7O	DN	Zidovudine
DM4KI7O	MI	DEB3CV1
DM4KI7O	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DM4KI7O	MT	DME
DM4KI7O	MA	Metabolism
DM4KI7O	RN	Determination of UDP-glucuronosyltransferase UGT2B7 activity in human liver microsomes by ultra-performance liquid chromatography with MS detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jul 1;870(1):84-90.
DM4KI7O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18573701

DMVRIC2	DI	DMVRIC2
DMVRIC2	DN	Zileuton
DMVRIC2	MI	TT2J34L
DMVRIC2	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMVRIC2	MT	DTT
DMVRIC2	MA	Inhibitor
DMVRIC2	RN	5-lipoxygenase inhibitor zileuton attenuates ischemic brain damage: involvement of matrix metalloproteinase 9. Neurol Res. 2009 Oct;31(8):848-52.
DMVRIC2	RU	https://pubmed.ncbi.nlm.nih.gov/19309543

DMVRIC2	DI	DMVRIC2
DMVRIC2	DN	Zileuton
DMVRIC2	MI	DEJGDUW
DMVRIC2	MN	Cytochrome P450 1A2 (CYP1A2)
DMVRIC2	MT	DME
DMVRIC2	MA	Metabolism
DMVRIC2	RN	Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
DMVRIC2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19754423

DMVRIC2	DI	DMVRIC2
DMVRIC2	DN	Zileuton
DMVRIC2	MI	DE5IED8
DMVRIC2	MN	Cytochrome P450 2C9 (CYP2C9)
DMVRIC2	MT	DME
DMVRIC2	MA	Metabolism
DMVRIC2	RN	Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite, Abbott-66193. Drug Metab Dispos. 1995 Oct;23(10):1163-74.
DMVRIC2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8654206

DMVRIC2	DI	DMVRIC2
DMVRIC2	DN	Zileuton
DMVRIC2	MI	DE4LYSA
DMVRIC2	MN	Cytochrome P450 3A4 (CYP3A4)
DMVRIC2	MT	DME
DMVRIC2	MA	Metabolism
DMVRIC2	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMVRIC2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMVRIC2	DI	DMVRIC2
DMVRIC2	DN	Zileuton
DMVRIC2	MI	DE073H6
DMVRIC2	MN	Prostaglandin G/H synthase 1 (COX-1)
DMVRIC2	MT	DME
DMVRIC2	MA	Metabolism
DMVRIC2	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMVRIC2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMVRIC2	DI	DMVRIC2
DMVRIC2	DN	Zileuton
DMVRIC2	MI	DE85D2P
DMVRIC2	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMVRIC2	MT	DME
DMVRIC2	MA	Metabolism
DMVRIC2	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMVRIC2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DTD3FHQ
DMZ4R3Q	MN	Iron-regulated transporter 1 (SLC40A1)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	Ferroportin-mediated iron transport: expression and regulation. Biochim Biophys Acta. 2012 Sep;1823(9):1426-33.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/22440327

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DT1BO38
DMZ4R3Q	MN	Zinc transporter 1 (SLC30A1)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	Zinc transporters ZnT1 (Slc30a1), Zip8 (Slc39a8), and Zip10 (Slc39a10) in mouse red blood cells are differentially regulated during erythroid development and by dietary zinc deficiency. J Nutr. 2008 Nov;138(11):2076-83.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/18936201

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DTYBI73
DMZ4R3Q	MN	Zinc transporter 10 (SLC30A10)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	Mutations in SLC30A10 cause parkinsonism and dystonia with hypermanganesemia, polycythemia, and chronic liver disease. Am J Hum Genet. 2012 Mar 9;90(3):467-77.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/22341971

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DTIAF6C
DMZ4R3Q	MN	Zinc transporter 2 (SLC30A2)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	Compound heterozygous mutations in SLC30A2/ZnT2 results in low milk zinc concentrations: a novel mechanism for zinc deficiency in a breast-fed infant. PLoS One. 2013 May 31;8(5):e64045.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/23741301

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DTKMECW
DMZ4R3Q	MN	Zinc transporter 3 (SLC30A3)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	Loss of synaptic Zn2+ transporter function increases risk of febrile seizures. Sci Rep. 2015 Dec 9;5:17816.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/26647834

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DT280XI
DMZ4R3Q	MN	Zinc transporter 4 (SLC30A4)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	Mutation analysis of the zinc transporter gene SLC30A4 reveals no association with periodic catatonia on chromosome 15q15. J Neural Transm (Vienna). 2003 Nov;110(11):1329-32.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/14628196

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DTVHQT2
DMZ4R3Q	MN	Zinc transporter 5 (SLC30A5)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	Altered expression of two zinc transporters, SLC30A5 and SLC30A6, underlies a mammary gland disorder of reduced zinc secretion into milk. Genes Nutr. 2015 Sep;10(5):487.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/26319140

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DTKPRIL
DMZ4R3Q	MN	Zinc transporter 6 (SLC30A6)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	Altered expression of two zinc transporters, SLC30A5 and SLC30A6, underlies a mammary gland disorder of reduced zinc secretion into milk. Genes Nutr. 2015 Sep;10(5):487.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/26319140

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DTQK38X
DMZ4R3Q	MN	Zinc transporter 7 (SLC30A7)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	Znt7 (Slc30a7)-deficient mice display reduced body zinc status and body fat accumulation. J Biol Chem. 2007 Dec 21;282(51):37053-63.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/17954933

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DT7NVLY
DMZ4R3Q	MN	Zinc transporter 8 (SLC30A8)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	Zinc transporter 8 (ZnT8) and cell function. Trends Endocrinol Metab. 2014 Aug;25(8):415-24.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/24751356

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DT2I79L
DMZ4R3Q	MN	Zinc transporter 9 (SLC30A9)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	SLC30A9 mutation affecting intracellular zinc homeostasis causes a novel cerebro-renal syndrome. Brain. 2017 Apr 1;140(4):928-939.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/28334855

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DTDQSAM
DMZ4R3Q	MN	Zinc transporter SLC39A7 (SLC39A7)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	A ZIP6-ZIP10 heteromer controls NCAM1 phosphorylation and integration into focal adhesion complexes during epithelial-to-mesenchymal transition. Sci Rep. 2017 Jan 18;7:40313.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/28098160

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DTLWPXS
DMZ4R3Q	MN	Zinc transporter ZIP1 (SLC39A1)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	SLC transporters as a novel class of tumour suppressors: identity, function and molecular mechanisms. Biochem J. 2016 May 1;473(9):1113-24.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/27118869

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DTK02RZ
DMZ4R3Q	MN	Zinc transporter ZIP10 (SLC39A10)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	Zinc transporter SLC39A10/ZIP10 facilitates antiapoptotic signaling during early B-cell development. Proc Natl Acad Sci U S A. 2014 Aug 12;111(32):11780-5.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/25074913

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DTEOAND
DMZ4R3Q	MN	Zinc transporter ZIP11 (SLC39A11)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	Gastric and colonic zinc transporter ZIP11 (Slc39a11) in mice responds to dietary zinc and exhibits nuclear localization. J Nutr. 2013 Dec;143(12):1882-8.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/24089422

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DT1UIT5
DMZ4R3Q	MN	Zinc transporter ZIP12 (SLC39A12)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	The zinc transporter ZIP12 regulates the pulmonary vascular response to chronic hypoxia. Nature. 2015 Aug 20;524(7565):356-60.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/26258299

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DTOTKBS
DMZ4R3Q	MN	Zinc transporter ZIP13 (SLC39A13)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	Promotion of vesicular zinc efflux by ZIP13 and its implications for spondylocheiro dysplastic Ehlers-Danlos syndrome. Proc Natl Acad Sci U S A. 2012 Dec 18;109(51):E3530-8.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/23213233

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DTZ6IJW
DMZ4R3Q	MN	Zinc transporter ZIP14 (SLC39A14)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	SLC39A14 deficiency alters manganese homeostasis and excretion resulting in brain manganese accumulation and motor deficits in mice. Proc Natl Acad Sci U S A. 2018 Feb 20;115(8):E1769-E1778.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/29437953

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DTL8VXO
DMZ4R3Q	MN	Zinc transporter ZIP2 (SLC39A2)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	Reassessment of the Transport Mechanism of the Human Zinc Transporter SLC39A2. Biochemistry. 2018 Jul 3;57(26):3976-3986.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/29791142

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DTH08M7
DMZ4R3Q	MN	Zinc transporter ZIP3 (SLC39A3)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	The SLC39 family of zinc transporters. Mol Aspects Med. 2013 Apr-Jun;34(2-3):612-9.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/23506894

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DTEZCUM
DMZ4R3Q	MN	Zinc transporter ZIP4 (SLC39A4)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	Extreme population differences in the human zinc transporter ZIP4 (SLC39A4) are explained by positive selection in Sub-Saharan Africa. PLoS Genet. 2014 Feb 20;10(2):e1004128.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/24586184

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DTN9ACR
DMZ4R3Q	MN	Zinc transporter ZIP5 (SLC39A5)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	The mammalian Zip5 protein is a zinc transporter that localizes to the basolateral surface of polarized cells. J Biol Chem. 2004 Dec 3;279(49):51433-41.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/15322118

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DTT1S93
DMZ4R3Q	MN	Zinc transporter ZIP6 (SLC39A6)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	A ZIP6-ZIP10 heteromer controls NCAM1 phosphorylation and integration into focal adhesion complexes during epithelial-to-mesenchymal transition. Sci Rep. 2017 Jan 18;7:40313.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/28098160

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DTLPQGT
DMZ4R3Q	MN	Zinc transporter ZIP8 (SLC39A8)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	Zinc transporters ZnT1 (Slc30a1), Zip8 (Slc39a8), and Zip10 (Slc39a10) in mouse red blood cells are differentially regulated during erythroid development and by dietary zinc deficiency. J Nutr. 2008 Nov;138(11):2076-83.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/18936201

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DTJH79E
DMZ4R3Q	MN	Zinc transporter ZIP9 (SLC39A9)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	A ZIP6-ZIP10 heteromer controls NCAM1 phosphorylation and integration into focal adhesion complexes during epithelial-to-mesenchymal transition. Sci Rep. 2017 Jan 18;7:40313.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/28098160

DMK4OL7	DI	DMK4OL7
DMK4OL7	DN	Zinostatin stimalamer
DMK4OL7	MI	TTUTN1I
DMK4OL7	MN	Human Deoxyribonucleic acid (hDNA)
DMK4OL7	MT	DTT
DMK4OL7	MA	Modulator
DMK4OL7	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMK4OL7	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DMM58JY	DI	DMM58JY
DMM58JY	DN	Ziprasidone
DMM58JY	MI	DE4LYSA
DMM58JY	MN	Cytochrome P450 3A4 (CYP3A4)
DMM58JY	MT	DME
DMM58JY	MA	Metabolism
DMM58JY	RN	Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008 Jun;9(5):410-8.
DMM58JY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18537577

DMM58JY	DI	DMM58JY
DMM58JY	DN	Ziprasidone
DMM58JY	MI	TTEX248
DMM58JY	MN	Dopamine D2 receptor (D2R)
DMM58JY	MT	DTT
DMM58JY	MA	Agonist
DMM58JY	RN	Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone). JClin Psychopharmacol. 2008 Dec;28(6):608-17.
DMM58JY	RU	https://pubmed.ncbi.nlm.nih.gov/19011428

DMM58JY	DI	DMM58JY
DMM58JY	DN	Ziprasidone
DMM58JY	MI	TTLA931
DMM58JY	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMM58JY	MT	DTT
DMM58JY	MA	Binder
DMM58JY	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMM58JY	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMM58JY	DI	DMM58JY
DMM58JY	DN	Ziprasidone
DMM58JY	MI	DTUGYRD
DMM58JY	MN	P-glycoprotein 1 (ABCB1)
DMM58JY	MT	DTP
DMM58JY	MA	Substrate
DMM58JY	RN	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
DMM58JY	RU	https://doi.org/10.1016/j.addr.2011.12.008

DMN4H2O	DI	DMN4H2O
DMN4H2O	DN	Zithromax
DMN4H2O	MI	TTUWYEA
DMN4H2O	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DMN4H2O	MT	DTT
DMN4H2O	MA	Modulator
DMN4H2O	RN	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
DMN4H2O	RU	https://www.ncbi.nlm.nih.gov/pubmed/27899562

DMN4H2O	DI	DMN4H2O
DMN4H2O	DN	Zithromax
DMN4H2O	MI	DE4LYSA
DMN4H2O	MN	Cytochrome P450 3A4 (CYP3A4)
DMN4H2O	MT	DME
DMN4H2O	MA	Metabolism
DMN4H2O	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMN4H2O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMIXC7G	DI	DMIXC7G
DMIXC7G	DN	Zoledronate
DMIXC7G	MI	TTIKWV4
DMIXC7G	MN	Geranyltranstransferase (FDPS)
DMIXC7G	MT	DTT
DMIXC7G	MA	Modulator
DMIXC7G	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMIXC7G	RU	https://www.fda.gov/

DMIXC7G	DI	DMIXC7G
DMIXC7G	DN	Zoledronate
DMIXC7G	MI	DTSYQGK
DMIXC7G	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMIXC7G	MT	DTP
DMIXC7G	MA	Substrate
DMIXC7G	RN	Zoledronic acid is synergic with vinblastine to induce apoptosis in a multidrug resistance protein-1 dependent way: an in vitro study. Cell Biol Int. 2006 Mar;30(3):278-82.
DMIXC7G	RU	https://doi.org/10.1016/j.cellbi.2005.11.008

DM57O90	DI	DM57O90
DM57O90	DN	Zolgensma
DM57O90	MI	TT8QL6X
DM57O90	MN	Survival motor neuron protein (SMN1)
DM57O90	MT	DTT
DM57O90	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services.
DM57O90	RU	https://www.fda.gov/vaccines-blood-biologics/zolgensma

DM1IB4Q	DI	DM1IB4Q
DM1IB4Q	DN	Zolmitriptan
DM1IB4Q	MI	TTK8CXU
DM1IB4Q	MN	5-HT 1B receptor (HTR1B)
DM1IB4Q	MT	DTT
DM1IB4Q	MA	Modulator
DM1IB4Q	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM1IB4Q	RU	https://www.fda.gov/

DM1IB4Q	DI	DM1IB4Q
DM1IB4Q	DN	Zolmitriptan
DM1IB4Q	MI	TT6MSOK
DM1IB4Q	MN	5-HT 1D receptor (HTR1D)
DM1IB4Q	MT	DTT
DM1IB4Q	MA	Modulator
DM1IB4Q	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM1IB4Q	RU	https://www.fda.gov/

DM1IB4Q	DI	DM1IB4Q
DM1IB4Q	DN	Zolmitriptan
DM1IB4Q	MI	DEJGDUW
DM1IB4Q	MN	Cytochrome P450 1A2 (CYP1A2)
DM1IB4Q	MT	DME
DM1IB4Q	MA	Metabolism
DM1IB4Q	RN	In vitro metabolism of zolmitriptan in rat cytochromes induced with beta-naphthoflavone and the interaction between six drugs and zolmitriptan. Chem Biol Interact. 2003 Dec 15;146(3):263-72.
DM1IB4Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14642738

DM1IB4Q	DI	DM1IB4Q
DM1IB4Q	DN	Zolmitriptan
DM1IB4Q	MI	DERE4TU
DM1IB4Q	MN	Monoamine oxidase type A (MAO-A)
DM1IB4Q	MT	DME
DM1IB4Q	MA	Metabolism
DM1IB4Q	RN	Med-psych drug-drug interactions update. Psychosomatics. 2002 May;43(3):245-7.
DM1IB4Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/12075043

DM1IB4Q	DI	DM1IB4Q
DM1IB4Q	DN	Zolmitriptan
DM1IB4Q	MI	DTT79CX
DM1IB4Q	MN	Organic cation transporter 1 (SLC22A1)
DM1IB4Q	MT	DTP
DM1IB4Q	MA	Substrate
DM1IB4Q	RN	OCT1 mediates hepatic uptake of sumatriptan and loss-of-function OCT1 polymorphisms affect sumatriptan pharmacokinetics. Clin Pharmacol Ther. 2016 Jun;99(6):633-41.
DM1IB4Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/26659468

DM1IB4Q	DI	DM1IB4Q
DM1IB4Q	DN	Zolmitriptan
DM1IB4Q	MI	DTUGYRD
DM1IB4Q	MN	P-glycoprotein 1 (ABCB1)
DM1IB4Q	MT	DTP
DM1IB4Q	MA	Substrate
DM1IB4Q	RN	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
DM1IB4Q	RU	https://doi.org/10.1016/j.addr.2011.12.008

DMWOSKJ	DI	DMWOSKJ
DMWOSKJ	DN	Zolpidem
DMWOSKJ	MI	DEJGDUW
DMWOSKJ	MN	Cytochrome P450 1A2 (CYP1A2)
DMWOSKJ	MT	DME
DMWOSKJ	MA	Metabolism
DMWOSKJ	RN	Adverse reactions to zolpidem: case reports and a review of the literature. Prim Care Companion J Clin Psychiatry. 2010;12(6). pii: PCC.09r00849.
DMWOSKJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21494350

DMWOSKJ	DI	DMWOSKJ
DMWOSKJ	DN	Zolpidem
DMWOSKJ	MI	DE5IED8
DMWOSKJ	MN	Cytochrome P450 2C9 (CYP2C9)
DMWOSKJ	MT	DME
DMWOSKJ	MA	Metabolism
DMWOSKJ	RN	The influences of CYP2C9*1/*3 genotype on the pharmacokinetics of zolpidem. Arch Pharm Res. 2018 Sep;41(9):931-936.
DMWOSKJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30178440

DMWOSKJ	DI	DMWOSKJ
DMWOSKJ	DN	Zolpidem
DMWOSKJ	MI	DECB0K3
DMWOSKJ	MN	Cytochrome P450 2D6 (CYP2D6)
DMWOSKJ	MT	DME
DMWOSKJ	MA	Metabolism
DMWOSKJ	RN	Effect of zolpidem on human cytochrome P450 activity, and on transport mediated by P-glycoprotein. Biopharm Drug Dispos. 2002 Dec;23(9):361-7.
DMWOSKJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12469329

DMWOSKJ	DI	DMWOSKJ
DMWOSKJ	DN	Zolpidem
DMWOSKJ	MI	DE4LYSA
DMWOSKJ	MN	Cytochrome P450 3A4 (CYP3A4)
DMWOSKJ	MT	DME
DMWOSKJ	MA	Metabolism
DMWOSKJ	RN	Zolpidem pharmacokinetics and pharmacodynamics in metabolic interactions involving CYP3A: sex as a differentiating factor. Eur J Clin Pharmacol. 2010 Sep;66(9):955.
DMWOSKJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20552178

DMWOSKJ	DI	DMWOSKJ
DMWOSKJ	DN	Zolpidem
DMWOSKJ	MI	DEIBDNY
DMWOSKJ	MN	Cytochrome P450 3A5 (CYP3A5)
DMWOSKJ	MT	DME
DMWOSKJ	MA	Metabolism
DMWOSKJ	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA166170041)
DMWOSKJ	RU	https://www.pharmgkb.org/vip/PA166170041/relationships

DMWOSKJ	DI	DMWOSKJ
DMWOSKJ	DN	Zolpidem
DMWOSKJ	MI	DERD86B
DMWOSKJ	MN	Cytochrome P450 3A7 (CYP3A7)
DMWOSKJ	MT	DME
DMWOSKJ	MA	Metabolism
DMWOSKJ	RN	Principles of Clinical Pharmacology (Third Edition). 2012, Pages 417-436
DMWOSKJ	RU	https://doi.org/10.1016/B978-0-12-385471-1.00025-8

DMWOSKJ	DI	DMWOSKJ
DMWOSKJ	DN	Zolpidem
DMWOSKJ	MI	TT1MPAY
DMWOSKJ	MN	GABA(A) receptor alpha-1 (GABRA1)
DMWOSKJ	MT	DTT
DMWOSKJ	MA	Modulator
DMWOSKJ	RN	Zolpidem, a selective GABA(A) receptor alpha1 subunit agonist, induces comparable Fos expression in oxytocinergic neurons of the hypothalamic paraventricular and accessory but not supraoptic nuclei in the rat.Brain Res Bull.2006 Dec 11;71(1-3):200-7.
DMWOSKJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/17113947

DMWOSKJ	DI	DMWOSKJ
DMWOSKJ	DN	Zolpidem
DMWOSKJ	MI	TTEX6LM
DMWOSKJ	MN	GABA(A) receptor gamma-3 (GABRG3)
DMWOSKJ	MT	DTT
DMWOSKJ	MA	Modulator (allosteric modulator)
DMWOSKJ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415).
DMWOSKJ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415

DMWOSKJ	DI	DMWOSKJ
DMWOSKJ	DN	Zolpidem
DMWOSKJ	MI	DEGTFWK
DMWOSKJ	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMWOSKJ	MT	DME
DMWOSKJ	MA	Metabolism
DMWOSKJ	RN	Zolpidem extended-release: a single insomnia treatment option for sleep induction and sleep maintenance symptoms. Am J Ther. 2007 May-Jun;14(3):299-305.
DMWOSKJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17515707

DM0DTF7	DI	DM0DTF7
DM0DTF7	DN	Zonisamide
DM0DTF7	MI	DE8UGTM
DM0DTF7	MN	Aldehyde oxidase (AOX)
DM0DTF7	MT	DME
DM0DTF7	MA	Metabolism
DM0DTF7	RN	The role of mammalian intestinal bacteria in the reductive metabolism of zonisamide. J Pharm Pharmacol. 1997 Mar;49(3):253-6.
DM0DTF7	RU	https://pubmed.ncbi.nlm.nih.gov/9231340

DM0DTF7	DI	DM0DTF7
DM0DTF7	DN	Zonisamide
DM0DTF7	MI	DE4LYSA
DM0DTF7	MN	Cytochrome P450 3A4 (CYP3A4)
DM0DTF7	MT	DME
DM0DTF7	MA	Metabolism
DM0DTF7	RN	Pharmacokinetics and drug interactions with zonisamide. Epilepsia. 2007 Mar;48(3):435-41.
DM0DTF7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17319920

DM0DTF7	DI	DM0DTF7
DM0DTF7	DN	Zonisamide
DM0DTF7	MI	DEIBDNY
DM0DTF7	MN	Cytochrome P450 3A5 (CYP3A5)
DM0DTF7	MT	DME
DM0DTF7	MA	Metabolism
DM0DTF7	RN	Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data. Eur J Clin Pharmacol. 1998 Apr;54(2):177-83.
DM0DTF7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9626925

DM0DTF7	DI	DM0DTF7
DM0DTF7	DN	Zonisamide
DM0DTF7	MI	DERD86B
DM0DTF7	MN	Cytochrome P450 3A7 (CYP3A7)
DM0DTF7	MT	DME
DM0DTF7	MA	Metabolism
DM0DTF7	RN	Differential catalytic properties in metabolism of endogenous and exogenous substrates among CYP3A enzymes expressed in COS-7 cells. Biochim Biophys Acta. 1998 May 8;1380(3):297-304.
DM0DTF7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9555064

DM0DTF7	DI	DM0DTF7
DM0DTF7	DN	Zonisamide
DM0DTF7	MI	DEGTFWK
DM0DTF7	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM0DTF7	MT	DME
DM0DTF7	MA	Metabolism
DM0DTF7	RN	Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients. Epilepsy Res. 2004 Nov;62(1):1-11.
DM0DTF7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15519127

DM0DTF7	DI	DM0DTF7
DM0DTF7	DN	Zonisamide
DM0DTF7	MI	TTRK8B9
DM0DTF7	MN	Sodium channel unspecific (NaC)
DM0DTF7	MT	DTT
DM0DTF7	MA	Blocker
DM0DTF7	RN	Antiepileptic drugs and relapse after epilepsy surgery. Epileptic Disord. 2008 Sep;10(3):193-8.
DM0DTF7	RU	https://pubmed.ncbi.nlm.nih.gov/18782687

DM0DTF7	DI	DM0DTF7
DM0DTF7	DN	Zonisamide
DM0DTF7	MI	DEYGVN4
DM0DTF7	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM0DTF7	MT	DME
DM0DTF7	MA	Metabolism
DM0DTF7	RN	Actual and Predicted Pharmacokinetic Interactions Between Anticonvulsants and Antiretrovirals.
DM0DTF7	RU	https://hivclinic.ca/archive/main/drugs_interact_files/anticonvulsant-int.pdf

DMPI6Z0	DI	DMPI6Z0
DMPI6Z0	DN	Zopiclone
DMPI6Z0	MI	DES5XRU
DMPI6Z0	MN	Cytochrome P450 2C8 (CYP2C8)
DMPI6Z0	MT	DME
DMPI6Z0	MA	Metabolism
DMPI6Z0	RN	Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism. Drug Metab Dispos. 1999 Sep;27(9):1068-73.
DMPI6Z0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10460808

DMPI6Z0	DI	DMPI6Z0
DMPI6Z0	DN	Zopiclone
DMPI6Z0	MI	DE5IED8
DMPI6Z0	MN	Cytochrome P450 2C9 (CYP2C9)
DMPI6Z0	MT	DME
DMPI6Z0	MA	Metabolism
DMPI6Z0	RN	Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism. Drug Metab Dispos. 1999 Sep;27(9):1068-73.
DMPI6Z0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10460808

DMPI6Z0	DI	DMPI6Z0
DMPI6Z0	DN	Zopiclone
DMPI6Z0	MI	DEVDYN7
DMPI6Z0	MN	Cytochrome P450 2E1 (CYP2E1)
DMPI6Z0	MT	DME
DMPI6Z0	MA	Metabolism
DMPI6Z0	RN	Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia. Clin Ther. 2006 Apr;28(4):491-516.
DMPI6Z0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16750462

DMPI6Z0	DI	DMPI6Z0
DMPI6Z0	DN	Zopiclone
DMPI6Z0	MI	DE4LYSA
DMPI6Z0	MN	Cytochrome P450 3A4 (CYP3A4)
DMPI6Z0	MT	DME
DMPI6Z0	MA	Metabolism
DMPI6Z0	RN	Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia. Clin Ther. 2006 Apr;28(4):491-516.
DMPI6Z0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16750462

DMPI6Z0	DI	DMPI6Z0
DMPI6Z0	DN	Zopiclone
DMPI6Z0	MI	TTAN6JD
DMPI6Z0	MN	Glutamate receptor AMPA (GRIA)
DMPI6Z0	MT	DTT
DMPI6Z0	MA	Binder
DMPI6Z0	RN	Eszopiclone: its use in the treatment of insomnia. Neuropsychiatr Dis Treat. 2007 Aug;3(4):441-453.
DMPI6Z0	RU	https://pubmed.ncbi.nlm.nih.gov/19300573

DMPI6Z0	DI	DMPI6Z0
DMPI6Z0	DN	Zopiclone
DMPI6Z0	MI	DE073H6
DMPI6Z0	MN	Prostaglandin G/H synthase 1 (COX-1)
DMPI6Z0	MT	DME
DMPI6Z0	MA	Metabolism
DMPI6Z0	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMPI6Z0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMRMCXW	DI	DMRMCXW
DMRMCXW	DN	Zotarolimus
DMRMCXW	MI	TTCJG29
DMRMCXW	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMRMCXW	MT	DTT
DMRMCXW	MA	Modulator
DMRMCXW	RN	Natural products to drugs: natural product-derived compounds in clinical trials. Nat Prod Rep. 2008 Jun;25(3):475-516.
DMRMCXW	RU	https://pubmed.ncbi.nlm.nih.gov/18497896

DMF3VXA	DI	DMF3VXA
DMF3VXA	DN	Zotepine
DMF3VXA	MI	TTJQOD7
DMF3VXA	MN	5-HT 2A receptor (HTR2A)
DMF3VXA	MT	DTT
DMF3VXA	MA	Inhibitor
DMF3VXA	RN	Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501.
DMF3VXA	RU	https://pubmed.ncbi.nlm.nih.gov/11170639

DMF3VXA	DI	DMF3VXA
DMF3VXA	DN	Zotepine
DMF3VXA	MI	DE6OQ3W
DMF3VXA	MN	Cytochrome P450 1A1 (CYP1A1)
DMF3VXA	MT	DME
DMF3VXA	MA	Metabolism
DMF3VXA	RN	Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes. Xenobiotica. 1999 Mar;29(3):217-29.
DMF3VXA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10219963

DMF3VXA	DI	DMF3VXA
DMF3VXA	DN	Zotepine
DMF3VXA	MI	DEJGDUW
DMF3VXA	MN	Cytochrome P450 1A2 (CYP1A2)
DMF3VXA	MT	DME
DMF3VXA	MA	Metabolism
DMF3VXA	RN	Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes. Xenobiotica. 1999 Mar;29(3):217-29.
DMF3VXA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10219963

DMF3VXA	DI	DMF3VXA
DMF3VXA	DN	Zotepine
DMF3VXA	MI	DEPKLMQ
DMF3VXA	MN	Cytochrome P450 2B6 (CYP2B6)
DMF3VXA	MT	DME
DMF3VXA	MA	Metabolism
DMF3VXA	RN	Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes. Xenobiotica. 1999 Mar;29(3):217-29.
DMF3VXA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10219963

DMF3VXA	DI	DMF3VXA
DMF3VXA	DN	Zotepine
DMF3VXA	MI	DECB0K3
DMF3VXA	MN	Cytochrome P450 2D6 (CYP2D6)
DMF3VXA	MT	DME
DMF3VXA	MA	Metabolism
DMF3VXA	RN	Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes. Xenobiotica. 1999 Mar;29(3):217-29.
DMF3VXA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10219963

DMF3VXA	DI	DMF3VXA
DMF3VXA	DN	Zotepine
DMF3VXA	MI	DE4LYSA
DMF3VXA	MN	Cytochrome P450 3A4 (CYP3A4)
DMF3VXA	MT	DME
DMF3VXA	MA	Metabolism
DMF3VXA	RN	New antipsychotic agents for schizophrenia: pharmacokinetics and metabolism update. Curr Opin Investig Drugs. 2002 Jul;3(7):1073-80.
DMF3VXA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12186270

DMF3VXA	DI	DMF3VXA
DMF3VXA	DN	Zotepine
DMF3VXA	MI	DEIBDNY
DMF3VXA	MN	Cytochrome P450 3A5 (CYP3A5)
DMF3VXA	MT	DME
DMF3VXA	MA	Metabolism
DMF3VXA	RN	Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes. Xenobiotica. 1999 Mar;29(3):217-29.
DMF3VXA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10219963

DMF3VXA	DI	DMF3VXA
DMF3VXA	DN	Zotepine
DMF3VXA	MI	DEGTFWK
DMF3VXA	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMF3VXA	MT	DME
DMF3VXA	MA	Metabolism
DMF3VXA	RN	Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes. Xenobiotica. 1999 Mar;29(3):217-29.
DMF3VXA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10219963

DMKYD5N	DI	DMKYD5N
DMKYD5N	DN	Zuclopenthixol
DMKYD5N	MI	DECB0K3
DMKYD5N	MN	Cytochrome P450 2D6 (CYP2D6)
DMKYD5N	MT	DME
DMKYD5N	MA	Metabolism
DMKYD5N	RN	Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol. Eur J Clin Pharmacol. 2016 Feb;72(2):175-84.
DMKYD5N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26514968

DMKYD5N	DI	DMKYD5N
DMKYD5N	DN	Zuclopenthixol
DMKYD5N	MI	TTEX248
DMKYD5N	MN	Dopamine D2 receptor (D2R)
DMKYD5N	MT	DTT
DMKYD5N	MA	Antagonist
DMKYD5N	RN	An ethopharmacological assessment of the effects of zuclopenthixol on agonistic interactions in male mice. Methods Find Exp Clin Pharmacol. 1999 Jan-Feb;21(1):11-5.
DMKYD5N	RU	https://pubmed.ncbi.nlm.nih.gov/10222441

DMRCOU5	DI	DMRCOU5
DMRCOU5	DN	Dicycloplatin
DMRCOU5	MI	TTUTN1I
DMRCOU5	MN	Human Deoxyribonucleic acid (hDNA)
DMRCOU5	MT	DTT
DMRCOU5	MA	Inhibitor
DMRCOU5	RN	Dicycloplatin, a novel platinum analog in chemotherapy: synthesis of chinese pre-clinical and clinical profile and emerging mechanistic studies. Anticancer Res. 2014 Jan;34(1):455-63.
DMRCOU5	RU	https://pubmed.ncbi.nlm.nih.gov/24403501

DMBZ27L	DI	DMBZ27L
DMBZ27L	DN	Favipiravir
DMBZ27L	MI	TT79JGK
DMBZ27L	MN	Mycobacterium RNA polymerase (MycB RNAP)
DMBZ27L	MT	DTT
DMBZ27L	MA	Modulator
DMBZ27L	RN	Favipiravir (T-705), a novel viral RNA polymerase inhibitor.Antiviral Res.2013 Nov;100(2):446-54.
DMBZ27L	RU	https://www.ncbi.nlm.nih.gov/pubmed/24084488

DMDWYUN	DI	DMDWYUN
DMDWYUN	DN	HBI-8000
DMDWYUN	MI	TTBH0VX
DMDWYUN	MN	Histone deacetylase (HDAC)
DMDWYUN	MT	DTT
DMDWYUN	MA	Inhibitor
DMDWYUN	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMDWYUN	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMDWYUN	DI	DMDWYUN
DMDWYUN	DN	HBI-8000
DMDWYUN	MI	TT6R7JZ
DMDWYUN	MN	Histone deacetylase 1 (HDAC1)
DMDWYUN	MT	DTT
DMDWYUN	MA	Modulator
DMDWYUN	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMDWYUN	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM5GFIK	DI	DM5GFIK
DM5GFIK	DN	Icotinib hydrochloride
DM5GFIK	MI	DEJGDUW
DM5GFIK	MN	Cytochrome P450 1A2 (CYP1A2)
DM5GFIK	MT	DME
DM5GFIK	MA	Metabolism
DM5GFIK	RN	Metabolic pathway of icotinib in vitro: the differential roles of CYP3A4, CYP3A5, and CYP1A2 on potential pharmacokinetic drug-drug interaction. J Pharm Sci. 2018 Apr;107(4):979-983.
DM5GFIK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29247736

DM5GFIK	DI	DM5GFIK
DM5GFIK	DN	Icotinib hydrochloride
DM5GFIK	MI	DE4LYSA
DM5GFIK	MN	Cytochrome P450 3A4 (CYP3A4)
DM5GFIK	MT	DME
DM5GFIK	MA	Metabolism
DM5GFIK	RN	Metabolic pathway of icotinib in vitro: the differential roles of CYP3A4, CYP3A5, and CYP1A2 on potential pharmacokinetic drug-drug interaction. J Pharm Sci. 2018 Apr;107(4):979-983.
DM5GFIK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29247736

DM5GFIK	DI	DM5GFIK
DM5GFIK	DN	Icotinib hydrochloride
DM5GFIK	MI	DEIBDNY
DM5GFIK	MN	Cytochrome P450 3A5 (CYP3A5)
DM5GFIK	MT	DME
DM5GFIK	MA	Metabolism
DM5GFIK	RN	Metabolic pathway of icotinib in vitro: the differential roles of CYP3A4, CYP3A5, and CYP1A2 on potential pharmacokinetic drug-drug interaction. J Pharm Sci. 2018 Apr;107(4):979-983.
DM5GFIK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29247736

DM5GFIK	DI	DM5GFIK
DM5GFIK	DN	Icotinib hydrochloride
DM5GFIK	MI	TTGKNB4
DM5GFIK	MN	Epidermal growth factor receptor (EGFR)
DM5GFIK	MT	DTT
DM5GFIK	MA	Antagonist
DM5GFIK	RN	Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Lung Cancer. 2011 Aug;73(2):195-202.
DM5GFIK	RU	https://pubmed.ncbi.nlm.nih.gov/21144613

DM5GIWZ	DI	DM5GIWZ
DM5GIWZ	DN	Mirogabalin
DM5GIWZ	MI	TTFK1JQ
DM5GIWZ	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DM5GIWZ	MT	DTT
DM5GIWZ	MA	Modulator
DM5GIWZ	RN	Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study. Diabetes Care. 2014 Dec;37(12):3253-61.
DM5GIWZ	RU	https://pubmed.ncbi.nlm.nih.gov/25231896

DMY67U8	DI	DMY67U8
DMY67U8	DN	Trapidil
DMY67U8	MI	TTST7KB
DMY67U8	MN	Fibroblast growth factor receptor 3 (FGFR3)
DMY67U8	MT	DTT
DMY67U8	MA	Inhibitor
DMY67U8	RN	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
DMY67U8	RU	https://pubmed.ncbi.nlm.nih.gov/19249983

DMY67U8	DI	DMY67U8
DMY67U8	DN	Trapidil
DMY67U8	MI	TTI2WET
DMY67U8	MN	Platelet-derived growth factor receptor (PDGFR)
DMY67U8	MT	DTT
DMY67U8	MA	Inhibitor
DMY67U8	RN	Osteitis fibrosa is mediated by Platelet-Derived Growth Factor-A via a phosphoinositide 3-kinase-dependent signaling pathway in a rat model for chr... Endocrinology. 2008 Nov;149(11):5735-46.
DMY67U8	RU	https://pubmed.ncbi.nlm.nih.gov/18635661

DMVZL26	DI	DMVZL26
DMVZL26	DN	3,4-Dihydroxycinnamic Acid
DMVZL26	MI	TT2J34L
DMVZL26	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMVZL26	MT	DTT
DMVZL26	MA	Inhibitor
DMVZL26	RN	Phenidone protects the nigral dopaminergic neurons from LPS-induced neurotoxicity. Neurosci Lett. 2008 Nov 7;445(1):1-6.
DMVZL26	RU	https://pubmed.ncbi.nlm.nih.gov/18760329

DMVZL26	DI	DMVZL26
DMVZL26	DN	3,4-Dihydroxycinnamic Acid
DMVZL26	MI	TT2AST1
DMVZL26	MN	Macrophage migration inhibitory factor (MIF)
DMVZL26	MT	DTT
DMVZL26	MA	Inhibitor
DMVZL26	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMVZL26	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DML6CN4	DI	DML6CN4
DML6CN4	DN	Acemetacin
DML6CN4	MI	DEB3CV1
DML6CN4	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DML6CN4	MT	DME
DML6CN4	MA	Metabolism
DML6CN4	RN	Seyffart G. (1992). Drug dosage in renal insufficiency (2nd ed.). Springer Science+Business Media Dordrecht.
DML6CN4	RU	https://link.springer.com/content/pdf/bfm%3A978-94-011-3804-8%2F1.pdf

DM4UE3K	DI	DM4UE3K
DM4UE3K	DN	Acetylcarnitine
DM4UE3K	MI	DT3HUVD
DM4UE3K	MN	Organic cation/carnitine transporter 2 (SLC22A5)
DM4UE3K	MT	DTP
DM4UE3K	MA	Substrate
DM4UE3K	RN	Cloning and functional characterization of a novel up-regulator, cartregulin, of carnitine transporter, OCTN2. Arch Biochem Biophys. 2006 Aug 1;452(1):29-37.
DM4UE3K	RU	http://www.ncbi.nlm.nih.gov/pubmed/16839516

DM1237M	DI	DM1237M
DM1237M	DN	Alfacalcidol
DM1237M	MI	DERSX5P
DM1237M	MN	Cytochrome P450 2J2 (CYP2J2)
DM1237M	MT	DME
DM1237M	MA	Metabolism
DM1237M	RN	Characterization of rat and human CYP2J enzymes as Vitamin D 25-hydroxylases. Steroids. 2006 Oct;71(10):849-56.
DM1237M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16842832

DM1237M	DI	DM1237M
DM1237M	DN	Alfacalcidol
DM1237M	MI	DEBS639
DM1237M	MN	Vitamin D(3) 25-hydroxylase (CYP27A1)
DM1237M	MT	DME
DM1237M	MA	Metabolism
DM1237M	RN	Kidney microsomal 25- and 1alpha-hydroxylase in vitamin D metabolism: catalytic properties, molecular cloning, cellular localization and expression during development. Biochim Biophys Acta. 2002 Feb 28;1580(2-3):133-44.
DM1237M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11880238

DMY2AH1	DI	DMY2AH1
DMY2AH1	DN	Aminophenazone
DMY2AH1	MI	DEJGDUW
DMY2AH1	MN	Cytochrome P450 1A2 (CYP1A2)
DMY2AH1	MT	DME
DMY2AH1	MA	Metabolism
DMY2AH1	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMY2AH1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMY2AH1	DI	DMY2AH1
DMY2AH1	DN	Aminophenazone
DMY2AH1	MI	DEZMWRE
DMY2AH1	MN	Cytochrome P450 2C18 (CYP2C18)
DMY2AH1	MT	DME
DMY2AH1	MA	Metabolism
DMY2AH1	RN	Contribution of human hepatic cytochrome P450s and steroidogenic CYP17 to the N-demethylation of aminopyrine. Xenobiotica. 1999 Feb;29(2):187-93.
DMY2AH1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10199594

DMY2AH1	DI	DMY2AH1
DMY2AH1	DN	Aminophenazone
DMY2AH1	MI	DES5XRU
DMY2AH1	MN	Cytochrome P450 2C8 (CYP2C8)
DMY2AH1	MT	DME
DMY2AH1	MA	Metabolism
DMY2AH1	RN	Contribution of human hepatic cytochrome P450s and steroidogenic CYP17 to the N-demethylation of aminopyrine. Xenobiotica. 1999 Feb;29(2):187-93.
DMY2AH1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10199594

DMY2AH1	DI	DMY2AH1
DMY2AH1	DN	Aminophenazone
DMY2AH1	MI	DE5IED8
DMY2AH1	MN	Cytochrome P450 2C9 (CYP2C9)
DMY2AH1	MT	DME
DMY2AH1	MA	Metabolism
DMY2AH1	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMY2AH1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMY2AH1	DI	DMY2AH1
DMY2AH1	DN	Aminophenazone
DMY2AH1	MI	DECB0K3
DMY2AH1	MN	Cytochrome P450 2D6 (CYP2D6)
DMY2AH1	MT	DME
DMY2AH1	MA	Metabolism
DMY2AH1	RN	Contribution of human hepatic cytochrome P450s and steroidogenic CYP17 to the N-demethylation of aminopyrine. Xenobiotica. 1999 Feb;29(2):187-93.
DMY2AH1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10199594

DMY2AH1	DI	DMY2AH1
DMY2AH1	DN	Aminophenazone
DMY2AH1	MI	DE4LYSA
DMY2AH1	MN	Cytochrome P450 3A4 (CYP3A4)
DMY2AH1	MT	DME
DMY2AH1	MA	Metabolism
DMY2AH1	RN	Contribution of human hepatic cytochrome P450s and steroidogenic CYP17 to the N-demethylation of aminopyrine. Xenobiotica. 1999 Feb;29(2):187-93.
DMY2AH1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10199594

DMY2AH1	DI	DMY2AH1
DMY2AH1	DN	Aminophenazone
DMY2AH1	MI	DERD86B
DMY2AH1	MN	Cytochrome P450 3A7 (CYP3A7)
DMY2AH1	MT	DME
DMY2AH1	MA	Metabolism
DMY2AH1	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMY2AH1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMY2AH1	DI	DMY2AH1
DMY2AH1	DN	Aminophenazone
DMY2AH1	MI	DEGTFWK
DMY2AH1	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMY2AH1	MT	DME
DMY2AH1	MA	Metabolism
DMY2AH1	RN	Inhibition of human hepatic cytochrome P450s and steroidogenic CYP17 by nonylphenol. Biol Pharm Bull. 2002 Feb;25(2):235-8.
DMY2AH1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11853173

DMY2AH1	DI	DMY2AH1
DMY2AH1	DN	Aminophenazone
DMY2AH1	MI	DEX2KIA
DMY2AH1	MN	Steroid 17-alpha-monooxygenase (CYP17A1)
DMY2AH1	MT	DME
DMY2AH1	MA	Metabolism
DMY2AH1	RN	Contribution of human hepatic cytochrome P450s and steroidogenic CYP17 to the N-demethylation of aminopyrine. Xenobiotica. 1999 Feb;29(2):187-93.
DMY2AH1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10199594

DMWDEN0	DI	DMWDEN0
DMWDEN0	DN	Amylin
DMWDEN0	MI	DE0LW4X
DMWDEN0	MN	Matrix metalloproteinase-2 (MMP-2)
DMWDEN0	MT	DME
DMWDEN0	MA	Metabolism
DMWDEN0	RN	Matrix metalloproteinase-9 reduces islet amyloid formation by degrading islet amyloid polypeptide. J Biol Chem. 2013 Feb 1;288(5):3553-9.
DMWDEN0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23229548

DMWDEN0	DI	DMWDEN0
DMWDEN0	DN	Amylin
DMWDEN0	MI	DEA0BDX
DMWDEN0	MN	Matrix metalloproteinase-9 (MMP-9)
DMWDEN0	MT	DME
DMWDEN0	MA	Metabolism
DMWDEN0	RN	Matrix metalloproteinase-9 reduces islet amyloid formation by degrading islet amyloid polypeptide. J Biol Chem. 2013 Feb 1;288(5):3553-9.
DMWDEN0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23229548

DMWDEN0	DI	DMWDEN0
DMWDEN0	DN	Amylin
DMWDEN0	MI	TTD0CIQ
DMWDEN0	MN	Melanocortin receptor 4 (MC4R)
DMWDEN0	MT	DTT
DMWDEN0	MA	Agonist
DMWDEN0	RN	Novel anti-obesity drugs. Expert Opin Investig Drugs. 2000 Jun;9(6):1317-26.
DMWDEN0	RU	https://pubmed.ncbi.nlm.nih.gov/11060745

DM8EKSV	DI	DM8EKSV
DM8EKSV	DN	Anti-MIF antibodies
DM8EKSV	MI	TT2AST1
DM8EKSV	MN	Macrophage migration inhibitory factor (MIF)
DM8EKSV	MT	DTT
DM8EKSV	MA	Inhibitor
DM8EKSV	RN	Neutralization of Macrophage Migration Inhibitory Factor (MIF) by Fully Human Antibodies Correlates with Their Specificity for the beta-Sheet Structure of MIF. J Biol Chem. 2012 March 2; 287(10): 7446-7455.
DM8EKSV	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3293543/

DML1VXW	DI	DML1VXW
DML1VXW	DN	Arotinolol
DML1VXW	MI	DECB0K3
DML1VXW	MN	Cytochrome P450 2D6 (CYP2D6)
DML1VXW	MT	DME
DML1VXW	MA	Metabolism
DML1VXW	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DML1VXW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DMB7WYM	DI	DMB7WYM
DMB7WYM	DN	ATOSIBAN
DMB7WYM	MI	TTSCIUP
DMB7WYM	MN	Oxytocin receptor (OTR)
DMB7WYM	MT	DTT
DMB7WYM	MA	Inhibitor
DMB7WYM	RN	Pyridobenzodiazepines: a novel class of orally active, vasopressin V2 receptor selective agonists. Bioorg Med Chem Lett. 2006 Feb 15;16(4):954-9.
DMB7WYM	RU	https://pubmed.ncbi.nlm.nih.gov/16297621

DMB7WYM	DI	DMB7WYM
DMB7WYM	DN	ATOSIBAN
DMB7WYM	MI	TT4TFGN
DMB7WYM	MN	Vasopressin V1a receptor (V1AR)
DMB7WYM	MT	DTT
DMB7WYM	MA	Inhibitor
DMB7WYM	RN	The discovery of GSK221149A: a potent and selective oxytocin antagonist. Bioorg Med Chem Lett. 2008 Jan 1;18(1):90-4.
DMB7WYM	RU	https://pubmed.ncbi.nlm.nih.gov/18032036

DMB7WYM	DI	DMB7WYM
DMB7WYM	DN	ATOSIBAN
DMB7WYM	MI	TTL9MHW
DMB7WYM	MN	Vasopressin V1b receptor (V1BR)
DMB7WYM	MT	DTT
DMB7WYM	MA	Inhibitor
DMB7WYM	RN	The discovery of GSK221149A: a potent and selective oxytocin antagonist. Bioorg Med Chem Lett. 2008 Jan 1;18(1):90-4.
DMB7WYM	RU	https://pubmed.ncbi.nlm.nih.gov/18032036

DMB7WYM	DI	DMB7WYM
DMB7WYM	DN	ATOSIBAN
DMB7WYM	MI	TTK8R02
DMB7WYM	MN	Vasopressin V2 receptor (V2R)
DMB7WYM	MT	DTT
DMB7WYM	MA	Inhibitor
DMB7WYM	RN	The discovery of GSK221149A: a potent and selective oxytocin antagonist. Bioorg Med Chem Lett. 2008 Jan 1;18(1):90-4.
DMB7WYM	RU	https://pubmed.ncbi.nlm.nih.gov/18032036

DMA12HL	DI	DMA12HL
DMA12HL	DN	Azelnidipine
DMA12HL	MI	DE4LYSA
DMA12HL	MN	Cytochrome P450 3A4 (CYP3A4)
DMA12HL	MT	DME
DMA12HL	MA	Metabolism
DMA12HL	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (DRUG:D01145)
DMA12HL	RU	http://www.genome.jp/dbget-bin/www_bget?D01145

DMJSDBE	DI	DMJSDBE
DMJSDBE	DN	Barnidipine
DMJSDBE	MI	DE4LYSA
DMJSDBE	MN	Cytochrome P450 3A4 (CYP3A4)
DMJSDBE	MT	DME
DMJSDBE	MA	Metabolism
DMJSDBE	RN	Examination of metabolic pathways and identification of human liver cytochrome P450 isozymes responsible for the metabolism of barnidipine, a calcium channel blocker. Xenobiotica. 1997 Sep;27(9):885-900.
DMJSDBE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9381730

DMLKUG7	DI	DMLKUG7
DMLKUG7	DN	Beclabuvir
DMLKUG7	MI	DE4LYSA
DMLKUG7	MN	Cytochrome P450 3A4 (CYP3A4)
DMLKUG7	MT	DME
DMLKUG7	MA	Metabolism
DMLKUG7	RN	Application of static models to predict midazolam clinical interactions in the presence of single or multiple hepatitis C virus drugs. Drug Metab Dispos. 2016 Aug;44(8):1372-80.
DMLKUG7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27226352

DM5NW1E	DI	DM5NW1E
DM5NW1E	DN	Beclomethasone dipropionate
DM5NW1E	MI	DTUGYRD
DM5NW1E	MN	P-glycoprotein 1 (ABCB1)
DM5NW1E	MT	DTP
DM5NW1E	MA	Substrate
DM5NW1E	RN	Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux. Toxicol Appl Pharmacol. 2012 May 1;260(3):294-302.
DM5NW1E	RU	https://doi.org/10.1016/j.taap.2012.03.008

DMWNP6B	DI	DMWNP6B
DMWNP6B	DN	Benidipine
DMWNP6B	MI	DE4LYSA
DMWNP6B	MN	Cytochrome P450 3A4 (CYP3A4)
DMWNP6B	MT	DME
DMWNP6B	MA	Metabolism
DMWNP6B	RN	Characterization of benidipine and its enantiomers' metabolism by human liver cytochrome P450 enzymes. Drug Metab Dispos. 2007 Sep;35(9):1518-24.
DMWNP6B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17537876

DMWNP6B	DI	DMWNP6B
DMWNP6B	DN	Benidipine
DMWNP6B	MI	DEIBDNY
DMWNP6B	MN	Cytochrome P450 3A5 (CYP3A5)
DMWNP6B	MT	DME
DMWNP6B	MA	Metabolism
DMWNP6B	RN	Characterization of benidipine and its enantiomers' metabolism by human liver cytochrome P450 enzymes. Drug Metab Dispos. 2007 Sep;35(9):1518-24.
DMWNP6B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17537876

DMHKZX1	DI	DMHKZX1
DMHKZX1	DN	Benzethonium
DMHKZX1	MI	DECB0K3
DMHKZX1	MN	Cytochrome P450 2D6 (CYP2D6)
DMHKZX1	MT	DME
DMHKZX1	MA	Metabolism
DMHKZX1	RN	Transport, metabolism, and in vivo population pharmacokinetics of the chloro benztropine analogs, a class of compounds extensively evaluated in animal models of drug abuse. J Pharmacol Exp Ther. 2007 Jan;320(1):344-53.
DMHKZX1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17003230

DMHKZX1	DI	DMHKZX1
DMHKZX1	DN	Benzethonium
DMHKZX1	MI	DEGTFWK
DMHKZX1	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMHKZX1	MT	DME
DMHKZX1	MA	Metabolism
DMHKZX1	RN	Transport, metabolism, and in vivo population pharmacokinetics of the chloro benztropine analogs, a class of compounds extensively evaluated in animal models of drug abuse. J Pharmacol Exp Ther. 2007 Jan;320(1):344-53.
DMHKZX1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17003230

DML634R	DI	DML634R
DML634R	DN	Beraprost
DML634R	MI	DES5XRU
DML634R	MN	Cytochrome P450 2C8 (CYP2C8)
DML634R	MT	DME
DML634R	MA	Metabolism
DML634R	RN	Evaluation of drug-drug interaction potential of beraprost sodium mediated by P450 in vitro. Yakugaku Zasshi. 2008 Oct;128(10):1459-65.
DML634R	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18827466

DMWL182	DI	DMWL182
DMWL182	DN	Beraprost
DMWL182	MI	TTOFYT1
DMWL182	MN	Prostacyclin receptor (PTGIR)
DMWL182	MT	DTT
DMWL182	MA	Agonist
DMWL182	RN	Prostaglandin I2 IP Receptor Agonist, Beraprost, Prevents Transient Global Cerebral Ischemia Induced Hippocampal CA1 Injury in Aging Mice. J Neurol Disord. 2014;2:1000174.
DMWL182	RU	https://pubmed.ncbi.nlm.nih.gov/25584359

DMC5Q8X	DI	DMC5Q8X
DMC5Q8X	DN	Berberine
DMC5Q8X	MI	DTT79CX
DMC5Q8X	MN	Organic cation transporter 1 (SLC22A1)
DMC5Q8X	MT	DTP
DMC5Q8X	MA	Substrate
DMC5Q8X	RN	Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1). Naunyn Schmiedebergs Arch Pharmacol. 2008 Feb;376(6):449-61.
DMC5Q8X	RU	https://doi.org/10.1007/s00210-007-0219-x

DMC5Q8X	DI	DMC5Q8X
DMC5Q8X	DN	Berberine
DMC5Q8X	MI	DTUGYRD
DMC5Q8X	MN	P-glycoprotein 1 (ABCB1)
DMC5Q8X	MT	DTP
DMC5Q8X	MA	Substrate
DMC5Q8X	RN	P-glycoprotein-mediated transport of berberine across Caco-2 cell monolayers. J Pharm Sci. 2002 Dec;91(12):2614-21.
DMC5Q8X	RU	http://www.ncbi.nlm.nih.gov/pubmed/12434406

DMC5Q8X	DI	DMC5Q8X
DMC5Q8X	DN	Berberine
DMC5Q8X	MI	TTUJFD0
DMC5Q8X	MN	Telomerase reverse transcriptase (TERT)
DMC5Q8X	MT	DTT
DMC5Q8X	MA	Inhibitor
DMC5Q8X	RN	Stage specificity of Plasmodium falciparum telomerase and its inhibition by berberine. Parasitol Int. 2002 Mar;51(1):99-103.
DMC5Q8X	RU	https://pubmed.ncbi.nlm.nih.gov/11880232

DMGXD5T	DI	DMGXD5T
DMGXD5T	DN	Brotizolam
DMGXD5T	MI	DE4LYSA
DMGXD5T	MN	Cytochrome P450 3A4 (CYP3A4)
DMGXD5T	MT	DME
DMGXD5T	MA	Metabolism
DMGXD5T	RN	Inhibition of the metabolism of brotizolam by erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in brotizolam metabolism. Br J Clin Pharmacol. 2005 Aug;60(2):172-5.
DMGXD5T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16042670

DMXZU73	DI	DMXZU73
DMXZU73	DN	Carbapenem
DMXZU73	MI	DESIWFO
DMXZU73	MN	Beta-lactamase (blaB)
DMXZU73	MT	DME
DMXZU73	MA	Metabolism
DMXZU73	RN	EBR-1, a novel Ambler subclass B1 beta-lactamase from Empedobacter brevis. Antimicrob Agents Chemother. 2002 Oct;46(10):3223-7.
DMXZU73	RU	https://pubmed.ncbi.nlm.nih.gov/12234848

DMXZU73	DI	DMXZU73
DMXZU73	DN	Carbapenem
DMXZU73	MI	DEBKS91
DMXZU73	MN	Beta-lactamase (blaB)
DMXZU73	MT	DME
DMXZU73	MA	Metabolism
DMXZU73	RN	Investigation of carbapenemases and aminoglycoside modifying enzymes of Acinetobacter baumannii isolates recovered from patients admitted to intensive care units in a tertiary-care hospital in Brazil. Rev Soc Bras Med Trop. 2019 Dec 20;53:e20190044.
DMXZU73	RU	https://pubmed.ncbi.nlm.nih.gov/31859941

DMJKWPZ	DI	DMJKWPZ
DMJKWPZ	DN	Cefpirome
DMJKWPZ	MI	DEEAL81
DMJKWPZ	MN	Beta-lactamase (blaB)
DMJKWPZ	MT	DME
DMJKWPZ	MA	Metabolism
DMJKWPZ	RN	Oral streptococcal strains isolated from odontogenic infections and their susceptibility to antibiotics. Rev Med Chir Soc Med Nat Iasi. 2006 Oct-Dec;110(4):1012-5.
DMJKWPZ	RU	https://pubmed.ncbi.nlm.nih.gov/17438917

DMJKWPZ	DI	DMJKWPZ
DMJKWPZ	DN	Cefpirome
DMJKWPZ	MI	DEMIUB2
DMJKWPZ	MN	Beta-lactamase (blaB)
DMJKWPZ	MT	DME
DMJKWPZ	MA	Metabolism
DMJKWPZ	RN	Oral streptococcal strains isolated from odontogenic infections and their susceptibility to antibiotics. Rev Med Chir Soc Med Nat Iasi. 2006 Oct-Dec;110(4):1012-5.
DMJKWPZ	RU	https://pubmed.ncbi.nlm.nih.gov/17438917

DMPZTRC	DI	DMPZTRC
DMPZTRC	DN	Ceftazidine
DMPZTRC	MI	DEBKS91
DMPZTRC	MN	Beta-lactamase (blaB)
DMPZTRC	MT	DME
DMPZTRC	MA	Metabolism
DMPZTRC	RN	Drug-resistant genes carried by Acinetobacter baumanii isolated from patients with lower respiratory tract infection. Chin Med J (Engl). 2010 Sep;123(18):2571-5.
DMPZTRC	RU	https://pubmed.ncbi.nlm.nih.gov/21034630

DMYGEH7	DI	DMYGEH7
DMYGEH7	DN	Ceftolozane sulfate
DMYGEH7	MI	TTJP4SM
DMYGEH7	MN	Bacterial Penicillin binding protein (Bact PBP)
DMYGEH7	MT	DTT
DMYGEH7	MA	Modulator
DMYGEH7	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMYGEH7	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMYTGW0	DI	DMYTGW0
DMYTGW0	DN	Celiprolol
DMYTGW0	MI	DECB0K3
DMYTGW0	MN	Cytochrome P450 2D6 (CYP2D6)
DMYTGW0	MT	DME
DMYTGW0	MA	Metabolism
DMYTGW0	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DMYTGW0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DM6C4YJ	DI	DM6C4YJ
DM6C4YJ	DN	Chlorphenamine
DM6C4YJ	MI	DECB0K3
DM6C4YJ	MN	Cytochrome P450 2D6 (CYP2D6)
DM6C4YJ	MT	DME
DM6C4YJ	MA	Metabolism
DM6C4YJ	RN	The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. Br J Clin Pharmacol. 2002 May;53(5):519-25.
DM6C4YJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11994058

DM6C4YJ	DI	DM6C4YJ
DM6C4YJ	DN	Chlorphenamine
DM6C4YJ	MI	DE4LYSA
DM6C4YJ	MN	Cytochrome P450 3A4 (CYP3A4)
DM6C4YJ	MT	DME
DM6C4YJ	MA	Metabolism
DM6C4YJ	RN	Drug Interactions Flockhart Table
DM6C4YJ	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM6C4YJ	DI	DM6C4YJ
DM6C4YJ	DN	Chlorphenamine
DM6C4YJ	MI	DEIBDNY
DM6C4YJ	MN	Cytochrome P450 3A5 (CYP3A5)
DM6C4YJ	MT	DME
DM6C4YJ	MA	Metabolism
DM6C4YJ	RN	Drug Interactions Flockhart Table
DM6C4YJ	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM6C4YJ	DI	DM6C4YJ
DM6C4YJ	DN	Chlorphenamine
DM6C4YJ	MI	DERD86B
DM6C4YJ	MN	Cytochrome P450 3A7 (CYP3A7)
DM6C4YJ	MT	DME
DM6C4YJ	MA	Metabolism
DM6C4YJ	RN	Drug Interactions Flockhart Table
DM6C4YJ	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM0N19Y	DI	DM0N19Y
DM0N19Y	DN	Chondroitin sulfate
DM0N19Y	MI	DELTYX6
DM0N19Y	MN	Alpha-L-iduronidase (IDUA)
DM0N19Y	MT	DME
DM0N19Y	MA	Metabolism
DM0N19Y	RN	MFN human ref: Chondroitin sulfate degradation.
DM0N19Y	RU	http://mummichog.org/shuzhao/mfn1.9/humanpngs2/mfn1v9path123.png

DM0N19Y	DI	DM0N19Y
DM0N19Y	DN	Chondroitin sulfate
DM0N19Y	MI	DEHKRDS
DM0N19Y	MN	Arylsulfatase B (ARSB)
DM0N19Y	MT	DME
DM0N19Y	MA	Metabolism
DM0N19Y	RN	MFN human ref: Chondroitin sulfate degradation.
DM0N19Y	RU	http://mummichog.org/shuzhao/mfn1.9/humanpngs2/mfn1v9path123.png

DM0N19Y	DI	DM0N19Y
DM0N19Y	DN	Chondroitin sulfate
DM0N19Y	MI	DEP54UE
DM0N19Y	MN	Beta-glucuronidase (GUSB)
DM0N19Y	MT	DME
DM0N19Y	MA	Metabolism
DM0N19Y	RN	MFN human ref: Chondroitin sulfate degradation.
DM0N19Y	RU	http://mummichog.org/shuzhao/mfn1.9/humanpngs2/mfn1v9path123.png

DM0N19Y	DI	DM0N19Y
DM0N19Y	DN	Chondroitin sulfate
DM0N19Y	MI	DEQIZP2
DM0N19Y	MN	Chondroitin 6-sulfotransferase (CHST3)
DM0N19Y	MT	DME
DM0N19Y	MA	Metabolism
DM0N19Y	RN	Variants in chondroitin sulfate metabolism genes in thrombotic storm. Thromb Res. 2018 Jan;161:43-51.
DM0N19Y	RU	https://pubmed.ncbi.nlm.nih.gov/29178990

DM0N19Y	DI	DM0N19Y
DM0N19Y	DN	Chondroitin sulfate
DM0N19Y	MI	DEH31BC
DM0N19Y	MN	Hyaluronate lyase (hyaL)
DM0N19Y	MT	DME
DM0N19Y	MA	Metabolism
DM0N19Y	RN	nan
DM0N19Y	RU	nan

DM0N19Y	DI	DM0N19Y
DM0N19Y	DN	Chondroitin sulfate
DM0N19Y	MI	DEV7UZD
DM0N19Y	MN	Hyaluronoglucosaminidase (nagH)
DM0N19Y	MT	DME
DM0N19Y	MA	Metabolism
DM0N19Y	RN	nan
DM0N19Y	RU	nan

DM0N19Y	DI	DM0N19Y
DM0N19Y	DN	Chondroitin sulfate
DM0N19Y	MI	DEL45C2
DM0N19Y	MN	Iduronate 2-sulfatase (IDS)
DM0N19Y	MT	DME
DM0N19Y	MA	Metabolism
DM0N19Y	RN	MFN human ref: Chondroitin sulfate degradation.
DM0N19Y	RU	http://mummichog.org/shuzhao/mfn1.9/humanpngs2/mfn1v9path123.png

DM0N19Y	DI	DM0N19Y
DM0N19Y	DN	Chondroitin sulfate
DM0N19Y	MI	DE6AY40
DM0N19Y	MN	N-acetyl-beta-glucosaminidase beta (HEXB)
DM0N19Y	MT	DME
DM0N19Y	MA	Metabolism
DM0N19Y	RN	MFN human ref: Chondroitin sulfate degradation.
DM0N19Y	RU	http://mummichog.org/shuzhao/mfn1.9/humanpngs2/mfn1v9path123.png

DMBG0N4	DI	DMBG0N4
DMBG0N4	DN	Cibenzoline
DMBG0N4	MI	DECB0K3
DMBG0N4	MN	Cytochrome P450 2D6 (CYP2D6)
DMBG0N4	MT	DME
DMBG0N4	MA	Metabolism
DMBG0N4	RN	Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A. Drug Metab Dispos. 2000 Sep;28(9):1128-34.
DMBG0N4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10950860

DMBG0N4	DI	DMBG0N4
DMBG0N4	DN	Cibenzoline
DMBG0N4	MI	DE4LYSA
DMBG0N4	MN	Cytochrome P450 3A4 (CYP3A4)
DMBG0N4	MT	DME
DMBG0N4	MA	Metabolism
DMBG0N4	RN	Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A. Drug Metab Dispos. 2000 Sep;28(9):1128-34.
DMBG0N4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10950860

DMSW5QP	DI	DMSW5QP
DMSW5QP	DN	Cotrimoxazole
DMSW5QP	MI	DEP0IWS
DMSW5QP	MN	Beta-lactamase (blaB)
DMSW5QP	MT	DME
DMSW5QP	MA	Metabolism
DMSW5QP	RN	Analysis of the drug-resistant characteristics of Klebsiella pneumoniae isolated from the respiratory tract and CTX-M ESBL genes. Genet Mol Res. 2015 Oct 5;14(4):12043-8.
DMSW5QP	RU	https://pubmed.ncbi.nlm.nih.gov/26505351

DMLMOIJ	DI	DMLMOIJ
DMLMOIJ	DN	Cyproterone acetate
DMLMOIJ	MI	DE4LYSA
DMLMOIJ	MN	Cytochrome P450 3A4 (CYP3A4)
DMLMOIJ	MT	DME
DMLMOIJ	MA	Metabolism
DMLMOIJ	RN	Progestogens in menopausal hormone therapy. Prz Menopauzalny. 2015 Jun;14(2):134-43.
DMLMOIJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26327902

DMV6KFY	DI	DMV6KFY
DMV6KFY	DN	Dapoxetine
DMV6KFY	MI	DECB0K3
DMV6KFY	MN	Cytochrome P450 2D6 (CYP2D6)
DMV6KFY	MT	DME
DMV6KFY	MA	Metabolism
DMV6KFY	RN	Dapoxetine: a new option in the medical management of premature ejaculation. Ther Adv Urol. 2012 Oct;4(5):233-51.
DMV6KFY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23024705

DMV6KFY	DI	DMV6KFY
DMV6KFY	DN	Dapoxetine
DMV6KFY	MI	DE4LYSA
DMV6KFY	MN	Cytochrome P450 3A4 (CYP3A4)
DMV6KFY	MT	DME
DMV6KFY	MA	Metabolism
DMV6KFY	RN	Pharmacokinetics of single and multiple escalating doses of dapoxetine in healthy volunteers. Clinical Pharmacology Therapeutics, 2004, 75(2):P32.
DMV6KFY	RU	https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1016/j.clpt.2003.11.123

DMV6KFY	DI	DMV6KFY
DMV6KFY	DN	Dapoxetine
DMV6KFY	MI	DEJ73Q9
DMV6KFY	MN	Dimethylaniline oxidase 1 (FMO1)
DMV6KFY	MT	DME
DMV6KFY	MA	Metabolism
DMV6KFY	RN	Pharmacokinetics of single and multiple escalating doses of dapoxetine in healthy volunteers. Clinical Pharmacology Therapeutics, 2004, 75(2):P32.
DMV6KFY	RU	https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1016/j.clpt.2003.11.123

DMV5KTJ	DI	DMV5KTJ
DMV5KTJ	DN	Demegestone
DMV5KTJ	MI	DE4LYSA
DMV5KTJ	MN	Cytochrome P450 3A4 (CYP3A4)
DMV5KTJ	MT	DME
DMV5KTJ	MA	Metabolism
DMV5KTJ	RN	Drug interactions between rifamycin antibiotics and hormonal contraception: a systematic review. BJOG. 2018 Jun;125(7):804-811.
DMV5KTJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29130574

DMN2Q5I	DI	DMN2Q5I
DMN2Q5I	DN	Diacerein
DMN2Q5I	MI	TTRYK0X
DMN2Q5I	MN	Interleukin-1 beta (IL1B)
DMN2Q5I	MT	DTT
DMN2Q5I	MA	Inhibitor
DMN2Q5I	RN	Non-surgical treatment of osteoarthritis of large joints - new aspects. Wien Med Wochenschr. 2009;159(3-4):76-86.
DMN2Q5I	RU	https://pubmed.ncbi.nlm.nih.gov/19247594

DMTX0PZ	DI	DMTX0PZ
DMTX0PZ	DN	Dibekacin
DMTX0PZ	MI	DE5WGIM
DMTX0PZ	MN	Aminoglycoside phosphotransferase (aph-Ib)
DMTX0PZ	MT	DME
DMTX0PZ	MA	Metabolism
DMTX0PZ	RN	Novel aminoglycoside 2''-phosphotransferase identified in a gram-negative pathogen. Antimicrob Agents Chemother. 2013 Jan;57(1):452-7.
DMTX0PZ	RU	https://pubmed.ncbi.nlm.nih.gov/23129050

DMZ5Y1P	DI	DMZ5Y1P
DMZ5Y1P	DN	Dichloroacetate
DMZ5Y1P	MI	TTCZOF2
DMZ5Y1P	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMZ5Y1P	MT	DTT
DMZ5Y1P	MA	Inhibitor
DMZ5Y1P	RN	Comparison of Antitumor Effects of Combined and Separate Treatment with NO Synthase Inhibitor T1023 and PDK1 Inhibitor Dichloroacetate. Bull Exp Biol Med. 2019 Nov;168(1):92-94.
DMZ5Y1P	RU	https://pubmed.ncbi.nlm.nih.gov/31768777

DMB0FWL	DI	DMB0FWL
DMB0FWL	DN	Dihydrocodeine
DMB0FWL	MI	DECB0K3
DMB0FWL	MN	Cytochrome P450 2D6 (CYP2D6)
DMB0FWL	MT	DME
DMB0FWL	MA	Metabolism
DMB0FWL	RN	The role of active metabolites in dihydrocodeine effects. Int J Clin Pharmacol Ther. 2003 Mar;41(3):95-106.
DMB0FWL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12665158

DMB0FWL	DI	DMB0FWL
DMB0FWL	DN	Dihydrocodeine
DMB0FWL	MI	DE4LYSA
DMB0FWL	MN	Cytochrome P450 3A4 (CYP3A4)
DMB0FWL	MT	DME
DMB0FWL	MA	Metabolism
DMB0FWL	RN	Pharmacokinetics of dihydrocodeine and its active metabolite after single and multiple oral dosing. Br J Clin Pharmacol. 1999 Sep;48(3):317-22.
DMB0FWL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10510141

DMB0FWL	DI	DMB0FWL
DMB0FWL	DN	Dihydrocodeine
DMB0FWL	MI	TTN4QDT
DMB0FWL	MN	Opioid receptor (OPR)
DMB0FWL	MT	DTT
DMB0FWL	MA	Modulator
DMB0FWL	RN	Affinities of dihydrocodeine and its metabolites to opioid receptors. Pharmacol Toxicol. 2002 Aug;91(2):57-63.
DMB0FWL	RU	https://pubmed.ncbi.nlm.nih.gov/12420793

DMB0FWL	DI	DMB0FWL
DMB0FWL	DN	Dihydrocodeine
DMB0FWL	MI	DENUPDX
DMB0FWL	MN	UDP-glucuronosyltransferase 2B4 (UGT2B4)
DMB0FWL	MT	DME
DMB0FWL	MA	Metabolism
DMB0FWL	RN	Adult and infant pharmacokinetic profiling of dihydrocodeine using physiologically based pharmacokinetic modeling. Biopharm Drug Dispos. 2019 Nov;40(9):350-357.
DMB0FWL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31691978

DMB0FWL	DI	DMB0FWL
DMB0FWL	DN	Dihydrocodeine
DMB0FWL	MI	DEB3CV1
DMB0FWL	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMB0FWL	MT	DME
DMB0FWL	MA	Metabolism
DMB0FWL	RN	Adult and infant pharmacokinetic profiling of dihydrocodeine using physiologically based pharmacokinetic modeling. Biopharm Drug Dispos. 2019 Nov;40(9):350-357.
DMB0FWL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31691978

DM3S8XC	DI	DM3S8XC
DM3S8XC	DN	Dihydrotestosterone
DM3S8XC	MI	DE7P2FB
DM3S8XC	MN	Aldo-keto reductase 1C1 (AKR1C1)
DM3S8XC	MT	DME
DM3S8XC	MA	Metabolism
DM3S8XC	RN	Human 3-alpha hydroxysteroid dehydrogenase type 3 (3alpha-HSD3): the V54L mutation restricting the steroid alternative binding and enhancing the 20alpha-HSD activity. J Steroid Biochem Mol Biol. 2014 May;141:135-43.
DM3S8XC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24434280

DM3S8XC	DI	DM3S8XC
DM3S8XC	DN	Dihydrotestosterone
DM3S8XC	MI	TTS64P2
DM3S8XC	MN	Androgen receptor (AR)
DM3S8XC	MT	DTT
DM3S8XC	MA	Modulator
DM3S8XC	RN	Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor. Mol Endocrinol. 2002 Jul;16(7):1492-501.
DM3S8XC	RU	https://www.ncbi.nlm.nih.gov/pubmed/12089345

DM3S8XC	DI	DM3S8XC
DM3S8XC	DN	Dihydrotestosterone
DM3S8XC	MI	TTKPW01
DM3S8XC	MN	Androgen receptor messenger RNA (AR mRNA)
DM3S8XC	MT	DTT
DM3S8XC	MA	Agonist
DM3S8XC	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 628).
DM3S8XC	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=628

DM3S8XC	DI	DM3S8XC
DM3S8XC	DN	Dihydrotestosterone
DM3S8XC	MI	DEQX145
DM3S8XC	MN	Aromatase (CYP19A1)
DM3S8XC	MT	DME
DM3S8XC	MA	Metabolism
DM3S8XC	RN	Identifying susceptibility genes for prostate cancer--a family-based association study of polymorphisms in CYP17, CYP19, CYP11A1, and LH-beta. Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):2035-9.
DM3S8XC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16103457

DM3S8XC	DI	DM3S8XC
DM3S8XC	DN	Dihydrotestosterone
DM3S8XC	MI	DTUGYRD
DM3S8XC	MN	P-glycoprotein 1 (ABCB1)
DM3S8XC	MT	DTP
DM3S8XC	MA	Substrate
DM3S8XC	RN	P-glycoprotein increases the efflux of the androgen dihydrotestosterone and reduces androgen responsive gene activity in prostate tumor cells. Prostate. 2004 Apr 1;59(1):77-90.
DM3S8XC	RU	https://doi.org/10.1002/pros.10354

DM3S8XC	DI	DM3S8XC
DM3S8XC	DN	Dihydrotestosterone
DM3S8XC	MI	DEX2KIA
DM3S8XC	MN	Steroid 17-alpha-monooxygenase (CYP17A1)
DM3S8XC	MT	DME
DM3S8XC	MA	Metabolism
DM3S8XC	RN	Identifying susceptibility genes for prostate cancer--a family-based association study of polymorphisms in CYP17, CYP19, CYP11A1, and LH-beta. Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):2035-9.
DM3S8XC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16103457

DM3S8XC	DI	DM3S8XC
DM3S8XC	DN	Dihydrotestosterone
DM3S8XC	MI	DEYGVN4
DM3S8XC	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM3S8XC	MT	DME
DM3S8XC	MA	Metabolism
DM3S8XC	RN	UDP-glucuronosyltransferase 2B15 (UGT2B15) and UGT2B17 enzymes are major determinants of the androgen response in prostate cancer LNCaP cells. J Biol Chem. 2007 Nov 16;282(46):33466-74.
DM3S8XC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17848572

DM3YH4I	DI	DM3YH4I
DM3YH4I	DN	D-Serine
DM3YH4I	MI	DTC54PX
DM3YH4I	MN	Alanine/serine/cysteine/threonine transporter 1 (SLC1A4)
DM3YH4I	MT	DTP
DM3YH4I	MA	Substrate
DM3YH4I	RN	D-Serine Is a Substrate for Neutral Amino Acid Transporters ASCT1/SLC1A4 and ASCT2/SLC1A5, and Is Transported by Both Subtypes in Rat Hippocampal Astrocyte Cultures. PLoS One. 2016 Jun 7;11(6):e0156551.
DM3YH4I	RU	http://www.ncbi.nlm.nih.gov/pubmed/27272177

DM3YH4I	DI	DM3YH4I
DM3YH4I	DN	D-Serine
DM3YH4I	MI	DTW7AE3
DM3YH4I	MN	Alanine/serine/cysteine/threonine transporter 2 (SLC1A5)
DM3YH4I	MT	DTP
DM3YH4I	MA	Substrate
DM3YH4I	RN	D-Serine Is a Substrate for Neutral Amino Acid Transporters ASCT1/SLC1A4 and ASCT2/SLC1A5, and Is Transported by Both Subtypes in Rat Hippocampal Astrocyte Cultures. PLoS One. 2016 Jun 7;11(6):e0156551.
DM3YH4I	RU	http://www.ncbi.nlm.nih.gov/pubmed/27272177

DM3YH4I	DI	DM3YH4I
DM3YH4I	DN	D-Serine
DM3YH4I	MI	DERZQ2Y
DM3YH4I	MN	D-amino-acid oxidase (DAO)
DM3YH4I	MT	DME
DM3YH4I	MA	Metabolism
DM3YH4I	RN	Focus on the role of D-serine and D-amino acid oxidase in amyotrophic lateral sclerosis/motor neuron disease (ALS). Front Mol Biosci. 2018 Feb 13;5:8.
DM3YH4I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29487852

DM3YH4I	DI	DM3YH4I
DM3YH4I	DN	D-Serine
DM3YH4I	MI	TTLD29N
DM3YH4I	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DM3YH4I	MT	DTT
DM3YH4I	MA	Inhibitor
DM3YH4I	RN	Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
DM3YH4I	RU	https://pubmed.ncbi.nlm.nih.gov/11752352

DM3YH4I	DI	DM3YH4I
DM3YH4I	DN	D-Serine
DM3YH4I	MI	DEKOQX7
DM3YH4I	MN	Serine racemase (SRR)
DM3YH4I	MT	DME
DM3YH4I	MA	Metabolism
DM3YH4I	RN	D-Serine made by serine racemase in Drosophila intestine plays a physiological role in sleep. Nat Commun. 2019 May 7;10(1):1986.
DM3YH4I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31064979

DM3YH4I	DI	DM3YH4I
DM3YH4I	DN	D-Serine
DM3YH4I	MI	TTF45NW
DM3YH4I	MN	Strychnine-binding glycine receptor (GLRA1)
DM3YH4I	MT	DTT
DM3YH4I	MA	Inhibitor
DM3YH4I	RN	Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
DM3YH4I	RU	https://pubmed.ncbi.nlm.nih.gov/11752352

DMQRX24	DI	DMQRX24
DMQRX24	DN	Ebastine
DMQRX24	MI	DERSX5P
DMQRX24	MN	Cytochrome P450 2J2 (CYP2J2)
DMQRX24	MT	DME
DMQRX24	MA	Metabolism
DMQRX24	RN	Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity. Drug Metab Dispos. 2012 May;40(5):943-51.
DMQRX24	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22328583

DMQRX24	DI	DMQRX24
DMQRX24	DN	Ebastine
DMQRX24	MI	DE4LYSA
DMQRX24	MN	Cytochrome P450 3A4 (CYP3A4)
DMQRX24	MT	DME
DMQRX24	MA	Metabolism
DMQRX24	RN	Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A. Drug Metab Dispos. 2006 Nov;34(11):1793-7.
DMQRX24	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16896065

DMQRX24	DI	DMQRX24
DMQRX24	DN	Ebastine
DMQRX24	MI	DE3GT9C
DMQRX24	MN	Cytochrome P450 4F2 (CYP4F2)
DMQRX24	MT	DME
DMQRX24	MA	Metabolism
DMQRX24	RN	cDNA cloning and expression of a novel cytochrome p450 (cyp4f12) from human small intestine. Biochem Biophys Res Commun. 2001 Feb 2;280(4):1135-41.
DMQRX24	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11162645

DMH21D9	DI	DMH21D9
DMH21D9	DN	Ebastine
DMH21D9	MI	DTUGYRD
DMH21D9	MN	P-glycoprotein 1 (ABCB1)
DMH21D9	MT	DTP
DMH21D9	MA	Substrate
DMH21D9	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMH21D9	RU	https://doi.org/10.1007/s11095-012-0935-x

DM9WPIH	DI	DM9WPIH
DM9WPIH	DN	Ergonovine maleate
DM9WPIH	MI	DE4LYSA
DM9WPIH	MN	Cytochrome P450 3A4 (CYP3A4)
DM9WPIH	MT	DME
DM9WPIH	MA	Metabolism
DM9WPIH	RN	Rational prescription of drugs within similar therapeutic or structural class for gastrointestinal disease treatment: drug metabolism and its related interactions. World J Gastroenterol. 2007 Nov 14;13(42):5618-28.
DM9WPIH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17948937

DMKEGI3	DI	DMKEGI3
DMKEGI3	DN	Esmirtazapine
DMKEGI3	MI	DECB0K3
DMKEGI3	MN	Cytochrome P450 2D6 (CYP2D6)
DMKEGI3	MT	DME
DMKEGI3	MA	Metabolism
DMKEGI3	RN	Residual effects of esmirtazapine on actual driving performance: overall findings and an exploratory analysis into the role of CYP2D6 phenotype. Psychopharmacology (Berl). 2011 May;215(2):321-32.
DMKEGI3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21246188

DM7ITZK	DI	DM7ITZK
DM7ITZK	DN	Ethinylestradiol propanesulfonate
DM7ITZK	MI	DE4LYSA
DM7ITZK	MN	Cytochrome P450 3A4 (CYP3A4)
DM7ITZK	MT	DME
DM7ITZK	MA	Metabolism
DM7ITZK	RN	The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos. 2004 Nov;32(11):1209-12.
DM7ITZK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304426

DM8TNX3	DI	DM8TNX3
DM8TNX3	DN	Etizolam
DM8TNX3	MI	DEZMWRE
DM8TNX3	MN	Cytochrome P450 2C18 (CYP2C18)
DM8TNX3	MT	DME
DM8TNX3	MA	Metabolism
DM8TNX3	RN	Etizolam (INN) Pre-Review Report.
DM8TNX3	RU	https://erowid.org/pharms/etizolam/etizolam_article1_who_2016.pdf

DM8TNX3	DI	DM8TNX3
DM8TNX3	DN	Etizolam
DM8TNX3	MI	DE4LYSA
DM8TNX3	MN	Cytochrome P450 3A4 (CYP3A4)
DM8TNX3	MT	DME
DM8TNX3	MA	Metabolism
DM8TNX3	RN	Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism. Eur J Clin Pharmacol. 2004 Aug;60(6):427-30.
DM8TNX3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15232663

DM8TNX3	DI	DM8TNX3
DM8TNX3	DN	Etizolam
DM8TNX3	MI	DEGTFWK
DM8TNX3	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM8TNX3	MT	DME
DM8TNX3	MA	Metabolism
DM8TNX3	RN	Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines. J Clin Pharm Ther. 2007 Aug;32(4):333-41.
DM8TNX3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17635335

DMR7U8F	DI	DMR7U8F
DMR7U8F	DN	Etoperidone
DMR7U8F	MI	DE4LYSA
DMR7U8F	MN	Cytochrome P450 3A4 (CYP3A4)
DMR7U8F	MT	DME
DMR7U8F	MA	Metabolism
DMR7U8F	RN	In vitro identification of metabolic pathways and cytochrome P450 enzymes involved in the metabolism of etoperidone. Xenobiotica. 2002 Nov;32(11):949-62.
DMR7U8F	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12487725

DM9R1YU	DI	DM9R1YU
DM9R1YU	DN	Gestodene
DM9R1YU	MI	DE4LYSA
DM9R1YU	MN	Cytochrome P450 3A4 (CYP3A4)
DM9R1YU	MT	DME
DM9R1YU	MA	Metabolism
DM9R1YU	RN	Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1'-hydroxylation. Br J Clin Pharmacol. 2000 Oct;50(4):333-7.
DM9R1YU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11012556

DMDN4A1	DI	DMDN4A1
DMDN4A1	DN	Glitazone
DMDN4A1	MI	TTZMAO3
DMDN4A1	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMDN4A1	MT	DTT
DMDN4A1	MA	Agonist
DMDN4A1	RN	Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42.
DMDN4A1	RU	https://pubmed.ncbi.nlm.nih.gov/10828060

DMF72W3	DI	DMF72W3
DMF72W3	DN	Glyceryl trinitrate
DMF72W3	MI	DEAPJSO
DMF72W3	MN	Microsomal glutathione S-transferase 1 (MGST1)
DMF72W3	MT	DME
DMF72W3	MA	Metabolism
DMF72W3	RN	Microsomal glutathione transferase 1: mechanism and functional roles. Drug Metab Rev. 2011 May;43(2):300-6.
DMF72W3	RU	https://pubmed.ncbi.nlm.nih.gov/21495795

DM0OX31	DI	DM0OX31
DM0OX31	DN	Glypromate
DM0OX31	MI	DEIZ2D9
DM0OX31	MN	Tripeptidase (pepT)
DM0OX31	MT	DME
DM0OX31	MA	Metabolism
DM0OX31	RN	Tripeptidase gene (pepT) of Lactococcus lactis: molecular cloning and nucleotide sequencing of pepT and construction of a chromosomal deletion mutant. J Bacteriol. 1994 May;176(10):2854-61.
DM0OX31	RU	https://pubmed.ncbi.nlm.nih.gov/8188586

DM9BPLW	DI	DM9BPLW
DM9BPLW	DN	Grazoprevir
DM9BPLW	MI	DE4LYSA
DM9BPLW	MN	Cytochrome P450 3A4 (CYP3A4)
DM9BPLW	MT	DME
DM9BPLW	MA	Metabolism
DM9BPLW	RN	FDA label of Elbasvir and grazoprevir. The 2020 official website of the U.S. Food and Drug Administration.
DM9BPLW	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208261s002lbl.pdf

DMPN5IH	DI	DMPN5IH
DMPN5IH	DN	Guanfacine
DMPN5IH	MI	DTUGYRD
DMPN5IH	MN	P-glycoprotein 1 (ABCB1)
DMPN5IH	MT	DTP
DMPN5IH	MA	Substrate
DMPN5IH	RN	An in vitro evaluation of guanfacine as a substrate for P-glycoprotein. Neuropsychiatr Dis Treat. 2011;7:501-5.
DMPN5IH	RU	https://doi.org/10.2147/NDT.S24153

DMLYXBF	DI	DMLYXBF
DMLYXBF	DN	Guanoxan
DMLYXBF	MI	DECB0K3
DMLYXBF	MN	Cytochrome P450 2D6 (CYP2D6)
DMLYXBF	MT	DME
DMLYXBF	MA	Metabolism
DMLYXBF	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMLYXBF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM4OQRD	DI	DM4OQRD
DM4OQRD	DN	HIF-1alpha
DM4OQRD	MI	TT0LF7H
DM4OQRD	MN	Fibroblast growth factor receptor (FGFR)
DM4OQRD	MT	DTT
DM4OQRD	MA	Antagonist
DM4OQRD	RN	Tumor angiogenesis as a therapeutic target. Drug Discov Today. 2001 Oct 1;6(19):1005-1024.
DM4OQRD	RU	https://pubmed.ncbi.nlm.nih.gov/11576867

DM4OQRD	DI	DM4OQRD
DM4OQRD	DN	HIF-1alpha
DM4OQRD	MI	TTQHWNA
DM4OQRD	MN	Hypoxia-inducible factor 1 alpha (HIF-1A)
DM4OQRD	MT	DTT
DM4OQRD	MA	Inhibitor
DM4OQRD	RN	A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther. 2008 Nov;7(11):3598-608.
DM4OQRD	RU	https://pubmed.ncbi.nlm.nih.gov/18974394

DMYOC29	DI	DMYOC29
DMYOC29	DN	Hirudin
DMYOC29	MI	TT6L509
DMYOC29	MN	Coagulation factor IIa (F2)
DMYOC29	MT	DTT
DMYOC29	MA	Inhibitor
DMYOC29	RN	Probing the hirudin-thrombin interaction by incorporation of noncoded amino acids and molecular dynamics simulation. Biochemistry. 2002 Nov 19;41(46):13556-69.
DMYOC29	RU	https://pubmed.ncbi.nlm.nih.gov/12427016

DM0WD1V	DI	DM0WD1V
DM0WD1V	DN	Human calcitonin
DM0WD1V	MI	DE7PT32
DM0WD1V	MN	Alanyl aminopeptidase (ANPEP)
DM0WD1V	MT	DME
DM0WD1V	MA	Metabolism
DM0WD1V	RN	Renal metabolism of calcitonin. Am J Physiol. 1988 Apr;254(4 Pt 2):F593-600.
DM0WD1V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=2833122

DM0WD1V	DI	DM0WD1V
DM0WD1V	DN	Human calcitonin
DM0WD1V	MI	DELOWRJ
DM0WD1V	MN	Alpha-N-acetylglucosaminidase (NAG)
DM0WD1V	MT	DME
DM0WD1V	MA	Metabolism
DM0WD1V	RN	Renal metabolism of calcitonin. Am J Physiol. 1988 Apr;254(4 Pt 2):F593-600.
DM0WD1V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=2833122

DM0WD1V	DI	DM0WD1V
DM0WD1V	DN	Human calcitonin
DM0WD1V	MI	DEA3VM1
DM0WD1V	MN	Phosphoglucomutase 1 (PGM1)
DM0WD1V	MT	DME
DM0WD1V	MA	Metabolism
DM0WD1V	RN	Renal metabolism of calcitonin. Am J Physiol. 1988 Apr;254(4 Pt 2):F593-600.
DM0WD1V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=2833122

DMABXOZ	DI	DMABXOZ
DMABXOZ	DN	Hyaluronic acid
DMABXOZ	MI	DEV7UZD
DMABXOZ	MN	Hyaluronoglucosaminidase (nagH)
DMABXOZ	MT	DME
DMABXOZ	MA	Metabolism
DMABXOZ	RN	An extracellular enzyme with hyaluronidase and chondroitinase activities from some oral anaerobic spirochaetes. Microbiology. 1996 Sep;142 ( Pt 9):2567-76.
DMABXOZ	RU	https://pubmed.ncbi.nlm.nih.gov/8828225

DM8NWFD	DI	DM8NWFD
DM8NWFD	DN	Hypericum
DM8NWFD	MI	TTAWNKZ
DM8NWFD	MN	Norepinephrine transporter (NET)
DM8NWFD	MT	DTT
DM8NWFD	MA	Inhibitor
DM8NWFD	RN	The experimental and clinical pharmacology of St John's Wort (Hypericum perforatum L.). Mol Psychiatry. 1999 Jul;4(4):333-8.
DM8NWFD	RU	https://pubmed.ncbi.nlm.nih.gov/10483049

DMVXLOD	DI	DMVXLOD
DMVXLOD	DN	Imrecoxib
DMVXLOD	MI	DE5IED8
DMVXLOD	MN	Cytochrome P450 2C9 (CYP2C9)
DMVXLOD	MT	DME
DMVXLOD	MA	Metabolism
DMVXLOD	RN	Lack of effect of Imrecoxib, an innovative and moderate COX-2 inhibitor, on pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. Sci Rep. 2019 Oct 31;9(1):15774.
DMVXLOD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31673051

DMVXLOD	DI	DMVXLOD
DMVXLOD	DN	Imrecoxib
DMVXLOD	MI	TT8NGED
DMVXLOD	MN	Prostaglandin G/H synthase 1 (COX-1)
DMVXLOD	MT	DTT
DMVXLOD	MA	Inhibitor
DMVXLOD	RN	Synthesis and anti-inflammatory activity of the major metabolites of imrecoxib. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2270-2.
DMVXLOD	RU	https://pubmed.ncbi.nlm.nih.gov/19286379

DMVXLOD	DI	DMVXLOD
DMVXLOD	DN	Imrecoxib
DMVXLOD	MI	TTVKILB
DMVXLOD	MN	Prostaglandin G/H synthase 2 (COX-2)
DMVXLOD	MT	DTT
DMVXLOD	MA	Inhibitor
DMVXLOD	RN	Synthesis and anti-inflammatory activity of the major metabolites of imrecoxib. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2270-2.
DMVXLOD	RU	https://pubmed.ncbi.nlm.nih.gov/19286379

DM2R496	DI	DM2R496
DM2R496	DN	Indenolol
DM2R496	MI	DECB0K3
DM2R496	MN	Cytochrome P450 2D6 (CYP2D6)
DM2R496	MT	DME
DM2R496	MA	Metabolism
DM2R496	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DM2R496	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DMVPLNC	DI	DMVPLNC
DMVPLNC	DN	Ingrezza
DMVPLNC	MI	TTNZRI3
DMVPLNC	MN	Synaptic vesicle amine transporter (SLC18A2)
DMVPLNC	MT	DTT
DMVPLNC	MA	Antagonist
DMVPLNC	RN	VMAT2 Inhibitors and the Path to Ingrezza (Valbenazine). Prog Med Chem. 2018;57(1):87-111.
DMVPLNC	RU	https://pubmed.ncbi.nlm.nih.gov/29680151

DM7U58J	DI	DM7U58J
DM7U58J	DN	Isoflavone
DM7U58J	MI	DEUX61H
DM7U58J	MN	Biphenyl dioxygenase (bphC)
DM7U58J	MT	DME
DM7U58J	MA	Metabolism
DM7U58J	RN	Flavonoids biotransformation by bacterial non-heme dioxygenases, biphenyl and naphthalene dioxygenase. Appl Microbiol Biotechnol. 2011 Jul;91(2):219-28.
DM7U58J	RU	https://pubmed.ncbi.nlm.nih.gov/21626021

DM7U58J	DI	DM7U58J
DM7U58J	DN	Isoflavone
DM7U58J	MI	DEE76YZ
DM7U58J	MN	Naphthalene dioxygenase (doxB)
DM7U58J	MT	DME
DM7U58J	MA	Metabolism
DM7U58J	RN	Flavonoids biotransformation by bacterial non-heme dioxygenases, biphenyl and naphthalene dioxygenase. Appl Microbiol Biotechnol. 2011 Jul;91(2):219-28.
DM7U58J	RU	https://pubmed.ncbi.nlm.nih.gov/21626021

DM170OH	DI	DM170OH
DM170OH	DN	Ketazolam
DM170OH	MI	DE4LYSA
DM170OH	MN	Cytochrome P450 3A4 (CYP3A4)
DM170OH	MT	DME
DM170OH	MA	Metabolism
DM170OH	RN	Metabolic profile of oxazepam and related benzodiazepines: clinical and forensic aspects. Drug Metab Rev. 2017 Nov;49(4):451-463.
DM170OH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28903606

DMQP5I3	DI	DMQP5I3
DMQP5I3	DN	Lacidipine
DMQP5I3	MI	DE4LYSA
DMQP5I3	MN	Cytochrome P450 3A4 (CYP3A4)
DMQP5I3	MT	DME
DMQP5I3	MA	Metabolism
DMQP5I3	RN	The effects of lacidipine on the steady/state plasma concentrations of simvastatin in healthy subjects. Br J Clin Pharmacol. 2001 Feb;51(2):147-52.
DMQP5I3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11259986

DM5FABJ	DI	DM5FABJ
DM5FABJ	DN	LAROPIPRANT
DM5FABJ	MI	TTPADOQ
DM5FABJ	MN	HMG-CoA reductase (HMGCR)
DM5FABJ	MT	DTT
DM5FABJ	MA	Inhibitor
DM5FABJ	RN	A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
DM5FABJ	RU	https://pubmed.ncbi.nlm.nih.gov/23467907

DM5FABJ	DI	DM5FABJ
DM5FABJ	DN	LAROPIPRANT
DM5FABJ	MI	TTOFYT1
DM5FABJ	MN	Prostacyclin receptor (PTGIR)
DM5FABJ	MT	DTT
DM5FABJ	MA	Inhibitor
DM5FABJ	RN	Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
DM5FABJ	RU	https://pubmed.ncbi.nlm.nih.gov/17300164

DM5FABJ	DI	DM5FABJ
DM5FABJ	DN	LAROPIPRANT
DM5FABJ	MI	TTNVEIR
DM5FABJ	MN	Prostaglandin D2 receptor (PTGDR)
DM5FABJ	MT	DTT
DM5FABJ	MA	Inhibitor
DM5FABJ	RN	Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
DM5FABJ	RU	https://pubmed.ncbi.nlm.nih.gov/17300164

DM5FABJ	DI	DM5FABJ
DM5FABJ	DN	LAROPIPRANT
DM5FABJ	MI	TTQDMX5
DM5FABJ	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DM5FABJ	MT	DTT
DM5FABJ	MA	Inhibitor
DM5FABJ	RN	Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
DM5FABJ	RU	https://pubmed.ncbi.nlm.nih.gov/17300164

DM5FABJ	DI	DM5FABJ
DM5FABJ	DN	LAROPIPRANT
DM5FABJ	MI	TT1ZAVI
DM5FABJ	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DM5FABJ	MT	DTT
DM5FABJ	MA	Inhibitor
DM5FABJ	RN	Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
DM5FABJ	RU	https://pubmed.ncbi.nlm.nih.gov/17300164

DM5FABJ	DI	DM5FABJ
DM5FABJ	DN	LAROPIPRANT
DM5FABJ	MI	TTT2ZAR
DM5FABJ	MN	Prostaglandin F2-alpha receptor (PTGFR)
DM5FABJ	MT	DTT
DM5FABJ	MA	Inhibitor
DM5FABJ	RN	Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
DM5FABJ	RU	https://pubmed.ncbi.nlm.nih.gov/17300164

DM5FABJ	DI	DM5FABJ
DM5FABJ	DN	LAROPIPRANT
DM5FABJ	MI	TT2O84V
DM5FABJ	MN	Thromboxane A2 receptor (TBXA2R)
DM5FABJ	MT	DTT
DM5FABJ	MA	Inhibitor
DM5FABJ	RN	Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
DM5FABJ	RU	https://pubmed.ncbi.nlm.nih.gov/17300164

DM92S6N	DI	DM92S6N
DM92S6N	DN	Levamlodipine
DM92S6N	MI	DE4LYSA
DM92S6N	MN	Cytochrome P450 3A4 (CYP3A4)
DM92S6N	MT	DME
DM92S6N	MA	Metabolism
DM92S6N	RN	Amlodipine metabolism in human liver microsomes and roles of CYP3A4/5 in the dihydropyridine dehydrogenation. Drug Metab Dispos. 2014 Feb;42(2):245-9.
DM92S6N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24301608

DM92S6N	DI	DM92S6N
DM92S6N	DN	Levamlodipine
DM92S6N	MI	TTXHYV6
DM92S6N	MN	Voltage-gated L-type calcium channel (L-CaC)
DM92S6N	MT	DTT
DM92S6N	MA	Modulator
DM92S6N	RN	Effects of (S)-amlodipine and (R)-amlodipine on L-type calcium channel current of rat ventricular myocytes and cytosolic calcium of aortic smooth muscle cells. Pharmazie. 2008 Jun;63(6):470-4.
DM92S6N	RU	https://pubmed.ncbi.nlm.nih.gov/18604992

DM82JP0	DI	DM82JP0
DM82JP0	DN	Lynestrenol
DM82JP0	MI	DE5IED8
DM82JP0	MN	Cytochrome P450 2C9 (CYP2C9)
DM82JP0	MT	DME
DM82JP0	MA	Metabolism
DM82JP0	RN	Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone. J Steroid Biochem Mol Biol. 2008 May;110(1-2):56-66.
DM82JP0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18356043

DM82JP0	DI	DM82JP0
DM82JP0	DN	Lynestrenol
DM82JP0	MI	DE4LYSA
DM82JP0	MN	Cytochrome P450 3A4 (CYP3A4)
DM82JP0	MT	DME
DM82JP0	MA	Metabolism
DM82JP0	RN	Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone. J Steroid Biochem Mol Biol. 2008 May;110(1-2):56-66.
DM82JP0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18356043

DM82JP0	DI	DM82JP0
DM82JP0	DN	Lynestrenol
DM82JP0	MI	DEGTFWK
DM82JP0	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM82JP0	MT	DME
DM82JP0	MA	Metabolism
DM82JP0	RN	Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone. J Steroid Biochem Mol Biol. 2008 May;110(1-2):56-66.
DM82JP0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18356043

DM0UGYX	DI	DM0UGYX
DM0UGYX	DN	Medifoxamine
DM0UGYX	MI	DEJVYAZ
DM0UGYX	MN	Cytochrome P450 2A6 (CYP2A6)
DM0UGYX	MT	DME
DM0UGYX	MA	Metabolism
DM0UGYX	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM0UGYX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM0UGYX	DI	DM0UGYX
DM0UGYX	DN	Medifoxamine
DM0UGYX	MI	DE4LYSA
DM0UGYX	MN	Cytochrome P450 3A4 (CYP3A4)
DM0UGYX	MT	DME
DM0UGYX	MA	Metabolism
DM0UGYX	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM0UGYX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DME1X96	DI	DME1X96
DME1X96	DN	Mexazolam
DME1X96	MI	DE4LYSA
DME1X96	MN	Cytochrome P450 3A4 (CYP3A4)
DME1X96	MT	DME
DME1X96	MA	Metabolism
DME1X96	RN	A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. Drug Metab Dispos. 2001 Mar;29(3):282-8.
DME1X96	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11181496

DM2VOQ3	DI	DM2VOQ3
DM2VOQ3	DN	Mosapride
DM2VOQ3	MI	TT07C3Y
DM2VOQ3	MN	5-HT 4 receptor (HTR4)
DM2VOQ3	MT	DTT
DM2VOQ3	MA	Agonist
DM2VOQ3	RN	The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol. 2008 Jul;378(1):125-37.
DM2VOQ3	RU	https://pubmed.ncbi.nlm.nih.gov/18415081

DM2VOQ3	DI	DM2VOQ3
DM2VOQ3	DN	Mosapride
DM2VOQ3	MI	DE4LYSA
DM2VOQ3	MN	Cytochrome P450 3A4 (CYP3A4)
DM2VOQ3	MT	DME
DM2VOQ3	MA	Metabolism
DM2VOQ3	RN	The involvement of flavin-containing monooxygenase but not CYP3A4 in metabolism of itopride hydrochloride, a gastroprokinetic agent: comparison with cisapride and mosapride citrate. Drug Metab Dispos. 2000 Oct;28(10):1231-7.
DM2VOQ3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10997945

DMVILAD	DI	DMVILAD
DMVILAD	DN	MOTILIN
DMVILAD	MI	TT953CX
DMVILAD	MN	Motilin receptor (MLNR)
DMVILAD	MT	DTT
DMVILAD	MA	Inhibitor
DMVILAD	RN	Discovery of a new class of macrocyclic antagonists to the human motilin receptor. J Med Chem. 2006 Nov 30;49(24):7190-7.
DMVILAD	RU	https://pubmed.ncbi.nlm.nih.gov/17125271

DMHEAB1	DI	DMHEAB1
DMHEAB1	DN	Neupro
DMHEAB1	MI	TTWFZ1N
DMHEAB1	MN	Dopamine receptor (DR)
DMHEAB1	MT	DTT
DMHEAB1	MA	Agonist
DMHEAB1	RN	Rotigotine Transdermal Patch: A Review in Parkinson's Disease. CNS Drugs. 2019 Jul;33(7):707-718.
DMHEAB1	RU	https://pubmed.ncbi.nlm.nih.gov/31243728

DMRP8XB	DI	DMRP8XB
DMRP8XB	DN	Nomegestrol
DMRP8XB	MI	DE4LYSA
DMRP8XB	MN	Cytochrome P450 3A4 (CYP3A4)
DMRP8XB	MT	DME
DMRP8XB	MA	Metabolism
DMRP8XB	RN	Progestogens in menopausal hormone therapy. Prz Menopauzalny. 2015 Jun;14(2):134-43.
DMRP8XB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26327902

DMVAOME	DI	DMVAOME
DMVAOME	DN	Oleandomycin
DMVAOME	MI	DEYGVN4
DMVAOME	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMVAOME	MT	DME
DMVAOME	MA	Metabolism
DMVAOME	RN	Inversion of the anomeric configuration of the transferred sugar during inactivation of the macrolide antibiotic oleandomycin catalyzed by a macrolide glycosyltransferase. FEBS Lett. 2000 Jul 7;476(3):186-9.
DMVAOME	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10913610

DMQIMTK	DI	DMQIMTK
DMQIMTK	DN	Ombitasvir
DMQIMTK	MI	DTUGYRD
DMQIMTK	MN	P-glycoprotein 1 (ABCB1)
DMQIMTK	MT	DTP
DMQIMTK	MA	Substrate
DMQIMTK	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DMQIMTK	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DMPSKA5	DI	DMPSKA5
DMPSKA5	DN	Ortho-phosphate
DMPSKA5	MI	DEQ3EWA
DMPSKA5	MN	Maltose phosphorylase (malP)
DMPSKA5	MT	DME
DMPSKA5	MA	Metabolism
DMPSKA5	RN	Maltose phosphorylase from Lactobacillus brevis: purification, characterization, and application in a biosensor for ortho-phosphate. Enzyme Microb Technol. 1997 Nov 1;21(6):413-20.
DMPSKA5	RU	https://pubmed.ncbi.nlm.nih.gov/9343859

DMU1JVW	DI	DMU1JVW
DMU1JVW	DN	Otilonium
DMU1JVW	MI	DE4LYSA
DMU1JVW	MN	Cytochrome P450 3A4 (CYP3A4)
DMU1JVW	MT	DME
DMU1JVW	MA	Metabolism
DMU1JVW	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DMU1JVW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DMIGKA1	DI	DMIGKA1
DMIGKA1	DN	Ozagrel
DMIGKA1	MI	TTQBR95
DMIGKA1	MN	Stress-activated protein kinase 2a (p38 alpha)
DMIGKA1	MT	DTT
DMIGKA1	MA	Inhibitor
DMIGKA1	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMIGKA1	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMY2AEF	DI	DMY2AEF
DMY2AEF	DN	PAI-1
DMY2AEF	MI	TTGY7WI
DMY2AEF	MN	Urokinase-type plasminogen activator (PLAU)
DMY2AEF	MT	DTT
DMY2AEF	MA	Inhibitor
DMY2AEF	RN	Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst. 1995 May 17;87(10):751-6.
DMY2AEF	RU	https://pubmed.ncbi.nlm.nih.gov/7563153

DMIV8CT	DI	DMIV8CT
DMIV8CT	DN	Parecoxib
DMIV8CT	MI	DE4LYSA
DMIV8CT	MN	Cytochrome P450 3A4 (CYP3A4)
DMIV8CT	MT	DME
DMIV8CT	MA	Metabolism
DMIV8CT	RN	Simultaneous determination of parecoxib and its main metabolites valdecoxib and hydroxylated valdecoxib in mouse plasma with a sensitive LC-MS/MS method to elucidate the decreased drug metabolism of tumor bearing mice. J Pharm Biomed Anal. 2018 Sep 5;158:1-7.
DMIV8CT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29843006

DMIV8CT	DI	DMIV8CT
DMIV8CT	DN	Parecoxib
DMIV8CT	MI	TTSZDQU
DMIV8CT	MN	Lactotransferrin (LTF)
DMIV8CT	MT	DTT
DMIV8CT	MA	Inhibitor
DMIV8CT	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMIV8CT	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMQY873	DI	DMQY873
DMQY873	DN	Pentifylline
DMQY873	MI	DEJGDUW
DMQY873	MN	Cytochrome P450 1A2 (CYP1A2)
DMQY873	MT	DME
DMQY873	MA	Metabolism
DMQY873	RN	PharmGKB summary: caffeine pathway. Pharmacogenet Genomics. 2012 May;22(5):389-95.
DMQY873	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22293536

DM4OIMZ	DI	DM4OIMZ
DM4OIMZ	DN	Pinaverium
DM4OIMZ	MI	DE4LYSA
DM4OIMZ	MN	Cytochrome P450 3A4 (CYP3A4)
DM4OIMZ	MT	DME
DM4OIMZ	MA	Metabolism
DM4OIMZ	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DM4OIMZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DMWRYUH	DI	DMWRYUH
DMWRYUH	DN	Prasterone sulfate
DMWRYUH	MI	DERD86B
DMWRYUH	MN	Cytochrome P450 3A7 (CYP3A7)
DMWRYUH	MT	DME
DMWRYUH	MA	Metabolism
DMWRYUH	RN	CYP3A7*1C polymorphism, serum dehydroepiandrosterone sulfate level, and bone mineral density in postmenopausal women. Calcif Tissue Int. 2007 Mar;80(3):154-9.
DMWRYUH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17334880

DM6VFO1	DI	DM6VFO1
DM6VFO1	DN	Pregnenolone
DM6VFO1	MI	DEN0GVQ
DM6VFO1	MN	Beta-HSD adrenal and gonadal type (HSD3B2)
DM6VFO1	MT	DME
DM6VFO1	MA	Metabolism
DM6VFO1	RN	Structure/function relationships responsible for the kinetic differences between human type 1 and type 2 3beta-hydroxysteroid dehydrogenase and for the catalysis of the type 1 activity. J Biol Chem. 2002 Nov 8;277(45):42795-801.
DM6VFO1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12205101

DM6VFO1	DI	DM6VFO1
DM6VFO1	DN	Pregnenolone
DM6VFO1	MI	DE4LYSA
DM6VFO1	MN	Cytochrome P450 3A4 (CYP3A4)
DM6VFO1	MT	DME
DM6VFO1	MA	Metabolism
DM6VFO1	RN	Cytochrome P450 expression and regulation in CYP3A4/CYP2D6 double transgenic humanized mice. Drug Metab Dispos. 2008 Feb;36(2):435-41.
DM6VFO1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18048490

DM6VFO1	DI	DM6VFO1
DM6VFO1	DN	Pregnenolone
DM6VFO1	MI	DERDQWN
DM6VFO1	MN	Dihydrotestosterone oxidoreductase (HSD3B1)
DM6VFO1	MT	DME
DM6VFO1	MA	Metabolism
DM6VFO1	RN	Structure/function relationships responsible for the kinetic differences between human type 1 and type 2 3beta-hydroxysteroid dehydrogenase and for the catalysis of the type 1 activity. J Biol Chem. 2002 Nov 8;277(45):42795-801.
DM6VFO1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12205101

DM6VFO1	DI	DM6VFO1
DM6VFO1	DN	Pregnenolone
DM6VFO1	MI	TTPNQAC
DM6VFO1	MN	Estrogen-related receptor-alpha (ESRRA)
DM6VFO1	MT	DTT
DM6VFO1	MA	Agonist
DM6VFO1	RN	Suppression of adrenal function by low-dose prednisone: assessment with 24-hour urinary steroid hormone profiles--a review of five cases. Altern Med Rev. 2006 Mar;11(1):40-6.
DM6VFO1	RU	https://pubmed.ncbi.nlm.nih.gov/16597193

DM6VFO1	DI	DM6VFO1
DM6VFO1	DN	Pregnenolone
DM6VFO1	MI	DE0P6LK
DM6VFO1	MN	Sulfotransferase 2A1 (SULT2A1)
DM6VFO1	MT	DME
DM6VFO1	MA	Metabolism
DM6VFO1	RN	Expression and characterization of the human 3 beta-hydroxysteroid sulfotransferases (SULT2B1a and SULT2B1b). J Steroid Biochem Mol Biol. 2001 Jun;77(4-5):261-9.
DM6VFO1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11457664

DM6VFO1	DI	DM6VFO1
DM6VFO1	DN	Pregnenolone
DM6VFO1	MI	DEZBN53
DM6VFO1	MN	Sulfotransferase 2B1 (SULT2B1)
DM6VFO1	MT	DME
DM6VFO1	MA	Metabolism
DM6VFO1	RN	Expression and characterization of the human 3 beta-hydroxysteroid sulfotransferases (SULT2B1a and SULT2B1b). J Steroid Biochem Mol Biol. 2001 Jun;77(4-5):261-9.
DM6VFO1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11457664

DM8PTSY	DI	DM8PTSY
DM8PTSY	DN	Prenylamine
DM8PTSY	MI	DE4LYSA
DM8PTSY	MN	Cytochrome P450 3A4 (CYP3A4)
DM8PTSY	MT	DME
DM8PTSY	MA	Metabolism
DM8PTSY	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DM8PTSY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DM37FKA	DI	DM37FKA
DM37FKA	DN	Primovist
DM37FKA	MI	DT3D8F0
DM37FKA	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM37FKA	MT	DTP
DM37FKA	MA	Substrate
DM37FKA	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DM37FKA	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DM37FKA	DI	DM37FKA
DM37FKA	DN	Primovist
DM37FKA	MI	DT9C1TS
DM37FKA	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM37FKA	MT	DTP
DM37FKA	MA	Substrate
DM37FKA	RN	Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic anion transporters. Drug Metab Dispos. 2010 Jul;38(7):1024-8.
DM37FKA	RU	http://www.ncbi.nlm.nih.gov/pubmed/20406852

DMXL43T	DI	DMXL43T
DMXL43T	DN	Prulifloxacin
DMXL43T	MI	DESDN74
DMXL43T	MN	Serum paraoxonase/arylesterase 1 (PON1)
DMXL43T	MT	DME
DMXL43T	MA	Metabolism
DMXL43T	RN	Paraoxonases-1, -2 and -3: what are their functions? Chem Biol Interact. 2016 Nov 25;259(Pt B):51-62.
DMXL43T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27238723

DMF8CJ9	DI	DMF8CJ9
DMF8CJ9	DN	Pyridine
DMF8CJ9	MI	TTKNWZ4
DMF8CJ9	MN	Thromboxane-A synthase (TBXAS1)
DMF8CJ9	MT	DTT
DMF8CJ9	MA	Inhibitor
DMF8CJ9	RN	Highly selective inhibitors of thromboxane synthetase. 2. Pyridine derivatives. J Med Chem. 1981 Oct;24(10):1149-55.
DMF8CJ9	RU	https://pubmed.ncbi.nlm.nih.gov/7199089

DMBPN7T	DI	DMBPN7T
DMBPN7T	DN	Rupatadine
DMBPN7T	MI	DE5IED8
DMBPN7T	MN	Cytochrome P450 2C9 (CYP2C9)
DMBPN7T	MT	DME
DMBPN7T	MA	Metabolism
DMBPN7T	RN	Product Monograph of Xtandi Rupatadine (as rupatadine fumarate).
DMBPN7T	RU	http://www.pedia-pharm.com/en/wp-content/uploads/sites/3/2017/02/RUPALL-monograph-EN.pdf

DMBPN7T	DI	DMBPN7T
DMBPN7T	DN	Rupatadine
DMBPN7T	MI	DE4LYSA
DMBPN7T	MN	Cytochrome P450 3A4 (CYP3A4)
DMBPN7T	MT	DME
DMBPN7T	MA	Metabolism
DMBPN7T	RN	Rupatadine: pharmacological profile and its use in the treatment of allergic disorders. Expert Opin Pharmacother. 2006 Oct;7(14):1989-2001.
DMBPN7T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17020424

DMBPN7T	DI	DMBPN7T
DMBPN7T	DN	Rupatadine
DMBPN7T	MI	DEIBDNY
DMBPN7T	MN	Cytochrome P450 3A5 (CYP3A5)
DMBPN7T	MT	DME
DMBPN7T	MA	Metabolism
DMBPN7T	RN	CYP3A5*3 and MDR1 C3435T are influencing factors of inter-subject variability in rupatadine pharmacokinetics in healthy Chinese volunteers. Eur J Drug Metab Pharmacokinet. 2016 Apr;41(2):117-24.
DMBPN7T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25427746

DMBPN7T	DI	DMBPN7T
DMBPN7T	DN	Rupatadine
DMBPN7T	MI	TTTIBOJ
DMBPN7T	MN	Histamine H1 receptor (H1R)
DMBPN7T	MT	DTT
DMBPN7T	MA	Inhibitor
DMBPN7T	RN	Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.
DMBPN7T	RU	https://pubmed.ncbi.nlm.nih.gov/16220969

DMBPN7T	DI	DMBPN7T
DMBPN7T	DN	Rupatadine
DMBPN7T	MI	TTQL5VC
DMBPN7T	MN	Platelet-activating factor receptor (PTAFR)
DMBPN7T	MT	DTT
DMBPN7T	MA	Inhibitor
DMBPN7T	RN	Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.
DMBPN7T	RU	https://pubmed.ncbi.nlm.nih.gov/16220969

DMXBYQR	DI	DMXBYQR
DMXBYQR	DN	Silymarin
DMXBYQR	MI	TT2J34L
DMXBYQR	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMXBYQR	MT	DTT
DMXBYQR	MA	Inhibitor
DMXBYQR	RN	Anti-inflammatory and anti-arthritic activities of silymarin acting through inhibition of 5-lipoxygenase. Phytomedicine. 2000 Mar;7(1):21-4.
DMXBYQR	RU	https://pubmed.ncbi.nlm.nih.gov/10782486

DMXBYQR	DI	DMXBYQR
DMXBYQR	DN	Silymarin
DMXBYQR	MI	DEYGVN4
DMXBYQR	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMXBYQR	MT	DME
DMXBYQR	MA	Metabolism
DMXBYQR	RN	Role of UDP-glucuronosyltransferase 1A1 in the metabolism and pharmacokinetics of silymarin flavonolignans in patients with HCV and NAFLD. Molecules. 2017 Jan 15;22(1). pii: E142.
DMXBYQR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28098838

DMOSJD0	DI	DMOSJD0
DMOSJD0	DN	Sivelestat sodium hydrate
DMOSJD0	MI	TTPLTSQ
DMOSJD0	MN	Neutrophil elastase (NE)
DMOSJD0	MT	DTT
DMOSJD0	MA	Inhibitor
DMOSJD0	RN	Emerging therapies for treatment of acute lung injury and acute respiratory distress syndrome. Expert Opin Emerg Drugs. 2007 Sep;12(3):461-77.
DMOSJD0	RU	https://pubmed.ncbi.nlm.nih.gov/17874973

DMOSJD0	DI	DMOSJD0
DMOSJD0	DN	Sivelestat sodium hydrate
DMOSJD0	MI	TTEMV5X
DMOSJD0	MN	Serine protease unspecific (SP)
DMOSJD0	MT	DTT
DMOSJD0	MA	Inhibitor
DMOSJD0	RN	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
DMOSJD0	RU	https://pubmed.ncbi.nlm.nih.gov/16634702

DMTV7XH	DI	DMTV7XH
DMTV7XH	DN	SPN-812
DMTV7XH	MI	TT0K1SC
DMTV7XH	MN	5-HT 2B receptor (HTR2B)
DMTV7XH	MT	DTT
DMTV7XH	MA	Antagonist
DMTV7XH	RN	New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020 Aug 25;12:285-300.
DMTV7XH	RU	https://pubmed.ncbi.nlm.nih.gov/32943948

DMTV7XH	DI	DMTV7XH
DMTV7XH	DN	SPN-812
DMTV7XH	MI	TTAWNKZ
DMTV7XH	MN	Norepinephrine transporter (NET)
DMTV7XH	MT	DTT
DMTV7XH	MA	Antagonist
DMTV7XH	RN	New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020 Aug 25;12:285-300.
DMTV7XH	RU	https://pubmed.ncbi.nlm.nih.gov/32943948

DM4TX7J	DI	DM4TX7J
DM4TX7J	DN	Talipexole
DM4TX7J	MI	TTEX248
DM4TX7J	MN	Dopamine D2 receptor (D2R)
DM4TX7J	MT	DTT
DM4TX7J	MA	Agonist
DM4TX7J	RN	Effects of talipexole on emesis-related changes in abdominal afferent vagal activity and ileal serotonin metabolism in rats. Res Commun Mol Pathol Pharmacol. 1997 Jan;95(1):67-82.
DM4TX7J	RU	https://pubmed.ncbi.nlm.nih.gov/9055350

DM62IPN	DI	DM62IPN
DM62IPN	DN	Tenofovir disoproxil
DM62IPN	MI	DE4LYSA
DM62IPN	MN	Cytochrome P450 3A4 (CYP3A4)
DM62IPN	MT	DME
DM62IPN	MA	Metabolism
DM62IPN	RN	FDA label of Bictegravir, emtricitabine, and tenofovir alafenamide. The 2020 official website of the U.S. Food and Drug Administration.
DM62IPN	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210251s000lbl.pdf

DMC40UY	DI	DMC40UY
DMC40UY	DN	Tenofovir disoproxil
DMC40UY	MI	DTUGYRD
DMC40UY	MN	P-glycoprotein 1 (ABCB1)
DMC40UY	MT	DTP
DMC40UY	MA	Substrate
DMC40UY	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMC40UY	RU	https://doi.org/10.1007/s11095-012-0935-x

DM2M47Y	DI	DM2M47Y
DM2M47Y	DN	TKM-ApoB
DM2M47Y	MI	TTN1IE2
DM2M47Y	MN	APOB messenger RNA (APOB mRNA)
DM2M47Y	MT	DTT
DM2M47Y	RN	Current Progress of siRNA/shRNA Therapeutics in Clinical Trials. Biotechnol J. 2011 September; 6(9): 1130-1146.
DM2M47Y	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388104/

DM7NSI0	DI	DM7NSI0
DM7NSI0	DN	Urethane
DM7NSI0	MI	DE08Z3W
DM7NSI0	MN	Cytosolic phospholipase A2 (PLA2G4A)
DM7NSI0	MT	DME
DM7NSI0	MA	Metabolism
DM7NSI0	RN	Phospholipase A2 pathway association with macrophage-mediated polycarbonate-urethane biodegradation. Biomaterials. 2005 Jun;26(18):3881-9.
DM7NSI0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15626436

DMCOJPS	DI	DMCOJPS
DMCOJPS	DN	Vonoprazan
DMCOJPS	MI	DEPKLMQ
DMCOJPS	MN	Cytochrome P450 2B6 (CYP2B6)
DMCOJPS	MT	DME
DMCOJPS	MA	Metabolism
DMCOJPS	RN	In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica. 2017 Dec;47(12):1027-1034.
DMCOJPS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27414183

DMCOJPS	DI	DMCOJPS
DMCOJPS	DN	Vonoprazan
DMCOJPS	MI	DECB0K3
DMCOJPS	MN	Cytochrome P450 2D6 (CYP2D6)
DMCOJPS	MT	DME
DMCOJPS	MA	Metabolism
DMCOJPS	RN	In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica. 2017 Dec;47(12):1027-1034.
DMCOJPS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27414183

DMCOJPS	DI	DMCOJPS
DMCOJPS	DN	Vonoprazan
DMCOJPS	MI	DE4LYSA
DMCOJPS	MN	Cytochrome P450 3A4 (CYP3A4)
DMCOJPS	MT	DME
DMCOJPS	MA	Metabolism
DMCOJPS	RN	In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica. 2017 Dec;47(12):1027-1034.
DMCOJPS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27414183

DMCOJPS	DI	DMCOJPS
DMCOJPS	DN	Vonoprazan
DMCOJPS	MI	DEGTFWK
DMCOJPS	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMCOJPS	MT	DME
DMCOJPS	MA	Metabolism
DMCOJPS	RN	In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica. 2017 Dec;47(12):1027-1034.
DMCOJPS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27414183

DMCOJPS	DI	DMCOJPS
DMCOJPS	DN	Vonoprazan
DMCOJPS	MI	DE0P6LK
DMCOJPS	MN	Sulfotransferase 2A1 (SULT2A1)
DMCOJPS	MT	DME
DMCOJPS	MA	Metabolism
DMCOJPS	RN	In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica. 2017 Dec;47(12):1027-1034.
DMCOJPS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27414183

DMKV32D	DI	DMKV32D
DMKV32D	DN	Xylometazoline
DMKV32D	MI	TT2NUT5
DMKV32D	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMKV32D	MT	DTT
DMKV32D	MA	Modulator
DMKV32D	RN	Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39.
DMKV32D	RU	https://pubmed.ncbi.nlm.nih.gov/20030735

DM9RJH7	DI	DM9RJH7
DM9RJH7	DN	Zaltoprofen
DM9RJH7	MI	DE5IED8
DM9RJH7	MN	Cytochrome P450 2C9 (CYP2C9)
DM9RJH7	MT	DME
DM9RJH7	MA	Metabolism
DM9RJH7	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM9RJH7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM9RJH7	DI	DM9RJH7
DM9RJH7	DN	Zaltoprofen
DM9RJH7	MI	DE073H6
DM9RJH7	MN	Prostaglandin G/H synthase 1 (COX-1)
DM9RJH7	MT	DME
DM9RJH7	MA	Metabolism
DM9RJH7	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM9RJH7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM9RJH7	DI	DM9RJH7
DM9RJH7	DN	Zaltoprofen
DM9RJH7	MI	DEB3CV1
DM9RJH7	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DM9RJH7	MT	DME
DM9RJH7	MA	Metabolism
DM9RJH7	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM9RJH7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMXIRA0	DI	DMXIRA0
DMXIRA0	DN	RLX030
DMXIRA0	MI	TTMAHD1
DMXIRA0	MN	Relaxin receptor 1 (RXFP1)
DMXIRA0	MT	DTT
DMXIRA0	MA	Modulator
DMXIRA0	RN	Design of the RELAXin in acute heart failure study. Am Heart J. 2012 Feb;163(2):149-55.e1.
DMXIRA0	RU	https://pubmed.ncbi.nlm.nih.gov/22305830

DMOML9Q	DI	DMOML9Q
DMOML9Q	DN	Pancrecarb
DMOML9Q	MI	TT7MRGU
DMOML9Q	MN	Chymotrypsin (CTR)
DMOML9Q	MT	DTT
DMOML9Q	MA	Modulator
DMOML9Q	RN	US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT.
DMOML9Q	RU	http://www.patentbuddy.com/Patent/20120251516?ft=true&sr=true

DMOML9Q	DI	DMOML9Q
DMOML9Q	DN	Pancrecarb
DMOML9Q	MI	TTCGSZ4
DMOML9Q	MN	Pancreatic alpha-amylase (AMY2A)
DMOML9Q	MT	DTT
DMOML9Q	MA	Modulator
DMOML9Q	RN	Clinical pipeline report, company report or official report of Digestive Care.
DMOML9Q	RU	http://www.digestivecare.com/release102708.shtm

DMOML9Q	DI	DMOML9Q
DMOML9Q	DN	Pancrecarb
DMOML9Q	MI	TTXMY0J
DMOML9Q	MN	Pancreatic triacylglycerol lipase (PNLIP)
DMOML9Q	MT	DTT
DMOML9Q	MA	Modulator
DMOML9Q	RN	Clinical pipeline report, company report or official report of Digestive Care.
DMOML9Q	RU	http://www.digestivecare.com/release102708.shtm

DMF2O4T	DI	DMF2O4T
DMF2O4T	DN	(S)-FLURBIPROFEN
DMF2O4T	MI	TT8JRS7
DMF2O4T	MN	Beta-secretase (BACE)
DMF2O4T	MT	DTT
DMF2O4T	MA	Inhibitor
DMF2O4T	RN	The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23.
DMF2O4T	RU	https://pubmed.ncbi.nlm.nih.gov/16455248

DMF2O4T	DI	DMF2O4T
DMF2O4T	DN	(S)-FLURBIPROFEN
DMF2O4T	MI	TT9W8GU
DMF2O4T	MN	Gamma-secretase (GS)
DMF2O4T	MT	DTT
DMF2O4T	MA	Inhibitor
DMF2O4T	RN	The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23.
DMF2O4T	RU	https://pubmed.ncbi.nlm.nih.gov/16455248

DMF2O4T	DI	DMF2O4T
DMF2O4T	DN	(S)-FLURBIPROFEN
DMF2O4T	MI	TTZ3S8C
DMF2O4T	MN	Presenilin 1 (PSEN1)
DMF2O4T	MT	DTT
DMF2O4T	MA	Inhibitor
DMF2O4T	RN	The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23.
DMF2O4T	RU	https://pubmed.ncbi.nlm.nih.gov/16455248

DMF2O4T	DI	DMF2O4T
DMF2O4T	DN	(S)-FLURBIPROFEN
DMF2O4T	MI	TTWN3F4
DMF2O4T	MN	Presenilin 2 (PSEN2)
DMF2O4T	MT	DTT
DMF2O4T	MA	Inhibitor
DMF2O4T	RN	The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23.
DMF2O4T	RU	https://pubmed.ncbi.nlm.nih.gov/16455248

DMF2O4T	DI	DMF2O4T
DMF2O4T	DN	(S)-FLURBIPROFEN
DMF2O4T	MI	TT8NGED
DMF2O4T	MN	Prostaglandin G/H synthase 1 (COX-1)
DMF2O4T	MT	DTT
DMF2O4T	MA	Inhibitor
DMF2O4T	RN	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
DMF2O4T	RU	https://pubmed.ncbi.nlm.nih.gov/15974585

DMF2O4T	DI	DMF2O4T
DMF2O4T	DN	(S)-FLURBIPROFEN
DMF2O4T	MI	TTVKILB
DMF2O4T	MN	Prostaglandin G/H synthase 2 (COX-2)
DMF2O4T	MT	DTT
DMF2O4T	MA	Inhibitor
DMF2O4T	RN	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
DMF2O4T	RU	https://pubmed.ncbi.nlm.nih.gov/15974585

DMBRFUQ	DI	DMBRFUQ
DMBRFUQ	DN	B-cell lymphoma vaccine
DMBRFUQ	MI	TT6MP2Z
DMBRFUQ	MN	GMCSFR-alpha (CSF2RA)
DMBRFUQ	MT	DTT
DMBRFUQ	RN	Idiotypevaccinetherapy (BiovaxID) infollicularlymphomain first complete remission: Phase III clinical trial results, Journal of Clinical Oncology, Vol 27, No 18S (June 20 Supplement), 2009: 2.
DMBRFUQ	RU	http://meeting.ascopubs.org/cgi/content/abstract/27/18S/2?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=Idiotype+vaccine+therapy+(BiovaxID)+in+follicular+lymphoma+&searchid=1&FIRSTINDEX=0&volume=27&issue=18S&resourcetype=HWCIT

DMP5O1U	DI	DMP5O1U
DMP5O1U	DN	GSK2696273
DMP5O1U	MI	TTLP57V
DMP5O1U	MN	Adenosine deaminase (ADA)
DMP5O1U	MT	DTT
DMP5O1U	MA	Modulator
DMP5O1U	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline.
DMP5O1U	RU	https://www.gsk.com/en-gb/media/press-releases/2015/gsk-fondazione-telethon-and-ospedale-san-raffaele-announce-eu-regulatory-submission-for-gene-therapy-to-treat-rare-disease-ada-scid/

DMXSDJU	DI	DMXSDJU
DMXSDJU	DN	MPL-containing Pollinex allergy desensitization vaccine
DMXSDJU	MI	TTISGCA
DMXSDJU	MN	Toll-like receptor 4 (TLR4)
DMXSDJU	MT	DTT
DMXSDJU	RN	Allergy Therapeutics PLC. News Announcement. Allergy Therapeutics. Clinical Trials. Allergy Therapeutics PLC. 11 October 2006.
DMXSDJU	RU	http://miranda.hemscott.com/ir/agy/ir.jsp?page=news_regulatory&article=36483600159086

DMLRKJX	DI	DMLRKJX
DMLRKJX	DN	Neugranin
DMLRKJX	MI	TT5TQ2W
DMLRKJX	MN	Granulocyte colony-stimulating factor (CSF3)
DMLRKJX	MT	DTT
DMLRKJX	MA	Modulator
DMLRKJX	RN	Development and Characterization of a Novel Fusion Protein of a Mutated Granulocyte Colony-Stimulating Factor and Human Serum Albumin in Pichia pastoris. PLoS One. 2014; 9(12): e115840.
DMLRKJX	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4275271/

DMUY09W	DI	DMUY09W
DMUY09W	DN	SK-NBP601
DMUY09W	MI	TT1290U
DMUY09W	MN	Coagulation factor VIII (F8)
DMUY09W	MT	DTT
DMUY09W	MA	Inhibitor
DMUY09W	RN	Clinical pipeline report, company report or official report of SK Chemicals.
DMUY09W	RU	http://www.skchemicals.com/en/about/rd_result.asp

DM26I8H	DI	DM26I8H
DM26I8H	DN	TK-DLI
DM26I8H	MI	TTP3QRF
DM26I8H	MN	Thymidine kinase 1 (TK1)
DM26I8H	MT	DTT
DM26I8H	MA	Modulator
DM26I8H	RN	Company report (Takara Bio)
DM26I8H	RU	http://www.takara-bio.com/news_e/2008/10/07.htm

DMYA6TR	DI	DMYA6TR
DMYA6TR	DN	Human coagulation factor X
DMYA6TR	MI	TTCIHJA
DMYA6TR	MN	Coagulation factor Xa (F10)
DMYA6TR	MT	DTT
DMYA6TR	MA	Modulator
DMYA6TR	RN	Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7.
DMYA6TR	RU	https://pubmed.ncbi.nlm.nih.gov/22844656

DMNCY1I	DI	DMNCY1I
DMNCY1I	DN	(-)-Phenserine
DMNCY1I	MI	TT1RS9F
DMNCY1I	MN	Acetylcholinesterase (AChE)
DMNCY1I	MT	DTT
DMNCY1I	MA	Inhibitor
DMNCY1I	RN	Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. Bioorg Med Chem. 2010 Jul 1;18(13):4687-93. 
DMNCY1I	RU	https://pubmed.ncbi.nlm.nih.gov/20627738

DMNCY1I	DI	DMNCY1I
DMNCY1I	DN	(-)-Phenserine
DMNCY1I	MI	TTEB0GD
DMNCY1I	MN	Cholinesterase (BCHE)
DMNCY1I	MT	DTT
DMNCY1I	MA	Inhibitor
DMNCY1I	RN	Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. Bioorg Med Chem. 2010 Jul 1;18(13):4687-93. 
DMNCY1I	RU	https://pubmed.ncbi.nlm.nih.gov/20627738

DMLRHM5	DI	DMLRHM5
DMLRHM5	DN	[3H](R)-(-)-baclofen
DMLRHM5	MI	TTDCVZW
DMLRHM5	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMLRHM5	MT	DTT
DMLRHM5	MA	Agonist
DMLRHM5	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 242).
DMLRHM5	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=242

DM3YEV0	DI	DM3YEV0
DM3YEV0	DN	131I-labelled aCD45
DM3YEV0	MI	TTUS45N
DM3YEV0	MN	Leukocyte common antigen (PTPRC)
DM3YEV0	MT	DTT
DM3YEV0	RN	131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood. 2006 Mar 1;107(5):2184-91.
DM3YEV0	RU	https://pubmed.ncbi.nlm.nih.gov/16254140

DMTZ1A5	DI	DMTZ1A5
DMTZ1A5	DN	13-cis-retinoic acid
DMTZ1A5	MI	TTOD7B3
DMTZ1A5	MN	Retinoic acid receptor (RAR)
DMTZ1A5	MT	DTT
DMTZ1A5	MA	Modulator
DMTZ1A5	RN	13-cis retinoic acid exerts its specific activity on human sebocytes through selective intracellular isomerization to all-trans retinoic acid and binding to retinoid acid receptors. J Invest Dermatol. 2000 Aug;115(2):321-7.
DMTZ1A5	RU	https://pubmed.ncbi.nlm.nih.gov/10951254

DMP5L8S	DI	DMP5L8S
DMP5L8S	DN	177Lu-DOTA-octreotate
DMP5L8S	MI	TTOMNR9
DMP5L8S	MN	Somatostatin receptor (SSTR)
DMP5L8S	MT	DTT
DMP5L8S	MA	Modulator
DMP5L8S	RN	Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. Pancreas. 2014 May;43(4):518-25.
DMP5L8S	RU	https://pubmed.ncbi.nlm.nih.gov/24632546

DMQ0IZ6	DI	DMQ0IZ6
DMQ0IZ6	DN	177Lu-labelled PSMA-617
DMQ0IZ6	MI	TT9G4N0
DMQ0IZ6	MN	Glutamate carboxypeptidase II (GCPII)
DMQ0IZ6	MT	DTT
DMQ0IZ6	RN	[177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer]. Nuklearmedizin. 2016 Jun 28;55(3):123-8.
DMQ0IZ6	RU	https://pubmed.ncbi.nlm.nih.gov/27350005

DMMZS2T	DI	DMMZS2T
DMMZS2T	DN	177-Lu-oxodotreotide
DMMZS2T	MI	TTOMNR9
DMMZS2T	MN	Somatostatin receptor (SSTR)
DMMZS2T	MT	DTT
DMMZS2T	MA	Agonist
DMMZS2T	RN	Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1(Suppl 1):S103-12.
DMMZS2T	RU	https://pubmed.ncbi.nlm.nih.gov/22388631

DMX178V	DI	DMX178V
DMX178V	DN	177-Lu-PSMA-617
DMX178V	MI	TT9G4N0
DMX178V	MN	Glutamate carboxypeptidase II (GCPII)
DMX178V	MT	DTT
DMX178V	MA	Agonist
DMX178V	RN	Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer. Cureus. 2020 Jun 30;12(6):e8921.
DMX178V	RU	https://pubmed.ncbi.nlm.nih.gov/32760622

DME2A8X	DI	DME2A8X
DME2A8X	DN	5-methoxypsoralen
DME2A8X	MI	DE6OQ3W
DME2A8X	MN	Cytochrome P450 1A1 (CYP1A1)
DME2A8X	MT	DME
DME2A8X	MA	Metabolism
DME2A8X	RN	Cytochrome P450 CYP1B1 interacts with 8-methoxypsoralen (8-MOP) and influences psoralen-ultraviolet A (PUVA) sensitivity. PLoS One. 2013 Sep 23;8(9):e75494.
DME2A8X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24086543

DME2A8X	DI	DME2A8X
DME2A8X	DN	5-methoxypsoralen
DME2A8X	MI	DEJGDUW
DME2A8X	MN	Cytochrome P450 1A2 (CYP1A2)
DME2A8X	MT	DME
DME2A8X	MA	Metabolism
DME2A8X	RN	Cytochrome P450 CYP1B1 interacts with 8-methoxypsoralen (8-MOP) and influences psoralen-ultraviolet A (PUVA) sensitivity. PLoS One. 2013 Sep 23;8(9):e75494.
DME2A8X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24086543

DME2A8X	DI	DME2A8X
DME2A8X	DN	5-methoxypsoralen
DME2A8X	MI	DE9QHP6
DME2A8X	MN	Cytochrome P450 1B1 (CYP1B1)
DME2A8X	MT	DME
DME2A8X	MA	Metabolism
DME2A8X	RN	Cytochrome P450 CYP1B1 interacts with 8-methoxypsoralen (8-MOP) and influences psoralen-ultraviolet A (PUVA) sensitivity. PLoS One. 2013 Sep 23;8(9):e75494.
DME2A8X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24086543

DME2A8X	DI	DME2A8X
DME2A8X	DN	5-methoxypsoralen
DME2A8X	MI	DEJVYAZ
DME2A8X	MN	Cytochrome P450 2A6 (CYP2A6)
DME2A8X	MT	DME
DME2A8X	MA	Metabolism
DME2A8X	RN	Cytochrome P450 CYP1B1 interacts with 8-methoxypsoralen (8-MOP) and influences psoralen-ultraviolet A (PUVA) sensitivity. PLoS One. 2013 Sep 23;8(9):e75494.
DME2A8X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24086543

DME2A8X	DI	DME2A8X
DME2A8X	DN	5-methoxypsoralen
DME2A8X	MI	DEVDYN7
DME2A8X	MN	Cytochrome P450 2E1 (CYP2E1)
DME2A8X	MT	DME
DME2A8X	MA	Metabolism
DME2A8X	RN	Cytochrome P450 CYP1B1 interacts with 8-methoxypsoralen (8-MOP) and influences psoralen-ultraviolet A (PUVA) sensitivity. PLoS One. 2013 Sep 23;8(9):e75494.
DME2A8X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24086543

DME2A8X	DI	DME2A8X
DME2A8X	DN	5-methoxypsoralen
DME2A8X	MI	DE4LYSA
DME2A8X	MN	Cytochrome P450 3A4 (CYP3A4)
DME2A8X	MT	DME
DME2A8X	MA	Metabolism
DME2A8X	RN	Metabolism of 5-methoxypsoralen by Saccharomyces cerevisiae. Photochem Photobiol. 1991 Nov;54(5):689-95.
DME2A8X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1798745

DM4OHMP	DI	DM4OHMP
DM4OHMP	DN	A-3309
DM4OHMP	MI	TTPI1M5
DM4OHMP	MN	Ileal sodium/bile acid cotransporter (SLC10A2)
DM4OHMP	MT	DTT
DM4OHMP	MA	Inhibitor
DM4OHMP	RN	Elobixibat for the treatment of constipation. Expert Opin Investig Drugs. 2013 Feb;22(2):277-84.
DM4OHMP	RU	https://pubmed.ncbi.nlm.nih.gov/23215781

DMJNSLU	DI	DMJNSLU
DMJNSLU	DN	AAV2-hRPE65v2
DMJNSLU	MI	TTBOH16
DMJNSLU	MN	Retinal pigment epithelium protein (RPE65)
DMJNSLU	MT	DTT
DMJNSLU	MA	Modulator
DMJNSLU	RN	AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med. 2012 Feb 8;4(120):120ra15.
DMJNSLU	RU	https://pubmed.ncbi.nlm.nih.gov/22323828

DMPDQ8T	DI	DMPDQ8T
DMPDQ8T	DN	AB-103
DMPDQ8T	MI	TTQ13FT
DMPDQ8T	MN	T-cell-specific surface glycoprotein CD28 (CD28)
DMPDQ8T	MT	DTT
DMPDQ8T	MA	Antagonist
DMPDQ8T	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPDQ8T	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMUES7Y	DI	DMUES7Y
DMUES7Y	DN	AB154
DMUES7Y	MI	TTWNL74
DMUES7Y	MN	V-set and immunoglobulin domain-containing protein 9 (TIGIT)
DMUES7Y	MT	DTT
DMUES7Y	MA	Inhibitor
DMUES7Y	RN	Clinical pipeline report, company report or official report of Arcus Biosciences.
DMUES7Y	RU	https://arcusbio.com/domvanalimab/

DMMWO7V	DI	DMMWO7V
DMMWO7V	DN	ABBV-951
DMMWO7V	MI	TTWFZ1N
DMMWO7V	MN	Dopamine receptor (DR)
DMMWO7V	MT	DTT
DMMWO7V	MA	Activator
DMMWO7V	RN	Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson's Disease. Ann Neurol. 2021 Jul;90(1):52-61.
DMMWO7V	RU	https://pubmed.ncbi.nlm.nih.gov/33772855

DMCKPG4	DI	DMCKPG4
DMCKPG4	DN	ABC294640
DMCKPG4	MI	TTCN0M9
DMCKPG4	MN	Sphingosine kinase 2 (SPHK2)
DMCKPG4	MT	DTT
DMCKPG4	MA	Modulator
DMCKPG4	RN	Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702.
DMCKPG4	RU	https://pubmed.ncbi.nlm.nih.gov/23954895

DM91LGU	DI	DM91LGU
DM91LGU	DN	Abexinostat
DM91LGU	MI	TTBH0VX
DM91LGU	MN	Histone deacetylase (HDAC)
DM91LGU	MT	DTT
DM91LGU	MA	Modulator
DM91LGU	RN	Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. Invest New Drugs. 2015 Apr;33(2):423-31.
DM91LGU	RU	https://pubmed.ncbi.nlm.nih.gov/25600050

DMMF5K4	DI	DMMF5K4
DMMF5K4	DN	ABL 001
DMMF5K4	MI	TTS7G69
DMMF5K4	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMMF5K4	MT	DTT
DMMF5K4	MA	Inhibitor
DMMF5K4	RN	ABL001, a Potent Allosteric Inhibitor of BCR-ABL, Prevents Emergence of Resistant Disease When Administered in Combination with Nilotinib in an in Vivo Murine Model of Chronic Myeloid Leukemia, NorthBuilding, 2014, 120-125.
DMMF5K4	RU	https://ash.confex.com/ash/2014/webprogram/Paper76344.html

DM7EVUF	DI	DM7EVUF
DM7EVUF	DN	ABL001
DM7EVUF	MI	TTS7G69
DM7EVUF	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DM7EVUF	MT	DTT
DM7EVUF	MA	Inhibitor
DM7EVUF	RN	Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. N Engl J Med. 2019 Dec 12;381(24):2315-2326.
DM7EVUF	RU	https://pubmed.ncbi.nlm.nih.gov/31826340

DM2J4YB	DI	DM2J4YB
DM2J4YB	DN	ABP 501
DM2J4YB	MI	TTF8CQI
DM2J4YB	MN	Tumor necrosis factor (TNF)
DM2J4YB	MT	DTT
DM2J4YB	RN	Case study: biosimilar anti TNFalpha (Adalimumab) analysis of Fc effector functions. BMC Proc. 2013; 7(Suppl 6): P30.
DM2J4YB	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3980296/

DMDXE4I	DI	DMDXE4I
DMDXE4I	DN	ABP959
DMDXE4I	MI	TTKANGO
DMDXE4I	MN	Complement C5 (CO5)
DMDXE4I	MT	DTT
DMDXE4I	MA	Inhibitor
DMDXE4I	RN	A randomized, double-blind, single-dose, three-arm, parallel group study to determine pharmacokinetic similarity of ABP 959 and eculizumab (Soliris ?) in healthy male subjects. Eur J Haematol. 2020 Jul;105(1):66-74.
DMDXE4I	RU	https://pubmed.ncbi.nlm.nih.gov/32196749

DMNE56X	DI	DMNE56X
DMNE56X	DN	ABT-263
DMNE56X	MI	TTJGNVC
DMNE56X	MN	Apoptosis regulator Bcl-2 (BCL-2)
DMNE56X	MT	DTT
DMNE56X	MA	Inhibitor
DMNE56X	RN	Clinical pipeline report, company report or official report of Roche (2009).
DMNE56X	RU	http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm

DMNE56X	DI	DMNE56X
DMNE56X	DN	ABT-263
DMNE56X	MI	TTQ79W8
DMNE56X	MN	Apoptosis regulator Bcl-W (BCL-W)
DMNE56X	MT	DTT
DMNE56X	MA	Inhibitor
DMNE56X	RN	Clinical pipeline report, company report or official report of Roche (2009).
DMNE56X	RU	http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm

DMNE56X	DI	DMNE56X
DMNE56X	DN	ABT-263
DMNE56X	MI	TTU1E82
DMNE56X	MN	Apoptosis regulator Bcl-xL (BCL-xL)
DMNE56X	MT	DTT
DMNE56X	MA	Inhibitor
DMNE56X	RN	Clinical pipeline report, company report or official report of Roche (2009).
DMNE56X	RU	http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm

DMNE56X	DI	DMNE56X
DMNE56X	DN	ABT-263
DMNE56X	MI	DE4LYSA
DMNE56X	MN	Cytochrome P450 3A4 (CYP3A4)
DMNE56X	MT	DME
DMNE56X	MA	Metabolism
DMNE56X	RN	Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-XL , in patients with cancer. J Clin Pharm Ther. 2014 Dec;39(6):680-4.
DMNE56X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25047139

DMNE56X	DI	DMNE56X
DMNE56X	DN	ABT-263
DMNE56X	MI	TTFCJ7S
DMNE56X	MN	G1/S-specific cyclin-D1 (CCND1)
DMNE56X	MT	DTT
DMNE56X	MA	Inhibitor
DMNE56X	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMNE56X	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMNE56X	DI	DMNE56X
DMNE56X	DN	ABT-263
DMNE56X	MI	DTUGYRD
DMNE56X	MN	P-glycoprotein 1 (ABCB1)
DMNE56X	MT	DTP
DMNE56X	MA	Substrate
DMNE56X	RN	The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein. Biochem Biophys Res Commun. 2011 May 6;408(2):344-9.
DMNE56X	RU	https://doi.org/10.1016/j.bbrc.2011.04.043

DMNQ869	DI	DMNQ869
DMNQ869	DN	ABT-267
DMNQ869	MI	DES5XRU
DMNQ869	MN	Cytochrome P450 2C8 (CYP2C8)
DMNQ869	MT	DME
DMNQ869	MA	Metabolism
DMNQ869	RN	Metabolism and disposition of pan-genotypic inhibitor of hepatitis C virus NS5A ombitasvir in humans. Drug Metab Dispos. 2016 Aug;44(8):1148-57.
DMNQ869	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27179128

DMNQ869	DI	DMNQ869
DMNQ869	DN	ABT-267
DMNQ869	MI	TTCJ2X8
DMNQ869	MN	Hepatitis C virus Non-structural 5A (HCV NS5A)
DMNQ869	MT	DTT
DMNQ869	MA	Modulator
DMNQ869	RN	Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. J Med Chem. 2014 Mar 13;57(5):2047-57.
DMNQ869	RU	https://pubmed.ncbi.nlm.nih.gov/24400777

DMJFD2I	DI	DMJFD2I
DMJFD2I	DN	ABT-492
DMJFD2I	MI	TTIXTO3
DMJFD2I	MN	Staphylococcus Topoisomerase IV (Stap-coc parC)
DMJFD2I	MT	DTT
DMJFD2I	MA	Modulator
DMJFD2I	RN	Contrasting Effects of Acidic pH on the Extracellular and Intracellular Activities of the Anti-Gram-Positive Fluoroquinolones Moxifloxacin and Delafloxacin against Staphylococcus aureus
DMJFD2I	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3028753

DMJFD2I	DI	DMJFD2I
DMJFD2I	DN	ABT-492
DMJFD2I	MI	DEYGVN4
DMJFD2I	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMJFD2I	MT	DME
DMJFD2I	MA	Metabolism
DMJFD2I	RN	Delafloxacin: place in therapy and review of microbiologic, clinical and pharmacologic properties. Infect Dis Ther. 2018 Jun;7(2):197-217.
DMJFD2I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29605887

DM3FIC2	DI	DM3FIC2
DM3FIC2	DN	ABT-761
DM3FIC2	MI	TT2J34L
DM3FIC2	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM3FIC2	MT	DTT
DM3FIC2	MA	Inhibitor
DM3FIC2	RN	Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circ Cardiovasc Imaging. 2010 May;3(3):298-307.
DM3FIC2	RU	https://pubmed.ncbi.nlm.nih.gov/20190281

DM3FIC2	DI	DM3FIC2
DM3FIC2	DN	ABT-761
DM3FIC2	MI	DE4LYSA
DM3FIC2	MN	Cytochrome P450 3A4 (CYP3A4)
DM3FIC2	MT	DME
DM3FIC2	MA	Metabolism
DM3FIC2	RN	Identification of the human liver cytochrome P450 enzymes involved in the in vitro metabolism of a novel 5-lipoxygenase inhibitor. Drug Metab Dispos. 1998 Oct;26(10):970-6.
DM3FIC2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9763401

DMREDYP	DI	DMREDYP
DMREDYP	DN	ABT-869
DMREDYP	MI	TTDCBX5
DMREDYP	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DMREDYP	MT	DTT
DMREDYP	MA	Modulator
DMREDYP	RN	Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther. 2006 Apr;5(4):995-1006.
DMREDYP	RU	https://pubmed.ncbi.nlm.nih.gov/16648571

DMYHSO2	DI	DMYHSO2
DMYHSO2	DN	ABT-874
DMYHSO2	MI	TTGW72V
DMYHSO2	MN	Interleukin-12 beta (IL12B)
DMYHSO2	MT	DTT
DMYHSO2	MA	Modulator
DMYHSO2	RN	Briakinumab for the treatment of plaque psoriasis.BioDrugs.2012 Feb 1;26(1):9-20.
DMYHSO2	RU	https://www.ncbi.nlm.nih.gov/pubmed/22077474

DM4HYMS	DI	DM4HYMS
DM4HYMS	DN	ABT-888
DM4HYMS	MI	TTEBCY8
DM4HYMS	MN	Poly [ADP-ribose] polymerase (PARP)
DM4HYMS	MT	DTT
DM4HYMS	MA	Modulator
DM4HYMS	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM4HYMS	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMQRL2Y	DI	DMQRL2Y
DMQRL2Y	DN	AC0010
DMQRL2Y	MI	TTG96HZ
DMQRL2Y	MN	EGFR messenger RNA (EGFR mRNA)
DMQRL2Y	MT	DTT
DMQRL2Y	MA	Inhibitor
DMQRL2Y	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQRL2Y	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMXZ9T3	DI	DMXZ9T3
DMXZ9T3	DN	AC-170
DMXZ9T3	MI	TTTIBOJ
DMXZ9T3	MN	Histamine H1 receptor (H1R)
DMXZ9T3	MT	DTT
DMXZ9T3	MA	Antagonist
DMXZ9T3	RN	Clinical pipeline report, company report or official report of NicOx SA.
DMXZ9T3	RU	http://www.nicox.com/rd/ac-170/

DM8Y4JS	DI	DM8Y4JS
DM8Y4JS	DN	AC220
DM8Y4JS	MI	TTGJCWZ
DM8Y4JS	MN	Fms-like tyrosine kinase 3 (FLT-3)
DM8Y4JS	MT	DTT
DM8Y4JS	MA	Inhibitor
DM8Y4JS	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM8Y4JS	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM1RMF5	DI	DM1RMF5
DM1RMF5	DN	Acadesine
DM1RMF5	MI	TTLAFZV
DM1RMF5	MN	AMP-activated protein kinase (AMPK)
DM1RMF5	MT	DTT
DM1RMF5	MA	Modulator
DM1RMF5	RN	Acadesine, an adenosine-regulating agent with the potential for widespread indications. Expert Opin Pharmacother. 2008 Aug;9(12):2137-44.
DM1RMF5	RU	https://pubmed.ncbi.nlm.nih.gov/18671468

DMY96O3	DI	DMY96O3
DMY96O3	DN	acelarin
DMY96O3	MI	TTUBNVO
DMY96O3	MN	DNA synthesis (DNA synth)
DMY96O3	MT	DTT
DMY96O3	MA	Inhibitor
DMY96O3	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMY96O3	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM3UQ9K	DI	DM3UQ9K
DM3UQ9K	DN	Acolbifene
DM3UQ9K	MI	TTZAYWL
DM3UQ9K	MN	Estrogen receptor (ESR)
DM3UQ9K	MT	DTT
DM3UQ9K	MA	Modulator
DM3UQ9K	RN	Bioactivation of the selective estrogen receptor modulator acolbifene to quinone methides. Chem Res Toxicol. 2005 Feb;18(2):174-82.
DM3UQ9K	RU	https://pubmed.ncbi.nlm.nih.gov/15720121

DMXYRPO	DI	DMXYRPO
DMXYRPO	DN	Act1
DMXYRPO	MI	TT4F7SL
DMXYRPO	MN	Gap junction alpha-1 protein (GJA1)
DMXYRPO	MT	DTT
DMXYRPO	MA	Modulator
DMXYRPO	RN	Company report (FirstString Research)
DMXYRPO	RU	http://firststringresearch.com/platform-technology/

DMVLWG7	DI	DMVLWG7
DMVLWG7	DN	Ad5FGF-4
DMVLWG7	MI	TTCEKVZ
DMVLWG7	MN	Fibroblast growth factor-4 (FGF4)
DMVLWG7	MT	DTT
DMVLWG7	MA	Modulator
DMVLWG7	RN	Angiogenic gene therapy with adenovirus 5 fibroblast growth factor-4 (Ad5FGF-4): a new option for the treatment of coronary artery disease. Am J Cardiol. 2003 Nov 7;92(9B):24N-31N.
DMVLWG7	RU	https://pubmed.ncbi.nlm.nih.gov/14615023

DMFIP35	DI	DMFIP35
DMFIP35	DN	Adhexil
DMFIP35	MI	TTWODQF
DMFIP35	MN	Fibrin (FG)
DMFIP35	MT	DTT
DMFIP35	MA	Modulator
DMFIP35	RN	Evaluation of a fibrin preparation containing tranexamic acid (Adhexil) in a rabbit uterine horn model of adhesions with and without bleeding and in a model with two surgical loci. Fertil Steril. 2010 Mar 1;93(4):1045-51.
DMFIP35	RU	https://pubmed.ncbi.nlm.nih.gov/19147133

DMLBYRA	DI	DMLBYRA
DMLBYRA	DN	ADX N05
DMLBYRA	MI	TT5TPI6
DMLBYRA	MN	Opioid receptor sigma 1 (OPRS1)
DMLBYRA	MT	DTT
DMLBYRA	MA	Modulator
DMLBYRA	RN	Clinical pipeline report, company report or official report of SK BioPhamaceuticals.
DMLBYRA	RU	http://www.skbp.com/etc/news_view_14.asp

DMAYO46	DI	DMAYO46
DMAYO46	DN	AEZS-108
DMAYO46	MI	TT8R70G
DMAYO46	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMAYO46	MT	DTT
DMAYO46	MA	Modulator
DMAYO46	RN	Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinicalstudies. Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):829-34.
DMAYO46	RU	https://pubmed.ncbi.nlm.nih.gov/10639165

DMS0ZBI	DI	DMS0ZBI
DMS0ZBI	DN	Ag-221
DMS0ZBI	MI	TTDTWV0
DMS0ZBI	MN	Isocitrate dehydrogenase (IDH)
DMS0ZBI	MT	DTT
DMS0ZBI	MA	Inhibitor
DMS0ZBI	RN	New Developments in the Pathogenesis and Therapeutic Targeting of the IDH1 Mutation in Glioma. Int J Med Sci. 2015; 12(3): 201-213.
DMS0ZBI	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4323358/

DMIE1WY	DI	DMIE1WY
DMIE1WY	DN	AG-881
DMIE1WY	MI	TTDTWV0
DMIE1WY	MN	Isocitrate dehydrogenase (IDH)
DMIE1WY	MT	DTT
DMIE1WY	MA	Inhibitor
DMIE1WY	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMIE1WY	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMYN3IH	DI	DMYN3IH
DMYN3IH	DN	AGI-1067
DMYN3IH	MI	TT1AVS7
DMYN3IH	MN	Second phase insulin secretion (SPI secr)
DMYN3IH	MT	DTT
DMYN3IH	MA	Inhibitor
DMYN3IH	RN	AGI-1067, a novel antioxidant and anti-inflammatory agent, enhances insulin release and protects mouse islets. Mol Cell Endocrinol. 2010 Jul 29;323(2):246-55.
DMYN3IH	RU	https://pubmed.ncbi.nlm.nih.gov/20211684

DMJRQDG	DI	DMJRQDG
DMJRQDG	DN	AG-SPT201
DMJRQDG	MI	TTF1QVM
DMJRQDG	MN	Gastric H(+)/K(+) ATPase alpha (ATP4A)
DMJRQDG	MT	DTT
DMJRQDG	MA	Modulator
DMJRQDG	RN	Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole. J Gastroenterol Hepatol. 1999 Mar;14(3):251-7.
DMJRQDG	RU	https://pubmed.ncbi.nlm.nih.gov/10197495

DMS2WV3	DI	DMS2WV3
DMS2WV3	DN	AIDSVAX
DMS2WV3	MI	TTBYP1X
DMS2WV3	MN	Human immunodeficiency virus Envelope glycoprotein gp120 (HIV gp120)
DMS2WV3	MT	DTT
DMS2WV3	RN	HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen. Drugs R D. 2003;4(4):249-53.
DMS2WV3	RU	https://pubmed.ncbi.nlm.nih.gov/12848591

DM8SYTE	DI	DM8SYTE
DM8SYTE	DN	AIR-insulin
DM8SYTE	MI	TTF89GD
DM8SYTE	MN	Interleukin-2 (IL2)
DM8SYTE	MT	DTT
DM8SYTE	MA	Modulator
DM8SYTE	RN	The AIR inhaled insulin system: system components and pharmacokinetic/glucodynamic data. Diabetes Technol Ther. 2007 Jun;9 Suppl 1:S41-7.
DM8SYTE	RU	https://pubmed.ncbi.nlm.nih.gov/17563303

DM5K6J4	DI	DM5K6J4
DM5K6J4	DN	AJM-300
DM5K6J4	MI	TT6S84X
DM5K6J4	MN	Integrin alpha-4/beta-1 (ITGA4/B1)
DM5K6J4	MT	DTT
DM5K6J4	MA	Modulator
DM5K6J4	RN	Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice. J Crohns Colitis. 2013 Dec;7(11):e533-42.
DM5K6J4	RU	https://pubmed.ncbi.nlm.nih.gov/23623333

DM2EJM3	DI	DM2EJM3
DM2EJM3	DN	AKB-6548
DM2EJM3	MI	TTJQFBG
DM2EJM3	MN	HIF-prolyl hydroxylase (HPH)
DM2EJM3	MT	DTT
DM2EJM3	MA	Modulator
DM2EJM3	RN	DOI: 10.1038/nrd4422
DM2EJM3	RU	http://www.nature.com/nrd/journal/v13/n11/fig_tab/nrd4422_T2.html

DM3WP0N	DI	DM3WP0N
DM3WP0N	DN	Al3818
DM3WP0N	MI	DE4LYSA
DM3WP0N	MN	Cytochrome P450 3A4 (CYP3A4)
DM3WP0N	MT	DME
DM3WP0N	MA	Metabolism
DM3WP0N	RN	Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018 Sep 19;11(1):120.
DM3WP0N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30231931

DM3WP0N	DI	DM3WP0N
DM3WP0N	DN	Al3818
DM3WP0N	MI	DEIBDNY
DM3WP0N	MN	Cytochrome P450 3A5 (CYP3A5)
DM3WP0N	MT	DME
DM3WP0N	MA	Metabolism
DM3WP0N	RN	Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018 Sep 19;11(1):120.
DM3WP0N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30231931

DM3WP0N	DI	DM3WP0N
DM3WP0N	DN	Al3818
DM3WP0N	MI	TT6PKBN
DM3WP0N	MN	Proto-oncogene c-Src (SRC)
DM3WP0N	MT	DTT
DM3WP0N	MA	Inhibitor
DM3WP0N	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3WP0N	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMK0QW6	DI	DMK0QW6
DMK0QW6	DN	Albinterferon alfa-2b
DMK0QW6	MI	TTSIUJ9
DMK0QW6	MN	Interferon-alpha 2 (IFNA2)
DMK0QW6	MT	DTT
DMK0QW6	MA	Modulator
DMK0QW6	RN	Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C. Curr Med Res Opin. 2009 Apr;25(4):991-1002.
DMK0QW6	RU	https://pubmed.ncbi.nlm.nih.gov/19275518

DMWAL73	DI	DMWAL73
DMWAL73	DN	Albutropin
DMWAL73	MI	TTT3YKH
DMWAL73	MN	Somatotropin (GH1)
DMWAL73	MT	DTT
DMWAL73	MA	Modulator
DMWAL73	RN	Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys. Eur J Pharmacol. 2002 Dec 5;456(1-3):149-58.
DMWAL73	RU	https://pubmed.ncbi.nlm.nih.gov/12450581

DMHKCIS	DI	DMHKCIS
DMHKCIS	DN	Aldoxorubicin
DMHKCIS	MI	TT0IHXV
DMHKCIS	MN	DNA topoisomerase II (TOP2)
DMHKCIS	MT	DTT
DMHKCIS	MA	Modulator
DMHKCIS	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMHKCIS	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMPH1RK	DI	DMPH1RK
DMPH1RK	DN	Alferminogene tadenovec
DMPH1RK	MI	TTCEKVZ
DMPH1RK	MN	Fibroblast growth factor-4 (FGF4)
DMPH1RK	MT	DTT
DMPH1RK	MA	Modulator
DMPH1RK	RN	Alferminogene tadenovec, an angiogenic FGF4 gene therapy for coronary artery disease. IDrugs. 2008 Apr;11(4):283-93.
DMPH1RK	RU	https://pubmed.ncbi.nlm.nih.gov/18379964

DMVHRL8	DI	DMVHRL8
DMVHRL8	DN	Alfimeprase
DMVHRL8	MI	TTWODQF
DMVHRL8	MN	Fibrin (FG)
DMVHRL8	MT	DTT
DMVHRL8	MA	Modulator
DMVHRL8	RN	Disulfide structure of alfimeprase: A recombinant analog of fibrolase. Protein Sci. 2001 June; 10(6): 1264-1267.
DMVHRL8	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374009/

DMBQK0X	DI	DMBQK0X
DMBQK0X	DN	Algenpantucel-L
DMBQK0X	MI	TTPJ1I3
DMBQK0X	MN	Galactosyltransferase (GALT)
DMBQK0X	MT	DTT
DMBQK0X	RN	Recent Treatment Advances and Novel Therapies in Pancreas Cancer: A Review. J Gastrointest Cancer. 2014; 45(2): 190-201.
DMBQK0X	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4024386/

DMQ509J	DI	DMQ509J
DMQ509J	DN	Alicaforsen
DMQ509J	MI	TTA1L39
DMQ509J	MN	ICAM1 messenger RNA (ICAM1 mRNA)
DMQ509J	MT	DTT
DMQ509J	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009).
DMQ509J	RU	http://www.isispharm.com/Pipeline/index.htm

DMQ509J	DI	DMQ509J
DMQ509J	DN	Alicaforsen
DMQ509J	MI	TTCT6F7
DMQ509J	MN	Intercellular adhesion molecule ICAM-1 (ICAM1)
DMQ509J	MT	DTT
DMQ509J	MA	Antagonist
DMQ509J	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQ509J	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DM9R2SD	DI	DM9R2SD
DM9R2SD	DN	Alilusem
DM9R2SD	MI	DTPFTEQ
DM9R2SD	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DM9R2SD	MT	DTP
DM9R2SD	MA	Substrate
DM9R2SD	RN	Characterization of the uptake mechanism for a novel loop diuretic, M17055, in Caco-2 cells: involvement of organic anion transporting polypeptide (OATP)-B. Pharm Res. 2007 Jan;24(1):90-8.
DM9R2SD	RU	https://doi.org/10.1007/s11095-006-9127-x

DM9R2SD	DI	DM9R2SD
DM9R2SD	DN	Alilusem
DM9R2SD	MI	TTYJL7K
DM9R2SD	MN	Sodium/potassium transport (Na/K trans)
DM9R2SD	MT	DTT
DM9R2SD	MA	Modulator
DM9R2SD	RN	US patent application no. 8,067,031, Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use.
DM9R2SD	RU	http://www.google.lv/patents/US8067031

DM83EBP	DI	DM83EBP
DM83EBP	DN	Alisporivir
DM83EBP	MI	TTATDGJ
DM83EBP	MN	Calcium signal-modulating cyclophilin ligand (CAML)
DM83EBP	MT	DTT
DM83EBP	MA	Inhibitor
DM83EBP	RN	DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS One. 2010 Oct 27;5(10):e13687.
DM83EBP	RU	https://pubmed.ncbi.nlm.nih.gov/21060866

DM83EBP	DI	DM83EBP
DM83EBP	DN	Alisporivir
DM83EBP	MI	DE4LYSA
DM83EBP	MN	Cytochrome P450 3A4 (CYP3A4)
DM83EBP	MT	DME
DM83EBP	MA	Metabolism
DM83EBP	RN	Profile of alisporivir and its potential in the treatment of hepatitis C. Drug Des Devel Ther. 2013;7:105-15.
DM83EBP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23440335

DMCHA27	DI	DMCHA27
DMCHA27	DN	Almonertinib
DMCHA27	MI	TTGKNB4
DMCHA27	MN	Epidermal growth factor receptor (EGFR)
DMCHA27	MT	DTT
DMCHA27	MA	Inhibitor
DMCHA27	RN	Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. J Thorac Oncol. 2020 Dec;15(12):1907-1918.
DMCHA27	RU	https://pubmed.ncbi.nlm.nih.gov/32916310

DMFUOM7	DI	DMFUOM7
DMFUOM7	DN	ALN-TTRsc
DMFUOM7	MI	TTC1I86
DMFUOM7	MN	Transthyretin (TTR)
DMFUOM7	MT	DTT
DMFUOM7	MA	Inhibitor
DMFUOM7	RN	Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc.
DMFUOM7	RU	http://www.alnylam.com/product-pipeline/ttr-amyloidosis-fap/

DMKLBHX	DI	DMKLBHX
DMKLBHX	DN	ALO-02
DMKLBHX	MI	TTN4QDT
DMKLBHX	MN	Opioid receptor (OPR)
DMKLBHX	MT	DTT
DMKLBHX	MA	Modulator
DMKLBHX	RN	Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex. J Pain. 2005 Jun;6(6):392-9.
DMKLBHX	RU	https://pubmed.ncbi.nlm.nih.gov/15943961

DM2RTGP	DI	DM2RTGP
DM2RTGP	DN	Alpha-glucosidase
DM2RTGP	MI	TTXWASR
DM2RTGP	MN	Intestinal maltase-glucoamylase (MGAM)
DM2RTGP	MT	DTT
DM2RTGP	MA	Modulator
DM2RTGP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2627).
DM2RTGP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2627

DM7EBH9	DI	DM7EBH9
DM7EBH9	DN	ALX-0081
DM7EBH9	MI	TT3SZBT
DM7EBH9	MN	von Willebrand factor (VWF)
DM7EBH9	MT	DTT
DM7EBH9	MA	Binder
DM7EBH9	RN	Clinical pipeline report, company report or official report of Ablynx
DM7EBH9	RU	http://hugin.info/137912/R/1338761/319541.pdf

DMG5BTD	DI	DMG5BTD
DMG5BTD	DN	ALZT-OP1
DMG5BTD	MI	TTE4KHA
DMG5BTD	MN	Amyloid beta A4 protein (APP)
DMG5BTD	MT	DTT
DMG5BTD	MA	Inhibitor
DMG5BTD	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMG5BTD	RU	http://phrma-docs.phrma.org/files/dmfile/MID-Update_Alzheimers-Disease_2017-Drug-List.pdf

DMGMNUE	DI	DMGMNUE
DMGMNUE	DN	AM0010
DMGMNUE	MI	TTT0Q1F
DMGMNUE	MN	Interleukin-10 (IL10)
DMGMNUE	MT	DTT
DMGMNUE	MA	Modulator
DMGMNUE	RN	Clinical pipeline report, company report or official report of ARMO BioSciences.
DMGMNUE	RU	http://www.armobio.com/drug-development

DM4E9PK	DI	DM4E9PK
DM4E9PK	DN	AM-111
DM4E9PK	MI	TTR2TXZ
DM4E9PK	MN	Jun N terminal kinase (JNK)
DM4E9PK	MT	DTT
DM4E9PK	MA	Modulator
DM4E9PK	RN	The JNK inhibitor XG-102 protects against TNBS-induced colitis.PLoS One.2012;7(3):e30985.
DM4E9PK	RU	https://www.ncbi.nlm.nih.gov/pubmed/22427801

DMVOY6B	DI	DMVOY6B
DMVOY6B	DN	AMD-070
DMVOY6B	MI	TTBID49
DMVOY6B	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMVOY6B	MT	DTT
DMVOY6B	MA	Antagonist
DMVOY6B	RN	Pharmacokinetic effect of AMD070, an Oral CXCR4 antagonist, on CYP3A4 and CYP2D6 substrates midazolam and dextromethorphan in healthy volunteers. J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):559-65.
DMVOY6B	RU	https://pubmed.ncbi.nlm.nih.gov/18362694

DM4FPM3	DI	DM4FPM3
DM4FPM3	DN	Amediplase
DM4FPM3	MI	TTGY7WI
DM4FPM3	MN	Urokinase-type plasminogen activator (PLAU)
DM4FPM3	MT	DTT
DM4FPM3	MA	Activator
DM4FPM3	RN	Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
DM4FPM3	RU	https://pubmed.ncbi.nlm.nih.gov/16503827

DMG324Y	DI	DMG324Y
DMG324Y	DN	AMG 145
DMG324Y	MI	TTBRG7E
DMG324Y	MN	Proprotein convertase subtilisin/kexin type 9 (PCSK9)
DMG324Y	MT	DTT
DMG324Y	MA	Modulator
DMG324Y	RN	PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015 Jan 24;385(9965):331-40.
DMG324Y	RU	https://pubmed.ncbi.nlm.nih.gov/25282519

DMQJXL4	DI	DMQJXL4
DMQJXL4	DN	AMG 386
DMQJXL4	MI	TTWNQ1T
DMQJXL4	MN	Angiopoietin-1 (ANGPT1)
DMQJXL4	MT	DTT
DMQJXL4	MA	Modulator
DMQJXL4	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMQJXL4	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMQJXL4	DI	DMQJXL4
DMQJXL4	DN	AMG 386
DMQJXL4	MI	TTKLQTJ
DMQJXL4	MN	Angiopoietin-2 (ANGPT2)
DMQJXL4	MT	DTT
DMQJXL4	MA	Modulator
DMQJXL4	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMQJXL4	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMQJXL4	DI	DMQJXL4
DMQJXL4	DN	AMG 386
DMQJXL4	MI	TT9W8GU
DMQJXL4	MN	Gamma-secretase (GS)
DMQJXL4	MT	DTT
DMQJXL4	MA	Inhibitor
DMQJXL4	RN	Clinical pipeline report, company report or official report of Roche (2009).
DMQJXL4	RU	http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm

DMQJXL4	DI	DMQJXL4
DMQJXL4	DN	AMG 386
DMQJXL4	MI	TTD0CIQ
DMQJXL4	MN	Melanocortin receptor 4 (MC4R)
DMQJXL4	MT	DTT
DMQJXL4	MA	Agonist
DMQJXL4	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DMQJXL4	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMQJXL4	DI	DMQJXL4
DMQJXL4	DN	AMG 386
DMQJXL4	MI	TTLA931
DMQJXL4	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMQJXL4	MT	DTT
DMQJXL4	MA	Agonist
DMQJXL4	RN	Clinical pipeline report, company report or official report of Roche (2009).
DMQJXL4	RU	http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm

DMQJXL4	DI	DMQJXL4
DMQJXL4	DN	AMG 386
DMQJXL4	MI	TTN4QDT
DMQJXL4	MN	Opioid receptor (OPR)
DMQJXL4	MT	DTT
DMQJXL4	MA	Agonist
DMQJXL4	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DMQJXL4	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DMQJXL4	DI	DMQJXL4
DMQJXL4	DN	AMG 386
DMQJXL4	MI	TTBW580
DMQJXL4	MN	TAX transcriptionally-activated glycoprotein 1 (OX40)
DMQJXL4	MT	DTT
DMQJXL4	MA	Modulator
DMQJXL4	RN	Clinical targeting of the TNF and TNFR superfamilies.Nat Rev Drug Discov.2013 Feb;12(2):147-68.
DMQJXL4	RU	https://www.ncbi.nlm.nih.gov/pubmed/23334208

DMS1X67	DI	DMS1X67
DMS1X67	DN	Amitifadine
DMS1X67	MI	TTVBI8W
DMS1X67	MN	Dopamine transporter (DAT)
DMS1X67	MT	DTT
DMS1X67	MA	Inhibitor
DMS1X67	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 927).
DMS1X67	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=927

DMS1X67	DI	DMS1X67
DMS1X67	DN	Amitifadine
DMS1X67	MI	TTAWNKZ
DMS1X67	MN	Norepinephrine transporter (NET)
DMS1X67	MT	DTT
DMS1X67	MA	Inhibitor
DMS1X67	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 926).
DMS1X67	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=926

DMS1X67	DI	DMS1X67
DMS1X67	DN	Amitifadine
DMS1X67	MI	TT3ROYC
DMS1X67	MN	Serotonin transporter (SERT)
DMS1X67	MT	DTT
DMS1X67	MA	Inhibitor
DMS1X67	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 928).
DMS1X67	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=928

DMF50XJ	DI	DMF50XJ
DMF50XJ	DN	Amitriptyline+ketamine
DMF50XJ	MI	TT9IK2Z
DMF50XJ	MN	N-methyl-D-aspartate receptor (NMDAR)
DMF50XJ	MT	DTT
DMF50XJ	MA	Antagonist
DMF50XJ	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DMF50XJ	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DMZ7AMY	DI	DMZ7AMY
DMZ7AMY	DN	Amivantamab
DMZ7AMY	MI	TTGKNB4
DMZ7AMY	MN	Epidermal growth factor receptor (EGFR)
DMZ7AMY	MT	DTT
DMZ7AMY	MA	Inhibitor
DMZ7AMY	RN	Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020 Aug;10(8):1194-1209.
DMZ7AMY	RU	https://pubmed.ncbi.nlm.nih.gov/32414908

DMZ7AMY	DI	DMZ7AMY
DMZ7AMY	DN	Amivantamab
DMZ7AMY	MI	TTNDSF4
DMZ7AMY	MN	Proto-oncogene c-Met (MET)
DMZ7AMY	MT	DTT
DMZ7AMY	MA	Inhibitor
DMZ7AMY	RN	Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020 Aug;10(8):1194-1209.
DMZ7AMY	RU	https://pubmed.ncbi.nlm.nih.gov/32414908

DMB9587	DI	DMB9587
DMB9587	DN	Amocarzine
DMB9587	MI	TT1RS9F
DMB9587	MN	Acetylcholinesterase (AChE)
DMB9587	MT	DTT
DMB9587	MA	Inhibitor
DMB9587	RN	Activity, mechanism of action and pharmacokinetics of 2-tert-butylbenzothiazole and CGP 6140 (amocarzine) antifilarial drugs. Acta Trop. 1992 Aug;51(3-4):195-211.
DMB9587	RU	https://pubmed.ncbi.nlm.nih.gov/1359747

DM6SGUB	DI	DM6SGUB
DM6SGUB	DN	Amrubicin
DM6SGUB	MI	DE3N2FM
DM6SGUB	MN	NADPH-cytochrome P450 reductase (CPR)
DM6SGUB	MT	DME
DM6SGUB	MA	Metabolism
DM6SGUB	RN	Characterization of the enzymes involved in the in vitro metabolism of amrubicin hydrochloride. Xenobiotica. 2005 Dec;35(12):1121-33.
DM6SGUB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16418065

DM8QIRN	DI	DM8QIRN
DM8QIRN	DN	AMT-011
DM8QIRN	MI	TTOF3WZ
DM8QIRN	MN	Lipoprotein lipase (LPL)
DM8QIRN	MT	DTT
DM8QIRN	MA	Modulator
DM8QIRN	RN	Alipogene tiparvovec for the treatment of lipoprotein lipase deficiency. Drugs Today (Barc). 2013 Mar;49(3):161-70.
DM8QIRN	RU	https://pubmed.ncbi.nlm.nih.gov/23527320

DMSO02K	DI	DMSO02K
DMSO02K	DN	AMT-061
DMSO02K	MI	TTFEZ5Q
DMSO02K	MN	Coagulation factor IX (F9)
DMSO02K	MT	DTT
DMSO02K	RN	Clinical pipeline report, company report or official report of uniQure.
DMSO02K	RU	http://uniqure.com/gene-therapy/hemophilia.php

DMP2BFG	DI	DMP2BFG
DMP2BFG	DN	Anacetrapib
DMP2BFG	MI	TTFQAYR
DMP2BFG	MN	Cholesteryl ester transfer protein (CETP)
DMP2BFG	MT	DTT
DMP2BFG	MA	Inhibitor
DMP2BFG	RN	Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (C... Br J Clin Pharmacol. 2009 May;67(5):520-6.
DMP2BFG	RU	https://pubmed.ncbi.nlm.nih.gov/19552746

DMP2BFG	DI	DMP2BFG
DMP2BFG	DN	Anacetrapib
DMP2BFG	MI	DE4LYSA
DMP2BFG	MN	Cytochrome P450 3A4 (CYP3A4)
DMP2BFG	MT	DME
DMP2BFG	MA	Metabolism
DMP2BFG	RN	Metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans. Drug Metab Dispos. 2010 Mar;38(3):474-83.
DMP2BFG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20016053

DM2F9YO	DI	DM2F9YO
DM2F9YO	DN	Anakinra
DM2F9YO	MI	TTT7FOP
DM2F9YO	MN	HUMAN interleukin-1 receptor 1 (IL1R1)
DM2F9YO	MT	DTT
DM2F9YO	MA	Antagonist
DM2F9YO	RN	FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (BLA) 125166.
DM2F9YO	RU	http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Addlsearch_drug_name

DM6HXTS	DI	DM6HXTS
DM6HXTS	DN	Anamorelin
DM6HXTS	MI	TTHCF4J
DM6HXTS	MN	Alpha-glucosidase (GLA)
DM6HXTS	MT	DTT
DM6HXTS	MA	Modulator
DM6HXTS	RN	Absorption, elimination, and metabolism of CS-1036, a novel -amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.Drug Metab Dispos.2013 Apr;41(4):878-87.
DM6HXTS	RU	https://www.ncbi.nlm.nih.gov/pubmed/23378626

DM6HXTS	DI	DM6HXTS
DM6HXTS	DN	Anamorelin
DM6HXTS	MI	TTWDC17
DM6HXTS	MN	Growth hormone secretagogue receptor 1 (GHSR)
DM6HXTS	MT	DTT
DM6HXTS	MA	Stimulator
DM6HXTS	RN	Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers. Growth Horm IGF Res. 2009 Jun;19(3):267-73.
DM6HXTS	RU	https://pubmed.ncbi.nlm.nih.gov/19196529

DMK2Y4V	DI	DMK2Y4V
DMK2Y4V	DN	Ancrod
DMK2Y4V	MI	TTZUXYS
DMK2Y4V	MN	Vitamin K-dependent protein C (PROC)
DMK2Y4V	MT	DTT
DMK2Y4V	MA	Modulator
DMK2Y4V	RN	Ancrod (Arvin) as an alternative to heparin anticoagulation for cardiopulmonary bypass. Anesthesiology. 1989 Dec;71(6):870-7.
DMK2Y4V	RU	https://pubmed.ncbi.nlm.nih.gov/2589675

DMLDB1X	DI	DMLDB1X
DMLDB1X	DN	Andecaliximab
DMLDB1X	MI	TT6X50U
DMLDB1X	MN	Matrix metalloproteinase-9 (MMP-9)
DMLDB1X	MT	DTT
DMLDB1X	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMLDB1X	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMX36BH	DI	DMX36BH
DMX36BH	DN	Andolast
DMX36BH	MI	TT1VOHK
DMX36BH	MN	Potassium channel unspecific (KC)
DMX36BH	MT	DTT
DMX36BH	MA	Opener
DMX36BH	RN	BK channel modulators: a comprehensive overview. Curr Med Chem. 2008;15(11):1126-46.
DMX36BH	RU	https://pubmed.ncbi.nlm.nih.gov/18473808

DMITJAK	DI	DMITJAK
DMITJAK	DN	Androsterone
DMITJAK	MI	DEOCWU3
DMITJAK	MN	Alcohol dehydrogenase class-II (ADH4)
DMITJAK	MT	DME
DMITJAK	MA	Metabolism
DMITJAK	RN	13-cis-retinoic acid competitively inhibits 3 alpha-hydroxysteroid oxidation by retinol dehydrogenase RoDH-4: a mechanism for its anti-androgenic effects in sebaceous glands? Biochem Biophys Res Commun. 2003 Mar 28;303(1):273-8.
DMITJAK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12646198

DMITJAK	DI	DMITJAK
DMITJAK	DN	Androsterone
DMITJAK	MI	DEGQTXO
DMITJAK	MN	Aldo-keto reductase 1C3 (AKR1C3)
DMITJAK	MT	DME
DMITJAK	MA	Metabolism
DMITJAK	RN	Expression and characterization of four recombinant human dihydrodiol dehydrogenase isoforms: oxidation of trans-7, 8-dihydroxy-7,8-dihydrobenzo[a]pyrene to the activated o-quinone metabolite benzo[a]pyrene-7,8-dione. Biochemistry. 1998 May 12;37(19):6781-90.
DMITJAK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9578563

DMITJAK	DI	DMITJAK
DMITJAK	DN	Androsterone
DMITJAK	MI	DER0XCH
DMITJAK	MN	Farnesol dehydrogenase (AKR1B15)
DMITJAK	MT	DME
DMITJAK	MA	Metabolism
DMITJAK	RN	Aldo-keto Reductase 1B15 (AKR1B15): a mitochondrial human aldo-keto reductase with activity toward steroids and 3-keto-acyl-CoA conjugates. J Biol Chem. 2015 Mar 6;290(10):6531-45.
DMITJAK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25577493

DMITJAK	DI	DMITJAK
DMITJAK	DN	Androsterone
DMITJAK	MI	TTNJYV2
DMITJAK	MN	Gamma-aminobutyric acid receptor (GAR)
DMITJAK	MT	DTT
DMITJAK	MA	Inhibitor
DMITJAK	RN	Neurosteroid analogues. 11. Alternative ring system scaffolds: gamma-aminobutyric acid receptor modulation and anesthetic actions of benz[f]indenes. J Med Chem. 2006 Jul 27;49(15):4595-605.
DMITJAK	RU	https://pubmed.ncbi.nlm.nih.gov/16854065

DMITJAK	DI	DMITJAK
DMITJAK	DN	Androsterone
DMITJAK	MI	DESD26P
DMITJAK	MN	UDP-glucuronosyltransferase 1A6 (UGT1A6)
DMITJAK	MT	DME
DMITJAK	MA	Metabolism
DMITJAK	RN	Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev. 1999 Nov;31(4):817-99.
DMITJAK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10575553

DM76GZ0	DI	DM76GZ0
DM76GZ0	DN	Angiotensin-(1-7)
DM76GZ0	MI	DEGPI81
DM76GZ0	MN	Angiotensin-converting enzyme 2 (ACE2)
DM76GZ0	MT	DME
DM76GZ0	MA	Metabolism
DM76GZ0	RN	Metabolism of angiotensin-(1-7) by angiotensin-converting enzyme. Hypertension. 1998 Jan;31(1 Pt 2):362-7.
DM76GZ0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9453329

DM76GZ0	DI	DM76GZ0
DM76GZ0	DN	Angiotensin-(1-7)
DM76GZ0	MI	TTOISYB
DM76GZ0	MN	Proto-oncogene Mas (MAS)
DM76GZ0	MT	DTT
DM76GZ0	MA	Agonist
DM76GZ0	RN	New therapeutic pathways in the RAS. J Renin Angiotensin Aldosterone Syst. 2012 Dec;13(4):505-8.
DM76GZ0	RU	https://pubmed.ncbi.nlm.nih.gov/23166114

DM3FPAQ	DI	DM3FPAQ
DM3FPAQ	DN	Anifrolumab
DM3FPAQ	MI	TTMQB37
DM3FPAQ	MN	Interferon alpha/beta receptor 2 (IFNAR2)
DM3FPAQ	MT	DTT
DM3FPAQ	MA	Antagonist
DM3FPAQ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3FPAQ	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMX0PWV	DI	DMX0PWV
DMX0PWV	DN	Anti-IL-23
DMX0PWV	MI	TT6H4QR
DMX0PWV	MN	Interleukin 23 receptor (IL23R)
DMX0PWV	MT	DTT
DMX0PWV	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2293).
DMX0PWV	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2293

DMUYOC8	DI	DMUYOC8
DMUYOC8	DN	AP12009
DMUYOC8	MI	TTY9TWO
DMUYOC8	MN	Transforming growth factor beta 2 (TGFB2)
DMUYOC8	MT	DTT
DMUYOC8	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DMUYOC8	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DMD8QTC	DI	DMD8QTC
DMD8QTC	DN	Apadenoson
DMD8QTC	MI	TTM2AOE
DMD8QTC	MN	Adenosine A2a receptor (ADORA2A)
DMD8QTC	MT	DTT
DMD8QTC	MA	Agonist
DMD8QTC	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3290).
DMD8QTC	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3290

DMVY0BU	DI	DMVY0BU
DMVY0BU	DN	Apaziquone
DMVY0BU	MI	TTUTN1I
DMVY0BU	MN	Human Deoxyribonucleic acid (hDNA)
DMVY0BU	MT	DTT
DMVY0BU	MA	Modulator
DMVY0BU	RN	EO9 (Apaziquone): from the clinic to the laboratory and back again
DMVY0BU	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3569998

DMT0A3Y	DI	DMT0A3Y
DMT0A3Y	DN	APD-334
DMT0A3Y	MI	TT9JZCK
DMT0A3Y	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMT0A3Y	MT	DTT
DMT0A3Y	MA	Agonist
DMT0A3Y	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMT0A3Y	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DM4HQ52	DI	DM4HQ52
DM4HQ52	DN	APL-2
DM4HQ52	MI	TTJGY7A
DM4HQ52	MN	Complement C3 (CO3)
DM4HQ52	MT	DTT
DM4HQ52	MA	Inhibitor
DM4HQ52	RN	Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612.
DM4HQ52	RU	https://pubmed.ncbi.nlm.nih.gov/30072728

DMBRQF5	DI	DMBRQF5
DMBRQF5	DN	ApoC-III
DMBRQF5	MI	TT3GKN5
DMBRQF5	MN	Lipase unspecific (LIP)
DMBRQF5	MT	DTT
DMBRQF5	MA	Inhibitor
DMBRQF5	RN	An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor Int J Clin Pract. 2008 May;62(5):799-809.
DMBRQF5	RU	https://pubmed.ncbi.nlm.nih.gov/18201179

DM1K78U	DI	DM1K78U
DM1K78U	DN	Apricitabine
DM1K78U	MI	TT84ETX
DM1K78U	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM1K78U	MT	DTT
DM1K78U	MA	Modulator
DM1K78U	RN	Multiple-dose pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in patients with HIV-1 infection. Clin Drug Investig. 2008;28(2):129-38.
DM1K78U	RU	https://www.ncbi.nlm.nih.gov/pubmed/18211121

DM2YQK8	DI	DM2YQK8
DM2YQK8	DN	AR-301
DM2YQK8	MI	TT5FLYB
DM2YQK8	MN	Staphylococcus Alpha-hemolysin (Stap-coc hly)
DM2YQK8	MT	DTT
DM2YQK8	MA	Inhibitor
DM2YQK8	RN	Clinical pipeline report, company report or official report of Aridis Pharmaceuticals.
DM2YQK8	RU	https://www.aridispharma.com/ar-301/

DMZB9RI	DI	DMZB9RI
DMZB9RI	DN	Arabaclofen
DMZB9RI	MI	TTDCVZW
DMZB9RI	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMZB9RI	MT	DTT
DMZB9RI	MA	Agonist
DMZB9RI	RN	Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome. Psychopharmacology (Berl). 2013 Jul;228(1):75-84.
DMZB9RI	RU	https://pubmed.ncbi.nlm.nih.gov/23436129

DMO628K	DI	DMO628K
DMO628K	DN	Arbaclofen placarbil
DMO628K	MI	TTEX6LM
DMO628K	MN	GABA(A) receptor gamma-3 (GABRG3)
DMO628K	MT	DTT
DMO628K	MA	Agonist
DMO628K	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMO628K	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMO628K	DI	DMO628K
DMO628K	DN	Arbaclofen placarbil
DMO628K	MI	TTDCVZW
DMO628K	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMO628K	MT	DTT
DMO628K	MA	Modulator
DMO628K	RN	Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen.J Pharmacol Exp Ther.2009 Sep;330(3):911-21.
DMO628K	RU	https://www.ncbi.nlm.nih.gov/pubmed/19502531

DMYNJHI	DI	DMYNJHI
DMYNJHI	DN	Arc029
DMYNJHI	MI	DEVDYN7
DMYNJHI	MN	Cytochrome P450 2E1 (CYP2E1)
DMYNJHI	MT	DME
DMYNJHI	MA	Metabolism
DMYNJHI	RN	Effect of nilvadipine, a dihydropyridine calcium antagonist, on cytochrome P450 activities in human hepatic microsomes. Biol Pharm Bull. 2004 Mar;27(3):415-7.
DMYNJHI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14993813

DMYNJHI	DI	DMYNJHI
DMYNJHI	DN	Arc029
DMYNJHI	MI	DE4LYSA
DMYNJHI	MN	Cytochrome P450 3A4 (CYP3A4)
DMYNJHI	MT	DME
DMYNJHI	MA	Metabolism
DMYNJHI	RN	Effect of nilvadipine, a dihydropyridine calcium antagonist, on cytochrome P450 activities in human hepatic microsomes. Biol Pharm Bull. 2004 Mar;27(3):415-7.
DMYNJHI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14993813

DMYNJHI	DI	DMYNJHI
DMYNJHI	DN	Arc029
DMYNJHI	MI	TTZIFHC
DMYNJHI	MN	Voltage-gated calcium channel alpha Cav1.2 (CACNA1C)
DMYNJHI	MT	DTT
DMYNJHI	MA	Inhibitor
DMYNJHI	RN	Dihydropyrimidines: novel calcium antagonists with potent and long-lasting vasodilative and antihypertensive activity. J Med Chem. 1989 Oct;32(10):2399-406.
DMYNJHI	RU	https://pubmed.ncbi.nlm.nih.gov/2552119

DMYNJHI	DI	DMYNJHI
DMYNJHI	DN	Arc029
DMYNJHI	MI	TT7RGTM
DMYNJHI	MN	Voltage-gated calcium channel alpha Cav1.3 (CACNA1D)
DMYNJHI	MT	DTT
DMYNJHI	MA	Inhibitor
DMYNJHI	RN	Dihydropyrimidines: novel calcium antagonists with potent and long-lasting vasodilative and antihypertensive activity. J Med Chem. 1989 Oct;32(10):2399-406.
DMYNJHI	RU	https://pubmed.ncbi.nlm.nih.gov/2552119

DM180DM	DI	DM180DM
DM180DM	DN	ARGX-113
DM180DM	MI	TTKLPHO
DM180DM	MN	Neonatal Fc receptor (FCGRT)
DM180DM	MT	DTT
DM180DM	MA	Antagonist
DM180DM	RN	Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology. 2019 Jun 4;92(23):e2661-e2673.
DM180DM	RU	https://pubmed.ncbi.nlm.nih.gov/31118245

DM84AD1	DI	DM84AD1
DM84AD1	DN	Arofylline
DM84AD1	MI	TTV5CGO
DM84AD1	MN	Phosphodiesterase 4 (PDE4)
DM84AD1	MT	DTT
DM84AD1	MA	Inhibitor
DM84AD1	RN	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
DM84AD1	RU	https://pubmed.ncbi.nlm.nih.gov/16634702

DM02BVQ	DI	DM02BVQ
DM02BVQ	DN	ARQ-087
DM02BVQ	MI	TT0LF7H
DM02BVQ	MN	Fibroblast growth factor receptor (FGFR)
DM02BVQ	MT	DTT
DM02BVQ	MA	Antagonist
DM02BVQ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM02BVQ	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM02BVQ	DI	DM02BVQ
DM02BVQ	DN	ARQ-087
DM02BVQ	MI	TTRLW2X
DM02BVQ	MN	Fibroblast growth factor receptor 1 (FGFR1)
DM02BVQ	MT	DTT
DM02BVQ	MA	Inhibitor
DM02BVQ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1808).
DM02BVQ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1808

DML61S4	DI	DML61S4
DML61S4	DN	ARQ-151
DML61S4	MI	TTV5CGO
DML61S4	MN	Phosphodiesterase 4 (PDE4)
DML61S4	MT	DTT
DML61S4	MA	Inhibitor
DML61S4	RN	Trial of Roflumilast Cream for Chronic Plaque Psoriasis. N Engl J Med. 2020 Jul 16;383(3):229-239.
DML61S4	RU	https://pubmed.ncbi.nlm.nih.gov/32668113

DMD7XWS	DI	DMD7XWS
DMD7XWS	DN	AS-013
DMD7XWS	MI	TTG1QMU
DMD7XWS	MN	Prostaglandin E2 receptor EP1 (PTGER1)
DMD7XWS	MT	DTT
DMD7XWS	MA	Agonist
DMD7XWS	RN	Effect of lipo-pro-prostaglandin E1, AS-013 on rat inner ear microcirculatory thrombosis. Prostaglandins Leukot Essent Fatty Acids. 1998 Sep;59(3):203-7.
DMD7XWS	RU	https://pubmed.ncbi.nlm.nih.gov/9844994

DMIV1WR	DI	DMIV1WR
DMIV1WR	DN	AS-12141
DMIV1WR	MI	DEVSIE6
DMIV1WR	MN	Glyceraldehyde-3-phosphate dehydrogenase (gap)
DMIV1WR	MT	DME
DMIV1WR	MA	Metabolism
DMIV1WR	RN	Cloning, expression and characterization of a mucin-binding GAPDH from Lactobacillus acidophilus. Int J Biol Macromol. 2016 Oct;91:338-46.
DMIV1WR	RU	https://pubmed.ncbi.nlm.nih.gov/27180300

DMK09D4	DI	DMK09D4
DMK09D4	DN	ASC09 + ritonavir
DMK09D4	MI	TT1D53B
DMK09D4	MN	COVID-19 3C-like protease (3CLpro)
DMK09D4	MT	DTT
DMK09D4	MA	Inhibitor
DMK09D4	RN	Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381.
DMK09D4	RU	https://pubmed.ncbi.nlm.nih.gov/32205870

DMWE3SC	DI	DMWE3SC
DMWE3SC	DN	ASC09 + ritonavir + oseltamivir
DMWE3SC	MI	TT1D53B
DMWE3SC	MN	COVID-19 3C-like protease (3CLpro)
DMWE3SC	MT	DTT
DMWE3SC	MA	Inhibitor
DMWE3SC	RN	Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381.
DMWE3SC	RU	https://pubmed.ncbi.nlm.nih.gov/32205870

DMND3AB	DI	DMND3AB
DMND3AB	DN	Asimadoline
DMND3AB	MI	TTQW87Y
DMND3AB	MN	Opioid receptor kappa (OPRK1)
DMND3AB	MT	DTT
DMND3AB	MA	Agonist
DMND3AB	RN	Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
DMND3AB	RU	https://pubmed.ncbi.nlm.nih.gov/16634703

DMND3AB	DI	DMND3AB
DMND3AB	DN	Asimadoline
DMND3AB	MI	DTUGYRD
DMND3AB	MN	P-glycoprotein 1 (ABCB1)
DMND3AB	MT	DTP
DMND3AB	MA	Substrate
DMND3AB	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMND3AB	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMVA8KU	DI	DMVA8KU
DMVA8KU	DN	ASP0113
DMVA8KU	MI	TTK938H
DMVA8KU	MN	Cytomegalovirus Deoxyribonucleic acid (CMV DNA)
DMVA8KU	MT	DTT
DMVA8KU	RN	VCL-CB01, an injectable bivalent plasmid DNA vaccine for potential protection against CMV disease and infection. Curr Opin Mol Ther. 2009 Oct;11(5):572-8.
DMVA8KU	RU	https://pubmed.ncbi.nlm.nih.gov/19806506

DMZ1UOI	DI	DMZ1UOI
DMZ1UOI	DN	Asp-015K
DMZ1UOI	MI	TT6DM01
DMZ1UOI	MN	Janus kinase 1 (JAK-1)
DMZ1UOI	MT	DTT
DMZ1UOI	MA	Inhibitor
DMZ1UOI	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2047).
DMZ1UOI	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2047

DMZ1UOI	DI	DMZ1UOI
DMZ1UOI	DN	Asp-015K
DMZ1UOI	MI	TTT7PJU
DMZ1UOI	MN	Janus kinase 3 (JAK-3)
DMZ1UOI	MT	DTT
DMZ1UOI	MA	Inhibitor
DMZ1UOI	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2049).
DMZ1UOI	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2049

DMZ1UOI	DI	DMZ1UOI
DMZ1UOI	DN	Asp-015K
DMZ1UOI	MI	DECVGJ3
DMZ1UOI	MN	Nicotinamide N-methyltransferase (NNMT)
DMZ1UOI	MT	DME
DMZ1UOI	MA	Metabolism
DMZ1UOI	RN	Human mass balance, metabolite profile and identification of metabolic enzymes of [14C]ASP015K, a novel oral janus kinase inhibitor. Xenobiotica. 2015;45(10):887-902.
DMZ1UOI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25986538

DMZ1UOI	DI	DMZ1UOI
DMZ1UOI	DN	Asp-015K
DMZ1UOI	MI	DE0P6LK
DMZ1UOI	MN	Sulfotransferase 2A1 (SULT2A1)
DMZ1UOI	MT	DME
DMZ1UOI	MA	Metabolism
DMZ1UOI	RN	Human mass balance, metabolite profile and identification of metabolic enzymes of [14C]ASP015K, a novel oral janus kinase inhibitor. Xenobiotica. 2015;45(10):887-902.
DMZ1UOI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25986538

DMZ1UOI	DI	DMZ1UOI
DMZ1UOI	DN	Asp-015K
DMZ1UOI	MI	TTJSQEF
DMZ1UOI	MN	Tyrosine-protein kinase (PTK)
DMZ1UOI	MT	DTT
DMZ1UOI	MA	Inhibitor
DMZ1UOI	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZ1UOI	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMR71ST	DI	DMR71ST
DMR71ST	DN	ASP1929
DMR71ST	MI	TTGKNB4
DMR71ST	MN	Epidermal growth factor receptor (EGFR)
DMR71ST	MT	DTT
DMR71ST	MA	Inhibitor
DMR71ST	RN	ClinicalTrials.gov (NCT04305795) An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors. U.S. National Institutes of Health.
DMR71ST	RU	https://clinicaltrials.gov/ct2/show/NCT04305795

DMGQ1TV	DI	DMGQ1TV
DMGQ1TV	DN	ASP1941
DMGQ1TV	MI	TTLWPVF
DMGQ1TV	MN	Sodium/glucose cotransporter 2 (SGLT2)
DMGQ1TV	MT	DTT
DMGQ1TV	MA	Modulator
DMGQ1TV	RN	Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.World J Diabetes.2015 Feb 15;6(1):136-44.
DMGQ1TV	RU	https://www.ncbi.nlm.nih.gov/pubmed/25685284

DM5N1OB	DI	DM5N1OB
DM5N1OB	DN	Asp-2151
DM5N1OB	MI	DE4LYSA
DM5N1OB	MN	Cytochrome P450 3A4 (CYP3A4)
DM5N1OB	MT	DME
DM5N1OB	MA	Metabolism
DM5N1OB	RN	Amenamevir: studies of potential CYP3A-mediated pharmacokinetic interactions with midazolam, cyclosporine, and ritonavir in healthy volunteers. Clin Pharmacol Drug Dev. 2018 Nov;7(8):844-859.
DM5N1OB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30044899

DM5N1OB	DI	DM5N1OB
DM5N1OB	DN	Asp-2151
DM5N1OB	MI	TTKCVJR
DM5N1OB	MN	Herpes simplex virus Helicase-primase (HSV UL8)
DM5N1OB	MT	DTT
DM5N1OB	MA	Inhibitor
DM5N1OB	RN	Efficacy of ASP2151, a helicase-primase inhibitor, against thymidine kinase-deficient herpes simplex virus type 2 infection in vitro and in vivo. Antiviral Res. 2012 Feb;93(2):301-4.
DM5N1OB	RU	https://pubmed.ncbi.nlm.nih.gov/22155691

DMLY0H5	DI	DMLY0H5
DMLY0H5	DN	Astuprotimut-R
DMLY0H5	MI	TTWSKHD
DMLY0H5	MN	Melanoma-associated antigen 3 (MAGEA3)
DMLY0H5	MT	DTT
DMLY0H5	MA	Modulator
DMLY0H5	RN	National Cancer Institute Drug Dictionary (drug id 600553).
DMLY0H5	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=600553

DM4HK8Z	DI	DM4HK8Z
DM4HK8Z	DN	ASTX727
DM4HK8Z	MI	TTHVCUP
DM4HK8Z	MN	DNA [cytosine-5]-methyltransferase (DNMT)
DM4HK8Z	MT	DTT
DM4HK8Z	MA	Inhibitor
DM4HK8Z	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM4HK8Z	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMRV4DT	DI	DMRV4DT
DMRV4DT	DN	AT1001
DMRV4DT	MI	TTLC8E1
DMRV4DT	MN	Haptoglobin (HP)
DMRV4DT	MT	DTT
DMRV4DT	MA	Modulator
DMRV4DT	RN	Zonulin, regulation of tight junctions, and autoimmune diseases
DMRV4DT	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3384703

DMVJW0S	DI	DMVJW0S
DMVJW0S	DN	AT-406
DMVJW0S	MI	TTQ5LRD
DMVJW0S	MN	Cellular inhibitor of apoptosis 1 (BIRC2)
DMVJW0S	MT	DTT
DMVJW0S	MA	Inhibitor
DMVJW0S	RN	Debio 1143, an antagonist of multiple inhibitor-of-apoptosis proteins, activates apoptosis and enhances radiosensitization of non-small cell lung c... Am J Cancer Res. 2014 Nov 19;4(6):943-51.
DMVJW0S	RU	https://pubmed.ncbi.nlm.nih.gov/25520882

DMVJW0S	DI	DMVJW0S
DMVJW0S	DN	AT-406
DMVJW0S	MI	TTIRY6K
DMVJW0S	MN	Cellular inhibitor of apoptosis 2 (BIRC3)
DMVJW0S	MT	DTT
DMVJW0S	MA	Inhibitor
DMVJW0S	RN	Debio 1143, an antagonist of multiple inhibitor-of-apoptosis proteins, activates apoptosis and enhances radiosensitization of non-small cell lung c... Am J Cancer Res. 2014 Nov 19;4(6):943-51.
DMVJW0S	RU	https://pubmed.ncbi.nlm.nih.gov/25520882

DMVJW0S	DI	DMVJW0S
DMVJW0S	DN	AT-406
DMVJW0S	MI	TTS74QB
DMVJW0S	MN	Inhibitor of apoptosis protein (hIAP)
DMVJW0S	MT	DTT
DMVJW0S	MA	Modulator
DMVJW0S	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7729).
DMVJW0S	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7729

DMVJW0S	DI	DMVJW0S
DMVJW0S	DN	AT-406
DMVJW0S	MI	TTR7B60
DMVJW0S	MN	X-linked inhibitor of apoptosis protein (XIAP)
DMVJW0S	MT	DTT
DMVJW0S	MA	Inhibitor
DMVJW0S	RN	Debio 1143, an antagonist of multiple inhibitor-of-apoptosis proteins, activates apoptosis and enhances radiosensitization of non-small cell lung c... Am J Cancer Res. 2014 Nov 19;4(6):943-51.
DMVJW0S	RU	https://pubmed.ncbi.nlm.nih.gov/25520882

DMQ94CT	DI	DMQ94CT
DMQ94CT	DN	AT9283
DMQ94CT	MI	TTPS3C0
DMQ94CT	MN	Aurora kinase A (AURKA)
DMQ94CT	MT	DTT
DMQ94CT	MA	Modulator
DMQ94CT	RN	A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study. Clin Cancer Res. 2015 Jan 15;21(2):267-73.
DMQ94CT	RU	https://pubmed.ncbi.nlm.nih.gov/25370467

DMQ94CT	DI	DMQ94CT
DMQ94CT	DN	AT9283
DMQ94CT	MI	TT5LS6T
DMQ94CT	MN	Aurora kinase B (AURKB)
DMQ94CT	MT	DTT
DMQ94CT	MA	Modulator
DMQ94CT	RN	A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study. Clin Cancer Res. 2015 Jan 15;21(2):267-73.
DMQ94CT	RU	https://pubmed.ncbi.nlm.nih.gov/25370467

DM8GFEV	DI	DM8GFEV
DM8GFEV	DN	Atacicept
DM8GFEV	MI	TTOI1RM
DM8GFEV	MN	A proliferation-inducing ligand (APRIL)
DM8GFEV	MT	DTT
DM8GFEV	MA	Modulator
DM8GFEV	RN	Atacicept: a new B lymphocyte-targeted therapy for multiple sclerosis. Nervenarzt. 2009 Dec;80(12):1462-72.
DM8GFEV	RU	https://pubmed.ncbi.nlm.nih.gov/19779889

DM4GXW3	DI	DM4GXW3
DM4GXW3	DN	Ataluren
DM4GXW3	MI	TT2TNRM
DM4GXW3	MN	Dystrophin nonsense mutant (DMD)
DM4GXW3	MT	DTT
DM4GXW3	MA	Modulator
DM4GXW3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7341).
DM4GXW3	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7341

DM4GXW3	DI	DM4GXW3
DM4GXW3	DN	Ataluren
DM4GXW3	MI	DE85D2P
DM4GXW3	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DM4GXW3	MT	DME
DM4GXW3	MA	Metabolism
DM4GXW3	RN	Ataluren pharmacokinetics in healthy Japanese and Caucasian subjects. Clin Pharmacol Drug Dev. 2019 Feb;8(2):172-178.
DM4GXW3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30629861

DM3QLK2	DI	DM3QLK2
DM3QLK2	DN	Atamestane + Toremifene
DM3QLK2	MI	TTSZLWK
DM3QLK2	MN	Aromatase (CYP19A1)
DM3QLK2	MT	DTT
DM3QLK2	MA	Modulator
DM3QLK2	RN	Toremifene-atamestane; alone or in combination: predictions from the preclinical intratumoral aromatase model. J Steroid Biochem Mol Biol. 2008 Jan;108(1-2):1-7.
DM3QLK2	RU	https://pubmed.ncbi.nlm.nih.gov/17942301

DM4VJ5Q	DI	DM4VJ5Q
DM4VJ5Q	DN	ATG-Fresenius S
DM4VJ5Q	MI	TTXQYT6
DM4VJ5Q	MN	T-cells (T-cells)
DM4VJ5Q	MT	DTT
DM4VJ5Q	RN	Clinical pipeline report, company report or official report of Neovii Biotech.
DM4VJ5Q	RU	http://www.neoviibiotech.com/products-and-pipeline/atg-fresenius.html

DMBR0QK	DI	DMBR0QK
DMBR0QK	DN	Atorvastatin
DMBR0QK	MI	TTDJB68
DMBR0QK	MN	HUMAN MYD88NF-kappa-B proinflammatory pathway (MYD88-NFKB pathway)
DMBR0QK	MT	DTT
DMBR0QK	MA	Inhibitor
DMBR0QK	RN	Statin therapy in COVID-19 infection. Eur Heart J Cardiovasc Pharmacother. 2020 Apr 29. pii: pvaa042.
DMBR0QK	RU	https://pubmed.ncbi.nlm.nih.gov/32347925

DMM74PK	DI	DMM74PK
DMM74PK	DN	Atrasentan
DMM74PK	MI	DE4LYSA
DMM74PK	MN	Cytochrome P450 3A4 (CYP3A4)
DMM74PK	MT	DME
DMM74PK	MA	Metabolism
DMM74PK	RN	Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. Clin Pharmacol Ther. 2006 Mar;79(3):186-96.
DMM74PK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16513443

DMM74PK	DI	DMM74PK
DMM74PK	DN	Atrasentan
DMM74PK	MI	TTKRD0G
DMM74PK	MN	Endothelin A receptor (EDNRA)
DMM74PK	MT	DTT
DMM74PK	MA	Antagonist
DMM74PK	RN	Effects of a selective ET(A)-receptor antagonist, atrasentan (ABT-627), in murine models of allergic asthma: demonstration of mouse strain specificity. Clin Sci (Lond). 2002 Aug;103 Suppl 48:367S-370S.
DMM74PK	RU	https://pubmed.ncbi.nlm.nih.gov/12193124

DMM74PK	DI	DMM74PK
DMM74PK	DN	Atrasentan
DMM74PK	MI	DTE2B1D
DMM74PK	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMM74PK	MT	DTP
DMM74PK	MA	Substrate
DMM74PK	RN	Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. Clin Pharmacol Ther. 2006 Mar;79(3):186-96.
DMM74PK	RU	https://doi.org/10.1016/j.clpt.2005.11.003

DMM74PK	DI	DMM74PK
DMM74PK	DN	Atrasentan
DMM74PK	MI	DT3D8F0
DMM74PK	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMM74PK	MT	DTP
DMM74PK	MA	Substrate
DMM74PK	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DMM74PK	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DMM74PK	DI	DMM74PK
DMM74PK	DN	Atrasentan
DMM74PK	MI	DT9C1TS
DMM74PK	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMM74PK	MT	DTP
DMM74PK	MA	Substrate
DMM74PK	RN	Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. Clin Pharmacol Ther. 2006 Mar;79(3):186-96.
DMM74PK	RU	https://doi.org/10.1016/j.clpt.2005.11.003

DM64WYC	DI	DM64WYC
DM64WYC	DN	Atx-101
DM64WYC	MI	TTLG1PD
DM64WYC	MN	Proliferating cell nuclear antigen (PCNA)
DM64WYC	MT	DTT
DM64WYC	MA	Immunomodulator
DM64WYC	RN	Targeting proliferating cell nuclear antigen and its protein interactions induces apoptosis in multiple myeloma cells. PLoS One. 2013 Jul 31;8(7):e70430.
DM64WYC	RU	https://pubmed.ncbi.nlm.nih.gov/23936203

DM0EQ9X	DI	DM0EQ9X
DM0EQ9X	DN	Av 133
DM0EQ9X	MI	TTNZRI3
DM0EQ9X	MN	Synaptic vesicle amine transporter (SLC18A2)
DM0EQ9X	MT	DTT
DM0EQ9X	MA	Enhancer
DM0EQ9X	RN	Brain imaging of vesicular monoamine transporter type 2 in healthy aging subjects by 18F-FP-(+)-DTBZ PET. PLoS One. 2013 Sep 30;8(9):e75952.
DM0EQ9X	RU	https://pubmed.ncbi.nlm.nih.gov/24098749

DMPW5UF	DI	DMPW5UF
DMPW5UF	DN	Avalglucosidase alfa
DMPW5UF	MI	TTLPC70
DMPW5UF	MN	Lysosomal alpha-glucosidase (GAA)
DMPW5UF	MT	DTT
DMPW5UF	MA	Replacement
DMPW5UF	RN	ClinicalTrials.gov (NCT02782741) Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease (COMET). U.S. National Institutes of Health.
DMPW5UF	RU	https://clinicaltrials.gov/ct2/show/NCT02782741

DMA86FL	DI	DMA86FL
DMA86FL	DN	Avastin+/-Tarceva
DMA86FL	MI	TT2J34L
DMA86FL	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMA86FL	MT	DTT
DMA86FL	MA	Inhibitor
DMA86FL	RN	Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80.
DMA86FL	RU	https://pubmed.ncbi.nlm.nih.gov/9371243

DMA86FL	DI	DMA86FL
DMA86FL	DN	Avastin+/-Tarceva
DMA86FL	MI	TTG8HIM
DMA86FL	MN	Dual specificity protein phosphatase 1 (DUSP1)
DMA86FL	MT	DTT
DMA86FL	MA	Inhibitor
DMA86FL	RN	Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases. Bioorg Med Chem. 2009 Mar 15;17(6):2276-81.
DMA86FL	RU	https://pubmed.ncbi.nlm.nih.gov/19028102

DMA86FL	DI	DMA86FL
DMA86FL	DN	Avastin+/-Tarceva
DMA86FL	MI	TTZJYKH
DMA86FL	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMA86FL	MT	DTT
DMA86FL	MA	Inhibitor
DMA86FL	RN	Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem. 2008 Mar 27;51(6):1706-18.
DMA86FL	RU	https://pubmed.ncbi.nlm.nih.gov/18318466

DMA86FL	DI	DMA86FL
DMA86FL	DN	Avastin+/-Tarceva
DMA86FL	MI	TTR0SWN
DMA86FL	MN	M-phase inducer phosphatase 2 (MPIP2)
DMA86FL	MT	DTT
DMA86FL	MA	Inhibitor
DMA86FL	RN	Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases. Bioorg Med Chem. 2009 Mar 15;17(6):2276-81.
DMA86FL	RU	https://pubmed.ncbi.nlm.nih.gov/19028102

DMA86FL	DI	DMA86FL
DMA86FL	DN	Avastin+/-Tarceva
DMA86FL	MI	TT3PQ2Y
DMA86FL	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DMA86FL	MT	DTT
DMA86FL	MA	Inhibitor
DMA86FL	RN	Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Chem Biol Interact. 2000 Jan 3;124(1):61-76.
DMA86FL	RU	https://pubmed.ncbi.nlm.nih.gov/10658902

DMA86FL	DI	DMA86FL
DMA86FL	DN	Avastin+/-Tarceva
DMA86FL	MI	TTJNTSI
DMA86FL	MN	Rotamase Pin1 (PIN1)
DMA86FL	MT	DTT
DMA86FL	MA	Inhibitor
DMA86FL	RN	Overexpression of PIN1 Enhances Cancer Growth and Aggressiveness with Cyclin D1 Induction in EBV-Associated Nasopharyngeal Carcinoma.PLoS One. 2016 Jun 3;11(6):e0156833. 
DMA86FL	RU	https://pubmed.ncbi.nlm.nih.gov/27258148

DMA86FL	DI	DMA86FL
DMA86FL	DN	Avastin+/-Tarceva
DMA86FL	MI	TTOHSBA
DMA86FL	MN	Vascular endothelial growth factor A (VEGFA)
DMA86FL	MT	DTT
DMA86FL	MA	Inhibitor
DMA86FL	RN	Clinical pipeline report, company report or official report of Genentech (2009).
DMA86FL	RU	http://www.gene.com/gene/pipeline/status/

DMRJK3U	DI	DMRJK3U
DMRJK3U	DN	Avotermin
DMRJK3U	MI	TTWOMY8
DMRJK3U	MN	Transforming growth factor beta 3 (TGFB3)
DMRJK3U	MT	DTT
DMRJK3U	MA	Modulator
DMRJK3U	RN	Discovery and development of avotermin (recombinant human transforming growth factor beta 3): a new class of prophylactic therapeutic for the improvement of scarring. Wound Repair Regen. 2011 Sep;19 Suppl 1:s38-48.
DMRJK3U	RU	https://pubmed.ncbi.nlm.nih.gov/21793965

DMV1SOR	DI	DMV1SOR
DMV1SOR	DN	AVP-786
DMV1SOR	MI	TT5TPI6
DMV1SOR	MN	Opioid receptor sigma 1 (OPRS1)
DMV1SOR	MT	DTT
DMV1SOR	MA	Modulator
DMV1SOR	RN	Antitussives and substance abuse. Subst Abuse Rehabil. 2013 Nov 6;4:75-82.
DMV1SOR	RU	https://pubmed.ncbi.nlm.nih.gov/24648790

DMV1SOR	DI	DMV1SOR
DMV1SOR	DN	AVP-786
DMV1SOR	MI	TT3ROYC
DMV1SOR	MN	Serotonin transporter (SERT)
DMV1SOR	MT	DTT
DMV1SOR	MA	Modulator
DMV1SOR	RN	Antitussives and substance abuse. Subst Abuse Rehabil. 2013 Nov 6;4:75-82.
DMV1SOR	RU	https://pubmed.ncbi.nlm.nih.gov/24648790

DM6WZG8	DI	DM6WZG8
DM6WZG8	DN	AXS-05
DM6WZG8	MI	TT9IK2Z
DM6WZG8	MN	N-methyl-D-aspartate receptor (NMDAR)
DM6WZG8	MT	DTT
DM6WZG8	MA	Antagonist
DM6WZG8	RN	Clinical pipeline report, company report or official report of Axsome Therapeutics.
DM6WZG8	RU	https://axsome.com/axs-pipeline/about-axs-05/

DMM6G5D	DI	DMM6G5D
DMM6G5D	DN	AZD0914
DMM6G5D	MI	TTN6J5F
DMM6G5D	MN	Bacterial DNA gyrase (Bact gyrase)
DMM6G5D	MT	DTT
DMM6G5D	MA	Modulator
DMM6G5D	RN	High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea.Antimicrob Agents Chemother.2014 Sep;58(9):5585-8.
DMM6G5D	RU	https://www.ncbi.nlm.nih.gov/pubmed/24982070

DM9SKW8	DI	DM9SKW8
DM9SKW8	DN	AZD5363
DM9SKW8	MI	TTWTSCV
DM9SKW8	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DM9SKW8	MT	DTT
DM9SKW8	MA	Inhibitor
DM9SKW8	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9SKW8	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM9SKW8	DI	DM9SKW8
DM9SKW8	DN	AZD5363
DM9SKW8	MI	TTAZ05C
DM9SKW8	MN	RAC-gamma serine/threonine-protein kinase (AKT3)
DM9SKW8	MT	DTT
DM9SKW8	MA	Modulator
DM9SKW8	RN	The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Blood. 2014 Oct 2;124(14):2190-5.
DM9SKW8	RU	https://pubmed.ncbi.nlm.nih.gov/25075128

DMLY9F1	DI	DMLY9F1
DMLY9F1	DN	Azetirelin
DMLY9F1	MI	TT4J8MF
DMLY9F1	MN	Thyrotropin-releasing hormone receptor (TRHR)
DMLY9F1	MT	DTT
DMLY9F1	MA	Modulator
DMLY9F1	RN	Intestinal absorption of azetirelin, a new thyrotropin-releasing hormone (TRH) analogue. II. In situ and in vitro absorption characteristics of azetirelin from the rat intestine. Biol Pharm Bull. 1995 Jul;18(7):976-9.
DMLY9F1	RU	https://pubmed.ncbi.nlm.nih.gov/7581253

DMLY9F1	DI	DMLY9F1
DMLY9F1	DN	Azetirelin
DMLY9F1	MI	DEIZ2D9
DMLY9F1	MN	Tripeptidase (pepT)
DMLY9F1	MT	DME
DMLY9F1	MA	Metabolism
DMLY9F1	RN	Metabolism of azetirelin, a new thyrotropin-releasing hormone (TRH) analogue, by intestinal microorganisms. Pharm Res. 1997 Aug;14(8):1004-7.
DMLY9F1	RU	https://pubmed.ncbi.nlm.nih.gov/9279880

DMUIBV8	DI	DMUIBV8
DMUIBV8	DN	Azimilide
DMUIBV8	MI	DECB0K3
DMUIBV8	MN	Cytochrome P450 2D6 (CYP2D6)
DMUIBV8	MT	DME
DMUIBV8	MA	Metabolism
DMUIBV8	RN	The metabolic profile of azimilide in man: in vivo and in vitro evaluations. J Pharm Sci. 2005 Sep;94(9):2084-95.
DMUIBV8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16052551

DMUIBV8	DI	DMUIBV8
DMUIBV8	DN	Azimilide
DMUIBV8	MI	DE4LYSA
DMUIBV8	MN	Cytochrome P450 3A4 (CYP3A4)
DMUIBV8	MT	DME
DMUIBV8	MA	Metabolism
DMUIBV8	RN	The metabolic profile of azimilide in man: in vivo and in vitro evaluations. J Pharm Sci. 2005 Sep;94(9):2084-95.
DMUIBV8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16052551

DMUIBV8	DI	DMUIBV8
DMUIBV8	DN	Azimilide
DMUIBV8	MI	DEIBDNY
DMUIBV8	MN	Cytochrome P450 3A5 (CYP3A5)
DMUIBV8	MT	DME
DMUIBV8	MA	Metabolism
DMUIBV8	RN	The metabolic profile of azimilide in man: in vivo and in vitro evaluations. J Pharm Sci. 2005 Sep;94(9):2084-95.
DMUIBV8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16052551

DMUIBV8	DI	DMUIBV8
DMUIBV8	DN	Azimilide
DMUIBV8	MI	TT1VOHK
DMUIBV8	MN	Potassium channel unspecific (KC)
DMUIBV8	MT	DTT
DMUIBV8	MA	Modulator
DMUIBV8	RN	Azimilide. Drugs. 2000 Feb;59(2):271-7; discussion 278-9.
DMUIBV8	RU	https://www.ncbi.nlm.nih.gov/pubmed/10730550

DM5Y4Q2	DI	DM5Y4Q2
DM5Y4Q2	DN	Azithromycin + hydroxychloroquine
DM5Y4Q2	MI	TTZGK1R
DM5Y4Q2	MN	HUMAN glycosylation of host receptor (GHR)
DM5Y4Q2	MT	DTT
DM5Y4Q2	MA	Inhibitor
DM5Y4Q2	RN	Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.
DM5Y4Q2	RU	https://pubmed.ncbi.nlm.nih.gov/32020029

DM5Y4Q2	DI	DM5Y4Q2
DM5Y4Q2	DN	Azithromycin + hydroxychloroquine
DM5Y4Q2	MI	TTD16BI
DM5Y4Q2	MN	HUMAN pH-dependent viral fusion/replication (pH-DVF/R)
DM5Y4Q2	MT	DTT
DM5Y4Q2	MA	Inhibitor
DM5Y4Q2	RN	Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.
DM5Y4Q2	RU	https://pubmed.ncbi.nlm.nih.gov/32020029

DM5Y4Q2	DI	DM5Y4Q2
DM5Y4Q2	DN	Azithromycin + hydroxychloroquine
DM5Y4Q2	MI	TT3A1EZ
DM5Y4Q2	MN	HUMAN toll-like receptor 7/9 signalling pathway (TLR7/9 pathway)
DM5Y4Q2	MT	DTT
DM5Y4Q2	MA	Inhibitor
DM5Y4Q2	RN	Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020 Mar;16(3):155-166.
DM5Y4Q2	RU	https://pubmed.ncbi.nlm.nih.gov/32034323

DMPV6B2	DI	DMPV6B2
DMPV6B2	DN	BA-058
DMPV6B2	MI	TTEPJL5
DMPV6B2	MN	Parathyroid hormone receptor (PTH2R)
DMPV6B2	MT	DTT
DMPV6B2	MA	Modulator
DMPV6B2	RN	Emerging therapies for the treatment of osteoporosis. J Midlife Health. 2013 Jul-Sep; 4(3): 147-152.
DMPV6B2	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3952405/

DMXBHR6	DI	DMXBHR6
DMXBHR6	DN	Balaglitazone
DMXBHR6	MI	DES5XRU
DMXBHR6	MN	Cytochrome P450 2C8 (CYP2C8)
DMXBHR6	MT	DME
DMXBHR6	MA	Metabolism
DMXBHR6	RN	Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther. 2005 May;77(5):404-14.
DMXBHR6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15900286

DMXBHR6	DI	DMXBHR6
DMXBHR6	DN	Balaglitazone
DMXBHR6	MI	DE4LYSA
DMXBHR6	MN	Cytochrome P450 3A4 (CYP3A4)
DMXBHR6	MT	DME
DMXBHR6	MA	Metabolism
DMXBHR6	RN	Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther. 2005 May;77(5):404-14.
DMXBHR6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15900286

DMXBHR6	DI	DMXBHR6
DMXBHR6	DN	Balaglitazone
DMXBHR6	MI	TTZMAO3
DMXBHR6	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMXBHR6	MT	DTT
DMXBHR6	MA	Modulator
DMXBHR6	RN	Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma () agonist.Mini Rev Med Chem.2012 Feb;12(2):87-97.
DMXBHR6	RU	https://www.ncbi.nlm.nih.gov/pubmed/22372600

DMUOFAC	DI	DMUOFAC
DMUOFAC	DN	Balixafortide
DMUOFAC	MI	TTBID49
DMUOFAC	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMUOFAC	MT	DTT
DMUOFAC	MA	Antagonist
DMUOFAC	RN	Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612.
DMUOFAC	RU	https://pubmed.ncbi.nlm.nih.gov/30072728

DMKMTDG	DI	DMKMTDG
DMKMTDG	DN	Balovaptan
DMKMTDG	MI	TT4TFGN
DMKMTDG	MN	Vasopressin V1a receptor (V1AR)
DMKMTDG	MT	DTT
DMKMTDG	MA	Antagonist
DMKMTDG	RN	Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder. J Med Chem. 2020 Feb 27;63(4):1511-1525.
DMKMTDG	RU	https://pubmed.ncbi.nlm.nih.gov/31951127

DMHQ5GK	DI	DMHQ5GK
DMHQ5GK	DN	Bapineuzumab
DMHQ5GK	MI	TTE4KHA
DMHQ5GK	MN	Amyloid beta A4 protein (APP)
DMHQ5GK	MT	DTT
DMHQ5GK	RN	Bapineuzumab: anti-beta-amyloid monoclonal antibodies for the treatment of Alzheimer's disease. Immunotherapy. 2010 Nov;2(6):767-82.
DMHQ5GK	RU	https://pubmed.ncbi.nlm.nih.gov/21091109

DMODA2X	DI	DMODA2X
DMODA2X	DN	Bardoxolone methyl
DMODA2X	MI	TTT2SVW
DMODA2X	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DMODA2X	MT	DTT
DMODA2X	MA	Antagonist
DMODA2X	RN	A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma. Mol Endocrinol. 2000 Oct;14(10):1550-6.
DMODA2X	RU	https://pubmed.ncbi.nlm.nih.gov/11043571

DMPRI14	DI	DMPRI14
DMPRI14	DN	Baricitinib
DMPRI14	MI	TTN9A16
DMPRI14	MN	HUMAN adaptor-associated kinase 1 (AAK1)
DMPRI14	MT	DTT
DMPRI14	MA	Inhibitor
DMPRI14	RN	Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020 Feb 15;395(10223):e30-e31.
DMPRI14	RU	https://pubmed.ncbi.nlm.nih.gov/32032529

DMPRI14	DI	DMPRI14
DMPRI14	DN	Baricitinib
DMPRI14	MI	TT0AGBL
DMPRI14	MN	HUMAN cyclin G-associated kinase (GAK)
DMPRI14	MT	DTT
DMPRI14	MA	Inhibitor
DMPRI14	RN	Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020 Feb 15;395(10223):e30-e31.
DMPRI14	RU	https://pubmed.ncbi.nlm.nih.gov/32032529

DMB147A	DI	DMB147A
DMB147A	DN	BAX-817
DMB147A	MI	TTF0EGX
DMB147A	MN	Coagulation factor VII (F7)
DMB147A	MT	DTT
DMB147A	MA	Inhibitor
DMB147A	RN	Clinical pipeline report, company report or official report of Baxter.
DMB147A	RU	http://investor.baxter.com/phoenix.zhtml?c=86121&p=irol-newsArticle&id=2025563

DM407I6	DI	DM407I6
DM407I6	DN	BAY 853934
DM407I6	MI	TTJQFBG
DM407I6	MN	HIF-prolyl hydroxylase (HPH)
DM407I6	MT	DTT
DM407I6	MA	Inhibitor
DM407I6	RN	Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia. ChemMedChem. 2018 May 23;13(10):988-1003.
DM407I6	RU	https://pubmed.ncbi.nlm.nih.gov/29485740

DMPW5SB	DI	DMPW5SB
DMPW5SB	DN	Bay 86-9766
DMPW5SB	MI	DE4LYSA
DMPW5SB	MN	Cytochrome P450 3A4 (CYP3A4)
DMPW5SB	MT	DME
DMPW5SB	MA	Metabolism
DMPW5SB	RN	Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer. Clin Cancer Res. 2013 Mar 1;19(5):1232-43.
DMPW5SB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23434733

DMPW5SB	DI	DMPW5SB
DMPW5SB	DN	Bay 86-9766
DMPW5SB	MI	TTROQ37
DMPW5SB	MN	MAPK/ERK kinase kinase (MAP3K)
DMPW5SB	MT	DTT
DMPW5SB	MA	Modulator
DMPW5SB	RN	RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.Cancer Res.2009 Sep 1;69(17):6839-47.
DMPW5SB	RU	https://www.ncbi.nlm.nih.gov/pubmed/19706763

DMPW5SB	DI	DMPW5SB
DMPW5SB	DN	Bay 86-9766
DMPW5SB	MI	DEGTFWK
DMPW5SB	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMPW5SB	MT	DME
DMPW5SB	MA	Metabolism
DMPW5SB	RN	Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer. Clin Cancer Res. 2013 Mar 1;19(5):1232-43.
DMPW5SB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23434733

DM09M3H	DI	DM09M3H
DM09M3H	DN	BAY 94-9027
DM09M3H	MI	TT1290U
DM09M3H	MN	Coagulation factor VIII (F8)
DM09M3H	MT	DTT
DM09M3H	MA	Modulator
DM09M3H	RN	Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. J Thromb Haemost. 2014 Apr;12(4):488-96.
DM09M3H	RU	https://pubmed.ncbi.nlm.nih.gov/24843882

DMWYPZF	DI	DMWYPZF
DMWYPZF	DN	BAY-35-3377
DMWYPZF	MI	TTN6J5F
DMWYPZF	MN	Bacterial DNA gyrase (Bact gyrase)
DMWYPZF	MT	DTT
DMWYPZF	MA	Inhibitor
DMWYPZF	RN	Antibiotics in the clinical pipeline in 2013. J Antibiot (Tokyo). 2013 Oct;66(10):571-91. 
DMWYPZF	RU	https://pubmed.ncbi.nlm.nih.gov/24002361

DMQG7ZM	DI	DMQG7ZM
DMQG7ZM	DN	Belagenpumatucel-L
DMQG7ZM	MI	TTI0KH6
DMQG7ZM	MN	TGF beta-2 messenger RNA (TGFB2 mRNA)
DMQG7ZM	MT	DTT
DMQG7ZM	RN	National Cancer Institute Drug Dictionary (drug id 590662).
DMQG7ZM	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=590662

DM71CK8	DI	DM71CK8
DM71CK8	DN	Beloranib
DM71CK8	MI	TTZL0OI
DM71CK8	MN	Methionine aminopeptidase 2 (METAP2)
DM71CK8	MT	DTT
DM71CK8	MA	Inhibitor
DM71CK8	RN	2011 Pipeline of Zafgen.
DM71CK8	RU	http://www.zafgen.com/approach-pipeline.html

DMLU8NX	DI	DMLU8NX
DMLU8NX	DN	Benserazide
DMLU8NX	MI	TTN451K
DMLU8NX	MN	Aromatic-L-amino-acid decarboxylase (DDC)
DMLU8NX	MT	DTT
DMLU8NX	MA	Inhibitor
DMLU8NX	RN	Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease. Semin Neurol. 2001;21(1):15-22.
DMLU8NX	RU	https://pubmed.ncbi.nlm.nih.gov/11346021

DMS9503	DI	DMS9503
DMS9503	DN	Benzylpenicillin
DMS9503	MI	TTTKCMH
DMS9503	MN	Bacterial Penicillin binding protein 1 (Bact pbp)
DMS9503	MT	DTT
DMS9503	MA	Binder
DMS9503	RN	Overexpression, purification and biochemical characterization of a class A high-molecular-mass penicillin-binding protein (PBP), PBP1* and its soluble derivative from Mycobacterium tuberculosis. Biochem J. 2002 Feb 1;361(Pt 3):635-9.
DMS9503	RU	https://pubmed.ncbi.nlm.nih.gov/11802794

DMS9503	DI	DMS9503
DMS9503	DN	Benzylpenicillin
DMS9503	MI	TT85JMW
DMS9503	MN	Bacterial Penicillin binding protein 3 (Bact mrcA)
DMS9503	MT	DTT
DMS9503	MA	Binder
DMS9503	RN	Association of amino acid substitutions in penicillin-binding protein 3 with beta-lactam resistance in beta-lactamase-negative ampicillin-resistant Haemophilus influenzae. Antimicrob Agents Chemother. 2001 Jun;45(6):1693-9.
DMS9503	RU	https://pubmed.ncbi.nlm.nih.gov/11353613

DMS9503	DI	DMS9503
DMS9503	DN	Benzylpenicillin
DMS9503	MI	DEV0KWQ
DMS9503	MN	Beta-lactamase (blaB)
DMS9503	MT	DME
DMS9503	MA	Metabolism
DMS9503	RN	Antimicrobial drugs used in the management of anaerobic infections in children. Drugs. 1983 Dec;26(6):520-9.
DMS9503	RU	https://pubmed.ncbi.nlm.nih.gov/6360636

DMS9503	DI	DMS9503
DMS9503	DN	Benzylpenicillin
DMS9503	MI	DET9I1W
DMS9503	MN	Beta-lactamase (blaB)
DMS9503	MT	DME
DMS9503	MA	Metabolism
DMS9503	RN	Purification and characterization of a new beta-lactamase from Bacteroides uniformis. Antimicrob Agents Chemother. 1995 Jul;39(7):1458-61.
DMS9503	RU	https://pubmed.ncbi.nlm.nih.gov/7492085

DMS9503	DI	DMS9503
DMS9503	DN	Benzylpenicillin
DMS9503	MI	DENJ2SQ
DMS9503	MN	Beta-lactamase (blaB)
DMS9503	MT	DME
DMS9503	MA	Metabolism
DMS9503	RN	Antimicrobial drugs used in the management of anaerobic infections in children. Drugs. 1983 Dec;26(6):520-9.
DMS9503	RU	https://pubmed.ncbi.nlm.nih.gov/6360636

DMS9503	DI	DMS9503
DMS9503	DN	Benzylpenicillin
DMS9503	MI	DESIWFO
DMS9503	MN	Beta-lactamase (blaB)
DMS9503	MT	DME
DMS9503	MA	Metabolism
DMS9503	RN	EBR-1, a novel Ambler subclass B1 beta-lactamase from Empedobacter brevis. Antimicrob Agents Chemother. 2002 Oct;46(10):3223-7.
DMS9503	RU	https://pubmed.ncbi.nlm.nih.gov/12234848

DMS9503	DI	DMS9503
DMS9503	DN	Benzylpenicillin
DMS9503	MI	DEQX0DG
DMS9503	MN	Beta-lactamase (blaB)
DMS9503	MT	DME
DMS9503	MA	Metabolism
DMS9503	RN	beta-lactamase production and antimicrobial susceptibility of oral heterogeneous Fusobacterium nucleatum populations in young children. Antimicrob Agents Chemother. 1999 May;43(5):1270-3.
DMS9503	RU	https://pubmed.ncbi.nlm.nih.gov/10223950

DMS9503	DI	DMS9503
DMS9503	DN	Benzylpenicillin
DMS9503	MI	DE37FJH
DMS9503	MN	Beta-lactamase (blaB)
DMS9503	MT	DME
DMS9503	MA	Metabolism
DMS9503	RN	Antimicrobial drugs used in the management of anaerobic infections in children. Drugs. 1983 Dec;26(6):520-9.
DMS9503	RU	https://pubmed.ncbi.nlm.nih.gov/6360636

DMS9503	DI	DMS9503
DMS9503	DN	Benzylpenicillin
DMS9503	MI	DEAILCM
DMS9503	MN	Beta-lactamase (blaB)
DMS9503	MT	DME
DMS9503	MA	Metabolism
DMS9503	RN	Beta-lactamase production in Prevotella intermedia, Prevotella nigrescens, and Prevotella pallens genotypes and in vitro susceptibilities to selected antimicrobial agents. Antimicrob Agents Chemother. 1999 Oct;43(10):2383-8.
DMS9503	RU	https://pubmed.ncbi.nlm.nih.gov/10508011

DMS9503	DI	DMS9503
DMS9503	DN	Benzylpenicillin
DMS9503	MI	DERPJ4F
DMS9503	MN	Beta-lactamase (blaB)
DMS9503	MT	DME
DMS9503	MA	Metabolism
DMS9503	RN	Characterization of the penA and penR genes of Burkholderia cepacia 249 which encode the chromosomal class A penicillinase and its LysR-type transcriptional regulator. Antimicrob Agents Chemother. 1997 Nov;41(11):2399-405.
DMS9503	RU	https://pubmed.ncbi.nlm.nih.gov/9371340

DMS9503	DI	DMS9503
DMS9503	DN	Benzylpenicillin
DMS9503	MI	DEBAZ7H
DMS9503	MN	Beta-lactamase (blaB)
DMS9503	MT	DME
DMS9503	MA	Metabolism
DMS9503	RN	Beta-lactamase production in Prevotella intermedia, Prevotella nigrescens, and Prevotella pallens genotypes and in vitro susceptibilities to selected antimicrobial agents. Antimicrob Agents Chemother. 1999 Oct;43(10):2383-8.
DMS9503	RU	https://pubmed.ncbi.nlm.nih.gov/10508011

DMS9503	DI	DMS9503
DMS9503	DN	Benzylpenicillin
DMS9503	MI	DEA5OYT
DMS9503	MN	Beta-lactamase (blaB)
DMS9503	MT	DME
DMS9503	MA	Metabolism
DMS9503	RN	Genetic and biochemical characterization of CGB-1, an Ambler class B carbapenem-hydrolyzing beta-lactamase from Chryseobacterium gleum. Antimicrob Agents Chemother. 2002 Sep;46(9):2791-6.
DMS9503	RU	https://pubmed.ncbi.nlm.nih.gov/12183230

DMS9503	DI	DMS9503
DMS9503	DN	Benzylpenicillin
DMS9503	MI	DEIU0XN
DMS9503	MN	N-acylhomoserine lactone acylase (lacA)
DMS9503	MT	DME
DMS9503	MA	Metabolism
DMS9503	RN	A novel quorum-quenching N-acylhomoserine lactone acylase from Acidovorax sp. strain MR-S7 mediates antibiotic resistance. Appl Environ Microbiol. 2017 Jun 16;83(13). pii: e00080-17.
DMS9503	RU	https://pubmed.ncbi.nlm.nih.gov/28455333

DMS9503	DI	DMS9503
DMS9503	DN	Benzylpenicillin
DMS9503	MI	DTVP67E
DMS9503	MN	Organic anion transporter 3 (SLC22A8)
DMS9503	MT	DTP
DMS9503	MA	Substrate
DMS9503	RN	Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab Dispos. 2011 Jun;39(6):1031-8.
DMS9503	RU	http://www.ncbi.nlm.nih.gov/pubmed/21383204

DMS9503	DI	DMS9503
DMS9503	DN	Benzylpenicillin
DMS9503	MI	DT3D8F0
DMS9503	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMS9503	MT	DTP
DMS9503	MA	Substrate
DMS9503	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DMS9503	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DMS9503	DI	DMS9503
DMS9503	DN	Benzylpenicillin
DMS9503	MI	DT9C1TS
DMS9503	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMS9503	MT	DTP
DMS9503	MA	Substrate
DMS9503	RN	Molecular characterization and inhibition of amanitin uptake into human hepatocytes. Toxicol Sci. 2006 May;91(1):140-9.
DMS9503	RU	http://www.ncbi.nlm.nih.gov/pubmed/16495352

DMS9503	DI	DMS9503
DMS9503	DN	Benzylpenicillin
DMS9503	MI	DTPFTEQ
DMS9503	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DMS9503	MT	DTP
DMS9503	MA	Substrate
DMS9503	RN	Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000 Jun 24;273(1):251-60.
DMS9503	RU	http://www.ncbi.nlm.nih.gov/pubmed/10873595

DMS9503	DI	DMS9503
DMS9503	DN	Benzylpenicillin
DMS9503	MI	DTVNRXW
DMS9503	MN	Organic anion transporting polypeptide 3A1 (SLCO3A1)
DMS9503	MT	DTP
DMS9503	MA	Substrate
DMS9503	RN	Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000 Jun 24;273(1):251-60.
DMS9503	RU	http://www.ncbi.nlm.nih.gov/pubmed/10873595

DMS9503	DI	DMS9503
DMS9503	DN	Benzylpenicillin
DMS9503	MI	DT8H2IC
DMS9503	MN	Organic anion transporting polypeptide 4A1 (SLCO4A1)
DMS9503	MT	DTP
DMS9503	MA	Substrate
DMS9503	RN	Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000 Jun 24;273(1):251-60.
DMS9503	RU	http://www.ncbi.nlm.nih.gov/pubmed/10873595

DMS9503	DI	DMS9503
DMS9503	DN	Benzylpenicillin
DMS9503	MI	DT9G7XN
DMS9503	MN	Peptide transporter 1 (SLC15A1)
DMS9503	MT	DTP
DMS9503	MA	Substrate
DMS9503	RN	Drug transport in corneal epithelium and blood-retina barrier: emerging role of transporters in ocular pharmacokinetics. Adv Drug Deliv Rev. 2006 Nov 15;58(11):1136-63.
DMS9503	RU	https://doi.org/10.1016/j.addr.2006.07.024

DM6RWBN	DI	DM6RWBN
DM6RWBN	DN	Beperminogene perplasmid
DM6RWBN	MI	TTNDSF4
DM6RWBN	MN	Proto-oncogene c-Met (MET)
DM6RWBN	MT	DTT
DM6RWBN	MA	Modulator
DM6RWBN	RN	Beperminogene perplasmid for the treatment of critical limb ischemia. Expert Rev Cardiovasc Ther. 2014 Oct;12(10):1145-56.
DM6RWBN	RU	https://pubmed.ncbi.nlm.nih.gov/25190335

DMLVNTA	DI	DMLVNTA
DMLVNTA	DN	Besipirdine
DMLVNTA	MI	TTNGILX
DMLVNTA	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMLVNTA	MT	DTT
DMLVNTA	MA	Antagonist
DMLVNTA	RN	Alpha-Adrenergic activity and cardiovascular effects of besipirdine HCl (HP 749) and metabolite P7480 in vitro and in the conscious rat and dog. J Pharmacol Exp Ther. 1997 Apr;281(1):337-46.
DMLVNTA	RU	https://pubmed.ncbi.nlm.nih.gov/9103515

DM0MI81	DI	DM0MI81
DM0MI81	DN	Bevacizumab + Erlotinib
DM0MI81	MI	TTGKNB4
DM0MI81	MN	Epidermal growth factor receptor (EGFR)
DM0MI81	MT	DTT
DM0MI81	MA	Inhibitor
DM0MI81	RN	Clinical pipeline report, company report or official report of Roche (2009).
DM0MI81	RU	http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm

DM0MI81	DI	DM0MI81
DM0MI81	DN	Bevacizumab + Erlotinib
DM0MI81	MI	TTOHSBA
DM0MI81	MN	Vascular endothelial growth factor A (VEGFA)
DM0MI81	MT	DTT
DM0MI81	MA	Inhibitor
DM0MI81	RN	Clinical pipeline report, company report or official report of Roche (2009).
DM0MI81	RU	http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm

DM9EXGI	DI	DM9EXGI
DM9EXGI	DN	Bevacizumab + Rituximab
DM9EXGI	MI	TTUE541
DM9EXGI	MN	Leukocyte surface antigen Leu-16 (CD20)
DM9EXGI	MT	DTT
DM9EXGI	RN	Clinical pipeline report, company report or official report of Roche (2009).
DM9EXGI	RU	http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm

DM9EXGI	DI	DM9EXGI
DM9EXGI	DN	Bevacizumab + Rituximab
DM9EXGI	MI	TTOHSBA
DM9EXGI	MN	Vascular endothelial growth factor A (VEGFA)
DM9EXGI	MT	DTT
DM9EXGI	MA	Inhibitor
DM9EXGI	RN	Clinical pipeline report, company report or official report of Roche (2009).
DM9EXGI	RU	http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm

DM9CEI5	DI	DM9CEI5
DM9CEI5	DN	Bevacizumab + Trastuzumab
DM9CEI5	MI	TT6EO5L
DM9CEI5	MN	Erbb2 tyrosine kinase receptor (HER2)
DM9CEI5	MT	DTT
DM9CEI5	RN	Clinical pipeline report, company report or official report of Roche (2009).
DM9CEI5	RU	http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm

DM9CEI5	DI	DM9CEI5
DM9CEI5	DN	Bevacizumab + Trastuzumab
DM9CEI5	MI	TTS4UGC
DM9CEI5	MN	Farnesoid X-activated receptor (FXR)
DM9CEI5	MT	DTT
DM9CEI5	MA	Antagonist
DM9CEI5	RN	Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity. J Biol Chem. 2002 Aug 30;277(35):31441-7.
DM9CEI5	RU	https://pubmed.ncbi.nlm.nih.gov/12052824

DM9CEI5	DI	DM9CEI5
DM9CEI5	DN	Bevacizumab + Trastuzumab
DM9CEI5	MI	TTOHSBA
DM9CEI5	MN	Vascular endothelial growth factor A (VEGFA)
DM9CEI5	MT	DTT
DM9CEI5	MA	Inhibitor
DM9CEI5	RN	Clinical pipeline report, company report or official report of Roche (2009).
DM9CEI5	RU	http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm

DMK56G0	DI	DMK56G0
DMK56G0	DN	Bexagliflozin
DMK56G0	MI	TTF8JAT
DMK56G0	MN	SLC5A2 messenger RNA (SLC5A2 mRNA)
DMK56G0	MT	DTT
DMK56G0	MA	Inhibitor
DMK56G0	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMK56G0	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DM7NJYC	DI	DM7NJYC
DM7NJYC	DN	BGB-A317
DM7NJYC	MI	TTNBFWK
DM7NJYC	MN	Programmed cell death protein 1 (PD-1)
DM7NJYC	MT	DTT
DM7NJYC	MA	Inhibitor
DM7NJYC	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7NJYC	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMNKBEC	DI	DMNKBEC
DMNKBEC	DN	BGJ398
DMNKBEC	MI	TT0LF7H
DMNKBEC	MN	Fibroblast growth factor receptor (FGFR)
DMNKBEC	MT	DTT
DMNKBEC	MA	Inhibitor
DMNKBEC	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMNKBEC	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMNKBEC	DI	DMNKBEC
DMNKBEC	DN	BGJ398
DMNKBEC	MI	TTRLW2X
DMNKBEC	MN	Fibroblast growth factor receptor 1 (FGFR1)
DMNKBEC	MT	DTT
DMNKBEC	MA	Modulator
DMNKBEC	RN	Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. J Bone Miner Res. 2013 Apr;28(4):899-911.
DMNKBEC	RU	https://pubmed.ncbi.nlm.nih.gov/23129509

DM3MXT8	DI	DM3MXT8
DM3MXT8	DN	BI 201335
DM3MXT8	MI	TT5FNQT
DM3MXT8	MN	Human immunodeficiency virus Protease (HIV PR)
DM3MXT8	MT	DTT
DM3MXT8	MA	Inhibitor
DM3MXT8	RN	2011 Pipeline of Boehringer Ingelheim Pharma.
DM3MXT8	RU	http://www.boehringer-ingelheim.com/

DMH3XDR	DI	DMH3XDR
DMH3XDR	DN	BI 425809
DMH3XDR	MI	TTHJTF7
DMH3XDR	MN	Glycine transporter GlyT-1 (SLC6A9)
DMH3XDR	MT	DTT
DMH3XDR	MA	Inhibitor
DMH3XDR	RN	Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study. Lancet Psychiatry. 2021 Mar;8(3):191-201.
DMH3XDR	RU	https://pubmed.ncbi.nlm.nih.gov/33610228

DMBH4FL	DI	DMBH4FL
DMBH4FL	DN	BI 655066
DMBH4FL	MI	TTC1GLB
DMBH4FL	MN	Interleukin-23 (IL23)
DMBH4FL	MT	DTT
DMBH4FL	RN	Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2015 Jul;136(1):116-124.e7.
DMBH4FL	RU	https://pubmed.ncbi.nlm.nih.gov/25769911

DM42GP9	DI	DM42GP9
DM42GP9	DN	Bicifadine
DM42GP9	MI	DEJGDUW
DM42GP9	MN	Cytochrome P450 1A2 (CYP1A2)
DM42GP9	MT	DME
DM42GP9	MA	Metabolism
DM42GP9	RN	In vitro metabolism of the analgesic bicifadine in the mouse, rat, monkey, and human. Drug Metab Dispos. 2007 Dec;35(12):2232-41.
DM42GP9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17881661

DM42GP9	DI	DM42GP9
DM42GP9	DN	Bicifadine
DM42GP9	MI	DECB0K3
DM42GP9	MN	Cytochrome P450 2D6 (CYP2D6)
DM42GP9	MT	DME
DM42GP9	MA	Metabolism
DM42GP9	RN	In vitro metabolism of the analgesic bicifadine in the mouse, rat, monkey, and human. Drug Metab Dispos. 2007 Dec;35(12):2232-41.
DM42GP9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17881661

DM42GP9	DI	DM42GP9
DM42GP9	DN	Bicifadine
DM42GP9	MI	TTAWNKZ
DM42GP9	MN	Norepinephrine transporter (NET)
DM42GP9	MT	DTT
DM42GP9	MA	Modulator
DM42GP9	RN	Preclinical Evaluation of the Abuse Potential of the Analgesic Bicifadine
DM42GP9	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202431

DM42GP9	DI	DM42GP9
DM42GP9	DN	Bicifadine
DM42GP9	MI	TT3ROYC
DM42GP9	MN	Serotonin transporter (SERT)
DM42GP9	MT	DTT
DM42GP9	MA	Modulator
DM42GP9	RN	Preclinical Evaluation of the Abuse Potential of the Analgesic Bicifadine
DM42GP9	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202431

DM57B9J	DI	DM57B9J
DM57B9J	DN	Biferonex
DM57B9J	MI	TT4TZ8J
DM57B9J	MN	Interferon-beta (IFNB1)
DM57B9J	MT	DTT
DM57B9J	MA	Modulator
DM57B9J	RN	Improving compliance with interferon-beta therapy in patients with multiple sclerosis. CNS Drugs. 2009;23(6):453-62.
DM57B9J	RU	https://pubmed.ncbi.nlm.nih.gov/19480465

DM51JW4	DI	DM51JW4
DM51JW4	DN	BIIB037
DM51JW4	MI	TTE4KHA
DM51JW4	MN	Amyloid beta A4 protein (APP)
DM51JW4	MT	DTT
DM51JW4	MA	Modulator
DM51JW4	RN	Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets . Immun Ageing. 2013; 10: 18.
DM51JW4	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681567/

DM0AEDT	DI	DM0AEDT
DM0AEDT	DN	BIIB067
DM0AEDT	MI	TT6RVLG
DM0AEDT	MN	Superoxide dismutase Cu-Zn (SOD Cu-Zn)
DM0AEDT	MT	DTT
DM0AEDT	MA	Inhibitor
DM0AEDT	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM0AEDT	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMR9TF1	DI	DMR9TF1
DMR9TF1	DN	Bimekizumab
DMR9TF1	MI	TT2B6PS
DMR9TF1	MN	Cytokine ML-1 (IL17F)
DMR9TF1	MT	DTT
DMR9TF1	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMR9TF1	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMR9TF1	DI	DMR9TF1
DMR9TF1	DN	Bimekizumab
DMR9TF1	MI	TTG0MT6
DMR9TF1	MN	Interleukin-17 (IL17)
DMR9TF1	MT	DTT
DMR9TF1	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMR9TF1	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMS2GA1	DI	DMS2GA1
DMS2GA1	DN	Bindarit
DMS2GA1	MI	TTNAY0P
DMS2GA1	MN	Monocyte chemotactic and activating factor (CCL2)
DMS2GA1	MT	DTT
DMS2GA1	MA	Inhibitor
DMS2GA1	RN	Bindarit: an anti-inflammatory small molecule that modulates the NF B pathway. Cell Cycle. 2012 Jan 1;11(1):159-69.
DMS2GA1	RU	https://pubmed.ncbi.nlm.nih.gov/22189654

DMVHF8G	DI	DMVHF8G
DMVHF8G	DN	Binodenoson
DMVHF8G	MI	TTM2AOE
DMVHF8G	MN	Adenosine A2a receptor (ADORA2A)
DMVHF8G	MT	DTT
DMVHF8G	MA	Agonist
DMVHF8G	RN	Coronary circulation responses to binodenoson, a selective adenosine A2A receptor agonist. Am J Cardiol. 2007 Jun 1;99(11):1507-12.
DMVHF8G	RU	https://pubmed.ncbi.nlm.nih.gov/17531571

DME76AP	DI	DME76AP
DME76AP	DN	Bis(olanzapine) pamoate monohydrate
DME76AP	MI	TTYSN63
DME76AP	MN	5-HT 2 receptor (5HT2R)
DME76AP	MT	DTT
DME76AP	MA	Modulator
DME76AP	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DME76AP	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DME76AP	DI	DME76AP
DME76AP	DN	Bis(olanzapine) pamoate monohydrate
DME76AP	MI	TTEX248
DME76AP	MN	Dopamine D2 receptor (D2R)
DME76AP	MT	DTT
DME76AP	MA	Modulator
DME76AP	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DME76AP	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMW34B1	DI	DMW34B1
DMW34B1	DN	BL-8040
DMW34B1	MI	TTBID49
DMW34B1	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMW34B1	MT	DTT
DMW34B1	MA	Antagonist
DMW34B1	RN	The CXCR4 Antagonist BL-8040 Efficiently Induces Apoptosis and Inhibits The Survival Of AML Cells. November 15, 2013; Blood: 122 (21).
DMW34B1	RU	http://www.bloodjournal.org/content/122/21/3939?sso-checked=true

DM7V9LH	DI	DM7V9LH
DM7V9LH	DN	Blisibimod
DM7V9LH	MI	TTWMIDN
DM7V9LH	MN	B-cell-activating factor (TNFSF13B)
DM7V9LH	MT	DTT
DM7V9LH	MA	Inhibitor
DM7V9LH	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7V9LH	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DM36C17	DI	DM36C17
DM36C17	DN	Blonanserin
DM36C17	MI	TTJQOD7
DM36C17	MN	5-HT 2A receptor (HTR2A)
DM36C17	MT	DTT
DM36C17	MA	Antagonist
DM36C17	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DM36C17	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DM36C17	DI	DM36C17
DM36C17	DN	Blonanserin
DM36C17	MI	DE4LYSA
DM36C17	MN	Cytochrome P450 3A4 (CYP3A4)
DM36C17	MT	DME
DM36C17	MA	Metabolism
DM36C17	RN	Profile of blonanserin for the treatment of schizophrenia. Neuropsychiatr Dis Treat. 2013;9:587-94.
DM36C17	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23766647

DM36C17	DI	DM36C17
DM36C17	DN	Blonanserin
DM36C17	MI	TTEX248
DM36C17	MN	Dopamine D2 receptor (D2R)
DM36C17	MT	DTT
DM36C17	MA	Antagonist
DM36C17	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DM36C17	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMBXR23	DI	DMBXR23
DMBXR23	DN	BMN-110
DMBXR23	MI	TTT9YPO
DMBXR23	MN	N-acetylgalactosamine 6 sulfatase (GALNS)
DMBXR23	MT	DTT
DMBXR23	MA	Modulator
DMBXR23	RN	Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study. J Inherit Metab Dis. 2014 Nov;37(6):979-90.
DMBXR23	RU	https://pubmed.ncbi.nlm.nih.gov/24810369

DMM9XL2	DI	DMM9XL2
DMM9XL2	DN	BMN-111
DMM9XL2	MI	TTRK0B9
DMM9XL2	MN	C-type natriuretic peptide (NPPC)
DMM9XL2	MT	DTT
DMM9XL2	MA	Modulator
DMM9XL2	RN	Clinical pipeline report, company report or official report of Biomarin.
DMM9XL2	RU	https://www.bmrn.com/pipeline/clinical-trials/achondroplasia.php

DM94Y6O	DI	DM94Y6O
DM94Y6O	DN	BMN-701
DM94Y6O	MI	TTLPC70
DM94Y6O	MN	Lysosomal alpha-glucosidase (GAA)
DM94Y6O	MT	DTT
DM94Y6O	MA	Modulator
DM94Y6O	RN	Clinical pipeline report, company report or official report of BioMarin Pharma.
DM94Y6O	RU	https://www.bmrn.com/pipeline/igf2-gaa-for-pompe-disease.php

DMDAN8H	DI	DMDAN8H
DMDAN8H	DN	BMS-582664
DMDAN8H	MI	TTST7KB
DMDAN8H	MN	Fibroblast growth factor receptor 3 (FGFR3)
DMDAN8H	MT	DTT
DMDAN8H	MA	Inhibitor
DMDAN8H	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMDAN8H	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMAR1YS	DI	DMAR1YS
DMAR1YS	DN	BMS-986165
DMAR1YS	MI	TTBYWP2
DMAR1YS	MN	TYK2 tyrosine kinase (TYK2)
DMAR1YS	MT	DTT
DMAR1YS	MA	Inhibitor
DMAR1YS	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMAR1YS	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM3MAYQ	DI	DM3MAYQ
DM3MAYQ	DN	BMS-986205
DM3MAYQ	MI	TTZJYKH
DM3MAYQ	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DM3MAYQ	MT	DTT
DM3MAYQ	MA	Inhibitor
DM3MAYQ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3MAYQ	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM2OBNW	DI	DM2OBNW
DM2OBNW	DN	Bococizumab
DM2OBNW	MI	TTBRG7E
DM2OBNW	MN	Proprotein convertase subtilisin/kexin type 9 (PCSK9)
DM2OBNW	MT	DTT
DM2OBNW	RN	The dyslipidaemia market. Nat Rev Drug Discov. 2014 Nov;13(11):807-8.
DM2OBNW	RU	https://pubmed.ncbi.nlm.nih.gov/25323928

DM6KRLW	DI	DM6KRLW
DM6KRLW	DN	BQ788
DM6KRLW	MI	TT3ZTGU
DM6KRLW	MN	Endothelin B receptor (EDNRB)
DM6KRLW	MT	DTT
DM6KRLW	MA	Antagonist
DM6KRLW	RN	BQ788, an endothelin ET(B) receptor antagonist, attenuates stab wound injury-induced reactive astrocytes in rat brain. Glia. 1999 May;26(3):268-71.
DM6KRLW	RU	https://pubmed.ncbi.nlm.nih.gov/10340767

DM942HP	DI	DM942HP
DM942HP	DN	Brivanib
DM942HP	MI	TTUTJGQ
DM942HP	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM942HP	MT	DTT
DM942HP	MA	Modulator
DM942HP	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM942HP	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMM0VO3	DI	DMM0VO3
DMM0VO3	DN	BSI-201
DMM0VO3	MI	TTEBCY8
DMM0VO3	MN	Poly [ADP-ribose] polymerase (PARP)
DMM0VO3	MT	DTT
DMM0VO3	MA	Modulator
DMM0VO3	RN	Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res. 2012 Mar 15;18(6):1655-62.
DMM0VO3	RU	https://pubmed.ncbi.nlm.nih.gov/22291137

DM50SNX	DI	DM50SNX
DM50SNX	DN	Bucelipase alfa
DM50SNX	MI	TTTRNQW
DM50SNX	MN	Bile-salt-activated lipase (CEL)
DM50SNX	MT	DTT
DM50SNX	MA	Modulator
DM50SNX	RN	ClinicalTrials.gov (NCT00743483) Efficacy of Bucelipase Alfa (BSSL) in Patients With Cystic Fibrosis and Pancreatic Insufficiency. U.S. National Institutes of Health.
DM50SNX	RU	https://clinicaltrials.gov/ct2/show/NCT00743483

DM1WEHC	DI	DM1WEHC
DM1WEHC	DN	Buparlisib
DM1WEHC	MI	TTEUNMR
DM1WEHC	MN	PI3-kinase alpha (PIK3CA)
DM1WEHC	MT	DTT
DM1WEHC	MA	Inhibitor
DM1WEHC	RN	Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44.
DM1WEHC	RU	https://pubmed.ncbi.nlm.nih.gov/19644473

DM1WEHC	DI	DM1WEHC
DM1WEHC	DN	Buparlisib
DM1WEHC	MI	TTTHBCA
DM1WEHC	MN	PI3-kinase beta (PIK3CB)
DM1WEHC	MT	DTT
DM1WEHC	MA	Inhibitor
DM1WEHC	RN	Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44.
DM1WEHC	RU	https://pubmed.ncbi.nlm.nih.gov/19644473

DM1WEHC	DI	DM1WEHC
DM1WEHC	DN	Buparlisib
DM1WEHC	MI	TTGBPJE
DM1WEHC	MN	PI3-kinase delta (PIK3CD)
DM1WEHC	MT	DTT
DM1WEHC	MA	Inhibitor
DM1WEHC	RN	Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44.
DM1WEHC	RU	https://pubmed.ncbi.nlm.nih.gov/19644473

DM1WEHC	DI	DM1WEHC
DM1WEHC	DN	Buparlisib
DM1WEHC	MI	TTHBTOP
DM1WEHC	MN	PI3-kinase gamma (PIK3CG)
DM1WEHC	MT	DTT
DM1WEHC	MA	Inhibitor
DM1WEHC	RN	Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44.
DM1WEHC	RU	https://pubmed.ncbi.nlm.nih.gov/19644473

DMAR9ND	DI	DMAR9ND
DMAR9ND	DN	Bupropion+Naltrexone
DMAR9ND	MI	TTVBI8W
DMAR9ND	MN	Dopamine transporter (DAT)
DMAR9ND	MT	DTT
DMAR9ND	MA	Inhibitor
DMAR9ND	RN	Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
DMAR9ND	RU	https://pubmed.ncbi.nlm.nih.gov/18473708

DMAR9ND	DI	DMAR9ND
DMAR9ND	DN	Bupropion+Naltrexone
DMAR9ND	MI	TTAWNKZ
DMAR9ND	MN	Norepinephrine transporter (NET)
DMAR9ND	MT	DTT
DMAR9ND	MA	Inhibitor
DMAR9ND	RN	Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
DMAR9ND	RU	https://pubmed.ncbi.nlm.nih.gov/18473708

DMAR9ND	DI	DMAR9ND
DMAR9ND	DN	Bupropion+Naltrexone
DMAR9ND	MI	TTN4QDT
DMAR9ND	MN	Opioid receptor (OPR)
DMAR9ND	MT	DTT
DMAR9ND	MA	Antagonist
DMAR9ND	RN	Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
DMAR9ND	RU	https://pubmed.ncbi.nlm.nih.gov/18473708

DM6RUKX	DI	DM6RUKX
DM6RUKX	DN	BVT.2733
DM6RUKX	MI	TTN7BL9
DM6RUKX	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DM6RUKX	MT	DTT
DM6RUKX	MA	Inhibitor
DM6RUKX	RN	Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology. 2003 Nov;144(11):4755-62.
DM6RUKX	RU	https://pubmed.ncbi.nlm.nih.gov/12960099

DM1ARHT	DI	DM1ARHT
DM1ARHT	DN	BYM338
DM1ARHT	MI	TTX2DRI
DM1ARHT	MN	Activin receptor type IIA (ACVR2A)
DM1ARHT	MT	DTT
DM1ARHT	MA	Inhibitor
DM1ARHT	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM1ARHT	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMPTCYB	DI	DMPTCYB
DMPTCYB	DN	Cadi-05
DMPTCYB	MI	TTY7ZHS
DMPTCYB	MN	Toll-like receptor 2 (TLR2)
DMPTCYB	MT	DTT
DMPTCYB	RN	Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012 August 1; 1(5): 699-716.
DMPTCYB	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3429574/

DMPTCYB	DI	DMPTCYB
DMPTCYB	DN	Cadi-05
DMPTCYB	MI	TTISGCA
DMPTCYB	MN	Toll-like receptor 4 (TLR4)
DMPTCYB	MT	DTT
DMPTCYB	RN	Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012 August 1; 1(5): 699-716.
DMPTCYB	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3429574/

DMPTCYB	DI	DMPTCYB
DMPTCYB	DN	Cadi-05
DMPTCYB	MI	TTSHG0T
DMPTCYB	MN	Toll-like receptor 9 (TLR9)
DMPTCYB	MT	DTT
DMPTCYB	RN	Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012 August 1; 1(5): 699-716.
DMPTCYB	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3429574/

DM6CHNJ	DI	DM6CHNJ
DM6CHNJ	DN	Camptothecin
DM6CHNJ	MI	DTI7UX6
DM6CHNJ	MN	Breast cancer resistance protein (ABCG2)
DM6CHNJ	MT	DTP
DM6CHNJ	MA	Substrate
DM6CHNJ	RN	The beta-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells. Phytother Res. 2010 Jan;24(1):146-9.
DM6CHNJ	RU	https://doi.org/10.1002/ptr.2860

DM6CHNJ	DI	DM6CHNJ
DM6CHNJ	DN	Camptothecin
DM6CHNJ	MI	TTGTQHC
DM6CHNJ	MN	DNA topoisomerase I (TOP1)
DM6CHNJ	MT	DTT
DM6CHNJ	MA	Modulator
DM6CHNJ	RN	Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006 Oct;6(10):789-802.
DM6CHNJ	RU	https://pubmed.ncbi.nlm.nih.gov/16990856

DM6CHNJ	DI	DM6CHNJ
DM6CHNJ	DN	Camptothecin
DM6CHNJ	MI	DTFI42L
DM6CHNJ	MN	Multidrug resistance-associated protein 2 (ABCC2)
DM6CHNJ	MT	DTP
DM6CHNJ	MA	Substrate
DM6CHNJ	RN	Pharmacogenetics of membrane transporters: an update on current approaches. Mol Biotechnol. 2010 Feb;44(2):152-67.
DM6CHNJ	RU	https://doi.org/10.1007/s12033-009-9220-6

DM6CHNJ	DI	DM6CHNJ
DM6CHNJ	DN	Camptothecin
DM6CHNJ	MI	DTCSGPB
DM6CHNJ	MN	Multidrug resistance-associated protein 4 (ABCC4)
DM6CHNJ	MT	DTP
DM6CHNJ	MA	Substrate
DM6CHNJ	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM6CHNJ	RU	https://doi.org/10.1007/s11095-012-0935-x

DMHJCGV	DI	DMHJCGV
DMHJCGV	DN	Candoxatril
DMHJCGV	MI	TT5TKPM
DMHJCGV	MN	Neutral endopeptidase (MME)
DMHJCGV	MT	DTT
DMHJCGV	MA	Inhibitor
DMHJCGV	RN	Neutral endopeptidase inhibitor suppresses the early phase of atrial electrical remodeling in a canine rapid atrial pacing model. Indian Pacing Electrophysiol J. 2008 Apr 1;8(2):102-13.
DMHJCGV	RU	https://pubmed.ncbi.nlm.nih.gov/18379655

DM4FHQR	DI	DM4FHQR
DM4FHQR	DN	Canfosfamide
DM4FHQR	MI	TT40K12
DM4FHQR	MN	Glutathione S-transferase P (GSTP1)
DM4FHQR	MT	DTT
DM4FHQR	MA	Modulator
DM4FHQR	RN	Mechanism of glutathione transferase P1-1-catalyzed activation of the prodrug canfosfamide (TLK286, TELCYTA). Biochemistry. 2013 Nov 12;52(45):8069-78.
DM4FHQR	RU	https://pubmed.ncbi.nlm.nih.gov/24066958

DMMZDJ6	DI	DMMZDJ6
DMMZDJ6	DN	Captopril
DMMZDJ6	MI	TTGFNPD
DMMZDJ6	MN	HUMAN angiotensin-converting enzyme (ACE)
DMMZDJ6	MT	DTT
DMMZDJ6	MA	Inhibitor
DMMZDJ6	RN	Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB. Curr Cardiol Rep. 2020 Apr 14;22(5):31.
DMMZDJ6	RU	https://pubmed.ncbi.nlm.nih.gov/32291526

DMUVMWZ	DI	DMUVMWZ
DMUVMWZ	DN	Carebastine
DMUVMWZ	MI	DERSX5P
DMUVMWZ	MN	Cytochrome P450 2J2 (CYP2J2)
DMUVMWZ	MT	DME
DMUVMWZ	MA	Metabolism
DMUVMWZ	RN	Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A. Drug Metab Dispos. 2006 Nov;34(11):1793-7.
DMUVMWZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16896065

DMUVMWZ	DI	DMUVMWZ
DMUVMWZ	DN	Carebastine
DMUVMWZ	MI	DE4LYSA
DMUVMWZ	MN	Cytochrome P450 3A4 (CYP3A4)
DMUVMWZ	MT	DME
DMUVMWZ	MA	Metabolism
DMUVMWZ	RN	Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A. Drug Metab Dispos. 2006 Nov;34(11):1793-7.
DMUVMWZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16896065

DMUVMWZ	DI	DMUVMWZ
DMUVMWZ	DN	Carebastine
DMUVMWZ	MI	TTTIBOJ
DMUVMWZ	MN	Histamine H1 receptor (H1R)
DMUVMWZ	MT	DTT
DMUVMWZ	MA	Antagonist
DMUVMWZ	RN	Emerging drugs for ocular allergy. Expert Opin Emerg Drugs. 2005 Aug;10(3):505-20.
DMUVMWZ	RU	https://pubmed.ncbi.nlm.nih.gov/16083326

DM4Y1SP	DI	DM4Y1SP
DM4Y1SP	DN	Carisbamate
DM4Y1SP	MI	TTRK8B9
DM4Y1SP	MN	Sodium channel unspecific (NaC)
DM4Y1SP	MT	DTT
DM4Y1SP	MA	Blocker
DM4Y1SP	RN	Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
DM4Y1SP	RU	https://pubmed.ncbi.nlm.nih.gov/19008076

DM4Y1SP	DI	DM4Y1SP
DM4Y1SP	DN	Carisbamate
DM4Y1SP	MI	DEYGVN4
DM4Y1SP	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM4Y1SP	MT	DME
DM4Y1SP	MA	Metabolism
DM4Y1SP	RN	Carisbamate addon therapy for drugresistant partial epilepsy. The Cochrane Library. John Wiley Sons, Ltd, 2016.
DM4Y1SP	RU	https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012121/full

DMPG4OM	DI	DMPG4OM
DMPG4OM	DN	CAZ AVI
DMPG4OM	MI	TTHI19T
DMPG4OM	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMPG4OM	MT	DTT
DMPG4OM	MA	Modulator
DMPG4OM	RN	NXL104 irreversibly inhibits the -lactamase from Mycobacterium tuberculosis. Biochemistry. 2012 Jun 5;51(22):4551-7.
DMPG4OM	RU	https://pubmed.ncbi.nlm.nih.gov/22587688

DM097UP	DI	DM097UP
DM097UP	DN	CBT-1
DM097UP	MI	TT3OT40
DM097UP	MN	Multidrug resistance protein 1 (ABCB1)
DM097UP	MT	DTT
DM097UP	MA	Modulator
DM097UP	RN	A pharmacodynamic study of the P-glycoprotein antagonist CBT-1 in combination with paclitaxel in solid tumors. Oncologist.2012;17(4):512.
DM097UP	RU	https://www.ncbi.nlm.nih.gov/pubmed/22416063

DMV7WSN	DI	DMV7WSN
DMV7WSN	DN	CC-25430
DMV7WSN	MI	DE4LYSA
DMV7WSN	MN	Cytochrome P450 3A4 (CYP3A4)
DMV7WSN	MT	DME
DMV7WSN	MA	Metabolism
DMV7WSN	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DMV7WSN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DMTNQB0	DI	DMTNQB0
DMTNQB0	DN	CC-486
DMTNQB0	MI	TT6S2FE
DMTNQB0	MN	DNA [cytosine-5]-methyltransferase 1 (DNMT1)
DMTNQB0	MT	DTT
DMTNQB0	MA	Inhibitor
DMTNQB0	RN	Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. Leukemia. 2016 Apr;30(4):889-96.
DMTNQB0	RU	https://pubmed.ncbi.nlm.nih.gov/26442612

DMTNQB0	DI	DMTNQB0
DMTNQB0	DN	CC-486
DMTNQB0	MI	TTVDSZ0
DMTNQB0	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMTNQB0	MT	DTT
DMTNQB0	MA	Inhibitor
DMTNQB0	RN	Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2003 Jan 16;46(2):210-3.
DMTNQB0	RU	https://pubmed.ncbi.nlm.nih.gov/12519059

DM5LQHB	DI	DM5LQHB
DM5LQHB	DN	CCX-168
DM5LQHB	MI	TTHXFA1
DM5LQHB	MN	C5a anaphylatoxin chemotactic receptor (C5AR1)
DM5LQHB	MT	DTT
DM5LQHB	MA	Antagonist
DM5LQHB	RN	Clinical pipeline report, company report or official report of ChemoCentryx.
DM5LQHB	RU	http://www.chemocentryx.com/pipeline/orphan-and-rare-diseases/

DMWO5ZR	DI	DMWO5ZR
DMWO5ZR	DN	Cediranib
DMWO5ZR	MI	DE4LYSA
DMWO5ZR	MN	Cytochrome P450 3A4 (CYP3A4)
DMWO5ZR	MT	DME
DMWO5ZR	MA	Metabolism
DMWO5ZR	RN	In vitro hepatic metabolism of cediranib, a potent vascular endothelial growth factor tyrosine kinase inhibitor: interspecies comparison and human enzymology. Drug Metab Dispos. 2010 Oct;38(10):1688-97.
DMWO5ZR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20634336

DMWO5ZR	DI	DMWO5ZR
DMWO5ZR	DN	Cediranib
DMWO5ZR	MI	TTUTJGQ
DMWO5ZR	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMWO5ZR	MT	DTT
DMWO5ZR	MA	Inhibitor
DMWO5ZR	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMWO5ZR	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMLWIU4	DI	DMLWIU4
DMLWIU4	DN	Cefluprenam
DMLWIU4	MI	TTJP4SM
DMLWIU4	MN	Bacterial Penicillin binding protein (Bact PBP)
DMLWIU4	MT	DTT
DMLWIU4	MA	Inhibitor
DMLWIU4	RN	Comparison of cefepime, cefpirome, and cefaclidine binding affinities for penicillin-binding proteins in Escherichia coli K-12 and Pseudomonas aeruginosa SC8329. Antimicrob Agents Chemother. 1991 Nov;35(11):2312-7.
DMLWIU4	RU	https://pubmed.ncbi.nlm.nih.gov/1804003

DMM76GL	DI	DMM76GL
DMM76GL	DN	Ceftobiprole
DMM76GL	MI	TTJP4SM
DMM76GL	MN	Bacterial Penicillin binding protein (Bact PBP)
DMM76GL	MT	DTT
DMM76GL	MA	Modulator
DMM76GL	RN	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and ... Antimicrob Agents Chemother. 2007 Jul;51(7):2621-4.
DMM76GL	RU	https://www.ncbi.nlm.nih.gov/pubmed/17470659

DMWLF2X	DI	DMWLF2X
DMWLF2X	DN	Ceftobiprole medocaril
DMWLF2X	MI	TTJP4SM
DMWLF2X	MN	Bacterial Penicillin binding protein (Bact PBP)
DMWLF2X	MT	DTT
DMWLF2X	MA	Binder
DMWLF2X	RN	Ceftobiprole medocaril for the treatment of community-acquired pneumonia. Expert Opin Pharmacother. 2018 Sep;19(13):1503-1509.
DMWLF2X	RU	https://pubmed.ncbi.nlm.nih.gov/30198789

DMIGX84	DI	DMIGX84
DMIGX84	DN	Cethromycin
DMIGX84	MI	TTLFGBV
DMIGX84	MN	Bacterial 23S ribosomal RNA (Bact 23S rRNA)
DMIGX84	MT	DTT
DMIGX84	MA	Inhibitor
DMIGX84	RN	How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
DMIGX84	RU	https://pubmed.ncbi.nlm.nih.gov/18621146

DMIGX84	DI	DMIGX84
DMIGX84	DN	Cethromycin
DMIGX84	MI	DEIBDNY
DMIGX84	MN	Cytochrome P450 3A5 (CYP3A5)
DMIGX84	MT	DME
DMIGX84	MA	Metabolism
DMIGX84	RN	CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levels. Clin Pharmacol Ther. 2004 Jun;75(6):516-28.
DMIGX84	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15179406

DMWAHTN	DI	DMWAHTN
DMWAHTN	DN	Cetilistat
DMWAHTN	MI	TTKYZA9
DMWAHTN	MN	Gastric triacylglycerol lipase (LIPF)
DMWAHTN	MT	DTT
DMWAHTN	MA	Modulator
DMWAHTN	RN	Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int J Obes (Lond). 2007 Mar;31(3):494-9.
DMWAHTN	RU	https://pubmed.ncbi.nlm.nih.gov/16953261

DMX9K3W	DI	DMX9K3W
DMX9K3W	DN	Cetraxal Otic
DMX9K3W	MI	TTE72ID
DMX9K3W	MN	Haemophilus influenzae DNA gyrase A (Hae-influ gyrA)
DMX9K3W	MT	DTT
DMX9K3W	MA	Modulator
DMX9K3W	RN	DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol. 2010 May 28;17(5):421-33.
DMX9K3W	RU	https://pubmed.ncbi.nlm.nih.gov/20534341

DMX9K3W	DI	DMX9K3W
DMX9K3W	DN	Cetraxal Otic
DMX9K3W	MI	TT1WJCI
DMX9K3W	MN	Streptococcus Topoisomerase IV A (Stre-coc parC)
DMX9K3W	MT	DTT
DMX9K3W	MA	Modulator
DMX9K3W	RN	DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol. 2010 May 28;17(5):421-33.
DMX9K3W	RU	https://pubmed.ncbi.nlm.nih.gov/20534341

DMIKMA9	DI	DMIKMA9
DMIKMA9	DN	CG-100649
DMIKMA9	MI	TTHQPL7
DMIKMA9	MN	Carbonic anhydrase I (CA-I)
DMIKMA9	MT	DTT
DMIKMA9	MA	Inhibitor
DMIKMA9	RN	Understanding the Dual Inhibition of COX-2 and Carbonic Anhydrase-II by Celecoxib and CG100649 Using Density Functional Theory Calculations and other Molecular Modelling Approaches. Protein Pept Lett. 2015;22(10):903-12.
DMIKMA9	RU	https://pubmed.ncbi.nlm.nih.gov/26095375

DMIKMA9	DI	DMIKMA9
DMIKMA9	DN	CG-100649
DMIKMA9	MI	TTANPDJ
DMIKMA9	MN	Carbonic anhydrase II (CA-II)
DMIKMA9	MT	DTT
DMIKMA9	MA	Inhibitor
DMIKMA9	RN	Understanding the Dual Inhibition of COX-2 and Carbonic Anhydrase-II by Celecoxib and CG100649 Using Density Functional Theory Calculations and other Molecular Modelling Approaches. Protein Pept Lett. 2015;22(10):903-12.
DMIKMA9	RU	https://pubmed.ncbi.nlm.nih.gov/26095375

DMIKMA9	DI	DMIKMA9
DMIKMA9	DN	CG-100649
DMIKMA9	MI	TTVKILB
DMIKMA9	MN	Prostaglandin G/H synthase 2 (COX-2)
DMIKMA9	MT	DTT
DMIKMA9	MA	Inhibitor
DMIKMA9	RN	Pharmacokinetic, pharmacodynamic, and safety/tolerability profiles of CG100649, a novel COX-2 inhibitor: results of a phase i, randomized, multiple-dose study in healthy Korean men and women. Clin Ther. 2015 Jan 1;37(1):197-210.
DMIKMA9	RU	https://pubmed.ncbi.nlm.nih.gov/25097102

DM1TJXA	DI	DM1TJXA
DM1TJXA	DN	Chloride
DM1TJXA	MI	TTTSOUD
DM1TJXA	MN	Candida Cytochrome P450 51 (Candi ERG11)
DM1TJXA	MT	DTT
DM1TJXA	MA	Modulator
DM1TJXA	RN	Isavuconazonium: first global approval. Drugs. 2015 May;75(7):817-22.
DM1TJXA	RU	https://pubmed.ncbi.nlm.nih.gov/25902926

DM1TJXA	DI	DM1TJXA
DM1TJXA	DN	Chloride
DM1TJXA	MI	DE4LYSA
DM1TJXA	MN	Cytochrome P450 3A4 (CYP3A4)
DM1TJXA	MT	DME
DM1TJXA	MA	Metabolism
DM1TJXA	RN	Metabolism of benzalkonium chlorides by human hepatic cytochromes P450. Chem Res Toxicol. 2019 Dec 16;32(12):2466-2478.
DM1TJXA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31730751

DMORSFB	DI	DMORSFB
DMORSFB	DN	Chloroquine
DMORSFB	MI	TTZGK1R
DMORSFB	MN	HUMAN glycosylation of host receptor (GHR)
DMORSFB	MT	DTT
DMORSFB	MA	Inhibitor
DMORSFB	RN	Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.
DMORSFB	RU	https://pubmed.ncbi.nlm.nih.gov/32020029

DMORSFB	DI	DMORSFB
DMORSFB	DN	Chloroquine
DMORSFB	MI	TTD16BI
DMORSFB	MN	HUMAN pH-dependent viral fusion/replication (pH-DVF/R)
DMORSFB	MT	DTT
DMORSFB	MA	Inhibitor
DMORSFB	RN	Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.
DMORSFB	RU	https://pubmed.ncbi.nlm.nih.gov/32020029

DM5X7DJ	DI	DM5X7DJ
DM5X7DJ	DN	Chlorpromazine
DM5X7DJ	MI	TTAIY2U
DM5X7DJ	MN	HUMAN clathrin-mediated endocytosis (RME)
DM5X7DJ	MT	DTT
DM5X7DJ	MA	Inhibitor
DM5X7DJ	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DM5X7DJ	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DM0Q6CM	DI	DM0Q6CM
DM0Q6CM	DN	CIGB-300
DM0Q6CM	MI	TTZ5NI7
DM0Q6CM	MN	Casein kinase II (CSNK2)
DM0Q6CM	MT	DTT
DM0Q6CM	MA	Modulator
DM0Q6CM	RN	Synergistic interactions of the anti-casein kinase 2 CIGB-300 peptide and chemotherapeutic agents in lung and cervical preclinical cancer models. Mol Clin Oncol. 2014 Nov;2(6):935-944.
DM0Q6CM	RU	https://pubmed.ncbi.nlm.nih.gov/25279177

DMP0NGX	DI	DMP0NGX
DMP0NGX	DN	Cilansetron
DMP0NGX	MI	TTPC4TU
DMP0NGX	MN	5-HT 3A receptor (HTR3A)
DMP0NGX	MT	DTT
DMP0NGX	MA	Modulator
DMP0NGX	RN	Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea.Expert Opin Investig Drugs.2005 Feb;14(2):185-93.
DMP0NGX	RU	https://www.ncbi.nlm.nih.gov/pubmed/15757394

DMEAOZ0	DI	DMEAOZ0
DMEAOZ0	DN	Cilengitide
DMEAOZ0	MI	TT69TQN
DMEAOZ0	MN	Integrin alpha-V/beta-3 (ITGAV/B3)
DMEAOZ0	MT	DTT
DMEAOZ0	MA	Modulator
DMEAOZ0	RN	The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells.PLoS One.2009;4(2):e4449.
DMEAOZ0	RU	https://www.ncbi.nlm.nih.gov/pubmed/19212436

DM1975O	DI	DM1975O
DM1975O	DN	Cilnidipine
DM1975O	MI	DE4LYSA
DM1975O	MN	Cytochrome P450 3A4 (CYP3A4)
DM1975O	MT	DME
DM1975O	MA	Metabolism
DM1975O	RN	Metabolism and metabolic inhibition of cilnidipine in human liver microsomes. Acta Pharmacol Sin. 2003 Mar;24(3):263-8.
DM1975O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12617777

DM1975O	DI	DM1975O
DM1975O	DN	Cilnidipine
DM1975O	MI	TT4FDG6
DM1975O	MN	Voltage-gated calcium channel alpha Cav2.2 (CACNA1B)
DM1975O	MT	DTT
DM1975O	MA	Blocker
DM1975O	RN	N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model. J Hypertens. 2002 May;20(5):993-1000.
DM1975O	RU	https://pubmed.ncbi.nlm.nih.gov/12011661

DM1975O	DI	DM1975O
DM1975O	DN	Cilnidipine
DM1975O	MI	TTXHYV6
DM1975O	MN	Voltage-gated L-type calcium channel (L-CaC)
DM1975O	MT	DTT
DM1975O	MA	Blocker
DM1975O	RN	N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model. J Hypertens. 2002 May;20(5):993-1000.
DM1975O	RU	https://pubmed.ncbi.nlm.nih.gov/12011661

DMU2J7Y	DI	DMU2J7Y
DMU2J7Y	DN	Ciltacabtagene autoleucel
DMU2J7Y	MI	TTZ3P4W
DMU2J7Y	MN	B-cell maturation protein (TNFRSF17)
DMU2J7Y	MT	DTT
DMU2J7Y	RN	ClinicalTrials.gov (NCT04181827) A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4). U.S. National Institutes of Health.
DMU2J7Y	RU	https://clinicaltrials.gov/ct2/show/NCT04181827

DMEGFYD	DI	DMEGFYD
DMEGFYD	DN	Cinitapride
DMEGFYD	MI	DES5XRU
DMEGFYD	MN	Cytochrome P450 2C8 (CYP2C8)
DMEGFYD	MT	DME
DMEGFYD	MA	Metabolism
DMEGFYD	RN	The prokinetic cinitapride has no clinically relevant pharmacokinetic interaction and effect on QT during coadministration with ketoconazole. Drug Metab Dispos. 2007 Jul;35(7):1149-56.
DMEGFYD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17437965

DMEGFYD	DI	DMEGFYD
DMEGFYD	DN	Cinitapride
DMEGFYD	MI	DE4LYSA
DMEGFYD	MN	Cytochrome P450 3A4 (CYP3A4)
DMEGFYD	MT	DME
DMEGFYD	MA	Metabolism
DMEGFYD	RN	The prokinetic cinitapride has no clinically relevant pharmacokinetic interaction and effect on QT during coadministration with ketoconazole. Drug Metab Dispos. 2007 Jul;35(7):1149-56.
DMEGFYD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17437965

DM803GL	DI	DM803GL
DM803GL	DN	CIPEMASTAT
DM803GL	MI	TTMX39J
DM803GL	MN	Matrix metalloproteinase-1 (MMP-1)
DM803GL	MT	DTT
DM803GL	MA	Modulator
DM803GL	RN	Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis. Infect Immun. 2014 Apr;82(4):1710-8.
DM803GL	RU	https://pubmed.ncbi.nlm.nih.gov/24491581

DM803GL	DI	DM803GL
DM803GL	DN	CIPEMASTAT
DM803GL	MI	TTGA1IV
DM803GL	MN	Matrix metalloproteinase-8 (MMP-8)
DM803GL	MT	DTT
DM803GL	MA	Modulator
DM803GL	RN	Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis. Infect Immun. 2014 Apr;82(4):1710-8.
DM803GL	RU	https://pubmed.ncbi.nlm.nih.gov/24491581

DMJ9ZIY	DI	DMJ9ZIY
DMJ9ZIY	DN	CK-2017357
DMJ9ZIY	MI	TTYUMF5
DMJ9ZIY	MN	Fast skeletal muscle troponin complex (TNNC2)
DMJ9ZIY	MT	DTT
DMJ9ZIY	MA	Modulator
DMJ9ZIY	RN	Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases. Nat Med. 2012 Feb 19;18(3):452-5.
DMJ9ZIY	RU	https://pubmed.ncbi.nlm.nih.gov/22344294

DMTSONL	DI	DMTSONL
DMTSONL	DN	Claritin/Singulair
DMTSONL	MI	TTGKOY9
DMTSONL	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DMTSONL	MT	DTT
DMTSONL	MA	Modulator
DMTSONL	RN	Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics. 2001 Sep;108(3):E48.
DMTSONL	RU	https://pubmed.ncbi.nlm.nih.gov/11533366

DMPQR1D	DI	DMPQR1D
DMPQR1D	DN	Claudiximab
DMPQR1D	MI	TT6PKBX
DMPQR1D	MN	Claudin-18 (CLDN18)
DMPQR1D	MT	DTT
DMPQR1D	RN	Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms. Int J Cancer. 2014 Feb 1;134(3):731-9.
DMPQR1D	RU	https://pubmed.ncbi.nlm.nih.gov/23900716

DMQSBX4	DI	DMQSBX4
DMQSBX4	DN	Clazosentan
DMQSBX4	MI	TTKRD0G
DMQSBX4	MN	Endothelin A receptor (EDNRA)
DMQSBX4	MT	DTT
DMQSBX4	MA	Antagonist
DMQSBX4	RN	Effects of the selective endothelin A (ET(A)) receptor antagonist Clazosentan on cerebral perfusion and cerebral oxygenation following severe subar... Acta Neurochir (Wien). 2007;149(9):911-8; discussion 918.
DMQSBX4	RU	https://pubmed.ncbi.nlm.nih.gov/17700991

DMQSBX4	DI	DMQSBX4
DMQSBX4	DN	Clazosentan
DMQSBX4	MI	TTCV6O0
DMQSBX4	MN	Endothelin receptor (EDNR)
DMQSBX4	MT	DTT
DMQSBX4	MA	Antagonist
DMQSBX4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQSBX4	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMR21Q3	DI	DMR21Q3
DMR21Q3	DN	Clevudine
DMR21Q3	MI	TTS5K1M
DMR21Q3	MN	Hepatitis B virus Reverse transcriptase (HBV RT)
DMR21Q3	MT	DTT
DMR21Q3	MA	Inhibitor
DMR21Q3	RN	2011 Pipeline of Bukwang.
DMR21Q3	RU	http://bkmedical.en.ecplaza.net/

DMSPN58	DI	DMSPN58
DMSPN58	DN	Clomethiazole
DMSPN58	MI	DEJVYAZ
DMSPN58	MN	Cytochrome P450 2A6 (CYP2A6)
DMSPN58	MT	DME
DMSPN58	MA	Metabolism
DMSPN58	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMSPN58	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMSPN58	DI	DMSPN58
DMSPN58	DN	Clomethiazole
DMSPN58	MI	DEPKLMQ
DMSPN58	MN	Cytochrome P450 2B6 (CYP2B6)
DMSPN58	MT	DME
DMSPN58	MA	Metabolism
DMSPN58	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMSPN58	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMSPN58	DI	DMSPN58
DMSPN58	DN	Clomethiazole
DMSPN58	MI	DE4LYSA
DMSPN58	MN	Cytochrome P450 3A4 (CYP3A4)
DMSPN58	MT	DME
DMSPN58	MA	Metabolism
DMSPN58	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMSPN58	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMSPN58	DI	DMSPN58
DMSPN58	DN	Clomethiazole
DMSPN58	MI	TTEX6LM
DMSPN58	MN	GABA(A) receptor gamma-3 (GABRG3)
DMSPN58	MT	DTT
DMSPN58	MA	Modulator
DMSPN58	RN	Electrophysiological actions of gamma-aminobutyric acid and clomethiazole on recombinant GABA(A) receptors. Eur J Pharmacol. 2002 Oct 11;452(3):255-62.
DMSPN58	RU	https://www.ncbi.nlm.nih.gov/pubmed/12359265

DMSPN58	DI	DMSPN58
DMSPN58	DN	Clomethiazole
DMSPN58	MI	DEGTFWK
DMSPN58	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMSPN58	MT	DME
DMSPN58	MA	Metabolism
DMSPN58	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMSPN58	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMFQ1WX	DI	DMFQ1WX
DMFQ1WX	DN	CLS006
DMFQ1WX	MI	TTL3N71
DMFQ1WX	MN	Virus Replication (Viru Repli)
DMFQ1WX	MT	DTT
DMFQ1WX	MA	Inhibitor
DMFQ1WX	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMFQ1WX	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMASPWR	DI	DMASPWR
DMASPWR	DN	CM-2395
DMASPWR	MI	TTSQIFT
DMASPWR	MN	5-HT 1A receptor (HTR1A)
DMASPWR	MT	DTT
DMASPWR	MA	Agonist
DMASPWR	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
DMASPWR	RU	http://adisinsight.springer.com/drugs/800031127

DMASPWR	DI	DMASPWR
DMASPWR	DN	CM-2395
DMASPWR	MI	TT4C8EA
DMASPWR	MN	Dopamine D3 receptor (D3R)
DMASPWR	MT	DTT
DMASPWR	MA	Agonist
DMASPWR	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
DMASPWR	RU	http://adisinsight.springer.com/drugs/800031127

DMASPWR	DI	DMASPWR
DMASPWR	DN	CM-2395
DMASPWR	MI	TTE0A2F
DMASPWR	MN	Dopamine D4 receptor (D4R)
DMASPWR	MT	DTT
DMASPWR	MA	Agonist
DMASPWR	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
DMASPWR	RU	http://adisinsight.springer.com/drugs/800031127

DMASPWR	DI	DMASPWR
DMASPWR	DN	CM-2395
DMASPWR	MI	TT5TPI6
DMASPWR	MN	Opioid receptor sigma 1 (OPRS1)
DMASPWR	MT	DTT
DMASPWR	MA	Agonist
DMASPWR	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
DMASPWR	RU	http://adisinsight.springer.com/drugs/800031127

DMLMN2F	DI	DMLMN2F
DMLMN2F	DN	CM-AT
DMLMN2F	MI	TT7MRGU
DMLMN2F	MN	Chymotrypsin (CTR)
DMLMN2F	MT	DTT
DMLMN2F	MA	Modulator
DMLMN2F	RN	Drugmakers dance with autism. Nat Biotechnol. 2010 Aug;28(8):772-4.
DMLMN2F	RU	https://pubmed.ncbi.nlm.nih.gov/20697394

DMC4X7L	DI	DMC4X7L
DMC4X7L	DN	CMS-024-02
DMC4X7L	MI	TTBH0VX
DMC4X7L	MN	Histone deacetylase (HDAC)
DMC4X7L	MT	DTT
DMC4X7L	MA	Modulator
DMC4X7L	RN	US patent application no. 2012,0302,505, Cyclodextrin-based polymers for therapeutic delivery.
DMC4X7L	RU	http://www.google.com/patents/US20120302505

DM9Y3B5	DI	DM9Y3B5
DM9Y3B5	DN	CMX-001
DM9Y3B5	MI	TTATL6Y
DM9Y3B5	MN	DNA-dependent DNA polymerase (DPOL)
DM9Y3B5	MT	DTT
DM9Y3B5	MA	Inhibitor
DM9Y3B5	RN	Detection of Molluscum Contagiosum Virus (MCV) DNA in the Plasma of an Immunocompromised Patient and Possible Reduction of MCV DNA With CMX-001. J Infect Dis. 2012 March 1; 205(5): 794-797.
DM9Y3B5	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3274371/

DMB4JPG	DI	DMB4JPG
DMB4JPG	DN	CNTX-4975
DMB4JPG	MI	TTMI6F5
DMB4JPG	MN	Transient receptor potential cation channel V1 (TRPV1)
DMB4JPG	MT	DTT
DMB4JPG	MA	Agonist
DMB4JPG	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMB4JPG	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMWZ2TU	DI	DMWZ2TU
DMWZ2TU	DN	CO-1686
DMWZ2TU	MI	TTGKNB4
DMWZ2TU	MN	Epidermal growth factor receptor (EGFR)
DMWZ2TU	MT	DTT
DMWZ2TU	MA	Modulator
DMWZ2TU	RN	Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015 Apr 30;372(18):1700-9.
DMWZ2TU	RU	https://pubmed.ncbi.nlm.nih.gov/25923550

DMN9ETB	DI	DMN9ETB
DMN9ETB	DN	Contusugene ladenovec
DMN9ETB	MI	TT7SBF5
DMN9ETB	MN	Cellular tumor antigen p53 (TP53)
DMN9ETB	MT	DTT
DMN9ETB	MA	Modulator
DMN9ETB	RN	A review of contusugene ladenovec (Advexin) p53 therapy. Curr Opin Mol Ther. 2009 Feb;11(1):54-61.
DMN9ETB	RU	https://pubmed.ncbi.nlm.nih.gov/19169960

DMA0WEK	DI	DMA0WEK
DMA0WEK	DN	Coprexa
DMA0WEK	MI	TT6RVLG
DMA0WEK	MN	Superoxide dismutase Cu-Zn (SOD Cu-Zn)
DMA0WEK	MT	DTT
DMA0WEK	MA	Inhibitor
DMA0WEK	RN	Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res. 2006 Aug 15;12(16):4974-82.
DMA0WEK	RU	https://pubmed.ncbi.nlm.nih.gov/16914587

DMBS3UG	DI	DMBS3UG
DMBS3UG	DN	CORT-125134
DMBS3UG	MI	TTYRL6O
DMBS3UG	MN	Glucocorticoid receptor (NR3C1)
DMBS3UG	MT	DTT
DMBS3UG	MA	Antagonist
DMBS3UG	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMBS3UG	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMMEAOL	DI	DMMEAOL
DMMEAOL	DN	Coversin
DMMEAOL	MI	TTKANGO
DMMEAOL	MN	Complement C5 (CO5)
DMMEAOL	MT	DTT
DMMEAOL	MA	Inhibitor
DMMEAOL	RN	Use of the complement inhibitor Coversin to treat HSCT-associated TMA. Blood Adv. 2017 Jul 3;1(16):1254-1258.
DMMEAOL	RU	https://pubmed.ncbi.nlm.nih.gov/29296765

DMZIM37	DI	DMZIM37
DMZIM37	DN	CP-868596
DMZIM37	MI	TT8FYO9
DMZIM37	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMZIM37	MT	DTT
DMZIM37	MA	Modulator
DMZIM37	RN	The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations.Invest New Drugs.2015 Apr;33(2):300-9.
DMZIM37	RU	https://www.ncbi.nlm.nih.gov/pubmed/25597754

DMZIM37	DI	DMZIM37
DMZIM37	DN	CP-868596
DMZIM37	MI	TT6PKBN
DMZIM37	MN	Proto-oncogene c-Src (SRC)
DMZIM37	MT	DTT
DMZIM37	MA	Inhibitor
DMZIM37	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZIM37	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM2EO5M	DI	DM2EO5M
DM2EO5M	DN	CPC-211
DM2EO5M	MI	DEQPEMB
DM2EO5M	MN	Glutathione S-transferase zeta-1 (GSTZ1)
DM2EO5M	MT	DME
DM2EO5M	MA	Metabolism
DM2EO5M	RN	Personalized dosing of dichloroacetate using GSTZ1 clinical genotyping assay. Genet Test Mol Biomarkers. 2018 Apr;22(4):266-269.
DM2EO5M	RU	https://pubmed.ncbi.nlm.nih.gov/29641284

DMPXOYJ	DI	DMPXOYJ
DMPXOYJ	DN	CPI-0610
DMPXOYJ	MI	TTE4BSY
DMPXOYJ	MN	Bromodomain and extraterminal domain protein (BET)
DMPXOYJ	MT	DTT
DMPXOYJ	MA	Inhibitor
DMPXOYJ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPXOYJ	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMPXOYJ	DI	DMPXOYJ
DMPXOYJ	DN	CPI-0610
DMPXOYJ	MI	TTRA6BO
DMPXOYJ	MN	Bromodomain-containing protein 4 (BRD4)
DMPXOYJ	MT	DTT
DMPXOYJ	MA	Modulator
DMPXOYJ	RN	Targeting bromodomains: epigenetic readers of lysine acetylation.Nat Rev Drug Discov.2014 May;13(5):337-56.
DMPXOYJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/24751816

DM5XUQL	DI	DM5XUQL
DM5XUQL	DN	CPI-613
DM5XUQL	MI	TTH8T6I
DM5XUQL	MN	Alpha-ketoglutarate dehydrogenase (OGDH)
DM5XUQL	MT	DTT
DM5XUQL	MA	Modulator
DM5XUQL	RN	A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process. Cancer Metab. 2014 Mar 10;2(1):4.
DM5XUQL	RU	https://pubmed.ncbi.nlm.nih.gov/24612826

DM62E7C	DI	DM62E7C
DM62E7C	DN	CPL-7075
DM62E7C	MI	TTF8CQI
DM62E7C	MN	Tumor necrosis factor (TNF)
DM62E7C	MT	DTT
DM62E7C	MA	Inhibitor
DM62E7C	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DM62E7C	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DM60TVK	DI	DM60TVK
DM60TVK	DN	CQA 206-291
DM60TVK	MI	TTEX248
DM60TVK	MN	Dopamine D2 receptor (D2R)
DM60TVK	MT	DTT
DM60TVK	MA	Agonist
DM60TVK	RN	The antiparkinsonian activity of CQA 206-291, a new D2 dopamine receptor agonist. Clin Neuropharmacol. 1989 Feb;12(1):55-9.
DM60TVK	RU	https://pubmed.ncbi.nlm.nih.gov/2565766

DMKD2BQ	DI	DMKD2BQ
DMKD2BQ	DN	Creatine ALS-08
DMKD2BQ	MI	DTPKTHL
DMKD2BQ	MN	Creatine transporter 1 (SLC6A8)
DMKD2BQ	MT	DTP
DMKD2BQ	MA	Substrate
DMKD2BQ	RN	Astrocytic -aminobutyric acid (GABA) transporters mediate guanidinoacetate transport in rat brain. 2018 Feb;113:1-7.
DMKD2BQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/29175673

DMKD2BQ	DI	DMKD2BQ
DMKD2BQ	DN	Creatine ALS-08
DMKD2BQ	MI	TTZ1DV7
DMKD2BQ	MN	Mitochondrial function (MF)
DMKD2BQ	MT	DTT
DMKD2BQ	MA	Modulator
DMKD2BQ	RN	The therapeutic role of creatine in Huntington's disease. Pharmacol Ther. 2005 Nov;108(2):193-207.
DMKD2BQ	RU	https://pubmed.ncbi.nlm.nih.gov/16055197

DMKD2BQ	DI	DMKD2BQ
DMKD2BQ	DN	Creatine ALS-08
DMKD2BQ	MI	DTZOKFJ
DMKD2BQ	MN	Monocarboxylate transporter 12 (SLC16A12)
DMKD2BQ	MT	DTP
DMKD2BQ	MA	Substrate
DMKD2BQ	RN	Mutation in the Monocarboxylate Transporter 12 Gene Affects Guanidinoacetate Excretion but Does Not Cause Glucosuria. J Am Soc Nephrol. 2016 May;27(5):1426-36.
DMKD2BQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/26376857

DM7QI29	DI	DM7QI29
DM7QI29	DN	Crenezumab
DM7QI29	MI	TTE4KHA
DM7QI29	MN	Amyloid beta A4 protein (APP)
DM7QI29	MT	DTT
DM7QI29	MA	Modulator
DM7QI29	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
DM7QI29	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402

DM5F24X	DI	DM5F24X
DM5F24X	DN	Crocin
DM5F24X	MI	DTUGYRD
DM5F24X	MN	P-glycoprotein 1 (ABCB1)
DM5F24X	MT	DTP
DM5F24X	MA	Substrate
DM5F24X	RN	Carotenoids reverse multidrug resistance in cancer cells by interfering with ABC-transporters. Phytomedicine. 2012 Aug 15;19(11):977-87.
DM5F24X	RU	https://doi.org/10.1016/j.phymed.2012.05.010

DM67P0F	DI	DM67P0F
DM67P0F	DN	CS-038
DM67P0F	MI	TTJ584C
DM67P0F	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DM67P0F	MT	DTT
DM67P0F	MA	Modulator
DM67P0F	RN	Determination of chiglitazar, a dual alpha/gamma peroxisome proliferator-activated receptor (PPAR) agonist, in human plasma by liquid chromatograph... Pharmazie. 2007 Nov;62(11):825-9.
DM67P0F	RU	https://www.ncbi.nlm.nih.gov/pubmed/18065097

DM67P0F	DI	DM67P0F
DM67P0F	DN	CS-038
DM67P0F	MI	TTZMAO3
DM67P0F	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DM67P0F	MT	DTT
DM67P0F	MA	Modulator
DM67P0F	RN	Determination of chiglitazar, a dual alpha/gamma peroxisome proliferator-activated receptor (PPAR) agonist, in human plasma by liquid chromatograph... Pharmazie. 2007 Nov;62(11):825-9.
DM67P0F	RU	https://www.ncbi.nlm.nih.gov/pubmed/18065097

DMSY0NE	DI	DMSY0NE
DMSY0NE	DN	CS1001
DMSY0NE	MI	TT8ZLTI
DMSY0NE	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMSY0NE	MT	DTT
DMSY0NE	RN	GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy. Transl Lung Cancer Res. 2020 Oct;9(5):2008-2015.
DMSY0NE	RU	https://pubmed.ncbi.nlm.nih.gov/33209620

DM1PV4Y	DI	DM1PV4Y
DM1PV4Y	DN	CS-600G
DM1PV4Y	MI	DEB3CV1
DM1PV4Y	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DM1PV4Y	MT	DME
DM1PV4Y	MA	Metabolism
DM1PV4Y	RN	Exploring the metabolism of loxoprofen in liver microsomes: the role of cytochrome P450 and UDP-glucuronosyltransferase in its biotransformation. Pharmaceutics. 2018 Aug 2;10(3). pii: E112.
DM1PV4Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30072626

DM4CSDH	DI	DM4CSDH
DM4CSDH	DN	CS-8958
DM4CSDH	MI	TT50QJ3
DM4CSDH	MN	Influenza Neuraminidase (Influ NA)
DM4CSDH	MT	DTT
DM4CSDH	MA	Inhibitor
DM4CSDH	RN	Developing new antiviral agents for influenza treatment: what does the future hold Clin Infect Dis. 2009 Jan 1;48 Suppl 1:S3-13.
DM4CSDH	RU	https://pubmed.ncbi.nlm.nih.gov/19067613

DMV574J	DI	DMV574J
DMV574J	DN	CSL312
DMV574J	MI	TTMXD0O
DMV574J	MN	Coagulation factor XII (F12)
DMV574J	MT	DTT
DMV574J	MA	Inhibitor
DMV574J	RN	Clinical pipeline report, company report or official report of CSL Behring.
DMV574J	RU	https://www.cslbehring.com/r-and-d/product-pipeline

DMZJGVL	DI	DMZJGVL
DMZJGVL	DN	CSL-654
DMZJGVL	MI	TTFEZ5Q
DMZJGVL	MN	Coagulation factor IX (F9)
DMZJGVL	MT	DTT
DMZJGVL	MA	Modulator
DMZJGVL	RN	Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood. 2012 September 20; 120(12): 2405-2411.
DMZJGVL	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3448255/

DMU2ZFK	DI	DMU2ZFK
DMU2ZFK	DN	CT-2584
DMU2ZFK	MI	TTUAIKM
DMU2ZFK	MN	Cholinephosphate cytidylyltransferase (PCYT1B)
DMU2ZFK	MT	DTT
DMU2ZFK	MA	Modulator
DMU2ZFK	RN	Pharmacological inhibition of phosphatidylcholine biosynthesis is associated with induction of phosphatidylinositol accumulation and cytolysis of neoplastic cell lines. Cancer Res. 2000 Sep 15;60(18):5204-13.
DMU2ZFK	RU	https://pubmed.ncbi.nlm.nih.gov/11016649

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	TTXV4FI
DMQPH29	MN	Albendazole monooxygenase (CYP3A4)
DMQPH29	MT	DTT
DMQPH29	MA	Inhibitor
DMQPH29	RN	Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues. Eur J Med Chem. 2008 Aug;43(8):1621-31.
DMQPH29	RU	https://pubmed.ncbi.nlm.nih.gov/18249473

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	TTE4KHA
DMQPH29	MN	Amyloid beta A4 protein (APP)
DMQPH29	MT	DTT
DMQPH29	MA	Inhibitor
DMQPH29	RN	Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. J Med Chem. 2006 Oct 5;49(20):6111-9.
DMQPH29	RU	https://pubmed.ncbi.nlm.nih.gov/17004725

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	TTUNARX
DMQPH29	MN	Carbonic anhydrase (CA)
DMQPH29	MT	DTT
DMQPH29	MA	Inhibitor
DMQPH29	RN	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
DMQPH29	RU	https://pubmed.ncbi.nlm.nih.gov/20674354

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	TTHQPL7
DMQPH29	MN	Carbonic anhydrase I (CA-I)
DMQPH29	MT	DTT
DMQPH29	MA	Inhibitor
DMQPH29	RN	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
DMQPH29	RU	https://pubmed.ncbi.nlm.nih.gov/20674354

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	TTANPDJ
DMQPH29	MN	Carbonic anhydrase II (CA-II)
DMQPH29	MT	DTT
DMQPH29	MA	Inhibitor
DMQPH29	RN	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
DMQPH29	RU	https://pubmed.ncbi.nlm.nih.gov/20674354

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	TTZHA0O
DMQPH29	MN	Carbonic anhydrase IV (CA-IV)
DMQPH29	MT	DTT
DMQPH29	MA	Inhibitor
DMQPH29	RN	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
DMQPH29	RU	https://pubmed.ncbi.nlm.nih.gov/20674354

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	TT2LVK8
DMQPH29	MN	Carbonic anhydrase IX (CA-IX)
DMQPH29	MT	DTT
DMQPH29	MA	Inhibitor
DMQPH29	RN	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
DMQPH29	RU	https://pubmed.ncbi.nlm.nih.gov/20674354

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	TTCFSPE
DMQPH29	MN	Carbonic anhydrase VI (CA-VI)
DMQPH29	MT	DTT
DMQPH29	MA	Inhibitor
DMQPH29	RN	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
DMQPH29	RU	https://pubmed.ncbi.nlm.nih.gov/20674354

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	TTSYM0R
DMQPH29	MN	Carbonic anhydrase XII (CA-XII)
DMQPH29	MT	DTT
DMQPH29	MA	Inhibitor
DMQPH29	RN	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
DMQPH29	RU	https://pubmed.ncbi.nlm.nih.gov/20674354

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	TTEYTKG
DMQPH29	MN	Carbonic anhydrase XIV (CA-XIV)
DMQPH29	MT	DTT
DMQPH29	MA	Inhibitor
DMQPH29	RN	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
DMQPH29	RU	https://pubmed.ncbi.nlm.nih.gov/20674354

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	TTHVCUP
DMQPH29	MN	DNA [cytosine-5]-methyltransferase (DNMT)
DMQPH29	MT	DTT
DMQPH29	MA	Inhibitor
DMQPH29	RN	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
DMQPH29	RU	https://pubmed.ncbi.nlm.nih.gov/20006515

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	TT6VZ78
DMQPH29	MN	DNA [cytosine-5]-methyltransferase 3B (DNMT3B)
DMQPH29	MT	DTT
DMQPH29	MA	Inhibitor
DMQPH29	RN	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
DMQPH29	RU	https://pubmed.ncbi.nlm.nih.gov/20006515

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	TTHY57M
DMQPH29	MN	Matrix metalloproteinase-13 (MMP-13)
DMQPH29	MT	DTT
DMQPH29	MA	Inhibitor
DMQPH29	RN	High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg Med Chem. 2009 Feb 1;17(3):990-1005.
DMQPH29	RU	https://pubmed.ncbi.nlm.nih.gov/18358729

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	TT6X50U
DMQPH29	MN	Matrix metalloproteinase-9 (MMP-9)
DMQPH29	MT	DTT
DMQPH29	MA	Inhibitor
DMQPH29	RN	Synthesis and biological evaluation of curcuminoid pyrazoles as new therapeutic agents in inflammatory bowel disease: effect on matrix metalloprote... Bioorg Med Chem. 2009 Feb 1;17(3):1290-6.
DMQPH29	RU	https://pubmed.ncbi.nlm.nih.gov/19128977

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	TT0JLSD
DMQPH29	MN	Multidrug resistance protein (MDR)
DMQPH29	MT	DTT
DMQPH29	MA	Inhibitor
DMQPH29	RN	Thiazolides: a new class of antiviral drugs. Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):667-74.
DMQPH29	RU	https://pubmed.ncbi.nlm.nih.gov/19442032

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	DEZWDKE
DMQPH29	MN	NADPH-dependent curcumin reductase (curA)
DMQPH29	MT	DME
DMQPH29	MA	Metabolism
DMQPH29	RN	Discovery of the curcumin metabolic pathway involving a unique enzyme in an intestinal microorganism. Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6615-20.
DMQPH29	RU	https://pubmed.ncbi.nlm.nih.gov/21467222

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	TTF10I9
DMQPH29	MN	Nitric-oxide synthase inducible (NOS2)
DMQPH29	MT	DTT
DMQPH29	MA	Inhibitor
DMQPH29	RN	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
DMQPH29	RU	https://pubmed.ncbi.nlm.nih.gov/18077363

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	DTUGYRD
DMQPH29	MN	P-glycoprotein 1 (ABCB1)
DMQPH29	MT	DTP
DMQPH29	MA	Substrate
DMQPH29	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMQPH29	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	TT8NGED
DMQPH29	MN	Prostaglandin G/H synthase 1 (COX-1)
DMQPH29	MT	DTT
DMQPH29	MA	Inhibitor
DMQPH29	RN	Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammator... Bioorg Med Chem Lett. 2005 Apr 1;15(7):1793-7.
DMQPH29	RU	https://pubmed.ncbi.nlm.nih.gov/15780608

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	TTVKILB
DMQPH29	MN	Prostaglandin G/H synthase 2 (COX-2)
DMQPH29	MT	DTT
DMQPH29	MA	Inhibitor
DMQPH29	RN	Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammator... Bioorg Med Chem Lett. 2005 Apr 1;15(7):1793-7.
DMQPH29	RU	https://pubmed.ncbi.nlm.nih.gov/15780608

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	DEYGVN4
DMQPH29	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMQPH29	MT	DME
DMQPH29	MA	Metabolism
DMQPH29	RN	Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Biol Chem. 2004 Jan 9;279(2):1429-41.
DMQPH29	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14557274

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	DEZO4N3
DMQPH29	MN	UDP-glucuronosyltransferase 1A7 (UGT1A7)
DMQPH29	MT	DME
DMQPH29	MA	Metabolism
DMQPH29	RN	Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Biol Chem. 2004 Jan 9;279(2):1429-41.
DMQPH29	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14557274

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	DE2GB8N
DMQPH29	MN	UDP-glucuronosyltransferase 1A8 (UGT1A8)
DMQPH29	MT	DME
DMQPH29	MA	Metabolism
DMQPH29	RN	Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Biol Chem. 2004 Jan 9;279(2):1429-41.
DMQPH29	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14557274

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	DE85D2P
DMQPH29	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMQPH29	MT	DME
DMQPH29	MA	Metabolism
DMQPH29	RN	Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Biol Chem. 2004 Jan 9;279(2):1429-41.
DMQPH29	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14557274

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	TT7RJY8
DMQPH29	MN	Xanthine dehydrogenase/oxidase (XDH)
DMQPH29	MT	DTT
DMQPH29	MA	Inhibitor
DMQPH29	RN	Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin. J Nat Prod. 2009 Apr;72(4):725-31.
DMQPH29	RU	https://pubmed.ncbi.nlm.nih.gov/19388706

DMIQ31Y	DI	DMIQ31Y
DMIQ31Y	DN	Custirsen
DMIQ31Y	MI	TTRL76H
DMIQ31Y	MN	Clusterin messenger RNA (Clusterin mRNA)
DMIQ31Y	MT	DTT
DMIQ31Y	RN	Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors. Eur J Cancer. 2009 Jul;45(10):1846-54.
DMIQ31Y	RU	https://pubmed.ncbi.nlm.nih.gov/19342222

DM0JA9N	DI	DM0JA9N
DM0JA9N	DN	Cyrtominetin
DM0JA9N	MI	TT5FLYB
DM0JA9N	MN	Staphylococcus Alpha-hemolysin (Stap-coc hly)
DM0JA9N	MT	DTT
DM0JA9N	MA	Modulator
DM0JA9N	RN	Molecular insight into the inhibition mechanism of cyrtominetin to alpha-hemolysin by molecular dynamics simulation. Eur J Med Chem. 2013 Apr;62:320-8.
DM0JA9N	RU	https://pubmed.ncbi.nlm.nih.gov/23376250

DMUF0BJ	DI	DMUF0BJ
DMUF0BJ	DN	CYTISINE
DMUF0BJ	MI	TTF4E0J
DMUF0BJ	MN	Neuronal acetylcholine receptor alpha-2 (CHRNA2)
DMUF0BJ	MT	DTT
DMUF0BJ	MA	Inhibitor
DMUF0BJ	RN	Synthesis and pharmacological evaluation of novel 9- and 10-substituted cytisine derivatives. Nicotinic ligands of enhanced subtype selectivity. J Med Chem. 2006 May 4;49(9):2673-6.
DMUF0BJ	RU	https://pubmed.ncbi.nlm.nih.gov/16640326

DMUF0BJ	DI	DMUF0BJ
DMUF0BJ	DN	CYTISINE
DMUF0BJ	MI	TT4H1MQ
DMUF0BJ	MN	Neuronal acetylcholine receptor alpha-4 (CHRNA4)
DMUF0BJ	MT	DTT
DMUF0BJ	MA	Inhibitor
DMUF0BJ	RN	Epibatidine isomers and analogues: structure-activity relationships. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5493-7.
DMUF0BJ	RU	https://pubmed.ncbi.nlm.nih.gov/16934977

DMUF0BJ	DI	DMUF0BJ
DMUF0BJ	DN	CYTISINE
DMUF0BJ	MI	TTLA931
DMUF0BJ	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMUF0BJ	MT	DTT
DMUF0BJ	MA	Inhibitor
DMUF0BJ	RN	3,5-Bicyclic aryl piperidines: a novel class of alpha4beta2 neuronal nicotinic receptor partial agonists for smoking cessation. Bioorg Med Chem Lett. 2005 Nov 15;15(22):4889-97.
DMUF0BJ	RU	https://pubmed.ncbi.nlm.nih.gov/16171993

DMUF0BJ	DI	DMUF0BJ
DMUF0BJ	DN	CYTISINE
DMUF0BJ	MI	TT5KPZR
DMUF0BJ	MN	Neuronal acetylcholine receptor beta-2 (CHRNB2)
DMUF0BJ	MT	DTT
DMUF0BJ	MA	Inhibitor
DMUF0BJ	RN	Epibatidine isomers and analogues: structure-activity relationships. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5493-7.
DMUF0BJ	RU	https://pubmed.ncbi.nlm.nih.gov/16934977

DMUF0BJ	DI	DMUF0BJ
DMUF0BJ	DN	CYTISINE
DMUF0BJ	MI	TTTVAFQ
DMUF0BJ	MN	Neuronal acetylcholine receptor beta-4 (CHRNB4)
DMUF0BJ	MT	DTT
DMUF0BJ	MA	Inhibitor
DMUF0BJ	RN	Deconstructing cytisine: The syntheses of (+/-)-cyfusine and (+/-)-cyclopropylcyfusine, fused ring analogs of cytisine. Bioorg Med Chem Lett. 2008 Apr 1;18(7):2316-9.
DMUF0BJ	RU	https://pubmed.ncbi.nlm.nih.gov/18356044

DMUF0BJ	DI	DMUF0BJ
DMUF0BJ	DN	CYTISINE
DMUF0BJ	MI	TTJSZTB
DMUF0BJ	MN	Nicotinic acetylcholine receptor (nAChR)
DMUF0BJ	MT	DTT
DMUF0BJ	MA	Antagonist
DMUF0BJ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMUF0BJ	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMYJ2QB	DI	DMYJ2QB
DMYJ2QB	DN	D2A21
DMYJ2QB	MI	TTXT4D5
DMYJ2QB	MN	Bacterial Cell membrane (Bact CM)
DMYJ2QB	MT	DTT
DMYJ2QB	MA	Modulator
DMYJ2QB	RN	In Vitro Microbicidal Activities of Cecropin Peptides D2A21 and D4E1 and Gel Formulations Containing 0.1 to 2% D2A21 against Chlamydia trachomatis. Antimicrob Agents Chemother. 2002 January; 46(1): 34-41.
DMYJ2QB	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC126975/

DM9FAJM	DI	DM9FAJM
DM9FAJM	DN	D-5519
DM9FAJM	MI	TTPNQAC
DM9FAJM	MN	Estrogen-related receptor-alpha (ESRRA)
DM9FAJM	MT	DTT
DM9FAJM	MA	Modulator
DM9FAJM	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007199)
DM9FAJM	RU	http://adisinsight.springer.com/drugs/800007199

DM6S4R2	DI	DM6S4R2
DM6S4R2	DN	DA-3031
DM6S4R2	MI	TT5TQ2W
DM6S4R2	MN	Granulocyte colony-stimulating factor (CSF3)
DM6S4R2	MT	DTT
DM6S4R2	MA	Modulator
DM6S4R2	RN	A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer.Invest New Drugs.2013 Oct;31(5):1300-6.
DM6S4R2	RU	https://www.ncbi.nlm.nih.gov/pubmed/23677653

DMP2SGN	DI	DMP2SGN
DMP2SGN	DN	Dabelotine
DMP2SGN	MI	TTVIREA
DMP2SGN	MN	Adrenergic receptor (ADR)
DMP2SGN	MT	DTT
DMP2SGN	MA	Modulator
DMP2SGN	RN	US patent application no. 2007,0049,576, Neurogenesis by muscarinic receptor modulation.
DMP2SGN	RU	http://www.google.nl/patents/US20070049576

DMRDZ4X	DI	DMRDZ4X
DMRDZ4X	DN	Dabigatran etexilate
DMRDZ4X	MI	DEB30C5
DMRDZ4X	MN	Carboxylesterase 1 (CES1)
DMRDZ4X	MT	DME
DMRDZ4X	MA	Metabolism
DMRDZ4X	RN	Pharmacogenomics of novel direct oral anticoagulants: newly identified genes and genetic variants. J Pers Med. 2019 Jan 17;9(1). pii: E7.
DMRDZ4X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30658513

DMRDZ4X	DI	DMRDZ4X
DMRDZ4X	DN	Dabigatran etexilate
DMRDZ4X	MI	DETHCPD
DMRDZ4X	MN	Carboxylesterase 2 (CES2)
DMRDZ4X	MT	DME
DMRDZ4X	MA	Metabolism
DMRDZ4X	RN	Pharmacogenomics of novel direct oral anticoagulants: newly identified genes and genetic variants. J Pers Med. 2019 Jan 17;9(1). pii: E7.
DMRDZ4X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30658513

DMRDZ4X	DI	DMRDZ4X
DMRDZ4X	DN	Dabigatran etexilate
DMRDZ4X	MI	DE85D2P
DMRDZ4X	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMRDZ4X	MT	DME
DMRDZ4X	MA	Metabolism
DMRDZ4X	RN	Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. Drug Metab Dispos. 2010 Sep;38(9):1567-75.
DMRDZ4X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20551237

DMRDZ4X	DI	DMRDZ4X
DMRDZ4X	DN	Dabigatran etexilate
DMRDZ4X	MI	DEB3CV1
DMRDZ4X	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMRDZ4X	MT	DME
DMRDZ4X	MA	Metabolism
DMRDZ4X	RN	Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. Drug Metab Dispos. 2010 Sep;38(9):1567-75.
DMRDZ4X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20551237

DMKNCVM	DI	DMKNCVM
DMKNCVM	DN	Dalcetrapib
DMKNCVM	MI	TTFQAYR
DMKNCVM	MN	Cholesteryl ester transfer protein (CETP)
DMKNCVM	MT	DTT
DMKNCVM	MA	Inhibitor
DMKNCVM	RN	Clinical pipeline report, company report or official report of Roche (2009).
DMKNCVM	RU	http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm

DMKNCVM	DI	DMKNCVM
DMKNCVM	DN	Dalcetrapib
DMKNCVM	MI	DE4LYSA
DMKNCVM	MN	Cytochrome P450 3A4 (CYP3A4)
DMKNCVM	MT	DME
DMKNCVM	MA	Metabolism
DMKNCVM	RN	In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates. Curr Med Res Opin. 2009 Apr;25(4):891-902.
DMKNCVM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19245299

DM1C95G	DI	DM1C95G
DM1C95G	DN	DARE-BV1
DM1C95G	MI	TTUWYEA
DM1C95G	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DM1C95G	MT	DTT
DM1C95G	RN	Characterization of Escherichia coli 50S ribosomal protein L31. FEMS Microbiol Lett. 1999 Nov 15;180(2):345-9.
DM1C95G	RU	https://pubmed.ncbi.nlm.nih.gov/10556732

DMR2JD4	DI	DMR2JD4
DMR2JD4	DN	Darotropium + 642444
DMR2JD4	MI	TTZ9SOR
DMR2JD4	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMR2JD4	MT	DTT
DMR2JD4	MA	Agonist
DMR2JD4	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMR2JD4	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DM2FV5N	DI	DM2FV5N
DM2FV5N	DN	Darunavir + cobicistat
DM2FV5N	MI	TT1D53B
DM2FV5N	MN	COVID-19 3C-like protease (3CLpro)
DM2FV5N	MT	DTT
DM2FV5N	MA	Inhibitor
DM2FV5N	RN	Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381.
DM2FV5N	RU	https://pubmed.ncbi.nlm.nih.gov/32205870

DMF3V01	DI	DMF3V01
DMF3V01	DN	Darunavir + ritonavir + favipiravir + hydroxychloroquine
DMF3V01	MI	TTZGK1R
DMF3V01	MN	HUMAN glycosylation of host receptor (GHR)
DMF3V01	MT	DTT
DMF3V01	MA	Inhibitor
DMF3V01	RN	Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.
DMF3V01	RU	https://pubmed.ncbi.nlm.nih.gov/32020029

DMF3V01	DI	DMF3V01
DMF3V01	DN	Darunavir + ritonavir + favipiravir + hydroxychloroquine
DMF3V01	MI	TTD16BI
DMF3V01	MN	HUMAN pH-dependent viral fusion/replication (pH-DVF/R)
DMF3V01	MT	DTT
DMF3V01	MA	Inhibitor
DMF3V01	RN	Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.
DMF3V01	RU	https://pubmed.ncbi.nlm.nih.gov/32020029

DMF3V01	DI	DMF3V01
DMF3V01	DN	Darunavir + ritonavir + favipiravir + hydroxychloroquine
DMF3V01	MI	TT3A1EZ
DMF3V01	MN	HUMAN toll-like receptor 7/9 signalling pathway (TLR7/9 pathway)
DMF3V01	MT	DTT
DMF3V01	MA	Inhibitor
DMF3V01	RN	Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020 Mar;16(3):155-166.
DMF3V01	RU	https://pubmed.ncbi.nlm.nih.gov/32034323

DMN9BO3	DI	DMN9BO3
DMN9BO3	DN	Darunavir + ritonavir + oseltamivir + hydroxychloroquine
DMN9BO3	MI	TTZGK1R
DMN9BO3	MN	HUMAN glycosylation of host receptor (GHR)
DMN9BO3	MT	DTT
DMN9BO3	MA	Inhibitor
DMN9BO3	RN	Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.
DMN9BO3	RU	https://pubmed.ncbi.nlm.nih.gov/32020029

DMN9BO3	DI	DMN9BO3
DMN9BO3	DN	Darunavir + ritonavir + oseltamivir + hydroxychloroquine
DMN9BO3	MI	TTD16BI
DMN9BO3	MN	HUMAN pH-dependent viral fusion/replication (pH-DVF/R)
DMN9BO3	MT	DTT
DMN9BO3	MA	Inhibitor
DMN9BO3	RN	Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.
DMN9BO3	RU	https://pubmed.ncbi.nlm.nih.gov/32020029

DMN9BO3	DI	DMN9BO3
DMN9BO3	DN	Darunavir + ritonavir + oseltamivir + hydroxychloroquine
DMN9BO3	MI	TT3A1EZ
DMN9BO3	MN	HUMAN toll-like receptor 7/9 signalling pathway (TLR7/9 pathway)
DMN9BO3	MT	DTT
DMN9BO3	MA	Inhibitor
DMN9BO3	RN	Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020 Mar;16(3):155-166.
DMN9BO3	RU	https://pubmed.ncbi.nlm.nih.gov/32034323

DMN8DQH	DI	DMN8DQH
DMN8DQH	DN	Darusentan
DMN8DQH	MI	TTKRD0G
DMN8DQH	MN	Endothelin A receptor (EDNRA)
DMN8DQH	MT	DTT
DMN8DQH	MA	Antagonist
DMN8DQH	RN	Endothelin ETA receptor blockade with darusentan increases sodium and potassium excretion in aging rats. J Cardiovasc Pharmacol. 2006 Mar;47(3):456-62.
DMN8DQH	RU	https://pubmed.ncbi.nlm.nih.gov/16633090

DMD7K9X	DI	DMD7K9X
DMD7K9X	DN	Davunetide
DMD7K9X	MI	TTS87KH
DMD7K9X	MN	Microtubule-associated protein tau (MAPT)
DMD7K9X	MT	DTT
DMD7K9X	MA	Modulator
DMD7K9X	RN	Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des. 2011;17(31):3413-7.
DMD7K9X	RU	https://pubmed.ncbi.nlm.nih.gov/21902667

DMUX7Z8	DI	DMUX7Z8
DMUX7Z8	DN	DE-117
DMUX7Z8	MI	TT1ZAVI
DMUX7Z8	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DMUX7Z8	MT	DTT
DMUX7Z8	MA	Agonist
DMUX7Z8	RN	Clinical pipeline report, company report or official report of Santen Pharmaceutical.
DMUX7Z8	RU	http://www.santeninc.com/research/moa/

DM0GUV2	DI	DM0GUV2
DM0GUV2	DN	DE-766
DM0GUV2	MI	TTGKNB4
DM0GUV2	MN	Epidermal growth factor receptor (EGFR)
DM0GUV2	MT	DTT
DM0GUV2	MA	Modulator
DM0GUV2	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
DM0GUV2	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797

DM2R15Q	DI	DM2R15Q
DM2R15Q	DN	DENBUFYLLINE
DM2R15Q	MI	TTZ97H5
DM2R15Q	MN	Phosphodiesterase 4A (PDE4A)
DM2R15Q	MT	DTT
DM2R15Q	MA	Inhibitor
DM2R15Q	RN	Pyrazolopyrimidine-2,4-dione sulfonamides: novel and selective calcitonin inducers. J Med Chem. 2002 May 23;45(11):2342-5.
DM2R15Q	RU	https://pubmed.ncbi.nlm.nih.gov/12014973

DM2R15Q	DI	DM2R15Q
DM2R15Q	DN	DENBUFYLLINE
DM2R15Q	MI	TTVIAT9
DM2R15Q	MN	Phosphodiesterase 4B (PDE4B)
DM2R15Q	MT	DTT
DM2R15Q	MA	Inhibitor
DM2R15Q	RN	Pyrazolopyrimidine-2,4-dione sulfonamides: novel and selective calcitonin inducers. J Med Chem. 2002 May 23;45(11):2342-5.
DM2R15Q	RU	https://pubmed.ncbi.nlm.nih.gov/12014973

DM2R15Q	DI	DM2R15Q
DM2R15Q	DN	DENBUFYLLINE
DM2R15Q	MI	TTSKMI8
DM2R15Q	MN	Phosphodiesterase 4D (PDE4D)
DM2R15Q	MT	DTT
DM2R15Q	MA	Inhibitor
DM2R15Q	RN	Pyrazolopyrimidine-2,4-dione sulfonamides: novel and selective calcitonin inducers. J Med Chem. 2002 May 23;45(11):2342-5.
DM2R15Q	RU	https://pubmed.ncbi.nlm.nih.gov/12014973

DM2ATZB	DI	DM2ATZB
DM2ATZB	DN	Deoxynojirimycin
DM2ATZB	MI	TTHCF4J
DM2ATZB	MN	Alpha-glucosidase (GLA)
DM2ATZB	MT	DTT
DM2ATZB	MA	Inhibitor
DM2ATZB	RN	Nitrogen-in-the-ring pyranoses and furanoses: structural basis of inhibition of mammalian glycosidases. J Med Chem. 1994 Oct 28;37(22):3701-6.
DM2ATZB	RU	https://pubmed.ncbi.nlm.nih.gov/7966130

DM2ATZB	DI	DM2ATZB
DM2ATZB	DN	Deoxynojirimycin
DM2ATZB	MI	TTXWASR
DM2ATZB	MN	Intestinal maltase-glucoamylase (MGAM)
DM2ATZB	MT	DTT
DM2ATZB	MA	Inhibitor
DM2ATZB	RN	Nitrogen-in-the-ring pyranoses and furanoses: structural basis of inhibition of mammalian glycosidases. J Med Chem. 1994 Oct 28;37(22):3701-6.
DM2ATZB	RU	https://pubmed.ncbi.nlm.nih.gov/7966130

DM2ATZB	DI	DM2ATZB
DM2ATZB	DN	Deoxynojirimycin
DM2ATZB	MI	TTLPC70
DM2ATZB	MN	Lysosomal alpha-glucosidase (GAA)
DM2ATZB	MT	DTT
DM2ATZB	MA	Inhibitor
DM2ATZB	RN	In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures. Bioorg Med Chem. 2008 Aug 1;16(15):7330-6.
DM2ATZB	RU	https://pubmed.ncbi.nlm.nih.gov/18595718

DMDLU4Z	DI	DMDLU4Z
DMDLU4Z	DN	Desmoteplase
DMDLU4Z	MI	TTP86E2
DMDLU4Z	MN	Plasminogen (PLG)
DMDLU4Z	MT	DTT
DMDLU4Z	MA	Activator
DMDLU4Z	RN	Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke. 2003 Feb;34(2):537-43.
DMDLU4Z	RU	https://pubmed.ncbi.nlm.nih.gov/12574572

DMRH291	DI	DMRH291
DMRH291	DN	Dexanabinol
DMRH291	MI	TT9IK2Z
DMRH291	MN	N-methyl-D-aspartate receptor (NMDAR)
DMRH291	MT	DTT
DMRH291	MA	Antagonist
DMRH291	RN	Emerging treatments for traumatic brain injury. Expert Opin Emerg Drugs. 2009 Mar;14(1):67-84.
DMRH291	RU	https://pubmed.ncbi.nlm.nih.gov/19249984

DM1WNGJ	DI	DM1WNGJ
DM1WNGJ	DN	DFP-10917
DM1WNGJ	MI	TTABD5E
DM1WNGJ	MN	DNA replication (DNA repli)
DM1WNGJ	MT	DTT
DM1WNGJ	MA	Inhibitor
DM1WNGJ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM1WNGJ	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMOUGX1	DI	DMOUGX1
DMOUGX1	DN	Diamyd
DMOUGX1	MI	TT7UY6K
DMOUGX1	MN	Glutamate decarboxylase 2 (GAD2)
DMOUGX1	MT	DTT
DMOUGX1	MA	Immunomodulator
DMOUGX1	RN	Clinical pipeline report, company report or official report of Diamyd Medical.
DMOUGX1	RU	http://www.diamyd.com/docs/gadProducts.aspx?section=products

DM4XBM7	DI	DM4XBM7
DM4XBM7	DN	DiaPep-277
DM4XBM7	MI	TT9HL5R
DM4XBM7	MN	Mitochondrial matrix protein P1 (HSPD1)
DM4XBM7	MT	DTT
DM4XBM7	MA	Modulator
DM4XBM7	RN	Therapy with the hsp60 peptide DiaPep277 in C-peptide positive type 1 diabetes patients. Diabetes Metab Res Rev. 2007 May;23(4):269-75.
DM4XBM7	RU	https://pubmed.ncbi.nlm.nih.gov/17024692

DMHZBEO	DI	DMHZBEO
DMHZBEO	DN	Difelikefalin
DMHZBEO	MI	TTQW87Y
DMHZBEO	MN	Opioid receptor kappa (OPRK1)
DMHZBEO	MT	DTT
DMHZBEO	MA	Agonist
DMHZBEO	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMHZBEO	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMU4T9Y	DI	DMU4T9Y
DMU4T9Y	DN	Dimesna
DMU4T9Y	MI	DTQ23VB
DMU4T9Y	MN	Organic anion transporter 1 (SLC22A6)
DMU4T9Y	MT	DTP
DMU4T9Y	MA	Substrate
DMU4T9Y	RN	In vitro and in vivo assessment of renal drug transporters in the disposition of mesna and dimesna. J Clin Pharmacol. 2012 Apr;52(4):530-42.
DMU4T9Y	RU	http://www.ncbi.nlm.nih.gov/pubmed/21505084

DMU4T9Y	DI	DMU4T9Y
DMU4T9Y	DN	Dimesna
DMU4T9Y	MI	DTVP67E
DMU4T9Y	MN	Organic anion transporter 3 (SLC22A8)
DMU4T9Y	MT	DTP
DMU4T9Y	MA	Substrate
DMU4T9Y	RN	In vitro and in vivo assessment of renal drug transporters in the disposition of mesna and dimesna. J Clin Pharmacol. 2012 Apr;52(4):530-42.
DMU4T9Y	RU	http://www.ncbi.nlm.nih.gov/pubmed/21505084

DM19CFZ	DI	DM19CFZ
DM19CFZ	DN	DIMS-0150
DM19CFZ	MI	TTKLNRV
DM19CFZ	MN	NFKB messenger RNA (NFKB mRNA)
DM19CFZ	MT	DTT
DM19CFZ	RN	News and Analysis. Nature Reviews Drug Discovery 12, 179 (March 2013).
DM19CFZ	RU	http://www.nature.com/nrd/journal/v12/n3/full/nrd3963.html

DMG8U6M	DI	DMG8U6M
DMG8U6M	DN	DIPROTEVERINE HYDROCHLORIDE
DMG8U6M	MI	TT5HONZ
DMG8U6M	MN	Calcium channel unspecific (CaC)
DMG8U6M	MT	DTT
DMG8U6M	MA	Antagonist
DMG8U6M	RN	Prenatal toxicity studies in rats and rabbits with the calcium channel blocker diproteverine. Reprod Toxicol. 1996 Jan-Feb;10(1):43-9.
DMG8U6M	RU	https://pubmed.ncbi.nlm.nih.gov/8998385

DM64QG9	DI	DM64QG9
DM64QG9	DN	Diquafosol
DM64QG9	MI	TTOZHQC
DM64QG9	MN	P2Y purinoceptor 2 (P2RY2)
DM64QG9	MT	DTT
DM64QG9	MA	Agonist
DM64QG9	RN	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
DM64QG9	RU	https://pubmed.ncbi.nlm.nih.gov/16634702

DMJS8V3	DI	DMJS8V3
DMJS8V3	DN	Disufenton sodium
DMJS8V3	MI	TT8E7Z0
DMJS8V3	MN	Free radical (FRD)
DMJS8V3	MT	DTT
DMJS8V3	MA	Modulator
DMJS8V3	RN	NXY-059, a free radical--trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke. 2001 Jan;32(1):190-8.
DMJS8V3	RU	https://pubmed.ncbi.nlm.nih.gov/11136936

DMMKGBP	DI	DMMKGBP
DMMKGBP	DN	D-Methionine
DMMKGBP	MI	TTZL0OI
DMMKGBP	MN	Methionine aminopeptidase 2 (METAP2)
DMMKGBP	MT	DTT
DMMKGBP	MA	Inhibitor
DMMKGBP	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMMKGBP	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMO7BQS	DI	DMO7BQS
DMO7BQS	DN	DMP-444
DMO7BQS	MI	TT38RM1
DMO7BQS	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DMO7BQS	MT	DTT
DMO7BQS	MA	Modulator
DMO7BQS	RN	Evaluation of Tc-99m-labeled glycoprotein IIb/IIIa receptor antagonist DMP444 SPECT in patients with infective endocarditis. Clin Nucl Med. 2003 Jun;28(6):480-4.
DMO7BQS	RU	https://pubmed.ncbi.nlm.nih.gov/12911097

DMQLSMB	DI	DMQLSMB
DMQLSMB	DN	Dociparstat sodium
DMQLSMB	MI	TTSG7Q5
DMQLSMB	MN	Platelet factor 4 (PF4)
DMQLSMB	MT	DTT
DMQLSMB	MA	Inhibitor
DMQLSMB	RN	Clinical pipeline report, company report or official report of Chimerix.
DMQLSMB	RU	https://www.chimerix.com/our-science/dstat/

DMQLSMB	DI	DMQLSMB
DMQLSMB	DN	Dociparstat sodium
DMQLSMB	MI	TT4UGTF
DMQLSMB	MN	Stromal cell-derived factor 1 (CXCL12)
DMQLSMB	MT	DTT
DMQLSMB	MA	Inhibitor
DMQLSMB	RN	Clinical pipeline report, company report or official report of Chimerix.
DMQLSMB	RU	https://www.chimerix.com/our-science/dstat/

DMH8IT5	DI	DMH8IT5
DMH8IT5	DN	Donaperminogene seltoplasmid
DMH8IT5	MI	TT4V2JM
DMH8IT5	MN	Hepatocyte growth factor (HGF)
DMH8IT5	MT	DTT
DMH8IT5	MA	Replacement
DMH8IT5	RN	Clinical pipeline report, company report or official report of ViroMed.
DMH8IT5	RU	http://menu.itooza.com/cmsupload/contdown.php?sn=20190912100403_fd_image_119_65_142__1669.pdf&rsn=ViroMed_May_30_2018.pdf

DM97S10	DI	DM97S10
DM97S10	DN	DP-b99
DM97S10	MI	TT6X50U
DM97S10	MN	Matrix metalloproteinase-9 (MMP-9)
DM97S10	MT	DTT
DM97S10	MA	Inhibitor
DM97S10	RN	DP-b99 modulates matrix metalloproteinase activity and neuronal plasticity. PLoS One. 2014 Jun 11;9(6):e99789.
DM97S10	RU	https://pubmed.ncbi.nlm.nih.gov/24918931

DMWUN1S	DI	DMWUN1S
DMWUN1S	DN	Drisapersen
DMWUN1S	MI	TTWLFXU
DMWUN1S	MN	Dystrophin messenger RNA (DMD mRNA)
DMWUN1S	MT	DTT
DMWUN1S	RN	PRO-051, an antisense oligonucleotide for the potential treatment of Duchenne muscular dystrophy. Curr Opin Mol Ther. 2010 Aug;12(4):478-86.
DMWUN1S	RU	https://pubmed.ncbi.nlm.nih.gov/20677099

DMM0HAE	DI	DMM0HAE
DMM0HAE	DN	DSC-127
DMM0HAE	MI	TTOISYB
DMM0HAE	MN	Proto-oncogene Mas (MAS)
DMM0HAE	MT	DTT
DMM0HAE	MA	Agonist
DMM0HAE	RN	New therapeutic pathways in the RAS. J Renin Angiotensin Aldosterone Syst. 2012 Dec;13(4):505-8.
DMM0HAE	RU	https://pubmed.ncbi.nlm.nih.gov/23166114

DM6P8HU	DI	DM6P8HU
DM6P8HU	DN	Dutasteride + tamsulosin
DM6P8HU	MI	TTNGILX
DM6P8HU	MN	Adrenergic receptor alpha-1A (ADRA1A)
DM6P8HU	MT	DTT
DM6P8HU	MA	Antagonist
DM6P8HU	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DM6P8HU	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DM6P8HU	DI	DM6P8HU
DM6P8HU	DN	Dutasteride + tamsulosin
DM6P8HU	MI	TT2A0DR
DM6P8HU	MN	Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A)
DM6P8HU	MT	DTT
DM6P8HU	MA	Inhibitor
DM6P8HU	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DM6P8HU	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMM5VTA	DI	DMM5VTA
DMM5VTA	DN	Dutogliptin
DMM5VTA	MI	TTDIGC1
DMM5VTA	MN	Dipeptidyl peptidase 4 (DPP-4)
DMM5VTA	MT	DTT
DMM5VTA	MA	Inhibitor
DMM5VTA	RN	Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial. Diabetes Obes Metab. 2010 Apr;12(4):348-55.
DMM5VTA	RU	https://pubmed.ncbi.nlm.nih.gov/20380656

DMAFUIR	DI	DMAFUIR
DMAFUIR	DN	DWP-431
DMAFUIR	MI	TTP3IGX
DMAFUIR	MN	Bone morphogenetic protein 2 (BMP2)
DMAFUIR	MT	DTT
DMAFUIR	MA	Modulator
DMAFUIR	RN	Complications with the use of bone morphogenetic protein 2 (BMP-2) in spine surgery. Spine J. 2014 Mar 1;14(3):552-9.
DMAFUIR	RU	https://pubmed.ncbi.nlm.nih.gov/24412416

DMM1YC4	DI	DMM1YC4
DMM1YC4	DN	E-101
DMM1YC4	MI	TTVCZPI
DMM1YC4	MN	Myeloperoxidase (MPO)
DMM1YC4	MT	DTT
DMM1YC4	MA	Modulator
DMM1YC4	RN	In vitro antibacterial activity of E-101 Solution, a novel myeloperoxidase-mediated antimicrobial, against Gram-positive and Gram-negative pathogens. J Antimicrob Chemother. 2011 Feb;66(2):335-42.
DMM1YC4	RU	https://pubmed.ncbi.nlm.nih.gov/21118915

DMTNUJ8	DI	DMTNUJ8
DMTNUJ8	DN	E-2609
DMTNUJ8	MI	TT8JRS7
DMTNUJ8	MN	Beta-secretase (BACE)
DMTNUJ8	MT	DTT
DMTNUJ8	MA	Inhibitor
DMTNUJ8	RN	Targeting the beta secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol. 2014 March; 13(3): 319-329.
DMTNUJ8	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086426/

DMTNUJ8	DI	DMTNUJ8
DMTNUJ8	DN	E-2609
DMTNUJ8	MI	TTJUNZF
DMTNUJ8	MN	Beta-secretase 1 (BACE1)
DMTNUJ8	MT	DTT
DMTNUJ8	MA	Inhibitor
DMTNUJ8	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMTNUJ8	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM42PFT	DI	DM42PFT
DM42PFT	DN	E-3810
DM42PFT	MI	TTRLW2X
DM42PFT	MN	Fibroblast growth factor receptor 1 (FGFR1)
DM42PFT	MT	DTT
DM42PFT	MA	Inhibitor
DM42PFT	RN	E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. 
DM42PFT	RU	https://pubmed.ncbi.nlm.nih.gov/21212416

DM42PFT	DI	DM42PFT
DM42PFT	DN	E-3810
DM42PFT	MI	TTGJVQM
DM42PFT	MN	Fibroblast growth factor receptor 2 (FGFR2)
DM42PFT	MT	DTT
DM42PFT	MA	Inhibitor
DM42PFT	RN	E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. 
DM42PFT	RU	https://pubmed.ncbi.nlm.nih.gov/21212416

DM42PFT	DI	DM42PFT
DM42PFT	DN	E-3810
DM42PFT	MI	TTST7KB
DM42PFT	MN	Fibroblast growth factor receptor 3 (FGFR3)
DM42PFT	MT	DTT
DM42PFT	MA	Inhibitor
DM42PFT	RN	E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. 
DM42PFT	RU	https://pubmed.ncbi.nlm.nih.gov/21212416

DM42PFT	DI	DM42PFT
DM42PFT	DN	E-3810
DM42PFT	MI	TT8FYO9
DM42PFT	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DM42PFT	MT	DTT
DM42PFT	MA	Inhibitor
DM42PFT	RN	E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. 
DM42PFT	RU	https://pubmed.ncbi.nlm.nih.gov/21212416

DM42PFT	DI	DM42PFT
DM42PFT	DN	E-3810
DM42PFT	MI	TTI7421
DM42PFT	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM42PFT	MT	DTT
DM42PFT	MA	Inhibitor
DM42PFT	RN	E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. 
DM42PFT	RU	https://pubmed.ncbi.nlm.nih.gov/21212416

DM42PFT	DI	DM42PFT
DM42PFT	DN	E-3810
DM42PFT	MI	TT2Q6G1
DM42PFT	MN	Vascular endothelial growth factor receptor 1 (FLT-1)
DM42PFT	MT	DTT
DM42PFT	MA	Inhibitor
DM42PFT	RN	E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. 
DM42PFT	RU	https://pubmed.ncbi.nlm.nih.gov/21212416

DM42PFT	DI	DM42PFT
DM42PFT	DN	E-3810
DM42PFT	MI	TTUTJGQ
DM42PFT	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM42PFT	MT	DTT
DM42PFT	MA	Inhibitor
DM42PFT	RN	E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. 
DM42PFT	RU	https://pubmed.ncbi.nlm.nih.gov/21212416

DM42PFT	DI	DM42PFT
DM42PFT	DN	E-3810
DM42PFT	MI	TTDCBX5
DM42PFT	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DM42PFT	MT	DTT
DM42PFT	MA	Inhibitor
DM42PFT	RN	E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. 
DM42PFT	RU	https://pubmed.ncbi.nlm.nih.gov/21212416

DMUHS5Q	DI	DMUHS5Q
DMUHS5Q	DN	E-913
DMUHS5Q	MI	TT2CEJG
DMUHS5Q	MN	C-C chemokine receptor type 5 (CCR5)
DMUHS5Q	MT	DTT
DMUHS5Q	MA	Antagonist
DMUHS5Q	RN	Species selectivity of small-molecular antagonists for the CCR5 chemokine receptor. Int Immunopharmacol. 2007 Dec 5;7(12):1528-34.
DMUHS5Q	RU	https://pubmed.ncbi.nlm.nih.gov/17920529

DMLA1ER	DI	DMLA1ER
DMLA1ER	DN	EC20
DMLA1ER	MI	TTVC37M
DMLA1ER	MN	Folate receptor alpha (FOLR1)
DMLA1ER	MT	DTT
DMLA1ER	MA	Modulator
DMLA1ER	RN	EP patent application no. 2822386, Folate receptor alpha binding ligands.
DMLA1ER	RU	http://www.google.com/patents/EP2822386A1?cl=en

DMS9R43	DI	DMS9R43
DMS9R43	DN	Ecopipam
DMS9R43	MI	TTZFYLI
DMS9R43	MN	Dopamine D1 receptor (D1R)
DMS9R43	MT	DTT
DMS9R43	MA	Modulator
DMS9R43	RN	A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome.Clin Neuropharmacol.2014 Jan-Feb;37(1):26-30.
DMS9R43	RU	https://www.ncbi.nlm.nih.gov/pubmed/24434529

DMRLXAI	DI	DMRLXAI
DMRLXAI	DN	ED-71
DMRLXAI	MI	DE5FUD0
DMRLXAI	MN	Methylsterol monooxygenase 1 (MSMO1)
DMRLXAI	MT	DME
DMRLXAI	MA	Metabolism
DMRLXAI	RN	Human hepatic metabolism of the anti-osteoporosis drug eldecalcitol involves sterol C4-methyl oxidase. Pharmacol Res Perspect. 2015 Mar;3(2):e00120.
DMRLXAI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26038696

DMYVBF6	DI	DMYVBF6
DMYVBF6	DN	Edasalonexent
DMYVBF6	MI	TTSXVID
DMYVBF6	MN	Nuclear factor NF-kappa-B (NFKB)
DMYVBF6	MT	DTT
DMYVBF6	MA	Inhibitor
DMYVBF6	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMYVBF6	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM3ZL7D	DI	DM3ZL7D
DM3ZL7D	DN	Edotecarin
DM3ZL7D	MI	DTI7UX6
DM3ZL7D	MN	Breast cancer resistance protein (ABCG2)
DM3ZL7D	MT	DTP
DM3ZL7D	MA	Substrate
DM3ZL7D	RN	Pharmacogenomic importance of ABCG2. Pharmacogenomics. 2008 Aug;9(8):1005-9.
DM3ZL7D	RU	https://doi.org/10.2217/14622416.9.8.1005

DM3ZL7D	DI	DM3ZL7D
DM3ZL7D	DN	Edotecarin
DM3ZL7D	MI	TTGTQHC
DM3ZL7D	MN	DNA topoisomerase I (TOP1)
DM3ZL7D	MT	DTT
DM3ZL7D	MA	Inhibitor
DM3ZL7D	RN	Edotecarin: a novel topoisomerase I inhibitor. Clin Colorectal Cancer. 2005 May;5(1):27-36.
DM3ZL7D	RU	https://pubmed.ncbi.nlm.nih.gov/15929804

DMX7BM4	DI	DMX7BM4
DMX7BM4	DN	Efaproxyn
DMX7BM4	MI	TTQO71U
DMX7BM4	MN	Hemoglobin (HB)
DMX7BM4	MT	DTT
DMX7BM4	MA	Inhibitor
DMX7BM4	RN	Increased oxygenation of intracranial tumors by efaproxyn (efaproxiral), an allosteric hemoglobin modifier: In vivo EPR oximetry study. Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1503-9.
DMX7BM4	RU	https://pubmed.ncbi.nlm.nih.gov/15817356

DMKA2PI	DI	DMKA2PI
DMKA2PI	DN	Efpeglenatide
DMKA2PI	MI	TTVIMDE
DMKA2PI	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMKA2PI	MT	DTT
DMKA2PI	MA	Agonist
DMKA2PI	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMKA2PI	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMCMJRA	DI	DMCMJRA
DMCMJRA	DN	EGF816
DMCMJRA	MI	TTGKNB4
DMCMJRA	MN	Epidermal growth factor receptor (EGFR)
DMCMJRA	MT	DTT
DMCMJRA	MA	Inhibitor
DMCMJRA	RN	Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov. 2013 Dec;3(12):1404-15.
DMCMJRA	RU	https://pubmed.ncbi.nlm.nih.gov/24065731

DMB2C0E	DI	DMB2C0E
DMB2C0E	DN	Elagolix
DMB2C0E	MI	TT8R70G
DMB2C0E	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMB2C0E	MT	DTT
DMB2C0E	MA	Antagonist
DMB2C0E	RN	Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain. Womens Health (Lond Engl). 2015 Jan;11(1):19-28.
DMB2C0E	RU	https://pubmed.ncbi.nlm.nih.gov/25581052

DMW6C81	DI	DMW6C81
DMW6C81	DN	Eltoprazine
DMW6C81	MI	TTSQIFT
DMW6C81	MN	5-HT 1A receptor (HTR1A)
DMW6C81	MT	DTT
DMW6C81	MA	Agonist
DMW6C81	RN	Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
DMW6C81	RU	http://www.jazzpharma.com/products/

DMW6C81	DI	DMW6C81
DMW6C81	DN	Eltoprazine
DMW6C81	MI	TTK8CXU
DMW6C81	MN	5-HT 1B receptor (HTR1B)
DMW6C81	MT	DTT
DMW6C81	MA	Agonist
DMW6C81	RN	Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
DMW6C81	RU	http://www.jazzpharma.com/products/

DMW6C81	DI	DMW6C81
DMW6C81	DN	Eltoprazine
DMW6C81	MI	TTWJBZ5
DMW6C81	MN	5-HT 2C receptor (HTR2C)
DMW6C81	MT	DTT
DMW6C81	MA	Antagonist
DMW6C81	RN	Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
DMW6C81	RU	http://www.jazzpharma.com/products/

DMZKTYJ	DI	DMZKTYJ
DMZKTYJ	DN	Enmetazobactam
DMZKTYJ	MI	TTHI19T
DMZKTYJ	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMZKTYJ	MT	DTT
DMZKTYJ	MA	Inhibitor
DMZKTYJ	RN	Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum--Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2020 May 21;64(6):e00180-20.
DMZKTYJ	RU	https://pubmed.ncbi.nlm.nih.gov/32253209

DMIKDCQ	DI	DMIKDCQ
DMIKDCQ	DN	Ensartinib
DMIKDCQ	MI	TTPMQSO
DMIKDCQ	MN	ALK tyrosine kinase receptor (ALK)
DMIKDCQ	MT	DTT
DMIKDCQ	MA	Inhibitor
DMIKDCQ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMIKDCQ	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM7EOBQ	DI	DM7EOBQ
DM7EOBQ	DN	Entacapone+levodopa+carbidopa
DM7EOBQ	MI	TTKWFB8
DM7EOBQ	MN	Catechol-O-methyl-transferase (COMT)
DM7EOBQ	MT	DTT
DM7EOBQ	MA	Inhibitor
DM7EOBQ	RN	Emerging drugs for restless legs syndrome. Expert Opin Emerg Drugs. 2005 Aug;10(3):537-52.
DM7EOBQ	RU	https://pubmed.ncbi.nlm.nih.gov/16083328

DM7EOBQ	DI	DM7EOBQ
DM7EOBQ	DN	Entacapone+levodopa+carbidopa
DM7EOBQ	MI	TTEX248
DM7EOBQ	MN	Dopamine D2 receptor (D2R)
DM7EOBQ	MT	DTT
DM7EOBQ	MA	Agonist
DM7EOBQ	RN	Emerging drugs for restless legs syndrome. Expert Opin Emerg Drugs. 2005 Aug;10(3):537-52.
DM7EOBQ	RU	https://pubmed.ncbi.nlm.nih.gov/16083328

DMTWLXY	DI	DMTWLXY
DMTWLXY	DN	Entresto
DMTWLXY	MI	DE4LYSA
DMTWLXY	MN	Cytochrome P450 3A4 (CYP3A4)
DMTWLXY	MT	DME
DMTWLXY	MA	Metabolism
DMTWLXY	RN	FDA label of Sacubitril and valsartan. The 2020 official website of the U.S. Food and Drug Administration.
DMTWLXY	RU	https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/entresto.pdf

DM5H0R9	DI	DM5H0R9
DM5H0R9	DN	Enzastaurin
DM5H0R9	MI	DE4LYSA
DM5H0R9	MN	Cytochrome P450 3A4 (CYP3A4)
DM5H0R9	MT	DME
DM5H0R9	MA	Metabolism
DM5H0R9	RN	Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics. Invest New Drugs. 2013 Jun;31(3):653-60.
DM5H0R9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22766773

DM5H0R9	DI	DM5H0R9
DM5H0R9	DN	Enzastaurin
DM5H0R9	MI	TTHBTOP
DM5H0R9	MN	PI3-kinase gamma (PIK3CG)
DM5H0R9	MT	DTT
DM5H0R9	MA	Inhibitor
DM5H0R9	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM5H0R9	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM5H0R9	DI	DM5H0R9
DM5H0R9	DN	Enzastaurin
DM5H0R9	MI	TTYPXQF
DM5H0R9	MN	Protein kinase C beta (PRKCB)
DM5H0R9	MT	DTT
DM5H0R9	MA	Modulator
DM5H0R9	RN	The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines. Leuk Lymphoma. 2008 Jul;49(7):1374-83.
DM5H0R9	RU	https://pubmed.ncbi.nlm.nih.gov/18452078

DM5H0R9	DI	DM5H0R9
DM5H0R9	DN	Enzastaurin
DM5H0R9	MI	TTWTSCV
DM5H0R9	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DM5H0R9	MT	DTT
DM5H0R9	MA	Inhibitor
DM5H0R9	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM5H0R9	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMEX86V	DI	DMEX86V
DMEX86V	DN	Epcoritamab
DMEX86V	MI	TTUE541
DMEX86V	MN	Leukocyte surface antigen Leu-16 (CD20)
DMEX86V	MT	DTT
DMEX86V	MA	Inhibitor
DMEX86V	RN	Clinical pipeline report, company report or official report of Genmab.
DMEX86V	RU	https://www.genmab.com/pipeline/

DMEX86V	DI	DMEX86V
DMEX86V	DN	Epcoritamab
DMEX86V	MI	TTUN7MC
DMEX86V	MN	T-cell surface glycoprotein CD3 (CD3)
DMEX86V	MT	DTT
DMEX86V	MA	Inhibitor
DMEX86V	RN	Clinical pipeline report, company report or official report of Genmab.
DMEX86V	RU	https://www.genmab.com/pipeline/

DM1SMAI	DI	DM1SMAI
DM1SMAI	DN	Eperisone
DM1SMAI	MI	DERSX5P
DM1SMAI	MN	Cytochrome P450 2J2 (CYP2J2)
DM1SMAI	MT	DME
DM1SMAI	MA	Metabolism
DM1SMAI	RN	Characterization of human cytochrome P450 enzymes involved in the biotransformation of eperisone. Xenobiotica. 2009 Jan;39(1):1-10.
DM1SMAI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19219743

DM1SMAI	DI	DM1SMAI
DM1SMAI	DN	Eperisone
DM1SMAI	MI	DE4LYSA
DM1SMAI	MN	Cytochrome P450 3A4 (CYP3A4)
DM1SMAI	MT	DME
DM1SMAI	MA	Metabolism
DM1SMAI	RN	Characterization of human cytochrome P450 enzymes involved in the biotransformation of eperisone. Xenobiotica. 2009 Jan;39(1):1-10.
DM1SMAI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19219743

DM1SMAI	DI	DM1SMAI
DM1SMAI	DN	Eperisone
DM1SMAI	MI	TTCRJKY
DM1SMAI	MN	Voltage-gated calcium channel (Cav)
DM1SMAI	MT	DTT
DM1SMAI	MA	Modulator
DM1SMAI	RN	Suppression of calcium current in a snail neurone by eperisone and its analogues. Eur J Pharmacol. 1989 Sep 22;168(3):299-305.
DM1SMAI	RU	https://pubmed.ncbi.nlm.nih.gov/2555204

DM08XIN	DI	DM08XIN
DM08XIN	DN	EPIANDROSTERONE
DM08XIN	MI	TTKN8W0
DM08XIN	MN	Glucose-6-phosphate dehydrogenase (G6PD)
DM08XIN	MT	DTT
DM08XIN	MA	Inhibitor
DM08XIN	RN	Inhibition of Trypanosoma brucei glucose-6-phosphate dehydrogenase by human steroids and their effects on the viability of cultured parasites. Bioorg Med Chem. 2009 Mar 15;17(6):2483-9.
DM08XIN	RU	https://pubmed.ncbi.nlm.nih.gov/19231202

DMCGWBJ	DI	DMCGWBJ
DMCGWBJ	DN	Epigallocatechin gallate
DMCGWBJ	MI	TT7AOUD
DMCGWBJ	MN	Fatty acid synthase (FASN)
DMCGWBJ	MT	DTT
DMCGWBJ	MA	Inhibitor
DMCGWBJ	RN	Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
DMCGWBJ	RU	https://pubmed.ncbi.nlm.nih.gov/16722653

DMCGWBJ	DI	DMCGWBJ
DMCGWBJ	DN	Epigallocatechin gallate
DMCGWBJ	MI	TT84ETX
DMCGWBJ	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMCGWBJ	MT	DTT
DMCGWBJ	MA	Inhibitor
DMCGWBJ	RN	Simplified catechin-gallate inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett. 2001 Oct 22;11(20):2763-7.
DMCGWBJ	RU	https://pubmed.ncbi.nlm.nih.gov/11591519

DMCGWBJ	DI	DMCGWBJ
DMCGWBJ	DN	Epigallocatechin gallate
DMCGWBJ	MI	TTJ4QE7
DMCGWBJ	MN	Matrix metalloproteinase-14 (MMP-14)
DMCGWBJ	MT	DTT
DMCGWBJ	MA	Inhibitor
DMCGWBJ	RN	Regioselective synthesis of methylated epigallocatechin gallate via nitrobenzenesulfonyl (Ns) protecting group. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4171-4.
DMCGWBJ	RU	https://pubmed.ncbi.nlm.nih.gov/19524436

DMCGWBJ	DI	DMCGWBJ
DMCGWBJ	DN	Epigallocatechin gallate
DMCGWBJ	MI	TTLM12X
DMCGWBJ	MN	Matrix metalloproteinase-2 (MMP-2)
DMCGWBJ	MT	DTT
DMCGWBJ	MA	Inhibitor
DMCGWBJ	RN	Regioselective synthesis of methylated epigallocatechin gallate via nitrobenzenesulfonyl (Ns) protecting group. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4171-4.
DMCGWBJ	RU	https://pubmed.ncbi.nlm.nih.gov/19524436

DMCGWBJ	DI	DMCGWBJ
DMCGWBJ	DN	Epigallocatechin gallate
DMCGWBJ	MI	TTPLTSQ
DMCGWBJ	MN	Neutrophil elastase (NE)
DMCGWBJ	MT	DTT
DMCGWBJ	MA	Inhibitor
DMCGWBJ	RN	Evaluation of human neutrophil elastase inhibitory effect of iridoid glycosides from Hedyotis diffusa. Bioorg Med Chem Lett. 2010 Jan 15;20(2):513-5.
DMCGWBJ	RU	https://pubmed.ncbi.nlm.nih.gov/20004577

DMCGWBJ	DI	DMCGWBJ
DMCGWBJ	DN	Epigallocatechin gallate
DMCGWBJ	MI	TTHPFTS
DMCGWBJ	MN	Plasmodium Beta-hydroxyacyl-ACP dehydratase (Malaria FabZ)
DMCGWBJ	MT	DTT
DMCGWBJ	MA	Inhibitor
DMCGWBJ	RN	Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
DMCGWBJ	RU	https://pubmed.ncbi.nlm.nih.gov/16722653

DMCGWBJ	DI	DMCGWBJ
DMCGWBJ	DN	Epigallocatechin gallate
DMCGWBJ	MI	TTNX2CS
DMCGWBJ	MN	Plasmodium Enoyl-ACP reductase (Malaria fabI)
DMCGWBJ	MT	DTT
DMCGWBJ	MA	Inhibitor
DMCGWBJ	RN	Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR). J Med Chem. 2007 Feb 22;50(4):765-75.
DMCGWBJ	RU	https://pubmed.ncbi.nlm.nih.gov/17263522

DMCGWBJ	DI	DMCGWBJ
DMCGWBJ	DN	Epigallocatechin gallate
DMCGWBJ	MI	TTBE4IR
DMCGWBJ	MN	Plasmodium Oxoacyl-[acyl-carrier protein] reductase (Malaria fabG)
DMCGWBJ	MT	DTT
DMCGWBJ	MA	Inhibitor
DMCGWBJ	RN	Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
DMCGWBJ	RU	https://pubmed.ncbi.nlm.nih.gov/16722653

DMCGWBJ	DI	DMCGWBJ
DMCGWBJ	DN	Epigallocatechin gallate
DMCGWBJ	MI	TTE14XG
DMCGWBJ	MN	Squalene monooxygenase (SQLE)
DMCGWBJ	MT	DTT
DMCGWBJ	MA	Inhibitor
DMCGWBJ	RN	Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4.
DMCGWBJ	RU	https://pubmed.ncbi.nlm.nih.gov/11520216

DM9QPOU	DI	DM9QPOU
DM9QPOU	DN	Epoetin zeta
DM9QPOU	MI	TTAUX24
DM9QPOU	MN	Erythropoietin Receptor (EPOR)
DM9QPOU	MT	DTT
DM9QPOU	MA	Modulator
DM9QPOU	RN	Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia. Adv Ther. 2008 Nov;25(11):1215-28.
DM9QPOU	RU	https://pubmed.ncbi.nlm.nih.gov/18931828

DMITJRU	DI	DMITJRU
DMITJRU	DN	Epothilon
DMITJRU	MI	TTML2WA
DMITJRU	MN	Tubulin (TUB)
DMITJRU	MT	DTT
DMITJRU	MA	Stablizer
DMITJRU	RN	Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.
DMITJRU	RU	https://pubmed.ncbi.nlm.nih.gov/18764727

DMI1ZXV	DI	DMI1ZXV
DMI1ZXV	DN	Epratuzumab
DMI1ZXV	MI	TTM6QSK
DMI1ZXV	MN	B-cell receptor CD22 (CD22)
DMI1ZXV	MT	DTT
DMI1ZXV	RN	New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
DMI1ZXV	RU	https://pubmed.ncbi.nlm.nih.gov/19265486

DM35T1O	DI	DM35T1O
DM35T1O	DN	Epristeride
DM35T1O	MI	TT2A0DR
DM35T1O	MN	Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A)
DM35T1O	MT	DTT
DM35T1O	MA	Inhibitor
DM35T1O	RN	Discovery of a novel hybrid from finasteride and epristeride as 5alpha-reductase inhibitor. Bioorg Med Chem Lett. 2011 Jan 1;21(1):475-8.
DM35T1O	RU	https://pubmed.ncbi.nlm.nih.gov/21094046

DMTV7ZM	DI	DMTV7ZM
DMTV7ZM	DN	Eptastigmine
DMTV7ZM	MI	TT1RS9F
DMTV7ZM	MN	Acetylcholinesterase (AChE)
DMTV7ZM	MT	DTT
DMTV7ZM	MA	Inhibitor
DMTV7ZM	RN	Eptastigmine: ten years of pharmacology, toxicology, pharmacokinetic, and clinical studies. CNS Drug Rev. 2001 Winter;7(4):369-86.
DMTV7ZM	RU	https://pubmed.ncbi.nlm.nih.gov/11830755

DMTV7ZM	DI	DMTV7ZM
DMTV7ZM	DN	Eptastigmine
DMTV7ZM	MI	TTEB0GD
DMTV7ZM	MN	Cholinesterase (BCHE)
DMTV7ZM	MT	DTT
DMTV7ZM	MA	Inhibitor
DMTV7ZM	RN	Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine. J Med Chem. 2006 Apr 6;49(7):2174-85.
DMTV7ZM	RU	https://pubmed.ncbi.nlm.nih.gov/16570913

DM6BU57	DI	DM6BU57
DM6BU57	DN	Eraxis/Vfend
DM6BU57	MI	TTZMS1L
DM6BU57	MN	Fungal Papulacandin B resistance protein 1 (Fung FKS1)
DM6BU57	MT	DTT
DM6BU57	MA	Inhibitor
DM6BU57	RN	Pfizer. Product Development Pipeline. March 31 2009.
DM6BU57	RU	http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf

DM9YI2C	DI	DM9YI2C
DM9YI2C	DN	ErepoXen
DM9YI2C	MI	TTAUX24
DM9YI2C	MN	Erythropoietin Receptor (EPOR)
DM9YI2C	MT	DTT
DM9YI2C	MA	Agonist
DM9YI2C	RN	Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. Haematologica. 2006 Aug;91(8):1076-83.
DM9YI2C	RU	https://pubmed.ncbi.nlm.nih.gov/16885048

DMKQZ0L	DI	DMKQZ0L
DMKQZ0L	DN	ERITORAN
DMKQZ0L	MI	TTISGCA
DMKQZ0L	MN	Toll-like receptor 4 (TLR4)
DMKQZ0L	MT	DTT
DMKQZ0L	MA	Inhibitor
DMKQZ0L	RN	Small molecule modulators of toll-like receptors. J Med Chem. 2008 Nov 13;51(21):6621-6.
DMKQZ0L	RU	https://pubmed.ncbi.nlm.nih.gov/18828583

DMVU687	DI	DMVU687
DMVU687	DN	Esketamine
DMVU687	MI	DEPKLMQ
DMVU687	MN	Cytochrome P450 2B6 (CYP2B6)
DMVU687	MT	DME
DMVU687	MA	Metabolism
DMVU687	RN	Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos. 2002 Jul;30(7):853-8.
DMVU687	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12065445

DMVU687	DI	DMVU687
DMVU687	DN	Esketamine
DMVU687	MI	DE5IED8
DMVU687	MN	Cytochrome P450 2C9 (CYP2C9)
DMVU687	MT	DME
DMVU687	MA	Metabolism
DMVU687	RN	Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos. 2002 Jul;30(7):853-8.
DMVU687	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12065445

DMVU687	DI	DMVU687
DMVU687	DN	Esketamine
DMVU687	MI	DE4LYSA
DMVU687	MN	Cytochrome P450 3A4 (CYP3A4)
DMVU687	MT	DME
DMVU687	MA	Metabolism
DMVU687	RN	Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos. 2002 Jul;30(7):853-8.
DMVU687	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12065445

DMVU687	DI	DMVU687
DMVU687	DN	Esketamine
DMVU687	MI	DEGTFWK
DMVU687	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMVU687	MT	DME
DMVU687	MA	Metabolism
DMVU687	RN	Metabolism and metabolomics of ketamine: a toxicological approach. Forensic Sci Res. 2017 Feb 20;2(1):2-10.
DMVU687	RU	https://www.ncbi.nlm.nih.gov/pubmed/30483613

DMVU687	DI	DMVU687
DMVU687	DN	Esketamine
DMVU687	MI	TT9IK2Z
DMVU687	MN	N-methyl-D-aspartate receptor (NMDAR)
DMVU687	MT	DTT
DMVU687	MA	Antagonist
DMVU687	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMVU687	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DM8RBHJ	DI	DM8RBHJ
DM8RBHJ	DN	Esomeprazole magnesium + Aspirin
DM8RBHJ	MI	TTF1QVM
DM8RBHJ	MN	Gastric H(+)/K(+) ATPase alpha (ATP4A)
DM8RBHJ	MT	DTT
DM8RBHJ	MA	Inhibitor
DM8RBHJ	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DM8RBHJ	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DM4YGWA	DI	DM4YGWA
DM4YGWA	DN	Esonarimod
DM4YGWA	MI	TTGD6BY
DM4YGWA	MN	TNF-alpha/IL-1 beta production (TNFA/IL1B produ)
DM4YGWA	MT	DTT
DM4YGWA	MA	Modulator
DM4YGWA	RN	KE-758, an active metabolite of the new anti-rheumatic drug KE-298, suppresses production of tumor necrosis factor-alpha and interleukin-1 beta in THP-1, a human monocyte cell line. Drugs Exp Clin Res. 2002;28(5):197-205.
DM4YGWA	RU	https://pubmed.ncbi.nlm.nih.gov/12635495

DMXLGED	DI	DMXLGED
DMXLGED	DN	esuberaprost
DMXLGED	MI	TTOFYT1
DMXLGED	MN	Prostacyclin receptor (PTGIR)
DMXLGED	MT	DTT
DMXLGED	MA	Agonist
DMXLGED	RN	Specific binding of the new stable epoprostenol analogue beraprost sodium to prostacyclin receptors on human and rat platelets. Arzneimittelforschung. 1989 Apr;39(4):495-9.
DMXLGED	RU	https://pubmed.ncbi.nlm.nih.gov/2665758

DMQHX1Y	DI	DMQHX1Y
DMQHX1Y	DN	Etirinotecan pegol
DMQHX1Y	MI	TTGTQHC
DMQHX1Y	MN	DNA topoisomerase I (TOP1)
DMQHX1Y	MT	DTT
DMQHX1Y	MA	Inhibitor
DMQHX1Y	RN	Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models. Cancer Chemother Pharmacol. 2014 Dec;74(6):1125-37.
DMQHX1Y	RU	https://pubmed.ncbi.nlm.nih.gov/25228368

DMCDZ15	DI	DMCDZ15
DMCDZ15	DN	Evacetrapib
DMCDZ15	MI	TTFQAYR
DMCDZ15	MN	Cholesteryl ester transfer protein (CETP)
DMCDZ15	MT	DTT
DMCDZ15	MA	Inhibitor
DMCDZ15	RN	The dyslipidaemia market. Nat Rev Drug Discov. 2014 Nov;13(11):807-8.
DMCDZ15	RU	https://pubmed.ncbi.nlm.nih.gov/25323928

DMCDZ15	DI	DMCDZ15
DMCDZ15	DN	Evacetrapib
DMCDZ15	MI	DES5XRU
DMCDZ15	MN	Cytochrome P450 2C8 (CYP2C8)
DMCDZ15	MT	DME
DMCDZ15	MA	Metabolism
DMCDZ15	RN	Identification of cytochrome P450 enzymes involved in the metabolism of 4'-methoxy-alpha-pyrrolidinopropiophenone (MOPPP), a designer drug, in human liver microsomes. Xenobiotica. 2003 Oct;33(10):989-98.
DMCDZ15	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14555336

DMCDZ15	DI	DMCDZ15
DMCDZ15	DN	Evacetrapib
DMCDZ15	MI	DE4LYSA
DMCDZ15	MN	Cytochrome P450 3A4 (CYP3A4)
DMCDZ15	MT	DME
DMCDZ15	MA	Metabolism
DMCDZ15	RN	Identification of cytochrome P450 enzymes involved in the metabolism of 4'-methoxy-alpha-pyrrolidinopropiophenone (MOPPP), a designer drug, in human liver microsomes. Xenobiotica. 2003 Oct;33(10):989-98.
DMCDZ15	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14555336

DMG4UJ6	DI	DMG4UJ6
DMG4UJ6	DN	EVK-001
DMG4UJ6	MI	TTWFZ1N
DMG4UJ6	MN	Dopamine receptor (DR)
DMG4UJ6	MT	DTT
DMG4UJ6	MA	Antagonist
DMG4UJ6	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMG4UJ6	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMLQO7F	DI	DMLQO7F
DMLQO7F	DN	EVP-6124
DMLQO7F	MI	TTLA931
DMLQO7F	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMLQO7F	MT	DTT
DMLQO7F	MA	Modulator
DMLQO7F	RN	Normalizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia. J Psychiatr Pract. 2014 Jan;20(1):12-24.
DMLQO7F	RU	https://pubmed.ncbi.nlm.nih.gov/24419307

DMCA7FN	DI	DMCA7FN
DMCA7FN	DN	Exatecan
DMCA7FN	MI	DTI7UX6
DMCA7FN	MN	Breast cancer resistance protein (ABCG2)
DMCA7FN	MT	DTP
DMCA7FN	MA	Substrate
DMCA7FN	RN	Pharmacogenomic importance of ABCG2. Pharmacogenomics. 2008 Aug;9(8):1005-9.
DMCA7FN	RU	https://doi.org/10.2217/14622416.9.8.1005

DMCA7FN	DI	DMCA7FN
DMCA7FN	DN	Exatecan
DMCA7FN	MI	DE4LYSA
DMCA7FN	MN	Cytochrome P450 3A4 (CYP3A4)
DMCA7FN	MT	DME
DMCA7FN	MA	Metabolism
DMCA7FN	RN	Phase I and pharmacological study of a new camptothecin derivative, exatecan mesylate (DX-8951f), infused over 30 minutes every three weeks. Clin Cancer Res. 2001 Oct;7(10):3056-64.
DMCA7FN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11595695

DMCA7FN	DI	DMCA7FN
DMCA7FN	DN	Exatecan
DMCA7FN	MI	TTGTQHC
DMCA7FN	MN	DNA topoisomerase I (TOP1)
DMCA7FN	MT	DTT
DMCA7FN	MA	Inhibitor
DMCA7FN	RN	Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks. Clin Cancer Res. 2001 Dec;7(12):3963-70.
DMCA7FN	RU	https://pubmed.ncbi.nlm.nih.gov/11751488

DMBY56U	DI	DMBY56U
DMBY56U	DN	EXISULIND
DMBY56U	MI	TTJ0IQB
DMBY56U	MN	Phosphodiesterase 5A (PDE5A)
DMBY56U	MT	DTT
DMBY56U	MA	Modulator
DMBY56U	RN	Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res. 2000 Jul 1;60(13):3338-42.
DMBY56U	RU	https://pubmed.ncbi.nlm.nih.gov/10910034

DMOKT7Y	DI	DMOKT7Y
DMOKT7Y	DN	FARGLITAZAR
DMOKT7Y	MI	TTZMAO3
DMOKT7Y	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMOKT7Y	MT	DTT
DMOKT7Y	MA	Modulator
DMOKT7Y	RN	Rosiglitazone (BRL49653), a PPARgamma-selective agonist, causes peroxisome proliferator-like liver effects in obese mice. J Lipid Res. 1999 Jul;40(7):1177-84.
DMOKT7Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/10393202

DM83SEB	DI	DM83SEB
DM83SEB	DN	Faricimab
DM83SEB	MI	TTKLQTJ
DM83SEB	MN	Angiopoietin-2 (ANGPT2)
DM83SEB	MT	DTT
DM83SEB	RN	Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200.
DM83SEB	RU	https://pubmed.ncbi.nlm.nih.gov/33471572

DM83SEB	DI	DM83SEB
DM83SEB	DN	Faricimab
DM83SEB	MI	TTOHSBA
DM83SEB	MN	Vascular endothelial growth factor A (VEGFA)
DM83SEB	MT	DTT
DM83SEB	RN	Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200.
DM83SEB	RU	https://pubmed.ncbi.nlm.nih.gov/33471572

DMFLWX1	DI	DMFLWX1
DMFLWX1	DN	Farletuzumab
DMFLWX1	MI	TTVC37M
DMFLWX1	MN	Folate receptor alpha (FOLR1)
DMFLWX1	MT	DTT
DMFLWX1	MA	Modulator
DMFLWX1	RN	Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.Gynecol Oncol.2013 Jun;129(3):452-8.
DMFLWX1	RU	https://www.ncbi.nlm.nih.gov/pubmed/23474348

DMTGYSO	DI	DMTGYSO
DMTGYSO	DN	Fasiglifam hemihydrate
DMTGYSO	MI	TTB8FUC
DMTGYSO	MN	Free fatty acid receptor 1 (GPR40)
DMTGYSO	MT	DTT
DMTGYSO	MA	Modulator
DMTGYSO	RN	A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1. PLoS One. 2013 Oct 10;8(10):e76280.
DMTGYSO	RU	https://pubmed.ncbi.nlm.nih.gov/24130766

DM5PRLA	DI	DM5PRLA
DM5PRLA	DN	Fasinumab
DM5PRLA	MI	TTDN3LF
DM5PRLA	MN	Nerve growth factor (NGF)
DM5PRLA	MT	DTT
DM5PRLA	MA	Inhibitor
DM5PRLA	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM5PRLA	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM8E51L	DI	DM8E51L
DM8E51L	DN	FASORACETAM
DM8E51L	MI	TTAN6JD
DM8E51L	MN	Glutamate receptor AMPA (GRIA)
DM8E51L	MT	DTT
DM8E51L	MA	Modulator
DM8E51L	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DM8E51L	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM35GBS	DI	DM35GBS
DM35GBS	DN	Favipiravir
DM35GBS	MI	TTV1095
DM35GBS	MN	COVID-19 RNA-directed RNA polymerase (RdRp)
DM35GBS	MT	DTT
DM35GBS	MA	Inhibitor
DM35GBS	RN	Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv. Posted April 15, 2020.
DM35GBS	RU	https://doi.org/10.1101/2020.03.17.20037432

DM0762O	DI	DM0762O
DM0762O	DN	Fenfluramine
DM0762O	MI	TT85JO3
DM0762O	MN	5-HT receptor (5HTR)
DM0762O	MT	DTT
DM0762O	MA	Antagonist
DM0762O	RN	Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418.
DM0762O	RU	https://pubmed.ncbi.nlm.nih.gov/15977970

DMRD5SP	DI	DMRD5SP
DMRD5SP	DN	Fenretinide
DMRD5SP	MI	DES5XRU
DMRD5SP	MN	Cytochrome P450 2C8 (CYP2C8)
DMRD5SP	MT	DME
DMRD5SP	MA	Metabolism
DMRD5SP	RN	Characterization of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases. Br J Pharmacol. 2011 Feb;162(4):989-99.
DMRD5SP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21054342

DMRD5SP	DI	DMRD5SP
DMRD5SP	DN	Fenretinide
DMRD5SP	MI	TTOD7B3
DMRD5SP	MN	Retinoic acid receptor (RAR)
DMRD5SP	MT	DTT
DMRD5SP	MA	Modulator
DMRD5SP	RN	National Cancer Institute Drug Dictionary (drug id 39582).
DMRD5SP	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=39582

DM4NX0C	DI	DM4NX0C
DM4NX0C	DN	Fevipiprant
DM4NX0C	MI	TTQDMX5
DM4NX0C	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DM4NX0C	MT	DTT
DM4NX0C	MA	Antagonist
DM4NX0C	RN	Fevipiprant in the treatment of asthma. Expert Opin Investig Drugs. 2018 Feb;27(2):199-207.
DM4NX0C	RU	https://pubmed.ncbi.nlm.nih.gov/29363343

DM4XSQ2	DI	DM4XSQ2
DM4XSQ2	DN	FG-4592
DM4XSQ2	MI	TTMHFRY
DM4XSQ2	MN	HIF-prolyl hydroxylase 1 (HPH-1)
DM4XSQ2	MT	DTT
DM4XSQ2	MA	Inhibitor
DM4XSQ2	RN	The latest advances in kidney diseases and related disorders. Drug News Perspect. 2007 Dec;20(10):647-54.
DM4XSQ2	RU	https://pubmed.ncbi.nlm.nih.gov/18301799

DM4XSQ2	DI	DM4XSQ2
DM4XSQ2	DN	FG-4592
DM4XSQ2	MI	TT9ISBX
DM4XSQ2	MN	HIF-prolyl hydroxylase 2 (HPH-2)
DM4XSQ2	MT	DTT
DM4XSQ2	MA	Inhibitor
DM4XSQ2	RN	Crystalline forms of a prolyl hydroxylase inhibitor. US9115085.
DM4XSQ2	RU	http://www.freepatentsonline.com/US9115085.html

DMFZ81T	DI	DMFZ81T
DMFZ81T	DN	Fidanacogene elaparvovec
DMFZ81T	MI	TTFEZ5Q
DMFZ81T	MN	Coagulation factor IX (F9)
DMFZ81T	MT	DTT
DMFZ81T	MA	Replacement
DMFZ81T	RN	Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX-Padua. J Thromb Haemost. 2021 May;19(5):1212-1218.
DMFZ81T	RU	https://pubmed.ncbi.nlm.nih.gov/33636038

DMZL1I8	DI	DMZL1I8
DMZL1I8	DN	Fidarestat
DMZL1I8	MI	TTFBNVI
DMZL1I8	MN	Aldose reductase (AKR1B1)
DMZL1I8	MT	DTT
DMZL1I8	MA	Inhibitor
DMZL1I8	RN	Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care. 2001 Oct;24(10):1776-82.
DMZL1I8	RU	https://pubmed.ncbi.nlm.nih.gov/11574441

DMM4FJ3	DI	DMM4FJ3
DMM4FJ3	DN	Finerenone
DMM4FJ3	MI	TT26PHO
DMM4FJ3	MN	Mineralocorticoid receptor  (MR)
DMM4FJ3	MT	DTT
DMM4FJ3	MA	Antagonist
DMM4FJ3	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMM4FJ3	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMMQ7BY	DI	DMMQ7BY
DMMQ7BY	DN	Fitusiran
DMMQ7BY	MI	TTZ4MD5
DMMQ7BY	MN	SERPINC1 messenger RNA (SERPINC1 mRNA)
DMMQ7BY	MT	DTT
DMMQ7BY	MA	Inhibitor
DMMQ7BY	RN	Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy. N Engl J Med. 2017 Aug 31;377(9):819-828.
DMMQ7BY	RU	https://pubmed.ncbi.nlm.nih.gov/28691885

DM6R2XF	DI	DM6R2XF
DM6R2XF	DN	FKB238
DM6R2XF	MI	TT9HKJA
DM6R2XF	MN	Vascular endothelial growth factor (VEGF)
DM6R2XF	MT	DTT
DM6R2XF	MA	Inhibitor
DM6R2XF	RN	Clinical pipeline report, company report or official report of Fujifilm.
DM6R2XF	RU	https://fujifilmkyowakirin-biologics.com/en/pipeline/

DMPSG4D	DI	DMPSG4D
DMPSG4D	DN	Flobufen
DMPSG4D	MI	TT2J34L
DMPSG4D	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMPSG4D	MT	DTT
DMPSG4D	MA	Modulator
DMPSG4D	RN	Pharmacological profile of the novel potent antirheumatic 4-(2',4'-difluorobiphenyl-4-yl)-2-methyl-4-oxobutanoic acid. Arzneimittelforschung. 1997 May;47(5):648-52.
DMPSG4D	RU	https://pubmed.ncbi.nlm.nih.gov/9205780

DMKL5AT	DI	DMKL5AT
DMKL5AT	DN	Flurpiridaz F 18
DMKL5AT	MI	TTRU1NG
DMKL5AT	MN	Mitochondrial complex I (NDUFA13)
DMKL5AT	MT	DTT
DMKL5AT	MA	Inhibitor
DMKL5AT	RN	The next generation of cardiac positron emission tomography imaging agents: discovery of flurpiridaz F-18 for detection of coronary disease. Semin Nucl Med. 2011 Jul;41(4):305-13.
DMKL5AT	RU	https://pubmed.ncbi.nlm.nih.gov/21624564

DM5S4DL	DI	DM5S4DL
DM5S4DL	DN	Forigerimod
DM5S4DL	MI	TTPVYKI
DM5S4DL	MN	Signal transduction unspecific (ST)
DM5S4DL	MT	DTT
DM5S4DL	MA	Modulator
DM5S4DL	RN	Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial. Arthritis Rheum. 2008 Dec;58(12):3873-83.
DM5S4DL	RU	https://pubmed.ncbi.nlm.nih.gov/19035498

DM8L3JU	DI	DM8L3JU
DM8L3JU	DN	Fosclin
DM8L3JU	MI	TTLH4J3
DM8L3JU	MN	Plasmodium DOXP reductoisomerase (Malaria DXR)
DM8L3JU	MT	DTT
DM8L3JU	MA	Inhibitor
DM8L3JU	RN	Fosmidomycin-clindamycin for Plasmodium falciparum Infections in African children. J Infect Dis. 2004 Mar 1;189(5):901-8.
DM8L3JU	RU	https://pubmed.ncbi.nlm.nih.gov/14976608

DM3274D	DI	DM3274D
DM3274D	DN	Fostamatinib disodium
DM3274D	MI	TTOU65C
DM3274D	MN	Tyrosine-protein kinase SYK (SYK)
DM3274D	MT	DTT
DM3274D	MA	Inhibitor
DM3274D	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3274D	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DM823WQ	DI	DM823WQ
DM823WQ	DN	FP-1201
DM823WQ	MI	TT4TZ8J
DM823WQ	MN	Interferon-beta (IFNB1)
DM823WQ	MT	DTT
DM823WQ	MA	Modulator
DM823WQ	RN	The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study.Lancet Respir Med. 2014 Feb;2(2):98-107.
DM823WQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/24503265

DMGF8MZ	DI	DMGF8MZ
DMGF8MZ	DN	FPL-62064
DMGF8MZ	MI	TT2J34L
DMGF8MZ	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMGF8MZ	MT	DTT
DMGF8MZ	MA	Modulator
DMGF8MZ	RN	FPL 62064, a topically active 5-lipoxygenase/cyclooxygenase inhibitor. Agents Actions. 1990 Jun;30(3-4):432-42.
DMGF8MZ	RU	https://pubmed.ncbi.nlm.nih.gov/2117338

DMHOSCQ	DI	DMHOSCQ
DMHOSCQ	DN	Fruquintinib
DMHOSCQ	MI	TTVJ1D8
DMHOSCQ	MN	Vascular endothelial growth factor receptor (VEGFR)
DMHOSCQ	MT	DTT
DMHOSCQ	MA	Inhibitor
DMHOSCQ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMHOSCQ	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMHOSCQ	DI	DMHOSCQ
DMHOSCQ	DN	Fruquintinib
DMHOSCQ	MI	TT2Q6G1
DMHOSCQ	MN	Vascular endothelial growth factor receptor 1 (FLT-1)
DMHOSCQ	MT	DTT
DMHOSCQ	MA	Inhibitor
DMHOSCQ	RN	Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635-45.
DMHOSCQ	RU	https://pubmed.ncbi.nlm.nih.gov/25482937

DMHOSCQ	DI	DMHOSCQ
DMHOSCQ	DN	Fruquintinib
DMHOSCQ	MI	TTUTJGQ
DMHOSCQ	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMHOSCQ	MT	DTT
DMHOSCQ	MA	Inhibitor
DMHOSCQ	RN	Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635-45.
DMHOSCQ	RU	https://pubmed.ncbi.nlm.nih.gov/25482937

DMHOSCQ	DI	DMHOSCQ
DMHOSCQ	DN	Fruquintinib
DMHOSCQ	MI	TTDCBX5
DMHOSCQ	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DMHOSCQ	MT	DTT
DMHOSCQ	MA	Inhibitor
DMHOSCQ	RN	Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635-45.
DMHOSCQ	RU	https://pubmed.ncbi.nlm.nih.gov/25482937

DM1YVLM	DI	DM1YVLM
DM1YVLM	DN	FST-201
DM1YVLM	MI	TTYRL6O
DM1YVLM	MN	Glucocorticoid receptor (NR3C1)
DM1YVLM	MT	DTT
DM1YVLM	MA	Agonist
DM1YVLM	RN	A combination povidone-iodine 0.4%/dexamethasone 0.1% ophthalmic suspension in the treatment of adenoviral conjunctivitis. Adv Ther. 2009 Aug;26(8):776-83.
DM1YVLM	RU	https://pubmed.ncbi.nlm.nih.gov/19756415

DMDKYVE	DI	DMDKYVE
DMDKYVE	DN	FT-0624878
DMDKYVE	MI	DEI2XLV
DMDKYVE	MN	Phosphoenolpyruvate carboxykinase (pckG)
DMDKYVE	MT	DME
DMDKYVE	MA	Metabolism
DMDKYVE	RN	nan
DMDKYVE	RU	nan

DMF4I1V	DI	DMF4I1V
DMF4I1V	DN	FT-0710230
DMF4I1V	MI	DECB0K3
DMF4I1V	MN	Cytochrome P450 2D6 (CYP2D6)
DMF4I1V	MT	DME
DMF4I1V	MA	Metabolism
DMF4I1V	RN	Interpretation of opiate urine drug screens.
DMF4I1V	RU	https://www.healthpartners.com/ucm/groups/public/@hp/@public/@ime/@content/documents/documents/cntrb_031044.pdf

DMK38MV	DI	DMK38MV
DMK38MV	DN	Fulranumab
DMK38MV	MI	TTEDJN4
DMK38MV	MN	Low-affinity nerve growth factor receptor (NGFR)
DMK38MV	MT	DTT
DMK38MV	MA	Antagonist
DMK38MV	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1888).
DMK38MV	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1888

DMP83UZ	DI	DMP83UZ
DMP83UZ	DN	Fumaric acid
DMP83UZ	MI	TT93WF5
DMP83UZ	MN	Interferon-gamma (IFNG)
DMP83UZ	MT	DTT
DMP83UZ	MA	Binder
DMP83UZ	RN	Emerging oral drugs for multiple sclerosis. Expert Opin Emerg Drugs. 2008 Sep;13(3):465-77.
DMP83UZ	RU	https://pubmed.ncbi.nlm.nih.gov/18764723

DMZARP1	DI	DMZARP1
DMZARP1	DN	FV-100
DMZARP1	MI	TTP3QRF
DMZARP1	MN	Thymidine kinase 1 (TK1)
DMZARP1	MT	DTT
DMZARP1	MA	Inhibitor
DMZARP1	RN	Specific recognition of the bicyclic pyrimidine nucleoside analogs, a new class of highly potent and selective inhibitors of varicella-zoster virus (VZV), by the VZV-encoded thymidine kinase. Mol Pharmacol. 2002 Feb;61(2):249-54.
DMZARP1	RU	https://pubmed.ncbi.nlm.nih.gov/11809847

DMMNP2F	DI	DMMNP2F
DMMNP2F	DN	G17DT
DMMNP2F	MI	TT4LRVO
DMMNP2F	MN	Gastrin (GAST)
DMMNP2F	MT	DTT
DMMNP2F	RN	G17DT: an antigastrin immunogen for the treatment of gastrointestinal malignancy. Expert Opin Biol Ther. 2007 Mar;7(3):397-404.
DMMNP2F	RU	https://pubmed.ncbi.nlm.nih.gov/17309331

DMXJMKF	DI	DMXJMKF
DMXJMKF	DN	Ganaxolone
DMXJMKF	MI	TTGXH6N
DMXJMKF	MN	GABA(A) receptor delta (GABRD)
DMXJMKF	MT	DTT
DMXJMKF	MA	Modulator
DMXJMKF	RN	Ganaxolone, a selective, high-affinity steroid modulator of the gamma-aminobutyric acid-A receptor, exacerbates seizures in animal models of absence. Ann Neurol. 1998 Oct;44(4):688-91.
DMXJMKF	RU	https://www.ncbi.nlm.nih.gov/pubmed/9778270

DMXJMKF	DI	DMXJMKF
DMXJMKF	DN	Ganaxolone
DMXJMKF	MI	TTEX6LM
DMXJMKF	MN	GABA(A) receptor gamma-3 (GABRG3)
DMXJMKF	MT	DTT
DMXJMKF	MA	Agonist
DMXJMKF	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMXJMKF	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMWX90U	DI	DMWX90U
DMWX90U	DN	Gantenerumab
DMWX90U	MI	TTE4KHA
DMWX90U	MN	Amyloid beta A4 protein (APP)
DMWX90U	MT	DTT
DMWX90U	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMWX90U	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMO3ITF	DI	DMO3ITF
DMO3ITF	DN	GASTRAZOLE
DMO3ITF	MI	TTVFO0U
DMO3ITF	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMO3ITF	MT	DTT
DMO3ITF	MA	Antagonist
DMO3ITF	RN	Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. Br J Cancer. 2006 April 24; 94(8): 1107-1115.
DMO3ITF	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361246/

DMT4QHD	DI	DMT4QHD
DMT4QHD	DN	GDC-0032
DMT4QHD	MI	TTEUNMR
DMT4QHD	MN	PI3-kinase alpha (PIK3CA)
DMT4QHD	MT	DTT
DMT4QHD	MA	Modulator
DMT4QHD	RN	Company report (BioOncology)
DMT4QHD	RU	http://www.biooncology.com/pipeline-molecules/taselisib-gdc-0032

DMT4QHD	DI	DMT4QHD
DMT4QHD	DN	GDC-0032
DMT4QHD	MI	TTHBTOP
DMT4QHD	MN	PI3-kinase gamma (PIK3CG)
DMT4QHD	MT	DTT
DMT4QHD	MA	Inhibitor
DMT4QHD	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMT4QHD	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMWBZJD	DI	DMWBZJD
DMWBZJD	DN	GDC-0068
DMWBZJD	MI	TTWTSCV
DMWBZJD	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DMWBZJD	MT	DTT
DMWBZJD	MA	Inhibitor
DMWBZJD	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMWBZJD	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMBEL3Q	DI	DMBEL3Q
DMBEL3Q	DN	GDC-0853
DMBEL3Q	MI	TTGM6VW
DMBEL3Q	MN	Tyrosine-protein kinase BTK (ATK)
DMBEL3Q	MT	DTT
DMBEL3Q	MA	Inhibitor
DMBEL3Q	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMBEL3Q	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMTUV7L	DI	DMTUV7L
DMTUV7L	DN	GED-0301
DMTUV7L	MI	TTW06P4
DMTUV7L	MN	Mothers against decapentaplegic homolog 7 (SMAD7)
DMTUV7L	MT	DTT
DMTUV7L	MA	Inhibitor
DMTUV7L	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMTUV7L	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMTUV7L	DI	DMTUV7L
DMTUV7L	DN	GED-0301
DMTUV7L	MI	TT0J32Z
DMTUV7L	MN	Smad7 messenger RNA (Smad7 mRNA)
DMTUV7L	MT	DTT
DMTUV7L	MA	Inhibitor
DMTUV7L	RN	A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn's disease. Aliment Pharmacol Ther. 2012 Nov;36(9):850-7.
DMTUV7L	RU	https://pubmed.ncbi.nlm.nih.gov/22971085

DM4GWL7	DI	DM4GWL7
DM4GWL7	DN	Gefapixant
DM4GWL7	MI	TT2THBD
DM4GWL7	MN	P2X purinoceptor 3 (P2RX3)
DM4GWL7	MT	DTT
DM4GWL7	MA	Inhibitor
DM4GWL7	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DM4GWL7	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMZKGPV	DI	DMZKGPV
DMZKGPV	DN	Gemigliptin
DMZKGPV	MI	TTDIGC1
DMZKGPV	MN	Dipeptidyl peptidase 4 (DPP-4)
DMZKGPV	MT	DTT
DMZKGPV	MA	Inhibitor
DMZKGPV	RN	Evaluation of the pharmacokinetics of the DPP-4 inhibitor gemigliptin when coadministered with rosuvastatin or irbesartan to healthy subjects. Curr Med Res Opin. 2015 Feb;31(2):229-41.
DMZKGPV	RU	https://pubmed.ncbi.nlm.nih.gov/25350224

DM1WMOK	DI	DM1WMOK
DM1WMOK	DN	Generx
DM1WMOK	MI	TTCEKVZ
DM1WMOK	MN	Fibroblast growth factor-4 (FGF4)
DM1WMOK	MT	DTT
DM1WMOK	MA	Replacement
DM1WMOK	RN	Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials. J Am Coll Cardiol. 2007 Sep 11;50(11):1038-46.
DM1WMOK	RU	https://pubmed.ncbi.nlm.nih.gov/17825712

DM7ZOAE	DI	DM7ZOAE
DM7ZOAE	DN	GFT-505
DM7ZOAE	MI	TTJ584C
DM7ZOAE	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DM7ZOAE	MT	DTT
DM7ZOAE	MA	Modulator
DM7ZOAE	RN	Dual peroxisome proliferator-activated receptor / agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.Diabetes Care.2013 Oct;36(10):2923-30.
DM7ZOAE	RU	https://www.ncbi.nlm.nih.gov/pubmed/23715754

DM7ZOAE	DI	DM7ZOAE
DM7ZOAE	DN	GFT-505
DM7ZOAE	MI	TT2JWF6
DM7ZOAE	MN	Peroxisome proliferator-activated receptor delta (PPARD)
DM7ZOAE	MT	DTT
DM7ZOAE	MA	Modulator
DM7ZOAE	RN	Dual peroxisome proliferator-activated receptor / agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.Diabetes Care.2013 Oct;36(10):2923-30.
DM7ZOAE	RU	https://www.ncbi.nlm.nih.gov/pubmed/23715754

DMR6YH3	DI	DMR6YH3
DMR6YH3	DN	GLP-1
DMR6YH3	MI	TTVIMDE
DMR6YH3	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMR6YH3	MT	DTT
DMR6YH3	MA	Modulator
DMR6YH3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249).
DMR6YH3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=249

DMEFCTP	DI	DMEFCTP
DMEFCTP	DN	Glufosfamide
DMEFCTP	MI	TTUBNVO
DMEFCTP	MN	DNA synthesis (DNA synth)
DMEFCTP	MT	DTT
DMEFCTP	MA	Inhibitor
DMEFCTP	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMEFCTP	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMEFCTP	DI	DMEFCTP
DMEFCTP	DN	Glufosfamide
DMEFCTP	MI	TTUTN1I
DMEFCTP	MN	Human Deoxyribonucleic acid (hDNA)
DMEFCTP	MT	DTT
DMEFCTP	MA	Modulator
DMEFCTP	RN	A novel alkylating agent, glufosfamide, enhances the activity of gemcitabine in vitro and in vivo. Neoplasia. 2007 Aug;9(8):625-33.
DMEFCTP	RU	https://www.ncbi.nlm.nih.gov/pubmed/17786181

DMOUT89	DI	DMOUT89
DMOUT89	DN	Glutamic acid
DMOUT89	MI	DE8PQ7T
DMOUT89	MN	D-aspartate oxidase (DDO)
DMOUT89	MT	DME
DMOUT89	MA	Metabolism
DMOUT89	RN	Secreted d-aspartate oxidase functions in C. elegans reproduction and development. FEBS J. 2019 Jan;286(1):124-138.
DMOUT89	RU	https://pubmed.ncbi.nlm.nih.gov/30387556

DM8M2N3	DI	DM8M2N3
DM8M2N3	DN	Glycyrrhizin
DM8M2N3	MI	TTN7BL9
DM8M2N3	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DM8M2N3	MT	DTT
DM8M2N3	MA	Inhibitor
DM8M2N3	RN	Discovery of novel dual functional agent as PPARgamma agonist and 11beta-HSD1 inhibitor for the treatment of diabetes. Bioorg Med Chem. 2009 Aug 1;17(15):5722-32.
DM8M2N3	RU	https://pubmed.ncbi.nlm.nih.gov/19574056

DM8M2N3	DI	DM8M2N3
DM8M2N3	DN	Glycyrrhizin
DM8M2N3	MI	DE4LYSA
DM8M2N3	MN	Cytochrome P450 3A4 (CYP3A4)
DM8M2N3	MT	DME
DM8M2N3	MA	Metabolism
DM8M2N3	RN	Effect of glycyrrhizin on the activity of CYP3A enzyme in humans. Eur J Clin Pharmacol. 2010 Aug;66(8):805-810.
DM8M2N3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20393696

DM8M2N3	DI	DM8M2N3
DM8M2N3	DN	Glycyrrhizin
DM8M2N3	MI	DEIBDNY
DM8M2N3	MN	Cytochrome P450 3A5 (CYP3A5)
DM8M2N3	MT	DME
DM8M2N3	MA	Metabolism
DM8M2N3	RN	Effect of glycyrrhizin on the activity of CYP3A enzyme in humans. Eur J Clin Pharmacol. 2010 Aug;66(8):805-810.
DM8M2N3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20393696

DM8M2N3	DI	DM8M2N3
DM8M2N3	DN	Glycyrrhizin
DM8M2N3	MI	DERD86B
DM8M2N3	MN	Cytochrome P450 3A7 (CYP3A7)
DM8M2N3	MT	DME
DM8M2N3	MA	Metabolism
DM8M2N3	RN	Effect of glycyrrhizin on the activity of CYP3A enzyme in humans. Eur J Clin Pharmacol. 2010 Aug;66(8):805-810.
DM8M2N3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20393696

DM8M2N3	DI	DM8M2N3
DM8M2N3	DN	Glycyrrhizin
DM8M2N3	MI	DTFI42L
DM8M2N3	MN	Multidrug resistance-associated protein 2 (ABCC2)
DM8M2N3	MT	DTP
DM8M2N3	MA	Substrate
DM8M2N3	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM8M2N3	RU	https://doi.org/10.1007/s11095-012-0935-x

DM8M2N3	DI	DM8M2N3
DM8M2N3	DN	Glycyrrhizin
DM8M2N3	MI	DTQ3ZHF
DM8M2N3	MN	Multidrug resistance-associated protein 3 (ABCC3)
DM8M2N3	MT	DTP
DM8M2N3	MA	Substrate
DM8M2N3	RN	The combination of glycyrrhizin and lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of multidrug resistance-associated proteins. Int J Oncol. 2007 Dec;31(6):1465-72.
DM8M2N3	RU	http://www.spandidos-publications.com/ijo/31/6/1465

DMQCZ4N	DI	DMQCZ4N
DMQCZ4N	DN	Glyminox
DMQCZ4N	MI	TT84ETX
DMQCZ4N	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMQCZ4N	MT	DTT
DMQCZ4N	MA	Inhibitor
DMQCZ4N	RN	Glyminox Biosyn. Curr Opin Investig Drugs. 2004 Feb;5(2):222-31.
DMQCZ4N	RU	https://pubmed.ncbi.nlm.nih.gov/15043398

DMOHUR2	DI	DMOHUR2
DMOHUR2	DN	GLYX-13
DMOHUR2	MI	TT9IK2Z
DMOHUR2	MN	N-methyl-D-aspartate receptor (NMDAR)
DMOHUR2	MT	DTT
DMOHUR2	MA	Agonist
DMOHUR2	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMOHUR2	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMQIE7U	DI	DMQIE7U
DMQIE7U	DN	GMA102
DMQIE7U	MI	TTVIMDE
DMQIE7U	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMQIE7U	MT	DTT
DMQIE7U	MA	Inhibitor
DMQIE7U	RN	Clinical pipeline report, company report or official report of Gmax Biopharm.
DMQIE7U	RU	http://www.gmaxbiopharm.com/wap_product_detailen/id/2.html

DM2XSG0	DI	DM2XSG0
DM2XSG0	DN	GMA105
DM2XSG0	MI	TTVIMDE
DM2XSG0	MN	Glucagon-like peptide 1 receptor (GLP1R)
DM2XSG0	MT	DTT
DM2XSG0	MA	Inhibitor
DM2XSG0	RN	Clinical pipeline report, company report or official report of Gmax Biopharm.
DM2XSG0	RU	http://www.gmaxbiopharm.com/wap_product_detailen/id/3.html

DMJ432G	DI	DMJ432G
DMJ432G	DN	GMI-1070
DMJ432G	MI	TTAU4D6
DMJ432G	MN	E-selectin (SELE)
DMJ432G	MT	DTT
DMJ432G	MA	Inhibitor
DMJ432G	RN	Deal watch: Pfizer deal for selectin inhibitor highlights potential of glycomimetic drugs. Nat Rev Drug Discov. 2011 Dec 1;10(12):890.
DMJ432G	RU	https://pubmed.ncbi.nlm.nih.gov/22129980

DMJ432G	DI	DMJ432G
DMJ432G	DN	GMI-1070
DMJ432G	MI	TT2IYXF
DMJ432G	MN	L-selectin (SELL)
DMJ432G	MT	DTT
DMJ432G	MA	Inhibitor
DMJ432G	RN	Deal watch: Pfizer deal for selectin inhibitor highlights potential of glycomimetic drugs. Nat Rev Drug Discov. 2011 Dec 1;10(12):890.
DMJ432G	RU	https://pubmed.ncbi.nlm.nih.gov/22129980

DMJ432G	DI	DMJ432G
DMJ432G	DN	GMI-1070
DMJ432G	MI	TTE5VG0
DMJ432G	MN	P-selectin (SELP)
DMJ432G	MT	DTT
DMJ432G	MA	Inhibitor
DMJ432G	RN	Deal watch: Pfizer deal for selectin inhibitor highlights potential of glycomimetic drugs. Nat Rev Drug Discov. 2011 Dec 1;10(12):890.
DMJ432G	RU	https://pubmed.ncbi.nlm.nih.gov/22129980

DMJ432G	DI	DMJ432G
DMJ432G	DN	GMI-1070
DMJ432G	MI	TTBGONL
DMJ432G	MN	Selectin (SEL)
DMJ432G	MT	DTT
DMJ432G	MA	Antagonist
DMJ432G	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMJ432G	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DMDTGWQ	DI	DMDTGWQ
DMDTGWQ	DN	GMI-1271
DMDTGWQ	MI	TTAU4D6
DMDTGWQ	MN	E-selectin (SELE)
DMDTGWQ	MT	DTT
DMDTGWQ	MA	Inhibitor
DMDTGWQ	RN	Clinical pipeline report, company report or official report of glycomimetics.
DMDTGWQ	RU	http://www.glycomimetics.com/programs-pipeline/gmi-1271/

DM0LQ94	DI	DM0LQ94
DM0LQ94	DN	GnRH
DM0LQ94	MI	TT8R70G
DM0LQ94	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DM0LQ94	MT	DTT
DM0LQ94	MA	Modulator
DM0LQ94	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 256).
DM0LQ94	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=256

DMKWV4B	DI	DMKWV4B
DMKWV4B	DN	Golnerminogene pradenovac
DMKWV4B	MI	TTF8CQI
DMKWV4B	MN	Tumor necrosis factor (TNF)
DMKWV4B	MT	DTT
DMKWV4B	MA	Modulator
DMKWV4B	RN	TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience... Ann Surg Oncol. 2005 Oct;12(10):825-30.
DMKWV4B	RU	https://pubmed.ncbi.nlm.nih.gov/16132372

DMZS2R7	DI	DMZS2R7
DMZS2R7	DN	Granexin gel
DMZS2R7	MI	TT4F7SL
DMZS2R7	MN	Gap junction alpha-1 protein (GJA1)
DMZS2R7	MT	DTT
DMZS2R7	MA	Modulator
DMZS2R7	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMZS2R7	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DM4Y7WV	DI	DM4Y7WV
DM4Y7WV	DN	GRASPA
DM4Y7WV	MI	TT4WT91
DM4Y7WV	MN	Asparaginase (ASRGL1)
DM4Y7WV	MT	DTT
DM4Y7WV	MA	Modulator
DM4Y7WV	RN	l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial. Br J Haematol. 2011 Apr;153(1):58-65.
DM4Y7WV	RU	https://pubmed.ncbi.nlm.nih.gov/21332712

DM71GPM	DI	DM71GPM
DM71GPM	DN	Grippol Plus
DM71GPM	MI	TT3J5ZI
DM71GPM	MN	Cell mediated immunity response (CMIR)
DM71GPM	MT	DTT
DM71GPM	RN	Clinical pipeline report, company report or official report of Petrovax.
DM71GPM	RU	http://petrovax.com/medication/catalog/grippallplus/

DMB34TZ	DI	DMB34TZ
DMB34TZ	DN	Grippol TC
DMB34TZ	MI	TT3J5ZI
DMB34TZ	MN	Cell mediated immunity response (CMIR)
DMB34TZ	MT	DTT
DMB34TZ	RN	Clinical pipeline report, company report or official report of Petrovax.
DMB34TZ	RU	http://petrovax.com/medication/catalog/grippallplus/

DMHN3PG	DI	DMHN3PG
DMHN3PG	DN	GRT-6005
DMHN3PG	MI	TTKWM86
DMHN3PG	MN	Opioid receptor mu (MOP)
DMHN3PG	MT	DTT
DMHN3PG	MA	Modulator
DMHN3PG	RN	Cebranopadol: a first in-class example of a nociceptin/orphanin FQ receptor and opioid receptor agonist. Br J Anaesth. 2015 Mar;114(3):364-6.
DMHN3PG	RU	https://pubmed.ncbi.nlm.nih.gov/25248647

DMNZO7M	DI	DMNZO7M
DMNZO7M	DN	GS-441524
DMNZO7M	MI	TTS824E
DMNZO7M	MN	COVID-19 replicase polyprotein 1ab (pp1ab)
DMNZO7M	MT	DTT
DMNZO7M	MA	Inhibitor
DMNZO7M	RN	Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses. One Health. 2020 Mar 27;9:100128.
DMNZO7M	RU	https://pubmed.ncbi.nlm.nih.gov/32258351

DMP8MDW	DI	DMP8MDW
DMP8MDW	DN	GS-5745
DMP8MDW	MI	TT6X50U
DMP8MDW	MN	Matrix metalloproteinase-9 (MMP-9)
DMP8MDW	MT	DTT
DMP8MDW	MA	Modulator
DMP8MDW	RN	National Cancer Institute Drug Dictionary (drug id 747683).
DMP8MDW	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=747683

DMGJQVI	DI	DMGJQVI
DMGJQVI	DN	GS-6615
DMGJQVI	MI	TT40BO8
DMGJQVI	MN	Late inward sodium current (LISC)
DMGJQVI	MT	DTT
DMGJQVI	MA	Modulator
DMGJQVI	RN	Clinical pipeline report, company report or official report of Gilead.
DMGJQVI	RU	http://www.gilead.com/news/press-releases/2014/5/gilead-announces-phase-1-data-for-investigational-therapy-gs6615-in-patients-with-long-qt3-syndrome

DM936V7	DI	DM936V7
DM936V7	DN	GS-9674
DM936V7	MI	TTS4UGC
DM936V7	MN	Farnesoid X-activated receptor (FXR)
DM936V7	MT	DTT
DM936V7	MA	Agonist
DM936V7	RN	The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. Hepatology. 2019 Sep;70(3):788-801.
DM936V7	RU	https://pubmed.ncbi.nlm.nih.gov/30661255

DMT8J0I	DI	DMT8J0I
DMT8J0I	DN	GSK1265744
DMT8J0I	MI	TT5FH9Y
DMT8J0I	MN	Human immunodeficiency virus Integrase (HIV IN)
DMT8J0I	MT	DTT
DMT8J0I	MA	Inhibitor
DMT8J0I	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMT8J0I	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMT8J0I	DI	DMT8J0I
DMT8J0I	DN	GSK1265744
DMT8J0I	MI	DEYGVN4
DMT8J0I	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMT8J0I	MT	DME
DMT8J0I	MA	Metabolism
DMT8J0I	RN	Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans. Xenobiotica. 2016;46(2):147-62.
DMT8J0I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26134155

DMT8J0I	DI	DMT8J0I
DMT8J0I	DN	GSK1265744
DMT8J0I	MI	DE85D2P
DMT8J0I	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMT8J0I	MT	DME
DMT8J0I	MA	Metabolism
DMT8J0I	RN	Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans. Xenobiotica. 2016;46(2):147-62.
DMT8J0I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26134155

DMRNGD2	DI	DMRNGD2
DMRNGD2	DN	GSK1278863
DMRNGD2	MI	DES5XRU
DMRNGD2	MN	Cytochrome P450 2C8 (CYP2C8)
DMRNGD2	MT	DME
DMRNGD2	MA	Metabolism
DMRNGD2	RN	Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects. Drug Metab Pharmacokinet. 2015 Dec;30(6):410-8.
DMRNGD2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26643993

DMRNGD2	DI	DMRNGD2
DMRNGD2	DN	GSK1278863
DMRNGD2	MI	TTMHFRY
DMRNGD2	MN	HIF-prolyl hydroxylase 1 (HPH-1)
DMRNGD2	MT	DTT
DMRNGD2	MA	Inhibitor
DMRNGD2	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMRNGD2	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMSMFN2	DI	DMSMFN2
DMSMFN2	DN	GSK2140944
DMSMFN2	MI	TT0IHXV
DMSMFN2	MN	DNA topoisomerase II (TOP2)
DMSMFN2	MT	DTT
DMSMFN2	MA	Inhibitor
DMSMFN2	RN	Determination of disk diffusion and MIC quality control guidelines for GSK2140944, a novel bacterial type II topoisomerase inhibitor antimicrobial agent. J Clin Microbiol. 2014 Jul;52(7):2629-32.
DMSMFN2	RU	https://pubmed.ncbi.nlm.nih.gov/24759716

DMWL2XD	DI	DMWL2XD
DMWL2XD	DN	GSK2402968
DMWL2XD	MI	TTWLFXU
DMWL2XD	MN	Dystrophin messenger RNA (DMD mRNA)
DMWL2XD	MT	DTT
DMWL2XD	MA	Modulator
DMWL2XD	RN	Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol. 2014 Oct;13(10):987-96.
DMWL2XD	RU	https://pubmed.ncbi.nlm.nih.gov/25209738

DMUVZAO	DI	DMUVZAO
DMUVZAO	DN	GSK642444
DMUVZAO	MI	TT2CJVK
DMUVZAO	MN	Adrenergic receptor beta-2 (ADRB2)
DMUVZAO	MT	DTT
DMUVZAO	MA	Agonist
DMUVZAO	RN	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
DMUVZAO	RU	https://pubmed.ncbi.nlm.nih.gov/28919714

DMPS7U2	DI	DMPS7U2
DMPS7U2	DN	GTPL-9088
DMPS7U2	MI	DE4LYSA
DMPS7U2	MN	Cytochrome P450 3A4 (CYP3A4)
DMPS7U2	MT	DME
DMPS7U2	MA	Metabolism
DMPS7U2	RN	Product Information of Eumovate.
DMPS7U2	RU	https://www.medsafe.govt.nz/Profs/Datasheet/e/Eumovatecrm.pdf

DM9Y3EG	DI	DM9Y3EG
DM9Y3EG	DN	Guadecitabine
DM9Y3EG	MI	TT6S2FE
DM9Y3EG	MN	DNA [cytosine-5]-methyltransferase 1 (DNMT1)
DM9Y3EG	MT	DTT
DM9Y3EG	MA	Inhibitor
DM9Y3EG	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9Y3EG	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMN4E7T	DI	DMN4E7T
DMN4E7T	DN	Guaiacol
DMN4E7T	MI	TTANPDJ
DMN4E7T	MN	Carbonic anhydrase II (CA-II)
DMN4E7T	MT	DTT
DMN4E7T	MA	Inhibitor
DMN4E7T	RN	Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols. Bioorg Med Chem. 2009 Apr 15;17(8):3207-11.
DMN4E7T	RU	https://pubmed.ncbi.nlm.nih.gov/19231207

DMN4E7T	DI	DMN4E7T
DMN4E7T	DN	Guaiacol
DMN4E7T	MI	DEXL6TZ
DMN4E7T	MN	Thyroid peroxidase (TPO)
DMN4E7T	MT	DME
DMN4E7T	MA	Metabolism
DMN4E7T	RN	Kinetic characterization of human thyroperoxidase. Normal and pathological enzyme expression in Baculovirus system: a molecular model of functional expression. Mol Cell Endocrinol. 2015 Mar 15;404:9-15.
DMN4E7T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25576858

DMIWLJE	DI	DMIWLJE
DMIWLJE	DN	Guanine
DMIWLJE	MI	TTLSWP6
DMIWLJE	MN	GTP cyclohydrolase-I (GCH1)
DMIWLJE	MT	DTT
DMIWLJE	MA	Inhibitor
DMIWLJE	RN	GTP cyclohydrolase I feedback regulatory protein-dependent and -independent inhibitors of GTP cyclohydrolase I. Arch Biochem Biophys. 2001 Apr 1;388(1):67-73.
DMIWLJE	RU	https://pubmed.ncbi.nlm.nih.gov/11361142

DMHULRK	DI	DMHULRK
DMHULRK	DN	GV1001
DMHULRK	MI	TTUJFD0
DMHULRK	MN	Telomerase reverse transcriptase (TERT)
DMHULRK	MT	DTT
DMHULRK	RN	Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study. Br J Cancer. 2006 Dec 4;95(11):1474-82.
DMHULRK	RU	https://pubmed.ncbi.nlm.nih.gov/17060934

DMAXTFO	DI	DMAXTFO
DMAXTFO	DN	H1N1 influenza vaccine
DMAXTFO	MI	TT3J5ZI
DMAXTFO	MN	Cell mediated immunity response (CMIR)
DMAXTFO	MT	DTT
DMAXTFO	RN	Clinical pipeline report, company report or official report of Sanofi Pasteur.
DMAXTFO	RU	http://www.sanofipasteur.com/en/articles/sanofi-pasteur-s-a-h1n1-vaccine-humenza-recommended-by-european-medicines-agency.aspx

DM9CMI3	DI	DM9CMI3
DM9CMI3	DN	H5N1 influenza vaccine
DM9CMI3	MI	TT3J5ZI
DM9CMI3	MN	Cell mediated immunity response (CMIR)
DM9CMI3	MT	DTT
DM9CMI3	RN	Characterization of a whole, inactivated influenza (H5N1) vaccine. Influenza and Other Respiratory Viruses Volume 2, Issue 6, pages 261-266, November 2008.
DM9CMI3	RU	http://onlinelibrary.wiley.com/doi/10.1111/j.1750-2659.2008.00066.x/full

DMQ38JZ	DI	DMQ38JZ
DMQ38JZ	DN	HB-AS02V
DMQ38JZ	MI	TT3J5ZI
DMQ38JZ	MN	Cell mediated immunity response (CMIR)
DMQ38JZ	MT	DTT
DMQ38JZ	RN	Safety and immunogenicity of an investigational adjuvanted hepatitis B vaccine (HB-AS02V) in healthy adults. Hum Vaccin. 2010 Jul;6(7):578-84.
DMQ38JZ	RU	https://pubmed.ncbi.nlm.nih.gov/20523113

DMB06MU	DI	DMB06MU
DMB06MU	DN	HC-1119
DMB06MU	MI	TTS64P2
DMB06MU	MN	Androgen receptor (AR)
DMB06MU	MT	DTT
DMB06MU	MA	Inhibitor
DMB06MU	RN	Clinical pipeline report, company report or official report of Hinova Pharmaceuticals.
DMB06MU	RU	http://www.hinovapharma.com/en/chanpinxianguan.html

DMB9U5E	DI	DMB9U5E
DMB9U5E	DN	HE3286
DMB9U5E	MI	DE4LYSA
DMB9U5E	MN	Cytochrome P450 3A4 (CYP3A4)
DMB9U5E	MT	DME
DMB9U5E	MA	Metabolism
DMB9U5E	RN	Studies of the pharmacology of 17alpha-ethynyl-androst-5-ene-3beta,7beta,17beta-triol, a synthetic anti-inflammatory androstene. Int J Clin Exp Med. 2011;4(2):119-35.
DMB9U5E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21686136

DMQTLVB	DI	DMQTLVB
DMQTLVB	DN	Hebergel
DMQTLVB	MI	TTSIUJ9
DMQTLVB	MN	Interferon-alpha 2 (IFNA2)
DMQTLVB	MT	DTT
DMQTLVB	MA	Modulator
DMQTLVB	RN	Evaluation of recombinant human interferon alpha-2b structure and stability by in-gel tryptic digestion, H/D exchange and mass spectrometry. J Pharm Biomed Anal. 2006 Feb 24;40(3):781-7.
DMQTLVB	RU	https://pubmed.ncbi.nlm.nih.gov/16316735

DMUE843	DI	DMUE843
DMUE843	DN	Hematide
DMUE843	MI	TTAUX24
DMUE843	MN	Erythropoietin Receptor (EPOR)
DMUE843	MT	DTT
DMUE843	MA	Agonist
DMUE843	RN	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
DMUE843	RU	https://pubmed.ncbi.nlm.nih.gov/23370234

DMGFULM	DI	DMGFULM
DMGFULM	DN	Heparin low molecular weight
DMGFULM	MI	TT4QPUL
DMGFULM	MN	Antithrombin-III (ATIII)
DMGFULM	MT	DTT
DMGFULM	MA	Modulator
DMGFULM	RN	Effects of low molecular weight heparin on a severely antithrombin III-decreased disseminated intravascular coagulation model in rabbits. Thromb Res. 1995 Dec 1;80(5):391-8.
DMGFULM	RU	https://pubmed.ncbi.nlm.nih.gov/8588200

DMXAZ47	DI	DMXAZ47
DMXAZ47	DN	HGH-CTP
DMXAZ47	MI	TTT3YKH
DMXAZ47	MN	Somatotropin (GH1)
DMXAZ47	MT	DTT
DMXAZ47	MA	Agonist
DMXAZ47	RN	Developments in human growth hormone preparations: sustained-release, prolonged half-life, novel injection devices, and alternative delivery routes. Int J Nanomedicine. 2014; 9: 3527-3538.
DMXAZ47	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122423/

DM6QOVN	DI	DM6QOVN
DM6QOVN	DN	HKI-272
DM6QOVN	MI	DE4LYSA
DM6QOVN	MN	Cytochrome P450 3A4 (CYP3A4)
DM6QOVN	MT	DME
DM6QOVN	MA	Metabolism
DM6QOVN	RN	Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations. Expert Opin Drug Metab Toxicol. 2016 Aug;12(8):947-57.
DM6QOVN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27284682

DM6QOVN	DI	DM6QOVN
DM6QOVN	DN	HKI-272
DM6QOVN	MI	TTGKNB4
DM6QOVN	MN	Epidermal growth factor receptor (EGFR)
DM6QOVN	MT	DTT
DM6QOVN	MA	Inhibitor
DM6QOVN	RN	Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cyst... Bioorg Med Chem. 2007 Jun 1;15(11):3635-48.
DM6QOVN	RU	https://pubmed.ncbi.nlm.nih.gov/17416531

DM6QOVN	DI	DM6QOVN
DM6QOVN	DN	HKI-272
DM6QOVN	MI	TTR5TV4
DM6QOVN	MN	ERBB2 messenger RNA (HER2 mRNA)
DM6QOVN	MT	DTT
DM6QOVN	MA	Inhibitor
DM6QOVN	RN	Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19936-41.
DM6QOVN	RU	https://pubmed.ncbi.nlm.nih.gov/18077425

DM6QOVN	DI	DM6QOVN
DM6QOVN	DN	HKI-272
DM6QOVN	MI	TT6EO5L
DM6QOVN	MN	Erbb2 tyrosine kinase receptor (HER2)
DM6QOVN	MT	DTT
DM6QOVN	MA	Inhibitor
DM6QOVN	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DM6QOVN	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DM6QOVN	DI	DM6QOVN
DM6QOVN	DN	HKI-272
DM6QOVN	MI	TTUTJGQ
DM6QOVN	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM6QOVN	MT	DTT
DM6QOVN	MA	Inhibitor
DM6QOVN	RN	Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cyst... Bioorg Med Chem. 2007 Jun 1;15(11):3635-48.
DM6QOVN	RU	https://pubmed.ncbi.nlm.nih.gov/17416531

DM29XGY	DI	DM29XGY
DM29XGY	DN	HMPL-004
DM29XGY	MI	TTBD054
DM29XGY	MN	Inflammation pathogenesis (IP)
DM29XGY	MT	DTT
DM29XGY	MA	Antagonist
DM29XGY	RN	Clinical pipeline report, company report or official report of Hutchison Medi Pharma.
DM29XGY	RU	http://www.hmplglobal.com/en/hmpl-004/

DMAVIPZ	DI	DMAVIPZ
DMAVIPZ	DN	HSR-803
DMAVIPZ	MI	DEP76YL
DMAVIPZ	MN	Dimethylaniline oxidase 3 (FMO3)
DMAVIPZ	MT	DME
DMAVIPZ	MA	Metabolism
DMAVIPZ	RN	Development of a physiologically based pharmacokinetic model to predict the effects of flavin-containing monooxygenase 3 (FMO3) polymorphisms on itopride exposure. Biopharm Drug Dispos. 2017 Sep;38(6):389-393.
DMAVIPZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28255999

DMBER0Q	DI	DMBER0Q
DMBER0Q	DN	Hu5F9-G4
DMBER0Q	MI	TT28S46
DMBER0Q	MN	Leukocyte surface antigen CD47 (CD47)
DMBER0Q	MT	DTT
DMBER0Q	MA	Inhibitor
DMBER0Q	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMBER0Q	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMXZAL2	DI	DMXZAL2
DMXZAL2	DN	Hydroxychloroquine
DMXZAL2	MI	TTZGK1R
DMXZAL2	MN	HUMAN glycosylation of host receptor (GHR)
DMXZAL2	MT	DTT
DMXZAL2	MA	Inhibitor
DMXZAL2	RN	Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.
DMXZAL2	RU	https://pubmed.ncbi.nlm.nih.gov/32020029

DMXZAL2	DI	DMXZAL2
DMXZAL2	DN	Hydroxychloroquine
DMXZAL2	MI	TTD16BI
DMXZAL2	MN	HUMAN pH-dependent viral fusion/replication (pH-DVF/R)
DMXZAL2	MT	DTT
DMXZAL2	MA	Inhibitor
DMXZAL2	RN	Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.
DMXZAL2	RU	https://pubmed.ncbi.nlm.nih.gov/32020029

DMXZAL2	DI	DMXZAL2
DMXZAL2	DN	Hydroxychloroquine
DMXZAL2	MI	TT3A1EZ
DMXZAL2	MN	HUMAN toll-like receptor 7/9 signalling pathway (TLR7/9 pathway)
DMXZAL2	MT	DTT
DMXZAL2	MA	Inhibitor
DMXZAL2	RN	Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020 Mar;16(3):155-166.
DMXZAL2	RU	https://pubmed.ncbi.nlm.nih.gov/32034323

DMIGFOR	DI	DMIGFOR
DMIGFOR	DN	I3C
DMIGFOR	MI	TTSHAEB
DMIGFOR	MN	NF-kappa-B inhibitor alpha (NFKBIA)
DMIGFOR	MT	DTT
DMIGFOR	MA	Inhibitor
DMIGFOR	RN	Protective effect of Indole-3-carbinol, an NF-B inhibitor in experimental paradigm of Parkinson's disease: In silico and in vivo studies. Brain Behav Immun. 2020 Nov;90:108-137.
DMIGFOR	RU	https://pubmed.ncbi.nlm.nih.gov/32800927

DM5KL8E	DI	DM5KL8E
DM5KL8E	DN	IBI-308
DM5KL8E	MI	TTNBFWK
DM5KL8E	MN	Programmed cell death protein 1 (PD-1)
DM5KL8E	MT	DTT
DM5KL8E	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DM5KL8E	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DM9G5XD	DI	DM9G5XD
DM9G5XD	DN	IB-MECA
DM9G5XD	MI	TTJFY5U
DM9G5XD	MN	Adenosine A3 receptor (ADORA3)
DM9G5XD	MT	DTT
DM9G5XD	MA	Agonist
DM9G5XD	RN	A role for central A3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett. 1993 Dec 20;336(1):57-60.
DM9G5XD	RU	https://pubmed.ncbi.nlm.nih.gov/8262217

DMT67EH	DI	DMT67EH
DMT67EH	DN	Ibodutant
DMT67EH	MI	TTYO0A3
DMT67EH	MN	Substance-K receptor (TACR2)
DMT67EH	MT	DTT
DMT67EH	MA	Antagonist
DMT67EH	RN	Antagonist profile of ibodutant at the tachykinin NK2 receptor in guinea pig isolated bronchi. Eur J Pharmacol. 2013 Nov 15;720(1-3):180-5.
DMT67EH	RU	https://pubmed.ncbi.nlm.nih.gov/24436990

DMOJQGT	DI	DMOJQGT
DMOJQGT	DN	ICARIIN
DMOJQGT	MI	TTJ0IQB
DMOJQGT	MN	Phosphodiesterase 5A (PDE5A)
DMOJQGT	MT	DTT
DMOJQGT	MA	Inhibitor
DMOJQGT	RN	Potent inhibition of human phosphodiesterase-5 by icariin derivatives. J Nat Prod. 2008 Sep;71(9):1513-7.
DMOJQGT	RU	https://pubmed.ncbi.nlm.nih.gov/18778098

DM3OU54	DI	DM3OU54
DM3OU54	DN	ICI 118,551
DM3OU54	MI	TT2CJVK
DM3OU54	MN	Adrenergic receptor beta-2 (ADRB2)
DM3OU54	MT	DTT
DM3OU54	MA	Antagonist
DM3OU54	RN	Selective beta 2-adrenoceptor antagonists: derivatives of ICI 118,551 and a binary aryloxypropanolamine. J Pharm Pharmacol. 1988 Nov;40(11):803-5.
DM3OU54	RU	https://pubmed.ncbi.nlm.nih.gov/2907563

DM7YNV9	DI	DM7YNV9
DM7YNV9	DN	Iclaprim
DM7YNV9	MI	TTV8DM2
DM7YNV9	MN	Bacterial Dihydrofolate reductase (Bact DHFR)
DM7YNV9	MT	DTT
DM7YNV9	MA	Modulator
DM7YNV9	RN	Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections.Future Microbiol.2009 Mar;4(2):131-44.
DM7YNV9	RU	https://www.ncbi.nlm.nih.gov/pubmed/19257839

DM7YNV9	DI	DM7YNV9
DM7YNV9	DN	Iclaprim
DM7YNV9	MI	DE5IED8
DM7YNV9	MN	Cytochrome P450 2C9 (CYP2C9)
DM7YNV9	MT	DME
DM7YNV9	MA	Metabolism
DM7YNV9	RN	An updated review of iclaprim: a potent and rapidly bactericidal antibiotic for the treatment of skin and skin structure infections and nosocomial pneumonia caused by gram-positive including multidrug-resistant bacteria. Open Forum Infect Dis. 2018 Jan 6;5(2):ofy003.
DM7YNV9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29423421

DM7YNV9	DI	DM7YNV9
DM7YNV9	DN	Iclaprim
DM7YNV9	MI	DECB0K3
DM7YNV9	MN	Cytochrome P450 2D6 (CYP2D6)
DM7YNV9	MT	DME
DM7YNV9	MA	Metabolism
DM7YNV9	RN	An updated review of iclaprim: a potent and rapidly bactericidal antibiotic for the treatment of skin and skin structure infections and nosocomial pneumonia caused by gram-positive including multidrug-resistant bacteria. Open Forum Infect Dis. 2018 Jan 6;5(2):ofy003.
DM7YNV9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29423421

DM7YNV9	DI	DM7YNV9
DM7YNV9	DN	Iclaprim
DM7YNV9	MI	DE4LYSA
DM7YNV9	MN	Cytochrome P450 3A4 (CYP3A4)
DM7YNV9	MT	DME
DM7YNV9	MA	Metabolism
DM7YNV9	RN	An updated review of iclaprim: a potent and rapidly bactericidal antibiotic for the treatment of skin and skin structure infections and nosocomial pneumonia caused by gram-positive including multidrug-resistant bacteria. Open Forum Infect Dis. 2018 Jan 6;5(2):ofy003.
DM7YNV9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29423421

DM7YNV9	DI	DM7YNV9
DM7YNV9	DN	Iclaprim
DM7YNV9	MI	TTYZVDJ
DM7YNV9	MN	Dihydrofolate reductase (DHFR)
DM7YNV9	MT	DTT
DM7YNV9	MA	Inhibitor
DM7YNV9	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7YNV9	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM7YNV9	DI	DM7YNV9
DM7YNV9	DN	Iclaprim
DM7YNV9	MI	TT9B4N3
DM7YNV9	MN	Prostaglandin receptor (PTGR)
DM7YNV9	MT	DTT
DM7YNV9	MA	Modulator
DM7YNV9	RN	Novel ocular antihypertensive compounds in clinical trials. Clin Ophthalmol. 2011; 5: 667-677.
DM7YNV9	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3104796/

DMU72KL	DI	DMU72KL
DMU72KL	DN	ICP-022
DMU72KL	MI	TTGM6VW
DMU72KL	MN	Tyrosine-protein kinase BTK (ATK)
DMU72KL	MT	DTT
DMU72KL	MA	Inhibitor
DMU72KL	RN	Clinical pipeline report, company report or official report of InnoCare Pharma.
DMU72KL	RU	https://www.innocarepharma.com/en/pipeline/our-pipeline/

DMBIZ7H	DI	DMBIZ7H
DMBIZ7H	DN	ICT-107
DMBIZ7H	MI	TTMPZ7V
DMBIZ7H	MN	Interleukin 13 receptor alpha-2 (IL13RA2)
DMBIZ7H	MT	DTT
DMBIZ7H	RN	Clinical pipeline report, company report or official report of ImmunoCellular Therapeutics.
DMBIZ7H	RU	http://www.imuc.com/pipeline/ict-107

DMSP0X8	DI	DMSP0X8
DMSP0X8	DN	IDAZOXAN HYDROCHLORIDE
DMSP0X8	MI	TT2NUT5
DMSP0X8	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMSP0X8	MT	DTT
DMSP0X8	MA	Modulator
DMSP0X8	RN	Different sites of action for alpha 2-adrenoceptor antagonists in the modulation of noradrenaline release and contraction response in the vas deferens of the rat. J Pharm Pharmacol. 1992 Mar;44(3):231-4.
DMSP0X8	RU	https://pubmed.ncbi.nlm.nih.gov/1354730

DMV3DHQ	DI	DMV3DHQ
DMV3DHQ	DN	IDDBCP161883
DMV3DHQ	MI	TTDIGC1
DMV3DHQ	MN	Dipeptidyl peptidase 4 (DPP-4)
DMV3DHQ	MT	DTT
DMV3DHQ	MA	Inhibitor
DMV3DHQ	RN	Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes. Diabetes Metab Syndr Obes. 2013 May 6;6:187-95.
DMV3DHQ	RU	https://pubmed.ncbi.nlm.nih.gov/23671395

DM3A701	DI	DM3A701
DM3A701	DN	IDP-122
DM3A701	MI	TTP3UTW
DM3A701	MN	Steroid hormone receptor ERR (ESRR)
DM3A701	MT	DTT
DM3A701	MA	Agonist
DM3A701	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3A701	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMRLVUD	DI	DMRLVUD
DMRLVUD	DN	Imagabalin
DMRLVUD	MI	TTFK1JQ
DMRLVUD	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMRLVUD	MT	DTT
DMRLVUD	MA	Agonist
DMRLVUD	RN	Methodology for rapid measures of glutamate release in rat brain slices using ceramic-based microelectrode arrays: basic characterization and drug pharmacology. Brain Res. 2011 Jul 15;1401:1-9.
DMRLVUD	RU	https://pubmed.ncbi.nlm.nih.gov/21664606

DMM9JEF	DI	DMM9JEF
DMM9JEF	DN	Imatinib
DMM9JEF	MI	TTE63HY
DMM9JEF	MN	HUMAN fusion protein Bcr-Abl (Bcr-Abl)
DMM9JEF	MT	DTT
DMM9JEF	MA	Inhibitor
DMM9JEF	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DMM9JEF	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DM7BCWT	DI	DM7BCWT
DM7BCWT	DN	Imiglitazar
DM7BCWT	MI	TTJ584C
DM7BCWT	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DM7BCWT	MT	DTT
DM7BCWT	MA	Modulator
DM7BCWT	RN	A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes. Eur J Pharmacol. 2004 Jul 8;495(1):17-26.
DM7BCWT	RU	https://pubmed.ncbi.nlm.nih.gov/15219816

DM7BCWT	DI	DM7BCWT
DM7BCWT	DN	Imiglitazar
DM7BCWT	MI	TTZMAO3
DM7BCWT	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DM7BCWT	MT	DTT
DM7BCWT	MA	Modulator
DM7BCWT	RN	A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes. Eur J Pharmacol. 2004 Jul 8;495(1):17-26.
DM7BCWT	RU	https://pubmed.ncbi.nlm.nih.gov/15219816

DM735FA	DI	DM735FA
DM735FA	DN	IMO-2125
DM735FA	MI	TTSHG0T
DM735FA	MN	Toll-like receptor 9 (TLR9)
DM735FA	MT	DTT
DM735FA	MA	Agonist
DM735FA	RN	Clinical pipeline report, company report or official report of Idera Pharmaceuticals (2011).
DM735FA	RU	http://www.iderapharma.com/

DMIJGT9	DI	DMIJGT9
DMIJGT9	DN	INCB24360
DMIJGT9	MI	TTZJYKH
DMIJGT9	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMIJGT9	MT	DTT
DMIJGT9	MA	Inhibitor
DMIJGT9	RN	Incyte. Product Development Pipeline.
DMIJGT9	RU	http://www.incyte.com/drugs_product_pipeline.html

DMZA2K0	DI	DMZA2K0
DMZA2K0	DN	INCSHR1210
DMZA2K0	MI	TTNBFWK
DMZA2K0	MN	Programmed cell death protein 1 (PD-1)
DMZA2K0	MT	DTT
DMZA2K0	MA	Inhibitor
DMZA2K0	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZA2K0	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMLG96Z	DI	DMLG96Z
DMLG96Z	DN	INM-176
DMLG96Z	MI	TT1RS9F
DMLG96Z	MN	Acetylcholinesterase (AChE)
DMLG96Z	MT	DTT
DMLG96Z	MA	Inhibitor
DMLG96Z	RN	The memory ameliorating effects of INM-176, an ethanolic extract of Angelica gigas, against scopolamine- or Abeta(1-42)-induced cognitive dysfunction in mice. J Ethnopharmacol. 2012 Sep 28;143(2):611-20.
DMLG96Z	RU	https://pubmed.ncbi.nlm.nih.gov/22846435

DM5L8QT	DI	DM5L8QT
DM5L8QT	DN	INO-1001
DM5L8QT	MI	TTEBCY8
DM5L8QT	MN	Poly [ADP-ribose] polymerase (PARP)
DM5L8QT	MT	DTT
DM5L8QT	MA	Modulator
DM5L8QT	RN	Therapeutic injection of PARP inhibitor INO-1001 preserves cardiac function in porcine myocardial ischemia and reperfusion without reducing infarct size. Shock. 2010 May;33(5):507-12.
DM5L8QT	RU	https://pubmed.ncbi.nlm.nih.gov/20395771

DMUS1F8	DI	DMUS1F8
DMUS1F8	DN	Inolimomab
DMUS1F8	MI	TT10Y9E
DMUS1F8	MN	Interleukin 2 receptor alpha (IL2RA)
DMUS1F8	MT	DTT
DMUS1F8	MA	Modulator
DMUS1F8	RN	Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease.Biol Blood Marrow Transplant.2006 Nov;12(11):1135-41.
DMUS1F8	RU	https://www.ncbi.nlm.nih.gov/pubmed/17085306

DMOTH6V	DI	DMOTH6V
DMOTH6V	DN	Interferon alpha 2a
DMOTH6V	MI	TTSIUJ9
DMOTH6V	MN	Interferon-alpha 2 (IFNA2)
DMOTH6V	MT	DTT
DMOTH6V	MA	Modulator
DMOTH6V	RN	Hairy cell leukemia associated with large granular lymphocyte leukemia: immunologic and genomic study, effect of interferon treatment. Blood. 1988 Aug;72(2):655-60.
DMOTH6V	RU	https://pubmed.ncbi.nlm.nih.gov/2840988

DMZA47Y	DI	DMZA47Y
DMZA47Y	DN	Iomab-B
DMZA47Y	MI	TTUS45N
DMZA47Y	MN	Leukocyte common antigen (PTPRC)
DMZA47Y	MT	DTT
DMZA47Y	RN	Clinical pipeline report, company report or official report of Actinium Pharmaceuticals.
DMZA47Y	RU	http://www.actiniumpharma.com/products/pipeline/iomab-b/

DMSV12M	DI	DMSV12M
DMSV12M	DN	Isavuconazole
DMSV12M	MI	DE4LYSA
DMSV12M	MN	Cytochrome P450 3A4 (CYP3A4)
DMSV12M	MT	DME
DMSV12M	MA	Metabolism
DMSV12M	RN	Pharmacokinetic evaluation of CYP3A4-mediated drug-drug interactions of isavuconazole with rifampin, ketoconazole, midazolam, and ethinyl estradiol/norethindrone in healthy adults. Clin Pharmacol Drug Dev. 2017 Jan;6(1):44-53.
DMSV12M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27273461

DMQZI7K	DI	DMQZI7K
DMQZI7K	DN	ISIS 23722
DMQZI7K	MI	TTTPU1G
DMQZI7K	MN	Apoptosis inhibitor survivin (BIRC5)
DMQZI7K	MT	DTT
DMQZI7K	MA	Modulator
DMQZI7K	RN	Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression.Eur J Cancer.2012 Mar;48(5):763-71.
DMQZI7K	RU	https://www.ncbi.nlm.nih.gov/pubmed/22088485

DMKWBJR	DI	DMKWBJR
DMKWBJR	DN	ISIS-PKK
DMKWBJR	MI	TTN0PCX
DMKWBJR	MN	Plasma kallikrein messenger RNA (KLKB1 mRNA)
DMKWBJR	MT	DTT
DMKWBJR	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals.
DMKWBJR	RU	https://www.isispharm.com/pipeline/isis-pkkrx/

DM4U5NF	DI	DM4U5NF
DM4U5NF	DN	ISIS-TTR
DM4U5NF	MI	TTPOYU7
DM4U5NF	MN	Transthyretin messenger RNA (TTR mRNA)
DM4U5NF	MT	DTT
DM4U5NF	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
DM4U5NF	RU	http://www.isispharm.com/index.htm

DMBJTVL	DI	DMBJTVL
DMBJTVL	DN	Isotretinoin
DMBJTVL	MI	TTNHMO8
DMBJTVL	MN	COVID-19 papain-like proteinase (PL-PRO)
DMBJTVL	MT	DTT
DMBJTVL	MA	Inhibitor
DMBJTVL	RN	ClinicalTrials.gov (NCT04361422) Isotretinoin in Treatment of COVID-19. U.S. National Institutes of Health.
DMBJTVL	RU	https://clinicaltrials.gov/ct2/show/NCT04361422

DMP61YB	DI	DMP61YB
DMP61YB	DN	ISRAPAFANT
DMP61YB	MI	TTQL5VC
DMP61YB	MN	Platelet-activating factor receptor (PTAFR)
DMP61YB	MT	DTT
DMP61YB	MA	Antagonist
DMP61YB	RN	Amino acid residues critical for endoplasmic reticulum export and trafficking of platelet-activating factor receptor. J Biol Chem. 2010 Feb 19;285(8):5931-40.
DMP61YB	RU	https://pubmed.ncbi.nlm.nih.gov/20007715

DMNDGWE	DI	DMNDGWE
DMNDGWE	DN	IT-101
DMNDGWE	MI	TTQHWNA
DMNDGWE	MN	Hypoxia-inducible factor 1 alpha (HIF-1A)
DMNDGWE	MT	DTT
DMNDGWE	MA	Inhibitor
DMNDGWE	RN	CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer. Breast Cancer Res Treat. 2015 Apr;150(3):559-67.
DMNDGWE	RU	https://pubmed.ncbi.nlm.nih.gov/25833208

DMFZBNE	DI	DMFZBNE
DMFZBNE	DN	ITF2357
DMFZBNE	MI	TTBH0VX
DMFZBNE	MN	Histone deacetylase (HDAC)
DMFZBNE	MT	DTT
DMFZBNE	MA	Inhibitor
DMFZBNE	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMFZBNE	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMFZBNE	DI	DMFZBNE
DMFZBNE	DN	ITF2357
DMFZBNE	MI	TT6R7JZ
DMFZBNE	MN	Histone deacetylase 1 (HDAC1)
DMFZBNE	MT	DTT
DMFZBNE	MA	Inhibitor
DMFZBNE	RN	Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9.
DMFZBNE	RU	https://pubmed.ncbi.nlm.nih.gov/19552608

DMFZBNE	DI	DMFZBNE
DMFZBNE	DN	ITF2357
DMFZBNE	MI	TTRMX3V
DMFZBNE	MN	Janus kinase 2 (JAK-2)
DMFZBNE	MT	DTT
DMFZBNE	MA	Inhibitor
DMFZBNE	RN	Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9.
DMFZBNE	RU	https://pubmed.ncbi.nlm.nih.gov/19552608

DMUQ1DO	DI	DMUQ1DO
DMUQ1DO	DN	ITI-007
DMUQ1DO	MI	TTJQOD7
DMUQ1DO	MN	5-HT 2A receptor (HTR2A)
DMUQ1DO	MT	DTT
DMUQ1DO	MA	Antagonist
DMUQ1DO	RN	Clinical pipeline report, company report or official report of Intra-Cellular Therapies, Inc.
DMUQ1DO	RU	http://www.intracellulartherapies.com/products-technology/iti-007.html

DMUQ1DO	DI	DMUQ1DO
DMUQ1DO	DN	ITI-007
DMUQ1DO	MI	TT85JO3
DMUQ1DO	MN	5-HT receptor (5HTR)
DMUQ1DO	MT	DTT
DMUQ1DO	MA	Antagonist
DMUQ1DO	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMUQ1DO	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMUQ1DO	DI	DMUQ1DO
DMUQ1DO	DN	ITI-007
DMUQ1DO	MI	TT3ROYC
DMUQ1DO	MN	Serotonin transporter (SERT)
DMUQ1DO	MT	DTT
DMUQ1DO	MA	Antagonist
DMUQ1DO	RN	Clinical pipeline report, company report or official report of Intra-Cellular Therapies, Inc.
DMUQ1DO	RU	http://www.intracellulartherapies.com/products-technology/iti-007.html

DMGWVLX	DI	DMGWVLX
DMGWVLX	DN	Itolizumab
DMGWVLX	MI	TTMF6KC
DMGWVLX	MN	T-cell differentiation antigen CD6 (TP120)
DMGWVLX	MT	DTT
DMGWVLX	RN	Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study. J Am Acad Dermatol. 2014 Sep;71(3):484-92.
DMGWVLX	RU	https://pubmed.ncbi.nlm.nih.gov/24703722

DM7MLTR	DI	DM7MLTR
DM7MLTR	DN	Itopride
DM7MLTR	MI	DEP76YL
DM7MLTR	MN	Dimethylaniline oxidase 3 (FMO3)
DM7MLTR	MT	DME
DM7MLTR	MA	Metabolism
DM7MLTR	RN	Development of a physiologically based pharmacokinetic model to predict the effects of flavin-containing monooxygenase 3 (FMO3) polymorphisms on itopride exposure. Biopharm Drug Dispos. 2017 Sep;38(6):389-393.
DM7MLTR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28255999

DMNORK8	DI	DMNORK8
DMNORK8	DN	Jakafi
DMNORK8	MI	DE4LYSA
DMNORK8	MN	Cytochrome P450 3A4 (CYP3A4)
DMNORK8	MT	DME
DMNORK8	MA	Metabolism
DMNORK8	RN	Ruxolitinib: in the treatment of myelofibrosis. Drugs. 2012 Nov 12;72(16):2117-27.
DMNORK8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23061804

DM8FSPV	DI	DM8FSPV
DM8FSPV	DN	JTZ-951
DM8FSPV	MI	TTJQFBG
DM8FSPV	MN	HIF-prolyl hydroxylase (HPH)
DM8FSPV	MT	DTT
DM8FSPV	MA	Modulator
DM8FSPV	RN	DOI: 10.1038/nrneph.2015.82
DM8FSPV	RU	http://www.nature.com/nrneph/journal/v11/n7/fig_tab/nrneph.2015.82_T1.html

DM5WCV4	DI	DM5WCV4
DM5WCV4	DN	JX-594
DM5WCV4	MI	TTNYZG2
DM5WCV4	MN	Granulocyte-macrophage colony-stimulating factor (CSF2)
DM5WCV4	MT	DTT
DM5WCV4	MA	Modulator
DM5WCV4	RN	Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther. 2006 Sep;14(3):361-70.
DM5WCV4	RU	https://pubmed.ncbi.nlm.nih.gov/16905462

DM9J0KD	DI	DM9J0KD
DM9J0KD	DN	K-103-IP
DM9J0KD	MI	TTK0943
DM9J0KD	MN	Prostaglandin G/H synthase (COX)
DM9J0KD	MT	DTT
DM9J0KD	MA	Modulator
DM9J0KD	RN	ClinicalTrials.gov (NCT02089425) An Efficacy and Safety Study for the Treatment of Mild to Moderate Acute Pain Associated With Ankle Strain or Sprain.. U.S. National Institutes of Health.
DM9J0KD	RU	https://clinicaltrials.gov/ct2/show/NCT02089425

DMCRGY4	DI	DMCRGY4
DMCRGY4	DN	Karenitecin
DMCRGY4	MI	DTI7UX6
DMCRGY4	MN	Breast cancer resistance protein (ABCG2)
DMCRGY4	MT	DTP
DMCRGY4	MA	Substrate
DMCRGY4	RN	Pharmacogenomic importance of ABCG2. Pharmacogenomics. 2008 Aug;9(8):1005-9.
DMCRGY4	RU	https://doi.org/10.2217/14622416.9.8.1005

DMCRGY4	DI	DMCRGY4
DMCRGY4	DN	Karenitecin
DMCRGY4	MI	DES5XRU
DMCRGY4	MN	Cytochrome P450 2C8 (CYP2C8)
DMCRGY4	MT	DME
DMCRGY4	MA	Metabolism
DMCRGY4	RN	Evaluation of in vitro drug interactions with karenitecin, a novel, highly lipophilic camptothecin derivative in phase II clinical development. J Clin Pharmacol. 2003 Sep;43(9):1008-14.
DMCRGY4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12971034

DMCRGY4	DI	DMCRGY4
DMCRGY4	DN	Karenitecin
DMCRGY4	MI	DECB0K3
DMCRGY4	MN	Cytochrome P450 2D6 (CYP2D6)
DMCRGY4	MT	DME
DMCRGY4	MA	Metabolism
DMCRGY4	RN	Evaluation of in vitro drug interactions with karenitecin, a novel, highly lipophilic camptothecin derivative in phase II clinical development. J Clin Pharmacol. 2003 Sep;43(9):1008-14.
DMCRGY4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12971034

DMCRGY4	DI	DMCRGY4
DMCRGY4	DN	Karenitecin
DMCRGY4	MI	DE4LYSA
DMCRGY4	MN	Cytochrome P450 3A4 (CYP3A4)
DMCRGY4	MT	DME
DMCRGY4	MA	Metabolism
DMCRGY4	RN	Evaluation of in vitro drug interactions with karenitecin, a novel, highly lipophilic camptothecin derivative in phase II clinical development. J Clin Pharmacol. 2003 Sep;43(9):1008-14.
DMCRGY4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12971034

DMCRGY4	DI	DMCRGY4
DMCRGY4	DN	Karenitecin
DMCRGY4	MI	TT2GPK3
DMCRGY4	MN	DNA topoisomerase (TOP)
DMCRGY4	MT	DTT
DMCRGY4	MA	Inhibitor
DMCRGY4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMCRGY4	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMCRGY4	DI	DMCRGY4
DMCRGY4	DN	Karenitecin
DMCRGY4	MI	TTGTQHC
DMCRGY4	MN	DNA topoisomerase I (TOP1)
DMCRGY4	MT	DTT
DMCRGY4	MA	Inhibitor
DMCRGY4	RN	Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350. Mol Pharmacol.2000 Mar;57(3):453-9.
DMCRGY4	RU	https://pubmed.ncbi.nlm.nih.gov/10692484

DMCRGY4	DI	DMCRGY4
DMCRGY4	DN	Karenitecin
DMCRGY4	MI	DT3D8F0
DMCRGY4	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMCRGY4	MT	DTP
DMCRGY4	MA	Substrate
DMCRGY4	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DMCRGY4	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DM8VO16	DI	DM8VO16
DM8VO16	DN	KH-902
DM8VO16	MI	TTVJ1D8
DM8VO16	MN	Vascular endothelial growth factor receptor (VEGFR)
DM8VO16	MT	DTT
DM8VO16	MA	Modulator
DM8VO16	RN	Effects of intravitreal injection of KH902, a vascular endothelial growth factor receptor decoy, on the retinas of streptozotocin-induced diabetic rats. Diabetes Obes Metab. 2012 Jul;14(7):644-53.
DM8VO16	RU	https://pubmed.ncbi.nlm.nih.gov/22340191

DMSDBPG	DI	DMSDBPG
DMSDBPG	DN	KN046
DMSDBPG	MI	TTI2S1D
DMSDBPG	MN	Cytotoxic T-lymphocyte protein 4 (CTLA-4)
DMSDBPG	MT	DTT
DMSDBPG	MA	Inhibitor
DMSDBPG	RN	Clinical pipeline report, company report or official report of Alphamab Oncology.
DMSDBPG	RU	http://www.alphamabonc.com/pipeline/kn046.html

DMSDBPG	DI	DMSDBPG
DMSDBPG	DN	KN046
DMSDBPG	MI	TT8ZLTI
DMSDBPG	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMSDBPG	MT	DTT
DMSDBPG	MA	Inhibitor
DMSDBPG	RN	Clinical pipeline report, company report or official report of Alphamab Oncology.
DMSDBPG	RU	http://www.alphamabonc.com/pipeline/kn046.html

DMP5G1K	DI	DMP5G1K
DMP5G1K	DN	KPS-0373
DMP5G1K	MI	TT2Z39D
DMP5G1K	MN	Thyrotropin-releasing hormone (TRH)
DMP5G1K	MT	DTT
DMP5G1K	MA	Modulator
DMP5G1K	RN	DOI: 10.1002/mdc3.12057
DMP5G1K	RU	http://www.movementdisorders.org/MDS/Journals/Clinical-Practice-E-Journal-Overview/Movement-Disorders-Clinical-Practice-E-Journal-Volume-1-Issue-4/Treatment-Options-in-Degenerative-Cerebellar-Ataxia-A-Systematic-Review.htm

DMM2LTC	DI	DMM2LTC
DMM2LTC	DN	KSI-301
DMM2LTC	MI	TT9HKJA
DMM2LTC	MN	Vascular endothelial growth factor (VEGF)
DMM2LTC	MT	DTT
DMM2LTC	MA	Inhibitor
DMM2LTC	RN	Clinical pipeline report, company report or official report of Kodiak Sciences.
DMM2LTC	RU	https://kodiak.com/our-pipeline/

DMP3GI2	DI	DMP3GI2
DMP3GI2	DN	KW-3357
DMP3GI2	MI	TT4QPUL
DMP3GI2	MN	Antithrombin-III (ATIII)
DMP3GI2	MT	DTT
DMP3GI2	MA	Modulator
DMP3GI2	RN	Company report (kyowa-kirin)
DMP3GI2	RU	http://www.kyowa-kirin.com/news_releases/2014/e20140801_01.html

DMF0NA9	DI	DMF0NA9
DMF0NA9	DN	KX-01
DMF0NA9	MI	TT6PKBN
DMF0NA9	MN	Proto-oncogene c-Src (SRC)
DMF0NA9	MT	DTT
DMF0NA9	MA	Inhibitor
DMF0NA9	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMF0NA9	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMWTPCA	DI	DMWTPCA
DMWTPCA	DN	L-651582
DMWTPCA	MI	DE4LYSA
DMWTPCA	MN	Cytochrome P450 3A4 (CYP3A4)
DMWTPCA	MT	DME
DMWTPCA	MA	Metabolism
DMWTPCA	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DMWTPCA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DMWTPCA	DI	DMWTPCA
DMWTPCA	DN	L-651582
DMWTPCA	MI	TTH18TF
DMWTPCA	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMWTPCA	MT	DTT
DMWTPCA	MA	Modulator
DMWTPCA	RN	The antiproliferative and antimetastatic compound L651582 inhibits muscarinic acetylcholine receptor-stimulated calcium influx and arachidonic acid release. J Pharmacol Exp Ther. 1991 Jun;257(3):967-71.
DMWTPCA	RU	https://pubmed.ncbi.nlm.nih.gov/1646332

DMI3YLK	DI	DMI3YLK
DMI3YLK	DN	LA-EP2006
DMI3YLK	MI	TT5TQ2W
DMI3YLK	MN	Granulocyte colony-stimulating factor (CSF3)
DMI3YLK	MT	DTT
DMI3YLK	MA	Modulator
DMI3YLK	RN	National Cancer Institute Drug Dictionary (drug id 724518).
DMI3YLK	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=724518

DMA2NYS	DI	DMA2NYS
DMA2NYS	DN	Lampalizumab
DMA2NYS	MI	TT8D13I
DMA2NYS	MN	Complement factor D (CFD)
DMA2NYS	MT	DTT
DMA2NYS	MA	Inhibitor
DMA2NYS	RN	In Vivo Stability Profiles of Anti-factor D Molecules Support Long-Acting Delivery Approaches. Mol Pharm. 2019 Jan 7;16(1):86-95.
DMA2NYS	RU	https://pubmed.ncbi.nlm.nih.gov/30444371

DMFJLB6	DI	DMFJLB6
DMFJLB6	DN	Lanabecestat
DMFJLB6	MI	TT8JRS7
DMFJLB6	MN	Beta-secretase (BACE)
DMFJLB6	MT	DTT
DMFJLB6	MA	Inhibitor
DMFJLB6	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMFJLB6	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM4EGPN	DI	DM4EGPN
DM4EGPN	DN	Lanperisone
DM4EGPN	MI	TT84DRB
DM4EGPN	MN	Voltage-gated sodium channel alpha Nav1.4 (SCN4A)
DM4EGPN	MT	DTT
DM4EGPN	MA	Modulator
DM4EGPN	RN	Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec;315(3):1237-46.
DM4EGPN	RU	https://pubmed.ncbi.nlm.nih.gov/16126840

DMMA0C7	DI	DMMA0C7
DMMA0C7	DN	Laquinamod
DMMA0C7	MI	TTZF0K2
DMMA0C7	MN	C-X-C motif chemokine 2 (CXCL2)
DMMA0C7	MT	DTT
DMMA0C7	MA	Modulator
DMMA0C7	RN	Multiple sclerosis: current and future treatment options. Endocr Metab Immune Disord Drug Targets. 2007 Dec;7(4):292-9.
DMMA0C7	RU	https://pubmed.ncbi.nlm.nih.gov/18220950

DM3IWS8	DI	DM3IWS8
DM3IWS8	DN	Laquinimod
DM3IWS8	MI	DE4LYSA
DM3IWS8	MN	Cytochrome P450 3A4 (CYP3A4)
DM3IWS8	MT	DME
DM3IWS8	MA	Metabolism
DM3IWS8	RN	Oral laquinimod treatment in multiple sclerosis. Neurologia. 2011 Mar;26(2):111-7.
DM3IWS8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21163185

DM3IWS8	DI	DM3IWS8
DM3IWS8	DN	Laquinimod
DM3IWS8	MI	TTSXVID
DM3IWS8	MN	Nuclear factor NF-kappa-B (NFKB)
DM3IWS8	MT	DTT
DM3IWS8	MA	Modulator
DM3IWS8	RN	Reduced astrocytic NF- B activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol. 2012 Sep;124(3):411-24.
DM3IWS8	RU	https://pubmed.ncbi.nlm.nih.gov/22766690

DMH2EA1	DI	DMH2EA1
DMH2EA1	DN	Laromustine
DMH2EA1	MI	TTUTN1I
DMH2EA1	MN	Human Deoxyribonucleic acid (hDNA)
DMH2EA1	MT	DTT
DMH2EA1	MA	Binder
DMH2EA1	RN	Phase I study of temozolomide and laromustine (VNP40101M) in patients with relapsed or refractory leukemia. Clin Lymphoma Myeloma Leuk. 2010 Jun;10(3):211-6.
DMH2EA1	RU	https://pubmed.ncbi.nlm.nih.gov/20511167

DMAJM12	DI	DMAJM12
DMAJM12	DN	LATIN T1D
DMAJM12	MI	TTVIMDE
DMAJM12	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMAJM12	MT	DTT
DMAJM12	MA	Agonist
DMAJM12	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249).
DMAJM12	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=249

DM09RKB	DI	DM09RKB
DM09RKB	DN	LC-150444
DM09RKB	MI	TTDIGC1
DM09RKB	MN	Dipeptidyl peptidase 4 (DPP-4)
DM09RKB	MT	DTT
DM09RKB	MA	Inhibitor
DM09RKB	RN	Clinical pipeline report, company report or official report of ShangHai APIs Chemical.
DM09RKB	RU	http://www.apischemical.com/APIsproducts4/850649-62-6,Alogliptin(SYR-322).htm

DMT4K0Z	DI	DMT4K0Z
DMT4K0Z	DN	L-citrulline
DMT4K0Z	MI	DTP7AEQ
DMT4K0Z	MN	Glycoprotein-associated amino acid transporter b0, +AT1 (SLC7A9)
DMT4K0Z	MT	DTP
DMT4K0Z	MA	Substrate
DMT4K0Z	RN	Transport characteristics of L-citrulline in renal apical membrane of proximal tubular cells. Biopharm Drug Dispos. 2009 Apr;30(3):126-37.
DMT4K0Z	RU	http://www.ncbi.nlm.nih.gov/pubmed/19322909

DMT4K0Z	DI	DMT4K0Z
DMT4K0Z	DN	L-citrulline
DMT4K0Z	MI	TTI1PRE
DMT4K0Z	MN	G-protein coupled receptor GPCR33 (GPRC6A)
DMT4K0Z	MT	DTT
DMT4K0Z	MA	Agonist
DMT4K0Z	RN	Deorphanization of GPRC6A: a promiscuous L-alpha-amino acid receptor with preference for basic amino acids. Mol Pharmacol. 2005 Mar;67(3):589-97.
DMT4K0Z	RU	https://pubmed.ncbi.nlm.nih.gov/15576628

DMFLJHQ	DI	DMFLJHQ
DMFLJHQ	DN	LCQ908
DMFLJHQ	MI	TTF8P9I
DMFLJHQ	MN	Diacylglycerol acyltransferase 1 (DGAT1)
DMFLJHQ	MT	DTT
DMFLJHQ	MA	Modulator
DMFLJHQ	RN	DGAT1 inhibitors as anti-obesity and anti-diabetic agents. Curr Opin Drug Discov Devel. 2010 Jul;13(4):489-96.
DMFLJHQ	RU	https://pubmed.ncbi.nlm.nih.gov/20597032

DMFLJHQ	DI	DMFLJHQ
DMFLJHQ	DN	LCQ908
DMFLJHQ	MI	DEYGVN4
DMFLJHQ	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMFLJHQ	MT	DME
DMFLJHQ	MA	Metabolism
DMFLJHQ	RN	Pradigastat disposition in humans: in vivo and in vitro investigations. Xenobiotica. 2017 Dec;47(12):1077-1089.
DMFLJHQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27855567

DMFLJHQ	DI	DMFLJHQ
DMFLJHQ	DN	LCQ908
DMFLJHQ	MI	DEF2WXN
DMFLJHQ	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMFLJHQ	MT	DME
DMFLJHQ	MA	Metabolism
DMFLJHQ	RN	Pradigastat disposition in humans: in vivo and in vitro investigations. Xenobiotica. 2017 Dec;47(12):1077-1089.
DMFLJHQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27855567

DMFLJHQ	DI	DMFLJHQ
DMFLJHQ	DN	LCQ908
DMFLJHQ	MI	DEB3CV1
DMFLJHQ	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMFLJHQ	MT	DME
DMFLJHQ	MA	Metabolism
DMFLJHQ	RN	Pradigastat disposition in humans: in vivo and in vitro investigations. Xenobiotica. 2017 Dec;47(12):1077-1089.
DMFLJHQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27855567

DMQP0X5	DI	DMQP0X5
DMQP0X5	DN	Lebrikizumab
DMQP0X5	MI	TT0GVCH
DMQP0X5	MN	Interleukin-13 (IL13)
DMQP0X5	MT	DTT
DMQP0X5	MA	Modulator
DMQP0X5	RN	The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. 
DMQP0X5	RU	https://www.ncbi.nlm.nih.gov/pubmed/23197041

DMMX75K	DI	DMMX75K
DMMX75K	DN	LEE011
DMMX75K	MI	TT0PG8F
DMMX75K	MN	Cyclin-dependent kinase 4 (CDK4)
DMMX75K	MT	DTT
DMMX75K	MA	Modulator
DMMX75K	RN	Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82.
DMMX75K	RU	https://pubmed.ncbi.nlm.nih.gov/24045179

DMMX75K	DI	DMMX75K
DMMX75K	DN	LEE011
DMMX75K	MI	TTO0FDJ
DMMX75K	MN	Cyclin-dependent kinase 6 (CDK6)
DMMX75K	MT	DTT
DMMX75K	MA	Modulator
DMMX75K	RN	Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82.
DMMX75K	RU	https://pubmed.ncbi.nlm.nih.gov/24045179

DMSCGM8	DI	DMSCGM8
DMSCGM8	DN	LentiGlobin
DMSCGM8	MI	TTM6HK1
DMSCGM8	MN	Hemoglobin subunit beta (HBB)
DMSCGM8	MT	DTT
DMSCGM8	MA	Modulator
DMSCGM8	RN	Preclinical evaluation of efficacy and safety of an improved lentiviral vector for the treatment of beta-thalassemia and sickle cell disease. Curr Gene Ther. 2015;15(1):64-81.
DMSCGM8	RU	https://pubmed.ncbi.nlm.nih.gov/25429463

DMSRIT4	DI	DMSRIT4
DMSRIT4	DN	Lenzilumab
DMSRIT4	MI	TTPZGYX
DMSRIT4	MN	HUMAN colony-stimulating factor (GM-CSF)
DMSRIT4	MT	DTT
DMSRIT4	MA	Inhibitor
DMSRIT4	RN	The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. J Autoimmun. 2020 Apr 17:102468.
DMSRIT4	RU	https://pubmed.ncbi.nlm.nih.gov/32317220

DMOTCIU	DI	DMOTCIU
DMOTCIU	DN	Lerisetron
DMOTCIU	MI	TTNXLKE
DMOTCIU	MN	5-HT 3 receptor (5HT3R)
DMOTCIU	MT	DTT
DMOTCIU	MA	Antagonist
DMOTCIU	RN	Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar;11(1):137-51.
DMOTCIU	RU	https://pubmed.ncbi.nlm.nih.gov/16503832

DMAYC76	DI	DMAYC76
DMAYC76	DN	Levomequitazine
DMAYC76	MI	TT7CXIM
DMAYC76	MN	Histamine receptor (HR)
DMAYC76	MT	DTT
DMAYC76	MA	Antagonist
DMAYC76	RN	Oxidation of histamine H1 antagonist mequitazine is catalyzed by cytochrome P450 2D6 in human liver microsomes. J Pharmacol Exp Ther. 1998 Feb;284(2):437-42.
DMAYC76	RU	https://pubmed.ncbi.nlm.nih.gov/9454781

DM103O8	DI	DM103O8
DM103O8	DN	Ligelizumab
DM103O8	MI	TTYJQTF
DM103O8	MN	Immunoglobulin E (IgE)
DM103O8	MT	DTT
DM103O8	MA	Inhibitor
DM103O8	RN	Clinical pipeline report, company report or official report of Novartis.
DM103O8	RU	https://www.novartis.com/our-science/novartis-global-pipeline?search_api_views_fulltext=Ligelizumab&field_pipeline_filing_date=All

DMNM93X	DI	DMNM93X
DMNM93X	DN	Linagliptin
DMNM93X	MI	TTF928K
DMNM93X	MN	HUMAN dipeptidyl peptidase 4 (DPP-4)
DMNM93X	MT	DTT
DMNM93X	MA	Inhibitor
DMNM93X	RN	DPP4 inhibition: preventing SARS-CoV-2 infection and/or progression of COVID-19 Diabetes Metab Res Rev. 2020 Apr 26.
DMNM93X	RU	https://pubmed.ncbi.nlm.nih.gov/32336007

DM0ZOGX	DI	DM0ZOGX
DM0ZOGX	DN	Linopirdine
DM0ZOGX	MI	DE4LYSA
DM0ZOGX	MN	Cytochrome P450 3A4 (CYP3A4)
DM0ZOGX	MT	DME
DM0ZOGX	MA	Metabolism
DM0ZOGX	RN	Induction of cytochromes P-450 2B and 3A in mice following the dietary administration of the novel cognitive enhancer linopirdine. Drug Metab Dispos. 1994 Jan-Feb;22(1):65-73.
DM0ZOGX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8149892

DM0ZOGX	DI	DM0ZOGX
DM0ZOGX	DN	Linopirdine
DM0ZOGX	MI	DEIBDNY
DM0ZOGX	MN	Cytochrome P450 3A5 (CYP3A5)
DM0ZOGX	MT	DME
DM0ZOGX	MA	Metabolism
DM0ZOGX	RN	Induction of cytochromes P-450 2B and 3A in mice following the dietary administration of the novel cognitive enhancer linopirdine. Drug Metab Dispos. 1994 Jan-Feb;22(1):65-73.
DM0ZOGX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8149892

DM0ZOGX	DI	DM0ZOGX
DM0ZOGX	DN	Linopirdine
DM0ZOGX	MI	DERD86B
DM0ZOGX	MN	Cytochrome P450 3A7 (CYP3A7)
DM0ZOGX	MT	DME
DM0ZOGX	MA	Metabolism
DM0ZOGX	RN	Induction of cytochromes P-450 2B and 3A in mice following the dietary administration of the novel cognitive enhancer linopirdine. Drug Metab Dispos. 1994 Jan-Feb;22(1):65-73.
DM0ZOGX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8149892

DM0ZOGX	DI	DM0ZOGX
DM0ZOGX	DN	Linopirdine
DM0ZOGX	MI	TTIVDM3
DM0ZOGX	MN	Voltage-gated potassium channel Kv7.3 (KCNQ3)
DM0ZOGX	MT	DTT
DM0ZOGX	MA	Modulator
DM0ZOGX	RN	The M-channel blocker linopirdine is an agonist of the capsaicin receptor TRPV1. J Pharmacol Sci. 2010;114(3):332-40.
DM0ZOGX	RU	https://pubmed.ncbi.nlm.nih.gov/21099148

DMNF4UH	DI	DMNF4UH
DMNF4UH	DN	Liprotamase
DMNF4UH	MI	TT7MRGU
DMNF4UH	MN	Chymotrypsin (CTR)
DMNF4UH	MT	DTT
DMNF4UH	MA	Modulator
DMNF4UH	RN	Clinical pipeline report, company report or official report of Anthera Pharmaceuticals.
DMNF4UH	RU	http://investor.anthera.com/releasedetail.cfm?releaseid=859598

DMNF4UH	DI	DMNF4UH
DMNF4UH	DN	Liprotamase
DMNF4UH	MI	TTCGSZ4
DMNF4UH	MN	Pancreatic alpha-amylase (AMY2A)
DMNF4UH	MT	DTT
DMNF4UH	MA	Modulator
DMNF4UH	RN	Clinical pipeline report, company report or official report of Anthera Pharmaceuticals.
DMNF4UH	RU	http://investor.anthera.com/releasedetail.cfm?releaseid=859598

DMNF4UH	DI	DMNF4UH
DMNF4UH	DN	Liprotamase
DMNF4UH	MI	TTXMY0J
DMNF4UH	MN	Pancreatic triacylglycerol lipase (PNLIP)
DMNF4UH	MT	DTT
DMNF4UH	MA	Modulator
DMNF4UH	RN	Clinical pipeline report, company report or official report of Anthera Pharmaceuticals.
DMNF4UH	RU	http://investor.anthera.com/releasedetail.cfm?releaseid=859598

DMKZRBP	DI	DMKZRBP
DMKZRBP	DN	Litoxetine
DMKZRBP	MI	TTNXLKE
DMKZRBP	MN	5-HT 3 receptor (5HT3R)
DMKZRBP	MT	DTT
DMKZRBP	MA	Modulator
DMKZRBP	RN	Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties. Eur J Pharmacol. 1993 Mar 2;232(2-3):139-45.
DMKZRBP	RU	https://www.ncbi.nlm.nih.gov/pubmed/8385615

DMKZRBP	DI	DMKZRBP
DMKZRBP	DN	Litoxetine
DMKZRBP	MI	TT3ROYC
DMKZRBP	MN	Serotonin transporter (SERT)
DMKZRBP	MT	DTT
DMKZRBP	MA	Modulator
DMKZRBP	RN	Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties. Eur J Pharmacol. 1993 Mar 2;232(2-3):139-45.
DMKZRBP	RU	https://www.ncbi.nlm.nih.gov/pubmed/8385615

DMDN4ZP	DI	DMDN4ZP
DMDN4ZP	DN	Lixivaptan
DMDN4ZP	MI	TTV9GOF
DMDN4ZP	MN	Histidine decarboxylase (HDC)
DMDN4ZP	MT	DTT
DMDN4ZP	MA	Inhibitor
DMDN4ZP	RN	Clinical pipeline report, company report or official report of Biofrontera (2009).
DMDN4ZP	RU	http://www.biofrontera.com/index.php?id=5

DMDN4ZP	DI	DMDN4ZP
DMDN4ZP	DN	Lixivaptan
DMDN4ZP	MI	TTK8R02
DMDN4ZP	MN	Vasopressin V2 receptor (V2R)
DMDN4ZP	MT	DTT
DMDN4ZP	MA	Antagonist
DMDN4ZP	RN	Emerging drugs for acute and chronic heart failure: current and future developments. Expert Opin Emerg Drugs. 2007 Mar;12(1):75-95.
DMDN4ZP	RU	https://pubmed.ncbi.nlm.nih.gov/17355215

DM4OAIU	DI	DM4OAIU
DM4OAIU	DN	LMI070
DM4OAIU	MI	TT8QL6X
DM4OAIU	MN	Survival motor neuron protein (SMN1)
DM4OAIU	MT	DTT
DM4OAIU	MA	Modulator
DM4OAIU	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM4OAIU	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMOFIBM	DI	DMOFIBM
DMOFIBM	DN	LMT-X
DMOFIBM	MI	TTS87KH
DMOFIBM	MN	Microtubule-associated protein tau (MAPT)
DMOFIBM	MT	DTT
DMOFIBM	MA	Inhibitor
DMOFIBM	RN	Clinical pipeline report, company report or official report of TauRx.
DMOFIBM	RU	http://taurx.com/press-releases-announcements.html

DMOFIBM	DI	DMOFIBM
DMOFIBM	DN	LMT-X
DMOFIBM	MI	TT9RZ03
DMOFIBM	MN	TAR DNA binding protein 43 (TARDBP)
DMOFIBM	MT	DTT
DMOFIBM	MA	Inhibitor
DMOFIBM	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMOFIBM	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMOFIBM	DI	DMOFIBM
DMOFIBM	DN	LMT-X
DMOFIBM	MI	TTZGF8B
DMOFIBM	MN	Tau protein aggregation (TauA)
DMOFIBM	MT	DTT
DMOFIBM	MA	Modulator
DMOFIBM	RN	Successes and Failures for Drugs in Late-Stage Development for Alzheimer's Disease. Correction in: volume 31 on page 81.
DMOFIBM	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000701/

DM9EZM0	DI	DM9EZM0
DM9EZM0	DN	LNP023
DM9EZM0	MI	TTA0P7K
DM9EZM0	MN	Complement factor B (CFB)
DM9EZM0	MT	DTT
DM9EZM0	MA	Inhibitor
DM9EZM0	RN	Discovery of 4-((2 S,4 S)-4-Ethoxy-1-((5-methoxy-7-methyl-1 H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases. J Med Chem. 2020 Jun 11;63(11):5697-5722.
DM9EZM0	RU	https://pubmed.ncbi.nlm.nih.gov/32073845

DMQNVR8	DI	DMQNVR8
DMQNVR8	DN	Lopinavir + ritonavir
DMQNVR8	MI	TT1D53B
DMQNVR8	MN	COVID-19 3C-like protease (3CLpro)
DMQNVR8	MT	DTT
DMQNVR8	MA	Inhibitor
DMQNVR8	RN	Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381.
DMQNVR8	RU	https://pubmed.ncbi.nlm.nih.gov/32205870

DMX0O9U	DI	DMX0O9U
DMX0O9U	DN	Lopinavir + ritonavir + favipiravir
DMX0O9U	MI	TT1D53B
DMX0O9U	MN	COVID-19 3C-like protease (3CLpro)
DMX0O9U	MT	DTT
DMX0O9U	MA	Inhibitor
DMX0O9U	RN	Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381.
DMX0O9U	RU	https://pubmed.ncbi.nlm.nih.gov/32205870

DMNY05F	DI	DMNY05F
DMNY05F	DN	Lopinavir + ritonavir + oseltamivir
DMNY05F	MI	TT1D53B
DMNY05F	MN	COVID-19 3C-like protease (3CLpro)
DMNY05F	MT	DTT
DMNY05F	MA	Inhibitor
DMNY05F	RN	Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381.
DMNY05F	RU	https://pubmed.ncbi.nlm.nih.gov/32205870

DMTL5Q0	DI	DMTL5Q0
DMTL5Q0	DN	Losartan
DMTL5Q0	MI	TTPKMXQ
DMTL5Q0	MN	HUMAN type-1 angiotensin II receptor (AGTR1)
DMTL5Q0	MT	DTT
DMTL5Q0	MA	Blocker
DMTL5Q0	RN	Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic. Nat Rev Nephrol. 2020 Apr 3.
DMTL5Q0	RU	https://pubmed.ncbi.nlm.nih.gov/32246101

DMIL37Z	DI	DMIL37Z
DMIL37Z	DN	Losmapimod
DMIL37Z	MI	TTQBR95
DMIL37Z	MN	Stress-activated protein kinase 2a (p38 alpha)
DMIL37Z	MT	DTT
DMIL37Z	MA	Inhibitor
DMIL37Z	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMIL37Z	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMWGRQD	DI	DMWGRQD
DMWGRQD	DN	LU AE58054
DMWGRQD	MI	TTJS8PY
DMWGRQD	MN	5-HT 6 receptor (HTR6)
DMWGRQD	MT	DTT
DMWGRQD	MA	Enhancer
DMWGRQD	RN	Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol. 2010 Sep;13(8):1021-33.
DMWGRQD	RU	https://pubmed.ncbi.nlm.nih.gov/20569520

DMWGRQD	DI	DMWGRQD
DMWGRQD	DN	LU AE58054
DMWGRQD	MI	DECB0K3
DMWGRQD	MN	Cytochrome P450 2D6 (CYP2D6)
DMWGRQD	MT	DME
DMWGRQD	MA	Metabolism
DMWGRQD	RN	Idalopirdine as a treatment for Alzheimer's disease. Expert Opin Investig Drugs. 2015;24(7):981-7.
DMWGRQD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26022777

DMWGRQD	DI	DMWGRQD
DMWGRQD	DN	LU AE58054
DMWGRQD	MI	DE4LYSA
DMWGRQD	MN	Cytochrome P450 3A4 (CYP3A4)
DMWGRQD	MT	DME
DMWGRQD	MA	Metabolism
DMWGRQD	RN	Idalopirdine as a treatment for Alzheimer's disease. Expert Opin Investig Drugs. 2015;24(7):981-7.
DMWGRQD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26022777

DMNAYUJ	DI	DMNAYUJ
DMNAYUJ	DN	Lu AF35700
DMNAYUJ	MI	TTEX248
DMNAYUJ	MN	Dopamine D2 receptor (D2R)
DMNAYUJ	MT	DTT
DMNAYUJ	MA	Modulator
DMNAYUJ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMNAYUJ	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMMLXA9	DI	DMMLXA9
DMMLXA9	DN	LX-4211
DMMLXA9	MI	TT2UE56
DMMLXA9	MN	Sodium/glucose cotransporter 1 (SGLT1)
DMMLXA9	MT	DTT
DMMLXA9	MA	Modulator
DMMLXA9	RN	LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012 Aug;92(2):158-69.
DMMLXA9	RU	https://pubmed.ncbi.nlm.nih.gov/22739142

DMMLXA9	DI	DMMLXA9
DMMLXA9	DN	LX-4211
DMMLXA9	MI	TTLWPVF
DMMLXA9	MN	Sodium/glucose cotransporter 2 (SGLT2)
DMMLXA9	MT	DTT
DMMLXA9	MA	Modulator
DMMLXA9	RN	LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012 Aug;92(2):158-69.
DMMLXA9	RU	https://pubmed.ncbi.nlm.nih.gov/22739142

DM1BXMY	DI	DM1BXMY
DM1BXMY	DN	LY2605541
DM1BXMY	MI	TTZOPHG
DM1BXMY	MN	Insulin (INS)
DM1BXMY	MT	DTT
DM1BXMY	MA	Modulator
DM1BXMY	RN	LY2605541--a preferential hepato-specific insulin analogue. Diabetes. 2014 Feb;63(2):390-2.
DM1BXMY	RU	https://pubmed.ncbi.nlm.nih.gov/24464715

DMEZ0H5	DI	DMEZ0H5
DMEZ0H5	DN	LY2963016
DMEZ0H5	MI	TTZOPHG
DMEZ0H5	MN	Insulin (INS)
DMEZ0H5	MT	DTT
DMEZ0H5	MA	Agonist
DMEZ0H5	RN	Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus ) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study. Diabetes Obes Metab.2015 Aug;17(8):726-33.
DMEZ0H5	RU	https://pubmed.ncbi.nlm.nih.gov/25974640

DMWZIRJ	DI	DMWZIRJ
DMWZIRJ	DN	LY404039
DMWZIRJ	MI	TT8A9EF
DMWZIRJ	MN	Metabotropic glutamate receptor 3 (mGluR3)
DMWZIRJ	MT	DTT
DMWZIRJ	MA	Agonist
DMWZIRJ	RN	Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia. Expert Opin Ther Pat. 2009 Sep;19(9):1259-75.
DMWZIRJ	RU	https://pubmed.ncbi.nlm.nih.gov/19552508

DM7WORZ	DI	DM7WORZ
DM7WORZ	DN	LY-686017
DM7WORZ	MI	TTZPO1L
DM7WORZ	MN	Substance-P receptor (TACR1)
DM7WORZ	MT	DTT
DM7WORZ	MA	Antagonist
DM7WORZ	RN	Stress-related neuropeptides and alcoholism: CRH, NPY and beyond. Alcohol. 2009 November; 43(7): 491-498.
DM7WORZ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2804869/

DM6LVCQ	DI	DM6LVCQ
DM6LVCQ	DN	LY-CoV555
DM6LVCQ	MI	TTZ3COY
DM6LVCQ	MN	COVID-19 spike glycoprotein (S)
DM6LVCQ	MT	DTT
DM6LVCQ	MA	Inhibitor
DM6LVCQ	RN	Neutralizing Antibody LY-CoV555 for Outpatient Covid-19. Reply. N Engl J Med. 2021 Jan 14;384(2):189.
DM6LVCQ	RU	https://pubmed.ncbi.nlm.nih.gov/33378611

DMGNC6T	DI	DMGNC6T
DMGNC6T	DN	M-0011
DMGNC6T	MI	TTT2KE3
DMGNC6T	MN	Alpha-mannosidase (MANA)
DMGNC6T	MT	DTT
DMGNC6T	MA	Modulator
DMGNC6T	RN	ClinicalTrials.gov (NCT01681953) A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis. U.S. National Institutes of Health.
DMGNC6T	RU	https://clinicaltrials.gov/ct2/show/NCT01681953

DM7ZFBA	DI	DM7ZFBA
DM7ZFBA	DN	M100907
DM7ZFBA	MI	TTJQOD7
DM7ZFBA	MN	5-HT 2A receptor (HTR2A)
DM7ZFBA	MT	DTT
DM7ZFBA	MA	Antagonist
DM7ZFBA	RN	Antagonism of 5-hydroxytryptamine(2a) receptors attenuates the behavioral effects of cocaine in rats. J Pharmacol Exp Ther. 2001 Apr;297(1):357-63.
DM7ZFBA	RU	https://pubmed.ncbi.nlm.nih.gov/11259563

DM7ZFBA	DI	DM7ZFBA
DM7ZFBA	DN	M100907
DM7ZFBA	MI	TTWJBZ5
DM7ZFBA	MN	5-HT 2C receptor (HTR2C)
DM7ZFBA	MT	DTT
DM7ZFBA	MA	Inhibitor
DM7ZFBA	RN	Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists ... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12.
DM7ZFBA	RU	https://pubmed.ncbi.nlm.nih.gov/20493697

DM7ZFBA	DI	DM7ZFBA
DM7ZFBA	DN	M100907
DM7ZFBA	MI	TTQ6VDM
DM7ZFBA	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DM7ZFBA	MT	DTT
DM7ZFBA	MA	Inhibitor
DM7ZFBA	RN	Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists ... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12.
DM7ZFBA	RU	https://pubmed.ncbi.nlm.nih.gov/20493697

DMZ6VD5	DI	DMZ6VD5
DMZ6VD5	DN	M-518101
DMZ6VD5	MI	TTUST1O
DMZ6VD5	MN	Phosphodiesterase (PDE)
DMZ6VD5	MT	DTT
DMZ6VD5	MA	Inhibitor
DMZ6VD5	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZ6VD5	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DM1PRT6	DI	DM1PRT6
DM1PRT6	DN	M710
DM1PRT6	MI	TT9HKJA
DM1PRT6	MN	Vascular endothelial growth factor (VEGF)
DM1PRT6	MT	DTT
DM1PRT6	MA	Inhibitor
DM1PRT6	RN	ClinicalTrials.gov (NCT03610646) Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea in Subjects With Diabetic Macular Edema. U.S. National Institutes of Health.
DM1PRT6	RU	https://clinicaltrials.gov/ct2/show/NCT03610646

DM8D13S	DI	DM8D13S
DM8D13S	DN	MABp1
DM8D13S	MI	TTPM6HI
DM8D13S	MN	Interleukin-1 alpha (IL1A)
DM8D13S	MT	DTT
DM8D13S	MA	Inhibitor
DM8D13S	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM8D13S	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMVXUR0	DI	DMVXUR0
DMVXUR0	DN	Magrolimab
DMVXUR0	MI	TTN2JFW
DMVXUR0	MN	T-cell surface glycoprotein CD4 (CD4)
DMVXUR0	MT	DTT
DMVXUR0	MA	Inhibitor
DMVXUR0	RN	Current and emerging strategies for management of myelodysplastic syndromes. Blood Rev. 2021 Jul;48:100791.
DMVXUR0	RU	https://pubmed.ncbi.nlm.nih.gov/33423844

DMJPGUA	DI	DMJPGUA
DMJPGUA	DN	Manidipine
DMJPGUA	MI	DERSX5P
DMJPGUA	MN	Cytochrome P450 2J2 (CYP2J2)
DMJPGUA	MT	DME
DMJPGUA	MA	Metabolism
DMJPGUA	RN	Inhibitory effects of antihypertensive drugs on human cytochrome P450 2J2 activity: Potent inhibition by azelnidipine and manidipine. Chem Biol Interact. 2019 Jun 1;306:1-9.
DMJPGUA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30965050

DMJPGUA	DI	DMJPGUA
DMJPGUA	DN	Manidipine
DMJPGUA	MI	DE4LYSA
DMJPGUA	MN	Cytochrome P450 3A4 (CYP3A4)
DMJPGUA	MT	DME
DMJPGUA	MA	Metabolism
DMJPGUA	RN	Effect of grapefruit juice on the disposition of manidipine enantiomers in healthy subjects. Br J Clin Pharmacol. 2006 May;61(5):533-7.
DMJPGUA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16669846

DMJPGUA	DI	DMJPGUA
DMJPGUA	DN	Manidipine
DMJPGUA	MI	TTEAID7
DMJPGUA	MN	Trypanosoma Cruzipain (Trypano CYSP)
DMJPGUA	MT	DTT
DMJPGUA	MA	Inhibitor
DMJPGUA	RN	Colloid formation by drugs in simulated intestinal fluid. J Med Chem. 2010 May 27;53(10):4259-65.
DMJPGUA	RU	https://pubmed.ncbi.nlm.nih.gov/20426472

DMR23M1	DI	DMR23M1
DMR23M1	DN	Mapracorat
DMR23M1	MI	TTYRL6O
DMR23M1	MN	Glucocorticoid receptor (NR3C1)
DMR23M1	MT	DTT
DMR23M1	MA	Agonist
DMR23M1	RN	Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases. Br J Pharmacol. 2009 Oct;158(4):1088-103.
DMR23M1	RU	https://pubmed.ncbi.nlm.nih.gov/19422381

DMJCF1O	DI	DMJCF1O
DMJCF1O	DN	Maralixibat
DMJCF1O	MI	TTPI1M5
DMJCF1O	MN	Ileal sodium/bile acid cotransporter (SLC10A2)
DMJCF1O	MT	DTT
DMJCF1O	MA	Inhibitor
DMJCF1O	RN	Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders. Hepatol Int. 2020 Sep;14(5):677-689.
DMJCF1O	RU	https://pubmed.ncbi.nlm.nih.gov/32653991

DM3GTAL	DI	DM3GTAL
DM3GTAL	DN	Maribavir
DM3GTAL	MI	DE4LYSA
DM3GTAL	MN	Cytochrome P450 3A4 (CYP3A4)
DM3GTAL	MT	DME
DM3GTAL	MA	Metabolism
DM3GTAL	RN	Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults. Antimicrob Agents Chemother. 2006 Apr;50(4):1130-5.
DM3GTAL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16569820

DM3GTAL	DI	DM3GTAL
DM3GTAL	DN	Maribavir
DM3GTAL	MI	TTXQ04B
DM3GTAL	MN	Cytomegalovirus Ganciclovir kinase (CMV UL97)
DM3GTAL	MT	DTT
DM3GTAL	MA	Inhibitor
DM3GTAL	RN	The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J Virol. 2003 Jan;77(2):905-14.
DM3GTAL	RU	https://pubmed.ncbi.nlm.nih.gov/12502806

DM6V34C	DI	DM6V34C
DM6V34C	DN	Marimastat
DM6V34C	MI	TTMX39J
DM6V34C	MN	Matrix metalloproteinase-1 (MMP-1)
DM6V34C	MT	DTT
DM6V34C	MA	Inhibitor
DM6V34C	RN	Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat. Eur J Pharmacol. 2007 Mar 15;559(1):75-81.
DM6V34C	RU	https://pubmed.ncbi.nlm.nih.gov/17234180

DM6V34C	DI	DM6V34C
DM6V34C	DN	Marimastat
DM6V34C	MI	TTLM12X
DM6V34C	MN	Matrix metalloproteinase-2 (MMP-2)
DM6V34C	MT	DTT
DM6V34C	MA	Inhibitor
DM6V34C	RN	Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat. Eur J Pharmacol. 2007 Mar 15;559(1):75-81.
DM6V34C	RU	https://pubmed.ncbi.nlm.nih.gov/17234180

DM6V34C	DI	DM6V34C
DM6V34C	DN	Marimastat
DM6V34C	MI	TTMTWOS
DM6V34C	MN	Matrix metalloproteinase-7 (MMP-7)
DM6V34C	MT	DTT
DM6V34C	MA	Inhibitor
DM6V34C	RN	Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat. Eur J Pharmacol. 2007 Mar 15;559(1):75-81.
DM6V34C	RU	https://pubmed.ncbi.nlm.nih.gov/17234180

DME9QGW	DI	DME9QGW
DME9QGW	DN	Marizomib
DME9QGW	MI	TTU7ZMG
DME9QGW	MN	Proteasome (PS)
DME9QGW	MT	DTT
DME9QGW	MA	Inhibitor
DME9QGW	RN	Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets. 2011 Mar;11(3):254-84.
DME9QGW	RU	https://pubmed.ncbi.nlm.nih.gov/21247382

DMRSNEU	DI	DMRSNEU
DMRSNEU	DN	Masitinib
DMRSNEU	MI	TT6PKBN
DMRSNEU	MN	Proto-oncogene c-Src (SRC)
DMRSNEU	MT	DTT
DMRSNEU	MA	Inhibitor
DMRSNEU	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMRSNEU	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMRSNEU	DI	DMRSNEU
DMRSNEU	DN	Masitinib
DMRSNEU	MI	TTJSQEF
DMRSNEU	MN	Tyrosine-protein kinase (PTK)
DMRSNEU	MT	DTT
DMRSNEU	MA	Inhibitor
DMRSNEU	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMRSNEU	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMK9BP2	DI	DMK9BP2
DMK9BP2	DN	Mavacamten
DMK9BP2	MI	TTITSMB
DMK9BP2	MN	Myosin (MYO)
DMK9BP2	MT	DTT
DMK9BP2	MA	Inhibitor
DMK9BP2	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMK9BP2	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMBPY9Z	DI	DMBPY9Z
DMBPY9Z	DN	MBG453
DMBPY9Z	MI	TT1RWL7
DMBPY9Z	MN	Hepatitis A virus cellular receptor 2 (TIM3)
DMBPY9Z	MT	DTT
DMBPY9Z	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMBPY9Z	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMVZ57G	DI	DMVZ57G
DMVZ57G	DN	MD1003
DMVZ57G	MI	TTSXVID
DMVZ57G	MN	Nuclear factor NF-kappa-B (NFKB)
DMVZ57G	MT	DTT
DMVZ57G	MA	Inhibitor
DMVZ57G	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMVZ57G	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM5X849	DI	DM5X849
DM5X849	DN	MEDI4736
DM5X849	MI	TT8ZLTI
DM5X849	MN	Programmed cell death 1 ligand 1 (PD-L1)
DM5X849	MT	DTT
DM5X849	MA	Modulator
DM5X849	RN	National Cancer Institute Drug Dictionary (drug id 740856).
DM5X849	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=740856

DM4W8RE	DI	DM4W8RE
DM4W8RE	DN	Melagatran
DM4W8RE	MI	TT2WR1T
DM4W8RE	MN	Cationic trypsinogen (PRSS1)
DM4W8RE	MT	DTT
DM4W8RE	MA	Inhibitor
DM4W8RE	RN	Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety. Bioorg Med Chem Lett. 2006 May 15;16(10):2641-7.
DM4W8RE	RU	https://pubmed.ncbi.nlm.nih.gov/16517159

DM4W8RE	DI	DM4W8RE
DM4W8RE	DN	Melagatran
DM4W8RE	MI	TT6L509
DM4W8RE	MN	Coagulation factor IIa (F2)
DM4W8RE	MT	DTT
DM4W8RE	MA	Inhibitor
DM4W8RE	RN	Orally active thrombin inhibitors. Part 2: optimization of the P2-moiety. Bioorg Med Chem Lett. 2006 May 15;16(10):2648-53.
DM4W8RE	RU	https://pubmed.ncbi.nlm.nih.gov/16460939

DM4W8RE	DI	DM4W8RE
DM4W8RE	DN	Melagatran
DM4W8RE	MI	TTCIHJA
DM4W8RE	MN	Coagulation factor Xa (F10)
DM4W8RE	MT	DTT
DM4W8RE	MA	Inhibitor
DM4W8RE	RN	Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety. Bioorg Med Chem Lett. 2006 May 15;16(10):2641-7.
DM4W8RE	RU	https://pubmed.ncbi.nlm.nih.gov/16517159

DM4W8RE	DI	DM4W8RE
DM4W8RE	DN	Melagatran
DM4W8RE	MI	DTUGYRD
DM4W8RE	MN	P-glycoprotein 1 (ABCB1)
DM4W8RE	MT	DTP
DM4W8RE	MA	Substrate
DM4W8RE	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM4W8RE	RU	https://doi.org/10.1007/s11095-012-0935-x

DM4W8RE	DI	DM4W8RE
DM4W8RE	DN	Melagatran
DM4W8RE	MI	TTP86E2
DM4W8RE	MN	Plasminogen (PLG)
DM4W8RE	MT	DTT
DM4W8RE	MA	Inhibitor
DM4W8RE	RN	Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety. Bioorg Med Chem Lett. 2006 May 15;16(10):2641-7.
DM4W8RE	RU	https://pubmed.ncbi.nlm.nih.gov/16517159

DMQEC6Z	DI	DMQEC6Z
DMQEC6Z	DN	Melanoma vaccine
DMQEC6Z	MI	TT362RB
DMQEC6Z	MN	MART-1 melanoma antigen (MLANA)
DMQEC6Z	MT	DTT
DMQEC6Z	RN	National Cancer Institute Drug Dictionary (drug id 685201).
DMQEC6Z	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=685201

DMQEC6Z	DI	DMQEC6Z
DMQEC6Z	DN	Melanoma vaccine
DMQEC6Z	MI	TT8MK59
DMQEC6Z	MN	Melanocytes lineage-specific antigen GP100 (PMEL)
DMQEC6Z	MT	DTT
DMQEC6Z	RN	National Cancer Institute Drug Dictionary (drug id 685201).
DMQEC6Z	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=685201

DMQEC6Z	DI	DMQEC6Z
DMQEC6Z	DN	Melanoma vaccine
DMQEC6Z	MI	TTULVH8
DMQEC6Z	MN	Tyrosinase (TYR)
DMQEC6Z	MT	DTT
DMQEC6Z	RN	National Cancer Institute Drug Dictionary (drug id 685201).
DMQEC6Z	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=685201

DM8Z0I3	DI	DM8Z0I3
DM8Z0I3	DN	MF-101
DM8Z0I3	MI	TTOM3J0
DM8Z0I3	MN	Estrogen receptor beta (ESR2)
DM8Z0I3	MT	DTT
DM8Z0I3	MA	Antagonist
DM8Z0I3	RN	MF101, a selective estrogen receptor beta modulator for the treatment of menopausal hot flushes: a phase II clinical trial. Menopause. 2009 May-Jun;16(3):458-65.
DM8Z0I3	RU	https://pubmed.ncbi.nlm.nih.gov/19182698

DMRKTCP	DI	DMRKTCP
DMRKTCP	DN	MGA012
DMRKTCP	MI	TTNBFWK
DMRKTCP	MN	Programmed cell death protein 1 (PD-1)
DMRKTCP	MT	DTT
DMRKTCP	MA	Inhibitor
DMRKTCP	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMRKTCP	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMCJRL1	DI	DMCJRL1
DMCJRL1	DN	MGN-1703
DMCJRL1	MI	TTSHG0T
DMCJRL1	MN	Toll-like receptor 9 (TLR9)
DMCJRL1	MT	DTT
DMCJRL1	MA	Agonist
DMCJRL1	RN	Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. J Cancer Res Clin Oncol. 2014 Sep;140(9):1615-24.
DMCJRL1	RU	https://pubmed.ncbi.nlm.nih.gov/24816725

DMZHN5B	DI	DMZHN5B
DMZHN5B	DN	MIM-D3
DMZHN5B	MI	TTTDVOJ
DMZHN5B	MN	Tropomyosin-related kinase A (TrkA)
DMZHN5B	MT	DTT
DMZHN5B	MA	Agonist
DMZHN5B	RN	Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. Clin Ophthalmol. 2013; 7: 1275-1285.
DMZHN5B	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699314/

DMCJY35	DI	DMCJY35
DMCJY35	DN	MIN-101
DMCJY35	MI	TTJQOD7
DMCJY35	MN	5-HT 2A receptor (HTR2A)
DMCJY35	MT	DTT
DMCJY35	MA	Antagonist
DMCJY35	RN	Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598). J Pharmacol Exp Ther. 1992 Jan;260(1):146-59.
DMCJY35	RU	https://pubmed.ncbi.nlm.nih.gov/1370538

DMCJY35	DI	DMCJY35
DMCJY35	DN	MIN-101
DMCJY35	MI	TT9NXW4
DMCJY35	MN	Sigma intracellular receptor 2 (TMEM97)
DMCJY35	MT	DTT
DMCJY35	MA	Antagonist
DMCJY35	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMCJY35	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DM7R3N5	DI	DM7R3N5
DM7R3N5	DN	Mirikizumab
DM7R3N5	MI	TTRTK6Y
DM7R3N5	MN	Interleukin-12 alpha (IL12A)
DM7R3N5	MT	DTT
DM7R3N5	MA	Inhibitor
DM7R3N5	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7R3N5	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM5S4LX	DI	DM5S4LX
DM5S4LX	DN	Mirvetuximab soravtansine
DM5S4LX	MI	TTVC37M
DM5S4LX	MN	Folate receptor alpha (FOLR1)
DM5S4LX	MT	DTT
DM5S4LX	MA	Antagonist
DM5S4LX	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM5S4LX	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM3PSUF	DI	DM3PSUF
DM3PSUF	DN	MK-3102
DM3PSUF	MI	TTDIGC1
DM3PSUF	MN	Dipeptidyl peptidase 4 (DPP-4)
DM3PSUF	MT	DTT
DM3PSUF	MA	Modulator
DM3PSUF	RN	Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. J Med Chem. 2014 Apr 24;57(8):3205-12.
DM3PSUF	RU	https://pubmed.ncbi.nlm.nih.gov/24660890

DMQBF7O	DI	DMQBF7O
DMQBF7O	DN	MK-3222
DMQBF7O	MI	TTC1GLB
DMQBF7O	MN	Interleukin-23 (IL23)
DMQBF7O	MT	DTT
DMQBF7O	RN	Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015 Oct;173(4):930-9.
DMQBF7O	RU	https://pubmed.ncbi.nlm.nih.gov/26042589

DMGNHC2	DI	DMGNHC2
DMGNHC2	DN	MK-3415A
DMGNHC2	MI	TT64H8L
DMGNHC2	MN	Clostridium difficile Toxin A (CD toxA)
DMGNHC2	MT	DTT
DMGNHC2	RN	ClinicalTrials.gov (NCT01513239) A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002). U.S. National Institutes of Health.
DMGNHC2	RU	https://clinicaltrials.gov/ct2/show/NCT01513239

DMGNHC2	DI	DMGNHC2
DMGNHC2	DN	MK-3415A
DMGNHC2	MI	TTQH65V
DMGNHC2	MN	Clostridium difficile Toxin B (CD toxB)
DMGNHC2	MT	DTT
DMGNHC2	RN	ClinicalTrials.gov (NCT01513239) A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002). U.S. National Institutes of Health.
DMGNHC2	RU	https://clinicaltrials.gov/ct2/show/NCT01513239

DMA25NO	DI	DMA25NO
DMA25NO	DN	MK-4214
DMA25NO	MI	TT5TQ2W
DMA25NO	MN	Granulocyte colony-stimulating factor (CSF3)
DMA25NO	MT	DTT
DMA25NO	MA	Modulator
DMA25NO	RN	DOI: 10.1038/nbt0710-636a
DMA25NO	RU	http://www.nature.com/nbt/journal/v28/n7/full/nbt0710-636a.html

DMLYGH4	DI	DMLYGH4
DMLYGH4	DN	MK-4827
DMLYGH4	MI	DEP54UE
DMLYGH4	MN	Beta-glucuronidase (GUSB)
DMLYGH4	MT	DME
DMLYGH4	MA	Metabolism
DMLYGH4	RN	Summary of FDA-approved anticancer cytotoxic drugs at May 2019.
DMLYGH4	RU	https://www.mdpi.com/2073-4409/8/9/1013/s1

DMLYGH4	DI	DMLYGH4
DMLYGH4	DN	MK-4827
DMLYGH4	MI	DEB30C5
DMLYGH4	MN	Carboxylesterase 1 (CES1)
DMLYGH4	MT	DME
DMLYGH4	MA	Metabolism
DMLYGH4	RN	Summary of FDA-approved anticancer cytotoxic drugs at May 2019.
DMLYGH4	RU	https://www.mdpi.com/2073-4409/8/9/1013/s1

DMLYGH4	DI	DMLYGH4
DMLYGH4	DN	MK-4827
DMLYGH4	MI	DE6OQ3W
DMLYGH4	MN	Cytochrome P450 1A1 (CYP1A1)
DMLYGH4	MT	DME
DMLYGH4	MA	Metabolism
DMLYGH4	RN	Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem. 2009 Nov 26;52(22):7170-85.
DMLYGH4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19873981

DMLYGH4	DI	DMLYGH4
DMLYGH4	DN	MK-4827
DMLYGH4	MI	TTEBCY8
DMLYGH4	MN	Poly [ADP-ribose] polymerase (PARP)
DMLYGH4	MT	DTT
DMLYGH4	MA	Modulator
DMLYGH4	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMLYGH4	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM84LO5	DI	DM84LO5
DM84LO5	DN	MK-8109
DM84LO5	MI	TTVC37M
DM84LO5	MN	Folate receptor alpha (FOLR1)
DM84LO5	MT	DTT
DM84LO5	MA	Modulator
DM84LO5	RN	A current review of folate receptor alpha as a potential tumor target in non-small-cell lung cancer. Drug Des Devel Ther. 2015; 9: 4989-4996.
DM84LO5	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560517/

DMK301H	DI	DMK301H
DMK301H	DN	MK-8742
DMK301H	MI	TTCJ2X8
DMK301H	MN	Hepatitis C virus Non-structural 5A (HCV NS5A)
DMK301H	MT	DTT
DMK301H	MA	Modulator
DMK301H	RN	Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. ChemMedChem. 2013 Dec;8(12):1930-40.
DMK301H	RU	https://pubmed.ncbi.nlm.nih.gov/24127258

DMT8IAJ	DI	DMT8IAJ
DMT8IAJ	DN	MK-8808
DMT8IAJ	MI	TTUE541
DMT8IAJ	MN	Leukocyte surface antigen Leu-16 (CD20)
DMT8IAJ	MT	DTT
DMT8IAJ	MA	Agonist
DMT8IAJ	RN	Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003 Oct 20;22(47):7359-68.
DMT8IAJ	RU	https://pubmed.ncbi.nlm.nih.gov/14576843

DMP36KD	DI	DMP36KD
DMP36KD	DN	MLN4924
DMP36KD	MI	TTVKOPM
DMP36KD	MN	NEDD8-activating enzyme (NAE)
DMP36KD	MT	DTT
DMP36KD	MA	Modulator
DMP36KD	RN	Targeting Cullin-RING ligases by MLN4924 induces autophagy via modulating the HIF1-REDD1-TSC1-mTORC1-DEPTOR axis.Cell Death Dis.2012 Sep 6;3:e386.
DMP36KD	RU	https://www.ncbi.nlm.nih.gov/pubmed/22951983

DMP36KD	DI	DMP36KD
DMP36KD	DN	MLN4924
DMP36KD	MI	TTNDC4K
DMP36KD	MN	Ubiquitin-like protein Nedd8 (NEDD8)
DMP36KD	MT	DTT
DMP36KD	MA	Inhibitor
DMP36KD	RN	Promoting tumorigenesis in nasopharyngeal carcinoma, NEDD8 serves as a potential theranostic target.Cell Death Dis. 2017 Jun 1;8(6):e2834. 
DMP36KD	RU	https://pubmed.ncbi.nlm.nih.gov/28569775

DMO8PT9	DI	DMO8PT9
DMO8PT9	DN	MLN8237
DMO8PT9	MI	TTPS3C0
DMO8PT9	MN	Aurora kinase A (AURKA)
DMO8PT9	MT	DTT
DMO8PT9	MA	Inhibitor
DMO8PT9	RN	Effect of Aurora A kinase inhibitor MLN8237 combined with rituximab on antitumor activity in preclinical B-cell non-Hodgkin's lymphoma models. Journal of Clinical Oncology, 2009:8553.
DMO8PT9	RU	http://meeting.ascopubs.org/cgi/content/abstract/27/15S/8553

DMFWE9S	DI	DMFWE9S
DMFWE9S	DN	Mobocertinib
DMFWE9S	MI	TT2M7YX
DMFWE9S	MN	EGFR Exon20ins mutant (EGFR Exon20ins)
DMFWE9S	MT	DTT
DMFWE9S	MA	Inhibitor
DMFWE9S	RN	Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer. Cancer Discov. 2021 Feb 25;candisc.1683.2020.
DMFWE9S	RU	https://pubmed.ncbi.nlm.nih.gov/33632773

DM2TNJ1	DI	DM2TNJ1
DM2TNJ1	DN	Molgramostim
DM2TNJ1	MI	TT6MP2Z
DM2TNJ1	MN	GMCSFR-alpha (CSF2RA)
DM2TNJ1	MT	DTT
DM2TNJ1	MA	Agonist
DM2TNJ1	RN	Clinical pipeline report, company report or official report of gensci-china.
DM2TNJ1	RU	http://www.gensci-china.com/gensci/cp1_somatropinAQ.asp?MaxID=3

DMF98Q0	DI	DMF98Q0
DMF98Q0	DN	Momelotinib
DMF98Q0	MI	DEJGDUW
DMF98Q0	MN	Cytochrome P450 1A2 (CYP1A2)
DMF98Q0	MT	DME
DMF98Q0	MA	Metabolism
DMF98Q0	RN	Pharmacokinetics and disposition of momelotinib revealed a disproportionate human metabolite-resolution for clinical development. Drug Metab Dispos. 2018 Mar;46(3):237-247.
DMF98Q0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29311136

DMF98Q0	DI	DMF98Q0
DMF98Q0	DN	Momelotinib
DMF98Q0	MI	DES5XRU
DMF98Q0	MN	Cytochrome P450 2C8 (CYP2C8)
DMF98Q0	MT	DME
DMF98Q0	MA	Metabolism
DMF98Q0	RN	Pharmacokinetics and disposition of momelotinib revealed a disproportionate human metabolite-resolution for clinical development. Drug Metab Dispos. 2018 Mar;46(3):237-247.
DMF98Q0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29311136

DMF98Q0	DI	DMF98Q0
DMF98Q0	DN	Momelotinib
DMF98Q0	MI	DE5IED8
DMF98Q0	MN	Cytochrome P450 2C9 (CYP2C9)
DMF98Q0	MT	DME
DMF98Q0	MA	Metabolism
DMF98Q0	RN	Pharmacokinetics and disposition of momelotinib revealed a disproportionate human metabolite-resolution for clinical development. Drug Metab Dispos. 2018 Mar;46(3):237-247.
DMF98Q0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29311136

DMF98Q0	DI	DMF98Q0
DMF98Q0	DN	Momelotinib
DMF98Q0	MI	DE4LYSA
DMF98Q0	MN	Cytochrome P450 3A4 (CYP3A4)
DMF98Q0	MT	DME
DMF98Q0	MA	Metabolism
DMF98Q0	RN	Pharmacokinetics and disposition of momelotinib revealed a disproportionate human metabolite-resolution for clinical development. Drug Metab Dispos. 2018 Mar;46(3):237-247.
DMF98Q0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29311136

DMF98Q0	DI	DMF98Q0
DMF98Q0	DN	Momelotinib
DMF98Q0	MI	TTRMX3V
DMF98Q0	MN	Janus kinase 2 (JAK-2)
DMF98Q0	MT	DTT
DMF98Q0	MA	Modulator
DMF98Q0	RN	Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis.Leukemia.2015 Mar;29(3):741-4.
DMF98Q0	RU	https://www.ncbi.nlm.nih.gov/pubmed/25322686

DMF98Q0	DI	DMF98Q0
DMF98Q0	DN	Momelotinib
DMF98Q0	MI	DEGTFWK
DMF98Q0	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMF98Q0	MT	DME
DMF98Q0	MA	Metabolism
DMF98Q0	RN	Pharmacokinetics and disposition of momelotinib revealed a disproportionate human metabolite-resolution for clinical development. Drug Metab Dispos. 2018 Mar;46(3):237-247.
DMF98Q0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29311136

DMQ1FU8	DI	DMQ1FU8
DMQ1FU8	DN	Montelukast
DMQ1FU8	MI	TTSB6CA
DMQ1FU8	MN	HUMAN cysteinyl leukotriene receptor (CysLTR)
DMQ1FU8	MT	DTT
DMQ1FU8	MA	Antagonist
DMQ1FU8	RN	As a potential treatment of COVID-19: Montelukast. Med Hypotheses. 2020 May 11;142:109828.
DMQ1FU8	RU	https://pubmed.ncbi.nlm.nih.gov/32416408

DMPVW6H	DI	DMPVW6H
DMPVW6H	DN	Morphine-6-glucuronide
DMPVW6H	MI	TTKWM86
DMPVW6H	MN	Opioid receptor mu (MOP)
DMPVW6H	MT	DTT
DMPVW6H	MA	Agonist
DMPVW6H	RN	Emerging analgesics in cancer pain management. Expert Opin Emerg Drugs. 2005 Feb;10(1):151-71.
DMPVW6H	RU	https://pubmed.ncbi.nlm.nih.gov/15757410

DMPVW6H	DI	DMPVW6H
DMPVW6H	DN	Morphine-6-glucuronide
DMPVW6H	MI	DTUGYRD
DMPVW6H	MN	P-glycoprotein 1 (ABCB1)
DMPVW6H	MT	DTP
DMPVW6H	MA	Substrate
DMPVW6H	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMPVW6H	RU	https://doi.org/10.1007/s11095-012-0935-x

DM15ZIB	DI	DM15ZIB
DM15ZIB	DN	Mosunetuzumab
DM15ZIB	MI	TTUE541
DM15ZIB	MN	Leukocyte surface antigen Leu-16 (CD20)
DM15ZIB	MT	DTT
DM15ZIB	MA	Inhibitor
DM15ZIB	RN	Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
DM15ZIB	RU	https://pubmed.ncbi.nlm.nih.gov/32859946

DM15ZIB	DI	DM15ZIB
DM15ZIB	DN	Mosunetuzumab
DM15ZIB	MI	TTUN7MC
DM15ZIB	MN	T-cell surface glycoprotein CD3 (CD3)
DM15ZIB	MT	DTT
DM15ZIB	MA	Inhibitor
DM15ZIB	RN	Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
DM15ZIB	RU	https://pubmed.ncbi.nlm.nih.gov/32859946

DMB24H7	DI	DMB24H7
DMB24H7	DN	Motavizumab
DMB24H7	MI	TT57ID8
DMB24H7	MN	Respiratory syncytial virus protein F (RSV F)
DMB24H7	MT	DTT
DMB24H7	MA	Modulator
DMB24H7	RN	Motavizumab. Correction in: MAbs. 2010 Sep-Oct; 2(5): 591.
DMB24H7	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2759493/

DM8K5Z6	DI	DM8K5Z6
DM8K5Z6	DN	Motexafin lutetium
DM8K5Z6	MI	TTS78AZ
DM8K5Z6	MN	Prostate specific antigen (KLK3)
DM8K5Z6	MT	DTT
DM8K5Z6	MA	Modulator
DM8K5Z6	RN	Motexafin lutetium-photodynamic therapy of prostate cancer: short- and long-term effects on prostate-specific antigen. Clin Cancer Res. 2008 Aug 1;14(15):4869-76.
DM8K5Z6	RU	https://pubmed.ncbi.nlm.nih.gov/18676760

DM9K3LM	DI	DM9K3LM
DM9K3LM	DN	MPDL-3280A
DM9K3LM	MI	TT8ZLTI
DM9K3LM	MN	Programmed cell death 1 ligand 1 (PD-L1)
DM9K3LM	MT	DTT
DM9K3LM	MA	Modulator
DM9K3LM	RN	Targeted immunotherapy for non-small cell lung cancer. World J Clin Oncol. 2014 May 10; 5(2): 39-47.
DM9K3LM	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4014795/

DMNDCFY	DI	DMNDCFY
DMNDCFY	DN	MPL-S
DMNDCFY	MI	TTF10I9
DMNDCFY	MN	Nitric-oxide synthase inducible (NOS2)
DMNDCFY	MT	DTT
DMNDCFY	MA	Modulator
DMNDCFY	RN	Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages. Infect Immun. 1997 Aug;65(8):3239-47.
DMNDCFY	RU	https://pubmed.ncbi.nlm.nih.gov/9234781

DMDV4EP	DI	DMDV4EP
DMDV4EP	DN	MRTX849
DMDV4EP	MI	TT3LH46
DMDV4EP	MN	KRAS G12C mutant (KRAS G12C)
DMDV4EP	MT	DTT
DMDV4EP	MA	Inhibitor
DMDV4EP	RN	Clinical pipeline report, company report or official report of Mirati Therapeutics.
DMDV4EP	RU	https://www.mirati.com/science/pipeline/

DMUNBMA	DI	DMUNBMA
DMUNBMA	DN	MT-1621
DMUNBMA	MI	TT7KNZQ
DMUNBMA	MN	Thymidine kinase 2 (Mt-TK2)
DMUNBMA	MT	DTT
DMUNBMA	MA	Replacement
DMUNBMA	RN	Clinical pipeline report, company report or official report of Modis Therapeutics.
DMUNBMA	RU	https://www.modistx.com/product/

DMZPEHY	DI	DMZPEHY
DMZPEHY	DN	Multi-epitope peptide melanoma vaccine
DMZPEHY	MI	TT362RB
DMZPEHY	MN	MART-1 melanoma antigen (MLANA)
DMZPEHY	MT	DTT
DMZPEHY	RN	Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in-adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. Correction in: volume 35 on page 650.
DMZPEHY	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3483091/

DMZPEHY	DI	DMZPEHY
DMZPEHY	DN	Multi-epitope peptide melanoma vaccine
DMZPEHY	MI	TT8MK59
DMZPEHY	MN	Melanocytes lineage-specific antigen GP100 (PMEL)
DMZPEHY	MT	DTT
DMZPEHY	RN	Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in-adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. Correction in: volume 35 on page 650.
DMZPEHY	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3483091/

DMZPEHY	DI	DMZPEHY
DMZPEHY	DN	Multi-epitope peptide melanoma vaccine
DMZPEHY	MI	TTULVH8
DMZPEHY	MN	Tyrosinase (TYR)
DMZPEHY	MT	DTT
DMZPEHY	RN	Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in-adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. Correction in: volume 35 on page 650.
DMZPEHY	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3483091/

DMG3NFZ	DI	DMG3NFZ
DMG3NFZ	DN	Muraglitazar
DMG3NFZ	MI	DES5XRU
DMG3NFZ	MN	Cytochrome P450 2C8 (CYP2C8)
DMG3NFZ	MT	DME
DMG3NFZ	MA	Metabolism
DMG3NFZ	RN	Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar. Drug Metab Dispos. 2007 Jan;35(1):139-49.
DMG3NFZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17062778

DMG3NFZ	DI	DMG3NFZ
DMG3NFZ	DN	Muraglitazar
DMG3NFZ	MI	DE5IED8
DMG3NFZ	MN	Cytochrome P450 2C9 (CYP2C9)
DMG3NFZ	MT	DME
DMG3NFZ	MA	Metabolism
DMG3NFZ	RN	Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar. Drug Metab Dispos. 2007 Jan;35(1):139-49.
DMG3NFZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17062778

DMG3NFZ	DI	DMG3NFZ
DMG3NFZ	DN	Muraglitazar
DMG3NFZ	MI	DECB0K3
DMG3NFZ	MN	Cytochrome P450 2D6 (CYP2D6)
DMG3NFZ	MT	DME
DMG3NFZ	MA	Metabolism
DMG3NFZ	RN	Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar. Drug Metab Dispos. 2007 Jan;35(1):139-49.
DMG3NFZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17062778

DMG3NFZ	DI	DMG3NFZ
DMG3NFZ	DN	Muraglitazar
DMG3NFZ	MI	DE4LYSA
DMG3NFZ	MN	Cytochrome P450 3A4 (CYP3A4)
DMG3NFZ	MT	DME
DMG3NFZ	MA	Metabolism
DMG3NFZ	RN	Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar. Drug Metab Dispos. 2007 Jan;35(1):139-49.
DMG3NFZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17062778

DMG3NFZ	DI	DMG3NFZ
DMG3NFZ	DN	Muraglitazar
DMG3NFZ	MI	DEGTFWK
DMG3NFZ	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMG3NFZ	MT	DME
DMG3NFZ	MA	Metabolism
DMG3NFZ	RN	Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar. Drug Metab Dispos. 2007 Jan;35(1):139-49.
DMG3NFZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17062778

DMG3NFZ	DI	DMG3NFZ
DMG3NFZ	DN	Muraglitazar
DMG3NFZ	MI	TTJ584C
DMG3NFZ	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMG3NFZ	MT	DTT
DMG3NFZ	MA	Modulator
DMG3NFZ	RN	Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with... Clin Ther. 2005 Aug;27(8):1181-95.
DMG3NFZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/16199244

DMG3NFZ	DI	DMG3NFZ
DMG3NFZ	DN	Muraglitazar
DMG3NFZ	MI	TTZMAO3
DMG3NFZ	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMG3NFZ	MT	DTT
DMG3NFZ	MA	Modulator
DMG3NFZ	RN	Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with... Clin Ther. 2005 Aug;27(8):1181-95.
DMG3NFZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/16199244

DMG3NFZ	DI	DMG3NFZ
DMG3NFZ	DN	Muraglitazar
DMG3NFZ	MI	DEYGVN4
DMG3NFZ	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMG3NFZ	MT	DME
DMG3NFZ	MA	Metabolism
DMG3NFZ	RN	Characterization of the UDP glucuronosyltransferase activity of human liver microsomes genotyped for the UGT1A1*28 polymorphism. Drug Metab Dispos. 2007 Dec;35(12):2270-80.
DMG3NFZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17898154

DMG3NFZ	DI	DMG3NFZ
DMG3NFZ	DN	Muraglitazar
DMG3NFZ	MI	DEF2WXN
DMG3NFZ	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMG3NFZ	MT	DME
DMG3NFZ	MA	Metabolism
DMG3NFZ	RN	Characterization of the UDP glucuronosyltransferase activity of human liver microsomes genotyped for the UGT1A1*28 polymorphism. Drug Metab Dispos. 2007 Dec;35(12):2270-80.
DMG3NFZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17898154

DMG3NFZ	DI	DMG3NFZ
DMG3NFZ	DN	Muraglitazar
DMG3NFZ	MI	DE85D2P
DMG3NFZ	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMG3NFZ	MT	DME
DMG3NFZ	MA	Metabolism
DMG3NFZ	RN	Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar. Drug Metab Dispos. 2007 Jan;35(1):139-49.
DMG3NFZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17062778

DMUQ390	DI	DMUQ390
DMUQ390	DN	Murepavadin
DMUQ390	MI	TTJZ7GF
DMUQ390	MN	Pseudomonas LPS-assembly protein LptD (Pseudo lptD)
DMUQ390	MT	DTT
DMUQ390	MA	Antagonist
DMUQ390	RN	Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612.
DMUQ390	RU	https://pubmed.ncbi.nlm.nih.gov/30072728

DMS9GE1	DI	DMS9GE1
DMS9GE1	DN	MyoCell SDF-1
DMS9GE1	MI	TT4UGTF
DMS9GE1	MN	Stromal cell-derived factor 1 (CXCL12)
DMS9GE1	MT	DTT
DMS9GE1	MA	Modulator
DMS9GE1	RN	Stromal cell-derived factor-1 (SDF-1): homing factor for engineered regenerative medicine. Expert Opin Biol Ther. 2011 Feb;11(2):189-97.
DMS9GE1	RU	https://pubmed.ncbi.nlm.nih.gov/21219236

DMY60DT	DI	DMY60DT
DMY60DT	DN	N8-GP
DMY60DT	MI	TT1290U
DMY60DT	MN	Coagulation factor VIII (F8)
DMY60DT	MT	DTT
DMY60DT	MA	Modulator
DMY60DT	RN	Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost. 2013 Apr;11(4):670-8.
DMY60DT	RU	https://pubmed.ncbi.nlm.nih.gov/23398640

DMHKJ5I	DI	DMHKJ5I
DMHKJ5I	DN	Nabiximols
DMHKJ5I	MI	DE5IED8
DMHKJ5I	MN	Cytochrome P450 2C9 (CYP2C9)
DMHKJ5I	MT	DME
DMHKJ5I	MA	Metabolism
DMHKJ5I	RN	Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015 Oct;12(4):699-730.
DMHKJ5I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26264914

DMHKJ5I	DI	DMHKJ5I
DMHKJ5I	DN	Nabiximols
DMHKJ5I	MI	DECB0K3
DMHKJ5I	MN	Cytochrome P450 2D6 (CYP2D6)
DMHKJ5I	MT	DME
DMHKJ5I	MA	Metabolism
DMHKJ5I	RN	Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014 Feb;46(1):86-95.
DMHKJ5I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24160757

DMHKJ5I	DI	DMHKJ5I
DMHKJ5I	DN	Nabiximols
DMHKJ5I	MI	DE4LYSA
DMHKJ5I	MN	Cytochrome P450 3A4 (CYP3A4)
DMHKJ5I	MT	DME
DMHKJ5I	MA	Metabolism
DMHKJ5I	RN	Pharmacokinetic evaluation of nabiximols for the treatment of multiple sclerosis pain. Expert Opin Drug Metab Toxicol. 2013 Sep;9(9):1219-28.
DMHKJ5I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23621668

DMHKJ5I	DI	DMHKJ5I
DMHKJ5I	DN	Nabiximols
DMHKJ5I	MI	DEIBDNY
DMHKJ5I	MN	Cytochrome P450 3A5 (CYP3A5)
DMHKJ5I	MT	DME
DMHKJ5I	MA	Metabolism
DMHKJ5I	RN	Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014 Feb;46(1):86-95.
DMHKJ5I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24160757

DMHKJ5I	DI	DMHKJ5I
DMHKJ5I	DN	Nabiximols
DMHKJ5I	MI	DEGTFWK
DMHKJ5I	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMHKJ5I	MT	DME
DMHKJ5I	MA	Metabolism
DMHKJ5I	RN	Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015 Oct;12(4):699-730.
DMHKJ5I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26264914

DMDZ6Q3	DI	DMDZ6Q3
DMDZ6Q3	DN	Napabucasin
DMDZ6Q3	MI	TTH8FZW
DMDZ6Q3	MN	Signal transducer and activator of transcription 3 (STAT3)
DMDZ6Q3	MT	DTT
DMDZ6Q3	MA	Inhibitor
DMDZ6Q3	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMDZ6Q3	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMKP45D	DI	DMKP45D
DMKP45D	DN	Naproxcinod
DMKP45D	MI	TTK0943
DMKP45D	MN	Prostaglandin G/H synthase (COX)
DMKP45D	MT	DTT
DMKP45D	MA	Modulator
DMKP45D	RN	Naproxcinod, a new cyclooxygenase-inhibiting nitric oxide donator (CINOD). Expert Opin Biol Ther. 2009 May;9(5):649-57.
DMKP45D	RU	https://pubmed.ncbi.nlm.nih.gov/19392579

DMIC56X	DI	DMIC56X
DMIC56X	DN	NASVAC
DMIC56X	MI	TT6KSF7
DMIC56X	MN	Hepatitis B virus Large envelope protein (HBV S)
DMIC56X	MT	DTT
DMIC56X	RN	In vitro stimulation with HBV therapeutic vaccine candidate Nasvac activates B and T cells from chronic hepatitis B patients and healthy donors. Mol Immunol. 2015 Feb;63(2):320-7.
DMIC56X	RU	https://pubmed.ncbi.nlm.nih.gov/25193323

DMIC56X	DI	DMIC56X
DMIC56X	DN	NASVAC
DMIC56X	MI	TTRF7Q8
DMIC56X	MN	Natural killer cell receptor (NKCR)
DMIC56X	MT	DTT
DMIC56X	RN	In vitro stimulation with HBV therapeutic vaccine candidate Nasvac activates B and T cells from chronic hepatitis B patients and healthy donors. Mol Immunol. 2015 Feb;63(2):320-7.
DMIC56X	RU	https://pubmed.ncbi.nlm.nih.gov/25193323

DMRSI1M	DI	DMRSI1M
DMRSI1M	DN	NAV5001
DMRSI1M	MI	TTVBI8W
DMRSI1M	MN	Dopamine transporter (DAT)
DMRSI1M	MT	DTT
DMRSI1M	MA	Modulator
DMRSI1M	RN	Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse. 1998 Jun;29(2):128-41.
DMRSI1M	RU	https://pubmed.ncbi.nlm.nih.gov/9593103

DMVO1C0	DI	DMVO1C0
DMVO1C0	DN	NBI-98854
DMVO1C0	MI	DECB0K3
DMVO1C0	MN	Cytochrome P450 2D6 (CYP2D6)
DMVO1C0	MT	DME
DMVO1C0	MA	Metabolism
DMVO1C0	RN	Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective. Expert Rev Neurother. 2018 Apr;18(4):323-332.
DMVO1C0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29557243

DMVO1C0	DI	DMVO1C0
DMVO1C0	DN	NBI-98854
DMVO1C0	MI	TTNZRI3
DMVO1C0	MN	Synaptic vesicle amine transporter (SLC18A2)
DMVO1C0	MT	DTT
DMVO1C0	MA	Inhibitor
DMVO1C0	RN	NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study. Mov Disord. 2015 Oct;30(12):1681-7.
DMVO1C0	RU	https://pubmed.ncbi.nlm.nih.gov/26346941

DMFD249	DI	DMFD249
DMFD249	DN	Nebracetam
DMFD249	MI	TTZ9SOR
DMFD249	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMFD249	MT	DTT
DMFD249	MA	Agonist
DMFD249	RN	Effects of nebracetam (WEB 1881 FU), a novel nootropic, as a M1-muscarinic agonist. Jpn J Pharmacol. 1991 Jan;55(1):177-80.
DMFD249	RU	https://pubmed.ncbi.nlm.nih.gov/2041225

DMDBY30	DI	DMDBY30
DMDBY30	DN	Nelipepimut S
DMDBY30	MI	TT6EO5L
DMDBY30	MN	Erbb2 tyrosine kinase receptor (HER2)
DMDBY30	MT	DTT
DMDBY30	MA	Inhibitor
DMDBY30	RN	The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response. Immunotherapy. 2014;6(5):519-31.
DMDBY30	RU	https://pubmed.ncbi.nlm.nih.gov/24896623

DMH9EUA	DI	DMH9EUA
DMH9EUA	DN	Nemolizumab
DMH9EUA	MI	TT9HPX0
DMH9EUA	MN	Interleukin 31 receptor (IL31R)
DMH9EUA	MT	DTT
DMH9EUA	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMH9EUA	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMIPNBG	DI	DMIPNBG
DMIPNBG	DN	Nemonaxacin
DMIPNBG	MI	TTIXTO3
DMIPNBG	MN	Staphylococcus Topoisomerase IV (Stap-coc parC)
DMIPNBG	MT	DTT
DMIPNBG	MA	Modulator
DMIPNBG	RN	In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.J Antimicrob Chemother.2009 Dec;64(6):1226-9.
DMIPNBG	RU	https://www.ncbi.nlm.nih.gov/pubmed/19833635

DMVP7HI	DI	DMVP7HI
DMVP7HI	DN	Nestorone
DMVP7HI	MI	TTUV8G9
DMVP7HI	MN	Progesterone receptor (PGR)
DMVP7HI	MT	DTT
DMVP7HI	MA	Agonist
DMVP7HI	RN	Efficacy of the selective progesterone receptor agonist Nestorone for chronic experimental autoimmune encephalomyelitis. J Neuroimmunol. 2014 Nov 15;276(1-2):89-97.
DMVP7HI	RU	https://pubmed.ncbi.nlm.nih.gov/25200475

DMTKRY1	DI	DMTKRY1
DMTKRY1	DN	Netivudine
DMTKRY1	MI	TTIU7X1
DMTKRY1	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMTKRY1	MT	DTT
DMTKRY1	MA	Modulator
DMTKRY1	RN	Current pharmacological approaches to the therapy of varicella zoster virus infections: a guide to treatment. Drugs. 1999 Feb;57(2):187-206.
DMTKRY1	RU	https://pubmed.ncbi.nlm.nih.gov/10188760

DMEKAYI	DI	DMEKAYI
DMEKAYI	DN	Netupitant
DMEKAYI	MI	DE5IED8
DMEKAYI	MN	Cytochrome P450 2C9 (CYP2C9)
DMEKAYI	MT	DME
DMEKAYI	MA	Metabolism
DMEKAYI	RN	Effect of netupitant, a highly selective NK?receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives. Support Care Cancer. 2013 Oct;21(10):2879-87.
DMEKAYI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23748441

DMEKAYI	DI	DMEKAYI
DMEKAYI	DN	Netupitant
DMEKAYI	MI	DECB0K3
DMEKAYI	MN	Cytochrome P450 2D6 (CYP2D6)
DMEKAYI	MT	DME
DMEKAYI	MA	Metabolism
DMEKAYI	RN	Effect of netupitant, a highly selective NK?receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives. Support Care Cancer. 2013 Oct;21(10):2879-87.
DMEKAYI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23748441

DMEKAYI	DI	DMEKAYI
DMEKAYI	DN	Netupitant
DMEKAYI	MI	DE4LYSA
DMEKAYI	MN	Cytochrome P450 3A4 (CYP3A4)
DMEKAYI	MT	DME
DMEKAYI	MA	Metabolism
DMEKAYI	RN	Complementary pharmacokinetic profiles of netupitant and palonosetron support the rationale for their oral fixed combination for the prevention of chemotherapy-induced nausea and vomiting. J Clin Pharmacol. 2019 Apr;59(4):472-487.
DMEKAYI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30412271

DMEKAYI	DI	DMEKAYI
DMEKAYI	DN	Netupitant
DMEKAYI	MI	TTZPO1L
DMEKAYI	MN	Substance-P receptor (TACR1)
DMEKAYI	MT	DTT
DMEKAYI	MA	Antagonist
DMEKAYI	RN	Netupitant and palonosetron trigger NK1 receptor internalization in NG108-15 cells. Exp Brain Res. 2014 Aug;232(8):2637-44.
DMEKAYI	RU	https://pubmed.ncbi.nlm.nih.gov/24969614

DME617W	DI	DME617W
DME617W	DN	Neucardin
DME617W	MI	TTEH395
DME617W	MN	Pro-neuregulin-1 (Pro-NRG1)
DME617W	MT	DTT
DME617W	MA	Modulator
DME617W	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DME617W	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMYTC4I	DI	DMYTC4I
DMYTC4I	DN	NeuVax
DMYTC4I	MI	TT6EO5L
DMYTC4I	MN	Erbb2 tyrosine kinase receptor (HER2)
DMYTC4I	MT	DTT
DMYTC4I	RN	The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response. Immunotherapy. 2014;6(5):519-31.
DMYTC4I	RU	https://pubmed.ncbi.nlm.nih.gov/24896623

DMJ2KIE	DI	DMJ2KIE
DMJ2KIE	DN	NI-101
DMJ2KIE	MI	TTE4KHA
DMJ2KIE	MN	Amyloid beta A4 protein (APP)
DMJ2KIE	MT	DTT
DMJ2KIE	RN	Disease-modifying drugs in Alzheimer's disease. Drug Des Devel Ther. 2013; 7: 1471-1479.
DMJ2KIE	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3862506/

DMFBNA3	DI	DMFBNA3
DMFBNA3	DN	Nicaraven
DMFBNA3	MI	TTVDSZ0
DMFBNA3	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMFBNA3	MT	DTT
DMFBNA3	MA	Modulator
DMFBNA3	RN	Inhibition of poly (ADP-ribose) polymerase as a protective effect of nicaraven in ionizing radiation- and ara-C-induced cell death. Anticancer Res. 2006 Sep-Oct;26(5A):3421-7.
DMFBNA3	RU	https://pubmed.ncbi.nlm.nih.gov/17094462

DM376WT	DI	DM376WT
DM376WT	DN	NKTR 214
DM376WT	MI	TT9721Y
DM376WT	MN	Interleukin 2 receptor beta (IL2RB)
DM376WT	MT	DTT
DM376WT	MA	Agonist
DM376WT	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM376WT	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM45DS8	DI	DM45DS8
DM45DS8	DN	NKTR-181
DM45DS8	MI	TTKWM86
DM45DS8	MN	Opioid receptor mu (MOP)
DM45DS8	MT	DTT
DM45DS8	MA	Agonist
DM45DS8	RN	A Review of Abuse-Deterrent Opioids For Chronic Nonmalignant Pain. P T. 2012 July; 37(7): 412-418.
DM45DS8	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411218/

DMACYW6	DI	DMACYW6
DMACYW6	DN	NKTR-214
DMACYW6	MI	TT9721Y
DMACYW6	MN	Interleukin 2 receptor beta (IL2RB)
DMACYW6	MT	DTT
DMACYW6	MA	Agonist
DMACYW6	RN	Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. Nat Commun. 2020 Jan 31;11(1):661.
DMACYW6	RU	https://pubmed.ncbi.nlm.nih.gov/32005826

DMDJLY9	DI	DMDJLY9
DMDJLY9	DN	NM-702
DMDJLY9	MI	TTUST1O
DMDJLY9	MN	Phosphodiesterase (PDE)
DMDJLY9	MT	DTT
DMDJLY9	MA	Inhibitor
DMDJLY9	RN	The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J Am Coll Cardiol. 2006 Dec 19;48(12):2539-45.
DMDJLY9	RU	https://pubmed.ncbi.nlm.nih.gov/17174195

DMDJLY9	DI	DMDJLY9
DMDJLY9	DN	NM-702
DMDJLY9	MI	TTKNWZ4
DMDJLY9	MN	Thromboxane-A synthase (TBXAS1)
DMDJLY9	MT	DTT
DMDJLY9	MA	Inhibitor
DMDJLY9	RN	The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J Am Coll Cardiol. 2006 Dec 19;48(12):2539-45.
DMDJLY9	RU	https://pubmed.ncbi.nlm.nih.gov/17174195

DMDGK83	DI	DMDGK83
DMDGK83	DN	NN1841
DMDGK83	MI	TTAXGIP
DMDGK83	MN	Coagulation factor XIII (F13B)
DMDGK83	MT	DTT
DMDGK83	MA	Modulator
DMDGK83	RN	Catridecacog: a breakthrough in the treatment of congenital factor XIII A-subunit deficiency. J Blood Med. 2014 Jul 9;5:107-13.
DMDGK83	RU	https://pubmed.ncbi.nlm.nih.gov/25031548

DM0QV27	DI	DM0QV27
DM0QV27	DN	NN5401
DM0QV27	MI	TTCBFJO
DM0QV27	MN	Insulin receptor (INSR)
DM0QV27	MT	DTT
DM0QV27	MA	Modulator
DM0QV27	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800).
DM0QV27	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800

DM1PI9G	DI	DM1PI9G
DM1PI9G	DN	NN8717
DM1PI9G	MI	TTAXGIP
DM1PI9G	MN	Coagulation factor XIII (F13B)
DM1PI9G	MT	DTT
DM1PI9G	MA	Modulator
DM1PI9G	RN	Topical recombinant thrombin at a concentration of 1000 IU/mL reliably shortens in vivo TTH and delivers durable hemostasis in the presence of heparin anticoagulation and clopidogrel platelet inhibition in a rabbit model of vascular bleeding. Ann Surg Innov Res. 2009; 3: 14.
DM1PI9G	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2786906/

DMOF0CA	DI	DMOF0CA
DMOF0CA	DN	Nolatrexed
DMOF0CA	MI	DTI7UX6
DMOF0CA	MN	Breast cancer resistance protein (ABCG2)
DMOF0CA	MT	DTP
DMOF0CA	MA	Substrate
DMOF0CA	RN	Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34.
DMOF0CA	RU	https://doi.org/10.1007/s00280-006-0230-9

DMOF0CA	DI	DMOF0CA
DMOF0CA	DN	Nolatrexed
DMOF0CA	MI	TTU6BFZ
DMOF0CA	MN	Candida Thymidylate synthase (Candi TMP1)
DMOF0CA	MT	DTT
DMOF0CA	MA	Inhibitor
DMOF0CA	RN	A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administration. Br J Cancer. 1999 Feb;79(5-6):915-20.
DMOF0CA	RU	https://pubmed.ncbi.nlm.nih.gov/10070890

DMMC3Y8	DI	DMMC3Y8
DMMC3Y8	DN	NPC-01
DMMC3Y8	MI	TTZAYWL
DMMC3Y8	MN	Estrogen receptor (ESR)
DMMC3Y8	MT	DTT
DMMC3Y8	MA	Modulator
DMMC3Y8	RN	ClinicalTrials.gov (NCT01246791) Pharmacokinetics of NPC-01 After Single Oral Administration in Healthy Female Volunteers. U.S. National Institutes of Health.
DMMC3Y8	RU	https://clinicaltrials.gov/ct2/show/NCT01246791

DMMC3Y8	DI	DMMC3Y8
DMMC3Y8	DN	NPC-01
DMMC3Y8	MI	TTUV8G9
DMMC3Y8	MN	Progesterone receptor (PGR)
DMMC3Y8	MT	DTT
DMMC3Y8	MA	Agonist
DMMC3Y8	RN	ClinicalTrials.gov (NCT01246791) Pharmacokinetics of NPC-01 After Single Oral Administration in Healthy Female Volunteers. U.S. National Institutes of Health.
DMMC3Y8	RU	https://clinicaltrials.gov/ct2/show/NCT01246791

DMCMIJ1	DI	DMCMIJ1
DMCMIJ1	DN	NT0202
DMCMIJ1	MI	TTIU98M
DMCMIJ1	MN	Trace amine-associated receptor-1 (TAAR1)
DMCMIJ1	MT	DTT
DMCMIJ1	MA	Agonist
DMCMIJ1	RN	Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes. Neuropharmacology. 2014 Oct;85:499-507.
DMCMIJ1	RU	https://pubmed.ncbi.nlm.nih.gov/24950453

DMA16IL	DI	DMA16IL
DMA16IL	DN	NU-100
DMA16IL	MI	TT4TZ8J
DMA16IL	MN	Interferon-beta (IFNB1)
DMA16IL	MT	DTT
DMA16IL	MA	Modulator
DMA16IL	RN	PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update. Biologics. 2013; 7: 131-138.
DMA16IL	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686537/

DM8JWNA	DI	DM8JWNA
DM8JWNA	DN	NVP-LAQ824
DM8JWNA	MI	TTBH0VX
DM8JWNA	MN	Histone deacetylase (HDAC)
DM8JWNA	MT	DTT
DM8JWNA	MA	Inhibitor
DM8JWNA	RN	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
DM8JWNA	RU	https://pubmed.ncbi.nlm.nih.gov/19249983

DM8JWNA	DI	DM8JWNA
DM8JWNA	DN	NVP-LAQ824
DM8JWNA	MI	TT6R7JZ
DM8JWNA	MN	Histone deacetylase 1 (HDAC1)
DM8JWNA	MT	DTT
DM8JWNA	MA	Inhibitor
DM8JWNA	RN	NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 1;102(7):2615-22.
DM8JWNA	RU	https://pubmed.ncbi.nlm.nih.gov/12816865

DM3L2GT	DI	DM3L2GT
DM3L2GT	DN	O6-Benzylguanine alkylade
DM3L2GT	MI	TTJ8DV7
DM3L2GT	MN	O-6-methylguanine-DNA-alkyltransferase (MGMT)
DM3L2GT	MT	DTT
DM3L2GT	MA	Modulator
DM3L2GT	RN	Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol. 2009 Mar 10;27(8):1262-7.
DM3L2GT	RU	https://pubmed.ncbi.nlm.nih.gov/19204199

DMENDP6	DI	DMENDP6
DMENDP6	DN	OBI-1
DMENDP6	MI	TT1290U
DMENDP6	MN	Coagulation factor VIII (F8)
DMENDP6	MT	DTT
DMENDP6	MA	Modulator
DMENDP6	RN	Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. Haemophilia. 2015 Mar;21(2):162-70.
DMENDP6	RU	https://pubmed.ncbi.nlm.nih.gov/25623166

DM7KI4E	DI	DM7KI4E
DM7KI4E	DN	Oblimersen
DM7KI4E	MI	TTJGNVC
DM7KI4E	MN	Apoptosis regulator Bcl-2 (BCL-2)
DM7KI4E	MT	DTT
DM7KI4E	MA	Inhibitor
DM7KI4E	RN	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
DM7KI4E	RU	https://pubmed.ncbi.nlm.nih.gov/19249983

DMEDSVJ	DI	DMEDSVJ
DMEDSVJ	DN	Ociperlimab
DMEDSVJ	MI	TTWNL74
DMEDSVJ	MN	V-set and immunoglobulin domain-containing protein 9 (TIGIT)
DMEDSVJ	MT	DTT
DMEDSVJ	MA	Inhibitor
DMEDSVJ	RN	Clinical pipeline report, company report or official report of BeiGene.
DMEDSVJ	RU	https://www.beigene.com/science-and-product-portfolio/pipeline/ociperlimab

DM1EO3G	DI	DM1EO3G
DM1EO3G	DN	Odanacatib
DM1EO3G	MI	TTDZN01
DM1EO3G	MN	Cathepsin K (CTSK)
DM1EO3G	MT	DTT
DM1EO3G	MA	Inhibitor
DM1EO3G	RN	A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
DM1EO3G	RU	https://pubmed.ncbi.nlm.nih.gov/23467907

DM1EO3G	DI	DM1EO3G
DM1EO3G	DN	Odanacatib
DM1EO3G	MI	DES5XRU
DM1EO3G	MN	Cytochrome P450 2C8 (CYP2C8)
DM1EO3G	MT	DME
DM1EO3G	MA	Metabolism
DM1EO3G	RN	Disposition and metabolism of the cathepsin K inhibitor odanacatib in humans. Drug Metab Dispos. 2014 May;42(5):818-27.
DM1EO3G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24553380

DM1EO3G	DI	DM1EO3G
DM1EO3G	DN	Odanacatib
DM1EO3G	MI	DE4LYSA
DM1EO3G	MN	Cytochrome P450 3A4 (CYP3A4)
DM1EO3G	MT	DME
DM1EO3G	MA	Metabolism
DM1EO3G	RN	Disposition and metabolism of the cathepsin K inhibitor odanacatib in humans. Drug Metab Dispos. 2014 May;42(5):818-27.
DM1EO3G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24553380

DMYN391	DI	DMYN391
DMYN391	DN	Odevixibat
DMYN391	MI	TTPI1M5
DMYN391	MN	Ileal sodium/bile acid cotransporter (SLC10A2)
DMYN391	MT	DTT
DMYN391	MA	Inhibitor
DMYN391	RN	Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders. Hepatol Int. 2020 Sep;14(5):677-689.
DMYN391	RU	https://pubmed.ncbi.nlm.nih.gov/32653991

DMBWO5T	DI	DMBWO5T
DMBWO5T	DN	ODT-8
DMBWO5T	MI	TTIND6G
DMBWO5T	MN	Somatostatin receptor type 1 (SSTR1)
DMBWO5T	MT	DTT
DMBWO5T	MA	Inhibitor
DMBWO5T	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DMBWO5T	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DMBWO5T	DI	DMBWO5T
DMBWO5T	DN	ODT-8
DMBWO5T	MI	TTZ6T9E
DMBWO5T	MN	Somatostatin receptor type 2 (SSTR2)
DMBWO5T	MT	DTT
DMBWO5T	MA	Inhibitor
DMBWO5T	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DMBWO5T	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DMBWO5T	DI	DMBWO5T
DMBWO5T	DN	ODT-8
DMBWO5T	MI	TTJX3UE
DMBWO5T	MN	Somatostatin receptor type 3 (SSTR3)
DMBWO5T	MT	DTT
DMBWO5T	MA	Inhibitor
DMBWO5T	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DMBWO5T	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DMBWO5T	DI	DMBWO5T
DMBWO5T	DN	ODT-8
DMBWO5T	MI	TTAE1BR
DMBWO5T	MN	Somatostatin receptor type 4 (SSTR4)
DMBWO5T	MT	DTT
DMBWO5T	MA	Inhibitor
DMBWO5T	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DMBWO5T	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DMBWO5T	DI	DMBWO5T
DMBWO5T	DN	ODT-8
DMBWO5T	MI	TT2BC4G
DMBWO5T	MN	Somatostatin receptor type 5 (SSTR5)
DMBWO5T	MT	DTT
DMBWO5T	MA	Inhibitor
DMBWO5T	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DMBWO5T	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DM1FBZ7	DI	DM1FBZ7
DM1FBZ7	DN	Olodaterol/tiotropium bromide
DM1FBZ7	MI	DECB0K3
DM1FBZ7	MN	Cytochrome P450 2D6 (CYP2D6)
DM1FBZ7	MT	DME
DM1FBZ7	MA	Metabolism
DM1FBZ7	RN	Tiotropium rromide/olodaterol (Stiolto Respimat): once-daily combination therapy for the maintenance of COPD. P T. 2016 Feb;41(2):97-102.
DM1FBZ7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26908999

DM1FBZ7	DI	DM1FBZ7
DM1FBZ7	DN	Olodaterol/tiotropium bromide
DM1FBZ7	MI	DE4LYSA
DM1FBZ7	MN	Cytochrome P450 3A4 (CYP3A4)
DM1FBZ7	MT	DME
DM1FBZ7	MA	Metabolism
DM1FBZ7	RN	Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD. Treat Respir Med. 2004;3(4):247-68.
DM1FBZ7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15350163

DM4Z9QI	DI	DM4Z9QI
DM4Z9QI	DN	Olokizumab
DM4Z9QI	MI	TTT1V78
DM4Z9QI	MN	Interleukin-6 (IL6)
DM4Z9QI	MT	DTT
DM4Z9QI	MA	Modulator
DM4Z9QI	RN	Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Ann Rheum Dis. 2014 September; 73(9): 1607-1615.
DM4Z9QI	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145439/

DM624TW	DI	DM624TW
DM624TW	DN	Omecamtiv mecarbil
DM624TW	MI	TT9WOBN
DM624TW	MN	Cardiac myosin (MYBPC3)
DM624TW	MT	DTT
DM624TW	MA	Modulator
DM624TW	RN	CK-1827452, a sarcomere-directed cardiac myosin activator for acute and chronic heart disease. IDrugs. 2009 Apr;12(4):243-51.
DM624TW	RU	https://pubmed.ncbi.nlm.nih.gov/19350469

DMBWY8V	DI	DMBWY8V
DMBWY8V	DN	Omega-6-FA
DMBWY8V	MI	DE87OZS
DMBWY8V	MN	Arachidonate 5-lipoxygenase (ALOX5)
DMBWY8V	MT	DME
DMBWY8V	MA	Metabolism
DMBWY8V	RN	Health implications of high dietary omega-6 polyunsaturated Fatty acids. J Nutr Metab. 2012;2012:539426.
DMBWY8V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22570770

DMBWY8V	DI	DMBWY8V
DMBWY8V	DN	Omega-6-FA
DMBWY8V	MI	DE05S8C
DMBWY8V	MN	Fatty acid desaturase 1 (FADS1)
DMBWY8V	MT	DME
DMBWY8V	MA	Metabolism
DMBWY8V	RN	Health implications of high dietary omega-6 polyunsaturated Fatty acids. J Nutr Metab. 2012;2012:539426.
DMBWY8V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22570770

DMBWY8V	DI	DMBWY8V
DMBWY8V	DN	Omega-6-FA
DMBWY8V	MI	DEDI4B8
DMBWY8V	MN	Fatty acid desaturase 2 (FADS2)
DMBWY8V	MT	DME
DMBWY8V	MA	Metabolism
DMBWY8V	RN	Health implications of high dietary omega-6 polyunsaturated Fatty acids. J Nutr Metab. 2012;2012:539426.
DMBWY8V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22570770

DMBWY8V	DI	DMBWY8V
DMBWY8V	DN	Omega-6-FA
DMBWY8V	MI	DE492CE
DMBWY8V	MN	Prostaglandin G/H synthase 2 (COX-2)
DMBWY8V	MT	DME
DMBWY8V	MA	Metabolism
DMBWY8V	RN	Health implications of high dietary omega-6 polyunsaturated Fatty acids. J Nutr Metab. 2012;2012:539426.
DMBWY8V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22570770

DMK6QBZ	DI	DMK6QBZ
DMK6QBZ	DN	OMS721
DMK6QBZ	MI	TTR01E9
DMK6QBZ	MN	Mannan-binding lectin serine protease-2 (MASP2)
DMK6QBZ	MT	DTT
DMK6QBZ	MA	Inhibitor
DMK6QBZ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMK6QBZ	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMU86DM	DI	DMU86DM
DMU86DM	DN	ONO-1101
DMU86DM	MI	DECB0K3
DMU86DM	MN	Cytochrome P450 2D6 (CYP2D6)
DMU86DM	MT	DME
DMU86DM	MA	Metabolism
DMU86DM	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DMU86DM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DM06KRC	DI	DM06KRC
DM06KRC	DN	Oregovomab
DM06KRC	MI	TTC1PS3
DM06KRC	MN	Ovarian carcinoma antigen CA125 (MUC16)
DM06KRC	MT	DTT
DM06KRC	RN	MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer. 2014; 13: 129.
DM06KRC	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4046138/

DMWD3IV	DI	DMWD3IV
DMWD3IV	DN	Oseltamivir + hydroxychloroquine
DMWD3IV	MI	TTZGK1R
DMWD3IV	MN	HUMAN glycosylation of host receptor (GHR)
DMWD3IV	MT	DTT
DMWD3IV	MA	Inhibitor
DMWD3IV	RN	Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.
DMWD3IV	RU	https://pubmed.ncbi.nlm.nih.gov/32020029

DMWD3IV	DI	DMWD3IV
DMWD3IV	DN	Oseltamivir + hydroxychloroquine
DMWD3IV	MI	TTD16BI
DMWD3IV	MN	HUMAN pH-dependent viral fusion/replication (pH-DVF/R)
DMWD3IV	MT	DTT
DMWD3IV	MA	Inhibitor
DMWD3IV	RN	Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.
DMWD3IV	RU	https://pubmed.ncbi.nlm.nih.gov/32020029

DMWD3IV	DI	DMWD3IV
DMWD3IV	DN	Oseltamivir + hydroxychloroquine
DMWD3IV	MI	TT3A1EZ
DMWD3IV	MN	HUMAN toll-like receptor 7/9 signalling pathway (TLR7/9 pathway)
DMWD3IV	MT	DTT
DMWD3IV	MA	Inhibitor
DMWD3IV	RN	Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020 Mar;16(3):155-166.
DMWD3IV	RU	https://pubmed.ncbi.nlm.nih.gov/32034323

DMHKZLF	DI	DMHKZLF
DMHKZLF	DN	OSI-906
DMHKZLF	MI	TTHRID2
DMHKZLF	MN	Insulin-like growth factor I receptor (IGF1R)
DMHKZLF	MT	DTT
DMHKZLF	MA	Inhibitor
DMHKZLF	RN	Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family... Bioorg Med Chem Lett. 2010 Apr 15;20(8):2452-5.
DMHKZLF	RU	https://pubmed.ncbi.nlm.nih.gov/20346655

DM7R145	DI	DM7R145
DM7R145	DN	Otesaconazole
DM7R145	MI	TTTSOUD
DM7R145	MN	Candida Cytochrome P450 51 (Candi ERG11)
DM7R145	MT	DTT
DM7R145	MA	Inhibitor
DM7R145	RN	Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis. Antimicrob Agents Chemother. 2015 Sep;59(9):5567-73.
DM7R145	RU	https://pubmed.ncbi.nlm.nih.gov/26124165

DMLMS6J	DI	DMLMS6J
DMLMS6J	DN	OTL-101
DMLMS6J	MI	TTLP57V
DMLMS6J	MN	Adenosine deaminase (ADA)
DMLMS6J	MT	DTT
DMLMS6J	MA	Replacement
DMLMS6J	RN	Clinical pipeline report, company report or official report of Orchard Therapeutics.
DMLMS6J	RU	https://www.orchard-tx.com/approach/pipeline/

DM3BK2Y	DI	DM3BK2Y
DM3BK2Y	DN	OTL-103
DM3BK2Y	MI	TTE8T73
DM3BK2Y	MN	Wiskott-Aldrich syndrome protein (WAS)
DM3BK2Y	MT	DTT
DM3BK2Y	MA	Replacement
DM3BK2Y	RN	Clinical pipeline report, company report or official report of Orchard Therapeutics.
DM3BK2Y	RU	https://www.orchard-tx.com/approach/pipeline/

DM5DRMY	DI	DM5DRMY
DM5DRMY	DN	P1101
DM5DRMY	MI	TT95SOA
DM5DRMY	MN	Interferon alpha (IFNA)
DM5DRMY	MT	DTT
DM5DRMY	MA	Inhibitor
DM5DRMY	RN	Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b. Am J Hematol. 2015 Apr;90(4):288-94.
DM5DRMY	RU	https://pubmed.ncbi.nlm.nih.gov/25545244

DM7WYXJ	DI	DM7WYXJ
DM7WYXJ	DN	P-1101
DM7WYXJ	MI	TTSIUJ9
DM7WYXJ	MN	Interferon-alpha 2 (IFNA2)
DM7WYXJ	MT	DTT
DM7WYXJ	MA	Modulator
DM7WYXJ	RN	Effects of PEG-interferon-alpha-2A on Schistosoma mansoni infection in mice. J Parasitol. 2010 Aug;96(4):703-8.
DM7WYXJ	RU	https://pubmed.ncbi.nlm.nih.gov/20486736

DM9PVHX	DI	DM9PVHX
DM9PVHX	DN	P2B-001
DM9PVHX	MI	TTEX248
DM9PVHX	MN	Dopamine D2 receptor (D2R)
DM9PVHX	MT	DTT
DM9PVHX	MA	Inhibitor
DM9PVHX	RN	Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol. 1998 May-Jun;21(3):141-51.
DM9PVHX	RU	https://pubmed.ncbi.nlm.nih.gov/9617505

DM9PVHX	DI	DM9PVHX
DM9PVHX	DN	P2B-001
DM9PVHX	MI	TT4C8EA
DM9PVHX	MN	Dopamine D3 receptor (D3R)
DM9PVHX	MT	DTT
DM9PVHX	MA	Inhibitor
DM9PVHX	RN	Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol. 1998 May-Jun;21(3):141-51.
DM9PVHX	RU	https://pubmed.ncbi.nlm.nih.gov/9617505

DM9PVHX	DI	DM9PVHX
DM9PVHX	DN	P2B-001
DM9PVHX	MI	TTGP7BY
DM9PVHX	MN	Monoamine oxidase type B (MAO-B)
DM9PVHX	MT	DTT
DM9PVHX	MA	Inhibitor
DM9PVHX	RN	Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease. Am J Geriatr Pharmacother. 2006 Dec;4(4):330-46.
DM9PVHX	RU	https://pubmed.ncbi.nlm.nih.gov/17296539

DM1T6ZN	DI	DM1T6ZN
DM1T6ZN	DN	Pacritinib
DM1T6ZN	MI	TTGJCWZ
DM1T6ZN	MN	Fms-like tyrosine kinase 3 (FLT-3)
DM1T6ZN	MT	DTT
DM1T6ZN	MA	Modulator
DM1T6ZN	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1807).
DM1T6ZN	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1807

DM1T6ZN	DI	DM1T6ZN
DM1T6ZN	DN	Pacritinib
DM1T6ZN	MI	TTRMX3V
DM1T6ZN	MN	Janus kinase 2 (JAK-2)
DM1T6ZN	MT	DTT
DM1T6ZN	MA	Modulator
DM1T6ZN	RN	National Cancer Institute Drug Dictionary (drug id 609888).
DM1T6ZN	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=609888

DMFKOR9	DI	DMFKOR9
DMFKOR9	DN	Pafuramidine
DMFKOR9	MI	DE3GT9C
DMFKOR9	MN	Cytochrome P450 4F2 (CYP4F2)
DMFKOR9	MT	DME
DMFKOR9	MA	Metabolism
DMFKOR9	RN	Human enteric microsomal CYP4F enzymes O-demethylate the antiparasitic prodrug pafuramidine. Drug Metab Dispos. 2007 Nov;35(11):2067-75.
DMFKOR9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17709372

DMFKOR9	DI	DMFKOR9
DMFKOR9	DN	Pafuramidine
DMFKOR9	MI	TTUTN1I
DMFKOR9	MN	Human Deoxyribonucleic acid (hDNA)
DMFKOR9	MT	DTT
DMFKOR9	MA	Modulator
DMFKOR9	RN	DNA Minor Groove Induced Dimerization of Heterocyclic Cations: Compound Structure, Binding Affinity and Specificity for a TTAA Site
DMFKOR9	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988403

DMAD2OZ	DI	DMAD2OZ
DMAD2OZ	DN	Palovarotene
DMAD2OZ	MI	TT1Q3IE
DMAD2OZ	MN	Retinoic acid receptor gamma (RARG)
DMAD2OZ	MT	DTT
DMAD2OZ	MA	Agonist
DMAD2OZ	RN	Randomised controlled trial for emphysema with a selective agonist of the gamma-type retinoic acid receptor. Eur Respir J. 2012 Aug;40(2):306-12.
DMAD2OZ	RU	https://pubmed.ncbi.nlm.nih.gov/22282548

DM4SKYI	DI	DM4SKYI
DM4SKYI	DN	PAMAQUESIDE
DM4SKYI	MI	TT61VTP
DM4SKYI	MN	Cholesterol uptake (Chole uptake)
DM4SKYI	MT	DTT
DM4SKYI	MA	Modulator
DM4SKYI	RN	Comparison of synthetic saponin cholesterol absorption inhibitors in rabbits: evidence for a non-stoichiometric, intestinal mechanism of action. J Lipid Res. 1999 Mar;40(3):464-74.
DM4SKYI	RU	https://pubmed.ncbi.nlm.nih.gov/10064735

DMIRYU9	DI	DMIRYU9
DMIRYU9	DN	Pancopride
DMIRYU9	MI	TTNXLKE
DMIRYU9	MN	5-HT 3 receptor (5HT3R)
DMIRYU9	MT	DTT
DMIRYU9	MA	Inhibitor
DMIRYU9	RN	Pancopride, a potent and long-acting 5-HT3 receptor antagonist, is orally effective against anticancer drug-evoked emesis. Eur J Pharmacol. 1992 Nov 10;222(2-3):257-64.
DMIRYU9	RU	https://pubmed.ncbi.nlm.nih.gov/1451737

DMEW5Z8	DI	DMEW5Z8
DMEW5Z8	DN	PARABEN
DMEW5Z8	MI	TTUNARX
DMEW5Z8	MN	Carbonic anhydrase (CA)
DMEW5Z8	MT	DTT
DMEW5Z8	MA	Inhibitor
DMEW5Z8	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DMEW5Z8	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DMEW5Z8	DI	DMEW5Z8
DMEW5Z8	DN	PARABEN
DMEW5Z8	MI	TTHQPL7
DMEW5Z8	MN	Carbonic anhydrase I (CA-I)
DMEW5Z8	MT	DTT
DMEW5Z8	MA	Inhibitor
DMEW5Z8	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DMEW5Z8	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DMEW5Z8	DI	DMEW5Z8
DMEW5Z8	DN	PARABEN
DMEW5Z8	MI	TTANPDJ
DMEW5Z8	MN	Carbonic anhydrase II (CA-II)
DMEW5Z8	MT	DTT
DMEW5Z8	MA	Inhibitor
DMEW5Z8	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DMEW5Z8	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DMEW5Z8	DI	DMEW5Z8
DMEW5Z8	DN	PARABEN
DMEW5Z8	MI	TTZHA0O
DMEW5Z8	MN	Carbonic anhydrase IV (CA-IV)
DMEW5Z8	MT	DTT
DMEW5Z8	MA	Inhibitor
DMEW5Z8	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DMEW5Z8	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DMEW5Z8	DI	DMEW5Z8
DMEW5Z8	DN	PARABEN
DMEW5Z8	MI	TT2LVK8
DMEW5Z8	MN	Carbonic anhydrase IX (CA-IX)
DMEW5Z8	MT	DTT
DMEW5Z8	MA	Inhibitor
DMEW5Z8	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DMEW5Z8	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DMEW5Z8	DI	DMEW5Z8
DMEW5Z8	DN	PARABEN
DMEW5Z8	MI	TTCFSPE
DMEW5Z8	MN	Carbonic anhydrase VI (CA-VI)
DMEW5Z8	MT	DTT
DMEW5Z8	MA	Inhibitor
DMEW5Z8	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DMEW5Z8	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DMEW5Z8	DI	DMEW5Z8
DMEW5Z8	DN	PARABEN
DMEW5Z8	MI	TTSYM0R
DMEW5Z8	MN	Carbonic anhydrase XII (CA-XII)
DMEW5Z8	MT	DTT
DMEW5Z8	MA	Inhibitor
DMEW5Z8	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DMEW5Z8	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DMEW5Z8	DI	DMEW5Z8
DMEW5Z8	DN	PARABEN
DMEW5Z8	MI	TTEYTKG
DMEW5Z8	MN	Carbonic anhydrase XIV (CA-XIV)
DMEW5Z8	MT	DTT
DMEW5Z8	MA	Inhibitor
DMEW5Z8	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DMEW5Z8	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DM3H2U4	DI	DM3H2U4
DM3H2U4	DN	Patrome
DM3H2U4	MI	TTN451K
DM3H2U4	MN	Aromatic-L-amino-acid decarboxylase (DDC)
DM3H2U4	MT	DTT
DM3H2U4	MA	Modulator
DM3H2U4	RN	The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells. Clin Cancer Res. 2000 Nov;6(11):4365-72.
DM3H2U4	RU	https://pubmed.ncbi.nlm.nih.gov/11106255

DMHXTAQ	DI	DMHXTAQ
DMHXTAQ	DN	Pazufloxacin
DMHXTAQ	MI	TTN6J5F
DMHXTAQ	MN	Bacterial DNA gyrase (Bact gyrase)
DMHXTAQ	MT	DTT
DMHXTAQ	MA	Inhibitor
DMHXTAQ	RN	Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob Agents Chemother. 2001 Dec;45(12):3544-7.
DMHXTAQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/11709337

DMHXTAQ	DI	DMHXTAQ
DMHXTAQ	DN	Pazufloxacin
DMHXTAQ	MI	TTFK8YB
DMHXTAQ	MN	Bacterial DNA topoisomerase 4A (Bact parC)
DMHXTAQ	MT	DTT
DMHXTAQ	MA	Inhibitor
DMHXTAQ	RN	Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob Agents Chemother. 2001 Dec;45(12):3544-7.
DMHXTAQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/11709337

DMP3G0W	DI	DMP3G0W
DMP3G0W	DN	Pazufloxacin
DMP3G0W	MI	DTUGYRD
DMP3G0W	MN	P-glycoprotein 1 (ABCB1)
DMP3G0W	MT	DTP
DMP3G0W	MA	Substrate
DMP3G0W	RN	Possible involvement of P-glycoprotein in renal excretion of pazufloxacin in rats. Eur J Pharmacol. 2004 Oct 6;501(1-3):151-9.
DMP3G0W	RU	https://doi.org/10.1016/j.ejphar.2004.08.013

DMJBHO0	DI	DMJBHO0
DMJBHO0	DN	PC-DAC:Insulin
DMJBHO0	MI	TTZOPHG
DMJBHO0	MN	Insulin (INS)
DMJBHO0	MT	DTT
DMJBHO0	MA	Modulator
DMJBHO0	RN	Development and Testing of Solid Dose Formulations Containing Polysialic Acid Insulin Conjugate: Next Generation of Long-Acting Insulin. J Diabetes Sci Technol. 2010 May; 4(3): 532-539.
DMJBHO0	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2901028/

DMMBC5W	DI	DMMBC5W
DMMBC5W	DN	PDGF-BB
DMMBC5W	MI	TTQA6SX
DMMBC5W	MN	Platelet-derived growth factor B (PDGFB)
DMMBC5W	MT	DTT
DMMBC5W	MA	Modulator
DMMBC5W	RN	Clinical pipeline report, company report or official report of Adocia.
DMMBC5W	RU	http://www.adocia.fr/WP/products/bc-pdgf-bb-en/

DM53J6B	DI	DM53J6B
DM53J6B	DN	PDR001
DM53J6B	MI	TTNBFWK
DM53J6B	MN	Programmed cell death protein 1 (PD-1)
DM53J6B	MT	DTT
DM53J6B	MA	Antagonist
DM53J6B	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM53J6B	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMBKWAF	DI	DMBKWAF
DMBKWAF	DN	Peg-G-CSF
DMBKWAF	MI	TTC70AJ
DMBKWAF	MN	Granulocyte colony-stimulating factor receptor (G-CSF-R)
DMBKWAF	MT	DTT
DMBKWAF	MA	Stimulator
DMBKWAF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1719).
DMBKWAF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1719

DMK6OFY	DI	DMK6OFY
DMK6OFY	DN	Peginterferon lambda-1a
DMK6OFY	MI	TTM624L
DMK6OFY	MN	Interleukin-29 (IL29)
DMK6OFY	MT	DTT
DMK6OFY	MA	Agonist
DMK6OFY	RN	Preclinical and clinical development of pegylated interferon-lambda 1 in chronic hepatitis C. J Interferon Cytokine Res. 2010 Aug;30(8):591-5.
DMK6OFY	RU	https://pubmed.ncbi.nlm.nih.gov/20645873

DMESAZK	DI	DMESAZK
DMESAZK	DN	Peretinoin
DMESAZK	MI	TTOD7B3
DMESAZK	MN	Retinoic acid receptor (RAR)
DMESAZK	MT	DTT
DMESAZK	MA	Modulator
DMESAZK	RN	Peretinoin, an acyclic retinoid, improves the hepatic gene signature of chronic hepatitis C following curative therapy of hepatocellular carcinoma. BMC Cancer. 2013 Apr 15;13:191.
DMESAZK	RU	https://pubmed.ncbi.nlm.nih.gov/23587162

DMUP5Z0	DI	DMUP5Z0
DMUP5Z0	DN	PF-03084014
DMUP5Z0	MI	TTE4KHA
DMUP5Z0	MN	Amyloid beta A4 protein (APP)
DMUP5Z0	MT	DTT
DMUP5Z0	MA	Inhibitor
DMUP5Z0	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMUP5Z0	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMUP5Z0	DI	DMUP5Z0
DMUP5Z0	DN	PF-03084014
DMUP5Z0	MI	TT9W8GU
DMUP5Z0	MN	Gamma-secretase (GS)
DMUP5Z0	MT	DTT
DMUP5Z0	MA	Modulator
DMUP5Z0	RN	Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014.J Pharmacol Exp Ther.2010 Jul;334(1):269-77.
DMUP5Z0	RU	https://www.ncbi.nlm.nih.gov/pubmed/20363853

DM0TWCY	DI	DM0TWCY
DM0TWCY	DN	PF-04950615
DM0TWCY	MI	TTBRG7E
DM0TWCY	MN	Proprotein convertase subtilisin/kexin type 9 (PCSK9)
DM0TWCY	MT	DTT
DM0TWCY	RN	Phase 3 data for PCSK9 inhibitor wows. Nat Biotechnol. 2013 Dec;31(12):1057-8.
DM0TWCY	RU	https://pubmed.ncbi.nlm.nih.gov/24316621

DM8J29L	DI	DM8J29L
DM8J29L	DN	PF-04965842
DM8J29L	MI	TTJSQEF
DM8J29L	MN	Tyrosine-protein kinase (PTK)
DM8J29L	MT	DTT
DM8J29L	MA	Inhibitor
DM8J29L	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM8J29L	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM23BUP	DI	DM23BUP
DM23BUP	DN	PF-05280014
DM23BUP	MI	TT6EO5L
DM23BUP	MN	Erbb2 tyrosine kinase receptor (HER2)
DM23BUP	MT	DTT
DM23BUP	MA	Antagonist
DM23BUP	RN	Comparative nonclinical assessments of the proposed biosimilar PF-05280014 and trastuzumab (Herceptin( )). BioDrugs. 2014 Oct;28(5):451-9.
DM23BUP	RU	https://pubmed.ncbi.nlm.nih.gov/25001079

DMNZOCK	DI	DMNZOCK
DMNZOCK	DN	PF-05280586
DMNZOCK	MI	TTUE541
DMNZOCK	MN	Leukocyte surface antigen Leu-16 (CD20)
DMNZOCK	MT	DTT
DMNZOCK	MA	Antagonist
DMNZOCK	RN	Comparative nonclinical assessments of the proposed biosimilar PF-05280586 and rituximab (MabThera ). Toxicol Pathol. 2014 Oct;42(7):1069-81.
DMNZOCK	RU	https://pubmed.ncbi.nlm.nih.gov/24604381

DM2GF14	DI	DM2GF14
DM2GF14	DN	PF-06410293
DM2GF14	MI	TTF8CQI
DM2GF14	MN	Tumor necrosis factor (TNF)
DM2GF14	MT	DTT
DM2GF14	RN	Apoptosis and the FLIP and NF-kappa B proteins as pharmacodynamic criteria for biosimilar TNF-alpha antagonists. Biologics. 2014 Jul 31;8:211-20.
DM2GF14	RU	https://pubmed.ncbi.nlm.nih.gov/25114503

DMM4C95	DI	DMM4C95
DMM4C95	DN	PF-06438179
DMM4C95	MI	TTF8CQI
DMM4C95	MN	Tumor necrosis factor (TNF)
DMM4C95	MT	DTT
DMM4C95	MA	Inhibitor
DMM4C95	RN	Biosimilars in the therapy of inflammatory bowel diseases. Eur J Gastroenterol Hepatol. 2014 Jun;26(6):581-7.
DMM4C95	RU	https://pubmed.ncbi.nlm.nih.gov/24722561

DMVHZDP	DI	DMVHZDP
DMVHZDP	DN	PF-06439535
DMVHZDP	MI	TT9HKJA
DMVHZDP	MN	Vascular endothelial growth factor (VEGF)
DMVHZDP	MT	DTT
DMVHZDP	RN	National Cancer Institute Drug Dictionary (drug id 43234).
DMVHZDP	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=43234

DMW63TQ	DI	DMW63TQ
DMW63TQ	DN	PF-06741086
DMW63TQ	MI	TT068JH
DMW63TQ	MN	Tissue factor pathway inhibitor (TFPI)
DMW63TQ	MT	DTT
DMW63TQ	MA	Inhibitor
DMW63TQ	RN	Neutralizing Antibody Assay Development with High Drug and Target Tolerance to Support Clinical Development of an Anti-TFPI Therapeutic Monoclonal Antibody. AAPS J. 2019 Mar 29;21(3):46.
DMW63TQ	RU	https://pubmed.ncbi.nlm.nih.gov/30927117

DMWPA4L	DI	DMWPA4L
DMWPA4L	DN	PF-07055480
DMWPA4L	MI	TT1290U
DMWPA4L	MN	Coagulation factor VIII (F8)
DMWPA4L	MT	DTT
DMWPA4L	MA	Replacement
DMWPA4L	RN	Clinical pipeline report, company report or official report of Pfizer.
DMWPA4L	RU	https://www.pfizer.com/science/rare-diseases/pipeline

DMS1EQ7	DI	DMS1EQ7
DMS1EQ7	DN	PF-1228305
DMS1EQ7	MI	TTKRD0G
DMS1EQ7	MN	Endothelin A receptor (EDNRA)
DMS1EQ7	MT	DTT
DMS1EQ7	MA	Antagonist
DMS1EQ7	RN	Pfizer. Product Development Pipeline. March 31 2009.
DMS1EQ7	RU	http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf

DMJ7IKW	DI	DMJ7IKW
DMJ7IKW	DN	PF-4494700
DMJ7IKW	MI	TTMO9HF
DMJ7IKW	MN	Advanced glycosylation end product receptor (AGER)
DMJ7IKW	MT	DTT
DMJ7IKW	MA	Antagonist
DMJ7IKW	RN	Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer's disease. Expert Opin Investig Drugs. 2015 Mar;24(3):393-9.
DMJ7IKW	RU	https://pubmed.ncbi.nlm.nih.gov/25586103

DM5DAP3	DI	DM5DAP3
DM5DAP3	DN	PGF2ALPHA-IE
DM5DAP3	MI	TTT2ZAR
DM5DAP3	MN	Prostaglandin F2-alpha receptor (PTGFR)
DM5DAP3	MT	DTT
DM5DAP3	MA	Modulator
DM5DAP3	RN	Role of nitric oxide in PGF2 alpha-induced ocular hyperemia. Exp Eye Res. 1994 Oct;59(4):401-7.
DM5DAP3	RU	https://pubmed.ncbi.nlm.nih.gov/7532135

DM8Y12A	DI	DM8Y12A
DM8Y12A	DN	PH-80
DM8Y12A	MI	TTOASGR
DM8Y12A	MN	Neuroepithelial receptor (NR)
DM8Y12A	MT	DTT
DM8Y12A	MA	Modulator
DM8Y12A	RN	Patents by Assignee Pherin Corporation.
DM8Y12A	RU	http://patents.justia.com/assignee/pherin-corporation

DMDC7OH	DI	DMDC7OH
DMDC7OH	DN	PH94B NS
DMDC7OH	MI	TTCI43M
DMDC7OH	MN	GABA(A) receptor (GABAR)
DMDC7OH	MT	DTT
DMDC7OH	MA	Modulator
DMDC7OH	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMDC7OH	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMVEHM4	DI	DMVEHM4
DMVEHM4	DN	Phentermine+topiramate
DMVEHM4	MI	TTUNARX
DMVEHM4	MN	Carbonic anhydrase (CA)
DMVEHM4	MT	DTT
DMVEHM4	MA	Inhibitor
DMVEHM4	RN	Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
DMVEHM4	RU	https://pubmed.ncbi.nlm.nih.gov/18473708

DMVEHM4	DI	DMVEHM4
DMVEHM4	DN	Phentermine+topiramate
DMVEHM4	MI	TTNJYV2
DMVEHM4	MN	Gamma-aminobutyric acid receptor (GAR)
DMVEHM4	MT	DTT
DMVEHM4	MA	Modulator
DMVEHM4	RN	Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
DMVEHM4	RU	https://pubmed.ncbi.nlm.nih.gov/18473708

DMGZPX6	DI	DMGZPX6
DMGZPX6	DN	PI-88
DMGZPX6	MI	TTDCBX5
DMGZPX6	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DMGZPX6	MT	DTT
DMGZPX6	MA	Modulator
DMGZPX6	RN	Company report (Medigen)
DMGZPX6	RU	http://www.medigen.com.tw/en/muparfostat-pi-88/

DM7OSHC	DI	DM7OSHC
DM7OSHC	DN	Pinaverium bromide
DM7OSHC	MI	TTXHYV6
DM7OSHC	MN	Voltage-gated L-type calcium channel (L-CaC)
DM7OSHC	MT	DTT
DM7OSHC	MA	Blocker
DM7OSHC	RN	Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
DM7OSHC	RU	https://pubmed.ncbi.nlm.nih.gov/16634703

DMRG1X3	DI	DMRG1X3
DMRG1X3	DN	Pirtobrutinib
DMRG1X3	MI	TTGM6VW
DMRG1X3	MN	Tyrosine-protein kinase BTK (ATK)
DMRG1X3	MT	DTT
DMRG1X3	MA	Inhibitor
DMRG1X3	RN	Targeting BTK in CLL: Beyond Ibrutinib. Curr Hematol Malig Rep. 2019 Jun;14(3):197-205.
DMRG1X3	RU	https://pubmed.ncbi.nlm.nih.gov/31028669

DMQGR45	DI	DMQGR45
DMQGR45	DN	Pixantrone
DMQGR45	MI	TT0IHXV
DMQGR45	MN	DNA topoisomerase II (TOP2)
DMQGR45	MT	DTT
DMQGR45	MA	Modulator
DMQGR45	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMQGR45	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMCA6BW	DI	DMCA6BW
DMCA6BW	DN	Pixykine
DMCA6BW	MI	TT6MP2Z
DMCA6BW	MN	GMCSFR-alpha (CSF2RA)
DMCA6BW	MT	DTT
DMCA6BW	MA	Modulator
DMCA6BW	RN	Phase I/II trial of PIXY321 (granulocyte-macrophage colony stimulating factor/interleukin-3 fusion protein) for treatment of inherited and acquired... Br J Haematol. 1998 Nov;103(2):304-7.
DMCA6BW	RU	https://www.ncbi.nlm.nih.gov/pubmed/9827896

DM1RWMY	DI	DM1RWMY
DM1RWMY	DN	Plasma derived factor VIII PEGylated liposomal
DM1RWMY	MI	TT1290U
DM1RWMY	MN	Coagulation factor VIII (F8)
DM1RWMY	MT	DTT
DM1RWMY	MA	Modulator
DM1RWMY	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2607).
DM1RWMY	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2607

DMD7L48	DI	DMD7L48
DMD7L48	DN	Plinabulin
DMD7L48	MI	TTKIGZF
DMD7L48	MN	Guanine nucleotide exchange factor (GNEF)
DMD7L48	MT	DTT
DMD7L48	MA	Stimulator
DMD7L48	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMD7L48	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMD7L48	DI	DMD7L48
DMD7L48	DN	Plinabulin
DMD7L48	MI	TTYFKSZ
DMD7L48	MN	Tubulin beta (TUBB)
DMD7L48	MT	DTT
DMD7L48	MA	Modulator
DMD7L48	RN	NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs. 2006 Jan;17(1):25-31.
DMD7L48	RU	https://www.ncbi.nlm.nih.gov/pubmed/16317287

DMJ8AUE	DI	DMJ8AUE
DMJ8AUE	DN	Plitidepsin
DMJ8AUE	MI	DEJVYAZ
DMJ8AUE	MN	Cytochrome P450 2A6 (CYP2A6)
DMJ8AUE	MT	DME
DMJ8AUE	MA	Metabolism
DMJ8AUE	RN	In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug. Invest New Drugs. 2007 Feb;25(1):9-19.
DMJ8AUE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16633717

DMJ8AUE	DI	DMJ8AUE
DMJ8AUE	DN	Plitidepsin
DMJ8AUE	MI	DEVDYN7
DMJ8AUE	MN	Cytochrome P450 2E1 (CYP2E1)
DMJ8AUE	MT	DME
DMJ8AUE	MA	Metabolism
DMJ8AUE	RN	In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug. Invest New Drugs. 2007 Feb;25(1):9-19.
DMJ8AUE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16633717

DMJ8AUE	DI	DMJ8AUE
DMJ8AUE	DN	Plitidepsin
DMJ8AUE	MI	DE4LYSA
DMJ8AUE	MN	Cytochrome P450 3A4 (CYP3A4)
DMJ8AUE	MT	DME
DMJ8AUE	MA	Metabolism
DMJ8AUE	RN	In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug. Invest New Drugs. 2007 Feb;25(1):9-19.
DMJ8AUE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16633717

DMJ8AUE	DI	DMJ8AUE
DMJ8AUE	DN	Plitidepsin
DMJ8AUE	MI	TTSQC14
DMJ8AUE	MN	Palmitoyl-protein thioesterase 1 (PPT1)
DMJ8AUE	MT	DTT
DMJ8AUE	MA	Modulator
DMJ8AUE	RN	Mode of action and pharmacogenomic biomarkers for exceptional responders to didemnin B
DMJ8AUE	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433765

DMV8EXG	DI	DMV8EXG
DMV8EXG	DN	PolyHeme
DMV8EXG	MI	TTQO71U
DMV8EXG	MN	Hemoglobin (HB)
DMV8EXG	MT	DTT
DMV8EXG	MA	Modulator
DMV8EXG	RN	Blood substitutes- the polyheme trials. Mcgill J Med. 2008 January; 11(1): 59-65.
DMV8EXG	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2322929/

DMTD7AB	DI	DMTD7AB
DMTD7AB	DN	Pracinostat
DMTD7AB	MI	DEJGDUW
DMTD7AB	MN	Cytochrome P450 1A2 (CYP1A2)
DMTD7AB	MT	DME
DMTD7AB	MA	Metabolism
DMTD7AB	RN	Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics. Drug Metab Dispos. 2011 Dec;39(12):2219-32.
DMTD7AB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21873472

DMTD7AB	DI	DMTD7AB
DMTD7AB	DN	Pracinostat
DMTD7AB	MI	DE4LYSA
DMTD7AB	MN	Cytochrome P450 3A4 (CYP3A4)
DMTD7AB	MT	DME
DMTD7AB	MA	Metabolism
DMTD7AB	RN	Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics. Drug Metab Dispos. 2011 Dec;39(12):2219-32.
DMTD7AB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21873472

DMTD7AB	DI	DMTD7AB
DMTD7AB	DN	Pracinostat
DMTD7AB	MI	TTBH0VX
DMTD7AB	MN	Histone deacetylase (HDAC)
DMTD7AB	MT	DTT
DMTD7AB	MA	Modulator
DMTD7AB	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8365).
DMTD7AB	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8365

DM2ZYX9	DI	DM2ZYX9
DM2ZYX9	DN	Pradaxa
DM2ZYX9	MI	DEB30C5
DM2ZYX9	MN	Carboxylesterase 1 (CES1)
DM2ZYX9	MT	DME
DM2ZYX9	MA	Metabolism
DM2ZYX9	RN	Conventional liquid chromatography/triple quadrupole mass spectrometry based metabolite identification and semi-quantitative estimation approach in the investigation of in vitro dabigatran etexilate metabolism. Anal Bioanal Chem. 2013 Feb;405(5):1695-704.
DM2ZYX9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23239178

DM2ZYX9	DI	DM2ZYX9
DM2ZYX9	DN	Pradaxa
DM2ZYX9	MI	DETHCPD
DM2ZYX9	MN	Carboxylesterase 2 (CES2)
DM2ZYX9	MT	DME
DM2ZYX9	MA	Metabolism
DM2ZYX9	RN	Conventional liquid chromatography/triple quadrupole mass spectrometry based metabolite identification and semi-quantitative estimation approach in the investigation of in vitro dabigatran etexilate metabolism. Anal Bioanal Chem. 2013 Feb;405(5):1695-704.
DM2ZYX9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23239178

DMOMDXI	DI	DMOMDXI
DMOMDXI	DN	Pratosartan
DMOMDXI	MI	TT8DBY3
DMOMDXI	MN	Angiotensin II receptor type-1 (AGTR1)
DMOMDXI	MT	DTT
DMOMDXI	MA	Antagonist
DMOMDXI	RN	Clinical efficacy of a new angiotensin II type 1 receptor blocker, pratosartan, in hypertensive patients. Hypertens Res. 2008 Feb;31(2):281-7.
DMOMDXI	RU	https://pubmed.ncbi.nlm.nih.gov/18360048

DMLSOB7	DI	DMLSOB7
DMLSOB7	DN	Premarin/Pravachol
DMLSOB7	MI	TTZAYWL
DMLSOB7	MN	Estrogen receptor (ESR)
DMLSOB7	MT	DTT
DMLSOB7	MA	Modulator
DMLSOB7	RN	Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003 Jul;2(7):517-26.
DMLSOB7	RU	https://pubmed.ncbi.nlm.nih.gov/12815379

DMLSOB7	DI	DMLSOB7
DMLSOB7	DN	Premarin/Pravachol
DMLSOB7	MI	TTOM3J0
DMLSOB7	MN	Estrogen receptor beta (ESR2)
DMLSOB7	MT	DTT
DMLSOB7	MA	Modulator
DMLSOB7	RN	Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003 Jul;2(7):517-26.
DMLSOB7	RU	https://pubmed.ncbi.nlm.nih.gov/12815379

DMLSOB7	DI	DMLSOB7
DMLSOB7	DN	Premarin/Pravachol
DMLSOB7	MI	TTPADOQ
DMLSOB7	MN	HMG-CoA reductase (HMGCR)
DMLSOB7	MT	DTT
DMLSOB7	MA	Modulator
DMLSOB7	RN	Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003 Jul;2(7):517-26.
DMLSOB7	RU	https://pubmed.ncbi.nlm.nih.gov/12815379

DMX9YLR	DI	DMX9YLR
DMX9YLR	DN	Pridopidine
DMX9YLR	MI	TTEX248
DMX9YLR	MN	Dopamine D2 receptor (D2R)
DMX9YLR	MT	DTT
DMX9YLR	MA	Modulator
DMX9YLR	RN	Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease. Clin Neuropharmacol. 2010 Sep-Oct;33(5):260-4.
DMX9YLR	RU	https://pubmed.ncbi.nlm.nih.gov/20616707

DMD1FTP	DI	DMD1FTP
DMD1FTP	DN	PRO-140
DMD1FTP	MI	TT2CEJG
DMD1FTP	MN	C-C chemokine receptor type 5 (CCR5)
DMD1FTP	MT	DTT
DMD1FTP	MA	Antagonist
DMD1FTP	RN	Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication. J Pharmacol Exp Ther. 2011 Jun;337(3):655-62.
DMD1FTP	RU	https://pubmed.ncbi.nlm.nih.gov/21389095

DM5FZH4	DI	DM5FZH4
DM5FZH4	DN	ProstaVac
DM5FZH4	MI	TTS78AZ
DM5FZH4	MN	Prostate specific antigen (KLK3)
DM5FZH4	MT	DTT
DM5FZH4	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2373).
DM5FZH4	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2373

DMVU8RW	DI	DMVU8RW
DMVU8RW	DN	PRT4445
DMVU8RW	MI	TTCIHJA
DMVU8RW	MN	Coagulation factor Xa (F10)
DMVU8RW	MT	DTT
DMVU8RW	MA	Modulator
DMVU8RW	RN	Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7.
DMVU8RW	RU	https://pubmed.ncbi.nlm.nih.gov/22844656

DMEH641	DI	DMEH641
DMEH641	DN	PRX-302
DMEH641	MI	TTS78AZ
DMEH641	MN	Prostate specific antigen (KLK3)
DMEH641	MT	DTT
DMEH641	MA	Modulator
DMEH641	RN	Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2011 May;59(5):747-54.
DMEH641	RU	https://pubmed.ncbi.nlm.nih.gov/21129846

DMIZJ8M	DI	DMIZJ8M
DMIZJ8M	DN	Psoralen
DMIZJ8M	MI	TT3WG5C
DMIZJ8M	MN	Monoamine oxidase type A (MAO-A)
DMIZJ8M	MT	DTT
DMIZJ8M	MA	Inhibitor
DMIZJ8M	RN	Inhibition of rat brain monoamine oxidase activities by psoralen and isopsoralen: implications for the treatment of affective disorders. Pharmacol Toxicol. 2001 Feb;88(2):75-80.
DMIZJ8M	RU	https://pubmed.ncbi.nlm.nih.gov/11169165

DMIZJ8M	DI	DMIZJ8M
DMIZJ8M	DN	Psoralen
DMIZJ8M	MI	TTGP7BY
DMIZJ8M	MN	Monoamine oxidase type B (MAO-B)
DMIZJ8M	MT	DTT
DMIZJ8M	MA	Inhibitor
DMIZJ8M	RN	Inhibition of rat brain monoamine oxidase activities by psoralen and isopsoralen: implications for the treatment of affective disorders. Pharmacol Toxicol. 2001 Feb;88(2):75-80.
DMIZJ8M	RU	https://pubmed.ncbi.nlm.nih.gov/11169165

DMTSN8L	DI	DMTSN8L
DMTSN8L	DN	PT005
DMTSN8L	MI	TT2CJVK
DMTSN8L	MN	Adrenergic receptor beta-2 (ADRB2)
DMTSN8L	MT	DTT
DMTSN8L	MA	Agonist
DMTSN8L	RN	Clinical pipeline report, company report or official report of Pearl Therapeutics.
DMTSN8L	RU	http://www.pearltherapeutics.com/PT005

DML1KTO	DI	DML1KTO
DML1KTO	DN	PT2977
DML1KTO	MI	TTDMLNT
DML1KTO	MN	Hypoxia-inducible factor 2 alpha (HIF-2A)
DML1KTO	MT	DTT
DML1KTO	MA	Inhibitor
DML1KTO	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DML1KTO	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMMJ63A	DI	DMMJ63A
DMMJ63A	DN	PT-304
DMMJ63A	MI	TT84ETX
DMMJ63A	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMMJ63A	MT	DTT
DMMJ63A	MA	Inhibitor
DMMJ63A	RN	Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36.
DMMJ63A	RU	https://pubmed.ncbi.nlm.nih.gov/8523406

DMVDCGZ	DI	DMVDCGZ
DMVDCGZ	DN	Pyridoxamine
DMVDCGZ	MI	TTMO9HF
DMVDCGZ	MN	Advanced glycosylation end product receptor (AGER)
DMVDCGZ	MT	DTT
DMVDCGZ	MA	Inhibitor
DMVDCGZ	RN	Pyridoxamine, an inhibitor of advanced glycation end product (AGE) formation ameliorates insulin resistance in obese, type 2 diabetic mice. Protein Pept Lett. 2010 Sep;17(9):1177-81.
DMVDCGZ	RU	https://pubmed.ncbi.nlm.nih.gov/20441560

DMVDCGZ	DI	DMVDCGZ
DMVDCGZ	DN	Pyridoxamine
DMVDCGZ	MI	DE3Z1RA
DMVDCGZ	MN	Pyridoxamine-phosphate oxidase (PNPO)
DMVDCGZ	MT	DME
DMVDCGZ	MA	Metabolism
DMVDCGZ	RN	An LC-MS/MS-based method for the quantification of pyridox(am)ine 5'-phosphate oxidase activity in dried blood spots from patients with epilepsy. Anal Chem. 2017 Sep 5;89(17):8892-8900.
DMVDCGZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28782931

DMPCFXN	DI	DMPCFXN
DMPCFXN	DN	QAW-039
DMPCFXN	MI	TTNVEIR
DMPCFXN	MN	Prostaglandin D2 receptor (PTGDR)
DMPCFXN	MT	DTT
DMPCFXN	MA	Antagonist
DMPCFXN	RN	Effect Of QAW039, An Oral Prostaglandin D2 Receptor (DP2/CRTh2) Antagonist, Upon Sputum And Bronchial Eosinophilic Inflammation And Clinical Outcomes In Treatment-Resistant Asthma: A Phase 2a Randomized Placebo-Controlled Trial. American Thoracic Society Journals. 2015.
DMPCFXN	RU	http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2015.191.1_MeetingAbstracts.A6361

DMDU5Y2	DI	DMDU5Y2
DMDU5Y2	DN	QPI-1002
DMDU5Y2	MI	TT7SBF5
DMDU5Y2	MN	Cellular tumor antigen p53 (TP53)
DMDU5Y2	MT	DTT
DMDU5Y2	MA	Modulator
DMDU5Y2	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMDU5Y2	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMUWXEB	DI	DMUWXEB
DMUWXEB	DN	QPI-1007
DMUWXEB	MI	TT12VNG
DMUWXEB	MN	Caspase 2 messenger RNA (CASP2 mRNA)
DMUWXEB	MT	DTT
DMUWXEB	RN	Toxicological and pharmacokinetic properties of QPI-1007, a chemically modified synthetic siRNA targeting caspase 2 mRNA, following intravitreal injection. Nucleic Acid Ther. 2014 Aug;24(4):258-66.
DMUWXEB	RU	https://pubmed.ncbi.nlm.nih.gov/25054518

DMDCQW0	DI	DMDCQW0
DMDCQW0	DN	Quinotolast
DMDCQW0	MI	TT7KY5U
DMDCQW0	MN	Histamine/peptide leukotriene release (His/p-LT rele)
DMDCQW0	MT	DTT
DMDCQW0	MA	Modulator
DMDCQW0	RN	Effects of quinotolast, a new orally active antiallergic drug, on experimental allergic models. Jpn J Pharmacol. 1993 Sep;63(1):73-81.
DMDCQW0	RU	https://pubmed.ncbi.nlm.nih.gov/7505860

DMSFX75	DI	DMSFX75
DMSFX75	DN	QVA-149
DMSFX75	MI	TT2CJVK
DMSFX75	MN	Adrenergic receptor beta-2 (ADRB2)
DMSFX75	MT	DTT
DMSFX75	MA	Agonist
DMSFX75	RN	Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94.
DMSFX75	RU	https://pubmed.ncbi.nlm.nih.gov/19265487

DM4K9WH	DI	DM4K9WH
DM4K9WH	DN	R1678
DM4K9WH	MI	TTHJTF7
DM4K9WH	MN	Glycine transporter GlyT-1 (SLC6A9)
DM4K9WH	MT	DTT
DM4K9WH	MA	Blocker
DM4K9WH	RN	Clinical pipeline report, company report or official report of Roche (2009).
DM4K9WH	RU	http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm

DM9Z4N5	DI	DM9Z4N5
DM9Z4N5	DN	RA101495
DM9Z4N5	MI	TTKANGO
DM9Z4N5	MN	Complement C5 (CO5)
DM9Z4N5	MT	DTT
DM9Z4N5	MA	Inhibitor
DM9Z4N5	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9Z4N5	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM8RLJ5	DI	DM8RLJ5
DM8RLJ5	DN	RAD-1901
DM8RLJ5	MI	TTZAYWL
DM8RLJ5	MN	Estrogen receptor (ESR)
DM8RLJ5	MT	DTT
DM8RLJ5	MA	Modulator
DM8RLJ5	RN	RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models. Anticancer Drugs. 2015 Oct;26(9):948-56.
DM8RLJ5	RU	https://pubmed.ncbi.nlm.nih.gov/26164151

DMN1ZEU	DI	DMN1ZEU
DMN1ZEU	DN	Radiosensitizer gene therapy
DMN1ZEU	MI	TTP3QRF
DMN1ZEU	MN	Thymidine kinase 1 (TK1)
DMN1ZEU	MT	DTT
DMN1ZEU	MA	Inhibitor
DMN1ZEU	RN	Pronounced antitumor effects and tumor radiosensitization of double suicide gene therapy. Clin Cancer Res. 1997 Nov;3(11):2081-8.
DMN1ZEU	RU	https://pubmed.ncbi.nlm.nih.gov/9815600

DMWA74Y	DI	DMWA74Y
DMWA74Y	DN	Radotinib
DMWA74Y	MI	TTS7G69
DMWA74Y	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMWA74Y	MT	DTT
DMWA74Y	MA	Modulator
DMWA74Y	RN	Danusertib, an aurora kinase inhibitor.Expert Opin Investig Drugs.2012 Mar;21(3):383-93.
DMWA74Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/22242557

DMFSHEM	DI	DMFSHEM
DMFSHEM	DN	Ragaglitazar
DMFSHEM	MI	TTJ584C
DMFSHEM	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMFSHEM	MT	DTT
DMFSHEM	MA	Modulator
DMFSHEM	RN	Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. J Clin Pharmacol. 2003 Nov;43(11):1244-56.
DMFSHEM	RU	https://pubmed.ncbi.nlm.nih.gov/14551179

DMFSHEM	DI	DMFSHEM
DMFSHEM	DN	Ragaglitazar
DMFSHEM	MI	TTZMAO3
DMFSHEM	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMFSHEM	MT	DTT
DMFSHEM	MA	Modulator
DMFSHEM	RN	Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. J Clin Pharmacol. 2003 Nov;43(11):1244-56.
DMFSHEM	RU	https://pubmed.ncbi.nlm.nih.gov/14551179

DMUNMY0	DI	DMUNMY0
DMUNMY0	DN	Ralfinamide
DMUNMY0	MI	TTRK8B9
DMUNMY0	MN	Sodium channel unspecific (NaC)
DMUNMY0	MT	DTT
DMUNMY0	MA	Blocker
DMUNMY0	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DMUNMY0	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DMUNMY0	DI	DMUNMY0
DMUNMY0	DN	Ralfinamide
DMUNMY0	MI	TT4FDG6
DMUNMY0	MN	Voltage-gated calcium channel alpha Cav2.2 (CACNA1B)
DMUNMY0	MT	DTT
DMUNMY0	MA	Blocker
DMUNMY0	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DMUNMY0	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DMD5QRS	DI	DMD5QRS
DMD5QRS	DN	Ranirestat
DMD5QRS	MI	TTFBNVI
DMD5QRS	MN	Aldose reductase (AKR1B1)
DMD5QRS	MT	DTT
DMD5QRS	MA	Inhibitor
DMD5QRS	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2768).
DMD5QRS	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2768

DMVKL3B	DI	DMVKL3B
DMVKL3B	DN	Ravulizumab
DMVKL3B	MI	TTN0GJ5
DMVKL3B	MN	HUMAN complement C5 protein (C5)
DMVKL3B	MT	DTT
DMVKL3B	MA	Inhibitor
DMVKL3B	RN	Complement as a target in COVID-19 Nat Rev Immunol. 2020 Apr 23.
DMVKL3B	RU	https://pubmed.ncbi.nlm.nih.gov/32327719

DMPJTZ1	DI	DMPJTZ1
DMPJTZ1	DN	RBP-7000
DMPJTZ1	MI	TTEX248
DMPJTZ1	MN	Dopamine D2 receptor (D2R)
DMPJTZ1	MT	DTT
DMPJTZ1	MA	Modulator
DMPJTZ1	RN	Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment. Clin Pharmacokinet. 2014 Jun;53(6):533-43.
DMPJTZ1	RU	https://pubmed.ncbi.nlm.nih.gov/24464285

DMDZW8K	DI	DMDZW8K
DMDZW8K	DN	RBT-101
DMDZW8K	MI	TTX4GLS
DMDZW8K	MN	Mammalian target of rapamycin complex 1 (mTORC1)
DMDZW8K	MT	DTT
DMDZW8K	MA	Inhibitor
DMDZW8K	RN	Constrained peptides' time to shine. Nat Rev Drug Discov. 2018 Jul 30;17(8):531-533.
DMDZW8K	RU	https://pubmed.ncbi.nlm.nih.gov/30057410

DM2GHCR	DI	DM2GHCR
DM2GHCR	DN	Rebamipide
DM2GHCR	MI	DE4LYSA
DM2GHCR	MN	Cytochrome P450 3A4 (CYP3A4)
DM2GHCR	MT	DME
DM2GHCR	MA	Metabolism
DM2GHCR	RN	Involvement of cytochrome P450 in the metabolism of rebamipide by the human liver. Xenobiotica. 2002 Jul;32(7):573-86.
DM2GHCR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12162853

DM2GHCR	DI	DM2GHCR
DM2GHCR	DN	Rebamipide
DM2GHCR	MI	TT5Y4EM
DM2GHCR	MN	N-formyl peptide receptor (FPR1)
DM2GHCR	MT	DTT
DM2GHCR	MA	Antagonist
DM2GHCR	RN	Rebamipide suppresses formyl-methionyl-leucyl-phenylalanine (fMLP)-induced superoxide production by inhibiting fMLP-receptor binding in human neutrophils. J Pharmacol Exp Ther. 2001 Apr;297(1):388-94.
DM2GHCR	RU	https://pubmed.ncbi.nlm.nih.gov/11259567

DM8HVNR	DI	DM8HVNR
DM8HVNR	DN	Recombinant acidic fibroblast growth factor
DM8HVNR	MI	TT5HU6Z
DM8HVNR	MN	Fibroblast growth factor (FGF)
DM8HVNR	MT	DTT
DM8HVNR	MA	Modulator
DM8HVNR	RN	Molecular characterization of recombinant human acidic fibroblast growth factor produced in E. coli: comparative studies with human basic fibroblast growth factor. Mol Endocrinol. 1990 Jun;4(6):869-79.
DM8HVNR	RU	https://pubmed.ncbi.nlm.nih.gov/1700280

DMOWQAF	DI	DMOWQAF
DMOWQAF	DN	Recombinant human iduronate-2-sulfatase
DMOWQAF	MI	TTNY2AP
DMOWQAF	MN	Iduronate 2-sulfatase (IDS)
DMOWQAF	MT	DTT
DMOWQAF	MA	Modulator
DMOWQAF	RN	The effect of recombinant human iduronate-2-sulfatase (Idursulfase) on growth in young patients with mucopolysaccharidosis type II. PLoS One. 2014 Jan 13;9(1):e85074.
DMOWQAF	RU	https://pubmed.ncbi.nlm.nih.gov/24454794

DM7JFDO	DI	DM7JFDO
DM7JFDO	DN	Recombinant von Willebrand factor/recombinant Factor VIII complex
DM7JFDO	MI	TT1290U
DM7JFDO	MN	Coagulation factor VIII (F8)
DM7JFDO	MT	DTT
DM7JFDO	MA	Modulator
DM7JFDO	RN	6 Factor VIII Concentrates, Factor VIII/von Willebrand Factor Concentrates, Factor IX Concentrates, Activated Prothrombin Complex Concentrates. Transfus Med Hemother. 2009 December; 36(6): 409-418.
DM7JFDO	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2997296/

DM7JFDO	DI	DM7JFDO
DM7JFDO	DN	Recombinant von Willebrand factor/recombinant Factor VIII complex
DM7JFDO	MI	TT3SZBT
DM7JFDO	MN	von Willebrand factor (VWF)
DM7JFDO	MT	DTT
DM7JFDO	MA	Modulator
DM7JFDO	RN	6 Factor VIII Concentrates, Factor VIII/von Willebrand Factor Concentrates, Factor IX Concentrates, Activated Prothrombin Complex Concentrates. Transfus Med Hemother. 2009 December; 36(6): 409-418.
DM7JFDO	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2997296/

DM34GOF	DI	DM34GOF
DM34GOF	DN	REL-1017
DM34GOF	MI	TT9IK2Z
DM34GOF	MN	N-methyl-D-aspartate receptor (NMDAR)
DM34GOF	MT	DTT
DM34GOF	MA	Antagonist
DM34GOF	RN	N-Methyl-D-aspartate receptor antagonist d-methadone produces rapid, mTORC1-dependent antidepressant effects. Neuropsychopharmacology. 2019 Dec;44(13):2230-2238.
DM34GOF	RU	https://pubmed.ncbi.nlm.nih.gov/31454827

DMOWINT	DI	DMOWINT
DMOWINT	DN	Reloxaliase
DMOWINT	MI	TTMDQIJ
DMOWINT	MN	Oxalate absorption (Oxalate absor)
DMOWINT	MT	DTT
DMOWINT	MA	Replacement
DMOWINT	RN	Clinical pipeline report, company report or official report of Allena Pharmaceuticals.
DMOWINT	RU	https://www.allenapharma.com/reloxaliase

DM3YXP8	DI	DM3YXP8
DM3YXP8	DN	Remacemide
DM3YXP8	MI	DE4LYSA
DM3YXP8	MN	Cytochrome P450 3A4 (CYP3A4)
DM3YXP8	MT	DME
DM3YXP8	MA	Metabolism
DM3YXP8	RN	Influence of cytochrome P450 induction on the pharmacokinetics and pharmacodynamics of remacemide hydrochloride. Epilepsy Res. 2002 May;49(3):247-54.
DM3YXP8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12076846

DM3YXP8	DI	DM3YXP8
DM3YXP8	DN	Remacemide
DM3YXP8	MI	TT9IK2Z
DM3YXP8	MN	N-methyl-D-aspartate receptor (NMDAR)
DM3YXP8	MT	DTT
DM3YXP8	MA	Agonist
DM3YXP8	RN	Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
DM3YXP8	RU	https://pubmed.ncbi.nlm.nih.gov/16377242

DM49IGE	DI	DM49IGE
DM49IGE	DN	Remdesivir
DM49IGE	MI	TTV1095
DM49IGE	MN	COVID-19 RNA-directed RNA polymerase (RdRp)
DM49IGE	MT	DTT
DM49IGE	MA	Inhibitor
DM49IGE	RN	Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.
DM49IGE	RU	https://pubmed.ncbi.nlm.nih.gov/32020029

DM49IGE	DI	DM49IGE
DM49IGE	DN	Remdesivir
DM49IGE	MI	TTOA6YT
DM49IGE	MN	MERS-CoV RNA-directed RNA polymerase (RdRp)
DM49IGE	MT	DTT
DM49IGE	MA	Inhibitor
DM49IGE	RN	Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020 Jan 10;11(1):222.
DM49IGE	RU	https://pubmed.ncbi.nlm.nih.gov/31924756

DM49IGE	DI	DM49IGE
DM49IGE	DN	Remdesivir
DM49IGE	MI	TTKXI53
DM49IGE	MN	SARS-CoV RNA-directed RNA polymerase (RdRp)
DM49IGE	MT	DTT
DM49IGE	MA	Inhibitor
DM49IGE	RN	Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020 Jan 10;11(1):222.
DM49IGE	RU	https://pubmed.ncbi.nlm.nih.gov/31924756

DM7HQNX	DI	DM7HQNX
DM7HQNX	DN	Renzapride
DM7HQNX	MI	TTNXLKE
DM7HQNX	MN	5-HT 3 receptor (5HT3R)
DM7HQNX	MT	DTT
DM7HQNX	MA	Modulator
DM7HQNX	RN	Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome. Drugs R D. 2008;9(1):37-63.
DM7HQNX	RU	https://www.ncbi.nlm.nih.gov/pubmed/18095752

DM7HQNX	DI	DM7HQNX
DM7HQNX	DN	Renzapride
DM7HQNX	MI	TT07C3Y
DM7HQNX	MN	5-HT 4 receptor (HTR4)
DM7HQNX	MT	DTT
DM7HQNX	MA	Modulator
DM7HQNX	RN	Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome. Drugs R D. 2008;9(1):37-63.
DM7HQNX	RU	https://www.ncbi.nlm.nih.gov/pubmed/18095752

DMVBA7I	DI	DMVBA7I
DMVBA7I	DN	Reparixin
DMVBA7I	MI	TTMWT8Z
DMVBA7I	MN	C-X-C chemokine receptor type 1 (CXCR1)
DMVBA7I	MT	DTT
DMVBA7I	MA	Modulator
DMVBA7I	RN	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
DMVBA7I	RU	https://pubmed.ncbi.nlm.nih.gov/15974585

DMVBA7I	DI	DMVBA7I
DMVBA7I	DN	Reparixin
DMVBA7I	MI	TT30C9G
DMVBA7I	MN	C-X-C chemokine receptor type 2 (CXCR2)
DMVBA7I	MT	DTT
DMVBA7I	MA	Modulator
DMVBA7I	RN	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
DMVBA7I	RU	https://pubmed.ncbi.nlm.nih.gov/15974585

DMDEJX9	DI	DMDEJX9
DMDEJX9	DN	Reproxalap
DMDEJX9	MI	TTZEX7Y
DMDEJX9	MN	Malondialdehyde (MDA)
DMDEJX9	MT	DTT
DMDEJX9	MA	Inhibitor
DMDEJX9	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMDEJX9	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMFMWYC	DI	DMFMWYC
DMFMWYC	DN	Resatorvid
DMFMWYC	MI	TTISGCA
DMFMWYC	MN	Toll-like receptor 4 (TLR4)
DMFMWYC	MT	DTT
DMFMWYC	MA	Antagonist
DMFMWYC	RN	Clinical pipeline report, company report or official report of Takeda (2009).
DMFMWYC	RU	http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf

DM3RWXL	DI	DM3RWXL
DM3RWXL	DN	Resveratrol
DM3RWXL	MI	DTI7UX6
DM3RWXL	MN	Breast cancer resistance protein (ABCG2)
DM3RWXL	MT	DTP
DM3RWXL	MA	Substrate
DM3RWXL	RN	The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
DM3RWXL	RU	http://www.ncbi.nlm.nih.gov/pubmed/17032904

DM3RWXL	DI	DM3RWXL
DM3RWXL	DN	Resveratrol
DM3RWXL	MI	DEJGDUW
DM3RWXL	MN	Cytochrome P450 1A2 (CYP1A2)
DM3RWXL	MT	DME
DM3RWXL	MA	Metabolism
DM3RWXL	RN	Involvement of cytochrome P450 1A2 in the biotransformation of trans-resveratrol in human liver microsomes. Biochem Pharmacol. 2004 Aug 15;68(4):773-82.
DM3RWXL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15276085

DM3RWXL	DI	DM3RWXL
DM3RWXL	DN	Resveratrol
DM3RWXL	MI	DTSYQGK
DM3RWXL	MN	Multidrug resistance-associated protein 1 (ABCC1)
DM3RWXL	MT	DTP
DM3RWXL	MA	Substrate
DM3RWXL	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM3RWXL	RU	https://doi.org/10.1007/s11095-012-0935-x

DM3RWXL	DI	DM3RWXL
DM3RWXL	DN	Resveratrol
DM3RWXL	MI	DTCSGPB
DM3RWXL	MN	Multidrug resistance-associated protein 4 (ABCC4)
DM3RWXL	MT	DTP
DM3RWXL	MA	Substrate
DM3RWXL	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM3RWXL	RU	https://doi.org/10.1007/s11095-012-0935-x

DM3RWXL	DI	DM3RWXL
DM3RWXL	DN	Resveratrol
DM3RWXL	MI	TTUF2HO
DM3RWXL	MN	NAD-dependent deacetylase sirtuin-1 (SIRT1)
DM3RWXL	MT	DTT
DM3RWXL	MA	Inhibitor
DM3RWXL	RN	Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15.
DM3RWXL	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435179

DM3RWXL	DI	DM3RWXL
DM3RWXL	DN	Resveratrol
DM3RWXL	MI	DEZWDKE
DM3RWXL	MN	NADPH-dependent curcumin reductase (curA)
DM3RWXL	MT	DME
DM3RWXL	MA	Metabolism
DM3RWXL	RN	Discovery of the curcumin metabolic pathway involving a unique enzyme in an intestinal microorganism. Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6615-20.
DM3RWXL	RU	https://pubmed.ncbi.nlm.nih.gov/21467222

DM3RWXL	DI	DM3RWXL
DM3RWXL	DN	Resveratrol
DM3RWXL	MI	TT8NGED
DM3RWXL	MN	Prostaglandin G/H synthase 1 (COX-1)
DM3RWXL	MT	DTT
DM3RWXL	MA	Modulator
DM3RWXL	RN	Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2: a mechanistic approach to the design of COX-1 selective agents. J Biol Chem. 2004 May 21;279(21):22727-37.
DM3RWXL	RU	https://pubmed.ncbi.nlm.nih.gov/15020596

DM3RWXL	DI	DM3RWXL
DM3RWXL	DN	Resveratrol
DM3RWXL	MI	DEYMAD4
DM3RWXL	MN	Sulfotransferase 1C2 (SULT1C2)
DM3RWXL	MT	DME
DM3RWXL	MA	Metabolism
DM3RWXL	RN	Correlation of reactive oxygen species levels with resveratrol sensitivities of anaplastic thyroid cancer cells. Oxid Med Cell Longev. 2018 Jul 10;2018:6235417.
DM3RWXL	RU	https://pubmed.ncbi.nlm.nih.gov/30116486

DMOYGZF	DI	DMOYGZF
DMOYGZF	DN	Retosiban
DMOYGZF	MI	TTSCIUP
DMOYGZF	MN	Oxytocin receptor (OTR)
DMOYGZF	MT	DTT
DMOYGZF	MA	Modulator
DMOYGZF	RN	The Effect of an Oxytocin Receptor Antagonist (Retosiban, GSK221149A) on the Response of Human Myometrial Explants to Prolonged Mechanical Stretch.Endocrinology.2015 Oct;156(10):3511-6.
DMOYGZF	RU	https://www.ncbi.nlm.nih.gov/pubmed/26207346

DM5E73H	DI	DM5E73H
DM5E73H	DN	Revusiran
DM5E73H	MI	TTPOYU7
DM5E73H	MN	Transthyretin messenger RNA (TTR mRNA)
DM5E73H	MT	DTT
DM5E73H	RN	Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc.
DM5E73H	RU	http://www.alnylam.com/product-pipeline/ttr-amyloidosis-fac/

DMQ4CSX	DI	DMQ4CSX
DMQ4CSX	DN	Rezafungin
DMQ4CSX	MI	TT0SFXH
DMQ4CSX	MN	Fungal 1,3-beta-glucan synthase (Fung GSC2)
DMQ4CSX	MT	DTT
DMQ4CSX	MA	Inhibitor
DMQ4CSX	RN	Antifungal drugs: What brings the future?. Med Mycol. 2019 Jun 1;57(Supplement_3):S328-S343.
DMQ4CSX	RU	https://pubmed.ncbi.nlm.nih.gov/31292663

DMTQJE0	DI	DMTQJE0
DMTQJE0	DN	RG3638
DMTQJE0	MI	TTNDSF4
DMTQJE0	MN	Proto-oncogene c-Met (MET)
DMTQJE0	MT	DTT
DMTQJE0	MA	Modulator
DMTQJE0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
DMTQJE0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815

DMER75Y	DI	DMER75Y
DMER75Y	DN	RG6013
DMER75Y	MI	TTFEZ5Q
DMER75Y	MN	Coagulation factor IX (F9)
DMER75Y	MT	DTT
DMER75Y	RN	Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation. J Thromb Haemost. 2014 Feb;12(2):206-13.
DMER75Y	RU	https://pubmed.ncbi.nlm.nih.gov/24738137

DMJRFYB	DI	DMJRFYB
DMJRFYB	DN	RG7201
DMJRFYB	MI	TTN7Y4P
DMJRFYB	MN	Sodium/glucose cotransporter 2 (SLC5A4)
DMJRFYB	MT	DTT
DMJRFYB	MA	Modulator
DMJRFYB	RN	Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol. 2014 Mar 28;13:65.
DMJRFYB	RU	https://pubmed.ncbi.nlm.nih.gov/24678906

DMF5GZI	DI	DMF5GZI
DMF5GZI	DN	RG7388
DMF5GZI	MI	TT0JESD
DMF5GZI	MN	Erbb4 tyrosine kinase receptor (Erbb-4)
DMF5GZI	MT	DTT
DMF5GZI	MA	Inhibitor
DMF5GZI	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1799).
DMF5GZI	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1799

DMF5GZI	DI	DMF5GZI
DMF5GZI	DN	RG7388
DMF5GZI	MI	TT08GJW
DMF5GZI	MN	Ubiquitin-protein ligase E3 Mdm2 (MDM2)
DMF5GZI	MT	DTT
DMF5GZI	MA	Modulator
DMF5GZI	RN	Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma. Oncotarget. 2015 Apr 30;6(12):10207-21.
DMF5GZI	RU	https://pubmed.ncbi.nlm.nih.gov/25844600

DMDVAFP	DI	DMDVAFP
DMDVAFP	DN	RG7601
DMDVAFP	MI	TTJGNVC
DMDVAFP	MN	Apoptosis regulator Bcl-2 (BCL-2)
DMDVAFP	MT	DTT
DMDVAFP	MA	Modulator
DMDVAFP	RN	ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013 Feb;19(2):202-8.
DMDVAFP	RU	https://pubmed.ncbi.nlm.nih.gov/23291630

DMGOTK4	DI	DMGOTK4
DMGOTK4	DN	Rhumab Beta7
DMGOTK4	MI	TTLT9XQ
DMGOTK4	MN	Integrin beta-7 (ITGB7)
DMGOTK4	MT	DTT
DMGOTK4	RN	A randomised phase I study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis. Gut. 2013 Aug;62(8):1122-30.
DMGOTK4	RU	https://pubmed.ncbi.nlm.nih.gov/22717454

DMLHEU7	DI	DMLHEU7
DMLHEU7	DN	Ridaforolimus
DMLHEU7	MI	TTCJG29
DMLHEU7	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMLHEU7	MT	DTT
DMLHEU7	MA	Inhibitor
DMLHEU7	RN	A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
DMLHEU7	RU	https://pubmed.ncbi.nlm.nih.gov/23467907

DMYXOHV	DI	DMYXOHV
DMYXOHV	DN	Rifalazil
DMYXOHV	MI	TTIJ5EB
DMYXOHV	MN	Bacterial RNA polymerase switch region (Bact RNAP-SR)
DMYXOHV	MT	DTT
DMYXOHV	MA	Inhibitor
DMYXOHV	RN	Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8.
DMYXOHV	RU	https://pubmed.ncbi.nlm.nih.gov/17691942

DMYXOHV	DI	DMYXOHV
DMYXOHV	DN	Rifalazil
DMYXOHV	MI	DE4LYSA
DMYXOHV	MN	Cytochrome P450 3A4 (CYP3A4)
DMYXOHV	MT	DME
DMYXOHV	MA	Metabolism
DMYXOHV	RN	Identification of enzymes responsible for rifalazil metabolism in human liver microsomes. Xenobiotica. 2000 Jun;30(6):565-74.
DMYXOHV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10923859

DMKTS2M	DI	DMKTS2M
DMKTS2M	DN	Rifaximin DR
DMKTS2M	MI	TTHKJLN
DMKTS2M	MN	DNA-directed RNA polymerase (RNAP)
DMKTS2M	MT	DTT
DMKTS2M	MA	Inhibitor
DMKTS2M	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMKTS2M	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMOSTXF	DI	DMOSTXF
DMOSTXF	DN	Rigosertib
DMOSTXF	MI	TTHBTOP
DMOSTXF	MN	PI3-kinase gamma (PIK3CG)
DMOSTXF	MT	DTT
DMOSTXF	MA	Modulator
DMOSTXF	RN	Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. Clin Cancer Res. 2014 Mar 15;20(6):1656-65.
DMOSTXF	RU	https://pubmed.ncbi.nlm.nih.gov/24493827

DMOSTXF	DI	DMOSTXF
DMOSTXF	DN	Rigosertib
DMOSTXF	MI	TTIYVQP
DMOSTXF	MN	Polo-like kinase 1 (PLK1)
DMOSTXF	MT	DTT
DMOSTXF	MA	Modulator
DMOSTXF	RN	Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. Clin Cancer Res. 2014 Mar 15;20(6):1656-65.
DMOSTXF	RU	https://pubmed.ncbi.nlm.nih.gov/24493827

DMGTCI0	DI	DMGTCI0
DMGTCI0	DN	Rilimogene galvacirepvec
DMGTCI0	MI	TTS78AZ
DMGTCI0	MN	Prostate specific antigen (KLK3)
DMGTCI0	MT	DTT
DMGTCI0	MA	Modulator
DMGTCI0	RN	Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010 Mar 1;28(7):1099-105.
DMGTCI0	RU	https://pubmed.ncbi.nlm.nih.gov/20100959

DMP6IMQ	DI	DMP6IMQ
DMP6IMQ	DN	Rindopepimut
DMP6IMQ	MI	TTGKNB4
DMP6IMQ	MN	Epidermal growth factor receptor (EGFR)
DMP6IMQ	MT	DTT
DMP6IMQ	MA	Modulator
DMP6IMQ	RN	Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme. Curr Opin Mol Ther. 2010 Dec;12(6):741-54.
DMP6IMQ	RU	https://pubmed.ncbi.nlm.nih.gov/21154166

DMYX7VI	DI	DMYX7VI
DMYX7VI	DN	Rintatolimod
DMYX7VI	MI	TTD24Y0
DMYX7VI	MN	Toll-like receptor 3 (TLR3)
DMYX7VI	MT	DTT
DMYX7VI	RN	A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome. PLoS One. 2012;7(3):e31334.
DMYX7VI	RU	https://pubmed.ncbi.nlm.nih.gov/22431963

DM13V0P	DI	DM13V0P
DM13V0P	DN	Rivoceranib
DM13V0P	MI	TTUTJGQ
DM13V0P	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM13V0P	MT	DTT
DM13V0P	MA	Antagonist
DM13V0P	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM13V0P	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMBY31K	DI	DMBY31K
DMBY31K	DN	Rivoglitazone
DMBY31K	MI	DES5XRU
DMBY31K	MN	Cytochrome P450 2C8 (CYP2C8)
DMBY31K	MT	DME
DMBY31K	MA	Metabolism
DMBY31K	RN	In vitro metabolism of rivoglitazone, a novel peroxisome proliferator-activated receptor gama agonist, in rat, monkey, and human liver microsomes and freshly isolated hepatocytes. Drug Metab Dispos. 2011 Jul;39(7):1311-9.
DMBY31K	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21511943

DMBY31K	DI	DMBY31K
DMBY31K	DN	Rivoglitazone
DMBY31K	MI	DE4LYSA
DMBY31K	MN	Cytochrome P450 3A4 (CYP3A4)
DMBY31K	MT	DME
DMBY31K	MA	Metabolism
DMBY31K	RN	Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther. 2005 May;77(5):404-14.
DMBY31K	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15900286

DMBY31K	DI	DMBY31K
DMBY31K	DN	Rivoglitazone
DMBY31K	MI	TTZMAO3
DMBY31K	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMBY31K	MT	DTT
DMBY31K	MA	Agonist
DMBY31K	RN	A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes. Diabetes Obes Metab. 2011 Sep;13(9):806-13.
DMBY31K	RU	https://pubmed.ncbi.nlm.nih.gov/21492364

DMBY31K	DI	DMBY31K
DMBY31K	DN	Rivoglitazone
DMBY31K	MI	DEF2WXN
DMBY31K	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMBY31K	MT	DME
DMBY31K	MA	Metabolism
DMBY31K	RN	In vitro metabolism of rivoglitazone, a novel peroxisome proliferator-activated receptor gama agonist, in rat, monkey, and human liver microsomes and freshly isolated hepatocytes. Drug Metab Dispos. 2011 Jul;39(7):1311-9.
DMBY31K	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21511943

DMBY31K	DI	DMBY31K
DMBY31K	DN	Rivoglitazone
DMBY31K	MI	DEB3CV1
DMBY31K	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMBY31K	MT	DME
DMBY31K	MA	Metabolism
DMBY31K	RN	In vitro metabolism of rivoglitazone, a novel peroxisome proliferator-activated receptor gama agonist, in rat, monkey, and human liver microsomes and freshly isolated hepatocytes. Drug Metab Dispos. 2011 Jul;39(7):1311-9.
DMBY31K	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21511943

DMVQ5X1	DI	DMVQ5X1
DMVQ5X1	DN	Roclatan
DMVQ5X1	MI	TTAWNKZ
DMVQ5X1	MN	Norepinephrine transporter (NET)
DMVQ5X1	MT	DTT
DMVQ5X1	MA	Modulator
DMVQ5X1	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMVQ5X1	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMVQ5X1	DI	DMVQ5X1
DMVQ5X1	DN	Roclatan
DMVQ5X1	MI	TTMQO60
DMVQ5X1	MN	Rho-associated protein kinase (ROCK)
DMVQ5X1	MT	DTT
DMVQ5X1	MA	Modulator
DMVQ5X1	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMVQ5X1	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMSZPR3	DI	DMSZPR3
DMSZPR3	DN	Rolofylline
DMSZPR3	MI	TTK25J1
DMSZPR3	MN	Adenosine A1 receptor (ADORA1)
DMSZPR3	MT	DTT
DMSZPR3	MA	Antagonist
DMSZPR3	RN	Association between the PDE4D gene and ischaemic stroke in the Chinese Han population. Clin Sci (Lond). 2009 Aug 17;117(7):265-72.
DMSZPR3	RU	https://pubmed.ncbi.nlm.nih.gov/19196240

DMSZPR3	DI	DMSZPR3
DMSZPR3	DN	Rolofylline
DMSZPR3	MI	DE4LYSA
DMSZPR3	MN	Cytochrome P450 3A4 (CYP3A4)
DMSZPR3	MT	DME
DMSZPR3	MA	Metabolism
DMSZPR3	RN	Simultaneous pharmacokinetic model for rolofylline and both M1-trans and M1-cis metabolites. AAPS J. 2013 Apr;15(2):498-504.
DMSZPR3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23355301

DMPIDXT	DI	DMPIDXT
DMPIDXT	DN	Rosiglitazone + metformin
DMPIDXT	MI	TTPS3C0
DMPIDXT	MN	Aurora kinase A (AURKA)
DMPIDXT	MT	DTT
DMPIDXT	MA	Inhibitor
DMPIDXT	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMPIDXT	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMPIDXT	DI	DMPIDXT
DMPIDXT	DN	Rosiglitazone + metformin
DMPIDXT	MI	TT5LS6T
DMPIDXT	MN	Aurora kinase B (AURKB)
DMPIDXT	MT	DTT
DMPIDXT	MA	Inhibitor
DMPIDXT	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMPIDXT	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMPIDXT	DI	DMPIDXT
DMPIDXT	DN	Rosiglitazone + metformin
DMPIDXT	MI	TTRLW2X
DMPIDXT	MN	Fibroblast growth factor receptor 1 (FGFR1)
DMPIDXT	MT	DTT
DMPIDXT	MA	Inhibitor
DMPIDXT	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMPIDXT	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMPIDXT	DI	DMPIDXT
DMPIDXT	DN	Rosiglitazone + metformin
DMPIDXT	MI	TTZMAO3
DMPIDXT	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMPIDXT	MT	DTT
DMPIDXT	MA	Agonist
DMPIDXT	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMPIDXT	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMPIDXT	DI	DMPIDXT
DMPIDXT	DN	Rosiglitazone + metformin
DMPIDXT	MI	TTI2WET
DMPIDXT	MN	Platelet-derived growth factor receptor (PDGFR)
DMPIDXT	MT	DTT
DMPIDXT	MA	Inhibitor
DMPIDXT	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMPIDXT	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMPIDXT	DI	DMPIDXT
DMPIDXT	DN	Rosiglitazone + metformin
DMPIDXT	MI	TTUTJGQ
DMPIDXT	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMPIDXT	MT	DTT
DMPIDXT	MA	Inhibitor
DMPIDXT	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMPIDXT	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DM18B72	DI	DM18B72
DM18B72	DN	Rosiglitazone + simvastatin
DM18B72	MI	TTZMAO3
DM18B72	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DM18B72	MT	DTT
DM18B72	MA	Agonist
DM18B72	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DM18B72	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMNGCAD	DI	DMNGCAD
DMNGCAD	DN	Rova-T
DMNGCAD	MI	TT1C9K6
DMNGCAD	MN	Delta-like protein 3 (DLL3)
DMNGCAD	MT	DTT
DMNGCAD	MA	Inhibitor
DMNGCAD	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMNGCAD	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DM9T8OF	DI	DM9T8OF
DM9T8OF	DN	RQ-00000004
DM9T8OF	MI	TTLOKXP
DM9T8OF	MN	Gastric H(+)/K(+) ATPase (Proton pump)
DM9T8OF	MT	DTT
DM9T8OF	MA	Modulator
DM9T8OF	RN	N-(2-hydroxyethyl)-N,2-dimethyl-8-{[(4R)-5-methyl-3,4-dihydro-2H-chromen-4-yl]amino}imidazo[1,2-a]pyridine-6-carboxamide (PF-03716556), a novel, potent, and selective acid pump antagonist for the treatment of gastroesophageal reflux disease. J Pharmacol Exp Ther. 2009 Feb;328(2):671-9.
DM9T8OF	RU	https://pubmed.ncbi.nlm.nih.gov/18981288

DMQM2FH	DI	DMQM2FH
DMQM2FH	DN	RRx-001
DMQM2FH	MI	TT8E7Z0
DMQM2FH	MN	Free radical (FRD)
DMQM2FH	MT	DTT
DMQM2FH	MA	Modulator
DMQM2FH	RN	Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials. Cancer Res. 2012 May 15;72(10):2600-8.
DMQM2FH	RU	https://pubmed.ncbi.nlm.nih.gov/22589277

DM62QTW	DI	DM62QTW
DM62QTW	DN	RTB101
DM62QTW	MI	TT4GO0F
DM62QTW	MN	CREB-regulated transcription coactivator 1 (TORC1)
DM62QTW	MT	DTT
DM62QTW	MA	Inhibitor
DM62QTW	RN	Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612.
DM62QTW	RU	https://pubmed.ncbi.nlm.nih.gov/30072728

DMDWU1S	DI	DMDWU1S
DMDWU1S	DN	Rubitecan
DMDWU1S	MI	TTGTQHC
DMDWU1S	MN	DNA topoisomerase I (TOP1)
DMDWU1S	MT	DTT
DMDWU1S	MA	Inhibitor
DMDWU1S	RN	Rubitecan. Expert Opin Investig Drugs. 2006 Jan;15(1):71-9.
DMDWU1S	RU	https://pubmed.ncbi.nlm.nih.gov/16370935

DMDWU1S	DI	DMDWU1S
DMDWU1S	DN	Rubitecan
DMDWU1S	MI	DTCSGPB
DMDWU1S	MN	Multidrug resistance-associated protein 4 (ABCC4)
DMDWU1S	MT	DTP
DMDWU1S	MA	Substrate
DMDWU1S	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMDWU1S	RU	https://doi.org/10.1007/s11095-012-0935-x

DMQOCD8	DI	DMQOCD8
DMQOCD8	DN	RUBOXISTAURIN HYDROCHLORIDE
DMQOCD8	MI	TTYPXQF
DMQOCD8	MN	Protein kinase C beta (PRKCB)
DMQOCD8	MT	DTT
DMQOCD8	MA	Modulator
DMQOCD8	RN	Ruboxistaurin: LY 333531. Drugs R D. 2007;8(3):193-9.
DMQOCD8	RU	https://pubmed.ncbi.nlm.nih.gov/17472415

DM25TMP	DI	DM25TMP
DM25TMP	DN	Rubraca rucaparib
DM25TMP	MI	TTEBCY8
DM25TMP	MN	Poly [ADP-ribose] polymerase (PARP)
DM25TMP	MT	DTT
DM25TMP	MA	Inhibitor
DM25TMP	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM25TMP	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM20KYR	DI	DM20KYR
DM20KYR	DN	Ruxolitinib
DM20KYR	MI	TTWKB01
DM20KYR	MN	HUMAN janus kinase 1 (JAK-1)
DM20KYR	MT	DTT
DM20KYR	MA	Inhibitor
DM20KYR	RN	The Use of Anti-Inflammatory Drugs in the Treatment of People With Severe Coronavirus Disease 2019 (COVID-19): The Perspectives of Clinical Immunologists From China. Clin Immunol. 2020 May;214:108393.
DM20KYR	RU	https://pubmed.ncbi.nlm.nih.gov/32222466

DM20KYR	DI	DM20KYR
DM20KYR	DN	Ruxolitinib
DM20KYR	MI	TT0F5HE
DM20KYR	MN	HUMAN janus kinase 2 (JAK-2)
DM20KYR	MT	DTT
DM20KYR	MA	Inhibitor
DM20KYR	RN	The Use of Anti-Inflammatory Drugs in the Treatment of People With Severe Coronavirus Disease 2019 (COVID-19): The Perspectives of Clinical Immunologists From China. Clin Immunol. 2020 May;214:108393.
DM20KYR	RU	https://pubmed.ncbi.nlm.nih.gov/32222466

DMAYTIH	DI	DMAYTIH
DMAYTIH	DN	S-06911
DMAYTIH	MI	TTK59TV
DMAYTIH	MN	Vitamin D3 receptor (VDR)
DMAYTIH	MT	DTT
DMAYTIH	MA	Inhibitor
DMAYTIH	RN	Evidence for tissue- and cell-type selective activation of the vitamin D receptor by Ro-26-9228, a noncalcemic analog of vitamin D3. J Cell Biochem. 2003 Feb 1;88(2):267-73.
DMAYTIH	RU	https://pubmed.ncbi.nlm.nih.gov/12520525

DMXY34J	DI	DMXY34J
DMXY34J	DN	S-110
DMXY34J	MI	TTHVCUP
DMXY34J	MN	DNA [cytosine-5]-methyltransferase (DNMT)
DMXY34J	MT	DTT
DMXY34J	MA	Inhibitor
DMXY34J	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMXY34J	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DMXY34J	DI	DMXY34J
DMXY34J	DN	S-110
DMXY34J	MI	TT6S2FE
DMXY34J	MN	DNA [cytosine-5]-methyltransferase 1 (DNMT1)
DMXY34J	MT	DTT
DMXY34J	MA	Inhibitor
DMXY34J	RN	S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol Cancer Ther. 2010 May;9(5):1443-50.
DMXY34J	RU	https://pubmed.ncbi.nlm.nih.gov/20442312

DM408GM	DI	DM408GM
DM408GM	DN	S-474474
DM408GM	MI	TT8DBY3
DM408GM	MN	Angiotensin II receptor type-1 (AGTR1)
DM408GM	MT	DTT
DM408GM	MA	Blocker
DM408GM	RN	Clinical pipeline report, company report or official report of Shionogi (2011).
DM408GM	RU	http://www.shionogi.co.jp/index_e.html

DM7F2VG	DI	DM7F2VG
DM7F2VG	DN	SA-237
DM7F2VG	MI	TT0E5SK
DM7F2VG	MN	Interleukin 6 receptor (IL6R)
DM7F2VG	MT	DTT
DM7F2VG	MA	Antagonist
DM7F2VG	RN	IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics International Conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CA. MAbs. 2013 March 1; 5(2): 178-201.
DM7F2VG	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893229/

DMGR98T	DI	DMGR98T
DMGR98T	DN	SAGE-217
DMGR98T	MI	TTEX6LM
DMGR98T	MN	GABA(A) receptor gamma-3 (GABRG3)
DMGR98T	MT	DTT
DMGR98T	MA	Modulator
DMGR98T	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMGR98T	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMI1R5S	DI	DMI1R5S
DMI1R5S	DN	SAIT101
DMI1R5S	MI	TTUE541
DMI1R5S	MN	Leukocyte surface antigen Leu-16 (CD20)
DMI1R5S	MT	DTT
DMI1R5S	RN	Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy. Front Oncol. 2018 Jun 4;8:163.
DMI1R5S	RU	https://pubmed.ncbi.nlm.nih.gov/29915719

DMKHLRT	DI	DMKHLRT
DMKHLRT	DN	SAND-26
DMKHLRT	MI	TTDIGC1
DMKHLRT	MN	Dipeptidyl peptidase 4 (DPP-4)
DMKHLRT	MT	DTT
DMKHLRT	RN	Clinical pipeline report, company report or official report of Siesonline.
DMKHLRT	RU	http://www.siesonline.it/en/wp-content/uploads/2013/05/21.pdf

DMXAO4J	DI	DMXAO4J
DMXAO4J	DN	SAR153191
DMXAO4J	MI	TT0E5SK
DMXAO4J	MN	Interleukin 6 receptor (IL6R)
DMXAO4J	MT	DTT
DMXAO4J	MA	Antagonist
DMXAO4J	RN	Pharma & Vaccines. Product Development Pipeline. April 29 2009.
DMXAO4J	RU	http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf

DMHFBOG	DI	DMHFBOG
DMHFBOG	DN	SAR231893
DMHFBOG	MI	TTDWHC3
DMHFBOG	MN	Interleukin 4 receptor alpha (IL4R)
DMHFBOG	MT	DTT
DMHFBOG	MA	Modulator
DMHFBOG	RN	Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013 Jun 27;368(26):2455-66.
DMHFBOG	RU	https://pubmed.ncbi.nlm.nih.gov/23688323

DMR0EWV	DI	DMR0EWV
DMR0EWV	DN	SAR342434
DMR0EWV	MI	TTZOPHG
DMR0EWV	MN	Insulin (INS)
DMR0EWV	MT	DTT
DMR0EWV	MA	Modulator
DMR0EWV	RN	Biosimilar insulins: a European perspective. Diabetes Obes Metab. 2015 May; 17(5): 445-451.
DMR0EWV	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403967/

DMXGE3O	DI	DMXGE3O
DMXGE3O	DN	SAR408701
DMXGE3O	MI	TTY6DTE
DMXGE3O	MN	Carcinoembryonic antigen CEA (CD66e)
DMXGE3O	MT	DTT
DMXGE3O	RN	ClinicalTrials.gov (NCT02187848) Evaluation of SAR408701 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
DMXGE3O	RU	https://clinicaltrials.gov/ct2/show/NCT02187848

DMDMAE4	DI	DMDMAE4
DMDMAE4	DN	SAR438584
DMDMAE4	MI	TT57ID8
DMDMAE4	MN	Respiratory syncytial virus protein F (RSV F)
DMDMAE4	MT	DTT
DMDMAE4	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040470)
DMDMAE4	RU	http://adisinsight.springer.com/drugs/800040470

DM8HCFD	DI	DM8HCFD
DM8HCFD	DN	Sarilumab
DM8HCFD	MI	TTDVAKP
DM8HCFD	MN	HUMAN interleukin-6 receptor (IL6R)
DM8HCFD	MT	DTT
DM8HCFD	MA	Blocker
DM8HCFD	RN	IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015 May;16(5):448-57.
DM8HCFD	RU	https://pubmed.ncbi.nlm.nih.gov/25898198

DMUVSG4	DI	DMUVSG4
DMUVSG4	DN	Sasanlimab
DMUVSG4	MI	TTNBFWK
DMUVSG4	MN	Programmed cell death protein 1 (PD-1)
DMUVSG4	MT	DTT
DMUVSG4	RN	Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody. Mol Cancer Ther. 2020 Oct;19(10):2105-2116.
DMUVSG4	RU	https://pubmed.ncbi.nlm.nih.gov/32847983

DME5PN3	DI	DME5PN3
DME5PN3	DN	Satavaptan
DME5PN3	MI	TTK8R02
DME5PN3	MN	Vasopressin V2 receptor (V2R)
DME5PN3	MT	DTT
DME5PN3	MA	Antagonist
DME5PN3	RN	Post-translational import of protein into the endoplasmic reticulum of a trypanosome: an in vitro system for discovery of anti-trypanosomal chemical entities. Biochem J. 2009 Apr 15;419(2):507-17.
DME5PN3	RU	https://pubmed.ncbi.nlm.nih.gov/19196237

DMALFKX	DI	DMALFKX
DMALFKX	DN	Savolitinib
DMALFKX	MI	TTNDSF4
DMALFKX	MN	Proto-oncogene c-Met (MET)
DMALFKX	MT	DTT
DMALFKX	MA	Inhibitor
DMALFKX	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMALFKX	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMAPRWV	DI	DMAPRWV
DMAPRWV	DN	SaxaDapa FDC
DMAPRWV	MI	TTDIGC1
DMAPRWV	MN	Dipeptidyl peptidase 4 (DPP-4)
DMAPRWV	MT	DTT
DMAPRWV	MA	Modulator
DMAPRWV	RN	Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. Cardiol Rev. 2010 Jul-Aug;18(4):213-7.
DMAPRWV	RU	https://pubmed.ncbi.nlm.nih.gov/20539105

DMAPRWV	DI	DMAPRWV
DMAPRWV	DN	SaxaDapa FDC
DMAPRWV	MI	TTN7Y4P
DMAPRWV	MN	Sodium/glucose cotransporter 2 (SLC5A4)
DMAPRWV	MT	DTT
DMAPRWV	MA	Modulator
DMAPRWV	RN	Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. Cardiol Rev. 2010 Jul-Aug;18(4):213-7.
DMAPRWV	RU	https://pubmed.ncbi.nlm.nih.gov/20539105

DMME6GJ	DI	DMME6GJ
DMME6GJ	DN	SB12
DMME6GJ	MI	TTKANGO
DMME6GJ	MN	Complement C5 (CO5)
DMME6GJ	MT	DTT
DMME6GJ	MA	Inhibitor
DMME6GJ	RN	Clinical promise of next-generation complement therapeutics. Nat Rev Drug Discov. 2019 Sep;18(9):707-729.
DMME6GJ	RU	https://pubmed.ncbi.nlm.nih.gov/31324874

DM6L4ZT	DI	DM6L4ZT
DM6L4ZT	DN	SB-742457
DM6L4ZT	MI	TTJS8PY
DM6L4ZT	MN	5-HT 6 receptor (HTR6)
DM6L4ZT	MT	DTT
DM6L4ZT	MA	Antagonist
DM6L4ZT	RN	5-HT6 receptors and Alzheimer's disease. Alzheimers Res Ther. 2013; 5(2): 15.
DM6L4ZT	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706851/

DM6XNJR	DI	DM6XNJR
DM6XNJR	DN	SC-46553
DM6XNJR	MI	DEUO7V8
DM6XNJR	MN	Beta-glucosidase (bglA)
DM6XNJR	MT	DME
DM6XNJR	MA	Metabolism
DM6XNJR	RN	Constitutive beta-glucosidases hydrolyzing ginsenoside Rb1 and Rb2 from human intestinal bacteria. Biol Pharm Bull. 2000 Dec;23(12):1481-5.
DM6XNJR	RU	https://pubmed.ncbi.nlm.nih.gov/11145182

DM6XNJR	DI	DM6XNJR
DM6XNJR	DN	SC-46553
DM6XNJR	MI	DE4LKZ9
DM6XNJR	MN	Beta-glucosidase (bglA)
DM6XNJR	MT	DME
DM6XNJR	MA	Metabolism
DM6XNJR	RN	Constitutive beta-glucosidases hydrolyzing ginsenoside Rb1 and Rb2 from human intestinal bacteria. Biol Pharm Bull. 2000 Dec;23(12):1481-5.
DM6XNJR	RU	https://pubmed.ncbi.nlm.nih.gov/11145182

DM6XNJR	DI	DM6XNJR
DM6XNJR	DN	SC-46553
DM6XNJR	MI	DEM6GYO
DM6XNJR	MN	Beta-glucosidase (bglA)
DM6XNJR	MT	DME
DM6XNJR	MA	Metabolism
DM6XNJR	RN	nan
DM6XNJR	RU	nan

DM6XNJR	DI	DM6XNJR
DM6XNJR	DN	SC-46553
DM6XNJR	MI	DE9N4OU
DM6XNJR	MN	Beta-glucosidase (bglA)
DM6XNJR	MT	DME
DM6XNJR	MA	Metabolism
DM6XNJR	RN	Characterization of the ginsenoside-transforming recombinant beta-glucosidase from Actinosynnema mirum and bioconversion of major ginsenosides into minor ginsenosides. Appl Microbiol Biotechnol. 2013 Jan;97(2):649-59.
DM6XNJR	RU	https://pubmed.ncbi.nlm.nih.gov/22911093

DMK1IPV	DI	DMK1IPV
DMK1IPV	DN	SCY-078
DMK1IPV	MI	TT0SFXH
DMK1IPV	MN	Fungal 1,3-beta-glucan synthase (Fung GSC2)
DMK1IPV	MT	DTT
DMK1IPV	MA	Inhibitor
DMK1IPV	RN	Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model. Antimicrob Agents Chemother. 2015 Feb;59(2):1265-72.
DMK1IPV	RU	https://pubmed.ncbi.nlm.nih.gov/25512406

DMAMTGI	DI	DMAMTGI
DMAMTGI	DN	SD-101
DMAMTGI	MI	TTSHG0T
DMAMTGI	MN	Toll-like receptor 9 (TLR9)
DMAMTGI	MT	DTT
DMAMTGI	RN	Novel drugs targeting Toll-like receptors for antiviral therapy. Future Virol. 2014 September; 9(9): 811-829.
DMAMTGI	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303062/

DM9DEYL	DI	DM9DEYL
DM9DEYL	DN	SD-6010
DM9DEYL	MI	TTF10I9
DM9DEYL	MN	Nitric-oxide synthase inducible (NOS2)
DM9DEYL	MT	DTT
DM9DEYL	MA	Inhibitor
DM9DEYL	RN	A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee. Ann Rheum Dis. 2013 Feb;72(2):187-95.
DM9DEYL	RU	https://pubmed.ncbi.nlm.nih.gov/23144445

DMBD4K3	DI	DMBD4K3
DMBD4K3	DN	Selinexor
DMBD4K3	MI	DE4LYSA
DMBD4K3	MN	Cytochrome P450 3A4 (CYP3A4)
DMBD4K3	MT	DME
DMBD4K3	MA	Metabolism
DMBD4K3	RN	FDA label of Selinexor. The 2020 official website of the U.S. Food and Drug Administration.
DMBD4K3	RU	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212306Orig1s000MultidisciplineR.pdf

DMBD4K3	DI	DMBD4K3
DMBD4K3	DN	Selinexor
DMBD4K3	MI	TTCJUR4
DMBD4K3	MN	Exportin-1 (XPO1)
DMBD4K3	MT	DTT
DMBD4K3	MA	Inhibitor
DMBD4K3	RN	Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents. Semin Cancer Biol. 2014 August; 0: 62-73.
DMBD4K3	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108511/

DMBD4K3	DI	DMBD4K3
DMBD4K3	DN	Selinexor
DMBD4K3	MI	DE4ZHS1
DMBD4K3	MN	Glutathione S-transferase alpha-1 (GSTA1)
DMBD4K3	MT	DME
DMBD4K3	MA	Metabolism
DMBD4K3	RN	FDA label of Selinexor. The 2020 official website of the U.S. Food and Drug Administration.
DMBD4K3	RU	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212306Orig1s000MultidisciplineR.pdf

DMBD4K3	DI	DMBD4K3
DMBD4K3	DN	Selinexor
DMBD4K3	MI	DEYGVN4
DMBD4K3	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMBD4K3	MT	DME
DMBD4K3	MA	Metabolism
DMBD4K3	RN	FDA label of Selinexor. The 2020 official website of the U.S. Food and Drug Administration.
DMBD4K3	RU	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212306Orig1s000MultidisciplineR.pdf

DMC7W6R	DI	DMC7W6R
DMC7W6R	DN	Selumetinib
DMC7W6R	MI	TTIDAPM
DMC7W6R	MN	ERK activator kinase 1 (MEK1)
DMC7W6R	MT	DTT
DMC7W6R	MA	Inhibitor
DMC7W6R	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMC7W6R	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMC7W6R	DI	DMC7W6R
DMC7W6R	DN	Selumetinib
DMC7W6R	MI	TTTW2NY
DMC7W6R	MN	ERK activator kinase 2 (MEK2)
DMC7W6R	MT	DTT
DMC7W6R	MA	Inhibitor
DMC7W6R	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMC7W6R	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMC7W6R	DI	DMC7W6R
DMC7W6R	DN	Selumetinib
DMC7W6R	MI	TTROQ37
DMC7W6R	MN	MAPK/ERK kinase kinase (MAP3K)
DMC7W6R	MT	DTT
DMC7W6R	MA	Modulator
DMC7W6R	RN	Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells.Br J Cancer.2012 May 8;106(10):1648-59.
DMC7W6R	RU	https://www.ncbi.nlm.nih.gov/pubmed/22569000

DML83IW	DI	DML83IW
DML83IW	DN	Semagacestat
DML83IW	MI	DE4LYSA
DML83IW	MN	Cytochrome P450 3A4 (CYP3A4)
DML83IW	MT	DME
DML83IW	MA	Metabolism
DML83IW	RN	Disposition and metabolism of semagacestat, a {gamma}-secretase inhibitor, in humans. Drug Metab Dispos. 2010 Apr;38(4):554-65.
DML83IW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20075192

DML83IW	DI	DML83IW
DML83IW	DN	Semagacestat
DML83IW	MI	DEIBDNY
DML83IW	MN	Cytochrome P450 3A5 (CYP3A5)
DML83IW	MT	DME
DML83IW	MA	Metabolism
DML83IW	RN	Disposition and metabolism of semagacestat, a {gamma}-secretase inhibitor, in humans. Drug Metab Dispos. 2010 Apr;38(4):554-65.
DML83IW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20075192

DML83IW	DI	DML83IW
DML83IW	DN	Semagacestat
DML83IW	MI	TT9W8GU
DML83IW	MN	Gamma-secretase (GS)
DML83IW	MT	DTT
DML83IW	MA	Modulator
DML83IW	RN	A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013 Jul 25;369(4):341-50.
DML83IW	RU	https://pubmed.ncbi.nlm.nih.gov/23883379

DMKL9QO	DI	DMKL9QO
DMKL9QO	DN	Seocalcitol
DMKL9QO	MI	TTK59TV
DMKL9QO	MN	Vitamin D3 receptor (VDR)
DMKL9QO	MT	DTT
DMKL9QO	MA	Inhibitor
DMKL9QO	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMKL9QO	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMG2QP4	DI	DMG2QP4
DMG2QP4	DN	SEP-363856
DMG2QP4	MI	TTSQIFT
DMG2QP4	MN	5-HT 1A receptor (HTR1A)
DMG2QP4	MT	DTT
DMG2QP4	MA	Agonist
DMG2QP4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMG2QP4	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMG2QP4	DI	DMG2QP4
DMG2QP4	DN	SEP-363856
DMG2QP4	MI	TTIU98M
DMG2QP4	MN	Trace amine-associated receptor-1 (TAAR1)
DMG2QP4	MT	DTT
DMG2QP4	MA	Agonist
DMG2QP4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMG2QP4	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM5VH6U	DI	DM5VH6U
DM5VH6U	DN	Serlopitant
DM5VH6U	MI	TTZPO1L
DM5VH6U	MN	Substance-P receptor (TACR1)
DM5VH6U	MT	DTT
DM5VH6U	MA	Antagonist
DM5VH6U	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM5VH6U	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMZ61IA	DI	DMZ61IA
DMZ61IA	DN	Setipiprant
DMZ61IA	MI	TTNVEIR
DMZ61IA	MN	Prostaglandin D2 receptor (PTGDR)
DMZ61IA	MT	DTT
DMZ61IA	MA	Antagonist
DMZ61IA	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZ61IA	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMZ61IA	DI	DMZ61IA
DMZ61IA	DN	Setipiprant
DMZ61IA	MI	TTQDMX5
DMZ61IA	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMZ61IA	MT	DTT
DMZ61IA	MA	Antagonist
DMZ61IA	RN	Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics. Clin Exp Allergy. 2014 Aug;44(8):1044-52.
DMZ61IA	RU	https://pubmed.ncbi.nlm.nih.gov/24964348

DM1NQDW	DI	DM1NQDW
DM1NQDW	DN	SGI110
DM1NQDW	MI	TT6S2FE
DM1NQDW	MN	DNA [cytosine-5]-methyltransferase 1 (DNMT1)
DM1NQDW	MT	DTT
DM1NQDW	MA	Modulator
DM1NQDW	RN	Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts. Epigenetics. 2015;10(3):237-46.
DM1NQDW	RU	https://pubmed.ncbi.nlm.nih.gov/25793777

DM4N1SP	DI	DM4N1SP
DM4N1SP	DN	Shigamabs
DM4N1SP	MI	TT1HYOF
DM4N1SP	MN	Bacterial Shiga toxin 2 subunit B (Bact stxII)
DM4N1SP	MT	DTT
DM4N1SP	MA	Modulator
DM4N1SP	RN	Antibacterial antibodies gain traction. Nat Rev Drug Discov. 2015 Nov;14(11):737-8. 
DM4N1SP	RU	https://www.ncbi.nlm.nih.gov/pubmed/26514853

DMEWRXA	DI	DMEWRXA
DMEWRXA	DN	SHP647
DMEWRXA	MI	TTBD6I7
DMEWRXA	MN	Mucosal addressin cell adhesion molecule 1 (MADCAM1)
DMEWRXA	MT	DTT
DMEWRXA	MA	Inhibitor
DMEWRXA	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMEWRXA	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMMIWCE	DI	DMMIWCE
DMMIWCE	DN	Sifuvirtide
DMMIWCE	MI	TTG90S6
DMMIWCE	MN	Human immunodeficiency virus Glycoprotein 41 (HIV gp41)
DMMIWCE	MT	DTT
DMMIWCE	MA	Modulator
DMMIWCE	RN	Broad antiviral activity and crystal structure of HIV-1 fusion inhibitor sifuvirtide.J Biol Chem.2012 Feb 24;287(9):6788-96.
DMMIWCE	RU	https://www.ncbi.nlm.nih.gov/pubmed/22228771

DM4YDAJ	DI	DM4YDAJ
DM4YDAJ	DN	Sildenafil
DM4YDAJ	MI	TTRYFSB
DM4YDAJ	MN	HUMAN phosphodiesterase type 5 (PDE5)
DM4YDAJ	MT	DTT
DM4YDAJ	MA	Inhibitor
DM4YDAJ	RN	Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus. J Virol. 2005 Feb;79(3):1966-9. doi: 10.1128/JVI.79.3.1966-1969.2005.
DM4YDAJ	RU	https://pubmed.ncbi.nlm.nih.gov/15650225

DMVO7UW	DI	DMVO7UW
DMVO7UW	DN	Siltuximab
DMVO7UW	MI	TTJH4Y5
DMVO7UW	MN	HUMAN interleukin 6 (IL6)
DMVO7UW	MT	DTT
DMVO7UW	MA	Inhibitor
DMVO7UW	RN	Siltuximab. In: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006. 2018 Dec 3.
DMVO7UW	RU	https://pubmed.ncbi.nlm.nih.gov/29999789

DM18QHT	DI	DM18QHT
DM18QHT	DN	Simvastatin acid
DM18QHT	MI	DTUGYRD
DM18QHT	MN	P-glycoprotein 1 (ABCB1)
DM18QHT	MT	DTP
DM18QHT	MA	Substrate
DM18QHT	RN	Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin. Pharm Res. 2004 Sep;21(9):1686-91.
DM18QHT	RU	https://doi.org/10.1023/B:PHAM.0000041466.84653.8c

DMK8AQP	DI	DMK8AQP
DMK8AQP	DN	Sirukumab
DMK8AQP	MI	TT0E5SK
DMK8AQP	MN	Interleukin 6 receptor (IL6R)
DMK8AQP	MT	DTT
DMK8AQP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2310).
DMK8AQP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2310

DMK8AQP	DI	DMK8AQP
DMK8AQP	DN	Sirukumab
DMK8AQP	MI	TTT1V78
DMK8AQP	MN	Interleukin-6 (IL6)
DMK8AQP	MT	DTT
DMK8AQP	MA	Inhibitor
DMK8AQP	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMK8AQP	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DM6BZCV	DI	DM6BZCV
DM6BZCV	DN	Sivelestat
DM6BZCV	MI	TTPLTSQ
DM6BZCV	MN	Neutrophil elastase (NE)
DM6BZCV	MT	DTT
DM6BZCV	MA	Inhibitor
DM6BZCV	RN	Neutrophil elastase inhibitor (sivelestat) reduces the levels of inflammatory mediators by inhibiting NF-kB. Inflamm Res. 2009 Apr;58(4):198-203.
DM6BZCV	RU	https://pubmed.ncbi.nlm.nih.gov/19169649

DM6BZCV	DI	DM6BZCV
DM6BZCV	DN	Sivelestat
DM6BZCV	MI	TT3NKIB
DM6BZCV	MN	Pancreatic elastase 1 (CELA1)
DM6BZCV	MT	DTT
DM6BZCV	MA	Inhibitor
DM6BZCV	RN	Sivelestat (selective neutrophil elastase inhibitor) improves the mortality rate of sepsis associated with both acute respiratory distress syndrome... Shock. 2010 Jan;33(1):14-8.
DM6BZCV	RU	https://pubmed.ncbi.nlm.nih.gov/19487982

DMWOF1E	DI	DMWOF1E
DMWOF1E	DN	SKY59
DMWOF1E	MI	TTKANGO
DMWOF1E	MN	Complement C5 (CO5)
DMWOF1E	MT	DTT
DMWOF1E	MA	Inhibitor
DMWOF1E	RN	The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. Blood. 2020 Mar 19;135(12):912-920.
DMWOF1E	RU	https://pubmed.ncbi.nlm.nih.gov/31978221

DMH7W9X	DI	DMH7W9X
DMH7W9X	DN	SNDX-275
DMH7W9X	MI	TTBH0VX
DMH7W9X	MN	Histone deacetylase (HDAC)
DMH7W9X	MT	DTT
DMH7W9X	MA	Inhibitor
DMH7W9X	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMH7W9X	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMH7W9X	DI	DMH7W9X
DMH7W9X	DN	SNDX-275
DMH7W9X	MI	TT6R7JZ
DMH7W9X	MN	Histone deacetylase 1 (HDAC1)
DMH7W9X	MT	DTT
DMH7W9X	MA	Inhibitor
DMH7W9X	RN	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
DMH7W9X	RU	https://pubmed.ncbi.nlm.nih.gov/19249983

DMOQKAD	DI	DMOQKAD
DMOQKAD	DN	SNF472
DMOQKAD	MI	TTGUHMF
DMOQKAD	MN	Hydroxyapatite (HA)
DMOQKAD	MT	DTT
DMOQKAD	MA	Binder
DMOQKAD	RN	Clinical pipeline report, company report or official report of Sanifit.
DMOQKAD	RU	https://www.sanifit.com/lead-compound-snf472/

DMZE2JO	DI	DMZE2JO
DMZE2JO	DN	SNS-595
DMZE2JO	MI	TT0IHXV
DMZE2JO	MN	DNA topoisomerase II (TOP2)
DMZE2JO	MT	DTT
DMZE2JO	MA	Modulator
DMZE2JO	RN	A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia.Haematologica.2015 Feb;100(2):231-7.
DMZE2JO	RU	https://www.ncbi.nlm.nih.gov/pubmed/25381131

DMPBA0D	DI	DMPBA0D
DMPBA0D	DN	Sofpironium bromide
DMPBA0D	MI	TTUPDWN
DMPBA0D	MN	Cholinergic receptor unspecific (CHR)
DMPBA0D	MT	DTT
DMPBA0D	MA	Antagonist
DMPBA0D	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPBA0D	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM0HIU5	DI	DM0HIU5
DM0HIU5	DN	Solanezumab
DM0HIU5	MI	TTE4KHA
DM0HIU5	MN	Amyloid beta A4 protein (APP)
DM0HIU5	MT	DTT
DM0HIU5	MA	Modulator
DM0HIU5	RN	Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23;370(4):311-21.
DM0HIU5	RU	https://pubmed.ncbi.nlm.nih.gov/24450890

DM6QZIA	DI	DM6QZIA
DM6QZIA	DN	Solithromycin
DM6QZIA	MI	TTUWYEA
DM6QZIA	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DM6QZIA	MT	DTT
DM6QZIA	MA	Modulator
DM6QZIA	RN	Company report (cempra)
DM6QZIA	RU	http://www.cempra.com/products/Solithromycin-cem-101/

DMLAYTP	DI	DMLAYTP
DMLAYTP	DN	Soluble ferric pyrophosphate
DMLAYTP	MI	TTUDR0C
DMLAYTP	MN	Iron (Fe)
DMLAYTP	MT	DTT
DMLAYTP	MA	Modulator
DMLAYTP	RN	A micronised, dispersible ferric pyrophosphate with high relative bioavailability in man. Br J Nutr. 2004 Jan;91(1):107-12.
DMLAYTP	RU	https://pubmed.ncbi.nlm.nih.gov/14748943

DMIG4OX	DI	DMIG4OX
DMIG4OX	DN	SOTB07
DMIG4OX	MI	TTZ97H5
DMIG4OX	MN	Phosphodiesterase 4A (PDE4A)
DMIG4OX	MT	DTT
DMIG4OX	MA	Inhibitor
DMIG4OX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1300).
DMIG4OX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1300

DMIG4OX	DI	DMIG4OX
DMIG4OX	DN	SOTB07
DMIG4OX	MI	TTVIAT9
DMIG4OX	MN	Phosphodiesterase 4B (PDE4B)
DMIG4OX	MT	DTT
DMIG4OX	MA	Inhibitor
DMIG4OX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1301).
DMIG4OX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1301

DMIG4OX	DI	DMIG4OX
DMIG4OX	DN	SOTB07
DMIG4OX	MI	TTSKMI8
DMIG4OX	MN	Phosphodiesterase 4D (PDE4D)
DMIG4OX	MT	DTT
DMIG4OX	MA	Inhibitor
DMIG4OX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1303).
DMIG4OX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1303

DMLSV74	DI	DMLSV74
DMLSV74	DN	Sotorasib
DMLSV74	MI	TT3LH46
DMLSV74	MN	KRAS G12C mutant (KRAS G12C)
DMLSV74	MT	DTT
DMLSV74	MA	Inhibitor
DMLSV74	RN	Clinical pipeline report, company report or official report of Amgen.
DMLSV74	RU	https://www.amgenpipeline.com/

DMMP51W	DI	DMMP51W
DMMP51W	DN	sparsentan
DMMP51W	MI	TT8DBY3
DMMP51W	MN	Angiotensin II receptor type-1 (AGTR1)
DMMP51W	MT	DTT
DMMP51W	MA	Antagonist
DMMP51W	RN	Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.
DMMP51W	RU	https://pubmed.ncbi.nlm.nih.gov/16220969

DMMP51W	DI	DMMP51W
DMMP51W	DN	sparsentan
DMMP51W	MI	TTKRD0G
DMMP51W	MN	Endothelin A receptor (EDNRA)
DMMP51W	MT	DTT
DMMP51W	MA	Antagonist
DMMP51W	RN	Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.
DMMP51W	RU	https://pubmed.ncbi.nlm.nih.gov/16220969

DM4TOEQ	DI	DM4TOEQ
DM4TOEQ	DN	Spartalizumab
DM4TOEQ	MI	TTNBFWK
DM4TOEQ	MN	Programmed cell death protein 1 (PD-1)
DM4TOEQ	MT	DTT
DM4TOEQ	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DM4TOEQ	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DM7NV1I	DI	DM7NV1I
DM7NV1I	DN	SPD-465
DM7NV1I	MI	TTIU98M
DM7NV1I	MN	Trace amine-associated receptor-1 (TAAR1)
DM7NV1I	MT	DTT
DM7NV1I	MA	Agonist
DM7NV1I	RN	Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes. Neuropharmacology. 2014 Oct;85:499-507.
DM7NV1I	RU	https://pubmed.ncbi.nlm.nih.gov/24950453

DMVJNFI	DI	DMVJNFI
DMVJNFI	DN	Spermidine
DMVJNFI	MI	TTR7UJ3
DMVJNFI	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMVJNFI	MT	DTT
DMVJNFI	MA	Inhibitor
DMVJNFI	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMVJNFI	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMVJNFI	DI	DMVJNFI
DMVJNFI	DN	Spermidine
DMVJNFI	MI	DTOFXP5
DMVJNFI	MN	MFS-type transporter SLC18B1 (SLC18B1)
DMVJNFI	MT	DTP
DMVJNFI	MA	Substrate
DMVJNFI	RN	Identification of a mammalian vesicular polyamine transporter. Sci Rep. 2014 Oct 30;4:6836.
DMVJNFI	RU	http://www.ncbi.nlm.nih.gov/pubmed/25355561

DMVJNFI	DI	DMVJNFI
DMVJNFI	DN	Spermidine
DMVJNFI	MI	DTT79CX
DMVJNFI	MN	Organic cation transporter 1 (SLC22A1)
DMVJNFI	MT	DTP
DMVJNFI	MA	Substrate
DMVJNFI	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMVJNFI	RU	https://doi.org/10.1007/s11095-012-0935-x

DMVJNFI	DI	DMVJNFI
DMVJNFI	DN	Spermidine
DMVJNFI	MI	DEMWO83
DMVJNFI	MN	Putrescine acetyltransferase (SSAT1)
DMVJNFI	MT	DME
DMVJNFI	MA	Metabolism
DMVJNFI	RN	The use of novel C-methylated spermidine derivatives to investigate the regulation of polyamine metabolism. J Med Chem. 2011 Jul 14;54(13):4611-8.
DMVJNFI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21639123

DMACVEI	DI	DMACVEI
DMACVEI	DN	SPI-2012
DMACVEI	MI	TT5TQ2W
DMACVEI	MN	Granulocyte colony-stimulating factor (CSF3)
DMACVEI	MT	DTT
DMACVEI	MA	Modulator
DMACVEI	RN	Company report (Sppirx)
DMACVEI	RU	http://www.sppirx.com/338-spectrum-products-development-spi2012.html

DM3PS2E	DI	DM3PS2E
DM3PS2E	DN	Squalamine
DM3PS2E	MI	TTGKIED
DM3PS2E	MN	Fibroblast growth factor-2 (FGF2)
DM3PS2E	MT	DTT
DM3PS2E	MA	Modulator
DM3PS2E	RN	Clinical pipeline report, company report or official report of Ohr Pharmaceutical.
DM3PS2E	RU	http://www.ohrpharmaceutical.com/research/squalamine

DM3PS2E	DI	DM3PS2E
DM3PS2E	DN	Squalamine
DM3PS2E	MI	TTSM78N
DM3PS2E	MN	Platelet-derived growth factor A (PDGFA)
DM3PS2E	MT	DTT
DM3PS2E	MA	Inhibitor
DM3PS2E	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3PS2E	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DM3PS2E	DI	DM3PS2E
DM3PS2E	DN	Squalamine
DM3PS2E	MI	TT9HKJA
DM3PS2E	MN	Vascular endothelial growth factor (VEGF)
DM3PS2E	MT	DTT
DM3PS2E	MA	Modulator
DM3PS2E	RN	Clinical pipeline report, company report or official report of Ohr Pharmaceutical.
DM3PS2E	RU	http://www.ohrpharmaceutical.com/research/squalamine

DM1ODMR	DI	DM1ODMR
DM1ODMR	DN	SR46349B
DM1ODMR	MI	TTJQOD7
DM1ODMR	MN	5-HT 2A receptor (HTR2A)
DM1ODMR	MT	DTT
DM1ODMR	MA	Modulator
DM1ODMR	RN	SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology. 2002 Sep;27(3):430-41.
DM1ODMR	RU	https://www.ncbi.nlm.nih.gov/pubmed/12225700

DM1ODMR	DI	DM1ODMR
DM1ODMR	DN	SR46349B
DM1ODMR	MI	TTWJBZ5
DM1ODMR	MN	5-HT 2C receptor (HTR2C)
DM1ODMR	MT	DTT
DM1ODMR	MA	Modulator
DM1ODMR	RN	SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology. 2002 Sep;27(3):430-41.
DM1ODMR	RU	https://www.ncbi.nlm.nih.gov/pubmed/12225700

DMT71EX	DI	DMT71EX
DMT71EX	DN	SSR-126517E
DMT71EX	MI	TTCIHJA
DMT71EX	MN	Coagulation factor Xa (F10)
DMT71EX	MT	DTT
DMT71EX	MA	Inhibitor
DMT71EX	RN	Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7.
DMT71EX	RU	https://pubmed.ncbi.nlm.nih.gov/22844656

DMVLKDX	DI	DMVLKDX
DMVLKDX	DN	Streptokinase rectal suppository
DMVLKDX	MI	TT2VCLI
DMVLKDX	MN	Streptococcus Streptokinase (Stre-coc skc)
DMVLKDX	MT	DTT
DMVLKDX	MA	Modulator
DMVLKDX	RN	Pharmacovigilance program to monitor adverse reactions of recombinant streptokinase in acute myocardial infarction. BMC Clin Pharmacol. 2005 Nov 2;5:5.
DMVLKDX	RU	https://www.ncbi.nlm.nih.gov/pubmed/16262910

DMPOTM4	DI	DMPOTM4
DMPOTM4	DN	Sulfatinib
DMPOTM4	MI	TTRLW2X
DMPOTM4	MN	Fibroblast growth factor receptor 1 (FGFR1)
DMPOTM4	MT	DTT
DMPOTM4	MA	Inhibitor
DMPOTM4	RN	Clinical pipeline report, company report or official report of Hutchison Medi Pharma.
DMPOTM4	RU	http://www.hmplglobal.com/en/sulfatinib/

DMPOTM4	DI	DMPOTM4
DMPOTM4	DN	Sulfatinib
DMPOTM4	MI	TT7MRDV
DMPOTM4	MN	Macrophage colony-stimulating factor 1 receptor (CSF1R)
DMPOTM4	MT	DTT
DMPOTM4	MA	Inhibitor
DMPOTM4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPOTM4	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMPOTM4	DI	DMPOTM4
DMPOTM4	DN	Sulfatinib
DMPOTM4	MI	TTVJ1D8
DMPOTM4	MN	Vascular endothelial growth factor receptor (VEGFR)
DMPOTM4	MT	DTT
DMPOTM4	MA	Inhibitor
DMPOTM4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPOTM4	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMPOTM4	DI	DMPOTM4
DMPOTM4	DN	Sulfatinib
DMPOTM4	MI	TT2Q6G1
DMPOTM4	MN	Vascular endothelial growth factor receptor 1 (FLT-1)
DMPOTM4	MT	DTT
DMPOTM4	MA	Inhibitor
DMPOTM4	RN	Clinical pipeline report, company report or official report of Hutchison Medi Pharma.
DMPOTM4	RU	http://www.hmplglobal.com/en/sulfatinib/

DMPOTM4	DI	DMPOTM4
DMPOTM4	DN	Sulfatinib
DMPOTM4	MI	TTUTJGQ
DMPOTM4	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMPOTM4	MT	DTT
DMPOTM4	MA	Inhibitor
DMPOTM4	RN	Clinical pipeline report, company report or official report of Hutchison Medi Pharma.
DMPOTM4	RU	http://www.hmplglobal.com/en/sulfatinib/

DMPOTM4	DI	DMPOTM4
DMPOTM4	DN	Sulfatinib
DMPOTM4	MI	TTDCBX5
DMPOTM4	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DMPOTM4	MT	DTT
DMPOTM4	MA	Inhibitor
DMPOTM4	RN	Clinical pipeline report, company report or official report of Hutchison Medi Pharma.
DMPOTM4	RU	http://www.hmplglobal.com/en/sulfatinib/

DMMD856	DI	DMMD856
DMMD856	DN	Sulopenem
DMMD856	MI	TTJP4SM
DMMD856	MN	Bacterial Penicillin binding protein (Bact PBP)
DMMD856	MT	DTT
DMMD856	MA	Modulator
DMMD856	RN	In vitro antibacterial activity of a new parenteral penem, sulopenem. Jpn J Antibiot. 1996 Apr;49(4):324-37.
DMMD856	RU	https://pubmed.ncbi.nlm.nih.gov/8786624

DM07653	DI	DM07653
DM07653	DN	SULTHIAME
DM07653	MI	TTANPDJ
DM07653	MN	Carbonic anhydrase II (CA-II)
DM07653	MT	DTT
DM07653	MA	Inhibitor
DM07653	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM07653	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMYHV17	DI	DMYHV17
DMYHV17	DN	Sumanirole
DMYHV17	MI	DEJGDUW
DMYHV17	MN	Cytochrome P450 1A2 (CYP1A2)
DMYHV17	MT	DME
DMYHV17	MA	Metabolism
DMYHV17	RN	Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas. Eur J Endocrinol. 2019 Jan 1;180(1):31-40.
DMYHV17	RU	http://www.ncbi.nlm.nih.gov/pubmed/30400048

DMYHV17	DI	DMYHV17
DMYHV17	DN	Sumanirole
DMYHV17	MI	TTEX248
DMYHV17	MN	Dopamine D2 receptor (D2R)
DMYHV17	MT	DTT
DMYHV17	MA	Agonist
DMYHV17	RN	Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42.
DMYHV17	RU	https://pubmed.ncbi.nlm.nih.gov/18991661

DMXNZQK	DI	DMXNZQK
DMXNZQK	DN	SUN-101
DMXNZQK	MI	TTOXS3C
DMXNZQK	MN	Muscarinic acetylcholine receptor (CHRM)
DMXNZQK	MT	DTT
DMXNZQK	MA	Inhibitor
DMXNZQK	RN	Long-acting bronchodilators in COPD: Where are we now and where are we going Breathe 06/2014; 10(2):110-120.
DMXNZQK	RU	http://breathe.ersjournals.com/content/10/2/110

DMH2FN1	DI	DMH2FN1
DMH2FN1	DN	Suronacrine maleate
DMH2FN1	MI	TT1RS9F
DMH2FN1	MN	Acetylcholinesterase (AChE)
DMH2FN1	MT	DTT
DMH2FN1	MA	Modulator
DMH2FN1	RN	Potential clinical use of an adrenergic/cholinergic agent (HP 128) in the treatment of Alzheimer's disease. Ann N Y Acad Sci. 1991;640:263-7.
DMH2FN1	RU	https://www.ncbi.nlm.nih.gov/pubmed/1776748

DMH2FN1	DI	DMH2FN1
DMH2FN1	DN	Suronacrine maleate
DMH2FN1	MI	TTAWNKZ
DMH2FN1	MN	Norepinephrine transporter (NET)
DMH2FN1	MT	DTT
DMH2FN1	MA	Modulator
DMH2FN1	RN	Potential clinical use of an adrenergic/cholinergic agent (HP 128) in the treatment of Alzheimer's disease. Ann N Y Acad Sci. 1991;640:263-7.
DMH2FN1	RU	https://www.ncbi.nlm.nih.gov/pubmed/1776748

DMY7WH1	DI	DMY7WH1
DMY7WH1	DN	Sutimlimab
DMY7WH1	MI	TT7LRQH
DMY7WH1	MN	Complement C1s component (C1S)
DMY7WH1	MT	DTT
DMY7WH1	MA	Inhibitor
DMY7WH1	RN	Antibodies to watch in 2020. MAbs. Jan-Dec 2020;12(1):1703531.
DMY7WH1	RU	https://pubmed.ncbi.nlm.nih.gov/31847708

DM3BO8G	DI	DM3BO8G
DM3BO8G	DN	SUVN-G3031
DM3BO8G	MI	TT9JNIC
DM3BO8G	MN	Histamine H3 receptor (H3R)
DM3BO8G	MT	DTT
DM3BO8G	MA	Antagonist
DM3BO8G	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3BO8G	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMOVEDH	DI	DMOVEDH
DMOVEDH	DN	SYM-004
DMOVEDH	MI	TTGKNB4
DMOVEDH	MN	Epidermal growth factor receptor (EGFR)
DMOVEDH	MT	DTT
DMOVEDH	RN	Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab. Neoplasia. 2013 Oct;15(10):1196-206.
DMOVEDH	RU	https://pubmed.ncbi.nlm.nih.gov/24204198

DMRUEKC	DI	DMRUEKC
DMRUEKC	DN	Synthetic conjugated estrogen
DMRUEKC	MI	TTZAYWL
DMRUEKC	MN	Estrogen receptor (ESR)
DMRUEKC	MT	DTT
DMRUEKC	MA	Modulator
DMRUEKC	RN	Relief of hot flushes with new plant-derived 10-component synthetic conjugated estrogens. Obstet Gynecol. 2004 Feb;103(2):245-53.
DMRUEKC	RU	https://pubmed.ncbi.nlm.nih.gov/14754691

DMXU4ON	DI	DMXU4ON
DMXU4ON	DN	Synthetic hypericin
DMXU4ON	MI	DTI7UX6
DMXU4ON	MN	Breast cancer resistance protein (ABCG2)
DMXU4ON	MT	DTP
DMXU4ON	MA	Substrate
DMXU4ON	RN	Drug efflux transporters, MRP1 and BCRP, affect the outcome of hypericin-mediated photodynamic therapy in HT-29 adenocarcinoma cells. Photochem Photobiol Sci. 2009 Dec;8(12):1716-23.
DMXU4ON	RU	https://doi.org/10.1039/b9pp00086k

DMXU4ON	DI	DMXU4ON
DMXU4ON	DN	Synthetic hypericin
DMXU4ON	MI	TTYVX59
DMXU4ON	MN	Protein kinase C (PRKC)
DMXU4ON	MT	DTT
DMXU4ON	MA	Inhibitor
DMXU4ON	RN	Characterization of the interaction of hypericin with protein kinase C in U-87 MG human glioma cells. Photochem Photobiol. 2006 May-Jun;82(3):720-8.
DMXU4ON	RU	https://pubmed.ncbi.nlm.nih.gov/16396605

DM9L1AC	DI	DM9L1AC
DM9L1AC	DN	SYR-472
DM9L1AC	MI	TTDIGC1
DM9L1AC	MN	Dipeptidyl peptidase 4 (DPP-4)
DM9L1AC	MT	DTT
DM9L1AC	MA	Inhibitor
DM9L1AC	RN	SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014 Feb;2(2):125-32.
DM9L1AC	RU	https://pubmed.ncbi.nlm.nih.gov/24622716

DMR32KN	DI	DMR32KN
DMR32KN	DN	TA-6366
DMR32KN	MI	DEB30C5
DMR32KN	MN	Carboxylesterase 1 (CES1)
DMR32KN	MT	DME
DMR32KN	MA	Metabolism
DMR32KN	RN	Inhibition of human liver carboxylesterase (hCE1) by organophosphate ester flame retardants and plasticizers: implications for pharmacotherapy. Toxicol Sci. 2019 Jul 3. pii: kfz149.
DMR32KN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31268531

DMKSAG1	DI	DMKSAG1
DMKSAG1	DN	Tabalumab
DMKSAG1	MI	TTWMIDN
DMKSAG1	MN	B-cell-activating factor (TNFSF13B)
DMKSAG1	MT	DTT
DMKSAG1	MA	Modulator
DMKSAG1	RN	Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors. Ann Rheum Dis. 2013 Sep 1;72(9):1461-8.
DMKSAG1	RU	https://pubmed.ncbi.nlm.nih.gov/23268367

DMW5PHL	DI	DMW5PHL
DMW5PHL	DN	Taberminogene vadenovec
DMW5PHL	MI	TTDCBX5
DMW5PHL	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DMW5PHL	MT	DTT
DMW5PHL	MA	Modulator
DMW5PHL	RN	Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol Sci. 2014 Nov;35(11):604-20.
DMW5PHL	RU	https://pubmed.ncbi.nlm.nih.gov/25312588

DM1NTVQ	DI	DM1NTVQ
DM1NTVQ	DN	Tadekinig alfa
DM1NTVQ	MI	TTRICUF
DM1NTVQ	MN	Interleukin-18 (IL18)
DM1NTVQ	MT	DTT
DM1NTVQ	MA	Inhibitor
DM1NTVQ	RN	Clinical pipeline report, company report or official report of AB2 Bio.
DM1NTVQ	RU	http://www.ab2bio.com/en/products.36.html

DMCF6SX	DI	DMCF6SX
DMCF6SX	DN	TAK-491
DMCF6SX	MI	TT8DBY3
DMCF6SX	MN	Angiotensin II receptor type-1 (AGTR1)
DMCF6SX	MT	DTT
DMCF6SX	MA	Modulator
DMCF6SX	RN	2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
DMCF6SX	RU	https://pubmed.ncbi.nlm.nih.gov/22293555

DM2H8FZ	DI	DM2H8FZ
DM2H8FZ	DN	TAK-700
DM2H8FZ	MI	TTRA5BZ
DM2H8FZ	MN	Steroid 17-alpha-monooxygenase (S17AH)
DM2H8FZ	MT	DTT
DM2H8FZ	MA	Modulator
DM2H8FZ	RN	Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys. J Steroid Biochem Mol Biol. 2012 Apr;129(3-5):115-28.
DM2H8FZ	RU	https://pubmed.ncbi.nlm.nih.gov/22249003

DMIM5AP	DI	DMIM5AP
DMIM5AP	DN	TAK-875
DMIM5AP	MI	DE4LYSA
DMIM5AP	MN	Cytochrome P450 3A4 (CYP3A4)
DMIM5AP	MT	DME
DMIM5AP	MA	Metabolism
DMIM5AP	RN	Disposition and metabolism of the G protein-coupled receptor 40 agonist TAK-875 (fasiglifam) in rats, dogs, and humans. Xenobiotica. 2019 Apr;49(4):433-445.
DMIM5AP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29557709

DMIM5AP	DI	DMIM5AP
DMIM5AP	DN	TAK-875
DMIM5AP	MI	DEIBDNY
DMIM5AP	MN	Cytochrome P450 3A5 (CYP3A5)
DMIM5AP	MT	DME
DMIM5AP	MA	Metabolism
DMIM5AP	RN	Disposition and metabolism of the G protein-coupled receptor 40 agonist TAK-875 (fasiglifam) in rats, dogs, and humans. Xenobiotica. 2019 Apr;49(4):433-445.
DMIM5AP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29557709

DMIM5AP	DI	DMIM5AP
DMIM5AP	DN	TAK-875
DMIM5AP	MI	TTB8FUC
DMIM5AP	MN	Free fatty acid receptor 1 (GPR40)
DMIM5AP	MT	DTT
DMIM5AP	MA	Modulator
DMIM5AP	RN	Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Obes Metab. 2015 Jul;17(7):675-81.
DMIM5AP	RU	https://pubmed.ncbi.nlm.nih.gov/25787200

DMIM5AP	DI	DMIM5AP
DMIM5AP	DN	TAK-875
DMIM5AP	MI	DEF2WXN
DMIM5AP	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMIM5AP	MT	DME
DMIM5AP	MA	Metabolism
DMIM5AP	RN	Disposition and metabolism of the G protein-coupled receptor 40 agonist TAK-875 (fasiglifam) in rats, dogs, and humans. Xenobiotica. 2019 Apr;49(4):433-445.
DMIM5AP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29557709

DM1IZ5D	DI	DM1IZ5D
DM1IZ5D	DN	Talabostat
DM1IZ5D	MI	TTJGLZF
DM1IZ5D	MN	Dipeptidyl peptidase 8 (DPP-8)
DM1IZ5D	MT	DTT
DM1IZ5D	MA	Inhibitor
DM1IZ5D	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM1IZ5D	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM1IZ5D	DI	DM1IZ5D
DM1IZ5D	DN	Talabostat
DM1IZ5D	MI	TTNDUL7
DM1IZ5D	MN	Dipeptidyl peptidase 9 (DPP-9)
DM1IZ5D	MT	DTT
DM1IZ5D	MA	Inhibitor
DM1IZ5D	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM1IZ5D	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM1IZ5D	DI	DM1IZ5D
DM1IZ5D	DN	Talabostat
DM1IZ5D	MI	TTGPQ0F
DM1IZ5D	MN	Prolyl endopeptidase FAP (FAP)
DM1IZ5D	MT	DTT
DM1IZ5D	MA	Inhibitor
DM1IZ5D	RN	Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer. Cancer Biol Ther. 2007 Nov;6(11):1691-9.
DM1IZ5D	RU	https://pubmed.ncbi.nlm.nih.gov/18032930

DMV7T64	DI	DMV7T64
DMV7T64	DN	Talactoferrin
DMV7T64	MI	TTSZDQU
DMV7T64	MN	Lactotransferrin (LTF)
DMV7T64	MT	DTT
DMV7T64	MA	Modulator
DMV7T64	RN	Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study. Am J Surg. 2007 Jan;193(1):49-54.
DMV7T64	RU	https://pubmed.ncbi.nlm.nih.gov/17188087

DM3G74J	DI	DM3G74J
DM3G74J	DN	Tamibarotene
DM3G74J	MI	TTW38KT
DM3G74J	MN	Retinoic acid receptor alpha (RARA)
DM3G74J	MT	DTT
DM3G74J	MA	Modulator
DM3G74J	RN	Tamibarotene: a candidate retinoid drug for Alzheimer's disease. Biol Pharm Bull. 2012;35(8):1206-12.
DM3G74J	RU	https://pubmed.ncbi.nlm.nih.gov/22863914

DM3G74J	DI	DM3G74J
DM3G74J	DN	Tamibarotene
DM3G74J	MI	TTISP28
DM3G74J	MN	Retinoic acid receptor beta (RARB)
DM3G74J	MT	DTT
DM3G74J	MA	Modulator
DM3G74J	RN	Tamibarotene: a candidate retinoid drug for Alzheimer's disease. Biol Pharm Bull. 2012;35(8):1206-12.
DM3G74J	RU	https://pubmed.ncbi.nlm.nih.gov/22863914

DMJKWMA	DI	DMJKWMA
DMJKWMA	DN	Tanezumab
DMJKWMA	MI	TTDN3LF
DMJKWMA	MN	Nerve growth factor (NGF)
DMJKWMA	MT	DTT
DMJKWMA	MA	Inhibitor
DMJKWMA	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMJKWMA	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMWM4D0	DI	DMWM4D0
DMWM4D0	DN	TAS-120
DMWM4D0	MI	TT5HU6Z
DMWM4D0	MN	Fibroblast growth factor (FGF)
DMWM4D0	MT	DTT
DMWM4D0	MA	Inhibitor
DMWM4D0	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMWM4D0	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMWM4D0	DI	DMWM4D0
DMWM4D0	DN	TAS-120
DMWM4D0	MI	TT0LF7H
DMWM4D0	MN	Fibroblast growth factor receptor (FGFR)
DMWM4D0	MT	DTT
DMWM4D0	MA	Antagonist
DMWM4D0	RN	TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities. Molecular Cancer Therapeutics. 01/2014; 12(11_Supplement):A270-A270.
DMWM4D0	RU	http://mct.aacrjournals.org/content/12/11_Supplement/A270.short

DMPYET9	DI	DMPYET9
DMPYET9	DN	Taspoglutide
DMPYET9	MI	TTVIMDE
DMPYET9	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMPYET9	MT	DTT
DMPYET9	MA	Agonist
DMPYET9	RN	Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes. Diabet Med. 2009 Nov;26(11):1156-64.
DMPYET9	RU	https://pubmed.ncbi.nlm.nih.gov/19929995

DM9GSVQ	DI	DM9GSVQ
DM9GSVQ	DN	Tasquinimod
DM9GSVQ	MI	TT0TMQG
DM9GSVQ	MN	Calgranulin B (S100A9)
DM9GSVQ	MT	DTT
DM9GSVQ	MA	Modulator
DM9GSVQ	RN	Mechanisms of action of tasquinimod on the tumour microenvironment. Cancer Chemother Pharmacol. 2014; 73(1): 1-8.
DM9GSVQ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889691/

DMD6AUX	DI	DMD6AUX
DMD6AUX	DN	Tat-NR2B9c
DMD6AUX	MI	TT9PB26
DMD6AUX	MN	Presynaptic density protein 95 (DLG4)
DMD6AUX	MT	DTT
DMD6AUX	MA	Inhibitor
DMD6AUX	RN	Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain. Nature. 2012 Feb 29;483(7388):213-7.
DMD6AUX	RU	https://pubmed.ncbi.nlm.nih.gov/22388811

DML6GAN	DI	DML6GAN
DML6GAN	DN	Taxol/Paraplatin/Herceptin
DML6GAN	MI	TTJGNVC
DML6GAN	MN	Apoptosis regulator Bcl-2 (BCL-2)
DML6GAN	MT	DTT
DML6GAN	MA	Modulator
DML6GAN	RN	Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer. 2005 Dec;6(5):425-32.
DML6GAN	RU	https://pubmed.ncbi.nlm.nih.gov/16381626

DML6GAN	DI	DML6GAN
DML6GAN	DN	Taxol/Paraplatin/Herceptin
DML6GAN	MI	TT6EO5L
DML6GAN	MN	Erbb2 tyrosine kinase receptor (HER2)
DML6GAN	MT	DTT
DML6GAN	MA	Inhibitor
DML6GAN	RN	Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer. 2005 Dec;6(5):425-32.
DML6GAN	RU	https://pubmed.ncbi.nlm.nih.gov/16381626

DML6GAN	DI	DML6GAN
DML6GAN	DN	Taxol/Paraplatin/Herceptin
DML6GAN	MI	TTUTN1I
DML6GAN	MN	Human Deoxyribonucleic acid (hDNA)
DML6GAN	MT	DTT
DML6GAN	MA	Binder
DML6GAN	RN	Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2006 Jun 20;24(18):2786-92.
DML6GAN	RU	https://pubmed.ncbi.nlm.nih.gov/16782917

DMGKBZH	DI	DMGKBZH
DMGKBZH	DN	TD-1792
DMGKBZH	MI	TTLP6GN
DMGKBZH	MN	Bacterial DD-carboxypeptidase (Bact vanYB)
DMGKBZH	MT	DTT
DMGKBZH	MA	Inhibitor
DMGKBZH	RN	How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
DMGKBZH	RU	https://pubmed.ncbi.nlm.nih.gov/18621146

DMVSX6O	DI	DMVSX6O
DMVSX6O	DN	Tebipenem
DMVSX6O	MI	TT6OEDT
DMVSX6O	MN	Cannabinoid receptor 1 (CB1)
DMVSX6O	MT	DTT
DMVSX6O	MA	Antagonist
DMVSX6O	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DMVSX6O	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMTCR2O	DI	DMTCR2O
DMTCR2O	DN	Tecarfarin
DMTCR2O	MI	TTEUC8H
DMTCR2O	MN	Vitamin K epoxide reductase complex 1 (VKORC1)
DMTCR2O	MT	DTT
DMTCR2O	MA	Inhibitor
DMTCR2O	RN	Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants. J Clin Pharmacol. 2011Apr;51(4):561-74.
DMTCR2O	RU	https://pubmed.ncbi.nlm.nih.gov/20622200

DMKE187	DI	DMKE187
DMKE187	DN	Telmisartan
DMKE187	MI	TTPKMXQ
DMKE187	MN	HUMAN type-1 angiotensin II receptor (AGTR1)
DMKE187	MT	DTT
DMKE187	MA	Blocker
DMKE187	RN	Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic. Nat Rev Nephrol. 2020 Apr 3.
DMKE187	RU	https://pubmed.ncbi.nlm.nih.gov/32246101

DMHQRYE	DI	DMHQRYE
DMHQRYE	DN	Tenidap
DMHQRYE	MI	TT2J34L
DMHQRYE	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMHQRYE	MT	DTT
DMHQRYE	MA	Modulator
DMHQRYE	RN	The in vitro free radical scavenging activity of tenidap, a new dual cyclo-oxygenase and 5-1ipoxygenase inhibitor. Mediators Inflamm. 1992;1(2):141-3.
DMHQRYE	RU	https://pubmed.ncbi.nlm.nih.gov/18475454

DMHOV7D	DI	DMHOV7D
DMHOV7D	DN	Tenofovir alafenamide
DMHOV7D	MI	DTI7UX6
DMHOV7D	MN	Breast cancer resistance protein (ABCG2)
DMHOV7D	MT	DTP
DMHOV7D	MA	Substrate
DMHOV7D	RN	Pharmacokinetics of Tenofovir Alafenamide When Coadministered With Other HIV Antiretrovirals. J Acquir Immune Defic Syndr. 2018 Aug 1;78(4):465-472.
DMHOV7D	RU	http://www.ncbi.nlm.nih.gov/pubmed/29649076

DMHOV7D	DI	DMHOV7D
DMHOV7D	DN	Tenofovir alafenamide
DMHOV7D	MI	DTUGYRD
DMHOV7D	MN	P-glycoprotein 1 (ABCB1)
DMHOV7D	MT	DTP
DMHOV7D	MA	Substrate
DMHOV7D	RN	Pharmacokinetics of Tenofovir Alafenamide When Coadministered With Other HIV Antiretrovirals. J Acquir Immune Defic Syndr. 2018 Aug 1;78(4):465-472.
DMHOV7D	RU	http://www.ncbi.nlm.nih.gov/pubmed/29649076

DMZ3P6C	DI	DMZ3P6C
DMZ3P6C	DN	Teplizumab
DMZ3P6C	MI	TTBMAOZ
DMZ3P6C	MN	Regulatory protein unspecific (RGP)
DMZ3P6C	MT	DTT
DMZ3P6C	RN	Acquisition of regulatory function by human CD8(+) T cells treated with anti-CD3 antibody requires TNF. Eur J Immunol. 2010 Oct;40(10):2891-901.
DMZ3P6C	RU	https://pubmed.ncbi.nlm.nih.gov/21038470

DMZ3P6C	DI	DMZ3P6C
DMZ3P6C	DN	Teplizumab
DMZ3P6C	MI	TTV3XPL
DMZ3P6C	MN	T-cell surface glycoprotein CD3 gamma (CD3G)
DMZ3P6C	MT	DTT
DMZ3P6C	MA	Inhibitor
DMZ3P6C	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZ3P6C	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DM4MZXE	DI	DM4MZXE
DM4MZXE	DN	Terodiline
DM4MZXE	MI	DE4LYSA
DM4MZXE	MN	Cytochrome P450 3A4 (CYP3A4)
DM4MZXE	MT	DME
DM4MZXE	MA	Metabolism
DM4MZXE	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DM4MZXE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DMGRBN5	DI	DMGRBN5
DMGRBN5	DN	TESAGLITAZAR
DMGRBN5	MI	TTJ584C
DMGRBN5	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMGRBN5	MT	DTT
DMGRBN5	MA	Modulator
DMGRBN5	RN	Tesaglitazar, a dual PPAR-/ agonist, hamster carcinogenicity, investigative animal and clinical studies.Toxicol Pathol.2012;40(1):18-32.
DMGRBN5	RU	https://www.ncbi.nlm.nih.gov/pubmed/22131108

DMGRBN5	DI	DMGRBN5
DMGRBN5	DN	TESAGLITAZAR
DMGRBN5	MI	TTZMAO3
DMGRBN5	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMGRBN5	MT	DTT
DMGRBN5	MA	Modulator
DMGRBN5	RN	Tesaglitazar, a dual PPAR-/ agonist, hamster carcinogenicity, investigative animal and clinical studies.Toxicol Pathol.2012;40(1):18-32.
DMGRBN5	RU	https://www.ncbi.nlm.nih.gov/pubmed/22131108

DMMTKC6	DI	DMMTKC6
DMMTKC6	DN	TEV-48125
DMMTKC6	MI	TTAFORY
DMMTKC6	MN	Calcitonin gene-related peptide (CALC)
DMMTKC6	MT	DTT
DMMTKC6	RN	TEV-48125 for the preventive treatment of chronic migraine: Efficacy at early time points. Neurology. 2016 Jul 5;87(1):41-8.
DMMTKC6	RU	https://pubmed.ncbi.nlm.nih.gov/27281531

DM9R5J6	DI	DM9R5J6
DM9R5J6	DN	Tezepelumab
DM9R5J6	MI	TTHMW3T
DM9R5J6	MN	Thymic stromal lymphopoietin (TSLP)
DM9R5J6	MT	DTT
DM9R5J6	RN	Tezepelumab in Adults with Uncontrolled Asthma. N Engl J Med. 2017 Sep 7;377(10):936-946.
DM9R5J6	RU	https://pubmed.ncbi.nlm.nih.gov/28877011

DMLCXPD	DI	DMLCXPD
DMLCXPD	DN	TG-C
DMLCXPD	MI	TTR9XHZ
DMLCXPD	MN	Transforming growth factor beta 1 (TGFB1)
DMLCXPD	MT	DTT
DMLCXPD	MA	Modulator
DMLCXPD	RN	Clinical pipeline report, company report or official report of Tissue Gene, Inc.
DMLCXPD	RU	http://www.tissuegene.com/products/cartilage.html

DMPGH7N	DI	DMPGH7N
DMPGH7N	DN	ThermoProfen
DMPGH7N	MI	TT8NGED
DMPGH7N	MN	Prostaglandin G/H synthase 1 (COX-1)
DMPGH7N	MT	DTT
DMPGH7N	MA	Inhibitor
DMPGH7N	RN	Topical NSAID therapy for musculoskeletal pain. Pain Med. 2010 Apr;11(4):535-49.
DMPGH7N	RU	https://pubmed.ncbi.nlm.nih.gov/20210866

DMPGH7N	DI	DMPGH7N
DMPGH7N	DN	ThermoProfen
DMPGH7N	MI	TTVKILB
DMPGH7N	MN	Prostaglandin G/H synthase 2 (COX-2)
DMPGH7N	MT	DTT
DMPGH7N	MA	Inhibitor
DMPGH7N	RN	Topical NSAID therapy for musculoskeletal pain. Pain Med. 2010 Apr;11(4):535-49.
DMPGH7N	RU	https://pubmed.ncbi.nlm.nih.gov/20210866

DM3PA8H	DI	DM3PA8H
DM3PA8H	DN	THVD-201
DM3PA8H	MI	TTOXS3C
DM3PA8H	MN	Muscarinic acetylcholine receptor (CHRM)
DM3PA8H	MT	DTT
DM3PA8H	MA	Agonist
DM3PA8H	RN	Future therapies: Early trials and basic science. Can Urol Assoc J. 2013 Sep-Oct; 7(9-10 Suppl 4): S179-S180.
DM3PA8H	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3919188/

DM3DG5C	DI	DM3DG5C
DM3DG5C	DN	THX-TS01
DM3DG5C	MI	TT94IAG
DM3DG5C	MN	Cannabinoid receptor (CB)
DM3DG5C	MT	DTT
DM3DG5C	MA	Modulator
DM3DG5C	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3DG5C	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMMO6P0	DI	DMMO6P0
DMMO6P0	DN	Tifacogin
DMMO6P0	MI	TT068JH
DMMO6P0	MN	Tissue factor pathway inhibitor (TFPI)
DMMO6P0	MT	DTT
DMMO6P0	MA	Inhibitor
DMMO6P0	RN	Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003 Jul 9;290(2):238-47.
DMMO6P0	RU	https://pubmed.ncbi.nlm.nih.gov/12851279

DMZBGI8	DI	DMZBGI8
DMZBGI8	DN	Tilarginine acetate
DMZBGI8	MI	TTCM4B3
DMZBGI8	MN	Nitric-oxide synthase endothelial (NOS3)
DMZBGI8	MT	DTT
DMZBGI8	MA	Modulator
DMZBGI8	RN	Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA. 2007 Apr 18;297(15):1657-66.
DMZBGI8	RU	https://pubmed.ncbi.nlm.nih.gov/17387132

DMGYK2N	DI	DMGYK2N
DMGYK2N	DN	Tilsotolimod
DMGYK2N	MI	TTSHG0T
DMGYK2N	MN	Toll-like receptor 9 (TLR9)
DMGYK2N	MT	DTT
DMGYK2N	MA	Agonist
DMGYK2N	RN	Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma. Cancer Discov. 2021 Mar 11;candisc.1546.2020.
DMGYK2N	RU	https://pubmed.ncbi.nlm.nih.gov/33707233

DMBFE4K	DI	DMBFE4K
DMBFE4K	DN	Tirapazamine
DMBFE4K	MI	DEVDYN7
DMBFE4K	MN	Cytochrome P450 2E1 (CYP2E1)
DMBFE4K	MT	DME
DMBFE4K	MA	Metabolism
DMBFE4K	RN	Molecular mechanisms of tirapazamine (SR 4233, Win 59075)-induced hepatocyte toxicity under low oxygen concentrations. Br J Cancer. 1995 Apr;71(4):780-5.
DMBFE4K	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7710944

DMBFE4K	DI	DMBFE4K
DMBFE4K	DN	Tirapazamine
DMBFE4K	MI	TT0IHXV
DMBFE4K	MN	DNA topoisomerase II (TOP2)
DMBFE4K	MT	DTT
DMBFE4K	MA	Modulator
DMBFE4K	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMBFE4K	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMQNMAT	DI	DMQNMAT
DMQNMAT	DN	Tirzepatide
DMQNMAT	MI	TTVIMDE
DMQNMAT	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMQNMAT	MT	DTT
DMQNMAT	MA	Agonist
DMQNMAT	RN	Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab. 2021 Jan 23;106(2):388-396.
DMQNMAT	RU	https://pubmed.ncbi.nlm.nih.gov/33236115

DM95IPS	DI	DM95IPS
DM95IPS	DN	Tivanisiran
DM95IPS	MI	TT50OG3
DM95IPS	MN	TRPV1 messenger RNA (TRPV1 mRNA)
DM95IPS	MT	DTT
DM95IPS	MA	Inhibitor
DM95IPS	RN	Tivanisiran, a novel siRNA for the treatment of dry eye disease. Expert Opin Investig Drugs. 2018 Apr;27(4):421-426.
DM95IPS	RU	https://pubmed.ncbi.nlm.nih.gov/29569947

DMNVP8Q	DI	DMNVP8Q
DMNVP8Q	DN	Tivantinib
DMNVP8Q	MI	TTNDSF4
DMNVP8Q	MN	Proto-oncogene c-Met (MET)
DMNVP8Q	MT	DTT
DMNVP8Q	MA	Inhibitor
DMNVP8Q	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7948).
DMNVP8Q	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7948

DMYLT67	DI	DMYLT67
DMYLT67	DN	TKI258
DMYLT67	MI	DEJGDUW
DMYLT67	MN	Cytochrome P450 1A2 (CYP1A2)
DMYLT67	MT	DME
DMYLT67	MA	Metabolism
DMYLT67	RN	A drug-drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 Jan;81(1):73-80.
DMYLT67	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29101463

DMYLT67	DI	DMYLT67
DMYLT67	DN	TKI258
DMYLT67	MI	TTST7KB
DMYLT67	MN	Fibroblast growth factor receptor 3 (FGFR3)
DMYLT67	MT	DTT
DMYLT67	MA	Inhibitor
DMYLT67	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMYLT67	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMYLT67	DI	DMYLT67
DMYLT67	DN	TKI258
DMYLT67	MI	TTI2WET
DMYLT67	MN	Platelet-derived growth factor receptor (PDGFR)
DMYLT67	MT	DTT
DMYLT67	MA	Inhibitor
DMYLT67	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMYLT67	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMO1234	DI	DMO1234
DMO1234	DN	TNX-102
DMO1234	MI	TTJQOD7
DMO1234	MN	5-HT 2A receptor (HTR2A)
DMO1234	MT	DTT
DMO1234	MA	Antagonist
DMO1234	RN	Clinical pipeline report, company report or official report of Tonix Pharmaceuticals.
DMO1234	RU	http://www.tonixpharma.com/research-development/tnx-102-sl-for-fibromyalgia

DMO1234	DI	DMO1234
DMO1234	DN	TNX-102
DMO1234	MI	TT2NUT5
DMO1234	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMO1234	MT	DTT
DMO1234	MA	Antagonist
DMO1234	RN	Clinical pipeline report, company report or official report of Tonix Pharmaceuticals.
DMO1234	RU	http://www.tonixpharma.com/research-development/tnx-102-sl-for-fibromyalgia

DMYA41S	DI	DMYA41S
DMYA41S	DN	TNX-355
DMYA41S	MI	TTN2JFW
DMYA41S	MN	T-cell surface glycoprotein CD4 (CD4)
DMYA41S	MT	DTT
DMYA41S	MA	Binder
DMYA41S	RN	Progress in targeting HIV-1 entry. Drug Discov Today. 2005 Aug 15;10(16):1085-94.
DMYA41S	RU	https://pubmed.ncbi.nlm.nih.gov/16182193

DMFDNT0	DI	DMFDNT0
DMFDNT0	DN	Tocilizumab
DMFDNT0	MI	TTDVAKP
DMFDNT0	MN	HUMAN interleukin-6 receptor (IL6R)
DMFDNT0	MT	DTT
DMFDNT0	MA	Inhibitor
DMFDNT0	RN	Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report. Ann Oncol. 2020 Apr 2. pii: S0923-7534(20)36387-0.
DMFDNT0	RU	https://pubmed.ncbi.nlm.nih.gov/32247642

DMATC14	DI	DMATC14
DMATC14	DN	Tozadenant
DMATC14	MI	TTM2AOE
DMATC14	MN	Adenosine A2a receptor (ADORA2A)
DMATC14	MT	DTT
DMATC14	MA	Antagonist
DMATC14	RN	Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol. 2014 Aug;13(8):767-76.
DMATC14	RU	https://pubmed.ncbi.nlm.nih.gov/25008546

DMLKI2B	DI	DMLKI2B
DMLKI2B	DN	Trafermin
DMLKI2B	MI	TTGJVQM
DMLKI2B	MN	Fibroblast growth factor receptor 2 (FGFR2)
DMLKI2B	MT	DTT
DMLKI2B	MA	Activator
DMLKI2B	RN	Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
DMLKI2B	RU	https://pubmed.ncbi.nlm.nih.gov/17064227

DM6ENSJ	DI	DM6ENSJ
DM6ENSJ	DN	Tralokinumab
DM6ENSJ	MI	TTMPZ7V
DM6ENSJ	MN	Interleukin 13 receptor alpha-2 (IL13RA2)
DM6ENSJ	MT	DTT
DM6ENSJ	MA	Modulator
DM6ENSJ	RN	Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model.Am J Respir Cell Mol Biol.2014 May;50(5):985-94.
DM6ENSJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/24325475

DM6ENSJ	DI	DM6ENSJ
DM6ENSJ	DN	Tralokinumab
DM6ENSJ	MI	TT0GVCH
DM6ENSJ	MN	Interleukin-13 (IL13)
DM6ENSJ	MT	DTT
DM6ENSJ	MA	Inhibitor
DM6ENSJ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM6ENSJ	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM7BSRH	DI	DM7BSRH
DM7BSRH	DN	Tramiprosate
DM7BSRH	MI	TTE4KHA
DM7BSRH	MN	Amyloid beta A4 protein (APP)
DM7BSRH	MT	DTT
DM7BSRH	MA	Antagonist
DM7BSRH	RN	Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging. 2007 Apr;28(4):537-47.
DM7BSRH	RU	https://pubmed.ncbi.nlm.nih.gov/16675063

DMLB3I4	DI	DMLB3I4
DMLB3I4	DN	Trastuzumab-DM1
DMLB3I4	MI	TT6EO5L
DMLB3I4	MN	Erbb2 tyrosine kinase receptor (HER2)
DMLB3I4	MT	DTT
DMLB3I4	RN	Clinical pipeline report, company report or official report of Genentech (2009).
DMLB3I4	RU	http://www.gene.com/gene/pipeline/status/

DM1874J	DI	DM1874J
DM1874J	DN	TRC105
DM1874J	MI	TTB30LE
DM1874J	MN	Endoglin CD105 (ENG)
DM1874J	MT	DTT
DM1874J	MA	Modulator
DM1874J	RN	An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer. Clin Cancer Res. 2014 Dec 1;20(23):5918-26.
DM1874J	RU	https://pubmed.ncbi.nlm.nih.gov/25261556

DMOG2X1	DI	DMOG2X1
DMOG2X1	DN	Trebananib
DMOG2X1	MI	TTWNQ1T
DMOG2X1	MN	Angiopoietin-1 (ANGPT1)
DMOG2X1	MT	DTT
DMOG2X1	MA	Inhibitor
DMOG2X1	RN	Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report. Clin Cancer Res. 2017 Oct 15;23(20):6062-6069.
DMOG2X1	RU	https://pubmed.ncbi.nlm.nih.gov/28751444

DMOG2X1	DI	DMOG2X1
DMOG2X1	DN	Trebananib
DMOG2X1	MI	TTKLQTJ
DMOG2X1	MN	Angiopoietin-2 (ANGPT2)
DMOG2X1	MT	DTT
DMOG2X1	MA	Inhibitor
DMOG2X1	RN	Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report. Clin Cancer Res. 2017 Oct 15;23(20):6062-6069.
DMOG2X1	RU	https://pubmed.ncbi.nlm.nih.gov/28751444

DMOQ9H1	DI	DMOQ9H1
DMOQ9H1	DN	Tremelimumab
DMOQ9H1	MI	TTI2S1D
DMOQ9H1	MN	Cytotoxic T-lymphocyte protein 4 (CTLA-4)
DMOQ9H1	MT	DTT
DMOQ9H1	MA	Modulator
DMOQ9H1	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2743).
DMOQ9H1	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2743

DMS57DJ	DI	DMS57DJ
DMS57DJ	DN	Trimegestone/ethinyl estradiol
DMS57DJ	MI	TTZAYWL
DMS57DJ	MN	Estrogen receptor (ESR)
DMS57DJ	MT	DTT
DMS57DJ	MA	Modulator
DMS57DJ	RN	Differential effects of estrogens and progestins on the anticoagulant tissue factor pathway inhibitor in the rat. J Steroid Biochem Mol Biol. 2005 Mar;94(4):361-8.
DMS57DJ	RU	https://pubmed.ncbi.nlm.nih.gov/15857755

DMCMDVR	DI	DMCMDVR
DMCMDVR	DN	Triptolide
DMCMDVR	MI	DE4LYSA
DMCMDVR	MN	Cytochrome P450 3A4 (CYP3A4)
DMCMDVR	MT	DME
DMCMDVR	MA	Metabolism
DMCMDVR	RN	Preclinical pharmacokinetics of triptolide: a potential antitumor drug. Curr Drug Metab. 2019;20(2):147-154.
DMCMDVR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30112986

DMCMDVR	DI	DMCMDVR
DMCMDVR	DN	Triptolide
DMCMDVR	MI	TTSXVID
DMCMDVR	MN	Nuclear factor NF-kappa-B (NFKB)
DMCMDVR	MT	DTT
DMCMDVR	MA	Inhibitor
DMCMDVR	RN	Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells. Oncogene. 2001 Nov 29;20(55):8009-18.
DMCMDVR	RU	https://pubmed.ncbi.nlm.nih.gov/11753684

DMHDNK0	DI	DMHDNK0
DMHDNK0	DN	TroVax
DMHDNK0	MI	TT70MLA
DMHDNK0	MN	Oncotrophoblast glycoprotein 5T4 (TPBG)
DMHDNK0	MT	DTT
DMHDNK0	RN	Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res. 2010 Nov 15;16(22):5539-47.
DMHDNK0	RU	https://pubmed.ncbi.nlm.nih.gov/20881001

DM0QNF4	DI	DM0QNF4
DM0QNF4	DN	TRx0237
DM0QNF4	MI	TTS87KH
DM0QNF4	MN	Microtubule-associated protein tau (MAPT)
DM0QNF4	MT	DTT
DM0QNF4	MA	Inhibitor
DM0QNF4	RN	Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model. Curr Alzheimer Res. 2020;17(3):285-296.
DM0QNF4	RU	https://pubmed.ncbi.nlm.nih.gov/32091331

DMAFPHB	DI	DMAFPHB
DMAFPHB	DN	TRYPTAMINE
DMAFPHB	MI	TTJQOD7
DMAFPHB	MN	5-HT 2A receptor (HTR2A)
DMAFPHB	MT	DTT
DMAFPHB	MA	Inhibitor
DMAFPHB	RN	Central serotonin receptors as targets for drug research. J Med Chem. 1987 Jan;30(1):1-12.
DMAFPHB	RU	https://pubmed.ncbi.nlm.nih.gov/3543362

DMAFPHB	DI	DMAFPHB
DMAFPHB	DN	TRYPTAMINE
DMAFPHB	MI	TT3WG5C
DMAFPHB	MN	Monoamine oxidase type A (MAO-A)
DMAFPHB	MT	DTT
DMAFPHB	MA	Inhibitor
DMAFPHB	RN	Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
DMAFPHB	RU	https://pubmed.ncbi.nlm.nih.gov/15013009

DMAFPHB	DI	DMAFPHB
DMAFPHB	DN	TRYPTAMINE
DMAFPHB	MI	TTGP7BY
DMAFPHB	MN	Monoamine oxidase type B (MAO-B)
DMAFPHB	MT	DTT
DMAFPHB	MA	Inhibitor
DMAFPHB	RN	Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
DMAFPHB	RU	https://pubmed.ncbi.nlm.nih.gov/15013009

DMPBJ8W	DI	DMPBJ8W
DMPBJ8W	DN	Turoctocog alfa
DMPBJ8W	MI	TT1290U
DMPBJ8W	MN	Coagulation factor VIII (F8)
DMPBJ8W	MT	DTT
DMPBJ8W	MA	Modulator
DMPBJ8W	RN	The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight ), in patients with hemophilia A. J Thromb Haemost. 2015 Mar;13(3):370-9.
DMPBJ8W	RU	https://pubmed.ncbi.nlm.nih.gov/25495795

DM71ZL6	DI	DM71ZL6
DM71ZL6	DN	TZTX-001
DM71ZL6	MI	TTZAYWL
DM71ZL6	MN	Estrogen receptor (ESR)
DM71ZL6	MT	DTT
DM71ZL6	MA	Modulator
DM71ZL6	RN	Clinical pipeline report, company report or official report of Pharmabiz.
DM71ZL6	RU	http://www.pharmabiz.com/PrintArticle.aspx?aid=77569&sid=2

DMN72OM	DI	DMN72OM
DMN72OM	DN	U300
DMN72OM	MI	TTZOPHG
DMN72OM	MN	Insulin (INS)
DMN72OM	MT	DTT
DMN72OM	MA	Modulator
DMN72OM	RN	U300, a novel long-acting insulin formulation. Expert Opin Biol Ther. 2014 Dec;14(12):1849-60.
DMN72OM	RU	https://pubmed.ncbi.nlm.nih.gov/25311556

DMHTY9W	DI	DMHTY9W
DMHTY9W	DN	Ublituximab
DMHTY9W	MI	TTUE541
DMHTY9W	MN	Leukocyte surface antigen Leu-16 (CD20)
DMHTY9W	MT	DTT
DMHTY9W	RN	The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenstr m macroglobulinemia. Haematologica. 2015 Apr;100(4):e147-51.
DMHTY9W	RU	https://pubmed.ncbi.nlm.nih.gov/25552707

DMKUOVP	DI	DMKUOVP
DMKUOVP	DN	Ublituximab + umbralisib
DMKUOVP	MI	TTUE541
DMKUOVP	MN	Leukocyte surface antigen Leu-16 (CD20)
DMKUOVP	MT	DTT
DMKUOVP	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMKUOVP	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM90AG2	DI	DM90AG2
DM90AG2	DN	Ularitide
DM90AG2	MI	TTJME02
DM90AG2	MN	Atrial natriuretic peptide receptor A (NPR1)
DM90AG2	MT	DTT
DM90AG2	MA	Modulator
DM90AG2	RN	Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies. Eur Heart J. 2015 Mar 21;36(12):715-23.
DM90AG2	RU	https://pubmed.ncbi.nlm.nih.gov/25670819

DMIQCFG	DI	DMIQCFG
DMIQCFG	DN	Ulinastatin
DMIQCFG	MI	TT2WR1T
DMIQCFG	MN	Cationic trypsinogen (PRSS1)
DMIQCFG	MT	DTT
DMIQCFG	MA	Modulator
DMIQCFG	RN	Intravenous administration of ulinastatin (human urinary trypsin inhibitor) in severe sepsis: a multicenter randomized controlled study. Intensive Care Med. 2014 Jun;40(6):830-8.
DMIQCFG	RU	https://pubmed.ncbi.nlm.nih.gov/24737258

DM6PMNR	DI	DM6PMNR
DM6PMNR	DN	Ulocuplumab
DM6PMNR	MI	TTBID49
DM6PMNR	MN	C-X-C chemokine receptor type 4 (CXCR4)
DM6PMNR	MT	DTT
DM6PMNR	MA	Antagonist
DM6PMNR	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM6PMNR	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMCWM03	DI	DMCWM03
DMCWM03	DN	Unfractionated heparin
DMCWM03	MI	TT4QPUL
DMCWM03	MN	Antithrombin-III (ATIII)
DMCWM03	MT	DTT
DMCWM03	MA	Modulator
DMCWM03	RN	Heparin with low affinity to antithrombin III inhibits the activation of prothrombin in normal plasma. Thromb Res. 1982 Nov 15;28(4):487-97.
DMCWM03	RU	https://pubmed.ncbi.nlm.nih.gov/7164033

DM0DIEZ	DI	DM0DIEZ
DM0DIEZ	DN	UNI-rhIL-11
DM0DIEZ	MI	TTZPLJS
DM0DIEZ	MN	Interleukin 11 receptor alpha (IL11RA)
DM0DIEZ	MT	DTT
DM0DIEZ	MA	Modulator
DM0DIEZ	RN	Clinical study of rhIL-11 for prevention and treatment of chemotherapy-induced thrombocytopenia. Ai Zheng. 2002 Aug;21(8):892-5.
DM0DIEZ	RU	https://pubmed.ncbi.nlm.nih.gov/12478901

DMM2OZH	DI	DMM2OZH
DMM2OZH	DN	Ushercell
DMM2OZH	MI	TTAUG8D
DMM2OZH	MN	Human immunodeficiency virus Transmission (HIV Tran)
DMM2OZH	MT	DTT
DMM2OZH	MA	Modulator
DMM2OZH	RN	Short Communication: Enhancement of HIV Infection by Cellulose Sulfate. AIDS Res Hum Retroviruses. 2008 July; 24(7): 925-929.
DMM2OZH	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2927036/

DMD2O0L	DI	DMD2O0L
DMD2O0L	DN	UX-001
DMD2O0L	MI	TTQ8J1V
DMD2O0L	MN	Bacterial Deoxy-manno-octulosonate cytidylyltransferase (Bact kdsB)
DMD2O0L	MT	DTT
DMD2O0L	MA	Inhibitor
DMD2O0L	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD2O0L	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD2O0L	DI	DMD2O0L
DMD2O0L	DN	UX-001
DMD2O0L	MI	TT50QJ3
DMD2O0L	MN	Influenza Neuraminidase (Influ NA)
DMD2O0L	MT	DTT
DMD2O0L	MA	Inhibitor
DMD2O0L	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD2O0L	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMDCFXJ	DI	DMDCFXJ
DMDCFXJ	DN	Vaborbactam
DMDCFXJ	MI	TTHI19T
DMDCFXJ	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMDCFXJ	MT	DTT
DMDCFXJ	MA	Inhibitor
DMDCFXJ	RN	Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017 Oct 24;61(11):e01443-17.
DMDCFXJ	RU	https://pubmed.ncbi.nlm.nih.gov/28848018

DM9LH10	DI	DM9LH10
DM9LH10	DN	Vadastuximab talirine
DM9LH10	MI	TTJVYO3
DM9LH10	MN	Myeloid cell surface antigen CD33 (CD33)
DM9LH10	MT	DTT
DM9LH10	MA	Antagonist
DM9LH10	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9LH10	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM9J5Q4	DI	DM9J5Q4
DM9J5Q4	DN	VAL-083
DM9J5Q4	MI	TTUTN1I
DM9J5Q4	MN	Human Deoxyribonucleic acid (hDNA)
DM9J5Q4	MT	DTT
DM9J5Q4	MA	Modulator
DM9J5Q4	RN	Effect of 1,2:5,6-dianhydrogalactitol and 1,2:5,6-dianhydro-3,4-diacetylgalactitol on DNA synthesis in the cells of melanoma B16, bone marrow, small intestine epithelium, spleen and liver of mice. Biull Eksp Biol Med. 1984 Sep;98(9):301-3.
DM9J5Q4	RU	https://pubmed.ncbi.nlm.nih.gov/6487788

DMMKE2H	DI	DMMKE2H
DMMKE2H	DN	Valoctocogene roxaparvovec
DMMKE2H	MI	TT1290U
DMMKE2H	MN	Coagulation factor VIII (F8)
DMMKE2H	MT	DTT
DMMKE2H	MA	Replacement
DMMKE2H	RN	Clinical pipeline report, company report or official report of BioMarin Pharmaceutical.
DMMKE2H	RU	https://www.biomarin.com/our-treatments/pipeline/

DMQL0KF	DI	DMQL0KF
DMQL0KF	DN	Vanadate
DMQL0KF	MI	TTZVSJ2
DMQL0KF	MN	Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A)
DMQL0KF	MT	DTT
DMQL0KF	MA	Inhibitor
DMQL0KF	RN	Expression and functional characterization of a Plasmodium falciparum Ca2+-ATPase (PfATP4) belonging to a subclass unique to apicomplexan organisms. J Biol Chem. 2001 Apr 6;276(14):10782-7.
DMQL0KF	RU	https://pubmed.ncbi.nlm.nih.gov/11145964

DMLIMEA	DI	DMLIMEA
DMLIMEA	DN	Varespladib methyl
DMLIMEA	MI	TT2XHSJ
DMLIMEA	MN	Secretory phospholipase A2 (sPLA2)
DMLIMEA	MT	DTT
DMLIMEA	MA	Modulator
DMLIMEA	RN	Varespladib. Am J Cardiovasc Drugs. 2011;11(2):137-43.
DMLIMEA	RU	https://pubmed.ncbi.nlm.nih.gov/21446779

DMANKTO	DI	DMANKTO
DMANKTO	DN	Vatreptacog alfa (activated)
DMANKTO	MI	TTF0EGX
DMANKTO	MN	Coagulation factor VII (F7)
DMANKTO	MT	DTT
DMANKTO	MA	Modulator
DMANKTO	RN	Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. J Thromb Haemost. 2012 Jan;10(1):81-9.
DMANKTO	RU	https://pubmed.ncbi.nlm.nih.gov/22470921

DMX04CA	DI	DMX04CA
DMX04CA	DN	VB-111
DMX04CA	MI	TTF0RCZ
DMX04CA	MN	Apoptosis mediating surface antigen FAS (FAS)
DMX04CA	MT	DTT
DMX04CA	MA	Modulator
DMX04CA	RN	Phase I dose-escalation study of VB-111, an antiangiogenic virotherapy, in patients with advanced solid tumors.Clin Cancer Res.2013 Jul 15;19(14):3996-4007.
DMX04CA	RU	https://www.ncbi.nlm.nih.gov/pubmed/23589178

DMX04CA	DI	DMX04CA
DMX04CA	DN	VB-111
DMX04CA	MI	TTG043C
DMX04CA	MN	Tumor necrosis factor receptor type I (TNF-R1)
DMX04CA	MT	DTT
DMX04CA	MA	Modulator
DMX04CA	RN	Phase I dose-escalation study of VB-111, an antiangiogenic virotherapy, in patients with advanced solid tumors.Clin Cancer Res.2013 Jul 15;19(14):3996-4007.
DMX04CA	RU	https://www.ncbi.nlm.nih.gov/pubmed/23589178

DMXHI89	DI	DMXHI89
DMXHI89	DN	Velac Gel
DMXHI89	MI	TTOD7B3
DMXHI89	MN	Retinoic acid receptor (RAR)
DMXHI89	MT	DTT
DMXHI89	MA	Inhibitor
DMXHI89	RN	Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell. 1991 Aug 23;66(4):663-74.
DMXHI89	RU	https://pubmed.ncbi.nlm.nih.gov/1652368

DMJBU9V	DI	DMJBU9V
DMJBU9V	DN	Velimogene aliplasmid
DMJBU9V	MI	TTGS10J
DMJBU9V	MN	HLA class I antigen B-7 (HLA-B)
DMJBU9V	MT	DTT
DMJBU9V	MA	Modulator
DMJBU9V	RN	Velimogene aliplasmid. Expert Opin Biol Ther. 2010 May;10(5):841-51.
DMJBU9V	RU	https://pubmed.ncbi.nlm.nih.gov/20367461

DM6L5ZQ	DI	DM6L5ZQ
DM6L5ZQ	DN	Vercirnon
DM6L5ZQ	MI	TTIPS8B
DM6L5ZQ	MN	C-C chemokine receptor type 9 (CCR9)
DM6L5ZQ	MT	DTT
DM6L5ZQ	MA	Modulator
DM6L5ZQ	RN	GSK-1605786, a selective small-molecule antagonist of the CCR9 chemokine receptor for the treatment of Crohn's disease. IDrugs. 2010 Jul;13(7):472-81.
DM6L5ZQ	RU	https://pubmed.ncbi.nlm.nih.gov/20582872

DMOQ81Y	DI	DMOQ81Y
DMOQ81Y	DN	Vernakalant
DMOQ81Y	MI	DECB0K3
DMOQ81Y	MN	Cytochrome P450 2D6 (CYP2D6)
DMOQ81Y	MT	DME
DMOQ81Y	MA	Metabolism
DMOQ81Y	RN	Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors. J Clin Pharmacol. 2009 Jan;49(1):17-29.
DMOQ81Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18927241

DM4CGH5	DI	DM4CGH5
DM4CGH5	DN	verubecestat
DM4CGH5	MI	TT8JRS7
DM4CGH5	MN	Beta-secretase (BACE)
DM4CGH5	MT	DTT
DM4CGH5	MA	Modulator
DM4CGH5	RN	BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimers Res Ther. 2014 Dec 24;6(9):89.
DM4CGH5	RU	https://pubmed.ncbi.nlm.nih.gov/25621019

DM4CGH5	DI	DM4CGH5
DM4CGH5	DN	verubecestat
DM4CGH5	MI	TTJUNZF
DM4CGH5	MN	Beta-secretase 1 (BACE1)
DM4CGH5	MT	DTT
DM4CGH5	MA	Inhibitor
DM4CGH5	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM4CGH5	RU	http://phrma-docs.phrma.org/files/dmfile/MID-Update_Alzheimers-Disease_2017-Drug-List.pdf

DMMQ2U9	DI	DMMQ2U9
DMMQ2U9	DN	VGX-3100
DMMQ2U9	MI	TTE2N95
DMMQ2U9	MN	Human papillomavirus protein E6 (HPV E6)
DMMQ2U9	MT	DTT
DMMQ2U9	MA	Modulator
DMMQ2U9	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMMQ2U9	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMMQ2U9	DI	DMMQ2U9
DMMQ2U9	DN	VGX-3100
DMMQ2U9	MI	TT3CPZW
DMMQ2U9	MN	Human papillomavirus protein E7 (HPV E7)
DMMQ2U9	MT	DTT
DMMQ2U9	MA	Modulator
DMMQ2U9	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMMQ2U9	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMCWNZG	DI	DMCWNZG
DMCWNZG	DN	Vibegron
DMCWNZG	MI	DTUGYRD
DMCWNZG	MN	P-glycoprotein 1 (ABCB1)
DMCWNZG	MT	DTP
DMCWNZG	MA	Substrate
DMCWNZG	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
DMCWNZG	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01665

DMLO0KD	DI	DMLO0KD
DMLO0KD	DN	Vicineum
DMLO0KD	MI	TTZ8WH4
DMLO0KD	MN	Tumor-associated calcium signal transducer 1 (EPCAM)
DMLO0KD	MT	DTT
DMLO0KD	RN	Clinical pipeline report, company report or official report of Sesen Bio.
DMLO0KD	RU	https://sesenbio.com/our-programs/

DMMTW9K	DI	DMMTW9K
DMMTW9K	DN	Vicriviroc
DMMTW9K	MI	TT2CEJG
DMMTW9K	MN	C-C chemokine receptor type 5 (CCR5)
DMMTW9K	MT	DTT
DMMTW9K	MA	Antagonist
DMMTW9K	RN	HIV entry: new insights and implications for patient management. Curr Opin Infect Dis. 2009 Feb;22(1):35-42.
DMMTW9K	RU	https://pubmed.ncbi.nlm.nih.gov/19532079

DMMTW9K	DI	DMMTW9K
DMMTW9K	DN	Vicriviroc
DMMTW9K	MI	DE5IED8
DMMTW9K	MN	Cytochrome P450 2C9 (CYP2C9)
DMMTW9K	MT	DME
DMMTW9K	MA	Metabolism
DMMTW9K	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMMTW9K	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMMTW9K	DI	DMMTW9K
DMMTW9K	DN	Vicriviroc
DMMTW9K	MI	DE4LYSA
DMMTW9K	MN	Cytochrome P450 3A4 (CYP3A4)
DMMTW9K	MT	DME
DMMTW9K	MA	Metabolism
DMMTW9K	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMMTW9K	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMMTW9K	DI	DMMTW9K
DMMTW9K	DN	Vicriviroc
DMMTW9K	MI	DEIBDNY
DMMTW9K	MN	Cytochrome P450 3A5 (CYP3A5)
DMMTW9K	MT	DME
DMMTW9K	MA	Metabolism
DMMTW9K	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMMTW9K	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMJFNR9	DI	DMJFNR9
DMJFNR9	DN	Viramidine
DMJFNR9	MI	TTL7C8Q
DMJFNR9	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMJFNR9	MT	DTT
DMJFNR9	MA	Inhibitor
DMJFNR9	RN	Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25.
DMJFNR9	RU	https://pubmed.ncbi.nlm.nih.gov/17139286

DMXYM1H	DI	DMXYM1H
DMXYM1H	DN	Visilizumab
DMXYM1H	MI	TTBMAOZ
DMXYM1H	MN	Regulatory protein unspecific (RGP)
DMXYM1H	MT	DTT
DMXYM1H	RN	Visilizumab induces apoptosis of mucosal T lymphocytes in ulcerative colitis through activation of caspase 3 and 8 dependent pathways. Clin Immunol. 2008 Jun;127(3):322-9.
DMXYM1H	RU	https://pubmed.ncbi.nlm.nih.gov/18424236

DMQGV5P	DI	DMQGV5P
DMQGV5P	DN	VLB-01
DMQGV5P	MI	TT32JK8
DMQGV5P	MN	Melatonin receptor type 1B (MTNR1B)
DMQGV5P	MT	DTT
DMQGV5P	MA	Modulator
DMQGV5P	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMQGV5P	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMSW80U	DI	DMSW80U
DMSW80U	DN	VM-202
DMSW80U	MI	TT4V2JM
DMSW80U	MN	Hepatocyte growth factor (HGF)
DMSW80U	MT	DTT
DMSW80U	MA	Modulator
DMSW80U	RN	Therapeutic angiogenesis using naked DNA expressing two isoforms of the hepatocyte growth factor in a porcine acute myocardial infarction model. Eur J Cardiothorac Surg. 2008 Oct;34(4):857-63.
DMSW80U	RU	https://pubmed.ncbi.nlm.nih.gov/18620865

DM4P5UJ	DI	DM4P5UJ
DM4P5UJ	DN	VM-501
DM4P5UJ	MI	TTGUYTR
DM4P5UJ	MN	Interleukin-11 (IL11)
DM4P5UJ	MT	DTT
DM4P5UJ	MA	Agonist
DM4P5UJ	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033052)
DM4P5UJ	RU	http://adisinsight.springer.com/drugs/800033052

DMOFH1M	DI	DMOFH1M
DMOFH1M	DN	Volasertib
DMOFH1M	MI	TTIYVQP
DMOFH1M	MN	Polo-like kinase 1 (PLK1)
DMOFH1M	MT	DTT
DMOFH1M	MA	Modulator
DMOFH1M	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2168).
DMOFH1M	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2168

DM5T4IS	DI	DM5T4IS
DM5T4IS	DN	VP-102
DM5T4IS	MI	TTLA7IX
DM5T4IS	MN	Protein phosphatase 1A (PPM1A)
DM5T4IS	MT	DTT
DM5T4IS	MA	Inhibitor
DM5T4IS	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM5T4IS	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM5T4IS	DI	DM5T4IS
DM5T4IS	DN	VP-102
DM5T4IS	MI	TTHTKNY
DM5T4IS	MN	Serine/threonine PP2A-alpha (PPP2CA)
DM5T4IS	MT	DTT
DM5T4IS	MA	Inhibitor
DM5T4IS	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM5T4IS	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMWMT5N	DI	DMWMT5N
DMWMT5N	DN	VRS-317
DMWMT5N	MI	TTT3YKH
DMWMT5N	MN	Somatotropin (GH1)
DMWMT5N	MT	DTT
DMWMT5N	MA	Modulator
DMWMT5N	RN	Company report (Versartis)
DMWMT5N	RU	http://www.versartis.com/content/productpipeline/vrs-317.htm

DMM1Z9G	DI	DMM1Z9G
DMM1Z9G	DN	Vutrisiran
DMM1Z9G	MI	TTPOYU7
DMM1Z9G	MN	Transthyretin messenger RNA (TTR mRNA)
DMM1Z9G	MT	DTT
DMM1Z9G	MA	Inhibitor
DMM1Z9G	RN	Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals.
DMM1Z9G	RU	https://www.alnylam.com/alnylam-rnai-pipeline/

DMJBXO3	DI	DMJBXO3
DMJBXO3	DN	VX-661
DMJBXO3	MI	TTRLZHP
DMJBXO3	MN	cAMP-dependent chloride channel (CFTR)
DMJBXO3	MT	DTT
DMJBXO3	MA	Regulator
DMJBXO3	RN	CFTR Modulators for the Treatment of Cystic Fibrosis. P T. 2014 Jul;39(7):500-11.
DMJBXO3	RU	https://pubmed.ncbi.nlm.nih.gov/25083129

DMJBXO3	DI	DMJBXO3
DMJBXO3	DN	VX-661
DMJBXO3	MI	DEIBDNY
DMJBXO3	MN	Cytochrome P450 3A5 (CYP3A5)
DMJBXO3	MT	DME
DMJBXO3	MA	Metabolism
DMJBXO3	RN	Pharmacokinetic and drug-drug interaction profiles of the combination of Tezacaftor/Ivacaftor. Clin Transl Sci. 2019 May;12(3):267-275.
DMJBXO3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30694595

DMM2JXP	DI	DMM2JXP
DMM2JXP	DN	VX-787
DMM2JXP	MI	TT62KQV
DMM2JXP	MN	Influenza Polymerase basic protein 2 (Influ PB2)
DMM2JXP	MT	DTT
DMM2JXP	MA	Inhibitor
DMM2JXP	RN	Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2. J Med Chem. 2014 Aug 14;57(15):6668-78.
DMM2JXP	RU	https://pubmed.ncbi.nlm.nih.gov/25019388

DM1JCW8	DI	DM1JCW8
DM1JCW8	DN	Xaliproden
DM1JCW8	MI	TTSQIFT
DM1JCW8	MN	5-HT 1A receptor (HTR1A)
DM1JCW8	MT	DTT
DM1JCW8	MA	Antagonist
DM1JCW8	RN	Pharma & Vaccines. Product Development Pipeline. April 29 2009.
DM1JCW8	RU	http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf

DMK34MZ	DI	DMK34MZ
DMK34MZ	DN	Xilonix
DMK34MZ	MI	TTPM6HI
DMK34MZ	MN	Interleukin-1 alpha (IL1A)
DMK34MZ	MT	DTT
DMK34MZ	MA	Modulator
DMK34MZ	RN	Clinical pipeline report, company report or official report of xbiotech.
DMK34MZ	RU	http://www.xbiotech.com/clinical/oncology.html

DMJ6F5C	DI	DMJ6F5C
DMJ6F5C	DN	XL019
DMJ6F5C	MI	TTRMX3V
DMJ6F5C	MN	Janus kinase 2 (JAK-2)
DMJ6F5C	MT	DTT
DMJ6F5C	MA	Inhibitor
DMJ6F5C	RN	Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9.
DMJ6F5C	RU	https://pubmed.ncbi.nlm.nih.gov/19552608

DMOKQV7	DI	DMOKQV7
DMOKQV7	DN	XOMA 052
DMOKQV7	MI	TTRYK0X
DMOKQV7	MN	Interleukin-1 beta (IL1B)
DMOKQV7	MT	DTT
DMOKQV7	RN	Gevokizumab, an anti-IL-1beta mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease. Curr Opin Mol Ther. 2010 Dec;12(6):755-69.
DMOKQV7	RU	https://pubmed.ncbi.nlm.nih.gov/21154167

DMOLR5W	DI	DMOLR5W
DMOLR5W	DN	Yttrium (90Y) clivatuzumab tetraxetan
DMOLR5W	MI	TTBHFYQ
DMOLR5W	MN	Mucin-1 (MUC1)
DMOLR5W	MT	DTT
DMOLR5W	RN	Clinical pipeline report, company report or official report of Immunomedics.
DMOLR5W	RU	http://www.immunomedics.com/clivatuzumab-demo.shtml

DMEY1F3	DI	DMEY1F3
DMEY1F3	DN	Zabofloxacin
DMEY1F3	MI	TTN6J5F
DMEY1F3	MN	Bacterial DNA gyrase (Bact gyrase)
DMEY1F3	MT	DTT
DMEY1F3	MA	Modulator
DMEY1F3	RN	DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae.Int J Antimicrob Agents.2010 Jul;36(1):97-8.
DMEY1F3	RU	https://www.ncbi.nlm.nih.gov/pubmed/20403681

DMEY1F3	DI	DMEY1F3
DMEY1F3	DN	Zabofloxacin
DMEY1F3	MI	TTIXTO3
DMEY1F3	MN	Staphylococcus Topoisomerase IV (Stap-coc parC)
DMEY1F3	MT	DTT
DMEY1F3	MA	Modulator
DMEY1F3	RN	DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae.Int J Antimicrob Agents.2010 Jul;36(1):97-8.
DMEY1F3	RU	https://www.ncbi.nlm.nih.gov/pubmed/20403681

DM52QEZ	DI	DM52QEZ
DM52QEZ	DN	Zalutumumab
DM52QEZ	MI	TTGKNB4
DM52QEZ	MN	Epidermal growth factor receptor (EGFR)
DM52QEZ	MT	DTT
DM52QEZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
DM52QEZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797

DMKB4ZY	DI	DMKB4ZY
DMKB4ZY	DN	Zanolimumab
DMKB4ZY	MI	TTN2JFW
DMKB4ZY	MN	T-cell surface glycoprotein CD4 (CD4)
DMKB4ZY	MT	DTT
DMKB4ZY	RN	Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood. 2007 Jun 1;109(11):4655-62.
DMKB4ZY	RU	https://pubmed.ncbi.nlm.nih.gov/17311990

DM9HUYP	DI	DM9HUYP
DM9HUYP	DN	ZANOTERONE
DM9HUYP	MI	TTS64P2
DM9HUYP	MN	Androgen receptor (AR)
DM9HUYP	MT	DTT
DM9HUYP	MA	Inhibitor
DM9HUYP	RN	Antiandrogenic steroidal sulfonyl heterocycles. Utility of electrostatic complementarity in defining bioisosteric sulfonyl heterocycles. J Med Chem. 1992 May 15;35(10):1663-70.
DM9HUYP	RU	https://pubmed.ncbi.nlm.nih.gov/1588549

DMF30HL	DI	DMF30HL
DMF30HL	DN	Zarnestra
DMF30HL	MI	TTXQKM3
DMF30HL	MN	Farnesyl protein transferase (Ftase)
DMF30HL	MT	DTT
DMF30HL	MA	Modulator
DMF30HL	RN	Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia. Biologics. 2008 Sep;2(3):491-500.
DMF30HL	RU	https://www.ncbi.nlm.nih.gov/pubmed/19707379

DMF30HL	DI	DMF30HL
DMF30HL	DN	Zarnestra
DMF30HL	MI	TTIKWV4
DMF30HL	MN	Geranyltranstransferase (FDPS)
DMF30HL	MT	DTT
DMF30HL	MA	Inhibitor
DMF30HL	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMF30HL	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMWDEFC	DI	DMWDEFC
DMWDEFC	DN	Zatosetron maleate
DMWDEFC	MI	TTNXLKE
DMWDEFC	MN	5-HT 3 receptor (5HT3R)
DMWDEFC	MT	DTT
DMWDEFC	MA	Modulator
DMWDEFC	RN	Pilot study of zatosetron (LY277359) maleate, a 5-hydroxytryptamine-3 antagonist, in the treatment of anxiety. J Clin Psychopharmacol. 1999 Apr;19(2):125-31.
DMWDEFC	RU	https://www.ncbi.nlm.nih.gov/pubmed/10211913

DMP8ESD	DI	DMP8ESD
DMP8ESD	DN	Zicronapine
DMP8ESD	MI	TTJQOD7
DMP8ESD	MN	5-HT 2A receptor (HTR2A)
DMP8ESD	MT	DTT
DMP8ESD	MA	Modulator
DMP8ESD	RN	Clinical pipeline report, company report or official report of Lundbeck.
DMP8ESD	RU	http://investor.lundbeck.com/releasedetail.cfm?ReleaseID=608605

DMP8ESD	DI	DMP8ESD
DMP8ESD	DN	Zicronapine
DMP8ESD	MI	TTZFYLI
DMP8ESD	MN	Dopamine D1 receptor (D1R)
DMP8ESD	MT	DTT
DMP8ESD	MA	Modulator
DMP8ESD	RN	Clinical pipeline report, company report or official report of Lundbeck.
DMP8ESD	RU	http://investor.lundbeck.com/releasedetail.cfm?ReleaseID=608605

DMP8ESD	DI	DMP8ESD
DMP8ESD	DN	Zicronapine
DMP8ESD	MI	TTEX248
DMP8ESD	MN	Dopamine D2 receptor (D2R)
DMP8ESD	MT	DTT
DMP8ESD	MA	Modulator
DMP8ESD	RN	Clinical pipeline report, company report or official report of Lundbeck.
DMP8ESD	RU	http://investor.lundbeck.com/releasedetail.cfm?ReleaseID=608605

DM09TVB	DI	DM09TVB
DM09TVB	DN	Zimura
DM09TVB	MI	TTKANGO
DM09TVB	MN	Complement C5 (CO5)
DM09TVB	MT	DTT
DM09TVB	MA	Inhibitor
DM09TVB	RN	C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. Ophthalmology. 2021 Apr;128(4):576-586.
DM09TVB	RU	https://pubmed.ncbi.nlm.nih.gov/32882310

DMFWMKZ	DI	DMFWMKZ
DMFWMKZ	DN	ZK-93423
DMFWMKZ	MI	TT1MPAY
DMFWMKZ	MN	GABA(A) receptor alpha-1 (GABRA1)
DMFWMKZ	MT	DTT
DMFWMKZ	MA	Inhibitor
DMFWMKZ	RN	Structural requirements for agonist actions at the benzodiazepine receptor: studies with analogues of 6-(benzyloxy)-4-(methoxymethyl)-beta-carbolin... J Med Chem. 1990 Mar;33(3):1062-9.
DMFWMKZ	RU	https://pubmed.ncbi.nlm.nih.gov/1968513

DMFWMKZ	DI	DMFWMKZ
DMFWMKZ	DN	ZK-93423
DMFWMKZ	MI	TTZA1NY
DMFWMKZ	MN	GABA(A) receptor beta-2 (GABRB2)
DMFWMKZ	MT	DTT
DMFWMKZ	MA	Inhibitor
DMFWMKZ	RN	Structural requirements for agonist actions at the benzodiazepine receptor: studies with analogues of 6-(benzyloxy)-4-(methoxymethyl)-beta-carbolin... J Med Chem. 1990 Mar;33(3):1062-9.
DMFWMKZ	RU	https://pubmed.ncbi.nlm.nih.gov/1968513

DMFWMKZ	DI	DMFWMKZ
DMFWMKZ	DN	ZK-93423
DMFWMKZ	MI	TT06RH5
DMFWMKZ	MN	GABA(A) receptor gamma-2 (GABRG2)
DMFWMKZ	MT	DTT
DMFWMKZ	MA	Inhibitor
DMFWMKZ	RN	Structural requirements for agonist actions at the benzodiazepine receptor: studies with analogues of 6-(benzyloxy)-4-(methoxymethyl)-beta-carbolin... J Med Chem. 1990 Mar;33(3):1062-9.
DMFWMKZ	RU	https://pubmed.ncbi.nlm.nih.gov/1968513

DMFWMKZ	DI	DMFWMKZ
DMFWMKZ	DN	ZK-93423
DMFWMKZ	MI	TTNJYV2
DMFWMKZ	MN	Gamma-aminobutyric acid receptor (GAR)
DMFWMKZ	MT	DTT
DMFWMKZ	MA	Inhibitor
DMFWMKZ	RN	Structural requirements for agonist actions at the benzodiazepine receptor: studies with analogues of 6-(benzyloxy)-4-(methoxymethyl)-beta-carbolin... J Med Chem. 1990 Mar;33(3):1062-9.
DMFWMKZ	RU	https://pubmed.ncbi.nlm.nih.gov/1968513

DM5ST9Z	DI	DM5ST9Z
DM5ST9Z	DN	Zolbetuximab
DM5ST9Z	MI	TT6PKBX
DM5ST9Z	MN	Claudin-18 (CLDN18)
DM5ST9Z	MT	DTT
DM5ST9Z	RN	FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol. 2021 May;32(5):609-619.
DM5ST9Z	RU	https://pubmed.ncbi.nlm.nih.gov/33610734

DM8L7JD	DI	DM8L7JD
DM8L7JD	DN	Zoniporide hydrochloride
DM8L7JD	MI	TTGSEFH
DM8L7JD	MN	Sodium/hydrogen exchanger 1 (SLC9A1)
DM8L7JD	MT	DTT
DM8L7JD	MA	Inhibitor
DM8L7JD	RN	Zoniporde: a potent and selective inhibitor of the human sodium-hydrogen exchanger isoform 1 (NHE-1). Cardiovasc Drug Rev. 2003 Spring;21(1):17-32.
DM8L7JD	RU	https://pubmed.ncbi.nlm.nih.gov/12595915

DMMBJYC	DI	DMMBJYC
DMMBJYC	DN	ZYH-1
DMMBJYC	MI	TTJ584C
DMMBJYC	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMMBJYC	MT	DTT
DMMBJYC	MA	Modulator
DMMBJYC	RN	Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARalpha agonist with moderate PPARgamma agonist activity in healthy human subjects. Clin Drug Investig. 2013 Nov;33(11):809-16.
DMMBJYC	RU	https://pubmed.ncbi.nlm.nih.gov/24062180

DMMBJYC	DI	DMMBJYC
DMMBJYC	DN	ZYH-1
DMMBJYC	MI	TTZMAO3
DMMBJYC	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMMBJYC	MT	DTT
DMMBJYC	MA	Modulator
DMMBJYC	RN	Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARalpha agonist with moderate PPARgamma agonist activity in healthy human subjects. Clin Drug Investig. 2013 Nov;33(11):809-16.
DMMBJYC	RU	https://pubmed.ncbi.nlm.nih.gov/24062180

DM12UX6	DI	DM12UX6
DM12UX6	DN	131 I-omburtamab
DM12UX6	MI	TT6CQUM
DM12UX6	MN	B7 homolog 3 (CD276)
DM12UX6	MT	DTT
DM12UX6	MA	Inhibitor
DM12UX6	RN	IntraOmmaya compartmental radioimmunotherapy using 131 I-omburtamab-pharmacokinetic modeling to optimize therapeutic index. Eur J Nucl Med Mol Imaging. 2021 Apr;48(4):1166-1177.
DM12UX6	RU	https://pubmed.ncbi.nlm.nih.gov/33047248

DMZ0T24	DI	DMZ0T24
DMZ0T24	DN	Abagovomab
DMZ0T24	MI	TTC1PS3
DMZ0T24	MN	Ovarian carcinoma antigen CA125 (MUC16)
DMZ0T24	MT	DTT
DMZ0T24	RN	Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer. Immunotherapy. 2011 Feb;3(2):153-62.
DMZ0T24	RU	https://pubmed.ncbi.nlm.nih.gov/21322756

DMKY9GI	DI	DMKY9GI
DMKY9GI	DN	Activated recombinant FVII-albumin fusion protein
DMKY9GI	MI	TTF0EGX
DMKY9GI	MN	Coagulation factor VII (F7)
DMKY9GI	MT	DTT
DMKY9GI	MA	Modulator
DMKY9GI	RN	ClinicalTrials.gov (NCT01542619) A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin (rVIIa-FP) in Healthy Male Volunteers. U.S. National Institutes of Health.
DMKY9GI	RU	https://clinicaltrials.gov/ct2/show/NCT01542619

DMKY9GI	DI	DMKY9GI
DMKY9GI	DN	Activated recombinant FVII-albumin fusion protein
DMKY9GI	MI	TTFNGC9
DMKY9GI	MN	Serum albumin (ALB)
DMKY9GI	MT	DTT
DMKY9GI	MA	Modulator
DMKY9GI	RN	ClinicalTrials.gov (NCT01542619) A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin (rVIIa-FP) in Healthy Male Volunteers. U.S. National Institutes of Health.
DMKY9GI	RU	https://clinicaltrials.gov/ct2/show/NCT01542619

DM6GTMD	DI	DM6GTMD
DM6GTMD	DN	ADX-48621
DM6GTMD	MI	TTHS256
DM6GTMD	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM6GTMD	MT	DTT
DM6GTMD	MA	Modulator
DM6GTMD	RN	Pipeline of Addex Pharma. Addex Pharma. 2009.
DM6GTMD	RU	http://www.addexpharma.com/pipeline-old/adx48621/

DMMHSLC	DI	DMMHSLC
DMMHSLC	DN	Afq056
DMMHSLC	MI	DE6OQ3W
DMMHSLC	MN	Cytochrome P450 1A1 (CYP1A1)
DMMHSLC	MT	DME
DMMHSLC	MA	Metabolism
DMMHSLC	RN	Methods to Assess Pulmonary Metabolism.
DMMHSLC	RU	https://edoc.unibas.ch/69409/1/110219_Doctoral_Thesis_Yildiz_Yilmaz.pdf

DMMHSLC	DI	DMMHSLC
DMMHSLC	DN	Afq056
DMMHSLC	MI	TTHS256
DMMHSLC	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMMHSLC	MT	DTT
DMMHSLC	MA	Modulator
DMMHSLC	RN	Metabolism and disposition of the metabotropic glutamate receptor 5 antagonist (mGluR5) mavoglurant (AFQ056) in healthy subjects. Drug Metab Dispos. 2013 Sep;41(9):1626-41.
DMMHSLC	RU	https://pubmed.ncbi.nlm.nih.gov/23775850

DMGC970	DI	DMGC970
DMGC970	DN	AG-013
DMGC970	MI	TTNOJIZ
DMGC970	MN	Trefoil factor-1 (TFF1)
DMGC970	MT	DTT
DMGC970	MA	Modulator
DMGC970	RN	AG013, a mouth rinse formulation of Lactococcus lactis secreting human Trefoil Factor 1, provides a safe and efficacious therapeutic tool for treating oral mucositis. Oral Oncol. 2010 Jul;46(7):564-70.
DMGC970	RU	https://pubmed.ncbi.nlm.nih.gov/20542722

DMD741P	DI	DMD741P
DMD741P	DN	Alagebrium chloride
DMD741P	MI	TTMO9HF
DMD741P	MN	Advanced glycosylation end product receptor (AGER)
DMD741P	MT	DTT
DMD741P	MA	Breaker
DMD741P	RN	Effect of the age cross-link breaker alagebrium on anterior segment physiology, morphology, and ocular age and rage. Trans Am Ophthalmol Soc. 2009 Dec;107:146-58.
DMD741P	RU	https://pubmed.ncbi.nlm.nih.gov/20126491

DM36HBS	DI	DM36HBS
DM36HBS	DN	ALXN1101
DM36HBS	MI	TTH13AB
DM36HBS	MN	Cyclic pyranopterin monophosphate synthase (MOCS1)
DM36HBS	MT	DTT
DM36HBS	MA	Modulator
DM36HBS	RN	ClinicalTrials.gov (NCT02047461) Safety & Efficacy Study of ALXN1101 in Pediatric Patients With MoCD Type A Currently Treated With rcPMP. U.S. National Institutes of Health.
DM36HBS	RU	https://clinicaltrials.gov/ct2/show/NCT02047461

DMBFOAZ	DI	DMBFOAZ
DMBFOAZ	DN	AMG520
DMBFOAZ	MI	TTJUNZF
DMBFOAZ	MN	Beta-secretase 1 (BACE1)
DMBFOAZ	MT	DTT
DMBFOAZ	MA	Inhibitor
DMBFOAZ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMBFOAZ	RU	http://phrma-docs.phrma.org/files/dmfile/MID-Update_Alzheimers-Disease_2017-Drug-List.pdf

DMN6F1W	DI	DMN6F1W
DMN6F1W	DN	Amiodarone
DMN6F1W	MI	TTHQJ2Y
DMN6F1W	MN	HUMAN two pore channel subtype 2 (TPC2)
DMN6F1W	MT	DTT
DMN6F1W	MA	Blocker
DMN6F1W	RN	Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020 Mar 27;11(1):1620.
DMN6F1W	RU	https://pubmed.ncbi.nlm.nih.gov/32221306

DMJRU3A	DI	DMJRU3A
DMJRU3A	DN	AMO-02
DMJRU3A	MI	TTRSMW9
DMJRU3A	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMJRU3A	MT	DTT
DMJRU3A	MA	Inhibitor
DMJRU3A	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMJRU3A	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMDLGRO	DI	DMDLGRO
DMDLGRO	DN	Aramchol
DMDLGRO	MI	TT6RIOV
DMDLGRO	MN	Acyl-CoA desaturase (SCD)
DMDLGRO	MT	DTT
DMDLGRO	MA	Inhibitor
DMDLGRO	RN	The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014 Dec;12(12):2085-91.e1.
DMDLGRO	RU	https://pubmed.ncbi.nlm.nih.gov/24815326

DMS8QF9	DI	DMS8QF9
DMS8QF9	DN	Arimoclomol
DMS8QF9	MI	TTG91S4
DMS8QF9	MN	Heat shock protein (HSP)
DMS8QF9	MT	DTT
DMS8QF9	MA	Modulator
DMS8QF9	RN	Arimoclomol, a coinducer of heat shock proteins for the potential treatment of amyotrophic lateral sclerosis. IDrugs. 2010 Jul;13(7):482-96.
DMS8QF9	RU	https://pubmed.ncbi.nlm.nih.gov/20582873

DM15VBJ	DI	DM15VBJ
DM15VBJ	DN	Artemisone
DM15VBJ	MI	TT9X7H4
DM15VBJ	MN	Beta-hematin formation (BHF)
DM15VBJ	MT	DTT
DM15VBJ	MA	Modulator
DM15VBJ	RN	Anticancer Properties of Distinct Antimalarial Drug Classes. PLoS One. 2013; 8(12): e82962.
DM15VBJ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3877007/

DMZGKXW	DI	DMZGKXW
DMZGKXW	DN	Atogepant
DMZGKXW	MI	TTQ4ESF
DMZGKXW	MN	Calgranulin D (S100A12)
DMZGKXW	MT	DTT
DMZGKXW	MA	Antagonist
DMZGKXW	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZGKXW	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMVB4OS	DI	DMVB4OS
DMVB4OS	DN	AVN 211
DMVB4OS	MI	TTJS8PY
DMVB4OS	MN	5-HT 6 receptor (HTR6)
DMVB4OS	MT	DTT
DMVB4OS	MA	Modulator
DMVB4OS	RN	Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. Curr Opin Investig Drugs. 2010 January; 11(1): 80-91.
DMVB4OS	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3346261/

DM5YHU2	DI	DM5YHU2
DM5YHU2	DN	Avoralstat
DM5YHU2	MI	TTDJ4MY
DM5YHU2	MN	Kininogen (KNG1)
DM5YHU2	MT	DTT
DM5YHU2	MA	Inhibitor
DM5YHU2	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM5YHU2	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DM5YHU2	DI	DM5YHU2
DM5YHU2	DN	Avoralstat
DM5YHU2	MI	TTJLNAW
DM5YHU2	MN	Tissue kallikrein (KLK2)
DM5YHU2	MT	DTT
DM5YHU2	MA	Inhibitor
DM5YHU2	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM5YHU2	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DMJQHXD	DI	DMJQHXD
DMJQHXD	DN	AZD3293
DMJQHXD	MI	TT8JRS7
DMJQHXD	MN	Beta-secretase (BACE)
DMJQHXD	MT	DTT
DMJQHXD	MA	Modulator
DMJQHXD	RN	AZD3293 A novel BACE1 inhibitor: safety, tolerability, and effects on plasma and CSF A-beta peptides following single- and multiple-dose administration. Neurobiology of Aging. May 20, 2008.
DMJQHXD	RU	http://www.neurobiologyofaging.org/article/S0197-4580(08)00131-0/abstract

DM3827C	DI	DM3827C
DM3827C	DN	AZD4547
DM3827C	MI	TT0LF7H
DM3827C	MN	Fibroblast growth factor receptor (FGFR)
DM3827C	MT	DTT
DM3827C	MA	Inhibitor
DM3827C	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3827C	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM3827C	DI	DM3827C
DM3827C	DN	AZD4547
DM3827C	MI	TTRLW2X
DM3827C	MN	Fibroblast growth factor receptor 1 (FGFR1)
DM3827C	MT	DTT
DM3827C	MA	Modulator
DM3827C	RN	AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012 Apr 15;72(8):2045-56.
DM3827C	RU	https://pubmed.ncbi.nlm.nih.gov/22369928

DMHWE5R	DI	DMHWE5R
DMHWE5R	DN	Batabulin
DMHWE5R	MI	TTYFKSZ
DMHWE5R	MN	Tubulin beta (TUBB)
DMHWE5R	MT	DTT
DMHWE5R	MA	Inhibitor
DMHWE5R	RN	Hydrophilic, pro-drug analogues of T138067 are efficacious in controlling tumor growth in vivo and show a decreased ability to cross the blood brain barrier. J Med Chem. 2001 Oct 25;44(22):3599-605.
DMHWE5R	RU	https://pubmed.ncbi.nlm.nih.gov/11606124

DMKT16N	DI	DMKT16N
DMKT16N	DN	Bevacizumab
DMKT16N	MI	TT140V6
DMKT16N	MN	HUMAN vascular endothelial growth factor (VEGF)
DMKT16N	MT	DTT
DMKT16N	MA	Inhibitor
DMKT16N	RN	ClinicalTrials.gov (NCT04275414) Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia (BEST-CP)
DMKT16N	RU	https://clinicaltrials.gov/ct2/show/NCT04275414

DMUSJ3D	DI	DMUSJ3D
DMUSJ3D	DN	BIIB-088
DMUSJ3D	MI	TTHBDA9
DMUSJ3D	MN	X-linked retinitis pigmentosa GTPase regulator (RPGR)
DMUSJ3D	MT	DTT
DMUSJ3D	RN	ClinicalTrials.gov (NCT04850118) A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations. U.S. National Institutes of Health.
DMUSJ3D	RU	https://clinicaltrials.gov/ct2/show/NCT04850118

DMYFQJL	DI	DMYFQJL
DMYFQJL	DN	BNV-222
DMYFQJL	MI	TTFBNVI
DMYFQJL	MN	Aldose reductase (AKR1B1)
DMYFQJL	MT	DTT
DMYFQJL	MA	Inhibitor
DMYFQJL	RN	ClinicalTrials.gov (NCT02332005) 12-Month Efficacy and Safety of Diepalrestat in Adults With Diabetic Peripheral Neuropathy, a DB, Placebo-Controlled Study (DE-DPN). U.S. National Institutes of Health.
DMYFQJL	RU	https://clinicaltrials.gov/ct2/show/NCT02332005

DMV52CP	DI	DMV52CP
DMV52CP	DN	Bucindolol
DMV52CP	MI	TTR6W5O
DMV52CP	MN	Adrenergic receptor beta-1 (ADRB1)
DMV52CP	MT	DTT
DMV52CP	MA	Modulator
DMV52CP	RN	Bucindolol has serotonin and alpha-adrenoceptor blocking properties. J Cardiovasc Pharmacol. 1985;7 Suppl 7:S67-9.
DMV52CP	RU	https://www.ncbi.nlm.nih.gov/pubmed/2412063

DMV52CP	DI	DMV52CP
DMV52CP	DN	Bucindolol
DMV52CP	MI	TT2CJVK
DMV52CP	MN	Adrenergic receptor beta-2 (ADRB2)
DMV52CP	MT	DTT
DMV52CP	MA	Modulator
DMV52CP	RN	Bucindolol has serotonin and alpha-adrenoceptor blocking properties. J Cardiovasc Pharmacol. 1985;7 Suppl 7:S67-9.
DMV52CP	RU	https://www.ncbi.nlm.nih.gov/pubmed/2412063

DMV52CP	DI	DMV52CP
DMV52CP	DN	Bucindolol
DMV52CP	MI	DECB0K3
DMV52CP	MN	Cytochrome P450 2D6 (CYP2D6)
DMV52CP	MT	DME
DMV52CP	MA	Metabolism
DMV52CP	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DMV52CP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DM31VZT	DI	DM31VZT
DM31VZT	DN	CAD-106
DM31VZT	MI	TTE4KHA
DM31VZT	MN	Amyloid beta A4 protein (APP)
DM31VZT	MT	DTT
DM31VZT	RN	The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci. 2011 Jun 22;31(25):9323-31.
DM31VZT	RU	https://pubmed.ncbi.nlm.nih.gov/21697382

DMVLXMG	DI	DMVLXMG
DMVLXMG	DN	Camostat mesylate
DMVLXMG	MI	TT3FDB1
DMVLXMG	MN	HUMAN transmembrane protease serine 2 (TMPRSS2)
DMVLXMG	MT	DTT
DMVLXMG	MA	Inhibitor
DMVLXMG	RN	SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271-280.e8.
DMVLXMG	RU	https://pubmed.ncbi.nlm.nih.gov/32142651

DMST3FM	DI	DMST3FM
DMST3FM	DN	CART-19
DMST3FM	MI	TTW640A
DMST3FM	MN	B-lymphocyte surface antigen B4 (CD19)
DMST3FM	MT	DTT
DMST3FM	MA	CAR-T-Cell-Therapy
DMST3FM	RN	ClinicalTrials.gov (NCT03027739) CART-19 Cells For MRD Positive CD19+ ALL
DMST3FM	RU	https://clinicaltrials.gov/ct2/show/NCT03027739

DM45Z3P	DI	DM45Z3P
DM45Z3P	DN	CD123/CLL1 CAR-T Cells
DM45Z3P	MI	TTENHJ0
DM45Z3P	MN	Interleukin 3 receptor alpha (IL3RA)
DM45Z3P	MT	DTT
DM45Z3P	MA	CAR-T-Cell-Therapy(Dual specific)
DM45Z3P	RN	ClinicalTrials.gov (NCT03631576) CD123/CLL1 CAR-T Cells for R/R AML
DM45Z3P	RU	https://clinicaltrials.gov/ct2/show/NCT03631576

DM45Z3P	DI	DM45Z3P
DM45Z3P	DN	CD123/CLL1 CAR-T Cells
DM45Z3P	MI	TT70N8V
DM45Z3P	MN	Myeloid inhibitory C-type lectin-like receptor (CD371)
DM45Z3P	MT	DTT
DM45Z3P	MA	CAR-T-Cell-Therapy(Dual specific)
DM45Z3P	RN	ClinicalTrials.gov (NCT03631576) CD123/CLL1 CAR-T Cells for R/R AML
DM45Z3P	RU	https://clinicaltrials.gov/ct2/show/NCT03631576

DM32148	DI	DM32148
DM32148	DN	CD19 CAR T cells
DM32148	MI	TTW640A
DM32148	MN	B-lymphocyte surface antigen B4 (CD19)
DM32148	MT	DTT
DM32148	MA	CAR-T-Cell-Therapy
DM32148	RN	ClinicalTrials.gov (NCT03391726) CART-19 Cells for R/R B-cell Lymphoma
DM32148	RU	https://clinicaltrials.gov/ct2/show/NCT03391726

DMFCLT6	DI	DMFCLT6
DMFCLT6	DN	CE-224535
DMFCLT6	MI	TT473XN
DMFCLT6	MN	P2X purinoceptor 7 (P2RX7)
DMFCLT6	MT	DTT
DMFCLT6	MA	Antagonist
DMFCLT6	RN	Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. J Rheumatol. 2012 Apr;39(4):720-7.
DMFCLT6	RU	https://pubmed.ncbi.nlm.nih.gov/22382341

DMXCD69	DI	DMXCD69
DMXCD69	DN	CEP1347
DMXCD69	MI	TTUNSIX
DMXCD69	MN	Mixed lineage kinase 1 (MAP3K9)
DMXCD69	MT	DTT
DMXCD69	MA	Inhibitor
DMXCD69	RN	Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
DMXCD69	RU	https://pubmed.ncbi.nlm.nih.gov/11804650

DMUOMBZ	DI	DMUOMBZ
DMUOMBZ	DN	CLL1 CAR-T Cell
DMUOMBZ	MI	TT70N8V
DMUOMBZ	MN	Myeloid inhibitory C-type lectin-like receptor (CD371)
DMUOMBZ	MT	DTT
DMUOMBZ	MA	CAR-T-Cell-Therapy(Dual specific)
DMUOMBZ	RN	ClinicalTrials.gov (NCT03631576) CD123/CLL1 CAR-T Cells for R/R AML
DMUOMBZ	RU	https://clinicaltrials.gov/ct2/show/NCT03631576

DMX9V8K	DI	DMX9V8K
DMX9V8K	DN	Contigoside B
DMX9V8K	MI	TTFBNVI
DMX9V8K	MN	Aldose reductase (AKR1B1)
DMX9V8K	MT	DTT
DMX9V8K	MA	Inhibitor
DMX9V8K	RN	Effect of Polygonum hydropiper sulfated flavonoids on lens aldose reductase and related enzymes. J Nat Prod. 1996 Apr;59(4):443-5.
DMX9V8K	RU	https://pubmed.ncbi.nlm.nih.gov/8699190

DMX9V8K	DI	DMX9V8K
DMX9V8K	DN	Contigoside B
DMX9V8K	MI	TTL69WB
DMX9V8K	MN	Angiotensin-converting enzyme (ACE)
DMX9V8K	MT	DTT
DMX9V8K	MA	Inhibitor
DMX9V8K	RN	Inhibitory effects of various flavonoids isolated from leaves of persimmon on angiotensin-converting enzyme activity. J Nat Prod. 1987 Jul-Aug;50(4):680-3.
DMX9V8K	RU	https://pubmed.ncbi.nlm.nih.gov/3430165

DMX9V8K	DI	DMX9V8K
DMX9V8K	DN	Contigoside B
DMX9V8K	MI	DEXLYGD
DMX9V8K	MN	Beta-glucosidase (bglA)
DMX9V8K	MT	DME
DMX9V8K	MA	Metabolism
DMX9V8K	RN	Identification of rutin deglycosylated metabolites produced by human intestinal bacteria using UPLC-Q-TOF/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Jun 1;898:95-100.
DMX9V8K	RU	https://pubmed.ncbi.nlm.nih.gov/22583754

DMX9V8K	DI	DMX9V8K
DMX9V8K	DN	Contigoside B
DMX9V8K	MI	DEZXOEW
DMX9V8K	MN	Beta-glucosidase (bglA)
DMX9V8K	MT	DME
DMX9V8K	MA	Metabolism
DMX9V8K	RN	Identification of rutin deglycosylated metabolites produced by human intestinal bacteria using UPLC-Q-TOF/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Jun 1;898:95-100.
DMX9V8K	RU	https://pubmed.ncbi.nlm.nih.gov/22583754

DMX9V8K	DI	DMX9V8K
DMX9V8K	DN	Contigoside B
DMX9V8K	MI	DE4WCJL
DMX9V8K	MN	Beta-glucosidase (bglA)
DMX9V8K	MT	DME
DMX9V8K	MA	Metabolism
DMX9V8K	RN	Identification of rutin deglycosylated metabolites produced by human intestinal bacteria using UPLC-Q-TOF/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Jun 1;898:95-100.
DMX9V8K	RU	https://pubmed.ncbi.nlm.nih.gov/22583754

DMJYTUQ	DI	DMJYTUQ
DMJYTUQ	DN	CR-845
DMJYTUQ	MI	TTQW87Y
DMJYTUQ	MN	Opioid receptor kappa (OPRK1)
DMJYTUQ	MT	DTT
DMJYTUQ	MA	Agonist
DMJYTUQ	RN	Peptide Kappa Opioid Receptor Ligands: Potential for Drug Development. AAPS J. 2009 June; 11(2): 312-322.
DMJYTUQ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2691465/

DMSR7D2	DI	DMSR7D2
DMSR7D2	DN	CX-516
DMSR7D2	MI	TTAN6JD
DMSR7D2	MN	Glutamate receptor AMPA (GRIA)
DMSR7D2	MT	DTT
DMSR7D2	MA	Modulator
DMSR7D2	RN	Autism spectrum disorders: emerging pharmacotherapy. Expert Opin Emerg Drugs. 2005 Aug;10(3):521-36.
DMSR7D2	RU	https://pubmed.ncbi.nlm.nih.gov/16083327

DML906E	DI	DML906E
DML906E	DN	CY-1503
DML906E	MI	TTAU4D6
DML906E	MN	E-selectin (SELE)
DML906E	MT	DTT
DML906E	MA	Modulator
DML906E	RN	Adjunctive selectin blockade successfully reduces infarct size beyond thrombolysis in the electrolytic canine coronary artery model. Circulation. 1995 Aug 1;92(3):492-9.
DML906E	RU	https://pubmed.ncbi.nlm.nih.gov/7543381

DML906E	DI	DML906E
DML906E	DN	CY-1503
DML906E	MI	TTE5VG0
DML906E	MN	P-selectin (SELP)
DML906E	MT	DTT
DML906E	MA	Modulator
DML906E	RN	Adjunctive selectin blockade successfully reduces infarct size beyond thrombolysis in the electrolytic canine coronary artery model. Circulation. 1995 Aug 1;92(3):492-9.
DML906E	RU	https://pubmed.ncbi.nlm.nih.gov/7543381

DMYVKM5	DI	DMYVKM5
DMYVKM5	DN	Darbufelone
DMYVKM5	MI	TT2J34L
DMYVKM5	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMYVKM5	MT	DTT
DMYVKM5	MA	Modulator
DMYVKM5	RN	Novel dual cyclooxygenase and lipoxygenase inhibitors targeting hyaluronan-CD44v6 pathway and inducing cytotoxicity in colon cancer cells. Bioorg Med Chem. 2013 May 1;21(9):2551-9.
DMYVKM5	RU	https://pubmed.ncbi.nlm.nih.gov/23517721

DMYVKM5	DI	DMYVKM5
DMYVKM5	DN	Darbufelone
DMYVKM5	MI	TTVKILB
DMYVKM5	MN	Prostaglandin G/H synthase 2 (COX-2)
DMYVKM5	MT	DTT
DMYVKM5	MA	Modulator
DMYVKM5	RN	Novel dual cyclooxygenase and lipoxygenase inhibitors targeting hyaluronan-CD44v6 pathway and inducing cytotoxicity in colon cancer cells. Bioorg Med Chem. 2013 May 1;21(9):2551-9.
DMYVKM5	RU	https://pubmed.ncbi.nlm.nih.gov/23517721

DMZV3SY	DI	DMZV3SY
DMZV3SY	DN	Denagliptin
DMZV3SY	MI	TTDIGC1
DMZV3SY	MN	Dipeptidyl peptidase 4 (DPP-4)
DMZV3SY	MT	DTT
DMZV3SY	MA	Inhibitor
DMZV3SY	RN	Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87.
DMZV3SY	RU	https://pubmed.ncbi.nlm.nih.gov/19149538

DMVSIN2	DI	DMVSIN2
DMVSIN2	DN	Emapalumab
DMVSIN2	MI	TTR10KI
DMVSIN2	MN	HUMAN interferon gamma (IFNG)
DMVSIN2	MT	DTT
DMVSIN2	MA	Inhibitor
DMVSIN2	RN	Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). Virology. 2004 Nov 10;329(1):11-7. doi: 10.1016/j.virol.2004.08.011.
DMVSIN2	RU	https://pubmed.ncbi.nlm.nih.gov/15476870

DMH8VMP	DI	DMH8VMP
DMH8VMP	DN	Emixustat
DMH8VMP	MI	TTBOH16
DMH8VMP	MN	Retinal pigment epithelium protein (RPE65)
DMH8VMP	MT	DTT
DMH8VMP	MA	Inhibitor
DMH8VMP	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMH8VMP	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMOYE70	DI	DMOYE70
DMOYE70	DN	Fexinidazole
DMOYE70	MI	DEJGDUW
DMOYE70	MN	Cytochrome P450 1A2 (CYP1A2)
DMOYE70	MT	DME
DMOYE70	MA	Metabolism
DMOYE70	RN	Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis. 2010 Dec 21;4(12):e923.
DMOYE70	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21200426

DMOYE70	DI	DMOYE70
DMOYE70	DN	Fexinidazole
DMOYE70	MI	DEPKLMQ
DMOYE70	MN	Cytochrome P450 2B6 (CYP2B6)
DMOYE70	MT	DME
DMOYE70	MA	Metabolism
DMOYE70	RN	Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis. 2010 Dec 21;4(12):e923.
DMOYE70	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21200426

DMOYE70	DI	DMOYE70
DMOYE70	DN	Fexinidazole
DMOYE70	MI	DECB0K3
DMOYE70	MN	Cytochrome P450 2D6 (CYP2D6)
DMOYE70	MT	DME
DMOYE70	MA	Metabolism
DMOYE70	RN	Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis. 2010 Dec 21;4(12):e923.
DMOYE70	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21200426

DMOYE70	DI	DMOYE70
DMOYE70	DN	Fexinidazole
DMOYE70	MI	DE4LYSA
DMOYE70	MN	Cytochrome P450 3A4 (CYP3A4)
DMOYE70	MT	DME
DMOYE70	MA	Metabolism
DMOYE70	RN	Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis. 2010 Dec 21;4(12):e923.
DMOYE70	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21200426

DMOYE70	DI	DMOYE70
DMOYE70	DN	Fexinidazole
DMOYE70	MI	DEIBDNY
DMOYE70	MN	Cytochrome P450 3A5 (CYP3A5)
DMOYE70	MT	DME
DMOYE70	MA	Metabolism
DMOYE70	RN	Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis. 2010 Dec 21;4(12):e923.
DMOYE70	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21200426

DMOYE70	DI	DMOYE70
DMOYE70	DN	Fexinidazole
DMOYE70	MI	DEGTFWK
DMOYE70	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMOYE70	MT	DME
DMOYE70	MA	Metabolism
DMOYE70	RN	Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis. 2010 Dec 21;4(12):e923.
DMOYE70	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21200426

DMH7CSQ	DI	DMH7CSQ
DMH7CSQ	DN	Gavilimomab
DMH7CSQ	MI	TT5UJWD
DMH7CSQ	MN	Basigin (BSG)
DMH7CSQ	MT	DTT
DMH7CSQ	RN	National Cancer Institute Drug Dictionary (drug id 38221).
DMH7CSQ	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=38221

DM0JETC	DI	DM0JETC
DM0JETC	DN	Genistein
DM0JETC	MI	DTI7UX6
DM0JETC	MN	Breast cancer resistance protein (ABCG2)
DM0JETC	MT	DTP
DM0JETC	MA	Substrate
DM0JETC	RN	Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2. J Pharm Sci. 2012 May;101(5):1888-97.
DM0JETC	RU	https://doi.org/10.1002/jps.23069

DM0JETC	DI	DM0JETC
DM0JETC	DN	Genistein
DM0JETC	MI	DEJGDUW
DM0JETC	MN	Cytochrome P450 1A2 (CYP1A2)
DM0JETC	MT	DME
DM0JETC	MA	Metabolism
DM0JETC	RN	Differential mechanisms for the inhibition of human cytochrome P450 1A2 by apigenin and genistein. J Biochem Mol Toxicol. 2010 Jul-Aug;24(4):230-4.
DM0JETC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20806393

DM0JETC	DI	DM0JETC
DM0JETC	DN	Genistein
DM0JETC	MI	TTOM3J0
DM0JETC	MN	Estrogen receptor beta (ESR2)
DM0JETC	MT	DTT
DM0JETC	MA	Modulator
DM0JETC	RN	Company report (Axcentua)
DM0JETC	RU	http://axcentua.com/science/genistein/

DM0JETC	DI	DM0JETC
DM0JETC	DN	Genistein
DM0JETC	MI	DE0P6LK
DM0JETC	MN	Sulfotransferase 2A1 (SULT2A1)
DM0JETC	MT	DME
DM0JETC	MA	Metabolism
DM0JETC	RN	Sulfation of environmental estrogens by cytosolic human sulfotransferases. Drug Metab Pharmacokinet. 2002;17(3):221-8.
DM0JETC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15618673

DMW7TZV	DI	DMW7TZV
DMW7TZV	DN	GS-6207
DMW7TZV	MI	TTTWS2G
DMW7TZV	MN	Human immunodeficiency virus Capsid p24 (HIV p24)
DMW7TZV	MT	DTT
DMW7TZV	MA	Inhibitor
DMW7TZV	RN	Clinical pipeline report, company report or official report of Gilead Sciences.
DMW7TZV	RU	https://www.gilead.com/science-and-medicine/pipeline

DMMTL7V	DI	DMMTL7V
DMMTL7V	DN	Hemoglobin raffimer
DMMTL7V	MI	TTQO71U
DMMTL7V	MN	Hemoglobin (HB)
DMMTL7V	MT	DTT
DMMTL7V	MA	Modulator
DMMTL7V	RN	Use of hemoglobin raffimer for postoperative life-threatening anemia in a Jehovah's Witness. Can J Anaesth. 2005 Apr;52(4):369-73.
DMMTL7V	RU	https://pubmed.ncbi.nlm.nih.gov/15814750

DMPLQ1V	DI	DMPLQ1V
DMPLQ1V	DN	IFX-1
DMPLQ1V	MI	TTRJ91Q
DMPLQ1V	MN	HUMAN complement C5 alpha (C5A)
DMPLQ1V	MT	DTT
DMPLQ1V	MA	Inhibitor
DMPLQ1V	RN	03-2020-InflaRx Doses First Patient in Multicenter Randomized Clinical Trial in Severe Progressed COVID-19 Pneumonia in Europe upon Receipt of Initial Positive Human Data with InflaRxs anti-C5a Technology
DMPLQ1V	RU	https://www.inflarx.de/Home/Investors/Press-Releases/03-2020-InflaRx-Doses-First-Patient-in-Multicenter-Randomized-Clinical-Trial-in-Severe-Progressed-COVID-19-Pneumonia-in-Europe-upon-Receipt-of-Initial-Positive-Human-Data-with-InflaRx-s-anti-C5a-Technology.html

DMONWJ4	DI	DMONWJ4
DMONWJ4	DN	Imetelstat
DMONWJ4	MI	TTUJFD0
DMONWJ4	MN	Telomerase reverse transcriptase (TERT)
DMONWJ4	MT	DTT
DMONWJ4	MA	Inhibitor
DMONWJ4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMONWJ4	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DMIUA3M	DI	DMIUA3M
DMIUA3M	DN	Imprime PGG
DMIUA3M	MI	TTJGY7A
DMIUA3M	MN	Complement C3 (CO3)
DMIUA3M	MT	DTT
DMIUA3M	MA	Modulator
DMIUA3M	RN	National Cancer Institute Drug Dictionary (drug id 599816).
DMIUA3M	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=599816

DM5UJ9P	DI	DM5UJ9P
DM5UJ9P	DN	IMU-838
DM5UJ9P	MI	TT3UY29
DM5UJ9P	MN	HUMAN dihydroorotate dehydrogenase (DHODH)
DM5UJ9P	MT	DTT
DM5UJ9P	MA	Inhibitor
DM5UJ9P	RN	IMU-838 Targeting DHODH
DM5UJ9P	RU	https://www.immunic-therapeutics.com/imu838/

DMC3794	DI	DMC3794
DMC3794	DN	Indium-111
DMC3794	MI	TTGKNB4
DMC3794	MN	Epidermal growth factor receptor (EGFR)
DMC3794	MT	DTT
DMC3794	RN	Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody. Mol Cancer Ther. 2015 May;14(5):1141-51.
DMC3794	RU	https://pubmed.ncbi.nlm.nih.gov/25731184

DMGPJ5U	DI	DMGPJ5U
DMGPJ5U	DN	JNJ-54861911
DMGPJ5U	MI	TT8JRS7
DMGPJ5U	MN	Beta-secretase (BACE)
DMGPJ5U	MT	DTT
DMGPJ5U	MA	Inhibitor
DMGPJ5U	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMGPJ5U	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMBJ4IZ	DI	DMBJ4IZ
DMBJ4IZ	DN	LECOZOTAN HYDROCHLORIDE
DMBJ4IZ	MI	TTSQIFT
DMBJ4IZ	MN	5-HT 1A receptor (HTR1A)
DMBJ4IZ	MT	DTT
DMBJ4IZ	MA	Antagonist
DMBJ4IZ	RN	A positron emission tomography study to assess binding of lecozotan, a novel 5-hydroxytryptamine-1A silent antagonist, to brain 5-HT1A receptors in... Clin Pharmacol Ther. 2008 Jan;83(1):86-96.
DMBJ4IZ	RU	https://pubmed.ncbi.nlm.nih.gov/17507923

DMEUGZL	DI	DMEUGZL
DMEUGZL	DN	Legumain-cleavable doxorubicin prodrugs
DMEUGZL	MI	TTPTWV5
DMEUGZL	MN	Legumain (LGMN)
DMEUGZL	MT	DTT
DMEUGZL	MA	Modulator
DMEUGZL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2380).
DMEUGZL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2380

DM4OYXE	DI	DM4OYXE
DM4OYXE	DN	LIAROZOLE
DM4OYXE	MI	TTSZLWK
DM4OYXE	MN	Aromatase (CYP19A1)
DM4OYXE	MT	DTT
DM4OYXE	MA	Inhibitor
DM4OYXE	RN	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
DM4OYXE	RU	https://pubmed.ncbi.nlm.nih.gov/20413308

DM4OYXE	DI	DM4OYXE
DM4OYXE	DN	LIAROZOLE
DM4OYXE	MI	TTD7Q0R
DM4OYXE	MN	Cytochrome P450 26 (CYP26A1)
DM4OYXE	MT	DTT
DM4OYXE	MA	Inhibitor
DM4OYXE	RN	Novel azolyl-(phenylmethyl)]aryl/heteroarylamines: potent CYP26 inhibitors and enhancers of all-trans retinoic acid activity in neuroblastoma cells. Bioorg Med Chem. 2008 Sep 1;16(17):8301-13.
DM4OYXE	RU	https://pubmed.ncbi.nlm.nih.gov/18722776

DMI215P	DI	DMI215P
DMI215P	DN	Lopinavir + ritonavir + interferon beta-1b
DMI215P	MI	TTWOH4Q
DMI215P	MN	MERS-CoV 3C-like proteinase (3CLpro)
DMI215P	MT	DTT
DMI215P	MA	Inhibitor
DMI215P	RN	Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381.
DMI215P	RU	https://pubmed.ncbi.nlm.nih.gov/32205870

DMP8HW1	DI	DMP8HW1
DMP8HW1	DN	LY2157299
DMP8HW1	MI	TTP4520
DMP8HW1	MN	TGF-beta receptor type I (TGFBR1)
DMP8HW1	MT	DTT
DMP8HW1	MA	Modulator
DMP8HW1	RN	Cardiac Safety of TGF-beta Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study. Cardiovasc Toxicol. 2015 Oct;15(4):309-23.
DMP8HW1	RU	https://pubmed.ncbi.nlm.nih.gov/25488804

DMP8HW1	DI	DMP8HW1
DMP8HW1	DN	LY2157299
DMP8HW1	MI	TTR9XHZ
DMP8HW1	MN	Transforming growth factor beta 1 (TGFB1)
DMP8HW1	MT	DTT
DMP8HW1	MA	Inhibitor
DMP8HW1	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMP8HW1	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMUQWRD	DI	DMUQWRD
DMUQWRD	DN	LYS-SAF302
DMUQWRD	MI	TTPJ2SH
DMUQWRD	MN	N-sulphoglucosamine sulphohydrolase (SGSH)
DMUQWRD	MT	DTT
DMUQWRD	MA	Replacement
DMUQWRD	RN	Clinical pipeline report, company report or official report of Lysogene.
DMUQWRD	RU	https://www.lysogene.com/lys-saf302/

DM948AP	DI	DM948AP
DM948AP	DN	MAb114
DM948AP	MI	TT2F0AU
DM948AP	MN	Ebola virus Envelope glycoprotein (EV GP)
DM948AP	MT	DTT
DM948AP	RN	Ansuvimab: First Approval. Drugs. 2021 Apr;81(5):595-598.
DM948AP	RU	https://pubmed.ncbi.nlm.nih.gov/33751449

DMONYS9	DI	DMONYS9
DMONYS9	DN	MBX-102
DMONYS9	MI	TTZMAO3
DMONYS9	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMONYS9	MT	DTT
DMONYS9	MA	Agonist
DMONYS9	RN	MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema. Mol Endocrinol. 2009 Jul;23(7):975-88.
DMONYS9	RU	https://pubmed.ncbi.nlm.nih.gov/19389808

DMNTCV4	DI	DMNTCV4
DMNTCV4	DN	MBX-8025
DMNTCV4	MI	TT2JWF6
DMNTCV4	MN	Peroxisome proliferator-activated receptor delta (PPARD)
DMNTCV4	MT	DTT
DMNTCV4	MA	Agonist
DMNTCV4	RN	ClinicalTrials.gov (NCT00701883) Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol. U. S. National Institute of Health. 2008.
DMNTCV4	RU	https://clinicaltrials.gov/ct2/show/NCT00701883

DMBIO6E	DI	DMBIO6E
DMBIO6E	DN	Meclinertant
DMBIO6E	MI	TTTUMEP
DMBIO6E	MN	Neurotensin receptor type 1 (NTSR1)
DMBIO6E	MT	DTT
DMBIO6E	MA	Antagonist
DMBIO6E	RN	Neurotensin inversely modulates maternal aggression. Neuroscience. 2009 Feb 18;158(4):1215-23.
DMBIO6E	RU	https://pubmed.ncbi.nlm.nih.gov/19118604

DMFE0P1	DI	DMFE0P1
DMFE0P1	DN	Metformin glycinate
DMFE0P1	MI	TTCBFJO
DMFE0P1	MN	Insulin receptor (INSR)
DMFE0P1	MT	DTT
DMFE0P1	MA	Inhibitor
DMFE0P1	RN	Effect of Metformin Glycinate on Glycated Hemoglobin A1c Concentration and Insulin Sensitivity in Drug-Naive Adult Patients with Type 2 Diabetes Mellitus. Diabetes Technol Ther. 2012 December; 14(12): 1140-1144.
DMFE0P1	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3521136/

DM752PU	DI	DM752PU
DM752PU	DN	MGCD516
DM752PU	MI	TTU8W4S
DM752PU	MN	Protein kinase (PK)
DM752PU	MT	DTT
DM752PU	MA	Inhibitor
DM752PU	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM752PU	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM752PU	DI	DM752PU
DM752PU	DN	MGCD516
DM752PU	MI	TTNDSF4
DM752PU	MN	Proto-oncogene c-Met (MET)
DM752PU	MT	DTT
DM752PU	MA	Inhibitor
DM752PU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
DM752PU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815

DM752PU	DI	DM752PU
DM752PU	DN	MGCD516
DM752PU	MI	TT4DXQT
DM752PU	MN	Proto-oncogene c-Ret (RET)
DM752PU	MT	DTT
DM752PU	MA	Inhibitor
DM752PU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2185).
DM752PU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2185

DM752PU	DI	DM752PU
DM752PU	DN	MGCD516
DM752PU	MI	TTUTJGQ
DM752PU	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM752PU	MT	DTT
DM752PU	MA	Inhibitor
DM752PU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1813).
DM752PU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1813

DM752PU	DI	DM752PU
DM752PU	DN	MGCD516
DM752PU	MI	TTDCBX5
DM752PU	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DM752PU	MT	DTT
DM752PU	MA	Inhibitor
DM752PU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1814).
DM752PU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1814

DM2YNMI	DI	DM2YNMI
DM2YNMI	DN	MK-1654
DM2YNMI	MI	TT57ID8
DM2YNMI	MN	Respiratory syncytial virus protein F (RSV F)
DM2YNMI	MT	DTT
DM2YNMI	MA	Inhibitor
DM2YNMI	RN	A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein. Nat Commun. 2019 Sep 12;10(1):4153.
DM2YNMI	RU	https://pubmed.ncbi.nlm.nih.gov/31515478

DMDQOWT	DI	DMDQOWT
DMDQOWT	DN	MOR-208
DMDQOWT	MI	TTW640A
DMDQOWT	MN	B-lymphocyte surface antigen B4 (CD19)
DMDQOWT	MT	DTT
DMDQOWT	RN	A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60.
DMDQOWT	RU	https://pubmed.ncbi.nlm.nih.gov/25301708

DMKMZW2	DI	DMKMZW2
DMKMZW2	DN	MTC-DOX
DMKMZW2	MI	TT0IHXV
DMKMZW2	MN	DNA topoisomerase II (TOP2)
DMKMZW2	MT	DTT
DMKMZW2	MA	Modulator
DMKMZW2	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMKMZW2	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM16PWF	DI	DM16PWF
DM16PWF	DN	N1-methylnicotinamide
DM16PWF	MI	DTT79CX
DM16PWF	MN	Organic cation transporter 1 (SLC22A1)
DM16PWF	MT	DTP
DM16PWF	MA	Substrate
DM16PWF	RN	Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997 Jul;16(7):871-81.
DM16PWF	RU	http://www.ncbi.nlm.nih.gov/pubmed/9260930

DM8D6O2	DI	DM8D6O2
DM8D6O2	DN	Nafamostat
DM8D6O2	MI	TTZ3COY
DM8D6O2	MN	COVID-19 spike glycoprotein (S)
DM8D6O2	MT	DTT
DM8D6O2	MA	Inhibitor
DM8D6O2	RN	Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150.
DM8D6O2	RU	https://pubmed.ncbi.nlm.nih.gov/32127666

DM8D6O2	DI	DM8D6O2
DM8D6O2	DN	Nafamostat
DM8D6O2	MI	TT85VHW
DM8D6O2	MN	MERS-CoV spike glycoprotein (S)
DM8D6O2	MT	DTT
DM8D6O2	MA	Inhibitor
DM8D6O2	RN	Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay Antimicrob Agents Chemother. 2016 Oct 21;60(11):6532-6539.
DM8D6O2	RU	https://pubmed.ncbi.nlm.nih.gov/27550352

DMD5AEB	DI	DMD5AEB
DMD5AEB	DN	NAL-GLU
DMD5AEB	MI	TT0ID4A
DMD5AEB	MN	Leutinizing-hormone-releasing hormone (GNRH1)
DMD5AEB	MT	DTT
DMD5AEB	RN	The gonadotropin-releasing hormone antagonist (Nal-Glu) acutely blocks the luteinizing hormone surge but allows for resumption of folliculogenesis in normal women. Am J Obstet Gynecol. 1991 Dec;165(6Pt 1):1811-7.
DMD5AEB	RU	https://pubmed.ncbi.nlm.nih.gov/1750480

DM901ZW	DI	DM901ZW
DM901ZW	DN	Naptumomab estafenatox
DM901ZW	MI	TT70MLA
DM901ZW	MN	Oncotrophoblast glycoprotein 5T4 (TPBG)
DM901ZW	MT	DTT
DM901ZW	MA	Immunomodulator
DM901ZW	RN	Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin. Curr Oncol Rep. 2014 Feb;16(2):370.
DM901ZW	RU	https://pubmed.ncbi.nlm.nih.gov/24445502

DM3MJUS	DI	DM3MJUS
DM3MJUS	DN	NBTX-001
DM3MJUS	MI	TT9IK2Z
DM3MJUS	MN	N-methyl-D-aspartate receptor (NMDAR)
DM3MJUS	MT	DTT
DM3MJUS	MA	Antagonist
DM3MJUS	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3MJUS	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DM0798Z	DI	DM0798Z
DM0798Z	DN	NLG8189
DM0798Z	MI	TTZJYKH
DM0798Z	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DM0798Z	MT	DTT
DM0798Z	MA	Inhibitor
DM0798Z	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM0798Z	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM4H78P	DI	DM4H78P
DM4H78P	DN	NT-501
DM4H78P	MI	TTT2F9E
DM4H78P	MN	Ciliary neurotrophic factor receptor alpha (CNTFR)
DM4H78P	MT	DTT
DM4H78P	MA	Modulator
DM4H78P	RN	Clinical pipeline report, company report or official report of Neurotech.
DM4H78P	RU	http://www.neurotechusa.com/cntfrenexus.html

DMT13UA	DI	DMT13UA
DMT13UA	DN	Olokizumab
DMT13UA	MI	TTJH4Y5
DMT13UA	MN	HUMAN interleukin 6 (IL6)
DMT13UA	MT	DTT
DMT13UA	MA	Inhibitor
DMT13UA	RN	Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling. MAbs. 2014 May-Jun;6(3):774-82.
DMT13UA	RU	https://pubmed.ncbi.nlm.nih.gov/24670876

DMTIESG	DI	DMTIESG
DMTIESG	DN	Omburtamab
DMTIESG	MI	TT6CQUM
DMTIESG	MN	B7 homolog 3 (CD276)
DMTIESG	MT	DTT
DMTIESG	MA	Inhibitor
DMTIESG	RN	Mast cell proliferation in the cerebrospinal fluid after intraventricular administration of anti-B7H3 immunotherapy. Cancer Immunol Immunother. 2021 Feb 3.
DMTIESG	RU	https://pubmed.ncbi.nlm.nih.gov/33533945

DMPDA17	DI	DMPDA17
DMPDA17	DN	Omburtamab I-131
DMPDA17	MI	TT6CQUM
DMPDA17	MN	B7 homolog 3 (CD276)
DMPDA17	MT	DTT
DMPDA17	MA	Inhibitor
DMPDA17	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPDA17	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMCA2PJ	DI	DMCA2PJ
DMCA2PJ	DN	ONO-2506
DMCA2PJ	MI	TTMXGCW
DMCA2PJ	MN	Adrenergic receptor beta-3 (ADRB3)
DMCA2PJ	MT	DTT
DMCA2PJ	MA	Agonist
DMCA2PJ	RN	FR149175, a beta 3-adrenoceptor-selective agonist, is a possible therapeutic agent for non-insulin-dependent diabetes mellitus. Jpn J Pharmacol. 1997 May;74(1):109-12.
DMCA2PJ	RU	https://pubmed.ncbi.nlm.nih.gov/9195306

DMCA2PJ	DI	DMCA2PJ
DMCA2PJ	DN	ONO-2506
DMCA2PJ	MI	TTQ0V86
DMCA2PJ	MN	S100 calcium-binding protein B (S100B)
DMCA2PJ	MT	DTT
DMCA2PJ	MA	Modulator
DMCA2PJ	RN	Arundic acid (ONO-2506) ameliorates delayed ischemic brain damage by preventing astrocytic overproduction of S100B.Curr Drug Targets CNS Neurol Disord.2005 Apr;4(2):127-42.
DMCA2PJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/15857298

DMCTRLN	DI	DMCTRLN
DMCTRLN	DN	OT-101
DMCTRLN	MI	TTI0KH6
DMCTRLN	MN	TGF beta-2 messenger RNA (TGFB2 mRNA)
DMCTRLN	MT	DTT
DMCTRLN	MA	Inhibitor
DMCTRLN	RN	Clinical pipeline report, company report or official report of Oncotelic.
DMCTRLN	RU	https://www.oncotelic.com/pipeline/

DMURH4X	DI	DMURH4X
DMURH4X	DN	Oxypurinol
DMURH4X	MI	DT2WLAD
DMURH4X	MN	Urate anion exchanger 1 (SLC22A12)
DMURH4X	MT	DTP
DMURH4X	MA	Substrate
DMURH4X	RN	Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone. Drug Metab Dispos. 2005 Dec;33(12):1791-5.
DMURH4X	RU	http://www.ncbi.nlm.nih.gov/pubmed/16135657

DMURH4X	DI	DMURH4X
DMURH4X	DN	Oxypurinol
DMURH4X	MI	TT7RJY8
DMURH4X	MN	Xanthine dehydrogenase/oxidase (XDH)
DMURH4X	MT	DTT
DMURH4X	MA	Inhibitor
DMURH4X	RN	Oxypurinol as an inhibitor of xanthine oxidase-catalyzed production of superoxide radical. Biochem Pharmacol. 1988 Jan 15;37(2):349-52.
DMURH4X	RU	https://pubmed.ncbi.nlm.nih.gov/2829916

DM0NZDT	DI	DM0NZDT
DM0NZDT	DN	Pactimibe
DM0NZDT	MI	DECB0K3
DM0NZDT	MN	Cytochrome P450 2D6 (CYP2D6)
DM0NZDT	MT	DME
DM0NZDT	MA	Metabolism
DM0NZDT	RN	Novel binding mode of the acidic CYP2D6 substrates pactimibe and its metabolite R-125528. Drug Metab Dispos. 2008 Sep;36(9):1938-43.
DM0NZDT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18524873

DM0NZDT	DI	DM0NZDT
DM0NZDT	DN	Pactimibe
DM0NZDT	MI	TTMF541
DM0NZDT	MN	Liver carboxylesterase (CES1)
DM0NZDT	MT	DTT
DM0NZDT	MA	Inhibitor
DM0NZDT	RN	Novel indoline-based acyl-CoA:cholesterol acyltransferase inhibitor with antiperoxidative activity: improvement of physicochemical properties and b... J Med Chem. 2008 Aug 14;51(15):4823-33.
DM0NZDT	RU	https://pubmed.ncbi.nlm.nih.gov/18620381

DMRZ1F2	DI	DMRZ1F2
DMRZ1F2	DN	Padsevonil
DMRZ1F2	MI	TTCI43M
DMRZ1F2	MN	GABA(A) receptor (GABAR)
DMRZ1F2	MT	DTT
DMRZ1F2	MA	Inhibitor
DMRZ1F2	RN	Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Characterization in Rodent Seizure and Epilepsy Models. J Pharmacol Exp Ther. 2020 Jan;372(1):11-20.
DMRZ1F2	RU	https://pubmed.ncbi.nlm.nih.gov/31619464

DMRZ1F2	DI	DMRZ1F2
DMRZ1F2	DN	Padsevonil
DMRZ1F2	MI	TTT3P91
DMRZ1F2	MN	Synaptic vesicle glycoprotein 2A (SV2A)
DMRZ1F2	MT	DTT
DMRZ1F2	MA	Inhibitor
DMRZ1F2	RN	Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Characterization in Rodent Seizure and Epilepsy Models. J Pharmacol Exp Ther. 2020 Jan;372(1):11-20.
DMRZ1F2	RU	https://pubmed.ncbi.nlm.nih.gov/31619464

DMHWY2G	DI	DMHWY2G
DMHWY2G	DN	Pagoclone
DMHWY2G	MI	TTEX6LM
DMHWY2G	MN	GABA(A) receptor gamma-3 (GABRG3)
DMHWY2G	MT	DTT
DMHWY2G	MA	Modulator
DMHWY2G	RN	Evaluation of the abuse potential of pagoclone, a partial GABAA agonist. J Clin Psychopharmacol. 2006 Jun;26(3):268-73.
DMHWY2G	RU	https://pubmed.ncbi.nlm.nih.gov/16702891

DMBJ15R	DI	DMBJ15R
DMBJ15R	DN	Pexacerfont
DMBJ15R	MI	TT7EFHR
DMBJ15R	MN	Corticotropin-releasing factor receptor 1 (CRHR1)
DMBJ15R	MT	DTT
DMBJ15R	MA	Antagonist
DMBJ15R	RN	Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
DMBJ15R	RU	https://pubmed.ncbi.nlm.nih.gov/18172433

DMYKNME	DI	DMYKNME
DMYKNME	DN	PF-06651600
DMYKNME	MI	TTT7PJU
DMYKNME	MN	Janus kinase 3 (JAK-3)
DMYKNME	MT	DTT
DMYKNME	MA	Inhibitor
DMYKNME	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMYKNME	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM1QSM3	DI	DM1QSM3
DM1QSM3	DN	Phenol
DM1QSM3	MI	TTUNARX
DM1QSM3	MN	Carbonic anhydrase (CA)
DM1QSM3	MT	DTT
DM1QSM3	MA	Inhibitor
DM1QSM3	RN	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
DM1QSM3	RU	https://pubmed.ncbi.nlm.nih.gov/20674354

DM1QSM3	DI	DM1QSM3
DM1QSM3	DN	Phenol
DM1QSM3	MI	TTHQPL7
DM1QSM3	MN	Carbonic anhydrase I (CA-I)
DM1QSM3	MT	DTT
DM1QSM3	MA	Inhibitor
DM1QSM3	RN	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
DM1QSM3	RU	https://pubmed.ncbi.nlm.nih.gov/20674354

DM1QSM3	DI	DM1QSM3
DM1QSM3	DN	Phenol
DM1QSM3	MI	TTANPDJ
DM1QSM3	MN	Carbonic anhydrase II (CA-II)
DM1QSM3	MT	DTT
DM1QSM3	MA	Inhibitor
DM1QSM3	RN	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
DM1QSM3	RU	https://pubmed.ncbi.nlm.nih.gov/20674354

DM1QSM3	DI	DM1QSM3
DM1QSM3	DN	Phenol
DM1QSM3	MI	TTZHA0O
DM1QSM3	MN	Carbonic anhydrase IV (CA-IV)
DM1QSM3	MT	DTT
DM1QSM3	MA	Inhibitor
DM1QSM3	RN	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
DM1QSM3	RU	https://pubmed.ncbi.nlm.nih.gov/20674354

DM1QSM3	DI	DM1QSM3
DM1QSM3	DN	Phenol
DM1QSM3	MI	TT2LVK8
DM1QSM3	MN	Carbonic anhydrase IX (CA-IX)
DM1QSM3	MT	DTT
DM1QSM3	MA	Inhibitor
DM1QSM3	RN	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
DM1QSM3	RU	https://pubmed.ncbi.nlm.nih.gov/20674354

DM1QSM3	DI	DM1QSM3
DM1QSM3	DN	Phenol
DM1QSM3	MI	TTSYM0R
DM1QSM3	MN	Carbonic anhydrase XII (CA-XII)
DM1QSM3	MT	DTT
DM1QSM3	MA	Inhibitor
DM1QSM3	RN	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
DM1QSM3	RU	https://pubmed.ncbi.nlm.nih.gov/20674354

DM1QSM3	DI	DM1QSM3
DM1QSM3	DN	Phenol
DM1QSM3	MI	TTEYTKG
DM1QSM3	MN	Carbonic anhydrase XIV (CA-XIV)
DM1QSM3	MT	DTT
DM1QSM3	MA	Inhibitor
DM1QSM3	RN	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
DM1QSM3	RU	https://pubmed.ncbi.nlm.nih.gov/20674354

DM1QSM3	DI	DM1QSM3
DM1QSM3	DN	Phenol
DM1QSM3	MI	DEVDYN7
DM1QSM3	MN	Cytochrome P450 2E1 (CYP2E1)
DM1QSM3	MT	DME
DM1QSM3	MA	Metabolism
DM1QSM3	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM1QSM3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM1QSM3	DI	DM1QSM3
DM1QSM3	DN	Phenol
DM1QSM3	MI	DED5AT3
DM1QSM3	MN	Cytochrome P450 2F1 (CYP2F1)
DM1QSM3	MT	DME
DM1QSM3	MA	Metabolism
DM1QSM3	RN	Cytochrome P450 isozymes involved in the metabolism of phenol, a benzene metabolite. Toxicol Lett. 2001 Dec 15;125(1-3):117-23.
DM1QSM3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11701230

DM1QSM3	DI	DM1QSM3
DM1QSM3	DN	Phenol
DM1QSM3	MI	DEYGVN4
DM1QSM3	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM1QSM3	MT	DME
DM1QSM3	MA	Metabolism
DM1QSM3	RN	Identification of aspartic acid and histidine residues mediating the reaction mechanism and the substrate specificity of the human UDP-glucuronosyltransferases 1A. J Biol Chem. 2007 Dec 14;282(50):36514-24.
DM1QSM3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17956868

DM1SV8I	DI	DM1SV8I
DM1SV8I	DN	PHN-131
DM1SV8I	MI	TTQW87Y
DM1SV8I	MN	Opioid receptor kappa (OPRK1)
DM1SV8I	MT	DTT
DM1SV8I	MA	Agonist
DM1SV8I	RN	Nalbuphine: an autoradiographic opioid receptor binding profile in the central nervous system of an agonist/antagonist analgesic. J Pharmacol Exp Ther. 1988 Jan;244(1):391-402.
DM1SV8I	RU	https://pubmed.ncbi.nlm.nih.gov/2826773

DMPWH30	DI	DMPWH30
DMPWH30	DN	Pimagedine HCl
DMPWH30	MI	TTF10I9
DMPWH30	MN	Nitric-oxide synthase inducible (NOS2)
DMPWH30	MT	DTT
DMPWH30	MA	Inhibitor
DMPWH30	RN	Nitric oxide associated with iNOS expression inhibits acetylcholinesterase activity and induces memory impairment during acute hypobaric hypoxia. Brain Res. 2008 Sep 16;1230:138-49.
DMPWH30	RU	https://pubmed.ncbi.nlm.nih.gov/18639532

DM0EFQS	DI	DM0EFQS
DM0EFQS	DN	Plasminogen
DM0EFQS	MI	TTP86E2
DM0EFQS	MN	Plasminogen (PLG)
DM0EFQS	MT	DTT
DM0EFQS	MA	Modulator
DM0EFQS	RN	Structure and function of the plasminogen/plasmin system. Thromb Haemost. 2005 Apr;93(4):647-54.
DM0EFQS	RU	https://pubmed.ncbi.nlm.nih.gov/15841308

DMCGK6X	DI	DMCGK6X
DMCGK6X	DN	PRO 140
DMCGK6X	MI	TT2CEJG
DMCGK6X	MN	C-C chemokine receptor type 5 (CCR5)
DMCGK6X	MT	DTT
DMCGK6X	MA	Inhibitor
DMCGK6X	RN	The return of PRO 140, a CCR5-directed mAb. Curr Opin HIV AIDS. 2018 Jul;13(4):346-353.
DMCGK6X	RU	https://pubmed.ncbi.nlm.nih.gov/29708899

DMZI4OV	DI	DMZI4OV
DMZI4OV	DN	QLT-091001
DMZI4OV	MI	DES5XRU
DMZI4OV	MN	Cytochrome P450 2C8 (CYP2C8)
DMZI4OV	MT	DME
DMZI4OV	MA	Metabolism
DMZI4OV	RN	Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by human cytochrome P450 enzymes. Xenobiotica. 1999 Mar;29(3):231-41.
DMZI4OV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10219964

DMB8UQ3	DI	DMB8UQ3
DMB8UQ3	DN	Ramatroban
DMB8UQ3	MI	TTQDMX5
DMB8UQ3	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMB8UQ3	MT	DTT
DMB8UQ3	MA	Antagonist
DMB8UQ3	RN	CRTH2-specific binding characteristics of [3H]ramatroban and its effects on PGD2-, 15-deoxy-Delta12, 14-PGJ2- and indomethacin-induced agonist resp... Eur J Pharmacol. 2005 Nov 7;524(1-3):30-7.
DMB8UQ3	RU	https://pubmed.ncbi.nlm.nih.gov/16256979

DMB8UQ3	DI	DMB8UQ3
DMB8UQ3	DN	Ramatroban
DMB8UQ3	MI	TT2O84V
DMB8UQ3	MN	Thromboxane A2 receptor (TBXA2R)
DMB8UQ3	MT	DTT
DMB8UQ3	MA	Antagonist
DMB8UQ3	RN	Participation in cysteinyl leukotrienes and thromboxane A2 in nasal congestion model in Brown Norway rats. Int Immunopharmacol. 2007 Nov;7(11):1483-7.
DMB8UQ3	RU	https://pubmed.ncbi.nlm.nih.gov/17761352

DM1LFUN	DI	DM1LFUN
DM1LFUN	DN	Ravidasvir
DM1LFUN	MI	TTCJ2X8
DM1LFUN	MN	Hepatitis C virus Non-structural 5A (HCV NS5A)
DM1LFUN	MT	DTT
DM1LFUN	MA	Inhibitor
DM1LFUN	RN	Clinical pipeline report, company report or official report of Presidio Pharmaceuticals.
DM1LFUN	RU	http://www.presidiopharma.com/

DML9FD4	DI	DML9FD4
DML9FD4	DN	Rinfabate
DML9FD4	MI	TTHRID2
DML9FD4	MN	Insulin-like growth factor I receptor (IGF1R)
DML9FD4	MT	DTT
DML9FD4	MA	Modulator
DML9FD4	RN	Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3. Drugs R D. 2005;6(2):120-7.
DML9FD4	RU	https://pubmed.ncbi.nlm.nih.gov/15777106

DMWZ6DK	DI	DMWZ6DK
DMWZ6DK	DN	Roledumab
DMWZ6DK	MI	TTLCKI8
DMWZ6DK	MN	Blood group Rh(D) polypeptide (RHD)
DMWZ6DK	MT	DTT
DMWZ6DK	RN	Pharmacokinetics and safety of roledumab, a novel human recombinant monoclonal anti-RhD antibody with an optimized Fc for improved engagement of FCgammaRIII, in healthy volunteers. Vox Sang. 2012 Oct;103(3):213-22.
DMWZ6DK	RU	https://pubmed.ncbi.nlm.nih.gov/22568808

DMNIYSZ	DI	DMNIYSZ
DMNIYSZ	DN	RP101
DMNIYSZ	MI	TTP3QRF
DMNIYSZ	MN	Thymidine kinase 1 (TK1)
DMNIYSZ	MT	DTT
DMNIYSZ	MA	Inhibitor
DMNIYSZ	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMNIYSZ	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMOJLCV	DI	DMOJLCV
DMOJLCV	DN	SAR164877
DMOJLCV	MI	TTDN3LF
DMOJLCV	MN	Nerve growth factor (NGF)
DMOJLCV	MT	DTT
DMOJLCV	MA	Modulator
DMOJLCV	RN	Fate of novel painkiller mAbs hangs in balance.Nat Biotechnol.2011 Mar;29(3):173-4.
DMOJLCV	RU	https://www.ncbi.nlm.nih.gov/pubmed/21389990

DMH7IPW	DI	DMH7IPW
DMH7IPW	DN	Sarizotan
DMH7IPW	MI	TTSQIFT
DMH7IPW	MN	5-HT 1A receptor (HTR1A)
DMH7IPW	MT	DTT
DMH7IPW	MA	Modulator
DMH7IPW	RN	Dual ligands targeting dopamine D2 and serotonin 5-HT1A receptors as new antipsychotical or anti-Parkinsonian agents.Curr Med Chem.2014;21(4):437-57.
DMH7IPW	RU	https://www.ncbi.nlm.nih.gov/pubmed/24164194

DMH7IPW	DI	DMH7IPW
DMH7IPW	DN	Sarizotan
DMH7IPW	MI	DEJGDUW
DMH7IPW	MN	Cytochrome P450 1A2 (CYP1A2)
DMH7IPW	MT	DME
DMH7IPW	MA	Metabolism
DMH7IPW	RN	In vitro characterization of sarizotan metabolism: hepatic clearance, identification and characterization of metabolites, drug-metabolizing enzyme identification, and evaluation of cytochrome p450 inhibition. Drug Metab Dispos. 2010 Jun;38(6):905-16.
DMH7IPW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20219851

DMH7IPW	DI	DMH7IPW
DMH7IPW	DN	Sarizotan
DMH7IPW	MI	DES5XRU
DMH7IPW	MN	Cytochrome P450 2C8 (CYP2C8)
DMH7IPW	MT	DME
DMH7IPW	MA	Metabolism
DMH7IPW	RN	In vitro characterization of sarizotan metabolism: hepatic clearance, identification and characterization of metabolites, drug-metabolizing enzyme identification, and evaluation of cytochrome p450 inhibition. Drug Metab Dispos. 2010 Jun;38(6):905-16.
DMH7IPW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20219851

DMH7IPW	DI	DMH7IPW
DMH7IPW	DN	Sarizotan
DMH7IPW	MI	DE5IED8
DMH7IPW	MN	Cytochrome P450 2C9 (CYP2C9)
DMH7IPW	MT	DME
DMH7IPW	MA	Metabolism
DMH7IPW	RN	In vitro characterization of sarizotan metabolism: hepatic clearance, identification and characterization of metabolites, drug-metabolizing enzyme identification, and evaluation of cytochrome p450 inhibition. Drug Metab Dispos. 2010 Jun;38(6):905-16.
DMH7IPW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20219851

DMH7IPW	DI	DMH7IPW
DMH7IPW	DN	Sarizotan
DMH7IPW	MI	DE4LYSA
DMH7IPW	MN	Cytochrome P450 3A4 (CYP3A4)
DMH7IPW	MT	DME
DMH7IPW	MA	Metabolism
DMH7IPW	RN	In vitro characterization of sarizotan metabolism: hepatic clearance, identification and characterization of metabolites, drug-metabolizing enzyme identification, and evaluation of cytochrome p450 inhibition. Drug Metab Dispos. 2010 Jun;38(6):905-16.
DMH7IPW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20219851

DMH7IPW	DI	DMH7IPW
DMH7IPW	DN	Sarizotan
DMH7IPW	MI	TTEX248
DMH7IPW	MN	Dopamine D2 receptor (D2R)
DMH7IPW	MT	DTT
DMH7IPW	MA	Modulator
DMH7IPW	RN	Dual ligands targeting dopamine D2 and serotonin 5-HT1A receptors as new antipsychotical or anti-Parkinsonian agents.Curr Med Chem.2014;21(4):437-57.
DMH7IPW	RU	https://www.ncbi.nlm.nih.gov/pubmed/24164194

DM31L9K	DI	DM31L9K
DM31L9K	DN	Sepofarsen
DM31L9K	MI	TT3XBOV
DM31L9K	MN	CEP290 messenger RNA (CEP290 mRNA)
DM31L9K	MT	DTT
DM31L9K	MA	Inhibitor
DM31L9K	RN	Clinical pipeline report, company report or official report of ProQR Therapeutics.
DM31L9K	RU	https://www.proqr.com/pipeline

DMTV5XC	DI	DMTV5XC
DMTV5XC	DN	Sitafloxacin
DMTV5XC	MI	DTUGYRD
DMTV5XC	MN	P-glycoprotein 1 (ABCB1)
DMTV5XC	MT	DTP
DMTV5XC	MA	Substrate
DMTV5XC	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMTV5XC	RU	https://doi.org/10.1007/s11095-012-0935-x

DM30JWZ	DI	DM30JWZ
DM30JWZ	DN	SM04554
DM30JWZ	MI	TTFPSHI
DM30JWZ	MN	Wnt signaling pathway (Wnt pathway)
DM30JWZ	MT	DTT
DM30JWZ	MA	Modulator
DM30JWZ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM30JWZ	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMD9ISG	DI	DMD9ISG
DMD9ISG	DN	SM-88
DMD9ISG	MI	TT8E7Z0
DMD9ISG	MN	Free radical (FRD)
DMD9ISG	MT	DTT
DMD9ISG	MA	Stimulator
DMD9ISG	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMD9ISG	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM5WQ2U	DI	DM5WQ2U
DM5WQ2U	DN	SR-123781A
DM5WQ2U	MI	TT6L509
DM5WQ2U	MN	Coagulation factor IIa (F2)
DM5WQ2U	MT	DTT
DM5WQ2U	MA	Modulator
DM5WQ2U	RN	SR123781A, a synthetic heparin mimetic. Thromb Haemost. 2001 May;85(5):852-60.
DM5WQ2U	RU	https://pubmed.ncbi.nlm.nih.gov/11372679

DM5WQ2U	DI	DM5WQ2U
DM5WQ2U	DN	SR-123781A
DM5WQ2U	MI	TTCIHJA
DM5WQ2U	MN	Coagulation factor Xa (F10)
DM5WQ2U	MT	DTT
DM5WQ2U	MA	Modulator
DM5WQ2U	RN	SR123781A, a synthetic heparin mimetic. Thromb Haemost. 2001 May;85(5):852-60.
DM5WQ2U	RU	https://pubmed.ncbi.nlm.nih.gov/11372679

DMKGQF0	DI	DMKGQF0
DMKGQF0	DN	Suvodirsen
DMKGQF0	MI	TTWLFXU
DMKGQF0	MN	Dystrophin messenger RNA (DMD mRNA)
DMKGQF0	MT	DTT
DMKGQF0	MA	Inhibitor
DMKGQF0	RN	Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020 Oct;19(10):673-694.
DMKGQF0	RU	https://pubmed.ncbi.nlm.nih.gov/32782413

DMWE3GB	DI	DMWE3GB
DMWE3GB	DN	TG-4010
DMWE3GB	MI	TTF89GD
DMWE3GB	MN	Interleukin-2 (IL2)
DMWE3GB	MT	DTT
DMWE3GB	MA	Modulator
DMWE3GB	RN	A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J Thorac Oncol. 2008 Jul;3(7):735-44.
DMWE3GB	RU	https://pubmed.ncbi.nlm.nih.gov/18594319

DMWE3GB	DI	DMWE3GB
DMWE3GB	DN	TG-4010
DMWE3GB	MI	TTBHFYQ
DMWE3GB	MN	Mucin-1 (MUC1)
DMWE3GB	MT	DTT
DMWE3GB	MA	Modulator
DMWE3GB	RN	A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J Thorac Oncol. 2008 Jul;3(7):735-44.
DMWE3GB	RU	https://pubmed.ncbi.nlm.nih.gov/18594319

DMVDTR2	DI	DMVDTR2
DMVDTR2	DN	Thymoquinone
DMVDTR2	MI	TTQ57WJ
DMVDTR2	MN	Apoptosis regulator BAX (BAX)
DMVDTR2	MT	DTT
DMVDTR2	MA	Inhibitor
DMVDTR2	RN	Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside. Drug Discov Today. 2020 Jul;25(7):1189-1197.
DMVDTR2	RU	https://pubmed.ncbi.nlm.nih.gov/32389641

DMVDTR2	DI	DMVDTR2
DMVDTR2	DN	Thymoquinone
DMVDTR2	MI	TTJGNVC
DMVDTR2	MN	Apoptosis regulator Bcl-2 (BCL-2)
DMVDTR2	MT	DTT
DMVDTR2	MA	Inhibitor
DMVDTR2	RN	Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside. Drug Discov Today. 2020 Jul;25(7):1189-1197.
DMVDTR2	RU	https://pubmed.ncbi.nlm.nih.gov/32389641

DMVDTR2	DI	DMVDTR2
DMVDTR2	DN	Thymoquinone
DMVDTR2	MI	TT7SBF5
DMVDTR2	MN	Cellular tumor antigen p53 (TP53)
DMVDTR2	MT	DTT
DMVDTR2	MA	Inhibitor
DMVDTR2	RN	Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside. Drug Discov Today. 2020 Jul;25(7):1189-1197.
DMVDTR2	RU	https://pubmed.ncbi.nlm.nih.gov/32389641

DM23ARP	DI	DM23ARP
DM23ARP	DN	V-710
DM23ARP	MI	TTE0AHP
DM23ARP	MN	Staphylococcus Iron-regulated surface determinant B (Stap-coc isdB)
DM23ARP	MT	DTT
DM23ARP	RN	Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. JAMA. 2013 Apr 3;309(13):1368-78.
DM23ARP	RU	https://pubmed.ncbi.nlm.nih.gov/23549582

DMDG8Q3	DI	DMDG8Q3
DMDG8Q3	DN	Varlitinib
DMDG8Q3	MI	TTGKNB4
DMDG8Q3	MN	Epidermal growth factor receptor (EGFR)
DMDG8Q3	MT	DTT
DMDG8Q3	MA	Modulator
DMDG8Q3	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMDG8Q3	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMDG8Q3	DI	DMDG8Q3
DMDG8Q3	DN	Varlitinib
DMDG8Q3	MI	TT6EO5L
DMDG8Q3	MN	Erbb2 tyrosine kinase receptor (HER2)
DMDG8Q3	MT	DTT
DMDG8Q3	MA	Modulator
DMDG8Q3	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMDG8Q3	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMTROUI	DI	DMTROUI
DMTROUI	DN	Vazegepant
DMTROUI	MI	TT67OLB
DMTROUI	MN	HUMAN calcitonin gene-related peptide type 1 receptor (CALCRL)
DMTROUI	MT	DTT
DMTROUI	MA	Inhibitor
DMTROUI	RN	Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen
DMTROUI	RU	https://clinicaltrials.gov/ct2/show/NCT04346615

DMGKRAJ	DI	DMGKRAJ
DMGKRAJ	DN	VB4-845
DMGKRAJ	MI	TTZ8WH4
DMGKRAJ	MN	Tumor-associated calcium signal transducer 1 (EPCAM)
DMGKRAJ	MT	DTT
DMGKRAJ	RN	A bispecific EpCAM/CD133 targeted toxin is effective against carcinoma. Target Oncol. 2014 September; 9(3): 239-249.
DMGKRAJ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3994189/

DM0ASTP	DI	DM0ASTP
DM0ASTP	DN	Verapamil
DM0ASTP	MI	TTHQJ2Y
DM0ASTP	MN	HUMAN two pore channel subtype 2 (TPC2)
DM0ASTP	MT	DTT
DM0ASTP	MA	Blocker
DM0ASTP	RN	Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020 Mar 27;11(1):1620.
DM0ASTP	RU	https://pubmed.ncbi.nlm.nih.gov/32221306

DM4WQBO	DI	DM4WQBO
DM4WQBO	DN	VM-1500
DM4WQBO	MI	TT84ETX
DM4WQBO	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM4WQBO	MT	DTT
DM4WQBO	MA	Inhibitor
DM4WQBO	RN	127 afety, pharmokinetics and efficacy of VM-1500, a novel reverse transcriptase inhibitor, In healthy volunteers and HIV-infected patients. J Acquir Immune Defic Syndr. 2014 April; 65(Suppl 2): 52.
DM4WQBO	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4149639/

DM5G1NT	DI	DM5G1NT
DM5G1NT	DN	VX-210
DM5G1NT	MI	TTXEVN8
DM5G1NT	MN	Transforming protein Rho (RHO)
DM5G1NT	MT	DTT
DM5G1NT	MA	Inhibitor
DM5G1NT	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM5G1NT	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM2U3MX	DI	DM2U3MX
DM2U3MX	DN	VX-509
DM2U3MX	MI	TTT7PJU
DM2U3MX	MN	Janus kinase 3 (JAK-3)
DM2U3MX	MT	DTT
DM2U3MX	MA	Inhibitor
DM2U3MX	RN	Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.
DM2U3MX	RU	https://pubmed.ncbi.nlm.nih.gov/24818516

DMHXJ68	DI	DMHXJ68
DMHXJ68	DN	WVE-210201
DMHXJ68	MI	TT48MP6
DMHXJ68	MN	Dystrophin (DMD)
DMHXJ68	MT	DTT
DMHXJ68	MA	Modulator
DMHXJ68	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMHXJ68	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM78DOT	DI	DM78DOT
DM78DOT	DN	AllerB
DM78DOT	MI	TT9V5JH
DM78DOT	MN	Phospholipase A2 (PLA2G1B)
DM78DOT	MT	DTT
DM78DOT	MA	Inhibitor
DM78DOT	RN	Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol. 1998 Jun;101(6 Pt 1):747-54.
DM78DOT	RU	https://pubmed.ncbi.nlm.nih.gov/9648701

DMJM9LZ	DI	DMJM9LZ
DMJM9LZ	DN	LB80380
DMJM9LZ	MI	TTS5K1M
DMJM9LZ	MN	Hepatitis B virus Reverse transcriptase (HBV RT)
DMJM9LZ	MT	DTT
DMJM9LZ	MA	Inhibitor
DMJM9LZ	RN	2011 Pipeline of LG Life Sciences.
DMJM9LZ	RU	http://www.lgls.com/

DMXB4NL	DI	DMXB4NL
DMXB4NL	DN	MEDI4893
DMXB4NL	MI	TT5FLYB
DMXB4NL	MN	Staphylococcus Alpha-hemolysin (Stap-coc hly)
DMXB4NL	MT	DTT
DMXB4NL	RN	Mechanisms of neutralization of a human anti-alpha-toxin antibody. J Biol Chem. 2014 Oct 24;289(43):29874-80.
DMXB4NL	RU	https://pubmed.ncbi.nlm.nih.gov/25210036

DMEARCM	DI	DMEARCM
DMEARCM	DN	OrM3
DMEARCM	MI	TTH18TF
DMEARCM	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMEARCM	MT	DTT
DMEARCM	MA	Antagonist
DMEARCM	RN	Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94.
DMEARCM	RU	https://pubmed.ncbi.nlm.nih.gov/19265487

DMOE582	DI	DMOE582
DMOE582	DN	TZP-101
DMOE582	MI	TTWDC17
DMOE582	MN	Growth hormone secretagogue receptor 1 (GHSR)
DMOE582	MT	DTT
DMOE582	MA	Agonist
DMOE582	RN	Contribution of protein binding to the pharmacokinetics of the ghrelin receptor agonist TZP-101 in healthy volunteers and adults with symptomatic gastroparesis: two randomized, double-blind studies and a binding profile study. Clin Drug Investig. 2009;29(6):409-18. 
DMOE582	RU	https://pubmed.ncbi.nlm.nih.gov/19432500

DMUB8WN	DI	DMUB8WN
DMUB8WN	DN	Aerovant
DMUB8WN	MI	TTDWHC3
DMUB8WN	MN	Interleukin 4 receptor alpha (IL4R)
DMUB8WN	MT	DTT
DMUB8WN	MA	Antagonist
DMUB8WN	RN	Aerovance starts trial of Aerovant for uncontrolled asthma. Aerovance. March 3, 2009.
DMUB8WN	RU	http://www.news-medical.net/news/2009/03/03/46411.aspx

DMSC8YW	DI	DMSC8YW
DMSC8YW	DN	ANA773
DMSC8YW	MI	TTRJ1K4
DMSC8YW	MN	Toll-like receptor 7 (TLR7)
DMSC8YW	MT	DTT
DMSC8YW	MA	Agonist
DMSC8YW	RN	Clinical pipeline report, company report or official report of Anadys Pharmaceuticals (2011).
DMSC8YW	RU	http://www.anadyspharma.com/

DMJBDL0	DI	DMJBDL0
DMJBDL0	DN	BIIB104
DMJBDL0	MI	TTAN6JD
DMJBDL0	MN	Glutamate receptor AMPA (GRIA)
DMJBDL0	MT	DTT
DMJBDL0	MA	Activator
DMJBDL0	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMJBDL0	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DM0TH9A	DI	DM0TH9A
DM0TH9A	DN	Bimosiamose
DM0TH9A	MI	TTAU4D6
DM0TH9A	MN	E-selectin (SELE)
DM0TH9A	MT	DTT
DM0TH9A	MA	Inhibitor
DM0TH9A	RN	Effects of the pan-selectin antagonist bimosiamose (TBC1269) in experimental human endotoxemia. Shock. 2008 Apr;29(4):475-82.
DM0TH9A	RU	https://pubmed.ncbi.nlm.nih.gov/18598003

DMR6LXM	DI	DMR6LXM
DMR6LXM	DN	CAP-232
DMR6LXM	MI	TT4LOT8
DMR6LXM	MN	Pyruvate kinase M2 (PKM)
DMR6LXM	MT	DTT
DMR6LXM	MA	Modulator
DMR6LXM	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMR6LXM	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMLQ3PO	DI	DMLQ3PO
DMLQ3PO	DN	INCB13739
DMLQ3PO	MI	TTN7BL9
DMLQ3PO	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMLQ3PO	MT	DTT
DMLQ3PO	MA	Inhibitor
DMLQ3PO	RN	Incyte's Selective Oral Inhibitor Of 11beta-HSD1 Demonstrates Improvements In Insulin Sensitivity And Lowers Cholesterol Levels In Type 2 Diabetics. Incyte. 2008.
DMLQ3PO	RU	http://www.medicalnewstoday.com/articles/110647.php

DMLQ3PO	DI	DMLQ3PO
DMLQ3PO	DN	INCB13739
DMLQ3PO	MI	TTWC6MY
DMLQ3PO	MN	Protein tyrosine phosphatase (PTP)
DMLQ3PO	MT	DTT
DMLQ3PO	MA	Inhibitor
DMLQ3PO	RN	Induction of endothelial cell surface adhesion molecules by tumor necrosis factor is blocked by protein tyrosine phosphatase inhibitors: role of the nuclear transcription factor NF-kappa B. Eur J Immunol. 1997 Sep;27(9):2172-9.
DMLQ3PO	RU	https://pubmed.ncbi.nlm.nih.gov/9341756

DMMWC6F	DI	DMMWC6F
DMMWC6F	DN	INCB9471
DMMWC6F	MI	TT2CEJG
DMMWC6F	MN	C-C chemokine receptor type 5 (CCR5)
DMMWC6F	MT	DTT
DMMWC6F	MA	Antagonist
DMMWC6F	RN	Species selectivity of small-molecular antagonists for the CCR5 chemokine receptor. Int Immunopharmacol. 2007 Dec 5;7(12):1528-34.
DMMWC6F	RU	https://pubmed.ncbi.nlm.nih.gov/17920529

DMYZU6G	DI	DMYZU6G
DMYZU6G	DN	MEM-1003
DMYZU6G	MI	TTXHYV6
DMYZU6G	MN	Voltage-gated L-type calcium channel (L-CaC)
DMYZU6G	MT	DTT
DMYZU6G	MA	Modulator
DMYZU6G	RN	Efficacy of MEM 1003, a novel calcium channel blocker, in delay and trace eyeblink conditioning in older rabbits. Neurobiol Aging. 2007 May;28(5):766-73.
DMYZU6G	RU	https://pubmed.ncbi.nlm.nih.gov/16621170

DMGM1IR	DI	DMGM1IR
DMGM1IR	DN	RhuDex
DMGM1IR	MI	TTFZDNP
DMGM1IR	MN	Activation B7-1 antigen (CD80)
DMGM1IR	MT	DTT
DMGM1IR	MA	Inhibitor
DMGM1IR	RN	A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma. Clin Cancer Res. 2011 Apr 1;17(7):1998-2005.
DMGM1IR	RU	https://pubmed.ncbi.nlm.nih.gov/21447719

DMKJDR6	DI	DMKJDR6
DMKJDR6	DN	VX-702
DMKJDR6	MI	TTQBR95
DMKJDR6	MN	Stress-activated protein kinase 2a (p38 alpha)
DMKJDR6	MT	DTT
DMKJDR6	MA	Modulator
DMKJDR6	RN	Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009 May;60(5):1232-41.
DMKJDR6	RU	https://pubmed.ncbi.nlm.nih.gov/19404957

DMAV426	DI	DMAV426
DMAV426	DN	(S)-oxybutynin
DMAV426	MI	TTZ9SOR
DMAV426	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMAV426	MT	DTT
DMAV426	MA	Antagonist
DMAV426	RN	Enantiomers of oxybutynin: in vitro pharmacological characterization at M1, M2 and M3 muscarinic receptors and in vivo effects on urinary bladder contraction, mydriasis and salivary secretion in guinea pigs. J Pharmacol Exp Ther. 1991 Feb;256(2):562-7.
DMAV426	RU	https://pubmed.ncbi.nlm.nih.gov/1993995

DMGDOS2	DI	DMGDOS2
DMGDOS2	DN	(Z)-endoxifen
DMGDOS2	MI	DTUGYRD
DMGDOS2	MN	P-glycoprotein 1 (ABCB1)
DMGDOS2	MT	DTP
DMGDOS2	MA	Substrate
DMGDOS2	RN	P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration. J Pharmacol Exp Ther. 2011 Jun;337(3):710-7.
DMGDOS2	RU	https://doi.org/10.1124/jpet.110.178301

DMV86DY	DI	DMV86DY
DMV86DY	DN	[131I]-BC8
DMV86DY	MI	TTUS45N
DMV86DY	MN	Leukocyte common antigen (PTPRC)
DMV86DY	MT	DTT
DMV86DY	RN	Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood. 1995 Feb 15;85(4):1122-31.
DMV86DY	RU	https://pubmed.ncbi.nlm.nih.gov/7849300

DM4VWXI	DI	DM4VWXI
DM4VWXI	DN	[131I]-Metuximab
DM4VWXI	MI	TT5UJWD
DM4VWXI	MN	Basigin (BSG)
DM4VWXI	MT	DTT
DM4VWXI	RN	Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials. Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):435-44.
DM4VWXI	RU	https://pubmed.ncbi.nlm.nih.gov/16690431

DMSLMY7	DI	DMSLMY7
DMSLMY7	DN	11C-PBR-28
DMSLMY7	MI	TTPTXIN
DMSLMY7	MN	Translocator protein (TSPO)
DMSLMY7	MT	DTT
DMSLMY7	MA	Binder
DMSLMY7	RN	PET imaging with [11C]PBR28 can localize and quantify upregulated peripheral benzodiazepine receptors associated with cerebral ischemia in rat. Neurosci Lett. 2007 Jan 16;411(3):200-5.
DMSLMY7	RU	https://pubmed.ncbi.nlm.nih.gov/17127001

DMTIED1	DI	DMTIED1
DMTIED1	DN	131I-TM-601
DMTIED1	MI	TTCYAXN
DMTIED1	MN	Chloride channel unspecific (ClC)
DMTIED1	MT	DTT
DMTIED1	MA	Inhibitor
DMTIED1	RN	Imaging glioma extent with 131I-TM-601. J Nucl Med. 2005 Apr;46(4):580-6.
DMTIED1	RU	https://pubmed.ncbi.nlm.nih.gov/15809479

DM4EP6Y	DI	DM4EP6Y
DM4EP6Y	DN	13-DEOXYADRIAMYCIN HYDROCHLORIDE
DM4EP6Y	MI	TT0IHXV
DM4EP6Y	MN	DNA topoisomerase II (TOP2)
DM4EP6Y	MT	DTT
DM4EP6Y	MA	Modulator
DM4EP6Y	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM4EP6Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM4EP6Y	DI	DM4EP6Y
DM4EP6Y	DN	13-DEOXYADRIAMYCIN HYDROCHLORIDE
DM4EP6Y	MI	TTUTN1I
DM4EP6Y	MN	Human Deoxyribonucleic acid (hDNA)
DM4EP6Y	MT	DTT
DM4EP6Y	MA	Modulator
DM4EP6Y	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM4EP6Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMNF38S	DI	DMNF38S
DMNF38S	DN	16,16-dimethyl-PGE2
DMNF38S	MI	TT1ZAVI
DMNF38S	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DMNF38S	MT	DTT
DMNF38S	MA	Agonist
DMNF38S	RN	Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
DMNF38S	RU	https://pubmed.ncbi.nlm.nih.gov/9313928

DMNF38S	DI	DMNF38S
DMNF38S	DN	16,16-dimethyl-PGE2
DMNF38S	MI	TTPNGDE
DMNF38S	MN	Prostaglandin E2 receptor EP3 (PTGER3)
DMNF38S	MT	DTT
DMNF38S	MA	Agonist
DMNF38S	RN	Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
DMNF38S	RU	https://pubmed.ncbi.nlm.nih.gov/9313928

DMNF38S	DI	DMNF38S
DMNF38S	DN	16,16-dimethyl-PGE2
DMNF38S	MI	TT79WV3
DMNF38S	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DMNF38S	MT	DTT
DMNF38S	MA	Agonist
DMNF38S	RN	Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
DMNF38S	RU	https://pubmed.ncbi.nlm.nih.gov/9313928

DMT8GVU	DI	DMT8GVU
DMT8GVU	DN	177Lu-DOTATATE
DMT8GVU	MI	TTOMNR9
DMT8GVU	MN	Somatostatin receptor (SSTR)
DMT8GVU	MT	DTT
DMT8GVU	MA	Modulator
DMT8GVU	RN	Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. Pancreas. 2014 May;43(4):518-25.
DMT8GVU	RU	https://pubmed.ncbi.nlm.nih.gov/24632546

DMT8GVU	DI	DMT8GVU
DMT8GVU	DN	177Lu-DOTATATE
DMT8GVU	MI	TTAE1BR
DMT8GVU	MN	Somatostatin receptor type 4 (SSTR4)
DMT8GVU	MT	DTT
DMT8GVU	MA	Inhibitor
DMT8GVU	RN	New Drug in Development Shows Improved Progression-Free Survival for Patients with Advanced Metastatic Midgut Neuroendocrine Tumors
DMT8GVU	RU	https://www.cancercommons.org/tag/177lu-dotatate/

DM2TSMD	DI	DM2TSMD
DM2TSMD	DN	177Lu-labelled NeoBOMB1
DM2TSMD	MI	TTC1MVT
DM2TSMD	MN	Gastrin-releasing peptide receptor (GRPR)
DM2TSMD	MT	DTT
DM2TSMD	RN	68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology. J Nucl Med. 2017 Feb;58(2):293-299.
DM2TSMD	RU	https://pubmed.ncbi.nlm.nih.gov/27609789

DM8JVIB	DI	DM8JVIB
DM8JVIB	DN	18F-LMI-1195
DM8JVIB	MI	TTAWNKZ
DM8JVIB	MN	Norepinephrine transporter (NET)
DM8JVIB	MT	DTT
DM8JVIB	MA	Enhancer
DM8JVIB	RN	Assessment of the 18F-labeled PET tracer LMI1195 for imaging norepinephrine handling in rat hearts. J Nucl Med. 2013 Jul;54(7):1142-6.
DM8JVIB	RU	https://pubmed.ncbi.nlm.nih.gov/23670901

DMZWNQF	DI	DMZWNQF
DMZWNQF	DN	2'3'-Dideoxyinosine
DMZWNQF	MI	TTMCF1Y
DMZWNQF	MN	Purine nucleoside phosphorylase (PNP)
DMZWNQF	MT	DTT
DMZWNQF	MA	Inhibitor
DMZWNQF	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMZWNQF	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMBOL4K	DI	DMBOL4K
DMBOL4K	DN	264W94
DMBOL4K	MI	TTPI1M5
DMBOL4K	MN	Ileal sodium/bile acid cotransporter (SLC10A2)
DMBOL4K	MT	DTT
DMBOL4K	MA	Modulator
DMBOL4K	RN	Inhibition of apical sodium-dependent bile acid transporter as a novel treatment for diabetes. Am J Physiol Endocrinol Metab. 2012 Jan 1;302(1):E68-76.
DMBOL4K	RU	https://pubmed.ncbi.nlm.nih.gov/21934041

DMGBPME	DI	DMGBPME
DMGBPME	DN	2-Methoxyestradiol
DMGBPME	MI	DE6OQ3W
DMGBPME	MN	Cytochrome P450 1A1 (CYP1A1)
DMGBPME	MT	DME
DMGBPME	MA	Metabolism
DMGBPME	RN	Role of 2-methoxyestradiol, an Endogenous Estrogen Metabolite, in Health and Disease. Mini Rev Med Chem. 2015;15(5):427-38.
DMGBPME	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25723461

DMGBPME	DI	DMGBPME
DMGBPME	DN	2-Methoxyestradiol
DMGBPME	MI	TTQHWNA
DMGBPME	MN	Hypoxia-inducible factor 1 alpha (HIF-1A)
DMGBPME	MT	DTT
DMGBPME	MA	Modulator
DMGBPME	RN	2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squam... Clin Cancer Res. 2004 Dec 15;10(24):8665-73.
DMGBPME	RU	https://www.ncbi.nlm.nih.gov/pubmed/15623651

DMX9MSL	DI	DMX9MSL
DMX9MSL	DN	2X-121
DMX9MSL	MI	TTEBCY8
DMX9MSL	MN	Poly [ADP-ribose] polymerase (PARP)
DMX9MSL	MT	DTT
DMX9MSL	MA	Inhibitor
DMX9MSL	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMX9MSL	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMX9MSL	DI	DMX9MSL
DMX9MSL	DN	2X-121
DMX9MSL	MI	TTKSAQZ
DMX9MSL	MN	Tankyrase (TNKS)
DMX9MSL	MT	DTT
DMX9MSL	MA	Inhibitor
DMX9MSL	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMX9MSL	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DML8M5T	DI	DML8M5T
DML8M5T	DN	3,5-diiodothyropropionic acid
DML8M5T	MI	DE4LYSA
DML8M5T	MN	Cytochrome P450 3A4 (CYP3A4)
DML8M5T	MT	DME
DML8M5T	MA	Metabolism
DML8M5T	RN	Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid. 2014 Dec;24(12):1670-751.
DML8M5T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25266247

DMTLR6Y	DI	DMTLR6Y
DMTLR6Y	DN	3K3A-APC
DMTLR6Y	MI	TTZUXYS
DMTLR6Y	MN	Vitamin K-dependent protein C (PROC)
DMTLR6Y	MT	DTT
DMTLR6Y	MA	Modulator
DMTLR6Y	RN	Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified activated protein C for ischemic stroke. Curr Pharm Des. 2012;18(27):4215-22.
DMTLR6Y	RU	https://pubmed.ncbi.nlm.nih.gov/22632606

DMPFVJB	DI	DMPFVJB
DMPFVJB	DN	5-hydroxymethyl-2-furfural
DMPFVJB	MI	TTQO71U
DMPFVJB	MN	Hemoglobin (HB)
DMPFVJB	MT	DTT
DMPFVJB	MA	Modulator
DMPFVJB	RN	5-hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells. Br J Haematol. 2005 Feb;128(4):552-61.
DMPFVJB	RU	https://pubmed.ncbi.nlm.nih.gov/15686467

DMHBN8X	DI	DMHBN8X
DMHBN8X	DN	60P002
DMHBN8X	MI	TTQL5VC
DMHBN8X	MN	Platelet-activating factor receptor (PTAFR)
DMHBN8X	MT	DTT
DMHBN8X	MA	Antagonist
DMHBN8X	RN	Clinical pipeline report, company report or official report of 60 Degrees Pharmaceuticals.
DMHBN8X	RU	https://60degreespharma.com/research-development/clinical-pipeline/

DMOV0AP	DI	DMOV0AP
DMOV0AP	DN	842166X
DMOV0AP	MI	TTMSFAW
DMOV0AP	MN	Cannabinoid receptor 2 (CB2)
DMOV0AP	MT	DTT
DMOV0AP	MA	Agonist
DMOV0AP	RN	The agonist binding mechanism of human CB2 receptor studied by molecular dynamics simulation, free energy calculation and 3D-QSAR studies. Yao Xue Xue Bao. 2013 Sep;48(9):1436-49.
DMOV0AP	RU	https://pubmed.ncbi.nlm.nih.gov/24358778

DML4GU1	DI	DML4GU1
DML4GU1	DN	99mTc-MIP-1404
DML4GU1	MI	TT9G4N0
DML4GU1	MN	Glutamate carboxypeptidase II (GCPII)
DML4GU1	MT	DTT
DML4GU1	MA	Modulator
DML4GU1	RN	99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer. J Nucl Med. 2013 Aug;54(8):1369-76.
DML4GU1	RU	https://pubmed.ncbi.nlm.nih.gov/23733925

DMX2LO3	DI	DMX2LO3
DMX2LO3	DN	99mTc-RP-128
DMX2LO3	MI	TTYG378
DMX2LO3	MN	Tuftsin receptor (TR)
DMX2LO3	MT	DTT
DMX2LO3	MA	Modulator
DMX2LO3	RN	WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.
DMX2LO3	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20131212&CC=WO&NR=2013185032A1&KC=A1

DMQXYRG	DI	DMQXYRG
DMQXYRG	DN	9-AMINOCAMPTOTHECIN
DMQXYRG	MI	DTI7UX6
DMQXYRG	MN	Breast cancer resistance protein (ABCG2)
DMQXYRG	MT	DTP
DMQXYRG	MA	Substrate
DMQXYRG	RN	Pharmacogenomic importance of ABCG2. Pharmacogenomics. 2008 Aug;9(8):1005-9.
DMQXYRG	RU	https://doi.org/10.2217/14622416.9.8.1005

DMQXYRG	DI	DMQXYRG
DMQXYRG	DN	9-AMINOCAMPTOTHECIN
DMQXYRG	MI	DE6OQ3W
DMQXYRG	MN	Cytochrome P450 1A1 (CYP1A1)
DMQXYRG	MT	DME
DMQXYRG	MA	Metabolism
DMQXYRG	RN	Cytochrome P450 3A-mediated metabolism of the topoisomerase I inhibitor 9-aminocamptothecin: impact on cancer therapy. Int J Oncol. 2014 Aug;45(2):877-86.
DMQXYRG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24889073

DMQXYRG	DI	DMQXYRG
DMQXYRG	DN	9-AMINOCAMPTOTHECIN
DMQXYRG	MI	DE4LYSA
DMQXYRG	MN	Cytochrome P450 3A4 (CYP3A4)
DMQXYRG	MT	DME
DMQXYRG	MA	Metabolism
DMQXYRG	RN	Cytochrome P450 3A-mediated metabolism of the topoisomerase I inhibitor 9-aminocamptothecin: impact on cancer therapy. Int J Oncol. 2014 Aug;45(2):877-86.
DMQXYRG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24889073

DMQXYRG	DI	DMQXYRG
DMQXYRG	DN	9-AMINOCAMPTOTHECIN
DMQXYRG	MI	TTGTQHC
DMQXYRG	MN	DNA topoisomerase I (TOP1)
DMQXYRG	MT	DTT
DMQXYRG	MA	Inhibitor
DMQXYRG	RN	Intraperitoneal topoisomerase-I inhibitors. Preliminary findings with 9-aminocamptothecin. Ann N Y Acad Sci. 2000;922:178-87.
DMQXYRG	RU	https://pubmed.ncbi.nlm.nih.gov/11193893

DM57TY3	DI	DM57TY3
DM57TY3	DN	9-ING-41
DM57TY3	MI	TTRSMW9
DM57TY3	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DM57TY3	MT	DTT
DM57TY3	MA	Inhibitor
DM57TY3	RN	9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer. Sci Rep. 2019 Dec 27;9(1):19977.
DM57TY3	RU	https://pubmed.ncbi.nlm.nih.gov/31882719

DM6ZIES	DI	DM6ZIES
DM6ZIES	DN	A-6
DM6ZIES	MI	TTWFBT7
DM6ZIES	MN	Extracellular matrix receptor III (CD44)
DM6ZIES	MT	DTT
DM6ZIES	MA	Modulator
DM6ZIES	RN	Modulation of CD44 Activity by A6-Peptide.Front Immunol.2015 Mar 30;6:135.
DM6ZIES	RU	https://www.ncbi.nlm.nih.gov/pubmed/25870596

DMHOLB7	DI	DMHOLB7
DMHOLB7	DN	A-85380
DMHOLB7	MI	TTJSZTB
DMHOLB7	MN	Nicotinic acetylcholine receptor (nAChR)
DMHOLB7	MT	DTT
DMHOLB7	MA	Agonist
DMHOLB7	RN	The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control. Expert Opin Investig Drugs. 2001 Oct;10(10):1819-30.
DMHOLB7	RU	https://pubmed.ncbi.nlm.nih.gov/11772288

DMOGDCQ	DI	DMOGDCQ
DMOGDCQ	DN	Ab-01
DMOGDCQ	MI	TTZO9B0
DMOGDCQ	MN	Interleukin 21 receptor (IL21R)
DMOGDCQ	MT	DTT
DMOGDCQ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2304).
DMOGDCQ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2304

DMEW62S	DI	DMEW62S
DMEW62S	DN	AB-106
DMEW62S	MI	TTSZ6Y3
DMEW62S	MN	Proto-oncogene c-Ros (ROS1)
DMEW62S	MT	DTT
DMEW62S	MA	Inhibitor
DMEW62S	RN	Clinical pipeline report, company report or official report of AnHeart Therapeutics.
DMEW62S	RU	https://anhearttherapeutics.com/pipeline/

DMEW62S	DI	DMEW62S
DMEW62S	DN	AB-106
DMEW62S	MI	TTJOCTY
DMEW62S	MN	Tropomyosin receptor kinase (Trk)
DMEW62S	MT	DTT
DMEW62S	MA	Inhibitor
DMEW62S	RN	Clinical pipeline report, company report or official report of AnHeart Therapeutics.
DMEW62S	RU	https://anhearttherapeutics.com/pipeline/

DM48DPS	DI	DM48DPS
DM48DPS	DN	AB-729
DM48DPS	MI	TT43YWN
DM48DPS	MN	Hepatitis B virus messenger RNA (HBV mRNA)
DM48DPS	MT	DTT
DM48DPS	MA	Inhibitor
DM48DPS	RN	Clinical pipeline report, company report or official report of Arbutus Biopharma.
DM48DPS	RU	http://www.arbutusbio.com/portfolio/ab-729-galnac-rnai.php

DM4ZLTY	DI	DM4ZLTY
DM4ZLTY	DN	ABBV-2222
DM4ZLTY	MI	TTRLZHP
DM4ZLTY	MN	cAMP-dependent chloride channel (CFTR)
DM4ZLTY	MT	DTT
DM4ZLTY	MA	Modulator
DM4ZLTY	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DM4ZLTY	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMT6H3J	DI	DMT6H3J
DMT6H3J	DN	AbGn-168
DMT6H3J	MI	TTS5K8U
DMT6H3J	MN	P-selectin glycoprotein ligand 1 (SELPLG)
DMT6H3J	MT	DTT
DMT6H3J	RN	Clinical pipeline report, company report or official report of Avarx.
DMT6H3J	RU	http://www.avarx.com/AvaRx/SubDomains/bucket3739906636580370793/Listings/bucket460336945731305549/Public.Listing.display.html

DMQ6KZM	DI	DMQ6KZM
DMQ6KZM	DN	ABI-009
DMQ6KZM	MI	TTCJG29
DMQ6KZM	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMQ6KZM	MT	DTT
DMQ6KZM	MA	Inhibitor
DMQ6KZM	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQ6KZM	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM59OJ2	DI	DM59OJ2
DM59OJ2	DN	Abicipar pegol
DM59OJ2	MI	TTOHSBA
DM59OJ2	MN	Vascular endothelial growth factor A (VEGFA)
DM59OJ2	MT	DTT
DM59OJ2	MA	Inhibitor
DM59OJ2	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM59OJ2	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMX1KDM	DI	DMX1KDM
DMX1KDM	DN	ABI-H0731
DMX1KDM	MI	TTM42UJ
DMX1KDM	MN	Hepatitis B virus Capsid protein (HBV C)
DMX1KDM	MT	DTT
DMX1KDM	MA	Inhibitor
DMX1KDM	RN	Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial. Lancet Gastroenterol Hepatol. 2020 Feb;5(2):152-166.
DMX1KDM	RU	https://pubmed.ncbi.nlm.nih.gov/31711752

DM6X70G	DI	DM6X70G
DM6X70G	DN	ABI-H2158
DM6X70G	MI	TTM42UJ
DM6X70G	MN	Hepatitis B virus Capsid protein (HBV C)
DM6X70G	MT	DTT
DM6X70G	MA	Inhibitor
DM6X70G	RN	Clinical pipeline report, company report or official report of Assembly Biosciences.
DM6X70G	RU	https://www.assemblybio.com/pipeline/

DMTCXSG	DI	DMTCXSG
DMTCXSG	DN	Abituzumab
DMTCXSG	MI	TTT1R2L
DMTCXSG	MN	Integrin alpha-V (ITGAV)
DMTCXSG	MT	DTT
DMTCXSG	RN	Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. Ann Oncol. 2015 Jan;26(1):132-40.
DMTCXSG	RU	https://pubmed.ncbi.nlm.nih.gov/25319061

DM23UQ9	DI	DM23UQ9
DM23UQ9	DN	ABT-122
DM23UQ9	MI	TTG0MT6
DM23UQ9	MN	Interleukin-17 (IL17)
DM23UQ9	MT	DTT
DM23UQ9	MA	Modulator
DM23UQ9	RN	DOI: 10.1136/annrheumdis-2015-eular.4042
DM23UQ9	RU	http://ard.bmj.com/content/74/Suppl_2/479.2.abstract

DM23UQ9	DI	DM23UQ9
DM23UQ9	DN	ABT-122
DM23UQ9	MI	TTF8CQI
DM23UQ9	MN	Tumor necrosis factor (TNF)
DM23UQ9	MT	DTT
DM23UQ9	MA	Modulator
DM23UQ9	RN	DOI: 10.1136/annrheumdis-2015-eular.4042
DM23UQ9	RU	http://ard.bmj.com/content/74/Suppl_2/479.2.abstract

DM2OS51	DI	DM2OS51
DM2OS51	DN	ABT-126
DM2OS51	MI	TTLA931
DM2OS51	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DM2OS51	MT	DTT
DM2OS51	MA	Modulator
DM2OS51	RN	A phase 2 randomized, controlled trial of the alpha7 agonist ABT-126 in mild-to-moderate Alzheimer's dementia. Alzheimer's & Dementia: Translational Research & Clinical Interventions Volume 1, Issue 1, June 2015, Pages 81-90.
DM2OS51	RU	http://www.sciencedirect.com/science/article/pii/S2352873715000104

DMN3S1B	DI	DMN3S1B
DMN3S1B	DN	ABT-229
DMN3S1B	MI	TTQ6VDM
DMN3S1B	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMN3S1B	MT	DTT
DMN3S1B	MA	Inhibitor
DMN3S1B	RN	9-Dihydroerythromycin ethers as motilin agonists--developing structure-activity relationships for potency and safety. Bioorg Med Chem. 2010 Nov 1;18(21):7651-8.
DMN3S1B	RU	https://pubmed.ncbi.nlm.nih.gov/20869254

DM7X54F	DI	DM7X54F
DM7X54F	DN	ABT-288
DM7X54F	MI	TT9JNIC
DM7X54F	MN	Histamine H3 receptor (H3R)
DM7X54F	MT	DTT
DM7X54F	MA	Modulator
DM7X54F	RN	A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer's dementia.J Alzheimers Dis.2014;42(3):959-71.
DM7X54F	RU	https://www.ncbi.nlm.nih.gov/pubmed/25024314

DM6WN2D	DI	DM6WN2D
DM6WN2D	DN	ABT-308
DM6WN2D	MI	TTMPZ7V
DM6WN2D	MN	Interleukin 13 receptor alpha-2 (IL13RA2)
DM6WN2D	MT	DTT
DM6WN2D	MA	Antagonist
DM6WN2D	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM6WN2D	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DMMZOYN	DI	DMMZOYN
DMMZOYN	DN	ABT-348
DMMZOYN	MI	TTPS3C0
DMMZOYN	MN	Aurora kinase A (AURKA)
DMMZOYN	MT	DTT
DMMZOYN	MA	Modulator
DMMZOYN	RN	Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. J Pharmacol Exp Ther. 2012 Dec;343(3):617-27.
DMMZOYN	RU	https://pubmed.ncbi.nlm.nih.gov/22935731

DMMZOYN	DI	DMMZOYN
DMMZOYN	DN	ABT-348
DMMZOYN	MI	TT5LS6T
DMMZOYN	MN	Aurora kinase B (AURKB)
DMMZOYN	MT	DTT
DMMZOYN	MA	Modulator
DMMZOYN	RN	Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. J Pharmacol Exp Ther. 2012 Dec;343(3):617-27.
DMMZOYN	RU	https://pubmed.ncbi.nlm.nih.gov/22935731

DMMZOYN	DI	DMMZOYN
DMMZOYN	DN	ABT-348
DMMZOYN	MI	TTLYXIT
DMMZOYN	MN	Aurora kinase C (AURKC)
DMMZOYN	MT	DTT
DMMZOYN	MA	Modulator
DMMZOYN	RN	Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. J Pharmacol Exp Ther. 2012 Dec;343(3):617-27.
DMMZOYN	RU	https://pubmed.ncbi.nlm.nih.gov/22935731

DM7XW5Y	DI	DM7XW5Y
DM7XW5Y	DN	ABT-384
DM7XW5Y	MI	DE4LYSA
DM7XW5Y	MN	Cytochrome P450 3A4 (CYP3A4)
DM7XW5Y	MT	DME
DM7XW5Y	MA	Metabolism
DM7XW5Y	RN	Effect of ketoconazole on the pharmacokinetics of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor ABT-384 and its two active metabolites in healthy volunteers: population analysis of data from a drug-drug interaction study. Drug Metab Dispos. 2013 May;41(5):1035-45.
DM7XW5Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23431112

DMGUTPN	DI	DMGUTPN
DMGUTPN	DN	ABT-414
DMGUTPN	MI	TTGKNB4
DMGUTPN	MN	Epidermal growth factor receptor (EGFR)
DMGUTPN	MT	DTT
DMGUTPN	RN	Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development. Mar Drugs. 2014 January; 12(1): 255-278.
DMGUTPN	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3917273/

DMNAU1V	DI	DMNAU1V
DMNAU1V	DN	ABT-436
DMNAU1V	MI	TTL9MHW
DMNAU1V	MN	Vasopressin V1b receptor (V1BR)
DMNAU1V	MT	DTT
DMNAU1V	MA	Modulator
DMNAU1V	RN	The vasopressin Avprlb receptor: Molecular and pharmacological studies. Stress. 2011 January; 14(1): 98-115.
DMNAU1V	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016603/

DMFW860	DI	DMFW860
DMFW860	DN	ABT-450
DMFW860	MI	TT5FNQT
DMFW860	MN	Human immunodeficiency virus Protease (HIV PR)
DMFW860	MT	DTT
DMFW860	MA	Inhibitor
DMFW860	RN	Clinical pipeline report, company report or official report of Abbott Laboratories (2011)
DMFW860	RU	http://www.abbott.com/index2.htm

DMPDVM8	DI	DMPDVM8
DMPDVM8	DN	ABT-510
DMPDVM8	MI	TTKI0H1
DMPDVM8	MN	Thrombospondin-1 (THBS1)
DMPDVM8	MT	DTT
DMPDVM8	MA	Modulator
DMPDVM8	RN	A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am J Clin Oncol. 2007 Jun;30(3):303-9.
DMPDVM8	RU	https://pubmed.ncbi.nlm.nih.gov/17551310

DMEWQ4X	DI	DMEWQ4X
DMEWQ4X	DN	ABT-639
DMEWQ4X	MI	TTZPWGN
DMEWQ4X	MN	Voltage-gated calcium channel alpha Cav3.2 (CACNA1H)
DMEWQ4X	MT	DTT
DMEWQ4X	MA	Modulator
DMEWQ4X	RN	Effects of a T-type calcium channel blocker, ABT-639, on spontaneous activity in C-nociceptors in patients with painful diabetic neuropathy: a randomized controlled trial. Pain. 2015 Nov;156(11):2175-83.
DMEWQ4X	RU	https://pubmed.ncbi.nlm.nih.gov/26035253

DMLEO2Z	DI	DMLEO2Z
DMLEO2Z	DN	ABT-652
DMLEO2Z	MI	TT9JNIC
DMLEO2Z	MN	Histamine H3 receptor (H3R)
DMLEO2Z	MT	DTT
DMLEO2Z	MA	Modulator
DMLEO2Z	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032225)
DMLEO2Z	RU	http://adisinsight.springer.com/drugs/800032225

DMNG35S	DI	DMNG35S
DMNG35S	DN	ABT-751
DMNG35S	MI	DED5UR3
DMNG35S	MN	Sulfotransferase 1B1 (SULT1B1)
DMNG35S	MT	DME
DMNG35S	MA	Metabolism
DMNG35S	RN	Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751. Pharmacogenet Genomics. 2013 Jul;23(7):374-81.
DMNG35S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23670235

DMNG35S	DI	DMNG35S
DMNG35S	DN	ABT-751
DMNG35S	MI	TTYFKSZ
DMNG35S	MN	Tubulin beta (TUBB)
DMNG35S	MT	DTT
DMNG35S	MA	Modulator
DMNG35S	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMNG35S	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMNG35S	DI	DMNG35S
DMNG35S	DN	ABT-751
DMNG35S	MI	DEYGVN4
DMNG35S	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMNG35S	MT	DME
DMNG35S	MA	Metabolism
DMNG35S	RN	Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751. Pharmacogenet Genomics. 2013 Jul;23(7):374-81.
DMNG35S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23670235

DM6PTIX	DI	DM6PTIX
DM6PTIX	DN	ABT-981
DM6PTIX	MI	TTPM6HI
DM6PTIX	MN	Interleukin-1 alpha (IL1A)
DM6PTIX	MT	DTT
DM6PTIX	MA	Modulator
DM6PTIX	RN	Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1alpha and IL-1beta. MAbs. 2015;7(3):605-19.
DM6PTIX	RU	https://pubmed.ncbi.nlm.nih.gov/25764208

DM6PTIX	DI	DM6PTIX
DM6PTIX	DN	ABT-981
DM6PTIX	MI	TTRYK0X
DM6PTIX	MN	Interleukin-1 beta (IL1B)
DM6PTIX	MT	DTT
DM6PTIX	MA	Modulator
DM6PTIX	RN	Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1alpha and IL-1beta. MAbs. 2015;7(3):605-19.
DM6PTIX	RU	https://pubmed.ncbi.nlm.nih.gov/25764208

DM9Y1XB	DI	DM9Y1XB
DM9Y1XB	DN	ABT-RTA-408
DM9Y1XB	MI	TTA6ZN2
DM9Y1XB	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DM9Y1XB	MT	DTT
DM9Y1XB	MA	Modulator
DM9Y1XB	RN	National Cancer Institute Drug Dictionary (drug id 756624).
DM9Y1XB	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=756624

DM91U0R	DI	DM91U0R
DM91U0R	DN	ABX-EGF
DM91U0R	MI	TTGKNB4
DM91U0R	MN	Epidermal growth factor receptor (EGFR)
DM91U0R	MT	DTT
DM91U0R	RN	Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer. 2002 Mar 1;94(5):1593-611.
DM91U0R	RU	https://pubmed.ncbi.nlm.nih.gov/11920518

DMCZFMS	DI	DMCZFMS
DMCZFMS	DN	ABX-IL8
DMCZFMS	MI	TTCTE1G
DMCZFMS	MN	Interleukin-8 (IL8)
DMCZFMS	MT	DTT
DMCZFMS	RN	Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol. 2002 Jul;161(1):125-34.
DMCZFMS	RU	https://pubmed.ncbi.nlm.nih.gov/12107097

DMNVFZA	DI	DMNVFZA
DMNVFZA	DN	AC-1202
DMNVFZA	MI	TTNHYJL
DMNVFZA	MN	Ketogenesis (KG)
DMNVFZA	MT	DTT
DMNVFZA	MA	Modulator
DMNVFZA	RN	Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond). 2009 Aug 10;6:31.
DMNVFZA	RU	https://pubmed.ncbi.nlm.nih.gov/19664276

DMB0TNL	DI	DMB0TNL
DMB0TNL	DN	AC-201
DMB0TNL	MI	TTCQIBE
DMB0TNL	MN	Caspase-1 (CASP1)
DMB0TNL	MT	DTT
DMB0TNL	MA	Inhibitor
DMB0TNL	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMB0TNL	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMB0TNL	DI	DMB0TNL
DMB0TNL	DN	AC-201
DMB0TNL	MI	TTRYK0X
DMB0TNL	MN	Interleukin-1 beta (IL1B)
DMB0TNL	MT	DTT
DMB0TNL	MA	Inhibitor
DMB0TNL	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMB0TNL	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DM3TUBR	DI	DM3TUBR
DM3TUBR	DN	Acalabrutinib
DM3TUBR	MI	TTOWPER
DM3TUBR	MN	HUMAN bruton tyrosine kinase (BTK)
DM3TUBR	MT	DTT
DM3TUBR	MA	Inhibitor
DM3TUBR	RN	AstraZeneca initiates CALAVI clinical trial with Calquence against COVID-19
DM3TUBR	RU	https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-initiates-calavi-clinical-trial-with-calquence-against-covid-19.html

DM0FGDO	DI	DM0FGDO
DM0FGDO	DN	ACCLAIM
DM0FGDO	MI	TTCM4B3
DM0FGDO	MN	Nitric-oxide synthase endothelial (NOS3)
DM0FGDO	MT	DTT
DM0FGDO	MA	Stimulator
DM0FGDO	RN	CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
DM0FGDO	RU	http://www.centerwatch.com/

DMZ8PY0	DI	DMZ8PY0
DMZ8PY0	DN	ACE-031
DMZ8PY0	MI	TTSWPH8
DMZ8PY0	MN	Growth/differentiation factor 8 (GDF-8)
DMZ8PY0	MT	DTT
DMZ8PY0	MA	Inhibitor
DMZ8PY0	RN	A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve. 2013 Mar;47(3):416-23.
DMZ8PY0	RU	https://pubmed.ncbi.nlm.nih.gov/23169607

DMIVUFL	DI	DMIVUFL
DMIVUFL	DN	ACH-1625
DMIVUFL	MI	TT5FNQT
DMIVUFL	MN	Human immunodeficiency virus Protease (HIV PR)
DMIVUFL	MT	DTT
DMIVUFL	MA	Inhibitor
DMIVUFL	RN	Clinical pipeline report, company report or official report of Achillion (2011).
DMIVUFL	RU	http://www.achillion.com/main.aspx?pn=ProductPipeline&fl=l

DM0RPY5	DI	DM0RPY5
DM0RPY5	DN	ACH-3102
DM0RPY5	MI	TTCJ2X8
DM0RPY5	MN	Hepatitis C virus Non-structural 5A (HCV NS5A)
DM0RPY5	MT	DTT
DM0RPY5	MA	Modulator
DM0RPY5	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM0RPY5	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMLVCZR	DI	DMLVCZR
DMLVCZR	DN	ACH-4471
DMLVCZR	MI	TT8D13I
DMLVCZR	MN	Complement factor D (CFD)
DMLVCZR	MT	DTT
DMLVCZR	MA	Inhibitor
DMLVCZR	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMLVCZR	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMPR8E9	DI	DMPR8E9
DMPR8E9	DN	ACP-001
DMPR8E9	MI	TTT3YKH
DMPR8E9	MN	Somatotropin (GH1)
DMPR8E9	MT	DTT
DMPR8E9	MA	Modulator
DMPR8E9	RN	ClinicalTrials.gov (NCT01947907) Safety, PK/PD and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD). U.S. National Institutes of Health.
DMPR8E9	RU	https://clinicaltrials.gov/ct2/show/NCT01947907

DMMG61B	DI	DMMG61B
DMMG61B	DN	ACT-GRO-777
DMMG61B	MI	TTCSZH7
DMMG61B	MN	Nucleolin (NCL)
DMMG61B	MT	DTT
DMMG61B	RN	Nucleic Acid Aptamers as Potential Therapeutic and Diagnostic Agents for Lymphoma. J Cancer Ther. 2013 June 1; 4(4): 872-890.
DMMG61B	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4104705/

DMKBIPR	DI	DMKBIPR
DMKBIPR	DN	Actimab-A
DMKBIPR	MI	TTJVYO3
DMKBIPR	MN	Myeloid cell surface antigen CD33 (CD33)
DMKBIPR	MT	DTT
DMKBIPR	MA	Inhibitor
DMKBIPR	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMKBIPR	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM9GRTK	DI	DM9GRTK
DM9GRTK	DN	ACYLINE
DM9GRTK	MI	TT8R70G
DM9GRTK	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DM9GRTK	MT	DTT
DM9GRTK	MA	Inhibitor
DM9GRTK	RN	Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77.
DM9GRTK	RU	https://pubmed.ncbi.nlm.nih.gov/17402723

DMLV9GS	DI	DMLV9GS
DMLV9GS	DN	AD04
DMLV9GS	MI	TTNXLKE
DMLV9GS	MN	5-HT 3 receptor (5HT3R)
DMLV9GS	MT	DTT
DMLV9GS	MA	Antagonist
DMLV9GS	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMLV9GS	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMMFLXN	DI	DMMFLXN
DMMFLXN	DN	AD-452
DMMFLXN	MI	TTXM6JN
DMMFLXN	MN	Cytokine receptor unspecific (CRF)
DMMFLXN	MT	DTT
DMMFLXN	MA	Modulator
DMMFLXN	RN	Detection of apoptosis by RT-PCR array in mefloquine-induced cochlear damage. Journal of Otology Volume 6, Issue 1, June 2011, Pages 1-9.
DMMFLXN	RU	http://www.sciencedirect.com/science/article/pii/S1672293011500017

DM8GHIX	DI	DM8GHIX
DM8GHIX	DN	ADC-3680
DM8GHIX	MI	TTQDMX5
DM8GHIX	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DM8GHIX	MT	DTT
DM8GHIX	MA	Antagonist
DM8GHIX	RN	Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugs. Expert Opin Investig Drugs. 2014 Jan;23(1):55-66.
DM8GHIX	RU	https://pubmed.ncbi.nlm.nih.gov/24073896

DM821BS	DI	DM821BS
DM821BS	DN	Adipiplon
DM821BS	MI	TT37EDJ
DM821BS	MN	GABA(A) receptor alpha-3 (GABRA3)
DM821BS	MT	DTT
DM821BS	MA	Modulator
DM821BS	RN	Discriminative stimulus properties of GABAA receptor positive allosteric modulators TPA023, ocinaplon and NG2-73 in rats trained to discriminate chlordiazepoxide or zolpidem. Eur J Pharmacol. 2011 Oct 1;668(1-2):190-3.
DM821BS	RU	https://pubmed.ncbi.nlm.nih.gov/21762686

DMMUPTN	DI	DMMUPTN
DMMUPTN	DN	ADL-5747
DMMUPTN	MI	TT27RFC
DMMUPTN	MN	Opioid receptor delta (OPRD1)
DMMUPTN	MT	DTT
DMMUPTN	MA	Agonist
DMMUPTN	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317).
DMMUPTN	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=317

DMDQH9A	DI	DMDQH9A
DMDQH9A	DN	ADL-5859
DMDQH9A	MI	TT27RFC
DMDQH9A	MN	Opioid receptor delta (OPRD1)
DMDQH9A	MT	DTT
DMDQH9A	MA	Agonist
DMDQH9A	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317).
DMDQH9A	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=317

DM819CO	DI	DM819CO
DM819CO	DN	ADMVA
DM819CO	MI	TTFBNVI
DM819CO	MN	Aldose reductase (AKR1B1)
DM819CO	MT	DTT
DM819CO	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2768).
DM819CO	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2768

DMJSWXL	DI	DMJSWXL
DMJSWXL	DN	Ad-p53
DMJSWXL	MI	TT7SBF5
DMJSWXL	MN	Cellular tumor antigen p53 (TP53)
DMJSWXL	MT	DTT
DMJSWXL	MA	Modulator
DMJSWXL	RN	Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer. Cancer Gene Ther. 2003 Mar;10(3):224-38.
DMJSWXL	RU	https://pubmed.ncbi.nlm.nih.gov/12637944

DMRYH3M	DI	DMRYH3M
DMRYH3M	DN	ADP-A2M4
DMRYH3M	MI	TT9EQUY
DMRYH3M	MN	Melanoma-associated antigen 4 (MAGEA4)
DMRYH3M	MT	DTT
DMRYH3M	RN	Clinical pipeline report, company report or official report of Adaptimmune.
DMRYH3M	RU	https://www.adaptimmune.com/pipeline/adp-a2m4

DME384W	DI	DME384W
DME384W	DN	AdPEDR
DME384W	MI	TTR59S1
DME384W	MN	Pigment epithelium-derived factor (SERPINF1)
DME384W	MT	DTT
DME384W	MA	Inhibitor
DME384W	RN	Future pharmacological treatment options for nonexudative and exudative age-related macular degeneration. Expert Opin Emerg Drugs. 2005 Feb;10(1):119-35.
DME384W	RU	https://pubmed.ncbi.nlm.nih.gov/15757408

DMCNTFW	DI	DMCNTFW
DMCNTFW	DN	Ad-RTS-hIL-12
DMCNTFW	MI	TTG68FB
DMCNTFW	MN	Interleukine 12 (IL-12)
DMCNTFW	MT	DTT
DMCNTFW	MA	Replacement
DMCNTFW	RN	Clinical pipeline report, company report or official report of Ziopharm Oncology.
DMCNTFW	RU	https://ziopharm.com/controlled-il-12/

DMM6B2Y	DI	DMM6B2Y
DMM6B2Y	DN	ADU- S100
DMM6B2Y	MI	TTT402Y
DMM6B2Y	MN	Stimulator of interferon genes protein (TMEM173)
DMM6B2Y	MT	DTT
DMM6B2Y	MA	Agonist
DMM6B2Y	RN	Magnitude of Therapeutic STING Activation Determines CD8 + T Cell-Mediated Anti-tumor Immunity. Cell Rep. 2018 Dec 11;25(11):3074-3085.e5.
DMM6B2Y	RU	https://pubmed.ncbi.nlm.nih.gov/30540940

DM8HBUI	DI	DM8HBUI
DM8HBUI	DN	ADU-S100
DM8HBUI	MI	TTT402Y
DM8HBUI	MN	Stimulator of interferon genes protein (TMEM173)
DM8HBUI	MT	DTT
DM8HBUI	MA	Activator
DM8HBUI	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM8HBUI	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMGVKHQ	DI	DMGVKHQ
DMGVKHQ	DN	ADX10059
DMGVKHQ	MI	TTHS256
DMGVKHQ	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMGVKHQ	MT	DTT
DMGVKHQ	MA	Modulator
DMGVKHQ	RN	A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and... Gut. 2009 Sep;58(9):1192-9.
DMGVKHQ	RU	https://pubmed.ncbi.nlm.nih.gov/19460767

DMC8NAO	DI	DMC8NAO
DMC8NAO	DN	ADXS-HPV
DMC8NAO	MI	TT3CPZW
DMC8NAO	MN	Human papillomavirus protein E7 (HPV E7)
DMC8NAO	MT	DTT
DMC8NAO	RN	ADXS11-001 immunotherapy targeting HPV-E7: updated survival and safety data from a phase 2 study in Indian women with recurrent/refractory cervical cancer. Journal for ImmunoTherapy of Cancer, 2013, 1(Suppl 1):P231.
DMC8NAO	RU	http://www.immunotherapyofcancer.org/content/1/S1/P231

DMJVN89	DI	DMJVN89
DMJVN89	DN	AEB07
DMJVN89	MI	TTYVX59
DMJVN89	MN	Protein kinase C (PRKC)
DMJVN89	MT	DTT
DMJVN89	MA	Inhibitor
DMJVN89	RN	What's next in the pipeline. Am J Transplant. 2008 Oct;8(10):1972-81.
DMJVN89	RU	https://pubmed.ncbi.nlm.nih.gov/18828764

DMQ1GH4	DI	DMQ1GH4
DMQ1GH4	DN	AEF0117
DMQ1GH4	MI	TT6OEDT
DMQ1GH4	MN	Cannabinoid receptor 1 (CB1)
DMQ1GH4	MT	DTT
DMQ1GH4	MA	Antagonist
DMQ1GH4	RN	Clinical pipeline report, company report or official report of Affimed Therapeutics.
DMQ1GH4	RU	https://brain.labex.u-bordeaux.fr/Actions/Focus/CannaPreg-i6901.html

DMSBLOU	DI	DMSBLOU
DMSBLOU	DN	AEG-33773
DMSBLOU	MI	TTHYBIX
DMSBLOU	MN	Heat shock protein 70 (HSP70)
DMSBLOU	MT	DTT
DMSBLOU	MA	Inhibitor
DMSBLOU	RN	Mitogen-activated protein kinase kinase kinase 12 (MAP3K12; DLK); c-jun N-terminal kinase (JNK). SciBX 2(11); doi:10.1038/scibx.2009.462. March 19 2009
DMSBLOU	RU	http://www.nature.com/scibx/journal/v2/n11/full/scibx.2009.462.html

DMI5TXZ	DI	DMI5TXZ
DMI5TXZ	DN	AEM-28
DMI5TXZ	MI	TTKS9CB
DMI5TXZ	MN	Apolipoprotein E (APOE)
DMI5TXZ	MT	DTT
DMI5TXZ	MA	Modulator
DMI5TXZ	RN	Clinical pipeline report, company report or official report of LipimetiX.
DMI5TXZ	RU	http://www.lipimetix.com/technology.html

DMNO7BC	DI	DMNO7BC
DMNO7BC	DN	AeroLEF
DMNO7BC	MI	TTN4QDT
DMNO7BC	MN	Opioid receptor (OPR)
DMNO7BC	MT	DTT
DMNO7BC	MA	Agonist
DMNO7BC	RN	Current Research on Opioid Receptor Function. Curr Drug Targets. 2012 February; 13(2): 230-246.
DMNO7BC	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3371376/

DMFO2G5	DI	DMFO2G5
DMFO2G5	DN	Afabicin
DMFO2G5	MI	TTZBRVL
DMFO2G5	MN	Staphylococcus Enoyl ACP reductase (Stap-coc fabI)
DMFO2G5	MT	DTT
DMFO2G5	MA	Inhibitor
DMFO2G5	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMFO2G5	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMFORDT	DI	DMFORDT
DMFORDT	DN	Afimoxifene
DMFORDT	MI	TTZAYWL
DMFORDT	MN	Estrogen receptor (ESR)
DMFORDT	MT	DTT
DMFORDT	MA	Modulator
DMFORDT	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620).
DMFORDT	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=620

DMFORDT	DI	DMFORDT
DMFORDT	DN	Afimoxifene
DMFORDT	MI	DTUGYRD
DMFORDT	MN	P-glycoprotein 1 (ABCB1)
DMFORDT	MT	DTP
DMFORDT	MA	Substrate
DMFORDT	RN	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
DMFORDT	RU	http://www.ncbi.nlm.nih.gov/pubmed/7914405

DMFORDT	DI	DMFORDT
DMFORDT	DN	Afimoxifene
DMFORDT	MI	DEYGVN4
DMFORDT	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMFORDT	MT	DME
DMFORDT	MA	Metabolism
DMFORDT	RN	Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos. 2007 Nov;35(11):2006-14.
DMFORDT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17664247

DMFORDT	DI	DMFORDT
DMFORDT	DN	Afimoxifene
DMFORDT	MI	DE2GB8N
DMFORDT	MN	UDP-glucuronosyltransferase 1A8 (UGT1A8)
DMFORDT	MT	DME
DMFORDT	MA	Metabolism
DMFORDT	RN	Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos. 2007 Nov;35(11):2006-14.
DMFORDT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17664247

DMN45IC	DI	DMN45IC
DMN45IC	DN	AFM13
DMN45IC	MI	TTIFOC0
DMN45IC	MN	Immunoglobulin gamma Fc receptor IIIA (FCGR3A)
DMN45IC	MT	DTT
DMN45IC	RN	Clinical pipeline report, company report or official report of Affimed Therapeutics.
DMN45IC	RU	https://www.affimed.com/rock-platform/pipeline/

DMN45IC	DI	DMN45IC
DMN45IC	DN	AFM13
DMN45IC	MI	TT2GM5R
DMN45IC	MN	Lymphocyte activation antigen CD30 (TNFRSF8)
DMN45IC	MT	DTT
DMN45IC	RN	Clinical pipeline report, company report or official report of Affimed Therapeutics.
DMN45IC	RU	https://www.affimed.com/rock-platform/pipeline/

DMTFE9Y	DI	DMTFE9Y
DMTFE9Y	DN	AFN-1252
DMTFE9Y	MI	TTZBRVL
DMTFE9Y	MN	Staphylococcus Enoyl ACP reductase (Stap-coc fabI)
DMTFE9Y	MT	DTT
DMTFE9Y	MA	Inhibitor
DMTFE9Y	RN	Activity of AFN-1252, a novel FabI inhibitor, against Staphylococcus aureus in an in vitro pharmacodynamic model simulating human pharmacokinetics. J Chemother. 2013 Feb;25(1):32-5.
DMTFE9Y	RU	https://pubmed.ncbi.nlm.nih.gov/23433442

DM6AJKC	DI	DM6AJKC
DM6AJKC	DN	AFN-1720
DM6AJKC	MI	TTVTX4N
DM6AJKC	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DM6AJKC	MT	DTT
DM6AJKC	MA	Inhibitor
DM6AJKC	RN	Affinium Pharmaceuticals Announces the Initiation of a Phase 1 Intravenous Clinical Trial of a New Antibiotic Prodrug, and the Closing of a Follow-on Financing Round. PR Newswire Sep. 4, 2013 10:16 PM.
DM6AJKC	RU	http://www.virtualizationconference.com/node/2779672

DM1FJ2B	DI	DM1FJ2B
DM1FJ2B	DN	AFP464
DM1FJ2B	MI	TT2QPV9
DM1FJ2B	MN	Aryl hydrocarbon receptor signaling pathway (AhR pathway)
DM1FJ2B	MT	DTT
DM1FJ2B	MA	Suppressor
DM1FJ2B	RN	Clinical pipeline report, company report or official report of AFP464.
DM1FJ2B	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/afp464

DMD3XMG	DI	DMD3XMG
DMD3XMG	DN	AFTVac
DMD3XMG	MI	TT6MP2Z
DMD3XMG	MN	GMCSFR-alpha (CSF2RA)
DMD3XMG	MT	DTT
DMD3XMG	RN	Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res. 2004 Mar 1;10(5):1574-9.
DMD3XMG	RU	https://pubmed.ncbi.nlm.nih.gov/15014006

DMD3XMG	DI	DMD3XMG
DMD3XMG	DN	AFTVac
DMD3XMG	MI	TT9721Y
DMD3XMG	MN	Interleukin 2 receptor beta (IL2RB)
DMD3XMG	MT	DTT
DMD3XMG	RN	Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res. 2004 Mar 1;10(5):1574-9.
DMD3XMG	RU	https://pubmed.ncbi.nlm.nih.gov/15014006

DMA9FKY	DI	DMA9FKY
DMA9FKY	DN	AG140699
DMA9FKY	MI	TTVDSZ0
DMA9FKY	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMA9FKY	MT	DTT
DMA9FKY	MA	Inhibitor
DMA9FKY	RN	Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov. 2005 May;4(5):421-40.
DMA9FKY	RU	https://pubmed.ncbi.nlm.nih.gov/15864271

DMNQ5T2	DI	DMNQ5T2
DMNQ5T2	DN	AG-858
DMNQ5T2	MI	TTHYBIX
DMNQ5T2	MN	Heat shock protein 70 (HSP70)
DMNQ5T2	MT	DTT
DMNQ5T2	RN	Preparation of a Heat Shock Proteins 70-based Vaccine from DC-tumor fusion cells. Methods Mol Biol. 2011; 787: 255-265.
DMNQ5T2	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4088345/

DMPO7UG	DI	DMPO7UG
DMPO7UG	DN	AGEN2034
DMPO7UG	MI	TTNBFWK
DMPO7UG	MN	Programmed cell death protein 1 (PD-1)
DMPO7UG	MT	DTT
DMPO7UG	MA	Inhibitor
DMPO7UG	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPO7UG	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMP5Y1A	DI	DMP5Y1A
DMP5Y1A	DN	AGN-199981
DMP5Y1A	MI	TTWM4TY
DMP5Y1A	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMP5Y1A	MT	DTT
DMP5Y1A	MA	Agonist
DMP5Y1A	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DMP5Y1A	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DM4KOAC	DI	DM4KOAC
DM4KOAC	DN	AGN-241751
DM4KOAC	MI	TT9IK2Z
DM4KOAC	MN	N-methyl-D-aspartate receptor (NMDAR)
DM4KOAC	MT	DTT
DM4KOAC	MA	Modulator
DM4KOAC	RN	Positive modulation of NMDA receptors by AGN-241751 exerts rapid antidepressant-like effects via excitatory neurons. Neuropsychopharmacology. 2021 Mar;46(4):799-808.
DM4KOAC	RU	https://pubmed.ncbi.nlm.nih.gov/33059355

DMLQRFO	DI	DMLQRFO
DMLQRFO	DN	AGN-2979
DMLQRFO	MI	TTZSJHV
DMLQRFO	MN	Tryptophan 5-hydroxylase 1 (TPH1)
DMLQRFO	MT	DTT
DMLQRFO	MA	Modulator
DMLQRFO	RN	Antidepressant-like action of AGN 2979, a tryptophan hydroxylase activation inhibitor, in a chronic mild stress model of depression in rats. Eur Neuropsychopharmacol. 2001 Oct;11(5):351-7.
DMLQRFO	RU	https://pubmed.ncbi.nlm.nih.gov/11597821

DMMGAUK	DI	DMMGAUK
DMMGAUK	DN	AGN-XX/YY
DMMGAUK	MI	TT2NUT5
DMMGAUK	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMMGAUK	MT	DTT
DMMGAUK	MA	Agonist
DMMGAUK	RN	Patent WO2008058220 A2.
DMMGAUK	RU	http://www.google.com/patents/WO2008058220A2?cl=en

DM2POHA	DI	DM2POHA
DM2POHA	DN	AGS-16C3F
DM2POHA	MI	TTD4TKP
DM2POHA	MN	Phosphodiesterase I beta (ENPP3)
DM2POHA	MT	DTT
DM2POHA	MA	Inhibitor
DM2POHA	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM2POHA	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMMKASG	DI	DMMKASG
DMMKASG	DN	AGTC-0106
DMMKASG	MI	TTA7UJC
DMMKASG	MN	Alpha-1-antitrypsin (SERPINA1)
DMMKASG	MT	DTT
DMMKASG	MA	Modulator
DMMKASG	RN	First gene therapy nears landmark European market authorization. Nat Biotechnol. 2012 Sep;30(9):807-9.
DMMKASG	RU	https://pubmed.ncbi.nlm.nih.gov/22965030

DMXJ8Z4	DI	DMXJ8Z4
DMXJ8Z4	DN	AK104
DMXJ8Z4	MI	TTI2S1D
DMXJ8Z4	MN	Cytotoxic T-lymphocyte protein 4 (CTLA-4)
DMXJ8Z4	MT	DTT
DMXJ8Z4	MA	Inhibitor
DMXJ8Z4	RN	Clinical pipeline report, company report or official report of Akeso Biopharma.
DMXJ8Z4	RU	https://akesobio-umb.azurewebsites.net/en/rd-and-science/pipelines/

DMXJ8Z4	DI	DMXJ8Z4
DMXJ8Z4	DN	AK104
DMXJ8Z4	MI	TTNBFWK
DMXJ8Z4	MN	Programmed cell death protein 1 (PD-1)
DMXJ8Z4	MT	DTT
DMXJ8Z4	MA	Inhibitor
DMXJ8Z4	RN	Clinical pipeline report, company report or official report of Akeso Biopharma.
DMXJ8Z4	RU	https://akesobio-umb.azurewebsites.net/en/rd-and-science/pipelines/

DMKNRYH	DI	DMKNRYH
DMKNRYH	DN	AKB-9778
DMKNRYH	MI	TT9VGXW
DMKNRYH	MN	Angiopoietin 1 receptor (TEK)
DMKNRYH	MT	DTT
DMKNRYH	MA	Activator
DMKNRYH	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMKNRYH	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMKNRYH	DI	DMKNRYH
DMKNRYH	DN	AKB-9778
DMKNRYH	MI	TT64I9Q
DMKNRYH	MN	Protein tyrosine phosphatase beta (PTPRB)
DMKNRYH	MT	DTT
DMKNRYH	MA	Modulator
DMKNRYH	RN	Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression.J Natl Cancer Inst.2013 Aug 21;105(16):1188-201.
DMKNRYH	RU	https://www.ncbi.nlm.nih.gov/pubmed/23899555

DMR8W7Y	DI	DMR8W7Y
DMR8W7Y	DN	AKCEA-ANGPTL3-LRX
DMR8W7Y	MI	TTUO98L
DMR8W7Y	MN	Angiopoietin-related protein 3 (ANGPTL3)
DMR8W7Y	MT	DTT
DMR8W7Y	MA	Inhibitor
DMR8W7Y	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMR8W7Y	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMCTWIB	DI	DMCTWIB
DMCTWIB	DN	AL102
DMCTWIB	MI	TT9W8GU
DMCTWIB	MN	Gamma-secretase (GS)
DMCTWIB	MT	DTT
DMCTWIB	MA	Inhibitor
DMCTWIB	RN	Clinical pipeline report, company report or official report of Ayala Pharmaceuticals.
DMCTWIB	RU	https://www.ayalapharma.com/pipeline/investigational-therapies-al101-and-al102

DM3P91Z	DI	DM3P91Z
DM3P91Z	DN	Alacizumab pegol
DM3P91Z	MI	TTUTJGQ
DM3P91Z	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM3P91Z	MT	DTT
DM3P91Z	RN	Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2. Clin Cancer Res. 2007 Dec 1;13(23):7113-8.
DM3P91Z	RU	https://pubmed.ncbi.nlm.nih.gov/18056191

DM2U530	DI	DM2U530
DM2U530	DN	ALD-401
DM2U530	MI	TTFLN4T
DM2U530	MN	Mitochondrial aldehyde dehydrogenase (ALDH2)
DM2U530	MT	DTT
DM2U530	MA	Modulator
DM2U530	RN	A novel aldehyde dehydrogenase-3 activator leads to adult salivary stem cell enrichment in vivo. Clin Cancer Res. 2011 Dec 1;17(23):7265-72.
DM2U530	RU	https://pubmed.ncbi.nlm.nih.gov/21998334

DM6RBYT	DI	DM6RBYT
DM6RBYT	DN	ALD-403
DM6RBYT	MI	TTAFORY
DM6RBYT	MN	Calcitonin gene-related peptide (CALC)
DM6RBYT	MT	DTT
DM6RBYT	MA	Modulator
DM6RBYT	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM6RBYT	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMPWSBL	DI	DMPWSBL
DMPWSBL	DN	ALD-518
DMPWSBL	MI	TTT1V78
DMPWSBL	MN	Interleukin-6 (IL6)
DMPWSBL	MT	DTT
DMPWSBL	MA	Modulator
DMPWSBL	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMPWSBL	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMUA0XC	DI	DMUA0XC
DMUA0XC	DN	ALF-5755
DMUA0XC	MI	TTL4H8N
DMUA0XC	MN	Regenerating human pro-islet peptide (REG3A)
DMUA0XC	MT	DTT
DMUA0XC	MA	Modulator
DMUA0XC	RN	HIP/PAP prevents excitotoxic neuronal death and promotes plasticity. Ann Clin Transl Neurol. 2014 October; 1(10): 739-754.
DMUA0XC	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4241802/

DMR2YPF	DI	DMR2YPF
DMR2YPF	DN	ALG-1001
DMR2YPF	MI	TT9HKJA
DMR2YPF	MN	Vascular endothelial growth factor (VEGF)
DMR2YPF	MT	DTT
DMR2YPF	MA	Modulator
DMR2YPF	RN	Future therapies of wet age-related macular degeneration. J Ophthalmol. 2015;2015:138070.
DMR2YPF	RU	https://pubmed.ncbi.nlm.nih.gov/25802751

DME3ZYC	DI	DME3ZYC
DME3ZYC	DN	ALKS 4230
DME3ZYC	MI	TTAJU0S
DME3ZYC	MN	Interleukin 2 receptor (IL2R)
DME3ZYC	MT	DTT
DME3ZYC	MA	Agonist
DME3ZYC	RN	ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. J Immunother Cancer. 2020 Apr;8(1):e000673.
DME3ZYC	RU	https://pubmed.ncbi.nlm.nih.gov/32317293

DMF3QN1	DI	DMF3QN1
DMF3QN1	DN	ALKS33
DMF3QN1	MI	TTKWM86
DMF3QN1	MN	Opioid receptor mu (MOP)
DMF3QN1	MT	DTT
DMF3QN1	MA	Inhibitor
DMF3QN1	RN	Syntheses of novel high affinity ligands for opioid receptors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2289-94.
DMF3QN1	RU	https://pubmed.ncbi.nlm.nih.gov/19282177

DMWYMJN	DI	DMWYMJN
DMWYMJN	DN	ALN-CC5
DMWYMJN	MI	TT2LJRF
DMWYMJN	MN	C5 messenger RNA (C5 mRNA)
DMWYMJN	MT	DTT
DMWYMJN	MA	Inhibitor
DMWYMJN	RN	Investigational RNAi Therapeutic Targeting C5 Is Efficacious in Pre-clinical Models of Myasthenia Gravis. Mol Ther Methods Clin Dev. 2019 May 10;13:484-492.
DMWYMJN	RU	https://pubmed.ncbi.nlm.nih.gov/31193726

DMEYNQA	DI	DMEYNQA
DMEYNQA	DN	ALN-RSV01
DMEYNQA	MI	TTWSF5D
DMEYNQA	MN	HRSV Nucleoprotein messenger RNA (HRSV N mRNA)
DMEYNQA	MT	DTT
DMEYNQA	MA	Inhibitor
DMEYNQA	RN	Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res. 2008 Mar;77(3):225-31.
DMEYNQA	RU	https://pubmed.ncbi.nlm.nih.gov/18242722

DMJPV5X	DI	DMJPV5X
DMJPV5X	DN	Alovudine
DMJPV5X	MI	TT84ETX
DMJPV5X	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMJPV5X	MT	DTT
DMJPV5X	MA	Modulator
DMJPV5X	RN	Multiple-dose pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in patients with HIV-1 infection. Clin Drug Investig. 2008;28(2):129-38.
DMJPV5X	RU	https://www.ncbi.nlm.nih.gov/pubmed/18211121

DM5EFXZ	DI	DM5EFXZ
DM5EFXZ	DN	Alpha-1 antitrypsin
DM5EFXZ	MI	TT2WR1T
DM5EFXZ	MN	Cationic trypsinogen (PRSS1)
DM5EFXZ	MT	DTT
DM5EFXZ	MA	Modulator
DM5EFXZ	RN	US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT.
DM5EFXZ	RU	http://www.patentbuddy.com/Patent/20120251516?ft=true&sr=true

DMLBWT1	DI	DMLBWT1
DMLBWT1	DN	ALRN-6924
DMLBWT1	MI	TT9OUDQ
DMLBWT1	MN	p53-binding protein Mdm4 (MDM4)
DMLBWT1	MT	DTT
DMLBWT1	MA	Inhibitor
DMLBWT1	RN	Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612.
DMLBWT1	RU	https://pubmed.ncbi.nlm.nih.gov/30072728

DMLBWT1	DI	DMLBWT1
DMLBWT1	DN	ALRN-6924
DMLBWT1	MI	TT08GJW
DMLBWT1	MN	Ubiquitin-protein ligase E3 Mdm2 (MDM2)
DMLBWT1	MT	DTT
DMLBWT1	MA	Antagonist
DMLBWT1	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMLBWT1	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM9KL7P	DI	DM9KL7P
DM9KL7P	DN	ALT-801
DM9KL7P	MI	TT7SBF5
DM9KL7P	MN	Cellular tumor antigen p53 (TP53)
DM9KL7P	MT	DTT
DM9KL7P	MA	Immunomodulator (Immunostimulant)
DM9KL7P	RN	Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res. 2011 Dec 15;17(24):7765-75.
DM9KL7P	RU	https://pubmed.ncbi.nlm.nih.gov/21994418

DMK3U1X	DI	DMK3U1X
DMK3U1X	DN	ALT-803
DMK3U1X	MI	TTGN89I
DMK3U1X	MN	Interleukin 15 receptor alpha (IL15RA)
DMK3U1X	MT	DTT
DMK3U1X	MA	Agonist
DMK3U1X	RN	Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor alphaSu/Fc fusion complex in syngeneic murine models of multiple myeloma. Cancer Res. 2013 May 15;73(10):3075-86.
DMK3U1X	RU	https://pubmed.ncbi.nlm.nih.gov/23644531

DMGJ71F	DI	DMGJ71F
DMGJ71F	DN	ALT-836
DMGJ71F	MI	TT38MDJ
DMGJ71F	MN	Tissue factor (F3)
DMGJ71F	MT	DTT
DMGJ71F	MA	Inhibitor
DMGJ71F	RN	ImmunoPET of tissue factor expression in triple-negative breast cancer with a radiolabeled antibody Fab fragment. Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1295-303.
DMGJ71F	RU	https://pubmed.ncbi.nlm.nih.gov/25801992

DMLSK01	DI	DMLSK01
DMLSK01	DN	Altrakincept
DMLSK01	MI	TTDWHC3
DMLSK01	MN	Interleukin 4 receptor alpha (IL4R)
DMLSK01	MT	DTT
DMLSK01	MA	Modulator
DMLSK01	RN	The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. 
DMLSK01	RU	https://www.ncbi.nlm.nih.gov/pubmed/23197041

DMXSFA0	DI	DMXSFA0
DMXSFA0	DN	ALV-003
DMXSFA0	MI	TTNGKET
DMXSFA0	MN	Prolyl endopeptidase (PREP)
DMXSFA0	MT	DTT
DMXSFA0	MA	Modulator
DMXSFA0	RN	The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivo. Clin Immunol. 2010 Mar;134(3):289-95.
DMXSFA0	RU	https://pubmed.ncbi.nlm.nih.gov/19942485

DMO1VHC	DI	DMO1VHC
DMO1VHC	DN	ALX-0061
DMO1VHC	MI	TT0E5SK
DMO1VHC	MN	Interleukin 6 receptor (IL6R)
DMO1VHC	MT	DTT
DMO1VHC	RN	The preclinical pharmacology of the high affinity anti-IL-6R Nanobody ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Res Ther. 2015 May 20;17:135.
DMO1VHC	RU	https://pubmed.ncbi.nlm.nih.gov/25994180

DMCAFXM	DI	DMCAFXM
DMCAFXM	DN	ALX-101
DMCAFXM	MI	TTM1EQF
DMCAFXM	MN	Oxysterols receptor LXR (NR1H)
DMCAFXM	MT	DTT
DMCAFXM	MA	Agonist
DMCAFXM	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMCAFXM	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMV934L	DI	DMV934L
DMV934L	DN	ALX-40-4C
DMV934L	MI	TTT3ZC9
DMV934L	MN	Human immunodeficiency virus Tat protein (HIV tat)
DMV934L	MT	DTT
DMV934L	MA	Modulator
DMV934L	RN	Anti-human immunodeficiency virus type 1 activity of an oligocationic compound mediated via gp120 V3 interactions. J Virol. 1996 May;70(5):2825-31.
DMV934L	RU	https://pubmed.ncbi.nlm.nih.gov/8627756

DMH5LFR	DI	DMH5LFR
DMH5LFR	DN	ALXN6000
DMH5LFR	MI	TT0BE68
DMH5LFR	MN	Membrane glycoprotein OX2 (CD200)
DMH5LFR	MT	DTT
DMH5LFR	RN	American Society of Hematology, 52nd Annual Meeting and Exposition. P T. 2011 February; 36(2): 100-103.
DMH5LFR	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3086088/

DM7ZQAT	DI	DM7ZQAT
DM7ZQAT	DN	ALZ-801
DM7ZQAT	MI	TTE4KHA
DM7ZQAT	MN	Amyloid beta A4 protein (APP)
DM7ZQAT	MT	DTT
DM7ZQAT	MA	Inhibitor
DM7ZQAT	RN	Oral Clinical Candidate ALZ-801 in Alzheon's pipeline. 2012.
DM7ZQAT	RU	http://www.alzheon.com/?page_id=280

DM9UMSJ	DI	DM9UMSJ
DM9UMSJ	DN	AM001
DM9UMSJ	MI	TTOE7I0
DM9UMSJ	MN	Rap guanine nucleotide exchange factor 3 (RAPGEF3)
DM9UMSJ	MT	DTT
DM9UMSJ	MA	Inhibitor
DM9UMSJ	RN	Identification of a pharmacological inhibitor of Epac1 that protects the heart against acute and chronic models of cardiac stress. Cardiovasc Res. 2019 Oct 1;115(12):1766-1777.
DM9UMSJ	RU	https://pubmed.ncbi.nlm.nih.gov/30873562

DMGVQI8	DI	DMGVQI8
DMGVQI8	DN	AM-001
DMGVQI8	MI	TTRLW2X
DMGVQI8	MN	Fibroblast growth factor receptor 1 (FGFR1)
DMGVQI8	MT	DTT
DMGVQI8	MA	Antagonist
DMGVQI8	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029917)
DMGVQI8	RU	http://adisinsight.springer.com/drugs/800029917

DMBWNX5	DI	DMBWNX5
DMBWNX5	DN	AMA-76
DMBWNX5	MI	TTMQO60
DMBWNX5	MN	Rho-associated protein kinase (ROCK)
DMBWNX5	MT	DTT
DMBWNX5	MA	Modulator
DMBWNX5	RN	AMA0076, a novel, locally acting Rho kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia. Invest Ophthalmol Vis Sci. 2014 Feb 18;55(2):1006-16.
DMBWNX5	RU	https://pubmed.ncbi.nlm.nih.gov/24474276

DMEB3T9	DI	DMEB3T9
DMEB3T9	DN	Amdoxovir
DMEB3T9	MI	TT84ETX
DMEB3T9	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMEB3T9	MT	DTT
DMEB3T9	MA	Modulator
DMEB3T9	RN	Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118). Antivir Ther. 2006;11(5):619-23.
DMEB3T9	RU	https://www.ncbi.nlm.nih.gov/pubmed/16964830

DMIVZ3M	DI	DMIVZ3M
DMIVZ3M	DN	AME-133v
DMIVZ3M	MI	TTUE541
DMIVZ3M	MN	Leukocyte surface antigen Leu-16 (CD20)
DMIVZ3M	MT	DTT
DMIVZ3M	RN	Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcgammaRIIIa-genotyped patients with previously treated follicular lymphoma. Clin Cancer Res. 2012 Mar 1;18(5):1395-403.
DMIVZ3M	RU	https://pubmed.ncbi.nlm.nih.gov/22223529

DMUMCB9	DI	DMUMCB9
DMUMCB9	DN	Amelubant
DMUMCB9	MI	TTN53ZF
DMUMCB9	MN	Leukotriene B4 receptor 1 (LTB4R)
DMUMCB9	MT	DTT
DMUMCB9	MA	Antagonist
DMUMCB9	RN	Leukotriene receptor antagonists in children with cystic fibrosis lung disease : anti-inflammatory and clinical effects. Paediatr Drugs. 2005;7(6):353-63.
DMUMCB9	RU	https://pubmed.ncbi.nlm.nih.gov/16356023

DMGOFL3	DI	DMGOFL3
DMGOFL3	DN	AMG 151
DMGOFL3	MI	TTDLNGZ
DMGOFL3	MN	Glucokinase (GCK)
DMGOFL3	MT	DTT
DMGOFL3	MA	Inhibitor
DMGOFL3	RN	This week in therapeutics Endocrine disease. SciBX 2(37); doi:10.1038/scibx.2009.1408. Sept. 24, 2009
DMGOFL3	RU	http://www.nature.com/scibx/journal/v2/n37/pdf/scibx.2009.1408.pdf

DMPQHOR	DI	DMPQHOR
DMPQHOR	DN	AMG 208
DMPQHOR	MI	TTNDSF4
DMPQHOR	MN	Proto-oncogene c-Met (MET)
DMPQHOR	MT	DTT
DMPQHOR	MA	Modulator
DMPQHOR	RN	A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors. Oncotarget. 2015 Jul 30;6(21):18693-706.
DMPQHOR	RU	https://pubmed.ncbi.nlm.nih.gov/26155941

DM65PTO	DI	DM65PTO
DM65PTO	DN	AMG 232
DM65PTO	MI	TT08GJW
DM65PTO	MN	Ubiquitin-protein ligase E3 Mdm2 (MDM2)
DM65PTO	MT	DTT
DM65PTO	MA	Modulator
DM65PTO	RN	Discovery of a small molecule MDM2 inhibitor (AMG 232) for treating cancer. J Med Chem. 2014 Aug 14;57(15):6332-41.
DM65PTO	RU	https://pubmed.ncbi.nlm.nih.gov/24967612

DMO72IF	DI	DMO72IF
DMO72IF	DN	AMG 301
DMO72IF	MI	TT5OREU
DMO72IF	MN	PACAP type I receptor (PAC1R)
DMO72IF	MT	DTT
DMO72IF	MA	Inhibitor
DMO72IF	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMO72IF	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMI3WFG	DI	DMI3WFG
DMI3WFG	DN	AMG 334
DMI3WFG	MI	TTY6O0Q
DMI3WFG	MN	Calcitonin gene-related peptide receptor (CGRPR)
DMI3WFG	MT	DTT
DMI3WFG	MA	Modulator
DMI3WFG	RN	EHMTI-0315. AMG 334, the first potent and selective human monoclonal antibody antagonist against the CGRP receptor. J Headache Pain. 2014; 15(Suppl 1): G43.
DMI3WFG	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4182181/

DMIOUEY	DI	DMIOUEY
DMIOUEY	DN	AMG 337
DMIOUEY	MI	TTNDSF4
DMIOUEY	MN	Proto-oncogene c-Met (MET)
DMIOUEY	MT	DTT
DMIOUEY	MA	Modulator
DMIOUEY	RN	J Clin Oncol 32:5s, 2014 (suppl; abstr 2508).
DMIOUEY	RU	http://meetinglibrary.asco.org/content/127112-144

DM0DRAZ	DI	DM0DRAZ
DM0DRAZ	DN	AMG 479
DM0DRAZ	MI	TTHRID2
DM0DRAZ	MN	Insulin-like growth factor I receptor (IGF1R)
DM0DRAZ	MT	DTT
DM0DRAZ	MA	Inhibitor
DM0DRAZ	RN	Clinical pipeline report, company report or official report of Amgen (2009).
DM0DRAZ	RU	http://www.amgen.com/science/pipe.jsp

DME6QH1	DI	DME6QH1
DME6QH1	DN	AMG 557
DME6QH1	MI	TTB9Z8R
DME6QH1	MN	B7-related protein 1 (B7RP1)
DME6QH1	MT	DTT
DME6QH1	MA	Modulator
DME6QH1	RN	Administration Of AMG 557, A Human Anti-B7RP-1 (ICOSL) Antibody, Leads To The Selective Inhibition Of Anti-KLH IgG Responses In Subjects With SLE: Results Of A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Sequential, Rising, Multiple-Dose Study. San Diego, CA October 25-30, 2013
DME6QH1	RU	http://www.blackwellpublishing.com/acrmeeting/abstract.asp?MeetingID=799&id=109110

DMY1XJH	DI	DMY1XJH
DMY1XJH	DN	AMG 570
DMY1XJH	MI	TTB9Z8R
DMY1XJH	MN	B7-related protein 1 (B7RP1)
DMY1XJH	MT	DTT
DMY1XJH	MA	Inhibitor
DMY1XJH	RN	Development of an ICOSL and BAFF bispecific inhibitor AMG 570 for systemic lupus erythematosus treatment. Clin Exp Rheumatol. Nov-Dec 2019;37(6):906-914.
DMY1XJH	RU	https://pubmed.ncbi.nlm.nih.gov/30789152

DMY1XJH	DI	DMY1XJH
DMY1XJH	DN	AMG 570
DMY1XJH	MI	TTWMIDN
DMY1XJH	MN	B-cell-activating factor (TNFSF13B)
DMY1XJH	MT	DTT
DMY1XJH	MA	Inhibitor
DMY1XJH	RN	Development of an ICOSL and BAFF bispecific inhibitor AMG 570 for systemic lupus erythematosus treatment. Clin Exp Rheumatol. Nov-Dec 2019;37(6):906-914.
DMY1XJH	RU	https://pubmed.ncbi.nlm.nih.gov/30789152

DMFXN2T	DI	DMFXN2T
DMFXN2T	DN	AMG 745
DMFXN2T	MI	TTSWPH8
DMFXN2T	MN	Growth/differentiation factor 8 (GDF-8)
DMFXN2T	MT	DTT
DMFXN2T	MA	Antagonist
DMFXN2T	RN	The role of myostatin in muscle wasting: an overview. J Cachexia Sarcopenia Muscle. 2011 September; 2(3): 143-151.
DMFXN2T	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3177043/

DMWPGB8	DI	DMWPGB8
DMWPGB8	DN	Amg 747
DMWPGB8	MI	TTHJTF7
DMWPGB8	MN	Glycine transporter GlyT-1 (SLC6A9)
DMWPGB8	MT	DTT
DMWPGB8	MA	Modulator
DMWPGB8	RN	Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain. Nat Rev Drug Discov. 2013 Nov;12(11):866-85.
DMWPGB8	RU	https://pubmed.ncbi.nlm.nih.gov/24172334

DM973N4	DI	DM973N4
DM973N4	DN	AMG 853
DM973N4	MI	TTNVEIR
DM973N4	MN	Prostaglandin D2 receptor (PTGDR)
DM973N4	MT	DTT
DM973N4	MA	Modulator
DM973N4	RN	Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients.J Allergy Clin Immunol.2013 Feb;131(2):339-45.
DM973N4	RU	https://www.ncbi.nlm.nih.gov/pubmed/23174659

DM973N4	DI	DM973N4
DM973N4	DN	AMG 853
DM973N4	MI	TTQDMX5
DM973N4	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DM973N4	MT	DTT
DM973N4	MA	Modulator
DM973N4	RN	Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients.J Allergy Clin Immunol.2013 Feb;131(2):339-45.
DM973N4	RU	https://www.ncbi.nlm.nih.gov/pubmed/23174659

DM3H0IX	DI	DM3H0IX
DM3H0IX	DN	AMG 890
DM3H0IX	MI	TTU9LGY
DM3H0IX	MN	Apolipoprotein A messenger RNA (LPA mRNA)
DM3H0IX	MT	DTT
DM3H0IX	MA	Inhibitor
DM3H0IX	RN	Clinical pipeline report, company report or official report of Amgen.
DM3H0IX	RU	https://www.amgenpipeline.com/

DMODJTX	DI	DMODJTX
DMODJTX	DN	AMG-181
DMODJTX	MI	TT4BT06
DMODJTX	MN	Integrin alpha-4 (ITGA4)
DMODJTX	MT	DTT
DMODJTX	MA	Inhibitor
DMODJTX	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMODJTX	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMODJTX	DI	DMODJTX
DMODJTX	DN	AMG-181
DMODJTX	MI	TTLT9XQ
DMODJTX	MN	Integrin beta-7 (ITGB7)
DMODJTX	MT	DTT
DMODJTX	RN	Pharmacology of AMG 181, a human anti-alpha4 beta7 antibody that specifically alters trafficking of gut-homing T cells. Br J Pharmacol. 2013 May;169(1):51-68.
DMODJTX	RU	https://pubmed.ncbi.nlm.nih.gov/23425116

DM1T3KQ	DI	DM1T3KQ
DM1T3KQ	DN	AMG-714
DM1T3KQ	MI	TTJFA35
DM1T3KQ	MN	Interleukin-15 (IL15)
DM1T3KQ	MT	DTT
DM1T3KQ	RN	Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
DM1T3KQ	RU	https://pubmed.ncbi.nlm.nih.gov/18321156

DMJ4GPR	DI	DMJ4GPR
DMJ4GPR	DN	AMP-579
DMJ4GPR	MI	TTK25J1
DMJ4GPR	MN	Adenosine A1 receptor (ADORA1)
DMJ4GPR	MT	DTT
DMJ4GPR	MA	Modulator
DMJ4GPR	RN	Adenosine A1/A2a receptor agonist AMP-579 induces acute and delayed preconditioning against in vivo myocardial stunning. Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2746-53.
DMJ4GPR	RU	https://pubmed.ncbi.nlm.nih.gov/15271662

DMJ4GPR	DI	DMJ4GPR
DMJ4GPR	DN	AMP-579
DMJ4GPR	MI	TTM2AOE
DMJ4GPR	MN	Adenosine A2a receptor (ADORA2A)
DMJ4GPR	MT	DTT
DMJ4GPR	MA	Modulator
DMJ4GPR	RN	Adenosine A1/A2a receptor agonist AMP-579 induces acute and delayed preconditioning against in vivo myocardial stunning. Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2746-53.
DMJ4GPR	RU	https://pubmed.ncbi.nlm.nih.gov/15271662

DMGE8FK	DI	DMGE8FK
DMGE8FK	DN	AMR-001
DMGE8FK	MI	TTZAVYN
DMGE8FK	MN	Hematopoietic progenitor cell antigen CD34 (CD34)
DMGE8FK	MT	DTT
DMGE8FK	MA	Modulator
DMGE8FK	RN	National Cancer Institute Drug Dictionary (drug id 743421).
DMGE8FK	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=743421

DMOB01U	DI	DMOB01U
DMOB01U	DN	Amsilarotene
DMOB01U	MI	TTOD7B3
DMOB01U	MN	Retinoic acid receptor (RAR)
DMOB01U	MT	DTT
DMOB01U	MA	Antagonist
DMOB01U	RN	Initial clinical trial of oral TAC-101, a novel retinoic acid receptor-alpha selective retinoid, in patients with advanced cancer. J Clin Oncol. 2002 Aug 15;20(16):3522-32.
DMOB01U	RU	https://pubmed.ncbi.nlm.nih.gov/12177113

DMS0GA6	DI	DMS0GA6
DMS0GA6	DN	AMY-101
DMS0GA6	MI	TTJGY7A
DMS0GA6	MN	Complement C3 (CO3)
DMS0GA6	MT	DTT
DMS0GA6	MA	Inhibitor
DMS0GA6	RN	The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol. 2020 Jun;215:108450.
DMS0GA6	RU	https://pubmed.ncbi.nlm.nih.gov/32360516

DMT3S10	DI	DMT3S10
DMT3S10	DN	AN0128
DMT3S10	MI	TTF8CQI
DMT3S10	MN	Tumor necrosis factor (TNF)
DMT3S10	MT	DTT
DMT3S10	MA	Inhibitor
DMT3S10	RN	Inhibition of experimental periodontitis by a topical boron-based antimicrobial. J Dent Res. 2008 Feb;87(2):148-52.
DMT3S10	RU	https://pubmed.ncbi.nlm.nih.gov/18218841

DMJ7QP8	DI	DMJ7QP8
DMJ7QP8	DN	AN-019
DMJ7QP8	MI	TTS7G69
DMJ7QP8	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMJ7QP8	MT	DTT
DMJ7QP8	MA	Inhibitor
DMJ7QP8	RN	Design, synthesis and preclinical evaluation of NRC-AN-019. Int J Oncol. 2013 Jan;42(1):168-78.
DMJ7QP8	RU	https://pubmed.ncbi.nlm.nih.gov/23151973

DM3JNXS	DI	DM3JNXS
DM3JNXS	DN	AN-1792
DM3JNXS	MI	TTE4KHA
DM3JNXS	MN	Amyloid beta A4 protein (APP)
DM3JNXS	MT	DTT
DM3JNXS	MA	Inhibitor
DM3JNXS	RN	Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol. 2006 Sep;169(3):1048-63.
DM3JNXS	RU	https://pubmed.ncbi.nlm.nih.gov/16936277

DMDK7CL	DI	DMDK7CL
DMDK7CL	DN	AN-2898
DMDK7CL	MI	TTZ97H5
DMDK7CL	MN	Phosphodiesterase 4A (PDE4A)
DMDK7CL	MT	DTT
DMDK7CL	MA	Inhibitor
DMDK7CL	RN	An assessment of the genetic toxicology of novel boron-containing therapeutic agents. Environ Mol Mutagen. 2013 Jun;54(5):338-46.
DMDK7CL	RU	https://pubmed.ncbi.nlm.nih.gov/23625818

DMDK7CL	DI	DMDK7CL
DMDK7CL	DN	AN-2898
DMDK7CL	MI	TTVIAT9
DMDK7CL	MN	Phosphodiesterase 4B (PDE4B)
DMDK7CL	MT	DTT
DMDK7CL	MA	Inhibitor
DMDK7CL	RN	An assessment of the genetic toxicology of novel boron-containing therapeutic agents. Environ Mol Mutagen. 2013 Jun;54(5):338-46.
DMDK7CL	RU	https://pubmed.ncbi.nlm.nih.gov/23625818

DMDK7CL	DI	DMDK7CL
DMDK7CL	DN	AN-2898
DMDK7CL	MI	TTSKMI8
DMDK7CL	MN	Phosphodiesterase 4D (PDE4D)
DMDK7CL	MT	DTT
DMDK7CL	MA	Inhibitor
DMDK7CL	RN	An assessment of the genetic toxicology of novel boron-containing therapeutic agents. Environ Mol Mutagen. 2013 Jun;54(5):338-46.
DMDK7CL	RU	https://pubmed.ncbi.nlm.nih.gov/23625818

DMG7IEN	DI	DMG7IEN
DMG7IEN	DN	Anatibant
DMG7IEN	MI	TTGY8IW
DMG7IEN	MN	B2 bradykinin receptor (BDKRB2)
DMG7IEN	MT	DTT
DMG7IEN	MA	Antagonist
DMG7IEN	RN	Inhibition of bradykinin B2 receptors before, not after onset of experimental subarachnoid hemorrhage prevents brain edema formation and improves functional outcome. Crit Care Med. 2009 Jul;37(7):2228-34.
DMG7IEN	RU	https://pubmed.ncbi.nlm.nih.gov/19487935

DMTG2O0	DI	DMTG2O0
DMTG2O0	DN	Anrukinzumab
DMTG2O0	MI	TT0GVCH
DMTG2O0	MN	Interleukin-13 (IL13)
DMTG2O0	MT	DTT
DMTG2O0	MA	Modulator
DMTG2O0	RN	Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study.Gut.2015 Jun;64(6):894-900.
DMTG2O0	RU	https://www.ncbi.nlm.nih.gov/pubmed/25567115

DMHVZ27	DI	DMHVZ27
DMHVZ27	DN	Anti-CD137
DMHVZ27	MI	TTPW9LJ
DMHVZ27	MN	Co-stimulatory molecule 4-1BB (CD137)
DMHVZ27	MT	DTT
DMHVZ27	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1878).
DMHVZ27	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1878

DMPRIHK	DI	DMPRIHK
DMPRIHK	DN	Anti-CD3 and anti-Her2/neu bispecific antibody-armed activated T cells
DMPRIHK	MI	TT6EO5L
DMPRIHK	MN	Erbb2 tyrosine kinase receptor (HER2)
DMPRIHK	MT	DTT
DMPRIHK	RN	Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors. J Hematother Stem Cell Res. 2001 Apr;10(2):247-60.
DMPRIHK	RU	https://pubmed.ncbi.nlm.nih.gov/11359672

DMVQHBK	DI	DMVQHBK
DMVQHBK	DN	Anti-GD2 CART
DMVQHBK	MI	TT80ARU
DMVQHBK	MN	Ganglioside GD2 (GD2)
DMVQHBK	MT	DTT
DMVQHBK	MA	CAR-T-Cell-Therapy
DMVQHBK	RN	ClinicalTrials.gov (NCT02765243) Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma
DMVQHBK	RU	https://clinicaltrials.gov/ct2/show/NCT02765243

DMVRNAO	DI	DMVRNAO
DMVRNAO	DN	Anti-IP10
DMVRNAO	MI	TTQOVYA
DMVRNAO	MN	C-X-C motif chemokine 10 (CXCL10)
DMVRNAO	MT	DTT
DMVRNAO	RN	Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut. 2014 Mar;63(3):442-50.
DMVRNAO	RU	https://pubmed.ncbi.nlm.nih.gov/23461895

DMJO402	DI	DMJO402
DMJO402	DN	Anti-LAG3
DMJO402	MI	TTNVXAW
DMJO402	MN	Lymphocyte activation gene 3 protein (LAG3)
DMJO402	MT	DTT
DMJO402	MA	Inhibitor
DMJO402	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMJO402	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMQ58YH	DI	DMQ58YH
DMQ58YH	DN	Anti-LT alpha
DMQ58YH	MI	TTP73TM
DMQ58YH	MN	Lymphotoxin-alpha (LTA)
DMQ58YH	MT	DTT
DMQ58YH	RN	Clinical pipeline report, company report or official report of Genentech (2011).
DMQ58YH	RU	http://www.gene.com/gene/index.jsp

DMQFU1R	DI	DMQFU1R
DMQFU1R	DN	Anti-M1 prime
DMQFU1R	MI	TTA5LWY
DMQFU1R	MN	M1-prime segment of membrane-expressed IgE (M1 IgE)
DMQFU1R	MT	DTT
DMQFU1R	RN	Clinical pipeline report, company report or official report of Genentech (2011).
DMQFU1R	RU	http://www.gene.com/gene/index.jsp

DMJPZDC	DI	DMJPZDC
DMJPZDC	DN	Anti-PSCA mab
DMJPZDC	MI	TT9T4AV
DMJPZDC	MN	Prostate stem cell antigen (PSCA)
DMJPZDC	MT	DTT
DMJPZDC	MA	Modulator
DMJPZDC	RN	Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial. Cancer Chemother Pharmacol. 2012 Mar;69(3):763-71.
DMJPZDC	RU	https://pubmed.ncbi.nlm.nih.gov/22020316

DMDKRS3	DI	DMDKRS3
DMDKRS3	DN	Antistasin
DMDKRS3	MI	TTCIHJA
DMDKRS3	MN	Coagulation factor Xa (F10)
DMDKRS3	MT	DTT
DMDKRS3	MA	Inhibitor
DMDKRS3	RN	Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci. 2002 Jan;23(1):25-32.
DMDKRS3	RU	https://pubmed.ncbi.nlm.nih.gov/11804648

DMRGQVZ	DI	DMRGQVZ
DMRGQVZ	DN	Antroquinonol
DMRGQVZ	MI	TT6S2FE
DMRGQVZ	MN	DNA [cytosine-5]-methyltransferase 1 (DNMT1)
DMRGQVZ	MT	DTT
DMRGQVZ	MA	Inhibitor
DMRGQVZ	RN	Antroquinonol D, isolated from Antrodia camphorata, with DNA demethylation and anticancer potential. J Agric Food Chem. 2014 Jun 18;62(24):5625-35.
DMRGQVZ	RU	https://pubmed.ncbi.nlm.nih.gov/24784321

DMMJOZD	DI	DMMJOZD
DMMJOZD	DN	ANW-32821
DMMJOZD	MI	DEKP5HX
DMMJOZD	MN	Cholesterol 24-hydroxylase (CYP46A1)
DMMJOZD	MT	DME
DMMJOZD	MA	Metabolism
DMMJOZD	RN	Cholesterol-metabolizing cytochromes P450. Drug Metab Dispos. 2006 Apr;34(4):513-20.
DMMJOZD	RU	https://pubmed.ncbi.nlm.nih.gov/16434543

DMMJOZD	DI	DMMJOZD
DMMJOZD	DN	ANW-32821
DMMJOZD	MI	DE98XPV
DMMJOZD	MN	Cholesterol desmolase (CYP11A1)
DMMJOZD	MT	DME
DMMJOZD	MA	Metabolism
DMMJOZD	RN	Cholesterol-metabolizing cytochromes P450. Drug Metab Dispos. 2006 Apr;34(4):513-20.
DMMJOZD	RU	https://pubmed.ncbi.nlm.nih.gov/16434543

DMMJOZD	DI	DMMJOZD
DMMJOZD	DN	ANW-32821
DMMJOZD	MI	DELIXR8
DMMJOZD	MN	Cytochrome P450 125A1 (cyp125)
DMMJOZD	MT	DME
DMMJOZD	MA	Metabolism
DMMJOZD	RN	Function, essentiality, and expression of cytochrome P450 enzymes and their cognate redox partners in Mycobacterium tuberculosis: are they drug targets? Appl Microbiol Biotechnol. 2019 May;103(9):3597-3614.
DMMJOZD	RU	https://pubmed.ncbi.nlm.nih.gov/30810776

DMMJOZD	DI	DMMJOZD
DMMJOZD	DN	ANW-32821
DMMJOZD	MI	DE6ZDK4
DMMJOZD	MN	Cytochrome P450 125A3 (cyp125)
DMMJOZD	MT	DME
DMMJOZD	MA	Metabolism
DMMJOZD	RN	Cholesterol ester oxidation by mycobacterial cytochrome P450. J Biol Chem. 2014 Oct 31;289(44):30417-25.
DMMJOZD	RU	https://pubmed.ncbi.nlm.nih.gov/25210044

DMMJOZD	DI	DMMJOZD
DMMJOZD	DN	ANW-32821
DMMJOZD	MI	DEMQ20F
DMMJOZD	MN	Cytochrome P450 142A1 (cyp142)
DMMJOZD	MT	DME
DMMJOZD	MA	Metabolism
DMMJOZD	RN	Function, essentiality, and expression of cytochrome P450 enzymes and their cognate redox partners in Mycobacterium tuberculosis: are they drug targets? Appl Microbiol Biotechnol. 2019 May;103(9):3597-3614.
DMMJOZD	RU	https://pubmed.ncbi.nlm.nih.gov/30810776

DMMJOZD	DI	DMMJOZD
DMMJOZD	DN	ANW-32821
DMMJOZD	MI	DEPUK4S
DMMJOZD	MN	Cytochrome P450 142A2 (cyp142)
DMMJOZD	MT	DME
DMMJOZD	MA	Metabolism
DMMJOZD	RN	Cholesterol ester oxidation by mycobacterial cytochrome P450. J Biol Chem. 2014 Oct 31;289(44):30417-25.
DMMJOZD	RU	https://pubmed.ncbi.nlm.nih.gov/25210044

DMMJOZD	DI	DMMJOZD
DMMJOZD	DN	ANW-32821
DMMJOZD	MI	DEDZRQ1
DMMJOZD	MN	Cytochrome P450 7A1 (CYP7A1)
DMMJOZD	MT	DME
DMMJOZD	MA	Metabolism
DMMJOZD	RN	Cholesterol-metabolizing cytochromes P450. Drug Metab Dispos. 2006 Apr;34(4):513-20.
DMMJOZD	RU	https://pubmed.ncbi.nlm.nih.gov/16434543

DMMJOZD	DI	DMMJOZD
DMMJOZD	DN	ANW-32821
DMMJOZD	MI	DEBS639
DMMJOZD	MN	Vitamin D(3) 25-hydroxylase (CYP27A1)
DMMJOZD	MT	DME
DMMJOZD	MA	Metabolism
DMMJOZD	RN	Cholesterol-metabolizing cytochromes P450. Drug Metab Dispos. 2006 Apr;34(4):513-20.
DMMJOZD	RU	https://pubmed.ncbi.nlm.nih.gov/16434543

DMYBQEF	DI	DMYBQEF
DMYBQEF	DN	AP26113
DMYBQEF	MI	TTPMQSO
DMYBQEF	MN	ALK tyrosine kinase receptor (ALK)
DMYBQEF	MT	DTT
DMYBQEF	MA	Modulator
DMYBQEF	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMYBQEF	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM3ICYL	DI	DM3ICYL
DM3ICYL	DN	AP-301-IH
DM3ICYL	MI	TTF8CQI
DM3ICYL	MN	Tumor necrosis factor (TNF)
DM3ICYL	MT	DTT
DM3ICYL	MA	Inhibitor
DM3ICYL	RN	AP301, a synthetic peptide mimicking the lectin-like domain of TNF, enhances amiloride-sensitive Na(+) current in primary dog, pig and rat alveolar type II cells. Pulm Pharmacol Ther. 2013 Jun;26(3):356-63.
DM3ICYL	RU	https://pubmed.ncbi.nlm.nih.gov/23313096

DMISQOZ	DI	DMISQOZ
DMISQOZ	DN	AP-761
DMISQOZ	MI	TTQDMX5
DMISQOZ	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMISQOZ	MT	DTT
DMISQOZ	MA	Antagonist
DMISQOZ	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028464)
DMISQOZ	RU	http://adisinsight.springer.com/drugs/800028464

DM1B8IT	DI	DM1B8IT
DM1B8IT	DN	Apadoline
DM1B8IT	MI	TTQW87Y
DM1B8IT	MN	Opioid receptor kappa (OPRK1)
DM1B8IT	MT	DTT
DM1B8IT	MA	Agonist
DM1B8IT	RN	Novel developments with selective, non-peptidic kappa-opioid receptor agonists. Expert Opin Investig Drugs. 1997 Oct;6(10):1351-68.
DM1B8IT	RU	https://pubmed.ncbi.nlm.nih.gov/15989506

DMQMV9F	DI	DMQMV9F
DMQMV9F	DN	Apaxifylline
DMQMV9F	MI	TTK25J1
DMQMV9F	MN	Adenosine A1 receptor (ADORA1)
DMQMV9F	MT	DTT
DMQMV9F	MA	Antagonist
DMQMV9F	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004779)
DMQMV9F	RU	http://adisinsight.springer.com/drugs/800004779

DM3VP19	DI	DM3VP19
DM3VP19	DN	APC-8015F
DM3VP19	MI	TTCT6F7
DM3VP19	MN	Intercellular adhesion molecule ICAM-1 (ICAM1)
DM3VP19	MT	DTT
DM3VP19	MA	Modulator
DM3VP19	RN	National Cancer Institute Drug Dictionary (drug id 561410).
DM3VP19	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=561410

DMNQ7DV	DI	DMNQ7DV
DMNQ7DV	DN	APD-209
DMNQ7DV	MI	TT2CJVK
DMNQ7DV	MN	Adrenergic receptor beta-2 (ADRB2)
DMNQ7DV	MT	DTT
DMNQ7DV	MA	Agonist
DMNQ7DV	RN	Drugs in development for treatment of patients with cancer-related anorexia and cachexia syndrome. Retraction in: Drug Des Devel Ther. 2013; 7: 1385.
DMNQ7DV	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3746778/

DM3XT5V	DI	DM3XT5V
DM3XT5V	DN	APD371
DM3XT5V	MI	TTMSFAW
DM3XT5V	MN	Cannabinoid receptor 2 (CB2)
DM3XT5V	MT	DTT
DM3XT5V	MA	Agonist
DM3XT5V	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3XT5V	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM1VITS	DI	DM1VITS
DM1VITS	DN	APD-403
DM1VITS	MI	TTEX248
DM1VITS	MN	Dopamine D2 receptor (D2R)
DM1VITS	MT	DTT
DM1VITS	MA	Antagonist
DM1VITS	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 215).
DM1VITS	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=215

DM9LZ0M	DI	DM9LZ0M
DM9LZ0M	DN	APD-515
DM9LZ0M	MI	TTOXS3C
DM9LZ0M	MN	Muscarinic acetylcholine receptor (CHRM)
DM9LZ0M	MT	DTT
DM9LZ0M	MA	Agonist
DM9LZ0M	RN	Clinical pipeline report, company report or official report of Acacia Pharma.
DM9LZ0M	RU	http://www.acaciapharma.com/pipeline/apd515

DM0FXMZ	DI	DM0FXMZ
DM0FXMZ	DN	APG-101
DM0FXMZ	MI	TTF0RCZ
DM0FXMZ	MN	Apoptosis mediating surface antigen FAS (FAS)
DM0FXMZ	MT	DTT
DM0FXMZ	MA	Inhibitor
DM0FXMZ	RN	Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients. Int Immunopharmacol. 2012 May;13(1):93-100.
DM0FXMZ	RU	https://pubmed.ncbi.nlm.nih.gov/22446296

DMIFA0L	DI	DMIFA0L
DMIFA0L	DN	APG-115
DMIFA0L	MI	TT7SBF5
DMIFA0L	MN	Cellular tumor antigen p53 (TP53)
DMIFA0L	MT	DTT
DMIFA0L	MA	Inhibitor
DMIFA0L	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMIFA0L	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMIFA0L	DI	DMIFA0L
DMIFA0L	DN	APG-115
DMIFA0L	MI	TT08GJW
DMIFA0L	MN	Ubiquitin-protein ligase E3 Mdm2 (MDM2)
DMIFA0L	MT	DTT
DMIFA0L	MA	Inhibitor
DMIFA0L	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMIFA0L	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM756GE	DI	DM756GE
DM756GE	DN	APH-0812
DM756GE	MI	TTBH0VX
DM756GE	MN	Histone deacetylase (HDAC)
DM756GE	MT	DTT
DM756GE	MA	Inhibitor
DM756GE	RN	Targeting the protein kinase C family: are we there yet. Nat Rev Cancer. 2007 Jul;7(7):554-62.
DM756GE	RU	https://pubmed.ncbi.nlm.nih.gov/17585335

DM756GE	DI	DM756GE
DM756GE	DN	APH-0812
DM756GE	MI	TTYVX59
DM756GE	MN	Protein kinase C (PRKC)
DM756GE	MT	DTT
DM756GE	MA	Inhibitor
DM756GE	RN	Targeting the protein kinase C family: are we there yet. Nat Rev Cancer. 2007 Jul;7(7):554-62.
DM756GE	RU	https://pubmed.ncbi.nlm.nih.gov/17585335

DMHIS6Z	DI	DMHIS6Z
DMHIS6Z	DN	Apilimod
DMHIS6Z	MI	TT0S3MP
DMHIS6Z	MN	HUMAN phosphatidylinositol 3-phosphate 5-kinase (PIKfyve)
DMHIS6Z	MT	DTT
DMHIS6Z	MA	Inhibitor
DMHIS6Z	RN	A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals. April 17, 2020.
DMHIS6Z	RU	https://www.biorxiv.org/content/10.1101/2020.04.16.044016v1

DM4N2O0	DI	DM4N2O0
DM4N2O0	DN	Apilimod dimesylate
DM4N2O0	MI	TTA4M1N
DM4N2O0	MN	Phosphatidylinositol-3-phosphate 5-kinase (PIP5K3)
DM4N2O0	MT	DTT
DM4N2O0	MA	Inhibitor
DM4N2O0	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM4N2O0	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM7IGO9	DI	DM7IGO9
DM7IGO9	DN	Apimostinel
DM7IGO9	MI	TT9IK2Z
DM7IGO9	MN	N-methyl-D-aspartate receptor (NMDAR)
DM7IGO9	MT	DTT
DM7IGO9	MA	Partial agonist
DM7IGO9	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7IGO9	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMP0LST	DI	DMP0LST
DMP0LST	DN	APL-101
DMP0LST	MI	TTNDSF4
DMP0LST	MN	Proto-oncogene c-Met (MET)
DMP0LST	MT	DTT
DMP0LST	MA	Inhibitor
DMP0LST	RN	Clinical pipeline report, company report or official report of Apollomics.
DMP0LST	RU	https://www.apollomicsinc.com/zh-hans/pipeline-drugs/apl-101/

DMGJ1X2	DI	DMGJ1X2
DMGJ1X2	DN	Aplindore fumarate
DMGJ1X2	MI	TTEX248
DMGJ1X2	MN	Dopamine D2 receptor (D2R)
DMGJ1X2	MT	DTT
DMGJ1X2	MA	Agonist
DMGJ1X2	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMGJ1X2	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMGNFBC	DI	DMGNFBC
DMGNFBC	DN	APN301
DMGNFBC	MI	TT80ARU
DMGNFBC	MN	Ganglioside GD2 (GD2)
DMGNFBC	MT	DTT
DMGNFBC	MA	Inhibitor
DMGNFBC	RN	Clinical pipeline report, company report or official report of Apeiron Biologics.
DMGNFBC	RU	https://www.apeiron-biologics.com/childrens-oncology-group-and-apeiron-to-jointly-conduct-phase-ii-study-in-neuroblastoma-with-hu14-18-il2-apn301/

DM32YTJ	DI	DM32YTJ
DM32YTJ	DN	APN-301
DM32YTJ	MI	TTF89GD
DM32YTJ	MN	Interleukin-2 (IL2)
DM32YTJ	MT	DTT
DM32YTJ	MA	Modulator
DM32YTJ	RN	Clinical pipeline report, company report or official report of APEIRON Biologics.
DM32YTJ	RU	http://www.apeiron-biologics.com/index.php/projects/apn301-hu14-18-il2.html

DMEXN7V	DI	DMEXN7V
DMEXN7V	DN	APN401
DMEXN7V	MI	TTHRAIJ
DMEXN7V	MN	CBLB messenger RNA (CBLB mRNA)
DMEXN7V	MT	DTT
DMEXN7V	MA	Inhibitor
DMEXN7V	RN	Clinical pipeline report, company report or official report of Apeiron Biologics.
DMEXN7V	RU	https://www.apeiron-biologics.com/science/#apn401

DMKVP7E	DI	DMKVP7E
DMKVP7E	DN	Apolizumab
DMKVP7E	MI	TTYA75N
DMKVP7E	MN	MHC class II antigen DR (HLA-DR)
DMKVP7E	MT	DTT
DMKVP7E	MA	Modulator
DMKVP7E	RN	A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study.
DMKVP7E	RU	https://www.ncbi.nlm.nih.gov/pubmed/17071489

DM6B9HP	DI	DM6B9HP
DM6B9HP	DN	Apomine
DM6B9HP	MI	TTS4UGC
DM6B9HP	MN	Farnesoid X-activated receptor (FXR)
DM6B9HP	MT	DTT
DM6B9HP	MA	Agonist
DM6B9HP	RN	The nuclear receptors FXR and LXRalpha: potential targets for the development of drugs affecting lipid metabolism and neoplastic diseases. Curr Pharm Des. 2001 Mar;7(4):231-59.
DM6B9HP	RU	https://pubmed.ncbi.nlm.nih.gov/11254888

DMNFADH	DI	DMNFADH
DMNFADH	DN	APR-246
DMNFADH	MI	TT7SBF5
DMNFADH	MN	Cellular tumor antigen p53 (TP53)
DMNFADH	MT	DTT
DMNFADH	MA	Stimulator
DMNFADH	RN	APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell Death Dis. 2013 Oct 24;4:e881. 
DMNFADH	RU	https://pubmed.ncbi.nlm.nih.gov/24157875

DM8W4N9	DI	DM8W4N9
DM8W4N9	DN	Apratastat
DM8W4N9	MI	TTMX39J
DM8W4N9	MN	Matrix metalloproteinase-1 (MMP-1)
DM8W4N9	MT	DTT
DM8W4N9	MA	Inhibitor
DM8W4N9	RN	Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1605-9.
DM8W4N9	RU	https://pubmed.ncbi.nlm.nih.gov/16426848

DM8W4N9	DI	DM8W4N9
DM8W4N9	DN	Apratastat
DM8W4N9	MI	TTHY57M
DM8W4N9	MN	Matrix metalloproteinase-13 (MMP-13)
DM8W4N9	MT	DTT
DM8W4N9	MA	Modulator
DM8W4N9	RN	Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1605-9.
DM8W4N9	RU	https://pubmed.ncbi.nlm.nih.gov/16426848

DM8W4N9	DI	DM8W4N9
DM8W4N9	DN	Apratastat
DM8W4N9	MI	TT6AZXG
DM8W4N9	MN	TNF alpha converting enzyme (ADAM17)
DM8W4N9	MT	DTT
DM8W4N9	MA	Modulator
DM8W4N9	RN	Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1605-9.
DM8W4N9	RU	https://pubmed.ncbi.nlm.nih.gov/16426848

DMEJICQ	DI	DMEJICQ
DMEJICQ	DN	Aprocitentan
DMEJICQ	MI	TTCV6O0
DMEJICQ	MN	Endothelin receptor (EDNR)
DMEJICQ	MT	DTT
DMEJICQ	MA	Antagonist
DMEJICQ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMEJICQ	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMX2P5G	DI	DMX2P5G
DMX2P5G	DN	APX005M
DMX2P5G	MI	TTN6Y9A
DMX2P5G	MN	CD40L receptor (CD40)
DMX2P5G	MT	DTT
DMX2P5G	MA	Agonist
DMX2P5G	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMX2P5G	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMU6NBO	DI	DMU6NBO
DMU6NBO	DN	APX3330
DMU6NBO	MI	TTHGL48
DMU6NBO	MN	AP endonuclease 1 (APEX1)
DMU6NBO	MT	DTT
DMU6NBO	MA	Inhibitor
DMU6NBO	RN	Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic. NPJ Precis Oncol. 2017;1:19.
DMU6NBO	RU	https://pubmed.ncbi.nlm.nih.gov/28825044

DM1USXR	DI	DM1USXR
DM1USXR	DN	AQ-13
DM1USXR	MI	TTKY2NS
DM1USXR	MN	Duffy antigen chemokine receptor (ACKR1)
DM1USXR	MT	DTT
DM1USXR	MA	Modulator
DM1USXR	RN	From control to eradication of malaria: the end of being stuck in second gear . Asian Pacific Journal of Tropical Medicine Volume 3, Issue 5, May 2010, Pages 412-420.
DM1USXR	RU	http://www.sciencedirect.com/science/article/pii/S1995764510601010

DMD2RFO	DI	DMD2RFO
DMD2RFO	DN	AQW-051
DMD2RFO	MI	TTLA931
DMD2RFO	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMD2RFO	MT	DTT
DMD2RFO	MA	Agonist
DMD2RFO	RN	AQW051, a novel and selective nicotinic acetylcholine receptor alpha7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys. Parkinsonism Relat Disord. 2014 Nov;20(11):1119-23.
DMD2RFO	RU	https://pubmed.ncbi.nlm.nih.gov/25172125

DMCH3G5	DI	DMCH3G5
DMCH3G5	DN	AQX-1125
DMCH3G5	MI	TTTP2Z1
DMCH3G5	MN	SH2 domain inositol 5'-phosphatase 1 (INPP5D)
DMCH3G5	MT	DTT
DMCH3G5	MA	Agonist
DMCH3G5	RN	Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 2. Efficacy studies in allergic and pulmonary inflammation models in vivo. Br J Pharmacol. 2013 Mar;168(6):1519-29.
DMCH3G5	RU	https://pubmed.ncbi.nlm.nih.gov/23121409

DM93CTQ	DI	DM93CTQ
DM93CTQ	DN	AR08
DM93CTQ	MI	TTVIREA
DM93CTQ	MN	Adrenergic receptor (ADR)
DM93CTQ	MT	DTT
DM93CTQ	MA	Modulator
DM93CTQ	RN	Optimizing treatments for nicotine dependence by increasing cognitive performance during withdrawal. Expert Opin Drug Discov. 2014 June; 9(6): 579-594.
DM93CTQ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4287224/

DM5TC43	DI	DM5TC43
DM5TC43	DN	AR-12286
DM5TC43	MI	TTMQO60
DM5TC43	MN	Rho-associated protein kinase (ROCK)
DM5TC43	MT	DTT
DM5TC43	MA	Modulator
DM5TC43	RN	Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension. Am J Ophthalmol. 2011 Nov;152(5):834-41.e1.
DM5TC43	RU	https://pubmed.ncbi.nlm.nih.gov/21794845

DM8A71F	DI	DM8A71F
DM8A71F	DN	AR-67
DM8A71F	MI	TTGTQHC
DM8A71F	MN	DNA topoisomerase I (TOP1)
DM8A71F	MT	DTT
DM8A71F	MA	Inhibitor
DM8A71F	RN	Protracted dosing of the lipophilic camptothecin analogue AR-67 in non-small cell lung cancer xenografts and humans. Cancer Chemother Pharmacol. 2014 Jul;74(1):45-54.
DM8A71F	RU	https://pubmed.ncbi.nlm.nih.gov/24807458

DMJHA6Q	DI	DMJHA6Q
DMJHA6Q	DN	Ar9281
DMJHA6Q	MI	TT7WVHI
DMJHA6Q	MN	Soluble epoxide hydrolase (EPHX2)
DMJHA6Q	MT	DTT
DMJHA6Q	MA	Inhibitor
DMJHA6Q	RN	Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem. 2007 Aug 9;50(16):3825-40.
DMJHA6Q	RU	https://pubmed.ncbi.nlm.nih.gov/17616115

DM7PCLY	DI	DM7PCLY
DM7PCLY	DN	ARC1779
DM7PCLY	MI	TT3SZBT
DM7PCLY	MN	von Willebrand factor (VWF)
DM7PCLY	MT	DTT
DM7PCLY	MA	Inhibitor
DM7PCLY	RN	Short-Acting Anti-VWF (von Willebrand Factor) Aptamer Improves the Recovery, Survival, and Hemostatic Functions of Refrigerated Platelets. Arterioscler Thromb Vasc Biol. 2019 Oct;39(10):2028-2037.
DM7PCLY	RU	https://pubmed.ncbi.nlm.nih.gov/31315441

DM9LNXS	DI	DM9LNXS
DM9LNXS	DN	ARI-3037MO
DM9LNXS	MI	TTRHEQ4
DM9LNXS	MN	Diacylglycerol O-acyltransferase 2 (DGAT2)
DM9LNXS	MT	DTT
DM9LNXS	MA	Inhibitor
DM9LNXS	RN	2011 Pipeline of Arisaph Pharmaceuticals.
DM9LNXS	RU	http://www.arisaph.com/

DM9LNXS	DI	DM9LNXS
DM9LNXS	DN	ARI-3037MO
DM9LNXS	MI	TT8WFXV
DM9LNXS	MN	Hydroxycarboxylic acid receptor 3 (HCAR3)
DM9LNXS	MT	DTT
DM9LNXS	MA	Agonist
DM9LNXS	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9LNXS	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DM9LNXS	DI	DM9LNXS
DM9LNXS	DN	ARI-3037MO
DM9LNXS	MI	TTWNV8U
DM9LNXS	MN	Nicotinic acid receptor (HCAR2)
DM9LNXS	MT	DTT
DM9LNXS	MA	Agonist
DM9LNXS	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9LNXS	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DML3PJF	DI	DML3PJF
DML3PJF	DN	ARN-810
DML3PJF	MI	TTZAYWL
DML3PJF	MN	Estrogen receptor (ESR)
DML3PJF	MT	DTT
DML3PJF	MA	Modulator
DML3PJF	RN	Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts. J Med Chem.2015 Jun 25;58(12):4888-904.
DML3PJF	RU	https://pubmed.ncbi.nlm.nih.gov/25879485

DM2UP6Z	DI	DM2UP6Z
DM2UP6Z	DN	ARO-AAT
DM2UP6Z	MI	TT2L4TV
DM2UP6Z	MN	SERPINA1 messenger RNA (SERPINA1 mRNA)
DM2UP6Z	MT	DTT
DM2UP6Z	RN	Clinical pipeline report, company report or official report of Arrowhead Pharmaceuticals.
DM2UP6Z	RU	https://arrowheadpharma.com/pipeline/

DM5WK0J	DI	DM5WK0J
DM5WK0J	DN	ARQ 092
DM5WK0J	MI	TTWTSCV
DM5WK0J	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DM5WK0J	MT	DTT
DM5WK0J	MA	Inhibitor
DM5WK0J	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM5WK0J	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DM5WK0J	DI	DM5WK0J
DM5WK0J	DN	ARQ 092
DM5WK0J	MI	TTAZ05C
DM5WK0J	MN	RAC-gamma serine/threonine-protein kinase (AKT3)
DM5WK0J	MT	DTT
DM5WK0J	MA	Modulator
DM5WK0J	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM5WK0J	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMRG0A3	DI	DMRG0A3
DMRG0A3	DN	ARQ 531
DMRG0A3	MI	TTGM6VW
DMRG0A3	MN	Tyrosine-protein kinase BTK (ATK)
DMRG0A3	MT	DTT
DMRG0A3	MA	Inhibitor
DMRG0A3	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMRG0A3	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMH5CAL	DI	DMH5CAL
DMH5CAL	DN	ARQ 761
DMH5CAL	MI	TT8XK6L
DMH5CAL	MN	Quinone reductase 1 (NQO1)
DMH5CAL	MT	DTT
DMH5CAL	MA	Inhibitor
DMH5CAL	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMH5CAL	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMYEIOH	DI	DMYEIOH
DMYEIOH	DN	ARQ-154
DMYEIOH	MI	TTV5CGO
DMYEIOH	MN	Phosphodiesterase 4 (PDE4)
DMYEIOH	MT	DTT
DMYEIOH	MA	Inhibitor
DMYEIOH	RN	Clinical pipeline report, company report or official report of Arcutis Biotherapeutics.
DMYEIOH	RU	https://arcutis.com/trial/arq-154/

DM0VGDC	DI	DM0VGDC
DM0VGDC	DN	ARRY-382
DM0VGDC	MI	TT731LW
DM0VGDC	MN	Colony stimulating factor-1 receptor (CSF-1R)
DM0VGDC	MT	DTT
DM0VGDC	MA	Modulator
DM0VGDC	RN	Company report (Array)
DM0VGDC	RU	http://www.arraybiopharma.com/product-pipeline/other-compounds/arry-382/

DM0VGDC	DI	DM0VGDC
DM0VGDC	DN	ARRY-382
DM0VGDC	MI	TT7MRDV
DM0VGDC	MN	Macrophage colony-stimulating factor 1 receptor (CSF1R)
DM0VGDC	MT	DTT
DM0VGDC	MA	Inhibitor
DM0VGDC	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM0VGDC	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM17469	DI	DM17469
DM17469	DN	ARRY-502
DM17469	MI	TTQDMX5
DM17469	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DM17469	MT	DTT
DM17469	MA	Modulator
DM17469	RN	Clinical pipeline report, company report or official report of Array BioPharma (Drug: ARRY-502).
DM17469	RU	http://www.arraybiopharma.com/product-pipeline/other-compounds/arry-502/

DMTOI7S	DI	DMTOI7S
DMTOI7S	DN	ARRY-520
DMTOI7S	MI	TTTRP0H
DMTOI7S	MN	Kinesin-like protein KIF11 (KIF11)
DMTOI7S	MT	DTT
DMTOI7S	MA	Inhibitor
DMTOI7S	RN	Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells. Leukemia. 2009 Oct;23(10):1755-62.
DMTOI7S	RU	https://pubmed.ncbi.nlm.nih.gov/19458629

DMJ48AB	DI	DMJ48AB
DMJ48AB	DN	ARRY-797
DMJ48AB	MI	TTYT93M
DMJ48AB	MN	MAP kinase p38 (MAPK12)
DMJ48AB	MT	DTT
DMJ48AB	MA	Inhibitor
DMJ48AB	RN	Array BioPharmas ARRY-797 Meets Primary Endpoint in Clinical Proof of Concept Trial in Osteoarthritis Patients Whose Pain is Poorly Controlled by NSAIDs
DMJ48AB	RU	http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-newsArticle&ID=1720505&highlight=

DMJ48AB	DI	DMJ48AB
DMJ48AB	DN	ARRY-797
DMJ48AB	MI	TTWELHI
DMJ48AB	MN	Stress-activated protein kinase (p38)
DMJ48AB	MT	DTT
DMJ48AB	MA	Inhibitor
DMJ48AB	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMJ48AB	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DML27AE	DI	DML27AE
DML27AE	DN	Arverapamil
DML27AE	MI	TT5HONZ
DML27AE	MN	Calcium channel unspecific (CaC)
DML27AE	MT	DTT
DML27AE	MA	Modulator
DML27AE	RN	BJMP 2010;3(4):a342
DML27AE	RU	http://bjmp.org/files/2010-3-4/bjmp-2010-3-4-a342.pdf

DML27AE	DI	DML27AE
DML27AE	DN	Arverapamil
DML27AE	MI	DTUGYRD
DML27AE	MN	P-glycoprotein 1 (ABCB1)
DML27AE	MT	DTP
DML27AE	MA	Substrate
DML27AE	RN	Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther. 2000 May;293(2):376-82.
DML27AE	RU	http://jpet.aspetjournals.org/content/293/2/376.long

DMMX1EJ	DI	DMMX1EJ
DMMX1EJ	DN	AS-1402
DMMX1EJ	MI	TTBHFYQ
DMMX1EJ	MN	Mucin-1 (MUC1)
DMMX1EJ	MT	DTT
DMMX1EJ	RN	Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer. Breast Cancer Res. 2009;11(5):R73.
DMMX1EJ	RU	https://pubmed.ncbi.nlm.nih.gov/19811637

DMTUMYX	DI	DMTUMYX
DMTUMYX	DN	AS-902330
DMTUMYX	MI	TT6ICRA
DMTUMYX	MN	Fibroblast growth factor-18 (FGF18)
DMTUMYX	MT	DTT
DMTUMYX	MA	Modulator
DMTUMYX	RN	Intraarticular sprifermin (recombinant human fibroblast growth factor 18) in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2014 Jul;66(7):1820-31.
DMTUMYX	RU	https://pubmed.ncbi.nlm.nih.gov/24740822

DMNVU28	DI	DMNVU28
DMNVU28	DN	ASB17061
DMNVU28	MI	TT8VUE0
DMNVU28	MN	Chymase (CYM)
DMNVU28	MT	DTT
DMNVU28	MA	Modulator
DMNVU28	RN	Immunology of atopic eczema: overcoming the Th1/Th2 paradigm. Allergy. 2013 Aug;68(8):974-82.
DMNVU28	RU	https://pubmed.ncbi.nlm.nih.gov/23889510

DMMBVCJ	DI	DMMBVCJ
DMMBVCJ	DN	ASCJ-9
DMMBVCJ	MI	TTS64P2
DMMBVCJ	MN	Androgen receptor (AR)
DMMBVCJ	MT	DTT
DMMBVCJ	MA	Enhancer
DMMBVCJ	RN	Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling. Cell Death Dis. 2013 Aug 8;4:e764.
DMMBVCJ	RU	https://pubmed.ncbi.nlm.nih.gov/23928703

DMDQS4W	DI	DMDQS4W
DMDQS4W	DN	ASC-J9
DMDQS4W	MI	TTS64P2
DMDQS4W	MN	Androgen receptor (AR)
DMDQS4W	MT	DTT
DMDQS4W	MA	Inhibitor
DMDQS4W	RN	New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells. Am J Pathol. 2013 Feb;182(2):460-73.
DMDQS4W	RU	https://pubmed.ncbi.nlm.nih.gov/23219429

DMZF68E	DI	DMZF68E
DMZF68E	DN	Ascrolimus
DMZF68E	MI	TTFH2RS
DMZF68E	MN	FK506-binding protein (FKBP)
DMZF68E	MT	DTT
DMZF68E	MA	Modulator
DMZF68E	RN	Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit. 1995 Dec;17(6):584-91.
DMZF68E	RU	https://pubmed.ncbi.nlm.nih.gov/8588225

DM1CLKO	DI	DM1CLKO
DM1CLKO	DN	ASKP-1240
DM1CLKO	MI	TTN6Y9A
DM1CLKO	MN	CD40L receptor (CD40)
DM1CLKO	MT	DTT
DM1CLKO	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1874).
DM1CLKO	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1874

DM35S2I	DI	DM35S2I
DM35S2I	DN	ASM-024
DM35S2I	MI	TTJSZTB
DM35S2I	MN	Nicotinic acetylcholine receptor (nAChR)
DM35S2I	MT	DTT
DM35S2I	MA	Agonist
DM35S2I	RN	Effects of ASM-024, a modulator of acetylcholine receptor function, on airway responsiveness and allergen-induced responses in patients with mild asthma. Can Respir J. 2015 Jul-Aug;22(4):230-4.
DM35S2I	RU	https://pubmed.ncbi.nlm.nih.gov/26252534

DMTHR4U	DI	DMTHR4U
DMTHR4U	DN	ASM8
DMTHR4U	MI	TTU3Y87
DMTHR4U	MN	CCR3 messenger RNA (CCR3 mRNA)
DMTHR4U	MT	DTT
DMTHR4U	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 60).
DMTHR4U	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=60

DM92X7N	DI	DM92X7N
DM92X7N	DN	ASN002
DM92X7N	MI	TT2HUPM
DM92X7N	MN	SYK messenger RNA (SYK mRNA)
DM92X7N	MT	DTT
DM92X7N	MA	Inhibitor
DM92X7N	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM92X7N	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMWPGLS	DI	DMWPGLS
DMWPGLS	DN	ASN100
DMWPGLS	MI	TT5FLYB
DMWPGLS	MN	Staphylococcus Alpha-hemolysin (Stap-coc hly)
DMWPGLS	MT	DTT
DMWPGLS	MA	Modulator
DMWPGLS	RN	Antibacterial antibodies gain traction. Nat Rev Drug Discov. 2015 Nov;14(11):737-8. 
DMWPGLS	RU	https://www.ncbi.nlm.nih.gov/pubmed/26514853

DMWPGLS	DI	DMWPGLS
DMWPGLS	DN	ASN100
DMWPGLS	MI	TTKE96O
DMWPGLS	MN	Staphylococcus Five leukocidin toxins (Stap-coc lukF)
DMWPGLS	MT	DTT
DMWPGLS	MA	Modulator
DMWPGLS	RN	Antibacterial antibodies gain traction. Nat Rev Drug Discov. 2015 Nov;14(11):737-8. 
DMWPGLS	RU	https://www.ncbi.nlm.nih.gov/pubmed/26514853

DM6HJ3V	DI	DM6HJ3V
DM6HJ3V	DN	ASP0819
DM6HJ3V	MI	TT7M9I6
DM6HJ3V	MN	Calcium-activated potassium channel KCa3.1 (KCNN4)
DM6HJ3V	MT	DTT
DM6HJ3V	MA	Activator
DM6HJ3V	RN	Efficacy and Safety of ASP0819 in Patients with Fibromyalgia: Results of a Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial. J Pain Res. 2020 Dec 10;13:3355-3369.
DM6HJ3V	RU	https://pubmed.ncbi.nlm.nih.gov/33328761

DME8XD7	DI	DME8XD7
DME8XD7	DN	ASP-1707
DME8XD7	MI	TT8R70G
DME8XD7	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DME8XD7	MT	DTT
DME8XD7	MA	Antagonist
DME8XD7	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032657)
DME8XD7	RU	http://adisinsight.springer.com/drugs/800032657

DMBADQV	DI	DMBADQV
DMBADQV	DN	ASP-3291
DMBADQV	MI	TTEOSZT
DMBADQV	MN	Melanocortin receptor (MCR)
DMBADQV	MT	DTT
DMBADQV	MA	Modulator
DMBADQV	RN	Clinical pipeline report, company report or official report of Drais Pharmaceuticals.
DMBADQV	RU	http://www.draispharma.com/press.php

DM4KTN6	DI	DM4KTN6
DM4KTN6	DN	ASP-3652
DM4KTN6	MI	TTMXGCW
DM4KTN6	MN	Adrenergic receptor beta-3 (ADRB3)
DM4KTN6	MT	DTT
DM4KTN6	MA	Agonist
DM4KTN6	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029610)
DM4KTN6	RU	http://adisinsight.springer.com/drugs/800029610

DMZUAH2	DI	DMZUAH2
DMZUAH2	DN	ASP-4901
DMZUAH2	MI	TTZOEBC
DMZUAH2	MN	Phosphodiesterase 9 (PDE9)
DMZUAH2	MT	DTT
DMZUAH2	MA	Inhibitor
DMZUAH2	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033070)
DMZUAH2	RU	http://adisinsight.springer.com/drugs/800033070

DMTF24A	DI	DMTF24A
DMTF24A	DN	ASP-7035
DMTF24A	MI	TTK8R02
DMTF24A	MN	Vasopressin V2 receptor (V2R)
DMTF24A	MT	DTT
DMTF24A	MA	Agonist
DMTF24A	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030285)
DMTF24A	RU	http://adisinsight.springer.com/drugs/800030285

DMGDF2X	DI	DMGDF2X
DMGDF2X	DN	ASP-7147
DMGDF2X	MI	TTC1MVT
DMGDF2X	MN	Gastrin-releasing peptide receptor (GRPR)
DMGDF2X	MT	DTT
DMGDF2X	MA	Antagonist
DMGDF2X	RN	Astellas and Drais Partner To Develop Third Astellas Compound through Tacurion
DMGDF2X	RU	http://www.astellas.com/en/corporate/news/detail/astellas-and-drais-partner-to-.html

DM3TN1A	DI	DM3TN1A
DM3TN1A	DN	ASP7991
DM3TN1A	MI	TTBUYHA
DM3TN1A	MN	Extracellular calcium-sensing receptor (CASR)
DM3TN1A	MT	DTT
DM3TN1A	MA	Agonist
DM3TN1A	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035616)
DM3TN1A	RU	http://adisinsight.springer.com/drugs/800035616

DMR1MIV	DI	DMR1MIV
DMR1MIV	DN	ASP8062
DMR1MIV	MI	TTDCVZW
DMR1MIV	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMR1MIV	MT	DTT
DMR1MIV	MA	Modulator
DMR1MIV	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMR1MIV	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMYK1JU	DI	DMYK1JU
DMYK1JU	DN	ASP8232
DMYK1JU	MI	TT7HC21
DMYK1JU	MN	Membrane copper amine oxidase (AOC3)
DMYK1JU	MT	DTT
DMYK1JU	MA	Inhibitor
DMYK1JU	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMYK1JU	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMHLXUY	DI	DMHLXUY
DMHLXUY	DN	ASP8273
DMHLXUY	MI	TTGKNB4
DMHLXUY	MN	Epidermal growth factor receptor (EGFR)
DMHLXUY	MT	DTT
DMHLXUY	MA	Inhibitor
DMHLXUY	RN	Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation positive NSCLC, Journal of Clinical Oncology, Vol 33, No 15_suppl (May 20 Supplement), 2015: 8083.
DMHLXUY	RU	http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8083

DMBZQS7	DI	DMBZQS7
DMBZQS7	DN	ASP-8477
DMBZQS7	MI	TTVJ1D8
DMBZQS7	MN	Vascular endothelial growth factor receptor (VEGFR)
DMBZQS7	MT	DTT
DMBZQS7	MA	Modulator
DMBZQS7	RN	ClinicalTrials.gov (NCT02065349) A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety. U.S. National Institutes of Health.
DMBZQS7	RU	https://clinicaltrials.gov/ct2/show/NCT02065349

DM2MSGF	DI	DM2MSGF
DM2MSGF	DN	ASP9831
DM2MSGF	MI	TTV5CGO
DM2MSGF	MN	Phosphodiesterase 4 (PDE4)
DM2MSGF	MT	DTT
DM2MSGF	MA	Inhibitor
DM2MSGF	RN	Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2014 Oct;12(10):1724-30.e5.
DM2MSGF	RU	https://pubmed.ncbi.nlm.nih.gov/24530600

DMMKW8L	DI	DMMKW8L
DMMKW8L	DN	ASTX660
DMMKW8L	MI	TTK3WBU
DMMKW8L	MN	XIAP messenger RNA (XIAP mRNA)
DMMKW8L	MT	DTT
DMMKW8L	MA	Inhibitor
DMMKW8L	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMMKW8L	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMARIQK	DI	DMARIQK
DMARIQK	DN	AT-527
DMARIQK	MI	TTSUKYD
DMARIQK	MN	Virus RNA-dependent RNA polymerase (Viru RdRP)
DMARIQK	MT	DTT
DMARIQK	MA	Inhibitor
DMARIQK	RN	AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19. Antimicrob Agents Chemother. 2021 Mar 18;65(4):e02479-20.
DMARIQK	RU	https://pubmed.ncbi.nlm.nih.gov/33558299

DM35KDA	DI	DM35KDA
DM35KDA	DN	Ataciguat
DM35KDA	MI	TTJME02
DM35KDA	MN	Atrial natriuretic peptide receptor A (NPR1)
DM35KDA	MT	DTT
DM35KDA	MA	Activator
DM35KDA	RN	Pharma & Vaccines. Product Development Pipeline. April 29 2009.
DM35KDA	RU	http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf

DM6ABD9	DI	DM6ABD9
DM6ABD9	DN	ATHX-105
DM6ABD9	MI	TTWJBZ5
DM6ABD9	MN	5-HT 2C receptor (HTR2C)
DM6ABD9	MT	DTT
DM6ABD9	MA	Agonist
DM6ABD9	RN	Pharmacological targeting of the serotonergic system for the treatment of obesity. J Physiol. 2009 January 1; 587(Pt 1): 49-60.
DM6ABD9	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2670022/

DMWP59B	DI	DMWP59B
DMWP59B	DN	ATI-2042
DMWP59B	MI	TT5HONZ
DMWP59B	MN	Calcium channel unspecific (CaC)
DMWP59B	MT	DTT
DMWP59B	MA	Agonist
DMWP59B	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMWP59B	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMWP59B	DI	DMWP59B
DMWP59B	DN	ATI-2042
DMWP59B	MI	TTM7WCE
DMWP59B	MN	Ion channel unspecific (IC)
DMWP59B	MT	DTT
DMWP59B	MA	Antagonist
DMWP59B	RN	A randomized trial of budiodarone in paroxysmal atrial fibrillation. J Interv Card Electrophysiol. 2012 Jun;34(1):1-9.
DMWP59B	RU	https://pubmed.ncbi.nlm.nih.gov/22205496

DMWP59B	DI	DMWP59B
DMWP59B	DN	ATI-2042
DMWP59B	MI	TT1VOHK
DMWP59B	MN	Potassium channel unspecific (KC)
DMWP59B	MT	DTT
DMWP59B	MA	Agonist
DMWP59B	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMWP59B	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMWP59B	DI	DMWP59B
DMWP59B	DN	ATI-2042
DMWP59B	MI	TTRK8B9
DMWP59B	MN	Sodium channel unspecific (NaC)
DMWP59B	MT	DTT
DMWP59B	MA	Agonist
DMWP59B	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMWP59B	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMT5QYJ	DI	DMT5QYJ
DMT5QYJ	DN	ATI-2173
DMT5QYJ	MI	TTT4SY6
DMT5QYJ	MN	Hepatitis B virus Polymerase (HBV P)
DMT5QYJ	MT	DTT
DMT5QYJ	MA	Inhibitor
DMT5QYJ	RN	ATI-2173, a Novel Liver-Targeted Non-Chain-Terminating Nucleotide for Hepatitis B Virus Cure Regimens. Antimicrob Agents Chemother. 2020 Aug 20;64(9):e00836-20.
DMT5QYJ	RU	https://pubmed.ncbi.nlm.nih.gov/32540975

DMTY6OF	DI	DMTY6OF
DMTY6OF	DN	ATI-501
DMTY6OF	MI	TT6DM01
DMTY6OF	MN	Janus kinase 1 (JAK-1)
DMTY6OF	MT	DTT
DMTY6OF	MA	Inhibitor
DMTY6OF	RN	Clinical pipeline report, company report or official report of Aclaris Therapeutics.
DMTY6OF	RU	https://www.aclaristx.com/pipeline/

DMTY6OF	DI	DMTY6OF
DMTY6OF	DN	ATI-501
DMTY6OF	MI	TTT7PJU
DMTY6OF	MN	Janus kinase 3 (JAK-3)
DMTY6OF	MT	DTT
DMTY6OF	MA	Inhibitor
DMTY6OF	RN	Clinical pipeline report, company report or official report of Aclaris Therapeutics.
DMTY6OF	RU	https://www.aclaristx.com/pipeline/

DM8NODR	DI	DM8NODR
DM8NODR	DN	ATI-502
DM8NODR	MI	TT6DM01
DM8NODR	MN	Janus kinase 1 (JAK-1)
DM8NODR	MT	DTT
DM8NODR	MA	Inhibitor
DM8NODR	RN	ClinicalTrials.gov (NCT03759340) ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT). U.S. National Institutes of Health.
DM8NODR	RU	https://clinicaltrials.gov/ct2/show/NCT03759340

DM8NODR	DI	DM8NODR
DM8NODR	DN	ATI-502
DM8NODR	MI	TTT7PJU
DM8NODR	MN	Janus kinase 3 (JAK-3)
DM8NODR	MT	DTT
DM8NODR	MA	Inhibitor
DM8NODR	RN	ClinicalTrials.gov (NCT03759340) ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT). U.S. National Institutes of Health.
DM8NODR	RU	https://clinicaltrials.gov/ct2/show/NCT03759340

DMK3VYU	DI	DMK3VYU
DMK3VYU	DN	ATI-502
DMK3VYU	MI	TTJSQEF
DMK3VYU	MN	Tyrosine-protein kinase (PTK)
DMK3VYU	MT	DTT
DMK3VYU	MA	Inhibitor
DMK3VYU	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMK3VYU	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMYAQV2	DI	DMYAQV2
DMYAQV2	DN	ATL101
DMYAQV2	MI	TT9G4N0
DMYAQV2	MN	Glutamate carboxypeptidase II (GCPII)
DMYAQV2	MT	DTT
DMYAQV2	MA	Modulator
DMYAQV2	RN	Clinical pipeline report, company report or official report of Atlab pharma.
DMYAQV2	RU	http://www.atlab-pharma.com/pipeline_atl101.html

DMD0I29	DI	DMD0I29
DMD0I29	DN	ATL-104
DMD0I29	MI	TTDB5IS
DMD0I29	MN	Receptor unspecific (Rec)
DMD0I29	MT	DTT
DMD0I29	MA	Modulator
DMD0I29	RN	Treatment of oral mucositis after peripheral blood SCT with ATL-104 mouthwash: results from a randomized, double-blind, placebo-controlled trial. Bone Marrow Transplant. 2009 Apr;43(7):563-9.
DMD0I29	RU	https://pubmed.ncbi.nlm.nih.gov/18997832

DM3POT6	DI	DM3POT6
DM3POT6	DN	ATL1102
DM3POT6	MI	TTJMF9P
DM3POT6	MN	ITGA4 messenger RNA (ITGA4 mRNA)
DM3POT6	MT	DTT
DM3POT6	MA	Modulator
DM3POT6	RN	CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS.Neurology.2014 Nov 11;83(20):1780-8.
DM3POT6	RU	https://www.ncbi.nlm.nih.gov/pubmed/25239835

DM7I56B	DI	DM7I56B
DM7I56B	DN	ATM AVI
DM7I56B	MI	TTUE541
DM7I56B	MN	Leukocyte surface antigen Leu-16 (CD20)
DM7I56B	MT	DTT
DM7I56B	MA	Modulator
DM7I56B	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628).
DM7I56B	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2628

DM4T9RS	DI	DM4T9RS
DM4T9RS	DN	ATN-161
DM4T9RS	MI	TTH4QIS
DM4T9RS	MN	Integrin alpha-5/beta-1 (ITGA5/B1)
DM4T9RS	MT	DTT
DM4T9RS	MA	Antagonist
DM4T9RS	RN	A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther. 2006 Sep;5(9):2271-80.
DM4T9RS	RU	https://pubmed.ncbi.nlm.nih.gov/16985061

DM4T9RS	DI	DM4T9RS
DM4T9RS	DN	ATN-161
DM4T9RS	MI	TT69TQN
DM4T9RS	MN	Integrin alpha-V/beta-3 (ITGAV/B3)
DM4T9RS	MT	DTT
DM4T9RS	MA	Antagonist
DM4T9RS	RN	A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther. 2006 Sep;5(9):2271-80.
DM4T9RS	RU	https://pubmed.ncbi.nlm.nih.gov/16985061

DMQJ5DV	DI	DMQJ5DV
DMQJ5DV	DN	ATN-224
DMQJ5DV	MI	TT6RVLG
DMQJ5DV	MN	Superoxide dismutase Cu-Zn (SOD Cu-Zn)
DMQJ5DV	MT	DTT
DMQJ5DV	MA	Inhibitor
DMQJ5DV	RN	Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res. 2006 Aug 15;12(16):4974-82.
DMQJ5DV	RU	https://pubmed.ncbi.nlm.nih.gov/16914587

DMUXO3Z	DI	DMUXO3Z
DMUXO3Z	DN	AUS-131
DMUXO3Z	MI	DEUX61H
DMUXO3Z	MN	Biphenyl dioxygenase (bphC)
DMUXO3Z	MT	DME
DMUXO3Z	MA	Metabolism
DMUXO3Z	RN	Flavonoids biotransformation by bacterial non-heme dioxygenases, biphenyl and naphthalene dioxygenase. Appl Microbiol Biotechnol. 2011 Jul;91(2):219-28.
DMUXO3Z	RU	https://pubmed.ncbi.nlm.nih.gov/21626021

DMZMSQJ	DI	DMZMSQJ
DMZMSQJ	DN	AUS-131
DMZMSQJ	MI	TTOM3J0
DMZMSQJ	MN	Estrogen receptor beta (ESR2)
DMZMSQJ	MT	DTT
DMZMSQJ	MA	Agonist
DMZMSQJ	RN	S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr. 2005 May;81(5):1072-9.
DMZMSQJ	RU	https://pubmed.ncbi.nlm.nih.gov/15883431

DMN7VK1	DI	DMN7VK1
DMN7VK1	DN	AV-101
DMN7VK1	MI	TT9IK2Z
DMN7VK1	MN	N-methyl-D-aspartate receptor (NMDAR)
DMN7VK1	MT	DTT
DMN7VK1	MA	Antagonist
DMN7VK1	RN	Clinical pipeline report, company report or official report of VistaGen Therapeutics, Inc.
DMN7VK1	RU	http://www.vistagen.com/?page_id=198

DMDL9WU	DI	DMDL9WU
DMDL9WU	DN	AV-201
DMDL9WU	MI	TTN451K
DMDL9WU	MN	Aromatic-L-amino-acid decarboxylase (DDC)
DMDL9WU	MT	DTT
DMDL9WU	MA	Modulator
DMDL9WU	RN	UCSF report
DMDL9WU	RU	http://pdcenter.neurology.ucsf.edu/research/learn-about-closed-studies/gene-therapy-aadc-phase-i

DMASRP3	DI	DMASRP3
DMASRP3	DN	AVA-101
DMASRP3	MI	TT9HKJA
DMASRP3	MN	Vascular endothelial growth factor (VEGF)
DMASRP3	MT	DTT
DMASRP3	MA	Modulator
DMASRP3	RN	Clinical pipeline report, company report or official report of Avalanche Biotechnologies.
DMASRP3	RU	http://www.avalanchebiotech.com/

DMORJD4	DI	DMORJD4
DMORJD4	DN	AVB-500
DMORJD4	MI	TT69QD2
DMORJD4	MN	AXL receptor tyrosine kinase ligand (GAS6)
DMORJD4	MT	DTT
DMORJD4	MA	Inhibitor
DMORJD4	RN	Clinical pipeline report, company report or official report of Aravive.
DMORJD4	RU	https://aravive.com/pipeline/

DMLAOHX	DI	DMLAOHX
DMLAOHX	DN	Avdoralimab
DMLAOHX	MI	TTQLO2H
DMLAOHX	MN	HUMAN C5a receptor (C5aR)
DMLAOHX	MT	DTT
DMLAOHX	MA	Inhibitor
DMLAOHX	RN	Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV. Emerg Microbes Infect. 2018 Apr 24;7(1):77.
DMLAOHX	RU	https://pubmed.ncbi.nlm.nih.gov/29691378

DMESMHU	DI	DMESMHU
DMESMHU	DN	AVE-0657
DMESMHU	MI	TTFZVPO
DMESMHU	MN	Sodium/hydrogen exchanger 3 (SLC9A3)
DMESMHU	MT	DTT
DMESMHU	MA	Inhibitor
DMESMHU	RN	Inhibition of central Na(+)/H(+) exchanger type 3 can alleviate sleep apnea in Sprague-Dawley rats. Chin Med J (Engl). 2014;127(1):48-53.
DMESMHU	RU	https://pubmed.ncbi.nlm.nih.gov/24384423

DMA42BV	DI	DMA42BV
DMA42BV	DN	AVE-2268
DMA42BV	MI	TTLWPVF
DMA42BV	MN	Sodium/glucose cotransporter 2 (SGLT2)
DMA42BV	MT	DTT
DMA42BV	MA	Modulator
DMA42BV	RN	Effects of AVE2268, a substituted glycopyranoside, on urinary glucose excretion and blood glucose in mice and rats. Arzneimittelforschung. 2008;58(11):574-80.
DMA42BV	RU	https://pubmed.ncbi.nlm.nih.gov/19137908

DMQGI73	DI	DMQGI73
DMQGI73	DN	AVI-4557
DMQGI73	MI	TTWP7HQ
DMQGI73	MN	CYP3A4 messenger RNA (CYP3A4 mRNA)
DMQGI73	MT	DTT
DMQGI73	RN	Phosphorodiamidate morpholino antisense oligomers inhibit expression of human cytochrome P450 3A4 and alter selected drug metabolism. Drug Metab Dispos. 2002 Jul;30(7):757-62.
DMQGI73	RU	https://pubmed.ncbi.nlm.nih.gov/12065433

DMUOYQR	DI	DMUOYQR
DMUOYQR	DN	AVI-5126
DMUOYQR	MI	TTNQ5ZP
DMUOYQR	MN	Myc messenger RNA (MYC mRNA)
DMUOYQR	MT	DTT
DMUOYQR	RN	Efficacy of a phosphorodiamidate morpholino oligomer antisense compound in the inhibition of corneal transplant rejection in a rat cornea transplant model. J Ocul Pharmacol Ther. 2012 Apr;28(2):194-201.
DMUOYQR	RU	https://pubmed.ncbi.nlm.nih.gov/22149555

DMJFLBC	DI	DMJFLBC
DMJFLBC	DN	AVN 101
DMJFLBC	MI	TTJS8PY
DMJFLBC	MN	5-HT 6 receptor (HTR6)
DMJFLBC	MT	DTT
DMJFLBC	MA	Modulator
DMJFLBC	RN	Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. Curr Opin Investig Drugs. 2010 January; 11(1): 80-91.
DMJFLBC	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3346261/

DMK2LGM	DI	DMK2LGM
DMK2LGM	DN	AVN 322
DMK2LGM	MI	TTJS8PY
DMK2LGM	MN	5-HT 6 receptor (HTR6)
DMK2LGM	MT	DTT
DMK2LGM	MA	Modulator
DMK2LGM	RN	5-HT6 receptors and Alzheimer's disease. Alzheimers Res Ther. 2013; 5(2): 15.
DMK2LGM	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706851/

DMOGFNI	DI	DMOGFNI
DMOGFNI	DN	AVN-101
DMOGFNI	MI	TTO9X1H
DMOGFNI	MN	5-HT 7 receptor (HTR7)
DMOGFNI	MT	DTT
DMOGFNI	MA	Antagonist
DMOGFNI	RN	AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders. J Alzheimers Dis. 2016 May 25;53(2):583-620.
DMOGFNI	RU	https://pubmed.ncbi.nlm.nih.gov/27232215

DMVADGZ	DI	DMVADGZ
DMVADGZ	DN	AWD-12-281
DMVADGZ	MI	TTZ97H5
DMVADGZ	MN	Phosphodiesterase 4A (PDE4A)
DMVADGZ	MT	DTT
DMVADGZ	MA	Inhibitor
DMVADGZ	RN	The phosphodiesterase 4 inhibitor AWD 12-281 is active in a new guinea-pig model of allergic skin inflammation predictive of human skin penetration and suppresses both Th1 and Th2 cytokines in mice. J Pharm Pharmacol. 2005 Dec;57(12):1609-17.
DMVADGZ	RU	https://pubmed.ncbi.nlm.nih.gov/16354405

DMVADGZ	DI	DMVADGZ
DMVADGZ	DN	AWD-12-281
DMVADGZ	MI	TTVIAT9
DMVADGZ	MN	Phosphodiesterase 4B (PDE4B)
DMVADGZ	MT	DTT
DMVADGZ	MA	Inhibitor
DMVADGZ	RN	The phosphodiesterase 4 inhibitor AWD 12-281 is active in a new guinea-pig model of allergic skin inflammation predictive of human skin penetration and suppresses both Th1 and Th2 cytokines in mice. J Pharm Pharmacol. 2005 Dec;57(12):1609-17.
DMVADGZ	RU	https://pubmed.ncbi.nlm.nih.gov/16354405

DMVADGZ	DI	DMVADGZ
DMVADGZ	DN	AWD-12-281
DMVADGZ	MI	TTSKMI8
DMVADGZ	MN	Phosphodiesterase 4D (PDE4D)
DMVADGZ	MT	DTT
DMVADGZ	MA	Inhibitor
DMVADGZ	RN	The phosphodiesterase 4 inhibitor AWD 12-281 is active in a new guinea-pig model of allergic skin inflammation predictive of human skin penetration and suppresses both Th1 and Th2 cytokines in mice. J Pharm Pharmacol. 2005 Dec;57(12):1609-17.
DMVADGZ	RU	https://pubmed.ncbi.nlm.nih.gov/16354405

DMTAEMB	DI	DMTAEMB
DMTAEMB	DN	AX-200
DMTAEMB	MI	TTC70AJ
DMTAEMB	MN	Granulocyte colony-stimulating factor receptor (G-CSF-R)
DMTAEMB	MT	DTT
DMTAEMB	MA	Modulator
DMTAEMB	RN	Granulocyte colony-stimulating factor in patients with acute ischemic stroke: results of the AX200 for Ischemic Stroke trial. Stroke. 2013 Oct;44(10):2681-7.
DMTAEMB	RU	https://pubmed.ncbi.nlm.nih.gov/23963331

DMTQ1Y3	DI	DMTQ1Y3
DMTQ1Y3	DN	AXL-1717
DMTQ1Y3	MI	TTHRID2
DMTQ1Y3	MN	Insulin-like growth factor I receptor (IGF1R)
DMTQ1Y3	MT	DTT
DMTQ1Y3	MA	Inhibitor
DMTQ1Y3	RN	Clinical Phase I study with an Insulin-like Growth Factor-1 receptor inhibitor: experiences in patients with squamous non-small cell lung carcinoma. Acta Oncol. 2011 Apr;50(3):441-7.
DMTQ1Y3	RU	https://pubmed.ncbi.nlm.nih.gov/20698809

DM4CJNE	DI	DM4CJNE
DM4CJNE	DN	AYX-1
DM4CJNE	MI	TTUQREN
DM4CJNE	MN	Early growth response protein 1 (EGR-1)
DM4CJNE	MT	DTT
DM4CJNE	MA	Inhibitor
DM4CJNE	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM4CJNE	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMHFUJT	DI	DMHFUJT
DMHFUJT	DN	AZ-01, PEGylated interferon-beta
DMHFUJT	MI	TT4TZ8J
DMHFUJT	MN	Interferon-beta (IFNB1)
DMHFUJT	MT	DTT
DMHFUJT	MA	Modulator
DMHFUJT	RN	PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update. Biologics. 2013; 7: 131-138.
DMHFUJT	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686537/

DM9LKYP	DI	DM9LKYP
DM9LKYP	DN	AZ-40140
DM9LKYP	MI	TTMXGCW
DM9LKYP	MN	Adrenergic receptor beta-3 (ADRB3)
DM9LKYP	MT	DTT
DM9LKYP	MA	Agonist
DM9LKYP	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DM9LKYP	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMM0N1F	DI	DMM0N1F
DMM0N1F	DN	AZD-0865
DMM0N1F	MI	TTLOKXP
DMM0N1F	MN	Gastric H(+)/K(+) ATPase (Proton pump)
DMM0N1F	MT	DTT
DMM0N1F	MA	Modulator
DMM0N1F	RN	Mechanism of action of AZD0865, a K+-competitive inhibitor of gastric H+,K+-ATPase. Biochem Pharmacol. 2007 Jan 15;73(2):198-205.
DMM0N1F	RU	https://pubmed.ncbi.nlm.nih.gov/17081503

DM7B1AR	DI	DM7B1AR
DM7B1AR	DN	AZD-1446
DM7B1AR	MI	TTL1ATN
DM7B1AR	MN	Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2)
DM7B1AR	MT	DTT
DM7B1AR	MA	Modulator
DM7B1AR	RN	A randomized, double-blind, placebo-controlled crossover study of 4 2* nicotinic acetylcholine receptor agonist AZD1446 (TC-6683) in adults with attention-deficit/hyperactivity disorder.Psychopharmacology (Berl). 2014 Mar;231(6):1251-65.
DM7B1AR	RU	https://www.ncbi.nlm.nih.gov/pubmed/23640072

DMLK59M	DI	DMLK59M
DMLK59M	DN	AZD1480
DMLK59M	MI	TTRMX3V
DMLK59M	MN	Janus kinase 2 (JAK-2)
DMLK59M	MT	DTT
DMLK59M	MA	Modulator
DMLK59M	RN	The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell. 2009 Dec 8;16(6):487-97.
DMLK59M	RU	https://pubmed.ncbi.nlm.nih.gov/19962667

DMUE90I	DI	DMUE90I
DMUE90I	DN	AZD1656
DMUE90I	MI	TTDLNGZ
DMUE90I	MN	Glucokinase (GCK)
DMUE90I	MT	DTT
DMUE90I	MA	Activator
DMUE90I	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DMUE90I	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DMX5SG7	DI	DMX5SG7
DMX5SG7	DN	AZD1772//RDX5791
DMX5SG7	MI	TTFZVPO
DMX5SG7	MN	Sodium/hydrogen exchanger 3 (SLC9A3)
DMX5SG7	MT	DTT
DMX5SG7	MA	Modulator
DMX5SG7	RN	RDX5791, a First-in-Class Minimally Systemic NHE3 Inhibitor in Clinical Development for CIC and IBS-C, Increases Intestinal Sodium Leading to Enhanced Intestinal Fluid Volume and Transit. Gastroenterology. 2011;140(suppl 1):S99.
DMX5SG7	RU	http://www.gastrojournal.org/article/S0016-5085(11)60405-8/pdf

DMMCL9F	DI	DMMCL9F
DMMCL9F	DN	AZD1981
DMMCL9F	MI	TTQDMX5
DMMCL9F	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMMCL9F	MT	DTT
DMMCL9F	MA	Antagonist
DMMCL9F	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DMMCL9F	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DMOEARH	DI	DMOEARH
DMOEARH	DN	Azd2014
DMOEARH	MI	DES5XRU
DMOEARH	MN	Cytochrome P450 2C8 (CYP2C8)
DMOEARH	MT	DME
DMOEARH	MA	Metabolism
DMOEARH	RN	First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor AZD2014. Clin Cancer Res. 2015 Aug 1;21(15):3412-9.
DMOEARH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25805799

DMOEARH	DI	DMOEARH
DMOEARH	DN	Azd2014
DMOEARH	MI	DE4LYSA
DMOEARH	MN	Cytochrome P450 3A4 (CYP3A4)
DMOEARH	MT	DME
DMOEARH	MA	Metabolism
DMOEARH	RN	First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor AZD2014. Clin Cancer Res. 2015 Aug 1;21(15):3412-9.
DMOEARH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25805799

DMOEARH	DI	DMOEARH
DMOEARH	DN	Azd2014
DMOEARH	MI	DEIBDNY
DMOEARH	MN	Cytochrome P450 3A5 (CYP3A5)
DMOEARH	MT	DME
DMOEARH	MA	Metabolism
DMOEARH	RN	First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor AZD2014. Clin Cancer Res. 2015 Aug 1;21(15):3412-9.
DMOEARH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25805799

DMOEARH	DI	DMOEARH
DMOEARH	DN	Azd2014
DMOEARH	MI	TTX4GLS
DMOEARH	MN	Mammalian target of rapamycin complex 1 (mTORC1)
DMOEARH	MT	DTT
DMOEARH	MA	Inhibitor
DMOEARH	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMOEARH	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMOEARH	DI	DMOEARH
DMOEARH	DN	Azd2014
DMOEARH	MI	TTCJG29
DMOEARH	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMOEARH	MT	DTT
DMOEARH	MA	Inhibitor
DMOEARH	RN	Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014. Biochem Biophys Res Commun. 2014 Jan 10;443(2):406-12.
DMOEARH	RU	https://pubmed.ncbi.nlm.nih.gov/24309100

DMOEARH	DI	DMOEARH
DMOEARH	DN	Azd2014
DMOEARH	MI	TTWDKCL
DMOEARH	MN	Target of rapamycin complex 2 MAPKAP1 (MTORC2)
DMOEARH	MT	DTT
DMOEARH	MA	Inhibitor
DMOEARH	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMOEARH	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMGQSVX	DI	DMGQSVX
DMGQSVX	DN	AZD-2115
DMGQSVX	MI	TT2CJVK
DMGQSVX	MN	Adrenergic receptor beta-2 (ADRB2)
DMGQSVX	MT	DTT
DMGQSVX	MA	Agonist
DMGQSVX	RN	Evaluation of WO-2012085582 and WO-2012085583 two identified MABAs: backups to AZD-2115. Expert Opin Ther Pat. 2012 Nov;22(11):1377-83.
DMGQSVX	RU	https://pubmed.ncbi.nlm.nih.gov/22917191

DMGQSVX	DI	DMGQSVX
DMGQSVX	DN	AZD-2115
DMGQSVX	MI	TTOXS3C
DMGQSVX	MN	Muscarinic acetylcholine receptor (CHRM)
DMGQSVX	MT	DTT
DMGQSVX	MA	Agonist
DMGQSVX	RN	Evaluation of WO-2012085582 and WO-2012085583 two identified MABAs: backups to AZD-2115. Expert Opin Ther Pat. 2012 Nov;22(11):1377-83.
DMGQSVX	RU	https://pubmed.ncbi.nlm.nih.gov/22917191

DM8FZOG	DI	DM8FZOG
DM8FZOG	DN	AZD-2327
DM8FZOG	MI	TT27RFC
DM8FZOG	MN	Opioid receptor delta (OPRD1)
DM8FZOG	MT	DTT
DM8FZOG	MA	Agonist
DM8FZOG	RN	Preclinical pharmacology of AZD2327: a highly selective agonist of the delta-opioid receptor. J Pharmacol Exp Ther. 2011 Jul;338(1):195-204.
DM8FZOG	RU	https://pubmed.ncbi.nlm.nih.gov/21444630

DMF34UY	DI	DMF34UY
DMF34UY	DN	AZD-2423
DMF34UY	MI	TTFZYTO
DMF34UY	MN	C-C chemokine receptor type 2 (CCR2)
DMF34UY	MT	DTT
DMF34UY	MA	Antagonist
DMF34UY	RN	CA patent application no. 841416, Method of selecting therapeutic indications.
DMF34UY	RU	http://www.google.com/patents/CA2841416A1?cl=en

DMZLGQV	DI	DMZLGQV
DMZLGQV	DN	AZD2624
DMZLGQV	MI	TTBPGLU
DMZLGQV	MN	Neuromedin-K receptor (TACR3)
DMZLGQV	MT	DTT
DMZLGQV	MA	Modulator
DMZLGQV	RN	The selective neurokinin 3 antagonist AZD2624 does not improve symptoms or cognition in schizophrenia: a proof-of-principle study.J Clin Psychopharmacol.2014 Apr;34(2):199-204.
DMZLGQV	RU	https://www.ncbi.nlm.nih.gov/pubmed/24525659

DMYUNXP	DI	DMYUNXP
DMYUNXP	DN	AZD2811
DMYUNXP	MI	TTCY4SB
DMYUNXP	MN	Aurora kinase (AURK)
DMYUNXP	MT	DTT
DMYUNXP	MA	Inhibitor
DMYUNXP	RN	Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo. Sci Transl Med. 2016 Feb 10;8(325):325ra17.
DMYUNXP	RU	https://pubmed.ncbi.nlm.nih.gov/26865565

DM6AI9N	DI	DM6AI9N
DM6AI9N	DN	AZD-2927
DM6AI9N	MI	TTM7WCE
DM6AI9N	MN	Ion channel unspecific (IC)
DM6AI9N	MT	DTT
DM6AI9N	MA	Modulator
DM6AI9N	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7704).
DM6AI9N	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7704

DME8Z5M	DI	DME8Z5M
DME8Z5M	DN	AZD-3199
DME8Z5M	MI	TT2CJVK
DME8Z5M	MN	Adrenergic receptor beta-2 (ADRB2)
DME8Z5M	MT	DTT
DME8Z5M	MA	Agonist
DME8Z5M	RN	Clinical pharmacokinetics of AZD3199, an inhaled ultra-long-acting beta2-adrenoreceptor agonist (uLABA). Drug Des Devel Ther. 2015; 9: 753-762.
DME8Z5M	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4330041/

DMANC59	DI	DMANC59
DMANC59	DN	AZD-3241
DMANC59	MI	TTVCZPI
DMANC59	MN	Myeloperoxidase (MPO)
DMANC59	MT	DTT
DMANC59	MA	Inhibitor
DMANC59	RN	Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease. Brain. 2015 Sep;138(Pt 9):2687-700.
DMANC59	RU	https://pubmed.ncbi.nlm.nih.gov/26137956

DML9M5S	DI	DML9M5S
DML9M5S	DN	AZD-4017
DML9M5S	MI	TTN7BL9
DML9M5S	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DML9M5S	MT	DTT
DML9M5S	MA	Inhibitor
DML9M5S	RN	New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches. 2012. Chapter 5. Page(131).
DML9M5S	RU	https://books.google.com.hk/books?id=0rmlVGhlJ0IC&pg=PA131&lpg=PA131&dq=RG-7234++New+Therapeutic+Strategies+for+Type+2+Diabetes&source=bl&ots=toqK7w4uiI&sig=sx5iyfQWH2bTCSZmT5aUQiKfPuM&hl=zh-CN&sa=X&ved=0CB0Q6AEwAGoVChMIsZ_k6dDGyAIViLeOCh0oUQpr#v=onepage&q=RG-7234%20%20New%20Therapeutic%20Strategies%20for%20Type%202%20Diabetes&f=false

DM8SVIY	DI	DM8SVIY
DM8SVIY	DN	AZD4635
DM8SVIY	MI	TTM2AOE
DM8SVIY	MN	Adenosine A2a receptor (ADORA2A)
DM8SVIY	MT	DTT
DM8SVIY	MA	Antagonist
DM8SVIY	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM8SVIY	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMFVL5J	DI	DMFVL5J
DMFVL5J	DN	AZD-4877
DMFVL5J	MI	TTTRP0H
DMFVL5J	MN	Kinesin-like protein KIF11 (KIF11)
DMFVL5J	MT	DTT
DMFVL5J	MA	Inhibitor
DMFVL5J	RN	Kinesins and cancer. Nat Rev Cancer. 2012 Jul 24;12(8):527-39.
DMFVL5J	RU	https://pubmed.ncbi.nlm.nih.gov/22825217

DM3JSFK	DI	DM3JSFK
DM3JSFK	DN	AZD-5069
DM3JSFK	MI	TT30C9G
DM3JSFK	MN	C-X-C chemokine receptor type 2 (CXCR2)
DM3JSFK	MT	DTT
DM3JSFK	MA	Inhibitor
DM3JSFK	RN	Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist. J Pharmacol Exp Ther. 2015 May;353(2):340-50.
DM3JSFK	RU	https://pubmed.ncbi.nlm.nih.gov/25736418

DMOZ04X	DI	DMOZ04X
DMOZ04X	DN	AZD-5213
DMOZ04X	MI	TT9JNIC
DMOZ04X	MN	Histamine H3 receptor (H3R)
DMOZ04X	MT	DTT
DMOZ04X	MA	Antagonist
DMOZ04X	RN	SAR110894, a potent histamine H receptor antagonist, displays procognitive effects in rodents. Pharmacol Biochem Behav. 2012 Aug;102(2):203-14.
DMOZ04X	RU	https://pubmed.ncbi.nlm.nih.gov/22542742

DMJ8V3K	DI	DMJ8V3K
DMJ8V3K	DN	AZD5312
DMJ8V3K	MI	TTS64P2
DMJ8V3K	MN	Androgen receptor (AR)
DMJ8V3K	MT	DTT
DMJ8V3K	MA	Modulator
DMJ8V3K	RN	Company report (Astrazeneca)
DMJ8V3K	RU	https://www.astrazeneca.com/our-company/media-centre/press-releases/2014/astrazeneca-isis-pharmaceuticals-oligonucleotide-oncology-cardiovascular-metabolic-diseases-13112014.html

DM0PFNC	DI	DM0PFNC
DM0PFNC	DN	AZD6738
DM0PFNC	MI	TT8ZYBQ
DM0PFNC	MN	Serine/threonine-protein kinase ATR (FRP1)
DM0PFNC	MT	DTT
DM0PFNC	MA	Inhibitor
DM0PFNC	RN	National Cancer Institute Drug Dictionary (drug id 754022).
DM0PFNC	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=754022

DMIBXK0	DI	DMIBXK0
DMIBXK0	DN	AZD-7009
DMIBXK0	MI	TT1VOHK
DMIBXK0	MN	Potassium channel unspecific (KC)
DMIBXK0	MT	DTT
DMIBXK0	MA	Modulator
DMIBXK0	RN	Rapid slowing of the atrial fibrillatory rate after administration of AZD7009 predicts conversion of atrial fibrillation. J Electrocardiol. 2014 May-Jun;47(3):316-23.
DMIBXK0	RU	https://pubmed.ncbi.nlm.nih.gov/24508473

DMC48SP	DI	DMC48SP
DMC48SP	DN	AZD-7268
DMC48SP	MI	TTN4QDT
DMC48SP	MN	Opioid receptor (OPR)
DMC48SP	MT	DTT
DMC48SP	MA	Modulator
DMC48SP	RN	EP patent application no. 2774991, Drug delivery system for use in the treatment or diagnosis of neurological disorders.
DMC48SP	RU	http://www.google.com/patents/EP2774991A1?cl=en

DMXF26Y	DI	DMXF26Y
DMXF26Y	DN	AZD7325
DMXF26Y	MI	TTAN6JD
DMXF26Y	MN	Glutamate receptor AMPA (GRIA)
DMXF26Y	MT	DTT
DMXF26Y	MA	Agonist
DMXF26Y	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DMXF26Y	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DMEW3K9	DI	DMEW3K9
DMEW3K9	DN	AZD7624
DMEW3K9	MI	TTWELHI
DMEW3K9	MN	Stress-activated protein kinase (p38)
DMEW3K9	MT	DTT
DMEW3K9	MA	Inhibitor
DMEW3K9	RN	Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2015 Mar;24(3):383-92.
DMEW3K9	RU	https://pubmed.ncbi.nlm.nih.gov/25599809

DMLXFM6	DI	DMLXFM6
DMLXFM6	DN	AZD-8683
DMLXFM6	MI	TTOXS3C
DMLXFM6	MN	Muscarinic acetylcholine receptor (CHRM)
DMLXFM6	MT	DTT
DMLXFM6	MA	Antagonist
DMLXFM6	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 17).
DMLXFM6	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=17

DM0M7QW	DI	DM0M7QW
DM0M7QW	DN	AZD-8848
DM0M7QW	MI	TTRJ1K4
DM0M7QW	MN	Toll-like receptor 7 (TLR7)
DM0M7QW	MT	DTT
DM0M7QW	MA	Agonist
DM0M7QW	RN	Repeated intranasal TLR7 stimulation reduces allergen responsiveness in allergic rhinitis. Respir Res. 2012 Jun 22;13:53.
DM0M7QW	RU	https://pubmed.ncbi.nlm.nih.gov/22726593

DMFLCW4	DI	DMFLCW4
DMFLCW4	DN	AZD8931
DMFLCW4	MI	TT6EO5L
DMFLCW4	MN	Erbb2 tyrosine kinase receptor (HER2)
DMFLCW4	MT	DTT
DMFLCW4	MA	Inhibitor
DMFLCW4	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DMFLCW4	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DMJGYPK	DI	DMJGYPK
DMJGYPK	DN	AZD9056
DMJGYPK	MI	TT473XN
DMJGYPK	MN	P2X purinoceptor 7 (P2RX7)
DMJGYPK	MT	DTT
DMJGYPK	MA	Antagonist
DMJGYPK	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DMJGYPK	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DMVKPEZ	DI	DMVKPEZ
DMVKPEZ	DN	AZD-9164
DMVKPEZ	MI	TTOXS3C
DMVKPEZ	MN	Muscarinic acetylcholine receptor (CHRM)
DMVKPEZ	MT	DTT
DMVKPEZ	MA	Antagonist
DMVKPEZ	RN	The discovery of AZD9164, a novel muscarinic M3 antagonist. Bioorg Med Chem Lett. 2011 Dec 15;21(24):7440-6.
DMVKPEZ	RU	https://pubmed.ncbi.nlm.nih.gov/22047691

DMB87M3	DI	DMB87M3
DMB87M3	DN	AZD9668
DMB87M3	MI	TTPLTSQ
DMB87M3	MN	Neutrophil elastase (NE)
DMB87M3	MT	DTT
DMB87M3	MA	Inhibitor
DMB87M3	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DMB87M3	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DMQOTHP	DI	DMQOTHP
DMQOTHP	DN	AZD9833
DMQOTHP	MI	TTZAYWL
DMQOTHP	MN	Estrogen receptor (ESR)
DMQOTHP	MT	DTT
DMQOTHP	MA	Degrader
DMQOTHP	RN	Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist. J Med Chem. 2020 Dec 10;63(23):14530-14559.
DMQOTHP	RU	https://pubmed.ncbi.nlm.nih.gov/32910656

DME0JMV	DI	DME0JMV
DME0JMV	DN	AZX-100
DME0JMV	MI	TT5IP87
DME0JMV	MN	Heat shock protein 20 (HSP20)
DME0JMV	MT	DTT
DME0JMV	MA	Modulator
DME0JMV	RN	Internalization and intracellular trafficking of a PTD-conjugated anti-fibrotic peptide, AZX100, in human dermal keloid fibroblasts. J Pharm Sci. 2010 Jul;99(7):3100-21.
DME0JMV	RU	https://pubmed.ncbi.nlm.nih.gov/20140957

DMOMDA4	DI	DMOMDA4
DMOMDA4	DN	B-701
DMOMDA4	MI	TTST7KB
DMOMDA4	MN	Fibroblast growth factor receptor 3 (FGFR3)
DMOMDA4	MT	DTT
DMOMDA4	MA	Antagonist
DMOMDA4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMOMDA4	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM7586F	DI	DM7586F
DM7586F	DN	Bafetinib
DM7586F	MI	TTS7G69
DM7586F	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DM7586F	MT	DTT
DM7586F	MA	Modulator
DM7586F	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM7586F	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM7586F	DI	DM7586F
DM7586F	DN	Bafetinib
DM7586F	MI	TT1RWNJ
DM7586F	MN	Tyrosine-protein kinase Lyn (JTK8)
DM7586F	MT	DTT
DM7586F	MA	Modulator
DM7586F	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM7586F	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM4C7E6	DI	DM4C7E6
DM4C7E6	DN	BAICALEIN
DM4C7E6	MI	TT2J34L
DM4C7E6	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM4C7E6	MT	DTT
DM4C7E6	MA	Inhibitor
DM4C7E6	RN	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
DM4C7E6	RU	https://pubmed.ncbi.nlm.nih.gov/1848292

DM4C7E6	DI	DM4C7E6
DM4C7E6	DN	BAICALEIN
DM4C7E6	MI	TTV9A7R
DM4C7E6	MN	Lactoylglutathione lyase (GLO1)
DM4C7E6	MT	DTT
DM4C7E6	MA	Inhibitor
DM4C7E6	RN	Structure-activity relationship of human GLO I inhibitory natural flavonoids and their growth inhibitory effects. Bioorg Med Chem. 2008 Apr 1;16(7):3969-75.
DM4C7E6	RU	https://pubmed.ncbi.nlm.nih.gov/18258440

DM4C7E6	DI	DM4C7E6
DM4C7E6	DN	BAICALEIN
DM4C7E6	MI	TT2IYXF
DM4C7E6	MN	L-selectin (SELL)
DM4C7E6	MT	DTT
DM4C7E6	MA	Inhibitor
DM4C7E6	RN	Rational design of novel, potent small molecule pan-selectin antagonists. J Med Chem. 2007 Mar 22;50(6):1101-15.
DM4C7E6	RU	https://pubmed.ncbi.nlm.nih.gov/17302397

DM4C7E6	DI	DM4C7E6
DM4C7E6	DN	BAICALEIN
DM4C7E6	MI	TTNGKET
DM4C7E6	MN	Prolyl endopeptidase (PREP)
DM4C7E6	MT	DTT
DM4C7E6	MA	Inhibitor
DM4C7E6	RN	Baicalin, a prodrug able to reach the CNS, is a prolyl oligopeptidase inhibitor. Bioorg Med Chem. 2008 Aug 1;16(15):7516-24.
DM4C7E6	RU	https://pubmed.ncbi.nlm.nih.gov/18650094

DM4C7E6	DI	DM4C7E6
DM4C7E6	DN	BAICALEIN
DM4C7E6	MI	TTE5VG0
DM4C7E6	MN	P-selectin (SELP)
DM4C7E6	MT	DTT
DM4C7E6	MA	Inhibitor
DM4C7E6	RN	Rational design of novel, potent small molecule pan-selectin antagonists. J Med Chem. 2007 Mar 22;50(6):1101-15.
DM4C7E6	RU	https://pubmed.ncbi.nlm.nih.gov/17302397

DM4C7E6	DI	DM4C7E6
DM4C7E6	DN	BAICALEIN
DM4C7E6	MI	TTF8CQI
DM4C7E6	MN	Tumor necrosis factor (TNF)
DM4C7E6	MT	DTT
DM4C7E6	MA	Inhibitor
DM4C7E6	RN	Discovery of the inhibitors of tumor necrosis factor alpha with structure-based virtual screening. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6195-8.
DM4C7E6	RU	https://pubmed.ncbi.nlm.nih.gov/20850306

DM4C7E6	DI	DM4C7E6
DM4C7E6	DN	BAICALEIN
DM4C7E6	MI	TT7RJY8
DM4C7E6	MN	Xanthine dehydrogenase/oxidase (XDH)
DM4C7E6	MT	DTT
DM4C7E6	MA	Inhibitor
DM4C7E6	RN	Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod. 1988 Mar-Apr;51(2):345-8.
DM4C7E6	RU	https://pubmed.ncbi.nlm.nih.gov/3379415

DM3WCL4	DI	DM3WCL4
DM3WCL4	DN	Baltaleucel-T
DM3WCL4	MI	TTXQYT6
DM3WCL4	MN	T-cells (T-cells)
DM3WCL4	MT	DTT
DM3WCL4	MA	Immunomodulator
DM3WCL4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3WCL4	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMSZOXQ	DI	DMSZOXQ
DMSZOXQ	DN	Baminercept
DMSZOXQ	MI	TTFO0PM
DMSZOXQ	MN	Lymphotoxin beta receptor (LTBR)
DMSZOXQ	MT	DTT
DMSZOXQ	MA	Antagonist
DMSZOXQ	RN	ClinicalTrials.gov (NCT01552681) Baminercept in Sj ren's Syndrome. U.S. National Institutes of Health.
DMSZOXQ	RU	https://clinicaltrials.gov/ct2/show/NCT01552681

DM0TZEP	DI	DM0TZEP
DM0TZEP	DN	Bamosiran
DM0TZEP	MI	TTG8ZWP
DM0TZEP	MN	ADRB2 messenger RNA (ADRB2 mRNA)
DM0TZEP	MT	DTT
DM0TZEP	MA	Inhibitor
DM0TZEP	RN	Clinical pipeline report, company report or official report of Sylentis.
DM0TZEP	RU	https://www.sylentis.com/index.php/en/pipeline/bamosiran

DMW03YD	DI	DMW03YD
DMW03YD	DN	BAN2401
DMW03YD	MI	TTE4KHA
DMW03YD	MN	Amyloid beta A4 protein (APP)
DMW03YD	MT	DTT
DMW03YD	MA	Modulator
DMW03YD	RN	The murine version of BAN2401 (mAb158) selectively reduces amyloid-beta protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J Alzheimers Dis. 2015;43(2):575-88.
DMW03YD	RU	https://pubmed.ncbi.nlm.nih.gov/25096615

DMWI0X3	DI	DMWI0X3
DMWI0X3	DN	Barusiban
DMWI0X3	MI	TTSCIUP
DMWI0X3	MN	Oxytocin receptor (OTR)
DMWI0X3	MT	DTT
DMWI0X3	MA	Antagonist
DMWI0X3	RN	The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol. 2009 Jun;200(6):627.e1-10.
DMWI0X3	RU	https://pubmed.ncbi.nlm.nih.gov/19306963

DMQ8J0U	DI	DMQ8J0U
DMQ8J0U	DN	Basmisanil
DMQ8J0U	MI	TTNZPQ1
DMQ8J0U	MN	GABA(A) receptor alpha-5 (GABRA5)
DMQ8J0U	MT	DTT
DMQ8J0U	MA	Modulator
DMQ8J0U	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQ8J0U	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DM6CVZ5	DI	DM6CVZ5
DM6CVZ5	DN	Bavisant
DM6CVZ5	MI	TT9JNIC
DM6CVZ5	MN	Histamine H3 receptor (H3R)
DM6CVZ5	MT	DTT
DM6CVZ5	MA	Antagonist
DM6CVZ5	RN	Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder. CNS Drugs. 2012 May 1;26(5):421-34.
DM6CVZ5	RU	https://pubmed.ncbi.nlm.nih.gov/22519922

DM4JGNH	DI	DM4JGNH
DM4JGNH	DN	BAY 1067197
DM4JGNH	MI	TTK25J1
DM4JGNH	MN	Adenosine A1 receptor (ADORA1)
DM4JGNH	MT	DTT
DM4JGNH	MA	Modulator
DM4JGNH	RN	Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist. Current Issue vol. 111 no. 12 Celine Valant, 4614-4619.
DM4JGNH	RU	http://www.pnas.org/content/111/12/4614

DMHKTGX	DI	DMHKTGX
DMHKTGX	DN	BAY 1142524
DMHKTGX	MI	TT8VUE0
DMHKTGX	MN	Chymase (CYM)
DMHKTGX	MT	DTT
DMHKTGX	MA	Inhibitor
DMHKTGX	RN	Pharmacokinetics, Safety, and Tolerability of the Novel Chymase Inhibitor BAY 1142524 in Healthy Male Volunteers. Clin Pharmacol Drug Dev. 2019 May;8(4):467-479.
DMHKTGX	RU	https://pubmed.ncbi.nlm.nih.gov/29878583

DM8SNEM	DI	DM8SNEM
DM8SNEM	DN	BAY 11-42524
DM8SNEM	MI	TT8VUE0
DM8SNEM	MN	Chymase (CYM)
DM8SNEM	MT	DTT
DM8SNEM	MA	Inhibitor
DM8SNEM	RN	ClinicalTrials.gov (NCT02452515) A Single-blind Pilot Study to Investigate Safety and Tolerability of the Chymase Inhibitor BAY1142524 in Clinically Stable Patients With Left-ventricular Dysfunction.
DM8SNEM	RU	https://clinicaltrials.gov/ct2/show/NCT02452515

DM450XS	DI	DM450XS
DM450XS	DN	BAY 2253651
DM450XS	MI	TTGR91N
DM450XS	MN	TWIK-related acid-sensitive potassium channel 1 (TASK1)
DM450XS	MT	DTT
DM450XS	MA	Inhibitor
DM450XS	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DM450XS	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMSUB64	DI	DMSUB64
DMSUB64	DN	BAY 57-1293
DMSUB64	MI	TTKCVJR
DMSUB64	MN	Herpes simplex virus Helicase-primase (HSV UL8)
DMSUB64	MT	DTT
DMSUB64	MA	Inhibitor
DMSUB64	RN	Helicase primase: targeting the Achilles heel of herpes simplex viruses. Antivir Chem Chemother. 2004 May;15(3):135-40.
DMSUB64	RU	https://pubmed.ncbi.nlm.nih.gov/15266895

DMA75FG	DI	DMA75FG
DMA75FG	DN	BAY 794980
DMA75FG	MI	TT1290U
DMA75FG	MN	Coagulation factor VIII (F8)
DMA75FG	MT	DTT
DMA75FG	MA	Modulator
DMA75FG	RN	Efficacy and safety of prophylaxis with once-weekly BAY 79-4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients. A randomised, active-controlled, double-blind study. Thromb Haemost. 2012 Nov;108(5):913-22.
DMA75FG	RU	https://pubmed.ncbi.nlm.nih.gov/23014711

DMCPUKG	DI	DMCPUKG
DMCPUKG	DN	BAY 85-8501
DMCPUKG	MI	TTPLTSQ
DMCPUKG	MN	Neutrophil elastase (NE)
DMCPUKG	MT	DTT
DMCPUKG	MA	Modulator
DMCPUKG	RN	Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 5-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases. ChemMedChem. 2015 Jul;10(7):1163-73.
DMCPUKG	RU	https://pubmed.ncbi.nlm.nih.gov/26083237

DMRZLU4	DI	DMRZLU4
DMRZLU4	DN	BAY 86-5044
DMRZLU4	MI	TTKPW01
DMRZLU4	MN	Androgen receptor messenger RNA (AR mRNA)
DMRZLU4	MT	DTT
DMRZLU4	MA	Inhibitor
DMRZLU4	RN	Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist. J Med Chem. 2000 Dec 28;43(26):5010-6.
DMRZLU4	RU	https://pubmed.ncbi.nlm.nih.gov/11150172

DMRZLU4	DI	DMRZLU4
DMRZLU4	DN	BAY 86-5044
DMRZLU4	MI	TTYRL6O
DMRZLU4	MN	Glucocorticoid receptor (NR3C1)
DMRZLU4	MT	DTT
DMRZLU4	MA	Inhibitor
DMRZLU4	RN	Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist. J Med Chem. 2000 Dec 28;43(26):5010-6.
DMRZLU4	RU	https://pubmed.ncbi.nlm.nih.gov/11150172

DMRZLU4	DI	DMRZLU4
DMRZLU4	DN	BAY 86-5044
DMRZLU4	MI	TTHL6YX
DMRZLU4	MN	Progesterone (PG)
DMRZLU4	MT	DTT
DMRZLU4	MA	Antagonist
DMRZLU4	RN	Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer. Ann Oncol. 2013 Oct;24(10):2543-8.
DMRZLU4	RU	https://pubmed.ncbi.nlm.nih.gov/23788750

DMRZLU4	DI	DMRZLU4
DMRZLU4	DN	BAY 86-5044
DMRZLU4	MI	TTUV8G9
DMRZLU4	MN	Progesterone receptor (PGR)
DMRZLU4	MT	DTT
DMRZLU4	MA	Inhibitor
DMRZLU4	RN	Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist. J Med Chem. 2000 Dec 28;43(26):5010-6.
DMRZLU4	RU	https://pubmed.ncbi.nlm.nih.gov/11150172

DMCSGJ2	DI	DMCSGJ2
DMCSGJ2	DN	BAY1163877
DMCSGJ2	MI	TT0LF7H
DMCSGJ2	MN	Fibroblast growth factor receptor (FGFR)
DMCSGJ2	MT	DTT
DMCSGJ2	MA	Antagonist
DMCSGJ2	RN	Preclinical profile of BAY 1163877 - a selective pan-FGFR inhibitor in phase 1 clinical trial. Cancer Research. 10/2014; 74(19 Supplement):1739-1739.
DMCSGJ2	RU	http://cancerres.aacrjournals.org/content/74/19_Supplement/1739

DM83IYE	DI	DM83IYE
DM83IYE	DN	BAY1193397
DM83IYE	MI	TT2NUT5
DM83IYE	MN	Adrenergic receptor alpha-2C (ADRA2C)
DM83IYE	MT	DTT
DM83IYE	MA	Antagonist
DM83IYE	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM83IYE	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMYSQMW	DI	DMYSQMW
DMYSQMW	DN	BAY-1902607
DMYSQMW	MI	TT2THBD
DMYSQMW	MN	P2X purinoceptor 3 (P2RX3)
DMYSQMW	MT	DTT
DMYSQMW	MA	Inhibitor
DMYSQMW	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMYSQMW	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMM7Q68	DI	DMM7Q68
DMM7Q68	DN	BAY-2253651
DMM7Q68	MI	TTGR91N
DMM7Q68	MN	TWIK-related acid-sensitive potassium channel 1 (TASK1)
DMM7Q68	MT	DTT
DMM7Q68	MA	Inhibitor
DMM7Q68	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMM7Q68	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMVA5NS	DI	DMVA5NS
DMVA5NS	DN	BAY-57-9352
DMVA5NS	MI	TTI2WET
DMVA5NS	MN	Platelet-derived growth factor receptor (PDGFR)
DMVA5NS	MT	DTT
DMVA5NS	MA	Inhibitor
DMVA5NS	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMVA5NS	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMVA5NS	DI	DMVA5NS
DMVA5NS	DN	BAY-57-9352
DMVA5NS	MI	TTVJ1D8
DMVA5NS	MN	Vascular endothelial growth factor receptor (VEGFR)
DMVA5NS	MT	DTT
DMVA5NS	MA	Inhibitor
DMVA5NS	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMVA5NS	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DMVA5NS	DI	DMVA5NS
DMVA5NS	DN	BAY-57-9352
DMVA5NS	MI	TTUTJGQ
DMVA5NS	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMVA5NS	MT	DTT
DMVA5NS	MA	Inhibitor
DMVA5NS	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMVA5NS	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DM7NHLC	DI	DM7NHLC
DM7NHLC	DN	BAY-85-3934
DM7NHLC	MI	TTMHFRY
DM7NHLC	MN	HIF-prolyl hydroxylase 1 (HPH-1)
DM7NHLC	MT	DTT
DM7NHLC	MA	Inhibitor
DM7NHLC	RN	Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects. PLoS One. 2014 Nov 13;9(11):e111838.
DM7NHLC	RU	https://pubmed.ncbi.nlm.nih.gov/25392999

DM2XE80	DI	DM2XE80
DM2XE80	DN	BAY-X-7195
DM2XE80	MI	TTGKOY9
DM2XE80	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DM2XE80	MT	DTT
DM2XE80	MA	Modulator
DM2XE80	RN	The effect of a novel leukotriene C4/D4 antagonist, BAY-x-7195, on experimental allergic reactions. Prostaglandins. 1995 Nov-Dec;50(5-6):269-85.
DM2XE80	RU	https://www.ncbi.nlm.nih.gov/pubmed/8838238

DM2XE80	DI	DM2XE80
DM2XE80	DN	BAY-X-7195
DM2XE80	MI	TT0PZR5
DM2XE80	MN	Leukotriene CysLT2 receptor (CYSLTR2)
DM2XE80	MT	DTT
DM2XE80	MA	Modulator
DM2XE80	RN	The effect of a novel leukotriene C4/D4 antagonist, BAY-x-7195, on experimental allergic reactions. Prostaglandins. 1995 Nov-Dec;50(5-6):269-85.
DM2XE80	RU	https://www.ncbi.nlm.nih.gov/pubmed/8838238

DMLO18H	DI	DMLO18H
DMLO18H	DN	BAY-Y-5959
DMLO18H	MI	TTXHYV6
DMLO18H	MN	Voltage-gated L-type calcium channel (L-CaC)
DMLO18H	MT	DTT
DMLO18H	MA	Modulator
DMLO18H	RN	Hemodynamic effects of a calcium channel promoter, BAY y 5959, are preserved after chronic administration in ischemic heart failure in conscious dogs. J Pharmacol Exp Ther. 1998 Aug;286(2):760-6.
DMLO18H	RU	https://pubmed.ncbi.nlm.nih.gov/9694931

DMB0UF9	DI	DMB0UF9
DMB0UF9	DN	Bb2121
DMB0UF9	MI	TTZ3P4W
DMB0UF9	MN	B-cell maturation protein (TNFRSF17)
DMB0UF9	MT	DTT
DMB0UF9	MA	Immunomodulator
DMB0UF9	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMB0UF9	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMR59I4	DI	DMR59I4
DMR59I4	DN	BBI-5000
DMR59I4	MI	TTQDMX5
DMR59I4	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMR59I4	MT	DTT
DMR59I4	MA	Antagonist
DMR59I4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMR59I4	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMDSNIR	DI	DMDSNIR
DMDSNIR	DN	BBI503
DMDSNIR	MI	TTPV9O1
DMDSNIR	MN	Cancer stemness kinase (CSK)
DMDSNIR	MT	DTT
DMDSNIR	MA	Inhibitor
DMDSNIR	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMDSNIR	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMDSNIR	DI	DMDSNIR
DMDSNIR	DN	BBI503
DMDSNIR	MI	TTPMIQ9
DMDSNIR	MN	Serine/threonine-protein kinase (STK)
DMDSNIR	MT	DTT
DMDSNIR	MA	Inhibitor
DMDSNIR	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMDSNIR	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMY1UGV	DI	DMY1UGV
DMY1UGV	DN	Bc-3781 intravenous
DMY1UGV	MI	TT2VX74
DMY1UGV	MN	Bacterial Protein synthesis (Bact PROS)
DMY1UGV	MT	DTT
DMY1UGV	MA	Modulator
DMY1UGV	RN	Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010. Antimicrob Agents Chemother. 2013 Sep;57(9):4489-95.
DMY1UGV	RU	https://pubmed.ncbi.nlm.nih.gov/23836172

DMY1UGV	DI	DMY1UGV
DMY1UGV	DN	Bc-3781 intravenous
DMY1UGV	MI	DE4LYSA
DMY1UGV	MN	Cytochrome P450 3A4 (CYP3A4)
DMY1UGV	MT	DME
DMY1UGV	MA	Metabolism
DMY1UGV	RN	BC-3781: Evaluation of the CYP3A Interaction Potential.
DMY1UGV	RU	https://www.nabriva.com/Portals/_default/Skins/ProfessionalUs/pdfs/2011-bc-3781-and-cyp3a-interaction-potential.pdf

DMMKCJ6	DI	DMMKCJ6
DMMKCJ6	DN	BC-7013
DMMKCJ6	MI	TTUWYEA
DMMKCJ6	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DMMKCJ6	MT	DTT
DMMKCJ6	MA	Modulator
DMMKCJ6	RN	Company report (briva)
DMMKCJ6	RU	http://www.nabriva.com/fileadmin/content/ICAAC_2009/F1-1521_In_vitro_antibacterial_spectrum_of_BC-7013.pdf

DM2BO9W	DI	DM2BO9W
DM2BO9W	DN	BCP-13498
DM2BO9W	MI	DEJGDUW
DM2BO9W	MN	Cytochrome P450 1A2 (CYP1A2)
DM2BO9W	MT	DME
DM2BO9W	MA	Metabolism
DM2BO9W	RN	Acetaminophen activation by human liver cytochromes P450IIE1 and P450IA2. Arch Biochem Biophys. 1989 Jun;271(2):270-83.
DM2BO9W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=2729995

DM2BO9W	DI	DM2BO9W
DM2BO9W	DN	BCP-13498
DM2BO9W	MI	DECB0K3
DM2BO9W	MN	Cytochrome P450 2D6 (CYP2D6)
DM2BO9W	MT	DME
DM2BO9W	MA	Metabolism
DM2BO9W	RN	Involvement of human cytochrome P450 2D6 in the bioactivation of acetaminophen. Drug Metab Dispos. 2000 Dec;28(12):1397-400.
DM2BO9W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11095574

DM2BO9W	DI	DM2BO9W
DM2BO9W	DN	BCP-13498
DM2BO9W	MI	DEVDYN7
DM2BO9W	MN	Cytochrome P450 2E1 (CYP2E1)
DM2BO9W	MT	DME
DM2BO9W	MA	Metabolism
DM2BO9W	RN	Involvement of human cytochrome P450 2D6 in the bioactivation of acetaminophen. Drug Metab Dispos. 2000 Dec;28(12):1397-400.
DM2BO9W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11095574

DM2BO9W	DI	DM2BO9W
DM2BO9W	DN	BCP-13498
DM2BO9W	MI	DE0P6LK
DM2BO9W	MN	Sulfotransferase 2A1 (SULT2A1)
DM2BO9W	MT	DME
DM2BO9W	MA	Metabolism
DM2BO9W	RN	Interindividual variability in acetaminophen sulfation by human fetal liver: implications for pharmacogenetic investigations of drug-induced birth defects. Birth Defects Res A Clin Mol Teratol. 2008 Mar;82(3):155-65.
DM2BO9W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18232020

DM2BO9W	DI	DM2BO9W
DM2BO9W	DN	BCP-13498
DM2BO9W	MI	DEYGVN4
DM2BO9W	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM2BO9W	MT	DME
DM2BO9W	MA	Metabolism
DM2BO9W	RN	Paracetamol glucuronidation by recombinant rat and human phenol UDP-glucuronosyltransferases. Biochem Pharmacol. 1993 May 5;45(9):1809-14.
DM2BO9W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8494539

DM2BO9W	DI	DM2BO9W
DM2BO9W	DN	BCP-13498
DM2BO9W	MI	DEL5N6Y
DM2BO9W	MN	UDP-glucuronosyltransferase 1A10 (UGT1A10)
DM2BO9W	MT	DME
DM2BO9W	MA	Metabolism
DM2BO9W	RN	UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther. 2005 Apr;106(1):97-132.
DM2BO9W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15781124

DM2BO9W	DI	DM2BO9W
DM2BO9W	DN	BCP-13498
DM2BO9W	MI	DESD26P
DM2BO9W	MN	UDP-glucuronosyltransferase 1A6 (UGT1A6)
DM2BO9W	MT	DME
DM2BO9W	MA	Metabolism
DM2BO9W	RN	Human UGT1A6 pharmacogenetics: identification of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells. Pharmacogenetics. 2004 Aug;14(8):487-99.
DM2BO9W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15284531

DM2BO9W	DI	DM2BO9W
DM2BO9W	DN	BCP-13498
DM2BO9W	MI	DE85D2P
DM2BO9W	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DM2BO9W	MT	DME
DM2BO9W	MA	Metabolism
DM2BO9W	RN	Polymorphic expression of UGT1A9 is associated with variable acetaminophen glucuronidation in neonates: a population pharmacokinetic and pharmacogenetic study. Clin Pharmacokinet. 2018 Oct;57(10):1325-1336.
DM2BO9W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29654492

DMUFY4K	DI	DMUFY4K
DMUFY4K	DN	BCT303
DMUFY4K	MI	TTTSEPU
DMUFY4K	MN	Thyroid hormone receptor alpha (THRA)
DMUFY4K	MT	DTT
DMUFY4K	MA	Modulator
DMUFY4K	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMUFY4K	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMUFY4K	DI	DMUFY4K
DMUFY4K	DN	BCT303
DMUFY4K	MI	TTGER3L
DMUFY4K	MN	Thyroid hormone receptor beta (THRB)
DMUFY4K	MT	DTT
DMUFY4K	MA	Modulator
DMUFY4K	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMUFY4K	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMRSG31	DI	DMRSG31
DMRSG31	DN	BCX-3408
DMRSG31	MI	TTMCF1Y
DMRSG31	MN	Purine nucleoside phosphorylase (PNP)
DMRSG31	MT	DTT
DMRSG31	MA	Inhibitor
DMRSG31	RN	BCX-4208 (RO5092888), a Purine Nucleoside Phosphorylase (PNP) Inhibitor, Is a Novel, Potent Orally Active Anti-T-Cell and B-Cell Agent. 50th ASH Annual Meeting and Exposition. 2008.
DMRSG31	RU	http://ash.confex.com/ash/2008/webprogram/Paper7315.html

DMKFJXP	DI	DMKFJXP
DMKFJXP	DN	BDB001
DMKFJXP	MI	TTOK0LR
DMKFJXP	MN	Toll-like receptor (TLR)
DMKFJXP	MT	DTT
DMKFJXP	MA	Agonist
DMKFJXP	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMKFJXP	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM2Q50G	DI	DM2Q50G
DM2Q50G	DN	Belnacasan
DM2Q50G	MI	TTCQIBE
DM2Q50G	MN	Caspase-1 (CASP1)
DM2Q50G	MT	DTT
DM2Q50G	MA	Inhibitor
DM2Q50G	RN	(S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydr... J Pharmacol Exp Ther. 2007 May;321(2):509-16.
DM2Q50G	RU	https://pubmed.ncbi.nlm.nih.gov/17289835

DMWNYIE	DI	DMWNYIE
DMWNYIE	DN	Bemarituzumab
DMWNYIE	MI	TTGKIED
DMWNYIE	MN	Fibroblast growth factor-2 (FGF2)
DMWNYIE	MT	DTT
DMWNYIE	MA	Antagonist
DMWNYIE	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMWNYIE	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM0YCPL	DI	DM0YCPL
DM0YCPL	DN	Bemcentinib
DM0YCPL	MI	TTZPY6J
DM0YCPL	MN	Tyrosine-protein kinase UFO (AXL)
DM0YCPL	MT	DTT
DM0YCPL	MA	Inhibitor
DM0YCPL	RN	AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells. J Thorac Oncol. 2020 Jun;15(6):973-999.
DM0YCPL	RU	https://pubmed.ncbi.nlm.nih.gov/32018052

DMUL6GY	DI	DMUL6GY
DMUL6GY	DN	BEMORADAN
DMUL6GY	MI	TT06AWU
DMUL6GY	MN	Phosphodiesterase 3A (PDE3A)
DMUL6GY	MT	DTT
DMUL6GY	MA	Inhibitor
DMUL6GY	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMUL6GY	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMRC0EQ	DI	DMRC0EQ
DMRC0EQ	DN	Bertilimumab
DMRC0EQ	MI	TTCF05Y
DMRC0EQ	MN	Small-inducible cytokine A11 (CCL11)
DMRC0EQ	MT	DTT
DMRC0EQ	MA	Modulator
DMRC0EQ	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMRC0EQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMJ2REU	DI	DMJ2REU
DMJ2REU	DN	Berubicin
DMJ2REU	MI	TT0IHXV
DMJ2REU	MN	DNA topoisomerase II (TOP2)
DMJ2REU	MT	DTT
DMJ2REU	MA	Modulator
DMJ2REU	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMJ2REU	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM7583A	DI	DM7583A
DM7583A	DN	Beta-caryophyllene
DM7583A	MI	TTMSFAW
DM7583A	MN	Cannabinoid receptor 2 (CB2)
DM7583A	MT	DTT
DM7583A	MA	Agonist
DM7583A	RN	The cannabinoid CB1 receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain. Eur Neuropsychopharmacol. 2014 Apr;24(4):608-20.
DM7583A	RU	https://pubmed.ncbi.nlm.nih.gov/24210682

DMMI84K	DI	DMMI84K
DMMI84K	DN	Beta-lapachone
DMMI84K	MI	TTGTQHC
DMMI84K	MN	DNA topoisomerase I (TOP1)
DMMI84K	MT	DTT
DMMI84K	MA	Modulator
DMMI84K	RN	Cancer therapy with beta-lapachone. Curr Cancer Drug Targets. 2002 Sep;2(3):227-42.
DMMI84K	RU	https://pubmed.ncbi.nlm.nih.gov/12188909

DMMI84K	DI	DMMI84K
DMMI84K	DN	Beta-lapachone
DMMI84K	MI	DENP5RY
DMMI84K	MN	Quinone reductase 1 (NQO1)
DMMI84K	MT	DME
DMMI84K	MA	Metabolism
DMMI84K	RN	Beta-lapachone, a modulator of NAD metabolism, prevents health declines in aged mice. PLoS One. 2012;7(10):e47122.
DMMI84K	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23071729

DML2D8Q	DI	DML2D8Q
DML2D8Q	DN	Bevirimat
DML2D8Q	MI	TTFGZB6
DML2D8Q	MN	Human immunodeficiency virus GAG protein (HIV gag)
DML2D8Q	MT	DTT
DML2D8Q	MA	Inhibitor
DML2D8Q	RN	Synthesis and biological evaluation of a new derivative of bevirimat that targets the Gag CA-SP1 cleavage site. Eur J Med Chem. 2013 Apr;62:453-65.
DML2D8Q	RU	https://pubmed.ncbi.nlm.nih.gov/23399723

DML2D8Q	DI	DML2D8Q
DML2D8Q	DN	Bevirimat
DML2D8Q	MI	DEF2WXN
DML2D8Q	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DML2D8Q	MT	DME
DML2D8Q	MA	Metabolism
DML2D8Q	RN	Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection. Antivir Chem Chemother. 2008;19(3):107-13.
DML2D8Q	RU	https://www.intmedpress.com/serveFile.cfm?sUID=ebccbb0b-de4a-42d4-ae2b-ca2304d75f56

DML2D8Q	DI	DML2D8Q
DML2D8Q	DN	Bevirimat
DML2D8Q	MI	DELOY3P
DML2D8Q	MN	UDP-glucuronosyltransferase 1A4 (UGT1A4)
DML2D8Q	MT	DME
DML2D8Q	MA	Metabolism
DML2D8Q	RN	Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection. Antivir Chem Chemother. 2008;19(3):107-13.
DML2D8Q	RU	https://www.intmedpress.com/serveFile.cfm?sUID=ebccbb0b-de4a-42d4-ae2b-ca2304d75f56

DML2D8Q	DI	DML2D8Q
DML2D8Q	DN	Bevirimat
DML2D8Q	MI	DEB3CV1
DML2D8Q	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DML2D8Q	MT	DME
DML2D8Q	MA	Metabolism
DML2D8Q	RN	Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection. Antivir Chem Chemother. 2008;19(3):107-13.
DML2D8Q	RU	https://www.intmedpress.com/serveFile.cfm?sUID=ebccbb0b-de4a-42d4-ae2b-ca2304d75f56

DMKBRDL	DI	DMKBRDL
DMKBRDL	DN	BEZ235
DMKBRDL	MI	TTHBTOP
DMKBRDL	MN	PI3-kinase gamma (PIK3CG)
DMKBRDL	MT	DTT
DMKBRDL	MA	Modulator
DMKBRDL	RN	The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses. Neoplasia. 2012 Jan;14(1):34-43.
DMKBRDL	RU	https://www.ncbi.nlm.nih.gov/pubmed/22355272

DMKBRDL	DI	DMKBRDL
DMKBRDL	DN	BEZ235
DMKBRDL	MI	TTCJG29
DMKBRDL	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMKBRDL	MT	DTT
DMKBRDL	MA	Modulator
DMKBRDL	RN	The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses. Neoplasia. 2012 Jan;14(1):34-43.
DMKBRDL	RU	https://www.ncbi.nlm.nih.gov/pubmed/22355272

DMVUX1C	DI	DMVUX1C
DMVUX1C	DN	BFH-772
DMVUX1C	MI	TTVJ1D8
DMVUX1C	MN	Vascular endothelial growth factor receptor (VEGFR)
DMVUX1C	MT	DTT
DMVUX1C	MA	Agonist
DMVUX1C	RN	CA patent application no. 841416, Method of selecting therapeutic indications.
DMVUX1C	RU	http://www.google.com/patents/CA2841416A1?cl=en

DMRO6XT	DI	DMRO6XT
DMRO6XT	DN	BGB-290
DMRO6XT	MI	TTEBCY8
DMRO6XT	MN	Poly [ADP-ribose] polymerase (PARP)
DMRO6XT	MT	DTT
DMRO6XT	MA	Inhibitor
DMRO6XT	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMRO6XT	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMRO6XT	DI	DMRO6XT
DMRO6XT	DN	BGB-290
DMRO6XT	MI	TTKSAQZ
DMRO6XT	MN	Tankyrase (TNKS)
DMRO6XT	MT	DTT
DMRO6XT	MA	Modulator
DMRO6XT	RN	National Cancer Institute Drug Dictionary (drug id 769217).
DMRO6XT	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=769217

DMQCFSM	DI	DMQCFSM
DMQCFSM	DN	BGB-3112
DMQCFSM	MI	TTGM6VW
DMQCFSM	MN	Tyrosine-protein kinase BTK (ATK)
DMQCFSM	MT	DTT
DMQCFSM	MA	Inhibitor
DMQCFSM	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQCFSM	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMDI43Y	DI	DMDI43Y
DMDI43Y	DN	BGB-324
DMDI43Y	MI	TTZPY6J
DMDI43Y	MN	Tyrosine-protein kinase UFO (AXL)
DMDI43Y	MT	DTT
DMDI43Y	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1835).
DMDI43Y	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1835

DM1X3L0	DI	DM1X3L0
DM1X3L0	DN	BGB-3245
DM1X3L0	MI	TTB18GJ
DM1X3L0	MN	Proto-oncogene c-RAF (c-RAF)
DM1X3L0	MT	DTT
DM1X3L0	MA	Inhibitor
DM1X3L0	RN	Clinical pipeline report, company report or official report of BeiGene.
DM1X3L0	RU	https://www.beigene.com/science-and-product-portfolio/pipeline

DMS2MQ5	DI	DMS2MQ5
DMS2MQ5	DN	BGC-20-1531
DMS2MQ5	MI	TT79WV3
DMS2MQ5	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DMS2MQ5	MT	DTT
DMS2MQ5	MA	Antagonist
DMS2MQ5	RN	BGC20-1531, a novel, potent and selective prostanoid EP4 receptor antagonist: a putative new treatment for migraine headache. Br J Pharmacol. 2009 January; 156(2): 316-327.
DMS2MQ5	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697835/

DMYDM68	DI	DMYDM68
DMYDM68	DN	BGP-15
DMYDM68	MI	TTR2TXZ
DMYDM68	MN	Jun N terminal kinase (JNK)
DMYDM68	MT	DTT
DMYDM68	MA	Inhibitor
DMYDM68	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMYDM68	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMYDM68	DI	DMYDM68
DMYDM68	DN	BGP-15
DMYDM68	MI	TTEBCY8
DMYDM68	MN	Poly [ADP-ribose] polymerase (PARP)
DMYDM68	MT	DTT
DMYDM68	MA	Modulator
DMYDM68	RN	BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases. Mol Cell Biochem. 2012 Jun;365(1-2):129-37.
DMYDM68	RU	https://pubmed.ncbi.nlm.nih.gov/22350755

DMO4MNQ	DI	DMO4MNQ
DMO4MNQ	DN	BGS-649
DMO4MNQ	MI	TTSZLWK
DMO4MNQ	MN	Aromatase (CYP19A1)
DMO4MNQ	MT	DTT
DMO4MNQ	MA	Inhibitor
DMO4MNQ	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032111)
DMO4MNQ	RU	http://adisinsight.springer.com/drugs/800032111

DMSROM4	DI	DMSROM4
DMSROM4	DN	BHQ880
DMSROM4	MI	TTE3RAC
DMSROM4	MN	Dickkopf-related protein 1 (DKK1)
DMSROM4	MT	DTT
DMSROM4	MA	Inhibitor
DMSROM4	RN	Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood. 2009 Jul 9;114(2):371-9.
DMSROM4	RU	https://pubmed.ncbi.nlm.nih.gov/19417213

DM7ZM1H	DI	DM7ZM1H
DM7ZM1H	DN	BHT-3009
DM7ZM1H	MI	TT2RY5P
DM7ZM1H	MN	Myelin basic protein (MBP)
DM7ZM1H	MT	DTT
DM7ZM1H	RN	BHT-3009, a myelin basic protein-encoding plasmid for the treatment of multiple sclerosis. Curr Opin Mol Ther. 2009 Aug;11(4):463-70.
DM7ZM1H	RU	https://pubmed.ncbi.nlm.nih.gov/19649992

DM740BS	DI	DM740BS
DM740BS	DN	BI 1358894
DM740BS	MI	TTX0H5W
DM740BS	MN	Short transient receptor potential channel 4 (TRPC4)
DM740BS	MT	DTT
DM740BS	MA	Inhibitor
DM740BS	RN	Clinical pipeline report, company report or official report of Boehringer Ingelheim.
DM740BS	RU	https://www.boehringer-ingelheim.pt/press-release/hydra-biosciences-and-boehringer-ingelheim-announce-worldwide-collaboration-develop

DM740BS	DI	DM740BS
DM740BS	DN	BI 1358894
DM740BS	MI	TT32NQ1
DM740BS	MN	Short transient receptor potential channel 5 (TRPC5)
DM740BS	MT	DTT
DM740BS	MA	Inhibitor
DM740BS	RN	Clinical pipeline report, company report or official report of Boehringer Ingelheim.
DM740BS	RU	https://www.boehringer-ingelheim.pt/press-release/hydra-biosciences-and-boehringer-ingelheim-announce-worldwide-collaboration-develop

DMMSGAT	DI	DMMSGAT
DMMSGAT	DN	BI 207127
DMMSGAT	MI	TTMVBWH
DMMSGAT	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMMSGAT	MT	DTT
DMMSGAT	MA	Inhibitor
DMMSGAT	RN	2011 Pipeline of Boehringer Ingelheim Pharma.
DMMSGAT	RU	http://www.boehringer-ingelheim.com/

DMJSADP	DI	DMJSADP
DMJSADP	DN	BI 2536
DMJSADP	MI	TTIYVQP
DMJSADP	MN	Polo-like kinase 1 (PLK1)
DMJSADP	MT	DTT
DMJSADP	MA	Inhibitor
DMJSADP	RN	Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009 Jun;14(6):559-70.
DMJSADP	RU	https://pubmed.ncbi.nlm.nih.gov/19474163

DM1NMGJ	DI	DM1NMGJ
DM1NMGJ	DN	BI 456906
DM1NMGJ	MI	TTVIMDE
DM1NMGJ	MN	Glucagon-like peptide 1 receptor (GLP1R)
DM1NMGJ	MT	DTT
DM1NMGJ	MA	Agonist
DM1NMGJ	RN	Clinical pipeline report, company report or official report of Boehringer Ingelheim.
DM1NMGJ	RU	https://www.boehringer-ingelheim.us/press-release/boehringer-ingelheim-and-zealand-pharma-advance-dual-acting-glp-1glucagon-agonist-bi

DMF86P2	DI	DMF86P2
DMF86P2	DN	BI 655064
DMF86P2	MI	TTN6Y9A
DMF86P2	MN	CD40L receptor (CD40)
DMF86P2	MT	DTT
DMF86P2	MA	Inhibitor
DMF86P2	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMF86P2	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMF86P2	DI	DMF86P2
DMF86P2	DN	BI 655064
DMF86P2	MI	TTIJP3Q
DMF86P2	MN	TNF related activation protein (CD40LG)
DMF86P2	MT	DTT
DMF86P2	RN	FRI0167 Patient-Reported Outcomes (PROS) During Treatment with Mavrilimumab, A Fully Human Monoclonal Antibody Targeting GMCSFR-Alpha, In the Phase IIB Earth Explorer 1 Study
DMF86P2	RU	http://ard.bmj.com/content/74/Suppl_2/483.3.abstract

DMJFDS0	DI	DMJFDS0
DMJFDS0	DN	BI-409306
DMJFDS0	MI	TTZOEBC
DMJFDS0	MN	Phosphodiesterase 9 (PDE9)
DMJFDS0	MT	DTT
DMJFDS0	MA	Inhibitor
DMJFDS0	RN	Clinical pipeline report, company report or official report of Boehringer Ingelheim pipeline.
DMJFDS0	RU	https://www.boehringer-ingelheim.com/research_development/drug_discovery/pipeline.html

DMZR9OU	DI	DMZR9OU
DMZR9OU	DN	BI-44370
DMZR9OU	MI	TTY6O0Q
DMZR9OU	MN	Calcitonin gene-related peptide receptor (CGRPR)
DMZR9OU	MT	DTT
DMZR9OU	MA	Antagonist
DMZR9OU	RN	BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia. 2011 Apr;31(5):573-84.
DMZR9OU	RU	https://pubmed.ncbi.nlm.nih.gov/21172952

DMSZQHX	DI	DMSZQHX
DMSZQHX	DN	BI-505
DMSZQHX	MI	TTCT6F7
DMSZQHX	MN	Intercellular adhesion molecule ICAM-1 (ICAM1)
DMSZQHX	MT	DTT
DMSZQHX	RN	A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo. Cancer Cell. 2013 Apr 15;23(4):502-15.
DMSZQHX	RU	https://pubmed.ncbi.nlm.nih.gov/23597564

DMSZQHX	DI	DMSZQHX
DMSZQHX	DN	BI-505
DMSZQHX	MI	TTZPY6J
DMSZQHX	MN	Tyrosine-protein kinase UFO (AXL)
DMSZQHX	MT	DTT
DMSZQHX	MA	Inhibitor
DMSZQHX	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMSZQHX	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DM9FZYT	DI	DM9FZYT
DM9FZYT	DN	BI-655130
DM9FZYT	MI	TTUS18T
DM9FZYT	MN	IL-1 receptor-like 2 (IL1RL2)
DM9FZYT	MT	DTT
DM9FZYT	MA	Antagonist
DM9FZYT	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9FZYT	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMWH7Z5	DI	DMWH7Z5
DMWH7Z5	DN	BI-836826
DMWH7Z5	MI	TTFCW29
DMWH7Z5	MN	Leukocyte antigen CD37 (CD37)
DMWH7Z5	MT	DTT
DMWH7Z5	RN	Anti-CD37 antibodies for chronic lymphocytic leukemia. Expert Opin Biol Ther. 2014 May;14(5):651-61.
DMWH7Z5	RU	https://pubmed.ncbi.nlm.nih.gov/24555705

DMUVMY9	DI	DMUVMY9
DMUVMY9	DN	BI-836858
DMUVMY9	MI	TTJVYO3
DMUVMY9	MN	Myeloid cell surface antigen CD33 (CD33)
DMUVMY9	MT	DTT
DMUVMY9	RN	The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Rev. 2014 Jul;28(4):143-53.
DMUVMY9	RU	https://pubmed.ncbi.nlm.nih.gov/24809231

DMG3ON2	DI	DMG3ON2
DMG3ON2	DN	BIA 3-202
DMG3ON2	MI	TTKWFB8
DMG3ON2	MN	Catechol-O-methyl-transferase (COMT)
DMG3ON2	MT	DTT
DMG3ON2	MA	Inhibitor
DMG3ON2	RN	Chemical synthesis and characterization of conjugates of a novel catechol-O-methyltransferase inhibitor. Bioconjug Chem. 2002 Sep-Oct;13(5):1112-8.
DMG3ON2	RU	https://pubmed.ncbi.nlm.nih.gov/12236793

DMHYZEK	DI	DMHYZEK
DMHYZEK	DN	BIBH 1
DMHYZEK	MI	TTGPQ0F
DMHYZEK	MN	Prolyl endopeptidase FAP (FAP)
DMHYZEK	MT	DTT
DMHYZEK	RN	A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 2003 May;9(5):1639-47.
DMHYZEK	RU	https://pubmed.ncbi.nlm.nih.gov/12738716

DM9OXEJ	DI	DM9OXEJ
DM9OXEJ	DN	BIIB 023
DM9OXEJ	MI	TTBTDM1
DM9OXEJ	MN	TNF-related weak inducer of apoptosis (TWEAK)
DM9OXEJ	MT	DTT
DM9OXEJ	MA	Modulator
DM9OXEJ	RN	ClinicalTrials.gov (NCT00771329) BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis. U.S. National Institutes of Health.
DM9OXEJ	RU	https://clinicaltrials.gov/ct2/show/NCT00771329

DM293JT	DI	DM293JT
DM293JT	DN	BIIB 033
DM293JT	MI	TTZYQ80
DM293JT	MN	Leucine-rich repeat neuronal protein 1 (LINGO1)
DM293JT	MT	DTT
DM293JT	RN	Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033. Neurol Neuroimmunol Neuroinflamm. 2014 Aug 21;1(2):e18.
DM293JT	RU	https://pubmed.ncbi.nlm.nih.gov/25340070

DMH7RJ1	DI	DMH7RJ1
DMH7RJ1	DN	BIIB014
DMH7RJ1	MI	TTM2AOE
DMH7RJ1	MN	Adenosine A2a receptor (ADORA2A)
DMH7RJ1	MT	DTT
DMH7RJ1	MA	Antagonist
DMH7RJ1	RN	Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54.
DMH7RJ1	RU	https://pubmed.ncbi.nlm.nih.gov/17016425

DMH7RJ1	DI	DMH7RJ1
DMH7RJ1	DN	BIIB014
DMH7RJ1	MI	DE4LYSA
DMH7RJ1	MN	Cytochrome P450 3A4 (CYP3A4)
DMH7RJ1	MT	DME
DMH7RJ1	MA	Metabolism
DMH7RJ1	RN	Frontiers in CNS Drug Discovery. Edited by Atta-ur Rahman, M. Iqbal Choudhary. Page: 318.
DMH7RJ1	RU	https://books.google.nl/books?id=ip-Pz5C3_loC&pg=PA318&lpg=PA318&dq=BIIB014++metabolizing+enzyme&source=bl&ots=G8YeDCzw5_&sig=ACfU3U1ZkEaPcDy58jtvOlzdzR-s3sNz4g&hl=zh-CN&sa=X&ved=2ahUKEwiGkem-7rnnAhVP4qQKHfNzAi4Q6AEwFXoECAwQAQ#v=onepage&q=BIIB014%20%20metabolizing%20enzyme&f=false

DMPAJ41	DI	DMPAJ41
DMPAJ41	DN	BIIB-021
DMPAJ41	MI	TT78R5H
DMPAJ41	MN	Heat shock protein 90 alpha (HSP90A)
DMPAJ41	MT	DTT
DMPAJ41	MA	Inhibitor
DMPAJ41	RN	BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther. 2009 Apr;8(4):921-9.
DMPAJ41	RU	https://pubmed.ncbi.nlm.nih.gov/19372565

DMZO2SY	DI	DMZO2SY
DMZO2SY	DN	BIIB054
DMZO2SY	MI	TT08OSU
DMZO2SY	MN	Synuclein alpha (SNCA)
DMZO2SY	MT	DTT
DMZO2SY	MA	Inhibitor
DMZO2SY	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZO2SY	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMLV1ET	DI	DMLV1ET
DMLV1ET	DN	BIIB074
DMLV1ET	MI	TT4G2JS
DMLV1ET	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DMLV1ET	MT	DTT
DMLV1ET	MA	Inhibitor
DMLV1ET	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMLV1ET	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DM263RP	DI	DM263RP
DM263RP	DN	BIIB092
DM263RP	MI	TTS87KH
DM263RP	MN	Microtubule-associated protein tau (MAPT)
DM263RP	MT	DTT
DM263RP	MA	Inhibitor
DM263RP	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM263RP	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM2J36F	DI	DM2J36F
DM2J36F	DN	BILN-2061
DM2J36F	MI	TTWXB3E
DM2J36F	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DM2J36F	MT	DTT
DM2J36F	MA	Inhibitor
DM2J36F	RN	Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology. 2005 Apr;41(4):832-5.
DM2J36F	RU	https://pubmed.ncbi.nlm.nih.gov/15732092

DMAG4SX	DI	DMAG4SX
DMAG4SX	DN	BILR-355
DMAG4SX	MI	TT84ETX
DMAG4SX	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMAG4SX	MT	DTT
DMAG4SX	MA	Inhibitor
DMAG4SX	RN	Evaluation of steady-state pharmacokinetic interactions between ritonavir-boosted BILR 355, a non-nucleoside reverse transcriptase inhibitor, and lamivudine/zidovudine in healthy subjects. J Clin Pharm Ther. 2012 Feb;37(1):81-8.
DMAG4SX	RU	https://pubmed.ncbi.nlm.nih.gov/21128991

DM6EIZG	DI	DM6EIZG
DM6EIZG	DN	BIM23A760
DM6EIZG	MI	TT2J34L
DM6EIZG	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM6EIZG	MT	DTT
DM6EIZG	MA	Inhibitor
DM6EIZG	RN	Preview of potential therapeutic applications of leukotriene B4 inhibitors in dermatology. Skin Pharmacol Appl Skin Physiol. 2000 Sep-Oct;13(5):235-45.
DM6EIZG	RU	https://pubmed.ncbi.nlm.nih.gov/10940813

DM6EIZG	DI	DM6EIZG
DM6EIZG	DN	BIM23A760
DM6EIZG	MI	TTEX248
DM6EIZG	MN	Dopamine D2 receptor (D2R)
DM6EIZG	MT	DTT
DM6EIZG	MA	Modulator
DM6EIZG	RN	BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide. J Endocrinol Invest. 2005;28(11 Suppl International):21-7.
DM6EIZG	RU	https://pubmed.ncbi.nlm.nih.gov/16625841

DMH7Q4E	DI	DMH7Q4E
DMH7Q4E	DN	Bimagrumab
DMH7Q4E	MI	TTRG4QN
DMH7Q4E	MN	Activin receptor type II (ACVR2)
DMH7Q4E	MT	DTT
DMH7Q4E	MA	Inhibitor
DMH7Q4E	RN	Effects of bimagrumab, an activin receptor type II inhibitor, on pituitary neurohormonal axes. Clin Endocrinol (Oxf). 2018 Jun;88(6):908-919.
DMH7Q4E	RU	https://pubmed.ncbi.nlm.nih.gov/29566437

DMBRL19	DI	DMBRL19
DMBRL19	DN	Bimakalim
DMBRL19	MI	TT1VOHK
DMBRL19	MN	Potassium channel unspecific (KC)
DMBRL19	MT	DTT
DMBRL19	MA	Agonist
DMBRL19	RN	Lack of anti-ischemic efficacy of the potassium channel opener bimakalim in patients with stable angina pectoris. Cardiovasc Drugs Ther. 2004 Jan;18(1):37-46.
DMBRL19	RU	https://pubmed.ncbi.nlm.nih.gov/15115902

DMB9LRJ	DI	DMB9LRJ
DMB9LRJ	DN	Bintrafusp alfa
DMB9LRJ	MI	TT8ZLTI
DMB9LRJ	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMB9LRJ	MT	DTT
DMB9LRJ	RN	Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. J Thorac Oncol. 2020 Jul;15(7):1210-1222.
DMB9LRJ	RU	https://pubmed.ncbi.nlm.nih.gov/32173464

DMB9LRJ	DI	DMB9LRJ
DMB9LRJ	DN	Bintrafusp alfa
DMB9LRJ	MI	TTO3HT7
DMB9LRJ	MN	Transforming growth factor beta (TGFB)
DMB9LRJ	MT	DTT
DMB9LRJ	RN	Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. J Thorac Oncol. 2020 Jul;15(7):1210-1222.
DMB9LRJ	RU	https://pubmed.ncbi.nlm.nih.gov/32173464

DM6N05H	DI	DM6N05H
DM6N05H	DN	BIO-11006
DM6N05H	MI	TTHRM39
DM6N05H	MN	Myristoylated alanine-rich C-kinase substrate (MARCKS)
DM6N05H	MT	DTT
DM6N05H	MA	Inhibitor
DM6N05H	RN	Inhibition of myristoylated alanine-rich C kinase substrate (MARCKS) protein inhibits ozone-induced airway neutrophilia and inflammation. Exp Lung Res. 2010 Mar;36(2):75-84.
DM6N05H	RU	https://pubmed.ncbi.nlm.nih.gov/20205598

DMPNYXQ	DI	DMPNYXQ
DMPNYXQ	DN	BIO-11006
DMPNYXQ	MI	TTHRM39
DMPNYXQ	MN	Myristoylated alanine-rich C-kinase substrate (MARCKS)
DMPNYXQ	MT	DTT
DMPNYXQ	MA	Inhibitor
DMPNYXQ	RN	An Inhaled Inhibitor of Myristoylated Alanine-Rich C Kinase Substrate Reverses LPS-Induced Acute Lung Injury in Mice. Am J Respir Cell Mol Biol. 2016 Nov;55(5):617-622.
DMPNYXQ	RU	https://pubmed.ncbi.nlm.nih.gov/27556883

DMKICA3	DI	DMKICA3
DMKICA3	DN	BIO-1211
DMKICA3	MI	TT4BT06
DMKICA3	MN	Integrin alpha-4 (ITGA4)
DMKICA3	MT	DTT
DMKICA3	MA	Antagonist
DMKICA3	RN	A small-molecule, tight-binding inhibitor of the integrin alpha(4)beta(1) blocks antigen-induced airway responses and inflammation in experimental asthma in sheep. Am J Respir Crit Care Med. 2000 Aug;162(2 Pt 1):603-11.
DMKICA3	RU	https://pubmed.ncbi.nlm.nih.gov/10934094

DM7PT8R	DI	DM7PT8R
DM7PT8R	DN	BioE-743
DM7PT8R	MI	TT8XK6L
DM7PT8R	MN	Quinone reductase 1 (NQO1)
DM7PT8R	MT	DTT
DM7PT8R	MA	Modulator
DM7PT8R	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7PT8R	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM6PBUM	DI	DM6PBUM
DM6PBUM	DN	Birinapant
DM6PBUM	MI	TTQ5LRD
DM6PBUM	MN	Cellular inhibitor of apoptosis 1 (BIRC2)
DM6PBUM	MT	DTT
DM6PBUM	MA	Modulator
DM6PBUM	RN	cIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK1- and RIPK3-dependent manner. Blood. 2014 Apr 17;123(16):2562-72.
DM6PBUM	RU	https://pubmed.ncbi.nlm.nih.gov/24497535

DM6PBUM	DI	DM6PBUM
DM6PBUM	DN	Birinapant
DM6PBUM	MI	TTR7B60
DM6PBUM	MN	X-linked inhibitor of apoptosis protein (XIAP)
DM6PBUM	MT	DTT
DM6PBUM	MA	Modulator
DM6PBUM	RN	cIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK1- and RIPK3-dependent manner. Blood. 2014 Apr 17;123(16):2562-72.
DM6PBUM	RU	https://pubmed.ncbi.nlm.nih.gov/24497535

DMW76V0	DI	DMW76V0
DMW76V0	DN	Bisantrene
DMW76V0	MI	DTI7UX6
DMW76V0	MN	Breast cancer resistance protein (ABCG2)
DMW76V0	MT	DTP
DMW76V0	MA	Substrate
DMW76V0	RN	Pharmacogenomic importance of ABCG2. Pharmacogenomics. 2008 Aug;9(8):1005-9.
DMW76V0	RU	https://doi.org/10.2217/14622416.9.8.1005

DMW76V0	DI	DMW76V0
DMW76V0	DN	Bisantrene
DMW76V0	MI	DTUGYRD
DMW76V0	MN	P-glycoprotein 1 (ABCB1)
DMW76V0	MT	DTP
DMW76V0	MA	Substrate
DMW76V0	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMW76V0	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMVDO93	DI	DMVDO93
DMVDO93	DN	BL-1020
DMVDO93	MI	TTEX248
DMVDO93	MN	Dopamine D2 receptor (D2R)
DMVDO93	MT	DTT
DMVDO93	MA	Antagonist
DMVDO93	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMVDO93	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMVDO93	DI	DMVDO93
DMVDO93	DN	BL-1020
DMVDO93	MI	TTNJYV2
DMVDO93	MN	Gamma-aminobutyric acid receptor (GAR)
DMVDO93	MT	DTT
DMVDO93	MA	Agonist
DMVDO93	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMVDO93	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DM8R71T	DI	DM8R71T
DM8R71T	DN	BL-22
DM8R71T	MI	TTM6QSK
DM8R71T	MN	B-cell receptor CD22 (CD22)
DM8R71T	MT	DTT
DM8R71T	RN	Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res. 2010 Mar 15;16(6):1894-903.
DM8R71T	RU	https://pubmed.ncbi.nlm.nih.gov/20215554

DMSBPJI	DI	DMSBPJI
DMSBPJI	DN	BL-7040
DMSBPJI	MI	TTSHG0T
DMSBPJI	MN	Toll-like receptor 9 (TLR9)
DMSBPJI	MT	DTT
DMSBPJI	MA	Activator
DMSBPJI	RN	Gut feeling: MicroRNA discriminators of the intestinal TLR9-cholinergic links. Int Immunopharmacol. 2015 Nov;29(1):8-14.
DMSBPJI	RU	https://pubmed.ncbi.nlm.nih.gov/26003847

DMKO0BQ	DI	DMKO0BQ
DMKO0BQ	DN	BLD-2660
DMKO0BQ	MI	TT45V0U
DMKO0BQ	MN	HUMAN calpain-1/calpain small subunit 1 heterodimer (CAPN1/CAPNS1)
DMKO0BQ	MT	DTT
DMKO0BQ	MA	Inhibitor
DMKO0BQ	RN	ClinicalTrials.gov (NCT04334460) Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects. U.S. National Institutes of Health.
DMKO0BQ	RU	https://clinicaltrials.gov/ct2/show/NCT04334460

DMKO0BQ	DI	DMKO0BQ
DMKO0BQ	DN	BLD-2660
DMKO0BQ	MI	TTO361H
DMKO0BQ	MN	HUMAN calpain-2/calpain small subunit 1 heterodimer (CAPN2/CAPNS1)
DMKO0BQ	MT	DTT
DMKO0BQ	MA	Inhibitor
DMKO0BQ	RN	ClinicalTrials.gov (NCT04334460) Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects. U.S. National Institutes of Health.
DMKO0BQ	RU	https://clinicaltrials.gov/ct2/show/NCT04334460

DMYK1DR	DI	DMYK1DR
DMYK1DR	DN	BLI-1005
DMYK1DR	MI	TTAWNKZ
DMYK1DR	MN	Norepinephrine transporter (NET)
DMYK1DR	MT	DTT
DMYK1DR	MA	Inhibitor
DMYK1DR	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMYK1DR	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMG1LVA	DI	DMG1LVA
DMG1LVA	DN	BLZ-945
DMG1LVA	MI	TTC70AJ
DMG1LVA	MN	Granulocyte colony-stimulating factor receptor (G-CSF-R)
DMG1LVA	MT	DTT
DMG1LVA	MA	Inhibitor
DMG1LVA	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1719).
DMG1LVA	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1719

DMG1LVA	DI	DMG1LVA
DMG1LVA	DN	BLZ-945
DMG1LVA	MI	TT7MRDV
DMG1LVA	MN	Macrophage colony-stimulating factor 1 receptor (CSF1R)
DMG1LVA	MT	DTT
DMG1LVA	MA	Antagonist
DMG1LVA	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMG1LVA	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMQI43G	DI	DMQI43G
DMQI43G	DN	BMS 650032
DMQI43G	MI	DEJVYAZ
DMQI43G	MN	Cytochrome P450 2A6 (CYP2A6)
DMQI43G	MT	DME
DMQI43G	MA	Metabolism
DMQI43G	RN	Australian Public Assessment Report for asunaprevir.
DMQI43G	RU	https://www.tga.gov.au/sites/default/files/auspar-asunaprevir-151214.pdf

DMQI43G	DI	DMQI43G
DMQI43G	DN	BMS 650032
DMQI43G	MI	DEPKLMQ
DMQI43G	MN	Cytochrome P450 2B6 (CYP2B6)
DMQI43G	MT	DME
DMQI43G	MA	Metabolism
DMQI43G	RN	Australian Public Assessment Report for asunaprevir.
DMQI43G	RU	https://www.tga.gov.au/sites/default/files/auspar-asunaprevir-151214.pdf

DMQI43G	DI	DMQI43G
DMQI43G	DN	BMS 650032
DMQI43G	MI	DE5IED8
DMQI43G	MN	Cytochrome P450 2C9 (CYP2C9)
DMQI43G	MT	DME
DMQI43G	MA	Metabolism
DMQI43G	RN	Australian Public Assessment Report for asunaprevir.
DMQI43G	RU	https://www.tga.gov.au/sites/default/files/auspar-asunaprevir-151214.pdf

DMQI43G	DI	DMQI43G
DMQI43G	DN	BMS 650032
DMQI43G	MI	DECB0K3
DMQI43G	MN	Cytochrome P450 2D6 (CYP2D6)
DMQI43G	MT	DME
DMQI43G	MA	Metabolism
DMQI43G	RN	Asunaprevir: a review of preclinical and clinical pharmacokinetics and drug-drug interactions. Clin Pharmacokinet. 2015 Dec;54(12):1205-22.
DMQI43G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26177803

DMQI43G	DI	DMQI43G
DMQI43G	DN	BMS 650032
DMQI43G	MI	DE4LYSA
DMQI43G	MN	Cytochrome P450 3A4 (CYP3A4)
DMQI43G	MT	DME
DMQI43G	MA	Metabolism
DMQI43G	RN	Characterization of ADME properties of [(14)C]asunaprevir (BMS-650032) in humans. Xenobiotica. 2016;46(1):52-64.
DMQI43G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26153443

DMQI43G	DI	DMQI43G
DMQI43G	DN	BMS 650032
DMQI43G	MI	DEIBDNY
DMQI43G	MN	Cytochrome P450 3A5 (CYP3A5)
DMQI43G	MT	DME
DMQI43G	MA	Metabolism
DMQI43G	RN	Characterization of ADME properties of [(14)C]asunaprevir (BMS-650032) in humans. Xenobiotica. 2016;46(1):52-64.
DMQI43G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26153443

DMQI43G	DI	DMQI43G
DMQI43G	DN	BMS 650032
DMQI43G	MI	TT5FNQT
DMQI43G	MN	Human immunodeficiency virus Protease (HIV PR)
DMQI43G	MT	DTT
DMQI43G	MA	Inhibitor
DMQI43G	RN	2011 Pipeline of Bristol-Myers Squibb.
DMQI43G	RU	http://www.bms.com/pages/default.aspx

DMQI43G	DI	DMQI43G
DMQI43G	DN	BMS 650032
DMQI43G	MI	DEGTFWK
DMQI43G	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMQI43G	MT	DME
DMQI43G	MA	Metabolism
DMQI43G	RN	Australian Public Assessment Report for asunaprevir.
DMQI43G	RU	https://www.tga.gov.au/sites/default/files/auspar-asunaprevir-151214.pdf

DMQI43G	DI	DMQI43G
DMQI43G	DN	BMS 650032
DMQI43G	MI	DTUGYRD
DMQI43G	MN	P-glycoprotein 1 (ABCB1)
DMQI43G	MT	DTP
DMQI43G	MA	Substrate
DMQI43G	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
DMQI43G	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01665

DMKH4PI	DI	DMKH4PI
DMKH4PI	DN	BMS 791325
DMKH4PI	MI	TTMVBWH
DMKH4PI	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMKH4PI	MT	DTT
DMKH4PI	MA	Inhibitor
DMKH4PI	RN	2011 Pipeline of Bristol-Myers Squibb.
DMKH4PI	RU	http://www.bms.com/pages/default.aspx

DMDPLEM	DI	DMDPLEM
DMDPLEM	DN	BMS-184476
DMDPLEM	MI	TTML2WA
DMDPLEM	MN	Tubulin (TUB)
DMDPLEM	MT	DTT
DMDPLEM	MA	Inhibitor
DMDPLEM	RN	Phase I trial of the novel taxane BMS-184476 administered in combination with carboplatin every 21 days. Br J Cancer. 2004 July 19; 91(2): 213-218.
DMDPLEM	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409820/

DML1CK2	DI	DML1CK2
DML1CK2	DN	BMS-188797
DML1CK2	MI	TTML2WA
DML1CK2	MN	Tubulin (TUB)
DML1CK2	MT	DTT
DML1CK2	MA	Inhibitor
DML1CK2	RN	Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies. Clin Cancer Res. 2003 Nov 1;9(14):5187-94.
DML1CK2	RU	https://pubmed.ncbi.nlm.nih.gov/14613998

DMJUV6C	DI	DMJUV6C
DMJUV6C	DN	BMS-223131
DMJUV6C	MI	TT1AQ50
DMJUV6C	MN	Charybdotoxin receptor beta-4 (BKbeta4)
DMJUV6C	MT	DTT
DMJUV6C	MA	Modulator
DMJUV6C	RN	Effect of 4-(5-chloro-2-hydroxyphenyl)-3-(2-hydroxyethyl)-6-(trifluoromethyl)-quinolin-2(1H)-one (BMS-223131), a novel opener of large conductance ... J Pharmacol Exp Ther. 2005 May;313(2):840-7.
DMJUV6C	RU	https://pubmed.ncbi.nlm.nih.gov/15701710

DMQL3VS	DI	DMQL3VS
DMQL3VS	DN	BMS-275183
DMQL3VS	MI	TTML2WA
DMQL3VS	MN	Tubulin (TUB)
DMQL3VS	MT	DTT
DMQL3VS	MA	Inhibitor
DMQL3VS	RN	A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies. Invest New Drugs. 2011 Dec;29(6):1426-31.
DMQL3VS	RU	https://pubmed.ncbi.nlm.nih.gov/20680660

DMGYXFP	DI	DMGYXFP
DMGYXFP	DN	BMS-582949
DMGYXFP	MI	TTGFK5X
DMGYXFP	MN	Protein kinase unspecific (PK)
DMGYXFP	MT	DTT
DMGYXFP	MA	Modulator
DMGYXFP	RN	Synthesis and evaluation of carbamoylmethylene linked prodrugs of BMS-582949, a clinical p38alpha inhibitor. Bioorg Med Chem Lett. 2013 May 15;23(10):3028-33.
DMGYXFP	RU	https://pubmed.ncbi.nlm.nih.gov/23578688

DMGYXFP	DI	DMGYXFP
DMGYXFP	DN	BMS-582949
DMGYXFP	MI	TTWELHI
DMGYXFP	MN	Stress-activated protein kinase (p38)
DMGYXFP	MT	DTT
DMGYXFP	MA	Inhibitor
DMGYXFP	RN	Synthesis and evaluation of carbamoylmethylene linked prodrugs of BMS-582949, a clinical p38alpha inhibitor. Bioorg Med Chem Lett. 2013 May 15;23(10):3028-33.
DMGYXFP	RU	https://pubmed.ncbi.nlm.nih.gov/23578688

DMDPQV5	DI	DMDPQV5
DMDPQV5	DN	BMS-599626
DMDPQV5	MI	TTGKNB4
DMDPQV5	MN	Epidermal growth factor receptor (EGFR)
DMDPQV5	MT	DTT
DMDPQV5	MA	Inhibitor
DMDPQV5	RN	AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo. Invest New Drugs. 2011 Aug;29(4):554-61.
DMDPQV5	RU	https://pubmed.ncbi.nlm.nih.gov/20119866

DMDPQV5	DI	DMDPQV5
DMDPQV5	DN	BMS-599626
DMDPQV5	MI	TT6EO5L
DMDPQV5	MN	Erbb2 tyrosine kinase receptor (HER2)
DMDPQV5	MT	DTT
DMDPQV5	MA	Inhibitor
DMDPQV5	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMDPQV5	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMX302C	DI	DMX302C
DMX302C	DN	BMS-690514
DMX302C	MI	TTGKNB4
DMX302C	MN	Epidermal growth factor receptor (EGFR)
DMX302C	MT	DTT
DMX302C	MA	Inhibitor
DMX302C	RN	Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci. 2010 Aug;99(8):3579-93.
DMX302C	RU	https://pubmed.ncbi.nlm.nih.gov/20166197

DMX302C	DI	DMX302C
DMX302C	DN	BMS-690514
DMX302C	MI	TTR5TV4
DMX302C	MN	ERBB2 messenger RNA (HER2 mRNA)
DMX302C	MT	DTT
DMX302C	MA	Inhibitor
DMX302C	RN	Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci. 2010 Aug;99(8):3579-93.
DMX302C	RU	https://pubmed.ncbi.nlm.nih.gov/20166197

DMX302C	DI	DMX302C
DMX302C	DN	BMS-690514
DMX302C	MI	TTGJCWZ
DMX302C	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMX302C	MT	DTT
DMX302C	MA	Inhibitor
DMX302C	RN	Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci. 2010 Aug;99(8):3579-93.
DMX302C	RU	https://pubmed.ncbi.nlm.nih.gov/20166197

DMX302C	DI	DMX302C
DMX302C	DN	BMS-690514
DMX302C	MI	TTUTJGQ
DMX302C	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMX302C	MT	DTT
DMX302C	MA	Inhibitor
DMX302C	RN	Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci. 2010 Aug;99(8):3579-93.
DMX302C	RU	https://pubmed.ncbi.nlm.nih.gov/20166197

DM51LTG	DI	DM51LTG
DM51LTG	DN	BMS-708163
DM51LTG	MI	TT9W8GU
DM51LTG	MN	Gamma-secretase (GS)
DM51LTG	MT	DTT
DM51LTG	MA	Modulator
DM51LTG	RN	Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol. 2012 Nov;69(11):1430-40.
DM51LTG	RU	https://pubmed.ncbi.nlm.nih.gov/22892585

DMTVGY7	DI	DMTVGY7
DMTVGY7	DN	BMS-770767
DMTVGY7	MI	TTN7BL9
DMTVGY7	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMTVGY7	MT	DTT
DMTVGY7	MA	Modulator
DMTVGY7	RN	New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches. 2012. Chapter 5. Page(131).
DMTVGY7	RU	https://books.google.com.hk/books?id=0rmlVGhlJ0IC&pg=PA131&lpg=PA131&dq=RG-7234++New+Therapeutic+Strategies+for+Type+2+Diabetes&source=bl&ots=toqK7w4uiI&sig=sx5iyfQWH2bTCSZmT5aUQiKfPuM&hl=zh-CN&sa=X&ved=0CB0Q6AEwAGoVChMIsZ_k6dDGyAIViLeOCh0oUQpr#v=onepage&q=RG-7234%20%20New%20Therapeutic%20Strategies%20for%20Type%202%20Diabetes&f=false

DMKY638	DI	DMKY638
DMKY638	DN	BMS-813160
DMKY638	MI	TTFZYTO
DMKY638	MN	C-C chemokine receptor type 2 (CCR2)
DMKY638	MT	DTT
DMKY638	MA	Modulator
DMKY638	RN	A dual CCR2/CCR5 chemokine antagonist, BMS-813160. Expert Opin Ther Pat. 2011 Dec;21(12):1919-24.
DMKY638	RU	https://pubmed.ncbi.nlm.nih.gov/21936726

DMKY638	DI	DMKY638
DMKY638	DN	BMS-813160
DMKY638	MI	TT2CEJG
DMKY638	MN	C-C chemokine receptor type 5 (CCR5)
DMKY638	MT	DTT
DMKY638	MA	Modulator
DMKY638	RN	A dual CCR2/CCR5 chemokine antagonist, BMS-813160. Expert Opin Ther Pat. 2011 Dec;21(12):1919-24.
DMKY638	RU	https://pubmed.ncbi.nlm.nih.gov/21936726

DMT8L6P	DI	DMT8L6P
DMT8L6P	DN	BMS-817399
DMT8L6P	MI	TTC24WT
DMT8L6P	MN	C-C chemokine receptor type 1 (CCR1)
DMT8L6P	MT	DTT
DMT8L6P	MA	Modulator
DMT8L6P	RN	Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritis. J Med Chem. 2014 Sep 25;57(18):7550-64.
DMT8L6P	RU	https://pubmed.ncbi.nlm.nih.gov/25101488

DMF46PD	DI	DMF46PD
DMF46PD	DN	BMS-911543
DMF46PD	MI	TTRMX3V
DMF46PD	MN	Janus kinase 2 (JAK-2)
DMF46PD	MT	DTT
DMF46PD	MA	Modulator
DMF46PD	RN	Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2. Leukemia. 2012 Feb;26(2):280-8.
DMF46PD	RU	https://pubmed.ncbi.nlm.nih.gov/22015772

DMN28WK	DI	DMN28WK
DMN28WK	DN	BMS-919373
DMN28WK	MI	TTW0CMT
DMN28WK	MN	Voltage-gated potassium channel Kv1.5 (KCNA5)
DMN28WK	MT	DTT
DMN28WK	MA	Inhibitor
DMN28WK	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035504)
DMN28WK	RU	http://adisinsight.springer.com/drugs/800035504

DMUTS1W	DI	DMUTS1W
DMUTS1W	DN	BMS-936557
DMUTS1W	MI	TTQOVYA
DMUTS1W	MN	C-X-C motif chemokine 10 (CXCL10)
DMUTS1W	MT	DTT
DMUTS1W	RN	Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut. 2014 Mar;63(3):442-50.
DMUTS1W	RU	https://pubmed.ncbi.nlm.nih.gov/23461895

DM7XV4R	DI	DM7XV4R
DM7XV4R	DN	BMS-954561
DM7XV4R	MI	TTJSZTB
DM7XV4R	MN	Nicotinic acetylcholine receptor (nAChR)
DM7XV4R	MT	DTT
DM7XV4R	MA	Modulator
DM7XV4R	RN	EP patent application no. 2774991, Drug delivery system for use in the treatment or diagnosis of neurological disorders.
DM7XV4R	RU	http://www.google.com/patents/EP2774991A1?cl=en

DMMEAGO	DI	DMMEAGO
DMMEAGO	DN	BMS-955176
DMMEAGO	MI	TT5TOX7
DMMEAGO	MN	Human immunodeficiency virus Maturation (HIV Mat)
DMMEAGO	MT	DTT
DMMEAGO	MA	Inhibitor
DMMEAGO	RN	Clinical pipeline report, company report or official report of Bristol-Myers Squibb.
DMMEAGO	RU	http://news.bms.com/press-release/study-next-generation-investigational-hiv-1-maturation-inhibitor-shows-positive-result

DMVJXOH	DI	DMVJXOH
DMVJXOH	DN	BMS-986012
DMVJXOH	MI	TTW7KYV
DMVJXOH	MN	Fucosyl GM1 (FucGM1)
DMVJXOH	MT	DTT
DMVJXOH	MA	Inhibitor
DMVJXOH	RN	A Novel, Fully Human Anti-fucosyl-GM1 Antibody Demonstrates Potent In Vitro and In Vivo Antitumor Activity in Preclinical Models of Small Cell Lung Cancer. Clin Cancer Res. 2018 Oct 15;24(20):5178-5189.
DMVJXOH	RU	https://pubmed.ncbi.nlm.nih.gov/30021910

DMHMV6E	DI	DMHMV6E
DMHMV6E	DN	BMS-986020
DMHMV6E	MI	TTQ6S1K
DMHMV6E	MN	Lysophosphatidic acid receptor 1 (LPAR1)
DMHMV6E	MT	DTT
DMHMV6E	MA	Antagonist
DMHMV6E	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMHMV6E	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMIZKEC	DI	DMIZKEC
DMIZKEC	DN	BMS-986036
DMIZKEC	MI	TTQ916P
DMIZKEC	MN	Fibroblast growth factor-21 (FGF21)
DMIZKEC	MT	DTT
DMIZKEC	MA	Agonist
DMIZKEC	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMIZKEC	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMTKDIP	DI	DMTKDIP
DMTKDIP	DN	BMS-986141
DMTKDIP	MI	TT3I4WV
DMTKDIP	MN	Prostate apoptosis response-4 (PAWR)
DMTKDIP	MT	DTT
DMTKDIP	MA	Antagonist
DMTKDIP	RN	Protease activated receptor 4 (PAR4) antagonists: Research progress on small molecules in the field of antiplatelet agents. Eur J Med Chem. 2021 Jan 1;209:112893.
DMTKDIP	RU	https://pubmed.ncbi.nlm.nih.gov/33049608

DMZB8AJ	DI	DMZB8AJ
DMZB8AJ	DN	BMS-986142
DMZB8AJ	MI	TTGM6VW
DMZB8AJ	MN	Tyrosine-protein kinase BTK (ATK)
DMZB8AJ	MT	DTT
DMZB8AJ	MA	Inhibitor
DMZB8AJ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZB8AJ	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DM4QHZS	DI	DM4QHZS
DM4QHZS	DN	BMS-986177
DM4QHZS	MI	TTDM4ZU
DM4QHZS	MN	Factor XI messenger RNA (F11 mRNA)
DM4QHZS	MT	DTT
DM4QHZS	MA	Inhibitor
DM4QHZS	RN	Discovery methods of coagulation-inhibiting drugs. Expert Opin Drug Discov. 2017 Dec;12(12):1195-1205.
DM4QHZS	RU	https://pubmed.ncbi.nlm.nih.gov/28952381

DM5OU2W	DI	DM5OU2W
DM5OU2W	DN	BMS-986253
DM5OU2W	MI	TT3JF7X
DM5OU2W	MN	HUMAN interleukin 8 (IL8)
DM5OU2W	MT	DTT
DM5OU2W	MA	Inhibitor
DM5OU2W	RN	ClinicalTrials.gov (NCT04347226) Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19. U.S. National Institutes of Health.
DM5OU2W	RU	https://clinicaltrials.gov/ct2/show/NCT04347226

DM42B0C	DI	DM42B0C
DM42B0C	DN	BMS-986253
DM42B0C	MI	TTCTE1G
DM42B0C	MN	Interleukin-8 (IL8)
DM42B0C	MT	DTT
DM42B0C	MA	Inhibitor
DM42B0C	RN	Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors. J Immunother Cancer. 2019 Sep 5;7(1):240.
DM42B0C	RU	https://pubmed.ncbi.nlm.nih.gov/31488216

DMSRVXO	DI	DMSRVXO
DMSRVXO	DN	BMS-986263
DMSRVXO	MI	TTPSWQG
DMSRVXO	MN	SERPINH1 messenger RNA (SERPINH1 mRNA)
DMSRVXO	MT	DTT
DMSRVXO	MA	Inhibitor
DMSRVXO	RN	A Fit-for-Purpose Method for the Detection of Human Antibodies to Surface-Exposed Components of BMS-986263, a Lipid Nanoparticle-Based Drug Product Containing a siRNA Drug Substance. AAPS J. 2019 Jul 22;21(5):92.
DMSRVXO	RU	https://pubmed.ncbi.nlm.nih.gov/31332587

DMUM2KA	DI	DMUM2KA
DMUM2KA	DN	BN82451
DMUM2KA	MI	TTK0943
DMUM2KA	MN	Prostaglandin G/H synthase (COX)
DMUM2KA	MT	DTT
DMUM2KA	MA	Inhibitor
DMUM2KA	RN	Emerging drug therapies in Huntington's disease. Expert Opin Emerg Drugs. 2009 Jun;14(2):273-97.
DMUM2KA	RU	https://pubmed.ncbi.nlm.nih.gov/19453283

DMUM2KA	DI	DMUM2KA
DMUM2KA	DN	BN82451
DMUM2KA	MI	TTRK8B9
DMUM2KA	MN	Sodium channel unspecific (NaC)
DMUM2KA	MT	DTT
DMUM2KA	MA	Blocker
DMUM2KA	RN	Emerging drug therapies in Huntington's disease. Expert Opin Emerg Drugs. 2009 Jun;14(2):273-97.
DMUM2KA	RU	https://pubmed.ncbi.nlm.nih.gov/19453283

DMJC8DR	DI	DMJC8DR
DMJC8DR	DN	BNC-105
DMJC8DR	MI	TTYFKSZ
DMJC8DR	MN	Tubulin beta (TUBB)
DMJC8DR	MT	DTT
DMJC8DR	MA	Modulator
DMJC8DR	RN	The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer.Cancer Biol Ther.2014;15(11):1552-60.
DMJC8DR	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482941

DMEGDWA	DI	DMEGDWA
DMEGDWA	DN	BNC-210
DMEGDWA	MI	TTNJYV2
DMEGDWA	MN	Gamma-aminobutyric acid receptor (GAR)
DMEGDWA	MT	DTT
DMEGDWA	MA	Modulator
DMEGDWA	RN	50 years of hurdles and hope in anxiolytic drug discovery. Nat Rev Drug Discov. 2013 Sep;12(9):667-87. 
DMEGDWA	RU	https://pubmed.ncbi.nlm.nih.gov/23989795

DMRWG8B	DI	DMRWG8B
DMRWG8B	DN	BNT321
DMRWG8B	MI	TTD9I12
DMRWG8B	MN	Carbohydrate antigen 19-9 (CA 19-9)
DMRWG8B	MT	DTT
DMRWG8B	MA	Inhibitor
DMRWG8B	RN	Clinical pipeline report, company report or official report of BioNTech.
DMRWG8B	RU	https://biontech.de/science/pipeline

DM8JQZC	DI	DM8JQZC
DM8JQZC	DN	BNZ-1
DM8JQZC	MI	TTJFA35
DM8JQZC	MN	Interleukin-15 (IL15)
DM8JQZC	MT	DTT
DM8JQZC	MA	Inhibitor
DM8JQZC	RN	Clinical pipeline report, company report or official report of Bioniz Therapeutics.
DM8JQZC	RU	https://bioniz.com/pipeline/bnz-1/

DM8JQZC	DI	DM8JQZC
DM8JQZC	DN	BNZ-1
DM8JQZC	MI	TTF89GD
DM8JQZC	MN	Interleukin-2 (IL2)
DM8JQZC	MT	DTT
DM8JQZC	MA	Inhibitor
DM8JQZC	RN	Clinical pipeline report, company report or official report of Bioniz Therapeutics.
DM8JQZC	RU	https://bioniz.com/pipeline/bnz-1/

DM8JQZC	DI	DM8JQZC
DM8JQZC	DN	BNZ-1
DM8JQZC	MI	TT0JTFD
DM8JQZC	MN	Interleukin-9 (IL9)
DM8JQZC	MT	DTT
DM8JQZC	MA	Inhibitor
DM8JQZC	RN	Clinical pipeline report, company report or official report of Bioniz Therapeutics.
DM8JQZC	RU	https://bioniz.com/pipeline/bnz-1/

DMZ70GE	DI	DMZ70GE
DMZ70GE	DN	BOS-228
DMZ70GE	MI	TTJP4SM
DMZ70GE	MN	Bacterial Penicillin binding protein (Bact PBP)
DMZ70GE	MT	DTT
DMZ70GE	MA	Inhibitor
DMZ70GE	RN	Clinical pipeline report, company report or official report of Boston Pharmaceuticals.
DMZ70GE	RU	https://www.bostonpharmaceuticals.com/infectious-disease

DMKDGI8	DI	DMKDGI8
DMKDGI8	DN	BP-100-1-01
DMKDGI8	MI	TTEYRJ9
DMKDGI8	MN	GRB2 messenger RNA (GRB2 mRNA)
DMKDGI8	MT	DTT
DMKDGI8	MA	Modulator
DMKDGI8	RN	ClinicalTrials.gov (NCT01159028) Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS. U.S. National Institutes of Health.
DMKDGI8	RU	https://clinicaltrials.gov/ct2/show/NCT01159028

DMWVPO0	DI	DMWVPO0
DMWVPO0	DN	BPN14770
DMWVPO0	MI	TTSKMI8
DMWVPO0	MN	Phosphodiesterase 4D (PDE4D)
DMWVPO0	MT	DTT
DMWVPO0	MA	Inhibitor
DMWVPO0	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMWVPO0	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMDYZRS	DI	DMDYZRS
DMDYZRS	DN	BPS-804
DMDYZRS	MI	TTYRO4F
DMDYZRS	MN	Sclerostin (SOST)
DMDYZRS	MT	DTT
DMDYZRS	RN	WO patent application no. 2010,1001,79, Self-forming gel system for sustained drug delivery.
DMDYZRS	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20100910&CC=WO&NR=2010100179A2&KC=A2

DM0MO8I	DI	DM0MO8I
DM0MO8I	DN	BQ-123
DM0MO8I	MI	TTKRD0G
DM0MO8I	MN	Endothelin A receptor (EDNRA)
DM0MO8I	MT	DTT
DM0MO8I	MA	Antagonist
DM0MO8I	RN	Endothelin in heart failure: a promising therapeutic target Heart. 1997 Feb;77(2):93-4.
DM0MO8I	RU	https://pubmed.ncbi.nlm.nih.gov/9068384

DM0MO8I	DI	DM0MO8I
DM0MO8I	DN	BQ-123
DM0MO8I	MI	DTFI42L
DM0MO8I	MN	Multidrug resistance-associated protein 2 (ABCC2)
DM0MO8I	MT	DTP
DM0MO8I	MA	Substrate
DM0MO8I	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM0MO8I	RU	https://doi.org/10.1007/s11095-012-0935-x

DM0MO8I	DI	DM0MO8I
DM0MO8I	DN	BQ-123
DM0MO8I	MI	DTE2B1D
DM0MO8I	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DM0MO8I	MT	DTP
DM0MO8I	MA	Substrate
DM0MO8I	RN	Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
DM0MO8I	RU	http://www.ncbi.nlm.nih.gov/pubmed/11159893

DM0MO8I	DI	DM0MO8I
DM0MO8I	DN	BQ-123
DM0MO8I	MI	DT3D8F0
DM0MO8I	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM0MO8I	MT	DTP
DM0MO8I	MA	Substrate
DM0MO8I	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DM0MO8I	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DM0MO8I	DI	DM0MO8I
DM0MO8I	DN	BQ-123
DM0MO8I	MI	DT9C1TS
DM0MO8I	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM0MO8I	MT	DTP
DM0MO8I	MA	Substrate
DM0MO8I	RN	Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
DM0MO8I	RU	http://www.ncbi.nlm.nih.gov/pubmed/11159893

DMNFKVW	DI	DMNFKVW
DMNFKVW	DN	BR-4628
DMNFKVW	MI	TT26PHO
DMNFKVW	MN	Mineralocorticoid receptor  (MR)
DMNFKVW	MT	DTT
DMNFKVW	MA	Antagonist
DMNFKVW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 626).
DMNFKVW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=626

DM3TRF7	DI	DM3TRF7
DM3TRF7	DN	Brasofensine
DM3TRF7	MI	TT3ROYC
DM3TRF7	MN	Serotonin transporter (SERT)
DM3TRF7	MT	DTT
DM3TRF7	MA	Modulator
DM3TRF7	RN	Brasofensine NeuroSearch. Curr Opin Investig Drugs. 2000 Dec;1(4):504-7.
DM3TRF7	RU	https://pubmed.ncbi.nlm.nih.gov/11249705

DMKGM42	DI	DMKGM42
DMKGM42	DN	BREQUINAR
DMKGM42	MI	TTLVP78
DMKGM42	MN	Dihydroorotate dehydrogenase (DHODH)
DMKGM42	MT	DTT
DMKGM42	MA	Modulator
DMKGM42	RN	DOI: 10.1203/00006450-198807000-00137
DMKGM42	RU	http://www.nature.com/pr/journal/v24/n1/abs/pr1988506a.html

DMXI9BP	DI	DMXI9BP
DMXI9BP	DN	Brilacidin
DMXI9BP	MI	TTXT4D5
DMXI9BP	MN	Bacterial Cell membrane (Bact CM)
DMXI9BP	MT	DTT
DMXI9BP	MA	Enhancer
DMXI9BP	RN	Comparative mechanistic studies of brilacidin, daptomycin, and the antimicrobial peptide LL16. Antimicrob Agents Chemother. 2014 Sep;58(9):5136-45.
DMXI9BP	RU	https://pubmed.ncbi.nlm.nih.gov/24936592

DMLD80M	DI	DMLD80M
DMLD80M	DN	Brivoligide
DMLD80M	MI	TTE8LGD
DMLD80M	MN	EGR1 messenger RNA (EGR1 mRNA)
DMLD80M	MT	DTT
DMLD80M	MA	Inhibitor
DMLD80M	RN	ClinicalTrials.gov (NCT04104919) Study to Evaluate a Preop Dose of Brivoligide Injection for Pain After Mastectomy in Patients With High PCS Scores. U.S. National Institutes of Health.
DMLD80M	RU	https://clinicaltrials.gov/ct2/show/NCT04104919

DMLFGHX	DI	DMLFGHX
DMLFGHX	DN	BRL 35135
DMLFGHX	MI	TTR6W5O
DMLFGHX	MN	Adrenergic receptor beta-1 (ADRB1)
DMLFGHX	MT	DTT
DMLFGHX	MA	Agonist
DMLFGHX	RN	Clinical pharmacology of beta 3-adrenoceptors. Br J Clin Pharmacol. 1996 Sep;42(3):291-300.
DMLFGHX	RU	https://pubmed.ncbi.nlm.nih.gov/8877018

DMUI5PA	DI	DMUI5PA
DMUI5PA	DN	Brostallicin
DMUI5PA	MI	TTOVXHF
DMUI5PA	MN	Human Deoxyribonucleic acid minor groove (hDNA min)
DMUI5PA	MT	DTT
DMUI5PA	MA	Inhibitor
DMUI5PA	RN	Brostallicin (PNU-166196), a new minor groove DNA binder: preclinical and clinical activity. Expert Opin Investig Drugs. 2009 Dec;18(12):1939-46.
DMUI5PA	RU	https://pubmed.ncbi.nlm.nih.gov/19938904

DM1ZOCK	DI	DM1ZOCK
DM1ZOCK	DN	Bryostatin-1
DM1ZOCK	MI	TTBZ7OD
DM1ZOCK	MN	Protein kinase C epsilon (PRKCE)
DM1ZOCK	MT	DTT
DM1ZOCK	MA	Activator
DM1ZOCK	RN	Protein kinase epsilon dampens the secretory response of model intestinal epithelia during ischemia. Surgery. 2001 Aug;130(2):310-8.
DM1ZOCK	RU	https://pubmed.ncbi.nlm.nih.gov/11490365

DM2LZIY	DI	DM2LZIY
DM2LZIY	DN	BT-061
DM2LZIY	MI	TTN2JFW
DM2LZIY	MN	T-cell surface glycoprotein CD4 (CD4)
DM2LZIY	MT	DTT
DM2LZIY	RN	Tregalizumab (BT-061) increases regulatory T cell function. Boosting regulatory T-cell function with the humanized CD4-specific humanized monoclonal antibody Tregalizumab (BT-061). Immunol Cell Biol.2015 Apr;93(4):321-2.
DM2LZIY	RU	https://pubmed.ncbi.nlm.nih.gov/25666094

DMYO185	DI	DMYO185
DMYO185	DN	BT-062
DMYO185	MI	TTYDSVG
DMYO185	MN	Syndecan-1 (SDC1)
DMYO185	MT	DTT
DMYO185	RN	The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res. 2009 Jun 15;15(12):4028-37.
DMYO185	RU	https://pubmed.ncbi.nlm.nih.gov/19509164

DMDWP0U	DI	DMDWP0U
DMDWP0U	DN	BTA-798
DMDWP0U	MI	TT8R3VP
DMDWP0U	MN	Rhinovirus Capsid protein (HRV VP)
DMDWP0U	MT	DTT
DMDWP0U	MA	Inhibitor
DMDWP0U	RN	Combating enterovirus replication: state-of-the-art on antiviral research. Biochem Pharmacol. 2012 Jan 15;83(2):185-92.
DMDWP0U	RU	https://pubmed.ncbi.nlm.nih.gov/21889497

DMS6ZA0	DI	DMS6ZA0
DMS6ZA0	DN	BTD-001
DMS6ZA0	MI	TTCI43M
DMS6ZA0	MN	GABA(A) receptor (GABAR)
DMS6ZA0	MT	DTT
DMS6ZA0	MA	Antagonist
DMS6ZA0	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMS6ZA0	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMY5IX4	DI	DMY5IX4
DMY5IX4	DN	BTL-TML-001
DMY5IX4	MI	TTL3N71
DMY5IX4	MN	Virus Replication (Viru Repli)
DMY5IX4	MT	DTT
DMY5IX4	MA	Inhibitor
DMY5IX4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMY5IX4	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMA9238	DI	DMA9238
DMA9238	DN	BTRX-246040
DMA9238	MI	TTNT7K8
DMA9238	MN	Nociceptin receptor (OPRL1)
DMA9238	MT	DTT
DMA9238	MA	Antagonist
DMA9238	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMA9238	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMWPDUZ	DI	DMWPDUZ
DMWPDUZ	DN	BTRX-335140
DMWPDUZ	MI	TTQW87Y
DMWPDUZ	MN	Opioid receptor kappa (OPRK1)
DMWPDUZ	MT	DTT
DMWPDUZ	MA	Antagonist
DMWPDUZ	RN	Clinical pipeline report, company report or official report of BlackThorn Therapeutics.
DMWPDUZ	RU	https://www.blackthornrx.com/btrx-335140-kappa-opioid-receptor-antagonist/

DMIEPJG	DI	DMIEPJG
DMIEPJG	DN	BTT-1023
DMIEPJG	MI	TT7HC21
DMIEPJG	MN	Membrane copper amine oxidase (AOC3)
DMIEPJG	MT	DTT
DMIEPJG	RN	Preclinical evaluation of a radioiodinated fully human antibody for in vivo imaging of vascular adhesion protein-1-positive vasculature in inflammation. J Nucl Med. 2013 Aug;54(8):1315-9.
DMIEPJG	RU	https://pubmed.ncbi.nlm.nih.gov/23847292

DMZC4V0	DI	DMZC4V0
DMZC4V0	DN	Buproprion+zonisamide
DMZC4V0	MI	TTTQR47
DMZC4V0	MN	Solute carrier family 22 member 8 (SLC22A8)
DMZC4V0	MT	DTT
DMZC4V0	MA	Blocker
DMZC4V0	RN	Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
DMZC4V0	RU	https://pubmed.ncbi.nlm.nih.gov/18473708

DMNB4XK	DI	DMNB4XK
DMNB4XK	DN	BVD-523
DMNB4XK	MI	TTKPV6O
DMNB4XK	MN	Ephrin type-B receptor 2 (EPHB2)
DMNB4XK	MT	DTT
DMNB4XK	MA	Inhibitor
DMNB4XK	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMNB4XK	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMNB4XK	DI	DMNB4XK
DMNB4XK	DN	BVD-523
DMNB4XK	MI	TT1MG9E
DMNB4XK	MN	Extracellular signal-regulated kinase 1 (ERK1)
DMNB4XK	MT	DTT
DMNB4XK	MA	Modulator
DMNB4XK	RN	DOI: 10.1158/1538-7445.AM2015-4693
DMNB4XK	RU	http://cancerres.aacrjournals.org/content/75/15_Supplement/4693?cited-by=yes&legid=canres;75/15_Supplement/4693

DMNB4XK	DI	DMNB4XK
DMNB4XK	DN	BVD-523
DMNB4XK	MI	TT4TQBX
DMNB4XK	MN	Extracellular signal-regulated kinase 2 (ERK2)
DMNB4XK	MT	DTT
DMNB4XK	MA	Modulator
DMNB4XK	RN	DOI: 10.1158/1538-7445.AM2015-4693
DMNB4XK	RU	http://cancerres.aacrjournals.org/content/75/15_Supplement/4693?cited-by=yes&legid=canres;75/15_Supplement/4693

DM8CWL0	DI	DM8CWL0
DM8CWL0	DN	BVT.28949
DM8CWL0	MI	TTJQOD7
DM8CWL0	MN	5-HT 2A receptor (HTR2A)
DM8CWL0	MT	DTT
DM8CWL0	MA	Antagonist
DM8CWL0	RN	Novel ocular antihypertensive compounds in clinical trials. Clin Ophthalmol. 2011; 5: 667-677.
DM8CWL0	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3104796/

DMD8GNB	DI	DMD8GNB
DMD8GNB	DN	BXT-51072
DMD8GNB	MI	TTF10I9
DMD8GNB	MN	Nitric-oxide synthase inducible (NOS2)
DMD8GNB	MT	DTT
DMD8GNB	MA	Modulator
DMD8GNB	RN	Shear stress induces iNOS expression in cultured smooth muscle cells: role of oxidative stress. Am J Physiol Cell Physiol. 2000 Dec;279(6):C1880-8.
DMD8GNB	RU	https://pubmed.ncbi.nlm.nih.gov/11078703

DMTRONK	DI	DMTRONK
DMTRONK	DN	BZL-101
DMTRONK	MI	TT34ECM
DMTRONK	MN	Cell cycle (CC)
DMTRONK	MT	DTT
DMTRONK	MA	Inhibitor
DMTRONK	RN	BZL101, a phytochemical extract from the Scutellaria barbata plant, disrupts proliferation of human breast and prostate cancer cells through distinct mechanisms dependent on the cancer cell phenotype. Cancer Biol Ther. 2010 Aug 15;10(4):397-405.
DMTRONK	RU	https://www.ncbi.nlm.nih.gov/pubmed/20574166

DMGE058	DI	DMGE058
DMGE058	DN	Cabiralizumab
DMGE058	MI	TTNYZG2
DMGE058	MN	Granulocyte-macrophage colony-stimulating factor (CSF2)
DMGE058	MT	DTT
DMGE058	MA	Antagonist
DMGE058	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMGE058	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMGE058	DI	DMGE058
DMGE058	DN	Cabiralizumab
DMGE058	MI	TT7MRDV
DMGE058	MN	Macrophage colony-stimulating factor 1 receptor (CSF1R)
DMGE058	MT	DTT
DMGE058	MA	Antagonist
DMGE058	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMGE058	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMGXCY9	DI	DMGXCY9
DMGXCY9	DN	Calcium phosphate
DMGXCY9	MI	DT42EWA
DMGXCY9	MN	Sodium-dependent phosphate transport protein 2A (SLC34A1)
DMGXCY9	MT	DTP
DMGXCY9	MA	Substrate
DMGXCY9	RN	Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50.
DMGXCY9	RU	http://www.ncbi.nlm.nih.gov/pubmed/23398154

DMDV8MK	DI	DMDV8MK
DMDV8MK	DN	CALDARET HYDRATE
DMDV8MK	MI	TT619TC
DMDV8MK	MN	Sodium/calcium exchanger (SLC)
DMDV8MK	MT	DTT
DMDV8MK	MA	Modulator
DMDV8MK	RN	Caldaret, an intracellular Ca2+ handling modulator, limits infarct size of reperfused canine heart. J Pharmacol Sci. 2007 Feb;103(2):222-33.
DMDV8MK	RU	https://pubmed.ncbi.nlm.nih.gov/17299242

DMAKSMX	DI	DMAKSMX
DMAKSMX	DN	Camicinal
DMAKSMX	MI	TT953CX
DMAKSMX	MN	Motilin receptor (MLNR)
DMAKSMX	MT	DTT
DMAKSMX	MA	Modulator
DMAKSMX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 297).
DMAKSMX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=297

DMQ7UL8	DI	DMQ7UL8
DMQ7UL8	DN	Camostat
DMQ7UL8	MI	DTT79CX
DMQ7UL8	MN	Organic cation transporter 1 (SLC22A1)
DMQ7UL8	MT	DTP
DMQ7UL8	MA	Substrate
DMQ7UL8	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMQ7UL8	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DMQ7UL8	DI	DMQ7UL8
DMQ7UL8	DN	Camostat
DMQ7UL8	MI	TTEMV5X
DMQ7UL8	MN	Serine protease unspecific (SP)
DMQ7UL8	MT	DTT
DMQ7UL8	MA	Inhibitor
DMQ7UL8	RN	Camostat mesilate inhibits prostasin activity and reduces blood pressure and renal injury in salt-sensitive hypertension. J Hypertens. 2009 Jan;27(1):181-9.
DMQ7UL8	RU	https://pubmed.ncbi.nlm.nih.gov/19145783

DMEZLFT	DI	DMEZLFT
DMEZLFT	DN	Camsirubicin
DMEZLFT	MI	TTCGY2K
DMEZLFT	MN	DNA topoisomerase II alpha (TOP2A)
DMEZLFT	MT	DTT
DMEZLFT	MA	Inhibitor
DMEZLFT	RN	Clinical pipeline report, company report or official report of Monopar Therapeutics.
DMEZLFT	RU	https://www.monopartx.com/pipeline/Camsirubicin

DMEYIVW	DI	DMEYIVW
DMEYIVW	DN	CAP1-6D
DMEYIVW	MI	TTY6DTE
DMEYIVW	MN	Carcinoembryonic antigen CEA (CD66e)
DMEYIVW	MT	DTT
DMEYIVW	MA	Modulator
DMEYIVW	RN	Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res. 1997 Oct 15;57(20):4570-7.
DMEYIVW	RU	https://pubmed.ncbi.nlm.nih.gov/9377571

DMJKLHU	DI	DMJKLHU
DMJKLHU	DN	CAP-7.1
DMJKLHU	MI	TT0IHXV
DMJKLHU	MN	DNA topoisomerase II (TOP2)
DMJKLHU	MT	DTT
DMJKLHU	MA	Modulator
DMJKLHU	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMJKLHU	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMYWO62	DI	DMYWO62
DMYWO62	DN	Capadenoson
DMYWO62	MI	TTK25J1
DMYWO62	MN	Adenosine A1 receptor (ADORA1)
DMYWO62	MT	DTT
DMYWO62	MA	Agonist
DMYWO62	RN	A1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Investig Drugs. 2008 Dec;17(12):1901-10.
DMYWO62	RU	https://pubmed.ncbi.nlm.nih.gov/19012505

DMY4OMS	DI	DMY4OMS
DMY4OMS	DN	Carabersat
DMY4OMS	MI	TTSB7ZR
DMY4OMS	MN	Trigeminal ganglion stimulation-induced response (TGSR)
DMY4OMS	MT	DTT
DMY4OMS	MA	Modulator
DMY4OMS	RN	Tonabersat (SB-220453) a novel benzopyran with anticonvulsant properties attenuates trigeminal nerve-induced neurovascular reflexes. Br J Pharmacol. 2001 April; 132(7): 1549-1557.
DMY4OMS	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1572685/

DMN5JCX	DI	DMN5JCX
DMN5JCX	DN	Carboxyamidotriazole orotate
DMN5JCX	MI	TTF89GD
DMN5JCX	MN	Interleukin-2 (IL2)
DMN5JCX	MT	DTT
DMN5JCX	MA	Inhibitor
DMN5JCX	RN	J Clin Oncol 32:5s, 2014 (suppl; abstr 2071).
DMN5JCX	RU	http://meetinglibrary.asco.org/content/132006-144

DM7ADGX	DI	DM7ADGX
DM7ADGX	DN	Carfentanil
DM7ADGX	MI	DE2PJF5
DM7ADGX	MN	Acid cholesteryl ester hydrolase (LIPA)
DM7ADGX	MT	DME
DM7ADGX	MA	Metabolism
DM7ADGX	RN	Metabolism of carfentanil, an ultra-potent opioid, in human liver microsomes and human hepatocytes by high-resolution mass spectrometry. AAPS J. 2016 Nov;18(6):1489-1499.
DM7ADGX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27495118

DM7ADGX	DI	DM7ADGX
DM7ADGX	DN	Carfentanil
DM7ADGX	MI	DE4LYSA
DM7ADGX	MN	Cytochrome P450 3A4 (CYP3A4)
DM7ADGX	MT	DME
DM7ADGX	MA	Metabolism
DM7ADGX	RN	Metabolism of carfentanil, an ultra-potent opioid, in human liver microsomes and human hepatocytes by high-resolution mass spectrometry. AAPS J. 2016 Nov;18(6):1489-1499.
DM7ADGX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27495118

DM7ADGX	DI	DM7ADGX
DM7ADGX	DN	Carfentanil
DM7ADGX	MI	TT27RFC
DM7ADGX	MN	Opioid receptor delta (OPRD1)
DM7ADGX	MT	DTT
DM7ADGX	MA	Agonist
DM7ADGX	RN	Wax PM, Becker CE, Curry SC: Unexpected gas casualties in Moscow: a medical toxicology perspective. Ann Emerg Med. 2003 May;41(5):700-5.
DM7ADGX	RU	https://pubmed.ncbi.nlm.nih.gov/12712038

DM7ADGX	DI	DM7ADGX
DM7ADGX	DN	Carfentanil
DM7ADGX	MI	TTQW87Y
DM7ADGX	MN	Opioid receptor kappa (OPRK1)
DM7ADGX	MT	DTT
DM7ADGX	MA	Agonist
DM7ADGX	RN	Wax PM, Becker CE, Curry SC: Unexpected gas casualties in Moscow: a medical toxicology perspective. Ann Emerg Med. 2003 May;41(5):700-5.
DM7ADGX	RU	https://pubmed.ncbi.nlm.nih.gov/12712038

DM7ADGX	DI	DM7ADGX
DM7ADGX	DN	Carfentanil
DM7ADGX	MI	TTKWM86
DM7ADGX	MN	Opioid receptor mu (MOP)
DM7ADGX	MT	DTT
DM7ADGX	MA	Agonist
DM7ADGX	RN	Wax PM, Becker CE, Curry SC: Unexpected gas casualties in Moscow: a medical toxicology perspective. Ann Emerg Med. 2003 May;41(5):700-5.
DM7ADGX	RU	https://pubmed.ncbi.nlm.nih.gov/12712038

DMAUN15	DI	DMAUN15
DMAUN15	DN	Carlumab
DMAUN15	MI	TTNAY0P
DMAUN15	MN	Monocyte chemotactic and activating factor (CCL2)
DMAUN15	MT	DTT
DMAUN15	RN	Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study. Target Oncol. 2015 Mar;10(1):111-23.
DMAUN15	RU	https://pubmed.ncbi.nlm.nih.gov/24928772

DMN6TKI	DI	DMN6TKI
DMN6TKI	DN	Carmoterol
DMN6TKI	MI	TT2CJVK
DMN6TKI	MN	Adrenergic receptor beta-2 (ADRB2)
DMN6TKI	MT	DTT
DMN6TKI	MA	Agonist
DMN6TKI	RN	Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94.
DMN6TKI	RU	https://pubmed.ncbi.nlm.nih.gov/19265487

DMTBFXW	DI	DMTBFXW
DMTBFXW	DN	CART 19
DMTBFXW	MI	TTW640A
DMTBFXW	MN	B-lymphocyte surface antigen B4 (CD19)
DMTBFXW	MT	DTT
DMTBFXW	MA	CAR-T-Cell-Therapy
DMTBFXW	RN	ClinicalTrials.gov (NCT02935543) CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL
DMTBFXW	RU	https://clinicaltrials.gov/ct2/show/NCT02935543

DM28A5D	DI	DM28A5D
DM28A5D	DN	CAR-T cells targeting CD19
DM28A5D	MI	TTW640A
DM28A5D	MN	B-lymphocyte surface antigen B4 (CD19)
DM28A5D	MT	DTT
DM28A5D	MA	CAR-T-Cell-Therapy
DM28A5D	RN	ClinicalTrials.gov (NCT03196830) CAR-T for R/R B-NHL
DM28A5D	RU	https://clinicaltrials.gov/ct2/show/NCT03196830

DM3RU0A	DI	DM3RU0A
DM3RU0A	DN	CAR-T cells targeting CD20
DM3RU0A	MI	TTUE541
DM3RU0A	MN	Leukocyte surface antigen Leu-16 (CD20)
DM3RU0A	MT	DTT
DM3RU0A	MA	CAR-T-Cell-Therapy
DM3RU0A	RN	ClinicalTrials.gov (NCT03196830) CAR-T for R/R B-NHL
DM3RU0A	RU	https://clinicaltrials.gov/ct2/show/NCT03196830

DM6XN4C	DI	DM6XN4C
DM6XN4C	DN	CAR-T cells targeting CD22
DM6XN4C	MI	TTM6QSK
DM6XN4C	MN	B-cell receptor CD22 (CD22)
DM6XN4C	MT	DTT
DM6XN4C	MA	CAR-T-Cell-Therapy
DM6XN4C	RN	ClinicalTrials.gov (NCT03196830) CAR-T for R/R B-NHL
DM6XN4C	RU	https://clinicaltrials.gov/ct2/show/NCT03196830

DML0KWM	DI	DML0KWM
DML0KWM	DN	CAR-T cells targeting CD30
DML0KWM	MI	TT2GM5R
DML0KWM	MN	Lymphocyte activation antigen CD30 (TNFRSF8)
DML0KWM	MT	DTT
DML0KWM	MA	CAR-T-Cell-Therapy
DML0KWM	RN	ClinicalTrials.gov (NCT03196830) CAR-T for R/R B-NHL
DML0KWM	RU	https://clinicaltrials.gov/ct2/show/NCT03196830

DMHQKN6	DI	DMHQKN6
DMHQKN6	DN	CART-19
DMHQKN6	MI	TTW640A
DMHQKN6	MN	B-lymphocyte surface antigen B4 (CD19)
DMHQKN6	MT	DTT
DMHQKN6	MA	CAR-T-Cell-Therapy
DMHQKN6	RN	ClinicalTrials.gov (NCT01029366) CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy
DMHQKN6	RU	https://clinicaltrials.gov/ct2/show/NCT01029366

DMZUV7T	DI	DMZUV7T
DMZUV7T	DN	CART-19 cells
DMZUV7T	MI	TTW640A
DMZUV7T	MN	B-lymphocyte surface antigen B4 (CD19)
DMZUV7T	MT	DTT
DMZUV7T	MA	CAR-T-Cell-Therapy
DMZUV7T	RN	ClinicalTrials.gov (NCT01551043) Allo CART-19 Protocol
DMZUV7T	RU	https://clinicaltrials.gov/ct2/show/NCT01551043

DMQBP7R	DI	DMQBP7R
DMQBP7R	DN	CAT 1004
DMQBP7R	MI	TTUIZKC
DMQBP7R	MN	DNA-binding factor KBF1 (p105)
DMQBP7R	MT	DTT
DMQBP7R	MA	Inhibitor
DMQBP7R	RN	Clinical pipeline report, company report or official report of Catabasis Pharmaceuticals Inc.
DMQBP7R	RU	http://www.catabasis.com/clinical-trials-cat-1004-movedmd.php

DMQBP7R	DI	DMQBP7R
DMQBP7R	DN	CAT 1004
DMQBP7R	MI	TTSXVID
DMQBP7R	MN	Nuclear factor NF-kappa-B (NFKB)
DMQBP7R	MT	DTT
DMQBP7R	MA	Inhibitor
DMQBP7R	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQBP7R	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DM2IFYZ	DI	DM2IFYZ
DM2IFYZ	DN	CB-10-01
DM2IFYZ	MI	TTUJFD0
DM2IFYZ	MN	Telomerase reverse transcriptase (TERT)
DM2IFYZ	MT	DTT
DM2IFYZ	RN	Telomerase immunity from bench to bedside: round one. J Transl Med. 2007 Feb 26;5:12.
DM2IFYZ	RU	https://pubmed.ncbi.nlm.nih.gov/17324292

DM094UH	DI	DM094UH
DM094UH	DN	CB-839
DM094UH	MI	TTCW0KX
DM094UH	MN	Glutaminase (GLS)
DM094UH	MT	DTT
DM094UH	MA	Modulator
DM094UH	RN	Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther. 2014 Apr;13(4):890-901.
DM094UH	RU	https://pubmed.ncbi.nlm.nih.gov/24523301

DMK4FRU	DI	DMK4FRU
DMK4FRU	DN	CBLB-502
DMK4FRU	MI	TTCXP8J
DMK4FRU	MN	Toll-like receptor 5 (TLR5)
DMK4FRU	MT	DTT
DMK4FRU	MA	Agonist
DMK4FRU	RN	Recombinant TLR5 agonist CBLB502 promotes NK cell-mediated anti-CMV immunity in mice. PLoS One. 2014 May 30;9(5):e96165.
DMK4FRU	RU	https://pubmed.ncbi.nlm.nih.gov/24879439

DMSBNTZ	DI	DMSBNTZ
DMSBNTZ	DN	CBX-129801
DMSBNTZ	MI	TTKF4WV
DMSBNTZ	MN	Connecting peptide (C-peptide)
DMSBNTZ	MT	DTT
DMSBNTZ	MA	Modulator
DMSBNTZ	RN	ClinicalTrials.gov (NCT01681290) Safety and Efficacy of CBX129801 in Patients With Type 1 Diabetes. U.S. National Institutes of Health.
DMSBNTZ	RU	https://clinicaltrials.gov/ct2/show/NCT01681290

DMQ874W	DI	DMQ874W
DMQ874W	DN	CC-1088
DMQ874W	MI	TTZ97H5
DMQ874W	MN	Phosphodiesterase 4A (PDE4A)
DMQ874W	MT	DTT
DMQ874W	MA	Inhibitor
DMQ874W	RN	Thalidomide analogs and PDE4 inhibition. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2669-74.
DMQ874W	RU	https://pubmed.ncbi.nlm.nih.gov/9873600

DMQ874W	DI	DMQ874W
DMQ874W	DN	CC-1088
DMQ874W	MI	TTVIAT9
DMQ874W	MN	Phosphodiesterase 4B (PDE4B)
DMQ874W	MT	DTT
DMQ874W	MA	Inhibitor
DMQ874W	RN	Thalidomide analogs and PDE4 inhibition. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2669-74.
DMQ874W	RU	https://pubmed.ncbi.nlm.nih.gov/9873600

DMQ874W	DI	DMQ874W
DMQ874W	DN	CC-1088
DMQ874W	MI	TTSKMI8
DMQ874W	MN	Phosphodiesterase 4D (PDE4D)
DMQ874W	MT	DTT
DMQ874W	MA	Inhibitor
DMQ874W	RN	Thalidomide analogs and PDE4 inhibition. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2669-74.
DMQ874W	RU	https://pubmed.ncbi.nlm.nih.gov/9873600

DMNE7L3	DI	DMNE7L3
DMNE7L3	DN	CC-220
DMNE7L3	MI	TTDKGTC
DMNE7L3	MN	Protein cereblon (CRBN)
DMNE7L3	MT	DTT
DMNE7L3	MA	Inhibitor
DMNE7L3	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMNE7L3	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMJR9H0	DI	DMJR9H0
DMJR9H0	DN	CC-292
DMJR9H0	MI	TTGM6VW
DMJR9H0	MN	Tyrosine-protein kinase BTK (ATK)
DMJR9H0	MT	DTT
DMJR9H0	MA	Modulator
DMJR9H0	RN	Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J Pharmacol Exp Ther. 2013 Aug;346(2):219-28.
DMJR9H0	RU	https://pubmed.ncbi.nlm.nih.gov/23709115

DMPMO6G	DI	DMPMO6G
DMPMO6G	DN	CC-401
DMPMO6G	MI	TTR2TXZ
DMPMO6G	MN	Jun N terminal kinase (JNK)
DMPMO6G	MT	DTT
DMPMO6G	MA	Modulator
DMPMO6G	RN	Signal integration by JNK and p38 MAPK pathways in cancer development.Nat Rev Cancer.2009 Aug;9(8):537-49.
DMPMO6G	RU	https://www.ncbi.nlm.nih.gov/pubmed/19629069

DM0EDHJ	DI	DM0EDHJ
DM0EDHJ	DN	CC-90011
DM0EDHJ	MI	TTNR0UQ
DM0EDHJ	MN	Lysine-specific histone demethylase 1 (LSD)
DM0EDHJ	MT	DTT
DM0EDHJ	MA	Inhibitor
DM0EDHJ	RN	Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1). J Med Chem. 2020 Dec 10;63(23):14522-14529.
DM0EDHJ	RU	https://pubmed.ncbi.nlm.nih.gov/33034194

DMHVEGJ	DI	DMHVEGJ
DMHVEGJ	DN	CC-930
DMHVEGJ	MI	TTR2TXZ
DMHVEGJ	MN	Jun N terminal kinase (JNK)
DMHVEGJ	MT	DTT
DMHVEGJ	MA	Modulator
DMHVEGJ	RN	In vitro metabolism of a novel JNK inhibitor tanzisertib: interspecies differences in oxido-reduction and characterization of enzymes involved in metabolism. Xenobiotica. 2015;45(6):465-80.
DMHVEGJ	RU	https://pubmed.ncbi.nlm.nih.gov/25475995

DMJ9XCO	DI	DMJ9XCO
DMJ9XCO	DN	CCX-140
DMJ9XCO	MI	TTFZYTO
DMJ9XCO	MN	C-C chemokine receptor type 2 (CCR2)
DMJ9XCO	MT	DTT
DMJ9XCO	MA	Antagonist
DMJ9XCO	RN	Present and future in the treatment of diabetic kidney disease. J Diabetes Res. 2015;2015:801348.
DMJ9XCO	RU	https://pubmed.ncbi.nlm.nih.gov/25945357

DMSHV9C	DI	DMSHV9C
DMSHV9C	DN	CCX-354
DMSHV9C	MI	TTC24WT
DMSHV9C	MN	C-C chemokine receptor type 1 (CCR1)
DMSHV9C	MT	DTT
DMSHV9C	MA	Antagonist
DMSHV9C	RN	Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial. Ann Rheum Dis. 2013 Mar;72(3):337-44.
DMSHV9C	RU	https://pubmed.ncbi.nlm.nih.gov/22589376

DMPVAUT	DI	DMPVAUT
DMPVAUT	DN	CCX872
DMPVAUT	MI	TTFZYTO
DMPVAUT	MN	C-C chemokine receptor type 2 (CCR2)
DMPVAUT	MT	DTT
DMPVAUT	MA	Inhibitor
DMPVAUT	RN	Therapeutic use of a clinical stage CCR2 inhibitor, CCX872, in obesity-associated steatohepatitis. The Lancet Volume 383, Supplement 1, 26 February 2014, Pages S78.
DMPVAUT	RU	http://www.sciencedirect.com/science/article/pii/S014067361460341X

DMEK580	DI	DMEK580
DMEK580	DN	CD19 CAR T cells
DMEK580	MI	TTW640A
DMEK580	MN	B-lymphocyte surface antigen B4 (CD19)
DMEK580	MT	DTT
DMEK580	MA	CAR-T-Cell-Therapy
DMEK580	RN	ClinicalTrials.gov (NCT02846584) a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies
DMEK580	RU	https://clinicaltrials.gov/ct2/show/NCT02846584

DMQJBUK	DI	DMQJBUK
DMQJBUK	DN	CD19-targeting CAR T cells
DMQJBUK	MI	TTW640A
DMQJBUK	MN	B-lymphocyte surface antigen B4 (CD19)
DMQJBUK	MT	DTT
DMQJBUK	MA	CAR-T-Cell-Therapy
DMQJBUK	RN	ClinicalTrials.gov (NCT02132624) CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.
DMQJBUK	RU	https://clinicaltrials.gov/ct2/show/NCT02132624

DMQGI8R	DI	DMQGI8R
DMQGI8R	DN	CD20 CAR T cells
DMQGI8R	MI	TTUE541
DMQGI8R	MN	Leukocyte surface antigen Leu-16 (CD20)
DMQGI8R	MT	DTT
DMQGI8R	MA	CAR-T-Cell-Therapy
DMQGI8R	RN	ClinicalTrials.gov (NCT02846584) a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies
DMQGI8R	RU	https://clinicaltrials.gov/ct2/show/NCT02846584

DMXYLTI	DI	DMXYLTI
DMXYLTI	DN	CDP323
DMXYLTI	MI	TT6S84X
DMXYLTI	MN	Integrin alpha-4/beta-1 (ITGA4/B1)
DMXYLTI	MT	DTT
DMXYLTI	MA	Modulator
DMXYLTI	RN	Pharmacodynamic consequences of administration of VLA-4 antagonist CDP323 to multiple sclerosis subjects: a randomized, double-blind phase 1/2 study.PLoS One.2013;8(3):e58438.
DMXYLTI	RU	https://www.ncbi.nlm.nih.gov/pubmed/23472197

DM3YB2C	DI	DM3YB2C
DM3YB2C	DN	CDP-6038
DM3YB2C	MI	TTT1V78
DM3YB2C	MN	Interleukin-6 (IL6)
DM3YB2C	MT	DTT
DM3YB2C	MA	Modulator
DM3YB2C	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM3YB2C	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM8UQJG	DI	DM8UQJG
DM8UQJG	DN	CDX-1307
DM8UQJG	MI	TTUH273
DM8UQJG	MN	Choriogonadotropin beta (CG-beta)
DM8UQJG	MT	DTT
DM8UQJG	RN	CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer. Expert Rev Vaccines. 2011 Jun;10(6):733-42.
DM8UQJG	RU	https://pubmed.ncbi.nlm.nih.gov/21692696

DMCGNJ6	DI	DMCGNJ6
DMCGNJ6	DN	CDX-1401
DMCGNJ6	MI	TTE5ITK
DMCGNJ6	MN	Cancer/testis antigen 1 (NY-ESO-1)
DMCGNJ6	MT	DTT
DMCGNJ6	MA	Modulator
DMCGNJ6	RN	National Cancer Institute Drug Dictionary (drug id 651880).
DMCGNJ6	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=651880

DMKRFCO	DI	DMKRFCO
DMKRFCO	DN	CDX-301
DMKRFCO	MI	TTGJCWZ
DMKRFCO	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMKRFCO	MT	DTT
DMKRFCO	MA	Inhibitor
DMKRFCO	RN	Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers. Bone Marrow Transplant. 2015 Jul;50(7):924-30.
DMKRFCO	RU	https://pubmed.ncbi.nlm.nih.gov/25915810

DM5GKYD	DI	DM5GKYD
DM5GKYD	DN	CDX-3379
DM5GKYD	MI	TTDC8N2
DM5GKYD	MN	Erbb3 tyrosine kinase receptor (Erbb-3)
DM5GKYD	MT	DTT
DM5GKYD	MA	Antagonist
DM5GKYD	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM5GKYD	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM6Z9BV	DI	DM6Z9BV
DM6Z9BV	DN	CeaVac
DM6Z9BV	MI	TTY6DTE
DM6Z9BV	MN	Carcinoembryonic antigen CEA (CD66e)
DM6Z9BV	MT	DTT
DM6Z9BV	RN	Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J Clin Oncol. 1999 Sep;17(9):2889-5.
DM6Z9BV	RU	https://pubmed.ncbi.nlm.nih.gov/10561367

DM1S2FZ	DI	DM1S2FZ
DM1S2FZ	DN	Cemdisiran
DM1S2FZ	MI	TT2LJRF
DM1S2FZ	MN	C5 messenger RNA (C5 mRNA)
DM1S2FZ	MT	DTT
DM1S2FZ	MA	Inhibitor
DM1S2FZ	RN	Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals.
DM1S2FZ	RU	https://www.alnylam.com/alnylam-rnai-pipeline/

DMCT8EY	DI	DMCT8EY
DMCT8EY	DN	Cenderitide
DMCT8EY	MI	TTJME02
DMCT8EY	MN	Atrial natriuretic peptide receptor A (NPR1)
DMCT8EY	MT	DTT
DMCT8EY	MA	Agonist
DMCT8EY	RN	2011 Pipeline of Nile Therapeutics.
DMCT8EY	RU	http://www.nilethera.com/pipeline.html

DMU3P1K	DI	DMU3P1K
DMU3P1K	DN	Cenerimod
DMU3P1K	MI	TT2DLFI
DMU3P1K	MN	Lysosphingolipid receptor (LSPR)
DMU3P1K	MT	DTT
DMU3P1K	MA	Agonist
DMU3P1K	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMU3P1K	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMMN21R	DI	DMMN21R
DMMN21R	DN	Cenersen
DMMN21R	MI	TT12KOD
DMMN21R	MN	P53 messenger RNA (TP53 mRNA)
DMMN21R	MT	DTT
DMMN21R	RN	Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia. Cancer. 2012 Jan 15;118(2):418-27.
DMMN21R	RU	https://pubmed.ncbi.nlm.nih.gov/21717444

DM4V8WF	DI	DM4V8WF
DM4V8WF	DN	Cenicriviroc
DM4V8WF	MI	TTFZYTO
DM4V8WF	MN	C-C chemokine receptor type 2 (CCR2)
DM4V8WF	MT	DTT
DM4V8WF	MA	Antagonist
DM4V8WF	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM4V8WF	RU	http://phrma-docs.phrma.org/files/dmfile/2017-HIV-AIDS-MID-Drug-List.pdf

DM4V8WF	DI	DM4V8WF
DM4V8WF	DN	Cenicriviroc
DM4V8WF	MI	TT2CEJG
DM4V8WF	MN	C-C chemokine receptor type 5 (CCR5)
DM4V8WF	MT	DTT
DM4V8WF	MA	Modulator
DM4V8WF	RN	The dual CCR5 and CCR2 inhibitor cenicriviroc does not redistribute HIV into extracellular space: implications for plasma viral load and intracellular DNA decline. J Antimicrob Chemother. 2015 Mar;70(3):750-6.
DM4V8WF	RU	https://pubmed.ncbi.nlm.nih.gov/25433008

DM4V8WF	DI	DM4V8WF
DM4V8WF	DN	Cenicriviroc
DM4V8WF	MI	DES5XRU
DM4V8WF	MN	Cytochrome P450 2C8 (CYP2C8)
DM4V8WF	MT	DME
DM4V8WF	MA	Metabolism
DM4V8WF	RN	Pharmacokinetics, safety, and CCR2/CCR5 antagonist activity of cenicriviroc in participants with mild or moderate hepatic impairment. Clin Transl Sci. 2016 Jun;9(3):139-48.
DM4V8WF	RU	https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.12397

DM4V8WF	DI	DM4V8WF
DM4V8WF	DN	Cenicriviroc
DM4V8WF	MI	DE4LYSA
DM4V8WF	MN	Cytochrome P450 3A4 (CYP3A4)
DM4V8WF	MT	DME
DM4V8WF	MA	Metabolism
DM4V8WF	RN	Pharmacokinetics, safety, and CCR2/CCR5 antagonist activity of cenicriviroc in participants with mild or moderate hepatic impairment. Clin Transl Sci. 2016 Jun;9(3):139-48.
DM4V8WF	RU	https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.12397

DMWUQI9	DI	DMWUQI9
DMWUQI9	DN	CER-001
DMWUQI9	MI	TT7GN3U
DMWUQI9	MN	Apolipoprotein A-I (APOA1)
DMWUQI9	MT	DTT
DMWUQI9	MA	Modulator
DMWUQI9	RN	Clinical pipeline report, company report or official report of Cerenis.
DMWUQI9	RU	http://www.cerenis.com/en/our-therapies/cer-001

DMSABRI	DI	DMSABRI
DMSABRI	DN	CERC-301
DMSABRI	MI	TTN9D8E
DMSABRI	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMSABRI	MT	DTT
DMSABRI	MA	Antagonist
DMSABRI	RN	Inhibition of in vivo [(3)H]MK-801 binding by NMDA receptor open channel blockers and GluN2B antagonists in rats and mice. Eur J Pharmacol. 2015 Nov 5;766:1-8.
DMSABRI	RU	https://pubmed.ncbi.nlm.nih.gov/26325093

DM3SZ7P	DI	DM3SZ7P
DM3SZ7P	DN	CERC-801
DM3SZ7P	MI	DE3OP9S
DM3SZ7P	MN	Galactose kinase (GALK1)
DM3SZ7P	MT	DME
DM3SZ7P	MA	Metabolism
DM3SZ7P	RN	Molecular and biochemical characterization of human galactokinase and its small molecule inhibitors. Chem Biol Interact. 2010 Dec 5;188(3):376-85.
DM3SZ7P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20696150

DM3SZ7P	DI	DM3SZ7P
DM3SZ7P	DN	CERC-801
DM3SZ7P	MI	DEVSIE6
DM3SZ7P	MN	Glyceraldehyde-3-phosphate dehydrogenase (gap)
DM3SZ7P	MT	DME
DM3SZ7P	MA	Metabolism
DM3SZ7P	RN	Cloning, expression and characterization of a mucin-binding GAPDH from Lactobacillus acidophilus. Int J Biol Macromol. 2016 Oct;91:338-46.
DM3SZ7P	RU	https://pubmed.ncbi.nlm.nih.gov/27180300

DM3SZ7P	DI	DM3SZ7P
DM3SZ7P	DN	CERC-801
DM3SZ7P	MI	DETP28W
DM3SZ7P	MN	L-arabinose isomerase (araA)
DM3SZ7P	MT	DME
DM3SZ7P	MA	Metabolism
DM3SZ7P	RN	The acid tolerant L-arabinose isomerase from the food grade Lactobacillus sakei 23K is an attractive D-tagatose producer. Bioresour Technol. 2010 Dec;101(23):9171-7.
DM3SZ7P	RU	https://pubmed.ncbi.nlm.nih.gov/20688514

DM3SZ7P	DI	DM3SZ7P
DM3SZ7P	DN	CERC-801
DM3SZ7P	MI	DEU37LK
DM3SZ7P	MN	L-arabinose isomerase (araA)
DM3SZ7P	MT	DME
DM3SZ7P	MA	Metabolism
DM3SZ7P	RN	Biochemical properties of L-arabinose isomerase from Clostridium hylemonae to produce D-tagatose as a functional sweetener. PLoS One. 2018 Apr 23;13(4):e0196099.
DM3SZ7P	RU	https://pubmed.ncbi.nlm.nih.gov/29684065

DM3SZ7P	DI	DM3SZ7P
DM3SZ7P	DN	CERC-801
DM3SZ7P	MI	DEYWLRK
DM3SZ7P	MN	Sulfotransferase 1A1 (SULT1A1)
DM3SZ7P	MT	DME
DM3SZ7P	MA	Metabolism
DM3SZ7P	RN	Sulfation of the galactose residues in the glycosaminoglycan-protein linkage region by recombinant human chondroitin 6-O-sulfotransferase-1. J Biol Chem. 2008 Oct 10;283(41):27438-43.
DM3SZ7P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18697746

DMSCR2H	DI	DMSCR2H
DMSCR2H	DN	Cerdulatinib
DMSCR2H	MI	TT6DM01
DMSCR2H	MN	Janus kinase 1 (JAK-1)
DMSCR2H	MT	DTT
DMSCR2H	MA	Inhibitor
DMSCR2H	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMSCR2H	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMSCR2H	DI	DMSCR2H
DMSCR2H	DN	Cerdulatinib
DMSCR2H	MI	TTRMX3V
DMSCR2H	MN	Janus kinase 2 (JAK-2)
DMSCR2H	MT	DTT
DMSCR2H	MA	Modulator
DMSCR2H	RN	Company report (Portola Pharmaceuticals)
DMSCR2H	RU	https://www.portola.com/blog/cerdulatinib-a-unique-and-promising-investigational-treatment-for-patients-with-hematologic-cancers/

DMSCR2H	DI	DMSCR2H
DMSCR2H	DN	Cerdulatinib
DMSCR2H	MI	TTT7PJU
DMSCR2H	MN	Janus kinase 3 (JAK-3)
DMSCR2H	MT	DTT
DMSCR2H	MA	Inhibitor
DMSCR2H	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMSCR2H	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMSCR2H	DI	DMSCR2H
DMSCR2H	DN	Cerdulatinib
DMSCR2H	MI	TTOU65C
DMSCR2H	MN	Tyrosine-protein kinase SYK (SYK)
DMSCR2H	MT	DTT
DMSCR2H	MA	Modulator
DMSCR2H	RN	Company report (Portola Pharmaceuticals)
DMSCR2H	RU	https://www.portola.com/blog/cerdulatinib-a-unique-and-promising-investigational-treatment-for-patients-with-hematologic-cancers/

DMNW5I9	DI	DMNW5I9
DMNW5I9	DN	CERE-110
DMNW5I9	MI	TTDN3LF
DMNW5I9	MN	Nerve growth factor (NGF)
DMNW5I9	MT	DTT
DMNW5I9	MA	Modulator
DMNW5I9	RN	CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease. Curr Opin Mol Ther. 2010 Apr;12(2):240-7.
DMNW5I9	RU	https://pubmed.ncbi.nlm.nih.gov/20373268

DMS01AX	DI	DMS01AX
DMS01AX	DN	CERE-120
DMS01AX	MI	TTWFC4G
DMS01AX	MN	Netrin (NET)
DMS01AX	MT	DTT
DMS01AX	MA	Modulator
DMS01AX	RN	Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease. Mol Ther. 2007 Jan;15(1):62-8.
DMS01AX	RU	https://pubmed.ncbi.nlm.nih.gov/17164776

DMAWKSM	DI	DMAWKSM
DMAWKSM	DN	CetuGEX
DMAWKSM	MI	TTGKNB4
DMAWKSM	MN	Epidermal growth factor receptor (EGFR)
DMAWKSM	MT	DTT
DMAWKSM	RN	Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther. 2011 May 1;11(9):777-92.
DMAWKSM	RU	https://pubmed.ncbi.nlm.nih.gov/21293176

DMP56WJ	DI	DMP56WJ
DMP56WJ	DN	CF102
DMP56WJ	MI	TTJFY5U
DMP56WJ	MN	Adenosine A3 receptor (ADORA3)
DMP56WJ	MT	DTT
DMP56WJ	MA	Agonist
DMP56WJ	RN	2011 Pipeline of Can-Fite BioPharm.
DMP56WJ	RU	http://www.canfite.com/pipeline.html

DM3BN4W	DI	DM3BN4W
DM3BN4W	DN	CFI-400945
DM3BN4W	MI	TTGPNZQ
DM3BN4W	MN	Polo-like kinase 4 (PLK4)
DM3BN4W	MT	DTT
DM3BN4W	MA	Inhibitor
DM3BN4W	RN	Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent. Cancer Cell. 2014 Aug 11;26(2):163-76.
DM3BN4W	RU	https://pubmed.ncbi.nlm.nih.gov/25043604

DM1TWIE	DI	DM1TWIE
DM1TWIE	DN	CFZ533
DM1TWIE	MI	TTN6Y9A
DM1TWIE	MN	CD40L receptor (CD40)
DM1TWIE	MT	DTT
DM1TWIE	MA	Inhibitor
DM1TWIE	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM1TWIE	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMWY609	DI	DMWY609
DMWY609	DN	CG201
DMWY609	MI	TT0ID4A
DMWY609	MN	Leutinizing-hormone-releasing hormone (GNRH1)
DMWY609	MT	DTT
DMWY609	MA	Modulator
DMWY609	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMWY609	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMFAKGR	DI	DMFAKGR
DMFAKGR	DN	CG-400549
DMFAKGR	MI	TTZBRVL
DMFAKGR	MN	Staphylococcus Enoyl ACP reductase (Stap-coc fabI)
DMFAKGR	MT	DTT
DMFAKGR	MA	Inhibitor
DMFAKGR	RN	In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea. Antimicrob Agents Chemother. 2007 Jul;51(7):2591-3.
DMFAKGR	RU	https://pubmed.ncbi.nlm.nih.gov/17420210

DM17JSI	DI	DM17JSI
DM17JSI	DN	CGC-11047
DM17JSI	MI	TTUTN1I
DM17JSI	MN	Human Deoxyribonucleic acid (hDNA)
DM17JSI	MT	DTT
DM17JSI	MA	Modulator
DM17JSI	RN	Gene expression analysis of HCT116 colon tumor-derived cells treated with the polyamine analog PG-11047. Cancer Genomics Proteomics. 2009 May-Jun;6(3):161-75.
DM17JSI	RU	https://pubmed.ncbi.nlm.nih.gov/19487545

DMYNTQV	DI	DMYNTQV
DMYNTQV	DN	CGP-28014
DMYNTQV	MI	TTKWFB8
DMYNTQV	MN	Catechol-O-methyl-transferase (COMT)
DMYNTQV	MT	DTT
DMYNTQV	MA	Modulator
DMYNTQV	RN	CGP 28014, a new inhibitor of cerebral catechol-O-methylation with a non-catechol structure. Naunyn Schmiedebergs Arch Pharmacol. 1990 Sep;342(3):305-11.
DMYNTQV	RU	https://pubmed.ncbi.nlm.nih.gov/1980718

DMKS7RJ	DI	DMKS7RJ
DMKS7RJ	DN	CGS-15873A
DMKS7RJ	MI	TTEX248
DMKS7RJ	MN	Dopamine D2 receptor (D2R)
DMKS7RJ	MT	DTT
DMKS7RJ	MA	Modulator
DMKS7RJ	RN	Biochemical and pharmacological characterization of the putative dopamine autoreceptor agonist benzopyranopyridine, CGS 15873A. Article first published online: 5 OCT 2004.
DMKS7RJ	RU	http://onlinelibrary.wiley.com/doi/10.1002/ddr.430180303/abstract

DMLQRYH	DI	DMLQRYH
DMLQRYH	DN	CH-4051
DMLQRYH	MI	TTYZVDJ
DMLQRYH	MN	Dihydrofolate reductase (DHFR)
DMLQRYH	MT	DTT
DMLQRYH	MA	Inhibitor
DMLQRYH	RN	CH-1504, a metabolically inert antifolate for the potential treatment of rheumatoid arthritis. IDrugs. 2010 Aug;13(8):559-67.
DMLQRYH	RU	https://pubmed.ncbi.nlm.nih.gov/20721827

DMQ2O8V	DI	DMQ2O8V
DMQ2O8V	DN	CHF-3381
DMQ2O8V	MI	TT3WG5C
DMQ2O8V	MN	Monoamine oxidase type A (MAO-A)
DMQ2O8V	MT	DTT
DMQ2O8V	MA	Inhibitor
DMQ2O8V	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DMQ2O8V	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DMQ2O8V	DI	DMQ2O8V
DMQ2O8V	DN	CHF-3381
DMQ2O8V	MI	TTGP7BY
DMQ2O8V	MN	Monoamine oxidase type B (MAO-B)
DMQ2O8V	MT	DTT
DMQ2O8V	MA	Inhibitor
DMQ2O8V	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DMQ2O8V	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DMQ2O8V	DI	DMQ2O8V
DMQ2O8V	DN	CHF-3381
DMQ2O8V	MI	TT9IK2Z
DMQ2O8V	MN	N-methyl-D-aspartate receptor (NMDAR)
DMQ2O8V	MT	DTT
DMQ2O8V	MA	Antagonist
DMQ2O8V	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DMQ2O8V	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DMTE071	DI	DMTE071
DMTE071	DN	CHF-5074
DMTE071	MI	TT9W8GU
DMTE071	MN	Gamma-secretase (GS)
DMTE071	MT	DTT
DMTE071	MA	Modulator
DMTE071	RN	CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease.Br J Pharmacol.2009 Mar;156(6):982-93.
DMTE071	RU	https://www.ncbi.nlm.nih.gov/pubmed/19239474

DMALN2M	DI	DMALN2M
DMALN2M	DN	Cholyl lysyl fluorescein
DMALN2M	MI	DTQ3ZHF
DMALN2M	MN	Multidrug resistance-associated protein 3 (ABCC3)
DMALN2M	MT	DTP
DMALN2M	MA	Substrate
DMALN2M	RN	The emerging role of transport systems in liver function tests. Eur J Pharmacol. 2012 Jan 30;675(1-3):1-5.
DMALN2M	RU	https://doi.org/10.1016/j.ejphar.2011.11.048

DMALN2M	DI	DMALN2M
DMALN2M	DN	Cholyl lysyl fluorescein
DMALN2M	MI	DT3D8F0
DMALN2M	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMALN2M	MT	DTP
DMALN2M	MA	Substrate
DMALN2M	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DMALN2M	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DMULZ4W	DI	DMULZ4W
DMULZ4W	DN	CHR-2797
DMULZ4W	MI	TTWLEZV
DMULZ4W	MN	Aminopeptidase (AMP)
DMULZ4W	MT	DTT
DMULZ4W	MA	Inhibitor
DMULZ4W	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMULZ4W	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMULZ4W	DI	DMULZ4W
DMULZ4W	DN	CHR-2797
DMULZ4W	MI	TT371QC
DMULZ4W	MN	Puromycin-sensitive aminopeptidase (NPEPPS)
DMULZ4W	MT	DTT
DMULZ4W	MA	Inhibitor
DMULZ4W	RN	CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells. Cancer Res. 2008 Aug 15;68(16):6669-79.
DMULZ4W	RU	https://pubmed.ncbi.nlm.nih.gov/18701491

DMMRKPF	DI	DMMRKPF
DMMRKPF	DN	CHS-131
DMMRKPF	MI	TTZMAO3
DMMRKPF	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMMRKPF	MT	DTT
DMMRKPF	MA	Modulator
DMMRKPF	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMMRKPF	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMLRTN1	DI	DMLRTN1
DMLRTN1	DN	CI-1012
DMLRTN1	MI	TT3NH7G
DMLRTN1	MN	Human immunodeficiency virus Deoxyribonucleic acid (HIV DNA)
DMLRTN1	MT	DTT
DMLRTN1	MA	Inhibitor
DMLRTN1	RN	WO patent application no. 2006,0835,53, Diketo acids with nucleobase scaffolds: anti-hiv replication inhibitors targeted at hiv integrase.
DMLRTN1	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20060810&CC=WO&NR=2006083553A2&KC=A2

DMSI8N3	DI	DMSI8N3
DMSI8N3	DN	CI-1033
DMSI8N3	MI	TTGKNB4
DMSI8N3	MN	Epidermal growth factor receptor (EGFR)
DMSI8N3	MT	DTT
DMSI8N3	MA	Inhibitor
DMSI8N3	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMSI8N3	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMSI8N3	DI	DMSI8N3
DMSI8N3	DN	CI-1033
DMSI8N3	MI	TT6EO5L
DMSI8N3	MN	Erbb2 tyrosine kinase receptor (HER2)
DMSI8N3	MT	DTT
DMSI8N3	MA	Inhibitor
DMSI8N3	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMSI8N3	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMSI8N3	DI	DMSI8N3
DMSI8N3	DN	CI-1033
DMSI8N3	MI	TT0JESD
DMSI8N3	MN	Erbb4 tyrosine kinase receptor (Erbb-4)
DMSI8N3	MT	DTT
DMSI8N3	MA	Inhibitor
DMSI8N3	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMSI8N3	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMSI8N3	DI	DMSI8N3
DMSI8N3	DN	CI-1033
DMSI8N3	MI	TTWTSCV
DMSI8N3	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DMSI8N3	MT	DTT
DMSI8N3	MA	Inhibitor
DMSI8N3	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMSI8N3	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMCFLRH	DI	DMCFLRH
DMCFLRH	DN	Cibinetide
DMCFLRH	MI	TTAUX24
DMCFLRH	MN	Erythropoietin Receptor (EPOR)
DMCFLRH	MT	DTT
DMCFLRH	MA	Agonist
DMCFLRH	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMCFLRH	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMGTZLW	DI	DMGTZLW
DMGTZLW	DN	Cicletanine
DMGTZLW	MI	DEYGVN4
DMGTZLW	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMGTZLW	MT	DME
DMGTZLW	MA	Metabolism
DMGTZLW	RN	Induction and inhibition of cicletanine metabolism in cultured hepatocytes and liver microsomes from rats. Fundam Clin Pharmacol. 2000 Sep-Oct;14(5):509-18.
DMGTZLW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11129092

DMTKSVA	DI	DMTKSVA
DMTKSVA	DN	CIMICOXIB
DMTKSVA	MI	TTVKILB
DMTKSVA	MN	Prostaglandin G/H synthase 2 (COX-2)
DMTKSVA	MT	DTT
DMTKSVA	MA	Modulator
DMTKSVA	RN	Pharmacokinetic profiles of the novel COX-2 selective inhibitor cimicoxib in dogs.Vet J.2014 Apr;200(1):77-81.
DMTKSVA	RU	https://www.ncbi.nlm.nih.gov/pubmed/24461644

DMGEAM6	DI	DMGEAM6
DMGEAM6	DN	Cinaciguat
DMGEAM6	MI	TTLBYH1
DMGEAM6	MN	Guanylate cyclase soluble beta-1 (GUCY1B1)
DMGEAM6	MT	DTT
DMGEAM6	MA	Activator
DMGEAM6	RN	Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Circulation. 2009 Jun 2;119(21):2781-8.
DMGEAM6	RU	https://pubmed.ncbi.nlm.nih.gov/19451356

DM98RW0	DI	DM98RW0
DM98RW0	DN	Cirmtuzumab
DM98RW0	MI	TTDEJAU
DM98RW0	MN	Neurotrophic tyrosine kinase ROR1 (ROR1)
DM98RW0	MT	DTT
DM98RW0	MA	Antagonist
DM98RW0	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM98RW0	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMNRYPF	DI	DMNRYPF
DMNRYPF	DN	Cixutumumab
DMNRYPF	MI	TTHRID2
DMNRYPF	MN	Insulin-like growth factor I receptor (IGF1R)
DMNRYPF	MT	DTT
DMNRYPF	MA	Modulator
DMNRYPF	RN	Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model. Ann Oncol. 2015 Jul;26(7):1459-64.
DMNRYPF	RU	https://pubmed.ncbi.nlm.nih.gov/25858498

DMOFTRE	DI	DMOFTRE
DMOFTRE	DN	Cizolirtine
DMOFTRE	MI	TTVSFJW
DMOFTRE	MN	Calcitonin gene-related peptide 1 (CALCA)
DMOFTRE	MT	DTT
DMOFTRE	MA	Inhibitor
DMOFTRE	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DMOFTRE	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DMTSVJM	DI	DMTSVJM
DMTSVJM	DN	CJM112
DMTSVJM	MI	TTG0MT6
DMTSVJM	MN	Interleukin-17 (IL17)
DMTSVJM	MT	DTT
DMTSVJM	MA	Inhibitor
DMTSVJM	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMTSVJM	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM9FHV8	DI	DM9FHV8
DM9FHV8	DN	CK-2127107
DM9FHV8	MI	TTYUMF5
DM9FHV8	MN	Fast skeletal muscle troponin complex (TNNC2)
DM9FHV8	MT	DTT
DM9FHV8	MA	Modulator
DM9FHV8	RN	Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases. Nat Med. 2012 Feb 19;18(3):452-5.
DM9FHV8	RU	https://pubmed.ncbi.nlm.nih.gov/22344294

DMW9F1G	DI	DMW9F1G
DMW9F1G	DN	CKD602
DMW9F1G	MI	DTI7UX6
DMW9F1G	MN	Breast cancer resistance protein (ABCG2)
DMW9F1G	MT	DTP
DMW9F1G	MA	Substrate
DMW9F1G	RN	Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells. Pharm Res. 2008 Nov;25(11):2601-12.
DMW9F1G	RU	http://www.ncbi.nlm.nih.gov/pubmed/18654741

DMW9F1G	DI	DMW9F1G
DMW9F1G	DN	CKD602
DMW9F1G	MI	TTGTQHC
DMW9F1G	MN	DNA topoisomerase I (TOP1)
DMW9F1G	MT	DTT
DMW9F1G	MA	Inhibitor
DMW9F1G	RN	Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor. Arch Pharm Res. 1998 Oct;21(5):581-90.
DMW9F1G	RU	https://pubmed.ncbi.nlm.nih.gov/9875499

DMW9F1G	DI	DMW9F1G
DMW9F1G	DN	CKD602
DMW9F1G	MI	DTFI42L
DMW9F1G	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMW9F1G	MT	DTP
DMW9F1G	MA	Substrate
DMW9F1G	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMW9F1G	RU	https://doi.org/10.1007/s11095-012-0935-x

DMW9F1G	DI	DMW9F1G
DMW9F1G	DN	CKD602
DMW9F1G	MI	DTUGYRD
DMW9F1G	MN	P-glycoprotein 1 (ABCB1)
DMW9F1G	MT	DTP
DMW9F1G	MA	Substrate
DMW9F1G	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMW9F1G	RU	https://doi.org/10.1007/s11095-012-0935-x

DMXH1KC	DI	DMXH1KC
DMXH1KC	DN	CL-316,243
DMXH1KC	MI	TTMXGCW
DMXH1KC	MN	Adrenergic receptor beta-3 (ADRB3)
DMXH1KC	MT	DTT
DMXH1KC	MA	Agonist
DMXH1KC	RN	Beta 3-adrenoceptor agonists as anti-diabetic and anti-obesity drugs in humans. Curr Pharm Des. 2001 Sep;7(14):1433-49.
DMXH1KC	RU	https://pubmed.ncbi.nlm.nih.gov/11472270

DMXH1KC	DI	DMXH1KC
DMXH1KC	DN	CL-316,243
DMXH1KC	MI	TTI12YJ
DMXH1KC	MN	Mitochondrial uncoupling protein 1 (UCP1)
DMXH1KC	MT	DTT
DMXH1KC	MA	Inducer
DMXH1KC	RN	Anti-obesity and anti-diabetic effects of CL316,243, a highly specific beta 3-adrenoceptor agonist, in Otsuka Long-Evans Tokushima Fatty rats: induction of uncoupling protein and activation of glucose transporter 4 in white fat. Eur J Endocrinol. 1997 Apr;136(4):429-37.
DMXH1KC	RU	https://pubmed.ncbi.nlm.nih.gov/9150705

DMXH1KC	DI	DMXH1KC
DMXH1KC	DN	CL-316,243
DMXH1KC	MI	TTSC2YM
DMXH1KC	MN	Mitochondrial uncoupling protein 2 (UCP2)
DMXH1KC	MT	DTT
DMXH1KC	MA	Inducer
DMXH1KC	RN	Anti-obesity and anti-diabetic effects of CL316,243, a highly specific beta 3-adrenoceptor agonist, in Otsuka Long-Evans Tokushima Fatty rats: induction of uncoupling protein and activation of glucose transporter 4 in white fat. Eur J Endocrinol. 1997 Apr;136(4):429-37.
DMXH1KC	RU	https://pubmed.ncbi.nlm.nih.gov/9150705

DMXH1KC	DI	DMXH1KC
DMXH1KC	DN	CL-316,243
DMXH1KC	MI	TT12RJK
DMXH1KC	MN	Mitochondrial uncoupling protein 3 (UCP3)
DMXH1KC	MT	DTT
DMXH1KC	MA	Inducer
DMXH1KC	RN	Anti-obesity and anti-diabetic effects of CL316,243, a highly specific beta 3-adrenoceptor agonist, in Otsuka Long-Evans Tokushima Fatty rats: induction of uncoupling protein and activation of glucose transporter 4 in white fat. Eur J Endocrinol. 1997 Apr;136(4):429-37.
DMXH1KC	RU	https://pubmed.ncbi.nlm.nih.gov/9150705

DMSF7WJ	DI	DMSF7WJ
DMSF7WJ	DN	CL-329167
DMSF7WJ	MI	TT8DBY3
DMSF7WJ	MN	Angiotensin II receptor type-1 (AGTR1)
DMSF7WJ	MT	DTT
DMSF7WJ	MA	Antagonist
DMSF7WJ	RN	Distribution and function of cardiac angiotensin AT1- and AT2-receptor subtypes in hypertrophied rat hearts. Am J Physiol. 1994 Aug;267(2 Pt 2):H844-52.
DMSF7WJ	RU	https://pubmed.ncbi.nlm.nih.gov/8067441

DM6ZOUV	DI	DM6ZOUV
DM6ZOUV	DN	Clazakizumab
DM6ZOUV	MI	TTJH4Y5
DM6ZOUV	MN	HUMAN interleukin 6 (IL6)
DM6ZOUV	MT	DTT
DM6ZOUV	MA	Inhibitor
DM6ZOUV	RN	Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS) J Autoimmun. 2020 Apr 10:102452.
DM6ZOUV	RU	https://pubmed.ncbi.nlm.nih.gov/32291137

DMAIW6C	DI	DMAIW6C
DMAIW6C	DN	Clazakizumab
DMAIW6C	MI	TTT1V78
DMAIW6C	MN	Interleukin-6 (IL6)
DMAIW6C	MT	DTT
DMAIW6C	MA	Inhibitor
DMAIW6C	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMAIW6C	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMU6R3O	DI	DMU6R3O
DMU6R3O	DN	CLG561
DMU6R3O	MI	TTLA0VS
DMU6R3O	MN	Complement factor P (CFP)
DMU6R3O	MT	DTT
DMU6R3O	MA	Inhibitor
DMU6R3O	RN	Complement inhibition as a therapeutic strategy in retinal disorders. Expert Opin Biol Ther. 2019 Apr;19(4):335-342.
DMU6R3O	RU	https://pubmed.ncbi.nlm.nih.gov/30686077

DMH2VS0	DI	DMH2VS0
DMH2VS0	DN	CLP-1001
DMH2VS0	MI	TTWN7KV
DMH2VS0	MN	Na-K-Cl cotransporter (NKCC)
DMH2VS0	MT	DTT
DMH2VS0	MA	Modulator
DMH2VS0	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034446)
DMH2VS0	RU	http://adisinsight.springer.com/drugs/800034446

DMAW4EL	DI	DMAW4EL
DMAW4EL	DN	CLR-1404
DMAW4EL	MI	TTHBTOP
DMAW4EL	MN	PI3-kinase gamma (PIK3CG)
DMAW4EL	MT	DTT
DMAW4EL	MA	Inhibitor
DMAW4EL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2155).
DMAW4EL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2155

DM3Z6IQ	DI	DM3Z6IQ
DM3Z6IQ	DN	CLR-3001
DM3Z6IQ	MI	TTEX248
DM3Z6IQ	MN	Dopamine D2 receptor (D2R)
DM3Z6IQ	MT	DTT
DM3Z6IQ	MA	Modulator
DM3Z6IQ	RN	Clinical pipeline report, company report or official report of Clera Inc.
DM3Z6IQ	RU	http://clera.com/cognition/

DM3Z6IQ	DI	DM3Z6IQ
DM3Z6IQ	DN	CLR-3001
DM3Z6IQ	MI	TT3ROYC
DM3Z6IQ	MN	Serotonin transporter (SERT)
DM3Z6IQ	MT	DTT
DM3Z6IQ	MA	Inhibitor
DM3Z6IQ	RN	Clinical pipeline report, company report or official report of Clera Inc.
DM3Z6IQ	RU	http://clera.com/cognition/

DMQSIY1	DI	DMQSIY1
DMQSIY1	DN	CLS003
DMQSIY1	MI	TTL3N71
DMQSIY1	MN	Virus Replication (Viru Repli)
DMQSIY1	MT	DTT
DMQSIY1	MA	Inhibitor
DMQSIY1	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQSIY1	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM1NCUY	DI	DM1NCUY
DM1NCUY	DN	CMI-392
DM1NCUY	MI	TT2J34L
DM1NCUY	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM1NCUY	MT	DTT
DM1NCUY	MA	Modulator
DM1NCUY	RN	Anti-inflammatory activities of LDP-392, a dual PAF receptor antagonist and 5-lipoxygenase inhibitor. Pharmacol Res. 2001 Sep;44(3):213-20.
DM1NCUY	RU	https://pubmed.ncbi.nlm.nih.gov/11529688

DM1NCUY	DI	DM1NCUY
DM1NCUY	DN	CMI-392
DM1NCUY	MI	TTQL5VC
DM1NCUY	MN	Platelet-activating factor receptor (PTAFR)
DM1NCUY	MT	DTT
DM1NCUY	MA	Modulator
DM1NCUY	RN	Anti-inflammatory activities of LDP-392, a dual PAF receptor antagonist and 5-lipoxygenase inhibitor. Pharmacol Res. 2001 Sep;44(3):213-20.
DM1NCUY	RU	https://pubmed.ncbi.nlm.nih.gov/11529688

DM7GELO	DI	DM7GELO
DM7GELO	DN	CMVpp65-A0201
DM7GELO	MI	TTNDHVE
DM7GELO	MN	Cytomegalovirus 65kDa phosphoprotein (HCV UL83)
DM7GELO	MT	DTT
DM7GELO	RN	National Cancer Institute Drug Dictionary (drug id 599982).
DM7GELO	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=599982

DMPSCVY	DI	DMPSCVY
DMPSCVY	DN	CMX-2043
DMPSCVY	MI	TTNDSF4
DMPSCVY	MN	Proto-oncogene c-Met (MET)
DMPSCVY	MT	DTT
DMPSCVY	MA	Modulator
DMPSCVY	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPSCVY	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMPSCVY	DI	DMPSCVY
DMPSCVY	DN	CMX-2043
DMPSCVY	MI	TTWTSCV
DMPSCVY	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DMPSCVY	MT	DTT
DMPSCVY	MA	Modulator
DMPSCVY	RN	Pre-clinical and Clinical Safety Studies of CMX-2043: a cytoprotective lipoic acid analogue for ischaemia-reperfusion injury. Basic Clin Pharmacol Toxicol. 2014 Nov;115(5):456-64.
DMPSCVY	RU	https://pubmed.ncbi.nlm.nih.gov/24751172

DM0MTP8	DI	DM0MTP8
DM0MTP8	DN	CN-105
DM0MTP8	MI	TTKS9CB
DM0MTP8	MN	Apolipoprotein E (APOE)
DM0MTP8	MT	DTT
DM0MTP8	MA	Agonist
DM0MTP8	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM0MTP8	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DM16KJ3	DI	DM16KJ3
DM16KJ3	DN	CNS-5161
DM16KJ3	MI	TT9IK2Z
DM16KJ3	MN	N-methyl-D-aspartate receptor (NMDAR)
DM16KJ3	MT	DTT
DM16KJ3	MA	Antagonist
DM16KJ3	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DM16KJ3	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DM2PEU5	DI	DM2PEU5
DM2PEU5	DN	CNSB-001
DM2PEU5	MI	TTN4QDT
DM2PEU5	MN	Opioid receptor (OPR)
DM2PEU5	MT	DTT
DM2PEU5	MA	Agonist
DM2PEU5	RN	Molecular Mechanisms of Opioid Receptor-Dependent Signaling and Behavior. Anesthesiology. 2011 December; 115(6): 1363-1381.
DM2PEU5	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3698859/

DM2PEU5	DI	DM2PEU5
DM2PEU5	DN	CNSB-001
DM2PEU5	MI	TTQ29KF
DM2PEU5	MN	Voltage-gated potassium channel Kv7 (KCNQ)
DM2PEU5	MT	DTT
DM2PEU5	MA	Agonist
DM2PEU5	RN	The Kv7 potassium channel activator flupirtine affects clinical excitability parameters of myelinated axons in isolated rat sural nerve. J Peripher Nerv Syst. 2010 Mar;15(1):63-72.
DM2PEU5	RU	https://pubmed.ncbi.nlm.nih.gov/20433607

DMOR8SY	DI	DMOR8SY
DMOR8SY	DN	CNT0-1959
DMOR8SY	MI	TTC1GLB
DMOR8SY	MN	Interleukin-23 (IL23)
DMOR8SY	MT	DTT
DMOR8SY	RN	Interleukin-23 in the pathogenesis and treatment of psoriasis. Skin Therapy Lett. 2015 Mar-Apr;20(2):1-4.
DMOR8SY	RU	https://pubmed.ncbi.nlm.nih.gov/25807335

DM6RQXB	DI	DM6RQXB
DM6RQXB	DN	CNTO-6785
DM6RQXB	MI	TT69OHW
DM6RQXB	MN	Interleukin 17 receptor (IL17R)
DM6RQXB	MT	DTT
DM6RQXB	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM6RQXB	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DM6RQXB	DI	DM6RQXB
DM6RQXB	DN	CNTO-6785
DM6RQXB	MI	TTG0MT6
DM6RQXB	MN	Interleukin-17 (IL17)
DM6RQXB	MT	DTT
DM6RQXB	RN	Targeting the IL-17-T(H)17 pathway. Nat Rev Drug Discov. 2015 Jan;14(1):11-2. 
DM6RQXB	RU	https://pubmed.ncbi.nlm.nih.gov/25549584

DMLT7JV	DI	DMLT7JV
DMLT7JV	DN	CNV-2197944
DMLT7JV	MI	TT4FDG6
DMLT7JV	MN	Voltage-gated calcium channel alpha Cav2.2 (CACNA1B)
DMLT7JV	MT	DTT
DMLT7JV	MA	Blocker
DMLT7JV	RN	Clinical pipeline report, company report or official report of Convergence Pharmaceuticals Ltd.
DMLT7JV	RU	http://www.convergencepharma.com/index.asp?page_id=30

DMH5GQU	DI	DMH5GQU
DMH5GQU	DN	CO-101
DMH5GQU	MI	TTUTN1I
DMH5GQU	MN	Human Deoxyribonucleic acid (hDNA)
DMH5GQU	MT	DTT
DMH5GQU	MA	Inhibitor
DMH5GQU	RN	Cellular pharmacology of gemcitabine. Ann Oncol. 2006 May;17 Suppl 5:v7-12.
DMH5GQU	RU	https://pubmed.ncbi.nlm.nih.gov/16807468

DMH5GQU	DI	DMH5GQU
DMH5GQU	DN	CO-101
DMH5GQU	MI	TTBWDI0
DMH5GQU	MN	Ribonucleoside-diphosphate reductase M2 (RRM2)
DMH5GQU	MT	DTT
DMH5GQU	MA	Inhibitor
DMH5GQU	RN	Cellular pharmacology of gemcitabine. Ann Oncol. 2006 May;17 Suppl 5:v7-12.
DMH5GQU	RU	https://pubmed.ncbi.nlm.nih.gov/16807468

DMF4MX9	DI	DMF4MX9
DMF4MX9	DN	Cobomarsen
DMF4MX9	MI	TT1GNRQ
DMF4MX9	MN	microRNA hsa-miR-155 (MIR155)
DMF4MX9	MT	DTT
DMF4MX9	MA	Inhibitor
DMF4MX9	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMF4MX9	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMDWG36	DI	DMDWG36
DMDWG36	DN	Codrituzumab
DMDWG36	MI	TTJTSX4
DMDWG36	MN	Glypican-3 (GPC3)
DMDWG36	MT	DTT
DMDWG36	MA	Inhibitor
DMDWG36	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMDWG36	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMO0VGH	DI	DMO0VGH
DMO0VGH	DN	Coenzyme Q10 analog
DMO0VGH	MI	TT8XK6L
DMO0VGH	MN	Quinone reductase 1 (NQO1)
DMO0VGH	MT	DTT
DMO0VGH	MA	Modulator
DMO0VGH	RN	Therapeutic strategies for Leber's hereditary optic neuropathy: A current update. Intractable Rare Dis Res. 2013 November; 2(4): 130-135.
DMO0VGH	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4204556/

DMNC76I	DI	DMNC76I
DMNC76I	DN	COL-1077
DMNC76I	MI	TTRK8B9
DMNC76I	MN	Sodium channel unspecific (NaC)
DMNC76I	MT	DTT
DMNC76I	MA	Antagonist
DMNC76I	RN	Clinical pipeline report, company report or official report of Columbia Laboratories.
DMNC76I	RU	http://companies.einnews.com/news/columbia-laboratories-news

DMSGFOY	DI	DMSGFOY
DMSGFOY	DN	Coltuximab ravtansine
DMSGFOY	MI	TTW640A
DMSGFOY	MN	B-lymphocyte surface antigen B4 (CD19)
DMSGFOY	MT	DTT
DMSGFOY	MA	Inhibitor
DMSGFOY	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMSGFOY	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMI2GSK	DI	DMI2GSK
DMI2GSK	DN	Coluracetam
DMI2GSK	MI	TTAN6JD
DMI2GSK	MN	Glutamate receptor AMPA (GRIA)
DMI2GSK	MT	DTT
DMI2GSK	MA	Modulator
DMI2GSK	RN	MKC-231, a choline uptake enhancer: (2) Effect on synthesis and release of acetylcholine in AF64A-treated rats. J Neural Transm. 2008 Jul;115(7):1027-35.
DMI2GSK	RU	https://pubmed.ncbi.nlm.nih.gov/18446264

DMGCTX5	DI	DMGCTX5
DMGCTX5	DN	Combined PR1/WT1 vaccine
DMGCTX5	MI	TT5MLC4
DMGCTX5	MN	Leukocyte proteinase-3 (PRTN3)
DMGCTX5	MT	DTT
DMGCTX5	RN	Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008 Jan 1;111(1):236-42.
DMGCTX5	RU	https://pubmed.ncbi.nlm.nih.gov/17875804

DMGCTX5	DI	DMGCTX5
DMGCTX5	DN	Combined PR1/WT1 vaccine
DMGCTX5	MI	TTZ8UT4
DMGCTX5	MN	Wilms tumor protein (WT1)
DMGCTX5	MT	DTT
DMGCTX5	RN	Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008 Jan 1;111(1):236-42.
DMGCTX5	RU	https://pubmed.ncbi.nlm.nih.gov/17875804

DM2UOSN	DI	DM2UOSN
DM2UOSN	DN	Conatumumab
DM2UOSN	MI	TT6OEDT
DM2UOSN	MN	Cannabinoid receptor 1 (CB1)
DM2UOSN	MT	DTT
DM2UOSN	MA	Agonist
DM2UOSN	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DM2UOSN	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DM2UOSN	DI	DM2UOSN
DM2UOSN	DN	Conatumumab
DM2UOSN	MI	TTW20TU
DM2UOSN	MN	TRAIL receptor 2 (TRAIL-R2)
DM2UOSN	MT	DTT
DM2UOSN	MA	Agonist
DM2UOSN	RN	Clinical pipeline report, company report or official report of Amgen (2009).
DM2UOSN	RU	http://www.amgen.com/science/pipe.jsp

DM2UOSN	DI	DM2UOSN
DM2UOSN	DN	Conatumumab
DM2UOSN	MI	TT90XZ8
DM2UOSN	MN	Voltage-gated sodium channel alpha Nav1.8 (SCN10A)
DM2UOSN	MT	DTT
DM2UOSN	MA	Binder
DM2UOSN	RN	Pathobiology of visceral pain: molecular mechanisms and therapeutic implications. II. Genetic approaches to pain therapy. Am J Physiol Gastrointest Liver Physiol. 2000 Apr;278(4):G507-12.
DM2UOSN	RU	https://pubmed.ncbi.nlm.nih.gov/10762603

DMZ0F65	DI	DMZ0F65
DMZ0F65	DN	Contezolid
DMZ0F65	MI	TTLIZBJ
DMZ0F65	MN	Protein synthesis (hPRO synth)
DMZ0F65	MT	DTT
DMZ0F65	MA	Inhibitor
DMZ0F65	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZ0F65	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMMOHUA	DI	DMMOHUA
DMMOHUA	DN	Contezolid acefosamil
DMMOHUA	MI	TTLIZBJ
DMMOHUA	MN	Protein synthesis (hPRO synth)
DMMOHUA	MT	DTT
DMMOHUA	MA	Inhibitor
DMMOHUA	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMMOHUA	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMER82Z	DI	DMER82Z
DMER82Z	DN	COR-1
DMER82Z	MI	TTR6W5O
DMER82Z	MN	Adrenergic receptor beta-1 (ADRB1)
DMER82Z	MT	DTT
DMER82Z	MA	Antagonist
DMER82Z	RN	Administration of the cyclic peptide COR-1 in humans (phase I study): ex vivo measurements of anti-beta1-adrenergic receptor antibody neutralization and of immune parameters. Eur J Heart Fail. 2012 Nov;14(11):1230-9.
DMER82Z	RU	https://pubmed.ncbi.nlm.nih.gov/22968742

DMHBOUX	DI	DMHBOUX
DMHBOUX	DN	CORT125281
DMHBOUX	MI	TTOZRK6
DMHBOUX	MN	Glucocorticoid receptor messenger RNA (GCR mRNA)
DMHBOUX	MT	DTT
DMHBOUX	MA	Antagonist
DMHBOUX	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMHBOUX	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMVKW0N	DI	DMVKW0N
DMVKW0N	DN	Coumate
DMVKW0N	MI	TTSZLWK
DMVKW0N	MN	Aromatase (CYP19A1)
DMVKW0N	MT	DTT
DMVKW0N	MA	Inhibitor
DMVKW0N	RN	Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template. J Med Chem. 2010 Mar 11;53(5):2155-70.
DMVKW0N	RU	https://pubmed.ncbi.nlm.nih.gov/20148564

DMVKW0N	DI	DMVKW0N
DMVKW0N	DN	Coumate
DMVKW0N	MI	TTUNARX
DMVKW0N	MN	Carbonic anhydrase (CA)
DMVKW0N	MT	DTT
DMVKW0N	MA	Inhibitor
DMVKW0N	RN	Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6.
DMVKW0N	RU	https://pubmed.ncbi.nlm.nih.gov/18640037

DMVKW0N	DI	DMVKW0N
DMVKW0N	DN	Coumate
DMVKW0N	MI	TTHQPL7
DMVKW0N	MN	Carbonic anhydrase I (CA-I)
DMVKW0N	MT	DTT
DMVKW0N	MA	Inhibitor
DMVKW0N	RN	Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6.
DMVKW0N	RU	https://pubmed.ncbi.nlm.nih.gov/18640037

DMVKW0N	DI	DMVKW0N
DMVKW0N	DN	Coumate
DMVKW0N	MI	TTANPDJ
DMVKW0N	MN	Carbonic anhydrase II (CA-II)
DMVKW0N	MT	DTT
DMVKW0N	MA	Inhibitor
DMVKW0N	RN	Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6.
DMVKW0N	RU	https://pubmed.ncbi.nlm.nih.gov/18640037

DMVKW0N	DI	DMVKW0N
DMVKW0N	DN	Coumate
DMVKW0N	MI	TTZHA0O
DMVKW0N	MN	Carbonic anhydrase IV (CA-IV)
DMVKW0N	MT	DTT
DMVKW0N	MA	Inhibitor
DMVKW0N	RN	Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6.
DMVKW0N	RU	https://pubmed.ncbi.nlm.nih.gov/18640037

DMVKW0N	DI	DMVKW0N
DMVKW0N	DN	Coumate
DMVKW0N	MI	TT2LVK8
DMVKW0N	MN	Carbonic anhydrase IX (CA-IX)
DMVKW0N	MT	DTT
DMVKW0N	MA	Inhibitor
DMVKW0N	RN	Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6.
DMVKW0N	RU	https://pubmed.ncbi.nlm.nih.gov/18640037

DMVKW0N	DI	DMVKW0N
DMVKW0N	DN	Coumate
DMVKW0N	MI	TTCFSPE
DMVKW0N	MN	Carbonic anhydrase VI (CA-VI)
DMVKW0N	MT	DTT
DMVKW0N	MA	Inhibitor
DMVKW0N	RN	Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6.
DMVKW0N	RU	https://pubmed.ncbi.nlm.nih.gov/18640037

DMVKW0N	DI	DMVKW0N
DMVKW0N	DN	Coumate
DMVKW0N	MI	TTSYM0R
DMVKW0N	MN	Carbonic anhydrase XII (CA-XII)
DMVKW0N	MT	DTT
DMVKW0N	MA	Inhibitor
DMVKW0N	RN	Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6.
DMVKW0N	RU	https://pubmed.ncbi.nlm.nih.gov/18640037

DMVKW0N	DI	DMVKW0N
DMVKW0N	DN	Coumate
DMVKW0N	MI	TTEYTKG
DMVKW0N	MN	Carbonic anhydrase XIV (CA-XIV)
DMVKW0N	MT	DTT
DMVKW0N	MA	Inhibitor
DMVKW0N	RN	Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6.
DMVKW0N	RU	https://pubmed.ncbi.nlm.nih.gov/18640037

DMVKW0N	DI	DMVKW0N
DMVKW0N	DN	Coumate
DMVKW0N	MI	TTHM0R1
DMVKW0N	MN	Steryl-sulfatase (STS)
DMVKW0N	MT	DTT
DMVKW0N	MA	Inhibitor
DMVKW0N	RN	Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template. J Med Chem. 2010 Mar 11;53(5):2155-70.
DMVKW0N	RU	https://pubmed.ncbi.nlm.nih.gov/20148564

DM2K5VP	DI	DM2K5VP
DM2K5VP	DN	Coxsackievirus A21
DM2K5VP	MI	TT5Z9WY
DM2K5VP	MN	Complement decay-accelerating factor (CD55)
DM2K5VP	MT	DTT
DM2K5VP	MA	Inhibitor
DM2K5VP	RN	Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma. Br J Haematol. 2007 Apr;137(2):133-41.
DM2K5VP	RU	https://pubmed.ncbi.nlm.nih.gov/17391493

DM8X5Q1	DI	DM8X5Q1
DM8X5Q1	DN	CP101
DM8X5Q1	MI	TT9IK2Z
DM8X5Q1	MN	N-methyl-D-aspartate receptor (NMDAR)
DM8X5Q1	MT	DTT
DM8X5Q1	MA	Antagonist
DM8X5Q1	RN	The neuroprotective effect of the forebrain-selective NMDA antagonist CP101,606 upon focal ischemic brain damage caused by acute subdural hematoma in the rat. J Neurotrauma. 1997 Jun;14(6):409-17.
DM8X5Q1	RU	https://pubmed.ncbi.nlm.nih.gov/9219855

DMIU19E	DI	DMIU19E
DMIU19E	DN	CP-101,606
DMIU19E	MI	TTN9D8E
DMIU19E	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMIU19E	MT	DTT
DMIU19E	MA	Antagonist
DMIU19E	RN	NMDA receptors as targets for drug action in neuropathic pain. Eur J Pharmacol. 2001 Oct 19;429(1-3):71-8.
DMIU19E	RU	https://pubmed.ncbi.nlm.nih.gov/11698028

DMSWLM5	DI	DMSWLM5
DMSWLM5	DN	CP-122721
DMSWLM5	MI	DECB0K3
DMSWLM5	MN	Cytochrome P450 2D6 (CYP2D6)
DMSWLM5	MT	DME
DMSWLM5	MA	Metabolism
DMSWLM5	RN	In vitro metabolism of CP-122,721 ((2S,3S)-2-phenyl-3-[(5-trifluoromethoxy-2-methoxy)benzylamino]piperidine), a non-peptide antagonist of the substance P receptor. Drug Metab Pharmacokinet. 2007 Oct;22(5):336-49.
DMSWLM5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17965517

DMSWLM5	DI	DMSWLM5
DMSWLM5	DN	CP-122721
DMSWLM5	MI	DE4LYSA
DMSWLM5	MN	Cytochrome P450 3A4 (CYP3A4)
DMSWLM5	MT	DME
DMSWLM5	MA	Metabolism
DMSWLM5	RN	In vitro metabolism of CP-122,721 ((2S,3S)-2-phenyl-3-[(5-trifluoromethoxy-2-methoxy)benzylamino]piperidine), a non-peptide antagonist of the substance P receptor. Drug Metab Pharmacokinet. 2007 Oct;22(5):336-49.
DMSWLM5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17965517

DMSWLM5	DI	DMSWLM5
DMSWLM5	DN	CP-122721
DMSWLM5	MI	DTUGYRD
DMSWLM5	MN	P-glycoprotein 1 (ABCB1)
DMSWLM5	MT	DTP
DMSWLM5	MA	Substrate
DMSWLM5	RN	P-glycoprotein efflux at the blood-brain barrier mediates differences in brain disposition and pharmacodynamics between two structurally related neurokinin-1 receptor antagonists. J Pharmacol Exp Ther. 2001 Sep;298(3):1252-9.
DMSWLM5	RU	http://www.ncbi.nlm.nih.gov/pubmed/11504828

DMSWLM5	DI	DMSWLM5
DMSWLM5	DN	CP-122721
DMSWLM5	MI	TTZPO1L
DMSWLM5	MN	Substance-P receptor (TACR1)
DMSWLM5	MT	DTT
DMSWLM5	MA	Antagonist
DMSWLM5	RN	A review of drug options in age-related macular degeneration therapy and potential new agents. Expert Opin Pharmacother. 2006 Dec;7(17):2355-68.
DMSWLM5	RU	https://pubmed.ncbi.nlm.nih.gov/17109611

DMVO5DR	DI	DMVO5DR
DMVO5DR	DN	CP-331684
DMVO5DR	MI	TTMXGCW
DMVO5DR	MN	Adrenergic receptor beta-3 (ADRB3)
DMVO5DR	MT	DTT
DMVO5DR	MA	Agonist
DMVO5DR	RN	CN patent application no. 1717230, Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor.
DMVO5DR	RU	https://www.google.com/patents/CN1717230A?cl=en

DMEYMTX	DI	DMEYMTX
DMEYMTX	DN	CP-461
DMEYMTX	MI	TTJGW1Z
DMEYMTX	MN	Phosphodiesterase 2A (PDE2A)
DMEYMTX	MT	DTT
DMEYMTX	MA	Inhibitor
DMEYMTX	RN	Sulindac and its derivatives: a novel class of anticancer agents. Curr Opin Investig Drugs. 2001 May;2(5):677-83.
DMEYMTX	RU	https://pubmed.ncbi.nlm.nih.gov/11569947

DMZEJLB	DI	DMZEJLB
DMZEJLB	DN	CP-533536
DMZEJLB	MI	TT1ZAVI
DMZEJLB	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DMZEJLB	MT	DTT
DMZEJLB	MA	Agonist
DMZEJLB	RN	Pfizer. Product Development Pipeline. March 31 2009.
DMZEJLB	RU	http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf

DMX054A	DI	DMX054A
DMX054A	DN	CP-547632
DMX054A	MI	TTUTJGQ
DMX054A	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMX054A	MT	DTT
DMX054A	MA	Inhibitor
DMX054A	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMX054A	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMKJFDM	DI	DMKJFDM
DMKJFDM	DN	CP-601927
DMKJFDM	MI	TTL1ATN
DMKJFDM	MN	Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2)
DMKJFDM	MT	DTT
DMKJFDM	MA	Modulator
DMKJFDM	RN	Toxicity study in juvenile rats with the alpha4beta2 nicotinic acetylcholine receptor partial agonist CP-601,927. Birth Defects Res B Dev Reprod Toxicol. 2011 Aug;92(4):323-32.
DMKJFDM	RU	https://pubmed.ncbi.nlm.nih.gov/21594972

DMUJ0W7	DI	DMUJ0W7
DMUJ0W7	DN	CP-724714
DMUJ0W7	MI	DTI7UX6
DMUJ0W7	MN	Breast cancer resistance protein (ABCG2)
DMUJ0W7	MT	DTP
DMUJ0W7	MA	Substrate
DMUJ0W7	RN	Multi-drug-resistance-reverting agents: 2-aryloxazole and 2-arylthiazole derivatives as potent BCRP or MRP1 inhibitors. ChemMedChem. 2009 Feb;4(2):188-95.
DMUJ0W7	RU	https://doi.org/10.1002/cmdc.200800329

DMUJ0W7	DI	DMUJ0W7
DMUJ0W7	DN	CP-724714
DMUJ0W7	MI	TT6EO5L
DMUJ0W7	MN	Erbb2 tyrosine kinase receptor (HER2)
DMUJ0W7	MT	DTT
DMUJ0W7	MA	Inhibitor
DMUJ0W7	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMUJ0W7	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMT3ORQ	DI	DMT3ORQ
DMT3ORQ	DN	CP-80794
DMT3ORQ	MI	TTB2MXP
DMT3ORQ	MN	Angiotensinogenase renin (REN)
DMT3ORQ	MT	DTT
DMT3ORQ	MA	Inhibitor
DMT3ORQ	RN	Synergistic effect on reduction in blood pressure with coadministration of the renin inhibitor, CP-80,794, and the angiotensin converting enzyme inhibitor, captopril. J Cardiovasc Pharmacol. 1992 Jul;20(1):75-82.
DMT3ORQ	RU	https://pubmed.ncbi.nlm.nih.gov/1383634

DM6MUCX	DI	DM6MUCX
DM6MUCX	DN	CpG-10101
DM6MUCX	MI	TTSHG0T
DM6MUCX	MN	Toll-like receptor 9 (TLR9)
DM6MUCX	MT	DTT
DM6MUCX	MA	Agonist
DM6MUCX	RN	Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist. Antivir Ther. 2007;12(5):741-51.
DM6MUCX	RU	https://pubmed.ncbi.nlm.nih.gov/17713157

DMK9NQI	DI	DMK9NQI
DMK9NQI	DN	CPP-115
DMK9NQI	MI	TTT2LD9
DMK9NQI	MN	GABA transaminase (ABAT)
DMK9NQI	MT	DTT
DMK9NQI	MA	Inhibitor
DMK9NQI	RN	Clinical pipeline report, company report or official report of Catalyst Pharma.
DMK9NQI	RU	http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=633588

DMK7DFM	DI	DMK7DFM
DMK7DFM	DN	CPX-POM
DMK7DFM	MI	TTX09M4
DMK7DFM	MN	Ribonucleotide reductase (RIR)
DMK7DFM	MT	DTT
DMK7DFM	MA	Inhibitor
DMK7DFM	RN	Preclinical Pharmacokinetics of Fosciclopirox, a Novel Treatment of Urothelial Cancers, in Rats and Dogs. J Pharmacol Exp Ther. 2019 Aug;370(2):148-159.
DMK7DFM	RU	https://pubmed.ncbi.nlm.nih.gov/31113837

DMHJEZS	DI	DMHJEZS
DMHJEZS	DN	CR-3294
DMHJEZS	MI	TTF10I9
DMHJEZS	MN	Nitric-oxide synthase inducible (NOS2)
DMHJEZS	MT	DTT
DMHJEZS	MA	Inhibitor
DMHJEZS	RN	Efficacy of CR3294, a new benzamidine derivative, in the prevention of 5-fluorouracil-induced gastrointestinal mucositis and diarrhea in mice. Cancer Chemother Pharmacol. 2010 October; 66(5): 819-827.
DMHJEZS	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2926937/

DMNC1AF	DI	DMNC1AF
DMNC1AF	DN	CR-665
DMNC1AF	MI	TTQW87Y
DMNC1AF	MN	Opioid receptor kappa (OPRK1)
DMNC1AF	MT	DTT
DMNC1AF	MA	Agonist
DMNC1AF	RN	Analgesic efficacy of peripheral kappa-opioid receptor agonist CR665 compared to oxycodone in a multi-modal, multi-tissue experimental human pain model: selective effect on visceral pain. Anesthesiology. 2009 Sep;111(3):616-24.
DMNC1AF	RU	https://pubmed.ncbi.nlm.nih.gov/19672186

DMQ47U6	DI	DMQ47U6
DMQ47U6	DN	CR8020
DMQ47U6	MI	TTF4CAM
DMQ47U6	MN	Influenza Hemagglutinin (Influ HA)
DMQ47U6	MT	DTT
DMQ47U6	RN	Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin. J Virol. 2014 Dec;88(23):13580-92.
DMQ47U6	RU	https://pubmed.ncbi.nlm.nih.gov/25210195

DMO1ZGX	DI	DMO1ZGX
DMO1ZGX	DN	CRILVASTATIN
DMO1ZGX	MI	TTPADOQ
DMO1ZGX	MN	HMG-CoA reductase (HMGCR)
DMO1ZGX	MT	DTT
DMO1ZGX	MA	Inhibitor
DMO1ZGX	RN	Differences in hypolipidaemic effects of two statins on Hep G2 cells or human hepatocytes in primary culture. Br J Pharmacol. 1996 Aug;118(7):1862-8.
DMO1ZGX	RU	https://pubmed.ncbi.nlm.nih.gov/8842455

DMQUWXY	DI	DMQUWXY
DMQUWXY	DN	CRLX101
DMQUWXY	MI	TTGTQHC
DMQUWXY	MN	DNA topoisomerase I (TOP1)
DMQUWXY	MT	DTT
DMQUWXY	MA	Modulator
DMQUWXY	RN	Company report (Ceruleanrx)
DMQUWXY	RU	http://ceruleanrx.com/platform-pipeline/crlx101.php

DM85WID	DI	DM85WID
DM85WID	DN	Crobenetine
DM85WID	MI	TTRK8B9
DM85WID	MN	Sodium channel unspecific (NaC)
DM85WID	MT	DTT
DM85WID	MA	Antagonist
DM85WID	RN	Analgesic activity of a novel use-dependent sodium channel blocker, crobenetine, in mono-arthritic rats. Br J Pharmacol. 2001 Dec;134(8):1742-8.
DM85WID	RU	https://pubmed.ncbi.nlm.nih.gov/11739251

DM129T7	DI	DM129T7
DM129T7	DN	CROMOGLYCATE LISETIL HYDROCHLORIDE
DM129T7	MI	TTE87WJ
DM129T7	MN	Calcium-activated potassium channel KCa1.1 (KCNMA1)
DM129T7	MT	DTT
DM129T7	MA	Modulator
DM129T7	RN	The significance of chloride in the inhibitory action of disodium cromoglycate on immunologically-stimulated rat peritoneal mast cells. Biochim Biophys Acta. 2011 Sep;1810(9):867-74.
DM129T7	RU	https://pubmed.ncbi.nlm.nih.gov/21635937

DMXU5LZ	DI	DMXU5LZ
DMXU5LZ	DN	CRS-207
DMXU5LZ	MI	TT4RXME
DMXU5LZ	MN	Mesothelin (MSLN)
DMXU5LZ	MT	DTT
DMXU5LZ	RN	Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol. 2015 Apr 20;33(12):1325-33.
DMXU5LZ	RU	https://pubmed.ncbi.nlm.nih.gov/25584002

DM16IMT	DI	DM16IMT
DM16IMT	DN	CRYPTOPHYCIN 52
DM16IMT	MI	TTML2WA
DM16IMT	MN	Tubulin (TUB)
DM16IMT	MT	DTT
DM16IMT	MA	Inhibitor
DM16IMT	RN	Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer. Lung Cancer. 2003 Feb;39(2):197-9.
DM16IMT	RU	https://pubmed.ncbi.nlm.nih.gov/12581573

DMZCG91	DI	DMZCG91
DMZCG91	DN	CSL-112
DMZCG91	MI	TT7GN3U
DMZCG91	MN	Apolipoprotein A-I (APOA1)
DMZCG91	MT	DTT
DMZCG91	MA	Modulator
DMZCG91	RN	CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice. Atherosclerosis. 2014 Jan;232(1):110-8.
DMZCG91	RU	https://pubmed.ncbi.nlm.nih.gov/24401224

DMQXL1T	DI	DMQXL1T
DMQXL1T	DN	CT 327
DMQXL1T	MI	TTTDVOJ
DMQXL1T	MN	Tropomyosin-related kinase A (TrkA)
DMQXL1T	MT	DTT
DMQXL1T	MA	Inhibitor
DMQXL1T	RN	Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis. Acta Derm Venereol. 2015 May;95(5):542-8.
DMQXL1T	RU	https://pubmed.ncbi.nlm.nih.gov/25594427

DMBRKZ7	DI	DMBRKZ7
DMBRKZ7	DN	CT1812
DMBRKZ7	MI	TT9NXW4
DMBRKZ7	MN	Sigma intracellular receptor 2 (TMEM97)
DMBRKZ7	MT	DTT
DMBRKZ7	MA	Antagonist
DMBRKZ7	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMBRKZ7	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMSGYNP	DI	DMSGYNP
DMSGYNP	DN	CTK0H-9987
DMSGYNP	MI	DEEHWOG
DMSGYNP	MN	Azoreductase (azoR)
DMSGYNP	MT	DME
DMSGYNP	MA	Metabolism
DMSGYNP	RN	The role of the gut flora in the metabolism of prontosil and neoprontosil in the rat. Xenobiotica. 1971 Mar;1(2):143-56.
DMSGYNP	RU	https://pubmed.ncbi.nlm.nih.gov/5173017

DMSGYNP	DI	DMSGYNP
DMSGYNP	DN	CTK0H-9987
DMSGYNP	MI	DEPF49Q
DMSGYNP	MN	Azoreductase (azoR)
DMSGYNP	MT	DME
DMSGYNP	MA	Metabolism
DMSGYNP	RN	Developing a metagenomic view of xenobiotic metabolism. Pharmacol Res. 2013 Mar;69(1):21-31.
DMSGYNP	RU	https://pubmed.ncbi.nlm.nih.gov/22902524

DMSGYNP	DI	DMSGYNP
DMSGYNP	DN	CTK0H-9987
DMSGYNP	MI	DEMW0RC
DMSGYNP	MN	Azoreductase (azoR)
DMSGYNP	MT	DME
DMSGYNP	MA	Metabolism
DMSGYNP	RN	Developing a metagenomic view of xenobiotic metabolism. Pharmacol Res. 2013 Mar;69(1):21-31.
DMSGYNP	RU	https://pubmed.ncbi.nlm.nih.gov/22902524

DMSGYNP	DI	DMSGYNP
DMSGYNP	DN	CTK0H-9987
DMSGYNP	MI	DETP059
DMSGYNP	MN	Azoreductase (azoR)
DMSGYNP	MT	DME
DMSGYNP	MA	Metabolism
DMSGYNP	RN	Developing a metagenomic view of xenobiotic metabolism. Pharmacol Res. 2013 Mar;69(1):21-31.
DMSGYNP	RU	https://pubmed.ncbi.nlm.nih.gov/22902524

DMMPC6W	DI	DMMPC6W
DMMPC6W	DN	CTL019
DMMPC6W	MI	TTW640A
DMMPC6W	MN	B-lymphocyte surface antigen B4 (CD19)
DMMPC6W	MT	DTT
DMMPC6W	MA	CAR-T-Cell-Therapy
DMMPC6W	RN	ClinicalTrials.gov (NCT02445248) Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients. U.S. National Institutes of Health.
DMMPC6W	RU	https://clinicaltrials.gov/ct2/show/NCT02445248

DM3SYOK	DI	DM3SYOK
DM3SYOK	DN	CTP-543
DM3SYOK	MI	TT6DM01
DM3SYOK	MN	Janus kinase 1 (JAK-1)
DM3SYOK	MT	DTT
DM3SYOK	MA	Inhibitor
DM3SYOK	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3SYOK	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMBT46Y	DI	DMBT46Y
DMBT46Y	DN	CTP-543
DMBT46Y	MI	TT6DM01
DMBT46Y	MN	Janus kinase 1 (JAK-1)
DMBT46Y	MT	DTT
DMBT46Y	MA	Inhibitor
DMBT46Y	RN	Clinical pipeline report, company report or official report of Concert Pharmaceuticals.
DMBT46Y	RU	https://www.concertpharma.com/product-pipeline/ctp-543/

DM3SYOK	DI	DM3SYOK
DM3SYOK	DN	CTP-543
DM3SYOK	MI	TTRMX3V
DM3SYOK	MN	Janus kinase 2 (JAK-2)
DM3SYOK	MT	DTT
DM3SYOK	MA	Inhibitor
DM3SYOK	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3SYOK	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMBT46Y	DI	DMBT46Y
DMBT46Y	DN	CTP-543
DMBT46Y	MI	TTRMX3V
DMBT46Y	MN	Janus kinase 2 (JAK-2)
DMBT46Y	MT	DTT
DMBT46Y	MA	Inhibitor
DMBT46Y	RN	Clinical pipeline report, company report or official report of Concert Pharmaceuticals.
DMBT46Y	RU	https://www.concertpharma.com/product-pipeline/ctp-543/

DMYPXQ2	DI	DMYPXQ2
DMYPXQ2	DN	CVBT-141H
DMYPXQ2	MI	TTMY81X
DMYPXQ2	MN	Heparin-binding growth factor 1 (FGF1)
DMYPXQ2	MT	DTT
DMYPXQ2	MA	Modulator
DMYPXQ2	RN	Clinical pipeline report, company report or official report of CVBT.
DMYPXQ2	RU	http://cvbt.com/index.php?pr=Severe_CHD

DMCN9GX	DI	DMCN9GX
DMCN9GX	DN	CVX-045
DMCN9GX	MI	TTKI0H1
DMCN9GX	MN	Thrombospondin-1 (THBS1)
DMCN9GX	MT	DTT
DMCN9GX	MA	Agonist
DMCN9GX	RN	Antitumor efficacy of a thrombospondin 1 mimetic CovX-body. Transl Oncol. 2011 Aug;4(4):249-57.
DMCN9GX	RU	https://pubmed.ncbi.nlm.nih.gov/21804921

DMVZT2I	DI	DMVZT2I
DMVZT2I	DN	CX-072
DMVZT2I	MI	TT8ZLTI
DMVZT2I	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMVZT2I	MT	DTT
DMVZT2I	MA	Inhibitor
DMVZT2I	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMVZT2I	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMS2WB5	DI	DMS2WB5
DMS2WB5	DN	CX157
DMS2WB5	MI	TT3WG5C
DMS2WB5	MN	Monoamine oxidase type A (MAO-A)
DMS2WB5	MT	DTT
DMS2WB5	MA	Inhibitor
DMS2WB5	RN	Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157. Neuropsychopharmacology. 2010 Feb;35(3):623-31.
DMS2WB5	RU	https://pubmed.ncbi.nlm.nih.gov/19890267

DMJD7H4	DI	DMJD7H4
DMJD7H4	DN	CX-1739
DMJD7H4	MI	TTAN6JD
DMJD7H4	MN	Glutamate receptor AMPA (GRIA)
DMJD7H4	MT	DTT
DMJD7H4	MA	Agonist
DMJD7H4	RN	AMPAKINE enhancement of social interaction in the BTBR mouse model of autism. Neuropharmacology. 2013 Jan;64:268-82.
DMJD7H4	RU	https://pubmed.ncbi.nlm.nih.gov/22801296

DMA5D6T	DI	DMA5D6T
DMA5D6T	DN	CX1789
DMA5D6T	MI	TTAN6JD
DMA5D6T	MN	Glutamate receptor AMPA (GRIA)
DMA5D6T	MT	DTT
DMA5D6T	MA	Agonist
DMA5D6T	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMA5D6T	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMU62I8	DI	DMU62I8
DMU62I8	DN	CX2009
DMU62I8	MI	TT2AFT6
DMU62I8	MN	Activated leukocyte cell adhesionmolecule (ALCAM)
DMU62I8	MT	DTT
DMU62I8	RN	Clinical pipeline report, company report or official report of CytomX Therapeutics.
DMU62I8	RU	https://cytomx.com/pipeline/

DMWE7B9	DI	DMWE7B9
DMWE7B9	DN	CX-4945
DMWE7B9	MI	TTZ5NI7
DMWE7B9	MN	Casein kinase II (CSNK2)
DMWE7B9	MT	DTT
DMWE7B9	MA	Modulator
DMWE7B9	RN	CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway. Leukemia. 2013 Oct;27(10):2094-6.
DMWE7B9	RU	https://pubmed.ncbi.nlm.nih.gov/23900138

DMWE7B9	DI	DMWE7B9
DMWE7B9	DN	CX-4945
DMWE7B9	MI	TTER6YH
DMWE7B9	MN	Casein kinase II alpha (CSNK2A1)
DMWE7B9	MT	DTT
DMWE7B9	MA	Inhibitor
DMWE7B9	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMWE7B9	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMM65W1	DI	DMM65W1
DMM65W1	DN	CX-717
DMM65W1	MI	TTAN6JD
DMM65W1	MN	Glutamate receptor AMPA (GRIA)
DMM65W1	MT	DTT
DMM65W1	MA	Modulator
DMM65W1	RN	Acute sleep deprivation: the effects of the AMPAKINE compound CX717 on human cognitive performance, alertness and recovery sleep. J Psychopharmacol. 2012 Aug;26(8):1047-57.
DMM65W1	RU	https://pubmed.ncbi.nlm.nih.gov/21940760

DM3GEHC	DI	DM3GEHC
DM3GEHC	DN	CX-8998
DM3GEHC	MI	TTT6NKW
DM3GEHC	MN	Voltage-gated T-type calcium channel (T-CaC)
DM3GEHC	MT	DTT
DM3GEHC	MA	Modulator
DM3GEHC	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3GEHC	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMM7Z6K	DI	DMM7Z6K
DMM7Z6K	DN	CXA10
DMM7Z6K	MI	TT3Z6Y9
DMM7Z6K	MN	Cysteines of Keap1 (KEAP1 Cysteines)
DMM7Z6K	MT	DTT
DMM7Z6K	MA	Inactivator
DMM7Z6K	RN	The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases. Biophys Rev. 2017 Feb;9(1):41-56.
DMM7Z6K	RU	https://pubmed.ncbi.nlm.nih.gov/28510041

DMM7Z6K	DI	DMM7Z6K
DMM7Z6K	DN	CXA10
DMM7Z6K	MI	TTA6ZN2
DMM7Z6K	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMM7Z6K	MT	DTT
DMM7Z6K	MA	Activator
DMM7Z6K	RN	The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases. Biophys Rev. 2017 Feb;9(1):41-56.
DMM7Z6K	RU	https://pubmed.ncbi.nlm.nih.gov/28510041

DM3JFZ2	DI	DM3JFZ2
DM3JFZ2	DN	CXL
DM3JFZ2	MI	TTHI19T
DM3JFZ2	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DM3JFZ2	MT	DTT
DM3JFZ2	MA	Modulator
DM3JFZ2	RN	Beta-Lactam Antibiotics Renaissance. Antibiotics. 2014, 3(2), 193-215.
DM3JFZ2	RU	http://www.mdpi.com/2079-6382/3/2/193

DMXR8WN	DI	DMXR8WN
DMXR8WN	DN	CYCLOPLATAM
DMXR8WN	MI	TTYVX59
DMXR8WN	MN	Protein kinase C (PRKC)
DMXR8WN	MT	DTT
DMXR8WN	MA	Inhibitor
DMXR8WN	RN	Effect of anti-tumor agents cisplatin and cycloplatam on membrane protein kinase C activity in murine T-lymphocytes. Biokhimiia. 1996 Oct;61(10):1866-73.
DMXR8WN	RU	https://pubmed.ncbi.nlm.nih.gov/9011234

DM0DT45	DI	DM0DT45
DM0DT45	DN	CYSTEMUSTINE
DM0DT45	MI	TTUTN1I
DM0DT45	MN	Human Deoxyribonucleic acid (hDNA)
DM0DT45	MT	DTT
DM0DT45	MA	Binder
DM0DT45	RN	A new O6-alkylguanine-DNA alkyltransferase inhibitor associated with a nitrosourea (cystemustine) validates a strategy of melanoma-targeted therapy in murine B16 and human-resistant M4Beu melanoma xenograft models. J Pharmacol Exp Ther. 2008 Jul;326(1):171-7.
DM0DT45	RU	https://pubmed.ncbi.nlm.nih.gov/18411412

DMMWIHC	DI	DMMWIHC
DMMWIHC	DN	CYT 99007
DMMWIHC	MI	TTAWI51
DMMWIHC	MN	Interleukin 7 receptor alpha (IL7R)
DMMWIHC	MT	DTT
DMMWIHC	MA	Binder
DMMWIHC	RN	Perspectives on interleukin-7 therapy in HIV infection. Curr Opin HIV AIDS. 2007 May;2(3):228-33.
DMMWIHC	RU	https://pubmed.ncbi.nlm.nih.gov/19372891

DM4LJH8	DI	DM4LJH8
DM4LJH8	DN	CYT003
DM4LJH8	MI	TTSHG0T
DM4LJH8	MN	Toll-like receptor 9 (TLR9)
DM4LJH8	MT	DTT
DM4LJH8	MA	Agonist
DM4LJH8	RN	CYT003, a TLR9 agonist, in persistent allergic asthma - a randomized placebo-controlled Phase 2b study. Allergy. 2015 Sep;70(9):1160-8.
DM4LJH8	RU	https://pubmed.ncbi.nlm.nih.gov/26042362

DMIRSWE	DI	DMIRSWE
DMIRSWE	DN	CYT-006-AngQb
DMIRSWE	MI	TTGN1ZA
DMIRSWE	MN	Angiotensin II receptor (AGTR)
DMIRSWE	MT	DTT
DMIRSWE	RN	CYT-006-AngQb, a vaccine against angiotensin II for the potential treatment of hypertension. Curr Opin Investig Drugs. 2009 Mar;10(3):269-75.
DMIRSWE	RU	https://pubmed.ncbi.nlm.nih.gov/19333885

DMUDMHA	DI	DMUDMHA
DMUDMHA	DN	CZEN-002
DMUDMHA	MI	TTSXVID
DMUDMHA	MN	Nuclear factor NF-kappa-B (NFKB)
DMUDMHA	MT	DTT
DMUDMHA	MA	Modulator
DMUDMHA	RN	US patent application no. US20100278784 A1.
DMUDMHA	RU	https://www.google.com.ar/patents/US20100278784

DMP6MH9	DI	DMP6MH9
DMP6MH9	DN	DA-8031
DMP6MH9	MI	TT3ROYC
DMP6MH9	MN	Serotonin transporter (SERT)
DMP6MH9	MT	DTT
DMP6MH9	MA	Inhibitor
DMP6MH9	RN	Effect of DA-8031, a novel oral compound for premature ejaculation, on male rat sexual behavior. Int J Urol. 2014 Mar;21(3):325-9.
DMP6MH9	RU	https://pubmed.ncbi.nlm.nih.gov/23968141

DMACTBM	DI	DMACTBM
DMACTBM	DN	DAC-060
DMACTBM	MI	TTBH0VX
DMACTBM	MN	Histone deacetylase (HDAC)
DMACTBM	MT	DTT
DMACTBM	MA	Inhibitor
DMACTBM	RN	Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Correction in: volume 4 on page 1369.
DMACTBM	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3341130/

DM2U45Q	DI	DM2U45Q
DM2U45Q	DN	Danegaptide
DM2U45Q	MI	TTJO6E9
DM2U45Q	MN	Gap junction protein (GJP)
DM2U45Q	MT	DTT
DM2U45Q	MA	Modulator
DM2U45Q	RN	The gap junction modifier, GAP-134 [(2S,4R)-1-(2-aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic acid], improves conduction and reduces atrial fibrillation/flutter in the canine sterile pericarditis model. J Pharmacol Exp Ther. 2009 Jun;329(3):1127-33.
DM2U45Q	RU	https://pubmed.ncbi.nlm.nih.gov/19252062

DM20MDU	DI	DM20MDU
DM20MDU	DN	Danoprevir
DM20MDU	MI	DE4LYSA
DM20MDU	MN	Cytochrome P450 3A4 (CYP3A4)
DM20MDU	MT	DME
DM20MDU	MA	Metabolism
DM20MDU	RN	Comprehensive Medicinal Chemistry III. Page: 569.
DM20MDU	RU	https://books.google.fr/books?id=iZHUDQAAQBAJ&pg=RA1-PA569&lpg=RA1-PA569&dq=Danoprevir+metabolizing+enzyme+metabolize&source=bl&ots=PaQ6yPgIDJ&sig=ACfU3U1Rask-Lef8fItwvzwnqUH9ud6e2Q&hl=zh-CN&sa=X&ved=2ahUKEwi8oo2mxrfnAhUQyxoKHV0GBtAQ6AEwCHoECAsQAQ

DM20MDU	DI	DM20MDU
DM20MDU	DN	Danoprevir
DM20MDU	MI	TT5FNQT
DM20MDU	MN	Human immunodeficiency virus Protease (HIV PR)
DM20MDU	MT	DTT
DM20MDU	MA	Inhibitor
DM20MDU	RN	2011 Pipeline of InterMune.
DM20MDU	RU	http://www.intermune.com/pipeline

DM20MDU	DI	DM20MDU
DM20MDU	DN	Danoprevir
DM20MDU	MI	DT3D8F0
DM20MDU	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM20MDU	MT	DTP
DM20MDU	MA	Substrate
DM20MDU	RN	FDA Drug Development and Drug Interactions
DM20MDU	RU	https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2

DM20MDU	DI	DM20MDU
DM20MDU	DN	Danoprevir
DM20MDU	MI	DT9C1TS
DM20MDU	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM20MDU	MT	DTP
DM20MDU	MA	Substrate
DM20MDU	RN	FDA Drug Development and Drug Interactions
DM20MDU	RU	https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2

DM7IH48	DI	DM7IH48
DM7IH48	DN	Dapansutrile
DM7IH48	MI	TT4EN8X
DM7IH48	MN	Caterpiller protein 1.1 (NLRP3)
DM7IH48	MT	DTT
DM7IH48	MA	Inhibitor
DM7IH48	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7IH48	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMIYFWA	DI	DMIYFWA
DMIYFWA	DN	Dapirolizumab pegol
DMIYFWA	MI	TTIJP3Q
DMIYFWA	MN	TNF related activation protein (CD40LG)
DMIYFWA	MT	DTT
DMIYFWA	MA	Inhibitor
DMIYFWA	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMIYFWA	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMR5J6K	DI	DMR5J6K
DMR5J6K	DN	DAPITANT
DMR5J6K	MI	TTZPO1L
DMR5J6K	MN	Substance-P receptor (TACR1)
DMR5J6K	MT	DTT
DMR5J6K	MA	Antagonist
DMR5J6K	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004225)
DMR5J6K	RU	http://adisinsight.springer.com/drugs/800004225

DMCU74R	DI	DMCU74R
DMCU74R	DN	Daporinad
DMCU74R	MI	TTD1WIG
DMCU74R	MN	Nicotinamide phosphoribosyltransferase (NAMPT)
DMCU74R	MT	DTT
DMCU74R	MA	Inhibitor
DMCU74R	RN	Anticancer agent CHS-828 inhibits cellular synthesis of NAD. Biochem Biophys Res Commun. 2008 Mar 21;367(4):799-804.
DMCU74R	RU	https://pubmed.ncbi.nlm.nih.gov/18201551

DM0Y8JP	DI	DM0Y8JP
DM0Y8JP	DN	DAS-181
DM0Y8JP	MI	TT50QJ3
DM0Y8JP	MN	Influenza Neuraminidase (Influ NA)
DM0Y8JP	MT	DTT
DM0Y8JP	MA	Inhibitor
DM0Y8JP	RN	Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein. PLoS One. 2009 Nov 6;4(11):e7838.
DM0Y8JP	RU	https://pubmed.ncbi.nlm.nih.gov/19893749

DMM3BPL	DI	DMM3BPL
DMM3BPL	DN	DAS-431
DMM3BPL	MI	TTZFYLI
DMM3BPL	MN	Dopamine D1 receptor (D1R)
DMM3BPL	MT	DTT
DMM3BPL	MA	Agonist
DMM3BPL	RN	Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data. CNS Drug Rev. 2001 Fall;7(3):305-16.
DMM3BPL	RU	https://pubmed.ncbi.nlm.nih.gov/11607045

DM7JV4O	DI	DM7JV4O
DM7JV4O	DN	DB-041901
DM7JV4O	MI	DEOHI3U
DM7JV4O	MN	Beta-glucosidase (bglA)
DM7JV4O	MT	DME
DM7JV4O	MA	Metabolism
DM7JV4O	RN	Gut microbiota-mediated drug-antibiotic interactions. Drug Metab Dispos. 2015 Oct;43(10):1581-9.
DM7JV4O	RU	https://pubmed.ncbi.nlm.nih.gov/25926432

DMQRCX5	DI	DMQRCX5
DMQRCX5	DN	DCDS-4501A
DMQRCX5	MI	TTBN5I7
DMQRCX5	MN	B-cell-specific glycoprotein B29 (CD79B)
DMQRCX5	MT	DTT
DMQRCX5	RN	Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development. Mar Drugs. 2014 January; 12(1): 255-278.
DMQRCX5	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3917273/

DMCHWX1	DI	DMCHWX1
DMCHWX1	DN	DCR-PHXC
DMCHWX1	MI	TTW76JE
DMCHWX1	MN	LDHA messenger RNA (LDHA mRNA)
DMCHWX1	MT	DTT
DMCHWX1	MA	Inhibitor
DMCHWX1	RN	Hepatic Lactate Dehydrogenase A: An RNA Interference Target for the Treatment of All Known Types of Primary Hyperoxaluria. Kidney Int Rep. 2021 Feb 3;6(4):1088-1098.
DMCHWX1	RU	https://pubmed.ncbi.nlm.nih.gov/33912759

DM9REBL	DI	DM9REBL
DM9REBL	DN	DDP-225
DM9REBL	MI	TTNXLKE
DM9REBL	MN	5-HT 3 receptor (5HT3R)
DM9REBL	MT	DTT
DM9REBL	MA	Modulator
DM9REBL	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM9REBL	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM5XT3G	DI	DM5XT3G
DM5XT3G	DN	DE-098
DM5XT3G	MI	TTF0RCZ
DM5XT3G	MN	Apoptosis mediating surface antigen FAS (FAS)
DM5XT3G	MT	DTT
DM5XT3G	RN	ARG098, a novel anti-human Fas antibody, suppresses synovial hyperplasia and prevents cartilage destruction in a severe combined immunodeficient-HuRAg mouse model. BMC Musculoskeletal Disorders 2010,11:221.
DM5XT3G	RU	http://www.biomedcentral.com/1471-2474/11/221

DMCQL5I	DI	DMCQL5I
DMCQL5I	DN	DE-110
DMCQL5I	MI	TTYRL6O
DMCQL5I	MN	Glucocorticoid receptor (NR3C1)
DMCQL5I	MT	DTT
DMCQL5I	MA	Agonist
DMCQL5I	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031667)
DMCQL5I	RU	http://adisinsight.springer.com/drugs/800031667

DMZW50O	DI	DMZW50O
DMZW50O	DN	Debio 1347
DMZW50O	MI	TT0LF7H
DMZW50O	MN	Fibroblast growth factor receptor (FGFR)
DMZW50O	MT	DTT
DMZW50O	MA	Modulator
DMZW50O	RN	The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor. Mol Cancer Ther. 2014 Nov;13(11):2547-58.
DMZW50O	RU	https://pubmed.ncbi.nlm.nih.gov/25169980

DMZW50O	DI	DMZW50O
DMZW50O	DN	Debio 1347
DMZW50O	MI	TTRLW2X
DMZW50O	MN	Fibroblast growth factor receptor 1 (FGFR1)
DMZW50O	MT	DTT
DMZW50O	MA	Inhibitor
DMZW50O	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZW50O	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMZW50O	DI	DMZW50O
DMZW50O	DN	Debio 1347
DMZW50O	MI	TTGJVQM
DMZW50O	MN	Fibroblast growth factor receptor 2 (FGFR2)
DMZW50O	MT	DTT
DMZW50O	MA	Inhibitor
DMZW50O	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZW50O	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMZW50O	DI	DMZW50O
DMZW50O	DN	Debio 1347
DMZW50O	MI	TTST7KB
DMZW50O	MN	Fibroblast growth factor receptor 3 (FGFR3)
DMZW50O	MT	DTT
DMZW50O	MA	Inhibitor
DMZW50O	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZW50O	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM1H7UK	DI	DM1H7UK
DM1H7UK	DN	Dectrekumab
DM1H7UK	MI	TT0GVCH
DM1H7UK	MN	Interleukin-13 (IL13)
DM1H7UK	MT	DTT
DM1H7UK	MA	Inhibitor
DM1H7UK	RN	Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol. 2015 Feb;135(2):500-7.
DM1H7UK	RU	https://pubmed.ncbi.nlm.nih.gov/25226850

DMX4DQH	DI	DMX4DQH
DMX4DQH	DN	Delanzomib
DMX4DQH	MI	TTU7ZMG
DMX4DQH	MN	Proteasome (PS)
DMX4DQH	MT	DTT
DMX4DQH	MA	Modulator
DMX4DQH	RN	Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE. Int Immunopharmacol. 2012 Jan;12(1):257-70.
DMX4DQH	RU	https://pubmed.ncbi.nlm.nih.gov/22178195

DMS2WIN	DI	DMS2WIN
DMS2WIN	DN	Delphinidin
DMS2WIN	MI	TTUTJGQ
DMS2WIN	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMS2WIN	MT	DTT
DMS2WIN	MA	Modulator
DMS2WIN	RN	Delphinidin, a dietary anthocyanidin, inhibits vascular endothelial growth factor receptor-2 phosphorylation. Carcinogenesis. 2006 May;27(5):989-96.
DMS2WIN	RU	https://pubmed.ncbi.nlm.nih.gov/16308314

DM5CB8U	DI	DM5CB8U
DM5CB8U	DN	DELTIBANT
DM5CB8U	MI	TTGY8IW
DM5CB8U	MN	B2 bradykinin receptor (BDKRB2)
DM5CB8U	MT	DTT
DM5CB8U	MA	Modulator
DM5CB8U	RN	CP-0127, a novel potent bradykinin antagonist, increases survival in rat and rabbit models of endotoxin shock. Agents Actions Suppl. 1992;38 ( Pt 3):413-20.
DM5CB8U	RU	https://pubmed.ncbi.nlm.nih.gov/1462875

DML4PMG	DI	DML4PMG
DML4PMG	DN	Dendritic cell vaccine
DML4PMG	MI	TTUJFD0
DML4PMG	MN	Telomerase reverse transcriptase (TERT)
DML4PMG	MT	DTT
DML4PMG	RN	In vitro activation of cytotoxic T-lymphocytes by hTERT-pulsed dendritic cells. J Immunotoxicol. 2009 Dec;6(4):243-8.
DML4PMG	RU	https://pubmed.ncbi.nlm.nih.gov/19908943

DM7GPMB	DI	DM7GPMB
DM7GPMB	DN	Depatuxizumab
DM7GPMB	MI	TTGKNB4
DM7GPMB	MN	Epidermal growth factor receptor (EGFR)
DM7GPMB	MT	DTT
DM7GPMB	MA	Antagonist
DM7GPMB	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7GPMB	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMH96JW	DI	DMH96JW
DMH96JW	DN	Dersalazine
DMH96JW	MI	TTQL5VC
DMH96JW	MN	Platelet-activating factor receptor (PTAFR)
DMH96JW	MT	DTT
DMH96JW	MA	Inhibitor
DMH96JW	RN	The intestinal anti-inflammatory effect of dersalazine sodium is related to a down-regulation in IL-17 production in experimental models of rodent colitis. Br J Pharmacol. 2012 February; 165(3): 729-740.
DMH96JW	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3315044/

DM63P1W	DI	DM63P1W
DM63P1W	DN	Descartes-08
DM63P1W	MI	TTZ3P4W
DM63P1W	MN	B-cell maturation protein (TNFRSF17)
DM63P1W	MT	DTT
DM63P1W	MA	CAR-T-Cell-Therapy
DM63P1W	RN	ClinicalTrials.gov (NCT03448978) Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma
DM63P1W	RU	https://clinicaltrials.gov/ct2/show/NCT03448978

DM1UO4S	DI	DM1UO4S
DM1UO4S	DN	Descartes-11
DM1UO4S	MI	TTZ3P4W
DM1UO4S	MN	B-cell maturation protein (TNFRSF17)
DM1UO4S	MT	DTT
DM1UO4S	RN	Clinical pipeline report, company report or official report of Cartesian Therapeutics.
DM1UO4S	RU	https://www.cartesiantherapeutics.com/clinical-trials/

DMTY4KN	DI	DMTY4KN
DMTY4KN	DN	Dexefaroxan
DMTY4KN	MI	TTM2AOE
DMTY4KN	MN	Adenosine A2a receptor (ADORA2A)
DMTY4KN	MT	DTT
DMTY4KN	MA	Agonist
DMTY4KN	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMTY4KN	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMTY4KN	DI	DMTY4KN
DMTY4KN	DN	Dexefaroxan
DMTY4KN	MI	TTJSZTB
DMTY4KN	MN	Nicotinic acetylcholine receptor (nAChR)
DMTY4KN	MT	DTT
DMTY4KN	MA	Agonist
DMTY4KN	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMTY4KN	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DM52HUD	DI	DM52HUD
DM52HUD	DN	Dexloxiglumide
DM52HUD	MI	TTCG0AL
DM52HUD	MN	Cholecystokinin receptor type A (CCKAR)
DM52HUD	MT	DTT
DM52HUD	MA	Inhibitor
DM52HUD	RN	Full agonists of CCK8 containing a nonhydrolyzable sulfated tyrosine residue. J Med Chem. 1989 Feb;32(2):445-9.
DM52HUD	RU	https://pubmed.ncbi.nlm.nih.gov/2464062

DM52HUD	DI	DM52HUD
DM52HUD	DN	Dexloxiglumide
DM52HUD	MI	DEPKLMQ
DM52HUD	MN	Cytochrome P450 2B6 (CYP2B6)
DM52HUD	MT	DME
DM52HUD	MA	Metabolism
DM52HUD	RN	Effect of azole antifungals ketoconazole and fluconazole on the pharmacokinetics of dexloxiglumide. Br J Clin Pharmacol. 2005 Nov;60(5):498-507.
DM52HUD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16236040

DM52HUD	DI	DM52HUD
DM52HUD	DN	Dexloxiglumide
DM52HUD	MI	DE5IED8
DM52HUD	MN	Cytochrome P450 2C9 (CYP2C9)
DM52HUD	MT	DME
DM52HUD	MA	Metabolism
DM52HUD	RN	Pharmacokinetic profile of dexloxiglumide. Clin Pharmacokinet. 2006;45(12):1177-88.
DM52HUD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17112294

DM52HUD	DI	DM52HUD
DM52HUD	DN	Dexloxiglumide
DM52HUD	MI	DE4LYSA
DM52HUD	MN	Cytochrome P450 3A4 (CYP3A4)
DM52HUD	MT	DME
DM52HUD	MA	Metabolism
DM52HUD	RN	Pharmacokinetic profile of dexloxiglumide. Clin Pharmacokinet. 2006;45(12):1177-88.
DM52HUD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17112294

DM52HUD	DI	DM52HUD
DM52HUD	DN	Dexloxiglumide
DM52HUD	MI	DEIBDNY
DM52HUD	MN	Cytochrome P450 3A5 (CYP3A5)
DM52HUD	MT	DME
DM52HUD	MA	Metabolism
DM52HUD	RN	Pharmacokinetic profile of dexloxiglumide. Clin Pharmacokinet. 2006;45(12):1177-88.
DM52HUD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17112294

DM52HUD	DI	DM52HUD
DM52HUD	DN	Dexloxiglumide
DM52HUD	MI	TTVFO0U
DM52HUD	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DM52HUD	MT	DTT
DM52HUD	MA	Inhibitor
DM52HUD	RN	Synthesis and stereochemical structure-activity relationships of 1,3-dioxoperhydropyrido[1,2-c]pyrimidine derivatives: potent and selective cholecy... J Med Chem. 1997 Oct 10;40(21):3402-7.
DM52HUD	RU	https://pubmed.ncbi.nlm.nih.gov/9341915

DM9L15R	DI	DM9L15R
DM9L15R	DN	Dextofisopam
DM9L15R	MI	TTNJYV2
DM9L15R	MN	Gamma-aminobutyric acid receptor (GAR)
DM9L15R	MT	DTT
DM9L15R	MA	Agonist
DM9L15R	RN	Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
DM9L15R	RU	https://pubmed.ncbi.nlm.nih.gov/16634703

DM9L15R	DI	DM9L15R
DM9L15R	DN	Dextofisopam
DM9L15R	MI	TTPTXIN
DM9L15R	MN	Translocator protein (TSPO)
DM9L15R	MT	DTT
DM9L15R	MA	Agonist
DM9L15R	RN	Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
DM9L15R	RU	https://pubmed.ncbi.nlm.nih.gov/16634703

DMFI5J4	DI	DMFI5J4
DMFI5J4	DN	Dextromethorphan+quinidine
DMFI5J4	MI	TTSZLWK
DMFI5J4	MN	Aromatase (CYP19A1)
DMFI5J4	MT	DTT
DMFI5J4	MA	Inhibitor
DMFI5J4	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DMFI5J4	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DMFI5J4	DI	DMFI5J4
DMFI5J4	DN	Dextromethorphan+quinidine
DMFI5J4	MI	TT9IK2Z
DMFI5J4	MN	N-methyl-D-aspartate receptor (NMDAR)
DMFI5J4	MT	DTT
DMFI5J4	MA	Antagonist
DMFI5J4	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DMFI5J4	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DMS9Y1T	DI	DMS9Y1T
DMS9Y1T	DN	DG-17
DMS9Y1T	MI	TT5FNQT
DMS9Y1T	MN	Human immunodeficiency virus Protease (HIV PR)
DMS9Y1T	MT	DTT
DMS9Y1T	MA	Inhibitor
DMS9Y1T	RN	Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. AIDS. 1999 April 16; 13(6): 661-667.
DMS9Y1T	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2566777/

DMK6FYR	DI	DMK6FYR
DMK6FYR	DN	DiabeCell
DMK6FYR	MI	TTXQYT6
DMK6FYR	MN	T-cells (T-cells)
DMK6FYR	MT	DTT
DMK6FYR	MA	Modulator
DMK6FYR	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMK6FYR	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMTJOEL	DI	DMTJOEL
DMTJOEL	DN	DIADENOSINE TETRAPHOSPHATE
DMTJOEL	MI	TTSLI08
DMTJOEL	MN	Adenosine receptor (ADOR)
DMTJOEL	MT	DTT
DMTJOEL	MA	Modulator
DMTJOEL	RN	Negative chronotropic and inotropic effects exerted by diadenosine hexaphosphate (AP6A) via A1-adenosine receptors. Br J Pharmacol. 1996 Nov;119(5):835-44.
DMTJOEL	RU	https://pubmed.ncbi.nlm.nih.gov/8922729

DM7AFJ8	DI	DM7AFJ8
DM7AFJ8	DN	Diannexin
DM7AFJ8	MI	TT2Z83I
DM7AFJ8	MN	Annexin A5 (ANXA5)
DM7AFJ8	MT	DTT
DM7AFJ8	MA	Modulator
DM7AFJ8	RN	Expression and purification of recombinant human annexin V in Escherichia coli. Prep Biochem Biotechnol. 2000 Nov;30(4):305-12.
DM7AFJ8	RU	https://pubmed.ncbi.nlm.nih.gov/11065275

DM20ATW	DI	DM20ATW
DM20ATW	DN	Diflomotecan
DM20ATW	MI	DTI7UX6
DM20ATW	MN	Breast cancer resistance protein (ABCG2)
DM20ATW	MT	DTP
DM20ATW	MA	Substrate
DM20ATW	RN	Pharmacogenomic importance of ABCG2. Pharmacogenomics. 2008 Aug;9(8):1005-9.
DM20ATW	RU	https://doi.org/10.2217/14622416.9.8.1005

DM20ATW	DI	DM20ATW
DM20ATW	DN	Diflomotecan
DM20ATW	MI	TTGTQHC
DM20ATW	MN	DNA topoisomerase I (TOP1)
DM20ATW	MT	DTT
DM20ATW	MA	Inhibitor
DM20ATW	RN	Diflomotecan, a promising homocamptothecin for cancer therapy. Expert Opin Investig Drugs. 2009 Jan;18(1):69-75.
DM20ATW	RU	https://pubmed.ncbi.nlm.nih.gov/19053883

DMTLB92	DI	DMTLB92
DMTLB92	DN	DI-Leu16-IL2
DMTLB92	MI	TTUE541
DMTLB92	MN	Leukocyte surface antigen Leu-16 (CD20)
DMTLB92	MT	DTT
DMTLB92	MA	Modulator
DMTLB92	RN	National Cancer Institute Drug Dictionary (drug id 599668).
DMTLB92	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=599668

DMBYJ92	DI	DMBYJ92
DMBYJ92	DN	Dilmapimod
DMBYJ92	MI	TTQBR95
DMBYJ92	MN	Stress-activated protein kinase 2a (p38 alpha)
DMBYJ92	MT	DTT
DMBYJ92	MA	Inhibitor
DMBYJ92	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMBYJ92	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMCATH2	DI	DMCATH2
DMCATH2	DN	Dilpacimab
DMCATH2	MI	TTV23LH
DMCATH2	MN	Delta-like protein 4 (DLL4)
DMCATH2	MT	DTT
DMCATH2	RN	Apoptogenic activity of 2alpha,3alpha-dihydroxyurs-12-ene-28-oic acid from Prunella vulgaris var. lilacina is mediated via mitochondria-dependent activation of caspase cascade regulated by Bcl-2 in human acute leukemia Jurkat T cells. J Ethnopharmacol. 2011 Jun 1;135(3):626-35.
DMCATH2	RU	https://pubmed.ncbi.nlm.nih.gov/21473903

DMCATH2	DI	DMCATH2
DMCATH2	DN	Dilpacimab
DMCATH2	MI	TT9HKJA
DMCATH2	MN	Vascular endothelial growth factor (VEGF)
DMCATH2	MT	DTT
DMCATH2	RN	Apoptogenic activity of 2alpha,3alpha-dihydroxyurs-12-ene-28-oic acid from Prunella vulgaris var. lilacina is mediated via mitochondria-dependent activation of caspase cascade regulated by Bcl-2 in human acute leukemia Jurkat T cells. J Ethnopharmacol. 2011 Jun 1;135(3):626-35.
DMCATH2	RU	https://pubmed.ncbi.nlm.nih.gov/21473903

DM96NHM	DI	DM96NHM
DM96NHM	DN	Dimiracetam
DM96NHM	MI	TT9IK2Z
DM96NHM	MN	N-methyl-D-aspartate receptor (NMDAR)
DM96NHM	MT	DTT
DM96NHM	MA	Antagonist
DM96NHM	RN	Broad spectrum and prolonged efficacy of dimiracetam in models of neuropathic pain. Neuropharmacology. 2014 Jun;81:85-94.
DM96NHM	RU	https://pubmed.ncbi.nlm.nih.gov/24486381

DM2QBDS	DI	DM2QBDS
DM2QBDS	DN	Disitertide
DM2QBDS	MI	TTR9XHZ
DM2QBDS	MN	Transforming growth factor beta 1 (TGFB1)
DM2QBDS	MT	DTT
DM2QBDS	MA	Inhibitor
DM2QBDS	RN	Perspectives of TGF-beta inhibition in pancreatic and hepatocellular carcinomas. Oncotarget. 2014 January; 5(1): 78-94.
DM2QBDS	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960190/

DMYC2LE	DI	DMYC2LE
DMYC2LE	DN	Disufenton
DMYC2LE	MI	TTLQTHB
DMYC2LE	MN	Extracellular sulfatase Sulf-2 (SULF2)
DMYC2LE	MT	DTT
DMYC2LE	MA	Inhibitor
DMYC2LE	RN	The human sulfatase 2 inhibitor 2,4-disulfonylphenyl-tert-butylnitrone (OKN-007) has an antitumor effect in hepatocellular carcinoma mediated via suppression of TGFB1/SMAD2 and Hedgehog/GLI1 signaling. Genes Chromosomes Cancer. 2013 Mar;52(3):225-36.
DMYC2LE	RU	https://pubmed.ncbi.nlm.nih.gov/23109092

DMBMKV8	DI	DMBMKV8
DMBMKV8	DN	Disulfiram
DMBMKV8	MI	TTNHMO8
DMBMKV8	MN	COVID-19 papain-like proteinase (PL-PRO)
DMBMKV8	MT	DTT
DMBMKV8	MA	Inhibitor
DMBMKV8	RN	Structure of Mpro from COVID-19 virus and discovery of its inhibitors. Nature. 2020 Apr 9.
DMBMKV8	RU	https://pubmed.ncbi.nlm.nih.gov/32272481

DMBMKV8	DI	DMBMKV8
DMBMKV8	DN	Disulfiram
DMBMKV8	MI	TTYJOLE
DMBMKV8	MN	MERS-CoV papain-like proteinase (PL-PRO)
DMBMKV8	MT	DTT
DMBMKV8	MA	Inhibitor
DMBMKV8	RN	Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150.
DMBMKV8	RU	https://pubmed.ncbi.nlm.nih.gov/32127666

DMBMKV8	DI	DMBMKV8
DMBMKV8	DN	Disulfiram
DMBMKV8	MI	TTRGHB2
DMBMKV8	MN	SARS-CoV papain-like proteinase (PL-PRO)
DMBMKV8	MT	DTT
DMBMKV8	MA	Inhibitor
DMBMKV8	RN	Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150.
DMBMKV8	RU	https://pubmed.ncbi.nlm.nih.gov/32127666

DMOHT5V	DI	DMOHT5V
DMOHT5V	DN	DKN-01
DMOHT5V	MI	TTE3RAC
DMOHT5V	MN	Dickkopf-related protein 1 (DKK1)
DMOHT5V	MT	DTT
DMOHT5V	MA	Inhibitor
DMOHT5V	RN	The anti-DKK1 antibody DKN-01 as an immunomodulatory combination partner for the treatment of cancer. Expert Opin Investig Drugs. 2020 Jul;29(7):639-644.
DMOHT5V	RU	https://pubmed.ncbi.nlm.nih.gov/32408777

DMDJUWG	DI	DMDJUWG
DMDJUWG	DN	DLX-105
DMDJUWG	MI	TTF8CQI
DMDJUWG	MN	Tumor necrosis factor (TNF)
DMDJUWG	MT	DTT
DMDJUWG	RN	Cyclic AMP inhibition of tumor necrosis factor alpha production induced by amyloidogenic C-terminal peptide of Alzheimer's amyloid precursor protein in macrophages: involvement of multiple intracellular pathways and cyclic AMP response element binding protein. Mol Pharmacol. 2003 Mar;63(3):690-8.
DMDJUWG	RU	https://pubmed.ncbi.nlm.nih.gov/12606779

DM0157T	DI	DM0157T
DM0157T	DN	DM199
DM0157T	MI	TTGY8IW
DM0157T	MN	B2 bradykinin receptor (BDKRB2)
DM0157T	MT	DTT
DM0157T	MA	Activator
DM0157T	RN	Pharmacological effects of recombinant human tissue kallikrein on bradykinin B2 receptors. Pharmacol Res Perspect. 2015 Mar;3(2):e00119.
DM0157T	RU	https://pubmed.ncbi.nlm.nih.gov/26038695

DMMSIG7	DI	DMMSIG7
DMMSIG7	DN	DM-71
DMMSIG7	MI	TTCBFJO
DMMSIG7	MN	Insulin receptor (INSR)
DMMSIG7	MT	DTT
DMMSIG7	MA	Modulator
DMMSIG7	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800).
DMMSIG7	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800

DM1HG3U	DI	DM1HG3U
DM1HG3U	DN	DM-99
DM1HG3U	MI	TTCBFJO
DM1HG3U	MN	Insulin receptor (INSR)
DM1HG3U	MT	DTT
DM1HG3U	MA	Agonist
DM1HG3U	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800).
DM1HG3U	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800

DMBC7HZ	DI	DMBC7HZ
DMBC7HZ	DN	DM-CHOC-PEN
DMBC7HZ	MI	TTUTN1I
DMBC7HZ	MN	Human Deoxyribonucleic acid (hDNA)
DMBC7HZ	MT	DTT
DMBC7HZ	MA	Modulator
DMBC7HZ	RN	Carbonate and carbamate derivatives of 4-demethylpenclomedine as novel anticancer agents. Cancer Chemother Pharmacol. 2009 September; 64(4): 829-835.
DMBC7HZ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2717391/

DM725UG	DI	DM725UG
DM725UG	DN	DN24-02
DM725UG	MI	TT6EO5L
DM725UG	MN	Erbb2 tyrosine kinase receptor (HER2)
DM725UG	MT	DTT
DM725UG	MA	Modulator
DM725UG	RN	Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer. J Clin Oncol. 2007 Aug 20;25(24):3680-7.
DM725UG	RU	https://pubmed.ncbi.nlm.nih.gov/17704416

DMDTVYC	DI	DMDTVYC
DMDTVYC	DN	DNCB
DMDTVYC	MI	DER3H9C
DMDTVYC	MN	Lipocalin-type prostaglandin-D synthase (PTGDS)
DMDTVYC	MT	DME
DMDTVYC	MA	Metabolism
DMDTVYC	RN	Glutathione transferases immobilized on nanoporous alumina: flow system kinetics, screening, and stability. Anal Biochem. 2014 Feb 1;446:59-63.
DMDTVYC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24157647

DMDTVYC	DI	DMDTVYC
DMDTVYC	DN	DNCB
DMDTVYC	MI	DE3OALH
DMDTVYC	MN	Prostaglandin E synthase 2 (PTGES2)
DMDTVYC	MT	DME
DMDTVYC	MA	Metabolism
DMDTVYC	RN	Human microsomal prostaglandin E synthase-1: purification, functional characterization, and projection structure determination. J Biol Chem. 2003 Jun 20;278(25):22199-209.
DMDTVYC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12672824

DM89D6C	DI	DM89D6C
DM89D6C	DN	DNL758
DM89D6C	MI	TTAIQSN
DM89D6C	MN	Receptor-interacting protein 1 (RIPK1)
DM89D6C	MT	DTT
DM89D6C	MA	Inhibitor
DM89D6C	RN	Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target. Nat Rev Drug Discov. 2020 Aug;19(8):553-571.
DM89D6C	RU	https://pubmed.ncbi.nlm.nih.gov/32669658

DM0QDC9	DI	DM0QDC9
DM0QDC9	DN	Dolastatin 10
DM0QDC9	MI	DTUGYRD
DM0QDC9	MN	P-glycoprotein 1 (ABCB1)
DM0QDC9	MT	DTP
DM0QDC9	MA	Substrate
DM0QDC9	RN	Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem. 1996 Feb 9;271(6):3163-71.
DM0QDC9	RU	http://www.ncbi.nlm.nih.gov/pubmed/8621716

DMDUV1S	DI	DMDUV1S
DMDUV1S	DN	DOLASTATIN-10
DMDUV1S	MI	TTML2WA
DMDUV1S	MN	Tubulin (TUB)
DMDUV1S	MT	DTT
DMDUV1S	MA	Inhibitor
DMDUV1S	RN	Synthesis and biological activity of chimeric structures derived from the cytotoxic natural compounds dolastatin 10 and dolastatin 15. J Med Chem. 1998 Apr 23;41(9):1524-30.
DMDUV1S	RU	https://pubmed.ncbi.nlm.nih.gov/9554885

DMDUV1S	DI	DMDUV1S
DMDUV1S	DN	DOLASTATIN-10
DMDUV1S	MI	TTYFKSZ
DMDUV1S	MN	Tubulin beta (TUBB)
DMDUV1S	MT	DTT
DMDUV1S	MA	Inhibitor
DMDUV1S	RN	Total synthesis and biological evaluation of ustiloxin natural products and two analogs. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4804-7.
DMDUV1S	RU	https://pubmed.ncbi.nlm.nih.gov/16837194

DMDUV1S	DI	DMDUV1S
DMDUV1S	DN	DOLASTATIN-10
DMDUV1S	MI	TTJ2PTI
DMDUV1S	MN	Tubulin beta-2 chain (TUBB2)
DMDUV1S	MT	DTT
DMDUV1S	MA	Inhibitor
DMDUV1S	RN	Total synthesis and biological evaluation of ustiloxin natural products and two analogs. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4804-7.
DMDUV1S	RU	https://pubmed.ncbi.nlm.nih.gov/16837194

DMCT08V	DI	DMCT08V
DMCT08V	DN	Domagrozumab
DMCT08V	MI	TTSWPH8
DMCT08V	MN	Growth/differentiation factor 8 (GDF-8)
DMCT08V	MT	DTT
DMCT08V	MA	Inhibitor
DMCT08V	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMCT08V	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM8VWPH	DI	DM8VWPH
DM8VWPH	DN	Doxorubicin-eluting beads
DM8VWPH	MI	TT0IHXV
DM8VWPH	MN	DNA topoisomerase II (TOP2)
DM8VWPH	MT	DTT
DM8VWPH	MA	Modulator
DM8VWPH	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM8VWPH	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM059CZ	DI	DM059CZ
DM059CZ	DN	DPK-060
DM059CZ	MI	TTXT4D5
DM059CZ	MN	Bacterial Cell membrane (Bact CM)
DM059CZ	MT	DTT
DM059CZ	MA	Enhancer
DM059CZ	RN	The re-emergence of natural products for drug discovery in the genomics era. Nat Rev Drug Discov. 2015 Feb;14(2):111-29. 
DM059CZ	RU	https://pubmed.ncbi.nlm.nih.gov/25614221

DMMC3XR	DI	DMMC3XR
DMMC3XR	DN	DPV-001
DMMC3XR	MI	TTOK0LR
DMMC3XR	MN	Toll-like receptor (TLR)
DMMC3XR	MT	DTT
DMMC3XR	MA	Modulator
DMMC3XR	RN	UbiVac's DRibble, autophagosome-enriched vaccines: Applications for cancer and infectious disease. UbiVac. 2013.
DMMC3XR	RU	http://ubivac.com/zap/?page_id=2668

DMGD3XT	DI	DMGD3XT
DMGD3XT	DN	DRL-17822
DMGD3XT	MI	TTFQAYR
DMGD3XT	MN	Cholesteryl ester transfer protein (CETP)
DMGD3XT	MT	DTT
DMGD3XT	MA	Inhibitor
DMGD3XT	RN	The dyslipidaemia market. Nat Rev Drug Discov. 2014 Nov;13(11):807-8.
DMGD3XT	RU	https://pubmed.ncbi.nlm.nih.gov/25323928

DM8WU3O	DI	DM8WU3O
DM8WU3O	DN	Drug 2862277
DM8WU3O	MI	TTG043C
DM8WU3O	MN	Tumor necrosis factor receptor type I (TNF-R1)
DM8WU3O	MT	DTT
DM8WU3O	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1870).
DM8WU3O	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1870

DMI69E5	DI	DMI69E5
DMI69E5	DN	DS-3201b
DMI69E5	MI	TTNJA0C
DMI69E5	MN	Enhancer of zeste homolog 1 (EZH1)
DMI69E5	MT	DTT
DMI69E5	MA	Inhibitor
DMI69E5	RN	Development of new agents for peripheral T-cell lymphoma. Expert Opin Biol Ther. 2019 Mar;19(3):197-209.
DMI69E5	RU	https://pubmed.ncbi.nlm.nih.gov/30658046

DMI69E5	DI	DMI69E5
DMI69E5	DN	DS-3201b
DMI69E5	MI	TT9MZCQ
DMI69E5	MN	Enhancer of zeste homolog 2 (EZH2)
DMI69E5	MT	DTT
DMI69E5	MA	Inhibitor
DMI69E5	RN	Development of new agents for peripheral T-cell lymphoma. Expert Opin Biol Ther. 2019 Mar;19(3):197-209.
DMI69E5	RU	https://pubmed.ncbi.nlm.nih.gov/30658046

DMUXIRM	DI	DMUXIRM
DMUXIRM	DN	DS-8500
DMUXIRM	MI	TT7QNVC
DMUXIRM	MN	Glucose-dependent insulinotropic receptor (GPR119)
DMUXIRM	MT	DTT
DMUXIRM	MA	Modulator
DMUXIRM	RN	Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development. Curr Diabetes Rev. 2015 March; 11(1): 17-31.
DMUXIRM	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4428473/

DM6UGHA	DI	DM6UGHA
DM6UGHA	DN	DSP-6952
DM6UGHA	MI	TT07C3Y
DM6UGHA	MN	5-HT 4 receptor (HTR4)
DM6UGHA	MT	DTT
DM6UGHA	MA	Agonist
DM6UGHA	RN	DSP-6952, a high affinity serotonin (5-HT4) receptor partial agonist. Sumitomo Dainippon Pharma Co. Ltd.
DM6UGHA	RU	http://www.biocentury.com/products/dsp-6952

DMU2GP4	DI	DMU2GP4
DMU2GP4	DN	DT-1687
DMU2GP4	MI	TTICZ1O
DMU2GP4	MN	Metabotropic glutamate receptor 4 (mGluR4)
DMU2GP4	MT	DTT
DMU2GP4	MA	Modulator
DMU2GP4	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 292).
DMU2GP4	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=292

DMV84OK	DI	DMV84OK
DMV84OK	DN	DTI-0009
DMV84OK	MI	TTK25J1
DMV84OK	MN	Adenosine A1 receptor (ADORA1)
DMV84OK	MT	DTT
DMV84OK	MA	Agonist
DMV84OK	RN	Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta. 2011 May;1808(5):1290-308.
DMV84OK	RU	https://pubmed.ncbi.nlm.nih.gov/21185259

DMX27IT	DI	DMX27IT
DMX27IT	DN	DTRM-555
DMX27IT	MI	TTGM6VW
DMX27IT	MN	Tyrosine-protein kinase BTK (ATK)
DMX27IT	MT	DTT
DMX27IT	MA	Inhibitor
DMX27IT	RN	ClinicalTrials.gov (NCT04305444) Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas. U.S. National Institutes of Health.
DMX27IT	RU	https://clinicaltrials.gov/ct2/show/NCT04305444

DM1ZJYS	DI	DM1ZJYS
DM1ZJYS	DN	Dusigitumab
DM1ZJYS	MI	TTE8WGO
DM1ZJYS	MN	Insulin-like growth factor-II (IGF2)
DM1ZJYS	MT	DTT
DM1ZJYS	MA	Inhibitor
DM1ZJYS	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM1ZJYS	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM7USVA	DI	DM7USVA
DM7USVA	DN	Duvelisib
DM7USVA	MI	TTK5FVJ
DM7USVA	MN	HUMAN PI3-kinase delta (PIK3CD)
DM7USVA	MT	DTT
DM7USVA	MA	Inhibitor
DM7USVA	RN	ClinicalTrials.gov (NCT04372602) Duvelisib to Combat COVID-19. U.S. National Institutes of Health.
DM7USVA	RU	https://clinicaltrials.gov/ct2/show/NCT04372602

DM7USVA	DI	DM7USVA
DM7USVA	DN	Duvelisib
DM7USVA	MI	TTHXGLJ
DM7USVA	MN	HUMAN PI3-kinase gamma (PIK3CG)
DM7USVA	MT	DTT
DM7USVA	MA	Inhibitor
DM7USVA	RN	ClinicalTrials.gov (NCT04372602) Duvelisib to Combat COVID-19. U.S. National Institutes of Health.
DM7USVA	RU	https://clinicaltrials.gov/ct2/show/NCT04372602

DMUGBQK	DI	DMUGBQK
DMUGBQK	DN	DVC1-0101
DMUGBQK	MI	TTGKIED
DMUGBQK	MN	Fibroblast growth factor-2 (FGF2)
DMUGBQK	MT	DTT
DMUGBQK	MA	Modulator
DMUGBQK	RN	DVC1-0101 to treat peripheral arterial disease: a Phase I/IIa open-label dose-escalation clinical trial. Mol Ther. 2013 Mar;21(3):707-14.
DMUGBQK	RU	https://pubmed.ncbi.nlm.nih.gov/23319060

DMQKU2F	DI	DMQKU2F
DMQKU2F	DN	DWP-05195
DMQKU2F	MI	TTMI6F5
DMQKU2F	MN	Transient receptor potential cation channel V1 (TRPV1)
DMQKU2F	MT	DTT
DMQKU2F	MA	Antagonist
DMQKU2F	RN	TRPV1 Antagonists as Analgesic Agents. The Open Pain Journal, 2013, 6, (Suppl 1: M11), 108-118 .
DMQKU2F	RU	http://benthamopen.com/contents/pdf/TOPAINJ/TOPAINJ-6-108.pdf

DMBFZET	DI	DMBFZET
DMBFZET	DN	DX-890
DMBFZET	MI	TTPLTSQ
DMBFZET	MN	Neutrophil elastase (NE)
DMBFZET	MT	DTT
DMBFZET	MA	Inhibitor
DMBFZET	RN	Emerging therapies for treatment of acute lung injury and acute respiratory distress syndrome. Expert Opin Emerg Drugs. 2007 Sep;12(3):461-77.
DMBFZET	RU	https://pubmed.ncbi.nlm.nih.gov/17874973

DMDYWM8	DI	DMDYWM8
DMDYWM8	DN	E-10030
DMDYWM8	MI	TTQA6SX
DMDYWM8	MN	Platelet-derived growth factor B (PDGFB)
DMDYWM8	MT	DTT
DMDYWM8	MA	Antagonist
DMDYWM8	RN	Aptamers as therapeutics. Nat Rev Drug Discov. 2010 Jul;9(7):537-50.
DMDYWM8	RU	https://pubmed.ncbi.nlm.nih.gov/20592747

DMLS269	DI	DMLS269
DMLS269	DN	E-1224
DMLS269	MI	TTTSOUD
DMLS269	MN	Candida Cytochrome P450 51 (Candi ERG11)
DMLS269	MT	DTT
DMLS269	MA	Inhibitor
DMLS269	RN	Recent Developments in Sterol 14-demethylase Inhibitors for Chagas Disease. Int J Parasitol Drugs Drug Resist. 2012 Dec;2:236-242.
DMLS269	RU	https://pubmed.ncbi.nlm.nih.gov/23277882

DMK8SY6	DI	DMK8SY6
DMK8SY6	DN	E2027
DMK8SY6	MI	TTZOEBC
DMK8SY6	MN	Phosphodiesterase 9 (PDE9)
DMK8SY6	MT	DTT
DMK8SY6	MA	Antagonist
DMK8SY6	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMK8SY6	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMC5PB2	DI	DMC5PB2
DMC5PB2	DN	E-4716
DMC5PB2	MI	TTTIBOJ
DMC5PB2	MN	Histamine H1 receptor (H1R)
DMC5PB2	MT	DTT
DMC5PB2	MA	Modulator
DMC5PB2	RN	Population pharmacokinetics of epinastine, a histamine H1 receptor antagonist, in adults and children. Br J Clin Pharmacol. 2005 Jan;59(1):43-53.
DMC5PB2	RU	https://pubmed.ncbi.nlm.nih.gov/15606439

DMQERC6	DI	DMQERC6
DMQERC6	DN	E5555
DMQERC6	MI	TTL935N
DMQERC6	MN	Proteinase activated receptor 1 (F2R)
DMQERC6	MT	DTT
DMQERC6	MA	Antagonist
DMQERC6	RN	Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin-Acute Coronary Syndromes Trial. Circulation. 2011 May 3;123(17):1843-53.
DMQERC6	RU	https://pubmed.ncbi.nlm.nih.gov/21502577

DM1S489	DI	DM1S489
DM1S489	DN	E6005
DM1S489	MI	DEB30C5
DM1S489	MN	Carboxylesterase 1 (CES1)
DM1S489	MT	DME
DM1S489	MA	Metabolism
DM1S489	RN	Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: results of a randomized, vehicle-controlled, multicenter clinical trial. J Dermatol. 2014 Jul;41(7):577-85.
DM1S489	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24942594

DM1S489	DI	DM1S489
DM1S489	DN	E6005
DM1S489	MI	TTV5CGO
DM1S489	MN	Phosphodiesterase 4 (PDE4)
DM1S489	MT	DTT
DM1S489	MA	Inhibitor
DM1S489	RN	Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model. J Pharmacol Exp Ther. 2013 Jul;346(1):105-12.
DM1S489	RU	https://pubmed.ncbi.nlm.nih.gov/23674603

DMOSL9P	DI	DMOSL9P
DMOSL9P	DN	E6201
DMOSL9P	MI	TTROQ37
DMOSL9P	MN	MAPK/ERK kinase kinase (MAP3K)
DMOSL9P	MT	DTT
DMOSL9P	MA	Modulator
DMOSL9P	RN	E6201, a novel kinase inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-1 and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase-1: in vivo effects on cutaneous inflammatory responses by topical administration. J Pharmacol Exp Ther. 2010 Oct;335(1):23-31.
DMOSL9P	RU	https://pubmed.ncbi.nlm.nih.gov/20627998

DMUWJI4	DI	DMUWJI4
DMUWJI4	DN	E-6700
DMUWJI4	MI	TT2J34L
DMUWJI4	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMUWJI4	MT	DTT
DMUWJI4	MA	Modulator
DMUWJI4	RN	Structure-activity relationships of (E)-3-(1,4-benzoquinonyl)-2-[(3-pyridyl)-alkyl]-2-propenoic acid derivatives that inhibit both 5-lipoxygenase and thromboxane A2 synthetase. J Med Chem. 1996 Aug 2;39(16):3148-57.
DMUWJI4	RU	https://pubmed.ncbi.nlm.nih.gov/8759636

DMUWJI4	DI	DMUWJI4
DMUWJI4	DN	E-6700
DMUWJI4	MI	TTKNWZ4
DMUWJI4	MN	Thromboxane-A synthase (TBXAS1)
DMUWJI4	MT	DTT
DMUWJI4	MA	Modulator
DMUWJI4	RN	Structure-activity relationships of (E)-3-(1,4-benzoquinonyl)-2-[(3-pyridyl)-alkyl]-2-propenoic acid derivatives that inhibit both 5-lipoxygenase and thromboxane A2 synthetase. J Med Chem. 1996 Aug 2;39(16):3148-57.
DMUWJI4	RU	https://pubmed.ncbi.nlm.nih.gov/8759636

DMAHGKE	DI	DMAHGKE
DMAHGKE	DN	E7016
DMAHGKE	MI	TTEBCY8
DMAHGKE	MN	Poly [ADP-ribose] polymerase (PARP)
DMAHGKE	MT	DTT
DMAHGKE	MA	Modulator
DMAHGKE	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMAHGKE	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMZRXTL	DI	DMZRXTL
DMZRXTL	DN	E7820
DMZRXTL	MI	TTSJ542
DMZRXTL	MN	Integrin alpha-2 (ITGA2)
DMZRXTL	MT	DTT
DMZRXTL	MA	Inhibitor
DMZRXTL	RN	Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies. Clin Cancer Res. 2011 Jan 1;17(1):193-200.
DMZRXTL	RU	https://pubmed.ncbi.nlm.nih.gov/21208908

DM8K5IF	DI	DM8K5IF
DM8K5IF	DN	E7850
DM8K5IF	MI	TT9ABMF
DM8K5IF	MN	Serine/threonine-protein kinase Chk2 (RAD53)
DM8K5IF	MT	DTT
DM8K5IF	MA	Modulator
DM8K5IF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1988).
DM8K5IF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1988

DM753H8	DI	DM753H8
DM753H8	DN	EB8018
DM753H8	MI	TTTCRU2
DM753H8	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM753H8	MT	DTT
DM753H8	MA	Inhibitor
DM753H8	RN	Clinical pipeline report, company report or official report of Enterome Biosciences.
DM753H8	RU	https://www.enterome.com/#pipeline

DM0KVJC	DI	DM0KVJC
DM0KVJC	DN	EC-145
DM0KVJC	MI	TTVC37M
DM0KVJC	MN	Folate receptor alpha (FOLR1)
DM0KVJC	MT	DTT
DM0KVJC	MA	Modulator
DM0KVJC	RN	Significance of Folate Receptor alpha and Thymidylate Synthase Protein Expression in Patients with Non-Small Cell Lung Cancer treated with Pemetrexed. J Thorac Oncol. 2013 January; 8(1): 19-30.
DM0KVJC	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3645936/

DM1LDIP	DI	DM1LDIP
DM1LDIP	DN	Econail
DM1LDIP	MI	TTTSOUD
DM1LDIP	MN	Candida Cytochrome P450 51 (Candi ERG11)
DM1LDIP	MT	DTT
DM1LDIP	MA	Inhibitor
DM1LDIP	RN	Azole binding properties of Candida albicans sterol 14-alpha demethylase (CaCYP51). Antimicrob Agents Chemother. 2010 Oct;54(10):4235-45.
DM1LDIP	RU	https://pubmed.ncbi.nlm.nih.gov/20625155

DMKAUM9	DI	DMKAUM9
DMKAUM9	DN	Eculizumab
DMKAUM9	MI	TTN0GJ5
DMKAUM9	MN	HUMAN complement C5 protein (C5)
DMKAUM9	MT	DTT
DMKAUM9	MA	Inhibitor
DMKAUM9	RN	Complement as a target in COVID-19 Nat Rev Immunol. 2020 Apr 23.
DMKAUM9	RU	https://pubmed.ncbi.nlm.nih.gov/32327719

DMQ08AJ	DI	DMQ08AJ
DMQ08AJ	DN	Edotreotide
DMQ08AJ	MI	TTOMNR9
DMQ08AJ	MN	Somatostatin receptor (SSTR)
DMQ08AJ	MT	DTT
DMQ08AJ	MA	Modulator
DMQ08AJ	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMQ08AJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMGJYZ8	DI	DMGJYZ8
DMGJYZ8	DN	EDP-305
DMGJYZ8	MI	TTS4UGC
DMGJYZ8	MN	Farnesoid X-activated receptor (FXR)
DMGJYZ8	MT	DTT
DMGJYZ8	MA	Agonist
DMGJYZ8	RN	A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction. Liver Int. 2020 Jul;40(7):1655-1669.
DMGJYZ8	RU	https://pubmed.ncbi.nlm.nih.gov/32329946

DM5WZ0O	DI	DM5WZ0O
DM5WZ0O	DN	EDP-420
DM5WZ0O	MI	TTLFGBV
DM5WZ0O	MN	Bacterial 23S ribosomal RNA (Bact 23S rRNA)
DM5WZ0O	MT	DTT
DM5WZ0O	MA	Inhibitor
DM5WZ0O	RN	EDP-420, a Bicyclolide (Bridged Bicyclic Macrolide), Is Active against Mycobacterium avium. Antimicrob Agents Chemother. 2007 May; 51(5): 1666-1670.
DM5WZ0O	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1855536/

DM32UOC	DI	DM32UOC
DM32UOC	DN	EDP-938
DM32UOC	MI	TT25A0I
DM32UOC	MN	Respiratory syncytial virus protein N (RSV N)
DM32UOC	MT	DTT
DM32UOC	MA	Inhibitor
DM32UOC	RN	EDP-938, a novel nucleoprotein inhibitor of respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate model. PLoS Pathog. 2021 Mar 15;17(3):e1009428.
DM32UOC	RU	https://pubmed.ncbi.nlm.nih.gov/33720995

DMX4RSD	DI	DMX4RSD
DMX4RSD	DN	EFEGATRAN SULFATE HYDRATE
DMX4RSD	MI	TT6L509
DMX4RSD	MN	Coagulation factor IIa (F2)
DMX4RSD	MT	DTT
DMX4RSD	MA	Inhibitor
DMX4RSD	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMX4RSD	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMX6RZG	DI	DMX6RZG
DMX6RZG	DN	EFT508
DMX6RZG	MI	TTRECN3
DMX6RZG	MN	MAP kinase signal-integrating kinase 2 (MKNK2)
DMX6RZG	MT	DTT
DMX6RZG	MA	Inhibitor
DMX6RZG	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMX6RZG	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMX6RZG	DI	DMX6RZG
DMX6RZG	DN	EFT508
DMX6RZG	MI	TTEZAUX
DMX6RZG	MN	MAPK signal-integrating kinase 1 (MKNK1)
DMX6RZG	MT	DTT
DMX6RZG	MA	Inhibitor
DMX6RZG	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMX6RZG	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMBHP56	DI	DMBHP56
DMBHP56	DN	Efungumab
DMBHP56	MI	TT78R5H
DMBHP56	MN	Heat shock protein 90 alpha (HSP90A)
DMBHP56	MT	DTT
DMBHP56	RN	Efungumab: a novel agent in the treatment of invasive candidiasis. Ann Pharmacother. 2009 Nov;43(11):1818-23.
DMBHP56	RU	https://pubmed.ncbi.nlm.nih.gov/19773528

DM6L5TR	DI	DM6L5TR
DM6L5TR	DN	EGEN-001
DM6L5TR	MI	TTGW72V
DM6L5TR	MN	Interleukin-12 beta (IL12B)
DM6L5TR	MT	DTT
DM6L5TR	MA	Modulator
DM6L5TR	RN	National Cancer Institute Drug Dictionary (drug id 454593).
DM6L5TR	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=454593

DMN1SWB	DI	DMN1SWB
DMN1SWB	DN	EGS-21
DMN1SWB	MI	TTCBFJO
DMN1SWB	MN	Insulin receptor (INSR)
DMN1SWB	MT	DTT
DMN1SWB	MA	Modulator
DMN1SWB	RN	Ceramides and glucosylceramides are independent antagonists of insulin signaling. J Biol Chem. 2014 Jan 10;289(2):723-34.
DMN1SWB	RU	https://pubmed.ncbi.nlm.nih.gov/24214972

DML7WP0	DI	DML7WP0
DML7WP0	DN	Eldacimibe
DML7WP0	MI	TTMF541
DML7WP0	MN	Liver carboxylesterase (CES1)
DML7WP0	MT	DTT
DML7WP0	MA	Modulator
DML7WP0	RN	Prospects for drug therapy for hyperlipoproteinaemia. Diabete Metab. 1995 Apr;21(2):139-46.
DML7WP0	RU	https://pubmed.ncbi.nlm.nih.gov/7621974

DMCSXI4	DI	DMCSXI4
DMCSXI4	DN	Elezanumab
DMCSXI4	MI	TTURJV4
DMCSXI4	MN	Repulsive guidance molecule A (RGMA)
DMCSXI4	MT	DTT
DMCSXI4	MA	Inhibitor
DMCSXI4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMCSXI4	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMIOGZM	DI	DMIOGZM
DMIOGZM	DN	ELIPRODIL
DMIOGZM	MI	TTLD29N
DMIOGZM	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMIOGZM	MT	DTT
DMIOGZM	MA	Inhibitor
DMIOGZM	RN	4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist. J Med Chem. 1999 Jul 29;42(15):2993-3000.
DMIOGZM	RU	https://pubmed.ncbi.nlm.nih.gov/10425109

DMIOGZM	DI	DMIOGZM
DMIOGZM	DN	ELIPRODIL
DMIOGZM	MI	TTN9D8E
DMIOGZM	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMIOGZM	MT	DTT
DMIOGZM	MA	Inhibitor
DMIOGZM	RN	4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist. J Med Chem. 1999 Jul 29;42(15):2993-3000.
DMIOGZM	RU	https://pubmed.ncbi.nlm.nih.gov/10425109

DMB38KH	DI	DMB38KH
DMB38KH	DN	Elisidepsin
DMB38KH	MI	TTDC8N2
DMB38KH	MN	Erbb3 tyrosine kinase receptor (Erbb-3)
DMB38KH	MT	DTT
DMB38KH	MA	Inhibitor
DMB38KH	RN	Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models. Eur J Cancer. 2009 Jul;45(10):1855-64.
DMB38KH	RU	https://pubmed.ncbi.nlm.nih.gov/19346126

DMR50I7	DI	DMR50I7
DMR50I7	DN	Elsamitrucin
DMR50I7	MI	TT0IHXV
DMR50I7	MN	DNA topoisomerase II (TOP2)
DMR50I7	MT	DTT
DMR50I7	MA	Modulator
DMR50I7	RN	Elsamicin A binding to DNA. A comparative thermodynamic characterization. FEBS Lett. 2004 Oct 8;576(1-2):68-72.
DMR50I7	RU	https://pubmed.ncbi.nlm.nih.gov/15474012

DMB7CPG	DI	DMB7CPG
DMB7CPG	DN	Elsiglutide
DMB7CPG	MI	TT1YWO5
DMB7CPG	MN	Glucagon-like peptide 2 receptor (GLP2R)
DMB7CPG	MT	DTT
DMB7CPG	MA	Modulator
DMB7CPG	RN	Poster Abstracts. Volume 10, Issue Supplement S8, pages 126-209, December 2014.
DMB7CPG	RU	http://onlinelibrary.wiley.com/doi/10.1111/ajco.12305/abstract

DMYOUB6	DI	DMYOUB6
DMYOUB6	DN	EMA-401
DMYOUB6	MI	TTQVOEI
DMYOUB6	MN	Angiotensin II receptor type-2 (AGTR2)
DMYOUB6	MT	DTT
DMYOUB6	MA	Antagonist
DMYOUB6	RN	Clinical pipeline report, company report or official report of Spinifex.
DMYOUB6	RU	http://www.spinifexpharma.com/EMA401-DEVELOPMENT.html

DMCLT2F	DI	DMCLT2F
DMCLT2F	DN	Emepepimut-S
DMCLT2F	MI	TTBHFYQ
DMCLT2F	MN	Mucin-1 (MUC1)
DMCLT2F	MT	DTT
DMCLT2F	RN	Emepepimut-S for non-small cell lung cancer. Expert Opin Biol Ther. 2011 Aug;11(8):1091-7.
DMCLT2F	RU	https://pubmed.ncbi.nlm.nih.gov/21689064

DMT4MKF	DI	DMT4MKF
DMT4MKF	DN	Emibetuzumab
DMT4MKF	MI	TTNDSF4
DMT4MKF	MN	Proto-oncogene c-Met (MET)
DMT4MKF	MT	DTT
DMT4MKF	MA	Inhibitor
DMT4MKF	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMT4MKF	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMQH1NV	DI	DMQH1NV
DMQH1NV	DN	Emivirine
DMQH1NV	MI	DE4LYSA
DMQH1NV	MN	Cytochrome P450 3A4 (CYP3A4)
DMQH1NV	MT	DME
DMQH1NV	MA	Metabolism
DMQH1NV	RN	Safety assessment, in vitro and in vivo, and pharmacokinetics of emivirine, a potent and selective nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2000 Jan;44(1):123-30.
DMQH1NV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10602732

DMQH1NV	DI	DMQH1NV
DMQH1NV	DN	Emivirine
DMQH1NV	MI	DEIBDNY
DMQH1NV	MN	Cytochrome P450 3A5 (CYP3A5)
DMQH1NV	MT	DME
DMQH1NV	MA	Metabolism
DMQH1NV	RN	Safety assessment, in vitro and in vivo, and pharmacokinetics of emivirine, a potent and selective nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2000 Jan;44(1):123-30.
DMQH1NV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10602732

DMQH1NV	DI	DMQH1NV
DMQH1NV	DN	Emivirine
DMQH1NV	MI	TT84ETX
DMQH1NV	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMQH1NV	MT	DTT
DMQH1NV	MA	Modulator
DMQH1NV	RN	Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.Clin Ther.2009 Apr;31(4):692-704.
DMQH1NV	RU	https://www.ncbi.nlm.nih.gov/pubmed/19446143

DMDEL3F	DI	DMDEL3F
DMDEL3F	DN	EMZ701
DMDEL3F	MI	TTSYFMA
DMDEL3F	MN	Interferon alpha/beta receptor 1 (IFNAR1)
DMDEL3F	MT	DTT
DMDEL3F	MA	Modulator
DMDEL3F	RN	Patent EP2766021 A1.
DMDEL3F	RU	http://www.google.com/patents/EP2766021A1?cl=en

DMGFZOL	DI	DMGFZOL
DMGFZOL	DN	Enadoline
DMGFZOL	MI	TTQW87Y
DMGFZOL	MN	Opioid receptor kappa (OPRK1)
DMGFZOL	MT	DTT
DMGFZOL	MA	Agonist
DMGFZOL	RN	Enadoline, a selective kappa-opioid receptor agonist shows potent antihyperalgesic and antiallodynic actions in a rat model of surgical pain. Pain. 1999 Mar;80(1-2):383-9.
DMGFZOL	RU	https://pubmed.ncbi.nlm.nih.gov/10204752

DMM8Z3Q	DI	DMM8Z3Q
DMM8Z3Q	DN	Encequidar
DMM8Z3Q	MI	TTJUXV6
DMM8Z3Q	MN	Multidrug resistance protein 3 (ABCB4)
DMM8Z3Q	MT	DTT
DMM8Z3Q	MA	Inhibitor
DMM8Z3Q	RN	Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor. J Med Chem. 2021 Apr 8;64(7):3677-3693.
DMM8Z3Q	RU	https://pubmed.ncbi.nlm.nih.gov/33729781

DM8NLDI	DI	DM8NLDI
DM8NLDI	DN	Endostatin
DM8NLDI	MI	TTBPXMA
DM8NLDI	MN	Prolactin receptor (PRLR)
DM8NLDI	MT	DTT
DM8NLDI	MA	Modulator
DM8NLDI	RN	Prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer. Cancer Res. 2003 Jul 1;63(13):3598-604.
DM8NLDI	RU	https://pubmed.ncbi.nlm.nih.gov/12839947

DMTX8IZ	DI	DMTX8IZ
DMTX8IZ	DN	Endoxifen
DMTX8IZ	MI	TTZAYWL
DMTX8IZ	MN	Estrogen receptor (ESR)
DMTX8IZ	MT	DTT
DMTX8IZ	MA	Modulator
DMTX8IZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620).
DMTX8IZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=620

DMMIHSO	DI	DMMIHSO
DMMIHSO	DN	ENERGI-F701
DMMIHSO	MI	TTLAFZV
DMMIHSO	MN	AMP-activated protein kinase (AMPK)
DMMIHSO	MT	DTT
DMMIHSO	MA	Activator
DMMIHSO	RN	Clinical pipeline report, company report or official report of Energenesis Biomedical.
DMMIHSO	RU	https://www.energenesis-biomedical.com/_en/tech_detail.php?id=186

DM96NCR	DI	DM96NCR
DM96NCR	DN	Eniluracil
DM96NCR	MI	TTZPS91
DM96NCR	MN	Dihydrothymine dehydrogenase (DPYD)
DM96NCR	MT	DTT
DM96NCR	MA	Modulator
DM96NCR	RN	Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase. Expert Opin Investig Drugs. 2000 Jul;9(7):1635-49.
DM96NCR	RU	https://pubmed.ncbi.nlm.nih.gov/11060767

DMJZVPB	DI	DMJZVPB
DMJZVPB	DN	ENMD-2076
DMJZVPB	MI	TTPS3C0
DMJZVPB	MN	Aurora kinase A (AURKA)
DMJZVPB	MT	DTT
DMJZVPB	MA	Inhibitor
DMJZVPB	RN	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
DMJZVPB	RU	https://pubmed.ncbi.nlm.nih.gov/19568282

DMJZVPB	DI	DMJZVPB
DMJZVPB	DN	ENMD-2076
DMJZVPB	MI	TTU8W4S
DMJZVPB	MN	Protein kinase (PK)
DMJZVPB	MT	DTT
DMJZVPB	MA	Inhibitor
DMJZVPB	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMJZVPB	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMDS20X	DI	DMDS20X
DMDS20X	DN	Enoblituzumab
DMDS20X	MI	TT6CQUM
DMDS20X	MN	B7 homolog 3 (CD276)
DMDS20X	MT	DTT
DMDS20X	MA	Inhibitor
DMDS20X	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMDS20X	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMLPRZJ	DI	DMLPRZJ
DMLPRZJ	DN	Ensaculin hydrochloride
DMLPRZJ	MI	TTSQIFT
DMLPRZJ	MN	5-HT 1A receptor (HTR1A)
DMLPRZJ	MT	DTT
DMLPRZJ	MA	Modulator
DMLPRZJ	RN	Ensaculin (KA-672 HCl): a multitransmitter approach to dementia treatment. CNS Drug Rev. 2002 Summer;8(2):143-58.
DMLPRZJ	RU	https://pubmed.ncbi.nlm.nih.gov/12177685

DM69NF1	DI	DM69NF1
DM69NF1	DN	EP-101
DM69NF1	MI	TTOXS3C
DM69NF1	MN	Muscarinic acetylcholine receptor (CHRM)
DM69NF1	MT	DTT
DM69NF1	MA	Antagonist
DM69NF1	RN	Long-acting muscarinic receptor antagonists for the treatment of respiratory disease. Pulm Pharmacol Ther. 2013 Jun;26(3):307-17.
DM69NF1	RU	https://pubmed.ncbi.nlm.nih.gov/23274274

DMPC4EK	DI	DMPC4EK
DMPC4EK	DN	EP-217609
DMPC4EK	MI	TT6L509
DMPC4EK	MN	Coagulation factor IIa (F2)
DMPC4EK	MT	DTT
DMPC4EK	MA	Modulator
DMPC4EK	RN	Specificity and selectivity profile of EP217609: a new neutralizable dual-action anticoagulant that targets thrombin and factor Xa.Blood.2012 Mar 8;119(10):2187-95.
DMPC4EK	RU	https://www.ncbi.nlm.nih.gov/pubmed/22144183

DMPC4EK	DI	DMPC4EK
DMPC4EK	DN	EP-217609
DMPC4EK	MI	TTCIHJA
DMPC4EK	MN	Coagulation factor Xa (F10)
DMPC4EK	MT	DTT
DMPC4EK	MA	Modulator
DMPC4EK	RN	Specificity and selectivity profile of EP217609: a new neutralizable dual-action anticoagulant that targets thrombin and factor Xa.Blood.2012 Mar 8;119(10):2187-95.
DMPC4EK	RU	https://www.ncbi.nlm.nih.gov/pubmed/22144183

DMZT7EP	DI	DMZT7EP
DMZT7EP	DN	EPI 589
DMZT7EP	MI	TTIB5LO
DMZT7EP	MN	Quinone reductase (NQO)
DMZT7EP	MT	DTT
DMZT7EP	MA	Modulator
DMZT7EP	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZT7EP	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMWK26Q	DI	DMWK26Q
DMWK26Q	DN	EPX-200
DMWK26Q	MI	TT85JO3
DMWK26Q	MN	5-HT receptor (5HTR)
DMWK26Q	MT	DTT
DMWK26Q	MA	Modulator
DMWK26Q	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMWK26Q	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMUXDGZ	DI	DMUXDGZ
DMUXDGZ	DN	EPX-300
DMUXDGZ	MI	TT85JO3
DMUXDGZ	MN	5-HT receptor (5HTR)
DMUXDGZ	MT	DTT
DMUXDGZ	MA	Modulator
DMUXDGZ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMUXDGZ	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMD4YRG	DI	DMD4YRG
DMD4YRG	DN	EQ-917
DMD4YRG	MI	TTGTQHC
DMD4YRG	MN	DNA topoisomerase I (TOP1)
DMD4YRG	MT	DTT
DMD4YRG	MA	Inhibitor
DMD4YRG	RN	The efficacy and toxicity of belotecan (CKD-602), a camptothericin analogue topoisomerase I inhibitor, in patients with recurrent or refractory epithelial ovarian cancer. J Chemother. 2010 Jun;22(3):197-200.
DMD4YRG	RU	https://pubmed.ncbi.nlm.nih.gov/20566426

DMCEPUA	DI	DMCEPUA
DMCEPUA	DN	ERB-041
DMCEPUA	MI	TTOM3J0
DMCEPUA	MN	Estrogen receptor beta (ESR2)
DMCEPUA	MT	DTT
DMCEPUA	MA	Agonist
DMCEPUA	RN	Erb-041, an estrogen receptor-beta agonist, inhibits skin photocarcinogenesis in SKH-1 hairless mice by downregulating the WNT signaling pathway. Cancer Prev Res (Phila). 2014 Feb;7(2):186-98.
DMCEPUA	RU	https://pubmed.ncbi.nlm.nih.gov/24217507

DMU1XZD	DI	DMU1XZD
DMU1XZD	DN	Erteberel
DMU1XZD	MI	TTOM3J0
DMU1XZD	MN	Estrogen receptor beta (ESR2)
DMU1XZD	MT	DTT
DMU1XZD	MA	Agonist
DMU1XZD	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031986)
DMU1XZD	RU	http://adisinsight.springer.com/drugs/800031986

DM5Z3VP	DI	DM5Z3VP
DM5Z3VP	DN	Ertumaxomab
DM5Z3VP	MI	TT6EO5L
DM5Z3VP	MN	Erbb2 tyrosine kinase receptor (HER2)
DM5Z3VP	MT	DTT
DM5Z3VP	RN	Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. MAbs. 2012 Sep-Oct;4(5):614-22.
DM5Z3VP	RU	https://pubmed.ncbi.nlm.nih.gov/22820509

DM5Z3VP	DI	DM5Z3VP
DM5Z3VP	DN	Ertumaxomab
DM5Z3VP	MI	TTZAT79
DM5Z3VP	MN	T-cell surface glycoprotein CD3 epsilon (CD3E)
DM5Z3VP	MT	DTT
DM5Z3VP	RN	Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. MAbs. 2012 Sep-Oct;4(5):614-22.
DM5Z3VP	RU	https://pubmed.ncbi.nlm.nih.gov/22820509

DM5Z3VP	DI	DM5Z3VP
DM5Z3VP	DN	Ertumaxomab
DM5Z3VP	MI	TTV3XPL
DM5Z3VP	MN	T-cell surface glycoprotein CD3 gamma (CD3G)
DM5Z3VP	MT	DTT
DM5Z3VP	RN	Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. MAbs. 2012 Sep-Oct;4(5):614-22.
DM5Z3VP	RU	https://pubmed.ncbi.nlm.nih.gov/22820509

DMYZWDC	DI	DMYZWDC
DMYZWDC	DN	ESBA-105
DMYZWDC	MI	TTF8CQI
DMYZWDC	MN	Tumor necrosis factor (TNF)
DMYZWDC	MT	DTT
DMYZWDC	RN	Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye. Invest Ophthalmol Vis Sci. 2009 Feb;50(2):771-8.
DMYZWDC	RU	https://pubmed.ncbi.nlm.nih.gov/18757508

DMTB63Q	DI	DMTB63Q
DMTB63Q	DN	Estetrol
DMTB63Q	MI	TTZAYWL
DMTB63Q	MN	Estrogen receptor (ESR)
DMTB63Q	MT	DTT
DMTB63Q	MA	Modulator
DMTB63Q	RN	Clinical pipeline report, company report or official report of Pantarhei Bioscience.
DMTB63Q	RU	http://pantarheibio.com/pipeline/estetrol.htm

DM71BZV	DI	DM71BZV
DM71BZV	DN	Etamicastat
DM71BZV	MI	TTYIP79
DM71BZV	MN	Dopamine beta hydroxylase (DBH)
DM71BZV	MT	DTT
DM71BZV	MA	Inhibitor
DM71BZV	RN	Safety, tolerability, and pharmacokinetics of etamicastat, a novel dopamine-beta-hydroxylase inhibitor, in a rising multiple-dose study in young healthy subjects. Drugs R D. 2010;10(4):225-42.
DM71BZV	RU	https://pubmed.ncbi.nlm.nih.gov/21171669

DMOCID7	DI	DMOCID7
DMOCID7	DN	Etazolate
DMOCID7	MI	TTEX6LM
DMOCID7	MN	GABA(A) receptor gamma-3 (GABRG3)
DMOCID7	MT	DTT
DMOCID7	MA	Modulator
DMOCID7	RN	Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing. J Neurochem. 2008 Jul;106(1):392-404.
DMOCID7	RU	https://pubmed.ncbi.nlm.nih.gov/18397369

DM68K39	DI	DM68K39
DM68K39	DN	ETIPREDNOL DICLOACETATE
DM68K39	MI	TTYRL6O
DM68K39	MN	Glucocorticoid receptor (NR3C1)
DM68K39	MT	DTT
DM68K39	MA	Modulator
DM68K39	RN	Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate.Int J Inflam.2012;2012:789623.
DM68K39	RU	https://www.ncbi.nlm.nih.gov/pubmed/22536546

DMV96BY	DI	DMV96BY
DMV96BY	DN	ETS-6218
DMV96BY	MI	TT7CXIM
DMV96BY	MN	Histamine receptor (HR)
DMV96BY	MT	DTT
DMV96BY	MA	Modulator
DMV96BY	RN	Clinical pipeline report, company report or official report of e-Therapeutics.
DMV96BY	RU	http://www.etherapeutics.co.uk/wp-content/uploads/2014/12/etp-10594-ar-08-web.pdf

DMZOA2L	DI	DMZOA2L
DMZOA2L	DN	ETX-9101
DMZOA2L	MI	TT7CXIM
DMZOA2L	MN	Histamine receptor (HR)
DMZOA2L	MT	DTT
DMZOA2L	MA	Modulator
DMZOA2L	RN	Clinical pipeline report, company report or official report of e-Therapeutics.
DMZOA2L	RU	http://www.etherapeutics.co.uk/wp-content/uploads/2014/12/etp-10594-ar-08-web.pdf

DM1FCDH	DI	DM1FCDH
DM1FCDH	DN	EV-077
DM1FCDH	MI	TTKNWZ4
DM1FCDH	MN	Thromboxane-A synthase (TBXAS1)
DM1FCDH	MT	DTT
DM1FCDH	MA	Modulator
DM1FCDH	RN	Company report (Pharmaceuticalintelligence)
DM1FCDH	RU	http://pharmaceuticalintelligence.com/tag/diabetic-nephropathy/

DMWB94K	DI	DMWB94K
DMWB94K	DN	Evenamide
DMWB94K	MI	TTIG65Q
DMWB94K	MN	Voltage-gated sodium channel (Nav)
DMWB94K	MT	DTT
DMWB94K	MA	Blocker
DMWB94K	RN	Clinical pipeline report, company report or official report of Newron Pharmaceuticals.
DMWB94K	RU	https://www.newron.com/science#evenamide

DM8QXEY	DI	DM8QXEY
DM8QXEY	DN	Evt201
DM8QXEY	MI	TTCI43M
DM8QXEY	MN	GABA(A) receptor (GABAR)
DM8QXEY	MT	DTT
DM8QXEY	MA	Modulator
DM8QXEY	RN	The partial positive allosteric GABA(A) receptor modulator EVT 201 is efficacious and safe in the treatment of adult primary insomnia patients. Sleep Med. 2009 Sep;10(8):859-64.
DM8QXEY	RU	https://pubmed.ncbi.nlm.nih.gov/19345644

DMQGBM1	DI	DMQGBM1
DMQGBM1	DN	EVT-201
DMQGBM1	MI	TT1MPAY
DMQGBM1	MN	GABA(A) receptor alpha-1 (GABRA1)
DMQGBM1	MT	DTT
DMQGBM1	MA	Modulator
DMQGBM1	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMQGBM1	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMQGBM1	DI	DMQGBM1
DMQGBM1	DN	EVT-201
DMQGBM1	MI	TTEX6LM
DMQGBM1	MN	GABA(A) receptor gamma-3 (GABRG3)
DMQGBM1	MT	DTT
DMQGBM1	MA	Modulator
DMQGBM1	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415).
DMQGBM1	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415

DM73XNG	DI	DM73XNG
DM73XNG	DN	EVT302
DM73XNG	MI	TTGP7BY
DM73XNG	MN	Monoamine oxidase type B (MAO-B)
DM73XNG	MT	DTT
DM73XNG	MA	Inhibitor
DM73XNG	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM73XNG	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM4FBUH	DI	DM4FBUH
DM4FBUH	DN	EXC 001
DM4FBUH	MI	TTCJVNE
DM4FBUH	MN	CTGF messenger RNA (CTGF mRNA)
DM4FBUH	MT	DTT
DM4FBUH	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
DM4FBUH	RU	http://www.isispharm.com/index.htm

DMC1I56	DI	DMC1I56
DMC1I56	DN	Exherin
DMC1I56	MI	TT1WS0T
DMC1I56	MN	Neural cadherin (CDH2)
DMC1I56	MT	DTT
DMC1I56	MA	Binder
DMC1I56	RN	Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing soli... Ann Oncol. 2009 Apr;20(4):741-5.
DMC1I56	RU	https://pubmed.ncbi.nlm.nih.gov/19190075

DM5PBLM	DI	DM5PBLM
DM5PBLM	DN	EYP001
DM5PBLM	MI	TTS4UGC
DM5PBLM	MN	Farnesoid X-activated receptor (FXR)
DM5PBLM	MT	DTT
DM5PBLM	MA	Agonist
DM5PBLM	RN	Clinical pipeline report, company report or official report of ENYO Pharma.
DM5PBLM	RU	http://www.enyopharma.com/pipeline/eyp001-in-nash/

DM2L9CO	DI	DM2L9CO
DM2L9CO	DN	Ezatiostat
DM2L9CO	MI	TT40K12
DM2L9CO	MN	Glutathione S-transferase P (GSTP1)
DM2L9CO	MT	DTT
DM2L9CO	MA	Modulator
DM2L9CO	RN	National Cancer Institute Drug Dictionary (drug id 485244).
DM2L9CO	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=485244

DMJ4BKT	DI	DMJ4BKT
DMJ4BKT	DN	F-16-IL-2 fusion protein
DMJ4BKT	MI	TTUCPMY
DMJ4BKT	MN	Tenascin (TNC)
DMJ4BKT	MT	DTT
DMJ4BKT	MA	Modulator
DMJ4BKT	RN	National Cancer Institute Drug Dictionary (drug id 674718).
DMJ4BKT	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=674718

DMKP3SJ	DI	DMKP3SJ
DMKP3SJ	DN	F-351
DMKP3SJ	MI	TTRAXK5
DMKP3SJ	MN	Aminotransferase (AT)
DMKP3SJ	MT	DTT
DMKP3SJ	MA	Inhibitor
DMKP3SJ	RN	Expansion of the clavulanic acid gene cluster: identification and in vivo functional analysis of three new genes required for biosynthesis of clavulanic acid by Streptomyces clavuligerus. J Bacteriol. 2000 Jul;182(14):4087-95.
DMKP3SJ	RU	https://pubmed.ncbi.nlm.nih.gov/10869089

DM6UQNW	DI	DM6UQNW
DM6UQNW	DN	F4co vaccine
DM6UQNW	MI	TTTWS2G
DM6UQNW	MN	Human immunodeficiency virus Capsid p24 (HIV p24)
DM6UQNW	MT	DTT
DM6UQNW	RN	EP patent application no. 2621528, Vaccine.
DM6UQNW	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20130807&CC=EP&NR=2621528A1&KC=A1

DM6UQNW	DI	DM6UQNW
DM6UQNW	DN	F4co vaccine
DM6UQNW	MI	TTI3NXG
DM6UQNW	MN	Human immunodeficiency virus Matrix p17 (HIV MA)
DM6UQNW	MT	DTT
DM6UQNW	RN	EP patent application no. 2621528, Vaccine.
DM6UQNW	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20130807&CC=EP&NR=2621528A1&KC=A1

DM6UQNW	DI	DM6UQNW
DM6UQNW	DN	F4co vaccine
DM6UQNW	MI	TT4NXYM
DM6UQNW	MN	Human immunodeficiency virus Negative factor (HIV nef)
DM6UQNW	MT	DTT
DM6UQNW	RN	EP patent application no. 2621528, Vaccine.
DM6UQNW	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20130807&CC=EP&NR=2621528A1&KC=A1

DM6UQNW	DI	DM6UQNW
DM6UQNW	DN	F4co vaccine
DM6UQNW	MI	TT84ETX
DM6UQNW	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM6UQNW	MT	DTT
DM6UQNW	RN	EP patent application no. 2621528, Vaccine.
DM6UQNW	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20130807&CC=EP&NR=2621528A1&KC=A1

DMDNJ18	DI	DMDNJ18
DMDNJ18	DN	F-627
DMDNJ18	MI	TT5TQ2W
DMDNJ18	MN	Granulocyte colony-stimulating factor (CSF3)
DMDNJ18	MT	DTT
DMDNJ18	MA	Modulator
DMDNJ18	RN	Clinical pipeline report, company report or official report of Generon (Shanghai) Corporation Ltd.
DMDNJ18	RU	http://www.generonbiomed.com/html/en/index.php?ac=article&at=list&tid=29

DMBFPO1	DI	DMBFPO1
DMBFPO1	DN	F-8-IL-10 fusion protein
DMBFPO1	MI	TTT0Q1F
DMBFPO1	MN	Interleukin-10 (IL10)
DMBFPO1	MT	DTT
DMBFPO1	MA	Modulator
DMBFPO1	RN	Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther. 2009;11(5):R142.
DMBFPO1	RU	https://pubmed.ncbi.nlm.nih.gov/19781067

DM2CUS0	DI	DM2CUS0
DM2CUS0	DN	F901318
DM2CUS0	MI	TTTSUI2
DM2CUS0	MN	Aspergillus Dihydroorotate dehydrogenase (Aspergillus DHODH)
DM2CUS0	MT	DTT
DM2CUS0	MA	Inhibitor
DM2CUS0	RN	Effect of the Novel Antifungal Drug F901318 (Olorofim) on Growth and Viability of Aspergillus fumigatus. Antimicrob Agents Chemother. 2018 Jul 27;62(8):e00231-18.
DM2CUS0	RU	https://pubmed.ncbi.nlm.nih.gov/29891595

DMXB6KG	DI	DMXB6KG
DMXB6KG	DN	FAD-104
DMXB6KG	MI	TTUTN1I
DMXB6KG	MN	Human Deoxyribonucleic acid (hDNA)
DMXB6KG	MT	DTT
DMXB6KG	MA	Binder
DMXB6KG	RN	Biological activities of new anthracyclines containing fluorine, FAD104 and its metabolites. J Antibiot (Tokyo). 1990 May;43(5):556-65.
DMXB6KG	RU	https://pubmed.ncbi.nlm.nih.gov/1694165

DM6RKG3	DI	DM6RKG3
DM6RKG3	DN	Fadolmidine
DM6RKG3	MI	TTQ8AFT
DM6RKG3	MN	Adrenergic receptor Alpha-2 (ADRA2)
DM6RKG3	MT	DTT
DM6RKG3	MA	Agonist
DM6RKG3	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM6RKG3	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM6RKG3	DI	DM6RKG3
DM6RKG3	DN	Fadolmidine
DM6RKG3	MI	TT2NUT5
DM6RKG3	MN	Adrenergic receptor alpha-2C (ADRA2C)
DM6RKG3	MT	DTT
DM6RKG3	MA	Agonist
DM6RKG3	RN	Antinociceptive properties of fadolmidine (MPV-2426), a novel alpha2-adrenoceptor agonist. CNS Drug Rev. 2004 Summer;10(2):117-26.
DM6RKG3	RU	https://pubmed.ncbi.nlm.nih.gov/15179442

DMSFWT7	DI	DMSFWT7
DMSFWT7	DN	Famitinib
DMSFWT7	MI	DE6OQ3W
DMSFWT7	MN	Cytochrome P450 1A1 (CYP1A1)
DMSFWT7	MT	DME
DMSFWT7	MA	Metabolism
DMSFWT7	RN	Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
DMSFWT7	RU	http://www.ncbi.nlm.nih.gov/pubmed/23126373

DMSFWT7	DI	DMSFWT7
DMSFWT7	DN	Famitinib
DMSFWT7	MI	DEJGDUW
DMSFWT7	MN	Cytochrome P450 1A2 (CYP1A2)
DMSFWT7	MT	DME
DMSFWT7	MA	Metabolism
DMSFWT7	RN	Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
DMSFWT7	RU	http://www.ncbi.nlm.nih.gov/pubmed/23126373

DMSFWT7	DI	DMSFWT7
DMSFWT7	DN	Famitinib
DMSFWT7	MI	DE4LYSA
DMSFWT7	MN	Cytochrome P450 3A4 (CYP3A4)
DMSFWT7	MT	DME
DMSFWT7	MA	Metabolism
DMSFWT7	RN	Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
DMSFWT7	RU	http://www.ncbi.nlm.nih.gov/pubmed/23126373

DMSFWT7	DI	DMSFWT7
DMSFWT7	DN	Famitinib
DMSFWT7	MI	DEIBDNY
DMSFWT7	MN	Cytochrome P450 3A5 (CYP3A5)
DMSFWT7	MT	DME
DMSFWT7	MA	Metabolism
DMSFWT7	RN	Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
DMSFWT7	RU	http://www.ncbi.nlm.nih.gov/pubmed/23126373

DMSFWT7	DI	DMSFWT7
DMSFWT7	DN	Famitinib
DMSFWT7	MI	TTGJCWZ
DMSFWT7	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMSFWT7	MT	DTT
DMSFWT7	MA	Inhibitor
DMSFWT7	RN	Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
DMSFWT7	RU	https://pubmed.ncbi.nlm.nih.gov/23126373

DMSFWT7	DI	DMSFWT7
DMSFWT7	DN	Famitinib
DMSFWT7	MI	TT8FYO9
DMSFWT7	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMSFWT7	MT	DTT
DMSFWT7	MA	Inhibitor
DMSFWT7	RN	Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
DMSFWT7	RU	https://pubmed.ncbi.nlm.nih.gov/23126373

DMSFWT7	DI	DMSFWT7
DMSFWT7	DN	Famitinib
DMSFWT7	MI	TTI7421
DMSFWT7	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMSFWT7	MT	DTT
DMSFWT7	MA	Inhibitor
DMSFWT7	RN	Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
DMSFWT7	RU	https://pubmed.ncbi.nlm.nih.gov/23126373

DMSFWT7	DI	DMSFWT7
DMSFWT7	DN	Famitinib
DMSFWT7	MI	TTX41N9
DMSFWT7	MN	Tyrosine-protein kinase Kit (KIT)
DMSFWT7	MT	DTT
DMSFWT7	MA	Inhibitor
DMSFWT7	RN	Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
DMSFWT7	RU	https://pubmed.ncbi.nlm.nih.gov/23126373

DMSFWT7	DI	DMSFWT7
DMSFWT7	DN	Famitinib
DMSFWT7	MI	TT2Q6G1
DMSFWT7	MN	Vascular endothelial growth factor receptor 1 (FLT-1)
DMSFWT7	MT	DTT
DMSFWT7	MA	Inhibitor
DMSFWT7	RN	Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
DMSFWT7	RU	https://pubmed.ncbi.nlm.nih.gov/23126373

DMSFWT7	DI	DMSFWT7
DMSFWT7	DN	Famitinib
DMSFWT7	MI	TTUTJGQ
DMSFWT7	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMSFWT7	MT	DTT
DMSFWT7	MA	Inhibitor
DMSFWT7	RN	Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
DMSFWT7	RU	https://pubmed.ncbi.nlm.nih.gov/23126373

DMSFWT7	DI	DMSFWT7
DMSFWT7	DN	Famitinib
DMSFWT7	MI	TTDCBX5
DMSFWT7	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DMSFWT7	MT	DTT
DMSFWT7	MA	Inhibitor
DMSFWT7	RN	Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
DMSFWT7	RU	https://pubmed.ncbi.nlm.nih.gov/23126373

DM563NC	DI	DM563NC
DM563NC	DN	Fasitibant chloride
DM563NC	MI	TTGY8IW
DM563NC	MN	B2 bradykinin receptor (BDKRB2)
DM563NC	MT	DTT
DM563NC	MA	Antagonist
DM563NC	RN	Fasitibant chloride, a kinin B receptor antagonist, and dexamethasone interact to inhibit carrageenan-induced inflammatory arthritis in rats. Br J Pharmacol. 2012 Jun;166(4):1403-10.
DM563NC	RU	https://pubmed.ncbi.nlm.nih.gov/22251015

DMR3952	DI	DMR3952
DMR3952	DN	FBS-0701
DMR3952	MI	TTQO71U
DMR3952	MN	Hemoglobin (HB)
DMR3952	MT	DTT
DMR3952	MA	Modulator
DMR3952	RN	A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res. 2009 Dec 1;15(23):7144-52.
DMR3952	RU	https://pubmed.ncbi.nlm.nih.gov/22919029

DM3CVHQ	DI	DM3CVHQ
DM3CVHQ	DN	FE-202158
DM3CVHQ	MI	TT4TFGN
DM3CVHQ	MN	Vasopressin V1a receptor (V1AR)
DM3CVHQ	MT	DTT
DM3CVHQ	MA	Agonist
DM3CVHQ	RN	The selective vasopressin type 1a receptor agonist selepressin (FE 202158) blocks vascular leak in ovine severe sepsis*. Crit Care Med. 2014 Jul;42(7):e525-33.
DM3CVHQ	RU	https://pubmed.ncbi.nlm.nih.gov/24674922

DMDGZ1C	DI	DMDGZ1C
DMDGZ1C	DN	FE-202767
DMDGZ1C	MI	TTSCIUP
DMDGZ1C	MN	Oxytocin receptor (OTR)
DMDGZ1C	MT	DTT
DMDGZ1C	MA	Agonist
DMDGZ1C	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 369).
DMDGZ1C	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=369

DMICMXE	DI	DMICMXE
DMICMXE	DN	Ferroquine
DMICMXE	MI	DE5IED8
DMICMXE	MN	Cytochrome P450 2C9 (CYP2C9)
DMICMXE	MT	DME
DMICMXE	MA	Metabolism
DMICMXE	RN	In vitro metabolism of ferroquine (SSR97193) in animal and human hepatic models and antimalarial activity of major metabolites on Plasmodium falciparum. Drug Metab Dispos. 2006 Apr;34(4):667-82.
DMICMXE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16415117

DMICMXE	DI	DMICMXE
DMICMXE	DN	Ferroquine
DMICMXE	MI	DECB0K3
DMICMXE	MN	Cytochrome P450 2D6 (CYP2D6)
DMICMXE	MT	DME
DMICMXE	MA	Metabolism
DMICMXE	RN	In vitro metabolism of ferroquine (SSR97193) in animal and human hepatic models and antimalarial activity of major metabolites on Plasmodium falciparum. Drug Metab Dispos. 2006 Apr;34(4):667-82.
DMICMXE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16415117

DMICMXE	DI	DMICMXE
DMICMXE	DN	Ferroquine
DMICMXE	MI	DE4LYSA
DMICMXE	MN	Cytochrome P450 3A4 (CYP3A4)
DMICMXE	MT	DME
DMICMXE	MA	Metabolism
DMICMXE	RN	In vitro metabolism of ferroquine (SSR97193) in animal and human hepatic models and antimalarial activity of major metabolites on Plasmodium falciparum. Drug Metab Dispos. 2006 Apr;34(4):667-82.
DMICMXE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16415117

DMICMXE	DI	DMICMXE
DMICMXE	DN	Ferroquine
DMICMXE	MI	TT0OV9N
DMICMXE	MN	Haematin (HA)
DMICMXE	MT	DTT
DMICMXE	MA	Inhibitor
DMICMXE	RN	Insights into the mechanism of action of ferroquine. Relationship between physicochemical properties and antiplasmodial activity. Mol Pharm. 2005 May-Jun;2(3):185-93.
DMICMXE	RU	https://www.ncbi.nlm.nih.gov/pubmed/15934779

DMICMXE	DI	DMICMXE
DMICMXE	DN	Ferroquine
DMICMXE	MI	DEGTFWK
DMICMXE	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMICMXE	MT	DME
DMICMXE	MA	Metabolism
DMICMXE	RN	In vitro metabolism of ferroquine (SSR97193) in animal and human hepatic models and antimalarial activity of major metabolites on Plasmodium falciparum. Drug Metab Dispos. 2006 Apr;34(4):667-82.
DMICMXE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16415117

DMJX2P4	DI	DMJX2P4
DMJX2P4	DN	Fezakinumab
DMJX2P4	MI	TTLDX4N
DMJX2P4	MN	Interleukin-22 (IL22)
DMJX2P4	MT	DTT
DMJX2P4	RN	Emerging Therapies for the Treatment of Psoriasis. Dermatol Ther (Heidelb) 2012 December; 2(1): 16.
DMJX2P4	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3510410/

DM7RYL4	DI	DM7RYL4
DM7RYL4	DN	FG-2216
DM7RYL4	MI	TTJQFBG
DM7RYL4	MN	HIF-prolyl hydroxylase (HPH)
DM7RYL4	MT	DTT
DM7RYL4	MA	Modulator
DM7RYL4	RN	Inhibition of Prolyl Hydroxylases Increases Erythropoietin Production in ESRD
DM7RYL4	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3014028

DMXMC8I	DI	DMXMC8I
DMXMC8I	DN	FGF-1
DMXMC8I	MI	TTRLW2X
DMXMC8I	MN	Fibroblast growth factor receptor 1 (FGFR1)
DMXMC8I	MT	DTT
DMXMC8I	MA	Binder
DMXMC8I	RN	Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer. 2002 Jun 17;86(12):1864-70.
DMXMC8I	RU	https://pubmed.ncbi.nlm.nih.gov/12085177

DMCIGRB	DI	DMCIGRB
DMCIGRB	DN	Fialuridine
DMCIGRB	MI	TTIU7X1
DMCIGRB	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMCIGRB	MT	DTT
DMCIGRB	MA	Modulator
DMCIGRB	RN	Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts. Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3592-7.
DMCIGRB	RU	https://pubmed.ncbi.nlm.nih.gov/8622980

DMG65WH	DI	DMG65WH
DMG65WH	DN	Ficlatuzumab
DMG65WH	MI	TT4V2JM
DMG65WH	MN	Hepatocyte growth factor (HGF)
DMG65WH	MT	DTT
DMG65WH	MA	Inhibitor
DMG65WH	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMG65WH	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMNSYXB	DI	DMNSYXB
DMNSYXB	DN	Filibuvir
DMNSYXB	MI	TTMVBWH
DMNSYXB	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMNSYXB	MT	DTT
DMNSYXB	MA	Inhibitor
DMNSYXB	RN	Clinical pipeline report, company report or official report of Pfizer (2011).
DMNSYXB	RU	http://www.pfizer.com/home/

DMG439E	DI	DMG439E
DMG439E	DN	Fipamezole
DMG439E	MI	TTQ8AFT
DMG439E	MN	Adrenergic receptor Alpha-2 (ADRA2)
DMG439E	MT	DTT
DMG439E	MA	Antagonist
DMG439E	RN	Emerging drugs for Parkinson's disease. Expert Opin Emerg Drugs. 2006 Sep;11(3):403-17.
DMG439E	RU	https://pubmed.ncbi.nlm.nih.gov/16939381

DMW2QYT	DI	DMW2QYT
DMW2QYT	DN	Firategrast
DMW2QYT	MI	TT6S84X
DMW2QYT	MN	Integrin alpha-4/beta-1 (ITGA4/B1)
DMW2QYT	MT	DTT
DMW2QYT	MA	Modulator
DMW2QYT	RN	Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial.Lancet Neurol.2012 Feb;11(2):131-9.
DMW2QYT	RU	https://www.ncbi.nlm.nih.gov/pubmed/22226929

DMJSD5W	DI	DMJSD5W
DMJSD5W	DN	FK-070
DMJSD5W	MI	TT2O84V
DMJSD5W	MN	Thromboxane A2 receptor (TBXA2R)
DMJSD5W	MT	DTT
DMJSD5W	MA	Modulator
DMJSD5W	RN	Pharmacokinetic and pharmacodynamic properties of FK070 (KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers. J Pharm Pharmacol. 1996 Apr;48(4):380-5.
DMJSD5W	RU	https://pubmed.ncbi.nlm.nih.gov/8794987

DMJSD5W	DI	DMJSD5W
DMJSD5W	DN	FK-070
DMJSD5W	MI	TTKNWZ4
DMJSD5W	MN	Thromboxane-A synthase (TBXAS1)
DMJSD5W	MT	DTT
DMJSD5W	MA	Modulator
DMJSD5W	RN	Pharmacokinetic and pharmacodynamic properties of FK070 (KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers. J Pharm Pharmacol. 1996 Apr;48(4):380-5.
DMJSD5W	RU	https://pubmed.ncbi.nlm.nih.gov/8794987

DMEL15U	DI	DMEL15U
DMEL15U	DN	FK-143
DMEL15U	MI	TT2A0DR
DMEL15U	MN	Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A)
DMEL15U	MT	DTT
DMEL15U	MA	Modulator
DMEL15U	RN	FK143, a novel nonsteroidal inhibitor of steroid 5 alpha-reductase: (1) In vitro effects on human and animal prostatic enzymes. J Steroid Biochem Mol Biol. 1995 Apr;52(4):357-63.
DMEL15U	RU	https://www.ncbi.nlm.nih.gov/pubmed/7734404

DML5AE4	DI	DML5AE4
DML5AE4	DN	FK-3311
DML5AE4	MI	TTVKILB
DML5AE4	MN	Prostaglandin G/H synthase 2 (COX-2)
DML5AE4	MT	DTT
DML5AE4	MA	Modulator
DML5AE4	RN	Effects of the COX-2 inhibitor FK3311 on ischemia - reperfusion injury in the rat lung. J Invest Surg. 2007 May-Jun;20(3):175-80.
DML5AE4	RU	https://pubmed.ncbi.nlm.nih.gov/17613692

DMKVXYS	DI	DMKVXYS
DMKVXYS	DN	FK-409
DMKVXYS	MI	TTWNFC2
DMKVXYS	MN	Soluble guanylyl cyclase (GUCY2D)
DMKVXYS	MT	DTT
DMKVXYS	MA	Modulator
DMKVXYS	RN	Vasorelaxant mechanism of the new vasodilator, FK409. Eur J Pharmacol. 1993 Aug 15;246(3):205-12.
DMKVXYS	RU	https://www.ncbi.nlm.nih.gov/pubmed/7901040

DMGROQP	DI	DMGROQP
DMGROQP	DN	FK-505
DMGROQP	MI	TTFH2RS
DMGROQP	MN	FK506-binding protein (FKBP)
DMGROQP	MT	DTT
DMGROQP	MA	Modulator
DMGROQP	RN	Prevention of Cardiac Hypertrophy by Calcineurin Inhibition. Circulation Research. 1999; 84: 623-632.
DMGROQP	RU	http://circres.ahajournals.org/content/84/6/623.full.html

DMY61TJ	DI	DMY61TJ
DMY61TJ	DN	FK-614
DMY61TJ	MI	TTZMAO3
DMY61TJ	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMY61TJ	MT	DTT
DMY61TJ	MA	Agonist
DMY61TJ	RN	FK-614, a selective peroxisome proliferator-activated receptor gamma agonist, improves peripheral glucose utilization while decreasing hepatic insulin extraction in alloxan-induced diabetic dogs. Metabolism. 2005 Sep;54(9):1250-8.
DMY61TJ	RU	https://pubmed.ncbi.nlm.nih.gov/16125538

DMV0MZ3	DI	DMV0MZ3
DMV0MZ3	DN	FK-962
DMV0MZ3	MI	TTOMNR9
DMV0MZ3	MN	Somatostatin receptor (SSTR)
DMV0MZ3	MT	DTT
DMV0MZ3	MA	Modulator
DMV0MZ3	RN	FK960, a novel potential anti-dementia drug, enhances high K(+)-evoked release of somatostatin from rat hippocampal slices. Brain Res. 2001 Feb 16;892(1):111-7.
DMV0MZ3	RU	https://www.ncbi.nlm.nih.gov/pubmed/11172755

DM2O7NM	DI	DM2O7NM
DM2O7NM	DN	FKB01MD
DM2O7NM	MI	TTSQIFT
DM2O7NM	MN	5-HT 1A receptor (HTR1A)
DM2O7NM	MT	DTT
DM2O7NM	MA	Modulator
DM2O7NM	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM2O7NM	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DM2O7NM	DI	DM2O7NM
DM2O7NM	DN	FKB01MD
DM2O7NM	MI	TT6MSOK
DM2O7NM	MN	5-HT 1D receptor (HTR1D)
DM2O7NM	MT	DTT
DM2O7NM	MA	Agonist
DM2O7NM	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM2O7NM	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DM2O7NM	DI	DM2O7NM
DM2O7NM	DN	FKB01MD
DM2O7NM	MI	TTYSN63
DM2O7NM	MN	5-HT 2 receptor (5HT2R)
DM2O7NM	MT	DTT
DM2O7NM	MA	Inhibitor
DM2O7NM	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM2O7NM	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMPXH7N	DI	DMPXH7N
DMPXH7N	DN	FKW00GA
DMPXH7N	MI	TTSQIFT
DMPXH7N	MN	5-HT 1A receptor (HTR1A)
DMPXH7N	MT	DTT
DMPXH7N	MA	Antagonist
DMPXH7N	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPXH7N	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMPXH7N	DI	DMPXH7N
DMPXH7N	DN	FKW00GA
DMPXH7N	MI	TTJQOD7
DMPXH7N	MN	5-HT 2A receptor (HTR2A)
DMPXH7N	MT	DTT
DMPXH7N	MA	Antagonist
DMPXH7N	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPXH7N	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMKSUOI	DI	DMKSUOI
DMKSUOI	DN	Flavopiridol
DMKSUOI	MI	DTI7UX6
DMKSUOI	MN	Breast cancer resistance protein (ABCG2)
DMKSUOI	MT	DTP
DMKSUOI	MA	Substrate
DMKSUOI	RN	The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2. Mol Cancer Ther. 2012 Sep;11(9):2033-44.
DMKSUOI	RU	http://www.ncbi.nlm.nih.gov/pubmed/22778153

DMKSUOI	DI	DMKSUOI
DMKSUOI	DN	Flavopiridol
DMKSUOI	MI	TTMBO1Z
DMKSUOI	MN	Cyclin-dependent kinase (CDK)
DMKSUOI	MT	DTT
DMKSUOI	MA	Inhibitor
DMKSUOI	RN	Pharma & Vaccines. Product Development Pipeline. April 29 2009.
DMKSUOI	RU	http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf

DMKSUOI	DI	DMKSUOI
DMKSUOI	DN	Flavopiridol
DMKSUOI	MI	TT1LVF2
DMKSUOI	MN	Cyclin-dependent kinase 9 (CDK9)
DMKSUOI	MT	DTT
DMKSUOI	MA	Inhibitor
DMKSUOI	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMKSUOI	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMKSUOI	DI	DMKSUOI
DMKSUOI	DN	Flavopiridol
DMKSUOI	MI	TT31JXP
DMKSUOI	MN	Myophosphorylase (PYGM)
DMKSUOI	MT	DTT
DMKSUOI	MA	Inhibitor
DMKSUOI	RN	Pharma & Vaccines. Product Development Pipeline. April 29 2009.
DMKSUOI	RU	http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf

DMKSUOI	DI	DMKSUOI
DMKSUOI	DN	Flavopiridol
DMKSUOI	MI	DT3D8F0
DMKSUOI	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMKSUOI	MT	DTP
DMKSUOI	MA	Substrate
DMKSUOI	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DMKSUOI	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DMKSUOI	DI	DMKSUOI
DMKSUOI	DN	Flavopiridol
DMKSUOI	MI	DEYGVN4
DMKSUOI	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMKSUOI	MT	DME
DMKSUOI	MA	Metabolism
DMKSUOI	RN	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
DMKSUOI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429

DMCN4H6	DI	DMCN4H6
DMCN4H6	DN	Flezelastine
DMCN4H6	MI	TTEWNM1
DMCN4H6	MN	IL-1 synthesis/release (IL-1 synth/rele)
DMCN4H6	MT	DTT
DMCN4H6	MA	Modulator
DMCN4H6	RN	Effects of flezelastine and its enantiomers on LPS-induced IL-1 beta generation in vitro and LPS-induced pyrexia in vivo. Agents Actions. 1994 Mar;41(1-2):99-100.
DMCN4H6	RU	https://pubmed.ncbi.nlm.nih.gov/7915872

DMVR6OM	DI	DMVR6OM
DMVR6OM	DN	Flotetuzumab
DMVR6OM	MI	TTENHJ0
DMVR6OM	MN	Interleukin 3 receptor alpha (IL3RA)
DMVR6OM	MT	DTT
DMVR6OM	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMVR6OM	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMMQ1YU	DI	DMMQ1YU
DMMQ1YU	DN	FLUASTERONE
DMMQ1YU	MI	TT3V81G
DMMQ1YU	MN	Nuclear receptor unspecific (NR)
DMMQ1YU	MT	DTT
DMMQ1YU	MA	Modulator
DMMQ1YU	RN	Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Galpha(i2,3). J Biol Chem. 2002 Jun 14;277(24):21379-88.
DMMQ1YU	RU	https://pubmed.ncbi.nlm.nih.gov/11934890

DME01HT	DI	DME01HT
DME01HT	DN	Fluciclatide F-18
DME01HT	MI	TT69TQN
DME01HT	MN	Integrin alpha-V/beta-3 (ITGAV/B3)
DME01HT	MT	DTT
DME01HT	MA	Modulator
DME01HT	RN	Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy.J Nucl Med.2009 Jan;50(1):116-22.
DME01HT	RU	https://www.ncbi.nlm.nih.gov/pubmed/19091899

DM0G5O6	DI	DM0G5O6
DM0G5O6	DN	Flumatinib
DM0G5O6	MI	TT3PJMV
DM0G5O6	MN	Tyrosine-protein kinase ABL1 (ABL)
DM0G5O6	MT	DTT
DM0G5O6	MA	Inhibitor
DM0G5O6	RN	Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants. Cancer Sci. 2014 Jan;105(1):117-25.
DM0G5O6	RU	https://pubmed.ncbi.nlm.nih.gov/24205792

DMCEUOH	DI	DMCEUOH
DMCEUOH	DN	Fluoropeptide vaccine
DMCEUOH	MI	TTN2JFW
DMCEUOH	MN	T-cell surface glycoprotein CD4 (CD4)
DMCEUOH	MT	DTT
DMCEUOH	RN	A novel peptide-based pan-influenza A vaccine: a double blind, randomised clinical trial of immunogenicity and safety. Vaccine. 2015 Jan 3;33(2):396-402.
DMCEUOH	RU	https://pubmed.ncbi.nlm.nih.gov/24928790

DMCEUOH	DI	DMCEUOH
DMCEUOH	DN	Fluoropeptide vaccine
DMCEUOH	MI	TTMHA6L
DMCEUOH	MN	T-cell surface glycoprotein CD8 (CD8)
DMCEUOH	MT	DTT
DMCEUOH	RN	A novel peptide-based pan-influenza A vaccine: a double blind, randomised clinical trial of immunogenicity and safety. Vaccine. 2015 Jan 3;33(2):396-402.
DMCEUOH	RU	https://pubmed.ncbi.nlm.nih.gov/24928790

DMPBV9D	DI	DMPBV9D
DMPBV9D	DN	Flupirtine
DMPBV9D	MI	TTQ29KF
DMPBV9D	MN	Voltage-gated potassium channel Kv7 (KCNQ)
DMPBV9D	MT	DTT
DMPBV9D	MA	Modulator
DMPBV9D	RN	Treatment with the Kv7 potassium channel activator flupirtine is beneficial in two independent mouse models of pulmonary hypertension. Br J Pharmacol. 2009 August; 157(7): 1241-1249.
DMPBV9D	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2743843/

DMQX5UA	DI	DMQX5UA
DMQX5UA	DN	FLX-787
DMQX5UA	MI	TTFRV98
DMQX5UA	MN	Melanoma antigen gp75 (TYRP1)
DMQX5UA	MT	DTT
DMQX5UA	MA	Activator
DMQX5UA	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQX5UA	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMQX5UA	DI	DMQX5UA
DMQX5UA	DN	FLX-787
DMQX5UA	MI	TT79AOF
DMQX5UA	MN	Transient receptor potential channel (TRP channel)
DMQX5UA	MT	DTT
DMQX5UA	MA	Agonist
DMQX5UA	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQX5UA	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMB9ADM	DI	DMB9ADM
DMB9ADM	DN	FolateImmune
DMB9ADM	MI	TTVC37M
DMB9ADM	MN	Folate receptor alpha (FOLR1)
DMB9ADM	MT	DTT
DMB9ADM	MA	Modulator
DMB9ADM	RN	Responsiveness of the Effective Consumer Scale (EC-17). J Rheumatol. 2009 Sep;36(9):2087-91.
DMB9ADM	RU	https://pubmed.ncbi.nlm.nih.gov/19738218

DMJNO3D	DI	DMJNO3D
DMJNO3D	DN	Follicle stimulating hormone
DMJNO3D	MI	TT13GFV
DMJNO3D	MN	Follicle stimulating hormone (FSHB)
DMJNO3D	MT	DTT
DMJNO3D	MA	Modulator
DMJNO3D	RN	Company report (Glycotope)
DMJNO3D	RU	http://www.glycotope.com/glycotopes-fully-human-and-glycooptimized-recombinant-fsh-gextm-showed-superior-activity-and-excellent-tolerability-in-a-phase-ii-clinical-trial-for-in-vitro-fertilisation

DMUAXS5	DI	DMUAXS5
DMUAXS5	DN	FP-1039
DMUAXS5	MI	TTRLW2X
DMUAXS5	MN	Fibroblast growth factor receptor 1 (FGFR1)
DMUAXS5	MT	DTT
DMUAXS5	MA	Antagonist
DMUAXS5	RN	FGF1-gold nanoparticle conjugates targeting FGFR efficiently decrease cell viability upon NIR irradiation. Int J Nanomedicine. 2012; 7: 5915-5927.
DMUAXS5	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514973/

DMC1F2T	DI	DMC1F2T
DMC1F2T	DN	FP-1097
DMC1F2T	MI	TTZ9SOR
DMC1F2T	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMC1F2T	MT	DTT
DMC1F2T	MA	Antagonist
DMC1F2T	RN	Clinical pipeline report, company report or official report of FemmePharma.
DMC1F2T	RU	http://femmepharma.com/

DMC1F2T	DI	DMC1F2T
DMC1F2T	DN	FP-1097
DMC1F2T	MI	TTYEG6Q
DMC1F2T	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMC1F2T	MT	DTT
DMC1F2T	MA	Antagonist
DMC1F2T	RN	Clinical pipeline report, company report or official report of FemmePharma.
DMC1F2T	RU	http://femmepharma.com/

DMXOTMP	DI	DMXOTMP
DMXOTMP	DN	FPI-01
DMXOTMP	MI	TTZ8UT4
DMXOTMP	MN	Wilms tumor protein (WT1)
DMXOTMP	MT	DTT
DMXOTMP	RN	Clinical pipeline report, company report or official report of Formula Pharmaceuticals.
DMXOTMP	RU	http://www.formulapharma.com/fp1_01/default.asp

DMEL5SV	DI	DMEL5SV
DMEL5SV	DN	FR139317
DMEL5SV	MI	TTKRD0G
DMEL5SV	MN	Endothelin A receptor (EDNRA)
DMEL5SV	MT	DTT
DMEL5SV	MA	Antagonist
DMEL5SV	RN	Reduction of bFGF-induced smooth muscle cell proliferation and endothelin receptor mRNA expression by mevastatin and atorvastatin. Biochem Pharmacol. 2002 Aug 1;64(3):497-505.
DMEL5SV	RU	https://pubmed.ncbi.nlm.nih.gov/12147302

DMEL5SV	DI	DMEL5SV
DMEL5SV	DN	FR139317
DMEL5SV	MI	TTZPO1L
DMEL5SV	MN	Substance-P receptor (TACR1)
DMEL5SV	MT	DTT
DMEL5SV	MA	Antagonist
DMEL5SV	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMEL5SV	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMGO45I	DI	DMGO45I
DMGO45I	DN	FR-146687
DMGO45I	MI	TTTU72V
DMGO45I	MN	Steroid 5-alpha-reductase 1 (SRD5A1)
DMGO45I	MT	DTT
DMGO45I	MA	Inhibitor
DMGO45I	RN	Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. Br J Clin Pharmacol. 2002 Sep;54(3):283-94.
DMGO45I	RU	https://pubmed.ncbi.nlm.nih.gov/12236849

DMFZ084	DI	DMFZ084
DMFZ084	DN	Fresolimumab
DMFZ084	MI	TTO3HT7
DMFZ084	MN	Transforming growth factor beta (TGFB)
DMFZ084	MT	DTT
DMFZ084	MA	Inhibitor
DMFZ084	RN	Focal Irradiation and Systemic TGF Blockade in Metastatic Breast Cancer. Clin Cancer Res. 2018 Jun 1;24(11):2493-2504.
DMFZ084	RU	https://pubmed.ncbi.nlm.nih.gov/29476019

DM9ORUW	DI	DM9ORUW
DM9ORUW	DN	FRM-0962
DM9ORUW	MI	TTE4KHA
DM9ORUW	MN	Amyloid beta A4 protein (APP)
DM9ORUW	MT	DTT
DM9ORUW	MA	Modulator
DM9ORUW	RN	Gamma-secretase. SciBX 7(40); doi:10.1038/scibx.2014.1175. Oct. 16 2014
DM9ORUW	RU	http://www.nature.com/scibx/journal/v7/n40/full/scibx.2014.1175.html

DMZLBAW	DI	DMZLBAW
DMZLBAW	DN	Fucoxanthin
DMZLBAW	MI	TTSHAEB
DMZLBAW	MN	NF-kappa-B inhibitor alpha (NFKBIA)
DMZLBAW	MT	DTT
DMZLBAW	MA	Inhibitor
DMZLBAW	RN	Fucoxanthin inhibits the inflammatory response by suppressing the activation of NF-B and MAPKs in lipopolysaccharide-induced RAW 264.7 macrophages. Eur J Pharmacol. 2010 Dec 15;649(1-3):369-75.
DMZLBAW	RU	https://pubmed.ncbi.nlm.nih.gov/20868674

DMPQFTA	DI	DMPQFTA
DMPQFTA	DN	Fucoxanthin
DMPQFTA	MI	DTUGYRD
DMPQFTA	MN	P-glycoprotein 1 (ABCB1)
DMPQFTA	MT	DTP
DMPQFTA	MA	Substrate
DMPQFTA	RN	Carotenoids reverse multidrug resistance in cancer cells by interfering with ABC-transporters. Phytomedicine. 2012 Aug 15;19(11):977-87.
DMPQFTA	RU	https://doi.org/10.1016/j.phymed.2012.05.010

DMKHNXA	DI	DMKHNXA
DMKHNXA	DN	G100
DMKHNXA	MI	TTISGCA
DMKHNXA	MN	Toll-like receptor 4 (TLR4)
DMKHNXA	MT	DTT
DMKHNXA	MA	Antagonist
DMKHNXA	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMKHNXA	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMQO2IT	DI	DMQO2IT
DMQO2IT	DN	G1T38
DMQO2IT	MI	TT0PG8F
DMQO2IT	MN	Cyclin-dependent kinase 4 (CDK4)
DMQO2IT	MT	DTT
DMQO2IT	MA	Inhibitor
DMQO2IT	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQO2IT	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMQO2IT	DI	DMQO2IT
DMQO2IT	DN	G1T38
DMQO2IT	MI	TTO0FDJ
DMQO2IT	MN	Cyclin-dependent kinase 6 (CDK6)
DMQO2IT	MT	DTT
DMQO2IT	MA	Inhibitor
DMQO2IT	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQO2IT	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMQR9I8	DI	DMQR9I8
DMQR9I8	DN	G-202
DMQR9I8	MI	TT9G4N0
DMQR9I8	MN	Glutamate carboxypeptidase II (GCPII)
DMQR9I8	MT	DTT
DMQR9I8	MA	Inhibitor
DMQR9I8	RN	National Cancer Institute Drug Dictionary (drug id 666090).
DMQR9I8	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=666090

DMJY2TM	DI	DMJY2TM
DMJY2TM	DN	Gabapentin enacarbil
DMJY2TM	MI	DT342ZG
DMJY2TM	MN	Monocarboxylate transporter 1 (SLC16A1)
DMJY2TM	MT	DTP
DMJY2TM	MA	Substrate
DMJY2TM	RN	Overview of the proton-coupled MCT (SLC16A) family of transporters: characterization, function and role in the transport of the drug of abuse gamma-hydroxybutyric acid. AAPS J. 2008 Jun;10(2):311-21.
DMJY2TM	RU	https://doi.org/10.1208/s12248-008-9035-6

DMJY2TM	DI	DMJY2TM
DMJY2TM	DN	Gabapentin enacarbil
DMJY2TM	MI	DTE3TAW
DMJY2TM	MN	Sodium-coupled monocarboxylate transporter 1 (SLC5A8)
DMJY2TM	MT	DTP
DMJY2TM	MA	Substrate
DMJY2TM	RN	Clinical pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported prodrug of gabapentin, with naproxen and cimetidine. Br J Clin Pharmacol. 2010 May;69(5):498-507.
DMJY2TM	RU	http://www.ncbi.nlm.nih.gov/pubmed/20573085

DMJY2TM	DI	DMJY2TM
DMJY2TM	DN	Gabapentin enacarbil
DMJY2TM	MI	TT61XTV
DMJY2TM	MN	Sodium-dependent multivitamin transporter (SLC5A6)
DMJY2TM	MT	DTT
DMJY2TM	MA	Modulator
DMJY2TM	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMJY2TM	RU	https://www.fda.gov/

DMJY2TM	DI	DMJY2TM
DMJY2TM	DN	Gabapentin enacarbil
DMJY2TM	MI	DTD5Y4G
DMJY2TM	MN	Sodium-dependent multivitamin transporter (SLC5A6)
DMJY2TM	MT	DTP
DMJY2TM	MA	Substrate
DMJY2TM	RN	Clinical pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported prodrug of gabapentin, with naproxen and cimetidine. Br J Clin Pharmacol. 2010 May;69(5):498-507.
DMJY2TM	RU	http://www.ncbi.nlm.nih.gov/pubmed/20573085

DMTXCUS	DI	DMTXCUS
DMTXCUS	DN	Galiximab
DMTXCUS	MI	TTFZDNP
DMTXCUS	MN	Activation B7-1 antigen (CD80)
DMTXCUS	MT	DTT
DMTXCUS	RN	Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol. 2005 Jul 1;23(19):4390-8.
DMTXCUS	RU	https://pubmed.ncbi.nlm.nih.gov/15994148

DMXBR27	DI	DMXBR27
DMXBR27	DN	Gallopamil
DMXBR27	MI	TTL69WB
DMXBR27	MN	Angiotensin-converting enzyme (ACE)
DMXBR27	MT	DTT
DMXBR27	MA	Inhibitor
DMXBR27	RN	Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406. J Pharmacol Exp Ther. 2005 Dec;315(3):1306-13.
DMXBR27	RU	https://pubmed.ncbi.nlm.nih.gov/16144980

DMXBR27	DI	DMXBR27
DMXBR27	DN	Gallopamil
DMXBR27	MI	DE4LYSA
DMXBR27	MN	Cytochrome P450 3A4 (CYP3A4)
DMXBR27	MT	DME
DMXBR27	MA	Metabolism
DMXBR27	RN	Identification of human cytochrome P-450 isoforms involved in metabolism of R(+)- and S(-)-gallopamil: utility of in vitro disappearance rate. Drug Metab Dispos. 1999 Nov;27(11):1254-9.
DMXBR27	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10534309

DMXBR27	DI	DMXBR27
DMXBR27	DN	Gallopamil
DMXBR27	MI	TT5TKPM
DMXBR27	MN	Neutral endopeptidase (MME)
DMXBR27	MT	DTT
DMXBR27	MA	Inhibitor
DMXBR27	RN	Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406. J Pharmacol Exp Ther. 2005 Dec;315(3):1306-13.
DMXBR27	RU	https://pubmed.ncbi.nlm.nih.gov/16144980

DMXBR27	DI	DMXBR27
DMXBR27	DN	Gallopamil
DMXBR27	MI	DTUGYRD
DMXBR27	MN	P-glycoprotein 1 (ABCB1)
DMXBR27	MT	DTP
DMXBR27	MA	Substrate
DMXBR27	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMXBR27	RU	https://doi.org/10.1007/s11095-012-0935-x

DMXBR27	DI	DMXBR27
DMXBR27	DN	Gallopamil
DMXBR27	MI	TTE6THL
DMXBR27	MN	Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (ATP2A2)
DMXBR27	MT	DTT
DMXBR27	MA	Inhibitor
DMXBR27	RN	Interaction of D-600 with the transmembrane domain of the sarcoplasmic reticulum Ca(2+)-ATPase. Am J Physiol Cell Physiol. 2000 Jul;279(1):C166-72.
DMXBR27	RU	https://pubmed.ncbi.nlm.nih.gov/10898728

DMXBR27	DI	DMXBR27
DMXBR27	DN	Gallopamil
DMXBR27	MI	TTXHYV6
DMXBR27	MN	Voltage-gated L-type calcium channel (L-CaC)
DMXBR27	MT	DTT
DMXBR27	MA	Blocker
DMXBR27	RN	Role of apoptosis in the kidney after reperfusion. Orv Hetil. 2008 Feb 17;149(7):305-15.
DMXBR27	RU	https://pubmed.ncbi.nlm.nih.gov/18258561

DMAEWS1	DI	DMAEWS1
DMAEWS1	DN	GAM-501
DMAEWS1	MI	TTQA6SX
DMAEWS1	MN	Platelet-derived growth factor B (PDGFB)
DMAEWS1	MT	DTT
DMAEWS1	MA	Modulator
DMAEWS1	RN	Treatment of nonhealing diabetic foot ulcers with a platelet-derived growth factor gene-activated matrix (GAM501): results of a phase 1/2 trial. Wound Repair Regen. 2009 Nov-Dec;17(6):772-9.
DMAEWS1	RU	https://pubmed.ncbi.nlm.nih.gov/19821960

DM2IFJQ	DI	DM2IFJQ
DM2IFJQ	DN	GBL-310
DM2IFJQ	MI	TTVOE6D
DM2IFJQ	MN	Mitogen-activated protein kinase (MAPK)
DM2IFJQ	MT	DTT
DM2IFJQ	MA	Inhibitor
DM2IFJQ	RN	WO patent application no. 2010,0456,51, Methods for analyzing drug response.
DM2IFJQ	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20100422&CC=WO&NR=2010045651A1&KC=A1

DM2VO9T	DI	DM2VO9T
DM2VO9T	DN	GBR 830
DM2VO9T	MI	TTL31H0
DM2VO9T	MN	OX40L receptor (CD134)
DM2VO9T	MT	DTT
DM2VO9T	MA	Antagonist
DM2VO9T	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM2VO9T	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMYS6MW	DI	DMYS6MW
DMYS6MW	DN	GCS-100
DMYS6MW	MI	TTX1OI0
DMYS6MW	MN	Galectin (LGALS)
DMYS6MW	MT	DTT
DMYS6MW	MA	Modulator
DMYS6MW	RN	GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death. Blood. 2010 May 13;115(19):3939-48.
DMYS6MW	RU	https://pubmed.ncbi.nlm.nih.gov/20190189

DMY6WUV	DI	DMY6WUV
DMY6WUV	DN	GDC-0077
DMY6WUV	MI	TTHBTOP
DMY6WUV	MN	PI3-kinase gamma (PIK3CG)
DMY6WUV	MT	DTT
DMY6WUV	MA	Inhibitor
DMY6WUV	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMY6WUV	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMA9SEY	DI	DMA9SEY
DMA9SEY	DN	GDC-0084
DMA9SEY	MI	TTHBTOP
DMA9SEY	MN	PI3-kinase gamma (PIK3CG)
DMA9SEY	MT	DTT
DMA9SEY	MA	Inhibitor
DMA9SEY	RN	Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro Oncol. 2012 July; 14(7): 819-829.
DMA9SEY	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3379803/

DM1YAK6	DI	DM1YAK6
DM1YAK6	DN	GDC0941
DM1YAK6	MI	TTHBTOP
DM1YAK6	MN	PI3-kinase gamma (PIK3CG)
DM1YAK6	MT	DTT
DM1YAK6	MA	Inhibitor
DM1YAK6	RN	Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44.
DM1YAK6	RU	https://pubmed.ncbi.nlm.nih.gov/19644473

DMF3MV1	DI	DMF3MV1
DMF3MV1	DN	GDC-0980/RG7422
DMF3MV1	MI	TTHBTOP
DMF3MV1	MN	PI3-kinase gamma (PIK3CG)
DMF3MV1	MT	DTT
DMF3MV1	MA	Modulator
DMF3MV1	RN	GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther. 2011 Dec;10(12):2426-36.
DMF3MV1	RU	https://pubmed.ncbi.nlm.nih.gov/21998291

DMF3MV1	DI	DMF3MV1
DMF3MV1	DN	GDC-0980/RG7422
DMF3MV1	MI	TTCJG29
DMF3MV1	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMF3MV1	MT	DTT
DMF3MV1	MA	Modulator
DMF3MV1	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
DMF3MV1	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109

DMMQY0O	DI	DMMQY0O
DMMQY0O	DN	GED-0507-34-Levo
DMMQY0O	MI	TTZMAO3
DMMQY0O	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMMQY0O	MT	DTT
DMMQY0O	MA	Agonist
DMMQY0O	RN	PPAR-gamma in ulcerative colitis: a novel target for intervention. Curr Drug Targets. 2013 Nov;14(12):1501-7.
DMMQY0O	RU	https://pubmed.ncbi.nlm.nih.gov/23651165

DMJN09S	DI	DMJN09S
DMJN09S	DN	GEN-1
DMJN09S	MI	TTG68FB
DMJN09S	MN	Interleukine 12 (IL-12)
DMJN09S	MT	DTT
DMJN09S	MA	Replacement
DMJN09S	RN	Clinical pipeline report, company report or official report of Celsion.
DMJN09S	RU	https://celsion.com/gen-1/

DMO9WU8	DI	DMO9WU8
DMO9WU8	DN	Gepirone
DMO9WU8	MI	DTUGYRD
DMO9WU8	MN	P-glycoprotein 1 (ABCB1)
DMO9WU8	MT	DTP
DMO9WU8	MA	Substrate
DMO9WU8	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMO9WU8	RU	https://doi.org/10.1007/s11095-012-0935-x

DMD3RU8	DI	DMD3RU8
DMD3RU8	DN	GFT14
DMD3RU8	MI	TTJ584C
DMD3RU8	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMD3RU8	MT	DTT
DMD3RU8	MA	Agonist
DMD3RU8	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024296)
DMD3RU8	RU	http://adisinsight.springer.com/drugs/800024296

DMTY4PG	DI	DMTY4PG
DMTY4PG	DN	GI-4000
DMTY4PG	MI	TTW2R9X
DMTY4PG	MN	GTPase NRas (NRAS)
DMTY4PG	MT	DTT
DMTY4PG	RN	Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation. Clin Lung Cancer. 2014 Nov;15(6):405-10.
DMTY4PG	RU	https://pubmed.ncbi.nlm.nih.gov/25044103

DMQ0XZE	DI	DMQ0XZE
DMQ0XZE	DN	GI-4000 + gemcitabine
DMQ0XZE	MI	TTRHMTC
DMQ0XZE	MN	Mutated KRAS (mKRAS)
DMQ0XZE	MT	DTT
DMQ0XZE	MA	Modulator
DMQ0XZE	RN	Clinical pipeline report, company report or official report of GlobeImmune.
DMQ0XZE	RU	https://www.globeimmune.com/cancer/gi-4000/

DM72O6F	DI	DM72O6F
DM72O6F	DN	GI-6207
DM72O6F	MI	TTY6DTE
DM72O6F	MN	Carcinoembryonic antigen CEA (CD66e)
DM72O6F	MT	DTT
DM72O6F	MA	Modulator
DM72O6F	RN	Clinical pipeline report, company report or official report of GlobeImmune.
DM72O6F	RU	https://www.globeimmune.com/cancer/gi-6207/

DMOMS7R	DI	DMOMS7R
DMOMS7R	DN	GI-6301
DMOMS7R	MI	TTBXAHS
DMOMS7R	MN	T-box transcription factor T (TBXT)
DMOMS7R	MT	DTT
DMOMS7R	RN	Clinical pipeline report, company report or official report of GlobeImmune.
DMOMS7R	RU	https://www.globeimmune.com/cancer/gi-6301/

DMSKMET	DI	DMSKMET
DMSKMET	DN	Gimatecan
DMSKMET	MI	DTI7UX6
DMSKMET	MN	Breast cancer resistance protein (ABCG2)
DMSKMET	MT	DTP
DMSKMET	MA	Substrate
DMSKMET	RN	Pharmacogenomic importance of ABCG2. Pharmacogenomics. 2008 Aug;9(8):1005-9.
DMSKMET	RU	https://doi.org/10.2217/14622416.9.8.1005

DMSKMET	DI	DMSKMET
DMSKMET	DN	Gimatecan
DMSKMET	MI	TTGTQHC
DMSKMET	MN	DNA topoisomerase I (TOP1)
DMSKMET	MT	DTT
DMSKMET	MA	Inhibitor
DMSKMET	RN	Gimatecan and other camptothecin derivatives poison Leishmania DNA-topoisomerase IB leading to a strong leishmanicidal effect. Biochem Pharmacol. 2013 May 15;85(10):1433-40.
DMSKMET	RU	https://pubmed.ncbi.nlm.nih.gov/23466420

DMSKMET	DI	DMSKMET
DMSKMET	DN	Gimatecan
DMSKMET	MI	DT3D8F0
DMSKMET	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMSKMET	MT	DTP
DMSKMET	MA	Substrate
DMSKMET	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DMSKMET	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DMG3O2Z	DI	DMG3O2Z
DMG3O2Z	DN	Girentuximab I-124
DMG3O2Z	MI	TT2LVK8
DMG3O2Z	MN	Carbonic anhydrase IX (CA-IX)
DMG3O2Z	MT	DTT
DMG3O2Z	MA	Enhancer
DMG3O2Z	RN	Potential role of (124)I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer. Biologics. 2012;6:395-407.
DMG3O2Z	RU	https://pubmed.ncbi.nlm.nih.gov/23204838

DMLFSMX	DI	DMLFSMX
DMLFSMX	DN	GK1-399
DMLFSMX	MI	TTDLNGZ
DMLFSMX	MN	Glucokinase (GCK)
DMLFSMX	MT	DTT
DMLFSMX	MA	Inhibitor
DMLFSMX	RN	Clinical pipeline report, company report or official report of vTv Therapeutics, NCT02405260.
DMLFSMX	RU	http://vtvtherapeutics.com/pipeline/ttp399

DMOVB3Y	DI	DMOVB3Y
DMOVB3Y	DN	GKT-137831
DMOVB3Y	MI	TTFQVUT
DMOVB3Y	MN	NADPH oxidase (NOX)
DMOVB3Y	MT	DTT
DMOVB3Y	MA	Modulator
DMOVB3Y	RN	Nicotinamide Adenine Dinucleotide Phosphate Oxidase (NOX) in Experimental Liver Fibrosis: GKT137831 as a Novel Potential Therapeutic Agent. Hepatology. 2012 December; 56(6): 2316-2327.
DMOVB3Y	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493679/

DMOVB3Y	DI	DMOVB3Y
DMOVB3Y	DN	GKT-137831
DMOVB3Y	MI	TTQRBSJ
DMOVB3Y	MN	NADPH oxidase 4 (NOX4)
DMOVB3Y	MT	DTT
DMOVB3Y	MA	Modulator
DMOVB3Y	RN	Nicotinamide Adenine Dinucleotide Phosphate Oxidase (NOX) in Experimental Liver Fibrosis: GKT137831 as a Novel Potential Therapeutic Agent. Hepatology. 2012 December; 56(6): 2316-2327.
DMOVB3Y	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493679/

DM17OZM	DI	DM17OZM
DM17OZM	DN	GL-0817
DM17OZM	MI	TTWSKHD
DM17OZM	MN	Melanoma-associated antigen 3 (MAGEA3)
DM17OZM	MT	DTT
DM17OZM	MA	Immunomodulator
DM17OZM	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM17OZM	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMSVBND	DI	DMSVBND
DMSVBND	DN	Glecaprevir
DMSVBND	MI	DTUGYRD
DMSVBND	MN	P-glycoprotein 1 (ABCB1)
DMSVBND	MT	DTP
DMSVBND	MA	Substrate
DMSVBND	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DMSVBND	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DMPHCDL	DI	DMPHCDL
DMPHCDL	DN	GLPG-0634
DMPHCDL	MI	TT6DM01
DMPHCDL	MN	Janus kinase 1 (JAK-1)
DMPHCDL	MT	DTT
DMPHCDL	MA	Modulator
DMPHCDL	RN	Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.
DMPHCDL	RU	https://pubmed.ncbi.nlm.nih.gov/24818516

DMXO4T8	DI	DMXO4T8
DMXO4T8	DN	GLPG0974
DMXO4T8	MI	TT0FYAN
DMXO4T8	MN	Free fatty acid receptor 2 (FFAR2)
DMXO4T8	MT	DTT
DMXO4T8	MA	Antagonist
DMXO4T8	RN	Discovery and optimization of an azetidine chemical series as a free fatty acid receptor 2 (FFA2) antagonist: from hit to clinic. J Med Chem. 2014 Dec 11;57(23):10044-57.
DMXO4T8	RU	https://pubmed.ncbi.nlm.nih.gov/25380412

DMOCRYB	DI	DMOCRYB
DMOCRYB	DN	GLPG-1837
DMOCRYB	MI	TTRLZHP
DMOCRYB	MN	cAMP-dependent chloride channel (CFTR)
DMOCRYB	MT	DTT
DMOCRYB	MA	Enhancer
DMOCRYB	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMOCRYB	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMJ85FS	DI	DMJ85FS
DMJ85FS	DN	Glutathione-S-S-glutathione
DMJ85FS	MI	DTSYQGK
DMJ85FS	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMJ85FS	MT	DTP
DMJ85FS	MA	Substrate
DMJ85FS	RN	Anthracyclines modulate multidrug resistance protein (MRP) mediated organic anion transport. Biochim Biophys Acta. 1997 May 22;1326(1):12-22.
DMJ85FS	RU	http://www.ncbi.nlm.nih.gov/pubmed/9188796

DMJ85FS	DI	DMJ85FS
DMJ85FS	DN	Glutathione-S-S-glutathione
DMJ85FS	MI	DTFI42L
DMJ85FS	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMJ85FS	MT	DTP
DMJ85FS	MA	Substrate
DMJ85FS	RN	Purification of the human apical conjugate export pump MRP2 reconstitution and functional characterization as substrate-stimulated ATPase. Eur J Biochem. 1999 Oct 1;265(1):281-9.
DMJ85FS	RU	https://doi.org/10.1046/j.1432-1327.1999.00735.x

DMJ85FS	DI	DMJ85FS
DMJ85FS	DN	Glutathione-S-S-glutathione
DMJ85FS	MI	DTQ3ZHF
DMJ85FS	MN	Multidrug resistance-associated protein 3 (ABCC3)
DMJ85FS	MT	DTP
DMJ85FS	MA	Substrate
DMJ85FS	RN	MRP2 and 3 in health and disease. Cancer Lett. 2006 Mar 8;234(1):51-61.
DMJ85FS	RU	https://doi.org/10.1016/j.canlet.2005.05.051

DML6PO5	DI	DML6PO5
DML6PO5	DN	GM-CSF cancer vaccine
DML6PO5	MI	TT6MP2Z
DML6PO5	MN	GMCSFR-alpha (CSF2RA)
DML6PO5	MT	DTT
DML6PO5	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1707).
DML6PO5	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1707

DMLWKZ7	DI	DMLWKZ7
DMLWKZ7	DN	GO-203-2c
DMLWKZ7	MI	TTBHFYQ
DMLWKZ7	MN	Mucin-1 (MUC1)
DMLWKZ7	MT	DTT
DMLWKZ7	MA	Inhibitor
DMLWKZ7	RN	Clinical pipeline report, company report or official report of Genus Oncology.
DMLWKZ7	RU	http://www.genusoncology.com/phase-1-trial-GO-203-2c.php

DMKZN3A	DI	DMKZN3A
DMKZN3A	DN	Golotimod
DMKZN3A	MI	TTH8FZW
DMKZN3A	MN	Signal transducer and activator of transcription 3 (STAT3)
DMKZN3A	MT	DTT
DMKZN3A	MA	Inhibitor
DMKZN3A	RN	National Cancer Institute Drug Dictionary (drug id 617379).
DMKZN3A	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=617379

DMYWA0Z	DI	DMYWA0Z
DMYWA0Z	DN	GORALATIDE
DMYWA0Z	MI	TTLK6DR
DMYWA0Z	MN	Cyclin D1 synthesis (CCND1 synthesis)
DMYWA0Z	MT	DTT
DMYWA0Z	MA	Modulator
DMYWA0Z	RN	Reduction of heat-induced haemotoxicity in a hyperthermic purging protocol of murine acute myeloid leukaemic stem cells by AcSDKP. Br J Haematol. 1997 Dec;99(3):692-8.
DMYWA0Z	RU	https://pubmed.ncbi.nlm.nih.gov/9401086

DMJWE3I	DI	DMJWE3I
DMJWE3I	DN	Gossypol
DMJWE3I	MI	TTJGNVC
DMJWE3I	MN	Apoptosis regulator Bcl-2 (BCL-2)
DMJWE3I	MT	DTT
DMJWE3I	MA	Regulator
DMJWE3I	RN	Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40.
DMJWE3I	RU	https://pubmed.ncbi.nlm.nih.gov/16138106

DM38ARE	DI	DM38ARE
DM38ARE	DN	Gp100:209-217(210M) peptide vaccine
DM38ARE	MI	TT8MK59
DM38ARE	MN	Melanocytes lineage-specific antigen GP100 (PMEL)
DM38ARE	MT	DTT
DM38ARE	RN	National Cancer Institute Drug Dictionary (drug id 476335).
DM38ARE	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=476335

DMOHAS2	DI	DMOHAS2
DMOHAS2	DN	GPC-3298306
DMOHAS2	MI	TTJTSX4
DMOHAS2	MN	Glypican-3 (GPC3)
DMOHAS2	MT	DTT
DMOHAS2	RN	Usefulness of a novel oncofetal antigen, glypican-3, for diagnosis and immunotherapy of hepatocellular carcinoma. Nihon Rinsho Meneki Gakkai Kaishi. 2008 Oct;31(5):383-91.
DMOHAS2	RU	https://pubmed.ncbi.nlm.nih.gov/18974622

DMOQ7YI	DI	DMOQ7YI
DMOQ7YI	DN	GPD-1116
DMOQ7YI	MI	TTZ97H5
DMOQ7YI	MN	Phosphodiesterase 4A (PDE4A)
DMOQ7YI	MT	DTT
DMOQ7YI	MA	Inhibitor
DMOQ7YI	RN	Phosphodiesterase 4 inhibitor GPD-1116 markedly attenuates the development of cigarette smoke-induced emphysema in senescence-accelerated mice P1 s... Am J Physiol Lung Cell Mol Physiol. 2008 Feb;294(2):L196-204.
DMOQ7YI	RU	https://pubmed.ncbi.nlm.nih.gov/17993591

DMOQ7YI	DI	DMOQ7YI
DMOQ7YI	DN	GPD-1116
DMOQ7YI	MI	TTVIAT9
DMOQ7YI	MN	Phosphodiesterase 4B (PDE4B)
DMOQ7YI	MT	DTT
DMOQ7YI	MA	Inhibitor
DMOQ7YI	RN	Phosphodiesterase 4 inhibitor GPD-1116 markedly attenuates the development of cigarette smoke-induced emphysema in senescence-accelerated mice P1 s... Am J Physiol Lung Cell Mol Physiol. 2008 Feb;294(2):L196-204.
DMOQ7YI	RU	https://pubmed.ncbi.nlm.nih.gov/17993591

DMOQ7YI	DI	DMOQ7YI
DMOQ7YI	DN	GPD-1116
DMOQ7YI	MI	TTSKMI8
DMOQ7YI	MN	Phosphodiesterase 4D (PDE4D)
DMOQ7YI	MT	DTT
DMOQ7YI	MA	Inhibitor
DMOQ7YI	RN	Phosphodiesterase 4 inhibitor GPD-1116 markedly attenuates the development of cigarette smoke-induced emphysema in senescence-accelerated mice P1 s... Am J Physiol Lung Cell Mol Physiol. 2008 Feb;294(2):L196-204.
DMOQ7YI	RU	https://pubmed.ncbi.nlm.nih.gov/17993591

DM64ZYM	DI	DM64ZYM
DM64ZYM	DN	GPI-1485
DM64ZYM	MI	TTMW94E
DM64ZYM	MN	FK506-binding protein 1A (FKBP1A)
DM64ZYM	MT	DTT
DM64ZYM	MA	Binder
DM64ZYM	RN	Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42.
DM64ZYM	RU	https://pubmed.ncbi.nlm.nih.gov/18991661

DMHNIGB	DI	DMHNIGB
DMHNIGB	DN	GPX-150D
DMHNIGB	MI	TT0IHXV
DMHNIGB	MN	DNA topoisomerase II (TOP2)
DMHNIGB	MT	DTT
DMHNIGB	MA	Modulator
DMHNIGB	RN	Company report (Gem pharmaceuticals)
DMHNIGB	RU	http://www.gempharmaceuticals.com/targeted-therapy-approach.shtml

DMMZQ7V	DI	DMMZQ7V
DMMZQ7V	DN	Granotapide
DMMZQ7V	MI	TTUS1RD
DMMZQ7V	MN	Microsomal triglyceride transfer protein (MTTP)
DMMZQ7V	MT	DTT
DMMZQ7V	MA	Inhibitor
DMMZQ7V	RN	JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, suppresses food intake and gastric emptying with the elevation of plasma peptide YY and glucagon-like peptide-1 in a dietary fat-dependent manner. J Pharmacol Exp Ther. 2011 Mar;336(3):850-6.
DMMZQ7V	RU	https://pubmed.ncbi.nlm.nih.gov/21139060

DMWXJSZ	DI	DMWXJSZ
DMWXJSZ	DN	GRC-15300
DMWXJSZ	MI	TTMI6F5
DMWXJSZ	MN	Transient receptor potential cation channel V1 (TRPV1)
DMWXJSZ	MT	DTT
DMWXJSZ	MA	Antagonist
DMWXJSZ	RN	The discovery and development of analgesics: new mechanisms, new modalities. J Clin Invest. 2010 November 1; 120(11): 3753-3759.
DMWXJSZ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2966322/

DM9QF65	DI	DM9QF65
DM9QF65	DN	GR-MD-02
DM9QF65	MI	TTFPQV7
DM9QF65	MN	Galectin-3 (LGALS3)
DM9QF65	MT	DTT
DM9QF65	MA	Inhibitor
DM9QF65	RN	Therapy of experimental NASH and fibrosis with galectin inhibitors. PLoS One. 2013 Dec 18;8(12):e83481.
DM9QF65	RU	https://pubmed.ncbi.nlm.nih.gov/24367597

DMAHOEP	DI	DMAHOEP
DMAHOEP	DN	GRNVAC1
DMAHOEP	MI	TTUJFD0
DMAHOEP	MN	Telomerase reverse transcriptase (TERT)
DMAHOEP	MT	DTT
DMAHOEP	RN	Targeting telomerase-expressing cancer cells. J Cell Mol Med. 2011 Jul;15(7):1433-42.
DMAHOEP	RU	https://pubmed.ncbi.nlm.nih.gov/21332640

DMHQV6R	DI	DMHQV6R
DMHQV6R	DN	GS-4059
DMHQV6R	MI	TTGM6VW
DMHQV6R	MN	Tyrosine-protein kinase BTK (ATK)
DMHQV6R	MT	DTT
DMHQV6R	MA	Inhibitor
DMHQV6R	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMHQV6R	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMBDFN7	DI	DMBDFN7
DMBDFN7	DN	GS-4977
DMBDFN7	MI	TTOQCD8
DMBDFN7	MN	Apoptosis signal-regulating kinase 1 (MAP3K5)
DMBDFN7	MT	DTT
DMBDFN7	MA	Inhibitor
DMBDFN7	RN	Design of a phase 2 clinical trial of an ASK1 inhibitor, GS-4997, in patients with diabetic kidney disease. Nephron. 2015;129(1):29-33.
DMBDFN7	RU	https://pubmed.ncbi.nlm.nih.gov/25531162

DMNABMU	DI	DMNABMU
DMNABMU	DN	GS-4997
DMNABMU	MI	TTOQCD8
DMNABMU	MN	Apoptosis signal-regulating kinase 1 (MAP3K5)
DMNABMU	MT	DTT
DMNABMU	MA	Inhibitor
DMNABMU	RN	Design of a phase 2 clinical trial of an ASK1 inhibitor, GS-4997, in patients with diabetic kidney disease. Nephron. 2015;129(1):29-33.
DMNABMU	RU	https://pubmed.ncbi.nlm.nih.gov/25531162

DMDAHL6	DI	DMDAHL6
DMDAHL6	DN	GS-5806
DMDAHL6	MI	TT57ID8
DMDAHL6	MN	Respiratory syncytial virus protein F (RSV F)
DMDAHL6	MT	DTT
DMDAHL6	MA	Inhibitor
DMDAHL6	RN	Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study. J Med Chem. 2015 Feb 26;58(4):1630-43.
DMDAHL6	RU	https://pubmed.ncbi.nlm.nih.gov/25574686

DMSL3DX	DI	DMSL3DX
DMSL3DX	DN	GS-5885
DMSL3DX	MI	TTCJ2X8
DMSL3DX	MN	Hepatitis C virus Non-structural 5A (HCV NS5A)
DMSL3DX	MT	DTT
DMSL3DX	MA	Modulator
DMSL3DX	RN	Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J Med Chem. 2014 Mar 13;57(5):2033-46.
DMSL3DX	RU	https://pubmed.ncbi.nlm.nih.gov/24320933

DMSL3DX	DI	DMSL3DX
DMSL3DX	DN	GS-5885
DMSL3DX	MI	DTUGYRD
DMSL3DX	MN	P-glycoprotein 1 (ABCB1)
DMSL3DX	MT	DTP
DMSL3DX	MA	Substrate
DMSL3DX	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DMSL3DX	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DMV7ZU0	DI	DMV7ZU0
DMV7ZU0	DN	GS-6624
DMV7ZU0	MI	TTFSUHX
DMV7ZU0	MN	Lysyl oxidase homolog 2 (LOXL2)
DMV7ZU0	MT	DTT
DMV7ZU0	RN	National Cancer Institute Drug Dictionary (drug id 681814).
DMV7ZU0	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=681814

DMCZH5B	DI	DMCZH5B
DMCZH5B	DN	GS-9256
DMCZH5B	MI	TT5FNQT
DMCZH5B	MN	Human immunodeficiency virus Protease (HIV PR)
DMCZH5B	MT	DTT
DMCZH5B	MA	Inhibitor
DMCZH5B	RN	Clinical pipeline report, company report or official report of Gilead (2011).
DMCZH5B	RU	http://www.gilead.com/

DMF910Q	DI	DMF910Q
DMF910Q	DN	GS-9451
DMF910Q	MI	TTWXB3E
DMF910Q	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DMF910Q	MT	DTT
DMF910Q	MA	Modulator
DMF910Q	RN	Characterization of Resistance to the Protease Inhibitor GS-9451 in Hepatitis C Virus-Infected Patients. Antimicrob Agents Chemother. 2012 October; 56(10): 5289-5295.
DMF910Q	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3457362/

DMG5C8D	DI	DMG5C8D
DMG5C8D	DN	GS-9620
DMG5C8D	MI	DE4LYSA
DMG5C8D	MN	Cytochrome P450 3A4 (CYP3A4)
DMG5C8D	MT	DME
DMG5C8D	MA	Metabolism
DMG5C8D	RN	The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection. J Hepatol. 2015 Aug;63(2):320-8.
DMG5C8D	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25733157

DMG5C8D	DI	DMG5C8D
DMG5C8D	DN	GS-9620
DMG5C8D	MI	TTRJ1K4
DMG5C8D	MN	Toll-like receptor 7 (TLR7)
DMG5C8D	MT	DTT
DMG5C8D	MA	Modulator
DMG5C8D	RN	Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel Toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses. J Pharmacol Exp Ther. 2014 Jan;348(1):96-105.
DMG5C8D	RU	https://pubmed.ncbi.nlm.nih.gov/24133297

DMYU6P5	DI	DMYU6P5
DMYU6P5	DN	GS-9857
DMYU6P5	MI	TTWXB3E
DMYU6P5	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DMYU6P5	MT	DTT
DMYU6P5	MA	Inhibitor
DMYU6P5	RN	Clinical pipeline report, company report or official report of Gilead.
DMYU6P5	RU	http://www.gilead.com/research/pipeline

DM9Q2B6	DI	DM9Q2B6
DM9Q2B6	DN	GS-9876
DM9Q2B6	MI	TTOU65C
DM9Q2B6	MN	Tyrosine-protein kinase SYK (SYK)
DM9Q2B6	MT	DTT
DM9Q2B6	MA	Inhibitor
DM9Q2B6	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9Q2B6	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMKWCTR	DI	DMKWCTR
DMKWCTR	DN	GS-9973
DMKWCTR	MI	TTOU65C
DMKWCTR	MN	Tyrosine-protein kinase SYK (SYK)
DMKWCTR	MT	DTT
DMKWCTR	MA	Modulator
DMKWCTR	RN	An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43.
DMKWCTR	RU	https://pubmed.ncbi.nlm.nih.gov/25696919

DMQGPLO	DI	DMQGPLO
DMQGPLO	DN	GSK-1070806
DMQGPLO	MI	TTRICUF
DMQGPLO	MN	Interleukin-18 (IL18)
DMQGPLO	MT	DTT
DMQGPLO	RN	Targeting the IL-1 family members in skin inflammation. Curr Opin Investig Drugs. 2010 November; 11(11): 1211-1220.
DMQGPLO	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059231/

DMDMXKQ	DI	DMDMXKQ
DMDMXKQ	DN	GSK1292263
DMDMXKQ	MI	TT7QNVC
DMDMXKQ	MN	Glucose-dependent insulinotropic receptor (GPR119)
DMDMXKQ	MT	DTT
DMDMXKQ	MA	Modulator
DMDMXKQ	RN	Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies.PLoS One.2014 Apr 3;9(4):e92494.
DMDMXKQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/24699248

DM1EPMF	DI	DM1EPMF
DM1EPMF	DN	GSK1322322
DM1EPMF	MI	TTICO5G
DM1EPMF	MN	Staphylococcus Peptide deformylase (Stap-coc def)
DM1EPMF	MT	DTT
DM1EPMF	MA	Modulator
DM1EPMF	RN	Peptide deformylase: a new target in antibacterial, antimalarial and anticancer drug discovery. Curr Med Chem. 2015;22(2):214-36.
DM1EPMF	RU	https://pubmed.ncbi.nlm.nih.gov/25174923

DMA6RBF	DI	DMA6RBF
DMA6RBF	DN	GSK1325756
DMA6RBF	MI	TT30C9G
DMA6RBF	MN	C-X-C chemokine receptor type 2 (CXCR2)
DMA6RBF	MT	DTT
DMA6RBF	MA	Modulator
DMA6RBF	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMA6RBF	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM6HBGN	DI	DM6HBGN
DM6HBGN	DN	GSK-1399686
DM6HBGN	MI	TTUWYEA
DM6HBGN	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DM6HBGN	MT	DTT
DM6HBGN	MA	Modulator
DM6HBGN	RN	Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Therap Adv Gastroenterol. 2015 March; 8(2): 66-82.
DM6HBGN	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4314302/

DMZHB37	DI	DMZHB37
DMZHB37	DN	GSK2110183
DMZHB37	MI	TTWTSCV
DMZHB37	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DMZHB37	MT	DTT
DMZHB37	MA	Modulator
DMZHB37	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479).
DMZHB37	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1479

DMSHE70	DI	DMSHE70
DMSHE70	DN	GSK2141795
DMSHE70	MI	TTAZ05C
DMSHE70	MN	RAC-gamma serine/threonine-protein kinase (AKT3)
DMSHE70	MT	DTT
DMSHE70	MA	Modulator
DMSHE70	RN	Inhibiting the akt pathway in cancer treatment: three leading candidates. P T. 2011 Apr;36(4):225-7.
DMSHE70	RU	https://pubmed.ncbi.nlm.nih.gov/21572779

DMBWPZJ	DI	DMBWPZJ
DMBWPZJ	DN	GSK2245035
DMBWPZJ	MI	TTRJ1K4
DMBWPZJ	MN	Toll-like receptor 7 (TLR7)
DMBWPZJ	MT	DTT
DMBWPZJ	MA	Modulator
DMBWPZJ	RN	Early clinical evaluation of the intranasal TLR7 agonist GSK2245035: Use of translational biomarkers to guide dosing and confirm target engagement. Clin Pharmacol Ther. 2015 Oct;98(4):369-80.
DMBWPZJ	RU	https://pubmed.ncbi.nlm.nih.gov/26044169

DMG7YQL	DI	DMG7YQL
DMG7YQL	DN	GSK2245840
DMG7YQL	MI	TTUF2HO
DMG7YQL	MN	NAD-dependent deacetylase sirtuin-1 (SIRT1)
DMG7YQL	MT	DTT
DMG7YQL	MA	Modulator
DMG7YQL	RN	Sirtuin 1 activator SRT2104 protects Huntington's disease mice. Ann Clin Transl Neurol. 2014 Dec;1(12):1047-52.
DMG7YQL	RU	https://pubmed.ncbi.nlm.nih.gov/25574479

DMLFI7Q	DI	DMLFI7Q
DMLFI7Q	DN	GSK-2251052
DMLFI7Q	MI	TT37GL6
DMLFI7Q	MN	Staphylococcus Leucyl-tRNA synthetase (Stap-coc leuS)
DMLFI7Q	MT	DTT
DMLFI7Q	MA	Inhibitor
DMLFI7Q	RN	Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections. Antimicrob Agents Chemother. 2015 Jan;59(1):289-98.
DMLFI7Q	RU	https://pubmed.ncbi.nlm.nih.gov/25348524

DMIN0SV	DI	DMIN0SV
DMIN0SV	DN	GSK2269557
DMIN0SV	MI	TTWELHI
DMIN0SV	MN	Stress-activated protein kinase (p38)
DMIN0SV	MT	DTT
DMIN0SV	MA	Inhibitor
DMIN0SV	RN	Evaluation of WO2012032067 and WO2012055846: two selective PI3Kdelta inhibitors, which is GSK-2269557. Expert Opin Ther Pat. 2012 Aug;22(8):965-70.
DMIN0SV	RU	https://pubmed.ncbi.nlm.nih.gov/22765651

DM4BTH8	DI	DM4BTH8
DM4BTH8	DN	GSK2330672
DM4BTH8	MI	TTPI1M5
DM4BTH8	MN	Ileal sodium/bile acid cotransporter (SLC10A2)
DM4BTH8	MT	DTT
DM4BTH8	MA	Modulator
DM4BTH8	RN	Discovery of a highly potent, nonabsorbable apical sodium-dependent bile acid transporter inhibitor (GSK2330672) for treatment of type 2 diabetes. J Med Chem. 2013 Jun 27;56(12):5094-114.
DM4BTH8	RU	https://pubmed.ncbi.nlm.nih.gov/23678871

DMB0CXT	DI	DMB0CXT
DMB0CXT	DN	GSK2330811
DMB0CXT	MI	TTIVXSE
DMB0CXT	MN	Oncostatin-M (OSM)
DMB0CXT	MT	DTT
DMB0CXT	MA	Inhibitor
DMB0CXT	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMB0CXT	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMXUCG3	DI	DMXUCG3
DMXUCG3	DN	GSK233705
DMXUCG3	MI	TTH18TF
DMXUCG3	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMXUCG3	MT	DTT
DMXUCG3	MA	Antagonist
DMXUCG3	RN	Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94.
DMXUCG3	RU	https://pubmed.ncbi.nlm.nih.gov/19265487

DMRA3T2	DI	DMRA3T2
DMRA3T2	DN	GSK2339345
DMRA3T2	MI	TTRK8B9
DMRA3T2	MN	Sodium channel unspecific (NaC)
DMRA3T2	MT	DTT
DMRA3T2	MA	Modulator
DMRA3T2	RN	ClinicalTrials.gov (NCT01494636) The Safety, Tolerability, PK and PD of GSK2339345 in Healthy Subjects. U.S. National Institutes of Health.
DMRA3T2	RU	https://clinicaltrials.gov/ct2/show/NCT01494636

DMBJMZC	DI	DMBJMZC
DMBJMZC	DN	GSK239512
DMBJMZC	MI	TT9JNIC
DMBJMZC	MN	Histamine H3 receptor (H3R)
DMBJMZC	MT	DTT
DMBJMZC	MA	Antagonist
DMBJMZC	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMBJMZC	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMFAU3Z	DI	DMFAU3Z
DMFAU3Z	DN	GSK249320
DMFAU3Z	MI	TT9XFON
DMFAU3Z	MN	Myelin-associated glycoprotein (MAG)
DMFAU3Z	MT	DTT
DMFAU3Z	RN	First-time-in-human study with GSK249320, a myelin-associated glycoprotein inhibitor, in healthy volunteers. Clin Pharmacol Ther. 2013 Feb;93(2):163-9.
DMFAU3Z	RU	https://pubmed.ncbi.nlm.nih.gov/23267856

DMMAIY2	DI	DMMAIY2
DMMAIY2	DN	GSK-256073
DMMAIY2	MI	TTWNV8U
DMMAIY2	MN	Nicotinic acid receptor (HCAR2)
DMMAIY2	MT	DTT
DMMAIY2	MA	Agonist
DMMAIY2	RN	GSK256073, a selective agonist of G-protein coupled receptor 109A (GPR109A) reduces serum glucose in subjects with type 2 diabetes mellitus. Diabetes Obes Metab. 2013 Nov;15(11):1013-21.
DMMAIY2	RU	https://pubmed.ncbi.nlm.nih.gov/23701262

DMA2IXQ	DI	DMA2IXQ
DMA2IXQ	DN	GSK2586184
DMA2IXQ	MI	TT6DM01
DMA2IXQ	MN	Janus kinase 1 (JAK-1)
DMA2IXQ	MT	DTT
DMA2IXQ	MA	Modulator
DMA2IXQ	RN	DRESS syndrome and reversible liver function abnormalities in patients with systemic lupus erythematosus treated with the highly selective JAK-1 inhibitor GSK2586184. Lupus. 2015 May;24(6):648-9.
DMA2IXQ	RU	https://pubmed.ncbi.nlm.nih.gov/25724932

DMU5EVR	DI	DMU5EVR
DMU5EVR	DN	GSK2586881
DMU5EVR	MI	TTUI5H7
DMU5EVR	MN	Angiotensin-converting enzyme 2 (ACE2)
DMU5EVR	MT	DTT
DMU5EVR	MA	Modulator
DMU5EVR	RN	New Developments in the Pharmacological Treatment of Hypertension: Dead-End or a Glimmer at the Horizon . Curr Hypertens Rep. 2015; 17(6): 42.
DMU5EVR	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412646/

DM7V96W	DI	DM7V96W
DM7V96W	DN	GSK2798745
DM7V96W	MI	TTKP2SU
DM7V96W	MN	Transient receptor potential cation channel V4 (TRPV4)
DM7V96W	MT	DTT
DM7V96W	MA	Antagonist
DM7V96W	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DM7V96W	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMCIGRW	DI	DMCIGRW
DMCIGRW	DN	GSK2838232
DMCIGRW	MI	TT5TOX7
DMCIGRW	MN	Human immunodeficiency virus Maturation (HIV Mat)
DMCIGRW	MT	DTT
DMCIGRW	MA	Modulator
DMCIGRW	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037762)
DMCIGRW	RU	http://adisinsight.springer.com/drugs/800037762

DMT5YK7	DI	DMT5YK7
DMT5YK7	DN	GSK2890457
DMT5YK7	MI	TTF5WCR
DMT5YK7	MN	Endogenous gut peptide (EGP)
DMT5YK7	MT	DTT
DMT5YK7	MA	Modulator
DMT5YK7	RN	Investigational drugs in Phase II clinical trials for the treatment of obesity: implications for future development of novel therapies. Expert Opin Investig Drugs. 2014 Aug;23(8):1055-66.
DMT5YK7	RU	https://pubmed.ncbi.nlm.nih.gov/25000213

DM25YLM	DI	DM25YLM
DM25YLM	DN	GSK2981278
DM25YLM	MI	TTGV6LY
DM25YLM	MN	Nuclear receptor ROR-gamma (RORG)
DM25YLM	MT	DTT
DM25YLM	MA	Agonist
DM25YLM	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM25YLM	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DM7HNFV	DI	DM7HNFV
DM7HNFV	DN	GSK2982772
DM7HNFV	MI	TTAIQSN
DM7HNFV	MN	Receptor-interacting protein 1 (RIPK1)
DM7HNFV	MT	DTT
DM7HNFV	MA	Inhibitor
DM7HNFV	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7HNFV	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMCDAVK	DI	DMCDAVK
DMCDAVK	DN	GSK3036656
DMCDAVK	MI	TT46T5G
DMCDAVK	MN	Mycobacterium Leucine-tRNA ligase (MycB leuS)
DMCDAVK	MT	DTT
DMCDAVK	MA	Inhibitor
DMCDAVK	RN	Discovery of a Potent and Specific M. tuberculosis Leucyl-tRNA Synthetase Inhibitor: (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656). J Med Chem. 2017 Oct 12;60(19):8011-8026.
DMCDAVK	RU	https://pubmed.ncbi.nlm.nih.gov/28953378

DMEXKF4	DI	DMEXKF4
DMEXKF4	DN	GSK3196165
DMEXKF4	MI	TTNYZG2
DMEXKF4	MN	Granulocyte-macrophage colony-stimulating factor (CSF2)
DMEXKF4	MT	DTT
DMEXKF4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMEXKF4	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMPBK8N	DI	DMPBK8N
DMPBK8N	DN	GSK3228836
DMPBK8N	MI	TTSJVOI
DMPBK8N	MN	Hepatitis B virus Large envelope protein messenger RNA (HBV S mRNA)
DMPBK8N	MT	DTT
DMPBK8N	MA	Inhibitor
DMPBK8N	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline.
DMPBK8N	RU	https://www.gsk.com/en-gb/research-and-development/our-pipeline/

DMJRD7A	DI	DMJRD7A
DMJRD7A	DN	GSK3326595
DMJRD7A	MI	TTR1D7X
DMJRD7A	MN	Protein arginine methyltransferase 5 (PRMT5)
DMJRD7A	MT	DTT
DMJRD7A	MA	Inhibitor
DMJRD7A	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMJRD7A	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMO5JS3	DI	DMO5JS3
DMO5JS3	DN	GSK3389404
DMO5JS3	MI	TTSJVOI
DMO5JS3	MN	Hepatitis B virus Large envelope protein messenger RNA (HBV S mRNA)
DMO5JS3	MT	DTT
DMO5JS3	MA	Inhibitor
DMO5JS3	RN	A Randomized, Double-Blind, Placebo-Controlled, First-Time-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy Subjects. Clin Pharmacol Drug Dev. 2019 Aug;8(6):790-801.
DMO5JS3	RU	https://pubmed.ncbi.nlm.nih.gov/30861337

DMMOWT9	DI	DMMOWT9
DMMOWT9	DN	GSK3640254
DMMOWT9	MI	TT5TOX7
DMMOWT9	MN	Human immunodeficiency virus Maturation (HIV Mat)
DMMOWT9	MT	DTT
DMMOWT9	MA	Inhibitor
DMMOWT9	RN	Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next-generation HIV-1 maturation inhibitor. Pharmacol Res Perspect. 2020 Dec;8(6):e00671.
DMMOWT9	RU	https://pubmed.ncbi.nlm.nih.gov/33200887

DMV3TO4	DI	DMV3TO4
DMV3TO4	DN	GSK3810109
DMV3TO4	MI	TT2ISQT
DMV3TO4	MN	Human immunodeficiency virus Attachment (HIV att)
DMV3TO4	MT	DTT
DMV3TO4	MA	Inhibitor
DMV3TO4	RN	Clinical pipeline report, company report or official report of ViiV Healthcare.
DMV3TO4	RU	https://viivhealthcare.com/en-us/medicines-in-development/

DMV6SNU	DI	DMV6SNU
DMV6SNU	DN	GSK4069889
DMV6SNU	MI	TT1RWL7
DMV6SNU	MN	Hepatitis A virus cellular receptor 2 (TIM3)
DMV6SNU	MT	DTT
DMV6SNU	MA	Inhibitor
DMV6SNU	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline.
DMV6SNU	RU	https://www.gsk.com/en-gb/research-and-development/our-pipeline/

DM3ZL2O	DI	DM3ZL2O
DM3ZL2O	DN	GSK-557296
DM3ZL2O	MI	TTSCIUP
DM3ZL2O	MN	Oxytocin receptor (OTR)
DM3ZL2O	MT	DTT
DM3ZL2O	MA	Antagonist
DM3ZL2O	RN	Inhibition of ejaculation by the non-peptide oxytocin receptor antagonist GSK557296: a multi-level site of action. Br J Pharmacol. 2013 Aug;169(7):1477-85.
DM3ZL2O	RU	https://pubmed.ncbi.nlm.nih.gov/23530818

DMEVARK	DI	DMEVARK
DMEVARK	DN	GSK561679
DMEVARK	MI	TT7EFHR
DMEVARK	MN	Corticotropin-releasing factor receptor 1 (CRHR1)
DMEVARK	MT	DTT
DMEVARK	MA	Antagonist
DMEVARK	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMEVARK	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMGU05N	DI	DMGU05N
DMGU05N	DN	GSK598809
DMGU05N	MI	TT4C8EA
DMGU05N	MN	Dopamine D3 receptor (D3R)
DMGU05N	MT	DTT
DMGU05N	MA	Antagonist
DMGU05N	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMGU05N	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMTW79H	DI	DMTW79H
DMTW79H	DN	GSK683699
DMTW79H	MI	DECB0K3
DMTW79H	MN	Cytochrome P450 2D6 (CYP2D6)
DMTW79H	MT	DME
DMTW79H	MA	Metabolism
DMTW79H	RN	Cytochrome P450 2D catalyze steroid 21-hydroxylation in the brain. Endocrinology. 2004 Feb;145(2):699-705.
DMTW79H	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14563706

DMTW79H	DI	DMTW79H
DMTW79H	DN	GSK683699
DMTW79H	MI	TTPRKM0
DMTW79H	MN	GABA transporter GAT-1 (SLC6A1)
DMTW79H	MT	DTT
DMTW79H	MA	Inhibitor
DMTW79H	RN	Novel secoergoline derivatives inhibit both GABA and glutamate uptake in rat brain homogenates: synthesis, in vitro pharmacology, and modeling. J Med Chem. 2004 Nov 4;47(23):5620-9.
DMTW79H	RU	https://pubmed.ncbi.nlm.nih.gov/15509161

DMTW79H	DI	DMTW79H
DMTW79H	DN	GSK683699
DMTW79H	MI	TT8RXO5
DMTW79H	MN	GABA transporter-3 (SLC6A11)
DMTW79H	MT	DTT
DMTW79H	MA	Inhibitor
DMTW79H	RN	Epimeric cis-decahydroquinoline-5-carboxylic acids: effects on gamma-aminobutyric acid uptake and receptor binding in vitro. J Med Chem. 1981 Jul;24(7):788-94.
DMTW79H	RU	https://pubmed.ncbi.nlm.nih.gov/6268788

DMTW79H	DI	DMTW79H
DMTW79H	DN	GSK683699
DMTW79H	MI	TT1MPAY
DMTW79H	MN	GABA(A) receptor alpha-1 (GABRA1)
DMTW79H	MT	DTT
DMTW79H	MA	Inhibitor
DMTW79H	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DMTW79H	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DMTW79H	DI	DMTW79H
DMTW79H	DN	GSK683699
DMTW79H	MI	TTBMV1G
DMTW79H	MN	GABA(A) receptor alpha-2 (GABRA2)
DMTW79H	MT	DTT
DMTW79H	MA	Inhibitor
DMTW79H	RN	New anticonvulsants: Schiff bases of gamma-aminobutyric acid and gamma-aminobutyramide. J Med Chem. 1980 Jun;23(6):702-4.
DMTW79H	RU	https://pubmed.ncbi.nlm.nih.gov/7392039

DMTW79H	DI	DMTW79H
DMTW79H	DN	GSK683699
DMTW79H	MI	TT37EDJ
DMTW79H	MN	GABA(A) receptor alpha-3 (GABRA3)
DMTW79H	MT	DTT
DMTW79H	MA	Inhibitor
DMTW79H	RN	New anticonvulsants: Schiff bases of gamma-aminobutyric acid and gamma-aminobutyramide. J Med Chem. 1980 Jun;23(6):702-4.
DMTW79H	RU	https://pubmed.ncbi.nlm.nih.gov/7392039

DMTW79H	DI	DMTW79H
DMTW79H	DN	GSK683699
DMTW79H	MI	TTNZPQ1
DMTW79H	MN	GABA(A) receptor alpha-5 (GABRA5)
DMTW79H	MT	DTT
DMTW79H	MA	Inhibitor
DMTW79H	RN	New anticonvulsants: Schiff bases of gamma-aminobutyric acid and gamma-aminobutyramide. J Med Chem. 1980 Jun;23(6):702-4.
DMTW79H	RU	https://pubmed.ncbi.nlm.nih.gov/7392039

DMTW79H	DI	DMTW79H
DMTW79H	DN	GSK683699
DMTW79H	MI	TTZA1NY
DMTW79H	MN	GABA(A) receptor beta-2 (GABRB2)
DMTW79H	MT	DTT
DMTW79H	MA	Inhibitor
DMTW79H	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DMTW79H	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DMTW79H	DI	DMTW79H
DMTW79H	DN	GSK683699
DMTW79H	MI	TT06RH5
DMTW79H	MN	GABA(A) receptor gamma-2 (GABRG2)
DMTW79H	MT	DTT
DMTW79H	MA	Inhibitor
DMTW79H	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DMTW79H	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DMTW79H	DI	DMTW79H
DMTW79H	DN	GSK683699
DMTW79H	MI	TTDCVZW
DMTW79H	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMTW79H	MT	DTT
DMTW79H	MA	Inhibitor
DMTW79H	RN	3-Thienyl- and 3-furylaminobutyric acids. Synthesis and binding GABAB receptor studies. J Med Chem. 1991 Aug;34(8):2557-60.
DMTW79H	RU	https://pubmed.ncbi.nlm.nih.gov/1652022

DMTW79H	DI	DMTW79H
DMTW79H	DN	GSK683699
DMTW79H	MI	TTNJYV2
DMTW79H	MN	Gamma-aminobutyric acid receptor (GAR)
DMTW79H	MT	DTT
DMTW79H	MA	Inhibitor
DMTW79H	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DMTW79H	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DMTW79H	DI	DMTW79H
DMTW79H	DN	GSK683699
DMTW79H	MI	TT4BT06
DMTW79H	MN	Integrin alpha-4 (ITGA4)
DMTW79H	MT	DTT
DMTW79H	MA	Binder
DMTW79H	RN	Emerging drugs to treat Crohn's disease. Expert Opin Emerg Drugs. 2007 Mar;12(1):49-59.
DMTW79H	RU	https://pubmed.ncbi.nlm.nih.gov/17355213

DMTW79H	DI	DMTW79H
DMTW79H	DN	GSK683699
DMTW79H	MI	DT8Z563
DMTW79H	MN	Sodium- and chloride-dependent GABA transporter 1 (SLC6A1)
DMTW79H	MT	DTP
DMTW79H	MA	Substrate
DMTW79H	RN	Mutations in the GABA Transporter SLC6A1 Cause Epilepsy with Myoclonic-Atonic Seizures. Am J Hum Genet. 2015 May 7;96(5):808-15.
DMTW79H	RU	http://www.ncbi.nlm.nih.gov/pubmed/25865495

DMTW79H	DI	DMTW79H
DMTW79H	DN	GSK683699
DMTW79H	MI	DTXQYLR
DMTW79H	MN	Vesicular inhibitory amino acid transporter (SLC32A1)
DMTW79H	MT	DTP
DMTW79H	MA	Substrate
DMTW79H	RN	Wakefulness Is Governed by GABA and Histamine Cotransmission. Neuron. 2015 Jul 1;87(1):164-78.
DMTW79H	RU	http://www.ncbi.nlm.nih.gov/pubmed/26094607

DMPLKAH	DI	DMPLKAH
DMPLKAH	DN	GSK-706769
DMPLKAH	MI	TT2CEJG
DMPLKAH	MN	C-C chemokine receptor type 5 (CCR5)
DMPLKAH	MT	DTT
DMPLKAH	MA	Antagonist
DMPLKAH	RN	Tapping into combination pills for HIV. Nat Rev Drug Discov. 2009 Jun;8(6):439-40.
DMPLKAH	RU	https://pubmed.ncbi.nlm.nih.gov/19483700

DMIEXUM	DI	DMIEXUM
DMIEXUM	DN	GSK768974
DMIEXUM	MI	TTEPJL5
DMIEXUM	MN	Parathyroid hormone receptor (PTH2R)
DMIEXUM	MT	DTT
DMIEXUM	MA	Agonist
DMIEXUM	RN	Comparison of bone formation responses to parathyroid hormone(1-34), (1-31), and (2-34) in mice. Bone. 2000 Oct;27(4):471-8.
DMIEXUM	RU	https://pubmed.ncbi.nlm.nih.gov/11033441

DMX27Q1	DI	DMX27Q1
DMX27Q1	DN	GSK933776A
DMX27Q1	MI	TTE4KHA
DMX27Q1	MN	Amyloid beta A4 protein (APP)
DMX27Q1	MT	DTT
DMX27Q1	MA	Modulator
DMX27Q1	RN	Profile of gantenerumab and its potential in the treatment of Alzheimer's disease. Correction in: Drug Des Devel Ther. 2014; 8: 569.
DMX27Q1	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3832388/

DM6DKF9	DI	DM6DKF9
DM6DKF9	DN	GSK961081
DM6DKF9	MI	TT2CJVK
DM6DKF9	MN	Adrenergic receptor beta-2 (ADRB2)
DM6DKF9	MT	DTT
DM6DKF9	MA	Modulator
DM6DKF9	RN	Pharmacologic characterization of GSK-961081 (TD-5959), a first-in-class inhaled bifunctional bronchodilator possessing muscarinic receptor antagonist and 2-adrenoceptor agonist properties.J Pharmacol Exp Ther.2014 Oct;351(1):190-9.
DM6DKF9	RU	https://www.ncbi.nlm.nih.gov/pubmed/25100753

DM8N3OQ	DI	DM8N3OQ
DM8N3OQ	DN	GT-AADC
DM8N3OQ	MI	TTN451K
DM8N3OQ	MN	Aromatic-L-amino-acid decarboxylase (DDC)
DM8N3OQ	MT	DTT
DM8N3OQ	MA	Replacement
DM8N3OQ	RN	Clinical pipeline report, company report or official report of PTC Therapeutics.
DM8N3OQ	RU	https://www.ptcbio.com/our-pipeline/areas-of-interest/additional-areas/

DMN6IDO	DI	DMN6IDO
DMN6IDO	DN	GTP-010
DMN6IDO	MI	TTVIMDE
DMN6IDO	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMN6IDO	MT	DTT
DMN6IDO	MA	Agonist
DMN6IDO	RN	Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
DMN6IDO	RU	https://pubmed.ncbi.nlm.nih.gov/16634703

DM03NQS	DI	DM03NQS
DM03NQS	DN	GTP-200
DM03NQS	MI	TTWDC17
DM03NQS	MN	Growth hormone secretagogue receptor 1 (GHSR)
DM03NQS	MT	DTT
DM03NQS	MA	Agonist
DM03NQS	RN	Orphan GPCR research. Br J Pharmacol. 2008 March; 153(Suppl 1): S339-S346.
DM03NQS	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2268047/

DMEN5KA	DI	DMEN5KA
DMEN5KA	DN	GTS-21
DMEN5KA	MI	DEJGDUW
DMEN5KA	MN	Cytochrome P450 1A2 (CYP1A2)
DMEN5KA	MT	DME
DMEN5KA	MA	Metabolism
DMEN5KA	RN	Metabolism and disposition of GTS-21, a novel drug for Alzheimer's disease. Xenobiotica. 1999 Jul;29(7):747-62.
DMEN5KA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10456692

DMEN5KA	DI	DMEN5KA
DMEN5KA	DN	GTS-21
DMEN5KA	MI	TTLA931
DMEN5KA	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMEN5KA	MT	DTT
DMEN5KA	MA	Agonist
DMEN5KA	RN	The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21). Behav Brain Res. 2000 Aug;113(1-2):169-81.
DMEN5KA	RU	https://pubmed.ncbi.nlm.nih.gov/10942043

DMDWYZS	DI	DMDWYZS
DMDWYZS	DN	GTx-758
DMDWYZS	MI	TTZAYWL
DMDWYZS	MN	Estrogen receptor (ESR)
DMDWYZS	MT	DTT
DMDWYZS	MA	Modulator
DMDWYZS	RN	Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer. Eur Urol. 2015 Feb;67(2):334-41.
DMDWYZS	RU	https://pubmed.ncbi.nlm.nih.gov/24968970

DMY53PL	DI	DMY53PL
DMY53PL	DN	GW 597599
DMY53PL	MI	TTZPO1L
DMY53PL	MN	Substance-P receptor (TACR1)
DMY53PL	MT	DTT
DMY53PL	MA	Antagonist
DMY53PL	RN	Application of LC-NMR to the identification of bulk drug impurities in NK1 antagonist GW597599 (vestipitant). Magn Reson Chem. 2010 Jul;48(7):523-30.
DMY53PL	RU	https://pubmed.ncbi.nlm.nih.gov/20535779

DMZMCB1	DI	DMZMCB1
DMZMCB1	DN	GW274150
DMZMCB1	MI	TTF10I9
DMZMCB1	MN	Nitric-oxide synthase inducible (NOS2)
DMZMCB1	MT	DTT
DMZMCB1	MA	Modulator
DMZMCB1	RN	GW274150, a potent and highly selective inhibitor of iNOS, reduces experimental renal ischemia/reperfusion injury. Kidney Int. 2003 Mar;63(3):853-65.
DMZMCB1	RU	https://www.ncbi.nlm.nih.gov/pubmed/12631066

DMY3KSU	DI	DMY3KSU
DMY3KSU	DN	GW-42004
DMY3KSU	MI	TT6OEDT
DMY3KSU	MN	Cannabinoid receptor 1 (CB1)
DMY3KSU	MT	DTT
DMY3KSU	MA	Modulator
DMY3KSU	RN	Company report (Gwpharm)
DMY3KSU	RU	http://www.gwpharm.com/GW%20Pharmaceuticals%20Provides%20Update%20on%20Cannabinoid%20Pipeline.aspx

DMY3KSU	DI	DMY3KSU
DMY3KSU	DN	GW-42004
DMY3KSU	MI	TTMSFAW
DMY3KSU	MN	Cannabinoid receptor 2 (CB2)
DMY3KSU	MT	DTT
DMY3KSU	MA	Modulator
DMY3KSU	RN	Company report (Gwpharm)
DMY3KSU	RU	http://www.gwpharm.com/GW%20Pharmaceuticals%20Provides%20Update%20on%20Cannabinoid%20Pipeline.aspx

DMBX9C0	DI	DMBX9C0
DMBX9C0	DN	GW-427353
DMBX9C0	MI	TTMXGCW
DMBX9C0	MN	Adrenergic receptor beta-3 (ADRB3)
DMBX9C0	MT	DTT
DMBX9C0	MA	Agonist
DMBX9C0	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DMBX9C0	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMH0C8J	DI	DMH0C8J
DMH0C8J	DN	GW-813893
DMH0C8J	MI	TTCIHJA
DMH0C8J	MN	Coagulation factor Xa (F10)
DMH0C8J	MT	DTT
DMH0C8J	MA	Inhibitor
DMH0C8J	RN	Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7.
DMH0C8J	RU	https://pubmed.ncbi.nlm.nih.gov/22844656

DM489FT	DI	DM489FT
DM489FT	DN	GW-870086-X
DM489FT	MI	TTYRL6O
DM489FT	MN	Glucocorticoid receptor (NR3C1)
DM489FT	MT	DTT
DM489FT	MA	Agonist
DM489FT	RN	Unique response profile of trabecular meshwork cells to the novel selective glucocorticoid receptor agonist, GW870086X. Invest Ophthalmol Vis Sci. 2013 Mar 1;54(3):2100-7.
DM489FT	RU	https://pubmed.ncbi.nlm.nih.gov/23462748

DMQEC9P	DI	DMQEC9P
DMQEC9P	DN	GW-870086-X
DMQEC9P	MI	TTYRL6O
DMQEC9P	MN	Glucocorticoid receptor (NR3C1)
DMQEC9P	MT	DTT
DMQEC9P	MA	Agonist
DMQEC9P	RN	Unique response profile of trabecular meshwork cells to the novel selective glucocorticoid receptor agonist, GW870086X. Invest Ophthalmol Vis Sci. 2013 Mar 1;54(3):2100-7.
DMQEC9P	RU	https://pubmed.ncbi.nlm.nih.gov/23462748

DM8XH3S	DI	DM8XH3S
DM8XH3S	DN	H-1152
DM8XH3S	MI	TTZN7RP
DM8XH3S	MN	Rho-associated protein kinase 1 (ROCK1)
DM8XH3S	MT	DTT
DM8XH3S	MA	Inhibitor
DM8XH3S	RN	Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
DM8XH3S	RU	https://pubmed.ncbi.nlm.nih.gov/17064221

DMO4I61	DI	DMO4I61
DMO4I61	DN	H5N1 influenza vaccine
DMO4I61	MI	TT3J5ZI
DMO4I61	MN	Cell mediated immunity response (CMIR)
DMO4I61	MT	DTT
DMO4I61	RN	Anti-influenza agents from Traditional Chinese Medicine. Nat Prod Rep. 2010 Jan;27(12):1758-80.
DMO4I61	RU	https://pubmed.ncbi.nlm.nih.gov/20941447

DM74ZKN	DI	DM74ZKN
DM74ZKN	DN	HBI-3000
DM74ZKN	MI	TT5HONZ
DM74ZKN	MN	Calcium channel unspecific (CaC)
DM74ZKN	MT	DTT
DM74ZKN	MA	Blocker
DM74ZKN	RN	Electrophysiological properties of HBI-3000: a new antiarrhythmic agent with multiple-channel blocking properties in human ventricular myocytes. J Cardiovasc Pharmacol. 2011 Jan;57(1):79-85.
DM74ZKN	RU	https://pubmed.ncbi.nlm.nih.gov/20980921

DM74ZKN	DI	DM74ZKN
DM74ZKN	DN	HBI-3000
DM74ZKN	MI	TT1VOHK
DM74ZKN	MN	Potassium channel unspecific (KC)
DM74ZKN	MT	DTT
DM74ZKN	MA	Blocker
DM74ZKN	RN	Electrophysiological properties of HBI-3000: a new antiarrhythmic agent with multiple-channel blocking properties in human ventricular myocytes. J Cardiovasc Pharmacol. 2011 Jan;57(1):79-85.
DM74ZKN	RU	https://pubmed.ncbi.nlm.nih.gov/20980921

DM74ZKN	DI	DM74ZKN
DM74ZKN	DN	HBI-3000
DM74ZKN	MI	TTRK8B9
DM74ZKN	MN	Sodium channel unspecific (NaC)
DM74ZKN	MT	DTT
DM74ZKN	MA	Inhibitor
DM74ZKN	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DM74ZKN	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMSMCXN	DI	DMSMCXN
DMSMCXN	DN	HBV vaccine
DMSMCXN	MI	TT3J5ZI
DMSMCXN	MN	Cell mediated immunity response (CMIR)
DMSMCXN	MT	DTT
DMSMCXN	RN	ClinicalTrials.gov (NCT00508833) Safety and Efficacy of SmithKline Beecham (GlaxoSmithKline [GSK]) Biologicals' Candidate Adjuvanted Vaccines (287615). U.S. National Institutes of Health.
DMSMCXN	RU	https://clinicaltrials.gov/ct2/show/NCT00508833

DMX8C6J	DI	DMX8C6J
DMX8C6J	DN	HCB1019
DMX8C6J	MI	TT4F7SL
DMX8C6J	MN	Gap junction alpha-1 protein (GJA1)
DMX8C6J	MT	DTT
DMX8C6J	MA	Inhibitor
DMX8C6J	RN	Clinical pipeline report, company report or official report of OcuNexus Therapeutics.
DMX8C6J	RU	https://ocunexus.com/ophthalmic

DMRQGMZ	DI	DMRQGMZ
DMRQGMZ	DN	HD-003
DMRQGMZ	MI	TT20DOQ
DMRQGMZ	MN	Hydroxy radical elimination (HYRE)
DMRQGMZ	MT	DTT
DMRQGMZ	MA	Modulator
DMRQGMZ	RN	Creatinine and HMH (5-hydroxy-1-methylhydantoin, NZ-419) as intrinsic hydroxyl radical scavengers. Drug Discov Ther. 2011 Aug;5(4):162-75.
DMRQGMZ	RU	https://pubmed.ncbi.nlm.nih.gov/22466296

DMAX632	DI	DMAX632
DMAX632	DN	HDV-interferon
DMAX632	MI	TTV2CN0
DMAX632	MN	Interferon receptor (IFNR)
DMAX632	MT	DTT
DMAX632	MA	Modulator
DMAX632	RN	Interferon in HDV infection. Antiviral Res. 1994 Jul;24(2-3):165-74.
DMAX632	RU	https://pubmed.ncbi.nlm.nih.gov/7979316

DMV50R1	DI	DMV50R1
DMV50R1	DN	HE3235
DMV50R1	MI	DE4LYSA
DMV50R1	MN	Cytochrome P450 3A4 (CYP3A4)
DMV50R1	MT	DME
DMV50R1	MA	Metabolism
DMV50R1	RN	17alpha-alkynyl 3alpha, 17beta-androstanediol non-clinical and clinical pharmacology, pharmacokinetics and metabolism. Invest New Drugs. 2012 Feb;30(1):59-78.
DMV50R1	RU	http://www.ncbi.nlm.nih.gov/pubmed/20814732

DMV50R1	DI	DMV50R1
DMV50R1	DN	HE3235
DMV50R1	MI	DEGTFWK
DMV50R1	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMV50R1	MT	DME
DMV50R1	MA	Metabolism
DMV50R1	RN	17alpha-alkynyl 3alpha, 17beta-androstanediol non-clinical and clinical pharmacology, pharmacokinetics and metabolism. Invest New Drugs. 2012 Feb;30(1):59-78.
DMV50R1	RU	http://www.ncbi.nlm.nih.gov/pubmed/20814732

DMV50R1	DI	DMV50R1
DMV50R1	DN	HE3235
DMV50R1	MI	TTYA7V2
DMV50R1	MN	Prostate cance cell (PCC)
DMV50R1	MT	DTT
DMV50R1	MA	Inhibitor
DMV50R1	RN	17alpha-alkynyl 3alpha, 17beta-androstanediol non-clinical and clinical pharmacology, pharmacokinetics and metabolism. Invest New Drugs. 2012 Feb;30(1):59-78.
DMV50R1	RU	https://pubmed.ncbi.nlm.nih.gov/20814732

DM9OZU5	DI	DM9OZU5
DM9OZU5	DN	Heat shock protein vaccine
DM9OZU5	MI	TTG91S4
DM9OZU5	MN	Heat shock protein (HSP)
DM9OZU5	MT	DTT
DM9OZU5	RN	Heat shock proteins (HSPs) based anti-cancer vaccines. Curr Mol Med. 2012 Nov 1;12(9):1183-97.
DM9OZU5	RU	https://pubmed.ncbi.nlm.nih.gov/22804241

DM8QGPE	DI	DM8QGPE
DM8QGPE	DN	HepaStem
DM8QGPE	MI	TTGSVH2
DM8QGPE	MN	Phenylalanine hydroxylase (PAH)
DM8QGPE	MT	DTT
DM8QGPE	MA	Modulator
DM8QGPE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1240).
DM8QGPE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1240

DMX6B95	DI	DMX6B95
DMX6B95	DN	HER1-VSSP vaccine
DMX6B95	MI	TTGKNB4
DMX6B95	MN	Epidermal growth factor receptor (EGFR)
DMX6B95	MT	DTT
DMX6B95	RN	Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant. Int J Cancer. 2006 Nov 1;119(9):2190-9.
DMX6B95	RU	https://pubmed.ncbi.nlm.nih.gov/16841332

DM8TOS0	DI	DM8TOS0
DM8TOS0	DN	HER-2 Protein AutoVac
DM8TOS0	MI	TT6EO5L
DM8TOS0	MN	Erbb2 tyrosine kinase receptor (HER2)
DM8TOS0	MT	DTT
DM8TOS0	MA	Inhibitor
DM8TOS0	RN	Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2011 Nov 29;9(1):16-32.
DM8TOS0	RU	https://pubmed.ncbi.nlm.nih.gov/22124364

DMISETH	DI	DMISETH
DMISETH	DN	HER2/neu peptide vaccine
DMISETH	MI	TT6EO5L
DMISETH	MN	Erbb2 tyrosine kinase receptor (HER2)
DMISETH	MT	DTT
DMISETH	RN	N-terminally LRMK-linked HER-2 peptides, AE-37 [p776(774-788)] and AE-47 [Ava-F7(776-788)], aid differentiation of E75-TCR+CD8+ cells to perforin-positive cells. Anticancer Res. 2009 Jul;29(7):2427-35.
DMISETH	RU	https://pubmed.ncbi.nlm.nih.gov/19596910

DMQTREC	DI	DMQTREC
DMQTREC	DN	Her2-targeted autologous T-cell therapy
DMQTREC	MI	TT6EO5L
DMQTREC	MN	Erbb2 tyrosine kinase receptor (HER2)
DMQTREC	MT	DTT
DMQTREC	MA	Inhibitor
DMQTREC	RN	A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy. J Immunol Res. 2014;2014:326545.
DMQTREC	RU	https://pubmed.ncbi.nlm.nih.gov/25009822

DMI4C90	DI	DMI4C90
DMI4C90	DN	HF-0220
DMI4C90	MI	TTCYE56
DMI4C90	MN	Glutathione-dependent PGD synthase (HPGDS)
DMI4C90	MT	DTT
DMI4C90	MA	Stimulator
DMI4C90	RN	US patent application no. 2009,0062,529, Multi-cyclic compounds.
DMI4C90	RU	http://www.google.st/patents/US20090062529

DMDZE3B	DI	DMDZE3B
DMDZE3B	DN	HGT-1111
DMDZE3B	MI	TTYQANR
DMDZE3B	MN	Cerebroside-sulfatase (ARSA)
DMDZE3B	MT	DTT
DMDZE3B	MA	Modulator
DMDZE3B	RN	ClinicalTrials.gov (NCT00681811) Open-Label Extension Study of Recombinant Human Arylsulfatase A (HGT-1111) in Late Infantile MLD. U.S. National Institutes of Health.
DMDZE3B	RU	https://clinicaltrials.gov/ct2/show/NCT00681811

DMHZ4JI	DI	DMHZ4JI
DMHZ4JI	DN	HGT-1410
DMHZ4JI	MI	TTPJ2SH
DMHZ4JI	MN	N-sulphoglucosamine sulphohydrolase (SGSH)
DMHZ4JI	MT	DTT
DMHZ4JI	MA	Modulator
DMHZ4JI	RN	ClinicalTrials.gov (NCT01155778) Safety, Tolerability, Ascending Dose and Dose Frequency Study of rhHNS Via an IDDD in MPS IIIA Patients. U.S. National Institutes of Health.
DMHZ4JI	RU	https://clinicaltrials.gov/ct2/show/NCT01155778

DM0LA6E	DI	DM0LA6E
DM0LA6E	DN	HGTV43
DM0LA6E	MI	TTRP4JT
DM0LA6E	MN	Human immunodeficiency virus Rev messenger RNA (HIV rev mRNA)
DM0LA6E	MT	DTT
DM0LA6E	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DM0LA6E	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DM0LA6E	DI	DM0LA6E
DM0LA6E	DN	HGTV43
DM0LA6E	MI	TTFP96H
DM0LA6E	MN	Human immunodeficiency virus Tat messenger RNA (HIV tat mRNA)
DM0LA6E	MT	DTT
DM0LA6E	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DM0LA6E	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DM0LA6E	DI	DM0LA6E
DM0LA6E	DN	HGTV43
DM0LA6E	MI	TT6S84O
DM0LA6E	MN	Human immunodeficiency virus Trans-activation response element (HIV TAR RNA element)
DM0LA6E	MT	DTT
DM0LA6E	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DM0LA6E	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DMO10JI	DI	DMO10JI
DMO10JI	DN	HibTITER
DMO10JI	MI	TTC6JZQ
DMO10JI	MN	Haemophilus influenzae CRM197 (Hae-influ CRM197)
DMO10JI	MT	DTT
DMO10JI	RN	Immunogenicity and safety of Haemophilus influenzae type b conjugate vaccine (HibTITER) and a combination vaccine of diphtheria, tetanus, pertussis and HibTITER (TETRAMUNE) in two-month-old infants. J Microbiol Immunol Infect. 1998 Sep;31(3):180-6.
DMO10JI	RU	https://pubmed.ncbi.nlm.nih.gov/10496155

DMLQDBH	DI	DMLQDBH
DMLQDBH	DN	HM-5016504
DMLQDBH	MI	TTNDSF4
DMLQDBH	MN	Proto-oncogene c-Met (MET)
DMLQDBH	MT	DTT
DMLQDBH	MA	Inhibitor
DMLQDBH	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
DMLQDBH	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815

DMZ3BER	DI	DMZ3BER
DMZ3BER	DN	HM-78136B
DMZ3BER	MI	TTGKNB4
DMZ3BER	MN	Epidermal growth factor receptor (EGFR)
DMZ3BER	MT	DTT
DMZ3BER	MA	Inhibitor
DMZ3BER	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZ3BER	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMZ3BER	DI	DMZ3BER
DMZ3BER	DN	HM-78136B
DMZ3BER	MI	TT6EO5L
DMZ3BER	MN	Erbb2 tyrosine kinase receptor (HER2)
DMZ3BER	MT	DTT
DMZ3BER	MA	Inhibitor
DMZ3BER	RN	Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models. Int J Cancer. 2012 May 15;130(10):2445-54.
DMZ3BER	RU	https://pubmed.ncbi.nlm.nih.gov/21732342

DMMQZ3I	DI	DMMQZ3I
DMMQZ3I	DN	HMR59
DMMQZ3I	MI	TTBGTEJ
DMMQZ3I	MN	Membrane inhibitor of reactive lysis (CD59)
DMMQZ3I	MT	DTT
DMMQZ3I	MA	Replacement
DMMQZ3I	RN	Clinical pipeline report, company report or official report of Hemera Biosciences.
DMMQZ3I	RU	https://www.hemerabiosciences.com/hmr59/

DMA6HQJ	DI	DMA6HQJ
DMA6HQJ	DN	HO/03/03
DMA6HQJ	MI	TTYVX59
DMA6HQJ	MN	Protein kinase C (PRKC)
DMA6HQJ	MT	DTT
DMA6HQJ	MA	Modulator
DMA6HQJ	RN	WO patent application no. 2014,0853,81, Pharmaceutical combinations.
DMA6HQJ	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20140605&CC=WO&NR=2014085381A1&KC=A1

DMNOMV2	DI	DMNOMV2
DMNOMV2	DN	HP-184
DMNOMV2	MI	TTQ6VDM
DMNOMV2	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMNOMV2	MT	DTT
DMNOMV2	MA	Blocker
DMNOMV2	RN	Emerging drugs for spinal cord injury. Expert Opin Emerg Drugs. 2008 Mar;13(1):63-80.
DMNOMV2	RU	https://pubmed.ncbi.nlm.nih.gov/18321149

DMNOMV2	DI	DMNOMV2
DMNOMV2	DN	HP-184
DMNOMV2	MI	TTN9VTF
DMNOMV2	MN	Voltage-gated sodium channel alpha Nav1.9 (SCN11A)
DMNOMV2	MT	DTT
DMNOMV2	MA	Blocker
DMNOMV2	RN	Emerging drugs for spinal cord injury. Expert Opin Emerg Drugs. 2008 Mar;13(1):63-80.
DMNOMV2	RU	https://pubmed.ncbi.nlm.nih.gov/18321149

DMNZ35F	DI	DMNZ35F
DMNZ35F	DN	HP-228
DMNZ35F	MI	TTF10I9
DMNZ35F	MN	Nitric-oxide synthase inducible (NOS2)
DMNZ35F	MT	DTT
DMNZ35F	MA	Modulator
DMNZ35F	RN	HP-228, a novel synthetic peptide, inhibits the induction of nitric oxide synthase in vivo but not in vitro. J Pharmacol Exp Ther. 1995 Nov;275(2):584-91.
DMNZ35F	RU	https://pubmed.ncbi.nlm.nih.gov/7473142

DM3WSL2	DI	DM3WSL2
DM3WSL2	DN	HPH-116
DM3WSL2	MI	TT8Z1OP
DM3WSL2	MN	Human immunodeficiency virus Nucleocapsid p7 (HIV p7)
DM3WSL2	MT	DTT
DM3WSL2	MA	Modulator
DM3WSL2	RN	Clinical pipeline report, company report or official report of H-Phar.
DM3WSL2	RU	http://www.h-phar.com/Projects_Projet_1.php

DM25PQB	DI	DM25PQB
DM25PQB	DN	HPPH
DM25PQB	MI	DTI7UX6
DM25PQB	MN	Breast cancer resistance protein (ABCG2)
DM25PQB	MT	DTP
DM25PQB	MA	Substrate
DM25PQB	RN	Substrate affinity of photosensitizers derived from chlorophyll-a: the ABCG2 transporter affects the phototoxic response of side population stem cell-like cancer cells to photodynamic therapy. Mol Pharm. 2010 Oct 4;7(5):1789-804.
DM25PQB	RU	https://doi.org/10.1021/mp100154j

DM7QUN0	DI	DM7QUN0
DM7QUN0	DN	HQK-1001
DM7QUN0	MI	TTQO71U
DM7QUN0	MN	Hemoglobin (HB)
DM7QUN0	MT	DTT
DM7QUN0	MA	Inducer
DM7QUN0	RN	A phase 2 study of HQK-1001, an oral fetal haemoglobin inducer, in beta-thalassaemia intermedia. Br J Haematol. 2014 Feb;164(3):456-8.
DM7QUN0	RU	https://pubmed.ncbi.nlm.nih.gov/24224649

DM3WX0K	DI	DM3WX0K
DM3WX0K	DN	HQK-1004
DM3WX0K	MI	TTP3QRF
DM3WX0K	MN	Thymidine kinase 1 (TK1)
DM3WX0K	MT	DTT
DM3WX0K	MA	Modulator
DM3WX0K	RN	Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies. Curr Opin Oncol. 2001 Sep;13(5):360-7.
DM3WX0K	RU	https://pubmed.ncbi.nlm.nih.gov/11555713

DMQ30X2	DI	DMQ30X2
DMQ30X2	DN	HQP1351
DMQ30X2	MI	TTS7G69
DMQ30X2	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMQ30X2	MT	DTT
DMQ30X2	MA	Inhibitor
DMQ30X2	RN	Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors. Cell Biosci. 2019 Oct 26;9:88.
DMQ30X2	RU	https://pubmed.ncbi.nlm.nih.gov/31673329

DML4RCG	DI	DML4RCG
DML4RCG	DN	HS-110
DML4RCG	MI	TTFZDNP
DML4RCG	MN	Activation B7-1 antigen (CD80)
DML4RCG	MT	DTT
DML4RCG	RN	Clinical pipeline report, company report or official report of Heat Biologics.
DML4RCG	RU	http://www.heatbio.com/product-pipeline/hs-110

DML4RCG	DI	DML4RCG
DML4RCG	DN	HS-110
DML4RCG	MI	TTFPKXQ
DML4RCG	MN	Endoplasmin (HSP90B1)
DML4RCG	MT	DTT
DML4RCG	RN	Clinical pipeline report, company report or official report of Heat Biologics.
DML4RCG	RU	http://www.heatbio.com/product-pipeline/hs-110

DM2WP8F	DI	DM2WP8F
DM2WP8F	DN	HT-0712
DM2WP8F	MI	TTZ97H5
DM2WP8F	MN	Phosphodiesterase 4A (PDE4A)
DM2WP8F	MT	DTT
DM2WP8F	MA	Inhibitor
DM2WP8F	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1300).
DM2WP8F	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1300

DM2WP8F	DI	DM2WP8F
DM2WP8F	DN	HT-0712
DM2WP8F	MI	TTVIAT9
DM2WP8F	MN	Phosphodiesterase 4B (PDE4B)
DM2WP8F	MT	DTT
DM2WP8F	MA	Inhibitor
DM2WP8F	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1301).
DM2WP8F	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1301

DM2WP8F	DI	DM2WP8F
DM2WP8F	DN	HT-0712
DM2WP8F	MI	TTSKMI8
DM2WP8F	MN	Phosphodiesterase 4D (PDE4D)
DM2WP8F	MT	DTT
DM2WP8F	MA	Inhibitor
DM2WP8F	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1303).
DM2WP8F	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1303

DM2QIN1	DI	DM2QIN1
DM2QIN1	DN	HT-100
DM2QIN1	MI	TTXYCDZ
DM2QIN1	MN	Bifunctional aminoacyl-tRNA synthetase (EPRS)
DM2QIN1	MT	DTT
DM2QIN1	MA	Modulator
DM2QIN1	RN	Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase. Nat Chem Biol. 2012 Feb 12;8(3):311-7.
DM2QIN1	RU	https://pubmed.ncbi.nlm.nih.gov/22327401

DMURXMJ	DI	DMURXMJ
DMURXMJ	DN	HTI-101
DMURXMJ	MI	TT3C1VN
DMURXMJ	MN	Enzyme unspecific (Enz)
DMURXMJ	MT	DTT
DMURXMJ	MA	Antagonist
DMURXMJ	RN	Halozyme Therapeutics Announces New Studies From HTI-101 Presented at Proteoglycan Research Conference. Halozyme Therapeutics. JULY 12, 2006.
DMURXMJ	RU	http://www.prnewswire.com/news-releases/halozyme-therapeutics-announces-new-studies-from-hti-101-presented-at-proteoglycan-research-conference-56000982.html

DM9MKQ5	DI	DM9MKQ5
DM9MKQ5	DN	Hu3F8 mAb
DM9MKQ5	MI	TT80ARU
DM9MKQ5	MN	Ganglioside GD2 (GD2)
DM9MKQ5	MT	DTT
DM9MKQ5	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9MKQ5	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMKQ3MC	DI	DMKQ3MC
DMKQ3MC	DN	Human interferon alpha oral
DMKQ3MC	MI	TT95SOA
DMKQ3MC	MN	Interferon alpha (IFNA)
DMKQ3MC	MT	DTT
DMKQ3MC	MA	Modulator
DMKQ3MC	RN	Low-dose oral natural human interferon-alpha in 29 patients with HIV-1 infection: a double-blind, randomized, placebo-controlled trial. AIDS. 1992 Jun;6(6):563-9.
DMKQ3MC	RU	https://pubmed.ncbi.nlm.nih.gov/1388878

DM0NJWG	DI	DM0NJWG
DM0NJWG	DN	Human interleukin-2
DM0NJWG	MI	TTF89GD
DM0NJWG	MN	Interleukin-2 (IL2)
DM0NJWG	MT	DTT
DM0NJWG	MA	Modulator
DM0NJWG	RN	Clinical pipeline report, company report or official report of Immunservice.
DM0NJWG	RU	http://www.immunservice.com/index.php?page=regulatory

DMOPWSX	DI	DMOPWSX
DMOPWSX	DN	Ibrolipim
DMOPWSX	MI	TTOF3WZ
DMOPWSX	MN	Lipoprotein lipase (LPL)
DMOPWSX	MT	DTT
DMOPWSX	MA	Modulator
DMOPWSX	RN	NO-1886 (ibrolipim), a lipoprotein lipase activator, increases the expression of uncoupling protein 3 in skeletal muscle and suppresses fat accumulation in high-fat diet-induced obesity in rats. Metabolism. 2005 Dec;54(12):1587-92.
DMOPWSX	RU	https://pubmed.ncbi.nlm.nih.gov/16311090

DM37CX4	DI	DM37CX4
DM37CX4	DN	IC14
DM37CX4	MI	TTCLGZ8
DM37CX4	MN	HUAMN monocyte differentiation antigen CD14 (CD14)
DM37CX4	MT	DTT
DM37CX4	MA	Inhibitor
DM37CX4	RN	IC14 (Anti-CD14) Treatment in Patients With SARS-CoV-2 (COVID-19)
DM37CX4	RU	https://clinicaltrials.gov/ct2/show/NCT04391309

DMUFCQG	DI	DMUFCQG
DMUFCQG	DN	IC14
DMUFCQG	MI	TT6I7DC
DMUFCQG	MN	Monocyte differentiation antigen CD14 (CD14)
DMUFCQG	MT	DTT
DMUFCQG	RN	IC14, a CD14 specific monoclonal antibody, is a potential treatment for patients with severe sepsis. J Endotoxin Res. 2001;7(4):310-4.
DMUFCQG	RU	https://pubmed.ncbi.nlm.nih.gov/11717588

DMB1UYV	DI	DMB1UYV
DMB1UYV	DN	IC-485
DMB1UYV	MI	TTV5CGO
DMB1UYV	MN	Phosphodiesterase 4 (PDE4)
DMB1UYV	MT	DTT
DMB1UYV	MA	Inhibitor
DMB1UYV	RN	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
DMB1UYV	RU	https://pubmed.ncbi.nlm.nih.gov/16634702

DMP925B	DI	DMP925B
DMP925B	DN	ICA-105665
DMP925B	MI	TTIVDM3
DMP925B	MN	Voltage-gated potassium channel Kv7.3 (KCNQ3)
DMP925B	MT	DTT
DMP925B	MA	Activator
DMP925B	RN	New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels. Curr Neurol Neurosci Rep. 2008 Jul;8(4):345-52.
DMP925B	RU	https://pubmed.ncbi.nlm.nih.gov/18590620

DMRFY7I	DI	DMRFY7I
DMRFY7I	DN	ICA-17043
DMRFY7I	MI	TTMNI76
DMRFY7I	MN	Calcium-activated potassium channel (KCN)
DMRFY7I	MT	DTT
DMRFY7I	MA	Inhibitor
DMRFY7I	RN	Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82.
DMRFY7I	RU	https://pubmed.ncbi.nlm.nih.gov/18232633

DMRFY7I	DI	DMRFY7I
DMRFY7I	DN	ICA-17043
DMRFY7I	MI	TT7M9I6
DMRFY7I	MN	Calcium-activated potassium channel KCa3.1 (KCNN4)
DMRFY7I	MT	DTT
DMRFY7I	MA	Modulator
DMRFY7I	RN	Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia.Expert Opin Investig Drugs.2009 Feb;18(2):231-9.
DMRFY7I	RU	https://www.ncbi.nlm.nih.gov/pubmed/19236269

DMGHQ37	DI	DMGHQ37
DMGHQ37	DN	Icaritin
DMGHQ37	MI	TTZAYWL
DMGHQ37	MN	Estrogen receptor (ESR)
DMGHQ37	MT	DTT
DMGHQ37	MA	Modulator
DMGHQ37	RN	A novel prenylflavone restricts breast cancer cell growth through AhR-mediated destabilization of ER protein.Carcinogenesis.2012 May;33(5):1089-97.
DMGHQ37	RU	https://www.ncbi.nlm.nih.gov/pubmed/22345291

DMC13BQ	DI	DMC13BQ
DMC13BQ	DN	ICO-25
DMC13BQ	MI	TTBHFYQ
DMC13BQ	MN	Mucin-1 (MUC1)
DMC13BQ	MT	DTT
DMC13BQ	RN	The role of epithelial antigens in diagnosis and staging of breast cancer. Arkh Patol. 2002 Nov-Dec;64(6):13-5.
DMC13BQ	RU	https://pubmed.ncbi.nlm.nih.gov/12534220

DMTXNZK	DI	DMTXNZK
DMTXNZK	DN	Icofungipen
DMTXNZK	MI	TT2GPK3
DMTXNZK	MN	DNA topoisomerase (TOP)
DMTXNZK	MT	DTT
DMTXNZK	MA	Inhibitor
DMTXNZK	RN	Crystallization and preliminary X-ray analysis of anti-cancer agent 3-(9-acridinylamino)-5-(hydroxymethyl)aniline complexed with the DNA hexamer d(CGTACG)2. Biochim Biophys Acta. 2003 Jan 3;1625(1):27-9.
DMTXNZK	RU	https://pubmed.ncbi.nlm.nih.gov/12527422

DMTXNZK	DI	DMTXNZK
DMTXNZK	DN	Icofungipen
DMTXNZK	MI	TTBZHDM
DMTXNZK	MN	Fungal Isoleucyl t-RNA synthetase (Fung ILS1)
DMTXNZK	MT	DTT
DMTXNZK	MA	Modulator
DMTXNZK	RN	Efficacy, plasma pharmacokinetics, and safety of icofungipen, an inhibitor of Candida isoleucyl-tRNA synthetase, in treatment of experimental disseminated candidiasis in persistently neutropenic rabbits. Antimicrob Agents Chemother. 2005 May;49(5):2084-92.
DMTXNZK	RU	https://pubmed.ncbi.nlm.nih.gov/15855534

DM524GR	DI	DM524GR
DM524GR	DN	ICP-192
DM524GR	MI	TT0LF7H
DM524GR	MN	Fibroblast growth factor receptor (FGFR)
DM524GR	MT	DTT
DM524GR	MA	Inhibitor
DM524GR	RN	Clinical pipeline report, company report or official report of InnoCare Pharma.
DM524GR	RU	https://www.innocarepharma.com/en/pipeline/our-pipeline/

DM7XIAJ	DI	DM7XIAJ
DM7XIAJ	DN	ID-93/GLA-SE
DM7XIAJ	MI	TTVH0YQ
DM7XIAJ	MN	Mycobacterium Fusion protein Rv2608-Rv3619-Rv3620-Rv1813 (MycB antigens)
DM7XIAJ	MT	DTT
DM7XIAJ	MA	Modulator
DM7XIAJ	RN	US patent application no. US20150182612 A1.
DM7XIAJ	RU	https://www.google.co.in/patents/US20150182612

DMABRXY	DI	DMABRXY
DMABRXY	DN	IDM-2101
DMABRXY	MI	TTY6DTE
DMABRXY	MN	Carcinoembryonic antigen CEA (CD66e)
DMABRXY	MT	DTT
DMABRXY	RN	Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol. 2008 Sep 20;26(27):4418-25.
DMABRXY	RU	https://pubmed.ncbi.nlm.nih.gov/18802154

DMABRXY	DI	DMABRXY
DMABRXY	DN	IDM-2101
DMABRXY	MI	TTWSKHD
DMABRXY	MN	Melanoma-associated antigen 3 (MAGEA3)
DMABRXY	MT	DTT
DMABRXY	RN	Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol. 2008 Sep 20;26(27):4418-25.
DMABRXY	RU	https://pubmed.ncbi.nlm.nih.gov/18802154

DMSRC5D	DI	DMSRC5D
DMSRC5D	DN	IDX899
DMSRC5D	MI	TT84ETX
DMSRC5D	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMSRC5D	MT	DTT
DMSRC5D	MA	Modulator
DMSRC5D	RN	Unexpected finding of delayed-onset seizures in HIV-positive, treatment-experienced subjects in the Phase IIb evaluation of fosdevirine (GSK2248761).Antivir Ther.2014;19(1):69-78.
DMSRC5D	RU	https://www.ncbi.nlm.nih.gov/pubmed/24158593

DMGWNCJ	DI	DMGWNCJ
DMGWNCJ	DN	Ifabotuzumab
DMGWNCJ	MI	TTHS2LR
DMGWNCJ	MN	Ephrin type-A receptor 3 (EPHA3)
DMGWNCJ	MT	DTT
DMGWNCJ	MA	Antagonist
DMGWNCJ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMGWNCJ	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMZP84Y	DI	DMZP84Y
DMZP84Y	DN	Ifetroban sodium
DMZP84Y	MI	TT2O84V
DMZP84Y	MN	Thromboxane A2 receptor (TBXA2R)
DMZP84Y	MT	DTT
DMZP84Y	MA	Antagonist
DMZP84Y	RN	AT-1 receptor antagonism modifies the mediation of endothelin-1, thromboxane A2, and catecholamines in the renal constrictor response to angiotensin II. Kidney Int Suppl. 2005 Jan;(93):S3-9.
DMZP84Y	RU	https://pubmed.ncbi.nlm.nih.gov/15613065

DM4H8EZ	DI	DM4H8EZ
DM4H8EZ	DN	IFN-alpha
DM4H8EZ	MI	TT95SOA
DM4H8EZ	MN	Interferon alpha (IFNA)
DM4H8EZ	MT	DTT
DM4H8EZ	MA	Modulator
DM4H8EZ	RN	WO patent application no. 2009,0153,36, Controlled release interferon drug products and treatment of hcv infection using same.
DM4H8EZ	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20090129&CC=WO&NR=2009015336A2&KC=A2

DMHI36A	DI	DMHI36A
DMHI36A	DN	IFX-1
DMHI36A	MI	TTKANGO
DMHI36A	MN	Complement C5 (CO5)
DMHI36A	MT	DTT
DMHI36A	MA	Inhibitor
DMHI36A	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMHI36A	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMH97XA	DI	DMH97XA
DMH97XA	DN	Igmesine
DMH97XA	MI	TTA7UJC
DMH97XA	MN	Alpha-1-antitrypsin (SERPINA1)
DMH97XA	MT	DTT
DMH97XA	MA	Modulator
DMH97XA	RN	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
DMH97XA	RU	https://pubmed.ncbi.nlm.nih.gov/16634702

DMH97XA	DI	DMH97XA
DMH97XA	DN	Igmesine
DMH97XA	MI	TT5TPI6
DMH97XA	MN	Opioid receptor sigma 1 (OPRS1)
DMH97XA	MT	DTT
DMH97XA	MA	Agonist
DMH97XA	RN	Antiamnesic and neuroprotective effects of donepezil against learning impairments induced in mice by exposure to carbon monoxide gas. J Pharmacol Exp Ther. 2006 Jun;317(3):1307-19.
DMH97XA	RU	https://pubmed.ncbi.nlm.nih.gov/16551835

DMIHQ5G	DI	DMIHQ5G
DMIHQ5G	DN	IL-2/CD40L-expressing leukemia vaccine
DMIHQ5G	MI	TTF89GD
DMIHQ5G	MN	Interleukin-2 (IL2)
DMIHQ5G	MT	DTT
DMIHQ5G	RN	Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and a... Blood. 2006 Feb 15;107(4):1332-41.
DMIHQ5G	RU	https://pubmed.ncbi.nlm.nih.gov/16249392

DMIHQ5G	DI	DMIHQ5G
DMIHQ5G	DN	IL-2/CD40L-expressing leukemia vaccine
DMIHQ5G	MI	TTIJP3Q
DMIHQ5G	MN	TNF related activation protein (CD40LG)
DMIHQ5G	MT	DTT
DMIHQ5G	RN	Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and a... Blood. 2006 Feb 15;107(4):1332-41.
DMIHQ5G	RU	https://pubmed.ncbi.nlm.nih.gov/16249392

DM1E4VP	DI	DM1E4VP
DM1E4VP	DN	IL-21
DM1E4VP	MI	TT9QEJ6
DM1E4VP	MN	Interleukin-21 (IL21)
DM1E4VP	MT	DTT
DM1E4VP	MA	Modulator
DM1E4VP	RN	National Cancer Institute Drug Dictionary (drug id 409696).
DM1E4VP	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=409696

DMYEGRH	DI	DMYEGRH
DMYEGRH	DN	IL-4R
DMYEGRH	MI	TTLGTKB
DMYEGRH	MN	Interleukin-4 (IL4)
DMYEGRH	MT	DTT
DMYEGRH	MA	Inhibitor
DMYEGRH	RN	Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol. 2001 Jun;107(6):963-70.
DMYEGRH	RU	https://pubmed.ncbi.nlm.nih.gov/11398072

DMDNHRA	DI	DMDNHRA
DMDNHRA	DN	Ilodecakin
DMDNHRA	MI	TTT0Q1F
DMDNHRA	MN	Interleukin-10 (IL10)
DMDNHRA	MT	DTT
DMDNHRA	MA	Modulator
DMDNHRA	RN	Ilodecakin. Schering-Plough Corp. IDrugs. 1999 Oct;2(10):1045-58.
DMDNHRA	RU	https://pubmed.ncbi.nlm.nih.gov/16118714

DMUJ1WV	DI	DMUJ1WV
DMUJ1WV	DN	IMCgp100
DMUJ1WV	MI	TT8MK59
DMUJ1WV	MN	Melanocytes lineage-specific antigen GP100 (PMEL)
DMUJ1WV	MT	DTT
DMUJ1WV	MA	Modulator
DMUJ1WV	RN	Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors
DMUJ1WV	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3624013

DMUJ1WV	DI	DMUJ1WV
DMUJ1WV	DN	IMCgp100
DMUJ1WV	MI	TT7AKW1
DMUJ1WV	MN	T-cell receptor (TCR)
DMUJ1WV	MT	DTT
DMUJ1WV	MA	Modulator
DMUJ1WV	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMUJ1WV	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMUJ1WV	DI	DMUJ1WV
DMUJ1WV	DN	IMCgp100
DMUJ1WV	MI	TTV3XPL
DMUJ1WV	MN	T-cell surface glycoprotein CD3 gamma (CD3G)
DMUJ1WV	MT	DTT
DMUJ1WV	MA	Inhibitor
DMUJ1WV	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMUJ1WV	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMU1MR9	DI	DMU1MR9
DMU1MR9	DN	IMD-1041
DMU1MR9	MI	TTJ3E9X
DMU1MR9	MN	Inhibitor of nuclear factor kappa-B kinase beta (IKKB)
DMU1MR9	MT	DTT
DMU1MR9	MA	Inhibitor
DMU1MR9	RN	Inhibition of I B phosphorylation prevents load-induced cardiac dysfunction in mice. Am J Physiol Heart Circ Physiol. 2012 Dec 15;303(12):H1435-45.
DMU1MR9	RU	https://pubmed.ncbi.nlm.nih.gov/23042949

DMMQFG2	DI	DMMQFG2
DMMQFG2	DN	Imeglimin
DMMQFG2	MI	TTLAFZV
DMMQFG2	MN	AMP-activated protein kinase (AMPK)
DMMQFG2	MT	DTT
DMMQFG2	MA	Modulator
DMMQFG2	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032542)
DMMQFG2	RU	http://adisinsight.springer.com/drugs/800032542

DML9AVG	DI	DML9AVG
DML9AVG	DN	IMG-7289
DML9AVG	MI	TTNR0UQ
DML9AVG	MN	Lysine-specific histone demethylase 1 (LSD)
DML9AVG	MT	DTT
DML9AVG	MA	Inhibitor
DML9AVG	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DML9AVG	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMNJ491	DI	DMNJ491
DMNJ491	DN	IMGN529
DMNJ491	MI	TTFCW29
DMNJ491	MN	Leukocyte antigen CD37 (CD37)
DMNJ491	MT	DTT
DMNJ491	RN	The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model. Leukemia. 2014 Jul;28(7):1501-10.
DMNJ491	RU	https://pubmed.ncbi.nlm.nih.gov/24445867

DMIUC3M	DI	DMIUC3M
DMIUC3M	DN	IMGN901
DMIUC3M	MI	TTUBJQ3
DMIUC3M	MN	Neural cell adhesion molecule (NCAM)
DMIUC3M	MT	DTT
DMIUC3M	MA	Modulator
DMIUC3M	RN	Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models. MAbs. 2014 Mar-Apr;6(2):556-66.
DMIUC3M	RU	https://pubmed.ncbi.nlm.nih.gov/24492307

DME3POC	DI	DME3POC
DME3POC	DN	Imisopasem manganese
DME3POC	MI	TT9O4C5
DME3POC	MN	Superoxide dismutase Mn (SOD Mn)
DME3POC	MT	DTT
DME3POC	MA	Modulator
DME3POC	RN	The manganese superoxide dismutase mimetic, M40403, protects adult mice from lethal total body irradiation. Free Radic Res. 2010 May;44(5):529-40.
DME3POC	RU	https://pubmed.ncbi.nlm.nih.gov/20298121

DM6IQ3V	DI	DM6IQ3V
DM6IQ3V	DN	IMO-2055
DM6IQ3V	MI	TTSHG0T
DM6IQ3V	MN	Toll-like receptor 9 (TLR9)
DM6IQ3V	MT	DTT
DM6IQ3V	MA	Agonist
DM6IQ3V	RN	Clinical pipeline report, company report or official report of Idera Pharmaceuticals (2011).
DM6IQ3V	RU	http://www.iderapharma.com/

DMM549D	DI	DMM549D
DMM549D	DN	IMO-3100
DMM549D	MI	TTRJ1K4
DMM549D	MN	Toll-like receptor 7 (TLR7)
DMM549D	MT	DTT
DMM549D	MA	Modulator
DMM549D	RN	Company report (Iderapharma)
DMM549D	RU	http://ir.iderapharma.com/phoenix.zhtml?c=208904&p=irol-newsArticle&ID=1816887

DMM549D	DI	DMM549D
DMM549D	DN	IMO-3100
DMM549D	MI	TTSHG0T
DMM549D	MN	Toll-like receptor 9 (TLR9)
DMM549D	MT	DTT
DMM549D	MA	Modulator
DMM549D	RN	Company report (Iderapharma)
DMM549D	RU	http://ir.iderapharma.com/phoenix.zhtml?c=208904&p=irol-newsArticle&ID=1816887

DMDPNCJ	DI	DMDPNCJ
DMDPNCJ	DN	IMO-8400
DMDPNCJ	MI	TTOK0LR
DMDPNCJ	MN	Toll-like receptor (TLR)
DMDPNCJ	MT	DTT
DMDPNCJ	MA	Antagonist
DMDPNCJ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMDPNCJ	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DMTN16K	DI	DMTN16K
DMTN16K	DN	Implitapide
DMTN16K	MI	TTUS1RD
DMTN16K	MN	Microsomal triglyceride transfer protein (MTTP)
DMTN16K	MT	DTT
DMTN16K	MA	Inhibitor
DMTN16K	RN	Novel nonstatin strategies to lower low-density lipoprotein cholesterol. Curr Atheroscler Rep. 2009 Jan;11(1):67-70.
DMTN16K	RU	https://pubmed.ncbi.nlm.nih.gov/19080731

DMB1N6P	DI	DMB1N6P
DMB1N6P	DN	Impoyz
DMB1N6P	MI	DE4LYSA
DMB1N6P	MN	Cytochrome P450 3A4 (CYP3A4)
DMB1N6P	MT	DME
DMB1N6P	MA	Metabolism
DMB1N6P	RN	Cytochrome p450: a target for drug development for skin diseases. J Invest Dermatol. 2004 Sep;123(3):417-25.
DMB1N6P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304077

DM15MRZ	DI	DM15MRZ
DM15MRZ	DN	IMR-687
DM15MRZ	MI	TTZOEBC
DM15MRZ	MN	Phosphodiesterase 9 (PDE9)
DM15MRZ	MT	DTT
DM15MRZ	MA	Inhibitor
DM15MRZ	RN	Clinical pipeline report, company report or official report of Imara.
DM15MRZ	RU	https://imaratx.com/our-programs/

DMNUXKA	DI	DMNUXKA
DMNUXKA	DN	INCAGN01876
DMNUXKA	MI	TTG6LA7
DMNUXKA	MN	Activation-inducible TNFR family receptor (TNFRSF18)
DMNUXKA	MT	DTT
DMNUXKA	MA	Agonist
DMNUXKA	RN	Clinical pipeline report, company report or official report of Agenus.
DMNUXKA	RU	https://agenusbio.com/pipeline/

DMK7OHI	DI	DMK7OHI
DMK7OHI	DN	INCAGN01949
DMK7OHI	MI	TTL31H0
DMK7OHI	MN	OX40L receptor (CD134)
DMK7OHI	MT	DTT
DMK7OHI	MA	Agonist
DMK7OHI	RN	Sequential therapy with INCAGN01949 followed by ipilimumab and nivolumab in two patients with advanced ovarian carcinoma. Gynecol Oncol Rep. 2020 Oct 1;34:100655.
DMK7OHI	RU	https://pubmed.ncbi.nlm.nih.gov/33083509

DMFG8TI	DI	DMFG8TI
DMFG8TI	DN	INCB00928
DMFG8TI	MI	TTJNBQA
DMFG8TI	MN	Activin receptor-like kinase 2 (ALK-2)
DMFG8TI	MT	DTT
DMFG8TI	MA	Inhibitor
DMFG8TI	RN	Clinical pipeline report, company report or official report of Incyte.
DMFG8TI	RU	https://www.incyte.com/what-we-do/pharmaceutical-portfolio

DMD9RV3	DI	DMD9RV3
DMD9RV3	DN	INCB039110
DMD9RV3	MI	TT6DM01
DMD9RV3	MN	Janus kinase 1 (JAK-1)
DMD9RV3	MT	DTT
DMD9RV3	MA	Inhibitor
DMD9RV3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2047).
DMD9RV3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2047

DMD9RV3	DI	DMD9RV3
DMD9RV3	DN	INCB039110
DMD9RV3	MI	TTRMX3V
DMD9RV3	MN	Janus kinase 2 (JAK-2)
DMD9RV3	MT	DTT
DMD9RV3	MA	Inhibitor
DMD9RV3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2048).
DMD9RV3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2048

DMZJP2T	DI	DMZJP2T
DMZJP2T	DN	INCB50465
DMZJP2T	MI	TTGBPJE
DMZJP2T	MN	PI3-kinase delta (PIK3CD)
DMZJP2T	MT	DTT
DMZJP2T	MA	Inhibitor
DMZJP2T	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZJP2T	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMDK0HX	DI	DMDK0HX
DMDK0HX	DN	INCB54707
DMDK0HX	MI	TT6DM01
DMDK0HX	MN	Janus kinase 1 (JAK-1)
DMDK0HX	MT	DTT
DMDK0HX	MA	Inhibitor
DMDK0HX	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMDK0HX	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMJN9PU	DI	DMJN9PU
DMJN9PU	DN	INCB86550
DMJN9PU	MI	TT8ZLTI
DMJN9PU	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMJN9PU	MT	DTT
DMJN9PU	MA	Inhibitor
DMJN9PU	RN	National Cancer Institute Drug Dictionary (drug name INCB086550).
DMJN9PU	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pd-l1-inhibitor-incb086550

DM6OFJ8	DI	DM6OFJ8
DM6OFJ8	DN	Indibulin
DM6OFJ8	MI	TTML2WA
DM6OFJ8	MN	Tubulin (TUB)
DM6OFJ8	MT	DTT
DM6OFJ8	MA	Stablizer
DM6OFJ8	RN	2011 Pipeline of ZioPharm.
DM6OFJ8	RU	http://www.ziopharm.com/clinical_dev.php

DM9SX6Y	DI	DM9SX6Y
DM9SX6Y	DN	Indisulam
DM9SX6Y	MI	TT2LVK8
DM9SX6Y	MN	Carbonic anhydrase IX (CA-IX)
DM9SX6Y	MT	DTT
DM9SX6Y	MA	Modulator
DM9SX6Y	RN	Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-assoc... Bioorg Med Chem Lett. 2004 Jan 5;14(1):217-23.
DM9SX6Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/14684331

DM9SX6Y	DI	DM9SX6Y
DM9SX6Y	DN	Indisulam
DM9SX6Y	MI	DE5IED8
DM9SX6Y	MN	Cytochrome P450 2C9 (CYP2C9)
DM9SX6Y	MT	DME
DM9SX6Y	MA	Metabolism
DM9SX6Y	RN	PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression. Clin Pharmacol Ther. 2008 Jun;83(6):829-39.
DM9SX6Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17851564

DM9SX6Y	DI	DM9SX6Y
DM9SX6Y	DN	Indisulam
DM9SX6Y	MI	DEGTFWK
DM9SX6Y	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM9SX6Y	MT	DME
DM9SX6Y	MA	Metabolism
DM9SX6Y	RN	CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity. Clin Cancer Res. 2007 May 15;13(10):2970-6.
DM9SX6Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17504998

DMU5SZP	DI	DMU5SZP
DMU5SZP	DN	Inecalcitol oral
DMU5SZP	MI	TTK59TV
DMU5SZP	MN	Vitamin D3 receptor (VDR)
DMU5SZP	MT	DTT
DMU5SZP	MA	Agonist
DMU5SZP	RN	Inecalcitol, an analog of 1,25D3, displays enhanced antitumor activity through the induction of apoptosis in a squamous cell carcinoma model system. Cell Cycle. 2013 Mar 1;12(5):743-52.
DMU5SZP	RU	https://pubmed.ncbi.nlm.nih.gov/23388458

DMEO9Y7	DI	DMEO9Y7
DMEO9Y7	DN	INGAP peptide
DMEO9Y7	MI	TTGMYVE
DMEO9Y7	MN	Phosphofructokinase 2 (PFK2)
DMEO9Y7	MT	DTT
DMEO9Y7	MA	Modulator
DMEO9Y7	RN	A Pentadecapeptide Fragment of Islet Neogenesis-Associated Protein Increases Beta-Cell Mass and Reverses Diabetes in C57BL/6J Mice. Ann Surg. 2004 November; 240(5): 875-884.
DMEO9Y7	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1356495/

DMF7J6D	DI	DMF7J6D
DMF7J6D	DN	INGN-225
DMF7J6D	MI	TT7SBF5
DMF7J6D	MN	Cellular tumor antigen p53 (TP53)
DMF7J6D	MT	DTT
DMF7J6D	RN	INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opin Biol Ther. 2010 Jun;10(6):983-91.
DMF7J6D	RU	https://pubmed.ncbi.nlm.nih.gov/20420527

DM6P91T	DI	DM6P91T
DM6P91T	DN	INGN-241
DM6P91T	MI	TT1EPXZ
DM6P91T	MN	Interleukin-24 (IL24)
DM6P91T	MT	DTT
DM6P91T	MA	Inhibitor
DM6P91T	RN	Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Mol Ther. 2005 Jan;11(1):160-72.
DM6P91T	RU	https://pubmed.ncbi.nlm.nih.gov/15585417

DMGO7QT	DI	DMGO7QT
DMGO7QT	DN	INK128
DMGO7QT	MI	TTCJG29
DMGO7QT	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMGO7QT	MT	DTT
DMGO7QT	MA	Inhibitor
DMGO7QT	RN	2011 Pipeline of Intellikine.
DMGO7QT	RU	http://www.intellikine.com/pipeline/

DMKRGVJ	DI	DMKRGVJ
DMKRGVJ	DN	INS-1
DMKRGVJ	MI	TTZ7WFL
DMKRGVJ	MN	Glucose metabolism (Glucose metab)
DMKRGVJ	MT	DTT
DMKRGVJ	MA	Modulator
DMKRGVJ	RN	Herbal constituent sequoyitol improves hyperglycemia and glucose intolerance by targeting hepatocytes, adipocytes, and beta-cells. Am J Physiol Endocrinol Metab. 2012 April 15; 302(8): E932-E940.
DMKRGVJ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3330724/

DMF93RQ	DI	DMF93RQ
DMF93RQ	DN	INS-37217
DMF93RQ	MI	TTOZHQC
DMF93RQ	MN	P2Y purinoceptor 2 (P2RY2)
DMF93RQ	MT	DTT
DMF93RQ	MA	Agonist
DMF93RQ	RN	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
DMF93RQ	RU	https://pubmed.ncbi.nlm.nih.gov/16634702

DMKZUVC	DI	DMKZUVC
DMKZUVC	DN	INS-50589
DMKZUVC	MI	TTZ1DT0
DMKZUVC	MN	P2Y purinoceptor 12 (P2RY12)
DMKZUVC	MT	DTT
DMKZUVC	MA	Modulator
DMKZUVC	RN	Rapid and reversible modulation of platelet function in man by a novel P2Y(12) ADP-receptor antagonist, INS50589. Platelets. 2007 Aug;18(5):346-56.
DMKZUVC	RU	https://pubmed.ncbi.nlm.nih.gov/17654304

DMNKAFQ	DI	DMNKAFQ
DMNKAFQ	DN	Instiladrin
DMNKAFQ	MI	TTSIUJ9
DMNKAFQ	MN	Interferon-alpha 2 (IFNA2)
DMNKAFQ	MT	DTT
DMNKAFQ	MA	Modulator
DMNKAFQ	RN	ClinicalTrials.gov (NCT01687244) Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer. U.S. National Institutes of Health.
DMNKAFQ	RU	https://clinicaltrials.gov/ct2/show/NCT01687244

DMYTKF5	DI	DMYTKF5
DMYTKF5	DN	Interferon
DMYTKF5	MI	TT6ONYI
DMYTKF5	MN	Interferon (IFN)
DMYTKF5	MT	DTT
DMYTKF5	MA	Modulator
DMYTKF5	RN	Low-dose oral interferon alpha as prophylaxis against viral respiratory illness: a double-blind, parallel controlled trial during an influenza pandemic year. Influenza Other Respir Viruses. 2013 Sep;7(5):854-62.
DMYTKF5	RU	https://pubmed.ncbi.nlm.nih.gov/23398960

DMVACTU	DI	DMVACTU
DMVACTU	DN	Interferon alpha-2b
DMVACTU	MI	TTSIUJ9
DMVACTU	MN	Interferon-alpha 2 (IFNA2)
DMVACTU	MT	DTT
DMVACTU	MA	Modulator
DMVACTU	RN	Clinical pipeline report, company report or official report of Avarx.
DMVACTU	RU	http://www.avarx.com/AvaRx/SubDomains/Company271/Listings/bucketc9a4f99040669fa206037a416235/Public.Listing.display.html

DMQSA7H	DI	DMQSA7H
DMQSA7H	DN	Interferon beta 1a
DMQSA7H	MI	TT4TZ8J
DMQSA7H	MN	Interferon-beta (IFNB1)
DMQSA7H	MT	DTT
DMQSA7H	MA	Modulator
DMQSA7H	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMQSA7H	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM8YF01	DI	DM8YF01
DM8YF01	DN	Interferon-alpha lozenge
DM8YF01	MI	TT95SOA
DM8YF01	MN	Interferon alpha (IFNA)
DM8YF01	MT	DTT
DM8YF01	MA	Modulator
DM8YF01	RN	Interferon-alpha. Amarillo Biosciences. Curr Opin Investig Drugs. 2002 May;3(5):693-7.
DM8YF01	RU	https://pubmed.ncbi.nlm.nih.gov/12090541

DMBXEG9	DI	DMBXEG9
DMBXEG9	DN	Intetumumab
DMBXEG9	MI	TT69TQN
DMBXEG9	MN	Integrin alpha-V/beta-3 (ITGAV/B3)
DMBXEG9	MT	DTT
DMBXEG9	MA	Modulator
DMBXEG9	RN	A randomised, phase II study of intetumumab, an anti-alphav-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer. 2011 Jul 26;105(3):346-52.
DMBXEG9	RU	https://pubmed.ncbi.nlm.nih.gov/21750555

DMSTJ6Q	DI	DMSTJ6Q
DMSTJ6Q	DN	INX-189
DMSTJ6Q	MI	TTMVBWH
DMSTJ6Q	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMSTJ6Q	MT	DTT
DMSTJ6Q	MA	Inhibitor
DMSTJ6Q	RN	Clinical pipeline report, company report or official report of Bristol-Myers Squibb.
DMSTJ6Q	RU	http://news.bms.com/press-release/financial-news/bristol-myers-squibb-discontinues-development-bms-986094-investigationa

DMNW0DG	DI	DMNW0DG
DMNW0DG	DN	Iodine-131-tositumomab
DMNW0DG	MI	TTUE541
DMNW0DG	MN	Leukocyte surface antigen Leu-16 (CD20)
DMNW0DG	MT	DTT
DMNW0DG	RN	Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood. 2008 Aug 1;112(3):830-5.
DMNW0DG	RU	https://pubmed.ncbi.nlm.nih.gov/18502830

DM5F0QY	DI	DM5F0QY
DM5F0QY	DN	IONIS-416858
DM5F0QY	MI	TTDM4ZU
DM5F0QY	MN	Factor XI messenger RNA (F11 mRNA)
DM5F0QY	MT	DTT
DM5F0QY	MA	Inhibitor
DM5F0QY	RN	Clinical pipeline report, company report or official report of Ionis Pharmaceuticals.
DM5F0QY	RU	https://www.ionispharma.com/ionis-innovation/pipeline/

DM6PDX2	DI	DM6PDX2
DM6PDX2	DN	IONIS-C9Rx
DM6PDX2	MI	TTA4SHR
DM6PDX2	MN	C9orf72 messenger RNA (C9orf72 mRNA)
DM6PDX2	MT	DTT
DM6PDX2	MA	Inhibitor
DM6PDX2	RN	Clinical pipeline report, company report or official report of Ionis Pharmaceuticals.
DM6PDX2	RU	https://www.ionispharma.com/ionis-innovation/pipeline/

DM5LM3O	DI	DM5LM3O
DM5LM3O	DN	IONIS-DNM2-2.5Rx
DM5LM3O	MI	TTVRA5G
DM5LM3O	MN	DNM2 messenger RNA (DNM2 mRNA)
DM5LM3O	MT	DTT
DM5LM3O	MA	Inhibitor
DM5LM3O	RN	Clinical pipeline report, company report or official report of Ionis Pharmaceuticals.
DM5LM3O	RU	https://www.ionispharma.com/ionis-innovation/pipeline/

DMJ2763	DI	DMJ2763
DMJ2763	DN	IONIS-FB-LRx
DMJ2763	MI	TT3SGK7
DMJ2763	MN	CFB messenger RNA (CFB mRNA)
DMJ2763	MT	DTT
DMJ2763	MA	Inhibitor
DMJ2763	RN	Clinical pipeline report, company report or official report of Ionis Pharmaceuticals.
DMJ2763	RU	https://www.ionispharma.com/ionis-innovation/pipeline/

DMWV2N1	DI	DMWV2N1
DMWV2N1	DN	IONIS-GCCRRX
DMWV2N1	MI	TTYRL6O
DMWV2N1	MN	Glucocorticoid receptor (NR3C1)
DMWV2N1	MT	DTT
DMWV2N1	MA	Antagonist
DMWV2N1	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMWV2N1	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMB4GD9	DI	DMB4GD9
DMB4GD9	DN	IONIS-GCGR-Rx
DMB4GD9	MI	TTLMJSC
DMB4GD9	MN	Glucagon receptor messenger RNA (GCGR mRNA)
DMB4GD9	MT	DTT
DMB4GD9	MA	Inhibitor
DMB4GD9	RN	Clinical pipeline report, company report or official report of Ionis Pharmaceuticals.
DMB4GD9	RU	https://www.ionispharma.com/ionis-innovation/pipeline/

DMGTJUP	DI	DMGTJUP
DMGTJUP	DN	IONIS-PTP1BRX
DMGTJUP	MI	TTMS7KP
DMGTJUP	MN	Protein-tyrosine phosphatase 1B (PTP1B)
DMGTJUP	MT	DTT
DMGTJUP	MA	Inhibitor
DMGTJUP	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMGTJUP	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DM7VJE1	DI	DM7VJE1
DM7VJE1	DN	IONIS-TMPRSS6-LRx
DM7VJE1	MI	TTNIUKC
DM7VJE1	MN	TMPRSS6 messenger RNA (TMPRSS6 mRNA)
DM7VJE1	MT	DTT
DM7VJE1	MA	Inhibitor
DM7VJE1	RN	Clinical pipeline report, company report or official report of Ionis Pharmaceuticals.
DM7VJE1	RU	https://www.ionispharma.com/ionis-innovation/pipeline/

DM5TMYC	DI	DM5TMYC
DM5TMYC	DN	iOWH032
DM5TMYC	MI	TTRLZHP
DM5TMYC	MN	cAMP-dependent chloride channel (CFTR)
DM5TMYC	MT	DTT
DM5TMYC	MA	Inhibitor
DM5TMYC	RN	Developing novel antisecretory drugs to treat infectious diarrhea. Future Med Chem. 2011 Aug;3(10):1317-25.
DM5TMYC	RU	https://pubmed.ncbi.nlm.nih.gov/21859305

DMANRGW	DI	DMANRGW
DMANRGW	DN	IP10 C8
DMANRGW	MI	TTPHMWB
DMANRGW	MN	Aminopeptidase N (ANPEP)
DMANRGW	MT	DTT
DMANRGW	MA	Modulator
DMANRGW	RN	Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions. Clin Chem Lab Med. 2009;47(3):253-61.
DMANRGW	RU	https://pubmed.ncbi.nlm.nih.gov/19327105

DMANRGW	DI	DMANRGW
DMANRGW	DN	IP10 C8
DMANRGW	MI	TTDIGC1
DMANRGW	MN	Dipeptidyl peptidase 4 (DPP-4)
DMANRGW	MT	DTT
DMANRGW	MA	Modulator
DMANRGW	RN	Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions. Clin Chem Lab Med. 2009;47(3):253-61.
DMANRGW	RU	https://pubmed.ncbi.nlm.nih.gov/19327105

DMDUVCZ	DI	DMDUVCZ
DMDUVCZ	DN	IPH-2101
DMDUVCZ	MI	TT4UXPE
DMDUVCZ	MN	MHC class I NK cell receptor 2DL1 (CD158A)
DMDUVCZ	MT	DTT
DMDUVCZ	MA	Modulator
DMDUVCZ	RN	Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8.
DMDUVCZ	RU	https://pubmed.ncbi.nlm.nih.gov/25510242

DMDUVCZ	DI	DMDUVCZ
DMDUVCZ	DN	IPH-2101
DMDUVCZ	MI	TTU0P73
DMDUVCZ	MN	MHC class I NK cell receptor 2DL2 (CD158b1)
DMDUVCZ	MT	DTT
DMDUVCZ	MA	Modulator
DMDUVCZ	RN	Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8.
DMDUVCZ	RU	https://pubmed.ncbi.nlm.nih.gov/25510242

DMDUVCZ	DI	DMDUVCZ
DMDUVCZ	DN	IPH-2101
DMDUVCZ	MI	TTEX3SI
DMDUVCZ	MN	MHC class I NK cell receptor 2DL3 (CD158b2)
DMDUVCZ	MT	DTT
DMDUVCZ	MA	Modulator
DMDUVCZ	RN	Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8.
DMDUVCZ	RU	https://pubmed.ncbi.nlm.nih.gov/25510242

DMDUVCZ	DI	DMDUVCZ
DMDUVCZ	DN	IPH-2101
DMDUVCZ	MI	TTVWAGF
DMDUVCZ	MN	MHC class I NK cell receptor 2DS1 (CD158h)
DMDUVCZ	MT	DTT
DMDUVCZ	MA	Modulator
DMDUVCZ	RN	Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8.
DMDUVCZ	RU	https://pubmed.ncbi.nlm.nih.gov/25510242

DMDUVCZ	DI	DMDUVCZ
DMDUVCZ	DN	IPH-2101
DMDUVCZ	MI	TTV3CFI
DMDUVCZ	MN	MHC class I NK cell receptor 2DS2 (CD158j)
DMDUVCZ	MT	DTT
DMDUVCZ	MA	Modulator
DMDUVCZ	RN	Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8.
DMDUVCZ	RU	https://pubmed.ncbi.nlm.nih.gov/25510242

DMPBR0D	DI	DMPBR0D
DMPBR0D	DN	IPH-2102
DMPBR0D	MI	TT4UXPE
DMPBR0D	MN	MHC class I NK cell receptor 2DL1 (CD158A)
DMPBR0D	MT	DTT
DMPBR0D	MA	Antagonist
DMPBR0D	RN	Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8.
DMPBR0D	RU	https://pubmed.ncbi.nlm.nih.gov/25510242

DMPBR0D	DI	DMPBR0D
DMPBR0D	DN	IPH-2102
DMPBR0D	MI	TTU0P73
DMPBR0D	MN	MHC class I NK cell receptor 2DL2 (CD158b1)
DMPBR0D	MT	DTT
DMPBR0D	MA	Antagonist
DMPBR0D	RN	Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8.
DMPBR0D	RU	https://pubmed.ncbi.nlm.nih.gov/25510242

DMPBR0D	DI	DMPBR0D
DMPBR0D	DN	IPH-2102
DMPBR0D	MI	TTEX3SI
DMPBR0D	MN	MHC class I NK cell receptor 2DL3 (CD158b2)
DMPBR0D	MT	DTT
DMPBR0D	MA	Antagonist
DMPBR0D	RN	Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8.
DMPBR0D	RU	https://pubmed.ncbi.nlm.nih.gov/25510242

DMQH2SF	DI	DMQH2SF
DMQH2SF	DN	IPH4102
DMQH2SF	MI	TTQH3N0
DMQH2SF	MN	MHC class I NK cell receptor 3DL2 (CD158k)
DMQH2SF	MT	DTT
DMQH2SF	MA	Antagonist
DMQH2SF	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQH2SF	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMG5Q7F	DI	DMG5Q7F
DMG5Q7F	DN	IPI-549
DMG5Q7F	MI	TTHBTOP
DMG5Q7F	MN	PI3-kinase gamma (PIK3CG)
DMG5Q7F	MT	DTT
DMG5Q7F	MA	Inhibitor
DMG5Q7F	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMG5Q7F	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMW2IF9	DI	DMW2IF9
DMW2IF9	DN	IR502
DMW2IF9	MI	TT7AKW1
DMW2IF9	MN	T-cell receptor (TCR)
DMW2IF9	MT	DTT
DMW2IF9	MA	Modulator
DMW2IF9	RN	WO patent application no. 2004,0677,06, Production of multimeric proteins.
DMW2IF9	RU	http://www.google.com/patents/WO2004067706A2?cl=en

DMQ3RWN	DI	DMQ3RWN
DMQ3RWN	DN	Iralukast
DMQ3RWN	MI	TTGKOY9
DMQ3RWN	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DMQ3RWN	MT	DTT
DMQ3RWN	MA	Modulator
DMQ3RWN	RN	Pharmacological characterization of the cysteinyl-leukotriene antagonists CGP 45715A (iralukast) and CGP 57698 in human airways in vitro. Br J Pharmacol. 1998 Feb;123(3):590-8.
DMQ3RWN	RU	https://pubmed.ncbi.nlm.nih.gov/9504401

DMI874B	DI	DMI874B
DMI874B	DN	Iratumumab
DMI874B	MI	TT2GM5R
DMI874B	MN	Lymphocyte activation antigen CD30 (TNFRSF8)
DMI874B	MT	DTT
DMI874B	RN	Utilizing CD30 expression as a rational target for therapy of lymphoma. J Hematol Oncol. 2012; 5(Suppl 1): A2.
DMI874B	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3337265/

DMCAFVN	DI	DMCAFVN
DMCAFVN	DN	IRT-102
DMCAFVN	MI	TT6IEYX
DMCAFVN	MN	Opioid receptor zeta (OGFR)
DMCAFVN	MT	DTT
DMCAFVN	MA	Modulator
DMCAFVN	RN	The opiate receptor binding interactions of 3H-methionine enkephalin, an opioid peptide. Eur J Pharmacol. 1978 Feb 1;47(3):319-31.
DMCAFVN	RU	https://pubmed.ncbi.nlm.nih.gov/204498

DMODLN7	DI	DMODLN7
DMODLN7	DN	IRX-2
DMODLN7	MI	TTXM6JN
DMODLN7	MN	Cytokine receptor unspecific (CRF)
DMODLN7	MT	DTT
DMODLN7	MA	Modulator
DMODLN7	RN	Clinical pipeline report, company report or official report of IRX Therapeutics.
DMODLN7	RU	http://www.irxtherapeutics.com/prod_irx2.html

DMHOJ8W	DI	DMHOJ8W
DMHOJ8W	DN	Isatoribine
DMHOJ8W	MI	TTRJ1K4
DMHOJ8W	MN	Toll-like receptor 7 (TLR7)
DMHOJ8W	MT	DTT
DMHOJ8W	MA	Agonist
DMHOJ8W	RN	Discovery of ANA975: an oral prodrug of the TLR-7 agonist isatoribine. Nucleosides Nucleotides Nucleic Acids. 2007;26(6-7):635-40.
DMHOJ8W	RU	https://pubmed.ncbi.nlm.nih.gov/18066870

DMBZK3P	DI	DMBZK3P
DMBZK3P	DN	ISF35
DMBZK3P	MI	TTIJP3Q
DMBZK3P	MN	TNF related activation protein (CD40LG)
DMBZK3P	MT	DTT
DMBZK3P	MA	Binder
DMBZK3P	RN	Intratumoral injection of Ad-ISF35 (Chimeric CD154) breaks tolerance and induces lymphoma tumor regression. Hum Gene Ther. 2015 Jan;26(1):14-25.
DMBZK3P	RU	https://pubmed.ncbi.nlm.nih.gov/25382101

DMUPD4G	DI	DMUPD4G
DMUPD4G	DN	ISIS 113715
DMUPD4G	MI	TTELIN2
DMUPD4G	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMUPD4G	MT	DTT
DMUPD4G	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009).
DMUPD4G	RU	http://www.isispharm.com/Pipeline/index.htm

DMQ3C05	DI	DMQ3C05
DMQ3C05	DN	ISIS-APO(a)
DMQ3C05	MI	TTU9LGY
DMQ3C05	MN	Apolipoprotein A messenger RNA (LPA mRNA)
DMQ3C05	MT	DTT
DMQ3C05	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals.
DMQ3C05	RU	https://www.isispharm.com/pipeline/isis-apoarx/

DML84CN	DI	DML84CN
DML84CN	DN	ISIS-CRPRx
DML84CN	MI	TTWRN6M
DML84CN	MN	CRP messenger RNA (CRP mRNA)
DML84CN	MT	DTT
DML84CN	MA	Modulator
DML84CN	RN	Antisense oligonucleotides on neurobehavior, respiratory, and cardiovascular function, and hERG channel current studies. J Pharmacol Toxicol Methods. 2014 Jan-Feb;69(1):49-60.
DML84CN	RU	https://pubmed.ncbi.nlm.nih.gov/24211663

DMRN543	DI	DMRN543
DMRN543	DN	ISIS-EIF4E
DMRN543	MI	TTNBTCW
DMRN543	MN	eIF4E-BP2 messenger RNA (eIF4E-BP2 mRNA)
DMRN543	MT	DTT
DMRN543	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
DMRN543	RU	http://www.isispharm.com/index.htm

DMNVZDT	DI	DMNVZDT
DMNVZDT	DN	ISIS-FGFR4
DMNVZDT	MI	TT1KX2S
DMNVZDT	MN	FGFR4 messenger RNA (FGFR4 mRNA)
DMNVZDT	MT	DTT
DMNVZDT	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
DMNVZDT	RU	http://www.isispharm.com/index.htm

DMHETPI	DI	DMHETPI
DMHETPI	DN	ISIS-FXI
DMHETPI	MI	TTDM4ZU
DMHETPI	MN	Factor XI messenger RNA (F11 mRNA)
DMHETPI	MT	DTT
DMHETPI	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
DMHETPI	RU	http://www.isispharm.com/index.htm

DMICMNU	DI	DMICMNU
DMICMNU	DN	ISIS-GCCR
DMICMNU	MI	TTOZRK6
DMICMNU	MN	Glucocorticoid receptor messenger RNA (GCR mRNA)
DMICMNU	MT	DTT
DMICMNU	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
DMICMNU	RU	http://www.isispharm.com/index.htm

DMHNYWP	DI	DMHNYWP
DMHNYWP	DN	ISIS-GCGR
DMHNYWP	MI	TTLMJSC
DMHNYWP	MN	Glucagon receptor messenger RNA (GCGR mRNA)
DMHNYWP	MT	DTT
DMHNYWP	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
DMHNYWP	RU	http://www.isispharm.com/index.htm

DM4RXDQ	DI	DM4RXDQ
DM4RXDQ	DN	ISIS-HBV
DM4RXDQ	MI	TT43YWN
DM4RXDQ	MN	Hepatitis B virus messenger RNA (HBV mRNA)
DM4RXDQ	MT	DTT
DM4RXDQ	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals.
DM4RXDQ	RU	https://www.isispharm.com/pipeline/isis-hbvrx/

DMJGVXT	DI	DMJGVXT
DMJGVXT	DN	ISIS-PTP1Brx
DMJGVXT	MI	TTELIN2
DMJGVXT	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMJGVXT	MT	DTT
DMJGVXT	MA	Modulator
DMJGVXT	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals.
DMJGVXT	RU	https://www.isispharm.com/pipeline/isis-ptp1brx/

DM2RS0V	DI	DM2RS0V
DM2RS0V	DN	Isofagomine tartrate
DM2RS0V	MI	TT1B5PU
DM2RS0V	MN	Glucosylceramidase (GBA)
DM2RS0V	MT	DTT
DM2RS0V	MA	Inhibitor
DM2RS0V	RN	Identification of pharmacological chaperones for Gaucher disease and characterization of their effects on beta-glucocerebrosidase by hydrogen/deuterium exchange mass spectrometry. Chembiochem. 2008 Nov 3;9(16):2650-62.
DM2RS0V	RU	https://pubmed.ncbi.nlm.nih.gov/18972510

DMP2BWX	DI	DMP2BWX
DMP2BWX	DN	Ispinesib
DMP2BWX	MI	TTTRP0H
DMP2BWX	MN	Kinesin-like protein KIF11 (KIF11)
DMP2BWX	MT	DTT
DMP2BWX	MA	Inhibitor
DMP2BWX	RN	Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2009 Dec 15;53(7):1255-63.
DMP2BWX	RU	https://pubmed.ncbi.nlm.nih.gov/19554570

DMCY9PO	DI	DMCY9PO
DMCY9PO	DN	Itarnafloxin
DMCY9PO	MI	TTCSZH7
DMCY9PO	MN	Nucleolin (NCL)
DMCY9PO	MT	DTT
DMCY9PO	MA	Inhibitor
DMCY9PO	RN	Targeting G-quadruplexes in gene promoters: a novel anticancer strategy . Nat Rev Drug Discov. 2011 April; 10(4): 261-275.
DMCY9PO	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3119469/

DMDZWPL	DI	DMDZWPL
DMDZWPL	DN	ITCA-638
DMDZWPL	MI	TTS2TGF
DMDZWPL	MN	Interferon-omega (IFNW1)
DMDZWPL	MT	DTT
DMDZWPL	MA	Modulator
DMDZWPL	RN	Interferons and viral infections. Biofactors. 2009 Jan-Feb;35(1):14-20.
DMDZWPL	RU	https://pubmed.ncbi.nlm.nih.gov/19319841

DM5UFRO	DI	DM5UFRO
DM5UFRO	DN	Itriglumide
DM5UFRO	MI	TTVFO0U
DM5UFRO	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DM5UFRO	MT	DTT
DM5UFRO	MA	Antagonist
DM5UFRO	RN	Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases. Curr Top Med Chem. 2007; 7(12): 1211-1231.
DM5UFRO	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2718729/

DMCJX79	DI	DMCJX79
DMCJX79	DN	ITV-1
DMCJX79	MI	TTG90S6
DMCJX79	MN	Human immunodeficiency virus Glycoprotein 41 (HIV gp41)
DMCJX79	MT	DTT
DMCJX79	RN	Clinical pipeline report, company report or official report of Immunotech Laboratories.
DMCJX79	RU	http://www.immunotechlab.com/ipf/

DMJV3AX	DI	DMJV3AX
DMJV3AX	DN	IVA337
DMJV3AX	MI	TTRMIZ7
DMJV3AX	MN	Peroxisome proliferator-activated receptor (PPAR)
DMJV3AX	MT	DTT
DMJV3AX	MA	Agonist
DMJV3AX	RN	Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension. Ann Rheum Dis. 2017 Nov;76(11):1931-1940.
DMJV3AX	RU	https://pubmed.ncbi.nlm.nih.gov/28801346

DM0OYLQ	DI	DM0OYLQ
DM0OYLQ	DN	I-vation
DM0OYLQ	MI	TTJL8VG
DM0OYLQ	MN	Corticosteroid-binding globulin (SERPINA6)
DM0OYLQ	MT	DTT
DM0OYLQ	MA	Modulator
DM0OYLQ	RN	Cortisol binding in rat skeletal muscle. J Biol Chem. 1975 Feb 25;250(4):1207-11.
DM0OYLQ	RU	https://pubmed.ncbi.nlm.nih.gov/163248

DM457XO	DI	DM457XO
DM457XO	DN	IW-1701
DM457XO	MI	TT6HPVC
DM457XO	MN	Guanylate cyclase (GC)
DM457XO	MT	DTT
DM457XO	MA	Stimulator 
DM457XO	RN	Clinical pipeline report, company report or official report of Cyclerion Therapeutics.
DM457XO	RU	https://www.cyclerion.com/other-clinical-assets/

DMK2T7J	DI	DMK2T7J
DMK2T7J	DN	IW-1973
DMK2T7J	MI	TT23PYC
DMK2T7J	MN	Soluble guanylate cyclase (GCS)
DMK2T7J	MT	DTT
DMK2T7J	MA	Agonist
DMK2T7J	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMK2T7J	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMP42W1	DI	DMP42W1
DMP42W1	DN	IW-6118
DMP42W1	MI	TTDP1UC
DMP42W1	MN	Fatty acid amide hydrolase (FAAH)
DMP42W1	MT	DTT
DMP42W1	MA	Modulator
DMP42W1	RN	The Discovery and Development of Inhibitors of Fatty Acid Amide Hydrolase (FAAH). Bioorg Med Chem Lett. 2011 August 15; 21(16): 4674-4685.
DMP42W1	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3146581/

DM3WSDR	DI	DM3WSDR
DM3WSDR	DN	IXT-m200
DM3WSDR	MI	TT3UEY0
DM3WSDR	MN	Methamphetamine (Meth)
DM3WSDR	MT	DTT
DM3WSDR	MA	Antagonist
DM3WSDR	RN	Clinical pipeline report, company report or official report of InterveXion Therapeutics.
DM3WSDR	RU	http://intervexion.com/research-development/anti-methamphetamine-products/

DM9XKJU	DI	DM9XKJU
DM9XKJU	DN	J 591 Lu-177
DM9XKJU	MI	TT9G4N0
DM9XKJU	MN	Glutamate carboxypeptidase II (GCPII)
DM9XKJU	MT	DTT
DM9XKJU	MA	Modulator
DM9XKJU	RN	Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013 Sep 15;19(18):5182-91.
DM9XKJU	RU	https://pubmed.ncbi.nlm.nih.gov/23714732

DMKU6MW	DI	DMKU6MW
DMKU6MW	DN	JB991
DMKU6MW	MI	TT9B4N3
DMKU6MW	MN	Prostaglandin receptor (PTGR)
DMKU6MW	MT	DTT
DMKU6MW	MA	Agonist
DMKU6MW	RN	US patent application no. 2006,0041,016, Composition and method for the treatment of psoriasis.
DMKU6MW	RU	http://www.google.com/patents/US20060041016

DM89ASO	DI	DM89ASO
DM89ASO	DN	JCAR015
DM89ASO	MI	TTW640A
DM89ASO	MN	B-lymphocyte surface antigen B4 (CD19)
DM89ASO	MT	DTT
DM89ASO	MA	CAR-T-Cell-Therapy
DM89ASO	RN	ClinicalTrials.gov (NCT02535364) Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL).
DM89ASO	RU	https://clinicaltrials.gov/ct2/show/NCT02535364

DMM02VJ	DI	DMM02VJ
DMM02VJ	DN	JI-101
DMM02VJ	MI	TT0JESD
DMM02VJ	MN	Erbb4 tyrosine kinase receptor (Erbb-4)
DMM02VJ	MT	DTT
DMM02VJ	MA	Modulator
DMM02VJ	RN	A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort.Invest New Drugs.2015 Dec;33(6):1217-24.
DMM02VJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26365907

DMARQ0H	DI	DMARQ0H
DMARQ0H	DN	JKB-122
DMARQ0H	MI	TTN4QDT
DMARQ0H	MN	Opioid receptor (OPR)
DMARQ0H	MT	DTT
DMARQ0H	MA	Modulator
DMARQ0H	RN	WO patent application no. 2011,1401,90, Tetrazolones as inhibitors of fatty acid synthase.
DMARQ0H	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20111110&CC=WO&NR=2011140190A1&KC=A1

DMJSVRL	DI	DMJSVRL
DMJSVRL	DN	JM216
DMJSVRL	MI	TTUTN1I
DMJSVRL	MN	Human Deoxyribonucleic acid (hDNA)
DMJSVRL	MT	DTT
DMJSVRL	MA	Modulator
DMJSVRL	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMJSVRL	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMBXWJ5	DI	DMBXWJ5
DMBXWJ5	DN	JNJ 63723283
DMBXWJ5	MI	TTNBFWK
DMBXWJ5	MN	Programmed cell death protein 1 (PD-1)
DMBXWJ5	MT	DTT
DMBXWJ5	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMBXWJ5	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMY7Q3I	DI	DMY7Q3I
DMY7Q3I	DN	JNJ-10229570
DMY7Q3I	MI	TT6QAJ3
DMY7Q3I	MN	Melanocortin receptor 5 (MC5R)
DMY7Q3I	MT	DTT
DMY7Q3I	MA	Antagonist
DMY7Q3I	RN	A melanocortin receptor 1 and 5 antagonist inhibits sebaceous gland differentiation and the production of sebum-specific lipids. J Dermatol Sci. 2011 Jul;63(1):23-32.
DMY7Q3I	RU	https://pubmed.ncbi.nlm.nih.gov/21602033

DM7OTQS	DI	DM7OTQS
DM7OTQS	DN	JNJ-10311795
DM7OTQS	MI	TTQAJF1
DM7OTQS	MN	Cathepsin G (CTSG)
DM7OTQS	MT	DTT
DM7OTQS	MA	Inhibitor
DM7OTQS	RN	Discovery of potent, selective, orally active, nonpeptide inhibitors of human mast cell chymase. J Med Chem. 2007 Apr 19;50(8):1727-30.
DM7OTQS	RU	https://pubmed.ncbi.nlm.nih.gov/17361995

DM7OTQS	DI	DM7OTQS
DM7OTQS	DN	JNJ-10311795
DM7OTQS	MI	TT8VUE0
DM7OTQS	MN	Chymase (CYM)
DM7OTQS	MT	DTT
DM7OTQS	MA	Inhibitor
DM7OTQS	RN	Discovery of potent, selective, orally active, nonpeptide inhibitors of human mast cell chymase. J Med Chem. 2007 Apr 19;50(8):1727-30.
DM7OTQS	RU	https://pubmed.ncbi.nlm.nih.gov/17361995

DMPFG7H	DI	DMPFG7H
DMPFG7H	DN	JNJ-16269110
DMPFG7H	MI	TTUS1RD
DMPFG7H	MN	Microsomal triglyceride transfer protein (MTTP)
DMPFG7H	MT	DTT
DMPFG7H	MA	Inhibitor
DMPFG7H	RN	ClinicalTrials.gov (NCT00672386) A Study of the Safety and Effectiveness of a R256918 in Patients With Type 2 Diabetes. U.S. National Institutes of Health.
DMPFG7H	RU	https://clinicaltrials.gov/ct2/show/NCT00672386

DM1GRCU	DI	DM1GRCU
DM1GRCU	DN	JNJ-17216498
DM1GRCU	MI	TT9JNIC
DM1GRCU	MN	Histamine H3 receptor (H3R)
DM1GRCU	MT	DTT
DM1GRCU	MA	Antagonist
DM1GRCU	RN	Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist. Br J Pharmacol. 2004 Nov;143(5):649-61.
DM1GRCU	RU	https://pubmed.ncbi.nlm.nih.gov/15466448

DMV1T59	DI	DMV1T59
DMV1T59	DN	JNJ-18038683
DMV1T59	MI	TTO9X1H
DMV1T59	MN	5-HT 7 receptor (HTR7)
DMV1T59	MT	DTT
DMV1T59	MA	Antagonist
DMV1T59	RN	Selective pharmacological blockade of the 5-HT7 receptor attenuates light and 8-OH-DPAT induced phase shifts of mouse circadian wheel running activity. Front Behav Neurosci. 2015 Jan 15;8:453.
DMV1T59	RU	https://pubmed.ncbi.nlm.nih.gov/25642174

DMKIE9C	DI	DMKIE9C
DMKIE9C	DN	JNJ-26481585
DMKIE9C	MI	TTBH0VX
DMKIE9C	MN	Histone deacetylase (HDAC)
DMKIE9C	MT	DTT
DMKIE9C	MA	Modulator
DMKIE9C	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7503).
DMKIE9C	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7503

DMQD1GN	DI	DMQD1GN
DMQD1GN	DN	JNJ-32729463
DMQD1GN	MI	TTN6J5F
DMQD1GN	MN	Bacterial DNA gyrase (Bact gyrase)
DMQD1GN	MT	DTT
DMQD1GN	MA	Inhibitor
DMQD1GN	RN	Antistaphylococcal activities of the new fluoroquinolone JNJ-Q2. Antimicrob Agents Chemother. 2011 Dec;55(12):5512-21.
DMQD1GN	RU	https://pubmed.ncbi.nlm.nih.gov/21911562

DMQD1GN	DI	DMQD1GN
DMQD1GN	DN	JNJ-32729463
DMQD1GN	MI	TTFK8YB
DMQD1GN	MN	Bacterial DNA topoisomerase 4A (Bact parC)
DMQD1GN	MT	DTT
DMQD1GN	MA	Inhibitor
DMQD1GN	RN	Antistaphylococcal activities of the new fluoroquinolone JNJ-Q2. Antimicrob Agents Chemother. 2011 Dec;55(12):5512-21.
DMQD1GN	RU	https://pubmed.ncbi.nlm.nih.gov/21911562

DMV41P5	DI	DMV41P5
DMV41P5	DN	JNJ-37822681
DMV41P5	MI	DE4LYSA
DMV41P5	MN	Cytochrome P450 3A4 (CYP3A4)
DMV41P5	MT	DME
DMV41P5	MA	Metabolism
DMV41P5	RN	CYP3A4 and 3A5 catalysed alprazolam metabolism in vitro and in vivo. International Clinical Psychopharmacology, 2006, 21(4):A33.
DMV41P5	RU	https://www.researchgate.net/figure/Cloning-and-expression-CYP3A43-and-CYP3A4-and-metabolism-of-alprazolam-in-vitro-by_fig13_5310993

DMV41P5	DI	DMV41P5
DMV41P5	DN	JNJ-37822681
DMV41P5	MI	TTEX248
DMV41P5	MN	Dopamine D2 receptor (D2R)
DMV41P5	MT	DTT
DMV41P5	MA	Agonist
DMV41P5	RN	Population pharmacokinetics of JNJ-37822681, a selective fast-dissociating dopamine D receptor antagonist, in healthy subjects and subjects with schizophrenia and dose selection based on simulated D receptor occupancy. Clin Pharmacokinet. 2013 Nov;52(11):1005-15.
DMV41P5	RU	https://pubmed.ncbi.nlm.nih.gov/23754735

DM9UMIO	DI	DM9UMIO
DM9UMIO	DN	JNJ-38518168
DM9UMIO	MI	TTXJ178
DM9UMIO	MN	Histamine H4 receptor (H4R)
DM9UMIO	MT	DTT
DM9UMIO	MA	Antagonist
DM9UMIO	RN	The histamine H4 receptor: from orphan to the clinic. Front Pharmacol. 2015; 6: 65.
DM9UMIO	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379874/

DM0WY3H	DI	DM0WY3H
DM0WY3H	DN	JNJ-39220675
DM0WY3H	MI	TT9JNIC
DM0WY3H	MN	Histamine H3 receptor (H3R)
DM0WY3H	MT	DTT
DM0WY3H	MA	Antagonist
DM0WY3H	RN	JNJ-39220675, a novel selective histamine H3 receptor antagonist, reduces the abuse-related effects of alcohol in rats. Psychopharmacology (Berl). 2011 Apr;214(4):829-41.
DM0WY3H	RU	https://pubmed.ncbi.nlm.nih.gov/21086115

DMUOEKM	DI	DMUOEKM
DMUOEKM	DN	JNJ-39393406
DMUOEKM	MI	TTLA931
DMUOEKM	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMUOEKM	MT	DTT
DMUOEKM	MA	Modulator
DMUOEKM	RN	Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study. Neuropharmacology. 2013 Jan;64:197-204.
DMUOEKM	RU	https://pubmed.ncbi.nlm.nih.gov/22766391

DM219SF	DI	DM219SF
DM219SF	DN	JNJ-40346527
DM219SF	MI	TT731LW
DM219SF	MN	Colony stimulating factor-1 receptor (CSF-1R)
DM219SF	MT	DTT
DM219SF	MA	Modulator
DM219SF	RN	An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma. Clin Cancer Res. 2015 Apr 15;21(8):1843-50.
DM219SF	RU	https://pubmed.ncbi.nlm.nih.gov/25628399

DM72GZO	DI	DM72GZO
DM72GZO	DN	JNJ-42165279
DM72GZO	MI	TTDP1UC
DM72GZO	MN	Fatty acid amide hydrolase (FAAH)
DM72GZO	MT	DTT
DM72GZO	MA	Inhibitor
DM72GZO	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM72GZO	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMJ1FXL	DI	DMJ1FXL
DMJ1FXL	DN	JNJ-53718678
DMJ1FXL	MI	TT57ID8
DMJ1FXL	MN	Respiratory syncytial virus protein F (RSV F)
DMJ1FXL	MT	DTT
DMJ1FXL	MA	Inhibitor
DMJ1FXL	RN	Antiviral Activity of Oral JNJ-53718678 in Healthy Adult Volunteers Challenged With Respiratory Syncytial Virus: A Placebo-Controlled Study. J Infect Dis. 2018 Jul 24;218(5):748-756.
DMJ1FXL	RU	https://pubmed.ncbi.nlm.nih.gov/29684148

DM9RW6H	DI	DM9RW6H
DM9RW6H	DN	JNJ-56136379
DM9RW6H	MI	TTM42UJ
DM9RW6H	MN	Hepatitis B virus Capsid protein (HBV C)
DM9RW6H	MT	DTT
DM9RW6H	MA	Inhibitor
DM9RW6H	RN	JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection. Gastroenterology. 2020 Aug;159(2):521-533.e9.
DM9RW6H	RU	https://pubmed.ncbi.nlm.nih.gov/32343960

DME2S4D	DI	DME2S4D
DME2S4D	DN	JNJ-61393215
DME2S4D	MI	TT60Q8D
DME2S4D	MN	Orexin receptor type 1 (HCRTR1)
DME2S4D	MT	DTT
DME2S4D	MA	Antagonist
DME2S4D	RN	Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans. Transl Psychiatry. 2020 Sep 7;10(1):308.
DME2S4D	RU	https://pubmed.ncbi.nlm.nih.gov/32895369

DMVSUH1	DI	DMVSUH1
DMVSUH1	DN	JNJ-64565111
DMVSUH1	MI	TT0NUFM
DMVSUH1	MN	Glucagon (GCG)
DMVSUH1	MT	DTT
DMVSUH1	MA	Agonist
DMVSUH1	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMVSUH1	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DM3ICO6	DI	DM3ICO6
DM3ICO6	DN	JNJ-74494550
DM3ICO6	MI	TTNCIE0
DM3ICO6	MN	CD70 antigen (CD27-L)
DM3ICO6	MT	DTT
DM3ICO6	RN	Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. Nat Med. 2020 Sep;26(9):1459-1467.
DM3ICO6	RU	https://pubmed.ncbi.nlm.nih.gov/32601337

DMXTKCR	DI	DMXTKCR
DMXTKCR	DN	JT02
DMXTKCR	MI	TTQOVYA
DMXTKCR	MN	C-X-C motif chemokine 10 (CXCL10)
DMXTKCR	MT	DTT
DMXTKCR	MA	Inhibitor
DMXTKCR	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMXTKCR	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DM2LBHN	DI	DM2LBHN
DM2LBHN	DN	JTE-051
DM2LBHN	MI	TT3C80U
DM2LBHN	MN	T-cell-specific kinase (ITK)
DM2LBHN	MT	DTT
DM2LBHN	MA	Inhibitor
DM2LBHN	RN	Characterisation of a K390R ITK Kinase Dead Transgenic Mouse - Implications for ITK as a Therapeutic Target. PLoS One. 2014; 9(9): e107490.
DM2LBHN	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4174519/

DM1945H	DI	DM1945H
DM1945H	DN	JTT-251
DM1945H	MI	TT3UNDH
DM1945H	MN	Pyruvate dehydrogenase kinase (PDHK)
DM1945H	MT	DTT
DM1945H	MA	Inhibitor
DM1945H	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM1945H	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMGLVBI	DI	DMGLVBI
DMGLVBI	DN	JTT-302
DMGLVBI	MI	TTFQAYR
DMGLVBI	MN	Cholesteryl ester transfer protein (CETP)
DMGLVBI	MT	DTT
DMGLVBI	MA	Inhibitor
DMGLVBI	RN	The dyslipidaemia market. Nat Rev Drug Discov. 2014 Nov;13(11):807-8.
DMGLVBI	RU	https://pubmed.ncbi.nlm.nih.gov/25323928

DM50M2R	DI	DM50M2R
DM50M2R	DN	JTT-654
DM50M2R	MI	TTN7BL9
DM50M2R	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DM50M2R	MT	DTT
DM50M2R	MA	Inhibitor
DM50M2R	RN	New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches. 2012. Chapter 5. Page(131).
DM50M2R	RU	https://books.google.com.hk/books?id=0rmlVGhlJ0IC&pg=PA131&lpg=PA131&dq=RG-7234++New+Therapeutic+Strategies+for+Type+2+Diabetes&source=bl&ots=toqK7w4uiI&sig=sx5iyfQWH2bTCSZmT5aUQiKfPuM&hl=zh-CN&sa=X&ved=0CB0Q6AEwAGoVChMIsZ_k6dDGyAIViLeOCh0oUQpr#v=onepage&q=RG-7234%20%20New%20Therapeutic%20Strategies%20for%20Type%202%20Diabetes&f=false

DMED5J6	DI	DMED5J6
DMED5J6	DN	JTT-851
DMED5J6	MI	TTB8FUC
DMED5J6	MN	Free fatty acid receptor 1 (GPR40)
DMED5J6	MT	DTT
DMED5J6	MA	Agonist
DMED5J6	RN	Treatment of Type 2 Diabetes by Free Fatty Acid Receptor Agonists. Front Endocrinol (Lausanne) 2014; 5: 137.
DMED5J6	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4147718/

DMGXTOP	DI	DMGXTOP
DMGXTOP	DN	JTX-2011
DMGXTOP	MI	TTE5VP6
DMGXTOP	MN	Inducible T-cell costimulator (ICOS)
DMGXTOP	MT	DTT
DMGXTOP	MA	Agonist
DMGXTOP	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMGXTOP	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMOT0M7	DI	DMOT0M7
DMOT0M7	DN	JTX-4014
DMOT0M7	MI	TTNBFWK
DMOT0M7	MN	Programmed cell death protein 1 (PD-1)
DMOT0M7	MT	DTT
DMOT0M7	MA	Inhibitor
DMOT0M7	RN	Clinical pipeline report, company report or official report of Jounce Therapeutics.
DMOT0M7	RU	https://jouncetx.com/our-pipeline/

DMZKYNO	DI	DMZKYNO
DMZKYNO	DN	Juvidex
DMZKYNO	MI	TTPNE41
DMZKYNO	MN	CI Man-6-P receptor (IGF2R)
DMZKYNO	MT	DTT
DMZKYNO	MA	Modulator
DMZKYNO	RN	Hypertrophic Scarring and Keloids: Pathomechanisms and Current and Emerging Treatment Strategies. Mol Med. 2011 Jan-Feb; 17(1-2): 113-125.
DMZKYNO	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3022978/

DMPMU38	DI	DMPMU38
DMPMU38	DN	JVRS-100
DMPMU38	MI	TTSHG0T
DMPMU38	MN	Toll-like receptor 9 (TLR9)
DMPMU38	MT	DTT
DMPMU38	RN	Cationic lipid/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone ) increases antibody response, cellular immunity, and antigenically drifted protection. Vaccine. 2009 June 12; 27(29):3811-3820.
DMPMU38	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2690618/

DMD4OK0	DI	DMD4OK0
DMD4OK0	DN	K-134
DMD4OK0	MI	TTZCG4L
DMD4OK0	MN	Phosphodiesterase 3 (PDE3)
DMD4OK0	MT	DTT
DMD4OK0	MA	Modulator
DMD4OK0	RN	A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. J Vasc Surg. 2012 Feb;55(2):381-389.e1.
DMD4OK0	RU	https://pubmed.ncbi.nlm.nih.gov/22119244

DMZCVD7	DI	DMZCVD7
DMZCVD7	DN	K-201
DMZCVD7	MI	TT1VOHK
DMZCVD7	MN	Potassium channel unspecific (KC)
DMZCVD7	MT	DTT
DMZCVD7	MA	Modulator
DMZCVD7	RN	Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy 
DMZCVD7	RU	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3340112

DMQVN6P	DI	DMQVN6P
DMQVN6P	DN	K-604
DMQVN6P	MI	TTMF541
DMQVN6P	MN	Liver carboxylesterase (CES1)
DMQVN6P	MT	DTT
DMQVN6P	MA	Inhibitor
DMQVN6P	RN	A selective ACAT-1 inhibitor, K-604, suppresses fatty streak lesions in fat-fed hamsters without affecting plasma cholesterol levels. Atherosclerosis. 2007 Apr;191(2):290-7.
DMQVN6P	RU	https://pubmed.ncbi.nlm.nih.gov/16820149

DMJLNZQ	DI	DMJLNZQ
DMJLNZQ	DN	K-828-AB
DMJLNZQ	MI	TTT2LD9
DMJLNZQ	MN	GABA transaminase (ABAT)
DMJLNZQ	MT	DTT
DMJLNZQ	MA	Inhibitor
DMJLNZQ	RN	Phase II clinical trial of K-828-AB for treating behavioral and psychological symptoms of dementia. Kowa Co. Ltd.
DMJLNZQ	RU	http://www.biocentury.com/products/k-828-ab

DMMSTCF	DI	DMMSTCF
DMMSTCF	DN	K-832
DMMSTCF	MI	TTSD92E
DMMSTCF	MN	Interleukin-1 (IL1)
DMMSTCF	MT	DTT
DMMSTCF	MA	Inhibitor
DMMSTCF	RN	Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
DMMSTCF	RU	https://pubmed.ncbi.nlm.nih.gov/18321156

DMTMCPZ	DI	DMTMCPZ
DMTMCPZ	DN	KB001A
DMTMCPZ	MI	TTLK9NJ
DMTMCPZ	MN	Pseudomonas PcrV protein type III (Pseudo pcrV)
DMTMCPZ	MT	DTT
DMTMCPZ	MA	Inhibitor
DMTMCPZ	RN	KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. J Cyst Fibros. 2018 Jul;17(4):484-491.
DMTMCPZ	RU	https://pubmed.ncbi.nlm.nih.gov/29292092

DM60G5O	DI	DM60G5O
DM60G5O	DN	KB002/003
DM60G5O	MI	TTNYZG2
DM60G5O	MN	Granulocyte-macrophage colony-stimulating factor (CSF2)
DM60G5O	MT	DTT
DM60G5O	MA	Modulator
DM60G5O	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM60G5O	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM74KIM	DI	DM74KIM
DM74KIM	DN	KB-003
DM74KIM	MI	TTNYZG2
DM74KIM	MN	Granulocyte-macrophage colony-stimulating factor (CSF2)
DM74KIM	MT	DTT
DM74KIM	RN	US patent application no. 2010,0158,905, Combination therapy of arthritis with tranilast.
DM74KIM	RU	https://www.google.com/patents/US20100158905

DMZ4MCG	DI	DMZ4MCG
DMZ4MCG	DN	KB-6806
DMZ4MCG	MI	TTNXLKE
DMZ4MCG	MN	5-HT 3 receptor (5HT3R)
DMZ4MCG	MT	DTT
DMZ4MCG	MA	Antagonist
DMZ4MCG	RN	Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar;11(1):137-51.
DMZ4MCG	RU	https://pubmed.ncbi.nlm.nih.gov/16503832

DMEFW3G	DI	DMEFW3G
DMEFW3G	DN	KD019
DMEFW3G	MI	TTI4ZX2
DMEFW3G	MN	Ephrin type-B receptor 4 (EPHB4)
DMEFW3G	MT	DTT
DMEFW3G	MA	Modulator
DMEFW3G	RN	XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib. J Thorac Oncol. 2012 Jan;7(1):219-26.
DMEFW3G	RU	https://pubmed.ncbi.nlm.nih.gov/22011666

DMEFW3G	DI	DMEFW3G
DMEFW3G	DN	KD019
DMEFW3G	MI	TTJSQEF
DMEFW3G	MN	Tyrosine-protein kinase (PTK)
DMEFW3G	MT	DTT
DMEFW3G	MA	Inhibitor
DMEFW3G	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMEFW3G	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM548TK	DI	DM548TK
DM548TK	DN	KD025
DM548TK	MI	TTGWKQJ
DM548TK	MN	Rho-associated protein kinase 2 (ROCK2)
DM548TK	MT	DTT
DM548TK	MA	Inhibitor
DM548TK	RN	Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):16814-9.
DM548TK	RU	https://pubmed.ncbi.nlm.nih.gov/25385601

DME1WV2	DI	DME1WV2
DME1WV2	DN	KD-7040
DME1WV2	MI	TTF10I9
DME1WV2	MN	Nitric-oxide synthase inducible (NOS2)
DME1WV2	MT	DTT
DME1WV2	MA	Inhibitor
DME1WV2	RN	WO patent application no. 2014,0214,08, Method for treating cancer by anticancer agent co-administration.
DME1WV2	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20140206&CC=WO&NR=2014021408A1&KC=A1

DMFO6MH	DI	DMFO6MH
DMFO6MH	DN	Kevetrin
DMFO6MH	MI	TT7SBF5
DMFO6MH	MN	Cellular tumor antigen p53 (TP53)
DMFO6MH	MT	DTT
DMFO6MH	MA	Stimulator
DMFO6MH	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMFO6MH	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMF6CTI	DI	DMF6CTI
DMF6CTI	DN	KHK-6188
DMF6CTI	MI	TTMSFAW
DMF6CTI	MN	Cannabinoid receptor 2 (CB2)
DMF6CTI	MT	DTT
DMF6CTI	MA	Agonist
DMF6CTI	RN	Recent Development of CB2 Selective and Peripheral CB1/CB2 Cannabinoid Receptor Ligands. Current Medicinal Chemistry . 10/2013; 21(2).
DMF6CTI	RU	http://www.researchgate.net/publication/258114758_Recent_Development_of_CB2_Selective_and_Peripheral_CB1CB2_Cannabinoid_Receptor_Ligands

DM40HOY	DI	DM40HOY
DM40HOY	DN	KLH-2109
DM40HOY	MI	TT8R70G
DM40HOY	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DM40HOY	MT	DTT
DM40HOY	MA	Agonist
DM40HOY	RN	Clinical pipeline report, company report or official report of Avarx.
DM40HOY	RU	http://www.avarx.com/AvaRx/SubDomains/bucket2705902527756613996/Listings/bucket5664821816690947691/Public.Listing.display.html

DM05TBE	DI	DM05TBE
DM05TBE	DN	KLS-0611
DM05TBE	MI	TTHBUXE
DM05TBE	MN	Mucin (MUC)
DM05TBE	MT	DTT
DM05TBE	MA	Stimulator
DM05TBE	RN	WO patent application no. 2011,1034,23, Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors.
DM05TBE	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20110825&CC=WO&NR=2011103423A1&KC=A1

DMNLH9W	DI	DMNLH9W
DMNLH9W	DN	KN026
DMNLH9W	MI	TT6EO5L
DMNLH9W	MN	Erbb2 tyrosine kinase receptor (HER2)
DMNLH9W	MT	DTT
DMNLH9W	MA	Inhibitor
DMNLH9W	RN	Clinical pipeline report, company report or official report of Alphamab Oncology.
DMNLH9W	RU	http://www.alphamabonc.com/pipeline/kn026.html

DMKLMG6	DI	DMKLMG6
DMKLMG6	DN	KN035
DMKLMG6	MI	TT8ZLTI
DMKLMG6	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMKLMG6	MT	DTT
DMKLMG6	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMKLMG6	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMQZ5HF	DI	DMQZ5HF
DMQZ5HF	DN	KNI-272
DMQZ5HF	MI	DE4LYSA
DMQZ5HF	MN	Cytochrome P450 3A4 (CYP3A4)
DMQZ5HF	MT	DME
DMQZ5HF	MA	Metabolism
DMQZ5HF	RN	Metabolic characterization of a tripeptide human immunodeficiency virus type 1 protease inhibitor, KNI-272, in rat liver microsomes. Antimicrob Agents Chemother. 1999 Mar;43(3):549-56.
DMQZ5HF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10049266

DMQZ5HF	DI	DMQZ5HF
DMQZ5HF	DN	KNI-272
DMQZ5HF	MI	TT5FNQT
DMQZ5HF	MN	Human immunodeficiency virus Protease (HIV PR)
DMQZ5HF	MT	DTT
DMQZ5HF	MA	Modulator
DMQZ5HF	RN	Oxidative modifications of kynostatin-272, a potent human immunodeficiency virus type 1 protease inhibitor: potential mechanism for altered activit... Antimicrob Agents Chemother. 2002 Feb;46(2):402-8.
DMQZ5HF	RU	https://www.ncbi.nlm.nih.gov/pubmed/11796349

DMCO8UZ	DI	DMCO8UZ
DMCO8UZ	DN	KP-496
DMCO8UZ	MI	TTGKOY9
DMCO8UZ	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DMCO8UZ	MT	DTT
DMCO8UZ	MA	Modulator
DMCO8UZ	RN	Effects of KP-496, a novel dual antagonist for leukotriene D4 and thromboxane A2 receptors, on contractions induced by various agonists in the guinea pig trachea. Allergol Int. 2006 Dec;55(4):403-10.
DMCO8UZ	RU	https://pubmed.ncbi.nlm.nih.gov/17130683

DMCO8UZ	DI	DMCO8UZ
DMCO8UZ	DN	KP-496
DMCO8UZ	MI	TT2O84V
DMCO8UZ	MN	Thromboxane A2 receptor (TBXA2R)
DMCO8UZ	MT	DTT
DMCO8UZ	MA	Modulator
DMCO8UZ	RN	Effects of KP-496, a novel dual antagonist for leukotriene D4 and thromboxane A2 receptors, on contractions induced by various agonists in the guinea pig trachea. Allergol Int. 2006 Dec;55(4):403-10.
DMCO8UZ	RU	https://pubmed.ncbi.nlm.nih.gov/17130683

DM4WHOS	DI	DM4WHOS
DM4WHOS	DN	KPP203
DM4WHOS	MI	TT7BQRM
DM4WHOS	MN	Sphingosine-1 phosphate receptor (S1PR)
DM4WHOS	MT	DTT
DM4WHOS	MA	Agonist
DM4WHOS	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM4WHOS	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMQDLVW	DI	DMQDLVW
DMQDLVW	DN	KRP-104
DMQDLVW	MI	TTDIGC1
DMQDLVW	MN	Dipeptidyl peptidase 4 (DPP-4)
DMQDLVW	MT	DTT
DMQDLVW	MA	Modulator
DMQDLVW	RN	Clinical pipeline report, company report or official report of Activx.
DMQDLVW	RU	http://www.activx.com/press/news_20080821.html

DMOW9X2	DI	DMOW9X2
DMOW9X2	DN	KRP-203
DMOW9X2	MI	TT9JZCK
DMOW9X2	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMOW9X2	MT	DTT
DMOW9X2	MA	Agonist
DMOW9X2	RN	Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702.
DMOW9X2	RU	https://pubmed.ncbi.nlm.nih.gov/23954895

DM08F12	DI	DM08F12
DM08F12	DN	KT6-971
DM08F12	MI	TTNA5ZS
DM08F12	MN	Cholesterol absorption (Chole absorp)
DM08F12	MT	DTT
DM08F12	MA	Inhibitor
DM08F12	RN	Intestinal and Hepatic Niemann-Pick C1-Like 1. Correction in: Diabetes Metab J. 2013 December; 37(6): 486-487.
DM08F12	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3753488/

DMZL48U	DI	DMZL48U
DMZL48U	DN	KUR-111
DMZL48U	MI	TT6F7GZ
DMZL48U	MN	Parathyroid hormone (PTH)
DMZL48U	MT	DTT
DMZL48U	MA	Modulator
DMZL48U	RN	Company report (Cytos)
DMZL48U	RU	http://www.cytos.com/kur-111/

DM2N0Z3	DI	DM2N0Z3
DM2N0Z3	DN	KUR-211
DM2N0Z3	MI	TTWODQF
DM2N0Z3	MN	Fibrin (FG)
DM2N0Z3	MT	DTT
DM2N0Z3	MA	Modulator
DM2N0Z3	RN	Clinical pipeline report, company report or official report of Kuros.
DM2N0Z3	RU	http://www.kuros.ch/cms/front_content.php?idcat=78

DMB4HCY	DI	DMB4HCY
DMB4HCY	DN	KUR-212
DMB4HCY	MI	TTWODQF
DMB4HCY	MN	Fibrin (FG)
DMB4HCY	MT	DTT
DMB4HCY	MA	Modulator
DMB4HCY	RN	Clinical pipeline report, company report or official report of Kuros.
DMB4HCY	RU	http://www.kuros.ch/cms/front_content.php?idcat=80

DMK4VOU	DI	DMK4VOU
DMK4VOU	DN	KVD001
DMK4VOU	MI	TTMF8H9
DMK4VOU	MN	Plasma kallikrein (KLKB1)
DMK4VOU	MT	DTT
DMK4VOU	MA	Inhibitor
DMK4VOU	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMK4VOU	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DM5N4OA	DI	DM5N4OA
DM5N4OA	DN	KVD824
DM5N4OA	MI	TTMF8H9
DM5N4OA	MN	Plasma kallikrein (KLKB1)
DM5N4OA	MT	DTT
DM5N4OA	MA	Inhibitor
DM5N4OA	RN	Clinical pipeline report, company report or official report of KalVista Pharmaceuticals.
DM5N4OA	RU	https://www.kalvista.com/products-pipeline/kvd824-hae

DMJGL72	DI	DMJGL72
DMJGL72	DN	KW-2478
DMJGL72	MI	TT78R5H
DMJGL72	MN	Heat shock protein 90 alpha (HSP90A)
DMJGL72	MT	DTT
DMJGL72	MA	Modulator
DMJGL72	RN	Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib. Blood Cancer J. 2012 Apr;2(4):e68.
DMJGL72	RU	https://pubmed.ncbi.nlm.nih.gov/22829970

DM15RZO	DI	DM15RZO
DM15RZO	DN	KYMRIAH
DM15RZO	MI	TTW640A
DM15RZO	MN	B-lymphocyte surface antigen B4 (CD19)
DM15RZO	MT	DTT
DM15RZO	MA	CAR-T-Cell-Therapy
DM15RZO	RN	ClinicalTrials.gov (NCT03642626) MT2017-45 :CAR-T Cell Therapy for Heme Malignancies
DM15RZO	RU	https://clinicaltrials.gov/ct2/show/NCT03642626

DMLHPVW	DI	DMLHPVW
DMLHPVW	DN	L1-79
DMLHPVW	MI	TTUHP71
DMLHPVW	MN	Tyrosine 3-monooxygenase (TH)
DMLHPVW	MT	DTT
DMLHPVW	MA	Inhibitor
DMLHPVW	RN	Effect of L1-79 on Core Symptoms of Autism Spectrum Disorder: A Case Series. Clin Ther. 2019 Oct;41(10):1972-1981.
DMLHPVW	RU	https://pubmed.ncbi.nlm.nih.gov/31492568

DMI2XP1	DI	DMI2XP1
DMI2XP1	DN	L19-IL-2 fusion protein
DMI2XP1	MI	TTF89GD
DMI2XP1	MN	Interleukin-2 (IL2)
DMI2XP1	MT	DTT
DMI2XP1	RN	National Cancer Institute Drug Dictionary (drug id 665656).
DMI2XP1	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=665656

DMW6NMP	DI	DMW6NMP
DMW6NMP	DN	L19-TNF-alpha
DMW6NMP	MI	TTPJ921
DMW6NMP	MN	Fibronectin (FN1)
DMW6NMP	MT	DTT
DMW6NMP	RN	National Cancer Institute Drug Dictionary (drug id 686947).
DMW6NMP	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=686947

DMA0DSJ	DI	DMA0DSJ
DMA0DSJ	DN	L-694,458
DMA0DSJ	MI	TTPLTSQ
DMA0DSJ	MN	Neutrophil elastase (NE)
DMA0DSJ	MT	DTT
DMA0DSJ	MA	Inhibitor
DMA0DSJ	RN	Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs. 2002 Jul;11(7):965-80.
DMA0DSJ	RU	https://pubmed.ncbi.nlm.nih.gov/12084007

DMB7WT1	DI	DMB7WT1
DMB7WT1	DN	L-697,661
DMB7WT1	MI	TT84ETX
DMB7WT1	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMB7WT1	MT	DTT
DMB7WT1	MA	Modulator
DMB7WT1	RN	Mechanism of resistance to U-90152S and sensitization to L-697,661 by a proline to leucine change at residue 236 of human immunodeficiency virus ty... FEBS Lett. 1995 Feb 13;359(2-3):233-8.
DMB7WT1	RU	https://www.ncbi.nlm.nih.gov/pubmed/7532595

DMTGR25	DI	DMTGR25
DMTGR25	DN	L-745,870
DMTGR25	MI	TTE0A2F
DMTGR25	MN	Dopamine D4 receptor (D4R)
DMTGR25	MT	DTT
DMTGR25	MA	Antagonist
DMTGR25	RN	Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI. Psychopharmacology (Berl). 2009 Apr;203(2):265-77.
DMTGR25	RU	https://pubmed.ncbi.nlm.nih.gov/18604600

DMNO5UE	DI	DMNO5UE
DMNO5UE	DN	Labetuzumab I-131
DMNO5UE	MI	TTY6DTE
DMNO5UE	MN	Carcinoembryonic antigen CEA (CD66e)
DMNO5UE	MT	DTT
DMNO5UE	RN	National Cancer Institute Drug Dictionary (drug id 692828).
DMNO5UE	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=692828

DM7063I	DI	DM7063I
DM7063I	DN	LADIRUBICIN
DM7063I	MI	TTUTN1I
DM7063I	MN	Human Deoxyribonucleic acid (hDNA)
DM7063I	MT	DTT
DM7063I	MA	Binder
DM7063I	RN	The power and potential of doxorubicin-DNA adducts. IUBMB Life. 2005 Feb;57(2):73-81.
DM7063I	RU	https://pubmed.ncbi.nlm.nih.gov/16036566

DMJSY3Q	DI	DMJSY3Q
DMJSY3Q	DN	Ladostigil
DMJSY3Q	MI	TT1RS9F
DMJSY3Q	MN	Acetylcholinesterase (AChE)
DMJSY3Q	MT	DTT
DMJSY3Q	MA	Inhibitor
DMJSY3Q	RN	Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets. 2012 Apr;13(4):483-94.
DMJSY3Q	RU	https://pubmed.ncbi.nlm.nih.gov/22280345

DMJSY3Q	DI	DMJSY3Q
DMJSY3Q	DN	Ladostigil
DMJSY3Q	MI	TT3WG5C
DMJSY3Q	MN	Monoamine oxidase type A (MAO-A)
DMJSY3Q	MT	DTT
DMJSY3Q	MA	Inhibitor
DMJSY3Q	RN	Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets. 2012 Apr;13(4):483-94.
DMJSY3Q	RU	https://pubmed.ncbi.nlm.nih.gov/22280345

DMJSY3Q	DI	DMJSY3Q
DMJSY3Q	DN	Ladostigil
DMJSY3Q	MI	TTGP7BY
DMJSY3Q	MN	Monoamine oxidase type B (MAO-B)
DMJSY3Q	MT	DTT
DMJSY3Q	MA	Inhibitor
DMJSY3Q	RN	Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets. 2012 Apr;13(4):483-94.
DMJSY3Q	RU	https://pubmed.ncbi.nlm.nih.gov/22280345

DMSIGAB	DI	DMSIGAB
DMSIGAB	DN	L-alanosine
DMSIGAB	MI	TTEWTCR
DMSIGAB	MN	Adenine synthesis (Adeni synth)
DMSIGAB	MT	DTT
DMSIGAB	MA	Modulator
DMSIGAB	RN	Circadian pharmacology of L-alanosine (SDX-102) in mice. Mol Cancer Ther. 2006 Feb;5(2):337-46.
DMSIGAB	RU	https://pubmed.ncbi.nlm.nih.gov/16505107

DMR0N74	DI	DMR0N74
DMR0N74	DN	LAM-002
DMR0N74	MI	TTA4M1N
DMR0N74	MN	Phosphatidylinositol-3-phosphate 5-kinase (PIP5K3)
DMR0N74	MT	DTT
DMR0N74	MA	Inhibitor
DMR0N74	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMR0N74	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM7MBV6	DI	DM7MBV6
DM7MBV6	DN	Lancovutide
DM7MBV6	MI	TTCYAXN
DM7MBV6	MN	Chloride channel unspecific (ClC)
DM7MBV6	MT	DTT
DM7MBV6	MA	Modulator
DM7MBV6	RN	Airway-rehydrating agents for the treatment of cystic fibrosis: past, present, and future. Ann Pharmacother. 2011 Jan;45(1):49-59.
DM7MBV6	RU	https://pubmed.ncbi.nlm.nih.gov/21156814

DM1VK96	DI	DM1VK96
DM1VK96	DN	LANEPITANT
DM1VK96	MI	TTZPO1L
DM1VK96	MN	Substance-P receptor (TACR1)
DM1VK96	MT	DTT
DM1VK96	MA	Antagonist
DM1VK96	RN	NK1 receptor antagonists as a new treatment for corneal neovascularization. Invest Ophthalmol Vis Sci. 2014 Sep 16;55(10):6783-94.
DM1VK96	RU	https://pubmed.ncbi.nlm.nih.gov/25228541

DMPRZX4	DI	DMPRZX4
DMPRZX4	DN	LAS 100977
DMPRZX4	MI	TT2CJVK
DMPRZX4	MN	Adrenergic receptor beta-2 (ADRB2)
DMPRZX4	MT	DTT
DMPRZX4	MA	Agonist
DMPRZX4	RN	Pharmacological characterization of abediterol, a novel inhaled beta(2)-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models. J Pharmacol Exp Ther. 2012 Aug;342(2):497-509.
DMPRZX4	RU	https://pubmed.ncbi.nlm.nih.gov/22588259

DM3WY0B	DI	DM3WY0B
DM3WY0B	DN	LAS-41002
DM3WY0B	MI	TTYRL6O
DM3WY0B	MN	Glucocorticoid receptor (NR3C1)
DM3WY0B	MT	DTT
DM3WY0B	MA	Modulator
DM3WY0B	RN	Barrier-Restoring Therapies in Atopic Dermatitis: Current Approaches and Future Perspectives. Dermatol Res Pract. 2012; 2012: 923134.
DM3WY0B	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3432345/

DMC04SR	DI	DMC04SR
DMC04SR	DN	LB-100
DMC04SR	MI	TTRKDL6
DMC04SR	MN	Serine/threonine PP2A (PP2A)
DMC04SR	MT	DTT
DMC04SR	MA	Inhibitor
DMC04SR	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMC04SR	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMC04SR	DI	DMC04SR
DMC04SR	DN	LB-100
DMC04SR	MI	TTHTKNY
DMC04SR	MN	Serine/threonine PP2A-alpha (PPP2CA)
DMC04SR	MT	DTT
DMC04SR	MA	Inhibitor
DMC04SR	RN	Inhibition of protein phosphatase 2A enhances cytotoxicity and accessibility of chemotherapeutic drugs to hepatocellular carcinomas. Mol Cancer Ther. 2014 Aug;13(8):2062-72.
DMC04SR	RU	https://pubmed.ncbi.nlm.nih.gov/24867249

DM0OHX3	DI	DM0OHX3
DM0OHX3	DN	LB-30870
DM0OHX3	MI	TT6L509
DM0OHX3	MN	Coagulation factor IIa (F2)
DM0OHX3	MT	DTT
DM0OHX3	MA	Inhibitor
DM0OHX3	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DM0OHX3	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMQZJNA	DI	DMQZJNA
DMQZJNA	DN	LCAR-B38M CAR-T Cell
DMQZJNA	MI	TTZ3P4W
DMQZJNA	MN	B-cell maturation protein (TNFRSF17)
DMQZJNA	MT	DTT
DMQZJNA	MA	CAR-T-Cell-Therapy
DMQZJNA	RN	ClinicalTrials.gov (NCT03758417) A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
DMQZJNA	RU	https://clinicaltrials.gov/ct2/show/NCT03758417

DMY4IWC	DI	DMY4IWC
DMY4IWC	DN	LCB-2183
DMY4IWC	MI	TT7CXIM
DMY4IWC	MN	Histamine receptor (HR)
DMY4IWC	MT	DTT
DMY4IWC	MA	Modulator
DMY4IWC	RN	LCB 2183 inhibits the inflammation associated with oxazolone-induced contact sensitivity. Int J Immunopharmacol. 1994 Aug;16(8):675-83.
DMY4IWC	RU	https://pubmed.ncbi.nlm.nih.gov/7989136

DMTM4QA	DI	DMTM4QA
DMTM4QA	DN	LCL161
DMTM4QA	MI	TTS74QB
DMTM4QA	MN	Inhibitor of apoptosis protein (hIAP)
DMTM4QA	MT	DTT
DMTM4QA	MA	Modulator
DMTM4QA	RN	National Cancer Institute Drug Dictionary (drug id 670651).
DMTM4QA	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=670651

DMM9F25	DI	DMM9F25
DMM9F25	DN	LDE225
DMM9F25	MI	TT8J1S3
DMM9F25	MN	Smoothened homolog (SMO)
DMM9F25	MT	DTT
DMM9F25	MA	Modulator
DMM9F25	RN	Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells. Br J Cancer. 2014 Sep 9;111(6):1168-79.
DMM9F25	RU	https://pubmed.ncbi.nlm.nih.gov/25093491

DMIEZUB	DI	DMIEZUB
DMIEZUB	DN	L-DOS47
DMIEZUB	MI	TTUTJGQ
DMIEZUB	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMIEZUB	MT	DTT
DMIEZUB	RN	Clinical pipeline report, company report or official report of Helix BioPharma.
DMIEZUB	RU	https://www.helixbiopharma.com/pipeline/

DMS6E9J	DI	DMS6E9J
DMS6E9J	DN	Lefitolimod
DMS6E9J	MI	TTSHG0T
DMS6E9J	MN	Toll-like receptor 9 (TLR9)
DMS6E9J	MT	DTT
DMS6E9J	MA	Agonist
DMS6E9J	RN	Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors. Oncoimmunology. 2019 Sep 20;8(12):e1659096.
DMS6E9J	RU	https://pubmed.ncbi.nlm.nih.gov/31741757

DMV2YDK	DI	DMV2YDK
DMV2YDK	DN	LEISH-F1
DMV2YDK	MI	TT3J5ZI
DMV2YDK	MN	Cell mediated immunity response (CMIR)
DMV2YDK	MT	DTT
DMV2YDK	RN	A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine. 2011 Apr 27;29(19):3531-7.
DMV2YDK	RU	https://pubmed.ncbi.nlm.nih.gov/21414377

DMZKBMG	DI	DMZKBMG
DMZKBMG	DN	Lenapenem hydrochloride hydrate
DMZKBMG	MI	TTJP4SM
DMZKBMG	MN	Bacterial Penicillin binding protein (Bact PBP)
DMZKBMG	MT	DTT
DMZKBMG	MA	Inhibitor
DMZKBMG	RN	Affinities of BO-2727 for bacterial penicillin-binding proteins and morphological change of gram-negative rods. J Antibiot (Tokyo). 1997 Feb;50(2):139-42.
DMZKBMG	RU	https://pubmed.ncbi.nlm.nih.gov/9099223

DMWAD93	DI	DMWAD93
DMWAD93	DN	Leniolisib
DMWAD93	MI	TTGBPJE
DMWAD93	MN	PI3-kinase delta (PIK3CD)
DMWAD93	MT	DTT
DMWAD93	MA	Inhibitor
DMWAD93	RN	Effective "activated PI3K syndrome"-targeted therapy with the PI3K inhibitor leniolisib. Blood. 2017 Nov 23;130(21):2307-2316.
DMWAD93	RU	https://pubmed.ncbi.nlm.nih.gov/28972011

DMR1MQW	DI	DMR1MQW
DMR1MQW	DN	Lenzilumab
DMR1MQW	MI	TTNYZG2
DMR1MQW	MN	Granulocyte-macrophage colony-stimulating factor (CSF2)
DMR1MQW	MT	DTT
DMR1MQW	MA	Antagonist
DMR1MQW	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMR1MQW	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM7W0JE	DI	DM7W0JE
DM7W0JE	DN	LEO 124249
DM7W0JE	MI	TTJSQEF
DM7W0JE	MN	Tyrosine-protein kinase (PTK)
DM7W0JE	MT	DTT
DM7W0JE	MA	Inhibitor
DM7W0JE	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7W0JE	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMZ6Y0T	DI	DMZ6Y0T
DMZ6Y0T	DN	LEO-32731
DMZ6Y0T	MI	TTV5CGO
DMZ6Y0T	MN	Phosphodiesterase 4 (PDE4)
DMZ6Y0T	MT	DTT
DMZ6Y0T	MA	Inhibitor
DMZ6Y0T	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZ6Y0T	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM6DL5K	DI	DM6DL5K
DM6DL5K	DN	Leridistim
DM6DL5K	MI	TTPYS82
DM6DL5K	MN	Interleukin 3 receptor (CSF2RB)
DM6DL5K	MT	DTT
DM6DL5K	MA	Agonist
DM6DL5K	RN	Leridistim, a chimeric dual G-CSF and IL-3 receptor agonist, enhances multilineage hematopoietic recovery in a nonhuman primate model of radiation-induced myelosuppression: effect of schedule, dose, and route of administration. Stem Cells. 2001;19(6):522-33.
DM6DL5K	RU	https://pubmed.ncbi.nlm.nih.gov/11713344

DMMQ6VT	DI	DMMQ6VT
DMMQ6VT	DN	Leronlimab
DMMQ6VT	MI	TTH91NV
DMMQ6VT	MN	HUMAN C-C chemokine receptor 5 (CCR5)
DMMQ6VT	MT	DTT
DMMQ6VT	MA	Inhibitor
DMMQ6VT	RN	Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19
DMMQ6VT	RU	https://www.medrxiv.org/content/10.1101/2020.05.02.20084673v1.full.pdf

DMSEVBH	DI	DMSEVBH
DMSEVBH	DN	Lersivirine
DMSEVBH	MI	DE4LYSA
DMSEVBH	MN	Cytochrome P450 3A4 (CYP3A4)
DMSEVBH	MT	DME
DMSEVBH	MA	Metabolism
DMSEVBH	RN	Excretion and metabolism of lersivirine (5-{[3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile), a next-generation non-nucleoside reverse transcriptase inhibitor, after administration of [14C]Lersivirine to healthy volunteers. Drug Metab Dispos. 2010 May;38(5):789-800.
DMSEVBH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20124396

DMSEVBH	DI	DMSEVBH
DMSEVBH	DN	Lersivirine
DMSEVBH	MI	TT84ETX
DMSEVBH	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMSEVBH	MT	DTT
DMSEVBH	MA	Inhibitor
DMSEVBH	RN	Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers. Clin Ther.2010 Oct;32(11):1889-95.
DMSEVBH	RU	https://pubmed.ncbi.nlm.nih.gov/21095483

DMSEVBH	DI	DMSEVBH
DMSEVBH	DN	Lersivirine
DMSEVBH	MI	DEB3CV1
DMSEVBH	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMSEVBH	MT	DME
DMSEVBH	MA	Metabolism
DMSEVBH	RN	Excretion and metabolism of lersivirine (5-{[3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile), a next-generation non-nucleoside reverse transcriptase inhibitor, after administration of [14C]Lersivirine to healthy volunteers. Drug Metab Dispos. 2010 May;38(5):789-800.
DMSEVBH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20124396

DMW50NF	DI	DMW50NF
DMW50NF	DN	LE-SN38
DMW50NF	MI	DTI7UX6
DMW50NF	MN	Breast cancer resistance protein (ABCG2)
DMW50NF	MT	DTP
DMW50NF	MA	Substrate
DMW50NF	RN	Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. Biochem Biophys Res Commun. 2001 Nov 9;288(4):827-32.
DMW50NF	RU	http://www.ncbi.nlm.nih.gov/pubmed/11688982

DMW50NF	DI	DMW50NF
DMW50NF	DN	LE-SN38
DMW50NF	MI	TTGTQHC
DMW50NF	MN	DNA topoisomerase I (TOP1)
DMW50NF	MT	DTT
DMW50NF	MA	Inhibitor
DMW50NF	RN	Analysis of type of cell death induced by topoisomerase inhibitor SN-38 in human oral squamous cell carcinoma cell lines. Anticancer Res. 2012 Nov;32(11):4823-32.
DMW50NF	RU	https://pubmed.ncbi.nlm.nih.gov/23155248

DMW50NF	DI	DMW50NF
DMW50NF	DN	LE-SN38
DMW50NF	MI	DTSYQGK
DMW50NF	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMW50NF	MT	DTP
DMW50NF	MA	Substrate
DMW50NF	RN	ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol. 1999 May;55(5):921-8.
DMW50NF	RU	http://molpharm.aspetjournals.org/content/55/5/921

DMW50NF	DI	DMW50NF
DMW50NF	DN	LE-SN38
DMW50NF	MI	DTFI42L
DMW50NF	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMW50NF	MT	DTP
DMW50NF	MA	Substrate
DMW50NF	RN	Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters. Cancer Res. 1998 Nov 15;58(22):5137-43.
DMW50NF	RU	http://www.ncbi.nlm.nih.gov/pubmed/9823324

DMW50NF	DI	DMW50NF
DMW50NF	DN	LE-SN38
DMW50NF	MI	DTCSGPB
DMW50NF	MN	Multidrug resistance-associated protein 4 (ABCC4)
DMW50NF	MT	DTP
DMW50NF	MA	Substrate
DMW50NF	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMW50NF	RU	https://doi.org/10.1007/s11095-012-0935-x

DMW50NF	DI	DMW50NF
DMW50NF	DN	LE-SN38
DMW50NF	MI	DT3D8F0
DMW50NF	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMW50NF	MT	DTP
DMW50NF	MA	Substrate
DMW50NF	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DMW50NF	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DMW50NF	DI	DMW50NF
DMW50NF	DN	LE-SN38
DMW50NF	MI	DT9C1TS
DMW50NF	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMW50NF	MT	DTP
DMW50NF	MA	Substrate
DMW50NF	RN	Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes. Cancer Lett. 2008 Feb 18;260(1-2):163-9.
DMW50NF	RU	http://www.ncbi.nlm.nih.gov/pubmed/18082941

DMW50NF	DI	DMW50NF
DMW50NF	DN	LE-SN38
DMW50NF	MI	DEYGVN4
DMW50NF	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMW50NF	MT	DME
DMW50NF	MA	Metabolism
DMW50NF	RN	Effects of green tea compounds on irinotecan metabolism. Drug Metab Dispos. 2007 Feb;35(2):228-33.
DMW50NF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17108060

DMW50NF	DI	DMW50NF
DMW50NF	DN	LE-SN38
DMW50NF	MI	DE85D2P
DMW50NF	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMW50NF	MT	DME
DMW50NF	MA	Metabolism
DMW50NF	RN	Correlation between plasma concentration ratios of SN-38 glucuronide and SN-38 and neutropenia induction in patients with colorectal cancer and wild-type UGT1A1 gene. Oncol Lett. 2012 Mar;3(3):694-698.
DMW50NF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22740978

DMIFGLY	DI	DMIFGLY
DMIFGLY	DN	Leukemia cancer vaccine
DMIFGLY	MI	TT6MP2Z
DMIFGLY	MN	GMCSFR-alpha (CSF2RA)
DMIFGLY	MT	DTT
DMIFGLY	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1707).
DMIFGLY	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1707

DM5LQEI	DI	DM5LQEI
DM5LQEI	DN	Leuvectin
DM5LQEI	MI	TTF89GD
DM5LQEI	MN	Interleukin-2 (IL2)
DM5LQEI	MT	DTT
DM5LQEI	MA	Modulator
DM5LQEI	RN	Intratumoral interleukin 2 for renal-cell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid complex. World J Urol. 2000 Apr;18(2):152-6.
DM5LQEI	RU	https://pubmed.ncbi.nlm.nih.gov/10854152

DMOS5JZ	DI	DMOS5JZ
DMOS5JZ	DN	Lexatumumab
DMOS5JZ	MI	TTW20TU
DMOS5JZ	MN	TRAIL receptor 2 (TRAIL-R2)
DMOS5JZ	MT	DTT
DMOS5JZ	RN	National Cancer Institute Drug Dictionary (drug id 528015).
DMOS5JZ	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=528015

DMLEX1D	DI	DMLEX1D
DMLEX1D	DN	Lexibulin
DMLEX1D	MI	TTYFKSZ
DMLEX1D	MN	Tubulin beta (TUBB)
DMLEX1D	MT	DTT
DMLEX1D	MA	Inhibitor
DMLEX1D	RN	National Cancer Institute Drug Dictionary (drug id 598799).
DMLEX1D	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=598799

DMZ2YBE	DI	DMZ2YBE
DMZ2YBE	DN	Lexipafant
DMZ2YBE	MI	TT84ETX
DMZ2YBE	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMZ2YBE	MT	DTT
DMZ2YBE	MA	Inhibitor
DMZ2YBE	RN	Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416.
DMZ2YBE	RU	https://pubmed.ncbi.nlm.nih.gov/18764719

DMZ2YBE	DI	DMZ2YBE
DMZ2YBE	DN	Lexipafant
DMZ2YBE	MI	TTQL5VC
DMZ2YBE	MN	Platelet-activating factor receptor (PTAFR)
DMZ2YBE	MT	DTT
DMZ2YBE	MA	Modulator
DMZ2YBE	RN	Lexipafant and acute pancreatitis: a critical appraisal of the clinical trials.Eur J Surg.2002;168(4):215-9.
DMZ2YBE	RU	https://www.ncbi.nlm.nih.gov/pubmed/12440758

DMCT1RQ	DI	DMCT1RQ
DMCT1RQ	DN	LFG-316
DMCT1RQ	MI	TTKANGO
DMCT1RQ	MN	Complement C5 (CO5)
DMCT1RQ	MT	DTT
DMCT1RQ	RN	Advances in the management of macular degeneration. F1000Prime Rep. 2014; 6: 29.
DMCT1RQ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017905/

DM9T8A2	DI	DM9T8A2
DM9T8A2	DN	LGD-4665
DM9T8A2	MI	TTIHYA4
DM9T8A2	MN	Thrombopoietin receptor (MPL)
DM9T8A2	MT	DTT
DM9T8A2	MA	Agonist
DM9T8A2	RN	Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54.
DM9T8A2	RU	https://pubmed.ncbi.nlm.nih.gov/18537519

DMPL9KG	DI	DMPL9KG
DMPL9KG	DN	LGD-6972
DMPL9KG	MI	TT9O6WS
DMPL9KG	MN	Glucagon receptor (GCGR)
DMPL9KG	MT	DTT
DMPL9KG	MA	Antagonist
DMPL9KG	RN	Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development. Curr Diabetes Rev. 2015 March; 11(1): 17-31.
DMPL9KG	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4428473/

DMA0RI9	DI	DMA0RI9
DMA0RI9	DN	LIDORESTAT
DMA0RI9	MI	TTFBNVI
DMA0RI9	MN	Aldose reductase (AKR1B1)
DMA0RI9	MT	DTT
DMA0RI9	MA	Inhibitor
DMA0RI9	RN	Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors ... J Med Chem. 2005 May 5;48(9):3141-52.
DMA0RI9	RU	https://pubmed.ncbi.nlm.nih.gov/15857120

DM32NWD	DI	DM32NWD
DM32NWD	DN	LIK-066
DM32NWD	MI	TT2UE56
DM32NWD	MN	Sodium/glucose cotransporter 1 (SGLT1)
DM32NWD	MT	DTT
DM32NWD	MA	Inhibitor
DM32NWD	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 915).
DM32NWD	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=915

DM32NWD	DI	DM32NWD
DM32NWD	DN	LIK-066
DM32NWD	MI	TTLWPVF
DM32NWD	MN	Sodium/glucose cotransporter 2 (SGLT2)
DM32NWD	MT	DTT
DM32NWD	MA	Inhibitor
DM32NWD	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM32NWD	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DM9ZHRS	DI	DM9ZHRS
DM9ZHRS	DN	LIM-0705
DM9ZHRS	MI	TTK8XD6
DM9ZHRS	MN	ATP-binding cassette transporter (ABCA)
DM9ZHRS	MT	DTT
DM9ZHRS	MA	Activator
DM9ZHRS	RN	WO patent application no. 2010,0428,86, Pyrone analogs for therapeutic treatment.
DM9ZHRS	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20100415&CC=WO&NR=2010042886A2&KC=A2

DMSHGWN	DI	DMSHGWN
DMSHGWN	DN	Lintopride
DMSHGWN	MI	TTNXLKE
DMSHGWN	MN	5-HT 3 receptor (5HT3R)
DMSHGWN	MT	DTT
DMSHGWN	MA	Modulator
DMSHGWN	RN	The effects of lintopride, a 5HT-4 antagonist, on oesophageal motility. Aliment Pharmacol Ther. 1995 Oct;9(5):563-9.
DMSHGWN	RU	https://pubmed.ncbi.nlm.nih.gov/8580279

DMSHGWN	DI	DMSHGWN
DMSHGWN	DN	Lintopride
DMSHGWN	MI	TT07C3Y
DMSHGWN	MN	5-HT 4 receptor (HTR4)
DMSHGWN	MT	DTT
DMSHGWN	MA	Modulator
DMSHGWN	RN	The effects of lintopride, a 5HT-4 antagonist, on oesophageal motility. Aliment Pharmacol Ther. 1995 Oct;9(5):563-9.
DMSHGWN	RU	https://pubmed.ncbi.nlm.nih.gov/8580279

DMWY0V1	DI	DMWY0V1
DMWY0V1	DN	LIPO-5
DMWY0V1	MI	TTFGZB6
DMWY0V1	MN	Human immunodeficiency virus GAG protein (HIV gag)
DMWY0V1	MT	DTT
DMWY0V1	RN	HIV specific responses induced in nonhuman primates with ANRS HIV-Lipo-5 vaccine combined with rMVA-HIV prime or boost immunizations. Vaccine. 2015 May 11;33(20):2354-9.
DMWY0V1	RU	https://pubmed.ncbi.nlm.nih.gov/25839103

DMWY0V1	DI	DMWY0V1
DMWY0V1	DN	LIPO-5
DMWY0V1	MI	TT4NXYM
DMWY0V1	MN	Human immunodeficiency virus Negative factor (HIV nef)
DMWY0V1	MT	DTT
DMWY0V1	RN	HIV specific responses induced in nonhuman primates with ANRS HIV-Lipo-5 vaccine combined with rMVA-HIV prime or boost immunizations. Vaccine. 2015 May 11;33(20):2354-9.
DMWY0V1	RU	https://pubmed.ncbi.nlm.nih.gov/25839103

DMNGT89	DI	DMNGT89
DMNGT89	DN	Lirilumab
DMNGT89	MI	TTAZF9M
DMNGT89	MN	RAS-like protein KIR (GEM)
DMNGT89	MT	DTT
DMNGT89	MA	Modulator
DMNGT89	RN	Anti-tumoral efficacy of therapeutic human anti-KIR antibody (Lirilumab/BMS-986015/IPH2102) in a preclinical xenograft tumor model. J Immunother Cancer. 2013; 1(Suppl 1): P40.
DMNGT89	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991278/

DMD4KAU	DI	DMD4KAU
DMD4KAU	DN	LIRIMILAST
DMD4KAU	MI	TTZ97H5
DMD4KAU	MN	Phosphodiesterase 4A (PDE4A)
DMD4KAU	MT	DTT
DMD4KAU	MA	Inhibitor
DMD4KAU	RN	Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking . Br J Pharmacol. 2008 October; 155(3): 288-290.
DMD4KAU	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2567889/

DMD4KAU	DI	DMD4KAU
DMD4KAU	DN	LIRIMILAST
DMD4KAU	MI	TTVIAT9
DMD4KAU	MN	Phosphodiesterase 4B (PDE4B)
DMD4KAU	MT	DTT
DMD4KAU	MA	Inhibitor
DMD4KAU	RN	Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36.
DMD4KAU	RU	https://pubmed.ncbi.nlm.nih.gov/21948793

DMD4KAU	DI	DMD4KAU
DMD4KAU	DN	LIRIMILAST
DMD4KAU	MI	TTSKMI8
DMD4KAU	MN	Phosphodiesterase 4D (PDE4D)
DMD4KAU	MT	DTT
DMD4KAU	MA	Inhibitor
DMD4KAU	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMD4KAU	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMVU9X1	DI	DMVU9X1
DMVU9X1	DN	Lisofylline
DMVU9X1	MI	DEJGDUW
DMVU9X1	MN	Cytochrome P450 1A2 (CYP1A2)
DMVU9X1	MT	DME
DMVU9X1	MA	Metabolism
DMVU9X1	RN	Physiologically based modeling of lisofylline pharmacokinetics following intravenous administration in mice. Eur J Drug Metab Pharmacokinet. 2016 Aug;41(4):403-12.
DMVU9X1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25663650

DMZ3OU6	DI	DMZ3OU6
DMZ3OU6	DN	Lithium
DMZ3OU6	MI	TTRZQE3
DMZ3OU6	MN	Glycogen synthase kinase-3 alpha (GSK-3A)
DMZ3OU6	MT	DTT
DMZ3OU6	MA	Inhibitor
DMZ3OU6	RN	The GSK3 kinase inhibitor lithium produces unexpected hyperphosphorylation of -catenin, a GSK3 substrate, in human glioblastoma cells. Biol Open. 2018 Jan 26;7(1):bio030874.
DMZ3OU6	RU	https://pubmed.ncbi.nlm.nih.gov/29212798

DMZ3OU6	DI	DMZ3OU6
DMZ3OU6	DN	Lithium
DMZ3OU6	MI	TTRSMW9
DMZ3OU6	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMZ3OU6	MT	DTT
DMZ3OU6	MA	Inhibitor
DMZ3OU6	RN	The GSK3 kinase inhibitor lithium produces unexpected hyperphosphorylation of -catenin, a GSK3 substrate, in human glioblastoma cells. Biol Open. 2018 Jan 26;7(1):bio030874.
DMZ3OU6	RU	https://pubmed.ncbi.nlm.nih.gov/29212798

DM3XRUH	DI	DM3XRUH
DM3XRUH	DN	LJN452
DM3XRUH	MI	TTS4UGC
DM3XRUH	MN	Farnesoid X-activated receptor (FXR)
DM3XRUH	MT	DTT
DM3XRUH	MA	Agonist
DM3XRUH	RN	FXR modulators for enterohepatic and metabolic diseases.Expert Opin Ther Pat. 2018 Nov;28(11):765-782.
DM3XRUH	RU	https://www.ncbi.nlm.nih.gov/pubmed/30259754

DMVM13R	DI	DMVM13R
DMVM13R	DN	LJPC-401
DMVM13R	MI	TTPCG5T
DMVM13R	MN	Hepcidin (HAMP)
DMVM13R	MT	DTT
DMVM13R	MA	Agonist
DMVM13R	RN	ClinicalTrials.gov (NCT03395704) A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis. U.S. National Institutes of Health.
DMVM13R	RU	https://clinicaltrials.gov/ct2/show/NCT03395704

DMCFGP3	DI	DMCFGP3
DMCFGP3	DN	LKA651
DMCFGP3	MI	TTQG4NR
DMCFGP3	MN	Erythropoietin (EPO)
DMCFGP3	MT	DTT
DMCFGP3	RN	Clinical pipeline report, company report or official report of Novartis.
DMCFGP3	RU	https://www.novartis.com/our-science/novartis-global-pipeline?search_api_views_fulltext=LKA651&field_pipeline_filing_date=All

DMSJOE3	DI	DMSJOE3
DMSJOE3	DN	LM-030
DMSJOE3	MI	TT5L2VC
DMSJOE3	MN	Kallikrein-related peptidase (KLK)
DMSJOE3	MT	DTT
DMSJOE3	MA	Inhibitor
DMSJOE3	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMSJOE3	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMW6VA0	DI	DMW6VA0
DMW6VA0	DN	LM-1507.NA
DMW6VA0	MI	TTGKOY9
DMW6VA0	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DMW6VA0	MT	DTT
DMW6VA0	MA	Antagonist
DMW6VA0	RN	Pharmacological differences among CysLT(1) receptor antagonists with respect to LTC(4) and LTD(4) in human lung parenchyma. Biochem Pharmacol. 2002 Apr 15;63(8):1537-46.
DMW6VA0	RU	https://pubmed.ncbi.nlm.nih.gov/11996896

DMG7RAV	DI	DMG7RAV
DMG7RAV	DN	LMB-2
DMG7RAV	MI	TT10Y9E
DMG7RAV	MN	Interleukin 2 receptor alpha (IL2RA)
DMG7RAV	MT	DTT
DMG7RAV	MA	Modulator
DMG7RAV	RN	Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol. 2000 Apr;18(8):1622-36.
DMG7RAV	RU	https://pubmed.ncbi.nlm.nih.gov/10764422

DMQOXNL	DI	DMQOXNL
DMQOXNL	DN	LMB763
DMQOXNL	MI	TTS4UGC
DMQOXNL	MN	Farnesoid X-activated receptor (FXR)
DMQOXNL	MT	DTT
DMQOXNL	MA	Agonist
DMQOXNL	RN	Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis. J Med Chem. 2020 Apr 23;63(8):3868-3880.
DMQOXNL	RU	https://pubmed.ncbi.nlm.nih.gov/31940200

DM01SR6	DI	DM01SR6
DM01SR6	DN	L-NAME
DM01SR6	MI	TTCM4B3
DM01SR6	MN	Nitric-oxide synthase endothelial (NOS3)
DM01SR6	MT	DTT
DM01SR6	MA	Inhibitor
DM01SR6	RN	Counter-regulation by atorvastatin of gene modulations induced by L-NAME hypertension is associated with vascular protection. Vascul Pharmacol. 2009 Oct;51(4):253-61.
DM01SR6	RU	https://pubmed.ncbi.nlm.nih.gov/19586617

DMT3KB4	DI	DMT3KB4
DMT3KB4	DN	Lobeline
DMT3KB4	MI	TTNZRI3
DMT3KB4	MN	Synaptic vesicle amine transporter (SLC18A2)
DMT3KB4	MT	DTT
DMT3KB4	MA	Inhibitor
DMT3KB4	RN	Design, synthesis and interaction at the vesicular monoamine transporter-2 of lobeline analogs: potential pharmacotherapies for the treatment of psychostimulant abuse. Curr Top Med Chem. 2011;11(9):1103-27.
DMT3KB4	RU	https://pubmed.ncbi.nlm.nih.gov/21050177

DMN0VS2	DI	DMN0VS2
DMN0VS2	DN	Lopinavir + ritonavir + ribavirin + interferon beta-1b
DMN0VS2	MI	TT1D53B
DMN0VS2	MN	COVID-19 3C-like protease (3CLpro)
DMN0VS2	MT	DTT
DMN0VS2	MA	Inhibitor
DMN0VS2	RN	Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381.
DMN0VS2	RU	https://pubmed.ncbi.nlm.nih.gov/32205870

DMN0VS2	DI	DMN0VS2
DMN0VS2	DN	Lopinavir + ritonavir + ribavirin + interferon beta-1b
DMN0VS2	MI	TTV1095
DMN0VS2	MN	COVID-19 RNA-directed RNA polymerase (RdRp)
DMN0VS2	MT	DTT
DMN0VS2	MA	Inhibitor
DMN0VS2	RN	Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150.
DMN0VS2	RU	https://pubmed.ncbi.nlm.nih.gov/32127666

DM0GZTD	DI	DM0GZTD
DM0GZTD	DN	L-ornithine phenylacetate
DM0GZTD	MI	TTSXVID
DM0GZTD	MN	Nuclear factor NF-kappa-B (NFKB)
DM0GZTD	MT	DTT
DM0GZTD	MA	Modulator
DM0GZTD	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM0GZTD	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DME8O5K	DI	DME8O5K
DME8O5K	DN	LOU064
DME8O5K	MI	TTGM6VW
DME8O5K	MN	Tyrosine-protein kinase BTK (ATK)
DME8O5K	MT	DTT
DME8O5K	MA	Inhibitor
DME8O5K	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DME8O5K	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMIV9ZE	DI	DMIV9ZE
DMIV9ZE	DN	LOXORIBINE
DMIV9ZE	MI	TTRJ1K4
DMIV9ZE	MN	Toll-like receptor 7 (TLR7)
DMIV9ZE	MT	DTT
DMIV9ZE	MA	Agonist
DMIV9ZE	RN	The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol. 2003 Nov;33(11):2987-97.
DMIV9ZE	RU	https://pubmed.ncbi.nlm.nih.gov/14579267

DM7BN5W	DI	DM7BN5W
DM7BN5W	DN	LPN023
DM7BN5W	MI	TTA0P7K
DM7BN5W	MN	Complement factor B (CFB)
DM7BN5W	MT	DTT
DM7BN5W	MA	Inhibitor
DM7BN5W	RN	Complement Inhibitors in Clinical Trials for Glomerular Diseases. Front Immunol. 2019 Sep 27;10:2166.
DM7BN5W	RU	https://pubmed.ncbi.nlm.nih.gov/31611870

DMZQBCL	DI	DMZQBCL
DMZQBCL	DN	LR3001
DMZQBCL	MI	TT8V13P
DMZQBCL	MN	Myb messenger RNA (MYB mRNA)
DMZQBCL	MT	DTT
DMZQBCL	RN	Genta obtains orphan drug designation for C-Myb Antisense (LR3001) in chronic myelocytic leukemia. Genta. 2005.
DMZQBCL	RU	http://www.drugs.com/news/genta-obtains-orphan-designation-c-myb-antisense-lr3001-chronic-myelocytic-leukemia-3031.html

DM0TZPL	DI	DM0TZPL
DM0TZPL	DN	LS-71719
DM0TZPL	MI	DEPR1Y7
DM0TZPL	MN	Beta-galactosidase (bgaB)
DM0TZPL	MT	DME
DM0TZPL	MA	Metabolism
DM0TZPL	RN	Diverse galactooligosaccharides consumption by bifidobacteria: implications of beta-galactosidase--LacS operon. Biosci Biotechnol Biochem. 2015;79(4):664-72.
DM0TZPL	RU	https://pubmed.ncbi.nlm.nih.gov/25483279

DME26RS	DI	DME26RS
DME26RS	DN	LTB4
DME26RS	MI	DEFCMPI
DME26RS	MN	Leukotriene B4 omega-hydroxylase (CYP4F3)
DME26RS	MT	DME
DME26RS	MA	Metabolism
DME26RS	RN	Leukotriene B4: metabolism and signal transduction. Arch Biochem Biophys. 2001 Jan 15;385(2):231-41.
DME26RS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11368003

DME26RS	DI	DME26RS
DME26RS	DN	LTB4
DME26RS	MI	TTN53ZF
DME26RS	MN	Leukotriene B4 receptor 1 (LTB4R)
DME26RS	MT	DTT
DME26RS	MA	Agonist
DME26RS	RN	LTB4 promotes insulin resistance in obese mice by acting on macrophages, hepatocytes and myocytes. Nat Med. 2015 Mar;21(3):239-47.
DME26RS	RU	https://pubmed.ncbi.nlm.nih.gov/25706874

DME26RS	DI	DME26RS
DME26RS	DN	LTB4
DME26RS	MI	TTVJX54
DME26RS	MN	Leukotriene B4 receptor 2 (LTB4R2)
DME26RS	MT	DTT
DME26RS	MA	Inhibitor
DME26RS	RN	Diaryl ether/carboxylic acid derivatives of LY255283: Receptor antagonists of leukotriene B4, Bioorg. Med. Chem. Lett. 3(10):1985-1990 (1993).
DME26RS	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01810003

DMXEQ0R	DI	DMXEQ0R
DMXEQ0R	DN	LTX-109
DMXEQ0R	MI	TTXT4D5
DMXEQ0R	MN	Bacterial Cell membrane (Bact CM)
DMXEQ0R	MT	DTT
DMXEQ0R	MA	Modulator
DMXEQ0R	RN	A synthetic antimicrobial peptidomimetic (LTX 109): stereochemical impact on membrane disruption. J Med Chem. 2011 Aug 25;54(16):5786-95.
DMXEQ0R	RU	https://pubmed.ncbi.nlm.nih.gov/21732630

DMJOYNZ	DI	DMJOYNZ
DMJOYNZ	DN	Lu AF11167
DMJOYNZ	MI	TTJW4LU
DMJOYNZ	MN	Phosphodiesterase 10A (PDE10)
DMJOYNZ	MT	DTT
DMJOYNZ	MA	Inhibitor
DMJOYNZ	RN	PDE10A Inhibitors-Clinical Failure or Window Into Antipsychotic Drug Action?. Front Neurosci. 2021 Jan 20;14:600178.
DMJOYNZ	RU	https://pubmed.ncbi.nlm.nih.gov/33551724

DM2ZUXK	DI	DM2ZUXK
DM2ZUXK	DN	Lu-AA34893
DM2ZUXK	MI	TT85JO3
DM2ZUXK	MN	5-HT receptor (5HTR)
DM2ZUXK	MT	DTT
DM2ZUXK	MA	Modulator
DM2ZUXK	RN	Encyclopedia of Psychopharmacology. Ian Stolerman. 2010. Page(105).
DM2ZUXK	RU	https://books.google.com.hk/books?id=qoyYobgX0uwC&pg=PA105&lpg=PA105&dq=Lu-AA34893++Serotonin+transporter&source=bl&ots=Y8wHg_Wpnq&sig=QOjSsHQcRslsmIZnyU6GU1bGY_s&hl=zh-CN&sa=X&ved=0CDAQ6AEwA2oVChMIwZvmieS7yAIVAsKOCh2rAgWU#v=onepage&q=Lu-AA34893%20%20Serotonin%20transporter&f=false

DM2ZUXK	DI	DM2ZUXK
DM2ZUXK	DN	Lu-AA34893
DM2ZUXK	MI	TT3ROYC
DM2ZUXK	MN	Serotonin transporter (SERT)
DM2ZUXK	MT	DTT
DM2ZUXK	MA	Modulator
DM2ZUXK	RN	Encyclopedia of Psychopharmacology. Ian Stolerman. 2010. Page(105).
DM2ZUXK	RU	https://books.google.com.hk/books?id=qoyYobgX0uwC&pg=PA105&lpg=PA105&dq=Lu-AA34893++Serotonin+transporter&source=bl&ots=Y8wHg_Wpnq&sig=QOjSsHQcRslsmIZnyU6GU1bGY_s&hl=zh-CN&sa=X&ved=0CDAQ6AEwA2oVChMIwZvmieS7yAIVAsKOCh2rAgWU#v=onepage&q=Lu-AA34893%20%20Serotonin%20transporter&f=false

DM34FWR	DI	DM34FWR
DM34FWR	DN	Lu-AA39959
DM34FWR	MI	TTM7WCE
DM34FWR	MN	Ion channel unspecific (IC)
DM34FWR	MT	DTT
DM34FWR	MA	Modulator
DM34FWR	RN	Lundbeck: leading the way in the treatment of CNS disorders.
DM34FWR	RU	http://onlinelibrary.wiley.com/doi/10.1002/fps.78/pdf

DMY2L7V	DI	DMY2L7V
DMY2L7V	DN	Lucatumumab
DMY2L7V	MI	TTIJP3Q
DMY2L7V	MN	TNF related activation protein (CD40LG)
DMY2L7V	MT	DTT
DMY2L7V	MA	Modulator
DMY2L7V	RN	Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia.Leuk Lymphoma.2012 Nov;53(11):2136-42.
DMY2L7V	RU	https://www.ncbi.nlm.nih.gov/pubmed/22475052

DMCKNBA	DI	DMCKNBA
DMCKNBA	DN	Lufironil
DMCKNBA	MI	TTNH25W
DMCKNBA	MN	Prolyl 4-hydroxylasesubunit alpha-1 (P4HA1)
DMCKNBA	MT	DTT
DMCKNBA	MA	Modulator
DMCKNBA	RN	Interference in clinical laboratory tests, with special regard to the bilirubin assay: effects of a metabolite of the new prolyl 4-hydroxylase inhibitor, Lufironil. Eur J Clin Chem Clin Biochem. 1994Jul;32(7):515-20.
DMCKNBA	RU	https://pubmed.ncbi.nlm.nih.gov/7981331

DMGWZ93	DI	DMGWZ93
DMGWZ93	DN	Lulizumab pegol
DMGWZ93	MI	TTQ13FT
DMGWZ93	MN	T-cell-specific surface glycoprotein CD28 (CD28)
DMGWZ93	MT	DTT
DMGWZ93	MA	Modulator
DMGWZ93	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMGWZ93	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMQZXDW	DI	DMQZXDW
DMQZXDW	DN	Lum001
DMQZXDW	MI	TTPI1M5
DMQZXDW	MN	Ileal sodium/bile acid cotransporter (SLC10A2)
DMQZXDW	MT	DTT
DMQZXDW	MA	Inhibitor
DMQZXDW	RN	Current research on the treatment of primary sclerosing cholangitis. Intractable Rare Dis Res. 2015 Feb; 4(1): 1-6.
DMQZXDW	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322589/

DMQZXDW	DI	DMQZXDW
DMQZXDW	DN	Lum001
DMQZXDW	MI	TTWZRY5
DMQZXDW	MN	Sodium/bile acid cotransporter (SLC10A1)
DMQZXDW	MT	DTT
DMQZXDW	MA	Inhibitor
DMQZXDW	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQZXDW	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMCLWDJ	DI	DMCLWDJ
DMCLWDJ	DN	Lumacaftor
DMCLWDJ	MI	TTRLZHP
DMCLWDJ	MN	cAMP-dependent chloride channel (CFTR)
DMCLWDJ	MT	DTT
DMCLWDJ	MA	Regulator
DMCLWDJ	RN	A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med. 2014 Jul;2(7):527-38.
DMCLWDJ	RU	https://pubmed.ncbi.nlm.nih.gov/24973281

DMLTI39	DI	DMLTI39
DMLTI39	DN	Lumiliximab
DMLTI39	MI	TTCH6MU
DMLTI39	MN	Lymphocyte IgE receptor (CD23)
DMLTI39	MT	DTT
DMLTI39	RN	Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects. J Allergy Clin Immunol. 2005 Oct;116(4):780-8.
DMLTI39	RU	https://pubmed.ncbi.nlm.nih.gov/16210051

DMLRU9I	DI	DMLRU9I
DMLRU9I	DN	Lunacalcipol
DMLRU9I	MI	TT82UI1
DMLRU9I	MN	Cytochrome P450 24 (CYP24A1)
DMLRU9I	MT	DTT
DMLRU9I	MA	Inhibitor
DMLRU9I	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022679)
DMLRU9I	RU	http://adisinsight.springer.com/drugs/800022679

DMZ2XAP	DI	DMZ2XAP
DMZ2XAP	DN	LX-1031
DMZ2XAP	MI	TT7ZK9C
DMZ2XAP	MN	Tryptophan 5-hydroxylase (TPH)
DMZ2XAP	MT	DTT
DMZ2XAP	MA	Inhibitor
DMZ2XAP	RN	LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome. IDrugs. 2010 Dec;13(12):921-8.
DMZ2XAP	RU	https://pubmed.ncbi.nlm.nih.gov/21154152

DMLA8H3	DI	DMLA8H3
DMLA8H3	DN	LX2931
DMLA8H3	MI	TT618Q2
DMLA8H3	MN	Sphingosine-1-phosphate lyase 1 (SGPL1)
DMLA8H3	MT	DTT
DMLA8H3	MA	Inhibitor
DMLA8H3	RN	Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702.
DMLA8H3	RU	https://pubmed.ncbi.nlm.nih.gov/23954895

DMLBD5I	DI	DMLBD5I
DMLBD5I	DN	LXE408
DMLBD5I	MI	TTSVQWU
DMLBD5I	MN	Leishmania major Proteasome (Leishm Proteasome)
DMLBD5I	MT	DTT
DMLBD5I	MA	Inhibitor
DMLBD5I	RN	Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases. J Med Chem. 2020 Oct 8;63(19):10773-10781.
DMLBD5I	RU	https://pubmed.ncbi.nlm.nih.gov/32667203

DM5IX9M	DI	DM5IX9M
DM5IX9M	DN	LY-156735
DM5IX9M	MI	TT0WAIE
DM5IX9M	MN	Melatonin receptor type 1A (MTNR1A)
DM5IX9M	MT	DTT
DM5IX9M	MA	Agonist
DM5IX9M	RN	Melatonin and sleep in aging population. Exp Gerontol. 2005 Dec;40(12):911-25.
DM5IX9M	RU	https://pubmed.ncbi.nlm.nih.gov/16183237

DMTBFE4	DI	DMTBFE4
DMTBFE4	DN	LY2090314
DMTBFE4	MI	TTRZQE3
DMTBFE4	MN	Glycogen synthase kinase-3 alpha (GSK-3A)
DMTBFE4	MT	DTT
DMTBFE4	MA	Modulator
DMTBFE4	RN	Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
DMTBFE4	RU	https://www.ncbi.nlm.nih.gov/pubmed/27828716

DMTBFE4	DI	DMTBFE4
DMTBFE4	DN	LY2090314
DMTBFE4	MI	TTRSMW9
DMTBFE4	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMTBFE4	MT	DTT
DMTBFE4	MA	Modulator
DMTBFE4	RN	Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
DMTBFE4	RU	https://www.ncbi.nlm.nih.gov/pubmed/27828716

DMU81BH	DI	DMU81BH
DMU81BH	DN	LY-2189102
DMU81BH	MI	TTRYK0X
DMU81BH	MN	Interleukin-1 beta (IL1B)
DMU81BH	MT	DTT
DMU81BH	RN	Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1beta antibody, in patients with type 2 diabetes. Diabetes Care. 2013Aug;36(8):2239-46.
DMU81BH	RU	https://pubmed.ncbi.nlm.nih.gov/23514733

DMH3YKJ	DI	DMH3YKJ
DMH3YKJ	DN	LY2382770
DMH3YKJ	MI	TTO3HT7
DMH3YKJ	MN	Transforming growth factor beta (TGFB)
DMH3YKJ	MT	DTT
DMH3YKJ	MA	Inhibitor
DMH3YKJ	RN	A phase I dose-escalation study to a predefined dose of a transforming growth factor-1 monoclonal antibody (TM1) in patients with metastatic cancer. Int J Oncol. 2014 Dec;45(6):2221-31.
DMH3YKJ	RU	https://pubmed.ncbi.nlm.nih.gov/25270361

DMZOIP4	DI	DMZOIP4
DMZOIP4	DN	LY-2409021
DMZOIP4	MI	TT9O6WS
DMZOIP4	MN	Glucagon receptor (GCGR)
DMZOIP4	MT	DTT
DMZOIP4	MA	Antagonist
DMZOIP4	RN	Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes. Diabetes Obes Metab. 2015 Apr;17(4):414-22.
DMZOIP4	RU	https://pubmed.ncbi.nlm.nih.gov/25656305

DMKYMS2	DI	DMKYMS2
DMKYMS2	DN	LY-2428757
DMKYMS2	MI	TTVIMDE
DMKYMS2	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMKYMS2	MT	DTT
DMKYMS2	MA	Stimulator
DMKYMS2	RN	Role and development of GLP-1 receptor agonists in the management of diabetes. Diabetes Metab Syndr Obes. 2009; 2: 37-49.
DMKYMS2	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2818016/

DMLTSDC	DI	DMLTSDC
DMLTSDC	DN	LY-2456302
DMLTSDC	MI	TTQW87Y
DMLTSDC	MN	Opioid receptor kappa (OPRK1)
DMLTSDC	MT	DTT
DMLTSDC	MA	Antagonist
DMLTSDC	RN	LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. Neuropharmacology. 2014 Feb;77:131-44.
DMLTSDC	RU	https://pubmed.ncbi.nlm.nih.gov/24071566

DMM5JAN	DI	DMM5JAN
DMM5JAN	DN	LY2495655
DMM5JAN	MI	TTSWPH8
DMM5JAN	MN	Growth/differentiation factor 8 (GDF-8)
DMM5JAN	MT	DTT
DMM5JAN	MA	Modulator
DMM5JAN	RN	Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Curr Opin Support Palliat Care. 2013 November; 7(4): 352-360.
DMM5JAN	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3819341/

DMCV602	DI	DMCV602
DMCV602	DN	LY2523355
DMCV602	MI	TTTRP0H
DMCV602	MN	Kinesin-like protein KIF11 (KIF11)
DMCV602	MT	DTT
DMCV602	MA	Modulator
DMCV602	RN	Kinesins and cancer. Nat Rev Cancer. 2012 Jul 24;12(8):527-39.
DMCV602	RU	https://pubmed.ncbi.nlm.nih.gov/22825217

DMTVU2Q	DI	DMTVU2Q
DMTVU2Q	DN	LY2541546
DMTVU2Q	MI	TTYRO4F
DMTVU2Q	MN	Sclerostin (SOST)
DMTVU2Q	MT	DTT
DMTVU2Q	RN	Rat-specific decreases in platelet count caused by a humanized monoclonal antibody against sclerostin. Toxicol Sci. 2012 Feb;125(2):586-94.
DMTVU2Q	RU	https://pubmed.ncbi.nlm.nih.gov/22106037

DM81UJW	DI	DM81UJW
DM81UJW	DN	LY-2590443
DM81UJW	MI	TTZPO1L
DM81UJW	MN	Substance-P receptor (TACR1)
DM81UJW	MT	DTT
DM81UJW	MA	Antagonist
DM81UJW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 360).
DM81UJW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=360

DMMI0RH	DI	DMMI0RH
DMMI0RH	DN	LY-2599506
DMMI0RH	MI	TTDLNGZ
DMMI0RH	MN	Glucokinase (GCK)
DMMI0RH	MT	DTT
DMMI0RH	MA	Inhibitor
DMMI0RH	RN	This week in therapeutics Endocrine disease. SciBX 2(37); doi:10.1038/scibx.2009.1408. Sept. 24, 2009
DMMI0RH	RU	http://www.nature.com/scibx/journal/v2/n37/pdf/scibx.2009.1408.pdf

DMCXRZF	DI	DMCXRZF
DMCXRZF	DN	LY2603618
DMCXRZF	MI	TTTU902
DMCXRZF	MN	Checkpoint kinase-1 (CHK1)
DMCXRZF	MT	DTT
DMCXRZF	MA	Modulator
DMCXRZF	RN	Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. Invest New Drugs. 2014 Apr;32(2):213-26.
DMCXRZF	RU	https://pubmed.ncbi.nlm.nih.gov/24114124

DMCXRZF	DI	DMCXRZF
DMCXRZF	DN	LY2603618
DMCXRZF	MI	DECB0K3
DMCXRZF	MN	Cytochrome P450 2D6 (CYP2D6)
DMCXRZF	MT	DME
DMCXRZF	MA	Metabolism
DMCXRZF	RN	Disposition and metabolism of LY2603618, a Chk-1 inhibitor following intravenous administration in patients with advanced and/or metastatic solid tumors. Xenobiotica. 2014 Sep;44(9):827-41.
DMCXRZF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24666335

DMCXRZF	DI	DMCXRZF
DMCXRZF	DN	LY2603618
DMCXRZF	MI	DE4LYSA
DMCXRZF	MN	Cytochrome P450 3A4 (CYP3A4)
DMCXRZF	MT	DME
DMCXRZF	MA	Metabolism
DMCXRZF	RN	Disposition and metabolism of LY2603618, a Chk-1 inhibitor following intravenous administration in patients with advanced and/or metastatic solid tumors. Xenobiotica. 2014 Sep;44(9):827-41.
DMCXRZF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24666335

DM4XMF7	DI	DM4XMF7
DM4XMF7	DN	LY2606368
DM4XMF7	MI	TTTU902
DM4XMF7	MN	Checkpoint kinase-1 (CHK1)
DM4XMF7	MT	DTT
DM4XMF7	MA	Inhibitor
DM4XMF7	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM4XMF7	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM4EF9Y	DI	DM4EF9Y
DM4EF9Y	DN	LY-2608204
DM4EF9Y	MI	TTDLNGZ
DM4EF9Y	MN	Glucokinase (GCK)
DM4EF9Y	MT	DTT
DM4EF9Y	MA	Activator
DM4EF9Y	RN	Clinical pipeline report, company report or official report of Eli Lilly.
DM4EF9Y	RU	http://www.lillytrials.com/initiated/initiated.html

DMFGNB4	DI	DMFGNB4
DMFGNB4	DN	LY-2623091
DMFGNB4	MI	TT26PHO
DMFGNB4	MN	Mineralocorticoid receptor  (MR)
DMFGNB4	MT	DTT
DMFGNB4	MA	Antagonist
DMFGNB4	RN	Nonsteroidal antagonists of the mineralocorticoid receptor. Curr Opin Nephrol Hypertens. 2015 Sep;24(5):417-24.
DMFGNB4	RU	https://pubmed.ncbi.nlm.nih.gov/26083526

DMTPQUA	DI	DMTPQUA
DMTPQUA	DN	LY-2624803
DMTPQUA	MI	TTTIBOJ
DMTPQUA	MN	Histamine H1 receptor (H1R)
DMTPQUA	MT	DTT
DMTPQUA	MA	Modulator
DMTPQUA	RN	Current Phase II investigational therapies for insomnia. Expert Opin Investig Drugs. 2015 Mar;24(3):401-11.
DMTPQUA	RU	https://pubmed.ncbi.nlm.nih.gov/25423562

DMZASMP	DI	DMZASMP
DMZASMP	DN	LY2784544
DMZASMP	MI	TTRMX3V
DMZASMP	MN	Janus kinase 2 (JAK-2)
DMZASMP	MT	DTT
DMZASMP	MA	Modulator
DMZASMP	RN	Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F. Blood Cancer J. 2013 Apr 12;3:e109.
DMZASMP	RU	https://pubmed.ncbi.nlm.nih.gov/23584399

DM0KJDY	DI	DM0KJDY
DM0KJDY	DN	LY2801653
DM0KJDY	MI	TTU8W4S
DM0KJDY	MN	Protein kinase (PK)
DM0KJDY	MT	DTT
DM0KJDY	MA	Inhibitor
DM0KJDY	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM0KJDY	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM0KJDY	DI	DM0KJDY
DM0KJDY	DN	LY2801653
DM0KJDY	MI	TTNDSF4
DM0KJDY	MN	Proto-oncogene c-Met (MET)
DM0KJDY	MT	DTT
DM0KJDY	MA	Modulator
DM0KJDY	RN	Clinical pipeline report, company report or official report of Eli Lilly.
DM0KJDY	RU	http://www.lillyoncologypipeline.com/met-inhibitor.aspx

DMO8IEZ	DI	DMO8IEZ
DMO8IEZ	DN	LY-2828360
DMO8IEZ	MI	TTMSFAW
DMO8IEZ	MN	Cannabinoid receptor 2 (CB2)
DMO8IEZ	MT	DTT
DMO8IEZ	MA	Agonist
DMO8IEZ	RN	Recent Development of CB2 Selective and Peripheral CB1/CB2 Cannabinoid Receptor Ligands. Current Medicinal Chemistry . 10/2013; 21(2).
DMO8IEZ	RU	http://www.researchgate.net/publication/258114758_Recent_Development_of_CB2_Selective_and_Peripheral_CB1CB2_Cannabinoid_Receptor_Ligands

DMZ0DMY	DI	DMZ0DMY
DMZ0DMY	DN	LY2874455
DMZ0DMY	MI	TTGJVQM
DMZ0DMY	MN	Fibroblast growth factor receptor 2 (FGFR2)
DMZ0DMY	MT	DTT
DMZ0DMY	MA	Modulator
DMZ0DMY	RN	Company report (Eli Lilly) (drug: LY2874455)
DMZ0DMY	RU	http://www.lillyoncologypipeline.com/fgfr-inhibitor.aspx

DMQV1OU	DI	DMQV1OU
DMQV1OU	DN	LY-2875358
DMQV1OU	MI	TTNDSF4
DMQV1OU	MN	Proto-oncogene c-Met (MET)
DMQV1OU	MT	DTT
DMQV1OU	RN	Clinical pipeline report, company report or official report of Eli Lilly.
DMQV1OU	RU	http://www.lillyoncologypipeline.com/met-antibody.aspx

DMV14LM	DI	DMV14LM
DMV14LM	DN	LY2886721
DMV14LM	MI	TT8JRS7
DMV14LM	MN	Beta-secretase (BACE)
DMV14LM	MT	DTT
DMV14LM	MA	Modulator
DMV14LM	RN	Lessons from a BACE1 inhibitor trial: off-site but not off base.Alzheimers Dement.2014 Oct;10(5 Suppl):S411-9.
DMV14LM	RU	https://www.ncbi.nlm.nih.gov/pubmed/24530026

DMRDEKZ	DI	DMRDEKZ
DMRDEKZ	DN	LY2928057
DMRDEKZ	MI	TT6Y1PG
DMRDEKZ	MN	Solute carrier family 40 member 1 (SLC40A1)
DMRDEKZ	MT	DTT
DMRDEKZ	MA	Modulator
DMRDEKZ	RN	Targeting the Hepcidin-Ferroportin Axis to Develop New Treatment Strategies for Anemia of Chronic Disease and Anemia of Inflammation. Am J Hematol. 2012 April; 87(4): 392-400.
DMRDEKZ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3653431/

DM4N6EK	DI	DM4N6EK
DM4N6EK	DN	LY293558
DM4N6EK	MI	TT0MYE2
DM4N6EK	MN	Glutamate receptor ionotropic kainate 1 (GRIK1)
DM4N6EK	MT	DTT
DM4N6EK	MA	Modulator
DM4N6EK	RN	Pharmacogenetics of new analgesics. Br J Pharmacol. 2011 Jun;163(3):447-60.
DM4N6EK	RU	https://pubmed.ncbi.nlm.nih.gov/20942817

DMB5L6Q	DI	DMB5L6Q
DMB5L6Q	DN	LY-2940094
DMB5L6Q	MI	TTNT7K8
DMB5L6Q	MN	Nociceptin receptor (OPRL1)
DMB5L6Q	MT	DTT
DMB5L6Q	MA	Modulator
DMB5L6Q	RN	Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs. Biochemical Pharmacology Volume 95, Issue 2, 15 May 2015, Pages 81-97.
DMB5L6Q	RU	http://www.sciencedirect.com/science/article/pii/S0006295215001562

DML6XWR	DI	DML6XWR
DML6XWR	DN	LY2944876
DML6XWR	MI	TT9O6WS
DML6XWR	MN	Glucagon receptor (GCGR)
DML6XWR	MT	DTT
DML6XWR	MA	Modulator
DML6XWR	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DML6XWR	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DML6XWR	DI	DML6XWR
DML6XWR	DN	LY2944876
DML6XWR	MI	TTVIMDE
DML6XWR	MN	Glucagon-like peptide 1 receptor (GLP1R)
DML6XWR	MT	DTT
DML6XWR	MA	Modulator
DML6XWR	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DML6XWR	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMRVEHY	DI	DMRVEHY
DMRVEHY	DN	LY3012212
DMRVEHY	MI	TT2Q6G1
DMRVEHY	MN	Vascular endothelial growth factor receptor 1 (FLT-1)
DMRVEHY	MT	DTT
DMRVEHY	MA	Modulator
DMRVEHY	RN	Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study. Invest New Drugs. 2014 Apr;32(2):303-11.
DMRVEHY	RU	https://pubmed.ncbi.nlm.nih.gov/23903897

DMFMKQ3	DI	DMFMKQ3
DMFMKQ3	DN	LY3015014
DMFMKQ3	MI	TTBRG7E
DMFMKQ3	MN	Proprotein convertase subtilisin/kexin type 9 (PCSK9)
DMFMKQ3	MT	DTT
DMFMKQ3	RN	The dyslipidaemia market. Nat Rev Drug Discov. 2014 Nov;13(11):807-8.
DMFMKQ3	RU	https://pubmed.ncbi.nlm.nih.gov/25323928

DMD9KYF	DI	DMD9KYF
DMD9KYF	DN	LY3023414
DMD9KYF	MI	TTEUNMR
DMD9KYF	MN	PI3-kinase alpha (PIK3CA)
DMD9KYF	MT	DTT
DMD9KYF	MA	Modulator
DMD9KYF	RN	Company report (Lilly)
DMD9KYF	RU	http://www.lillyoncologypipeline.com/pi3kmtor-dual-inhibitor.aspx

DMD9KYF	DI	DMD9KYF
DMD9KYF	DN	LY3023414
DMD9KYF	MI	TTCJG29
DMD9KYF	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMD9KYF	MT	DTT
DMD9KYF	MA	Modulator
DMD9KYF	RN	Company report (Lilly)
DMD9KYF	RU	http://www.lillyoncologypipeline.com/pi3kmtor-dual-inhibitor.aspx

DMDFZK8	DI	DMDFZK8
DMDFZK8	DN	LY3113593
DMDFZK8	MI	TT07RIB
DMDFZK8	MN	Bone morphogenetic protein 6 (BMP6)
DMDFZK8	MT	DTT
DMDFZK8	MA	Inhibitor
DMDFZK8	RN	Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease. Br J Clin Pharmacol. 2019 May;85(5):935-948.
DMDFZK8	RU	https://pubmed.ncbi.nlm.nih.gov/30677788

DMAC457	DI	DMAC457
DMAC457	DN	LY3127804
DMAC457	MI	TT0APVH
DMAC457	MN	HUMAN angiopoietin-2 (ANG-2)
DMAC457	MT	DTT
DMAC457	MA	Inhibitor
DMAC457	RN	Updates: Lilly's Global COVID-19 Response
DMAC457	RU	https://www.lilly.com/news/stories/coronavirus-covid19-global-response

DM7IFNB	DI	DM7IFNB
DM7IFNB	DN	LY3202626
DM7IFNB	MI	TT8JRS7
DM7IFNB	MN	Beta-secretase (BACE)
DM7IFNB	MT	DTT
DM7IFNB	MA	Inhibitor
DM7IFNB	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7IFNB	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMGMC8H	DI	DMGMC8H
DMGMC8H	DN	LY333531
DMGMC8H	MI	DE4LYSA
DMGMC8H	MN	Cytochrome P450 3A4 (CYP3A4)
DMGMC8H	MT	DME
DMGMC8H	MA	Metabolism
DMGMC8H	RN	The interactions of a selective protein kinase C beta inhibitor with the human cytochromes P450. Drug Metab Dispos. 2002 Sep;30(9):957-61.
DMGMC8H	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12167559

DMGMC8H	DI	DMGMC8H
DMGMC8H	DN	LY333531
DMGMC8H	MI	TT9SL3Q
DMGMC8H	MN	Polypeptide deformylase (PDF)
DMGMC8H	MT	DTT
DMGMC8H	MA	Inhibitor
DMGMC8H	RN	Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs. J Mol Biol. 2000 Jan 14;295(2):307-23.
DMGMC8H	RU	https://pubmed.ncbi.nlm.nih.gov/10623528

DMGMC8H	DI	DMGMC8H
DMGMC8H	DN	LY333531
DMGMC8H	MI	TTYPXQF
DMGMC8H	MN	Protein kinase C beta (PRKCB)
DMGMC8H	MT	DTT
DMGMC8H	MA	Inhibitor
DMGMC8H	RN	Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes. 2003 Feb;52(2):512-8.
DMGMC8H	RU	https://pubmed.ncbi.nlm.nih.gov/12540629

DM43O9N	DI	DM43O9N
DM43O9N	DN	LY-334370
DM43O9N	MI	TT0MI3F
DM43O9N	MN	5-HT 1F receptor (HTR1F)
DM43O9N	MT	DTT
DM43O9N	MA	Modulator
DM43O9N	RN	Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet. 2001 Oct 13;358(9289):1230-4.
DM43O9N	RU	https://www.ncbi.nlm.nih.gov/pubmed/11675061

DMD09CT	DI	DMD09CT
DMD09CT	DN	LY-362884
DMD09CT	MI	TTMXGCW
DMD09CT	MN	Adrenergic receptor beta-3 (ADRB3)
DMD09CT	MT	DTT
DMD09CT	MA	Agonist
DMD09CT	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DMD09CT	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMZCU7I	DI	DMZCU7I
DMZCU7I	DN	LY-377604
DMZCU7I	MI	TTMXGCW
DMZCU7I	MN	Adrenergic receptor beta-3 (ADRB3)
DMZCU7I	MT	DTT
DMZCU7I	MA	Agonist
DMZCU7I	RN	Combination of a Beta Adrenoceptor Modulator and a Norepinephrine-Serotonin Uptake Inhibitor for the Treatment of Obesity. ACS Med Chem Lett. 2011 August 11; 2(8): 583-586.
DMZCU7I	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4018109/

DM8OG0J	DI	DM8OG0J
DM8OG0J	DN	LY-517717
DM8OG0J	MI	TTCIHJA
DM8OG0J	MN	Coagulation factor Xa (F10)
DM8OG0J	MT	DTT
DM8OG0J	MA	Inhibitor
DM8OG0J	RN	Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7.
DM8OG0J	RU	https://pubmed.ncbi.nlm.nih.gov/22844656

DMBM2I9	DI	DMBM2I9
DMBM2I9	DN	LY-518674
DMBM2I9	MI	TTJ584C
DMBM2I9	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMBM2I9	MT	DTT
DMBM2I9	MA	Agonist
DMBM2I9	RN	Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2009 Jan;29(1):140-6.
DMBM2I9	RU	https://pubmed.ncbi.nlm.nih.gov/18988892

DMMSBW5	DI	DMMSBW5
DMMSBW5	DN	LY-545694
DMMSBW5	MI	TTDXZ24
DMMSBW5	MN	Glutamate receptor ionotropic (GRI)
DMMSBW5	MT	DTT
DMMSBW5	MA	Antagonist
DMMSBW5	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019739)
DMMSBW5	RU	http://adisinsight.springer.com/drugs/800019739

DMP05GL	DI	DMP05GL
DMP05GL	DN	LYC-30937
DMP05GL	MI	TT5WKM8
DMP05GL	MN	ATP phosphatase (ATPase)
DMP05GL	MT	DTT
DMP05GL	MA	Modulator
DMP05GL	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMP05GL	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMV8WU9	DI	DMV8WU9
DMV8WU9	DN	LYC-55716
DMV8WU9	MI	TTGV6LY
DMV8WU9	MN	Nuclear receptor ROR-gamma (RORG)
DMV8WU9	MT	DTT
DMV8WU9	MA	Agonist
DMV8WU9	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMV8WU9	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM23Y6K	DI	DM23Y6K
DM23Y6K	DN	LYS228
DM23Y6K	MI	TT85JMW
DM23Y6K	MN	Bacterial Penicillin binding protein 3 (Bact mrcA)
DM23Y6K	MT	DTT
DM23Y6K	MA	Binder
DM23Y6K	RN	Mode of Action of the Monobactam LYS228 and Mechanisms Decreasing In Vitro Susceptibility in Escherichia coli and Klebsiella pneumoniae. Antimicrob Agents Chemother. 2018 Sep 24;62(10):e01200-18.
DM23Y6K	RU	https://pubmed.ncbi.nlm.nih.gov/30061293

DML0I2Z	DI	DML0I2Z
DML0I2Z	DN	M118
DML0I2Z	MI	TT4QPUL
DML0I2Z	MN	Antithrombin-III (ATIII)
DML0I2Z	MT	DTT
DML0I2Z	MA	Inhibitor
DML0I2Z	RN	Clinical pipeline report, company report or official report of Momentapharma.
DML0I2Z	RU	http://www.momentapharma.com/pipeline/adomiparin.php

DMZ7YX3	DI	DMZ7YX3
DMZ7YX3	DN	M-16209
DMZ7YX3	MI	TTFBNVI
DMZ7YX3	MN	Aldose reductase (AKR1B1)
DMZ7YX3	MT	DTT
DMZ7YX3	MA	Inhibitor
DMZ7YX3	RN	Effects of novel aldose reductase inhibitors, M16209 and M16287, on streptozotocin-induced diabetic neuropathy in rats. Eur J Pharmacol. 1991 Feb 7;193(2):185-91.
DMZ7YX3	RU	https://pubmed.ncbi.nlm.nih.gov/1828768

DMC5MQD	DI	DMC5MQD
DMC5MQD	DN	M2951
DMC5MQD	MI	TTGM6VW
DMC5MQD	MN	Tyrosine-protein kinase BTK (ATK)
DMC5MQD	MT	DTT
DMC5MQD	MA	Inhibitor
DMC5MQD	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMC5MQD	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMJCULI	DI	DMJCULI
DMJCULI	DN	M7824
DMJCULI	MI	TT8ZLTI
DMJCULI	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMJCULI	MT	DTT
DMJCULI	MA	Inhibitor
DMJCULI	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMJCULI	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMJCULI	DI	DMJCULI
DMJCULI	DN	M7824
DMJCULI	MI	TTNBFWK
DMJCULI	MN	Programmed cell death protein 1 (PD-1)
DMJCULI	MT	DTT
DMJCULI	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMJCULI	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMJCULI	DI	DMJCULI
DMJCULI	DN	M7824
DMJCULI	MI	TTO3HT7
DMJCULI	MN	Transforming growth factor beta (TGFB)
DMJCULI	MT	DTT
DMJCULI	MA	Inhibitor
DMJCULI	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMJCULI	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMQOBH4	DI	DMQOBH4
DMQOBH4	DN	mab 1-7F9
DMQOBH4	MI	TT4UXPE
DMQOBH4	MN	MHC class I NK cell receptor 2DL1 (CD158A)
DMQOBH4	MT	DTT
DMQOBH4	RN	Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo. Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12879-84.
DMQOBH4	RU	https://pubmed.ncbi.nlm.nih.gov/19561305

DMQOBH4	DI	DMQOBH4
DMQOBH4	DN	mab 1-7F9
DMQOBH4	MI	TTU0P73
DMQOBH4	MN	MHC class I NK cell receptor 2DL2 (CD158b1)
DMQOBH4	MT	DTT
DMQOBH4	RN	Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo. Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12879-84.
DMQOBH4	RU	https://pubmed.ncbi.nlm.nih.gov/19561305

DMQOBH4	DI	DMQOBH4
DMQOBH4	DN	mab 1-7F9
DMQOBH4	MI	TTEX3SI
DMQOBH4	MN	MHC class I NK cell receptor 2DL3 (CD158b2)
DMQOBH4	MT	DTT
DMQOBH4	RN	Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo. Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12879-84.
DMQOBH4	RU	https://pubmed.ncbi.nlm.nih.gov/19561305

DMBYDNE	DI	DMBYDNE
DMBYDNE	DN	Managlinat dialanetil
DMBYDNE	MI	TTWHDVK
DMBYDNE	MN	Fructose-1,6-bisphosphatase (FBP)
DMBYDNE	MT	DTT
DMBYDNE	MA	Modulator
DMBYDNE	RN	MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes. Proc Natl Acad Sci U S A. 2005 May 31;102(22):7970-5.
DMBYDNE	RU	https://pubmed.ncbi.nlm.nih.gov/15911772

DMB4A8I	DI	DMB4A8I
DMB4A8I	DN	MANOALIDE
DMB4A8I	MI	TT9V5JH
DMB4A8I	MN	Phospholipase A2 (PLA2G1B)
DMB4A8I	MT	DTT
DMB4A8I	MA	Modulator
DMB4A8I	RN	Manoalide, a phospholipase A2 inhibitor, inhibits arachidonate incorporation and turnover in brain phospholipids of the awake rat. Neurochem Res. 1998 Oct;23(10):1251-7.
DMB4A8I	RU	https://www.ncbi.nlm.nih.gov/pubmed/9804280

DMGQ175	DI	DMGQ175
DMGQ175	DN	Mapatumumab
DMGQ175	MI	TT5WLRX
DMGQ175	MN	TRAIL receptor 1 (TRAIL-R1)
DMGQ175	MT	DTT
DMGQ175	MA	Modulator
DMGQ175	RN	National Cancer Institute Drug Dictionary (drug id 486626).
DMGQ175	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=486626

DMDTI0L	DI	DMDTI0L
DMDTI0L	DN	Masilukast
DMDTI0L	MI	TTGKOY9
DMDTI0L	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DMDTI0L	MT	DTT
DMDTI0L	MA	Modulator
DMDTI0L	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMDTI0L	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM2458E	DI	DM2458E
DM2458E	DN	Matuzumab
DM2458E	MI	TTGKNB4
DM2458E	MN	Epidermal growth factor receptor (EGFR)
DM2458E	MT	DTT
DM2458E	RN	Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Cancer Cell. 2008 Apr;13(4):365-73.
DM2458E	RU	https://pubmed.ncbi.nlm.nih.gov/18394559

DMMVFRC	DI	DMMVFRC
DMMVFRC	DN	Mavrilimumab
DMMVFRC	MI	TT6MP2Z
DMMVFRC	MN	GMCSFR-alpha (CSF2RA)
DMMVFRC	MT	DTT
DMMVFRC	RN	Clinical pipeline report, company report or official report of MedImmune (2011).
DMMVFRC	RU	http://www.medimmune.com/research_pipeline.aspx

DMMVFRC	DI	DMMVFRC
DMMVFRC	DN	Mavrilimumab
DMMVFRC	MI	TTNYZG2
DMMVFRC	MN	Granulocyte-macrophage colony-stimulating factor (CSF2)
DMMVFRC	MT	DTT
DMMVFRC	MA	Antagonist
DMMVFRC	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMMVFRC	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMWLIPJ	DI	DMWLIPJ
DMWLIPJ	DN	MAXY-G34
DMWLIPJ	MI	TTC70AJ
DMWLIPJ	MN	Granulocyte colony-stimulating factor receptor (G-CSF-R)
DMWLIPJ	MT	DTT
DMWLIPJ	MA	Agonist
DMWLIPJ	RN	Survival efficacy of the PEGylated G-CSFs Maxy-G34 and neulasta in a mouse model of lethal H-ARS, and residual bone marrow damage in treated survivors. Health Phys. 2014 Jan;106(1):21-38.
DMWLIPJ	RU	https://pubmed.ncbi.nlm.nih.gov/24276547

DMJKHVX	DI	DMJKHVX
DMJKHVX	DN	Mazapertine succinate
DMJKHVX	MI	TTSQIFT
DMJKHVX	MN	5-HT 1A receptor (HTR1A)
DMJKHVX	MT	DTT
DMJKHVX	MA	Modulator
DMJKHVX	RN	Dual ligands targeting dopamine D2 and serotonin 5-HT1A receptors as new antipsychotical or anti-Parkinsonian agents.Curr Med Chem.2014;21(4):437-57.
DMJKHVX	RU	https://www.ncbi.nlm.nih.gov/pubmed/24164194

DMJKHVX	DI	DMJKHVX
DMJKHVX	DN	Mazapertine succinate
DMJKHVX	MI	TTEX248
DMJKHVX	MN	Dopamine D2 receptor (D2R)
DMJKHVX	MT	DTT
DMJKHVX	MA	Modulator
DMJKHVX	RN	Dual ligands targeting dopamine D2 and serotonin 5-HT1A receptors as new antipsychotical or anti-Parkinsonian agents.Curr Med Chem.2014;21(4):437-57.
DMJKHVX	RU	https://www.ncbi.nlm.nih.gov/pubmed/24164194

DMHU8SJ	DI	DMHU8SJ
DMHU8SJ	DN	MB07803
DMHU8SJ	MI	TTWHDVK
DMHU8SJ	MN	Fructose-1,6-bisphosphatase (FBP)
DMHU8SJ	MT	DTT
DMHU8SJ	MA	Modulator
DMHU8SJ	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMHU8SJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM6JTSZ	DI	DM6JTSZ
DM6JTSZ	DN	MB-07811
DM6JTSZ	MI	DE4LYSA
DM6JTSZ	MN	Cytochrome P450 3A4 (CYP3A4)
DM6JTSZ	MT	DME
DM6JTSZ	MA	Metabolism
DM6JTSZ	RN	Preclinical pharmacokinetics of a HepDirect prodrug of a novel phosphonate-containing thyroid hormone receptor agonist. Drug Metab Dispos. 2008 Nov;36(11):2393-403.
DM6JTSZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18703645

DM6JTSZ	DI	DM6JTSZ
DM6JTSZ	DN	MB-07811
DM6JTSZ	MI	TTGER3L
DM6JTSZ	MN	Thyroid hormone receptor beta (THRB)
DM6JTSZ	MT	DTT
DM6JTSZ	MA	Modulator
DM6JTSZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 589).
DM6JTSZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=589

DMLPNVS	DI	DMLPNVS
DMLPNVS	DN	MB-102
DMLPNVS	MI	TTENHJ0
DMLPNVS	MN	Interleukin 3 receptor alpha (IL3RA)
DMLPNVS	MT	DTT
DMLPNVS	MA	CAR-T-Cell-Therapy
DMLPNVS	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMLPNVS	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM3RBJW	DI	DM3RBJW
DM3RBJW	DN	MB-11055
DM3RBJW	MI	TTLAFZV
DM3RBJW	MN	AMP-activated protein kinase (AMPK)
DM3RBJW	MT	DTT
DM3RBJW	MA	Modulator
DM3RBJW	RN	Antidiabetes and antiobesity effect of cryptotanshinone via activation of AMP-activated protein kinase.Mol Pharmacol.2007 Jul;72(1):62-72.
DM3RBJW	RU	https://www.ncbi.nlm.nih.gov/pubmed/17429005

DMRSN2C	DI	DMRSN2C
DMRSN2C	DN	MB-12066
DMRSN2C	MI	TTUF2HO
DMRSN2C	MN	NAD-dependent deacetylase sirtuin-1 (SIRT1)
DMRSN2C	MT	DTT
DMRSN2C	MA	Modulator
DMRSN2C	RN	Pharmacological activation of Sirt1 ameliorates polyglutamine-induced toxicity through the regulation of autophagy.PLoS One.2013 Jun 10;8(6):e64953.
DMRSN2C	RU	https://www.ncbi.nlm.nih.gov/pubmed/23762270

DM0AOID	DI	DM0AOID
DM0AOID	DN	MB-CART19.1
DM0AOID	MI	TTW640A
DM0AOID	MN	B-lymphocyte surface antigen B4 (CD19)
DM0AOID	MT	DTT
DM0AOID	MA	CAR-T-Cell-Therapy
DM0AOID	RN	ClinicalTrials.gov (NCT03321123) MB-CART19.1 in Patients With R/R ALL
DM0AOID	RU	https://clinicaltrials.gov/ct2/show/NCT03321123

DMJVU7Y	DI	DMJVU7Y
DMJVU7Y	DN	MBL-HCV1
DMJVU7Y	MI	TTDBG95
DMJVU7Y	MN	Hepatitis C virus Envelope glycoprotein E2 (HCV NS1)
DMJVU7Y	MT	DTT
DMJVU7Y	MA	Modulator
DMJVU7Y	RN	Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study. Am J Transplant. 2013 Apr;13(4):1047-54.
DMJVU7Y	RU	https://pubmed.ncbi.nlm.nih.gov/23356386

DMQMTO1	DI	DMQMTO1
DMQMTO1	DN	MBX-2044
DMQMTO1	MI	TTZMAO3
DMQMTO1	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMQMTO1	MT	DTT
DMQMTO1	MA	Agonist
DMQMTO1	RN	MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema. Mol Endocrinol. 2009 Jul;23(7):975-88.
DMQMTO1	RU	https://pubmed.ncbi.nlm.nih.gov/19389808

DM0W3R7	DI	DM0W3R7
DM0W3R7	DN	MCLA-128
DM0W3R7	MI	TT6EO5L
DM0W3R7	MN	Erbb2 tyrosine kinase receptor (HER2)
DM0W3R7	MT	DTT
DM0W3R7	MA	Antagonist
DM0W3R7	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM0W3R7	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM0CL4I	DI	DM0CL4I
DM0CL4I	DN	MCS-110
DM0CL4I	MI	TT731LW
DM0CL4I	MN	Colony stimulating factor-1 receptor (CSF-1R)
DM0CL4I	MT	DTT
DM0CL4I	MA	Modulator
DM0CL4I	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM0CL4I	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMX4U0B	DI	DMX4U0B
DMX4U0B	DN	MCS-18
DMX4U0B	MI	TTY7ZHS
DMX4U0B	MN	Toll-like receptor 2 (TLR2)
DMX4U0B	MT	DTT
DMX4U0B	MA	Modulator
DMX4U0B	RN	The novel arthritis-drug substance MCS-18 attenuates the antibody production in vivo. Acta Microbiol Immunol Hung. 2008 Mar;55(1):15-31.
DMX4U0B	RU	https://pubmed.ncbi.nlm.nih.gov/18507149

DMDR2SZ	DI	DMDR2SZ
DMDR2SZ	DN	MCT-125
DMDR2SZ	MI	TTAWNKZ
DMDR2SZ	MN	Norepinephrine transporter (NET)
DMDR2SZ	MT	DTT
DMDR2SZ	MA	Inhibitor
DMDR2SZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 926).
DMDR2SZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=926

DM5DSGJ	DI	DM5DSGJ
DM5DSGJ	DN	MD-0727
DM5DSGJ	MI	TTNA5ZS
DM5DSGJ	MN	Cholesterol absorption (Chole absorp)
DM5DSGJ	MT	DTT
DM5DSGJ	MA	Modulator
DM5DSGJ	RN	Th-P16:297 Early clinical characterization of MD-0727, a novel cholesterol absorption inhibitor, in healthy subjects. Atherosclerosis Supplements Volume 7, Issue 3, 2006, Pages 558-559.
DM5DSGJ	RU	http://www.sciencedirect.com/science/article/pii/S1567568806822555

DM9FXU7	DI	DM9FXU7
DM9FXU7	DN	MDL-27192
DM9FXU7	MI	TT9IK2Z
DM9FXU7	MN	N-methyl-D-aspartate receptor (NMDAR)
DM9FXU7	MT	DTT
DM9FXU7	MA	Modulator
DM9FXU7	RN	Preclinical characterization of MDL 27,192 as a potential broad spectrum anticonvulsant agent with neuroprotective properties. Epilepsy Res. 1997 Apr;27(1):41-54.
DM9FXU7	RU	https://pubmed.ncbi.nlm.nih.gov/9169290

DMCK8SX	DI	DMCK8SX
DMCK8SX	DN	MDX-1097
DMCK8SX	MI	TT1HM0R
DMCK8SX	MN	Kappa myeloma antigen (KMA)
DMCK8SX	MT	DTT
DMCK8SX	RN	MDX-1097 induces antibody-dependent cellular cytotoxicity against kappa multiple myeloma cells and its activity is augmented by lenalidomide. Br J Haematol. 2015 May;169(3):333-43.
DMCK8SX	RU	https://pubmed.ncbi.nlm.nih.gov/25653020

DM0EZWI	DI	DM0EZWI
DM0EZWI	DN	MDX-1100
DM0EZWI	MI	TTQOVYA
DM0EZWI	MN	C-X-C motif chemokine 10 (CXCL10)
DM0EZWI	MT	DTT
DM0EZWI	RN	A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2012 Jun;64(6):1730-9.
DM0EZWI	RU	https://pubmed.ncbi.nlm.nih.gov/22147649

DMKMSC4	DI	DMKMSC4
DMKMSC4	DN	MDX-1342
DMKMSC4	MI	TTW640A
DMKMSC4	MN	B-lymphocyte surface antigen B4 (CD19)
DMKMSC4	MT	DTT
DMKMSC4	RN	A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies. Cancer Immunol Immunother. 2010 Feb;59(2):257-65.
DMKMSC4	RU	https://pubmed.ncbi.nlm.nih.gov/19657637

DMO84TL	DI	DMO84TL
DMO84TL	DN	ME-3407
DMO84TL	MI	TT18ETS
DMO84TL	MN	Myosin light kinase (MYLK)
DMO84TL	MT	DTT
DMO84TL	MA	Inhibitor
DMO84TL	RN	ME-3407, a new antiulcer agent, inhibits acid secretion by interfering with redistribution of H(+)-K(+)-ATPase. Am J Physiol. 1997 May;272(5 Pt 1):G1122-34.
DMO84TL	RU	https://pubmed.ncbi.nlm.nih.gov/9176222

DMX9Y7V	DI	DMX9Y7V
DMX9Y7V	DN	MEDETOMIDINE
DMX9Y7V	MI	TTNGILX
DMX9Y7V	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMX9Y7V	MT	DTT
DMX9Y7V	MA	Inhibitor
DMX9Y7V	RN	A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
DMX9Y7V	RU	https://pubmed.ncbi.nlm.nih.gov/7914537

DMX9Y7V	DI	DMX9Y7V
DMX9Y7V	DN	MEDETOMIDINE
DMX9Y7V	MI	TTBRKXS
DMX9Y7V	MN	Adrenergic receptor alpha-1B (ADRA1B)
DMX9Y7V	MT	DTT
DMX9Y7V	MA	Inhibitor
DMX9Y7V	RN	A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
DMX9Y7V	RU	https://pubmed.ncbi.nlm.nih.gov/7914537

DMX9Y7V	DI	DMX9Y7V
DMX9Y7V	DN	MEDETOMIDINE
DMX9Y7V	MI	TT34BHT
DMX9Y7V	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMX9Y7V	MT	DTT
DMX9Y7V	MA	Inhibitor
DMX9Y7V	RN	A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
DMX9Y7V	RU	https://pubmed.ncbi.nlm.nih.gov/7914537

DMX9Y7V	DI	DMX9Y7V
DMX9Y7V	DN	MEDETOMIDINE
DMX9Y7V	MI	TTWG9A4
DMX9Y7V	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMX9Y7V	MT	DTT
DMX9Y7V	MA	Inhibitor
DMX9Y7V	RN	A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
DMX9Y7V	RU	https://pubmed.ncbi.nlm.nih.gov/7914537

DMX9Y7V	DI	DMX9Y7V
DMX9Y7V	DN	MEDETOMIDINE
DMX9Y7V	MI	TTWM4TY
DMX9Y7V	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMX9Y7V	MT	DTT
DMX9Y7V	MA	Inhibitor
DMX9Y7V	RN	A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
DMX9Y7V	RU	https://pubmed.ncbi.nlm.nih.gov/7914537

DMX9Y7V	DI	DMX9Y7V
DMX9Y7V	DN	MEDETOMIDINE
DMX9Y7V	MI	TT2NUT5
DMX9Y7V	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMX9Y7V	MT	DTT
DMX9Y7V	MA	Inhibitor
DMX9Y7V	RN	A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
DMX9Y7V	RU	https://pubmed.ncbi.nlm.nih.gov/7914537

DMSV60C	DI	DMSV60C
DMSV60C	DN	MEDI0382
DMSV60C	MI	TT0NUFM
DMSV60C	MN	Glucagon (GCG)
DMSV60C	MT	DTT
DMSV60C	MA	Agonist
DMSV60C	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMSV60C	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMOXKIC	DI	DMOXKIC
DMOXKIC	DN	MEDI3902
DMOXKIC	MI	TTLK9NJ
DMOXKIC	MN	Pseudomonas PcrV protein type III (Pseudo pcrV)
DMOXKIC	MT	DTT
DMOXKIC	RN	A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci Transl Med. 2014 Nov 12;6(262):262ra155.
DMOXKIC	RU	https://pubmed.ncbi.nlm.nih.gov/25391481

DMOXKIC	DI	DMOXKIC
DMOXKIC	DN	MEDI3902
DMOXKIC	MI	TTTPDRC
DMOXKIC	MN	Pseudomonas Psl exopolysaccharide (Pseudo pslG)
DMOXKIC	MT	DTT
DMOXKIC	RN	A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci Transl Med. 2014 Nov 12;6(262):262ra155.
DMOXKIC	RU	https://pubmed.ncbi.nlm.nih.gov/25391481

DMDYVN8	DI	DMDYVN8
DMDYVN8	DN	MEDI-528
DMDYVN8	MI	TT0JTFD
DMDYVN8	MN	Interleukin-9 (IL9)
DMDYVN8	MT	DTT
DMDYVN8	MA	Inhibitor
DMDYVN8	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DMDYVN8	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DMPKWR3	DI	DMPKWR3
DMPKWR3	DN	MEDI-546
DMPKWR3	MI	TTSYFMA
DMPKWR3	MN	Interferon alpha/beta receptor 1 (IFNAR1)
DMPKWR3	MT	DTT
DMPKWR3	MA	Modulator
DMPKWR3	RN	Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-alpha receptor 1 antibody. MAbs. 2015;7(2):428-39.
DMPKWR3	RU	https://pubmed.ncbi.nlm.nih.gov/25606664

DMBTVFE	DI	DMBTVFE
DMBTVFE	DN	MEDI-551
DMBTVFE	MI	TTW640A
DMBTVFE	MN	B-lymphocyte surface antigen B4 (CD19)
DMBTVFE	MT	DTT
DMBTVFE	RN	Clinical pipeline report, company report or official report of MedImmune (2011).
DMBTVFE	RU	http://www.medimmune.com/research_pipeline.aspx

DMI9WVM	DI	DMI9WVM
DMI9WVM	DN	MEDI-575
DMI9WVM	MI	TT8FYO9
DMI9WVM	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMI9WVM	MT	DTT
DMI9WVM	RN	Clinical pipeline report, company report or official report of MedImmune (2011).
DMI9WVM	RU	http://www.medimmune.com/research_pipeline.aspx

DMU4CS8	DI	DMU4CS8
DMU4CS8	DN	MEDI6012
DMU4CS8	MI	TTGZ91P
DMU4CS8	MN	Lecithin-cholesterol acyltransferase (LCAT)
DMU4CS8	MT	DTT
DMU4CS8	MA	Modulator
DMU4CS8	RN	Familial lecithin-cholesterol acyltransferase (LCAT) deficiency; a differential of proteinuria. J Nephropathol. 2015 January; 4(1): 25-28.
DMU4CS8	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4316582/

DMGD1YP	DI	DMGD1YP
DMGD1YP	DN	MEDI9929
DMGD1YP	MI	TTHMW3T
DMGD1YP	MN	Thymic stromal lymphopoietin (TSLP)
DMGD1YP	MT	DTT
DMGD1YP	MA	Modulator
DMGD1YP	RN	Human immunoglobulin G2Lambda monoclonal antibody directed against thymic stromal lymphopoietin (MEDI9929). European medicines agency science medicines health (EMEA-001613-PIP01-14). European Union. 2015.
DMGD1YP	RU	http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/pips/EMEA-001613-PIP01-14/pip_001268.jsp&mid=WC0b01ac058001d129

DM2C1YN	DI	DM2C1YN
DM2C1YN	DN	MEGF0444A
DM2C1YN	MI	TT7WD0H
DM2C1YN	MN	Epidermal growth factor-like protein 7 (EGFL7)
DM2C1YN	MT	DTT
DM2C1YN	MA	Modulator
DM2C1YN	RN	A first-in-human phase Ia open-label dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) administered intravenously in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts) May 2011 vol.29 no.15_suppl 2614.
DM2C1YN	RU	http://meeting.ascopubs.org/cgi/content/abstract/29/15_suppl/2614

DMHOF7T	DI	DMHOF7T
DMHOF7T	DN	MEHD-7945A
DMHOF7T	MI	TTGKNB4
DMHOF7T	MN	Epidermal growth factor receptor (EGFR)
DMHOF7T	MT	DTT
DMHOF7T	MA	Modulator
DMHOF7T	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMHOF7T	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMHOF7T	DI	DMHOF7T
DMHOF7T	DN	MEHD-7945A
DMHOF7T	MI	TTDC8N2
DMHOF7T	MN	Erbb3 tyrosine kinase receptor (Erbb-3)
DMHOF7T	MT	DTT
DMHOF7T	MA	Modulator
DMHOF7T	RN	Company report (Biooncology)
DMHOF7T	RU	http://www.biooncology.com/pipeline-molecules/anti-her3

DMVJ6WS	DI	DMVJ6WS
DMVJ6WS	DN	Melogliptin
DMVJ6WS	MI	TTDIGC1
DMVJ6WS	MN	Dipeptidyl peptidase 4 (DPP-4)
DMVJ6WS	MT	DTT
DMVJ6WS	MA	Inhibitor
DMVJ6WS	RN	Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87.
DMVJ6WS	RU	https://pubmed.ncbi.nlm.nih.gov/19149538

DMPNDYU	DI	DMPNDYU
DMPNDYU	DN	MEM-3454
DMPNDYU	MI	TTLA931
DMPNDYU	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMPNDYU	MT	DTT
DMPNDYU	MA	Antagonist
DMPNDYU	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMPNDYU	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMUMCWS	DI	DMUMCWS
DMUMCWS	DN	MEMP1972A
DMUMCWS	MI	TTYJQTF
DMUMCWS	MN	Immunoglobulin E (IgE)
DMUMCWS	MT	DTT
DMUMCWS	RN	International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 25, No. 4, 2011
DMUMCWS	RU	http://www.who.int/medicines/publications/druginformation/innlists/Final_PL106.pdf

DMIVR9K	DI	DMIVR9K
DMIVR9K	DN	MER-3001
DMIVR9K	MI	TTZOPHG
DMIVR9K	MN	Insulin (INS)
DMIVR9K	MT	DTT
DMIVR9K	MA	Modulator
DMIVR9K	RN	Clinical pipeline report, company report or official report of Mercia Pharma Inc.
DMIVR9K	RU	http://merciapharma.com/?page_id=81

DM89QXT	DI	DM89QXT
DM89QXT	DN	MET409
DM89QXT	MI	TTS4UGC
DM89QXT	MN	Farnesoid X-activated receptor (FXR)
DM89QXT	MT	DTT
DM89QXT	MA	Agonist
DM89QXT	RN	Clinical pipeline report, company report or official report of Metacrine.
DM89QXT	RU	https://www.metacrine.com/programs/

DMNST69	DI	DMNST69
DMNST69	DN	Metaiodobenzylguanidine I-131
DMNST69	MI	TTAWNKZ
DMNST69	MN	Norepinephrine transporter (NET)
DMNST69	MT	DTT
DMNST69	MA	Modulator
DMNST69	RN	Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG. Clin Cancer Res. 2014 Apr 15;20(8):2182-91.
DMNST69	RU	https://pubmed.ncbi.nlm.nih.gov/24573553

DMSZFTP	DI	DMSZFTP
DMSZFTP	DN	Met-enkephalin
DMSZFTP	MI	TT27RFC
DMSZFTP	MN	Opioid receptor delta (OPRD1)
DMSZFTP	MT	DTT
DMSZFTP	MA	Agonist
DMSZFTP	RN	Delta-opioid receptor agonists inhibit neuromuscular transmission in human colon. Eur J Pharmacol. 1994 Sep 1;262(1-2):33-9.
DMSZFTP	RU	https://pubmed.ncbi.nlm.nih.gov/7813576

DMSZFTP	DI	DMSZFTP
DMSZFTP	DN	Met-enkephalin
DMSZFTP	MI	TTKWM86
DMSZFTP	MN	Opioid receptor mu (MOP)
DMSZFTP	MT	DTT
DMSZFTP	MA	Inhibitor
DMSZFTP	RN	Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60.
DMSZFTP	RU	https://pubmed.ncbi.nlm.nih.gov/17350835

DMS7FRI	DI	DMS7FRI
DMS7FRI	DN	Methanesulfonyl fluoride
DMS7FRI	MI	TT1RS9F
DMS7FRI	MN	Acetylcholinesterase (AChE)
DMS7FRI	MT	DTT
DMS7FRI	MA	Inhibitor
DMS7FRI	RN	A randomized phase I study of methanesulfonyl fluoride, an irreversible cholinesterase inhibitor, for the treatment of Alzheimer's disease. Br J Clin Pharmacol. 2013 May;75(5):1231-9.
DMS7FRI	RU	https://pubmed.ncbi.nlm.nih.gov/23116458

DMHSL87	DI	DMHSL87
DMHSL87	DN	Methoxyestradiol
DMHSL87	MI	TT6RVLG
DMHSL87	MN	Superoxide dismutase Cu-Zn (SOD Cu-Zn)
DMHSL87	MT	DTT
DMHSL87	MA	Inhibitor
DMHSL87	RN	Antitumor effects of photodynamic therapy are potentiated by 2-methoxyestradiol. A superoxide dismutase inhibitor. J Biol Chem. 2003 Jan 3;278(1):407-14.
DMHSL87	RU	https://pubmed.ncbi.nlm.nih.gov/12409296

DM5GQD7	DI	DM5GQD7
DM5GQD7	DN	Metoprine
DM5GQD7	MI	TT2B6EV
DM5GQD7	MN	Histamine N-methyltransferase (HNMT)
DM5GQD7	MT	DTT
DM5GQD7	MA	Inhibitor
DM5GQD7	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM5GQD7	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM5GQD7	DI	DM5GQD7
DM5GQD7	DN	Metoprine
DM5GQD7	MI	TT9SL3Q
DM5GQD7	MN	Polypeptide deformylase (PDF)
DM5GQD7	MT	DTT
DM5GQD7	MA	Inhibitor
DM5GQD7	RN	Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34.
DM5GQD7	RU	https://pubmed.ncbi.nlm.nih.gov/16612649

DMIXT2Y	DI	DMIXT2Y
DMIXT2Y	DN	MGAH22
DMIXT2Y	MI	TT6EO5L
DMIXT2Y	MN	Erbb2 tyrosine kinase receptor (HER2)
DMIXT2Y	MT	DTT
DMIXT2Y	MA	Modulator
DMIXT2Y	RN	Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcgamma receptor binding properties. Breast Cancer Res. 2011; 13(6): R123.
DMIXT2Y	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3326565/

DMPBTVK	DI	DMPBTVK
DMPBTVK	DN	MGB-BP-3
DMPBTVK	MI	TTS1W4A
DMPBTVK	MN	Bacterial Deoxyribonucleic acid (Bact DNA)
DMPBTVK	MT	DTT
DMPBTVK	MA	Binder
DMPBTVK	RN	Clinical pipeline report, company report or official report of MGB Biopharma.
DMPBTVK	RU	https://www.mgb-biopharma.com/wp-content/uploads/SMi-MGB-Biopharma-Presentation.pdf

DM726HX	DI	DM726HX
DM726HX	DN	MGCD-0103
DM726HX	MI	TTBH0VX
DM726HX	MN	Histone deacetylase (HDAC)
DM726HX	MT	DTT
DM726HX	MA	Inhibitor
DM726HX	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM726HX	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM726HX	DI	DM726HX
DM726HX	DN	MGCD-0103
DM726HX	MI	TT6R7JZ
DM726HX	MN	Histone deacetylase 1 (HDAC1)
DM726HX	MT	DTT
DM726HX	MA	Inhibitor
DM726HX	RN	Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32.
DM726HX	RU	https://pubmed.ncbi.nlm.nih.gov/19721445

DMRPCF2	DI	DMRPCF2
DMRPCF2	DN	MGCD265
DMRPCF2	MI	TTU8W4S
DMRPCF2	MN	Protein kinase (PK)
DMRPCF2	MT	DTT
DMRPCF2	MA	Inhibitor
DMRPCF2	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMRPCF2	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMRPCF2	DI	DMRPCF2
DMRPCF2	DN	MGCD265
DMRPCF2	MI	TTZPY6J
DMRPCF2	MN	Tyrosine-protein kinase UFO (AXL)
DMRPCF2	MT	DTT
DMRPCF2	MA	Modulator
DMRPCF2	RN	Company report (Mirati Therapeutics: formerly MethylGene)
DMRPCF2	RU	http://www.mirati.com/programs/mgcd265/

DMRSK2I	DI	DMRSK2I
DMRSK2I	DN	MGCD290
DMRSK2I	MI	TTVO9RI
DMRSK2I	MN	Fungal Probable histone deacetylase HOS2 (Fung HOS2)
DMRSK2I	MT	DTT
DMRSK2I	MA	Inhibitor
DMRSK2I	RN	Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens. J Clin Microbiol. 2009 Dec;47(12):3797-804.
DMRSK2I	RU	https://pubmed.ncbi.nlm.nih.gov/19794038

DMNYPW7	DI	DMNYPW7
DMNYPW7	DN	MGI-114
DMNYPW7	MI	DE4Q2OE
DMNYPW7	MN	Prostaglandin reductase 1 (PTGR1)
DMNYPW7	MT	DME
DMNYPW7	MA	Metabolism
DMNYPW7	RN	Up-regulation of human prostaglandin reductase 1 improves the efficacy of hydroxymethylacylfulvene, an antitumor chemotherapeutic agent. J Pharmacol Exp Ther. 2012 Nov;343(2):426-33.
DMNYPW7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22895897

DM1HC9R	DI	DM1HC9R
DM1HC9R	DN	MGL-3196
DM1HC9R	MI	TTGER3L
DM1HC9R	MN	Thyroid hormone receptor beta (THRB)
DM1HC9R	MT	DTT
DM1HC9R	MA	Agonist
DM1HC9R	RN	Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-beta agonist. Atherosclerosis. 2013 Oct;230(2):373-80.
DM1HC9R	RU	https://pubmed.ncbi.nlm.nih.gov/24075770

DME5CSV	DI	DME5CSV
DME5CSV	DN	Mibampator
DME5CSV	MI	TTAN6JD
DME5CSV	MN	Glutamate receptor AMPA (GRIA)
DME5CSV	MT	DTT
DME5CSV	MA	Agonist
DME5CSV	RN	Mibampator (LY451395) Randomized Clinical Trial for Agitation/Aggression in Alzheimer's disease. Int Psychogeriatr. 2013 May; 25(5): 707-719.
DME5CSV	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3938603/

DMGCRKY	DI	DMGCRKY
DMGCRKY	DN	Midismase
DMGCRKY	MI	TT6RVLG
DMGCRKY	MN	Superoxide dismutase Cu-Zn (SOD Cu-Zn)
DMGCRKY	MT	DTT
DMGCRKY	MA	Modulator
DMGCRKY	RN	A lecithinized superoxide dismutase (PC-SOD) improves ulcerative colitis
DMGCRKY	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2659364

DMN45RI	DI	DMN45RI
DMN45RI	DN	MIJ821
DMN45RI	MI	TTN9D8E
DMN45RI	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMN45RI	MT	DTT
DMN45RI	MA	Modulator
DMN45RI	RN	Clinical pipeline report, company report or official report of Cadent Therapeutics.
DMN45RI	RU	https://www.cipherbio.com/data-viz/organization/Cadent%2BTherapeutics/products

DM50Z4U	DI	DM50Z4U
DM50Z4U	DN	Milataxel
DM50Z4U	MI	TTML2WA
DM50Z4U	MN	Tubulin (TUB)
DM50Z4U	MT	DTT
DM50Z4U	MA	Inhibitor
DM50Z4U	RN	J Clin Oncol 28, 2010 (suppl; abstr e13075).
DM50Z4U	RU	http://meetinglibrary.asco.org/content/54296-74

DMSLIW6	DI	DMSLIW6
DMSLIW6	DN	MIN-117
DMSLIW6	MI	TTSQIFT
DMSLIW6	MN	5-HT 1A receptor (HTR1A)
DMSLIW6	MT	DTT
DMSLIW6	MA	Antagonist
DMSLIW6	RN	Company report (Minerva Neurosciences),MIN-101,Schizophrenia, 6 trials completed; Once a day formulation completed , Phase IIa completed; Phase IIb enrollment ongoing and expected to continue over the last 3 quarters of 2015.
DMSLIW6	RU	http://minervaneurosciences.com/

DMSLIW6	DI	DMSLIW6
DMSLIW6	DN	MIN-117
DMSLIW6	MI	TT85JO3
DMSLIW6	MN	5-HT receptor (5HTR)
DMSLIW6	MT	DTT
DMSLIW6	MA	Antagonist
DMSLIW6	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMSLIW6	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMSLIW6	DI	DMSLIW6
DMSLIW6	DN	MIN-117
DMSLIW6	MI	TTVBI8W
DMSLIW6	MN	Dopamine transporter (DAT)
DMSLIW6	MT	DTT
DMSLIW6	MA	Inhibitor
DMSLIW6	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMSLIW6	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMSLIW6	DI	DMSLIW6
DMSLIW6	DN	MIN-117
DMSLIW6	MI	TT3ROYC
DMSLIW6	MN	Serotonin transporter (SERT)
DMSLIW6	MT	DTT
DMSLIW6	MA	Inhibitor
DMSLIW6	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMSLIW6	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMZFW8V	DI	DMZFW8V
DMZFW8V	DN	MIN-202
DMZFW8V	MI	TT9N02I
DMZFW8V	MN	Orexin receptor type 2 (HCRTR2)
DMZFW8V	MT	DTT
DMZFW8V	MA	Antagonist
DMZFW8V	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZFW8V	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMWJMFZ	DI	DMWJMFZ
DMWJMFZ	DN	Miravirsen
DMWJMFZ	MI	TTP03CE
DMWJMFZ	MN	Hepatitis C virus microRNA miR-122 (HCV MIR122)
DMWJMFZ	MT	DTT
DMWJMFZ	MA	Modulator
DMWJMFZ	RN	Miravirsen (SPC3649) can inhibit the biogenesis of miR-122.Nucleic Acids Res.2014 Jan;42(1):609-21.
DMWJMFZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/24068553

DM7K4YR	DI	DM7K4YR
DM7K4YR	DN	MIS-416
DM7K4YR	MI	TTYPUHA
DM7K4YR	MN	Pattern recognition receptor NOD2 (NOD2)
DM7K4YR	MT	DTT
DM7K4YR	MA	Modulator
DM7K4YR	RN	DOI: 10.1371/journal.pone.0087712
DM7K4YR	RU	http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0087712

DM7K4YR	DI	DM7K4YR
DM7K4YR	DN	MIS-416
DM7K4YR	MI	TTSHG0T
DM7K4YR	MN	Toll-like receptor 9 (TLR9)
DM7K4YR	MT	DTT
DM7K4YR	MA	Modulator
DM7K4YR	RN	DOI: 10.1371/journal.pone.0087712
DM7K4YR	RU	http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0087712

DMOJ7QA	DI	DMOJ7QA
DMOJ7QA	DN	Mitemcinal fumarate
DMOJ7QA	MI	TT953CX
DMOJ7QA	MN	Motilin receptor (MLNR)
DMOJ7QA	MT	DTT
DMOJ7QA	MA	Agonist
DMOJ7QA	RN	Clinical pipeline report, company report or official report of Roche (2009).
DMOJ7QA	RU	http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm

DMIRPSA	DI	DMIRPSA
DMIRPSA	DN	Mitoglitazone
DMIRPSA	MI	TTCBFJO
DMIRPSA	MN	Insulin receptor (INSR)
DMIRPSA	MT	DTT
DMIRPSA	MA	Modulator
DMIRPSA	RN	An evaluation of MSDC-0160, a prototype mTOT modulating insulin sensitizer, in patients with mild Alzheimer's disease. Curr Alzheimer Res. 2014;11(6):564-73.
DMIRPSA	RU	https://pubmed.ncbi.nlm.nih.gov/24931567

DMIRPSA	DI	DMIRPSA
DMIRPSA	DN	Mitoglitazone
DMIRPSA	MI	TTSJH2W
DMIRPSA	MN	Mitochondrial protein unspecific (MP)
DMIRPSA	MT	DTT
DMIRPSA	MA	Modulator
DMIRPSA	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMIRPSA	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMKPZ0Q	DI	DMKPZ0Q
DMKPZ0Q	DN	Mitoquinone
DMKPZ0Q	MI	TTULV0X
DMKPZ0Q	MN	Reactive oxygen species (ROS)
DMKPZ0Q	MT	DTT
DMKPZ0Q	MA	Inhibitor
DMKPZ0Q	RN	Mitoquinone (MitoQ) Inhibits Platelet Activation Steps by Reducing ROS Levels. Int J Mol Sci. 2020 Aug 27;21(17):6192.
DMKPZ0Q	RU	https://pubmed.ncbi.nlm.nih.gov/32867213

DM2NF6X	DI	DM2NF6X
DM2NF6X	DN	MIV-210
DM2NF6X	MI	TTS5K1M
DM2NF6X	MN	Hepatitis B virus Reverse transcriptase (HBV RT)
DM2NF6X	MT	DTT
DM2NF6X	MA	Modulator
DM2NF6X	RN	Emerging antivirals for the treatment of hepatitis B
DM2NF6X	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4069299

DMWFTRJ	DI	DMWFTRJ
DMWFTRJ	DN	MK-0354
DMWFTRJ	MI	TTWNV8U
DMWFTRJ	MN	Nicotinic acid receptor (HCAR2)
DMWFTRJ	MT	DTT
DMWFTRJ	MA	Inhibitor
DMWFTRJ	RN	GPR109a agonists. Part 2: pyrazole-acids as agonists of the human orphan G-protein coupled receptor GPR109a. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4472-4.
DMWFTRJ	RU	https://pubmed.ncbi.nlm.nih.gov/20615702

DMLTAES	DI	DMLTAES
DMLTAES	DN	MK-0752
DMLTAES	MI	TT9W8GU
DMLTAES	MN	Gamma-secretase (GS)
DMLTAES	MT	DTT
DMLTAES	MA	Modulator
DMLTAES	RN	Determination of the gamma-secretase inhibitor MK-0752 in human plasma by online extraction and electrospray tandem mass spectrometry (HTLC-ESI-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Sep 1;878(25):2348-52.
DMLTAES	RU	https://pubmed.ncbi.nlm.nih.gov/20702149

DM2CJB4	DI	DM2CJB4
DM2CJB4	DN	MK-0773
DM2CJB4	MI	TTS64P2
DM2CJB4	MN	Androgen receptor (AR)
DM2CJB4	MT	DTT
DM2CJB4	MA	Modulator
DM2CJB4	RN	Discovery of the selective androgen receptor modulator MK-0773 using a rational development strategy based on differential transcriptional requirements for androgenic anabolism versus reproductive physiology. J Biol Chem. 2010 May 28;285(22):17054-64.
DM2CJB4	RU	https://pubmed.ncbi.nlm.nih.gov/20356837

DMRT8K4	DI	DMRT8K4
DMRT8K4	DN	MK-0812
DMRT8K4	MI	TTFZYTO
DMRT8K4	MN	C-C chemokine receptor type 2 (CCR2)
DMRT8K4	MT	DTT
DMRT8K4	MA	Antagonist
DMRT8K4	RN	Assessment of chemokine receptor function on monocytes in whole blood: In vitro and ex vivo evaluations of a CCR2 antagonist. J Immunol Methods. 2010 Jan 31;352(1-2):101-10.
DMRT8K4	RU	https://pubmed.ncbi.nlm.nih.gov/19913021

DM0568C	DI	DM0568C
DM0568C	DN	MK-0873
DM0568C	MI	TTZ97H5
DM0568C	MN	Phosphodiesterase 4A (PDE4A)
DM0568C	MT	DTT
DM0568C	MA	Inhibitor
DM0568C	RN	MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers. Pulm Pharmacol Ther. 2008;21(3):573-7.
DM0568C	RU	https://pubmed.ncbi.nlm.nih.gov/18321743

DM0568C	DI	DM0568C
DM0568C	DN	MK-0873
DM0568C	MI	TTVIAT9
DM0568C	MN	Phosphodiesterase 4B (PDE4B)
DM0568C	MT	DTT
DM0568C	MA	Inhibitor
DM0568C	RN	MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers. Pulm Pharmacol Ther. 2008;21(3):573-7.
DM0568C	RU	https://pubmed.ncbi.nlm.nih.gov/18321743

DM0568C	DI	DM0568C
DM0568C	DN	MK-0873
DM0568C	MI	TTSKMI8
DM0568C	MN	Phosphodiesterase 4D (PDE4D)
DM0568C	MT	DTT
DM0568C	MA	Inhibitor
DM0568C	RN	MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers. Pulm Pharmacol Ther. 2008;21(3):573-7.
DM0568C	RU	https://pubmed.ncbi.nlm.nih.gov/18321743

DM8ZTW7	DI	DM8ZTW7
DM8ZTW7	DN	MK-1029
DM8ZTW7	MI	TTNVEIR
DM8ZTW7	MN	Prostaglandin D2 receptor (PTGDR)
DM8ZTW7	MT	DTT
DM8ZTW7	MA	Inhibitor
DM8ZTW7	RN	Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugs. Expert Opin Investig Drugs. 2014 Jan;23(1):55-66.
DM8ZTW7	RU	https://pubmed.ncbi.nlm.nih.gov/24073896

DMEDITW	DI	DMEDITW
DMEDITW	DN	MK-1454
DMEDITW	MI	TTT402Y
DMEDITW	MN	Stimulator of interferon genes protein (TMEM173)
DMEDITW	MT	DTT
DMEDITW	MA	Agonist
DMEDITW	RN	National Cancer Institute Drug Dictionary (drug name MK1454).
DMEDITW	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/sting-agonist-mk-1454

DM3WDZ5	DI	DM3WDZ5
DM3WDZ5	DN	MK-1775
DM3WDZ5	MI	TTJFOAL
DM3WDZ5	MN	Wee1-like protein kinase (WEE1)
DM3WDZ5	MT	DTT
DM3WDZ5	MA	Inhibitor
DM3WDZ5	RN	A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
DM3WDZ5	RU	https://pubmed.ncbi.nlm.nih.gov/23467907

DMVJB09	DI	DMVJB09
DMVJB09	DN	MK-1903
DMVJB09	MI	TTWNV8U
DMVJB09	MN	Nicotinic acid receptor (HCAR2)
DMVJB09	MT	DTT
DMVJB09	MA	Agonist
DMVJB09	RN	Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression. Sci Transl Med. 2012 Aug 22;4(148):148ra115.
DMVJB09	RU	https://pubmed.ncbi.nlm.nih.gov/22914621

DMT1OZ6	DI	DMT1OZ6
DMT1OZ6	DN	MK-2206
DMT1OZ6	MI	TT0A1R8
DMT1OZ6	MN	E2 ubiquitin-conjugating enzyme T (UBE2T)
DMT1OZ6	MT	DTT
DMT1OZ6	MA	Inhibitor
DMT1OZ6	RN	UBE2T promotes nasopharyngeal carcinoma cell proliferation, invasion, and metastasis by activating the AKT/GSK3/-catenin pathway.Oncotarget. 2016 Mar 22;7(12):15161-72. 
DMT1OZ6	RU	https://pubmed.ncbi.nlm.nih.gov/26943030

DMT1OZ6	DI	DMT1OZ6
DMT1OZ6	DN	MK-2206
DMT1OZ6	MI	TTAZ05C
DMT1OZ6	MN	RAC-gamma serine/threonine-protein kinase (AKT3)
DMT1OZ6	MT	DTT
DMT1OZ6	MA	Modulator
DMT1OZ6	RN	First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.J Clin Oncol.2011 Dec 10;29(35):4688-95.
DMT1OZ6	RU	https://www.ncbi.nlm.nih.gov/pubmed/22025163

DM1M57I	DI	DM1M57I
DM1M57I	DN	MK-2578
DM1M57I	MI	TTQG4NR
DM1M57I	MN	Erythropoietin (EPO)
DM1M57I	MT	DTT
DM1M57I	MA	Agonist
DM1M57I	RN	Merck ditches biogeneric. Nat Biotechnol. 2010 Jul;28(7):636.
DM1M57I	RU	https://pubmed.ncbi.nlm.nih.gov/20622817

DM6OLGC	DI	DM6OLGC
DM6OLGC	DN	MK-3207
DM6OLGC	MI	TTY6O0Q
DM6OLGC	MN	Calcitonin gene-related peptide receptor (CGRPR)
DM6OLGC	MT	DTT
DM6OLGC	MA	Antagonist
DM6OLGC	RN	Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist. J Pharmacol Exp Ther. 2010 Apr;333(1):152-60.
DM6OLGC	RU	https://pubmed.ncbi.nlm.nih.gov/20065019

DM347TQ	DI	DM347TQ
DM347TQ	DN	MK-3697
DM347TQ	MI	TT9N02I
DM347TQ	MN	Orexin receptor type 2 (HCRTR2)
DM347TQ	MT	DTT
DM347TQ	MA	Modulator
DM347TQ	RN	Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. Bioorg Med Chem Lett. 2014 Oct 15;24(20):4884-90.
DM347TQ	RU	https://pubmed.ncbi.nlm.nih.gov/25248679

DMSPWX6	DI	DMSPWX6
DMSPWX6	DN	MK-5172
DMSPWX6	MI	TT5FNQT
DMSPWX6	MN	Human immunodeficiency virus Protease (HIV PR)
DMSPWX6	MT	DTT
DMSPWX6	MA	Inhibitor
DMSPWX6	RN	Clinical pipeline report, company report or official report of Merck (2011).
DMSPWX6	RU	http://www.merck.com/index.html

DMHTIGU	DI	DMHTIGU
DMHTIGU	DN	MK-5442
DMHTIGU	MI	TTBUYHA
DMHTIGU	MN	Extracellular calcium-sensing receptor (CASR)
DMHTIGU	MT	DTT
DMHTIGU	MA	Modulator
DMHTIGU	RN	Antagonist for calcium-sensing receptor. JTT-305/MK-5442. Clin Calcium. 2011 Jan;21(1):89-93.
DMHTIGU	RU	https://pubmed.ncbi.nlm.nih.gov/21187599

DMLMV0O	DI	DMLMV0O
DMLMV0O	DN	MK-7655
DMLMV0O	MI	TTHI19T
DMLMV0O	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMLMV0O	MT	DTT
DMLMV0O	MA	Inhibitor
DMLMV0O	RN	Discovery of MK-7655, a beta-lactamase inhibitor for combination with Primaxin . Bioorg Med Chem Lett. 2014 Feb 1;24(3):780-5.
DMLMV0O	RU	https://pubmed.ncbi.nlm.nih.gov/24433862

DMG6KXB	DI	DMG6KXB
DMG6KXB	DN	MK-8245
DMG6KXB	MI	TT6RIOV
DMG6KXB	MN	Acyl-CoA desaturase (SCD)
DMG6KXB	MT	DTT
DMG6KXB	MA	Inhibitor
DMG6KXB	RN	Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. J Med Chem. 2011 Jul 28;54(14):5082-96.
DMG6KXB	RU	https://pubmed.ncbi.nlm.nih.gov/21661758

DMD6E5W	DI	DMD6E5W
DMD6E5W	DN	MK-8342
DMD6E5W	MI	TTUV8G9
DMD6E5W	MN	Progesterone receptor (PGR)
DMD6E5W	MT	DTT
DMD6E5W	MA	Agonist
DMD6E5W	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 627).
DMD6E5W	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=627

DMVNAYE	DI	DMVNAYE
DMVNAYE	DN	MK-8521
DMVNAYE	MI	TT0NUFM
DMVNAYE	MN	Glucagon (GCG)
DMVNAYE	MT	DTT
DMVNAYE	MA	Co-agonist
DMVNAYE	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMVNAYE	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMVNAYE	DI	DMVNAYE
DMVNAYE	DN	MK-8521
DMVNAYE	MI	TT9O6WS
DMVNAYE	MN	Glucagon receptor (GCGR)
DMVNAYE	MT	DTT
DMVNAYE	MA	Co-agonist
DMVNAYE	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMVNAYE	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMQHS6B	DI	DMQHS6B
DMQHS6B	DN	MK-866
DMQHS6B	MI	TT2J34L
DMQHS6B	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMQHS6B	MT	DTT
DMQHS6B	MA	Modulator
DMQHS6B	RN	Inhibition of leukotriene synthesis with MK-886 prevents a rise in blood pressure and reduces noradrenaline-evoked contraction in L-NAME-treated rats
DMQHS6B	RU	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1574003

DMXKOW6	DI	DMXKOW6
DMXKOW6	DN	MKC-1106-MT
DMXKOW6	MI	TT362RB
DMXKOW6	MN	MART-1 melanoma antigen (MLANA)
DMXKOW6	MT	DTT
DMXKOW6	MA	Modulator
DMXKOW6	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMXKOW6	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMXKOW6	DI	DMXKOW6
DMXKOW6	DN	MKC-1106-MT
DMXKOW6	MI	TTULVH8
DMXKOW6	MN	Tyrosinase (TYR)
DMXKOW6	MT	DTT
DMXKOW6	MA	Modulator
DMXKOW6	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMXKOW6	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM3I71U	DI	DM3I71U
DM3I71U	DN	MKT-077
DM3I71U	MI	TTMTPG3
DM3I71U	MN	Mortalin (HSPA9)
DM3I71U	MT	DTT
DM3I71U	MA	Modulator
DM3I71U	RN	Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation of p53 function. Cancer Res. 2000 Dec 15;60(24):6818-21.
DM3I71U	RU	https://pubmed.ncbi.nlm.nih.gov/11156371

DMQSO4L	DI	DMQSO4L
DMQSO4L	DN	ML-04
DMQSO4L	MI	TT2O4W9
DMQSO4L	MN	Luteinizing hormone receptor (LHCGR)
DMQSO4L	MT	DTT
DMQSO4L	MA	Modulator
DMQSO4L	RN	Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors. Nucl Med Biol. 2007 Jan;34(1):55-70.
DMQSO4L	RU	https://pubmed.ncbi.nlm.nih.gov/17210462

DMI4E9K	DI	DMI4E9K
DMI4E9K	DN	MLN0264
DMI4E9K	MI	TTLDPRG
DMI4E9K	MN	Guanylyl cyclase C (GUCY2C)
DMI4E9K	MT	DTT
DMI4E9K	MA	Modulator
DMI4E9K	RN	J Clin Oncol 31, 2013 (suppl; abstr TPS3646).
DMI4E9K	RU	http://meetinglibrary.asco.org/content/111779-132

DM24SOL	DI	DM24SOL
DM24SOL	DN	MLN1202
DM24SOL	MI	TTFZYTO
DM24SOL	MN	C-C chemokine receptor type 2 (CCR2)
DM24SOL	MT	DTT
DM24SOL	MA	Antagonist
DM24SOL	RN	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
DM24SOL	RU	https://pubmed.ncbi.nlm.nih.gov/16634702

DM24SOL	DI	DM24SOL
DM24SOL	DN	MLN1202
DM24SOL	MI	TTUPB12
DM24SOL	MN	Measles virus Fusion glycoprotein (MeV F)
DM24SOL	MT	DTT
DM24SOL	MA	Inhibitor
DM24SOL	RN	Emerging drugs for respiratory syncytial virus infection. Expert Opin Emerg Drugs. 2009 Jun;14(2):207-17.
DM24SOL	RU	https://pubmed.ncbi.nlm.nih.gov/19453286

DMBR8NF	DI	DMBR8NF
DMBR8NF	DN	MLN2480
DMBR8NF	MI	TT0EOB8
DMBR8NF	MN	B-Raf messenger RNA (BRAF mRNA)
DMBR8NF	MT	DTT
DMBR8NF	MA	Inhibitor
DMBR8NF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1943).
DMBR8NF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1943

DMBR8NF	DI	DMBR8NF
DMBR8NF	DN	MLN2480
DMBR8NF	MI	TTAN5W2
DMBR8NF	MN	Raf messenger RNA (Raf mRNA)
DMBR8NF	MT	DTT
DMBR8NF	MA	Inhibitor
DMBR8NF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2184).
DMBR8NF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2184

DMBR8NF	DI	DMBR8NF
DMBR8NF	DN	MLN2480
DMBR8NF	MI	TTQ9K3Y
DMBR8NF	MN	Serine/threonine-protein kinase Raf (RAF)
DMBR8NF	MT	DTT
DMBR8NF	MA	Inhibitor
DMBR8NF	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMBR8NF	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMJHVZC	DI	DMJHVZC
DMJHVZC	DN	MLN-591RL
DMJHVZC	MI	TT9G4N0
DMJHVZC	MN	Glutamate carboxypeptidase II (GCPII)
DMJHVZC	MT	DTT
DMJHVZC	RN	Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors. EJNMMI Res. 2015 Apr 29;5:28.
DMJHVZC	RU	https://pubmed.ncbi.nlm.nih.gov/25984435

DMXJWNS	DI	DMXJWNS
DMXJWNS	DN	MM-093
DMXJWNS	MI	TTCFEA1
DMXJWNS	MN	Alpha-fetoprotein (AFP)
DMXJWNS	MT	DTT
DMXJWNS	MA	Modulator
DMXJWNS	RN	MM-093, a recombinant human alpha-fetoprotein for the potential treatment of rheumatoid arthritis and other autoimmune diseases. Curr Opin Mol Ther. 2007 Dec;9(6):603-10.
DMXJWNS	RU	https://pubmed.ncbi.nlm.nih.gov/18041671

DMO7MBS	DI	DMO7MBS
DMO7MBS	DN	MM-111
DMO7MBS	MI	TT6EO5L
DMO7MBS	MN	Erbb2 tyrosine kinase receptor (HER2)
DMO7MBS	MT	DTT
DMO7MBS	MA	Modulator
DMO7MBS	RN	Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. 
DMO7MBS	RU	https://www.ncbi.nlm.nih.gov/pubmed/25359367

DMDJRU1	DI	DMDJRU1
DMDJRU1	DN	MM-121
DMDJRU1	MI	TTDC8N2
DMDJRU1	MN	Erbb3 tyrosine kinase receptor (Erbb-3)
DMDJRU1	MT	DTT
DMDJRU1	MA	Modulator
DMDJRU1	RN	Company report (Merrimack)
DMDJRU1	RU	http://investors.merrimack.com/releasedetail.cfm?releaseid=897168

DM2RJ4D	DI	DM2RJ4D
DM2RJ4D	DN	MM-141
DM2RJ4D	MI	TTDC8N2
DM2RJ4D	MN	Erbb3 tyrosine kinase receptor (Erbb-3)
DM2RJ4D	MT	DTT
DM2RJ4D	MA	Modulator
DM2RJ4D	RN	MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther. 2014 Feb;13(2):410-25.
DM2RJ4D	RU	https://pubmed.ncbi.nlm.nih.gov/24282274

DM2RJ4D	DI	DM2RJ4D
DM2RJ4D	DN	MM-141
DM2RJ4D	MI	TTHRID2
DM2RJ4D	MN	Insulin-like growth factor I receptor (IGF1R)
DM2RJ4D	MT	DTT
DM2RJ4D	MA	Modulator
DM2RJ4D	RN	MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther. 2014 Feb;13(2):410-25.
DM2RJ4D	RU	https://pubmed.ncbi.nlm.nih.gov/24282274

DM2RJ4D	DI	DM2RJ4D
DM2RJ4D	DN	MM-141
DM2RJ4D	MI	TTCJG29
DM2RJ4D	MN	Serine/threonine-protein kinase mTOR (mTOR)
DM2RJ4D	MT	DTT
DM2RJ4D	MA	Inhibitor
DM2RJ4D	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM2RJ4D	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM6VPIO	DI	DM6VPIO
DM6VPIO	DN	MM36
DM6VPIO	MI	TT0JLSD
DM6VPIO	MN	Multidrug resistance protein (MDR)
DM6VPIO	MT	DTT
DM6VPIO	MA	Inhibitor
DM6VPIO	RN	Thiazolides: a new class of antiviral drugs. Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):667-74.
DM6VPIO	RU	https://pubmed.ncbi.nlm.nih.gov/19442032

DMBX2RE	DI	DMBX2RE
DMBX2RE	DN	MN-221
DMBX2RE	MI	TT2CJVK
DMBX2RE	MN	Adrenergic receptor beta-2 (ADRB2)
DMBX2RE	MT	DTT
DMBX2RE	MA	Agonist
DMBX2RE	RN	Investigation of beta(2)-adrenoceptor subtype selectivity and organ specificity for bedoradrine (KUR-1246), a novel tocolytic beta-adrenergic receptor stimulant. J Obstet Gynaecol Res. 2009 Jun;35(3):405-13.
DMBX2RE	RU	https://pubmed.ncbi.nlm.nih.gov/19527375

DMUGN4B	DI	DMUGN4B
DMUGN4B	DN	MN-305
DMUGN4B	MI	TTSQIFT
DMUGN4B	MN	5-HT 1A receptor (HTR1A)
DMUGN4B	MT	DTT
DMUGN4B	MA	Agonist
DMUGN4B	RN	Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
DMUGN4B	RU	https://pubmed.ncbi.nlm.nih.gov/18172433

DMQA3MV	DI	DMQA3MV
DMQA3MV	DN	MNX-100
DMQA3MV	MI	TT2MN5K
DMQA3MV	MN	Phosphorylated protein kinase B (pAKT)
DMQA3MV	MT	DTT
DMQA3MV	MA	Modulator
DMQA3MV	RN	Clinical pipeline report, company report or official report of MetronomX.
DMQA3MV	RU	http://www.metronomxgroup.com/mnx-100.php

DMGK1JE	DI	DMGK1JE
DMGK1JE	DN	MORAb-004
DMGK1JE	MI	TTYJWT7
DMGK1JE	MN	Endosialin (CD248)
DMGK1JE	MT	DTT
DMGK1JE	MA	Modulator
DMGK1JE	RN	A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumors. Clin Cancer Res. 2015 Mar 15;21(6):1281-8.
DMGK1JE	RU	https://pubmed.ncbi.nlm.nih.gov/25398449

DMCXNIP	DI	DMCXNIP
DMCXNIP	DN	MORAb-009
DMCXNIP	MI	TT4RXME
DMCXNIP	MN	Mesothelin (MSLN)
DMCXNIP	MT	DTT
DMCXNIP	RN	Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014 Dec 1;20(23):5927-36.
DMCXNIP	RU	https://pubmed.ncbi.nlm.nih.gov/25231400

DMYCITZ	DI	DMYCITZ
DMYCITZ	DN	MP-101
DMYCITZ	MI	TTXJ47W
DMYCITZ	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMYCITZ	MT	DTT
DMYCITZ	MA	Agonist
DMYCITZ	RN	ClinicalTrials.gov (NCT03044249) A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression. U.S. National Institutes of Health.
DMYCITZ	RU	https://clinicaltrials.gov/ct2/show/NCT03044249

DMYCITZ	DI	DMYCITZ
DMYCITZ	DN	MP-101
DMYCITZ	MI	TT8A9EF
DMYCITZ	MN	Metabotropic glutamate receptor 3 (mGluR3)
DMYCITZ	MT	DTT
DMYCITZ	MA	Agonist
DMYCITZ	RN	ClinicalTrials.gov (NCT03044249) A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression. U.S. National Institutes of Health.
DMYCITZ	RU	https://clinicaltrials.gov/ct2/show/NCT03044249

DMELUAK	DI	DMELUAK
DMELUAK	DN	MP470
DMELUAK	MI	TT8FYO9
DMELUAK	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMELUAK	MT	DTT
DMELUAK	MA	Modulator
DMELUAK	RN	Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul;74(1):195-204.
DMELUAK	RU	https://pubmed.ncbi.nlm.nih.gov/24849582

DMELUAK	DI	DMELUAK
DMELUAK	DN	MP470
DMELUAK	MI	TTX41N9
DMELUAK	MN	Tyrosine-protein kinase Kit (KIT)
DMELUAK	MT	DTT
DMELUAK	MA	Modulator
DMELUAK	RN	Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul;74(1):195-204.
DMELUAK	RU	https://pubmed.ncbi.nlm.nih.gov/24849582

DMMRYEK	DI	DMMRYEK
DMMRYEK	DN	MPSK3169A
DMMRYEK	MI	TTNIZ2B
DMMRYEK	MN	PCSK9 messenger RNA (PCSK9 mRNA)
DMMRYEK	MT	DTT
DMMRYEK	MA	Modulator
DMMRYEK	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2388).
DMMRYEK	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2388

DMQR23W	DI	DMQR23W
DMQR23W	DN	MRE-0094
DMQR23W	MI	TTM2AOE
DMQR23W	MN	Adenosine A2a receptor (ADORA2A)
DMQR23W	MT	DTT
DMQR23W	MA	Agonist
DMQR23W	RN	Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
DMQR23W	RU	https://pubmed.ncbi.nlm.nih.gov/17064227

DMJK8L1	DI	DMJK8L1
DMJK8L1	DN	MRG002
DMJK8L1	MI	TT6EO5L
DMJK8L1	MN	Erbb2 tyrosine kinase receptor (HER2)
DMJK8L1	MT	DTT
DMJK8L1	RN	ClinicalTrials.gov (NCT04839510) A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer. U.S. National Institutes of Health.
DMJK8L1	RU	https://clinicaltrials.gov/ct2/show/NCT04839510

DM9M5WV	DI	DM9M5WV
DM9M5WV	DN	MRG-201
DM9M5WV	MI	TTK982E
DM9M5WV	MN	Collagen (CO)
DM9M5WV	MT	DTT
DM9M5WV	MA	Modulator
DM9M5WV	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9M5WV	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DM9M5WV	DI	DM9M5WV
DM9M5WV	DN	MRG-201
DM9M5WV	MI	TT1GNRQ
DM9M5WV	MN	microRNA hsa-miR-155 (MIR155)
DM9M5WV	MT	DTT
DM9M5WV	MA	Modulator
DM9M5WV	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9M5WV	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMQZWYE	DI	DMQZWYE
DMQZWYE	DN	MRX-4
DMQZWYE	MI	TT9V5JH
DMQZWYE	MN	Phospholipase A2 (PLA2G1B)
DMQZWYE	MT	DTT
DMQZWYE	MA	Inhibitor
DMQZWYE	RN	Phospholipase A2, group IVA (cytosolic, calcium-dependent) (PLA2G4A). SciBX 1(41); doi:10.1038/scibx.2008.999. Nov. 13 2008
DMQZWYE	RU	http://www.nature.com/scibx/journal/v1/n41/full/scibx.2008.999.html

DMLVQKF	DI	DMLVQKF
DMLVQKF	DN	MRX-6
DMLVQKF	MI	TT9V5JH
DMLVQKF	MN	Phospholipase A2 (PLA2G1B)
DMLVQKF	MT	DTT
DMLVQKF	MA	Inhibitor
DMLVQKF	RN	A novel treatment of contact dermatitis by topical application of phospholipase A2 inhibitor: a double-blind placebo-controlled pilot study. Int J Immunopathol Pharmacol. 2007 Jan-Mar;20(1):191-5.
DMLVQKF	RU	https://pubmed.ncbi.nlm.nih.gov/17346444

DMH1DYU	DI	DMH1DYU
DMH1DYU	DN	MSC1936369B
DMH1DYU	MI	DE4LYSA
DMH1DYU	MN	Cytochrome P450 3A4 (CYP3A4)
DMH1DYU	MT	DME
DMH1DYU	MA	Metabolism
DMH1DYU	RN	Metabolism of the MEK1/2 inhibitor pimasertib involves a novel conjugation with phosphoethanolamine in patients with solid tumors. Drug Metab Dispos. 2017 Feb;45(2):174-182.
DMH1DYU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27934635

DMH1DYU	DI	DMH1DYU
DMH1DYU	DN	MSC1936369B
DMH1DYU	MI	TTROQ37
DMH1DYU	MN	MAPK/ERK kinase kinase (MAP3K)
DMH1DYU	MT	DTT
DMH1DYU	MA	Modulator
DMH1DYU	RN	Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. Int J Cancer. 2013 Nov;133(9):2089-101.
DMH1DYU	RU	https://pubmed.ncbi.nlm.nih.gov/23629727

DMH1DYU	DI	DMH1DYU
DMH1DYU	DN	MSC1936369B
DMH1DYU	MI	DEGTFWK
DMH1DYU	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMH1DYU	MT	DME
DMH1DYU	MA	Metabolism
DMH1DYU	RN	Metabolism of the MEK1/2 inhibitor pimasertib involves a novel conjugation with phosphoethanolamine in patients with solid tumors. Drug Metab Dispos. 2017 Feb;45(2):174-182.
DMH1DYU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27934635

DMGUI51	DI	DMGUI51
DMGUI51	DN	MSDC-0602
DMGUI51	MI	TTCBFJO
DMGUI51	MN	Insulin receptor (INSR)
DMGUI51	MT	DTT
DMGUI51	MA	Modulator
DMGUI51	RN	Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor gamma-sparing thiazolidinedione. J Biol Chem. 2012 Jul 6;287(28):23537-48.
DMGUI51	RU	https://pubmed.ncbi.nlm.nih.gov/22621923

DMUM370	DI	DMUM370
DMUM370	DN	MSH-1001
DMUM370	MI	TT1VOHK
DMUM370	MN	Potassium channel unspecific (KC)
DMUM370	MT	DTT
DMUM370	MA	Opener
DMUM370	RN	KR-31378, a potassium-channel opener, induces the protection of retinal ganglion cells in rat retinal ischemic models. J Pharmacol Sci. 2009 Apr;109(4):511-7.
DMUM370	RU	https://pubmed.ncbi.nlm.nih.gov/19372634

DMSE9TH	DI	DMSE9TH
DMSE9TH	DN	MT-1303
DMSE9TH	MI	TT9JZCK
DMSE9TH	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMSE9TH	MT	DTT
DMSE9TH	MA	Modulator
DMSE9TH	RN	Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis. CNS Drugs. 2015 Jul;29(7):565-75.
DMSE9TH	RU	https://pubmed.ncbi.nlm.nih.gov/26239599

DM7I0MT	DI	DM7I0MT
DM7I0MT	DN	MT203
DM7I0MT	MI	TTNYZG2
DM7I0MT	MN	Granulocyte-macrophage colony-stimulating factor (CSF2)
DM7I0MT	MT	DTT
DM7I0MT	MA	Modulator
DM7I0MT	RN	GM-CSF as a target in inflammatory/autoimmune disease: current evidence and future therapeutic potential. Expert Rev Clin Immunol. 2015 Apr;11(4):457-65.
DM7I0MT	RU	https://pubmed.ncbi.nlm.nih.gov/25748625

DMCNL7Z	DI	DMCNL7Z
DMCNL7Z	DN	MT-3724
DMCNL7Z	MI	TTUE541
DMCNL7Z	MN	Leukocyte surface antigen Leu-16 (CD20)
DMCNL7Z	MT	DTT
DMCNL7Z	MA	Inhibitor
DMCNL7Z	RN	Clinical pipeline report, company report or official report of Molecular Templates.
DMCNL7Z	RU	https://www.mtem.com/pipeline/mt-3724

DMXSZA4	DI	DMXSZA4
DMXSZA4	DN	MT-3995
DMXSZA4	MI	TT26PHO
DMXSZA4	MN	Mineralocorticoid receptor  (MR)
DMXSZA4	MT	DTT
DMXSZA4	MA	Antagonist
DMXSZA4	RN	Nonsteroidal antagonists of the mineralocorticoid receptor. Curr Opin Nephrol Hypertens. 2015 Sep;24(5):417-24.
DMXSZA4	RU	https://pubmed.ncbi.nlm.nih.gov/26083526

DM7VG8L	DI	DM7VG8L
DM7VG8L	DN	MTC-896
DM7VG8L	MI	TT6QAJ3
DM7VG8L	MN	Melanocortin receptor 5 (MC5R)
DM7VG8L	MT	DTT
DM7VG8L	MA	Antagonist
DM7VG8L	RN	Clinical pipeline report, company report or official report of Avarx.
DM7VG8L	RU	http://www.avarx.com/AvaRx/SubDomains/Company231/Listings/231/Public.Listing.display.html

DMT0K4F	DI	DMT0K4F
DMT0K4F	DN	MTR105
DMT0K4F	MI	TTCM4B3
DMT0K4F	MN	Nitric-oxide synthase endothelial (NOS3)
DMT0K4F	MT	DTT
DMT0K4F	MA	Inhibitor
DMT0K4F	RN	Nitric oxide synthase inhibitor (MTR-105) during open-heart surgery. A pilot double-blind placebo-controlled study of hemodynamic effects and safety. Cardiology. 2008;111(3):181-7.
DMT0K4F	RU	https://pubmed.ncbi.nlm.nih.gov/18434722

DML7N4B	DI	DML7N4B
DML7N4B	DN	MUC1-Poly-ICLC
DML7N4B	MI	TTBHFYQ
DML7N4B	MN	Mucin-1 (MUC1)
DML7N4B	MT	DTT
DML7N4B	RN	Early in vivo signaling profiles in MUC1-specific CD4+ T cells responding to two different MUC1-targeting vaccines in two different microenvironments. Oncoimmunology. 2013 Mar 1;2(3):e23429.
DML7N4B	RU	https://pubmed.ncbi.nlm.nih.gov/23802084

DMN68ZL	DI	DMN68ZL
DMN68ZL	DN	Multi-epitope tyrosinase/gp100 vaccine
DMN68ZL	MI	TT8MK59
DMN68ZL	MN	Melanocytes lineage-specific antigen GP100 (PMEL)
DMN68ZL	MT	DTT
DMN68ZL	RN	ClinicalTrials.gov (NCT00003362) Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma. U.S. National Institutes of Health.
DMN68ZL	RU	https://clinicaltrials.gov/ct2/show/NCT00003362

DMN68ZL	DI	DMN68ZL
DMN68ZL	DN	Multi-epitope tyrosinase/gp100 vaccine
DMN68ZL	MI	TTULVH8
DMN68ZL	MN	Tyrosinase (TYR)
DMN68ZL	MT	DTT
DMN68ZL	RN	ClinicalTrials.gov (NCT00003362) Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma. U.S. National Institutes of Health.
DMN68ZL	RU	https://clinicaltrials.gov/ct2/show/NCT00003362

DMM6KZR	DI	DMM6KZR
DMM6KZR	DN	Mutant ras vaccine
DMM6KZR	MI	TTW2R9X
DMM6KZR	MN	GTPase NRas (NRAS)
DMM6KZR	MT	DTT
DMM6KZR	RN	The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors. J Transl Med. 2014 Feb 24;12:55.
DMM6KZR	RU	https://pubmed.ncbi.nlm.nih.gov/24565030

DMKDN1C	DI	DMKDN1C
DMKDN1C	DN	MVA-85A
DMKDN1C	MI	TTZYJ8U
DMKDN1C	MN	Mycobacterium Antigen complex 85A (MycB fbpA)
DMKDN1C	MT	DTT
DMKDN1C	RN	MVA-85A, a novel candidate booster vaccine for the prevention of tuberculosis in children and adults. Curr Opin Mol Ther. 2010 Feb;12(1):124-34.
DMKDN1C	RU	https://pubmed.ncbi.nlm.nih.gov/20140824

DMDN6FO	DI	DMDN6FO
DMDN6FO	DN	MVI-816
DMDN6FO	MI	TTBRZQS
DMDN6FO	MN	Prostatic acid phosphatase (ACPP)
DMDN6FO	MT	DTT
DMDN6FO	MA	Modulator
DMDN6FO	RN	Company report (Madisonvaccine)
DMDN6FO	RU	http://www.madisonvaccinesinc.com/Home/News

DM25VY8	DI	DM25VY8
DM25VY8	DN	Mydicar
DM25VY8	MI	TTE6THL
DM25VY8	MN	Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (ATP2A2)
DM25VY8	MT	DTT
DM25VY8	MA	Modulator
DM25VY8	RN	Clinical pipeline report, company report or official report of Celladon.
DM25VY8	RU	http://www.celladon.com/mydicar/

DMO1XUK	DI	DMO1XUK
DMO1XUK	DN	Myeloma cancer vaccine
DMO1XUK	MI	TT6MP2Z
DMO1XUK	MN	GMCSFR-alpha (CSF2RA)
DMO1XUK	MT	DTT
DMO1XUK	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1707).
DMO1XUK	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1707

DM9BREJ	DI	DM9BREJ
DM9BREJ	DN	MYK-491
DM9BREJ	MI	TTITSMB
DM9BREJ	MN	Myosin (MYO)
DM9BREJ	MT	DTT
DM9BREJ	MA	Activator
DM9BREJ	RN	Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial. Eur J Heart Fail. 2020 Sep;22(9):1649-1658.
DM9BREJ	RU	https://pubmed.ncbi.nlm.nih.gov/32558989

DMQKSGI	DI	DMQKSGI
DMQKSGI	DN	Myo-inositol
DMQKSGI	MI	TTE4KHA
DMQKSGI	MN	Amyloid beta A4 protein (APP)
DMQKSGI	MT	DTT
DMQKSGI	MA	Inhibitor
DMQKSGI	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQKSGI	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMQKSGI	DI	DMQKSGI
DMQKSGI	DN	Myo-inositol
DMQKSGI	MI	DE0J45Y
DMQKSGI	MN	Inositol dehydrogenase (idh)
DMQKSGI	MT	DME
DMQKSGI	MA	Metabolism
DMQKSGI	RN	Purification, crystallization and room-temperature X-ray diffraction of inositol dehydrogenase LcIDH2 from Lactobacillus casei BL23. Acta Crystallogr F Struct Biol Commun. 2014 Jul;70(Pt 7):979-83.
DMQKSGI	RU	https://pubmed.ncbi.nlm.nih.gov/25005103

DMQKSGI	DI	DMQKSGI
DMQKSGI	DN	Myo-inositol
DMQKSGI	MI	DEDUGWF
DMQKSGI	MN	Inositol dehydrogenase (idh)
DMQKSGI	MT	DME
DMQKSGI	MA	Metabolism
DMQKSGI	RN	Purification, crystallization and room-temperature X-ray diffraction of inositol dehydrogenase LcIDH2 from Lactobacillus casei BL23. Acta Crystallogr F Struct Biol Commun. 2014 Jul;70(Pt 7):979-83.
DMQKSGI	RU	https://pubmed.ncbi.nlm.nih.gov/25005103

DMQKSGI	DI	DMQKSGI
DMQKSGI	DN	Myo-inositol
DMQKSGI	MI	TTI0TCK
DMQKSGI	MN	Mycobacterium CDP-diacylglycerol-inositol phosphatidyltransferase (MycB pssA)
DMQKSGI	MT	DTT
DMQKSGI	MA	Inhibitor
DMQKSGI	RN	Phosphatidylinositol synthesis in mycobacteria. Biochim Biophys Acta. 1999 Jan 4;1436(3):437-50.
DMQKSGI	RU	https://pubmed.ncbi.nlm.nih.gov/9989274

DMQKSGI	DI	DMQKSGI
DMQKSGI	DN	Myo-inositol
DMQKSGI	MI	DT8ACN1
DMQKSGI	MN	Sodium/myo-inositol cotransporter (SLC5A3)
DMQKSGI	MT	DTP
DMQKSGI	MA	Substrate
DMQKSGI	RN	Identification of a novel Na+/myo-inositol cotransporter. J Biol Chem. 2002 Sep 20;277(38):35219-24.
DMQKSGI	RU	http://www.ncbi.nlm.nih.gov/pubmed/12133831

DMQKSGI	DI	DMQKSGI
DMQKSGI	DN	Myo-inositol
DMQKSGI	MI	DT2CAPQ
DMQKSGI	MN	Sodium/myo-inositol cotransporter 2 (SLC5A11)
DMQKSGI	MT	DTP
DMQKSGI	MA	Substrate
DMQKSGI	RN	The sodium/glucose cotransport family SLC5. Pflugers Arch. 2004 Feb;447(5):510-8.
DMQKSGI	RU	http://www.ncbi.nlm.nih.gov/pubmed/12748858

DMUK6HC	DI	DMUK6HC
DMUK6HC	DN	N-5984
DMUK6HC	MI	TTMXGCW
DMUK6HC	MN	Adrenergic receptor beta-3 (ADRB3)
DMUK6HC	MT	DTT
DMUK6HC	MA	Agonist
DMUK6HC	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DMUK6HC	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMN7EUO	DI	DMN7EUO
DMN7EUO	DN	N6022
DMN7EUO	MI	TTVG0SN
DMN7EUO	MN	S-nitrosoglutathione reductase (CBR1)
DMN7EUO	MT	DTT
DMN7EUO	MA	Inhibitor
DMN7EUO	RN	Mechanism of inhibition for N6022, a first-in-class drug targeting S-nitrosoglutathione reductase. Biochemistry. 2012 Mar 13;51(10):2157-68.
DMN7EUO	RU	https://pubmed.ncbi.nlm.nih.gov/22335564

DM7P0WR	DI	DM7P0WR
DM7P0WR	DN	NAI-acne
DM7P0WR	MI	TTYQIFM
DM7P0WR	MN	Staphylococcus Elongation factor Tu (Stap-coc tuf)
DM7P0WR	MT	DTT
DM7P0WR	MA	Modulator
DM7P0WR	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031008)
DM7P0WR	RU	http://adisinsight.springer.com/drugs/800031008

DMSWUNX	DI	DMSWUNX
DMSWUNX	DN	Naratuximab emtansine
DMSWUNX	MI	TTFCW29
DMSWUNX	MN	Leukocyte antigen CD37 (CD37)
DMSWUNX	MT	DTT
DMSWUNX	MA	Inhibitor
DMSWUNX	RN	Clinical pipeline report, company report or official report of Debiopharm.
DMSWUNX	RU	https://www.debiopharm.com/drug-development/pipeline/debio-1562/

DMD0E8U	DI	DMD0E8U
DMD0E8U	DN	Naveglitazar
DMD0E8U	MI	TTJ584C
DMD0E8U	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMD0E8U	MT	DTT
DMD0E8U	MA	Modulator
DMD0E8U	RN	The disposition and metabolism of naveglitazar, a peroxisome proliferator-activated receptor alpha-gamma dual, gamma-dominant agonist in mice, rats... Drug Metab Dispos. 2007 Jan;35(1):51-61.
DMD0E8U	RU	https://pubmed.ncbi.nlm.nih.gov/17012539

DMD0E8U	DI	DMD0E8U
DMD0E8U	DN	Naveglitazar
DMD0E8U	MI	TTZMAO3
DMD0E8U	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMD0E8U	MT	DTT
DMD0E8U	MA	Modulator
DMD0E8U	RN	The disposition and metabolism of naveglitazar, a peroxisome proliferator-activated receptor alpha-gamma dual, gamma-dominant agonist in mice, rats... Drug Metab Dispos. 2007 Jan;35(1):51-61.
DMD0E8U	RU	https://pubmed.ncbi.nlm.nih.gov/17012539

DMH9JFZ	DI	DMH9JFZ
DMH9JFZ	DN	NBI-5788
DMH9JFZ	MI	TT2RY5P
DMH9JFZ	MN	Myelin basic protein (MBP)
DMH9JFZ	MT	DTT
DMH9JFZ	MA	Binder
DMH9JFZ	RN	NBI-5788, an altered MBP83-99 peptide, induces a T-helper 2-like immune response in multiple sclerosis patients. Ann Neurol. 2000 Nov;48(5):758-65.
DMH9JFZ	RU	https://pubmed.ncbi.nlm.nih.gov/11079539

DMT6O2E	DI	DMT6O2E
DMT6O2E	DN	NC318
DMT6O2E	MI	TTBSZPF
DMT6O2E	MN	Sialic acid-binding immunoglobulin-like lectin 15 (SIGLEC15)
DMT6O2E	MT	DTT
DMT6O2E	MA	Inhibitor
DMT6O2E	RN	Clinical pipeline report, company report or official report of NextCure.
DMT6O2E	RU	http://www.nextcure.com/pipeline/

DMVQKB3	DI	DMVQKB3
DMVQKB3	DN	NCI-C50000
DMVQKB3	MI	DE4LYSA
DMVQKB3	MN	Cytochrome P450 3A4 (CYP3A4)
DMVQKB3	MT	DME
DMVQKB3	MA	Metabolism
DMVQKB3	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DMVQKB3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DM4W28K	DI	DM4W28K
DM4W28K	DN	NCX 1022
DM4W28K	MI	TTK0943
DM4W28K	MN	Prostaglandin G/H synthase (COX)
DM4W28K	MT	DTT
DM4W28K	MA	Modulator
DM4W28K	RN	Anti-inflammatory effects of nitric oxide-releasing hydrocortisone NCX 1022, in a murine model of contact dermatitis. Br J Pharmacol. 2004 Nov;143(5):618-25.
DM4W28K	RU	https://pubmed.ncbi.nlm.nih.gov/15313880

DM2YIZH	DI	DM2YIZH
DM2YIZH	DN	NCX-1000
DM2YIZH	MI	TTZY5KP
DM2YIZH	MN	Caspase (CASP)
DM2YIZH	MT	DTT
DM2YIZH	MA	Modulator
DM2YIZH	RN	Liver delivery of NO by NCX-1000 protects against acute liver failure and mitochondrial dysfunction induced by APAP in mice. Br J Pharmacol. 2004 Sep;143(1):33-42.
DM2YIZH	RU	https://pubmed.ncbi.nlm.nih.gov/15345658

DMOX1CU	DI	DMOX1CU
DMOX1CU	DN	NCX-4016
DMOX1CU	MI	TTK0943
DMOX1CU	MN	Prostaglandin G/H synthase (COX)
DMOX1CU	MT	DTT
DMOX1CU	MA	Inhibitor
DMOX1CU	RN	Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
DMOX1CU	RU	https://pubmed.ncbi.nlm.nih.gov/16503827

DM6S83X	DI	DM6S83X
DM6S83X	DN	NDDP
DM6S83X	MI	TTUTN1I
DM6S83X	MN	Human Deoxyribonucleic acid (hDNA)
DM6S83X	MT	DTT
DM6S83X	MA	Binder
DM6S83X	RN	Cell death and DNA fragmentation induced by liposomal platinum(II) complex, L-NDDP in A2780 and A2780/PDD cells. Anticancer Res. 1994 Mar-Apr;14(2A):421-6.
DM6S83X	RU	https://pubmed.ncbi.nlm.nih.gov/8017841

DMVIRN3	DI	DMVIRN3
DMVIRN3	DN	N-DESMETHYLCLOZAPINE
DMVIRN3	MI	TTZ9SOR
DMVIRN3	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMVIRN3	MT	DTT
DMVIRN3	MA	Modulator
DMVIRN3	RN	N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarin... Neuropsychopharmacology. 2005 Nov;30(11):1986-95.
DMVIRN3	RU	https://www.ncbi.nlm.nih.gov/pubmed/15900318

DMUPZFO	DI	DMUPZFO
DMUPZFO	DN	Neihulizumab
DMUPZFO	MI	TTS5K8U
DMUPZFO	MN	P-selectin glycoprotein ligand 1 (SELPLG)
DMUPZFO	MT	DTT
DMUPZFO	MA	Inhibitor
DMUPZFO	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMUPZFO	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMSVWI7	DI	DMSVWI7
DMSVWI7	DN	Neladenoson bialanate
DMSVWI7	MI	TT92EIB
DMSVWI7	MN	ADORA1 messenger RNA (ADORA1 mRNA)
DMSVWI7	MT	DTT
DMSVWI7	MA	Agonist
DMSVWI7	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMSVWI7	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DM4LKFO	DI	DM4LKFO
DM4LKFO	DN	NELOTANSERIN
DM4LKFO	MI	TTJQOD7
DM4LKFO	MN	5-HT 2A receptor (HTR2A)
DM4LKFO	MT	DTT
DM4LKFO	MA	Modulator
DM4LKFO	RN	Nelotanserin, a novel selective human 5-hydroxytryptamine2A inverse agonist for the treatment of insomnia.J Pharmacol Exp Ther.2010 Jan;332(1):281-90.
DM4LKFO	RU	https://www.ncbi.nlm.nih.gov/pubmed/19841476

DMNM9DZ	DI	DMNM9DZ
DMNM9DZ	DN	Nepicastat oral
DMNM9DZ	MI	TTYIP79
DMNM9DZ	MN	Dopamine beta hydroxylase (DBH)
DMNM9DZ	MT	DTT
DMNM9DZ	MA	Inhibitor
DMNM9DZ	RN	Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine-beta-hydroxylase. Br J Pharmacol. 1997 Aug;121(8):1803-9.
DMNM9DZ	RU	https://pubmed.ncbi.nlm.nih.gov/9283721

DM3ORVD	DI	DM3ORVD
DM3ORVD	DN	Neramexane
DM3ORVD	MI	TT9IK2Z
DM3ORVD	MN	N-methyl-D-aspartate receptor (NMDAR)
DM3ORVD	MT	DTT
DM3ORVD	MA	Antagonist
DM3ORVD	RN	Emerging analgesics in cancer pain management. Expert Opin Emerg Drugs. 2005 Feb;10(1):151-71.
DM3ORVD	RU	https://pubmed.ncbi.nlm.nih.gov/15757410

DMBJ3GL	DI	DMBJ3GL
DMBJ3GL	DN	Nerenone
DMBJ3GL	MI	TT26PHO
DMBJ3GL	MN	Mineralocorticoid receptor  (MR)
DMBJ3GL	MT	DTT
DMBJ3GL	MA	Antagonist
DMBJ3GL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 626).
DMBJ3GL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=626

DM8H7OA	DI	DM8H7OA
DM8H7OA	DN	Netoglitazone
DM8H7OA	MI	DE4LYSA
DM8H7OA	MN	Cytochrome P450 3A4 (CYP3A4)
DM8H7OA	MT	DME
DM8H7OA	MA	Metabolism
DM8H7OA	RN	Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther. 2005 May;77(5):404-14.
DM8H7OA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15900286

DM8H7OA	DI	DM8H7OA
DM8H7OA	DN	Netoglitazone
DM8H7OA	MI	TTZMAO3
DM8H7OA	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DM8H7OA	MT	DTT
DM8H7OA	MA	Modulator
DM8H7OA	RN	Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. Bone. 2006 Jan;38(1):74-84.
DM8H7OA	RU	https://www.ncbi.nlm.nih.gov/pubmed/16137931

DMOZW4C	DI	DMOZW4C
DMOZW4C	DN	Neublastin
DMOZW4C	MI	TT63XRS
DMOZW4C	MN	GDNF receptor alpha-3 (GFRA3)
DMOZW4C	MT	DTT
DMOZW4C	MA	Modulator
DMOZW4C	RN	First-In-Human, Double-Blind, Placebo-Controlled, Randomized, Dose-Escalation Study of BG00010, a Glial Cell Line-Derived Neurotrophic Factor Family Member, in Subjects with Unilateral Sciatica. PLoSOne. 2015 May 11;10(5):e0125034.
DMOZW4C	RU	https://pubmed.ncbi.nlm.nih.gov/25962165

DMIQDFW	DI	DMIQDFW
DMIQDFW	DN	Neu-P11
DMIQDFW	MI	TTSQIFT
DMIQDFW	MN	5-HT 1A receptor (HTR1A)
DMIQDFW	MT	DTT
DMIQDFW	MA	Agonist
DMIQDFW	RN	Clinical pipeline report, company report or official report of Neurim Pharmaceuticals.
DMIQDFW	RU	http://www.neurim.com/products/

DMIQDFW	DI	DMIQDFW
DMIQDFW	DN	Neu-P11
DMIQDFW	MI	TT6MSOK
DMIQDFW	MN	5-HT 1D receptor (HTR1D)
DMIQDFW	MT	DTT
DMIQDFW	MA	Agonist
DMIQDFW	RN	Clinical pipeline report, company report or official report of Neurim Pharmaceuticals.
DMIQDFW	RU	http://www.neurim.com/products/

DMIQDFW	DI	DMIQDFW
DMIQDFW	DN	Neu-P11
DMIQDFW	MI	TT0WAIE
DMIQDFW	MN	Melatonin receptor type 1A (MTNR1A)
DMIQDFW	MT	DTT
DMIQDFW	MA	Agonist
DMIQDFW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 288).
DMIQDFW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=288

DMINQP1	DI	DMINQP1
DMINQP1	DN	NEUROPEPTIDE-Y
DMINQP1	MI	TTRK9JT
DMINQP1	MN	Neuropeptide Y receptor type 1 (NPY1R)
DMINQP1	MT	DTT
DMINQP1	MA	Inhibitor
DMINQP1	RN	5-OHKF and NorKA, depsipeptides from a Hawaiian collection of Bryopsis pennata: binding properties for NorKA to the human neuropeptide Y Y1 receptor. J Nat Prod. 2009 Dec;72(12):2172-6.
DMINQP1	RU	https://pubmed.ncbi.nlm.nih.gov/19916528

DMINQP1	DI	DMINQP1
DMINQP1	DN	NEUROPEPTIDE-Y
DMINQP1	MI	TTJ6WK9
DMINQP1	MN	Neuropeptide Y receptor type 2 (NPY2R)
DMINQP1	MT	DTT
DMINQP1	MA	Inhibitor
DMINQP1	RN	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
DMINQP1	RU	https://pubmed.ncbi.nlm.nih.gov/18983139

DML5S71	DI	DML5S71
DML5S71	DN	Nexopamil
DML5S71	MI	TTYSN63
DML5S71	MN	5-HT 2 receptor (5HT2R)
DML5S71	MT	DTT
DML5S71	MA	Modulator
DML5S71	RN	Inhibition by the combined Ca2+ and 5-HT2 receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage. J Cardiovasc Pharmacol. 1993 Nov;22(5):687-94.
DML5S71	RU	https://pubmed.ncbi.nlm.nih.gov/7506319

DML5S71	DI	DML5S71
DML5S71	DN	Nexopamil
DML5S71	MI	TT5HONZ
DML5S71	MN	Calcium channel unspecific (CaC)
DML5S71	MT	DTT
DML5S71	MA	Blocker
DML5S71	RN	Inhibition by the combined Ca2+ and 5-HT2 receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage. J Cardiovasc Pharmacol. 1993 Nov;22(5):687-94.
DML5S71	RU	https://pubmed.ncbi.nlm.nih.gov/7506319

DMJKBAY	DI	DMJKBAY
DMJKBAY	DN	NGX-267
DMJKBAY	MI	TTZ9SOR
DMJKBAY	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMJKBAY	MT	DTT
DMJKBAY	MA	Agonist
DMJKBAY	RN	Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur J Pharmacol. 2009 Mar 1;605(1-3):53-6.
DMJKBAY	RU	https://pubmed.ncbi.nlm.nih.gov/19168056

DMDY01J	DI	DMDY01J
DMDY01J	DN	NHS-IL2-LT
DMDY01J	MI	TTUTN1I
DMDY01J	MN	Human Deoxyribonucleic acid (hDNA)
DMDY01J	MT	DTT
DMDY01J	MA	Modulator
DMDY01J	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMDY01J	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMRQUH4	DI	DMRQUH4
DMRQUH4	DN	NI-0801
DMRQUH4	MI	TTQOVYA
DMRQUH4	MN	C-X-C motif chemokine 10 (CXCL10)
DMRQUH4	MT	DTT
DMRQUH4	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029267)
DMRQUH4	RU	http://adisinsight.springer.com/drugs/800029267

DMKLJMI	DI	DMKLJMI
DMKLJMI	DN	NIC-002
DMKLJMI	MI	TTJSZTB
DMKLJMI	MN	Nicotinic acetylcholine receptor (nAChR)
DMKLJMI	MT	DTT
DMKLJMI	RN	Therapeutic advances in the treatment of nicotine addiction: present and future. Ther Adv Chronic Dis. 2010 May; 1(3): 95-106.
DMKLJMI	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513862/

DMG7XOC	DI	DMG7XOC
DMG7XOC	DN	NIC5-15
DMG7XOC	MI	TTE4KHA
DMG7XOC	MN	Amyloid beta A4 protein (APP)
DMG7XOC	MT	DTT
DMG7XOC	MA	Inhibitor
DMG7XOC	RN	Combating neurodegenerative disease with chemical probes and model systems. Nat Chem Biol. 2014 Nov;10(11):911-20.
DMG7XOC	RU	https://pubmed.ncbi.nlm.nih.gov/25325702

DM21Z68	DI	DM21Z68
DM21Z68	DN	Nimacimab
DM21Z68	MI	TT6OEDT
DM21Z68	MN	Cannabinoid receptor 1 (CB1)
DM21Z68	MT	DTT
DM21Z68	MA	Antagonist
DM21Z68	RN	Clinical pipeline report, company report or official report of Bird Rock Bio.
DM21Z68	RU	http://www.birdrockbio.com/our-pipeline/nimacimab/

DMPER4A	DI	DMPER4A
DMPER4A	DN	NIR178
DMPER4A	MI	TTSLI08
DMPER4A	MN	Adenosine receptor (ADOR)
DMPER4A	MT	DTT
DMPER4A	MA	Antagonist
DMPER4A	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPER4A	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM81SDB	DI	DM81SDB
DM81SDB	DN	Niravoline
DM81SDB	MI	TTQW87Y
DM81SDB	MN	Opioid receptor kappa (OPRK1)
DM81SDB	MT	DTT
DM81SDB	MA	Modulator
DM81SDB	RN	Effect of niravoline (RU51599), a kappa-opioid receptor agonist, on tumour-origin brain oedema. Acta Neurochir (Wien). 1999;141(7):771-8.
DM81SDB	RU	https://www.ncbi.nlm.nih.gov/pubmed/10481790

DM8LBYT	DI	DM8LBYT
DM8LBYT	DN	NIS793
DM8LBYT	MI	TTO3HT7
DM8LBYT	MN	Transforming growth factor beta (TGFB)
DM8LBYT	MT	DTT
DM8LBYT	MA	Inhibitor
DM8LBYT	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM8LBYT	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMQHBSX	DI	DMQHBSX
DMQHBSX	DN	NITD609
DMQHBSX	MI	TTJFY5U
DMQHBSX	MN	Adenosine A3 receptor (ADORA3)
DMQHBSX	MT	DTT
DMQHBSX	MA	Inhibitor
DMQHBSX	RN	Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010 Sep 3;329(5996):1175-80.
DMQHBSX	RU	https://pubmed.ncbi.nlm.nih.gov/20813948

DMQHBSX	DI	DMQHBSX
DMQHBSX	DN	NITD609
DMQHBSX	MI	TTQ6VDM
DMQHBSX	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMQHBSX	MT	DTT
DMQHBSX	MA	Inhibitor
DMQHBSX	RN	Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010 Sep 3;329(5996):1175-80.
DMQHBSX	RU	https://pubmed.ncbi.nlm.nih.gov/20813948

DMAOUZV	DI	DMAOUZV
DMAOUZV	DN	Nivatrotamab
DMAOUZV	MI	TT80ARU
DMAOUZV	MN	Ganglioside GD2 (GD2)
DMAOUZV	MT	DTT
DMAOUZV	MA	Inhibitor
DMAOUZV	RN	Clinical pipeline report, company report or official report of Y-mAbs Therapeutics.
DMAOUZV	RU	https://ymabs.com/research-development/pipeline/

DMAOUZV	DI	DMAOUZV
DMAOUZV	DN	Nivatrotamab
DMAOUZV	MI	TTUN7MC
DMAOUZV	MN	T-cell surface glycoprotein CD3 (CD3)
DMAOUZV	MT	DTT
DMAOUZV	MA	Inhibitor
DMAOUZV	RN	Clinical pipeline report, company report or official report of Y-mAbs Therapeutics.
DMAOUZV	RU	https://ymabs.com/research-development/pipeline/

DMUX8JZ	DI	DMUX8JZ
DMUX8JZ	DN	Nivocasan
DMUX8JZ	MI	TTCQIBE
DMUX8JZ	MN	Caspase-1 (CASP1)
DMUX8JZ	MT	DTT
DMUX8JZ	MA	Modulator
DMUX8JZ	RN	Combined effects of an antioxidant and caspase inhibitor on the reversal of hepatic fibrosis in rats. Apoptosis. 2013 Dec;18(12):1481-91.
DMUX8JZ	RU	https://pubmed.ncbi.nlm.nih.gov/24045874

DMTVGMZ	DI	DMTVGMZ
DMTVGMZ	DN	NKP 608
DMTVGMZ	MI	TTZPO1L
DMTVGMZ	MN	Substance-P receptor (TACR1)
DMTVGMZ	MT	DTT
DMTVGMZ	MA	Antagonist
DMTVGMZ	RN	Neurokinin-1-receptor antagonism decreases anxiety and emotional arousal circuit response to noxious visceral distension in women with irritable bowel syndrome: a pilot study. Aliment Pharmacol Ther.2012 Feb;35(3):360-7.
DMTVGMZ	RU	https://pubmed.ncbi.nlm.nih.gov/22221140

DMKD5ZO	DI	DMKD5ZO
DMKD5ZO	DN	NN-8226
DMKD5ZO	MI	TTNZMY2
DMKD5ZO	MN	Interleukin-20 (IL20)
DMKD5ZO	MT	DTT
DMKD5ZO	RN	Handbook of Therapeutic Antibodies. 2014. 1. Page(995).
DMKD5ZO	RU	https://books.google.com.hk/books?id=svHsBQAAQBAJ&pg=PA995&lpg=PA995&dq=NN-8828++++++ANTI&source=bl&ots=OSgek3Ucgf&sig=8iYcf4GKsCAvCCC1QHsKqxZK3YQ&hl=zh-CN&sa=X&ved=0CEwQ6AEwBmoVChMIyrS7qtXGyAIVA0COCh20lgxt#v=onepage&q=NN-8828%20%20%20%20%20%20ANTI&f=false

DM3IEHP	DI	DM3IEHP
DM3IEHP	DN	NN8555
DM3IEHP	MI	TTLRN4A
DM3IEHP	MN	NKG2 D activating NK receptor (KLRK1)
DM3IEHP	MT	DTT
DM3IEHP	MA	Antagonist
DM3IEHP	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3IEHP	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMCFPBE	DI	DMCFPBE
DMCFPBE	DN	NN8765
DMCFPBE	MI	TTC4IMS
DMCFPBE	MN	NKG2-A/B-activating NK receptor (NKG2A)
DMCFPBE	MT	DTT
DMCFPBE	MA	Modulator
DMCFPBE	RN	Handbook of Therapeutic Antibodies. 2014. 1. Page(1098).
DMCFPBE	RU	https://books.google.com.hk/books?id=svHsBQAAQBAJ&pg=PA2173&lpg=PA2173&dq=%22NN-8765%22+++drug&source=bl&ots=OSgek3Ubee&sig=uPqJzQ0sfWmrddc5W83GKlUI4JQ&hl=zh-CN&sa=X&ved=0CBoQ6AEwAGoVChMI3cTx8NTGyAIVTgWOCh29iQZt

DMDTNOS	DI	DMDTNOS
DMDTNOS	DN	NNC-0123-0000-0338
DMDTNOS	MI	TTZOPHG
DMDTNOS	MN	Insulin (INS)
DMDTNOS	MT	DTT
DMDTNOS	MA	Modulator
DMDTNOS	RN	ClinicalTrials.gov (NCT01334034) Safety of NNC 0123-0000-0338 in Healthy Subjects. U.S. National Institutes of Health.
DMDTNOS	RU	https://clinicaltrials.gov/ct2/show/NCT01334034

DMU3KOH	DI	DMU3KOH
DMU3KOH	DN	NNC-0151-0000-0000
DMU3KOH	MI	TTKANGO
DMU3KOH	MN	Complement C5 (CO5)
DMU3KOH	MT	DTT
DMU3KOH	RN	Complement-targeted therapeutics. Nat Biotechnol. 2007 Nov;25(11):1265-75.
DMU3KOH	RU	https://pubmed.ncbi.nlm.nih.gov/17989689

DMPZ97S	DI	DMPZ97S
DMPZ97S	DN	NNZ-2566
DMPZ97S	MI	TT9RTYG
DMPZ97S	MN	Neuropeptide receptor (NPR)
DMPZ97S	MT	DTT
DMPZ97S	MA	Modulator
DMPZ97S	RN	NNZ-2566 treatment inhibits neuroinflammation and pro-inflammatory cytokine expression induced by experimental penetrating ballistic-like brain injury in rats. J Neuroinflammation. 2009 Aug 5;6:19.
DMPZ97S	RU	https://pubmed.ncbi.nlm.nih.gov/19656406

DME8IFQ	DI	DME8IFQ
DME8IFQ	DN	Noberastine
DME8IFQ	MI	TTTIBOJ
DME8IFQ	MN	Histamine H1 receptor (H1R)
DME8IFQ	MT	DTT
DME8IFQ	MA	Antagonist
DME8IFQ	RN	A double-blind placebo controlled dose response study of noberastine on histamine induced weal and flare. Eur J Clin Pharmacol. 1991;40(1):83-5.
DME8IFQ	RU	https://pubmed.ncbi.nlm.nih.gov/1676366

DMEHOI1	DI	DMEHOI1
DMEHOI1	DN	Novaferon
DMEHOI1	MI	TTSIUJ9
DMEHOI1	MN	Interferon-alpha 2 (IFNA2)
DMEHOI1	MT	DTT
DMEHOI1	MA	Modulator
DMEHOI1	RN	Novaferon, a novel recombinant protein produced by DNA-shuffling of IFN-alpha, shows antitumor effect in vitro and in vivo. Cancer Cell Int. 2014; 14: 8.
DMEHOI1	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3976097/

DMHG3UR	DI	DMHG3UR
DMHG3UR	DN	NOX-E36
DMHG3UR	MI	TTNAY0P
DMHG3UR	MN	Monocyte chemotactic and activating factor (CCL2)
DMHG3UR	MT	DTT
DMHG3UR	MA	Inhibitor
DMHG3UR	RN	Crystal structure of a mirror-image L-RNA aptamer (Spiegelmer) in complex with the natural L-protein target CCL2. Nat Commun. 2015 Apr 22;6:6923.
DMHG3UR	RU	https://pubmed.ncbi.nlm.nih.gov/25901662

DM5HPZU	DI	DM5HPZU
DM5HPZU	DN	NOX-H94
DM5HPZU	MI	TTPCG5T
DM5HPZU	MN	Hepcidin (HAMP)
DM5HPZU	MT	DTT
DM5HPZU	MA	Inhibitor
DM5HPZU	RN	The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys. Blood. 2013 Mar 21;121(12):2311-5.
DM5HPZU	RU	https://pubmed.ncbi.nlm.nih.gov/23349391

DMP1W9Z	DI	DMP1W9Z
DMP1W9Z	DN	NP-01
DMP1W9Z	MI	TTCBFJO
DMP1W9Z	MN	Insulin receptor (INSR)
DMP1W9Z	MT	DTT
DMP1W9Z	MA	Agonist
DMP1W9Z	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800).
DMP1W9Z	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800

DMLMZ6Q	DI	DMLMZ6Q
DMLMZ6Q	DN	NP-2
DMLMZ6Q	MI	TTN4QDT
DMLMZ6Q	MN	Opioid receptor (OPR)
DMLMZ6Q	MT	DTT
DMLMZ6Q	MA	Antagonist
DMLMZ6Q	RN	Vascular endothelial growth factor receptor-1 and neuropilin-2 form complexes. J Biol Chem. 2001 Jun 1;276(22):18688-94.
DMLMZ6Q	RU	https://pubmed.ncbi.nlm.nih.gov/11278319

DME6KAF	DI	DME6KAF
DME6KAF	DN	NPC-15199
DME6KAF	MI	TTW6MKR
DME6KAF	MN	Calcium release (Ca rele)
DME6KAF	MT	DTT
DME6KAF	MA	Modulator
DME6KAF	RN	NPC-15199, a novel anti-inflammatory agent, mobilizes intracellular Ca2+ in bladder female transitional carcinoma (BFTC) cells. Chin J Physiol. 2000 Mar 31;43(1):29-33.
DME6KAF	RU	https://pubmed.ncbi.nlm.nih.gov/10857466

DM9VEAL	DI	DM9VEAL
DM9VEAL	DN	NPC-1C
DM9VEAL	MI	TT34I9F
DM9VEAL	MN	Neoplasm antigen (NA)
DM9VEAL	MT	DTT
DM9VEAL	RN	National Cancer Institute Drug Dictionary (drug id 663436).
DM9VEAL	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=663436

DM3DQXG	DI	DM3DQXG
DM3DQXG	DN	NPSP-795
DM3DQXG	MI	TTEPJL5
DM3DQXG	MN	Parathyroid hormone receptor (PTH2R)
DM3DQXG	MT	DTT
DM3DQXG	MA	Modulator
DM3DQXG	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 332).
DM3DQXG	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=332

DMYXOU2	DI	DMYXOU2
DMYXOU2	DN	NRX-4204
DMYXOU2	MI	TTH029C
DMYXOU2	MN	Retinoic acid receptor RXR-gamma (RXRG)
DMYXOU2	MT	DTT
DMYXOU2	MA	Modulator
DMYXOU2	RN	DOI: 10.1038/scibx.2010.766
DMYXOU2	RU	http://www.nature.com/scibx/journal/v3/n25/full/scibx.2010.766.html

DM9EFH0	DI	DM9EFH0
DM9EFH0	DN	NS 1209
DM9EFH0	MI	TT0MYE2
DM9EFH0	MN	Glutamate receptor ionotropic kainate 1 (GRIK1)
DM9EFH0	MT	DTT
DM9EFH0	MA	Modulator
DM9EFH0	RN	The efficacy of the AMPA receptor antagonist NS1209 and lidocaine in nerve injury pain: a randomized, double-blind, placebo-controlled, three-way crossover study. Anesth Analg. 2009 Apr;108(4):1311-9.
DM9EFH0	RU	https://pubmed.ncbi.nlm.nih.gov/19299805

DMI5HFU	DI	DMI5HFU
DMI5HFU	DN	NS 2359
DMI5HFU	MI	TTVBI8W
DMI5HFU	MN	Dopamine transporter (DAT)
DMI5HFU	MT	DTT
DMI5HFU	MA	Inhibitor
DMI5HFU	RN	Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
DMI5HFU	RU	https://pubmed.ncbi.nlm.nih.gov/18172433

DMI5HFU	DI	DMI5HFU
DMI5HFU	DN	NS 2359
DMI5HFU	MI	TTAWNKZ
DMI5HFU	MN	Norepinephrine transporter (NET)
DMI5HFU	MT	DTT
DMI5HFU	MA	Inhibitor
DMI5HFU	RN	Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
DMI5HFU	RU	https://pubmed.ncbi.nlm.nih.gov/18172433

DMI5HFU	DI	DMI5HFU
DMI5HFU	DN	NS 2359
DMI5HFU	MI	TT3ROYC
DMI5HFU	MN	Serotonin transporter (SERT)
DMI5HFU	MT	DTT
DMI5HFU	MA	Inhibitor
DMI5HFU	RN	Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
DMI5HFU	RU	https://pubmed.ncbi.nlm.nih.gov/18172433

DMMUR6V	DI	DMMUR6V
DMMUR6V	DN	NS-2710
DMMUR6V	MI	TT37EDJ
DMMUR6V	MN	GABA(A) receptor alpha-3 (GABRA3)
DMMUR6V	MT	DTT
DMMUR6V	MA	Modulator
DMMUR6V	RN	GABAA receptor subtype-selective modulators. I. alpha2/alpha3-selective agonists as non-sedating anxiolytics. Curr Top Med Chem. 2011;11(9):1176-202.
DMMUR6V	RU	https://pubmed.ncbi.nlm.nih.gov/21050172

DM3H82Q	DI	DM3H82Q
DM3H82Q	DN	NS-7
DM3H82Q	MI	TTRK8B9
DM3H82Q	MN	Sodium channel unspecific (NaC)
DM3H82Q	MT	DTT
DM3H82Q	MA	Modulator
DM3H82Q	RN	Preferential inhibition by a novel Na(+)/Ca(2+) channel blocker NS-7 of severe to mild hypoxic injury in rat cerebrocortical slices: A possible involvement of a highly voltage-dependent blockade of Ca(2+) channel. J Pharmacol Exp Ther. 2000 May;293(2):522-9.
DM3H82Q	RU	https://pubmed.ncbi.nlm.nih.gov/10773024

DMPJQZG	DI	DMPJQZG
DMPJQZG	DN	NSC-645809
DMPJQZG	MI	DTI7UX6
DMPJQZG	MN	Breast cancer resistance protein (ABCG2)
DMPJQZG	MT	DTP
DMPJQZG	MA	Substrate
DMPJQZG	RN	C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells. Biochem Pharmacol. 2007 Jun 30;74(1):41-53.
DMPJQZG	RU	https://doi.org/10.1016/j.bcp.2007.03.028

DMPJQZG	DI	DMPJQZG
DMPJQZG	DN	NSC-645809
DMPJQZG	MI	TTJLP0R
DMPJQZG	MN	Quinone reductase 2 (NQO2)
DMPJQZG	MT	DTT
DMPJQZG	MA	Inhibitor
DMPJQZG	RN	Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2. Bioorg Med Chem Lett. 2010 May 1;20(9):2832-6.
DMPJQZG	RU	https://pubmed.ncbi.nlm.nih.gov/20356739

DMRYLBW	DI	DMRYLBW
DMRYLBW	DN	NTO-1151
DMRYLBW	MI	TTRBUYN
DMRYLBW	MN	Ribonuclease (RNase)
DMRYLBW	MT	DTT
DMRYLBW	MA	Modulator
DMRYLBW	RN	Clinical pipeline report, company report or official report of Nanotherapeutics.
DMRYLBW	RU	http://www.nanotherapeutics.com/triapine/

DMORNVB	DI	DMORNVB
DMORNVB	DN	NU-172
DMORNVB	MI	TT6L509
DMORNVB	MN	Coagulation factor IIa (F2)
DMORNVB	MT	DTT
DMORNVB	MA	Inhibitor
DMORNVB	RN	Nucleic acid aptamers: clinical applications and promising new horizons. Curr Med Chem. 2011; 18(27): 4206-4214.
DMORNVB	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3260938/

DMO0C5R	DI	DMO0C5R
DMO0C5R	DN	NU300
DMO0C5R	MI	TTC6JZQ
DMO0C5R	MN	Haemophilus influenzae CRM197 (Hae-influ CRM197)
DMO0C5R	MT	DTT
DMO0C5R	MA	Modulator
DMO0C5R	RN	ClinicalTrials.gov (NCT02140047) Exploratory Clinical Study of MT-2301. U.S. National Institutes of Health.
DMO0C5R	RU	https://clinicaltrials.gov/ct2/show/NCT02140047

DMOJA5G	DI	DMOJA5G
DMOJA5G	DN	Nuplazid
DMOJA5G	MI	TTJQOD7
DMOJA5G	MN	5-HT 2A receptor (HTR2A)
DMOJA5G	MT	DTT
DMOJA5G	MA	Agonist
DMOJA5G	RN	The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug. Psychopharmacology (Berl). 2018 Nov;235(11):3083-3091.
DMOJA5G	RU	https://pubmed.ncbi.nlm.nih.gov/30288594

DMOJA5G	DI	DMOJA5G
DMOJA5G	DN	Nuplazid
DMOJA5G	MI	TTWJBZ5
DMOJA5G	MN	5-HT 2C receptor (HTR2C)
DMOJA5G	MT	DTT
DMOJA5G	MA	Agonist
DMOJA5G	RN	The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug. Psychopharmacology (Berl). 2018 Nov;235(11):3083-3091.
DMOJA5G	RU	https://pubmed.ncbi.nlm.nih.gov/30288594

DMTYXQF	DI	DMTYXQF
DMTYXQF	DN	NVP-AUY922
DMTYXQF	MI	TT78R5H
DMTYXQF	MN	Heat shock protein 90 alpha (HSP90A)
DMTYXQF	MT	DTT
DMTYXQF	MA	Inhibitor
DMTYXQF	RN	Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008 Oct;8(7):761-82.
DMTYXQF	RU	https://pubmed.ncbi.nlm.nih.gov/18855578

DM2UJ1H	DI	DM2UJ1H
DM2UJ1H	DN	NW-3509
DM2UJ1H	MI	TTRK8B9
DM2UJ1H	MN	Sodium channel unspecific (NaC)
DM2UJ1H	MT	DTT
DM2UJ1H	MA	Blocker
DM2UJ1H	RN	Clinical pipeline report, company report or official report of Newron.
DM2UJ1H	RU	http://www.newron.com/eng/Default.aspx?SEZ=3&PAG=52

DMMBAIH	DI	DMMBAIH
DMMBAIH	DN	NXN-188
DMMBAIH	MI	TTK8CXU
DMMBAIH	MN	5-HT 1B receptor (HTR1B)
DMMBAIH	MT	DTT
DMMBAIH	MA	Modulator
DMMBAIH	RN	Company report (NeurAxon)
DMMBAIH	RU	http://www.neuraxon.com/103110.html

DMMBAIH	DI	DMMBAIH
DMMBAIH	DN	NXN-188
DMMBAIH	MI	TT6MSOK
DMMBAIH	MN	5-HT 1D receptor (HTR1D)
DMMBAIH	MT	DTT
DMMBAIH	MA	Modulator
DMMBAIH	RN	Company report (NeurAxon)
DMMBAIH	RU	http://www.neuraxon.com/103110.html

DMMBAIH	DI	DMMBAIH
DMMBAIH	DN	NXN-188
DMMBAIH	MI	TTZUFI5
DMMBAIH	MN	Nitric-oxide synthase brain (NOS1)
DMMBAIH	MT	DTT
DMMBAIH	MA	Inhibitor
DMMBAIH	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMMBAIH	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMWVBS2	DI	DMWVBS2
DMWVBS2	DN	NXN-462
DMWVBS2	MI	TTZUFI5
DMWVBS2	MN	Nitric-oxide synthase brain (NOS1)
DMWVBS2	MT	DTT
DMWVBS2	MA	Inhibitor
DMWVBS2	RN	ClinicalTrials.gov (NCT01748877) Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia. U.S. National Institutes of Health.
DMWVBS2	RU	https://clinicaltrials.gov/ct2/show/NCT01748877

DM1P60V	DI	DM1P60V
DM1P60V	DN	NYX-2925
DM1P60V	MI	TT9IK2Z
DM1P60V	MN	N-methyl-D-aspartate receptor (NMDAR)
DM1P60V	MT	DTT
DM1P60V	MA	Modulator
DM1P60V	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM1P60V	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMX04O8	DI	DMX04O8
DMX04O8	DN	NYX-2925
DMX04O8	MI	TT9IK2Z
DMX04O8	MN	N-methyl-D-aspartate receptor (NMDAR)
DMX04O8	MT	DTT
DMX04O8	MA	Modulator
DMX04O8	RN	NYX-2925 Is a Novel N-Methyl-d-Aspartate Receptor Modulator that Induces Rapid and Long-Lasting Analgesia in Rat Models of Neuropathic Pain. J Pharmacol Exp Ther. 2018 Sep;366(3):485-497.
DMX04O8	RU	https://pubmed.ncbi.nlm.nih.gov/29986951

DMAVM2E	DI	DMAVM2E
DMAVM2E	DN	NYX-783
DMAVM2E	MI	TT9IK2Z
DMAVM2E	MN	N-methyl-D-aspartate receptor (NMDAR)
DMAVM2E	MT	DTT
DMAVM2E	MA	Modulator
DMAVM2E	RN	Clinical pipeline report, company report or official report of Aptinyx.
DMAVM2E	RU	https://www.aptinyx.com/pipeline/

DMXM34I	DI	DMXM34I
DMXM34I	DN	O-304
DMXM34I	MI	TTLAFZV
DMXM34I	MN	AMP-activated protein kinase (AMPK)
DMXM34I	MT	DTT
DMXM34I	MA	Activator
DMXM34I	RN	Clinical pipeline report, company report or official report of Betagenon.
DMXM34I	RU	https://betagenon.com/research-development/o304-our-ampk-activator

DMPF9ZM	DI	DMPF9ZM
DMPF9ZM	DN	Obatoclax
DMPF9ZM	MI	TTJGNVC
DMPF9ZM	MN	Apoptosis regulator Bcl-2 (BCL-2)
DMPF9ZM	MT	DTT
DMPF9ZM	MA	Inhibitor
DMPF9ZM	RN	Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):285-9.
DMPF9ZM	RU	https://pubmed.ncbi.nlm.nih.gov/20709666

DMPF9ZM	DI	DMPF9ZM
DMPF9ZM	DN	Obatoclax
DMPF9ZM	MI	TTU1E82
DMPF9ZM	MN	Apoptosis regulator Bcl-xL (BCL-xL)
DMPF9ZM	MT	DTT
DMPF9ZM	MA	Inhibitor
DMPF9ZM	RN	Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):285-9.
DMPF9ZM	RU	https://pubmed.ncbi.nlm.nih.gov/20709666

DMPF9ZM	DI	DMPF9ZM
DMPF9ZM	DN	Obatoclax
DMPF9ZM	MI	TTL53M6
DMPF9ZM	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DMPF9ZM	MT	DTT
DMPF9ZM	MA	Inhibitor
DMPF9ZM	RN	Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):285-9.
DMPF9ZM	RU	https://pubmed.ncbi.nlm.nih.gov/20709666

DMJIBSG	DI	DMJIBSG
DMJIBSG	DN	OBE-101
DMJIBSG	MI	TTTIBOJ
DMJIBSG	MN	Histamine H1 receptor (H1R)
DMJIBSG	MT	DTT
DMJIBSG	MA	Modulator
DMJIBSG	RN	Betahistine in the treatment of M ni re's disease. Neuropsychiatr Dis Treat. 2007 August; 3(4): 429-440.
DMJIBSG	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2655085/

DM5D6Y7	DI	DM5D6Y7
DM5D6Y7	DN	OBI-3424
DM5D6Y7	MI	TTUTN1I
DM5D6Y7	MN	Human Deoxyribonucleic acid (hDNA)
DM5D6Y7	MT	DTT
DM5D6Y7	RN	OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL. Clin Cancer Res. 2019 Jul 15;25(14):4493-4503.
DM5D6Y7	RU	https://pubmed.ncbi.nlm.nih.gov/31015346

DMVXZC4	DI	DMVXZC4
DMVXZC4	DN	OBP-601
DMVXZC4	MI	TT84ETX
DMVXZC4	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMVXZC4	MT	DTT
DMVXZC4	MA	Inhibitor
DMVXZC4	RN	Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2012 Oct;56(10):5000-8.
DMVXZC4	RU	https://pubmed.ncbi.nlm.nih.gov/22733071

DM1JBD8	DI	DM1JBD8
DM1JBD8	DN	OC-000459
DM1JBD8	MI	TTQDMX5
DM1JBD8	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DM1JBD8	MT	DTT
DM1JBD8	MA	Antagonist
DM1JBD8	RN	Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis. Allergy. 2013 Mar;68(3):375-85.
DM1JBD8	RU	https://pubmed.ncbi.nlm.nih.gov/23379537

DMP6B59	DI	DMP6B59
DMP6B59	DN	Ocaperidone
DMP6B59	MI	TTJQOD7
DMP6B59	MN	5-HT 2A receptor (HTR2A)
DMP6B59	MT	DTT
DMP6B59	MA	Modulator
DMP6B59	RN	Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598). J Pharmacol Exp Ther. 1992 Jan;260(1):146-59.
DMP6B59	RU	https://pubmed.ncbi.nlm.nih.gov/1370538

DMP6B59	DI	DMP6B59
DMP6B59	DN	Ocaperidone
DMP6B59	MI	TTSECX1
DMP6B59	MN	Connective tissue growth factor (CTGF)
DMP6B59	MT	DTT
DMP6B59	MA	Inhibitor
DMP6B59	RN	Current and emerging drugs for idiopathic pulmonary fibrosis. Expert Opin Emerg Drugs. 2007 Nov;12(4):627-46.
DMP6B59	RU	https://pubmed.ncbi.nlm.nih.gov/17979604

DMP6B59	DI	DMP6B59
DMP6B59	DN	Ocaperidone
DMP6B59	MI	TTEX248
DMP6B59	MN	Dopamine D2 receptor (D2R)
DMP6B59	MT	DTT
DMP6B59	MA	Modulator
DMP6B59	RN	Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598). J Pharmacol Exp Ther. 1992 Jan;260(1):146-59.
DMP6B59	RU	https://pubmed.ncbi.nlm.nih.gov/1370538

DM8TDBY	DI	DM8TDBY
DM8TDBY	DN	OCFENTANIL
DM8TDBY	MI	TTN4QDT
DM8TDBY	MN	Opioid receptor (OPR)
DM8TDBY	MT	DTT
DM8TDBY	MA	Modulator
DM8TDBY	RN	Comparison of ocfentanil and fentanyl as supplements to general anesthesia. Anesth Analg. 1991 Nov;73(5):622-6.
DM8TDBY	RU	https://pubmed.ncbi.nlm.nih.gov/1952145

DMT9QI2	DI	DMT9QI2
DMT9QI2	DN	OCV-101
DMT9QI2	MI	TT2Q6G1
DMT9QI2	MN	Vascular endothelial growth factor receptor 1 (FLT-1)
DMT9QI2	MT	DTT
DMT9QI2	MA	Modulator
DMT9QI2	RN	Phase I trial of OTS11101, an anti-angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor.Cancer Sci.2013 Jan;104(1):98-104.
DMT9QI2	RU	https://www.ncbi.nlm.nih.gov/pubmed/23020774

DMK0MJP	DI	DMK0MJP
DMK0MJP	DN	Odelepran
DMK0MJP	MI	TTN4QDT
DMK0MJP	MN	Opioid receptor (OPR)
DMK0MJP	MT	DTT
DMK0MJP	MA	Antagonist
DMK0MJP	RN	A phase 2, placebo-controlled study of the opioid receptor antagonist LY2196044 for the treatment of alcohol dependence. Alcohol Clin Exp Res. 2014 Feb;38(2):511-20.
DMK0MJP	RU	https://pubmed.ncbi.nlm.nih.gov/24010675

DMJL4A7	DI	DMJL4A7
DMJL4A7	DN	O-desulfated heparin
DMJL4A7	MI	TT4QPUL
DMJL4A7	MN	Antithrombin-III (ATIII)
DMJL4A7	MT	DTT
DMJL4A7	MA	Modulator
DMJL4A7	RN	Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. J Clin Invest. 1981 Jan;67(1):223-8.
DMJL4A7	RU	https://pubmed.ncbi.nlm.nih.gov/6778897

DMWCBY7	DI	DMWCBY7
DMWCBY7	DN	Odiparcil
DMWCBY7	MI	TT6L509
DMWCBY7	MN	Coagulation factor IIa (F2)
DMWCBY7	MT	DTT
DMWCBY7	MA	Inhibitor
DMWCBY7	RN	A comparison of the beta-D-xyloside, odiparcil, to warfarin in a rat model of venous thrombosis. J Thromb Haemost. 2006 Sep;4(9):1989-96.
DMWCBY7	RU	https://pubmed.ncbi.nlm.nih.gov/16961606

DMVC90W	DI	DMVC90W
DMVC90W	DN	Oglemilast
DMVC90W	MI	TTZ97H5
DMVC90W	MN	Phosphodiesterase 4A (PDE4A)
DMVC90W	MT	DTT
DMVC90W	MA	Inhibitor
DMVC90W	RN	Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking . Br J Pharmacol. 2008 October; 155(3): 288-290.
DMVC90W	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2567889/

DMVC90W	DI	DMVC90W
DMVC90W	DN	Oglemilast
DMVC90W	MI	TTVIAT9
DMVC90W	MN	Phosphodiesterase 4B (PDE4B)
DMVC90W	MT	DTT
DMVC90W	MA	Inhibitor
DMVC90W	RN	Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking . Br J Pharmacol. 2008 October; 155(3): 288-290.
DMVC90W	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2567889/

DMVC90W	DI	DMVC90W
DMVC90W	DN	Oglemilast
DMVC90W	MI	TTSKMI8
DMVC90W	MN	Phosphodiesterase 4D (PDE4D)
DMVC90W	MT	DTT
DMVC90W	MA	Inhibitor
DMVC90W	RN	Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking . Br J Pharmacol. 2008 October; 155(3): 288-290.
DMVC90W	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2567889/

DMJTU8D	DI	DMJTU8D
DMJTU8D	DN	OGX-427
DMJTU8D	MI	TTMG98T
DMJTU8D	MN	Heat shock protein 27 (HSP27)
DMJTU8D	MT	DTT
DMJTU8D	MA	Modulator
DMJTU8D	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMJTU8D	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMNEHY1	DI	DMNEHY1
DMNEHY1	DN	OI338GT
DMNEHY1	MI	TTVIMDE
DMNEHY1	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMNEHY1	MT	DTT
DMNEHY1	MA	Modulator
DMNEHY1	RN	Clinical pipeline report, company report or official report of Novo Nordisk A/S.
DMNEHY1	RU	http://www.novonordisk.com/bin/getPDF.1781915.pdf

DMVW5KR	DI	DMVW5KR
DMVW5KR	DN	Olcegepant
DMVW5KR	MI	TTY6O0Q
DMVW5KR	MN	Calcitonin gene-related peptide receptor (CGRPR)
DMVW5KR	MT	DTT
DMVW5KR	MA	Modulator
DMVW5KR	RN	Olcegepant, a non-peptide CGRP1 antagonist for migraine treatment. IDrugs. 2007 Aug;10(8):566-74.
DMVW5KR	RU	https://www.ncbi.nlm.nih.gov/pubmed/17665333

DM0RA8F	DI	DM0RA8F
DM0RA8F	DN	Oleoyl-estrone
DM0RA8F	MI	TTXJ47W
DM0RA8F	MN	Metabotropic glutamate receptor 2 (mGluR2)
DM0RA8F	MT	DTT
DM0RA8F	MA	Agonist
DM0RA8F	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM0RA8F	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM0RA8F	DI	DM0RA8F
DM0RA8F	DN	Oleoyl-estrone
DM0RA8F	MI	TT8A9EF
DM0RA8F	MN	Metabotropic glutamate receptor 3 (mGluR3)
DM0RA8F	MT	DTT
DM0RA8F	MA	Agonist
DM0RA8F	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM0RA8F	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMXL7HO	DI	DMXL7HO
DMXL7HO	DN	OLX10010
DMXL7HO	MI	TTIL516
DMXL7HO	MN	CCN2 messenger RNA (CCN2 mRNA)
DMXL7HO	MT	DTT
DMXL7HO	MA	Inhibitor
DMXL7HO	RN	Clinical pipeline report, company report or official report of Olix Pharmaceuticals.
DMXL7HO	RU	https://www.olixpharma.com/eng/rnd/rnd03_olx101a.php

DMLMNFX	DI	DMLMNFX
DMLMNFX	DN	Omaveloxolone
DMLMNFX	MI	TTA6ZN2
DMLMNFX	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMLMNFX	MT	DTT
DMLMNFX	MA	Activator
DMLMNFX	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMLMNFX	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMH9RTV	DI	DMH9RTV
DMH9RTV	DN	Omigapil
DMH9RTV	MI	TTUGSWA
DMH9RTV	MN	Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
DMH9RTV	MT	DTT
DMH9RTV	MA	Modulator
DMH9RTV	RN	Neuroprotection by pharmacologic blockade of the GAPDH death cascade. Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3887-9.
DMH9RTV	RU	https://pubmed.ncbi.nlm.nih.gov/16505364

DMWC36Y	DI	DMWC36Y
DMWC36Y	DN	OMS405
DMWC36Y	MI	TTZMAO3
DMWC36Y	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMWC36Y	MT	DTT
DMWC36Y	MA	Agonist
DMWC36Y	RN	Clinical pipeline report, company report or official report of Avarx.
DMWC36Y	RU	http://www.avarx.com/AvaRx/SubDomains/bucket4984694478449561395/Listings/bucket4040741479008611375/Public.Listing.display.html

DMA4OGL	DI	DMA4OGL
DMA4OGL	DN	OMS824
DMA4OGL	MI	TTJW4LU
DMA4OGL	MN	Phosphodiesterase 10A (PDE10)
DMA4OGL	MT	DTT
DMA4OGL	MA	Inhibitor
DMA4OGL	RN	New Drugs/Drug News. P T. 2013 November; 38(11): 667-672.
DMA4OGL	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875261/

DMT6E5N	DI	DMT6E5N
DMT6E5N	DN	Onapristone
DMT6E5N	MI	DE4LYSA
DMT6E5N	MN	Cytochrome P450 3A4 (CYP3A4)
DMT6E5N	MT	DME
DMT6E5N	MA	Metabolism
DMT6E5N	RN	Drug-metabolizing enzymes and transporters: expression in the human prostate and roles in prostate drug disposition. J Androl. 2006 Mar-Apr;27(2):138-50.
DMT6E5N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16330661

DMT6E5N	DI	DMT6E5N
DMT6E5N	DN	Onapristone
DMT6E5N	MI	TTUV8G9
DMT6E5N	MN	Progesterone receptor (PGR)
DMT6E5N	MT	DTT
DMT6E5N	MA	Modulator
DMT6E5N	RN	Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer. Eur J Cancer. 1999 Feb;35(2):214-8.
DMT6E5N	RU	https://www.ncbi.nlm.nih.gov/pubmed/10448262

DMM5SCF	DI	DMM5SCF
DMM5SCF	DN	ONC201
DMM5SCF	MI	TTEX248
DMM5SCF	MN	Dopamine D2 receptor (D2R)
DMM5SCF	MT	DTT
DMM5SCF	MA	Antagonist
DMM5SCF	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMM5SCF	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMM5SCF	DI	DMM5SCF
DMM5SCF	DN	ONC201
DMM5SCF	MI	TT4C8EA
DMM5SCF	MN	Dopamine D3 receptor (D3R)
DMM5SCF	MT	DTT
DMM5SCF	MA	Antagonist
DMM5SCF	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMM5SCF	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMM5SCF	DI	DMM5SCF
DMM5SCF	DN	ONC201
DMM5SCF	MI	TTWFZ1N
DMM5SCF	MN	Dopamine receptor (DR)
DMM5SCF	MT	DTT
DMM5SCF	MA	Antagonist
DMM5SCF	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMM5SCF	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMKIZAL	DI	DMKIZAL
DMKIZAL	DN	ONO-1603
DMKIZAL	MI	TTNGKET
DMKIZAL	MN	Prolyl endopeptidase (PREP)
DMKIZAL	MT	DTT
DMKIZAL	MA	Modulator
DMKIZAL	RN	ONO-1603, a potential antidementia drug, shows neuroprotective effects and increases m3-muscarinic receptor mRNA levels in differentiating rat cerebellar granule neurons. Neurosci Lett. 1996 Aug 23;214(2-3):151-4.
DMKIZAL	RU	https://pubmed.ncbi.nlm.nih.gov/8878106

DMOT0WR	DI	DMOT0WR
DMOT0WR	DN	ONO-2333Ms
DMOT0WR	MI	TT7EFHR
DMOT0WR	MN	Corticotropin-releasing factor receptor 1 (CRHR1)
DMOT0WR	MT	DTT
DMOT0WR	MA	Antagonist
DMOT0WR	RN	Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism. Drug Alcohol Depend. 2013 Mar 1;128(3):175-86.
DMOT0WR	RU	https://pubmed.ncbi.nlm.nih.gov/23294766

DMOGYQ0	DI	DMOGYQ0
DMOGYQ0	DN	ONO-2952
DMOGYQ0	MI	TTPTXIN
DMOGYQ0	MN	Translocator protein (TSPO)
DMOGYQ0	MT	DTT
DMOGYQ0	MA	Antagonist
DMOGYQ0	RN	Anti-stress effects of ONO-2952, a novel translocator protein 18 kDa antagonist, in rats. Neuropharmacology. 2015 Jul 17;99:51-66.
DMOGYQ0	RU	https://pubmed.ncbi.nlm.nih.gov/26189762

DMQGO74	DI	DMQGO74
DMQGO74	DN	ONO-3307
DMQGO74	MI	TTZBFA0
DMQGO74	MN	Protease unspecific (PRO)
DMQGO74	MT	DTT
DMQGO74	MA	Modulator
DMQGO74	RN	Inhibitory effects of ONO-3307 on various proteases and tissue thromboplastin in vitro and on experimental thrombosis in vivo. Jpn J Pharmacol. 1989 Dec;51(4):455-63.
DMQGO74	RU	https://pubmed.ncbi.nlm.nih.gov/2515329

DMX4MVP	DI	DMX4MVP
DMX4MVP	DN	ONO-4053
DMX4MVP	MI	TTNVEIR
DMX4MVP	MN	Prostaglandin D2 receptor (PTGDR)
DMX4MVP	MT	DTT
DMX4MVP	MA	Antagonist
DMX4MVP	RN	Effect of ONO-4053, a DP1 (prostaglandin D2 receptor) Antagonist, on Prostaglandin D2-Induced Nasal Congestion. Journal of Allergy and Clinical Immunology Volume 135, Issue 2, Supplement, February 2015, Pages AB219.
DMX4MVP	RU	http://www.sciencedirect.com/science/article/pii/S0091674914034332

DMLUM3Y	DI	DMLUM3Y
DMLUM3Y	DN	ONO-4641
DMLUM3Y	MI	TT9JZCK
DMLUM3Y	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMLUM3Y	MT	DTT
DMLUM3Y	MA	Agonist
DMLUM3Y	RN	Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702.
DMLUM3Y	RU	https://pubmed.ncbi.nlm.nih.gov/23954895

DMFX3P1	DI	DMFX3P1
DMFX3P1	DN	ONO-5129
DMFX3P1	MI	TTJ584C
DMFX3P1	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMFX3P1	MT	DTT
DMFX3P1	MA	Modulator
DMFX3P1	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMFX3P1	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMFX3P1	DI	DMFX3P1
DMFX3P1	DN	ONO-5129
DMFX3P1	MI	TTZMAO3
DMFX3P1	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMFX3P1	MT	DTT
DMFX3P1	MA	Modulator
DMFX3P1	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMFX3P1	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMRT28X	DI	DMRT28X
DMRT28X	DN	ONO-6126
DMRT28X	MI	DTUGYRD
DMRT28X	MN	P-glycoprotein 1 (ABCB1)
DMRT28X	MT	DTP
DMRT28X	MA	Substrate
DMRT28X	RN	Fingerprint-based in silico models for the prediction of P-glycoprotein substrates and inhibitors. Bioorg Med Chem. 2012 Sep 15;20(18):5388-95.
DMRT28X	RU	https://doi.org/10.1016/j.bmc.2012.03.045

DMRT28X	DI	DMRT28X
DMRT28X	DN	ONO-6126
DMRT28X	MI	TTV5CGO
DMRT28X	MN	Phosphodiesterase 4 (PDE4)
DMRT28X	MT	DTT
DMRT28X	MA	Inhibitor
DMRT28X	RN	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
DMRT28X	RU	https://pubmed.ncbi.nlm.nih.gov/16634702

DM5O6GC	DI	DM5O6GC
DM5O6GC	DN	ONO-9054
DM5O6GC	MI	TTPNGDE
DM5O6GC	MN	Prostaglandin E2 receptor EP3 (PTGER3)
DM5O6GC	MT	DTT
DM5O6GC	MA	Modulator
DM5O6GC	RN	IOP-Lowering Effect of ONO-9054, A Novel Dual Agonist of Prostanoid EP3 and FP Receptors, in Monkeys. Invest Ophthalmol Vis Sci. 2015 Apr;56(4):2547-52.
DM5O6GC	RU	https://pubmed.ncbi.nlm.nih.gov/25788650

DM5O6GC	DI	DM5O6GC
DM5O6GC	DN	ONO-9054
DM5O6GC	MI	TTT2ZAR
DM5O6GC	MN	Prostaglandin F2-alpha receptor (PTGFR)
DM5O6GC	MT	DTT
DM5O6GC	MA	Modulator
DM5O6GC	RN	IOP-Lowering Effect of ONO-9054, A Novel Dual Agonist of Prostanoid EP3 and FP Receptors, in Monkeys. Invest Ophthalmol Vis Sci. 2015 Apr;56(4):2547-52.
DM5O6GC	RU	https://pubmed.ncbi.nlm.nih.gov/25788650

DMCUGI8	DI	DMCUGI8
DMCUGI8	DN	ONO-AE1-437
DMCUGI8	MI	TT79WV3
DMCUGI8	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DMCUGI8	MT	DTT
DMCUGI8	MA	Agonist
DMCUGI8	RN	An EP4 receptor agonist prevents indomethacin-induced closure of rat ductus arteriosus in vivo. Pediatr Res. 2004 Oct;56(4):586-90.
DMCUGI8	RU	https://pubmed.ncbi.nlm.nih.gov/15295094

DMS8Q7A	DI	DMS8Q7A
DMS8Q7A	DN	Ontazolast
DMS8Q7A	MI	TTTWGIX
DMS8Q7A	MN	Leukotriene receptor (LTR)
DMS8Q7A	MT	DTT
DMS8Q7A	MA	Modulator
DMS8Q7A	RN	Effects of progesterone and leukotriene receptor antagonists in experimental models of P-glycoprotein-related resistance. Eur J Med Res. 1997 Apr 21;2(4):159-64.
DMS8Q7A	RU	https://pubmed.ncbi.nlm.nih.gov/9110922

DM0FJIE	DI	DM0FJIE
DM0FJIE	DN	Ontuxizumab
DM0FJIE	MI	TTYJWT7
DM0FJIE	MN	Endosialin (CD248)
DM0FJIE	MT	DTT
DM0FJIE	MA	Inhibitor
DM0FJIE	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM0FJIE	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMB1WF3	DI	DMB1WF3
DMB1WF3	DN	OPC-14523
DMB1WF3	MI	TTSQIFT
DMB1WF3	MN	5-HT 1A receptor (HTR1A)
DMB1WF3	MT	DTT
DMB1WF3	MA	Modulator
DMB1WF3	RN	Antidepressant-like responses to the combined sigma and 5-HT1A receptor agonist OPC-14523. Neuropharmacology. 2001 Dec;41(8):976-88.
DMB1WF3	RU	https://www.ncbi.nlm.nih.gov/pubmed/11747902

DMB1WF3	DI	DMB1WF3
DMB1WF3	DN	OPC-14523
DMB1WF3	MI	TT5TPI6
DMB1WF3	MN	Opioid receptor sigma 1 (OPRS1)
DMB1WF3	MT	DTT
DMB1WF3	MA	Modulator
DMB1WF3	RN	Antidepressant-like responses to the combined sigma and 5-HT1A receptor agonist OPC-14523. Neuropharmacology. 2001 Dec;41(8):976-88.
DMB1WF3	RU	https://www.ncbi.nlm.nih.gov/pubmed/11747902

DMIK2AD	DI	DMIK2AD
DMIK2AD	DN	OPC-64005
DMIK2AD	MI	TT8G3Z7
DMIK2AD	MN	Serotoninnorepinephrinedopamine reuptake (SNDR)
DMIK2AD	MT	DTT
DMIK2AD	MA	Inhibitor
DMIK2AD	RN	Clinical pipeline report, company report or official report of Otsuka Pharmaceutical.
DMIK2AD	RU	https://www.otsuka.co.jp/en/research-and-development/pipeline/

DML6TAS	DI	DML6TAS
DML6TAS	DN	OPI-1002
DML6TAS	MI	TT12KOD
DML6TAS	MN	P53 messenger RNA (TP53 mRNA)
DML6TAS	MT	DTT
DML6TAS	RN	2011 Pipeline of Quark Pharm.
DML6TAS	RU	http://www.quarkpharma.com/qbi-en/home/homepage/

DM1IBRT	DI	DM1IBRT
DM1IBRT	DN	OPN-305
DM1IBRT	MI	TTY7ZHS
DM1IBRT	MN	Toll-like receptor 2 (TLR2)
DM1IBRT	MT	DTT
DM1IBRT	RN	Treatment with OPN-305, a humanized anti-Toll-Like receptor-2 antibody, reduces myocardial ischemia/reperfusion injury in pigs. Circ Cardiovasc Interv. 2012 Apr;5(2):279-87.
DM1IBRT	RU	https://pubmed.ncbi.nlm.nih.gov/22354933

DMYG1ZQ	DI	DMYG1ZQ
DMYG1ZQ	DN	OPNT001
DMYG1ZQ	MI	TTKWM86
DMYG1ZQ	MN	Opioid receptor mu (MOP)
DMYG1ZQ	MT	DTT
DMYG1ZQ	MA	Antagonist
DMYG1ZQ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMYG1ZQ	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DM16RIC	DI	DM16RIC
DM16RIC	DN	Oprozomib
DM16RIC	MI	TTU7ZMG
DM16RIC	MN	Proteasome (PS)
DM16RIC	MT	DTT
DM16RIC	MA	Modulator
DM16RIC	RN	A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood. 2010 Dec 2;116(23):4906-15.
DM16RIC	RU	https://pubmed.ncbi.nlm.nih.gov/20805366

DMS4XFI	DI	DMS4XFI
DMS4XFI	DN	OPT-302
DMS4XFI	MI	TT0QUFV
DMS4XFI	MN	Vascular endothelial growth factor C (VEGFC)
DMS4XFI	MT	DTT
DMS4XFI	MA	Inhibitor
DMS4XFI	RN	Clinical pipeline report, company report or official report of Opthea.
DMS4XFI	RU	https://opthea.com/

DMS4XFI	DI	DMS4XFI
DMS4XFI	DN	OPT-302
DMS4XFI	MI	TTOM5H4
DMS4XFI	MN	Vascular endothelial growth factor D (VEGFD)
DMS4XFI	MT	DTT
DMS4XFI	MA	Inhibitor
DMS4XFI	RN	Clinical pipeline report, company report or official report of Opthea.
DMS4XFI	RU	https://opthea.com/

DMR3P98	DI	DMR3P98
DMR3P98	DN	ORG 34517/34850
DMR3P98	MI	TTYRL6O
DMR3P98	MN	Glucocorticoid receptor (NR3C1)
DMR3P98	MT	DTT
DMR3P98	MA	Antagonist
DMR3P98	RN	Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
DMR3P98	RU	https://pubmed.ncbi.nlm.nih.gov/18172433

DMR3P98	DI	DMR3P98
DMR3P98	DN	ORG 34517/34850
DMR3P98	MI	TTBFROQ
DMR3P98	MN	S-adenosylmethionine decarboxylase proenzyme (AMD1)
DMR3P98	MT	DTT
DMR3P98	MA	Inhibitor
DMR3P98	RN	A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumours. Br J Cancer. 2000 Sep;83(5):594-601.
DMR3P98	RU	https://pubmed.ncbi.nlm.nih.gov/10944598

DMAWXJT	DI	DMAWXJT
DMAWXJT	DN	ORG-13011
DMAWXJT	MI	TTSQIFT
DMAWXJT	MN	5-HT 1A receptor (HTR1A)
DMAWXJT	MT	DTT
DMAWXJT	MA	Antagonist
DMAWXJT	RN	Antagonism of the 5-HT1A receptor stimulus in a conditioned taste aversion procedure. Eur Neuropsychopharmacol. 1999 Jun;9(4):345-9.
DMAWXJT	RU	https://pubmed.ncbi.nlm.nih.gov/10422896

DMWN2EC	DI	DMWN2EC
DMWN2EC	DN	ORG-25935
DMWN2EC	MI	TTHJTF7
DMWN2EC	MN	Glycine transporter GlyT-1 (SLC6A9)
DMWN2EC	MT	DTT
DMWN2EC	MA	Inhibitor
DMWN2EC	RN	The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trial. J Clin Psychopharmacol. 2014 Apr;34(2):190-8.
DMWN2EC	RU	https://pubmed.ncbi.nlm.nih.gov/24525661

DMDZ4R2	DI	DMDZ4R2
DMDZ4R2	DN	Org-30029
DMDZ4R2	MI	TTZCG4L
DMDZ4R2	MN	Phosphodiesterase 3 (PDE3)
DMDZ4R2	MT	DTT
DMDZ4R2	MA	Modulator
DMDZ4R2	RN	Effects of the positive inotropic agent Org 30029 on developed force and aequorin light transients in intact canine ventricular myocardium. Circ Res. 1993 Mar;72(3):597-606.
DMDZ4R2	RU	https://pubmed.ncbi.nlm.nih.gov/8431987

DMIO59F	DI	DMIO59F
DMIO59F	DN	ORG-34517
DMIO59F	MI	TTYRL6O
DMIO59F	MN	Glucocorticoid receptor (NR3C1)
DMIO59F	MT	DTT
DMIO59F	MA	Antagonist
DMIO59F	RN	Differential effects of the new glucocorticoid receptor antagonist ORG 34517 and RU486 (mifepristone) on glucocorticoid receptor nuclear translocation in the AtT20 cell line. Ann N Y Acad Sci. 2008 Dec;1148:536-41.
DMIO59F	RU	https://pubmed.ncbi.nlm.nih.gov/19120154

DM8ARQW	DI	DM8ARQW
DM8ARQW	DN	ORM-12741
DM8ARQW	MI	TT2NUT5
DM8ARQW	MN	Adrenergic receptor alpha-2C (ADRA2C)
DM8ARQW	MT	DTT
DM8ARQW	MA	Antagonist
DM8ARQW	RN	A double-blind, randomized, placebo-controlled crossover trial of the alpha2C-adrenoceptor antagonist ORM-12741 for prevention of cold-induced vasospasm in patients with systemic sclerosis. Rheumatology (Oxford). 2014 May;53(5):948-52.
DM8ARQW	RU	https://pubmed.ncbi.nlm.nih.gov/24489014

DMRIO6D	DI	DMRIO6D
DMRIO6D	DN	ORMD-0901
DMRIO6D	MI	TTVIMDE
DMRIO6D	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMRIO6D	MT	DTT
DMRIO6D	MA	Agonist
DMRIO6D	RN	Novel glucagon-like peptide-1 analog delivered orally reduces postprandial glucose excursions in porcine and canine models. J Diabetes Sci Technol. 2010 Nov 1;4(6):1516-23.
DMRIO6D	RU	https://pubmed.ncbi.nlm.nih.gov/21129350

DM1EK5D	DI	DM1EK5D
DM1EK5D	DN	Ortataxel
DM1EK5D	MI	DTI7UX6
DM1EK5D	MN	Breast cancer resistance protein (ABCG2)
DM1EK5D	MT	DTP
DM1EK5D	MA	Substrate
DM1EK5D	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM1EK5D	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DM1EK5D	DI	DM1EK5D
DM1EK5D	DN	Ortataxel
DM1EK5D	MI	TT0JLSD
DM1EK5D	MN	Multidrug resistance protein (MDR)
DM1EK5D	MT	DTT
DM1EK5D	MA	Modulator
DM1EK5D	RN	Clinical pipeline report, company report or official report of Spectrum Phamaceuticals (2009).
DM1EK5D	RU	http://www.spectrumpharm.com/products_Spectrum.html

DM1EK5D	DI	DM1EK5D
DM1EK5D	DN	Ortataxel
DM1EK5D	MI	TTF8CQI
DM1EK5D	MN	Tumor necrosis factor (TNF)
DM1EK5D	MT	DTT
DM1EK5D	MA	Inhibitor
DM1EK5D	RN	New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
DM1EK5D	RU	https://pubmed.ncbi.nlm.nih.gov/19265486

DMSO846	DI	DMSO846
DMSO846	DN	Orvepitant
DMSO846	MI	TTZPO1L
DMSO846	MN	Substance-P receptor (TACR1)
DMSO846	MT	DTT
DMSO846	MA	Antagonist
DMSO846	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMSO846	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMJX3O8	DI	DMJX3O8
DMJX3O8	DN	OSI-027
DMJX3O8	MI	TTCJG29
DMJX3O8	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMJX3O8	MT	DTT
DMJX3O8	MA	Inhibitor
DMJX3O8	RN	Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44.
DMJX3O8	RU	https://pubmed.ncbi.nlm.nih.gov/19644473

DMBVI6E	DI	DMBVI6E
DMBVI6E	DN	Ostabolin-C
DMBVI6E	MI	TT6F7GZ
DMBVI6E	MN	Parathyroid hormone (PTH)
DMBVI6E	MT	DTT
DMBVI6E	MA	Modulator
DMBVI6E	RN	ZT-031, a cyclized analog of parathyroid hormone(1-31) for the potential treatment of osteoporosis. IDrugs. 2008 Nov;11(11):827-40.
DMBVI6E	RU	https://www.ncbi.nlm.nih.gov/pubmed/18988128

DMHKIOF	DI	DMHKIOF
DMHKIOF	DN	OT551
DMHKIOF	MI	TTA6ZN2
DMHKIOF	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMHKIOF	MT	DTT
DMHKIOF	MA	Activator
DMHKIOF	RN	Nitroxide pharmaceutical development for age-related degeneration and disease. Front Genet. 2015 Nov 6;6:325.
DMHKIOF	RU	https://pubmed.ncbi.nlm.nih.gov/26594225

DMTNOXQ	DI	DMTNOXQ
DMTNOXQ	DN	OT-551
DMTNOXQ	MI	TTA6ZN2
DMTNOXQ	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMTNOXQ	MT	DTT
DMTNOXQ	MA	Inhibitor
DMTNOXQ	RN	New hope for dry AMD. Nat Rev Drug Discov. 2013 Jul;12(7):501-2.
DMTNOXQ	RU	https://pubmed.ncbi.nlm.nih.gov/23812264

DMFNDBC	DI	DMFNDBC
DMFNDBC	DN	Otelixizumab
DMFNDBC	MI	TTUN7MC
DMFNDBC	MN	T-cell surface glycoprotein CD3 (CD3)
DMFNDBC	MT	DTT
DMFNDBC	MA	Modulator
DMFNDBC	RN	Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.Diabetes Care.2014 Oct;37(10):2746-54.
DMFNDBC	RU	https://www.ncbi.nlm.nih.gov/pubmed/25011949

DM1AQLW	DI	DM1AQLW
DM1AQLW	DN	Otilimab
DM1AQLW	MI	TTPZGYX
DM1AQLW	MN	HUMAN colony-stimulating factor (GM-CSF)
DM1AQLW	MT	DTT
DM1AQLW	MA	Inhibitor
DM1AQLW	RN	The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. J Autoimmun. 2020 Apr 17:102468.
DM1AQLW	RU	https://pubmed.ncbi.nlm.nih.gov/32317220

DMAZIND	DI	DMAZIND
DMAZIND	DN	Otlertuzumab
DMAZIND	MI	TTFCW29
DMAZIND	MN	Leukocyte antigen CD37 (CD37)
DMAZIND	MT	DTT
DMAZIND	MA	Inhibitor
DMAZIND	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMAZIND	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM5Q9RY	DI	DM5Q9RY
DM5Q9RY	DN	OX-914
DM5Q9RY	MI	TTZ97H5
DM5Q9RY	MN	Phosphodiesterase 4A (PDE4A)
DM5Q9RY	MT	DTT
DM5Q9RY	MA	Inhibitor
DM5Q9RY	RN	Orexo announces Phase IIa data on OX914 in rhinitis. Orexo. 24th March, 2009.
DM5Q9RY	RU	http://feed.ne.cision.com/wpyfs/00/00/00/00/00/0E/79/F6/wkr0003.pdf

DM5Q9RY	DI	DM5Q9RY
DM5Q9RY	DN	OX-914
DM5Q9RY	MI	TTVIAT9
DM5Q9RY	MN	Phosphodiesterase 4B (PDE4B)
DM5Q9RY	MT	DTT
DM5Q9RY	MA	Inhibitor
DM5Q9RY	RN	Orexo announces Phase IIa data on OX914 in rhinitis. Orexo. 24th March, 2009.
DM5Q9RY	RU	http://feed.ne.cision.com/wpyfs/00/00/00/00/00/0E/79/F6/wkr0003.pdf

DM5Q9RY	DI	DM5Q9RY
DM5Q9RY	DN	OX-914
DM5Q9RY	MI	TTSKMI8
DM5Q9RY	MN	Phosphodiesterase 4D (PDE4D)
DM5Q9RY	MT	DTT
DM5Q9RY	MA	Inhibitor
DM5Q9RY	RN	Orexo announces Phase IIa data on OX914 in rhinitis. Orexo. 24th March, 2009.
DM5Q9RY	RU	http://feed.ne.cision.com/wpyfs/00/00/00/00/00/0E/79/F6/wkr0003.pdf

DMBM47Z	DI	DMBM47Z
DMBM47Z	DN	Oxazolidinones
DMBM47Z	MI	TT38DW5
DMBM47Z	MN	Bacterial 16S ribosomal RNA (Bact 16S rRNA)
DMBM47Z	MT	DTT
DMBM47Z	MA	Inhibitor
DMBM47Z	RN	Ribosomal RNA is the target for oxazolidinones, a novel class of translational inhibitors. RNA. 1999 Jul;5(7):939-46.
DMBM47Z	RU	https://pubmed.ncbi.nlm.nih.gov/10411137

DMBM47Z	DI	DMBM47Z
DMBM47Z	DN	Oxazolidinones
DMBM47Z	MI	TTLFGBV
DMBM47Z	MN	Bacterial 23S ribosomal RNA (Bact 23S rRNA)
DMBM47Z	MT	DTT
DMBM47Z	MA	Inhibitor
DMBM47Z	RN	Ribosomal RNA is the target for oxazolidinones, a novel class of translational inhibitors. RNA. 1999 Jul;5(7):939-46.
DMBM47Z	RU	https://pubmed.ncbi.nlm.nih.gov/10411137

DMSNL51	DI	DMSNL51
DMSNL51	DN	Oxfendazole
DMSNL51	MI	DTI7UX6
DMSNL51	MN	Breast cancer resistance protein (ABCG2)
DMSNL51	MT	DTP
DMSNL51	MA	Substrate
DMSNL51	RN	Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2). Drug Metab Dispos. 2005 May;33(5):614-8.
DMSNL51	RU	http://www.ncbi.nlm.nih.gov/pubmed/15703302

DMC3PJS	DI	DMC3PJS
DMC3PJS	DN	Oxytrex
DMC3PJS	MI	TTN4QDT
DMC3PJS	MN	Opioid receptor (OPR)
DMC3PJS	MT	DTT
DMC3PJS	MA	Modulator
DMC3PJS	RN	Oxytrex: an oxycodone and ultra-low-dose naltrexone formulation. Expert Opin Investig Drugs. 2007 Aug;16(8):1277-83.
DMC3PJS	RU	https://pubmed.ncbi.nlm.nih.gov/17685875

DMEGTH1	DI	DMEGTH1
DMEGTH1	DN	Ozarelix
DMEGTH1	MI	TT8R70G
DMEGTH1	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMEGTH1	MT	DTT
DMEGTH1	MA	Modulator
DMEGTH1	RN	Ozarelix, a fourth generation GnRH antagonist, induces apoptosis in hormone refractory androgen receptor negative prostate cancer cells modulating expression and activity of death receptors. Prostate. 2010 Sep 1;70(12):1340-9.
DMEGTH1	RU	https://pubmed.ncbi.nlm.nih.gov/20623634

DMEYQPN	DI	DMEYQPN
DMEYQPN	DN	P-1736
DMEYQPN	MI	TTB8FUC
DMEYQPN	MN	Free fatty acid receptor 1 (GPR40)
DMEYQPN	MT	DTT
DMEYQPN	MA	Modulator
DMEYQPN	RN	Discovery of p1736, a novel antidiabetic compound that improves peripheral insulin sensitivity in mice models. PLoS One. 2013 Oct 23;8(10):e77946.
DMEYQPN	RU	https://pubmed.ncbi.nlm.nih.gov/24194903

DMMJUHD	DI	DMMJUHD
DMMJUHD	DN	P-276
DMMJUHD	MI	TTH6V3D
DMMJUHD	MN	Cyclin-dependent kinase 1 (CDK1)
DMMJUHD	MT	DTT
DMMJUHD	MA	Inhibitor
DMMJUHD	RN	P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther. 2007 Mar;6(3):926-34.
DMMJUHD	RU	https://pubmed.ncbi.nlm.nih.gov/17363487

DMMJUHD	DI	DMMJUHD
DMMJUHD	DN	P-276
DMMJUHD	MI	TT0PG8F
DMMJUHD	MN	Cyclin-dependent kinase 4 (CDK4)
DMMJUHD	MT	DTT
DMMJUHD	MA	Inhibitor
DMMJUHD	RN	Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154.
DMMJUHD	RU	https://pubmed.ncbi.nlm.nih.gov/21253554

DM9DJL2	DI	DM9DJL2
DM9DJL2	DN	P276-00
DM9DJL2	MI	TTH6V3D
DM9DJL2	MN	Cyclin-dependent kinase 1 (CDK1)
DM9DJL2	MT	DTT
DM9DJL2	MA	Inhibitor
DM9DJL2	RN	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
DM9DJL2	RU	https://pubmed.ncbi.nlm.nih.gov/19568282

DM9DJL2	DI	DM9DJL2
DM9DJL2	DN	P276-00
DM9DJL2	MI	TT0PG8F
DM9DJL2	MN	Cyclin-dependent kinase 4 (CDK4)
DM9DJL2	MT	DTT
DM9DJL2	MA	Inhibitor
DM9DJL2	RN	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
DM9DJL2	RU	https://pubmed.ncbi.nlm.nih.gov/19568282

DM9DJL2	DI	DM9DJL2
DM9DJL2	DN	P276-00
DM9DJL2	MI	TT1LVF2
DM9DJL2	MN	Cyclin-dependent kinase 9 (CDK9)
DM9DJL2	MT	DTT
DM9DJL2	MA	Inhibitor
DM9DJL2	RN	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
DM9DJL2	RU	https://pubmed.ncbi.nlm.nih.gov/19568282

DMW1OI6	DI	DMW1OI6
DMW1OI6	DN	P32/98
DMW1OI6	MI	TTDIGC1
DMW1OI6	MN	Dipeptidyl peptidase 4 (DPP-4)
DMW1OI6	MT	DTT
DMW1OI6	MA	Inhibitor
DMW1OI6	RN	Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes. 2002 Apr;51(4):943-50.
DMW1OI6	RU	https://pubmed.ncbi.nlm.nih.gov/11916911

DMCBEYH	DI	DMCBEYH
DMCBEYH	DN	P54
DMCBEYH	MI	TTUIZKC
DMCBEYH	MN	DNA-binding factor KBF1 (p105)
DMCBEYH	MT	DTT
DMCBEYH	MA	Modulator
DMCBEYH	RN	Identification of p54(nrb) and the 14-3-3 Protein HS1 as TNF-alpha-inducible genes related to cell cycle control and apoptosis in human arterial endothelial cells. J Biochem Mol Biol. 2005 Jul 31;38(4):447-56.
DMCBEYH	RU	https://pubmed.ncbi.nlm.nih.gov/16053712

DMG8NLI	DI	DMG8NLI
DMG8NLI	DN	P-9808
DMG8NLI	MI	TTT0HW3
DMG8NLI	MN	Porphobilinogen deaminase (HMBS)
DMG8NLI	MT	DTT
DMG8NLI	MA	Modulator
DMG8NLI	RN	Safety, pharmacokinetics and pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion. Clin Pharmacokinet. 2007;46(4):335-49.
DMG8NLI	RU	https://pubmed.ncbi.nlm.nih.gov/17375984

DM3816P	DI	DM3816P
DM3816P	DN	PAC-14028
DM3816P	MI	TTMI6F5
DM3816P	MN	Transient receptor potential cation channel V1 (TRPV1)
DM3816P	MT	DTT
DM3816P	MA	Antagonist
DM3816P	RN	Development of PAC-14028, a novel transient receptor potential vanilloid type 1 (TRPV1) channel antagonist as a new drug for refractory skin diseases. Arch Pharm Res. 2012 Mar;35(3):393-6.
DM3816P	RU	https://pubmed.ncbi.nlm.nih.gov/22477184

DMMIYZ7	DI	DMMIYZ7
DMMIYZ7	DN	Palifosfamide
DMMIYZ7	MI	TT6S2FE
DMMIYZ7	MN	DNA [cytosine-5]-methyltransferase 1 (DNMT1)
DMMIYZ7	MT	DTT
DMMIYZ7	MA	Inhibitor
DMMIYZ7	RN	Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin. Anticancer Drugs. 2012 Feb;23(2):173-84.
DMMIYZ7	RU	https://pubmed.ncbi.nlm.nih.gov/22027537

DMX8ZAQ	DI	DMX8ZAQ
DMX8ZAQ	DN	Paliroden
DMX8ZAQ	MI	TT9HLZ0
DMX8ZAQ	MN	Glutamate receptor AMPA 2 (GRIA2)
DMX8ZAQ	MT	DTT
DMX8ZAQ	MA	Modulator
DMX8ZAQ	RN	Mechanism of inhibition of the GluA2 AMPA receptor channel opening by talampanel and its enantiomer: the stereochemistry of the 4-methyl group on the diazepine ring of 2,3-benzodiazepine derivatives.ACS Chem Neurosci.2013 Apr 17;4(4):635-44.
DMX8ZAQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/23402301

DMAZ460	DI	DMAZ460
DMAZ460	DN	Pankomab-GEX
DMAZ460	MI	TTBHFYQ
DMAZ460	MN	Mucin-1 (MUC1)
DMAZ460	MT	DTT
DMAZ460	RN	Staining of MUC1 in ovarian cancer tissues with PankoMab-GEX detecting the tumour-associated epitope, TA-MUC1, as compared to antibodies HMFG-1 and 115D8. Histol Histopathol. 2013 Feb;28(2):239-44.
DMAZ460	RU	https://pubmed.ncbi.nlm.nih.gov/23275306

DMV27SP	DI	DMV27SP
DMV27SP	DN	Panobacumab
DMV27SP	MI	TT4ESMB
DMV27SP	MN	Pseudomonas Lipopolysaccharide (Pseudo LPS)
DMV27SP	MT	DTT
DMV27SP	MA	Modulator
DMV27SP	RN	Antibacterial antibodies gain traction. Nat Rev Drug Discov. 2015 Nov;14(11):737-8. 
DMV27SP	RU	https://www.ncbi.nlm.nih.gov/pubmed/26514853

DMPO4M1	DI	DMPO4M1
DMPO4M1	DN	Paquinimod
DMPO4M1	MI	TT0TMQG
DMPO4M1	MN	Calgranulin B (S100A9)
DMPO4M1	MT	DTT
DMPO4M1	MA	Inhibitor
DMPO4M1	RN	Prophylactic treatment with S100A9 inhibitor paquinimod reduces pathology in experimental collagenase-induced osteoarthritis. Ann Rheum Dis. 2015 Dec;74(12):2254-8.
DMPO4M1	RU	https://pubmed.ncbi.nlm.nih.gov/25969431

DMD275X	DI	DMD275X
DMD275X	DN	Pardoprunox
DMD275X	MI	TTEX248
DMD275X	MN	Dopamine D2 receptor (D2R)
DMD275X	MT	DTT
DMD275X	MA	Agonist
DMD275X	RN	Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
DMD275X	RU	https://pubmed.ncbi.nlm.nih.gov/18172433

DM4N7BT	DI	DM4N7BT
DM4N7BT	DN	Paritaprevir
DM4N7BT	MI	DTUGYRD
DM4N7BT	MN	P-glycoprotein 1 (ABCB1)
DM4N7BT	MT	DTP
DM4N7BT	MA	Substrate
DM4N7BT	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DM4N7BT	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DMYBIFS	DI	DMYBIFS
DMYBIFS	DN	Parsaclisib
DMYBIFS	MI	TTGBPJE
DMYBIFS	MN	PI3-kinase delta (PIK3CD)
DMYBIFS	MT	DTT
DMYBIFS	MA	Inhibitor
DMYBIFS	RN	Parsaclisib, a potent and highly selective PI3K inhibitor, in patients with relapsed or refractory B-cell malignancies. Blood. 2019 Apr 18;133(16):1742-1752.
DMYBIFS	RU	https://pubmed.ncbi.nlm.nih.gov/30803990

DMCQBFT	DI	DMCQBFT
DMCQBFT	DN	Parthenolide
DMCQBFT	MI	TTJ3E9X
DMCQBFT	MN	Inhibitor of nuclear factor kappa-B kinase beta (IKKB)
DMCQBFT	MT	DTT
DMCQBFT	MA	Inhibitor
DMCQBFT	RN	The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chem Biol. 2001 Aug;8(8):759-66.
DMCQBFT	RU	https://pubmed.ncbi.nlm.nih.gov/11514225

DMCQBFT	DI	DMCQBFT
DMCQBFT	DN	Parthenolide
DMCQBFT	MI	TTSXVID
DMCQBFT	MN	Nuclear factor NF-kappa-B (NFKB)
DMCQBFT	MT	DTT
DMCQBFT	MA	Inhibitor
DMCQBFT	RN	Hypoxia-induced neutrophil survival is mediated by HIF-1alpha-dependent NF-kappaB activity. J Exp Med. 2005 Jan 3;201(1):105-15.
DMCQBFT	RU	https://pubmed.ncbi.nlm.nih.gov/15630139

DMU3XJP	DI	DMU3XJP
DMU3XJP	DN	Pascolizumab
DMU3XJP	MI	TTLGTKB
DMU3XJP	MN	Interleukin-4 (IL4)
DMU3XJP	MT	DTT
DMU3XJP	MA	Modulator
DMU3XJP	RN	The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. 
DMU3XJP	RU	https://www.ncbi.nlm.nih.gov/pubmed/23197041

DM2NJYC	DI	DM2NJYC
DM2NJYC	DN	Patidegib
DM2NJYC	MI	TT4LXBC
DM2NJYC	MN	Hedgehog signaling pathway (HS pathway)
DM2NJYC	MT	DTT
DM2NJYC	MA	Inhibitor
DM2NJYC	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM2NJYC	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMU0812	DI	DMU0812
DMU0812	DN	PAZ-320
DMU0812	MI	TTXWASR
DMU0812	MN	Intestinal maltase-glucoamylase (MGAM)
DMU0812	MT	DTT
DMU0812	MA	Modulator
DMU0812	RN	Treatment With Novel Galactomannan Derivative Reduces 2-Hour Postprandial Glucose Excursions in Individuals With Type 2 Diabetes Treated With Oral Medications and/or Insulin. J Diabetes Sci Technol. 2014 September; 8(5): 1018-1022.
DMU0812	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4455361/

DMVJD2W	DI	DMVJD2W
DMVJD2W	DN	Pazopanib + Tyverb/Tykerb
DMVJD2W	MI	TTGKNB4
DMVJD2W	MN	Epidermal growth factor receptor (EGFR)
DMVJD2W	MT	DTT
DMVJD2W	MA	Inhibitor
DMVJD2W	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMVJD2W	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMVJD2W	DI	DMVJD2W
DMVJD2W	DN	Pazopanib + Tyverb/Tykerb
DMVJD2W	MI	TT6EO5L
DMVJD2W	MN	Erbb2 tyrosine kinase receptor (HER2)
DMVJD2W	MT	DTT
DMVJD2W	MA	Inhibitor
DMVJD2W	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMVJD2W	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMZCI04	DI	DMZCI04
DMZCI04	DN	PB-1023
DMZCI04	MI	TT0NUFM
DMZCI04	MN	Glucagon (GCG)
DMZCI04	MT	DTT
DMZCI04	MA	Agonist
DMZCI04	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZCI04	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMZCI04	DI	DMZCI04
DMZCI04	DN	PB-1023
DMZCI04	MI	TTVIMDE
DMZCI04	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMZCI04	MT	DTT
DMZCI04	MA	Modulator
DMZCI04	RN	On-target Effects of GLP-1 Receptor Agonists on Thyroid C-cells in Rats and Mice. Toxicol Pathol February 2013 vol. 41 no. 2 303-309.
DMZCI04	RU	http://tpx.sagepub.com/content/41/2/303.full

DM8MJ3F	DI	DM8MJ3F
DM8MJ3F	DN	PB1046
DM8MJ3F	MI	TT4O5P0
DM8MJ3F	MN	Helodermin-preferring VIP receptor (VIPR2)
DM8MJ3F	MT	DTT
DM8MJ3F	MA	Agonist
DM8MJ3F	RN	Clinical pipeline report, company report or official report of PhaseBio Pharmaceuticals.
DM8MJ3F	RU	http://phasebio.com/clinical-development-pipeline/vasomera/

DM05WIU	DI	DM05WIU
DM05WIU	DN	PBI-05204
DM05WIU	MI	TTQ38E9
DM05WIU	MN	Sodium/potassium-transporting ATPase (SPT ATPase)
DM05WIU	MT	DTT
DM05WIU	MA	Inhibitor
DM05WIU	RN	First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf- beta and p70s6k, in patients with advanced solid tumors. Invest New Drugs. 2014 Dec;32(6):1204-12.
DM05WIU	RU	https://pubmed.ncbi.nlm.nih.gov/24919855

DMPXK27	DI	DMPXK27
DMPXK27	DN	PBI-4050
DMPXK27	MI	TTB8FUC
DMPXK27	MN	Free fatty acid receptor 1 (GPR40)
DMPXK27	MT	DTT
DMPXK27	MA	Agonist
DMPXK27	RN	Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2019 Mar 18;53(3):1800663.
DMPXK27	RU	https://pubmed.ncbi.nlm.nih.gov/30578394

DMPXK27	DI	DMPXK27
DMPXK27	DN	PBI-4050
DMPXK27	MI	TTG0MQD
DMPXK27	MN	Inflammation-related GPCR EX33 (GPR84)
DMPXK27	MT	DTT
DMPXK27	MA	Antagonist
DMPXK27	RN	Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2019 Mar 18;53(3):1800663.
DMPXK27	RU	https://pubmed.ncbi.nlm.nih.gov/30578394

DMKWGS1	DI	DMKWGS1
DMKWGS1	DN	PBT-2
DMKWGS1	MI	TTS87KH
DMKWGS1	MN	Microtubule-associated protein tau (MAPT)
DMKWGS1	MT	DTT
DMKWGS1	MA	Modulator
DMKWGS1	RN	PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J Alzheimers Dis. 2010;20(2):509-16.
DMKWGS1	RU	https://pubmed.ncbi.nlm.nih.gov/20164561

DMYRIHZ	DI	DMYRIHZ
DMYRIHZ	DN	PCL-016
DMYRIHZ	MI	TT3J1EK
DMYRIHZ	MN	Zinc finger protein (ZNF)
DMYRIHZ	MT	DTT
DMYRIHZ	MA	Modulator
DMYRIHZ	RN	US patent application no. 2005,0239,723, Compositions and methods useful for treatment of acne.
DMYRIHZ	RU	http://www.google.com/patents/US20050239723

DMYFRTB	DI	DMYFRTB
DMYFRTB	DN	PCM-075
DMYFRTB	MI	TTIYVQP
DMYFRTB	MN	Polo-like kinase 1 (PLK1)
DMYFRTB	MT	DTT
DMYFRTB	MA	Inhibitor
DMYFRTB	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMYFRTB	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMUHDX3	DI	DMUHDX3
DMUHDX3	DN	PC-SOD
DMUHDX3	MI	TT6RVLG
DMUHDX3	MN	Superoxide dismutase Cu-Zn (SOD Cu-Zn)
DMUHDX3	MT	DTT
DMUHDX3	MA	Modulator
DMUHDX3	RN	A lecithinized superoxide dismutase (PC-SOD) improves ulcerative colitis
DMUHDX3	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2659364

DM27D4J	DI	DM27D4J
DM27D4J	DN	PD-0325901
DM27D4J	MI	TTROQ37
DM27D4J	MN	MAPK/ERK kinase kinase (MAP3K)
DM27D4J	MT	DTT
DM27D4J	MA	Modulator
DM27D4J	RN	MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013; 6: 27.
DM27D4J	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626705/

DMXAH4G	DI	DMXAH4G
DMXAH4G	DN	PD-143188
DMXAH4G	MI	TTEX248
DMXAH4G	MN	Dopamine D2 receptor (D2R)
DMXAH4G	MT	DTT
DMXAH4G	MA	Modulator
DMXAH4G	RN	Anxiolytic effects of dopamine receptor ligands: I. Involvement of dopamine autoreceptors. Life Sci. 1998;62(7):649-63.
DMXAH4G	RU	https://pubmed.ncbi.nlm.nih.gov/9472724

DMWVBTQ	DI	DMWVBTQ
DMWVBTQ	DN	PD-145065
DMWVBTQ	MI	TTKRD0G
DMWVBTQ	MN	Endothelin A receptor (EDNRA)
DMWVBTQ	MT	DTT
DMWVBTQ	MA	Modulator
DMWVBTQ	RN	Reversal of established responses to endothelin-1 in vivo and in vitro by the endothelin receptor antagonists, BQ-123 and PD 145065. Br J Pharmacol. 1994 May;112(1):207-13.
DMWVBTQ	RU	https://pubmed.ncbi.nlm.nih.gov/8032643

DMWVBTQ	DI	DMWVBTQ
DMWVBTQ	DN	PD-145065
DMWVBTQ	MI	TT3ZTGU
DMWVBTQ	MN	Endothelin B receptor (EDNRB)
DMWVBTQ	MT	DTT
DMWVBTQ	MA	Modulator
DMWVBTQ	RN	Reversal of established responses to endothelin-1 in vivo and in vitro by the endothelin receptor antagonists, BQ-123 and PD 145065. Br J Pharmacol. 1994 May;112(1):207-13.
DMWVBTQ	RU	https://pubmed.ncbi.nlm.nih.gov/8032643

DMPW28M	DI	DMPW28M
DMPW28M	DN	PD-200390
DMPW28M	MI	TT729IR
DMPW28M	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DMPW28M	MT	DTT
DMPW28M	MA	Modulator
DMPW28M	RN	Pfizer. Product Development Pipeline. March 31 2009.
DMPW28M	RU	http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf

DM6F5EV	DI	DM6F5EV
DM6F5EV	DN	PD-360324
DM6F5EV	MI	TT731LW
DM6F5EV	MN	Colony stimulating factor-1 receptor (CSF-1R)
DM6F5EV	MT	DTT
DM6F5EV	MA	Modulator
DM6F5EV	RN	Monoclonal antibody against macrophage colony-stimulating factor suppresses circulating monocytes and tissue macrophage function but does not alter cell infiltration/activation in cutaneous lesions or clinical outcomes in patients with cutaneous lupus erythematosus.Clin Exp Immunol.2016 Feb;183(2):258-70.
DM6F5EV	RU	https://www.ncbi.nlm.nih.gov/pubmed/26376111

DMGP9VN	DI	DMGP9VN
DMGP9VN	DN	PDC-1421
DMGP9VN	MI	TTAWNKZ
DMGP9VN	MN	Norepinephrine transporter (NET)
DMGP9VN	MT	DTT
DMGP9VN	MA	Inhibitor
DMGP9VN	RN	Clinical pipeline report, company report or official report of BioInvent.
DMGP9VN	RU	https://www.biolite.com.tw/tw/medicine/bli1005.html

DM6OC53	DI	DM6OC53
DM6OC53	DN	PDX-101
DM6OC53	MI	DE4LYSA
DM6OC53	MN	Cytochrome P450 3A4 (CYP3A4)
DM6OC53	MT	DME
DM6OC53	MA	Metabolism
DM6OC53	RN	Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients. PLoS One. 2013;8(1):e54522.
DM6OC53	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23382909

DM6OC53	DI	DM6OC53
DM6OC53	DN	PDX-101
DM6OC53	MI	TTBH0VX
DM6OC53	MN	Histone deacetylase (HDAC)
DM6OC53	MT	DTT
DM6OC53	MA	Modulator
DM6OC53	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM6OC53	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM6OC53	DI	DM6OC53
DM6OC53	DN	PDX-101
DM6OC53	MI	DEYGVN4
DM6OC53	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM6OC53	MT	DME
DM6OC53	MA	Metabolism
DM6OC53	RN	Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer. J Clin Pharmacol. 2016 Apr;56(4):461-73.
DM6OC53	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26313268

DMFL96Z	DI	DMFL96Z
DMFL96Z	DN	Pegamotecan
DMFL96Z	MI	TTGTQHC
DMFL96Z	MN	DNA topoisomerase I (TOP1)
DMFL96Z	MT	DTT
DMFL96Z	MA	Inhibitor
DMFL96Z	RN	A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer Chemother Pharmacol. 2009 Jan;63(2):363-70.
DMFL96Z	RU	https://pubmed.ncbi.nlm.nih.gov/18398613

DMPD3X6	DI	DMPD3X6
DMPD3X6	DN	Pegmusirudin
DMPD3X6	MI	TT6L509
DMPD3X6	MN	Coagulation factor IIa (F2)
DMPD3X6	MT	DTT
DMPD3X6	MA	Modulator
DMPD3X6	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362).
DMPD3X6	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2362

DM26YJ1	DI	DM26YJ1
DM26YJ1	DN	PEGPH20
DM26YJ1	MI	TTXFI1K
DM26YJ1	MN	Hyaluronidase (HYAL)
DM26YJ1	MT	DTT
DM26YJ1	MA	Modulator
DM26YJ1	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM26YJ1	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMX9ZM4	DI	DMX9ZM4
DMX9ZM4	DN	PEG-SN38
DMX9ZM4	MI	DE4LYSA
DMX9ZM4	MN	Cytochrome P450 3A4 (CYP3A4)
DMX9ZM4	MT	DME
DMX9ZM4	MA	Metabolism
DMX9ZM4	RN	Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer. Cancer Chemother Pharmacol. 2013 Jun;71(6):1499-506.
DMX9ZM4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23543270

DMX9ZM4	DI	DMX9ZM4
DMX9ZM4	DN	PEG-SN38
DMX9ZM4	MI	TTGTQHC
DMX9ZM4	MN	DNA topoisomerase I (TOP1)
DMX9ZM4	MT	DTT
DMX9ZM4	MA	Inhibitor
DMX9ZM4	RN	EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors. PLoS One. 2012;7(9):e45248.
DMX9ZM4	RU	https://pubmed.ncbi.nlm.nih.gov/23028879

DMTDANB	DI	DMTDANB
DMTDANB	DN	Pegsunercept
DMTDANB	MI	TTF8CQI
DMTDANB	MN	Tumor necrosis factor (TNF)
DMTDANB	MT	DTT
DMTDANB	MA	Inhibitor
DMTDANB	RN	Diabetes-enhanced tumor necrosis factor-alpha production promotes apoptosis and the loss of retinal microvascular cells in type 1 and type 2 models of diabetic retinopathy. Am J Pathol. 2008 May;172(5):1411-8.
DMTDANB	RU	https://pubmed.ncbi.nlm.nih.gov/18403591

DMBPJ9U	DI	DMBPJ9U
DMBPJ9U	DN	PEGylated pitrakinra
DMBPJ9U	MI	TT0GVCH
DMBPJ9U	MN	Interleukin-13 (IL13)
DMBPJ9U	MT	DTT
DMBPJ9U	MA	Modulator
DMBPJ9U	RN	The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. 
DMBPJ9U	RU	https://www.ncbi.nlm.nih.gov/pubmed/23197041

DMBPJ9U	DI	DMBPJ9U
DMBPJ9U	DN	PEGylated pitrakinra
DMBPJ9U	MI	TTLGTKB
DMBPJ9U	MN	Interleukin-4 (IL4)
DMBPJ9U	MT	DTT
DMBPJ9U	MA	Modulator
DMBPJ9U	RN	The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. 
DMBPJ9U	RU	https://www.ncbi.nlm.nih.gov/pubmed/23197041

DMOMN31	DI	DMOMN31
DMOMN31	DN	PEITC
DMOMN31	MI	DTI7UX6
DMOMN31	MN	Breast cancer resistance protein (ABCG2)
DMOMN31	MT	DTP
DMOMN31	MA	Substrate
DMOMN31	RN	A prediction model of substrates and non-substrates of breast cancer resistance protein (BCRP) developed by GA-CG-SVM method. Comput Biol Med. 2011 Nov;41(11):1006-13.
DMOMN31	RU	https://doi.org/10.1016/j.compbiomed.2011.08.009

DMOMN31	DI	DMOMN31
DMOMN31	DN	PEITC
DMOMN31	MI	DE4ZHS1
DMOMN31	MN	Glutathione S-transferase alpha-1 (GSTA1)
DMOMN31	MT	DME
DMOMN31	MA	Metabolism
DMOMN31	RN	Pharmacokinetics and pharmacodynamics of phenethyl isothiocyanate: implications in breast cancer prevention. AAPS J. 2014 Jul;16(4):705-13.
DMOMN31	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24821055

DMOMN31	DI	DMOMN31
DMOMN31	DN	PEITC
DMOMN31	MI	DTSYQGK
DMOMN31	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMOMN31	MT	DTP
DMOMN31	MA	Substrate
DMOMN31	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMOMN31	RU	https://doi.org/10.1007/s11095-012-0935-x

DMOMN31	DI	DMOMN31
DMOMN31	DN	PEITC
DMOMN31	MI	DTFI42L
DMOMN31	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMOMN31	MT	DTP
DMOMN31	MA	Substrate
DMOMN31	RN	Transport of dietary phenethyl isothiocyanate is mediated by multidrug resistance protein 2 but not P-glycoprotein. Biochem Pharmacol. 2005 Aug 15;70(4):640-7.
DMOMN31	RU	https://doi.org/10.1016/j.bcp.2005.05.025

DMIW453	DI	DMIW453
DMIW453	DN	Pelitinib
DMIW453	MI	TTGKNB4
DMIW453	MN	Epidermal growth factor receptor (EGFR)
DMIW453	MT	DTT
DMIW453	MA	Modulator
DMIW453	RN	EGFR tyrosine kinase inhibitor pelitinib regulates radiation-induced p65-dependent telomerase activation in squamous cell carcinoma.Radiat Res.2013 Mar;179(3):304-12.
DMIW453	RU	https://www.ncbi.nlm.nih.gov/pubmed/23379415

DMR6USG	DI	DMR6USG
DMR6USG	DN	PELITREXOL
DMR6USG	MI	TTEXB9Z
DMR6USG	MN	Glycinamide ribonucleotide formyltransferase (GART)
DMR6USG	MT	DTT
DMR6USG	MA	Inhibitor
DMR6USG	RN	Results of 2 phase I studies of intravenous (iv) pelitrexol (AG2037), a glycinamide ribonucleotide formyltransferase (GARFT) inhibitor, in patients (pts) with solid tumors. J Clin Oncol (Meeting Abstracts) July 2004 vol. 22 no. 14_suppl 3075.
DMR6USG	RU	http://meeting.ascopubs.org/cgi/content/short/22/14_suppl/3075

DMGY5JC	DI	DMGY5JC
DMGY5JC	DN	Pentacea
DMGY5JC	MI	TTY6DTE
DMGY5JC	MN	Carcinoembryonic antigen CEA (CD66e)
DMGY5JC	MT	DTT
DMGY5JC	RN	Antibody fragments: Hope and hype. MAbs. 2010 Jan-Feb; 2(1): 77-83.
DMGY5JC	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2828581/

DMNU48O	DI	DMNU48O
DMNU48O	DN	Peptide YY 3-36
DMNU48O	MI	TTVFJLX
DMNU48O	MN	Peptide tyrosine tyrosine PYY (PYY)
DMNU48O	MT	DTT
DMNU48O	MA	Modulator
DMNU48O	RN	Clinical pipeline report, company report or official report of Emisphere.
DMNU48O	RU	http://ir.emisphere.com/releasedetail.cfm?releaseid=356364

DMFM6OU	DI	DMFM6OU
DMFM6OU	DN	PerioPatch
DMFM6OU	MI	TTHS7CM
DMFM6OU	MN	Beta-glucuronidase (GUSB)
DMFM6OU	MT	DTT
DMFM6OU	MA	Modulator
DMFM6OU	RN	Clinical pipeline report, company report or official report of Izun Pharmaceuticals.
DMFM6OU	RU	http://izunpharma.com/products/periopatch/

DMNM4CK	DI	DMNM4CK
DMNM4CK	DN	PF-00734200
DMNM4CK	MI	TTDIGC1
DMNM4CK	MN	Dipeptidyl peptidase 4 (DPP-4)
DMNM4CK	MT	DTT
DMNM4CK	MA	Modulator
DMNM4CK	RN	Efficacy and safety of the dipeptidyl peptidase-4 inhibitor PF-734200 added to metformin in Type 2 diabetes.Diabet Med.2011 Apr;28(4):464-9.
DMNM4CK	RU	https://www.ncbi.nlm.nih.gov/pubmed/21392067

DMJPE61	DI	DMJPE61
DMJPE61	DN	PF-02545920
DMJPE61	MI	TTJW4LU
DMJPE61	MN	Phosphodiesterase 10A (PDE10)
DMJPE61	MT	DTT
DMJPE61	MA	Inhibitor
DMJPE61	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMJPE61	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DMTJWNE	DI	DMTJWNE
DMTJWNE	DN	PF-03446962
DMTJWNE	MI	TTGYPTC
DMTJWNE	MN	Activin receptor-like kinase-1 (ACVRL1)
DMTJWNE	MT	DTT
DMTJWNE	MA	Modulator
DMTJWNE	RN	ALK1 as an emerging target for antiangiogenic therapy of cancer. Blood. 2011 June 30; 117(26): 6999-7006.
DMTJWNE	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3143549/

DM826SW	DI	DM826SW
DM826SW	DN	PF-04236921
DM826SW	MI	TTF6I40
DM826SW	MN	Interleukin (IL)
DM826SW	MT	DTT
DM826SW	MA	Inhibitor
DM826SW	RN	US patent application no. 2010,0158,905, Combination therapy of arthritis with tranilast.
DM826SW	RU	https://www.google.com/patents/US20100158905

DM826SW	DI	DM826SW
DM826SW	DN	PF-04236921
DM826SW	MI	TTT1V78
DM826SW	MN	Interleukin-6 (IL6)
DM826SW	MT	DTT
DM826SW	MA	Inhibitor
DM826SW	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM826SW	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMPRYU1	DI	DMPRYU1
DMPRYU1	DN	PF-04457845
DMPRYU1	MI	TTDP1UC
DMPRYU1	MN	Fatty acid amide hydrolase (FAAH)
DMPRYU1	MT	DTT
DMPRYU1	MA	Inhibitor
DMPRYU1	RN	Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor. ACS Med Chem Lett. 2011 Feb 10;2(2):91-96.
DMPRYU1	RU	https://pubmed.ncbi.nlm.nih.gov/21666860

DMZMUIL	DI	DMZMUIL
DMZMUIL	DN	PF-04518600
DMZMUIL	MI	TTL31H0
DMZMUIL	MN	OX40L receptor (CD134)
DMZMUIL	MT	DTT
DMZMUIL	MA	Agonist
DMZMUIL	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZMUIL	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMA9MBR	DI	DMA9MBR
DMA9MBR	DN	PF-04523655
DMA9MBR	MI	TT0AWFK
DMA9MBR	MN	HIF-1 responsive protein RTP801 (DDIT4)
DMA9MBR	MT	DTT
DMA9MBR	RN	Teaming up to tackle RNAi delivery challenge. Nat Rev Drug Discov. 2009 Jul;8(7):525-6.
DMA9MBR	RU	https://pubmed.ncbi.nlm.nih.gov/19568274

DMS610L	DI	DMS610L
DMS610L	DN	PF-04691502
DMS610L	MI	TTHBTOP
DMS610L	MN	PI3-kinase gamma (PIK3CG)
DMS610L	MT	DTT
DMS610L	MA	Modulator
DMS610L	RN	PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.Mol Cancer Ther.2011 Nov;10(11):2189-99.
DMS610L	RU	https://www.ncbi.nlm.nih.gov/pubmed/21750219

DMS610L	DI	DMS610L
DMS610L	DN	PF-04691502
DMS610L	MI	TTCJG29
DMS610L	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMS610L	MT	DTT
DMS610L	MA	Modulator
DMS610L	RN	PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.Mol Cancer Ther.2011 Nov;10(11):2189-99.
DMS610L	RU	https://www.ncbi.nlm.nih.gov/pubmed/21750219

DMQMF4O	DI	DMQMF4O
DMQMF4O	DN	PF-04937319
DMQMF4O	MI	TTDLNGZ
DMQMF4O	MN	Glucokinase (GCK)
DMQMF4O	MT	DTT
DMQMF4O	MA	Modulator
DMQMF4O	RN	Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes. Diabetes Obes Metab. 2015 Aug;17(8):751-9.
DMQMF4O	RU	https://pubmed.ncbi.nlm.nih.gov/25885172

DMRAFBK	DI	DMRAFBK
DMRAFBK	DN	PF-04958242
DMRAFBK	MI	TTAN6JD
DMRAFBK	MN	Glutamate receptor AMPA (GRIA)
DMRAFBK	MT	DTT
DMRAFBK	MA	Activator
DMRAFBK	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMRAFBK	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DM94NBE	DI	DM94NBE
DM94NBE	DN	PF-04991532
DM94NBE	MI	TTDLNGZ
DM94NBE	MN	Glucokinase (GCK)
DM94NBE	MT	DTT
DM94NBE	MA	Activator
DM94NBE	RN	The hepatoselective glucokinase activator PF-04991532 ameliorates hyperglycemia without causing hepatic steatosis in diabetic rats. PLoS One. 2014 May 23;9(5):e97139.
DM94NBE	RU	https://pubmed.ncbi.nlm.nih.gov/24858947

DMD74BJ	DI	DMD74BJ
DMD74BJ	DN	PF-05089771
DMD74BJ	MI	TT4G2JS
DMD74BJ	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DMD74BJ	MT	DTT
DMD74BJ	MA	Blocker
DMD74BJ	RN	Primary erythromelalgia: a review. Orphanet J Rare Dis. 2015 Sep 30;10:127.
DMD74BJ	RU	https://pubmed.ncbi.nlm.nih.gov/26419464

DMLQ3OK	DI	DMLQ3OK
DMLQ3OK	DN	PF-05175157
DMLQ3OK	MI	TTY84UG
DMLQ3OK	MN	Acetyl-CoA carboxylase 2 (ACACB)
DMLQ3OK	MT	DTT
DMLQ3OK	MA	Inhibitor
DMLQ3OK	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1264).
DMLQ3OK	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1264

DMPVQYR	DI	DMPVQYR
DMPVQYR	DN	PF-05212377
DMPVQYR	MI	TTJS8PY
DMPVQYR	MN	5-HT 6 receptor (HTR6)
DMPVQYR	MT	DTT
DMPVQYR	MA	Antagonist
DMPVQYR	RN	PF-05212377 Alzheimer's Disease (Phase 2). Pfizer.
DMPVQYR	RU	http://www.alzforum.org/therapeutics/pf-05212377

DMBL3VD	DI	DMBL3VD
DMBL3VD	DN	PF-05212384
DMBL3VD	MI	TTHBTOP
DMBL3VD	MN	PI3-kinase gamma (PIK3CG)
DMBL3VD	MT	DTT
DMBL3VD	MA	Modulator
DMBL3VD	RN	First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer. Clin Cancer Res. 2015 Apr 15;21(8):1888-95.
DMBL3VD	RU	https://pubmed.ncbi.nlm.nih.gov/25652454

DMBL3VD	DI	DMBL3VD
DMBL3VD	DN	PF-05212384
DMBL3VD	MI	TTCJG29
DMBL3VD	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMBL3VD	MT	DTT
DMBL3VD	MA	Modulator
DMBL3VD	RN	First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer. Clin Cancer Res. 2015 Apr 15;21(8):1888-95.
DMBL3VD	RU	https://pubmed.ncbi.nlm.nih.gov/25652454

DMQLZOF	DI	DMQLZOF
DMQLZOF	DN	PF-06252616
DMQLZOF	MI	TTSWPH8
DMQLZOF	MN	Growth/differentiation factor 8 (GDF-8)
DMQLZOF	MT	DTT
DMQLZOF	RN	Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Curr Opin Support Palliat Care. 2013 November; 7(4): 352-360.
DMQLZOF	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3819341/

DMUAOFM	DI	DMUAOFM
DMUAOFM	DN	PF-06290510
DMUAOFM	MI	TTE6QWF
DMUAOFM	MN	Staphylococcus Capsular polysaccharide CP5 (Stap-coc CP5)
DMUAOFM	MT	DTT
DMUAOFM	RN	ClinicalTrials.gov (NCT01364571) Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years. U.S. National Institutes of Health.
DMUAOFM	RU	https://clinicaltrials.gov/ct2/show/NCT01364571

DMUAOFM	DI	DMUAOFM
DMUAOFM	DN	PF-06290510
DMUAOFM	MI	TT4SVB7
DMUAOFM	MN	Staphylococcus Capsular polysaccharide CP8 (Stap-coc CP8)
DMUAOFM	MT	DTT
DMUAOFM	RN	ClinicalTrials.gov (NCT01364571) Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years. U.S. National Institutes of Health.
DMUAOFM	RU	https://clinicaltrials.gov/ct2/show/NCT01364571

DMUAOFM	DI	DMUAOFM
DMUAOFM	DN	PF-06290510
DMUAOFM	MI	TTWGZ64
DMUAOFM	MN	Staphylococcus Clumping factor A (Stap-coc ClfA)
DMUAOFM	MT	DTT
DMUAOFM	RN	ClinicalTrials.gov (NCT01364571) Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years. U.S. National Institutes of Health.
DMUAOFM	RU	https://clinicaltrials.gov/ct2/show/NCT01364571

DMUAOFM	DI	DMUAOFM
DMUAOFM	DN	PF-06290510
DMUAOFM	MI	TTBWX8P
DMUAOFM	MN	Staphylococcus Manganese transporter C (Stap-coc MntC)
DMUAOFM	MT	DTT
DMUAOFM	RN	ClinicalTrials.gov (NCT01364571) Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years. U.S. National Institutes of Health.
DMUAOFM	RU	https://clinicaltrials.gov/ct2/show/NCT01364571

DMN94QM	DI	DMN94QM
DMN94QM	DN	PF-06291874
DMN94QM	MI	TT9O6WS
DMN94QM	MN	Glucagon receptor (GCGR)
DMN94QM	MT	DTT
DMN94QM	MA	Antagonist
DMN94QM	RN	Clinical pipeline report, company report or official report of pfizer.
DMN94QM	RU	http://www.pfizer.com/sites/default/files/product-pipeline/110614_Pipeline_Update.pdf

DMKM7EW	DI	DMKM7EW
DMKM7EW	DN	PF-06463922
DMKM7EW	MI	TTPMQSO
DMKM7EW	MN	ALK tyrosine kinase receptor (ALK)
DMKM7EW	MT	DTT
DMKM7EW	MA	Inhibitor
DMKM7EW	RN	PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models. Cancer Cell. 2015 Jul 13;28(1):70-81.
DMKM7EW	RU	https://pubmed.ncbi.nlm.nih.gov/26144315

DM9S3P7	DI	DM9S3P7
DM9S3P7	DN	PF-06473871
DM9S3P7	MI	TTIL516
DM9S3P7	MN	CCN2 messenger RNA (CCN2 mRNA)
DM9S3P7	MT	DTT
DM9S3P7	MA	Inhibitor
DM9S3P7	RN	A Placebo-controlled Study of PF-06473871 (Anti-Connective Tissue Growth Factor Antisense Oligonucleotide) in Reducing Hypertrophic Skin Scarring. Plast Reconstr Surg Glob Open. 2018 Sep 6;6(9):e1861.
DM9S3P7	RU	https://pubmed.ncbi.nlm.nih.gov/30349773

DMMGSFV	DI	DMMGSFV
DMMGSFV	DN	PF-06700841
DMMGSFV	MI	TT6DM01
DMMGSFV	MN	Janus kinase 1 (JAK-1)
DMMGSFV	MT	DTT
DMMGSFV	MA	Inhibitor
DMMGSFV	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMMGSFV	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMMGSFV	DI	DMMGSFV
DMMGSFV	DN	PF-06700841
DMMGSFV	MI	TTBYWP2
DMMGSFV	MN	TYK2 tyrosine kinase (TYK2)
DMMGSFV	MT	DTT
DMMGSFV	MA	Inhibitor
DMMGSFV	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMMGSFV	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM8C1H4	DI	DM8C1H4
DM8C1H4	DN	PF-06823859
DM8C1H4	MI	TT4TZ8J
DM8C1H4	MN	Interferon-beta (IFNB1)
DM8C1H4	MT	DTT
DM8C1H4	MA	Blocker
DM8C1H4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM8C1H4	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM5H8V1	DI	DM5H8V1
DM5H8V1	DN	PF-06826647
DM5H8V1	MI	TTBYWP2
DM5H8V1	MN	TYK2 tyrosine kinase (TYK2)
DM5H8V1	MT	DTT
DM5H8V1	MA	Inhibitor
DM5H8V1	RN	Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases. J Med Chem. 2020 Nov 25;63(22):13561-13577.
DM5H8V1	RU	https://pubmed.ncbi.nlm.nih.gov/32787094

DM7EJ8S	DI	DM7EJ8S
DM7EJ8S	DN	PF-06882961
DM7EJ8S	MI	TTVIMDE
DM7EJ8S	MN	Glucagon-like peptide 1 receptor (GLP1R)
DM7EJ8S	MT	DTT
DM7EJ8S	MA	Agonist
DM7EJ8S	RN	Differential GLP-1R Binding and Activation by Peptide and Non-peptide Agonists. Mol Cell. 2020 Nov 5;80(3):485-500.e7.
DM7EJ8S	RU	https://pubmed.ncbi.nlm.nih.gov/33027691

DM8T6KQ	DI	DM8T6KQ
DM8T6KQ	DN	PF-232798
DM8T6KQ	MI	TT2CEJG
DM8T6KQ	MN	C-C chemokine receptor type 5 (CCR5)
DM8T6KQ	MT	DTT
DM8T6KQ	MA	Antagonist
DM8T6KQ	RN	An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798). J Med Chem. 2011 Jan 13;54(1):67-77.
DM8T6KQ	RU	https://pubmed.ncbi.nlm.nih.gov/21128663

DMO02LU	DI	DMO02LU
DMO02LU	DN	PF-3463275
DMO02LU	MI	TTHJTF7
DMO02LU	MN	Glycine transporter GlyT-1 (SLC6A9)
DMO02LU	MT	DTT
DMO02LU	MA	Inhibitor
DMO02LU	RN	Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain. Nat Rev Drug Discov. 2013 Nov;12(11):866-85.
DMO02LU	RU	https://pubmed.ncbi.nlm.nih.gov/24172334

DMC2FAL	DI	DMC2FAL
DMC2FAL	DN	PF-3893787
DMC2FAL	MI	TTXJ178
DMC2FAL	MN	Histamine H4 receptor (H4R)
DMC2FAL	MT	DTT
DMC2FAL	MA	Antagonist
DMC2FAL	RN	Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist. Bioorg Med Chem Lett. 2011 Nov 1;21(21):6596-602.
DMC2FAL	RU	https://pubmed.ncbi.nlm.nih.gov/21920751

DM3DWKN	DI	DM3DWKN
DM3DWKN	DN	PF-4191834
DM3DWKN	MI	TT2J34L
DM3DWKN	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM3DWKN	MT	DTT
DM3DWKN	MA	Inhibitor
DM3DWKN	RN	Pharmacology of PF-4191834, a novel, selective non-redox 5-lipoxygenase inhibitor effective in inflammation and pain. J Pharmacol Exp Ther. 2010 Jul;334(1):294-301.
DM3DWKN	RU	https://pubmed.ncbi.nlm.nih.gov/20378715

DM81D4I	DI	DM81D4I
DM81D4I	DN	PF-4447943
DM81D4I	MI	TTZOEBC
DM81D4I	MN	Phosphodiesterase 9 (PDE9)
DM81D4I	MT	DTT
DM81D4I	MA	Inhibitor
DM81D4I	RN	A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer's disease. Curr Alzheimer Res. 2014;11(5):413-21.
DM81D4I	RU	https://pubmed.ncbi.nlm.nih.gov/24801218

DML38VU	DI	DML38VU
DML38VU	DN	PF-446687
DML38VU	MI	TTD0CIQ
DML38VU	MN	Melanocortin receptor 4 (MC4R)
DML38VU	MT	DTT
DML38VU	MA	Modulator
DML38VU	RN	Melanocortin Receptor Agonists Facilitate Oxytocin-Dependent Partner Preference Formation in the Prairie Vole. Neuropsychopharmacology. 2015 Jul;40(8):1856-65.
DML38VU	RU	https://pubmed.ncbi.nlm.nih.gov/25652247

DM3YIKR	DI	DM3YIKR
DM3YIKR	DN	PF-4523655
DM3YIKR	MI	TTVEOY6
DM3YIKR	MN	RTP801 messenger RNA (RTP801 mRNA)
DM3YIKR	MT	DTT
DM3YIKR	RN	DNA-damage-inducible transcript 4 (DDIT4; RTP801). SciBX 3(20); doi:10.1038/scibx.2010.629. May 20 2010
DM3YIKR	RU	http://www.nature.com/scibx/journal/v3/n20/full/scibx.2010.629.html

DM24I0N	DI	DM24I0N
DM24I0N	DN	PF-4878691
DM24I0N	MI	TTRJ1K4
DM24I0N	MN	Toll-like receptor 7 (TLR7)
DM24I0N	MT	DTT
DM24I0N	MA	Agonist
DM24I0N	RN	The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691). Clin Pharmacol Ther. 2011 Jun;89(6):821-9.
DM24I0N	RU	https://pubmed.ncbi.nlm.nih.gov/21451504

DM3C8GQ	DI	DM3C8GQ
DM3C8GQ	DN	PF-489791
DM3C8GQ	MI	TTJ0IQB
DM3C8GQ	MN	Phosphodiesterase 5A (PDE5A)
DM3C8GQ	MT	DTT
DM3C8GQ	MA	Inhibitor
DM3C8GQ	RN	Highlights of the society for medicinesresearch symposium held december 10th 2009 at the national heart and lung institute, London, UK. Drugs of the Future 2010, 35(4): 349-358.
DM3C8GQ	RU	https://www.smr.org.uk/smr/archive/pastmeetings/Downloads/SMR_Dec_09_Report.pdf

DM0KRLJ	DI	DM0KRLJ
DM0KRLJ	DN	PF-885706
DM0KRLJ	MI	TT07C3Y
DM0KRLJ	MN	5-HT 4 receptor (HTR4)
DM0KRLJ	MT	DTT
DM0KRLJ	MA	Agonist
DM0KRLJ	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025579)
DM0KRLJ	RU	http://adisinsight.springer.com/drugs/800025579

DMF5YEN	DI	DMF5YEN
DMF5YEN	DN	PG-102
DMF5YEN	MI	TTIJP3Q
DMF5YEN	MN	TNF related activation protein (CD40LG)
DMF5YEN	MT	DTT
DMF5YEN	MA	Modulator
DMF5YEN	RN	Induction of an altered CD40 signaling complex by an antagonistic human monoclonal antibody to CD40.J Immunol.2015 May 1;194(9):4319-27.
DMF5YEN	RU	https://www.ncbi.nlm.nih.gov/pubmed/25795759

DMJTYO4	DI	DMJTYO4
DMJTYO4	DN	PGL-2
DMJTYO4	MI	TTHM0R1
DMJTYO4	MN	Steryl-sulfatase (STS)
DMJTYO4	MT	DTT
DMJTYO4	MA	Inhibitor
DMJTYO4	RN	Synergistic effects of E2MATE and norethindrone acetate on steroid sulfatase inhibition: a randomized phase I proof-of-principle clinical study in women of reproductive age. Reprod Sci. 2014 Oct;21(10):1256-65.
DMJTYO4	RU	https://pubmed.ncbi.nlm.nih.gov/24604234

DMKA705	DI	DMKA705
DMKA705	DN	PGL-2001
DMKA705	MI	TTHM0R1
DMKA705	MN	Steryl-sulfatase (STS)
DMKA705	MT	DTT
DMKA705	MA	Inhibitor
DMKA705	RN	Synergistic effects of E2MATE and norethindrone acetate on steroid sulfatase inhibition: a randomized phase I proof-of-principle clinical study in women of reproductive age. Reprod Sci. 2014 Oct;21(10):1256-65.
DMKA705	RU	https://pubmed.ncbi.nlm.nih.gov/24604234

DM9JGTQ	DI	DM9JGTQ
DM9JGTQ	DN	PH10 nasal spray
DM9JGTQ	MI	TT3FOGT
DM9JGTQ	MN	Chemosensory receptor (CheR)
DM9JGTQ	MT	DTT
DM9JGTQ	MA	Modulator
DM9JGTQ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9JGTQ	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DM71HVW	DI	DM71HVW
DM71HVW	DN	PH-794428
DM71HVW	MI	TTKMAZ6
DM71HVW	MN	Growth hormone receptor (GHR)
DM71HVW	MT	DTT
DM71HVW	MA	Modulator
DM71HVW	RN	PEGylation of somatropin (recombinant human growth hormone): impact on its clearance in humans.Xenobiotica.2008 Oct;38(10):1340-51.
DM71HVW	RU	https://www.ncbi.nlm.nih.gov/pubmed/18802875

DMGYBZI	DI	DMGYBZI
DMGYBZI	DN	PHA-739358
DMGYBZI	MI	TT9RTBL
DMGYBZI	MN	Aurora B messenger RNA (AURKB mRNA)
DMGYBZI	MT	DTT
DMGYBZI	MA	Inhibitor
DMGYBZI	RN	Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. J Med Chem. 2005 Apr 21;48(8):3080-4.
DMGYBZI	RU	https://pubmed.ncbi.nlm.nih.gov/15828847

DMGYBZI	DI	DMGYBZI
DMGYBZI	DN	PHA-739358
DMGYBZI	MI	TTPS3C0
DMGYBZI	MN	Aurora kinase A (AURKA)
DMGYBZI	MT	DTT
DMGYBZI	MA	Inhibitor
DMGYBZI	RN	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
DMGYBZI	RU	https://pubmed.ncbi.nlm.nih.gov/19568282

DMGYBZI	DI	DMGYBZI
DMGYBZI	DN	PHA-739358
DMGYBZI	MI	TT5LS6T
DMGYBZI	MN	Aurora kinase B (AURKB)
DMGYBZI	MT	DTT
DMGYBZI	MA	Inhibitor
DMGYBZI	RN	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
DMGYBZI	RU	https://pubmed.ncbi.nlm.nih.gov/19568282

DMGYBZI	DI	DMGYBZI
DMGYBZI	DN	PHA-739358
DMGYBZI	MI	TTLYXIT
DMGYBZI	MN	Aurora kinase C (AURKC)
DMGYBZI	MT	DTT
DMGYBZI	MA	Inhibitor
DMGYBZI	RN	Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. J Med Chem. 2005 Apr 21;48(8):3080-4.
DMGYBZI	RU	https://pubmed.ncbi.nlm.nih.gov/15828847

DMS2Q9G	DI	DMS2Q9G
DMS2Q9G	DN	PHA848125
DMS2Q9G	MI	TT7HF4W
DMS2Q9G	MN	Cyclin-dependent kinase 2 (CDK2)
DMS2Q9G	MT	DTT
DMS2Q9G	MA	Inhibitor
DMS2Q9G	RN	Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor. J Med Chem. 2009 Aug 27;52(16):5152-63.
DMS2Q9G	RU	https://pubmed.ncbi.nlm.nih.gov/19603809

DMRP3CV	DI	DMRP3CV
DMRP3CV	DN	Phenylalanine hydroxylase
DMRP3CV	MI	TTGSVH2
DMRP3CV	MN	Phenylalanine hydroxylase (PAH)
DMRP3CV	MT	DTT
DMRP3CV	MA	Modulator
DMRP3CV	RN	Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial. Lancet. 2014 Jul 5;384(9937):37-44.
DMRP3CV	RU	https://pubmed.ncbi.nlm.nih.gov/24743000

DMBHPDW	DI	DMBHPDW
DMBHPDW	DN	Phenylbutyrate
DMBHPDW	MI	TTNJYV2
DMBHPDW	MN	Gamma-aminobutyric acid receptor (GAR)
DMBHPDW	MT	DTT
DMBHPDW	MA	Agonist
DMBHPDW	RN	Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
DMBHPDW	RU	https://pubmed.ncbi.nlm.nih.gov/17604499

DMBHPDW	DI	DMBHPDW
DMBHPDW	DN	Phenylbutyrate
DMBHPDW	MI	TT6R7JZ
DMBHPDW	MN	Histone deacetylase 1 (HDAC1)
DMBHPDW	MT	DTT
DMBHPDW	MA	Inhibitor
DMBHPDW	RN	Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
DMBHPDW	RU	https://pubmed.ncbi.nlm.nih.gov/17604499

DMBHPDW	DI	DMBHPDW
DMBHPDW	DN	Phenylbutyrate
DMBHPDW	MI	TTRK8B9
DMBHPDW	MN	Sodium channel unspecific (NaC)
DMBHPDW	MT	DTT
DMBHPDW	MA	Blocker
DMBHPDW	RN	Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
DMBHPDW	RU	https://pubmed.ncbi.nlm.nih.gov/17604499

DMJWD62	DI	DMJWD62
DMJWD62	DN	phorbol 12-myristate 13-acetate
DMJWD62	MI	TTGJFK1
DMJWD62	MN	Calcium-activated potassium channel KCa4.1 (KCNT1)
DMJWD62	MT	DTT
DMJWD62	MA	Activator
DMJWD62	RN	Opposite regulation of Slick and Slack K+ channels by neuromodulators. J Neurosci. 2006 May 10;26(19):5059-68.
DMJWD62	RU	https://pubmed.ncbi.nlm.nih.gov/16687497

DMJWD62	DI	DMJWD62
DMJWD62	DN	phorbol 12-myristate 13-acetate
DMJWD62	MI	TTLU5FO
DMJWD62	MN	Calcium-activated potassium channel KCa4.2 (KCNT2)
DMJWD62	MT	DTT
DMJWD62	MA	Inhibitor (gating inhibitor)
DMJWD62	RN	Opposite regulation of Slick and Slack K+ channels by neuromodulators. J Neurosci. 2006 May 10;26(19):5059-68.
DMJWD62	RU	https://pubmed.ncbi.nlm.nih.gov/16687497

DMJWD62	DI	DMJWD62
DMJWD62	DN	phorbol 12-myristate 13-acetate
DMJWD62	MI	TTEO25X
DMJWD62	MN	Inward rectifier potassium channel Kir3.4 (KCNJ5)
DMJWD62	MT	DTT
DMJWD62	MA	Inhibitor (gating inhibitor)
DMJWD62	RN	Molecular basis for the inhibition of G protein-coupled inward rectifier K(+) channels by protein kinase C. Proc Natl Acad Sci U S A. 2004 Jan 27;101(4):1087-92.
DMJWD62	RU	https://pubmed.ncbi.nlm.nih.gov/14732702

DMJWD62	DI	DMJWD62
DMJWD62	DN	phorbol 12-myristate 13-acetate
DMJWD62	MI	TTKP2SU
DMJWD62	MN	Transient receptor potential cation channel V4 (TRPV4)
DMJWD62	MT	DTT
DMJWD62	MA	Activator
DMJWD62	RN	Activation of TRPV4 channels (hVRL-2/mTRP12) by phorbol derivatives. J Biol Chem. 2002 Apr 19;277(16):13569-77.
DMJWD62	RU	https://pubmed.ncbi.nlm.nih.gov/11827975

DM4FIWC	DI	DM4FIWC
DM4FIWC	DN	PI-88/Taxotere
DM4FIWC	MI	TTJGNVC
DM4FIWC	MN	Apoptosis regulator Bcl-2 (BCL-2)
DM4FIWC	MT	DTT
DM4FIWC	MA	Modulator
DM4FIWC	RN	Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Ann Oncol. 2010 Jun;21(6):1302-7.
DM4FIWC	RU	https://pubmed.ncbi.nlm.nih.gov/19917571

DM4FIWC	DI	DM4FIWC
DM4FIWC	DN	PI-88/Taxotere
DM4FIWC	MI	TT63KYR
DM4FIWC	MN	Tubulin beta-1 chain (TUBB1)
DM4FIWC	MT	DTT
DM4FIWC	MA	Modulator
DM4FIWC	RN	Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Ann Oncol. 2010 Jun;21(6):1302-7.
DM4FIWC	RU	https://pubmed.ncbi.nlm.nih.gov/19917571

DM3ZEYL	DI	DM3ZEYL
DM3ZEYL	DN	Piboserod
DM3ZEYL	MI	TT07C3Y
DM3ZEYL	MN	5-HT 4 receptor (HTR4)
DM3ZEYL	MT	DTT
DM3ZEYL	MA	Antagonist
DM3ZEYL	RN	Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
DM3ZEYL	RU	https://pubmed.ncbi.nlm.nih.gov/11293643

DMYL7VR	DI	DMYL7VR
DMYL7VR	DN	Piclamilast
DMYL7VR	MI	TTZ97H5
DMYL7VR	MN	Phosphodiesterase 4A (PDE4A)
DMYL7VR	MT	DTT
DMYL7VR	MA	Inhibitor
DMYL7VR	RN	Effects of piclamilast, a selective phosphodiesterase-4 inhibitor, on oxidative burst of sputum cells from mild asthmatics and stable COPD patients. Lung. 2004;182(6):369-77.
DMYL7VR	RU	https://pubmed.ncbi.nlm.nih.gov/15765929

DMYL7VR	DI	DMYL7VR
DMYL7VR	DN	Piclamilast
DMYL7VR	MI	TTVIAT9
DMYL7VR	MN	Phosphodiesterase 4B (PDE4B)
DMYL7VR	MT	DTT
DMYL7VR	MA	Inhibitor
DMYL7VR	RN	Effects of piclamilast, a selective phosphodiesterase-4 inhibitor, on oxidative burst of sputum cells from mild asthmatics and stable COPD patients. Lung. 2004;182(6):369-77.
DMYL7VR	RU	https://pubmed.ncbi.nlm.nih.gov/15765929

DMYL7VR	DI	DMYL7VR
DMYL7VR	DN	Piclamilast
DMYL7VR	MI	TTSKMI8
DMYL7VR	MN	Phosphodiesterase 4D (PDE4D)
DMYL7VR	MT	DTT
DMYL7VR	MA	Inhibitor
DMYL7VR	RN	Effects of piclamilast, a selective phosphodiesterase-4 inhibitor, on oxidative burst of sputum cells from mild asthmatics and stable COPD patients. Lung. 2004;182(6):369-77.
DMYL7VR	RU	https://pubmed.ncbi.nlm.nih.gov/15765929

DMMO46E	DI	DMMO46E
DMMO46E	DN	Pidilizumab
DMMO46E	MI	TT8ZLTI
DMMO46E	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMMO46E	MT	DTT
DMMO46E	RN	PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother. 2011 Jun;34(5):409-18.
DMMO46E	RU	https://pubmed.ncbi.nlm.nih.gov/21577144

DMAFZ84	DI	DMAFZ84
DMAFZ84	DN	PIKAMILONE
DMAFZ84	MI	TTNJYV2
DMAFZ84	MN	Gamma-aminobutyric acid receptor (GAR)
DMAFZ84	MT	DTT
DMAFZ84	MA	Modulator
DMAFZ84	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMAFZ84	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM96VWD	DI	DM96VWD
DM96VWD	DN	PINOCEMBRIN
DM96VWD	MI	TTI84H7
DM96VWD	MN	Cytochrome P450 1B1 (CYP1B1)
DM96VWD	MT	DTT
DM96VWD	MA	Inhibitor
DM96VWD	RN	Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5.
DM96VWD	RU	https://pubmed.ncbi.nlm.nih.gov/20696580

DM276N1	DI	DM276N1
DM276N1	DN	Piritrexim
DM276N1	MI	DTI7UX6
DM276N1	MN	Breast cancer resistance protein (ABCG2)
DM276N1	MT	DTP
DM276N1	MA	Substrate
DM276N1	RN	Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34.
DM276N1	RU	https://doi.org/10.1007/s00280-006-0230-9

DM276N1	DI	DM276N1
DM276N1	DN	Piritrexim
DM276N1	MI	TTYZVDJ
DM276N1	MN	Dihydrofolate reductase (DHFR)
DM276N1	MT	DTT
DM276N1	MA	Modulator
DM276N1	RN	Structural variations of piritrexim, a lipophilic inhibitor of human dihydrofolate reductase: synthesis, antitumor activity and molecular modeling ... Eur J Med Chem. 2004 Dec;39(12):1079-88.
DM276N1	RU	https://www.ncbi.nlm.nih.gov/pubmed/15571870

DMC3T2S	DI	DMC3T2S
DMC3T2S	DN	PIRODOMAST
DMC3T2S	MI	TTTWGIX
DMC3T2S	MN	Leukotriene receptor (LTR)
DMC3T2S	MT	DTT
DMC3T2S	MA	Modulator
DMC3T2S	RN	Antiallergy activity of Sch 37224, a new inhibitor of leukotriene formation. J Pharmacol Exp Ther. 1988 Dec;247(3):997-1003.
DMC3T2S	RU	https://pubmed.ncbi.nlm.nih.gov/2462630

DMHI6GE	DI	DMHI6GE
DMHI6GE	DN	Pirsidomine
DMHI6GE	MI	TT6HPVC
DMHI6GE	MN	Guanylate cyclase (GC)
DMHI6GE	MT	DTT
DMHI6GE	MA	Modulator
DMHI6GE	RN	Activation of soluble guanylyl cyclase by the nitrovasodilator 3-morpholinosydnonimine involves formation of S-nitrosoglutathione. Mol Pharmacol. 1998 Jul;54(1):207-12.
DMHI6GE	RU	https://pubmed.ncbi.nlm.nih.gov/9658207

DMKEV7N	DI	DMKEV7N
DMKEV7N	DN	PK1
DMKEV7N	MI	TTCGY2K
DMKEV7N	MN	DNA topoisomerase II alpha (TOP2A)
DMKEV7N	MT	DTT
DMKEV7N	MA	Modulator
DMKEV7N	RN	Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol. 2009 Jun;34(6):1629-36.
DMKEV7N	RU	https://pubmed.ncbi.nlm.nih.gov/19424581

DMHUCQS	DI	DMHUCQS
DMHUCQS	DN	PL-3994
DMHUCQS	MI	TTJME02
DMHUCQS	MN	Atrial natriuretic peptide receptor A (NPR1)
DMHUCQS	MT	DTT
DMHUCQS	MA	Agonist
DMHUCQS	RN	In vitro and in vivo pharmacological profile of PL-3994, a novel cyclic peptide (Hept-cyclo(Cys-His-Phe-d-Ala-Gly-Arg-d-Nle-Asp-Arg-Ile-Ser-Cys)-Tyr-[Arg mimetic]-NH2) natriuretic peptide receptor-A agonist that is resistant to neutral endopeptidase and acts as a bronchodilator. Pulm Pharmacol Ther. 2013 April; 26(2): 229-238.
DMHUCQS	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4070431/

DMYUO6B	DI	DMYUO6B
DMYUO6B	DN	PlaMavax
DMYUO6B	MI	TTDUK07
DMYUO6B	MN	Plasmodium Thrombospondin relate anonymous protein (Plasm TRAP)
DMYUO6B	MT	DTT
DMYUO6B	RN	Lipid kinase enters the malaria stage. SciBX 6(48); doi:10.1038/scibx.2013.1373. Dec. 19 2013
DMYUO6B	RU	http://www.nature.com/scibx/journal/v6/n48/full/scibx.2013.1373.html

DMOB1EM	DI	DMOB1EM
DMOB1EM	DN	Plasmin
DMOB1EM	MI	TTWODQF
DMOB1EM	MN	Fibrin (FG)
DMOB1EM	MT	DTT
DMOB1EM	MA	Modulator
DMOB1EM	RN	ClinicalTrials.gov (NCT01014975) A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients. U.S. National Institutes of Health.
DMOB1EM	RU	https://clinicaltrials.gov/ct2/show/NCT01014975

DMK10ZC	DI	DMK10ZC
DMK10ZC	DN	PLECONARIL
DMK10ZC	MI	TT87Q2D
DMK10ZC	MN	Picornavirus Capsid protein VP1 (PicVir VP1)
DMK10ZC	MT	DTT
DMK10ZC	MA	Modulator
DMK10ZC	RN	Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses. Antimicrob Agents Chemother. 2005 Nov;49(11):4492-9.
DMK10ZC	RU	https://pubmed.ncbi.nlm.nih.gov/16251287

DM7Y60I	DI	DM7Y60I
DM7Y60I	DN	Plevitrexed
DM7Y60I	MI	TTU6BFZ
DM7Y60I	MN	Candida Thymidylate synthase (Candi TMP1)
DM7Y60I	MT	DTT
DM7Y60I	MA	Inhibitor
DM7Y60I	RN	Cooperative inhibition of human thymidylate synthase by mixtures of active site binding and allosteric inhibitors. Biochemistry. 2007 Mar 13;46(10):2823-30.
DM7Y60I	RU	https://pubmed.ncbi.nlm.nih.gov/17297914

DMTL39C	DI	DMTL39C
DMTL39C	DN	Plevitrexed (R)-isomer
DMTL39C	MI	TTU6BFZ
DMTL39C	MN	Candida Thymidylate synthase (Candi TMP1)
DMTL39C	MT	DTT
DMTL39C	MA	Inhibitor
DMTL39C	RN	Cooperative inhibition of human thymidylate synthase by mixtures of active site binding and allosteric inhibitors. Biochemistry. 2007 Mar 13;46(10):2823-30.
DMTL39C	RU	https://pubmed.ncbi.nlm.nih.gov/17297914

DMTL39C	DI	DMTL39C
DMTL39C	DN	Plevitrexed (R)-isomer
DMTL39C	MI	TT5FOMZ
DMTL39C	MN	Thymidylate synthase (TYMS)
DMTL39C	MT	DTT
DMTL39C	MA	Inhibitor
DMTL39C	RN	Differential effect of 1,10-phenanthroline on mammalian, yeast, and parasite glycosylphosphatidylinositol anchor synthesis. Biochem Biophys Res Commun. 2001 Nov 16;288(5):1112-8.
DMTL39C	RU	https://pubmed.ncbi.nlm.nih.gov/11700026

DMRTD7I	DI	DMRTD7I
DMRTD7I	DN	PLX8394
DMRTD7I	MI	TTWCGQT
DMRTD7I	MN	Serine/threonine-protein kinase B-raf (BRAF)
DMRTD7I	MT	DTT
DMRTD7I	MA	Inhibitor
DMRTD7I	RN	Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors. Pigment Cell Melanoma Res. 2014 Mar;27(2):253-62.
DMRTD7I	RU	https://pubmed.ncbi.nlm.nih.gov/24283590

DMMKOPX	DI	DMMKOPX
DMMKOPX	DN	PM-00104
DMMKOPX	MI	TTUTN1I
DMMKOPX	MN	Human Deoxyribonucleic acid (hDNA)
DMMKOPX	MT	DTT
DMMKOPX	MA	Modulator
DMMKOPX	RN	Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response. Haematologica. 2011 May;96(5):687-95.
DMMKOPX	RU	https://pubmed.ncbi.nlm.nih.gov/21330323

DMS34YO	DI	DMS34YO
DMS34YO	DN	PM184
DMS34YO	MI	TTHVQ4N
DMS34YO	MN	Tubulin polymerization (TubP)
DMS34YO	MT	DTT
DMS34YO	MA	Inhibitor
DMS34YO	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMS34YO	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM0OVZ2	DI	DM0OVZ2
DM0OVZ2	DN	PMID27841036-Compound-37
DM0OVZ2	MI	TTVDSZ0
DM0OVZ2	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DM0OVZ2	MT	DTT
DM0OVZ2	MA	Inhibitor
DM0OVZ2	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DM0OVZ2	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DM0OVZ2	DI	DM0OVZ2
DM0OVZ2	DN	PMID27841036-Compound-37
DM0OVZ2	MI	TTQ4V96
DM0OVZ2	MN	Poly [ADP-ribose] polymerase 2 (PARP2)
DM0OVZ2	MT	DTT
DM0OVZ2	MA	Inhibitor
DM0OVZ2	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DM0OVZ2	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DM0OVZ2	DI	DM0OVZ2
DM0OVZ2	DN	PMID27841036-Compound-37
DM0OVZ2	MI	TTVUSO7
DM0OVZ2	MN	Tankyrase-1 (TNKS-1)
DM0OVZ2	MT	DTT
DM0OVZ2	MA	Inhibitor
DM0OVZ2	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DM0OVZ2	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DM0OVZ2	DI	DM0OVZ2
DM0OVZ2	DN	PMID27841036-Compound-37
DM0OVZ2	MI	TTFQI4H
DM0OVZ2	MN	Tankyrase-2 (TNKS-2)
DM0OVZ2	MT	DTT
DM0OVZ2	MA	Inhibitor
DM0OVZ2	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DM0OVZ2	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DMZUAJ4	DI	DMZUAJ4
DMZUAJ4	DN	PMX-53
DMZUAJ4	MI	TTXV4FI
DMZUAJ4	MN	Albendazole monooxygenase (CYP3A4)
DMZUAJ4	MT	DTT
DMZUAJ4	MA	Inhibitor
DMZUAJ4	RN	Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92.
DMZUAJ4	RU	https://pubmed.ncbi.nlm.nih.gov/16876401

DMZUAJ4	DI	DMZUAJ4
DMZUAJ4	DN	PMX-53
DMZUAJ4	MI	TTHXFA1
DMZUAJ4	MN	C5a anaphylatoxin chemotactic receptor (C5AR1)
DMZUAJ4	MT	DTT
DMZUAJ4	MA	Modulator
DMZUAJ4	RN	Company report (Arana Therapeutics)
DMZUAJ4	RU	http://www.asx.com.au/asxpdf/20090219/pdf/31g4hr7254nxxr.pdf

DMZUAJ4	DI	DMZUAJ4
DMZUAJ4	DN	PMX-53
DMZUAJ4	MI	TTD0CIQ
DMZUAJ4	MN	Melanocortin receptor 4 (MC4R)
DMZUAJ4	MT	DTT
DMZUAJ4	MA	Inhibitor
DMZUAJ4	RN	Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92.
DMZUAJ4	RU	https://pubmed.ncbi.nlm.nih.gov/16876401

DMZUAJ4	DI	DMZUAJ4
DMZUAJ4	DN	PMX-53
DMZUAJ4	MI	TTNT7K8
DMZUAJ4	MN	Nociceptin receptor (OPRL1)
DMZUAJ4	MT	DTT
DMZUAJ4	MA	Inhibitor
DMZUAJ4	RN	Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92.
DMZUAJ4	RU	https://pubmed.ncbi.nlm.nih.gov/16876401

DMZUAJ4	DI	DMZUAJ4
DMZUAJ4	DN	PMX-53
DMZUAJ4	MI	TTYO0A3
DMZUAJ4	MN	Substance-K receptor (TACR2)
DMZUAJ4	MT	DTT
DMZUAJ4	MA	Inhibitor
DMZUAJ4	RN	Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92.
DMZUAJ4	RU	https://pubmed.ncbi.nlm.nih.gov/16876401

DMZUAJ4	DI	DMZUAJ4
DMZUAJ4	DN	PMX-53
DMZUAJ4	MI	TT4TFGN
DMZUAJ4	MN	Vasopressin V1a receptor (V1AR)
DMZUAJ4	MT	DTT
DMZUAJ4	MA	Inhibitor
DMZUAJ4	RN	Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92.
DMZUAJ4	RU	https://pubmed.ncbi.nlm.nih.gov/16876401

DMWT73D	DI	DMWT73D
DMWT73D	DN	PMX-60056
DMWT73D	MI	TT4QPUL
DMWT73D	MN	Antithrombin-III (ATIII)
DMWT73D	MT	DTT
DMWT73D	MA	Antagonist
DMWT73D	RN	Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Correction in: Chest. 2013 August; 144(2): 721.
DMWT73D	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278070/

DMUVON0	DI	DMUVON0
DMUVON0	DN	PNT-2258
DMUVON0	MI	TTFOUV4
DMUVON0	MN	BCL-2 messenger RNA (BCL2 mRNA)
DMUVON0	MT	DTT
DMUVON0	RN	Clinical pipeline report, company report or official report of ProNAi.
DMUVON0	RU	http://pronai.com/pnt2258-targeting-bcl2/

DMM8IAQ	DI	DMM8IAQ
DMM8IAQ	DN	PNU-142731A
DMM8IAQ	MI	TT26HJ8
DMM8IAQ	MN	Eosinophil/lymphocyte-rich accumulation (ELR accum)
DMM8IAQ	MT	DTT
DMM8IAQ	MA	Modulator
DMM8IAQ	RN	Preclinical evaluation of anti-inflammatory activities of the novel pyrrolopyrimidine PNU-142731A, a potential treatment for asthma. J Pharmacol Exp Ther. 1999 Jul;290(1):188-95.
DMM8IAQ	RU	https://pubmed.ncbi.nlm.nih.gov/10381775

DM4OT29	DI	DM4OT29
DM4OT29	DN	POL-6326
DM4OT29	MI	TTBID49
DM4OT29	MN	C-X-C chemokine receptor type 4 (CXCR4)
DM4OT29	MT	DTT
DM4OT29	MA	Antagonist
DM4OT29	RN	CXCR4 inhibitors: tumor vasculature and therapeutic challenges. Recent Pat Anticancer Drug Discov. 2012 Sep;7(3):251-64.
DM4OT29	RU	https://pubmed.ncbi.nlm.nih.gov/22376154

DMFCIKN	DI	DMFCIKN
DMFCIKN	DN	Polivy
DMFCIKN	MI	TTBN5I7
DMFCIKN	MN	B-cell-specific glycoprotein B29 (CD79B)
DMFCIKN	MT	DTT
DMFCIKN	MA	Agonist
DMFCIKN	RN	Polatuzumab Vedotin: First Global Approval. Drugs. 2019 Sep;79(13):1467-1475.
DMFCIKN	RU	https://pubmed.ncbi.nlm.nih.gov/31352604

DMUXEBQ	DI	DMUXEBQ
DMUXEBQ	DN	Polyamine
DMUXEBQ	MI	DT01CKS
DMUXEBQ	MN	Lymphocyte activation antigen 4F2 (SLC3A2)
DMUXEBQ	MT	DTP
DMUXEBQ	MA	Substrate
DMUXEBQ	RN	Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma.
DMUXEBQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/30700572

DMXROM7	DI	DMXROM7
DMXROM7	DN	Polyglutamate camptothecin
DMXROM7	MI	TTGTQHC
DMXROM7	MN	DNA topoisomerase I (TOP1)
DMXROM7	MT	DTT
DMXROM7	MA	Inhibitor
DMXROM7	RN	Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006 Oct;6(10):789-802.
DMXROM7	RU	https://pubmed.ncbi.nlm.nih.gov/16990856

DM2570B	DI	DM2570B
DM2570B	DN	Poly-ICLC
DM2570B	MI	TTD24Y0
DM2570B	MN	Toll-like receptor 3 (TLR3)
DM2570B	MT	DTT
DM2570B	MA	Inducer
DM2570B	RN	Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med. 2007 Feb 12;5:10.
DM2570B	RU	https://pubmed.ncbi.nlm.nih.gov/17295916

DM3QDA6	DI	DM3QDA6
DM3QDA6	DN	Polynoma-1
DM3QDA6	MI	TT362RB
DM3QDA6	MN	MART-1 melanoma antigen (MLANA)
DM3QDA6	MT	DTT
DM3QDA6	RN	An immuno-oncology company developing a novel polyvalent antigen therapy for the treatment of melanoma. Polynoma. 2015.
DM3QDA6	RU	http://www.polynoma.com/

DM3QDA6	DI	DM3QDA6
DM3QDA6	DN	Polynoma-1
DM3QDA6	MI	TTWSKHD
DM3QDA6	MN	Melanoma-associated antigen 3 (MAGEA3)
DM3QDA6	MT	DTT
DM3QDA6	RN	An immuno-oncology company developing a novel polyvalent antigen therapy for the treatment of melanoma. Polynoma. 2015.
DM3QDA6	RU	http://www.polynoma.com/

DM3QDA6	DI	DM3QDA6
DM3QDA6	DN	Polynoma-1
DM3QDA6	MI	TTULVH8
DM3QDA6	MN	Tyrosinase (TYR)
DM3QDA6	MT	DTT
DM3QDA6	RN	An immuno-oncology company developing a novel polyvalent antigen therapy for the treatment of melanoma. Polynoma. 2015.
DM3QDA6	RU	http://www.polynoma.com/

DMIAZ13	DI	DMIAZ13
DMIAZ13	DN	Ponezumab
DMIAZ13	MI	TTE4KHA
DMIAZ13	MN	Amyloid beta A4 protein (APP)
DMIAZ13	MT	DTT
DMIAZ13	RN	Structural basis of C-terminal beta-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease. J Mol Biol. 2012 Aug 24;421(4-5):525-36.
DMIAZ13	RU	https://pubmed.ncbi.nlm.nih.gov/22197375

DM5HMTB	DI	DM5HMTB
DM5HMTB	DN	Porphobilinogen
DM5HMTB	MI	TTJHKYD
DM5HMTB	MN	Delta-aminolevulinic acid dehydratase (ALAD)
DM5HMTB	MT	DTT
DM5HMTB	MA	Inhibitor
DM5HMTB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM5HMTB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMH0LM2	DI	DMH0LM2
DMH0LM2	DN	POT-4
DMH0LM2	MI	TTJGY7A
DMH0LM2	MN	Complement C3 (CO3)
DMH0LM2	MT	DTT
DMH0LM2	MA	Inhibitor
DMH0LM2	RN	Compstatin: A Complement Inhibitor on its Way to Clinical Application. Adv Exp Med Biol. 2008; 632: 273-292.
DMH0LM2	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2700864/

DMTE8DC	DI	DMTE8DC
DMTE8DC	DN	Pozelimab
DMTE8DC	MI	TTKANGO
DMTE8DC	MN	Complement C5 (CO5)
DMTE8DC	MT	DTT
DMTE8DC	MA	Inhibitor
DMTE8DC	RN	Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5. PLoS One. 2020 May 8;15(5):e0231892.
DMTE8DC	RU	https://pubmed.ncbi.nlm.nih.gov/32384086

DM4EHVB	DI	DM4EHVB
DM4EHVB	DN	PPI-668
DM4EHVB	MI	TTCJ2X8
DM4EHVB	MN	Hepatitis C virus Non-structural 5A (HCV NS5A)
DM4EHVB	MT	DTT
DM4EHVB	MA	Modulator
DM4EHVB	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM4EHVB	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMM6J5Z	DI	DMM6J5Z
DMM6J5Z	DN	PQ-912
DMM6J5Z	MI	TTJ7YTV
DMM6J5Z	MN	Glutaminyl cyclase (QPCT)
DMM6J5Z	MT	DTT
DMM6J5Z	MA	Inhibitor
DMM6J5Z	RN	Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer s Disease ImmunotherapyRoxanna Perez-Garmendia, Goar Gevorkian. Curr Neuropharmacol. 2013 September; 11(5): 491-498.
DMM6J5Z	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763757/

DMMCYZ8	DI	DMMCYZ8
DMMCYZ8	DN	PQR309
DMMCYZ8	MI	TTTHBCA
DMMCYZ8	MN	PI3-kinase beta (PIK3CB)
DMMCYZ8	MT	DTT
DMMCYZ8	MA	Inhibitor
DMMCYZ8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2154).
DMMCYZ8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2154

DMMCYZ8	DI	DMMCYZ8
DMMCYZ8	DN	PQR309
DMMCYZ8	MI	TTHBTOP
DMMCYZ8	MN	PI3-kinase gamma (PIK3CG)
DMMCYZ8	MT	DTT
DMMCYZ8	MA	Inhibitor
DMMCYZ8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2155).
DMMCYZ8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2155

DMMCYZ8	DI	DMMCYZ8
DMMCYZ8	DN	PQR309
DMMCYZ8	MI	TTCJG29
DMMCYZ8	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMMCYZ8	MT	DTT
DMMCYZ8	MA	Inhibitor
DMMCYZ8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
DMMCYZ8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109

DM1O0DV	DI	DM1O0DV
DM1O0DV	DN	Pradefovir
DM1O0DV	MI	DE4LYSA
DM1O0DV	MN	Cytochrome P450 3A4 (CYP3A4)
DM1O0DV	MT	DME
DM1O0DV	MA	Metabolism
DM1O0DV	RN	Metabolic activation of pradefovir by CYP3A4 and its potential as an inhibitor or inducer. Antimicrob Agents Chemother. 2006 Sep;50(9):2926-31.
DM1O0DV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16940083

DM1O0DV	DI	DM1O0DV
DM1O0DV	DN	Pradefovir
DM1O0DV	MI	TTS5K1M
DM1O0DV	MN	Hepatitis B virus Reverse transcriptase (HBV RT)
DM1O0DV	MT	DTT
DM1O0DV	MA	Modulator
DM1O0DV	RN	DOI: 10.1128/AAC.01566-05
DM1O0DV	RU	http://aac.asm.org/content/50/9/2926.full

DMIVMR3	DI	DMIVMR3
DMIVMR3	DN	Prajmaline
DMIVMR3	MI	DECB0K3
DMIVMR3	MN	Cytochrome P450 2D6 (CYP2D6)
DMIVMR3	MT	DME
DMIVMR3	MA	Metabolism
DMIVMR3	RN	Pharmacokinetics of N-propylajmaline in relation to polymorphic sparteine oxidation. Klin Wochenschr. 1985 Nov 15;63(22):1180-6.
DMIVMR3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=4079282

DM73UTG	DI	DM73UTG
DM73UTG	DN	PRALNACASAN
DM73UTG	MI	TTCQIBE
DM73UTG	MN	Caspase-1 (CASP1)
DM73UTG	MT	DTT
DM73UTG	MA	Modulator
DM73UTG	RN	Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthritis Cartilage. 2003 Oct;11(10):738-46.
DM73UTG	RU	https://pubmed.ncbi.nlm.nih.gov/13129693

DMBH7XI	DI	DMBH7XI
DMBH7XI	DN	Pramiconazole
DMBH7XI	MI	TTTSOUD
DMBH7XI	MN	Candida Cytochrome P450 51 (Candi ERG11)
DMBH7XI	MT	DTT
DMBH7XI	MA	Modulator
DMBH7XI	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMBH7XI	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMZT8FS	DI	DMZT8FS
DMZT8FS	DN	Preverex
DMZT8FS	MI	TTU5CF1
DMZT8FS	MN	Actin polymerization (Actin poly)
DMZT8FS	MT	DTT
DMZT8FS	MA	Modulator
DMZT8FS	RN	Chronic hypoxia differentially up-regulates protein kinase C-mediated ovine uterine arterial contraction via actin polymerization signaling in pregnancy. Biol Reprod. 2012 Dec 21;87(6):142.
DMZT8FS	RU	https://pubmed.ncbi.nlm.nih.gov/23136295

DMK8PTH	DI	DMK8PTH
DMK8PTH	DN	PRM-151
DMK8PTH	MI	TTNJ5A6
DMK8PTH	MN	Neuronal pentraxin-2 (NPTX2)
DMK8PTH	MT	DTT
DMK8PTH	MA	Modulator
DMK8PTH	RN	PRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis. Drug News Perspect. 2010 Jun;23(5):305-15.
DMK8PTH	RU	https://pubmed.ncbi.nlm.nih.gov/20603654

DMBZ6CP	DI	DMBZ6CP
DMBZ6CP	DN	PRN1008
DMBZ6CP	MI	TTGM6VW
DMBZ6CP	MN	Tyrosine-protein kinase BTK (ATK)
DMBZ6CP	MT	DTT
DMBZ6CP	MA	Inhibitor
DMBZ6CP	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMBZ6CP	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DM5ZTE4	DI	DM5ZTE4
DM5ZTE4	DN	PRO-001
DM5ZTE4	MI	TT2EDHU
DM5ZTE4	MN	Insulin-degrading enzyme (IDE)
DM5ZTE4	MT	DTT
DM5ZTE4	MA	Modulator
DM5ZTE4	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2371).
DM5ZTE4	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2371

DMFYABR	DI	DMFYABR
DMFYABR	DN	PRO-044
DMFYABR	MI	TTWLFXU
DMFYABR	MN	Dystrophin messenger RNA (DMD mRNA)
DMFYABR	MT	DTT
DMFYABR	RN	Update on neuromuscular disorders in pediatric orthopaedics: Duchenne muscular dystrophy, myelomeningocele, and cerebral palsy. J Pediatr Orthop. 2014 Oct-Nov;34 Suppl 1:S44-8.
DMFYABR	RU	https://pubmed.ncbi.nlm.nih.gov/25207736

DMMEL6B	DI	DMMEL6B
DMMEL6B	DN	PRO22
DMMEL6B	MI	TTSXVID
DMMEL6B	MN	Nuclear factor NF-kappa-B (NFKB)
DMMEL6B	MT	DTT
DMMEL6B	MA	Inhibitor
DMMEL6B	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMMEL6B	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMF9RB4	DI	DMF9RB4
DMF9RB4	DN	Procysteine
DMF9RB4	MI	DEJ1LMB
DMF9RB4	MN	Pyroglutamase (OPLAH)
DMF9RB4	MT	DME
DMF9RB4	MA	Metabolism
DMF9RB4	RN	Increased expression of the MGMT repair protein mediated by cysteine prodrugs and chemopreventative natural products in human lymphocytes and tumor cell lines. Carcinogenesis. 2007 Feb;28(2):378-89.
DMF9RB4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16950796

DMF9RB4	DI	DMF9RB4
DMF9RB4	DN	Procysteine
DMF9RB4	MI	TTULV0X
DMF9RB4	MN	Reactive oxygen species (ROS)
DMF9RB4	MT	DTT
DMF9RB4	MA	Modulator
DMF9RB4	RN	Protective effect of procysteine on Acinetobacter pneumonia in hyperoxic conditions. J Antimicrob Chemother. 2013 Oct;68(10):2305-10.
DMF9RB4	RU	https://pubmed.ncbi.nlm.nih.gov/23681269

DM4MF9V	DI	DM4MF9V
DM4MF9V	DN	proglumide
DM4MF9V	MI	TTCG0AL
DM4MF9V	MN	Cholecystokinin receptor type A (CCKAR)
DM4MF9V	MT	DTT
DM4MF9V	MA	Antagonist
DM4MF9V	RN	Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists. Arzneimittelforschung. 1987 Nov;37(11):1265-8.
DM4MF9V	RU	https://pubmed.ncbi.nlm.nih.gov/3440035

DMZIQ8G	DI	DMZIQ8G
DMZIQ8G	DN	Prolarix
DMZIQ8G	MI	TTJLP0R
DMZIQ8G	MN	Quinone reductase 2 (NQO2)
DMZIQ8G	MT	DTT
DMZIQ8G	MA	Inhibitor
DMZIQ8G	RN	CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
DMZIQ8G	RU	http://www.centerwatch.com/

DME25TI	DI	DME25TI
DME25TI	DN	Prosaptide TX14(A)
DME25TI	MI	TTDB5IS
DME25TI	MN	Receptor unspecific (Rec)
DME25TI	MT	DTT
DME25TI	MA	Modulator
DME25TI	RN	Central action of prosaptide TX14(A) against gp120-induced allodynia in rats. European Journal of Pain Volume 12, Issue 1, January 2008, Pages 76-81.
DME25TI	RU	http://www.sciencedirect.com/science/article/pii/S1090380107000584

DMM7F1E	DI	DMM7F1E
DMM7F1E	DN	PRUVANSERIN
DMM7F1E	MI	TTJQOD7
DMM7F1E	MN	5-HT 2A receptor (HTR2A)
DMM7F1E	MT	DTT
DMM7F1E	MA	Modulator
DMM7F1E	RN	5-HT(2A) inverse-agonists for the treatment of insomnia. Curr Top Med Chem. 2008;8(11):969-76.
DMM7F1E	RU	https://www.ncbi.nlm.nih.gov/pubmed/18673166

DMKTP8E	DI	DMKTP8E
DMKTP8E	DN	PRX002
DMKTP8E	MI	TT08OSU
DMKTP8E	MN	Synuclein alpha (SNCA)
DMKTP8E	MT	DTT
DMKTP8E	MA	Inhibitor
DMKTP8E	RN	Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-alpha-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2018 Oct 1;75(10):1206-1214.
DMKTP8E	RU	https://pubmed.ncbi.nlm.nih.gov/29913017

DM1JNDV	DI	DM1JNDV
DM1JNDV	DN	PRX00933
DM1JNDV	MI	TTWJBZ5
DM1JNDV	MN	5-HT 2C receptor (HTR2C)
DM1JNDV	MT	DTT
DM1JNDV	MA	Agonist
DM1JNDV	RN	2011 Pipeline of Proximagen Group plc.
DM1JNDV	RU	http://www.proximagen.com/science/pipeline/

DMR7H2V	DI	DMR7H2V
DMR7H2V	DN	PRX-08066
DMR7H2V	MI	TT0K1SC
DMR7H2V	MN	5-HT 2B receptor (HTR2B)
DMR7H2V	MT	DTT
DMR7H2V	MA	Antagonist
DMR7H2V	RN	Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
DMR7H2V	RU	https://pubmed.ncbi.nlm.nih.gov/17064221

DMEVXS1	DI	DMEVXS1
DMEVXS1	DN	PRX-3140
DMEVXS1	MI	TT07C3Y
DMEVXS1	MN	5-HT 4 receptor (HTR4)
DMEVXS1	MT	DTT
DMEVXS1	MA	Modulator
DMEVXS1	RN	Clinical pipeline report, company report or official report of Nanotherapeutics.
DMEVXS1	RU	http://www.nanotherapeutics.com/prx-3140/

DM7YWVT	DI	DM7YWVT
DM7YWVT	DN	PRX-321
DM7YWVT	MI	TTDWHC3
DM7YWVT	MN	Interleukin 4 receptor alpha (IL4R)
DM7YWVT	MT	DTT
DM7YWVT	MA	Agonist
DM7YWVT	RN	Convection-enhanced drug delivery of interleukin-4 Pseudomonas exotoxin (PRX321): increased distribution and magnetic resonance monitoring. J Pharmacol Exp Ther. 2009 Aug;330(2):520-5.
DM7YWVT	RU	https://pubmed.ncbi.nlm.nih.gov/19478131

DMHZIFJ	DI	DMHZIFJ
DMHZIFJ	DN	PS-938285
DMHZIFJ	MI	TT30C9G
DMHZIFJ	MN	C-X-C chemokine receptor type 2 (CXCR2)
DMHZIFJ	MT	DTT
DMHZIFJ	MA	Antagonist
DMHZIFJ	RN	CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
DMHZIFJ	RU	http://www.centerwatch.com/

DMCSN69	DI	DMCSN69
DMCSN69	DN	PT2385
DMCSN69	MI	TTSN6QU
DMCSN69	MN	HIF1-alpha messenger RNA (HIF1A mRNA)
DMCSN69	MT	DTT
DMCSN69	MA	Inhibitor
DMCSN69	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMCSN69	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMCSN69	DI	DMCSN69
DMCSN69	DN	PT2385
DMCSN69	MI	TTWPA54
DMCSN69	MN	HIF2-alpha messenger RNA (EPAS1 mRNA)
DMCSN69	MT	DTT
DMCSN69	MA	Inhibitor
DMCSN69	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMCSN69	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMCSN69	DI	DMCSN69
DMCSN69	DN	PT2385
DMCSN69	MI	TTDMLNT
DMCSN69	MN	Hypoxia-inducible factor 2 alpha (HIF-2A)
DMCSN69	MT	DTT
DMCSN69	MA	Inhibitor
DMCSN69	RN	Hypoxia-inducible factor 2: a novel target in gliomas.Future Med Chem. 2018 Sep 1;10(18):2227-2236. 
DMCSN69	RU	https://pubmed.ncbi.nlm.nih.gov/30089425

DMP9TKE	DI	DMP9TKE
DMP9TKE	DN	PTC299
DMP9TKE	MI	TT2J34L
DMP9TKE	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMP9TKE	MT	DTT
DMP9TKE	MA	Inhibitor
DMP9TKE	RN	Therapeutic intervention in a rat model of ARDS: I. Dual inhibition of arachidonic acid metabolism. Circ Shock. 1990 Nov;32(3):231-42.
DMP9TKE	RU	https://pubmed.ncbi.nlm.nih.gov/2124522

DMP9TKE	DI	DMP9TKE
DMP9TKE	DN	PTC299
DMP9TKE	MI	TTOHSBA
DMP9TKE	MN	Vascular endothelial growth factor A (VEGFA)
DMP9TKE	MT	DTT
DMP9TKE	MA	Modulator
DMP9TKE	RN	Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study.J Neurooncol.2015 Jan;121(1):217-24.
DMP9TKE	RU	https://www.ncbi.nlm.nih.gov/pubmed/25407389

DMOYS8A	DI	DMOYS8A
DMOYS8A	DN	PTG-300
DMOYS8A	MI	TTPCG5T
DMOYS8A	MN	Hepcidin (HAMP)
DMOYS8A	MT	DTT
DMOYS8A	MA	Replacement
DMOYS8A	RN	Clinical pipeline report, company report or official report of Protagonist Therapeutics.
DMOYS8A	RU	https://www.protagonist-inc.com/pipeline/#overview

DMV17HK	DI	DMV17HK
DMV17HK	DN	PTI-125
DMV17HK	MI	TTSTRZY
DMV17HK	MN	Filamin A (FLNA)
DMV17HK	MT	DTT
DMV17HK	MA	Inhibitor
DMV17HK	RN	Reducing amyloid-related Alzheimer's disease pathogenesis by a small molecule targeting filamin A. J Neurosci. 2012 Jul 18;32(29):9773-84.
DMV17HK	RU	https://pubmed.ncbi.nlm.nih.gov/22815492

DM0ZIT2	DI	DM0ZIT2
DM0ZIT2	DN	PTX-200
DM0ZIT2	MI	TTWTSCV
DM0ZIT2	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DM0ZIT2	MT	DTT
DM0ZIT2	MA	Inhibitor
DM0ZIT2	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM0ZIT2	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMJIMXH	DI	DMJIMXH
DMJIMXH	DN	Puerarin
DMJIMXH	MI	TTWJBZ5
DMJIMXH	MN	5-HT 2C receptor (HTR2C)
DMJIMXH	MT	DTT
DMJIMXH	MA	Modulator
DMJIMXH	RN	NPI-031G (puerarin) reduces anxiogenic effects of alcohol withdrawal or benzodiazepine inverse or 5-HT2C agonists. Pharmacol Biochem Behav. 2003 Jun;75(3):619-25.
DMJIMXH	RU	https://www.ncbi.nlm.nih.gov/pubmed/12895679

DMW7L0Y	DI	DMW7L0Y
DMW7L0Y	DN	PUL-042
DMW7L0Y	MI	TTAVUMS
DMW7L0Y	MN	HUMAN toll-like receptor 2 (TLR2)
DMW7L0Y	MT	DTT
DMW7L0Y	MA	Agonist
DMW7L0Y	RN	Pulmotects lead product, PUL-042, is a clinical stage inhaled therapeutic that in preclinical studies stimulates the innate immune system in minutes to provide immediate and effective protection against all major classes of pathogens that lasts for days.
DMW7L0Y	RU	https://pulmotect.com/product/

DMW7L0Y	DI	DMW7L0Y
DMW7L0Y	DN	PUL-042
DMW7L0Y	MI	TTLSU52
DMW7L0Y	MN	HUMAN toll-like receptor 6 (TLR6)
DMW7L0Y	MT	DTT
DMW7L0Y	MA	Agonist
DMW7L0Y	RN	Pulmotects lead product, PUL-042, is a clinical stage inhaled therapeutic that in preclinical studies stimulates the innate immune system in minutes to provide immediate and effective protection against all major classes of pathogens that lasts for days.
DMW7L0Y	RU	https://pulmotect.com/product/

DMW7L0Y	DI	DMW7L0Y
DMW7L0Y	DN	PUL-042
DMW7L0Y	MI	TT2LBCR
DMW7L0Y	MN	HUMAN toll-like receptor 9 (TLR9)
DMW7L0Y	MT	DTT
DMW7L0Y	MA	Agonist
DMW7L0Y	RN	Pulmotects lead product, PUL-042, is a clinical stage inhaled therapeutic that in preclinical studies stimulates the innate immune system in minutes to provide immediate and effective protection against all major classes of pathogens that lasts for days.
DMW7L0Y	RU	https://pulmotect.com/product/

DMBUSNL	DI	DMBUSNL
DMBUSNL	DN	Pumosetrag
DMBUSNL	MI	TTNXLKE
DMBUSNL	MN	5-HT 3 receptor (5HT3R)
DMBUSNL	MT	DTT
DMBUSNL	MA	Modulator
DMBUSNL	RN	Novel partial 5HT3 agonist pumosetrag reduces acid reflux events in uninvestigated GERD patients after a standard refluxogenic meal: a randomized, double-blind, placebo-controlled pharmacodynamic study.Neurogastroenterol Motil.2014 Jan;26(1):13-20.
DMBUSNL	RU	https://www.ncbi.nlm.nih.gov/pubmed/24001105

DMVUGF7	DI	DMVUGF7
DMVUGF7	DN	PUR-0110
DMVUGF7	MI	TT4EWFY
DMVUGF7	MN	TNF/IL-10 release (TNF/IL10 rele)
DMVUGF7	MT	DTT
DMVUGF7	MA	Modulator
DMVUGF7	RN	PCT-233, a novel modulator of pro- and anti-inflammatory cytokine production. Clin Exp Immunol. 2004 Mar;135(3):440-7.
DMVUGF7	RU	https://pubmed.ncbi.nlm.nih.gov/15008976

DM6DK9A	DI	DM6DK9A
DM6DK9A	DN	PVX-410
DM6DK9A	MI	TT7ILZ1
DM6DK9A	MN	SLAM family member 7 SLAMF7 (CS1)
DM6DK9A	MT	DTT
DM6DK9A	MA	Modulator
DM6DK9A	RN	Market watch: Upcoming catalysts in Q2 2015. Nat Rev Drug Discov. 2015 Apr;14(4):228.
DM6DK9A	RU	https://pubmed.ncbi.nlm.nih.gov/25764988

DMLVHAJ	DI	DMLVHAJ
DMLVHAJ	DN	PX-12
DMLVHAJ	MI	TTZJ5U9
DMLVHAJ	MN	Thioredoxin (TXN)
DMLVHAJ	MT	DTT
DMLVHAJ	MA	Inhibitor
DMLVHAJ	RN	2-[(1-methylpropyl)dithio]-1H-imidazole inhibits tubulin polymerization through cysteine oxidation. Mol Cancer Ther. 2008 Jan;7(1):143-51.
DMLVHAJ	RU	https://pubmed.ncbi.nlm.nih.gov/18202017

DMYISJK	DI	DMYISJK
DMYISJK	DN	PX-866
DMYISJK	MI	TTHBTOP
DMYISJK	MN	PI3-kinase gamma (PIK3CG)
DMYISJK	MT	DTT
DMYISJK	MA	Inhibitor
DMYISJK	RN	Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44.
DMYISJK	RU	https://pubmed.ncbi.nlm.nih.gov/19644473

DMNSRY7	DI	DMNSRY7
DMNSRY7	DN	PXL-770
DMNSRY7	MI	TTLAFZV
DMNSRY7	MN	AMP-activated protein kinase (AMPK)
DMNSRY7	MT	DTT
DMNSRY7	MA	Activator
DMNSRY7	RN	Clinical pipeline report, company report or official report of Poxel SA.
DMNSRY7	RU	https://www.poxelpharma.com/en_us/product-pipeline/pxl770

DMLQK6E	DI	DMLQK6E
DMLQK6E	DN	PYM-50028
DMLQK6E	MI	TTSMLOH
DMLQK6E	MN	Brain-derived neurotrophic factor (BDNF)
DMLQK6E	MT	DTT
DMLQK6E	MA	Agonist
DMLQK6E	RN	PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease. FASEB J. 2008 Jul;22(7):2488-97.
DMLQK6E	RU	https://pubmed.ncbi.nlm.nih.gov/18364399

DMSOPAU	DI	DMSOPAU
DMSOPAU	DN	Pyrazoloacridine
DMSOPAU	MI	DEJGDUW
DMSOPAU	MN	Cytochrome P450 1A2 (CYP1A2)
DMSOPAU	MT	DME
DMSOPAU	MA	Metabolism
DMSOPAU	RN	The metabolism of pyrazoloacridine (NSC 366140) by cytochromes p450 and flavin monooxygenase in human liver microsomes. Clin Cancer Res. 2004 Feb 15;10(4):1471-80.
DMSOPAU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14977851

DMSOPAU	DI	DMSOPAU
DMSOPAU	DN	Pyrazoloacridine
DMSOPAU	MI	DE4LYSA
DMSOPAU	MN	Cytochrome P450 3A4 (CYP3A4)
DMSOPAU	MT	DME
DMSOPAU	MA	Metabolism
DMSOPAU	RN	The metabolism of pyrazoloacridine (NSC 366140) by cytochromes p450 and flavin monooxygenase in human liver microsomes. Clin Cancer Res. 2004 Feb 15;10(4):1471-80.
DMSOPAU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14977851

DMSOPAU	DI	DMSOPAU
DMSOPAU	DN	Pyrazoloacridine
DMSOPAU	MI	TT0IHXV
DMSOPAU	MN	DNA topoisomerase II (TOP2)
DMSOPAU	MT	DTT
DMSOPAU	MA	Modulator
DMSOPAU	RN	Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II. Clin Cancer Res. 1998 Mar;4(3):683-91.
DMSOPAU	RU	https://pubmed.ncbi.nlm.nih.gov/9533538

DM1794O	DI	DM1794O
DM1794O	DN	Pyrethroids
DM1794O	MI	DEMI4VE
DM1794O	MN	Carboxylesterase 3 (CES3)
DM1794O	MT	DME
DM1794O	MA	Metabolism
DM1794O	RN	Pyrethroids: mammalian metabolism and toxicity. J Agric Food Chem. 2011 Apr 13;59(7):2786-91.
DM1794O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21133409

DM1794O	DI	DM1794O
DM1794O	DN	Pyrethroids
DM1794O	MI	DEVDYN7
DM1794O	MN	Cytochrome P450 2E1 (CYP2E1)
DM1794O	MT	DME
DM1794O	MA	Metabolism
DM1794O	RN	Pyrethroids: mammalian metabolism and toxicity. J Agric Food Chem. 2011 Apr 13;59(7):2786-91.
DM1794O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21133409

DMU5H3A	DI	DMU5H3A
DMU5H3A	DN	PZ-128
DMU5H3A	MI	TTL935N
DMU5H3A	MN	Proteinase activated receptor 1 (F2R)
DMU5H3A	MT	DTT
DMU5H3A	MA	Antagonist
DMU5H3A	RN	PAR1 (Protease-Activated Receptor 1) Pepducin Therapy Targeting Myocardial Necrosis in Coronary Artery Disease and Acute Coronary Syndrome Patients Undergoing Cardiac Catheterization: A Randomized, Placebo-Controlled, Phase 2 Study. Arterioscler Thromb Vasc Biol. 2020 Dec;40(12):2990-3003.
DMU5H3A	RU	https://pubmed.ncbi.nlm.nih.gov/33028101

DME71WA	DI	DME71WA
DME71WA	DN	Q301
DME71WA	MI	TT2J34L
DME71WA	MN	Arachidonate 5-lipoxygenase (5-LOX)
DME71WA	MT	DTT
DME71WA	MA	Inhibitor
DME71WA	RN	Clinical pipeline report, company report or official report of Qurient.
DME71WA	RU	http://www.qurient.com/bbs/content.php?co_id=q301

DMIZYV1	DI	DMIZYV1
DMIZYV1	DN	QAV-680
DMIZYV1	MI	TTQDMX5
DMIZYV1	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMIZYV1	MT	DTT
DMIZYV1	MA	Antagonist
DMIZYV1	RN	Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases. Bioorg Med Chem. 2013 Nov 1;21(21):6582-91.
DMIZYV1	RU	https://pubmed.ncbi.nlm.nih.gov/24021582

DMXY0H2	DI	DMXY0H2
DMXY0H2	DN	QAX-028
DMXY0H2	MI	TTOXS3C
DMXY0H2	MN	Muscarinic acetylcholine receptor (CHRM)
DMXY0H2	MT	DTT
DMXY0H2	MA	Antagonist
DMXY0H2	RN	EP patent application no. 2398798, Triazolopyridine derivatives as p38 map kinase inhibitors.
DMXY0H2	RU	http://www.google.com/patents/EP2398798A1?cl=en

DMUWFI7	DI	DMUWFI7
DMUWFI7	DN	QAX-576
DMUWFI7	MI	TT0GVCH
DMUWFI7	MN	Interleukin-13 (IL13)
DMUWFI7	MT	DTT
DMUWFI7	MA	Modulator
DMUWFI7	RN	Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol. 2015 Feb;135(2):500-7.
DMUWFI7	RU	https://pubmed.ncbi.nlm.nih.gov/25226850

DMAFUHK	DI	DMAFUHK
DMAFUHK	DN	QGC-001
DMAFUHK	MI	TTGMFY7
DMAFUHK	MN	Aspartyl aminopeptidase (DNPEP)
DMAFUHK	MT	DTT
DMAFUHK	MA	Inhibitor
DMAFUHK	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMAFUHK	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMAFUHK	DI	DMAFUHK
DMAFUHK	DN	QGC-001
DMAFUHK	MI	TT9PBIL
DMAFUHK	MN	Glutamyl aminopeptidase (ENPEP)
DMAFUHK	MT	DTT
DMAFUHK	MA	Inhibitor
DMAFUHK	RN	Clinical pipeline report, company report or official report of Quantum Genomics.
DMAFUHK	RU	http://www.quantum-genomics.com/www/en/science/programme-qgc001/

DMKVIWM	DI	DMKVIWM
DMKVIWM	DN	QR-333
DMKVIWM	MI	TTFBNVI
DMKVIWM	MN	Aldose reductase (AKR1B1)
DMKVIWM	MT	DTT
DMKVIWM	MA	Inhibitor
DMKVIWM	RN	A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report. J Diabetes Complications. 2005 Sep-Oct;19(5):247-53.
DMKVIWM	RU	https://pubmed.ncbi.nlm.nih.gov/16112498

DMIUS5X	DI	DMIUS5X
DMIUS5X	DN	R1507
DMIUS5X	MI	TTHRID2
DMIUS5X	MN	Insulin-like growth factor I receptor (IGF1R)
DMIUS5X	MT	DTT
DMIUS5X	MA	Inhibitor
DMIUS5X	RN	Clinical pipeline report, company report or official report of Roche (2009).
DMIUS5X	RU	http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm

DMP7J0S	DI	DMP7J0S
DMP7J0S	DN	R411
DMP7J0S	MI	TT6S84X
DMP7J0S	MN	Integrin alpha-4/beta-1 (ITGA4/B1)
DMP7J0S	MT	DTT
DMP7J0S	MA	Modulator
DMP7J0S	RN	Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov. 2010 Oct;9(10):804-20.
DMP7J0S	RU	https://pubmed.ncbi.nlm.nih.gov/20885411

DM79YAS	DI	DM79YAS
DM79YAS	DN	Racotumomab
DM79YAS	MI	TTSFNKW
DM79YAS	MN	Tumor antigen NGcGM3 (NGcGM3)
DM79YAS	MT	DTT
DM79YAS	MA	Modulator
DM79YAS	RN	Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides - preclinical and clinical data. Front Oncol. 2012; 2: 150.
DM79YAS	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3478665/

DMOI9EL	DI	DMOI9EL
DMOI9EL	DN	Radezolid
DMOI9EL	MI	TT2VX74
DMOI9EL	MN	Bacterial Protein synthesis (Bact PROS)
DMOI9EL	MT	DTT
DMOI9EL	MA	Inhibitor
DMOI9EL	RN	Antibiotics in the clinical pipeline in 2011. J Antibiot (Tokyo). 2011 Jun;64(6):413-25.
DMOI9EL	RU	https://pubmed.ncbi.nlm.nih.gov/21587262

DMC56T4	DI	DMC56T4
DMC56T4	DN	RAF265
DMC56T4	MI	TTUTJGQ
DMC56T4	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMC56T4	MT	DTT
DMC56T4	MA	Modulator
DMC56T4	RN	RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications. Invest New Drugs. 2013 Feb;31(1):200-5.
DMC56T4	RU	https://pubmed.ncbi.nlm.nih.gov/22773056

DM7G4Y9	DI	DM7G4Y9
DM7G4Y9	DN	Ralinepag
DM7G4Y9	MI	TTOFYT1
DM7G4Y9	MN	Prostacyclin receptor (PTGIR)
DM7G4Y9	MT	DTT
DM7G4Y9	MA	Agonist
DM7G4Y9	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7G4Y9	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMBFZSX	DI	DMBFZSX
DMBFZSX	DN	RALURIDINE
DMBFZSX	MI	TT84ETX
DMBFZSX	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMBFZSX	MT	DTT
DMBFZSX	MA	Inhibitor
DMBFZSX	RN	5-Chloro-2',3'-dideoxy-3'-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile. Antimicrob Agents Chemother. 1994 Jul;38(7):1590-603.
DMBFZSX	RU	https://pubmed.ncbi.nlm.nih.gov/7526782

DMP2DNS	DI	DMP2DNS
DMP2DNS	DN	Rambazole
DMP2DNS	MI	TTD7Q0R
DMP2DNS	MN	Cytochrome P450 26 (CYP26A1)
DMP2DNS	MT	DTT
DMP2DNS	MA	Inhibitor
DMP2DNS	RN	Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
DMP2DNS	RU	https://pubmed.ncbi.nlm.nih.gov/19249988

DMP2DNS	DI	DMP2DNS
DMP2DNS	DN	Rambazole
DMP2DNS	MI	TTYO0A3
DMP2DNS	MN	Substance-K receptor (TACR2)
DMP2DNS	MT	DTT
DMP2DNS	MA	Antagonist
DMP2DNS	RN	Pharmacology of an original and selective nonpeptide antagonist ligand for the human tachykinin NK2 receptor. Eur J Pharmacol. 2005 Jun 1;516(2):104-11.
DMP2DNS	RU	https://pubmed.ncbi.nlm.nih.gov/15925360

DMO2TYL	DI	DMO2TYL
DMO2TYL	DN	Ramipril
DMO2TYL	MI	TTGFNPD
DMO2TYL	MN	HUMAN angiotensin-converting enzyme (ACE)
DMO2TYL	MT	DTT
DMO2TYL	MA	Inhibitor
DMO2TYL	RN	Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB. Curr Cardiol Rep. 2020 Apr 14;22(5):31.
DMO2TYL	RU	https://pubmed.ncbi.nlm.nih.gov/32291526

DMM15RI	DI	DMM15RI
DMM15RI	DN	Ranpirnase
DMM15RI	MI	TTRBUYN
DMM15RI	MN	Ribonuclease (RNase)
DMM15RI	MT	DTT
DMM15RI	MA	Modulator
DMM15RI	RN	Ranpirnase (Onconase), a cytotoxic amphibian ribonuclease, manipulates tumour physiological parameters as a selective killer and a potential enhancer for chemotherapy and radiation in cancer therapy.Expert Opin Biol Ther. 2008 Jun;8(6):813-27.
DMM15RI	RU	https://pubmed.ncbi.nlm.nih.gov/18476793

DMK2E0N	DI	DMK2E0N
DMK2E0N	DN	RAXOFELAST
DMK2E0N	MI	TTV0YFR
DMK2E0N	MN	Lipid peroxidation (LPO)
DMK2E0N	MT	DTT
DMK2E0N	MA	Modulator
DMK2E0N	RN	Lipid peroxidation inhibition by raxofelast improves angiogenesis and wound healing in experimental burn wounds. Shock. 2005 Jul;24(1):85-91.
DMK2E0N	RU	https://pubmed.ncbi.nlm.nih.gov/15988325

DMIG98L	DI	DMIG98L
DMIG98L	DN	RC-3095
DMIG98L	MI	TTC1MVT
DMIG98L	MN	Gastrin-releasing peptide receptor (GRPR)
DMIG98L	MT	DTT
DMIG98L	MA	Inhibitor
DMIG98L	RN	Lipid modification of GRN163, an N3'--&gt;P5' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene. 2005 Aug 4;24(33):5262-8.
DMIG98L	RU	https://pubmed.ncbi.nlm.nih.gov/15940257

DM1TKG4	DI	DM1TKG4
DM1TKG4	DN	RDEA3170
DM1TKG4	MI	TTA592U
DM1TKG4	MN	Urate anion exchanger 1 (URAT1)
DM1TKG4	MT	DTT
DM1TKG4	MA	Modulator
DM1TKG4	RN	The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality. BMC Nephrol. 2013; 14: 164.
DM1TKG4	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3750299/

DMNWYHD	DI	DMNWYHD
DMNWYHD	DN	RDEA-684
DMNWYHD	MI	TTA592U
DMNWYHD	MN	Urate anion exchanger 1 (URAT1)
DMNWYHD	MT	DTT
DMNWYHD	MA	Inhibitor
DMNWYHD	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1031).
DMNWYHD	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1031

DM4CIKA	DI	DM4CIKA
DM4CIKA	DN	RDP58
DM4CIKA	MI	TTF8CQI
DM4CIKA	MN	Tumor necrosis factor (TNF)
DM4CIKA	MT	DTT
DM4CIKA	MA	Inhibitor
DM4CIKA	RN	RDP58, a locally active TNF inhibitor, is effective in the dextran sulphate mouse model of chronic colitis. Inflamm Res. 2002 Nov;51(11):522-31.
DM4CIKA	RU	https://pubmed.ncbi.nlm.nih.gov/12540016

DM2CJ4O	DI	DM2CJ4O
DM2CJ4O	DN	Rebmab-100
DM2CJ4O	MI	TTUPAD7
DM2CJ4O	MN	Galactoside 3(4)-L-fucosyltransferase (FUT3)
DM2CJ4O	MT	DTT
DM2CJ4O	RN	A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant/refractory ovarian, fallopian tube and primary peritoneal carcinoma. Gynecol Oncol. 2015 Aug;138(2):272-7.
DM2CJ4O	RU	https://pubmed.ncbi.nlm.nih.gov/26026738

DML8N3Y	DI	DML8N3Y
DML8N3Y	DN	Recifercept
DML8N3Y	MI	TTST7KB
DML8N3Y	MN	Fibroblast growth factor receptor 3 (FGFR3)
DML8N3Y	MT	DTT
DML8N3Y	RN	In vitro and in vivo characterization of Recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia. PLoS One. 2020 Dec 28;15(12):e0244368.
DML8N3Y	RU	https://pubmed.ncbi.nlm.nih.gov/33370388

DMCSR8I	DI	DMCSR8I
DMCSR8I	DN	Recoflavone
DMCSR8I	MI	TTSXVID
DMCSR8I	MN	Nuclear factor NF-kappa-B (NFKB)
DMCSR8I	MT	DTT
DMCSR8I	MA	Modulator
DMCSR8I	RN	DA-6034, a derivative of flavonoid, prevents and ameliorates dextran sulfate sodium-induced colitis and inhibits colon carcinogenesis. Exp Biol Med (Maywood). 2008 Feb;233(2):180-91.
DMCSR8I	RU	https://pubmed.ncbi.nlm.nih.gov/18222973

DMURX4B	DI	DMURX4B
DMURX4B	DN	Recombinant batroxobin
DMURX4B	MI	TTWODQF
DMURX4B	MN	Fibrin (FG)
DMURX4B	MT	DTT
DMURX4B	MA	Modulator
DMURX4B	RN	Functional characterization of recombinant batroxobin, a snake venom thrombin-like enzyme, expressed from Pichia pastoris. FEBS Lett. 2004 Jul 30;571(1-3):67-73.
DMURX4B	RU	https://pubmed.ncbi.nlm.nih.gov/15280019

DMV0A28	DI	DMV0A28
DMV0A28	DN	Recombinant RGD-hirudin
DMV0A28	MI	TT6L509
DMV0A28	MN	Coagulation factor IIa (F2)
DMV0A28	MT	DTT
DMV0A28	MA	Modulator
DMV0A28	RN	The NMR solution structure of recombinant RGD-hirudin. Biochem Biophys Res Commun. 2007 Aug 17;360(1):103-8.
DMV0A28	RU	https://pubmed.ncbi.nlm.nih.gov/17585879

DMSJ3Z5	DI	DMSJ3Z5
DMSJ3Z5	DN	REGN1979
DMSJ3Z5	MI	TTUE541
DMSJ3Z5	MN	Leukocyte surface antigen Leu-16 (CD20)
DMSJ3Z5	MT	DTT
DMSJ3Z5	MA	Inhibitor
DMSJ3Z5	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMSJ3Z5	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMTBRPO	DI	DMTBRPO
DMTBRPO	DN	REGN910-3
DMTBRPO	MI	TTKLQTJ
DMTBRPO	MN	Angiopoietin-2 (ANGPT2)
DMTBRPO	MT	DTT
DMTBRPO	MA	Inhibitor
DMTBRPO	RN	ClinicalTrials.gov (NCT02713204) Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX). U.S. National Institutes of Health.
DMTBRPO	RU	https://clinicaltrials.gov/ct2/show/NCT02713204

DM0KBML	DI	DM0KBML
DM0KBML	DN	REGN-COV2
DM0KBML	MI	TTZ3COY
DM0KBML	MN	COVID-19 spike glycoprotein (S)
DM0KBML	MT	DTT
DM0KBML	MA	Inhibitor
DM0KBML	RN	REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med. 2021 Jan 21;384(3):238-251.
DM0KBML	RU	https://pubmed.ncbi.nlm.nih.gov/33332778

DM13OVF	DI	DM13OVF
DM13OVF	DN	REMD 477
DM13OVF	MI	TT9O6WS
DM13OVF	MN	Glucagon receptor (GCGR)
DM13OVF	MT	DTT
DM13OVF	MA	Antagonist
DM13OVF	RN	Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trial. Diabetes Obes Metab. 2018 May;20(5):1302-1305.
DM13OVF	RU	https://pubmed.ncbi.nlm.nih.gov/29283470

DMJIB89	DI	DMJIB89
DMJIB89	DN	Remetinostat
DMJIB89	MI	TTBH0VX
DMJIB89	MN	Histone deacetylase (HDAC)
DMJIB89	MT	DTT
DMJIB89	MA	Inhibitor
DMJIB89	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMJIB89	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM2USXP	DI	DM2USXP
DM2USXP	DN	Remlarsen
DM2USXP	MI	TTO60BY
DM2USXP	MN	microRNA hsa-miR-29b (MIR29b)
DM2USXP	MT	DTT
DM2USXP	MA	Replacement
DM2USXP	RN	A MicroRNA-29 Mimic (Remlarsen) Represses Extracellular Matrix Expression and Fibroplasia in the Skin. J Invest Dermatol. 2019 May;139(5):1073-1081.
DM2USXP	RU	https://pubmed.ncbi.nlm.nih.gov/30472058

DMZFV3E	DI	DMZFV3E
DMZFV3E	DN	Remogli ozin-etabonate
DMZFV3E	MI	TTN7Y4P
DMZFV3E	MN	Sodium/glucose cotransporter 2 (SLC5A4)
DMZFV3E	MT	DTT
DMZFV3E	MA	Modulator
DMZFV3E	RN	Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus. BMC Pharmacol Toxicol.2013 Apr 30;14:25.
DMZFV3E	RU	https://pubmed.ncbi.nlm.nih.gov/23631443

DMW4YK1	DI	DMW4YK1
DMW4YK1	DN	Remogliflozin etabonate
DMW4YK1	MI	TTLWPVF
DMW4YK1	MN	Sodium/glucose cotransporter 2 (SGLT2)
DMW4YK1	MT	DTT
DMW4YK1	MA	Inhibitor
DMW4YK1	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMW4YK1	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMW4YK1	DI	DMW4YK1
DMW4YK1	DN	Remogliflozin etabonate
DMW4YK1	MI	TTN7Y4P
DMW4YK1	MN	Sodium/glucose cotransporter 2 (SLC5A4)
DMW4YK1	MT	DTT
DMW4YK1	MA	Blocker
DMW4YK1	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMW4YK1	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMTGU6K	DI	DMTGU6K
DMTGU6K	DN	REN-1654
DMTGU6K	MI	TTX1JEN
DMTGU6K	MN	JNK signaling pathway (JNK pathway)
DMTGU6K	MT	DTT
DMTGU6K	MA	Modulator
DMTGU6K	RN	US patent application no. 2006,0270,742, Compositions and methods for the treatment of neurodegenerative diseases.
DMTGU6K	RU	http://www.google.com/patents/US20060270742

DMTGU6K	DI	DMTGU6K
DMTGU6K	DN	REN-1654
DMTGU6K	MI	TT7KPH1
DMTGU6K	MN	MAPK/ERK signaling pathway (MAPK pathway)
DMTGU6K	MT	DTT
DMTGU6K	MA	Modulator
DMTGU6K	RN	US patent application no. 2006,0270,742, Compositions and methods for the treatment of neurodegenerative diseases.
DMTGU6K	RU	http://www.google.com/patents/US20060270742

DMQ73AY	DI	DMQ73AY
DMQ73AY	DN	Reovirus
DMQ73AY	MI	TTW2R9X
DMQ73AY	MN	GTPase NRas (NRAS)
DMQ73AY	MT	DTT
DMQ73AY	MA	Modulator
DMQ73AY	RN	Reovirus (Reolysin) as a potential therapy for malignant peripheral nerve sheath tumors.
DMQ73AY	RU	http://cancerres.aacrjournals.org/content/72/8_Supplement/2488.short

DMT5QSD	DI	DMT5QSD
DMT5QSD	DN	Resimmune
DMT5QSD	MI	TTZAT79
DMT5QSD	MN	T-cell surface glycoprotein CD3 epsilon (CD3E)
DMT5QSD	MT	DTT
DMT5QSD	MA	Modulator
DMT5QSD	RN	Resimmune, an anti-CD3 recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma.Haematologica.2015 Jun;100(6):794-800.
DMT5QSD	RU	https://www.ncbi.nlm.nih.gov/pubmed/25795722

DMP62L5	DI	DMP62L5
DMP62L5	DN	Resiniferatoxin
DMP62L5	MI	TTMI6F5
DMP62L5	MN	Transient receptor potential cation channel V1 (TRPV1)
DMP62L5	MT	DTT
DMP62L5	MA	Activator
DMP62L5	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DMP62L5	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DML6XSP	DI	DML6XSP
DML6XSP	DN	Resiquimod
DML6XSP	MI	TTRJ1K4
DML6XSP	MN	Toll-like receptor 7 (TLR7)
DML6XSP	MT	DTT
DML6XSP	MA	Modulator
DML6XSP	RN	TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).Vaccine.2005 Nov 1;23(45):5263-70.
DML6XSP	RU	https://www.ncbi.nlm.nih.gov/pubmed/16081189

DML6XSP	DI	DML6XSP
DML6XSP	DN	Resiquimod
DML6XSP	MI	TT8CWFK
DML6XSP	MN	Toll-like receptor 8 (TLR8)
DML6XSP	MT	DTT
DML6XSP	MA	Modulator
DML6XSP	RN	TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).Vaccine.2005 Nov 1;23(45):5263-70.
DML6XSP	RU	https://www.ncbi.nlm.nih.gov/pubmed/16081189

DMNE1FR	DI	DMNE1FR
DMNE1FR	DN	Resminostat
DMNE1FR	MI	TT6R7JZ
DMNE1FR	MN	Histone deacetylase 1 (HDAC1)
DMNE1FR	MT	DTT
DMNE1FR	MA	Inhibitor
DMNE1FR	RN	2011 Pipeline of 4SC AG.
DMNE1FR	RU	http://www.pharmaceutical-market-research.com/publications/pharmaceutical_companies/4sc_ag_product_pipeline_review.html

DMM4EJI	DI	DMM4EJI
DMM4EJI	DN	Resten-NG
DMM4EJI	MI	TTNQ5ZP
DMM4EJI	MN	Myc messenger RNA (MYC mRNA)
DMM4EJI	MT	DTT
DMM4EJI	RN	Local delivery of c-myc neutrally charged antisense oligonucleotides with transport catheter inhibits myointimal hyperplasia and positively affects vascular remodeling in the rabbit balloon injury model. Catheter Cardiovasc Interv. 2001 Oct;54(2):247-56.
DMM4EJI	RU	https://pubmed.ncbi.nlm.nih.gov/11590694

DMVXZJ4	DI	DMVXZJ4
DMVXZJ4	DN	RetinoStat
DMVXZJ4	MI	TT63DI9
DMVXZJ4	MN	Endostatin (COL18A1)
DMVXZJ4	MT	DTT
DMVXZJ4	MA	Modulator
DMVXZJ4	RN	Safety and biodistribution of an equine infectious anemia virus-based gene therapy, RetinoStat( ), for age-related macular degeneration. Hum Gene Ther. 2012 Sep;23(9):980-91.
DMVXZJ4	RU	https://pubmed.ncbi.nlm.nih.gov/22716662

DMVXZJ4	DI	DMVXZJ4
DMVXZJ4	DN	RetinoStat
DMVXZJ4	MI	TTP86E2
DMVXZJ4	MN	Plasminogen (PLG)
DMVXZJ4	MT	DTT
DMVXZJ4	MA	Modulator
DMVXZJ4	RN	Safety and biodistribution of an equine infectious anemia virus-based gene therapy, RetinoStat( ), for age-related macular degeneration. Hum Gene Ther. 2012 Sep;23(9):980-91.
DMVXZJ4	RU	https://pubmed.ncbi.nlm.nih.gov/22716662

DMJ37UX	DI	DMJ37UX
DMJ37UX	DN	Revacept
DMJ37UX	MI	TTTJUVZ
DMJ37UX	MN	Platelet glycoprotein VI (GP6)
DMJ37UX	MT	DTT
DMJ37UX	MA	Inhibitor
DMJ37UX	RN	Novel antiplatelet drug revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans. Circulation.2011 May 3;123(17):1891-9.
DMJ37UX	RU	https://pubmed.ncbi.nlm.nih.gov/21502572

DM1FS2W	DI	DM1FS2W
DM1FS2W	DN	Revamilast
DM1FS2W	MI	TTZ97H5
DM1FS2W	MN	Phosphodiesterase 4A (PDE4A)
DM1FS2W	MT	DTT
DM1FS2W	MA	Inhibitor
DM1FS2W	RN	WO patent application no. 2012,1109,46, Pharmaceutical composition comprising the pde4 enzyme inhibitor revamilast and a disease modifying agent, preferably methotrexate .
DM1FS2W	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20120823&CC=WO&NR=2012110946A1&KC=A1

DM1FS2W	DI	DM1FS2W
DM1FS2W	DN	Revamilast
DM1FS2W	MI	TTVIAT9
DM1FS2W	MN	Phosphodiesterase 4B (PDE4B)
DM1FS2W	MT	DTT
DM1FS2W	MA	Inhibitor
DM1FS2W	RN	WO patent application no. 2012,1109,46, Pharmaceutical composition comprising the pde4 enzyme inhibitor revamilast and a disease modifying agent, preferably methotrexate .
DM1FS2W	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20120823&CC=WO&NR=2012110946A1&KC=A1

DM1FS2W	DI	DM1FS2W
DM1FS2W	DN	Revamilast
DM1FS2W	MI	TTSKMI8
DM1FS2W	MN	Phosphodiesterase 4D (PDE4D)
DM1FS2W	MT	DTT
DM1FS2W	MA	Inhibitor
DM1FS2W	RN	WO patent application no. 2012,1109,46, Pharmaceutical composition comprising the pde4 enzyme inhibitor revamilast and a disease modifying agent, preferably methotrexate .
DM1FS2W	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20120823&CC=WO&NR=2012110946A1&KC=A1

DMFIVSR	DI	DMFIVSR
DMFIVSR	DN	R-flurbiprofen
DMFIVSR	MI	TT8JRS7
DMFIVSR	MN	Beta-secretase (BACE)
DMFIVSR	MT	DTT
DMFIVSR	MA	Inhibitor
DMFIVSR	RN	The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23.
DMFIVSR	RU	https://pubmed.ncbi.nlm.nih.gov/16455248

DMFIVSR	DI	DMFIVSR
DMFIVSR	DN	R-flurbiprofen
DMFIVSR	MI	TT9W8GU
DMFIVSR	MN	Gamma-secretase (GS)
DMFIVSR	MT	DTT
DMFIVSR	MA	Inhibitor
DMFIVSR	RN	The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23.
DMFIVSR	RU	https://pubmed.ncbi.nlm.nih.gov/16455248

DMFIVSR	DI	DMFIVSR
DMFIVSR	DN	R-flurbiprofen
DMFIVSR	MI	TTZ3S8C
DMFIVSR	MN	Presenilin 1 (PSEN1)
DMFIVSR	MT	DTT
DMFIVSR	MA	Inhibitor
DMFIVSR	RN	The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23.
DMFIVSR	RU	https://pubmed.ncbi.nlm.nih.gov/16455248

DMFIVSR	DI	DMFIVSR
DMFIVSR	DN	R-flurbiprofen
DMFIVSR	MI	TTWN3F4
DMFIVSR	MN	Presenilin 2 (PSEN2)
DMFIVSR	MT	DTT
DMFIVSR	MA	Inhibitor
DMFIVSR	RN	The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23.
DMFIVSR	RU	https://pubmed.ncbi.nlm.nih.gov/16455248

DMQ8K93	DI	DMQ8K93
DMQ8K93	DN	RFT-5.dgA
DMQ8K93	MI	TT10Y9E
DMQ8K93	MN	Interleukin 2 receptor alpha (IL2RA)
DMQ8K93	MT	DTT
DMQ8K93	MA	Modulator
DMQ8K93	RN	Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma. Ann Oncol. 2003 May;14(5):729-36.
DMQ8K93	RU	https://www.ncbi.nlm.nih.gov/pubmed/12702527

DM2UGT7	DI	DM2UGT7
DM2UGT7	DN	RG-101
DM2UGT7	MI	TTP03CE
DM2UGT7	MN	Hepatitis C virus microRNA miR-122 (HCV MIR122)
DM2UGT7	MT	DTT
DM2UGT7	MA	Modulator
DM2UGT7	RN	Company report (Isis Pharmaceuticals)
DM2UGT7	RU	https://www.isispharm.com/pipeline/rg-101/

DMT1ZX0	DI	DMT1ZX0
DMT1ZX0	DN	RG1577
DMT1ZX0	MI	TTGP7BY
DMT1ZX0	MN	Monoamine oxidase type B (MAO-B)
DMT1ZX0	MT	DTT
DMT1ZX0	MA	Modulator
DMT1ZX0	RN	Sembragiline Alzheimer's Disease (Phase 2). Evotech AG, Roche.
DMT1ZX0	RU	http://www.alzforum.org/therapeutics/sembragiline

DMT4QRD	DI	DMT4QRD
DMT4QRD	DN	RG-4929
DMT4QRD	MI	TTN7BL9
DMT4QRD	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMT4QRD	MT	DTT
DMT4QRD	MA	Inhibitor
DMT4QRD	RN	New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches. 2012. Chapter 5. Page(131).
DMT4QRD	RU	https://books.google.com.hk/books?id=0rmlVGhlJ0IC&pg=PA131&lpg=PA131&dq=RG-7234++New+Therapeutic+Strategies+for+Type+2+Diabetes&source=bl&ots=toqK7w4uiI&sig=sx5iyfQWH2bTCSZmT5aUQiKfPuM&hl=zh-CN&sa=X&ved=0CB0Q6AEwAGoVChMIsZ_k6dDGyAIViLeOCh0oUQpr#v=onepage&q=RG-7234%20%20New%20Therapeutic%20Strategies%20for%20Type%202%20Diabetes&f=false

DMEFD0B	DI	DMEFD0B
DMEFD0B	DN	RG6100
DMEFD0B	MI	TTS87KH
DMEFD0B	MN	Microtubule-associated protein tau (MAPT)
DMEFD0B	MT	DTT
DMEFD0B	MA	Inhibitor
DMEFD0B	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMEFD0B	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMX8JYN	DI	DMX8JYN
DMX8JYN	DN	RG-7090
DMX8JYN	MI	TTHS256
DMX8JYN	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMX8JYN	MT	DTT
DMX8JYN	MA	Antagonist
DMX8JYN	RN	The challenges of clinical trials in fragile X syndrome. Psychopharmacology (Berl) 2014; 231(6): 1237-1250.
DMX8JYN	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932172/

DM8JMNL	DI	DM8JMNL
DM8JMNL	DN	RG7155
DM8JMNL	MI	TT731LW
DM8JMNL	MN	Colony stimulating factor-1 receptor (CSF-1R)
DM8JMNL	MT	DTT
DM8JMNL	MA	Modulator
DM8JMNL	RN	Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014 Jun 16;25(6):846-59.
DM8JMNL	RU	https://pubmed.ncbi.nlm.nih.gov/24898549

DM8JMNL	DI	DM8JMNL
DM8JMNL	DN	RG7155
DM8JMNL	MI	TT0IQER
DM8JMNL	MN	Macrophage colony-stimulating factor 1 (CSF1)
DM8JMNL	MT	DTT
DM8JMNL	MA	Antagonist
DM8JMNL	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM8JMNL	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM8J9DC	DI	DM8J9DC
DM8J9DC	DN	RG7221
DM8J9DC	MI	TTKLQTJ
DM8J9DC	MN	Angiopoietin-2 (ANGPT2)
DM8J9DC	MT	DTT
DM8J9DC	MA	Modulator
DM8J9DC	RN	Company report (Roche pipeline: July 27, 2017)
DM8J9DC	RU	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm

DM8J9DC	DI	DM8J9DC
DM8J9DC	DN	RG7221
DM8J9DC	MI	TTOHSBA
DM8J9DC	MN	Vascular endothelial growth factor A (VEGFA)
DM8J9DC	MT	DTT
DM8J9DC	MA	Modulator
DM8J9DC	RN	Bispecific antibodies and their applications
DM8J9DC	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687327

DM5RAB9	DI	DM5RAB9
DM5RAB9	DN	RG-7234
DM5RAB9	MI	TT9H85R
DM5RAB9	MN	Corticosteroid 11-beta-dehydrogenase 2 (HSD11B2)
DM5RAB9	MT	DTT
DM5RAB9	MA	Inhibitor
DM5RAB9	RN	New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches. 2012. Chapter 5. Page(131).
DM5RAB9	RU	https://books.google.com.hk/books?id=0rmlVGhlJ0IC&pg=PA131&lpg=PA131&dq=RG-7234++New+Therapeutic+Strategies+for+Type+2+Diabetes&source=bl&ots=toqK7w4uiI&sig=sx5iyfQWH2bTCSZmT5aUQiKfPuM&hl=zh-CN&sa=X&ved=0CB0Q6AEwAGoVChMIsZ_k6dDGyAIViLeOCh0oUQpr#v=onepage&q=RG-7234%20%20New%20Therapeutic%20Strategies%20for%20Type%202%20Diabetes&f=false

DMB4M6O	DI	DMB4M6O
DMB4M6O	DN	RG7314
DMB4M6O	MI	TT4TFGN
DMB4M6O	MN	Vasopressin V1a receptor (V1AR)
DMB4M6O	MT	DTT
DMB4M6O	MA	Modulator
DMB4M6O	RN	Social Communication is an Emerging Target for Pharmacotherapy in Autism Spectrum Disorder - A Review of the Literature on Potential Agents. J Can Acad Child Adolesc Psychiatry. 2014 February; 23(1):20-30.
DMB4M6O	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3917666/

DMVXGU0	DI	DMVXGU0
DMVXGU0	DN	RG7596
DMVXGU0	MI	TTBN5I7
DMVXGU0	MN	B-cell-specific glycoprotein B29 (CD79B)
DMVXGU0	MT	DTT
DMVXGU0	MA	Modulator
DMVXGU0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2852).
DMVXGU0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2852

DMDGPKS	DI	DMDGPKS
DMDGPKS	DN	RG7625
DMDGPKS	MI	TTUMQVO
DMDGPKS	MN	Cathepsin S (CTSS)
DMDGPKS	MT	DTT
DMDGPKS	MA	Antagonist
DMDGPKS	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMDGPKS	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DM6CNFW	DI	DM6CNFW
DM6CNFW	DN	RG7686
DM6CNFW	MI	TTJTSX4
DM6CNFW	MN	Glypican-3 (GPC3)
DM6CNFW	MT	DTT
DM6CNFW	RN	First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2013 Feb 15;19(4):920-8.
DM6CNFW	RU	https://pubmed.ncbi.nlm.nih.gov/23362325

DMK5PYS	DI	DMK5PYS
DMK5PYS	DN	RG7745
DMK5PYS	MI	TTF4CAM
DMK5PYS	MN	Influenza Hemagglutinin (Influ HA)
DMK5PYS	MT	DTT
DMK5PYS	RN	Clinical pipeline report, company report or official report of Roche.
DMK5PYS	RU	http://www.roche.com/irp2q13e-annex.pdf

DM452RF	DI	DM452RF
DM452RF	DN	RG7880
DM452RF	MI	TTLDX4N
DM452RF	MN	Interleukin-22 (IL22)
DM452RF	MT	DTT
DM452RF	MA	Modulator
DM452RF	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM452RF	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DM2SWI8	DI	DM2SWI8
DM2SWI8	DN	RG7888
DM2SWI8	MI	TTBW580
DM2SWI8	MN	TAX transcriptionally-activated glycoprotein 1 (OX40)
DM2SWI8	MT	DTT
DM2SWI8	RN	Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models. J Immunother Cancer. 2014; 2(Suppl 3): P105.
DM2SWI8	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288389/

DME1YMX	DI	DME1YMX
DME1YMX	DN	RG7935
DME1YMX	MI	TT08OSU
DME1YMX	MN	Synuclein alpha (SNCA)
DME1YMX	MT	DTT
DME1YMX	RN	alpha-Synuclein in Parkinson's Disease. Cold Spring Harb Perspect Med. 2012 February; 2(2): a009399.
DME1YMX	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3281589/

DMCHZAN	DI	DMCHZAN
DMCHZAN	DN	RGH-896
DMCHZAN	MI	TTN9D8E
DMCHZAN	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMCHZAN	MT	DTT
DMCHZAN	MA	Antagonist
DMCHZAN	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DMCHZAN	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DM4AC2F	DI	DM4AC2F
DM4AC2F	DN	RGI-2001
DM4AC2F	MI	TT7AKW1
DM4AC2F	MN	T-cell receptor (TCR)
DM4AC2F	MT	DTT
DM4AC2F	MA	Modulator
DM4AC2F	RN	Pharmacologic expansion of donor-derived, naturally occurring CD4(+)Foxp3(+) regulatory T cells reduces acute graft-versus-host disease lethality without abrogating the graft-versus-leukemia effect in murine models. Biol Blood Marrow Transplant. 2011 Aug;17(8):1154-68.
DM4AC2F	RU	https://pubmed.ncbi.nlm.nih.gov/21145405

DMSF10P	DI	DMSF10P
DMSF10P	DN	RGN-259
DMSF10P	MI	TTH5WZF
DMSF10P	MN	Actin (ACT)
DMSF10P	MT	DTT
DMSF10P	MA	Modulator
DMSF10P	RN	Thymosin beta4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015 May;34(5):491-6.
DMSF10P	RU	https://pubmed.ncbi.nlm.nih.gov/25826322

DMBSXR9	DI	DMBSXR9
DMBSXR9	DN	rhACE2
DMBSXR9	MI	TTYRG7F
DMBSXR9	MN	HUMAN angiotensin-converting enzyme 2 (ACE2)
DMBSXR9	MT	DTT
DMBSXR9	MA	Inhibitor
DMBSXR9	RN	ClinicalTrials.gov (NCT04287686) Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19
DMBSXR9	RU	https://clinicaltrials.gov/ct2/show/NCT04346797

DMN1EFR	DI	DMN1EFR
DMN1EFR	DN	RhGDF-5
DMN1EFR	MI	TT37XV9
DMN1EFR	MN	Growth/differentiation factor 5 (GDF-5)
DMN1EFR	MT	DTT
DMN1EFR	MA	Modulator
DMN1EFR	RN	Superior effect of MD05, beta-tricalcium phosphate coated with recombinant human growth/differentiation factor-5, compared to conventional bone substitutes in the rat calvarial defect model. J Periodontol. 2006 Sep;77(9):1582-90.
DMN1EFR	RU	https://pubmed.ncbi.nlm.nih.gov/16945037

DMO9QB8	DI	DMO9QB8
DMO9QB8	DN	R-IFN-1a
DMO9QB8	MI	TTSYFMA
DMO9QB8	MN	Interferon alpha/beta receptor 1 (IFNAR1)
DMO9QB8	MT	DTT
DMO9QB8	MA	Modulator
DMO9QB8	RN	Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b. J Neurol Sci.1999 Oct 15;168(2):131-6.
DMO9QB8	RU	https://pubmed.ncbi.nlm.nih.gov/10526196

DM3L51O	DI	DM3L51O
DM3L51O	DN	Rilopirox
DM3L51O	MI	TT2J34L
DM3L51O	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM3L51O	MT	DTT
DM3L51O	MA	Inhibitor
DM3L51O	RN	Therapy of seborrheic eczema with an antifungal agent with an antiphlogistic effect. Mycoses. 1991;34 Suppl 1:91-3.
DM3L51O	RU	https://pubmed.ncbi.nlm.nih.gov/1840158

DMSC7TN	DI	DMSC7TN
DMSC7TN	DN	Rimacalib
DMSC7TN	MI	TTFYL58
DMSC7TN	MN	CaM-kinase II (CAMK2)
DMSC7TN	MT	DTT
DMSC7TN	MA	Modulator
DMSC7TN	RN	Role for CaMKII inhibition in rheumatoid arthritis: effects on HIF-1-induced VEGF production by rheumatoid synovial fibroblasts. Ann N Y Acad Sci. 2009 Sep;1173:706-11.
DMSC7TN	RU	https://pubmed.ncbi.nlm.nih.gov/19758219

DM2VO97	DI	DM2VO97
DM2VO97	DN	RK-023
DM2VO97	MI	TT30NW6
DM2VO97	MN	Chloride channel protein 2 (CLC-2)
DM2VO97	MT	DTT
DM2VO97	MA	Modulator
DM2VO97	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM2VO97	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMVU1R9	DI	DMVU1R9
DMVU1R9	DN	RM-1929
DMVU1R9	MI	TTGKNB4
DMVU1R9	MN	Epidermal growth factor receptor (EGFR)
DMVU1R9	MT	DTT
DMVU1R9	MA	Antagonist
DMVU1R9	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMVU1R9	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM20CIM	DI	DM20CIM
DM20CIM	DN	RNF43-721
DM20CIM	MI	TTD91BL
DM20CIM	MN	RING finger protein 43 (RNF43)
DM20CIM	MT	DTT
DM20CIM	MA	Modulator
DM20CIM	RN	Phase I clinical trial of a novel peptide vaccine in combination with UFT/LV for metastatic colorectal cancer. Exp Ther Med. 2011 Jan-Feb; 2(1): 73-79.
DM20CIM	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3440656/

DMDNRU1	DI	DMDNRU1
DMDNRU1	DN	RNS-60
DMDNRU1	MI	TTO7FVG
DMDNRU1	MN	Heat shock protein 90 (HSP90)
DMDNRU1	MT	DTT
DMDNRU1	MA	Modulator
DMDNRU1	RN	Clinical pipeline report, company report or official report of Revalesio.
DMDNRU1	RU	http://revalesio.com/about-our-technology/

DM83QCL	DI	DM83QCL
DM83QCL	DN	Ro 31-7453
DM83QCL	MI	TTH6V3D
DM83QCL	MN	Cyclin-dependent kinase 1 (CDK1)
DM83QCL	MT	DTT
DM83QCL	MA	Inhibitor
DM83QCL	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DM83QCL	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DM83QCL	DI	DM83QCL
DM83QCL	DN	Ro 31-7453
DM83QCL	MI	TT7HF4W
DM83QCL	MN	Cyclin-dependent kinase 2 (CDK2)
DM83QCL	MT	DTT
DM83QCL	MA	Inhibitor
DM83QCL	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DM83QCL	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DM83QCL	DI	DM83QCL
DM83QCL	DN	Ro 31-7453
DM83QCL	MI	TT0PG8F
DM83QCL	MN	Cyclin-dependent kinase 4 (CDK4)
DM83QCL	MT	DTT
DM83QCL	MA	Inhibitor
DM83QCL	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DM83QCL	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMA2UYE	DI	DMA2UYE
DMA2UYE	DN	Ro-24-7429
DMA2UYE	MI	TTT3ZC9
DMA2UYE	MN	Human immunodeficiency virus Tat protein (HIV tat)
DMA2UYE	MT	DTT
DMA2UYE	MA	Modulator
DMA2UYE	RN	A randomized trial of the activity and safety of Ro 24-7429 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection. The AIDS Clinical Trials Group 213 Team. J Infect Dis. 1995 Nov;172(5):1246-52.
DMA2UYE	RU	https://pubmed.ncbi.nlm.nih.gov/7594660

DMV319J	DI	DMV319J
DMV319J	DN	RO-4905417
DMV319J	MI	TTS5K8U
DMV319J	MN	P-selectin glycoprotein ligand 1 (SELPLG)
DMV319J	MT	DTT
DMV319J	RN	WO patent application no. 2013,0144,05, Methods.
DMV319J	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20130131&CC=WO&NR=2013014405A2&KC=A2

DMXA6B3	DI	DMXA6B3
DMXA6B3	DN	RO-4929097
DMXA6B3	MI	TT9W8GU
DMXA6B3	MN	Gamma-secretase (GS)
DMXA6B3	MT	DTT
DMXA6B3	MA	Modulator
DMXA6B3	RN	Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol. 2012 Jul 1;30(19):2348-53.
DMXA6B3	RU	https://pubmed.ncbi.nlm.nih.gov/22529266

DMNTC7O	DI	DMNTC7O
DMNTC7O	DN	RO-4995819
DMNTC7O	MI	TTXJ47W
DMNTC7O	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMNTC7O	MT	DTT
DMNTC7O	MA	Modulator
DMNTC7O	RN	Novel glutamatergic drugs for the treatment of mood disorders. Neuropsychiatr Dis Treat. 2013; 9: 1101-1112.
DMNTC7O	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747027/

DMNTC7O	DI	DMNTC7O
DMNTC7O	DN	RO-4995819
DMNTC7O	MI	TT8A9EF
DMNTC7O	MN	Metabotropic glutamate receptor 3 (mGluR3)
DMNTC7O	MT	DTT
DMNTC7O	MA	Modulator
DMNTC7O	RN	Novel glutamatergic drugs for the treatment of mood disorders. Neuropsychiatr Dis Treat. 2013; 9: 1101-1112.
DMNTC7O	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747027/

DMZJREM	DI	DMZJREM
DMZJREM	DN	RO-4998452
DMZJREM	MI	TTLWPVF
DMZJREM	MN	Sodium/glucose cotransporter 2 (SGLT2)
DMZJREM	MT	DTT
DMZJREM	MA	Modulator
DMZJREM	RN	A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus.Diabetes Obes Metab.2015 Oct;17(10):984-93.
DMZJREM	RU	https://www.ncbi.nlm.nih.gov/pubmed/26179482

DM3U9BY	DI	DM3U9BY
DM3U9BY	DN	RO-5126766
DM3U9BY	MI	TTROQ37
DM3U9BY	MN	MAPK/ERK kinase kinase (MAP3K)
DM3U9BY	MT	DTT
DM3U9BY	MA	Modulator
DM3U9BY	RN	The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells.PLoS One.2014 Nov 25;9(11):e113217.
DM3U9BY	RU	https://www.ncbi.nlm.nih.gov/pubmed/25422890

DM3U9BY	DI	DM3U9BY
DM3U9BY	DN	RO-5126766
DM3U9BY	MI	TTQ9K3Y
DM3U9BY	MN	Serine/threonine-protein kinase Raf (RAF)
DM3U9BY	MT	DTT
DM3U9BY	MA	Modulator
DM3U9BY	RN	The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells.PLoS One.2014 Nov 25;9(11):e113217.
DM3U9BY	RU	https://www.ncbi.nlm.nih.gov/pubmed/25422890

DMUB3OY	DI	DMUB3OY
DMUB3OY	DN	RO-5323441
DMUB3OY	MI	TT48I1Y
DMUB3OY	MN	Placenta growth factor (PlGF)
DMUB3OY	MT	DTT
DMUB3OY	MA	Inhibitor
DMUB3OY	RN	RO5323441, a humanized monoclonal antibody against the placenta growth factor, blocks PlGF-induced VEGFR-1 phosphorylation in vitro and tumor growth in vivo. Cancer Research. 01/2011.
DMUB3OY	RU	http://cancerres.aacrjournals.org/content/70/8_Supplement/1370.abstract

DMD3WNP	DI	DMD3WNP
DMD3WNP	DN	RO5520985
DMD3WNP	MI	TTKLQTJ
DMD3WNP	MN	Angiopoietin-2 (ANGPT2)
DMD3WNP	MT	DTT
DMD3WNP	MA	Modulator
DMD3WNP	RN	Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. 
DMD3WNP	RU	https://www.ncbi.nlm.nih.gov/pubmed/25359367

DMD3WNP	DI	DMD3WNP
DMD3WNP	DN	RO5520985
DMD3WNP	MI	TTOHSBA
DMD3WNP	MN	Vascular endothelial growth factor A (VEGFA)
DMD3WNP	MT	DTT
DMD3WNP	MA	Modulator
DMD3WNP	RN	Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. 
DMD3WNP	RU	https://www.ncbi.nlm.nih.gov/pubmed/25359367

DM8A120	DI	DM8A120
DM8A120	DN	RO7121661
DM8A120	MI	TT1RWL7
DM8A120	MN	Hepatitis A virus cellular receptor 2 (TIM3)
DM8A120	MT	DTT
DM8A120	MA	Inhibitor
DM8A120	RN	Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.
DM8A120	RU	https://pubmed.ncbi.nlm.nih.gov/31175342

DM8A120	DI	DM8A120
DM8A120	DN	RO7121661
DM8A120	MI	TTNBFWK
DM8A120	MN	Programmed cell death protein 1 (PD-1)
DM8A120	MT	DTT
DM8A120	MA	Inhibitor
DM8A120	RN	Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.
DM8A120	RU	https://pubmed.ncbi.nlm.nih.gov/31175342

DMSTH01	DI	DMSTH01
DMSTH01	DN	Rocilinostat
DMSTH01	MI	TTBH0VX
DMSTH01	MN	Histone deacetylase (HDAC)
DMSTH01	MT	DTT
DMSTH01	MA	Inhibitor
DMSTH01	RN	National Cancer Institute Drug Dictionary (drug id 698408).
DMSTH01	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=698408

DMYEZ5J	DI	DMYEZ5J
DMYEZ5J	DN	Romilkimab
DMYEZ5J	MI	TT0GVCH
DMYEZ5J	MN	Interleukin-13 (IL13)
DMYEZ5J	MT	DTT
DMYEZ5J	MA	Inhibitor
DMYEZ5J	RN	A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2020 Dec;79(12):1600-1607.
DMYEZ5J	RU	https://pubmed.ncbi.nlm.nih.gov/32963047

DMYEZ5J	DI	DMYEZ5J
DMYEZ5J	DN	Romilkimab
DMYEZ5J	MI	TTLGTKB
DMYEZ5J	MN	Interleukin-4 (IL4)
DMYEZ5J	MT	DTT
DMYEZ5J	MA	Inhibitor
DMYEZ5J	RN	A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2020 Dec;79(12):1600-1607.
DMYEZ5J	RU	https://pubmed.ncbi.nlm.nih.gov/32963047

DMBJN19	DI	DMBJN19
DMBJN19	DN	Rontalizumab
DMBJN19	MI	TT95SOA
DMBJN19	MN	Interferon alpha (IFNA)
DMBJN19	MT	DTT
DMBJN19	RN	Clinical pipeline report, company report or official report of Genentech (2011).
DMBJN19	RU	http://www.gene.com/gene/index.jsp

DMKQXDB	DI	DMKQXDB
DMKQXDB	DN	Rostafuroxin
DMKQXDB	MI	TTQ38E9
DMKQXDB	MN	Sodium/potassium-transporting ATPase (SPT ATPase)
DMKQXDB	MT	DTT
DMKQXDB	MA	Modulator
DMKQXDB	RN	Rostafuroxin: an ouabain antagonist that corrects renal and vascular Na+-K+- ATPase alterations in ouabain and adducin-dependent hypertension. Am J Physiol Regul Integr Comp Physiol. 2006 Mar;290(3):R529-35.
DMKQXDB	RU	https://pubmed.ncbi.nlm.nih.gov/16467500

DMXB9RS	DI	DMXB9RS
DMXB9RS	DN	ROTIGAPTIDE
DMXB9RS	MI	TTJO6E9
DMXB9RS	MN	Gap junction protein (GJP)
DMXB9RS	MT	DTT
DMXB9RS	MA	Modulator
DMXB9RS	RN	The antiarrhythmic peptide rotigaptide (ZP123) increases gap junction intercellular communication in cardiac myocytes and HeLa cells expressing connexin 43. Br J Pharmacol. 2006 Mar;147(5):486-95.
DMXB9RS	RU	https://pubmed.ncbi.nlm.nih.gov/16415913

DMIZMYQ	DI	DMIZMYQ
DMIZMYQ	DN	Roxatidine
DMIZMYQ	MI	DEJVYAZ
DMIZMYQ	MN	Cytochrome P450 2A6 (CYP2A6)
DMIZMYQ	MT	DME
DMIZMYQ	MA	Metabolism
DMIZMYQ	RN	Cytochrome P450 enzymes involved in the metabolic pathway of the histamine 2 (H2)-receptor antagonist roxatidine acetate by human liver microsomes. Arzneimittelforschung. 2001;51(8):651-8.
DMIZMYQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11556126

DMIZMYQ	DI	DMIZMYQ
DMIZMYQ	DN	Roxatidine
DMIZMYQ	MI	DECB0K3
DMIZMYQ	MN	Cytochrome P450 2D6 (CYP2D6)
DMIZMYQ	MT	DME
DMIZMYQ	MA	Metabolism
DMIZMYQ	RN	Cytochrome P450 enzymes involved in the metabolic pathway of the histamine 2 (H2)-receptor antagonist roxatidine acetate by human liver microsomes. Arzneimittelforschung. 2001;51(8):651-8.
DMIZMYQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11556126

DM15QL9	DI	DM15QL9
DM15QL9	DN	ROXINDOLE
DM15QL9	MI	TTEX248
DM15QL9	MN	Dopamine D2 receptor (D2R)
DM15QL9	MT	DTT
DM15QL9	MA	Inhibitor
DM15QL9	RN	Indolebutylamines as selective 5-HT(1A) agonists. J Med Chem. 2004 Sep 9;47(19):4677-83.
DM15QL9	RU	https://pubmed.ncbi.nlm.nih.gov/15341483

DMK0NGB	DI	DMK0NGB
DMK0NGB	DN	Rozanolixizumab
DMK0NGB	MI	TTPY4SE
DMK0NGB	MN	Immunoglobulin Fc receptor (FCR)
DMK0NGB	MT	DTT
DMK0NGB	MA	Antagonist
DMK0NGB	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMK0NGB	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM4N6PF	DI	DM4N6PF
DM4N6PF	DN	RP-49356
DM4N6PF	MI	TT1VOHK
DM4N6PF	MN	Potassium channel unspecific (KC)
DM4N6PF	MT	DTT
DM4N6PF	MA	Opener
DM4N6PF	RN	Effects of pinacidil, RP 49356 and nicorandil on ATP-sensitive potassium channels in insulin-secreting cells. Br J Pharmacol. 1990 Mar;99(3):487-92.
DM4N6PF	RU	https://pubmed.ncbi.nlm.nih.gov/2158844

DMKUE8O	DI	DMKUE8O
DMKUE8O	DN	RP5063
DMKUE8O	MI	TTSQIFT
DMKUE8O	MN	5-HT 1A receptor (HTR1A)
DMKUE8O	MT	DTT
DMKUE8O	MA	Antagonist
DMKUE8O	RN	Drug Development in Schizophrenia: Summary and Table. Pharmaceutical Medicine October 2014, Volume 28, Issue 5, pp 265-271
DMKUE8O	RU	http://link.springer.com/article/10.1007%2Fs40290-014-0070-6

DMKUE8O	DI	DMKUE8O
DMKUE8O	DN	RP5063
DMKUE8O	MI	TTJQOD7
DMKUE8O	MN	5-HT 2A receptor (HTR2A)
DMKUE8O	MT	DTT
DMKUE8O	MA	Partial agonist
DMKUE8O	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMKUE8O	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMKUE8O	DI	DMKUE8O
DMKUE8O	DN	RP5063
DMKUE8O	MI	TTO9X1H
DMKUE8O	MN	5-HT 7 receptor (HTR7)
DMKUE8O	MT	DTT
DMKUE8O	MA	Partial agonist
DMKUE8O	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMKUE8O	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMKUE8O	DI	DMKUE8O
DMKUE8O	DN	RP5063
DMKUE8O	MI	TTEX248
DMKUE8O	MN	Dopamine D2 receptor (D2R)
DMKUE8O	MT	DTT
DMKUE8O	MA	Antagonist
DMKUE8O	RN	Drug Development in Schizophrenia: Summary and Table. Pharmaceutical Medicine October 2014, Volume 28, Issue 5, pp 265-271
DMKUE8O	RU	http://link.springer.com/article/10.1007%2Fs40290-014-0070-6

DMKUE8O	DI	DMKUE8O
DMKUE8O	DN	RP5063
DMKUE8O	MI	TT4C8EA
DMKUE8O	MN	Dopamine D3 receptor (D3R)
DMKUE8O	MT	DTT
DMKUE8O	MA	Partial agonist
DMKUE8O	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMKUE8O	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMKUE8O	DI	DMKUE8O
DMKUE8O	DN	RP5063
DMKUE8O	MI	TTE0A2F
DMKUE8O	MN	Dopamine D4 receptor (D4R)
DMKUE8O	MT	DTT
DMKUE8O	MA	Partial agonist
DMKUE8O	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMKUE8O	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMKUE8O	DI	DMKUE8O
DMKUE8O	DN	RP5063
DMKUE8O	MI	TTTIBOJ
DMKUE8O	MN	Histamine H1 receptor (H1R)
DMKUE8O	MT	DTT
DMKUE8O	MA	Partial agonist
DMKUE8O	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMKUE8O	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMKUE8O	DI	DMKUE8O
DMKUE8O	DN	RP5063
DMKUE8O	MI	TT8G3Z7
DMKUE8O	MN	Serotoninnorepinephrinedopamine reuptake (SNDR)
DMKUE8O	MT	DTT
DMKUE8O	MA	Partial agonist
DMKUE8O	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMKUE8O	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMYILGK	DI	DMYILGK
DMYILGK	DN	RP6530
DMYILGK	MI	TTGBPJE
DMYILGK	MN	PI3-kinase delta (PIK3CD)
DMYILGK	MT	DTT
DMYILGK	MA	Inhibitor
DMYILGK	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMYILGK	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM4L5VJ	DI	DM4L5VJ
DM4L5VJ	DN	R-phenserine
DM4L5VJ	MI	TT1RS9F
DM4L5VJ	MN	Acetylcholinesterase (AChE)
DM4L5VJ	MT	DTT
DM4L5VJ	MA	Inhibitor
DM4L5VJ	RN	An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Curr Alzheimer Res. 2005 Jul;2(3):281-90.
DM4L5VJ	RU	https://pubmed.ncbi.nlm.nih.gov/15974893

DMSJU5B	DI	DMSJU5B
DMSJU5B	DN	RP-L102
DMSJU5B	MI	TTV5HJS
DMSJU5B	MN	Fanconi anemia group A protein (FANCA)
DMSJU5B	MT	DTT
DMSJU5B	MA	Replacement
DMSJU5B	RN	Clinical pipeline report, company report or official report of Rocket Pharmaceuticals.
DMSJU5B	RU	https://rocketpharma.com/our-disease-focus/

DMLD4VQ	DI	DMLD4VQ
DMLD4VQ	DN	RPL-554
DMLD4VQ	MI	TTZCG4L
DMLD4VQ	MN	Phosphodiesterase 3 (PDE3)
DMLD4VQ	MT	DTT
DMLD4VQ	MA	Modulator
DMLD4VQ	RN	Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.Lancet Respir Med.2013 Nov;1(9):714-27.
DMLD4VQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/24429275

DM0BFJ5	DI	DM0BFJ5
DM0BFJ5	DN	RPSGL-Ig
DM0BFJ5	MI	TTE5VG0
DM0BFJ5	MN	P-selectin (SELP)
DM0BFJ5	MT	DTT
DM0BFJ5	MA	Inhibitor
DM0BFJ5	RN	rPSGL-1-Ig, a recombinant PSGL-1-Ig fusion protein, ameliorates LPS-induced acute lung injury in mice by inhibiting neutrophil migration. Cell Mol Biol (Noisy-le-grand). 2015 Feb 28;61(1):1-6.
DM0BFJ5	RU	https://pubmed.ncbi.nlm.nih.gov/25817339

DMBHN4K	DI	DMBHN4K
DMBHN4K	DN	RQ-00000005
DMBHN4K	MI	TTWDC17
DMBHN4K	MN	Growth hormone secretagogue receptor 1 (GHSR)
DMBHN4K	MT	DTT
DMBHN4K	MA	Agonist
DMBHN4K	RN	Hypotensive effects of ghrelin receptor agonists mediated through a novel receptor. Br J Pharmacol. 2014 Mar;171(5):1275-86.
DMBHN4K	RU	https://pubmed.ncbi.nlm.nih.gov/24670149

DMMYTRU	DI	DMMYTRU
DMMYTRU	DN	RQ-00000007 (oral)
DMMYTRU	MI	TT79WV3
DMMYTRU	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DMMYTRU	MT	DTT
DMMYTRU	MA	Antagonist
DMMYTRU	RN	Clinical pipeline report, company report or official report of Avarx.
DMMYTRU	RU	http://www.avarx.com/AvaRx/SubDomains/bucket5733245651167129819/Listings/bucket2137138075456035728/Public.Listing.display.html

DMSH108	DI	DMSH108
DMSH108	DN	R-roscovitine
DMSH108	MI	TTMBO1Z
DMSH108	MN	Cyclin-dependent kinase (CDK)
DMSH108	MT	DTT
DMSH108	MA	Inhibitor
DMSH108	RN	Therapeutic efficacy of seliciclib in combination with ionizing radiation for human nasopharyngeal carcinoma.Clin Cancer Res. 2009 Jun 1;15(11):3716-24.
DMSH108	RU	https://pubmed.ncbi.nlm.nih.gov/19470731

DMSH108	DI	DMSH108
DMSH108	DN	R-roscovitine
DMSH108	MI	TTH6V3D
DMSH108	MN	Cyclin-dependent kinase 1 (CDK1)
DMSH108	MT	DTT
DMSH108	MA	Inhibitor
DMSH108	RN	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
DMSH108	RU	https://pubmed.ncbi.nlm.nih.gov/19568282

DMSH108	DI	DMSH108
DMSH108	DN	R-roscovitine
DMSH108	MI	TT7HF4W
DMSH108	MN	Cyclin-dependent kinase 2 (CDK2)
DMSH108	MT	DTT
DMSH108	MA	Inhibitor
DMSH108	RN	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
DMSH108	RU	https://pubmed.ncbi.nlm.nih.gov/19568282

DMSH108	DI	DMSH108
DMSH108	DN	R-roscovitine
DMSH108	MI	TTQYF7G
DMSH108	MN	Cyclin-dependent kinase 7 (CDK7)
DMSH108	MT	DTT
DMSH108	MA	Inhibitor
DMSH108	RN	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
DMSH108	RU	https://pubmed.ncbi.nlm.nih.gov/19568282

DMSH108	DI	DMSH108
DMSH108	DN	R-roscovitine
DMSH108	MI	DEPKLMQ
DMSH108	MN	Cytochrome P450 2B6 (CYP2B6)
DMSH108	MT	DME
DMSH108	MA	Metabolism
DMSH108	RN	Metabolism of the trisubstituted purine cyclin-dependent kinase inhibitor seliciclib (R-roscovitine) in vitro and in vivo. Drug Metab Dispos. 2008 Mar;36(3):561-70.
DMSH108	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18048486

DMSH108	DI	DMSH108
DMSH108	DN	R-roscovitine
DMSH108	MI	DE4LYSA
DMSH108	MN	Cytochrome P450 3A4 (CYP3A4)
DMSH108	MT	DME
DMSH108	MA	Metabolism
DMSH108	RN	Metabolism of the trisubstituted purine cyclin-dependent kinase inhibitor seliciclib (R-roscovitine) in vitro and in vivo. Drug Metab Dispos. 2008 Mar;36(3):561-70.
DMSH108	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18048486

DMSH108	DI	DMSH108
DMSH108	DN	R-roscovitine
DMSH108	MI	DTUGYRD
DMSH108	MN	P-glycoprotein 1 (ABCB1)
DMSH108	MT	DTP
DMSH108	MA	Substrate
DMSH108	RN	ATP-binding cassette B1 transports seliciclib (R-roscovitine), a cyclin-dependent kinase inhibitor. Drug Metab Dispos. 2010 Nov;38(11):2000-6.
DMSH108	RU	https://doi.org/10.1124/dmd.110.032805

DMGLCVU	DI	DMGLCVU
DMGLCVU	DN	R-salbutamol sulphate
DMGLCVU	MI	TT2CJVK
DMGLCVU	MN	Adrenergic receptor beta-2 (ADRB2)
DMGLCVU	MT	DTT
DMGLCVU	MA	Agonist
DMGLCVU	RN	Pharmacokinetics and extrapulmonary beta 2 adrenoceptor activity of nebulised racemic salbutamol and its R and S isomers in healthy volunteers. Thorax. 1997 Oct;52(10):849-52.
DMGLCVU	RU	https://pubmed.ncbi.nlm.nih.gov/9404370

DMAJH75	DI	DMAJH75
DMAJH75	DN	RSV-604
DMAJH75	MI	TT25A0I
DMAJH75	MN	Respiratory syncytial virus protein N (RSV N)
DMAJH75	MT	DTT
DMAJH75	MA	Inhibitor
DMAJH75	RN	Mechanism of action for respiratory syncytial virus inhibitor RSV604. Antimicrob Agents Chemother. 2015 Feb;59(2):1080-7.
DMAJH75	RU	https://pubmed.ncbi.nlm.nih.gov/25451060

DM3FS1G	DI	DM3FS1G
DM3FS1G	DN	RT-001
DM3FS1G	MI	TTB52WU
DM3FS1G	MN	Bacterial Botulinum toxin A (Bact botA)
DM3FS1G	MT	DTT
DM3FS1G	MA	Modulator
DM3FS1G	RN	Clinical pipeline report, company report or official report of Revance Therapeutics.
DM3FS1G	RU	http://www.revance.com/mechanism-of-action-rt001/

DM8DVC9	DI	DM8DVC9
DM8DVC9	DN	RT-400
DM8DVC9	MI	TTIY658
DM8DVC9	MN	Corticotropin-releasing factor receptor 2 (CRHR2)
DM8DVC9	MT	DTT
DM8DVC9	MA	Agonist
DM8DVC9	RN	Advances in therapeutic peptides targeting G protein-coupled receptors. Nat Rev Drug Discov. 2020 Jun;19(6):389-413.
DM8DVC9	RU	https://pubmed.ncbi.nlm.nih.gov/32494050

DM45NHF	DI	DM45NHF
DM45NHF	DN	RTR-003632
DM45NHF	MI	DESDN74
DM45NHF	MN	Serum paraoxonase/arylesterase 1 (PON1)
DM45NHF	MT	DME
DM45NHF	MA	Metabolism
DM45NHF	RN	Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos. 2000 Nov;28(11):1335-42.
DM45NHF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11038162

DMVCXZK	DI	DMVCXZK
DMVCXZK	DN	Rupintrivir
DMVCXZK	MI	TTGW0DV
DMVCXZK	MN	Rhinovirus Protease 3C (HRV P3C)
DMVCXZK	MT	DTT
DMVCXZK	MA	Modulator
DMVCXZK	RN	Enterovirus 71 and coxsackievirus A16 3C proteases: binding to rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design. J Virol. 2011 Oct;85(19):10319-31.
DMVCXZK	RU	https://pubmed.ncbi.nlm.nih.gov/21795339

DMSW5XJ	DI	DMSW5XJ
DMSW5XJ	DN	RV521
DMSW5XJ	MI	TT57ID8
DMSW5XJ	MN	Respiratory syncytial virus protein F (RSV F)
DMSW5XJ	MT	DTT
DMSW5XJ	MA	Inhibitor
DMSW5XJ	RN	Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus Fusion. J Med Chem. 2021 Apr 8;64(7):3658-3676.
DMSW5XJ	RU	https://pubmed.ncbi.nlm.nih.gov/33729773

DM652CM	DI	DM652CM
DM652CM	DN	RV-568
DM652CM	MI	TTU8W4S
DM652CM	MN	Protein kinase (PK)
DM652CM	MT	DTT
DM652CM	MA	Inhibitor
DM652CM	RN	Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2015 Mar;24(3):383-92.
DM652CM	RU	https://pubmed.ncbi.nlm.nih.gov/25599809

DM3C9F8	DI	DM3C9F8
DM3C9F8	DN	RVT-505
DM3C9F8	MI	TT037IE
DM3C9F8	MN	Aryl hydrocarbon receptor (AHR)
DM3C9F8	MT	DTT
DM3C9F8	MA	Modulator
DM3C9F8	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3C9F8	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMTBAV3	DI	DMTBAV3
DMTBAV3	DN	RX-0201
DMTBAV3	MI	TTWTSCV
DMTBAV3	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DMTBAV3	MT	DTT
DMTBAV3	MA	Inhibitor
DMTBAV3	RN	CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
DMTBAV3	RU	http://www.centerwatch.com/

DME8ARP	DI	DME8ARP
DME8ARP	DN	RX-3117
DME8ARP	MI	TT6S2FE
DME8ARP	MN	DNA [cytosine-5]-methyltransferase 1 (DNMT1)
DME8ARP	MT	DTT
DME8ARP	MA	Inhibitor
DME8ARP	RN	Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360). Invest New Drugs. 2013 Dec;31(6):1444-57.
DME8ARP	RU	https://pubmed.ncbi.nlm.nih.gov/24048768

DMBOZPH	DI	DMBOZPH
DMBOZPH	DN	RX-5902
DMBOZPH	MI	TTOTSW1
DMBOZPH	MN	ATP-dependent RNA helicase DDX5 (DDX5)
DMBOZPH	MT	DTT
DMBOZPH	MA	Modulator
DMBOZPH	RN	Company report (Rexahn)
DMBOZPH	RU	http://investors.rexahn.com/releasedetail.cfm?releaseid=895381

DMBOZPH	DI	DMBOZPH
DMBOZPH	DN	RX-5902
DMBOZPH	MI	TTZKPVC
DMBOZPH	MN	Phosphorylated p68 RNA helicase (pDDX5)
DMBOZPH	MT	DTT
DMBOZPH	MA	Inhibitor
DMBOZPH	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMBOZPH	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMXG9ES	DI	DMXG9ES
DMXG9ES	DN	RXI-109
DMXG9ES	MI	TTIL516
DMXG9ES	MN	CCN2 messenger RNA (CCN2 mRNA)
DMXG9ES	MT	DTT
DMXG9ES	MA	Inhibitor
DMXG9ES	RN	The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019 Jun;18(6):421-446.
DMXG9ES	RU	https://pubmed.ncbi.nlm.nih.gov/30846871

DM4KWEF	DI	DM4KWEF
DM4KWEF	DN	S-0509
DM4KWEF	MI	TTVFO0U
DM4KWEF	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DM4KWEF	MT	DTT
DM4KWEF	MA	Antagonist
DM4KWEF	RN	Selective action of a CCK-B/gastrin receptor antagonist, S-0509, on pentagastrin-, peptone meal- and beer-stimulated gastric acid secretion in dogs. Aliment Pharmacol Ther. 2000 Apr;14(4):479-88.
DM4KWEF	RU	https://pubmed.ncbi.nlm.nih.gov/10759628

DM9KTSG	DI	DM9KTSG
DM9KTSG	DN	S-1360
DM9KTSG	MI	TT5FH9Y
DM9KTSG	MN	Human immunodeficiency virus Integrase (HIV IN)
DM9KTSG	MT	DTT
DM9KTSG	MA	Inhibitor
DM9KTSG	RN	HIV-1 integrase inhibitors: an emerging clinical reality. Drugs R D. 2007;8(3):155-68.
DM9KTSG	RU	https://pubmed.ncbi.nlm.nih.gov/17472411

DMKTLSD	DI	DMKTLSD
DMKTLSD	DN	S-15535
DMKTLSD	MI	TTSQIFT
DMKTLSD	MN	5-HT 1A receptor (HTR1A)
DMKTLSD	MT	DTT
DMKTLSD	MA	Antagonist
DMKTLSD	RN	S 15535, a benzodioxopiperazine acting as presynaptic agonist and postsynaptic 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal scopolamine. Br J Pharmacol. 1999 Nov;128(6):1207-14.
DMKTLSD	RU	https://pubmed.ncbi.nlm.nih.gov/10578133

DML2D30	DI	DML2D30
DML2D30	DN	S-16924
DML2D30	MI	TTSQIFT
DML2D30	MN	5-HT 1A receptor (HTR1A)
DML2D30	MT	DTT
DML2D30	MA	Modulator
DML2D30	RN	S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol. J Pharmacol Exp Ther. 1998 Sep;286(3):1341-55.
DML2D30	RU	https://pubmed.ncbi.nlm.nih.gov/9732398

DMTAX8B	DI	DMTAX8B
DMTAX8B	DN	S-2150
DMTAX8B	MI	TT5HONZ
DMTAX8B	MN	Calcium channel unspecific (CaC)
DMTAX8B	MT	DTT
DMTAX8B	MA	Modulator
DMTAX8B	RN	Pharmacodynamics of S-2150, a simultaneous calcium-blocking and alpha1-inhibiting antihypertensive drug, in rats. J Pharm Pharmacol. 2000 Mar;52(3):273-80.
DMTAX8B	RU	https://pubmed.ncbi.nlm.nih.gov/10757414

DM26IH8	DI	DM26IH8
DM26IH8	DN	S-297995
DM26IH8	MI	TTN4QDT
DM26IH8	MN	Opioid receptor (OPR)
DM26IH8	MT	DTT
DM26IH8	MA	Antagonist
DM26IH8	RN	Clinical pipeline report, company report or official report of Shionogi (2011).
DM26IH8	RU	http://www.shionogi.co.jp/index_e.html

DMU7ZMH	DI	DMU7ZMH
DMU7ZMH	DN	S-364735
DMU7ZMH	MI	TT5FH9Y
DMU7ZMH	MN	Human immunodeficiency virus Integrase (HIV IN)
DMU7ZMH	MT	DTT
DMU7ZMH	MA	Inhibitor
DMU7ZMH	RN	The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral. Antimicrob Agents Chemother. 2008 Mar;52(3):901-8.
DMU7ZMH	RU	https://pubmed.ncbi.nlm.nih.gov/18160521

DMD8XOY	DI	DMD8XOY
DMD8XOY	DN	S-38093
DMD8XOY	MI	TT9JNIC
DMD8XOY	MN	Histamine H3 receptor (H3R)
DMD8XOY	MT	DTT
DMD8XOY	MA	Antagonist
DMD8XOY	RN	Histamine H3 Receptors and Sleep-Wake Regulation. JPET January 2011 vol. 336 no. 1 17-23.
DMD8XOY	RU	http://jpet.aspetjournals.org/content/336/1/17.full

DMXDVNZ	DI	DMXDVNZ
DMXDVNZ	DN	S-555739
DMXDVNZ	MI	TTNVEIR
DMXDVNZ	MN	Prostaglandin D2 receptor (PTGDR)
DMXDVNZ	MT	DTT
DMXDVNZ	MA	Antagonist
DMXDVNZ	RN	Clinical pipeline report, company report or official report of Shionogi (2011).
DMXDVNZ	RU	http://www.shionogi.co.jp/index_e.html

DM3GRKY	DI	DM3GRKY
DM3GRKY	DN	S-707106
DM3GRKY	MI	TTCBFJO
DM3GRKY	MN	Insulin receptor (INSR)
DM3GRKY	MT	DTT
DM3GRKY	MA	Modulator
DM3GRKY	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800).
DM3GRKY	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800

DMZGNOJ	DI	DMZGNOJ
DMZGNOJ	DN	S-777469
DMZGNOJ	MI	TTMSFAW
DMZGNOJ	MN	Cannabinoid receptor 2 (CB2)
DMZGNOJ	MT	DTT
DMZGNOJ	MA	Agonist
DMZGNOJ	RN	Emerging drugs for atopic dermatitis. Expert Opin Emerg Drugs. 2009 Mar;14(1):165-79.
DMZGNOJ	RU	https://pubmed.ncbi.nlm.nih.gov/19216704

DMRZA6G	DI	DMRZA6G
DMRZA6G	DN	S-8921
DMRZA6G	MI	TTPI1M5
DMRZA6G	MN	Ileal sodium/bile acid cotransporter (SLC10A2)
DMRZA6G	MT	DTT
DMRZA6G	MA	Inhibitor
DMRZA6G	RN	Inhibition of ileal Na+/bile acid cotransporter by S-8921 reduces serum cholesterol and prevents atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol. 1998 Aug;18(8):1304-11.
DMRZA6G	RU	https://pubmed.ncbi.nlm.nih.gov/9714138

DMBZO8N	DI	DMBZO8N
DMBZO8N	DN	Sabarubicin
DMBZO8N	MI	TT0IHXV
DMBZO8N	MN	DNA topoisomerase II (TOP2)
DMBZO8N	MT	DTT
DMBZO8N	MA	Modulator
DMBZO8N	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMBZO8N	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMKDP57	DI	DMKDP57
DMKDP57	DN	Safotibant
DMKDP57	MI	TTG5QIA
DMKDP57	MN	B1 bradykinin receptor (BDKRB1)
DMKDP57	MT	DTT
DMKDP57	MA	Modulator
DMKDP57	RN	The role of kinin receptors in cancer and therapeutic opportunities. Cancer Letters Volume 345, Issue 1, 1 April 2014, Pages 27-38.
DMKDP57	RU	http://www.sciencedirect.com/science/article/pii/S030438351300829X

DMRFK0B	DI	DMRFK0B
DMRFK0B	DN	SAGE-217b
DMRFK0B	MI	TTGXH6N
DMRFK0B	MN	GABA(A) receptor delta (GABRD)
DMRFK0B	MT	DTT
DMRFK0B	MA	Immunostimulant
DMRFK0B	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMRFK0B	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DM5NC39	DI	DM5NC39
DM5NC39	DN	SAGE-324
DM5NC39	MI	TTCI43M
DM5NC39	MN	GABA(A) receptor (GABAR)
DM5NC39	MT	DTT
DM5NC39	MA	Modulator
DM5NC39	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DM5NC39	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DM9RC7D	DI	DM9RC7D
DM9RC7D	DN	SAGE-718
DM9RC7D	MI	TT9IK2Z
DM9RC7D	MN	N-methyl-D-aspartate receptor (NMDAR)
DM9RC7D	MT	DTT
DM9RC7D	MA	Modulator
DM9RC7D	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DM9RC7D	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMRSU4X	DI	DMRSU4X
DMRSU4X	DN	Salirasib
DMRSU4X	MI	TTW2R9X
DMRSU4X	MN	GTPase NRas (NRAS)
DMRSU4X	MT	DTT
DMRSU4X	MA	Antagonist
DMRSU4X	RN	The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer. Methods Enzymol. 2008;439:467-89.
DMRSU4X	RU	https://pubmed.ncbi.nlm.nih.gov/18374183

DMRSU4X	DI	DMRSU4X
DMRSU4X	DN	Salirasib
DMRSU4X	MI	TTCJG29
DMRSU4X	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMRSU4X	MT	DTT
DMRSU4X	MA	Modulator
DMRSU4X	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
DMRSU4X	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109

DMQVC3E	DI	DMQVC3E
DMQVC3E	DN	Salvianolic acid B
DMQVC3E	MI	TTZHNQA
DMQVC3E	MN	Insulin-like growth factor-binding protein 3 (IGFBP3)
DMQVC3E	MT	DTT
DMQVC3E	MA	Inhibitor
DMQVC3E	RN	Salvianolic acid B improves myocardial function in diabetic cardiomyopathy by suppressing IGFBP3. J Mol Cell Cardiol. 2020 Feb;139:98-112.
DMQVC3E	RU	https://pubmed.ncbi.nlm.nih.gov/31982427

DM0298B	DI	DM0298B
DM0298B	DN	Salvicine
DM0298B	MI	TT0IHXV
DM0298B	MN	DNA topoisomerase II (TOP2)
DM0298B	MT	DTT
DM0298B	MA	Modulator
DM0298B	RN	Salvicine, a novel topoisomerase II inhibitor, exerts its potent anticancer activity by ROS generation. Acta Pharmacol Sin. 2007 Sep;28(9):1460-5.
DM0298B	RU	https://pubmed.ncbi.nlm.nih.gov/17723179

DMHVJZ6	DI	DMHVJZ6
DMHVJZ6	DN	SAM-531
DMHVJZ6	MI	TTJS8PY
DMHVJZ6	MN	5-HT 6 receptor (HTR6)
DMHVJZ6	MT	DTT
DMHVJZ6	MA	Antagonist
DMHVJZ6	RN	Activation of 5-HT6 receptors modulates sleep-wake activity and hippocampal theta oscillation. ACS Chem Neurosci. 2013 Jan 16;4(1):191-9.
DMHVJZ6	RU	https://pubmed.ncbi.nlm.nih.gov/23336058

DMXTOVE	DI	DMXTOVE
DMXTOVE	DN	Sampatrilat
DMXTOVE	MI	TT5TKPM
DMXTOVE	MN	Neutral endopeptidase (MME)
DMXTOVE	MT	DTT
DMXTOVE	MA	Modulator
DMXTOVE	RN	Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects. Am J Hypertens. 1999 Jun;12(6):563-71.
DMXTOVE	RU	https://pubmed.ncbi.nlm.nih.gov/10371365

DMP5Z9N	DI	DMP5Z9N
DMP5Z9N	DN	SAN-300
DMP5Z9N	MI	TTPERWV
DMP5Z9N	MN	Integrin alpha-1 (VLA-1)
DMP5Z9N	MT	DTT
DMP5Z9N	MA	Antagonist
DMP5Z9N	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMP5Z9N	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMDMQW0	DI	DMDMQW0
DMDMQW0	DN	SAR-100842
DMDMQW0	MI	TTE2YJR
DMDMQW0	MN	Lysophosphatidate-3 receptor (LPAR3)
DMDMQW0	MT	DTT
DMDMQW0	MA	Modulator
DMDMQW0	RN	Promising Pharmacological Directions in the World of Lysophosphatidic Acid Signaling. Biomol Ther (Seoul) 2015 January; 23(1): 1-11.
DMDMQW0	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4286743/

DMDMQW0	DI	DMDMQW0
DMDMQW0	DN	SAR-100842
DMDMQW0	MI	TTQ6S1K
DMDMQW0	MN	Lysophosphatidic acid receptor 1 (LPAR1)
DMDMQW0	MT	DTT
DMDMQW0	MA	Modulator
DMDMQW0	RN	Promising Pharmacological Directions in the World of Lysophosphatidic Acid Signaling. Biomol Ther (Seoul) 2015 January; 23(1): 1-11.
DMDMQW0	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4286743/

DMCLEXM	DI	DMCLEXM
DMCLEXM	DN	SAR-110894
DMCLEXM	MI	TT9JNIC
DMCLEXM	MN	Histamine H3 receptor (H3R)
DMCLEXM	MT	DTT
DMCLEXM	MA	Antagonist
DMCLEXM	RN	SAR110894, a potent histamine H receptor antagonist, displays procognitive effects in rodents. Pharmacol Biochem Behav. 2012 Aug;102(2):203-14.
DMCLEXM	RU	https://pubmed.ncbi.nlm.nih.gov/22542742

DMMCA9V	DI	DMMCA9V
DMMCA9V	DN	SAR-113945
DMMCA9V	MI	TTJ3E9X
DMMCA9V	MN	Inhibitor of nuclear factor kappa-B kinase beta (IKKB)
DMMCA9V	MT	DTT
DMMCA9V	MA	Inhibitor
DMMCA9V	RN	The NF B pathway: a therapeutic target in glioblastoma. Oncotarget. 2011 August; 2(8): 646-653.
DMMCA9V	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3248209/

DMJ34G6	DI	DMJ34G6
DMJ34G6	DN	SAR-125844
DMJ34G6	MI	TTNDSF4
DMJ34G6	MN	Proto-oncogene c-Met (MET)
DMJ34G6	MT	DTT
DMJ34G6	MA	Inhibitor
DMJ34G6	RN	The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer. Mol Cancer Ther. 2015 Feb;14(2):384-94.
DMJ34G6	RU	https://pubmed.ncbi.nlm.nih.gov/25504634

DMUICJD	DI	DMUICJD
DMUICJD	DN	SAR-156597
DMUICJD	MI	TTDWHC3
DMUICJD	MN	Interleukin 4 receptor alpha (IL4R)
DMUICJD	MT	DTT
DMUICJD	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1697).
DMUICJD	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1697

DMUICJD	DI	DMUICJD
DMUICJD	DN	SAR-156597
DMUICJD	MI	TT0GVCH
DMUICJD	MN	Interleukin-13 (IL13)
DMUICJD	MT	DTT
DMUICJD	MA	Modulator
DMUICJD	RN	Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. 
DMUICJD	RU	https://www.ncbi.nlm.nih.gov/pubmed/25359367

DMUICJD	DI	DMUICJD
DMUICJD	DN	SAR-156597
DMUICJD	MI	TTLGTKB
DMUICJD	MN	Interleukin-4 (IL4)
DMUICJD	MT	DTT
DMUICJD	MA	Modulator
DMUICJD	RN	Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. 
DMUICJD	RU	https://www.ncbi.nlm.nih.gov/pubmed/25359367

DMQM7IL	DI	DMQM7IL
DMQM7IL	DN	SAR245409
DMQM7IL	MI	TTHBTOP
DMQM7IL	MN	PI3-kinase gamma (PIK3CG)
DMQM7IL	MT	DTT
DMQM7IL	MA	Inhibitor
DMQM7IL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2156).
DMQM7IL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2156

DMQM7IL	DI	DMQM7IL
DMQM7IL	DN	SAR245409
DMQM7IL	MI	TTCJG29
DMQM7IL	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMQM7IL	MT	DTT
DMQM7IL	MA	Inhibitor
DMQM7IL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
DMQM7IL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109

DMBJU2G	DI	DMBJU2G
DMBJU2G	DN	SAR-260093
DMBJU2G	MI	TT7QNVC
DMBJU2G	MN	Glucose-dependent insulinotropic receptor (GPR119)
DMBJU2G	MT	DTT
DMBJU2G	MA	Agonist
DMBJU2G	RN	GPR119 agonists for the treatment of type 2 diabetes. Expert Opin Ther Pat. 2009 Oct;19(10):1339-59.
DMBJU2G	RU	https://pubmed.ncbi.nlm.nih.gov/19780700

DMEGNHZ	DI	DMEGNHZ
DMEGNHZ	DN	SAR279356
DMEGNHZ	MI	TTAFD3Y
DMEGNHZ	MN	Poly-N-acetyl glucosamine (PNAG)
DMEGNHZ	MT	DTT
DMEGNHZ	MA	Modulator
DMEGNHZ	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMEGNHZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM63QY0	DI	DM63QY0
DM63QY0	DN	SAR292833
DM63QY0	MI	TT946IA
DM63QY0	MN	Transient receptor potential cation channel V3 (TRPV3)
DM63QY0	MT	DTT
DM63QY0	MA	Modulator
DM63QY0	RN	Pharmacological profiling of the TRPV3 channel in recombinant and native assays. Br J Pharmacol. 2014 May;171(10):2631-44.
DM63QY0	RU	https://pubmed.ncbi.nlm.nih.gov/23848361

DMJ9RN8	DI	DMJ9RN8
DMJ9RN8	DN	SAR-339658
DMJ9RN8	MI	TTMSB0A
DMJ9RN8	MN	Integrin alpha-2/beta-1 (ITGA2/B1)
DMJ9RN8	MT	DTT
DMJ9RN8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2578).
DMJ9RN8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2578

DMOSCBF	DI	DMOSCBF
DMOSCBF	DN	SAR-3419
DMOSCBF	MI	TTW640A
DMOSCBF	MN	B-lymphocyte surface antigen B4 (CD19)
DMOSCBF	MT	DTT
DMOSCBF	RN	A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2014 Jan 1;20(1):213-20.
DMOSCBF	RU	https://pubmed.ncbi.nlm.nih.gov/24132920

DMS1YPZ	DI	DMS1YPZ
DMS1YPZ	DN	SAR391786
DMS1YPZ	MI	TTSWPH8
DMS1YPZ	MN	Growth/differentiation factor 8 (GDF-8)
DMS1YPZ	MT	DTT
DMS1YPZ	RN	Myostatin (GDF-8) as a key factor linking muscle mass and bone structure. J Musculoskelet Neuronal Interact. 2010 Mar;10(1):56-63.
DMS1YPZ	RU	https://pubmed.ncbi.nlm.nih.gov/20190380

DMF95KD	DI	DMF95KD
DMF95KD	DN	SAR-407899
DMF95KD	MI	TTZN7RP
DMF95KD	MN	Rho-associated protein kinase 1 (ROCK1)
DMF95KD	MT	DTT
DMF95KD	MA	Inhibitor
DMF95KD	RN	The Rho kinase inhibitor SAR407899 potently inhibits endothelin-1-induced constriction of renal resistance arteries. J Hypertens. 2012 May;30(5):980-9.
DMF95KD	RU	https://pubmed.ncbi.nlm.nih.gov/22388233

DM6Q295	DI	DM6Q295
DM6Q295	DN	SAR566658
DM6Q295	MI	TTCFSPE
DM6Q295	MN	Carbonic anhydrase VI (CA-VI)
DM6Q295	MT	DTT
DM6Q295	MA	Inhibitor
DM6Q295	RN	An Antibody-Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor Activities. Mol Cancer Ther. 2020 Aug;19(8):1660-1669.
DM6Q295	RU	https://pubmed.ncbi.nlm.nih.gov/32451330

DMT4FI5	DI	DMT4FI5
DMT4FI5	DN	SAR-566658
DMT4FI5	MI	TTBHFYQ
DMT4FI5	MN	Mucin-1 (MUC1)
DMT4FI5	MT	DTT
DMT4FI5	RN	Integrating in vitro signaling and drug response data from single cell network profiling (SCNP) to inform on individual's AML biology.Molecular Cancer Therapeutics. 11/2011; 10(Supplement 1):A73-A73.
DMT4FI5	RU	http://mct.aacrjournals.org/content/12/11_Supplement/A73.short

DMG9MN2	DI	DMG9MN2
DMG9MN2	DN	SAR97276
DMG9MN2	MI	TTQ2GJ0
DMG9MN2	MN	Plasmodial phospholipid metabolism (PPP metab)
DMG9MN2	MT	DTT
DMG9MN2	MA	Antagonist
DMG9MN2	RN	Transport and pharmacodynamics of albitiazolium, an antimalarial drug candidate. Br J Pharmacol. 2012 August; 166(8): 2263-2276.
DMG9MN2	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437492/

DMBLHGP	DI	DMBLHGP
DMBLHGP	DN	Saracatinib
DMBLHGP	MI	TT6PKBN
DMBLHGP	MN	Proto-oncogene c-Src (SRC)
DMBLHGP	MT	DTT
DMBLHGP	MA	Modulator
DMBLHGP	RN	Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Expert Opin Investig Drugs.2010 Aug;19(8):931-45.
DMBLHGP	RU	https://www.ncbi.nlm.nih.gov/pubmed/20557276

DMBLHGP	DI	DMBLHGP
DMBLHGP	DN	Saracatinib
DMBLHGP	MI	TT3PJMV
DMBLHGP	MN	Tyrosine-protein kinase ABL1 (ABL)
DMBLHGP	MT	DTT
DMBLHGP	MA	Modulator
DMBLHGP	RN	Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Expert Opin Investig Drugs.2010 Aug;19(8):931-45.
DMBLHGP	RU	https://www.ncbi.nlm.nih.gov/pubmed/20557276

DMUE0AK	DI	DMUE0AK
DMUE0AK	DN	Saratin
DMUE0AK	MI	TTE5Q4N
DMUE0AK	MN	VWF-dependent platelet-collagen conversion (VDDPCC)
DMUE0AK	MT	DTT
DMUE0AK	MA	Inhibitor
DMUE0AK	RN	Antithrombotic effects of saratin on human atherosclerotic plaques. Thromb Haemost. 2004 Jul;92(1):191-200.
DMUE0AK	RU	https://pubmed.ncbi.nlm.nih.gov/15213861

DM5R89X	DI	DM5R89X
DM5R89X	DN	SARIPIDEM
DM5R89X	MI	TTEX6LM
DM5R89X	MN	GABA(A) receptor gamma-3 (GABRG3)
DM5R89X	MT	DTT
DM5R89X	MA	Modulator
DM5R89X	RN	Behavioural effects of novel benzodiazepine (omega) receptor agonists and partial agonists: increases in punished responding and antagonism of the pentylenetetrazole cue. Behav Pharmacol. 1995 Mar;6(2):116-126.
DM5R89X	RU	https://pubmed.ncbi.nlm.nih.gov/11224318

DM1M0PR	DI	DM1M0PR
DM1M0PR	DN	Saruplase
DM1M0PR	MI	TTGY7WI
DM1M0PR	MN	Urokinase-type plasminogen activator (PLAU)
DM1M0PR	MT	DTT
DM1M0PR	MA	Activator
DM1M0PR	RN	Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction. Thromb Haemost. 1994 Nov;72(5):740-4.
DM1M0PR	RU	https://pubmed.ncbi.nlm.nih.gov/7534946

DM27KFY	DI	DM27KFY
DM27KFY	DN	SB-207266A
DM27KFY	MI	TT07C3Y
DM27KFY	MN	5-HT 4 receptor (HTR4)
DM27KFY	MT	DTT
DM27KFY	MA	Antagonist
DM27KFY	RN	Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
DM27KFY	RU	https://pubmed.ncbi.nlm.nih.gov/11293643

DM8TKG5	DI	DM8TKG5
DM8TKG5	DN	SB-265610
DM8TKG5	MI	TT30C9G
DM8TKG5	MN	C-X-C chemokine receptor type 2 (CXCR2)
DM8TKG5	MT	DTT
DM8TKG5	MA	Antagonist
DM8TKG5	RN	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
DM8TKG5	RU	https://pubmed.ncbi.nlm.nih.gov/16634702

DM4NY58	DI	DM4NY58
DM4NY58	DN	SB-623
DM4NY58	MI	TT6R7JZ
DM4NY58	MN	Histone deacetylase 1 (HDAC1)
DM4NY58	MT	DTT
DM4NY58	MA	Inhibitor
DM4NY58	RN	Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92.
DM4NY58	RU	https://pubmed.ncbi.nlm.nih.gov/17896917

DMYLBOU	DI	DMYLBOU
DMYLBOU	DN	SB-649868
DMYLBOU	MI	TT60Q8D
DMYLBOU	MN	Orexin receptor type 1 (HCRTR1)
DMYLBOU	MT	DTT
DMYLBOU	MA	Antagonist
DMYLBOU	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMYLBOU	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMCY785	DI	DMCY785
DMCY785	DN	SB-656933
DMCY785	MI	TT30C9G
DMCY785	MN	C-X-C chemokine receptor type 2 (CXCR2)
DMCY785	MT	DTT
DMCY785	MA	Antagonist
DMCY785	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMCY785	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMRYHWI	DI	DMRYHWI
DMRYHWI	DN	SB-705498
DMRYHWI	MI	TTMI6F5
DMRYHWI	MN	Transient receptor potential cation channel V1 (TRPV1)
DMRYHWI	MT	DTT
DMRYHWI	MA	Blocker
DMRYHWI	RN	Analgesic potential of TRPV1 antagonists. Biochem Pharmacol. 2009 Aug 1;78(3):211-6.
DMRYHWI	RU	https://pubmed.ncbi.nlm.nih.gov/19481638

DMRWE5D	DI	DMRWE5D
DMRWE5D	DN	SB-728-T
DMRWE5D	MI	TT2CEJG
DMRWE5D	MN	C-C chemokine receptor type 5 (CCR5)
DMRWE5D	MT	DTT
DMRWE5D	MA	Modulator
DMRWE5D	RN	Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV. N Engl J Med. 2014 March 6; 370(10): 901-910.
DMRWE5D	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4084652/

DM6XJ9S	DI	DM6XJ9S
DM6XJ9S	DN	SB-743921
DM6XJ9S	MI	TTTRP0H
DM6XJ9S	MN	Kinesin-like protein KIF11 (KIF11)
DM6XJ9S	MT	DTT
DM6XJ9S	MA	Inhibitor
DM6XJ9S	RN	Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Jan-Feb;31(1):47-57.
DM6XJ9S	RU	https://pubmed.ncbi.nlm.nih.gov/19357798

DMJRK6D	DI	DMJRK6D
DMJRK6D	DN	SB-9200
DMJRK6D	MI	TTYPUHA
DMJRK6D	MN	Pattern recognition receptor NOD2 (NOD2)
DMJRK6D	MT	DTT
DMJRK6D	MA	Modulator
DMJRK6D	RN	Company reprot (Spring Bank Pharmaceuticals) (drug: SB 9200)
DMJRK6D	RU	http://springbankpharm.com/spring-bank-pharmaceuticals-presents-preclinical-and-clinical-data-on-immunomodulatory-agent-sb-9200-at-the-2015-annual-meeting-of-the-european-association-for-the-study-of-the-liver/

DMJRK6D	DI	DMJRK6D
DMJRK6D	DN	SB-9200
DMJRK6D	MI	TTVB0O3
DMJRK6D	MN	Retinoic acid-inducible gene-1 (RIG-1)
DMJRK6D	MT	DTT
DMJRK6D	MA	Modulator
DMJRK6D	RN	Company reprot (Spring Bank Pharmaceuticals) (drug: SB 9200)
DMJRK6D	RU	http://springbankpharm.com/spring-bank-pharmaceuticals-presents-preclinical-and-clinical-data-on-immunomodulatory-agent-sb-9200-at-the-2015-annual-meeting-of-the-european-association-for-the-study-of-the-liver/

DMG1VXR	DI	DMG1VXR
DMG1VXR	DN	SBC-014
DMG1VXR	MI	TTC70AJ
DMG1VXR	MN	Granulocyte colony-stimulating factor receptor (G-CSF-R)
DMG1VXR	MT	DTT
DMG1VXR	MA	Modulator
DMG1VXR	RN	A glycosylated recombinant human granulocyte colony stimulating factor produced in a novel protein production system (AVI-014) in healthy subjects: a first-in human, single dose, controlled study. BMC Clin Pharmacol. 2009; 9: 2.
DMG1VXR	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2639539/

DMSUQFJ	DI	DMSUQFJ
DMSUQFJ	DN	SBI-087
DMSUQFJ	MI	TTUE541
DMSUQFJ	MN	Leukocyte surface antigen Leu-16 (CD20)
DMSUQFJ	MT	DTT
DMSUQFJ	MA	Inhibitor
DMSUQFJ	RN	Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders. Clin Exp Immunol. 2009 August; 157(2): 198-208.
DMSUQFJ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2730845/

DMGH4Q0	DI	DMGH4Q0
DMGH4Q0	DN	SC-47085
DMGH4Q0	MI	DEEHWOG
DMGH4Q0	MN	Azoreductase (azoR)
DMGH4Q0	MT	DME
DMGH4Q0	MA	Metabolism
DMGH4Q0	RN	Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease. Drugs. 1991 Apr;41(4):647-64.
DMGH4Q0	RU	https://pubmed.ncbi.nlm.nih.gov/1711964

DM180VX	DI	DM180VX
DM180VX	DN	SC-49483
DM180VX	MI	TTXWASR
DM180VX	MN	Intestinal maltase-glucoamylase (MGAM)
DM180VX	MT	DTT
DM180VX	MA	Inhibitor
DM180VX	RN	Pathology of perbutylated-N-butyl-1-deoxynojiromycin (an alpha-glucosidase-1 inhibitor) in Sprague-Dawley rats. Toxicol Pathol. 1996 Sep-Oct;24(5):531-8.
DM180VX	RU	https://pubmed.ncbi.nlm.nih.gov/8923673

DM58HR7	DI	DM58HR7
DM58HR7	DN	SC-75416
DM58HR7	MI	TTVKILB
DM58HR7	MN	Prostaglandin G/H synthase 2 (COX-2)
DM58HR7	MT	DTT
DM58HR7	MA	Inhibitor
DM58HR7	RN	Modeling and simulation to support dose selection and clinical development of SC-75416, a selective COX-2 inhibitor for the treatment of acute and ... Clin Pharmacol Ther. 2008 Jun;83(6):857-66.
DM58HR7	RU	https://pubmed.ncbi.nlm.nih.gov/17882158

DMMWCZS	DI	DMMWCZS
DMMWCZS	DN	SCH 420814
DMMWCZS	MI	TTM2AOE
DMMWCZS	MN	Adenosine A2a receptor (ADORA2A)
DMMWCZS	MT	DTT
DMMWCZS	MA	Antagonist
DMMWCZS	RN	Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54.
DMMWCZS	RU	https://pubmed.ncbi.nlm.nih.gov/17016425

DMPUAOE	DI	DMPUAOE
DMPUAOE	DN	SCH-527123
DMPUAOE	MI	TTMWT8Z
DMPUAOE	MN	C-X-C chemokine receptor type 1 (CXCR1)
DMPUAOE	MT	DTT
DMPUAOE	MA	Antagonist
DMPUAOE	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPUAOE	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMPUAOE	DI	DMPUAOE
DMPUAOE	DN	SCH-527123
DMPUAOE	MI	TT30C9G
DMPUAOE	MN	C-X-C chemokine receptor type 2 (CXCR2)
DMPUAOE	MT	DTT
DMPUAOE	MA	Modulator
DMPUAOE	RN	CXCR2 Antagonist MK-7123.A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.Am J Respir Crit Care Med.2015 May 1;191(9):1001-11.
DMPUAOE	RU	https://www.ncbi.nlm.nih.gov/pubmed/25695403

DMPUAOE	DI	DMPUAOE
DMPUAOE	DN	SCH-527123
DMPUAOE	MI	TTBD6I7
DMPUAOE	MN	Mucosal addressin cell adhesion molecule 1 (MADCAM1)
DMPUAOE	MT	DTT
DMPUAOE	RN	Emerging drugs to treat Crohn's disease. Expert Opin Emerg Drugs. 2007 Mar;12(1):49-59.
DMPUAOE	RU	https://pubmed.ncbi.nlm.nih.gov/17355213

DMBJY1Z	DI	DMBJY1Z
DMBJY1Z	DN	SCH-900271
DMBJY1Z	MI	TTWNV8U
DMBJY1Z	MN	Nicotinic acid receptor (HCAR2)
DMBJY1Z	MT	DTT
DMBJY1Z	MA	Modulator
DMBJY1Z	RN	Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia. ACS Med Chem Lett. 2011 Nov 24;3(1):63-8.
DMBJY1Z	RU	https://pubmed.ncbi.nlm.nih.gov/24900372

DM67EMK	DI	DM67EMK
DM67EMK	DN	SCH-900776
DM67EMK	MI	TTTU902
DM67EMK	MN	Checkpoint kinase-1 (CHK1)
DM67EMK	MT	DTT
DM67EMK	MA	Inhibitor
DM67EMK	RN	Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther. 2011 Apr;10(4):591-602.
DM67EMK	RU	https://pubmed.ncbi.nlm.nih.gov/21321066

DMPBKUZ	DI	DMPBKUZ
DMPBKUZ	DN	SCH-900978
DMPBKUZ	MI	TTZPO1L
DMPBKUZ	MN	Substance-P receptor (TACR1)
DMPBKUZ	MT	DTT
DMPBKUZ	MA	Antagonist
DMPBKUZ	RN	Clinical pipeline report, company report or official report of OPKO Health, Inc.
DMPBKUZ	RU	http://investor.opko.com/secfiling.cfm?filingID=950123-10-54487&CIK=944809

DM1C9NQ	DI	DM1C9NQ
DM1C9NQ	DN	SCY-635
DM1C9NQ	MI	TTATDGJ
DM1C9NQ	MN	Calcium signal-modulating cyclophilin ligand (CAML)
DM1C9NQ	MT	DTT
DM1C9NQ	MA	Modulator
DM1C9NQ	RN	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro. Antimicrob Agents Chemother. 2010 Feb;54(2):660-72.
DM1C9NQ	RU	https://pubmed.ncbi.nlm.nih.gov/19933795

DM80HOV	DI	DM80HOV
DM80HOV	DN	SDF-1
DM80HOV	MI	TT4UGTF
DM80HOV	MN	Stromal cell-derived factor 1 (CXCL12)
DM80HOV	MT	DTT
DM80HOV	MA	Inhibitor
DM80HOV	RN	SDF-1 in myocardial repair. Gene Ther. 2012 Jun;19(6):583-7. 
DM80HOV	RU	https://pubmed.ncbi.nlm.nih.gov/22673496

DMPZ67G	DI	DMPZ67G
DMPZ67G	DN	SDZ-281-240
DMPZ67G	MI	TTMW94E
DMPZ67G	MN	FK506-binding protein 1A (FKBP1A)
DMPZ67G	MT	DTT
DMPZ67G	MA	Modulator
DMPZ67G	RN	Clearing of psoriasis by a novel immunosuppressive macrolide. J Invest Dermatol. 1996 Apr;106(4):701-10.
DMPZ67G	RU	https://pubmed.ncbi.nlm.nih.gov/8618008

DM2YIOE	DI	DM2YIOE
DM2YIOE	DN	SDZ-MAR-327
DM2YIOE	MI	TTSQIFT
DM2YIOE	MN	5-HT 1A receptor (HTR1A)
DM2YIOE	MT	DTT
DM2YIOE	MA	Modulator
DM2YIOE	RN	DOI: 10.1038/sj.mp.4002062
DM2YIOE	RU	http://www.nature.com/mp/journal/v12/n10/fig_tab/4002062t1.html

DM2YIOE	DI	DM2YIOE
DM2YIOE	DN	SDZ-MAR-327
DM2YIOE	MI	TTEX248
DM2YIOE	MN	Dopamine D2 receptor (D2R)
DM2YIOE	MT	DTT
DM2YIOE	MA	Modulator
DM2YIOE	RN	DOI: 10.1038/sj.mp.4002062
DM2YIOE	RU	http://www.nature.com/mp/journal/v12/n10/fig_tab/4002062t1.html

DMTQ2K0	DI	DMTQ2K0
DMTQ2K0	DN	SelG1
DMTQ2K0	MI	TTE5VG0
DMTQ2K0	MN	P-selectin (SELP)
DMTQ2K0	MT	DTT
DMTQ2K0	RN	Clinical pipeline report, company report or official report of Selexys Pharmaceuticals (2011).
DMTQ2K0	RU	http://www.selexys.com/product_pipeline.asp

DMST4OR	DI	DMST4OR
DMST4OR	DN	Selgantolimod
DMST4OR	MI	TT8CWFK
DMST4OR	MN	Toll-like receptor 8 (TLR8)
DMST4OR	MT	DTT
DMST4OR	MA	Agonist
DMST4OR	RN	Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B. J Med Chem. 2020 Sep 24;63(18):10188-10203.
DMST4OR	RU	https://pubmed.ncbi.nlm.nih.gov/32407112

DMDLOBZ	DI	DMDLOBZ
DMDLOBZ	DN	Selinexor oral
DMDLOBZ	MI	TTCJUR4
DMDLOBZ	MN	Exportin-1 (XPO1)
DMDLOBZ	MT	DTT
DMDLOBZ	MA	Inhibitor
DMDLOBZ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMDLOBZ	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMQM3IX	DI	DMQM3IX
DMQM3IX	DN	SELODENOSON
DMQM3IX	MI	TTK25J1
DMQM3IX	MN	Adenosine A1 receptor (ADORA1)
DMQM3IX	MT	DTT
DMQM3IX	MA	Agonist
DMQM3IX	RN	Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta. 2011 May;1808(5):1290-308.
DMQM3IX	RU	https://pubmed.ncbi.nlm.nih.gov/21185259

DMJH6EL	DI	DMJH6EL
DMJH6EL	DN	Selurampanel
DMJH6EL	MI	TTAN6JD
DMJH6EL	MN	Glutamate receptor AMPA (GRIA)
DMJH6EL	MT	DTT
DMJH6EL	MA	Antagonist
DMJH6EL	RN	BGG492 (selurampanel), an AMPA/kainate receptor antagonist drug for epilepsy. Expert Opin Investig Drugs. 2014 Jan;23(1):107-13.
DMJH6EL	RU	https://pubmed.ncbi.nlm.nih.gov/24147649

DMIJNLG	DI	DMIJNLG
DMIJNLG	DN	Semapimod
DMIJNLG	MI	TTB18GJ
DMIJNLG	MN	Proto-oncogene c-RAF (c-RAF)
DMIJNLG	MT	DTT
DMIJNLG	MA	Modulator
DMIJNLG	RN	Specific inhibition of c-Raf activity by semapimod induces clinical remission in severe Crohn's disease. J Immunol. 2005 Aug 15;175(4):2293-300.
DMIJNLG	RU	https://pubmed.ncbi.nlm.nih.gov/16081798

DMLDBQ5	DI	DMLDBQ5
DMLDBQ5	DN	SEN-196
DMLDBQ5	MI	TTUF2HO
DMLDBQ5	MN	NAD-dependent deacetylase sirtuin-1 (SIRT1)
DMLDBQ5	MT	DTT
DMLDBQ5	MA	Inhibitor
DMLDBQ5	RN	Sirtuin 1 (SIRT1): the misunderstood HDAC. J Biomol Screen. 2011 Dec;16(10):1153-69.
DMLDBQ5	RU	https://pubmed.ncbi.nlm.nih.gov/22086720

DMOH8LD	DI	DMOH8LD
DMOH8LD	DN	Senktide
DMOH8LD	MI	TT4BT06
DMOH8LD	MN	Integrin alpha-4 (ITGA4)
DMOH8LD	MT	DTT
DMOH8LD	MA	Inhibitor
DMOH8LD	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMOH8LD	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMOH8LD	DI	DMOH8LD
DMOH8LD	DN	Senktide
DMOH8LD	MI	TTBPGLU
DMOH8LD	MN	Neuromedin-K receptor (TACR3)
DMOH8LD	MT	DTT
DMOH8LD	MA	Agonist
DMOH8LD	RN	Implication of nigral tachykinin NK3 receptors in the maintenance of hypertension in spontaneously hypertensive rats: a pharmacologic and autoradiographic study. Br J Pharmacol. 2003 Feb;138(4):554-63.
DMOH8LD	RU	https://pubmed.ncbi.nlm.nih.gov/12598409

DMA12HB	DI	DMA12HB
DMA12HB	DN	SEP--4199
DMA12HB	MI	TT85JO3
DMA12HB	MN	5-HT receptor (5HTR)
DMA12HB	MT	DTT
DMA12HB	MA	Antagonist
DMA12HB	RN	ClinicalTrials.gov (NCT03543410) A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression. U.S. National Institutes of Health.
DMA12HB	RU	https://clinicaltrials.gov/ct2/show/NCT03543410

DMA12HB	DI	DMA12HB
DMA12HB	DN	SEP--4199
DMA12HB	MI	TTEX248
DMA12HB	MN	Dopamine D2 receptor (D2R)
DMA12HB	MT	DTT
DMA12HB	MA	Antagonist
DMA12HB	RN	ClinicalTrials.gov (NCT03543410) A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression. U.S. National Institutes of Health.
DMA12HB	RU	https://clinicaltrials.gov/ct2/show/NCT03543410

DMD8RU0	DI	DMD8RU0
DMD8RU0	DN	SEphB4-HSA
DMD8RU0	MI	TTKPV6O
DMD8RU0	MN	Ephrin type-B receptor 2 (EPHB2)
DMD8RU0	MT	DTT
DMD8RU0	MA	Inhibitor
DMD8RU0	RN	National Cancer Institute Drug Dictionary (drug name SEphB4-HSA).
DMD8RU0	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/recombinant-ephb4-hsa-fusion-protein

DMDW5ZC	DI	DMDW5ZC
DMDW5ZC	DN	SER-100
DMDW5ZC	MI	TTNT7K8
DMDW5ZC	MN	Nociceptin receptor (OPRL1)
DMDW5ZC	MT	DTT
DMDW5ZC	MA	Agonist
DMDW5ZC	RN	Clinical pipeline report, company report or official report of Serodus ASA.
DMDW5ZC	RU	http://www.serodus.com/Pipeline/SER100TRISH

DMYT470	DI	DMYT470
DMYT470	DN	Seribantumab
DMYT470	MI	TTDC8N2
DMYT470	MN	Erbb3 tyrosine kinase receptor (Erbb-3)
DMYT470	MT	DTT
DMYT470	MA	Antagonist
DMYT470	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMYT470	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMTNDM2	DI	DMTNDM2
DMTNDM2	DN	Setrobuvir
DMTNDM2	MI	TTMVBWH
DMTNDM2	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMTNDM2	MT	DTT
DMTNDM2	MA	Inhibitor
DMTNDM2	RN	Clinical pipeline report, company report or official report of Anadys Pharmaceuticals (2011).
DMTNDM2	RU	http://www.anadyspharma.com/

DM9IMEZ	DI	DM9IMEZ
DM9IMEZ	DN	Seviteronel
DM9IMEZ	MI	TTRA5BZ
DM9IMEZ	MN	Steroid 17-alpha-monooxygenase (S17AH)
DM9IMEZ	MT	DTT
DM9IMEZ	MA	Inhibitor
DM9IMEZ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9IMEZ	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DML10K3	DI	DML10K3
DML10K3	DN	SF1126
DML10K3	MI	TTHBTOP
DML10K3	MN	PI3-kinase gamma (PIK3CG)
DML10K3	MT	DTT
DML10K3	MA	Modulator
DML10K3	RN	An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo.Cancer Chemother Pharmacol.2013 Apr;71(4):867-81.
DML10K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/23355037

DML10K3	DI	DML10K3
DML10K3	DN	SF1126
DML10K3	MI	TTCJG29
DML10K3	MN	Serine/threonine-protein kinase mTOR (mTOR)
DML10K3	MT	DTT
DML10K3	MA	Inhibitor
DML10K3	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DML10K3	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMVIWNK	DI	DMVIWNK
DMVIWNK	DN	SFV IL-12 gene therapy
DMVIWNK	MI	TTGW72V
DMVIWNK	MN	Interleukin-12 beta (IL12B)
DMVIWNK	MT	DTT
DMVIWNK	MA	Modulator
DMVIWNK	RN	Clinical pipeline report, company report or official report of Trademarkia.
DMVIWNK	RU	http://www.trademarkia.com/lipovil-12-79009798.html

DMAQW9M	DI	DMAQW9M
DMAQW9M	DN	SFX-01
DMAQW9M	MI	TTA6ZN2
DMAQW9M	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMAQW9M	MT	DTT
DMAQW9M	MA	Activator
DMAQW9M	RN	Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat Rev Drug Discov. 2019 Apr;18(4):295-317.
DMAQW9M	RU	https://pubmed.ncbi.nlm.nih.gov/30610225

DMJ9M5D	DI	DMJ9M5D
DMJ9M5D	DN	SGN-30
DMJ9M5D	MI	TT2GM5R
DMJ9M5D	MN	Lymphocyte activation antigen CD30 (TNFRSF8)
DMJ9M5D	MT	DTT
DMJ9M5D	RN	The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res. 2002 Jul 1;62(13):3736-42.
DMJ9M5D	RU	https://pubmed.ncbi.nlm.nih.gov/12097283

DMA4LNE	DI	DMA4LNE
DMA4LNE	DN	SGN-LIV1A
DMA4LNE	MI	TTZN1CF
DMA4LNE	MN	Solute carrier family 39 member 6 (SLC39A6)
DMA4LNE	MT	DTT
DMA4LNE	RN	SGN-LIV1A: a novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer. Mol Cancer Ther. 2014 Dec;13(12):2991-3000.
DMA4LNE	RU	https://pubmed.ncbi.nlm.nih.gov/25253783

DM5XYFH	DI	DM5XYFH
DM5XYFH	DN	SGS742
DM5XYFH	MI	TTDCVZW
DM5XYFH	MN	Gamma-aminobutyric acid B receptor (GABBR)
DM5XYFH	MT	DTT
DM5XYFH	MA	Modulator
DM5XYFH	RN	SGS742: the first GABA(B) receptor antagonist in clinical trials. Biochem Pharmacol. 2004 Oct 15;68(8):1479-87.
DM5XYFH	RU	https://pubmed.ncbi.nlm.nih.gov/15451390

DMLYIPA	DI	DMLYIPA
DMLYIPA	DN	SGT-53
DMLYIPA	MI	TT7SBF5
DMLYIPA	MN	Cellular tumor antigen p53 (TP53)
DMLYIPA	MT	DTT
DMLYIPA	MA	Stimulator
DMLYIPA	RN	Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther. 2013 Apr;20(4):222-8.
DMLYIPA	RU	https://pubmed.ncbi.nlm.nih.gov/23470564

DMGIRM1	DI	DMGIRM1
DMGIRM1	DN	SH-529
DMGIRM1	MI	TT470F3
DMGIRM1	MN	TNF alpha production (TNFA produ)
DMGIRM1	MT	DTT
DMGIRM1	MA	Modulator
DMGIRM1	RN	Particulate beta-glucan induces TNF-alpha production in wound macrophages via a redox-sensitive NF- beta-dependent pathway. Wound Repair Regen. 2011 May-Jun;19(3):411-9.
DMGIRM1	RU	https://pubmed.ncbi.nlm.nih.gov/21518092

DMIQB13	DI	DMIQB13
DMIQB13	DN	SHAPE
DMIQB13	MI	TTBH0VX
DMIQB13	MN	Histone deacetylase (HDAC)
DMIQB13	MT	DTT
DMIQB13	MA	Inhibitor
DMIQB13	RN	Clinical pipeline report, company report or official report of Tetralogic pharmaceuticals.
DMIQB13	RU	http://tetralogicpharma.com/shape/

DMT4UC1	DI	DMT4UC1
DMT4UC1	DN	Sibrotuzumab
DMT4UC1	MI	TTGPQ0F
DMT4UC1	MN	Prolyl endopeptidase FAP (FAP)
DMT4UC1	MT	DTT
DMT4UC1	MA	Inhibitor
DMT4UC1	RN	A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 2003 May;9(5):1639-47.
DMT4UC1	RU	https://pubmed.ncbi.nlm.nih.gov/12738716

DM39RXO	DI	DM39RXO
DM39RXO	DN	SiG12D-LODER
DM39RXO	MI	TT9TVNM
DM39RXO	MN	KRAS G12D mutant messenger RNA (KRAS mRNA)
DM39RXO	MT	DTT
DM39RXO	MA	Inhibitor
DM39RXO	RN	Clinical pipeline report, company report or official report of Silenseed.
DM39RXO	RU	https://www.silenseed.com/kras-loder-for-pancreatic-cancer/

DM75RFJ	DI	DM75RFJ
DM75RFJ	DN	Siplizumab
DM75RFJ	MI	TTJDUNO
DM75RFJ	MN	T-cell surface antigen CD2 (CD2)
DM75RFJ	MT	DTT
DM75RFJ	RN	Emerging drugs for moderate-to-severe psoriasis. Expert Opin Emerg Drugs. 2005 Feb;10(1):35-52.
DM75RFJ	RU	https://pubmed.ncbi.nlm.nih.gov/15757402

DMTXHJ9	DI	DMTXHJ9
DMTXHJ9	DN	Sirolimus
DMTXHJ9	MI	TT7HQAF
DMTXHJ9	MN	HUMAN mammalian target of rapamycin (mTOR)
DMTXHJ9	MT	DTT
DMTXHJ9	MA	Inhibitor
DMTXHJ9	RN	Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov. 2020 Mar 16;6:14.
DMTXHJ9	RU	https://pubmed.ncbi.nlm.nih.gov/32194980

DM90DTM	DI	DM90DTM
DM90DTM	DN	Sirukumab
DM90DTM	MI	TTJH4Y5
DM90DTM	MN	HUMAN interleukin 6 (IL6)
DM90DTM	MT	DTT
DM90DTM	MA	Inhibitor
DM90DTM	RN	Sirukumab: A Potential Treatment for Mood Disorders Adv Ther. 2017 Jan;34(1):78-90.
DM90DTM	RU	https://pubmed.ncbi.nlm.nih.gov/27913990

DMA9VGW	DI	DMA9VGW
DMA9VGW	DN	Sitafloxacin
DMA9VGW	MI	TTN6J5F
DMA9VGW	MN	Bacterial DNA gyrase (Bact gyrase)
DMA9VGW	MT	DTT
DMA9VGW	MA	Inhibitor
DMA9VGW	RN	Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae. J Antimicrob Chemother. 2008 Jul;62(1):98-104.
DMA9VGW	RU	https://pubmed.ncbi.nlm.nih.gov/18390884

DMA9VGW	DI	DMA9VGW
DMA9VGW	DN	Sitafloxacin
DMA9VGW	MI	TTFK8YB
DMA9VGW	MN	Bacterial DNA topoisomerase 4A (Bact parC)
DMA9VGW	MT	DTT
DMA9VGW	MA	Inhibitor
DMA9VGW	RN	Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae. J Antimicrob Chemother. 2008 Jul;62(1):98-104.
DMA9VGW	RU	https://pubmed.ncbi.nlm.nih.gov/18390884

DMY3JWO	DI	DMY3JWO
DMY3JWO	DN	Sitamaquine
DMY3JWO	MI	DECB0K3
DMY3JWO	MN	Cytochrome P450 2D6 (CYP2D6)
DMY3JWO	MT	DME
DMY3JWO	MA	Metabolism
DMY3JWO	RN	Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics. Antimicrob Agents Chemother. 2015 Jul;59(7):3864-9.
DMY3JWO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25870069

DMNRHMX	DI	DMNRHMX
DMNRHMX	DN	SKF-110679
DMNRHMX	MI	TTKMAZ6
DMNRHMX	MN	Growth hormone receptor (GHR)
DMNRHMX	MT	DTT
DMNRHMX	MA	Modulator
DMNRHMX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1093).
DMNRHMX	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1093

DMRHD6B	DI	DMRHD6B
DMRHD6B	DN	SKL-NP
DMRHD6B	MI	TTKLW9S
DMRHD6B	MN	Hyperpolarization cyclic nucleotide-gated channel (HCN)
DMRHD6B	MT	DTT
DMRHD6B	MA	Modulator
DMRHD6B	RN	A Novel Carbamoyloxy Arylalkanoyl Arylpiperazine Compound (SKL-NP) Inhibits Hyperpolarization-Activated Cyclic Nucleotide-Gated (HCN) Channel Currents in Rat Dorsal Root Ganglion Neurons. Korean J Physiol Pharmacol. 2012 Aug;16(4):237-41.
DMRHD6B	RU	https://pubmed.ncbi.nlm.nih.gov/22915988

DMCDON3	DI	DMCDON3
DMCDON3	DN	SLV 306
DMCDON3	MI	TT1BGDH
DMCDON3	MN	Endothelin-converting enzyme (ECE)
DMCDON3	MT	DTT
DMCDON3	MA	Modulator
DMCDON3	RN	The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. Life Sci. 2012 Oct 15;91(13-14):743-8.
DMCDON3	RU	https://pubmed.ncbi.nlm.nih.gov/22480515

DMCDON3	DI	DMCDON3
DMCDON3	DN	SLV 306
DMCDON3	MI	TT5TKPM
DMCDON3	MN	Neutral endopeptidase (MME)
DMCDON3	MT	DTT
DMCDON3	MA	Modulator
DMCDON3	RN	The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. Life Sci. 2012 Oct 15;91(13-14):743-8.
DMCDON3	RU	https://pubmed.ncbi.nlm.nih.gov/22480515

DM867BJ	DI	DM867BJ
DM867BJ	DN	SLV320
DM867BJ	MI	TTK25J1
DM867BJ	MN	Adenosine A1 receptor (ADORA1)
DM867BJ	MT	DTT
DM867BJ	MA	Antagonist
DM867BJ	RN	Role of matrix metalloproteinases and their tissue inhibitors as potential biomarkers of left ventricular remodelling in the athlete's heart. Clin Sci (Lond). 2009 Jul 16;117(4):157-64.
DM867BJ	RU	https://pubmed.ncbi.nlm.nih.gov/19196241

DMXCJKY	DI	DMXCJKY
DMXCJKY	DN	SLV-334
DMXCJKY	MI	TT1BGDH
DMXCJKY	MN	Endothelin-converting enzyme (ECE)
DMXCJKY	MT	DTT
DMXCJKY	MA	Modulator
DMXCJKY	RN	Clinical trials in traumatic brain injury: past experience and current developments.Neurotherapeutics.2010 Jan;7(1):115-26.
DMXCJKY	RU	https://www.ncbi.nlm.nih.gov/pubmed/20129503

DMXCJKY	DI	DMXCJKY
DMXCJKY	DN	SLV-334
DMXCJKY	MI	TT5TKPM
DMXCJKY	MN	Neutral endopeptidase (MME)
DMXCJKY	MT	DTT
DMXCJKY	MA	Modulator
DMXCJKY	RN	Clinical trials in traumatic brain injury: past experience and current developments.Neurotherapeutics.2010 Jan;7(1):115-26.
DMXCJKY	RU	https://www.ncbi.nlm.nih.gov/pubmed/20129503

DMM3AI8	DI	DMM3AI8
DMM3AI8	DN	SLx-4090
DMM3AI8	MI	TTUS1RD
DMM3AI8	MN	Microsomal triglyceride transfer protein (MTTP)
DMM3AI8	MT	DTT
DMM3AI8	MA	Modulator
DMM3AI8	RN	A small-molecule inhibitor of enterocytic microsomal triglyceride transfer protein, SLx-4090: biochemical, pharmacodynamic, pharmacokinetic, and safety profile. J Pharmacol Exp Ther. 2011 Jun;337(3):775-85.
DMM3AI8	RU	https://pubmed.ncbi.nlm.nih.gov/21406547

DMOLTAD	DI	DMOLTAD
DMOLTAD	DN	SM-04690
DMOLTAD	MI	TTFPSHI
DMOLTAD	MN	Wnt signaling pathway (Wnt pathway)
DMOLTAD	MT	DTT
DMOLTAD	MA	Modulator
DMOLTAD	RN	Clinical pipeline report, company report or official report of Phrma.org Arthritis 2014.
DMOLTAD	RU	http://www.phrma.org/sites/default/files/pdf/2014-meds-in-dev-arthritis.pdf

DMTJOQX	DI	DMTJOQX
DMTJOQX	DN	SMP-986
DMTJOQX	MI	TTOXS3C
DMTJOQX	MN	Muscarinic acetylcholine receptor (CHRM)
DMTJOQX	MT	DTT
DMTJOQX	MA	Antagonist
DMTJOQX	RN	DUAL INHIBITION OF Na+-CHANNEL AND MUSCARINIC RECEPTORS BY SMP-986 EFFICIENTLY IMPROVED VOIDING FUNCTION COMPARED TO ANTI-MUSCARINIC AGENTS IN TWO CONSCIOUS RAT MODELS OF DETRUSOR OVERACTIVITY. The Journal of Urology Volume 179, Issue 4, Supplement, April 2008, Pages 129.
DMTJOQX	RU	http://www.sciencedirect.com/science/article/pii/S0022534708603717

DMTJOQX	DI	DMTJOQX
DMTJOQX	DN	SMP-986
DMTJOQX	MI	TTRK8B9
DMTJOQX	MN	Sodium channel unspecific (NaC)
DMTJOQX	MT	DTT
DMTJOQX	MA	Antagonist
DMTJOQX	RN	DUAL INHIBITION OF Na+-CHANNEL AND MUSCARINIC RECEPTORS BY SMP-986 EFFICIENTLY IMPROVED VOIDING FUNCTION COMPARED TO ANTI-MUSCARINIC AGENTS IN TWO CONSCIOUS RAT MODELS OF DETRUSOR OVERACTIVITY. The Journal of Urology Volume 179, Issue 4, Supplement, April 2008, Pages 129.
DMTJOQX	RU	http://www.sciencedirect.com/science/article/pii/S0022534708603717

DMCD6G1	DI	DMCD6G1
DMCD6G1	DN	SMT-C1100
DMCD6G1	MI	TTNO1VA
DMCD6G1	MN	Utrophin (UTRN)
DMCD6G1	MT	DTT
DMCD6G1	MA	Regulator (upregulator)
DMCD6G1	RN	Safety, tolerability, and pharmacokinetics of SMT C1100, a 2-arylbenzoxazole utrophin modulator, following single- and multiple-dose administration to healthy male adult volunteers. J Clin Pharmacol.2015 Jun;55(6):698-707.
DMCD6G1	RU	https://pubmed.ncbi.nlm.nih.gov/25651188

DMPN314	DI	DMPN314
DMPN314	DN	SNA-120
DMPN314	MI	TTTDVOJ
DMPN314	MN	Tropomyosin-related kinase A (TrkA)
DMPN314	MT	DTT
DMPN314	MA	Inhibitor
DMPN314	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPN314	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMO4EYX	DI	DMO4EYX
DMO4EYX	DN	Soblidotin
DMO4EYX	MI	TTML2WA
DMO4EYX	MN	Tubulin (TUB)
DMO4EYX	MT	DTT
DMO4EYX	MA	Modulator
DMO4EYX	RN	Antitumor activity of TZT-1027 (Soblidotin). Anticancer Res. 2006 May-Jun;26(3A):1973-81.
DMO4EYX	RU	https://pubmed.ncbi.nlm.nih.gov/16827132

DMKNIVG	DI	DMKNIVG
DMKNIVG	DN	Sodium butyrate
DMKNIVG	MI	TT6R7JZ
DMKNIVG	MN	Histone deacetylase 1 (HDAC1)
DMKNIVG	MT	DTT
DMKNIVG	MA	Inhibitor
DMKNIVG	RN	Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006 Sep;5(9):769-84.
DMKNIVG	RU	https://pubmed.ncbi.nlm.nih.gov/16955068

DMH5MVE	DI	DMH5MVE
DMH5MVE	DN	Sodium stibogluconate
DMH5MVE	MI	TTNJKC3
DMH5MVE	MN	Leishmania DNA topoisomerase I (Leishm TOP1)
DMH5MVE	MT	DTT
DMH5MVE	MA	Modulator
DMH5MVE	RN	Inhibition of Leishmania donovani promastigote DNA topoisomerase I and human monocyte DNA topoisomerases I and II by antimonial drugs and classical antitopoisomerase agents. J Parasitol. 2004 Oct;90(5):1155-62.
DMH5MVE	RU	https://pubmed.ncbi.nlm.nih.gov/15562618

DM157U0	DI	DM157U0
DM157U0	DN	Sofinicline
DM157U0	MI	TTL1ATN
DM157U0	MN	Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2)
DM157U0	MT	DTT
DM157U0	MA	Modulator
DM157U0	RN	Sofinicline: a novel nicotinic acetylcholine receptor agonist in the treatment of attention-deficit/hyperactivity disorder. Expert Opin Investig Drugs. 2014 Aug;23(8):1157-63.
DM157U0	RU	https://pubmed.ncbi.nlm.nih.gov/24965900

DML2ZWR	DI	DML2ZWR
DML2ZWR	DN	Solubilized type 1 native bovine collagen
DML2ZWR	MI	TTUABC1
DML2ZWR	MN	Collagen I (COL1A2)
DML2ZWR	MT	DTT
DML2ZWR	MA	Modulator
DML2ZWR	RN	Company report (Argentisrx)
DML2ZWR	RU	http://www.argentisrx.com/arg201-development-to-date.html

DMKCBSM	DI	DMKCBSM
DMKCBSM	DN	SOM3355
DMKCBSM	MI	TTNZRI3
DMKCBSM	MN	Synaptic vesicle amine transporter (SLC18A2)
DMKCBSM	MT	DTT
DMKCBSM	MA	Inhibitor
DMKCBSM	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMKCBSM	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMTVS3A	DI	DMTVS3A
DMTVS3A	DN	Somatoprim
DMTVS3A	MI	TTOMNR9
DMTVS3A	MN	Somatostatin receptor (SSTR)
DMTVS3A	MT	DTT
DMTVS3A	MA	Modulator
DMTVS3A	RN	DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours.Eur J Endocrinol.2012 Feb;166(2):223-34.
DMTVS3A	RU	https://www.ncbi.nlm.nih.gov/pubmed/22065857

DMK3RL8	DI	DMK3RL8
DMK3RL8	DN	Somatropin intranasal rhGH
DMK3RL8	MI	TTT3YKH
DMK3RL8	MN	Somatotropin (GH1)
DMK3RL8	MT	DTT
DMK3RL8	MA	Modulator
DMK3RL8	RN	Long-term efficacy and safety of somatropin for adult growth hormone deficiency.Treat Endocrinol.2003;2(2):109-20.
DMK3RL8	RU	https://www.ncbi.nlm.nih.gov/pubmed/15871547

DME53YS	DI	DME53YS
DME53YS	DN	Sotrastaurin acetate
DME53YS	MI	TTFJ8Q1
DME53YS	MN	Protein kinase C alpha (PRKCA)
DME53YS	MT	DTT
DME53YS	MA	Inhibitor
DME53YS	RN	Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
DME53YS	RU	https://pubmed.ncbi.nlm.nih.gov/19249988

DME53YS	DI	DME53YS
DME53YS	DN	Sotrastaurin acetate
DME53YS	MI	TTYPXQF
DME53YS	MN	Protein kinase C beta (PRKCB)
DME53YS	MT	DTT
DME53YS	MA	Inhibitor
DME53YS	RN	Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
DME53YS	RU	https://pubmed.ncbi.nlm.nih.gov/19249988

DME53YS	DI	DME53YS
DME53YS	DN	Sotrastaurin acetate
DME53YS	MI	TT8QL1J
DME53YS	MN	Protein kinase C theta (PRKCQ)
DME53YS	MT	DTT
DME53YS	MA	Inhibitor
DME53YS	RN	Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
DME53YS	RU	https://pubmed.ncbi.nlm.nih.gov/19249988

DM2UKJV	DI	DM2UKJV
DM2UKJV	DN	SP-333
DM2UKJV	MI	TTLDPRG
DM2UKJV	MN	Guanylyl cyclase C (GUCY2C)
DM2UKJV	MT	DTT
DM2UKJV	MA	Agonist
DM2UKJV	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM2UKJV	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DM9OPK3	DI	DM9OPK3
DM9OPK3	DN	SPD-556
DM9OPK3	MI	TTK8R02
DM9OPK3	MN	Vasopressin V2 receptor (V2R)
DM9OPK3	MT	DTT
DM9OPK3	MA	Antagonist
DM9OPK3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 368).
DM9OPK3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=368

DMJH2AC	DI	DMJH2AC
DMJH2AC	DN	SPD-557
DMJH2AC	MI	TT07C3Y
DMJH2AC	MN	5-HT 4 receptor (HTR4)
DMJH2AC	MT	DTT
DMJH2AC	MA	Agonist
DMJH2AC	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 9).
DMJH2AC	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=9

DMKJ9LU	DI	DMKJ9LU
DMKJ9LU	DN	SPD602
DMKJ9LU	MI	TTUDR0C
DMKJ9LU	MN	Iron (Fe)
DMKJ9LU	MT	DTT
DMKJ9LU	MA	Modulator
DMKJ9LU	RN	ClinicalTrials.gov (NCT01604941) Pharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy. U.S. National Institutes of Health.
DMKJ9LU	RU	https://clinicaltrials.gov/ct2/show/NCT01604941

DM26AHR	DI	DM26AHR
DM26AHR	DN	SPI-1005
DM26AHR	MI	TTNHMO8
DM26AHR	MN	COVID-19 papain-like proteinase (PL-PRO)
DM26AHR	MT	DTT
DM26AHR	MA	Inhibitor
DM26AHR	RN	Structure of Mpro from COVID-19 virus and discovery of its inhibitors. Nature. 2020 Apr 9.
DM26AHR	RU	https://pubmed.ncbi.nlm.nih.gov/32272481

DMNPRMC	DI	DMNPRMC
DMNPRMC	DN	SPI-1620
DMNPRMC	MI	TT3ZTGU
DMNPRMC	MN	Endothelin B receptor (EDNRB)
DMNPRMC	MT	DTT
DMNPRMC	MA	Agonist
DMNPRMC	RN	Clinical pipeline report, company report or official report of Spectrum Phamaceuticals (2009).
DMNPRMC	RU	http://www.spectrumpharm.com/products_Spectrum.html

DMHC2AW	DI	DMHC2AW
DMHC2AW	DN	SPI-205
DMHC2AW	MI	TTEDJN4
DMHC2AW	MN	Low-affinity nerve growth factor receptor (NGFR)
DMHC2AW	MT	DTT
DMHC2AW	MA	Modulator
DMHC2AW	RN	AIT-082 NeoTherapeutics Inc. IDrugs. 1998 Oct;1(6):694-9.
DMHC2AW	RU	https://www.ncbi.nlm.nih.gov/pubmed/18465624

DM7NJWY	DI	DM7NJWY
DM7NJWY	DN	Spiroglumide
DM7NJWY	MI	TTVBI8W
DM7NJWY	MN	Dopamine transporter (DAT)
DM7NJWY	MT	DTT
DM7NJWY	MA	Inhibitor
DM7NJWY	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DM7NJWY	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DM7NJWY	DI	DM7NJWY
DM7NJWY	DN	Spiroglumide
DM7NJWY	MI	TTVFO0U
DM7NJWY	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DM7NJWY	MT	DTT
DM7NJWY	MA	Antagonist
DM7NJWY	RN	Effect of dexloxiglumide and spiroglumide, two new CCK-receptor antagonists, on gastric emptying and secretion in the rat: evaluation of their receptor selectivity in vivo. Aliment Pharmacol Ther. 1996 Jun;10(3):411-9.
DM7NJWY	RU	https://pubmed.ncbi.nlm.nih.gov/8791971

DM7NJWY	DI	DM7NJWY
DM7NJWY	DN	Spiroglumide
DM7NJWY	MI	TTAWNKZ
DM7NJWY	MN	Norepinephrine transporter (NET)
DM7NJWY	MT	DTT
DM7NJWY	MA	Inhibitor
DM7NJWY	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DM7NJWY	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DMRXCUQ	DI	DMRXCUQ
DMRXCUQ	DN	SPL-108
DMRXCUQ	MI	TTWFBT7
DMRXCUQ	MN	Extracellular matrix receptor III (CD44)
DMRXCUQ	MT	DTT
DMRXCUQ	MA	Inhibitor
DMRXCUQ	RN	Clinical pipeline report, company report or official report of Splash Pharmaceuticals.
DMRXCUQ	RU	http://www.splashpharma.com/new-page

DMZIC4Q	DI	DMZIC4Q
DMZIC4Q	DN	SPN-812
DMZIC4Q	MI	TTAWNKZ
DMZIC4Q	MN	Norepinephrine transporter (NET)
DMZIC4Q	MT	DTT
DMZIC4Q	MA	Inhibitor
DMZIC4Q	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZIC4Q	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMOVQP8	DI	DMOVQP8
DMOVQP8	DN	SPP-600
DMOVQP8	MI	TTB2MXP
DMOVQP8	MN	Angiotensinogenase renin (REN)
DMOVQP8	MT	DTT
DMOVQP8	MA	Inhibitor
DMOVQP8	RN	Effect of SPP 635, a renin inhibitor, on intraocular pressure in glaucomatous monkey eyes. Exp Eye Res. 2012 Jan;94(1):146-9.
DMOVQP8	RU	https://pubmed.ncbi.nlm.nih.gov/22173206

DMFAO5G	DI	DMFAO5G
DMFAO5G	DN	S-PRAnt
DMFAO5G	MI	TTUV8G9
DMFAO5G	MN	Progesterone receptor (PGR)
DMFAO5G	MT	DTT
DMFAO5G	MA	Antagonist
DMFAO5G	RN	BAY 1002670: a novel, highly potent and selective progesterone receptor modulator for gynaecological therapies. Hum Reprod. 2013 Aug;28(8):2253-64.
DMFAO5G	RU	https://pubmed.ncbi.nlm.nih.gov/23739217

DMWK9BX	DI	DMWK9BX
DMWK9BX	DN	SQ-109
DMWK9BX	MI	DECB0K3
DMWK9BX	MN	Cytochrome P450 2D6 (CYP2D6)
DMWK9BX	MT	DME
DMWK9BX	MA	Metabolism
DMWK9BX	RN	Interspecies pharmacokinetics and in vitro metabolism of SQ109. Br J Pharmacol. 2006 Mar;147(5):476-85.
DMWK9BX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16432511

DMWK9BX	DI	DMWK9BX
DMWK9BX	DN	SQ-109
DMWK9BX	MI	DEGTFWK
DMWK9BX	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMWK9BX	MT	DME
DMWK9BX	MA	Metabolism
DMWK9BX	RN	Interspecies pharmacokinetics and in vitro metabolism of SQ109. Br J Pharmacol. 2006 Mar;147(5):476-85.
DMWK9BX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16432511

DMWK9BX	DI	DMWK9BX
DMWK9BX	DN	SQ-109
DMWK9BX	MI	TTTLB3R
DMWK9BX	MN	Mycobacterium Membrane protein mmpL3 (MycB mmpL3)
DMWK9BX	MT	DTT
DMWK9BX	MA	Modulator
DMWK9BX	RN	SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2012 Apr;56(4):1797-809.
DMWK9BX	RU	https://pubmed.ncbi.nlm.nih.gov/22252828

DMRFO34	DI	DMRFO34
DMRFO34	DN	SR 16234
DMRFO34	MI	TTZAYWL
DMRFO34	MN	Estrogen receptor (ESR)
DMRFO34	MT	DTT
DMRFO34	MA	Modulator
DMRFO34	RN	National Cancer Institute Drug Dictionary (drug id 599816).
DMRFO34	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=599816

DMNAECP	DI	DMNAECP
DMNAECP	DN	SR-147778
DMNAECP	MI	TT6OEDT
DMNAECP	MN	Cannabinoid receptor 1 (CB1)
DMNAECP	MT	DTT
DMNAECP	MA	Modulator
DMNAECP	RN	Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits 9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.Br J Clin Pharmacol.2013 Jul;76(1):65-77.
DMNAECP	RU	https://www.ncbi.nlm.nih.gov/pubmed/23278647

DMFDA4Y	DI	DMFDA4Y
DMFDA4Y	DN	SR-2640
DMFDA4Y	MI	TTTWGIX
DMFDA4Y	MN	Leukotriene receptor (LTR)
DMFDA4Y	MT	DTT
DMFDA4Y	MA	Modulator
DMFDA4Y	RN	Effect of the leukotriene LTD4/LTE4 antagonist, SR 2640, in ulcerative colitis: an open clinical study. Prostaglandins Leukot Essent Fatty Acids. 1991 Mar;42(3):181-4.
DMFDA4Y	RU	https://pubmed.ncbi.nlm.nih.gov/1677467

DMQSN7B	DI	DMQSN7B
DMQSN7B	DN	SR-31747
DMQSN7B	MI	TT4VQZX
DMQSN7B	MN	Cholestenol delta-isomerase (EBP)
DMQSN7B	MT	DTT
DMQSN7B	MA	Modulator
DMQSN7B	RN	Both the immunosuppressant SR31747 and the antiestrogen tamoxifen bind to an emopamil-insensitive site of mammalian Delta8-Delta7 sterol isomerase. J Pharmacol Exp Ther. 1998 Jun;285(3):1296-302.
DMQSN7B	RU	https://pubmed.ncbi.nlm.nih.gov/9618436

DMTOCIV	DI	DMTOCIV
DMTOCIV	DN	SR-43845
DMTOCIV	MI	TTB2MXP
DMTOCIV	MN	Angiotensinogenase renin (REN)
DMTOCIV	MT	DTT
DMTOCIV	MA	Inhibitor
DMTOCIV	RN	Effects of a renin inhibitor, SR 43845, and of captopril on blood pressure and plasma active renin in conscious sodium-replete macaca. J Hypertens Suppl. 1989 Apr;7(2):S33-5.
DMTOCIV	RU	https://pubmed.ncbi.nlm.nih.gov/2666612

DMW6UA3	DI	DMW6UA3
DMW6UA3	DN	SR-46559A
DMW6UA3	MI	TTZ9SOR
DMW6UA3	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMW6UA3	MT	DTT
DMW6UA3	MA	Agonist
DMW6UA3	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMW6UA3	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM5GAC4	DI	DM5GAC4
DM5GAC4	DN	SRD-441
DM5GAC4	MI	TTZBFA0
DM5GAC4	MN	Protease unspecific (PRO)
DM5GAC4	MT	DTT
DM5GAC4	MA	Inhibitor
DM5GAC4	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029807)
DM5GAC4	RU	http://adisinsight.springer.com/drugs/800029807

DMYAXNM	DI	DMYAXNM
DMYAXNM	DN	SRK-015
DMYAXNM	MI	TTM8I2X
DMYAXNM	MN	Myostatin (MSTN)
DMYAXNM	MT	DTT
DMYAXNM	MA	Inhibitor
DMYAXNM	RN	Clinical pipeline report, company report or official report of Scholar Rock.
DMYAXNM	RU	https://scholarrock.com/our-pipeline/spinal-muscular-atrophy/

DMR09IH	DI	DMR09IH
DMR09IH	DN	SRP-9001
DMR09IH	MI	TT48MP6
DMR09IH	MN	Dystrophin (DMD)
DMR09IH	MT	DTT
DMR09IH	MA	Replacement
DMR09IH	RN	Clinical pipeline report, company report or official report of Sarepta Therapeutics.
DMR09IH	RU	https://www.sarepta.com/products-pipeline/pipeline

DMKOTUJ	DI	DMKOTUJ
DMKOTUJ	DN	SRX246
DMKOTUJ	MI	TT4TFGN
DMKOTUJ	MN	Vasopressin V1a receptor (V1AR)
DMKOTUJ	MT	DTT
DMKOTUJ	MA	Antagonist
DMKOTUJ	RN	Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial. J Clin Med. 2020 Nov 16;9(11):3682.
DMKOTUJ	RU	https://pubmed.ncbi.nlm.nih.gov/33207828

DMMU41F	DI	DMMU41F
DMMU41F	DN	SRX-246
DMMU41F	MI	TT4TFGN
DMMU41F	MN	Vasopressin V1a receptor (V1AR)
DMMU41F	MT	DTT
DMMU41F	MA	Antagonist
DMMU41F	RN	Pharmacokinetics and metabolism of SRX246: a potent and selective vasopressin 1a antagonist. J Pharm Sci. 2013 Jun;102(6):2033-43.
DMMU41F	RU	https://pubmed.ncbi.nlm.nih.gov/23471831

DMGJEB8	DI	DMGJEB8
DMGJEB8	DN	SSR125543
DMGJEB8	MI	TT7EFHR
DMGJEB8	MN	Corticotropin-releasing factor receptor 1 (CRHR1)
DMGJEB8	MT	DTT
DMGJEB8	MA	Antagonist
DMGJEB8	RN	Pharma & Vaccines. Product Development Pipeline. April 29 2009.
DMGJEB8	RU	http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf

DMCMD93	DI	DMCMD93
DMCMD93	DN	SSR149415
DMCMD93	MI	TTSCIUP
DMCMD93	MN	Oxytocin receptor (OTR)
DMCMD93	MT	DTT
DMCMD93	MA	Inhibitor
DMCMD93	RN	Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6018-22.
DMCMD93	RU	https://pubmed.ncbi.nlm.nih.gov/19800231

DMCMD93	DI	DMCMD93
DMCMD93	DN	SSR149415
DMCMD93	MI	TT4TFGN
DMCMD93	MN	Vasopressin V1a receptor (V1AR)
DMCMD93	MT	DTT
DMCMD93	MA	Inhibitor
DMCMD93	RN	Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6018-22.
DMCMD93	RU	https://pubmed.ncbi.nlm.nih.gov/19800231

DMCMD93	DI	DMCMD93
DMCMD93	DN	SSR149415
DMCMD93	MI	TTL9MHW
DMCMD93	MN	Vasopressin V1b receptor (V1BR)
DMCMD93	MT	DTT
DMCMD93	MA	Antagonist
DMCMD93	RN	Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
DMCMD93	RU	https://pubmed.ncbi.nlm.nih.gov/18172433

DMCMD93	DI	DMCMD93
DMCMD93	DN	SSR149415
DMCMD93	MI	TTK8R02
DMCMD93	MN	Vasopressin V2 receptor (V2R)
DMCMD93	MT	DTT
DMCMD93	MA	Inhibitor
DMCMD93	RN	Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6018-22.
DMCMD93	RU	https://pubmed.ncbi.nlm.nih.gov/19800231

DMA0QZH	DI	DMA0QZH
DMA0QZH	DN	SSR-180575
DMA0QZH	MI	TTPTXIN
DMA0QZH	MN	Translocator protein (TSPO)
DMA0QZH	MT	DTT
DMA0QZH	MA	Inhibitor
DMA0QZH	RN	SSR180575 (7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide), a peripheral benzodiazepine receptor ligand, promotes neuronal survival and repair. J PharmacolExp Ther. 2002 Jun;301(3):1067-78.
DMA0QZH	RU	https://pubmed.ncbi.nlm.nih.gov/12023539

DMVZ01T	DI	DMVZ01T
DMVZ01T	DN	SSR240600
DMVZ01T	MI	TTZPO1L
DMVZ01T	MN	Substance-P receptor (TACR1)
DMVZ01T	MT	DTT
DMVZ01T	MA	Antagonist
DMVZ01T	RN	SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]- 4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin-1 receptor: I. biochemical and pharmacological characterization. J Pharmacol Exp Ther. 2002 Dec;303(3):1171-9.
DMVZ01T	RU	https://pubmed.ncbi.nlm.nih.gov/12438541

DMFNZPY	DI	DMFNZPY
DMFNZPY	DN	SSR-240612
DMFNZPY	MI	TTG5QIA
DMFNZPY	MN	B1 bradykinin receptor (BDKRB1)
DMFNZPY	MT	DTT
DMFNZPY	MA	Antagonist
DMFNZPY	RN	The kinin B1 receptor antagonist SSR240612 reverses tactile and cold allodynia in an experimental rat model of insulin resistance. Br J Pharmacol. 2007 September; 152(2): 280-287.
DMFNZPY	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1978253/

DMGTB2Q	DI	DMGTB2Q
DMGTB2Q	DN	SSR411298
DMGTB2Q	MI	TTDP1UC
DMGTB2Q	MN	Fatty acid amide hydrolase (FAAH)
DMGTB2Q	MT	DTT
DMGTB2Q	MA	Inhibitor
DMGTB2Q	RN	Pharma & Vaccines. Product Development Pipeline. April 29 2009.
DMGTB2Q	RU	http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf

DMRGTZ2	DI	DMRGTZ2
DMRGTZ2	DN	SSTarbaclofen
DMRGTZ2	MI	TTDCVZW
DMRGTZ2	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMRGTZ2	MT	DTT
DMRGTZ2	MA	Modulator
DMRGTZ2	RN	Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Sci Transl Med. 2012 Sep 19;4(152):152ra128.
DMRGTZ2	RU	https://www.ncbi.nlm.nih.gov/pubmed/22993295

DMH4C3M	DI	DMH4C3M
DMH4C3M	DN	STA-5326
DMH4C3M	MI	TTRTK6Y
DMH4C3M	MN	Interleukin-12 alpha (IL12A)
DMH4C3M	MT	DTT
DMH4C3M	MA	Inhibitor
DMH4C3M	RN	Therapeutic effect of the potent IL-12/IL-23 inhibitor STA-5326 on experimental autoimmune uveoretinitis. Arthritis Res Ther. 2008;10(5):R122.
DMH4C3M	RU	https://pubmed.ncbi.nlm.nih.gov/18847496

DMEG4TC	DI	DMEG4TC
DMEG4TC	DN	Stannsoporfin
DMEG4TC	MI	TTI6V2A
DMEG4TC	MN	Heme oxygenase 1 (HMOX1)
DMEG4TC	MT	DTT
DMEG4TC	MA	Inhibitor
DMEG4TC	RN	Chemoprevention of severe neonatal hyperbilirubinemia. Semin Perinatol. 2004 Oct;28(5):365-8.
DMEG4TC	RU	https://pubmed.ncbi.nlm.nih.gov/15686268

DMJ1DIB	DI	DMJ1DIB
DMJ1DIB	DN	S-tenatoprazole
DMJ1DIB	MI	TTLOKXP
DMJ1DIB	MN	Gastric H(+)/K(+) ATPase (Proton pump)
DMJ1DIB	MT	DTT
DMJ1DIB	MA	Modulator
DMJ1DIB	RN	Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in heal... Aliment Pharmacol Ther. 2004 Mar 15;19(6):655-62.
DMJ1DIB	RU	https://www.ncbi.nlm.nih.gov/pubmed/15023167

DMKVBL8	DI	DMKVBL8
DMKVBL8	DN	Stenoparib
DMKVBL8	MI	TTVDSZ0
DMKVBL8	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMKVBL8	MT	DTT
DMKVBL8	MA	Inhibitor
DMKVBL8	RN	Clinical pipeline report, company report or official report of Allarity Therapeutics.
DMKVBL8	RU	https://allarity.com/pipeline/stenoparib/

DMKVBL8	DI	DMKVBL8
DMKVBL8	DN	Stenoparib
DMKVBL8	MI	TTQ4V96
DMKVBL8	MN	Poly [ADP-ribose] polymerase 2 (PARP2)
DMKVBL8	MT	DTT
DMKVBL8	MA	Inhibitor
DMKVBL8	RN	Clinical pipeline report, company report or official report of Allarity Therapeutics.
DMKVBL8	RU	https://allarity.com/pipeline/stenoparib/

DMKVBL8	DI	DMKVBL8
DMKVBL8	DN	Stenoparib
DMKVBL8	MI	TTVUSO7
DMKVBL8	MN	Tankyrase-1 (TNKS-1)
DMKVBL8	MT	DTT
DMKVBL8	MA	Inhibitor
DMKVBL8	RN	Clinical pipeline report, company report or official report of Allarity Therapeutics.
DMKVBL8	RU	https://allarity.com/pipeline/stenoparib/

DMKVBL8	DI	DMKVBL8
DMKVBL8	DN	Stenoparib
DMKVBL8	MI	TTFQI4H
DMKVBL8	MN	Tankyrase-2 (TNKS-2)
DMKVBL8	MT	DTT
DMKVBL8	MA	Inhibitor
DMKVBL8	RN	Clinical pipeline report, company report or official report of Allarity Therapeutics.
DMKVBL8	RU	https://allarity.com/pipeline/stenoparib/

DMR9COG	DI	DMR9COG
DMR9COG	DN	STX-100
DMR9COG	MI	TTIQSVM
DMR9COG	MN	Integrin alpha-V/beta-6 (ITGAV/B6)
DMR9COG	MT	DTT
DMR9COG	MA	Antagonist
DMR9COG	RN	Integrin-mediated regulation of TGFbeta in fibrosis. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease Volume 1832, Issue 7, July 2013, Pages 891-896.
DMR9COG	RU	http://www.sciencedirect.com/science/article/pii/S0925443912002281

DMLNKX7	DI	DMLNKX7
DMLNKX7	DN	STX-107
DMLNKX7	MI	TTHS256
DMLNKX7	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMLNKX7	MT	DTT
DMLNKX7	MA	Antagonist
DMLNKX7	RN	Social Communication is an Emerging Target for Pharmacotherapy in Autism Spectrum Disorder - A Review of the Literature on Potential Agents. J Can Acad Child Adolesc Psychiatry. 2014 February; 23(1):20-30.
DMLNKX7	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3917666/

DMJK5CT	DI	DMJK5CT
DMJK5CT	DN	STX-140
DMJK5CT	MI	TTANPDJ
DMJK5CT	MN	Carbonic anhydrase II (CA-II)
DMJK5CT	MT	DTT
DMJK5CT	MA	Inhibitor
DMJK5CT	RN	Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents. J Med Chem. 2008 Mar 13;51(5):1295-308.
DMJK5CT	RU	https://pubmed.ncbi.nlm.nih.gov/18260615

DMJK5CT	DI	DMJK5CT
DMJK5CT	DN	STX-140
DMJK5CT	MI	TTHM0R1
DMJK5CT	MN	Steryl-sulfatase (STS)
DMJK5CT	MT	DTT
DMJK5CT	MA	Inhibitor
DMJK5CT	RN	2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity. J Med Chem. 2006 Dec 28;49(26):7683-96.
DMJK5CT	RU	https://pubmed.ncbi.nlm.nih.gov/17181151

DMO9LBE	DI	DMO9LBE
DMO9LBE	DN	SUN N4057
DMO9LBE	MI	TTSQIFT
DMO9LBE	MN	5-HT 1A receptor (HTR1A)
DMO9LBE	MT	DTT
DMO9LBE	MA	Agonist
DMO9LBE	RN	Experimental study of pharmacological hypothermia: enhanced neuroprotective effect of a novel 5-HT 1 A agonist SUN N4057 by the pharmacological hypothermia. No To Shinkei. 2001 Sep;53(9):853-8.
DMO9LBE	RU	https://pubmed.ncbi.nlm.nih.gov/11596480

DMPK34E	DI	DMPK34E
DMPK34E	DN	Sun13834
DMPK34E	MI	TT8VUE0
DMPK34E	MN	Chymase (CYM)
DMPK34E	MT	DTT
DMPK34E	MA	Modulator
DMPK34E	RN	Oral chymase inhibitor SUN13834 ameliorates skin inflammation as well as pruritus in mouse model for atopic dermatitis.Eur J Pharmacol.2008 Dec 28;601(1-3):186-91.
DMPK34E	RU	https://www.ncbi.nlm.nih.gov/pubmed/18996112

DMPK34E	DI	DMPK34E
DMPK34E	DN	Sun13834
DMPK34E	MI	DECB0K3
DMPK34E	MN	Cytochrome P450 2D6 (CYP2D6)
DMPK34E	MT	DME
DMPK34E	MA	Metabolism
DMPK34E	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMPK34E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMPK34E	DI	DMPK34E
DMPK34E	DN	Sun13834
DMPK34E	MI	TTV5CGO
DMPK34E	MN	Phosphodiesterase 4 (PDE4)
DMPK34E	MT	DTT
DMPK34E	MA	Inhibitor
DMPK34E	RN	Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol. 1994 Jun 2;258(1-2):85-94.
DMPK34E	RU	https://pubmed.ncbi.nlm.nih.gov/7925603

DMSWPA6	DI	DMSWPA6
DMSWPA6	DN	Superoxide dismutase
DMSWPA6	MI	TT6RVLG
DMSWPA6	MN	Superoxide dismutase Cu-Zn (SOD Cu-Zn)
DMSWPA6	MT	DTT
DMSWPA6	MA	Modulator
DMSWPA6	RN	Polyhemoglobin-superoxide dismutase-catalase-carbonic anhydrase: a novel biotechnology-based blood substitute that transports both oxygen and carbon dioxide and also acts as an antioxidant.Artif Cells Blood Substit Immobil Biotechnol.2011 Jun;39(3):127-36.
DMSWPA6	RU	https://www.ncbi.nlm.nih.gov/pubmed/21574914

DMAIGTE	DI	DMAIGTE
DMAIGTE	DN	SurVaxM
DMAIGTE	MI	TTTPU1G
DMAIGTE	MN	Apoptosis inhibitor survivin (BIRC5)
DMAIGTE	MT	DTT
DMAIGTE	MA	Inhibitor
DMAIGTE	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMAIGTE	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM2KQ71	DI	DM2KQ71
DM2KQ71	DN	Sutezolid
DM2KQ71	MI	TT2VX74
DM2KQ71	MN	Bacterial Protein synthesis (Bact PROS)
DM2KQ71	MT	DTT
DM2KQ71	MA	Modulator
DM2KQ71	RN	Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila. Antimicrob Agents Chemother. 2010 Jun;54(6):2549-59.
DM2KQ71	RU	https://pubmed.ncbi.nlm.nih.gov/20385852

DM2KQ71	DI	DM2KQ71
DM2KQ71	DN	Sutezolid
DM2KQ71	MI	DE4LYSA
DM2KQ71	MN	Cytochrome P450 3A4 (CYP3A4)
DM2KQ71	MT	DME
DM2KQ71	MA	Metabolism
DM2KQ71	RN	TB and HIV therapeutics: pharmacology research priorities. AIDS Res Treat. 2012;2012:874083.
DM2KQ71	RU	https://www.hindawi.com/journals/art/2012/874083/

DMQD753	DI	DMQD753
DMQD753	DN	SUVN-502
DMQD753	MI	TTJS8PY
DMQD753	MN	5-HT 6 receptor (HTR6)
DMQD753	MT	DTT
DMQD753	MA	Antagonist
DMQD753	RN	Novel and Potent 5-Piperazinyl Methyl-N1-aryl Sulfonyl Indole Derivatives as 5-HT6 Receptor Ligands. ACS Med Chem Lett. 2010 October 14; 1(7): 340-344.
DMQD753	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007800/

DMZV27P	DI	DMZV27P
DMZV27P	DN	SXC-2023
DMZV27P	MI	TTBZMIO
DMZV27P	MN	Cystine/glutamate transporter (SLC7A11)
DMZV27P	MT	DTT
DMZV27P	MA	Activator
DMZV27P	RN	Clinical pipeline report, company report or official report of Promentis Pharmaceuticals.
DMZV27P	RU	https://promentispharma.com/technology/sxc-2023/

DMXLE71	DI	DMXLE71
DMXLE71	DN	SYL-040012
DMXLE71	MI	TTG8ZWP
DMXLE71	MN	ADRB2 messenger RNA (ADRB2 mRNA)
DMXLE71	MT	DTT
DMXLE71	RN	In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma. Mol Ther. 2014 Jan;22(1):81-91.
DMXLE71	RU	https://pubmed.ncbi.nlm.nih.gov/24025749

DMDF7XB	DI	DMDF7XB
DMDF7XB	DN	SYN120
DMDF7XB	MI	TTJQOD7
DMDF7XB	MN	5-HT 2A receptor (HTR2A)
DMDF7XB	MT	DTT
DMDF7XB	MA	Antagonist
DMDF7XB	RN	Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov. 2018 Nov;17(11):804-822.
DMDF7XB	RU	https://pubmed.ncbi.nlm.nih.gov/30262889

DMDF7XB	DI	DMDF7XB
DMDF7XB	DN	SYN120
DMDF7XB	MI	TTJS8PY
DMDF7XB	MN	5-HT 6 receptor (HTR6)
DMDF7XB	MT	DTT
DMDF7XB	MA	Antagonist
DMDF7XB	RN	Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov. 2018 Nov;17(11):804-822.
DMDF7XB	RU	https://pubmed.ncbi.nlm.nih.gov/30262889

DMPW0UL	DI	DMPW0UL
DMPW0UL	DN	SYN-120
DMPW0UL	MI	TTJS8PY
DMPW0UL	MN	5-HT 6 receptor (HTR6)
DMPW0UL	MT	DTT
DMPW0UL	MA	Antagonist
DMPW0UL	RN	The Serotonin-6 Receptor as a Novel Therapeutic Target. Exp Neurobiol. 2011 December; 20(4): 159-168.
DMPW0UL	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3268149/

DMF9Z2T	DI	DMF9Z2T
DMF9Z2T	DN	T-2007
DMF9Z2T	MI	TTEX6LM
DMF9Z2T	MN	GABA(A) receptor gamma-3 (GABRG3)
DMF9Z2T	MT	DTT
DMF9Z2T	MA	Agonist
DMF9Z2T	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415).
DMF9Z2T	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415

DM06GDC	DI	DM06GDC
DM06GDC	DN	T2c-001
DM06GDC	MI	TTXQYT6
DM06GDC	MN	T-cells (T-cells)
DM06GDC	MT	DTT
DM06GDC	MA	Modulator
DM06GDC	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DM06GDC	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM5C70M	DI	DM5C70M
DM5C70M	DN	T-607
DM5C70M	MI	TTYFKSZ
DM5C70M	MN	Tubulin beta (TUBB)
DM5C70M	MT	DTT
DM5C70M	MA	Inhibitor
DM5C70M	RN	Nucleophilic reactions of N-ethoxycarbonyliminopyridinium ylide with alpha,beta-unsaturated carbonyl compounds. Volume 28, Issue 6, 1972, Pages 1469-1476.
DM5C70M	RU	http://www.sciencedirect.com/science/article/pii/0040402072880293

DMD72F4	DI	DMD72F4
DMD72F4	DN	T-817MA
DMD72F4	MI	TTE4KHA
DMD72F4	MN	Amyloid beta A4 protein (APP)
DMD72F4	MT	DTT
DMD72F4	MA	Inhibitor
DMD72F4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMD72F4	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMD72F4	DI	DMD72F4
DMD72F4	DN	T-817MA
DMD72F4	MI	TTV0YFR
DMD72F4	MN	Lipid peroxidation (LPO)
DMD72F4	MT	DTT
DMD72F4	MA	Modulator
DMD72F4	RN	A neuroprotective agent, T-817MA (1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl} azetidin-3-ol maleate), prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. Neuropharmacology. 2008 Oct;55(5):654-60.
DMD72F4	RU	https://pubmed.ncbi.nlm.nih.gov/18573265

DM4JFMZ	DI	DM4JFMZ
DM4JFMZ	DN	T-82
DM4JFMZ	MI	TT1RS9F
DM4JFMZ	MN	Acetylcholinesterase (AChE)
DM4JFMZ	MT	DTT
DM4JFMZ	MA	Inhibitor
DM4JFMZ	RN	Effects of T-82, a novel acetylcholinesterase inhibitor, on impaired learning and memory in passive avoidance task in rats. Eur J Pharmacol. 2003 Mar 28;465(1-2):97-103.
DM4JFMZ	RU	https://pubmed.ncbi.nlm.nih.gov/12650838

DMMWPSQ	DI	DMMWPSQ
DMMWPSQ	DN	TA-2005
DMMWPSQ	MI	TT2CJVK
DMMWPSQ	MN	Adrenergic receptor beta-2 (ADRB2)
DMMWPSQ	MT	DTT
DMMWPSQ	MA	Agonist
DMMWPSQ	RN	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
DMMWPSQ	RU	https://pubmed.ncbi.nlm.nih.gov/16634702

DMZ7I51	DI	DMZ7I51
DMZ7I51	DN	TA-270
DMZ7I51	MI	TT2J34L
DMZ7I51	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMZ7I51	MT	DTT
DMZ7I51	MA	Inhibitor
DMZ7I51	RN	TA-270 [4-hydroxy-1-methyl-3-octyloxy-7-sinapinoylamino-2(1H)-quinolinone], an anti-asthmatic agent, inhibits leukotriene production induced by IgE... J Pharmacol Exp Ther. 2003 Nov;307(2):583-8.
DMZ7I51	RU	https://pubmed.ncbi.nlm.nih.gov/12970384

DMZTAJL	DI	DMZTAJL
DMZTAJL	DN	TA-7906
DMZTAJL	MI	TTZ97H5
DMZTAJL	MN	Phosphodiesterase 4A (PDE4A)
DMZTAJL	MT	DTT
DMZTAJL	MA	Inhibitor
DMZTAJL	RN	Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors. Clin Exp Immunol. 2002 Jun;128(3):460-6.
DMZTAJL	RU	https://pubmed.ncbi.nlm.nih.gov/12067300

DMZTAJL	DI	DMZTAJL
DMZTAJL	DN	TA-7906
DMZTAJL	MI	TTVIAT9
DMZTAJL	MN	Phosphodiesterase 4B (PDE4B)
DMZTAJL	MT	DTT
DMZTAJL	MA	Inhibitor
DMZTAJL	RN	Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors. Clin Exp Immunol. 2002 Jun;128(3):460-6.
DMZTAJL	RU	https://pubmed.ncbi.nlm.nih.gov/12067300

DMZTAJL	DI	DMZTAJL
DMZTAJL	DN	TA-7906
DMZTAJL	MI	TTSKMI8
DMZTAJL	MN	Phosphodiesterase 4D (PDE4D)
DMZTAJL	MT	DTT
DMZTAJL	MA	Inhibitor
DMZTAJL	RN	Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors. Clin Exp Immunol. 2002 Jun;128(3):460-6.
DMZTAJL	RU	https://pubmed.ncbi.nlm.nih.gov/12067300

DMAZHT0	DI	DMAZHT0
DMAZHT0	DN	TA-8995
DMAZHT0	MI	TTFQAYR
DMAZHT0	MN	Cholesteryl ester transfer protein (CETP)
DMAZHT0	MT	DTT
DMAZHT0	MA	Inhibitor
DMAZHT0	RN	Amgen To Acquire Privately-Held Dezima Pharma
DMAZHT0	RU	http://www.amgen.com/media/media_pr_detail.jsp?releaseID=2088272

DMNL9HO	DI	DMNL9HO
DMNL9HO	DN	Tabimorelin
DMNL9HO	MI	TTWDC17
DMNL9HO	MN	Growth hormone secretagogue receptor 1 (GHSR)
DMNL9HO	MT	DTT
DMNL9HO	MA	Modulator
DMNL9HO	RN	Pharmacological characterisation of a new oral GH secretagogue, NN703. Eur J Endocrinol. 1999 Aug;141(2):180-9.
DMNL9HO	RU	https://pubmed.ncbi.nlm.nih.gov/10427162

DMP1873	DI	DMP1873
DMP1873	DN	TAK-063
DMP1873	MI	TTJW4LU
DMP1873	MN	Phosphodiesterase 10A (PDE10)
DMP1873	MT	DTT
DMP1873	MA	Inhibitor
DMP1873	RN	Characterization of Binding and Inhibitory Properties of TAK-063, a Novel Phosphodiesterase 10A Inhibitor. PLoS One. 2015; 10(3): e0122197.
DMP1873	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4376699/

DMHPEFS	DI	DMHPEFS
DMHPEFS	DN	TAK-128
DMHPEFS	MI	TT2O84V
DMHPEFS	MN	Thromboxane A2 receptor (TBXA2R)
DMHPEFS	MT	DTT
DMHPEFS	MA	Modulator
DMHPEFS	RN	ClinicalTrials.gov (NCT00229437) Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy. U.S. National Institutes of Health.
DMHPEFS	RU	https://clinicaltrials.gov/ct2/show/NCT00229437

DM81UAZ	DI	DM81UAZ
DM81UAZ	DN	TAK-272
DM81UAZ	MI	TTB2MXP
DM81UAZ	MN	Angiotensinogenase renin (REN)
DM81UAZ	MT	DTT
DM81UAZ	MA	Modulator
DM81UAZ	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033655)
DM81UAZ	RU	http://adisinsight.springer.com/drugs/800033655

DMEYKRN	DI	DMEYKRN
DMEYKRN	DN	TAK-379
DMEYKRN	MI	TTCBFJO
DMEYKRN	MN	Insulin receptor (INSR)
DMEYKRN	MT	DTT
DMEYKRN	MA	Modulator
DMEYKRN	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800).
DMEYKRN	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800

DMD51RN	DI	DMD51RN
DMD51RN	DN	TAK-448
DMD51RN	MI	TTU2O6T
DMD51RN	MN	Metastasis-suppressor KiSS-1 (KISS1)
DMD51RN	MT	DTT
DMD51RN	MA	Modulator
DMD51RN	RN	Pharmacologic profiles of investigational kisspeptin/metastin analogues, TAK-448 and TAK-683, in adult male rats in comparison to the GnRH analogue leuprolide.Eur J Pharmacol.2014 Jul 15;735:77-85.
DMD51RN	RU	https://www.ncbi.nlm.nih.gov/pubmed/24747751

DMNB4P1	DI	DMNB4P1
DMNB4P1	DN	TAK-653
DMNB4P1	MI	TTAN6JD
DMNB4P1	MN	Glutamate receptor AMPA (GRIA)
DMNB4P1	MT	DTT
DMNB4P1	MA	Activator
DMNB4P1	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMNB4P1	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMJH3U0	DI	DMJH3U0
DMJH3U0	DN	TAK-659
DMJH3U0	MI	TTGJCWZ
DMJH3U0	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMJH3U0	MT	DTT
DMJH3U0	MA	Inhibitor
DMJH3U0	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMJH3U0	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMJH3U0	DI	DMJH3U0
DMJH3U0	DN	TAK-659
DMJH3U0	MI	TTOU65C
DMJH3U0	MN	Tyrosine-protein kinase SYK (SYK)
DMJH3U0	MT	DTT
DMJH3U0	MA	Inhibitor
DMJH3U0	RN	J Clin Oncol 32:5s, 2014 (suppl; abstr 8580).
DMJH3U0	RU	http://meetinglibrary.asco.org/content/134551-144

DMZKPI8	DI	DMZKPI8
DMZKPI8	DN	TAK-715
DMZKPI8	MI	TTWELHI
DMZKPI8	MN	Stress-activated protein kinase (p38)
DMZKPI8	MT	DTT
DMZKPI8	MA	Inhibitor
DMZKPI8	RN	Inhibition of Wnt/beta-catenin signaling by p38 MAP kinase inhibitors is explained by cross-reactivity with casein kinase Idelta/ . Chem Biol. 2011 Apr 22;18(4):485-94.
DMZKPI8	RU	https://pubmed.ncbi.nlm.nih.gov/21513885

DMWPSJR	DI	DMWPSJR
DMWPSJR	DN	TAK-831
DMWPSJR	MI	TT7Y3EJ
DMWPSJR	MN	D-amino acid oxidase (DAO)
DMWPSJR	MT	DTT
DMWPSJR	MA	Inhibitor
DMWPSJR	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMWPSJR	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMZEU6M	DI	DMZEU6M
DMZEU6M	DN	TAK-831
DMZEU6M	MI	TT7Y3EJ
DMZEU6M	MN	D-amino acid oxidase (DAO)
DMZEU6M	MT	DTT
DMZEU6M	MA	Inhibitor
DMZEU6M	RN	Mechanistic Multilayer Quantitative Model for Nonlinear Pharmacokinetics, Target Occupancy and Pharmacodynamics (PK/TO/PD) Relationship of D-Amino Acid Oxidase Inhibitor, TAK-831 in Mice. Pharm Res. 2020 Aug 5;37(8):164.
DMZEU6M	RU	https://pubmed.ncbi.nlm.nih.gov/32901384

DMBQD9H	DI	DMBQD9H
DMBQD9H	DN	TAK-906
DMBQD9H	MI	TTEX248
DMBQD9H	MN	Dopamine D2 receptor (D2R)
DMBQD9H	MT	DTT
DMBQD9H	MA	Inhibitor
DMBQD9H	RN	Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D 2 /D 3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants. Clin Pharmacol Drug Dev. 2021 Jan 18.
DMBQD9H	RU	https://pubmed.ncbi.nlm.nih.gov/33462988

DMBQD9H	DI	DMBQD9H
DMBQD9H	DN	TAK-906
DMBQD9H	MI	TT4C8EA
DMBQD9H	MN	Dopamine D3 receptor (D3R)
DMBQD9H	MT	DTT
DMBQD9H	MA	Inhibitor
DMBQD9H	RN	Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D 2 /D 3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants. Clin Pharmacol Drug Dev. 2021 Jan 18.
DMBQD9H	RU	https://pubmed.ncbi.nlm.nih.gov/33462988

DMOZAMN	DI	DMOZAMN
DMOZAMN	DN	TAK-935
DMOZAMN	MI	TT4EB85
DMOZAMN	MN	Cholesterol 24-hydroxylase (CYP46A1)
DMOZAMN	MT	DTT
DMOZAMN	MA	Inhibitor
DMOZAMN	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040983)
DMOZAMN	RU	http://adisinsight.springer.com/drugs/800040983

DMARVFG	DI	DMARVFG
DMARVFG	DN	Talacotuzumab
DMARVFG	MI	TTENHJ0
DMARVFG	MN	Interleukin 3 receptor alpha (IL3RA)
DMARVFG	MT	DTT
DMARVFG	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMARVFG	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMJOM5L	DI	DMJOM5L
DMJOM5L	DN	Talampanel
DMJOM5L	MI	TTAN6JD
DMJOM5L	MN	Glutamate receptor AMPA (GRIA)
DMJOM5L	MT	DTT
DMJOM5L	MA	Antagonist
DMJOM5L	RN	Talampanel suppresses the acute and chronic effects of seizures in a rodent neonatal seizure model. Epilepsia. 2009 Apr;50(4):694-701.
DMJOM5L	RU	https://pubmed.ncbi.nlm.nih.gov/19220413

DMQKZDT	DI	DMQKZDT
DMQKZDT	DN	Talnetant
DMQKZDT	MI	TTBPGLU
DMQKZDT	MN	Neuromedin-K receptor (TACR3)
DMQKZDT	MT	DTT
DMQKZDT	MA	Antagonist
DMQKZDT	RN	Pharmacological characterization of senktide-induced tail whips. Neuropharmacology. 2010 Jan;58(1):259-67.
DMQKZDT	RU	https://pubmed.ncbi.nlm.nih.gov/19540857

DMNLQHK	DI	DMNLQHK
DMNLQHK	DN	Tanespimycin
DMNLQHK	MI	TT78R5H
DMNLQHK	MN	Heat shock protein 90 alpha (HSP90A)
DMNLQHK	MT	DTT
DMNLQHK	MA	Inhibitor
DMNLQHK	RN	Tanespimycin: the opportunities and challenges of targeting heat shock protein 90. Expert Opin Investig Drugs. 2009 Jun;18(6):861-8.
DMNLQHK	RU	https://pubmed.ncbi.nlm.nih.gov/19466875

DM1TSHL	DI	DM1TSHL
DM1TSHL	DN	Taprenepag
DM1TSHL	MI	TT1ZAVI
DM1TSHL	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DM1TSHL	MT	DTT
DM1TSHL	MA	Agonist
DM1TSHL	RN	A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension. Curr Eye Res. 2011 Sep;36(9):809-17.
DM1TSHL	RU	https://pubmed.ncbi.nlm.nih.gov/21851167

DMDB4EJ	DI	DMDB4EJ
DMDB4EJ	DN	Tarafenacin
DMDB4EJ	MI	TTQ13Z5
DMDB4EJ	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMDB4EJ	MT	DTT
DMDB4EJ	MA	Antagonist
DMDB4EJ	RN	In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment of overactive bladder. Br J Pharmacol. 2009 Mar;156(5):807-17.
DMDB4EJ	RU	https://pubmed.ncbi.nlm.nih.gov/19222482

DM95FR3	DI	DM95FR3
DM95FR3	DN	Tarextumab
DM95FR3	MI	TT82FVD
DM95FR3	MN	Notch-2 receptor (NOTCH2)
DM95FR3	MT	DTT
DM95FR3	MA	Modulator
DM95FR3	RN	Company report (OncoMed Pharmaceuticals)
DM95FR3	RU	http://www.oncomed.com/Pipeline.html

DM95FR3	DI	DM95FR3
DM95FR3	DN	Tarextumab
DM95FR3	MI	TTVX7IA
DM95FR3	MN	Notch-3 receptor (NOTCH3)
DM95FR3	MT	DTT
DM95FR3	MA	Modulator
DM95FR3	RN	Company report (OncoMed Pharmaceuticals)
DM95FR3	RU	http://www.oncomed.com/Pipeline.html

DMA7ISF	DI	DMA7ISF
DMA7ISF	DN	Tarloxotinib
DMA7ISF	MI	TTGKNB4
DMA7ISF	MN	Epidermal growth factor receptor (EGFR)
DMA7ISF	MT	DTT
DMA7ISF	MA	Inhibitor
DMA7ISF	RN	Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes. Clin Cancer Res. 2021 Mar 1;27(5):1463-1475.
DMA7ISF	RU	https://pubmed.ncbi.nlm.nih.gov/33355298

DMA7ISF	DI	DMA7ISF
DMA7ISF	DN	Tarloxotinib
DMA7ISF	MI	TT6EO5L
DMA7ISF	MN	Erbb2 tyrosine kinase receptor (HER2)
DMA7ISF	MT	DTT
DMA7ISF	MA	Inhibitor
DMA7ISF	RN	Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes. Clin Cancer Res. 2021 Mar 1;27(5):1463-1475.
DMA7ISF	RU	https://pubmed.ncbi.nlm.nih.gov/33355298

DML97KB	DI	DML97KB
DML97KB	DN	TAS-106
DML97KB	MI	TT79JGK
DML97KB	MN	Mycobacterium RNA polymerase (MycB RNAP)
DML97KB	MT	DTT
DML97KB	MA	Modulator
DML97KB	RN	Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies.Invest New Drugs.2012 Feb;30(1):316-26.
DML97KB	RU	https://www.ncbi.nlm.nih.gov/pubmed/20839029

DM3D52L	DI	DM3D52L
DM3D52L	DN	TAS-114
DM3D52L	MI	TTH6MBO
DM3D52L	MN	dUTP pyrophosphatase (DUT)
DM3D52L	MT	DTT
DM3D52L	MA	Inhibitor
DM3D52L	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3D52L	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM9QFW2	DI	DM9QFW2
DM9QFW2	DN	Tau-binding PET tracer
DM9QFW2	MI	TTS87KH
DM9QFW2	MN	Microtubule-associated protein tau (MAPT)
DM9QFW2	MT	DTT
DM9QFW2	MA	Modulator
DM9QFW2	RN	Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des. 2011;17(31):3413-7.
DM9QFW2	RU	https://pubmed.ncbi.nlm.nih.gov/21902667

DMZX0VF	DI	DMZX0VF
DMZX0VF	DN	Tavokinogene telseplasmid
DMZX0VF	MI	TTG68FB
DMZX0VF	MN	Interleukine 12 (IL-12)
DMZX0VF	MT	DTT
DMZX0VF	MA	Replacement
DMZX0VF	RN	Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients. Ann Oncol. 2020 Apr;31(4):532-540.
DMZX0VF	RU	https://pubmed.ncbi.nlm.nih.gov/32147213

DM4I6XK	DI	DM4I6XK
DM4I6XK	DN	TB-402
DM4I6XK	MI	TT1290U
DM4I6XK	MN	Coagulation factor VIII (F8)
DM4I6XK	MT	DTT
DM4I6XK	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2607).
DM4I6XK	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2607

DMDPBMH	DI	DMDPBMH
DMDPBMH	DN	TB-403
DMDPBMH	MI	TT48I1Y
DMDPBMH	MN	Placenta growth factor (PlGF)
DMDPBMH	MT	DTT
DMDPBMH	MA	Inhibitor
DMDPBMH	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMDPBMH	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMZTOJ6	DI	DMZTOJ6
DMZTOJ6	DN	TBA-7371
DMZTOJ6	MI	TTLOHU4
DMZTOJ6	MN	Mycobacterium Decaprenylphosphoryl-beta-D-ribose oxidase (McyB dprE1)
DMZTOJ6	MT	DTT
DMZTOJ6	MA	Inhibitor
DMZTOJ6	RN	Clinical pipeline report, company report or official report of TB Alliance.
DMZTOJ6	RU	https://www.tballiance.org/portfolio/trial/12010

DMZCA0K	DI	DMZCA0K
DMZCA0K	DN	TBC-3711
DMZCA0K	MI	TTKRD0G
DMZCA0K	MN	Endothelin A receptor (EDNRA)
DMZCA0K	MT	DTT
DMZCA0K	MA	Antagonist
DMZCA0K	RN	TBC3711, an ET(A) receptor antagonist, reduces neonatal hypoxia-induced pulmonary hypertension in piglets. Pediatr Res. 2001 Sep;50(3):374-83.
DMZCA0K	RU	https://pubmed.ncbi.nlm.nih.gov/11518825

DMM5BVG	DI	DMM5BVG
DMM5BVG	DN	TBR-760
DMM5BVG	MI	TTEX248
DMM5BVG	MN	Dopamine D2 receptor (D2R)
DMM5BVG	MT	DTT
DMM5BVG	MA	Agonist
DMM5BVG	RN	TBR-760, a Dopamine-Somatostatin Compound, Arrests Growth of Aggressive Nonfunctioning Pituitary Adenomas in Mice. Endocrinology. 2020 Aug 1;161(8):bqaa101.
DMM5BVG	RU	https://pubmed.ncbi.nlm.nih.gov/32591776

DMM5BVG	DI	DMM5BVG
DMM5BVG	DN	TBR-760
DMM5BVG	MI	TTZ6T9E
DMM5BVG	MN	Somatostatin receptor type 2 (SSTR2)
DMM5BVG	MT	DTT
DMM5BVG	MA	Agonist
DMM5BVG	RN	TBR-760, a Dopamine-Somatostatin Compound, Arrests Growth of Aggressive Nonfunctioning Pituitary Adenomas in Mice. Endocrinology. 2020 Aug 1;161(8):bqaa101.
DMM5BVG	RU	https://pubmed.ncbi.nlm.nih.gov/32591776

DM8AM60	DI	DM8AM60
DM8AM60	DN	TC-5214
DM8AM60	MI	TT35UGH
DM8AM60	MN	Neuronal acetylcholine receptor alpha-3/beta-4 (CHRNA3/B4)
DM8AM60	MT	DTT
DM8AM60	MA	Antagonist
DM8AM60	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM8AM60	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM8AM60	DI	DM8AM60
DM8AM60	DN	TC-5214
DM8AM60	MI	TT5KPZR
DM8AM60	MN	Neuronal acetylcholine receptor beta-2 (CHRNB2)
DM8AM60	MT	DTT
DM8AM60	MA	Antagonist
DM8AM60	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM8AM60	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMWPI2U	DI	DMWPI2U
DMWPI2U	DN	TC-6499-12
DMWPI2U	MI	TTL1ATN
DMWPI2U	MN	Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2)
DMWPI2U	MT	DTT
DMWPI2U	MA	Modulator
DMWPI2U	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMWPI2U	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMNFP21	DI	DMNFP21
DMNFP21	DN	TC-6987
DMNFP21	MI	TTLA931
DMNFP21	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMNFP21	MT	DTT
DMNFP21	MA	Modulator
DMNFP21	RN	ClinicalTrials.gov (NCT01293669) Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
DMNFP21	RU	https://clinicaltrials.gov/ct2/show/NCT01293669

DM9PVNJ	DI	DM9PVNJ
DM9PVNJ	DN	TCN-032
DM9PVNJ	MI	TTXT3PU
DM9PVNJ	MN	Influenza M2 protein (Influ M)
DM9PVNJ	MT	DTT
DM9PVNJ	RN	Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proc Natl Acad Sci U S A. 2010 July 13; 107(28): 12658-12663.
DM9PVNJ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2906546/

DMJ3KPO	DI	DMJ3KPO
DMJ3KPO	DN	TD-101
DMJ3KPO	MI	TT2FX8W
DMJ3KPO	MN	Keratin 6A messenger RNA (KRT6A mRNA)
DMJ3KPO	MT	DTT
DMJ3KPO	RN	First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther. 2010 Feb;18(2):442-6.
DMJ3KPO	RU	https://pubmed.ncbi.nlm.nih.gov/19935778

DMTJMK5	DI	DMTJMK5
DMTJMK5	DN	TD-1211
DMTJMK5	MI	TTKWM86
DMTJMK5	MN	Opioid receptor mu (MOP)
DMTJMK5	MT	DTT
DMTJMK5	MA	Modulator
DMTJMK5	RN	The in vitro pharmacological profile of TD-1211, a neutral opioid receptor antagonist. Naunyn Schmiedebergs Arch Pharmacol. 2013 Jun;386(6):479-91.
DMTJMK5	RU	https://pubmed.ncbi.nlm.nih.gov/23549670

DM6SANW	DI	DM6SANW
DM6SANW	DN	TD-5108
DM6SANW	MI	TT07C3Y
DM6SANW	MN	5-HT 4 receptor (HTR4)
DM6SANW	MT	DTT
DM6SANW	MA	Agonist
DM6SANW	RN	The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol. 2008 Jul;378(1):125-37.
DM6SANW	RU	https://pubmed.ncbi.nlm.nih.gov/18415081

DM3C9NV	DI	DM3C9NV
DM3C9NV	DN	TD-8954
DM3C9NV	MI	TT07C3Y
DM3C9NV	MN	5-HT 4 receptor (HTR4)
DM3C9NV	MT	DTT
DM3C9NV	MA	Modulator
DM3C9NV	RN	The Pharmacology of TD-8954, a Potent and Selective 5-HT(4) Receptor Agonist with Gastrointestinal Prokinetic Properties. Front Pharmacol. 2011 May 30;2:25.
DM3C9NV	RU	https://pubmed.ncbi.nlm.nih.gov/21687517

DMQD5NA	DI	DMQD5NA
DMQD5NA	DN	TD-9855
DMQD5NA	MI	TTAWNKZ
DMQD5NA	MN	Norepinephrine transporter (NET)
DMQD5NA	MT	DTT
DMQD5NA	MA	Modulator
DMQD5NA	RN	Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. Int J Neuropsychopharmacol. 2014 Dec 13;18(2). pii: pyu027.
DMQD5NA	RU	https://pubmed.ncbi.nlm.nih.gov/25522383

DMQD5NA	DI	DMQD5NA
DMQD5NA	DN	TD-9855
DMQD5NA	MI	TT3ROYC
DMQD5NA	MN	Serotonin transporter (SERT)
DMQD5NA	MT	DTT
DMQD5NA	MA	Modulator
DMQD5NA	RN	Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. Int J Neuropsychopharmacol. 2014 Dec 13;18(2). pii: pyu027.
DMQD5NA	RU	https://pubmed.ncbi.nlm.nih.gov/25522383

DM6YI5T	DI	DM6YI5T
DM6YI5T	DN	Tegobuvir
DM6YI5T	MI	TTMVBWH
DM6YI5T	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DM6YI5T	MT	DTT
DM6YI5T	MA	Inhibitor
DM6YI5T	RN	Clinical pipeline report, company report or official report of Gilead (2011).
DM6YI5T	RU	http://www.gilead.com/

DM9AWSO	DI	DM9AWSO
DM9AWSO	DN	Telapristone
DM9AWSO	MI	TTUV8G9
DM9AWSO	MN	Progesterone receptor (PGR)
DM9AWSO	MT	DTT
DM9AWSO	MA	Antagonist
DM9AWSO	RN	In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. J Steroid Biochem Mol Biol. 2004 Mar;88(3):277-88.
DM9AWSO	RU	https://pubmed.ncbi.nlm.nih.gov/15120421

DMFT5D6	DI	DMFT5D6
DMFT5D6	DN	Telcagepant
DMFT5D6	MI	TTY6O0Q
DMFT5D6	MN	Calcitonin gene-related peptide receptor (CGRPR)
DMFT5D6	MT	DTT
DMFT5D6	MA	Antagonist
DMFT5D6	RN	CGRP antagonists: novel concept for treatment of migraine. Med Monatsschr Pharm. 2009 May;32(5):182-5.
DMFT5D6	RU	https://pubmed.ncbi.nlm.nih.gov/19469188

DM8UCNK	DI	DM8UCNK
DM8UCNK	DN	Telisotuzumab vedotin
DM8UCNK	MI	TTNDSF4
DM8UCNK	MN	Proto-oncogene c-Met (MET)
DM8UCNK	MT	DTT
DM8UCNK	RN	Clinical pipeline report, company report or official report of AbbVie.
DM8UCNK	RU	https://www.abbvie.com/our-science/pipeline/abbv-399.html

DMUQH78	DI	DMUQH78
DMUQH78	DN	Tempol
DMUQH78	MI	TT6RVLG
DMUQH78	MN	Superoxide dismutase Cu-Zn (SOD Cu-Zn)
DMUQH78	MT	DTT
DMUQH78	MA	Modulator
DMUQH78	RN	The superoxide dismutase mimetic, tempol, reduces the bioavailability of nitric oxide and does not alter L-NAME-induced hypertension in rats. Basic Clin Pharmacol Toxicol. 2005 Jul;97(1):29-34.
DMUQH78	RU	https://www.ncbi.nlm.nih.gov/pubmed/15943756

DMVS61L	DI	DMVS61L
DMVS61L	DN	Tepoxalin
DMVS61L	MI	TT2J34L
DMVS61L	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMVS61L	MT	DTT
DMVS61L	MA	Inhibitor
DMVS61L	RN	Preclinical toxicity evaluation of tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, in Sprague-Dawley rats and beagle dogs. Fundam Appl Toxicol. 1996 Sep;33(1):38-48.
DMVS61L	RU	https://pubmed.ncbi.nlm.nih.gov/8812216

DMVS61L	DI	DMVS61L
DMVS61L	DN	Tepoxalin
DMVS61L	MI	TTLGTKB
DMVS61L	MN	Interleukin-4 (IL4)
DMVS61L	MT	DTT
DMVS61L	MA	Inhibitor
DMVS61L	RN	Therapeutic interference with interferon-gamma (IFN-gamma) and soluble IL-4 receptor (sIL-4R) in allergic diseases. Behring Inst Mitt. 1995 Jun;(96):118-30.
DMVS61L	RU	https://pubmed.ncbi.nlm.nih.gov/7575347

DMC3P45	DI	DMC3P45
DMC3P45	DN	Terameprocol
DMC3P45	MI	TTZEP6S
DMC3P45	MN	Transcription factor Sp1 (SP1)
DMC3P45	MT	DTT
DMC3P45	MA	Modulator
DMC3P45	RN	Terameprocol, a novel site-specific transcription inhibitor with anticancer activity. IDrugs. 2008 Mar;11(3):204-14.
DMC3P45	RU	https://pubmed.ncbi.nlm.nih.gov/18311658

DMZNFPG	DI	DMZNFPG
DMZNFPG	DN	Terguride
DMZNFPG	MI	DE4LYSA
DMZNFPG	MN	Cytochrome P450 3A4 (CYP3A4)
DMZNFPG	MT	DME
DMZNFPG	MA	Metabolism
DMZNFPG	RN	Cytochromes P450 and experimental models of drug metabolism. J Cell Mol Med. 2002 Apr-Jun;6(2):189-98.
DMZNFPG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12169204

DMR4YEG	DI	DMR4YEG
DMR4YEG	DN	Tesidolumab
DMR4YEG	MI	TTKANGO
DMR4YEG	MN	Complement C5 (CO5)
DMR4YEG	MT	DTT
DMR4YEG	MA	Inhibitor
DMR4YEG	RN	Intravenous immunoglobulin significantly reduces exposure of concomitantly administered anti-C5 monoclonal antibody tesidolumab. Am J Transplant. 2020 Sep;20(9):2581-2588.
DMR4YEG	RU	https://pubmed.ncbi.nlm.nih.gov/32301258

DM1KGS7	DI	DM1KGS7
DM1KGS7	DN	Tesofensine
DM1KGS7	MI	TTCBFJO
DM1KGS7	MN	Insulin receptor (INSR)
DM1KGS7	MT	DTT
DM1KGS7	MA	Inhibitor
DM1KGS7	RN	The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant. Eur J Pharmacol. 2010 Jun 25;636(1-3):88-95.
DM1KGS7	RU	https://pubmed.ncbi.nlm.nih.gov/20385125

DMMK6IT	DI	DMMK6IT
DMMK6IT	DN	Testogen TDS
DMMK6IT	MI	TTS64P2
DMMK6IT	MN	Androgen receptor (AR)
DMMK6IT	MT	DTT
DMMK6IT	MA	Modulator
DMMK6IT	RN	Evidence for a role of testosterone-androgen receptor interactions in mediating masculine sexual behavior in male rats. Endocrinology. 1989 Feb;124(2):618-26.
DMMK6IT	RU	https://pubmed.ncbi.nlm.nih.gov/2912689

DMR5GSB	DI	DMR5GSB
DMR5GSB	DN	Tetrahydrouridine
DMR5GSB	MI	TTQ12RK
DMR5GSB	MN	Cytidine deaminase (CDA)
DMR5GSB	MT	DTT
DMR5GSB	MA	Modulator
DMR5GSB	RN	Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levels. PLoS One. 2012;7(5):e37424.
DMR5GSB	RU	https://pubmed.ncbi.nlm.nih.gov/22616006

DMGNK67	DI	DMGNK67
DMGNK67	DN	TETRAPLATIN TETRANITRATE
DMGNK67	MI	TTUTN1I
DMGNK67	MN	Human Deoxyribonucleic acid (hDNA)
DMGNK67	MT	DTT
DMGNK67	MA	Binder
DMGNK67	RN	Differential cytotoxicity, uptake and DNA binding of tetraplatin and analogous isomers in sensitive and resistant cancer cell lines. Anticancer Drugs. 1993 Apr;4(2):251-8.
DMGNK67	RU	https://pubmed.ncbi.nlm.nih.gov/8490203

DM2LBC3	DI	DM2LBC3
DM2LBC3	DN	TEW-7197
DM2LBC3	MI	TTP4520
DM2LBC3	MN	TGF-beta receptor type I (TGFBR1)
DM2LBC3	MT	DTT
DM2LBC3	MA	Modulator
DM2LBC3	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM2LBC3	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM2LBC3	DI	DM2LBC3
DM2LBC3	DN	TEW-7197
DM2LBC3	MI	TTO3HT7
DM2LBC3	MN	Transforming growth factor beta (TGFB)
DM2LBC3	MT	DTT
DM2LBC3	MA	Antagonist
DM2LBC3	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM2LBC3	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMF61ML	DI	DMF61ML
DMF61ML	DN	TF0023
DMF61ML	MI	TT6L509
DMF61ML	MN	Coagulation factor IIa (F2)
DMF61ML	MT	DTT
DMF61ML	MA	Inhibitor
DMF61ML	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMF61ML	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DM2ZLWH	DI	DM2ZLWH
DM2ZLWH	DN	TG-0054
DM2ZLWH	MI	TTBID49
DM2ZLWH	MN	C-X-C chemokine receptor type 4 (CXCR4)
DM2ZLWH	MT	DTT
DM2ZLWH	MA	Inhibitor
DM2ZLWH	RN	CXCR4 Antagonist TG-0054 Mobilizes Mesenchymal Stem Cells, Attenuates Inflammation, and Preserves Cardiac Systolic Function in a Porcine Model of Myocardial Infarction. Cell Transplant. 2015;24(7):1313-28.
DM2ZLWH	RU	https://pubmed.ncbi.nlm.nih.gov/24823505

DMPH1AG	DI	DMPH1AG
DMPH1AG	DN	TG100801
DMPH1AG	MI	TT9HKJA
DMPH1AG	MN	Vascular endothelial growth factor (VEGF)
DMPH1AG	MT	DTT
DMPH1AG	MA	Inhibitor
DMPH1AG	RN	Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. J Cell Physiol. 2008 Jul;216(1):29-37.
DMPH1AG	RU	https://pubmed.ncbi.nlm.nih.gov/18330892

DMZ571Y	DI	DMZ571Y
DMZ571Y	DN	TG-2349
DMZ571Y	MI	TTRHUKY
DMZ571Y	MN	Hepatitis C virus Serine protease NS4A (HCV NS4A)
DMZ571Y	MT	DTT
DMZ571Y	MA	Modulator
DMZ571Y	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMZ571Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMJ2FTU	DI	DMJ2FTU
DMJ2FTU	DN	TGBA01AD
DMJ2FTU	MI	TTSQIFT
DMJ2FTU	MN	5-HT 1A receptor (HTR1A)
DMJ2FTU	MT	DTT
DMJ2FTU	MA	Modulator
DMJ2FTU	RN	Company report (Fabrekramer)
DMJ2FTU	RU	http://www.fabrekramer.com/?page_id=66

DMJ2FTU	DI	DMJ2FTU
DMJ2FTU	DN	TGBA01AD
DMJ2FTU	MI	TT6MSOK
DMJ2FTU	MN	5-HT 1D receptor (HTR1D)
DMJ2FTU	MT	DTT
DMJ2FTU	MA	Modulator
DMJ2FTU	RN	Company report (Fabrekramer)
DMJ2FTU	RU	http://www.fabrekramer.com/?page_id=66

DMNXJ5B	DI	DMNXJ5B
DMNXJ5B	DN	TGFK08AA
DMNXJ5B	MI	TTSQIFT
DMNXJ5B	MN	5-HT 1A receptor (HTR1A)
DMNXJ5B	MT	DTT
DMNXJ5B	MA	Modulator
DMNXJ5B	RN	50 years of hurdles and hope in anxiolytic drug discovery. Nat Rev Drug Discov. 2013 Sep;12(9):667-87. 
DMNXJ5B	RU	https://pubmed.ncbi.nlm.nih.gov/23989795

DMGWE4H	DI	DMGWE4H
DMGWE4H	DN	TGFK09SD
DMGWE4H	MI	TTSQIFT
DMGWE4H	MN	5-HT 1A receptor (HTR1A)
DMGWE4H	MT	DTT
DMGWE4H	MA	Modulator
DMGWE4H	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032503)
DMGWE4H	RU	http://adisinsight.springer.com/drugs/800032503

DMQ6ANE	DI	DMQ6ANE
DMQ6ANE	DN	TGOF02N
DMQ6ANE	MI	TTYSN63
DMQ6ANE	MN	5-HT 2 receptor (5HT2R)
DMQ6ANE	MT	DTT
DMQ6ANE	MA	Modulator
DMQ6ANE	RN	Clinical pipeline report, company report or official report of Fabre-Kramer Pharmaceuticals.
DMQ6ANE	RU	http://www.fabrekramer.com/?page_id=76

DMI57ZA	DI	DMI57ZA
DMI57ZA	DN	TGWOOAA
DMI57ZA	MI	TTSQIFT
DMI57ZA	MN	5-HT 1A receptor (HTR1A)
DMI57ZA	MT	DTT
DMI57ZA	MA	Antagonist
DMI57ZA	RN	Clinical pipeline report, company report or official report of Fabre-Kramer Pharmaceuticals.
DMI57ZA	RU	http://www.fabrekramer.com/?page_id=70

DMI57ZA	DI	DMI57ZA
DMI57ZA	DN	TGWOOAA
DMI57ZA	MI	TTYSN63
DMI57ZA	MN	5-HT 2 receptor (5HT2R)
DMI57ZA	MT	DTT
DMI57ZA	MA	Antagonist
DMI57ZA	RN	Clinical pipeline report, company report or official report of Fabre-Kramer Pharmaceuticals.
DMI57ZA	RU	http://www.fabrekramer.com/?page_id=70

DMFU0JY	DI	DMFU0JY
DMFU0JY	DN	TH-302
DMFU0JY	MI	TTUTN1I
DMFU0JY	MN	Human Deoxyribonucleic acid (hDNA)
DMFU0JY	MT	DTT
DMFU0JY	MA	Modulator
DMFU0JY	RN	Company report (Threshold Pharmaceuticals)
DMFU0JY	RU	http://www.thresholdpharm.com/what-is-th-302

DMW8X05	DI	DMW8X05
DMW8X05	DN	THR-149
DMW8X05	MI	TTMF8H9
DMW8X05	MN	Plasma kallikrein (KLKB1)
DMW8X05	MT	DTT
DMW8X05	MA	Inhibitor
DMW8X05	RN	Clinical pipeline report, company report or official report of Oxurion.
DMW8X05	RU	https://www.oxurion.com/product/thr-149-pkal-inhibitor

DMBO021	DI	DMBO021
DMBO021	DN	THR-18
DMBO021	MI	TTTO43N
DMBO021	MN	Endothelial plasminogen activator inhibitor (SERPINE1)
DMBO021	MT	DTT
DMBO021	MA	Activator
DMBO021	RN	THR-18, a 18-mer peptide derived from PAI-1, is neuroprotective and improves thrombolysis by tPA in rat stroke models. Neurol Res. 2011 Nov;33(9):983-90.
DMBO021	RU	https://pubmed.ncbi.nlm.nih.gov/22081002

DMAVQR1	DI	DMAVQR1
DMAVQR1	DN	THR-184
DMAVQR1	MI	TTKOBRA
DMAVQR1	MN	Bone morphogenetic protein 7 (BMP7)
DMAVQR1	MT	DTT
DMAVQR1	MA	Agonist
DMAVQR1	RN	Perioperative THR-184 and AKI after Cardiac Surgery. J Am Soc Nephrol. 2018 Feb;29(2):670-679.
DMAVQR1	RU	https://pubmed.ncbi.nlm.nih.gov/29203473

DM1BYNF	DI	DM1BYNF
DM1BYNF	DN	THRX-198321
DM1BYNF	MI	TT2CJVK
DM1BYNF	MN	Adrenergic receptor beta-2 (ADRB2)
DM1BYNF	MT	DTT
DM1BYNF	MA	Modulator
DM1BYNF	RN	THRX-198321 is a bifunctional muscarinic receptor antagonist and beta2-adrenoceptor agonist (MABA) that binds in a bimodal and multivalent manner. Mol Pharmacol. 2011 Mar;79(3):389-99.
DM1BYNF	RU	https://pubmed.ncbi.nlm.nih.gov/21139051

DM4BLJM	DI	DM4BLJM
DM4BLJM	DN	Thymoctonan
DM4BLJM	MI	TTF89GD
DM4BLJM	MN	Interleukin-2 (IL2)
DM4BLJM	MT	DTT
DM4BLJM	MA	Modulator
DM4BLJM	RN	Evaluation of efficacy and safety of thymus humoral factor-gamma 2 in the management of chronic hepatitis B. J Hepatol. 1995 Jul;23(1):21-7.
DM4BLJM	RU	https://pubmed.ncbi.nlm.nih.gov/8530805

DME4LA1	DI	DME4LA1
DME4LA1	DN	Tideglusib
DME4LA1	MI	TTRSMW9
DME4LA1	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DME4LA1	MT	DTT
DME4LA1	MA	Inhibitor
DME4LA1	RN	Evidence for irreversible inhibition of glycogen synthase kinase-3beta by tideglusib. J Biol Chem. 2012 Jan 6;287(2):893-904.
DME4LA1	RU	https://pubmed.ncbi.nlm.nih.gov/22102280

DM5XRMA	DI	DM5XRMA
DM5XRMA	DN	Tipapkinogene sovacivec
DM5XRMA	MI	TTE2N95
DM5XRMA	MN	Human papillomavirus protein E6 (HPV E6)
DM5XRMA	MT	DTT
DM5XRMA	MA	Modulator
DM5XRMA	RN	Immune therapy for human papillomaviruses-related cancers
DM5XRMA	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4259927

DM5XRMA	DI	DM5XRMA
DM5XRMA	DN	Tipapkinogene sovacivec
DM5XRMA	MI	TT3CPZW
DM5XRMA	MN	Human papillomavirus protein E7 (HPV E7)
DM5XRMA	MT	DTT
DM5XRMA	MA	Modulator
DM5XRMA	RN	Immune therapy for human papillomaviruses-related cancers
DM5XRMA	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4259927

DMS9BDQ	DI	DMS9BDQ
DMS9BDQ	DN	Tipelukast
DMS9BDQ	MI	TT2J34L
DMS9BDQ	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMS9BDQ	MT	DTT
DMS9BDQ	MA	Modulator
DMS9BDQ	RN	Company report (MediciNova)
DMS9BDQ	RU	http://medicinova.com/clinical-development/core/mn-001-nash/

DMS9BDQ	DI	DMS9BDQ
DMS9BDQ	DN	Tipelukast
DMS9BDQ	MI	TTZCG4L
DMS9BDQ	MN	Phosphodiesterase 3 (PDE3)
DMS9BDQ	MT	DTT
DMS9BDQ	MA	Modulator
DMS9BDQ	RN	Company report (MediciNova)
DMS9BDQ	RU	http://medicinova.com/clinical-development/core/mn-001-nash/

DM1SB94	DI	DM1SB94
DM1SB94	DN	Tiprelestat
DM1SB94	MI	TT5MLC4
DM1SB94	MN	Leukocyte proteinase-3 (PRTN3)
DM1SB94	MT	DTT
DM1SB94	MA	Modulator
DM1SB94	RN	Company report (Proteo Biotech AG)
DM1SB94	RU	http://proteo.us/proteo-inc/r-und-d/lead-product-elafin.html

DM1SB94	DI	DM1SB94
DM1SB94	DN	Tiprelestat
DM1SB94	MI	TTPLTSQ
DM1SB94	MN	Neutrophil elastase (NE)
DM1SB94	MT	DTT
DM1SB94	MA	Modulator
DM1SB94	RN	Company report (Proteo Biotech AG)
DM1SB94	RU	http://proteo.us/proteo-inc/r-und-d/lead-product-elafin.html

DMT8SMO	DI	DMT8SMO
DMT8SMO	DN	TKA-731
DMT8SMO	MI	TTZPO1L
DMT8SMO	MN	Substance-P receptor (TACR1)
DMT8SMO	MT	DTT
DMT8SMO	MA	Antagonist
DMT8SMO	RN	The NK1-receptor antagonist TKA731 in painful diabetic neuropathy: a randomised, controlled trial. Eur J Pain. 2006 Aug;10(6):567-71.
DMT8SMO	RU	https://pubmed.ncbi.nlm.nih.gov/16199188

DMGWP8L	DI	DMGWP8L
DMGWP8L	DN	TLC-388
DMGWP8L	MI	TTGTQHC
DMGWP8L	MN	DNA topoisomerase I (TOP1)
DMGWP8L	MT	DTT
DMGWP8L	MA	Inhibitor
DMGWP8L	RN	Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience. Oncology. 1999;56(1):1-12.
DMGWP8L	RU	https://pubmed.ncbi.nlm.nih.gov/9885371

DMVXLQ7	DI	DMVXLQ7
DMVXLQ7	DN	TLN-4601
DMVXLQ7	MI	TTPTXIN
DMVXLQ7	MN	Translocator protein (TSPO)
DMVXLQ7	MT	DTT
DMVXLQ7	MA	Modulator
DMVXLQ7	RN	TLN-4601 peripheral benzodiazepine receptor (PBR/TSPO) binding properties do not mediate apoptosis but confer tumor-specific accumulation.Biochem Pharmacol.2010 Nov 15;80(10):1572-9.
DMVXLQ7	RU	https://www.ncbi.nlm.nih.gov/pubmed/20655882

DMKV5UM	DI	DMKV5UM
DMKV5UM	DN	TM-601
DMKV5UM	MI	TTCYAXN
DMKV5UM	MN	Chloride channel unspecific (ClC)
DMKV5UM	MT	DTT
DMKV5UM	MA	Inhibitor
DMKV5UM	RN	NMR sequential assignments and solution structure of chlorotoxin, a small scorpion toxin that blocks chloride channels. Biochemistry. 1995 Jan 10;34(1):13-21.
DMKV5UM	RU	https://pubmed.ncbi.nlm.nih.gov/7819188

DMW145U	DI	DMW145U
DMW145U	DN	TMC-310911
DMW145U	MI	TT5FNQT
DMW145U	MN	Human immunodeficiency virus Protease (HIV PR)
DMW145U	MT	DTT
DMW145U	MA	Inhibitor
DMW145U	RN	Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates. Chemistry & Biology Volume 21, Issue 9, 18 September 2014, Pages 1115-1142.
DMW145U	RU	http://www.sciencedirect.com/science/article/pii/S1074552114002890

DME8PFQ	DI	DME8PFQ
DME8PFQ	DN	TMX-049
DME8PFQ	MI	TT7RJY8
DME8PFQ	MN	Xanthine dehydrogenase/oxidase (XDH)
DME8PFQ	MT	DTT
DME8PFQ	MA	Inhibitor
DME8PFQ	RN	Clinical pipeline report, company report or official report of Teijin Pharma.
DME8PFQ	RU	https://www.teijin.com/news/2019/20190920_3737.html

DMH4BFD	DI	DMH4BFD
DMH4BFD	DN	TN-871
DMH4BFD	MI	TTTD45S
DMH4BFD	MN	Neurotransmitter release (NT rele)
DMH4BFD	MT	DTT
DMH4BFD	MA	Modulator
DMH4BFD	RN	Effects of an indene-derivative, TN-871, on synaptic transmission in a sympathetic ganglion: presynaptic actions on neurotransmitter release. Bull Tokyo Med Dent Univ. 1995 Mar;42(1):19-29.
DMH4BFD	RU	https://pubmed.ncbi.nlm.nih.gov/7895315

DM3AIF7	DI	DM3AIF7
DM3AIF7	DN	TNF alpha kinoid
DM3AIF7	MI	TTF8CQI
DM3AIF7	MN	Tumor necrosis factor (TNF)
DM3AIF7	MT	DTT
DM3AIF7	RN	Modulation of Anti-Tumor Necrosis Factor Alpha (TNF-alpha) Antibody Secretion in Mice Immunized with TNF-alpha Kinoid. Clin Vaccine Immunol. 2012 May; 19(5): 699-703.
DM3AIF7	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3346328/

DM8DZKI	DI	DM8DZKI
DM8DZKI	DN	TNP-2092
DM8DZKI	MI	TTN6J5F
DM8DZKI	MN	Bacterial DNA gyrase (Bact gyrase)
DM8DZKI	MT	DTT
DM8DZKI	MA	Inhibitor
DM8DZKI	RN	Clinical pipeline report, company report or official report of TenNor Therapeutics.
DM8DZKI	RU	http://www.tennorx.com/en/h-col-158.html

DM8DZKI	DI	DM8DZKI
DM8DZKI	DN	TNP-2092
DM8DZKI	MI	TTFK8YB
DM8DZKI	MN	Bacterial DNA topoisomerase 4A (Bact parC)
DM8DZKI	MT	DTT
DM8DZKI	MA	Inhibitor
DM8DZKI	RN	Clinical pipeline report, company report or official report of TenNor Therapeutics.
DM8DZKI	RU	http://www.tennorx.com/en/h-col-158.html

DMAJ6YL	DI	DMAJ6YL
DMAJ6YL	DN	TNX-1300
DMAJ6YL	MI	TTX7ZJ3
DMAJ6YL	MN	Cocaine (Coca)
DMAJ6YL	MT	DTT
DMAJ6YL	MA	Degrader
DMAJ6YL	RN	Clinical pipeline report, company report or official report of Tonix Pharmaceuticals.
DMAJ6YL	RU	https://www.tonixpharma.com/pipeline/overview

DMBIJZ6	DI	DMBIJZ6
DMBIJZ6	DN	Tocopherol
DMBIJZ6	MI	DE4LYSA
DMBIJZ6	MN	Cytochrome P450 3A4 (CYP3A4)
DMBIJZ6	MT	DME
DMBIJZ6	MA	Metabolism
DMBIJZ6	RN	A new compound-specific pleiotropic effect of statins: modification of plasma gamma-tocopherol levels. Atherosclerosis. 2007 Jul;193(1):229-33.
DMBIJZ6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16860808

DMBIJZ6	DI	DMBIJZ6
DMBIJZ6	DN	Tocopherol
DMBIJZ6	MI	DE3GT9C
DMBIJZ6	MN	Cytochrome P450 4F2 (CYP4F2)
DMBIJZ6	MT	DME
DMBIJZ6	MA	Metabolism
DMBIJZ6	RN	Discovery, characterization, and significance of the cytochrome P450 omega-hydroxylase pathway of vitamin E catabolism. Ann N Y Acad Sci. 2004 Dec;1031:13-21.
DMBIJZ6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15753130

DMLCUAS	DI	DMLCUAS
DMLCUAS	DN	TOFIMILAST
DMLCUAS	MI	TTZ97H5
DMLCUAS	MN	Phosphodiesterase 4A (PDE4A)
DMLCUAS	MT	DTT
DMLCUAS	MA	Inhibitor
DMLCUAS	RN	GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization. J Pharmacol Exp Ther. 2011 Apr;337(1):145-54.
DMLCUAS	RU	https://pubmed.ncbi.nlm.nih.gov/21205923

DMLCUAS	DI	DMLCUAS
DMLCUAS	DN	TOFIMILAST
DMLCUAS	MI	TTVIAT9
DMLCUAS	MN	Phosphodiesterase 4B (PDE4B)
DMLCUAS	MT	DTT
DMLCUAS	MA	Inhibitor
DMLCUAS	RN	Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36.
DMLCUAS	RU	https://pubmed.ncbi.nlm.nih.gov/21948793

DMLCUAS	DI	DMLCUAS
DMLCUAS	DN	TOFIMILAST
DMLCUAS	MI	TTSKMI8
DMLCUAS	MN	Phosphodiesterase 4D (PDE4D)
DMLCUAS	MT	DTT
DMLCUAS	MA	Inhibitor
DMLCUAS	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMLCUAS	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMTGNWU	DI	DMTGNWU
DMTGNWU	DN	Tofisopam
DMTGNWU	MI	TTJW4LU
DMTGNWU	MN	Phosphodiesterase 10A (PDE10)
DMTGNWU	MT	DTT
DMTGNWU	MA	Inhibitor
DMTGNWU	RN	The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna). 2010 Nov;117(11):1319-25.
DMTGNWU	RU	https://pubmed.ncbi.nlm.nih.gov/20967473

DMTGNWU	DI	DMTGNWU
DMTGNWU	DN	Tofisopam
DMTGNWU	MI	TTJGW1Z
DMTGNWU	MN	Phosphodiesterase 2A (PDE2A)
DMTGNWU	MT	DTT
DMTGNWU	MA	Inhibitor
DMTGNWU	RN	The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna). 2010 Nov;117(11):1319-25.
DMTGNWU	RU	https://pubmed.ncbi.nlm.nih.gov/20967473

DMTGNWU	DI	DMTGNWU
DMTGNWU	DN	Tofisopam
DMTGNWU	MI	TTZCG4L
DMTGNWU	MN	Phosphodiesterase 3 (PDE3)
DMTGNWU	MT	DTT
DMTGNWU	MA	Inhibitor
DMTGNWU	RN	The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna). 2010 Nov;117(11):1319-25.
DMTGNWU	RU	https://pubmed.ncbi.nlm.nih.gov/20967473

DMTGNWU	DI	DMTGNWU
DMTGNWU	DN	Tofisopam
DMTGNWU	MI	TTZ97H5
DMTGNWU	MN	Phosphodiesterase 4A (PDE4A)
DMTGNWU	MT	DTT
DMTGNWU	MA	Inhibitor
DMTGNWU	RN	The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna). 2010 Nov;117(11):1319-25.
DMTGNWU	RU	https://pubmed.ncbi.nlm.nih.gov/20967473

DMVJWPR	DI	DMVJWPR
DMVJWPR	DN	TOK-001
DMVJWPR	MI	TTS64P2
DMVJWPR	MN	Androgen receptor (AR)
DMVJWPR	MT	DTT
DMVJWPR	MA	Inhibitor
DMVJWPR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8638).
DMVJWPR	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8638

DMW17KS	DI	DMW17KS
DMW17KS	DN	TOL-3021
DMW17KS	MI	TTUTN1I
DMW17KS	MN	Human Deoxyribonucleic acid (hDNA)
DMW17KS	MT	DTT
DMW17KS	MA	Modulator
DMW17KS	RN	Clinical pipeline report, company report or official report of Tolerion.
DMW17KS	RU	http://www.tolerioninc.com/TOL-3021_press_release.html

DMORFZD	DI	DMORFZD
DMORFZD	DN	Tolamba
DMORFZD	MI	TTSHG0T
DMORFZD	MN	Toll-like receptor 9 (TLR9)
DMORFZD	MT	DTT
DMORFZD	RN	Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br J Haematol. 2009 August; 146(3): 282-291.
DMORFZD	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747261/

DMT4OPL	DI	DMT4OPL
DMT4OPL	DN	Tonabersat
DMT4OPL	MI	TT6MSOK
DMT4OPL	MN	5-HT 1D receptor (HTR1D)
DMT4OPL	MT	DTT
DMT4OPL	MA	Agonist
DMT4OPL	RN	The potential anti-migraine compound SB-220453 does not contract human isolated blood vessels or myocardium; a comparison with sumatriptan. Cephalalgia. 2000 Jul;20(6):538-45.
DMT4OPL	RU	https://pubmed.ncbi.nlm.nih.gov/11075836

DMBH316	DI	DMBH316
DMBH316	DN	Tonapofylline
DMBH316	MI	TTK25J1
DMBH316	MN	Adenosine A1 receptor (ADORA1)
DMBH316	MT	DTT
DMBH316	MA	Inhibitor
DMBH316	RN	2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
DMBH316	RU	https://pubmed.ncbi.nlm.nih.gov/20188574

DMBH316	DI	DMBH316
DMBH316	DN	Tonapofylline
DMBH316	MI	TTM2AOE
DMBH316	MN	Adenosine A2a receptor (ADORA2A)
DMBH316	MT	DTT
DMBH316	MA	Inhibitor
DMBH316	RN	2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
DMBH316	RU	https://pubmed.ncbi.nlm.nih.gov/20188574

DMBH316	DI	DMBH316
DMBH316	DN	Tonapofylline
DMBH316	MI	TTNE7KG
DMBH316	MN	Adenosine A2b receptor (ADORA2B)
DMBH316	MT	DTT
DMBH316	MA	Inhibitor
DMBH316	RN	2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
DMBH316	RU	https://pubmed.ncbi.nlm.nih.gov/20188574

DMBH316	DI	DMBH316
DMBH316	DN	Tonapofylline
DMBH316	MI	TTJFY5U
DMBH316	MN	Adenosine A3 receptor (ADORA3)
DMBH316	MT	DTT
DMBH316	MA	Inhibitor
DMBH316	RN	2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
DMBH316	RU	https://pubmed.ncbi.nlm.nih.gov/20188574

DMA04DE	DI	DMA04DE
DMA04DE	DN	Topiroxostat
DMA04DE	MI	DE85D2P
DMA04DE	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMA04DE	MT	DME
DMA04DE	MA	Metabolism
DMA04DE	RN	Characterization of N-glucuronidation of 4-(5-pyridin-4-yl-1H-[1,2,4]triazol-3-yl) pyridine-2-carbonitrile (FYX-051): a new xanthine oxidoreductase inhibitor. Drug Metab Dispos. 2007 Dec;35(12):2143-8.
DMA04DE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17761779

DMA04DE	DI	DMA04DE
DMA04DE	DN	Topiroxostat
DMA04DE	MI	TT7RJY8
DMA04DE	MN	Xanthine dehydrogenase/oxidase (XDH)
DMA04DE	MT	DTT
DMA04DE	MA	Inhibitor
DMA04DE	RN	QT/QTc study conducted in Japanese adult healthy subjects: a novel xanthine oxidase inhibitor topiroxostat was not associated with QT prolongation. J Clin Pharmacol. 2014 Apr;54(4):446-52.
DMA04DE	RU	https://pubmed.ncbi.nlm.nih.gov/24214189

DM2HDTM	DI	DM2HDTM
DM2HDTM	DN	Tosagestin
DM2HDTM	MI	TTUV8G9
DM2HDTM	MN	Progesterone receptor (PGR)
DM2HDTM	MT	DTT
DM2HDTM	MA	Agonist
DM2HDTM	RN	Effects of progestins on the proliferation of estrogen-dependent human breast cancer cells under growth factor-defined conditions. J Steroid Biochem Mol Biol. 1992 Jun;42(5):457-65.
DM2HDTM	RU	https://pubmed.ncbi.nlm.nih.gov/1616875

DMAWLVB	DI	DMAWLVB
DMAWLVB	DN	TPI ASM8
DMAWLVB	MI	TTPYS82
DMAWLVB	MN	Interleukin 3 receptor (CSF2RB)
DMAWLVB	MT	DTT
DMAWLVB	MA	Modulator
DMAWLVB	RN	Target mRNA inhibition by oligonucleotide drugs in man. Nucleic Acids Res.2012 Nov;40(21):10585-95.
DMAWLVB	RU	https://www.ncbi.nlm.nih.gov/pubmed/22989709

DMSA2LZ	DI	DMSA2LZ
DMSA2LZ	DN	TPI-1020
DMSA2LZ	MI	TTYRL6O
DMSA2LZ	MN	Glucocorticoid receptor (NR3C1)
DMSA2LZ	MT	DTT
DMSA2LZ	MA	Antagonist
DMSA2LZ	RN	Bronchoprotection in conscious guinea pigs by budesonide and the NO-donating analogue, TPI 1020, alone and combined with tiotropium or formoterol. Br J Pharmacol. 2012 Oct;167(3):515-26.
DMSA2LZ	RU	https://pubmed.ncbi.nlm.nih.gov/22563753

DMC5TV6	DI	DMC5TV6
DMC5TV6	DN	TPI-287
DMC5TV6	MI	TT1WDO0
DMC5TV6	MN	Microtubule (MicroTu)
DMC5TV6	MT	DTT
DMC5TV6	MA	Stabilizer
DMC5TV6	RN	TPI-287, a new taxane family member, reduces the brain metastatic colonization of breast cancer cells. Mol Cancer Ther. 2012 Sep;11(9):1959-67.
DMC5TV6	RU	https://pubmed.ncbi.nlm.nih.gov/22622283

DM4R23C	DI	DM4R23C
DM4R23C	DN	TPM-1/Morphine
DM4R23C	MI	TT27RFC
DM4R23C	MN	Opioid receptor delta (OPRD1)
DM4R23C	MT	DTT
DM4R23C	MA	Inhibitor
DM4R23C	RN	Molecular Mechanisms of Opioid Receptor-Dependent Signaling and Behavior. Anesthesiology. 2011 December; 115(6): 1363-1381.
DM4R23C	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3698859/

DM4R23C	DI	DM4R23C
DM4R23C	DN	TPM-1/Morphine
DM4R23C	MI	TTQW87Y
DM4R23C	MN	Opioid receptor kappa (OPRK1)
DM4R23C	MT	DTT
DM4R23C	MA	Inhibitor
DM4R23C	RN	Molecular Mechanisms of Opioid Receptor-Dependent Signaling and Behavior. Anesthesiology. 2011 December; 115(6): 1363-1381.
DM4R23C	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3698859/

DM4R23C	DI	DM4R23C
DM4R23C	DN	TPM-1/Morphine
DM4R23C	MI	TTKWM86
DM4R23C	MN	Opioid receptor mu (MOP)
DM4R23C	MT	DTT
DM4R23C	MA	Inhibitor
DM4R23C	RN	Molecular Mechanisms of Opioid Receptor-Dependent Signaling and Behavior. Anesthesiology. 2011 December; 115(6): 1363-1381.
DM4R23C	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3698859/

DMYP7TO	DI	DMYP7TO
DMYP7TO	DN	Trametinib + 2141795
DMYP7TO	MI	TTWTSCV
DMYP7TO	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DMYP7TO	MT	DTT
DMYP7TO	MA	Modulator
DMYP7TO	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479).
DMYP7TO	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1479

DMU1LXS	DI	DMU1LXS
DMU1LXS	DN	Trastuzumab Emtansine
DMU1LXS	MI	DE7P2FB
DMU1LXS	MN	Aldo-keto reductase 1C1 (AKR1C1)
DMU1LXS	MT	DME
DMU1LXS	MA	Metabolism
DMU1LXS	RN	The role of carbonyl reducing enzymes in oxcarbazepine in vitro metabolism in man. Chem Biol Interact. 2014 Sep 5;220:241-7.
DMU1LXS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25063510

DMU1LXS	DI	DMU1LXS
DMU1LXS	DN	Trastuzumab Emtansine
DMU1LXS	MI	DEOY5ZM
DMU1LXS	MN	Aldo-keto reductase 1C2 (AKR1C2)
DMU1LXS	MT	DME
DMU1LXS	MA	Metabolism
DMU1LXS	RN	The role of carbonyl reducing enzymes in oxcarbazepine in vitro metabolism in man. Chem Biol Interact. 2014 Sep 5;220:241-7.
DMU1LXS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25063510

DMU1LXS	DI	DMU1LXS
DMU1LXS	DN	Trastuzumab Emtansine
DMU1LXS	MI	DEGQTXO
DMU1LXS	MN	Aldo-keto reductase 1C3 (AKR1C3)
DMU1LXS	MT	DME
DMU1LXS	MA	Metabolism
DMU1LXS	RN	The role of carbonyl reducing enzymes in oxcarbazepine in vitro metabolism in man. Chem Biol Interact. 2014 Sep 5;220:241-7.
DMU1LXS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25063510

DMU1LXS	DI	DMU1LXS
DMU1LXS	DN	Trastuzumab Emtansine
DMU1LXS	MI	DEAJN47
DMU1LXS	MN	Aldo-keto reductase 1C4 (AKR1C4)
DMU1LXS	MT	DME
DMU1LXS	MA	Metabolism
DMU1LXS	RN	The role of carbonyl reducing enzymes in oxcarbazepine in vitro metabolism in man. Chem Biol Interact. 2014 Sep 5;220:241-7.
DMU1LXS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25063510

DMU1LXS	DI	DMU1LXS
DMU1LXS	DN	Trastuzumab Emtansine
DMU1LXS	MI	DE4LYSA
DMU1LXS	MN	Cytochrome P450 3A4 (CYP3A4)
DMU1LXS	MT	DME
DMU1LXS	MA	Metabolism
DMU1LXS	RN	Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet. 2000 Sep;39(3):203-14.
DMU1LXS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11020135

DMU1LXS	DI	DMU1LXS
DMU1LXS	DN	Trastuzumab Emtansine
DMU1LXS	MI	DEIBDNY
DMU1LXS	MN	Cytochrome P450 3A5 (CYP3A5)
DMU1LXS	MT	DME
DMU1LXS	MA	Metabolism
DMU1LXS	RN	Trastuzumab emtansine. An inadequately assessed combination of two cytotoxic drugs. Prescrire Int. 2014 Dec;23(155):289.
DMU1LXS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25629144

DMU1LXS	DI	DMU1LXS
DMU1LXS	DN	Trastuzumab Emtansine
DMU1LXS	MI	DEIVKZ8
DMU1LXS	MN	NADPH-dependent carbonyl reductase 3 (CBR3)
DMU1LXS	MT	DME
DMU1LXS	MA	Metabolism
DMU1LXS	RN	The role of carbonyl reducing enzymes in oxcarbazepine in vitro metabolism in man. Chem Biol Interact. 2014 Sep 5;220:241-7.
DMU1LXS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25063510

DM1ZQEN	DI	DM1ZQEN
DM1ZQEN	DN	TRAXOPRODIL MESYLATE
DM1ZQEN	MI	TT9IK2Z
DM1ZQEN	MN	N-methyl-D-aspartate receptor (NMDAR)
DM1ZQEN	MT	DTT
DM1ZQEN	MA	Modulator
DM1ZQEN	RN	The effect of the selective NMDA receptor antagonist traxoprodil in the treatment of traumatic brain injury. J Neurotrauma. 2005 Dec;22(12):1428-43.
DM1ZQEN	RU	https://pubmed.ncbi.nlm.nih.gov/16379581

DM7XZY5	DI	DM7XZY5
DM7XZY5	DN	Triapine
DM7XZY5	MI	TTBWDI0
DM7XZY5	MN	Ribonucleoside-diphosphate reductase M2 (RRM2)
DM7XZY5	MT	DTT
DM7XZY5	MA	Modulator
DM7XZY5	RN	PAN-811 inhibits oxidative stress-induced cell death of human Alzheimer's disease-derived and age-matched olfactory neuroepithelial cells via suppression of intracellular reactive oxygen species. J Alzheimers Dis. 2009;17(3):611-9.
DM7XZY5	RU	https://pubmed.ncbi.nlm.nih.gov/19433896

DMWU41P	DI	DMWU41P
DMWU41P	DN	TRIDMAC
DMWU41P	MI	TTJSZTB
DMWU41P	MN	Nicotinic acetylcholine receptor (nAChR)
DMWU41P	MT	DTT
DMWU41P	MA	Antagonist
DMWU41P	RN	Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
DMWU41P	RU	https://pubmed.ncbi.nlm.nih.gov/18172433

DM13G5R	DI	DM13G5R
DM13G5R	DN	TRK-170
DM13G5R	MI	TT6S84X
DM13G5R	MN	Integrin alpha-4/beta-1 (ITGA4/B1)
DM13G5R	MT	DTT
DM13G5R	MA	Modulator
DM13G5R	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM13G5R	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM13G5R	DI	DM13G5R
DM13G5R	DN	TRK-170
DM13G5R	MI	TT7ZMI1
DM13G5R	MN	Integrin alpha-4/beta-7 (ITGA4/B7)
DM13G5R	MT	DTT
DM13G5R	MA	Modulator
DM13G5R	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM13G5R	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM64NYP	DI	DM64NYP
DM64NYP	DN	TRN-157
DM64NYP	MI	TTQ13Z5
DM64NYP	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DM64NYP	MT	DTT
DM64NYP	MA	Antagonist
DM64NYP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 15).
DM64NYP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=15

DMMQYF6	DI	DMMQYF6
DMMQYF6	DN	TRO-19622
DMMQYF6	MI	TTAN6JD
DMMQYF6	MN	Glutamate receptor AMPA (GRIA)
DMMQYF6	MT	DTT
DMMQYF6	MA	Antagonist
DMMQYF6	RN	Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
DMMQYF6	RU	https://pubmed.ncbi.nlm.nih.gov/17604499

DMR8Y4F	DI	DMR8Y4F
DMR8Y4F	DN	Troplasminogen alfa
DMR8Y4F	MI	TTP86E2
DMR8Y4F	MN	Plasminogen (PLG)
DMR8Y4F	MT	DTT
DMR8Y4F	MA	Modulator
DMR8Y4F	RN	V-10153 (Vernalis). Curr Opin Investig Drugs. 2005 Sep;6(9):951-5.
DMR8Y4F	RU	https://pubmed.ncbi.nlm.nih.gov/16187695

DMAZ2L6	DI	DMAZ2L6
DMAZ2L6	DN	TROXACITABINE
DMAZ2L6	MI	TTUTN1I
DMAZ2L6	MN	Human Deoxyribonucleic acid (hDNA)
DMAZ2L6	MT	DTT
DMAZ2L6	MA	Binder
DMAZ2L6	RN	Troxacitabine. Bull Cancer. 2004 Mar;91(3):213-8.
DMAZ2L6	RU	https://pubmed.ncbi.nlm.nih.gov/15171046

DMHEWT7	DI	DMHEWT7
DMHEWT7	DN	TRU-015
DMHEWT7	MI	TTUE541
DMHEWT7	MN	Leukocyte surface antigen Leu-16 (CD20)
DMHEWT7	MT	DTT
DMHEWT7	MA	Antagonist
DMHEWT7	RN	TRU-015, a small modular immunopharmaceutical (SMIP drug candidate directed against CD20, demonstrates clinical improvement in subjects with rheumatoid arthritis. Arthritis Res Ther. 2007; 9(Suppl 3): P32.
DMHEWT7	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4061958/

DMVX6H0	DI	DMVX6H0
DMVX6H0	DN	TRV027
DMVX6H0	MI	TT8DBY3
DMVX6H0	MN	Angiotensin II receptor type-1 (AGTR1)
DMVX6H0	MT	DTT
DMVX6H0	MA	Antagonist
DMVX6H0	RN	First clinical experience with TRV027: pharmacokinetics and pharmacodynamics in healthy volunteers. J Clin Pharmacol. 2013 Sep;53(9):892-9.
DMVX6H0	RU	https://pubmed.ncbi.nlm.nih.gov/23813302

DMMNXIW	DI	DMMNXIW
DMMNXIW	DN	TS-022
DMMNXIW	MI	TTNVEIR
DMMNXIW	MN	Prostaglandin D2 receptor (PTGDR)
DMMNXIW	MT	DTT
DMMNXIW	MA	Agonist
DMMNXIW	RN	Effects of TS-022, a newly developed prostanoid DP1 receptor agonist, on experimental pruritus, cutaneous barrier disruptions and atopic dermatitis... Eur J Pharmacol. 2007 Feb 5;556(1-3):207-14.
DMMNXIW	RU	https://pubmed.ncbi.nlm.nih.gov/17141215

DMZE6Y9	DI	DMZE6Y9
DMZE6Y9	DN	TT-100
DMZE6Y9	MI	TTGKNB4
DMZE6Y9	MN	Epidermal growth factor receptor (EGFR)
DMZE6Y9	MT	DTT
DMZE6Y9	MA	Inhibitor
DMZE6Y9	RN	BiPar Sciences Co-founder Reunites Management Team At TriAct Therapeutics to Advance Clinical Stage Cancer Programs. TriAct Therapeutics. Sept. 10, 2009.
DMZE6Y9	RU	http://globenewswire.com/news-release/2009/09/10/404398/173021/en/BiPar-Sciences-Co-founder-Reunites-Management-Team-At-TriAct-Therapeutics-to-Advance-Clinical-Stage-Cancer-Programs.html

DMZE6Y9	DI	DMZE6Y9
DMZE6Y9	DN	TT-100
DMZE6Y9	MI	TTHRID2
DMZE6Y9	MN	Insulin-like growth factor I receptor (IGF1R)
DMZE6Y9	MT	DTT
DMZE6Y9	MA	Inhibitor
DMZE6Y9	RN	BiPar Sciences Co-founder Reunites Management Team At TriAct Therapeutics to Advance Clinical Stage Cancer Programs. TriAct Therapeutics. Sept. 10, 2009.
DMZE6Y9	RU	http://globenewswire.com/news-release/2009/09/10/404398/173021/en/BiPar-Sciences-Co-founder-Reunites-Management-Team-At-TriAct-Therapeutics-to-Advance-Clinical-Stage-Cancer-Programs.html

DMSIXG4	DI	DMSIXG4
DMSIXG4	DN	TT-173
DMSIXG4	MI	TT38MDJ
DMSIXG4	MN	Tissue factor (F3)
DMSIXG4	MT	DTT
DMSIXG4	MA	Modulator
DMSIXG4	RN	TETIS study: evaluation of new topical hemostatic agent TT-173 in tooth extraction. Clin Oral Investig. 2016 Jun;20(5):1055-63.
DMSIXG4	RU	https://pubmed.ncbi.nlm.nih.gov/26374745

DMCDMFP	DI	DMCDMFP
DMCDMFP	DN	TT-223
DMCDMFP	MI	TTVFO0U
DMCDMFP	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMCDMFP	MT	DTT
DMCDMFP	MA	Modulator
DMCDMFP	RN	The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans. Int J Obes Relat Metab Disord. 2000 Mar;24(3):288-98.
DMCDMFP	RU	https://pubmed.ncbi.nlm.nih.gov/10757621

DMRQ0SA	DI	DMRQ0SA
DMRQ0SA	DN	TT-401
DMRQ0SA	MI	TT9O6WS
DMRQ0SA	MN	Glucagon receptor (GCGR)
DMRQ0SA	MT	DTT
DMRQ0SA	MA	Agonist
DMRQ0SA	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMRQ0SA	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMRQ0SA	DI	DMRQ0SA
DMRQ0SA	DN	TT-401
DMRQ0SA	MI	TTVIMDE
DMRQ0SA	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMRQ0SA	MT	DTT
DMRQ0SA	MA	Modulator
DMRQ0SA	RN	Relationship between systemic cytokines and complement factor H Y402H polymorphism in patients with dry age-related macular degeneration. Am J Ophthalmol. 2013 Dec;156(6):1176-83.
DMRQ0SA	RU	https://pubmed.ncbi.nlm.nih.gov/24083687

DM6TAFE	DI	DM6TAFE
DM6TAFE	DN	TTAC-0001
DM6TAFE	MI	TTUTJGQ
DM6TAFE	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM6TAFE	MT	DTT
DM6TAFE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1813).
DM6TAFE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1813

DMBNU1W	DI	DMBNU1W
DMBNU1W	DN	TTP-054
DMBNU1W	MI	TTVIMDE
DMBNU1W	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMBNU1W	MT	DTT
DMBNU1W	MA	Modulator
DMBNU1W	RN	Small Molecule Drug Discovery at the Glucagon-Like Peptide-1 Receptor. Exp Diabetes Res. 2012; 2012: 709893.
DMBNU1W	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3352573/

DMZ6RG2	DI	DMZ6RG2
DMZ6RG2	DN	TTP273
DMZ6RG2	MI	TTVIMDE
DMZ6RG2	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMZ6RG2	MT	DTT
DMZ6RG2	MA	Agonist
DMZ6RG2	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZ6RG2	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMBKQSZ	DI	DMBKQSZ
DMBKQSZ	DN	TTP399
DMBKQSZ	MI	TTDLNGZ
DMBKQSZ	MN	Glucokinase (GCK)
DMBKQSZ	MT	DTT
DMBKQSZ	MA	Activator
DMBKQSZ	RN	Clinical pipeline report, company report or official report of vTv Therapeutics.
DMBKQSZ	RU	https://vtvtherapeutics.com/pipeline/ttp399/

DMMNTOW	DI	DMMNTOW
DMMNTOW	DN	TTP435
DMMNTOW	MI	TT4DE1O
DMMNTOW	MN	Agouti-related protein (AGRP)
DMMNTOW	MT	DTT
DMMNTOW	MA	Inhibitor
DMMNTOW	RN	Clinical pipeline report, company report or official report of TransTech Pharma (2011).
DMMNTOW	RU	http://www.ttpharma.com/

DMR37X8	DI	DMR37X8
DMR37X8	DN	TTP-448
DMR37X8	MI	TTMO9HF
DMR37X8	MN	Advanced glycosylation end product receptor (AGER)
DMR37X8	MT	DTT
DMR37X8	MA	Modulator
DMR37X8	RN	Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer's disease. Expert Opin Investig Drugs. 2015 Mar;24(3):393-9.
DMR37X8	RU	https://pubmed.ncbi.nlm.nih.gov/25586103

DMCQARM	DI	DMCQARM
DMCQARM	DN	TTP889
DMCQARM	MI	TTFEZ5Q
DMCQARM	MN	Coagulation factor IX (F9)
DMCQARM	MT	DTT
DMCQARM	MA	Inhibitor
DMCQARM	RN	Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study. J Thromb Haemost. 2008 Mar;6(3):457-63.
DMCQARM	RU	https://pubmed.ncbi.nlm.nih.gov/18088349

DMCQARM	DI	DMCQARM
DMCQARM	DN	TTP889
DMCQARM	MI	TTUPB12
DMCQARM	MN	Measles virus Fusion glycoprotein (MeV F)
DMCQARM	MT	DTT
DMCQARM	MA	Inhibitor
DMCQARM	RN	Emerging drugs for respiratory syncytial virus infection. Expert Opin Emerg Drugs. 2009 Jun;14(2):207-17.
DMCQARM	RU	https://pubmed.ncbi.nlm.nih.gov/19453286

DMW7PFS	DI	DMW7PFS
DMW7PFS	DN	Turosteride
DMW7PFS	MI	TT2A0DR
DMW7PFS	MN	Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A)
DMW7PFS	MT	DTT
DMW7PFS	MA	Inhibitor
DMW7PFS	RN	Hormonal effects of turosteride, a 5 alpha-reductase inhibitor, in the rat. J Steroid Biochem Mol Biol. 1993 Nov;46(5):549-55.
DMW7PFS	RU	https://pubmed.ncbi.nlm.nih.gov/8240976

DM28M6I	DI	DM28M6I
DM28M6I	DN	TV-1102
DM28M6I	MI	TT2VIZQ
DM28M6I	MN	ITGAV messenger RNA (ITGAV mRNA)
DM28M6I	MT	DTT
DM28M6I	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DM28M6I	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DM19GUH	DI	DM19GUH
DM19GUH	DN	TVB-2640
DM19GUH	MI	TT7AOUD
DM19GUH	MN	Fatty acid synthase (FASN)
DM19GUH	MT	DTT
DM19GUH	MA	Inhibitor
DM19GUH	RN	Imidazopyridine-Based Fatty Acid Synthase Inhibitors That Show Anti-HCV Activity and in Vivo Target Modulation. ACS Med Chem Lett. 2013 January 10; 4(1): 113-117.
DM19GUH	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4027139/

DMP30SA	DI	DMP30SA
DMP30SA	DN	TVB-2640
DMP30SA	MI	TT7AOUD
DMP30SA	MN	Fatty acid synthase (FASN)
DMP30SA	MT	DTT
DMP30SA	MA	Inhibitor
DMP30SA	RN	Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities. Hepatology. 2020 Jul;72(1):103-118.
DMP30SA	RU	https://pubmed.ncbi.nlm.nih.gov/31630414

DMGYSZ0	DI	DMGYSZ0
DMGYSZ0	DN	TVI-Kidney-1
DMGYSZ0	MI	TTXQYT6
DMGYSZ0	MN	T-cells (T-cells)
DMGYSZ0	MT	DTT
DMGYSZ0	RN	Clinical pipeline report, company report or official report of TVAX Biomedical.
DMGYSZ0	RU	http://www.tvaxbiomedical.com/tvi-kidney.shtml

DMKJIDU	DI	DMKJIDU
DMKJIDU	DN	TZI-41078
DMKJIDU	MI	TTG3K2U
DMKJIDU	MN	Lipoxygenase (ALOX)
DMKJIDU	MT	DTT
DMKJIDU	MA	Modulator
DMKJIDU	RN	Hydroxylamine analogs of 2,6-di-t-butylphenols: dual inhibitors of cyclooxygenase and 5-lipoxygenase or selective 5-lipoxygenase inhibitors. Bioorg Med Chem. 1995 Apr;3(4):403-10.
DMKJIDU	RU	https://pubmed.ncbi.nlm.nih.gov/8581424

DMKJIDU	DI	DMKJIDU
DMKJIDU	DN	TZI-41078
DMKJIDU	MI	TTK0943
DMKJIDU	MN	Prostaglandin G/H synthase (COX)
DMKJIDU	MT	DTT
DMKJIDU	MA	Modulator
DMKJIDU	RN	Hydroxylamine analogs of 2,6-di-t-butylphenols: dual inhibitors of cyclooxygenase and 5-lipoxygenase or selective 5-lipoxygenase inhibitors. Bioorg Med Chem. 1995 Apr;3(4):403-10.
DMKJIDU	RU	https://pubmed.ncbi.nlm.nih.gov/8581424

DM4NXWE	DI	DM4NXWE
DM4NXWE	DN	UB-311
DM4NXWE	MI	TTE4KHA
DM4NXWE	MN	Amyloid beta A4 protein (APP)
DM4NXWE	MT	DTT
DM4NXWE	MA	Modulator
DM4NXWE	RN	Active immunotherapy options for Alzheimer's disease. Alzheimers Res Ther. 2014; 6(1): 7.
DM4NXWE	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979042/

DMXLAPF	DI	DMXLAPF
DMXLAPF	DN	UCB-11056
DMXLAPF	MI	TT0QZ8R
DMXLAPF	MN	cAMP formation (cAMP form)
DMXLAPF	MT	DTT
DMXLAPF	MA	Modulator
DMXLAPF	RN	ucb 11056, a new potential nootropic drug, amplifies induced cyclic AMP formation in rat brain tissue. J Neurochem. 1993 Dec;61(6):2256-61.
DMXLAPF	RU	https://pubmed.ncbi.nlm.nih.gov/8245976

DM5Z34K	DI	DM5Z34K
DM5Z34K	DN	UCB-35440
DM5Z34K	MI	TT2J34L
DM5Z34K	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM5Z34K	MT	DTT
DM5Z34K	MA	Modulator
DM5Z34K	RN	The effect of a novel, dual function histamine H1 receptor antagonist/5-lipoxygenase enzyme inhibitor on in vivo dermal inflammation and extravasat... Eur J Pharmacol. 2005 Jan 4;506(3):265-71.
DM5Z34K	RU	https://pubmed.ncbi.nlm.nih.gov/15627437

DM5Z34K	DI	DM5Z34K
DM5Z34K	DN	UCB-35440
DM5Z34K	MI	TTTIBOJ
DM5Z34K	MN	Histamine H1 receptor (H1R)
DM5Z34K	MT	DTT
DM5Z34K	MA	Modulator
DM5Z34K	RN	The effect of a novel, dual function histamine H1 receptor antagonist/5-lipoxygenase enzyme inhibitor on in vivo dermal inflammation and extravasat... Eur J Pharmacol. 2005 Jan 4;506(3):265-71.
DM5Z34K	RU	https://pubmed.ncbi.nlm.nih.gov/15627437

DMUNJZB	DI	DMUNJZB
DMUNJZB	DN	UCN-01
DMUNJZB	MI	DTI7UX6
DMUNJZB	MN	Breast cancer resistance protein (ABCG2)
DMUNJZB	MT	DTP
DMUNJZB	MA	Substrate
DMUNJZB	RN	Pharmacogenomic importance of ABCG2. Pharmacogenomics. 2008 Aug;9(8):1005-9.
DMUNJZB	RU	https://doi.org/10.2217/14622416.9.8.1005

DMUNJZB	DI	DMUNJZB
DMUNJZB	DN	UCN-01
DMUNJZB	MI	TTTU902
DMUNJZB	MN	Checkpoint kinase-1 (CHK1)
DMUNJZB	MT	DTT
DMUNJZB	MA	Inhibitor
DMUNJZB	RN	Characterization of an inhibitory dynamic pharmacophore for the ERCC1-XPA interaction using a combined molecular dynamics and virtual screening app... J Mol Graph Model. 2009 Sep;28(2):113-30.
DMUNJZB	RU	https://pubmed.ncbi.nlm.nih.gov/19473860

DMIERPK	DI	DMIERPK
DMIERPK	DN	UE-2343
DMIERPK	MI	TTN7BL9
DMIERPK	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMIERPK	MT	DTT
DMIERPK	MA	Inhibitor
DMIERPK	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMIERPK	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMWDJ15	DI	DMWDJ15
DMWDJ15	DN	UFT/leucovorin calcium
DMWDJ15	MI	TTU6BFZ
DMWDJ15	MN	Candida Thymidylate synthase (Candi TMP1)
DMWDJ15	MT	DTT
DMWDJ15	MA	Modulator
DMWDJ15	RN	Leucovorin enhancement of the effects of the fluoropyrimidines on thymidylate synthase. Cancer. 1989 Mar 15;63(6 Suppl):1008-12.
DMWDJ15	RU	https://pubmed.ncbi.nlm.nih.gov/2521810

DM2O4MI	DI	DM2O4MI
DM2O4MI	DN	UK-432097
DM2O4MI	MI	TTM2AOE
DM2O4MI	MN	Adenosine A2a receptor (ADORA2A)
DM2O4MI	MT	DTT
DM2O4MI	MA	Agonist
DM2O4MI	RN	Structure of an agonist-bound human A2A adenosine receptor. Science. 2011 Apr 15;332(6027):322-7.
DM2O4MI	RU	https://pubmed.ncbi.nlm.nih.gov/21393508

DM8LBUK	DI	DM8LBUK
DM8LBUK	DN	UNI-PH (1-34)
DM8LBUK	MI	TTEPJL5
DM8LBUK	MN	Parathyroid hormone receptor (PTH2R)
DM8LBUK	MT	DTT
DM8LBUK	MA	Modulator
DM8LBUK	RN	Parathyroid hormone for the treatment of osteoporosis: a systematic review. CMAJ. 2006 July 4; 175(1): 52-59.
DM8LBUK	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1482742/

DMOMI97	DI	DMOMI97
DMOMI97	DN	UNI-rE-4
DMOMI97	MI	TTVIMDE
DMOMI97	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMOMI97	MT	DTT
DMOMI97	MA	Modulator
DMOMI97	RN	Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results. Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):463-77.
DMOMI97	RU	https://pubmed.ncbi.nlm.nih.gov/19748064

DMFZULI	DI	DMFZULI
DMFZULI	DN	Upamostat
DMFZULI	MI	TTGY7WI
DMFZULI	MN	Urokinase-type plasminogen activator (PLAU)
DMFZULI	MT	DTT
DMFZULI	MA	Inhibitor
DMFZULI	RN	Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer. Br J Cancer. 2013 Mar 5;108(4):766-70.
DMFZULI	RU	https://pubmed.ncbi.nlm.nih.gov/23412098

DME6X27	DI	DME6X27
DME6X27	DN	UR-63325
DME6X27	MI	TTXJ178
DME6X27	MN	Histamine H4 receptor (H4R)
DME6X27	MT	DTT
DME6X27	MA	Antagonist
DME6X27	RN	Azines as histamine H4 receptor antagonists. Front Biosci (Schol Ed). 2012 Jan 1;4:967-87.
DME6X27	RU	https://pubmed.ncbi.nlm.nih.gov/22202103

DMY89BN	DI	DMY89BN
DMY89BN	DN	URC102
DMY89BN	MI	TTA592U
DMY89BN	MN	Urate anion exchanger 1 (URAT1)
DMY89BN	MT	DTT
DMY89BN	MA	Inhibitor
DMY89BN	RN	Clinical pipeline report, company report or official report of Chugai Pharmaceutical (2013).
DMY89BN	RU	http://www.chugai-pharm.co.jp/english/ir/reports_downloads/pipeline.html

DM6RTVG	DI	DM6RTVG
DM6RTVG	DN	Urelumab
DM6RTVG	MI	TTPW9LJ
DM6RTVG	MN	Co-stimulatory molecule 4-1BB (CD137)
DM6RTVG	MT	DTT
DM6RTVG	MA	Agonist
DM6RTVG	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM6RTVG	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM0YO4Q	DI	DM0YO4Q
DM0YO4Q	DN	Urocortin 2
DM0YO4Q	MI	TTIY658
DM0YO4Q	MN	Corticotropin-releasing factor receptor 2 (CRHR2)
DM0YO4Q	MT	DTT
DM0YO4Q	MA	Antagonist
DM0YO4Q	RN	Evolution of complementary peptide systems: teneurin C-terminal-associated peptides and corticotropin-releasing factor superfamilies. Ann N Y Acad Sci. 2009 Apr;1163:215-20.
DM0YO4Q	RU	https://pubmed.ncbi.nlm.nih.gov/19456342

DM4SOAW	DI	DM4SOAW
DM4SOAW	DN	URSOLIC ACID
DM4SOAW	MI	TTN7BL9
DM4SOAW	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DM4SOAW	MT	DTT
DM4SOAW	MA	Inhibitor
DM4SOAW	RN	11beta-Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational a... Bioorg Med Chem. 2010 Feb 15;18(4):1507-15.
DM4SOAW	RU	https://pubmed.ncbi.nlm.nih.gov/20100662

DM4SOAW	DI	DM4SOAW
DM4SOAW	DN	URSOLIC ACID
DM4SOAW	MI	TTZHY6R
DM4SOAW	MN	Glycogen phosphorylase muscle form (GP)
DM4SOAW	MT	DTT
DM4SOAW	MA	Inhibitor
DM4SOAW	RN	Synthesis of 3-deoxypentacyclic triterpene derivatives as inhibitors of glycogen phosphorylase. J Nat Prod. 2009 Aug;72(8):1414-8.
DM4SOAW	RU	https://pubmed.ncbi.nlm.nih.gov/19642687

DM4SOAW	DI	DM4SOAW
DM4SOAW	DN	URSOLIC ACID
DM4SOAW	MI	TTIU7X1
DM4SOAW	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DM4SOAW	MT	DTT
DM4SOAW	MA	Inhibitor
DM4SOAW	RN	DNA polymerase beta inhibitors from Baeckea gunniana. J Nat Prod. 1999 Dec;62(12):1624-6.
DM4SOAW	RU	https://pubmed.ncbi.nlm.nih.gov/10654412

DM4SOAW	DI	DM4SOAW
DM4SOAW	DN	URSOLIC ACID
DM4SOAW	MI	TT9V5JH
DM4SOAW	MN	Phospholipase A2 (PLA2G1B)
DM4SOAW	MT	DTT
DM4SOAW	MA	Inhibitor
DM4SOAW	RN	Synthesis of benzoyl phenyl benzoates as effective inhibitors for phospholipase A2 and hyaluronidase enzymes. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4100-4.
DM4SOAW	RU	https://pubmed.ncbi.nlm.nih.gov/15993585

DM4SOAW	DI	DM4SOAW
DM4SOAW	DN	URSOLIC ACID
DM4SOAW	MI	TTELIN2
DM4SOAW	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DM4SOAW	MT	DTT
DM4SOAW	MA	Inhibitor
DM4SOAW	RN	Cytotoxic and PTP1B inhibitory activities from Erythrina abyssinica. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6745-9.
DM4SOAW	RU	https://pubmed.ncbi.nlm.nih.gov/19836230

DMDPFTB	DI	DMDPFTB
DMDPFTB	DN	V-101
DMDPFTB	MI	TT2NUT5
DMDPFTB	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMDPFTB	MT	DTT
DMDPFTB	MA	Agonist
DMDPFTB	RN	Rosacea: update on management and emerging therapies. Skin Therapy Lett. 2012 Dec;17(10):1-4.
DMDPFTB	RU	https://pubmed.ncbi.nlm.nih.gov/23223767

DM1ODP6	DI	DM1ODP6
DM1ODP6	DN	VA-106483
DM1ODP6	MI	TTK8R02
DM1ODP6	MN	Vasopressin V2 receptor (V2R)
DM1ODP6	MT	DTT
DM1ODP6	MA	Inhibitor
DM1ODP6	RN	New benzylureas as a novel series of potent, nonpeptidic vasopressin V2 receptor agonists. J Med Chem. 2008 Dec 25;51(24):8124-34.
DM1ODP6	RU	https://pubmed.ncbi.nlm.nih.gov/19053774

DMAYWXD	DI	DMAYWXD
DMAYWXD	DN	VA-111913
DMAYWXD	MI	TT4TFGN
DMAYWXD	MN	Vasopressin V1a receptor (V1AR)
DMAYWXD	MT	DTT
DMAYWXD	MA	Antagonist
DMAYWXD	RN	Clinical pipeline report, company report or official report of Avarx.
DMAYWXD	RU	http://www.avarx.com/AvaRx/SubDomains/bucket304f365f4d5c821c892abf2b5eb4/Listings/bucket3e0f28b94cc197c9e1c49f1451ad/Public.Listing.display.html

DM9GZW6	DI	DM9GZW6
DM9GZW6	DN	Vabicaserin
DM9GZW6	MI	TT0K1SC
DM9GZW6	MN	5-HT 2B receptor (HTR2B)
DM9GZW6	MT	DTT
DM9GZW6	MA	Modulator
DM9GZW6	RN	Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111.
DM9GZW6	RU	https://www.ncbi.nlm.nih.gov/pubmed/24759548

DM9GZW6	DI	DM9GZW6
DM9GZW6	DN	Vabicaserin
DM9GZW6	MI	TTWJBZ5
DM9GZW6	MN	5-HT 2C receptor (HTR2C)
DM9GZW6	MT	DTT
DM9GZW6	MA	Modulator
DM9GZW6	RN	Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111.
DM9GZW6	RU	https://www.ncbi.nlm.nih.gov/pubmed/24759548

DMDAKZW	DI	DMDAKZW
DMDAKZW	DN	Vacc-4x
DMDAKZW	MI	TTTWS2G
DMDAKZW	MN	Human immunodeficiency virus Capsid p24 (HIV p24)
DMDAKZW	MT	DTT
DMDAKZW	RN	Clinical pipeline report, company report or official report of Bionor Pharma.
DMDAKZW	RU	http://www.bionorpharma.com/en/News/2011/Scientific/Vacc-4x+results+presented+in+Bangkok.b7C_wljS1c.ips

DMK7CYX	DI	DMK7CYX
DMK7CYX	DN	Vadimezan
DMK7CYX	MI	DEJGDUW
DMK7CYX	MN	Cytochrome P450 1A2 (CYP1A2)
DMK7CYX	MT	DME
DMK7CYX	MA	Metabolism
DMK7CYX	RN	Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. Biochem Pharmacol. 2003 Jun 1;65(11):1853-65.
DMK7CYX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12781337

DMK7CYX	DI	DMK7CYX
DMK7CYX	DN	Vadimezan
DMK7CYX	MI	TTSXVID
DMK7CYX	MN	Nuclear factor NF-kappa-B (NFKB)
DMK7CYX	MT	DTT
DMK7CYX	MA	Modulator
DMK7CYX	RN	Auckland Cancer Society Research Centre report
DMK7CYX	RU	https://www.fmhs.auckland.ac.nz/en/sms/about/our-departments/oncology/cancer-trials-nz/trials-and-research-projects/closed/asa404.html

DMK7CYX	DI	DMK7CYX
DMK7CYX	DN	Vadimezan
DMK7CYX	MI	DE85D2P
DMK7CYX	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMK7CYX	MT	DME
DMK7CYX	MA	Metabolism
DMK7CYX	RN	Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation. Drug Metab Rev. 2002 Nov;34(4):751-90.
DMK7CYX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12487149

DMK7CYX	DI	DMK7CYX
DMK7CYX	DN	Vadimezan
DMK7CYX	MI	DEB3CV1
DMK7CYX	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMK7CYX	MT	DME
DMK7CYX	MA	Metabolism
DMK7CYX	RN	Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. Biochem Pharmacol. 2003 Jun 1;65(11):1853-65.
DMK7CYX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12781337

DMIKH67	DI	DMIKH67
DMIKH67	DN	Valetizumab
DMIKH67	MI	TTMSB0A
DMIKH67	MN	Integrin alpha-2/beta-1 (ITGA2/B1)
DMIKH67	MT	DTT
DMIKH67	RN	Sulfonamide inhibitors of alpha2beta1 integrin reveal the essential role of collagen receptors in in vivo models of inflammation. Pharmacol Res Perspect. 2015 June; 3(3): e00146.
DMIKH67	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492762/

DMAEB9O	DI	DMAEB9O
DMAEB9O	DN	Valomaciclovir stearate
DMAEB9O	MI	TTIU7X1
DMAEB9O	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMAEB9O	MT	DTT
DMAEB9O	MA	Modulator
DMAEB9O	RN	Progress in the Development of New Therapies for Herpesvirus Infections. Curr Opin Virol. 2011 December 1; 1(6): 548-554.
DMAEB9O	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3230035/

DMFWZ2U	DI	DMFWZ2U
DMFWZ2U	DN	Valopicitabine dihydrochloride
DMFWZ2U	MI	TTMVBWH
DMFWZ2U	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMFWZ2U	MT	DTT
DMFWZ2U	MA	Modulator
DMFWZ2U	RN	Valopicitabine dihydrochloride:a specific polymerase inhibitor of hepatitis C virus. Curr Opin Investig Drugs. 2007 Feb;8(2):150-8.
DMFWZ2U	RU	https://pubmed.ncbi.nlm.nih.gov/17328231

DMCF5E0	DI	DMCF5E0
DMCF5E0	DN	Vaniprevir
DMCF5E0	MI	TT5FNQT
DMCF5E0	MN	Human immunodeficiency virus Protease (HIV PR)
DMCF5E0	MT	DTT
DMCF5E0	MA	Inhibitor
DMCF5E0	RN	Clinical pipeline report, company report or official report of Merck (2011).
DMCF5E0	RU	http://www.merck.com/index.html

DMNFVKC	DI	DMNFVKC
DMNFVKC	DN	Vapitadine
DMNFVKC	MI	TTTIBOJ
DMNFVKC	MN	Histamine H1 receptor (H1R)
DMNFVKC	MT	DTT
DMNFVKC	MA	Antagonist
DMNFVKC	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020866)
DMNFVKC	RU	http://adisinsight.springer.com/drugs/800020866

DMQSC5O	DI	DMQSC5O
DMQSC5O	DN	Varlilumab
DMQSC5O	MI	TTDO1MV
DMQSC5O	MN	T-cell activation antigen CD27 (CD27)
DMQSC5O	MT	DTT
DMQSC5O	MA	Inhibitor
DMQSC5O	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQSC5O	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMKU93J	DI	DMKU93J
DMKU93J	DN	VAS-203
DMKU93J	MI	TTCM4B3
DMKU93J	MN	Nitric-oxide synthase endothelial (NOS3)
DMKU93J	MT	DTT
DMKU93J	MA	Inhibitor
DMKU93J	RN	Nitric oxide synthase inhibition with the antipterin VAS203 improves outcome in moderate and severe traumatic brain injury: a placebo-controlled randomized Phase IIa trial (NOSTRA). J Neurotrauma. 2014 Oct 1;31(19):1599-606.
DMKU93J	RU	https://pubmed.ncbi.nlm.nih.gov/24831445

DMRJ5LP	DI	DMRJ5LP
DMRJ5LP	DN	Vasoactive intestinal peptide
DMRJ5LP	MI	TTCL30I
DMRJ5LP	MN	Vasoactive intestinal polypeptide receptor 1 (VIPR1)
DMRJ5LP	MT	DTT
DMRJ5LP	MA	Antagonist
DMRJ5LP	RN	Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
DMRJ5LP	RU	https://pubmed.ncbi.nlm.nih.gov/17064221

DMY0UEQ	DI	DMY0UEQ
DMY0UEQ	DN	VATALANIB
DMY0UEQ	MI	TTGKNB4
DMY0UEQ	MN	Epidermal growth factor receptor (EGFR)
DMY0UEQ	MT	DTT
DMY0UEQ	MA	Inhibitor
DMY0UEQ	RN	Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cyst... Bioorg Med Chem. 2007 Jun 1;15(11):3635-48.
DMY0UEQ	RU	https://pubmed.ncbi.nlm.nih.gov/17416531

DMY0UEQ	DI	DMY0UEQ
DMY0UEQ	DN	VATALANIB
DMY0UEQ	MI	TTUTJGQ
DMY0UEQ	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMY0UEQ	MT	DTT
DMY0UEQ	MA	Inhibitor
DMY0UEQ	RN	Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cyst... Bioorg Med Chem. 2007 Jun 1;15(11):3635-48.
DMY0UEQ	RU	https://pubmed.ncbi.nlm.nih.gov/17416531

DMY0UEQ	DI	DMY0UEQ
DMY0UEQ	DN	VATALANIB
DMY0UEQ	MI	TTDCBX5
DMY0UEQ	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DMY0UEQ	MT	DTT
DMY0UEQ	MA	Inhibitor
DMY0UEQ	RN	Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9.
DMY0UEQ	RU	https://pubmed.ncbi.nlm.nih.gov/15743202

DMY0UEQ	DI	DMY0UEQ
DMY0UEQ	DN	VATALANIB
DMY0UEQ	MI	TT1VAUK
DMY0UEQ	MN	VEGFR1 messenger RNA (VEGFR1 mRNA)
DMY0UEQ	MT	DTT
DMY0UEQ	MA	Inhibitor
DMY0UEQ	RN	Inhibitors of VEGF receptors-1 and -2 based on the 2-((pyridin-4-yl)ethyl)pyridine template. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1913-9.
DMY0UEQ	RU	https://pubmed.ncbi.nlm.nih.gov/16460936

DM3V7QO	DI	DM3V7QO
DM3V7QO	DN	Vatelizumab
DM3V7QO	MI	TTMSB0A
DM3V7QO	MN	Integrin alpha-2/beta-1 (ITGA2/B1)
DM3V7QO	MT	DTT
DM3V7QO	RN	Sulfonamide inhibitors of alpha2beta1 integrin reveal the essential role of collagen receptors in in vivo models of inflammation. Pharmacol Res Perspect. 2015 June; 3(3): e00146.
DM3V7QO	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492762/

DML2CPW	DI	DML2CPW
DML2CPW	DN	VAY736
DML2CPW	MI	TT7NJSE
DML2CPW	MN	B-cell-activating factor receptor (TNFRSF13C)
DML2CPW	MT	DTT
DML2CPW	RN	National Cancer Institute Drug Dictionary (drug id 762784).
DML2CPW	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=762784

DM0YWQ4	DI	DM0YWQ4
DM0YWQ4	DN	VB 1953
DM0YWQ4	MI	TTN6J5F
DM0YWQ4	MN	Bacterial DNA gyrase (Bact gyrase)
DM0YWQ4	MT	DTT
DM0YWQ4	MA	Inhibitor
DM0YWQ4	RN	Clinical pipeline report, company report or official report of Vyome Therapeutics.
DM0YWQ4	RU	https://www.vyometx.com/platform-strategy.html

DM0YWQ4	DI	DM0YWQ4
DM0YWQ4	DN	VB 1953
DM0YWQ4	MI	TTFK8YB
DM0YWQ4	MN	Bacterial DNA topoisomerase 4A (Bact parC)
DM0YWQ4	MT	DTT
DM0YWQ4	MA	Inhibitor
DM0YWQ4	RN	Clinical pipeline report, company report or official report of Vyome Therapeutics.
DM0YWQ4	RU	https://www.vyometx.com/platform-strategy.html

DM047HI	DI	DM047HI
DM047HI	DN	VBP15
DM047HI	MI	TTOZRK6
DM047HI	MN	Glucocorticoid receptor messenger RNA (GCR mRNA)
DM047HI	MT	DTT
DM047HI	MA	Agonist
DM047HI	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM047HI	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMAJ85O	DI	DMAJ85O
DMAJ85O	DN	VDA-1102
DMAJ85O	MI	TTK02H8
DMAJ85O	MN	Hexokinase-2 (HK2)
DMAJ85O	MT	DTT
DMAJ85O	MA	Modulator
DMAJ85O	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMAJ85O	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DME6I03	DI	DME6I03
DME6I03	DN	VDA-1102
DME6I03	MI	TTJLNAW
DME6I03	MN	Tissue kallikrein (KLK2)
DME6I03	MT	DTT
DME6I03	MA	Modulator
DME6I03	RN	Clinical pipeline report, company report or official report of Vidac Pharma.
DME6I03	RU	http://www.vidacpharma.com/vda-1102-iv-vidac-pharma

DME6I03	DI	DME6I03
DME6I03	DN	VDA-1102
DME6I03	MI	TTPZI04
DME6I03	MN	Voltage-dependent anion channel (VDAC)
DME6I03	MT	DTT
DME6I03	MA	Modulator
DME6I03	RN	Clinical pipeline report, company report or official report of Vidac Pharma.
DME6I03	RU	http://www.vidacpharma.com/vda-1102-iv-vidac-pharma

DMAJ85O	DI	DMAJ85O
DMAJ85O	DN	VDA-1102
DMAJ85O	MI	TTAMKGB
DMAJ85O	MN	Voltage-dependent anion-selective channel 1 (VDAC1)
DMAJ85O	MT	DTT
DMAJ85O	MA	Modulator
DMAJ85O	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMAJ85O	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM5BL4C	DI	DM5BL4C
DM5BL4C	DN	Veltuzumab
DM5BL4C	MI	TTUE541
DM5BL4C	MN	Leukocyte surface antigen Leu-16 (CD20)
DM5BL4C	MT	DTT
DM5BL4C	MA	Modulator
DM5BL4C	RN	Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura. Curr Opin Mol Ther. 2009 Apr;11(2):200-7.
DM5BL4C	RU	https://pubmed.ncbi.nlm.nih.gov/19330725

DMLPEZS	DI	DMLPEZS
DMLPEZS	DN	Venglustat
DMLPEZS	MI	TTPHEX3
DMLPEZS	MN	Ceramide glucosyltransferase (UGCG)
DMLPEZS	MT	DTT
DMLPEZS	MA	Inhibitor
DMLPEZS	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMLPEZS	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMFLZPC	DI	DMFLZPC
DMFLZPC	DN	VER 50589
DMFLZPC	MI	TT78R5H
DMFLZPC	MN	Heat shock protein 90 alpha (HSP90A)
DMFLZPC	MT	DTT
DMFLZPC	MA	Inhibitor
DMFLZPC	RN	Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008 Oct;8(7):761-82.
DMFLZPC	RU	https://pubmed.ncbi.nlm.nih.gov/18855578

DM104SP	DI	DM104SP
DM104SP	DN	Vericigiuat
DM104SP	MI	TTLBYH1
DM104SP	MN	Guanylate cyclase soluble beta-1 (GUCY1B1)
DM104SP	MT	DTT
DM104SP	MA	Modulator
DM104SP	RN	Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES). Eur J Heart Fail. 2014 Sep;16(9):1026-38.
DM104SP	RU	https://pubmed.ncbi.nlm.nih.gov/25056511

DMBQC3L	DI	DMBQC3L
DMBQC3L	DN	Verubulin
DMBQC3L	MI	TTYFKSZ
DMBQC3L	MN	Tubulin beta (TUBB)
DMBQC3L	MT	DTT
DMBQC3L	MA	Modulator
DMBQC3L	RN	Effects of the tumor-vasculature-disrupting agent verubulin and two heteroaryl analogues on cancer cells, endothelial cells, and blood vessels.ChemMedChem.2014 Apr;9(4):847-54.
DMBQC3L	RU	https://www.ncbi.nlm.nih.gov/pubmed/24678059

DM0POWG	DI	DM0POWG
DM0POWG	DN	Vidofludimus
DM0POWG	MI	TTLVP78
DM0POWG	MN	Dihydroorotate dehydrogenase (DHODH)
DM0POWG	MT	DTT
DM0POWG	MA	Modulator
DM0POWG	RN	Company report (4SC)
DM0POWG	RU	http://www.4sc.de/product-pipeline/clinical/vidofludimus

DME7VZD	DI	DME7VZD
DME7VZD	DN	Vilaprisan
DME7VZD	MI	DE4LYSA
DME7VZD	MN	Cytochrome P450 3A4 (CYP3A4)
DME7VZD	MT	DME
DME7VZD	MA	Metabolism
DME7VZD	RN	Characterization of the pharmacokinetics of vilaprisan: bioavailability, excretion, biotransformation, and drug-drug interaction potential. Clin Pharmacokinet. 2018 Aug;57(8):1001-1015.
DME7VZD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29330782

DME7VZD	DI	DME7VZD
DME7VZD	DN	Vilaprisan
DME7VZD	MI	TTUV8G9
DME7VZD	MN	Progesterone receptor (PGR)
DME7VZD	MT	DTT
DME7VZD	MA	Antagonist
DME7VZD	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033939)
DME7VZD	RU	http://adisinsight.springer.com/drugs/800033939

DME7VZD	DI	DME7VZD
DME7VZD	DN	Vilaprisan
DME7VZD	MI	DE4G629
DME7VZD	MN	Succinic semialdehyde reductase (AKR7A2)
DME7VZD	MT	DME
DME7VZD	MA	Metabolism
DME7VZD	RN	Characterization of the pharmacokinetics of vilaprisan: bioavailability, excretion, biotransformation, and drug-drug interaction potential. Clin Pharmacokinet. 2018 Aug;57(8):1001-1015.
DME7VZD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29330782

DM2X0SP	DI	DM2X0SP
DM2X0SP	DN	VIR-2218
DM2X0SP	MI	TTINUYD
DM2X0SP	MN	Hepatitis B virus Large envelope protein (HBV S)
DM2X0SP	MT	DTT
DM2X0SP	MA	Inhibitor
DM2X0SP	RN	Clinical pipeline report, company report or official report of Vir Biotechnology.
DM2X0SP	RU	https://www.vir.bio/pipeline/

DMEXMV5	DI	DMEXMV5
DMEXMV5	DN	Virexxa
DMEXMV5	MI	TTUV8G9
DMEXMV5	MN	Progesterone receptor (PGR)
DMEXMV5	MT	DTT
DMEXMV5	MA	Inducer
DMEXMV5	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 627).
DMEXMV5	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=627

DM1G6ME	DI	DM1G6ME
DM1G6ME	DN	VIS410
DM1G6ME	MI	TTF4CAM
DM1G6ME	MN	Influenza Hemagglutinin (Influ HA)
DM1G6ME	MT	DTT
DM1G6ME	MA	Inhibitor
DM1G6ME	RN	Clinical pipeline report, company report or official report of Visterra.
DM1G6ME	RU	http://www.visterrainc.com/#pipeline

DMY5NUR	DI	DMY5NUR
DMY5NUR	DN	VK-2809
DMY5NUR	MI	TTGER3L
DMY5NUR	MN	Thyroid hormone receptor beta (THRB)
DMY5NUR	MT	DTT
DMY5NUR	MA	Agonist
DMY5NUR	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMY5NUR	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMLT94F	DI	DMLT94F
DMLT94F	DN	VLS-101
DMLT94F	MI	TTDEJAU
DMLT94F	MN	Neurotrophic tyrosine kinase ROR1 (ROR1)
DMLT94F	MT	DTT
DMLT94F	RN	Clinical pipeline report, company report or official report of VelosBio.
DMLT94F	RU	https://velosbio.com/our-science/pipeline

DM4O17U	DI	DM4O17U
DM4O17U	DN	VLTS-589
DM4O17U	MI	TT69TQN
DM4O17U	MN	Integrin alpha-V/beta-3 (ITGAV/B3)
DM4O17U	MT	DTT
DM4O17U	MA	Modulator
DM4O17U	RN	AbbVie Licenses Phase II-Ready Antibody Programme to Receptos for Development in Eosinophilic Oesophagitis. 2013(4), Page 35.
DM4O17U	RU	http://ojs.pharmadeals.net:5555/index.php/pdr/article/view/cr1914/html

DM9KNJT	DI	DM9KNJT
DM9KNJT	DN	Vobarilizumab
DM9KNJT	MI	TT0E5SK
DM9KNJT	MN	Interleukin 6 receptor (IL6R)
DM9KNJT	MT	DTT
DM9KNJT	MA	Inhibitor
DM9KNJT	RN	Clinical pipeline report, company report or official report of Ablynx.
DM9KNJT	RU	https://www.ablynx.com/uploads/data/files/160706%20alx-0061%20c202%20webcast_final.pdf

DM9KNJT	DI	DM9KNJT
DM9KNJT	DN	Vobarilizumab
DM9KNJT	MI	TTFNGC9
DM9KNJT	MN	Serum albumin (ALB)
DM9KNJT	MT	DTT
DM9KNJT	MA	Inhibitor
DM9KNJT	RN	Clinical pipeline report, company report or official report of Ablynx.
DM9KNJT	RU	https://www.ablynx.com/uploads/data/files/160706%20alx-0061%20c202%20webcast_final.pdf

DMQMYP5	DI	DMQMYP5
DMQMYP5	DN	VOFOPITANT HYDROCHLORIDE
DMQMYP5	MI	TTZPO1L
DMQMYP5	MN	Substance-P receptor (TACR1)
DMQMYP5	MT	DTT
DMQMYP5	MA	Antagonist
DMQMYP5	RN	Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenicchemotherapy: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009 Jun;10(6):549-58.
DMQMYP5	RU	https://pubmed.ncbi.nlm.nih.gov/19428297

DMNQG24	DI	DMNQG24
DMNQG24	DN	Volociximab
DMNQG24	MI	TTH4QIS
DMNQG24	MN	Integrin alpha-5/beta-1 (ITGA5/B1)
DMNQG24	MT	DTT
DMNQG24	RN	Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol. 2006;5(4):273-86.
DMNQG24	RU	https://pubmed.ncbi.nlm.nih.gov/17024968

DMIM1U9	DI	DMIM1U9
DMIM1U9	DN	Vorolanib
DMIM1U9	MI	TTI2WET
DMIM1U9	MN	Platelet-derived growth factor receptor (PDGFR)
DMIM1U9	MT	DTT
DMIM1U9	MA	Inhibitor
DMIM1U9	RN	Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial. Chin J Cancer Res. 2021 Feb 28;33(1):103-114.
DMIM1U9	RU	https://pubmed.ncbi.nlm.nih.gov/33707933

DMIM1U9	DI	DMIM1U9
DMIM1U9	DN	Vorolanib
DMIM1U9	MI	TTVJ1D8
DMIM1U9	MN	Vascular endothelial growth factor receptor (VEGFR)
DMIM1U9	MT	DTT
DMIM1U9	MA	Inhibitor
DMIM1U9	RN	Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial. Chin J Cancer Res. 2021 Feb 28;33(1):103-114.
DMIM1U9	RU	https://pubmed.ncbi.nlm.nih.gov/33707933

DMW4LTI	DI	DMW4LTI
DMW4LTI	DN	Votucalis
DMW4LTI	MI	TT7CXIM
DMW4LTI	MN	Histamine receptor (HR)
DMW4LTI	MT	DTT
DMW4LTI	MA	Antagonist
DMW4LTI	RN	CA patent application no. 520580, Histamine binding compounds for treatment method for disease conditions mediated by neutrophils.
DMW4LTI	RU	http://www.google.com.ar/patents/CA2520580A1?cl=en

DMUQZT4	DI	DMUQZT4
DMUQZT4	DN	VPI-2690B
DMUQZT4	MI	TTHRID2
DMUQZT4	MN	Insulin-like growth factor I receptor (IGF1R)
DMUQZT4	MT	DTT
DMUQZT4	MA	Antagonist
DMUQZT4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMUQZT4	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMHET8R	DI	DMHET8R
DMHET8R	DN	VRC-HIVDNA016-00-VP
DMHET8R	MI	TTUIFO6
DMHET8R	MN	Human immunodeficiency virus Adenovector Ad35 (HIV Ad35)
DMHET8R	MT	DTT
DMHET8R	RN	ClinicalTrials.gov (NCT00123968) Safety of and Immune Response to an HIV-1 Vaccine (VRC-HIVDNA016-00-VP) and a Vaccine Booster (VRC-HIVADV014-00-VP) in HIV Uninfected East African Adults. U.S. National Institutes of Health.
DMHET8R	RU	https://clinicaltrials.gov/ct2/show/NCT00123968

DMGBLI3	DI	DMGBLI3
DMGBLI3	DN	VS-6063
DMGBLI3	MI	TTON5IT
DMGBLI3	MN	Focal adhesion kinase 1 (FAK)
DMGBLI3	MT	DTT
DMGBLI3	MA	Inhibitor
DMGBLI3	RN	Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst. 2013 Oct 2;105(19):1485-95.
DMGBLI3	RU	https://pubmed.ncbi.nlm.nih.gov/24062525

DMY9ZGN	DI	DMY9ZGN
DMY9ZGN	DN	VT-111a
DMY9ZGN	MI	TTEMV5X
DMY9ZGN	MN	Serine protease unspecific (SP)
DMY9ZGN	MT	DTT
DMY9ZGN	MA	Modulator
DMY9ZGN	RN	Viral Serpin Therapeutics: From Concept to Clinic. Methods Enzymol. 2011; 499: 301-329.
DMY9ZGN	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3558843/

DMCGK9H	DI	DMCGK9H
DMCGK9H	DN	VT-1129
DMCGK9H	MI	TT3C1VN
DMCGK9H	MN	Enzyme unspecific (Enz)
DMCGK9H	MT	DTT
DMCGK9H	MA	Inhibitor
DMCGK9H	RN	The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme. Antimicrob Agents Chemother. 2014 Dec;58(12):7121-7.
DMCGK9H	RU	https://pubmed.ncbi.nlm.nih.gov/25224009

DMCGK9H	DI	DMCGK9H
DMCGK9H	DN	VT-1129
DMCGK9H	MI	TT67TDP
DMCGK9H	MN	Lanosterol 14-alpha demethylase (CYP51A1)
DMCGK9H	MT	DTT
DMCGK9H	MA	Inhibitor
DMCGK9H	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMCGK9H	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMNY3J0	DI	DMNY3J0
DMNY3J0	DN	VTB-38543
DMNY3J0	MI	TTXA6PH
DMNY3J0	MN	Oxysterols receptor LXR-beta (NR1H2)
DMNY3J0	MT	DTT
DMNY3J0	MA	Agonist
DMNY3J0	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMNY3J0	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMCA8G1	DI	DMCA8G1
DMCA8G1	DN	VTP-43742
DMCA8G1	MI	TTGV6LY
DMCA8G1	MN	Nuclear receptor ROR-gamma (RORG)
DMCA8G1	MT	DTT
DMCA8G1	MA	Inhibitor
DMCA8G1	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMCA8G1	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMN6J18	DI	DMN6J18
DMN6J18	DN	Vupanorsen
DMN6J18	MI	TT59GO7
DMN6J18	MN	ANGPTL3 messenger RNA (ANGPTL3 mRNA)
DMN6J18	MT	DTT
DMN6J18	MA	Inhibitor
DMN6J18	RN	Clinical pipeline report, company report or official report of Ionis Pharmaceuticals.
DMN6J18	RU	https://www.ionispharma.com/ionis-innovation/pipeline/

DM6BKG2	DI	DM6BKG2
DM6BKG2	DN	VVP-808
DM6BKG2	MI	TTCBFJO
DM6BKG2	MN	Insulin receptor (INSR)
DM6BKG2	MT	DTT
DM6BKG2	MA	Modulator
DM6BKG2	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800).
DM6BKG2	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800

DMDKWA3	DI	DMDKWA3
DMDKWA3	DN	Vx-001
DMDKWA3	MI	TTUJFD0
DMDKWA3	MN	Telomerase reverse transcriptase (TERT)
DMDKWA3	MT	DTT
DMDKWA3	RN	Clinical pipeline report, company report or official report of Vaxon-biotech.
DMDKWA3	RU	http://vaxon-biotech.com/

DMZ3FE8	DI	DMZ3FE8
DMZ3FE8	DN	VX-135
DMZ3FE8	MI	TTMVBWH
DMZ3FE8	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMZ3FE8	MT	DTT
DMZ3FE8	MA	Inhibitor
DMZ3FE8	RN	All-oral HCV therapies near approval. Nat Rev Drug Discov. 2013 Jun;12(6):409-11. 
DMZ3FE8	RU	https://pubmed.ncbi.nlm.nih.gov/23722330

DMLWM4G	DI	DMLWM4G
DMLWM4G	DN	VX-15
DMLWM4G	MI	TT5TKPM
DMLWM4G	MN	Neutral endopeptidase (MME)
DMLWM4G	MT	DTT
DMLWM4G	MA	Inhibitor
DMLWM4G	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMLWM4G	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMLWM4G	DI	DMLWM4G
DMLWM4G	DN	VX-15
DMLWM4G	MI	TT5UT28
DMLWM4G	MN	Semaphorin-4D (SEMA4D)
DMLWM4G	MT	DTT
DMLWM4G	RN	Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Soli... Clin Cancer Res. 2016 Feb 15;22(4):827-36.
DMLWM4G	RU	https://pubmed.ncbi.nlm.nih.gov/26446947

DMGDB21	DI	DMGDB21
DMGDB21	DN	VX-150
DMGDB21	MI	TT90XZ8
DMGDB21	MN	Voltage-gated sodium channel alpha Nav1.8 (SCN10A)
DMGDB21	MT	DTT
DMGDB21	MA	Inhibitor
DMGDB21	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMGDB21	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMO3U4W	DI	DMO3U4W
DMO3U4W	DN	VX-222
DMO3U4W	MI	TTMVBWH
DMO3U4W	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMO3U4W	MT	DTT
DMO3U4W	MA	Inhibitor
DMO3U4W	RN	2011 Pipeline of Vertex.
DMO3U4W	RU	http://www.vrtx.com/current-projects.html

DMSTHG1	DI	DMSTHG1
DMSTHG1	DN	VX-371
DMSTHG1	MI	TTQM7TE
DMSTHG1	MN	Amiloride-sensitive sodium channel (ENaC)
DMSTHG1	MT	DTT
DMSTHG1	MA	Inhibitor
DMSTHG1	RN	The in vitro effect of nebulised hypertonic saline on human bronchial epithelium. Eur Respir J. 2018 May 17;51(5):1702652.
DMSTHG1	RU	https://pubmed.ncbi.nlm.nih.gov/29599187

DM93YKJ	DI	DM93YKJ
DM93YKJ	DN	VX-680
DM93YKJ	MI	TTPS3C0
DM93YKJ	MN	Aurora kinase A (AURKA)
DM93YKJ	MT	DTT
DM93YKJ	MA	Inhibitor
DM93YKJ	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DM93YKJ	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DM93YKJ	DI	DM93YKJ
DM93YKJ	DN	VX-680
DM93YKJ	MI	TT5LS6T
DM93YKJ	MN	Aurora kinase B (AURKB)
DM93YKJ	MT	DTT
DM93YKJ	MA	Inhibitor
DM93YKJ	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DM93YKJ	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DM93YKJ	DI	DM93YKJ
DM93YKJ	DN	VX-680
DM93YKJ	MI	TT860QF
DM93YKJ	MN	LCK tyrosine protein kinase (LCK)
DM93YKJ	MT	DTT
DM93YKJ	MA	Inhibitor
DM93YKJ	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DM93YKJ	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMJAEG6	DI	DMJAEG6
DMJAEG6	DN	VX-745
DMJAEG6	MI	TTYT93M
DMJAEG6	MN	MAP kinase p38 (MAPK12)
DMJAEG6	MT	DTT
DMJAEG6	MA	Inhibitor
DMJAEG6	RN	P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis. J Inflamm (Lond). 2008 Dec 4;5:22.
DMJAEG6	RU	https://pubmed.ncbi.nlm.nih.gov/19055838

DMJAEG6	DI	DMJAEG6
DMJAEG6	DN	VX-745
DMJAEG6	MI	TTQBR95
DMJAEG6	MN	Stress-activated protein kinase 2a (p38 alpha)
DMJAEG6	MT	DTT
DMJAEG6	MA	Inhibitor
DMJAEG6	RN	Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
DMJAEG6	RU	https://pubmed.ncbi.nlm.nih.gov/11804650

DMJAEG6	DI	DMJAEG6
DMJAEG6	DN	VX-745
DMJAEG6	MI	TT73U6C
DMJAEG6	MN	Stress-activated protein kinase 2b (p38 beta)
DMJAEG6	MT	DTT
DMJAEG6	MA	Inhibitor
DMJAEG6	RN	Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
DMJAEG6	RU	https://pubmed.ncbi.nlm.nih.gov/11804650

DMJUSM8	DI	DMJUSM8
DMJUSM8	DN	VX-759
DMJUSM8	MI	TTMVBWH
DMJUSM8	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMJUSM8	MT	DTT
DMJUSM8	MA	Inhibitor
DMJUSM8	RN	2011 Pipeline of Vertex.
DMJUSM8	RU	http://www.vrtx.com/current-projects.html

DME321B	DI	DME321B
DME321B	DN	VX-944
DME321B	MI	TTCAQMW
DME321B	MN	Inosine-5'-monophosphate dehydrogenase (IMPDH)
DME321B	MT	DTT
DME321B	MA	Inhibitor
DME321B	RN	Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway. Oncogene. 2005 Sep 1;24(38):5888-96.
DME321B	RU	https://pubmed.ncbi.nlm.nih.gov/15940263

DME321B	DI	DME321B
DME321B	DN	VX-944
DME321B	MI	TTL7C8Q
DME321B	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DME321B	MT	DTT
DME321B	MA	Inhibitor
DME321B	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DME321B	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DMPSBTL	DI	DMPSBTL
DMPSBTL	DN	VY-AADC
DMPSBTL	MI	TTN451K
DMPSBTL	MN	Aromatic-L-amino-acid decarboxylase (DDC)
DMPSBTL	MT	DTT
DMPSBTL	MA	Replacement
DMPSBTL	RN	Clinical pipeline report, company report or official report of Voyager Therapeutics.
DMPSBTL	RU	https://www.voyagertherapeutics.com/our-approach-programs/clinical-trials/

DMH6XJG	DI	DMH6XJG
DMH6XJG	DN	WCK-2349
DMH6XJG	MI	TTIXTO3
DMH6XJG	MN	Staphylococcus Topoisomerase IV (Stap-coc parC)
DMH6XJG	MT	DTT
DMH6XJG	MA	Modulator
DMH6XJG	RN	DOI: 10.1038/ja.2013.86
DMH6XJG	RU	http://www.nature.com/ja/journal/v66/n10/fig_tab/ja201386t3.html

DMVQARP	DI	DMVQARP
DMVQARP	DN	WCK-771
DMVQARP	MI	TTN6J5F
DMVQARP	MN	Bacterial DNA gyrase (Bact gyrase)
DMVQARP	MT	DTT
DMVQARP	MA	Modulator
DMVQARP	RN	Antistaphylococcal Activity of WCK 771, a Tricyclic Fluoroquinolone, in Animal Infection Models
DMVQARP	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC529196

DMVQARP	DI	DMVQARP
DMVQARP	DN	WCK-771
DMVQARP	MI	TTIXTO3
DMVQARP	MN	Staphylococcus Topoisomerase IV (Stap-coc parC)
DMVQARP	MT	DTT
DMVQARP	MA	Modulator
DMVQARP	RN	Antistaphylococcal Activity of WCK 771, a Tricyclic Fluoroquinolone, in Animal Infection Models
DMVQARP	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC529196

DMZ67Q0	DI	DMZ67Q0
DMZ67Q0	DN	WT1 peptide vaccine
DMZ67Q0	MI	TTZ8UT4
DMZ67Q0	MN	Wilms tumor protein (WT1)
DMZ67Q0	MT	DTT
DMZ67Q0	RN	Wilms' tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3beta sequence associated with remission in one patient is detectable in other vaccinated patients. Cancer ImmunolImmunother. 2012 Mar;61(3):313-22.
DMZ67Q0	RU	https://pubmed.ncbi.nlm.nih.gov/21898091

DMNFZYE	DI	DMNFZYE
DMNFZYE	DN	WT1-targeted autologous dendritic cell vaccine
DMNFZYE	MI	TTZ8UT4
DMNFZYE	MN	Wilms tumor protein (WT1)
DMNFZYE	MT	DTT
DMNFZYE	RN	ClinicalTrials.gov (NCT01686334) Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission. U.S. National Institutes of Health.
DMNFZYE	RU	https://clinicaltrials.gov/ct2/show/NCT01686334

DMFVNSB	DI	DMFVNSB
DMFVNSB	DN	WY-50295-tromethamine
DMFVNSB	MI	TT2J34L
DMFVNSB	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMFVNSB	MT	DTT
DMFVNSB	MA	Inhibitor
DMFVNSB	RN	WY-50295 tromethamine: a 5-lipoxygenase inhibitor without activity in human whole blood. Prostaglandins Leukot Essent Fatty Acids. 1999 Jan;60(1):31-41.
DMFVNSB	RU	https://pubmed.ncbi.nlm.nih.gov/10319915

DMW1NKO	DI	DMW1NKO
DMW1NKO	DN	X-82
DMW1NKO	MI	TTI2WET
DMW1NKO	MN	Platelet-derived growth factor receptor (PDGFR)
DMW1NKO	MT	DTT
DMW1NKO	MA	Modulator
DMW1NKO	RN	National Cancer Institute Drug Dictionary (drug id 695817).
DMW1NKO	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=695817

DMW1NKO	DI	DMW1NKO
DMW1NKO	DN	X-82
DMW1NKO	MI	TTVJ1D8
DMW1NKO	MN	Vascular endothelial growth factor receptor (VEGFR)
DMW1NKO	MT	DTT
DMW1NKO	MA	Inhibitor
DMW1NKO	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMW1NKO	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMW1NKO	DI	DMW1NKO
DMW1NKO	DN	X-82
DMW1NKO	MI	TT2Q6G1
DMW1NKO	MN	Vascular endothelial growth factor receptor 1 (FLT-1)
DMW1NKO	MT	DTT
DMW1NKO	MA	Modulator
DMW1NKO	RN	National Cancer Institute Drug Dictionary (drug id 695817).
DMW1NKO	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=695817

DMXG5WU	DI	DMXG5WU
DMXG5WU	DN	Xanomeline tartrate
DMXG5WU	MI	TTZ9SOR
DMXG5WU	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMXG5WU	MT	DTT
DMXG5WU	MA	Agonist
DMXG5WU	RN	Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur J Pharmacol. 2009 Mar 1;605(1-3):53-6.
DMXG5WU	RU	https://pubmed.ncbi.nlm.nih.gov/19168056

DM0NFMS	DI	DM0NFMS
DM0NFMS	DN	XEN-2174
DM0NFMS	MI	TTAWNKZ
DM0NFMS	MN	Norepinephrine transporter (NET)
DM0NFMS	MT	DTT
DM0NFMS	MA	Inhibitor
DM0NFMS	RN	Spinal noradrenaline transporter inhibition by reboxetine and Xen2174 reduces tactile hypersensitivity after surgery in rats. Pain. 2005 Feb;113(3):271-6.
DM0NFMS	RU	https://pubmed.ncbi.nlm.nih.gov/15661433

DMR69CG	DI	DMR69CG
DMR69CG	DN	XEN-402
DMR69CG	MI	TT4G2JS
DMR69CG	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DMR69CG	MT	DTT
DMR69CG	MA	Inhibitor
DMR69CG	RN	Treatment of Na(v)1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker. Pain. 2012 Jan;153(1):80-5.
DMR69CG	RU	https://pubmed.ncbi.nlm.nih.gov/22035805

DMG7PDY	DI	DMG7PDY
DMG7PDY	DN	XEN-D0501
DMG7PDY	MI	TTMI6F5
DMG7PDY	MN	Transient receptor potential cation channel V1 (TRPV1)
DMG7PDY	MT	DTT
DMG7PDY	MA	Antagonist
DMG7PDY	RN	An investigation of the safety and pharmacokinetics of the novel TRPV1 antagonist XEN-D0501 in healthy subjects. Br J Clin Pharmacol. 2011 Dec;72(6):921-31.
DMG7PDY	RU	https://pubmed.ncbi.nlm.nih.gov/21676011

DM4ZIDH	DI	DM4ZIDH
DM4ZIDH	DN	Xentuzumab
DM4ZIDH	MI	TTT6LOU
DM4ZIDH	MN	Insulin-like growth factor-I (IGF1)
DM4ZIDH	MT	DTT
DM4ZIDH	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM4ZIDH	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM4ZIDH	DI	DM4ZIDH
DM4ZIDH	DN	Xentuzumab
DM4ZIDH	MI	TTE8WGO
DM4ZIDH	MN	Insulin-like growth factor-II (IGF2)
DM4ZIDH	MT	DTT
DM4ZIDH	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM4ZIDH	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMML7BE	DI	DMML7BE
DMML7BE	DN	Xl147
DMML7BE	MI	DEAWHS8
DMML7BE	MN	Aldehyde oxidase (AOX1)
DMML7BE	MT	DME
DMML7BE	MA	Metabolism
DMML7BE	RN	Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes. Drug Metab Dispos. 2012 Feb;40(2):267-75.
DMML7BE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22031625

DMML7BE	DI	DMML7BE
DMML7BE	DN	Xl147
DMML7BE	MI	TTHBTOP
DMML7BE	MN	PI3-kinase gamma (PIK3CG)
DMML7BE	MT	DTT
DMML7BE	MA	Modulator
DMML7BE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2156).
DMML7BE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2156

DMMHX9K	DI	DMMHX9K
DMMHX9K	DN	XL-820
DMMHX9K	MI	TT8FYO9
DMMHX9K	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMMHX9K	MT	DTT
DMMHX9K	MA	Inhibitor
DMMHX9K	RN	National Cancer Institute Drug Dictionary (drug id 452042).
DMMHX9K	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=452042

DMMHX9K	DI	DMMHX9K
DMMHX9K	DN	XL-820
DMMHX9K	MI	TTI7421
DMMHX9K	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMMHX9K	MT	DTT
DMMHX9K	MA	Inhibitor
DMMHX9K	RN	National Cancer Institute Drug Dictionary (drug id 452042).
DMMHX9K	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=452042

DMMHX9K	DI	DMMHX9K
DMMHX9K	DN	XL-820
DMMHX9K	MI	TTX41N9
DMMHX9K	MN	Tyrosine-protein kinase Kit (KIT)
DMMHX9K	MT	DTT
DMMHX9K	MA	Inhibitor
DMMHX9K	RN	National Cancer Institute Drug Dictionary (drug id 452042).
DMMHX9K	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=452042

DMMHX9K	DI	DMMHX9K
DMMHX9K	DN	XL-820
DMMHX9K	MI	TTVJ1D8
DMMHX9K	MN	Vascular endothelial growth factor receptor (VEGFR)
DMMHX9K	MT	DTT
DMMHX9K	MA	Inhibitor
DMMHX9K	RN	National Cancer Institute Drug Dictionary (drug id 452042).
DMMHX9K	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=452042

DMHJTR2	DI	DMHJTR2
DMHJTR2	DN	XL880
DMHJTR2	MI	TTNDSF4
DMHJTR2	MN	Proto-oncogene c-Met (MET)
DMHJTR2	MT	DTT
DMHJTR2	MA	Modulator
DMHJTR2	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMHJTR2	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMHJTR2	DI	DMHJTR2
DMHJTR2	DN	XL880
DMHJTR2	MI	TTUTJGQ
DMHJTR2	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMHJTR2	MT	DTT
DMHJTR2	MA	Modulator
DMHJTR2	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMHJTR2	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMVB8EO	DI	DMVB8EO
DMVB8EO	DN	XLCART001
DMVB8EO	MI	TTW640A
DMVB8EO	MN	B-lymphocyte surface antigen B4 (CD19)
DMVB8EO	MT	DTT
DMVB8EO	MA	CAR-T-Cell-Therapy
DMVB8EO	RN	ClinicalTrials.gov (NCT03598179) XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects
DMVB8EO	RU	https://clinicaltrials.gov/ct2/show/NCT03598179

DMLIPY1	DI	DMLIPY1
DMLIPY1	DN	Xmab 5871
DMLIPY1	MI	TTW640A
DMLIPY1	MN	B-lymphocyte surface antigen B4 (CD19)
DMLIPY1	MT	DTT
DMLIPY1	MA	Modulator
DMLIPY1	RN	Suppression of rheumatoid arthritis B cells by XmAb5871, an anti-CD19 antibody that coengages B cell antigen receptor complex and Fc receptor IIb inhibitory receptor.Arthritis Rheumatol.2014 May;66(5):1153-64.
DMLIPY1	RU	https://www.ncbi.nlm.nih.gov/pubmed/24782179

DMLIPY1	DI	DMLIPY1
DMLIPY1	DN	Xmab 5871
DMLIPY1	MI	TT5RWKQ
DMLIPY1	MN	Immunoglobulin gamma Fc receptor IIB (FCGR2B)
DMLIPY1	MT	DTT
DMLIPY1	MA	Modulator
DMLIPY1	RN	CD19 as an attractive target for antibody-based therapy. MAbs. 2012 Sep-Oct;4(5):571-7.
DMLIPY1	RU	https://pubmed.ncbi.nlm.nih.gov/22820352

DMWEB07	DI	DMWEB07
DMWEB07	DN	XOMA-629
DMWEB07	MI	TTXCSDR
DMWEB07	MN	Protein bactericidal permeability-increasing (BPI)
DMWEB07	MT	DTT
DMWEB07	MA	Inhibitor
DMWEB07	RN	Modulating immunity as a therapy for bacterial infections. Nat Rev Microbiol. 2012 Mar 16;10(4):243-54.
DMWEB07	RU	https://pubmed.ncbi.nlm.nih.gov/22421877

DM8N3ZQ	DI	DM8N3ZQ
DM8N3ZQ	DN	XP-21279
DM8N3ZQ	MI	TTEX248
DM8N3ZQ	MN	Dopamine D2 receptor (D2R)
DM8N3ZQ	MT	DTT
DM8N3ZQ	MA	Agonist
DM8N3ZQ	RN	Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease. Mov Disord. 2014 Jan;29(1):75-82.
DM8N3ZQ	RU	https://pubmed.ncbi.nlm.nih.gov/24339234

DMELUYN	DI	DMELUYN
DMELUYN	DN	XP-23829
DMELUYN	MI	TTSXVID
DMELUYN	MN	Nuclear factor NF-kappa-B (NFKB)
DMELUYN	MT	DTT
DMELUYN	MA	Inhibitor
DMELUYN	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036491)
DMELUYN	RU	http://adisinsight.springer.com/drugs/800036491

DMOKUA5	DI	DMOKUA5
DMOKUA5	DN	XR-5000
DMOKUA5	MI	TTGTQHC
DMOKUA5	MN	DNA topoisomerase I (TOP1)
DMOKUA5	MT	DTT
DMOKUA5	MA	Modulator
DMOKUA5	RN	Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme. Ann Oncol. 2002 May;13(5):777-80.
DMOKUA5	RU	https://pubmed.ncbi.nlm.nih.gov/12075748

DMOKUA5	DI	DMOKUA5
DMOKUA5	DN	XR-5000
DMOKUA5	MI	TT0IHXV
DMOKUA5	MN	DNA topoisomerase II (TOP2)
DMOKUA5	MT	DTT
DMOKUA5	MA	Modulator
DMOKUA5	RN	Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme. Ann Oncol. 2002 May;13(5):777-80.
DMOKUA5	RU	https://pubmed.ncbi.nlm.nih.gov/12075748

DMPI6N0	DI	DMPI6N0
DMPI6N0	DN	XZK-monascus
DMPI6N0	MI	TTPADOQ
DMPI6N0	MN	HMG-CoA reductase (HMGCR)
DMPI6N0	MT	DTT
DMPI6N0	MA	Modulator
DMPI6N0	RN	NMR evaluation of total statin content and HMG-CoA reductase inhibition in red yeast rice (Monascus spp.) food supplements. Chin Med. 2012 Mar 22;7:8.
DMPI6N0	RU	https://pubmed.ncbi.nlm.nih.gov/22439629

DM54MAJ	DI	DM54MAJ
DM54MAJ	DN	YF-476
DM54MAJ	MI	TTVFO0U
DM54MAJ	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DM54MAJ	MT	DTT
DM54MAJ	MA	Inhibitor
DM54MAJ	RN	CCK-B receptor antagonist YF476 inhibits pancreatic enzyme secretion at a duodenal level in pigs. Scand J Gastroenterol. 2004 Sep;39(9):886-90.
DM54MAJ	RU	https://pubmed.ncbi.nlm.nih.gov/15513388

DMCHFB0	DI	DMCHFB0
DMCHFB0	DN	YH-4808
DMCHFB0	MI	TTLOKXP
DMCHFB0	MN	Gastric H(+)/K(+) ATPase (Proton pump)
DMCHFB0	MT	DTT
DMCHFB0	MA	Modulator
DMCHFB0	RN	Poor effectiveness of proton pump inhibitors in non-erosive reflux disease: the truth in the end! Neurogastroenterol Motil.2012 Aug;24(8):697-704.
DMCHFB0	RU	https://www.ncbi.nlm.nih.gov/pubmed/22783985

DM740LV	DI	DM740LV
DM740LV	DN	YKP-GI
DM740LV	MI	TT07C3Y
DM740LV	MN	5-HT 4 receptor (HTR4)
DM740LV	MT	DTT
DM740LV	MA	Agonist
DM740LV	RN	A randomized trial of 5-hydroxytryptamine4-receptor agonist, YKP10811, on colonic transit and bowel function in functional constipation. Clin Gastroenterol Hepatol. 2015 Apr;13(4):701-8.e1.
DM740LV	RU	https://pubmed.ncbi.nlm.nih.gov/25148765

DM5Q1W4	DI	DM5Q1W4
DM5Q1W4	DN	Ym155
DM5Q1W4	MI	DTT79CX
DM5Q1W4	MN	Organic cation transporter 1 (SLC22A1)
DM5Q1W4	MT	DTP
DM5Q1W4	MA	Substrate
DM5Q1W4	RN	Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant. Drug Metab Dispos. 2010 Jan;38(1):1-4.
DM5Q1W4	RU	http://www.ncbi.nlm.nih.gov/pubmed/19833842

DM5Q1W4	DI	DM5Q1W4
DM5Q1W4	DN	Ym155
DM5Q1W4	MI	DT9IDPW
DM5Q1W4	MN	Organic cation transporter 2 (SLC22A2)
DM5Q1W4	MT	DTP
DM5Q1W4	MA	Substrate
DM5Q1W4	RN	Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant. Drug Metab Dispos. 2010 Jan;38(1):1-4.
DM5Q1W4	RU	http://www.ncbi.nlm.nih.gov/pubmed/19833842

DMAZNVX	DI	DMAZNVX
DMAZNVX	DN	YM-264
DMAZNVX	MI	TTQL5VC
DMAZNVX	MN	Platelet-activating factor receptor (PTAFR)
DMAZNVX	MT	DTT
DMAZNVX	MA	Antagonist
DMAZNVX	RN	Effects of YM264, a novel PAF antagonist, on puromycin aminonucleoside-induced nephropathy in the rat. Biochem Biophys Res Commun. 1991 Apr 30;176(2):781-5.
DMAZNVX	RU	https://pubmed.ncbi.nlm.nih.gov/2025290

DMS7609	DI	DMS7609
DMS7609	DN	YM-358
DMS7609	MI	TT8DBY3
DMS7609	MN	Angiotensin II receptor type-1 (AGTR1)
DMS7609	MT	DTT
DMS7609	MA	Antagonist
DMS7609	RN	Effects of YM358, an angiotensin II type 1 (AT1) receptor antagonist, and enalapril on blood pressure and vasoconstriction in two renal hypertension models. Biol Pharm Bull. 2000 Feb;23(2):174-81.
DMS7609	RU	https://pubmed.ncbi.nlm.nih.gov/10706380

DMKJF6H	DI	DMKJF6H
DMKJF6H	DN	YM-430
DMKJF6H	MI	TTMXGCW
DMKJF6H	MN	Adrenergic receptor beta-3 (ADRB3)
DMKJF6H	MT	DTT
DMKJF6H	MA	Modulator
DMKJF6H	RN	Cardiovascular effects of YM430, a 1,4-dihydropyridine derivative with beta-adrenoceptor blocking activity, in dogs and rats. Biol Pharm Bull. 1997 Mar;20(3):230-6.
DMKJF6H	RU	https://pubmed.ncbi.nlm.nih.gov/9084878

DMRZBPI	DI	DMRZBPI
DMRZBPI	DN	YM-543
DMRZBPI	MI	TTLWPVF
DMRZBPI	MN	Sodium/glucose cotransporter 2 (SGLT2)
DMRZBPI	MT	DTT
DMRZBPI	MA	Modulator
DMRZBPI	RN	Pharmacological Characterization of YM543, a Newly Synthesized, Orally Active SGLT2 Selective Inhibitor. Endocr Res. 2013 Aug;38(3):168-183.
DMRZBPI	RU	https://www.ncbi.nlm.nih.gov/pubmed/23374077

DMUPJWH	DI	DMUPJWH
DMUPJWH	DN	YM-598
DMUPJWH	MI	TTKRD0G
DMUPJWH	MN	Endothelin A receptor (EDNRA)
DMUPJWH	MT	DTT
DMUPJWH	MA	Antagonist
DMUPJWH	RN	Role of the endothelin axis and its antagonists in the treatment of cancer. Br J Pharmacol. 2011 May; 163(2): 220-233.
DMUPJWH	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3087127/

DMU79X2	DI	DMU79X2
DMU79X2	DN	Ym-758
DMU79X2	MI	DT3D8F0
DMU79X2	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMU79X2	MT	DTP
DMU79X2	MA	Substrate
DMU79X2	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DMU79X2	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DM7KR4C	DI	DM7KR4C
DM7KR4C	DN	YM-934
DM7KR4C	MI	TT1VOHK
DM7KR4C	MN	Potassium channel unspecific (KC)
DM7KR4C	MT	DTT
DM7KR4C	MA	Blocker
DM7KR4C	RN	Potassium channel opener, YM 934, inhibits neurogenic plasma leakage in guinea pig airways. Am J Respir Crit Care Med. 1994 Nov;150(5 Pt 1):1379-83.
DM7KR4C	RU	https://pubmed.ncbi.nlm.nih.gov/7524979

DM0K8U7	DI	DM0K8U7
DM0K8U7	DN	YSIL6
DM0K8U7	MI	TTT1V78
DM0K8U7	MN	Interleukin-6 (IL6)
DM0K8U7	MT	DTT
DM0K8U7	MA	Inhibitor
DM0K8U7	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020380)
DM0K8U7	RU	http://adisinsight.springer.com/drugs/800020380

DM3YVKQ	DI	DM3YVKQ
DM3YVKQ	DN	YT-146
DM3YVKQ	MI	TTNE7KG
DM3YVKQ	MN	Adenosine A2b receptor (ADORA2B)
DM3YVKQ	MT	DTT
DM3YVKQ	MA	Agonist
DM3YVKQ	RN	Identification of adenosine A2 receptor-cAMP system in human aortic endothelial cells. Biochem Biophys Res Commun. 1994 Mar 15;199(2):905-10.
DM3YVKQ	RU	https://pubmed.ncbi.nlm.nih.gov/8135838

DM2M80G	DI	DM2M80G
DM2M80G	DN	Z 360
DM2M80G	MI	TTVFO0U
DM2M80G	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DM2M80G	MT	DTT
DM2M80G	MA	Modulator
DM2M80G	RN	Z-360, a novel cholecystokinin-2/gastrin receptor antagonist, inhibits gemcitabine-induced expression of the vascular endothelial growth factor gen... Biol Pharm Bull. 2010;33(2):216-22.
DM2M80G	RU	https://www.ncbi.nlm.nih.gov/pubmed/20118543

DMUT9OE	DI	DMUT9OE
DMUT9OE	DN	Zadaxin/lamivudine
DMUT9OE	MI	TTSYFMA
DMUT9OE	MN	Interferon alpha/beta receptor 1 (IFNAR1)
DMUT9OE	MT	DTT
DMUT9OE	MA	Modulator
DMUT9OE	RN	Zadaxin (thymosin alpha1) for the treatment of viral hepatitis. Expert Opin Investig Drugs. 1999 Mar;8(3):281-7.
DMUT9OE	RU	https://pubmed.ncbi.nlm.nih.gov/15992078

DMUT9OE	DI	DMUT9OE
DMUT9OE	DN	Zadaxin/lamivudine
DMUT9OE	MI	TTSHG0T
DMUT9OE	MN	Toll-like receptor 9 (TLR9)
DMUT9OE	MT	DTT
DMUT9OE	MA	Modulator
DMUT9OE	RN	Zadaxin (thymosin alpha1) for the treatment of viral hepatitis. Expert Opin Investig Drugs. 1999 Mar;8(3):281-7.
DMUT9OE	RU	https://pubmed.ncbi.nlm.nih.gov/15992078

DMJN3BA	DI	DMJN3BA
DMJN3BA	DN	Zalospirone
DMJN3BA	MI	TTSQIFT
DMJN3BA	MN	5-HT 1A receptor (HTR1A)
DMJN3BA	MT	DTT
DMJN3BA	MA	Agonist
DMJN3BA	RN	The serotonin 5-HT receptor agonist tandospirone improves executive function in common marmosets. Behav Brain Res. 2015 Jul 1;287:120-6.
DMJN3BA	RU	https://pubmed.ncbi.nlm.nih.gov/25804359

DMTYD8Q	DI	DMTYD8Q
DMTYD8Q	DN	ZD2079
DMTYD8Q	MI	TTMXGCW
DMTYD8Q	MN	Adrenergic receptor beta-3 (ADRB3)
DMTYD8Q	MT	DTT
DMTYD8Q	MA	Agonist
DMTYD8Q	RN	Urinary tract toxicity in rats following administration of beta 3-adrenoceptor agonists. Toxicol Pathol. 1999 Mar-Apr;27(2):165-70.
DMTYD8Q	RU	https://pubmed.ncbi.nlm.nih.gov/10207980

DMH85M0	DI	DMH85M0
DMH85M0	DN	ZD-6126
DMH85M0	MI	TTYFKSZ
DMH85M0	MN	Tubulin beta (TUBB)
DMH85M0	MT	DTT
DMH85M0	MA	Inhibitor
DMH85M0	RN	Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. Invest New Drugs. 2008 Apr;26(2):159-67.
DMH85M0	RU	https://pubmed.ncbi.nlm.nih.gov/18219445

DMPE2B9	DI	DMPE2B9
DMPE2B9	DN	ZD-7288
DMPE2B9	MI	TTKLW9S
DMPE2B9	MN	Hyperpolarization cyclic nucleotide-gated channel (HCN)
DMPE2B9	MT	DTT
DMPE2B9	MA	Modulator
DMPE2B9	RN	ZD 7288, an HCN channel blocker, attenuates chronic visceral pain in irritable bowel syndrome-like rats. World J Gastroenterol. 2014 Feb 28;20(8):2091-7.
DMPE2B9	RU	https://pubmed.ncbi.nlm.nih.gov/24587682

DM6VQTF	DI	DM6VQTF
DM6VQTF	DN	ZEN-3694
DM6VQTF	MI	TTE4BSY
DM6VQTF	MN	Bromodomain and extraterminal domain protein (BET)
DM6VQTF	MT	DTT
DM6VQTF	MA	Inhibitor
DM6VQTF	RN	Clinical pipeline report, company report or official report of Zenith Epigenetics.
DM6VQTF	RU	https://www.zenithepigenetics.com/programs/pipeline

DM9KB7A	DI	DM9KB7A
DM9KB7A	DN	ZGN-1061
DM9KB7A	MI	TTZL0OI
DM9KB7A	MN	Methionine aminopeptidase 2 (METAP2)
DM9KB7A	MT	DTT
DM9KB7A	MA	Inhibitor
DM9KB7A	RN	The methionine aminopeptidase 2 inhibitor ZGN-1061 improves glucose control and weight in overweight and obese individuals with type 2 diabetes: A randomized, placebo-controlled trial. Diabetes Obes Metab. 2020 Jul;22(7):1215-1219.
DM9KB7A	RU	https://pubmed.ncbi.nlm.nih.gov/32077231

DMJ94L0	DI	DMJ94L0
DMJ94L0	DN	ZK-91587
DMJ94L0	MI	TT26PHO
DMJ94L0	MN	Mineralocorticoid receptor  (MR)
DMJ94L0	MT	DTT
DMJ94L0	MA	Antagonist
DMJ94L0	RN	ZK91587: a novel synthetic antimineralocorticoid displays high affinity for corticosterone (type I) receptors in the rat hippocampus. Life Sci. 1988;43(19):1537-43.
DMJ94L0	RU	https://pubmed.ncbi.nlm.nih.gov/3193846

DM4MSLY	DI	DM4MSLY
DM4MSLY	DN	ZN-c3
DM4MSLY	MI	TTJFOAL
DM4MSLY	MN	Wee1-like protein kinase (WEE1)
DM4MSLY	MT	DTT
DM4MSLY	MA	Inhibitor
DM4MSLY	RN	Clinical pipeline report, company report or official report of Zentalis Pharmaceuticals.
DM4MSLY	RU	https://zentalis.com/our-pipeline/pipeline/

DMG7YI9	DI	DMG7YI9
DMG7YI9	DN	ZYH7
DMG7YI9	MI	TTJ584C
DMG7YI9	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMG7YI9	MT	DTT
DMG7YI9	MA	Agonist
DMG7YI9	RN	Clinical pipeline report, company report or official report of Zydus Cadila.
DMG7YI9	RU	https://zyduscadila.com/public/pdf/investorpresentation/Investor_Presentation_February_2020.pdf

DMTXBUV	DI	DMTXBUV
DMTXBUV	DN	BT1718
DMTXBUV	MI	TTJ4QE7
DMTXBUV	MN	Matrix metalloproteinase-14 (MMP-14)
DMTXBUV	MT	DTT
DMTXBUV	MA	Inhibitor
DMTXBUV	RN	ClinicalTrials.gov (NCT03486730) BT1718 in Patients With Advanced Solid Tumours.. U.S. National Institutes of Health.
DMTXBUV	RU	https://clinicaltrials.gov/ct2/show/NCT03486730

DM824EG	DI	DM824EG
DM824EG	DN	COVA322
DM824EG	MI	TTG0MT6
DM824EG	MN	Interleukin-17 (IL17)
DM824EG	MT	DTT
DM824EG	MA	Modulator
DM824EG	RN	Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. 
DM824EG	RU	https://www.ncbi.nlm.nih.gov/pubmed/25359367

DM824EG	DI	DM824EG
DM824EG	DN	COVA322
DM824EG	MI	TTF8CQI
DM824EG	MN	Tumor necrosis factor (TNF)
DM824EG	MT	DTT
DM824EG	MA	Modulator
DM824EG	RN	Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. 
DM824EG	RU	https://www.ncbi.nlm.nih.gov/pubmed/25359367

DMJ1NG4	DI	DMJ1NG4
DMJ1NG4	DN	Dalazatide
DMJ1NG4	MI	TTY3UE6
DMJ1NG4	MN	Voltage-gated potassium channel Kv1.3 (KCNA3)
DMJ1NG4	MT	DTT
DMJ1NG4	MA	Inhibitor
DMJ1NG4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMJ1NG4	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMV401D	DI	DMV401D
DMV401D	DN	Debio-0824
DMV401D	MI	TTY3UE6
DMV401D	MN	Voltage-gated potassium channel Kv1.3 (KCNA3)
DMV401D	MT	DTT
DMV401D	MA	Inhibitor
DMV401D	RN	Durable Pharmacological Responses from the Peptide ShK-186, a Specific Kv1.3 Channel Inhibitor That Suppresses T Cell Mediators of Autoimmune Disease. J Pharmacol Exp Ther. 2012 September; 342(3): 642-653.
DMV401D	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3422530/

DMT17XU	DI	DMT17XU
DMT17XU	DN	131I-radretumab
DMT17XU	MI	TTBVIQC
DMT17XU	MN	Integrin beta-1 (ITGB1)
DMT17XU	MT	DTT
DMT17XU	RN	Radretumab radioimmunotherapy in patients with brain metastasis: a 124I-L19SIP dosimetric PET study. Cancer Immunol Res. 2013 Aug;1(2):134-43.
DMT17XU	RU	https://pubmed.ncbi.nlm.nih.gov/24777501

DMVZ9XL	DI	DMVZ9XL
DMVZ9XL	DN	177Lu-labelled DOTA-JR11
DMVZ9XL	MI	TTOMNR9
DMVZ9XL	MN	Somatostatin receptor (SSTR)
DMVZ9XL	MT	DTT
DMVZ9XL	RN	Multimodal Imaging of 2-Cycle PRRT with 177 Lu-DOTA-JR11 and 177 Lu-DOTATOC in an Orthotopic Neuroendocrine Xenograft Tumor Mouse Model. J Nucl Med. 2021 Mar;62(3):393-398.
DMVZ9XL	RU	https://pubmed.ncbi.nlm.nih.gov/32859703

DMWPD7N	DI	DMWPD7N
DMWPD7N	DN	177Lu-labelled PSMA-R2
DMWPD7N	MI	TT9G4N0
DMWPD7N	MN	Glutamate carboxypeptidase II (GCPII)
DMWPD7N	MT	DTT
DMWPD7N	RN	Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608.
DMWPD7N	RU	https://pubmed.ncbi.nlm.nih.gov/32728208

DM6JLNT	DI	DM6JLNT
DM6JLNT	DN	177-Lu-NeoB
DM6JLNT	MI	TTC1MVT
DM6JLNT	MN	Gastrin-releasing peptide receptor (GRPR)
DM6JLNT	MT	DTT
DM6JLNT	MA	Antagonist
DM6JLNT	RN	68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology. J Nucl Med. 2017 Feb;58(2):293-299.
DM6JLNT	RU	https://pubmed.ncbi.nlm.nih.gov/27609789

DMF4AOE	DI	DMF4AOE
DMF4AOE	DN	177-Lu-PSMA-R2
DMF4AOE	MI	TT9G4N0
DMF4AOE	MN	Glutamate carboxypeptidase II (GCPII)
DMF4AOE	MT	DTT
DMF4AOE	MA	Agonist
DMF4AOE	RN	National Cancer Institute Drug Dictionary (drug name Lu-177-PSMA-R2).
DMF4AOE	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/lutetium-lu-177-psma-r2

DMCLKA4	DI	DMCLKA4
DMCLKA4	DN	2-hydroxyoleic acid
DMCLKA4	MI	TTBOE28
DMCLKA4	MN	Sphingomyelin synthase (SMS)
DMCLKA4	MT	DTT
DMCLKA4	MA	Modulator
DMCLKA4	RN	Sphingomyelin and sphingomyelin synthase (SMS) in the malignant transformation of glioma cells and in 2-hydroxyoleic acid therapy. Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):19569-74.
DMCLKA4	RU	https://pubmed.ncbi.nlm.nih.gov/22106271

DMYPQT4	DI	DMYPQT4
DMYPQT4	DN	4SCAR19 and 4SCAR123
DMYPQT4	MI	TTW640A
DMYPQT4	MN	B-lymphocyte surface antigen B4 (CD19)
DMYPQT4	MT	DTT
DMYPQT4	MA	CAR-T-Cell-Therapy(Dual specific)
DMYPQT4	RN	ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
DMYPQT4	RU	https://clinicaltrials.gov/ct2/show/NCT03125577

DMYPQT4	DI	DMYPQT4
DMYPQT4	DN	4SCAR19 and 4SCAR123
DMYPQT4	MI	TTENHJ0
DMYPQT4	MN	Interleukin 3 receptor alpha (IL3RA)
DMYPQT4	MT	DTT
DMYPQT4	MA	CAR-T-Cell-Therapy(Dual specific)
DMYPQT4	RN	ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
DMYPQT4	RU	https://clinicaltrials.gov/ct2/show/NCT03125577

DMFVTSG	DI	DMFVTSG
DMFVTSG	DN	4SCAR19 and 4SCAR20
DMFVTSG	MI	TTW640A
DMFVTSG	MN	B-lymphocyte surface antigen B4 (CD19)
DMFVTSG	MT	DTT
DMFVTSG	MA	CAR-T-Cell-Therapy(Dual specific)
DMFVTSG	RN	ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
DMFVTSG	RU	https://clinicaltrials.gov/ct2/show/NCT03125577

DMFVTSG	DI	DMFVTSG
DMFVTSG	DN	4SCAR19 and 4SCAR20
DMFVTSG	MI	TTUE541
DMFVTSG	MN	Leukocyte surface antigen Leu-16 (CD20)
DMFVTSG	MT	DTT
DMFVTSG	MA	CAR-T-Cell-Therapy(Dual specific)
DMFVTSG	RN	ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
DMFVTSG	RU	https://clinicaltrials.gov/ct2/show/NCT03125577

DM8CMUW	DI	DM8CMUW
DM8CMUW	DN	4SCAR19 and 4SCAR22
DM8CMUW	MI	TTM6QSK
DM8CMUW	MN	B-cell receptor CD22 (CD22)
DM8CMUW	MT	DTT
DM8CMUW	MA	CAR-T-Cell-Therapy(Dual specific)
DM8CMUW	RN	ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
DM8CMUW	RU	https://clinicaltrials.gov/ct2/show/NCT03125577

DM8CMUW	DI	DM8CMUW
DM8CMUW	DN	4SCAR19 and 4SCAR22
DM8CMUW	MI	TTW640A
DM8CMUW	MN	B-lymphocyte surface antigen B4 (CD19)
DM8CMUW	MT	DTT
DM8CMUW	MA	CAR-T-Cell-Therapy(Dual specific)
DM8CMUW	RN	ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
DM8CMUW	RU	https://clinicaltrials.gov/ct2/show/NCT03125577

DMUYFS1	DI	DMUYFS1
DMUYFS1	DN	4SCAR19 and 4SCAR30
DMUYFS1	MI	TTW640A
DMUYFS1	MN	B-lymphocyte surface antigen B4 (CD19)
DMUYFS1	MT	DTT
DMUYFS1	MA	CAR-T-Cell-Therapy(Dual specific)
DMUYFS1	RN	ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
DMUYFS1	RU	https://clinicaltrials.gov/ct2/show/NCT03125577

DMUYFS1	DI	DMUYFS1
DMUYFS1	DN	4SCAR19 and 4SCAR30
DMUYFS1	MI	TT2GM5R
DMUYFS1	MN	Lymphocyte activation antigen CD30 (TNFRSF8)
DMUYFS1	MT	DTT
DMUYFS1	MA	CAR-T-Cell-Therapy(Dual specific)
DMUYFS1	RN	ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
DMUYFS1	RU	https://clinicaltrials.gov/ct2/show/NCT03125577

DMZKFU7	DI	DMZKFU7
DMZKFU7	DN	4SCAR19 and 4SCAR38
DMZKFU7	MI	TTW640A
DMZKFU7	MN	B-lymphocyte surface antigen B4 (CD19)
DMZKFU7	MT	DTT
DMZKFU7	MA	CAR-T-Cell-Therapy(Dual specific)
DMZKFU7	RN	ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
DMZKFU7	RU	https://clinicaltrials.gov/ct2/show/NCT03125577

DMZKFU7	DI	DMZKFU7
DMZKFU7	DN	4SCAR19 and 4SCAR38
DMZKFU7	MI	TTPURFN
DMZKFU7	MN	Cyclic ADP-ribose hydrolase 1 (CD38)
DMZKFU7	MT	DTT
DMZKFU7	MA	CAR-T-Cell-Therapy(Dual specific)
DMZKFU7	RN	ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
DMZKFU7	RU	https://clinicaltrials.gov/ct2/show/NCT03125577

DMKC8F9	DI	DMKC8F9
DMKC8F9	DN	4SCAR19 and 4SCAR70
DMKC8F9	MI	TTW640A
DMKC8F9	MN	B-lymphocyte surface antigen B4 (CD19)
DMKC8F9	MT	DTT
DMKC8F9	MA	CAR-T-Cell-Therapy(Dual specific)
DMKC8F9	RN	ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
DMKC8F9	RU	https://clinicaltrials.gov/ct2/show/NCT03125577

DMKC8F9	DI	DMKC8F9
DMKC8F9	DN	4SCAR19 and 4SCAR70
DMKC8F9	MI	TTNCIE0
DMKC8F9	MN	CD70 antigen (CD27-L)
DMKC8F9	MT	DTT
DMKC8F9	MA	CAR-T-Cell-Therapy(Dual specific)
DMKC8F9	RN	ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
DMKC8F9	RU	https://clinicaltrials.gov/ct2/show/NCT03125577

DMIY1ZB	DI	DMIY1ZB
DMIY1ZB	DN	4SCAR19 cells
DMIY1ZB	MI	TTW640A
DMIY1ZB	MN	B-lymphocyte surface antigen B4 (CD19)
DMIY1ZB	MT	DTT
DMIY1ZB	MA	CAR-T-Cell-Therapy
DMIY1ZB	RN	ClinicalTrials.gov (NCT03050190) A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies
DMIY1ZB	RU	https://clinicaltrials.gov/ct2/show/NCT03050190

DMI8TW3	DI	DMI8TW3
DMI8TW3	DN	4SCAR19/22 T cells
DMI8TW3	MI	TTM6QSK
DMI8TW3	MN	B-cell receptor CD22 (CD22)
DMI8TW3	MT	DTT
DMI8TW3	MA	CAR-T-Cell-Therapy(Dual specific)
DMI8TW3	RN	ClinicalTrials.gov (NCT03098355) Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies
DMI8TW3	RU	https://clinicaltrials.gov/ct2/show/NCT03098355

DMI8TW3	DI	DMI8TW3
DMI8TW3	DN	4SCAR19/22 T cells
DMI8TW3	MI	TTW640A
DMI8TW3	MN	B-lymphocyte surface antigen B4 (CD19)
DMI8TW3	MT	DTT
DMI8TW3	MA	CAR-T-Cell-Therapy(Dual specific)
DMI8TW3	RN	ClinicalTrials.gov (NCT03098355) Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies
DMI8TW3	RU	https://clinicaltrials.gov/ct2/show/NCT03098355

DMEGSU5	DI	DMEGSU5
DMEGSU5	DN	4SCAR-GD2
DMEGSU5	MI	TT80ARU
DMEGSU5	MN	Ganglioside GD2 (GD2)
DMEGSU5	MT	DTT
DMEGSU5	MA	CAR-T-Cell-Therapy
DMEGSU5	RN	ClinicalTrials.gov (NCT02992210) Study on GD2 Positive Solid Tumors by 4SCAR-GD2
DMEGSU5	RU	https://clinicaltrials.gov/ct2/show/NCT02992210

DMM8J5W	DI	DMM8J5W
DMM8J5W	DN	4SCAR-PSMA
DMM8J5W	MI	TT9G4N0
DMM8J5W	MN	Glutamate carboxypeptidase II (GCPII)
DMM8J5W	MT	DTT
DMM8J5W	MA	CAR-T-Cell-Therapy
DMM8J5W	RN	ClinicalTrials.gov (NCT03185468) Intervention of Bladder Cancer by CAR-T
DMM8J5W	RU	https://clinicaltrials.gov/ct2/show/NCT03185468

DM129VT	DI	DM129VT
DM129VT	DN	514G3
DM129VT	MI	TTOWKQ9
DM129VT	MN	Staphylococcus IgG binding protein A  (Stap-coc SpA)
DM129VT	MT	DTT
DM129VT	MA	Inhibitor
DM129VT	RN	A natural human monoclonal antibody targeting Staphylococcus Protein A protects against Staphylococcus aureus bacteremia. PLoS One. 2018 Jan 24;13(1):e0190537.
DM129VT	RU	https://pubmed.ncbi.nlm.nih.gov/29364906

DMFAMNH	DI	DMFAMNH
DMFAMNH	DN	99mTc-rBitistatin
DMFAMNH	MI	TT38RM1
DMFAMNH	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DMFAMNH	MT	DTT
DMFAMNH	MA	Modulator
DMFAMNH	RN	Platelet binding and biodistribution of [99mTc]rBitistatin in animal species and humans. Nucl Med Biol. 2007 Oct;34(7):855-63.
DMFAMNH	RU	https://pubmed.ncbi.nlm.nih.gov/17921036

DMGTOIX	DI	DMGTOIX
DMGTOIX	DN	A166
DMGTOIX	MI	TT6EO5L
DMGTOIX	MN	Erbb2 tyrosine kinase receptor (HER2)
DMGTOIX	MT	DTT
DMGTOIX	RN	Clinical pipeline report, company report or official report of KLUS Pharma.
DMGTOIX	RU	https://www.kluspharma.com/pipeline

DMAPUZY	DI	DMAPUZY
DMAPUZY	DN	AAV1-FS344
DMAPUZY	MI	TTM8I2X
DMAPUZY	MN	Myostatin (MSTN)
DMAPUZY	MT	DTT
DMAPUZY	MA	Modulator
DMAPUZY	RN	Follistatin Gene Delivery Enhances Muscle Growth and Strength in Nonhuman Primates. Sci Transl Med. 2009 November 11; 1(6): 6ra15.
DMAPUZY	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2852878/

DMI27RF	DI	DMI27RF
DMI27RF	DN	AAV-AQP1
DMI27RF	MI	TTSF1KH
DMI27RF	MN	Aquaporin-1 (AQP1)
DMI27RF	MT	DTT
DMI27RF	RN	Clinical pipeline report, company report or official report of MeiraGTx.
DMI27RF	RU	https://meiragtx.com/research-development/pipeline/

DMNZJAE	DI	DMNZJAE
DMNZJAE	DN	AAV-CNGA3
DMNZJAE	MI	TTW0QOV
DMNZJAE	MN	Cyclic nucleotide-gated channel alpha-3 (CNGA3)
DMNZJAE	MT	DTT
DMNZJAE	RN	Clinical pipeline report, company report or official report of MeiraGTx.
DMNZJAE	RU	https://meiragtx.com/research-development/pipeline/

DM0CJAN	DI	DM0CJAN
DM0CJAN	DN	AAV-CNGB3
DM0CJAN	MI	TT0LJCG
DM0CJAN	MN	Cyclic nucleotide-gated channel beta-3 (CNGB3)
DM0CJAN	MT	DTT
DM0CJAN	RN	Clinical pipeline report, company report or official report of MeiraGTx.
DM0CJAN	RU	https://meiragtx.com/research-development/pipeline/

DMAH6UJ	DI	DMAH6UJ
DMAH6UJ	DN	AAV-RPE65
DMAH6UJ	MI	TTBOH16
DMAH6UJ	MN	Retinal pigment epithelium protein (RPE65)
DMAH6UJ	MT	DTT
DMAH6UJ	RN	Clinical pipeline report, company report or official report of MeiraGTx.
DMAH6UJ	RU	https://meiragtx.com/research-development/pipeline/

DM7TF49	DI	DM7TF49
DM7TF49	DN	AAV-RPGR
DM7TF49	MI	TTHBDA9
DM7TF49	MN	X-linked retinitis pigmentosa GTPase regulator (RPGR)
DM7TF49	MT	DTT
DM7TF49	RN	Clinical pipeline report, company report or official report of MeiraGTx.
DM7TF49	RU	https://meiragtx.com/research-development/pipeline/

DMDOXMN	DI	DMDOXMN
DMDOXMN	DN	AB928
DMDOXMN	MI	TTM2AOE
DMDOXMN	MN	Adenosine A2a receptor (ADORA2A)
DMDOXMN	MT	DTT
DMDOXMN	MA	Antagonist
DMDOXMN	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMDOXMN	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMDOXMN	DI	DMDOXMN
DMDOXMN	DN	AB928
DMDOXMN	MI	TTNE7KG
DMDOXMN	MN	Adenosine A2b receptor (ADORA2B)
DMDOXMN	MT	DTT
DMDOXMN	MA	Antagonist
DMDOXMN	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMDOXMN	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMUBLC3	DI	DMUBLC3
DMUBLC3	DN	ABO-101
DMUBLC3	MI	TTDM6HZ
DMUBLC3	MN	Alpha-N-acetylglucosaminidase (NAGLU)
DMUBLC3	MT	DTT
DMUBLC3	RN	Clinical pipeline report, company report or official report of Abeona Therapeutics.
DMUBLC3	RU	https://www.abeonatherapeutics.com/science

DMFJB35	DI	DMFJB35
DMFJB35	DN	ABO-102
DMFJB35	MI	TTPJ2SH
DMFJB35	MN	N-sulphoglucosamine sulphohydrolase (SGSH)
DMFJB35	MT	DTT
DMFJB35	RN	Clinical pipeline report, company report or official report of Abeona Therapeutics.
DMFJB35	RU	https://www.abeonatherapeutics.com/science

DM31NJU	DI	DM31NJU
DM31NJU	DN	ABY-025
DM31NJU	MI	TT6EO5L
DM31NJU	MN	Erbb2 tyrosine kinase receptor (HER2)
DM31NJU	MT	DTT
DM31NJU	MA	Enhancer
DM31NJU	RN	Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold. J Nucl Med. 2010 Jul;51(7):1131-8.
DM31NJU	RU	https://pubmed.ncbi.nlm.nih.gov/20554729

DMIRGTZ	DI	DMIRGTZ
DMIRGTZ	DN	ACHM-CNGA3
DMIRGTZ	MI	TTW0QOV
DMIRGTZ	MN	Cyclic nucleotide-gated channel alpha-3 (CNGA3)
DMIRGTZ	MT	DTT
DMIRGTZ	RN	Clinical pipeline report, company report or official report of Applied Genetic Technologies.
DMIRGTZ	RU	https://agtc.com/programs/achromatopsia/

DMC4ZQD	DI	DMC4ZQD
DMC4ZQD	DN	ACHM-CNGB3
DMC4ZQD	MI	TT0LJCG
DMC4ZQD	MN	Cyclic nucleotide-gated channel beta-3 (CNGB3)
DMC4ZQD	MT	DTT
DMC4ZQD	RN	Clinical pipeline report, company report or official report of Applied Genetic Technologies.
DMC4ZQD	RU	https://agtc.com/programs/achromatopsia/

DM5YDSU	DI	DM5YDSU
DM5YDSU	DN	ACI-24
DM5YDSU	MI	TTE4KHA
DM5YDSU	MN	Amyloid beta A4 protein (APP)
DM5YDSU	MT	DTT
DM5YDSU	RN	Immunotherapy for Alzheimer's disease: hoops and hurdles. Mol Neurodegener. 2013; 8: 36.
DM5YDSU	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4015631/

DM7IWTF	DI	DM7IWTF
DM7IWTF	DN	ACP-319
DM7IWTF	MI	TTGM6VW
DM7IWTF	MN	Tyrosine-protein kinase BTK (ATK)
DM7IWTF	MT	DTT
DM7IWTF	MA	Inhibitor
DM7IWTF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1948).
DM7IWTF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1948

DMEU86T	DI	DMEU86T
DMEU86T	DN	ACT017
DMEU86T	MI	TTTJUVZ
DMEU86T	MN	Platelet glycoprotein VI (GP6)
DMEU86T	MT	DTT
DMEU86T	MA	Inhibitor
DMEU86T	RN	Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab. Arterioscler Thromb Vasc Biol. 2019 May;39(5):956-964.
DMEU86T	RU	https://pubmed.ncbi.nlm.nih.gov/31017822

DM4L28K	DI	DM4L28K
DM4L28K	DN	Ad35-GRIN
DM4L28K	MI	TTFGZB6
DM4L28K	MN	Human immunodeficiency virus GAG protein (HIV gag)
DM4L28K	MT	DTT
DM4L28K	RN	A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936.
DM4L28K	RU	https://pubmed.ncbi.nlm.nih.gov/22870265

DM4L28K	DI	DM4L28K
DM4L28K	DN	Ad35-GRIN
DM4L28K	MI	TT4NXYM
DM4L28K	MN	Human immunodeficiency virus Negative factor (HIV nef)
DM4L28K	MT	DTT
DM4L28K	RN	A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936.
DM4L28K	RU	https://pubmed.ncbi.nlm.nih.gov/22870265

DM4L28K	DI	DM4L28K
DM4L28K	DN	Ad35-GRIN
DM4L28K	MI	TT84ETX
DM4L28K	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM4L28K	MT	DTT
DM4L28K	RN	A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936.
DM4L28K	RU	https://pubmed.ncbi.nlm.nih.gov/22870265

DMEGPSW	DI	DMEGPSW
DMEGPSW	DN	AdCh63 AMA1
DMEGPSW	MI	TTQZW34
DMEGPSW	MN	Plasmodium Apical membrane protein (Malaria AMA-1)
DMEGPSW	MT	DTT
DMEGPSW	RN	ClinicalTrials.gov (NCT01142765) Study to Assess Efficacy of New Malaria Vaccine Candidates AdCh63 AMA1, MVA AMA1, AdCh63 MSP1, MVA MSP1, AdCh63 ME-TRAP & MVA ME-TRAP. U.S. National Institutes of Health.
DMEGPSW	RU	https://clinicaltrials.gov/ct2/show/NCT01142765

DMBGXH5	DI	DMBGXH5
DMBGXH5	DN	AdCh63-MSP1
DMBGXH5	MI	TT68ZYJ
DMBGXH5	MN	Plasmodium Merozoite surface protein 1 (Malaria MSP-1)
DMBGXH5	MT	DTT
DMBGXH5	RN	Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection. Immunology. 2014 Apr;141(4):628-44.
DMBGXH5	RU	https://pubmed.ncbi.nlm.nih.gov/24303947

DMYOMSC	DI	DMYOMSC
DMYOMSC	DN	Aderbasib
DMYOMSC	MI	TTOMWSY
DMYOMSC	MN	Mammalian disintegrin-metalloprotease (ADAM10)
DMYOMSC	MT	DTT
DMYOMSC	MA	Modulator
DMYOMSC	RN	Company report (Incyte)
DMYOMSC	RU	http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NDQwNjgzfENoaWxkSUQ9NDYyNTAzfFR5cGU9MQ==&t=1

DMYOMSC	DI	DMYOMSC
DMYOMSC	DN	Aderbasib
DMYOMSC	MI	TT6AZXG
DMYOMSC	MN	TNF alpha converting enzyme (ADAM17)
DMYOMSC	MT	DTT
DMYOMSC	MA	Modulator
DMYOMSC	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMYOMSC	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM87H0S	DI	DM87H0S
DM87H0S	DN	ADG106
DM87H0S	MI	TTPW9LJ
DM87H0S	MN	Co-stimulatory molecule 4-1BB (CD137)
DM87H0S	MT	DTT
DM87H0S	MA	Inhibitor
DM87H0S	RN	Clinical pipeline report, company report or official report of Adagene.
DM87H0S	RU	https://www.adagene.com/pipeline/adg106/

DMB19IO	DI	DMB19IO
DMB19IO	DN	Ad-IL-12 DNA therapeutic
DMB19IO	MI	TTGW72V
DMB19IO	MN	Interleukin-12 beta (IL12B)
DMB19IO	MT	DTT
DMB19IO	MA	Modulator
DMB19IO	RN	National Cancer Institute Drug Dictionary (drug id 710508).
DMB19IO	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=710508

DMOPVET	DI	DMOPVET
DMOPVET	DN	ADXS-PSA
DMOPVET	MI	TTS78AZ
DMOPVET	MN	Prostate specific antigen (KLK3)
DMOPVET	MT	DTT
DMOPVET	MA	Modulator
DMOPVET	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2373).
DMOPVET	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2373

DMEOS5K	DI	DMEOS5K
DMEOS5K	DN	AEE-788
DMEOS5K	MI	TTGJVQM
DMEOS5K	MN	Fibroblast growth factor receptor 2 (FGFR2)
DMEOS5K	MT	DTT
DMEOS5K	MA	Inhibitor
DMEOS5K	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMEOS5K	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMEOS5K	DI	DMEOS5K
DMEOS5K	DN	AEE-788
DMEOS5K	MI	TTST7KB
DMEOS5K	MN	Fibroblast growth factor receptor 3 (FGFR3)
DMEOS5K	MT	DTT
DMEOS5K	MA	Inhibitor
DMEOS5K	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMEOS5K	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DM2HRYD	DI	DM2HRYD
DM2HRYD	DN	AEG35156
DM2HRYD	MI	TTK3WBU
DM2HRYD	MN	XIAP messenger RNA (XIAP mRNA)
DM2HRYD	MT	DTT
DM2HRYD	RN	Teaming up to tackle RNAi delivery challenge. Nat Rev Drug Discov. 2009 Jul;8(7):525-6.
DM2HRYD	RU	https://pubmed.ncbi.nlm.nih.gov/19568274

DMMNIBY	DI	DMMNIBY
DMMNIBY	DN	Aflunov
DMMNIBY	MI	TT3J5ZI
DMMNIBY	MN	Cell mediated immunity response (CMIR)
DMMNIBY	MT	DTT
DMMNIBY	RN	Aflunov( ): a prepandemic influenza vaccine. Expert Rev Vaccines. 2012 Feb;11(2):145-57.
DMMNIBY	RU	https://pubmed.ncbi.nlm.nih.gov/22309663

DMFTZX0	DI	DMFTZX0
DMFTZX0	DN	AFM24
DMFTZX0	MI	TTGKNB4
DMFTZX0	MN	Epidermal growth factor receptor (EGFR)
DMFTZX0	MT	DTT
DMFTZX0	RN	Clinical pipeline report, company report or official report of Affimed Therapeutics.
DMFTZX0	RU	https://www.affimed.com/rock-platform/pipeline/

DMFTZX0	DI	DMFTZX0
DMFTZX0	DN	AFM24
DMFTZX0	MI	TTIFOC0
DMFTZX0	MN	Immunoglobulin gamma Fc receptor IIIA (FCGR3A)
DMFTZX0	MT	DTT
DMFTZX0	RN	Clinical pipeline report, company report or official report of Affimed Therapeutics.
DMFTZX0	RU	https://www.affimed.com/rock-platform/pipeline/

DMRET3H	DI	DMRET3H
DMRET3H	DN	AG-013958
DMRET3H	MI	TTVJ1D8
DMRET3H	MN	Vascular endothelial growth factor receptor (VEGFR)
DMRET3H	MT	DTT
DMRET3H	MA	Inhibitor
DMRET3H	RN	Receptor Tyrosine Kinase Inhibitors AG013764 and AG013711 Reduce Choroidal Neovascularization in Rat Eye. Exp Eye Res. 2007 May; 84(5): 922-933.
DMRET3H	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1995411/

DMEN2L7	DI	DMEN2L7
DMEN2L7	DN	AG019
DMEN2L7	MI	TTT0Q1F
DMEN2L7	MN	Interleukin-10 (IL10)
DMEN2L7	MT	DTT
DMEN2L7	RN	ClinicalTrials.gov (NCT03751007) A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recently Diagnosed Type 1 Diabetes Mellitus (T1D). U.S. National Institutes of Health.
DMEN2L7	RU	https://clinicaltrials.gov/ct2/show/NCT03751007

DMAP5B4	DI	DMAP5B4
DMAP5B4	DN	AGEN1884
DMAP5B4	MI	TTI2S1D
DMAP5B4	MN	Cytotoxic T-lymphocyte protein 4 (CTLA-4)
DMAP5B4	MT	DTT
DMAP5B4	MA	Antagonist
DMAP5B4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMAP5B4	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMHZUF8	DI	DMHZUF8
DMHZUF8	DN	AGN-208397
DMHZUF8	MI	TT6EO5L
DMHZUF8	MN	Erbb2 tyrosine kinase receptor (HER2)
DMHZUF8	MT	DTT
DMHZUF8	MA	Inhibitor
DMHZUF8	RN	New hope for dry AMD. Nat Rev Drug Discov. 2013 Jul;12(7):501-2.
DMHZUF8	RU	https://pubmed.ncbi.nlm.nih.gov/23812264

DMTS51C	DI	DMTS51C
DMTS51C	DN	AGTC-501
DMTS51C	MI	TTHBDA9
DMTS51C	MN	X-linked retinitis pigmentosa GTPase regulator (RPGR)
DMTS51C	MT	DTT
DMTS51C	RN	ClinicalTrials.gov (NCT03316560) Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations. U.S. National Institutes of Health.
DMTS51C	RU	https://clinicaltrials.gov/ct2/show/NCT03316560

DMJVGIH	DI	DMJVGIH
DMJVGIH	DN	AIGIV
DMJVGIH	MI	TTRLPUB
DMJVGIH	MN	Bacillus anthracis Protective antigen (Anthrax PA)
DMJVGIH	MT	DTT
DMJVGIH	MA	Modulator
DMJVGIH	RN	Evaluation of intravenous anthrax immune globulin for treatment of inhalation anthrax. Antimicrob Agents Chemother. 2013 Nov;57(11):5684-92.
DMJVGIH	RU	https://pubmed.ncbi.nlm.nih.gov/23979731

DML0GIU	DI	DML0GIU
DML0GIU	DN	AIV001
DML0GIU	MI	TTVJ1D8
DML0GIU	MN	Vascular endothelial growth factor receptor (VEGFR)
DML0GIU	MT	DTT
DML0GIU	MA	Inhibitor
DML0GIU	RN	Clinical pipeline report, company report or official report of AiViva BioPharma.
DML0GIU	RU	https://aiviva.com/aiv001

DMNXLOT	DI	DMNXLOT
DMNXLOT	DN	ALAMIFOVIR
DMNXLOT	MI	TTMR83K
DMNXLOT	MN	Hepatitis B virus Reverse transcriptase priming/DNA synthesis (HBV RTP/DS)
DMNXLOT	MT	DTT
DMNXLOT	MA	Modulator
DMNXLOT	RN	Noncompetitive Inhibition of Hepatitis B Virus Reverse Transcriptase Protein Priming and DNA Synthesis by the Nucleoside Analog Clevudine. Correction in: Antimicrob Agents Chemother. 2013 November; 57(11): 5788.
DMNXLOT	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3754288/

DMGQX0U	DI	DMGQX0U
DMGQX0U	DN	ALX148
DMGQX0U	MI	TT28S46
DMGQX0U	MN	Leukocyte surface antigen CD47 (CD47)
DMGQX0U	MT	DTT
DMGQX0U	MA	Inhibitor
DMGQX0U	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMGQX0U	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMEF4L5	DI	DMEF4L5
DMEF4L5	DN	AMG888/U3-1287
DMEF4L5	MI	TTDC8N2
DMEF4L5	MN	Erbb3 tyrosine kinase receptor (Erbb-3)
DMEF4L5	MT	DTT
DMEF4L5	MA	Modulator
DMEF4L5	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1798).
DMEF4L5	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1798

DM7RNKM	DI	DM7RNKM
DM7RNKM	DN	AMT-060
DM7RNKM	MI	TTFEZ5Q
DM7RNKM	MN	Coagulation factor IX (F9)
DM7RNKM	MT	DTT
DM7RNKM	MA	Modulator
DM7RNKM	RN	Phase I/II clinical trial of AMT-060 for treating hemophilia B. uniQure N.V.
DM7RNKM	RU	http://www.biocentury.com/products/amt-060

DMR9H6B	DI	DMR9H6B
DMR9H6B	DN	AMXI 5001
DMR9H6B	MI	TTU1SOM
DMR9H6B	MN	Microtubule polymerization (MicroTu poly)
DMR9H6B	MT	DTT
DMR9H6B	MA	Inhibitor
DMR9H6B	RN	AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers. Am J Cancer Res. 2020 Aug 1;10(8):2649-2676.
DMR9H6B	RU	https://pubmed.ncbi.nlm.nih.gov/32905466

DMR9H6B	DI	DMR9H6B
DMR9H6B	DN	AMXI 5001
DMR9H6B	MI	TTVDSZ0
DMR9H6B	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMR9H6B	MT	DTT
DMR9H6B	MA	Inhibitor
DMR9H6B	RN	AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers. Am J Cancer Res. 2020 Aug 1;10(8):2649-2676.
DMR9H6B	RU	https://pubmed.ncbi.nlm.nih.gov/32905466

DMR9H6B	DI	DMR9H6B
DMR9H6B	DN	AMXI 5001
DMR9H6B	MI	TTQ4V96
DMR9H6B	MN	Poly [ADP-ribose] polymerase 2 (PARP2)
DMR9H6B	MT	DTT
DMR9H6B	MA	Inhibitor
DMR9H6B	RN	AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers. Am J Cancer Res. 2020 Aug 1;10(8):2649-2676.
DMR9H6B	RU	https://pubmed.ncbi.nlm.nih.gov/32905466

DMDHJNV	DI	DMDHJNV
DMDHJNV	DN	Annamycin
DMDHJNV	MI	TTCGY2K
DMDHJNV	MN	DNA topoisomerase II alpha (TOP2A)
DMDHJNV	MT	DTT
DMDHJNV	RN	Effect of structural modification at the 4, 3', and 2' positions of doxorubicin on topoisomerase II poisoning, apoptosis, and cytotoxicity in human melanoma cells. Arch Immunol Ther Exp (Warsz). May-Jun 2007;55(3):193-8.
DMDHJNV	RU	https://pubmed.ncbi.nlm.nih.gov/17557149

DM4D3YF	DI	DM4D3YF
DM4D3YF	DN	Anti-BCMA CAR-T cells
DM4D3YF	MI	TTZ3P4W
DM4D3YF	MN	B-cell maturation protein (TNFRSF17)
DM4D3YF	MT	DTT
DM4D3YF	MA	CAR-T-Cell-Therapy
DM4D3YF	RN	ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
DM4D3YF	RU	https://clinicaltrials.gov/ct2/show/NCT03638206

DMZ18IO	DI	DMZ18IO
DMZ18IO	DN	Anti-BCMA-CAR-transduced T cells
DMZ18IO	MI	TTZ3P4W
DMZ18IO	MN	B-cell maturation protein (TNFRSF17)
DMZ18IO	MT	DTT
DMZ18IO	MA	CAR-T-Cell-Therapy
DMZ18IO	RN	ClinicalTrials.gov (NCT02954445) A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies
DMZ18IO	RU	https://clinicaltrials.gov/ct2/show/NCT02954445

DMFV6TY	DI	DMFV6TY
DMFV6TY	DN	Anti-CD123-CAR-transduced T cells
DMFV6TY	MI	TTENHJ0
DMFV6TY	MN	Interleukin 3 receptor alpha (IL3RA)
DMFV6TY	MT	DTT
DMFV6TY	MA	CAR-T-Cell-Therapy
DMFV6TY	RN	ClinicalTrials.gov (NCT02937103) A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies
DMFV6TY	RU	https://clinicaltrials.gov/ct2/show/NCT02937103

DMLFB25	DI	DMLFB25
DMLFB25	DN	Anti-CD19 and Anti-CD20 CAR-T Cells
DMLFB25	MI	TTW640A
DMLFB25	MN	B-lymphocyte surface antigen B4 (CD19)
DMLFB25	MT	DTT
DMLFB25	MA	CAR-T-Cell-Therapy(Dual specific)
DMLFB25	RN	ClinicalTrials.gov (NCT03207178) Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma
DMLFB25	RU	https://clinicaltrials.gov/ct2/show/NCT03207178

DMLFB25	DI	DMLFB25
DMLFB25	DN	Anti-CD19 and Anti-CD20 CAR-T Cells
DMLFB25	MI	TTUE541
DMLFB25	MN	Leukocyte surface antigen Leu-16 (CD20)
DMLFB25	MT	DTT
DMLFB25	MA	CAR-T-Cell-Therapy(Dual specific)
DMLFB25	RN	ClinicalTrials.gov (NCT03207178) Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma
DMLFB25	RU	https://clinicaltrials.gov/ct2/show/NCT03207178

DMS326R	DI	DMS326R
DMS326R	DN	Anti-CD19 CAR T cells
DMS326R	MI	TTW640A
DMS326R	MN	B-lymphocyte surface antigen B4 (CD19)
DMS326R	MT	DTT
DMS326R	MA	CAR-T-Cell-Therapy
DMS326R	RN	ClinicalTrials.gov (NCT02842138) Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell Lymphoma
DMS326R	RU	https://clinicaltrials.gov/ct2/show/NCT02842138

DMHSLVJ	DI	DMHSLVJ
DMHSLVJ	DN	Anti-CD19 CAR transduced T cells
DMHSLVJ	MI	TTW640A
DMHSLVJ	MN	B-lymphocyte surface antigen B4 (CD19)
DMHSLVJ	MT	DTT
DMHSLVJ	MA	CAR-T-Cell-Therapy
DMHSLVJ	RN	ClinicalTrials.gov (NCT03191773) A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies
DMHSLVJ	RU	https://clinicaltrials.gov/ct2/show/NCT03191773

DM04HNB	DI	DM04HNB
DM04HNB	DN	Anti-CD19 CAR-T
DM04HNB	MI	TTW640A
DM04HNB	MN	B-lymphocyte surface antigen B4 (CD19)
DM04HNB	MT	DTT
DM04HNB	MA	CAR-T-Cell-Therapy
DM04HNB	RN	ClinicalTrials.gov (NCT02685670) Competitive Transfer of CD19-TCRz-CD28 and CD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma
DM04HNB	RU	https://clinicaltrials.gov/ct2/show/NCT02685670

DMDRYZK	DI	DMDRYZK
DMDRYZK	DN	Anti-CD19 CAR-T cells
DMDRYZK	MI	TTW640A
DMDRYZK	MN	B-lymphocyte surface antigen B4 (CD19)
DMDRYZK	MT	DTT
DMDRYZK	MA	CAR-T-Cell-Therapy
DMDRYZK	RN	ClinicalTrials.gov (NCT02851589) Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
DMDRYZK	RU	https://clinicaltrials.gov/ct2/show/NCT02851589

DMSFEOC	DI	DMSFEOC
DMSFEOC	DN	Anti-CD19 CAR-T cells
DMSFEOC	MI	TTW640A
DMSFEOC	MN	B-lymphocyte surface antigen B4 (CD19)
DMSFEOC	MT	DTT
DMSFEOC	MA	CAR-T-Cell-Therapy
DMSFEOC	RN	ClinicalTrials.gov (NCT02782351) Humanized CAR-T Therapy for Treatment of B Cell Malignancy
DMSFEOC	RU	https://clinicaltrials.gov/ct2/show/NCT02782351

DM1EH9D	DI	DM1EH9D
DM1EH9D	DN	Anti-CD19 CAR-T cells
DM1EH9D	MI	TTW640A
DM1EH9D	MN	B-lymphocyte surface antigen B4 (CD19)
DM1EH9D	MT	DTT
DM1EH9D	MA	CAR-T-Cell-Therapy
DM1EH9D	RN	ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
DM1EH9D	RU	https://clinicaltrials.gov/ct2/show/NCT03638206

DM92CUG	DI	DM92CUG
DM92CUG	DN	Anti-CD19 CAR-T cells
DM92CUG	MI	TTW640A
DM92CUG	MN	B-lymphocyte surface antigen B4 (CD19)
DM92CUG	MT	DTT
DM92CUG	MA	CAR-T-Cell-Therapy
DM92CUG	RN	ClinicalTrials.gov (NCT03366324) Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies
DM92CUG	RU	https://clinicaltrials.gov/ct2/show/NCT03366324

DMMUSHR	DI	DMMUSHR
DMMUSHR	DN	Anti-CD19/22-CAR vector-transduced T cells
DMMUSHR	MI	TTM6QSK
DMMUSHR	MN	B-cell receptor CD22 (CD22)
DMMUSHR	MT	DTT
DMMUSHR	MA	CAR-T-Cell-Therapy(Dual specific)
DMMUSHR	RN	ClinicalTrials.gov (NCT03185494) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22
DMMUSHR	RU	https://clinicaltrials.gov/ct2/show/NCT03185494

DMMUSHR	DI	DMMUSHR
DMMUSHR	DN	Anti-CD19/22-CAR vector-transduced T cells
DMMUSHR	MI	TTW640A
DMMUSHR	MN	B-lymphocyte surface antigen B4 (CD19)
DMMUSHR	MT	DTT
DMMUSHR	MA	CAR-T-Cell-Therapy(Dual specific)
DMMUSHR	RN	ClinicalTrials.gov (NCT03185494) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22
DMMUSHR	RU	https://clinicaltrials.gov/ct2/show/NCT03185494

DM1WB8H	DI	DM1WB8H
DM1WB8H	DN	Anti-CD19-CAR PBL
DM1WB8H	MI	TTW640A
DM1WB8H	MN	B-lymphocyte surface antigen B4 (CD19)
DM1WB8H	MT	DTT
DM1WB8H	MA	CAR-T-Cell-Therapy
DM1WB8H	RN	ClinicalTrials.gov (NCT00924326) CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma
DM1WB8H	RU	https://clinicaltrials.gov/ct2/show/NCT00924326

DMQXU4C	DI	DMQXU4C
DMQXU4C	DN	Anti-CD19-CAR vector-transduced T cells
DMQXU4C	MI	TTW640A
DMQXU4C	MN	B-lymphocyte surface antigen B4 (CD19)
DMQXU4C	MT	DTT
DMQXU4C	MA	CAR-T-Cell-Therapy
DMQXU4C	RN	ClinicalTrials.gov (NCT02081937) CART-19 Immunotherapy in Mantle Cell Lymphoma
DMQXU4C	RU	https://clinicaltrials.gov/ct2/show/NCT02081937

DMNTP23	DI	DMNTP23
DMNTP23	DN	Anti-CD19-CAR-T cells
DMNTP23	MI	TTW640A
DMNTP23	MN	B-lymphocyte surface antigen B4 (CD19)
DMNTP23	MT	DTT
DMNTP23	MA	CAR-T-Cell-Therapy
DMNTP23	RN	ClinicalTrials.gov (NCT02672501) A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia
DMNTP23	RU	https://clinicaltrials.gov/ct2/show/NCT02672501

DM4WEZL	DI	DM4WEZL
DM4WEZL	DN	Anti-CD20 CAR-T cells
DM4WEZL	MI	TTW640A
DM4WEZL	MN	B-lymphocyte surface antigen B4 (CD19)
DM4WEZL	MT	DTT
DM4WEZL	MA	CAR-T-Cell-Therapy(Dual specific)
DM4WEZL	RN	ClinicalTrials.gov (NCT02737085) the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)
DM4WEZL	RU	https://clinicaltrials.gov/ct2/show/NCT02737085

DM4WEZL	DI	DM4WEZL
DM4WEZL	DN	Anti-CD20 CAR-T cells
DM4WEZL	MI	TTUE541
DM4WEZL	MN	Leukocyte surface antigen Leu-16 (CD20)
DM4WEZL	MT	DTT
DM4WEZL	MA	CAR-T-Cell-Therapy(Dual specific)
DM4WEZL	RN	ClinicalTrials.gov (NCT02737085) the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)
DM4WEZL	RU	https://clinicaltrials.gov/ct2/show/NCT02737085

DMCDUJY	DI	DMCDUJY
DMCDUJY	DN	Anti-CD20-CAR vector-transduced autologous T cells
DMCDUJY	MI	TTUE541
DMCDUJY	MN	Leukocyte surface antigen Leu-16 (CD20)
DMCDUJY	MT	DTT
DMCDUJY	MA	CAR-T-Cell-Therapy
DMCDUJY	RN	ClinicalTrials.gov (NCT01735604) Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy
DMCDUJY	RU	https://clinicaltrials.gov/ct2/show/NCT01735604

DMXMK30	DI	DMXMK30
DMXMK30	DN	Anti-CD20-CAR-transduced T cells
DMXMK30	MI	TTUE541
DMXMK30	MN	Leukocyte surface antigen Leu-16 (CD20)
DMXMK30	MT	DTT
DMXMK30	MA	CAR-T-Cell-Therapy
DMXMK30	RN	ClinicalTrials.gov (NCT02710149) A Clinical Research of CD20-Targeted CAR-T in B Cell Malignancies
DMXMK30	RU	https://clinicaltrials.gov/ct2/show/NCT02710149

DMY6U8R	DI	DMY6U8R
DMY6U8R	DN	Anti-CD22 CAR-T cells
DMY6U8R	MI	TTM6QSK
DMY6U8R	MN	B-cell receptor CD22 (CD22)
DMY6U8R	MT	DTT
DMY6U8R	MA	CAR-T-Cell-Therapy
DMY6U8R	RN	ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
DMY6U8R	RU	https://clinicaltrials.gov/ct2/show/NCT03638206

DMTO9VF	DI	DMTO9VF
DMTO9VF	DN	Anti-CD22-CAR-transduced T cells
DMTO9VF	MI	TTM6QSK
DMTO9VF	MN	B-cell receptor CD22 (CD22)
DMTO9VF	MT	DTT
DMTO9VF	MA	CAR-T-Cell-Therapy
DMTO9VF	RN	ClinicalTrials.gov (NCT03262298) Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies
DMTO9VF	RU	https://clinicaltrials.gov/ct2/show/NCT03262298

DM8139V	DI	DM8139V
DM8139V	DN	Anti-CD30 CAR T cells
DM8139V	MI	TT2GM5R
DM8139V	MN	Lymphocyte activation antigen CD30 (TNFRSF8)
DM8139V	MT	DTT
DM8139V	MA	CAR-T-Cell-Therapy
DM8139V	RN	ClinicalTrials.gov (NCT02274584) CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)
DM8139V	RU	https://clinicaltrials.gov/ct2/show/NCT02274584

DMTZSPJ	DI	DMTZSPJ
DMTZSPJ	DN	Anti-CD30-CAR-transduced T cells
DMTZSPJ	MI	TT2GM5R
DMTZSPJ	MN	Lymphocyte activation antigen CD30 (TNFRSF8)
DMTZSPJ	MT	DTT
DMTZSPJ	MA	CAR-T-Cell-Therapy
DMTZSPJ	RN	ClinicalTrials.gov (NCT02958410) A Clinical Research of CD30-Targeted CAR-T in Lymphocyte Malignancies
DMTZSPJ	RU	https://clinicaltrials.gov/ct2/show/NCT02958410

DM9NPF6	DI	DM9NPF6
DM9NPF6	DN	Anti-CD33 CAR-T cells
DM9NPF6	MI	TTJVYO3
DM9NPF6	MN	Myeloid cell surface antigen CD33 (CD33)
DM9NPF6	MT	DTT
DM9NPF6	MA	CAR-T-Cell-Therapy
DM9NPF6	RN	ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
DM9NPF6	RU	https://clinicaltrials.gov/ct2/show/NCT03638206

DMTVXBY	DI	DMTVXBY
DMTVXBY	DN	Anti-CD38 CAR-T cells
DMTVXBY	MI	TTPURFN
DMTVXBY	MN	Cyclic ADP-ribose hydrolase 1 (CD38)
DMTVXBY	MT	DTT
DMTVXBY	MA	CAR-T-Cell-Therapy
DMTVXBY	RN	ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
DMTVXBY	RU	https://clinicaltrials.gov/ct2/show/NCT03638206

DMV5H0S	DI	DMV5H0S
DMV5H0S	DN	Anti-C-met CAR-T cells
DMV5H0S	MI	TTNDSF4
DMV5H0S	MN	Proto-oncogene c-Met (MET)
DMV5H0S	MT	DTT
DMV5H0S	MA	CAR-T-Cell-Therapy
DMV5H0S	RN	ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
DMV5H0S	RU	https://clinicaltrials.gov/ct2/show/NCT03638206

DMYKZB3	DI	DMYKZB3
DMYKZB3	DN	Anti-DR5 cells
DMYKZB3	MI	TTW20TU
DMYKZB3	MN	TRAIL receptor 2 (TRAIL-R2)
DMYKZB3	MT	DTT
DMYKZB3	MA	CAR-T-Cell-Therapy
DMYKZB3	RN	ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
DMYKZB3	RU	https://clinicaltrials.gov/ct2/show/NCT03638206

DM8EAGV	DI	DM8EAGV
DM8EAGV	DN	Anti-EGFR V III CAR-T cells
DM8EAGV	MI	TTZ6B2I
DM8EAGV	MN	Epidermal growth factor receptor variant III (EGFR vIII)
DM8EAGV	MT	DTT
DM8EAGV	MA	CAR-T-Cell-Therapy
DM8EAGV	RN	ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
DM8EAGV	RU	https://clinicaltrials.gov/ct2/show/NCT03638206

DMDKTYU	DI	DMDKTYU
DMDKTYU	DN	Anti-EGFRvIII CAR transduced PBL
DMDKTYU	MI	TTZ6B2I
DMDKTYU	MN	Epidermal growth factor receptor variant III (EGFR vIII)
DMDKTYU	MT	DTT
DMDKTYU	MA	CAR-T-Cell-Therapy
DMDKTYU	RN	ClinicalTrials.gov (NCT01454596) CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII. U.S. National Institutes of Health.
DMDKTYU	RU	https://clinicaltrials.gov/ct2/show/NCT01454596

DM8ENKS	DI	DM8ENKS
DM8ENKS	DN	Anti-Factor D
DM8ENKS	MI	TT8D13I
DM8ENKS	MN	Complement factor D (CFD)
DM8ENKS	MT	DTT
DM8ENKS	RN	Association for Research in Vision and Ophthalmology (ARVO)--2010 Annual Meeting. For Sight: The Future of Eye and Vision Research--part 1. IDrugs. 2010 Jul;13(7):427-9.
DM8ENKS	RU	https://pubmed.ncbi.nlm.nih.gov/20582862

DMQD6B9	DI	DMQD6B9
DMQD6B9	DN	Anti-HER2 CAR-T
DMQD6B9	MI	TT6EO5L
DMQD6B9	MN	Erbb2 tyrosine kinase receptor (HER2)
DMQD6B9	MT	DTT
DMQD6B9	MA	CAR-T-Cell-Therapy
DMQD6B9	RN	ClinicalTrials.gov (NCT02713984) A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
DMQD6B9	RU	https://clinicaltrials.gov/ct2/show/NCT02713984

DMQZJ3B	DI	DMQZJ3B
DMQZJ3B	DN	Anti-HIV ribozyme therapy
DMQZJ3B	MI	TTT3ZC9
DMQZJ3B	MN	Human immunodeficiency virus Tat protein (HIV tat)
DMQZJ3B	MT	DTT
DMQZJ3B	MA	Modulator
DMQZJ3B	RN	Clinical gene therapy research utilizing ribozymes: application to the treatment of HIV/AIDS. Methods Mol Biol. 2004;252:581-98.
DMQZJ3B	RU	https://pubmed.ncbi.nlm.nih.gov/15017082

DMXI03L	DI	DMXI03L
DMXI03L	DN	Anti-mesothelin CAR transduced PBL
DMXI03L	MI	TT4RXME
DMXI03L	MN	Mesothelin (MSLN)
DMXI03L	MT	DTT
DMXI03L	MA	CAR-T-Cell-Therapy
DMXI03L	RN	ClinicalTrials.gov (NCT01583686) CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
DMXI03L	RU	https://clinicaltrials.gov/ct2/show/NCT01583686

DM4NMBW	DI	DM4NMBW
DM4NMBW	DN	Anti-Mesothelin CAR-T cells
DM4NMBW	MI	TT4RXME
DM4NMBW	MN	Mesothelin (MSLN)
DM4NMBW	MT	DTT
DM4NMBW	MA	CAR-T-Cell-Therapy
DM4NMBW	RN	ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
DM4NMBW	RU	https://clinicaltrials.gov/ct2/show/NCT03638206

DM0C1IX	DI	DM0C1IX
DM0C1IX	DN	Anti-MUC1 CAR T Cells
DM0C1IX	MI	TTBHFYQ
DM0C1IX	MN	Mucin-1 (MUC1)
DM0C1IX	MT	DTT
DM0C1IX	MA	CAR-T-Cell-Therapy
DM0C1IX	RN	ClinicalTrials.gov (NCT02587689) Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor
DM0C1IX	RU	https://clinicaltrials.gov/ct2/show/NCT02587689

DMDHKN1	DI	DMDHKN1
DMDHKN1	DN	Anti-MUC1 CAR T Cells
DMDHKN1	MI	TTBHFYQ
DMDHKN1	MN	Mucin-1 (MUC1)
DMDHKN1	MT	DTT
DMDHKN1	MA	CAR-T-Cell-Therapy
DMDHKN1	RN	ClinicalTrials.gov (NCT03525782) Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC
DMDHKN1	RU	https://clinicaltrials.gov/ct2/show/NCT03525782

DMXYOTP	DI	DMXYOTP
DMXYOTP	DN	Anti-MUC1 CAR-T cells
DMXYOTP	MI	TTBHFYQ
DMXYOTP	MN	Mucin-1 (MUC1)
DMXYOTP	MT	DTT
DMXYOTP	MA	CAR-T-Cell-Therapy
DMXYOTP	RN	ClinicalTrials.gov (NCT03706326) CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer
DMXYOTP	RU	https://clinicaltrials.gov/ct2/show/NCT03706326

DMTQIB2	DI	DMTQIB2
DMTQIB2	DN	Anti-MUC1 CAR-T cells
DMTQIB2	MI	TTBHFYQ
DMTQIB2	MN	Mucin-1 (MUC1)
DMTQIB2	MT	DTT
DMTQIB2	MA	CAR-T-Cell-Therapy
DMTQIB2	RN	ClinicalTrials.gov (NCT02617134) CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor
DMTQIB2	RU	https://clinicaltrials.gov/ct2/show/NCT02617134

DM26VCZ	DI	DM26VCZ
DM26VCZ	DN	Anti-NY-ESO-1 CAR-T cells
DM26VCZ	MI	TTE5ITK
DM26VCZ	MN	Cancer/testis antigen 1 (NY-ESO-1)
DM26VCZ	MT	DTT
DM26VCZ	MA	CAR-T-Cell-Therapy
DM26VCZ	RN	ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
DM26VCZ	RU	https://clinicaltrials.gov/ct2/show/NCT03638206

DM2910G	DI	DM2910G
DM2910G	DN	Anti-VEGFR2 CD8 cell therapy
DM2910G	MI	TTMHA6L
DM2910G	MN	T-cell surface glycoprotein CD8 (CD8)
DM2910G	MT	DTT
DM2910G	MA	Modulator
DM2910G	RN	Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17561-6.
DM2910G	RU	https://pubmed.ncbi.nlm.nih.gov/23045683

DM2910G	DI	DM2910G
DM2910G	DN	Anti-VEGFR2 CD8 cell therapy
DM2910G	MI	TTUTJGQ
DM2910G	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM2910G	MT	DTT
DM2910G	MA	Modulator
DM2910G	RN	Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17561-6.
DM2910G	RU	https://pubmed.ncbi.nlm.nih.gov/23045683

DMXU98C	DI	DMXU98C
DMXU98C	DN	AO-176
DMXU98C	MI	TT28S46
DMXU98C	MN	Leukocyte surface antigen CD47 (CD47)
DMXU98C	MT	DTT
DMXU98C	MA	Inhibitor
DMXU98C	RN	Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding. Mol Cancer Ther. 2020 Mar;19(3):835-846.
DMXU98C	RU	https://pubmed.ncbi.nlm.nih.gov/31879362

DMBGA35	DI	DMBGA35
DMBGA35	DN	AP-1030
DMBGA35	MI	TT0MV2T
DMBGA35	MN	Melanocortin receptor 1 (MC1R)
DMBGA35	MT	DTT
DMBGA35	MA	Modulator
DMBGA35	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMBGA35	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMBGA35	DI	DMBGA35
DMBGA35	DN	AP-1030
DMBGA35	MI	TTD0CIQ
DMBGA35	MN	Melanocortin receptor 4 (MC4R)
DMBGA35	MT	DTT
DMBGA35	MA	Modulator
DMBGA35	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMBGA35	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM2LU8M	DI	DM2LU8M
DM2LU8M	DN	AP1903
DM2LU8M	MI	TTMW94E
DM2LU8M	MN	FK506-binding protein 1A (FKBP1A)
DM2LU8M	MT	DTT
DM2LU8M	MA	Modulator
DM2LU8M	RN	Using gene transfer to circumvent off-target effects. Gene Ther. 2008 May;15(10):759-64.
DM2LU8M	RU	https://pubmed.ncbi.nlm.nih.gov/18356813

DMJLMEF	DI	DMJLMEF
DMJLMEF	DN	AP-30663
DMJLMEF	MI	TTKU9YD
DMJLMEF	MN	Calcium-activated potassium channel KCa2 (KCNN)
DMJLMEF	MT	DTT
DMJLMEF	MA	Inhibitor
DMJLMEF	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMJLMEF	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DM71I53	DI	DM71I53
DM71I53	DN	APC-100
DM71I53	MI	TTS64P2
DM71I53	MN	Androgen receptor (AR)
DM71I53	MT	DTT
DM71I53	MA	Inhibitor
DM71I53	RN	2011 Pipeline of Adamis Pharmaceuticals.
DM71I53	RU	http://www.adamispharmaceuticals.com/

DM8O3R9	DI	DM8O3R9
DM8O3R9	DN	APG-1252
DM8O3R9	MI	TTJGNVC
DM8O3R9	MN	Apoptosis regulator Bcl-2 (BCL-2)
DM8O3R9	MT	DTT
DM8O3R9	MA	Inhibitor
DM8O3R9	RN	Bcl-2/Bcl-xl inhibitor APG-1252-M1 is a promising therapeutic strategy for gastric carcinoma. Cancer Med. 2020 Jun;9(12):4197-4206.
DM8O3R9	RU	https://pubmed.ncbi.nlm.nih.gov/32346976

DM8O3R9	DI	DM8O3R9
DM8O3R9	DN	APG-1252
DM8O3R9	MI	TTU1E82
DM8O3R9	MN	Apoptosis regulator Bcl-xL (BCL-xL)
DM8O3R9	MT	DTT
DM8O3R9	MA	Inhibitor
DM8O3R9	RN	Bcl-2/Bcl-xl inhibitor APG-1252-M1 is a promising therapeutic strategy for gastric carcinoma. Cancer Med. 2020 Jun;9(12):4197-4206.
DM8O3R9	RU	https://pubmed.ncbi.nlm.nih.gov/32346976

DMPWBM2	DI	DMPWBM2
DMPWBM2	DN	APG-2575
DMPWBM2	MI	TTJGNVC
DMPWBM2	MN	Apoptosis regulator Bcl-2 (BCL-2)
DMPWBM2	MT	DTT
DMPWBM2	MA	Inhibitor
DMPWBM2	RN	A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma. Oncol Res. 2020 Sep 1;28(4):331-344.
DMPWBM2	RU	https://pubmed.ncbi.nlm.nih.gov/32093809

DMV7Q6X	DI	DMV7Q6X
DMV7Q6X	DN	APN-201
DMV7Q6X	MI	TT6RVLG
DMV7Q6X	MN	Superoxide dismutase Cu-Zn (SOD Cu-Zn)
DMV7Q6X	MT	DTT
DMV7Q6X	MA	Modulator
DMV7Q6X	RN	Peyronie's disease: a critical appraisal of current diagnosis and treatment. Int J Impot Res. 2008 Sep-Oct;20(5):445-59.
DMV7Q6X	RU	https://pubmed.ncbi.nlm.nih.gov/18650828

DM76S3X	DI	DM76S3X
DM76S3X	DN	ARO-HBV
DM76S3X	MI	TT43YWN
DM76S3X	MN	Hepatitis B virus messenger RNA (HBV mRNA)
DM76S3X	MT	DTT
DM76S3X	MA	Inhibitor
DM76S3X	RN	Clinical pipeline report, company report or official report of Arrowhead Pharmaceuticals.
DM76S3X	RU	https://arrowheadpharma.com/pipeline/

DMI17NX	DI	DMI17NX
DMI17NX	DN	ART621
DMI17NX	MI	TTF8CQI
DMI17NX	MN	Tumor necrosis factor (TNF)
DMI17NX	MT	DTT
DMI17NX	MA	Inhibitor
DMI17NX	RN	Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
DMI17NX	RU	https://pubmed.ncbi.nlm.nih.gov/19249988

DMYCID5	DI	DMYCID5
DMYCID5	DN	ARV-110
DMYCID5	MI	TTS64P2
DMYCID5	MN	Androgen receptor (AR)
DMYCID5	MT	DTT
DMYCID5	MA	Degrader
DMYCID5	RN	Clinical pipeline report, company report or official report of Arvinas.
DMYCID5	RU	https://www.arvinas.com/pipeline-programs/androgen-receptor

DM276Y8	DI	DM276Y8
DM276Y8	DN	ARV-471
DM276Y8	MI	TTS64P2
DM276Y8	MN	Androgen receptor (AR)
DM276Y8	MT	DTT
DM276Y8	MA	Degrader
DM276Y8	RN	Targeting estrogen receptor alpha for degradation with PROTACs: A promising approach to overcome endocrine resistance. Eur J Med Chem. 2020 Nov 15;206:112689.
DM276Y8	RU	https://pubmed.ncbi.nlm.nih.gov/32829249

DMVNCSK	DI	DMVNCSK
DMVNCSK	DN	ASC-101
DMVNCSK	MI	TT3C1VN
DMVNCSK	MN	Enzyme unspecific (Enz)
DMVNCSK	MT	DTT
DMVNCSK	MA	Modulator
DMVNCSK	RN	ClinicalTrials.gov (NCT01983761) Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation. U.S. National Institutes of Health.
DMVNCSK	RU	https://clinicaltrials.gov/ct2/show/NCT01983761

DM8V0UL	DI	DM8V0UL
DM8V0UL	DN	ASP-9521
DM8V0UL	MI	TT5ZWB6
DM8V0UL	MN	Dihydrodiol dehydrogenase type I (AKR1C3)
DM8V0UL	MT	DTT
DM8V0UL	MA	Modulator
DM8V0UL	RN	Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study. Invest New Drugs. 2014 Oct;32(5):995-1004.
DM8V0UL	RU	https://pubmed.ncbi.nlm.nih.gov/24771350

DMVZXIA	DI	DMVZXIA
DMVZXIA	DN	ASTX029
DMVZXIA	MI	TT1MG9E
DMVZXIA	MN	Extracellular signal-regulated kinase 1 (ERK1)
DMVZXIA	MT	DTT
DMVZXIA	MA	Inhibitor
DMVZXIA	RN	Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
DMVZXIA	RU	https://astx.com/research-development/clinical-pipeline/

DMVZXIA	DI	DMVZXIA
DMVZXIA	DN	ASTX029
DMVZXIA	MI	TT4TQBX
DMVZXIA	MN	Extracellular signal-regulated kinase 2 (ERK2)
DMVZXIA	MT	DTT
DMVZXIA	MA	Inhibitor
DMVZXIA	RN	Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
DMVZXIA	RU	https://astx.com/research-development/clinical-pipeline/

DM9EM5G	DI	DM9EM5G
DM9EM5G	DN	ASTX295
DM9EM5G	MI	TT08GJW
DM9EM5G	MN	Ubiquitin-protein ligase E3 Mdm2 (MDM2)
DM9EM5G	MT	DTT
DM9EM5G	MA	Antagonist
DM9EM5G	RN	Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
DM9EM5G	RU	https://astx.com/research-development/clinical-pipeline/astx295-oral-murine-double-minute-2-mdm2-antagonist-solid-tumors/

DMSOQ6E	DI	DMSOQ6E
DMSOQ6E	DN	AT-342
DMSOQ6E	MI	TT34ZAF
DMSOQ6E	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMSOQ6E	MT	DTT
DMSOQ6E	MA	Replacement
DMSOQ6E	RN	ClinicalTrials.gov (NCT03223194) Gene Transfer Clinical Study in Crigler-Najjar Syndrome (VALENS). U.S. National Institutes of Health.
DMSOQ6E	RU	https://clinicaltrials.gov/ct2/show/NCT03223194

DM7O89Q	DI	DM7O89Q
DM7O89Q	DN	AT-777
DM7O89Q	MI	TTMVBWH
DM7O89Q	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DM7O89Q	MT	DTT
DM7O89Q	MA	Inhibitor
DM7O89Q	RN	Clinical pipeline report, company report or official report of Atea Pharmaceuticals.
DM7O89Q	RU	https://ateapharma.com/about-us/hepatitis-c/

DMB5X7Z	DI	DMB5X7Z
DMB5X7Z	DN	ATG002
DMB5X7Z	MI	TTJSZTB
DMB5X7Z	MN	Nicotinic acetylcholine receptor (nAChR)
DMB5X7Z	MT	DTT
DMB5X7Z	MA	Agonist
DMB5X7Z	RN	Athenagen Advances Angiogenesis Drug to Clinical Testing. Athenagen. JUNE 21, 2006.
DMB5X7Z	RU	http://www.prnewswire.com/news-releases/athenagen-advances-angiogenesis-drug-to-clinical-testing-56212977.html

DM84YEC	DI	DM84YEC
DM84YEC	DN	Atiprimod
DM84YEC	MI	TTH8FZW
DM84YEC	MN	Signal transducer and activator of transcription 3 (STAT3)
DM84YEC	MT	DTT
DM84YEC	MA	Inhibitor
DM84YEC	RN	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
DM84YEC	RU	https://pubmed.ncbi.nlm.nih.gov/19249983

DM75QY9	DI	DM75QY9
DM75QY9	DN	ATL-313
DM75QY9	MI	TTM2AOE
DM75QY9	MN	Adenosine A2a receptor (ADORA2A)
DM75QY9	MT	DTT
DM75QY9	MA	Agonist
DM75QY9	RN	Effect of novel A2A adenosine receptor agonist ATL 313 on Clostridium difficile toxin A-induced murine ileal enteritis. Infect Immun. 2006 May;74(5):2606-12.
DM75QY9	RU	https://pubmed.ncbi.nlm.nih.gov/16622196

DMLAKPI	DI	DMLAKPI
DMLAKPI	DN	AU101
DMLAKPI	MI	TTQ13FT
DMLAKPI	MN	T-cell-specific surface glycoprotein CD28 (CD28)
DMLAKPI	MT	DTT
DMLAKPI	MA	Immunomodulator
DMLAKPI	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMLAKPI	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMPAZ3U	DI	DMPAZ3U
DMPAZ3U	DN	AU105
DMPAZ3U	MI	TT6EO5L
DMPAZ3U	MN	Erbb2 tyrosine kinase receptor (HER2)
DMPAZ3U	MT	DTT
DMPAZ3U	MA	Immunomodulator
DMPAZ3U	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPAZ3U	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMG9OAV	DI	DMG9OAV
DMG9OAV	DN	AUTO1
DMG9OAV	MI	TTW640A
DMG9OAV	MN	B-lymphocyte surface antigen B4 (CD19)
DMG9OAV	MT	DTT
DMG9OAV	RN	Clinical pipeline report, company report or official report of Autolus Therapeutics.
DMG9OAV	RU	https://www.autolus.com/pipeline/

DM0PWX2	DI	DM0PWX2
DM0PWX2	DN	AUTO2
DM0PWX2	MI	TTZ3P4W
DM0PWX2	MN	B-cell maturation protein (TNFRSF17)
DM0PWX2	MT	DTT
DM0PWX2	MA	CAR-T-Cell-Therapy(Dual specific)
DM0PWX2	RN	ClinicalTrials.gov (NCT03287804) APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma
DM0PWX2	RU	https://clinicaltrials.gov/ct2/show/NCT03287804

DM0PWX2	DI	DM0PWX2
DM0PWX2	DN	AUTO2
DM0PWX2	MI	TTL9OD4
DM0PWX2	MN	Transmembrane activator and CAML interactor (TNFRSF13B)
DM0PWX2	MT	DTT
DM0PWX2	MA	CAR-T-Cell-Therapy(Dual specific)
DM0PWX2	RN	ClinicalTrials.gov (NCT03287804) APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma
DM0PWX2	RU	https://clinicaltrials.gov/ct2/show/NCT03287804

DMC5NSO	DI	DMC5NSO
DMC5NSO	DN	AUTO3
DMC5NSO	MI	TTM6QSK
DMC5NSO	MN	B-cell receptor CD22 (CD22)
DMC5NSO	MT	DTT
DMC5NSO	MA	CAR-T-Cell-Therapy(Dual specific)
DMC5NSO	RN	ClinicalTrials.gov (NCT03289455) CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell ALL
DMC5NSO	RU	https://clinicaltrials.gov/ct2/show/NCT03289455

DMC5NSO	DI	DMC5NSO
DMC5NSO	DN	AUTO3
DMC5NSO	MI	TTW640A
DMC5NSO	MN	B-lymphocyte surface antigen B4 (CD19)
DMC5NSO	MT	DTT
DMC5NSO	MA	CAR-T-Cell-Therapy(Dual specific)
DMC5NSO	RN	ClinicalTrials.gov (NCT03289455) CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell ALL
DMC5NSO	RU	https://clinicaltrials.gov/ct2/show/NCT03289455

DM2YTGQ	DI	DM2YTGQ
DM2YTGQ	DN	Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes
DM2YTGQ	MI	TTW640A
DM2YTGQ	MN	B-lymphocyte surface antigen B4 (CD19)
DM2YTGQ	MT	DTT
DM2YTGQ	MA	CAR-T-Cell-Therapy
DM2YTGQ	RN	ClinicalTrials.gov (NCT01865617) Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia
DM2YTGQ	RU	https://clinicaltrials.gov/ct2/show/NCT01865617

DMLOGI4	DI	DMLOGI4
DMLOGI4	DN	Autologous CD19-targeting CAR T cells
DMLOGI4	MI	TTW640A
DMLOGI4	MN	B-lymphocyte surface antigen B4 (CD19)
DMLOGI4	MT	DTT
DMLOGI4	MA	CAR-T-Cell-Therapy
DMLOGI4	RN	ClinicalTrials.gov (NCT02963038) CAR T Cells for Refractory B Cell Malignancy
DMLOGI4	RU	https://clinicaltrials.gov/ct2/show/NCT02963038

DMRS58M	DI	DMRS58M
DMRS58M	DN	Avrina
DMRS58M	MI	TTSXVID
DMRS58M	MN	Nuclear factor NF-kappa-B (NFKB)
DMRS58M	MT	DTT
DMRS58M	MA	Modulator
DMRS58M	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMRS58M	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMC1XHK	DI	DMC1XHK
DMC1XHK	DN	AVR-RD-01
DMC1XHK	MI	TTIS03D
DMC1XHK	MN	Alpha-galactosidase A (GLA)
DMC1XHK	MT	DTT
DMC1XHK	RN	Clinical pipeline report, company report or official report of Avrobio.
DMC1XHK	RU	https://www.avrobio.com/our-pipeline/

DMOPVIQ	DI	DMOPVIQ
DMOPVIQ	DN	AVX701
DMOPVIQ	MI	TTY6DTE
DMOPVIQ	MN	Carcinoembryonic antigen CEA (CD66e)
DMOPVIQ	MT	DTT
DMOPVIQ	MA	Modulator
DMOPVIQ	RN	Viral vector-based therapeutic cancer vaccines. Cancer J. 2011 Sep-Oct;17(5):359-71.
DMOPVIQ	RU	https://pubmed.ncbi.nlm.nih.gov/21952287

DM7O29W	DI	DM7O29W
DM7O29W	DN	AVX901
DM7O29W	MI	TT6EO5L
DM7O29W	MN	Erbb2 tyrosine kinase receptor (HER2)
DM7O29W	MT	DTT
DM7O29W	MA	Inhibitor
DM7O29W	RN	ClinicalTrials.gov (NCT01526473) A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901. U.S. National Institutes of Health.
DM7O29W	RU	https://clinicaltrials.gov/ct2/show/NCT01526473

DMWLZI6	DI	DMWLZI6
DMWLZI6	DN	AZD0466
DMWLZI6	MI	TTJGNVC
DMWLZI6	MN	Apoptosis regulator Bcl-2 (BCL-2)
DMWLZI6	MT	DTT
DMWLZI6	MA	Inhibitor
DMWLZI6	RN	Design and optimisation of dendrimer-conjugated Bcl-2/x L inhibitor, AZD0466, with improved therapeutic index for cancer therapy. Commun Biol. 2021 Jan 25;4(1):112.
DMWLZI6	RU	https://pubmed.ncbi.nlm.nih.gov/33495510

DMWLZI6	DI	DMWLZI6
DMWLZI6	DN	AZD0466
DMWLZI6	MI	TTU1E82
DMWLZI6	MN	Apoptosis regulator Bcl-xL (BCL-xL)
DMWLZI6	MT	DTT
DMWLZI6	MA	Inhibitor
DMWLZI6	RN	Design and optimisation of dendrimer-conjugated Bcl-2/x L inhibitor, AZD0466, with improved therapeutic index for cancer therapy. Commun Biol. 2021 Jan 25;4(1):112.
DMWLZI6	RU	https://pubmed.ncbi.nlm.nih.gov/33495510

DMT2FAP	DI	DMT2FAP
DMT2FAP	DN	AZD-2836
DMT2FAP	MI	TTCJ2X8
DMT2FAP	MN	Hepatitis C virus Non-structural 5A (HCV NS5A)
DMT2FAP	MT	DTT
DMT2FAP	MA	Modulator
DMT2FAP	RN	TARGETING THE NS5A PROTEIN OF HCV: AN EMERGING OPTION. Drugs Future. 2011 September; 36(9): 691-711.
DMT2FAP	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3558953/

DMD9Y5T	DI	DMD9Y5T
DMD9Y5T	DN	AZD7648
DMD9Y5T	MI	TTK3PY9
DMD9Y5T	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMD9Y5T	MT	DTT
DMD9Y5T	MA	Inhibitor
DMD9Y5T	RN	AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity. Nat Commun. 2019 Nov 7;10(1):5065.
DMD9Y5T	RU	https://pubmed.ncbi.nlm.nih.gov/31699977

DMPFGL8	DI	DMPFGL8
DMPFGL8	DN	BAL-101553
DMPFGL8	MI	TTML2WA
DMPFGL8	MN	Tubulin (TUB)
DMPFGL8	MT	DTT
DMPFGL8	MA	Inhibitor
DMPFGL8	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPFGL8	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMPFGL8	DI	DMPFGL8
DMPFGL8	DN	BAL-101553
DMPFGL8	MI	TTYFKSZ
DMPFGL8	MN	Tubulin beta (TUBB)
DMPFGL8	MT	DTT
DMPFGL8	MA	Inhibitor
DMPFGL8	RN	Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2015 Jun;62(6):1106-9.
DMPFGL8	RU	https://pubmed.ncbi.nlm.nih.gov/25407467

DMFA4CK	DI	DMFA4CK
DMFA4CK	DN	BAY 1902607
DMFA4CK	MI	TT2THBD
DMFA4CK	MN	P2X purinoceptor 3 (P2RX3)
DMFA4CK	MT	DTT
DMFA4CK	MA	Antagonist
DMFA4CK	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMFA4CK	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMH70A9	DI	DMH70A9
DMH70A9	DN	BCMA CAR T cells
DMH70A9	MI	TTZ3P4W
DMH70A9	MN	B-cell maturation protein (TNFRSF17)
DMH70A9	MT	DTT
DMH70A9	MA	CAR-T-Cell-Therapy
DMH70A9	RN	ClinicalTrials.gov (NCT03271632) Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
DMH70A9	RU	https://clinicaltrials.gov/ct2/show/NCT03271632

DM1DHPO	DI	DM1DHPO
DM1DHPO	DN	BCMA CAR-T
DM1DHPO	MI	TTZ3P4W
DM1DHPO	MN	B-cell maturation protein (TNFRSF17)
DM1DHPO	MT	DTT
DM1DHPO	MA	CAR-T-Cell-Therapy
DM1DHPO	RN	ClinicalTrials.gov (NCT03322735) Study of BCMA CAR-T in Multiple Myeloma
DM1DHPO	RU	https://clinicaltrials.gov/ct2/show/NCT03322735

DMZK7IT	DI	DMZK7IT
DMZK7IT	DN	BCT-100
DMZK7IT	MI	TTSANDR
DMZK7IT	MN	Arginase (ARG)
DMZK7IT	MT	DTT
DMZK7IT	MA	Modulator
DMZK7IT	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMZK7IT	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMJ5MPG	DI	DMJ5MPG
DMJ5MPG	DN	BDC-1001
DMJ5MPG	MI	TTY6DTE
DMJ5MPG	MN	Carcinoembryonic antigen CEA (CD66e)
DMJ5MPG	MT	DTT
DMJ5MPG	RN	Clinical pipeline report, company report or official report of Bolt Biotherapeutics.
DMJ5MPG	RU	https://www.boltbio.com/pipeline/

DMODTX5	DI	DMODTX5
DMODTX5	DN	BDTX-189
DMODTX5	MI	TTGKNB4
DMODTX5	MN	Epidermal growth factor receptor (EGFR)
DMODTX5	MT	DTT
DMODTX5	MA	Inhibitor
DMODTX5	RN	Clinical pipeline report, company report or official report of Black Diamond Therapeutics.
DMODTX5	RU	https://www.blackdiamondtherapeutics.com/pipeline/bdtx-189/

DMODTX5	DI	DMODTX5
DMODTX5	DN	BDTX-189
DMODTX5	MI	TT6EO5L
DMODTX5	MN	Erbb2 tyrosine kinase receptor (HER2)
DMODTX5	MT	DTT
DMODTX5	MA	Inhibitor
DMODTX5	RN	Clinical pipeline report, company report or official report of Black Diamond Therapeutics.
DMODTX5	RU	https://www.blackdiamondtherapeutics.com/pipeline/bdtx-189/

DMXVRI0	DI	DMXVRI0
DMXVRI0	DN	Beclanorsen
DMXVRI0	MI	TTFOUV4
DMXVRI0	MN	BCL-2 messenger RNA (BCL2 mRNA)
DMXVRI0	MT	DTT
DMXVRI0	RN	Combination of novel imidazopyridazine mps-1 kinase inhibitors and bcl-2 family protein inhibitors. ACS Med Chem Lett. 2014 Jul 30;6(1):7-8.
DMXVRI0	RU	https://pubmed.ncbi.nlm.nih.gov/25589916

DMVYTG7	DI	DMVYTG7
DMVYTG7	DN	BGB-283
DMVYTG7	MI	TTWCGQT
DMVYTG7	MN	Serine/threonine-protein kinase B-raf (BRAF)
DMVYTG7	MT	DTT
DMVYTG7	MA	Inhibitor
DMVYTG7	RN	BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers. Mol Cancer Ther. 2015 Oct;14(10):2187-97.
DMVYTG7	RU	https://pubmed.ncbi.nlm.nih.gov/26208524

DM5VG6S	DI	DM5VG6S
DM5VG6S	DN	BGB-A333
DM5VG6S	MI	TT8ZLTI
DM5VG6S	MN	Programmed cell death 1 ligand 1 (PD-L1)
DM5VG6S	MT	DTT
DM5VG6S	RN	Clinical pipeline report, company report or official report of BeiGene.
DM5VG6S	RU	https://www.beigene.com/science-and-product-portfolio/pipeline

DMI42Q0	DI	DMI42Q0
DMI42Q0	DN	BGB-A425
DMI42Q0	MI	TT1RWL7
DMI42Q0	MN	Hepatitis A virus cellular receptor 2 (TIM3)
DMI42Q0	MT	DTT
DMI42Q0	RN	Clinical pipeline report, company report or official report of BeiGene.
DMI42Q0	RU	https://www.beigene.com/science-and-product-portfolio/pipeline

DMXKDUL	DI	DMXKDUL
DMXKDUL	DN	BGT226
DMXKDUL	MI	TTHBTOP
DMXKDUL	MN	PI3-kinase gamma (PIK3CG)
DMXKDUL	MT	DTT
DMXKDUL	MA	Modulator
DMXKDUL	RN	Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma. Anticancer Drugs. 2012 Jan;23(1):131-8.
DMXKDUL	RU	https://pubmed.ncbi.nlm.nih.gov/21959532

DMXKDUL	DI	DMXKDUL
DMXKDUL	DN	BGT226
DMXKDUL	MI	TTCJG29
DMXKDUL	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMXKDUL	MT	DTT
DMXKDUL	MA	Modulator
DMXKDUL	RN	Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma. Anticancer Drugs. 2012 Jan;23(1):131-8.
DMXKDUL	RU	https://pubmed.ncbi.nlm.nih.gov/21959532

DMTOMWB	DI	DMTOMWB
DMTOMWB	DN	BI 1206
DMTOMWB	MI	TT5RWKQ
DMTOMWB	MN	Immunoglobulin gamma Fc receptor IIB (FCGR2B)
DMTOMWB	MT	DTT
DMTOMWB	RN	Clinical pipeline report, company report or official report of BioInvent.
DMTOMWB	RU	https://www.bioinvent.com/pipeline/bi-1206-in-solid-tumors/

DMR8EPF	DI	DMR8EPF
DMR8EPF	DN	BIIB-087
DMR8EPF	MI	TTT2CZY
DMR8EPF	MN	Retinoschisin (RS1)
DMR8EPF	MT	DTT
DMR8EPF	RN	ClinicalTrials.gov (NCT02416622) Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS). U.S. National Institutes of Health.
DMR8EPF	RU	https://clinicaltrials.gov/ct2/show/NCT02416622

DMV1EA9	DI	DMV1EA9
DMV1EA9	DN	BIL010t
DMV1EA9	MI	TT473XN
DMV1EA9	MN	P2X purinoceptor 7 (P2RX7)
DMV1EA9	MT	DTT
DMV1EA9	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMV1EA9	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMZEA9X	DI	DMZEA9X
DMZEA9X	DN	BIW-8962
DMZEA9X	MI	TTGOFW6
DMZEA9X	MN	Ganglioside GM2 activator (GM2A)
DMZEA9X	MT	DTT
DMZEA9X	RN	Genetically engineered humanized anti-ganglioside GM2 antibody against multiple organ metastasis produced by GM2-expressing small-cell lung cancer cells. Cancer Sci. 2011 Dec;102(12):2157-63.
DMZEA9X	RU	https://pubmed.ncbi.nlm.nih.gov/21895875

DMFKA4G	DI	DMFKA4G
DMFKA4G	DN	BLZ-100
DMFKA4G	MI	TTCYAXN
DMFKA4G	MN	Chloride channel unspecific (ClC)
DMFKA4G	MT	DTT
DMFKA4G	MA	Inhibitor
DMFKA4G	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMFKA4G	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMFKA4G	DI	DMFKA4G
DMFKA4G	DN	BLZ-100
DMFKA4G	MI	TT1GHVO
DMFKA4G	MN	Matrix metalloproteinase (MMP)
DMFKA4G	MT	DTT
DMFKA4G	MA	Inhibitor
DMFKA4G	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMFKA4G	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMFKA4G	DI	DMFKA4G
DMFKA4G	DN	BLZ-100
DMFKA4G	MI	TT6X50U
DMFKA4G	MN	Matrix metalloproteinase-9 (MMP-9)
DMFKA4G	MT	DTT
DMFKA4G	MA	Inhibitor
DMFKA4G	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMFKA4G	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMDQO0S	DI	DMDQO0S
DMDQO0S	DN	BMS-753493
DMDQO0S	MI	TTVC37M
DMDQO0S	MN	Folate receptor alpha (FOLR1)
DMDQO0S	MT	DTT
DMDQO0S	MA	Modulator
DMDQO0S	RN	A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors. Invest New Drugs. 2015 Apr;33(2):321-31.
DMDQO0S	RU	https://pubmed.ncbi.nlm.nih.gov/25380635

DMGM7QD	DI	DMGM7QD
DMGM7QD	DN	BMS-777607
DMGM7QD	MI	TTNDSF4
DMGM7QD	MN	Proto-oncogene c-Met (MET)
DMGM7QD	MT	DTT
DMGM7QD	MA	Inhibitor
DMGM7QD	RN	Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607... J Med Chem. 2009 Mar 12;52(5):1251-4.
DMGM7QD	RU	https://pubmed.ncbi.nlm.nih.gov/19260711

DM5HUY8	DI	DM5HUY8
DM5HUY8	DN	BMS-863233
DM5HUY8	MI	TTSMTDI
DM5HUY8	MN	CDC7-related kinase (CDC7)
DM5HUY8	MT	DTT
DM5HUY8	MA	Modulator
DM5HUY8	RN	Discovery of XL413, a potent and selective CDC7 inhibitor. Bioorg Med Chem Lett. 2012 Jun 1;22(11):3727-31.
DM5HUY8	RU	https://pubmed.ncbi.nlm.nih.gov/22560567

DMDCHM7	DI	DMDCHM7
DMDCHM7	DN	BMS-986016
DMDCHM7	MI	TTNVXAW
DMDCHM7	MN	Lymphocyte activation gene 3 protein (LAG3)
DMDCHM7	MT	DTT
DMDCHM7	MA	Modulator
DMDCHM7	RN	Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol. 2015 March; 7(2): 85-96.
DMDCHM7	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4346216/

DM6LDI4	DI	DM6LDI4
DM6LDI4	DN	BMS-986158
DM6LDI4	MI	TTE4BSY
DM6LDI4	MN	Bromodomain and extraterminal domain protein (BET)
DM6LDI4	MT	DTT
DM6LDI4	MA	Inhibitor
DM6LDI4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM6LDI4	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMM10J4	DI	DMM10J4
DMM10J4	DN	BMS-986288
DMM10J4	MI	TTI2S1D
DMM10J4	MN	Cytotoxic T-lymphocyte protein 4 (CTLA-4)
DMM10J4	MT	DTT
DMM10J4	MA	Inhibitor
DMM10J4	RN	Clinical pipeline report, company report or official report of CytomX Therapeutics.
DMM10J4	RU	https://cytomx.com/pipeline/

DMTEY1L	DI	DMTEY1L
DMTEY1L	DN	BMS-986315
DMTEY1L	MI	TTC4IMS
DMTEY1L	MN	NKG2-A/B-activating NK receptor (NKG2A)
DMTEY1L	MT	DTT
DMTEY1L	MA	Inhibitor
DMTEY1L	RN	ClinicalTrials.gov (NCT04349267) Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors. U.S. National Institutes of Health.
DMTEY1L	RU	https://clinicaltrials.gov/ct2/show/NCT04349267

DMA9MP5	DI	DMA9MP5
DMA9MP5	DN	BN-2629
DMA9MP5	MI	DTI7UX6
DMA9MP5	MN	Breast cancer resistance protein (ABCG2)
DMA9MP5	MT	DTP
DMA9MP5	MA	Substrate
DMA9MP5	RN	Optimization of the antitumor activity of sequence-specific pyrrolobenzodiazepine derivatives based on their affinity for ABC transporters. AAPS J. 2010 Dec;12(4):617-27.
DMA9MP5	RU	https://doi.org/10.1208/s12248-010-9225-x

DMA9MP5	DI	DMA9MP5
DMA9MP5	DN	BN-2629
DMA9MP5	MI	TTUTN1I
DMA9MP5	MN	Human Deoxyribonucleic acid (hDNA)
DMA9MP5	MT	DTT
DMA9MP5	MA	Binder
DMA9MP5	RN	Single-Nucleotide Polymorphisms in Rv2629 Are Specific for Mycobacterium tuberculosis Genotypes Beijing and Ghana but Not Associated with Rifampin Resistance . J Clin Microbiol. 2009 January; 47(1): 223-226.
DMA9MP5	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2620844/

DMGF2PU	DI	DMGF2PU
DMGF2PU	DN	BNT411
DMGF2PU	MI	TTRJ1K4
DMGF2PU	MN	Toll-like receptor 7 (TLR7)
DMGF2PU	MT	DTT
DMGF2PU	MA	Agonist
DMGF2PU	RN	Clinical pipeline report, company report or official report of BioNTech.
DMGF2PU	RU	https://biontech.de/science/pipeline

DMIMA4V	DI	DMIMA4V
DMIMA4V	DN	BPX-501
DMIMA4V	MI	TTXQYT6
DMIMA4V	MN	T-cells (T-cells)
DMIMA4V	MT	DTT
DMIMA4V	MA	Immunomodulator
DMIMA4V	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMIMA4V	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMV9QGW	DI	DMV9QGW
DMV9QGW	DN	BPX-601
DMV9QGW	MI	TT9T4AV
DMV9QGW	MN	Prostate stem cell antigen (PSCA)
DMV9QGW	MT	DTT
DMV9QGW	MA	CAR-T-Cell-Therapy
DMV9QGW	RN	ClinicalTrials.gov (NCT02744287) Use of Ligand-Inducible Autologous T Cells Engineered to Target PSCA on Tumor Cells in Selected Advanced Solid Tumors
DMV9QGW	RU	https://clinicaltrials.gov/ct2/show/NCT02744287

DMCEGP2	DI	DMCEGP2
DMCEGP2	DN	BrevaRex
DMCEGP2	MI	TTBHFYQ
DMCEGP2	MN	Mucin-1 (MUC1)
DMCEGP2	MT	DTT
DMCEGP2	RN	Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity. Ann Oncol. 2004 Dec;15(12):1825-33.
DMCEGP2	RU	https://pubmed.ncbi.nlm.nih.gov/15550589

DMQKXSW	DI	DMQKXSW
DMQKXSW	DN	BRN-3122594
DMQKXSW	MI	DE4LYSA
DMQKXSW	MN	Cytochrome P450 3A4 (CYP3A4)
DMQKXSW	MT	DME
DMQKXSW	MA	Metabolism
DMQKXSW	RN	Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35.
DMQKXSW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20482443

DMYBKMV	DI	DMYBKMV
DMYBKMV	DN	BT5528
DMYBKMV	MI	TTRJB2G
DMYBKMV	MN	Ephrin type-A receptor 2 (EPHA2)
DMYBKMV	MT	DTT
DMYBKMV	RN	MMAE Delivery Using the Bicycle Toxin Conjugate BT5528. Mol Cancer Ther. 2020 Jul;19(7):1385-1394.
DMYBKMV	RU	https://pubmed.ncbi.nlm.nih.gov/32398269

DM1FJW6	DI	DM1FJW6
DM1FJW6	DN	BT8009
DM1FJW6	MI	TTPO9EG
DM1FJW6	MN	Nectin cell adhesion molecule 4 (NECTIN4)
DM1FJW6	MT	DTT
DM1FJW6	RN	Clinical pipeline report, company report or official report of Bicycle Therapeutics.
DM1FJW6	RU	https://www.bicycletherapeutics.com/wp-content/uploads/BT8009-AACR-4479-Rigby.pdf

DMEWXFK	DI	DMEWXFK
DMEWXFK	DN	C 82
DMEWXFK	MI	TTRPKQG
DMEWXFK	MN	Beta-catenin (CTNNB1)
DMEWXFK	MT	DTT
DMEWXFK	MA	Inhibitor
DMEWXFK	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMEWXFK	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMEWXFK	DI	DMEWXFK
DMEWXFK	DN	C 82
DMEWXFK	MI	TTFRCTK
DMEWXFK	MN	CREB-binding protein (CREBBP)
DMEWXFK	MT	DTT
DMEWXFK	MA	Inhibitor
DMEWXFK	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMEWXFK	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMPJLS4	DI	DMPJLS4
DMPJLS4	DN	CAD-1883
DMPJLS4	MI	TTKU9YD
DMPJLS4	MN	Calcium-activated potassium channel KCa2 (KCNN)
DMPJLS4	MT	DTT
DMPJLS4	MA	Activator
DMPJLS4	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMPJLS4	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMUZIRY	DI	DMUZIRY
DMUZIRY	DN	Cal-1
DMUZIRY	MI	TT2CEJG
DMUZIRY	MN	C-C chemokine receptor type 5 (CCR5)
DMUZIRY	MT	DTT
DMUZIRY	MA	Modulator
DMUZIRY	RN	Preclinical safety and efficacy of an anti-HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor. Mol Ther Methods Clin Dev. 2014 Feb 12;1:11.
DMUZIRY	RU	https://pubmed.ncbi.nlm.nih.gov/26015947

DM6ZXWY	DI	DM6ZXWY
DM6ZXWY	DN	CAR.CD30 cells
DM6ZXWY	MI	TT2GM5R
DM6ZXWY	MN	Lymphocyte activation antigen CD30 (TNFRSF8)
DM6ZXWY	MT	DTT
DM6ZXWY	MA	CAR-T-Cell-Therapy
DM6ZXWY	RN	ClinicalTrials.gov (NCT02663297) Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
DM6ZXWY	RU	https://clinicaltrials.gov/ct2/show/NCT02663297

DMOI5PB	DI	DMOI5PB
DMOI5PB	DN	CARCIK-CD19
DMOI5PB	MI	TTW640A
DMOI5PB	MN	B-lymphocyte surface antigen B4 (CD19)
DMOI5PB	MT	DTT
DMOI5PB	MA	CAR-T-Cell-Therapy
DMOI5PB	RN	ClinicalTrials.gov (NCT03389035) Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT
DMOI5PB	RU	https://clinicaltrials.gov/ct2/show/NCT03389035

DMENIQ7	DI	DMENIQ7
DMENIQ7	DN	CAR-T cells targeting BCMA
DMENIQ7	MI	TTZ3P4W
DMENIQ7	MN	B-cell maturation protein (TNFRSF17)
DMENIQ7	MT	DTT
DMENIQ7	MA	CAR-T-Cell-Therapy
DMENIQ7	RN	ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
DMENIQ7	RU	https://clinicaltrials.gov/ct2/show/NCT03312205

DMIM9TZ	DI	DMIM9TZ
DMIM9TZ	DN	CAR-T cells targeting CD19
DMIM9TZ	MI	TTW640A
DMIM9TZ	MN	B-lymphocyte surface antigen B4 (CD19)
DMIM9TZ	MT	DTT
DMIM9TZ	MA	CAR-T-Cell-Therapy
DMIM9TZ	RN	ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
DMIM9TZ	RU	https://clinicaltrials.gov/ct2/show/NCT03312205

DMJVENR	DI	DMJVENR
DMJVENR	DN	CAR-T cells targeting CD2
DMJVENR	MI	TT80ARU
DMJVENR	MN	Ganglioside GD2 (GD2)
DMJVENR	MT	DTT
DMJVENR	MA	CAR-T-Cell-Therapy
DMJVENR	RN	ClinicalTrials.gov (NCT03356795) Intervention of CAR-T Against Cervical Cancer
DMJVENR	RU	https://clinicaltrials.gov/ct2/show/NCT03356795

DMVFHL9	DI	DMVFHL9
DMVFHL9	DN	CAR-T cells targeting CD22
DMVFHL9	MI	TTM6QSK
DMVFHL9	MN	B-cell receptor CD22 (CD22)
DMVFHL9	MT	DTT
DMVFHL9	MA	CAR-T-Cell-Therapy
DMVFHL9	RN	ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
DMVFHL9	RU	https://clinicaltrials.gov/ct2/show/NCT03312205

DMZHJV8	DI	DMZHJV8
DMZHJV8	DN	CAR-T cells targeting CD30
DMZHJV8	MI	TT2GM5R
DMZHJV8	MN	Lymphocyte activation antigen CD30 (TNFRSF8)
DMZHJV8	MT	DTT
DMZHJV8	MA	CAR-T-Cell-Therapy
DMZHJV8	RN	ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
DMZHJV8	RU	https://clinicaltrials.gov/ct2/show/NCT03312205

DM6VCPX	DI	DM6VCPX
DM6VCPX	DN	CAR-T cells targeting CEA
DM6VCPX	MI	TTY6DTE
DM6VCPX	MN	Carcinoembryonic antigen CEA (CD66e)
DM6VCPX	MT	DTT
DM6VCPX	MA	CAR-T-Cell-Therapy
DM6VCPX	RN	ClinicalTrials.gov (NCT02959151) A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy
DM6VCPX	RU	https://clinicaltrials.gov/ct2/show/NCT02959151

DMCPM92	DI	DMCPM92
DMCPM92	DN	CAR-T cells targeting CLL1
DMCPM92	MI	TT70N8V
DMCPM92	MN	Myeloid inhibitory C-type lectin-like receptor (CD371)
DMCPM92	MT	DTT
DMCPM92	MA	CAR-T-Cell-Therapy
DMCPM92	RN	ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
DMCPM92	RU	https://clinicaltrials.gov/ct2/show/NCT03312205

DMREQCF	DI	DMREQCF
DMREQCF	DN	CAR-T Cells targeting EpCAM
DMREQCF	MI	TTZ8WH4
DMREQCF	MN	Tumor-associated calcium signal transducer 1 (EPCAM)
DMREQCF	MT	DTT
DMREQCF	MA	CAR-T-Cell-Therapy
DMREQCF	RN	ClinicalTrials.gov (NCT03013712) A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer
DMREQCF	RU	https://clinicaltrials.gov/ct2/show/NCT03013712

DMN3C2I	DI	DMN3C2I
DMN3C2I	DN	CAR-T cells targeting EphA2
DMN3C2I	MI	TTRJB2G
DMN3C2I	MN	Ephrin type-A receptor 2 (EPHA2)
DMN3C2I	MT	DTT
DMN3C2I	MA	CAR-T-Cell-Therapy
DMN3C2I	RN	ClinicalTrials.gov (NCT02575261) CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients
DMN3C2I	RU	https://clinicaltrials.gov/ct2/show/NCT02575261

DMFCPG0	DI	DMFCPG0
DMFCPG0	DN	CAR-T cells targeting GD2
DMFCPG0	MI	TT80ARU
DMFCPG0	MN	Ganglioside GD2 (GD2)
DMFCPG0	MT	DTT
DMFCPG0	MA	CAR-T-Cell-Therapy
DMFCPG0	RN	ClinicalTrials.gov (NCT03252171) CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients
DMFCPG0	RU	https://clinicaltrials.gov/ct2/show/NCT03252171

DMT89K2	DI	DMT89K2
DMT89K2	DN	CAR-T cells targeting GD2
DMT89K2	MI	TT80ARU
DMT89K2	MN	Ganglioside GD2 (GD2)
DMT89K2	MT	DTT
DMT89K2	MA	CAR-T-Cell-Therapy
DMT89K2	RN	ClinicalTrials.gov (NCT03356808) Antigen-specific T Cells Against Lung Cancer
DMT89K2	RU	https://clinicaltrials.gov/ct2/show/NCT03356808

DMDSKR2	DI	DMDSKR2
DMDSKR2	DN	CAR-T cells targeting Glypican-3 (GPC3)
DMDSKR2	MI	TTJTSX4
DMDSKR2	MN	Glypican-3 (GPC3)
DMDSKR2	MT	DTT
DMDSKR2	MA	CAR-T-Cell-Therapy
DMDSKR2	RN	ClinicalTrials.gov (NCT02723942) CAR-T Cell Immunotherapy for HCC Targeting GPC3
DMDSKR2	RU	https://clinicaltrials.gov/ct2/show/NCT02723942

DM6H1MQ	DI	DM6H1MQ
DM6H1MQ	DN	CAR-T cells targeting GPC3
DM6H1MQ	MI	TTJTSX4
DM6H1MQ	MN	Glypican-3 (GPC3)
DM6H1MQ	MT	DTT
DM6H1MQ	MA	CAR-T-Cell-Therapy
DM6H1MQ	RN	ClinicalTrials.gov (NCT02959151) A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy
DM6H1MQ	RU	https://clinicaltrials.gov/ct2/show/NCT02959151

DM1W7LV	DI	DM1W7LV
DM1W7LV	DN	CAR-T cells targeting MAGE-A1
DM1W7LV	MI	TT63M7Q
DM1W7LV	MN	Melanoma-associated antigen 1 (MAGEA1)
DM1W7LV	MT	DTT
DM1W7LV	MA	CAR-T-Cell-Therapy
DM1W7LV	RN	ClinicalTrials.gov (NCT03356808) Antigen-specific T Cells Against Lung Cancer
DM1W7LV	RU	https://clinicaltrials.gov/ct2/show/NCT03356808

DMUBEX4	DI	DMUBEX4
DMUBEX4	DN	CAR-T cells targeting MAGE-A4
DMUBEX4	MI	TT9EQUY
DMUBEX4	MN	Melanoma-associated antigen 4 (MAGEA4)
DMUBEX4	MT	DTT
DMUBEX4	MA	CAR-T-Cell-Therapy
DMUBEX4	RN	ClinicalTrials.gov (NCT03356808) Antigen-specific T Cells Against Lung Cancer
DMUBEX4	RU	https://clinicaltrials.gov/ct2/show/NCT03356808

DMMAQJ7	DI	DMMAQJ7
DMMAQJ7	DN	CAR-T cells targeting Mesothelin
DMMAQJ7	MI	TT4RXME
DMMAQJ7	MN	Mesothelin (MSLN)
DMMAQJ7	MT	DTT
DMMAQJ7	MA	CAR-T-Cell-Therapy
DMMAQJ7	RN	ClinicalTrials.gov (NCT03356808) Antigen-specific T Cells Against Lung Cancer
DMMAQJ7	RU	https://clinicaltrials.gov/ct2/show/NCT03356808

DMPK35H	DI	DMPK35H
DMPK35H	DN	CAR-T cells targeting mesothelin
DMPK35H	MI	TT4RXME
DMPK35H	MN	Mesothelin (MSLN)
DMPK35H	MT	DTT
DMPK35H	MA	CAR-T-Cell-Therapy
DMPK35H	RN	ClinicalTrials.gov (NCT02959151) A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy
DMPK35H	RU	https://clinicaltrials.gov/ct2/show/NCT02959151

DM5FKU1	DI	DM5FKU1
DM5FKU1	DN	CAR-T cells targeting Muc1
DM5FKU1	MI	TTBHFYQ
DM5FKU1	MN	Mucin-1 (MUC1)
DM5FKU1	MT	DTT
DM5FKU1	MA	CAR-T-Cell-Therapy
DM5FKU1	RN	ClinicalTrials.gov (NCT03356795) Intervention of CAR-T Against Cervical Cancer
DM5FKU1	RU	https://clinicaltrials.gov/ct2/show/NCT03356795

DMBPN4K	DI	DMBPN4K
DMBPN4K	DN	CAR-T cells targeting MucI
DMBPN4K	MI	TTBHFYQ
DMBPN4K	MN	Mucin-1 (MUC1)
DMBPN4K	MT	DTT
DMBPN4K	MA	CAR-T-Cell-Therapy
DMBPN4K	RN	ClinicalTrials.gov (NCT03356808) Antigen-specific T Cells Against Lung Cancer
DMBPN4K	RU	https://clinicaltrials.gov/ct2/show/NCT03356808

DMW340V	DI	DMW340V
DMW340V	DN	CAR-T cells targeting PSMA
DMW340V	MI	TT9G4N0
DMW340V	MN	Glutamate carboxypeptidase II (GCPII)
DMW340V	MT	DTT
DMW340V	MA	CAR-T-Cell-Therapy
DMW340V	RN	ClinicalTrials.gov (NCT03356795) Intervention of CAR-T Against Cervical Cancer
DMW340V	RU	https://clinicaltrials.gov/ct2/show/NCT03356795

DM0MCTJ	DI	DM0MCTJ
DM0MCTJ	DN	CART-123 cells
DM0MCTJ	MI	TTENHJ0
DM0MCTJ	MN	Interleukin 3 receptor alpha (IL3RA)
DM0MCTJ	MT	DTT
DM0MCTJ	MA	CAR-T-Cell-Therapy
DM0MCTJ	RN	ClinicalTrials.gov (NCT03556982) CART-123 FOR Relapsed/Refractory Acute Myelocytic LeukemiaAML
DM0MCTJ	RU	https://clinicaltrials.gov/ct2/show/NCT03556982

DMUS79V	DI	DMUS79V
DMUS79V	DN	CART-138 cells
DMUS79V	MI	TTYDSVG
DMUS79V	MN	Syndecan-1 (SDC1)
DMUS79V	MT	DTT
DMUS79V	MA	CAR-T-Cell-Therapy
DMUS79V	RN	ClinicalTrials.gov (NCT01886976) Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138
DMUS79V	RU	https://clinicaltrials.gov/ct2/show/NCT01886976

DMB4HEW	DI	DMB4HEW
DMB4HEW	DN	CART-138 cells
DMB4HEW	MI	TTYDSVG
DMB4HEW	MN	Syndecan-1 (SDC1)
DMB4HEW	MT	DTT
DMB4HEW	MA	CAR-T-Cell-Therapy
DMB4HEW	RN	ClinicalTrials.gov (NCT03196414) Study of CART-138/BCMA Therapy for R/R Multiple Myeloma
DMB4HEW	RU	https://clinicaltrials.gov/ct2/show/NCT03196414

DMWYT4K	DI	DMWYT4K
DMWYT4K	DN	CART-19 cells
DMWYT4K	MI	TTW640A
DMWYT4K	MN	B-lymphocyte surface antigen B4 (CD19)
DMWYT4K	MT	DTT
DMWYT4K	MA	CAR-T-Cell-Therapy
DMWYT4K	RN	ClinicalTrials.gov (NCT03544021) CART-19 FOR Relapsed/Refractory Acute Lymphoblastic Leukemia ALL
DMWYT4K	RU	https://clinicaltrials.gov/ct2/show/NCT03544021

DMX0R1E	DI	DMX0R1E
DMX0R1E	DN	CART-19/22
DMX0R1E	MI	TTM6QSK
DMX0R1E	MN	B-cell receptor CD22 (CD22)
DMX0R1E	MT	DTT
DMX0R1E	MA	CAR-T-Cell-Therapy(Dual specific)
DMX0R1E	RN	ClinicalTrials.gov (NCT03614858) CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.
DMX0R1E	RU	https://clinicaltrials.gov/ct2/show/NCT03614858

DMX0R1E	DI	DMX0R1E
DMX0R1E	DN	CART-19/22
DMX0R1E	MI	TTW640A
DMX0R1E	MN	B-lymphocyte surface antigen B4 (CD19)
DMX0R1E	MT	DTT
DMX0R1E	MA	CAR-T-Cell-Therapy(Dual specific)
DMX0R1E	RN	ClinicalTrials.gov (NCT03614858) CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.
DMX0R1E	RU	https://clinicaltrials.gov/ct2/show/NCT03614858

DMVW1GY	DI	DMVW1GY
DMVW1GY	DN	CART-19/BCMA
DMVW1GY	MI	TTZ3P4W
DMVW1GY	MN	B-cell maturation protein (TNFRSF17)
DMVW1GY	MT	DTT
DMVW1GY	MA	CAR-T-Cell-Therapy(Dual specific)
DMVW1GY	RN	ClinicalTrials.gov (NCT03455972) Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT
DMVW1GY	RU	https://clinicaltrials.gov/ct2/show/NCT03455972

DMVW1GY	DI	DMVW1GY
DMVW1GY	DN	CART-19/BCMA
DMVW1GY	MI	TTW640A
DMVW1GY	MN	B-lymphocyte surface antigen B4 (CD19)
DMVW1GY	MT	DTT
DMVW1GY	MA	CAR-T-Cell-Therapy(Dual specific)
DMVW1GY	RN	ClinicalTrials.gov (NCT03455972) Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT
DMVW1GY	RU	https://clinicaltrials.gov/ct2/show/NCT03455972

DMKGU5F	DI	DMKGU5F
DMKGU5F	DN	CART20
DMKGU5F	MI	TTUE541
DMKGU5F	MN	Leukocyte surface antigen Leu-16 (CD20)
DMKGU5F	MT	DTT
DMKGU5F	MA	CAR-T-Cell-Therapy
DMKGU5F	RN	ClinicalTrials.gov (NCT02965157) Pilot Study of Anti-CD20-CAR-engineered T Cells in Patients With Chemotherapy Resistant or Refractory CD20+ Lymphoma
DMKGU5F	RU	https://clinicaltrials.gov/ct2/show/NCT02965157

DMLE8T9	DI	DMLE8T9
DMLE8T9	DN	CART30
DMLE8T9	MI	TT2GM5R
DMLE8T9	MN	Lymphocyte activation antigen CD30 (TNFRSF8)
DMLE8T9	MT	DTT
DMLE8T9	MA	CAR-T-Cell-Therapy
DMLE8T9	RN	ClinicalTrials.gov (NCT02259556) CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas
DMLE8T9	RU	https://clinicaltrials.gov/ct2/show/NCT02259556

DM81JIT	DI	DM81JIT
DM81JIT	DN	CART33 cells
DM81JIT	MI	TTJVYO3
DM81JIT	MN	Myeloid cell surface antigen CD33 (CD33)
DM81JIT	MT	DTT
DM81JIT	MA	CAR-T-Cell-Therapy
DM81JIT	RN	ClinicalTrials.gov (NCT01864902) Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33
DM81JIT	RU	https://clinicaltrials.gov/ct2/show/NCT01864902

DMWOYNT	DI	DMWOYNT
DMWOYNT	DN	CART-BCMA cells
DMWOYNT	MI	TTZ3P4W
DMWOYNT	MN	B-cell maturation protein (TNFRSF17)
DMWOYNT	MT	DTT
DMWOYNT	MA	CAR-T-Cell-Therapy
DMWOYNT	RN	ClinicalTrials.gov (NCT03196414) Study of CART-138/BCMA Therapy for R/R Multiple Myeloma
DMWOYNT	RU	https://clinicaltrials.gov/ct2/show/NCT03196414

DM3I267	DI	DM3I267
DM3I267	DN	CART-EGFR
DM3I267	MI	TTGKNB4
DM3I267	MN	Epidermal growth factor receptor (EGFR)
DM3I267	MT	DTT
DM3I267	MA	CAR-T-Cell-Therapy
DM3I267	RN	ClinicalTrials.gov (NCT01869166) Treatment of Chemotherapy Refractory EGFR(Epidermal Growth Factor Receptor) Positive Advanced Solid Tumors (CART-EGFR)
DM3I267	RU	https://clinicaltrials.gov/ct2/show/NCT01869166

DMMTDK1	DI	DMMTDK1
DMMTDK1	DN	CART-HER-2
DMMTDK1	MI	TT6EO5L
DMMTDK1	MN	Erbb2 tyrosine kinase receptor (HER2)
DMMTDK1	MT	DTT
DMMTDK1	MA	CAR-T-Cell-Therapy
DMMTDK1	RN	ClinicalTrials.gov (NCT01935843) Treatment of Chemotherapy Refractory Human Epidermalgrowth Factor Receptor-2( HER-2) Positive Advanced Solid Tumors
DMMTDK1	RU	https://clinicaltrials.gov/ct2/show/NCT01935843

DMKCJ75	DI	DMKCJ75
DMKCJ75	DN	CBL0102
DMKCJ75	MI	TTETDKQ
DMKCJ75	MN	Facilitates chromatin transcription complex (FACT)
DMKCJ75	MT	DTT
DMKCJ75	MA	Modulator
DMKCJ75	RN	Company report (Incuron)
DMKCJ75	RU	http://www.incuron.ru/en/news-en/item/2-incuron-announce-cbl0102-orphan-drug-status-for-hepatocellular-carcinoma

DMCWVPU	DI	DMCWVPU
DMCWVPU	DN	CBP-501
DMCWVPU	MI	TTMUG9D
DMCWVPU	MN	MAPK-activated protein kinase 2 (MAPKAPK2)
DMCWVPU	MT	DTT
DMCWVPU	MA	Inhibitor
DMCWVPU	RN	National Cancer Institute Drug Dictionary (drug id 577812).
DMCWVPU	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=577812

DMCWVPU	DI	DMCWVPU
DMCWVPU	DN	CBP-501
DMCWVPU	MI	TT3DCYJ
DMCWVPU	MN	Microtubule affinity regulating kinase 3 (MARK3)
DMCWVPU	MT	DTT
DMCWVPU	MA	Inhibitor
DMCWVPU	RN	National Cancer Institute Drug Dictionary (drug id 577812).
DMCWVPU	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=577812

DMMQYL9	DI	DMMQYL9
DMMQYL9	DN	CC-223
DMMQYL9	MI	DE5IED8
DMMQYL9	MN	Cytochrome P450 2C9 (CYP2C9)
DMMQYL9	MT	DME
DMMQYL9	MA	Metabolism
DMMQYL9	RN	Assessment of drug-drug interaction potential and PBPK modeling of CC-223, a potent inhibitor of the mammalian target of rapamycin kinase. Xenobiotica. 2019 Jan;49(1):54-70.
DMMQYL9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29297772

DMMQYL9	DI	DMMQYL9
DMMQYL9	DN	CC-223
DMMQYL9	MI	DE4LYSA
DMMQYL9	MN	Cytochrome P450 3A4 (CYP3A4)
DMMQYL9	MT	DME
DMMQYL9	MA	Metabolism
DMMQYL9	RN	Assessment of drug-drug interaction potential and PBPK modeling of CC-223, a potent inhibitor of the mammalian target of rapamycin kinase. Xenobiotica. 2019 Jan;49(1):54-70.
DMMQYL9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29297772

DMMQYL9	DI	DMMQYL9
DMMQYL9	DN	CC-223
DMMQYL9	MI	TTCJG29
DMMQYL9	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMMQYL9	MT	DTT
DMMQYL9	MA	Modulator
DMMQYL9	RN	CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization. Mol Cancer Ther. 2015 Jun;14(6):1295-305.
DMMQYL9	RU	https://pubmed.ncbi.nlm.nih.gov/25855786

DM9UZM1	DI	DM9UZM1
DM9UZM1	DN	CCS1477
DM9UZM1	MI	TTFRCTK
DM9UZM1	MN	CREB-binding protein (CREBBP)
DM9UZM1	MT	DTT
DM9UZM1	MA	Inhibitor
DM9UZM1	RN	Targeting the p300/CBP Axis in Lethal Prostate Cancer. Cancer Discov. 2021 May;11(5):1118-1137.
DM9UZM1	RU	https://pubmed.ncbi.nlm.nih.gov/33431496

DM9UZM1	DI	DM9UZM1
DM9UZM1	DN	CCS1477
DM9UZM1	MI	TTGH73N
DM9UZM1	MN	Histone acetyltransferase p300 (EP300)
DM9UZM1	MT	DTT
DM9UZM1	MA	Inhibitor
DM9UZM1	RN	Targeting the p300/CBP Axis in Lethal Prostate Cancer. Cancer Discov. 2021 May;11(5):1118-1137.
DM9UZM1	RU	https://pubmed.ncbi.nlm.nih.gov/33431496

DM2B1V0	DI	DM2B1V0
DM2B1V0	DN	CCT301-38 (targeting ROR2)
DM2B1V0	MI	TTUDPCI
DM2B1V0	MN	Neurotrophic tyrosine kinase ROR2 (ROR2)
DM2B1V0	MT	DTT
DM2B1V0	MA	CAR-T-Cell-Therapy
DM2B1V0	RN	ClinicalTrials.gov (NCT03393936) Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma
DM2B1V0	RU	https://clinicaltrials.gov/ct2/show/NCT03393936

DM0F9CD	DI	DM0F9CD
DM0F9CD	DN	CCT301-59 (targeting ROR2)
DM0F9CD	MI	TTUDPCI
DM0F9CD	MN	Neurotrophic tyrosine kinase ROR2 (ROR2)
DM0F9CD	MT	DTT
DM0F9CD	MA	CAR-T-Cell-Therapy
DM0F9CD	RN	ClinicalTrials.gov (NCT03393936) Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma
DM0F9CD	RU	https://clinicaltrials.gov/ct2/show/NCT03393936

DMHOWU5	DI	DMHOWU5
DMHOWU5	DN	CD123-specific gene-engineered T cells
DMHOWU5	MI	TTENHJ0
DMHOWU5	MN	Interleukin 3 receptor alpha (IL3RA)
DMHOWU5	MT	DTT
DMHOWU5	MA	CAR-T-Cell-Therapy
DMHOWU5	RN	ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
DMHOWU5	RU	https://clinicaltrials.gov/ct2/show/NCT03222674

DMHMC19	DI	DMHMC19
DMHMC19	DN	CD137 CAR-T Cell
DMHMC19	MI	TTPW9LJ
DMHMC19	MN	Co-stimulatory molecule 4-1BB (CD137)
DMHMC19	MT	DTT
DMHMC19	MA	CAR-T-Cell-Therapy
DMHMC19	RN	ClinicalTrials.gov (NCT02965092) CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies
DMHMC19	RU	https://clinicaltrials.gov/ct2/show/NCT02965092

DMCSGNU	DI	DMCSGNU
DMCSGNU	DN	CD138 CAR T cells
DMCSGNU	MI	TTYDSVG
DMCSGNU	MN	Syndecan-1 (SDC1)
DMCSGNU	MT	DTT
DMCSGNU	MA	CAR-T-Cell-Therapy
DMCSGNU	RN	ClinicalTrials.gov (NCT03271632) Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
DMCSGNU	RU	https://clinicaltrials.gov/ct2/show/NCT03271632

DMRJ3ND	DI	DMRJ3ND
DMRJ3ND	DN	CD19 and CD20 CAR-T Cells
DMRJ3ND	MI	TTW640A
DMRJ3ND	MN	B-lymphocyte surface antigen B4 (CD19)
DMRJ3ND	MT	DTT
DMRJ3ND	MA	CAR-T-Cell-Therapy(Dual specific)
DMRJ3ND	RN	ClinicalTrials.gov (NCT03398967) A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma
DMRJ3ND	RU	https://clinicaltrials.gov/ct2/show/NCT03398967

DMRJ3ND	DI	DMRJ3ND
DMRJ3ND	DN	CD19 and CD20 CAR-T Cells
DMRJ3ND	MI	TTUE541
DMRJ3ND	MN	Leukocyte surface antigen Leu-16 (CD20)
DMRJ3ND	MT	DTT
DMRJ3ND	MA	CAR-T-Cell-Therapy(Dual specific)
DMRJ3ND	RN	ClinicalTrials.gov (NCT03398967) A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma
DMRJ3ND	RU	https://clinicaltrials.gov/ct2/show/NCT03398967

DMQB7SZ	DI	DMQB7SZ
DMQB7SZ	DN	CD19 and CD22 CAR-T Cells
DMQB7SZ	MI	TTM6QSK
DMQB7SZ	MN	B-cell receptor CD22 (CD22)
DMQB7SZ	MT	DTT
DMQB7SZ	MA	CAR-T-Cell-Therapy(Dual specific)
DMQB7SZ	RN	ClinicalTrials.gov (NCT03398967) A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma
DMQB7SZ	RU	https://clinicaltrials.gov/ct2/show/NCT03398967

DM581CS	DI	DM581CS
DM581CS	DN	CD19 and CD22 CAR-T Cells
DM581CS	MI	TTM6QSK
DM581CS	MN	B-cell receptor CD22 (CD22)
DM581CS	MT	DTT
DM581CS	MA	CAR-T-Cell-Therapy(Dual specific)
DM581CS	RN	ClinicalTrials.gov (NCT03468153) Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma
DM581CS	RU	https://clinicaltrials.gov/ct2/show/NCT03468153

DMQB7SZ	DI	DMQB7SZ
DMQB7SZ	DN	CD19 and CD22 CAR-T Cells
DMQB7SZ	MI	TTW640A
DMQB7SZ	MN	B-lymphocyte surface antigen B4 (CD19)
DMQB7SZ	MT	DTT
DMQB7SZ	MA	CAR-T-Cell-Therapy(Dual specific)
DMQB7SZ	RN	ClinicalTrials.gov (NCT03398967) A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma
DMQB7SZ	RU	https://clinicaltrials.gov/ct2/show/NCT03398967

DM581CS	DI	DM581CS
DM581CS	DN	CD19 and CD22 CAR-T Cells
DM581CS	MI	TTW640A
DM581CS	MN	B-lymphocyte surface antigen B4 (CD19)
DM581CS	MT	DTT
DM581CS	MA	CAR-T-Cell-Therapy(Dual specific)
DM581CS	RN	ClinicalTrials.gov (NCT03468153) Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma
DM581CS	RU	https://clinicaltrials.gov/ct2/show/NCT03468153

DMQJ6YL	DI	DMQJ6YL
DMQJ6YL	DN	CD19 CAR Gene Transduced T Lymphocytes
DMQJ6YL	MI	TTW640A
DMQJ6YL	MN	B-lymphocyte surface antigen B4 (CD19)
DMQJ6YL	MT	DTT
DMQJ6YL	MA	CAR-T-Cell-Therapy
DMQJ6YL	RN	ClinicalTrials.gov (NCT02134262) Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes
DMQJ6YL	RU	https://clinicaltrials.gov/ct2/show/NCT02134262

DMMHLJQ	DI	DMMHLJQ
DMMHLJQ	DN	CD19 CAR T cells
DMMHLJQ	MI	TTW640A
DMMHLJQ	MN	B-lymphocyte surface antigen B4 (CD19)
DMMHLJQ	MT	DTT
DMMHLJQ	MA	CAR-T-Cell-Therapy
DMMHLJQ	RN	ClinicalTrials.gov (NCT02772198) T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies
DMMHLJQ	RU	https://clinicaltrials.gov/ct2/show/NCT02772198

DMUARWH	DI	DMUARWH
DMUARWH	DN	CD19 CAR T Cells
DMUARWH	MI	TTW640A
DMUARWH	MN	B-lymphocyte surface antigen B4 (CD19)
DMUARWH	MT	DTT
DMUARWH	MA	CAR-T-Cell-Therapy
DMUARWH	RN	ClinicalTrials.gov (NCT01475058) CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant
DMUARWH	RU	https://clinicaltrials.gov/ct2/show/NCT01475058

DMU348C	DI	DMU348C
DMU348C	DN	CD19 CART
DMU348C	MI	TTW640A
DMU348C	MN	B-lymphocyte surface antigen B4 (CD19)
DMU348C	MT	DTT
DMU348C	MA	CAR-T-Cell-Therapy
DMU348C	RN	ClinicalTrials.gov (NCT03146533) CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.
DMU348C	RU	https://clinicaltrials.gov/ct2/show/NCT03146533

DM69A1W	DI	DM69A1W
DM69A1W	DN	CD19 CART
DM69A1W	MI	TTW640A
DM69A1W	MN	B-lymphocyte surface antigen B4 (CD19)
DM69A1W	MT	DTT
DM69A1W	MA	CAR-T-Cell-Therapy
DM69A1W	RN	ClinicalTrials.gov (NCT03232619) CD19-CART Treatment for ALL
DM69A1W	RU	https://clinicaltrials.gov/ct2/show/NCT03232619

DMECGKO	DI	DMECGKO
DMECGKO	DN	CD19 CAR-T Cells
DMECGKO	MI	TTW640A
DMECGKO	MN	B-lymphocyte surface antigen B4 (CD19)
DMECGKO	MT	DTT
DMECGKO	MA	CAR-T-Cell-Therapy
DMECGKO	RN	ClinicalTrials.gov (NCT03263208) CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.
DMECGKO	RU	https://clinicaltrials.gov/ct2/show/NCT03263208

DM8KESD	DI	DM8KESD
DM8KESD	DN	CD19 CAR-T lymphocytes
DM8KESD	MI	TTW640A
DM8KESD	MN	B-lymphocyte surface antigen B4 (CD19)
DM8KESD	MT	DTT
DM8KESD	MA	CAR-T-Cell-Therapy
DM8KESD	RN	ClinicalTrials.gov (NCT03467256) CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL
DM8KESD	RU	https://clinicaltrials.gov/ct2/show/NCT03467256

DMGDK9C	DI	DMGDK9C
DMGDK9C	DN	CD19 specific CAR T cells
DMGDK9C	MI	TTW640A
DMGDK9C	MN	B-lymphocyte surface antigen B4 (CD19)
DMGDK9C	MT	DTT
DMGDK9C	MA	CAR-T-Cell-Therapy
DMGDK9C	RN	ClinicalTrials.gov (NCT02028455) A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia
DMGDK9C	RU	https://clinicaltrials.gov/ct2/show/NCT02028455

DM8RXFB	DI	DM8RXFB
DM8RXFB	DN	CD19 targeted chimeric antigen receptor T cells
DM8RXFB	MI	TTW640A
DM8RXFB	MN	B-lymphocyte surface antigen B4 (CD19)
DM8RXFB	MT	DTT
DM8RXFB	MA	CAR-T-Cell-Therapy
DM8RXFB	RN	ClinicalTrials.gov (NCT03118180) CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma
DM8RXFB	RU	https://clinicaltrials.gov/ct2/show/NCT03118180

DM79GPF	DI	DM79GPF
DM79GPF	DN	CD19.CAR T Cells
DM79GPF	MI	TTW640A
DM79GPF	MN	B-lymphocyte surface antigen B4 (CD19)
DM79GPF	MT	DTT
DM79GPF	MA	CAR-T-Cell-Therapy
DM79GPF	RN	ClinicalTrials.gov (NCT03676504) Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
DM79GPF	RU	https://clinicaltrials.gov/ct2/show/NCT03676504

DMNZ7F2	DI	DMNZ7F2
DMNZ7F2	DN	CD19.CAR-T cells
DMNZ7F2	MI	TTW640A
DMNZ7F2	MN	B-lymphocyte surface antigen B4 (CD19)
DMNZ7F2	MT	DTT
DMNZ7F2	MA	CAR-T-Cell-Therapy
DMNZ7F2	RN	ClinicalTrials.gov (NCT02652910) Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma
DMNZ7F2	RU	https://clinicaltrials.gov/ct2/show/NCT02652910

DMQE7TW	DI	DMQE7TW
DMQE7TW	DN	CD19-CAR T cell
DMQE7TW	MI	TTW640A
DMQE7TW	MN	B-lymphocyte surface antigen B4 (CD19)
DMQE7TW	MT	DTT
DMQE7TW	MA	CAR-T-Cell-Therapy
DMQE7TW	RN	ClinicalTrials.gov (NCT03373071) Anti-CD19 CAR T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and NHL
DMQE7TW	RU	https://clinicaltrials.gov/ct2/show/NCT03373071

DMKQRUJ	DI	DMKQRUJ
DMKQRUJ	DN	CD19-directed CAR-T cells
DMKQRUJ	MI	TTW640A
DMKQRUJ	MN	B-lymphocyte surface antigen B4 (CD19)
DMKQRUJ	MT	DTT
DMKQRUJ	MA	CAR-T-Cell-Therapy
DMKQRUJ	RN	ClinicalTrials.gov (NCT02537977) CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell Malignancy
DMKQRUJ	RU	https://clinicaltrials.gov/ct2/show/NCT02537977

DMI2OVA	DI	DMI2OVA
DMI2OVA	DN	CD19-targeting CAR T Cells
DMI2OVA	MI	TTW640A
DMI2OVA	MN	B-lymphocyte surface antigen B4 (CD19)
DMI2OVA	MT	DTT
DMI2OVA	MA	CAR-T-Cell-Therapy
DMI2OVA	RN	ClinicalTrials.gov (NCT02547948) CD19-targeting CAR T Cells for B Cell Lymphoma
DMI2OVA	RU	https://clinicaltrials.gov/ct2/show/NCT02547948

DM4MBUI	DI	DM4MBUI
DM4MBUI	DN	CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells
DM4MBUI	MI	TTM6QSK
DM4MBUI	MN	B-cell receptor CD22 (CD22)
DM4MBUI	MT	DTT
DM4MBUI	MA	CAR-T-Cell-Therapy(Dual specific)
DM4MBUI	RN	ClinicalTrials.gov (NCT02903810) Combination Transfer of CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells for B-cell Hematologic Malignancy
DM4MBUI	RU	https://clinicaltrials.gov/ct2/show/NCT02903810

DM4MBUI	DI	DM4MBUI
DM4MBUI	DN	CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells
DM4MBUI	MI	TTW640A
DM4MBUI	MN	B-lymphocyte surface antigen B4 (CD19)
DM4MBUI	MT	DTT
DM4MBUI	MA	CAR-T-Cell-Therapy(Dual specific)
DM4MBUI	RN	ClinicalTrials.gov (NCT02903810) Combination Transfer of CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells for B-cell Hematologic Malignancy
DM4MBUI	RU	https://clinicaltrials.gov/ct2/show/NCT02903810

DMHPZ8G	DI	DMHPZ8G
DMHPZ8G	DN	CD20-Specific CAR T Cells
DMHPZ8G	MI	TTUE541
DMHPZ8G	MN	Leukocyte surface antigen Leu-16 (CD20)
DMHPZ8G	MT	DTT
DMHPZ8G	MA	CAR-T-Cell-Therapy
DMHPZ8G	RN	ClinicalTrials.gov (NCT03277729) A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
DMHPZ8G	RU	https://clinicaltrials.gov/ct2/show/NCT03277729

DM40NEB	DI	DM40NEB
DM40NEB	DN	CD22 CAR-T
DM40NEB	MI	TTM6QSK
DM40NEB	MN	B-cell receptor CD22 (CD22)
DM40NEB	MT	DTT
DM40NEB	MA	CAR-T-Cell-Therapy
DM40NEB	RN	ClinicalTrials.gov (NCT02794961) CD22 Targeting CAR-T Therapy Against B Cell Hematological Malignancies
DM40NEB	RU	https://clinicaltrials.gov/ct2/show/NCT02794961

DM61MBG	DI	DM61MBG
DM61MBG	DN	CD22-Targeted CAR-T cells
DM61MBG	MI	TTM6QSK
DM61MBG	MN	B-cell receptor CD22 (CD22)
DM61MBG	MT	DTT
DM61MBG	MA	CAR-T-Cell-Therapy
DM61MBG	RN	ClinicalTrials.gov (NCT02935153) A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies
DM61MBG	RU	https://clinicaltrials.gov/ct2/show/NCT02935153

DMM35D2	DI	DMM35D2
DMM35D2	DN	CD33-specific gene-engineered T cells
DMM35D2	MI	TTJVYO3
DMM35D2	MN	Myeloid cell surface antigen CD33 (CD33)
DMM35D2	MT	DTT
DMM35D2	MA	CAR-T-Cell-Therapy
DMM35D2	RN	ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
DMM35D2	RU	https://clinicaltrials.gov/ct2/show/NCT03222674

DMFZS8A	DI	DMFZS8A
DMFZS8A	DN	CD38 and BCMA CAR-T Cells
DMFZS8A	MI	TTZ3P4W
DMFZS8A	MN	B-cell maturation protein (TNFRSF17)
DMFZS8A	MT	DTT
DMFZS8A	MA	CAR-T-Cell-Therapy(Dual specific)
DMFZS8A	RN	ClinicalTrials.gov (NCT03767751) A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma
DMFZS8A	RU	https://clinicaltrials.gov/ct2/show/NCT03767751

DMFZS8A	DI	DMFZS8A
DMFZS8A	DN	CD38 and BCMA CAR-T Cells
DMFZS8A	MI	TTPURFN
DMFZS8A	MN	Cyclic ADP-ribose hydrolase 1 (CD38)
DMFZS8A	MT	DTT
DMFZS8A	MA	CAR-T-Cell-Therapy(Dual specific)
DMFZS8A	RN	ClinicalTrials.gov (NCT03767751) A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma
DMFZS8A	RU	https://clinicaltrials.gov/ct2/show/NCT03767751

DMPS3I6	DI	DMPS3I6
DMPS3I6	DN	CD38 CAR T cells
DMPS3I6	MI	TTPURFN
DMPS3I6	MN	Cyclic ADP-ribose hydrolase 1 (CD38)
DMPS3I6	MT	DTT
DMPS3I6	MA	CAR-T-Cell-Therapy
DMPS3I6	RN	ClinicalTrials.gov (NCT03271632) Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
DMPS3I6	RU	https://clinicaltrials.gov/ct2/show/NCT03271632

DM0USBX	DI	DM0USBX
DM0USBX	DN	CD38 CAR-T Cell
DM0USBX	MI	TTPURFN
DM0USBX	MN	Cyclic ADP-ribose hydrolase 1 (CD38)
DM0USBX	MT	DTT
DM0USBX	MA	CAR-T-Cell-Therapy
DM0USBX	RN	ClinicalTrials.gov (NCT03754764) A Feasibility and Safety Study of CD38 CAR-T Cell Immunotherapy for Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T Adoptive Cellular Immunotherapy
DM0USBX	RU	https://clinicaltrials.gov/ct2/show/NCT03754764

DMCH98G	DI	DMCH98G
DMCH98G	DN	CD38-specific gene-engineered T cells
DMCH98G	MI	TTPURFN
DMCH98G	MN	Cyclic ADP-ribose hydrolase 1 (CD38)
DMCH98G	MT	DTT
DMCH98G	MA	CAR-T-Cell-Therapy
DMCH98G	RN	ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
DMCH98G	RU	https://clinicaltrials.gov/ct2/show/NCT03222674

DMS5OL0	DI	DMS5OL0
DMS5OL0	DN	CD56 CAR T cells
DMS5OL0	MI	TTVXPHT
DMS5OL0	MN	Neural cell adhesion molecule 1 (NCAM1)
DMS5OL0	MT	DTT
DMS5OL0	MA	CAR-T-Cell-Therapy
DMS5OL0	RN	ClinicalTrials.gov (NCT03271632) Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
DMS5OL0	RU	https://clinicaltrials.gov/ct2/show/NCT03271632

DM35XCT	DI	DM35XCT
DM35XCT	DN	CD56-specific gene-engineered T cells
DM35XCT	MI	TTVXPHT
DM35XCT	MN	Neural cell adhesion molecule 1 (NCAM1)
DM35XCT	MT	DTT
DM35XCT	MA	CAR-T-Cell-Therapy
DM35XCT	RN	ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
DM35XCT	RU	https://clinicaltrials.gov/ct2/show/NCT03222674

DMD1V7I	DI	DMD1V7I
DMD1V7I	DN	Celgosivir
DMD1V7I	MI	TTXWASR
DMD1V7I	MN	Intestinal maltase-glucoamylase (MGAM)
DMD1V7I	MT	DTT
DMD1V7I	MA	Modulator
DMD1V7I	RN	Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection.Curr Opin Investig Drugs.2009 Aug;10(8):860-70.
DMD1V7I	RU	https://www.ncbi.nlm.nih.gov/pubmed/19649930

DMAO04B	DI	DMAO04B
DMAO04B	DN	CEP-32496
DMAO04B	MI	TT4DXQT
DMAO04B	MN	Proto-oncogene c-Ret (RET)
DMAO04B	MT	DTT
DMAO04B	MA	Inhibitor
DMAO04B	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMAO04B	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMAO04B	DI	DMAO04B
DMAO04B	DN	CEP-32496
DMAO04B	MI	TTWCGQT
DMAO04B	MN	Serine/threonine-protein kinase B-raf (BRAF)
DMAO04B	MT	DTT
DMAO04B	MA	Inhibitor
DMAO04B	RN	Clinical pipeline report, company report or official report of Ambit Biosciences.
DMAO04B	RU	http://www.ambitbio.com/CEP32496

DMY8NUF	DI	DMY8NUF
DMY8NUF	DN	CEP-9722
DMY8NUF	MI	TTEBCY8
DMY8NUF	MN	Poly [ADP-ribose] polymerase (PARP)
DMY8NUF	MT	DTT
DMY8NUF	MA	Modulator
DMY8NUF	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMY8NUF	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMCR7EF	DI	DMCR7EF
DMCR7EF	DN	CEQ-508
DMCR7EF	MI	TTRPKQG
DMCR7EF	MN	Beta-catenin (CTNNB1)
DMCR7EF	MT	DTT
DMCR7EF	RN	Current Progress of siRNA/shRNA Therapeutics in Clinical Trials. Biotechnol J. 2011 September; 6(9): 1130-1146.
DMCR7EF	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388104/

DMUW6KP	DI	DMUW6KP
DMUW6KP	DN	CERC-803
DMUW6KP	MI	DEFYE6A
DMUW6KP	MN	L-fucose isomerase (fucI)
DMUW6KP	MT	DME
DMUW6KP	MA	Metabolism
DMUW6KP	RN	nan
DMUW6KP	RU	nan

DMD3XMW	DI	DMD3XMW
DMD3XMW	DN	Cethrin
DMD3XMW	MI	TTMQO60
DMD3XMW	MN	Rho-associated protein kinase (ROCK)
DMD3XMW	MT	DTT
DMD3XMW	MA	Modulator
DMD3XMW	RN	A phase I/IIa clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury. J Neurotrauma. 2011 May;28(5):787-96.
DMD3XMW	RU	https://pubmed.ncbi.nlm.nih.gov/21381984

DMJBQ96	DI	DMJBQ96
DMJBQ96	DN	Cetrelimab
DMJBQ96	MI	TTNBFWK
DMJBQ96	MN	Programmed cell death protein 1 (PD-1)
DMJBQ96	MT	DTT
DMJBQ96	RN	Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update. Int J Mol Sci. 2018 Dec 7;19(12):3924.
DMJBQ96	RU	https://pubmed.ncbi.nlm.nih.gov/30544512

DM2BXDU	DI	DM2BXDU
DM2BXDU	DN	CFG920
DM2BXDU	MI	TTRA5BZ
DM2BXDU	MN	Steroid 17-alpha-monooxygenase (S17AH)
DM2BXDU	MT	DTT
DM2BXDU	MA	Inhibitor
DM2BXDU	RN	Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int J Mol Sci. 2013 Jul 4;14(7):13958-78.
DM2BXDU	RU	https://pubmed.ncbi.nlm.nih.gov/23880851

DMB5KRA	DI	DMB5KRA
DMB5KRA	DN	CFI-402411
DMB5KRA	MI	TTSHWUP
DMB5KRA	MN	MEK kinase kinase 1 (MAP4K1)
DMB5KRA	MT	DTT
DMB5KRA	MA	Inhibitor
DMB5KRA	RN	Clinical pipeline report, company report or official report of Treadwell Therapeutics.
DMB5KRA	RU	https://treadwelltx.com/pipeline/

DMPYW28	DI	DMPYW28
DMPYW28	DN	CG-806
DMPYW28	MI	TTGM6VW
DMPYW28	MN	Tyrosine-protein kinase BTK (ATK)
DMPYW28	MT	DTT
DMPYW28	MA	Inhibitor
DMPYW28	RN	Clinical pipeline report, company report or official report of Aptose Biosciences.
DMPYW28	RU	https://www.aptose.com/product-pipeline/cg-806-for-b-cell

DMHNFXR	DI	DMHNFXR
DMHNFXR	DN	Chimeric Antigen Receptor Modified T cells Targeting CD19
DMHNFXR	MI	TTW640A
DMHNFXR	MN	B-lymphocyte surface antigen B4 (CD19)
DMHNFXR	MT	DTT
DMHNFXR	MA	CAR-T-Cell-Therapy
DMHNFXR	RN	ClinicalTrials.gov (NCT02349698) A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma
DMHNFXR	RU	https://clinicaltrials.gov/ct2/show/NCT02349698

DMIXPNG	DI	DMIXPNG
DMIXPNG	DN	CHR-3996
DMIXPNG	MI	TT6R7JZ
DMIXPNG	MN	Histone deacetylase 1 (HDAC1)
DMIXPNG	MT	DTT
DMIXPNG	MA	Inhibitor
DMIXPNG	RN	A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin Cancer Res. 2012 May 1;18(9):2687-94.
DMIXPNG	RU	https://pubmed.ncbi.nlm.nih.gov/22553374

DMIXPNG	DI	DMIXPNG
DMIXPNG	DN	CHR-3996
DMIXPNG	MI	TTSHTOI
DMIXPNG	MN	Histone deacetylase 2 (HDAC2)
DMIXPNG	MT	DTT
DMIXPNG	MA	Inhibitor
DMIXPNG	RN	A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin Cancer Res. 2012 May 1;18(9):2687-94.
DMIXPNG	RU	https://pubmed.ncbi.nlm.nih.gov/22553374

DMIXPNG	DI	DMIXPNG
DMIXPNG	DN	CHR-3996
DMIXPNG	MI	TT4YWTO
DMIXPNG	MN	Histone deacetylase 3 (HDAC3)
DMIXPNG	MT	DTT
DMIXPNG	MA	Inhibitor
DMIXPNG	RN	A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin Cancer Res. 2012 May 1;18(9):2687-94.
DMIXPNG	RU	https://pubmed.ncbi.nlm.nih.gov/22553374

DM90BUD	DI	DM90BUD
DM90BUD	DN	ChronSeal
DM90BUD	MI	TTNDSF4
DM90BUD	MN	Proto-oncogene c-Met (MET)
DM90BUD	MT	DTT
DM90BUD	MA	Inhibitor
DM90BUD	RN	Clinical pipeline report, company report or official report of Kringle Pharma.
DM90BUD	RU	http://www.kringle-pharma.com/en/news.html

DMRSI1O	DI	DMRSI1O
DMRSI1O	DN	ChronVac-C hepatitis C DNA vaccine
DMRSI1O	MI	TTZYW5V
DMRSI1O	MN	Hepatitis C virus Deoxyribonucleic acid (HCV DNA)
DMRSI1O	MT	DTT
DMRSI1O	RN	Clinical pipeline report, company report or official report of Inovio Pharmaceuticals.
DMRSI1O	RU	http://ir.inovio.com/news/news-releases/news-releases-details/2013/Inovio-Collaborator-ChronTech-Reports-Interim-Phase-II-Clinical-Study-Results-from-ChronVac-C-Vaccine-for-Hepatitis-C-Infection/default.aspx

DMTV4L7	DI	DMTV4L7
DMTV4L7	DN	CHS-828
DMTV4L7	MI	TTD1WIG
DMTV4L7	MN	Nicotinamide phosphoribosyltransferase (NAMPT)
DMTV4L7	MT	DTT
DMTV4L7	MA	Inhibitor
DMTV4L7	RN	Anticancer agent CHS-828 inhibits cellular synthesis of NAD. Biochem Biophys Res Commun. 2008 Mar 21;367(4):799-804.
DMTV4L7	RU	https://pubmed.ncbi.nlm.nih.gov/18201551

DMMVWSY	DI	DMMVWSY
DMMVWSY	DN	CK-101
DMMVWSY	MI	TTG96HZ
DMMVWSY	MN	EGFR messenger RNA (EGFR mRNA)
DMMVWSY	MT	DTT
DMMVWSY	MA	Inhibitor
DMMVWSY	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMMVWSY	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DML8US9	DI	DML8US9
DML8US9	DN	CLIC-1901
DML8US9	MI	TTW640A
DML8US9	MN	B-lymphocyte surface antigen B4 (CD19)
DML8US9	MT	DTT
DML8US9	MA	CAR-T-Cell-Therapy
DML8US9	RN	ClinicalTrials.gov (NCT03765177) CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies
DML8US9	RU	https://clinicaltrials.gov/ct2/show/NCT03765177

DMCT917	DI	DMCT917
DMCT917	DN	CLL1-specific gene-engineered T cells
DMCT917	MI	TT70N8V
DMCT917	MN	Myeloid inhibitory C-type lectin-like receptor (CD371)
DMCT917	MT	DTT
DMCT917	MA	CAR-T-Cell-Therapy
DMCT917	RN	ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
DMCT917	RU	https://clinicaltrials.gov/ct2/show/NCT03222674

DM2FSM5	DI	DM2FSM5
DM2FSM5	DN	CLR-1401
DM2FSM5	MI	TTHBTOP
DM2FSM5	MN	PI3-kinase gamma (PIK3CG)
DM2FSM5	MT	DTT
DM2FSM5	MA	Inhibitor
DM2FSM5	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2155).
DM2FSM5	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2155

DM64FY7	DI	DM64FY7
DM64FY7	DN	CLR457
DM64FY7	MI	TTHBTOP
DM64FY7	MN	PI3-kinase gamma (PIK3CG)
DM64FY7	MT	DTT
DM64FY7	MA	Modulator
DM64FY7	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM64FY7	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMWZOD7	DI	DMWZOD7
DMWZOD7	DN	CNVN-202
DMWZOD7	MI	TTJ8O14
DMWZOD7	MN	Tumor suppressor candidate 2 (TUSC2)
DMWZOD7	MT	DTT
DMWZOD7	MA	Suppressor
DMWZOD7	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018766)
DMWZOD7	RU	http://adisinsight.springer.com/drugs/800018766

DM1ZGUX	DI	DM1ZGUX
DM1ZGUX	DN	CPHPC
DM1ZGUX	MI	TTB7VAT
DM1ZGUX	MN	Serum amyloid P-component (APCS)
DM1ZGUX	MT	DTT
DM1ZGUX	MA	Modulator
DM1ZGUX	RN	Interaction of serum amyloid P component with hexanoyl bis(D-proline) (CPHPC).Acta Crystallogr D Biol Crystallogr.2014 Aug;70(Pt 8):2232-40.
DM1ZGUX	RU	https://www.ncbi.nlm.nih.gov/pubmed/25084341

DMJEXLI	DI	DMJEXLI
DMJEXLI	DN	CPI-0209
DMJEXLI	MI	TT9MZCQ
DMJEXLI	MN	Enhancer of zeste homolog 2 (EZH2)
DMJEXLI	MT	DTT
DMJEXLI	MA	Inhibitor
DMJEXLI	RN	ClinicalTrials.gov (NCT04104776) A Study of CPI-0209 in Patients With Advanced Tumors. U.S. National Institutes of Health.
DMJEXLI	RU	https://clinicaltrials.gov/ct2/show/NCT04104776

DM3XWJ8	DI	DM3XWJ8
DM3XWJ8	DN	CPI-1205
DM3XWJ8	MI	TT9MZCQ
DM3XWJ8	MN	Enhancer of zeste homolog 2 (EZH2)
DM3XWJ8	MT	DTT
DM3XWJ8	MA	Inhibitor
DM3XWJ8	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3XWJ8	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM6078F	DI	DM6078F
DM6078F	DN	CT84.66
DM6078F	MI	TTY6DTE
DM6078F	MN	Carcinoembryonic antigen CEA (CD66e)
DM6078F	MT	DTT
DM6078F	RN	Technology evaluation: cT84.66, City of Hope. Curr Opin Mol Ther. 2004 Feb;6(1):90-5.
DM6078F	RU	https://pubmed.ncbi.nlm.nih.gov/15011786

DM95XR8	DI	DM95XR8
DM95XR8	DN	CTCE-9908
DM95XR8	MI	TTBID49
DM95XR8	MN	C-X-C chemokine receptor type 4 (CXCR4)
DM95XR8	MT	DTT
DM95XR8	MA	Modulator
DM95XR8	RN	A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res. 2009 Aug;155(2):231-6.
DM95XR8	RU	https://pubmed.ncbi.nlm.nih.gov/19482312

DM90XQC	DI	DM90XQC
DM90XQC	DN	CTX001
DM90XQC	MI	TTR61MW
DM90XQC	MN	B-cell lymphoma/leukemia 11A (BCL11A)
DM90XQC	MT	DTT
DM90XQC	RN	Off-the-shelf' allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020 Mar;19(3):185-199.
DM90XQC	RU	https://pubmed.ncbi.nlm.nih.gov/31900462

DMJ7LP0	DI	DMJ7LP0
DMJ7LP0	DN	CTX110
DMJ7LP0	MI	TTQO71U
DMJ7LP0	MN	Hemoglobin (HB)
DMJ7LP0	MT	DTT
DMJ7LP0	RN	Clinical pipeline report, company report or official report of CRISPR Therapeutics.
DMJ7LP0	RU	http://www.crisprtx.com/programs/pipeline

DMHIQDC	DI	DMHIQDC
DMHIQDC	DN	CUDC-907
DMHIQDC	MI	TTBH0VX
DMHIQDC	MN	Histone deacetylase (HDAC)
DMHIQDC	MT	DTT
DMHIQDC	MA	Inhibitor
DMHIQDC	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMHIQDC	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMHIQDC	DI	DMHIQDC
DMHIQDC	DN	CUDC-907
DMHIQDC	MI	TTHBTOP
DMHIQDC	MN	PI3-kinase gamma (PIK3CG)
DMHIQDC	MT	DTT
DMHIQDC	MA	Modulator
DMHIQDC	RN	Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.Clin Cancer Res.2012 Aug 1;18(15):4104-13.
DMHIQDC	RU	https://www.ncbi.nlm.nih.gov/pubmed/22693356

DMCPZYT	DI	DMCPZYT
DMCPZYT	DN	CV-9201
DMCPZYT	MI	TTTPU1G
DMCPZYT	MN	Apoptosis inhibitor survivin (BIRC5)
DMCPZYT	MT	DTT
DMCPZYT	RN	National Cancer Institute Drug Dictionary (drug id 648549).
DMCPZYT	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=648549

DMCPZYT	DI	DMCPZYT
DMCPZYT	DN	CV-9201
DMCPZYT	MI	TTE5ITK
DMCPZYT	MN	Cancer/testis antigen 1 (NY-ESO-1)
DMCPZYT	MT	DTT
DMCPZYT	RN	National Cancer Institute Drug Dictionary (drug id 648549).
DMCPZYT	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=648549

DMCPZYT	DI	DMCPZYT
DMCPZYT	DN	CV-9201
DMCPZYT	MI	TT9M6NA
DMCPZYT	MN	Cancer/testis antigen MAGE-C1/CT7 (MAGEC1)
DMCPZYT	MT	DTT
DMCPZYT	RN	National Cancer Institute Drug Dictionary (drug id 648549).
DMCPZYT	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=648549

DMCPZYT	DI	DMCPZYT
DMCPZYT	DN	CV-9201
DMCPZYT	MI	TTKGUEB
DMCPZYT	MN	Melanoma-associated antigen C2 (MAGEC2)
DMCPZYT	MT	DTT
DMCPZYT	RN	National Cancer Institute Drug Dictionary (drug id 648549).
DMCPZYT	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=648549

DMCPZYT	DI	DMCPZYT
DMCPZYT	DN	CV-9201
DMCPZYT	MI	TT70MLA
DMCPZYT	MN	Oncotrophoblast glycoprotein 5T4 (TPBG)
DMCPZYT	MT	DTT
DMCPZYT	RN	National Cancer Institute Drug Dictionary (drug id 648549).
DMCPZYT	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=648549

DM03LWZ	DI	DM03LWZ
DM03LWZ	DN	CVX-060
DM03LWZ	MI	TTKLQTJ
DM03LWZ	MN	Angiopoietin-2 (ANGPT2)
DM03LWZ	MT	DTT
DM03LWZ	RN	Clinical pipeline report, company report or official report of CovX (2011).
DM03LWZ	RU	http://www.covx.com/pipeline.html

DMBUYIK	DI	DMBUYIK
DMBUYIK	DN	CWP232291
DMBUYIK	MI	TTFPSHI
DMBUYIK	MN	Wnt signaling pathway (Wnt pathway)
DMBUYIK	MT	DTT
DMBUYIK	MA	Inhibitor
DMBUYIK	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMBUYIK	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMUGMFN	DI	DMUGMFN
DMUGMFN	DN	CXB-909
DMUGMFN	MI	TTDN3LF
DMUGMFN	MN	Nerve growth factor (NGF)
DMUGMFN	MT	DTT
DMUGMFN	MA	Modulator
DMUGMFN	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMUGMFN	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DME6NMJ	DI	DME6NMJ
DME6NMJ	DN	CYT-0851
DME6NMJ	MI	TTC0G1L
DME6NMJ	MN	DNA repair protein RAD51 homolog 1 (RAD51)
DME6NMJ	MT	DTT
DME6NMJ	MA	Inhibitor
DME6NMJ	RN	National Cancer Institute Drug Dictionary (drug name CYT0851).
DME6NMJ	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/rad51-inhibitor-cyt-0851

DMJPSIL	DI	DMJPSIL
DMJPSIL	DN	Dapivirine
DMJPSIL	MI	DEIBDNY
DMJPSIL	MN	Cytochrome P450 3A5 (CYP3A5)
DMJPSIL	MT	DME
DMJPSIL	MA	Metabolism
DMJPSIL	RN	Metabolism Of Antiretroviral Drugs Used In Hiv Preexposure Prophylaxis
DMJPSIL	RU	https://jscholarship.library.jhu.edu/bitstream/handle/1774.2/39301/TO-DISSERTATION-2014.pdf?sequence=1&isAllowed=y

DMJPSIL	DI	DMJPSIL
DMJPSIL	DN	Dapivirine
DMJPSIL	MI	TT84ETX
DMJPSIL	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMJPSIL	MT	DTT
DMJPSIL	MA	Inhibitor
DMJPSIL	RN	Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416.
DMJPSIL	RU	https://pubmed.ncbi.nlm.nih.gov/18764719

DMJPSIL	DI	DMJPSIL
DMJPSIL	DN	Dapivirine
DMJPSIL	MI	DEYGVN4
DMJPSIL	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMJPSIL	MT	DME
DMJPSIL	MA	Metabolism
DMJPSIL	RN	Metabolism Of Antiretroviral Drugs Used In Hiv Preexposure Prophylaxis
DMJPSIL	RU	https://jscholarship.library.jhu.edu/bitstream/handle/1774.2/39301/TO-DISSERTATION-2014.pdf?sequence=1&isAllowed=y

DMJKFNU	DI	DMJKFNU
DMJKFNU	DN	DCC-2036
DMJKFNU	MI	TT9VGXW
DMJKFNU	MN	Angiopoietin 1 receptor (TEK)
DMJKFNU	MT	DTT
DMJKFNU	MA	Inhibitor
DMJKFNU	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMJKFNU	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMJKFNU	DI	DMJKFNU
DMJKFNU	DN	DCC-2036
DMJKFNU	MI	TT3PJMV
DMJKFNU	MN	Tyrosine-protein kinase ABL1 (ABL)
DMJKFNU	MT	DTT
DMJKFNU	MA	Modulator
DMJKFNU	RN	Company report (Deciphera Pharmaceuticals: Tumor-Targeted Programs and Indications)
DMJKFNU	RU	http://www.deciphera.com/pipeline

DMHW289	DI	DMHW289
DMHW289	DN	DCC-3014
DMHW289	MI	TT7MRDV
DMHW289	MN	Macrophage colony-stimulating factor 1 receptor (CSF1R)
DMHW289	MT	DTT
DMHW289	MA	Inhibitor
DMHW289	RN	Clinical pipeline report, company report or official report of Deciphera Pharmaceuticals.
DMHW289	RU	https://www.deciphera.com/pipeline/dcc-3014/

DMWE205	DI	DMWE205
DMWE205	DN	DCR-MYC
DMWE205	MI	TTVW4XU
DMWE205	MN	MYCBP messenger RNA (MYCBP mRNA)
DMWE205	MT	DTT
DMWE205	RN	National Cancer Institute Drug Dictionary (drug id 759983).
DMWE205	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=759983

DM0I5LM	DI	DM0I5LM
DM0I5LM	DN	DdRNAi therapy rHIV7-shl-TAR-CCR5RZ, stem cells
DM0I5LM	MI	TTJIH8Q
DM0I5LM	MN	CCR5 messenger RNA (CCR5 mRNA)
DM0I5LM	MT	DTT
DM0I5LM	RN	Progress on RNAi-based molecular medicines. Int J Nanomedicine. 2012; 7: 3971-3980.
DM0I5LM	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3418169/

DMCMT4V	DI	DMCMT4V
DMCMT4V	DN	Dexamethasone palmitate
DMCMT4V	MI	DE4LYSA
DMCMT4V	MN	Cytochrome P450 3A4 (CYP3A4)
DMCMT4V	MT	DME
DMCMT4V	MA	Metabolism
DMCMT4V	RN	Cytotoxicity of chloroacetanilide herbicide alachlor in HepG2 cells independent of CYP3A4 and CYP3A7. Food Chem Toxicol. 2007 May;45(5):871-7.
DMCMT4V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17207564

DMCMT4V	DI	DMCMT4V
DMCMT4V	DN	Dexamethasone palmitate
DMCMT4V	MI	TTPNQAC
DMCMT4V	MN	Estrogen-related receptor-alpha (ESRRA)
DMCMT4V	MT	DTT
DMCMT4V	MA	Agonist
DMCMT4V	RN	Dexamethasone treatment in childhood bacterial meningitis in Malawi: a randomised controlled trial. Lancet. 2002 Jul 20;360(9328):211-8.
DMCMT4V	RU	https://pubmed.ncbi.nlm.nih.gov/12133656

DMACPQO	DI	DMACPQO
DMACPQO	DN	Dihydrexidine
DMACPQO	MI	TTZFYLI
DMACPQO	MN	Dopamine D1 receptor (D1R)
DMACPQO	MT	DTT
DMACPQO	MA	Inhibitor
DMACPQO	RN	trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization o... J Med Chem. 2006 Nov 16;49(23):6848-57.
DMACPQO	RU	https://pubmed.ncbi.nlm.nih.gov/17154515

DM71BFM	DI	DM71BFM
DM71BFM	DN	DNA-Ad
DM71BFM	MI	TTQZW34
DM71BFM	MN	Plasmodium Apical membrane protein (Malaria AMA-1)
DM71BFM	MT	DTT
DM71BFM	RN	Sterile immunity to malaria after DNA prime/adenovirus boost immunization is associated with effector memory CD8+T cells targeting AMA1 class I epitopes. PLoS One. 2014 Sep 11;9(9):e106241.
DM71BFM	RU	https://pubmed.ncbi.nlm.nih.gov/25211344

DMK4VY9	DI	DMK4VY9
DMK4VY9	DN	DS-7300
DMK4VY9	MI	TT6CQUM
DMK4VY9	MN	B7 homolog 3 (CD276)
DMK4VY9	MT	DTT
DMK4VY9	MA	Inhibitor
DMK4VY9	RN	Clinical pipeline report, company report or official report of Daiichi Sankyo.
DMK4VY9	RU	https://www.daiichisankyo.com/rd/pipeline/

DMK4VY9	DI	DMK4VY9
DMK4VY9	DN	DS-7300
DMK4VY9	MI	TTGTQHC
DMK4VY9	MN	DNA topoisomerase I (TOP1)
DMK4VY9	MT	DTT
DMK4VY9	MA	Inhibitor
DMK4VY9	RN	Clinical pipeline report, company report or official report of Daiichi Sankyo.
DMK4VY9	RU	https://www.daiichisankyo.com/rd/pipeline/

DM7WK6N	DI	DM7WK6N
DM7WK6N	DN	DSP-0509
DM7WK6N	MI	TTRJ1K4
DM7WK6N	MN	Toll-like receptor 7 (TLR7)
DM7WK6N	MT	DTT
DM7WK6N	MA	Agonist
DM7WK6N	RN	Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma.
DM7WK6N	RU	https://www.ds-pharma.com/rd/clinical/pipeline.html

DM8K0PR	DI	DM8K0PR
DM8K0PR	DN	DSP-107
DM8K0PR	MI	TT28S46
DM8K0PR	MN	Leukocyte surface antigen CD47 (CD47)
DM8K0PR	MT	DTT
DM8K0PR	RN	Clinical pipeline report, company report or official report of KAHR Medical.
DM8K0PR	RU	https://kahrbio.com/technology/#pipeline

DMRXQCL	DI	DMRXQCL
DMRXQCL	DN	DT388IL-3
DMRXQCL	MI	TTPYS82
DMRXQCL	MN	Interleukin 3 receptor (CSF2RB)
DMRXQCL	MT	DTT
DMRXQCL	MA	Inhibitor
DMRXQCL	RN	Safety evaluation of DT388IL3, a diphtheria toxin/interleukin 3 fusion protein, in the cynomolgus monkey. Cancer Immunol Immunother. 2005 Aug;54(8):799-806.
DMRXQCL	RU	https://pubmed.ncbi.nlm.nih.gov/15614527

DM8M71U	DI	DM8M71U
DM8M71U	DN	DTX301
DM8M71U	MI	TT5KIO9
DM8M71U	MN	Ornithine transcarbamylase (OTC)
DM8M71U	MT	DTT
DM8M71U	MA	Replacement
DM8M71U	RN	Clinical pipeline report, company report or official report of Ultragenyx Pharmaceutical.
DM8M71U	RU	https://www.ultragenyx.com/pipeline/dtx-301-for-otc/

DM72DU3	DI	DM72DU3
DM72DU3	DN	DZD9008
DM72DU3	MI	TT2M7YX
DM72DU3	MN	EGFR Exon20ins mutant (EGFR Exon20ins)
DM72DU3	MT	DTT
DM72DU3	MA	Inhibitor
DM72DU3	RN	Clinical pipeline report, company report or official report of Dizal Pharmaceuticals.
DM72DU3	RU	http://www.dizalpharma.com/innovation/science

DMH2NKD	DI	DMH2NKD
DMH2NKD	DN	EB-101
DMH2NKD	MI	TTE4KHA
DMH2NKD	MN	Amyloid beta A4 protein (APP)
DMH2NKD	MT	DTT
DMH2NKD	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
DMH2NKD	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402

DMI71FN	DI	DMI71FN
DMI71FN	DN	EDO-S101
DMI71FN	MI	TTBH0VX
DMI71FN	MN	Histone deacetylase (HDAC)
DMI71FN	MT	DTT
DMI71FN	MA	Inhibitor
DMI71FN	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMI71FN	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMHRCQI	DI	DMHRCQI
DMHRCQI	DN	eFT226
DMHRCQI	MI	TTIGYVZ
DMHRCQI	MN	HUMAN eukaryotic initiation factor-4A (eIF4A)
DMHRCQI	MT	DTT
DMHRCQI	MA	Inhibitor
DMHRCQI	RN	Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase. J Med Chem. 2020 Jun 11;63(11):5879-5955.
DMHRCQI	RU	https://pubmed.ncbi.nlm.nih.gov/32470302

DMF7EX8	DI	DMF7EX8
DMF7EX8	DN	EGFR antisense DNA
DMF7EX8	MI	TTG96HZ
DMF7EX8	MN	EGFR messenger RNA (EGFR mRNA)
DMF7EX8	MT	DTT
DMF7EX8	RN	Antitumor Effects of EGFR Antisense Guanidine-Based Peptide Nucleic Acids in Cancer Models. ACS Chem Biol. 2013 February 15; 8(2): 345-352.
DMF7EX8	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3684443/

DMDWCOF	DI	DMDWCOF
DMDWCOF	DN	EGFR CART
DMDWCOF	MI	TTGKNB4
DMDWCOF	MN	Epidermal growth factor receptor (EGFR)
DMDWCOF	MT	DTT
DMDWCOF	MA	CAR-T-Cell-Therapy
DMDWCOF	RN	ClinicalTrials.gov (NCT03152435) EGFR CART Cells for Patients With Metastatic Colorectal Cancer
DMDWCOF	RU	https://clinicaltrials.gov/ct2/show/NCT03152435

DMC284G	DI	DMC284G
DMC284G	DN	EGFRvIII CAR
DMC284G	MI	TTZ6B2I
DMC284G	MN	Epidermal growth factor receptor variant III (EGFR vIII)
DMC284G	MT	DTT
DMC284G	MA	Modulator
DMC284G	RN	EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res. 2014 Feb 15;20(4):972-84.
DMC284G	RU	https://pubmed.ncbi.nlm.nih.gov/24352643

DM5FCO4	DI	DM5FCO4
DM5FCO4	DN	Elpamotide
DM5FCO4	MI	TTUTJGQ
DM5FCO4	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM5FCO4	MT	DTT
DM5FCO4	RN	Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors. Cancer Sci. 2012 Dec;103(12):2135-8.
DM5FCO4	RU	https://pubmed.ncbi.nlm.nih.gov/22957712

DM7CLEZ	DI	DM7CLEZ
DM7CLEZ	DN	Eltanexor oral
DM7CLEZ	MI	TTCJUR4
DM7CLEZ	MN	Exportin-1 (XPO1)
DM7CLEZ	MT	DTT
DM7CLEZ	MA	Inhibitor
DM7CLEZ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7CLEZ	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMCAUKW	DI	DMCAUKW
DMCAUKW	DN	EMB-01
DMCAUKW	MI	TTGKNB4
DMCAUKW	MN	Epidermal growth factor receptor (EGFR)
DMCAUKW	MT	DTT
DMCAUKW	MA	Inhibitor
DMCAUKW	RN	Clinical pipeline report, company report or official report of EpimAb Biotherapeutics.
DMCAUKW	RU	https://www.epimab.com/en/pipeline/1

DMMD10S	DI	DMMD10S
DMMD10S	DN	EMD 55900
DMMD10S	MI	TTGKNB4
DMMD10S	MN	Epidermal growth factor receptor (EGFR)
DMMD10S	MT	DTT
DMMD10S	RN	Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer. 2002 Mar 1;94(5):1593-611.
DMMD10S	RU	https://pubmed.ncbi.nlm.nih.gov/11920518

DMIOUFK	DI	DMIOUFK
DMIOUFK	DN	Emfilermin
DMIOUFK	MI	TTID542
DMIOUFK	MN	Leukemia inhibitory factor receptor (LIFR)
DMIOUFK	MT	DTT
DMIOUFK	MA	Inhibitor
DMIOUFK	RN	Population pharmacokinetic modelling of Emfilermin (recombinant human leukaemia inhibitory factor, r-hLIF) in healthy postmenopausal women and in infertile patients undergoing in vitro fertilization and embryo transfer. Br J Clin Pharmacol. 2004 May; 57(5): 576-585.
DMIOUFK	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884498/

DM1PQJO	DI	DM1PQJO
DM1PQJO	DN	Enapotamab vedotin
DM1PQJO	MI	TTZPY6J
DM1PQJO	MN	Tyrosine-protein kinase UFO (AXL)
DM1PQJO	MT	DTT
DM1PQJO	MA	Inhibitor
DM1PQJO	RN	Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer. JCI Insight. 2019 Nov 1;4(21):e128199.
DM1PQJO	RU	https://pubmed.ncbi.nlm.nih.gov/31600169

DMN0EMP	DI	DMN0EMP
DMN0EMP	DN	Epicatechin
DMN0EMP	MI	TTSJH2W
DMN0EMP	MN	Mitochondrial protein unspecific (MP)
DMN0EMP	MT	DTT
DMN0EMP	MA	Modulator
DMN0EMP	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMN0EMP	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMN0EMP	DI	DMN0EMP
DMN0EMP	DN	Epicatechin
DMN0EMP	MI	DTFI42L
DMN0EMP	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMN0EMP	MT	DTP
DMN0EMP	MA	Substrate
DMN0EMP	RN	Transport and metabolism of the tea flavonoid (-)-epicatechin by the human intestinal cell line Caco-2. Pharm Res. 2001 Oct;18(10):1420-5.
DMN0EMP	RU	https://doi.org/10.1023/A:1012200805593

DMN0EMP	DI	DMN0EMP
DMN0EMP	DN	Epicatechin
DMN0EMP	MI	TTPZ7AG
DMN0EMP	MN	Oxidoreductase unspecific (OR)
DMN0EMP	MT	DTT
DMN0EMP	MA	Modulator
DMN0EMP	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMN0EMP	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMN0EMP	DI	DMN0EMP
DMN0EMP	DN	Epicatechin
DMN0EMP	MI	TT8NGED
DMN0EMP	MN	Prostaglandin G/H synthase 1 (COX-1)
DMN0EMP	MT	DTT
DMN0EMP	MA	Inhibitor
DMN0EMP	RN	Mechanism-based inactivation of COX-1 by red wine m-hydroquinones: a structure-activity relationship study. J Nat Prod. 2004 Nov;67(11):1777-82.
DMN0EMP	RU	https://pubmed.ncbi.nlm.nih.gov/15568761

DMWSGZU	DI	DMWSGZU
DMWSGZU	DN	Epithalon
DMWSGZU	MI	TTUJFD0
DMWSGZU	MN	Telomerase reverse transcriptase (TERT)
DMWSGZU	MT	DTT
DMWSGZU	MA	Modulator
DMWSGZU	RN	Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003 Jun;135(6):590-2.
DMWSGZU	RU	https://pubmed.ncbi.nlm.nih.gov/12937682

DMTY96S	DI	DMTY96S
DMTY96S	DN	Eptacog beta
DMTY96S	MI	TTLPJWH
DMTY96S	MN	Thioredoxin reductase (PRDX5)
DMTY96S	MT	DTT
DMTY96S	MA	Inhibitor
DMTY96S	RN	APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell Death Dis. 2013 Oct 24;4:e881. 
DMTY96S	RU	https://pubmed.ncbi.nlm.nih.gov/24157875

DMN2FS3	DI	DMN2FS3
DMN2FS3	DN	EPZ-5676
DMN2FS3	MI	TTSZ8T1
DMN2FS3	MN	Histone-lysine N-methyltransferase (HLNM)
DMN2FS3	MT	DTT
DMN2FS3	MA	Modulator
DMN2FS3	RN	Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood. 2013 August 8; 122(6): 1017-1025.
DMN2FS3	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3739029/

DMNZ6VA	DI	DMNZ6VA
DMNZ6VA	DN	Erythropoietin-transfected autologous cell therapy
DMNZ6VA	MI	TTQG4NR
DMNZ6VA	MN	Erythropoietin (EPO)
DMNZ6VA	MT	DTT
DMNZ6VA	MA	Modulator
DMNZ6VA	RN	Mesenchymal stromal cells engineered to express erythropoietin induce anti-erythropoietin antibodies and anemia in allorecipients. Mol Ther. 2009 Feb;17(2):369-72. 
DMNZ6VA	RU	https://pubmed.ncbi.nlm.nih.gov/19088705

DMUNM4D	DI	DMUNM4D
DMUNM4D	DN	ESR0114
DMUNM4D	MI	TTGV6LY
DMUNM4D	MN	Nuclear receptor ROR-gamma (RORG)
DMUNM4D	MT	DTT
DMUNM4D	MA	Inhibitor
DMUNM4D	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMUNM4D	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMIREUZ	DI	DMIREUZ
DMIREUZ	DN	Ex vivo adenosine deaminase-transduced hematopoietic stem cell therapy
DMIREUZ	MI	TTLP57V
DMIREUZ	MN	Adenosine deaminase (ADA)
DMIREUZ	MT	DTT
DMIREUZ	MA	Modulator
DMIREUZ	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline.
DMIREUZ	RU	https://www.gsk.com/en-gb/media/press-releases/2015/gsk-fondazione-telethon-and-ospedale-san-raffaele-announce-eu-regulatory-submission-for-gene-therapy-to-treat-rare-disease-ada-scid/

DM64PM7	DI	DM64PM7
DM64PM7	DN	EXO-230
DM64PM7	MI	TT8NGED
DM64PM7	MN	Prostaglandin G/H synthase 1 (COX-1)
DM64PM7	MT	DTT
DM64PM7	MA	Agonist
DM64PM7	RN	Inhibiting Amadori-modified albumin formation improves biomarkers of podocyte damage in diabetic rats. Physiol Rep. 2013 September; 1(4): e00083.
DM64PM7	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831899/

DML6EVJ	DI	DML6EVJ
DML6EVJ	DN	F-14512
DML6EVJ	MI	TT0IHXV
DML6EVJ	MN	DNA topoisomerase II (TOP2)
DML6EVJ	MT	DTT
DML6EVJ	MA	Modulator
DML6EVJ	RN	Regulation by survivin of cancer cell death induced by F14512, a polyamine-containing inhibitor of DNA topoisomerase II.Apoptosis.2012 Apr;17(4):364-76.
DML6EVJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/22127645

DM49BX1	DI	DM49BX1
DM49BX1	DN	F-16-131I
DM49BX1	MI	TTUCPMY
DM49BX1	MN	Tenascin (TNC)
DM49BX1	MT	DTT
DM49BX1	RN	Tumor-Associated Fibroblasts and their Matrix. Springer. Margareta M. Mueller,Norbert E. Fusenig, 2011. Page(775).
DM49BX1	RU	https://books.google.com.hk/books?id=NthWAAAAcAAJ&pg=PA775&lpg=PA775&dq=%22F-16-131I%22&source=bl&ots=lx9eNOrJ9J&sig=TSJZ44F1Vb9V3iKhqn2bmzR0H4E&hl=zh-CN&sa=X&ved=0CBoQ6AEwAGoVChMIgayw4crGyAIVDEiOCh1b7Q2U#v=onepage&q=%22F-16-131I%22&f=false

DMQSF5C	DI	DMQSF5C
DMQSF5C	DN	FBT-A05
DMQSF5C	MI	TTUE541
DMQSF5C	MN	Leukocyte surface antigen Leu-16 (CD20)
DMQSF5C	MT	DTT
DMQSF5C	RN	Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial. J Transl Med. 2013 Jul 2;11:160.
DMQSF5C	RU	https://pubmed.ncbi.nlm.nih.gov/23815981

DMQ8VUW	DI	DMQ8VUW
DMQ8VUW	DN	FCN-437
DMQ8VUW	MI	TT0PG8F
DMQ8VUW	MN	Cyclin-dependent kinase 4 (CDK4)
DMQ8VUW	MT	DTT
DMQ8VUW	MA	Inhibitor
DMQ8VUW	RN	Clinical pipeline report, company report or official report of Fochon Pharmaceuticals.
DMQ8VUW	RU	http://fochon.com/what-we-do/fcn-411/

DMQ8VUW	DI	DMQ8VUW
DMQ8VUW	DN	FCN-437
DMQ8VUW	MI	TTO0FDJ
DMQ8VUW	MN	Cyclin-dependent kinase 6 (CDK6)
DMQ8VUW	MT	DTT
DMQ8VUW	MA	Inhibitor
DMQ8VUW	RN	Clinical pipeline report, company report or official report of Fochon Pharmaceuticals.
DMQ8VUW	RU	http://fochon.com/what-we-do/fcn-411/

DMRHOFB	DI	DMRHOFB
DMRHOFB	DN	Ferritarg P
DMRHOFB	MI	TT975ZT
DMRHOFB	MN	Ferritin (FTH1)
DMRHOFB	MT	DTT
DMRHOFB	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019964)
DMRHOFB	RU	http://adisinsight.springer.com/drugs/800019964

DM1XIMU	DI	DM1XIMU
DM1XIMU	DN	FF-10101
DM1XIMU	MI	TTGJCWZ
DM1XIMU	MN	Fms-like tyrosine kinase 3 (FLT-3)
DM1XIMU	MT	DTT
DM1XIMU	MA	Inhibitor
DM1XIMU	RN	A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations. Blood. 2018 Jan 25;131(4):426-438.
DM1XIMU	RU	https://pubmed.ncbi.nlm.nih.gov/29187377

DM0HSJK	DI	DM0HSJK
DM0HSJK	DN	FF-10501-01
DM0HSJK	MI	TTF63Z1
DM0HSJK	MN	Cell differentiation (CD)
DM0HSJK	MT	DTT
DM0HSJK	MA	Stimulator
DM0HSJK	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM0HSJK	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM72JE4	DI	DM72JE4
DM72JE4	DN	FF-10502
DM72JE4	MI	TTA0XPV
DM72JE4	MN	DNA polymerase beta (POLB)
DM72JE4	MT	DTT
DM72JE4	MA	Inhibitor
DM72JE4	RN	FF-10502, an Antimetabolite with Novel Activity on Dormant Cells, Is Superior to Gemcitabine for Targeting Pancreatic Cancer Cells. J Pharmacol Exp Ther. 2018 Jul;366(1):125-135.
DM72JE4	RU	https://pubmed.ncbi.nlm.nih.gov/29653962

DMWEJ0C	DI	DMWEJ0C
DMWEJ0C	DN	FGF401
DMWEJ0C	MI	TT1KX2S
DMWEJ0C	MN	FGFR4 messenger RNA (FGFR4 mRNA)
DMWEJ0C	MT	DTT
DMWEJ0C	MA	Antagonist
DMWEJ0C	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMWEJ0C	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMI7S39	DI	DMI7S39
DMI7S39	DN	FLX475
DMI7S39	MI	TT7HQD0
DMI7S39	MN	C-C chemokine receptor type 4 (CCR4)
DMI7S39	MT	DTT
DMI7S39	MA	Antagonist
DMI7S39	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMI7S39	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DME2W4T	DI	DME2W4T
DME2W4T	DN	Forodesine
DME2W4T	MI	TTMCF1Y
DME2W4T	MN	Purine nucleoside phosphorylase (PNP)
DME2W4T	MT	DTT
DME2W4T	MA	Inhibitor
DME2W4T	RN	Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 an... Blood. 2009 Aug 20;114(8):1563-75.
DME2W4T	RU	https://pubmed.ncbi.nlm.nih.gov/19541822

DM3ZN6Y	DI	DM3ZN6Y
DM3ZN6Y	DN	FPA-008
DM3ZN6Y	MI	TT731LW
DM3ZN6Y	MN	Colony stimulating factor-1 receptor (CSF-1R)
DM3ZN6Y	MT	DTT
DM3ZN6Y	MA	Modulator
DM3ZN6Y	RN	Company report (Five Prime Therapeutics)
DM3ZN6Y	RU	http://www.fiveprime.com/pipeline/fpa008

DM3ZN6Y	DI	DM3ZN6Y
DM3ZN6Y	DN	FPA-008
DM3ZN6Y	MI	TT7MRDV
DM3ZN6Y	MN	Macrophage colony-stimulating factor 1 receptor (CSF1R)
DM3ZN6Y	MT	DTT
DM3ZN6Y	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3ZN6Y	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DMXV6YP	DI	DMXV6YP
DMXV6YP	DN	Fus-1 tumor suppressor gene therapy
DMXV6YP	MI	TTJ8O14
DMXV6YP	MN	Tumor suppressor candidate 2 (TUSC2)
DMXV6YP	MT	DTT
DMXV6YP	MA	Suppressor
DMXV6YP	RN	INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201. Drugs R D. 2007;8(3):176-87.
DMXV6YP	RU	https://pubmed.ncbi.nlm.nih.gov/17472413

DMG48WN	DI	DMG48WN
DMG48WN	DN	G0-203-2c
DMG48WN	MI	TTBHFYQ
DMG48WN	MN	Mucin-1 (MUC1)
DMG48WN	MT	DTT
DMG48WN	MA	Modulator
DMG48WN	RN	Clinical pipeline report, company report or official report of Genus Oncology.
DMG48WN	RU	http://www.genusoncology.com/phase-1-trial-GO-203-2c.php

DMTV42K	DI	DMTV42K
DMTV42K	DN	G1
DMTV42K	MI	TTDSB34
DMTV42K	MN	G-protein coupled estrogen receptor 1 (GPER1)
DMTV42K	MT	DTT
DMTV42K	MA	Agonist
DMTV42K	RN	Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol. 2006 Apr;2(4):207-12.
DMTV42K	RU	https://pubmed.ncbi.nlm.nih.gov/16520733

DM32AKH	DI	DM32AKH
DM32AKH	DN	G-207 virus construct
DM32AKH	MI	TTX09M4
DM32AKH	MN	Ribonucleotide reductase (RIR)
DM32AKH	MT	DTT
DM32AKH	MA	Inhibitor
DM32AKH	RN	Anti-tumor effect of oncolytic herpes simplex virus G47delta on human nasopharyngeal carcinoma. Chin J Cancer. 2011 Dec;30(12):831-41.
DM32AKH	RU	https://pubmed.ncbi.nlm.nih.gov/22059912

DMQU4EI	DI	DMQU4EI
DMQU4EI	DN	Galnobax
DMQU4EI	MI	TTR6W5O
DMQU4EI	MN	Adrenergic receptor beta-1 (ADRB1)
DMQU4EI	MT	DTT
DMQU4EI	MA	Agonist
DMQU4EI	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQU4EI	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMN7QBE	DI	DMN7QBE
DMN7QBE	DN	GANTACURIUM CHLORIDE
DMN7QBE	MI	TTJSZTB
DMN7QBE	MN	Nicotinic acetylcholine receptor (nAChR)
DMN7QBE	MT	DTT
DMN7QBE	MA	Modulator
DMN7QBE	RN	Gantacurium and CW002 do not potentiate muscarinic receptor-mediated airway smooth muscle constriction in guinea pigs. Anesthesiology. 2010 April; 112(4): 892-899.
DMN7QBE	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2854830/

DMCT9NG	DI	DMCT9NG
DMCT9NG	DN	GB1275
DMCT9NG	MI	TTB69FJ
DMCT9NG	MN	Integrin alpha-M (ITGAM)
DMCT9NG	MT	DTT
DMCT9NG	MA	Agonist
DMCT9NG	RN	National Cancer Institute Drug Dictionary (drug name GB1275).
DMCT9NG	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/cd11b-agonist-gb1275

DM5VF04	DI	DM5VF04
DM5VF04	DN	GD2-CART01
DM5VF04	MI	TT80ARU
DM5VF04	MN	Ganglioside GD2 (GD2)
DM5VF04	MT	DTT
DM5VF04	MA	CAR-T-Cell-Therapy
DM5VF04	RN	ClinicalTrials.gov (NCT03373097) Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma
DM5VF04	RU	https://clinicaltrials.gov/ct2/show/NCT03373097

DM8J0MK	DI	DM8J0MK
DM8J0MK	DN	GEA-6414
DM8J0MK	MI	DE4OGUF
DM8J0MK	MN	Cytochrome P450 102A1 (cyp102)
DM8J0MK	MT	DME
DM8J0MK	MA	Metabolism
DM8J0MK	RN	Both reactivity and accessibility are important in cytochrome P450 metabolism: a combined DFT and MD study of fenamic acids in BM3 mutants. J Chem Inf Model. 2019 Feb 25;59(2):743-753.
DM8J0MK	RU	https://pubmed.ncbi.nlm.nih.gov/30758202

DM8J0MK	DI	DM8J0MK
DM8J0MK	DN	GEA-6414
DM8J0MK	MI	DE4LYSA
DM8J0MK	MN	Cytochrome P450 3A4 (CYP3A4)
DM8J0MK	MT	DME
DM8J0MK	MA	Metabolism
DM8J0MK	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DM8J0MK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DMD8RLY	DI	DMD8RLY
DMD8RLY	DN	GEN3009
DMD8RLY	MI	TTFCW29
DMD8RLY	MN	Leukocyte antigen CD37 (CD37)
DMD8RLY	MT	DTT
DMD8RLY	RN	Clinical pipeline report, company report or official report of AbbVie.
DMD8RLY	RU	https://www.abbvie.com/our-science/pipeline/gen-3009.html

DMZABYH	DI	DMZABYH
DMZABYH	DN	GEN3013
DMZABYH	MI	TTUE541
DMZABYH	MN	Leukocyte surface antigen Leu-16 (CD20)
DMZABYH	MT	DTT
DMZABYH	RN	DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 2020 Feb;52:102625.
DMZABYH	RU	https://pubmed.ncbi.nlm.nih.gov/31981978

DMZABYH	DI	DMZABYH
DMZABYH	DN	GEN3013
DMZABYH	MI	TTUN7MC
DMZABYH	MN	T-cell surface glycoprotein CD3 (CD3)
DMZABYH	MT	DTT
DMZABYH	RN	DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 2020 Feb;52:102625.
DMZABYH	RU	https://pubmed.ncbi.nlm.nih.gov/31981978

DMY1CP9	DI	DMY1CP9
DMY1CP9	DN	GLG-801
DMY1CP9	MI	TTH8FZW
DMY1CP9	MN	Signal transducer and activator of transcription 3 (STAT3)
DMY1CP9	MT	DTT
DMY1CP9	MA	Inhibitor
DMY1CP9	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMY1CP9	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM7DWLY	DI	DM7DWLY
DM7DWLY	DN	GLR2007
DM7DWLY	MI	TT0PG8F
DM7DWLY	MN	Cyclin-dependent kinase 4 (CDK4)
DM7DWLY	MT	DTT
DM7DWLY	MA	Inhibitor
DM7DWLY	RN	Clinical pipeline report, company report or official report of Gan & Lee Pharmaceuticals.
DM7DWLY	RU	http://www.ganlee.com/en/index.php?optionid=681&auto_id=68

DM7DWLY	DI	DM7DWLY
DM7DWLY	DN	GLR2007
DM7DWLY	MI	TTO0FDJ
DM7DWLY	MN	Cyclin-dependent kinase 6 (CDK6)
DM7DWLY	MT	DTT
DM7DWLY	MA	Inhibitor
DM7DWLY	RN	Clinical pipeline report, company report or official report of Gan & Lee Pharmaceuticals.
DM7DWLY	RU	http://www.ganlee.com/en/index.php?optionid=681&auto_id=68

DMGN679	DI	DMGN679
DMGN679	DN	GPC3-CART cells
DMGN679	MI	TTJTSX4
DMGN679	MN	Glypican-3 (GPC3)
DMGN679	MT	DTT
DMGN679	MA	CAR-T-Cell-Therapy
DMGN679	RN	ClinicalTrials.gov (NCT03130712) A Study of GPC3-targeted T Cells by Intratumor Injection for Advanced HCC (GPC3-CART)
DMGN679	RU	https://clinicaltrials.gov/ct2/show/NCT03130712

DM1GE67	DI	DM1GE67
DM1GE67	DN	GS-4224
DM1GE67	MI	TT8ZLTI
DM1GE67	MN	Programmed cell death 1 ligand 1 (PD-L1)
DM1GE67	MT	DTT
DM1GE67	MA	Inhibitor
DM1GE67	RN	Clinical pipeline report, company report or official report of Gilead Sciences.
DM1GE67	RU	https://www.gilead.com/science-and-medicine/pipeline

DMTJQ8S	DI	DMTJQ8S
DMTJQ8S	DN	GS-9219
DMTJQ8S	MI	TTIU7X1
DMTJQ8S	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMTJQ8S	MT	DTT
DMTJQ8S	MA	Inhibitor
DMTJQ8S	RN	GS-9219--a novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphoma. Clin Cancer Res. 2008 May 1;14(9):2824-32.
DMTJQ8S	RU	https://pubmed.ncbi.nlm.nih.gov/18451250

DM059OH	DI	DM059OH
DM059OH	DN	GSK3145095
DM059OH	MI	TTAIQSN
DM059OH	MN	Receptor-interacting protein 1 (RIPK1)
DM059OH	MT	DTT
DM059OH	MA	Inhibitor
DM059OH	RN	Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer. ACS Med Chem Lett. 2019 May 9;10(6):857-862.
DM059OH	RU	https://pubmed.ncbi.nlm.nih.gov/31223438

DMK2RIB	DI	DMK2RIB
DMK2RIB	DN	GTB-3550
DMK2RIB	MI	TT7KTSR
DMK2RIB	MN	Immunoglobulin gamma Fc receptor III (FCGR3)
DMK2RIB	MT	DTT
DMK2RIB	MA	Inhibitor
DMK2RIB	RN	Clinical pipeline report, company report or official report of GT Biopharma.
DMK2RIB	RU	https://www.gtbiopharma.com/product-pipeline/gtb-3550

DMK2RIB	DI	DMK2RIB
DMK2RIB	DN	GTB-3550
DMK2RIB	MI	TTJVYO3
DMK2RIB	MN	Myeloid cell surface antigen CD33 (CD33)
DMK2RIB	MT	DTT
DMK2RIB	MA	Inhibitor
DMK2RIB	RN	Clinical pipeline report, company report or official report of GT Biopharma.
DMK2RIB	RU	https://www.gtbiopharma.com/product-pipeline/gtb-3550

DM0S24D	DI	DM0S24D
DM0S24D	DN	GTU-TB vaccine
DM0S24D	MI	TTUTN1I
DM0S24D	MN	Human Deoxyribonucleic acid (hDNA)
DM0S24D	MT	DTT
DM0S24D	RN	Clinical pipeline report, company report or official report of hightechfinland.
DM0S24D	RU	http://www.hightechfinland.com/wwwdata/pdf/2013/Fitbiotech.pdf

DMIFCY2	DI	DMIFCY2
DMIFCY2	DN	H3B-6545
DMIFCY2	MI	DEJGDUW
DMIFCY2	MN	Cytochrome P450 1A2 (CYP1A2)
DMIFCY2	MT	DME
DMIFCY2	MA	Metabolism
DMIFCY2	RN	Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERalpha covalent antagonist (SERCA). Cancer Chemother Pharmacol. 2019 Jan;83(1):151-160.
DMIFCY2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30386887

DMIFCY2	DI	DMIFCY2
DMIFCY2	DN	H3B-6545
DMIFCY2	MI	DEPKLMQ
DMIFCY2	MN	Cytochrome P450 2B6 (CYP2B6)
DMIFCY2	MT	DME
DMIFCY2	MA	Metabolism
DMIFCY2	RN	Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERalpha covalent antagonist (SERCA). Cancer Chemother Pharmacol. 2019 Jan;83(1):151-160.
DMIFCY2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30386887

DMIFCY2	DI	DMIFCY2
DMIFCY2	DN	H3B-6545
DMIFCY2	MI	DES5XRU
DMIFCY2	MN	Cytochrome P450 2C8 (CYP2C8)
DMIFCY2	MT	DME
DMIFCY2	MA	Metabolism
DMIFCY2	RN	Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERalpha covalent antagonist (SERCA). Cancer Chemother Pharmacol. 2019 Jan;83(1):151-160.
DMIFCY2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30386887

DMIFCY2	DI	DMIFCY2
DMIFCY2	DN	H3B-6545
DMIFCY2	MI	DE5IED8
DMIFCY2	MN	Cytochrome P450 2C9 (CYP2C9)
DMIFCY2	MT	DME
DMIFCY2	MA	Metabolism
DMIFCY2	RN	Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERalpha covalent antagonist (SERCA). Cancer Chemother Pharmacol. 2019 Jan;83(1):151-160.
DMIFCY2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30386887

DMIFCY2	DI	DMIFCY2
DMIFCY2	DN	H3B-6545
DMIFCY2	MI	DECB0K3
DMIFCY2	MN	Cytochrome P450 2D6 (CYP2D6)
DMIFCY2	MT	DME
DMIFCY2	MA	Metabolism
DMIFCY2	RN	Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERalpha covalent antagonist (SERCA). Cancer Chemother Pharmacol. 2019 Jan;83(1):151-160.
DMIFCY2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30386887

DMIFCY2	DI	DMIFCY2
DMIFCY2	DN	H3B-6545
DMIFCY2	MI	DERSX5P
DMIFCY2	MN	Cytochrome P450 2J2 (CYP2J2)
DMIFCY2	MT	DME
DMIFCY2	MA	Metabolism
DMIFCY2	RN	Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERalpha covalent antagonist (SERCA). Cancer Chemother Pharmacol. 2019 Jan;83(1):151-160.
DMIFCY2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30386887

DMIFCY2	DI	DMIFCY2
DMIFCY2	DN	H3B-6545
DMIFCY2	MI	DE4LYSA
DMIFCY2	MN	Cytochrome P450 3A4 (CYP3A4)
DMIFCY2	MT	DME
DMIFCY2	MA	Metabolism
DMIFCY2	RN	Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERalpha covalent antagonist (SERCA). Cancer Chemother Pharmacol. 2019 Jan;83(1):151-160.
DMIFCY2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30386887

DMIFCY2	DI	DMIFCY2
DMIFCY2	DN	H3B-6545
DMIFCY2	MI	DEIBDNY
DMIFCY2	MN	Cytochrome P450 3A5 (CYP3A5)
DMIFCY2	MT	DME
DMIFCY2	MA	Metabolism
DMIFCY2	RN	Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERalpha covalent antagonist (SERCA). Cancer Chemother Pharmacol. 2019 Jan;83(1):151-160.
DMIFCY2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30386887

DMIFCY2	DI	DMIFCY2
DMIFCY2	DN	H3B-6545
DMIFCY2	MI	TTZAYWL
DMIFCY2	MN	Estrogen receptor (ESR)
DMIFCY2	MT	DTT
DMIFCY2	MA	Antagonist
DMIFCY2	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMIFCY2	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMIFCY2	DI	DMIFCY2
DMIFCY2	DN	H3B-6545
DMIFCY2	MI	DEGTFWK
DMIFCY2	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMIFCY2	MT	DME
DMIFCY2	MA	Metabolism
DMIFCY2	RN	Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERalpha covalent antagonist (SERCA). Cancer Chemother Pharmacol. 2019 Jan;83(1):151-160.
DMIFCY2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30386887

DMQWI7V	DI	DMQWI7V
DMQWI7V	DN	Hematopoietic stem cell gene therapy
DMQWI7V	MI	TTE8T73
DMQWI7V	MN	Wiskott-Aldrich syndrome protein (WAS)
DMQWI7V	MT	DTT
DMQWI7V	MA	Modulator
DMQWI7V	RN	Development of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome. Curr Opin Mol Ther. 2006 Oct;8(5):390-5.
DMQWI7V	RU	https://pubmed.ncbi.nlm.nih.gov/17078381

DM1U6VX	DI	DM1U6VX
DM1U6VX	DN	HER-2-targeting CAR T Cells
DM1U6VX	MI	TT6EO5L
DM1U6VX	MN	Erbb2 tyrosine kinase receptor (HER2)
DM1U6VX	MT	DTT
DM1U6VX	MA	CAR-T-Cell-Therapy
DM1U6VX	RN	ClinicalTrials.gov (NCT02547961) Chimeric Antigen Receptor-Modified T Cells for Breast Cancer
DM1U6VX	RU	https://clinicaltrials.gov/ct2/show/NCT02547961

DM0C5MV	DI	DM0C5MV
DM0C5MV	DN	HH2710
DM0C5MV	MI	TT1MG9E
DM0C5MV	MN	Extracellular signal-regulated kinase 1 (ERK1)
DM0C5MV	MT	DTT
DM0C5MV	MA	Inhibitor
DM0C5MV	RN	Clinical pipeline report, company report or official report of HaiHe Biopharma.
DM0C5MV	RU	https://www.haihepharma.com/en/research

DM0C5MV	DI	DM0C5MV
DM0C5MV	DN	HH2710
DM0C5MV	MI	TT4TQBX
DM0C5MV	MN	Extracellular signal-regulated kinase 2 (ERK2)
DM0C5MV	MT	DTT
DM0C5MV	MA	Inhibitor
DM0C5MV	RN	Clinical pipeline report, company report or official report of HaiHe Biopharma.
DM0C5MV	RU	https://www.haihepharma.com/en/research

DMJDVCW	DI	DMJDVCW
DMJDVCW	DN	HL-085
DMJDVCW	MI	TTZCRP3
DMJDVCW	MN	ERK activator kinase (MEK)
DMJDVCW	MT	DTT
DMJDVCW	MA	Inhibitor
DMJDVCW	RN	Current Development Status of MEK Inhibitors. Molecules. 2017 Sep 26;22(10):1551.
DMJDVCW	RU	https://pubmed.ncbi.nlm.nih.gov/28954413

DMDFG1O	DI	DMDFG1O
DMDFG1O	DN	HLF 1-11
DMDFG1O	MI	TTSZDQU
DMDFG1O	MN	Lactotransferrin (LTF)
DMDFG1O	MT	DTT
DMDFG1O	MA	Modulator
DMDFG1O	RN	The synthetic N-terminal peptide of human lactoferrin, hLF(1-11), is highly effective against experimental infection caused by multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2004 Dec;48(12):4919-21.
DMDFG1O	RU	https://pubmed.ncbi.nlm.nih.gov/15561882

DMV1SDA	DI	DMV1SDA
DMV1SDA	DN	HM43239
DMV1SDA	MI	TTGJCWZ
DMV1SDA	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMV1SDA	MT	DTT
DMV1SDA	MA	Inhibitor
DMV1SDA	RN	Clinical pipeline report, company report or official report of Hanmi Pharmaceutical.
DMV1SDA	RU	https://www.hanmipharm.com/ehanmi/handler/Rnd-FocusedPipelineD

DMV1SDA	DI	DMV1SDA
DMV1SDA	DN	HM43239
DMV1SDA	MI	TTOU65C
DMV1SDA	MN	Tyrosine-protein kinase SYK (SYK)
DMV1SDA	MT	DTT
DMV1SDA	MA	Inhibitor
DMV1SDA	RN	Clinical pipeline report, company report or official report of Hanmi Pharmaceutical.
DMV1SDA	RU	https://www.hanmipharm.com/ehanmi/handler/Rnd-FocusedPipelineD

DM1ZHML	DI	DM1ZHML
DM1ZHML	DN	HPN328
DM1ZHML	MI	TT1C9K6
DM1ZHML	MN	Delta-like protein 3 (DLL3)
DM1ZHML	MT	DTT
DM1ZHML	RN	Clinical pipeline report, company report or official report of Harpoon Therapeutics.
DM1ZHML	RU	https://www.harpoontx.com/pipeline/

DM86OJ0	DI	DM86OJ0
DM86OJ0	DN	HPN536
DM86OJ0	MI	TT4RXME
DM86OJ0	MN	Mesothelin (MSLN)
DM86OJ0	MT	DTT
DM86OJ0	RN	Clinical pipeline report, company report or official report of Harpoon Therapeutics.
DM86OJ0	RU	https://www.harpoontx.com/pipeline/

DMEY1AP	DI	DMEY1AP
DMEY1AP	DN	HSDB-3165
DMEY1AP	MI	DEULQ45
DMEY1AP	MN	Sodium/potassium-transporting ATPase gamma (FXYD2)
DMEY1AP	MT	DME
DMEY1AP	MA	Metabolism
DMEY1AP	RN	Rare mutations in renal sodium and potassium transporter genes exhibit impaired transport function. Curr Opin Nephrol Hypertens. 2014 Jan;23(1):1-8.
DMEY1AP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24253496

DM7C1AJ	DI	DM7C1AJ
DM7C1AJ	DN	HT-2157
DM7C1AJ	MI	TTOPAY7
DM7C1AJ	MN	Galanin receptor (GAL-R)
DM7C1AJ	MT	DTT
DM7C1AJ	MA	Antagonist
DM7C1AJ	RN	Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299. Proc Natl Acad Sci U S A. 2005 Nov 29;102(48):17489-94.
DM7C1AJ	RU	https://pubmed.ncbi.nlm.nih.gov/16287967

DMNHE43	DI	DMNHE43
DMNHE43	DN	HTU-PA
DMNHE43	MI	TTGY7WI
DMNHE43	MN	Urokinase-type plasminogen activator (PLAU)
DMNHE43	MT	DTT
DMNHE43	MA	Activator
DMNHE43	RN	Characterization of the dexamethasone-induced inhibitor of plasminogen activator in HTC hepatoma cells. J Biol Chem. 1986 Mar 25;261(9):4352-7.
DMNHE43	RU	https://pubmed.ncbi.nlm.nih.gov/2936742

DMIU1HY	DI	DMIU1HY
DMIU1HY	DN	HuM-195-Ac-225
DMIU1HY	MI	TTJVYO3
DMIU1HY	MN	Myeloid cell surface antigen CD33 (CD33)
DMIU1HY	MT	DTT
DMIU1HY	MA	Inhibitor
DMIU1HY	RN	J Clin Oncol 29: 2011 (suppl; abstr 6516).
DMIU1HY	RU	http://meetinglibrary.asco.org/content/77232-102

DMOVF6E	DI	DMOVF6E
DMOVF6E	DN	Humanized CD19 CAR-T cells
DMOVF6E	MI	TTW640A
DMOVF6E	MN	B-lymphocyte surface antigen B4 (CD19)
DMOVF6E	MT	DTT
DMOVF6E	MA	CAR-T-Cell-Therapy
DMOVF6E	RN	ClinicalTrials.gov (NCT03275493) Humanized CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia
DMOVF6E	RU	https://clinicaltrials.gov/ct2/show/NCT03275493

DM7U458	DI	DM7U458
DM7U458	DN	IDX-184
DM7U458	MI	TTE3PC9
DM7U458	MN	Hepatitis C virus Non-structural 5 (HCV NS5)
DM7U458	MT	DTT
DM7U458	MA	Inhibitor
DM7U458	RN	Genotype and Subtype Profiling of PSI-7977 as a Nucleotide Inhibitor of Hepatitis C Virus. Antimicrob Agents Chemother. 2012 June; 56(6): 3359-3368.
DM7U458	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3370800/

DMLEVFW	DI	DMLEVFW
DMLEVFW	DN	IFN alpha kinoid
DMLEVFW	MI	TT95SOA
DMLEVFW	MN	Interferon alpha (IFNA)
DMLEVFW	MT	DTT
DMLEVFW	MA	Modulator
DMLEVFW	RN	Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon alpha-kinoid. Arthritis Rheum. 2013 Feb;65(2):447-56.
DMLEVFW	RU	https://pubmed.ncbi.nlm.nih.gov/23203821

DM1CG47	DI	DM1CG47
DM1CG47	DN	IL-2 XL
DM1CG47	MI	TTF89GD
DM1CG47	MN	Interleukin-2 (IL2)
DM1CG47	MT	DTT
DM1CG47	MA	Modulator
DM1CG47	RN	Pharmacokinetics (PK) and immunologic responses in a phase I/II study of a sustained release formulation of IL-2 in renal cell carcinoma (RCC) patients. J Clin Oncol (Meeting Abstracts) June 2006 vol. 24 no. 18_suppl 2558.
DM1CG47	RU	http://meeting.ascopubs.org/cgi/content/short/24/18_suppl/2558

DMJ9CY4	DI	DMJ9CY4
DMJ9CY4	DN	IL-2/gene-modified lymphocytes
DMJ9CY4	MI	TTF89GD
DMJ9CY4	MN	Interleukin-2 (IL2)
DMJ9CY4	MT	DTT
DMJ9CY4	MA	Modulator
DMJ9CY4	RN	Genetic modification of human T lymphocytes for the treatment of hematologic malignancies. Haematologica. 2012 November; 97(11): 1622-1631.
DMJ9CY4	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3487433/

DMKV5D6	DI	DMKV5D6
DMKV5D6	DN	IM19 CAR-T
DMKV5D6	MI	TTW640A
DMKV5D6	MN	B-lymphocyte surface antigen B4 (CD19)
DMKV5D6	MT	DTT
DMKV5D6	MA	CAR-T-Cell-Therapy
DMKV5D6	RN	ClinicalTrials.gov (NCT03142646) Safety and Efficacy Evaluation of IM19 CAR-T Cells
DMKV5D6	RU	https://clinicaltrials.gov/ct2/show/NCT03142646

DMHQ2U8	DI	DMHQ2U8
DMHQ2U8	DN	IMC-F106C
DMHQ2U8	MI	TTPH7T0
DMHQ2U8	MN	Tumor expressed melanoma antigen (PRAME)
DMHQ2U8	MT	DTT
DMHQ2U8	RN	Clinical pipeline report, company report or official report of Immunocore.
DMHQ2U8	RU	https://www.immunocore.com/news/immunocore-announces-dosing-first-patient-fourth-immtac

DM09JOZ	DI	DM09JOZ
DM09JOZ	DN	ImMucin
DM09JOZ	MI	TTBHFYQ
DM09JOZ	MN	Mucin-1 (MUC1)
DM09JOZ	MT	DTT
DM09JOZ	RN	Phase I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients. Br J Haematol. 2015 Apr;169(1):44-56.
DM09JOZ	RU	https://pubmed.ncbi.nlm.nih.gov/25496030

DM18ZLW	DI	DM18ZLW
DM18ZLW	DN	IMP-321
DM18ZLW	MI	TTNVXAW
DM18ZLW	MN	Lymphocyte activation gene 3 protein (LAG3)
DM18ZLW	MT	DTT
DM18ZLW	MA	Immunomodulator
DM18ZLW	RN	A soluble form of lymphocyte activation gene-3 (IMP321) induces activation of a large range of human effector cytotoxic cells. J Immunol. 2007 Sep 15;179(6):4202-11.
DM18ZLW	RU	https://pubmed.ncbi.nlm.nih.gov/17785860

DM43ICH	DI	DM43ICH
DM43ICH	DN	IMSA101
DM43ICH	MI	TTT402Y
DM43ICH	MN	Stimulator of interferon genes protein (TMEM173)
DM43ICH	MT	DTT
DM43ICH	MA	Agonist
DM43ICH	RN	Clinical pipeline report, company report or official report of ImmuneSensor Therapeutics.
DM43ICH	RU	http://www.immunesensor.com/

DMNHZS4	DI	DMNHZS4
DMNHZS4	DN	IMX-110
DMNHZS4	MI	TTH8FZW
DMNHZS4	MN	Signal transducer and activator of transcription 3 (STAT3)
DMNHZS4	MT	DTT
DMNHZS4	MA	Inhibitor
DMNHZS4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMNHZS4	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM8XN4A	DI	DM8XN4A
DM8XN4A	DN	INCAGN1876
DM8XN4A	MI	TTG6LA7
DM8XN4A	MN	Activation-inducible TNFR family receptor (TNFRSF18)
DM8XN4A	MT	DTT
DM8XN4A	MA	Agonist
DM8XN4A	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM8XN4A	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM7OE3X	DI	DM7OE3X
DM7OE3X	DN	INCAGN1949
DM7OE3X	MI	TTL31H0
DM7OE3X	MN	OX40L receptor (CD134)
DM7OE3X	MT	DTT
DM7OE3X	MA	Agonist
DM7OE3X	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7OE3X	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM8124R	DI	DM8124R
DM8124R	DN	INCB01158
DM8124R	MI	TTSANDR
DM8124R	MN	Arginase (ARG)
DM8124R	MT	DTT
DM8124R	MA	Inhibitor
DM8124R	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM8124R	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM7TZL0	DI	DM7TZL0
DM7TZL0	DN	INCB054329
DM7TZL0	MI	TTE4BSY
DM7TZL0	MN	Bromodomain and extraterminal domain protein (BET)
DM7TZL0	MT	DTT
DM7TZL0	MA	Inhibitor
DM7TZL0	RN	The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies. Clin Cancer Res. 2019 Jan 1;25(1):300-311.
DM7TZL0	RU	https://pubmed.ncbi.nlm.nih.gov/30206163

DMG65CV	DI	DMG65CV
DMG65CV	DN	INCB057643
DMG65CV	MI	TTE4BSY
DMG65CV	MN	Bromodomain and extraterminal domain protein (BET)
DMG65CV	MT	DTT
DMG65CV	MA	Inhibitor
DMG65CV	RN	Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies. Clin Cancer Res. 2020 Mar 15;26(6):1247-1257.
DMG65CV	RU	https://pubmed.ncbi.nlm.nih.gov/31527168

DMED9QV	DI	DMED9QV
DMED9QV	DN	INCB40093
DMED9QV	MI	TTGBPJE
DMED9QV	MN	PI3-kinase delta (PIK3CD)
DMED9QV	MT	DTT
DMED9QV	MA	Inhibitor
DMED9QV	RN	INCB40093 is a selective PI3Kdelta inhibitor with potent antiproliferative activity against human B-cell tumors.
DMED9QV	RU	http://cancerres.aacrjournals.org/content/74/19_Supplement/4531.short

DMKMSP2	DI	DMKMSP2
DMKMSP2	DN	INCB53914
DMKMSP2	MI	TTA7WGU
DMKMSP2	MN	Serine/threonine-protein kinase pim (PIM)
DMKMSP2	MT	DTT
DMKMSP2	MA	Inhibitor
DMKMSP2	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMKMSP2	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMBGU7V	DI	DMBGU7V
DMBGU7V	DN	INCB57643
DMBGU7V	MI	TTRA6BO
DMBGU7V	MN	Bromodomain-containing protein 4 (BRD4)
DMBGU7V	MT	DTT
DMBGU7V	MA	Inhibitor
DMBGU7V	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMBGU7V	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMRLV7G	DI	DMRLV7G
DMRLV7G	DN	INCB59872
DMRLV7G	MI	TTNR0UQ
DMRLV7G	MN	Lysine-specific histone demethylase 1 (LSD)
DMRLV7G	MT	DTT
DMRLV7G	MA	Inhibitor
DMRLV7G	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMRLV7G	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMQO5UF	DI	DMQO5UF
DMQO5UF	DN	INCB62079
DMQO5UF	MI	TT5BR7T
DMQO5UF	MN	Fibroblast growth factor receptor 4 (FGFR4)
DMQO5UF	MT	DTT
DMQO5UF	MA	Inhibitor
DMQO5UF	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQO5UF	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMKNA94	DI	DMKNA94
DMKNA94	DN	INO-8875
DMKNA94	MI	TTK25J1
DMKNA94	MN	Adenosine A1 receptor (ADORA1)
DMKNA94	MT	DTT
DMKNA94	MA	Agonist
DMKNA94	RN	INO-8875, a highly selective A1 adenosine receptor agonist: evaluation of chronotropic, dromotropic, and hemodynamic effects in rats. J Pharmacol Exp Ther. 2013 Jan;344(1):59-67.
DMKNA94	RU	https://pubmed.ncbi.nlm.nih.gov/23055540

DMMZSIB	DI	DMMZSIB
DMMZSIB	DN	Interferon alpha 5
DMMZSIB	MI	TTLHGSF
DMMZSIB	MN	Interferon-alpha 5 (IFNA5)
DMMZSIB	MT	DTT
DMMZSIB	MA	Modulator
DMMZSIB	RN	Interferons and viral infections. Biofactors. 2009 Jan-Feb;35(1):14-20.
DMMZSIB	RU	https://pubmed.ncbi.nlm.nih.gov/19319841

DM9PJZT	DI	DM9PJZT
DM9PJZT	DN	Ipamorelin
DM9PJZT	MI	TTWDC17
DM9PJZT	MN	Growth hormone secretagogue receptor 1 (GHSR)
DM9PJZT	MT	DTT
DM9PJZT	MA	Modulator
DM9PJZT	RN	Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus.J Pharmacol Exp Ther.2009 Jun;329(3):1110-6.
DM9PJZT	RU	https://www.ncbi.nlm.nih.gov/pubmed/19289567

DM8E3N6	DI	DM8E3N6
DM8E3N6	DN	IPP-204106
DM8E3N6	MI	TTCSZH7
DM8E3N6	MN	Nucleolin (NCL)
DM8E3N6	MT	DTT
DM8E3N6	MA	Modulator
DM8E3N6	RN	Company report (ImmuPharma)
DM8E3N6	RU	http://www.immupharma.org/cancer-treatment

DM8E3N6	DI	DM8E3N6
DM8E3N6	DN	IPP-204106
DM8E3N6	MI	TTHBS98
DM8E3N6	MN	Nucleophosmin (NPM1)
DM8E3N6	MT	DTT
DM8E3N6	MA	Modulator
DM8E3N6	RN	Company report (ImmuPharma)
DM8E3N6	RU	http://www.immupharma.org/cancer-treatment

DMQ5EYJ	DI	DMQ5EYJ
DMQ5EYJ	DN	ISA-P53-01
DMQ5EYJ	MI	TT7SBF5
DMQ5EYJ	MN	Cellular tumor antigen p53 (TP53)
DMQ5EYJ	MT	DTT
DMQ5EYJ	RN	WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.
DMQ5EYJ	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20131212&CC=WO&NR=2013185032A1&KC=A1

DM1WD8F	DI	DM1WD8F
DM1WD8F	DN	ISB 1302
DM1WD8F	MI	TT6EO5L
DM1WD8F	MN	Erbb2 tyrosine kinase receptor (HER2)
DM1WD8F	MT	DTT
DM1WD8F	MA	Inhibitor
DM1WD8F	RN	Clinical pipeline report, company report or official report of Ichnos Sciences.
DM1WD8F	RU	https://ichnossciences.com/wp-content/uploads/Ichnos-Sciences-Corporate-Deck-Sept-25-2020-FINAL.pdf

DM1WD8F	DI	DM1WD8F
DM1WD8F	DN	ISB 1302
DM1WD8F	MI	TTUN7MC
DM1WD8F	MN	T-cell surface glycoprotein CD3 (CD3)
DM1WD8F	MT	DTT
DM1WD8F	MA	Inhibitor
DM1WD8F	RN	Clinical pipeline report, company report or official report of Ichnos Sciences.
DM1WD8F	RU	https://ichnossciences.com/wp-content/uploads/Ichnos-Sciences-Corporate-Deck-Sept-25-2020-FINAL.pdf

DMG107N	DI	DMG107N
DMG107N	DN	ISB 1342
DMG107N	MI	TTPURFN
DMG107N	MN	Cyclic ADP-ribose hydrolase 1 (CD38)
DMG107N	MT	DTT
DMG107N	MA	Inhibitor
DMG107N	RN	Clinical pipeline report, company report or official report of Ichnos Sciences.
DMG107N	RU	https://ichnossciences.com/wp-content/uploads/Ichnos-Sciences-Corporate-Deck-Sept-25-2020-FINAL.pdf

DMG107N	DI	DMG107N
DMG107N	DN	ISB 1342
DMG107N	MI	TTUN7MC
DMG107N	MN	T-cell surface glycoprotein CD3 (CD3)
DMG107N	MT	DTT
DMG107N	MA	Inhibitor
DMG107N	RN	Clinical pipeline report, company report or official report of Ichnos Sciences.
DMG107N	RU	https://ichnossciences.com/wp-content/uploads/Ichnos-Sciences-Corporate-Deck-Sept-25-2020-FINAL.pdf

DMH32LC	DI	DMH32LC
DMH32LC	DN	ISIS-DMPK
DMH32LC	MI	TTZQTY2
DMH32LC	MN	DMPK messenger RNA (DMPK mRNA)
DMH32LC	MT	DTT
DMH32LC	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals.
DMH32LC	RU	https://www.isispharm.com/pipeline/isis-dmpkrx/

DMDTNFB	DI	DMDTNFB
DMDTNFB	DN	ISIS-STAT3
DMDTNFB	MI	TTHJT3X
DMDTNFB	MN	STAT3 messenger RNA (STAT3 mRNA)
DMDTNFB	MT	DTT
DMDTNFB	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
DMDTNFB	RU	http://www.isispharm.com/index.htm

DMA41DO	DI	DMA41DO
DMA41DO	DN	Isunakinra
DMA41DO	MI	TT5BFT0
DMA41DO	MN	Interleukin-1 receptor (IL1R)
DMA41DO	MT	DTT
DMA41DO	MA	Inhibitor
DMA41DO	RN	Multicenter Study of a Novel Topical Interleukin-1 Receptor Inhibitor, Isunakinra, in Subjects With Moderate to Severe Dry Eye Disease. Eye Contact Lens. 2017 Sep;43(5):287-296.
DMA41DO	RU	https://pubmed.ncbi.nlm.nih.gov/27466718

DM08TH3	DI	DM08TH3
DM08TH3	DN	ITI-214
DM08TH3	MI	TTHQENC
DM08TH3	MN	Phosphodiesterase 1 (PDE1)
DM08TH3	MT	DTT
DM08TH3	MA	Inhibitor
DM08TH3	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM08TH3	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DM3KXMG	DI	DM3KXMG
DM3KXMG	DN	IZONSTERIDE
DM3KXMG	MI	TT2A0DR
DM3KXMG	MN	Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A)
DM3KXMG	MT	DTT
DM3KXMG	MA	Modulator
DM3KXMG	RN	Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible... Urology. 2004 Jan;63(1):114-9.
DM3KXMG	RU	https://www.ncbi.nlm.nih.gov/pubmed/14751361

DMNMV0D	DI	DMNMV0D
DMNMV0D	DN	JAB-3312
DMNMV0D	MI	TT7WUAV
DMNMV0D	MN	Protein-tyrosine phosphatase SHP-2 (PTPN11)
DMNMV0D	MT	DTT
DMNMV0D	MA	Inhibitor
DMNMV0D	RN	Clinical pipeline report, company report or official report of AbbVie.
DMNMV0D	RU	https://www.abbvie.com/our-science/pipeline/jab-3068-jab-3312.html

DMTMVEW	DI	DMTMVEW
DMTMVEW	DN	JCAR014
DMTMVEW	MI	TTW640A
DMTMVEW	MN	B-lymphocyte surface antigen B4 (CD19)
DMTMVEW	MT	DTT
DMTMVEW	MA	CAR-T-Cell-Therapy
DMTMVEW	RN	ClinicalTrials.gov (NCT02706405) JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
DMTMVEW	RU	https://clinicaltrials.gov/ct2/show/NCT02706405

DMJV2IF	DI	DMJV2IF
DMJV2IF	DN	JCAR017
DMJV2IF	MI	TTW640A
DMJV2IF	MN	B-lymphocyte surface antigen B4 (CD19)
DMJV2IF	MT	DTT
DMJV2IF	MA	CAR-T-Cell-Therapy
DMJV2IF	RN	ClinicalTrials.gov (NCT03436771) Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product
DMJV2IF	RU	https://clinicaltrials.gov/ct2/show/NCT03436771

DM8P7FC	DI	DM8P7FC
DM8P7FC	DN	JCARH125
DM8P7FC	MI	TTZ3P4W
DM8P7FC	MN	B-cell maturation protein (TNFRSF17)
DM8P7FC	MT	DTT
DM8P7FC	MA	CAR-T-Cell-Therapy
DM8P7FC	RN	ClinicalTrials.gov (NCT03436771) Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product
DM8P7FC	RU	https://clinicaltrials.gov/ct2/show/NCT03436771

DMD9X6U	DI	DMD9X6U
DMD9X6U	DN	JNJ-68284528
DMD9X6U	MI	TTZ3P4W
DMD9X6U	MN	B-cell maturation protein (TNFRSF17)
DMD9X6U	MT	DTT
DMD9X6U	MA	CAR-T-Cell-Therapy
DMD9X6U	RN	ClinicalTrials.gov (NCT03548207) A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma
DMD9X6U	RU	https://clinicaltrials.gov/ct2/show/NCT03548207

DMGEZVF	DI	DMGEZVF
DMGEZVF	DN	JS016
DMGEZVF	MI	TTZ3COY
DMGEZVF	MN	COVID-19 spike glycoprotein (S)
DMGEZVF	MT	DTT
DMGEZVF	MA	Inhibitor
DMGEZVF	RN	Clinical pipeline report, company report or official report of Lilly.
DMGEZVF	RU	https://www.lilly.com/discovery/clinical-development-pipeline#

DMELJDI	DI	DMELJDI
DMELJDI	DN	KAI-9803
DMELJDI	MI	TT9WJ8U
DMELJDI	MN	Protein kinase C delta (PRKCD)
DMELJDI	MT	DTT
DMELJDI	MA	Inhibitor
DMELJDI	RN	PKC delta and epsilon in drug targeting and therapeutics. Recent Pat DNA Gene Seq. 2009;3(2):96-101.
DMELJDI	RU	https://pubmed.ncbi.nlm.nih.gov/19519579

DM5U3IF	DI	DM5U3IF
DM5U3IF	DN	KB-004
DM5U3IF	MI	TTHS2LR
DM5U3IF	MN	Ephrin type-A receptor 3 (EPHA3)
DM5U3IF	MT	DTT
DM5U3IF	RN	Clinical pipeline report, company report or official report of Kalobios.
DM5U3IF	RU	http://kalobios.com/kb004

DMI9FXE	DI	DMI9FXE
DMI9FXE	DN	KBP-5074
DMI9FXE	MI	TT26PHO
DMI9FXE	MN	Mineralocorticoid receptor  (MR)
DMI9FXE	MT	DTT
DMI9FXE	MA	Antagonist
DMI9FXE	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMI9FXE	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMZ416B	DI	DMZ416B
DMZ416B	DN	KD020
DMZ416B	MI	TTUS1RD
DMZ416B	MN	Microsomal triglyceride transfer protein (MTTP)
DMZ416B	MT	DTT
DMZ416B	MA	Modulator
DMZ416B	RN	Clinical pipeline report, company report or official report of Kadmon Pharmaceuticals.
DMZ416B	RU	http://kadmon.com/press/kadmon-corporation-presents-encouraging-nonclinical-data-on-tesevatinib-kd019-at-aacr-annual-meeting/

DM0NZYC	DI	DM0NZYC
DM0NZYC	DN	KO-539
DM0NZYC	MI	TT0CZBQ
DM0NZYC	MN	Menin-MLL1 interaction (MEN1-KMT2A PPI)
DM0NZYC	MT	DTT
DM0NZYC	MA	Inhibitor
DM0NZYC	RN	Clinical pipeline report, company report or official report of Kura Oncology.
DM0NZYC	RU	https://kuraoncology.com/pipeline/#ko539

DML29RF	DI	DML29RF
DML29RF	DN	KP-100
DML29RF	MI	TTWC6MY
DML29RF	MN	Protein tyrosine phosphatase (PTP)
DML29RF	MT	DTT
DML29RF	MA	Inhibitor
DML29RF	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010512)
DML29RF	RU	http://adisinsight.springer.com/drugs/800010512

DMA5B1S	DI	DMA5B1S
DMA5B1S	DN	KRN-330
DMA5B1S	MI	TT96HUR
DMA5B1S	MN	Cell surface A33 antigen (GPA33)
DMA5B1S	MT	DTT
DMA5B1S	RN	Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer. Invest New Drugs. 2014 Aug;32(4):682-90.
DMA5B1S	RU	https://pubmed.ncbi.nlm.nih.gov/24691674

DME8JW1	DI	DME8JW1
DME8JW1	DN	KTE-C19 CAR
DME8JW1	MI	TTW640A
DME8JW1	MN	B-lymphocyte surface antigen B4 (CD19)
DME8JW1	MT	DTT
DME8JW1	MA	Inhibitor
DME8JW1	RN	Clinical pipeline report, company report or official report of Kite Pharma.
DME8JW1	RU	http://ir.kitepharma.com/releasedetail.cfm?releaseid=867609

DMXJ683	DI	DMXJ683
DMXJ683	DN	KY1044
DMXJ683	MI	TTE5VP6
DMXJ683	MN	Inducible T-cell costimulator (ICOS)
DMXJ683	MT	DTT
DMXJ683	MA	Inhibitor
DMXJ683	RN	Clinical pipeline report, company report or official report of Kymab.
DMXJ683	RU	https://www.kymab.com/pipeline/ky1044/

DMBEQ08	DI	DMBEQ08
DMBEQ08	DN	L-377202
DMBEQ08	MI	TT0IHXV
DMBEQ08	MN	DNA topoisomerase II (TOP2)
DMBEQ08	MT	DTT
DMBEQ08	MA	Modulator
DMBEQ08	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMBEQ08	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMFHV9L	DI	DMFHV9L
DMFHV9L	DN	Leber's congenital amaurosis gene therapy
DMFHV9L	MI	TTBOH16
DMFHV9L	MN	Retinal pigment epithelium protein (RPE65)
DMFHV9L	MT	DTT
DMFHV9L	MA	Modulator
DMFHV9L	RN	ClinicalTrials.gov (NCT00749957) Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis. U.S. National Institutes of Health.
DMFHV9L	RU	https://clinicaltrials.gov/ct2/show/NCT00749957

DMQN9ME	DI	DMQN9ME
DMQN9ME	DN	LGH-447
DMQN9ME	MI	TT69J2Z
DMQN9ME	MN	Serine/threonine-protein kinase pim-2 (PIM2)
DMQN9ME	MT	DTT
DMQN9ME	MA	Modulator
DMQN9ME	RN	Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers. Clin Cancer Res. 2014 Apr 1;20(7):1834-45.
DMQN9ME	RU	https://pubmed.ncbi.nlm.nih.gov/24474669

DMENF5K	DI	DMENF5K
DMENF5K	DN	Liatermin
DMENF5K	MI	TTF23ML
DMENF5K	MN	Glial cell line-derived neurotrophic factor (GDNF)
DMENF5K	MT	DTT
DMENF5K	MA	Modulator
DMENF5K	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMENF5K	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMEMRW0	DI	DMEMRW0
DMEMRW0	DN	Lipoteichoic acid
DMEMRW0	MI	TTY7ZHS
DMEMRW0	MN	Toll-like receptor 2 (TLR2)
DMEMRW0	MT	DTT
DMEMRW0	MA	Modulator
DMEMRW0	RN	Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccha... J Biol Chem. 2003 May 2;278(18):15587-94.
DMEMRW0	RU	https://pubmed.ncbi.nlm.nih.gov/12594207

DMGTB5N	DI	DMGTB5N
DMGTB5N	DN	LJM716
DMGTB5N	MI	TTDC8N2
DMGTB5N	MN	Erbb3 tyrosine kinase receptor (Erbb-3)
DMGTB5N	MT	DTT
DMGTB5N	RN	An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Cancer Res. 2013 Oct 1;73(19):6024-35.
DMGTB5N	RU	https://pubmed.ncbi.nlm.nih.gov/23928993

DMCJ10K	DI	DMCJ10K
DMCJ10K	DN	LM11A-31
DMCJ10K	MI	TTEDJN4
DMCJ10K	MN	Low-affinity nerve growth factor receptor (NGFR)
DMCJ10K	MT	DTT
DMCJ10K	MA	Modulator
DMCJ10K	RN	Small molecule p75NTR ligand prevents cognitive deficits and neurite degeneration in an Alzheimer's mouse model.Neurobiol Aging.2013 Aug;34(8):2052-63.
DMCJ10K	RU	https://www.ncbi.nlm.nih.gov/pubmed/23545424

DM095HQ	DI	DM095HQ
DM095HQ	DN	LM11A-31
DM095HQ	MI	TTEDJN4
DM095HQ	MN	Low-affinity nerve growth factor receptor (NGFR)
DM095HQ	MT	DTT
DM095HQ	MA	Modulator
DM095HQ	RN	Modulation of the p75 neurotrophin receptor using LM11A-31 prevents diabetes-induced retinal vascular permeability in mice via inhibition of inflammation and the RhoA kinase pathway. Diabetologia. 2019 Aug;62(8):1488-1500.
DM095HQ	RU	https://pubmed.ncbi.nlm.nih.gov/31073629

DMW3QGJ	DI	DMW3QGJ
DMW3QGJ	DN	LM-94
DMW3QGJ	MI	DEYGVN4
DMW3QGJ	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMW3QGJ	MT	DME
DMW3QGJ	MA	Metabolism
DMW3QGJ	RN	In vitro inhibitory effects of non-steroidal anti-inflammatory drugs on 4-methylumbelliferone glucuronidation in recombinant human UDP-glucuronosyltransferase 1A9--potent inhibition by niflumic acid. Biopharm Drug Dispos. 2006 Jan;27(1):1-6.
DMW3QGJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16278927

DMW3QGJ	DI	DMW3QGJ
DMW3QGJ	DN	LM-94
DMW3QGJ	MI	DELOY3P
DMW3QGJ	MN	UDP-glucuronosyltransferase 1A4 (UGT1A4)
DMW3QGJ	MT	DME
DMW3QGJ	MA	Metabolism
DMW3QGJ	RN	Identification of aspartic acid and histidine residues mediating the reaction mechanism and the substrate specificity of the human UDP-glucuronosyltransferases 1A. J Biol Chem. 2007 Dec 14;282(50):36514-24.
DMW3QGJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17956868

DMW3QGJ	DI	DMW3QGJ
DMW3QGJ	DN	LM-94
DMW3QGJ	MI	DEPF954
DMW3QGJ	MN	UDP-glucuronosyltransferase 1A5 (UGT1A5)
DMW3QGJ	MT	DME
DMW3QGJ	MA	Metabolism
DMW3QGJ	RN	A common polymorphic variant of UGT1A5 displays increased activity due to optimized cofactor binding. FEBS Lett. 2018 Jun;592(11):1837-1846.
DMW3QGJ	RU	https://pubmed.ncbi.nlm.nih.gov/29710432

DMW3QGJ	DI	DMW3QGJ
DMW3QGJ	DN	LM-94
DMW3QGJ	MI	DESD26P
DMW3QGJ	MN	UDP-glucuronosyltransferase 1A6 (UGT1A6)
DMW3QGJ	MT	DME
DMW3QGJ	MA	Metabolism
DMW3QGJ	RN	Identification of aspartic acid and histidine residues mediating the reaction mechanism and the substrate specificity of the human UDP-glucuronosyltransferases 1A. J Biol Chem. 2007 Dec 14;282(50):36514-24.
DMW3QGJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17956868

DMW3QGJ	DI	DMW3QGJ
DMW3QGJ	DN	LM-94
DMW3QGJ	MI	DE85D2P
DMW3QGJ	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMW3QGJ	MT	DME
DMW3QGJ	MA	Metabolism
DMW3QGJ	RN	The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities. Drug Metab Dispos. 2008 Jun;36(6):1056-62.
DMW3QGJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18362158

DMW3QGJ	DI	DMW3QGJ
DMW3QGJ	DN	LM-94
DMW3QGJ	MI	DE7TIN4
DMW3QGJ	MN	UDP-glucuronosyltransferase 2B11 (UGT2B11)
DMW3QGJ	MT	DME
DMW3QGJ	MA	Metabolism
DMW3QGJ	RN	cDNA cloning and expression of two new members of the human liver UDP-glucuronosyltransferase 2B subfamily. Biochem Biophys Res Commun. 1993 Jul 15;194(1):496-503.
DMW3QGJ	RU	https://pubmed.ncbi.nlm.nih.gov/8333863

DMYGNDI	DI	DMYGNDI
DMYGNDI	DN	LMP1-CAR-T cells
DMYGNDI	MI	TT0BI4Q
DMYGNDI	MN	Epstein-Barr virus Latent membrane protein 1 (EBV LMP1)
DMYGNDI	MT	DTT
DMYGNDI	MA	CAR-T-Cell-Therapy
DMYGNDI	RN	ClinicalTrials.gov (NCT02980315) A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application
DMYGNDI	RU	https://clinicaltrials.gov/ct2/show/NCT02980315

DMZNIAG	DI	DMZNIAG
DMZNIAG	DN	LS-172108
DMZNIAG	MI	DE4LYSA
DMZNIAG	MN	Cytochrome P450 3A4 (CYP3A4)
DMZNIAG	MT	DME
DMZNIAG	MA	Metabolism
DMZNIAG	RN	Biotransformation of tirilazad in human: 1. Cytochrome P450 3A-mediated hydroxylation of tirilazad mesylate in human liver microsomes. J Pharmacol Exp Ther. 1996 May;277(2):982-90.
DMZNIAG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8627581

DM5N04G	DI	DM5N04G
DM5N04G	DN	LT-1951
DM5N04G	MI	TTF10I9
DM5N04G	MN	Nitric-oxide synthase inducible (NOS2)
DM5N04G	MT	DTT
DM5N04G	MA	Modulator
DM5N04G	RN	Critical role of L-arginine in endothelial cell survival during oxidative stress. Circulation. 2003 May 27;107(20):2607-14.
DM5N04G	RU	https://pubmed.ncbi.nlm.nih.gov/12742995

DM2LYIN	DI	DM2LYIN
DM2LYIN	DN	LX-7101
DM2LYIN	MI	TTU8W4S
DM2LYIN	MN	Protein kinase (PK)
DM2LYIN	MT	DTT
DM2LYIN	MA	Inhibitor
DM2LYIN	RN	Design, synthesis and biological characterization of selective LIMK inhibitors. Bioorg Med Chem Lett. 2015 Sep 15;25(18):4005-10.
DM2LYIN	RU	https://pubmed.ncbi.nlm.nih.gov/26233434

DM65MEL	DI	DM65MEL
DM65MEL	DN	LXS196
DM65MEL	MI	TTYVX59
DM65MEL	MN	Protein kinase C (PRKC)
DM65MEL	MT	DTT
DM65MEL	MA	Inhibitor
DM65MEL	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM65MEL	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMHXTNW	DI	DMHXTNW
DMHXTNW	DN	LY-2228820
DMHXTNW	MI	TTWELHI
DMHXTNW	MN	Stress-activated protein kinase (p38)
DMHXTNW	MT	DTT
DMHXTNW	MA	Inhibitor
DMHXTNW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7959).
DMHXTNW	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7959

DMADEHZ	DI	DMADEHZ
DMADEHZ	DN	LY2880070
DMADEHZ	MI	TTTU902
DMADEHZ	MN	Checkpoint kinase-1 (CHK1)
DMADEHZ	MT	DTT
DMADEHZ	MA	Inhibitor
DMADEHZ	RN	A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer. Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 3581-3581.
DMADEHZ	RU	https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.3581

DMTJWIQ	DI	DMTJWIQ
DMTJWIQ	DN	LY2940680
DMTJWIQ	MI	DE4LYSA
DMTJWIQ	MN	Cytochrome P450 3A4 (CYP3A4)
DMTJWIQ	MT	DME
DMTJWIQ	MA	Metabolism
DMTJWIQ	RN	Phase I study of LY2940680, a Smo antagonist, in patients with advanced cancer including treatment-naive and previously treated basal cell carcinoma. Clin Cancer Res. 2018 May 1;24(9):2082-2091.
DMTJWIQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29483143

DMTJWIQ	DI	DMTJWIQ
DMTJWIQ	DN	LY2940680
DMTJWIQ	MI	TT8J1S3
DMTJWIQ	MN	Smoothened homolog (SMO)
DMTJWIQ	MT	DTT
DMTJWIQ	MA	Modulator
DMTJWIQ	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMTJWIQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM7T1CR	DI	DM7T1CR
DM7T1CR	DN	LY3016859
DM7T1CR	MI	TTYSB89
DM7T1CR	MN	Epiregulin (EREG)
DM7T1CR	MT	DTT
DM7T1CR	MA	Modulator
DM7T1CR	RN	Generation and activity of a humanized monoclonal antibody that selectively neutralizes the epidermal growth factor receptor ligands transforming growth factor-alpha and epiregulin. J Pharmacol Exp Ther. 2014 May;349(2):330-43.
DM7T1CR	RU	https://pubmed.ncbi.nlm.nih.gov/24518034

DM7T1CR	DI	DM7T1CR
DM7T1CR	DN	LY3016859
DM7T1CR	MI	TTTLQFR
DM7T1CR	MN	Transforming growth factor alpha (TGFA)
DM7T1CR	MT	DTT
DM7T1CR	MA	Modulator
DM7T1CR	RN	Generation and activity of a humanized monoclonal antibody that selectively neutralizes the epidermal growth factor receptor ligands transforming growth factor-alpha and epiregulin. J Pharmacol Exp Ther. 2014 May;349(2):330-43.
DM7T1CR	RU	https://pubmed.ncbi.nlm.nih.gov/24518034

DMC5SAW	DI	DMC5SAW
DMC5SAW	DN	LY3039478
DMC5SAW	MI	TTB1STW
DMC5SAW	MN	Notch-1 receptor (NOTCH1)
DMC5SAW	MT	DTT
DMC5SAW	MA	Inhibitor
DMC5SAW	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMC5SAW	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMC5SAW	DI	DMC5SAW
DMC5SAW	DN	LY3039478
DMC5SAW	MI	TTXDIK2
DMC5SAW	MN	Notch-4 receptor (NOTCH4)
DMC5SAW	MT	DTT
DMC5SAW	MA	Inhibitor
DMC5SAW	RN	J Clin Oncol 33, 2015 (suppl; abstr 2533).
DMC5SAW	RU	http://meetinglibrary.asco.org/content/144588-156

DM8RJTB	DI	DM8RJTB
DM8RJTB	DN	LY3295668
DM8RJTB	MI	TTPS3C0
DM8RJTB	MN	Aurora kinase A (AURKA)
DM8RJTB	MT	DTT
DM8RJTB	MA	Inhibitor
DM8RJTB	RN	Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy. Mol Cancer Ther. 2019 Dec;18(12):2207-2219.
DM8RJTB	RU	https://pubmed.ncbi.nlm.nih.gov/31530649

DMA1CSR	DI	DMA1CSR
DMA1CSR	DN	LY3499446
DMA1CSR	MI	TT3LH46
DMA1CSR	MN	KRAS G12C mutant (KRAS G12C)
DMA1CSR	MT	DTT
DMA1CSR	MA	Inhibitor
DMA1CSR	RN	KRAS: From undruggable to a druggable Cancer Target. Cancer Treat Rev. 2020 Sep;89:102070.
DMA1CSR	RU	https://pubmed.ncbi.nlm.nih.gov/32711246

DMK2L38	DI	DMK2L38
DMK2L38	DN	M3814
DMK2L38	MI	TTK3PY9
DMK2L38	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMK2L38	MT	DTT
DMK2L38	MA	Inhibitor
DMK2L38	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMK2L38	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMIRG15	DI	DMIRG15
DMIRG15	DN	MaC46/M87o
DMIRG15	MI	TTG90S6
DMIRG15	MN	Human immunodeficiency virus Glycoprotein 41 (HIV gp41)
DMIRG15	MT	DTT
DMIRG15	MA	Modulator
DMIRG15	RN	DOI: 10.1038/mt.sj.6300124
DMIRG15	RU	http://www.nature.com/mt/journal/v15/n5/full/6300124a.html

DM6H3YS	DI	DM6H3YS
DM6H3YS	DN	MAGE-A10 TCR
DM6H3YS	MI	TT7AKW1
DM6H3YS	MN	T-cell receptor (TCR)
DM6H3YS	MT	DTT
DM6H3YS	MA	Immunomodulator
DM6H3YS	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM6H3YS	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMFK5IX	DI	DMFK5IX
DMFK5IX	DN	MAK683
DMFK5IX	MI	TTFNJ4R
DMFK5IX	MN	Embryonic ectoderm development protein (EED)
DMFK5IX	MT	DTT
DMFK5IX	MA	Inhibitor
DMFK5IX	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMFK5IX	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMBZ68C	DI	DMBZ68C
DMBZ68C	DN	MALP-2S
DMBZ68C	MI	TTY7ZHS
DMBZ68C	MN	Toll-like receptor 2 (TLR2)
DMBZ68C	MT	DTT
DMBZ68C	MA	Modulator
DMBZ68C	RN	Failure of mycoplasma lipoprotein MALP-2 to induce NK cell activation through dendritic cell TLR2. Microbes Infect. 2011 Apr;13(4):350-8.
DMBZ68C	RU	https://pubmed.ncbi.nlm.nih.gov/21172450

DMBZ68C	DI	DMBZ68C
DMBZ68C	DN	MALP-2S
DMBZ68C	MI	TTWRI8V
DMBZ68C	MN	Toll-like receptor 6 (TLR6)
DMBZ68C	MT	DTT
DMBZ68C	MA	Modulator
DMBZ68C	RN	Failure of mycoplasma lipoprotein MALP-2 to induce NK cell activation through dendritic cell TLR2. Microbes Infect. 2011 Apr;13(4):350-8.
DMBZ68C	RU	https://pubmed.ncbi.nlm.nih.gov/21172450

DMH0ROP	DI	DMH0ROP
DMH0ROP	DN	Maltose
DMH0ROP	MI	DEST6E5
DMH0ROP	MN	Alpha-glucosidase (aglA)
DMH0ROP	MT	DME
DMH0ROP	MA	Metabolism
DMH0ROP	RN	Novel alpha-glucosidase from human gut microbiome: substrate specificities and their switch. FASEB J. 2010 Oct;24(10):3939-49.
DMH0ROP	RU	https://pubmed.ncbi.nlm.nih.gov/20581222

DMH0ROP	DI	DMH0ROP
DMH0ROP	DN	Maltose
DMH0ROP	MI	TTHCF4J
DMH0ROP	MN	Alpha-glucosidase (GLA)
DMH0ROP	MT	DTT
DMH0ROP	MA	Inhibitor
DMH0ROP	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMH0ROP	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMH0ROP	DI	DMH0ROP
DMH0ROP	DN	Maltose
DMH0ROP	MI	DEGLW18
DMH0ROP	MN	Cellobiose 2-epimerase (CE)
DMH0ROP	MT	DME
DMH0ROP	MA	Metabolism
DMH0ROP	RN	Cloning and sequencing of the gene for cellobiose 2-epimerase from a ruminal strain of Eubacterium cellulosolvens. FEMS Microbiol Lett. 2008 Oct;287(1):34-40.
DMH0ROP	RU	https://pubmed.ncbi.nlm.nih.gov/18710396

DMH0ROP	DI	DMH0ROP
DMH0ROP	DN	Maltose
DMH0ROP	MI	DENTGJO
DMH0ROP	MN	Cellobiose 2-epimerase (CE)
DMH0ROP	MT	DME
DMH0ROP	MA	Metabolism
DMH0ROP	RN	Cloning and sequencing of the gene for cellobiose 2-epimerase from a ruminal strain of Eubacterium cellulosolvens. FEMS Microbiol Lett. 2008 Oct;287(1):34-40.
DMH0ROP	RU	https://pubmed.ncbi.nlm.nih.gov/18710396

DMH0ROP	DI	DMH0ROP
DMH0ROP	DN	Maltose
DMH0ROP	MI	DE4XLDR
DMH0ROP	MN	Cellobiose 2-epimerase (CE)
DMH0ROP	MT	DME
DMH0ROP	MA	Metabolism
DMH0ROP	RN	Cloning and sequencing of the gene for cellobiose 2-epimerase from a ruminal strain of Eubacterium cellulosolvens. FEMS Microbiol Lett. 2008 Oct;287(1):34-40.
DMH0ROP	RU	https://pubmed.ncbi.nlm.nih.gov/18710396

DMH0ROP	DI	DMH0ROP
DMH0ROP	DN	Maltose
DMH0ROP	MI	DEGBVKJ
DMH0ROP	MN	Cellobiose 2-epimerase (CE)
DMH0ROP	MT	DME
DMH0ROP	MA	Metabolism
DMH0ROP	RN	Cloning and sequencing of the gene for cellobiose 2-epimerase from a ruminal strain of Eubacterium cellulosolvens. FEMS Microbiol Lett. 2008 Oct;287(1):34-40.
DMH0ROP	RU	https://pubmed.ncbi.nlm.nih.gov/18710396

DMH0ROP	DI	DMH0ROP
DMH0ROP	DN	Maltose
DMH0ROP	MI	DEDY9F6
DMH0ROP	MN	Cellobiose 2-epimerase (CE)
DMH0ROP	MT	DME
DMH0ROP	MA	Metabolism
DMH0ROP	RN	Cloning and sequencing of the gene for cellobiose 2-epimerase from a ruminal strain of Eubacterium cellulosolvens. FEMS Microbiol Lett. 2008 Oct;287(1):34-40.
DMH0ROP	RU	https://pubmed.ncbi.nlm.nih.gov/18710396

DMH0ROP	DI	DMH0ROP
DMH0ROP	DN	Maltose
DMH0ROP	MI	DERDXAF
DMH0ROP	MN	Cellobiose 2-epimerase (CE)
DMH0ROP	MT	DME
DMH0ROP	MA	Metabolism
DMH0ROP	RN	Cloning and sequencing of the gene for cellobiose 2-epimerase from a ruminal strain of Eubacterium cellulosolvens. FEMS Microbiol Lett. 2008 Oct;287(1):34-40.
DMH0ROP	RU	https://pubmed.ncbi.nlm.nih.gov/18710396

DMH0ROP	DI	DMH0ROP
DMH0ROP	DN	Maltose
DMH0ROP	MI	DEBW1FU
DMH0ROP	MN	Fructokinase (scrK)
DMH0ROP	MT	DME
DMH0ROP	MA	Metabolism
DMH0ROP	RN	Sugar metabolism by fusobacteria: regulation of transport, phosphorylation, and polymer formation by Fusobacterium mortiferum ATCC 25557. Infect Immun. 1991 Dec;59(12):4547-54.
DMH0ROP	RU	https://pubmed.ncbi.nlm.nih.gov/1937813

DMH0ROP	DI	DMH0ROP
DMH0ROP	DN	Maltose
DMH0ROP	MI	TTXWASR
DMH0ROP	MN	Intestinal maltase-glucoamylase (MGAM)
DMH0ROP	MT	DTT
DMH0ROP	MA	Inhibitor
DMH0ROP	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMH0ROP	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMH0ROP	DI	DMH0ROP
DMH0ROP	DN	Maltose
DMH0ROP	MI	DE7NXHG
DMH0ROP	MN	Maltose phosphorylase (malP)
DMH0ROP	MT	DME
DMH0ROP	MA	Metabolism
DMH0ROP	RN	Rational engineering of Lactobacillus acidophilus NCFM maltose phosphorylase into either trehalose or kojibiose dual specificity phosphorylase. Protein Eng Des Sel. 2010 Oct;23(10):781-7.
DMH0ROP	RU	https://pubmed.ncbi.nlm.nih.gov/20713411

DMH0ROP	DI	DMH0ROP
DMH0ROP	DN	Maltose
DMH0ROP	MI	DE5EO4Y
DMH0ROP	MN	Sucrase-isomaltase intestinal (SI)
DMH0ROP	MT	DME
DMH0ROP	MA	Metabolism
DMH0ROP	RN	Structural basis for substrate selectivity in human maltase-glucoamylase and sucrase-isomaltase N-terminal domains. J Biol Chem. 2010 Jun 4;285(23):17763-70.
DMH0ROP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20356844

DMXU7P6	DI	DMXU7P6
DMXU7P6	DN	MB-CART20.1
DMXU7P6	MI	TTUE541
DMXU7P6	MN	Leukocyte surface antigen Leu-16 (CD20)
DMXU7P6	MT	DTT
DMXU7P6	MA	CAR-T-Cell-Therapy
DMXU7P6	RN	ClinicalTrials.gov (NCT03664635) MB-CART20.1 Lymphoma
DMXU7P6	RU	https://clinicaltrials.gov/ct2/show/NCT03664635

DMS19IH	DI	DMS19IH
DMS19IH	DN	MBO7133
DMS19IH	MI	TTUTN1I
DMS19IH	MN	Human Deoxyribonucleic acid (hDNA)
DMS19IH	MT	DTT
DMS19IH	MA	Binder
DMS19IH	RN	Novel Cox-2 Inhibitor for Breast Cancer Therapy. Temple University School of Medicine Philadelphia, Pennsylvania 19140. July 2004.
DMS19IH	RU	http://www.dtic.mil/get-tr-doc/pdf?AD=ADA431390

DMTCADJ	DI	DMTCADJ
DMTCADJ	DN	McN3377
DMTCADJ	MI	TTHS256
DMTCADJ	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMTCADJ	MT	DTT
DMTCADJ	MA	Modulator
DMTCADJ	RN	Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
DMTCADJ	RU	https://pubmed.ncbi.nlm.nih.gov/16377242

DM6JN19	DI	DM6JN19
DM6JN19	DN	ME-344
DM6JN19	MI	TTX4GLS
DM6JN19	MN	Mammalian target of rapamycin complex 1 (mTORC1)
DM6JN19	MT	DTT
DM6JN19	MA	Inhibitor
DM6JN19	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM6JN19	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM6JN19	DI	DM6JN19
DM6JN19	DN	ME-344
DM6JN19	MI	TTCJG29
DM6JN19	MN	Serine/threonine-protein kinase mTOR (mTOR)
DM6JN19	MT	DTT
DM6JN19	MA	Inhibitor
DM6JN19	RN	National Cancer Institute Drug Dictionary (drug id 728650).
DM6JN19	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=728650

DM6JN19	DI	DM6JN19
DM6JN19	DN	ME-344
DM6JN19	MI	TTWDKCL
DM6JN19	MN	Target of rapamycin complex 2 MAPKAP1 (MTORC2)
DM6JN19	MT	DTT
DM6JN19	MA	Inhibitor
DM6JN19	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM6JN19	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMMB5CV	DI	DMMB5CV
DMMB5CV	DN	Medusa IL-2
DMMB5CV	MI	TTF89GD
DMMB5CV	MN	Interleukin-2 (IL2)
DMMB5CV	MT	DTT
DMMB5CV	MA	Modulator
DMMB5CV	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMMB5CV	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMJVFK7	DI	DMJVFK7
DMJVFK7	DN	Meplazumab
DMJVFK7	MI	TTG21IS
DMJVFK7	MN	HUMAN basigin (BSG)
DMJVFK7	MT	DTT
DMJVFK7	MA	Inhibitor
DMJVFK7	RN	Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial
DMJVFK7	RU	https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1

DMENFD6	DI	DMENFD6
DMENFD6	DN	Metelimumab
DMENFD6	MI	TTP4520
DMENFD6	MN	TGF-beta receptor type I (TGFBR1)
DMENFD6	MT	DTT
DMENFD6	RN	Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov. 2004 Dec;3(12):1011-22.
DMENFD6	RU	https://pubmed.ncbi.nlm.nih.gov/15573100

DME6PB0	DI	DME6PB0
DME6PB0	DN	MG7-CART
DME6PB0	MI	TTPW9LJ
DME6PB0	MN	Co-stimulatory molecule 4-1BB (CD137)
DME6PB0	MT	DTT
DME6PB0	MA	CAR-T-Cell-Therapy
DME6PB0	RN	ClinicalTrials.gov (NCT02862704) A Study of MG7 Redirected Autologous T Cells for Advanced MG7 Positive Liver Metastases(MG7-CART)
DME6PB0	RU	https://clinicaltrials.gov/ct2/show/NCT02862704

DME6PB0	DI	DME6PB0
DME6PB0	DN	MG7-CART
DME6PB0	MI	TTPXOQN
DME6PB0	MN	Gastric carcinoma-associated antigen MG7 (MG7)
DME6PB0	MT	DTT
DME6PB0	MA	CAR-T-Cell-Therapy
DME6PB0	RN	ClinicalTrials.gov (NCT02862704) A Study of MG7 Redirected Autologous T Cells for Advanced MG7 Positive Liver Metastases(MG7-CART)
DME6PB0	RU	https://clinicaltrials.gov/ct2/show/NCT02862704

DM1KZW0	DI	DM1KZW0
DM1KZW0	DN	MGC018
DM1KZW0	MI	TT6CQUM
DM1KZW0	MN	B7 homolog 3 (CD276)
DM1KZW0	MT	DTT
DM1KZW0	RN	Clinical pipeline report, company report or official report of MacroGenics.
DM1KZW0	RU	https://www.macrogenics.com/mgc018-b7-h3/

DMAHWLR	DI	DMAHWLR
DMAHWLR	DN	MGD007
DMAHWLR	MI	TT96HUR
DMAHWLR	MN	Cell surface A33 antigen (GPA33)
DMAHWLR	MT	DTT
DMAHWLR	MA	Modulator
DMAHWLR	RN	Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. 
DMAHWLR	RU	https://www.ncbi.nlm.nih.gov/pubmed/25359367

DMAHWLR	DI	DMAHWLR
DMAHWLR	DN	MGD007
DMAHWLR	MI	TTV3XPL
DMAHWLR	MN	T-cell surface glycoprotein CD3 gamma (CD3G)
DMAHWLR	MT	DTT
DMAHWLR	MA	Modulator
DMAHWLR	RN	Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. 
DMAHWLR	RU	https://www.ncbi.nlm.nih.gov/pubmed/25359367

DMCVMUL	DI	DMCVMUL
DMCVMUL	DN	MGD013
DMCVMUL	MI	TTNBFWK
DMCVMUL	MN	Programmed cell death protein 1 (PD-1)
DMCVMUL	MT	DTT
DMCVMUL	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMCVMUL	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DM4H7UY	DI	DM4H7UY
DM4H7UY	DN	Milatuzumab
DM4H7UY	MI	TTCMYP9
DM4H7UY	MN	HLA-DR antigens-associated invariant (CD74)
DM4H7UY	MT	DTT
DM4H7UY	RN	Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. Blood. 2011 Apr 28;117(17):4530-41.
DM4H7UY	RU	https://pubmed.ncbi.nlm.nih.gov/21228331

DM25QKC	DI	DM25QKC
DM25QKC	DN	MK-1308
DM25QKC	MI	TTI2S1D
DM25QKC	MN	Cytotoxic T-lymphocyte protein 4 (CTLA-4)
DM25QKC	MT	DTT
DM25QKC	MA	Inhibitor
DM25QKC	RN	Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Ann Oncol. 2021 Mar;32(3):395-403.
DM25QKC	RU	https://pubmed.ncbi.nlm.nih.gov/33276076

DM21WBH	DI	DM21WBH
DM21WBH	DN	MK-2461
DM21WBH	MI	TTKN7QR
DM21WBH	MN	BDNF/NT-3 growth factors receptor (TrkB)
DM21WBH	MT	DTT
DM21WBH	MA	Inhibitor
DM21WBH	RN	MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
DM21WBH	RU	https://pubmed.ncbi.nlm.nih.gov/20145145

DM21WBH	DI	DM21WBH
DM21WBH	DN	MK-2461
DM21WBH	MI	TTRLW2X
DM21WBH	MN	Fibroblast growth factor receptor 1 (FGFR1)
DM21WBH	MT	DTT
DM21WBH	MA	Inhibitor
DM21WBH	RN	MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
DM21WBH	RU	https://pubmed.ncbi.nlm.nih.gov/20145145

DM21WBH	DI	DM21WBH
DM21WBH	DN	MK-2461
DM21WBH	MI	TTGJVQM
DM21WBH	MN	Fibroblast growth factor receptor 2 (FGFR2)
DM21WBH	MT	DTT
DM21WBH	MA	Inhibitor
DM21WBH	RN	MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
DM21WBH	RU	https://pubmed.ncbi.nlm.nih.gov/20145145

DM21WBH	DI	DM21WBH
DM21WBH	DN	MK-2461
DM21WBH	MI	TTST7KB
DM21WBH	MN	Fibroblast growth factor receptor 3 (FGFR3)
DM21WBH	MT	DTT
DM21WBH	MA	Inhibitor
DM21WBH	RN	MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
DM21WBH	RU	https://pubmed.ncbi.nlm.nih.gov/20145145

DM21WBH	DI	DM21WBH
DM21WBH	DN	MK-2461
DM21WBH	MI	TTGJCWZ
DM21WBH	MN	Fms-like tyrosine kinase 3 (FLT-3)
DM21WBH	MT	DTT
DM21WBH	MA	Inhibitor
DM21WBH	RN	MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
DM21WBH	RU	https://pubmed.ncbi.nlm.nih.gov/20145145

DM21WBH	DI	DM21WBH
DM21WBH	DN	MK-2461
DM21WBH	MI	TTBQ3OC
DM21WBH	MN	Macrophage-stimulating protein receptor (RON)
DM21WBH	MT	DTT
DM21WBH	MA	Inhibitor
DM21WBH	RN	MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
DM21WBH	RU	https://pubmed.ncbi.nlm.nih.gov/20145145

DM21WBH	DI	DM21WBH
DM21WBH	DN	MK-2461
DM21WBH	MI	TTXABCW
DM21WBH	MN	NT-3 growth factor receptor (TrkC)
DM21WBH	MT	DTT
DM21WBH	MA	Inhibitor
DM21WBH	RN	MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
DM21WBH	RU	https://pubmed.ncbi.nlm.nih.gov/20145145

DM21WBH	DI	DM21WBH
DM21WBH	DN	MK-2461
DM21WBH	MI	TTI7421
DM21WBH	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM21WBH	MT	DTT
DM21WBH	MA	Inhibitor
DM21WBH	RN	MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
DM21WBH	RU	https://pubmed.ncbi.nlm.nih.gov/20145145

DM21WBH	DI	DM21WBH
DM21WBH	DN	MK-2461
DM21WBH	MI	TTNDSF4
DM21WBH	MN	Proto-oncogene c-Met (MET)
DM21WBH	MT	DTT
DM21WBH	MA	Inhibitor
DM21WBH	RN	MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
DM21WBH	RU	https://pubmed.ncbi.nlm.nih.gov/20145145

DM21WBH	DI	DM21WBH
DM21WBH	DN	MK-2461
DM21WBH	MI	TTO7LKR
DM21WBH	MN	Tyrosine-protein kinase Mer (MERTK)
DM21WBH	MT	DTT
DM21WBH	MA	Inhibitor
DM21WBH	RN	MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
DM21WBH	RU	https://pubmed.ncbi.nlm.nih.gov/20145145

DM21WBH	DI	DM21WBH
DM21WBH	DN	MK-2461
DM21WBH	MI	TTUTJGQ
DM21WBH	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM21WBH	MT	DTT
DM21WBH	MA	Inhibitor
DM21WBH	RN	MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
DM21WBH	RU	https://pubmed.ncbi.nlm.nih.gov/20145145

DM21WBH	DI	DM21WBH
DM21WBH	DN	MK-2461
DM21WBH	MI	TTDCBX5
DM21WBH	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DM21WBH	MT	DTT
DM21WBH	MA	Inhibitor
DM21WBH	RN	MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
DM21WBH	RU	https://pubmed.ncbi.nlm.nih.gov/20145145

DM21WBH	DI	DM21WBH
DM21WBH	DN	MK-2461
DM21WBH	MI	TT1VAUK
DM21WBH	MN	VEGFR1 messenger RNA (VEGFR1 mRNA)
DM21WBH	MT	DTT
DM21WBH	MA	Inhibitor
DM21WBH	RN	MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
DM21WBH	RU	https://pubmed.ncbi.nlm.nih.gov/20145145

DMCVBQD	DI	DMCVBQD
DMCVBQD	DN	MLN1117
DMCVBQD	MI	TTEUNMR
DMCVBQD	MN	PI3-kinase alpha (PIK3CA)
DMCVBQD	MT	DTT
DMCVBQD	MA	Inhibitor
DMCVBQD	RN	National Cancer Institute Drug Dictionary (drug id 714372).
DMCVBQD	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=714372

DMGC96P	DI	DMGC96P
DMGC96P	DN	MLN-2704
DMGC96P	MI	TT9G4N0
DMGC96P	MN	Glutamate carboxypeptidase II (GCPII)
DMGC96P	MT	DTT
DMGC96P	RN	Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J Clin Oncol. 2008 May 1;26(13):2147-54.
DMGC96P	RU	https://pubmed.ncbi.nlm.nih.gov/18362364

DMG7XHE	DI	DMG7XHE
DMG7XHE	DN	Monalizumab
DMG7XHE	MI	TTC4IMS
DMG7XHE	MN	NKG2-A/B-activating NK receptor (NKG2A)
DMG7XHE	MT	DTT
DMG7XHE	MA	Antagonist
DMG7XHE	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMG7XHE	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMXVIQN	DI	DMXVIQN
DMXVIQN	DN	MOR-103
DMXVIQN	MI	TT6MP2Z
DMXVIQN	MN	GMCSFR-alpha (CSF2RA)
DMXVIQN	MT	DTT
DMXVIQN	RN	MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial. Ann Rheum Dis. 2015 Jun;74(6):1058-64.
DMXVIQN	RU	https://pubmed.ncbi.nlm.nih.gov/24534756

DMR8AHJ	DI	DMR8AHJ
DMR8AHJ	DN	MOR-202
DMR8AHJ	MI	TTPURFN
DMR8AHJ	MN	Cyclic ADP-ribose hydrolase 1 (CD38)
DMR8AHJ	MT	DTT
DMR8AHJ	RN	Clinical pipeline report, company report or official report of MorphoSys.
DMR8AHJ	RU	https://www.morphosys.com/pipeline/proprietary-product-portfolio/mor202

DMR3VCY	DI	DMR3VCY
DMR3VCY	DN	MP0250
DMR3VCY	MI	TT4V2JM
DMR3VCY	MN	Hepatocyte growth factor (HGF)
DMR3VCY	MT	DTT
DMR3VCY	MA	Inhibitor
DMR3VCY	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMR3VCY	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMR3VCY	DI	DMR3VCY
DMR3VCY	DN	MP0250
DMR3VCY	MI	TTOHSBA
DMR3VCY	MN	Vascular endothelial growth factor A (VEGFA)
DMR3VCY	MT	DTT
DMR3VCY	MA	Inhibitor
DMR3VCY	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMR3VCY	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DME7PBN	DI	DME7PBN
DME7PBN	DN	mRNA-3704
DME7PBN	MI	TTCQ21Y
DME7PBN	MN	Methylmalonyl-CoA mutase (MMUT)
DME7PBN	MT	DTT
DME7PBN	MA	Replacement
DME7PBN	RN	Clinical pipeline report, company report or official report of Moderna Therapeutics.
DME7PBN	RU	https://www.modernatx.com/mrna-3705

DM35YFC	DI	DM35YFC
DM35YFC	DN	MS-1819
DM35YFC	MI	TTXMY0J
DM35YFC	MN	Pancreatic triacylglycerol lipase (PNLIP)
DM35YFC	MT	DTT
DM35YFC	MA	Modulator
DM35YFC	RN	Clinical pipeline report, company report or official report of AzurRx.
DM35YFC	RU	http://www.azurrx.com/news-events/press-releases/10-news-2014/58-http-www-azurrx-com-administrator-index-php-option-com-content-view-article-layout-edit

DMIS75V	DI	DMIS75V
DMIS75V	DN	MTL-CEPBA
DMIS75V	MI	TT5LWG1
DMIS75V	MN	CEBPA messenger RNA (CEBPA mRNA)
DMIS75V	MT	DTT
DMIS75V	MA	Activator
DMIS75V	RN	MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-alpha, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial. Clin Cancer Res. 2020 Aug 1;26(15):3936-3946.
DMIS75V	RU	https://pubmed.ncbi.nlm.nih.gov/32357963

DMFUDHM	DI	DMFUDHM
DMFUDHM	DN	MUC-1 CART cell immunotherapy
DMFUDHM	MI	TTBHFYQ
DMFUDHM	MN	Mucin-1 (MUC1)
DMFUDHM	MT	DTT
DMFUDHM	MA	CAR-T-Cell-Therapy
DMFUDHM	RN	ClinicalTrials.gov (NCT03633773) Safety and Efficacy Evaluation of MUC-1 CART in the Treatment of Intrahepatic Cholangiocarcinoma
DMFUDHM	RU	https://clinicaltrials.gov/ct2/show/NCT03633773

DMPNR0J	DI	DMPNR0J
DMPNR0J	DN	Muc1-specific gene-engineered T cells
DMPNR0J	MI	TTBHFYQ
DMPNR0J	MN	Mucin-1 (MUC1)
DMPNR0J	MT	DTT
DMPNR0J	MA	CAR-T-Cell-Therapy
DMPNR0J	RN	ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
DMPNR0J	RU	https://clinicaltrials.gov/ct2/show/NCT03222674

DMU6MJ1	DI	DMU6MJ1
DMU6MJ1	DN	NAHE-001
DMU6MJ1	MI	TTLHGSF
DMU6MJ1	MN	Interferon-alpha 5 (IFNA5)
DMU6MJ1	MT	DTT
DMU6MJ1	MA	Modulator
DMU6MJ1	RN	Interferons and viral infections. Biofactors. 2009 Jan-Feb;35(1):14-20.
DMU6MJ1	RU	https://pubmed.ncbi.nlm.nih.gov/19319841

DM5O4GR	DI	DM5O4GR
DM5O4GR	DN	NB1011
DM5O4GR	MI	TTU6BFZ
DM5O4GR	MN	Candida Thymidylate synthase (Candi TMP1)
DM5O4GR	MT	DTT
DM5O4GR	MA	Binder
DM5O4GR	RN	Kinetic properties of human thymidylate synthase, an anticancer drug target. Biochem Biophys Res Commun. 2003 Jul 25;307(2):297-300.
DM5O4GR	RU	https://pubmed.ncbi.nlm.nih.gov/12859954

DMTAODR	DI	DMTAODR
DMTAODR	DN	NBE-002
DMTAODR	MI	TTDEJAU
DMTAODR	MN	Neurotrophic tyrosine kinase ROR1 (ROR1)
DMTAODR	MT	DTT
DMTAODR	RN	Clinical pipeline report, company report or official report of NBE-Therapeutics.
DMTAODR	RU	https://www.nbe-therapeutics.com/technology/overview

DMZSIV1	DI	DMZSIV1
DMZSIV1	DN	NC410
DMZSIV1	MI	TTSI7A8
DMZSIV1	MN	Leukocyte-associated Ig-like receptor 1 (LAIR1)
DMZSIV1	MT	DTT
DMZSIV1	MA	Inhibitor
DMZSIV1	RN	Clinical pipeline report, company report or official report of NextCure.
DMZSIV1	RU	http://www.nextcure.com/pipeline/

DMCDQX0	DI	DMCDQX0
DMCDQX0	DN	ND-0801
DMCDQX0	MI	TTJSZTB
DMCDQX0	MN	Nicotinic acetylcholine receptor (nAChR)
DMCDQX0	MT	DTT
DMCDQX0	MA	Modulator
DMCDQX0	RN	Drugs in Clinical Development for Attention-Deficit/Hyperactivity Disorder: Summary and Table, 2013, Volume 27, Issue 4, 245-248.
DMCDQX0	RU	http://link.springer.com/article/10.1007/s40290-013-0026-2

DMPMF6L	DI	DMPMF6L
DMPMF6L	DN	Nepadutant
DMPMF6L	MI	TTYO0A3
DMPMF6L	MN	Substance-K receptor (TACR2)
DMPMF6L	MT	DTT
DMPMF6L	MA	Antagonist
DMPMF6L	RN	Emerging drugs for postoperative ileus. Expert Opin Emerg Drugs. 2007 Nov;12(4):619-26.
DMPMF6L	RU	https://pubmed.ncbi.nlm.nih.gov/17979603

DMXKOUC	DI	DMXKOUC
DMXKOUC	DN	Neu-120
DMXKOUC	MI	TTRSMW9
DMXKOUC	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMXKOUC	MT	DTT
DMXKOUC	MA	Modulator
DMXKOUC	RN	Company report (Neurim Pharmaceuticals)
DMXKOUC	RU	http://www.neurim.com/products/

DMXKOUC	DI	DMXKOUC
DMXKOUC	DN	Neu-120
DMXKOUC	MI	TTGP7BY
DMXKOUC	MN	Monoamine oxidase type B (MAO-B)
DMXKOUC	MT	DTT
DMXKOUC	MA	Modulator
DMXKOUC	RN	Company report (Neurim Pharmaceuticals)
DMXKOUC	RU	http://www.neurim.com/products/

DMEOLVP	DI	DMEOLVP
DMEOLVP	DN	NI-0401
DMEOLVP	MI	TTBMAOZ
DMEOLVP	MN	Regulatory protein unspecific (RGP)
DMEOLVP	MT	DTT
DMEOLVP	RN	Clinical pipeline report, company report or official report of NovImmune.
DMEOLVP	RU	http://www.novimmune.com/pipeline/ni-0401.html

DMMOA2X	DI	DMMOA2X
DMMOA2X	DN	Nikkomycin Z
DMMOA2X	MI	TTBGVF1
DMMOA2X	MN	Candida Chitin synthase 3 (Candi CHS3)
DMMOA2X	MT	DTT
DMMOA2X	MA	Modulator
DMMOA2X	RN	Inhibitory effect of nikkomycin Z on chitin synthases in Candida albicans. Yeast. 2002 Mar 15;19(4):341-9.
DMMOA2X	RU	https://pubmed.ncbi.nlm.nih.gov/11870857

DM7SMNJ	DI	DM7SMNJ
DM7SMNJ	DN	NKTR-255
DM7SMNJ	MI	TTGN89I
DM7SMNJ	MN	Interleukin 15 receptor alpha (IL15RA)
DM7SMNJ	MT	DTT
DM7SMNJ	MA	Agonist
DM7SMNJ	RN	Clinical pipeline report, company report or official report of Nektar Therapeutics.
DM7SMNJ	RU	https://www.nektar.com/pipeline/rd-pipeline/nktr-255

DMYR8LF	DI	DMYR8LF
DMYR8LF	DN	NKTR-262
DMYR8LF	MI	TTRJ1K4
DMYR8LF	MN	Toll-like receptor 7 (TLR7)
DMYR8LF	MT	DTT
DMYR8LF	MA	Agonist
DMYR8LF	RN	Clinical pipeline report, company report or official report of Nektar Therapeutics.
DMYR8LF	RU	https://www.nektar.com/pipeline/rd-pipeline/nktr-262

DMYR8LF	DI	DMYR8LF
DMYR8LF	DN	NKTR-262
DMYR8LF	MI	TT8CWFK
DMYR8LF	MN	Toll-like receptor 8 (TLR8)
DMYR8LF	MT	DTT
DMYR8LF	MA	Agonist
DMYR8LF	RN	Clinical pipeline report, company report or official report of Nektar Therapeutics.
DMYR8LF	RU	https://www.nektar.com/pipeline/rd-pipeline/nktr-262

DMDNJP5	DI	DMDNJP5
DMDNJP5	DN	NM21-1480
DMDNJP5	MI	TTPW9LJ
DMDNJP5	MN	Co-stimulatory molecule 4-1BB (CD137)
DMDNJP5	MT	DTT
DMDNJP5	MA	Modulator
DMDNJP5	RN	Clinical pipeline report, company report or official report of Numab Therapeutics.
DMDNJP5	RU	https://www.numab.com/wp-content/uploads/2019/03/190330_PRE_Numab_AACR-Poster-2019.pdf

DMDNJP5	DI	DMDNJP5
DMDNJP5	DN	NM21-1480
DMDNJP5	MI	TT8ZLTI
DMDNJP5	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMDNJP5	MT	DTT
DMDNJP5	MA	Modulator
DMDNJP5	RN	Clinical pipeline report, company report or official report of Numab Therapeutics.
DMDNJP5	RU	https://www.numab.com/wp-content/uploads/2019/03/190330_PRE_Numab_AACR-Poster-2019.pdf

DMDASRW	DI	DMDASRW
DMDASRW	DN	Norleucine
DMDASRW	MI	TT01M3K
DMDASRW	MN	Hepatocyte nuclear factor 1-alpha (HNF1A)
DMDASRW	MT	DTT
DMDASRW	MA	Inhibitor
DMDASRW	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMDASRW	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM78KMT	DI	DM78KMT
DM78KMT	DN	NPB-001-056
DM78KMT	MI	TTS7G69
DM78KMT	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DM78KMT	MT	DTT
DM78KMT	MA	Inhibitor
DM78KMT	RN	NPB001-05 inhibits Bcr-Abl kinase leading to apoptosis of imatinib-resistant cells. Front Biosci (Elite Ed). 2011 Jun 1;3:1273-88.
DM78KMT	RU	https://pubmed.ncbi.nlm.nih.gov/21622134

DMU9BCD	DI	DMU9BCD
DMU9BCD	DN	NS-018
DMU9BCD	MI	TTRMX3V
DMU9BCD	MN	Janus kinase 2 (JAK-2)
DMU9BCD	MT	DTT
DMU9BCD	MA	Modulator
DMU9BCD	RN	Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis. Blood Cancer J. 2014 Jan 10;4:e174.
DMU9BCD	RU	https://pubmed.ncbi.nlm.nih.gov/24413068

DMOYS1N	DI	DMOYS1N
DMOYS1N	DN	NT219
DMOYS1N	MI	TTF95B8
DMOYS1N	MN	Insulin receptor substrate 2 (IRS2)
DMOYS1N	MT	DTT
DMOYS1N	MA	Inhibitor
DMOYS1N	RN	Clinical pipeline report, company report or official report of Purple Biotech.
DMOYS1N	RU	https://purple-biotech.com/pipeline/#1NT-219

DMOYS1N	DI	DMOYS1N
DMOYS1N	DN	NT219
DMOYS1N	MI	TTADRX7
DMOYS1N	MN	Insulin receptor substrate-1 (IRS1)
DMOYS1N	MT	DTT
DMOYS1N	MA	Inhibitor
DMOYS1N	RN	Clinical pipeline report, company report or official report of Purple Biotech.
DMOYS1N	RU	https://purple-biotech.com/pipeline/#1NT-219

DMOYS1N	DI	DMOYS1N
DMOYS1N	DN	NT219
DMOYS1N	MI	TTH8FZW
DMOYS1N	MN	Signal transducer and activator of transcription 3 (STAT3)
DMOYS1N	MT	DTT
DMOYS1N	MA	Inhibitor
DMOYS1N	RN	Clinical pipeline report, company report or official report of Purple Biotech.
DMOYS1N	RU	https://purple-biotech.com/pipeline/#1NT-219

DMBQRGV	DI	DMBQRGV
DMBQRGV	DN	NT-501 CNTF
DMBQRGV	MI	TTGEM5Q
DMBQRGV	MN	Ciliary neurotrophic factor (CNTF)
DMBQRGV	MT	DTT
DMBQRGV	MA	Modulator
DMBQRGV	RN	Clinical pipeline report, company report or official report of Neurotech.
DMBQRGV	RU	http://www.neurotechusa.com/cntfrenexus.html

DMS0L6J	DI	DMS0L6J
DMS0L6J	DN	NY-ESO-TCR
DMS0L6J	MI	TT7AKW1
DMS0L6J	MN	T-cell receptor (TCR)
DMS0L6J	MT	DTT
DMS0L6J	MA	CAR-T-Cell-Therapy
DMS0L6J	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMS0L6J	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMD2L1U	DI	DMD2L1U
DMD2L1U	DN	OBI-888
DMD2L1U	MI	TT4UXTG
DMD2L1U	MN	Globohexaosylceramide (Globo H)
DMD2L1U	MT	DTT
DMD2L1U	RN	Clinical pipeline report, company report or official report of OBI Pharma.
DMD2L1U	RU	https://www.obipharma.com/obi-888-mab/

DMPB9OD	DI	DMPB9OD
DMPB9OD	DN	OBI-999
DMPB9OD	MI	TT4UXTG
DMPB9OD	MN	Globohexaosylceramide (Globo H)
DMPB9OD	MT	DTT
DMPB9OD	RN	Preclinical Studies of OBI-999: A Novel Globo H-Targeting Antibody-Drug Conjugate. Mol Cancer Ther. 2021 Jun;20(6):1121-1132.
DMPB9OD	RU	https://pubmed.ncbi.nlm.nih.gov/33722855

DM9MF08	DI	DM9MF08
DM9MF08	DN	OBP-301
DM9MF08	MI	TTUJFD0
DM9MF08	MN	Telomerase reverse transcriptase (TERT)
DM9MF08	MT	DTT
DM9MF08	MA	Inhibitor
DM9MF08	RN	Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):285-92.
DM9MF08	RU	https://pubmed.ncbi.nlm.nih.gov/14734481

DMOKVJD	DI	DMOKVJD
DMOKVJD	DN	ODM-207
DMOKVJD	MI	TTE4BSY
DMOKVJD	MN	Bromodomain and extraterminal domain protein (BET)
DMOKVJD	MT	DTT
DMOKVJD	MA	Inhibitor
DMOKVJD	RN	First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours. Br J Cancer. 2020 Dec;123(12):1730-1736.
DMOKVJD	RU	https://pubmed.ncbi.nlm.nih.gov/32989226

DMPLBDF	DI	DMPLBDF
DMPLBDF	DN	Omburtamab I-124
DMPLBDF	MI	TT6CQUM
DMPLBDF	MN	B7 homolog 3 (CD276)
DMPLBDF	MT	DTT
DMPLBDF	MA	Inhibitor
DMPLBDF	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPLBDF	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM2DHJS	DI	DM2DHJS
DM2DHJS	DN	ONC1-13B
DM2DHJS	MI	TTS64P2
DM2DHJS	MN	Androgen receptor (AR)
DM2DHJS	MT	DTT
DM2DHJS	MA	Antagonist
DM2DHJS	RN	Preclinical Development of ONC1-13B, Novel Antiandrogen for Prostate Cancer Treatment. J Cancer. 2014 Jan 21;5(2):133-42.
DM2DHJS	RU	https://pubmed.ncbi.nlm.nih.gov/24494031

DMV6GX7	DI	DMV6GX7
DMV6GX7	DN	ONO-7475
DMV6GX7	MI	TTO7LKR
DMV6GX7	MN	Tyrosine-protein kinase Mer (MERTK)
DMV6GX7	MT	DTT
DMV6GX7	MA	Inhibitor
DMV6GX7	RN	Clinical pipeline report, company report or official report of Ono Pharmaceutical.
DMV6GX7	RU	https://www.ono-pharma.com/ir/library/pipeline.html

DMV6GX7	DI	DMV6GX7
DMV6GX7	DN	ONO-7475
DMV6GX7	MI	TTZPY6J
DMV6GX7	MN	Tyrosine-protein kinase UFO (AXL)
DMV6GX7	MT	DTT
DMV6GX7	MA	Inhibitor
DMV6GX7	RN	Clinical pipeline report, company report or official report of Ono Pharmaceutical.
DMV6GX7	RU	https://www.ono-pharma.com/ir/library/pipeline.html

DMXLPYE	DI	DMXLPYE
DMXLPYE	DN	ONO-7579
DMXLPYE	MI	TTTDVOJ
DMXLPYE	MN	Tropomyosin-related kinase A (TrkA)
DMXLPYE	MT	DTT
DMXLPYE	MA	Inhibitor
DMXLPYE	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMXLPYE	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMGIN7J	DI	DMGIN7J
DMGIN7J	DN	Onyvax-105
DMGIN7J	MI	TT5Z9WY
DMGIN7J	MN	Complement decay-accelerating factor (CD55)
DMGIN7J	MT	DTT
DMGIN7J	RN	Technology evaluation: Onyvax-105, Onyvax. Curr Opin Mol Ther. 2003 Dec;5(6):668-72.
DMGIN7J	RU	https://pubmed.ncbi.nlm.nih.gov/14755894

DMIU26T	DI	DMIU26T
DMIU26T	DN	OP-1250
DMIU26T	MI	TTZAYWL
DMIU26T	MN	Estrogen receptor (ESR)
DMIU26T	MT	DTT
DMIU26T	MA	Antagonist
DMIU26T	RN	Clinical pipeline report, company report or official report of Olema Pharmaceuticals.
DMIU26T	RU	https://olema.com/pipeline/

DMELJIV	DI	DMELJIV
DMELJIV	DN	OPA-6566
DMELJIV	MI	TTM2AOE
DMELJIV	MN	Adenosine A2a receptor (ADORA2A)
DMELJIV	MT	DTT
DMELJIV	MA	Agonist
DMELJIV	RN	Clinical pipeline report, company report or official report of Acucela.
DMELJIV	RU	http://www.acucela.com/Read-About-Us/Press-Releases/Acucela-and-Otsuka-Pharmaceutical-Announce-the-(1)

DM6VGO3	DI	DM6VGO3
DM6VGO3	DN	OPB-31121
DM6VGO3	MI	TTH8FZW
DM6VGO3	MN	Signal transducer and activator of transcription 3 (STAT3)
DM6VGO3	MT	DTT
DM6VGO3	MA	Inhibitor
DM6VGO3	RN	OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. Cancer Lett. 2013 Jul 10;335(1):145-52.
DM6VGO3	RU	https://pubmed.ncbi.nlm.nih.gov/23402820

DMZB6LO	DI	DMZB6LO
DMZB6LO	DN	OPC-167832
DMZB6LO	MI	TTLOHU4
DMZB6LO	MN	Mycobacterium Decaprenylphosphoryl-beta-D-ribose oxidase (McyB dprE1)
DMZB6LO	MT	DTT
DMZB6LO	MA	Inhibitor
DMZB6LO	RN	OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor. Antimicrob Agents Chemother. 2020 May 21;64(6):e02020-19.
DMZB6LO	RU	https://pubmed.ncbi.nlm.nih.gov/32229496

DM471ZH	DI	DM471ZH
DM471ZH	DN	ORE-1001
DM471ZH	MI	TTUI5H7
DM471ZH	MN	Angiotensin-converting enzyme 2 (ACE2)
DM471ZH	MT	DTT
DM471ZH	MA	Inhibitor
DM471ZH	RN	Effects of the ACE2 inhibitor GL1001 on acute dextran sodium sulfate-induced colitis in mice. Inflamm Res. 2009 Nov;58(11):819-27.
DM471ZH	RU	https://pubmed.ncbi.nlm.nih.gov/19517214

DM27RXS	DI	DM27RXS
DM27RXS	DN	ORIN1001
DM27RXS	MI	TTOJ9QL
DM27RXS	MN	Endoplasmic reticulum to nucleus signaling 1 (ERN1)
DM27RXS	MT	DTT
DM27RXS	MA	Inhibitor
DM27RXS	RN	Clinical pipeline report, company report or official report of Orinove.
DM27RXS	RU	http://www.orinove.com/about261.html

DMWCJ1F	DI	DMWCJ1F
DMWCJ1F	DN	OT-58
DMWCJ1F	MI	TTVZJ7G
DMWCJ1F	MN	Cystathionine beta-synthase (CBS)
DMWCJ1F	MT	DTT
DMWCJ1F	MA	Replacement
DMWCJ1F	RN	Classical homocystinuria: From cystathionine beta-synthase deficiency to novel enzyme therapies. Biochimie. 2020 Jun;173:48-56.
DMWCJ1F	RU	https://pubmed.ncbi.nlm.nih.gov/31857119

DMYGK1D	DI	DMYGK1D
DMYGK1D	DN	OTL-300
DMYGK1D	MI	TTM6HK1
DMYGK1D	MN	Hemoglobin subunit beta (HBB)
DMYGK1D	MT	DTT
DMYGK1D	RN	Clinical pipeline report, company report or official report of Orchard Therapeutics.
DMYGK1D	RU	https://www.orchard-tx.com/approach/pipeline/

DMN0ZQ5	DI	DMN0ZQ5
DMN0ZQ5	DN	OTSGC-A24
DMN0ZQ5	MI	TT2Q6G1
DMN0ZQ5	MN	Vascular endothelial growth factor receptor 1 (FLT-1)
DMN0ZQ5	MT	DTT
DMN0ZQ5	RN	J Clin Oncol 33, 2015 (suppl 3; abstr 65).
DMN0ZQ5	RU	http://meetinglibrary.asco.org/content/140443-158

DMN0ZQ5	DI	DMN0ZQ5
DMN0ZQ5	DN	OTSGC-A24
DMN0ZQ5	MI	TTUTJGQ
DMN0ZQ5	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMN0ZQ5	MT	DTT
DMN0ZQ5	RN	J Clin Oncol 33, 2015 (suppl 3; abstr 65).
DMN0ZQ5	RU	http://meetinglibrary.asco.org/content/140443-158

DMI8RG1	DI	DMI8RG1
DMI8RG1	DN	OTX-015
DMI8RG1	MI	TTE4BSY
DMI8RG1	MN	Bromodomain and extraterminal domain protein (BET)
DMI8RG1	MT	DTT
DMI8RG1	MA	Inhibitor
DMI8RG1	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMI8RG1	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMI8RG1	DI	DMI8RG1
DMI8RG1	DN	OTX-015
DMI8RG1	MI	TTDP48B
DMI8RG1	MN	Bromodomain-containing protein 2 (BRD2)
DMI8RG1	MT	DTT
DMI8RG1	MA	Modulator
DMI8RG1	RN	Targeting bromodomains: epigenetic readers of lysine acetylation.Nat Rev Drug Discov.2014 May;13(5):337-56.
DMI8RG1	RU	https://www.ncbi.nlm.nih.gov/pubmed/24751816

DMI8RG1	DI	DMI8RG1
DMI8RG1	DN	OTX-015
DMI8RG1	MI	TTRA6BO
DMI8RG1	MN	Bromodomain-containing protein 4 (BRD4)
DMI8RG1	MT	DTT
DMI8RG1	MA	Modulator
DMI8RG1	RN	Targeting bromodomains: epigenetic readers of lysine acetylation.Nat Rev Drug Discov.2014 May;13(5):337-56.
DMI8RG1	RU	https://www.ncbi.nlm.nih.gov/pubmed/24751816

DMXF9DM	DI	DMXF9DM
DMXF9DM	DN	OXB-102
DMXF9DM	MI	TTN451K
DMXF9DM	MN	Aromatic-L-amino-acid decarboxylase (DDC)
DMXF9DM	MT	DTT
DMXF9DM	RN	Clinical pipeline report, company report or official report of Oxford BioMedica.
DMXF9DM	RU	https://www.oxb.com/pipeline

DMXF9DM	DI	DMXF9DM
DMXF9DM	DN	OXB-102
DMXF9DM	MI	TTLSWP6
DMXF9DM	MN	GTP cyclohydrolase-I (GCH1)
DMXF9DM	MT	DTT
DMXF9DM	RN	Clinical pipeline report, company report or official report of Oxford BioMedica.
DMXF9DM	RU	https://www.oxb.com/pipeline

DMXF9DM	DI	DMXF9DM
DMXF9DM	DN	OXB-102
DMXF9DM	MI	TTUHP71
DMXF9DM	MN	Tyrosine 3-monooxygenase (TH)
DMXF9DM	MT	DTT
DMXF9DM	RN	Clinical pipeline report, company report or official report of Oxford BioMedica.
DMXF9DM	RU	https://www.oxb.com/pipeline

DMTH75R	DI	DMTH75R
DMTH75R	DN	OXY-111A
DMTH75R	MI	TTQO71U
DMTH75R	MN	Hemoglobin (HB)
DMTH75R	MT	DTT
DMTH75R	MA	Enhancer
DMTH75R	RN	Modulating the oxygen affinity of human fetal haemoglobin with synthetic allosteric modulators. Br J Haematol. 1998 Sep;102(5):1165-71.
DMTH75R	RU	https://pubmed.ncbi.nlm.nih.gov/9753039

DM6V5OB	DI	DM6V5OB
DM6V5OB	DN	P-552-02
DM6V5OB	MI	TTRK8B9
DM6V5OB	MN	Sodium channel unspecific (NaC)
DM6V5OB	MT	DTT
DM6V5OB	MA	Blocker
DM6V5OB	RN	US patent application no. 2014,0221,286, Sodium channel blockers reduce glucagon secretion.
DM6V5OB	RU	https://www.google.com/patents/US20140221286

DMLSYJQ	DI	DMLSYJQ
DMLSYJQ	DN	PA-799
DMLSYJQ	MI	TTEUNMR
DMLSYJQ	MN	PI3-kinase alpha (PIK3CA)
DMLSYJQ	MT	DTT
DMLSYJQ	MA	Inhibitor
DMLSYJQ	RN	The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res. 2011 May 15;17(10):3272-81.
DMLSYJQ	RU	https://pubmed.ncbi.nlm.nih.gov/21558396

DMLSYJQ	DI	DMLSYJQ
DMLSYJQ	DN	PA-799
DMLSYJQ	MI	TTTHBCA
DMLSYJQ	MN	PI3-kinase beta (PIK3CB)
DMLSYJQ	MT	DTT
DMLSYJQ	MA	Inhibitor
DMLSYJQ	RN	The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res. 2011 May 15;17(10):3272-81.
DMLSYJQ	RU	https://pubmed.ncbi.nlm.nih.gov/21558396

DMLSYJQ	DI	DMLSYJQ
DMLSYJQ	DN	PA-799
DMLSYJQ	MI	TTGBPJE
DMLSYJQ	MN	PI3-kinase delta (PIK3CD)
DMLSYJQ	MT	DTT
DMLSYJQ	MA	Inhibitor
DMLSYJQ	RN	The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res. 2011 May 15;17(10):3272-81.
DMLSYJQ	RU	https://pubmed.ncbi.nlm.nih.gov/21558396

DMLSYJQ	DI	DMLSYJQ
DMLSYJQ	DN	PA-799
DMLSYJQ	MI	TTHBTOP
DMLSYJQ	MN	PI3-kinase gamma (PIK3CG)
DMLSYJQ	MT	DTT
DMLSYJQ	MA	Modulator
DMLSYJQ	RN	Company report (Chugai-pharm)
DMLSYJQ	RU	http://www.chugai-pharm.co.jp/html/meeting/pdf/140424ePresentation.pdf

DMZKFJO	DI	DMZKFJO
DMZKFJO	DN	PAT-SC1
DMZKFJO	MI	TT5Z9WY
DMZKFJO	MN	Complement decay-accelerating factor (CD55)
DMZKFJO	MT	DTT
DMZKFJO	RN	Ten-year follow-up of a prospective trial for the targeted therapy of gastric cancer with the human monoclonal antibody PAT-SC1. Oncol Rep. 2014 Mar;31(3):1059-66.
DMZKFJO	RU	https://pubmed.ncbi.nlm.nih.gov/24452482

DMJC2RU	DI	DMJC2RU
DMJC2RU	DN	PBCAR0191
DMJC2RU	MI	TTW640A
DMJC2RU	MN	B-lymphocyte surface antigen B4 (CD19)
DMJC2RU	MT	DTT
DMJC2RU	MA	CAR-T-Cell-Therapy
DMJC2RU	RN	ClinicalTrials.gov (NCT03666000) Dose-escalation Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL
DMJC2RU	RU	https://clinicaltrials.gov/ct2/show/NCT03666000

DM7NKWQ	DI	DM7NKWQ
DM7NKWQ	DN	PBCAR20A
DM7NKWQ	MI	TTUE541
DM7NKWQ	MN	Leukocyte surface antigen Leu-16 (CD20)
DM7NKWQ	MT	DTT
DM7NKWQ	RN	Clinical pipeline report, company report or official report of Precision Biosciences.
DM7NKWQ	RU	https://precisionbiosciences.com/pipeline/

DMSGM2L	DI	DMSGM2L
DMSGM2L	DN	PBCAR269A
DMSGM2L	MI	TTZ3P4W
DMSGM2L	MN	B-cell maturation protein (TNFRSF17)
DMSGM2L	MT	DTT
DMSGM2L	RN	Clinical pipeline report, company report or official report of Precision Biosciences.
DMSGM2L	RU	https://precisionbiosciences.com/pipeline/

DMGFPQ0	DI	DMGFPQ0
DMGFPQ0	DN	PBF509
DMGFPQ0	MI	TTM2AOE
DMGFPQ0	MN	Adenosine A2a receptor (ADORA2A)
DMGFPQ0	MT	DTT
DMGFPQ0	MA	Antagonist
DMGFPQ0	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMGFPQ0	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMSJ54W	DI	DMSJ54W
DMSJ54W	DN	PC14586
DMSJ54W	MI	TTJC50M
DMSJ54W	MN	P53 Y220C mutant (TP53 Y220C)
DMSJ54W	MT	DTT
DMSJ54W	MA	Reactivator
DMSJ54W	RN	Clinical pipeline report, company report or official report of PMV Pharmaceuticals.
DMSJ54W	RU	https://www.pmvpharma.com/pipeline/

DM9DR13	DI	DM9DR13
DM9DR13	DN	PCAR-019
DM9DR13	MI	TTW640A
DM9DR13	MN	B-lymphocyte surface antigen B4 (CD19)
DM9DR13	MT	DTT
DM9DR13	MA	CAR-T-Cell-Therapy
DM9DR13	RN	ClinicalTrials.gov (NCT02819583) CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
DM9DR13	RU	https://clinicaltrials.gov/ct2/show/NCT02819583

DM1D6BT	DI	DM1D6BT
DM1D6BT	DN	PEGylated hyaluronidase (human recombinant)
DM1D6BT	MI	TTXFI1K
DM1D6BT	MN	Hyaluronidase (HYAL)
DM1D6BT	MT	DTT
DM1D6BT	MA	Modulator
DM1D6BT	RN	Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look. Cancer Discov. 2011 September; 1(4): 291-296.
DM1D6BT	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3204883/

DMMAUOK	DI	DMMAUOK
DMMAUOK	DN	PEN-221
DMMAUOK	MI	TTZ6T9E
DMMAUOK	MN	Somatostatin receptor type 2 (SSTR2)
DMMAUOK	MT	DTT
DMMAUOK	MA	Modulator
DMMAUOK	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMMAUOK	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMLPTOF	DI	DMLPTOF
DMLPTOF	DN	PEN-866
DMLPTOF	MI	TTGTQHC
DMLPTOF	MN	DNA topoisomerase I (TOP1)
DMLPTOF	MT	DTT
DMLPTOF	MA	Inhibitor
DMLPTOF	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMLPTOF	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMM9L1R	DI	DMM9L1R
DMM9L1R	DN	PEP-223/CoVaccine HT
DMM9L1R	MI	TT8R70G
DMM9L1R	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMM9L1R	MT	DTT
DMM9L1R	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 256).
DMM9L1R	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=256

DM03GDJ	DI	DM03GDJ
DM03GDJ	DN	Pepinemab
DM03GDJ	MI	TT5UT28
DM03GDJ	MN	Semaphorin-4D (SEMA4D)
DM03GDJ	MT	DTT
DM03GDJ	MA	Inhibitor
DM03GDJ	RN	Clinical pipeline report, company report or official report of Vaccinex.
DM03GDJ	RU	https://vaccinex.com/pipeline/pepinemab-immuno-oncology/

DMBUJVX	DI	DMBUJVX
DMBUJVX	DN	Phenoxodiol
DMBUJVX	MI	TTOHFIY
DMBUJVX	MN	Sphingosine kinase 1 (SPHK1)
DMBUJVX	MT	DTT
DMBUJVX	MA	Modulator
DMBUJVX	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMBUJVX	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMBUJVX	DI	DMBUJVX
DMBUJVX	DN	Phenoxodiol
DMBUJVX	MI	TTR7B60
DMBUJVX	MN	X-linked inhibitor of apoptosis protein (XIAP)
DMBUJVX	MT	DTT
DMBUJVX	MA	Modulator
DMBUJVX	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMBUJVX	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMYEAB1	DI	DMYEAB1
DMYEAB1	DN	PIPERINE
DMYEAB1	MI	TT3WG5C
DMYEAB1	MN	Monoamine oxidase type A (MAO-A)
DMYEAB1	MT	DTT
DMYEAB1	MA	Inhibitor
DMYEAB1	RN	Proposed structural basis of interaction of piperine and related compounds with monoamine oxidases. Bioorg Med Chem Lett. 2010 Jan 15;20(2):537-40.
DMYEAB1	RU	https://pubmed.ncbi.nlm.nih.gov/19969454

DMYEAB1	DI	DMYEAB1
DMYEAB1	DN	PIPERINE
DMYEAB1	MI	TTGP7BY
DMYEAB1	MN	Monoamine oxidase type B (MAO-B)
DMYEAB1	MT	DTT
DMYEAB1	MA	Inhibitor
DMYEAB1	RN	Proposed structural basis of interaction of piperine and related compounds with monoamine oxidases. Bioorg Med Chem Lett. 2010 Jan 15;20(2):537-40.
DMYEAB1	RU	https://pubmed.ncbi.nlm.nih.gov/19969454

DMX168L	DI	DMX168L
DMX168L	DN	PLX2853
DMX168L	MI	TTRA6BO
DMX168L	MN	Bromodomain-containing protein 4 (BRD4)
DMX168L	MT	DTT
DMX168L	MA	Inhibitor
DMX168L	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMX168L	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM5DZEL	DI	DM5DZEL
DM5DZEL	DN	PLX9486
DM5DZEL	MI	TTX41N9
DM5DZEL	MN	Tyrosine-protein kinase Kit (KIT)
DM5DZEL	MT	DTT
DM5DZEL	MA	Inhibitor
DM5DZEL	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM5DZEL	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMQOW0H	DI	DMQOW0H
DMQOW0H	DN	PP-1420
DMQOW0H	MI	TTIB95A
DMQOW0H	MN	Pancreatic hormone (PH)
DMQOW0H	MT	DTT
DMQOW0H	MA	Modulator
DMQOW0H	RN	Pharmacokinetics, adverse effects and tolerability of a novel analogue of human pancreatic polypeptide, PP 1420. Br J Clin Pharmacol. 2012 Feb;73(2):232-9.
DMQOW0H	RU	https://pubmed.ncbi.nlm.nih.gov/21834938

DM0HTEF	DI	DM0HTEF
DM0HTEF	DN	PRI-724
DM0HTEF	MI	TTFRCTK
DM0HTEF	MN	CREB-binding protein (CREBBP)
DM0HTEF	MT	DTT
DM0HTEF	MA	Modulator
DM0HTEF	RN	Inhibition of Wnt/beta-catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis. Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14309-14.
DM0HTEF	RU	https://pubmed.ncbi.nlm.nih.gov/20660310

DM8J5H1	DI	DM8J5H1
DM8J5H1	DN	PRLX93936
DM8J5H1	MI	TTT48SQ
DM8J5H1	MN	Voltage-dependent anion-selective channel 3 (VDAC3)
DM8J5H1	MT	DTT
DM8J5H1	MA	Modulator
DM8J5H1	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM8J5H1	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMJ42E6	DI	DMJ42E6
DMJ42E6	DN	ProSavin
DMJ42E6	MI	TTN451K
DMJ42E6	MN	Aromatic-L-amino-acid decarboxylase (DDC)
DMJ42E6	MT	DTT
DMJ42E6	MA	Modulator
DMJ42E6	RN	Clinical pipeline report, company report or official report of Oxford BioMedica.
DMJ42E6	RU	http://www.oxfordbiomedica.co.uk/press-releases/oxford-biomedica-announces-successful-completion-of-prosavin-r-phase-i-ii-study-in-parkinson-s-disease/

DMJ42E6	DI	DMJ42E6
DMJ42E6	DN	ProSavin
DMJ42E6	MI	TTLSWP6
DMJ42E6	MN	GTP cyclohydrolase-I (GCH1)
DMJ42E6	MT	DTT
DMJ42E6	MA	Modulator
DMJ42E6	RN	Clinical pipeline report, company report or official report of Oxford BioMedica.
DMJ42E6	RU	http://www.oxfordbiomedica.co.uk/press-releases/oxford-biomedica-announces-successful-completion-of-prosavin-r-phase-i-ii-study-in-parkinson-s-disease/

DMJ42E6	DI	DMJ42E6
DMJ42E6	DN	ProSavin
DMJ42E6	MI	TTUHP71
DMJ42E6	MN	Tyrosine 3-monooxygenase (TH)
DMJ42E6	MT	DTT
DMJ42E6	MA	Modulator
DMJ42E6	RN	Clinical pipeline report, company report or official report of Oxford BioMedica.
DMJ42E6	RU	http://www.oxfordbiomedica.co.uk/press-releases/oxford-biomedica-announces-successful-completion-of-prosavin-r-phase-i-ii-study-in-parkinson-s-disease/

DMOUW65	DI	DMOUW65
DMOUW65	DN	PRX-102
DMOUW65	MI	TTIS03D
DMOUW65	MN	Alpha-galactosidase A (GLA)
DMOUW65	MT	DTT
DMOUW65	MA	Modulator
DMOUW65	RN	Characterization of a chemically modified plant cell culture expressed human alpha-Galactosidase-A enzyme for treatment of Fabry disease. Mol Genet Metab. 2015 Feb;114(2):259-67.
DMOUW65	RU	https://pubmed.ncbi.nlm.nih.gov/25155442

DM2CDLS	DI	DM2CDLS
DM2CDLS	DN	QLT-091568
DM2CDLS	MI	TTMXGCW
DM2CDLS	MN	Adrenergic receptor beta-3 (ADRB3)
DM2CDLS	MT	DTT
DM2CDLS	MA	Antagonist
DM2CDLS	RN	Clinical pipeline report, company report or official report of QLT Inc.
DM2CDLS	RU	http://www.qltinc.com/newsCenter/2009/091230.htm

DMZD7OA	DI	DMZD7OA
DMZD7OA	DN	Quaratusugene ozeplasmid
DMZD7OA	MI	TTJ8O14
DMZD7OA	MN	Tumor suppressor candidate 2 (TUSC2)
DMZD7OA	MT	DTT
DMZD7OA	RN	Clinical pipeline report, company report or official report of Genprex.
DMZD7OA	RU	https://www.genprex.com/technology/reqorsa/

DM614BA	DI	DM614BA
DM614BA	DN	Re-188-P-2045
DM614BA	MI	TTZ6T9E
DM614BA	MN	Somatostatin receptor type 2 (SSTR2)
DM614BA	MT	DTT
DM614BA	MA	Modulator
DM614BA	RN	The somatostatin analog 188Re-P2045 inhibits the growth of AR42J pancreatic tumor xenografts. J Nucl Med. 2014 Dec;55(12):2020-5.
DM614BA	RU	https://pubmed.ncbi.nlm.nih.gov/25359879

DMY3TAD	DI	DMY3TAD
DMY3TAD	DN	Recombinant factor VIIa PEGylated liposomal
DMY3TAD	MI	TTF0EGX
DMY3TAD	MN	Coagulation factor VII (F7)
DMY3TAD	MT	DTT
DMY3TAD	MA	Modulator
DMY3TAD	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2363).
DMY3TAD	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2363

DM7LOSK	DI	DM7LOSK
DM7LOSK	DN	REGN4018
DM7LOSK	MI	TTC1PS3
DM7LOSK	MN	Ovarian carcinoma antigen CA125 (MUC16)
DM7LOSK	MT	DTT
DM7LOSK	MA	Inhibitor
DM7LOSK	RN	A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer. Sci Transl Med. 2019 Jun 19;11(497):eaau7534.
DM7LOSK	RU	https://pubmed.ncbi.nlm.nih.gov/31217340

DM7LOSK	DI	DM7LOSK
DM7LOSK	DN	REGN4018
DM7LOSK	MI	TTUN7MC
DM7LOSK	MN	T-cell surface glycoprotein CD3 (CD3)
DM7LOSK	MT	DTT
DM7LOSK	MA	Inhibitor
DM7LOSK	RN	A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer. Sci Transl Med. 2019 Jun 19;11(497):eaau7534.
DM7LOSK	RU	https://pubmed.ncbi.nlm.nih.gov/31217340

DMAGX0Q	DI	DMAGX0Q
DMAGX0Q	DN	REGN5458
DMAGX0Q	MI	TTZ3P4W
DMAGX0Q	MN	B-cell maturation protein (TNFRSF17)
DMAGX0Q	MT	DTT
DMAGX0Q	MA	Inhibitor
DMAGX0Q	RN	A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells. Blood Adv. 2021 Mar 9;5(5):1291-1304.
DMAGX0Q	RU	https://pubmed.ncbi.nlm.nih.gov/33651100

DMAGX0Q	DI	DMAGX0Q
DMAGX0Q	DN	REGN5458
DMAGX0Q	MI	TTUN7MC
DMAGX0Q	MN	T-cell surface glycoprotein CD3 (CD3)
DMAGX0Q	MT	DTT
DMAGX0Q	MA	Inhibitor
DMAGX0Q	RN	A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells. Blood Adv. 2021 Mar 9;5(5):1291-1304.
DMAGX0Q	RU	https://pubmed.ncbi.nlm.nih.gov/33651100

DMRE0LU	DI	DMRE0LU
DMRE0LU	DN	REGN5459
DMRE0LU	MI	TTZ3P4W
DMRE0LU	MN	B-cell maturation protein (TNFRSF17)
DMRE0LU	MT	DTT
DMRE0LU	MA	Inhibitor
DMRE0LU	RN	Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals.
DMRE0LU	RU	https://www.regeneron.com/science/pipeline

DMRE0LU	DI	DMRE0LU
DMRE0LU	DN	REGN5459
DMRE0LU	MI	TTUN7MC
DMRE0LU	MN	T-cell surface glycoprotein CD3 (CD3)
DMRE0LU	MT	DTT
DMRE0LU	MA	Inhibitor
DMRE0LU	RN	Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals.
DMRE0LU	RU	https://www.regeneron.com/science/pipeline

DM0Y6WU	DI	DM0Y6WU
DM0Y6WU	DN	REGN5678
DM0Y6WU	MI	TT9G4N0
DM0Y6WU	MN	Glutamate carboxypeptidase II (GCPII)
DM0Y6WU	MT	DTT
DM0Y6WU	MA	Inhibitor
DM0Y6WU	RN	Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals.
DM0Y6WU	RU	https://www.regeneron.com/science/pipeline

DM0Y6WU	DI	DM0Y6WU
DM0Y6WU	DN	REGN5678
DM0Y6WU	MI	TTQ13FT
DM0Y6WU	MN	T-cell-specific surface glycoprotein CD28 (CD28)
DM0Y6WU	MT	DTT
DM0Y6WU	MA	Inhibitor
DM0Y6WU	RN	Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals.
DM0Y6WU	RU	https://www.regeneron.com/science/pipeline

DM5MFHO	DI	DM5MFHO
DM5MFHO	DN	REIC gene therapy
DM5MFHO	MI	TTY2ZV6
DM5MFHO	MN	Dickkopf-related protein 3 (DKK3)
DM5MFHO	MT	DTT
DM5MFHO	MA	Modulator
DM5MFHO	RN	Potential of adenovirus-mediated REIC/Dkk-3 gene therapy for use in the treatment of pancreatic cancer. J Gastroenterol Hepatol. 2014 May;29(5):973-83.
DM5MFHO	RU	https://pubmed.ncbi.nlm.nih.gov/24372695

DMDO6J1	DI	DMDO6J1
DMDO6J1	DN	Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs
DMDO6J1	MI	TTJTSX4
DMDO6J1	MN	Glypican-3 (GPC3)
DMDO6J1	MT	DTT
DMDO6J1	MA	CAR-T-Cell-Therapy
DMDO6J1	RN	ClinicalTrials.gov (NCT03084380) Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC)
DMDO6J1	RU	https://clinicaltrials.gov/ct2/show/NCT03084380

DMAGE91	DI	DMAGE91
DMAGE91	DN	RG7800
DMAGE91	MI	TT8QL6X
DMAGE91	MN	Survival motor neuron protein (SMN1)
DMAGE91	MT	DTT
DMAGE91	MA	Modulator
DMAGE91	RN	Assays for the Identification and Prioritization of Drug Candidates for Spinal Muscular Atrophy. Assay Drug Dev Technol. 2014 August 1; 12(6): 315-341.
DMAGE91	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4142828/

DM5AIKR	DI	DM5AIKR
DM5AIKR	DN	RGX-104
DM5AIKR	MI	TTM1EQF
DM5AIKR	MN	Oxysterols receptor LXR (NR1H)
DM5AIKR	MT	DTT
DM5AIKR	MA	Agonist
DM5AIKR	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM5AIKR	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMU3PD7	DI	DMU3PD7
DMU3PD7	DN	RGX-121
DMU3PD7	MI	TTNY2AP
DMU3PD7	MN	Iduronate 2-sulfatase (IDS)
DMU3PD7	MT	DTT
DMU3PD7	MA	Replacement
DMU3PD7	RN	Clinical pipeline report, company report or official report of REGENXBIO.
DMU3PD7	RU	https://www.regenxbio.com/rgx-121/

DMSDZ8U	DI	DMSDZ8U
DMSDZ8U	DN	Rintatolimod
DMSDZ8U	MI	TT1CN09
DMSDZ8U	MN	HUMAN toll-like receptor 3 (TLR3)
DMSDZ8U	MT	DTT
DMSDZ8U	MA	Agonist
DMSDZ8U	RN	Efficacy of rintatolimod in the treatment of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). Expert Rev Clin Pharmacol. 2016 Jun;9(6):755-70.
DMSDZ8U	RU	https://pubmed.ncbi.nlm.nih.gov/27045557

DM9FNC8	DI	DM9FNC8
DM9FNC8	DN	RP-3500
DM9FNC8	MI	TT8ZYBQ
DM9FNC8	MN	Serine/threonine-protein kinase ATR (FRP1)
DM9FNC8	MT	DTT
DM9FNC8	MA	Inhibitor
DM9FNC8	RN	Clinical pipeline report, company report or official report of Repare Therapeutics.
DM9FNC8	RU	https://www.reparerx.com/pipeline/

DMKVMWO	DI	DMKVMWO
DMKVMWO	DN	RP-L201
DMKVMWO	MI	TTIJWR7
DMKVMWO	MN	Integrin beta-2 (ITGB2)
DMKVMWO	MT	DTT
DMKVMWO	MA	Replacement
DMKVMWO	RN	Clinical pipeline report, company report or official report of Rocket Pharmaceuticals.
DMKVMWO	RU	https://rocketpharma.com/our-disease-focus/

DMXYHC7	DI	DMXYHC7
DMXYHC7	DN	RU-101
DMXYHC7	MI	TTFNGC9
DMXYHC7	MN	Serum albumin (ALB)
DMXYHC7	MT	DTT
DMXYHC7	MA	Modulator
DMXYHC7	RN	Albumin as a tear supplement in the treatment of severe dry eye. Br J Ophthalmol. 2003 October; 87(10): 1279-1283.
DMXYHC7	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1920766/

DM1LO8K	DI	DM1LO8K
DM1LO8K	DN	RVX-208
DM1LO8K	MI	TTRA6BO
DM1LO8K	MN	Bromodomain-containing protein 4 (BRD4)
DM1LO8K	MT	DTT
DM1LO8K	MA	Modulator
DM1LO8K	RN	Targeting bromodomains: epigenetic readers of lysine acetylation.Nat Rev Drug Discov.2014 May;13(5):337-56.
DM1LO8K	RU	https://www.ncbi.nlm.nih.gov/pubmed/24751816

DMCBQTF	DI	DMCBQTF
DMCBQTF	DN	S-3304
DMCBQTF	MI	TT1GHVO
DMCBQTF	MN	Matrix metalloproteinase (MMP)
DMCBQTF	MT	DTT
DMCBQTF	MA	Inhibitor
DMCBQTF	RN	Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers. Int J Clin Pharmacol Ther. 2005 Jun;43(6):282-93.
DMCBQTF	RU	https://pubmed.ncbi.nlm.nih.gov/15968885

DMVKQT8	DI	DMVKQT8
DMVKQT8	DN	SALACINOL
DMVKQT8	MI	TTXWASR
DMVKQT8	MN	Intestinal maltase-glucoamylase (MGAM)
DMVKQT8	MT	DTT
DMVKQT8	MA	Inhibitor
DMVKQT8	RN	Probing the active-site requirements of human intestinal N-terminal maltase-glucoamylase: Synthesis and enzyme inhibitory activities of a six-membe... Bioorg Med Chem. 2010 Nov 15;18(22):7794-8.
DMVKQT8	RU	https://pubmed.ncbi.nlm.nih.gov/20970346

DMVKQT8	DI	DMVKQT8
DMVKQT8	DN	SALACINOL
DMVKQT8	MI	TTLPC70
DMVKQT8	MN	Lysosomal alpha-glucosidase (GAA)
DMVKQT8	MT	DTT
DMVKQT8	MA	Inhibitor
DMVKQT8	RN	Alpha-glucosidase inhibitor from Kothala-himbutu (Salacia reticulata WIGHT). J Nat Prod. 2008 Jun;71(6):981-4.
DMVKQT8	RU	https://pubmed.ncbi.nlm.nih.gov/18547114

DMPXOGD	DI	DMPXOGD
DMPXOGD	DN	SAR-161271
DMPXOGD	MI	TTZOPHG
DMPXOGD	MN	Insulin (INS)
DMPXOGD	MT	DTT
DMPXOGD	MA	Modulator
DMPXOGD	RN	Clinical pipeline report, company report or official report of sanofi-aventis.
DMPXOGD	RU	http://en.sanofi.com/img/content/study/TDU10987_summary.pdf

DM6M8O4	DI	DM6M8O4
DM6M8O4	DN	SAR440234
DM6M8O4	MI	TTENHJ0
DM6M8O4	MN	Interleukin 3 receptor alpha (IL3RA)
DM6M8O4	MT	DTT
DM6M8O4	RN	Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.
DM6M8O4	RU	https://pubmed.ncbi.nlm.nih.gov/31175342

DM6M8O4	DI	DM6M8O4
DM6M8O4	DN	SAR440234
DM6M8O4	MI	TTUN7MC
DM6M8O4	MN	T-cell surface glycoprotein CD3 (CD3)
DM6M8O4	MT	DTT
DM6M8O4	RN	Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.
DM6M8O4	RU	https://pubmed.ncbi.nlm.nih.gov/31175342

DMD20YH	DI	DMD20YH
DMD20YH	DN	SAR-650984
DMD20YH	MI	TTPURFN
DMD20YH	MN	Cyclic ADP-ribose hydrolase 1 (CD38)
DMD20YH	MT	DTT
DMD20YH	RN	Clinical pipeline report, company report or official report of Sanofi-Aventis.
DMD20YH	RU	https://www.sanofioncology.com/m/pipeline/SAR650984.aspx

DMA8Z4N	DI	DMA8Z4N
DMA8Z4N	DN	SB-318
DMA8Z4N	MI	TT0IUKX
DMA8Z4N	MN	Alpha-L-iduronidase (IDUA)
DMA8Z4N	MT	DTT
DMA8Z4N	MA	Replacement
DMA8Z4N	RN	ClinicalTrials.gov (NCT02702115) Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I. U.S. National Institutes of Health.
DMA8Z4N	RU	https://clinicaltrials.gov/ct2/show/NCT02702115

DM98YFK	DI	DM98YFK
DM98YFK	DN	SB-913
DM98YFK	MI	TTNY2AP
DM98YFK	MN	Iduronate 2-sulfatase (IDS)
DM98YFK	MT	DTT
DM98YFK	MA	Replacement
DM98YFK	RN	ClinicalTrials.gov (NCT03041324) Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II. U.S. National Institutes of Health.
DM98YFK	RU	https://clinicaltrials.gov/ct2/show/NCT03041324

DMUP52Y	DI	DMUP52Y
DMUP52Y	DN	SB-FIX
DMUP52Y	MI	TTFEZ5Q
DMUP52Y	MN	Coagulation factor IX (F9)
DMUP52Y	MT	DTT
DMUP52Y	MA	Replacement
DMUP52Y	RN	ClinicalTrials.gov (NCT02695160) Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B. U.S. National Institutes of Health.
DMUP52Y	RU	https://clinicaltrials.gov/ct2/show/NCT02695160

DMS1NMO	DI	DMS1NMO
DMS1NMO	DN	SCRI-huCAR19v1
DMS1NMO	MI	TTW640A
DMS1NMO	MN	B-lymphocyte surface antigen B4 (CD19)
DMS1NMO	MT	DTT
DMS1NMO	MA	CAR-T-Cell-Therapy
DMS1NMO	RN	ClinicalTrials.gov (NCT03684889) CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma
DMS1NMO	RU	https://clinicaltrials.gov/ct2/show/NCT03684889

DMBFUOI	DI	DMBFUOI
DMBFUOI	DN	SECTA belomycin
DMBFUOI	MI	TTUTN1I
DMBFUOI	MN	Human Deoxyribonucleic acid (hDNA)
DMBFUOI	MT	DTT
DMBFUOI	MA	Binder
DMBFUOI	RN	Site-specific cleavage of RNA and DNA by complementary DNA--bleomycin A5 conjugates. Bioconjug Chem. 2003 Nov-Dec;14(6):1307-13.
DMBFUOI	RU	https://pubmed.ncbi.nlm.nih.gov/14624648

DMD37Q5	DI	DMD37Q5
DMD37Q5	DN	SEL24
DMD37Q5	MI	TTGJCWZ
DMD37Q5	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMD37Q5	MT	DTT
DMD37Q5	MA	Inhibitor
DMD37Q5	RN	A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia. Oncotarget. 2018 Mar 30;9(24):16917-16931.
DMD37Q5	RU	https://pubmed.ncbi.nlm.nih.gov/29682194

DMD37Q5	DI	DMD37Q5
DMD37Q5	DN	SEL24
DMD37Q5	MI	TTA7WGU
DMD37Q5	MN	Serine/threonine-protein kinase pim (PIM)
DMD37Q5	MT	DTT
DMD37Q5	MA	Inhibitor
DMD37Q5	RN	A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia. Oncotarget. 2018 Mar 30;9(24):16917-16931.
DMD37Q5	RU	https://pubmed.ncbi.nlm.nih.gov/29682194

DMH064K	DI	DMH064K
DMH064K	DN	SEL-24
DMH064K	MI	TTGJCWZ
DMH064K	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMH064K	MT	DTT
DMH064K	MA	Inhibitor
DMH064K	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMH064K	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMH064K	DI	DMH064K
DMH064K	DN	SEL-24
DMH064K	MI	TTTN5QW
DMH064K	MN	Serine/threonine-protein kinase pim-1 (PIM1)
DMH064K	MT	DTT
DMH064K	MA	Inhibitor
DMH064K	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2158).
DMH064K	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2158

DM4NK3J	DI	DM4NK3J
DM4NK3J	DN	SF0166
DM4NK3J	MI	TT69TQN
DM4NK3J	MN	Integrin alpha-V/beta-3 (ITGAV/B3)
DM4NK3J	MT	DTT
DM4NK3J	MA	Antagonist
DM4NK3J	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM4NK3J	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMRC7PI	DI	DMRC7PI
DMRC7PI	DN	SGN-CD33A
DMRC7PI	MI	TTJVYO3
DMRC7PI	MN	Myeloid cell surface antigen CD33 (CD33)
DMRC7PI	MT	DTT
DMRC7PI	RN	SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 2013 Aug 22;122(8):1455-63.
DMRC7PI	RU	https://pubmed.ncbi.nlm.nih.gov/23770776

DMADNY3	DI	DMADNY3
DMADNY3	DN	SHR-1314
DMADNY3	MI	TTG0MT6
DMADNY3	MN	Interleukin-17 (IL17)
DMADNY3	MT	DTT
DMADNY3	MA	Inhibitor
DMADNY3	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMADNY3	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMMUCH0	DI	DMMUCH0
DMMUCH0	DN	SHR2554
DMMUCH0	MI	TT9MZCQ
DMMUCH0	MN	Enhancer of zeste homolog 2 (EZH2)
DMMUCH0	MT	DTT
DMMUCH0	MA	Inhibitor
DMMUCH0	RN	Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021 Apr;20(4):265-286.
DMMUCH0	RU	https://pubmed.ncbi.nlm.nih.gov/33469207

DMZTQD8	DI	DMZTQD8
DMZTQD8	DN	Sirna-027
DMZTQD8	MI	TT1VAUK
DMZTQD8	MN	VEGFR1 messenger RNA (VEGFR1 mRNA)
DMZTQD8	MT	DTT
DMZTQD8	RN	2011 Pipeline of Sirna Therapeutics.
DMZTQD8	RU	http://www.sirna.com/

DMSOX57	DI	DMSOX57
DMSOX57	DN	SJCAR19
DMSOX57	MI	TTW640A
DMSOX57	MN	B-lymphocyte surface antigen B4 (CD19)
DMSOX57	MT	DTT
DMSOX57	MA	CAR-T-Cell-Therapy
DMSOX57	RN	ClinicalTrials.gov (NCT03573700) Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia
DMSOX57	RU	https://clinicaltrials.gov/ct2/show/NCT03573700

DMSTEFK	DI	DMSTEFK
DMSTEFK	DN	SKB264
DMSTEFK	MI	TTP2HE5
DMSTEFK	MN	Tumor associated calcium signal transducer 2 (TACSTD2)
DMSTEFK	MT	DTT
DMSTEFK	RN	ClinicalTrials.gov (NCT04152499) Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (A264). U.S. National Institutes of Health.
DMSTEFK	RU	https://clinicaltrials.gov/ct2/show/NCT04152499

DMOCHVE	DI	DMOCHVE
DMOCHVE	DN	SL-401
DMOCHVE	MI	TTPYS82
DMOCHVE	MN	Interleukin 3 receptor (CSF2RB)
DMOCHVE	MT	DTT
DMOCHVE	MA	Inhibitor
DMOCHVE	RN	Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014 Jul 17;124(3):385-92.
DMOCHVE	RU	https://pubmed.ncbi.nlm.nih.gov/24859366

DMEJT5Z	DI	DMEJT5Z
DMEJT5Z	DN	SN-32793
DMEJT5Z	MI	TTGKNB4
DMEJT5Z	MN	Epidermal growth factor receptor (EGFR)
DMEJT5Z	MT	DTT
DMEJT5Z	MA	Inhibitor
DMEJT5Z	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
DMEJT5Z	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797

DMCGX9Y	DI	DMCGX9Y
DMCGX9Y	DN	SNDX-5613
DMCGX9Y	MI	TT0CZBQ
DMCGX9Y	MN	Menin-MLL1 interaction (MEN1-KMT2A PPI)
DMCGX9Y	MT	DTT
DMCGX9Y	MA	Inhibitor
DMCGX9Y	RN	Clinical pipeline report, company report or official report of Syndax Pharmaceuticals.
DMCGX9Y	RU	https://syndax.com/pipeline/sndx-5613/

DMNV8SY	DI	DMNV8SY
DMNV8SY	DN	SNN-0029
DMNV8SY	MI	TTOHSBA
DMNV8SY	MN	Vascular endothelial growth factor A (VEGFA)
DMNV8SY	MT	DTT
DMNV8SY	MA	Modulator
DMNV8SY	RN	Clinical pipeline report, company report or official report of Neuronova.
DMNV8SY	RU	http://www.neuronova.com/index.php?option=com_content&task=view&id=40&Itemid=71

DM2X3BR	DI	DM2X3BR
DM2X3BR	DN	SNN-0031
DM2X3BR	MI	TTI7421
DM2X3BR	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM2X3BR	MT	DTT
DM2X3BR	MA	Modulator
DM2X3BR	RN	Company report (Neuronova)
DM2X3BR	RU	http://www.neuronova.com/index.php?option=com_content&task=view&id=41

DMIU0VP	DI	DMIU0VP
DMIU0VP	DN	SNX-5422
DMIU0VP	MI	TT78R5H
DMIU0VP	MN	Heat shock protein 90 alpha (HSP90A)
DMIU0VP	MT	DTT
DMIU0VP	MA	Inhibitor
DMIU0VP	RN	SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hema... Blood. 2009 Jan 22;113(4):846-55.
DMIU0VP	RU	https://pubmed.ncbi.nlm.nih.gov/18948577

DMIU0VP	DI	DMIU0VP
DMIU0VP	DN	SNX-5422
DMIU0VP	MI	TTH5YN2
DMIU0VP	MN	Heat shock protein 90 beta (HSP90B)
DMIU0VP	MT	DTT
DMIU0VP	MA	Inhibitor
DMIU0VP	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMIU0VP	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMXNTR7	DI	DMXNTR7
DMXNTR7	DN	SOBI003
DMXNTR7	MI	TTPJ2SH
DMXNTR7	MN	N-sulphoglucosamine sulphohydrolase (SGSH)
DMXNTR7	MT	DTT
DMXNTR7	MA	Replacement
DMXNTR7	RN	Clinical pipeline report, company report or official report of Swedish Orphan Biovitrum.
DMXNTR7	RU	https://www.sobi.com/en/press-releases/fda-accepts-investigational-new-drug-application-and-grants-fast-track-status

DMST6A3	DI	DMST6A3
DMST6A3	DN	Sodium pyruvate
DMST6A3	MI	TTZHA0O
DMST6A3	MN	Carbonic anhydrase IV (CA-IV)
DMST6A3	MT	DTT
DMST6A3	MA	Inhibitor
DMST6A3	RN	Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with carboxylates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):573-8.
DMST6A3	RU	https://pubmed.ncbi.nlm.nih.gov/15664815

DMST6A3	DI	DMST6A3
DMST6A3	DN	Sodium pyruvate
DMST6A3	MI	TTULV0X
DMST6A3	MN	Reactive oxygen species (ROS)
DMST6A3	MT	DTT
DMST6A3	MA	Antagonist
DMST6A3	RN	A molecular mechanism of pyruvate protection against cytotoxicity of reactive oxygen species in osteoblasts. Mol Pharmacol. 2006 Sep;70(3):925-35.
DMST6A3	RU	https://pubmed.ncbi.nlm.nih.gov/16766717

DM3GO0J	DI	DM3GO0J
DM3GO0J	DN	Sodium taurocholate
DM3GO0J	MI	DT7JELC
DM3GO0J	MN	Apical sodium-dependent bile acid transporter (SLC10A2)
DM3GO0J	MT	DTP
DM3GO0J	MA	Substrate
DM3GO0J	RN	Identification of a region of the ileal-type sodium/bile acid cotransporter interacting with a competitive bile acid transport inhibitor. Biochemistry. 2002 Dec 17;41(50):14916-24.
DM3GO0J	RU	http://www.ncbi.nlm.nih.gov/pubmed/12475240

DM3GO0J	DI	DM3GO0J
DM3GO0J	DN	Sodium taurocholate
DM3GO0J	MI	DT9NXMV
DM3GO0J	MN	ATP-binding cassette sub-family A member 8 (ABCA8)
DM3GO0J	MT	DTP
DM3GO0J	MA	Substrate
DM3GO0J	RN	Functional analysis of ABCA8, a new drug transporter. Biochem Biophys Res Commun. 2002 Oct 18;298(1):41-5.
DM3GO0J	RU	http://www.ncbi.nlm.nih.gov/pubmed/12379217

DM3GO0J	DI	DM3GO0J
DM3GO0J	DN	Sodium taurocholate
DM3GO0J	MI	DTJ0EW4
DM3GO0J	MN	Bile salt export pump (ABCB11)
DM3GO0J	MT	DTP
DM3GO0J	MA	Substrate
DM3GO0J	RN	Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin. J Pharmacol Exp Ther. 2005 Aug;314(2):876-82.
DM3GO0J	RU	http://www.ncbi.nlm.nih.gov/pubmed/15901796

DM3GO0J	DI	DM3GO0J
DM3GO0J	DN	Sodium taurocholate
DM3GO0J	MI	TTSDVTR
DM3GO0J	MN	G-protein coupled bile acid receptor 1 (GPBAR1)
DM3GO0J	MT	DTT
DM3GO0J	MA	Modulator
DM3GO0J	RN	Bile acids and sphingosine-1-phosphate receptor 2 in hepatic lipid metabolism.Acta Pharmaceutica Sinica B Volume 5, Issue 2, March 2015, Pages 151-157.
DM3GO0J	RU	http://www.sciencedirect.com/science/article/pii/S2211383514001300

DM3GO0J	DI	DM3GO0J
DM3GO0J	DN	Sodium taurocholate
DM3GO0J	MI	DTFI42L
DM3GO0J	MN	Multidrug resistance-associated protein 2 (ABCC2)
DM3GO0J	MT	DTP
DM3GO0J	MA	Substrate
DM3GO0J	RN	Functional analysis of ABCA8, a new drug transporter. Biochem Biophys Res Commun. 2002 Oct 18;298(1):41-5.
DM3GO0J	RU	http://www.ncbi.nlm.nih.gov/pubmed/12379217

DM3GO0J	DI	DM3GO0J
DM3GO0J	DN	Sodium taurocholate
DM3GO0J	MI	DTQ3ZHF
DM3GO0J	MN	Multidrug resistance-associated protein 3 (ABCC3)
DM3GO0J	MT	DTP
DM3GO0J	MA	Substrate
DM3GO0J	RN	Characterization of the role of polar amino acid residues within predicted transmembrane helix 17 in determining the substrate specificity of multidrug resistance protein 3. Biochemistry. 2003 Aug 26;42(33):9989-10000.
DM3GO0J	RU	http://www.ncbi.nlm.nih.gov/pubmed/12924948

DM3GO0J	DI	DM3GO0J
DM3GO0J	DN	Sodium taurocholate
DM3GO0J	MI	DTE2B1D
DM3GO0J	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DM3GO0J	MT	DTP
DM3GO0J	MA	Substrate
DM3GO0J	RN	Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology. 1995 Oct;109(4):1274-82.
DM3GO0J	RU	http://www.ncbi.nlm.nih.gov/pubmed/7557095

DM3GO0J	DI	DM3GO0J
DM3GO0J	DN	Sodium taurocholate
DM3GO0J	MI	DT3D8F0
DM3GO0J	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM3GO0J	MT	DTP
DM3GO0J	MA	Substrate
DM3GO0J	RN	Regulation of Organic Anion Transporting Polypeptides (OATP) 1B1- and OATP1B3-Mediated Transport: An Updated Review in the Context of OATP-Mediated Drug-Drug Interactions. Int J Mol Sci. 2018 Mar 14;19(3). pii: E855.
DM3GO0J	RU	http://www.ncbi.nlm.nih.gov/pubmed/29538325

DM3GO0J	DI	DM3GO0J
DM3GO0J	DN	Sodium taurocholate
DM3GO0J	MI	DT9C1TS
DM3GO0J	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM3GO0J	MT	DTP
DM3GO0J	MA	Substrate
DM3GO0J	RN	LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99.
DM3GO0J	RU	http://www.ncbi.nlm.nih.gov/pubmed/11375950

DM3GO0J	DI	DM3GO0J
DM3GO0J	DN	Sodium taurocholate
DM3GO0J	MI	DTPFTEQ
DM3GO0J	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DM3GO0J	MT	DTP
DM3GO0J	MA	Substrate
DM3GO0J	RN	Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther. 2004 Feb;308(2):438-45.
DM3GO0J	RU	http://www.ncbi.nlm.nih.gov/pubmed/14610227

DM3GO0J	DI	DM3GO0J
DM3GO0J	DN	Sodium taurocholate
DM3GO0J	MI	DT1V9AJ
DM3GO0J	MN	Organic solute transporter subunit beta (SLC51B)
DM3GO0J	MT	DTP
DM3GO0J	MA	Substrate
DM3GO0J	RN	OSTalpha-OSTbeta: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia. Hepatology. 2005 Dec;42(6):1270-9.
DM3GO0J	RU	http://www.ncbi.nlm.nih.gov/pubmed/16317684

DM3GO0J	DI	DM3GO0J
DM3GO0J	DN	Sodium taurocholate
DM3GO0J	MI	DT56EKP
DM3GO0J	MN	Sodium/taurocholate cotransporting polypeptide (SLC10A1)
DM3GO0J	MT	DTP
DM3GO0J	MA	Substrate
DM3GO0J	RN	Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1)by bosentan: a mechanism for species differences in hepatotoxicity. J Pharmacol Exp Ther. 2007 Jun;321(3):1170-8.
DM3GO0J	RU	http://www.ncbi.nlm.nih.gov/pubmed/17374746

DMEVGI9	DI	DMEVGI9
DMEVGI9	DN	SPK-7001
DMEVGI9	MI	TTOA18V
DMEVGI9	MN	Rab proteins geranylgeranyltransferase component A 1 (CHM)
DMEVGI9	MT	DTT
DMEVGI9	MA	Replacement
DMEVGI9	RN	Clinical pipeline report, company report or official report of Spark Therapeutics.
DMEVGI9	RU	https://sparktx.com/scientific-platform-programs/

DM8K7CN	DI	DM8K7CN
DM8K7CN	DN	SPK-8011
DM8K7CN	MI	TT1290U
DM8K7CN	MN	Coagulation factor VIII (F8)
DM8K7CN	MT	DTT
DM8K7CN	MA	Replacement
DM8K7CN	RN	Clinical pipeline report, company report or official report of Spark Therapeutics.
DM8K7CN	RU	https://sparktx.com/scientific-platform-programs/

DMCP8F3	DI	DMCP8F3
DMCP8F3	DN	SPK-8016
DMCP8F3	MI	TT1290U
DMCP8F3	MN	Coagulation factor VIII (F8)
DMCP8F3	MT	DTT
DMCP8F3	MA	Replacement
DMCP8F3	RN	Clinical pipeline report, company report or official report of Spark Therapeutics.
DMCP8F3	RU	https://sparktx.com/scientific-platform-programs/

DMJDV0K	DI	DMJDV0K
DMJDV0K	DN	SPR720
DMJDV0K	MI	TTS7LWX
DMJDV0K	MN	Bacterial DNA gyrase B (Bact gyrB)
DMJDV0K	MT	DTT
DMJDV0K	MA	Inhibitor
DMJDV0K	RN	Advancement of GyrB Inhibitors for Treatment of Infections Caused by Mycobacterium tuberculosis and Non-tuberculous Mycobacteria. ACS Infect Dis. 2020 Jun 12;6(6):1323-1331.
DMJDV0K	RU	https://pubmed.ncbi.nlm.nih.gov/32183511

DMG8JLC	DI	DMG8JLC
DMG8JLC	DN	SRP-9003
DMG8JLC	MI	TTEDCQ0
DMG8JLC	MN	Beta-sarcoglycan (SGCB)
DMG8JLC	MT	DTT
DMG8JLC	MA	Replacement
DMG8JLC	RN	Clinical pipeline report, company report or official report of Sarepta Therapeutics.
DMG8JLC	RU	https://www.sarepta.com/products-pipeline/pipeline

DMK095Z	DI	DMK095Z
DMK095Z	DN	SRP-9004
DMK095Z	MI	TTS9Q5V
DMK095Z	MN	Sarcoglycan alpha (SGCA)
DMK095Z	MT	DTT
DMK095Z	MA	Replacement
DMK095Z	RN	Clinical pipeline report, company report or official report of Sarepta Therapeutics.
DMK095Z	RU	https://www.sarepta.com/products-pipeline/pipeline

DMBCIXL	DI	DMBCIXL
DMBCIXL	DN	Stamulumab
DMBCIXL	MI	TTSWPH8
DMBCIXL	MN	Growth/differentiation factor 8 (GDF-8)
DMBCIXL	MT	DTT
DMBCIXL	RN	Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Curr Opin Support Palliat Care. 2013 November; 7(4): 352-360.
DMBCIXL	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3819341/

DMX3CNS	DI	DMX3CNS
DMX3CNS	DN	Stargen
DMX3CNS	MI	TTLB52K
DMX3CNS	MN	ATP-binding cassette transporter A4 (ABCA4)
DMX3CNS	MT	DTT
DMX3CNS	MA	Modulator
DMX3CNS	RN	Clinical pipeline report, company report or official report of Oxford BioMedica.
DMX3CNS	RU	http://www.oxfordbiomedica.co.uk/press-releases/oxford-biomedica-announces-positive-dsmb-review-of-ongoing-retinostat-r-and-stargen-clinical-studies/

DMZM6I2	DI	DMZM6I2
DMZM6I2	DN	Sym013
DMZM6I2	MI	TTGKNB4
DMZM6I2	MN	Epidermal growth factor receptor (EGFR)
DMZM6I2	MT	DTT
DMZM6I2	MA	Antagonist
DMZM6I2	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZM6I2	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMZM6I2	DI	DMZM6I2
DMZM6I2	DN	Sym013
DMZM6I2	MI	TT6EO5L
DMZM6I2	MN	Erbb2 tyrosine kinase receptor (HER2)
DMZM6I2	MT	DTT
DMZM6I2	MA	Inhibitor
DMZM6I2	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZM6I2	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMZM6I2	DI	DMZM6I2
DMZM6I2	DN	Sym013
DMZM6I2	MI	TTDC8N2
DMZM6I2	MN	Erbb3 tyrosine kinase receptor (Erbb-3)
DMZM6I2	MT	DTT
DMZM6I2	MA	Inhibitor
DMZM6I2	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZM6I2	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM9B7Z5	DI	DM9B7Z5
DM9B7Z5	DN	Sym015
DM9B7Z5	MI	TTGKNB4
DM9B7Z5	MN	Epidermal growth factor receptor (EGFR)
DM9B7Z5	MT	DTT
DM9B7Z5	MA	Antagonist
DM9B7Z5	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9B7Z5	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM9B7Z5	DI	DM9B7Z5
DM9B7Z5	DN	Sym015
DM9B7Z5	MI	TTNDSF4
DM9B7Z5	MN	Proto-oncogene c-Met (MET)
DM9B7Z5	MT	DTT
DM9B7Z5	MA	Inhibitor
DM9B7Z5	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9B7Z5	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMB2NP8	DI	DMB2NP8
DMB2NP8	DN	T-1249
DMB2NP8	MI	TTG90S6
DMB2NP8	MN	Human immunodeficiency virus Glycoprotein 41 (HIV gp41)
DMB2NP8	MT	DTT
DMB2NP8	MA	Inhibitor
DMB2NP8	RN	HIV entry inhibitors in clinical development. Curr Opin Pharmacol. 2002 Oct;2(5):523-8.
DMB2NP8	RU	https://pubmed.ncbi.nlm.nih.gov/12324253

DMWIH59	DI	DMWIH59
DMWIH59	DN	T2c-003
DMWIH59	MI	TTFBNVI
DMWIH59	MN	Aldose reductase (AKR1B1)
DMWIH59	MT	DTT
DMWIH59	MA	Modulator
DMWIH59	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2768).
DMWIH59	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2768

DM1FY97	DI	DM1FY97
DM1FY97	DN	T3D-959
DM1FY97	MI	TT2JWF6
DM1FY97	MN	Peroxisome proliferator-activated receptor delta (PPARD)
DM1FY97	MT	DTT
DM1FY97	MA	Modulator
DM1FY97	RN	Phrma report (2013 Alzheimers disease)
DM1FY97	RU	http://www.phrma.org/sites/default/files/Alzheimer's%202013.pdf

DM1FY97	DI	DM1FY97
DM1FY97	DN	T3D-959
DM1FY97	MI	TTZMAO3
DM1FY97	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DM1FY97	MT	DTT
DM1FY97	MA	Modulator
DM1FY97	RN	Phrma report (2013 Alzheimers disease)
DM1FY97	RU	http://www.phrma.org/sites/default/files/Alzheimer's%202013.pdf

DMCFSZ5	DI	DMCFSZ5
DMCFSZ5	DN	TAI-GPC3-CART cells
DMCFSZ5	MI	TTJTSX4
DMCFSZ5	MN	Glypican-3 (GPC3)
DMCFSZ5	MT	DTT
DMCFSZ5	MA	CAR-T-Cell-Therapy
DMCFSZ5	RN	ClinicalTrials.gov (NCT02715362) A Study of GPC3 Redirected Autologous T Cells for Advanced HCC
DMCFSZ5	RU	https://clinicaltrials.gov/ct2/show/NCT02715362

DMJSQXT	DI	DMJSQXT
DMJSQXT	DN	TAK-007
DMJSQXT	MI	TTW640A
DMJSQXT	MN	B-lymphocyte surface antigen B4 (CD19)
DMJSQXT	MT	DTT
DMJSQXT	RN	Clinical pipeline report, company report or official report of Takeda.
DMJSQXT	RU	https://www.takeda.com/newsroom/newsreleases/2020/takeda-opens-new-rd-cell-therapy-manufacturing-facility-to--support-expansion-of-next-generation-clinical-programs/

DM1AB4L	DI	DM1AB4L
DM1AB4L	DN	Talotrexin
DM1AB4L	MI	TTVC37M
DM1AB4L	MN	Folate receptor alpha (FOLR1)
DM1AB4L	MT	DTT
DM1AB4L	MA	Antagonist
DM1AB4L	RN	Cancer chemotherapy: targeting folic acid synthesis. Cancer Manag Res. 2010; 2: 293-301.
DM1AB4L	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033035/

DM13AH8	DI	DM13AH8
DM13AH8	DN	TAS-0728
DM13AH8	MI	TT6EO5L
DM13AH8	MN	Erbb2 tyrosine kinase receptor (HER2)
DM13AH8	MT	DTT
DM13AH8	MA	Inhibitor
DM13AH8	RN	TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models. Mol Cancer Ther. 2019 Apr;18(4):733-742.
DM13AH8	RU	https://pubmed.ncbi.nlm.nih.gov/30787176

DM2LZ8F	DI	DM2LZ8F
DM2LZ8F	DN	Taurocholic acid
DM2LZ8F	MI	DT7JELC
DM2LZ8F	MN	Apical sodium-dependent bile acid transporter (SLC10A2)
DM2LZ8F	MT	DTP
DM2LZ8F	MA	Substrate
DM2LZ8F	RN	Identification of a region of the ileal-type sodium/bile acid cotransporter interacting with a competitive bile acid transport inhibitor. Biochemistry. 2002 Dec 17;41(50):14916-24.
DM2LZ8F	RU	http://www.ncbi.nlm.nih.gov/pubmed/12475240

DM2LZ8F	DI	DM2LZ8F
DM2LZ8F	DN	Taurocholic acid
DM2LZ8F	MI	DTJ0EW4
DM2LZ8F	MN	Bile salt export pump (ABCB11)
DM2LZ8F	MT	DTP
DM2LZ8F	MA	Substrate
DM2LZ8F	RN	Inhibition of transport across the hepatocyte canalicular membrane by the antibiotic fusidate. Biochem Pharmacol. 2002 Jul 1;64(1):151-8.
DM2LZ8F	RU	http://www.ncbi.nlm.nih.gov/pubmed/12106615

DM2LZ8F	DI	DM2LZ8F
DM2LZ8F	DN	Taurocholic acid
DM2LZ8F	MI	TTTRNQW
DM2LZ8F	MN	Bile-salt-activated lipase (CEL)
DM2LZ8F	MT	DTT
DM2LZ8F	MA	Inhibitor
DM2LZ8F	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM2LZ8F	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM2LZ8F	DI	DM2LZ8F
DM2LZ8F	DN	Taurocholic acid
DM2LZ8F	MI	DTI7UX6
DM2LZ8F	MN	Breast cancer resistance protein (ABCG2)
DM2LZ8F	MT	DTP
DM2LZ8F	MA	Substrate
DM2LZ8F	RN	Characterization of the role of ABCG2 as a bile acid transporter in liver and placenta. Mol Pharmacol. 2012 Feb;81(2):273-83.
DM2LZ8F	RU	https://doi.org/10.1124/mol.111.075143

DM2LZ8F	DI	DM2LZ8F
DM2LZ8F	DN	Taurocholic acid
DM2LZ8F	MI	TTPI1M5
DM2LZ8F	MN	Ileal sodium/bile acid cotransporter (SLC10A2)
DM2LZ8F	MT	DTT
DM2LZ8F	MA	Modulator
DM2LZ8F	RN	Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter. Am J Physiol. 1998 Jan;274(1 Pt 1):G157-69.
DM2LZ8F	RU	https://pubmed.ncbi.nlm.nih.gov/9458785

DM2LZ8F	DI	DM2LZ8F
DM2LZ8F	DN	Taurocholic acid
DM2LZ8F	MI	DTQ3ZHF
DM2LZ8F	MN	Multidrug resistance-associated protein 3 (ABCC3)
DM2LZ8F	MT	DTP
DM2LZ8F	MA	Substrate
DM2LZ8F	RN	Characterization of the role of polar amino acid residues within predicted transmembrane helix 17 in determining the substrate specificity of multidrug resistance protein 3. Biochemistry. 2003 Aug 26;42(33):9989-10000.
DM2LZ8F	RU	http://www.ncbi.nlm.nih.gov/pubmed/12924948

DM2LZ8F	DI	DM2LZ8F
DM2LZ8F	DN	Taurocholic acid
DM2LZ8F	MI	DTCSGPB
DM2LZ8F	MN	Multidrug resistance-associated protein 4 (ABCC4)
DM2LZ8F	MT	DTP
DM2LZ8F	MA	Substrate
DM2LZ8F	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM2LZ8F	RU	https://doi.org/10.1007/s11095-012-0935-x

DM2LZ8F	DI	DM2LZ8F
DM2LZ8F	DN	Taurocholic acid
DM2LZ8F	MI	DTE2B1D
DM2LZ8F	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DM2LZ8F	MT	DTP
DM2LZ8F	MA	Substrate
DM2LZ8F	RN	Identification of multiple binding sites for substrate transport in bovine organic anion transporting polypeptide 1a2. Drug Metab Dispos. 2013 Mar;41(3):602-7.
DM2LZ8F	RU	http://www.ncbi.nlm.nih.gov/pubmed/23255551

DM2LZ8F	DI	DM2LZ8F
DM2LZ8F	DN	Taurocholic acid
DM2LZ8F	MI	DT3D8F0
DM2LZ8F	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM2LZ8F	MT	DTP
DM2LZ8F	MA	Substrate
DM2LZ8F	RN	Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem. 1999 Jun 11;274(24):17159-63.
DM2LZ8F	RU	http://www.ncbi.nlm.nih.gov/pubmed/10358072

DM2LZ8F	DI	DM2LZ8F
DM2LZ8F	DN	Taurocholic acid
DM2LZ8F	MI	DT9C1TS
DM2LZ8F	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM2LZ8F	MT	DTP
DM2LZ8F	MA	Substrate
DM2LZ8F	RN	Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65.
DM2LZ8F	RU	http://www.ncbi.nlm.nih.gov/pubmed/18321482

DM2LZ8F	DI	DM2LZ8F
DM2LZ8F	DN	Taurocholic acid
DM2LZ8F	MI	DTPFTEQ
DM2LZ8F	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DM2LZ8F	MT	DTP
DM2LZ8F	MA	Substrate
DM2LZ8F	RN	Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther. 2004 Feb;308(2):438-45.
DM2LZ8F	RU	http://www.ncbi.nlm.nih.gov/pubmed/14610227

DM2LZ8F	DI	DM2LZ8F
DM2LZ8F	DN	Taurocholic acid
DM2LZ8F	MI	DT8H2IC
DM2LZ8F	MN	Organic anion transporting polypeptide 4A1 (SLCO4A1)
DM2LZ8F	MT	DTP
DM2LZ8F	MA	Substrate
DM2LZ8F	RN	Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology. 2001 May;142(5):2005-12.
DM2LZ8F	RU	http://www.ncbi.nlm.nih.gov/pubmed/11316767

DM2LZ8F	DI	DM2LZ8F
DM2LZ8F	DN	Taurocholic acid
DM2LZ8F	MI	DTMEQ32
DM2LZ8F	MN	Organic solute transporter subunit alpha (SLC51A)
DM2LZ8F	MT	DTP
DM2LZ8F	MA	Substrate
DM2LZ8F	RN	Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem. 2003 Jul 25;278(30):27473-82.
DM2LZ8F	RU	http://www.ncbi.nlm.nih.gov/pubmed/12719432

DM2LZ8F	DI	DM2LZ8F
DM2LZ8F	DN	Taurocholic acid
DM2LZ8F	MI	DT1V9AJ
DM2LZ8F	MN	Organic solute transporter subunit beta (SLC51B)
DM2LZ8F	MT	DTP
DM2LZ8F	MA	Substrate
DM2LZ8F	RN	Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem. 2003 Jul 25;278(30):27473-82.
DM2LZ8F	RU	http://www.ncbi.nlm.nih.gov/pubmed/12719432

DM2LZ8F	DI	DM2LZ8F
DM2LZ8F	DN	Taurocholic acid
DM2LZ8F	MI	DT56EKP
DM2LZ8F	MN	Sodium/taurocholate cotransporting polypeptide (SLC10A1)
DM2LZ8F	MT	DTP
DM2LZ8F	MA	Substrate
DM2LZ8F	RN	Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity. J Pharmacol Exp Ther. 1999 Dec;291(3):1204-9.
DM2LZ8F	RU	http://www.ncbi.nlm.nih.gov/pubmed/10565843

DM5NICF	DI	DM5NICF
DM5NICF	DN	TBI-1501
DM5NICF	MI	TTW640A
DM5NICF	MN	B-lymphocyte surface antigen B4 (CD19)
DM5NICF	MT	DTT
DM5NICF	MA	CAR-T-Cell-Therapy
DM5NICF	RN	ClinicalTrials.gov (NCT03155191) Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia
DM5NICF	RU	https://clinicaltrials.gov/ct2/show/NCT03155191

DMR65X7	DI	DMR65X7
DMR65X7	DN	TC-110
DMR65X7	MI	TTW640A
DMR65X7	MN	B-lymphocyte surface antigen B4 (CD19)
DMR65X7	MT	DTT
DMR65X7	RN	Clinical pipeline report, company report or official report of TCR2 Therapeutics.
DMR65X7	RU	https://www.tcr2.com/hematological-malignancies#tc110

DM9S5I1	DI	DM9S5I1
DM9S5I1	DN	TC-210
DM9S5I1	MI	TT4RXME
DM9S5I1	MN	Mesothelin (MSLN)
DM9S5I1	MT	DTT
DM9S5I1	RN	Clinical pipeline report, company report or official report of TCR2 Therapeutics.
DM9S5I1	RU	https://www.tcr2.com/solid-tumors#tc210

DMZFIGQ	DI	DMZFIGQ
DMZFIGQ	DN	TG02
DMZFIGQ	MI	TTMBO1Z
DMZFIGQ	MN	Cyclin-dependent kinase (CDK)
DMZFIGQ	MT	DTT
DMZFIGQ	MA	Inhibitor
DMZFIGQ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZFIGQ	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMZFIGQ	DI	DMZFIGQ
DMZFIGQ	DN	TG02
DMZFIGQ	MI	TT7HF4W
DMZFIGQ	MN	Cyclin-dependent kinase 2 (CDK2)
DMZFIGQ	MT	DTT
DMZFIGQ	MA	Modulator
DMZFIGQ	RN	Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab Lett. 2012 Mar;6(1):33-42.
DMZFIGQ	RU	https://pubmed.ncbi.nlm.nih.gov/22372550

DMZFIGQ	DI	DMZFIGQ
DMZFIGQ	DN	TG02
DMZFIGQ	MI	DEJGDUW
DMZFIGQ	MN	Cytochrome P450 1A2 (CYP1A2)
DMZFIGQ	MT	DME
DMZFIGQ	MA	Metabolism
DMZFIGQ	RN	Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab Lett. 2012 Mar;6(1):33-42.
DMZFIGQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22372550

DMZFIGQ	DI	DMZFIGQ
DMZFIGQ	DN	TG02
DMZFIGQ	MI	DE4LYSA
DMZFIGQ	MN	Cytochrome P450 3A4 (CYP3A4)
DMZFIGQ	MT	DME
DMZFIGQ	MA	Metabolism
DMZFIGQ	RN	Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab Lett. 2012 Mar;6(1):33-42.
DMZFIGQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22372550

DMZFIGQ	DI	DMZFIGQ
DMZFIGQ	DN	TG02
DMZFIGQ	MI	TTU8W4S
DMZFIGQ	MN	Protein kinase (PK)
DMZFIGQ	MT	DTT
DMZFIGQ	MA	Inhibitor
DMZFIGQ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZFIGQ	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMON4IL	DI	DMON4IL
DMON4IL	DN	TG100-115
DMON4IL	MI	TTHBTOP
DMON4IL	MN	PI3-kinase gamma (PIK3CG)
DMON4IL	MT	DTT
DMON4IL	MA	Inhibitor
DMON4IL	RN	Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic can... J Pharmacol Exp Ther. 2009 Mar;328(3):758-65.
DMON4IL	RU	https://pubmed.ncbi.nlm.nih.gov/19056934

DMNKLZM	DI	DMNKLZM
DMNKLZM	DN	TgAAG76
DMNKLZM	MI	TTBOH16
DMNKLZM	MN	Retinal pigment epithelium protein (RPE65)
DMNKLZM	MT	DTT
DMNKLZM	MA	Modulator
DMNKLZM	RN	tgAAG76, an adeno-associated virus delivered gene therapy for the potential treatment of vision loss caused by RPE65 gene abnormalities. Curr Opin Mol Ther. 2010 Aug;12(4):471-7.
DMNKLZM	RU	https://pubmed.ncbi.nlm.nih.gov/20677098

DMDJLX7	DI	DMDJLX7
DMDJLX7	DN	Timcodar dimesilate
DMDJLX7	MI	TTFH2RS
DMDJLX7	MN	FK506-binding protein (FKBP)
DMDJLX7	MT	DTT
DMDJLX7	MA	Modulator
DMDJLX7	RN	Analysis of FK506, timcodar (VX-853) and FKBP51 and FKBP52 chaperones in control of glucocorticoid receptor activity and phosphorylation. Pharmacol Res Perspect. 2014 December; 2(6): e00076.
DMDJLX7	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186452/

DM0VXIM	DI	DM0VXIM
DM0VXIM	DN	TJ003234
DM0VXIM	MI	TTPZGYX
DM0VXIM	MN	HUMAN colony-stimulating factor (GM-CSF)
DM0VXIM	MT	DTT
DM0VXIM	MA	Inhibitor
DM0VXIM	RN	The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. J Autoimmun. 2020 Apr 17:102468.
DM0VXIM	RU	https://pubmed.ncbi.nlm.nih.gov/32317220

DMLROMP	DI	DMLROMP
DMLROMP	DN	TKM-PLK1
DMLROMP	MI	TTH4IP0
DMLROMP	MN	PLK1 messenger RNA (PLK1 mRNA)
DMLROMP	MT	DTT
DMLROMP	RN	Clinical pipeline report, company report or official report of Arbutus Biopharma.
DMLROMP	RU	http://arbutusbio.com/portfolio/tkm-plk1.php

DM6AXV9	DI	DM6AXV9
DM6AXV9	DN	TOL-101
DM6AXV9	MI	TT7AKW1
DM6AXV9	MN	T-cell receptor (TCR)
DM6AXV9	MT	DTT
DM6AXV9	RN	First-in-Human Study of the Safety and Efficacy of TOL101 Induction to Prevent Kidney Transplant Rejection. Am J Transplant. 2014 June; 14(6): 1346-1355.
DM6AXV9	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404309/

DMHTG8P	DI	DMHTG8P
DMHTG8P	DN	TP-0903
DMHTG8P	MI	TTZPY6J
DMHTG8P	MN	Tyrosine-protein kinase UFO (AXL)
DMHTG8P	MT	DTT
DMHTG8P	MA	Inhibitor
DMHTG8P	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMHTG8P	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM9FB2T	DI	DM9FB2T
DM9FB2T	DN	TPX-0005
DM9FB2T	MI	TTPMQSO
DM9FB2T	MN	ALK tyrosine kinase receptor (ALK)
DM9FB2T	MT	DTT
DM9FB2T	MA	Inhibitor
DM9FB2T	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9FB2T	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM9FB2T	DI	DM9FB2T
DM9FB2T	DN	TPX-0005
DM9FB2T	MI	TTSZ6Y3
DM9FB2T	MN	Proto-oncogene c-Ros (ROS1)
DM9FB2T	MT	DTT
DM9FB2T	MA	Inhibitor
DM9FB2T	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9FB2T	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM9FB2T	DI	DM9FB2T
DM9FB2T	DN	TPX-0005
DM9FB2T	MI	TTTDVOJ
DM9FB2T	MN	Tropomyosin-related kinase A (TrkA)
DM9FB2T	MT	DTT
DM9FB2T	MA	Inhibitor
DM9FB2T	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9FB2T	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMIVE67	DI	DMIVE67
DMIVE67	DN	TPX-0046
DMIVE67	MI	TT4DXQT
DMIVE67	MN	Proto-oncogene c-Ret (RET)
DMIVE67	MT	DTT
DMIVE67	MA	Inhibitor
DMIVE67	RN	Clinical pipeline report, company report or official report of Turning Point Therapeutics.
DMIVE67	RU	https://tptherapeutics.com/pipeline/tpx-0046/

DMIVE67	DI	DMIVE67
DMIVE67	DN	TPX-0046
DMIVE67	MI	TT6PKBN
DMIVE67	MN	Proto-oncogene c-Src (SRC)
DMIVE67	MT	DTT
DMIVE67	MA	Inhibitor
DMIVE67	RN	Clinical pipeline report, company report or official report of Turning Point Therapeutics.
DMIVE67	RU	https://tptherapeutics.com/pipeline/tpx-0046/

DM8D2LC	DI	DM8D2LC
DM8D2LC	DN	Tractinostat
DM8D2LC	MI	TTBH0VX
DM8D2LC	MN	Histone deacetylase (HDAC)
DM8D2LC	MT	DTT
DM8D2LC	MA	Inhibitor
DM8D2LC	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM8D2LC	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM1ZK4W	DI	DM1ZK4W
DM1ZK4W	DN	TRBC1
DM1ZK4W	MI	TT1DHW2
DM1ZK4W	MN	T-cell receptor beta constant 1 (TRBC1)
DM1ZK4W	MT	DTT
DM1ZK4W	MA	CAR-T-Cell-Therapy
DM1ZK4W	RN	ClinicalTrials.gov (NCT03590574) Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma
DM1ZK4W	RU	https://clinicaltrials.gov/ct2/show/NCT03590574

DMXI8CD	DI	DMXI8CD
DMXI8CD	DN	TRC-253
DMXI8CD	MI	TTKPW01
DMXI8CD	MN	Androgen receptor messenger RNA (AR mRNA)
DMXI8CD	MT	DTT
DMXI8CD	MA	Antagonist
DMXI8CD	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMXI8CD	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DML54PD	DI	DML54PD
DML54PD	DN	TriCAR-T-CD19
DML54PD	MI	TTW640A
DML54PD	MN	B-lymphocyte surface antigen B4 (CD19)
DML54PD	MT	DTT
DML54PD	MA	CAR-T-Cell-Therapy
DML54PD	RN	ClinicalTrials.gov (NCT03497533) Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19
DML54PD	RU	https://clinicaltrials.gov/ct2/show/NCT03497533

DM8IC5H	DI	DM8IC5H
DM8IC5H	DN	Triciribine
DM8IC5H	MI	DE7T5VX
DM8IC5H	MN	Adenosine kinase (ADK)
DM8IC5H	MT	DME
DM8IC5H	MA	Metabolism
DM8IC5H	RN	Phosphorylation of triciribine is necessary for activity against HIV type 1. AIDS Res Hum Retroviruses. 1998 Oct 10;14(15):1315-22.
DM8IC5H	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9788672

DM8IC5H	DI	DM8IC5H
DM8IC5H	DN	Triciribine
DM8IC5H	MI	TT84ETX
DM8IC5H	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM8IC5H	MT	DTT
DM8IC5H	MA	Inhibitor
DM8IC5H	RN	Design, synthesis and antiviral activity of novel 4,5-disubstituted 7-(beta-D-ribofuranosyl)pyrrolo[2,3-d][1,2,3]triazines and the novel 3-amino-5-... J Med Chem. 2005 Jun 2;48(11):3840-51.
DM8IC5H	RU	https://pubmed.ncbi.nlm.nih.gov/15916436

DMBN1XS	DI	DMBN1XS
DMBN1XS	DN	Triciribine prodrug
DMBN1XS	MI	TTWTSCV
DMBN1XS	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DMBN1XS	MT	DTT
DMBN1XS	MA	Inhibitor
DMBN1XS	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479).
DMBN1XS	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1479

DM9IQ4A	DI	DM9IQ4A
DM9IQ4A	DN	TRU-016
DM9IQ4A	MI	TTFCW29
DM9IQ4A	MN	Leukocyte antigen CD37 (CD37)
DM9IQ4A	MT	DTT
DM9IQ4A	MA	Modulator
DM9IQ4A	RN	TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies. Curr Opin Investig Drugs. 2009 Dec;10(12):1383-90.
DM9IQ4A	RU	https://pubmed.ncbi.nlm.nih.gov/19943209

DMQS5DY	DI	DMQS5DY
DMQS5DY	DN	TRX-518
DMQS5DY	MI	TTG6LA7
DMQS5DY	MN	Activation-inducible TNFR family receptor (TNFRSF18)
DMQS5DY	MT	DTT
DMQS5DY	RN	Immuno-oncology moves beyond PD-1. Nat Biotechnol. 2015 Jul;33(7):673-5.
DMQS5DY	RU	https://pubmed.ncbi.nlm.nih.gov/26153987

DMFOR9Y	DI	DMFOR9Y
DMFOR9Y	DN	TSR-011
DMFOR9Y	MI	TTPMQSO
DMFOR9Y	MN	ALK tyrosine kinase receptor (ALK)
DMFOR9Y	MT	DTT
DMFOR9Y	MA	Inhibitor
DMFOR9Y	RN	Treatment of ALK-positive non-small cell lung cancer. Arch Pathol Lab Med. 2012 Oct;136(10):1201-4.
DMFOR9Y	RU	https://pubmed.ncbi.nlm.nih.gov/23020724

DMH9RGV	DI	DMH9RGV
DMH9RGV	DN	TTP-814
DMH9RGV	MI	TTMS7KP
DMH9RGV	MN	Protein-tyrosine phosphatase 1B (PTP1B)
DMH9RGV	MT	DTT
DMH9RGV	MA	Inhibitor
DMH9RGV	RN	Protein tyrosine phosphatase 1B (PTP-1B; PTPN1). SciBX 5(7); doi:10.1038/scibx.2012.176. Feb. 16 2012
DMH9RGV	RU	http://www.nature.com/scibx/journal/v5/n7/full/scibx.2012.176.html

DMRJK26	DI	DMRJK26
DMRJK26	DN	UCART019
DMRJK26	MI	TTW640A
DMRJK26	MN	B-lymphocyte surface antigen B4 (CD19)
DMRJK26	MT	DTT
DMRJK26	MA	CAR-T-Cell-Therapy
DMRJK26	RN	ClinicalTrials.gov (NCT03166878) A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma
DMRJK26	RU	https://clinicaltrials.gov/ct2/show/NCT03166878

DMI0H3B	DI	DMI0H3B
DMI0H3B	DN	UshStat
DMI0H3B	MI	TTNIMDP
DMI0H3B	MN	Myosin-7 (MYH7)
DMI0H3B	MT	DTT
DMI0H3B	MA	Modulator
DMI0H3B	RN	EIAV-based retinal gene therapy in the shaker1 mouse model for usher syndrome type 1B: development of UshStat. PLoS One. 2014 Apr 4;9(4):e94272.
DMI0H3B	RU	https://pubmed.ncbi.nlm.nih.gov/24705452

DM6HPEC	DI	DM6HPEC
DM6HPEC	DN	USL311
DM6HPEC	MI	TTBID49
DM6HPEC	MN	C-X-C chemokine receptor type 4 (CXCR4)
DM6HPEC	MT	DTT
DM6HPEC	MA	Antagonist
DM6HPEC	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM6HPEC	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMPWHU6	DI	DMPWHU6
DMPWHU6	DN	V81444
DMPWHU6	MI	TTM2AOE
DMPWHU6	MN	Adenosine A2a receptor (ADORA2A)
DMPWHU6	MT	DTT
DMPWHU6	MA	Antagonist
DMPWHU6	RN	Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued. CNS Drugs. 2014 May;28(5):455-74.
DMPWHU6	RU	https://pubmed.ncbi.nlm.nih.gov/24687255

DM8A5E0	DI	DM8A5E0
DM8A5E0	DN	Vecabrutinib
DM8A5E0	MI	TTGM6VW
DM8A5E0	MN	Tyrosine-protein kinase BTK (ATK)
DM8A5E0	MT	DTT
DM8A5E0	MA	Inhibitor
DM8A5E0	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM8A5E0	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMAN21O	DI	DMAN21O
DMAN21O	DN	VG-101
DMAN21O	MI	TTOM3J0
DMAN21O	MN	Estrogen receptor beta (ESR2)
DMAN21O	MT	DTT
DMAN21O	MA	Agonist
DMAN21O	RN	Update on alternative therapies for vulvovaginal atrophy. Patient Prefer Adherence. 2011; 5: 533-536.
DMAN21O	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218114/

DMAMIU4	DI	DMAMIU4
DMAMIU4	DN	VIR-201
DMAMIU4	MI	TT93WF5
DMAMIU4	MN	Interferon-gamma (IFNG)
DMAMIU4	MT	DTT
DMAMIU4	MA	Modulator
DMAMIU4	RN	EP patent application no. 17782511, Nucleoside phosphonate conjugates as anti hiv agents.
DMAMIU4	RU	http://www.google.com.ar/patents/EP1778251B1?cl=en

DMN62MP	DI	DMN62MP
DMN62MP	DN	WASP gene therapy
DMN62MP	MI	TTE8T73
DMN62MP	MN	Wiskott-Aldrich syndrome protein (WAS)
DMN62MP	MT	DTT
DMN62MP	MA	Modulator
DMN62MP	RN	ClinicalTrials.gov (NCT01347242) Gene Therapy for Wiskott-Aldrich Syndrome (WAS). U.S. National Institutes of Health.
DMN62MP	RU	https://clinicaltrials.gov/ct2/show/NCT01347242

DMUGHWR	DI	DMUGHWR
DMUGHWR	DN	WP-1066
DMUGHWR	MI	TTKAWRQ
DMUGHWR	MN	JAK-STAT signaling pathway (JAK-STAT pathway)
DMUGHWR	MT	DTT
DMUGHWR	MA	Inhibitor
DMUGHWR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7972).
DMUGHWR	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7972

DMUGHWR	DI	DMUGHWR
DMUGHWR	DN	WP-1066
DMUGHWR	MI	TTH8FZW
DMUGHWR	MN	Signal transducer and activator of transcription 3 (STAT3)
DMUGHWR	MT	DTT
DMUGHWR	MA	Inhibitor
DMUGHWR	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMUGHWR	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM3FIMD	DI	DM3FIMD
DM3FIMD	DN	WT-4869
DM3FIMD	MI	TTZ8UT4
DM3FIMD	MN	Wilms tumor protein (WT1)
DM3FIMD	MT	DTT
DM3FIMD	MA	Modulator
DM3FIMD	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033385)
DM3FIMD	RU	http://adisinsight.springer.com/drugs/800033385

DMRABOS	DI	DMRABOS
DMRABOS	DN	WX-554
DMRABOS	MI	TTROQ37
DMRABOS	MN	MAPK/ERK kinase kinase (MAP3K)
DMRABOS	MT	DTT
DMRABOS	MA	Modulator
DMRABOS	RN	MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013; 6: 27.
DMRABOS	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626705/

DMZ9VCF	DI	DMZ9VCF
DMZ9VCF	DN	X-396
DMZ9VCF	MI	TTPMQSO
DMZ9VCF	MN	ALK tyrosine kinase receptor (ALK)
DMZ9VCF	MT	DTT
DMZ9VCF	MA	Inhibitor
DMZ9VCF	RN	Clinical pipeline report, company report or official report of Xcovery.
DMZ9VCF	RU	http://www.xcovery.com/our-science/alk-inhibitor/

DMU6TG7	DI	DMU6TG7
DMU6TG7	DN	XMT-1592
DMU6TG7	MI	TTQPZTM
DMU6TG7	MN	Sodium/phosphate cotransporter 2B (SLC34A2)
DMU6TG7	MT	DTT
DMU6TG7	RN	Clinical pipeline report, company report or official report of Mersana Therapeutics.
DMU6TG7	RU	https://www.mersana.com/pipeline/xmt-1592/

DM148HX	DI	DM148HX
DM148HX	DN	XToll
DM148HX	MI	TTWYMFE
DM148HX	MN	Mitochondrial 10kDa heat shock protein (HSPE1)
DM148HX	MT	DTT
DM148HX	MA	Modulator
DM148HX	RN	XToll, a recombinant chaperonin 10 as an anti-inflammatory immunomodulator. Curr Opin Investig Drugs. 2008 May;9(5):523-33.
DM148HX	RU	https://pubmed.ncbi.nlm.nih.gov/18465663

DMXSEHF	DI	DMXSEHF
DMXSEHF	DN	Y-39983
DMXSEHF	MI	TTMQO60
DMXSEHF	MN	Rho-associated protein kinase (ROCK)
DMXSEHF	MT	DTT
DMXSEHF	MA	Modulator
DMXSEHF	RN	Effects of Y-39983, a selective Rho-associated protein kinase inhibitor, on blood flow in optic nerve head in rabbits and axonal regeneration of retinal ganglion cells in rats.Curr Eye Res. 2011 Oct;36(10):964-70.
DMXSEHF	RU	https://www.ncbi.nlm.nih.gov/pubmed/21950703

DMIA9JD	DI	DMIA9JD
DMIA9JD	DN	YSCMA
DMIA9JD	MI	TTDIGC1
DMIA9JD	MN	Dipeptidyl peptidase 4 (DPP-4)
DMIA9JD	MT	DTT
DMIA9JD	RN	Establishment of monoclonal anti-human CD26 antibodies suitable for immunostaining of formalin-fixed tissue. Diagn Pathol. 2014 Feb 6;9:30.
DMIA9JD	RU	https://pubmed.ncbi.nlm.nih.gov/24502396

DMMQGPE	DI	DMMQGPE
DMMQGPE	DN	Zenocutuzomab
DMMQGPE	MI	TT6EO5L
DMMQGPE	MN	Erbb2 tyrosine kinase receptor (HER2)
DMMQGPE	MT	DTT
DMMQGPE	MA	Inhibitor
DMMQGPE	RN	Clinical pipeline report, company report or official report of Merus.
DMMQGPE	RU	https://merus.nl/pipeline/

DMMQGPE	DI	DMMQGPE
DMMQGPE	DN	Zenocutuzomab
DMMQGPE	MI	TTDC8N2
DMMQGPE	MN	Erbb3 tyrosine kinase receptor (Erbb-3)
DMMQGPE	MT	DTT
DMMQGPE	MA	Inhibitor
DMMQGPE	RN	Clinical pipeline report, company report or official report of Merus.
DMMQGPE	RU	https://merus.nl/pipeline/

DMDJSOH	DI	DMDJSOH
DMDJSOH	DN	ZK-001
DMDJSOH	MI	TTVB0Q9
DMDJSOH	MN	Platelet glycoprotein Ib alpha (CD42b)
DMDJSOH	MT	DTT
DMDJSOH	MA	Modulator
DMDJSOH	RN	Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis. Thromb Haemost. 2014 Feb;111(2):279-89.
DMDJSOH	RU	https://pubmed.ncbi.nlm.nih.gov/24172860

DMVG4OC	DI	DMVG4OC
DMVG4OC	DN	ZN-c5
DMVG4OC	MI	TTZAYWL
DMVG4OC	MN	Estrogen receptor (ESR)
DMVG4OC	MT	DTT
DMVG4OC	MA	Degrader
DMVG4OC	RN	Clinical pipeline report, company report or official report of Zentalis Pharmaceuticals.
DMVG4OC	RU	https://zentalis.com/our-pipeline/pipeline/

DMLV4U1	DI	DMLV4U1
DMLV4U1	DN	ZN-e4
DMLV4U1	MI	TTGKNB4
DMLV4U1	MN	Epidermal growth factor receptor (EGFR)
DMLV4U1	MT	DTT
DMLV4U1	MA	Inhibitor
DMLV4U1	RN	Clinical pipeline report, company report or official report of Zentalis Pharmaceuticals.
DMLV4U1	RU	https://zentalis.com/our-pipeline/pipeline/

DMPZE2G	DI	DMPZE2G
DMPZE2G	DN	ZPL521
DMPZE2G	MI	TTT1JVS
DMPZE2G	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DMPZE2G	MT	DTT
DMPZE2G	MA	Inhibitor
DMPZE2G	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPZE2G	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM459Q7	DI	DM459Q7
DM459Q7	DN	BMS-833923
DM459Q7	MI	TT8J1S3
DM459Q7	MN	Smoothened homolog (SMO)
DM459Q7	MT	DTT
DM459Q7	MA	Inhibitor
DM459Q7	RN	Clinical pipeline report, company report or official report of Exelixis (2011).
DM459Q7	RU	http://www.exelixis.com/pipeline

DMNCOE1	DI	DMNCOE1
DMNCOE1	DN	FRM-6308
DMNCOE1	MI	TTJW4LU
DMNCOE1	MN	Phosphodiesterase 10A (PDE10)
DMNCOE1	MT	DTT
DMNCOE1	MA	Inhibitor
DMNCOE1	RN	Massive schizophrenia genomics study offers new drug directions. Nat Rev Drug Discov. 2014 Sep;13(9):641-2.
DMNCOE1	RU	https://pubmed.ncbi.nlm.nih.gov/25131831

DMVWYOU	DI	DMVWYOU
DMVWYOU	DN	GGF
DMVWYOU	MI	TTEH395
DMVWYOU	MN	Pro-neuregulin-1 (Pro-NRG1)
DMVWYOU	MT	DTT
DMVWYOU	MA	Modulator
DMVWYOU	RN	Glial growth factor/neuregulin inhibits Schwann cell myelination and induces demyelination. J Cell Biol. 2001 Mar 19;152(6):1289-99.
DMVWYOU	RU	https://pubmed.ncbi.nlm.nih.gov/11257128

DMQGH76	DI	DMQGH76
DMQGH76	DN	S-222611
DMQGH76	MI	TTGKNB4
DMQGH76	MN	Epidermal growth factor receptor (EGFR)
DMQGH76	MT	DTT
DMQGH76	MA	Inhibitor
DMQGH76	RN	Clinical pipeline report, company report or official report of Shionogi (2011).
DMQGH76	RU	http://www.shionogi.co.jp/index_e.html

DMQGH76	DI	DMQGH76
DMQGH76	DN	S-222611
DMQGH76	MI	TT6EO5L
DMQGH76	MN	Erbb2 tyrosine kinase receptor (HER2)
DMQGH76	MT	DTT
DMQGH76	MA	Inhibitor
DMQGH76	RN	Clinical pipeline report, company report or official report of Shionogi (2011).
DMQGH76	RU	http://www.shionogi.co.jp/index_e.html

DMG74BY	DI	DMG74BY
DMG74BY	DN	(-)-3PPP, Maryland
DMG74BY	MI	TTEX248
DMG74BY	MN	Dopamine D2 receptor (D2R)
DMG74BY	MT	DTT
DMG74BY	MA	Agonist
DMG74BY	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMG74BY	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DM1CZSJ	DI	DM1CZSJ
DM1CZSJ	DN	(+)-JQ1
DM1CZSJ	MI	TTE4BSY
DM1CZSJ	MN	Bromodomain and extraterminal domain protein (BET)
DM1CZSJ	MT	DTT
DM1CZSJ	MA	Inhibitor
DM1CZSJ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM1CZSJ	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DM1CZSJ	DI	DM1CZSJ
DM1CZSJ	DN	(+)-JQ1
DM1CZSJ	MI	TT7CPI5
DM1CZSJ	MN	Bromodomain testis-specific protein (BRDT)
DM1CZSJ	MT	DTT
DM1CZSJ	MA	Inhibitor
DM1CZSJ	RN	Small-molecule inhibition of BRDT for male contraception. Cell. 2012 Aug 17;150(4):673-84.
DM1CZSJ	RU	https://pubmed.ncbi.nlm.nih.gov/22901802

DM1CZSJ	DI	DM1CZSJ
DM1CZSJ	DN	(+)-JQ1
DM1CZSJ	MI	TTRA6BO
DM1CZSJ	MN	Bromodomain-containing protein 4 (BRD4)
DM1CZSJ	MT	DTT
DM1CZSJ	MA	Inhibitor
DM1CZSJ	RN	Selective inhibition of BET bromodomains. Nature. 2010 Dec 23;468(7327):1067-73.
DM1CZSJ	RU	https://pubmed.ncbi.nlm.nih.gov/20871596

DMBOXA1	DI	DMBOXA1
DMBOXA1	DN	[3H]fenobam
DMBOXA1	MI	TTHS256
DMBOXA1	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMBOXA1	MT	DTT
DMBOXA1	MA	Modulator (allosteric modulator)
DMBOXA1	RN	Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agon... J Pharmacol Exp Ther. 2005 Nov;315(2):711-21.
DMBOXA1	RU	https://pubmed.ncbi.nlm.nih.gov/16040814

DMSCV02	DI	DMSCV02
DMSCV02	DN	[N-methyl-3H(3)]AZ-10419369
DMSCV02	MI	TTK8CXU
DMSCV02	MN	5-HT 1B receptor (HTR1B)
DMSCV02	MT	DTT
DMSCV02	MA	Antagonist
DMSCV02	RN	5-HT1B and other related serotonergic proteins are altered in APPswe mutation. Neurosci Lett. 2015 May 6;594:137-43.
DMSCV02	RU	https://pubmed.ncbi.nlm.nih.gov/25841787

DMSMRC1	DI	DMSMRC1
DMSMRC1	DN	1069C
DMSMRC1	MI	TTYFKSZ
DMSMRC1	MN	Tubulin beta (TUBB)
DMSMRC1	MT	DTT
DMSMRC1	MA	Modulator
DMSMRC1	RN	Patent WO2005108424 A1.
DMSMRC1	RU	http://www.google.com/patents/WO2005108424A1?cl=en

DM5IPHE	DI	DM5IPHE
DM5IPHE	DN	1192U90
DM5IPHE	MI	TTSQIFT
DM5IPHE	MN	5-HT 1A receptor (HTR1A)
DM5IPHE	MT	DTT
DM5IPHE	MA	Agonist
DM5IPHE	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DM5IPHE	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DM5IPHE	DI	DM5IPHE
DM5IPHE	DN	1192U90
DM5IPHE	MI	TTJQOD7
DM5IPHE	MN	5-HT 2A receptor (HTR2A)
DM5IPHE	MT	DTT
DM5IPHE	MA	Antagonist
DM5IPHE	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DM5IPHE	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DM5IPHE	DI	DM5IPHE
DM5IPHE	DN	1192U90
DM5IPHE	MI	TTEX248
DM5IPHE	MN	Dopamine D2 receptor (D2R)
DM5IPHE	MT	DTT
DM5IPHE	MA	Antagonist
DM5IPHE	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DM5IPHE	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMICUPT	DI	DMICUPT
DMICUPT	DN	11C-6-Me-BTA-1
DMICUPT	MI	TTE4KHA
DMICUPT	MN	Amyloid beta A4 protein (APP)
DMICUPT	MT	DTT
DMICUPT	MA	Modulator
DMICUPT	RN	Radiosynthesis and evaluation of [11C]BTA-1 and [11C]3'-Me-BTA-1 as potential radiotracers for in vivo imaging of beta-amyloid plaques. Nuklearmedizin. 2007;46(6):271-80.
DMICUPT	RU	https://pubmed.ncbi.nlm.nih.gov/18084683

DMYVDXW	DI	DMYVDXW
DMYVDXW	DN	11C-AZD-2184
DMYVDXW	MI	TTE4KHA
DMYVDXW	MN	Amyloid beta A4 protein (APP)
DMYVDXW	MT	DTT
DMYVDXW	MA	Binder
DMYVDXW	RN	Low background and high contrast PET imaging of amyloid-beta with [11C]AZD2995 and [11C]AZD2184 in Alzheimer's disease patients. Eur J Nucl Med Mol Imaging. 2013 April; 40(4): 580-593.
DMYVDXW	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590405/

DMQ0RXA	DI	DMQ0RXA
DMQ0RXA	DN	11C-GSK-215083
DMQ0RXA	MI	TTJS8PY
DMQ0RXA	MN	5-HT 6 receptor (HTR6)
DMQ0RXA	MT	DTT
DMQ0RXA	MA	Antagonist
DMQ0RXA	RN	Radiosynthesis and characterization of 11C-GSK215083 as a PET radioligand for the 5-HT6 receptor. J Nucl Med. 2012 Feb;53(2):295-303.
DMQ0RXA	RU	https://pubmed.ncbi.nlm.nih.gov/22223878

DMCFPX8	DI	DMCFPX8
DMCFPX8	DN	123-Iodine-labeled MFE-23
DMCFPX8	MI	TTY6DTE
DMCFPX8	MN	Carcinoembryonic antigen CEA (CD66e)
DMCFPX8	MT	DTT
DMCFPX8	RN	Crystal structure of the anti-(carcinoembryonic antigen) single-chain Fv antibody MFE-23 and a model for antigen binding based on intermolecular contacts.. Biochem J. 2000 March 1; 346(Pt 2): 519-528.
DMCFPX8	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1220881/

DM5ZC0E	DI	DM5ZC0E
DM5ZC0E	DN	124I-8H9
DM5ZC0E	MI	TT6CQUM
DM5ZC0E	MN	B7 homolog 3 (CD276)
DM5ZC0E	MT	DTT
DM5ZC0E	RN	National Cancer Institute Drug Dictionary (drug id 722029).
DM5ZC0E	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=722029

DMD751X	DI	DMD751X
DMD751X	DN	1614235 + 2330672
DMD751X	MI	TTPI1M5
DMD751X	MN	Ileal sodium/bile acid cotransporter (SLC10A2)
DMD751X	MT	DTT
DMD751X	MA	Modulator
DMD751X	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 960).
DMD751X	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=960

DMD751X	DI	DMD751X
DMD751X	DN	1614235 + 2330672
DMD751X	MI	TT2UE56
DMD751X	MN	Sodium/glucose cotransporter 1 (SGLT1)
DMD751X	MT	DTT
DMD751X	MA	Modulator
DMD751X	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 915).
DMD751X	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=915

DMFG1YA	DI	DMFG1YA
DMFG1YA	DN	177Lu-AMBA
DMFG1YA	MI	TTC1MVT
DMFG1YA	MN	Gastrin-releasing peptide receptor (GRPR)
DMFG1YA	MT	DTT
DMFG1YA	MA	Agonist
DMFG1YA	RN	Multimodality imaging and preclinical evaluation of 177Lu-AMBA for human prostate tumours in a murine model. Anticancer Res. 2010 Oct;30(10):4039-48.
DMFG1YA	RU	https://pubmed.ncbi.nlm.nih.gov/21036718

DMM2V74	DI	DMM2V74
DMM2V74	DN	177Lu-labelled CTT-1403
DMM2V74	MI	TT9G4N0
DMM2V74	MN	Glutamate carboxypeptidase II (GCPII)
DMM2V74	MT	DTT
DMM2V74	RN	Clinical pipeline report, company report or official report of Cancer Targeted Technologies.
DMM2V74	RU	https://www.cancertargetedtechnology.com/pipeline/ctt1403/

DMZ5YMX	DI	DMZ5YMX
DMZ5YMX	DN	18F-FEDAA-1106
DMZ5YMX	MI	TTPTXIN
DMZ5YMX	MN	Translocator protein (TSPO)
DMZ5YMX	MT	DTT
DMZ5YMX	MA	Modulator
DMZ5YMX	RN	Role of peripheral benzodiazepine receptors in mitochondrial, cellular, and cardiac damage induced by oxidative stress and ischemia-reperfusion. J Pharmacol Exp Ther. 2003 Sep;306(3):828-37.
DMZ5YMX	RU	https://pubmed.ncbi.nlm.nih.gov/12928523

DMGE3DY	DI	DMGE3DY
DMGE3DY	DN	18-MC
DMGE3DY	MI	TT35UGH
DMGE3DY	MN	Neuronal acetylcholine receptor alpha-3/beta-4 (CHRNA3/B4)
DMGE3DY	MT	DTT
DMGE3DY	MA	Antagonist
DMGE3DY	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMGE3DY	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMJ1SQY	DI	DMJ1SQY
DMJ1SQY	DN	19-28z T CELLS
DMJ1SQY	MI	TTW640A
DMJ1SQY	MN	B-lymphocyte surface antigen B4 (CD19)
DMJ1SQY	MT	DTT
DMJ1SQY	MA	CAR-T-Cell-Therapy
DMJ1SQY	RN	ClinicalTrials.gov (NCT01840566) High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma
DMJ1SQY	RU	https://clinicaltrials.gov/ct2/show/NCT01840566

DMQ8NTZ	DI	DMQ8NTZ
DMQ8NTZ	DN	192C86
DMQ8NTZ	MI	TTNVEIR
DMQ8NTZ	MN	Prostaglandin D2 receptor (PTGDR)
DMQ8NTZ	MT	DTT
DMQ8NTZ	MA	Modulator
DMQ8NTZ	RN	Prostanoid receptor antagonists: development strategies and therapeutic applications. Br J Pharmacol. 2009 September; 158(1): 104-145.
DMQ8NTZ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2795261/

DMN9MPX	DI	DMN9MPX
DMN9MPX	DN	212Pb-labelled DOTAMTATE
DMN9MPX	MI	TTOMNR9
DMN9MPX	MN	Somatostatin receptor (SSTR)
DMN9MPX	MT	DTT
DMN9MPX	RN	Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608.
DMN9MPX	RU	https://pubmed.ncbi.nlm.nih.gov/32728208

DM2SQBF	DI	DM2SQBF
DM2SQBF	DN	225Ac-labelled aCD33
DM2SQBF	MI	TTJVYO3
DM2SQBF	MN	Myeloid cell surface antigen CD33 (CD33)
DM2SQBF	MT	DTT
DM2SQBF	RN	Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608.
DM2SQBF	RU	https://pubmed.ncbi.nlm.nih.gov/32728208

DM3E2IY	DI	DM3E2IY
DM3E2IY	DN	225Ac-labelled aCD38
DM3E2IY	MI	TTPURFN
DM3E2IY	MN	Cyclic ADP-ribose hydrolase 1 (CD38)
DM3E2IY	MT	DTT
DM3E2IY	RN	Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608.
DM3E2IY	RU	https://pubmed.ncbi.nlm.nih.gov/32728208

DM1ZY6M	DI	DM1ZY6M
DM1ZY6M	DN	227Th-labelled MSLN-TTC
DM1ZY6M	MI	TT4RXME
DM1ZY6M	MN	Mesothelin (MSLN)
DM1ZY6M	MT	DTT
DM1ZY6M	RN	Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers. Clin Cancer Res. 2019 Aug 1;25(15):4723-4734.
DM1ZY6M	RU	https://pubmed.ncbi.nlm.nih.gov/31064781

DM7L45S	DI	DM7L45S
DM7L45S	DN	227Th-labelled PSMA-TTC
DM7L45S	MI	TT9G4N0
DM7L45S	MN	Glutamate carboxypeptidase II (GCPII)
DM7L45S	MT	DTT
DM7L45S	RN	Darolutamide Potentiates the Antitumor Efficacy of a PSMA-targeted Thorium-227 Conjugate by a Dual Mode of Action in Prostate Cancer Models. Clin Cancer Res. 2021 May 25.
DM7L45S	RU	https://pubmed.ncbi.nlm.nih.gov/34035067

DMDFA3E	DI	DMDFA3E
DMDFA3E	DN	349U85.HCL
DMDFA3E	MI	TTZCG4L
DMDFA3E	MN	Phosphodiesterase 3 (PDE3)
DMDFA3E	MT	DTT
DMDFA3E	MA	Modulator
DMDFA3E	RN	Pharmacokinetics and pharmacodynamics of a new cardiotonic vasodilator agent, 349U85, in normal subjects. Clin Pharmacol Ther. 1994 Jan;55(1):55-63.
DMDFA3E	RU	https://pubmed.ncbi.nlm.nih.gov/8299318

DM4Z1CH	DI	DM4Z1CH
DM4Z1CH	DN	4-aminosalicylate sodium
DM4Z1CH	MI	TTK0943
DM4Z1CH	MN	Prostaglandin G/H synthase (COX)
DM4Z1CH	MT	DTT
DM4Z1CH	MA	Modulator
DM4Z1CH	RN	5-aminosalicylic acid mediates expression of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase to suppress colorectal tumorigenesis. Anticancer Res. 2012 Apr;32(4):1193-202.
DM4Z1CH	RU	https://pubmed.ncbi.nlm.nih.gov/22493349

DM8XMPT	DI	DM8XMPT
DM8XMPT	DN	4SC-203
DM8XMPT	MI	TTGJCWZ
DM8XMPT	MN	Fms-like tyrosine kinase 3 (FLT-3)
DM8XMPT	MT	DTT
DM8XMPT	MA	Modulator
DM8XMPT	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM8XMPT	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMG75P3	DI	DMG75P3
DMG75P3	DN	4SC-205
DMG75P3	MI	TTTRP0H
DMG75P3	MN	Kinesin-like protein KIF11 (KIF11)
DMG75P3	MT	DTT
DMG75P3	MA	Inhibitor
DMG75P3	RN	2011 Pipeline of 4SC AG.
DMG75P3	RU	http://www.pharmaceutical-market-research.com/publications/pharmaceutical_companies/4sc_ag_product_pipeline_review.html

DM5RLM4	DI	DM5RLM4
DM5RLM4	DN	4SCAR19 cells
DM5RLM4	MI	TTW640A
DM5RLM4	MN	B-lymphocyte surface antigen B4 (CD19)
DM5RLM4	MT	DTT
DM5RLM4	MA	CAR-T-Cell-Therapy
DM5RLM4	RN	ClinicalTrials.gov (NCT02968472) A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia
DM5RLM4	RU	https://clinicaltrials.gov/ct2/show/NCT02968472

DM0351T	DI	DM0351T
DM0351T	DN	5-FP
DM0351T	MI	TTUTN1I
DM0351T	MN	Human Deoxyribonucleic acid (hDNA)
DM0351T	MT	DTT
DM0351T	MA	Binder
DM0351T	RN	Is the measurement of thymidylate synthase to determine suitability for treatment with 5-fluoropyrimidines ready for prime time. Clin Cancer Res. 2003 Apr;9(4):1235-9.
DM0351T	RU	https://pubmed.ncbi.nlm.nih.gov/12684389

DMOIE05	DI	DMOIE05
DMOIE05	DN	609A
DMOIE05	MI	TTNBFWK
DMOIE05	MN	Programmed cell death protein 1 (PD-1)
DMOIE05	MT	DTT
DMOIE05	MA	Inhibitor
DMOIE05	RN	Clinical pipeline report, company report or official report of 3SBio.
DMOIE05	RU	http://www.3sbio.com/en/news/details.aspx?id=111

DMQ789Z	DI	DMQ789Z
DMQ789Z	DN	8H9
DMQ789Z	MI	TTUCPMY
DMQ789Z	MN	Tenascin (TNC)
DMQ789Z	MT	DTT
DMQ789Z	RN	In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma. Cancer Res. 2004 Feb 15;64(4):1419-24.
DMQ789Z	RU	https://pubmed.ncbi.nlm.nih.gov/14973056

DMJR6TC	DI	DMJR6TC
DMJR6TC	DN	90Y-cG250
DMJR6TC	MI	TT2LVK8
DMJR6TC	MN	Carbonic anhydrase IX (CA-IX)
DMJR6TC	MT	DTT
DMJR6TC	RN	Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma. Int J Mol Sci. 2013 May 29;14(6):11402-23.
DMJR6TC	RU	https://pubmed.ncbi.nlm.nih.gov/23759990

DMJB6E2	DI	DMJB6E2
DMJB6E2	DN	99mTc-MIP-1405
DMJB6E2	MI	TT9G4N0
DMJB6E2	MN	Glutamate carboxypeptidase II (GCPII)
DMJB6E2	MT	DTT
DMJB6E2	MA	Modulator
DMJB6E2	RN	99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer. J Nucl Med. 2013 Aug;54(8):1369-76.
DMJB6E2	RU	https://pubmed.ncbi.nlm.nih.gov/23733925

DMYKPXJ	DI	DMYKPXJ
DMYKPXJ	DN	9cUAB-30
DMYKPXJ	MI	TTH029C
DMYKPXJ	MN	Retinoic acid receptor RXR-gamma (RXRG)
DMYKPXJ	MT	DTT
DMYKPXJ	MA	Modulator
DMYKPXJ	RN	In vitro metabolic characterization, phenotyping, and kinetic studies of 9cUAB30, a retinoid X receptor-specific retinoid. Drug Metab Dispos. 2007 Jul;35(7):1157-64.
DMYKPXJ	RU	https://pubmed.ncbi.nlm.nih.gov/17446266

DMGJ7A4	DI	DMGJ7A4
DMGJ7A4	DN	A/Anhui/05
DMGJ7A4	MI	TTF4CAM
DMGJ7A4	MN	Influenza Hemagglutinin (Influ HA)
DMGJ7A4	MT	DTT
DMGJ7A4	RN	A Human Antibody Recognizing a Conserved Epitope of H5 Hemagglutinin Broadly Neutralizes Highly Pathogenic Avian Influenza H5N1 Viruses. J Virol. 2012 March; 86(6): 2978-2989.
DMGJ7A4	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3302345/

DMRWTFG	DI	DMRWTFG
DMRWTFG	DN	A-337
DMRWTFG	MI	TTUN7MC
DMRWTFG	MN	T-cell surface glycoprotein CD3 (CD3)
DMRWTFG	MT	DTT
DMRWTFG	MA	Inhibitor
DMRWTFG	RN	Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.
DMRWTFG	RU	https://pubmed.ncbi.nlm.nih.gov/31175342

DMRWTFG	DI	DMRWTFG
DMRWTFG	DN	A-337
DMRWTFG	MI	TTZ8WH4
DMRWTFG	MN	Tumor-associated calcium signal transducer 1 (EPCAM)
DMRWTFG	MT	DTT
DMRWTFG	MA	Inhibitor
DMRWTFG	RN	Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.
DMRWTFG	RU	https://pubmed.ncbi.nlm.nih.gov/31175342

DM25CBW	DI	DM25CBW
DM25CBW	DN	A-348441
DM25CBW	MI	TTOZRK6
DM25CBW	MN	Glucocorticoid receptor messenger RNA (GCR mRNA)
DM25CBW	MT	DTT
DM25CBW	MA	Inhibitor
DM25CBW	RN	Synthesis and activity of novel bile-acid conjugated glucocorticoid receptor antagonists. Bioorg Med Chem Lett. 2006 Dec 1;16(23):6086-90.
DM25CBW	RU	https://pubmed.ncbi.nlm.nih.gov/16987661

DMX0JLI	DI	DMX0JLI
DMX0JLI	DN	A-837093
DMX0JLI	MI	TTMVBWH
DMX0JLI	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMX0JLI	MT	DTT
DMX0JLI	MA	Inhibitor
DMX0JLI	RN	Emerging drugs for hepatitis C. Expert Opin Emerg Drugs. 2008 Mar;13(1):1-19.
DMX0JLI	RU	https://pubmed.ncbi.nlm.nih.gov/18321145

DM92RQT	DI	DM92RQT
DM92RQT	DN	AAB-003/PF-05236812
DM92RQT	MI	TTE4KHA
DM92RQT	MN	Amyloid beta A4 protein (APP)
DM92RQT	MT	DTT
DM92RQT	MA	Modulator
DM92RQT	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
DM92RQT	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402

DMG4RK0	DI	DMG4RK0
DMG4RK0	DN	AAD-2004
DMG4RK0	MI	TTYLQ8V
DMG4RK0	MN	Prostaglandin E synthase (PTGES)
DMG4RK0	MT	DTT
DMG4RK0	MA	Inhibitor
DMG4RK0	RN	Concurrent blockade of free radical and microsomal prostaglandin E synthase-1-mediated PGE2 production improves safety and efficacy in a mouse model of amyotrophic lateral sclerosis. J Neurochem. 2012 Sep;122(5):952-61.
DMG4RK0	RU	https://pubmed.ncbi.nlm.nih.gov/22537108

DMIX5HF	DI	DMIX5HF
DMIX5HF	DN	AAV2/8-LSPhGAA
DMIX5HF	MI	TTHCF4J
DMIX5HF	MN	Alpha-glucosidase (GLA)
DMIX5HF	MT	DTT
DMIX5HF	RN	ClinicalTrials.gov (NCT03533673) AAV2/8-LSPhGAA in Late-Onset Pompe Disease. U.S. National Institutes of Health.
DMIX5HF	RU	https://clinicaltrials.gov/ct2/show/NCT03533673

DMIDEKB	DI	DMIDEKB
DMIDEKB	DN	AAV2-hFIX16
DMIDEKB	MI	TTFEZ5Q
DMIDEKB	MN	Coagulation factor IX (F9)
DMIDEKB	MT	DTT
DMIDEKB	MA	Modulator
DMIDEKB	RN	Assessing the potential for AAV vector genotoxicity in a murine model. Correction in: Blood. 2011 June 16; 117(24): 6739.
DMIDEKB	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3069673/

DMBG9HI	DI	DMBG9HI
DMBG9HI	DN	AB023
DMBG9HI	MI	TTJCPUT
DMBG9HI	MN	Coagulation factor XI (F11)
DMBG9HI	MT	DTT
DMBG9HI	MA	Inhibitor
DMBG9HI	RN	Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial. Arterioscler Thromb Vasc Biol. 2019 Apr;39(4):799-809.
DMBG9HI	RU	https://pubmed.ncbi.nlm.nih.gov/30700130

DMGONUE	DI	DMGONUE
DMGONUE	DN	AB680
DMGONUE	MI	TTK0O6Y
DMGONUE	MN	Ecto-5'-nucleotidase (CD73)
DMGONUE	MT	DTT
DMGONUE	MA	Inhibitor
DMGONUE	RN	Discovery of AB680: A Potent and Selective Inhibitor of CD73. J Med Chem. 2020 Oct 22;63(20):11448-11468.
DMGONUE	RU	https://pubmed.ncbi.nlm.nih.gov/32614585

DMYFB10	DI	DMYFB10
DMYFB10	DN	Abaperidone
DMYFB10	MI	TTJQOD7
DMYFB10	MN	5-HT 2A receptor (HTR2A)
DMYFB10	MT	DTT
DMYFB10	MA	Modulator
DMYFB10	RN	7-[3-(1-piperidinyl)propoxy]chromenones as potential atypical antipsychotics. 2. Pharmacological profile of 7-[3-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)-piperidin-1-yl]propoxy]-3-(hydroxymeth yl)chromen -4-one (abaperidone, FI-8602). J Med Chem. 1998 Dec 31;41(27):5402-9.
DMYFB10	RU	https://www.ncbi.nlm.nih.gov/pubmed/9876110

DMYFB10	DI	DMYFB10
DMYFB10	DN	Abaperidone
DMYFB10	MI	TTEX248
DMYFB10	MN	Dopamine D2 receptor (D2R)
DMYFB10	MT	DTT
DMYFB10	MA	Modulator
DMYFB10	RN	7-[3-(1-piperidinyl)propoxy]chromenones as potential atypical antipsychotics. 2. Pharmacological profile of 7-[3-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)-piperidin-1-yl]propoxy]-3-(hydroxymeth yl)chromen -4-one (abaperidone, FI-8602). J Med Chem. 1998 Dec 31;41(27):5402-9.
DMYFB10	RU	https://www.ncbi.nlm.nih.gov/pubmed/9876110

DMIQXDJ	DI	DMIQXDJ
DMIQXDJ	DN	ABBV-151
DMIQXDJ	MI	TTR9XHZ
DMIQXDJ	MN	Transforming growth factor beta 1 (TGFB1)
DMIQXDJ	MT	DTT
DMIQXDJ	MA	Inhibitor
DMIQXDJ	RN	Clinical pipeline report, company report or official report of AbbVie.
DMIQXDJ	RU	https://www.abbvie.com/our-science/pipeline/abbv-151.html

DM71Q69	DI	DM71Q69
DM71Q69	DN	ABBV-184
DM71Q69	MI	TTUN7MC
DM71Q69	MN	T-cell surface glycoprotein CD3 (CD3)
DM71Q69	MT	DTT
DM71Q69	RN	Clinical pipeline report, company report or official report of AbbVie.
DM71Q69	RU	https://www.abbvie.com/our-science/pipeline/abbv-184.html

DMUCF9L	DI	DMUCF9L
DMUCF9L	DN	ABBV-2451
DMUCF9L	MI	TTRLZHP
DMUCF9L	MN	cAMP-dependent chloride channel (CFTR)
DMUCF9L	MT	DTT
DMUCF9L	MA	Modulator
DMUCF9L	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMUCF9L	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMCZI8L	DI	DMCZI8L
DMCZI8L	DN	ABBV-257
DMCZI8L	MI	TTG0MT6
DMCZI8L	MN	Interleukin-17 (IL17)
DMCZI8L	MT	DTT
DMCZI8L	MA	Inhibitor
DMCZI8L	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMCZI8L	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMCZI8L	DI	DMCZI8L
DMCZI8L	DN	ABBV-257
DMCZI8L	MI	TTF8CQI
DMCZI8L	MN	Tumor necrosis factor (TNF)
DMCZI8L	MT	DTT
DMCZI8L	MA	Inhibitor
DMCZI8L	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMCZI8L	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMU6K37	DI	DMU6K37
DMU6K37	DN	ABBV-2737
DMU6K37	MI	TTRLZHP
DMU6K37	MN	cAMP-dependent chloride channel (CFTR)
DMU6K37	MT	DTT
DMU6K37	MA	Modulator
DMU6K37	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMU6K37	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMB01L5	DI	DMB01L5
DMB01L5	DN	ABBV-3067
DMB01L5	MI	TTRLZHP
DMB01L5	MN	cAMP-dependent chloride channel (CFTR)
DMB01L5	MT	DTT
DMB01L5	MA	Modulator
DMB01L5	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMB01L5	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DM49O6Y	DI	DM49O6Y
DM49O6Y	DN	ABBV-323
DM49O6Y	MI	TTN6Y9A
DM49O6Y	MN	CD40L receptor (CD40)
DM49O6Y	MT	DTT
DM49O6Y	MA	Antagonist
DM49O6Y	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM49O6Y	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMQGPRE	DI	DMQGPRE
DMQGPRE	DN	ABBV-399
DMQGPRE	MI	TTNDSF4
DMQGPRE	MN	Proto-oncogene c-Met (MET)
DMQGPRE	MT	DTT
DMQGPRE	MA	Inhibitor
DMQGPRE	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQGPRE	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMPD0KL	DI	DMPD0KL
DMPD0KL	DN	ABBV-428
DMPD0KL	MI	TTIJP3Q
DMPD0KL	MN	TNF related activation protein (CD40LG)
DMPD0KL	MT	DTT
DMPD0KL	MA	Stimulator
DMPD0KL	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPD0KL	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM87SM9	DI	DM87SM9
DM87SM9	DN	ABBV-467
DM87SM9	MI	TTL53M6
DM87SM9	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DM87SM9	MT	DTT
DM87SM9	MA	Inhibitor
DM87SM9	RN	Clinical pipeline report, company report or official report of AbbVie.
DM87SM9	RU	https://www.abbvie.com/our-science/pipeline/abbv-467.html

DM90EO3	DI	DM90EO3
DM90EO3	DN	ABBV-621
DM90EO3	MI	TTA5MS9
DM90EO3	MN	TNF related apoptosis inducing ligand (TNFSF10)
DM90EO3	MT	DTT
DM90EO3	MA	Agonist
DM90EO3	RN	Clinical pipeline report, company report or official report of AbbVie.
DM90EO3	RU	https://www.abbvie.com/our-science/pipeline/abbv-621.html

DMTEA9C	DI	DMTEA9C
DMTEA9C	DN	ABBV-744
DMTEA9C	MI	TTDP48B
DMTEA9C	MN	Bromodomain-containing protein 2 (BRD2)
DMTEA9C	MT	DTT
DMTEA9C	MA	Inhibitor
DMTEA9C	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMTEA9C	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMTEA9C	DI	DMTEA9C
DMTEA9C	DN	ABBV-744
DMTEA9C	MI	TTHE657
DMTEA9C	MN	Bromodomain-containing protein 3 (BRD3)
DMTEA9C	MT	DTT
DMTEA9C	MA	Inhibitor
DMTEA9C	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMTEA9C	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMTEA9C	DI	DMTEA9C
DMTEA9C	DN	ABBV-744
DMTEA9C	MI	TTRA6BO
DMTEA9C	MN	Bromodomain-containing protein 4 (BRD4)
DMTEA9C	MT	DTT
DMTEA9C	MA	Inhibitor
DMTEA9C	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMTEA9C	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMZM0T8	DI	DMZM0T8
DMZM0T8	DN	ABBV-838
DMZM0T8	MI	TT7ILZ1
DMZM0T8	MN	SLAM family member 7 SLAMF7 (CS1)
DMZM0T8	MT	DTT
DMZM0T8	MA	Inhibitor
DMZM0T8	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZM0T8	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMPXDL6	DI	DMPXDL6
DMPXDL6	DN	ABBV-CLS-579
DMPXDL6	MI	TTY8PUS
DMPXDL6	MN	Tyrosine-protein phosphatase non-receptor type 2 (PTPN2)
DMPXDL6	MT	DTT
DMPXDL6	MA	Inhibitor
DMPXDL6	RN	Clinical pipeline report, company report or official report of Calico Life Sciences.
DMPXDL6	RU	https://www.calicolabs.com/press/calico-and-abbvie-share-update-on-early-stage-clinical-programs

DMUSOM9	DI	DMUSOM9
DMUSOM9	DN	ABBV-CX-2029
DMUSOM9	MI	TT8MG4S
DMUSOM9	MN	Transferrin receptor protein 1 (TFRC)
DMUSOM9	MT	DTT
DMUSOM9	RN	Clinical pipeline report, company report or official report of AbbVie.
DMUSOM9	RU	https://www.abbvie.com/our-science/pipeline/abbv-2029.html

DM1KD7U	DI	DM1KD7U
DM1KD7U	DN	ABI-011
DM1KD7U	MI	TTB8Y9K
DM1KD7U	MN	Angiogenesis (AGG)
DM1KD7U	MT	DTT
DM1KD7U	MA	Inhibitor
DM1KD7U	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM1KD7U	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM1KD7U	DI	DM1KD7U
DM1KD7U	DN	ABI-011
DM1KD7U	MI	TTGTQHC
DM1KD7U	MN	DNA topoisomerase I (TOP1)
DM1KD7U	MT	DTT
DM1KD7U	MA	Modulator
DM1KD7U	RN	Company report (Indena)
DM1KD7U	RU	http://cn.indena.com/news/indena-nerviano-medical-sciences-agree-scale-new-high-potency-molecules-4/

DM1KD7U	DI	DM1KD7U
DM1KD7U	DN	ABI-011
DM1KD7U	MI	TT4V2JM
DM1KD7U	MN	Hepatocyte growth factor (HGF)
DM1KD7U	MT	DTT
DM1KD7U	MA	Inhibitor
DM1KD7U	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM1KD7U	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM1KD7U	DI	DM1KD7U
DM1KD7U	DN	ABI-011
DM1KD7U	MI	TTYFKSZ
DM1KD7U	MN	Tubulin beta (TUBB)
DM1KD7U	MT	DTT
DM1KD7U	MA	Modulator
DM1KD7U	RN	Company report (Indena)
DM1KD7U	RU	http://cn.indena.com/news/indena-nerviano-medical-sciences-agree-scale-new-high-potency-molecules-4/

DM1KD7U	DI	DM1KD7U
DM1KD7U	DN	ABI-011
DM1KD7U	MI	TTOHSBA
DM1KD7U	MN	Vascular endothelial growth factor A (VEGFA)
DM1KD7U	MT	DTT
DM1KD7U	MA	Inhibitor
DM1KD7U	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM1KD7U	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM4TN6W	DI	DM4TN6W
DM4TN6W	DN	ABI-H3733
DM4TN6W	MI	TTM42UJ
DM4TN6W	MN	Hepatitis B virus Capsid protein (HBV C)
DM4TN6W	MT	DTT
DM4TN6W	MA	Inhibitor
DM4TN6W	RN	Clinical pipeline report, company report or official report of Assembly Biosciences.
DM4TN6W	RU	https://www.assemblybio.com/pipeline/

DMS1HR3	DI	DMS1HR3
DMS1HR3	DN	ABM-1310
DMS1HR3	MI	TTWCGQT
DMS1HR3	MN	Serine/threonine-protein kinase B-raf (BRAF)
DMS1HR3	MT	DTT
DMS1HR3	MA	Inhibitor
DMS1HR3	RN	Clinical pipeline report, company report or official report of ABM Therapeutics.
DMS1HR3	RU	http://www.abmtx.com/site/development3

DMA4WEO	DI	DMA4WEO
DMA4WEO	DN	ABSK021
DMA4WEO	MI	TT7MRDV
DMA4WEO	MN	Macrophage colony-stimulating factor 1 receptor (CSF1R)
DMA4WEO	MT	DTT
DMA4WEO	MA	Inhibitor
DMA4WEO	RN	Clinical pipeline report, company report or official report of Abbisko Therapeutics.
DMA4WEO	RU	http://www.abbisko.com/page104?_l=en

DMG4H9Y	DI	DMG4H9Y
DMG4H9Y	DN	ABT-072
DMG4H9Y	MI	TTMVBWH
DMG4H9Y	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMG4H9Y	MT	DTT
DMG4H9Y	MA	Inhibitor
DMG4H9Y	RN	Clinical pipeline report, company report or official report of Abbott Laboratories (2011)
DMG4H9Y	RU	http://www.abbott.com/index2.htm

DMJFWPR	DI	DMJFWPR
DMJFWPR	DN	ABT-102
DMJFWPR	MI	TTMI6F5
DMJFWPR	MN	Transient receptor potential cation channel V1 (TRPV1)
DMJFWPR	MT	DTT
DMJFWPR	MA	Blocker
DMJFWPR	RN	Analgesic potential of TRPV1 antagonists. Biochem Pharmacol. 2009 Aug 1;78(3):211-6.
DMJFWPR	RU	https://pubmed.ncbi.nlm.nih.gov/19481638

DM1F50I	DI	DM1F50I
DM1F50I	DN	ABT-110
DM1F50I	MI	TTDN3LF
DM1F50I	MN	Nerve growth factor (NGF)
DM1F50I	MT	DTT
DM1F50I	MA	Modulator
DM1F50I	RN	Fate of novel painkiller mAbs hangs in balance.Nat Biotechnol.2011 Mar;29(3):173-4.
DM1F50I	RU	https://www.ncbi.nlm.nih.gov/pubmed/21389990

DMQ3O1U	DI	DMQ3O1U
DMQ3O1U	DN	ABT-165
DMQ3O1U	MI	TTV23LH
DMQ3O1U	MN	Delta-like protein 4 (DLL4)
DMQ3O1U	MT	DTT
DMQ3O1U	MA	Inhibitor
DMQ3O1U	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQ3O1U	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMQ3O1U	DI	DMQ3O1U
DMQ3O1U	DN	ABT-165
DMQ3O1U	MI	TT9HKJA
DMQ3O1U	MN	Vascular endothelial growth factor (VEGF)
DMQ3O1U	MT	DTT
DMQ3O1U	MA	Inhibitor
DMQ3O1U	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQ3O1U	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMR7OGL	DI	DMR7OGL
DMR7OGL	DN	ABT-239
DMR7OGL	MI	TT9JNIC
DMR7OGL	MN	Histamine H3 receptor (H3R)
DMR7OGL	MT	DTT
DMR7OGL	MA	Antagonist
DMR7OGL	RN	Use of the H3 receptor antagonist radioligand [3H]-A-349821 to reveal in vivo receptor occupancy of cognition enhancing H3 receptor antagonists. Br J Pharmacol. 2009 May;157(1):139-49.
DMR7OGL	RU	https://pubmed.ncbi.nlm.nih.gov/19413577

DM7TOWX	DI	DM7TOWX
DM7TOWX	DN	ABT-333
DM7TOWX	MI	DES5XRU
DM7TOWX	MN	Cytochrome P450 2C8 (CYP2C8)
DM7TOWX	MT	DME
DM7TOWX	MA	Metabolism
DM7TOWX	RN	Metabolism and disposition of hepatitis C polymerase inhibitor dasabuvir in humans. Drug Metab Dispos. 2016 Aug;44(8):1139-47.
DM7TOWX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27179126

DM7TOWX	DI	DM7TOWX
DM7TOWX	DN	ABT-333
DM7TOWX	MI	DECB0K3
DM7TOWX	MN	Cytochrome P450 2D6 (CYP2D6)
DM7TOWX	MT	DME
DM7TOWX	MA	Metabolism
DM7TOWX	RN	Metabolism and disposition of hepatitis C polymerase inhibitor dasabuvir in humans. Drug Metab Dispos. 2016 Aug;44(8):1139-47.
DM7TOWX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27179126

DM7TOWX	DI	DM7TOWX
DM7TOWX	DN	ABT-333
DM7TOWX	MI	DE4LYSA
DM7TOWX	MN	Cytochrome P450 3A4 (CYP3A4)
DM7TOWX	MT	DME
DM7TOWX	MA	Metabolism
DM7TOWX	RN	Metabolism and disposition of hepatitis C polymerase inhibitor dasabuvir in humans. Drug Metab Dispos. 2016 Aug;44(8):1139-47.
DM7TOWX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27179126

DM7TOWX	DI	DM7TOWX
DM7TOWX	DN	ABT-333
DM7TOWX	MI	TTMVBWH
DM7TOWX	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DM7TOWX	MT	DTT
DM7TOWX	MA	Inhibitor
DM7TOWX	RN	Clinical pipeline report, company report or official report of Abbott Laboratories (2011)
DM7TOWX	RU	http://www.abbott.com/index2.htm

DM7TOWX	DI	DM7TOWX
DM7TOWX	DN	ABT-333
DM7TOWX	MI	DTUGYRD
DM7TOWX	MN	P-glycoprotein 1 (ABCB1)
DM7TOWX	MT	DTP
DM7TOWX	MA	Substrate
DM7TOWX	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DM7TOWX	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DMWN7D3	DI	DMWN7D3
DMWN7D3	DN	ABT-354
DMWN7D3	MI	TTJS8PY
DMWN7D3	MN	5-HT 6 receptor (HTR6)
DMWN7D3	MT	DTT
DMWN7D3	MA	Modulator
DMWN7D3	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035134)
DMWN7D3	RU	http://adisinsight.springer.com/drugs/800035134

DM4KPV0	DI	DM4KPV0
DM4KPV0	DN	ABT-413
DM4KPV0	MI	TTS9BDA
DM4KPV0	MN	Spectrin non-erythroid beta chain 1 (SPTBN1)
DM4KPV0	MT	DTT
DM4KPV0	RN	The Discovery of Novel Selective D1 Dopaminergic Agonists: A-68930, A-77636, A-86929, and ABT-413. International Journal of Medicinal Chemistry Volume 2011 (2011), Article ID 424535, Page(8).
DM4KPV0	RU	http://www.hindawi.com/journals/ijmc/2011/424535/

DMVLPRT	DI	DMVLPRT
DMVLPRT	DN	ABT-700
DMVLPRT	MI	TTNDSF4
DMVLPRT	MN	Proto-oncogene c-Met (MET)
DMVLPRT	MT	DTT
DMVLPRT	MA	Modulator
DMVLPRT	RN	J Clin Oncol 32:5s, 2014 (suppl; abstr 2507).
DMVLPRT	RU	http://meetinglibrary.asco.org/content/134301-144

DMFH3JM	DI	DMFH3JM
DMFH3JM	DN	ABT-767
DMFH3JM	MI	TTEBCY8
DMFH3JM	MN	Poly [ADP-ribose] polymerase (PARP)
DMFH3JM	MT	DTT
DMFH3JM	MA	Modulator
DMFH3JM	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMFH3JM	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMB9N4J	DI	DMB9N4J
DMB9N4J	DN	ABT-957
DMB9N4J	MI	TTG5QB7
DMB9N4J	MN	Calpain-2 (CAPN2)
DMB9N4J	MT	DTT
DMB9N4J	MA	Modulator
DMB9N4J	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMB9N4J	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM9SYVJ	DI	DM9SYVJ
DM9SYVJ	DN	ABX-1431
DM9SYVJ	MI	TTZ963I
DM9SYVJ	MN	Monoglyceride lipase (MAGL)
DM9SYVJ	MT	DTT
DM9SYVJ	MA	Inhibitor
DM9SYVJ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9SYVJ	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMS3915	DI	DMS3915
DMS3915	DN	AC 165198
DMS3915	MI	TTUPB12
DMS3915	MN	Measles virus Fusion glycoprotein (MeV F)
DMS3915	MT	DTT
DMS3915	MA	Modulator
DMS3915	RN	WO patent application no. 2013,1306,83, Xten conjugate compositions and methods of making same.
DMS3915	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20130906&CC=WO&NR=2013130683A2&KC=A2

DMB5A63	DI	DMB5A63
DMB5A63	DN	AC0058TA
DMB5A63	MI	TTGM6VW
DMB5A63	MN	Tyrosine-protein kinase BTK (ATK)
DMB5A63	MT	DTT
DMB5A63	MA	Inhibitor
DMB5A63	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMB5A63	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DM36WTQ	DI	DM36WTQ
DM36WTQ	DN	AC-262271
DM36WTQ	MI	TTZ9SOR
DM36WTQ	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DM36WTQ	MT	DTT
DM36WTQ	MA	Agonist
DM36WTQ	RN	Phase I clinical trial of muscarinic agonist (AC-262271) for treating glaucoma. Acadia Pharmaceuticals.
DM36WTQ	RU	http://www.biocentury.com/products/ac-262271

DMPS6U9	DI	DMPS6U9
DMPS6U9	DN	AC430
DMPS6U9	MI	TTRMX3V
DMPS6U9	MN	Janus kinase 2 (JAK-2)
DMPS6U9	MT	DTT
DMPS6U9	MA	Modulator
DMPS6U9	RN	Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.
DMPS6U9	RU	https://pubmed.ncbi.nlm.nih.gov/24818516

DMJ36YH	DI	DMJ36YH
DMJ36YH	DN	ACE-011
DMJ36YH	MI	TTO3HT7
DMJ36YH	MN	Transforming growth factor beta (TGFB)
DMJ36YH	MT	DTT
DMJ36YH	MA	Inhibitor
DMJ36YH	RN	Clinical pipeline report, company report or official report of Acceleron Pharma (2011).
DMJ36YH	RU	http://www.acceleronpharma.com/

DMUBYFM	DI	DMUBYFM
DMUBYFM	DN	ACE-041
DMUBYFM	MI	TTAP4T1
DMUBYFM	MN	Growth/differentiation factor 2 (GDF2)
DMUBYFM	MT	DTT
DMUBYFM	MA	Modulator
DMUBYFM	RN	Company report (Acceleron Pharma)
DMUBYFM	RU	http://www.acceleronpharma.com/products/dalantercept/

DM19UTO	DI	DM19UTO
DM19UTO	DN	Acebilustat
DM19UTO	MI	TTXZEAJ
DM19UTO	MN	Leukotriene A-4 hydrolase (LTA4H)
DM19UTO	MT	DTT
DM19UTO	MA	Inhibitor
DM19UTO	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM19UTO	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMW6X0O	DI	DMW6X0O
DMW6X0O	DN	ACH-2684
DMW6X0O	MI	TTWXB3E
DMW6X0O	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DMW6X0O	MT	DTT
DMW6X0O	MA	Modulator
DMW6X0O	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMW6X0O	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM5SJO9	DI	DM5SJO9
DM5SJO9	DN	ACHN-975
DM5SJO9	MI	TT2D1J6
DM5SJO9	MN	Haemophilus influenzae Acetylglucosamine deacetylase (Hae-influ lpxC)
DM5SJO9	MT	DTT
DM5SJO9	MA	Modulator
DM5SJO9	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM5SJO9	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMKVE8X	DI	DMKVE8X
DMKVE8X	DN	Acriflavine
DMKVE8X	MI	TT5FH9Y
DMKVE8X	MN	Human immunodeficiency virus Integrase (HIV IN)
DMKVE8X	MT	DTT
DMKVE8X	MA	Modulator
DMKVE8X	RN	Why have ten or so nontoxic, retrovirus integrase inhibitors not been made available for AIDS treatment. Biomed Pharmacother. 1999 Dec;53(10):484-6.
DMKVE8X	RU	https://pubmed.ncbi.nlm.nih.gov/10665342

DMOZ3AT	DI	DMOZ3AT
DMOZ3AT	DN	ACT-178882
DMOZ3AT	MI	TTB2MXP
DMOZ3AT	MN	Angiotensinogenase renin (REN)
DMOZ3AT	MT	DTT
DMOZ3AT	MA	Inhibitor
DMOZ3AT	RN	Drug-drug interaction study of ACT-178882, a new renin inhibitor, and diltiazem in healthy subjects. Clin Drug Investig. 2013 Mar;33(3):207-13.
DMOZ3AT	RU	https://pubmed.ncbi.nlm.nih.gov/23381958

DM5KMYQ	DI	DM5KMYQ
DM5KMYQ	DN	Actimab-M
DM5KMYQ	MI	TTJVYO3
DM5KMYQ	MN	Myeloid cell surface antigen CD33 (CD33)
DM5KMYQ	MT	DTT
DM5KMYQ	MA	Inhibitor
DM5KMYQ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM5KMYQ	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMRDY0G	DI	DMRDY0G
DMRDY0G	DN	ACV-1
DMRDY0G	MI	TTJ49OM
DMRDY0G	MN	Neuronal acetylcholine receptor alpha-10 (CHRNA10)
DMRDY0G	MT	DTT
DMRDY0G	MA	Modulator
DMRDY0G	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMRDY0G	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM8VQ1S	DI	DM8VQ1S
DM8VQ1S	DN	AD-337
DM8VQ1S	MI	TT3ROYC
DM8VQ1S	MN	Serotonin transporter (SERT)
DM8VQ1S	MT	DTT
DM8VQ1S	MA	Modulator
DM8VQ1S	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM8VQ1S	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMG82ZA	DI	DMG82ZA
DMG82ZA	DN	Ad35-GRIN/ENV
DMG82ZA	MI	TTEC2T3
DMG82ZA	MN	Human immunodeficiency virus Envelope glycoprotein gp160 (HIV env)
DMG82ZA	MT	DTT
DMG82ZA	RN	A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936.
DMG82ZA	RU	https://pubmed.ncbi.nlm.nih.gov/22870265

DMG82ZA	DI	DMG82ZA
DMG82ZA	DN	Ad35-GRIN/ENV
DMG82ZA	MI	TTFGZB6
DMG82ZA	MN	Human immunodeficiency virus GAG protein (HIV gag)
DMG82ZA	MT	DTT
DMG82ZA	RN	A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936.
DMG82ZA	RU	https://pubmed.ncbi.nlm.nih.gov/22870265

DMG82ZA	DI	DMG82ZA
DMG82ZA	DN	Ad35-GRIN/ENV
DMG82ZA	MI	TT4NXYM
DMG82ZA	MN	Human immunodeficiency virus Negative factor (HIV nef)
DMG82ZA	MT	DTT
DMG82ZA	RN	A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936.
DMG82ZA	RU	https://pubmed.ncbi.nlm.nih.gov/22870265

DMG82ZA	DI	DMG82ZA
DMG82ZA	DN	Ad35-GRIN/ENV
DMG82ZA	MI	TTF7I5O
DMG82ZA	MN	Human immunodeficiency virus Rev protein (HIV rev)
DMG82ZA	MT	DTT
DMG82ZA	RN	A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936.
DMG82ZA	RU	https://pubmed.ncbi.nlm.nih.gov/22870265

DMG82ZA	DI	DMG82ZA
DMG82ZA	DN	Ad35-GRIN/ENV
DMG82ZA	MI	TT84ETX
DMG82ZA	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMG82ZA	MT	DTT
DMG82ZA	RN	A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936.
DMG82ZA	RU	https://pubmed.ncbi.nlm.nih.gov/22870265

DMFTGHX	DI	DMFTGHX
DMFTGHX	DN	Ad5CMV-NIS
DMFTGHX	MI	TTW7HI9
DMFTGHX	MN	Sodium/iodide cotransporter (SLC5A5)
DMFTGHX	MT	DTT
DMFTGHX	MA	Modulator
DMFTGHX	RN	Noninvasive Imaging and Radiovirotherapy of Prostate Cancer Using an Oncolytic Measles Virus Expressing the Sodium Iodide Symporter. Mol Ther. 2009 December; 17(12): 2041-2048.
DMFTGHX	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2810133/

DMMBQV3	DI	DMMBQV3
DMMBQV3	DN	Ad5-ENVA-48
DMMBQV3	MI	TTEC2T3
DMMBQV3	MN	Human immunodeficiency virus Envelope glycoprotein gp160 (HIV env)
DMMBQV3	MT	DTT
DMMBQV3	RN	ClinicalTrials.gov (NCT00695877) Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults. U.S. National Institutes of Health.
DMMBQV3	RU	https://clinicaltrials.gov/ct2/show/NCT00695877

DM2UMGE	DI	DM2UMGE
DM2UMGE	DN	Ad5-TRAIL
DM2UMGE	MI	TTA5MS9
DM2UMGE	MN	TNF related apoptosis inducing ligand (TNFSF10)
DM2UMGE	MT	DTT
DM2UMGE	MA	Modulator
DM2UMGE	RN	Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors. Cancer Gene Ther. 2006 Jun;13(6):628-32.
DM2UMGE	RU	https://pubmed.ncbi.nlm.nih.gov/16456549

DM16QSG	DI	DM16QSG
DM16QSG	DN	Adaphostin
DM16QSG	MI	TTS7G69
DM16QSG	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DM16QSG	MT	DTT
DM16QSG	MA	Inhibitor
DM16QSG	RN	Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood. 2002 Jan 15;99(2):664-71.
DM16QSG	RU	https://pubmed.ncbi.nlm.nih.gov/11781252

DM59EUY	DI	DM59EUY
DM59EUY	DN	ADCI
DM59EUY	MI	TT9IK2Z
DM59EUY	MN	N-methyl-D-aspartate receptor (NMDAR)
DM59EUY	MT	DTT
DM59EUY	MA	Modulator
DM59EUY	RN	The anticonvulsant SGB-017 (ADCI) blocks voltage-gated sodium channels in rat and human neurons: comparison with carbamazepine. Epilepsia. 2000 Mar;41(3):263-70.
DM59EUY	RU	https://pubmed.ncbi.nlm.nih.gov/10714396

DM59EUY	DI	DM59EUY
DM59EUY	DN	ADCI
DM59EUY	MI	TTRK8B9
DM59EUY	MN	Sodium channel unspecific (NaC)
DM59EUY	MT	DTT
DM59EUY	MA	Modulator
DM59EUY	RN	The anticonvulsant SGB-017 (ADCI) blocks voltage-gated sodium channels in rat and human neurons: comparison with carbamazepine. Epilepsia. 2000 Mar;41(3):263-70.
DM59EUY	RU	https://pubmed.ncbi.nlm.nih.gov/10714396

DMEXT97	DI	DMEXT97
DMEXT97	DN	ADG116
DMEXT97	MI	TTI2S1D
DMEXT97	MN	Cytotoxic T-lymphocyte protein 4 (CTLA-4)
DMEXT97	MT	DTT
DMEXT97	MA	Inhibitor
DMEXT97	RN	Clinical pipeline report, company report or official report of Adagene.
DMEXT97	RU	https://www.adagene.com/pipeline/adg116/

DMM45P9	DI	DMM45P9
DMM45P9	DN	Ad-IFN-alpha
DMM45P9	MI	TT95SOA
DMM45P9	MN	Interferon alpha (IFNA)
DMM45P9	MT	DTT
DMM45P9	MA	Modulator
DMM45P9	RN	2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
DMM45P9	RU	https://pubmed.ncbi.nlm.nih.gov/18246607

DMQVEZB	DI	DMQVEZB
DMQVEZB	DN	Adjustable basal insulin
DMQVEZB	MI	TTZOPHG
DMQVEZB	MN	Insulin (INS)
DMQVEZB	MT	DTT
DMQVEZB	MA	Modulator
DMQVEZB	RN	The future of basal insulin supplementation. Diabetes Technol Ther. 2011 Jun;13 Suppl 1:S103-8.
DMQVEZB	RU	https://pubmed.ncbi.nlm.nih.gov/21568722

DM9GLHO	DI	DM9GLHO
DM9GLHO	DN	Ad-OC-hsvTK/valacyclovir
DM9GLHO	MI	TTP3QRF
DM9GLHO	MN	Thymidine kinase 1 (TK1)
DM9GLHO	MT	DTT
DM9GLHO	MA	Inhibitor
DM9GLHO	RN	Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther. 2003 Feb 10;14(3):227-41.
DM9GLHO	RU	https://pubmed.ncbi.nlm.nih.gov/12639303

DMS6DPF	DI	DMS6DPF
DMS6DPF	DN	ADPT01
DMS6DPF	MI	TTNVXAW
DMS6DPF	MN	Lymphocyte activation gene 3 protein (LAG3)
DMS6DPF	MT	DTT
DMS6DPF	MA	Inhibitor
DMS6DPF	RN	Clinical pipeline report, company report or official report of Novartis.
DMS6DPF	RU	https://www.novartis.com/our-science/novartis-global-pipeline?search_api_views_fulltext=ADPT01&field_pipeline_filing_date=All

DMS6DPF	DI	DMS6DPF
DMS6DPF	DN	ADPT01
DMS6DPF	MI	TTNBFWK
DMS6DPF	MN	Programmed cell death protein 1 (PD-1)
DMS6DPF	MT	DTT
DMS6DPF	MA	Inhibitor
DMS6DPF	RN	Clinical pipeline report, company report or official report of Novartis.
DMS6DPF	RU	https://www.novartis.com/our-science/novartis-global-pipeline?search_api_views_fulltext=ADPT01&field_pipeline_filing_date=All

DM6NUCA	DI	DM6NUCA
DM6NUCA	DN	ADR-851
DM6NUCA	MI	TTNXLKE
DM6NUCA	MN	5-HT 3 receptor (5HT3R)
DM6NUCA	MT	DTT
DM6NUCA	MA	Modulator
DM6NUCA	RN	Analgesic effects of S and R isomers of the novel 5-HT3 receptor antagonists ADR-851 and ADR-882 in rats. Eur J Pharmacol. 1991 Oct 29;204(1):117-9.
DM6NUCA	RU	https://pubmed.ncbi.nlm.nih.gov/1804661

DMYHIAR	DI	DMYHIAR
DMYHIAR	DN	AdRTVP-1
DMYHIAR	MI	TTEQF1O
DMYHIAR	MN	Glioma pathogenesis-related protein 1 (GLIPR1)
DMYHIAR	MT	DTT
DMYHIAR	MA	Modulator
DMYHIAR	RN	Adenoviral vector-mediated RTVP-1 gene-modified tumor cell-based vaccine suppresses the development of experimental prostate cancer. Cancer Gene Ther. 2006 Jul;13(7):658-63.
DMYHIAR	RU	https://pubmed.ncbi.nlm.nih.gov/16485011

DMHIPF5	DI	DMHIPF5
DMHIPF5	DN	ADV-1002401
DMHIPF5	MI	TTDLNGZ
DMHIPF5	MN	Glucokinase (GCK)
DMHIPF5	MT	DTT
DMHIPF5	MA	Inhibitor
DMHIPF5	RN	The Hepatoselective Glucokinase Activator PF-04991532 Ameliorates Hyperglycemia without Causing Hepatic Steatosis in Diabetic Rats. PLoS One. 2014; 9(5): e97139.
DMHIPF5	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4032240/

DMH8Z9W	DI	DMH8Z9W
DMH8Z9W	DN	ADVAX
DMH8Z9W	MI	TTRPO9Z
DMH8Z9W	MN	TNF-alpha signaling pathway (TNFA pathway)
DMH8Z9W	MT	DTT
DMH8Z9W	MA	Modulator
DMH8Z9W	RN	Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine. PLoS One. 2010 Jan 25;5(1):e8617.
DMH8Z9W	RU	https://pubmed.ncbi.nlm.nih.gov/20111582

DMBUOX4	DI	DMBUOX4
DMBUOX4	DN	ADX71149
DMBUOX4	MI	TTXJ47W
DMBUOX4	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMBUOX4	MT	DTT
DMBUOX4	MA	Modulator
DMBUOX4	RN	MGlu2 receptor-mediated modulation of conditioned avoidance behavior in rats. European journal of pharmacology. 01/2014; 727(1).
DMBUOX4	RU	http://www.researchgate.net/publication/260023632_MGlu2_receptor-mediated_modulation_of_conditioned_avoidance_behavior_in_rats

DM7X2HK	DI	DM7X2HK
DM7X2HK	DN	AE-08
DM7X2HK	MI	TT8MK59
DM7X2HK	MN	Melanocytes lineage-specific antigen GP100 (PMEL)
DM7X2HK	MT	DTT
DM7X2HK	RN	Synthesis of labeled BCX-4208, a potent inhibitor of purine nucleoside phosphorylase. Drug Test Anal. 2009 Mar;1(3):125-7.
DM7X2HK	RU	https://pubmed.ncbi.nlm.nih.gov/20355185

DMQRKXP	DI	DMQRKXP
DMQRKXP	DN	AEA-35p
DMQRKXP	MI	TTYA75N
DMQRKXP	MN	MHC class II antigen DR (HLA-DR)
DMQRKXP	MT	DTT
DMQRKXP	RN	WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.
DMQRKXP	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20131212&CC=WO&NR=2013185032A1&KC=A1

DM8I4G0	DI	DM8I4G0
DM8I4G0	DN	AEB701
DM8I4G0	MI	TTYVX59
DM8I4G0	MN	Protein kinase C (PRKC)
DM8I4G0	MT	DTT
DM8I4G0	MA	Inhibitor
DM8I4G0	RN	Changes in Serum Cytokine Profile after AEB071 (Sotrastaurin) or Tacrolimus versus Their Combinations in Rat Heterotopic Cardiac Allografts. J Korean Soc Transplant. 2012 Dec;26(4):248-253.
DM8I4G0	RU	http://synapse.koreamed.org/DOIx.php?id=10.4285/jkstn.2012.26.4.248

DMQF982	DI	DMQF982
DMQF982	DN	AEW-541
DMQF982	MI	TTCBFJO
DMQF982	MN	Insulin receptor (INSR)
DMQF982	MT	DTT
DMQF982	MA	Inhibitor
DMQF982	RN	Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach. J Med Chem. 2009 Aug 27;52(16):4981-5004.
DMQF982	RU	https://pubmed.ncbi.nlm.nih.gov/19610618

DMQF982	DI	DMQF982
DMQF982	DN	AEW-541
DMQF982	MI	TTHRID2
DMQF982	MN	Insulin-like growth factor I receptor (IGF1R)
DMQF982	MT	DTT
DMQF982	MA	Inhibitor
DMQF982	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMQF982	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DM8LG2I	DI	DM8LG2I
DM8LG2I	DN	AF-130
DM8LG2I	MI	TT2THBD
DM8LG2I	MN	P2X purinoceptor 3 (P2RX3)
DM8LG2I	MT	DTT
DM8LG2I	MA	Antagonist
DM8LG2I	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM8LG2I	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMNF3GW	DI	DMNF3GW
DMNF3GW	DN	Afeletecan
DMNF3GW	MI	TTGTQHC
DMNF3GW	MN	DNA topoisomerase I (TOP1)
DMNF3GW	MT	DTT
DMNF3GW	MA	Inhibitor
DMNF3GW	RN	The fate of camptothecin glycoconjugate: report of a clinical hold during a phase II study of BAY 56-3722 (formerly BAY 38-3441), in patients with recurrent or metastatic colorectal cancer resistant/refractory to irinotecan. Invest New Drugs. 2012 June; 30(3): 1208-1210.
DMNF3GW	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3348469/

DM0I8RZ	DI	DM0I8RZ
DM0I8RZ	DN	Affitope AD-01
DM0I8RZ	MI	TTE4KHA
DM0I8RZ	MN	Amyloid beta A4 protein (APP)
DM0I8RZ	MT	DTT
DM0I8RZ	RN	Alzheimer's Disease and the Amyloid Cascade Hypothesis: A Critical Review. Int J Alzheimers Dis. 2012; 2012: 369808.
DM0I8RZ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3313573/

DMIFJZD	DI	DMIFJZD
DMIFJZD	DN	AFM11
DMIFJZD	MI	TTW640A
DMIFJZD	MN	B-lymphocyte surface antigen B4 (CD19)
DMIFJZD	MT	DTT
DMIFJZD	MA	Inhibitor
DMIFJZD	RN	A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells. MAbs. 2015;7(3):584-604.
DMIFJZD	RU	https://pubmed.ncbi.nlm.nih.gov/25875246

DMIFJZD	DI	DMIFJZD
DMIFJZD	DN	AFM11
DMIFJZD	MI	TTUN7MC
DMIFJZD	MN	T-cell surface glycoprotein CD3 (CD3)
DMIFJZD	MT	DTT
DMIFJZD	MA	Inhibitor
DMIFJZD	RN	A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells. MAbs. 2015;7(3):584-604.
DMIFJZD	RU	https://pubmed.ncbi.nlm.nih.gov/25875246

DMSX24U	DI	DMSX24U
DMSX24U	DN	AFO-18
DMSX24U	MI	TT3J5ZI
DMSX24U	MN	Cell mediated immunity response (CMIR)
DMSX24U	MT	DTT
DMSX24U	RN	ClinicalTrials.gov (NCT01009762) Immunization With HIV-1 Peptides in Adjuvant for Treatment of Patients With Chronic HIV-infection. U.S. National Institutes of Health.
DMSX24U	RU	https://clinicaltrials.gov/ct2/show/NCT01009762

DMHBUMZ	DI	DMHBUMZ
DMHBUMZ	DN	AFP TCR
DMHBUMZ	MI	TT7AKW1
DMHBUMZ	MN	T-cell receptor (TCR)
DMHBUMZ	MT	DTT
DMHBUMZ	MA	Immunomodulator
DMHBUMZ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMHBUMZ	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMY4WVK	DI	DMY4WVK
DMY4WVK	DN	AG-024322
DMY4WVK	MI	TTH6V3D
DMY4WVK	MN	Cyclin-dependent kinase 1 (CDK1)
DMY4WVK	MT	DTT
DMY4WVK	MA	Inhibitor
DMY4WVK	RN	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
DMY4WVK	RU	https://pubmed.ncbi.nlm.nih.gov/19568282

DMY4WVK	DI	DMY4WVK
DMY4WVK	DN	AG-024322
DMY4WVK	MI	TT7HF4W
DMY4WVK	MN	Cyclin-dependent kinase 2 (CDK2)
DMY4WVK	MT	DTT
DMY4WVK	MA	Inhibitor
DMY4WVK	RN	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
DMY4WVK	RU	https://pubmed.ncbi.nlm.nih.gov/19568282

DMY4WVK	DI	DMY4WVK
DMY4WVK	DN	AG-024322
DMY4WVK	MI	TT0PG8F
DMY4WVK	MN	Cyclin-dependent kinase 4 (CDK4)
DMY4WVK	MT	DTT
DMY4WVK	MA	Inhibitor
DMY4WVK	RN	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
DMY4WVK	RU	https://pubmed.ncbi.nlm.nih.gov/19568282

DMFU58V	DI	DMFU58V
DMFU58V	DN	AG2034
DMFU58V	MI	TTCSJBZ
DMFU58V	MN	GAR transformylase (GART)
DMFU58V	MT	DTT
DMFU58V	MA	Modulator
DMFU58V	RN	Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks. Cancer Chemother Pharmacol. 2000;45(5):423-7.
DMFU58V	RU	https://pubmed.ncbi.nlm.nih.gov/10803927

DMYTJG7	DI	DMYTJG7
DMYTJG7	DN	AG-270
DMYTJG7	MI	TTSMPXQ
DMYTJG7	MN	S-adenosylmethionine synthase type-2 (MAT2A)
DMYTJG7	MT	DTT
DMYTJG7	MA	Inhibitor
DMYTJG7	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMYTJG7	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMZTMEJ	DI	DMZTMEJ
DMZTMEJ	DN	AG-270
DMZTMEJ	MI	TTSMPXQ
DMZTMEJ	MN	S-adenosylmethionine synthase type-2 (MAT2A)
DMZTMEJ	MT	DTT
DMZTMEJ	MA	Inhibitor
DMZTMEJ	RN	Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous MTAP Deletion. J Med Chem. 2021 Apr 22;64(8):4430-4449.
DMZTMEJ	RU	https://pubmed.ncbi.nlm.nih.gov/33829783

DM7PLMJ	DI	DM7PLMJ
DM7PLMJ	DN	AG-707
DM7PLMJ	MI	TTHYBIX
DM7PLMJ	MN	Heat shock protein 70 (HSP70)
DM7PLMJ	MT	DTT
DM7PLMJ	MA	Modulator
DM7PLMJ	RN	A heat shock protein based polyvalent vaccine targeting HSV-2: CD4(+) and CD8(+) cellular immunity and protective efficacy. Vaccine. 2011 Nov 3;29(47):8530-41.
DM7PLMJ	RU	https://pubmed.ncbi.nlm.nih.gov/21767588

DMV6JFK	DI	DMV6JFK
DMV6JFK	DN	AGEN1181
DMV6JFK	MI	TTI2S1D
DMV6JFK	MN	Cytotoxic T-lymphocyte protein 4 (CTLA-4)
DMV6JFK	MT	DTT
DMV6JFK	MA	Inhibitor
DMV6JFK	RN	Clinical pipeline report, company report or official report of Agenus.
DMV6JFK	RU	https://agenusbio.com/agen1181-second-generation-anti-ctla-4/

DMAXVZ1	DI	DMAXVZ1
DMAXVZ1	DN	AGEN2373
DMAXVZ1	MI	TTPW9LJ
DMAXVZ1	MN	Co-stimulatory molecule 4-1BB (CD137)
DMAXVZ1	MT	DTT
DMAXVZ1	MA	Activator
DMAXVZ1	RN	Clinical pipeline report, company report or official report of Agenus.
DMAXVZ1	RU	https://agenusbio.com/agen2373-alpha-cd137/

DMVMIBY	DI	DMVMIBY
DMVMIBY	DN	AGG-523
DMVMIBY	MI	TTXSU2Y
DMVMIBY	MN	Aggrecanase (ADAMTS5)
DMVMIBY	MT	DTT
DMVMIBY	MA	Inhibitor
DMVMIBY	RN	Elevated aggrecanase activity in a rat model of joint injury is attenuated by an aggrecanase specific inhibitor. Osteoarthritis Cartilage. 2011 Mar;19(3):315-23.
DMVMIBY	RU	https://pubmed.ncbi.nlm.nih.gov/21163358

DMVHPOX	DI	DMVHPOX
DMVHPOX	DN	AGN-242266
DMVHPOX	MI	TTS4UGC
DMVHPOX	MN	Farnesoid X-activated receptor (FXR)
DMVHPOX	MT	DTT
DMVHPOX	MA	Agonist
DMVHPOX	RN	Clinical pipeline report, company report or official report of AbbVie.
DMVHPOX	RU	https://www.abbvie.com/our-science/pipeline/agn-242266-fxr-agonist.html

DMU21JF	DI	DMU21JF
DMU21JF	DN	AGS-009
DMU21JF	MI	TT95SOA
DMU21JF	MN	Interferon alpha (IFNA)
DMU21JF	MT	DTT
DMU21JF	RN	Emerging Therapies for Systemic Lupus Erythematosus - Focus on Targeting Interferon-alpha. Clin Immunol. 2012 June; 143(3): 210-221.
DMU21JF	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3358492/

DMDUIO4	DI	DMDUIO4
DMDUIO4	DN	AGS-348
DMDUIO4	MI	TTABNSJ
DMDUIO4	MN	Pyruvate kinase (PK)
DMDUIO4	MT	DTT
DMDUIO4	MA	Modulator
DMDUIO4	RN	Clinical pipeline report, company report or official report of Agios Pharmaceuticals.
DMDUIO4	RU	http://investor.agios.com/phoenix.zhtml?c=251862&p=irol-newsArticle&ID=1919588

DML79KE	DI	DML79KE
DML79KE	DN	AGT-182
DML79KE	MI	TTCBFJO
DML79KE	MN	Insulin receptor (INSR)
DML79KE	MT	DTT
DML79KE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800).
DML79KE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800

DMHMT49	DI	DMHMT49
DMHMT49	DN	AI3-23606
DMHMT49	MI	DEAN5EW
DMHMT49	MN	Nitroreductase (NTR)
DMHMT49	MT	DME
DMHMT49	MA	Metabolism
DMHMT49	RN	Overexpression, isotopic labeling, and spectral characterization of Enterobacter cloacae nitroreductase. Protein Expr Purif. 1998 Jun;13(1):53-60.
DMHMT49	RU	https://pubmed.ncbi.nlm.nih.gov/9631515

DMHMT49	DI	DMHMT49
DMHMT49	DN	AI3-23606
DMHMT49	MI	DEX5D46
DMHMT49	MN	Oxygen-insensitive NADPH nitroreductase A (nfsA)
DMHMT49	MT	DME
DMHMT49	MA	Metabolism
DMHMT49	RN	Delamanid is not metabolized by Salmonella or human nitroreductases: a possible mechanism for the lack of mutagenicity. Regul Toxicol Pharmacol. 2017 Mar;84:1-8.
DMHMT49	RU	https://pubmed.ncbi.nlm.nih.gov/27988333

DMHMT49	DI	DMHMT49
DMHMT49	DN	AI3-23606
DMHMT49	MI	DEOWDK1
DMHMT49	MN	Oxygen-insensitive NADPH nitroreductase B (nfsB)
DMHMT49	MT	DME
DMHMT49	MA	Metabolism
DMHMT49	RN	Delamanid is not metabolized by Salmonella or human nitroreductases: a possible mechanism for the lack of mutagenicity. Regul Toxicol Pharmacol. 2017 Mar;84:1-8.
DMHMT49	RU	https://pubmed.ncbi.nlm.nih.gov/27988333

DMHMT49	DI	DMHMT49
DMHMT49	DN	AI3-23606
DMHMT49	MI	DEKVGPX
DMHMT49	MN	Retro-nitroreductase (rNR)
DMHMT49	MT	DME
DMHMT49	MA	Metabolism
DMHMT49	RN	Retro-nitroreductase, a putative evolutionary precursor to Enterobacter cloacae strain 96-3 nitroreductase. Antioxid Redox Signal. 2001 Oct;3(5):747-55.
DMHMT49	RU	https://pubmed.ncbi.nlm.nih.gov/11761325

DMDA1UB	DI	DMDA1UB
DMDA1UB	DN	AI-850
DMDA1UB	MI	TTJGNVC
DMDA1UB	MN	Apoptosis regulator Bcl-2 (BCL-2)
DMDA1UB	MT	DTT
DMDA1UB	MA	Modulator
DMDA1UB	RN	Intravenous hydrophobic drug delivery: a porous particle formulation of paclitaxel (AI-850). Pharm Res. 2005 Mar;22(3):347-55.
DMDA1UB	RU	https://pubmed.ncbi.nlm.nih.gov/15835739

DMDA1UB	DI	DMDA1UB
DMDA1UB	DN	AI-850
DMDA1UB	MI	TT63KYR
DMDA1UB	MN	Tubulin beta-1 chain (TUBB1)
DMDA1UB	MT	DTT
DMDA1UB	MA	Modulator
DMDA1UB	RN	Intravenous hydrophobic drug delivery: a porous particle formulation of paclitaxel (AI-850). Pharm Res. 2005 Mar;22(3):347-55.
DMDA1UB	RU	https://pubmed.ncbi.nlm.nih.gov/15835739

DMSPBOW	DI	DMSPBOW
DMSPBOW	DN	AIC100
DMSPBOW	MI	TTCT6F7
DMSPBOW	MN	Intercellular adhesion molecule ICAM-1 (ICAM1)
DMSPBOW	MT	DTT
DMSPBOW	RN	Clinical pipeline report, company report or official report of AffyImmune Therapeutics.
DMSPBOW	RU	https://affyimmune.com/pipeline/

DMNHBMC	DI	DMNHBMC
DMNHBMC	DN	AIC-292
DMNHBMC	MI	TT84ETX
DMNHBMC	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMNHBMC	MT	DTT
DMNHBMC	MA	Inhibitor
DMNHBMC	RN	In vitro and in vivo activities of AIC292, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother. 2013 Nov;57(11):5320-9.
DMNHBMC	RU	https://pubmed.ncbi.nlm.nih.gov/23959304

DMW9ZFS	DI	DMW9ZFS
DMW9ZFS	DN	AIKO-150
DMW9ZFS	MI	TT27RFC
DMW9ZFS	MN	Opioid receptor delta (OPRD1)
DMW9ZFS	MT	DTT
DMW9ZFS	MA	Inhibitor
DMW9ZFS	RN	Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8.
DMW9ZFS	RU	https://pubmed.ncbi.nlm.nih.gov/19027293

DMW9ZFS	DI	DMW9ZFS
DMW9ZFS	DN	AIKO-150
DMW9ZFS	MI	TTQW87Y
DMW9ZFS	MN	Opioid receptor kappa (OPRK1)
DMW9ZFS	MT	DTT
DMW9ZFS	MA	Inhibitor
DMW9ZFS	RN	Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8.
DMW9ZFS	RU	https://pubmed.ncbi.nlm.nih.gov/19027293

DMW9ZFS	DI	DMW9ZFS
DMW9ZFS	DN	AIKO-150
DMW9ZFS	MI	TTKWM86
DMW9ZFS	MN	Opioid receptor mu (MOP)
DMW9ZFS	MT	DTT
DMW9ZFS	MA	Antagonist
DMW9ZFS	RN	Clinical pipeline report, company report or official report of signaturerx.
DMW9ZFS	RU	http://www.signaturerx.com/view.cfm/59/Abuse-Resistant-Opioids

DMHCBI0	DI	DMHCBI0
DMHCBI0	DN	AIP-303
DMHCBI0	MI	TT6EO5L
DMHCBI0	MN	Erbb2 tyrosine kinase receptor (HER2)
DMHCBI0	MT	DTT
DMHCBI0	RN	Clinical pipeline report, company report or official report of Adagene.
DMHCBI0	RU	https://www.advancedinnovativepartners.com/technology

DM6PN4H	DI	DM6PN4H
DM6PN4H	DN	AjvW2
DM6PN4H	MI	TT0IHXV
DM6PN4H	MN	DNA topoisomerase II (TOP2)
DM6PN4H	MT	DTT
DM6PN4H	MA	Inhibitor
DM6PN4H	RN	The catalytic DNA topoisomerase II inhibitor ICRF-193 and all-trans retinoic acid cooperatively induce granulocytic differentiation of acute promyelocytic leukemia cells: candidate drugs for chemo-differentiation therapy against acute promyelocytic leukemia. Exp Hematol. 2002 Nov;30(11):1273-82.
DM6PN4H	RU	https://pubmed.ncbi.nlm.nih.gov/12423680

DM6PN4H	DI	DM6PN4H
DM6PN4H	DN	AjvW2
DM6PN4H	MI	TT38RM1
DM6PN4H	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DM6PN4H	MT	DTT
DM6PN4H	RN	Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci. 2002 Jan;23(1):25-32.
DM6PN4H	RU	https://pubmed.ncbi.nlm.nih.gov/11804648

DM4FOX0	DI	DM4FOX0
DM4FOX0	DN	AK107
DM4FOX0	MI	TTV8N19
DM4FOX0	MN	Immune checkpoint (ICH)
DM4FOX0	MT	DTT
DM4FOX0	MA	Inhibitor
DM4FOX0	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM4FOX0	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM9JU8L	DI	DM9JU8L
DM9JU8L	DN	AKP-501
DM9JU8L	MI	TT13GFV
DM9JU8L	MN	Follicle stimulating hormone (FSHB)
DM9JU8L	MT	DTT
DM9JU8L	MA	Modulator
DM9JU8L	RN	AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist. Eur J Haematol. 2009 Apr;82(4):247-54.
DM9JU8L	RU	https://pubmed.ncbi.nlm.nih.gov/19183407

DMHD615	DI	DMHD615
DMHD615	DN	ALB-109564(a)
DMHD615	MI	TTYFKSZ
DMHD615	MN	Tubulin beta (TUBB)
DMHD615	MT	DTT
DMHD615	MA	Modulator
DMHD615	RN	2010 ASCO Annual Meeting
DMHD615	RU	http://meetinglibrary.asco.org/content/41250-74

DMYTIP4	DI	DMYTIP4
DMYTIP4	DN	Aleplasinin
DMYTIP4	MI	TT5QA2I
DMYTIP4	MN	Plasminogen activator inhibitor (PAI)
DMYTIP4	MT	DTT
DMYTIP4	MA	Inhibitor
DMYTIP4	RN	CN patent application no. 102046168, Pai-1 expression and activity inhibitors for the treatment of ocular disorders.
DMYTIP4	RU	http://www.google.com/patents/CN102046168A?cl=en

DMXMK5S	DI	DMXMK5S
DMXMK5S	DN	Alfa-interferon
DMXMK5S	MI	TTMQB37
DMXMK5S	MN	Interferon alpha/beta receptor 2 (IFNAR2)
DMXMK5S	MT	DTT
DMXMK5S	MA	Stimulator
DMXMK5S	RN	New drugs in development for the treatment of endometriosis. Expert Opin Investig Drugs. 2008 Aug;17(8):1187-202.
DMXMK5S	RU	https://pubmed.ncbi.nlm.nih.gov/18616415

DMGIAND	DI	DMGIAND
DMGIAND	DN	ALLO-501
DMGIAND	MI	TTW640A
DMGIAND	MN	B-lymphocyte surface antigen B4 (CD19)
DMGIAND	MT	DTT
DMGIAND	RN	Clinical pipeline report, company report or official report of Allogene Therapeutics.
DMGIAND	RU	https://www.allogene.com/pipeline#all0-501/501A

DMHE3MD	DI	DMHE3MD
DMHE3MD	DN	ALLO-715
DMHE3MD	MI	TTZ3P4W
DMHE3MD	MN	B-cell maturation protein (TNFRSF17)
DMHE3MD	MT	DTT
DMHE3MD	RN	Clinical pipeline report, company report or official report of Allogene Therapeutics.
DMHE3MD	RU	https://www.allogene.com/pipeline#all0-501/501A

DMCYV26	DI	DMCYV26
DMCYV26	DN	Allogeneic CART-19
DMCYV26	MI	TTW640A
DMCYV26	MN	B-lymphocyte surface antigen B4 (CD19)
DMCYV26	MT	DTT
DMCYV26	MA	CAR-T-Cell-Therapy
DMCYV26	RN	ClinicalTrials.gov (NCT02799550) Allogeneic CART-19 for Elderly Relapsed/Refractory CD19+ ALL
DMCYV26	RU	https://clinicaltrials.gov/ct2/show/NCT02799550

DM4RHM5	DI	DM4RHM5
DM4RHM5	DN	Allogeneic CART-33
DM4RHM5	MI	TTJVYO3
DM4RHM5	MN	Myeloid cell surface antigen CD33 (CD33)
DM4RHM5	MT	DTT
DM4RHM5	MA	CAR-T-Cell-Therapy
DM4RHM5	RN	ClinicalTrials.gov (NCT02799680) Allogeneic CART-33 for Relapsed/Refractory CD33+ AML
DM4RHM5	RU	https://clinicaltrials.gov/ct2/show/NCT02799680

DMCSEUY	DI	DMCSEUY
DMCSEUY	DN	ALN-TTR01
DMCSEUY	MI	TTPOYU7
DMCSEUY	MN	Transthyretin messenger RNA (TTR mRNA)
DMCSEUY	MT	DTT
DMCSEUY	MA	Inhibitor
DMCSEUY	RN	Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013 Aug 29;369(9):819-29.
DMCSEUY	RU	https://pubmed.ncbi.nlm.nih.gov/23984729

DM89DHO	DI	DM89DHO
DM89DHO	DN	ALN-VSP
DM89DHO	MI	TTBGTCW
DM89DHO	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DM89DHO	MT	DTT
DM89DHO	RN	Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc (2011).
DM89DHO	RU	http://www.alnylam.com/Programs-and-Pipeline/index.php

DMGFVYL	DI	DMGFVYL
DMGFVYL	DN	ALO-1567
DMGFVYL	MI	TTFBNVI
DMGFVYL	MN	Aldose reductase (AKR1B1)
DMGFVYL	MT	DTT
DMGFVYL	MA	Inhibitor
DMGFVYL	RN	Metabolism of the aldose reductase inhibitor ALO1567 in man. Br J Clin Pharmacol. 1991 Aug;32(2):221-7.
DMGFVYL	RU	https://pubmed.ncbi.nlm.nih.gov/1931471

DMIEKTF	DI	DMIEKTF
DMIEKTF	DN	Alofanib
DMIEKTF	MI	TTGJVQM
DMIEKTF	MN	Fibroblast growth factor receptor 2 (FGFR2)
DMIEKTF	MT	DTT
DMIEKTF	MA	Inhibitor
DMIEKTF	RN	Corrigendum to 'Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models' [Eur J Cancer 61 (2016) 20-28]. Eur J Cancer. 2017 Jan;70:156.
DMIEKTF	RU	https://pubmed.ncbi.nlm.nih.gov/27919550

DMP9VXQ	DI	DMP9VXQ
DMP9VXQ	DN	ALPHA-FMH
DMP9VXQ	MI	TTV9GOF
DMP9VXQ	MN	Histidine decarboxylase (HDC)
DMP9VXQ	MT	DTT
DMP9VXQ	MA	Modulator
DMP9VXQ	RN	Alpha-Fluoromethylhistidine. Kinetics of uptake and inhibition of histamine synthesis in basophil (2H3) cell cultures. Mol Pharmacol. 1985 Aug;28(2):191-9.
DMP9VXQ	RU	https://pubmed.ncbi.nlm.nih.gov/2410770

DMBVM1Q	DI	DMBVM1Q
DMBVM1Q	DN	AlphaMedix
DMBVM1Q	MI	TTOMNR9
DMBVM1Q	MN	Somatostatin receptor (SSTR)
DMBVM1Q	MT	DTT
DMBVM1Q	MA	Activator
DMBVM1Q	RN	Clinical pipeline report, company report or official report of Orano Med.
DMBVM1Q	RU	https://www.oranomed.com/en/pipeline

DMTD4EF	DI	DMTD4EF
DMTD4EF	DN	ALPN-202
DMTD4EF	MI	TTI2S1D
DMTD4EF	MN	Cytotoxic T-lymphocyte protein 4 (CTLA-4)
DMTD4EF	MT	DTT
DMTD4EF	MA	Inhibitor
DMTD4EF	RN	Clinical pipeline report, company report or official report of Alpine Immune Sciences.
DMTD4EF	RU	https://www.alpineimmunesciences.com/wp-content/uploads/2020/06/ALPN-202_AACR20_NEON-1_TIP.pdf

DMTD4EF	DI	DMTD4EF
DMTD4EF	DN	ALPN-202
DMTD4EF	MI	TT8ZLTI
DMTD4EF	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMTD4EF	MT	DTT
DMTD4EF	MA	Inhibitor
DMTD4EF	RN	Clinical pipeline report, company report or official report of Alpine Immune Sciences.
DMTD4EF	RU	https://www.alpineimmunesciences.com/wp-content/uploads/2020/06/ALPN-202_AACR20_NEON-1_TIP.pdf

DMUJCBT	DI	DMUJCBT
DMUJCBT	DN	Altiratinib
DMUJCBT	MI	TT9VGXW
DMUJCBT	MN	Angiopoietin 1 receptor (TEK)
DMUJCBT	MT	DTT
DMUJCBT	MA	Inhibitor
DMUJCBT	RN	Clinical pipeline report, company report or official report of Deciphera Pharmaceuticals.
DMUJCBT	RU	http://www.deciphera.com/article/deciphera-pharmaceuticals-announces-initiation-phase-1-cancer-trial-altiratinib-dcc-2701

DMUJCBT	DI	DMUJCBT
DMUJCBT	DN	Altiratinib
DMUJCBT	MI	TTXABCW
DMUJCBT	MN	NT-3 growth factor receptor (TrkC)
DMUJCBT	MT	DTT
DMUJCBT	MA	Inhibitor
DMUJCBT	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMUJCBT	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMUJCBT	DI	DMUJCBT
DMUJCBT	DN	Altiratinib
DMUJCBT	MI	TTNDSF4
DMUJCBT	MN	Proto-oncogene c-Met (MET)
DMUJCBT	MT	DTT
DMUJCBT	MA	Inhibitor
DMUJCBT	RN	Clinical pipeline report, company report or official report of Deciphera Pharmaceuticals.
DMUJCBT	RU	http://www.deciphera.com/article/deciphera-pharmaceuticals-announces-initiation-phase-1-cancer-trial-altiratinib-dcc-2701

DMUJCBT	DI	DMUJCBT
DMUJCBT	DN	Altiratinib
DMUJCBT	MI	TTTDVOJ
DMUJCBT	MN	Tropomyosin-related kinase A (TrkA)
DMUJCBT	MT	DTT
DMUJCBT	MA	Inhibitor
DMUJCBT	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMUJCBT	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMUJCBT	DI	DMUJCBT
DMUJCBT	DN	Altiratinib
DMUJCBT	MI	TTUTJGQ
DMUJCBT	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMUJCBT	MT	DTT
DMUJCBT	MA	Antagonist
DMUJCBT	RN	Clinical pipeline report, company report or official report of Deciphera Pharmaceuticals.
DMUJCBT	RU	http://www.deciphera.com/article/deciphera-pharmaceuticals-announces-initiation-phase-1-cancer-trial-altiratinib-dcc-2701

DM6KU93	DI	DM6KU93
DM6KU93	DN	Alvespimycin hydrochloride
DM6KU93	MI	TT78R5H
DM6KU93	MN	Heat shock protein 90 alpha (HSP90A)
DM6KU93	MT	DTT
DM6KU93	MA	Inhibitor
DM6KU93	RN	Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Jul;51(1):34-41.
DM6KU93	RU	https://pubmed.ncbi.nlm.nih.gov/18260120

DMBGI74	DI	DMBGI74
DMBGI74	DN	ALX-0141
DMBGI74	MI	TT9E8HR
DMBGI74	MN	Osteoclast differentiation factor (ODF)
DMBGI74	MT	DTT
DMBGI74	MA	Inhibitor
DMBGI74	RN	Clinical pipeline report, company report or official report of Ablynx.
DMBGI74	RU	http://www.ablynx.com/rd-portfolio/clinical-programmes/alx-0141/

DMIRYM8	DI	DMIRYM8
DMIRYM8	DN	ALX-0651
DMIRYM8	MI	TTBID49
DMIRYM8	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMIRYM8	MT	DTT
DMIRYM8	MA	Inhibitor
DMIRYM8	RN	Therapeutic antibodies directed at G protein-coupled receptors. MAbs. 2010 Nov-Dec; 2(6): 594-606.
DMIRYM8	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3011214/

DMJ8ACF	DI	DMJ8ACF
DMJ8ACF	DN	ALX-0761
DMJ8ACF	MI	TTG0MT6
DMJ8ACF	MN	Interleukin-17 (IL17)
DMJ8ACF	MT	DTT
DMJ8ACF	MA	Modulator
DMJ8ACF	RN	Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. 
DMJ8ACF	RU	https://www.ncbi.nlm.nih.gov/pubmed/25359367

DMJ8ACF	DI	DMJ8ACF
DMJ8ACF	DN	ALX-0761
DMJ8ACF	MI	TTVMO5W
DMJ8ACF	MN	Interleukin-25 (IL25)
DMJ8ACF	MT	DTT
DMJ8ACF	MA	Modulator
DMJ8ACF	RN	Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. 
DMJ8ACF	RU	https://www.ncbi.nlm.nih.gov/pubmed/25359367

DMLJWPN	DI	DMLJWPN
DMLJWPN	DN	Alx-5407
DMLJWPN	MI	TTHJTF7
DMLJWPN	MN	Glycine transporter GlyT-1 (SLC6A9)
DMLJWPN	MT	DTT
DMLJWPN	MA	Blocker
DMLJWPN	RN	ALX 5407: a potent, selective inhibitor of the hGlyT1 glycine transporter. Mol Pharmacol. 2001 Dec;60(6):1414-20.
DMLJWPN	RU	https://pubmed.ncbi.nlm.nih.gov/11723250

DMVXRYC	DI	DMVXRYC
DMVXRYC	DN	AM-211
DMVXRYC	MI	TTQDMX5
DMVXRYC	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMVXRYC	MT	DTT
DMVXRYC	MA	Antagonist
DMVXRYC	RN	Pharmacology of AM211, a potent and selective prostaglandin D2 receptor type 2 antagonist that is active in animal models of allergic inflammation. J Pharmacol Exp Ther. 2011 Jul;338(1):290-301.
DMVXRYC	RU	https://pubmed.ncbi.nlm.nih.gov/21487069

DM7Z8NP	DI	DM7Z8NP
DM7Z8NP	DN	AM-461
DM7Z8NP	MI	TTQDMX5
DM7Z8NP	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DM7Z8NP	MT	DTT
DM7Z8NP	MA	Antagonist
DM7Z8NP	RN	A novel DP2 receptor antagonist (AM-461): a patent evaluation of WO2011085033. Expert Opin Ther Pat. 2011 Dec;21(12):1931-6.
DM7Z8NP	RU	https://pubmed.ncbi.nlm.nih.gov/22082220

DM7CD8Z	DI	DM7CD8Z
DM7CD8Z	DN	AMAP-102
DM7CD8Z	MI	TTYSN63
DM7CD8Z	MN	5-HT 2 receptor (5HT2R)
DM7CD8Z	MT	DTT
DM7CD8Z	MA	Antagonist
DM7CD8Z	RN	Clinical pipeline report, company report or official report of Anamar.
DM7CD8Z	RU	http://anamar.com/rd/project-amap102/

DMFELMQ	DI	DMFELMQ
DMFELMQ	DN	AMEP
DMFELMQ	MI	TTH4QIS
DMFELMQ	MN	Integrin alpha-5/beta-1 (ITGA5/B1)
DMFELMQ	MT	DTT
DMFELMQ	MA	Modulator
DMFELMQ	RN	Gene electrotransfer of plasmid AMEP, an integrin-targeted therapy, has antitumor and antiangiogenic action in murine B16 melanoma.Gene Ther.2015 Jul;22(7):578-90.
DMFELMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25781650

DMFELMQ	DI	DMFELMQ
DMFELMQ	DN	AMEP
DMFELMQ	MI	TT69TQN
DMFELMQ	MN	Integrin alpha-V/beta-3 (ITGAV/B3)
DMFELMQ	MT	DTT
DMFELMQ	MA	Modulator
DMFELMQ	RN	Gene electrotransfer of plasmid AMEP, an integrin-targeted therapy, has antitumor and antiangiogenic action in murine B16 melanoma.Gene Ther.2015 Jul;22(7):578-90.
DMFELMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25781650

DMKF1O2	DI	DMKF1O2
DMKF1O2	DN	AMG 119
DMKF1O2	MI	TT1C9K6
DMKF1O2	MN	Delta-like protein 3 (DLL3)
DMKF1O2	MT	DTT
DMKF1O2	MA	Inhibitor
DMKF1O2	RN	Clinical pipeline report, company report or official report of Amgen.
DMKF1O2	RU	https://www.amgenpipeline.com/

DMM0HNF	DI	DMM0HNF
DMM0HNF	DN	AMG 160
DMM0HNF	MI	TT9G4N0
DMM0HNF	MN	Glutamate carboxypeptidase II (GCPII)
DMM0HNF	MT	DTT
DMM0HNF	MA	Inhibitor
DMM0HNF	RN	Clinical pipeline report, company report or official report of Amgen.
DMM0HNF	RU	https://www.amgenpipeline.com/

DMM0HNF	DI	DMM0HNF
DMM0HNF	DN	AMG 160
DMM0HNF	MI	TTUN7MC
DMM0HNF	MN	T-cell surface glycoprotein CD3 (CD3)
DMM0HNF	MT	DTT
DMM0HNF	MA	Inhibitor
DMM0HNF	RN	Clinical pipeline report, company report or official report of Amgen.
DMM0HNF	RU	https://www.amgenpipeline.com/

DMUETI2	DI	DMUETI2
DMUETI2	DN	AMG 167
DMUETI2	MI	TTYRO4F
DMUETI2	MN	Sclerostin (SOST)
DMUETI2	MT	DTT
DMUETI2	MA	Modulator
DMUETI2	RN	Osteoporosis - a current view of pharmacological prevention and treatment. Drug Des Devel Ther. 2013; 7: 435-448.
DMUETI2	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686324/

DMS72GN	DI	DMS72GN
DMS72GN	DN	AMG 172
DMS72GN	MI	TTNCIE0
DMS72GN	MN	CD70 antigen (CD27-L)
DMS72GN	MT	DTT
DMS72GN	MA	Modulator
DMS72GN	RN	National Cancer Institute Drug Dictionary (drug id 721679).
DMS72GN	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=721679

DM0Q7NO	DI	DM0Q7NO
DM0Q7NO	DN	AMG 176
DM0Q7NO	MI	TTL53M6
DM0Q7NO	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DM0Q7NO	MT	DTT
DM0Q7NO	MA	Inhibitor
DM0Q7NO	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM0Q7NO	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMWG2K6	DI	DMWG2K6
DMWG2K6	DN	AMG 199
DMWG2K6	MI	TTVO0JU
DMWG2K6	MN	Mucin-17 (MUC17)
DMWG2K6	MT	DTT
DMWG2K6	MA	Inhibitor
DMWG2K6	RN	Clinical pipeline report, company report or official report of Amgen.
DMWG2K6	RU	https://www.amgenpipeline.com/

DMWG2K6	DI	DMWG2K6
DMWG2K6	DN	AMG 199
DMWG2K6	MI	TTUN7MC
DMWG2K6	MN	T-cell surface glycoprotein CD3 (CD3)
DMWG2K6	MT	DTT
DMWG2K6	MA	Inhibitor
DMWG2K6	RN	Clinical pipeline report, company report or official report of Amgen.
DMWG2K6	RU	https://www.amgenpipeline.com/

DMA1I04	DI	DMA1I04
DMA1I04	DN	AMG 211
DMA1I04	MI	TTY6DTE
DMA1I04	MN	Carcinoembryonic antigen CEA (CD66e)
DMA1I04	MT	DTT
DMA1I04	MA	Immunomodulator
DMA1I04	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMA1I04	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMLQJ5P	DI	DMLQJ5P
DMLQJ5P	DN	AMG 228
DMLQJ5P	MI	TTG6LA7
DMLQJ5P	MN	Activation-inducible TNFR family receptor (TNFRSF18)
DMLQJ5P	MT	DTT
DMLQJ5P	MA	Agonist
DMLQJ5P	RN	Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors. J Immunother Cancer. 2018 Sep 25;6(1):93.
DMLQJ5P	RU	https://pubmed.ncbi.nlm.nih.gov/30253804

DMXYCZV	DI	DMXYCZV
DMXYCZV	DN	AMG 256
DMXYCZV	MI	TTZO9B0
DMXYCZV	MN	Interleukin 21 receptor (IL21R)
DMXYCZV	MT	DTT
DMXYCZV	MA	Agonist
DMXYCZV	RN	Clinical pipeline report, company report or official report of Amgen.
DMXYCZV	RU	https://www.amgenpipeline.com/

DM92YWD	DI	DM92YWD
DM92YWD	DN	AMG 282
DM92YWD	MI	TT5MD4P
DM92YWD	MN	Interleukin-33 (IL33)
DM92YWD	MT	DTT
DM92YWD	RN	Clinical pipeline report, company report or official report of Amgen.
DM92YWD	RU	http://www.amgenpipeline.com/pipeline/

DM9P0NA	DI	DM9P0NA
DM9P0NA	DN	AMG 319
DM9P0NA	MI	TTGBPJE
DM9P0NA	MN	PI3-kinase delta (PIK3CD)
DM9P0NA	MT	DTT
DM9P0NA	MA	Inhibitor
DM9P0NA	RN	National Cancer Institute Drug Dictionary (drug id 696292).
DM9P0NA	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=696292

DMC3G2E	DI	DMC3G2E
DMC3G2E	DN	AMG 330
DMC3G2E	MI	TTJVYO3
DMC3G2E	MN	Myeloid cell surface antigen CD33 (CD33)
DMC3G2E	MT	DTT
DMC3G2E	MA	Inhibitor
DMC3G2E	RN	Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia. Mol Cancer Ther. 2014 Jun;13(6):1549-57.
DMC3G2E	RU	https://pubmed.ncbi.nlm.nih.gov/24674885

DMC3G2E	DI	DMC3G2E
DMC3G2E	DN	AMG 330
DMC3G2E	MI	TTUN7MC
DMC3G2E	MN	T-cell surface glycoprotein CD3 (CD3)
DMC3G2E	MT	DTT
DMC3G2E	MA	Inhibitor
DMC3G2E	RN	Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia. Mol Cancer Ther. 2014 Jun;13(6):1549-57.
DMC3G2E	RU	https://pubmed.ncbi.nlm.nih.gov/24674885

DM7CNTG	DI	DM7CNTG
DM7CNTG	DN	AMG 397
DM7CNTG	MI	TTL53M6
DM7CNTG	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DM7CNTG	MT	DTT
DM7CNTG	MA	Inhibitor
DM7CNTG	RN	Clinical pipeline report, company report or official report of Amgen.
DM7CNTG	RU	https://www.amgenpipeline.com/

DMVQX5K	DI	DMVQX5K
DMVQX5K	DN	AMG 404
DMVQX5K	MI	TTNBFWK
DMVQX5K	MN	Programmed cell death protein 1 (PD-1)
DMVQX5K	MT	DTT
DMVQX5K	MA	Inhibitor
DMVQX5K	RN	ClinicalTrials.gov (NCT03853109) AMG 404 in Patients With Advanced Solid Tumors.. U.S. National Institutes of Health.
DMVQX5K	RU	https://clinicaltrials.gov/ct2/show/NCT03853109

DMYFZLA	DI	DMYFZLA
DMYFZLA	DN	AMG 420
DMYFZLA	MI	TTZ3P4W
DMYFZLA	MN	B-cell maturation protein (TNFRSF17)
DMYFZLA	MT	DTT
DMYFZLA	MA	Inhibitor
DMYFZLA	RN	Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma. J Clin Oncol. 2020 Mar 10;38(8):775-783.
DMYFZLA	RU	https://pubmed.ncbi.nlm.nih.gov/31895611

DMLAP8F	DI	DMLAP8F
DMLAP8F	DN	AMG 424
DMLAP8F	MI	TTPURFN
DMLAP8F	MN	Cyclic ADP-ribose hydrolase 1 (CD38)
DMLAP8F	MT	DTT
DMLAP8F	MA	Inhibitor
DMLAP8F	RN	Clinical pipeline report, company report or official report of Amgen.
DMLAP8F	RU	https://www.amgenpipeline.com/

DMLAP8F	DI	DMLAP8F
DMLAP8F	DN	AMG 424
DMLAP8F	MI	TTUN7MC
DMLAP8F	MN	T-cell surface glycoprotein CD3 (CD3)
DMLAP8F	MT	DTT
DMLAP8F	MA	Inhibitor
DMLAP8F	RN	Clinical pipeline report, company report or official report of Amgen.
DMLAP8F	RU	https://www.amgenpipeline.com/

DMI7JO6	DI	DMI7JO6
DMI7JO6	DN	AMG 427
DMI7JO6	MI	TTGJCWZ
DMI7JO6	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMI7JO6	MT	DTT
DMI7JO6	MA	Inhibitor
DMI7JO6	RN	Clinical pipeline report, company report or official report of Amgen.
DMI7JO6	RU	https://www.amgenpipeline.com/

DMI7JO6	DI	DMI7JO6
DMI7JO6	DN	AMG 427
DMI7JO6	MI	TTUN7MC
DMI7JO6	MN	T-cell surface glycoprotein CD3 (CD3)
DMI7JO6	MT	DTT
DMI7JO6	MA	Inhibitor
DMI7JO6	RN	Clinical pipeline report, company report or official report of Amgen.
DMI7JO6	RU	https://www.amgenpipeline.com/

DMG64PE	DI	DMG64PE
DMG64PE	DN	AMG 506
DMG64PE	MI	TTPW9LJ
DMG64PE	MN	Co-stimulatory molecule 4-1BB (CD137)
DMG64PE	MT	DTT
DMG64PE	MA	Inhibitor
DMG64PE	RN	Clinical pipeline report, company report or official report of Amgen.
DMG64PE	RU	https://www.amgenpipeline.com/

DMG64PE	DI	DMG64PE
DMG64PE	DN	AMG 506
DMG64PE	MI	TTGPQ0F
DMG64PE	MN	Prolyl endopeptidase FAP (FAP)
DMG64PE	MT	DTT
DMG64PE	MA	Inhibitor
DMG64PE	RN	Clinical pipeline report, company report or official report of Amgen.
DMG64PE	RU	https://www.amgenpipeline.com/

DM2POGY	DI	DM2POGY
DM2POGY	DN	AMG 509
DM2POGY	MI	TT9E64S
DM2POGY	MN	Metalloreductase STEAP1 (STEAP1)
DM2POGY	MT	DTT
DM2POGY	MA	Inhibitor
DM2POGY	RN	Clinical pipeline report, company report or official report of Amgen.
DM2POGY	RU	https://www.amgenpipeline.com/

DMNEFQ6	DI	DMNEFQ6
DMNEFQ6	DN	AMG 529
DMNEFQ6	MI	TTYM94H
DMNEFQ6	MN	Asialoglycoprotein receptor 1 (ASGR1)
DMNEFQ6	MT	DTT
DMNEFQ6	MA	Inhibitor
DMNEFQ6	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMNEFQ6	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMQ0N5Z	DI	DMQ0N5Z
DMQ0N5Z	DN	AMG 562
DMQ0N5Z	MI	TTW640A
DMQ0N5Z	MN	B-lymphocyte surface antigen B4 (CD19)
DMQ0N5Z	MT	DTT
DMQ0N5Z	MA	Inhibitor
DMQ0N5Z	RN	Clinical pipeline report, company report or official report of Amgen.
DMQ0N5Z	RU	https://www.amgenpipeline.com/

DMRMC7U	DI	DMRMC7U
DMRMC7U	DN	AMG 579
DMRMC7U	MI	TTJW4LU
DMRMC7U	MN	Phosphodiesterase 10A (PDE10)
DMRMC7U	MT	DTT
DMRMC7U	MA	Inhibitor
DMRMC7U	RN	Discovery of clinical candidate 1-(4-(3-(4-(1H-benzo[d]imidazole-2-carbonyl)phenoxy)pyrazin-2-yl)piperidin-1-yl)ethanone (AMG 579), a potent, selective, and efficacious inhibitor of phosphodiesterase10A (PDE10A). J Med Chem. 2014 Aug 14;57(15):6632-41.
DMRMC7U	RU	https://pubmed.ncbi.nlm.nih.gov/25062128

DMJFKW3	DI	DMJFKW3
DMJFKW3	DN	AMG 595
DMJFKW3	MI	TTGKNB4
DMJFKW3	MN	Epidermal growth factor receptor (EGFR)
DMJFKW3	MT	DTT
DMJFKW3	MA	Modulator
DMJFKW3	RN	AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma. Mol Cancer Ther. 2015 Jul;14(7):1614-24.
DMJFKW3	RU	https://pubmed.ncbi.nlm.nih.gov/25931519

DM4G1SP	DI	DM4G1SP
DM4G1SP	DN	AMG 596
DM4G1SP	MI	TTZ6B2I
DM4G1SP	MN	Epidermal growth factor receptor variant III (EGFR vIII)
DM4G1SP	MT	DTT
DM4G1SP	MA	Inhibitor
DM4G1SP	RN	Clinical pipeline report, company report or official report of Amgen.
DM4G1SP	RU	https://www.amgenpipeline.com/

DM4G1SP	DI	DM4G1SP
DM4G1SP	DN	AMG 596
DM4G1SP	MI	TTUN7MC
DM4G1SP	MN	T-cell surface glycoprotein CD3 (CD3)
DM4G1SP	MT	DTT
DM4G1SP	MA	Inhibitor
DM4G1SP	RN	Clinical pipeline report, company report or official report of Amgen.
DM4G1SP	RU	https://www.amgenpipeline.com/

DMA3B9T	DI	DMA3B9T
DMA3B9T	DN	AMG 673
DMA3B9T	MI	TTJVYO3
DMA3B9T	MN	Myeloid cell surface antigen CD33 (CD33)
DMA3B9T	MT	DTT
DMA3B9T	MA	Inhibitor
DMA3B9T	RN	Clinical pipeline report, company report or official report of Amgen.
DMA3B9T	RU	https://www.amgenpipeline.com/

DMA3B9T	DI	DMA3B9T
DMA3B9T	DN	AMG 673
DMA3B9T	MI	TTUN7MC
DMA3B9T	MN	T-cell surface glycoprotein CD3 (CD3)
DMA3B9T	MT	DTT
DMA3B9T	MA	Inhibitor
DMA3B9T	RN	Clinical pipeline report, company report or official report of Amgen.
DMA3B9T	RU	https://www.amgenpipeline.com/

DM6IT3M	DI	DM6IT3M
DM6IT3M	DN	AMG 701
DM6IT3M	MI	TTZ3P4W
DM6IT3M	MN	B-cell maturation protein (TNFRSF17)
DM6IT3M	MT	DTT
DM6IT3M	MA	Inhibitor
DM6IT3M	RN	Clinical pipeline report, company report or official report of Amgen.
DM6IT3M	RU	https://www.amgenpipeline.com/

DM6IT3M	DI	DM6IT3M
DM6IT3M	DN	AMG 701
DM6IT3M	MI	TTUN7MC
DM6IT3M	MN	T-cell surface glycoprotein CD3 (CD3)
DM6IT3M	MT	DTT
DM6IT3M	MA	Inhibitor
DM6IT3M	RN	Clinical pipeline report, company report or official report of Amgen.
DM6IT3M	RU	https://www.amgenpipeline.com/

DMLYP2N	DI	DMLYP2N
DMLYP2N	DN	AMG 757
DMLYP2N	MI	TT1C9K6
DMLYP2N	MN	Delta-like protein 3 (DLL3)
DMLYP2N	MT	DTT
DMLYP2N	MA	Inhibitor
DMLYP2N	RN	Clinical pipeline report, company report or official report of Amgen.
DMLYP2N	RU	https://www.amgenpipeline.com/

DMLYP2N	DI	DMLYP2N
DMLYP2N	DN	AMG 757
DMLYP2N	MI	TTUN7MC
DMLYP2N	MN	T-cell surface glycoprotein CD3 (CD3)
DMLYP2N	MT	DTT
DMLYP2N	MA	Inhibitor
DMLYP2N	RN	Clinical pipeline report, company report or official report of Amgen.
DMLYP2N	RU	https://www.amgenpipeline.com/

DMTGZN8	DI	DMTGZN8
DMTGZN8	DN	AMG 780
DMTGZN8	MI	TTWNQ1T
DMTGZN8	MN	Angiopoietin-1 (ANGPT1)
DMTGZN8	MT	DTT
DMTGZN8	MA	Modulator
DMTGZN8	RN	Development and preclinical testing of AMG 780, a fully human antibody targeting angiopoietin 1 (Ang1) and angiopoietin 2 (Ang2). Cancer Research. 10/2014; 74(19 Supplement):1022-1022.
DMTGZN8	RU	http://cancerres.aacrjournals.org/content/74/19_Supplement/1022

DMEIMBP	DI	DMEIMBP
DMEIMBP	DN	AMG 811
DMEIMBP	MI	TT93WF5
DMEIMBP	MN	Interferon-gamma (IFNG)
DMEIMBP	MT	DTT
DMEIMBP	MA	Modulator
DMEIMBP	RN	Pharmacokinetic and pharmacodynamic relationship of AMG 811, an anti-IFN-gamma IgG1 monoclonal antibody, in patients with systemic lupus erythematosus. Pharm Res. 2015 Feb;32(2):640-53.
DMEIMBP	RU	https://pubmed.ncbi.nlm.nih.gov/25213774

DMB6Q19	DI	DMB6Q19
DMB6Q19	DN	AMG 820
DMB6Q19	MI	TT731LW
DMB6Q19	MN	Colony stimulating factor-1 receptor (CSF-1R)
DMB6Q19	MT	DTT
DMB6Q19	MA	Modulator
DMB6Q19	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMB6Q19	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMB6Q19	DI	DMB6Q19
DMB6Q19	DN	AMG 820
DMB6Q19	MI	TTC70AJ
DMB6Q19	MN	Granulocyte colony-stimulating factor receptor (G-CSF-R)
DMB6Q19	MT	DTT
DMB6Q19	MA	Inhibitor
DMB6Q19	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMB6Q19	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM1FJ9C	DI	DM1FJ9C
DM1FJ9C	DN	AMG 876
DM1FJ9C	MI	TTUPB12
DM1FJ9C	MN	Measles virus Fusion glycoprotein (MeV F)
DM1FJ9C	MT	DTT
DM1FJ9C	MA	Modulator
DM1FJ9C	RN	Clinical pipeline report, company report or official report of Amgen.
DM1FJ9C	RU	http://www.amgenpipeline.com/pipeline/

DMASGXJ	DI	DMASGXJ
DMASGXJ	DN	AMG 900
DMASGXJ	MI	TTPS3C0
DMASGXJ	MN	Aurora kinase A (AURKA)
DMASGXJ	MT	DTT
DMASGXJ	MA	Modulator
DMASGXJ	RN	Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res. 2010 Dec 1;70(23):9846-54.
DMASGXJ	RU	https://pubmed.ncbi.nlm.nih.gov/20935223

DMASGXJ	DI	DMASGXJ
DMASGXJ	DN	AMG 900
DMASGXJ	MI	TT5LS6T
DMASGXJ	MN	Aurora kinase B (AURKB)
DMASGXJ	MT	DTT
DMASGXJ	MA	Modulator
DMASGXJ	RN	Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res. 2010 Dec 1;70(23):9846-54.
DMASGXJ	RU	https://pubmed.ncbi.nlm.nih.gov/20935223

DMASGXJ	DI	DMASGXJ
DMASGXJ	DN	AMG 900
DMASGXJ	MI	TTLYXIT
DMASGXJ	MN	Aurora kinase C (AURKC)
DMASGXJ	MT	DTT
DMASGXJ	MA	Modulator
DMASGXJ	RN	Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res. 2010 Dec 1;70(23):9846-54.
DMASGXJ	RU	https://pubmed.ncbi.nlm.nih.gov/20935223

DMCG7XL	DI	DMCG7XL
DMCG7XL	DN	AMG 910
DMCG7XL	MI	TT6PKBX
DMCG7XL	MN	Claudin-18 (CLDN18)
DMCG7XL	MT	DTT
DMCG7XL	MA	Inhibitor
DMCG7XL	RN	Clinical pipeline report, company report or official report of Amgen.
DMCG7XL	RU	https://www.amgenpipeline.com/

DMCG7XL	DI	DMCG7XL
DMCG7XL	DN	AMG 910
DMCG7XL	MI	TTUN7MC
DMCG7XL	MN	T-cell surface glycoprotein CD3 (CD3)
DMCG7XL	MT	DTT
DMCG7XL	MA	Inhibitor
DMCG7XL	RN	Clinical pipeline report, company report or official report of Amgen.
DMCG7XL	RU	https://www.amgenpipeline.com/

DMZQ2DK	DI	DMZQ2DK
DMZQ2DK	DN	AMG 986
DMZQ2DK	MI	TTJ8E43
DMZQ2DK	MN	Apelin receptor (APLNR)
DMZQ2DK	MT	DTT
DMZQ2DK	MA	Agonist
DMZQ2DK	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZQ2DK	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMEHOVF	DI	DMEHOVF
DMEHOVF	DN	AMG-139
DMEHOVF	MI	TTC1GLB
DMEHOVF	MN	Interleukin-23 (IL23)
DMEHOVF	MT	DTT
DMEHOVF	RN	Preclinical development of AMG 139, a human antibody specifically targeting IL-23. Br J Pharmacol. 2015 Jan;172(1):159-72.
DMEHOVF	RU	https://pubmed.ncbi.nlm.nih.gov/25205227

DMSHK23	DI	DMSHK23
DMSHK23	DN	AMG-191
DMSHK23	MI	TTX41N9
DMSHK23	MN	Tyrosine-protein kinase Kit (KIT)
DMSHK23	MT	DTT
DMSHK23	MA	Inhibitor
DMSHK23	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029529)
DMSHK23	RU	http://adisinsight.springer.com/drugs/800029529

DMJQDUC	DI	DMJQDUC
DMJQDUC	DN	Aminoguanidine
DMJQDUC	MI	TTFZYTO
DMJQDUC	MN	C-C chemokine receptor type 2 (CCR2)
DMJQDUC	MT	DTT
DMJQDUC	MA	Antagonist
DMJQDUC	RN	Incyte Announces Second Quarter 2005 Financial Results; Reports Positive Phase IIb Results for Reverset in Treatment-Experienced HIV Patients. Incyte Corporation. 2005.
DMJQDUC	RU	http://www.aegis.com/news/bw/2005/BW050801.html

DMJQDUC	DI	DMJQDUC
DMJQDUC	DN	Aminoguanidine
DMJQDUC	MI	TTF10I9
DMJQDUC	MN	Nitric-oxide synthase inducible (NOS2)
DMJQDUC	MT	DTT
DMJQDUC	MA	Inhibitor
DMJQDUC	RN	Inhibitory effects of aminoguanidine on thyroid follicular carcinoma development in inflamed capsular regions of rats treated with sulfadimethoxine... Cancer Sci. 2009 Oct;100(10):1794-800.
DMJQDUC	RU	https://pubmed.ncbi.nlm.nih.gov/19572977

DMH9M62	DI	DMH9M62
DMH9M62	DN	AMP-224
DMH9M62	MI	TTNBFWK
DMH9M62	MN	Programmed cell death protein 1 (PD-1)
DMH9M62	MT	DTT
DMH9M62	MA	Modulator
DMH9M62	RN	National Cancer Institute Drug Dictionary (drug id 700595).
DMH9M62	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=700595

DMT27PA	DI	DMT27PA
DMT27PA	DN	AMV564
DMT27PA	MI	TTJVYO3
DMT27PA	MN	Myeloid cell surface antigen CD33 (CD33)
DMT27PA	MT	DTT
DMT27PA	MA	Modulator
DMT27PA	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMT27PA	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMR35U4	DI	DMR35U4
DMR35U4	DN	AMXT1501
DMR35U4	MI	TTJR4Z5
DMR35U4	MN	Polyamine transport (Poly trans)
DMR35U4	MT	DTT
DMR35U4	MA	Inhibitor
DMR35U4	RN	AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport. Int J Cancer. 2013 Sep 15;133(6):1323-33.
DMR35U4	RU	https://pubmed.ncbi.nlm.nih.gov/23457004

DM8B2WQ	DI	DM8B2WQ
DM8B2WQ	DN	AN-2718
DM8B2WQ	MI	TT37GL6
DM8B2WQ	MN	Staphylococcus Leucyl-tRNA synthetase (Stap-coc leuS)
DM8B2WQ	MT	DTT
DM8B2WQ	MA	Inhibitor
DM8B2WQ	RN	Metalloid compounds as drugs. Res Pharm Sci. 2013 Jul-Sep; 8(3): 145-158.
DM8B2WQ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3764666/

DM67OU4	DI	DM67OU4
DM67OU4	DN	ANAVEX 2-73
DM67OU4	MI	TTZ9SOR
DM67OU4	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DM67OU4	MT	DTT
DM67OU4	MA	Agonist
DM67OU4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM67OU4	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM67OU4	DI	DM67OU4
DM67OU4	DN	ANAVEX 2-73
DM67OU4	MI	TT5TPI6
DM67OU4	MN	Opioid receptor sigma 1 (OPRS1)
DM67OU4	MT	DTT
DM67OU4	MA	Agonist
DM67OU4	RN	2011 Pipeline of Anavex.
DM67OU4	RU	http://anavex.com/pipeline.html

DM39QWN	DI	DM39QWN
DM39QWN	DN	ANS-6637
DM39QWN	MI	TTFLN4T
DM39QWN	MN	Mitochondrial aldehyde dehydrogenase (ALDH2)
DM39QWN	MT	DTT
DM39QWN	MA	Inhibitor
DM39QWN	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM39QWN	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DM3OFZC	DI	DM3OFZC
DM3OFZC	DN	Anti-BCMA CAR T cells
DM3OFZC	MI	TTZ3P4W
DM3OFZC	MN	B-cell maturation protein (TNFRSF17)
DM3OFZC	MT	DTT
DM3OFZC	MA	CAR-T-Cell-Therapy
DM3OFZC	RN	ClinicalTrials.gov (NCT03559764) Study of BCMA CAR-T in Multiple Myeloma
DM3OFZC	RU	https://clinicaltrials.gov/ct2/show/NCT03559764

DMNFO2B	DI	DMNFO2B
DMNFO2B	DN	Anti-BCMA CAR T cells
DMNFO2B	MI	TTZ3P4W
DMNFO2B	MN	B-cell maturation protein (TNFRSF17)
DMNFO2B	MT	DTT
DMNFO2B	MA	CAR-T-Cell-Therapy
DMNFO2B	RN	ClinicalTrials.gov (NCT02215967) Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma
DMNFO2B	RU	https://clinicaltrials.gov/ct2/show/NCT02215967

DMUKNDO	DI	DMUKNDO
DMUKNDO	DN	Anti-BCMA CART Cells
DMUKNDO	MI	TTZ3P4W
DMUKNDO	MN	B-cell maturation protein (TNFRSF17)
DMUKNDO	MT	DTT
DMUKNDO	MA	CAR-T-Cell-Therapy
DMUKNDO	RN	ClinicalTrials.gov (NCT03767725) Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma
DMUKNDO	RU	https://clinicaltrials.gov/ct2/show/NCT03767725

DM2TFUD	DI	DM2TFUD
DM2TFUD	DN	Anti-BCMA CAR-T cells
DM2TFUD	MI	TTZ3P4W
DM2TFUD	MN	B-cell maturation protein (TNFRSF17)
DM2TFUD	MT	DTT
DM2TFUD	MA	CAR-T-Cell-Therapy
DM2TFUD	RN	ClinicalTrials.gov (NCT03093168) BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma
DM2TFUD	RU	https://clinicaltrials.gov/ct2/show/NCT03093168

DMK25QD	DI	DMK25QD
DMK25QD	DN	Anti-BCMA CAR-T cells
DMK25QD	MI	TTZ3P4W
DMK25QD	MN	B-cell maturation protein (TNFRSF17)
DMK25QD	MT	DTT
DMK25QD	MA	CAR-T-Cell-Therapy
DMK25QD	RN	ClinicalTrials.gov (NCT03121625) CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
DMK25QD	RU	https://clinicaltrials.gov/ct2/show/NCT03121625

DMYIZFW	DI	DMYIZFW
DMYIZFW	DN	Anti-CD123 CAR-T cells
DMYIZFW	MI	TTENHJ0
DMYIZFW	MN	Interleukin 3 receptor alpha (IL3RA)
DMYIZFW	MT	DTT
DMYIZFW	MA	CAR-T-Cell-Therapy
DMYIZFW	RN	ClinicalTrials.gov (NCT03121625) CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
DMYIZFW	RU	https://clinicaltrials.gov/ct2/show/NCT03121625

DM82OS7	DI	DM82OS7
DM82OS7	DN	Anti-CD123 CAR-T treatment
DM82OS7	MI	TTENHJ0
DM82OS7	MN	Interleukin 3 receptor alpha (IL3RA)
DM82OS7	MT	DTT
DM82OS7	MA	CAR-T-Cell-Therapy
DM82OS7	RN	ClinicalTrials.gov (NCT03672851) Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Leukemia
DM82OS7	RU	https://clinicaltrials.gov/ct2/show/NCT03672851

DMGUM90	DI	DMGUM90
DMGUM90	DN	Anti-CD133-CAR vector-transduced T cells
DMGUM90	MI	TTXMZ81
DMGUM90	MN	Prominin-1 (PROM1)
DMGUM90	MT	DTT
DMGUM90	MA	CAR-T-Cell-Therapy
DMGUM90	RN	ClinicalTrials.gov (NCT02541370) Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133
DMGUM90	RU	https://clinicaltrials.gov/ct2/show/NCT02541370

DMCABUR	DI	DMCABUR
DMCABUR	DN	Anti-CD19 anti-CD20 Bispecific CAR-T
DMCABUR	MI	TTW640A
DMCABUR	MN	B-lymphocyte surface antigen B4 (CD19)
DMCABUR	MT	DTT
DMCABUR	MA	CAR-T-Cell-Therapy(Dual specific)
DMCABUR	RN	ClinicalTrials.gov (NCT03271515) Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL
DMCABUR	RU	https://clinicaltrials.gov/ct2/show/NCT03271515

DMCABUR	DI	DMCABUR
DMCABUR	DN	Anti-CD19 anti-CD20 Bispecific CAR-T
DMCABUR	MI	TTUE541
DMCABUR	MN	Leukocyte surface antigen Leu-16 (CD20)
DMCABUR	MT	DTT
DMCABUR	MA	CAR-T-Cell-Therapy(Dual specific)
DMCABUR	RN	ClinicalTrials.gov (NCT03271515) Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL
DMCABUR	RU	https://clinicaltrials.gov/ct2/show/NCT03271515

DMH789J	DI	DMH789J
DMH789J	DN	AntiCD19 CART
DMH789J	MI	TTW640A
DMH789J	MN	B-lymphocyte surface antigen B4 (CD19)
DMH789J	MT	DTT
DMH789J	MA	CAR-T-Cell-Therapy
DMH789J	RN	ClinicalTrials.gov (NCT03434769) AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma
DMH789J	RU	https://clinicaltrials.gov/ct2/show/NCT03434769

DM9W1BS	DI	DM9W1BS
DM9W1BS	DN	Anti-CD19 CAR-T
DM9W1BS	MI	TTW640A
DM9W1BS	MN	B-lymphocyte surface antigen B4 (CD19)
DM9W1BS	MT	DTT
DM9W1BS	MA	CAR-T-Cell-Therapy
DM9W1BS	RN	ClinicalTrials.gov (NCT03110640) Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma
DM9W1BS	RU	https://clinicaltrials.gov/ct2/show/NCT03110640

DMW549Y	DI	DMW549Y
DMW549Y	DN	Anti-CD19 CART Cells
DMW549Y	MI	TTW640A
DMW549Y	MN	B-lymphocyte surface antigen B4 (CD19)
DMW549Y	MT	DTT
DMW549Y	MA	CAR-T-Cell-Therapy
DMW549Y	RN	ClinicalTrials.gov (NCT03767725) Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma
DMW549Y	RU	https://clinicaltrials.gov/ct2/show/NCT03767725

DMUQ3C1	DI	DMUQ3C1
DMUQ3C1	DN	Anti-CD19 CAR-T cells
DMUQ3C1	MI	TTW640A
DMUQ3C1	MN	B-lymphocyte surface antigen B4 (CD19)
DMUQ3C1	MT	DTT
DMUQ3C1	MA	CAR-T-Cell-Therapy
DMUQ3C1	RN	ClinicalTrials.gov (NCT03121625) CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
DMUQ3C1	RU	https://clinicaltrials.gov/ct2/show/NCT03121625

DMUVYC5	DI	DMUVYC5
DMUVYC5	DN	Anti-CD19 EBV CTL therapy
DMUVYC5	MI	TTW640A
DMUVYC5	MN	B-lymphocyte surface antigen B4 (CD19)
DMUVYC5	MT	DTT
DMUVYC5	RN	Cytotoxic T cells transduced with chimeric anti-CD19 receptors prevent engraftment of primary lymphoblastic leukemia in vivo. Leukemia. 2010 May;24(5):1080-4.
DMUVYC5	RU	https://pubmed.ncbi.nlm.nih.gov/20220773

DMF93T2	DI	DMF93T2
DMF93T2	DN	Anti-CD19/BCMA CAR-T cells
DMF93T2	MI	TTZ3P4W
DMF93T2	MN	B-cell maturation protein (TNFRSF17)
DMF93T2	MT	DTT
DMF93T2	MA	CAR-T-Cell-Therapy(Dual specific)
DMF93T2	RN	ClinicalTrials.gov (NCT03706547) Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM
DMF93T2	RU	https://clinicaltrials.gov/ct2/show/NCT03706547

DMF93T2	DI	DMF93T2
DMF93T2	DN	Anti-CD19/BCMA CAR-T cells
DMF93T2	MI	TTW640A
DMF93T2	MN	B-lymphocyte surface antigen B4 (CD19)
DMF93T2	MT	DTT
DMF93T2	MA	CAR-T-Cell-Therapy(Dual specific)
DMF93T2	RN	ClinicalTrials.gov (NCT03706547) Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM
DMF93T2	RU	https://clinicaltrials.gov/ct2/show/NCT03706547

DMWKYSM	DI	DMWKYSM
DMWKYSM	DN	Anti-CD19-CAR
DMWKYSM	MI	TTW640A
DMWKYSM	MN	B-lymphocyte surface antigen B4 (CD19)
DMWKYSM	MT	DTT
DMWKYSM	MA	CAR-T-Cell-Therapy
DMWKYSM	RN	ClinicalTrials.gov (NCT01593696) Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma
DMWKYSM	RU	https://clinicaltrials.gov/ct2/show/NCT01593696

DMMRANJ	DI	DMMRANJ
DMMRANJ	DN	Anti-CD19-CAR T
DMMRANJ	MI	TTW640A
DMMRANJ	MN	B-lymphocyte surface antigen B4 (CD19)
DMMRANJ	MT	DTT
DMMRANJ	MA	CAR-T-Cell-Therapy
DMMRANJ	RN	ClinicalTrials.gov (NCT02546739) Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL
DMMRANJ	RU	https://clinicaltrials.gov/ct2/show/NCT02546739

DMYQFCN	DI	DMYQFCN
DMYQFCN	DN	Anti-CD19-CAR T cells
DMYQFCN	MI	TTW640A
DMYQFCN	MN	B-lymphocyte surface antigen B4 (CD19)
DMYQFCN	MT	DTT
DMYQFCN	MA	CAR-T-Cell-Therapy
DMYQFCN	RN	ClinicalTrials.gov (NCT02659943) T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies
DMYQFCN	RU	https://clinicaltrials.gov/ct2/show/NCT02659943

DMUFRDK	DI	DMUFRDK
DMUFRDK	DN	Anti-CD22
DMUFRDK	MI	TTM6QSK
DMUFRDK	MN	B-cell receptor CD22 (CD22)
DMUFRDK	MT	DTT
DMUFRDK	RN	2011 Pipeline of Seattle Genetics.
DMUFRDK	RU	http://www.seagen.com/product_pipeline.php

DMKL92E	DI	DMKL92E
DMKL92E	DN	Anti-CD22 CAR-T cells
DMKL92E	MI	TTM6QSK
DMKL92E	MN	B-cell receptor CD22 (CD22)
DMKL92E	MT	DTT
DMKL92E	MA	CAR-T-Cell-Therapy
DMKL92E	RN	ClinicalTrials.gov (NCT03121625) CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
DMKL92E	RU	https://clinicaltrials.gov/ct2/show/NCT03121625

DMTK78L	DI	DMTK78L
DMTK78L	DN	Anti-CD30 CAR-T cells
DMTK78L	MI	TT2GM5R
DMTK78L	MN	Lymphocyte activation antigen CD30 (TNFRSF8)
DMTK78L	MT	DTT
DMTK78L	MA	CAR-T-Cell-Therapy
DMTK78L	RN	ClinicalTrials.gov (NCT03121625) CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
DMTK78L	RU	https://clinicaltrials.gov/ct2/show/NCT03121625

DM2IEB7	DI	DM2IEB7
DM2IEB7	DN	Anti-CD30-CAR T cells
DM2IEB7	MI	TT2GM5R
DM2IEB7	MN	Lymphocyte activation antigen CD30 (TNFRSF8)
DM2IEB7	MT	DTT
DM2IEB7	MA	CAR-T-Cell-Therapy
DM2IEB7	RN	ClinicalTrials.gov (NCT03049449) T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas
DM2IEB7	RU	https://clinicaltrials.gov/ct2/show/NCT03049449

DMVSPZM	DI	DMVSPZM
DMVSPZM	DN	Anti-CD38 CAR-T cells
DMVSPZM	MI	TTPURFN
DMVSPZM	MN	Cyclic ADP-ribose hydrolase 1 (CD38)
DMVSPZM	MT	DTT
DMVSPZM	MA	CAR-T-Cell-Therapy
DMVSPZM	RN	ClinicalTrials.gov (NCT03464916) Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients
DMVSPZM	RU	https://clinicaltrials.gov/ct2/show/NCT03464916

DMZ2D0G	DI	DMZ2D0G
DMZ2D0G	DN	Anti-CD45 mabs
DMZ2D0G	MI	TTUS45N
DMZ2D0G	MN	Leukocyte common antigen (PTPRC)
DMZ2D0G	MT	DTT
DMZ2D0G	RN	CD45 monoclonal antibody-mediated cytolysis of human NK and T lymphoma cells. Haematologica. 2006 Jul;91(7):886-94.
DMZ2D0G	RU	https://pubmed.ncbi.nlm.nih.gov/16818275

DMMFL2P	DI	DMMFL2P
DMMFL2P	DN	Anti-CD7 CAR-T cells
DMMFL2P	MI	TTP6B8O
DMMFL2P	MN	T-cell antigen CD7 (CD7)
DMMFL2P	MT	DTT
DMMFL2P	MA	CAR-T-Cell-Therapy
DMMFL2P	RN	ClinicalTrials.gov (NCT03121625) CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
DMMFL2P	RU	https://clinicaltrials.gov/ct2/show/NCT03121625

DMDZR0V	DI	DMDZR0V
DMDZR0V	DN	Anti-CEA CAR-T cells
DMDZR0V	MI	TTY6DTE
DMDZR0V	MN	Carcinoembryonic antigen CEA (CD66e)
DMDZR0V	MT	DTT
DMDZR0V	MA	CAR-T-Cell-Therapy
DMDZR0V	RN	ClinicalTrials.gov (NCT03682744) CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
DMDZR0V	RU	https://clinicaltrials.gov/ct2/show/NCT03682744

DMA7L3O	DI	DMA7L3O
DMA7L3O	DN	Anti-CEA CAR-T cells
DMA7L3O	MI	TTY6DTE
DMA7L3O	MN	Carcinoembryonic antigen CEA (CD66e)
DMA7L3O	MT	DTT
DMA7L3O	MA	CAR-T-Cell-Therapy
DMA7L3O	RN	ClinicalTrials.gov (NCT02416466) CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases
DMA7L3O	RU	https://clinicaltrials.gov/ct2/show/NCT02416466

DMJA3H1	DI	DMJA3H1
DMJA3H1	DN	Anti-CEA-CAR T
DMJA3H1	MI	TTY6DTE
DMJA3H1	MN	Carcinoembryonic antigen CEA (CD66e)
DMJA3H1	MT	DTT
DMJA3H1	MA	CAR-T-Cell-Therapy
DMJA3H1	RN	ClinicalTrials.gov (NCT02349724) A Clinical Research of CAR T Cells Targeting CEA Positive Cancer
DMJA3H1	RU	https://clinicaltrials.gov/ct2/show/NCT02349724

DM0ZDJ5	DI	DM0ZDJ5
DM0ZDJ5	DN	Anti-EGFL7
DM0ZDJ5	MI	TT7WD0H
DM0ZDJ5	MN	Epidermal growth factor-like protein 7 (EGFL7)
DM0ZDJ5	MT	DTT
DM0ZDJ5	RN	Clinical pipeline report, company report or official report of Genentech (2009).
DM0ZDJ5	RU	http://www.gene.com/gene/pipeline/status/

DMIVUX1	DI	DMIVUX1
DMIVUX1	DN	Anti-EGFR CAR T
DMIVUX1	MI	TTGKNB4
DMIVUX1	MN	Epidermal growth factor receptor (EGFR)
DMIVUX1	MT	DTT
DMIVUX1	MA	CAR-T-Cell-Therapy
DMIVUX1	RN	ClinicalTrials.gov (NCT02331693) CAR T Cells in Treating Patients With Malignant Gliomas Overexpressing EGFR
DMIVUX1	RU	https://clinicaltrials.gov/ct2/show/NCT02331693

DM73920	DI	DM73920
DM73920	DN	Anti-EGFRvIII CAR T cells
DM73920	MI	TTZ6B2I
DM73920	MN	Epidermal growth factor receptor variant III (EGFR vIII)
DM73920	MT	DTT
DM73920	MA	CAR-T-Cell-Therapy
DM73920	RN	ClinicalTrials.gov (NCT02844062) Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme
DM73920	RU	https://clinicaltrials.gov/ct2/show/NCT02844062

DM6QENU	DI	DM6QENU
DM6QENU	DN	Anti-FGFR3
DM6QENU	MI	TTST7KB
DM6QENU	MN	Fibroblast growth factor receptor 3 (FGFR3)
DM6QENU	MT	DTT
DM6QENU	RN	Clinical pipeline report, company report or official report of Genentech (2011).
DM6QENU	RU	http://www.gene.com/gene/index.jsp

DMBVUFL	DI	DMBVUFL
DMBVUFL	DN	Anti-GD2 T-cells (1RG-CART)
DMBVUFL	MI	TT80ARU
DMBVUFL	MN	Ganglioside GD2 (GD2)
DMBVUFL	MT	DTT
DMBVUFL	MA	CAR-T-Cell-Therapy
DMBVUFL	RN	ClinicalTrials.gov (NCT02761915) A Cancer Research UK Trial of Anti-GD2 T-cells (1RG-CART)
DMBVUFL	RU	https://clinicaltrials.gov/ct2/show/NCT02761915

DMCNFZG	DI	DMCNFZG
DMCNFZG	DN	Anti-GD2-CAR engineered T cells
DMCNFZG	MI	TT80ARU
DMCNFZG	MN	Ganglioside GD2 (GD2)
DMCNFZG	MT	DTT
DMCNFZG	MA	CAR-T-Cell-Therapy
DMCNFZG	RN	ClinicalTrials.gov (NCT02107963) A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
DMCNFZG	RU	https://clinicaltrials.gov/ct2/show/NCT02107963

DMUMWFK	DI	DMUMWFK
DMUMWFK	DN	Anti-GPC3 CAR T
DMUMWFK	MI	TTJTSX4
DMUMWFK	MN	Glypican-3 (GPC3)
DMUMWFK	MT	DTT
DMUMWFK	MA	CAR-T-Cell-Therapy
DMUMWFK	RN	ClinicalTrials.gov (NCT02395250) Anti-GPC3 CAR T for Treating Patients With Advanced HCC
DMUMWFK	RU	https://clinicaltrials.gov/ct2/show/NCT02395250

DMK4GIS	DI	DMK4GIS
DMK4GIS	DN	Anti-hCD70 CAR transduced PBL
DMK4GIS	MI	TTNCIE0
DMK4GIS	MN	CD70 antigen (CD27-L)
DMK4GIS	MT	DTT
DMK4GIS	MA	CAR-T-Cell-Therapy
DMK4GIS	RN	ClinicalTrials.gov (NCT02830724) Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
DMK4GIS	RU	https://clinicaltrials.gov/ct2/show/NCT02830724

DMDMNJ6	DI	DMDMNJ6
DMDMNJ6	DN	Anti-HER3/EGFR DAF
DMDMNJ6	MI	TTGKNB4
DMDMNJ6	MN	Epidermal growth factor receptor (EGFR)
DMDMNJ6	MT	DTT
DMDMNJ6	MA	Modulator
DMDMNJ6	RN	Company report (Biooncology)
DMDMNJ6	RU	http://www.biooncology.com/pipeline-molecules/anti-her3

DMDMNJ6	DI	DMDMNJ6
DMDMNJ6	DN	Anti-HER3/EGFR DAF
DMDMNJ6	MI	TTDC8N2
DMDMNJ6	MN	Erbb3 tyrosine kinase receptor (Erbb-3)
DMDMNJ6	MT	DTT
DMDMNJ6	MA	Modulator
DMDMNJ6	RN	Company report (Biooncology)
DMDMNJ6	RU	http://www.biooncology.com/pipeline-molecules/anti-her3

DMY2MO4	DI	DMY2MO4
DMY2MO4	DN	Anti-meso-CAR T cells
DMY2MO4	MI	TT4RXME
DMY2MO4	MN	Mesothelin (MSLN)
DMY2MO4	MT	DTT
DMY2MO4	MA	CAR-T-Cell-Therapy
DMY2MO4	RN	ClinicalTrials.gov (NCT02580747) Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso
DMY2MO4	RU	https://clinicaltrials.gov/ct2/show/NCT02580747

DM5UQA9	DI	DM5UQA9
DM5UQA9	DN	Anti-meso-CAR vector transduced T cells
DM5UQA9	MI	TT4RXME
DM5UQA9	MN	Mesothelin (MSLN)
DM5UQA9	MT	DTT
DM5UQA9	MA	CAR-T-Cell-Therapy
DM5UQA9	RN	ClinicalTrials.gov (NCT02580747) Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso
DM5UQA9	RU	https://clinicaltrials.gov/ct2/show/NCT02580747

DM5BIM1	DI	DM5BIM1
DM5BIM1	DN	Anti-mesothelin CAR T Cells
DM5BIM1	MI	TT4RXME
DM5BIM1	MN	Mesothelin (MSLN)
DM5BIM1	MT	DTT
DM5BIM1	MA	CAR-T-Cell-Therapy
DM5BIM1	RN	ClinicalTrials.gov (NCT02930993) Anti-mesothelin CAR T Cells for Patients With Recurrent or Metastatic Malignant Tumors
DM5BIM1	RU	https://clinicaltrials.gov/ct2/show/NCT02930993

DMUKFCG	DI	DMUKFCG
DMUKFCG	DN	Anti-Mesothelin CAR-T cells
DMUKFCG	MI	TT4RXME
DMUKFCG	MN	Mesothelin (MSLN)
DMUKFCG	MT	DTT
DMUKFCG	MA	CAR-T-Cell-Therapy
DMUKFCG	RN	ClinicalTrials.gov (NCT03545815) Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.
DMUKFCG	RU	https://clinicaltrials.gov/ct2/show/NCT03545815

DMQ5ZND	DI	DMQ5ZND
DMQ5ZND	DN	Anti-MUC1 mab
DMQ5ZND	MI	TTBHFYQ
DMQ5ZND	MN	Mucin-1 (MUC1)
DMQ5ZND	MT	DTT
DMQ5ZND	MA	Modulator
DMQ5ZND	RN	Characterization of an anti-MUC1 monoclonal antibody with potential as a cancer vaccine. Hybrid Hybridomics. 2001;20(5-6):313-24.
DMQ5ZND	RU	https://pubmed.ncbi.nlm.nih.gov/11839249

DMRWI7E	DI	DMRWI7E
DMRWI7E	DN	Anti-N3pG-Abeta antibody
DMRWI7E	MI	TTE4KHA
DMRWI7E	MN	Amyloid beta A4 protein (APP)
DMRWI7E	MT	DTT
DMRWI7E	RN	LY3002813 Alzheimer's Disease (Phase 1). Eli Lilly & Co.
DMRWI7E	RU	http://www.alzforum.org/therapeutics/ly3002813

DMFZ52G	DI	DMFZ52G
DMFZ52G	DN	Anti-OX40 mab
DMFZ52G	MI	TTL31H0
DMFZ52G	MN	OX40L receptor (CD134)
DMFZ52G	MT	DTT
DMFZ52G	MA	Modulator
DMFZ52G	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1873).
DMFZ52G	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1873

DM0UL47	DI	DM0UL47
DM0UL47	DN	Anti-PD-L1
DM0UL47	MI	TT8ZLTI
DM0UL47	MN	Programmed cell death 1 ligand 1 (PD-L1)
DM0UL47	MT	DTT
DM0UL47	RN	Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012 Jun 28;366(26):2455-65.
DM0UL47	RU	https://pubmed.ncbi.nlm.nih.gov/22658128

DMWIJL1	DI	DMWIJL1
DMWIJL1	DN	Anti-PD-L1 CSR T cells
DMWIJL1	MI	TT8ZLTI
DMWIJL1	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMWIJL1	MT	DTT
DMWIJL1	MA	CAR-T-Cell-Therapy
DMWIJL1	RN	ClinicalTrials.gov (NCT02937844) Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme
DMWIJL1	RU	https://clinicaltrials.gov/ct2/show/NCT02937844

DMAESIY	DI	DMAESIY
DMAESIY	DN	ANX005
DMAESIY	MI	TT7LRQH
DMAESIY	MN	Complement C1s component (C1S)
DMAESIY	MT	DTT
DMAESIY	MA	Inhibitor
DMAESIY	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMAESIY	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM7XES6	DI	DM7XES6
DM7XES6	DN	ANX-042
DM7XES6	MI	TTWVLS6
DM7XES6	MN	Natriuretic peptide receptor (NPR3)
DM7XES6	MT	DTT
DM7XES6	MA	Modulator
DM7XES6	RN	Renin-Angiotensin Blockade Combined With Natriuretic Peptide System Augmentation: Novel Therapeutic Concepts to Combat Heart Failure. Circ Heart Fail. 2013 May; 6(3): 594-605.
DM7XES6	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3981104/

DMGDARN	DI	DMGDARN
DMGDARN	DN	AP32788
DMGDARN	MI	TTGKNB4
DMGDARN	MN	Epidermal growth factor receptor (EGFR)
DMGDARN	MT	DTT
DMGDARN	MA	Inhibitor
DMGDARN	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMGDARN	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM36FOG	DI	DM36FOG
DM36FOG	DN	APD-597
DM36FOG	MI	TT7QNVC
DM36FOG	MN	Glucose-dependent insulinotropic receptor (GPR119)
DM36FOG	MT	DTT
DM36FOG	MA	Agonist
DM36FOG	RN	Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile. Bioorg Med Chem Lett. 2012 Feb 15;22(4):1750-5.
DM36FOG	RU	https://pubmed.ncbi.nlm.nih.gov/22264481

DMRGF9Q	DI	DMRGF9Q
DMRGF9Q	DN	APD-916
DMRGF9Q	MI	TT9JNIC
DMRGF9Q	MN	Histamine H3 receptor (H3R)
DMRGF9Q	MT	DTT
DMRGF9Q	MA	Antagonist
DMRGF9Q	RN	Identification of biaryl sulfone derivatives as antagonists of the histamine H receptor: discovery of (R)-1-(2-(4'-(3-methoxypropylsulfonyl)biphenyl-4-yl)ethyl)-2-methylpyrrolidine (APD916). Bioorg Med Chem Lett. 2012 Jan 1;22(1):71-5.
DMRGF9Q	RU	https://pubmed.ncbi.nlm.nih.gov/22172695

DMLEKUY	DI	DMLEKUY
DMLEKUY	DN	APG-1387
DMLEKUY	MI	TTS74QB
DMLEKUY	MN	Inhibitor of apoptosis protein (hIAP)
DMLEKUY	MT	DTT
DMLEKUY	MA	Inhibitor
DMLEKUY	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMLEKUY	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMLEKUY	DI	DMLEKUY
DMLEKUY	DN	APG-1387
DMLEKUY	MI	TTR7B60
DMLEKUY	MN	X-linked inhibitor of apoptosis protein (XIAP)
DMLEKUY	MT	DTT
DMLEKUY	MA	Antagonist
DMLEKUY	RN	XIAP Limits Autophagic Degradation of Sox2 and Is A Therapeutic Target in Nasopharyngeal Carcinoma Stem Cells.Theranostics. 2018 Feb 5;8(6):1494-1510.
DMLEKUY	RU	https://pubmed.ncbi.nlm.nih.gov/29556337

DM6P93J	DI	DM6P93J
DM6P93J	DN	API-023
DM6P93J	MI	TTF1QVM
DM6P93J	MN	Gastric H(+)/K(+) ATPase alpha (ATP4A)
DM6P93J	MT	DTT
DM6P93J	MA	Inhibitor
DM6P93J	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 849).
DM6P93J	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=849

DM4WAC2	DI	DM4WAC2
DM4WAC2	DN	APL-501
DM4WAC2	MI	TTNBFWK
DM4WAC2	MN	Programmed cell death protein 1 (PD-1)
DM4WAC2	MT	DTT
DM4WAC2	MA	Inhibitor
DM4WAC2	RN	Clinical pipeline report, company report or official report of Apollomics.
DM4WAC2	RU	https://www.apollomicsinc.com/zh-hans/pipeline-drugs/apl-501/

DMPJBCR	DI	DMPJBCR
DMPJBCR	DN	APO-010
DMPJBCR	MI	TTF0RCZ
DMPJBCR	MN	Apoptosis mediating surface antigen FAS (FAS)
DMPJBCR	MT	DTT
DMPJBCR	MA	Binder
DMPJBCR	RN	APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo. Neuro Oncol. 2011 Feb;13(2):155-64.
DMPJBCR	RU	https://pubmed.ncbi.nlm.nih.gov/21183510

DMU8QD2	DI	DMU8QD2
DMU8QD2	DN	Apramycin
DMU8QD2	MI	TT38DW5
DMU8QD2	MN	Bacterial 16S ribosomal RNA (Bact 16S rRNA)
DMU8QD2	MT	DTT
DMU8QD2	MA	Inhibitor
DMU8QD2	RN	RNA as a target for small molecules. Curr Opin Chem Biol. 2000 Dec;4(6):678-86.
DMU8QD2	RU	https://pubmed.ncbi.nlm.nih.gov/11102874

DMXIKYR	DI	DMXIKYR
DMXIKYR	DN	APTO-253
DMXIKYR	MI	TTTI53X
DMXIKYR	MN	Kruppel like factor 4 (KLF4)
DMXIKYR	MT	DTT
DMXIKYR	MA	Inhibitor
DMXIKYR	RN	Phase 1 study of APTO-253 HCl, an inducer of KLF4, in patients with advanced or metastatic solid tumors. Invest New Drugs. 2015 Oct;33(5):1086-92.
DMXIKYR	RU	https://pubmed.ncbi.nlm.nih.gov/26268924

DMXDMH5	DI	DMXDMH5
DMXDMH5	DN	APVO414
DMXDMH5	MI	TT9G4N0
DMXDMH5	MN	Glutamate carboxypeptidase II (GCPII)
DMXDMH5	MT	DTT
DMXDMH5	MA	Inhibitor
DMXDMH5	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMXDMH5	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMUAMZY	DI	DMUAMZY
DMUAMZY	DN	APVO436
DMUAMZY	MI	TTENHJ0
DMUAMZY	MN	Interleukin 3 receptor alpha (IL3RA)
DMUAMZY	MT	DTT
DMUAMZY	MA	Inhibitor
DMUAMZY	RN	Clinical pipeline report, company report or official report of Aptevo.
DMUAMZY	RU	https://aptevotherapeutics.com/apvo436-anti-cd123-x-anti-cd3/

DMUAMZY	DI	DMUAMZY
DMUAMZY	DN	APVO436
DMUAMZY	MI	TTUN7MC
DMUAMZY	MN	T-cell surface glycoprotein CD3 (CD3)
DMUAMZY	MT	DTT
DMUAMZY	MA	Inhibitor
DMUAMZY	RN	Clinical pipeline report, company report or official report of Aptevo.
DMUAMZY	RU	https://aptevotherapeutics.com/apvo436-anti-cd123-x-anti-cd3/

DMXIMQT	DI	DMXIMQT
DMXIMQT	DN	APX-3330
DMXIMQT	MI	TTHGL48
DMXIMQT	MN	AP endonuclease 1 (APEX1)
DMXIMQT	MT	DTT
DMXIMQT	MA	Inhibitor
DMXIMQT	RN	Inhibition of APE1/Ref-1 redox activity with APX3330 blocks retinal angiogenesis in vitro and in vivo. Vision Res. 2011 Jan;51(1):93-100.
DMXIMQT	RU	https://pubmed.ncbi.nlm.nih.gov/20937296

DM4RK6P	DI	DM4RK6P
DM4RK6P	DN	AR-12
DM4RK6P	MI	TT9QBI6
DM4RK6P	MN	Phosphoinositide dependent protein kinase-1 (PDPK1)
DM4RK6P	MT	DTT
DM4RK6P	MA	Modulator
DM4RK6P	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM4RK6P	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMY0DPM	DI	DMY0DPM
DMY0DPM	DN	ARC-1905
DMY0DPM	MI	TTKANGO
DMY0DPM	MN	Complement C5 (CO5)
DMY0DPM	MT	DTT
DMY0DPM	RN	ClinicalTrials.gov (NCT00950638) A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration. U.S. National Institutes of Health.
DMY0DPM	RU	https://clinicaltrials.gov/ct2/show/NCT00950638

DMFJZK3	DI	DMFJZK3
DMFJZK3	DN	Arecoline
DMFJZK3	MI	TTZ9SOR
DMFJZK3	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMFJZK3	MT	DTT
DMFJZK3	MA	Inhibitor
DMFJZK3	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMFJZK3	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMPLHBI	DI	DMPLHBI
DMPLHBI	DN	ARI-0001 cells
DMPLHBI	MI	TTW640A
DMPLHBI	MN	B-lymphocyte surface antigen B4 (CD19)
DMPLHBI	MT	DTT
DMPLHBI	MA	CAR-T-Cell-Therapy
DMPLHBI	RN	ClinicalTrials.gov (NCT03144583) Pilot Study on the Infusion of ARI-0001 Cells in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy
DMPLHBI	RU	https://clinicaltrials.gov/ct2/show/NCT03144583

DMN4D3A	DI	DMN4D3A
DMN4D3A	DN	ARI-2243
DMN4D3A	MI	TTDIGC1
DMN4D3A	MN	Dipeptidyl peptidase 4 (DPP-4)
DMN4D3A	MT	DTT
DMN4D3A	MA	Modulator
DMN4D3A	RN	Incorporating Incretin-Based Therapies Into Clinical Practice: Differences Between Glucagon-Like Peptide 1 Receptor Agonists and Dipeptidyl Peptidase 4 Inhibitors. Mayo Clin Proc. 2010 December; 85(12 Suppl): S27-S37.
DMN4D3A	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2996165/

DMY5IM2	DI	DMY5IM2
DMY5IM2	DN	ARL-67085
DMY5IM2	MI	TTZ1DT0
DMY5IM2	MN	P2Y purinoceptor 12 (P2RY12)
DMY5IM2	MT	DTT
DMY5IM2	MA	Agonist
DMY5IM2	RN	Pharmacological characterization of the human P2Y11 receptor. Br J Pharmacol. 1999 Nov;128(6):1199-206.
DMY5IM2	RU	https://pubmed.ncbi.nlm.nih.gov/10578132

DMQUFNY	DI	DMQUFNY
DMQUFNY	DN	ARM210
DMQUFNY	MI	TT9YXM1
DMQUFNY	MN	Ryanodine receptor (RYR)
DMQUFNY	MT	DTT
DMQUFNY	MA	Modulator
DMQUFNY	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQUFNY	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DM4D85V	DI	DM4D85V
DM4D85V	DN	ARN-6039
DM4D85V	MI	TTGV6LY
DM4D85V	MN	Nuclear receptor ROR-gamma (RORG)
DM4D85V	MT	DTT
DM4D85V	MA	Agonist
DM4D85V	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM4D85V	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM5R7VI	DI	DM5R7VI
DM5R7VI	DN	ARN-6039
DM5R7VI	MI	TTGV6LY
DM5R7VI	MN	Nuclear receptor ROR-gamma (RORG)
DM5R7VI	MT	DTT
DM5R7VI	MA	Agonist
DM5R7VI	RN	Clinical pipeline report, company report or official report of Arrien Pharmaceuticals.
DM5R7VI	RU	https://www.arrienpharma.com/arn-6039.html

DMV5PEK	DI	DMV5PEK
DMV5PEK	DN	ARO-HIF2
DMV5PEK	MI	TTWPA54
DMV5PEK	MN	HIF2-alpha messenger RNA (EPAS1 mRNA)
DMV5PEK	MT	DTT
DMV5PEK	MA	Inhibitor
DMV5PEK	RN	National Cancer Institute Drug Dictionary (drug name ARO-HIF2).
DMV5PEK	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/hif2a-rnai-aro-hif2

DMCRLQZ	DI	DMCRLQZ
DMCRLQZ	DN	ARQ 621
DMCRLQZ	MI	TTTRP0H
DMCRLQZ	MN	Kinesin-like protein KIF11 (KIF11)
DMCRLQZ	MT	DTT
DMCRLQZ	MA	Modulator
DMCRLQZ	RN	Kinesins and cancer. Nat Rev Cancer. 2012 Jul 24;12(8):527-39.
DMCRLQZ	RU	https://pubmed.ncbi.nlm.nih.gov/22825217

DMP9ZT1	DI	DMP9ZT1
DMP9ZT1	DN	ARQ 736
DMP9ZT1	MI	TTWCGQT
DMP9ZT1	MN	Serine/threonine-protein kinase B-raf (BRAF)
DMP9ZT1	MT	DTT
DMP9ZT1	MA	Modulator
DMP9ZT1	RN	National Cancer Institute Drug Dictionary (drug id 688029).
DMP9ZT1	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=688029

DM7MWX0	DI	DM7MWX0
DM7MWX0	DN	ARQ 751
DM7MWX0	MI	TTWTSCV
DM7MWX0	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DM7MWX0	MT	DTT
DM7MWX0	MA	Inhibitor
DM7MWX0	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7MWX0	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM1FTEC	DI	DM1FTEC
DM1FTEC	DN	ARQ-171
DM1FTEC	MI	TTVJDNB
DM1FTEC	MN	E2F transcription factor 1 (E2F1)
DM1FTEC	MT	DTT
DM1FTEC	MA	Modulator
DM1FTEC	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025396)
DM1FTEC	RU	http://adisinsight.springer.com/drugs/800025396

DMBQWVR	DI	DMBQWVR
DMBQWVR	DN	ARQ-751
DMBQWVR	MI	TTQ7UAP
DMBQWVR	MN	RAC serine/threonine-protein kinase (AKT)
DMBQWVR	MT	DTT
DMBQWVR	MA	Inhibitor
DMBQWVR	RN	Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092. PLoS One. 2015 Oct 15;10(10):e0140479.
DMBQWVR	RU	https://pubmed.ncbi.nlm.nih.gov/26469692

DMMPTCK	DI	DMMPTCK
DMMPTCK	DN	ARRY-300
DMMPTCK	MI	TTROQ37
DMMPTCK	MN	MAPK/ERK kinase kinase (MAP3K)
DMMPTCK	MT	DTT
DMMPTCK	MA	Modulator
DMMPTCK	RN	MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013 Apr 12;6:27.
DMMPTCK	RU	https://pubmed.ncbi.nlm.nih.gov/23587417

DMCNV0M	DI	DMCNV0M
DMCNV0M	DN	ARRY-380
DMCNV0M	MI	TT6EO5L
DMCNV0M	MN	Erbb2 tyrosine kinase receptor (HER2)
DMCNV0M	MT	DTT
DMCNV0M	MA	Modulator
DMCNV0M	RN	ARRY-380, a Potent, Small Molecule Inhibitor of ErbB2, Increases Survival in Intracranial ErbB2+ Xenograft Models in Mice
DMCNV0M	RU	http://arraybiopharma.com/publications/arry-380-potent-small-molecule-inhibitor-erbb2-increases-survival-intracranial-erbb2-xenograft-models-mice/

DM4CZ2Y	DI	DM4CZ2Y
DM4CZ2Y	DN	ARX-424
DM4CZ2Y	MI	TT4TZ8J
DM4CZ2Y	MN	Interferon-beta (IFNB1)
DM4CZ2Y	MT	DTT
DM4CZ2Y	MA	Modulator
DM4CZ2Y	RN	PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update. Biologics. 2013; 7: 131-138.
DM4CZ2Y	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686537/

DMM9ORD	DI	DMM9ORD
DMM9ORD	DN	ASG-15ME
DMM9ORD	MI	TTTVEKI
DMM9ORD	MN	SLIT and NTRK-like family member 6 (SLITRK6)
DMM9ORD	MT	DTT
DMM9ORD	RN	Clinical pipeline report, company report or official report of Seattle Genetics.
DMM9ORD	RU	http://www.seattlegenetics.com/asg15me

DM0Z3JS	DI	DM0Z3JS
DM0Z3JS	DN	ASG-22ME
DM0Z3JS	MI	TTPO9EG
DM0Z3JS	MN	Nectin cell adhesion molecule 4 (NECTIN4)
DM0Z3JS	MT	DTT
DM0Z3JS	RN	2011 Pipeline of Seattle Genetics.
DM0Z3JS	RU	http://www.seagen.com/product_pipeline.php

DMD0BMN	DI	DMD0BMN
DMD0BMN	DN	ASG-5ME
DMD0BMN	MI	TT0NYDG
DMD0BMN	MN	Choline transporter-like protein 4 (SLC44A4)
DMD0BMN	MT	DTT
DMD0BMN	RN	2011 Pipeline of Seattle Genetics.
DMD0BMN	RU	http://www.seagen.com/product_pipeline.php

DMJCX6D	DI	DMJCX6D
DMJCX6D	DN	ASN003
DMJCX6D	MI	TTWCGQT
DMJCX6D	MN	Serine/threonine-protein kinase B-raf (BRAF)
DMJCX6D	MT	DTT
DMJCX6D	MA	Inhibitor
DMJCX6D	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMJCX6D	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMYHEUA	DI	DMYHEUA
DMYHEUA	DN	ASN007
DMYHEUA	MI	TT1MG9E
DMYHEUA	MN	Extracellular signal-regulated kinase 1 (ERK1)
DMYHEUA	MT	DTT
DMYHEUA	MA	Inhibitor
DMYHEUA	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMYHEUA	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM8DBT6	DI	DM8DBT6
DM8DBT6	DN	ASP-0777
DM8DBT6	MI	TT9IK2Z
DM8DBT6	MN	N-methyl-D-aspartate receptor (NMDAR)
DM8DBT6	MT	DTT
DM8DBT6	MA	Modulator
DM8DBT6	RN	US patent application no. 2011,0262,442, Compositions for treating cns disorders.
DM8DBT6	RU	https://www.google.com/patents/US20110262442

DMC80LV	DI	DMC80LV
DMC80LV	DN	ASP1948
DMC80LV	MI	TTIPJCB
DMC80LV	MN	Neuropilin-1 (NRP1)
DMC80LV	MT	DTT
DMC80LV	MA	Inhibitor
DMC80LV	RN	National Cancer Institute Drug Dictionary (drug name ASP1948).
DMC80LV	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-nrp1-antibody-asp1948

DMX4PWV	DI	DMX4PWV
DMX4PWV	DN	ASP1951
DMX4PWV	MI	TTG6LA7
DMX4PWV	MN	Activation-inducible TNFR family receptor (TNFRSF18)
DMX4PWV	MT	DTT
DMX4PWV	MA	Agonist
DMX4PWV	RN	ClinicalTrials.gov (NCT03799003) A Study of ASP1951 in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
DMX4PWV	RU	https://clinicaltrials.gov/ct2/show/NCT03799003

DMW72NJ	DI	DMW72NJ
DMW72NJ	DN	ASP3026
DMW72NJ	MI	TTPMQSO
DMW72NJ	MN	ALK tyrosine kinase receptor (ALK)
DMW72NJ	MT	DTT
DMW72NJ	MA	Modulator
DMW72NJ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7740).
DMW72NJ	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7740

DM1RD0T	DI	DM1RD0T
DM1RD0T	DN	ASP-4058
DM1RD0T	MI	TT9JZCK
DM1RD0T	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DM1RD0T	MT	DTT
DM1RD0T	MA	Modulator
DM1RD0T	RN	ASP4058, a novel agonist for sphingosine 1-phosphate receptors 1 and 5, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile. PLoS One. 2014 Oct 27;9(10):e110819.
DM1RD0T	RU	https://pubmed.ncbi.nlm.nih.gov/25347187

DM1RD0T	DI	DM1RD0T
DM1RD0T	DN	ASP-4058
DM1RD0T	MI	TTDZCKV
DM1RD0T	MN	Sphingosine-1-phosphate receptor 5 (S1PR5)
DM1RD0T	MT	DTT
DM1RD0T	MA	Modulator
DM1RD0T	RN	ASP4058, a novel agonist for sphingosine 1-phosphate receptors 1 and 5, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile. PLoS One. 2014 Oct 27;9(10):e110819.
DM1RD0T	RU	https://pubmed.ncbi.nlm.nih.gov/25347187

DMA71OL	DI	DMA71OL
DMA71OL	DN	ASP8374
DMA71OL	MI	TTWNL74
DMA71OL	MN	V-set and immunoglobulin domain-containing protein 9 (TIGIT)
DMA71OL	MT	DTT
DMA71OL	MA	Antagonist
DMA71OL	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMA71OL	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMCDMPW	DI	DMCDMPW
DMCDMPW	DN	ASP9801
DMCDMPW	MI	TTF89GD
DMCDMPW	MN	Interleukin-2 (IL2)
DMCDMPW	MT	DTT
DMCDMPW	RN	Clinical pipeline report, company report or official report of Astellas Pharma.
DMCDMPW	RU	https://www.astellas.com/system/files/2020-03/rdmeeting2019_pre_en2.pdf

DMCDMPW	DI	DMCDMPW
DMCDMPW	DN	ASP9801
DMCDMPW	MI	TT8FRMO
DMCDMPW	MN	Interleukin-7 (IL7)
DMCDMPW	MT	DTT
DMCDMPW	RN	Clinical pipeline report, company report or official report of Astellas Pharma.
DMCDMPW	RU	https://www.astellas.com/system/files/2020-03/rdmeeting2019_pre_en2.pdf

DMCN7WI	DI	DMCN7WI
DMCN7WI	DN	AST-005
DMCN7WI	MI	TTF8CQI
DMCN7WI	MN	Tumor necrosis factor (TNF)
DMCN7WI	MT	DTT
DMCN7WI	MA	Inhibitor
DMCN7WI	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMCN7WI	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM7C68W	DI	DM7C68W
DM7C68W	DN	AST-008
DM7C68W	MI	TTSHG0T
DM7C68W	MN	Toll-like receptor 9 (TLR9)
DM7C68W	MT	DTT
DM7C68W	MA	Agonist
DM7C68W	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7C68W	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMD83WO	DI	DMD83WO
DMD83WO	DN	AST-1306
DMD83WO	MI	TTGKNB4
DMD83WO	MN	Epidermal growth factor receptor (EGFR)
DMD83WO	MT	DTT
DMD83WO	MA	Modulator
DMD83WO	RN	AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo. PLoS One. 2011;6(7):e21487.
DMD83WO	RU	https://pubmed.ncbi.nlm.nih.gov/21789172

DMD2BIT	DI	DMD2BIT
DMD2BIT	DN	AT001/r84
DMD2BIT	MI	TTOHSBA
DMD2BIT	MN	Vascular endothelial growth factor A (VEGFA)
DMD2BIT	MT	DTT
DMD2BIT	RN	Clinical pipeline report, company report or official report of Affitech (2011).
DMD2BIT	RU	http://www.affitech.com/

DMYIPKJ	DI	DMYIPKJ
DMYIPKJ	DN	AT13148
DMYIPKJ	MI	TTMQO60
DMYIPKJ	MN	Rho-associated protein kinase (ROCK)
DMYIPKJ	MT	DTT
DMYIPKJ	MA	Modulator
DMYIPKJ	RN	Company report (Astex)
DMYIPKJ	RU	http://www.astx.com/pipeline/products/clinical

DM2B9E0	DI	DM2B9E0
DM2B9E0	DN	AT13387
DM2B9E0	MI	TT78R5H
DM2B9E0	MN	Heat shock protein 90 alpha (HSP90A)
DM2B9E0	MT	DTT
DM2B9E0	MA	Inhibitor
DM2B9E0	RN	Astex Presents Updates on AT13387, its HSP90 Inhibitor, and AT9283, its Multi-Targeted Kinase Inhibitor at the EORTC-NCI-AACR Cancer Conference. Astex. 2008.
DM2B9E0	RU	http://www.drugs.com/clinical_trials/astex-presents-updates-at13387-hsp90-inhibitor-at9283-multi-targeted-kinase-inhibitor-eortc-nci-5775.html

DMCE08M	DI	DMCE08M
DMCE08M	DN	AT7519
DMCE08M	MI	TT7HF4W
DMCE08M	MN	Cyclin-dependent kinase 2 (CDK2)
DMCE08M	MT	DTT
DMCE08M	MA	Inhibitor
DMCE08M	RN	Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Mol Cancer Ther. 2009 Feb;8(2):324-32.
DMCE08M	RU	https://pubmed.ncbi.nlm.nih.gov/19174555

DMHYO38	DI	DMHYO38
DMHYO38	DN	AT-787
DMHYO38	MI	TTMVBWH
DMHYO38	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMHYO38	MT	DTT
DMHYO38	MA	Inhibitor
DMHYO38	RN	Clinical pipeline report, company report or official report of Atea Pharmaceuticals.
DMHYO38	RU	https://ateapharma.com/about-us/hepatitis-c/

DM6O0TM	DI	DM6O0TM
DM6O0TM	DN	ATA2271
DM6O0TM	MI	TT4RXME
DM6O0TM	MN	Mesothelin (MSLN)
DM6O0TM	MT	DTT
DM6O0TM	RN	Clinical pipeline report, company report or official report of Atara Biotherapeutics.
DM6O0TM	RU	https://www.atarabio.com/pipeline/ata2271-ata3271/

DMIMH8L	DI	DMIMH8L
DMIMH8L	DN	ATD transdermal gel
DMIMH8L	MI	TTZAYWL
DMIMH8L	MN	Estrogen receptor (ESR)
DMIMH8L	MT	DTT
DMIMH8L	MA	Inhibitor
DMIMH8L	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620).
DMIMH8L	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=620

DM96JTX	DI	DM96JTX
DM96JTX	DN	ATEVIRDINE
DM96JTX	MI	TT84ETX
DM96JTX	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM96JTX	MT	DTT
DM96JTX	MA	Modulator
DM96JTX	RN	Targeting delavirdine/atevirdine resistant HIV-1: identification of (alkylamino)piperidine-containing bis(heteroaryl)piperazines as broad spectrum ... J Med Chem. 1996 Sep 13;39(19):3769-89.
DM96JTX	RU	https://pubmed.ncbi.nlm.nih.gov/8809165

DMWGKHZ	DI	DMWGKHZ
DMWGKHZ	DN	ATF-936
DMWGKHZ	MI	TTBUYHA
DMWGKHZ	MN	Extracellular calcium-sensing receptor (CASR)
DMWGKHZ	MT	DTT
DMWGKHZ	MA	Antagonist
DMWGKHZ	RN	ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans. Bone. 2011 Aug;49(2):233-41.
DMWGKHZ	RU	https://pubmed.ncbi.nlm.nih.gov/21514409

DMT5Z84	DI	DMT5Z84
DMT5Z84	DN	ATI-0917
DMT5Z84	MI	TTF7I5O
DMT5Z84	MN	Human immunodeficiency virus Rev protein (HIV rev)
DMT5Z84	MT	DTT
DMT5Z84	MA	Inhibitor
DMT5Z84	RN	Antiretroviral drugs in development. A report from HIV DART 2008: Frontiers in Drug Development for Antiretroviral Therapies, 9-12 December 2008, Rio Grande, Puerto Rico. Expert Opin Investig Drugs. 2009 Apr;18(4):549-53.
DMT5Z84	RU	https://pubmed.ncbi.nlm.nih.gov/19335283

DMBKO2W	DI	DMBKO2W
DMBKO2W	DN	ATI-355
DMBKO2W	MI	TT7GXMU
DMBKO2W	MN	Reticulon-4 (RTN4)
DMBKO2W	MT	DTT
DMBKO2W	RN	Limiting multiple sclerosis related axonopathy by blocking Nogo receptor and CRMP-2 phosphorylation. Brain. 2012 June; 135(6): 1794-1818.
DMBKO2W	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589918/

DM6GKMU	DI	DM6GKMU
DM6GKMU	DN	ATI-9242
DM6GKMU	MI	TTJQOD7
DM6GKMU	MN	5-HT 2A receptor (HTR2A)
DM6GKMU	MT	DTT
DM6GKMU	MA	Modulator
DM6GKMU	RN	Pharmacological characteristics of ATI-9242, a Novel Atypical Antipsychotic. FASEB J, April, 2010, 24(Meeting Abstract Supplement),773.12.
DM6GKMU	RU	http://www.fasebj.org/cgi/content/meeting_abstract/24/1_MeetingAbstracts/773.12

DM6GKMU	DI	DM6GKMU
DM6GKMU	DN	ATI-9242
DM6GKMU	MI	TTO9X1H
DM6GKMU	MN	5-HT 7 receptor (HTR7)
DM6GKMU	MT	DTT
DM6GKMU	MA	Modulator
DM6GKMU	RN	Pharmacological characteristics of ATI-9242, a Novel Atypical Antipsychotic. FASEB J, April, 2010, 24(Meeting Abstract Supplement),773.12.
DM6GKMU	RU	http://www.fasebj.org/cgi/content/meeting_abstract/24/1_MeetingAbstracts/773.12

DM6GKMU	DI	DM6GKMU
DM6GKMU	DN	ATI-9242
DM6GKMU	MI	TTEX248
DM6GKMU	MN	Dopamine D2 receptor (D2R)
DM6GKMU	MT	DTT
DM6GKMU	MA	Modulator
DM6GKMU	RN	Pharmacological characteristics of ATI-9242, a Novel Atypical Antipsychotic. FASEB J, April, 2010, 24(Meeting Abstract Supplement),773.12.
DM6GKMU	RU	http://www.fasebj.org/cgi/content/meeting_abstract/24/1_MeetingAbstracts/773.12

DMR93S5	DI	DMR93S5
DMR93S5	DN	ATL1103
DMR93S5	MI	TTHJWYD
DMR93S5	MN	GHR messenger RNA (GHR mRNA)
DMR93S5	MT	DTT
DMR93S5	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009).
DMR93S5	RU	http://www.isispharm.com/Pipeline/index.htm

DMZI4UX	DI	DMZI4UX
DMZI4UX	DN	ATLCAR.CD30 cells
DMZI4UX	MI	TT2GM5R
DMZI4UX	MN	Lymphocyte activation antigen CD30 (TNFRSF8)
DMZI4UX	MT	DTT
DMZI4UX	MA	CAR-T-Cell-Therapy
DMZI4UX	RN	ClinicalTrials.gov (NCT03602157) Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and NHL
DMZI4UX	RU	https://clinicaltrials.gov/ct2/show/NCT03602157

DM3IPSX	DI	DM3IPSX
DM3IPSX	DN	ATLCAR.CD30.CCR4 cells
DM3IPSX	MI	TT7HQD0
DM3IPSX	MN	C-C chemokine receptor type 4 (CCR4)
DM3IPSX	MT	DTT
DM3IPSX	MA	CAR-T-Cell-Therapy(Dual specific)
DM3IPSX	RN	ClinicalTrials.gov (NCT03602157) Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and NHL
DM3IPSX	RU	https://clinicaltrials.gov/ct2/show/NCT03602157

DM3IPSX	DI	DM3IPSX
DM3IPSX	DN	ATLCAR.CD30.CCR4 cells
DM3IPSX	MI	TT2GM5R
DM3IPSX	MN	Lymphocyte activation antigen CD30 (TNFRSF8)
DM3IPSX	MT	DTT
DM3IPSX	MA	CAR-T-Cell-Therapy(Dual specific)
DM3IPSX	RN	ClinicalTrials.gov (NCT03602157) Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and NHL
DM3IPSX	RU	https://clinicaltrials.gov/ct2/show/NCT03602157

DMU67HD	DI	DMU67HD
DMU67HD	DN	ATR-01
DMU67HD	MI	TTK3C21
DMU67HD	MN	Acetoacetyl-CoA thiolase (ACAT1)
DMU67HD	MT	DTT
DMU67HD	MA	Inhibitor
DMU67HD	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMU67HD	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DMUMVXK	DI	DMUMVXK
DMUMVXK	DN	ATR-101
DMUMVXK	MI	TT4V7ST
DMUMVXK	MN	Sterol O-acyltransferase (SOAT)
DMUMVXK	MT	DTT
DMUMVXK	MA	Modulator
DMUMVXK	RN	Company report (Atterocor)
DMUMVXK	RU	http://atterocor.com/pdf/Atterocor-ENDO-PR-61214.pdf

DMBCATZ	DI	DMBCATZ
DMBCATZ	DN	ATR-107
DMBCATZ	MI	TTZO9B0
DMBCATZ	MN	Interleukin 21 receptor (IL21R)
DMBCATZ	MT	DTT
DMBCATZ	RN	Anti-IL21 receptor monoclonal antibody (ATR-107): Safety, pharmacokinetics, and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study. J Clin Pharmacol. 2014 Jan;54(1):14-22.
DMBCATZ	RU	https://pubmed.ncbi.nlm.nih.gov/23913720

DMTG9EV	DI	DMTG9EV
DMTG9EV	DN	ATRC-101
DMTG9EV	MI	TTHC8EF
DMTG9EV	MN	Polyadenylate-binding protein 1 (PABPC1)
DMTG9EV	MT	DTT
DMTG9EV	RN	Clinical pipeline report, company report or official report of Atreca.
DMTG9EV	RU	https://www.atreca.com/pipeline/

DML4SIE	DI	DML4SIE
DML4SIE	DN	Atu-027
DML4SIE	MI	TTW3P4R
DML4SIE	MN	Protein kinase N3 (PKN3)
DML4SIE	MT	DTT
DML4SIE	MA	Modulator
DML4SIE	RN	Company report (Silence Therapeutics)
DML4SIE	RU	http://www.silence-therapeutics.com/pipeline/?doing_wp_cron=1455613779.0401461124420166015625#AboutAtu027

DMKNMAE	DI	DMKNMAE
DMKNMAE	DN	Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
DMKNMAE	MI	TTZ3P4W
DMKNMAE	MN	B-cell maturation protein (TNFRSF17)
DMKNMAE	MT	DTT
DMKNMAE	MA	CAR-T-Cell-Therapy
DMKNMAE	RN	ClinicalTrials.gov (NCT03338972) Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma
DMKNMAE	RU	https://clinicaltrials.gov/ct2/show/NCT03338972

DMQA1VT	DI	DMQA1VT
DMQA1VT	DN	Autologous cell based gene therapy
DMQA1VT	MI	TTCM4B3
DMQA1VT	MN	Nitric-oxide synthase endothelial (NOS3)
DMQA1VT	MT	DTT
DMQA1VT	MA	Modulator
DMQA1VT	RN	Feasibility of using autologous transplantation to evaluate hematopoietic stem cell-based gene therapy strategies in transgenic mouse models of human disease. Mol Ther. 2002 Sep;6(3):422-8.
DMQA1VT	RU	https://pubmed.ncbi.nlm.nih.gov/12231180

DMJW4TP	DI	DMJW4TP
DMJW4TP	DN	Autologous ET1402L1-CART cells
DMJW4TP	MI	TT3WAD0
DMJW4TP	MN	HLA-A02/AFP complex (HLA-A02/AFP)
DMJW4TP	MT	DTT
DMJW4TP	MA	CAR-T-Cell-Therapy
DMJW4TP	RN	ClinicalTrials.gov (NCT03349255) Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma
DMJW4TP	RU	https://clinicaltrials.gov/ct2/show/NCT03349255

DMARYFK	DI	DMARYFK
DMARYFK	DN	Autologous melanoma cell vaccine
DMARYFK	MI	TTNYZG2
DMARYFK	MN	Granulocyte-macrophage colony-stimulating factor (CSF2)
DMARYFK	MT	DTT
DMARYFK	MA	Modulator
DMARYFK	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMARYFK	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMZ763A	DI	DMZ763A
DMZ763A	DN	Autologous T Cells Expressing MET scFv CAR
DMZ763A	MI	TTNDSF4
DMZ763A	MN	Proto-oncogene c-Met (MET)
DMZ763A	MT	DTT
DMZ763A	MA	CAR-T-Cell-Therapy
DMZ763A	RN	ClinicalTrials.gov (NCT03060356) Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET)
DMZ763A	RU	https://clinicaltrials.gov/ct2/show/NCT03060356

DMTLU37	DI	DMTLU37
DMTLU37	DN	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1
DMTLU37	MI	TT4RXME
DMTLU37	MN	Mesothelin (MSLN)
DMTLU37	MT	DTT
DMTLU37	MA	CAR-T-Cell-Therapy
DMTLU37	RN	ClinicalTrials.gov (NCT01897415) Autologous Redirected RNA Meso CAR T Cells for Pancreatic Cancer
DMTLU37	RU	https://clinicaltrials.gov/ct2/show/NCT01897415

DMOAET3	DI	DMOAET3
DMOAET3	DN	Autologous T-cell therapy
DMOAET3	MI	TT9G4N0
DMOAET3	MN	Glutamate carboxypeptidase II (GCPII)
DMOAET3	MT	DTT
DMOAET3	RN	Antitumor activities of PSMA CD3 diabodies by redirected T-cell lysis of prostate cancer cells. Immunotherapy. 2013 Jan;5(1):27-38.
DMOAET3	RU	https://pubmed.ncbi.nlm.nih.gov/23256796

DMOAET3	DI	DMOAET3
DMOAET3	DN	Autologous T-cell therapy
DMOAET3	MI	TTZAT79
DMOAET3	MN	T-cell surface glycoprotein CD3 epsilon (CD3E)
DMOAET3	MT	DTT
DMOAET3	RN	Antitumor activities of PSMA CD3 diabodies by redirected T-cell lysis of prostate cancer cells. Immunotherapy. 2013 Jan;5(1):27-38.
DMOAET3	RU	https://pubmed.ncbi.nlm.nih.gov/23256796

DMOAET3	DI	DMOAET3
DMOAET3	DN	Autologous T-cell therapy
DMOAET3	MI	TTV3XPL
DMOAET3	MN	T-cell surface glycoprotein CD3 gamma (CD3G)
DMOAET3	MT	DTT
DMOAET3	RN	Antitumor activities of PSMA CD3 diabodies by redirected T-cell lysis of prostate cancer cells. Immunotherapy. 2013 Jan;5(1):27-38.
DMOAET3	RU	https://pubmed.ncbi.nlm.nih.gov/23256796

DMZLCTD	DI	DMZLCTD
DMZLCTD	DN	AV-203
DMZLCTD	MI	TTDC8N2
DMZLCTD	MN	Erbb3 tyrosine kinase receptor (Erbb-3)
DMZLCTD	MT	DTT
DMZLCTD	RN	Neuregulin 1 expression is a predictive biomarker for response to AV-203, an ERBB3 inhibitory antibody, in human tumor models. Clin Cancer Res. 2015 Mar 1;21(5):1106-14.
DMZLCTD	RU	https://pubmed.ncbi.nlm.nih.gov/25542901

DME630T	DI	DME630T
DME630T	DN	AV4025
DME630T	MI	TTCJ2X8
DME630T	MN	Hepatitis C virus Non-structural 5A (HCV NS5A)
DME630T	MT	DTT
DME630T	MA	Modulator
DME630T	RN	Discovery of novel highly potent hepatitis C virus NS5A inhibitor (AV4025). J Med Chem. 2014 Sep 25;57(18):7716-30.
DME630T	RU	https://pubmed.ncbi.nlm.nih.gov/25148100

DMVL87N	DI	DMVL87N
DMVL87N	DN	AV-965
DMVL87N	MI	TTSQIFT
DMVL87N	MN	5-HT 1A receptor (HTR1A)
DMVL87N	MT	DTT
DMVL87N	MA	Antagonist
DMVL87N	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025412)
DMVL87N	RU	http://adisinsight.springer.com/drugs/800025412

DMKCRMD	DI	DMKCRMD
DMKCRMD	DN	AVB-S6-500
DMKCRMD	MI	TTZPY6J
DMKCRMD	MN	Tyrosine-protein kinase UFO (AXL)
DMKCRMD	MT	DTT
DMKCRMD	MA	Inhibitor
DMKCRMD	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMKCRMD	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMSR91U	DI	DMSR91U
DMSR91U	DN	AVE0118
DMSR91U	MI	TT1VOHK
DMSR91U	MN	Potassium channel unspecific (KC)
DMSR91U	MT	DTT
DMSR91U	MA	Modulator
DMSR91U	RN	Neurogenic contraction induced by the antiarrhythmic compound, AVE 0118, in rat small mesenteric arteries.Basic Clin Pharmacol Toxicol.2014 Oct;115(4):315-20.
DMSR91U	RU	https://www.ncbi.nlm.nih.gov/pubmed/24629214

DM56VG2	DI	DM56VG2
DM56VG2	DN	AVE0897
DM56VG2	MI	TTJ584C
DM56VG2	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DM56VG2	MT	DTT
DM56VG2	MA	Agonist
DM56VG2	RN	Pharma & Vaccines. Product Development Pipeline. April 29 2009.
DM56VG2	RU	http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf

DMJY35M	DI	DMJY35M
DMJY35M	DN	AVE1701
DMJY35M	MI	TTC24WT
DMJY35M	MN	C-C chemokine receptor type 1 (CCR1)
DMJY35M	MT	DTT
DMJY35M	MA	Antagonist
DMJY35M	RN	Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
DMJY35M	RU	https://pubmed.ncbi.nlm.nih.gov/18321156

DMZNTHJ	DI	DMZNTHJ
DMZNTHJ	DN	AVE-8112
DMZNTHJ	MI	TTZ97H5
DMZNTHJ	MN	Phosphodiesterase 4A (PDE4A)
DMZNTHJ	MT	DTT
DMZNTHJ	MA	Inhibitor
DMZNTHJ	RN	Therapy for Parkinson's Disease: What is in the Pipeline . Neurotherapeutics. 2014 January; 11(1): 24-33.
DMZNTHJ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899489/

DMZNTHJ	DI	DMZNTHJ
DMZNTHJ	DN	AVE-8112
DMZNTHJ	MI	TTVIAT9
DMZNTHJ	MN	Phosphodiesterase 4B (PDE4B)
DMZNTHJ	MT	DTT
DMZNTHJ	MA	Inhibitor
DMZNTHJ	RN	Therapy for Parkinson's Disease: What is in the Pipeline . Neurotherapeutics. 2014 January; 11(1): 24-33.
DMZNTHJ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899489/

DMZNTHJ	DI	DMZNTHJ
DMZNTHJ	DN	AVE-8112
DMZNTHJ	MI	TTSKMI8
DMZNTHJ	MN	Phosphodiesterase 4D (PDE4D)
DMZNTHJ	MT	DTT
DMZNTHJ	MA	Inhibitor
DMZNTHJ	RN	Therapy for Parkinson's Disease: What is in the Pipeline . Neurotherapeutics. 2014 January; 11(1): 24-33.
DMZNTHJ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899489/

DMVUW8A	DI	DMVUW8A
DMVUW8A	DN	AVI-6002
DMVUW8A	MI	TTDJLWQ
DMVUW8A	MN	Ebola virus VP24 messenger RNA (EV VP24 mRNA)
DMVUW8A	MT	DTT
DMVUW8A	MA	Modulator
DMVUW8A	RN	Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections. Viruses. 2012 November; 4(11): 2806-2830.
DMVUW8A	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3509674/

DMVUW8A	DI	DMVUW8A
DMVUW8A	DN	AVI-6002
DMVUW8A	MI	TT3Z102
DMVUW8A	MN	Ebola virus VP35 messenger RNA (EV VP35 mRNA)
DMVUW8A	MT	DTT
DMVUW8A	MA	Modulator
DMVUW8A	RN	Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections. Viruses. 2012 November; 4(11): 2806-2830.
DMVUW8A	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3509674/

DMIJSDO	DI	DMIJSDO
DMIJSDO	DN	AVI-6003
DMIJSDO	MI	TTDJLWQ
DMIJSDO	MN	Ebola virus VP24 messenger RNA (EV VP24 mRNA)
DMIJSDO	MT	DTT
DMIJSDO	MA	Modulator
DMIJSDO	RN	Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections. Viruses. 2012 November; 4(11): 2806-2830.
DMIJSDO	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3509674/

DMIJSDO	DI	DMIJSDO
DMIJSDO	DN	AVI-6003
DMIJSDO	MI	TT3Z102
DMIJSDO	MN	Ebola virus VP35 messenger RNA (EV VP35 mRNA)
DMIJSDO	MT	DTT
DMIJSDO	MA	Modulator
DMIJSDO	RN	Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections. Viruses. 2012 November; 4(11): 2806-2830.
DMIJSDO	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3509674/

DMVD327	DI	DMVD327
DMVD327	DN	AVI-7288
DMVD327	MI	TT1E5A4
DMVD327	MN	Marburg virus NP messenger RNA (MV NP mRNA)
DMVD327	MT	DTT
DMVD327	RN	AVI-7288 for Marburg Virus in Nonhuman Primates and Humans. N Engl J Med. 2015 Jul 23;373(4):339-48.
DMVD327	RU	https://pubmed.ncbi.nlm.nih.gov/26200980

DMLI9U6	DI	DMLI9U6
DMLI9U6	DN	AVI-7537
DMLI9U6	MI	TTDJLWQ
DMLI9U6	MN	Ebola virus VP24 messenger RNA (EV VP24 mRNA)
DMLI9U6	MT	DTT
DMLI9U6	RN	Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections. Viruses. 2012 November; 4(11): 2806-2830.
DMLI9U6	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3509674/

DMZ39T6	DI	DMZ39T6
DMZ39T6	DN	AVID200
DMZ39T6	MI	TTO3HT7
DMZ39T6	MN	Transforming growth factor beta (TGFB)
DMZ39T6	MT	DTT
DMZ39T6	MA	Inhibitor
DMZ39T6	RN	TGF signaling underlies hematopoietic dysfunction and bone marrow failure in Shwachman-Diamond Syndrome. J Clin Invest. 2019 Jun 18;129(9):3821-3826.
DMZ39T6	RU	https://pubmed.ncbi.nlm.nih.gov/31211692

DMGAKR9	DI	DMGAKR9
DMGAKR9	DN	AVL-3288
DMGAKR9	MI	TTLA931
DMGAKR9	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMGAKR9	MT	DTT
DMGAKR9	MA	Modulator
DMGAKR9	RN	Differential immediate and sustained memory enhancing effects of alpha7 nicotinic receptor agonists and allosteric modulators in rats. PLoS One. 2011;6(11):e27014.
DMGAKR9	RU	https://pubmed.ncbi.nlm.nih.gov/22096516

DMNIVFJ	DI	DMNIVFJ
DMNIVFJ	DN	AVN-322
DMNIVFJ	MI	TTJS8PY
DMNIVFJ	MN	5-HT 6 receptor (HTR6)
DMNIVFJ	MT	DTT
DMNIVFJ	MA	Antagonist
DMNIVFJ	RN	AVN-322 is a Safe Orally Bio-Available Potent and Highly Selective Antagonist of 5-HT6R with Demonstrated Ability to Improve Impaired Memory in Animal Models. Curr Alzheimer Res. 2017;14(3):268-294.
DMNIVFJ	RU	https://pubmed.ncbi.nlm.nih.gov/27829340

DM8CYJ1	DI	DM8CYJ1
DM8CYJ1	DN	AVP-13358
DM8CYJ1	MI	TTYJQTF
DM8CYJ1	MN	Immunoglobulin E (IgE)
DM8CYJ1	MT	DTT
DM8CYJ1	MA	Inhibitor
DM8CYJ1	RN	Novel 2-(substituted phenyl)benzimidazole derivatives with potent activity against IgE, cytokines, and CD23 for the treatment of allergy and asthma. J Med Chem. 2004 Dec 16;47(26):6451-4.
DM8CYJ1	RU	https://pubmed.ncbi.nlm.nih.gov/15588078

DMMWEH6	DI	DMMWEH6
DMMWEH6	DN	AVP-21D9
DMMWEH6	MI	TT3YGCD
DMMWEH6	MN	Bacterial Protective antigen (Bact pagA)
DMMWEH6	MT	DTT
DMMWEH6	RN	Efficacy and Safety of AVP-21D9, an Anthrax Monoclonal Antibody, in Animal Models and Humans. Antimicrob Agents Chemother. 2014 July; 58(7): 3618-3625.
DMMWEH6	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4068543/

DMAKD0I	DI	DMAKD0I
DMAKD0I	DN	AVX-470
DMAKD0I	MI	TTF8CQI
DMAKD0I	MN	Tumor necrosis factor (TNF)
DMAKD0I	MT	DTT
DMAKD0I	MA	Inhibitor
DMAKD0I	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMAKD0I	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMAKD0I	DI	DMAKD0I
DMAKD0I	DN	AVX-470
DMAKD0I	MI	TTG043C
DMAKD0I	MN	Tumor necrosis factor receptor type I (TNF-R1)
DMAKD0I	MT	DTT
DMAKD0I	RN	Secretion of a TNFR:Fc fusion protein following pulmonary administration of pseudotyped adeno-associated virus vectors. J Virol. 2004 Nov;78(22):12355-65.
DMAKD0I	RU	https://pubmed.ncbi.nlm.nih.gov/15507622

DMRQ32K	DI	DMRQ32K
DMRQ32K	DN	AX-024
DMRQ32K	MI	TTMA3VF
DMRQ32K	MN	NCK adaptor protein 1 (NCK1)
DMRQ32K	MT	DTT
DMRQ32K	MA	Modulator
DMRQ32K	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMRQ32K	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMRQ32K	DI	DMRQ32K
DMRQ32K	DN	AX-024
DMRQ32K	MI	TTXQYT6
DMRQ32K	MN	T-cells (T-cells)
DMRQ32K	MT	DTT
DMRQ32K	MA	Inhibitor
DMRQ32K	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMRQ32K	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMFBMU7	DI	DMFBMU7
DMFBMU7	DN	Axatilamab
DMFBMU7	MI	TT7MRDV
DMFBMU7	MN	Macrophage colony-stimulating factor 1 receptor (CSF1R)
DMFBMU7	MT	DTT
DMFBMU7	MA	Antagonist
DMFBMU7	RN	Clinical pipeline report, company report or official report of Syndax Pharmaceuticals.
DMFBMU7	RU	https://syndax.com/pipeline/axatilimab/

DM6L5IP	DI	DM6L5IP
DM6L5IP	DN	Axitirome
DM6L5IP	MI	TTGER3L
DM6L5IP	MN	Thyroid hormone receptor beta (THRB)
DM6L5IP	MT	DTT
DM6L5IP	MA	Modulator
DM6L5IP	RN	Bacterial biosensors for screening isoform-selective ligands for human thyroid receptors alpha-1 and beta-1. FEBS Open Bio. 2012; 2: 247-253.
DM6L5IP	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3642162/

DM7ZU3B	DI	DM7ZU3B
DM7ZU3B	DN	AXT-914
DM7ZU3B	MI	TTBUYHA
DM7ZU3B	MN	Extracellular calcium-sensing receptor (CASR)
DM7ZU3B	MT	DTT
DM7ZU3B	MA	Antagonist
DM7ZU3B	RN	AXT914 a novel, orally-active parathyroid hormone-releasing drug in two early studies of healthy volunteers and postmenopausal women. Bone. 2014 Jul;64:204-10.
DM7ZU3B	RU	https://pubmed.ncbi.nlm.nih.gov/24769332

DMWCJEU	DI	DMWCJEU
DMWCJEU	DN	AZD0156
DMWCJEU	MI	TTKBM7V
DMWCJEU	MN	ATM serine/threonine kinase (ATM)
DMWCJEU	MT	DTT
DMWCJEU	MA	Inhibitor
DMWCJEU	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMWCJEU	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMHBEKM	DI	DMHBEKM
DMHBEKM	DN	AZD0284
DMHBEKM	MI	TTGV6LY
DMHBEKM	MN	Nuclear receptor ROR-gamma (RORG)
DMHBEKM	MT	DTT
DMHBEKM	MA	Agonist
DMHBEKM	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMHBEKM	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMMW72C	DI	DMMW72C
DMMW72C	DN	AZD-1152-HQPA
DMMW72C	MI	TT5LS6T
DMMW72C	MN	Aurora kinase B (AURKB)
DMMW72C	MT	DTT
DMMW72C	MA	Modulator
DMMW72C	RN	Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.Invest New Drugs.2013 Apr;31(2):370-80.
DMMW72C	RU	https://www.ncbi.nlm.nih.gov/pubmed/22661287

DMBEA6V	DI	DMBEA6V
DMBEA6V	DN	AZD1208
DMBEA6V	MI	TT69J2Z
DMBEA6V	MN	Serine/threonine-protein kinase pim-2 (PIM2)
DMBEA6V	MT	DTT
DMBEA6V	MA	Modulator
DMBEA6V	RN	AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood. 2014 Feb 6;123(6):905-13.
DMBEA6V	RU	https://pubmed.ncbi.nlm.nih.gov/24363397

DMYBX4N	DI	DMYBX4N
DMYBX4N	DN	AZD1390
DMYBX4N	MI	TTKBM7V
DMYBX4N	MN	ATM serine/threonine kinase (ATM)
DMYBX4N	MT	DTT
DMYBX4N	MA	Inhibitor
DMYBX4N	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMYBX4N	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM6UOXF	DI	DM6UOXF
DM6UOXF	DN	AZD1419
DM6UOXF	MI	TTSHG0T
DM6UOXF	MN	Toll-like receptor 9 (TLR9)
DM6UOXF	MT	DTT
DM6UOXF	MA	Agonist
DM6UOXF	RN	Clinical pipeline report, company report or official report of dynavax.
DM6UOXF	RU	http://investors.dynavax.com/releasedetail.cfm?releaseid=611310

DMQ1OX4	DI	DMQ1OX4
DMQ1OX4	DN	AZD1979
DMQ1OX4	MI	TTX4RTB
DMQ1OX4	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMQ1OX4	MT	DTT
DMQ1OX4	MA	Modulator
DMQ1OX4	RN	Phase I clinical trial of AZD1979 for treating obesity. AstraZeneca plc
DMQ1OX4	RU	http://www.biocentury.com/products/azd1979

DMZQEDY	DI	DMZQEDY
DMZQEDY	DN	AZD-2551
DMZQEDY	MI	TTZBFA0
DMZQEDY	MN	Protease unspecific (PRO)
DMZQEDY	MT	DTT
DMZQEDY	MA	Inhibitor
DMZQEDY	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029854)
DMZQEDY	RU	http://adisinsight.springer.com/drugs/800029854

DMXFYN0	DI	DMXFYN0
DMXFYN0	DN	AZD-3043
DMXFYN0	MI	TTEX6LM
DMXFYN0	MN	GABA(A) receptor gamma-3 (GABRG3)
DMXFYN0	MT	DTT
DMXFYN0	MA	Modulator
DMXFYN0	RN	AZD-3043: a novel, metabolically labile sedative-hypnotic agent with rapid and predictable emergence from hypnosis. Anesthesiology. 2012 Jun;116(6):1267-77.
DMXFYN0	RU	https://pubmed.ncbi.nlm.nih.gov/22531340

DMICW7D	DI	DMICW7D
DMICW7D	DN	AZD-3161
DMICW7D	MI	TTRK8B9
DMICW7D	MN	Sodium channel unspecific (NaC)
DMICW7D	MT	DTT
DMICW7D	MA	Modulator
DMICW7D	RN	Recent progress in sodium channel modulators for pain.Bioorganic & Medicinal Chemistry Letters Volume 24, Issue 16, 15 August 2014, Pages 3690-3699.
DMICW7D	RU	http://www.sciencedirect.com/science/article/pii/S0960894X14006660

DMC1BXV	DI	DMC1BXV
DMC1BXV	DN	AZD-3514
DMC1BXV	MI	TTS64P2
DMC1BXV	MN	Androgen receptor (AR)
DMC1BXV	MT	DTT
DMC1BXV	MA	Antagonist
DMC1BXV	RN	AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo. Mol Cancer Ther. 2013 Sep;12(9):1715-27.
DMC1BXV	RU	https://pubmed.ncbi.nlm.nih.gov/23861347

DM72FOD	DI	DM72FOD
DM72FOD	DN	Azd-3839
DM72FOD	MI	TT8JRS7
DM72FOD	MN	Beta-secretase (BACE)
DM72FOD	MT	DTT
DM72FOD	MA	Inhibitor
DM72FOD	RN	Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease. J Biol Chem. 2012 Nov 30;287(49):41245-57.
DM72FOD	RU	https://pubmed.ncbi.nlm.nih.gov/23048024

DM72FOD	DI	DM72FOD
DM72FOD	DN	Azd-3839
DM72FOD	MI	DE4LYSA
DM72FOD	MN	Cytochrome P450 3A4 (CYP3A4)
DM72FOD	MT	DME
DM72FOD	MA	Metabolism
DM72FOD	RN	MedChemExpress: AZD3839.
DM72FOD	RU	https://www.medchemexpress.com/AZD3839-free-base.html

DMOYPTK	DI	DMOYPTK
DMOYPTK	DN	AZD4573
DMOYPTK	MI	TT1LVF2
DMOYPTK	MN	Cyclin-dependent kinase 9 (CDK9)
DMOYPTK	MT	DTT
DMOYPTK	MA	Inhibitor
DMOYPTK	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMOYPTK	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM36EY7	DI	DM36EY7
DM36EY7	DN	AZD4721
DM36EY7	MI	TT30C9G
DM36EY7	MN	C-X-C chemokine receptor type 2 (CXCR2)
DM36EY7	MT	DTT
DM36EY7	MA	Antagonist
DM36EY7	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800038326)
DM36EY7	RU	http://adisinsight.springer.com/drugs/800038326

DMVWMUK	DI	DMVWMUK
DMVWMUK	DN	AZD4785
DMVWMUK	MI	TTB1RA4
DMVWMUK	MN	GTPase KRas (KRAS)
DMVWMUK	MT	DTT
DMVWMUK	MA	Inhibitor
DMVWMUK	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMVWMUK	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMRP3N8	DI	DMRP3N8
DMRP3N8	DN	AZD4831
DMRP3N8	MI	TTVCZPI
DMRP3N8	MN	Myeloperoxidase (MPO)
DMRP3N8	MT	DTT
DMRP3N8	MA	Modulator
DMRP3N8	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMRP3N8	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMQEO4V	DI	DMQEO4V
DMQEO4V	DN	AZD-5122
DMQEO4V	MI	TT30C9G
DMQEO4V	MN	C-X-C chemokine receptor type 2 (CXCR2)
DMQEO4V	MT	DTT
DMQEO4V	MA	Modulator
DMQEO4V	RN	Molecular Approaches To Target GPCRs in Cancer Therapy. Pharmaceuticals 2011, 4(4), 567-589.
DMQEO4V	RU	http://www.mdpi.com/1424-8247/4/4/567

DMW4GM2	DI	DMW4GM2
DMW4GM2	DN	AZD5153
DMW4GM2	MI	TTRA6BO
DMW4GM2	MN	Bromodomain-containing protein 4 (BRD4)
DMW4GM2	MT	DTT
DMW4GM2	MA	Inhibitor
DMW4GM2	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMW4GM2	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMBQ2TF	DI	DMBQ2TF
DMBQ2TF	DN	AZD-5438
DMBQ2TF	MI	TT7HF4W
DMBQ2TF	MN	Cyclin-dependent kinase 2 (CDK2)
DMBQ2TF	MT	DTT
DMBQ2TF	MA	Modulator
DMBQ2TF	RN	AZD5438, an inhibitor of Cdk1, 2, and 9, enhances the radiosensitivity of non-small cell lung carcinoma cells.Int J Radiat Oncol Biol Phys.2012 Nov 15;84(4):e507-14.
DMBQ2TF	RU	https://www.ncbi.nlm.nih.gov/pubmed/22795803

DMV6DF3	DI	DMV6DF3
DMV6DF3	DN	AZD5658
DMV6DF3	MI	TTDLNGZ
DMV6DF3	MN	Glucokinase (GCK)
DMV6DF3	MT	DTT
DMV6DF3	MA	Activator
DMV6DF3	RN	Clinical pipeline report, company report or official report of AstraZeneca (2011).
DMV6DF3	RU	http://www.astrazeneca.com/Home

DM7QGHO	DI	DM7QGHO
DM7QGHO	DN	AZD5991
DM7QGHO	MI	TTL53M6
DM7QGHO	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DM7QGHO	MT	DTT
DM7QGHO	MA	Inhibitor
DM7QGHO	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7QGHO	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM0WCR4	DI	DM0WCR4
DM0WCR4	DN	AZD-6088
DM0WCR4	MI	TTZ9SOR
DM0WCR4	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DM0WCR4	MT	DTT
DM0WCR4	MA	Agonist
DM0WCR4	RN	Evaluation of an Innovative Population Pharmacokinetic-Based Design for Behavioral Pharmacodynamic Endpoints. AAPS J. 2012 December; 14(4): 657-663.
DM0WCR4	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3475849/

DMW4VQF	DI	DMW4VQF
DMW4VQF	DN	AZD6423
DMW4VQF	MI	TT9IK2Z
DMW4VQF	MN	N-methyl-D-aspartate receptor (NMDAR)
DMW4VQF	MT	DTT
DMW4VQF	MA	Antagonist
DMW4VQF	RN	Biology of the NMDA Receptor. Marie L. Blanke and Antonius M.J. VanDongen. 2009.
DMW4VQF	RU	http://www.ncbi.nlm.nih.gov/books/NBK5283/

DM84WXZ	DI	DM84WXZ
DM84WXZ	DN	AZD-7295
DM84WXZ	MI	TTCJ2X8
DM84WXZ	MN	Hepatitis C virus Non-structural 5A (HCV NS5A)
DM84WXZ	MT	DTT
DM84WXZ	MA	Modulator
DM84WXZ	RN	TARGETING THE NS5A PROTEIN OF HCV: AN EMERGING OPTION. Drugs Future. 2011 September; 36(9): 691-711.
DM84WXZ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3558953/

DMS9I6A	DI	DMS9I6A
DMS9I6A	DN	AZD7687
DMS9I6A	MI	TTF8P9I
DMS9I6A	MN	Diacylglycerol acyltransferase 1 (DGAT1)
DMS9I6A	MT	DTT
DMS9I6A	MA	Inhibitor
DMS9I6A	RN	Clinical pipeline report, company report or official report of AstraZeneca (2011).
DMS9I6A	RU	http://www.astrazeneca.com/Home

DM1FW0C	DI	DM1FW0C
DM1FW0C	DN	AZD7762
DM1FW0C	MI	TTTU902
DM1FW0C	MN	Checkpoint kinase-1 (CHK1)
DM1FW0C	MT	DTT
DM1FW0C	MA	Inhibitor
DM1FW0C	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DM1FW0C	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DM8DMI0	DI	DM8DMI0
DM8DMI0	DN	AZD-8165
DM8DMI0	MI	TT6L509
DM8DMI0	MN	Coagulation factor IIa (F2)
DM8DMI0	MT	DTT
DM8DMI0	MA	Inhibitor
DM8DMI0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362).
DM8DMI0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2362

DMWYF1H	DI	DMWYF1H
DMWYF1H	DN	AZD8186
DMWYF1H	MI	TTTHBCA
DMWYF1H	MN	PI3-kinase beta (PIK3CB)
DMWYF1H	MT	DTT
DMWYF1H	MA	Inhibitor
DMWYF1H	RN	National Cancer Institute Drug Dictionary (drug id 751594).
DMWYF1H	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=751594

DMWYF1H	DI	DMWYF1H
DMWYF1H	DN	AZD8186
DMWYF1H	MI	TTHBTOP
DMWYF1H	MN	PI3-kinase gamma (PIK3CG)
DMWYF1H	MT	DTT
DMWYF1H	MA	Inhibitor
DMWYF1H	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMWYF1H	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMTD57A	DI	DMTD57A
DMTD57A	DN	AZD8329
DMTD57A	MI	TTN7BL9
DMTD57A	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMTD57A	MT	DTT
DMTD57A	MA	Inhibitor
DMTD57A	RN	Clinical pipeline report, company report or official report of AstraZeneca (2011).
DMTD57A	RU	http://www.astrazeneca.com/Home

DM9X20P	DI	DM9X20P
DM9X20P	DN	AZD-8418
DM9X20P	MI	TTAN6JD
DM9X20P	MN	Glutamate receptor AMPA (GRIA)
DM9X20P	MT	DTT
DM9X20P	MA	Modulator
DM9X20P	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031633)
DM9X20P	RU	http://adisinsight.springer.com/drugs/800031633

DM3EWUX	DI	DM3EWUX
DM3EWUX	DN	AZD8701
DM3EWUX	MI	TT1X3QF
DM3EWUX	MN	FOXP3 messenger RNA (FOXP3 mRNA)
DM3EWUX	MT	DTT
DM3EWUX	MA	Inhibitor
DM3EWUX	RN	Clinical pipeline report, company report or official report of Ionis Pharmaceuticals.
DM3EWUX	RU	https://www.ionispharma.com/ionis-innovation/pipeline/

DMPMDTH	DI	DMPMDTH
DMPMDTH	DN	Azd9496
DMPMDTH	MI	DES5XRU
DMPMDTH	MN	Cytochrome P450 2C8 (CYP2C8)
DMPMDTH	MT	DME
DMPMDTH	MA	Metabolism
DMPMDTH	RN	Complete substrate inhibition of cytochrome P450 2C8 by AZD9496, an oral selective estrogen receptor degrader. Drug Metab Dispos. 2018 Sep;46(9):1268-1276.
DMPMDTH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29921707

DMPMDTH	DI	DMPMDTH
DMPMDTH	DN	Azd9496
DMPMDTH	MI	TTZAYWL
DMPMDTH	MN	Estrogen receptor (ESR)
DMPMDTH	MT	DTT
DMPMDTH	MA	Antagonist
DMPMDTH	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPMDTH	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMAXHC0	DI	DMAXHC0
DMAXHC0	DN	AZD9567
DMAXHC0	MI	TTOZRK6
DMAXHC0	MN	Glucocorticoid receptor messenger RNA (GCR mRNA)
DMAXHC0	MT	DTT
DMAXHC0	MA	Modulator
DMAXHC0	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMAXHC0	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMWYHXG	DI	DMWYHXG
DMWYHXG	DN	AZD-9819
DMWYHXG	MI	TTPLTSQ
DMWYHXG	MN	Neutrophil elastase (NE)
DMWYHXG	MT	DTT
DMWYHXG	MA	Inhibitor
DMWYHXG	RN	Lipid Peroxide-Mediated Oxidative Rearrangement of the Pyrazinone Carboxamide Core of Neutrophil Elastase Inhibitor AZD9819 in Blood Plasma Samples. Drug Metab Dispos. 2015 Oct;43(10):1441-9.
DMWYHXG	RU	https://pubmed.ncbi.nlm.nih.gov/26203069

DM0LKHV	DI	DM0LKHV
DM0LKHV	DN	B7-2/GM-CSF
DM0LKHV	MI	TTZ9SOR
DM0LKHV	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DM0LKHV	MT	DTT
DM0LKHV	MA	Agonist
DM0LKHV	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DM0LKHV	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DM0LKHV	DI	DM0LKHV
DM0LKHV	DN	B7-2/GM-CSF
DM0LKHV	MI	TTQWUPT
DM0LKHV	MN	Thyroid hormone receptor (THR)
DM0LKHV	MT	DTT
DM0LKHV	MA	Agonist
DM0LKHV	RN	Sobetirome: a case history of bench-to-clinic drug discovery and development. Heart Fail Rev. 2010 Mar;15(2):177-82.
DM0LKHV	RU	https://pubmed.ncbi.nlm.nih.gov/19002578

DM5KU30	DI	DM5KU30
DM5KU30	DN	BAL-30072
DM5KU30	MI	TTJP4SM
DM5KU30	MN	Bacterial Penicillin binding protein (Bact PBP)
DM5KU30	MT	DTT
DM5KU30	MA	Inhibitor
DM5KU30	RN	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. Antimicrob Agents Chemother. 2010 Jun;54(6):2291-302.
DM5KU30	RU	https://pubmed.ncbi.nlm.nih.gov/20308379

DMAJPOX	DI	DMAJPOX
DMAJPOX	DN	Balapiravir
DMAJPOX	MI	TTMVBWH
DMAJPOX	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMAJPOX	MT	DTT
DMAJPOX	MA	Inhibitor
DMAJPOX	RN	R-1626, a specific oral NS5B polymerase inhibitor of hepatitis C virus. IDrugs. 2008 Oct;11(10):738-49.
DMAJPOX	RU	https://pubmed.ncbi.nlm.nih.gov/18828074

DM3415L	DI	DM3415L
DM3415L	DN	BAX-499
DM3415L	MI	TT068JH
DM3415L	MN	Tissue factor pathway inhibitor (TFPI)
DM3415L	MT	DTT
DM3415L	MA	Inhibitor
DM3415L	RN	Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein. J Thromb Haemost. 2013 Jun;11(6):1137-45.
DM3415L	RU	https://pubmed.ncbi.nlm.nih.gov/23528042

DMLRGX1	DI	DMLRGX1
DMLRGX1	DN	BAY 1082439
DMLRGX1	MI	TTTHBCA
DMLRGX1	MN	PI3-kinase beta (PIK3CB)
DMLRGX1	MT	DTT
DMLRGX1	MA	Modulator
DMLRGX1	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMLRGX1	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMYPU8V	DI	DMYPU8V
DMYPU8V	DN	BAY 1238097
DMYPU8V	MI	TTE4BSY
DMYPU8V	MN	Bromodomain and extraterminal domain protein (BET)
DMYPU8V	MT	DTT
DMYPU8V	MA	Inhibitor
DMYPU8V	RN	Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma. Br J Haematol. 2017 Sep;178(6):936-948.
DMYPU8V	RU	https://pubmed.ncbi.nlm.nih.gov/28653353

DMF9ALP	DI	DMF9ALP
DMF9ALP	DN	BAY 1817080
DMF9ALP	MI	TT2THBD
DMF9ALP	MN	P2X purinoceptor 3 (P2RX3)
DMF9ALP	MT	DTT
DMF9ALP	MA	Antagonist
DMF9ALP	RN	Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study. Eur Respir J. 2021 May 13;2004240.
DMF9ALP	RU	https://pubmed.ncbi.nlm.nih.gov/33986030

DMQIKZG	DI	DMQIKZG
DMQIKZG	DN	BAY 1834942
DMQIKZG	MI	TTIGH2W
DMQIKZG	MN	Normal cross-reacting antigen (CD66c)
DMQIKZG	MT	DTT
DMQIKZG	MA	Blocker
DMQIKZG	RN	ClinicalTrials.gov (NCT03596372) Study of BAY1834942 in Patients With Solid Tumors. U.S. National Institutes of Health.
DMQIKZG	RU	https://clinicaltrials.gov/ct2/show/NCT03596372

DMNVPI1	DI	DMNVPI1
DMNVPI1	DN	BAY 1905254
DMNVPI1	MI	TT0R2QD
DMNVPI1	MN	Ig-like domain-containing receptor 2 (ILDR2)
DMNVPI1	MT	DTT
DMNVPI1	MA	Inhibitor
DMNVPI1	RN	Characterization of BAY 1905254, an Immune Checkpoint Inhibitor Targeting the Immunoglobulin-Like Domain Containing Receptor 2 (ILDR2). Cancer Immunol Res. 2020 Jul;8(7):895-911.
DMNVPI1	RU	https://pubmed.ncbi.nlm.nih.gov/32312711

DMD9N12	DI	DMD9N12
DMD9N12	DN	BAY 2416964
DMD9N12	MI	TT037IE
DMD9N12	MN	Aryl hydrocarbon receptor (AHR)
DMD9N12	MT	DTT
DMD9N12	MA	Antagonist
DMD9N12	RN	ClinicalTrials.gov (NCT04069026) A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer. U.S. National Institutes of Health.
DMD9N12	RU	https://clinicaltrials.gov/ct2/show/NCT04069026

DM98EP5	DI	DM98EP5
DM98EP5	DN	BAY 2701439
DM98EP5	MI	TT6EO5L
DM98EP5	MN	Erbb2 tyrosine kinase receptor (HER2)
DM98EP5	MT	DTT
DM98EP5	MA	Inhibitor
DM98EP5	RN	National Cancer Institute Drug Dictionary (drug name BAY2701439).
DM98EP5	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/thorium-th-227-anti-her2-monoclonal-antibody-bay2701439

DM14XQN	DI	DM14XQN
DM14XQN	DN	BAY 79-4620
DM14XQN	MI	TT2LVK8
DM14XQN	MN	Carbonic anhydrase IX (CA-IX)
DM14XQN	MT	DTT
DM14XQN	RN	Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9. Mol Cancer Ther. 2012 Feb;11(2):340-9.
DM14XQN	RU	https://pubmed.ncbi.nlm.nih.gov/22147747

DM31RQS	DI	DM31RQS
DM31RQS	DN	BAY 86-8050
DM31RQS	MI	TTYCILE
DM31RQS	MN	Vasopressin receptor (VR)
DM31RQS	MT	DTT
DM31RQS	MA	Modulator
DM31RQS	RN	WO patent application no. 2015,0365,63, Disubstituted trifluormethyl pyrimidinones and use thereof as ccr2 antagonists.
DM31RQS	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20150319&CC=WO&NR=2015036563A1&KC=A1

DMCQEL6	DI	DMCQEL6
DMCQEL6	DN	BAY 94-9343
DMCQEL6	MI	TT4RXME
DMCQEL6	MN	Mesothelin (MSLN)
DMCQEL6	MT	DTT
DMCQEL6	MA	Modulator
DMCQEL6	RN	National Cancer Institute Drug Dictionary (drug id 712853).
DMCQEL6	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=712853

DM8U3Q2	DI	DM8U3Q2
DM8U3Q2	DN	BAY-1075553
DM8U3Q2	MI	TT9G4N0
DM8U3Q2	MN	Glutamate carboxypeptidase II (GCPII)
DM8U3Q2	MT	DTT
DM8U3Q2	MA	Modulator
DM8U3Q2	RN	Preclinical evaluation of BAY 1075553, a novel (18)F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):89-101.
DM8U3Q2	RU	https://pubmed.ncbi.nlm.nih.gov/23955632

DMTB4R8	DI	DMTB4R8
DMTB4R8	DN	BAY1125976
DMTB4R8	MI	TTAZ05C
DMTB4R8	MN	RAC-gamma serine/threonine-protein kinase (AKT3)
DMTB4R8	MT	DTT
DMTB4R8	MA	Modulator
DMTB4R8	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMTB4R8	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMVPAZ7	DI	DMVPAZ7
DMVPAZ7	DN	BAY1143572
DMVPAZ7	MI	TTQ7ABG
DMVPAZ7	MN	Positive transcription elongation factor b (P-TEFb)
DMVPAZ7	MT	DTT
DMVPAZ7	MA	Modulator
DMVPAZ7	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMVPAZ7	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMUK6YM	DI	DMUK6YM
DMUK6YM	DN	BAY1161909
DMUK6YM	MI	TTP7EGM
DMUK6YM	MN	Dual specificity protein kinase TTK (MPS1)
DMUK6YM	MT	DTT
DMUK6YM	MA	Inhibitor
DMUK6YM	RN	National Cancer Institute Drug Dictionary (drug id 761238).
DMUK6YM	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=761238

DM7L91K	DI	DM7L91K
DM7L91K	DN	BAY1179470
DM7L91K	MI	TTGJVQM
DM7L91K	MN	Fibroblast growth factor receptor 2 (FGFR2)
DM7L91K	MT	DTT
DM7L91K	MA	Antagonist
DM7L91K	RN	National Cancer Institute Drug Dictionary (drug id 751593).
DM7L91K	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=751593

DMCJNRL	DI	DMCJNRL
DMCJNRL	DN	BAY1251152
DMCJNRL	MI	TTQ7ABG
DMCJNRL	MN	Positive transcription elongation factor b (P-TEFb)
DMCJNRL	MT	DTT
DMCJNRL	MA	Inhibitor
DMCJNRL	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMCJNRL	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMPNBJ1	DI	DMPNBJ1
DMPNBJ1	DN	BAY1436032
DMPNBJ1	MI	TTXDKHT
DMPNBJ1	MN	Mutated oxalosuccinate decarboxylase (mIDH1)
DMPNBJ1	MT	DTT
DMPNBJ1	MA	Inhibitor
DMPNBJ1	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPNBJ1	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMNL5G7	DI	DMNL5G7
DMNL5G7	DN	BAY-1817080
DMNL5G7	MI	TT2THBD
DMNL5G7	MN	P2X purinoceptor 3 (P2RX3)
DMNL5G7	MT	DTT
DMNL5G7	MA	Inhibitor
DMNL5G7	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMNL5G7	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DM8V62T	DI	DM8V62T
DM8V62T	DN	BAY1834845
DM8V62T	MI	TTKFVXR
DM8V62T	MN	Renal carcinoma antigen NY-REN-64 (IRAK-4)
DM8V62T	MT	DTT
DM8V62T	MA	Inhibitor
DM8V62T	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM8V62T	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DML781M	DI	DML781M
DML781M	DN	BAY1895344
DML781M	MI	TT8ZYBQ
DML781M	MN	Serine/threonine-protein kinase ATR (FRP1)
DML781M	MT	DTT
DML781M	MA	Inhibitor
DML781M	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DML781M	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMRL6W5	DI	DMRL6W5
DMRL6W5	DN	BAY2402234
DMRL6W5	MI	TTLVP78
DMRL6W5	MN	Dihydroorotate dehydrogenase (DHODH)
DMRL6W5	MT	DTT
DMRL6W5	MA	Inhibitor
DMRL6W5	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMRL6W5	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMXIDWE	DI	DMXIDWE
DMXIDWE	DN	BAY-60-5521
DMXIDWE	MI	TTFQAYR
DMXIDWE	MN	Cholesteryl ester transfer protein (CETP)
DMXIDWE	MT	DTT
DMXIDWE	MA	Inhibitor
DMXIDWE	RN	Single dose pharmacokinetics, pharmacodynamics, tolerability and safety of BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein. Br J Clin Pharmacol. 2012 Feb;73(2):210-8.
DMXIDWE	RU	https://pubmed.ncbi.nlm.nih.gov/21838789

DMOUVE7	DI	DMOUVE7
DMOUVE7	DN	BAY-85-8102
DMOUVE7	MI	TTPTXIN
DMOUVE7	MN	Translocator protein (TSPO)
DMOUVE7	MT	DTT
DMOUVE7	MA	Agonist
DMOUVE7	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2879).
DMOUVE7	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2879

DM195JA	DI	DM195JA
DM195JA	DN	BAY-86-7548
DM195JA	MI	TTHYDUM
DM195JA	MN	Bombesin receptor (BS)
DM195JA	MT	DTT
DM195JA	MA	Enhancer
DM195JA	RN	Plasma pharmacokinetics, whole-body distribution, metabolism, and radiation dosimetry of 68Ga bombesin antagonist BAY 86-7548 in healthy men. J Nucl Med. 2013 Jun;54(6):867-72.
DM195JA	RU	https://pubmed.ncbi.nlm.nih.gov/23564761

DMSBWAQ	DI	DMSBWAQ
DMSBWAQ	DN	Bb21217
DMSBWAQ	MI	TTZ3P4W
DMSBWAQ	MN	B-cell maturation protein (TNFRSF17)
DMSBWAQ	MT	DTT
DMSBWAQ	MA	CAR-T-Cell-Therapy
DMSBWAQ	RN	ClinicalTrials.gov (NCT03274219) Study of bb21217 in Multiple Myeloma
DMSBWAQ	RU	https://clinicaltrials.gov/ct2/show/NCT03274219

DMTG9WM	DI	DMTG9WM
DMTG9WM	DN	BBI-6000
DMTG9WM	MI	TTGV6LY
DMTG9WM	MN	Nuclear receptor ROR-gamma (RORG)
DMTG9WM	MT	DTT
DMTG9WM	MA	Inhibitor
DMTG9WM	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMTG9WM	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM572ZL	DI	DM572ZL
DM572ZL	DN	BBP-398
DM572ZL	MI	TT7WUAV
DM572ZL	MN	Protein-tyrosine phosphatase SHP-2 (PTPN11)
DM572ZL	MT	DTT
DM572ZL	MA	Inhibitor
DM572ZL	RN	ClinicalTrials.gov (NCT04528836) First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
DM572ZL	RU	https://clinicaltrials.gov/ct2/show/NCT04528836

DMGFABM	DI	DMGFABM
DMGFABM	DN	BC-3205
DMGFABM	MI	TTUWYEA
DMGFABM	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DMGFABM	MT	DTT
DMGFABM	MA	Modulator
DMGFABM	RN	Disk Diffusion and MIC Quality Control Ranges for BC-3205 and BC-3781, Two Novel Pleuromutilin Antibiotics. J Clin Microbiol. 2012 October; 50(10): 3361-3364.
DMGFABM	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3457460/

DMM0VBU	DI	DMM0VBU
DMM0VBU	DN	BCA101
DMM0VBU	MI	TTGKNB4
DMM0VBU	MN	Epidermal growth factor receptor (EGFR)
DMM0VBU	MT	DTT
DMM0VBU	MA	Inhibitor
DMM0VBU	RN	ClinicalTrials.gov (NCT04429542) Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors. U.S. National Institutes of Health.
DMM0VBU	RU	https://clinicaltrials.gov/ct2/show/NCT04429542

DMM0VBU	DI	DMM0VBU
DMM0VBU	DN	BCA101
DMM0VBU	MI	TTO3HT7
DMM0VBU	MN	Transforming growth factor beta (TGFB)
DMM0VBU	MT	DTT
DMM0VBU	MA	Inhibitor
DMM0VBU	RN	ClinicalTrials.gov (NCT04429542) Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors. U.S. National Institutes of Health.
DMM0VBU	RU	https://clinicaltrials.gov/ct2/show/NCT04429542

DMZYCWT	DI	DMZYCWT
DMZYCWT	DN	BCI-632
DMZYCWT	MI	TTXJ47W
DMZYCWT	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMZYCWT	MT	DTT
DMZYCWT	MA	Antagonist
DMZYCWT	RN	Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists. J Med Chem. 2004 Aug 26;47(18):4570-87.
DMZYCWT	RU	https://pubmed.ncbi.nlm.nih.gov/15317467

DMZYCWT	DI	DMZYCWT
DMZYCWT	DN	BCI-632
DMZYCWT	MI	TT8A9EF
DMZYCWT	MN	Metabotropic glutamate receptor 3 (mGluR3)
DMZYCWT	MT	DTT
DMZYCWT	MA	Modulator
DMZYCWT	RN	Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists. J Med Chem. 2004 Aug 26;47(18):4570-87.
DMZYCWT	RU	https://pubmed.ncbi.nlm.nih.gov/15317467

DMRXDN3	DI	DMRXDN3
DMRXDN3	DN	BCI-838
DMRXDN3	MI	TTXJ47W
DMRXDN3	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMRXDN3	MT	DTT
DMRXDN3	MA	Modulator
DMRXDN3	RN	Metabotropic glutamate receptor subtype 2 (GRM2; MGLUR2); GRM3 (MGLUR3). SciBX 3(13); doi:10.1038/scibx.2010.413. April 1 2010
DMRXDN3	RU	http://www.nature.com/scibx/journal/v3/n13/full/scibx.2010.413.html

DMRXDN3	DI	DMRXDN3
DMRXDN3	DN	BCI-838
DMRXDN3	MI	TT8A9EF
DMRXDN3	MN	Metabotropic glutamate receptor 3 (mGluR3)
DMRXDN3	MT	DTT
DMRXDN3	MA	Modulator
DMRXDN3	RN	Metabotropic glutamate receptor subtype 2 (GRM2; MGLUR2); GRM3 (MGLUR3). SciBX 3(13); doi:10.1038/scibx.2010.413. April 1 2010
DMRXDN3	RU	http://www.nature.com/scibx/journal/v3/n13/full/scibx.2010.413.html

DMQ76B4	DI	DMQ76B4
DMQ76B4	DN	BCL11a shRNA
DMQ76B4	MI	TTPLHYK
DMQ76B4	MN	BCL11A messenger RNA (BCL11A mRNA)
DMQ76B4	MT	DTT
DMQ76B4	MA	Inhibitor
DMQ76B4	RN	Clinical pipeline report, company report or official report of bluebird bio.
DMQ76B4	RU	https://www.bluebirdbio.com/our-science/pipeline

DMZ51EX	DI	DMZ51EX
DMZ51EX	DN	BCL201
DMZ51EX	MI	TTJGNVC
DMZ51EX	MN	Apoptosis regulator Bcl-2 (BCL-2)
DMZ51EX	MT	DTT
DMZ51EX	MA	Inhibitor
DMZ51EX	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZ51EX	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMJ37LH	DI	DMJ37LH
DMJ37LH	DN	BCMA CART
DMJ37LH	MI	TTZ3P4W
DMJ37LH	MN	B-cell maturation protein (TNFRSF17)
DMJ37LH	MT	DTT
DMJ37LH	MA	CAR-T-Cell-Therapy
DMJ37LH	RN	ClinicalTrials.gov (NCT03549442) Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma
DMJ37LH	RU	https://clinicaltrials.gov/ct2/show/NCT03549442

DM2V4EO	DI	DM2V4EO
DM2V4EO	DN	BCMA CART and huCART19
DM2V4EO	MI	TTZ3P4W
DM2V4EO	MN	B-cell maturation protein (TNFRSF17)
DM2V4EO	MT	DTT
DM2V4EO	MA	CAR-T-Cell-Therapy(Dual specific)
DM2V4EO	RN	ClinicalTrials.gov (NCT03549442) Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma
DM2V4EO	RU	https://clinicaltrials.gov/ct2/show/NCT03549442

DM2V4EO	DI	DM2V4EO
DM2V4EO	DN	BCMA CART and huCART19
DM2V4EO	MI	TTW640A
DM2V4EO	MN	B-lymphocyte surface antigen B4 (CD19)
DM2V4EO	MT	DTT
DM2V4EO	MA	CAR-T-Cell-Therapy(Dual specific)
DM2V4EO	RN	ClinicalTrials.gov (NCT03549442) Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma
DM2V4EO	RU	https://clinicaltrials.gov/ct2/show/NCT03549442

DMJ4W5V	DI	DMJ4W5V
DMJ4W5V	DN	BCMA CAR-T Cells
DMJ4W5V	MI	TTZ3P4W
DMJ4W5V	MN	B-cell maturation protein (TNFRSF17)
DMJ4W5V	MT	DTT
DMJ4W5V	MA	CAR-T-Cell-Therapy
DMJ4W5V	RN	ClinicalTrials.gov (NCT03661554) BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma
DMJ4W5V	RU	https://clinicaltrials.gov/ct2/show/NCT03661554

DMZDLHV	DI	DMZDLHV
DMZDLHV	DN	BCMA nanobody CAR-T cells
DMZDLHV	MI	TTZ3P4W
DMZDLHV	MN	B-cell maturation protein (TNFRSF17)
DMZDLHV	MT	DTT
DMZDLHV	MA	CAR-T-Cell-Therapy
DMZDLHV	RN	ClinicalTrials.gov (NCT03664661) BCMA-CAR-T in Relapsed/Refractory Multiple Myeloma
DMZDLHV	RU	https://clinicaltrials.gov/ct2/show/NCT03664661

DMZ13WQ	DI	DMZ13WQ
DMZ13WQ	DN	BCMA-CD19 cCAR
DMZ13WQ	MI	TTZ3P4W
DMZ13WQ	MN	B-cell maturation protein (TNFRSF17)
DMZ13WQ	MT	DTT
DMZ13WQ	RN	Clinical pipeline report, company report or official report of iCell Gene Therapeutics.
DMZ13WQ	RU	https://icellgene.com/our-pipeline.html

DMZ13WQ	DI	DMZ13WQ
DMZ13WQ	DN	BCMA-CD19 cCAR
DMZ13WQ	MI	TTW640A
DMZ13WQ	MN	B-lymphocyte surface antigen B4 (CD19)
DMZ13WQ	MT	DTT
DMZ13WQ	RN	Clinical pipeline report, company report or official report of iCell Gene Therapeutics.
DMZ13WQ	RU	https://icellgene.com/our-pipeline.html

DMEPHMR	DI	DMEPHMR
DMEPHMR	DN	BCMA-CS1 cCAR
DMEPHMR	MI	TTZ3P4W
DMEPHMR	MN	B-cell maturation protein (TNFRSF17)
DMEPHMR	MT	DTT
DMEPHMR	RN	ClinicalTrials.gov (NCT04156269) BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma. U.S. National Institutes of Health.
DMEPHMR	RU	https://clinicaltrials.gov/ct2/show/NCT04156269

DMEPHMR	DI	DMEPHMR
DMEPHMR	DN	BCMA-CS1 cCAR
DMEPHMR	MI	TT7ILZ1
DMEPHMR	MN	SLAM family member 7 SLAMF7 (CS1)
DMEPHMR	MT	DTT
DMEPHMR	RN	ClinicalTrials.gov (NCT04156269) BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma. U.S. National Institutes of Health.
DMEPHMR	RU	https://clinicaltrials.gov/ct2/show/NCT04156269

DMW0ZDF	DI	DMW0ZDF
DMW0ZDF	DN	BCMA-specific CAR-expressing T Lymphocytes
DMW0ZDF	MI	TTZ3P4W
DMW0ZDF	MN	B-cell maturation protein (TNFRSF17)
DMW0ZDF	MT	DTT
DMW0ZDF	MA	CAR-T-Cell-Therapy
DMW0ZDF	RN	ClinicalTrials.gov (NCT03502577) BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (LY3039478) to Treat Relapsed or Persistent Multiple Myeloma
DMW0ZDF	RU	https://clinicaltrials.gov/ct2/show/NCT03502577

DMGAP53	DI	DMGAP53
DMGAP53	DN	BDD-10103
DMGAP53	MI	TTRK8B9
DMGAP53	MN	Sodium channel unspecific (NaC)
DMGAP53	MT	DTT
DMGAP53	MA	Modulator
DMGAP53	RN	Clinical pipeline report, company report or official report of Birds Pharma AG.
DMGAP53	RU	http://www.birdspharma.com/projects/bdd_10103/

DMUR49N	DI	DMUR49N
DMUR49N	DN	Begacestat
DMUR49N	MI	TT9W8GU
DMUR49N	MN	Gamma-secretase (GS)
DMUR49N	MT	DTT
DMUR49N	MA	Modulator
DMUR49N	RN	Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease. J Pharmacol Exp Ther. 2009 Nov;331(2):598-608.
DMUR49N	RU	https://pubmed.ncbi.nlm.nih.gov/19671883

DM9R0VA	DI	DM9R0VA
DM9R0VA	DN	Belerofon
DM9R0VA	MI	TTSYFMA
DM9R0VA	MN	Interferon alpha/beta receptor 1 (IFNAR1)
DM9R0VA	MT	DTT
DM9R0VA	MA	Modulator
DM9R0VA	RN	WO patent application no. 2009,0153,36, Controlled release interferon drug products and treatment of hcv infection using same.
DM9R0VA	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20090129&CC=WO&NR=2009015336A2&KC=A2

DM0ZNAR	DI	DM0ZNAR
DM0ZNAR	DN	Belvarafenib
DM0ZNAR	MI	TTB18GJ
DM0ZNAR	MN	Proto-oncogene c-RAF (c-RAF)
DM0ZNAR	MT	DTT
DM0ZNAR	MA	Inhibitor
DM0ZNAR	RN	Clinical pipeline report, company report or official report of Hanmi Pharmaceutical.
DM0ZNAR	RU	https://www.hanmipharm.com/ehanmi/handler/Rnd-Pipeline

DMN7J43	DI	DMN7J43
DMN7J43	DN	Benzo(a)pyrene
DMN7J43	MI	DTI7UX6
DMN7J43	MN	Breast cancer resistance protein (ABCG2)
DMN7J43	MT	DTP
DMN7J43	MA	Substrate
DMN7J43	RN	A prediction model of substrates and non-substrates of breast cancer resistance protein (BCRP) developed by GA-CG-SVM method. Comput Biol Med. 2011 Nov;41(11):1006-13.
DMN7J43	RU	https://doi.org/10.1016/j.compbiomed.2011.08.009

DMMW4HV	DI	DMMW4HV
DMMW4HV	DN	Benzoylphenylurea
DMMW4HV	MI	DTI7UX6
DMMW4HV	MN	Breast cancer resistance protein (ABCG2)
DMMW4HV	MT	DTP
DMMW4HV	MA	Substrate
DMMW4HV	RN	American Association for Cancer Research.
DMMW4HV	RU	http://www.aacrmeetingabstracts.org/cgi/content/abstract/2004/1/119-b

DMBUI2A	DI	DMBUI2A
DMBUI2A	DN	BETULINIC ACID
DMBUI2A	MI	TTIU7X1
DMBUI2A	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMBUI2A	MT	DTT
DMBUI2A	MA	Inhibitor
DMBUI2A	RN	DNA polymerase beta inhibitors from Tetracera boiviniana. J Nat Prod. 1999 Dec;62(12):1660-3.
DMBUI2A	RU	https://pubmed.ncbi.nlm.nih.gov/10654414

DM7RPSG	DI	DM7RPSG
DM7RPSG	DN	BF-1
DM7RPSG	MI	TT85JO3
DM7RPSG	MN	5-HT receptor (5HTR)
DM7RPSG	MT	DTT
DM7RPSG	MA	Modulator
DM7RPSG	RN	Serotonin (5-HT2B) receptor. SciBX 4(19); doi:10.1038/scibx.2011.534. May 12 2011
DM7RPSG	RU	http://www.nature.com/scibx/journal/v4/n19/full/scibx.2011.534.html

DMHELFU	DI	DMHELFU
DMHELFU	DN	BF-389
DMHELFU	MI	TT2J34L
DMHELFU	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMHELFU	MT	DTT
DMHELFU	MA	Modulator
DMHELFU	RN	Antiarthritic profile of BF-389--a novel anti-inflammatory agent with low ulcerogenic liability. Agents Actions. 1992 Sep;37(1-2):90-8.
DMHELFU	RU	https://pubmed.ncbi.nlm.nih.gov/1456184

DM84LXE	DI	DM84LXE
DM84LXE	DN	BGB-10188
DM84LXE	MI	TTGBPJE
DM84LXE	MN	PI3-kinase delta (PIK3CD)
DM84LXE	MT	DTT
DM84LXE	MA	Inhibitor
DM84LXE	RN	ClinicalTrials.gov (NCT04282018) Brief Title: Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab. U.S. National Institutes of Health.
DM84LXE	RU	https://clinicaltrials.gov/ct2/show/NCT04282018

DM7QTIC	DI	DM7QTIC
DM7QTIC	DN	BGB-11417
DM7QTIC	MI	TTJGNVC
DM7QTIC	MN	Apoptosis regulator Bcl-2 (BCL-2)
DM7QTIC	MT	DTT
DM7QTIC	MA	Inhibitor
DM7QTIC	RN	Clinical pipeline report, company report or official report of BeiGene.
DM7QTIC	RU	https://www.beigenemedical.com/CongressDocuments/Hu%20BGB-11417%20AACR%20Poster%202020.pdf

DMUP6M5	DI	DMUP6M5
DMUP6M5	DN	BGB-15025
DMUP6M5	MI	TTSHWUP
DMUP6M5	MN	MEK kinase kinase 1 (MAP4K1)
DMUP6M5	MT	DTT
DMUP6M5	MA	Inhibitor
DMUP6M5	RN	ClinicalTrials.gov (NCT04649385) BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors. U.S. National Institutes of Health.
DMUP6M5	RU	https://clinicaltrials.gov/ct2/show/NCT04649385

DMIF9DZ	DI	DMIF9DZ
DMIF9DZ	DN	BGB-3113
DMIF9DZ	MI	TTGM6VW
DMIF9DZ	MN	Tyrosine-protein kinase BTK (ATK)
DMIF9DZ	MT	DTT
DMIF9DZ	MA	Inhibitor
DMIF9DZ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMIF9DZ	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMQMEDH	DI	DMQMEDH
DMQMEDH	DN	BGB-A445
DMQMEDH	MI	TTL31H0
DMQMEDH	MN	OX40L receptor (CD134)
DMQMEDH	MT	DTT
DMQMEDH	RN	Clinical pipeline report, company report or official report of BeiGene.
DMQMEDH	RU	https://www.beigene.com/science-and-product-portfolio/pipeline

DMED4AJ	DI	DMED4AJ
DMED4AJ	DN	BGC-20-1259
DMED4AJ	MI	TT3ROYC
DMED4AJ	MN	Serotonin transporter (SERT)
DMED4AJ	MT	DTT
DMED4AJ	MA	Modulator
DMED4AJ	RN	Bifeprunox: a partial agonist at dopamine D2 and serotonin 1A receptors, influences nicotine-seeking behaviour in response to drug-associated stimuli in rats.Addict Biol.2012 Mar;17(2):274-86.
DMED4AJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/21521422

DMM2EZW	DI	DMM2EZW
DMM2EZW	DN	BHV-5000
DMM2EZW	MI	TT9IK2Z
DMM2EZW	MN	N-methyl-D-aspartate receptor (NMDAR)
DMM2EZW	MT	DTT
DMM2EZW	MA	Antagonist
DMM2EZW	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMM2EZW	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMUJ1EL	DI	DMUJ1EL
DMUJ1EL	DN	BI 113823
DMUJ1EL	MI	TTG5QIA
DMUJ1EL	MN	B1 bradykinin receptor (BDKRB1)
DMUJ1EL	MT	DTT
DMUJ1EL	MA	Modulator
DMUJ1EL	RN	The bradykinin B1 receptor antagonist BI113823 reverses inflammatory hyperalgesia by desensitization of peripheral and spinal neurons. Eur J Pain. 2015 Jan;19(1):132-42.
DMUJ1EL	RU	https://pubmed.ncbi.nlm.nih.gov/25088373

DMGMFXJ	DI	DMGMFXJ
DMGMFXJ	DN	BI 1701963
DMGMFXJ	MI	TTB1RA4
DMGMFXJ	MN	GTPase KRas (KRAS)
DMGMFXJ	MT	DTT
DMGMFXJ	MA	Inhibitor
DMGMFXJ	RN	Clinical pipeline report, company report or official report of Boehringer Ingelheim.
DMGMFXJ	RU	https://www.boehringer-ingelheim.com/press-release/first-pan-kras-inhibitor-advances-clinical-testing

DMFJGUL	DI	DMFJGUL
DMFJGUL	DN	BI 3011441
DMFJGUL	MI	TTZCRP3
DMFJGUL	MN	ERK activator kinase (MEK)
DMFJGUL	MT	DTT
DMFJGUL	MA	Inhibitor
DMFJGUL	RN	Clinical pipeline report, company report or official report of Boehringer Ingelheim.
DMFJGUL	RU	https://www.inoncology.com/ourpipeline/mek-inhibitor

DMWHZFS	DI	DMWHZFS
DMWHZFS	DN	BI 754091
DMWHZFS	MI	TTNBFWK
DMWHZFS	MN	Programmed cell death protein 1 (PD-1)
DMWHZFS	MT	DTT
DMWHZFS	MA	Inhibitor
DMWHZFS	RN	Clinical pipeline report, company report or official report of Boehringer Ingelheim.
DMWHZFS	RU	https://www.inoncology.com/ourpipeline/pd1-inhibitor

DMZMAOW	DI	DMZMAOW
DMZMAOW	DN	BI 765063
DMZMAOW	MI	TTBRJS9
DMZMAOW	MN	Inhibitory receptor SHPS-1 (SIRPA)
DMZMAOW	MT	DTT
DMZMAOW	MA	Antagonist
DMZMAOW	RN	Clinical pipeline report, company report or official report of OSE Immunotherapeutics.
DMZMAOW	RU	https://ose-immuno.com/en/ose-product/ose-172/

DMRI6YT	DI	DMRI6YT
DMRI6YT	DN	BI 836880
DMRI6YT	MI	TTKLQTJ
DMRI6YT	MN	Angiopoietin-2 (ANGPT2)
DMRI6YT	MT	DTT
DMRI6YT	MA	Blocker
DMRI6YT	RN	Clinical pipeline report, company report or official report of Boehringer Ingelheim.
DMRI6YT	RU	https://www.inoncology.com/ourpipeline/vegf-ang2-inhibitor

DMRI6YT	DI	DMRI6YT
DMRI6YT	DN	BI 836880
DMRI6YT	MI	TT9HKJA
DMRI6YT	MN	Vascular endothelial growth factor (VEGF)
DMRI6YT	MT	DTT
DMRI6YT	MA	Blocker
DMRI6YT	RN	Clinical pipeline report, company report or official report of Boehringer Ingelheim.
DMRI6YT	RU	https://www.inoncology.com/ourpipeline/vegf-ang2-inhibitor

DMMQ12N	DI	DMMQ12N
DMMQ12N	DN	BI 860585
DMMQ12N	MI	TTCJG29
DMMQ12N	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMMQ12N	MT	DTT
DMMQ12N	MA	Inhibitor
DMMQ12N	RN	Clinical pipeline report, company report or official report of tatcongress.
DMMQ12N	RU	http://tatcongress.org/wp-content/uploads/2014/05/tat2014-abstracts-poster-session-6_140217.pdf

DM7W5N2	DI	DM7W5N2
DM7W5N2	DN	BI 894999
DM7W5N2	MI	TTE4BSY
DM7W5N2	MN	Bromodomain and extraterminal domain protein (BET)
DM7W5N2	MT	DTT
DM7W5N2	MA	Inhibitor
DM7W5N2	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7W5N2	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMEPJ7C	DI	DMEPJ7C
DMEPJ7C	DN	BI 905677
DMEPJ7C	MI	TTSXOWE
DMEPJ7C	MN	LDL receptor related protein-6 (LRP-6)
DMEPJ7C	MT	DTT
DMEPJ7C	MA	Antagonist
DMEPJ7C	RN	Clinical pipeline report, company report or official report of Boehringer Ingelheim.
DMEPJ7C	RU	https://www.inoncology.com/ourpipeline/lrp56-antagonist

DMEPJ7C	DI	DMEPJ7C
DMEPJ7C	DN	BI 905677
DMEPJ7C	MI	TT7VMG4
DMEPJ7C	MN	Low-density lipoprotein receptor-related protein 5 (LRP5)
DMEPJ7C	MT	DTT
DMEPJ7C	MA	Antagonist
DMEPJ7C	RN	Clinical pipeline report, company report or official report of Boehringer Ingelheim.
DMEPJ7C	RU	https://www.inoncology.com/ourpipeline/lrp56-antagonist

DMXO3PV	DI	DMXO3PV
DMXO3PV	DN	BI 905681
DMXO3PV	MI	TT7VMG4
DMXO3PV	MN	Low-density lipoprotein receptor-related protein 5 (LRP5)
DMXO3PV	MT	DTT
DMXO3PV	MA	Antagonist
DMXO3PV	RN	Clinical pipeline report, company report or official report of Boehringer Ingelheim.
DMXO3PV	RU	https://www.inoncology.com/ourpipeline/lrp56-antagonist

DME9NYV	DI	DME9NYV
DME9NYV	DN	BI 905711
DME9NYV	MI	TTW20TU
DME9NYV	MN	TRAIL receptor 2 (TRAIL-R2)
DME9NYV	MT	DTT
DME9NYV	MA	Activator
DME9NYV	RN	Selective Tumor Cell Apoptosis and Tumor Regression in CDH17-Positive Colorectal Cancer Models using BI 905711, a Novel Liver-Sparing TRAILR2 Agonist. Mol Cancer Ther. 2021 Jan;20(1):96-108.
DME9NYV	RU	https://pubmed.ncbi.nlm.nih.gov/33037135

DM2Z4YQ	DI	DM2Z4YQ
DM2Z4YQ	DN	BI 907828
DM2Z4YQ	MI	TT08GJW
DM2Z4YQ	MN	Ubiquitin-protein ligase E3 Mdm2 (MDM2)
DM2Z4YQ	MT	DTT
DM2Z4YQ	MA	Inhibitor
DM2Z4YQ	RN	MDM2 inhibition: an important step forward in cancer therapy. Leukemia. 2020 Nov;34(11):2858-2874.
DM2Z4YQ	RU	https://pubmed.ncbi.nlm.nih.gov/32651541

DMKQHE5	DI	DMKQHE5
DMKQHE5	DN	BI-11634
DMKQHE5	MI	TTCIHJA
DMKQHE5	MN	Coagulation factor Xa (F10)
DMKQHE5	MT	DTT
DMKQHE5	MA	Inhibitor
DMKQHE5	RN	Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7.
DMKQHE5	RU	https://pubmed.ncbi.nlm.nih.gov/22844656

DMLJOAF	DI	DMLJOAF
DMLJOAF	DN	BI-135585
DMLJOAF	MI	TTN7BL9
DMLJOAF	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMLJOAF	MT	DTT
DMLJOAF	MA	Modulator
DMLJOAF	RN	New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches. 2012. Chapter 5. Page(131).
DMLJOAF	RU	https://books.google.com.hk/books?id=0rmlVGhlJ0IC&pg=PA131&lpg=PA131&dq=RG-7234++New+Therapeutic+Strategies+for+Type+2+Diabetes&source=bl&ots=toqK7w4uiI&sig=sx5iyfQWH2bTCSZmT5aUQiKfPuM&hl=zh-CN&sa=X&ved=0CB0Q6AEwAGoVChMIsZ_k6dDGyAIViLeOCh0oUQpr#v=onepage&q=RG-7234%20%20New%20Therapeutic%20Strategies%20for%20Type%202%20Diabetes&f=false

DM2KVM0	DI	DM2KVM0
DM2KVM0	DN	BI-44847
DM2KVM0	MI	TTLWPVF
DM2KVM0	MN	Sodium/glucose cotransporter 2 (SGLT2)
DM2KVM0	MT	DTT
DM2KVM0	MA	Modulator
DM2KVM0	RN	Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes
DM2KVM0	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437808

DM3JOIX	DI	DM3JOIX
DM3JOIX	DN	BI-754091
DM3JOIX	MI	TTNBFWK
DM3JOIX	MN	Programmed cell death protein 1 (PD-1)
DM3JOIX	MT	DTT
DM3JOIX	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DM3JOIX	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMNUY32	DI	DMNUY32
DMNUY32	DN	BI-811283
DMNUY32	MI	TT5LS6T
DMNUY32	MN	Aurora kinase B (AURKB)
DMNUY32	MT	DTT
DMNUY32	MA	Inhibitor
DMNUY32	RN	Aurora kinase inhibitors: progress towards the clinic. Invest New Drugs. 2012 Dec;30(6):2411-32.
DMNUY32	RU	https://pubmed.ncbi.nlm.nih.gov/22350019

DMOJZUE	DI	DMOJZUE
DMOJZUE	DN	BI-831266
DMOJZUE	MI	TT5LS6T
DMOJZUE	MN	Aurora kinase B (AURKB)
DMOJZUE	MT	DTT
DMOJZUE	MA	Modulator
DMOJZUE	RN	A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors. Invest New Drugs. 2015 Apr;33(2):409-22.
DMOJZUE	RU	https://pubmed.ncbi.nlm.nih.gov/25529193

DM4T916	DI	DM4T916
DM4T916	DN	BI-836845
DM4T916	MI	TTT6LOU
DM4T916	MN	Insulin-like growth factor-I (IGF1)
DM4T916	MT	DTT
DM4T916	MA	Modulator
DM4T916	RN	Pharmacodynamic and antineoplastic activity of BI 836845, a fully human IGF ligand-neutralizing antibody, and mechanistic rationale for combination with rapamycin.Mol Cancer Ther.2014 Feb;13(2):399-409.
DM4T916	RU	https://www.ncbi.nlm.nih.gov/pubmed/24296829

DMGFH7T	DI	DMGFH7T
DMGFH7T	DN	BI-836880
DMGFH7T	MI	TT9HKJA
DMGFH7T	MN	Vascular endothelial growth factor (VEGF)
DMGFH7T	MT	DTT
DMGFH7T	MA	Inhibitor
DMGFH7T	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMGFH7T	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMY4B6J	DI	DMY4B6J
DMY4B6J	DN	BI-847325
DMY4B6J	MI	TT5LS6T
DMY4B6J	MN	Aurora kinase B (AURKB)
DMY4B6J	MT	DTT
DMY4B6J	MA	Modulator
DMY4B6J	RN	doi: 10.1158/1535-7163.TARG-13-B281
DMY4B6J	RU	http://mct.aacrjournals.org/content/12/11_Supplement/B281.short

DMY4B6J	DI	DMY4B6J
DMY4B6J	DN	BI-847325
DMY4B6J	MI	TTROQ37
DMY4B6J	MN	MAPK/ERK kinase kinase (MAP3K)
DMY4B6J	MT	DTT
DMY4B6J	MA	Modulator
DMY4B6J	RN	doi: 10.1158/1535-7163.TARG-13-B281
DMY4B6J	RU	http://mct.aacrjournals.org/content/12/11_Supplement/B281.short

DMNOSYW	DI	DMNOSYW
DMNOSYW	DN	BI-853520
DMNOSYW	MI	TTON5IT
DMNOSYW	MN	Focal adhesion kinase 1 (FAK)
DMNOSYW	MT	DTT
DMNOSYW	MA	Modulator
DMNOSYW	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMNOSYW	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMP70FI	DI	DMP70FI
DMP70FI	DN	BIBT986
DMP70FI	MI	TTCIHJA
DMP70FI	MN	Coagulation factor Xa (F10)
DMP70FI	MT	DTT
DMP70FI	MA	Inhibitor
DMP70FI	RN	Pharmacokinetics and pharmacodynamics of BIBT 986, a novel small molecule dual inhibitor of thrombin and factor Xa. J Thromb Haemost. 2006 Jul;4(7):1502-9.
DMP70FI	RU	https://pubmed.ncbi.nlm.nih.gov/16839346

DMUBMN5	DI	DMUBMN5
DMUBMN5	DN	BIBV 308
DMUBMN5	MI	TT2O84V
DMUBMN5	MN	Thromboxane A2 receptor (TBXA2R)
DMUBMN5	MT	DTT
DMUBMN5	MA	Antagonist
DMUBMN5	RN	AT-1 receptor antagonism modifies the mediation of endothelin-1, thromboxane A2, and catecholamines in the renal constrictor response to angiotensin II. Kidney Int Suppl. 2005 Jan;(93):S3-9.
DMUBMN5	RU	https://pubmed.ncbi.nlm.nih.gov/15613065

DM79XGM	DI	DM79XGM
DM79XGM	DN	BIBX-1382
DM79XGM	MI	TTGKNB4
DM79XGM	MN	Epidermal growth factor receptor (EGFR)
DM79XGM	MT	DTT
DM79XGM	MA	Antagonist
DM79XGM	RN	Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. Eur J Cancer. 2002 May;38(8):1072-80.
DM79XGM	RU	https://pubmed.ncbi.nlm.nih.gov/12008195

DM5AW7J	DI	DM5AW7J
DM5AW7J	DN	BIIB 015
DM5AW7J	MI	TTN7HMG
DM5AW7J	MN	Teratocarcinoma-derived growth factor 1 (TDGF1)
DM5AW7J	MT	DTT
DM5AW7J	RN	An antibody-cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours. Eur J Cancer. 2011 Jul;47(11):1736-46.
DM5AW7J	RU	https://pubmed.ncbi.nlm.nih.gov/21458984

DMZ1V0E	DI	DMZ1V0E
DMZ1V0E	DN	BIIB 022
DMZ1V0E	MI	TTHRID2
DMZ1V0E	MN	Insulin-like growth factor I receptor (IGF1R)
DMZ1V0E	MT	DTT
DMZ1V0E	MA	Antagonist
DMZ1V0E	RN	A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors. Invest New Drugs. 2014 Jun;32(3):518-25.
DMZ1V0E	RU	https://pubmed.ncbi.nlm.nih.gov/24458261

DMTRF71	DI	DMTRF71
DMTRF71	DN	BIIB 028
DMTRF71	MI	TT78R5H
DMTRF71	MN	Heat shock protein 90 alpha (HSP90A)
DMTRF71	MT	DTT
DMTRF71	MA	Inhibitor
DMTRF71	RN	Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors. Clin Cancer Res. 2013 Sep 1;19(17):4824-31.
DMTRF71	RU	https://pubmed.ncbi.nlm.nih.gov/23873691

DMVS87W	DI	DMVS87W
DMVS87W	DN	BIIB068
DMVS87W	MI	TTGM6VW
DMVS87W	MN	Tyrosine-protein kinase BTK (ATK)
DMVS87W	MT	DTT
DMVS87W	MA	Inhibitor
DMVS87W	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMVS87W	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMUC6EP	DI	DMUC6EP
DMUC6EP	DN	BIIB095
DMUC6EP	MI	TT4G2JS
DMUC6EP	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DMUC6EP	MT	DTT
DMUC6EP	MA	Inhibitor
DMUC6EP	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMUC6EP	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DM9UZD7	DI	DM9UZD7
DM9UZD7	DN	Bile acid
DM9UZD7	MI	DEDZRQ1
DM9UZD7	MN	Cytochrome P450 7A1 (CYP7A1)
DM9UZD7	MT	DME
DM9UZD7	MA	Metabolism
DM9UZD7	RN	FGF15 activates Hippo signaling to suppress bile acid metabolism and liver tumorigenesis. Dev Cell. 2019 Feb 25;48(4):460-474.e9.
DM9UZD7	RU	https://pubmed.ncbi.nlm.nih.gov/30745141

DMBTSZD	DI	DMBTSZD
DMBTSZD	DN	BIMU-1
DMBTSZD	MI	TTNXLKE
DMBTSZD	MN	5-HT 3 receptor (5HT3R)
DMBTSZD	MT	DTT
DMBTSZD	MA	Modulator
DMBTSZD	RN	Gastroprokinetic properties of the benzimidazolone derivative BIMU 1, an agonist at 5-hydroxytryptamine4 and antagonist at 5-hydroxytryptamine3 receptors. Naunyn Schmiedebergs Arch Pharmacol. 1994 Apr;349(4):338-45.
DMBTSZD	RU	https://pubmed.ncbi.nlm.nih.gov/8058105

DMBTSZD	DI	DMBTSZD
DMBTSZD	DN	BIMU-1
DMBTSZD	MI	TT07C3Y
DMBTSZD	MN	5-HT 4 receptor (HTR4)
DMBTSZD	MT	DTT
DMBTSZD	MA	Modulator
DMBTSZD	RN	Gastroprokinetic properties of the benzimidazolone derivative BIMU 1, an agonist at 5-hydroxytryptamine4 and antagonist at 5-hydroxytryptamine3 receptors. Naunyn Schmiedebergs Arch Pharmacol. 1994 Apr;349(4):338-45.
DMBTSZD	RU	https://pubmed.ncbi.nlm.nih.gov/8058105

DMQ9KZW	DI	DMQ9KZW
DMQ9KZW	DN	Biomed 101
DMQ9KZW	MI	TTN53ZF
DMQ9KZW	MN	Leukotriene B4 receptor 1 (LTB4R)
DMQ9KZW	MT	DTT
DMQ9KZW	MA	Binder
DMQ9KZW	RN	Biomed 101, a leukotriene B4 inhibitor, may decrease IL-2 toxicity. 2003 ASCO Annual Meeting. 2003.
DMQ9KZW	RU	http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=23&abstractID=101740

DMQ9KZW	DI	DMQ9KZW
DMQ9KZW	DN	Biomed 101
DMQ9KZW	MI	TTVJX54
DMQ9KZW	MN	Leukotriene B4 receptor 2 (LTB4R2)
DMQ9KZW	MT	DTT
DMQ9KZW	MA	Inhibitor
DMQ9KZW	RN	Diaryl ether/carboxylic acid derivatives of LY255283: Receptor antagonists of leukotriene B4, Bioorg. Med. Chem. Lett. 3(10):1985-1990 (1993).
DMQ9KZW	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01810003

DMS4P6K	DI	DMS4P6K
DMS4P6K	DN	Biostrophin
DMS4P6K	MI	TT48MP6
DMS4P6K	MN	Dystrophin (DMD)
DMS4P6K	MT	DTT
DMS4P6K	MA	Modulator
DMS4P6K	RN	Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches. Nat Rev Genet. 2013 Jun;14(6):373-8. 
DMS4P6K	RU	https://pubmed.ncbi.nlm.nih.gov/23609411

DMGAR9Y	DI	DMGAR9Y
DMGAR9Y	DN	BIT225
DMGAR9Y	MI	TT5FNQT
DMGAR9Y	MN	Human immunodeficiency virus Protease (HIV PR)
DMGAR9Y	MT	DTT
DMGAR9Y	MA	Inhibitor
DMGAR9Y	RN	2011 Pipeline of Biotron.
DMGAR9Y	RU	http://www.biotron.com.au/

DM61JH5	DI	DM61JH5
DM61JH5	DN	BIWA 4
DM61JH5	MI	TTWFBT7
DM61JH5	MN	Extracellular matrix receptor III (CD44)
DM61JH5	MT	DTT
DM61JH5	RN	A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6064-72.
DM61JH5	RU	https://pubmed.ncbi.nlm.nih.gov/17062682

DMX9ER7	DI	DMX9ER7
DMX9ER7	DN	BIZELESIN
DMX9ER7	MI	TTUTN1I
DMX9ER7	MN	Human Deoxyribonucleic acid (hDNA)
DMX9ER7	MT	DTT
DMX9ER7	MA	Inhibitor
DMX9ER7	RN	Mapping of DNA alkylation sites induced by adozelesin and bizelesin in human cells by ligation-mediated polymerase chain reaction. Biochemistry. 1994 May 17;33(19):6024-30.
DMX9ER7	RU	https://pubmed.ncbi.nlm.nih.gov/8180230

DMAYSFK	DI	DMAYSFK
DMAYSFK	DN	BL-1021
DMAYSFK	MI	TTAWNKZ
DMAYSFK	MN	Norepinephrine transporter (NET)
DMAYSFK	MT	DTT
DMAYSFK	MA	Modulator
DMAYSFK	RN	Company report (BioLineRx)
DMAYSFK	RU	http://www.biolinerx.com/default.asp?pageid=13&itemid=13

DMAYSFK	DI	DMAYSFK
DMAYSFK	DN	BL-1021
DMAYSFK	MI	TT3ROYC
DMAYSFK	MN	Serotonin transporter (SERT)
DMAYSFK	MT	DTT
DMAYSFK	MA	Modulator
DMAYSFK	RN	Company report (BioLineRx)
DMAYSFK	RU	http://www.biolinerx.com/default.asp?pageid=13&itemid=13

DM27J3D	DI	DM27J3D
DM27J3D	DN	BLU-554
DM27J3D	MI	TT1KX2S
DM27J3D	MN	FGFR4 messenger RNA (FGFR4 mRNA)
DM27J3D	MT	DTT
DM27J3D	MA	Inhibitor
DM27J3D	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM27J3D	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMYHNV3	DI	DMYHNV3
DMYHNV3	DN	BLY719
DMYHNV3	MI	TTEUNMR
DMYHNV3	MN	PI3-kinase alpha (PIK3CA)
DMYHNV3	MT	DTT
DMYHNV3	MA	Inhibitor
DMYHNV3	RN	In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer. Anticancer Res. 2015 Jan;35(1):175-82.
DMYHNV3	RU	https://pubmed.ncbi.nlm.nih.gov/25550549

DMIRX3Z	DI	DMIRX3Z
DMIRX3Z	DN	BM-212
DMIRX3Z	MI	TTTLB3R
DMIRX3Z	MN	Mycobacterium Membrane protein mmpL3 (MycB mmpL3)
DMIRX3Z	MT	DTT
DMIRX3Z	MA	Modulator
DMIRX3Z	RN	MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212. Antimicrob Agents Chemother. 2012 Jan;56(1):324-31.
DMIRX3Z	RU	https://pubmed.ncbi.nlm.nih.gov/22024828

DM43RV5	DI	DM43RV5
DM43RV5	DN	BM-ca
DM43RV5	MI	TTUE541
DM43RV5	MN	Leukocyte surface antigen Leu-16 (CD20)
DM43RV5	MT	DTT
DM43RV5	RN	BM-ca is a newly defined type I/II anti-CD20 monoclonal antibody with unique biological properties. Int J Oncol. 2011 Feb;38(2):335-44.
DM43RV5	RU	https://pubmed.ncbi.nlm.nih.gov/21152859

DMJNFI2	DI	DMJNFI2
DMJNFI2	DN	BMEC-1217B
DMJNFI2	MI	TTFTSHD
DMJNFI2	MN	Cytokine unspecific (CYK)
DMJNFI2	MT	DTT
DMJNFI2	MA	Regulator
DMJNFI2	RN	ClinicalTrials.gov (NCT00425971) Safety Study of Anti-Asthma Agent BMEC-1217B. U.S. National Institutes of Health.
DMJNFI2	RU	https://clinicaltrials.gov/ct2/show/NCT00425971

DMTZ3A6	DI	DMTZ3A6
DMTZ3A6	DN	BMS-196085
DMTZ3A6	MI	TTMXGCW
DMTZ3A6	MN	Adrenergic receptor beta-3 (ADRB3)
DMTZ3A6	MT	DTT
DMTZ3A6	MA	Inhibitor
DMTZ3A6	RN	Arylpropanolamines: selective beta3 agonists arising from strategies to mitigate phase I metabolic transformations. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4290-6.
DMTZ3A6	RU	https://pubmed.ncbi.nlm.nih.gov/17533126

DM5M48F	DI	DM5M48F
DM5M48F	DN	BMS214662
DM5M48F	MI	TTXQKM3
DM5M48F	MN	Farnesyl protein transferase (Ftase)
DM5M48F	MT	DTT
DM5M48F	MA	Modulator
DM5M48F	RN	Farnesyltransferase inhibitor BMS-214662 induces apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia. 2004 Oct;18(10):1599-604.
DM5M48F	RU	https://www.ncbi.nlm.nih.gov/pubmed/15356656

DMGDJQR	DI	DMGDJQR
DMGDJQR	DN	BMS-394136
DMGDJQR	MI	TTW0CMT
DMGDJQR	MN	Voltage-gated potassium channel Kv1.5 (KCNA5)
DMGDJQR	MT	DTT
DMGDJQR	MA	Modulator
DMGDJQR	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMGDJQR	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMPK32V	DI	DMPK32V
DMPK32V	DN	BMS-754807
DMPK32V	MI	TTWTSCV
DMPK32V	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DMPK32V	MT	DTT
DMPK32V	MA	Inhibitor
DMPK32V	RN	Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in cli... J Med Chem. 2009 Dec 10;52(23):7360-3.
DMPK32V	RU	https://pubmed.ncbi.nlm.nih.gov/19778024

DMKR8S1	DI	DMKR8S1
DMKR8S1	DN	BMS-779788
DMKR8S1	MI	TTM1EQF
DMKR8S1	MN	Oxysterols receptor LXR (NR1H)
DMKR8S1	MT	DTT
DMKR8S1	MA	Modulator
DMKR8S1	RN	Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat Rev Drug Discov. 2014 Jun;13(6):433-44.
DMKR8S1	RU	https://pubmed.ncbi.nlm.nih.gov/24833295

DM2WMJ7	DI	DM2WMJ7
DM2WMJ7	DN	BMS-816336
DM2WMJ7	MI	TTN7BL9
DM2WMJ7	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DM2WMJ7	MT	DTT
DM2WMJ7	MA	Inhibitor
DM2WMJ7	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027626)
DM2WMJ7	RU	http://adisinsight.springer.com/drugs/800027626

DMCX0H7	DI	DMCX0H7
DMCX0H7	DN	BMS-820132
DMCX0H7	MI	TTDLNGZ
DMCX0H7	MN	Glucokinase (GCK)
DMCX0H7	MT	DTT
DMCX0H7	MA	Inhibitor
DMCX0H7	RN	Utilization of the Zucker Diabetic Fatty (ZDF) Rat Model for Investigating Hypoglycemia-related Toxicities. Toxicol Pathol. 2015 Aug;43(6):825-37.
DMCX0H7	RU	https://pubmed.ncbi.nlm.nih.gov/26085543

DMPQ5XC	DI	DMPQ5XC
DMPQ5XC	DN	BMS-824383
DMPQ5XC	MI	TTCJ2X8
DMPQ5XC	MN	Hepatitis C virus Non-structural 5A (HCV NS5A)
DMPQ5XC	MT	DTT
DMPQ5XC	MA	Inhibitor
DMPQ5XC	RN	2011 Pipeline of Bristol-Myers Squibb.
DMPQ5XC	RU	http://www.bms.com/pages/default.aspx

DMCW71N	DI	DMCW71N
DMCW71N	DN	BMS-830216
DMCW71N	MI	TTX4RTB
DMCW71N	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMCW71N	MT	DTT
DMCW71N	MA	Antagonist
DMCW71N	RN	2011 Pipeline of Bristol-Myers Squibb.
DMCW71N	RU	http://www.bms.com/pages/default.aspx

DMZS1D2	DI	DMZS1D2
DMZS1D2	DN	BMS-852927
DMZS1D2	MI	TTM1EQF
DMZS1D2	MN	Oxysterols receptor LXR (NR1H)
DMZS1D2	MT	DTT
DMZS1D2	MA	Modulator
DMZS1D2	RN	Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat Rev Drug Discov. 2014 Jun;13(6):433-44.
DMZS1D2	RU	https://pubmed.ncbi.nlm.nih.gov/24833295

DM7JW0B	DI	DM7JW0B
DM7JW0B	DN	BMS-903452
DM7JW0B	MI	TT7QNVC
DM7JW0B	MN	Glucose-dependent insulinotropic receptor (GPR119)
DM7JW0B	MT	DTT
DM7JW0B	MA	Modulator
DM7JW0B	RN	Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119. J MedChem. 2014 Sep 25;57(18):7499-508.
DM7JW0B	RU	https://pubmed.ncbi.nlm.nih.gov/25208139

DM3K8VM	DI	DM3K8VM
DM3K8VM	DN	BMS-908662
DM3K8VM	MI	TTWCGQT
DM3K8VM	MN	Serine/threonine-protein kinase B-raf (BRAF)
DM3K8VM	MT	DTT
DM3K8VM	MA	Inhibitor
DM3K8VM	RN	Clinical pipeline report, company report or official report of Exelixis (2011).
DM3K8VM	RU	http://www.exelixis.com/pipeline

DMG3J6C	DI	DMG3J6C
DMG3J6C	DN	BMS-933043
DMG3J6C	MI	TTLA931
DMG3J6C	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMG3J6C	MT	DTT
DMG3J6C	MA	Modulator
DMG3J6C	RN	Clinical pipeline report, company report or official report of Phrma.org Alzheimers 2012.
DMG3J6C	RU	http://phrma.org/sites/default/files/pdf/alzheimers2012.pdf

DMYIBFM	DI	DMYIBFM
DMYIBFM	DN	BMS-936561
DMYIBFM	MI	TTNCIE0
DMYIBFM	MN	CD70 antigen (CD27-L)
DMYIBFM	MT	DTT
DMYIBFM	MA	Modulator
DMYIBFM	RN	Pharmacokinetic characterization of BMS-936561, an anti-CD70 antibody-drug conjugate, in preclinical animal species and prediction of its pharmacok... Biopharm Drug Dispos. 2016 Mar;37(2):93-106.
DMYIBFM	RU	https://pubmed.ncbi.nlm.nih.gov/25869904

DMS4H1J	DI	DMS4H1J
DMS4H1J	DN	BMS-936564
DMS4H1J	MI	TTBID49
DMS4H1J	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMS4H1J	MT	DTT
DMS4H1J	MA	Modulator
DMS4H1J	RN	BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin Cancer Res. 2013 Jan 15;19(2):357-66.
DMS4H1J	RU	https://pubmed.ncbi.nlm.nih.gov/23213054

DMZ4WMT	DI	DMZ4WMT
DMZ4WMT	DN	BMS-986104
DMZ4WMT	MI	TT9JZCK
DMZ4WMT	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMZ4WMT	MT	DTT
DMZ4WMT	MA	Modulator
DMZ4WMT	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZ4WMT	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMYLFQR	DI	DMYLFQR
DMYLFQR	DN	BMS-986120
DMYLFQR	MI	TT3I4WV
DMYLFQR	MN	Prostate apoptosis response-4 (PAWR)
DMYLFQR	MT	DTT
DMYLFQR	MA	Antagonist
DMYLFQR	RN	PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex Vivo Thrombus Formation. Arterioscler Thromb Vasc Biol. 2018 Feb;38(2):448-456.
DMYLFQR	RU	https://pubmed.ncbi.nlm.nih.gov/29269513

DMXU5FK	DI	DMXU5FK
DMXU5FK	DN	BMS-986189
DMXU5FK	MI	TT8ZLTI
DMXU5FK	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMXU5FK	MT	DTT
DMXU5FK	MA	Inhibitor
DMXU5FK	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMXU5FK	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMHTEZ8	DI	DMHTEZ8
DMHTEZ8	DN	BMS-986249
DMHTEZ8	MI	TTI2S1D
DMHTEZ8	MN	Cytotoxic T-lymphocyte protein 4 (CTLA-4)
DMHTEZ8	MT	DTT
DMHTEZ8	RN	Clinical pipeline report, company report or official report of CytomX Therapeutics.
DMHTEZ8	RU	https://cytomx.com/pipeline/

DMTMUWJ	DI	DMTMUWJ
DMTMUWJ	DN	BMS-986299
DMTMUWJ	MI	TT4EN8X
DMTMUWJ	MN	Caterpiller protein 1.1 (NLRP3)
DMTMUWJ	MT	DTT
DMTMUWJ	MA	Agonist
DMTMUWJ	RN	National Cancer Institute Drug Dictionary (drug name BMS-986299).
DMTMUWJ	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/nlrp3-agonist-bms-986299

DMM3DBU	DI	DMM3DBU
DMM3DBU	DN	BMS-986301
DMM3DBU	MI	TTT402Y
DMM3DBU	MN	Stimulator of interferon genes protein (TMEM173)
DMM3DBU	MT	DTT
DMM3DBU	MA	Agonist
DMM3DBU	RN	Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy. J Clin Med. 2020 Oct 16;9(10):3323.
DMM3DBU	RU	https://pubmed.ncbi.nlm.nih.gov/33081170

DMB6FMH	DI	DMB6FMH
DMB6FMH	DN	BMTP-11
DMB6FMH	MI	TTZPLJS
DMB6FMH	MN	Interleukin 11 receptor alpha (IL11RA)
DMB6FMH	MT	DTT
DMB6FMH	MA	Modulator
DMB6FMH	RN	Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens. Clin Cancer Res. 2015 Jul 1;21(13):3041-51.
DMB6FMH	RU	https://pubmed.ncbi.nlm.nih.gov/25779950

DMW8VEH	DI	DMW8VEH
DMW8VEH	DN	BMY-43748
DMW8VEH	MI	TT0IHXV
DMW8VEH	MN	DNA topoisomerase II (TOP2)
DMW8VEH	MT	DTT
DMW8VEH	MA	Modulator
DMW8VEH	RN	Comparative metabolism of tosufloxacin and BMY 43748 in hepatocytes from rat, dog, monkey and man. Toxicol In Vitro. 1993 Jul;7(4):499-503.
DMW8VEH	RU	https://pubmed.ncbi.nlm.nih.gov/20732241

DMSBM6A	DI	DMSBM6A
DMSBM6A	DN	BNC-101
DMSBM6A	MI	TTTSGRH
DMSBM6A	MN	Leucine-rich repeat-containing GPCR 5 (LGR5)
DMSBM6A	MT	DTT
DMSBM6A	MA	Inhibitor
DMSBM6A	RN	Clinical pipeline report, company report or official report of Bionomics.
DMSBM6A	RU	https://www.bionomics.com.au/research-development/pipeline/oncology

DMI4UY3	DI	DMI4UY3
DMI4UY3	DN	BNC375
DMI4UY3	MI	TTLA931
DMI4UY3	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMI4UY3	MT	DTT
DMI4UY3	MA	Modulator
DMI4UY3	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMI4UY3	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMU790L	DI	DMU790L
DMU790L	DN	BOS172722
DMU790L	MI	TTP7EGM
DMU790L	MN	Dual specificity protein kinase TTK (MPS1)
DMU790L	MT	DTT
DMU790L	MA	Inhibitor
DMU790L	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMU790L	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM9L0D8	DI	DM9L0D8
DM9L0D8	DN	BOS172738
DM9L0D8	MI	TT4DXQT
DM9L0D8	MN	Proto-oncogene c-Ret (RET)
DM9L0D8	MT	DTT
DM9L0D8	MA	Inhibitor
DM9L0D8	RN	National Cancer Institute Drug Dictionary (drug name Zeteletinib).
DM9L0D8	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/zeteletinib

DMI826O	DI	DMI826O
DMI826O	DN	BP1002
DMI826O	MI	TTFOUV4
DMI826O	MN	BCL-2 messenger RNA (BCL2 mRNA)
DMI826O	MT	DTT
DMI826O	MA	Inhibitor
DMI826O	RN	Clinical pipeline report, company report or official report of Bio-Path Holdings.
DMI826O	RU	http://dnabilize.com/bp1002/

DMNY0U5	DI	DMNY0U5
DMNY0U5	DN	BPI-9016 M
DMNY0U5	MI	TTNDSF4
DMNY0U5	MN	Proto-oncogene c-Met (MET)
DMNY0U5	MT	DTT
DMNY0U5	MA	Inhibitor
DMNY0U5	RN	First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer. J Hematol Oncol. 2020 Jan 16;13(1):6.
DMNY0U5	RU	https://pubmed.ncbi.nlm.nih.gov/31948451

DMNY0U5	DI	DMNY0U5
DMNY0U5	DN	BPI-9016 M
DMNY0U5	MI	TTZPY6J
DMNY0U5	MN	Tyrosine-protein kinase UFO (AXL)
DMNY0U5	MT	DTT
DMNY0U5	MA	Inhibitor
DMNY0U5	RN	First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer. J Hematol Oncol. 2020 Jan 16;13(1):6.
DMNY0U5	RU	https://pubmed.ncbi.nlm.nih.gov/31948451

DM51MSD	DI	DM51MSD
DM51MSD	DN	BPX-101
DM51MSD	MI	TTIJP3Q
DM51MSD	MN	TNF related activation protein (CD40LG)
DM51MSD	MT	DTT
DM51MSD	RN	Activation of antigen-exposed iMC-DCs at the ight place and ight time promotes potent anti-tumor immunity. Oncoimmunology. 2012 May 1; 1(3): 362-363.
DM51MSD	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382847/

DMYERSD	DI	DMYERSD
DMYERSD	DN	BPX-701
DMYERSD	MI	TT7AKW1
DMYERSD	MN	T-cell receptor (TCR)
DMYERSD	MT	DTT
DMYERSD	MA	Immunomodulator
DMYERSD	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMYERSD	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMOQ2GB	DI	DMOQ2GB
DMOQ2GB	DN	BR6819
DMOQ2GB	MI	TTYCILE
DMOQ2GB	MN	Vasopressin receptor (VR)
DMOQ2GB	MT	DTT
DMOQ2GB	MA	Antagonist
DMOQ2GB	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMOQ2GB	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DM4R6UV	DI	DM4R6UV
DM4R6UV	DN	Bradykinin
DM4R6UV	MI	DEGPI81
DM4R6UV	MN	Angiotensin-converting enzyme 2 (ACE2)
DM4R6UV	MT	DME
DM4R6UV	MA	Metabolism
DM4R6UV	RN	Nunn's Applied Respiratory Physiology (Eighth Edition). Chapter 11 - Nonrespiratory Functions of the Lung.2017, Pages 203-214.e2
DM4R6UV	RU	https://www.sciencedirect.com/science/article/pii/B9780702062940000113

DM4R6UV	DI	DM4R6UV
DM4R6UV	DN	Bradykinin
DM4R6UV	MI	DEPWYLT
DM4R6UV	MN	Arginine carboxypeptidase (CPN1)
DM4R6UV	MT	DME
DM4R6UV	MA	Metabolism
DM4R6UV	RN	Regulation of chemerin bioactivity by plasma carboxypeptidase N, carboxypeptidase B (activated thrombin-activable fibrinolysis inhibitor), and platelets. J Biol Chem. 2009 Jan 9;284(2):751-8.
DM4R6UV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19010784

DM4R6UV	DI	DM4R6UV
DM4R6UV	DN	Bradykinin
DM4R6UV	MI	TTGY8IW
DM4R6UV	MN	B2 bradykinin receptor (BDKRB2)
DM4R6UV	MT	DTT
DM4R6UV	MA	Inhibitor
DM4R6UV	RN	Synthesis and biological evaluation of bradykinin B(1)/B(2) and selective B(1) receptor antagonists. J Med Chem. 2000 Jun 15;43(12):2382-6.
DM4R6UV	RU	https://pubmed.ncbi.nlm.nih.gov/10882364

DM4R6UV	DI	DM4R6UV
DM4R6UV	DN	Bradykinin
DM4R6UV	MI	DE1TNRG
DM4R6UV	MN	Carboxypeptidase M (CPM)
DM4R6UV	MT	DME
DM4R6UV	MA	Metabolism
DM4R6UV	RN	Interactions between carboxypeptidase M and kinin B1 receptor in endothelial cells. Inflamm Res. 2019 Oct;68(10):845-855.
DM4R6UV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31218444

DM4R6UV	DI	DM4R6UV
DM4R6UV	DN	Bradykinin
DM4R6UV	MI	DEHEZPI
DM4R6UV	MN	Cathepsin H (CTSH)
DM4R6UV	MT	DME
DM4R6UV	MA	Metabolism
DM4R6UV	RN	Human brain cathepsin H as a neuropeptide and bradykinin metabolizing enzyme. Peptides. 2003 Dec;24(12):1977-84.
DM4R6UV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15127951

DM4R6UV	DI	DM4R6UV
DM4R6UV	DN	Bradykinin
DM4R6UV	MI	DEG3S8C
DM4R6UV	MN	Cathepsin K (CTSK)
DM4R6UV	MT	DME
DM4R6UV	MA	Metabolism
DM4R6UV	RN	A cysteine-type carboxypeptidase, cathepsin X, generates peptide receptor agonists. Int Immunopharmacol. 2010 Jan;10(1):134-9.
DM4R6UV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19800993

DM4R6UV	DI	DM4R6UV
DM4R6UV	DN	Bradykinin
DM4R6UV	MI	DEIORCK
DM4R6UV	MN	Dipeptidyl peptidase II (DPP7)
DM4R6UV	MT	DME
DM4R6UV	MA	Metabolism
DM4R6UV	RN	Purification of two dipeptidyl aminopeptidases II from rat brain and their action on proline-containing neuropeptides. J Neurochem. 1989 Apr;52(4):1284-93.
DM4R6UV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=2564425

DM4R6UV	DI	DM4R6UV
DM4R6UV	DN	Bradykinin
DM4R6UV	MI	DEKBXUC
DM4R6UV	MN	PABA peptide hydrolase (MEP1B)
DM4R6UV	MT	DME
DM4R6UV	MA	Metabolism
DM4R6UV	RN	Human and mouse homo-oligomeric meprin A metalloendopeptidase: substrate and inhibitor specificities. Biol Chem. 2007 Nov;388(11):1163-72.
DM4R6UV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17976009

DM4R6UV	DI	DM4R6UV
DM4R6UV	DN	Bradykinin
DM4R6UV	MI	DEVSCNZ
DM4R6UV	MN	Prolyl endopeptidase (PREP)
DM4R6UV	MT	DME
DM4R6UV	MA	Metabolism
DM4R6UV	RN	Bradykinin release and inactivation in brain of rats submitted to an experimental model of Alzheimer's disease. Peptides. 2006 Dec;27(12):3363-9.
DM4R6UV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17030465

DM4R6UV	DI	DM4R6UV
DM4R6UV	DN	Bradykinin
DM4R6UV	MI	DE8E6X9
DM4R6UV	MN	Soluble aminopeptidase P (sAmp)
DM4R6UV	MT	DME
DM4R6UV	MA	Metabolism
DM4R6UV	RN	Cloning, expression, and characterization of human cytosolic aminopeptidase P: a single manganese(II)-dependent enzyme. Biochemistry. 2000 Dec 12;39(49):15121-8.
DM4R6UV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11106490

DM4R6UV	DI	DM4R6UV
DM4R6UV	DN	Bradykinin
DM4R6UV	MI	DE95LJC
DM4R6UV	MN	Thimet oligopeptidase (THOP1)
DM4R6UV	MT	DME
DM4R6UV	MA	Metabolism
DM4R6UV	RN	Expression and activity of thimet oligopeptidase (TOP) are modified in the hippocampus of subjects with temporal lobe epilepsy (TLE). Epilepsia. 2014 May;55(5):754-62.
DM4R6UV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24702695

DMK7BND	DI	DMK7BND
DMK7BND	DN	Briciclib
DMK7BND	MI	TTFCJ7S
DMK7BND	MN	G1/S-specific cyclin-D1 (CCND1)
DMK7BND	MT	DTT
DMK7BND	MA	Inhibitor
DMK7BND	RN	Clinical pipeline report, company report or official report of Onconova.
DMK7BND	RU	http://www.onconova.com/product-pipeline/briciclib.php

DM1V9YG	DI	DM1V9YG
DM1V9YG	DN	BRL-52656
DM1V9YG	MI	TTQW87Y
DM1V9YG	MN	Opioid receptor kappa (OPRK1)
DM1V9YG	MT	DTT
DM1V9YG	MA	Agonist
DM1V9YG	RN	Kappa-opioid receptors behind the blood-brain barrier are involved in the anti-hypertensive effects of systemically administered kappa-agonists in the conscious spontaneously hypertensive rat. J Pharm Pharmacol. 1999 Nov;51(11):1251-6.
DM1V9YG	RU	https://pubmed.ncbi.nlm.nih.gov/10632082

DMTDWIE	DI	DMTDWIE
DMTDWIE	DN	BRX-005
DMTDWIE	MI	TTHYBIX
DMTDWIE	MN	Heat shock protein 70 (HSP70)
DMTDWIE	MT	DTT
DMTDWIE	MA	Modulator
DMTDWIE	RN	Cardiovascular effects of BRX-005 comparison to bimoclomol. Life Sci. 2000 Aug 25;67(14):1783-9.
DMTDWIE	RU	https://pubmed.ncbi.nlm.nih.gov/11021362

DMS4H30	DI	DMS4H30
DMS4H30	DN	BT-063
DMS4H30	MI	TTDB5IS
DMS4H30	MN	Receptor unspecific (Rec)
DMS4H30	MT	DTT
DMS4H30	RN	Clinical pipeline report, company report or official report of Biotest.
DMS4H30	RU	http://www.biotest.com/de/en/r_d/pipeline/bt063.cfm

DMC8XHQ	DI	DMC8XHQ
DMC8XHQ	DN	BTX-A51
DMC8XHQ	MI	TTFQEMX
DMC8XHQ	MN	Casein kinase I alpha (CSNK1A1)
DMC8XHQ	MT	DTT
DMC8XHQ	MA	Inhibitor
DMC8XHQ	RN	Clinical pipeline report, company report or official report of BioTheryX.
DMC8XHQ	RU	https://www.biotheryx.com/pipeline/

DMC8XHQ	DI	DMC8XHQ
DMC8XHQ	DN	BTX-A51
DMC8XHQ	MI	TTQYF7G
DMC8XHQ	MN	Cyclin-dependent kinase 7 (CDK7)
DMC8XHQ	MT	DTT
DMC8XHQ	MA	Inhibitor
DMC8XHQ	RN	Clinical pipeline report, company report or official report of BioTheryX.
DMC8XHQ	RU	https://www.biotheryx.com/pipeline/

DMC8XHQ	DI	DMC8XHQ
DMC8XHQ	DN	BTX-A51
DMC8XHQ	MI	TT1LVF2
DMC8XHQ	MN	Cyclin-dependent kinase 9 (CDK9)
DMC8XHQ	MT	DTT
DMC8XHQ	MA	Inhibitor
DMC8XHQ	RN	Clinical pipeline report, company report or official report of BioTheryX.
DMC8XHQ	RU	https://www.biotheryx.com/pipeline/

DMJ56MS	DI	DMJ56MS
DMJ56MS	DN	BUTYLATEDHYDROXYTOLUENE
DMJ56MS	MI	TTANPDJ
DMJ56MS	MN	Carbonic anhydrase II (CA-II)
DMJ56MS	MT	DTT
DMJ56MS	MA	Inhibitor
DMJ56MS	RN	Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols. Bioorg Med Chem. 2009 Apr 15;17(8):3207-11.
DMJ56MS	RU	https://pubmed.ncbi.nlm.nih.gov/19231207

DM43GPX	DI	DM43GPX
DM43GPX	DN	BVI-007
DM43GPX	MI	TTCG5PE
DM43GPX	MN	Thrombopoietin (THPO)
DM43GPX	MT	DTT
DM43GPX	MA	Inhibitor
DM43GPX	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM43GPX	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DM43GPX	DI	DM43GPX
DM43GPX	DN	BVI-007
DM43GPX	MI	TTIHYA4
DM43GPX	MN	Thrombopoietin receptor (MPL)
DM43GPX	MT	DTT
DM43GPX	MA	Antagonist
DM43GPX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1722).
DM43GPX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1722

DMEP321	DI	DMEP321
DMEP321	DN	BVT-74316
DMEP321	MI	TTJS8PY
DMEP321	MN	5-HT 6 receptor (HTR6)
DMEP321	MT	DTT
DMEP321	MA	Antagonist
DMEP321	RN	Pharmacological targeting of the serotonergic system for the treatment of obesity. J Physiol. 2009 January 1; 587(Pt 1): 49-60.
DMEP321	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2670022/

DMY9L4C	DI	DMY9L4C
DMY9L4C	DN	BXCL702
DMY9L4C	MI	TT3C1VN
DMY9L4C	MN	Enzyme unspecific (Enz)
DMY9L4C	MT	DTT
DMY9L4C	MA	Inhibitor
DMY9L4C	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMY9L4C	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMH6B9J	DI	DMH6B9J
DMH6B9J	DN	BZ-55
DMH6B9J	MI	DE5IED8
DMH6B9J	MN	Cytochrome P450 2C9 (CYP2C9)
DMH6B9J	MT	DME
DMH6B9J	MA	Metabolism
DMH6B9J	RN	Clinically and pharmacologically relevant interactions of antidiabetic drugs. Ther Adv Endocrinol Metab. 2016 Apr;7(2):69-83.
DMH6B9J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27092232

DMOV2ZD	DI	DMOV2ZD
DMOV2ZD	DN	C188-9
DMOV2ZD	MI	TTHJT3X
DMOV2ZD	MN	STAT3 messenger RNA (STAT3 mRNA)
DMOV2ZD	MT	DTT
DMOV2ZD	MA	Inhibitor
DMOV2ZD	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMOV2ZD	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMOFT1V	DI	DMOFT1V
DMOFT1V	DN	C-2507
DMOFT1V	MI	TT5FH9Y
DMOFT1V	MN	Human immunodeficiency virus Integrase (HIV IN)
DMOFT1V	MT	DTT
DMOFT1V	MA	Inhibitor
DMOFT1V	RN	Elvitegravir: a new HIV integrase inhibitor. Antivir Chem Chemother. 2009 Oct 19;20(2):79-85.
DMOFT1V	RU	https://pubmed.ncbi.nlm.nih.gov/19843978

DMR0S8U	DI	DMR0S8U
DMR0S8U	DN	C326
DMR0S8U	MI	TTT1V78
DMR0S8U	MN	Interleukin-6 (IL6)
DMR0S8U	MT	DTT
DMR0S8U	MA	Inhibitor
DMR0S8U	RN	The molecular basis of hepcidin-resistant hereditary hemochromatosis. Blood. 2009 Jul 9;114(2):437-43.
DMR0S8U	RU	https://pubmed.ncbi.nlm.nih.gov/19383972

DMSO3JA	DI	DMSO3JA
DMSO3JA	DN	C7R-GD2.CART cells
DMSO3JA	MI	TT80ARU
DMSO3JA	MN	Ganglioside GD2 (GD2)
DMSO3JA	MT	DTT
DMSO3JA	MA	CAR-T-Cell-Therapy
DMSO3JA	RN	ClinicalTrials.gov (NCT03635632) C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma (GAIL-N)
DMSO3JA	RU	https://clinicaltrials.gov/ct2/show/NCT03635632

DMPQ1TM	DI	DMPQ1TM
DMPQ1TM	DN	CA-011
DMPQ1TM	MI	TTMI6F5
DMPQ1TM	MN	Transient receptor potential cation channel V1 (TRPV1)
DMPQ1TM	MT	DTT
DMPQ1TM	MA	Agonist
DMPQ1TM	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPQ1TM	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMYDNQ2	DI	DMYDNQ2
DMYDNQ2	DN	CA102N
DMYDNQ2	MI	TTVKILB
DMYDNQ2	MN	Prostaglandin G/H synthase 2 (COX-2)
DMYDNQ2	MT	DTT
DMYDNQ2	MA	Inhibitor
DMYDNQ2	RN	National Cancer Institute Drug Dictionary (drug name CA102N).
DMYDNQ2	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/nimesulide-hyaluronic-acid-conjugate-ca102n

DMOUHR4	DI	DMOUHR4
DMOUHR4	DN	CA-170
DMOUHR4	MI	TT8ZLTI
DMOUHR4	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMOUHR4	MT	DTT
DMOUHR4	MA	Inhibitor
DMOUHR4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMOUHR4	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMQ2OP0	DI	DMQ2OP0
DMQ2OP0	DN	CA-170
DMQ2OP0	MI	TT8ZLTI
DMQ2OP0	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMQ2OP0	MT	DTT
DMQ2OP0	MA	Inhibitor
DMQ2OP0	RN	CA-170 - A Potent Small-Molecule PD-L1 Inhibitor or Not?. Molecules. 2019 Aug 1;24(15):2804.
DMQ2OP0	RU	https://pubmed.ncbi.nlm.nih.gov/31374878

DMOUHR4	DI	DMOUHR4
DMOUHR4	DN	CA-170
DMOUHR4	MI	TT51SK8
DMOUHR4	MN	V-set immunoregulatory receptor (VSIR)
DMOUHR4	MT	DTT
DMOUHR4	MA	Inhibitor
DMOUHR4	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMOUHR4	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMWV8C6	DI	DMWV8C6
DMWV8C6	DN	CA-4948
DMWV8C6	MI	TTKFVXR
DMWV8C6	MN	Renal carcinoma antigen NY-REN-64 (IRAK-4)
DMWV8C6	MT	DTT
DMWV8C6	MA	Inhibitor
DMWV8C6	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMWV8C6	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMA1QUC	DI	DMA1QUC
DMA1QUC	DN	CAD-1833
DMA1QUC	MI	TTKU9YD
DMA1QUC	MN	Calcium-activated potassium channel KCa2 (KCNN)
DMA1QUC	MT	DTT
DMA1QUC	MA	Modulator
DMA1QUC	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMA1QUC	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMQ7WJI	DI	DMQ7WJI
DMQ7WJI	DN	CAF-01
DMQ7WJI	MI	TT3J5ZI
DMQ7WJI	MN	Cell mediated immunity response (CMIR)
DMQ7WJI	MT	DTT
DMQ7WJI	MA	Modulator
DMQ7WJI	RN	Mechanisms of Action of Adjuvants. Front Immunol. 2013; 4: 114.
DMQ7WJI	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3655441/

DMT4Z5B	DI	DMT4Z5B
DMT4Z5B	DN	CALAA-01
DMT4Z5B	MI	TTBWDI0
DMT4Z5B	MN	Ribonucleoside-diphosphate reductase M2 (RRM2)
DMT4Z5B	MT	DTT
DMT4Z5B	MA	Modulator
DMT4Z5B	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMT4Z5B	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMT4Z5B	DI	DMT4Z5B
DMT4Z5B	DN	CALAA-01
DMT4Z5B	MI	TTV5YEH
DMT4Z5B	MN	Transferrin (TF)
DMT4Z5B	MT	DTT
DMT4Z5B	MA	Modulator
DMT4Z5B	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMT4Z5B	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMQTUH8	DI	DMQTUH8
DMQTUH8	DN	Calanolide A
DMQTUH8	MI	DE4LYSA
DMQTUH8	MN	Cytochrome P450 3A4 (CYP3A4)
DMQTUH8	MT	DME
DMQTUH8	MA	Metabolism
DMQTUH8	RN	Metabolism of F18, a derivative of calanolide A, in human liver microsomes and cytosol. Front Pharmacol. 2017 Jul 19;8:479.
DMQTUH8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28769808

DMQTUH8	DI	DMQTUH8
DMQTUH8	DN	Calanolide A
DMQTUH8	MI	TT84ETX
DMQTUH8	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMQTUH8	MT	DTT
DMQTUH8	MA	Inhibitor
DMQTUH8	RN	Calanolide A: a natural non-nucleoside reverse transcriptase inhibitor. BETA. 1999 Apr;12(2):8-9.
DMQTUH8	RU	https://pubmed.ncbi.nlm.nih.gov/11366704

DM1FLXD	DI	DM1FLXD
DM1FLXD	DN	CAN04
DM1FLXD	MI	TTWS50K
DM1FLXD	MN	Interleukin 1 receptor accessory protein (IL1RAP)
DM1FLXD	MT	DTT
DM1FLXD	MA	Inhibitor
DM1FLXD	RN	A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors (CANFOUR)
DM1FLXD	RU	https://clinicaltrials.gov/ct2/show/NCT03267316

DM9ERH1	DI	DM9ERH1
DM9ERH1	DN	Capravirine
DM9ERH1	MI	DES5XRU
DM9ERH1	MN	Cytochrome P450 2C8 (CYP2C8)
DM9ERH1	MT	DME
DM9ERH1	MA	Metabolism
DM9ERH1	RN	Identification of enzymes responsible for primary and sequential oxygenation reactions of capravirine in human liver microsomes. Drug Metab Dispos. 2006 Nov;34(11):1798-802.
DM9ERH1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16914510

DM9ERH1	DI	DM9ERH1
DM9ERH1	DN	Capravirine
DM9ERH1	MI	DE5IED8
DM9ERH1	MN	Cytochrome P450 2C9 (CYP2C9)
DM9ERH1	MT	DME
DM9ERH1	MA	Metabolism
DM9ERH1	RN	Identification of enzymes responsible for primary and sequential oxygenation reactions of capravirine in human liver microsomes. Drug Metab Dispos. 2006 Nov;34(11):1798-802.
DM9ERH1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16914510

DM9ERH1	DI	DM9ERH1
DM9ERH1	DN	Capravirine
DM9ERH1	MI	DE4LYSA
DM9ERH1	MN	Cytochrome P450 3A4 (CYP3A4)
DM9ERH1	MT	DME
DM9ERH1	MA	Metabolism
DM9ERH1	RN	Identification of enzymes responsible for primary and sequential oxygenation reactions of capravirine in human liver microsomes. Drug Metab Dispos. 2006 Nov;34(11):1798-802.
DM9ERH1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16914510

DM9ERH1	DI	DM9ERH1
DM9ERH1	DN	Capravirine
DM9ERH1	MI	TT84ETX
DM9ERH1	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM9ERH1	MT	DTT
DM9ERH1	MA	Inhibitor
DM9ERH1	RN	Metabolism and excretion of capravirine, a new non-nucleoside reverse transcriptase inhibitor, alone and in combination with ritonavir in healthy volunteers. Drug Metab Dispos. 2004 Jul;32(7):689-98.
DM9ERH1	RU	https://pubmed.ncbi.nlm.nih.gov/15205383

DM9ERH1	DI	DM9ERH1
DM9ERH1	DN	Capravirine
DM9ERH1	MI	DEYGVN4
DM9ERH1	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM9ERH1	MT	DME
DM9ERH1	MA	Metabolism
DM9ERH1	RN	Metabolism and excretion of capravirine, a new non-nucleoside reverse transcriptase inhibitor, alone and in combination with ritonavir in healthy volunteers. Drug Metab Dispos. 2004 Jul;32(7):689-98.
DM9ERH1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15205383

DM8NLPI	DI	DM8NLPI
DM8NLPI	DN	CAR CD30 T cells
DM8NLPI	MI	TT2GM5R
DM8NLPI	MN	Lymphocyte activation antigen CD30 (TNFRSF8)
DM8NLPI	MT	DTT
DM8NLPI	MA	CAR-T-Cell-Therapy
DM8NLPI	RN	ClinicalTrials.gov (NCT01316146) Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30)
DM8NLPI	RU	https://clinicaltrials.gov/ct2/show/NCT01316146

DMA9M81	DI	DMA9M81
DMA9M81	DN	CAR138 T Cells
DMA9M81	MI	TTYDSVG
DMA9M81	MN	Syndecan-1 (SDC1)
DMA9M81	MT	DTT
DMA9M81	MA	CAR-T-Cell-Therapy
DMA9M81	RN	ClinicalTrials.gov (NCT03672318) Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma
DMA9M81	RU	https://clinicaltrials.gov/ct2/show/NCT03672318

DMXD4TC	DI	DMXD4TC
DMXD4TC	DN	CAR19 T cells carrying cytoplasmic activated PD-1
DMXD4TC	MI	TTW640A
DMXD4TC	MN	B-lymphocyte surface antigen B4 (CD19)
DMXD4TC	MT	DTT
DMXD4TC	MA	CAR-T-Cell-Therapy
DMXD4TC	RN	ClinicalTrials.gov (NCT03540303) Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma
DMXD4TC	RU	https://clinicaltrials.gov/ct2/show/NCT03540303

DM4CXE2	DI	DM4CXE2
DM4CXE2	DN	CAR-20/19-T Cells
DM4CXE2	MI	TTW640A
DM4CXE2	MN	B-lymphocyte surface antigen B4 (CD19)
DM4CXE2	MT	DTT
DM4CXE2	MA	CAR-T-Cell-Therapy(Dual specific)
DM4CXE2	RN	ClinicalTrials.gov (NCT03375619) Long-term Follow-up Study of Patients Receiving CAR-20/19-T Cells
DM4CXE2	RU	https://clinicaltrials.gov/ct2/show/NCT03375619

DM4CXE2	DI	DM4CXE2
DM4CXE2	DN	CAR-20/19-T Cells
DM4CXE2	MI	TTUE541
DM4CXE2	MN	Leukocyte surface antigen Leu-16 (CD20)
DM4CXE2	MT	DTT
DM4CXE2	MA	CAR-T-Cell-Therapy(Dual specific)
DM4CXE2	RN	ClinicalTrials.gov (NCT03375619) Long-term Follow-up Study of Patients Receiving CAR-20/19-T Cells
DM4CXE2	RU	https://clinicaltrials.gov/ct2/show/NCT03375619

DM4SNK8	DI	DM4SNK8
DM4SNK8	DN	CARD-024
DM4SNK8	MI	TTB2MXP
DM4SNK8	MN	Angiotensinogenase renin (REN)
DM4SNK8	MT	DTT
DM4SNK8	MA	Agonist
DM4SNK8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2413).
DM4SNK8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2413

DM5WKU1	DI	DM5WKU1
DM5WKU1	DN	Cardiotrophin-1
DM5WKU1	MI	TTXGTZU
DM5WKU1	MN	Cardiotrophin-1 (CTF1)
DM5WKU1	MT	DTT
DM5WKU1	MA	Stimulator
DM5WKU1	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM5WKU1	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMQH2DK	DI	DMQH2DK
DMQH2DK	DN	CAR-GPC3 T Cells
DMQH2DK	MI	TTJTSX4
DMQH2DK	MN	Glypican-3 (GPC3)
DMQH2DK	MT	DTT
DMQH2DK	MA	CAR-T-Cell-Therapy
DMQH2DK	RN	ClinicalTrials.gov (NCT02876978) Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma
DMQH2DK	RU	https://clinicaltrials.gov/ct2/show/NCT02876978

DMU6ZMX	DI	DMU6ZMX
DMU6ZMX	DN	Carmoxirole
DMU6ZMX	MI	TTEX248
DMU6ZMX	MN	Dopamine D2 receptor (D2R)
DMU6ZMX	MT	DTT
DMU6ZMX	MA	Agonist
DMU6ZMX	RN	Neurohumoral response to carmoxirole, a selective dopamine (D2) receptor agonist, in patients with chronic moderate heart failure. Cardiovasc Drugs Ther. 1998 Sep;12(4):387-94.
DMU6ZMX	RU	https://pubmed.ncbi.nlm.nih.gov/9825185

DMC7Y5F	DI	DMC7Y5F
DMC7Y5F	DN	CAR-T cells recognizing EpCAM
DMC7Y5F	MI	TTZ8WH4
DMC7Y5F	MN	Tumor-associated calcium signal transducer 1 (EPCAM)
DMC7Y5F	MT	DTT
DMC7Y5F	MA	CAR-T-Cell-Therapy
DMC7Y5F	RN	ClinicalTrials.gov (NCT02915445) EpCAM CAR-T for Treatment of Nasopharyngeal Carcinoma and Breast Cancer
DMC7Y5F	RU	https://clinicaltrials.gov/ct2/show/NCT02915445

DMTZADW	DI	DMTZADW
DMTZADW	DN	CAR-T cells targeting BCMA
DMTZADW	MI	TTZ3P4W
DMTZADW	MN	B-cell maturation protein (TNFRSF17)
DMTZADW	MT	DTT
DMTZADW	MA	CAR-T-Cell-Therapy
DMTZADW	RN	ClinicalTrials.gov (NCT03672253) CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma
DMTZADW	RU	https://clinicaltrials.gov/ct2/show/NCT03672253

DM3AHNX	DI	DM3AHNX
DM3AHNX	DN	CAR-T Cells targeting CD19
DM3AHNX	MI	TTW640A
DM3AHNX	MN	B-lymphocyte surface antigen B4 (CD19)
DM3AHNX	MT	DTT
DM3AHNX	MA	CAR-T-Cell-Therapy
DM3AHNX	RN	ClinicalTrials.gov (NCT03186118) Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia
DM3AHNX	RU	https://clinicaltrials.gov/ct2/show/NCT03186118

DMJK1R0	DI	DMJK1R0
DMJK1R0	DN	CAR-T cells targeting CD19
DMJK1R0	MI	TTW640A
DMJK1R0	MN	B-lymphocyte surface antigen B4 (CD19)
DMJK1R0	MT	DTT
DMJK1R0	MA	CAR-T-Cell-Therapy
DMJK1R0	RN	ClinicalTrials.gov (NCT03086954) Study Evaluating the Efficacy and Safety With CAR-T Immunotherapy for CD19 Positive Lymphoma
DMJK1R0	RU	https://clinicaltrials.gov/ct2/show/NCT03086954

DM6Z7AD	DI	DM6Z7AD
DM6Z7AD	DN	CAR-T cells targeting CD80/86
DM6Z7AD	MI	TTFZDNP
DM6Z7AD	MN	Activation B7-1 antigen (CD80)
DM6Z7AD	MT	DTT
DM6Z7AD	MA	CAR-T-Cell-Therapy
DM6Z7AD	RN	ClinicalTrials.gov (NCT03198052) HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers
DM6Z7AD	RU	https://clinicaltrials.gov/ct2/show/NCT03198052

DMX4ZDY	DI	DMX4ZDY
DMX4ZDY	DN	CAR-T Cells targeting CEA
DMX4ZDY	MI	TTY6DTE
DMX4ZDY	MN	Carcinoembryonic antigen CEA (CD66e)
DMX4ZDY	MT	DTT
DMX4ZDY	MA	CAR-T-Cell-Therapy
DMX4ZDY	RN	ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.
DMX4ZDY	RU	https://clinicaltrials.gov/ct2/show/NCT03267173

DMRSG04	DI	DMRSG04
DMRSG04	DN	CAR-T cells targeting EGFRviii
DMRSG04	MI	TTZ6B2I
DMRSG04	MN	Epidermal growth factor receptor variant III (EGFR vIII)
DMRSG04	MT	DTT
DMRSG04	MA	CAR-T-Cell-Therapy
DMRSG04	RN	ClinicalTrials.gov (NCT03170141) Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme
DMRSG04	RU	https://clinicaltrials.gov/ct2/show/NCT03170141

DMWAMNT	DI	DMWAMNT
DMWAMNT	DN	CAR-T Cells targeting EGFRvIII
DMWAMNT	MI	TTZ6B2I
DMWAMNT	MN	Epidermal growth factor receptor variant III (EGFR vIII)
DMWAMNT	MT	DTT
DMWAMNT	MA	CAR-T-Cell-Therapy
DMWAMNT	RN	ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.
DMWAMNT	RU	https://clinicaltrials.gov/ct2/show/NCT03267173

DMQ2Y1J	DI	DMQ2Y1J
DMQ2Y1J	DN	CAR-T cells targeting EpCAM
DMQ2Y1J	MI	TTZ8WH4
DMQ2Y1J	MN	Tumor-associated calcium signal transducer 1 (EPCAM)
DMQ2Y1J	MT	DTT
DMQ2Y1J	MA	CAR-T-Cell-Therapy
DMQ2Y1J	RN	ClinicalTrials.gov (NCT03563326) Intraperitoneal Infusion of EpCAM CAR-T Cell in Advanced Gastric Cancer With Peritoneal Metastasis (WCH-GC-CART)
DMQ2Y1J	RU	https://clinicaltrials.gov/ct2/show/NCT03563326

DMYCMNR	DI	DMYCMNR
DMYCMNR	DN	CAR-T Cells targeting HER2
DMYCMNR	MI	TT6EO5L
DMYCMNR	MN	Erbb2 tyrosine kinase receptor (HER2)
DMYCMNR	MT	DTT
DMYCMNR	MA	CAR-T-Cell-Therapy
DMYCMNR	RN	ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.
DMYCMNR	RU	https://clinicaltrials.gov/ct2/show/NCT03267173

DMLI5VG	DI	DMLI5VG
DMLI5VG	DN	CAR-T cells targeting HER2
DMLI5VG	MI	TT6EO5L
DMLI5VG	MN	Erbb2 tyrosine kinase receptor (HER2)
DMLI5VG	MT	DTT
DMLI5VG	MA	CAR-T-Cell-Therapy
DMLI5VG	RN	ClinicalTrials.gov (NCT03198052) HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers
DMLI5VG	RU	https://clinicaltrials.gov/ct2/show/NCT03198052

DMGI58S	DI	DMGI58S
DMGI58S	DN	CAR-T cells targeting Lewis-Y
DMGI58S	MI	TTV75BJ
DMGI58S	MN	Carbohydrate antigen Lewis-Y (Lewis-Y)
DMGI58S	MT	DTT
DMGI58S	MA	CAR-T-Cell-Therapy
DMGI58S	RN	ClinicalTrials.gov (NCT03198052) HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers
DMGI58S	RU	https://clinicaltrials.gov/ct2/show/NCT03198052

DMTZXSO	DI	DMTZXSO
DMTZXSO	DN	CAR-T cells targeting Mesothelin
DMTZXSO	MI	TT4RXME
DMTZXSO	MN	Mesothelin (MSLN)
DMTZXSO	MT	DTT
DMTZXSO	MA	CAR-T-Cell-Therapy
DMTZXSO	RN	ClinicalTrials.gov (NCT03198052) HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers
DMTZXSO	RU	https://clinicaltrials.gov/ct2/show/NCT03198052

DM6DULC	DI	DM6DULC
DM6DULC	DN	CAR-T Cells targeting Mesothelin
DM6DULC	MI	TT4RXME
DM6DULC	MN	Mesothelin (MSLN)
DM6DULC	MT	DTT
DM6DULC	MA	CAR-T-Cell-Therapy
DM6DULC	RN	ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.
DM6DULC	RU	https://clinicaltrials.gov/ct2/show/NCT03267173

DM6GRNC	DI	DM6GRNC
DM6GRNC	DN	CAR-T cells targeting MUC1
DM6GRNC	MI	TTBHFYQ
DM6GRNC	MN	Mucin-1 (MUC1)
DM6GRNC	MT	DTT
DM6GRNC	MA	CAR-T-Cell-Therapy
DM6GRNC	RN	ClinicalTrials.gov (NCT03198052) HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers
DM6GRNC	RU	https://clinicaltrials.gov/ct2/show/NCT03198052

DMNH1Y5	DI	DMNH1Y5
DMNH1Y5	DN	CAR-T Cells targeting MUCI
DMNH1Y5	MI	TTBHFYQ
DMNH1Y5	MN	Mucin-1 (MUC1)
DMNH1Y5	MT	DTT
DMNH1Y5	MA	CAR-T-Cell-Therapy
DMNH1Y5	RN	ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.
DMNH1Y5	RU	https://clinicaltrials.gov/ct2/show/NCT03267173

DMWIXLC	DI	DMWIXLC
DMWIXLC	DN	CAR-T Cells targeting PSCA
DMWIXLC	MI	TT9T4AV
DMWIXLC	MN	Prostate stem cell antigen (PSCA)
DMWIXLC	MT	DTT
DMWIXLC	MA	CAR-T-Cell-Therapy
DMWIXLC	RN	ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.
DMWIXLC	RU	https://clinicaltrials.gov/ct2/show/NCT03267173

DMU4G9J	DI	DMU4G9J
DMU4G9J	DN	CAR-T cells targeting PSCA
DMU4G9J	MI	TT9T4AV
DMU4G9J	MN	Prostate stem cell antigen (PSCA)
DMU4G9J	MT	DTT
DMU4G9J	MA	CAR-T-Cell-Therapy
DMU4G9J	RN	ClinicalTrials.gov (NCT03198052) HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers
DMU4G9J	RU	https://clinicaltrials.gov/ct2/show/NCT03198052

DMQ4UJ6	DI	DMQ4UJ6
DMQ4UJ6	DN	CART-10 cells
DMQ4UJ6	MI	TT5TKPM
DMQ4UJ6	MN	Neutral endopeptidase (MME)
DMQ4UJ6	MT	DTT
DMQ4UJ6	MA	CAR-T-Cell-Therapy
DMQ4UJ6	RN	ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
DMQ4UJ6	RU	https://clinicaltrials.gov/ct2/show/NCT03291444

DMAKZTW	DI	DMAKZTW
DMAKZTW	DN	CART-117 cells
DMAKZTW	MI	TTX41N9
DMAKZTW	MN	Tyrosine-protein kinase Kit (KIT)
DMAKZTW	MT	DTT
DMAKZTW	MA	CAR-T-Cell-Therapy
DMAKZTW	RN	ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
DMAKZTW	RU	https://clinicaltrials.gov/ct2/show/NCT03291444

DMD0XWR	DI	DMD0XWR
DMD0XWR	DN	CART123 cells
DMD0XWR	MI	TTENHJ0
DMD0XWR	MN	Interleukin 3 receptor alpha (IL3RA)
DMD0XWR	MT	DTT
DMD0XWR	MA	CAR-T-Cell-Therapy
DMD0XWR	RN	ClinicalTrials.gov (NCT03766126) Lentivirally Redirected CD123 Autologous T Cells in AML
DMD0XWR	RU	https://clinicaltrials.gov/ct2/show/NCT03766126

DMEN6YF	DI	DMEN6YF
DMEN6YF	DN	CART-123 cells
DMEN6YF	MI	TTENHJ0
DMEN6YF	MN	Interleukin 3 receptor alpha (IL3RA)
DMEN6YF	MT	DTT
DMEN6YF	MA	CAR-T-Cell-Therapy
DMEN6YF	RN	ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
DMEN6YF	RU	https://clinicaltrials.gov/ct2/show/NCT03291444

DM1R8P4	DI	DM1R8P4
DM1R8P4	DN	CART-19
DM1R8P4	MI	TTW640A
DM1R8P4	MN	B-lymphocyte surface antigen B4 (CD19)
DM1R8P4	MT	DTT
DM1R8P4	MA	CAR-T-Cell-Therapy
DM1R8P4	RN	ClinicalTrials.gov (NCT03101709) The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma
DM1R8P4	RU	https://clinicaltrials.gov/ct2/show/NCT03101709

DM8R2ZX	DI	DM8R2ZX
DM8R2ZX	DN	CART-19
DM8R2ZX	MI	TTW640A
DM8R2ZX	MN	B-lymphocyte surface antigen B4 (CD19)
DM8R2ZX	MT	DTT
DM8R2ZX	MA	CAR-T-Cell-Therapy
DM8R2ZX	RN	ClinicalTrials.gov (NCT02810223) Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic Leukemia
DM8R2ZX	RU	https://clinicaltrials.gov/ct2/show/NCT02810223

DMY218P	DI	DMY218P
DMY218P	DN	CART-19 autologous T-cells
DMY218P	MI	TTW640A
DMY218P	MN	B-lymphocyte surface antigen B4 (CD19)
DMY218P	MT	DTT
DMY218P	MA	CAR-T-Cell-Therapy
DMY218P	RN	ClinicalTrials.gov (NCT02476734) FDG-PET/CT Imaging as Early Predictor of DP
DMY218P	RU	https://clinicaltrials.gov/ct2/show/NCT02476734

DMM95XS	DI	DMM95XS
DMM95XS	DN	CART19 cell
DMM95XS	MI	TTW640A
DMM95XS	MN	B-lymphocyte surface antigen B4 (CD19)
DMM95XS	MT	DTT
DMM95XS	MA	CAR-T-Cell-Therapy
DMM95XS	RN	ClinicalTrials.gov (NCT03685786) CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT
DMM95XS	RU	https://clinicaltrials.gov/ct2/show/NCT03685786

DMHWVY1	DI	DMHWVY1
DMHWVY1	DN	CART-19 cells
DMHWVY1	MI	TTW640A
DMHWVY1	MN	B-lymphocyte surface antigen B4 (CD19)
DMHWVY1	MT	DTT
DMHWVY1	MA	CAR-T-Cell-Therapy
DMHWVY1	RN	ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
DMHWVY1	RU	https://clinicaltrials.gov/ct2/show/NCT03291444

DMKW27X	DI	DMKW27X
DMKW27X	DN	CART-19 cells
DMKW27X	MI	TTW640A
DMKW27X	MN	B-lymphocyte surface antigen B4 (CD19)
DMKW27X	MT	DTT
DMKW27X	MA	CAR-T-Cell-Therapy
DMKW27X	RN	ClinicalTrials.gov (NCT02924753) The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).
DMKW27X	RU	https://clinicaltrials.gov/ct2/show/NCT02924753

DMTCB8I	DI	DMTCB8I
DMTCB8I	DN	CART-19 T cells
DMTCB8I	MI	TTW640A
DMTCB8I	MN	B-lymphocyte surface antigen B4 (CD19)
DMTCB8I	MT	DTT
DMTCB8I	MA	CAR-T-Cell-Therapy
DMTCB8I	RN	ClinicalTrials.gov (NCT02135406) CART-19 for Multiple Myeloma
DMTCB8I	RU	https://clinicaltrials.gov/ct2/show/NCT02135406

DMR0Z65	DI	DMR0Z65
DMR0Z65	DN	CART-20 cells
DMR0Z65	MI	TTUE541
DMR0Z65	MN	Leukocyte surface antigen Leu-16 (CD20)
DMR0Z65	MT	DTT
DMR0Z65	MA	CAR-T-Cell-Therapy
DMR0Z65	RN	ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
DMR0Z65	RU	https://clinicaltrials.gov/ct2/show/NCT03291444

DM6X82R	DI	DM6X82R
DM6X82R	DN	CART22 cells
DM6X82R	MI	TTM6QSK
DM6X82R	MN	B-cell receptor CD22 (CD22)
DM6X82R	MT	DTT
DM6X82R	MA	CAR-T-Cell-Therapy
DM6X82R	RN	ClinicalTrials.gov (NCT02588456) Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia
DM6X82R	RU	https://clinicaltrials.gov/ct2/show/NCT02588456

DMLGJKE	DI	DMLGJKE
DMLGJKE	DN	CART-22 cells
DMLGJKE	MI	TTM6QSK
DMLGJKE	MN	B-cell receptor CD22 (CD22)
DMLGJKE	MT	DTT
DMLGJKE	MA	CAR-T-Cell-Therapy
DMLGJKE	RN	ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
DMLGJKE	RU	https://clinicaltrials.gov/ct2/show/NCT03291444

DMY3NWK	DI	DMY3NWK
DMY3NWK	DN	CART22 cells expressing anti-CD22 scFv TCRz:41BB
DMY3NWK	MI	TTM6QSK
DMY3NWK	MN	B-cell receptor CD22 (CD22)
DMY3NWK	MT	DTT
DMY3NWK	MA	CAR-T-Cell-Therapy
DMY3NWK	RN	ClinicalTrials.gov (NCT02650414) CD22 Redirected Autologous T Cells for ALL
DMY3NWK	RU	https://clinicaltrials.gov/ct2/show/NCT02650414

DM4XT15	DI	DM4XT15
DM4XT15	DN	CART22-65s cells
DM4XT15	MI	TTM6QSK
DM4XT15	MN	B-cell receptor CD22 (CD22)
DM4XT15	MT	DTT
DM4XT15	MA	CAR-T-Cell-Therapy
DM4XT15	RN	ClinicalTrials.gov (NCT03620058) CART22 Alone or in Combination With huCART19 for ALL
DM4XT15	RU	https://clinicaltrials.gov/ct2/show/NCT03620058

DMOJ1AH	DI	DMOJ1AH
DMOJ1AH	DN	CART22-65s cells and huCART19 Cells
DMOJ1AH	MI	TTM6QSK
DMOJ1AH	MN	B-cell receptor CD22 (CD22)
DMOJ1AH	MT	DTT
DMOJ1AH	MA	CAR-T-Cell-Therapy(Dual specific)
DMOJ1AH	RN	ClinicalTrials.gov (NCT03620058) CART22 Alone or in Combination With huCART19 for ALL
DMOJ1AH	RU	https://clinicaltrials.gov/ct2/show/NCT03620058

DMOJ1AH	DI	DMOJ1AH
DMOJ1AH	DN	CART22-65s cells and huCART19 Cells
DMOJ1AH	MI	TTW640A
DMOJ1AH	MN	B-lymphocyte surface antigen B4 (CD19)
DMOJ1AH	MT	DTT
DMOJ1AH	MA	CAR-T-Cell-Therapy(Dual specific)
DMOJ1AH	RN	ClinicalTrials.gov (NCT03620058) CART22 Alone or in Combination With huCART19 for ALL
DMOJ1AH	RU	https://clinicaltrials.gov/ct2/show/NCT03620058

DMBHCSL	DI	DMBHCSL
DMBHCSL	DN	CART-33 cells
DMBHCSL	MI	TTJVYO3
DMBHCSL	MN	Myeloid cell surface antigen CD33 (CD33)
DMBHCSL	MT	DTT
DMBHCSL	MA	CAR-T-Cell-Therapy
DMBHCSL	RN	ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
DMBHCSL	RU	https://clinicaltrials.gov/ct2/show/NCT03291444

DMRNIB9	DI	DMRNIB9
DMRNIB9	DN	CART-34 cells
DMRNIB9	MI	TTZAVYN
DMRNIB9	MN	Hematopoietic progenitor cell antigen CD34 (CD34)
DMRNIB9	MT	DTT
DMRNIB9	MA	CAR-T-Cell-Therapy
DMRNIB9	RN	ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
DMRNIB9	RU	https://clinicaltrials.gov/ct2/show/NCT03291444

DMKN8XD	DI	DMKN8XD
DMKN8XD	DN	CART-38 cells
DMKN8XD	MI	TTPURFN
DMKN8XD	MN	Cyclic ADP-ribose hydrolase 1 (CD38)
DMKN8XD	MT	DTT
DMKN8XD	MA	CAR-T-Cell-Therapy
DMKN8XD	RN	ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
DMKN8XD	RU	https://clinicaltrials.gov/ct2/show/NCT03291444

DMQTOBF	DI	DMQTOBF
DMQTOBF	DN	CART-56 cells
DMQTOBF	MI	TTVXPHT
DMQTOBF	MN	Neural cell adhesion molecule 1 (NCAM1)
DMQTOBF	MT	DTT
DMQTOBF	MA	CAR-T-Cell-Therapy
DMQTOBF	RN	ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
DMQTOBF	RU	https://clinicaltrials.gov/ct2/show/NCT03291444

DMVK3M2	DI	DMVK3M2
DMVK3M2	DN	CART-BCMA
DMVK3M2	MI	TTZ3P4W
DMVK3M2	MN	B-cell maturation protein (TNFRSF17)
DMVK3M2	MT	DTT
DMVK3M2	MA	CAR-T-Cell-Therapy
DMVK3M2	RN	ClinicalTrials.gov (NCT02546167) CART-BCMA Cells for Multiple Myeloma
DMVK3M2	RU	https://clinicaltrials.gov/ct2/show/NCT02546167

DM4OWJ8	DI	DM4OWJ8
DM4OWJ8	DN	CART-ddBCMA
DM4OWJ8	MI	TTZ3P4W
DM4OWJ8	MN	B-cell maturation protein (TNFRSF17)
DM4OWJ8	MT	DTT
DM4OWJ8	RN	Clinical pipeline report, company report or official report of Arcellx.
DM4OWJ8	RU	https://arcellx.com/pipeline/overview/

DMGPR1C	DI	DMGPR1C
DMGPR1C	DN	CART-EGFRvIII T cells
DMGPR1C	MI	TTZ6B2I
DMGPR1C	MN	Epidermal growth factor receptor variant III (EGFR vIII)
DMGPR1C	MT	DTT
DMGPR1C	MA	CAR-T-Cell-Therapy
DMGPR1C	RN	ClinicalTrials.gov (NCT02209376) Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma
DMGPR1C	RU	https://clinicaltrials.gov/ct2/show/NCT02209376

DM90QPK	DI	DM90QPK
DM90QPK	DN	CART-meso cells
DM90QPK	MI	TT4RXME
DM90QPK	MN	Mesothelin (MSLN)
DM90QPK	MT	DTT
DM90QPK	MA	CAR-T-Cell-Therapy
DM90QPK	RN	ClinicalTrials.gov (NCT02159716) CART-meso in Mesothelin Expressing Cancers
DM90QPK	RU	https://clinicaltrials.gov/ct2/show/NCT02159716

DMV84ZR	DI	DMV84ZR
DMV84ZR	DN	CARTmeso/19
DMV84ZR	MI	TTW640A
DMV84ZR	MN	B-lymphocyte surface antigen B4 (CD19)
DMV84ZR	MT	DTT
DMV84ZR	MA	CAR-T-Cell-Therapy(Dual specific)
DMV84ZR	RN	ClinicalTrials.gov (NCT03497819) Autologous CARTmeso/19 Against Pancreatic Cancer
DMV84ZR	RU	https://clinicaltrials.gov/ct2/show/NCT03497819

DMV84ZR	DI	DMV84ZR
DMV84ZR	DN	CARTmeso/19
DMV84ZR	MI	TT4RXME
DMV84ZR	MN	Mesothelin (MSLN)
DMV84ZR	MT	DTT
DMV84ZR	MA	CAR-T-Cell-Therapy(Dual specific)
DMV84ZR	RN	ClinicalTrials.gov (NCT03497819) Autologous CARTmeso/19 Against Pancreatic Cancer
DMV84ZR	RU	https://clinicaltrials.gov/ct2/show/NCT03497819

DMZ4I03	DI	DMZ4I03
DMZ4I03	DN	CART-meso-19 T cells
DMZ4I03	MI	TTW640A
DMZ4I03	MN	B-lymphocyte surface antigen B4 (CD19)
DMZ4I03	MT	DTT
DMZ4I03	MA	CAR-T-Cell-Therapy(Dual specific)
DMZ4I03	RN	ClinicalTrials.gov (NCT02465983) Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer
DMZ4I03	RU	https://clinicaltrials.gov/ct2/show/NCT02465983

DMZ4I03	DI	DMZ4I03
DMZ4I03	DN	CART-meso-19 T cells
DMZ4I03	MI	TT4RXME
DMZ4I03	MN	Mesothelin (MSLN)
DMZ4I03	MT	DTT
DMZ4I03	MA	CAR-T-Cell-Therapy(Dual specific)
DMZ4I03	RN	ClinicalTrials.gov (NCT02465983) Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer
DMZ4I03	RU	https://clinicaltrials.gov/ct2/show/NCT02465983

DMOJEXG	DI	DMOJEXG
DMOJEXG	DN	CART-Muc1 cells
DMOJEXG	MI	TTBHFYQ
DMOJEXG	MN	Mucin-1 (MUC1)
DMOJEXG	MT	DTT
DMOJEXG	MA	CAR-T-Cell-Therapy
DMOJEXG	RN	ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
DMOJEXG	RU	https://clinicaltrials.gov/ct2/show/NCT03291444

DM39LPN	DI	DM39LPN
DM39LPN	DN	CarVAC
DM39LPN	MI	TTW640A
DM39LPN	MN	B-lymphocyte surface antigen B4 (CD19)
DM39LPN	MT	DTT
DM39LPN	RN	ClinicalTrials.gov (NCT04156243) CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies. U.S. National Institutes of Health.
DM39LPN	RU	https://clinicaltrials.gov/ct2/show/NCT04156243

DMO53AD	DI	DMO53AD
DMO53AD	DN	Cavrotolimod
DMO53AD	MI	TTSHG0T
DMO53AD	MN	Toll-like receptor 9 (TLR9)
DMO53AD	MT	DTT
DMO53AD	MA	Agonist
DMO53AD	RN	Clinical pipeline report, company report or official report of Exicure.
DMO53AD	RU	https://www.exicuretx.com/pipeline/index.php

DM12GN7	DI	DM12GN7
DM12GN7	DN	CB-5083
DM12GN7	MI	TTHNLSB
DM12GN7	MN	Valosin-containing protein p97 (VCP)
DM12GN7	MT	DTT
DM12GN7	MA	Inhibitor
DM12GN7	RN	Pharmacological targeting of valosin containing protein (VCP) induces DNA damage and selectively kills canine lymphoma cells. BMC Cancer. 2015; 15: 479.
DM12GN7	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4479320/

DMOXDIY	DI	DMOXDIY
DMOXDIY	DN	CB-5339
DMOXDIY	MI	TTHNLSB
DMOXDIY	MN	Valosin-containing protein p97 (VCP)
DMOXDIY	MT	DTT
DMOXDIY	MA	Inhibitor
DMOXDIY	RN	Clinical pipeline report, company report or official report of Cleave Therapeutics.
DMOXDIY	RU	https://www.casipharmaceuticals.com/product-pipeline/cb-5339/

DMXQGKL	DI	DMXQGKL
DMXQGKL	DN	CB-813
DMXQGKL	MI	TTF0EGX
DMXQGKL	MN	Coagulation factor VII (F7)
DMXQGKL	MT	DTT
DMXQGKL	MA	Modulator
DMXQGKL	RN	Clinical pipeline report, company report or official report of Catalyst Biosciences.
DMXQGKL	RU	http://www.catalystbiosciences.com/news/15-06-24/

DMORN60	DI	DMORN60
DMORN60	DN	CBL0137
DMORN60	MI	TTETDKQ
DMORN60	MN	Facilitates chromatin transcription complex (FACT)
DMORN60	MT	DTT
DMORN60	MA	Modulator
DMORN60	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMORN60	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMOTLN4	DI	DMOTLN4
DMOTLN4	DN	CBT-101
DMOTLN4	MI	TTNDSF4
DMOTLN4	MN	Proto-oncogene c-Met (MET)
DMOTLN4	MT	DTT
DMOTLN4	MA	Inhibitor
DMOTLN4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMOTLN4	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMW1OKT	DI	DMW1OKT
DMW1OKT	DN	CBT-501
DMW1OKT	MI	TTNBFWK
DMW1OKT	MN	Programmed cell death protein 1 (PD-1)
DMW1OKT	MT	DTT
DMW1OKT	MA	Modulator
DMW1OKT	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMW1OKT	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM0SRAN	DI	DM0SRAN
DM0SRAN	DN	CC-122
DM0SRAN	MI	TTDKGTC
DM0SRAN	MN	Protein cereblon (CRBN)
DM0SRAN	MT	DTT
DM0SRAN	MA	Modulator
DM0SRAN	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM0SRAN	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMAYHT4	DI	DMAYHT4
DMAYHT4	DN	CC-31244
DMAYHT4	MI	TTMVBWH
DMAYHT4	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMAYHT4	MT	DTT
DMAYHT4	MA	Inhibitor
DMAYHT4	RN	Clinical pipeline report, company report or official report of Cocrystal Pharma.
DMAYHT4	RU	https://www.cocrystalpharma.com/development-pipeline/hepatitis-c/cc-31244

DMILHMC	DI	DMILHMC
DMILHMC	DN	CC8464
DMILHMC	MI	TT4G2JS
DMILHMC	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DMILHMC	MT	DTT
DMILHMC	MA	Inhibitor
DMILHMC	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMILHMC	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMXUT3Z	DI	DMXUT3Z
DMXUT3Z	DN	CC-8490
DMXUT3Z	MI	TTZAYWL
DMXUT3Z	MN	Estrogen receptor (ESR)
DMXUT3Z	MT	DTT
DMXUT3Z	MA	Modulator
DMXUT3Z	RN	Agents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in ER-negative glioma cells. Cancer Res. 2004 Dec 15;64(24):9115-23.
DMXUT3Z	RU	https://pubmed.ncbi.nlm.nih.gov/15604281

DMK0QDO	DI	DMK0QDO
DMK0QDO	DN	CC-90002
DMK0QDO	MI	TT28S46
DMK0QDO	MN	Leukocyte surface antigen CD47 (CD47)
DMK0QDO	MT	DTT
DMK0QDO	MA	Inhibitor
DMK0QDO	RN	National Cancer Institute Drug Dictionary (drug name CC 90002).
DMK0QDO	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-cd47-monoclonal-antibody-cc-90002

DMHJLB6	DI	DMHJLB6
DMHJLB6	DN	CC-90006
DMHJLB6	MI	TTNBFWK
DMHJLB6	MN	Programmed cell death protein 1 (PD-1)
DMHJLB6	MT	DTT
DMHJLB6	MA	Antagonist
DMHJLB6	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMHJLB6	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMKH3Z9	DI	DMKH3Z9
DMKH3Z9	DN	CC-90010
DMKH3Z9	MI	TTE4BSY
DMKH3Z9	MN	Bromodomain and extraterminal domain protein (BET)
DMKH3Z9	MT	DTT
DMKH3Z9	MA	Inhibitor
DMKH3Z9	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMKH3Z9	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMO0AJE	DI	DMO0AJE
DMO0AJE	DN	CC-90010
DMO0AJE	MI	TTE4BSY
DMO0AJE	MN	Bromodomain and extraterminal domain protein (BET)
DMO0AJE	MT	DTT
DMO0AJE	MA	Inhibitor
DMO0AJE	RN	Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma. Ann Oncol. 2020 Jun;31(6):780-788.
DMO0AJE	RU	https://pubmed.ncbi.nlm.nih.gov/32240793

DM1GV6O	DI	DM1GV6O
DM1GV6O	DN	CC-90011
DM1GV6O	MI	TTNR0UQ
DM1GV6O	MN	Lysine-specific histone demethylase 1 (LSD)
DM1GV6O	MT	DTT
DM1GV6O	MA	Inhibitor
DM1GV6O	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM1GV6O	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM1M4B8	DI	DM1M4B8
DM1M4B8	DN	CC-93269
DM1M4B8	MI	TTZ3P4W
DM1M4B8	MN	B-cell maturation protein (TNFRSF17)
DM1M4B8	MT	DTT
DM1M4B8	RN	T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma. Oncotarget. 2020 Nov 10;11(45):4076-4081.
DM1M4B8	RU	https://pubmed.ncbi.nlm.nih.gov/33227097

DM4581B	DI	DM4581B
DM4581B	DN	CC-94676
DM4581B	MI	TTS64P2
DM4581B	MN	Androgen receptor (AR)
DM4581B	MT	DTT
DM4581B	MA	Degrader
DM4581B	RN	ClinicalTrials.gov (NCT04428788) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer. U.S. National Institutes of Health.
DM4581B	RU	https://clinicaltrials.gov/ct2/show/NCT04428788

DM7E1W0	DI	DM7E1W0
DM7E1W0	DN	CC-95251
DM7E1W0	MI	TTBRJS9
DM7E1W0	MN	Inhibitory receptor SHPS-1 (SIRPA)
DM7E1W0	MT	DTT
DM7E1W0	RN	ClinicalTrials.gov (NCT03783403) A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPalpha, in Subjects With Advanced Solid and Hematologic Cancers. U.S. National Institutes of Health.
DM7E1W0	RU	https://clinicaltrials.gov/ct2/show/NCT03783403

DMJCIGN	DI	DMJCIGN
DMJCIGN	DN	CC-95775
DMJCIGN	MI	TTE4BSY
DMJCIGN	MN	Bromodomain and extraterminal domain protein (BET)
DMJCIGN	MT	DTT
DMJCIGN	MA	Inhibitor
DMJCIGN	RN	Clinical pipeline report, company report or official report of Bristol-Myers Squibb.
DMJCIGN	RU	https://www.bms.com/researchers-and-partners/in-the-pipeline.html

DMLONJG	DI	DMLONJG
DMLONJG	DN	CC-97540
DMLONJG	MI	TTW640A
DMLONJG	MN	B-lymphocyte surface antigen B4 (CD19)
DMLONJG	MT	DTT
DMLONJG	RN	A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
DMLONJG	RU	https://clinicaltrials.gov/ct2/show/NCT04231747

DM69YM1	DI	DM69YM1
DM69YM1	DN	CC-98633
DM69YM1	MI	TTZ3P4W
DM69YM1	MN	B-cell maturation protein (TNFRSF17)
DM69YM1	MT	DTT
DM69YM1	RN	ClinicalTrials.gov (NCT04394650) A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed and/or Refractory Multiple Myeloma. U.S. National Institutes of Health.
DM69YM1	RU	https://clinicaltrials.gov/ct2/show/NCT04394650

DM1UEBR	DI	DM1UEBR
DM1UEBR	DN	CC-99712
DM1UEBR	MI	TTZ3P4W
DM1UEBR	MN	B-cell maturation protein (TNFRSF17)
DM1UEBR	MT	DTT
DM1UEBR	RN	ClinicalTrials.gov (NCT04036461) A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma. U.S. National Institutes of Health.
DM1UEBR	RU	https://clinicaltrials.gov/ct2/show/NCT04036461

DM86CZJ	DI	DM86CZJ
DM86CZJ	DN	C-CAR011
DM86CZJ	MI	TTW640A
DM86CZJ	MN	B-lymphocyte surface antigen B4 (CD19)
DM86CZJ	MT	DTT
DM86CZJ	MA	CAR-T-Cell-Therapy
DM86CZJ	RN	ClinicalTrials.gov (NCT03299738) A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHL
DM86CZJ	RU	https://clinicaltrials.gov/ct2/show/NCT03299738

DMT35N2	DI	DMT35N2
DMT35N2	DN	C-CAR088
DMT35N2	MI	TTZ3P4W
DMT35N2	MN	B-cell maturation protein (TNFRSF17)
DMT35N2	MT	DTT
DMT35N2	MA	CAR-T-Cell-Therapy
DMT35N2	RN	ClinicalTrials.gov (NCT03751293) A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma
DMT35N2	RU	https://clinicaltrials.gov/ct2/show/NCT03751293

DMCFMHR	DI	DMCFMHR
DMCFMHR	DN	CCR5 mab
DMCFMHR	MI	TT2CEJG
DMCFMHR	MN	C-C chemokine receptor type 5 (CCR5)
DMCFMHR	MT	DTT
DMCFMHR	RN	CCR5 Monoclonal Antibodies for HIV-1 Therapy. Curr Opin HIV AIDS. 2009 March; 4(2): 104-111.
DMCFMHR	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2760828/

DMPTYE6	DI	DMPTYE6
DMPTYE6	DN	CCW702
DMPTYE6	MI	TT9G4N0
DMPTYE6	MN	Glutamate carboxypeptidase II (GCPII)
DMPTYE6	MT	DTT
DMPTYE6	RN	Clinical pipeline report, company report or official report of AbbVie.
DMPTYE6	RU	https://www.abbvie.com/our-science/pipeline/ccw702.html

DMPTYE6	DI	DMPTYE6
DMPTYE6	DN	CCW702
DMPTYE6	MI	TTUN7MC
DMPTYE6	MN	T-cell surface glycoprotein CD3 (CD3)
DMPTYE6	MT	DTT
DMPTYE6	RN	Clinical pipeline report, company report or official report of AbbVie.
DMPTYE6	RU	https://www.abbvie.com/our-science/pipeline/ccw702.html

DMCWVS7	DI	DMCWVS7
DMCWVS7	DN	CCX-025
DMCWVS7	MI	TTIPS8B
DMCWVS7	MN	C-C chemokine receptor type 9 (CCR9)
DMCWVS7	MT	DTT
DMCWVS7	MA	Antagonist
DMCWVS7	RN	Targeting T-cell migration in inflammatory bowel disease. J Intern Med. 2012 Nov;272(5):411-29.
DMCWVS7	RU	https://pubmed.ncbi.nlm.nih.gov/22946654

DMO7TES	DI	DMO7TES
DMO7TES	DN	CCX507
DMO7TES	MI	TTIPS8B
DMO7TES	MN	C-C chemokine receptor type 9 (CCR9)
DMO7TES	MT	DTT
DMO7TES	MA	Antagonist
DMO7TES	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMO7TES	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DM0XDYT	DI	DM0XDYT
DM0XDYT	DN	CD10-CART
DM0XDYT	MI	TT5TKPM
DM0XDYT	MN	Neutral endopeptidase (MME)
DM0XDYT	MT	DTT
DM0XDYT	MA	CAR-T-Cell-Therapy(Dual specific)
DM0XDYT	RN	ClinicalTrials.gov (NCT03407859) Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL
DM0XDYT	RU	https://clinicaltrials.gov/ct2/show/NCT03407859

DMDFY1R	DI	DMDFY1R
DMDFY1R	DN	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells
DMDFY1R	MI	TTENHJ0
DMDFY1R	MN	Interleukin 3 receptor alpha (IL3RA)
DMDFY1R	MT	DTT
DMDFY1R	MA	CAR-T-Cell-Therapy
DMDFY1R	RN	ClinicalTrials.gov (NCT03114670) Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT
DMDFY1R	RU	https://clinicaltrials.gov/ct2/show/NCT03114670

DMUJF9T	DI	DMUJF9T
DMUJF9T	DN	CD123-CD33 Ccar
DMUJF9T	MI	TTENHJ0
DMUJF9T	MN	Interleukin 3 receptor alpha (IL3RA)
DMUJF9T	MT	DTT
DMUJF9T	RN	Clinical pipeline report, company report or official report of iCell Gene Therapeutics.
DMUJF9T	RU	http://icellgene.com/our-pipeline.html

DMUJF9T	DI	DMUJF9T
DMUJF9T	DN	CD123-CD33 Ccar
DMUJF9T	MI	TTJVYO3
DMUJF9T	MN	Myeloid cell surface antigen CD33 (CD33)
DMUJF9T	MT	DTT
DMUJF9T	RN	Clinical pipeline report, company report or official report of iCell Gene Therapeutics.
DMUJF9T	RU	http://icellgene.com/our-pipeline.html

DM2AHXW	DI	DM2AHXW
DM2AHXW	DN	CD171 specific CAR T cells expressing EGFRt
DM2AHXW	MI	TTC9D3K
DM2AHXW	MN	Neural cell adhesion molecule L1 (L1CAM)
DM2AHXW	MT	DTT
DM2AHXW	MA	CAR-T-Cell-Therapy
DM2AHXW	RN	ClinicalTrials.gov (NCT02311621) Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01
DM2AHXW	RU	https://clinicaltrials.gov/ct2/show/NCT02311621

DM4PWNU	DI	DM4PWNU
DM4PWNU	DN	CD19 CAR T
DM4PWNU	MI	TTW640A
DM4PWNU	MN	B-lymphocyte surface antigen B4 (CD19)
DM4PWNU	MT	DTT
DM4PWNU	MA	CAR-T-Cell-Therapy
DM4PWNU	RN	ClinicalTrials.gov (NCT03559439) CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies
DM4PWNU	RU	https://clinicaltrials.gov/ct2/show/NCT03559439

DMCUBFR	DI	DMCUBFR
DMCUBFR	DN	CD19 CAR T Cells
DMCUBFR	MI	TTW640A
DMCUBFR	MN	B-lymphocyte surface antigen B4 (CD19)
DMCUBFR	MT	DTT
DMCUBFR	MA	CAR-T-Cell-Therapy
DMCUBFR	RN	ClinicalTrials.gov (NCT01853631) Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
DMCUBFR	RU	https://clinicaltrials.gov/ct2/show/NCT01853631

DMB8RI6	DI	DMB8RI6
DMB8RI6	DN	CD19 CAR T cells
DMB8RI6	MI	TTW640A
DMB8RI6	MN	B-lymphocyte surface antigen B4 (CD19)
DMB8RI6	MT	DTT
DMB8RI6	MA	CAR-T-Cell-Therapy
DMB8RI6	RN	ClinicalTrials.gov (NCT02975687) CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia
DMB8RI6	RU	https://clinicaltrials.gov/ct2/show/NCT02975687

DMYFWQT	DI	DMYFWQT
DMYFWQT	DN	CD19 CAR T-cells
DMYFWQT	MI	TTW640A
DMYFWQT	MN	B-lymphocyte surface antigen B4 (CD19)
DMYFWQT	MT	DTT
DMYFWQT	MA	CAR-T-Cell-Therapy
DMYFWQT	RN	ClinicalTrials.gov (NCT03298828) CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma
DMYFWQT	RU	https://clinicaltrials.gov/ct2/show/NCT03298828

DMJCT6Q	DI	DMJCT6Q
DMJCT6Q	DN	CD19 CAR T-cells
DMJCT6Q	MI	TTW640A
DMJCT6Q	MN	B-lymphocyte surface antigen B4 (CD19)
DMJCT6Q	MT	DTT
DMJCT6Q	MA	CAR-T-Cell-Therapy
DMJCT6Q	RN	ClinicalTrials.gov (NCT02443831) CARPALL: Immunotherapy With CD19 CAR T-cells for CD19+ Haematological Malignancies
DMJCT6Q	RU	https://clinicaltrials.gov/ct2/show/NCT02443831

DM6GNDP	DI	DM6GNDP
DM6GNDP	DN	CD19 CAR-T cells
DM6GNDP	MI	TTW640A
DM6GNDP	MN	B-lymphocyte surface antigen B4 (CD19)
DM6GNDP	MT	DTT
DM6GNDP	MA	CAR-T-Cell-Therapy
DM6GNDP	RN	ClinicalTrials.gov (NCT03671460) CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.
DM6GNDP	RU	https://clinicaltrials.gov/ct2/show/NCT03671460

DMNDACU	DI	DMNDACU
DMNDACU	DN	CD19 CAR-T cells
DMNDACU	MI	TTW640A
DMNDACU	MN	B-lymphocyte surface antigen B4 (CD19)
DMNDACU	MT	DTT
DMNDACU	MA	CAR-T-Cell-Therapy
DMNDACU	RN	ClinicalTrials.gov (NCT03064269) CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia
DMNDACU	RU	https://clinicaltrials.gov/ct2/show/NCT03064269

DM49RAT	DI	DM49RAT
DM49RAT	DN	CD19 Redirected Autologous T Cells
DM49RAT	MI	TTW640A
DM49RAT	MN	B-lymphocyte surface antigen B4 (CD19)
DM49RAT	MT	DTT
DM49RAT	MA	CAR-T-Cell-Therapy
DM49RAT	RN	ClinicalTrials.gov (NCT03030976) A Study of CD19 Redirected Autologous T Cells for CD19 Positive Systemic Lupus Erythematosus (SLE)
DM49RAT	RU	https://clinicaltrials.gov/ct2/show/NCT03030976

DMMO2EJ	DI	DMMO2EJ
DMMO2EJ	DN	CD19.CAR-aNKT cells
DMMO2EJ	MI	TTW640A
DMMO2EJ	MN	B-lymphocyte surface antigen B4 (CD19)
DMMO2EJ	MT	DTT
DMMO2EJ	MA	CAR-T-Cell-Therapy
DMMO2EJ	RN	ClinicalTrials.gov (NCT03774654) CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)
DMMO2EJ	RU	https://clinicaltrials.gov/ct2/show/NCT03774654

DMVONF0	DI	DMVONF0
DMVONF0	DN	CD19/CD22 CAR T cells
DMVONF0	MI	TTM6QSK
DMVONF0	MN	B-cell receptor CD22 (CD22)
DMVONF0	MT	DTT
DMVONF0	MA	CAR-T-Cell-Therapy(Dual specific)
DMVONF0	RN	ClinicalTrials.gov (NCT03241940) CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Children or Young Adults With Recurrent or Refractory CD19 Positive B Acute Lymphoblastic Leukemia
DMVONF0	RU	https://clinicaltrials.gov/ct2/show/NCT03241940

DMVONF0	DI	DMVONF0
DMVONF0	DN	CD19/CD22 CAR T cells
DMVONF0	MI	TTW640A
DMVONF0	MN	B-lymphocyte surface antigen B4 (CD19)
DMVONF0	MT	DTT
DMVONF0	MA	CAR-T-Cell-Therapy(Dual specific)
DMVONF0	RN	ClinicalTrials.gov (NCT03241940) CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Children or Young Adults With Recurrent or Refractory CD19 Positive B Acute Lymphoblastic Leukemia
DMVONF0	RU	https://clinicaltrials.gov/ct2/show/NCT03241940

DMKA2FL	DI	DMKA2FL
DMKA2FL	DN	CD19/CD22 CAR T-Cells
DMKA2FL	MI	TTM6QSK
DMKA2FL	MN	B-cell receptor CD22 (CD22)
DMKA2FL	MT	DTT
DMKA2FL	MA	CAR-T-Cell-Therapy(Dual specific)
DMKA2FL	RN	ClinicalTrials.gov (NCT03448393) CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
DMKA2FL	RU	https://clinicaltrials.gov/ct2/show/NCT03448393

DMKA2FL	DI	DMKA2FL
DMKA2FL	DN	CD19/CD22 CAR T-Cells
DMKA2FL	MI	TTW640A
DMKA2FL	MN	B-lymphocyte surface antigen B4 (CD19)
DMKA2FL	MT	DTT
DMKA2FL	MA	CAR-T-Cell-Therapy(Dual specific)
DMKA2FL	RN	ClinicalTrials.gov (NCT03448393) CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
DMKA2FL	RU	https://clinicaltrials.gov/ct2/show/NCT03448393

DMPADR1	DI	DMPADR1
DMPADR1	DN	CD19/CD22 Chimeric Antigen Receptor T Cells
DMPADR1	MI	TTM6QSK
DMPADR1	MN	B-cell receptor CD22 (CD22)
DMPADR1	MT	DTT
DMPADR1	MA	CAR-T-Cell-Therapy(Dual specific)
DMPADR1	RN	ClinicalTrials.gov (NCT03233854) CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Patients With Recurrent or Refractory CD19 Positive Diffuse Large B-Cell Lymphoma or B Acute Lymphoblastic Leukemia
DMPADR1	RU	https://clinicaltrials.gov/ct2/show/NCT03233854

DMPADR1	DI	DMPADR1
DMPADR1	DN	CD19/CD22 Chimeric Antigen Receptor T Cells
DMPADR1	MI	TTW640A
DMPADR1	MN	B-lymphocyte surface antigen B4 (CD19)
DMPADR1	MT	DTT
DMPADR1	MA	CAR-T-Cell-Therapy(Dual specific)
DMPADR1	RN	ClinicalTrials.gov (NCT03233854) CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Patients With Recurrent or Refractory CD19 Positive Diffuse Large B-Cell Lymphoma or B Acute Lymphoblastic Leukemia
DMPADR1	RU	https://clinicaltrials.gov/ct2/show/NCT03233854

DMGUQ8V	DI	DMGUQ8V
DMGUQ8V	DN	CD19+ CAR T Cells
DMGUQ8V	MI	TTW640A
DMGUQ8V	MN	B-lymphocyte surface antigen B4 (CD19)
DMGUQ8V	MT	DTT
DMGUQ8V	MA	CAR-T-Cell-Therapy
DMGUQ8V	RN	ClinicalTrials.gov (NCT02529813) CD19+ CAR T Cells for Lymphoid Malignancies
DMGUQ8V	RU	https://clinicaltrials.gov/ct2/show/NCT02529813

DMUR1MN	DI	DMUR1MN
DMUR1MN	DN	CD19-CAR and CD28-CAR T Cells
DMUR1MN	MI	TTW640A
DMUR1MN	MN	B-lymphocyte surface antigen B4 (CD19)
DMUR1MN	MT	DTT
DMUR1MN	MA	CAR-T-Cell-Therapy(Dual specific)
DMUR1MN	RN	ClinicalTrials.gov (NCT02146924) Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia
DMUR1MN	RU	https://clinicaltrials.gov/ct2/show/NCT02146924

DMUR1MN	DI	DMUR1MN
DMUR1MN	DN	CD19-CAR and CD28-CAR T Cells
DMUR1MN	MI	TTQ13FT
DMUR1MN	MN	T-cell-specific surface glycoprotein CD28 (CD28)
DMUR1MN	MT	DTT
DMUR1MN	MA	CAR-T-Cell-Therapy(Dual specific)
DMUR1MN	RN	ClinicalTrials.gov (NCT02146924) Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia
DMUR1MN	RU	https://clinicaltrials.gov/ct2/show/NCT02146924

DMJIW5Z	DI	DMJIW5Z
DMJIW5Z	DN	CD19-CAR-T Cells
DMJIW5Z	MI	TTW640A
DMJIW5Z	MN	B-lymphocyte surface antigen B4 (CD19)
DMJIW5Z	MT	DTT
DMJIW5Z	MA	CAR-T-Cell-Therapy
DMJIW5Z	RN	ClinicalTrials.gov (NCT03574168) CD19-CAR-T Cells in Patients With R/R B-ALL
DMJIW5Z	RU	https://clinicaltrials.gov/ct2/show/NCT03574168

DML07UZ	DI	DML07UZ
DML07UZ	DN	CD19-CAR-T2 Cells
DML07UZ	MI	TTW640A
DML07UZ	MN	B-lymphocyte surface antigen B4 (CD19)
DML07UZ	MT	DTT
DML07UZ	MA	CAR-T-Cell-Therapy
DML07UZ	RN	ClinicalTrials.gov (NCT02822326) Phase I Study of CD19-CAR-T2 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Acute Leukemia
DML07UZ	RU	https://clinicaltrials.gov/ct2/show/NCT02822326

DM3LRAF	DI	DM3LRAF
DM3LRAF	DN	CD19CAT-41BBZ CAR T-cells
DM3LRAF	MI	TTW640A
DM3LRAF	MN	B-lymphocyte surface antigen B4 (CD19)
DM3LRAF	MT	DTT
DM3LRAF	MA	CAR-T-Cell-Therapy
DM3LRAF	RN	ClinicalTrials.gov (NCT02935257) Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia Using CAR T-cells to Target CD19
DM3LRAF	RU	https://clinicaltrials.gov/ct2/show/NCT02935257

DMETGAQ	DI	DMETGAQ
DMETGAQ	DN	CD19-directed CAR-T cells
DMETGAQ	MI	TTW640A
DMETGAQ	MN	B-lymphocyte surface antigen B4 (CD19)
DMETGAQ	MT	DTT
DMETGAQ	MA	CAR-T-Cell-Therapy
DMETGAQ	RN	ClinicalTrials.gov (NCT03463928) A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia
DMETGAQ	RU	https://clinicaltrials.gov/ct2/show/NCT03463928

DM2OEQ9	DI	DM2OEQ9
DM2OEQ9	DN	CD19-directed CAR-T cells
DM2OEQ9	MI	TTW640A
DM2OEQ9	MN	B-lymphocyte surface antigen B4 (CD19)
DM2OEQ9	MT	DTT
DM2OEQ9	MA	CAR-T-Cell-Therapy
DM2OEQ9	RN	ClinicalTrials.gov (NCT03483688) A Phaseb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects
DM2OEQ9	RU	https://clinicaltrials.gov/ct2/show/NCT03483688

DMCZ3A2	DI	DMCZ3A2
DMCZ3A2	DN	CD19-targeted CART cells
DMCZ3A2	MI	TTW640A
DMCZ3A2	MN	B-lymphocyte surface antigen B4 (CD19)
DMCZ3A2	MT	DTT
DMCZ3A2	MA	CAR-T-Cell-Therapy
DMCZ3A2	RN	ClinicalTrials.gov (NCT03599375) Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic Leukemia
DMCZ3A2	RU	https://clinicaltrials.gov/ct2/show/NCT03599375

DMT7YOU	DI	DMT7YOU
DMT7YOU	DN	CD19t-haNK
DMT7YOU	MI	TTW640A
DMT7YOU	MN	B-lymphocyte surface antigen B4 (CD19)
DMT7YOU	MT	DTT
DMT7YOU	RN	ClinicalTrials.gov (NCT04052061) QUILT 3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma. U.S. National Institutes of Health.
DMT7YOU	RU	https://clinicaltrials.gov/ct2/show/NCT04052061

DMOHACZ	DI	DMOHACZ
DMOHACZ	DN	CD19-TriCAR-T
DMOHACZ	MI	TTW640A
DMOHACZ	MN	B-lymphocyte surface antigen B4 (CD19)
DMOHACZ	MT	DTT
DMOHACZ	MA	CAR-T-Cell-Therapy
DMOHACZ	RN	ClinicalTrials.gov (NCT03720496) Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCAR-T Cell Therapy
DMOHACZ	RU	https://clinicaltrials.gov/ct2/show/NCT03720496

DMGXS8L	DI	DMGXS8L
DMGXS8L	DN	CD20Bi aATC
DMGXS8L	MI	TTUE541
DMGXS8L	MN	Leukocyte surface antigen Leu-16 (CD20)
DMGXS8L	MT	DTT
DMGXS8L	MA	Modulator
DMGXS8L	RN	CD20-Targeted T Cells after Stem Cell Transplantation for High Risk and Refractory Non-Hodgkin's Lymphoma. Biol Blood Marrow Transplant. 2013 June; 19(6): 925-933.
DMGXS8L	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3794673/

DMGXS8L	DI	DMGXS8L
DMGXS8L	DN	CD20Bi aATC
DMGXS8L	MI	TTUN7MC
DMGXS8L	MN	T-cell surface glycoprotein CD3 (CD3)
DMGXS8L	MT	DTT
DMGXS8L	MA	Modulator
DMGXS8L	RN	CD20-Targeted T Cells after Stem Cell Transplantation for High Risk and Refractory Non-Hodgkin's Lymphoma. Biol Blood Marrow Transplant. 2013 June; 19(6): 925-933.
DMGXS8L	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3794673/

DMSJBUZ	DI	DMSJBUZ
DMSJBUZ	DN	CD20-CART
DMSJBUZ	MI	TTUE541
DMSJBUZ	MN	Leukocyte surface antigen Leu-16 (CD20)
DMSJBUZ	MT	DTT
DMSJBUZ	MA	CAR-T-Cell-Therapy(Dual specific)
DMSJBUZ	RN	ClinicalTrials.gov (NCT03407859) Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL
DMSJBUZ	RU	https://clinicaltrials.gov/ct2/show/NCT03407859

DM37OJN	DI	DM37OJN
DM37OJN	DN	CD20-CAR-T Cells
DM37OJN	MI	TTUE541
DM37OJN	MN	Leukocyte surface antigen Leu-16 (CD20)
DM37OJN	MT	DTT
DM37OJN	MA	CAR-T-Cell-Therapy
DM37OJN	RN	ClinicalTrials.gov (NCT03576807) The Clinical Research of Anti-CD20 CAR-T Cells in Patients With Refractory or Relapsed B Lymphocyte Lymphoma
DM37OJN	RU	https://clinicaltrials.gov/ct2/show/NCT03576807

DMUYTW3	DI	DMUYTW3
DMUYTW3	DN	CD20-CD19 cCAR
DMUYTW3	MI	TTW640A
DMUYTW3	MN	B-lymphocyte surface antigen B4 (CD19)
DMUYTW3	MT	DTT
DMUYTW3	RN	Clinical pipeline report, company report or official report of iCell Gene Therapeutics.
DMUYTW3	RU	http://icellgene.com/our-pipeline.html

DMUYTW3	DI	DMUYTW3
DMUYTW3	DN	CD20-CD19 cCAR
DMUYTW3	MI	TTUE541
DMUYTW3	MN	Leukocyte surface antigen Leu-16 (CD20)
DMUYTW3	MT	DTT
DMUYTW3	RN	Clinical pipeline report, company report or official report of iCell Gene Therapeutics.
DMUYTW3	RU	http://icellgene.com/our-pipeline.html

DMHMPK1	DI	DMHMPK1
DMHMPK1	DN	CD22-CART
DMHMPK1	MI	TTM6QSK
DMHMPK1	MN	B-cell receptor CD22 (CD22)
DMHMPK1	MT	DTT
DMHMPK1	MA	CAR-T-Cell-Therapy(Dual specific)
DMHMPK1	RN	ClinicalTrials.gov (NCT03407859) Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL
DMHMPK1	RU	https://clinicaltrials.gov/ct2/show/NCT03407859

DMP5V83	DI	DMP5V83
DMP5V83	DN	CD22-specific CAR T-cells also expressing an EGFRt
DMP5V83	MI	TTM6QSK
DMP5V83	MN	B-cell receptor CD22 (CD22)
DMP5V83	MT	DTT
DMP5V83	MA	CAR-T-Cell-Therapy
DMP5V83	RN	ClinicalTrials.gov (NCT03244306) A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma
DMP5V83	RU	https://clinicaltrials.gov/ct2/show/NCT03244306

DMFGQXB	DI	DMFGQXB
DMFGQXB	DN	CD28 and CD137 CAR-T Cells
DMFGQXB	MI	TTPW9LJ
DMFGQXB	MN	Co-stimulatory molecule 4-1BB (CD137)
DMFGQXB	MT	DTT
DMFGQXB	MA	CAR-T-Cell-Therapy(Dual specific)
DMFGQXB	RN	ClinicalTrials.gov (NCT02186860) Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia
DMFGQXB	RU	https://clinicaltrials.gov/ct2/show/NCT02186860

DMFGQXB	DI	DMFGQXB
DMFGQXB	DN	CD28 and CD137 CAR-T Cells
DMFGQXB	MI	TTQ13FT
DMFGQXB	MN	T-cell-specific surface glycoprotein CD28 (CD28)
DMFGQXB	MT	DTT
DMFGQXB	MA	CAR-T-Cell-Therapy(Dual specific)
DMFGQXB	RN	ClinicalTrials.gov (NCT02186860) Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia
DMFGQXB	RU	https://clinicaltrials.gov/ct2/show/NCT02186860

DM4VCJA	DI	DM4VCJA
DM4VCJA	DN	CD30 CAR T Cells
DM4VCJA	MI	TT2GM5R
DM4VCJA	MN	Lymphocyte activation antigen CD30 (TNFRSF8)
DM4VCJA	MT	DTT
DM4VCJA	MA	CAR-T-Cell-Therapy
DM4VCJA	RN	ClinicalTrials.gov (NCT02917083) CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
DM4VCJA	RU	https://clinicaltrials.gov/ct2/show/NCT02917083

DMYD31U	DI	DMYD31U
DMYD31U	DN	CD33-CAR-T Cell
DMYD31U	MI	TTJVYO3
DMYD31U	MN	Myeloid cell surface antigen CD33 (CD33)
DMYD31U	MT	DTT
DMYD31U	MA	CAR-T-Cell-Therapy
DMYD31U	RN	ClinicalTrials.gov (NCT03126864) Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia
DMYD31U	RU	https://clinicaltrials.gov/ct2/show/NCT03126864

DMNX0V7	DI	DMNX0V7
DMNX0V7	DN	CD38 CAR-T
DMNX0V7	MI	TTPURFN
DMNX0V7	MN	Cyclic ADP-ribose hydrolase 1 (CD38)
DMNX0V7	MT	DTT
DMNX0V7	RN	Clinical pipeline report, company report or official report of Sorrento Therapeutics.
DMNX0V7	RU	https://sorrentotherapeutics.com/research/pipeline/

DM09SW6	DI	DM09SW6
DM09SW6	DN	CD4CAR
DM09SW6	MI	TTN2JFW
DM09SW6	MN	T-cell surface glycoprotein CD4 (CD4)
DM09SW6	MT	DTT
DM09SW6	RN	Clinical pipeline report, company report or official report of iCell Gene Therapeutics.
DM09SW6	RU	https://icellgene.com/our-pipeline.html

DMHTNLJ	DI	DMHTNLJ
DMHTNLJ	DN	CD7.CAR/28zeta CAR T cells
DMHTNLJ	MI	TTP6B8O
DMHTNLJ	MN	T-cell antigen CD7 (CD7)
DMHTNLJ	MT	DTT
DMHTNLJ	MA	CAR-T-Cell-Therapy
DMHTNLJ	RN	ClinicalTrials.gov (NCT03690011) Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells
DMHTNLJ	RU	https://clinicaltrials.gov/ct2/show/NCT03690011

DM8DWOL	DI	DM8DWOL
DM8DWOL	DN	CDNA vaccine
DM8DWOL	MI	TTNYZG2
DM8DWOL	MN	Granulocyte-macrophage colony-stimulating factor (CSF2)
DM8DWOL	MT	DTT
DM8DWOL	MA	Modulator
DM8DWOL	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM8DWOL	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMN8I5Q	DI	DMN8I5Q
DMN8I5Q	DN	CDP-7657
DMN8I5Q	MI	TTIJP3Q
DMN8I5Q	MN	TNF related activation protein (CD40LG)
DMN8I5Q	MT	DTT
DMN8I5Q	RN	CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study. Arthritis Res Ther. 2015 Sep 3;17:234.
DMN8I5Q	RU	https://pubmed.ncbi.nlm.nih.gov/26335795

DM049IX	DI	DM049IX
DM049IX	DN	CDRI-97/78
DM049IX	MI	TTQ2GJ0
DM049IX	MN	Plasmodial phospholipid metabolism (PPP metab)
DM049IX	MT	DTT
DM049IX	MA	Modulator
DM049IX	RN	Single Ascending Dose Safety and Pharmacokinetics of CDRI-97/78: First-in-Human Study of a Novel Antimalarial Drug. Malar Res Treat. 2014;2014:372521.
DM049IX	RU	https://pubmed.ncbi.nlm.nih.gov/24800100

DMKUXB5	DI	DMKUXB5
DMKUXB5	DN	CDT-fenofibrate
DMKUXB5	MI	TTJ584C
DMKUXB5	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMKUXB5	MT	DTT
DMKUXB5	MA	Agonist
DMKUXB5	RN	Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998 Nov 10;98(19):2088-93.
DMKUXB5	RU	https://pubmed.ncbi.nlm.nih.gov/9808609

DMPVUGE	DI	DMPVUGE
DMPVUGE	DN	CDX-1127
DMPVUGE	MI	TTDO1MV
DMPVUGE	MN	T-cell activation antigen CD27 (CD27)
DMPVUGE	MT	DTT
DMPVUGE	MA	Modulator
DMPVUGE	RN	Clinical pipeline report, company report or official report of Celldex Therapeutics.
DMPVUGE	RU	http://www.celldex.com/pipeline/cdx-1127.php

DMS20X6	DI	DMS20X6
DMS20X6	DN	CDX-1135
DMS20X6	MI	TTEA8OW
DMS20X6	MN	Complement receptor type 1 (CR1)
DMS20X6	MT	DTT
DMS20X6	MA	Modulator
DMS20X6	RN	Complement activation is critical for placental ischemia-induced hypertension in the rat. Mol Immunol. 2013 Nov;56(1-2):91-7.
DMS20X6	RU	https://pubmed.ncbi.nlm.nih.gov/23685261

DMUGN0J	DI	DMUGN0J
DMUGN0J	DN	CDX-1140
DMUGN0J	MI	TTN6Y9A
DMUGN0J	MN	CD40L receptor (CD40)
DMUGN0J	MT	DTT
DMUGN0J	MA	Agonist
DMUGN0J	RN	Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy. Cancer Immunol Immunother. 2019 Feb;68(2):233-245.
DMUGN0J	RU	https://pubmed.ncbi.nlm.nih.gov/30382327

DMVDIWO	DI	DMVDIWO
DMVDIWO	DN	CDX-527
DMVDIWO	MI	TTNBFWK
DMVDIWO	MN	Programmed cell death protein 1 (PD-1)
DMVDIWO	MT	DTT
DMVDIWO	MA	Inhibitor
DMVDIWO	RN	Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy. Cancer Immunol Immunother. 2020 Oct;69(10):2125-2137.
DMVDIWO	RU	https://pubmed.ncbi.nlm.nih.gov/32451681

DMVDIWO	DI	DMVDIWO
DMVDIWO	DN	CDX-527
DMVDIWO	MI	TTDO1MV
DMVDIWO	MN	T-cell activation antigen CD27 (CD27)
DMVDIWO	MT	DTT
DMVDIWO	MA	Activator
DMVDIWO	RN	Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy. Cancer Immunol Immunother. 2020 Oct;69(10):2125-2137.
DMVDIWO	RU	https://pubmed.ncbi.nlm.nih.gov/32451681

DM45BHM	DI	DM45BHM
DM45BHM	DN	CEA CAR-T
DM45BHM	MI	TTY6DTE
DM45BHM	MN	Carcinoembryonic antigen CEA (CD66e)
DM45BHM	MT	DTT
DM45BHM	RN	Clinical pipeline report, company report or official report of Sorrento Therapeutics.
DM45BHM	RU	https://sorrentotherapeutics.com/research/immuno-oncology/car-t/

DMYDTJ6	DI	DMYDTJ6
DMYDTJ6	DN	CEP-11981
DMYDTJ6	MI	TT9VGXW
DMYDTJ6	MN	Angiopoietin 1 receptor (TEK)
DMYDTJ6	MT	DTT
DMYDTJ6	MA	Modulator
DMYDTJ6	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1842).
DMYDTJ6	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1842

DMYDTJ6	DI	DMYDTJ6
DMYDTJ6	DN	CEP-11981
DMYDTJ6	MI	TT2Q6G1
DMYDTJ6	MN	Vascular endothelial growth factor receptor 1 (FLT-1)
DMYDTJ6	MT	DTT
DMYDTJ6	MA	Modulator
DMYDTJ6	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8189).
DMYDTJ6	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8189

DMYDTJ6	DI	DMYDTJ6
DMYDTJ6	DN	CEP-11981
DMYDTJ6	MI	TTUTJGQ
DMYDTJ6	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMYDTJ6	MT	DTT
DMYDTJ6	MA	Inhibitor
DMYDTJ6	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMYDTJ6	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMYXQBF	DI	DMYXQBF
DMYXQBF	DN	CEP-37251
DMYXQBF	MI	TT9E8HR
DMYXQBF	MN	Osteoclast differentiation factor (ODF)
DMYXQBF	MT	DTT
DMYXQBF	MA	Inhibitor
DMYXQBF	RN	This week in therapeutics Cancer. SciBX 3(40); doi:10.1038/scibx.2010.1202. Oct. 14, 2010
DMYXQBF	RU	http://www.nature.com/scibx/journal/v3/n40/pdf/scibx.2010.1202.pdf

DMV632P	DI	DMV632P
DMV632P	DN	CEP-37440
DMV632P	MI	TTON5IT
DMV632P	MN	Focal adhesion kinase 1 (FAK)
DMV632P	MT	DTT
DMV632P	MA	Modulator
DMV632P	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMV632P	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMLBKZV	DI	DMLBKZV
DMLBKZV	DN	CER-002
DMLBKZV	MI	TT2JWF6
DMLBKZV	MN	Peroxisome proliferator-activated receptor delta (PPARD)
DMLBKZV	MT	DTT
DMLBKZV	MA	Agonist
DMLBKZV	RN	Fibrates, glitazones, and peroxisome proliferator-activated receptors. Arterioscler Thromb Vasc Biol. 2010 May; 30(5): 894-899.
DMLBKZV	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2997800/

DMGAW0H	DI	DMGAW0H
DMGAW0H	DN	CER-522
DMGAW0H	MI	TT7GN3U
DMGAW0H	MN	Apolipoprotein A-I (APOA1)
DMGAW0H	MT	DTT
DMGAW0H	MA	Modulator
DMGAW0H	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033541)
DMGAW0H	RU	http://adisinsight.springer.com/drugs/800033541

DMH701Q	DI	DMH701Q
DMH701Q	DN	CFI-402257
DMH701Q	MI	TTP7EGM
DMH701Q	MN	Dual specificity protein kinase TTK (MPS1)
DMH701Q	MT	DTT
DMH701Q	MA	Inhibitor
DMH701Q	RN	Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer. Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):3127-3132.
DMH701Q	RU	https://pubmed.ncbi.nlm.nih.gov/28270606

DM3U2VY	DI	DM3U2VY
DM3U2VY	DN	CG-200745
DM3U2VY	MI	TTBH0VX
DM3U2VY	MN	Histone deacetylase (HDAC)
DM3U2VY	MT	DTT
DM3U2VY	MA	Inhibitor
DM3U2VY	RN	Epigenetic modulation with HDAC inhibitor CG200745 induces anti-proliferation in non-small cell lung cancer cells. PLoS One. 2015 Mar 17;10(3):e0119379.
DM3U2VY	RU	https://pubmed.ncbi.nlm.nih.gov/25781604

DMTCLM3	DI	DMTCLM3
DMTCLM3	DN	CGM097
DMTCLM3	MI	TT7SBF5
DMTCLM3	MN	Cellular tumor antigen p53 (TP53)
DMTCLM3	MT	DTT
DMTCLM3	MA	Modulator
DMTCLM3	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMTCLM3	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMAY8I4	DI	DMAY8I4
DMAY8I4	DN	CGTG-102
DMAY8I4	MI	TTNYZG2
DMAY8I4	MN	Granulocyte-macrophage colony-stimulating factor (CSF2)
DMAY8I4	MT	DTT
DMAY8I4	MA	Modulator
DMAY8I4	RN	Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans. Int J Cancer. 2014 Aug 1;135(3):720-30.
DMAY8I4	RU	https://pubmed.ncbi.nlm.nih.gov/24374597

DMSDNU1	DI	DMSDNU1
DMSDNU1	DN	CHF 5407
DMSDNU1	MI	TTQ13Z5
DMSDNU1	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMSDNU1	MT	DTT
DMSDNU1	MA	Modulator
DMSDNU1	RN	Bronchodilator activity of (3R)-3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino] carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyc... J Pharmacol Exp Ther. 2010 Dec;335(3):622-35.
DMSDNU1	RU	https://www.ncbi.nlm.nih.gov/pubmed/20805306

DMTE18G	DI	DMTE18G
DMTE18G	DN	CHF-4227
DMTE18G	MI	TTZAYWL
DMTE18G	MN	Estrogen receptor (ESR)
DMTE18G	MT	DTT
DMTE18G	MA	Modulator
DMTE18G	RN	Pharmacological actions of a novel, potent, tissue-selective benzopyran estrogen. J Pharmacol Exp Ther. 2002 Oct;303(1):196-203.
DMTE18G	RU	https://pubmed.ncbi.nlm.nih.gov/12235251

DMSOB5D	DI	DMSOB5D
DMSOB5D	DN	Chi Lob 7/4
DMSOB5D	MI	TTIJP3Q
DMSOB5D	MN	TNF related activation protein (CD40LG)
DMSOB5D	MT	DTT
DMSOB5D	MA	Modulator
DMSOB5D	RN	Agonistic CD40 antibodies and cancer therapy
DMSOB5D	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590838

DM3L52Q	DI	DM3L52Q
DM3L52Q	DN	Chlorcyclizine
DM3L52Q	MI	DTSYQGK
DM3L52Q	MN	Multidrug resistance-associated protein 1 (ABCC1)
DM3L52Q	MT	DTP
DM3L52Q	MA	Substrate
DM3L52Q	RN	Carrier mediated transport of chlorpheniramine and chlorcyclizine across bovine olfactory mucosa: implications on nose-to-brain transport. J Pharm Sci. 2005 Mar;94(3):613-24.
DM3L52Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/15666293

DMJLZ8T	DI	DMJLZ8T
DMJLZ8T	DN	CHT-25
DMJLZ8T	MI	TT10Y9E
DMJLZ8T	MN	Interleukin 2 receptor alpha (IL2RA)
DMJLZ8T	MT	DTT
DMJLZ8T	MA	Modulator
DMJLZ8T	RN	A Phase I Clinical Trial of CHT-25 a 131I-Labeled Chimeric Anti-CD25 Antibody Showing Efficacy in Patients with Refractory Lymphoma. Clin Cancer Res. 2009 Dec 15;15(24):7701-7710.
DMJLZ8T	RU	https://pubmed.ncbi.nlm.nih.gov/20008855

DM2OB6S	DI	DM2OB6S
DM2OB6S	DN	CI-8993
DM2OB6S	MI	TT51SK8
DM2OB6S	MN	V-set immunoregulatory receptor (VSIR)
DM2OB6S	MT	DTT
DM2OB6S	MA	Antagonist
DM2OB6S	RN	Clinical pipeline report, company report or official report of Curis.
DM2OB6S	RU	https://www.curis.com/pipeline/ci-8993/

DM6SCUK	DI	DM6SCUK
DM6SCUK	DN	CI-959
DM6SCUK	MI	TT4IN7L
DM6SCUK	MN	Histamine release (His rele)
DM6SCUK	MT	DTT
DM6SCUK	MA	Modulator
DM6SCUK	RN	Cytoprotective effects of CI-959 in the rat gastric mucosa: modulation of leukocyte adhesion. Gastroenterology. 1995 Oct;109(4):1224-33.
DM6SCUK	RU	https://pubmed.ncbi.nlm.nih.gov/7557089

DM8T2KA	DI	DM8T2KA
DM8T2KA	DN	CI-966
DM8T2KA	MI	TTPRKM0
DM8T2KA	MN	GABA transporter GAT-1 (SLC6A1)
DM8T2KA	MT	DTT
DM8T2KA	MA	Modulator
DM8T2KA	RN	Tiagabine, SK&amp;F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur J Pharmacol. 1994 Oct 14;269(2):219-24.
DM8T2KA	RU	https://pubmed.ncbi.nlm.nih.gov/7851497

DMB2MKU	DI	DMB2MKU
DMB2MKU	DN	CIGB-128
DMB2MKU	MI	TTSIUJ9
DMB2MKU	MN	Interferon-alpha 2 (IFNA2)
DMB2MKU	MT	DTT
DMB2MKU	MA	Modulator
DMB2MKU	RN	Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.BMC Pharmacol Toxicol.2012 Dec 28;13:20.
DMB2MKU	RU	https://www.ncbi.nlm.nih.gov/pubmed/23272809

DMB2MKU	DI	DMB2MKU
DMB2MKU	DN	CIGB-128
DMB2MKU	MI	TT93WF5
DMB2MKU	MN	Interferon-gamma (IFNG)
DMB2MKU	MT	DTT
DMB2MKU	MA	Modulator
DMB2MKU	RN	Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.BMC Pharmacol Toxicol.2012 Dec 28;13:20.
DMB2MKU	RU	https://www.ncbi.nlm.nih.gov/pubmed/23272809

DMJFPK6	DI	DMJFPK6
DMJFPK6	DN	CIGB-228
DMJFPK6	MI	TT3CPZW
DMJFPK6	MN	Human papillomavirus protein E7 (HPV E7)
DMJFPK6	MT	DTT
DMJFPK6	RN	Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial. ISRN Obstet Gynecol. 2011; 2011: 292951.
DMJFPK6	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3118643/

DM8XM72	DI	DM8XM72
DM8XM72	DN	CIGB-500
DM8XM72	MI	TTSTYLU
DM8XM72	MN	Growth hormone secretion (GH secr)
DM8XM72	MT	DTT
DM8XM72	MA	Modulator
DM8XM72	RN	Growth hormone response in man to L-692,429, a novel nonpeptide mimic of growth hormone-releasing peptide-6. J Clin Endocrinol Metab. 1993 Nov;77(5):1393-7.
DM8XM72	RU	https://pubmed.ncbi.nlm.nih.gov/8077339

DMSGRA7	DI	DMSGRA7
DMSGRA7	DN	CIGB-M3
DMSGRA7	MI	TTY6DTE
DMSGRA7	MN	Carcinoembryonic antigen CEA (CD66e)
DMSGRA7	MT	DTT
DMSGRA7	RN	Phase I clinical trial of the (131)I-labeled anticarcinoembryonic antigen CIGB-M3 multivalent antibody fragment. Cancer Biother Radiopharm. 2011 Jun;26(3):353-63.
DMSGRA7	RU	https://pubmed.ncbi.nlm.nih.gov/21711100

DM7EAG8	DI	DM7EAG8
DM7EAG8	DN	Cilobradine
DM7EAG8	MI	TTKLW9S
DM7EAG8	MN	Hyperpolarization cyclic nucleotide-gated channel (HCN)
DM7EAG8	MT	DTT
DM7EAG8	MA	Modulator
DM7EAG8	RN	Use-dependent blockade of cardiac pacemaker current (If) by cilobradine and zatebradine. Eur J Pharmacol. 2003 Oct 8;478(2-3):161-71.
DM7EAG8	RU	https://pubmed.ncbi.nlm.nih.gov/14575801

DMJLNEF	DI	DMJLNEF
DMJLNEF	DN	Cipatinib
DMJLNEF	MI	TTGKNB4
DMJLNEF	MN	Epidermal growth factor receptor (EGFR)
DMJLNEF	MT	DTT
DMJLNEF	MA	Modulator
DMJLNEF	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMJLNEF	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMJLNEF	DI	DMJLNEF
DMJLNEF	DN	Cipatinib
DMJLNEF	MI	TT6EO5L
DMJLNEF	MN	Erbb2 tyrosine kinase receptor (HER2)
DMJLNEF	MT	DTT
DMJLNEF	MA	Modulator
DMJLNEF	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMJLNEF	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMQLODU	DI	DMQLODU
DMQLODU	DN	Citarinostat
DMQLODU	MI	TT5ZKDI
DMQLODU	MN	Histone deacetylase 6 (HDAC6)
DMQLODU	MT	DTT
DMQLODU	MA	Inhibitor
DMQLODU	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQLODU	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMRJF2Q	DI	DMRJF2Q
DMRJF2Q	DN	Citatuzumab bogatox
DMRJF2Q	MI	TTZ8WH4
DMRJF2Q	MN	Tumor-associated calcium signal transducer 1 (EPCAM)
DMRJF2Q	MT	DTT
DMRJF2Q	RN	Preclinical evaluation of VB6-845: an anti-EpCAM immunotoxin with reduced immunogenic potential. Cancer Biother Radiopharm. 2012 Nov;27(9):582-92.
DMRJF2Q	RU	https://pubmed.ncbi.nlm.nih.gov/22856424

DMRQX9H	DI	DMRQX9H
DMRQX9H	DN	CJ-12255
DMRQX9H	MI	TTZPO1L
DMRQX9H	MN	Substance-P receptor (TACR1)
DMRQX9H	MT	DTT
DMRQX9H	MA	Antagonist
DMRQX9H	RN	Neurokinin-1 receptor, a new modulator of lymphangiogenesis in obese-asthma phenotype. Life Sci. 2013 Aug 6;93(4):169-77.
DMRQX9H	RU	https://pubmed.ncbi.nlm.nih.gov/23792204

DMGSEB0	DI	DMGSEB0
DMGSEB0	DN	CKD-516
DMGSEB0	MI	TTYFKSZ
DMGSEB0	MN	Tubulin beta (TUBB)
DMGSEB0	MT	DTT
DMGSEB0	MA	Inhibitor
DMGSEB0	RN	CKD-516 displays vascular disrupting properties and enhances anti-tumor activity in combination with chemotherapy in a murine tumor model. Invest New Drugs. 2014 Jun;32(3):400-11.
DMGSEB0	RU	https://pubmed.ncbi.nlm.nih.gov/24202729

DMJX6SM	DI	DMJX6SM
DMJX6SM	DN	CKD-712
DMJX6SM	MI	TTKAWRQ
DMJX6SM	MN	JAK-STAT signaling pathway (JAK-STAT pathway)
DMJX6SM	MT	DTT
DMJX6SM	MA	Inhibitor
DMJX6SM	RN	HO-1 and JAK-2/STAT-1 signals are involved in preferential inhibition of iNOS over COX-2 gene expression by newly synthesized tetrahydroisoquinoline alkaloid, CKD712, in cells activated with lipopolysacchride. Cell Signal. 2008 Oct;20(10):1839-47.
DMJX6SM	RU	https://pubmed.ncbi.nlm.nih.gov/18634870

DM4UAPD	DI	DM4UAPD
DM4UAPD	DN	Clemizole
DM4UAPD	MI	DE4LYSA
DM4UAPD	MN	Cytochrome P450 3A4 (CYP3A4)
DM4UAPD	MT	DME
DM4UAPD	MA	Metabolism
DM4UAPD	RN	Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interaction. J Pharmacol Exp Ther. 2013 Feb;344(2):388-96.
DM4UAPD	RU	https://pubmed.ncbi.nlm.nih.gov/23143674

DM4UAPD	DI	DM4UAPD
DM4UAPD	DN	Clemizole
DM4UAPD	MI	TTALKDS
DM4UAPD	MN	Hepatitis C virus Non-structural 4B (HCV NS4B)
DM4UAPD	MT	DTT
DM4UAPD	MA	Modulator
DM4UAPD	RN	The hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitors. J Infect Dis. 2010 Jul 1;202(1):65-74.
DM4UAPD	RU	https://pubmed.ncbi.nlm.nih.gov/20486856

DM5EM04	DI	DM5EM04
DM5EM04	DN	CLL1-CD33 cCART cell therapy
DM5EM04	MI	TTJVYO3
DM5EM04	MN	Myeloid cell surface antigen CD33 (CD33)
DM5EM04	MT	DTT
DM5EM04	RN	Clinical pipeline report, company report or official report of iCell Gene Therapeutics.
DM5EM04	RU	http://icellgene.com/our-pipeline.html

DM5EM04	DI	DM5EM04
DM5EM04	DN	CLL1-CD33 cCART cell therapy
DM5EM04	MI	TT70N8V
DM5EM04	MN	Myeloid inhibitory C-type lectin-like receptor (CD371)
DM5EM04	MT	DTT
DM5EM04	RN	Clinical pipeline report, company report or official report of iCell Gene Therapeutics.
DM5EM04	RU	http://icellgene.com/our-pipeline.html

DM05R4C	DI	DM05R4C
DM05R4C	DN	CLN-081
DM05R4C	MI	TTGKNB4
DM05R4C	MN	Epidermal growth factor receptor (EGFR)
DM05R4C	MT	DTT
DM05R4C	MA	Inhibitor
DM05R4C	RN	TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations. Mol Cancer Ther. 2018 Aug;17(8):1648-1658.
DM05R4C	RU	https://pubmed.ncbi.nlm.nih.gov/29748209

DM2QBMI	DI	DM2QBMI
DM2QBMI	DN	CLP-1004
DM2QBMI	MI	TT1VOHK
DM2QBMI	MN	Potassium channel unspecific (KC)
DM2QBMI	MT	DTT
DM2QBMI	MA	Binder
DM2QBMI	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036783)
DM2QBMI	RU	http://adisinsight.springer.com/drugs/800036783

DM674MP	DI	DM674MP
DM674MP	DN	CLT030
DM674MP	MI	TT70N8V
DM674MP	MN	Myeloid inhibitory C-type lectin-like receptor (CD371)
DM674MP	MT	DTT
DM674MP	RN	Clinical pipeline report, company report or official report of Cellerant Therapeutics.
DM674MP	RU	https://www.cellerant.com/programs/clt030/

DMJQG25	DI	DMJQG25
DMJQG25	DN	CLX-0921
DMJQG25	MI	TTZMAO3
DMJQG25	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMJQG25	MT	DTT
DMJQG25	MA	Agonist
DMJQG25	RN	A novel peroxisome proliferator-activated gamma (PPAR gamma) agonist, CLX-0921, has potent antihyperglycemic activity with low adipogenic potential. Metabolism. 2003 Aug;52(8):1012-8.
DMJQG25	RU	https://pubmed.ncbi.nlm.nih.gov/12898466

DMMC6YR	DI	DMMC6YR
DMMC6YR	DN	CM2489
DMMC6YR	MI	TT5HONZ
DMMC6YR	MN	Calcium channel unspecific (CaC)
DMMC6YR	MT	DTT
DMMC6YR	MA	Modulator
DMMC6YR	RN	Molecular pharmacology of store-operated CRAC channels
DMMC6YR	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913763

DMSJVX3	DI	DMSJVX3
DMSJVX3	DN	CM3.1-AC100
DMSJVX3	MI	TTVIMDE
DMSJVX3	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMSJVX3	MT	DTT
DMSJVX3	MA	Agonist
DMSJVX3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249).
DMSJVX3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=249

DMY5V4U	DI	DMY5V4U
DMY5V4U	DN	CM-CS1 T-cell
DMY5V4U	MI	TTLRN4A
DMY5V4U	MN	NKG2 D activating NK receptor (KLRK1)
DMY5V4U	MT	DTT
DMY5V4U	MA	CAR-T-Cell-Therapy
DMY5V4U	RN	ClinicalTrials.gov (NCT02203825) Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands
DMY5V4U	RU	https://clinicaltrials.gov/ct2/show/NCT02203825

DMHBNKP	DI	DMHBNKP
DMHBNKP	DN	C-Met/PD-L1 CAR-T Cell
DMHBNKP	MI	TT8ZLTI
DMHBNKP	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMHBNKP	MT	DTT
DMHBNKP	MA	CAR-T-Cell-Therapy(Dual specific)
DMHBNKP	RN	ClinicalTrials.gov (NCT03672305) Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC
DMHBNKP	RU	https://clinicaltrials.gov/ct2/show/NCT03672305

DMHBNKP	DI	DMHBNKP
DMHBNKP	DN	C-Met/PD-L1 CAR-T Cell
DMHBNKP	MI	TTNDSF4
DMHBNKP	MN	Proto-oncogene c-Met (MET)
DMHBNKP	MT	DTT
DMHBNKP	MA	CAR-T-Cell-Therapy(Dual specific)
DMHBNKP	RN	ClinicalTrials.gov (NCT03672305) Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC
DMHBNKP	RU	https://clinicaltrials.gov/ct2/show/NCT03672305

DMGMI8P	DI	DMGMI8P
DMGMI8P	DN	CMP-001
DMGMI8P	MI	TTSHG0T
DMGMI8P	MN	Toll-like receptor 9 (TLR9)
DMGMI8P	MT	DTT
DMGMI8P	MA	Agonist
DMGMI8P	RN	Clinical pipeline report, company report or official report of Checkmate Pharmaceuticals.
DMGMI8P	RU	https://checkmatepharma.com/pipeline/

DM6NG3C	DI	DM6NG3C
DM6NG3C	DN	CMV glycoprotein B subunit vaccine
DM6NG3C	MI	TTUR18Y
DM6NG3C	MN	Cytomegalovirus Glycoprotein B (CMV gB)
DM6NG3C	MT	DTT
DM6NG3C	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline.
DM6NG3C	RU	http://www.gsk-clinicalstudyregister.com/study/108890#ps

DMMF0J3	DI	DMMF0J3
DMMF0J3	DN	CMX-157
DMMF0J3	MI	TT84ETX
DMMF0J3	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMMF0J3	MT	DTT
DMMF0J3	MA	Inhibitor
DMMF0J3	RN	Practical Considerations For Developing Nucleoside Reverse Transcriptase Inhibitors. Drug Discov Today Technol. 2012 Autumn; 9(3): e183-e193.
DMMF0J3	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612025/

DM8L36X	DI	DM8L36X
DM8L36X	DN	CNTO-3649
DM8L36X	MI	TTVIMDE
DM8L36X	MN	Glucagon-like peptide 1 receptor (GLP1R)
DM8L36X	MT	DTT
DM8L36X	MA	Agonist
DM8L36X	RN	GLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE*3-Leiden mice. PLoS One. 2012;7(11):e49152.
DM8L36X	RU	https://pubmed.ncbi.nlm.nih.gov/23133675

DMF8WAT	DI	DMF8WAT
DMF8WAT	DN	CNTO-5825
DMF8WAT	MI	TT0GVCH
DMF8WAT	MN	Interleukin-13 (IL13)
DMF8WAT	MT	DTT
DMF8WAT	RN	Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study. Br J Clin Pharmacol. 2013 May;75(5):1289-98.
DMF8WAT	RU	https://pubmed.ncbi.nlm.nih.gov/23043368

DMUBP0V	DI	DMUBP0V
DMUBP0V	DN	CNTO888
DMUBP0V	MI	TTNAY0P
DMUBP0V	MN	Monocyte chemotactic and activating factor (CCL2)
DMUBP0V	MT	DTT
DMUBP0V	RN	CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia. 2007 Jul;9(7):556-62.
DMUBP0V	RU	https://pubmed.ncbi.nlm.nih.gov/17710158

DMJPEVA	DI	DMJPEVA
DMJPEVA	DN	CNTX-0290
DMJPEVA	MI	TTAE1BR
DMJPEVA	MN	Somatostatin receptor type 4 (SSTR4)
DMJPEVA	MT	DTT
DMJPEVA	MA	Agonist
DMJPEVA	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMJPEVA	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMCOJM7	DI	DMCOJM7
DMCOJM7	DN	CNTX-6970
DMCOJM7	MI	TTFZYTO
DMCOJM7	MN	C-C chemokine receptor type 2 (CCR2)
DMCOJM7	MT	DTT
DMCOJM7	MA	Antagonist
DMCOJM7	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMCOJM7	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMMEFO0	DI	DMMEFO0
DMMEFO0	DN	COH29
DMMEFO0	MI	TTX09M4
DMMEFO0	MN	Ribonucleotide reductase (RIR)
DMMEFO0	MT	DTT
DMMEFO0	MA	Inhibitor
DMMEFO0	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMMEFO0	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMXQOHV	DI	DMXQOHV
DMXQOHV	DN	COM701
DMXQOHV	MI	TTOGCNT
DMXQOHV	MN	Transmembrane protein PVRIG (PVRIG)
DMXQOHV	MT	DTT
DMXQOHV	RN	Clinical pipeline report, company report or official report of Compugen.
DMXQOHV	RU	https://cgen.com/pipeline/com701-pvrig/

DMR6T8L	DI	DMR6T8L
DMR6T8L	DN	COM902
DMR6T8L	MI	TTWNL74
DMR6T8L	MN	V-set and immunoglobulin domain-containing protein 9 (TIGIT)
DMR6T8L	MT	DTT
DMR6T8L	RN	COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade. Cancer Immunol Immunother. 2021 Apr 26.
DMR6T8L	RU	https://pubmed.ncbi.nlm.nih.gov/33903974

DMTLP1N	DI	DMTLP1N
DMTLP1N	DN	Combinectin
DMTLP1N	MI	TTG90S6
DMTLP1N	MN	Human immunodeficiency virus Glycoprotein 41 (HIV gp41)
DMTLP1N	MT	DTT
DMTLP1N	MA	Inhibitor
DMTLP1N	RN	Clinical pipeline report, company report or official report of ViiV Healthcare.
DMTLP1N	RU	https://jvi.asm.org/content/jvi/early/2019/07/25/JVI.00907-19.full.pdf

DMTLP1N	DI	DMTLP1N
DMTLP1N	DN	Combinectin
DMTLP1N	MI	TTN2JFW
DMTLP1N	MN	T-cell surface glycoprotein CD4 (CD4)
DMTLP1N	MT	DTT
DMTLP1N	MA	Inhibitor
DMTLP1N	RN	Clinical pipeline report, company report or official report of ViiV Healthcare.
DMTLP1N	RU	https://jvi.asm.org/content/jvi/early/2019/07/25/JVI.00907-19.full.pdf

DMA7PWX	DI	DMA7PWX
DMA7PWX	DN	Combotox
DMA7PWX	MI	TTM6QSK
DMA7PWX	MN	B-cell receptor CD22 (CD22)
DMA7PWX	MT	DTT
DMA7PWX	MA	Modulator
DMA7PWX	RN	A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia.Br J Haematol.2011 Aug;154(4):471-6.
DMA7PWX	RU	https://www.ncbi.nlm.nih.gov/pubmed/21732928

DMA7PWX	DI	DMA7PWX
DMA7PWX	DN	Combotox
DMA7PWX	MI	TTW640A
DMA7PWX	MN	B-lymphocyte surface antigen B4 (CD19)
DMA7PWX	MT	DTT
DMA7PWX	MA	Modulator
DMA7PWX	RN	A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia.Br J Haematol.2011 Aug;154(4):471-6.
DMA7PWX	RU	https://www.ncbi.nlm.nih.gov/pubmed/21732928

DMULBZM	DI	DMULBZM
DMULBZM	DN	Cosibelimab
DMULBZM	MI	TT8ZLTI
DMULBZM	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMULBZM	MT	DTT
DMULBZM	RN	Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
DMULBZM	RU	https://clinicaltrials.gov/ct2/show/NCT03212404

DM6K3JQ	DI	DM6K3JQ
DM6K3JQ	DN	COTI-2
DM6K3JQ	MI	TT7SBF5
DM6K3JQ	MN	Cellular tumor antigen p53 (TP53)
DM6K3JQ	MT	DTT
DM6K3JQ	MA	Modulator
DM6K3JQ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM6K3JQ	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM32TFO	DI	DM32TFO
DM32TFO	DN	CP-870,893
DM32TFO	MI	TTN6Y9A
DM32TFO	MN	CD40L receptor (CD40)
DM32TFO	MT	DTT
DM32TFO	MA	Agonist
DM32TFO	RN	Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol. 2007 Mar 1;25(7):876-83.
DM32TFO	RU	https://pubmed.ncbi.nlm.nih.gov/17327609

DM3J1T9	DI	DM3J1T9
DM3J1T9	DN	CPC-212
DM3J1T9	MI	TT1RS9F
DM3J1T9	MN	Acetylcholinesterase (AChE)
DM3J1T9	MT	DTT
DM3J1T9	MA	Inhibitor
DM3J1T9	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3J1T9	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMDQG4Y	DI	DMDQG4Y
DMDQG4Y	DN	CPC-250
DMDQG4Y	MI	TT1RS9F
DMDQG4Y	MN	Acetylcholinesterase (AChE)
DMDQG4Y	MT	DTT
DMDQG4Y	MA	Inhibitor
DMDQG4Y	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMDQG4Y	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMVDYTG	DI	DMVDYTG
DMVDYTG	DN	CPG 52364
DMVDYTG	MI	TTRJ1K4
DMVDYTG	MN	Toll-like receptor 7 (TLR7)
DMVDYTG	MT	DTT
DMVDYTG	MA	Antagonist
DMVDYTG	RN	Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus. Lupus Foundation of America, Inc. 2007.
DMVDYTG	RU	http://www.lifesciencesworld.com/news/view/51194

DMVDYTG	DI	DMVDYTG
DMVDYTG	DN	CPG 52364
DMVDYTG	MI	TT8CWFK
DMVDYTG	MN	Toll-like receptor 8 (TLR8)
DMVDYTG	MT	DTT
DMVDYTG	MA	Antagonist
DMVDYTG	RN	Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus. Lupus Foundation of America, Inc. 2007.
DMVDYTG	RU	http://www.lifesciencesworld.com/news/view/51194

DMVDYTG	DI	DMVDYTG
DMVDYTG	DN	CPG 52364
DMVDYTG	MI	TTSHG0T
DMVDYTG	MN	Toll-like receptor 9 (TLR9)
DMVDYTG	MT	DTT
DMVDYTG	MA	Antagonist
DMVDYTG	RN	Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus. Lupus Foundation of America, Inc. 2007.
DMVDYTG	RU	http://www.lifesciencesworld.com/news/view/51194

DMJSFTX	DI	DMJSFTX
DMJSFTX	DN	CPI-006
DMJSFTX	MI	TTK0O6Y
DMJSFTX	MN	Ecto-5'-nucleotidase (CD73)
DMJSFTX	MT	DTT
DMJSFTX	RN	Clinical pipeline report, company report or official report of Corvus Pharmaceuticals.
DMJSFTX	RU	https://www.corvuspharma.com/our-science/our-pipeline/

DMMBQ20	DI	DMMBQ20
DMMBQ20	DN	CPI-818
DMMBQ20	MI	TT3C80U
DMMBQ20	MN	T-cell-specific kinase (ITK)
DMMBQ20	MT	DTT
DMMBQ20	MA	Inhibitor
DMMBQ20	RN	Clinical pipeline report, company report or official report of Corvus Pharmaceuticals.
DMMBQ20	RU	https://www.corvuspharma.com/our-science/our-pipeline/

DMFMGZR	DI	DMFMGZR
DMFMGZR	DN	CPL207-280CA
DMFMGZR	MI	TTB8FUC
DMFMGZR	MN	Free fatty acid receptor 1 (GPR40)
DMFMGZR	MT	DTT
DMFMGZR	MA	Agonist
DMFMGZR	RN	Targeting metabolic dysregulation for fibrosis therapy. Nat Rev Drug Discov. 2020 Jan;19(1):57-75.
DMFMGZR	RU	https://pubmed.ncbi.nlm.nih.gov/31548636

DMQCHU3	DI	DMQCHU3
DMQCHU3	DN	CPP -15
DMQCHU3	MI	TTT2LD9
DMQCHU3	MN	GABA transaminase (ABAT)
DMQCHU3	MT	DTT
DMQCHU3	MA	Modulator
DMQCHU3	RN	Clinical pipeline report, company report or official report of Catalyst Pharma.
DMQCHU3	RU	http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=633588

DMKWSFI	DI	DMKWSFI
DMKWSFI	DN	CR-002
DMKWSFI	MI	TTQA6SX
DMKWSFI	MN	Platelet-derived growth factor B (PDGFB)
DMKWSFI	MT	DTT
DMKWSFI	MA	Modulator
DMKWSFI	RN	A phase I study of CR002, a fully-human monoclonal antibody against platelet-derived growth factor-D. Int J Clin Pharmacol Ther. 2008 May;46(5):236-44.
DMKWSFI	RU	https://www.ncbi.nlm.nih.gov/pubmed/18538109

DMT7L30	DI	DMT7L30
DMT7L30	DN	CR-3465
DMT7L30	MI	TTGKOY9
DMT7L30	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DMT7L30	MT	DTT
DMT7L30	MA	Modulator
DMT7L30	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMT7L30	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMHDSYF	DI	DMHDSYF
DMHDSYF	DN	CRX-675
DMHDSYF	MI	TTISGCA
DMHDSYF	MN	Toll-like receptor 4 (TLR4)
DMHDSYF	MT	DTT
DMHDSYF	MA	Agonist
DMHDSYF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1754).
DMHDSYF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1754

DMG0SPO	DI	DMG0SPO
DMG0SPO	DN	CS-0777
DMG0SPO	MI	TT9JZCK
DMG0SPO	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMG0SPO	MT	DTT
DMG0SPO	MA	Modulator
DMG0SPO	RN	Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist. ACS Med Chem Lett. 2011 Mar 2;2(5):368-72.
DMG0SPO	RU	https://pubmed.ncbi.nlm.nih.gov/24900318

DMU8OCN	DI	DMU8OCN
DMU8OCN	DN	CS1-CAR T Therapy
DMU8OCN	MI	TT7ILZ1
DMU8OCN	MN	SLAM family member 7 SLAMF7 (CS1)
DMU8OCN	MT	DTT
DMU8OCN	MA	CAR-T-Cell-Therapy
DMU8OCN	RN	ClinicalTrials.gov (NCT03710421) CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory Multiple Myeloma
DMU8OCN	RU	https://clinicaltrials.gov/ct2/show/NCT03710421

DMRH740	DI	DMRH740
DMRH740	DN	CS-8080
DMRH740	MI	TTM1EQF
DMRH740	MN	Oxysterols receptor LXR (NR1H)
DMRH740	MT	DTT
DMRH740	MA	Modulator
DMRH740	RN	Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat Rev Drug Discov. 2014 Jun;13(6):433-44.
DMRH740	RU	https://pubmed.ncbi.nlm.nih.gov/24833295

DMO97RV	DI	DMO97RV
DMO97RV	DN	CSL-362
DMO97RV	MI	TTPYS82
DMO97RV	MN	Interleukin 3 receptor (CSF2RB)
DMO97RV	MT	DTT
DMO97RV	RN	Monoclonal antibody targeting of IL-3 receptor alpha with CSL362 effectively depletes CML progenitor and stem cells. Blood. 2014 Feb 20;123(8):1218-28.
DMO97RV	RU	https://pubmed.ncbi.nlm.nih.gov/24363400

DM7I39W	DI	DM7I39W
DM7I39W	DN	CSL-362-AML
DM7I39W	MI	TTENHJ0
DM7I39W	MN	Interleukin 3 receptor alpha (IL3RA)
DM7I39W	MT	DTT
DM7I39W	RN	Monoclonal antibody targeting of IL-3 receptor alpha with CSL362 effectively depletes CML progenitor and stem cells. Blood. 2014 Feb 20;123(8):1218-28.
DM7I39W	RU	https://pubmed.ncbi.nlm.nih.gov/24363400

DMI7XMU	DI	DMI7XMU
DMI7XMU	DN	CT 868
DMI7XMU	MI	TTYMKBE
DMI7XMU	MN	Gastric inhibitory polypeptide receptor (GIPR)
DMI7XMU	MT	DTT
DMI7XMU	MA	Modulator
DMI7XMU	RN	Clinical pipeline report, company report or official report of Carmot Therapeutics.
DMI7XMU	RU	http://carmot-therapeutics.us/pipeline/

DMI7XMU	DI	DMI7XMU
DMI7XMU	DN	CT 868
DMI7XMU	MI	TTVIMDE
DMI7XMU	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMI7XMU	MT	DTT
DMI7XMU	MA	Modulator
DMI7XMU	RN	Clinical pipeline report, company report or official report of Carmot Therapeutics.
DMI7XMU	RU	http://carmot-therapeutics.us/pipeline/

DMBCJW6	DI	DMBCJW6
DMBCJW6	DN	CT053
DMBCJW6	MI	TTZ3P4W
DMBCJW6	MN	B-cell maturation protein (TNFRSF17)
DMBCJW6	MT	DTT
DMBCJW6	RN	ClinicalTrials.gov (NCT03915184) Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2). U.S. National Institutes of Health.
DMBCJW6	RU	https://clinicaltrials.gov/ct2/show/NCT03915184

DMW16VR	DI	DMW16VR
DMW16VR	DN	CT-200
DMW16VR	MI	TTBH0VX
DMW16VR	MN	Histone deacetylase (HDAC)
DMW16VR	MT	DTT
DMW16VR	MA	Inhibitor
DMW16VR	RN	Clinical pipeline report, company report or official report of Celleron.
DMW16VR	RU	http://cellerontherapeutics.com/

DMHBK6L	DI	DMHBK6L
DMHBK6L	DN	CTAP-201
DMHBK6L	MI	TTK59TV
DMHBK6L	MN	Vitamin D3 receptor (VDR)
DMHBK6L	MT	DTT
DMHBK6L	MA	Agonist
DMHBK6L	RN	Vascular calcification and secondary hyperparathyroidism of severe chronic kidney disease and its relation to serum phosphate and calcium levels. Br J Pharmacol. 2009 April; 156(8): 1267-1278.
DMHBK6L	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697742/

DM2HES0	DI	DM2HES0
DM2HES0	DN	CTCE-0214
DM2HES0	MI	TTBID49
DM2HES0	MN	C-X-C chemokine receptor type 4 (CXCR4)
DM2HES0	MT	DTT
DM2HES0	MA	Agonist
DM2HES0	RN	Beneficial effect of a CXCR4 agonist in murine models of systemic inflammation. Inflammation. 2012 Feb;35(1):130-7.
DM2HES0	RU	https://pubmed.ncbi.nlm.nih.gov/21274742

DMIKX01	DI	DMIKX01
DMIKX01	DN	CTP-298
DMIKX01	MI	TT5FNQT
DMIKX01	MN	Human immunodeficiency virus Protease (HIV PR)
DMIKX01	MT	DTT
DMIKX01	MA	Inhibitor
DMIKX01	RN	Avanir Licenses Concert's Deuterium-Modified Dextromethorphan Products in Potential US$200 M Deal. Vol 2012 Issue 3 Page(38).
DMIKX01	RU	http://ojs.pharmadeals.net:5555/index.php/pdr/article/view/cr1696/html

DM68I93	DI	DM68I93
DM68I93	DN	CTS-21166
DM68I93	MI	TT8JRS7
DM68I93	MN	Beta-secretase (BACE)
DM68I93	MT	DTT
DM68I93	MA	Inhibitor
DM68I93	RN	ClinicalTrials.gov (NCT00621010) Safety Study of CTS21166 to Treat Alzheimer Disease. U. S. National Institutes of Health. 2008.
DM68I93	RU	https://clinicaltrials.gov/ct2/show/NCT00621010

DMAV86R	DI	DMAV86R
DMAV86R	DN	CTT1403
DMAV86R	MI	TT9G4N0
DMAV86R	MN	Glutamate carboxypeptidase II (GCPII)
DMAV86R	MT	DTT
DMAV86R	MA	Inhibitor
DMAV86R	RN	177 Lu-Labeled Phosphoramidate-Based PSMA Inhibitors: The Effect of an Albumin Binder on Biodistribution and Therapeutic Efficacy in Prostate Tumor-Bearing Mice. Theranostics. 2017 Apr 27;7(7):1928-1939.
DMAV86R	RU	https://pubmed.ncbi.nlm.nih.gov/28638478

DMHK9WR	DI	DMHK9WR
DMHK9WR	DN	CTX-101
DMHK9WR	MI	TTW640A
DMHK9WR	MN	B-lymphocyte surface antigen B4 (CD19)
DMHK9WR	MT	DTT
DMHK9WR	RN	Off-the-shelf' allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020 Mar;19(3):185-199.
DMHK9WR	RU	https://pubmed.ncbi.nlm.nih.gov/31900462

DMWS40H	DI	DMWS40H
DMWS40H	DN	CTX120
DMWS40H	MI	TTZ3P4W
DMWS40H	MN	B-cell maturation protein (TNFRSF17)
DMWS40H	MT	DTT
DMWS40H	RN	Clinical pipeline report, company report or official report of CRISPR Therapeutics.
DMWS40H	RU	http://www.crisprtx.com/programs/pipeline

DM926CH	DI	DM926CH
DM926CH	DN	CTX130
DM926CH	MI	TTNCIE0
DM926CH	MN	CD70 antigen (CD27-L)
DM926CH	MT	DTT
DM926CH	RN	Clinical pipeline report, company report or official report of CRISPR Therapeutics.
DM926CH	RU	http://www.crisprtx.com/programs/pipeline

DMMPKN3	DI	DMMPKN3
DMMPKN3	DN	CTX-471
DMMPKN3	MI	TTPW9LJ
DMMPKN3	MN	Co-stimulatory molecule 4-1BB (CD137)
DMMPKN3	MT	DTT
DMMPKN3	MA	Agonist
DMMPKN3	RN	Clinical pipeline report, company report or official report of Compass Therapeutics.
DMMPKN3	RU	https://www.compasstherapeutics.com/candidates/ctx-471-cd137-agonist/

DM9ZOMD	DI	DM9ZOMD
DM9ZOMD	DN	CUDC-101
DM9ZOMD	MI	TTGKNB4
DM9ZOMD	MN	Epidermal growth factor receptor (EGFR)
DM9ZOMD	MT	DTT
DM9ZOMD	MA	Modulator
DM9ZOMD	RN	A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Apr 1;21(7):1566-73.
DM9ZOMD	RU	https://pubmed.ncbi.nlm.nih.gov/25573383

DM9ZOMD	DI	DM9ZOMD
DM9ZOMD	DN	CUDC-101
DM9ZOMD	MI	TT6EO5L
DM9ZOMD	MN	Erbb2 tyrosine kinase receptor (HER2)
DM9ZOMD	MT	DTT
DM9ZOMD	MA	Modulator
DM9ZOMD	RN	A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Apr 1;21(7):1566-73.
DM9ZOMD	RU	https://pubmed.ncbi.nlm.nih.gov/25573383

DMYD37G	DI	DMYD37G
DMYD37G	DN	CV8102
DMYD37G	MI	TTVB0O3
DMYD37G	MN	Retinoic acid-inducible gene-1 (RIG-1)
DMYD37G	MT	DTT
DMYD37G	MA	Agonist
DMYD37G	RN	Clinical pipeline report, company report or official report of CureVac.
DMYD37G	RU	https://www.curevac.com/en/pipeline/

DMYD37G	DI	DMYD37G
DMYD37G	DN	CV8102
DMYD37G	MI	TTRJ1K4
DMYD37G	MN	Toll-like receptor 7 (TLR7)
DMYD37G	MT	DTT
DMYD37G	MA	Agonist
DMYD37G	RN	Clinical pipeline report, company report or official report of CureVac.
DMYD37G	RU	https://www.curevac.com/en/pipeline/

DMYD37G	DI	DMYD37G
DMYD37G	DN	CV8102
DMYD37G	MI	TT8CWFK
DMYD37G	MN	Toll-like receptor 8 (TLR8)
DMYD37G	MT	DTT
DMYD37G	MA	Agonist
DMYD37G	RN	Clinical pipeline report, company report or official report of CureVac.
DMYD37G	RU	https://www.curevac.com/en/pipeline/

DMTSIYZ	DI	DMTSIYZ
DMTSIYZ	DN	CVN058
DMTSIYZ	MI	TTNXLKE
DMTSIYZ	MN	5-HT 3 receptor (5HT3R)
DMTSIYZ	MT	DTT
DMTSIYZ	MA	Antagonist
DMTSIYZ	RN	Clinical pipeline report, company report or official report of Cerevance.
DMTSIYZ	RU	https://cerevance.com/pipeline/

DMY84TW	DI	DMY84TW
DMY84TW	DN	CVT-6883
DMY84TW	MI	TTNE7KG
DMY84TW	MN	Adenosine A2b receptor (ADORA2B)
DMY84TW	MT	DTT
DMY84TW	MA	Modulator
DMY84TW	RN	GS-6201, a selective blocker of the A2B adenosine receptor, attenuates cardiac remodeling after acute myocardial infarction in the mouse. J Pharmacol Exp Ther. 2012 Dec;343(3):587-95.
DMY84TW	RU	https://pubmed.ncbi.nlm.nih.gov/22923737

DMO23R0	DI	DMO23R0
DMO23R0	DN	CVX 096
DMO23R0	MI	TTVIMDE
DMO23R0	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMO23R0	MT	DTT
DMO23R0	MA	Modulator
DMO23R0	RN	Chemically programmed antibodies. Trends Biotechnol. 2014 April; 32(4): 186-197.
DMO23R0	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978777/

DMV74JC	DI	DMV74JC
DMV74JC	DN	CVX-241
DMV74JC	MI	TTKLQTJ
DMV74JC	MN	Angiopoietin-2 (ANGPT2)
DMV74JC	MT	DTT
DMV74JC	MA	Modulator
DMV74JC	RN	Chemical generation of bispecific antibodies. Proc Natl Acad Sci U S A. 2010 December 28; 107(52): 22611-22616.
DMV74JC	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3012461/

DMRD2B0	DI	DMRD2B0
DMRD2B0	DN	CXD-101
DMRD2B0	MI	TTBH0VX
DMRD2B0	MN	Histone deacetylase (HDAC)
DMRD2B0	MT	DTT
DMRD2B0	MA	Inhibitor
DMRD2B0	RN	Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients. Clin Microbiol Infect. 2010 Sep;16(9):1482-7.
DMRD2B0	RU	https://pubmed.ncbi.nlm.nih.gov/20002107

DM4GJ50	DI	DM4GJ50
DM4GJ50	DN	CXR-1002
DM4GJ50	MI	TTTN5QW
DM4GJ50	MN	Serine/threonine-protein kinase pim-1 (PIM1)
DM4GJ50	MT	DTT
DM4GJ50	MA	Inhibitor
DM4GJ50	RN	123 Antitumor activity of CXR1002, a novel anti-cancer clinical phase compound that induces ER stress and inhibits PIM kinases: Human tumor xenograft efficacy and in vitro mode of action. EJC Supplements, 2010; 8(7):45-46.
DM4GJ50	RU	http://www.researchgate.net/publication/251668212_123_Antitumor_activity_of_CXR1002_a_novel_anti-cancer_clinical_phase_compound_that_induces_ER_stress_and_inhibits_PIM_kinases_Human_tumor_xenograft_efficacy_and_in_vitro_mode_of_action

DMSM42V	DI	DMSM42V
DMSM42V	DN	CYAD-101
DMSM42V	MI	TTLRN4A
DMSM42V	MN	NKG2 D activating NK receptor (KLRK1)
DMSM42V	MT	DTT
DMSM42V	MA	CAR-T-Cell-Therapy
DMSM42V	RN	ClinicalTrials.gov (NCT03692429) alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
DMSM42V	RU	https://clinicaltrials.gov/ct2/show/NCT03692429

DM9ODT6	DI	DM9ODT6
DM9ODT6	DN	CYC065
DM9ODT6	MI	TT7HF4W
DM9ODT6	MN	Cyclin-dependent kinase 2 (CDK2)
DM9ODT6	MT	DTT
DM9ODT6	MA	Inhibitor
DM9ODT6	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9ODT6	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM9ODT6	DI	DM9ODT6
DM9ODT6	DN	CYC065
DM9ODT6	MI	TT1LVF2
DM9ODT6	MN	Cyclin-dependent kinase 9 (CDK9)
DM9ODT6	MT	DTT
DM9ODT6	MA	Inhibitor
DM9ODT6	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9ODT6	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMUMHXT	DI	DMUMHXT
DMUMHXT	DN	CYC116
DMUMHXT	MI	TTPS3C0
DMUMHXT	MN	Aurora kinase A (AURKA)
DMUMHXT	MT	DTT
DMUMHXT	MA	Inhibitor
DMUMHXT	RN	Clinical pipeline report, company report or official report of Cyclacel.
DMUMHXT	RU	http://investor.cyclacel.com/releasedetail.cfm?ReleaseID=625011

DMUMHXT	DI	DMUMHXT
DMUMHXT	DN	CYC116
DMUMHXT	MI	TT5LS6T
DMUMHXT	MN	Aurora kinase B (AURKB)
DMUMHXT	MT	DTT
DMUMHXT	MA	Inhibitor
DMUMHXT	RN	Clinical pipeline report, company report or official report of Cyclacel.
DMUMHXT	RU	http://investor.cyclacel.com/releasedetail.cfm?ReleaseID=625011

DMUMHXT	DI	DMUMHXT
DMUMHXT	DN	CYC116
DMUMHXT	MI	TTUTJGQ
DMUMHXT	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMUMHXT	MT	DTT
DMUMHXT	MA	Inhibitor
DMUMHXT	RN	Clinical pipeline report, company report or official report of Cyclacel.
DMUMHXT	RU	http://investor.cyclacel.com/releasedetail.cfm?ReleaseID=625011

DMC6PKJ	DI	DMC6PKJ
DMC6PKJ	DN	CYC140
DMC6PKJ	MI	TTIYVQP
DMC6PKJ	MN	Polo-like kinase 1 (PLK1)
DMC6PKJ	MT	DTT
DMC6PKJ	MA	Inhibitor
DMC6PKJ	RN	Clinical pipeline report, company report or official report of Cyclacel Pharmaceuticals.
DMC6PKJ	RU	https://cyclacel.com/research_programs_oncology_cyc140.shtml

DMI6EUB	DI	DMI6EUB
DMI6EUB	DN	Cyclolignan picropodophyllin
DMI6EUB	MI	TTHRID2
DMI6EUB	MN	Insulin-like growth factor I receptor (IGF1R)
DMI6EUB	MT	DTT
DMI6EUB	MA	Inhibitor
DMI6EUB	RN	The cyclolignan picropodophyllin attenuates intimal hyperplasia after rat carotid balloon injury by blocking insulin-like growth factor-1 receptor signaling. J Vasc Surg. 2007 Jul;46(1):108-15.
DMI6EUB	RU	https://pubmed.ncbi.nlm.nih.gov/17606126

DMAWVTX	DI	DMAWVTX
DMAWVTX	DN	Cyclopentenylcytosine
DMAWVTX	MI	TTN12BZ
DMAWVTX	MN	CTP synthase (CTPS1)
DMAWVTX	MT	DTT
DMAWVTX	MA	Inhibitor
DMAWVTX	RN	Molecular approaches for the treatment of hemorrhagic fever virus infections. Antiviral Res. 1993 Sep;22(1):45-75.
DMAWVTX	RU	https://pubmed.ncbi.nlm.nih.gov/8250543

DMNICD4	DI	DMNICD4
DMNICD4	DN	CYT-013-IL1bQb
DMNICD4	MI	TTRYK0X
DMNICD4	MN	Interleukin-1 beta (IL1B)
DMNICD4	MT	DTT
DMNICD4	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2623).
DMNICD4	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2623

DMTV09A	DI	DMTV09A
DMTV09A	DN	Cyt-1010
DMTV09A	MI	TTKWM86
DMTV09A	MN	Opioid receptor mu (MOP)
DMTV09A	MT	DTT
DMTV09A	MA	Agonist
DMTV09A	RN	Endomorphin-2: A Biased Agonist at the -Opioid Receptor. Mol Pharmacol. 2012 August; 82(2): 178-188.
DMTV09A	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400840/

DMJ83Z7	DI	DMJ83Z7
DMJ83Z7	DN	CYT-609
DMJ83Z7	MI	TTF8CQI
DMJ83Z7	MN	Tumor necrosis factor (TNF)
DMJ83Z7	MT	DTT
DMJ83Z7	MA	Modulator
DMJ83Z7	RN	Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine. Clin Cancer Res. 2010 December 15; 16(24): 6139-6149.
DMJ83Z7	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004980/

DMAY6X2	DI	DMAY6X2
DMAY6X2	DN	CZ-48
DMAY6X2	MI	TTGTQHC
DMAY6X2	MN	DNA topoisomerase I (TOP1)
DMAY6X2	MT	DTT
DMAY6X2	MA	Inhibitor
DMAY6X2	RN	Pharmacology of camptothecin esters. Ann N Y Acad Sci. 2000;922:216-23.
DMAY6X2	RU	https://pubmed.ncbi.nlm.nih.gov/11193897

DMGA1DS	DI	DMGA1DS
DMGA1DS	DN	D-0502
DMGA1DS	MI	TTZAYWL
DMGA1DS	MN	Estrogen receptor (ESR)
DMGA1DS	MT	DTT
DMGA1DS	MA	Degrader
DMGA1DS	RN	Clinical pipeline report, company report or official report of InventisBio.
DMGA1DS	RU	http://www.inventisbio.com/en/product.html?id=1

DMTP9ER	DI	DMTP9ER
DMTP9ER	DN	D-20133
DMTP9ER	MI	TT1UZQH
DMTP9ER	MN	Phospholipase C (PLC)
DMTP9ER	MT	DTT
DMTP9ER	MA	Inhibitor
DMTP9ER	RN	Novel Inhibitors of AKT: Assessment of a Different Approach Targeting the Pleckstrin Homology Domain. Curr Med Chem. 2011; 18(18): 2727-2742.
DMTP9ER	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091980/

DMIMK84	DI	DMIMK84
DMIMK84	DN	D2C7
DMIMK84	MI	TTGKNB4
DMIMK84	MN	Epidermal growth factor receptor (EGFR)
DMIMK84	MT	DTT
DMIMK84	RN	Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations. J Immunother Cancer. 2019 May 29;7(1):142.
DMIMK84	RU	https://pubmed.ncbi.nlm.nih.gov/31142380

DMIMK84	DI	DMIMK84
DMIMK84	DN	D2C7
DMIMK84	MI	TTZ6B2I
DMIMK84	MN	Epidermal growth factor receptor variant III (EGFR vIII)
DMIMK84	MT	DTT
DMIMK84	RN	Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations. J Immunother Cancer. 2019 May 29;7(1):142.
DMIMK84	RU	https://pubmed.ncbi.nlm.nih.gov/31142380

DM7V2OM	DI	DM7V2OM
DM7V2OM	DN	D-3263
DM7V2OM	MI	TTXDKTO
DM7V2OM	MN	Long transient receptor potential channel 8 (TRPM8)
DM7V2OM	MT	DTT
DM7V2OM	MA	Modulator
DM7V2OM	RN	Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL. Rev Urol. 2009 Spring; 11(2): 82-107.
DM7V2OM	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2725309/

DM4OTWL	DI	DM4OTWL
DM4OTWL	DN	DA-1229
DM4OTWL	MI	TTDIGC1
DM4OTWL	MN	Dipeptidyl peptidase 4 (DPP-4)
DM4OTWL	MT	DTT
DM4OTWL	MA	Inhibitor
DM4OTWL	RN	DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes. Life Sci. 2012 Jan 2;90(1-2):21-9.
DM4OTWL	RU	https://pubmed.ncbi.nlm.nih.gov/22056373

DMPJA64	DI	DMPJA64
DMPJA64	DN	DA-1241
DMPJA64	MI	TT7QNVC
DMPJA64	MN	Glucose-dependent insulinotropic receptor (GPR119)
DMPJA64	MT	DTT
DMPJA64	MA	Agonist
DMPJA64	RN	ClinicalTrials.gov (NCT03646721) A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM. U.S. National Institutes of Health.
DMPJA64	RU	https://clinicaltrials.gov/ct2/show/NCT03646721

DM4JG0B	DI	DM4JG0B
DM4JG0B	DN	DA-3607
DM4JG0B	MI	TTA5MS9
DM4JG0B	MN	TNF related apoptosis inducing ligand (TNFSF10)
DM4JG0B	MT	DTT
DM4JG0B	MA	Binder
DM4JG0B	RN	Cancer gene therapy using a novel secretable trimeric TRAIL. Gene Ther. 2006 Feb;13(4):330-8.
DM4JG0B	RU	https://pubmed.ncbi.nlm.nih.gov/16195699

DMKPAOD	DI	DMKPAOD
DMKPAOD	DN	DA-6886
DMKPAOD	MI	TT07C3Y
DMKPAOD	MN	5-HT 4 receptor (HTR4)
DMKPAOD	MT	DTT
DMKPAOD	MA	Agonist
DMKPAOD	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 9).
DMKPAOD	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=9

DMBRN2G	DI	DMBRN2G
DMBRN2G	DN	DA-697b
DMBRN2G	MI	TT3SZBT
DMBRN2G	MN	von Willebrand factor (VWF)
DMBRN2G	MT	DTT
DMBRN2G	MA	Inhibitor
DMBRN2G	RN	A new oral antiplatelet agent with potent antithrombotic properties: comparison of DZ-697b with clopidogrel a randomised phase I study. Thromb Haemost. 2010 Jan;103(1):205-12.
DMBRN2G	RU	https://pubmed.ncbi.nlm.nih.gov/20062928

DM9KS1A	DI	DM9KS1A
DM9KS1A	DN	DA-727
DM9KS1A	MI	TTGN1ZA
DM9KS1A	MN	Angiotensin II receptor (AGTR)
DM9KS1A	MT	DTT
DM9KS1A	MA	Modulator
DM9KS1A	RN	WO patent application no. 2009,0880,06, Combined pharmaceutical agent.
DM9KS1A	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20090716&CC=WO&NR=2009088006A1&KC=A1

DMQR4HA	DI	DMQR4HA
DMQR4HA	DN	DABIS MALEATE
DMQR4HA	MI	TTUTN1I
DMQR4HA	MN	Human Deoxyribonucleic acid (hDNA)
DMQR4HA	MT	DTT
DMQR4HA	MA	Binder
DMQR4HA	RN	DNA damage and sequence specificity of DNA binding of the new anti-cancer agent 1,4-bis(2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] heptane dimaleate (Dabis maleate)Broggini M1, Hartley JA, Mattes WB, Ponti M, Kohn KW, D'Incalci M.Author information1Laboratory of Cancer Chemotherapy, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.Erratum inBr J Cancer 1990 Jul;62(1):172. AbstractThe DNA damage and the sequence specificity of guanine-N7 alkylation produced by the novel, positively charged, antineoplastic agent 1,4-bis(2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] heptane dimaleate (Dabis maleate) and its uncharged tertiary amine analogue 1,4-bis(2'-chloroethyl)-1,4-diazacyclohexane (Dabis analogue) were investigated in L1210 cells and isolated DNA. Both compounds are cytotoxic in vitro causing an arrest of L1210 cells in G2/M phase of the cell cycle. In isolated DNA, Dabis maleate alkylates guanine at the N7-position with some differences in specificity compared to other alkylating agents (e.g. nitrogen mustard). Significant differences are also evident between Dabis maleate and Dabis analogue, suggesting that Dabis analogue is not the sole alkylating species of Dabis maleate. Using the alkaline elution technique a moderate number of DNA interstrand cross-links were detected in L1210 cells treated with both compounds, which were completely repaired within 24 h. Dabis maleate and Dabis analogue do not cause DNA single strand breaks or DNA protein cross-links at the doses at which DNA interstrand cross-links were detected.PMID: 2393411 [PubMed - indexed for MEDLINE] PMCID: PMC1971404 Free PMC ArticleSharePublication Types, MeSH Terms, SubstancesPublication TypesResearch Support, Non-U.S. Gov'tMeSH TermsAnimalsAntineoplastic Agents/pharmacology*Base SequenceBicycloCompounds/pharmacology*Bicyclo Compounds, Heterocyclic*Bridged Compounds/pharmacology*Cell Survival/drug effectsDNA Damage*DNA, Neoplasm/drug effects*Dose-Response Relationship, DrugHumansInterphase/drug effectsLeukemia L1210/pathologyTumor Cells, Cultured/drug effectsSubstancesAntineoplastic AgentsBicyclo CompoundsBicyclo Compounds, HeterocyclicBridged CompoundsDNA, Neoplasm1,4-bis(2'-chloroethyl)-1,4-diazabicyclo(2.2.1)heptaneLinkOut - more resourcesFull Text SourcesEurope PubMed CentralPubMed CentralPubMed Central CanadaOther Literature SourcesCOS Scholar UniverseAccess more work from the authors - ResearchGateMiscellaneousNCI CPTAC Assay PortalPubMed Commons home Br J Cancer. 1990 Feb;61(2):285-9.
DMQR4HA	RU	https://pubmed.ncbi.nlm.nih.gov/2393411

DM5TB76	DI	DM5TB76
DM5TB76	DN	DACRA 089
DM5TB76	MI	TTAT87F
DM5TB76	MN	Amylin receptor (IAPPR)
DM5TB76	MT	DTT
DM5TB76	MA	Agonist
DM5TB76	RN	A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference. Br J Pharmacol. 2017 Apr;174(7):591-602.
DM5TB76	RU	https://pubmed.ncbi.nlm.nih.gov/28109166

DM5TB76	DI	DM5TB76
DM5TB76	DN	DACRA 089
DM5TB76	MI	TTLWS2O
DM5TB76	MN	Calcitonin receptor (CALCR)
DM5TB76	MT	DTT
DM5TB76	MA	Agonist
DM5TB76	RN	A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference. Br J Pharmacol. 2017 Apr;174(7):591-602.
DM5TB76	RU	https://pubmed.ncbi.nlm.nih.gov/28109166

DMWT5RS	DI	DMWT5RS
DMWT5RS	DN	Daniquidone
DMWT5RS	MI	TTGTQHC
DMWT5RS	MN	DNA topoisomerase I (TOP1)
DMWT5RS	MT	DTT
DMWT5RS	MA	Modulator
DMWT5RS	RN	Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas.Cancer Chemother Pharmacol.2013 Oct;72(4):917-23.
DMWT5RS	RU	https://www.ncbi.nlm.nih.gov/pubmed/23912694

DMWT5RS	DI	DMWT5RS
DMWT5RS	DN	Daniquidone
DMWT5RS	MI	TT0IHXV
DMWT5RS	MN	DNA topoisomerase II (TOP2)
DMWT5RS	MT	DTT
DMWT5RS	MA	Modulator
DMWT5RS	RN	Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas.Cancer Chemother Pharmacol.2013 Oct;72(4):917-23.
DMWT5RS	RU	https://www.ncbi.nlm.nih.gov/pubmed/23912694

DM4A3U7	DI	DM4A3U7
DM4A3U7	DN	DAVLB-HYDRAZIDE
DM4A3U7	MI	TTYFKSZ
DM4A3U7	MN	Tubulin beta (TUBB)
DM4A3U7	MT	DTT
DM4A3U7	MA	Modulator
DM4A3U7	RN	An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site. Pharm Res. 2012 November; 29(11): 2943-2971.
DM4A3U7	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667160/

DM1K248	DI	DM1K248
DM1K248	DN	DB-053072
DM1K248	MI	DEBTUZ3
DM1K248	MN	D-Lactate dehydrogenase (ldhA)
DM1K248	MT	DME
DM1K248	MA	Metabolism
DM1K248	RN	Diverse allosteric and catalytic functions of tetrameric d-lactate dehydrogenases from three Gram-negative bacteria. AMB Express. 2014 Oct 28;4:76.
DM1K248	RU	https://pubmed.ncbi.nlm.nih.gov/25401076

DM1K248	DI	DM1K248
DM1K248	DN	DB-053072
DM1K248	MI	DEHUP0C
DM1K248	MN	D-Lactate dehydrogenase (ldhA)
DM1K248	MT	DME
DM1K248	MA	Metabolism
DM1K248	RN	Cloning of D-lactate dehydrogenase genes of Lactobacillus delbrueckii subsp. bulgaricus and their roles in D-lactic acid production. 3 Biotech. 2017 Jul;7(3):194.
DM1K248	RU	https://pubmed.ncbi.nlm.nih.gov/28664378

DM1K248	DI	DM1K248
DM1K248	DN	DB-053072
DM1K248	MI	DECY6JG
DM1K248	MN	D-Lactate dehydrogenase (ldhA)
DM1K248	MT	DME
DM1K248	MA	Metabolism
DM1K248	RN	Diverse allosteric and catalytic functions of tetrameric d-lactate dehydrogenases from three Gram-negative bacteria. AMB Express. 2014 Oct 28;4:76.
DM1K248	RU	https://pubmed.ncbi.nlm.nih.gov/25401076

DM1K248	DI	DM1K248
DM1K248	DN	DB-053072
DM1K248	MI	DEJEWXB
DM1K248	MN	D-Lactate dehydrogenase (ldhA)
DM1K248	MT	DME
DM1K248	MA	Metabolism
DM1K248	RN	Diverse allosteric and catalytic functions of tetrameric d-lactate dehydrogenases from three Gram-negative bacteria. AMB Express. 2014 Oct 28;4:76.
DM1K248	RU	https://pubmed.ncbi.nlm.nih.gov/25401076

DM1K248	DI	DM1K248
DM1K248	DN	DB-053072
DM1K248	MI	DESR17C
DM1K248	MN	L-Lactate dehydrogenase (ldh)
DM1K248	MT	DME
DM1K248	MA	Metabolism
DM1K248	RN	Purification, properties and immunological relationship of L (+)-lactate dehydrogenase from Lactobacillus casei. Eur J Biochem. 1976 Aug 16;67(2):543-55.
DM1K248	RU	https://pubmed.ncbi.nlm.nih.gov/823016

DM1K248	DI	DM1K248
DM1K248	DN	DB-053072
DM1K248	MI	DE5DTYB
DM1K248	MN	L-Lactate dehydrogenase (ldh)
DM1K248	MT	DME
DM1K248	MA	Metabolism
DM1K248	RN	Positive selection on D-lactate dehydrogenases of Lactobacillus delbrueckii subspecies bulgaricus. IET Syst Biol. 2015 Aug;9(4):172-9.
DM1K248	RU	https://pubmed.ncbi.nlm.nih.gov/26243834

DM1K248	DI	DM1K248
DM1K248	DN	DB-053072
DM1K248	MI	DE6QXYP
DM1K248	MN	Pyruvate oxidase (pyrO)
DM1K248	MT	DME
DM1K248	MA	Metabolism
DM1K248	RN	Metabolic gene-targeted monitoring of non-starter lactic acid bacteria during cheese ripening. Int J Food Microbiol. 2017 Sep 18;257:276-284.
DM1K248	RU	https://pubmed.ncbi.nlm.nih.gov/28735145

DM6K47B	DI	DM6K47B
DM6K47B	DN	DC/I540/KLH vaccine
DM6K47B	MI	TTUJFD0
DM6K47B	MN	Telomerase reverse transcriptase (TERT)
DM6K47B	MT	DTT
DM6K47B	RN	Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res. 2004 Feb 1;10(3):828-39.
DM6K47B	RU	https://pubmed.ncbi.nlm.nih.gov/14871958

DMLVG9D	DI	DMLVG9D
DMLVG9D	DN	DCC-3014
DMLVG9D	MI	TT7MRDV
DMLVG9D	MN	Macrophage colony-stimulating factor 1 receptor (CSF1R)
DMLVG9D	MT	DTT
DMLVG9D	MA	Inhibitor
DMLVG9D	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMLVG9D	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMQ8ACY	DI	DMQ8ACY
DMQ8ACY	DN	DCCCyB
DMQ8ACY	MI	TTHJTF7
DMQ8ACY	MN	Glycine transporter GlyT-1 (SLC6A9)
DMQ8ACY	MT	DTT
DMQ8ACY	MA	Modulator
DMQ8ACY	RN	Identification of an Orally Bioavailable, Potent, and Selective Inhibitor of GlyT1. ACS Med Chem Lett. 2010 October 14; 1(7): 350-354.
DMQ8ACY	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007840/

DMQIEFB	DI	DMQIEFB
DMQIEFB	DN	Debio 0827
DMQIEFB	MI	TT5TKPM
DMQIEFB	MN	Neutral endopeptidase (MME)
DMQIEFB	MT	DTT
DMQIEFB	MA	Inhibitor
DMQIEFB	RN	Clinical pipeline report, company report or official report of Debiopharm (2011).
DMQIEFB	RU	http://www.debiopharm.com/our-business/pipeline.html

DMWP3G1	DI	DMWP3G1
DMWP3G1	DN	Debio 0932
DMWP3G1	MI	TT78R5H
DMWP3G1	MN	Heat shock protein 90 alpha (HSP90A)
DMWP3G1	MT	DTT
DMWP3G1	MA	Inhibitor
DMWP3G1	RN	Clinical pipeline report, company report or official report of Debiopharm (2011).
DMWP3G1	RU	http://www.debiopharm.com/our-business/pipeline.html

DMPXLMB	DI	DMPXLMB
DMPXLMB	DN	Demobesin
DMPXLMB	MI	TTHYDUM
DMPXLMB	MN	Bombesin receptor (BS)
DMPXLMB	MT	DTT
DMPXLMB	MA	Antagonist
DMPXLMB	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 38).
DMPXLMB	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=38

DMTULGS	DI	DMTULGS
DMTULGS	DN	Demogastrin
DMTULGS	MI	TTVFO0U
DMTULGS	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMTULGS	MT	DTT
DMTULGS	MA	Modulator
DMTULGS	RN	Demonstration of new sites of expression of the CCK-B/gastrin receptor in pancreatic acinar AR42J cells using immunoelectron microscopy. Regul Pept. 1999 Oct 22;84(1-3):81-9.
DMTULGS	RU	https://pubmed.ncbi.nlm.nih.gov/10535412

DMURVPF	DI	DMURVPF
DMURVPF	DN	Dendritic cell vaccine
DMURVPF	MI	TT7SBF5
DMURVPF	MN	Cellular tumor antigen p53 (TP53)
DMURVPF	MT	DTT
DMURVPF	RN	Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother. 2004 Jul;53(7):633-41.
DMURVPF	RU	https://pubmed.ncbi.nlm.nih.gov/14985857

DMTR7EH	DI	DMTR7EH
DMTR7EH	DN	Desoxypeganine
DMTR7EH	MI	TT1RS9F
DMTR7EH	MN	Acetylcholinesterase (AChE)
DMTR7EH	MT	DTT
DMTR7EH	MA	Modulator
DMTR7EH	RN	Phase I clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: tolerance and pharmacokinetics study of escalating single oral doses. Methods Find Exp Clin Pharmacol. 2008 Mar;30(2):141-7.
DMTR7EH	RU	https://pubmed.ncbi.nlm.nih.gov/18560630

DMTR7EH	DI	DMTR7EH
DMTR7EH	DN	Desoxypeganine
DMTR7EH	MI	TT3WG5C
DMTR7EH	MN	Monoamine oxidase type A (MAO-A)
DMTR7EH	MT	DTT
DMTR7EH	MA	Modulator
DMTR7EH	RN	Phase I clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: tolerance and pharmacokinetics study of escalating single oral doses. Methods Find Exp Clin Pharmacol. 2008 Mar;30(2):141-7.
DMTR7EH	RU	https://pubmed.ncbi.nlm.nih.gov/18560630

DMAE9I0	DI	DMAE9I0
DMAE9I0	DN	Dexpirronium
DMAE9I0	MI	TTH18TF
DMAE9I0	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMAE9I0	MT	DTT
DMAE9I0	MA	Antagonist
DMAE9I0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 467).
DMAE9I0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=467

DMI8QNB	DI	DMI8QNB
DMI8QNB	DN	DFP 13318
DMI8QNB	MI	TTGTQHC
DMI8QNB	MN	DNA topoisomerase I (TOP1)
DMI8QNB	MT	DTT
DMI8QNB	MA	Inhibitor
DMI8QNB	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMI8QNB	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMY6QFH	DI	DMY6QFH
DMY6QFH	DN	DFP-11207
DMY6QFH	MI	TTU6BFZ
DMY6QFH	MN	Candida Thymidylate synthase (Candi TMP1)
DMY6QFH	MT	DTT
DMY6QFH	MA	Inhibitor
DMY6QFH	RN	National Cancer Institute Drug Dictionary (drug id 762603).
DMY6QFH	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=762603

DMGO4XJ	DI	DMGO4XJ
DMGO4XJ	DN	DFP-14927
DMGO4XJ	MI	TTATL6Y
DMGO4XJ	MN	DNA-dependent DNA polymerase (DPOL)
DMGO4XJ	MT	DTT
DMGO4XJ	MA	Inhibitor
DMGO4XJ	RN	National Cancer Institute Drug Dictionary (drug name DFP14927).
DMGO4XJ	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pegylated-deoxycytidine-analogue-dfp-14927

DMGO4XJ	DI	DMGO4XJ
DMGO4XJ	DN	DFP-14927
DMGO4XJ	MI	TTUTN1I
DMGO4XJ	MN	Human Deoxyribonucleic acid (hDNA)
DMGO4XJ	MT	DTT
DMGO4XJ	MA	Inhibitor
DMGO4XJ	RN	National Cancer Institute Drug Dictionary (drug name DFP14927).
DMGO4XJ	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pegylated-deoxycytidine-analogue-dfp-14927

DM6OJI1	DI	DM6OJI1
DM6OJI1	DN	DIAPLASININ
DM6OJI1	MI	TTTO43N
DM6OJI1	MN	Endothelial plasminogen activator inhibitor (SERPINE1)
DM6OJI1	MT	DTT
DM6OJI1	MA	Inhibitor
DM6OJI1	RN	Effect of the small molecule plasminogen activator inhibitor-1 (PAI-1) inhibitor, PAI-749, in clinical models of fibrinolysis. J Thromb Haemost. 2010 Jun;8(6):1333-9.
DM6OJI1	RU	https://pubmed.ncbi.nlm.nih.gov/20345708

DMPWOH9	DI	DMPWOH9
DMPWOH9	DN	DKY709
DMPWOH9	MI	TTKT5NV
DMPWOH9	MN	Zinc finger protein Helios (IKZF2)
DMPWOH9	MT	DTT
DMPWOH9	MA	Degrader
DMPWOH9	RN	Targeted protein degraders crowd into the clinic. Nat Rev Drug Discov. 2021 Apr;20(4):247-250.
DMPWOH9	RU	https://pubmed.ncbi.nlm.nih.gov/33737725

DMM8GZT	DI	DMM8GZT
DMM8GZT	DN	DL-017
DMM8GZT	MI	TT34BHT
DMM8GZT	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMM8GZT	MT	DTT
DMM8GZT	MA	Modulator
DMM8GZT	RN	Antihypertensive action and blockade of alpha1-adrenoceptors by DL-017, a quinazoline derivative. J Cardiovasc Pharmacol. 2001 Dec;38(6):893-9.
DMM8GZT	RU	https://pubmed.ncbi.nlm.nih.gov/11707693

DMCT4BA	DI	DMCT4BA
DMCT4BA	DN	DMUC-5754A
DMCT4BA	MI	TTC1PS3
DMCT4BA	MN	Ovarian carcinoma antigen CA125 (MUC16)
DMCT4BA	MT	DTT
DMCT4BA	RN	Maturing antibody-drug conjugate pipeline hits 30. Nat Rev Drug Discov. 2013 May;12(5):329-32.
DMCT4BA	RU	https://pubmed.ncbi.nlm.nih.gov/23629491

DMQFX8R	DI	DMQFX8R
DMQFX8R	DN	DN1406131
DMQFX8R	MI	TTZJYKH
DMQFX8R	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMQFX8R	MT	DTT
DMQFX8R	MA	Inhibitor
DMQFX8R	RN	ClinicalTrials.gov (NCT03641794) Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers. U.S. National Institutes of Health.
DMQFX8R	RU	https://clinicaltrials.gov/ct2/show/NCT03641794

DMQFX8R	DI	DMQFX8R
DMQFX8R	DN	DN1406131
DMQFX8R	MI	TTXNCBV
DMQFX8R	MN	Tryptophan 2,3-dioxygenase (TDO)
DMQFX8R	MT	DTT
DMQFX8R	MA	Inhibitor
DMQFX8R	RN	ClinicalTrials.gov (NCT03641794) Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers. U.S. National Institutes of Health.
DMQFX8R	RU	https://clinicaltrials.gov/ct2/show/NCT03641794

DM0JT9C	DI	DM0JT9C
DM0JT9C	DN	DN1508052
DM0JT9C	MI	TT8CWFK
DM0JT9C	MN	Toll-like receptor 8 (TLR8)
DM0JT9C	MT	DTT
DM0JT9C	MA	Agonist
DM0JT9C	RN	Clinical pipeline report, company report or official report of Shanghai De Novo Pharmatech.
DM0JT9C	RU	http://www.denovo-sh.com/En/technology.aspx?BaseInfoCateID=48&CateID=48

DMOSCQ9	DI	DMOSCQ9
DMOSCQ9	DN	DNL104
DMOSCQ9	MI	TTAIQSN
DMOSCQ9	MN	Receptor-interacting protein 1 (RIPK1)
DMOSCQ9	MT	DTT
DMOSCQ9	MA	Inhibitor
DMOSCQ9	RN	DNL104, a Centrally Penetrant RIPK1 Inhibitor, Inhibits RIP1 Kinase Phosphorylation in a Randomized Phase I Ascending Dose Study in Healthy Volunteers. Clin Pharmacol Ther. 2020 Feb;107(2):406-414.
DMOSCQ9	RU	https://pubmed.ncbi.nlm.nih.gov/31437302

DMZT89C	DI	DMZT89C
DMZT89C	DN	DNL151
DMZT89C	MI	TTK0FEA
DMZT89C	MN	Leucine-rich repeat kinase 2 (LRRK2)
DMZT89C	MT	DTT
DMZT89C	MA	Inhibitor
DMZT89C	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZT89C	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMFEORD	DI	DMFEORD
DMFEORD	DN	DNL201
DMFEORD	MI	TTK0FEA
DMFEORD	MN	Leucine-rich repeat kinase 2 (LRRK2)
DMFEORD	MT	DTT
DMFEORD	MA	Inhibitor
DMFEORD	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMFEORD	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMNSC0O	DI	DMNSC0O
DMNSC0O	DN	DNL747
DMNSC0O	MI	TTAIQSN
DMNSC0O	MN	Receptor-interacting protein 1 (RIPK1)
DMNSC0O	MT	DTT
DMNSC0O	MA	Inhibitor
DMNSC0O	RN	Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target. Nat Rev Drug Discov. 2020 Aug;19(8):553-571.
DMNSC0O	RU	https://pubmed.ncbi.nlm.nih.gov/32669658

DMZS350	DI	DMZS350
DMZS350	DN	Donor-derived CD19/22 bispecific CAR-T cells
DMZS350	MI	TTM6QSK
DMZS350	MN	B-cell receptor CD22 (CD22)
DMZS350	MT	DTT
DMZS350	MA	CAR-T-Cell-Therapy(Dual specific)
DMZS350	RN	ClinicalTrials.gov (NCT03463928) A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia
DMZS350	RU	https://clinicaltrials.gov/ct2/show/NCT03463928

DMZS350	DI	DMZS350
DMZS350	DN	Donor-derived CD19/22 bispecific CAR-T cells
DMZS350	MI	TTW640A
DMZS350	MN	B-lymphocyte surface antigen B4 (CD19)
DMZS350	MT	DTT
DMZS350	MA	CAR-T-Cell-Therapy(Dual specific)
DMZS350	RN	ClinicalTrials.gov (NCT03463928) A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia
DMZS350	RU	https://clinicaltrials.gov/ct2/show/NCT03463928

DMXZ6A0	DI	DMXZ6A0
DMXZ6A0	DN	DP-4088
DMXZ6A0	MI	TT6L509
DMXZ6A0	MN	Coagulation factor IIa (F2)
DMXZ6A0	MT	DTT
DMXZ6A0	MA	Inhibitor
DMXZ6A0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362).
DMXZ6A0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2362

DM4ZDOE	DI	DM4ZDOE
DM4ZDOE	DN	DpC
DM4ZDOE	MI	TTUDR0C
DM4ZDOE	MN	Iron (Fe)
DM4ZDOE	MT	DTT
DM4ZDOE	MA	Chelator
DM4ZDOE	RN	Anticancer Thiosemicarbazones: Chemical Properties, Interaction with Iron Metabolism, and Resistance Development. Antioxid Redox Signal. 2019 Mar 10;30(8):1062-1082.
DM4ZDOE	RU	https://pubmed.ncbi.nlm.nih.gov/29334758

DMJY9TW	DI	DMJY9TW
DMJY9TW	DN	DRF-1042
DMJY9TW	MI	TTGTQHC
DMJY9TW	MN	DNA topoisomerase I (TOP1)
DMJY9TW	MT	DTT
DMJY9TW	MA	Inhibitor
DMJY9TW	RN	Safety, tolerability, and pharmacokinetics of a capsule formulation of DRF-1042, a novel camptothecin analog, in refractory cancer patients in a bridging phase I study. J Clin Pharmacol. 2005 Apr;45(4):453-60.
DMJY9TW	RU	https://pubmed.ncbi.nlm.nih.gov/15778426

DM0DJPE	DI	DM0DJPE
DM0DJPE	DN	Drug 2838232
DM0DJPE	MI	TTMCA52
DM0DJPE	MN	Viral Maturation (VM)
DM0DJPE	MT	DTT
DM0DJPE	MA	Modulator
DM0DJPE	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037762)
DM0DJPE	RU	http://adisinsight.springer.com/drugs/800037762

DMM57CS	DI	DMM57CS
DMM57CS	DN	Drug 2849330
DMM57CS	MI	TTDC8N2
DMM57CS	MN	Erbb3 tyrosine kinase receptor (Erbb-3)
DMM57CS	MT	DTT
DMM57CS	RN	National Cancer Institute Drug Dictionary (drug id 754219).
DMM57CS	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=754219

DMNFEC6	DI	DMNFEC6
DMNFEC6	DN	Drug 2878175
DMNFEC6	MI	TTMVBWH
DMNFEC6	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMNFEC6	MT	DTT
DMNFEC6	MA	Inhibitor
DMNFEC6	RN	P1224 GSK2878175, A POTENT NON-NUCLEOSIDE INHIBITOR OF HCV NS5B WITH PAN-GENOTYPIC ACTIVITY. Journal of Hepatology Volume 60, Issue 1, Supplement, April 2014, Pages S496.
DMNFEC6	RU	http://www.sciencedirect.com/science/article/pii/S0168827814613842

DMWXQC9	DI	DMWXQC9
DMWXQC9	DN	Drug 2881078
DMWXQC9	MI	TTS64P2
DMWXQC9	MN	Androgen receptor (AR)
DMWXQC9	MT	DTT
DMWXQC9	MA	Modulator
DMWXQC9	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039743)
DMWXQC9	RU	http://adisinsight.springer.com/drugs/800039743

DMXCN37	DI	DMXCN37
DMXCN37	DN	DS-1040
DMXCN37	MI	TTP18AY
DMXCN37	MN	Carboxypeptidase B2 (CPB2)
DMXCN37	MT	DTT
DMXCN37	MA	Modulator
DMXCN37	RN	Clinical pipeline report, company report or official report of Daiichi Sankyo.
DMXCN37	RU	http://www.daiichisankyo.com/rd/pipeline/development_pipeline/index.html#details01

DMPR3A6	DI	DMPR3A6
DMPR3A6	DN	DS-1055
DMPR3A6	MI	TT0FAYT
DMPR3A6	MN	Transforming growth factor beta activator LRRC32 (LRRC32)
DMPR3A6	MT	DTT
DMPR3A6	MA	Inhibitor
DMPR3A6	RN	Clinical pipeline report, company report or official report of Daiichi Sankyo.
DMPR3A6	RU	https://www.daiichisankyo.com/media/press_release/detail/index_4081.html

DM42KZW	DI	DM42KZW
DM42KZW	DN	DS-1093
DM42KZW	MI	TTJQFBG
DM42KZW	MN	HIF-prolyl hydroxylase (HPH)
DM42KZW	MT	DTT
DM42KZW	MA	Modulator
DM42KZW	RN	Company report (Daiichisankyo)
DM42KZW	RU	http://www.daiichisankyo.com/rd/pipeline/pdf/Pipeline_EN.pdf

DM029TQ	DI	DM029TQ
DM029TQ	DN	DS-1150b
DM029TQ	MI	TTP6MT5
DM029TQ	MN	Glucose transporter type 4 (SLC2A4)
DM029TQ	MT	DTT
DM029TQ	MA	Modulator
DM029TQ	RN	Sanford-Burnham goes fourth. SciBX 7(22); doi:10.1038/scibx.2014.633. June 5 2014
DM029TQ	RU	http://www.nature.com/scibx/journal/v7/n22/full/scibx.2014.633.html

DMXST9F	DI	DMXST9F
DMXST9F	DN	DS-1205
DMXST9F	MI	TTZPY6J
DMXST9F	MN	Tyrosine-protein kinase UFO (AXL)
DMXST9F	MT	DTT
DMXST9F	MA	Inhibitor
DMXST9F	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMXST9F	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMNDGPT	DI	DMNDGPT
DMNDGPT	DN	DS-2969
DMNDGPT	MI	TTPBZUO
DMNDGPT	MN	Clostridium difficile DNA gyrase (CD gyr)
DMNDGPT	MT	DTT
DMNDGPT	MA	Inhibitor
DMNDGPT	RN	In Vitro and In Vivo Activities of DS-2969b, a Novel GyrB Inhibitor, against Clostridium difficile. Antimicrob Agents Chemother. 2018 Mar 27;62(4):e02157-17.
DMNDGPT	RU	https://pubmed.ncbi.nlm.nih.gov/29439962

DMA2B5Y	DI	DMA2B5Y
DMA2B5Y	DN	DS-3032
DMA2B5Y	MI	TT08GJW
DMA2B5Y	MN	Ubiquitin-protein ligase E3 Mdm2 (MDM2)
DMA2B5Y	MT	DTT
DMA2B5Y	MA	Inhibitor
DMA2B5Y	RN	Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov. 2014 Mar;13(3):217-36. 
DMA2B5Y	RU	https://pubmed.ncbi.nlm.nih.gov/24577402

DMG7I5J	DI	DMG7I5J
DMG7I5J	DN	DS-3078
DMG7I5J	MI	TTCJG29
DMG7I5J	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMG7I5J	MT	DTT
DMG7I5J	MA	Modulator
DMG7I5J	RN	A first-in-human Phase I study of DS-3078a, an oral TORC1/2 inhibitor, in patients with advanced solid tumors: Preliminary results, Mol Cancer Ther November,2013, 12, C173.
DMG7I5J	RU	http://mct.aacrjournals.org/content/12/11_Supplement/C173.abstract 

DMRLPFG	DI	DMRLPFG
DMRLPFG	DN	DS-3201
DMRLPFG	MI	TTNJA0C
DMRLPFG	MN	Enhancer of zeste homolog 1 (EZH1)
DMRLPFG	MT	DTT
DMRLPFG	MA	Inhibitor
DMRLPFG	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMRLPFG	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMRLPFG	DI	DMRLPFG
DMRLPFG	DN	DS-3201
DMRLPFG	MI	TT9MZCQ
DMRLPFG	MN	Enhancer of zeste homolog 2 (EZH2)
DMRLPFG	MT	DTT
DMRLPFG	MA	Inhibitor
DMRLPFG	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMRLPFG	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM6WN9X	DI	DM6WN9X
DM6WN9X	DN	DS-3801
DM6WN9X	MI	TT953CX
DM6WN9X	MN	Motilin receptor (MLNR)
DM6WN9X	MT	DTT
DM6WN9X	MA	Agonist
DM6WN9X	RN	Clinical pipeline report, company report or official report of Daiichi Sankyo.
DM6WN9X	RU	http://www.daiichisankyo.com/rd/pipeline/pdf/Pipeline_EN.pdf

DM0RD4F	DI	DM0RD4F
DM0RD4F	DN	DS-6051
DM0RD4F	MI	TTSZ6Y3
DM0RD4F	MN	Proto-oncogene c-Ros (ROS1)
DM0RD4F	MT	DTT
DM0RD4F	MA	Inhibitor
DM0RD4F	RN	National Cancer Institute Drug Dictionary (drug id 766123).
DM0RD4F	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=766123

DM0RD4F	DI	DM0RD4F
DM0RD4F	DN	DS-6051
DM0RD4F	MI	TTTDVOJ
DM0RD4F	MN	Tropomyosin-related kinase A (TrkA)
DM0RD4F	MT	DTT
DM0RD4F	MA	Inhibitor
DM0RD4F	RN	National Cancer Institute Drug Dictionary (drug id 766123).
DM0RD4F	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=766123

DMTKZ1Q	DI	DMTKZ1Q
DMTKZ1Q	DN	DS-6157
DMTKZ1Q	MI	TTGTQHC
DMTKZ1Q	MN	DNA topoisomerase I (TOP1)
DMTKZ1Q	MT	DTT
DMTKZ1Q	MA	Inhibitor
DMTKZ1Q	RN	Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody-Drug Conjugate. Cancer Discov. 2021 Jun;11(6):1508-1523.
DMTKZ1Q	RU	https://pubmed.ncbi.nlm.nih.gov/33579785

DMTKZ1Q	DI	DMTKZ1Q
DMTKZ1Q	DN	DS-6157
DMTKZ1Q	MI	TT26C7Z
DMTKZ1Q	MN	G-protein coupled receptor 20 (GPR20)
DMTKZ1Q	MT	DTT
DMTKZ1Q	MA	Inhibitor
DMTKZ1Q	RN	Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody-Drug Conjugate. Cancer Discov. 2021 Jun;11(6):1508-1523.
DMTKZ1Q	RU	https://pubmed.ncbi.nlm.nih.gov/33579785

DM7C4U9	DI	DM7C4U9
DM7C4U9	DN	DS-7309
DM7C4U9	MI	TTDLNGZ
DM7C4U9	MN	Glucokinase (GCK)
DM7C4U9	MT	DTT
DM7C4U9	MA	Inhibitor
DM7C4U9	RN	Glucokinase alternative. SciBX 6(45); doi:10.1038/scibx.2013.1279. Nov. 21 2013
DM7C4U9	RU	http://www.nature.com/scibx/journal/v6/n45/full/scibx.2013.1279.html

DMCFJM3	DI	DMCFJM3
DMCFJM3	DN	DS-7423
DMCFJM3	MI	TTHBTOP
DMCFJM3	MN	PI3-kinase gamma (PIK3CG)
DMCFJM3	MT	DTT
DMCFJM3	MA	Modulator
DMCFJM3	RN	Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423. PLoS One. 2014 Feb 4;9(2):e87220.
DMCFJM3	RU	https://pubmed.ncbi.nlm.nih.gov/24504419

DMCFJM3	DI	DMCFJM3
DMCFJM3	DN	DS-7423
DMCFJM3	MI	TTCJG29
DMCFJM3	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMCFJM3	MT	DTT
DMCFJM3	MA	Modulator
DMCFJM3	RN	Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423. PLoS One. 2014 Feb 4;9(2):e87220.
DMCFJM3	RU	https://pubmed.ncbi.nlm.nih.gov/24504419

DMJPUDW	DI	DMJPUDW
DMJPUDW	DN	DS-8273
DMJPUDW	MI	TTW20TU
DMJPUDW	MN	TRAIL receptor 2 (TRAIL-R2)
DMJPUDW	MT	DTT
DMJPUDW	MA	Agonist
DMJPUDW	RN	First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors. Invest New Drugs. 2017 Jun;35(3):298-306.
DMJPUDW	RU	https://pubmed.ncbi.nlm.nih.gov/28050790

DM31VNC	DI	DM31VNC
DM31VNC	DN	DS-8895
DM31VNC	MI	TTRJB2G
DM31VNC	MN	Ephrin type-A receptor 2 (EPHA2)
DM31VNC	MT	DTT
DM31VNC	RN	Clinical pipeline report, company report or official report of Daiichi Sankyo.
DM31VNC	RU	http://www.daiichisankyo.com/rd/pipeline/pdf/Pipeline_EN.pdf

DM4ZCY0	DI	DM4ZCY0
DM4ZCY0	DN	DSP-0337
DM4ZCY0	MI	TTH8FZW
DM4ZCY0	MN	Signal transducer and activator of transcription 3 (STAT3)
DM4ZCY0	MT	DTT
DM4ZCY0	MA	Inhibitor
DM4ZCY0	RN	Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells. J Exp Clin Cancer Res. 2019 Jul 5;38(1):289.
DM4ZCY0	RU	https://pubmed.ncbi.nlm.nih.gov/31277685

DMY95MZ	DI	DMY95MZ
DMY95MZ	DN	DSP-0565
DMY95MZ	MI	TT5HONZ
DMY95MZ	MN	Calcium channel unspecific (CaC)
DMY95MZ	MT	DTT
DMY95MZ	MA	Modulator
DMY95MZ	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035668)
DMY95MZ	RU	http://adisinsight.springer.com/drugs/800035668

DMJDP0E	DI	DMJDP0E
DMJDP0E	DN	DSP-1053
DMJDP0E	MI	TTSQIFT
DMJDP0E	MN	5-HT 1A receptor (HTR1A)
DMJDP0E	MT	DTT
DMJDP0E	MA	Antagonist
DMJDP0E	RN	DSP-1053, a novel serotonin reuptake inhibitor with 5-HT1A partial agonistic activity, displays fast antidepressant effect with minimal undesirable effects in juvenile rats. Pharmacol Res Perspect. 2015 Jun;3(3):e00142.
DMJDP0E	RU	https://pubmed.ncbi.nlm.nih.gov/26171224

DM4WSHG	DI	DM4WSHG
DM4WSHG	DN	DSP-1200
DM4WSHG	MI	TTJQOD7
DM4WSHG	MN	5-HT 2A receptor (HTR2A)
DM4WSHG	MT	DTT
DM4WSHG	MA	Antagonist
DM4WSHG	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM4WSHG	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DM4WSHG	DI	DM4WSHG
DM4WSHG	DN	DSP-1200
DM4WSHG	MI	TTWG9A4
DM4WSHG	MN	Adrenergic receptor alpha-2A (ADRA2A)
DM4WSHG	MT	DTT
DM4WSHG	MA	Antagonist
DM4WSHG	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM4WSHG	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DM4WSHG	DI	DM4WSHG
DM4WSHG	DN	DSP-1200
DM4WSHG	MI	TTEX248
DM4WSHG	MN	Dopamine D2 receptor (D2R)
DM4WSHG	MT	DTT
DM4WSHG	MA	Antagonist
DM4WSHG	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM4WSHG	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DM0WTMD	DI	DM0WTMD
DM0WTMD	DN	DSP-2230
DM0WTMD	MI	TT4G2JS
DM0WTMD	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DM0WTMD	MT	DTT
DM0WTMD	MA	Inhibitor
DM0WTMD	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DM0WTMD	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DM0WTMD	DI	DM0WTMD
DM0WTMD	DN	DSP-2230
DM0WTMD	MI	TT90XZ8
DM0WTMD	MN	Voltage-gated sodium channel alpha Nav1.8 (SCN10A)
DM0WTMD	MT	DTT
DM0WTMD	MA	Inhibitor
DM0WTMD	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DM0WTMD	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMYHU24	DI	DMYHU24
DMYHU24	DN	DSP-3905
DMYHU24	MI	TT4G2JS
DMYHU24	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DMYHU24	MT	DTT
DMYHU24	MA	Inhibitor
DMYHU24	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMYHU24	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMM86OH	DI	DMM86OH
DMM86OH	DN	DSP-6745
DMM86OH	MI	TT85JO3
DMM86OH	MN	5-HT receptor (5HTR)
DMM86OH	MT	DTT
DMM86OH	MA	Antagonist
DMM86OH	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMM86OH	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM2PYE0	DI	DM2PYE0
DM2PYE0	DN	DSP-8658
DM2PYE0	MI	TTZMAO3
DM2PYE0	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DM2PYE0	MT	DTT
DM2PYE0	MA	Modulator
DM2PYE0	RN	Effects of DSP-8658, a Novel Selective Peroxisome Proliferator-activated Receptors a/gamma Modulator, on Adipogenesis and Glucose Metabolism in Diabetic Obese Mice. Exp Clin Endocrinol Diabetes. 2015Sep;123(8):492-9.
DM2PYE0	RU	https://pubmed.ncbi.nlm.nih.gov/26011171

DM69ZBU	DI	DM69ZBU
DM69ZBU	DN	DST-2970
DM69ZBU	MI	TTRA5BZ
DM69ZBU	MN	Steroid 17-alpha-monooxygenase (S17AH)
DM69ZBU	MT	DTT
DM69ZBU	MA	Inhibitor
DM69ZBU	RN	Clinical pipeline report, company report or official report of DisperSol Technologies.
DM69ZBU	RU	https://www.dispersoltech.com/pipeline/

DMYFOJQ	DI	DMYFOJQ
DMYFOJQ	DN	DT-200
DMYFOJQ	MI	TTS64P2
DMYFOJQ	MN	Androgen receptor (AR)
DMYFOJQ	MT	DTT
DMYFOJQ	MA	Modulator
DMYFOJQ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMYFOJQ	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM5AGKV	DI	DM5AGKV
DM5AGKV	DN	DTRMWXHS-12
DM5AGKV	MI	TTGM6VW
DM5AGKV	MN	Tyrosine-protein kinase BTK (ATK)
DM5AGKV	MT	DTT
DM5AGKV	MA	Inhibitor
DM5AGKV	RN	ClinicalTrials.gov (NCT02900716) Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas. U.S. National Institutes of Health.
DM5AGKV	RU	https://clinicaltrials.gov/ct2/show/NCT02900716

DM1FX09	DI	DM1FX09
DM1FX09	DN	DT-TX-30
DM1FX09	MI	TT2O84V
DM1FX09	MN	Thromboxane A2 receptor (TBXA2R)
DM1FX09	MT	DTT
DM1FX09	MA	Antagonist
DM1FX09	RN	DTTX30, a combined thromboxane receptor antagonist and thromboxane synthetase inhibitor, prevents coronary thrombosis in anesthetized dogs. Basic Res Cardiol. 1997 Jun;92(3):181-90.
DM1FX09	RU	https://pubmed.ncbi.nlm.nih.gov/9226103

DM8WBNF	DI	DM8WBNF
DM8WBNF	DN	DTX401
DM8WBNF	MI	TTBQMJ8
DM8WBNF	MN	Glucose-6-phosphatase (G6PC)
DM8WBNF	MT	DTT
DM8WBNF	MA	Replacement
DM8WBNF	RN	Clinical pipeline report, company report or official report of Ultragenyx Pharmaceutical.
DM8WBNF	RU	https://www.ultragenyx.com/pipeline/dtx-401-for-gsd1a/

DM3P0H1	DI	DM3P0H1
DM3P0H1	DN	Duvortuxizumab
DM3P0H1	MI	TTW640A
DM3P0H1	MN	B-lymphocyte surface antigen B4 (CD19)
DM3P0H1	MT	DTT
DM3P0H1	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3P0H1	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMDSVRP	DI	DMDSVRP
DMDSVRP	DN	DV-1179
DMDSVRP	MI	TTRJ1K4
DMDSVRP	MN	Toll-like receptor 7 (TLR7)
DMDSVRP	MT	DTT
DMDSVRP	MA	Modulator
DMDSVRP	RN	Company report (Dynavax)
DMDSVRP	RU	http://www.dynavax.com/our-pipeline/immune-mediated-diseases/dv1179/

DMDSVRP	DI	DMDSVRP
DMDSVRP	DN	DV-1179
DMDSVRP	MI	TTSHG0T
DMDSVRP	MN	Toll-like receptor 9 (TLR9)
DMDSVRP	MT	DTT
DMDSVRP	MA	Modulator
DMDSVRP	RN	Company report (Dynavax)
DMDSVRP	RU	http://www.dynavax.com/our-pipeline/immune-mediated-diseases/dv1179/

DMJ0Y86	DI	DMJ0Y86
DMJ0Y86	DN	DV281
DMJ0Y86	MI	TTSHG0T
DMJ0Y86	MN	Toll-like receptor 9 (TLR9)
DMJ0Y86	MT	DTT
DMJ0Y86	MA	Agonist
DMJ0Y86	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMJ0Y86	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMQKDJZ	DI	DMQKDJZ
DMQKDJZ	DN	DWJ-208
DMQKDJZ	MI	TT4G2JS
DMQKDJZ	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DMQKDJZ	MT	DTT
DMQKDJZ	MA	Antagonist
DMQKDJZ	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMQKDJZ	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DM4XZY9	DI	DM4XZY9
DM4XZY9	DN	DWP-09031
DM4XZY9	MI	TTE4KHA
DM4XZY9	MN	Amyloid beta A4 protein (APP)
DM4XZY9	MT	DTT
DM4XZY9	MA	Inhibitor
DM4XZY9	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
DM4XZY9	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402

DMS1NC8	DI	DMS1NC8
DMS1NC8	DN	DZ-2640
DMS1NC8	MI	TTJP4SM
DMS1NC8	MN	Bacterial Penicillin binding protein (Bact PBP)
DMS1NC8	MT	DTT
DMS1NC8	MA	Modulator
DMS1NC8	RN	In vitro activity of DU-6681a, an active form of the new oral carbapenem compound DZ-2640, in comparison with that of R-95867, faropenem and oral cephalosporins. J Antimicrob Chemother. 2000 Jul;46(1):101-8.
DMS1NC8	RU	https://pubmed.ncbi.nlm.nih.gov/10882697

DMEQY4Z	DI	DMEQY4Z
DMEQY4Z	DN	DZD1516
DMEQY4Z	MI	TT6EO5L
DMEQY4Z	MN	Erbb2 tyrosine kinase receptor (HER2)
DMEQY4Z	MT	DTT
DMEQY4Z	MA	Inhibitor
DMEQY4Z	RN	ClinicalTrials.gov (NCT04509596) DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer. U.S. National Institutes of Health.
DMEQY4Z	RU	https://clinicaltrials.gov/ct2/show/NCT04509596

DM3LOF1	DI	DM3LOF1
DM3LOF1	DN	E 7974
DM3LOF1	MI	TTML2WA
DM3LOF1	MN	Tubulin (TUB)
DM3LOF1	MT	DTT
DM3LOF1	MA	Inhibitor
DM3LOF1	RN	Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.
DM3LOF1	RU	https://pubmed.ncbi.nlm.nih.gov/18764727

DMNEVKA	DI	DMNEVKA
DMNEVKA	DN	E2012
DMNEVKA	MI	TT9W8GU
DMNEVKA	MN	Gamma-secretase (GS)
DMNEVKA	MT	DTT
DMNEVKA	MA	Modulator
DMNEVKA	RN	Chemical Biology, Molecular Mechanism and Clinical Perspective of -Secretase Modulators in Alzheimer's Disease.Curr Neuropharmacol.2011 Dec;9(4):598-622.
DMNEVKA	RU	https://www.ncbi.nlm.nih.gov/pubmed/22798753

DMQDKYV	DI	DMQDKYV
DMQDKYV	DN	E-2212
DMQDKYV	MI	TT9W8GU
DMQDKYV	MN	Gamma-secretase (GS)
DMQDKYV	MT	DTT
DMQDKYV	MA	Modulator
DMQDKYV	RN	Development and mechanism of gamma-secretase modulators for Alzheimer's disease. Biochemistry. 2013 May 14;52(19):3197-216.
DMQDKYV	RU	https://pubmed.ncbi.nlm.nih.gov/23614767

DM4BD5U	DI	DM4BD5U
DM4BD5U	DN	E2730
DM4BD5U	MI	TTPW8EF
DM4BD5U	MN	Synaptic transmission (ST)
DM4BD5U	MT	DTT
DM4BD5U	MA	Modulator
DM4BD5U	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM4BD5U	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMFVT43	DI	DMFVT43
DMFVT43	DN	E7046
DMFVT43	MI	TT79WV3
DMFVT43	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DMFVT43	MT	DTT
DMFVT43	MA	Antagonist
DMFVT43	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMFVT43	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMDOCNW	DI	DMDOCNW
DMDOCNW	DN	E-7050
DMDOCNW	MI	TTNDSF4
DMDOCNW	MN	Proto-oncogene c-Met (MET)
DMDOCNW	MT	DTT
DMDOCNW	MA	Modulator
DMDOCNW	RN	E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models. Cancer Sci. 2010 Jan;101(1):210-5.
DMDOCNW	RU	https://pubmed.ncbi.nlm.nih.gov/19832844

DMDOCNW	DI	DMDOCNW
DMDOCNW	DN	E-7050
DMDOCNW	MI	TTUTJGQ
DMDOCNW	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMDOCNW	MT	DTT
DMDOCNW	MA	Modulator
DMDOCNW	RN	E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models. Cancer Sci. 2010 Jan;101(1):210-5.
DMDOCNW	RU	https://pubmed.ncbi.nlm.nih.gov/19832844

DM8TU5R	DI	DM8TU5R
DM8TU5R	DN	E7766
DM8TU5R	MI	TTT402Y
DM8TU5R	MN	Stimulator of interferon genes protein (TMEM173)
DM8TU5R	MT	DTT
DM8TU5R	MA	Agonist
DM8TU5R	RN	E7766, a Macrocycle-Bridged Stimulator of Interferon Genes (STING) Agonist with Potent Pan-Genotypic Activity. ChemMedChem. 2021 Jun 7;16(11):1740-1743.
DM8TU5R	RU	https://pubmed.ncbi.nlm.nih.gov/33522135

DM8RD4T	DI	DM8RD4T
DM8RD4T	DN	EC0489
DM8RD4T	MI	TTVC37M
DM8RD4T	MN	Folate receptor alpha (FOLR1)
DM8RD4T	MT	DTT
DM8RD4T	MA	Modulator
DM8RD4T	RN	National Cancer Institute Drug Dictionary (drug id 638649).
DM8RD4T	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=638649

DMXW07J	DI	DMXW07J
DMXW07J	DN	EDP-239
DMXW07J	MI	TTCJ2X8
DMXW07J	MN	Hepatitis C virus Non-structural 5A (HCV NS5A)
DMXW07J	MT	DTT
DMXW07J	MA	Modulator
DMXW07J	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMXW07J	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMWTVM1	DI	DMWTVM1
DMWTVM1	DN	EDP-322
DMWTVM1	MI	TT3OT40
DMWTVM1	MN	Multidrug resistance protein 1 (ABCB1)
DMWTVM1	MT	DTT
DMWTVM1	MA	Inhibitor
DMWTVM1	RN	In vitro activities of the novel bicyclolides modithromycin (EDP-420, EP-013420, S-013420) and EDP-322 against MDR clinical Neisseria gonorrhoeae isolates and international reference strains. J Antimicrob Chemother. 2015 Jan;70(1):173-7.
DMWTVM1	RU	https://pubmed.ncbi.nlm.nih.gov/25182063

DM8KRA3	DI	DM8KRA3
DM8KRA3	DN	EDP-514
DM8KRA3	MI	TTM42UJ
DM8KRA3	MN	Hepatitis B virus Capsid protein (HBV C)
DM8KRA3	MT	DTT
DM8KRA3	MA	Inhibitor
DM8KRA3	RN	Clinical pipeline report, company report or official report of Enanta Pharmaceuticals.
DM8KRA3	RU	https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Clinical-Trial-Progress-for-EDP-514-its-Lead-Core-Inhibitor-for-Hepatitis-B-Virus/default.aspx

DM3AD65	DI	DM3AD65
DM3AD65	DN	EGFR806-specific CAR T cell
DM3AD65	MI	TTGKNB4
DM3AD65	MN	Epidermal growth factor receptor (EGFR)
DM3AD65	MT	DTT
DM3AD65	MA	CAR-T-Cell-Therapy
DM3AD65	RN	ClinicalTrials.gov (NCT03638167) EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors
DM3AD65	RU	https://clinicaltrials.gov/ct2/show/NCT03638167

DMZN35T	DI	DMZN35T
DMZN35T	DN	EGFRt/19-28z/4-1BBL CAR T cells
DMZN35T	MI	TTW640A
DMZN35T	MN	B-lymphocyte surface antigen B4 (CD19)
DMZN35T	MT	DTT
DMZN35T	MA	CAR-T-Cell-Therapy
DMZN35T	RN	ClinicalTrials.gov (NCT03085173) A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies
DMZN35T	RU	https://clinicaltrials.gov/ct2/show/NCT03085173

DM6XWV4	DI	DM6XWV4
DM6XWV4	DN	EGFRvIII CAR T cells
DM6XWV4	MI	TTZ6B2I
DM6XWV4	MN	Epidermal growth factor receptor variant III (EGFR vIII)
DM6XWV4	MT	DTT
DM6XWV4	MA	CAR-T-Cell-Therapy
DM6XWV4	RN	ClinicalTrials.gov (NCT02664363) EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma
DM6XWV4	RU	https://clinicaltrials.gov/ct2/show/NCT02664363

DMA46RN	DI	DMA46RN
DMA46RN	DN	EGFRvIII-CARs
DMA46RN	MI	TTZ6B2I
DMA46RN	MN	Epidermal growth factor receptor variant III (EGFR vIII)
DMA46RN	MT	DTT
DMA46RN	MA	CAR-T-Cell-Therapy
DMA46RN	RN	ClinicalTrials.gov (NCT03283631) Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM
DMA46RN	RU	https://clinicaltrials.gov/ct2/show/NCT03283631

DMDPGCS	DI	DMDPGCS
DMDPGCS	DN	EGT-0001474
DMDPGCS	MI	TTLWPVF
DMDPGCS	MN	Sodium/glucose cotransporter 2 (SGLT2)
DMDPGCS	MT	DTT
DMDPGCS	MA	Modulator
DMDPGCS	RN	PhRMA report
DMDPGCS	RU	http://www.phrma.org/sites/default/files/pdf/diabetes2012.pdf

DMXAUB7	DI	DMXAUB7
DMXAUB7	DN	EI1071
DMXAUB7	MI	TT7MRDV
DMXAUB7	MN	Macrophage colony-stimulating factor 1 receptor (CSF1R)
DMXAUB7	MT	DTT
DMXAUB7	MA	Inhibitor
DMXAUB7	RN	Clinical pipeline report, company report or official report of Elixiron Immunotherapeutics.
DMXAUB7	RU	https://www.elixiron.com/

DMA4BRV	DI	DMA4BRV
DMA4BRV	DN	Elinogrel
DMA4BRV	MI	TTZ1DT0
DMA4BRV	MN	P2Y purinoceptor 12 (P2RY12)
DMA4BRV	MT	DTT
DMA4BRV	MA	Antagonist
DMA4BRV	RN	Elinogrel, a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events. Curr Opin Investig Drugs. 2010 Mar;11(3):340-8.
DMA4BRV	RU	https://pubmed.ncbi.nlm.nih.gov/20178048

DMM9S51	DI	DMM9S51
DMM9S51	DN	ELND-002
DMM9S51	MI	TT4BT06
DMM9S51	MN	Integrin alpha-4 (ITGA4)
DMM9S51	MT	DTT
DMM9S51	MA	Antagonist
DMM9S51	RN	Paxillin binding to the alpha 4 integrin subunit stimulates LFA-1 (integrin alpha L beta 2)-dependent T cell migration by augmenting the activation of focal adhesion kinase/proline-rich tyrosine kinase-2. J Immunol. 2003 Jun 15;170(12):5912-8.
DMM9S51	RU	https://pubmed.ncbi.nlm.nih.gov/12794117

DMLQYVD	DI	DMLQYVD
DMLQYVD	DN	ELND-004
DMLQYVD	MI	TT4BT06
DMLQYVD	MN	Integrin alpha-4 (ITGA4)
DMLQYVD	MT	DTT
DMLQYVD	MA	Inhibitor
DMLQYVD	RN	Paxillin binding to the alpha 4 integrin subunit stimulates LFA-1 (integrin alpha L beta 2)-dependent T cell migration by augmenting the activation of focal adhesion kinase/proline-rich tyrosine kinase-2. J Immunol. 2003 Jun 15;170(12):5912-8.
DMLQYVD	RU	https://pubmed.ncbi.nlm.nih.gov/12794117

DMQPI4V	DI	DMQPI4V
DMQPI4V	DN	ELOMOTECAN HYDROCHLORIDE
DMQPI4V	MI	TTGTQHC
DMQPI4V	MN	DNA topoisomerase I (TOP1)
DMQPI4V	MT	DTT
DMQPI4V	MA	Modulator
DMQPI4V	RN	The dual topoisomerase inhibitor, BN 80927, is highly potent against cell proliferation and tumor growth. Ann N Y Acad Sci. 2000;922:303-5.
DMQPI4V	RU	https://www.ncbi.nlm.nih.gov/pubmed/11193907

DMIV04R	DI	DMIV04R
DMIV04R	DN	Elpetrigine
DMIV04R	MI	TT5HONZ
DMIV04R	MN	Calcium channel unspecific (CaC)
DMIV04R	MT	DTT
DMIV04R	MA	Blocker
DMIV04R	RN	Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
DMIV04R	RU	http://www.jazzpharma.com/products/

DM4W7Z0	DI	DM4W7Z0
DM4W7Z0	DN	Emactuzumab
DM4W7Z0	MI	TT0IQER
DM4W7Z0	MN	Macrophage colony-stimulating factor 1 (CSF1)
DM4W7Z0	MT	DTT
DM4W7Z0	MA	Antagonist
DM4W7Z0	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM4W7Z0	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM6AMKZ	DI	DM6AMKZ
DM6AMKZ	DN	Embeconazole
DM6AMKZ	MI	TTTSOUD
DM6AMKZ	MN	Candida Cytochrome P450 51 (Candi ERG11)
DM6AMKZ	MT	DTT
DM6AMKZ	MA	Inhibitor
DM6AMKZ	RN	CS-758. Antifungal lanosterol 14alpha-demethylase inhibitor, 003, vol28, no3, 217-223.
DM6AMKZ	RU	http://cat.inist.fr/?aModele=afficheN&cpsidt=14796964

DM38JZU	DI	DM38JZU
DM38JZU	DN	EMD-1204831
DM38JZU	MI	TTNDSF4
DM38JZU	MN	Proto-oncogene c-Met (MET)
DM38JZU	MT	DTT
DM38JZU	MA	Inhibitor
DM38JZU	RN	2012 ASCO Annual Meeting.
DM38JZU	RU	http://meetinglibrary.asco.org/subcategories/2012%20ASCO%20Annual%20Meeting

DMQ6YAZ	DI	DMQ6YAZ
DMQ6YAZ	DN	EMD-534085
DMQ6YAZ	MI	TTBGTCW
DMQ6YAZ	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DMQ6YAZ	MT	DTT
DMQ6YAZ	MA	Inhibitor
DMQ6YAZ	RN	The discovery and optimization of hexahydro-2H-pyrano[3,2-c]quinolines (HHPQs) as potent and selective inhibitors of the mitotic kinesin-5. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1491-5.
DMQ6YAZ	RU	https://pubmed.ncbi.nlm.nih.gov/20149654

DMBIPQL	DI	DMBIPQL
DMBIPQL	DN	Enavatuzumab
DMBIPQL	MI	TTKPS7V
DMBIPQL	MN	TNF superfamily receptor 12A (TNFRSF12A)
DMBIPQL	MT	DTT
DMBIPQL	RN	Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb. J Cancer Res Clin Oncol. 2013 Feb;139(2):315-25.
DMBIPQL	RU	https://pubmed.ncbi.nlm.nih.gov/23073510

DMKPBVX	DI	DMKPBVX
DMKPBVX	DN	Englitazone sodium
DMKPBVX	MI	TTZMAO3
DMKPBVX	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMKPBVX	MT	DTT
DMKPBVX	MA	Agonist
DMKPBVX	RN	PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy. Int J Obes Relat Metab Disord. 2003 Feb;27(2):147-61.
DMKPBVX	RU	https://pubmed.ncbi.nlm.nih.gov/12586994

DMGLHYU	DI	DMGLHYU
DMGLHYU	DN	Enkastim-ev
DMGLHYU	MI	TTHYBIX
DMGLHYU	MN	Heat shock protein 70 (HSP70)
DMGLHYU	MT	DTT
DMGLHYU	MA	Modulator
DMGLHYU	RN	Company report (Multimmune)
DMGLHYU	RU	http://www.multimmune.com/mi-THERAPEUTICS-PIPELINE/

DM9BJ3G	DI	DM9BJ3G
DM9BJ3G	DN	ENMD-1198
DM9BJ3G	MI	TTQHWNA
DM9BJ3G	MN	Hypoxia-inducible factor 1 alpha (HIF-1A)
DM9BJ3G	MT	DTT
DM9BJ3G	MA	Inhibitor
DM9BJ3G	RN	ENMD-1198, a new analogue of 2-methoxyestradiol, displays both antiangiogenic and vascular-disrupting properties. Mol Cancer Ther. 2010 May;9(5):1408-18.
DM9BJ3G	RU	https://pubmed.ncbi.nlm.nih.gov/20442304

DMMJXAR	DI	DMMJXAR
DMMJXAR	DN	Entolimod
DMMJXAR	MI	TTCXP8J
DMMJXAR	MN	Toll-like receptor 5 (TLR5)
DMMJXAR	MT	DTT
DMMJXAR	MA	Agonist
DMMJXAR	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMMJXAR	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMQ6GUY	DI	DMQ6GUY
DMQ6GUY	DN	EOS100850
DMQ6GUY	MI	TTM2AOE
DMQ6GUY	MN	Adenosine A2a receptor (ADORA2A)
DMQ6GUY	MT	DTT
DMQ6GUY	MA	Antagonist
DMQ6GUY	RN	National Cancer Institute Drug Dictionary (drug name EOS100850).
DMQ6GUY	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/a2a-receptor-antagonist-eos100850

DMKR3GD	DI	DMKR3GD
DMKR3GD	DN	EP-42675
DMKR3GD	MI	TT6L509
DMKR3GD	MN	Coagulation factor IIa (F2)
DMKR3GD	MT	DTT
DMKR3GD	MA	Modulator
DMKR3GD	RN	EP42675, a synthetic parenteral dual-action anticoagulant: pharmacokinetics, pharmacodynamics, and absence of interactions with antiplatelet drugs. J Thromb Haemost. 2014 Jan;12(1):24-33.
DMKR3GD	RU	https://pubmed.ncbi.nlm.nih.gov/24237610

DMKR3GD	DI	DMKR3GD
DMKR3GD	DN	EP-42675
DMKR3GD	MI	TTCIHJA
DMKR3GD	MN	Coagulation factor Xa (F10)
DMKR3GD	MT	DTT
DMKR3GD	MA	Modulator
DMKR3GD	RN	EP42675, a synthetic parenteral dual-action anticoagulant: pharmacokinetics, pharmacodynamics, and absence of interactions with antiplatelet drugs. J Thromb Haemost. 2014 Jan;12(1):24-33.
DMKR3GD	RU	https://pubmed.ncbi.nlm.nih.gov/24237610

DM49RI7	DI	DM49RI7
DM49RI7	DN	EP-51216
DM49RI7	MI	TTKMAZ6
DM49RI7	MN	Growth hormone receptor (GHR)
DM49RI7	MT	DTT
DM49RI7	MA	Agonist
DM49RI7	RN	Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36.
DM49RI7	RU	https://pubmed.ncbi.nlm.nih.gov/16634704

DMW739O	DI	DMW739O
DMW739O	DN	EP-51389
DMW739O	MI	TTKMAZ6
DMW739O	MN	Growth hormone receptor (GHR)
DMW739O	MT	DTT
DMW739O	MA	Agonist
DMW739O	RN	Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36.
DMW739O	RU	https://pubmed.ncbi.nlm.nih.gov/16634704

DMV0MHI	DI	DMV0MHI
DMV0MHI	DN	EP-7041
DMV0MHI	MI	TTJCPUT
DMV0MHI	MN	Coagulation factor XI (F11)
DMV0MHI	MT	DTT
DMV0MHI	MA	Inhibitor
DMV0MHI	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMV0MHI	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMUFN29	DI	DMUFN29
DMUFN29	DN	EPI-7386
DMUFN29	MI	TTS64P2
DMUFN29	MN	Androgen receptor (AR)
DMUFN29	MT	DTT
DMUFN29	MA	Inhibitor
DMUFN29	RN	Clinical pipeline report, company report or official report of ESSA Pharma.
DMUFN29	RU	https://www.essapharma.com/pipeline/

DMAQYRL	DI	DMAQYRL
DMAQYRL	DN	Eptacog alfa
DMAQYRL	MI	TTF0EGX
DMAQYRL	MN	Coagulation factor VII (F7)
DMAQYRL	MT	DTT
DMAQYRL	MA	Modulator
DMAQYRL	RN	Recombinant factor VIIa (eptacog alfa): a review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders. BioDrugs. 2008;22(2):121-36.
DMAQYRL	RU	https://pubmed.ncbi.nlm.nih.gov/18345709

DMXI9P4	DI	DMXI9P4
DMXI9P4	DN	EPX-100
DMXI9P4	MI	TT85JO3
DMXI9P4	MN	5-HT receptor (5HTR)
DMXI9P4	MT	DTT
DMXI9P4	MA	Modulator
DMXI9P4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMXI9P4	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMKMR2X	DI	DMKMR2X
DMKMR2X	DN	ERB-257
DMKMR2X	MI	TTOM3J0
DMKMR2X	MN	Estrogen receptor beta (ESR2)
DMKMR2X	MT	DTT
DMKMR2X	MA	Agonist
DMKMR2X	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030075)
DMKMR2X	RU	http://adisinsight.springer.com/drugs/800030075

DM9YNTO	DI	DM9YNTO
DM9YNTO	DN	ERY974
DM9YNTO	MI	TTJTSX4
DM9YNTO	MN	Glypican-3 (GPC3)
DM9YNTO	MT	DTT
DM9YNTO	MA	Inhibitor
DM9YNTO	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9YNTO	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMY0HU6	DI	DMY0HU6
DMY0HU6	DN	ETC-1922159
DMY0HU6	MI	TTNFBTO
DMY0HU6	MN	Protein-serine O-palmitoleoyltransferase porcupine (PORCN)
DMY0HU6	MT	DTT
DMY0HU6	MA	Inhibitor
DMY0HU6	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMY0HU6	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMS436I	DI	DMS436I
DMS436I	DN	ETX201
DMS436I	MI	TTZXH48
DMS436I	MN	TNF receptor (TNFR)
DMS436I	MT	DTT
DMS436I	MA	Antagonist
DMS436I	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMS436I	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMY9ZAS	DI	DMY9ZAS
DMY9ZAS	DN	EUK-189
DMY9ZAS	MI	TTPS279
DMY9ZAS	MN	Catalase (CAT)
DMY9ZAS	MT	DTT
DMY9ZAS	MA	Modulator
DMY9ZAS	RN	Evaluation of EUK-189, a synthetic superoxide dismutase/catalase mimetic as a radiation countermeasure. Immunopharmacol Immunotoxicol. 2008;30(2):271-90.
DMY9ZAS	RU	https://pubmed.ncbi.nlm.nih.gov/18569084

DMY9ZAS	DI	DMY9ZAS
DMY9ZAS	DN	EUK-189
DMY9ZAS	MI	TT6RVLG
DMY9ZAS	MN	Superoxide dismutase Cu-Zn (SOD Cu-Zn)
DMY9ZAS	MT	DTT
DMY9ZAS	MA	Modulator
DMY9ZAS	RN	Evaluation of EUK-189, a synthetic superoxide dismutase/catalase mimetic as a radiation countermeasure. Immunopharmacol Immunotoxicol. 2008;30(2):271-90.
DMY9ZAS	RU	https://pubmed.ncbi.nlm.nih.gov/18569084

DMOG8IE	DI	DMOG8IE
DMOG8IE	DN	EVT 401
DMOG8IE	MI	TT473XN
DMOG8IE	MN	P2X purinoceptor 7 (P2RX7)
DMOG8IE	MT	DTT
DMOG8IE	MA	Antagonist
DMOG8IE	RN	Molecular and functional properties of P2X receptors ecent progress and persisting challenges. Purinergic Signal. 2012 September; 8(3): 375-417.
DMOG8IE	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3360091/

DMAKWQD	DI	DMAKWQD
DMAKWQD	DN	EVT100
DMAKWQD	MI	TTN9D8E
DMAKWQD	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMAKWQD	MT	DTT
DMAKWQD	MA	Antagonist
DMAKWQD	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMAKWQD	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DM3VC6T	DI	DM3VC6T
DM3VC6T	DN	EW-A-401
DM3VC6T	MI	TT2Q6G1
DM3VC6T	MN	Vascular endothelial growth factor receptor 1 (FLT-1)
DM3VC6T	MT	DTT
DM3VC6T	MA	Modulator
DM3VC6T	RN	DOI: http://dx.doi.org/10.1016/j.tips.2014.09.007
DM3VC6T	RU	http://www.cell.com/trends/pharmacological-sciences/fulltext/S0165-6147(14)00160-6

DM2NBC7	DI	DM2NBC7
DM2NBC7	DN	EZN-2968
DM2NBC7	MI	TTQHWNA
DM2NBC7	MN	Hypoxia-inducible factor 1 alpha (HIF-1A)
DM2NBC7	MT	DTT
DM2NBC7	MA	Modulator
DM2NBC7	RN	Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1), in patients with refractory solid tumors.Cancer Chemother Pharmacol.2014 Feb;73(2):343-8.
DM2NBC7	RU	https://www.ncbi.nlm.nih.gov/pubmed/24292632

DMXFY18	DI	DMXFY18
DMXFY18	DN	EZN-3042
DMXFY18	MI	TTTPU1G
DMXFY18	MN	Apoptosis inhibitor survivin (BIRC5)
DMXFY18	MT	DTT
DMXFY18	MA	Modulator
DMXFY18	RN	SPC3042: a proapoptotic survivin inhibitor.Mol Cancer Ther.2008 Sep;7(9):2736-45.
DMXFY18	RU	https://www.ncbi.nlm.nih.gov/pubmed/18790754

DMNPS59	DI	DMNPS59
DMNPS59	DN	EZN-4176
DMNPS59	MI	TTKPW01
DMNPS59	MN	Androgen receptor messenger RNA (AR mRNA)
DMNPS59	MT	DTT
DMNPS59	RN	2011 Pipeline of Santaris Pharma.
DMNPS59	RU	http://www.santaris.com/product-pipeline

DMAH12E	DI	DMAH12E
DMAH12E	DN	F-15845
DMAH12E	MI	TTZOVE0
DMAH12E	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DMAH12E	MT	DTT
DMAH12E	MA	Inhibitor
DMAH12E	RN	Selective inhibition of persistent sodium current by F 15845 prevents ischaemia-induced arrhythmias. Br J Pharmacol. 2010 Sep;161(1):79-91.
DMAH12E	RU	https://pubmed.ncbi.nlm.nih.gov/20718741

DML4JXZ	DI	DML4JXZ
DML4JXZ	DN	F-7TG
DML4JXZ	MI	TTF0EGX
DML4JXZ	MN	Coagulation factor VII (F7)
DML4JXZ	MT	DTT
DML4JXZ	MA	Modulator
DML4JXZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2363).
DML4JXZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2363

DM71HLX	DI	DM71HLX
DM71HLX	DN	FAZ053
DM71HLX	MI	TT8ZLTI
DM71HLX	MN	Programmed cell death 1 ligand 1 (PD-L1)
DM71HLX	MT	DTT
DM71HLX	MA	Inhibitor
DM71HLX	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM71HLX	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM13YK0	DI	DM13YK0
DM13YK0	DN	Ferroportin mab
DM13YK0	MI	TT6Y1PG
DM13YK0	MN	Solute carrier family 40 member 1 (SLC40A1)
DM13YK0	MT	DTT
DM13YK0	RN	The pathophysiology and pharmacology of hepcidin. Trends Pharmacol Sci. 2014 March; 35(3): 155-161.
DM13YK0	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978192/

DMS1O56	DI	DMS1O56
DMS1O56	DN	FF-10101-01
DMS1O56	MI	TTGJCWZ
DMS1O56	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMS1O56	MT	DTT
DMS1O56	MA	Inhibitor
DMS1O56	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMS1O56	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMX5290	DI	DMX5290
DMX5290	DN	FF-10502-01
DMX5290	MI	TTUBNVO
DMX5290	MN	DNA synthesis (DNA synth)
DMX5290	MT	DTT
DMX5290	MA	Inhibitor
DMX5290	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMX5290	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM2GHIP	DI	DM2GHIP
DM2GHIP	DN	FFC-14A
DM2GHIP	MI	TTUTN1I
DM2GHIP	MN	Human Deoxyribonucleic acid (hDNA)
DM2GHIP	MT	DTT
DM2GHIP	MA	Binder
DM2GHIP	RN	The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells. Cancer Lett. 2005 Aug 26;226(2):115-21.
DM2GHIP	RU	https://pubmed.ncbi.nlm.nih.gov/16039951

DM8U2IE	DI	DM8U2IE
DM8U2IE	DN	FGI-101-1A6
DM8U2IE	MI	TTHU7JA
DM8U2IE	MN	Tumor susceptibility gene protein 101 (TSG101)
DM8U2IE	MT	DTT
DM8U2IE	RN	ClinicalTrials.gov (NCT01299142) Safety and Pharmacokinetics Study of Human Monoclonal Antibody (FGI-101-1A6). U.S. National Institutes of Health.
DM8U2IE	RU	https://clinicaltrials.gov/ct2/show/NCT01299142

DMY61GX	DI	DMY61GX
DMY61GX	DN	FGLL
DMY61GX	MI	TTUBJQ3
DMY61GX	MN	Neural cell adhesion molecule (NCAM)
DMY61GX	MT	DTT
DMY61GX	MA	Modulator
DMY61GX	RN	An NCAM mimetic, FGL, alters hippocampal cellular morphometry in young adult (4 month-old) rats. Neurochem Res. 2013 Jun;38(6):1208-18.
DMY61GX	RU	https://pubmed.ncbi.nlm.nih.gov/23076631

DMLH2Q6	DI	DMLH2Q6
DMLH2Q6	DN	Figopitant
DMLH2Q6	MI	TTZPO1L
DMLH2Q6	MN	Substance-P receptor (TACR1)
DMLH2Q6	MT	DTT
DMLH2Q6	MA	Antagonist
DMLH2Q6	RN	Investigation of figopitant and its metabolites in rat tissue by combining whole-body autoradiography with liquid extraction surface analysis mass spectrometry. Drug Metab Dispos. 2012 Mar;40(3):419-25.
DMLH2Q6	RU	https://pubmed.ncbi.nlm.nih.gov/22184457

DM2SALJ	DI	DM2SALJ
DM2SALJ	DN	Flanvotumab
DM2SALJ	MI	TTFRV98
DM2SALJ	MN	Melanoma antigen gp75 (TYRP1)
DM2SALJ	MT	DTT
DM2SALJ	RN	National Cancer Institute Drug Dictionary (drug id 675217).
DM2SALJ	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=675217

DM7BMD6	DI	DM7BMD6
DM7BMD6	DN	FN-1501
DM7BMD6	MI	TT7HF4W
DM7BMD6	MN	Cyclin-dependent kinase 2 (CDK2)
DM7BMD6	MT	DTT
DM7BMD6	MA	Inhibitor
DM7BMD6	RN	Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518.
DM7BMD6	RU	https://pubmed.ncbi.nlm.nih.gov/29357250

DM7BMD6	DI	DM7BMD6
DM7BMD6	DN	FN-1501
DM7BMD6	MI	TT0PG8F
DM7BMD6	MN	Cyclin-dependent kinase 4 (CDK4)
DM7BMD6	MT	DTT
DM7BMD6	MA	Inhibitor
DM7BMD6	RN	Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518.
DM7BMD6	RU	https://pubmed.ncbi.nlm.nih.gov/29357250

DM7BMD6	DI	DM7BMD6
DM7BMD6	DN	FN-1501
DM7BMD6	MI	TTO0FDJ
DM7BMD6	MN	Cyclin-dependent kinase 6 (CDK6)
DM7BMD6	MT	DTT
DM7BMD6	MA	Inhibitor
DM7BMD6	RN	Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518.
DM7BMD6	RU	https://pubmed.ncbi.nlm.nih.gov/29357250

DM7BMD6	DI	DM7BMD6
DM7BMD6	DN	FN-1501
DM7BMD6	MI	TTGJCWZ
DM7BMD6	MN	Fms-like tyrosine kinase 3 (FLT-3)
DM7BMD6	MT	DTT
DM7BMD6	MA	Inhibitor
DM7BMD6	RN	Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518.
DM7BMD6	RU	https://pubmed.ncbi.nlm.nih.gov/29357250

DMKX174	DI	DMKX174
DMKX174	DN	FOR46
DMKX174	MI	TTMS7DF
DMKX174	MN	Membrane cofactor protein (CD46)
DMKX174	MT	DTT
DMKX174	RN	Clinical pipeline report, company report or official report of Fortis Therapeutics.
DMKX174	RU	https://fortistx.com/for46-pipeline/

DMH1NXO	DI	DMH1NXO
DMH1NXO	DN	FP-025
DMH1NXO	MI	TTXZ0KQ
DMH1NXO	MN	Matrix metalloproteinase-12 (MMP-12)
DMH1NXO	MT	DTT
DMH1NXO	MA	Inhibitor
DMH1NXO	RN	Potential clinical implications of recent matrix metalloproteinase inhibitor design strategies. Expert Rev Proteomics. 2015;12(5):445-7.
DMH1NXO	RU	https://www.ncbi.nlm.nih.gov/pubmed/26174966

DMV9FTH	DI	DMV9FTH
DMV9FTH	DN	FP-045
DMV9FTH	MI	TTFLN4T
DMV9FTH	MN	Mitochondrial aldehyde dehydrogenase (ALDH2)
DMV9FTH	MT	DTT
DMV9FTH	MA	Agonist
DMV9FTH	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMV9FTH	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DM8BG0M	DI	DM8BG0M
DM8BG0M	DN	FP-253-GDEPT
DM8BG0M	MI	TTVYIH7
DM8BG0M	MN	Schistosoma Purine nucleoside phosphorylase (sch PNP)
DM8BG0M	MT	DTT
DM8BG0M	MA	Modulator
DM8BG0M	RN	Purine nucleoside phosphorylase and fludarabine phosphate gene-directed enzyme prodrug therapy suppresses primary tumour growth and pseudo-metastases in a mouse model of prostate cancer. J Gene Med. 2004 Dec;6(12):1343-57.
DM8BG0M	RU	https://pubmed.ncbi.nlm.nih.gov/15493036

DM1EBRK	DI	DM1EBRK
DM1EBRK	DN	FPA144
DM1EBRK	MI	TTGKIED
DM1EBRK	MN	Fibroblast growth factor-2 (FGF2)
DM1EBRK	MT	DTT
DM1EBRK	MA	Antagonist
DM1EBRK	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM1EBRK	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMI9A1Z	DI	DMI9A1Z
DMI9A1Z	DN	FPI-1434
DMI9A1Z	MI	TTHRID2
DMI9A1Z	MN	Insulin-like growth factor I receptor (IGF1R)
DMI9A1Z	MT	DTT
DMI9A1Z	RN	Clinical pipeline report, company report or official report of Fusion Pharmaceuticals.
DMI9A1Z	RU	https://fusionpharma.com/fusion-pipeline/

DMUI8F3	DI	DMUI8F3
DMUI8F3	DN	Friulimicin
DMUI8F3	MI	TTXT4D5
DMUI8F3	MN	Bacterial Cell membrane (Bact CM)
DMUI8F3	MT	DTT
DMUI8F3	MA	Inhibitor
DMUI8F3	RN	Model membrane approaches to determine the role of calcium for the antimicrobial activity of friulimicin. Int J Antimicrob Agents. 2011 Mar;37(3):256-60.
DMUI8F3	RU	https://pubmed.ncbi.nlm.nih.gov/21306875

DM0QH9K	DI	DM0QH9K
DM0QH9K	DN	FS118
DM0QH9K	MI	TTNVXAW
DM0QH9K	MN	Lymphocyte activation gene 3 protein (LAG3)
DM0QH9K	MT	DTT
DM0QH9K	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DM0QH9K	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DM0QH9K	DI	DM0QH9K
DM0QH9K	DN	FS118
DM0QH9K	MI	TT8ZLTI
DM0QH9K	MN	Programmed cell death 1 ligand 1 (PD-L1)
DM0QH9K	MT	DTT
DM0QH9K	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DM0QH9K	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMPENAL	DI	DMPENAL
DMPENAL	DN	FSI-189
DMPENAL	MI	TTBRJS9
DMPENAL	MN	Inhibitory receptor SHPS-1 (SIRPA)
DMPENAL	MT	DTT
DMPENAL	RN	 T cells bring unconventional cancer-targeting to the clinic - again. Nat Biotechnol. 2020 Apr;38(4):389-391.
DMPENAL	RU	https://pubmed.ncbi.nlm.nih.gov/32265560

DMZOAT3	DI	DMZOAT3
DMZOAT3	DN	FT-1101
DMZOAT3	MI	TTE4BSY
DMZOAT3	MN	Bromodomain and extraterminal domain protein (BET)
DMZOAT3	MT	DTT
DMZOAT3	MA	Inhibitor
DMZOAT3	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZOAT3	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMCK3OI	DI	DMCK3OI
DMCK3OI	DN	FT-7051
DMCK3OI	MI	TTFRCTK
DMCK3OI	MN	CREB-binding protein (CREBBP)
DMCK3OI	MT	DTT
DMCK3OI	MA	Inhibitor
DMCK3OI	RN	Clinical pipeline report, company report or official report of FORMA Therapeutics.
DMCK3OI	RU	https://www.formatherapeutics.com/programs/metastatic-castration-resistant-prostate-cancer/

DMCK3OI	DI	DMCK3OI
DMCK3OI	DN	FT-7051
DMCK3OI	MI	TTGH73N
DMCK3OI	MN	Histone acetyltransferase p300 (EP300)
DMCK3OI	MT	DTT
DMCK3OI	MA	Inhibitor
DMCK3OI	RN	Clinical pipeline report, company report or official report of FORMA Therapeutics.
DMCK3OI	RU	https://www.formatherapeutics.com/programs/metastatic-castration-resistant-prostate-cancer/

DMGJNTQ	DI	DMGJNTQ
DMGJNTQ	DN	FT-819
DMGJNTQ	MI	TTW640A
DMGJNTQ	MN	B-lymphocyte surface antigen B4 (CD19)
DMGJNTQ	MT	DTT
DMGJNTQ	RN	Clinical pipeline report, company report or official report of Fate Therapeutics.
DMGJNTQ	RU	https://fatetherapeutics.com/pipeline/immuno-oncology-candidates/ft819/

DML028U	DI	DML028U
DML028U	DN	G1T28-1
DML028U	MI	TT0PG8F
DML028U	MN	Cyclin-dependent kinase 4 (CDK4)
DML028U	MT	DTT
DML028U	MA	Modulator
DML028U	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DML028U	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DML028U	DI	DML028U
DML028U	DN	G1T28-1
DML028U	MI	TTO0FDJ
DML028U	MN	Cyclin-dependent kinase 6 (CDK6)
DML028U	MT	DTT
DML028U	MA	Modulator
DML028U	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DML028U	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMRGP72	DI	DMRGP72
DMRGP72	DN	G1T-48
DMRGP72	MI	TTZAYWL
DMRGP72	MN	Estrogen receptor (ESR)
DMRGP72	MT	DTT
DMRGP72	MA	Degrader
DMRGP72	RN	G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer. Breast Cancer Res Treat. 2020 Apr;180(3):635-646.
DMRGP72	RU	https://pubmed.ncbi.nlm.nih.gov/32130619

DM3H6YC	DI	DM3H6YC
DM3H6YC	DN	G-619
DM3H6YC	MI	TT2O84V
DM3H6YC	MN	Thromboxane A2 receptor (TBXA2R)
DM3H6YC	MT	DTT
DM3H6YC	MA	Modulator
DM3H6YC	RN	G 619, a dual thromboxane synthase inhibitor and thromboxane A2 receptor antagonist, inhibits tumor necrosis factor-alpha biosynthesis. Eur J Pharmacol. 1995 Nov 3;286(1):31-9.
DM3H6YC	RU	https://pubmed.ncbi.nlm.nih.gov/8566149

DM3H6YC	DI	DM3H6YC
DM3H6YC	DN	G-619
DM3H6YC	MI	TTKNWZ4
DM3H6YC	MN	Thromboxane-A synthase (TBXAS1)
DM3H6YC	MT	DTT
DM3H6YC	MA	Modulator
DM3H6YC	RN	G 619, a dual thromboxane synthase inhibitor and thromboxane A2 receptor antagonist, inhibits tumor necrosis factor-alpha biosynthesis. Eur J Pharmacol. 1995 Nov 3;286(1):31-9.
DM3H6YC	RU	https://pubmed.ncbi.nlm.nih.gov/8566149

DMJLIQ2	DI	DMJLIQ2
DMJLIQ2	DN	GALAMUSTINE HYDROCHLORIDE
DMJLIQ2	MI	TTUTN1I
DMJLIQ2	MN	Human Deoxyribonucleic acid (hDNA)
DMJLIQ2	MT	DTT
DMJLIQ2	MA	Antagonist
DMJLIQ2	RN	6-[Bis(2-chloroethyl)amino]-6-deoxygalactopyranose hydrochloride (C6-galactose mustard), a new alkylating agent with reduced bone marrow toxicity. Cancer Res. 1987 Feb 1;47(3):696-9.
DMJLIQ2	RU	https://pubmed.ncbi.nlm.nih.gov/3802075

DMG9C4I	DI	DMG9C4I
DMG9C4I	DN	Galidesivir
DMG9C4I	MI	TTV1095
DMG9C4I	MN	COVID-19 RNA-directed RNA polymerase (RdRp)
DMG9C4I	MT	DTT
DMG9C4I	MA	Blocker
DMG9C4I	RN	BioCryst Begins Clinical Trial with Galidesivir for Treatment of Patients with COVID-19
DMG9C4I	RU	https://www.biospace.com/article/releases/biocryst-begins-clinical-trial-with-galidesivir-for-treatment-of-patients-with-covid-19/

DMG9C4I	DI	DMG9C4I
DMG9C4I	DN	Galidesivir
DMG9C4I	MI	TTOA6YT
DMG9C4I	MN	MERS-CoV RNA-directed RNA polymerase (RdRp)
DMG9C4I	MT	DTT
DMG9C4I	MA	Inhibitor
DMG9C4I	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DMG9C4I	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DMG9C4I	DI	DMG9C4I
DMG9C4I	DN	Galidesivir
DMG9C4I	MI	TTKXI53
DMG9C4I	MN	SARS-CoV RNA-directed RNA polymerase (RdRp)
DMG9C4I	MT	DTT
DMG9C4I	MA	Inhibitor
DMG9C4I	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DMG9C4I	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DMIXMQE	DI	DMIXMQE
DMIXMQE	DN	GAP T cells
DMIXMQE	MI	TTJTSX4
DMIXMQE	MN	Glypican-3 (GPC3)
DMIXMQE	MT	DTT
DMIXMQE	MA	CAR-T-Cell-Therapy
DMIXMQE	RN	ClinicalTrials.gov (NCT02932956) Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)
DMIXMQE	RU	https://clinicaltrials.gov/ct2/show/NCT02932956

DM52O7W	DI	DM52O7W
DM52O7W	DN	GBR1302
DM52O7W	MI	TT6EO5L
DM52O7W	MN	Erbb2 tyrosine kinase receptor (HER2)
DM52O7W	MT	DTT
DM52O7W	MA	Inhibitor
DM52O7W	RN	Clinical pipeline report, company report or official report of Glenmark Pharmaceuticals.
DM52O7W	RU	https://glenmarkpharma-us.com/wp-content/uploads/GBR-1302_Pharmacology_ASCO-18_-FINAL.pdf

DM52O7W	DI	DM52O7W
DM52O7W	DN	GBR1302
DM52O7W	MI	TTUN7MC
DM52O7W	MN	T-cell surface glycoprotein CD3 (CD3)
DM52O7W	MT	DTT
DM52O7W	MA	Inhibitor
DM52O7W	RN	Clinical pipeline report, company report or official report of Glenmark Pharmaceuticals.
DM52O7W	RU	https://glenmarkpharma-us.com/wp-content/uploads/GBR-1302_Pharmacology_ASCO-18_-FINAL.pdf

DMQBEYV	DI	DMQBEYV
DMQBEYV	DN	GC021109
DMQBEYV	MI	TTNVSKA
DMQBEYV	MN	P2Y purinoceptor 6 (P2RY6)
DMQBEYV	MT	DTT
DMQBEYV	MA	Agonist
DMQBEYV	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQBEYV	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM6R4DO	DI	DM6R4DO
DM6R4DO	DN	GC-1008
DM6R4DO	MI	TT5BDCY
DM6R4DO	MN	TGF-beta receptor (TGFBR)
DM6R4DO	MT	DTT
DM6R4DO	MA	Modulator
DM6R4DO	RN	Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGF) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma.PLoS One.2014 Mar 11;9(3):e90353.
DM6R4DO	RU	https://www.ncbi.nlm.nih.gov/pubmed/24618589

DMK96CE	DI	DMK96CE
DMK96CE	DN	GC-1113
DMK96CE	MI	TTQG4NR
DMK96CE	MN	Erythropoietin (EPO)
DMK96CE	MT	DTT
DMK96CE	MA	Modulator
DMK96CE	RN	A long-acting erythropoietin fused with noncytolytic human Fc for the treatment of anemia. Arch Pharm Res. 2012 May;35(5):757-9.
DMK96CE	RU	https://pubmed.ncbi.nlm.nih.gov/22644842

DMJ7WRI	DI	DMJ7WRI
DMJ7WRI	DN	GCC-1290K
DMJ7WRI	MI	TTYVX59
DMJ7WRI	MN	Protein kinase C (PRKC)
DMJ7WRI	MT	DTT
DMJ7WRI	MA	Modulator
DMJ7WRI	RN	Inhibitory effect of glutamate release from rat cerebrocortical synaptosomes by dextromethorphan and its metabolite 3-hydroxymorphinan. Neurochem Int. 2009 Jul;54(8):526-34.
DMJ7WRI	RU	https://pubmed.ncbi.nlm.nih.gov/19428798

DMJ7WRI	DI	DMJ7WRI
DMJ7WRI	DN	GCC-1290K
DMJ7WRI	MI	TTCRJKY
DMJ7WRI	MN	Voltage-gated calcium channel (Cav)
DMJ7WRI	MT	DTT
DMJ7WRI	MA	Modulator
DMJ7WRI	RN	Inhibitory effect of glutamate release from rat cerebrocortical synaptosomes by dextromethorphan and its metabolite 3-hydroxymorphinan. Neurochem Int. 2009 Jul;54(8):526-34.
DMJ7WRI	RU	https://pubmed.ncbi.nlm.nih.gov/19428798

DMHMZC7	DI	DMHMZC7
DMHMZC7	DN	GCC-4401
DMHMZC7	MI	TTCIHJA
DMHMZC7	MN	Coagulation factor Xa (F10)
DMHMZC7	MT	DTT
DMHMZC7	MA	Inhibitor
DMHMZC7	RN	Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7.
DMHMZC7	RU	https://pubmed.ncbi.nlm.nih.gov/22844656

DM9TD2N	DI	DM9TD2N
DM9TD2N	DN	GD2 T cells
DM9TD2N	MI	TT80ARU
DM9TD2N	MN	Ganglioside GD2 (GD2)
DM9TD2N	MT	DTT
DM9TD2N	MA	CAR-T-Cell-Therapy
DM9TD2N	RN	ClinicalTrials.gov (NCT01953900) iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma
DM9TD2N	RU	https://clinicaltrials.gov/ct2/show/NCT01953900

DMSE19U	DI	DMSE19U
DMSE19U	DN	GDC0134
DMSE19U	MI	TTF4AVB
DMSE19U	MN	Protein delta homolog 1 (DLK1)
DMSE19U	MT	DTT
DMSE19U	MA	Inhibitor
DMSE19U	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMSE19U	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM1B3UM	DI	DM1B3UM
DM1B3UM	DN	GDC-0152
DM1B3UM	MI	TTR7B60
DM1B3UM	MN	X-linked inhibitor of apoptosis protein (XIAP)
DM1B3UM	MT	DTT
DM1B3UM	MA	Modulator
DM1B3UM	RN	Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). J Med Chem. 2012 May 10;55(9):4101-13.
DM1B3UM	RU	https://pubmed.ncbi.nlm.nih.gov/22413863

DMUNFEP	DI	DMUNFEP
DMUNFEP	DN	GDC0310
DMUNFEP	MI	TT4G2JS
DMUNFEP	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DMUNFEP	MT	DTT
DMUNFEP	MA	Inhibitor
DMUNFEP	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMUNFEP	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM3Z2JB	DI	DM3Z2JB
DM3Z2JB	DN	GDC-0349
DM3Z2JB	MI	TTCJG29
DM3Z2JB	MN	Serine/threonine-protein kinase mTOR (mTOR)
DM3Z2JB	MT	DTT
DM3Z2JB	MA	Inhibitor
DM3Z2JB	RN	Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349. ACS Med Chem Lett. 2012 Nov 29;4(1):103-7.
DM3Z2JB	RU	https://pubmed.ncbi.nlm.nih.gov/24900569

DMDZ26X	DI	DMDZ26X
DMDZ26X	DN	GDC-0425
DMDZ26X	MI	TTTU902
DMDZ26X	MN	Checkpoint kinase-1 (CHK1)
DMDZ26X	MT	DTT
DMDZ26X	MA	Modulator
DMDZ26X	RN	Quantitative assessment of BCL-2:BIM complexes as a pharmacodynamic marker for venetoclax (ABT-199).
DMDZ26X	RU	http://cancerres.aacrjournals.org/content/75/15_Supplement/6

DMDY08K	DI	DMDY08K
DMDY08K	DN	GDC-0623
DMDY08K	MI	TTZCRP3
DMDY08K	MN	ERK activator kinase (MEK)
DMDY08K	MT	DTT
DMDY08K	MA	Inhibitor
DMDY08K	RN	Clinical pipeline report, company report or official report of Genentech (2011).
DMDY08K	RU	http://www.gene.com/gene/index.jsp

DMFC2OY	DI	DMFC2OY
DMFC2OY	DN	GDC-0994
DMFC2OY	MI	TT1MG9E
DMFC2OY	MN	Extracellular signal-regulated kinase 1 (ERK1)
DMFC2OY	MT	DTT
DMFC2OY	MA	Modulator
DMFC2OY	RN	ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
DMFC2OY	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4300142

DMFC2OY	DI	DMFC2OY
DMFC2OY	DN	GDC-0994
DMFC2OY	MI	TT4TQBX
DMFC2OY	MN	Extracellular signal-regulated kinase 2 (ERK2)
DMFC2OY	MT	DTT
DMFC2OY	MA	Modulator
DMFC2OY	RN	ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
DMFC2OY	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4300142

DMJA27W	DI	DMJA27W
DMJA27W	DN	GDC-5573
DMJA27W	MI	TTB18GJ
DMJA27W	MN	Proto-oncogene c-RAF (c-RAF)
DMJA27W	MT	DTT
DMJA27W	MA	Inhibitor
DMJA27W	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMJA27W	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMMF6UB	DI	DMMF6UB
DMMF6UB	DN	GE-1170A
DMMF6UB	MI	TTYQIFM
DMMF6UB	MN	Staphylococcus Elongation factor Tu (Stap-coc tuf)
DMMF6UB	MT	DTT
DMMF6UB	MA	Inhibitor
DMMF6UB	RN	GE2270A-resistant mutations in elongation factor Tu allow productive aminoacyl-tRNA binding to EF-Tu.GTP.GE2270A complexes. J Mol Biol. 2000 Dec 15;304(5):995-1005.
DMMF6UB	RU	https://pubmed.ncbi.nlm.nih.gov/11124042

DMJK7V0	DI	DMJK7V0
DMJK7V0	DN	Ge2270a
DMJK7V0	MI	TTG45NU
DMJK7V0	MN	Plasmodium Elongation factor 1-alpha 1 (Malaria MEF-1)
DMJK7V0	MT	DTT
DMJK7V0	MA	Inhibitor
DMJK7V0	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMJK7V0	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMDMKVL	DI	DMDMKVL
DMDMKVL	DN	GEM333
DMDMKVL	MI	TTJVYO3
DMDMKVL	MN	Myeloid cell surface antigen CD33 (CD33)
DMDMKVL	MT	DTT
DMDMKVL	MA	Inhibitor
DMDMKVL	RN	Clinical pipeline report, company report or official report of Gemoab.
DMDMKVL	RU	https://www.gemoab.com/gem333

DMDMKVL	DI	DMDMKVL
DMDMKVL	DN	GEM333
DMDMKVL	MI	TTUN7MC
DMDMKVL	MN	T-cell surface glycoprotein CD3 (CD3)
DMDMKVL	MT	DTT
DMDMKVL	MA	Inhibitor
DMDMKVL	RN	Clinical pipeline report, company report or official report of Gemoab.
DMDMKVL	RU	https://www.gemoab.com/gem333

DM3GSPR	DI	DM3GSPR
DM3GSPR	DN	GEM3PSCA
DM3GSPR	MI	TT9T4AV
DM3GSPR	MN	Prostate stem cell antigen (PSCA)
DM3GSPR	MT	DTT
DM3GSPR	MA	Inhibitor
DM3GSPR	RN	Clinical pipeline report, company report or official report of Gemoab.
DM3GSPR	RU	https://www.gemoab.com/gem3psca

DMV8IWJ	DI	DMV8IWJ
DMV8IWJ	DN	GEN1029
DMV8IWJ	MI	TTW20TU
DMV8IWJ	MN	TRAIL receptor 2 (TRAIL-R2)
DMV8IWJ	MT	DTT
DMV8IWJ	MA	Agonist
DMV8IWJ	RN	National Cancer Institute Drug Dictionary (drug name Tilogotamab).
DMV8IWJ	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tilogotamab

DMNP6T3	DI	DMNP6T3
DMNP6T3	DN	GEN1042
DMNP6T3	MI	TTN6Y9A
DMNP6T3	MN	CD40L receptor (CD40)
DMNP6T3	MT	DTT
DMNP6T3	MA	Agonist
DMNP6T3	RN	Clinical pipeline report, company report or official report of Genmab.
DMNP6T3	RU	https://www.genmab.com/pipeline/

DMNP6T3	DI	DMNP6T3
DMNP6T3	DN	GEN1042
DMNP6T3	MI	TTPW9LJ
DMNP6T3	MN	Co-stimulatory molecule 4-1BB (CD137)
DMNP6T3	MT	DTT
DMNP6T3	MA	Agonist
DMNP6T3	RN	Clinical pipeline report, company report or official report of Genmab.
DMNP6T3	RU	https://www.genmab.com/pipeline/

DMQ9317	DI	DMQ9317
DMQ9317	DN	GEN1044
DMQ9317	MI	TT70MLA
DMQ9317	MN	Oncotrophoblast glycoprotein 5T4 (TPBG)
DMQ9317	MT	DTT
DMQ9317	RN	Clinical pipeline report, company report or official report of AbbVie.
DMQ9317	RU	https://www.abbvie.com/our-science/pipeline/gen-1044.html

DMQ9317	DI	DMQ9317
DMQ9317	DN	GEN1044
DMQ9317	MI	TTUN7MC
DMQ9317	MN	T-cell surface glycoprotein CD3 (CD3)
DMQ9317	MT	DTT
DMQ9317	RN	Clinical pipeline report, company report or official report of AbbVie.
DMQ9317	RU	https://www.abbvie.com/our-science/pipeline/gen-1044.html

DMEWRNZ	DI	DMEWRNZ
DMEWRNZ	DN	GEN1046
DMEWRNZ	MI	TTPW9LJ
DMEWRNZ	MN	Co-stimulatory molecule 4-1BB (CD137)
DMEWRNZ	MT	DTT
DMEWRNZ	MA	Agonist
DMEWRNZ	RN	Clinical pipeline report, company report or official report of Genmab.
DMEWRNZ	RU	https://www.genmab.com/pipeline/

DMEWRNZ	DI	DMEWRNZ
DMEWRNZ	DN	GEN1046
DMEWRNZ	MI	TT8ZLTI
DMEWRNZ	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMEWRNZ	MT	DTT
DMEWRNZ	MA	Agonist
DMEWRNZ	RN	Clinical pipeline report, company report or official report of Genmab.
DMEWRNZ	RU	https://www.genmab.com/pipeline/

DMWR93D	DI	DMWR93D
DMWR93D	DN	Genaconazole
DMWR93D	MI	TTTSOUD
DMWR93D	MN	Candida Cytochrome P450 51 (Candi ERG11)
DMWR93D	MT	DTT
DMWR93D	MA	Modulator
DMWR93D	RN	New targets and delivery systems for antifungal therapy. Med Mycol. 2000;38 Suppl 1:335-47.
DMWR93D	RU	https://pubmed.ncbi.nlm.nih.gov/11204162

DMJP83V	DI	DMJP83V
DMJP83V	DN	Gene therapy, IFN-b
DMJP83V	MI	TT4TZ8J
DMJP83V	MN	Interferon-beta (IFNB1)
DMJP83V	MT	DTT
DMJP83V	MA	Modulator
DMJP83V	RN	Interferon-beta gene therapy for cancer: basic research to clinical application. Cancer Sci. 2004 Nov;95(11):858-65.
DMJP83V	RU	https://pubmed.ncbi.nlm.nih.gov/15546502

DMTGN0U	DI	DMTGN0U
DMTGN0U	DN	Genz 644282
DMTGN0U	MI	DTUGYRD
DMTGN0U	MN	P-glycoprotein 1 (ABCB1)
DMTGN0U	MT	DTP
DMTGN0U	MA	Substrate
DMTGN0U	RN	Molecular and cellular pharmacology of the novel noncamptothecin topoisomerase I inhibitor Genz-644282. Mol Cancer Ther. 2011 Aug;10(8):1490-9.
DMTGN0U	RU	https://doi.org/10.1158/1535-7163.MCT-10-1043

DMIXABW	DI	DMIXABW
DMIXABW	DN	Genz-644282
DMIXABW	MI	TTGTQHC
DMIXABW	MN	DNA topoisomerase I (TOP1)
DMIXABW	MT	DTT
DMIXABW	MA	Inhibitor
DMIXABW	RN	Genz-644282, a novel non-camptothecin topoisomerase I inhibitor for cancer treatment. Clin Cancer Res. 2011 May 1;17(9):2777-87.
DMIXABW	RU	https://pubmed.ncbi.nlm.nih.gov/21415217

DMA9UX2	DI	DMA9UX2
DMA9UX2	DN	Gerilimzumab
DMA9UX2	MI	TTT1V78
DMA9UX2	MN	Interleukin-6 (IL6)
DMA9UX2	MT	DTT
DMA9UX2	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMA9UX2	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMDMPKC	DI	DMDMPKC
DMDMPKC	DN	GGF-2
DMDMPKC	MI	TTEH395
DMDMPKC	MN	Pro-neuregulin-1 (Pro-NRG1)
DMDMPKC	MT	DTT
DMDMPKC	MA	Modulator
DMDMPKC	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMDMPKC	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM8U23L	DI	DM8U23L
DM8U23L	DN	GGTI-2418
DM8U23L	MI	TTXQKM3
DM8U23L	MN	Farnesyl protein transferase (Ftase)
DM8U23L	MT	DTT
DM8U23L	MA	Modulator
DM8U23L	RN	Company report (Prescient)
DM8U23L	RU	http://prescienttherapeutics.com/ptx-100/

DMKY1L4	DI	DMKY1L4
DMKY1L4	DN	Glucose-6-phosphate
DMKY1L4	MI	TTC67I0
DMKY1L4	MN	Bacterial Glucosamine-6-phosphate synthase (Bact glmS)
DMKY1L4	MT	DTT
DMKY1L4	MA	Inhibitor
DMKY1L4	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMKY1L4	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMKY1L4	DI	DMKY1L4
DMKY1L4	DN	Glucose-6-phosphate
DMKY1L4	MI	DTLHZFU
DMKY1L4	MN	Glucose-6-phosphate translocase (SLC37A4)
DMKY1L4	MT	DTP
DMKY1L4	MA	Substrate
DMKY1L4	RN	A novel mutation (A148V) in the glucose 6-phosphate translocase (SLC37A4) gene in a Korean patient with glycogen storage disease type 1b. J Korean Med Sci. 2005 Jun;20(3):499-501.
DMKY1L4	RU	http://www.ncbi.nlm.nih.gov/pubmed/15953877

DMKY1L4	DI	DMKY1L4
DMKY1L4	DN	Glucose-6-phosphate
DMKY1L4	MI	DTH9SQJ
DMKY1L4	MN	Glycerol-3-phosphate permease (SLC37A1)
DMKY1L4	MT	DTP
DMKY1L4	MA	Substrate
DMKY1L4	RN	SLC37A1 and SLC37A2 are phosphate-linked, glucose-6-phosphate antiporters. PLoS One. 2011;6(9):e23157.
DMKY1L4	RU	http://www.ncbi.nlm.nih.gov/pubmed/21949678

DM1PK0T	DI	DM1PK0T
DM1PK0T	DN	GLYCAR T cells
DM1PK0T	MI	TTJTSX4
DM1PK0T	MN	Glypican-3 (GPC3)
DM1PK0T	MT	DTT
DM1PK0T	MA	CAR-T-Cell-Therapy
DM1PK0T	RN	ClinicalTrials.gov (NCT02905188) Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)
DM1PK0T	RU	https://clinicaltrials.gov/ct2/show/NCT02905188

DMCKZUT	DI	DMCKZUT
DMCKZUT	DN	GlyT1 PET radiotracers
DMCKZUT	MI	TTHJTF7
DMCKZUT	MN	Glycine transporter GlyT-1 (SLC6A9)
DMCKZUT	MT	DTT
DMCKZUT	MA	Modulator
DMCKZUT	RN	Glycine Transport Inhibitors for the Treatment of Schizophrenia. Open Med Chem J. 2010; 4: 10-19.
DMCKZUT	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3023951/

DML1KSA	DI	DML1KSA
DML1KSA	DN	GMI-1359
DML1KSA	MI	TTBID49
DML1KSA	MN	C-X-C chemokine receptor type 4 (CXCR4)
DML1KSA	MT	DTT
DML1KSA	MA	Antagonist
DML1KSA	RN	Clinical pipeline report, company report or official report of GlycoMimetics.
DML1KSA	RU	http://glycomimetics.com/pipeline/programs/gmi-1359/

DML1KSA	DI	DML1KSA
DML1KSA	DN	GMI-1359
DML1KSA	MI	TTAU4D6
DML1KSA	MN	E-selectin (SELE)
DML1KSA	MT	DTT
DML1KSA	MA	Antagonist
DML1KSA	RN	Clinical pipeline report, company report or official report of GlycoMimetics.
DML1KSA	RU	http://glycomimetics.com/pipeline/programs/gmi-1359/

DMIFSN2	DI	DMIFSN2
DMIFSN2	DN	GMX1777
DMIFSN2	MI	TTD1WIG
DMIFSN2	MN	Nicotinamide phosphoribosyltransferase (NAMPT)
DMIFSN2	MT	DTT
DMIFSN2	MA	Modulator
DMIFSN2	RN	The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-... Mol Cell Biol. 2009 Nov;29(21):5872-88.
DMIFSN2	RU	https://pubmed.ncbi.nlm.nih.gov/19703994

DMD6H8B	DI	DMD6H8B
DMD6H8B	DN	GMZ-2
DMD6H8B	MI	TT3J5ZI
DMD6H8B	MN	Cell mediated immunity response (CMIR)
DMD6H8B	MT	DTT
DMD6H8B	RN	Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations. Malar J. 2011; 10: 359.
DMD6H8B	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3265551/

DMURO94	DI	DMURO94
DMURO94	DN	GNE Lipoplex
DMURO94	MI	TT4DP5S
DMURO94	MN	N-acetylmannosamine kinase (GNE)
DMURO94	MT	DTT
DMURO94	MA	Inhibitor
DMURO94	RN	Hereditary inclusion body myopathy: single patient response to intravenous dosing of GNE gene lipoplex. Hum Gene Ther. 2011 Nov;22(11):1331-41.
DMURO94	RU	https://pubmed.ncbi.nlm.nih.gov/21517694

DMYWDT4	DI	DMYWDT4
DMYWDT4	DN	GNKG-168
DMYWDT4	MI	TTSHG0T
DMYWDT4	MN	Toll-like receptor 9 (TLR9)
DMYWDT4	MT	DTT
DMYWDT4	MA	Modulator
DMYWDT4	RN	National Cancer Institute Drug Dictionary (drug id 662816).
DMYWDT4	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=662816

DMKMU2S	DI	DMKMU2S
DMKMU2S	DN	GNX102
DMKMU2S	MI	TTZUFEL
DMKMU2S	MN	Tumor-associated glycan antigen (TAGA)
DMKMU2S	MT	DTT
DMKMU2S	RN	Clinical pipeline report, company report or official report of GlycoNex.
DMKMU2S	RU	http://www.glyconex.com.tw/index.php/en-us/product-pipeline-us

DM035LO	DI	DM035LO
DM035LO	DN	GP-3269
DM035LO	MI	TTL732K
DM035LO	MN	Adenosine kinase (ADK)
DM035LO	MT	DTT
DM035LO	MA	Inhibitor
DM035LO	RN	Adenosine kinase inhibitors. 6. Synthesis, water solubility, and antinociceptive activity of 5-phenyl-7-(5-deoxy-beta-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidines substituted at C4 with glycinamides andrelated compounds. J Med Chem. 2005 Dec 1;48(24):7808-20.
DM035LO	RU	https://pubmed.ncbi.nlm.nih.gov/16302820

DM9JV80	DI	DM9JV80
DM9JV80	DN	Gp41 HIV-1 vaccine
DM9JV80	MI	TTG90S6
DM9JV80	MN	Human immunodeficiency virus Glycoprotein 41 (HIV gp41)
DM9JV80	MT	DTT
DM9JV80	MA	Modulator
DM9JV80	RN	Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine. PLoS One. 2010 Jan 25;5(1):e8617.
DM9JV80	RU	https://pubmed.ncbi.nlm.nih.gov/20111582

DM2MILF	DI	DM2MILF
DM2MILF	DN	GPA-TriMAR-T cells
DM2MILF	MI	TT9VL2N
DM2MILF	MN	Gp100[209-217] peptide (PMEL)
DM2MILF	MT	DTT
DM2MILF	MA	CAR-T-Cell-Therapy
DM2MILF	RN	ClinicalTrials.gov (NCT03649529) Treatment of Malignant Melanoma With GPA-TriMAR-T Cell Therapy
DM2MILF	RU	https://clinicaltrials.gov/ct2/show/NCT03649529

DMVWHS1	DI	DMVWHS1
DMVWHS1	DN	GPC3 targeting CAR-T cells
DMVWHS1	MI	TTJTSX4
DMVWHS1	MN	Glypican-3 (GPC3)
DMVWHS1	MT	DTT
DMVWHS1	MA	CAR-T-Cell-Therapy
DMVWHS1	RN	ClinicalTrials.gov (NCT03198546) GPC3-T2-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
DMVWHS1	RU	https://clinicaltrials.gov/ct2/show/NCT03198546

DM0ZQ48	DI	DM0ZQ48
DM0ZQ48	DN	GPI-16072
DM0ZQ48	MI	TT9G4N0
DM0ZQ48	MN	Glutamate carboxypeptidase II (GCPII)
DM0ZQ48	MT	DTT
DM0ZQ48	MA	Inhibitor
DM0ZQ48	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DM0ZQ48	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DM8MGSH	DI	DM8MGSH
DM8MGSH	DN	GPRC5D CAR-T cell therapy
DM8MGSH	MI	TTHRAPJ
DM8MGSH	MN	G-protein coupled receptor C 5D (GPRC5D)
DM8MGSH	MT	DTT
DM8MGSH	RN	GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019 Mar 27;11(485):eaau7746.
DM8MGSH	RU	https://pubmed.ncbi.nlm.nih.gov/30918115

DMFA2XQ	DI	DMFA2XQ
DMFA2XQ	DN	GQ1001
DMFA2XQ	MI	TT6EO5L
DMFA2XQ	MN	Erbb2 tyrosine kinase receptor (HER2)
DMFA2XQ	MT	DTT
DMFA2XQ	RN	Clinical pipeline report, company report or official report of GeneQuantum Healthcare.
DMFA2XQ	RU	http://www.genequantum.com/#/common/product?pid=12&id=13&type=7

DMZ0D3V	DI	DMZ0D3V
DMZ0D3V	DN	GRC-6211
DMZ0D3V	MI	TT0IHXV
DMZ0D3V	MN	DNA topoisomerase II (TOP2)
DMZ0D3V	MT	DTT
DMZ0D3V	MA	Inhibitor
DMZ0D3V	RN	Activity of fluoroquinolone antibiotics against Plasmodium falciparum in vitro. Antimicrob Agents Chemother. 1988 Aug;32(8):1182-6.
DMZ0D3V	RU	https://pubmed.ncbi.nlm.nih.gov/2847647

DMZ0D3V	DI	DMZ0D3V
DMZ0D3V	DN	GRC-6211
DMZ0D3V	MI	TTMI6F5
DMZ0D3V	MN	Transient receptor potential cation channel V1 (TRPV1)
DMZ0D3V	MT	DTT
DMZ0D3V	MA	Antagonist
DMZ0D3V	RN	GRC-6211, a new oral specific TRPV1 antagonist, decreases bladder overactivity and noxious bladder input in cystitis animal models. J Urol. 2009 Jan;181(1):379-86.
DMZ0D3V	RU	https://pubmed.ncbi.nlm.nih.gov/19010489

DMGF71W	DI	DMGF71W
DMGF71W	DN	GRN163
DMGF71W	MI	TTUJFD0
DMGF71W	MN	Telomerase reverse transcriptase (TERT)
DMGF71W	MT	DTT
DMGF71W	MA	Inhibitor
DMGF71W	RN	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
DMGF71W	RU	https://pubmed.ncbi.nlm.nih.gov/19249983

DMI319T	DI	DMI319T
DMI319T	DN	GS 9667
DMI319T	MI	TTK25J1
DMI319T	MN	Adenosine A1 receptor (ADORA1)
DMI319T	MT	DTT
DMI319T	MA	Agonist
DMI319T	RN	Reduction of free fatty acids, safety, and pharmacokinetics of oral GS-9667, an A(1) adenosine receptor partial agonist. J Clin Pharmacol. 2013 Apr;53(4):385-92.
DMI319T	RU	https://pubmed.ncbi.nlm.nih.gov/23427000

DMS25DL	DI	DMS25DL
DMS25DL	DN	GS-1423
DMS25DL	MI	TTK0O6Y
DMS25DL	MN	Ecto-5'-nucleotidase (CD73)
DMS25DL	MT	DTT
DMS25DL	RN	Clinical pipeline report, company report or official report of Agenus.
DMS25DL	RU	https://agenusbio.com/pipeline/

DMS25DL	DI	DMS25DL
DMS25DL	DN	GS-1423
DMS25DL	MI	TTO3HT7
DMS25DL	MN	Transforming growth factor beta (TGFB)
DMS25DL	MT	DTT
DMS25DL	RN	Clinical pipeline report, company report or official report of Agenus.
DMS25DL	RU	https://agenusbio.com/pipeline/

DMZVFOQ	DI	DMZVFOQ
DMZVFOQ	DN	GS-5829
DMZVFOQ	MI	TTE4BSY
DMZVFOQ	MN	Bromodomain and extraterminal domain protein (BET)
DMZVFOQ	MT	DTT
DMZVFOQ	MA	Inhibitor
DMZVFOQ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZVFOQ	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMRDNPC	DI	DMRDNPC
DMRDNPC	DN	GS-6620
DMRDNPC	MI	TTMVBWH
DMRDNPC	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMRDNPC	MT	DTT
DMRDNPC	MA	Inhibitor
DMRDNPC	RN	Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrug. Antimicrob Agents Chemother. 2014;58(4):1930-42.
DMRDNPC	RU	https://pubmed.ncbi.nlm.nih.gov/24419349

DMXG3T1	DI	DMXG3T1
DMXG3T1	DN	GS-6637
DMXG3T1	MI	TTFLN4T
DMXG3T1	MN	Mitochondrial aldehyde dehydrogenase (ALDH2)
DMXG3T1	MT	DTT
DMXG3T1	MA	Inhibitor
DMXG3T1	RN	Clinical pipeline report, company report or official report of Gilead.
DMXG3T1	RU	http://www.gilead.com/~/media/Files/pdfs/other/Gilead_Sciences_Company_Overview_FactSheet_080514.pdf

DMNX3US	DI	DMNX3US
DMNX3US	DN	GS-9820
DMNX3US	MI	TTGBPJE
DMNX3US	MN	PI3-kinase delta (PIK3CD)
DMNX3US	MT	DTT
DMNX3US	MA	Inhibitor
DMNX3US	RN	National Cancer Institute Drug Dictionary (drug id 741949).
DMNX3US	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=741949

DMMF5IE	DI	DMMF5IE
DMMF5IE	DN	GS-9883
DMMF5IE	MI	DE4LYSA
DMMF5IE	MN	Cytochrome P450 3A4 (CYP3A4)
DMMF5IE	MT	DME
DMMF5IE	MA	Metabolism
DMMF5IE	RN	Bictegravir, a novel integrase inhibitor for the treatment of HIV infection. Drugs Today (Barc). 2019 Nov;55(11):669-682.
DMMF5IE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31840682

DMMF5IE	DI	DMMF5IE
DMMF5IE	DN	GS-9883
DMMF5IE	MI	DEYGVN4
DMMF5IE	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMMF5IE	MT	DME
DMMF5IE	MA	Metabolism
DMMF5IE	RN	Bictegravir, a novel integrase inhibitor for the treatment of HIV infection. Drugs Today (Barc). 2019 Nov;55(11):669-682.
DMMF5IE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31840682

DMGHN98	DI	DMGHN98
DMGHN98	DN	GS-9901
DMGHN98	MI	TTGBPJE
DMGHN98	MN	PI3-kinase delta (PIK3CD)
DMGHN98	MT	DTT
DMGHN98	MA	Inhibitor
DMGHN98	RN	Clinical pipeline report, company report or official report of Gilead.
DMGHN98	RU	http://www.gilead.com/research/pipeline

DMSR5HD	DI	DMSR5HD
DMSR5HD	DN	GSI-136
DMSR5HD	MI	TT9W8GU
DMSR5HD	MN	Gamma-secretase (GS)
DMSR5HD	MT	DTT
DMSR5HD	MA	Modulator
DMSR5HD	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMSR5HD	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMO87YS	DI	DMO87YS
DMO87YS	DN	GSK065
DMO87YS	MI	TTIY56R
DMO87YS	MN	Kynurenine 3-hydroxylase (KMO)
DMO87YS	MT	DTT
DMO87YS	MA	Inhibitor
DMO87YS	RN	Structural and mechanistic basis of differentiated inhibitors of the acute pancreatitis target kynurenine-3-monooxygenase. Nat Commun. 2017 Jun 12;8:15827.
DMO87YS	RU	https://pubmed.ncbi.nlm.nih.gov/28604669

DMXRPT6	DI	DMXRPT6
DMXRPT6	DN	GSK1070916
DMXRPT6	MI	TT5LS6T
DMXRPT6	MN	Aurora kinase B (AURKB)
DMXRPT6	MT	DTT
DMXRPT6	MA	Modulator
DMXRPT6	RN	Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem. 2010 May 27;53(10):3973-4001.
DMXRPT6	RU	https://pubmed.ncbi.nlm.nih.gov/20420387

DMXRPT6	DI	DMXRPT6
DMXRPT6	DN	GSK1070916
DMXRPT6	MI	TTLYXIT
DMXRPT6	MN	Aurora kinase C (AURKC)
DMXRPT6	MT	DTT
DMXRPT6	MA	Modulator
DMXRPT6	RN	Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem. 2010 May 27;53(10):3973-4001.
DMXRPT6	RU	https://pubmed.ncbi.nlm.nih.gov/20420387

DMCJUI9	DI	DMCJUI9
DMCJUI9	DN	GSK1070916A
DMCJUI9	MI	TT5LS6T
DMCJUI9	MN	Aurora kinase B (AURKB)
DMCJUI9	MT	DTT
DMCJUI9	MA	Modulator
DMCJUI9	RN	Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem. 2010 May 27;53(10):3973-4001.
DMCJUI9	RU	https://pubmed.ncbi.nlm.nih.gov/20420387

DMCJUI9	DI	DMCJUI9
DMCJUI9	DN	GSK1070916A
DMCJUI9	MI	TTLYXIT
DMCJUI9	MN	Aurora kinase C (AURKC)
DMCJUI9	MT	DTT
DMCJUI9	MA	Modulator
DMCJUI9	RN	Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem. 2010 May 27;53(10):3973-4001.
DMCJUI9	RU	https://pubmed.ncbi.nlm.nih.gov/20420387

DMK3S9J	DI	DMK3S9J
DMK3S9J	DN	GSK1144814
DMK3S9J	MI	TTBPGLU
DMK3S9J	MN	Neuromedin-K receptor (TACR3)
DMK3S9J	MT	DTT
DMK3S9J	MA	Modulator
DMK3S9J	RN	Pharmacokinetics and central nervous system effects of the novel dual NK1 /NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers.Br J Clin Pharmacol.2013 May;75(5):1328-39.
DMK3S9J	RU	https://www.ncbi.nlm.nih.gov/pubmed/23067311

DMK3S9J	DI	DMK3S9J
DMK3S9J	DN	GSK1144814
DMK3S9J	MI	TTZPO1L
DMK3S9J	MN	Substance-P receptor (TACR1)
DMK3S9J	MT	DTT
DMK3S9J	MA	Modulator
DMK3S9J	RN	Pharmacokinetics and central nervous system effects of the novel dual NK1 /NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers.Br J Clin Pharmacol.2013 May;75(5):1328-39.
DMK3S9J	RU	https://www.ncbi.nlm.nih.gov/pubmed/23067311

DMNYGB8	DI	DMNYGB8
DMNYGB8	DN	GSK-1322888
DMNYGB8	MI	TT953CX
DMNYGB8	MN	Motilin receptor (MLNR)
DMNYGB8	MT	DTT
DMNYGB8	MA	Agonist
DMNYGB8	RN	ClinicalTrials.gov (NCT01294566) FTIH to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses of GSK1322888 in Healthy Caucasian and Japanese Volunteers. U.S. National Institutes of Health.
DMNYGB8	RU	https://clinicaltrials.gov/ct2/show/NCT01294566

DMZC9XU	DI	DMZC9XU
DMZC9XU	DN	GSK-1360707
DMZC9XU	MI	TTVBI8W
DMZC9XU	MN	Dopamine transporter (DAT)
DMZC9XU	MT	DTT
DMZC9XU	MA	Inhibitor
DMZC9XU	RN	Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography. J Pharmacol Exp Ther. 2013 Aug;346(2):311-7.
DMZC9XU	RU	https://pubmed.ncbi.nlm.nih.gov/23685546

DMZC9XU	DI	DMZC9XU
DMZC9XU	DN	GSK-1360707
DMZC9XU	MI	TTAWNKZ
DMZC9XU	MN	Norepinephrine transporter (NET)
DMZC9XU	MT	DTT
DMZC9XU	MA	Inhibitor
DMZC9XU	RN	Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography. J Pharmacol Exp Ther. 2013 Aug;346(2):311-7.
DMZC9XU	RU	https://pubmed.ncbi.nlm.nih.gov/23685546

DMZC9XU	DI	DMZC9XU
DMZC9XU	DN	GSK-1360707
DMZC9XU	MI	TT3ROYC
DMZC9XU	MN	Serotonin transporter (SERT)
DMZC9XU	MT	DTT
DMZC9XU	MA	Inhibitor
DMZC9XU	RN	Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography. J Pharmacol Exp Ther. 2013 Aug;346(2):311-7.
DMZC9XU	RU	https://pubmed.ncbi.nlm.nih.gov/23685546

DMEJMTR	DI	DMEJMTR
DMEJMTR	DN	GSK1440115
DMEJMTR	MI	TTW5UDX
DMEJMTR	MN	Urotensin II receptor (UTS2R)
DMEJMTR	MT	DTT
DMEJMTR	MA	Antagonist
DMEJMTR	RN	Effects of Urotensin II Receptor Antagonist, GSK1440115, in Asthma. Front Pharmacol. 2013; 4: 54.
DMEJMTR	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3638148/

DMWDQOV	DI	DMWDQOV
DMWDQOV	DN	GSK1482160
DMWDQOV	MI	TT473XN
DMWDQOV	MN	P2X purinoceptor 7 (P2RX7)
DMWDQOV	MT	DTT
DMWDQOV	MA	Antagonist
DMWDQOV	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMWDQOV	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DM2L7TH	DI	DM2L7TH
DM2L7TH	DN	GSK1521498
DM2L7TH	MI	TTKWM86
DM2L7TH	MN	Opioid receptor mu (MOP)
DM2L7TH	MT	DTT
DM2L7TH	MA	Agonist
DM2L7TH	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DM2L7TH	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DM7I1AQ	DI	DM7I1AQ
DM7I1AQ	DN	GSK1614235
DM7I1AQ	MI	TT2UE56
DM7I1AQ	MN	Sodium/glucose cotransporter 1 (SGLT1)
DM7I1AQ	MT	DTT
DM7I1AQ	MA	Blocker
DM7I1AQ	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DM7I1AQ	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMC6QE4	DI	DMC6QE4
DMC6QE4	DN	GSK1795091
DMC6QE4	MI	TTISGCA
DMC6QE4	MN	Toll-like receptor 4 (TLR4)
DMC6QE4	MT	DTT
DMC6QE4	MA	Agonist
DMC6QE4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMC6QE4	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMA41JD	DI	DMA41JD
DMA41JD	DN	GSK-1827771
DMA41JD	MI	TT51DEV
DMA41JD	MN	Interleukin 1 receptor type 2 (IL1R2)
DMA41JD	MT	DTT
DMA41JD	RN	WO patent application no. 2013,0077,63, Modulators of the nlrp3 inflammasome il-1ss pathway for the prevention and treatment of acne.
DMA41JD	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20130117&CC=WO&NR=2013007763A1&KC=A1

DMC14KV	DI	DMC14KV
DMC14KV	DN	GSK1995057
DMC14KV	MI	TTG043C
DMC14KV	MN	Tumor necrosis factor receptor type I (TNF-R1)
DMC14KV	MT	DTT
DMC14KV	RN	Autoantibodies to variable heavy (VH) chain Ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-alpha receptor 1. J Clin Immunol. 2013 Oct;33(7):1192-203.
DMC14KV	RU	https://pubmed.ncbi.nlm.nih.gov/23832582

DMRU4YV	DI	DMRU4YV
DMRU4YV	DN	GSK-2018682
DMRU4YV	MI	TT9JZCK
DMRU4YV	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMRU4YV	MT	DTT
DMRU4YV	MA	Agonist
DMRU4YV	RN	Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702.
DMRU4YV	RU	https://pubmed.ncbi.nlm.nih.gov/23954895

DMM7ZXR	DI	DMM7ZXR
DMM7ZXR	DN	GSK2126458
DMM7ZXR	MI	TTHBTOP
DMM7ZXR	MN	PI3-kinase gamma (PIK3CG)
DMM7ZXR	MT	DTT
DMM7ZXR	MA	Modulator
DMM7ZXR	RN	Company report (GSK)
DMM7ZXR	RU	http://www.gsk-clinicalstudyregister.com/study/113794#ps

DMRXW9P	DI	DMRXW9P
DMRXW9P	DN	GSK-2130579A
DMRXW9P	MI	TTZ8UT4
DMRXW9P	MN	Wilms tumor protein (WT1)
DMRXW9P	MT	DTT
DMRXW9P	RN	Spoilight on personalized medicine. A pharma matters report, Thomson Reuters, 2012.
DMRXW9P	RU	http://science.thomsonreuters.com.cn/media/spotlight_on_report_Q22012.pdf

DMUNVXR	DI	DMUNVXR
DMUNVXR	DN	GSK-2239633
DMUNVXR	MI	TT7HQD0
DMUNVXR	MN	C-C chemokine receptor type 4 (CCR4)
DMUNVXR	MT	DTT
DMUNVXR	MA	Antagonist
DMUNVXR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 61).
DMUNVXR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=61

DM5VS7B	DI	DM5VS7B
DM5VS7B	DN	GSK-2241658A
DM5VS7B	MI	TTE5ITK
DM5VS7B	MN	Cancer/testis antigen 1 (NY-ESO-1)
DM5VS7B	MT	DTT
DM5VS7B	RN	ClinicalTrials.gov (NCT01213472) Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma. U.S. National Institutes of Health.
DM5VS7B	RU	https://clinicaltrials.gov/ct2/show/NCT01213472

DMR24MI	DI	DMR24MI
DMR24MI	DN	GSK-2256098
DMR24MI	MI	TTON5IT
DMR24MI	MN	Focal adhesion kinase 1 (FAK)
DMR24MI	MT	DTT
DMR24MI	MA	Inhibitor
DMR24MI	RN	A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells. Cell Cycle. 2014;13(19):3143-9.
DMR24MI	RU	https://pubmed.ncbi.nlm.nih.gov/25486573

DM7FN12	DI	DM7FN12
DM7FN12	DN	GSK2256294
DM7FN12	MI	TT7WVHI
DM7FN12	MN	Soluble epoxide hydrolase (EPHX2)
DM7FN12	MT	DTT
DM7FN12	MA	Modulator
DM7FN12	RN	In vitro and in vivo characterization of a novel soluble epoxide hydrolase inhibitor. Prostaglandins Other Lipid Mediat. 2013 Jul-Aug;104-105:25-31.
DM7FN12	RU	https://pubmed.ncbi.nlm.nih.gov/23434473

DMOWTRL	DI	DMOWTRL
DMOWTRL	DN	GSK-2315698
DMOWTRL	MI	TTB7VAT
DMOWTRL	MN	Serum amyloid P-component (APCS)
DMOWTRL	MT	DTT
DMOWTRL	RN	Target Mediated Drug Disposition Model of CPHPC in Patients with Systemic Amyloidosis. CPT Pharmacometrics Syst Pharmacol. 2015 February; 4(2): e15.
DMOWTRL	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4360666/

DMZ5A6D	DI	DMZ5A6D
DMZ5A6D	DN	GSK2398852
DMZ5A6D	MI	TTB7VAT
DMZ5A6D	MN	Serum amyloid P-component (APCS)
DMZ5A6D	MT	DTT
DMZ5A6D	RN	ClinicalTrials.gov (NCT01777243) A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis. U.S. National Institutes of Health.
DMZ5A6D	RU	https://clinicaltrials.gov/ct2/show/NCT01777243

DMIVHDN	DI	DMIVHDN
DMIVHDN	DN	GSK2618960
DMIVHDN	MI	TT8FRMO
DMIVHDN	MN	Interleukin-7 (IL7)
DMIVHDN	MT	DTT
DMIVHDN	MA	Modulator
DMIVHDN	RN	ClinicalTrials.gov (NCT02293161) Single Ascending Doses Study of Anti- Interleukin-7 Receptor alpha Monoclonal Antibody (GSK2618960) in Healthy Volunteers. U.S. National Institutes of Health.
DMIVHDN	RU	https://clinicaltrials.gov/ct2/show/NCT02293161

DMCBGLW	DI	DMCBGLW
DMCBGLW	DN	GSK2636771
DMCBGLW	MI	TTTHBCA
DMCBGLW	MN	PI3-kinase beta (PIK3CB)
DMCBGLW	MT	DTT
DMCBGLW	MA	Inhibitor
DMCBGLW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7967).
DMCBGLW	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7967

DMQOM5V	DI	DMQOM5V
DMQOM5V	DN	GSK2646264
DMQOM5V	MI	TTOU65C
DMQOM5V	MN	Tyrosine-protein kinase SYK (SYK)
DMQOM5V	MT	DTT
DMQOM5V	MA	Inhibitor
DMQOM5V	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQOM5V	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM3KARJ	DI	DM3KARJ
DM3KARJ	DN	GSK2647544
DM3KARJ	MI	TTDNFMT
DM3KARJ	MN	Platelet-activating factor acetylhydrolase (PLA2G7)
DM3KARJ	MT	DTT
DM3KARJ	MA	Modulator
DM3KARJ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1432).
DM3KARJ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1432

DMAK89L	DI	DMAK89L
DMAK89L	DN	GSK2661380
DMAK89L	MI	TTNBFWK
DMAK89L	MN	Programmed cell death protein 1 (PD-1)
DMAK89L	MT	DTT
DMAK89L	MA	Inhibitor
DMAK89L	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2760).
DMAK89L	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2760

DMSGNVK	DI	DMSGNVK
DMSGNVK	DN	GSK2793660
DMSGNVK	MI	TT4H0V2
DMSGNVK	MN	Dipeptidyl peptidase I (CTSC)
DMSGNVK	MT	DTT
DMSGNVK	MA	Modulator
DMSGNVK	RN	ClinicalTrials.gov (NCT02058407) A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Food Effect of Single or Repeat Doses of GSK2793660 in Healthy Subjects. U.S. National Institutes of Health.
DMSGNVK	RU	https://clinicaltrials.gov/ct2/show/NCT02058407

DMJDVW4	DI	DMJDVW4
DMJDVW4	DN	GSK2816126
DMJDVW4	MI	TT9MZCQ
DMJDVW4	MN	Enhancer of zeste homolog 2 (EZH2)
DMJDVW4	MT	DTT
DMJDVW4	MA	Modulator
DMJDVW4	RN	National Cancer Institute Drug Dictionary (drug id 756211).
DMJDVW4	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=756211

DMU1X8K	DI	DMU1X8K
DMU1X8K	DN	GSK2820151
DMU1X8K	MI	TTE4BSY
DMU1X8K	MN	Bromodomain and extraterminal domain protein (BET)
DMU1X8K	MT	DTT
DMU1X8K	MA	Inhibitor
DMU1X8K	RN	ClinicalTrials.gov (NCT02630251) Dose Escalation Study of GSK2820151 in Subjects With Advanced or Recurrent Solid Tumors. U.S. National Institutes of Health.
DMU1X8K	RU	https://clinicaltrials.gov/ct2/show/NCT02630251

DMC47M9	DI	DMC47M9
DMC47M9	DN	GSK2831781
DMC47M9	MI	TTNVXAW
DMC47M9	MN	Lymphocyte activation gene 3 protein (LAG3)
DMC47M9	MT	DTT
DMC47M9	MA	Inhibitor
DMC47M9	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMC47M9	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM6KE4G	DI	DM6KE4G
DM6KE4G	DN	GSK2849330
DM6KE4G	MI	TTDC8N2
DM6KE4G	MN	Erbb3 tyrosine kinase receptor (Erbb-3)
DM6KE4G	MT	DTT
DM6KE4G	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1798).
DM6KE4G	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1798

DMT3V2W	DI	DMT3V2W
DMT3V2W	DN	GSK2879552
DMT3V2W	MI	TTNR0UQ
DMT3V2W	MN	Lysine-specific histone demethylase 1 (LSD)
DMT3V2W	MT	DTT
DMT3V2W	MA	Inhibitor
DMT3V2W	RN	A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC. Cancer Cell. 2015 Jul 13;28(1):57-69.
DMT3V2W	RU	https://pubmed.ncbi.nlm.nih.gov/26175415

DM4ZK6G	DI	DM4ZK6G
DM4ZK6G	DN	GSK3050002
DM4ZK6G	MI	TT2XAZY
DM4ZK6G	MN	Liver and activation-regulated chemokine (CCL20)
DM4ZK6G	MT	DTT
DM4ZK6G	MA	Inhibitor
DM4ZK6G	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM4ZK6G	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMCKNJX	DI	DMCKNJX
DMCKNJX	DN	GSK3052230
DMCKNJX	MI	TT5HU6Z
DMCKNJX	MN	Fibroblast growth factor (FGF)
DMCKNJX	MT	DTT
DMCKNJX	MA	Inhibitor
DMCKNJX	RN	National Cancer Institute Drug Dictionary (drug id 599037).
DMCKNJX	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=599037

DM70DYV	DI	DM70DYV
DM70DYV	DN	GSK311739
DM70DYV	MI	TTBH0VX
DM70DYV	MN	Histone deacetylase (HDAC)
DM70DYV	MT	DTT
DM70DYV	MA	Modulator
DM70DYV	RN	Clinical pipeline report, company report or official report of Phrma.org Leading Chronic Diseases Affecting Seniors 2014.
DM70DYV	RU	http://www.phrma.org/sites/default/files/pdf/2014-meds-in-dev-older-americans.pdf

DMQZSXD	DI	DMQZSXD
DMQZSXD	DN	GSK3117391
DMQZSXD	MI	TTBH0VX
DMQZSXD	MN	Histone deacetylase (HDAC)
DMQZSXD	MT	DTT
DMQZSXD	MA	Modulator
DMQZSXD	RN	The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet. 2009 January; 10(1): 32-42.
DMQZSXD	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3215088/

DM2KCIP	DI	DM2KCIP
DM2KCIP	DN	GSK3179106
DM2KCIP	MI	TT4DXQT
DM2KCIP	MN	Proto-oncogene c-Ret (RET)
DM2KCIP	MT	DTT
DM2KCIP	MA	Inhibitor
DM2KCIP	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM2KCIP	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMJAVN7	DI	DMJAVN7
DMJAVN7	DN	GSK3186899
DMJAVN7	MI	TTJ21A9
DMJAVN7	MN	Cyclin-dependent kinase 12 (CDK12)
DMJAVN7	MT	DTT
DMJAVN7	MA	Inhibitor
DMJAVN7	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline.
DMJAVN7	RU	https://www.gsk.com/en-gb/research-and-development/our-pipeline/

DMVEGND	DI	DMVEGND
DMVEGND	DN	GSK3368715
DMVEGND	MI	TTVOJAI
DMVEGND	MN	Protein arginine methyltransferase 1 (PRMT1)
DMVEGND	MT	DTT
DMVEGND	MA	Inhibitor
DMVEGND	RN	National Cancer Institute Drug Dictionary (drug name GSK6097608).
DMVEGND	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/prmt1-inhibitor-gsk3368715

DMIEAMU	DI	DMIEAMU
DMIEAMU	DN	GSK-356278
DMIEAMU	MI	TTZ97H5
DMIEAMU	MN	Phosphodiesterase 4A (PDE4A)
DMIEAMU	MT	DTT
DMIEAMU	MA	Inhibitor
DMIEAMU	RN	GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species. J Pharmacol Exp Ther. 2014 Jul;350(1):153-63.
DMIEAMU	RU	https://pubmed.ncbi.nlm.nih.gov/24784567

DMIEAMU	DI	DMIEAMU
DMIEAMU	DN	GSK-356278
DMIEAMU	MI	TTVIAT9
DMIEAMU	MN	Phosphodiesterase 4B (PDE4B)
DMIEAMU	MT	DTT
DMIEAMU	MA	Inhibitor
DMIEAMU	RN	GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species. J Pharmacol Exp Ther. 2014 Jul;350(1):153-63.
DMIEAMU	RU	https://pubmed.ncbi.nlm.nih.gov/24784567

DMIEAMU	DI	DMIEAMU
DMIEAMU	DN	GSK-356278
DMIEAMU	MI	TTSKMI8
DMIEAMU	MN	Phosphodiesterase 4D (PDE4D)
DMIEAMU	MT	DTT
DMIEAMU	MA	Inhibitor
DMIEAMU	RN	GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species. J Pharmacol Exp Ther. 2014 Jul;350(1):153-63.
DMIEAMU	RU	https://pubmed.ncbi.nlm.nih.gov/24784567

DMRYNJD	DI	DMRYNJD
DMRYNJD	DN	GSK3745417
DMRYNJD	MI	TTT402Y
DMRYNJD	MN	Stimulator of interferon genes protein (TMEM173)
DMRYNJD	MT	DTT
DMRYNJD	MA	Agonist
DMRYNJD	RN	National Cancer Institute Drug Dictionary (drug name GSK3745417).
DMRYNJD	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/sting-agonist-gsk3745417

DM1UQ4Y	DI	DM1UQ4Y
DM1UQ4Y	DN	GSK3845097
DM1UQ4Y	MI	TTE5ITK
DM1UQ4Y	MN	Cancer/testis antigen 1 (NY-ESO-1)
DM1UQ4Y	MT	DTT
DM1UQ4Y	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline.
DM1UQ4Y	RU	https://www.gsk.com/en-gb/research-and-development/our-pipeline/

DMN4I7P	DI	DMN4I7P
DMN4I7P	DN	GSK3901961
DMN4I7P	MI	TTE5ITK
DMN4I7P	MN	Cancer/testis antigen 1 (NY-ESO-1)
DMN4I7P	MT	DTT
DMN4I7P	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline.
DMN4I7P	RU	https://www.gsk.com/en-gb/research-and-development/our-pipeline/

DMI3FU6	DI	DMI3FU6
DMI3FU6	DN	GSK4074386
DMI3FU6	MI	TTNVXAW
DMI3FU6	MN	Lymphocyte activation gene 3 protein (LAG3)
DMI3FU6	MT	DTT
DMI3FU6	MA	Inhibitor
DMI3FU6	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline.
DMI3FU6	RU	https://www.gsk.com/en-gb/research-and-development/our-pipeline/

DM0P729	DI	DM0P729
DM0P729	DN	GSK461364
DM0P729	MI	TTIYVQP
DM0P729	MN	Polo-like kinase 1 (PLK1)
DM0P729	MT	DTT
DM0P729	MA	Inhibitor
DM0P729	RN	Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009 Jun;14(6):559-70.
DM0P729	RU	https://pubmed.ncbi.nlm.nih.gov/19474163

DMPAWBN	DI	DMPAWBN
DMPAWBN	DN	GSK525762
DMPAWBN	MI	TTE4BSY
DMPAWBN	MN	Bromodomain and extraterminal domain protein (BET)
DMPAWBN	MT	DTT
DMPAWBN	MA	Inhibitor
DMPAWBN	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPAWBN	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMPAWBN	DI	DMPAWBN
DMPAWBN	DN	GSK525762
DMPAWBN	MI	TTRA6BO
DMPAWBN	MN	Bromodomain-containing protein 4 (BRD4)
DMPAWBN	MT	DTT
DMPAWBN	MA	Modulator
DMPAWBN	RN	Targeting bromodomains: epigenetic readers of lysine acetylation.Nat Rev Drug Discov.2014 May;13(5):337-56.
DMPAWBN	RU	https://www.ncbi.nlm.nih.gov/pubmed/24751816

DM5E9LX	DI	DM5E9LX
DM5E9LX	DN	GSK586529
DM5E9LX	MI	TT7EFHR
DM5E9LX	MN	Corticotropin-releasing factor receptor 1 (CRHR1)
DM5E9LX	MT	DTT
DM5E9LX	MA	Antagonist
DM5E9LX	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DM5E9LX	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMWI0AL	DI	DMWI0AL
DMWI0AL	DN	GSK6097608
DMWI0AL	MI	TT83C4X
DMWI0AL	MN	T-cell surface protein tactile (CD96)
DMWI0AL	MT	DTT
DMWI0AL	MA	Antagonist
DMWI0AL	RN	National Cancer Institute Drug Dictionary (drug name GSK6097608).
DMWI0AL	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-cd96-monoclonal-antibody-gsk6097608

DMJPXZ4	DI	DMJPXZ4
DMJPXZ4	DN	GSK618334
DMJPXZ4	MI	DE3GT9C
DMJPXZ4	MN	Cytochrome P450 4F2 (CYP4F2)
DMJPXZ4	MT	DME
DMJPXZ4	MA	Metabolism
DMJPXZ4	RN	Product information - Gilenya.
DMJPXZ4	RU	http://www.medsafe.govt.nz/profs/datasheet/g/gilenyacap.pdf

DMJPXZ4	DI	DMJPXZ4
DMJPXZ4	DN	GSK618334
DMJPXZ4	MI	TT4C8EA
DMJPXZ4	MN	Dopamine D3 receptor (D3R)
DMJPXZ4	MT	DTT
DMJPXZ4	MA	Antagonist
DMJPXZ4	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMJPXZ4	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMJPXZ4	DI	DMJPXZ4
DMJPXZ4	DN	GSK618334
DMJPXZ4	MI	TTOHFIY
DMJPXZ4	MN	Sphingosine kinase 1 (SPHK1)
DMJPXZ4	MT	DTT
DMJPXZ4	MA	Inhibitor
DMJPXZ4	RN	Sphingosine kinase 1 is a potential therapeutic target for nasopharyngeal carcinoma.Oncotarget. 2016 Dec 6;7(49):80586-80598. 
DMJPXZ4	RU	https://pubmed.ncbi.nlm.nih.gov/27811359

DM7CIN4	DI	DM7CIN4
DM7CIN4	DN	GSK-625433
DM7CIN4	MI	TTMVBWH
DM7CIN4	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DM7CIN4	MT	DTT
DM7CIN4	MA	Inhibitor
DM7CIN4	RN	Preclinical Characterization of PF-00868554, a Potent Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase . Antimicrob Agents Chemother. 2009 June; 53(6): 2544-2552.
DM7CIN4	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687230/

DMRBVHE	DI	DMRBVHE
DMRBVHE	DN	GSK690693
DMRBVHE	MI	TTAZ05C
DMRBVHE	MN	RAC-gamma serine/threonine-protein kinase (AKT3)
DMRBVHE	MT	DTT
DMRBVHE	MA	Modulator
DMRBVHE	RN	Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity.Cancer Res.2008 Apr 1;68(7):2366-74.
DMRBVHE	RU	https://www.ncbi.nlm.nih.gov/pubmed/18381444

DM4LR0Y	DI	DM4LR0Y
DM4LR0Y	DN	GSK-958108
DM4LR0Y	MI	TTSQIFT
DM4LR0Y	MN	5-HT 1A receptor (HTR1A)
DM4LR0Y	MT	DTT
DM4LR0Y	MA	Antagonist
DM4LR0Y	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline.
DM4LR0Y	RU	https://gsk.sylogent.com/files/24664.pdf

DMX2J57	DI	DMX2J57
DMX2J57	DN	GT103
DMX2J57	MI	TTUW6OP
DMX2J57	MN	Complement factor H (CFH)
DMX2J57	MT	DTT
DMX2J57	MA	Inhibitor
DMX2J57	RN	Clinical pipeline report, company report or official report of Grid Therapeutics.
DMX2J57	RU	https://gridtherapeutics.com/research-development/gt103/

DM20HS7	DI	DM20HS7
DM20HS7	DN	GTP-004
DM20HS7	MI	TT1RS9F
DM20HS7	MN	Acetylcholinesterase (AChE)
DM20HS7	MT	DTT
DM20HS7	MA	Inhibitor
DM20HS7	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM20HS7	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM4T5LH	DI	DM4T5LH
DM4T5LH	DN	Guanosine
DM4T5LH	MI	TT1U2YM
DM4T5LH	MN	Cytomegalovirus DNA polymerase (CMV UL54)
DM4T5LH	MT	DTT
DM4T5LH	MA	Inhibitor
DM4T5LH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM4T5LH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM4T5LH	DI	DM4T5LH
DM4T5LH	DN	Guanosine
DM4T5LH	MI	TTIU7X1
DM4T5LH	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DM4T5LH	MT	DTT
DM4T5LH	MA	Inhibitor
DM4T5LH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM4T5LH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM4T5LH	DI	DM4T5LH
DM4T5LH	DN	Guanosine
DM4T5LH	MI	TTMCF1Y
DM4T5LH	MN	Purine nucleoside phosphorylase (PNP)
DM4T5LH	MT	DTT
DM4T5LH	MA	Inhibitor
DM4T5LH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM4T5LH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMM1RB6	DI	DMM1RB6
DMM1RB6	DN	GW-328267
DMM1RB6	MI	TTM2AOE
DMM1RB6	MN	Adenosine A2a receptor (ADORA2A)
DMM1RB6	MT	DTT
DMM1RB6	MA	Modulator
DMM1RB6	RN	ADENOSINE RECEPTORS AS TARGETS FOR THERAPEUTIC INTERVENTION IN ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE
DMM1RB6	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778268

DMOE5SZ	DI	DMOE5SZ
DMOE5SZ	DN	GW-409544
DMOE5SZ	MI	TTJ584C
DMOE5SZ	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMOE5SZ	MT	DTT
DMOE5SZ	MA	Modulator
DMOE5SZ	RN	Design novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approach. PLoS One. 2012;7(6):e38546.
DMOE5SZ	RU	https://pubmed.ncbi.nlm.nih.gov/22685582

DMOE5SZ	DI	DMOE5SZ
DMOE5SZ	DN	GW-409544
DMOE5SZ	MI	TTZMAO3
DMOE5SZ	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMOE5SZ	MT	DTT
DMOE5SZ	MA	Modulator
DMOE5SZ	RN	Design novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approach. PLoS One. 2012;7(6):e38546.
DMOE5SZ	RU	https://pubmed.ncbi.nlm.nih.gov/22685582

DMBDW93	DI	DMBDW93
DMBDW93	DN	GW-695634
DMBDW93	MI	TT84ETX
DMBDW93	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMBDW93	MT	DTT
DMBDW93	MA	Inhibitor
DMBDW93	RN	Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors. Curr Opin Investig Drugs. 2006 Feb;7(2):128-35.
DMBDW93	RU	https://pubmed.ncbi.nlm.nih.gov/16499282

DMQ46DN	DI	DMQ46DN
DMQ46DN	DN	GW-796406
DMQ46DN	MI	TTL69WB
DMQ46DN	MN	Angiotensin-converting enzyme (ACE)
DMQ46DN	MT	DTT
DMQ46DN	MA	Modulator
DMQ46DN	RN	Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406. J Pharmacol Exp Ther. 2005 Dec;315(3):1306-13.
DMQ46DN	RU	https://pubmed.ncbi.nlm.nih.gov/16144980

DMQ46DN	DI	DMQ46DN
DMQ46DN	DN	GW-796406
DMQ46DN	MI	TT5TKPM
DMQ46DN	MN	Neutral endopeptidase (MME)
DMQ46DN	MT	DTT
DMQ46DN	MA	Modulator
DMQ46DN	RN	Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406. J Pharmacol Exp Ther. 2005 Dec;315(3):1306-13.
DMQ46DN	RU	https://pubmed.ncbi.nlm.nih.gov/16144980

DMGO6M1	DI	DMGO6M1
DMGO6M1	DN	GZ402666
DMGO6M1	MI	TTLPC70
DMGO6M1	MN	Lysosomal alpha-glucosidase (GAA)
DMGO6M1	MT	DTT
DMGO6M1	MA	Modulator
DMGO6M1	RN	ClinicalTrials.gov (NCT01898364) Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients.. U.S. National Institutes of Health.
DMGO6M1	RU	https://clinicaltrials.gov/ct2/show/NCT01898364

DME6VX4	DI	DME6VX4
DME6VX4	DN	GZ402668
DME6VX4	MI	TTQT5S9
DME6VX4	MN	Cambridge pathology 1 antigen (CD52)
DME6VX4	MT	DTT
DME6VX4	RN	Characterization of a Next Generation Anti-CD52 Antibody. Neurology. April 6, 2015 vol. 84 no. 14.
DME6VX4	RU	http://www.neurology.org/content/84/14_Supplement/S20.006

DMTWNLY	DI	DMTWNLY
DMTWNLY	DN	GZ402674
DMTWNLY	MI	TTGTQHC
DMTWNLY	MN	DNA topoisomerase I (TOP1)
DMTWNLY	MT	DTT
DMTWNLY	MA	Modulator
DMTWNLY	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2636).
DMTWNLY	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2636

DMRCHOU	DI	DMRCHOU
DMRCHOU	DN	H-103
DMRCHOU	MI	TTHYBIX
DMRCHOU	MN	Heat shock protein 70 (HSP70)
DMRCHOU	MT	DTT
DMRCHOU	MA	Modulator
DMRCHOU	RN	A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients. Gene Ther. 2009 Mar;16(3):376-82.
DMRCHOU	RU	https://pubmed.ncbi.nlm.nih.gov/19092859

DMAYTRK	DI	DMAYTRK
DMAYTRK	DN	H3B-6527
DMAYTRK	MI	DE4LYSA
DMAYTRK	MN	Cytochrome P450 3A4 (CYP3A4)
DMAYTRK	MT	DME
DMAYTRK	MA	Metabolism
DMAYTRK	RN	Correlation of the in vitro biotransformation of H3B-6527 in dog and human hepatocytes with the in vivo metabolic profile of 14C-H3B-6527 in a dog mass balance study. Xenobiotica. 2020 Apr;50(4):458-467.
DMAYTRK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31305210

DMAYTRK	DI	DMAYTRK
DMAYTRK	DN	H3B-6527
DMAYTRK	MI	DEIBDNY
DMAYTRK	MN	Cytochrome P450 3A5 (CYP3A5)
DMAYTRK	MT	DME
DMAYTRK	MA	Metabolism
DMAYTRK	RN	Correlation of the in vitro biotransformation of H3B-6527 in dog and human hepatocytes with the in vivo metabolic profile of 14C-H3B-6527 in a dog mass balance study. Xenobiotica. 2020 Apr;50(4):458-467.
DMAYTRK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31305210

DMAYTRK	DI	DMAYTRK
DMAYTRK	DN	H3B-6527
DMAYTRK	MI	TT1KX2S
DMAYTRK	MN	FGFR4 messenger RNA (FGFR4 mRNA)
DMAYTRK	MT	DTT
DMAYTRK	MA	Inhibitor
DMAYTRK	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMAYTRK	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMMVXGR	DI	DMMVXGR
DMMVXGR	DN	H3B-8800
DMMVXGR	MI	TTXR78S
DMMVXGR	MN	SF3b complex (SF3b)
DMMVXGR	MT	DTT
DMMVXGR	MA	Modulator
DMMVXGR	RN	Clinical pipeline report, company report or official report of H3 Biomedicine.
DMMVXGR	RU	https://www.h3biomedicine.com/science/

DMHI8RS	DI	DMHI8RS
DMHI8RS	DN	HCBE-11
DMHI8RS	MI	TTFO0PM
DMHI8RS	MN	Lymphotoxin beta receptor (LTBR)
DMHI8RS	MT	DTT
DMHI8RS	RN	Lymphotoxin beta receptor activation on macrophages induces cross-tolerance to TLR4 and TLR9 ligands. J Immunol. 2012 Apr 1;188(7):3426-33.
DMHI8RS	RU	https://pubmed.ncbi.nlm.nih.gov/22357629

DMVRTCW	DI	DMVRTCW
DMVRTCW	DN	HDM201
DMVRTCW	MI	TT7SBF5
DMVRTCW	MN	Cellular tumor antigen p53 (TP53)
DMVRTCW	MT	DTT
DMVRTCW	MA	Inhibitor
DMVRTCW	RN	National Cancer Institute Drug Dictionary (drug id 761551).
DMVRTCW	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=761551

DMVRTCW	DI	DMVRTCW
DMVRTCW	DN	HDM201
DMVRTCW	MI	TT08GJW
DMVRTCW	MN	Ubiquitin-protein ligase E3 Mdm2 (MDM2)
DMVRTCW	MT	DTT
DMVRTCW	MA	Inhibitor
DMVRTCW	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMVRTCW	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMM7VOB	DI	DMM7VOB
DMM7VOB	DN	Hepapoietin
DMM7VOB	MI	TTNDSF4
DMM7VOB	MN	Proto-oncogene c-Met (MET)
DMM7VOB	MT	DTT
DMM7VOB	MA	Inhibitor
DMM7VOB	RN	Pharmacokinetics and biochemical effects of hepapoietin in patients with chronic liver disease. Alimentary Pharmacology & Therapeutics Volume 16, Issue 2, pages 235-242, February 2002.
DMM7VOB	RU	http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2036.2002.01110.x/full

DMBFYSR	DI	DMBFYSR
DMBFYSR	DN	Hepcidin mab
DMBFYSR	MI	TTPCG5T
DMBFYSR	MN	Hepcidin (HAMP)
DMBFYSR	MT	DTT
DMBFYSR	RN	The pathophysiology and pharmacology of hepcidin. Trends Pharmacol Sci. 2014 March; 35(3): 155-161.
DMBFYSR	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978192/

DMXETUQ	DI	DMXETUQ
DMXETUQ	DN	HER-2/HER-1 vaccine
DMXETUQ	MI	TTGKNB4
DMXETUQ	MN	Epidermal growth factor receptor (EGFR)
DMXETUQ	MT	DTT
DMXETUQ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
DMXETUQ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797

DMZXDBN	DI	DMZXDBN
DMZXDBN	DN	HER2-CAR T Cells
DMZXDBN	MI	TT6EO5L
DMZXDBN	MN	Erbb2 tyrosine kinase receptor (HER2)
DMZXDBN	MT	DTT
DMZXDBN	MA	CAR-T-Cell-Therapy
DMZXDBN	RN	ClinicalTrials.gov (NCT03696030) HER2-CAR T Cells in Treating Participants With Brain or Leptomeningeal Metastases
DMZXDBN	RU	https://clinicaltrials.gov/ct2/show/NCT03696030

DMJ52F9	DI	DMJ52F9
DMJ52F9	DN	HER2p63-71 peptide vaccine
DMJ52F9	MI	TT6EO5L
DMJ52F9	MN	Erbb2 tyrosine kinase receptor (HER2)
DMJ52F9	MT	DTT
DMJ52F9	RN	Development of a cancer vaccine: peptides, proteins, and DNA. Cancer Chemother Pharmacol. 2000;46 Suppl:S77-82.
DMJ52F9	RU	https://pubmed.ncbi.nlm.nih.gov/10950153

DMJKBWO	DI	DMJKBWO
DMJKBWO	DN	HER2-specific CAR T cell
DMJKBWO	MI	TT6EO5L
DMJKBWO	MN	Erbb2 tyrosine kinase receptor (HER2)
DMJKBWO	MT	DTT
DMJKBWO	MA	CAR-T-Cell-Therapy
DMJKBWO	RN	ClinicalTrials.gov (NCT03500991) HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors
DMJKBWO	RU	https://clinicaltrials.gov/ct2/show/NCT03500991

DM7UJ6E	DI	DM7UJ6E
DM7UJ6E	DN	HER2-specific T cells
DM7UJ6E	MI	TT6EO5L
DM7UJ6E	MN	Erbb2 tyrosine kinase receptor (HER2)
DM7UJ6E	MT	DTT
DM7UJ6E	MA	CAR-T-Cell-Therapy
DM7UJ6E	RN	ClinicalTrials.gov (NCT02442297) T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With Glioblastoma
DM7UJ6E	RU	https://clinicaltrials.gov/ct2/show/NCT02442297

DMDZQ23	DI	DMDZQ23
DMDZQ23	DN	HF-0299
DMDZQ23	MI	TTHRID2
DMDZQ23	MN	Insulin-like growth factor I receptor (IGF1R)
DMDZQ23	MT	DTT
DMDZQ23	MA	Modulator
DMDZQ23	RN	A primary adrenal steroid, 11beta-hydroxyandrostenedione, has an osteotropic effect and little androgenic activity. J Steroid Biochem Mol Biol. 2000 Nov 15;74(4):203-11.
DMDZQ23	RU	https://pubmed.ncbi.nlm.nih.gov/11162926

DMS9WXG	DI	DMS9WXG
DMS9WXG	DN	HGS-1029
DMS9WXG	MI	TTR7B60
DMS9WXG	MN	X-linked inhibitor of apoptosis protein (XIAP)
DMS9WXG	MT	DTT
DMS9WXG	MA	Antagonist
DMS9WXG	RN	Clinical pipeline report, company report or official report of Aegera Therapeutics Inc.
DMS9WXG	RU	http://www.aegera.com/aeg40826.php

DMQIE58	DI	DMQIE58
DMQIE58	DN	HH2853
DMQIE58	MI	TTNJA0C
DMQIE58	MN	Enhancer of zeste homolog 1 (EZH1)
DMQIE58	MT	DTT
DMQIE58	MA	Inhibitor
DMQIE58	RN	Clinical pipeline report, company report or official report of HaiHe Biopharma.
DMQIE58	RU	https://www.haihepharma.com/en/news/details/215

DMQIE58	DI	DMQIE58
DMQIE58	DN	HH2853
DMQIE58	MI	TT9MZCQ
DMQIE58	MN	Enhancer of zeste homolog 2 (EZH2)
DMQIE58	MT	DTT
DMQIE58	MA	Inhibitor
DMQIE58	RN	Clinical pipeline report, company report or official report of HaiHe Biopharma.
DMQIE58	RU	https://www.haihepharma.com/en/news/details/215

DMRQ4L6	DI	DMRQ4L6
DMRQ4L6	DN	HHCYH33
DMRQ4L6	MI	TTEUNMR
DMRQ4L6	MN	PI3-kinase alpha (PIK3CA)
DMRQ4L6	MT	DTT
DMRQ4L6	MA	Inhibitor
DMRQ4L6	RN	Adaptive resistance to PI3Kalpha-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cells. Cell Death Dis. 2021 Jan 14;12(1):85.
DMRQ4L6	RU	https://pubmed.ncbi.nlm.nih.gov/33446653

DM45MR0	DI	DM45MR0
DM45MR0	DN	HIP-2B
DM45MR0	MI	TTL4H8N
DM45MR0	MN	Regenerating human pro-islet peptide (REG3A)
DM45MR0	MT	DTT
DM45MR0	MA	Modulator
DM45MR0	RN	Hepatocarcinoma-intestine-pancreas/pancreatic associated protein (HIP/PAP) is expressed and secreted by proliferating ductules as well as by hepatocarcinoma and cholangiocarcinoma cells. Am J Pathol.1999 Nov;155(5):1525-33.
DM45MR0	RU	https://pubmed.ncbi.nlm.nih.gov/10550309

DMT3HKZ	DI	DMT3HKZ
DMT3HKZ	DN	HL-018
DMT3HKZ	MI	TT0FYAN
DMT3HKZ	MN	Free fatty acid receptor 2 (FFAR2)
DMT3HKZ	MT	DTT
DMT3HKZ	MA	Inhibitor
DMT3HKZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 226).
DMT3HKZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=226

DME4D7H	DI	DME4D7H
DME4D7H	DN	HM71224
DME4D7H	MI	TTGM6VW
DME4D7H	MN	Tyrosine-protein kinase BTK (ATK)
DME4D7H	MT	DTT
DME4D7H	MA	Inhibitor
DME4D7H	RN	HM71224, a selective Bruton's tyrosine kinase inhibitor, attenuates the development of murine lupus. Arthritis Res Ther. 2017 Sep 26;19(1):211.
DME4D7H	RU	https://pubmed.ncbi.nlm.nih.gov/28950886

DMXZ1A8	DI	DMXZ1A8
DMXZ1A8	DN	HMPL-523
DMXZ1A8	MI	TTOU65C
DMXZ1A8	MN	Tyrosine-protein kinase SYK (SYK)
DMXZ1A8	MT	DTT
DMXZ1A8	MA	Inhibitor
DMXZ1A8	RN	Clinical pipeline report, company report or official report of Hutchison MediPharma.
DMXZ1A8	RU	https://www.hutch-med.com/pipeline-and-products/our-pipeline/

DMEGN5I	DI	DMEGN5I
DMEGN5I	DN	HMPL-689
DMEGN5I	MI	TTGBPJE
DMEGN5I	MN	PI3-kinase delta (PIK3CD)
DMEGN5I	MT	DTT
DMEGN5I	MA	Inhibitor
DMEGN5I	RN	Clinical pipeline report, company report or official report of Hutchison MediPharma.
DMEGN5I	RU	https://www.hutch-med.com/pipeline-and-products/our-pipeline/

DM695QT	DI	DM695QT
DM695QT	DN	HMR-1031
DM695QT	MI	TT6S84X
DM695QT	MN	Integrin alpha-4/beta-1 (ITGA4/B1)
DM695QT	MT	DTT
DM695QT	MA	Modulator
DM695QT	RN	Pharmacoscintigraphic comparison of HMR 1031, a VLA-4 antagonist, in healthy volunteers following delivery via a nebulizer and a dry powder inhaler. Am J Ther. 2004 Mar-Apr;11(2):103-13.
DM695QT	RU	https://pubmed.ncbi.nlm.nih.gov/14999362

DMRYM03	DI	DMRYM03
DMRYM03	DN	HMS5552
DMRYM03	MI	TTDLNGZ
DMRYM03	MN	Glucokinase (GCK)
DMRYM03	MT	DTT
DMRYM03	MA	Activator
DMRYM03	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMRYM03	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMI0KQW	DI	DMI0KQW
DMI0KQW	DN	HPN217
DMI0KQW	MI	TTZ3P4W
DMI0KQW	MN	B-cell maturation protein (TNFRSF17)
DMI0KQW	MT	DTT
DMI0KQW	RN	Clinical pipeline report, company report or official report of AbbVie.
DMI0KQW	RU	https://www.abbvie.com/our-science/pipeline/hpn-217.html

DMLZDVR	DI	DMLZDVR
DMLZDVR	DN	HPN424
DMLZDVR	MI	TT9G4N0
DMLZDVR	MN	Glutamate carboxypeptidase II (GCPII)
DMLZDVR	MT	DTT
DMLZDVR	RN	Clinical pipeline report, company report or official report of Harpoon Therapeutics.
DMLZDVR	RU	https://www.harpoontx.com/pipeline/

DMUEZ7V	DI	DMUEZ7V
DMUEZ7V	DN	HPP404
DMUEZ7V	MI	TT9JNIC
DMUEZ7V	MN	Histamine H3 receptor (H3R)
DMUEZ7V	MT	DTT
DMUEZ7V	MA	Antagonist
DMUEZ7V	RN	Clinical pipeline report, company report or official report of TransTech Pharma (2011).
DMUEZ7V	RU	http://www.ttpharma.com/

DM5VSZR	DI	DM5VSZR
DM5VSZR	DN	HPP-607
DM5VSZR	MI	TTPS3C0
DM5VSZR	MN	Aurora kinase A (AURKA)
DM5VSZR	MT	DTT
DM5VSZR	MA	Inhibitor
DM5VSZR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1936).
DM5VSZR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1936

DM5VSZR	DI	DM5VSZR
DM5VSZR	DN	HPP-607
DM5VSZR	MI	TT5LS6T
DM5VSZR	MN	Aurora kinase B (AURKB)
DM5VSZR	MT	DTT
DM5VSZR	MA	Inhibitor
DM5VSZR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1936).
DM5VSZR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1936

DM5VSZR	DI	DM5VSZR
DM5VSZR	DN	HPP-607
DM5VSZR	MI	TTLYXIT
DM5VSZR	MN	Aurora kinase C (AURKC)
DM5VSZR	MT	DTT
DM5VSZR	MA	Inhibitor
DM5VSZR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1936).
DM5VSZR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1936

DMSLDHG	DI	DMSLDHG
DMSLDHG	DN	HPP-854
DMSLDHG	MI	TT8JRS7
DMSLDHG	MN	Beta-secretase (BACE)
DMSLDHG	MT	DTT
DMSLDHG	MA	Modulator
DMSLDHG	RN	BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimers Res Ther. 2014 Dec 24;6(9):89.
DMSLDHG	RU	https://pubmed.ncbi.nlm.nih.gov/25621019

DMZXG7Q	DI	DMZXG7Q
DMZXG7Q	DN	HPP971
DMZXG7Q	MI	TTA6ZN2
DMZXG7Q	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMZXG7Q	MT	DTT
DMZXG7Q	MA	Activator
DMZXG7Q	RN	Clinical pipeline report, company report or official report of vTv Therapeutics.
DMZXG7Q	RU	https://vtvtherapeutics.com/pipeline/nrf2-bach1-program/

DMJG4WR	DI	DMJG4WR
DMJG4WR	DN	HSDB-674
DMJG4WR	MI	DEDPI65
DMJG4WR	MN	Oxygen-insensitive NADPH nitroreductase A (nfsA)
DMJG4WR	MT	DME
DMJG4WR	MA	Metabolism
DMJG4WR	RN	Absorption of (-)-nicotine-l-N-oxide in man and its reduction in the gastrointestinal tract. J Pharm Pharmacol. 1970 Sep;22(9):722-3.
DMJG4WR	RU	https://pubmed.ncbi.nlm.nih.gov/4394772

DML6HP3	DI	DML6HP3
DML6HP3	DN	HSP-990
DML6HP3	MI	DE5IED8
DML6HP3	MN	Cytochrome P450 2C9 (CYP2C9)
DML6HP3	MT	DME
DML6HP3	MA	Metabolism
DML6HP3	RN	A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies. Br J Cancer. 2015 Feb 17;112(4):650-9.
DML6HP3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25625276

DMI4TEC	DI	DMI4TEC
DMI4TEC	DN	HTI-1090
DMI4TEC	MI	TTZJYKH
DMI4TEC	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMI4TEC	MT	DTT
DMI4TEC	MA	Inhibitor
DMI4TEC	RN	Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation. J Enzyme Inhib Med Chem. 2019 Dec;34(1):250-263.
DMI4TEC	RU	https://pubmed.ncbi.nlm.nih.gov/30734612

DMI4TEC	DI	DMI4TEC
DMI4TEC	DN	HTI-1090
DMI4TEC	MI	TTXNCBV
DMI4TEC	MN	Tryptophan 2,3-dioxygenase (TDO)
DMI4TEC	MT	DTT
DMI4TEC	MA	Inhibitor
DMI4TEC	RN	Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation. J Enzyme Inhib Med Chem. 2019 Dec;34(1):250-263.
DMI4TEC	RU	https://pubmed.ncbi.nlm.nih.gov/30734612

DMB3LQU	DI	DMB3LQU
DMB3LQU	DN	HuA33
DMB3LQU	MI	TT96HUR
DMB3LQU	MN	Cell surface A33 antigen (GPA33)
DMB3LQU	MT	DTT
DMB3LQU	RN	(124)I-huA33 antibody PET of colorectal cancer. J Nucl Med. 2011 Aug;52(8):1173-80.
DMB3LQU	RU	https://pubmed.ncbi.nlm.nih.gov/21764796

DM9VB4I	DI	DM9VB4I
DM9VB4I	DN	Hu-CART meso cells
DM9VB4I	MI	TT4RXME
DM9VB4I	MN	Mesothelin (MSLN)
DM9VB4I	MT	DTT
DM9VB4I	MA	CAR-T-Cell-Therapy
DM9VB4I	RN	ClinicalTrials.gov (NCT03054298) CAR T Cells in Mesothelin Expressing Cancers
DM9VB4I	RU	https://clinicaltrials.gov/ct2/show/NCT03054298

DMNAR29	DI	DMNAR29
DMNAR29	DN	HuCART19
DMNAR29	MI	TTW640A
DMNAR29	MN	B-lymphocyte surface antigen B4 (CD19)
DMNAR29	MT	DTT
DMNAR29	MA	CAR-T-Cell-Therapy
DMNAR29	RN	ClinicalTrials.gov (NCT02374333) Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy
DMNAR29	RU	https://clinicaltrials.gov/ct2/show/NCT02374333

DM4F8AU	DI	DM4F8AU
DM4F8AU	DN	HuCART-meso cells
DM4F8AU	MI	TT4RXME
DM4F8AU	MN	Mesothelin (MSLN)
DM4F8AU	MT	DTT
DM4F8AU	MA	CAR-T-Cell-Therapy
DM4F8AU	RN	ClinicalTrials.gov (NCT03323944) CAR T Cell Immunotherapy for Pancreatic Cancer
DM4F8AU	RU	https://clinicaltrials.gov/ct2/show/NCT03323944

DMDZBTY	DI	DMDZBTY
DMDZBTY	DN	HuM195/rGel
DMDZBTY	MI	TTJVYO3
DMDZBTY	MN	Myeloid cell surface antigen CD33 (CD33)
DMDZBTY	MT	DTT
DMDZBTY	RN	Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies. Haematologica. 2013 Feb;98(2):217-21.
DMDZBTY	RU	https://pubmed.ncbi.nlm.nih.gov/22875630

DM0W275	DI	DM0W275
DM0W275	DN	Human CD19 targeted T Cells
DM0W275	MI	TTW640A
DM0W275	MN	B-lymphocyte surface antigen B4 (CD19)
DM0W275	MT	DTT
DM0W275	MA	CAR-T-Cell-Therapy
DM0W275	RN	ClinicalTrials.gov (NCT03720457) Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma.
DM0W275	RU	https://clinicaltrials.gov/ct2/show/NCT03720457

DMVGBA1	DI	DMVGBA1
DMVGBA1	DN	HuMNC2-CAR44 T cells
DMVGBA1	MI	TTBHFYQ
DMVGBA1	MN	Mucin-1 (MUC1)
DMVGBA1	MT	DTT
DMVGBA1	RN	Clinical pipeline report, company report or official report of Minerva Biotechnologies.
DMVGBA1	RU	https://www.minervabio.com/minervabio.com/pipeline/

DMFRM15	DI	DMFRM15
DMFRM15	DN	HX-100
DMFRM15	MI	TTELV3W
DMFRM15	MN	Transformation-sensitive protein p120 (TRPA1)
DMFRM15	MT	DTT
DMFRM15	MA	Inhibitor
DMFRM15	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMFRM15	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMRE6UT	DI	DMRE6UT
DMRE6UT	DN	IBC-VS01
DMRE6UT	MI	TTZOPHG
DMRE6UT	MN	Insulin (INS)
DMRE6UT	MT	DTT
DMRE6UT	MA	Modulator
DMRE6UT	RN	Prevention of Type 1 Diabetes Mellitus using a Novel Vaccine. Ther Adv Endocrinol Metab. 2011 February; 2(1): 9-16.
DMRE6UT	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3474625/

DMXUJ1P	DI	DMXUJ1P
DMXUJ1P	DN	IBI188
DMXUJ1P	MI	TT28S46
DMXUJ1P	MN	Leukocyte surface antigen CD47 (CD47)
DMXUJ1P	MT	DTT
DMXUJ1P	MA	Blocker
DMXUJ1P	RN	Clinical pipeline report, company report or official report of Innovent Biologics.
DMXUJ1P	RU	https://www.innoventbio.com/ScienceAndProducts/Pipeline/ProductRAndD

DMYBHIR	DI	DMYBHIR
DMYBHIR	DN	IBI-20089
DMYBHIR	MI	TTYRL6O
DMYBHIR	MN	Glucocorticoid receptor (NR3C1)
DMYBHIR	MT	DTT
DMYBHIR	MA	Agonist
DMYBHIR	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMYBHIR	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMB83V4	DI	DMB83V4
DMB83V4	DN	IBI318
DMB83V4	MI	TT8ZLTI
DMB83V4	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMB83V4	MT	DTT
DMB83V4	MA	Inhibitor
DMB83V4	RN	Clinical pipeline report, company report or official report of Innovent.
DMB83V4	RU	http://innoventbio.com/#/news/208

DMB83V4	DI	DMB83V4
DMB83V4	DN	IBI318
DMB83V4	MI	TTNBFWK
DMB83V4	MN	Programmed cell death protein 1 (PD-1)
DMB83V4	MT	DTT
DMB83V4	MA	Inhibitor
DMB83V4	RN	Clinical pipeline report, company report or official report of Innovent.
DMB83V4	RU	http://innoventbio.com/#/news/208

DMHS29U	DI	DMHS29U
DMHS29U	DN	Iboctadekin
DMHS29U	MI	TTRICUF
DMHS29U	MN	Interleukin-18 (IL18)
DMHS29U	MT	DTT
DMHS29U	MA	Modulator
DMHS29U	RN	Chemoimmunotherapy using pegylated liposomal Doxorubicin and interleukin-18 in recurrent ovarian cancer: a phase I dose-escalation study. Cancer Immunol Res. 2013 Sep;1(3):168-78.
DMHS29U	RU	https://pubmed.ncbi.nlm.nih.gov/24777679

DMW1ZAM	DI	DMW1ZAM
DMW1ZAM	DN	Iboctadekin + Doxil
DMW1ZAM	MI	TT0IHXV
DMW1ZAM	MN	DNA topoisomerase II (TOP2)
DMW1ZAM	MT	DTT
DMW1ZAM	MA	Inhibitor
DMW1ZAM	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMW1ZAM	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMW1ZAM	DI	DMW1ZAM
DMW1ZAM	DN	Iboctadekin + Doxil
DMW1ZAM	MI	TTRICUF
DMW1ZAM	MN	Interleukin-18 (IL18)
DMW1ZAM	MT	DTT
DMW1ZAM	MA	Modulator
DMW1ZAM	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMW1ZAM	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMZCBMS	DI	DMZCBMS
DMZCBMS	DN	Iboctadekin + Rituximab
DMZCBMS	MI	TTRICUF
DMZCBMS	MN	Interleukin-18 (IL18)
DMZCBMS	MT	DTT
DMZCBMS	MA	Modulator
DMZCBMS	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMZCBMS	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMZCBMS	DI	DMZCBMS
DMZCBMS	DN	Iboctadekin + Rituximab
DMZCBMS	MI	TTUE541
DMZCBMS	MN	Leukocyte surface antigen Leu-16 (CD20)
DMZCBMS	MT	DTT
DMZCBMS	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMZCBMS	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMZCBMS	DI	DMZCBMS
DMZCBMS	DN	Iboctadekin + Rituximab
DMZCBMS	MI	DTUGYRD
DMZCBMS	MN	P-glycoprotein 1 (ABCB1)
DMZCBMS	MT	DTP
DMZCBMS	MA	Substrate
DMZCBMS	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMZCBMS	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMZCBMS	DI	DMZCBMS
DMZCBMS	DN	Iboctadekin + Rituximab
DMZCBMS	MI	TTN9VTF
DMZCBMS	MN	Voltage-gated sodium channel alpha Nav1.9 (SCN11A)
DMZCBMS	MT	DTT
DMZCBMS	MA	Blocker
DMZCBMS	RN	New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22.
DMZCBMS	RU	https://pubmed.ncbi.nlm.nih.gov/15934869

DMMPFZO	DI	DMMPFZO
DMMPFZO	DN	IC9.GD2.CAR.IL-15 T-cells
DMMPFZO	MI	TT80ARU
DMMPFZO	MN	Ganglioside GD2 (GD2)
DMMPFZO	MT	DTT
DMMPFZO	MA	CAR-T-Cell-Therapy
DMMPFZO	RN	ClinicalTrials.gov (NCT03721068) Phase I Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma
DMMPFZO	RU	https://clinicaltrials.gov/ct2/show/NCT03721068

DMP1ZF8	DI	DMP1ZF8
DMP1ZF8	DN	IC9-CAR19 cells
DMP1ZF8	MI	TTW640A
DMP1ZF8	MN	B-lymphocyte surface antigen B4 (CD19)
DMP1ZF8	MT	DTT
DMP1ZF8	MA	CAR-T-Cell-Therapy
DMP1ZF8	RN	ClinicalTrials.gov (NCT03016377) Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
DMP1ZF8	RU	https://clinicaltrials.gov/ct2/show/NCT03016377

DMNCBIU	DI	DMNCBIU
DMNCBIU	DN	IC9-CAR19 T cells
DMNCBIU	MI	TTW640A
DMNCBIU	MN	B-lymphocyte surface antigen B4 (CD19)
DMNCBIU	MT	DTT
DMNCBIU	MA	CAR-T-Cell-Therapy
DMNCBIU	RN	ClinicalTrials.gov (NCT03696784) Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
DMNCBIU	RU	https://clinicaltrials.gov/ct2/show/NCT03696784

DMRYHWA	DI	DMRYHWA
DMRYHWA	DN	IC9-GD2-CD28-OX40
DMRYHWA	MI	TT80ARU
DMRYHWA	MN	Ganglioside GD2 (GD2)
DMRYHWA	MT	DTT
DMRYHWA	MA	CAR-T-Cell-Therapy
DMRYHWA	RN	ClinicalTrials.gov (NCT01822652) 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN
DMRYHWA	RU	https://clinicaltrials.gov/ct2/show/NCT01822652

DMHG4Q9	DI	DMHG4Q9
DMHG4Q9	DN	ICAR19 CAR-T cells
DMHG4Q9	MI	TTW640A
DMHG4Q9	MN	B-lymphocyte surface antigen B4 (CD19)
DMHG4Q9	MT	DTT
DMHG4Q9	MA	CAR-T-Cell-Therapy
DMHG4Q9	RN	ClinicalTrials.gov (NCT03383952) A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia
DMHG4Q9	RU	https://clinicaltrials.gov/ct2/show/NCT03383952

DM3YZCV	DI	DM3YZCV
DM3YZCV	DN	ICAR30 T cells
DM3YZCV	MI	TT2GM5R
DM3YZCV	MN	Lymphocyte activation antigen CD30 (TNFRSF8)
DM3YZCV	MT	DTT
DM3YZCV	MA	CAR-T-Cell-Therapy
DM3YZCV	RN	ClinicalTrials.gov (NCT03383965) CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas
DM3YZCV	RU	https://clinicaltrials.gov/ct2/show/NCT03383965

DMY6V5T	DI	DMY6V5T
DMY6V5T	DN	ICasp9M28z T cell
DMY6V5T	MI	TT4RXME
DMY6V5T	MN	Mesothelin (MSLN)
DMY6V5T	MT	DTT
DMY6V5T	MA	CAR-T-Cell-Therapy
DMY6V5T	RN	ClinicalTrials.gov (NCT02414269) Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
DMY6V5T	RU	https://clinicaltrials.gov/ct2/show/NCT02414269

DM79W8K	DI	DM79W8K
DM79W8K	DN	ICo-007
DM79W8K	MI	TTAN5W2
DM79W8K	MN	Raf messenger RNA (Raf mRNA)
DM79W8K	MT	DTT
DM79W8K	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009).
DM79W8K	RU	http://www.isispharm.com/Pipeline/index.htm

DM64LVS	DI	DM64LVS
DM64LVS	DN	ICT-121
DM64LVS	MI	TTXMZ81
DM64LVS	MN	Prominin-1 (PROM1)
DM64LVS	MT	DTT
DM64LVS	RN	Immunotargeting of cancer stem cells. Contemp Oncol (Pozn) 2015; 19(1A): A52-A59.
DM64LVS	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322523/

DMNWPMO	DI	DMNWPMO
DMNWPMO	DN	IDH305
DMNWPMO	MI	TTV2A1R
DMNWPMO	MN	Oxalosuccinate decarboxylase (IDH1)
DMNWPMO	MT	DTT
DMNWPMO	MA	Inhibitor
DMNWPMO	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMNWPMO	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM1RNT7	DI	DM1RNT7
DM1RNT7	DN	IDR-1018
DM1RNT7	MI	TTXT4D5
DM1RNT7	MN	Bacterial Cell membrane (Bact CM)
DM1RNT7	MT	DTT
DM1RNT7	MA	Regulator
DM1RNT7	RN	Innate Defense Regulator Peptide 1018 in Wound Healing and Wound Infection. PLoS One. 2012; 7(8): e39373.
DM1RNT7	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412849/

DMYG3PZ	DI	DMYG3PZ
DMYG3PZ	DN	IDX-189
DMYG3PZ	MI	TTMVBWH
DMYG3PZ	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMYG3PZ	MT	DTT
DMYG3PZ	MA	Inhibitor
DMYG3PZ	RN	Clinical pipeline report, company report or official report of Idenix (2011).
DMYG3PZ	RU	http://www.idenix.com/

DMMPINS	DI	DMMPINS
DMMPINS	DN	IGM-2323
DMMPINS	MI	TTUE541
DMMPINS	MN	Leukocyte surface antigen Leu-16 (CD20)
DMMPINS	MT	DTT
DMMPINS	MA	Inhibitor
DMMPINS	RN	Clinical pipeline report, company report or official report of IGM Biosciences.
DMMPINS	RU	https://igmbio.com/pipeline/cd20-x-dc3/

DMMPINS	DI	DMMPINS
DMMPINS	DN	IGM-2323
DMMPINS	MI	TTUN7MC
DMMPINS	MN	T-cell surface glycoprotein CD3 (CD3)
DMMPINS	MT	DTT
DMMPINS	MA	Inhibitor
DMMPINS	RN	Clinical pipeline report, company report or official report of IGM Biosciences.
DMMPINS	RU	https://igmbio.com/pipeline/cd20-x-dc3/

DMFJXDZ	DI	DMFJXDZ
DMFJXDZ	DN	IGM-8444
DMFJXDZ	MI	TTW20TU
DMFJXDZ	MN	TRAIL receptor 2 (TRAIL-R2)
DMFJXDZ	MT	DTT
DMFJXDZ	MA	Agonist
DMFJXDZ	RN	Clinical pipeline report, company report or official report of IGM Biosciences.
DMFJXDZ	RU	https://igmbio.com/pipeline/death-receptor-5/

DM1MY26	DI	DM1MY26
DM1MY26	DN	IGN523
DM1MY26	MI	TT5CZSM
DM1MY26	MN	Lymphocyte activation antigen 4F2 (SLC3A2)
DM1MY26	MT	DTT
DM1MY26	RN	Antitumor activity of an anti-CD98 antibody. Int J Cancer. 2015 Aug 1;137(3):710-20.
DM1MY26	RU	https://pubmed.ncbi.nlm.nih.gov/25556716

DMDU54Y	DI	DMDU54Y
DMDU54Y	DN	IK-175
DMDU54Y	MI	TT037IE
DMDU54Y	MN	Aryl hydrocarbon receptor (AHR)
DMDU54Y	MT	DTT
DMDU54Y	MA	Antagonist
DMDU54Y	RN	Clinical pipeline report, company report or official report of Ikena Oncology.
DMDU54Y	RU	https://ikenaoncology.com/pipeline/immunotherapy/ahr-antagonist-program/

DMQ01MP	DI	DMQ01MP
DMQ01MP	DN	ILV-095
DMQ01MP	MI	TTLDX4N
DMQ01MP	MN	Interleukin-22 (IL22)
DMQ01MP	MT	DTT
DMQ01MP	RN	Emerging Therapies for the Treatment of Psoriasis. Dermatol Ther (Heidelb) 2012 December; 2(1): 16.
DMQ01MP	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3510410/

DM4MY9C	DI	DM4MY9C
DM4MY9C	DN	IM156
DM4MY9C	MI	TTLAFZV
DM4MY9C	MN	AMP-activated protein kinase (AMPK)
DM4MY9C	MT	DTT
DM4MY9C	MA	Inhibitor
DM4MY9C	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM4MY9C	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM43X0Q	DI	DM43X0Q
DM43X0Q	DN	IM19
DM43X0Q	MI	TTW640A
DM43X0Q	MN	B-lymphocyte surface antigen B4 (CD19)
DM43X0Q	MT	DTT
DM43X0Q	MA	CAR-T-Cell-Therapy
DM43X0Q	RN	ClinicalTrials.gov (NCT03528421) Assessment of Safety and Efficacy of IM19 for Relapsed or Refractory NHL Patients
DM43X0Q	RU	https://clinicaltrials.gov/ct2/show/NCT03528421

DMTNYIB	DI	DMTNYIB
DMTNYIB	DN	IM21 CART
DMTNYIB	MI	TTZ3P4W
DMTNYIB	MN	B-cell maturation protein (TNFRSF17)
DMTNYIB	MT	DTT
DMTNYIB	MA	CAR-T-Cell-Therapy
DMTNYIB	RN	ClinicalTrials.gov (NCT03711864) Safety and Efficacy of IM21 Car-t Cells in Patients With Recurrent or Refractory BCMA Positive Multiple Myeloma
DMTNYIB	RU	https://clinicaltrials.gov/ct2/show/NCT03711864

DML5O7T	DI	DML5O7T
DML5O7T	DN	IM23
DML5O7T	MI	TTENHJ0
DML5O7T	MN	Interleukin 3 receptor alpha (IL3RA)
DML5O7T	MT	DTT
DML5O7T	MA	CAR-T-Cell-Therapy
DML5O7T	RN	ClinicalTrials.gov (NCT03585517) Safety and Efficacy Evaluation of IM23 CAR-T Cells (IM23CAR-T)
DML5O7T	RU	https://clinicaltrials.gov/ct2/show/NCT03585517

DMD9U5Q	DI	DMD9U5Q
DMD9U5Q	DN	IMA 203
DMD9U5Q	MI	TTPH7T0
DMD9U5Q	MN	Tumor expressed melanoma antigen (PRAME)
DMD9U5Q	MT	DTT
DMD9U5Q	RN	Clinical pipeline report, company report or official report of Immatics.
DMD9U5Q	RU	https://immatics.com/our-pipeline/

DMWSI04	DI	DMWSI04
DMWSI04	DN	IMC-002
DMWSI04	MI	TT28S46
DMWSI04	MN	Leukocyte surface antigen CD47 (CD47)
DMWSI04	MT	DTT
DMWSI04	MA	Blocker
DMWSI04	RN	Clinical pipeline report, company report or official report of ImmuneOncia Therapeutics.
DMWSI04	RU	http://www.immuneoncia.com/immun/index.php/pipeline/

DMXI5ON	DI	DMXI5ON
DMXI5ON	DN	IMC-3C5
DMXI5ON	MI	TTDCBX5
DMXI5ON	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DMXI5ON	MT	DTT
DMXI5ON	MA	Modulator
DMXI5ON	RN	Bevacizumab and breast cancer: what does the future hold . Future Oncol. 2012 April; 8(4): 403-414.
DMXI5ON	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464486/

DMUYN26	DI	DMUYN26
DMUYN26	DN	IMC-CS4
DMUYN26	MI	TT731LW
DMUYN26	MN	Colony stimulating factor-1 receptor (CSF-1R)
DMUYN26	MT	DTT
DMUYN26	MA	Modulator
DMUYN26	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMUYN26	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMCZQNJ	DI	DMCZQNJ
DMCZQNJ	DN	IMC-EB10
DMCZQNJ	MI	TTGJCWZ
DMCZQNJ	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMCZQNJ	MT	DTT
DMCZQNJ	RN	IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples. Cancer Res. 2006 May 1;66(9):4843-51.
DMCZQNJ	RU	https://pubmed.ncbi.nlm.nih.gov/16651440

DMOFSLE	DI	DMOFSLE
DMOFSLE	DN	IMD-0354
DMOFSLE	MI	TTJ3E9X
DMOFSLE	MN	Inhibitor of nuclear factor kappa-B kinase beta (IKKB)
DMOFSLE	MT	DTT
DMOFSLE	MA	Inhibitor
DMOFSLE	RN	I B kinase beta inhibitor IMD-0354 suppresses airway remodelling in a Dermatophagoides pteronyssinus-sensitized mouse model of chronic asthma. Clin Exp Allergy. 2011 Jan;41(1):104-15.
DMOFSLE	RU	https://pubmed.ncbi.nlm.nih.gov/20573155

DMUVLC4	DI	DMUVLC4
DMUVLC4	DN	IMGC936
DMUVLC4	MI	TTTYQNS
DMUVLC4	MN	Cellular disintegrin-related protein (ADAM9)
DMUVLC4	MT	DTT
DMUVLC4	MA	Inhibitor
DMUVLC4	RN	Clinical pipeline report, company report or official report of ImmunoGen.
DMUVLC4	RU	https://www.immunogen.com/category/imgc936/

DMT9MHE	DI	DMT9MHE
DMT9MHE	DN	IMGN289
DMT9MHE	MI	TTGKNB4
DMT9MHE	MN	Epidermal growth factor receptor (EGFR)
DMT9MHE	MT	DTT
DMT9MHE	MA	Inhibitor
DMT9MHE	RN	World Antibody-Drug Conjugate Summit, October 15-16, 2013, San Francisco, CA. MAbs. 2014 January 1; 6(1): 18-29.
DMT9MHE	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3929441/

DMSYB83	DI	DMSYB83
DMSYB83	DN	IMGN-388
DMSYB83	MI	TTT1R2L
DMSYB83	MN	Integrin alpha-V (ITGAV)
DMSYB83	MT	DTT
DMSYB83	RN	Anti-alphav integrin monoclonal antibody intetumumab enhances the efficacy of radiation therapy and reduces metastasis of human cancer xenografts in nude rats. Cancer Res. 2010 Oct 1;70(19):7591-9.
DMSYB83	RU	https://pubmed.ncbi.nlm.nih.gov/20841470

DMR8OG2	DI	DMR8OG2
DMR8OG2	DN	IMGN-853
DMR8OG2	MI	TTVC37M
DMR8OG2	MN	Folate receptor alpha (FOLR1)
DMR8OG2	MT	DTT
DMR8OG2	MA	Inhibitor
DMR8OG2	RN	Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem. 2010 Jan;21(1):84-92.
DMR8OG2	RU	https://pubmed.ncbi.nlm.nih.gov/19891424

DMTFUM4	DI	DMTFUM4
DMTFUM4	DN	IMMU-114
DMTFUM4	MI	TTYA75N
DMTFUM4	MN	MHC class II antigen DR (HLA-DR)
DMTFUM4	MT	DTT
DMTFUM4	RN	The humanized anti-HLA-DR moAb, IMMU-114, depletes APCs and reduces alloreactive T cells: implications for preventing GVHD. Bone Marrow Transplant. 2012 Jul;47(7):967-80.
DMTFUM4	RU	https://pubmed.ncbi.nlm.nih.gov/22020022

DMEHWPC	DI	DMEHWPC
DMEHWPC	DN	IMO-9200
DMEHWPC	MI	TTOK0LR
DMEHWPC	MN	Toll-like receptor (TLR)
DMEHWPC	MT	DTT
DMEHWPC	MA	Antagonist
DMEHWPC	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMEHWPC	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMXSMF9	DI	DMXSMF9
DMXSMF9	DN	IMP-701
DMXSMF9	MI	TTNVXAW
DMXSMF9	MN	Lymphocyte activation gene 3 protein (LAG3)
DMXSMF9	MT	DTT
DMXSMF9	RN	IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study. J Immune Based Ther Vaccines. 2007 Mar 29;5:5.
DMXSMF9	RU	https://pubmed.ncbi.nlm.nih.gov/17394654

DMPXOVA	DI	DMPXOVA
DMPXOVA	DN	IN10018
DMPXOVA	MI	TTON5IT
DMPXOVA	MN	Focal adhesion kinase 1 (FAK)
DMPXOVA	MT	DTT
DMPXOVA	MA	Inhibitor
DMPXOVA	RN	Clinical pipeline report, company report or official report of InxMed.
DMPXOVA	RU	http://en.inxmed.com/intro/3.html

DMCQTLG	DI	DMCQTLG
DMCQTLG	DN	INB03
DMCQTLG	MI	TTF8CQI
DMCQTLG	MN	Tumor necrosis factor (TNF)
DMCQTLG	MT	DTT
DMCQTLG	MA	Inhibitor
DMCQTLG	RN	Clinical pipeline report, company report or official report of INmune Bio.
DMCQTLG	RU	https://inmunebio.com/index.php/en/science/inb03/overview

DM2FH10	DI	DM2FH10
DM2FH10	DN	INBRX-105
DM2FH10	MI	TTPW9LJ
DM2FH10	MN	Co-stimulatory molecule 4-1BB (CD137)
DM2FH10	MT	DTT
DM2FH10	MA	Agonist
DM2FH10	RN	Clinical pipeline report, company report or official report of Inhibrx.
DM2FH10	RU	https://inhibrx.com/inbrx-105/

DM2FH10	DI	DM2FH10
DM2FH10	DN	INBRX-105
DM2FH10	MI	TT8ZLTI
DM2FH10	MN	Programmed cell death 1 ligand 1 (PD-L1)
DM2FH10	MT	DTT
DM2FH10	MA	Inhibitor
DM2FH10	RN	Clinical pipeline report, company report or official report of Inhibrx.
DM2FH10	RU	https://inhibrx.com/inbrx-105/

DMUNSPI	DI	DMUNSPI
DMUNSPI	DN	INBRX-109
DMUNSPI	MI	TTW20TU
DMUNSPI	MN	TRAIL receptor 2 (TRAIL-R2)
DMUNSPI	MT	DTT
DMUNSPI	RN	Clinical pipeline report, company report or official report of Inhibrx.
DMUNSPI	RU	https://inhibrx.com/inbrx-109/

DMDSZNC	DI	DMDSZNC
DMDSZNC	DN	INCAGN2385
DMDSZNC	MI	TTNVXAW
DMDSZNC	MN	Lymphocyte activation gene 3 protein (LAG3)
DMDSZNC	MT	DTT
DMDSZNC	MA	Inhibitor
DMDSZNC	RN	Clinical pipeline report, company report or official report of Agenus.
DMDSZNC	RU	https://agenusbio.com/pipeline/

DM5SO1T	DI	DM5SO1T
DM5SO1T	DN	INCAGN2390
DM5SO1T	MI	TT1RWL7
DM5SO1T	MN	Hepatitis A virus cellular receptor 2 (TIM3)
DM5SO1T	MT	DTT
DM5SO1T	MA	Inhibitor
DM5SO1T	RN	Clinical pipeline report, company report or official report of Agenus.
DM5SO1T	RU	https://agenusbio.com/pipeline/

DMW7CLY	DI	DMW7CLY
DMW7CLY	DN	INCB15050
DMW7CLY	MI	TT2CEJG
DMW7CLY	MN	C-C chemokine receptor type 5 (CCR5)
DMW7CLY	MT	DTT
DMW7CLY	MA	Antagonist
DMW7CLY	RN	Incyte. Product Development Pipeline.
DMW7CLY	RU	http://www.incyte.com/drugs_product_pipeline.html

DMFOXGB	DI	DMFOXGB
DMFOXGB	DN	INCB81776
DMFOXGB	MI	TTO7LKR
DMFOXGB	MN	Tyrosine-protein kinase Mer (MERTK)
DMFOXGB	MT	DTT
DMFOXGB	MA	Inhibitor
DMFOXGB	RN	A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity. Front Oncol. 2020 Dec 7;10:598477.
DMFOXGB	RU	https://pubmed.ncbi.nlm.nih.gov/33425754

DMFOXGB	DI	DMFOXGB
DMFOXGB	DN	INCB81776
DMFOXGB	MI	TTZPY6J
DMFOXGB	MN	Tyrosine-protein kinase UFO (AXL)
DMFOXGB	MT	DTT
DMFOXGB	MA	Inhibitor
DMFOXGB	RN	A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity. Front Oncol. 2020 Dec 7;10:598477.
DMFOXGB	RU	https://pubmed.ncbi.nlm.nih.gov/33425754

DM5WCBM	DI	DM5WCBM
DM5WCBM	DN	ING-1
DM5WCBM	MI	TTZ8WH4
DM5WCBM	MN	Tumor-associated calcium signal transducer 1 (EPCAM)
DM5WCBM	MT	DTT
DM5WCBM	RN	ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas. Clin Cancer Res. 2004 Nov 15;10(22):7555-65.
DM5WCBM	RU	https://pubmed.ncbi.nlm.nih.gov/15569986

DM601GL	DI	DM601GL
DM601GL	DN	INNO-105
DM601GL	MI	TT6IEYX
DM601GL	MN	Opioid receptor zeta (OGFR)
DM601GL	MT	DTT
DM601GL	MA	Modulator
DM601GL	RN	National Cancer Institute Drug Dictionary (drug id 428488).
DM601GL	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=428488

DMG6S8U	DI	DMG6S8U
DMG6S8U	DN	INNO-305
DMG6S8U	MI	TTZ8UT4
DMG6S8U	MN	Wilms tumor protein (WT1)
DMG6S8U	MT	DTT
DMG6S8U	MA	Modulator
DMG6S8U	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023753)
DMG6S8U	RU	http://adisinsight.springer.com/drugs/800023753

DM90P1K	DI	DM90P1K
DM90P1K	DN	INO-3401
DM90P1K	MI	TTUTN1I
DM90P1K	MN	Human Deoxyribonucleic acid (hDNA)
DM90P1K	MT	DTT
DM90P1K	RN	ClinicalTrials.gov (NCT01403155) A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001. U.S. National Institutes of Health.
DM90P1K	RU	https://clinicaltrials.gov/ct2/show/NCT01403155

DMP6I9T	DI	DMP6I9T
DMP6I9T	DN	INO-3510
DMP6I9T	MI	TTUTN1I
DMP6I9T	MN	Human Deoxyribonucleic acid (hDNA)
DMP6I9T	MT	DTT
DMP6I9T	RN	Inovio Receives U.S. Patent for SynCon H1N1 Influenza Universal Vaccine. Inovio. March 26, 2012.
DMP6I9T	RU	http://www.prnewswire.com/news-releases/inovio-receives-us-patent-for-syncon-h1n1-influenza-universal-vaccine-144185625.html

DMA46DO	DI	DMA46DO
DMA46DO	DN	INS-117548
DMA46DO	MI	TTZN7RP
DMA46DO	MN	Rho-associated protein kinase 1 (ROCK1)
DMA46DO	MT	DTT
DMA46DO	MA	Modulator
DMA46DO	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMA46DO	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMA46DO	DI	DMA46DO
DMA46DO	DN	INS-117548
DMA46DO	MI	TTGWKQJ
DMA46DO	MN	Rho-associated protein kinase 2 (ROCK2)
DMA46DO	MT	DTT
DMA46DO	MA	Modulator
DMA46DO	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMA46DO	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMMR7CH	DI	DMMR7CH
DMMR7CH	DN	Insulin oral sublingual
DMMR7CH	MI	TTCBFJO
DMMR7CH	MN	Insulin receptor (INSR)
DMMR7CH	MT	DTT
DMMR7CH	MA	Modulator
DMMR7CH	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800).
DMMR7CH	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800

DM93QP2	DI	DM93QP2
DM93QP2	DN	Insulin transdermal
DM93QP2	MI	TTCBFJO
DM93QP2	MN	Insulin receptor (INSR)
DM93QP2	MT	DTT
DM93QP2	MA	Modulator
DM93QP2	RN	Transdermal drug delivery of insulin with ultradeformable carriers. Clin Pharmacokinet. 2003;42(5):461-74.
DM93QP2	RU	https://pubmed.ncbi.nlm.nih.gov/12739984

DMXPLMN	DI	DMXPLMN
DMXPLMN	DN	INTOPLICINE
DMXPLMN	MI	TTGTQHC
DMXPLMN	MN	DNA topoisomerase I (TOP1)
DMXPLMN	MT	DTT
DMXPLMN	MA	Modulator
DMXPLMN	RN	Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials. Mol Pharmacol. 1993 Oct;44(4):767-74.
DMXPLMN	RU	https://www.ncbi.nlm.nih.gov/pubmed/8232227

DMU03WD	DI	DMU03WD
DMU03WD	DN	IO-202
DMU03WD	MI	TTREOKA
DMU03WD	MN	Leukocyte immunoglobulin-like receptor B4 (LILRB4)
DMU03WD	MT	DTT
DMU03WD	MA	Inhibitor
DMU03WD	RN	Clinical pipeline report, company report or official report of Immune-Onc Therapeutics.
DMU03WD	RU	https://www.immune-onc.com/news/2020-09-16-io-202-fpi

DMNBPKS	DI	DMNBPKS
DMNBPKS	DN	Iofolastat I-124
DMNBPKS	MI	TT9G4N0
DMNBPKS	MN	Glutamate carboxypeptidase II (GCPII)
DMNBPKS	MT	DTT
DMNBPKS	MA	Inhibitor
DMNBPKS	RN	123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy. J Nucl Med. 2011 Jul;52(7):1087-93.
DMNBPKS	RU	https://pubmed.ncbi.nlm.nih.gov/21680691

DMY0QL7	DI	DMY0QL7
DMY0QL7	DN	Iomab-ACT
DMY0QL7	MI	TTUS45N
DMY0QL7	MN	Leukocyte common antigen (PTPRC)
DMY0QL7	MT	DTT
DMY0QL7	MA	Inhibitor
DMY0QL7	RN	Clinical pipeline report, company report or official report of Actinium Pharmaceuticals.
DMY0QL7	RU	https://www.actiniumpharma.com/product-pipeline/iomab-b

DMD7LHM	DI	DMD7LHM
DMD7LHM	DN	ION 224
DMD7LHM	MI	TT8N5V1
DMD7LHM	MN	DGAT2 messenger RNA (DGAT2 mRNA)
DMD7LHM	MT	DTT
DMD7LHM	MA	Inhibitor
DMD7LHM	RN	Clinical pipeline report, company report or official report of Ionis Pharmaceuticals.
DMD7LHM	RU	https://www.ionispharma.com/ionis-innovation/pipeline/

DMGN96R	DI	DMGN96R
DMGN96R	DN	Ipafricept
DMGN96R	MI	TTVZ87F
DMGN96R	MN	Wnt protein (WNT)
DMGN96R	MT	DTT
DMGN96R	MA	Modulator
DMGN96R	RN	Clinical pipeline report, company report or official report of OncoMed Pharmaceuticals.
DMGN96R	RU	http://www.oncomed.com/Pipeline.html

DMFEI6T	DI	DMFEI6T
DMFEI6T	DN	IPH5201
DMFEI6T	MI	TTYM8DJ
DMFEI6T	MN	Ectonucleoside triphosphate diphosphohydrolase 1 (CD39)
DMFEI6T	MT	DTT
DMFEI6T	MA	Inhibitor
DMFEI6T	RN	ClinicalTrials.gov (NCT04261075) IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.. U.S. National Institutes of Health.
DMFEI6T	RU	https://clinicaltrials.gov/ct2/show/NCT04261075

DMEIM5G	DI	DMEIM5G
DMEIM5G	DN	IPI-940
DMEIM5G	MI	TTDP1UC
DMEIM5G	MN	Fatty acid amide hydrolase (FAAH)
DMEIM5G	MT	DTT
DMEIM5G	MA	Inhibitor
DMEIM5G	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1400).
DMEIM5G	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1400

DMPKH6Y	DI	DMPKH6Y
DMPKH6Y	DN	IPL 550,260
DMPKH6Y	MI	TTO0YVN
DMPKH6Y	MN	Leukocyte (WBC)
DMPKH6Y	MT	DTT
DMPKH6Y	MA	Modulator
DMPKH6Y	RN	WO patent application no. 2005,0792,17, Oligonucleotide decoys and methods of use.
DMPKH6Y	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20050901&CC=WO&NR=2005079217A2&KC=A2

DMHW1LI	DI	DMHW1LI
DMHW1LI	DN	Iptakalim
DMHW1LI	MI	TT1VOHK
DMHW1LI	MN	Potassium channel unspecific (KC)
DMHW1LI	MT	DTT
DMHW1LI	MA	Opener
DMHW1LI	RN	Iptakalim: A novel multi-utility potassium channel opener. J Pharmacol Pharmacother. 2012 Jan;3(1):12-4.
DMHW1LI	RU	https://pubmed.ncbi.nlm.nih.gov/22368410

DMET0H4	DI	DMET0H4
DMET0H4	DN	IQB-9302
DMET0H4	MI	TTW0CMT
DMET0H4	MN	Voltage-gated potassium channel Kv1.5 (KCNA5)
DMET0H4	MT	DTT
DMET0H4	MA	Opener
DMET0H4	RN	Stereoselective effects of the enantiomers of a new local anaesthetic, IQB-9302, on a human cardiac potassium channel (Kv1.5). Br J Pharmacol. 2001 Jan;132(2):385-92.
DMET0H4	RU	https://pubmed.ncbi.nlm.nih.gov/11159686

DMHP71R	DI	DMHP71R
DMHP71R	DN	IQ-DAA
DMHP71R	MI	TTIQSC1
DMHP71R	MN	Bacterial Lethal factor (Bact lef)
DMHP71R	MT	DTT
DMHP71R	MA	Modulator
DMHP71R	RN	Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax.Future Microbiol.2009 Feb;4(1):35-43.
DMHP71R	RU	https://www.ncbi.nlm.nih.gov/pubmed/19207098

DMHP71R	DI	DMHP71R
DMHP71R	DN	IQ-DAA
DMHP71R	MI	TT3YGCD
DMHP71R	MN	Bacterial Protective antigen (Bact pagA)
DMHP71R	MT	DTT
DMHP71R	MA	Modulator
DMHP71R	RN	Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax.Future Microbiol.2009 Feb;4(1):35-43.
DMHP71R	RU	https://www.ncbi.nlm.nih.gov/pubmed/19207098

DMR3E4L	DI	DMR3E4L
DMR3E4L	DN	Irdabisant
DMR3E4L	MI	TT9JNIC
DMR3E4L	MN	Histamine H3 receptor (H3R)
DMR3E4L	MT	DTT
DMR3E4L	MA	Antagonist
DMR3E4L	RN	CEP-26401 (irdabisant), a potent and selective histamine H receptor antagonist/inverse agonist with cognition-enhancing and wake-promoting activities. J Pharmacol Exp Ther. 2012 Jan;340(1):124-33.
DMR3E4L	RU	https://pubmed.ncbi.nlm.nih.gov/22001260

DM5YUOM	DI	DM5YUOM
DM5YUOM	DN	Irofulven/Taxotere
DM5YUOM	MI	TTJGNVC
DM5YUOM	MN	Apoptosis regulator Bcl-2 (BCL-2)
DM5YUOM	MT	DTT
DM5YUOM	MA	Modulator
DM5YUOM	RN	Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models. Prostate. 2004 Apr 1;59(1):22-32.
DM5YUOM	RU	https://pubmed.ncbi.nlm.nih.gov/14991863

DM5YUOM	DI	DM5YUOM
DM5YUOM	DN	Irofulven/Taxotere
DM5YUOM	MI	TT63KYR
DM5YUOM	MN	Tubulin beta-1 chain (TUBB1)
DM5YUOM	MT	DTT
DM5YUOM	MA	Modulator
DM5YUOM	RN	Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models. Prostate. 2004 Apr 1;59(1):22-32.
DM5YUOM	RU	https://pubmed.ncbi.nlm.nih.gov/14991863

DM9SCME	DI	DM9SCME
DM9SCME	DN	IRX4204
DM9SCME	MI	TTP7WQM
DM9SCME	MN	Retinoic acid receptor RXR (RXR)
DM9SCME	MT	DTT
DM9SCME	MA	Agonist
DM9SCME	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9SCME	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM9SCME	DI	DM9SCME
DM9SCME	DN	IRX4204
DM9SCME	MI	TTH029C
DM9SCME	MN	Retinoic acid receptor RXR-gamma (RXRG)
DM9SCME	MT	DTT
DM9SCME	MA	Modulator
DM9SCME	RN	Selective brain penetrable Nurr1 transactivator for treating Parkinson's disease.Oncotarget.2016 Feb 16;7(7):7469-79.
DM9SCME	RU	https://www.ncbi.nlm.nih.gov/pubmed/26862735

DMCED9U	DI	DMCED9U
DMCED9U	DN	IRX-5183
DMCED9U	MI	TTW38KT
DMCED9U	MN	Retinoic acid receptor alpha (RARA)
DMCED9U	MT	DTT
DMCED9U	MA	Agonist
DMCED9U	RN	Retinoic acid receptor alpha and retinoid X receptor specific agonists reduce renal injury in established chronic glomerulonephritis of the rat. J Mol Med (Berl). 2004 Feb;82(2):116-25.
DMCED9U	RU	https://pubmed.ncbi.nlm.nih.gov/14712350

DMCED9U	DI	DMCED9U
DMCED9U	DN	IRX-5183
DMCED9U	MI	TTP7WQM
DMCED9U	MN	Retinoic acid receptor RXR (RXR)
DMCED9U	MT	DTT
DMCED9U	MA	Agonist
DMCED9U	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMCED9U	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMKO7EA	DI	DMKO7EA
DMKO7EA	DN	ISF-402
DMKO7EA	MI	TTCBFJO
DMKO7EA	MN	Insulin receptor (INSR)
DMKO7EA	MT	DTT
DMKO7EA	MA	Modulator
DMKO7EA	RN	Ability of GHTD-amide and analogs to enhance insulin activity through zinc chelation and dispersal of insulin oligomers. Peptides. 2009 Jun;30(6):1088-97.
DMKO7EA	RU	https://pubmed.ncbi.nlm.nih.gov/19463741

DMEJ4B7	DI	DMEJ4B7
DMEJ4B7	DN	ISIS 325568
DMEJ4B7	MI	TTLMJSC
DMEJ4B7	MN	Glucagon receptor messenger RNA (GCGR mRNA)
DMEJ4B7	MT	DTT
DMEJ4B7	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DMEJ4B7	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DM9Y51T	DI	DM9Y51T
DM9Y51T	DN	ISIS-ANGPTL3
DM9Y51T	MI	TT59GO7
DM9Y51T	MN	ANGPTL3 messenger RNA (ANGPTL3 mRNA)
DM9Y51T	MT	DTT
DM9Y51T	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals.
DM9Y51T	RU	https://www.isispharm.com/pipeline/isis-angptl3rx/

DMX3FN4	DI	DMX3FN4
DMX3FN4	DN	ISIS-APOCIII
DMX3FN4	MI	TTXOZQ1
DMX3FN4	MN	ApoC-III messenger RNA (APOC3 mRNA)
DMX3FN4	MT	DTT
DMX3FN4	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
DMX3FN4	RU	http://www.isispharm.com/index.htm

DM8P3N5	DI	DM8P3N5
DM8P3N5	DN	ISIS-AR
DM8P3N5	MI	TTKPW01
DM8P3N5	MN	Androgen receptor messenger RNA (AR mRNA)
DM8P3N5	MT	DTT
DM8P3N5	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals.
DM8P3N5	RU	https://www.isispharm.com/pipeline/isis-arrx/

DMQDUG4	DI	DMQDUG4
DMQDUG4	DN	ISIS-CRP
DMQDUG4	MI	TTWRN6M
DMQDUG4	MN	CRP messenger RNA (CRP mRNA)
DMQDUG4	MT	DTT
DMQDUG4	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009).
DMQDUG4	RU	http://www.isispharm.com/Pipeline/index.htm

DMQDUG4	DI	DMQDUG4
DMQDUG4	DN	ISIS-CRP
DMQDUG4	MI	TT860QF
DMQDUG4	MN	LCK tyrosine protein kinase (LCK)
DMQDUG4	MT	DTT
DMQDUG4	MA	Inhibitor
DMQDUG4	RN	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
DMQDUG4	RU	https://pubmed.ncbi.nlm.nih.gov/17850214

DMQDUG4	DI	DMQDUG4
DMQDUG4	DN	ISIS-CRP
DMQDUG4	MI	TT6PKBN
DMQDUG4	MN	Proto-oncogene c-Src (SRC)
DMQDUG4	MT	DTT
DMQDUG4	MA	Inhibitor
DMQDUG4	RN	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
DMQDUG4	RU	https://pubmed.ncbi.nlm.nih.gov/17850214

DMQDUG4	DI	DMQDUG4
DMQDUG4	DN	ISIS-CRP
DMQDUG4	MI	TTCQ2E5
DMQDUG4	MN	RIP2 messenger RNA (RIP2 mRNA)
DMQDUG4	MT	DTT
DMQDUG4	MA	Inhibitor
DMQDUG4	RN	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
DMQDUG4	RU	https://pubmed.ncbi.nlm.nih.gov/17850214

DMQDUG4	DI	DMQDUG4
DMQDUG4	DN	ISIS-CRP
DMQDUG4	MI	TT3PJMV
DMQDUG4	MN	Tyrosine-protein kinase ABL1 (ABL)
DMQDUG4	MT	DTT
DMQDUG4	MA	Inhibitor
DMQDUG4	RN	Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell lines. J Med Chem. 2008 Mar 13;51(5):1252-9.
DMQDUG4	RU	https://pubmed.ncbi.nlm.nih.gov/18257513

DMQDUG4	DI	DMQDUG4
DMQDUG4	DN	ISIS-CRP
DMQDUG4	MI	TT6TH8V
DMQDUG4	MN	Tyrosine-protein kinase BRK (PTK6)
DMQDUG4	MT	DTT
DMQDUG4	MA	Inhibitor
DMQDUG4	RN	Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res. 2004 Apr 1;10(7):2307-18.
DMQDUG4	RU	https://pubmed.ncbi.nlm.nih.gov/15073106

DMDKAIC	DI	DMDKAIC
DMDKAIC	DN	ISIS-SGLT2
DMDKAIC	MI	TTF8JAT
DMDKAIC	MN	SLC5A2 messenger RNA (SLC5A2 mRNA)
DMDKAIC	MT	DTT
DMDKAIC	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
DMDKAIC	RU	http://www.isispharm.com/index.htm

DMV1BTP	DI	DMV1BTP
DMV1BTP	DN	ISIS-SOD1
DMV1BTP	MI	TTP9K3Q
DMV1BTP	MN	SOD1 messenger RNA (SOD1 mRNA)
DMV1BTP	MT	DTT
DMV1BTP	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
DMV1BTP	RU	http://www.isispharm.com/index.htm

DMDB7KU	DI	DMDB7KU
DMDB7KU	DN	ISO-1
DMDB7KU	MI	TT2AST1
DMDB7KU	MN	Macrophage migration inhibitory factor (MIF)
DMDB7KU	MT	DTT
DMDB7KU	MA	Inhibitor
DMDB7KU	RN	The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. J Biol Chem. 2002 Jul 12;277(28):24976-82.
DMDB7KU	RU	https://pubmed.ncbi.nlm.nih.gov/11997397

DMBQ8CA	DI	DMBQ8CA
DMBQ8CA	DN	ISO-901
DMBQ8CA	MI	DEL4UKY
DMBQ8CA	MN	Methylenetetrahydrofolate dehydrogenase (folD)
DMBQ8CA	MT	DME
DMBQ8CA	MA	Metabolism
DMBQ8CA	RN	nan
DMBQ8CA	RU	nan

DMBQ8CA	DI	DMBQ8CA
DMBQ8CA	DN	ISO-901
DMBQ8CA	MI	DEH3KAT
DMBQ8CA	MN	Methylenetetrahydrofolate reductase (metF)
DMBQ8CA	MT	DME
DMBQ8CA	MA	Metabolism
DMBQ8CA	RN	Functional profiles of coronal and dentin caries in children. J Oral Microbiol. 2018 Jul 16;10(1):1495976.
DMBQ8CA	RU	https://pubmed.ncbi.nlm.nih.gov/30034639

DMBQ8CA	DI	DMBQ8CA
DMBQ8CA	DN	ISO-901
DMBQ8CA	MI	DEOXTPZ
DMBQ8CA	MN	Methylenetetrahydrofolate reductase (MTHFR)
DMBQ8CA	MT	DME
DMBQ8CA	MA	Metabolism
DMBQ8CA	RN	Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy? Cancer Chemother Pharmacol. 2006 Jun;57(6):835-40.
DMBQ8CA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16187112

DMR17YI	DI	DMR17YI
DMR17YI	DN	Isoquine
DMR17YI	MI	TTVG215
DMR17YI	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DMR17YI	MT	DTT
DMR17YI	MA	Inhibitor
DMR17YI	RN	Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for ... J Med Chem. 2009 Mar 12;52(5):1408-15.
DMR17YI	RU	https://pubmed.ncbi.nlm.nih.gov/19222165

DMR17YI	DI	DMR17YI
DMR17YI	DN	Isoquine
DMR17YI	MI	TTQ6VDM
DMR17YI	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMR17YI	MT	DTT
DMR17YI	MA	Inhibitor
DMR17YI	RN	Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for ... J Med Chem. 2009 Mar 12;52(5):1408-15.
DMR17YI	RU	https://pubmed.ncbi.nlm.nih.gov/19222165

DMBPV9W	DI	DMBPV9W
DMBPV9W	DN	IT-139
DMBPV9W	MI	TTW26OG
DMBPV9W	MN	Endoplasmic reticulum chaperone BiP (HSPA5)
DMBPV9W	MT	DTT
DMBPV9W	MA	Inhibitor
DMBPV9W	RN	NKP-1339, a first-in-class anticancer drug showing mild side effects and activity in patients suffering from advanced refractory cancer. BMC Pharmacol Toxicol. 2012; 13(Suppl 1): A82.
DMBPV9W	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3506350/

DMAYD7O	DI	DMAYD7O
DMAYD7O	DN	IT-141
DMAYD7O	MI	TTGTQHC
DMAYD7O	MN	DNA topoisomerase I (TOP1)
DMAYD7O	MT	DTT
DMAYD7O	MA	Inhibitor
DMAYD7O	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMAYD7O	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMY1DFK	DI	DMY1DFK
DMY1DFK	DN	ITASETRON
DMY1DFK	MI	TTNXLKE
DMY1DFK	MN	5-HT 3 receptor (5HT3R)
DMY1DFK	MT	DTT
DMY1DFK	MA	Modulator
DMY1DFK	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMY1DFK	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM702MU	DI	DM702MU
DM702MU	DN	ITX-5061
DM702MU	MI	DECB0K3
DM702MU	MN	Cytochrome P450 2D6 (CYP2D6)
DM702MU	MT	DME
DM702MU	MA	Metabolism
DM702MU	RN	ITX 5061 quantitation in human plasma with reverse phase liquid chromatography and mass spectrometry detection. Antivir Ther. 2013;18(3):329-36.
DM702MU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22954720

DM702MU	DI	DM702MU
DM702MU	DN	ITX-5061
DM702MU	MI	DE4LYSA
DM702MU	MN	Cytochrome P450 3A4 (CYP3A4)
DM702MU	MT	DME
DM702MU	MA	Metabolism
DM702MU	RN	ITX 5061 quantitation in human plasma with reverse phase liquid chromatography and mass spectrometry detection. Antivir Ther. 2013;18(3):329-36.
DM702MU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22954720

DM702MU	DI	DM702MU
DM702MU	DN	ITX-5061
DM702MU	MI	DEIBDNY
DM702MU	MN	Cytochrome P450 3A5 (CYP3A5)
DM702MU	MT	DME
DM702MU	MA	Metabolism
DM702MU	RN	ITX 5061 quantitation in human plasma with reverse phase liquid chromatography and mass spectrometry detection. Antivir Ther. 2013;18(3):329-36.
DM702MU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22954720

DM702MU	DI	DM702MU
DM702MU	DN	ITX-5061
DM702MU	MI	DEGTFWK
DM702MU	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM702MU	MT	DME
DM702MU	MA	Metabolism
DM702MU	RN	ITX 5061 quantitation in human plasma with reverse phase liquid chromatography and mass spectrometry detection. Antivir Ther. 2013;18(3):329-36.
DM702MU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22954720

DMSGEU6	DI	DMSGEU6
DMSGEU6	DN	JAB-3068
DMSGEU6	MI	TT7WUAV
DMSGEU6	MN	Protein-tyrosine phosphatase SHP-2 (PTPN11)
DMSGEU6	MT	DTT
DMSGEU6	MA	Inhibitor
DMSGEU6	RN	Clinical pipeline report, company report or official report of AbbVie.
DMSGEU6	RU	https://www.abbvie.com/our-science/pipeline/jab-3068-jab-3312.html

DM7XAV1	DI	DM7XAV1
DM7XAV1	DN	JBH492
DM7XAV1	MI	TT2GIDQ
DM7XAV1	MN	C-C chemokine receptor type 7 (CCR7)
DM7XAV1	MT	DTT
DM7XAV1	RN	ClinicalTrials.gov (NCT04240704) Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL). U.S. National Institutes of Health.
DM7XAV1	RU	https://clinicaltrials.gov/ct2/show/NCT04240704

DMR3SO5	DI	DMR3SO5
DMR3SO5	DN	JCAR018
DMR3SO5	MI	TTM6QSK
DMR3SO5	MN	B-cell receptor CD22 (CD22)
DMR3SO5	MT	DTT
DMR3SO5	MA	Immunomodulator
DMR3SO5	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMR3SO5	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM1T8KN	DI	DM1T8KN
DM1T8KN	DN	JCAR020
DM1T8KN	MI	TTC1PS3
DM1T8KN	MN	Ovarian carcinoma antigen CA125 (MUC16)
DM1T8KN	MT	DTT
DM1T8KN	MA	Immunomodulator
DM1T8KN	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM1T8KN	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM324RM	DI	DM324RM
DM324RM	DN	JCAR023
DM324RM	MI	TTC9D3K
DM324RM	MN	Neural cell adhesion molecule L1 (L1CAM)
DM324RM	MT	DTT
DM324RM	MA	CAR-T-Cell-Therapy
DM324RM	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM324RM	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMYR3IE	DI	DMYR3IE
DMYR3IE	DN	JES-9501
DMYR3IE	MI	TTEB0GD
DMYR3IE	MN	Cholinesterase (BCHE)
DMYR3IE	MT	DTT
DMYR3IE	MA	Modulator
DMYR3IE	RN	Dehydroevodiamine attenuates beta-amyloid peptide-induced amnesia in mice. Eur J Pharmacol. 2001 Feb 16;413(2-3):221-5.
DMYR3IE	RU	https://pubmed.ncbi.nlm.nih.gov/11226396

DMMI4XR	DI	DMMI4XR
DMMI4XR	DN	JNJ-17305600
DMMI4XR	MI	TTHJTF7
DMMI4XR	MN	Glycine transporter GlyT-1 (SLC6A9)
DMMI4XR	MT	DTT
DMMI4XR	MA	Inhibitor
DMMI4XR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 935).
DMMI4XR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=935

DMSQ3AZ	DI	DMSQ3AZ
DMSQ3AZ	DN	JNJ-26483327
DMSQ3AZ	MI	TTGKNB4
DMSQ3AZ	MN	Epidermal growth factor receptor (EGFR)
DMSQ3AZ	MT	DTT
DMSQ3AZ	MA	Inhibitor
DMSQ3AZ	RN	National Cancer Institute Drug Dictionary (drug id 596693).
DMSQ3AZ	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=596693

DMSQ3AZ	DI	DMSQ3AZ
DMSQ3AZ	DN	JNJ-26483327
DMSQ3AZ	MI	TT6EO5L
DMSQ3AZ	MN	Erbb2 tyrosine kinase receptor (HER2)
DMSQ3AZ	MT	DTT
DMSQ3AZ	MA	Inhibitor
DMSQ3AZ	RN	National Cancer Institute Drug Dictionary (drug id 596693).
DMSQ3AZ	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=596693

DMSQ3AZ	DI	DMSQ3AZ
DMSQ3AZ	DN	JNJ-26483327
DMSQ3AZ	MI	TT0JESD
DMSQ3AZ	MN	Erbb4 tyrosine kinase receptor (Erbb-4)
DMSQ3AZ	MT	DTT
DMSQ3AZ	MA	Inhibitor
DMSQ3AZ	RN	National Cancer Institute Drug Dictionary (drug id 596693).
DMSQ3AZ	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=596693

DMSQ3AZ	DI	DMSQ3AZ
DMSQ3AZ	DN	JNJ-26483327
DMSQ3AZ	MI	TT2B9KF
DMSQ3AZ	MN	Fyn tyrosine protein kinase (FYN)
DMSQ3AZ	MT	DTT
DMSQ3AZ	MA	Inhibitor
DMSQ3AZ	RN	National Cancer Institute Drug Dictionary (drug id 596693).
DMSQ3AZ	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=596693

DMSQ3AZ	DI	DMSQ3AZ
DMSQ3AZ	DN	JNJ-26483327
DMSQ3AZ	MI	TT860QF
DMSQ3AZ	MN	LCK tyrosine protein kinase (LCK)
DMSQ3AZ	MT	DTT
DMSQ3AZ	MA	Inhibitor
DMSQ3AZ	RN	National Cancer Institute Drug Dictionary (drug id 596693).
DMSQ3AZ	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=596693

DMSQ3AZ	DI	DMSQ3AZ
DMSQ3AZ	DN	JNJ-26483327
DMSQ3AZ	MI	TT1RWNJ
DMSQ3AZ	MN	Tyrosine-protein kinase Lyn (JTK8)
DMSQ3AZ	MT	DTT
DMSQ3AZ	MA	Inhibitor
DMSQ3AZ	RN	National Cancer Institute Drug Dictionary (drug id 596693).
DMSQ3AZ	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=596693

DMSQ3AZ	DI	DMSQ3AZ
DMSQ3AZ	DN	JNJ-26483327
DMSQ3AZ	MI	TTDCBX5
DMSQ3AZ	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DMSQ3AZ	MT	DTT
DMSQ3AZ	MA	Inhibitor
DMSQ3AZ	RN	National Cancer Institute Drug Dictionary (drug id 596693).
DMSQ3AZ	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=596693

DMSQ3AZ	DI	DMSQ3AZ
DMSQ3AZ	DN	JNJ-26483327
DMSQ3AZ	MI	TT0SQ8J
DMSQ3AZ	MN	Yes tyrosine kinase (YES)
DMSQ3AZ	MT	DTT
DMSQ3AZ	MA	Inhibitor
DMSQ3AZ	RN	National Cancer Institute Drug Dictionary (drug id 596693).
DMSQ3AZ	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=596693

DMNSJ3C	DI	DMNSJ3C
DMNSJ3C	DN	JNJ-26854165
DMNSJ3C	MI	TT08GJW
DMNSJ3C	MN	Ubiquitin-protein ligase E3 Mdm2 (MDM2)
DMNSJ3C	MT	DTT
DMNSJ3C	MA	Modulator
DMNSJ3C	RN	Serdemetan antagonizes the Mdm2-HIF1alpha axis leading to decreased levels of glycolytic enzymes. PLoS One. 2013 Sep 6;8(9):e74741.
DMNSJ3C	RU	https://pubmed.ncbi.nlm.nih.gov/24040331

DM49VWQ	DI	DM49VWQ
DM49VWQ	DN	JNJ-3534
DM49VWQ	MI	TTGV6LY
DM49VWQ	MN	Nuclear receptor ROR-gamma (RORG)
DM49VWQ	MT	DTT
DM49VWQ	MA	Modulator
DM49VWQ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM49VWQ	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMDIPW8	DI	DMDIPW8
DMDIPW8	DN	JNJ-38877605
DMDIPW8	MI	TTNDSF4
DMDIPW8	MN	Proto-oncogene c-Met (MET)
DMDIPW8	MT	DTT
DMDIPW8	MA	Inhibitor
DMDIPW8	RN	The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation. Clin Cancer Res. 2015 May 15;21(10):2297-304.
DMDIPW8	RU	https://pubmed.ncbi.nlm.nih.gov/25745036

DM45SGE	DI	DM45SGE
DM45SGE	DN	JNJ-39439335
DM45SGE	MI	TTMI6F5
DM45SGE	MN	Transient receptor potential cation channel V1 (TRPV1)
DM45SGE	MT	DTT
DM45SGE	MA	Antagonist
DM45SGE	RN	Benzo[d]imidazole Transient Receptor Potential Vanilloid 1 Antagonists for the Treatment of Pain: Discovery of trans-2-(2-{2-[2-(4-Trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol (Mavatrep). J Med Chem. 2015 May 14;58(9):3859-74.
DM45SGE	RU	https://pubmed.ncbi.nlm.nih.gov/25850459

DMOL9JR	DI	DMOL9JR
DMOL9JR	DN	JNJ-42491293
DMOL9JR	MI	TTXJ47W
DMOL9JR	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMOL9JR	MT	DTT
DMOL9JR	MA	Binder
DMOL9JR	RN	Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders. Nat Rev Drug Discov. 2014 Sep;13(9):692-708. 
DMOL9JR	RU	https://pubmed.ncbi.nlm.nih.gov/25176435

DMQ5ZVK	DI	DMQ5ZVK
DMQ5ZVK	DN	JNJ-54175446
DMQ5ZVK	MI	TT473XN
DMQ5ZVK	MN	P2X purinoceptor 7 (P2RX7)
DMQ5ZVK	MT	DTT
DMQ5ZVK	MA	Antagonist
DMQ5ZVK	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQ5ZVK	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMBV3P8	DI	DMBV3P8
DMBV3P8	DN	JNJ-54728518
DMBV3P8	MI	TTVIMDE
DMBV3P8	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMBV3P8	MT	DTT
DMBV3P8	MA	Agonist
DMBV3P8	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMBV3P8	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DM0QZJX	DI	DM0QZJX
DM0QZJX	DN	JNJ-55308942
DM0QZJX	MI	TT473XN
DM0QZJX	MN	P2X purinoceptor 7 (P2RX7)
DM0QZJX	MT	DTT
DM0QZJX	MA	Inhibitor
DM0QZJX	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DM0QZJX	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMSPQDM	DI	DMSPQDM
DMSPQDM	DN	JNJ-61610588
DMSPQDM	MI	TT51SK8
DMSPQDM	MN	V-set immunoregulatory receptor (VSIR)
DMSPQDM	MT	DTT
DMSPQDM	MA	Inhibitor
DMSPQDM	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMSPQDM	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM5SZAK	DI	DM5SZAK
DM5SZAK	DN	JNJ-63709178
DM5SZAK	MI	TTENHJ0
DM5SZAK	MN	Interleukin 3 receptor alpha (IL3RA)
DM5SZAK	MT	DTT
DM5SZAK	MA	Inhibitor
DM5SZAK	RN	Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors. Curr Opin Hematol. 2018 Mar;25(2):136-145.
DM5SZAK	RU	https://pubmed.ncbi.nlm.nih.gov/29206680

DM5SZAK	DI	DM5SZAK
DM5SZAK	DN	JNJ-63709178
DM5SZAK	MI	TTUN7MC
DM5SZAK	MN	T-cell surface glycoprotein CD3 (CD3)
DM5SZAK	MT	DTT
DM5SZAK	MA	Inhibitor
DM5SZAK	RN	Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors. Curr Opin Hematol. 2018 Mar;25(2):136-145.
DM5SZAK	RU	https://pubmed.ncbi.nlm.nih.gov/29206680

DMJFK6X	DI	DMJFK6X
DMJFK6X	DN	JNJ-63898081
DMJFK6X	MI	TT9G4N0
DMJFK6X	MN	Glutamate carboxypeptidase II (GCPII)
DMJFK6X	MT	DTT
DMJFK6X	MA	Inhibitor
DMJFK6X	RN	Clinical pipeline report, company report or official report of Genmab.
DMJFK6X	RU	https://www.genmab.com/pipeline/

DMLYAGD	DI	DMLYAGD
DMLYAGD	DN	JNJ-64264681
DMLYAGD	MI	TTGM6VW
DMLYAGD	MN	Tyrosine-protein kinase BTK (ATK)
DMLYAGD	MT	DTT
DMLYAGD	MA	Inhibitor
DMLYAGD	RN	A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
DMLYAGD	RU	https://clinicaltrials.gov/ct2/show/NCT04657224

DMYJCUP	DI	DMYJCUP
DMYJCUP	DN	JNJ-64417184
DMYJCUP	MI	TT6275O
DMYJCUP	MN	HRSV RNA-directed RNA polymerase L (HRSV L)
DMYJCUP	MT	DTT
DMYJCUP	MA	Inhibitor
DMYJCUP	RN	Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference. Antiviral Res. 2019 Jul;167:45-67.
DMYJCUP	RU	https://pubmed.ncbi.nlm.nih.gov/30974127

DMDBW2N	DI	DMDBW2N
DMDBW2N	DN	JNJ-64619178
DMDBW2N	MI	TTR1D7X
DMDBW2N	MN	Protein arginine methyltransferase 5 (PRMT5)
DMDBW2N	MT	DTT
DMDBW2N	MA	Inhibitor
DMDBW2N	RN	A patent review of arginine methyltransferase inhibitors (2010-2018). Expert Opin Ther Pat. 2019 Feb;29(2):97-114.
DMDBW2N	RU	https://pubmed.ncbi.nlm.nih.gov/30640571

DMQOHRA	DI	DMQOHRA
DMQOHRA	DN	JNJ-67571244
DMQOHRA	MI	TTJVYO3
DMQOHRA	MN	Myeloid cell surface antigen CD33 (CD33)
DMQOHRA	MT	DTT
DMQOHRA	MA	Inhibitor
DMQOHRA	RN	Clinical pipeline report, company report or official report of Genmab.
DMQOHRA	RU	https://www.genmab.com/pipeline/

DM6URNJ	DI	DM6URNJ
DM6URNJ	DN	JNJ-67856633
DM6URNJ	MI	TTCI81G
DM6URNJ	MN	MALT lymphoma-associated translocation (MALT1)
DM6URNJ	MT	DTT
DM6URNJ	MA	Inhibitor
DM6URNJ	RN	National Cancer Institute Drug Dictionary (drug name JNJ67856633).
DM6URNJ	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/malt1-inhibitor-jnj-67856633

DM6VR13	DI	DM6VR13
DM6VR13	DN	JNJ-69086420
DM6VR13	MI	TTJLNAW
DM6VR13	MN	Tissue kallikrein (KLK2)
DM6VR13	MT	DTT
DM6VR13	MA	Inhibitor
DM6VR13	RN	ClinicalTrials.gov (NCT04644770) A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer. U.S. National Institutes of Health.
DM6VR13	RU	https://clinicaltrials.gov/ct2/show/NCT04644770

DMY7CW1	DI	DMY7CW1
DMY7CW1	DN	JNJ-74699157
DMY7CW1	MI	TT3LH46
DMY7CW1	MN	KRAS G12C mutant (KRAS G12C)
DMY7CW1	MT	DTT
DMY7CW1	MA	Inhibitor
DMY7CW1	RN	KRAS: From undruggable to a druggable Cancer Target. Cancer Treat Rev. 2020 Sep;89:102070.
DMY7CW1	RU	https://pubmed.ncbi.nlm.nih.gov/32711246

DMFMWLQ	DI	DMFMWLQ
DMFMWLQ	DN	JS004
DMFMWLQ	MI	TTER58P
DMFMWLQ	MN	B- and T-lymphocyte attenuator (BTLA)
DMFMWLQ	MT	DTT
DMFMWLQ	MA	Inhibitor
DMFMWLQ	RN	Clinical pipeline report, company report or official report of Junshi Biosciences.
DMFMWLQ	RU	https://www.junshipharma.com/en/Treatment.html

DMVJWBS	DI	DMVJWBS
DMVJWBS	DN	JSI-1187
DMVJWBS	MI	TT1MG9E
DMVJWBS	MN	Extracellular signal-regulated kinase 1 (ERK1)
DMVJWBS	MT	DTT
DMVJWBS	MA	Inhibitor
DMVJWBS	RN	National Cancer Institute Drug Dictionary (drug name JSI1187).
DMVJWBS	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/erk1-2-inhibitor-jsi-1187

DMVJWBS	DI	DMVJWBS
DMVJWBS	DN	JSI-1187
DMVJWBS	MI	TT4TQBX
DMVJWBS	MN	Extracellular signal-regulated kinase 2 (ERK2)
DMVJWBS	MT	DTT
DMVJWBS	MA	Inhibitor
DMVJWBS	RN	National Cancer Institute Drug Dictionary (drug name JSI1187).
DMVJWBS	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/erk1-2-inhibitor-jsi-1187

DM4QIOH	DI	DM4QIOH
DM4QIOH	DN	JSM 6427
DM4QIOH	MI	TTHIZP9
DM4QIOH	MN	Integrin alpha-5 (ITGA5)
DM4QIOH	MT	DTT
DM4QIOH	MA	Antagonist
DM4QIOH	RN	An alpha5beta1 integrin inhibitor attenuates glioma growth. Mol Cell Neurosci. 2008 Dec;39(4):579-85.
DM4QIOH	RU	https://pubmed.ncbi.nlm.nih.gov/18804537

DM4QIOH	DI	DM4QIOH
DM4QIOH	DN	JSM 6427
DM4QIOH	MI	TTBVIQC
DM4QIOH	MN	Integrin beta-1 (ITGB1)
DM4QIOH	MT	DTT
DM4QIOH	MA	Antagonist
DM4QIOH	RN	An alpha5beta1 integrin inhibitor attenuates glioma growth. Mol Cell Neurosci. 2008 Dec;39(4):579-85.
DM4QIOH	RU	https://pubmed.ncbi.nlm.nih.gov/18804537

DM01JU8	DI	DM01JU8
DM01JU8	DN	JTE-451
DM01JU8	MI	TTGV6LY
DM01JU8	MN	Nuclear receptor ROR-gamma (RORG)
DM01JU8	MT	DTT
DM01JU8	MA	Antagonist
DM01JU8	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM01JU8	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMHMDC0	DI	DMHMDC0
DMHMDC0	DN	JWCAR029
DMHMDC0	MI	TTW640A
DMHMDC0	MN	B-lymphocyte surface antigen B4 (CD19)
DMHMDC0	MT	DTT
DMHMDC0	MA	CAR-T-Cell-Therapy
DMHMDC0	RN	ClinicalTrials.gov (NCT03344367) Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
DMHMDC0	RU	https://clinicaltrials.gov/ct2/show/NCT03344367

DMW5J9B	DI	DMW5J9B
DMW5J9B	DN	JX-929
DMW5J9B	MI	TTKRTP6
DMW5J9B	MN	Cytosine deaminase (AICDA)
DMW5J9B	MT	DTT
DMW5J9B	MA	Modulator
DMW5J9B	RN	Micromanaging oncolytic viruses. SciBX 1(42); doi:10.1038/scibx.2008.1014. Nov. 20 2008
DMW5J9B	RU	http://www.nature.com/scibx/journal/v1/n42/full/scibx.2008.1014.html

DMFKEVO	DI	DMFKEVO
DMFKEVO	DN	KA2237
DMFKEVO	MI	TTHBTOP
DMFKEVO	MN	PI3-kinase gamma (PIK3CG)
DMFKEVO	MT	DTT
DMFKEVO	MA	Inhibitor
DMFKEVO	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMFKEVO	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMW0H9Y	DI	DMW0H9Y
DMW0H9Y	DN	KA2507
DMW0H9Y	MI	TT5ZKDI
DMW0H9Y	MN	Histone deacetylase 6 (HDAC6)
DMW0H9Y	MT	DTT
DMW0H9Y	MA	Inhibitor
DMW0H9Y	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMW0H9Y	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMXYN1H	DI	DMXYN1H
DMXYN1H	DN	KAR5585
DMXYN1H	MI	TTZSJHV
DMXYN1H	MN	Tryptophan 5-hydroxylase 1 (TPH1)
DMXYN1H	MT	DTT
DMXYN1H	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMXYN1H	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMTYNRB	DI	DMTYNRB
DMTYNRB	DN	KD033
DMTYNRB	MI	TT8ZLTI
DMTYNRB	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMTYNRB	MT	DTT
DMTYNRB	MA	Inhibitor
DMTYNRB	RN	Clinical pipeline report, company report or official report of Kadmon.
DMTYNRB	RU	https://kadmon.com/clinical-pipeline/pipeline/kd033/

DMNFDYE	DI	DMNFDYE
DMNFDYE	DN	KD3010
DMNFDYE	MI	TT2JWF6
DMNFDYE	MN	Peroxisome proliferator-activated receptor delta (PPARD)
DMNFDYE	MT	DTT
DMNFDYE	MA	Agonist
DMNFDYE	RN	Kalypsys nearing completion of phase Ia study of KD3010 for metabolic disorders. Kalypsys. 2007.
DMNFDYE	RU	http://www.newsrx.com/newsletters/Health-Business-Week/2006-10-27/102320063331046HBW.html

DMZK7N8	DI	DMZK7N8
DMZK7N8	DN	Keratinocyte growth factor
DMZK7N8	MI	TTFY134
DMZK7N8	MN	Keratinocyte growth factor (FGF7)
DMZK7N8	MT	DTT
DMZK7N8	MA	Modulator
DMZK7N8	RN	Keratinocyte growth factor.Cell Biol Int.1995 May;19(5):399-411.
DMZK7N8	RU	https://www.ncbi.nlm.nih.gov/pubmed/7640656

DMQ6DLZ	DI	DMQ6DLZ
DMQ6DLZ	DN	KF-17837
DMQ6DLZ	MI	TTK25J1
DMQ6DLZ	MN	Adenosine A1 receptor (ADORA1)
DMQ6DLZ	MT	DTT
DMQ6DLZ	MA	Inhibitor
DMQ6DLZ	RN	2-Alkynyl-8-aryl-9-methyladenines as novel adenosine receptor antagonists: their synthesis and structure-activity relationships toward hepatic gluc... J Med Chem. 2001 Jan 18;44(2):170-9.
DMQ6DLZ	RU	https://pubmed.ncbi.nlm.nih.gov/11170626

DMQ6DLZ	DI	DMQ6DLZ
DMQ6DLZ	DN	KF-17837
DMQ6DLZ	MI	TTM2AOE
DMQ6DLZ	MN	Adenosine A2a receptor (ADORA2A)
DMQ6DLZ	MT	DTT
DMQ6DLZ	MA	Inhibitor
DMQ6DLZ	RN	Photoisomerization of a potent and selective adenosine A2 antagonist, (E)-1,3-Dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine. J Med Chem. 1993 Nov 12;36(23):3731-3.
DMQ6DLZ	RU	https://pubmed.ncbi.nlm.nih.gov/8246243

DMQ6DLZ	DI	DMQ6DLZ
DMQ6DLZ	DN	KF-17837
DMQ6DLZ	MI	TTNE7KG
DMQ6DLZ	MN	Adenosine A2b receptor (ADORA2B)
DMQ6DLZ	MT	DTT
DMQ6DLZ	MA	Inhibitor
DMQ6DLZ	RN	Photoisomerization of a potent and selective adenosine A2 antagonist, (E)-1,3-Dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine. J Med Chem. 1993 Nov 12;36(23):3731-3.
DMQ6DLZ	RU	https://pubmed.ncbi.nlm.nih.gov/8246243

DMR14VE	DI	DMR14VE
DMR14VE	DN	KH-901
DMR14VE	MI	TT6MP2Z
DMR14VE	MN	GMCSFR-alpha (CSF2RA)
DMR14VE	MT	DTT
DMR14VE	RN	Effects of KH901, a tumor-specific oncolytic recombinant adenovirus, on antitumor and expressing GM-CSF in xenograft tumor models. Sichuan Da Xue Xue Bao Yi Xue Ban. 2007 Jun;38(3):386-90.
DMR14VE	RU	https://pubmed.ncbi.nlm.nih.gov/17593813

DMLSUQ8	DI	DMLSUQ8
DMLSUQ8	DN	KHK2455
DMLSUQ8	MI	TTZJYKH
DMLSUQ8	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMLSUQ8	MT	DTT
DMLSUQ8	MA	Inhibitor
DMLSUQ8	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMLSUQ8	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMR7EF6	DI	DMR7EF6
DMR7EF6	DN	KHK-2866
DMR7EF6	MI	TT15SL0
DMR7EF6	MN	Proheparin-binding EGF-like growth factor (HBEGF)
DMR7EF6	MT	DTT
DMR7EF6	RN	ClinicalTrials.gov (NCT01279291) Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer. U.S. National Institutes of Health.
DMR7EF6	RU	https://clinicaltrials.gov/ct2/show/NCT01279291

DMIAVBL	DI	DMIAVBL
DMIAVBL	DN	Ki23819
DMIAVBL	MI	TTGJCWZ
DMIAVBL	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMIAVBL	MT	DTT
DMIAVBL	MA	Inhibitor
DMIAVBL	RN	Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase. Leukemia. 2005 Jun;19(6):930-5.
DMIAVBL	RU	https://pubmed.ncbi.nlm.nih.gov/15815726

DMUB3H9	DI	DMUB3H9
DMUB3H9	DN	KITE-439
DMUB3H9	MI	TT3CPZW
DMUB3H9	MN	Human papillomavirus protein E7 (HPV E7)
DMUB3H9	MT	DTT
DMUB3H9	MA	Inhibitor
DMUB3H9	RN	ClinicalTrials.gov (NCT03912831) Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers. U.S. National Institutes of Health.
DMUB3H9	RU	https://clinicaltrials.gov/ct2/show/NCT03912831

DMXR6HI	DI	DMXR6HI
DMXR6HI	DN	KITE-585
DMXR6HI	MI	TTZ3P4W
DMXR6HI	MN	B-cell maturation protein (TNFRSF17)
DMXR6HI	MT	DTT
DMXR6HI	MA	CAR-T-Cell-Therapy
DMXR6HI	RN	ClinicalTrials.gov (NCT03318861) A Study Evaluating the Safety and Efficacy of KITE-585 in Subjects With Relapsed/Refractory Multiple Myeloma
DMXR6HI	RU	https://clinicaltrials.gov/ct2/show/NCT03318861

DMBSI6Y	DI	DMBSI6Y
DMBSI6Y	DN	KITE-718
DMBSI6Y	MI	TTWSKHD
DMBSI6Y	MN	Melanoma-associated antigen 3 (MAGEA3)
DMBSI6Y	MT	DTT
DMBSI6Y	RN	ClinicalTrials.gov (NCT03139370) Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers. U.S. National Institutes of Health.
DMBSI6Y	RU	https://clinicaltrials.gov/ct2/show/NCT03139370

DMBSI6Y	DI	DMBSI6Y
DMBSI6Y	DN	KITE-718
DMBSI6Y	MI	TTJIWMO
DMBSI6Y	MN	Melanoma-associated antigen 6 (MAGEA6)
DMBSI6Y	MT	DTT
DMBSI6Y	RN	ClinicalTrials.gov (NCT03139370) Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers. U.S. National Institutes of Health.
DMBSI6Y	RU	https://clinicaltrials.gov/ct2/show/NCT03139370

DME8DUV	DI	DME8DUV
DME8DUV	DN	KM-023
DME8DUV	MI	TT84ETX
DME8DUV	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DME8DUV	MT	DTT
DME8DUV	MA	Inhibitor
DME8DUV	RN	Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjects. Drug Des Devel Ther. 2014 Sep 26;8:1613-9.
DME8DUV	RU	https://pubmed.ncbi.nlm.nih.gov/25302016

DMRAWGC	DI	DMRAWGC
DMRAWGC	DN	KM-819
DMRAWGC	MI	TTSKL3G
DMRAWGC	MN	FAS-associated factor 1 (FAF1)
DMRAWGC	MT	DTT
DMRAWGC	MA	Inhibitor
DMRAWGC	RN	A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson's disease, in healthy volunteers. Drug Des Devel Ther. 2019 Mar 29;13:1011-1022.
DMRAWGC	RU	https://pubmed.ncbi.nlm.nih.gov/30992659

DM1D2O0	DI	DM1D2O0
DM1D2O0	DN	KML-001
DM1D2O0	MI	TTUJFD0
DM1D2O0	MN	Telomerase reverse transcriptase (TERT)
DM1D2O0	MT	DTT
DM1D2O0	MA	Inhibitor
DM1D2O0	RN	National Cancer Institute Drug Dictionary (drug id 672554).
DM1D2O0	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=672554

DMZMSBI	DI	DMZMSBI
DMZMSBI	DN	KO-947
DMZMSBI	MI	TTKPV6O
DMZMSBI	MN	Ephrin type-B receptor 2 (EPHB2)
DMZMSBI	MT	DTT
DMZMSBI	MA	Inhibitor
DMZMSBI	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZMSBI	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM4953W	DI	DM4953W
DM4953W	DN	KOS-2187
DM4953W	MI	TT953CX
DM4953W	MN	Motilin receptor (MLNR)
DM4953W	MT	DTT
DM4953W	MA	Agonist
DM4953W	RN	Kosan Announces Selection of KOS-2187 As Motilide Clinical Candidate at World Congress of Gastroenterology Meeting. Kosan. 2006.
DM4953W	RU	http://www.redorbit.com/news/health/237602/kosan_announces_selection_of_kos2187_as_motilide_clinical_candidate_at/

DMSKI8W	DI	DMSKI8W
DMSKI8W	DN	KPG-121
DMSKI8W	MI	TTEZQ39
DMSKI8W	MN	Cerebron E3 ubiquitin ligase complex (CRL4-CRBN E3 ubiquitin ligase)
DMSKI8W	MT	DTT
DMSKI8W	MA	Modulator
DMSKI8W	RN	Clinical pipeline report, company report or official report of Kangpu Biopharmaceuticals.
DMSKI8W	RU	https://www.kangpugroup.com/research_development/pipeline.html

DM1O2X6	DI	DM1O2X6
DM1O2X6	DN	KPG-818
DM1O2X6	MI	TTEZQ39
DM1O2X6	MN	Cerebron E3 ubiquitin ligase complex (CRL4-CRBN E3 ubiquitin ligase)
DM1O2X6	MT	DTT
DM1O2X6	MA	Modulator
DM1O2X6	RN	Clinical pipeline report, company report or official report of Kangpu Biopharmaceuticals.
DM1O2X6	RU	https://www.kangpugroup.com/research_development/pipeline.html

DMYBHER	DI	DMYBHER
DMYBHER	DN	KPL-716
DMYBHER	MI	TT1RJXK
DMYBHER	MN	Interleukin-31 (IL31)
DMYBHER	MT	DTT
DMYBHER	MA	Inhibitor
DMYBHER	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMYBHER	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM9JXMD	DI	DM9JXMD
DM9JXMD	DN	KPT-9274
DM9JXMD	MI	TT7Y3BZ
DM9JXMD	MN	PAK-4 protein kinase (PAK4)
DM9JXMD	MT	DTT
DM9JXMD	MA	Inhibitor
DM9JXMD	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9JXMD	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMK0BTN	DI	DMK0BTN
DMK0BTN	DN	KQ-791
DMK0BTN	MI	TTMS7KP
DMK0BTN	MN	Protein-tyrosine phosphatase 1B (PTP1B)
DMK0BTN	MT	DTT
DMK0BTN	MA	Antagonist
DMK0BTN	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMK0BTN	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMODGJU	DI	DMODGJU
DMODGJU	DN	KRN633
DMODGJU	MI	TTUTJGQ
DMODGJU	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMODGJU	MT	DTT
DMODGJU	MA	Inhibitor
DMODGJU	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMODGJU	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DM8FQPX	DI	DM8FQPX
DM8FQPX	DN	KTN3379
DM8FQPX	MI	TTDC8N2
DM8FQPX	MN	Erbb3 tyrosine kinase receptor (Erbb-3)
DM8FQPX	MT	DTT
DM8FQPX	RN	A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK. Am J Transl Res. 2015; 7(4): 733-750.
DM8FQPX	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4455348/

DMTFWLE	DI	DMTFWLE
DMTFWLE	DN	KUC-7483
DMTFWLE	MI	TTMXGCW
DMTFWLE	MN	Adrenergic receptor beta-3 (ADRB3)
DMTFWLE	MT	DTT
DMTFWLE	MA	Agonist
DMTFWLE	RN	Effects of ritobegron (KUC-7483), a novel selective beta3-adrenoceptor agonist, on bladder function in cynomolgus monkey. J Pharmacol Exp Ther. 2012 Jul;342(1):163-8.
DMTFWLE	RU	https://pubmed.ncbi.nlm.nih.gov/22511202

DMKFVX5	DI	DMKFVX5
DMKFVX5	DN	KUL-7211
DMKFVX5	MI	TT2CJVK
DMKFVX5	MN	Adrenergic receptor beta-2 (ADRB2)
DMKFVX5	MT	DTT
DMKFVX5	MA	Modulator
DMKFVX5	RN	The potency of KUL-7211, a selective ureteral relaxant, in isolated canine ureter: comparison with various spasmolytics.Urol Res.2005 Dec;33(6):409-14.
DMKFVX5	RU	https://www.ncbi.nlm.nih.gov/pubmed/16133579

DMKFVX5	DI	DMKFVX5
DMKFVX5	DN	KUL-7211
DMKFVX5	MI	TTMXGCW
DMKFVX5	MN	Adrenergic receptor beta-3 (ADRB3)
DMKFVX5	MT	DTT
DMKFVX5	MA	Modulator
DMKFVX5	RN	The potency of KUL-7211, a selective ureteral relaxant, in isolated canine ureter: comparison with various spasmolytics.Urol Res.2005 Dec;33(6):409-14.
DMKFVX5	RU	https://www.ncbi.nlm.nih.gov/pubmed/16133579

DMKMN5R	DI	DMKMN5R
DMKMN5R	DN	KUR-501
DMKMN5R	MI	TT80ARU
DMKMN5R	MN	Ganglioside GD2 (GD2)
DMKMN5R	MT	DTT
DMKMN5R	RN	Clinical pipeline report, company report or official report of Kuur Therapeutics.
DMKMN5R	RU	https://kuurtx.com/product-overview/

DMS9LVC	DI	DMS9LVC
DMS9LVC	DN	KUR-502
DMS9LVC	MI	TTW640A
DMS9LVC	MN	B-lymphocyte surface antigen B4 (CD19)
DMS9LVC	MT	DTT
DMS9LVC	RN	Clinical pipeline report, company report or official report of Kuur Therapeutics.
DMS9LVC	RU	https://kuurtx.com/product-overview/

DMFO7RP	DI	DMFO7RP
DMFO7RP	DN	KW-2449
DMFO7RP	MI	TTRLW2X
DMFO7RP	MN	Fibroblast growth factor receptor 1 (FGFR1)
DMFO7RP	MT	DTT
DMFO7RP	RN	KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood. 2009 Aug 20;114(8):1607-17.
DMFO7RP	RU	https://pubmed.ncbi.nlm.nih.gov/19541823

DMFO7RP	DI	DMFO7RP
DMFO7RP	DN	KW-2449
DMFO7RP	MI	TTGJCWZ
DMFO7RP	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMFO7RP	MT	DTT
DMFO7RP	RN	KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood. 2009 Aug 20;114(8):1607-17.
DMFO7RP	RU	https://pubmed.ncbi.nlm.nih.gov/19541823

DMFO7RP	DI	DMFO7RP
DMFO7RP	DN	KW-2449
DMFO7RP	MI	TT3PJMV
DMFO7RP	MN	Tyrosine-protein kinase ABL1 (ABL)
DMFO7RP	MT	DTT
DMFO7RP	RN	KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood. 2009 Aug 20;114(8):1607-17.
DMFO7RP	RU	https://pubmed.ncbi.nlm.nih.gov/19541823

DMALK7F	DI	DMALK7F
DMALK7F	DN	KW-5092
DMALK7F	MI	TT1RS9F
DMALK7F	MN	Acetylcholinesterase (AChE)
DMALK7F	MT	DTT
DMALK7F	MA	Inhibitor
DMALK7F	RN	Oral administration of KW-5092, a novel gastroprokinetic agent with acetylcholinesterase inhibitory and acetylcholine release enhancing activities, causes a dose-dependent increase in the blood acetylcholine content of beagle dogs. Neurosci Lett. 1997 Mar 28;225(1):25-8.
DMALK7F	RU	https://pubmed.ncbi.nlm.nih.gov/9143009

DML4H05	DI	DML4H05
DML4H05	DN	KX2-361
DML4H05	MI	TT6PKBN
DML4H05	MN	Proto-oncogene c-Src (SRC)
DML4H05	MT	DTT
DML4H05	MA	Inhibitor
DML4H05	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2206).
DML4H05	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2206

DMWSC5L	DI	DMWSC5L
DMWSC5L	DN	L-778123
DMWSC5L	MI	TTXQKM3
DMWSC5L	MN	Farnesyl protein transferase (Ftase)
DMWSC5L	MT	DTT
DMWSC5L	MA	Modulator
DMWSC5L	RN	Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein trans... Mol Cancer Ther. 2002 Jul;1(9):747-58.
DMWSC5L	RU	https://www.ncbi.nlm.nih.gov/pubmed/12479371

DMWSC5L	DI	DMWSC5L
DMWSC5L	DN	L-778123
DMWSC5L	MI	TTX20QP
DMWSC5L	MN	Geranylgeranyl transferase I (GGTase-I)
DMWSC5L	MT	DTT
DMWSC5L	MA	Modulator
DMWSC5L	RN	Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein trans... Mol Cancer Ther. 2002 Jul;1(9):747-58.
DMWSC5L	RU	https://www.ncbi.nlm.nih.gov/pubmed/12479371

DMXKO1L	DI	DMXKO1L
DMXKO1L	DN	L-796568
DMXKO1L	MI	TTR6W5O
DMXKO1L	MN	Adrenergic receptor beta-1 (ADRB1)
DMXKO1L	MT	DTT
DMXKO1L	MA	Inhibitor
DMXKO1L	RN	Heterocyclic acetamide and benzamide derivatives as potent and selective beta3-adrenergic receptor agonists with improved rodent pharmacokinetic pr... Bioorg Med Chem Lett. 2010 Mar 15;20(6):1895-9.
DMXKO1L	RU	https://pubmed.ncbi.nlm.nih.gov/20181479

DMXKO1L	DI	DMXKO1L
DMXKO1L	DN	L-796568
DMXKO1L	MI	TT2CJVK
DMXKO1L	MN	Adrenergic receptor beta-2 (ADRB2)
DMXKO1L	MT	DTT
DMXKO1L	MA	Inhibitor
DMXKO1L	RN	Heterocyclic acetamide and benzamide derivatives as potent and selective beta3-adrenergic receptor agonists with improved rodent pharmacokinetic pr... Bioorg Med Chem Lett. 2010 Mar 15;20(6):1895-9.
DMXKO1L	RU	https://pubmed.ncbi.nlm.nih.gov/20181479

DM8ANIM	DI	DM8ANIM
DM8ANIM	DN	Lactermin
DM8ANIM	MI	TTDB5IS
DM8ANIM	MN	Receptor unspecific (Rec)
DM8ANIM	MT	DTT
DM8ANIM	MA	Modulator
DM8ANIM	RN	Mammalian lactoferrin receptors: structure and function. Cell Mol Life Sci. 2005 Nov;62(22):2560-75.
DM8ANIM	RU	https://pubmed.ncbi.nlm.nih.gov/16261254

DMO4GPK	DI	DMO4GPK
DMO4GPK	DN	Lactose
DMO4GPK	MI	DEQB4LT
DMO4GPK	MN	Beta-galactosidase (bgaB)
DMO4GPK	MT	DME
DMO4GPK	MA	Metabolism
DMO4GPK	RN	Identification and characterization of a novel beta-galactosidase from Victivallis vadensis ATCC BAA-548, an anaerobic fecal bacterium. J Microbiol. 2012 Dec;50(6):1034-40.
DMO4GPK	RU	https://pubmed.ncbi.nlm.nih.gov/23274992

DMO4GPK	DI	DMO4GPK
DMO4GPK	DN	Lactose
DMO4GPK	MI	DEGLW18
DMO4GPK	MN	Cellobiose 2-epimerase (CE)
DMO4GPK	MT	DME
DMO4GPK	MA	Metabolism
DMO4GPK	RN	Cloning and sequencing of the gene for cellobiose 2-epimerase from a ruminal strain of Eubacterium cellulosolvens. FEMS Microbiol Lett. 2008 Oct;287(1):34-40.
DMO4GPK	RU	https://pubmed.ncbi.nlm.nih.gov/18710396

DMO4GPK	DI	DMO4GPK
DMO4GPK	DN	Lactose
DMO4GPK	MI	DENTGJO
DMO4GPK	MN	Cellobiose 2-epimerase (CE)
DMO4GPK	MT	DME
DMO4GPK	MA	Metabolism
DMO4GPK	RN	Cloning and sequencing of the gene for cellobiose 2-epimerase from a ruminal strain of Eubacterium cellulosolvens. FEMS Microbiol Lett. 2008 Oct;287(1):34-40.
DMO4GPK	RU	https://pubmed.ncbi.nlm.nih.gov/18710396

DMO4GPK	DI	DMO4GPK
DMO4GPK	DN	Lactose
DMO4GPK	MI	DE4XLDR
DMO4GPK	MN	Cellobiose 2-epimerase (CE)
DMO4GPK	MT	DME
DMO4GPK	MA	Metabolism
DMO4GPK	RN	Cloning and sequencing of the gene for cellobiose 2-epimerase from a ruminal strain of Eubacterium cellulosolvens. FEMS Microbiol Lett. 2008 Oct;287(1):34-40.
DMO4GPK	RU	https://pubmed.ncbi.nlm.nih.gov/18710396

DMO4GPK	DI	DMO4GPK
DMO4GPK	DN	Lactose
DMO4GPK	MI	DEGBVKJ
DMO4GPK	MN	Cellobiose 2-epimerase (CE)
DMO4GPK	MT	DME
DMO4GPK	MA	Metabolism
DMO4GPK	RN	Cloning and sequencing of the gene for cellobiose 2-epimerase from a ruminal strain of Eubacterium cellulosolvens. FEMS Microbiol Lett. 2008 Oct;287(1):34-40.
DMO4GPK	RU	https://pubmed.ncbi.nlm.nih.gov/18710396

DMO4GPK	DI	DMO4GPK
DMO4GPK	DN	Lactose
DMO4GPK	MI	DEDY9F6
DMO4GPK	MN	Cellobiose 2-epimerase (CE)
DMO4GPK	MT	DME
DMO4GPK	MA	Metabolism
DMO4GPK	RN	Cloning and sequencing of the gene for cellobiose 2-epimerase from a ruminal strain of Eubacterium cellulosolvens. FEMS Microbiol Lett. 2008 Oct;287(1):34-40.
DMO4GPK	RU	https://pubmed.ncbi.nlm.nih.gov/18710396

DMC0VJF	DI	DMC0VJF
DMC0VJF	DN	Laevo-Bambuterol
DMC0VJF	MI	TTMXGCW
DMC0VJF	MN	Adrenergic receptor beta-3 (ADRB3)
DMC0VJF	MT	DTT
DMC0VJF	MA	Modulator
DMC0VJF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 29).
DMC0VJF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=29

DM7JNHU	DI	DM7JNHU
DM7JNHU	DN	LAM-001
DM7JNHU	MI	TTCJG29
DM7JNHU	MN	Serine/threonine-protein kinase mTOR (mTOR)
DM7JNHU	MT	DTT
DM7JNHU	MA	Inhibitor
DM7JNHU	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7JNHU	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DMQHWMJ	DI	DMQHWMJ
DMQHWMJ	DN	LAM-003
DMQHWMJ	MI	TTO7FVG
DMQHWMJ	MN	Heat shock protein 90 (HSP90)
DMQHWMJ	MT	DTT
DMQHWMJ	MA	Inhibitor
DMQHWMJ	RN	LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML. Blood Adv. 2019 Nov 26;3(22):3661-3673.
DMQHWMJ	RU	https://pubmed.ncbi.nlm.nih.gov/31751472

DM1C4UM	DI	DM1C4UM
DM1C4UM	DN	LAMB3-transduced autologous epidermal stem cells
DM1C4UM	MI	TT2WOUQ
DM1C4UM	MN	Laminin beta-3 chain (LAMB3)
DM1C4UM	MT	DTT
DM1C4UM	MA	Modulator
DM1C4UM	RN	Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat Med. 2006 Dec;12(12):1397-402.
DM1C4UM	RU	https://pubmed.ncbi.nlm.nih.gov/17115047

DMV80DP	DI	DMV80DP
DMV80DP	DN	LAS-186323
DMV80DP	MI	TTLVP78
DMV80DP	MN	Dihydroorotate dehydrogenase (DHODH)
DMV80DP	MT	DTT
DMV80DP	MA	Inhibitor
DMV80DP	RN	Clinical pipeline report, company report or official report of Aslanpharma.
DMV80DP	RU	http://www.aslanpharma.com/download/Press%20Release%20-%20Almirall-ASLAN%20Licensing.pdf

DM4YA0D	DI	DM4YA0D
DM4YA0D	DN	LBR-101
DM4YA0D	MI	TTY6O0Q
DM4YA0D	MN	Calcitonin gene-related peptide receptor (CGRPR)
DM4YA0D	MT	DTT
DM4YA0D	RN	Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program. Cephalalgia. 2013 Dec 23;34(7):483-492.
DM4YA0D	RU	https://pubmed.ncbi.nlm.nih.gov/24366980

DMJEACT	DI	DMJEACT
DMJEACT	DN	LC-1
DMJEACT	MI	TTSXVID
DMJEACT	MN	Nuclear factor NF-kappa-B (NFKB)
DMJEACT	MT	DTT
DMJEACT	MA	Inhibitor
DMJEACT	RN	A water soluble parthenolide analogue suppresses in vivo tumor growth of two tobacco associated cancers, lung and bladder cancer, by targeting NF- B and generating reactive oxygen species. Int J Cancer. 2011 May 15; 128(10): 2481-2494.
DMJEACT	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2982935/

DMHT3CB	DI	DMHT3CB
DMHT3CB	DN	LC-350189
DMHT3CB	MI	TT7RJY8
DMHT3CB	MN	Xanthine dehydrogenase/oxidase (XDH)
DMHT3CB	MT	DTT
DMHT3CB	MA	Inhibitor
DMHT3CB	RN	Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects. Drug Des Devel Ther. 2015 Aug 31;9:5033-49.
DMHT3CB	RU	https://pubmed.ncbi.nlm.nih.gov/26357467

DMEY2LK	DI	DMEY2LK
DMEY2LK	DN	LCAR-B4822M CAR-T Cell
DMEY2LK	MI	TTZ3P4W
DMEY2LK	MN	B-cell maturation protein (TNFRSF17)
DMEY2LK	MT	DTT
DMEY2LK	MA	CAR-T-Cell-Therapy
DMEY2LK	RN	ClinicalTrials.gov (NCT03674463) LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma
DMEY2LK	RU	https://clinicaltrials.gov/ct2/show/NCT03674463

DM9LYXQ	DI	DM9LYXQ
DM9LYXQ	DN	Leflunomide
DM9LYXQ	MI	TT3UY29
DM9LYXQ	MN	HUMAN dihydroorotate dehydrogenase (DHODH)
DM9LYXQ	MT	DTT
DM9LYXQ	MA	Inhibitor
DM9LYXQ	RN	On dihydroorotate dehydrogenases and their inhibitors and uses. J Med Chem. 2013 Apr 25;56(8):3148-67. doi: 10.1021/jm301848w.
DM9LYXQ	RU	https://pubmed.ncbi.nlm.nih.gov/23452331

DMKZVLH	DI	DMKZVLH
DMKZVLH	DN	Lefradafiban
DMKZVLH	MI	TT38RM1
DMKZVLH	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DMKZVLH	MT	DTT
DMKZVLH	MA	Modulator
DMKZVLH	RN	Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty. Heart. 2001 Apr;85(4):444-50.
DMKZVLH	RU	https://pubmed.ncbi.nlm.nih.gov/11250974

DM5INZP	DI	DM5INZP
DM5INZP	DN	LEQ-506
DM5INZP	MI	TT8J1S3
DM5INZP	MN	Smoothened homolog (SMO)
DM5INZP	MT	DTT
DM5INZP	MA	Inhibitor
DM5INZP	RN	Discovery of NVP-LEQ506, a second-generation inhibitor of smoothened. ChemMedChem. 2013 Aug;8(8):1261-5.
DM5INZP	RU	https://pubmed.ncbi.nlm.nih.gov/23821351

DMNHPOT	DI	DMNHPOT
DMNHPOT	DN	LErafAON
DMNHPOT	MI	TTAN5W2
DMNHPOT	MN	Raf messenger RNA (Raf mRNA)
DMNHPOT	MT	DTT
DMNHPOT	RN	Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel and gemcitabine. Anticancer Drugs. 2004 Mar;15(3):243-53.
DMNHPOT	RU	https://pubmed.ncbi.nlm.nih.gov/15014358

DM2B0TJ	DI	DM2B0TJ
DM2B0TJ	DN	Leukocyte interleukin
DM2B0TJ	MI	TT9721Y
DM2B0TJ	MN	Interleukin 2 receptor beta (IL2RB)
DM2B0TJ	MT	DTT
DM2B0TJ	MA	Modulator
DM2B0TJ	RN	Leukocyte Interleukin, Inj. (LI) augmentation of natural killer cells and cytolytic T-lymphocytes. Immunopharmacol Immunotoxicol. 1995 May;17(2):247-64.
DM2B0TJ	RU	https://pubmed.ncbi.nlm.nih.gov/7650289

DMI4O92	DI	DMI4O92
DMI4O92	DN	LFA-102
DMI4O92	MI	TTBPXMA
DMI4O92	MN	Prolactin receptor (PRLR)
DMI4O92	MT	DTT
DMI4O92	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1721).
DMI4O92	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1721

DMAG6BV	DI	DMAG6BV
DMAG6BV	DN	LGK974
DMAG6BV	MI	TTNFBTO
DMAG6BV	MN	Protein-serine O-palmitoleoyltransferase porcupine (PORCN)
DMAG6BV	MT	DTT
DMAG6BV	MA	Inhibitor
DMAG6BV	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMAG6BV	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMYK52O	DI	DMYK52O
DMYK52O	DN	LHC165
DMYK52O	MI	TTRJ1K4
DMYK52O	MN	Toll-like receptor 7 (TLR7)
DMYK52O	MT	DTT
DMYK52O	MA	Agonist
DMYK52O	RN	Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes. Eur J Med Chem. 2020 May 1;193:112238.
DMYK52O	RU	https://pubmed.ncbi.nlm.nih.gov/32203790

DMFNSHM	DI	DMFNSHM
DMFNSHM	DN	LHF-535
DMFNSHM	MI	TTD2IK3
DMFNSHM	MN	Lassa virus Pre-glycoprotein polyprotein GP complex (LASV GPC)
DMFNSHM	MT	DTT
DMFNSHM	MA	Inhibitor
DMFNSHM	RN	A potent Lassa virus antiviral targets an arenavirus virulence determinant. PLoS Pathog. 2018 Dec 21;14(12):e1007439.
DMFNSHM	RU	https://pubmed.ncbi.nlm.nih.gov/30576397

DMJRALD	DI	DMJRALD
DMJRALD	DN	LIPO-4
DMJRALD	MI	TTN2JFW
DMJRALD	MN	T-cell surface glycoprotein CD4 (CD4)
DMJRALD	MT	DTT
DMJRALD	RN	Long-term CD4(+) and CD8(+) T-cell responses induced in HIV-uninfected volunteers following intradermal or intramuscular administration of an HIV-lipopeptide vaccine (ANRS VAC16). Vaccine. 2013 Sep 13;31(40):4406-15.
DMJRALD	RU	https://pubmed.ncbi.nlm.nih.gov/23850610

DMJRALD	DI	DMJRALD
DMJRALD	DN	LIPO-4
DMJRALD	MI	TTMHA6L
DMJRALD	MN	T-cell surface glycoprotein CD8 (CD8)
DMJRALD	MT	DTT
DMJRALD	RN	Long-term CD4(+) and CD8(+) T-cell responses induced in HIV-uninfected volunteers following intradermal or intramuscular administration of an HIV-lipopeptide vaccine (ANRS VAC16). Vaccine. 2013 Sep 13;31(40):4406-15.
DMJRALD	RU	https://pubmed.ncbi.nlm.nih.gov/23850610

DMESZQU	DI	DMESZQU
DMESZQU	DN	Litenimod
DMESZQU	MI	TTSHG0T
DMESZQU	MN	Toll-like receptor 9 (TLR9)
DMESZQU	MT	DTT
DMESZQU	MA	Modulator
DMESZQU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1759).
DMESZQU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1759

DMR7LKC	DI	DMR7LKC
DMR7LKC	DN	LM-CD45
DMR7LKC	MI	TTUS45N
DMR7LKC	MN	Leukocyte common antigen (PTPRC)
DMR7LKC	MT	DTT
DMR7LKC	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002932)
DMR7LKC	RU	http://adisinsight.springer.com/drugs/800002932

DMU901D	DI	DMU901D
DMU901D	DN	L-MDAM
DMU901D	MI	TTYZVDJ
DMU901D	MN	Dihydrofolate reductase (DHFR)
DMU901D	MT	DTT
DMU901D	MA	Inhibitor
DMU901D	RN	Polyglutamylation of the dihydrofolate reductase inhibitor gamma-methylene-10-deazaaminopterin is not essential for antitumor activity. Clin Cancer Res. 1996 Apr;2(4):707-12.
DMU901D	RU	https://pubmed.ncbi.nlm.nih.gov/9816221

DMZU2G1	DI	DMZU2G1
DMZU2G1	DN	LMP-1/LMP-2 CTLs
DMZU2G1	MI	TT0BI4Q
DMZU2G1	MN	Epstein-Barr virus Latent membrane protein 1 (EBV LMP1)
DMZU2G1	MT	DTT
DMZU2G1	MA	Modulator
DMZU2G1	RN	In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation. Leuk Lymphoma. 2006 May;47(5):837-42.
DMZU2G1	RU	https://pubmed.ncbi.nlm.nih.gov/16753867

DMZU2G1	DI	DMZU2G1
DMZU2G1	DN	LMP-1/LMP-2 CTLs
DMZU2G1	MI	TTBK351
DMZU2G1	MN	Epstein-Barr virus Latent membrane protein 2 (EBV LMP2)
DMZU2G1	MT	DTT
DMZU2G1	MA	Modulator
DMZU2G1	RN	In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation. Leuk Lymphoma. 2006 May;47(5):837-42.
DMZU2G1	RU	https://pubmed.ncbi.nlm.nih.gov/16753867

DM4FW2E	DI	DM4FW2E
DM4FW2E	DN	LMP400
DM4FW2E	MI	TTGTQHC
DM4FW2E	MN	DNA topoisomerase I (TOP1)
DM4FW2E	MT	DTT
DM4FW2E	MA	Inhibitor
DM4FW2E	RN	Targeting Topoisomerase I in the Era of Precision Medicine. Clin Cancer Res. 2019 Nov 15;25(22):6581-6589.
DM4FW2E	RU	https://pubmed.ncbi.nlm.nih.gov/31227499

DMUCQYW	DI	DMUCQYW
DMUCQYW	DN	LMP744
DMUCQYW	MI	TTGTQHC
DMUCQYW	MN	DNA topoisomerase I (TOP1)
DMUCQYW	MT	DTT
DMUCQYW	MA	Inhibitor
DMUCQYW	RN	Targeting Topoisomerase I in the Era of Precision Medicine. Clin Cancer Res. 2019 Nov 15;25(22):6581-6589.
DMUCQYW	RU	https://pubmed.ncbi.nlm.nih.gov/31227499

DM9OA35	DI	DM9OA35
DM9OA35	DN	Long-acting erythropoietin conjugate
DM9OA35	MI	TTQG4NR
DM9OA35	MN	Erythropoietin (EPO)
DM9OA35	MT	DTT
DM9OA35	MA	Modulator
DM9OA35	RN	Company report (Pharmexcil)
DM9OA35	RU	http://www.pharmexcil.com/v1/docs/KoreanCompanies/hanmi.pdf

DMCKE90	DI	DMCKE90
DMCKE90	DN	Lopinavir + ritonavir + interferon apha + traditional chinese medicines granules
DMCKE90	MI	TT1D53B
DMCKE90	MN	COVID-19 3C-like protease (3CLpro)
DMCKE90	MT	DTT
DMCKE90	MA	Inhibitor
DMCKE90	RN	Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381.
DMCKE90	RU	https://pubmed.ncbi.nlm.nih.gov/32205870

DMDLTCU	DI	DMDLTCU
DMDLTCU	DN	Lotilibcin
DMDLTCU	MI	TTXT4D5
DMDLTCU	MN	Bacterial Cell membrane (Bact CM)
DMDLTCU	MT	DTT
DMDLTCU	MA	Modulator
DMDLTCU	RN	Bioactive natural products from Lysobacter. Nat Prod Rep. 2012 November 8; 29(11): 1277-1287.
DMDLTCU	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3468324/

DMDXFBJ	DI	DMDXFBJ
DMDXFBJ	DN	LOXO-195
DMDXFBJ	MI	TTTDVOJ
DMDXFBJ	MN	Tropomyosin-related kinase A (TrkA)
DMDXFBJ	MT	DTT
DMDXFBJ	MA	Inhibitor
DMDXFBJ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMDXFBJ	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMYIXQZ	DI	DMYIXQZ
DMYIXQZ	DN	LP-108
DMYIXQZ	MI	TTJGNVC
DMYIXQZ	MN	Apoptosis regulator Bcl-2 (BCL-2)
DMYIXQZ	MT	DTT
DMYIXQZ	RN	National Cancer Institute Drug Dictionary (drug name LP-108).
DMYIXQZ	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/bcl-2-inhibitor-lp-108

DM8VBQJ	DI	DM8VBQJ
DM8VBQJ	DN	LS-69767
DM8VBQJ	MI	DE0JX6R
DM8VBQJ	MN	Beta-galactosidase (bgaB)
DM8VBQJ	MT	DME
DM8VBQJ	MA	Metabolism
DM8VBQJ	RN	In vitro fermentation of fructooligosaccharides with human gut bacteria. Food Funct. 2015 Mar;6(3):947-54.
DM8VBQJ	RU	https://pubmed.ncbi.nlm.nih.gov/25653214

DM8VBQJ	DI	DM8VBQJ
DM8VBQJ	DN	LS-69767
DM8VBQJ	MI	DE8J31V
DM8VBQJ	MN	Beta-galactosidase (bgaB)
DM8VBQJ	MT	DME
DM8VBQJ	MA	Metabolism
DM8VBQJ	RN	In vitro fermentation of fructooligosaccharides with human gut bacteria. Food Funct. 2015 Mar;6(3):947-54.
DM8VBQJ	RU	https://pubmed.ncbi.nlm.nih.gov/25653214

DM8VBQJ	DI	DM8VBQJ
DM8VBQJ	DN	LS-69767
DM8VBQJ	MI	DEIEY19
DM8VBQJ	MN	Beta-galactosidase (bgaB)
DM8VBQJ	MT	DME
DM8VBQJ	MA	Metabolism
DM8VBQJ	RN	In vitro fermentation of fructooligosaccharides with human gut bacteria. Food Funct. 2015 Mar;6(3):947-54.
DM8VBQJ	RU	https://pubmed.ncbi.nlm.nih.gov/25653214

DM8VBQJ	DI	DM8VBQJ
DM8VBQJ	DN	LS-69767
DM8VBQJ	MI	DEH2VKT
DM8VBQJ	MN	Glycoside hydrolase (cscA)
DM8VBQJ	MT	DME
DM8VBQJ	MA	Metabolism
DM8VBQJ	RN	In vitro fermentation of fructooligosaccharides with human gut bacteria. Food Funct. 2015 Mar;6(3):947-54.
DM8VBQJ	RU	https://pubmed.ncbi.nlm.nih.gov/25653214

DM8VBQJ	DI	DM8VBQJ
DM8VBQJ	DN	LS-69767
DM8VBQJ	MI	DEWNRL1
DM8VBQJ	MN	Glycosyl hydrolase (glyH)
DM8VBQJ	MT	DME
DM8VBQJ	MA	Metabolism
DM8VBQJ	RN	In vitro fermentation of fructooligosaccharides with human gut bacteria. Food Funct. 2015 Mar;6(3):947-54.
DM8VBQJ	RU	https://pubmed.ncbi.nlm.nih.gov/25653214

DM8VBQJ	DI	DM8VBQJ
DM8VBQJ	DN	LS-69767
DM8VBQJ	MI	DEDZECR
DM8VBQJ	MN	Glycosyl hydrolase (glyH)
DM8VBQJ	MT	DME
DM8VBQJ	MA	Metabolism
DM8VBQJ	RN	In vitro fermentation of fructooligosaccharides with human gut bacteria. Food Funct. 2015 Mar;6(3):947-54.
DM8VBQJ	RU	https://pubmed.ncbi.nlm.nih.gov/25653214

DM8VBQJ	DI	DM8VBQJ
DM8VBQJ	DN	LS-69767
DM8VBQJ	MI	DEPDE7J
DM8VBQJ	MN	Glycosyl hydrolase (glyH)
DM8VBQJ	MT	DME
DM8VBQJ	MA	Metabolism
DM8VBQJ	RN	In vitro fermentation of fructooligosaccharides with human gut bacteria. Food Funct. 2015 Mar;6(3):947-54.
DM8VBQJ	RU	https://pubmed.ncbi.nlm.nih.gov/25653214

DM94E6W	DI	DM94E6W
DM94E6W	DN	LTT462
DM94E6W	MI	TTVOE6D
DM94E6W	MN	Mitogen-activated protein kinase (MAPK)
DM94E6W	MT	DTT
DM94E6W	MA	Inhibitor
DM94E6W	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM94E6W	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMQ0K95	DI	DMQ0K95
DMQ0K95	DN	Lu-02-750
DMQ0K95	MI	TTEX248
DMQ0K95	MN	Dopamine D2 receptor (D2R)
DMQ0K95	MT	DTT
DMQ0K95	MA	Agonist
DMQ0K95	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031195)
DMQ0K95	RU	http://adisinsight.springer.com/drugs/800031195

DMP9UO0	DI	DMP9UO0
DMP9UO0	DN	Lu-AE04621
DMP9UO0	MI	TTEX248
DMP9UO0	MN	Dopamine D2 receptor (D2R)
DMP9UO0	MT	DTT
DMP9UO0	MA	Modulator
DMP9UO0	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031909)
DMP9UO0	RU	http://adisinsight.springer.com/drugs/800031909

DMQI970	DI	DMQI970
DMQI970	DN	Lumoxiti
DMQI970	MI	TTM6QSK
DMQI970	MN	B-cell receptor CD22 (CD22)
DMQI970	MT	DTT
DMQI970	MA	Inhibitor
DMQI970	RN	Clinical pipeline report, company report or official report of Innate Pharma.
DMQI970	RU	https://www.innate-pharma.com/fr/produits/lumoxiti

DMPQE2S	DI	DMPQE2S
DMPQE2S	DN	LVGN6051
DMPQE2S	MI	TTPW9LJ
DMPQE2S	MN	Co-stimulatory molecule 4-1BB (CD137)
DMPQE2S	MT	DTT
DMPQE2S	MA	Activator
DMPQE2S	RN	Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcR affinity. Nat Commun. 2019 May 20;10(1):2141.
DMPQE2S	RU	https://pubmed.ncbi.nlm.nih.gov/31105267

DM8ZS7T	DI	DM8ZS7T
DM8ZS7T	DN	LX2761
DM8ZS7T	MI	TT2UE56
DM8ZS7T	MN	Sodium/glucose cotransporter 1 (SGLT1)
DM8ZS7T	MT	DTT
DM8ZS7T	MA	Inhibitor
DM8ZS7T	RN	Clinical pipeline report, company report or official report of Lexicon Pharmaceuticals.
DM8ZS7T	RU	https://www.lexpharma.com/pipeline/lx2761

DMO548K	DI	DMO548K
DMO548K	DN	LX9211
DMO548K	MI	TT0Z32T
DMO548K	MN	Adaptor-associated kinase 1 (AAK1)
DMO548K	MT	DTT
DMO548K	MA	Inhibitor
DMO548K	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMO548K	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMQE9PS	DI	DMQE9PS
DMQE9PS	DN	LXH254
DMQE9PS	MI	TTAN5W2
DMQE9PS	MN	Raf messenger RNA (Raf mRNA)
DMQE9PS	MT	DTT
DMQE9PS	MA	Inhibitor
DMQE9PS	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQE9PS	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM3OP41	DI	DM3OP41
DM3OP41	DN	LXR 623
DM3OP41	MI	TTM1EQF
DM3OP41	MN	Oxysterols receptor LXR (NR1H)
DM3OP41	MT	DTT
DM3OP41	MA	Modulator
DM3OP41	RN	Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat Rev Drug Discov. 2014 Jun;13(6):433-44.
DM3OP41	RU	https://pubmed.ncbi.nlm.nih.gov/24833295

DMCBV20	DI	DMCBV20
DMCBV20	DN	LY-2334737
DMCBV20	MI	TTUTN1I
DMCBV20	MN	Human Deoxyribonucleic acid (hDNA)
DMCBV20	MT	DTT
DMCBV20	MA	Modulator
DMCBV20	RN	Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013 Jun;71(6):1645-55.
DMCBV20	RU	https://pubmed.ncbi.nlm.nih.gov/23616084

DMCBV20	DI	DMCBV20
DMCBV20	DN	LY-2334737
DMCBV20	MI	TTBWDI0
DMCBV20	MN	Ribonucleoside-diphosphate reductase M2 (RRM2)
DMCBV20	MT	DTT
DMCBV20	MA	Modulator
DMCBV20	RN	Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013 Jun;71(6):1645-55.
DMCBV20	RU	https://pubmed.ncbi.nlm.nih.gov/23616084

DML8M3B	DI	DML8M3B
DML8M3B	DN	LY-2584702
DML8M3B	MI	TT7M3PI
DML8M3B	MN	Ribosomal protein S6 kinase (S6K)
DML8M3B	MT	DTT
DML8M3B	MA	Modulator
DML8M3B	RN	A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours.Eur J Cancer.2014 Mar;50(5):876-84.
DML8M3B	RU	https://www.ncbi.nlm.nih.gov/pubmed/24456794

DM289Z4	DI	DM289Z4
DM289Z4	DN	LY2624587
DM289Z4	MI	TTBID49
DM289Z4	MN	C-X-C chemokine receptor type 4 (CXCR4)
DM289Z4	MT	DTT
DM289Z4	MA	Antagonist
DM289Z4	RN	Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies. PLoS One. 2016 Mar 8;11(3):e0150585.
DM289Z4	RU	https://pubmed.ncbi.nlm.nih.gov/26954567

DM93AJW	DI	DM93AJW
DM93AJW	DN	LY2780301
DM93AJW	MI	TTAZ05C
DM93AJW	MN	RAC-gamma serine/threonine-protein kinase (AKT3)
DM93AJW	MT	DTT
DM93AJW	MA	Modulator
DM93AJW	RN	A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer. Invest New Drugs. 2015 Jun;33(3):710-9.
DM93AJW	RU	https://pubmed.ncbi.nlm.nih.gov/25902900

DM93AJW	DI	DM93AJW
DM93AJW	DN	LY2780301
DM93AJW	MI	TT7M3PI
DM93AJW	MN	Ribosomal protein S6 kinase (S6K)
DM93AJW	MT	DTT
DM93AJW	MA	Modulator
DM93AJW	RN	A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer. Invest New Drugs. 2015 Jun;33(3):710-9.
DM93AJW	RU	https://pubmed.ncbi.nlm.nih.gov/25902900

DM9NYHT	DI	DM9NYHT
DM9NYHT	DN	LY2787106
DM9NYHT	MI	TTPCG5T
DM9NYHT	MN	Hepcidin (HAMP)
DM9NYHT	MT	DTT
DM9NYHT	MA	Inhibitor
DM9NYHT	RN	A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. J Hematol Oncol. 2017 Mar 21;10(1):73.
DM9NYHT	RU	https://www.ncbi.nlm.nih.gov/pubmed/28327200

DM8LGWR	DI	DM8LGWR
DM8LGWR	DN	LY-2811376
DM8LGWR	MI	TT8JRS7
DM8LGWR	MN	Beta-secretase (BACE)
DM8LGWR	MT	DTT
DM8LGWR	MA	Inhibitor
DM8LGWR	RN	Neurodegenerative disease: Inhibiting beta-secretase in humans. Nature Reviews Drug Discovery 11, 21 (January 2012).
DM8LGWR	RU	http://www.nature.com/nrd/journal/v11/n1/full/nrd3645.html

DM8LGWR	DI	DM8LGWR
DM8LGWR	DN	LY-2811376
DM8LGWR	MI	DE4LYSA
DM8LGWR	MN	Cytochrome P450 3A4 (CYP3A4)
DM8LGWR	MT	DME
DM8LGWR	MA	Metabolism
DM8LGWR	RN	Robust central reduction of amyloid-beta in humans with an orally available, non-peptidic beta-secretase inhibitor. J Neurosci. 2011 Nov 16;31(46):16507-16.
DM8LGWR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22090477

DM5EXJV	DI	DM5EXJV
DM5EXJV	DN	LY-2881835
DM5EXJV	MI	TTB8FUC
DM5EXJV	MN	Free fatty acid receptor 1 (GPR40)
DM5EXJV	MT	DTT
DM5EXJV	MA	Modulator
DM5EXJV	RN	Treatment of Type 2 Diabetes by Free Fatty Acid Receptor Agonists. Front Endocrinol (Lausanne) 2014; 5: 137.
DM5EXJV	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4147718/

DMGLTE2	DI	DMGLTE2
DMGLTE2	DN	LY2922470
DMGLTE2	MI	TTB8FUC
DMGLTE2	MN	Free fatty acid receptor 1 (GPR40)
DMGLTE2	MT	DTT
DMGLTE2	MA	Agonist
DMGLTE2	RN	The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470). J Med Chem. 2016 Dec 22;59(24):10891-10916.
DMGLTE2	RU	https://pubmed.ncbi.nlm.nih.gov/27749056

DMY1AFS	DI	DMY1AFS
DMY1AFS	DN	LY294002
DMY1AFS	MI	TTHBTOP
DMY1AFS	MN	PI3-kinase gamma (PIK3CG)
DMY1AFS	MT	DTT
DMY1AFS	MA	Inhibitor
DMY1AFS	RN	Clinical pipeline report, company report or official report of Genentech (2009).
DMY1AFS	RU	http://www.gene.com/gene/pipeline/status/

DM16IX2	DI	DM16IX2
DM16IX2	DN	LY-2979165
DM16IX2	MI	TTXJ47W
DM16IX2	MN	Metabotropic glutamate receptor 2 (mGluR2)
DM16IX2	MT	DTT
DM16IX2	MA	Modulator
DM16IX2	RN	Annual Reports in Medicinal Chemistry. Volume 47, 2012, Page(78).
DM16IX2	RU	https://books.google.com.hk/books?id=y7GH165YoOsC&pg=PA78&lpg=PA78&dq=Annual+Reports+in+Medicinal+Chemistry++LY-2979165&source=bl&ots=oPRAtBeGRL&sig=la4YgUxL9zkXRln2i4EVFFFVzUg&hl=zh-CN&sa=X&ved=0CB4Q6AEwAGoVChMIsbb8qP3FyAIVC1iOCh3bcgiX#v=onepage&q=Annual%20Reports%20in%20Medicinal%20Chemistry%20%20LY-2979165&f=false

DM6PFCN	DI	DM6PFCN
DM6PFCN	DN	LY3009120
DM6PFCN	MI	TTQ9K3Y
DM6PFCN	MN	Serine/threonine-protein kinase Raf (RAF)
DM6PFCN	MT	DTT
DM6PFCN	MA	Modulator
DM6PFCN	RN	Company report (eli lily)
DM6PFCN	RU	http://www.lillyoncologypipeline.com/pan-raf-inhibitor.aspx

DMJPCHK	DI	DMJPCHK
DMJPCHK	DN	LY309887
DMJPCHK	MI	TTEXB9Z
DMJPCHK	MN	Glycinamide ribonucleotide formyltransferase (GART)
DMJPCHK	MT	DTT
DMJPCHK	MA	Inhibitor
DMJPCHK	RN	New antimetabolites in cancer chemotherapy and their clinical impact. Br J Cancer. 1998;78 Suppl 3:1-7.
DMJPCHK	RU	https://pubmed.ncbi.nlm.nih.gov/9717984

DM5OP86	DI	DM5OP86
DM5OP86	DN	LY3127804
DM5OP86	MI	TTKLQTJ
DM5OP86	MN	Angiopoietin-2 (ANGPT2)
DM5OP86	MT	DTT
DM5OP86	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM5OP86	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM9RTXM	DI	DM9RTXM
DM9RTXM	DN	LY3164530
DM9RTXM	MI	TTGKNB4
DM9RTXM	MN	Epidermal growth factor receptor (EGFR)
DM9RTXM	MT	DTT
DM9RTXM	MA	Modulator
DM9RTXM	RN	Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. 
DM9RTXM	RU	https://www.ncbi.nlm.nih.gov/pubmed/25359367

DM9RTXM	DI	DM9RTXM
DM9RTXM	DN	LY3164530
DM9RTXM	MI	TTNDSF4
DM9RTXM	MN	Proto-oncogene c-Met (MET)
DM9RTXM	MT	DTT
DM9RTXM	MA	Modulator
DM9RTXM	RN	Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. 
DM9RTXM	RU	https://www.ncbi.nlm.nih.gov/pubmed/25359367

DMQP6VB	DI	DMQP6VB
DMQP6VB	DN	LY3200882
DMQP6VB	MI	TTP4520
DMQP6VB	MN	TGF-beta receptor type I (TGFBR1)
DMQP6VB	MT	DTT
DMQP6VB	MA	Inhibitor
DMQP6VB	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQP6VB	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMFDAY7	DI	DMFDAY7
DMFDAY7	DN	LY3214996
DMFDAY7	MI	TT4TQBX
DMFDAY7	MN	Extracellular signal-regulated kinase 2 (ERK2)
DMFDAY7	MT	DTT
DMFDAY7	MA	Inhibitor
DMFDAY7	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMFDAY7	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMOV2ML	DI	DMOV2ML
DMOV2ML	DN	LY3300054
DMOV2ML	MI	TT8ZLTI
DMOV2ML	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMOV2ML	MT	DTT
DMOV2ML	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMOV2ML	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMG6HLE	DI	DMG6HLE
DMG6HLE	DN	LY3303560
DMG6HLE	MI	TTS87KH
DMG6HLE	MN	Microtubule-associated protein tau (MAPT)
DMG6HLE	MT	DTT
DMG6HLE	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMG6HLE	RU	http://phrma-docs.phrma.org/files/dmfile/MID-Update_Alzheimers-Disease_2017-Drug-List.pdf

DMD51GC	DI	DMD51GC
DMD51GC	DN	LY3321367
DMD51GC	MI	TT1RWL7
DMD51GC	MN	Hepatitis A virus cellular receptor 2 (TIM3)
DMD51GC	MT	DTT
DMD51GC	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMD51GC	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMONZ1L	DI	DMONZ1L
DMONZ1L	DN	LY3381916
DMONZ1L	MI	TTZJYKH
DMONZ1L	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMONZ1L	MT	DTT
DMONZ1L	MA	Inhibitor
DMONZ1L	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMONZ1L	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMB51K2	DI	DMB51K2
DMB51K2	DN	LY3405105
DMB51K2	MI	TTQYF7G
DMB51K2	MN	Cyclin-dependent kinase 7 (CDK7)
DMB51K2	MT	DTT
DMB51K2	MA	Inhibitor
DMB51K2	RN	CDK7 inhibitors as anticancer drugs. Cancer Metastasis Rev. 2020 Sep;39(3):805-823.
DMB51K2	RU	https://pubmed.ncbi.nlm.nih.gov/32385714

DMFU0H5	DI	DMFU0H5
DMFU0H5	DN	LY3410738
DMFU0H5	MI	TTV2A1R
DMFU0H5	MN	Oxalosuccinate decarboxylase (IDH1)
DMFU0H5	MT	DTT
DMFU0H5	MA	Inhibitor
DMFU0H5	RN	LY3410738, a novel inhibitor of mutant IDH1 is more effective than Ivosidenib and potentiates antileukemic activity of standard chemotherapy in preclinical models of acute myeloid leukemia (AML).  Cancer Res 2020;80(16 Suppl):Abstract nr 6417.
DMFU0H5	RU	https://cancerres.aacrjournals.org/content/80/16_Supplement/6417

DM5QO1A	DI	DM5QO1A
DM5QO1A	DN	LY3415244
DM5QO1A	MI	TT1RWL7
DM5QO1A	MN	Hepatitis A virus cellular receptor 2 (TIM3)
DM5QO1A	MT	DTT
DM5QO1A	MA	Inhibitor
DM5QO1A	RN	Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors. Clin Cancer Res. 2021 May 15;27(10):2773-2781.
DM5QO1A	RU	https://pubmed.ncbi.nlm.nih.gov/33441294

DM5QO1A	DI	DM5QO1A
DM5QO1A	DN	LY3415244
DM5QO1A	MI	TT8ZLTI
DM5QO1A	MN	Programmed cell death 1 ligand 1 (PD-L1)
DM5QO1A	MT	DTT
DM5QO1A	MA	Inhibitor
DM5QO1A	RN	Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors. Clin Cancer Res. 2021 May 15;27(10):2773-2781.
DM5QO1A	RU	https://pubmed.ncbi.nlm.nih.gov/33441294

DMZLIWX	DI	DMZLIWX
DMZLIWX	DN	LY3475070
DMZLIWX	MI	TTK0O6Y
DMZLIWX	MN	Ecto-5'-nucleotidase (CD73)
DMZLIWX	MT	DTT
DMZLIWX	MA	Inhibitor
DMZLIWX	RN	CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers. Front Immunol. 2020 Apr 15;11:508.
DMZLIWX	RU	https://pubmed.ncbi.nlm.nih.gov/32351498

DMY8W3S	DI	DMY8W3S
DMY8W3S	DN	LY3484356
DMY8W3S	MI	TTZAYWL
DMY8W3S	MN	Estrogen receptor (ESR)
DMY8W3S	MT	DTT
DMY8W3S	MA	Degrader
DMY8W3S	RN	ClinicalTrials.gov (NCT04647487) A Study of LY3484356 in Women With Breast Cancer Before Having Surgery (EMBER-2). U.S. National Institutes of Health.
DMY8W3S	RU	https://clinicaltrials.gov/ct2/show/NCT04647487

DMLXGAI	DI	DMLXGAI
DMLXGAI	DN	LYS-6KAKT1
DMLXGAI	MI	TTAZ05C
DMLXGAI	MN	RAC-gamma serine/threonine-protein kinase (AKT3)
DMLXGAI	MT	DTT
DMLXGAI	MA	Modulator
DMLXGAI	RN	DOI: 10.1016/S1359-6349(10)71767-5
DMLXGAI	RU	https://www.researchgate.net/publication/251667787_62_Preclinical_evaluation_of_LYS6KAKT1_a_novel_highly_selective_orally_bioavailable_dual_inhibitor_of_p70_S6_Kinase_and_AKT_currently_in_phase_I_clinical_trials_for_cancer

DMLXGAI	DI	DMLXGAI
DMLXGAI	DN	LYS-6KAKT1
DMLXGAI	MI	TT7M3PI
DMLXGAI	MN	Ribosomal protein S6 kinase (S6K)
DMLXGAI	MT	DTT
DMLXGAI	MA	Modulator
DMLXGAI	RN	DOI: 10.1016/S1359-6349(10)71767-5
DMLXGAI	RU	https://www.researchgate.net/publication/251667787_62_Preclinical_evaluation_of_LYS6KAKT1_a_novel_highly_selective_orally_bioavailable_dual_inhibitor_of_p70_S6_Kinase_and_AKT_currently_in_phase_I_clinical_trials_for_cancer

DMHDCSL	DI	DMHDCSL
DMHDCSL	DN	LZM009
DMHDCSL	MI	TTNBFWK
DMHDCSL	MN	Programmed cell death protein 1 (PD-1)
DMHDCSL	MT	DTT
DMHDCSL	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMHDCSL	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMK7UNL	DI	DMK7UNL
DMK7UNL	DN	M-0004
DMK7UNL	MI	TT07C3Y
DMK7UNL	MN	5-HT 4 receptor (HTR4)
DMK7UNL	MT	DTT
DMK7UNL	MA	Agonist
DMK7UNL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 9).
DMK7UNL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=9

DME6UNO	DI	DME6UNO
DME6UNO	DN	M012
DME6UNO	MI	TT6Y1PG
DME6UNO	MN	Solute carrier family 40 member 1 (SLC40A1)
DME6UNO	MT	DTT
DME6UNO	MA	Agonist
DME6UNO	RN	Hepcidin agonists as therapeutic tools. Blood. 2018 Apr 19;131(16):1790-1794.
DME6UNO	RU	https://pubmed.ncbi.nlm.nih.gov/29523504

DMP8QY2	DI	DMP8QY2
DMP8QY2	DN	M1774
DMP8QY2	MI	TT8ZYBQ
DMP8QY2	MN	Serine/threonine-protein kinase ATR (FRP1)
DMP8QY2	MT	DTT
DMP8QY2	MA	Inhibitor
DMP8QY2	RN	National Cancer Institute Drug Dictionary (drug name M1774).
DMP8QY2	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/atr-kinase-inhibitor-m1774

DM3PVBJ	DI	DM3PVBJ
DM3PVBJ	DN	M2698
DM3PVBJ	MI	TTWTSCV
DM3PVBJ	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DM3PVBJ	MT	DTT
DM3PVBJ	MA	Inhibitor
DM3PVBJ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3PVBJ	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM3PVBJ	DI	DM3PVBJ
DM3PVBJ	DN	M2698
DM3PVBJ	MI	TTAZ05C
DM3PVBJ	MN	RAC-gamma serine/threonine-protein kinase (AKT3)
DM3PVBJ	MT	DTT
DM3PVBJ	MA	Inhibitor
DM3PVBJ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3PVBJ	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM3PVBJ	DI	DM3PVBJ
DM3PVBJ	DN	M2698
DM3PVBJ	MI	TTG0U4H
DM3PVBJ	MN	Ribosomal protein S6 kinase beta-1 (S6K1)
DM3PVBJ	MT	DTT
DM3PVBJ	MA	Inhibitor
DM3PVBJ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3PVBJ	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM6PI5B	DI	DM6PI5B
DM6PI5B	DN	M3258
DM6PI5B	MI	TTEAD9J
DM6PI5B	MN	Proteasome beta-8 (PS beta-8)
DM6PI5B	MT	DTT
DM6PI5B	MA	Inhibitor
DM6PI5B	RN	Clinical pipeline report, company report or official report of EMD Serono.
DM6PI5B	RU	https://medical.emdserono.com/en_US/home/oncology/m3258.html

DMG98QO	DI	DMG98QO
DMG98QO	DN	M3541
DMG98QO	MI	TTKBM7V
DMG98QO	MN	ATM serine/threonine kinase (ATM)
DMG98QO	MT	DTT
DMG98QO	MA	Inhibitor
DMG98QO	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMG98QO	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMQBO3V	DI	DMQBO3V
DMQBO3V	DN	M4344
DMQBO3V	MI	TT8ZYBQ
DMQBO3V	MN	Serine/threonine-protein kinase ATR (FRP1)
DMQBO3V	MT	DTT
DMQBO3V	MA	Inhibitor
DMQBO3V	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQBO3V	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM6J085	DI	DM6J085
DM6J085	DN	M6223
DM6J085	MI	TTWNL74
DM6J085	MN	V-set and immunoglobulin domain-containing protein 9 (TIGIT)
DM6J085	MT	DTT
DM6J085	MA	Inhibitor
DM6J085	RN	ClinicalTrials.gov (NCT04457778) First in Human Study of M6223. U.S. National Institutes of Health.
DM6J085	RU	https://clinicaltrials.gov/ct2/show/NCT04457778

DMDK4MG	DI	DMDK4MG
DMDK4MG	DN	M7583
DMDK4MG	MI	TTGM6VW
DMDK4MG	MN	Tyrosine-protein kinase BTK (ATK)
DMDK4MG	MT	DTT
DMDK4MG	MA	Inhibitor
DMDK4MG	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMDK4MG	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM132EG	DI	DM132EG
DM132EG	DN	M802
DM132EG	MI	TT6EO5L
DM132EG	MN	Erbb2 tyrosine kinase receptor (HER2)
DM132EG	MT	DTT
DM132EG	MA	Inhibitor
DM132EG	RN	A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells. J Exp Clin Cancer Res. 2019 Aug 14;38(1):355.
DM132EG	RU	https://pubmed.ncbi.nlm.nih.gov/31412896

DM132EG	DI	DM132EG
DM132EG	DN	M802
DM132EG	MI	TTUN7MC
DM132EG	MN	T-cell surface glycoprotein CD3 (CD3)
DM132EG	MT	DTT
DM132EG	MA	Inhibitor
DM132EG	RN	A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells. J Exp Clin Cancer Res. 2019 Aug 14;38(1):355.
DM132EG	RU	https://pubmed.ncbi.nlm.nih.gov/31412896

DMZ9NVP	DI	DMZ9NVP
DMZ9NVP	DN	M8891
DMZ9NVP	MI	TTZL0OI
DMZ9NVP	MN	Methionine aminopeptidase 2 (METAP2)
DMZ9NVP	MT	DTT
DMZ9NVP	MA	Inhibitor
DMZ9NVP	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZ9NVP	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMZUM67	DI	DMZUM67
DMZUM67	DN	M9241
DMZUM67	MI	TTG68FB
DMZUM67	MN	Interleukine 12 (IL-12)
DMZUM67	MT	DTT
DMZUM67	MA	Replacement
DMZUM67	RN	Clinical pipeline report, company report or official report of EMD Serono.
DMZUM67	RU	https://medical.emdserono.com/content/healthcare/biopharma/usmi/en_US/home/immuno-oncology/m9241--nhs-il12--.html

DM59TI2	DI	DM59TI2
DM59TI2	DN	M9831
DM59TI2	MI	TTK3PY9
DM59TI2	MN	DNA-dependent protein kinase catalytic (PRKDC)
DM59TI2	MT	DTT
DM59TI2	MA	Inhibitor
DM59TI2	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM59TI2	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM0HKU7	DI	DM0HKU7
DM0HKU7	DN	Macozinone
DM0HKU7	MI	TTLOHU4
DM0HKU7	MN	Mycobacterium Decaprenylphosphoryl-beta-D-ribose oxidase (McyB dprE1)
DM0HKU7	MT	DTT
DM0HKU7	MA	Inhibitor
DM0HKU7	RN	Spirocyclic and Bicyclic 8-Nitrobenzothiazinones for Tuberculosis with Improved Physicochemical and Pharmacokinetic Properties. ACS Med Chem Lett. 2019 Feb 23;10(3):348-351.
DM0HKU7	RU	https://pubmed.ncbi.nlm.nih.gov/30891138

DM9F15C	DI	DM9F15C
DM9F15C	DN	MAU868
DM9F15C	MI	TT09JLE
DM9F15C	MN	BV virus Major capsid protein VP1 (BKV VP1)
DM9F15C	MT	DTT
DM9F15C	MA	Inhibitor
DM9F15C	RN	Clinical pipeline report, company report or official report of Amplyx Pharmaceuticals.
DM9F15C	RU	https://amplyx.com/our-pipeline/

DMMP7XG	DI	DMMP7XG
DMMP7XG	DN	MAXY-4
DMMP7XG	MI	TTFZDNP
DMMP7XG	MN	Activation B7-1 antigen (CD80)
DMMP7XG	MT	DTT
DMMP7XG	MA	Inhibitor
DMMP7XG	RN	Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 2011 Apr 29;332(6029):600-3.
DMMP7XG	RU	https://pubmed.ncbi.nlm.nih.gov/21474713

DMMP7XG	DI	DMMP7XG
DMMP7XG	DN	MAXY-4
DMMP7XG	MI	TTHGXBU
DMMP7XG	MN	T-lymphocyte activation antigen CD86 (FUN1)
DMMP7XG	MT	DTT
DMMP7XG	MA	Inhibitor
DMMP7XG	RN	Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 2011 Apr 29;332(6029):600-3.
DMMP7XG	RU	https://pubmed.ncbi.nlm.nih.gov/21474713

DMSZ8HT	DI	DMSZ8HT
DMSZ8HT	DN	MazF gene therapy
DMSZ8HT	MI	TTRBUYN
DMSZ8HT	MN	Ribonuclease (RNase)
DMSZ8HT	MT	DTT
DMSZ8HT	MA	Modulator
DMSZ8HT	RN	Clinical pipeline report, company report or official report of Takara Bio.
DMSZ8HT	RU	http://www.takara-bio.com/medi_e/

DMLA1QD	DI	DMLA1QD
DMLA1QD	DN	MB-101
DMLA1QD	MI	TTMPZ7V
DMLA1QD	MN	Interleukin 13 receptor alpha-2 (IL13RA2)
DMLA1QD	MT	DTT
DMLA1QD	MA	Immunomodulator
DMLA1QD	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMLA1QD	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMS0P5O	DI	DMS0P5O
DMS0P5O	DN	MB-103
DMS0P5O	MI	TT6EO5L
DMS0P5O	MN	Erbb2 tyrosine kinase receptor (HER2)
DMS0P5O	MT	DTT
DMS0P5O	RN	Clinical pipeline report, company report or official report of Mustang Bio.
DMS0P5O	RU	https://www.mustangbio.com/pipeline/

DMRP4BM	DI	DMRP4BM
DMRP4BM	DN	MB-104
DMRP4BM	MI	TT7ILZ1
DMRP4BM	MN	SLAM family member 7 SLAMF7 (CS1)
DMRP4BM	MT	DTT
DMRP4BM	RN	Clinical pipeline report, company report or official report of Mustang Bio.
DMRP4BM	RU	https://www.mustangbio.com/pipeline/

DMVGTP6	DI	DMVGTP6
DMVGTP6	DN	MB-105
DMVGTP6	MI	TT9T4AV
DMVGTP6	MN	Prostate stem cell antigen (PSCA)
DMVGTP6	MT	DTT
DMVGTP6	RN	Clinical pipeline report, company report or official report of Mustang Bio.
DMVGTP6	RU	https://www.mustangbio.com/pipeline/

DMPE0KD	DI	DMPE0KD
DMPE0KD	DN	MB-110
DMPE0KD	MI	TTCJ2X8
DMPE0KD	MN	Hepatitis C virus Non-structural 5A (HCV NS5A)
DMPE0KD	MT	DTT
DMPE0KD	MA	Inhibitor
DMPE0KD	RN	Clinical pipeline report, company report or official report of Microbio.
DMPE0KD	RU	https://www.microbio.com.tw/home_03.php?p=7&a=15

DM85AXS	DI	DM85AXS
DM85AXS	DN	MBS301
DM85AXS	MI	TT6EO5L
DM85AXS	MN	Erbb2 tyrosine kinase receptor (HER2)
DM85AXS	MT	DTT
DM85AXS	MA	Inhibitor
DM85AXS	RN	Clinical pipeline report, company report or official report of Beijing Mabworks Biotech.
DM85AXS	RU	http://www.mab-works.com/product/5.html

DMTXIZ1	DI	DMTXIZ1
DMTXIZ1	DN	MBX-700
DMTXIZ1	MI	TTMVBWH
DMTXIZ1	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMTXIZ1	MT	DTT
DMTXIZ1	MA	Inhibitor
DMTXIZ1	RN	Clinical pipeline report, company report or official report of Microbiotix Inc.
DMTXIZ1	RU	http://www.microbiotix.com/therapeutic-programs-hcv.htm

DMFIS4D	DI	DMFIS4D
DMFIS4D	DN	MCD-386
DMFIS4D	MI	TTZ9SOR
DMFIS4D	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMFIS4D	MT	DTT
DMFIS4D	MA	Agonist
DMFIS4D	RN	The processing of the selective M1 agonist CDD-0102-J by human hepatic drug metabolizing enzymes. Am J Ther. 2005 Jul-Aug;12(4):300-5.
DMFIS4D	RU	https://pubmed.ncbi.nlm.nih.gov/16041192

DM8CGUV	DI	DM8CGUV
DM8CGUV	DN	MCLA-145
DM8CGUV	MI	TTPW9LJ
DM8CGUV	MN	Co-stimulatory molecule 4-1BB (CD137)
DM8CGUV	MT	DTT
DM8CGUV	MA	Agonist
DM8CGUV	RN	Clinical pipeline report, company report or official report of Merus.
DM8CGUV	RU	https://merus.nl/publication-category/mcla-145/

DM8CGUV	DI	DM8CGUV
DM8CGUV	DN	MCLA-145
DM8CGUV	MI	TT8ZLTI
DM8CGUV	MN	Programmed cell death 1 ligand 1 (PD-L1)
DM8CGUV	MT	DTT
DM8CGUV	MA	Agonist
DM8CGUV	RN	Clinical pipeline report, company report or official report of Merus.
DM8CGUV	RU	https://merus.nl/pipeline/

DMF0O3X	DI	DMF0O3X
DMF0O3X	DN	MCLA-158
DMF0O3X	MI	TTGKNB4
DMF0O3X	MN	Epidermal growth factor receptor (EGFR)
DMF0O3X	MT	DTT
DMF0O3X	MA	Inhibitor
DMF0O3X	RN	Clinical pipeline report, company report or official report of Merus.
DMF0O3X	RU	https://merus.nl/pipeline/

DMF0O3X	DI	DMF0O3X
DMF0O3X	DN	MCLA-158
DMF0O3X	MI	TTTSGRH
DMF0O3X	MN	Leucine-rich repeat-containing GPCR 5 (LGR5)
DMF0O3X	MT	DTT
DMF0O3X	MA	Inhibitor
DMF0O3X	RN	Clinical pipeline report, company report or official report of Merus.
DMF0O3X	RU	https://merus.nl/pipeline/

DMW9YOJ	DI	DMW9YOJ
DMW9YOJ	DN	MCP-201
DMW9YOJ	MI	TT27RFC
DMW9YOJ	MN	Opioid receptor delta (OPRD1)
DMW9YOJ	MT	DTT
DMW9YOJ	MA	Agonist
DMW9YOJ	RN	US patent application no. 6,924,288, Enantiomerically pure opioid diarylmethylpiperzine and methods of using same.
DMW9YOJ	RU	http://www.google.com/patents/US6924288

DMW9YOJ	DI	DMW9YOJ
DMW9YOJ	DN	MCP-201
DMW9YOJ	MI	TTQW87Y
DMW9YOJ	MN	Opioid receptor kappa (OPRK1)
DMW9YOJ	MT	DTT
DMW9YOJ	MA	Agonist
DMW9YOJ	RN	US patent application no. 6,924,288, Enantiomerically pure opioid diarylmethylpiperzine and methods of using same.
DMW9YOJ	RU	http://www.google.com/patents/US6924288

DMW9YOJ	DI	DMW9YOJ
DMW9YOJ	DN	MCP-201
DMW9YOJ	MI	TTKWM86
DMW9YOJ	MN	Opioid receptor mu (MOP)
DMW9YOJ	MT	DTT
DMW9YOJ	MA	Agonist
DMW9YOJ	RN	US patent application no. 6,924,288, Enantiomerically pure opioid diarylmethylpiperzine and methods of using same.
DMW9YOJ	RU	http://www.google.com/patents/US6924288

DM65B7G	DI	DM65B7G
DM65B7G	DN	MCP-202
DM65B7G	MI	TT27RFC
DM65B7G	MN	Opioid receptor delta (OPRD1)
DM65B7G	MT	DTT
DM65B7G	MA	Agonist
DM65B7G	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018026)
DM65B7G	RU	http://adisinsight.springer.com/drugs/800018026

DMAESQI	DI	DMAESQI
DMAESQI	DN	MCY-M11
DMAESQI	MI	TT4RXME
DMAESQI	MN	Mesothelin (MSLN)
DMAESQI	MT	DTT
DMAESQI	RN	Clinical pipeline report, company report or official report of MaxCyte.
DMAESQI	RU	https://maxcyte.com/carma-cell-therapies-expands-phase-i-trial-of-anti-mesothelin-mrna-car-pbmc-cell-therapy-mcy-m11/

DM1DISM	DI	DM1DISM
DM1DISM	DN	MDAM (y-methylene-10-deazaaminopterin)
DM1DISM	MI	TTYZVDJ
DM1DISM	MN	Dihydrofolate reductase (DHFR)
DM1DISM	MT	DTT
DM1DISM	MA	Inhibitor
DM1DISM	RN	Evaluation of the importance of hydrophobic interactions in drug binding to dihydrofolate reductase. J Med Chem. 1988 Jan;31(1):129-37.
DM1DISM	RU	https://pubmed.ncbi.nlm.nih.gov/3275776

DMAQ24G	DI	DMAQ24G
DMAQ24G	DN	MDCO-216
DMAQ24G	MI	TT7GN3U
DMAQ24G	MN	Apolipoprotein A-I (APOA1)
DMAQ24G	MT	DTT
DMAQ24G	MA	Modulator
DMAQ24G	RN	MDCO-216 (Apo A-I Milano/POPC Complex) Administered to Cynomolgus Monkeys Induces Pronounced Changes in Plasma Lipids and Apolipoproteins. Circulation. 2011; 124: A10978.
DMAQ24G	RU	https://circ.ahajournals.org/cgi/content/meeting_abstract/124/21_MeetingAbstracts/A10978

DMC60S8	DI	DMC60S8
DMC60S8	DN	MDL-27531
DMC60S8	MI	TTZ8EM9
DMC60S8	MN	Glycine receptor (GlyR)
DMC60S8	MT	DTT
DMC60S8	MA	Modulator
DMC60S8	RN	MDL 27,531 reduces spontaneous hindlimb contractions in rats with chronic transections of the spinal cord. Neurosci Lett. 1992 Nov 23;147(1):101-5.
DMC60S8	RU	https://pubmed.ncbi.nlm.nih.gov/1480315

DML5FX2	DI	DML5FX2
DML5FX2	DN	MDX-018
DML5FX2	MI	TTCTE1G
DML5FX2	MN	Interleukin-8 (IL8)
DML5FX2	MT	DTT
DML5FX2	MA	Modulator
DML5FX2	RN	Company report (Genmab)
DML5FX2	RU	http://www.genmab.com/product-pipeline/products-in-development/humax-il8

DM0RIQF	DI	DM0RIQF
DM0RIQF	DN	MDX-1203
DM0RIQF	MI	TTNCIE0
DM0RIQF	MN	CD70 antigen (CD27-L)
DM0RIQF	MT	DTT
DM0RIQF	RN	J Clin Oncol 32:5s, 2014 (suppl; abstr 2558).
DM0RIQF	RU	http://meetinglibrary.asco.org/content/130447-144

DM3402P	DI	DM3402P
DM3402P	DN	MDX-1411
DM3402P	MI	TTNCIE0
DM3402P	MN	CD70 antigen (CD27-L)
DM3402P	MT	DTT
DM3402P	RN	Bristol-Myers Squibb swallows last of antibody pioneers. Nat Biotechnol. 2009 Sep;27(9):781-3.
DM3402P	RU	https://pubmed.ncbi.nlm.nih.gov/19741612

DMEMQ5J	DI	DMEMQ5J
DMEMQ5J	DN	ME-1071
DMEMQ5J	MI	TTHI19T
DMEMQ5J	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMEMQ5J	MT	DTT
DMEMQ5J	MA	Inhibitor
DMEMQ5J	RN	Multidrug-resistant Gram-negative bacterial infections: are you ready for the challenge. Curr Clin Pharmacol. 2014 Feb;9(1):27-38.
DMEMQ5J	RU	https://pubmed.ncbi.nlm.nih.gov/23489027

DM39PSZ	DI	DM39PSZ
DM39PSZ	DN	ME1100
DM39PSZ	MI	TTOVFH2
DM39PSZ	MN	Bacterial 30S ribosomal RNA (Bact 30S rRNA)
DM39PSZ	MT	DTT
DM39PSZ	MA	Inhibitor
DM39PSZ	RN	ClinicalTrials.gov (NCT01961830) Intrapulmonary Pharmacokinetics of ME1100 in Healthy Volunteers. U.S. National Institutes of Health.
DM39PSZ	RU	https://clinicaltrials.gov/ct2/show/NCT01961830

DMFNYQ9	DI	DMFNYQ9
DMFNYQ9	DN	ME-401
DMFNYQ9	MI	TTGBPJE
DMFNYQ9	MN	PI3-kinase delta (PIK3CD)
DMFNYQ9	MT	DTT
DMFNYQ9	MA	Inhibitor
DMFNYQ9	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMFNYQ9	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMYVBU6	DI	DMYVBU6
DMYVBU6	DN	MEDI0562
DMYVBU6	MI	TTL31H0
DMYVBU6	MN	OX40L receptor (CD134)
DMYVBU6	MT	DTT
DMYVBU6	MA	Agonist
DMYVBU6	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMYVBU6	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMPLFBV	DI	DMPLFBV
DMPLFBV	DN	MEDI0680
DMPLFBV	MI	TTNBFWK
DMPLFBV	MN	Programmed cell death protein 1 (PD-1)
DMPLFBV	MT	DTT
DMPLFBV	RN	A Phase Ib/II open-label study to evaluate the safety and efficacy of MEDI-551 in combination with immunomodulating therapy in patients with relapsed or refractory aggressive B cell lymphomas. J Immunother Cancer. 2014; 2(Suppl 3): P73.
DMPLFBV	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288733/

DMD9OVI	DI	DMD9OVI
DMD9OVI	DN	MEDI1191
DMD9OVI	MI	TTG68FB
DMD9OVI	MN	Interleukine 12 (IL-12)
DMD9OVI	MT	DTT
DMD9OVI	MA	Replacement
DMD9OVI	RN	Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment. Clin Cancer Res. 2020 Dec 1;26(23):6284-6298.
DMD9OVI	RU	https://pubmed.ncbi.nlm.nih.gov/32817076

DMQDBSU	DI	DMQDBSU
DMQDBSU	DN	MEDI1341
DMQDBSU	MI	TT08OSU
DMQDBSU	MN	Synuclein alpha (SNCA)
DMQDBSU	MT	DTT
DMQDBSU	MA	Inhibitor
DMQDBSU	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQDBSU	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMX0DUH	DI	DMX0DUH
DMX0DUH	DN	MEDI2228
DMX0DUH	MI	TTZ3P4W
DMX0DUH	MN	B-cell maturation protein (TNFRSF17)
DMX0DUH	MT	DTT
DMX0DUH	MA	Inhibitor
DMX0DUH	RN	A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma. Leukemia. 2020 Aug;34(8):2150-2162.
DMX0DUH	RU	https://pubmed.ncbi.nlm.nih.gov/32060401

DMCMYPX	DI	DMCMYPX
DMCMYPX	DN	MEDI-2338
DMCMYPX	MI	TTRICUF
DMCMYPX	MN	Interleukin-18 (IL18)
DMCMYPX	MT	DTT
DMCMYPX	MA	Modulator
DMCMYPX	RN	Cytokine inhibition in the treatment of COPD. Int J Chron Obstruct Pulmon Dis. 2014; 9: 397-412.
DMCMYPX	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010626/

DM0H5JD	DI	DM0H5JD
DM0H5JD	DN	MEDI3617
DM0H5JD	MI	TTKLQTJ
DM0H5JD	MN	Angiopoietin-2 (ANGPT2)
DM0H5JD	MT	DTT
DM0H5JD	MA	Inhibitor
DM0H5JD	RN	Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors. Clin Cancer Res. 2018 Jun 15;24(12):2749-2757.
DM0H5JD	RU	https://pubmed.ncbi.nlm.nih.gov/29559563

DMBI4EN	DI	DMBI4EN
DMBI4EN	DN	MEDI4212
DMBI4EN	MI	TTYJQTF
DMBI4EN	MN	Immunoglobulin E (IgE)
DMBI4EN	MT	DTT
DMBI4EN	MA	Modulator
DMBI4EN	RN	A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma. MAbs. 2014 May-Jun;6(3):756-64.
DMBI4EN	RU	https://pubmed.ncbi.nlm.nih.gov/24583620

DMNI60O	DI	DMNI60O
DMNI60O	DN	MEDI4276
DMNI60O	MI	TT6EO5L
DMNI60O	MN	Erbb2 tyrosine kinase receptor (HER2)
DMNI60O	MT	DTT
DMNI60O	MA	Modulator
DMNI60O	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMNI60O	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DME7BMT	DI	DME7BMT
DME7BMT	DN	MEDI4920
DME7BMT	MI	TTIJP3Q
DME7BMT	MN	TNF related activation protein (CD40LG)
DME7BMT	MT	DTT
DME7BMT	MA	Inhibitor
DME7BMT	RN	ClinicalTrials.gov (NCT02151110) A Phase 1, Randomized, Blinded, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety and Tolerability of MEDI4920 in Healthy Adults. U.S. National Institutes of Health.
DME7BMT	RU	https://clinicaltrials.gov/ct2/show/NCT02151110

DM3IJQ5	DI	DM3IJQ5
DM3IJQ5	DN	MEDI5117
DM3IJQ5	MI	TTT1V78
DM3IJQ5	MN	Interleukin-6 (IL6)
DM3IJQ5	MT	DTT
DM3IJQ5	MA	Modulator
DM3IJQ5	RN	Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics. J Mol Biol. 2011 Aug 26;411(4):791-807.
DM3IJQ5	RU	https://pubmed.ncbi.nlm.nih.gov/21723291

DM3WP70	DI	DM3WP70
DM3WP70	DN	MEDI-547
DM3WP70	MI	TTRJB2G
DM3WP70	MN	Ephrin type-A receptor 2 (EPHA2)
DM3WP70	MT	DTT
DM3WP70	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1822).
DM3WP70	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1822

DM6ADMG	DI	DM6ADMG
DM6ADMG	DN	MEDI-557
DM6ADMG	MI	TT57ID8
DM6ADMG	MN	Respiratory syncytial virus protein F (RSV F)
DM6ADMG	MT	DTT
DM6ADMG	RN	Motavizumab. Correction in: MAbs. 2010 Sep-Oct; 2(5): 591.
DM6ADMG	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2759493/

DMFWPLQ	DI	DMFWPLQ
DMFWPLQ	DN	MEDI-565
DMFWPLQ	MI	TTV3XPL
DMFWPLQ	MN	T-cell surface glycoprotein CD3 gamma (CD3G)
DMFWPLQ	MT	DTT
DMFWPLQ	MA	Modulator
DMFWPLQ	RN	Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. 
DMFWPLQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25359367

DMCJFLS	DI	DMCJFLS
DMCJFLS	DN	MEDI-570
DMCJFLS	MI	TTE5VP6
DMCJFLS	MN	Inducible T-cell costimulator (ICOS)
DMCJFLS	MT	DTT
DMCJFLS	MA	Modulator
DMCJFLS	RN	B-cell targeted therapeutics in clinical development. Arthritis Res Ther. 2013;15 Suppl 1:S4.
DMCJFLS	RU	https://pubmed.ncbi.nlm.nih.gov/23566679

DMNL8MO	DI	DMNL8MO
DMNL8MO	DN	MEDI-573
DMNL8MO	MI	TTT6LOU
DMNL8MO	MN	Insulin-like growth factor-I (IGF1)
DMNL8MO	MT	DTT
DMNL8MO	MA	Modulator
DMNL8MO	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMNL8MO	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMJ1E24	DI	DMJ1E24
DMJ1E24	DN	MEDI5752
DMJ1E24	MI	TTI2S1D
DMJ1E24	MN	Cytotoxic T-lymphocyte protein 4 (CTLA-4)
DMJ1E24	MT	DTT
DMJ1E24	MA	Inhibitor
DMJ1E24	RN	Bispecific Antibodies to PD-1 and CTLA4: Doubling Down on T Cells to Decouple Efficacy from Toxicity. Cancer Discov. 2021 May;11(5):1008-1010.
DMJ1E24	RU	https://pubmed.ncbi.nlm.nih.gov/33947716

DMJ1E24	DI	DMJ1E24
DMJ1E24	DN	MEDI5752
DMJ1E24	MI	TTNBFWK
DMJ1E24	MN	Programmed cell death protein 1 (PD-1)
DMJ1E24	MT	DTT
DMJ1E24	MA	Inhibitor
DMJ1E24	RN	Bispecific Antibodies to PD-1 and CTLA4: Doubling Down on T Cells to Decouple Efficacy from Toxicity. Cancer Discov. 2021 May;11(5):1008-1010.
DMJ1E24	RU	https://pubmed.ncbi.nlm.nih.gov/33947716

DMPW21Z	DI	DMPW21Z
DMPW21Z	DN	MEDI-578
DMPW21Z	MI	TTDN3LF
DMPW21Z	MN	Nerve growth factor (NGF)
DMPW21Z	MT	DTT
DMPW21Z	MA	Modulator
DMPW21Z	RN	Fate of novel painkiller mAbs hangs in balance.Nat Biotechnol.2011 Mar;29(3):173-4.
DMPW21Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/21389990

DM1YSMD	DI	DM1YSMD
DM1YSMD	DN	MEDI6383
DM1YSMD	MI	TTBW580
DM1YSMD	MN	TAX transcriptionally-activated glycoprotein 1 (OX40)
DM1YSMD	MT	DTT
DM1YSMD	RN	J Clin Oncol 33, 2015 (suppl; abstr 3056).
DM1YSMD	RU	http://meetinglibrary.asco.org/content/150554-156

DM8BXDI	DI	DM8BXDI
DM8BXDI	DN	MEDI7814
DM8BXDI	MI	TTKANGO
DM8BXDI	MN	Complement C5 (CO5)
DM8BXDI	MT	DTT
DM8BXDI	MA	Modulator
DM8BXDI	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM8BXDI	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM0J7UR	DI	DM0J7UR
DM0J7UR	DN	MEDI9197
DM0J7UR	MI	TTRJ1K4
DM0J7UR	MN	Toll-like receptor 7 (TLR7)
DM0J7UR	MT	DTT
DM0J7UR	MA	Agonist
DM0J7UR	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM0J7UR	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM0J7UR	DI	DM0J7UR
DM0J7UR	DN	MEDI9197
DM0J7UR	MI	TT8CWFK
DM0J7UR	MN	Toll-like receptor 8 (TLR8)
DM0J7UR	MT	DTT
DM0J7UR	MA	Agonist
DM0J7UR	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM0J7UR	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM1ALHT	DI	DM1ALHT
DM1ALHT	DN	MEDl-551
DM1ALHT	MI	TTW640A
DM1ALHT	MN	B-lymphocyte surface antigen B4 (CD19)
DM1ALHT	MT	DTT
DM1ALHT	RN	CD19 as an attractive target for antibody-based therapy. MAbs. 2012 Sep-Oct;4(5):571-7.
DM1ALHT	RU	https://pubmed.ncbi.nlm.nih.gov/22820352

DMA1KQV	DI	DMA1KQV
DMA1KQV	DN	MEM-1414
DMA1KQV	MI	TTZ97H5
DMA1KQV	MN	Phosphodiesterase 4A (PDE4A)
DMA1KQV	MT	DTT
DMA1KQV	MA	Inhibitor
DMA1KQV	RN	The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma. BMC Pulm Med. 2014 Oct 28;14:166.
DMA1KQV	RU	https://pubmed.ncbi.nlm.nih.gov/25351474

DMA1KQV	DI	DMA1KQV
DMA1KQV	DN	MEM-1414
DMA1KQV	MI	TTVIAT9
DMA1KQV	MN	Phosphodiesterase 4B (PDE4B)
DMA1KQV	MT	DTT
DMA1KQV	MA	Inhibitor
DMA1KQV	RN	The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma. BMC Pulm Med. 2014 Oct 28;14:166.
DMA1KQV	RU	https://pubmed.ncbi.nlm.nih.gov/25351474

DMA1KQV	DI	DMA1KQV
DMA1KQV	DN	MEM-1414
DMA1KQV	MI	TTSKMI8
DMA1KQV	MN	Phosphodiesterase 4D (PDE4D)
DMA1KQV	MT	DTT
DMA1KQV	MA	Inhibitor
DMA1KQV	RN	The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma. BMC Pulm Med. 2014 Oct 28;14:166.
DMA1KQV	RU	https://pubmed.ncbi.nlm.nih.gov/25351474

DME18UM	DI	DME18UM
DME18UM	DN	MER-102
DME18UM	MI	TT4QPUL
DME18UM	MN	Antithrombin-III (ATIII)
DME18UM	MT	DTT
DME18UM	MA	Inhibitor
DME18UM	RN	Clinical pipeline report, company report or official report of Merrion's GIPET technology.
DME18UM	RU	http://www.merrionpharma.com/content/portfolio/mer102.asp

DMQSJ9T	DI	DMQSJ9T
DMQSJ9T	DN	Meso-CART
DMQSJ9T	MI	TT4RXME
DMQSJ9T	MN	Mesothelin (MSLN)
DMQSJ9T	MT	DTT
DMQSJ9T	MA	CAR-T-Cell-Therapy
DMQSJ9T	RN	ClinicalTrials.gov (NCT02706782) A Study of Mesothelin Redirected Autologous T Cells for Advanced Pancreatic Carcinoma
DMQSJ9T	RU	https://clinicaltrials.gov/ct2/show/NCT02706782

DMHXA79	DI	DMHXA79
DMHXA79	DN	Mesothelin-targeted T cells
DMHXA79	MI	TT4RXME
DMHXA79	MN	Mesothelin (MSLN)
DMHXA79	MT	DTT
DMHXA79	MA	CAR-T-Cell-Therapy
DMHXA79	RN	ClinicalTrials.gov (NCT02792114) T-Cell Therapy for Advanced Breast Cancer
DMHXA79	RU	https://clinicaltrials.gov/ct2/show/NCT02792114

DMTQ4PN	DI	DMTQ4PN
DMTQ4PN	DN	Metastat
DMTQ4PN	MI	TTLM12X
DMTQ4PN	MN	Matrix metalloproteinase-2 (MMP-2)
DMTQ4PN	MT	DTT
DMTQ4PN	MA	Inhibitor
DMTQ4PN	RN	Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002 Sep;2(9):657-72.
DMTQ4PN	RU	https://pubmed.ncbi.nlm.nih.gov/12209155

DMQE4IX	DI	DMQE4IX
DMQE4IX	DN	MG-1102
DMQE4IX	MI	TTGUMYS
DMQE4IX	MN	Apolipoprotein(a) (LPA)
DMQE4IX	MT	DTT
DMQE4IX	MA	Modulator
DMQE4IX	RN	Targeted antivascular therapy with the apolipoprotein(a) kringle V, rhLK8, inhibits the growth and metastasis of human prostate cancer in an orthotopic nude mouse model. Neoplasia. 2012 Apr;14(4):335-43.
DMQE4IX	RU	https://pubmed.ncbi.nlm.nih.gov/22577348

DM2PVLH	DI	DM2PVLH
DM2PVLH	DN	MGA271
DM2PVLH	MI	TT6CQUM
DM2PVLH	MN	B7 homolog 3 (CD276)
DM2PVLH	MT	DTT
DM2PVLH	MA	Modulator
DM2PVLH	RN	T Cell Coinhibition and Immunotherapy in Human Breast Cancer. Discov Med. 2012 October; 14(77): 229-236.
DM2PVLH	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107447/

DMQB4VN	DI	DMQB4VN
DMQB4VN	DN	MGD006
DMQB4VN	MI	TTENHJ0
DMQB4VN	MN	Interleukin 3 receptor alpha (IL3RA)
DMQB4VN	MT	DTT
DMQB4VN	MA	Modulator
DMQB4VN	RN	A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates.Sci Transl Med.2015 May 27;7(289):289ra82.
DMQB4VN	RU	https://www.ncbi.nlm.nih.gov/pubmed/26019218

DMQB4VN	DI	DMQB4VN
DMQB4VN	DN	MGD006
DMQB4VN	MI	TTUN7MC
DMQB4VN	MN	T-cell surface glycoprotein CD3 (CD3)
DMQB4VN	MT	DTT
DMQB4VN	MA	Modulator
DMQB4VN	RN	A Phase I trial of MGD006 in patients with relapsed acute myeloid leukemia (AML). J Immunother Cancer. 2014; 2(Suppl 3): P87.
DMQB4VN	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288763/

DME4B8I	DI	DME4B8I
DME4B8I	DN	MGD009
DME4B8I	MI	TT6CQUM
DME4B8I	MN	B7 homolog 3 (CD276)
DME4B8I	MT	DTT
DME4B8I	MA	Immunomodulator
DME4B8I	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DME4B8I	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMA368V	DI	DMA368V
DMA368V	DN	MGD010
DMA368V	MI	TTBN5I7
DMA368V	MN	B-cell-specific glycoprotein B29 (CD79B)
DMA368V	MT	DTT
DMA368V	MA	Modulator
DMA368V	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMA368V	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMA368V	DI	DMA368V
DMA368V	DN	MGD010
DMA368V	MI	TT5RWKQ
DMA368V	MN	Immunoglobulin gamma Fc receptor IIB (FCGR2B)
DMA368V	MT	DTT
DMA368V	MA	Modulator
DMA368V	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMA368V	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMZN5QX	DI	DMZN5QX
DMZN5QX	DN	MGD014
DMZN5QX	MI	TTEC2T3
DMZN5QX	MN	Human immunodeficiency virus Envelope glycoprotein gp160 (HIV env)
DMZN5QX	MT	DTT
DMZN5QX	MA	Inhibitor
DMZN5QX	RN	Clinical pipeline report, company report or official report of MacroGenics.
DMZN5QX	RU	https://www.macrogenics.com/mgd014/

DMZN5QX	DI	DMZN5QX
DMZN5QX	DN	MGD014
DMZN5QX	MI	TTUN7MC
DMZN5QX	MN	T-cell surface glycoprotein CD3 (CD3)
DMZN5QX	MT	DTT
DMZN5QX	MA	Inhibitor
DMZN5QX	RN	Clinical pipeline report, company report or official report of MacroGenics.
DMZN5QX	RU	https://www.macrogenics.com/mgd014/

DM2BYWI	DI	DM2BYWI
DM2BYWI	DN	MGD019
DM2BYWI	MI	TTI2S1D
DM2BYWI	MN	Cytotoxic T-lymphocyte protein 4 (CTLA-4)
DM2BYWI	MT	DTT
DM2BYWI	MA	Inhibitor
DM2BYWI	RN	Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule. Cell Rep Med. 2020 Dec 22;1(9):100163.
DM2BYWI	RU	https://pubmed.ncbi.nlm.nih.gov/33377134

DM2BYWI	DI	DM2BYWI
DM2BYWI	DN	MGD019
DM2BYWI	MI	TTNBFWK
DM2BYWI	MN	Programmed cell death protein 1 (PD-1)
DM2BYWI	MT	DTT
DM2BYWI	MA	Inhibitor
DM2BYWI	RN	Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule. Cell Rep Med. 2020 Dec 22;1(9):100163.
DM2BYWI	RU	https://pubmed.ncbi.nlm.nih.gov/33377134

DMTS5VF	DI	DMTS5VF
DMTS5VF	DN	MGN-1706
DMTS5VF	MI	TTSHG0T
DMTS5VF	MN	Toll-like receptor 9 (TLR9)
DMTS5VF	MT	DTT
DMTS5VF	MA	Agonist
DMTS5VF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1759).
DMTS5VF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1759

DMU9VDS	DI	DMU9VDS
DMU9VDS	DN	Mibefradil
DMU9VDS	MI	DE4LYSA
DMU9VDS	MN	Cytochrome P450 3A4 (CYP3A4)
DMU9VDS	MT	DME
DMU9VDS	MA	Metabolism
DMU9VDS	RN	Effect of mibefradil on CYP3A4 in vivo. J Clin Pharmacol. 2003 Oct;43(10):1091-100.
DMU9VDS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14517191

DMU9VDS	DI	DMU9VDS
DMU9VDS	DN	Mibefradil
DMU9VDS	MI	DTUGYRD
DMU9VDS	MN	P-glycoprotein 1 (ABCB1)
DMU9VDS	MT	DTP
DMU9VDS	MA	Substrate
DMU9VDS	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMU9VDS	RU	https://doi.org/10.1007/s11095-012-0935-x

DMU9VDS	DI	DMU9VDS
DMU9VDS	DN	Mibefradil
DMU9VDS	MI	TTZPWGN
DMU9VDS	MN	Voltage-gated calcium channel alpha Cav3.2 (CACNA1H)
DMU9VDS	MT	DTT
DMU9VDS	MA	Inhibitor
DMU9VDS	RN	Mibefradil block of cloned T-type calcium channels. J Pharmacol Exp Ther. 2000 Oct;295(1):302-8.
DMU9VDS	RU	https://pubmed.ncbi.nlm.nih.gov/10991994

DMTUVCG	DI	DMTUVCG
DMTUVCG	DN	MIK665
DMTUVCG	MI	TTL53M6
DMTUVCG	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DMTUVCG	MT	DTT
DMTUVCG	MA	Inhibitor
DMTUVCG	RN	MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. Cell Death Dis. 2020 Jun 8;11(6):443.
DMTUVCG	RU	https://pubmed.ncbi.nlm.nih.gov/32513939

DMDER9S	DI	DMDER9S
DMDER9S	DN	Minnelide
DMDER9S	MI	TTHYBIX
DMDER9S	MN	Heat shock protein 70 (HSP70)
DMDER9S	MT	DTT
DMDER9S	MA	Inhibitor
DMDER9S	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMDER9S	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM5VEN9	DI	DM5VEN9
DM5VEN9	DN	Minnelide 001
DM5VEN9	MI	TTHYBIX
DM5VEN9	MN	Heat shock protein 70 (HSP70)
DM5VEN9	MT	DTT
DM5VEN9	MA	Modulator
DM5VEN9	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM5VEN9	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMCPF90	DI	DMCPF90
DMCPF90	DN	Mivebresib
DMCPF90	MI	TTE4BSY
DMCPF90	MN	Bromodomain and extraterminal domain protein (BET)
DMCPF90	MT	DTT
DMCPF90	MA	Inhibitor
DMCPF90	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMCPF90	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMFLP21	DI	DMFLP21
DMFLP21	DN	MK 8719
DMFLP21	MI	TT2I6UX
DMFLP21	MN	Beta-N-acetylhexosaminidase (OGA)
DMFLP21	MT	DTT
DMFLP21	MA	Inhibitor
DMFLP21	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMFLP21	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM2TAUR	DI	DM2TAUR
DM2TAUR	DN	MK-0731
DM2TAUR	MI	TTTRP0H
DM2TAUR	MN	Kinesin-like protein KIF11 (KIF11)
DM2TAUR	MT	DTT
DM2TAUR	MA	Inhibitor
DM2TAUR	RN	Kinesins and cancer. Nat Rev Cancer. 2012 Jul 24;12(8):527-39.
DM2TAUR	RU	https://pubmed.ncbi.nlm.nih.gov/22825217

DMHS79I	DI	DMHS79I
DMHS79I	DN	MK-1092
DMHS79I	MI	TTNVEIR
DMHS79I	MN	Prostaglandin D2 receptor (PTGDR)
DMHS79I	MT	DTT
DMHS79I	MA	Antagonist
DMHS79I	RN	The challenge of modulating -cell autoimmunity in type 1 diabetes. Lancet Diabetes Endocrinol. 2019 Jan;7(1):52-64.
DMHS79I	RU	https://pubmed.ncbi.nlm.nih.gov/30528099

DME1ZAH	DI	DME1ZAH
DME1ZAH	DN	MK-1496
DME1ZAH	MI	TTIYVQP
DME1ZAH	MN	Polo-like kinase 1 (PLK1)
DME1ZAH	MT	DTT
DME1ZAH	MA	Inhibitor
DME1ZAH	RN	J Clin Oncol 29: 2011 (suppl; abstr 3012).
DME1ZAH	RU	http://meetinglibrary.asco.org/content/73894-102

DMKNH8B	DI	DMKNH8B
DMKNH8B	DN	MK-2118
DMKNH8B	MI	TTT402Y
DMKNH8B	MN	Stimulator of interferon genes protein (TMEM173)
DMKNH8B	MT	DTT
DMKNH8B	MA	Agonist
DMKNH8B	RN	National Cancer Institute Drug Dictionary (drug name ML2118).
DMKNH8B	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/sting-agonist-mk-2118

DMUHOJP	DI	DMUHOJP
DMUHOJP	DN	MK-2637
DMUHOJP	MI	TTHJTF7
DMUHOJP	MN	Glycine transporter GlyT-1 (SLC6A9)
DMUHOJP	MT	DTT
DMUHOJP	MA	Modulator
DMUHOJP	RN	Characterization of the novel GlyT1 PET tracer [18F]MK-6577 in humans. Synapse. 2015 Jan;69(1):33-40.
DMUHOJP	RU	https://pubmed.ncbi.nlm.nih.gov/25196464

DM5EFPS	DI	DM5EFPS
DM5EFPS	DN	MK-3134
DM5EFPS	MI	TT9JNIC
DM5EFPS	MN	Histamine H3 receptor (H3R)
DM5EFPS	MT	DTT
DM5EFPS	MA	Agonist
DM5EFPS	RN	Additive effects of a cholinesterase inhibitor and a histamine inverse agonist on scopolamine deficits in humans. Psychopharmacology (Berl). 2011 Dec;218(3):513-24.
DM5EFPS	RU	https://pubmed.ncbi.nlm.nih.gov/21644059

DMG0Q27	DI	DMG0Q27
DMG0Q27	DN	MK-3281
DMG0Q27	MI	TTMVBWH
DMG0Q27	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMG0Q27	MT	DTT
DMG0Q27	MA	Inhibitor
DMG0Q27	RN	Clinical pipeline report, company report or official report of Merck (2011).
DMG0Q27	RU	http://www.merck.com/index.html

DMW2O5D	DI	DMW2O5D
DMW2O5D	DN	MK-3328
DMW2O5D	MI	TTHS256
DMW2O5D	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMW2O5D	MT	DTT
DMW2O5D	MA	Modulator
DMW2O5D	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 293).
DMW2O5D	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=293

DML5V76	DI	DML5V76
DML5V76	DN	MK-4166
DML5V76	MI	TTG6LA7
DML5V76	MN	Activation-inducible TNFR family receptor (TNFRSF18)
DML5V76	MT	DTT
DML5V76	RN	Immuno-oncology moves beyond PD-1. Nat Biotechnol. 2015 Jul;33(7):673-5.
DML5V76	RU	https://pubmed.ncbi.nlm.nih.gov/26153987

DMCA1NX	DI	DMCA1NX
DMCA1NX	DN	MK-4280
DMCA1NX	MI	TTNVXAW
DMCA1NX	MN	Lymphocyte activation gene 3 protein (LAG3)
DMCA1NX	MT	DTT
DMCA1NX	MA	Inhibitor
DMCA1NX	RN	Establishment of engineered cell-based assays mediating LAG3 and PD1 immune suppression enables potency measurement of blocking antibodies and assessment of signal transduction. J Immunol Methods. 2018 May;456:7-14.
DMCA1NX	RU	https://pubmed.ncbi.nlm.nih.gov/29427592

DMN40DU	DI	DMN40DU
DMN40DU	DN	MK-4621
DMN40DU	MI	TTVB0O3
DMN40DU	MN	Retinoic acid-inducible gene-1 (RIG-1)
DMN40DU	MT	DTT
DMN40DU	MA	Agonist
DMN40DU	RN	National Cancer Institute Drug Dictionary (drug name RGT100).
DMN40DU	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/rig-i-selective-ligand-rgt100

DMCT37W	DI	DMCT37W
DMCT37W	DN	MK-4830
DMCT37W	MI	TTHC6XU
DMCT37W	MN	Leukocyte immunoglobulin-like receptor B2 (LILRB2)
DMCT37W	MT	DTT
DMCT37W	MA	Inhibitor
DMCT37W	RN	National Cancer Institute Drug Dictionary (drug name MK4830).
DMCT37W	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-ilt4-monoclonal-antibody-mk-4830

DMFGYKS	DI	DMFGYKS
DMFGYKS	DN	MK-5108
DMFGYKS	MI	TTPS3C0
DMFGYKS	MN	Aurora kinase A (AURKA)
DMFGYKS	MT	DTT
DMFGYKS	MA	Inhibitor
DMFGYKS	RN	A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
DMFGYKS	RU	https://pubmed.ncbi.nlm.nih.gov/23467907

DMFGYKS	DI	DMFGYKS
DMFGYKS	DN	MK-5108
DMFGYKS	MI	TT5LS6T
DMFGYKS	MN	Aurora kinase B (AURKB)
DMFGYKS	MT	DTT
DMFGYKS	MA	Inhibitor
DMFGYKS	RN	A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
DMFGYKS	RU	https://pubmed.ncbi.nlm.nih.gov/23467907

DMSA27Z	DI	DMSA27Z
DMSA27Z	DN	MK-6186
DMSA27Z	MI	TT84ETX
DMSA27Z	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMSA27Z	MT	DTT
DMSA27Z	MA	Inhibitor
DMSA27Z	RN	Antiviral activity and in vitro mutation development pathways of MK-6186, a novel nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother. 2012 Jun;56(6):3324-35.
DMSA27Z	RU	https://pubmed.ncbi.nlm.nih.gov/22391531

DMZUA5C	DI	DMZUA5C
DMZUA5C	DN	MK-6302
DMZUA5C	MI	TTC70AJ
DMZUA5C	MN	Granulocyte colony-stimulating factor receptor (G-CSF-R)
DMZUA5C	MT	DTT
DMZUA5C	MA	Modulator
DMZUA5C	RN	Merck ditches biogeneric. Nat Biotechnol. 2010 Jul;28(7):636.
DMZUA5C	RU	https://pubmed.ncbi.nlm.nih.gov/20622817

DMV8BI4	DI	DMV8BI4
DMV8BI4	DN	MK-6325
DMV8BI4	MI	TTRHUKY
DMV8BI4	MN	Hepatitis C virus Serine protease NS4A (HCV NS4A)
DMV8BI4	MT	DTT
DMV8BI4	MA	Modulator
DMV8BI4	RN	Synthesis of bis-macrocyclic HCV protease inhibitor MK-6325 via intramolecular sp -sp Suzuki-Miyaura coupling and ring closing metathesis. Org Lett. 2015 Mar 20;17(6):1533-6.
DMV8BI4	RU	https://pubmed.ncbi.nlm.nih.gov/25754231

DMBSXZ1	DI	DMBSXZ1
DMBSXZ1	DN	MK-7162
DMBSXZ1	MI	TTZJYKH
DMBSXZ1	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMBSXZ1	MT	DTT
DMBSXZ1	MA	Inhibitor
DMBSXZ1	RN	ClinicalTrials.gov (NCT03364049) Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002). U.S. National Institutes of Health.
DMBSXZ1	RU	https://clinicaltrials.gov/ct2/show/NCT03364049

DMLQOF1	DI	DMLQOF1
DMLQOF1	DN	MK-7246
DMLQOF1	MI	TTQDMX5
DMLQOF1	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMLQOF1	MT	DTT
DMLQOF1	MA	Modulator
DMLQOF1	RN	Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases. Bioorg Med Chem Lett. 2011 Jan 1;21(1):288-93.
DMLQOF1	RU	https://pubmed.ncbi.nlm.nih.gov/21106375

DMLQOF1	DI	DMLQOF1
DMLQOF1	DN	MK-7246
DMLQOF1	MI	DEAZDL8
DMLQOF1	MN	UDP-glucuronosyltransferase 2B17 (UGT2B17)
DMLQOF1	MT	DME
DMLQOF1	MA	Metabolism
DMLQOF1	RN	UGT2B17 genetic polymorphisms dramatically affect the pharmacokinetics of MK-7246 in healthy subjects in a first-in-human study. Clin Pharmacol Ther. 2012 Jul;92(1):96-102.
DMLQOF1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22669291

DMJ2Q6H	DI	DMJ2Q6H
DMJ2Q6H	DN	MK-7288
DMJ2Q6H	MI	TT9JNIC
DMJ2Q6H	MN	Histamine H3 receptor (H3R)
DMJ2Q6H	MT	DTT
DMJ2Q6H	MA	Agonist
DMJ2Q6H	RN	Early-stage comparative effectiveness: randomized controlled trial with histamine inverse agonist MK-7288 in excessive daytime sleepiness patients. J Clin Pharmacol. 2013 Dec;53(12):1294-302.
DMJ2Q6H	RU	https://pubmed.ncbi.nlm.nih.gov/24122944

DMA1EDN	DI	DMA1EDN
DMA1EDN	DN	MK-8033
DMA1EDN	MI	TTNDSF4
DMA1EDN	MN	Proto-oncogene c-Met (MET)
DMA1EDN	MT	DTT
DMA1EDN	MA	Inhibitor
DMA1EDN	RN	A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
DMA1EDN	RU	https://pubmed.ncbi.nlm.nih.gov/23467907

DMLCTI5	DI	DMLCTI5
DMLCTI5	DN	MK-8353
DMLCTI5	MI	TTKPV6O
DMLCTI5	MN	Ephrin type-B receptor 2 (EPHB2)
DMLCTI5	MT	DTT
DMLCTI5	MA	Inhibitor
DMLCTI5	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMLCTI5	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMHTWBL	DI	DMHTWBL
DMHTWBL	DN	MK-8504
DMHTWBL	MI	TT84ETX
DMHTWBL	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMHTWBL	MT	DTT
DMHTWBL	MA	Inhibitor
DMHTWBL	RN	ClinicalTrials.gov (NCT03188523) Activity of MK-8504 in Anti-retroviral-naive, Human Immunodeficiency Virus 1 (HIV-1) Infected Participants (MK-8504-002). U.S. National Institutes of Health.
DMHTWBL	RU	https://clinicaltrials.gov/ct2/show/NCT03188523

DMQHPME	DI	DMQHPME
DMQHPME	DN	MK-8583
DMQHPME	MI	TT84ETX
DMQHPME	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMQHPME	MT	DTT
DMQHPME	MA	Inhibitor
DMQHPME	RN	ClinicalTrials.gov (NCT03552536) MK-8583 Single Dose Study in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8583-002). U.S. National Institutes of Health.
DMQHPME	RU	https://clinicaltrials.gov/ct2/show/NCT03552536

DMETIBD	DI	DMETIBD
DMETIBD	DN	MK-8719
DMETIBD	MI	TT2I6UX
DMETIBD	MN	Beta-N-acetylhexosaminidase (OGA)
DMETIBD	MT	DTT
DMETIBD	MA	Inhibitor
DMETIBD	RN	Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies. J Med Chem. 2019 Nov 27;62(22):10062-10097.
DMETIBD	RU	https://pubmed.ncbi.nlm.nih.gov/31487175

DMAS1RB	DI	DMAS1RB
DMAS1RB	DN	MK-8776
DMAS1RB	MI	TTTU902
DMAS1RB	MN	Checkpoint kinase-1 (CHK1)
DMAS1RB	MT	DTT
DMAS1RB	MA	Inhibitor
DMAS1RB	RN	Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells. Int J Mol Sci. 2019 Aug 22;20(17):4095.
DMAS1RB	RU	https://pubmed.ncbi.nlm.nih.gov/31443367

DMDB3OK	DI	DMDB3OK
DMDB3OK	DN	MLN-3126
DMDB3OK	MI	TTIPS8B
DMDB3OK	MN	C-C chemokine receptor type 9 (CCR9)
DMDB3OK	MT	DTT
DMDB3OK	MA	Antagonist
DMDB3OK	RN	Targeting T-cell migration in inflammatory bowel disease. J Intern Med. 2012 Nov;272(5):411-29.
DMDB3OK	RU	https://pubmed.ncbi.nlm.nih.gov/22946654

DMCVO2Y	DI	DMCVO2Y
DMCVO2Y	DN	MLN-576
DMCVO2Y	MI	TTGTQHC
DMCVO2Y	MN	DNA topoisomerase I (TOP1)
DMCVO2Y	MT	DTT
DMCVO2Y	MA	Modulator
DMCVO2Y	RN	In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II. Anticancer Drugs. 2002 Jan;13(1):15-28.
DMCVO2Y	RU	https://pubmed.ncbi.nlm.nih.gov/11914637

DMCVO2Y	DI	DMCVO2Y
DMCVO2Y	DN	MLN-576
DMCVO2Y	MI	TT0IHXV
DMCVO2Y	MN	DNA topoisomerase II (TOP2)
DMCVO2Y	MT	DTT
DMCVO2Y	MA	Modulator
DMCVO2Y	RN	In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II. Anticancer Drugs. 2002 Jan;13(1):15-28.
DMCVO2Y	RU	https://pubmed.ncbi.nlm.nih.gov/11914637

DMWK951	DI	DMWK951
DMWK951	DN	MLN7243
DMWK951	MI	TTU8HT1
DMWK951	MN	Ubiquitin-activating enzyme (UBA)
DMWK951	MT	DTT
DMWK951	MA	Modulator
DMWK951	RN	National Cancer Institute Drug Dictionary (drug id 757275).
DMWK951	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=757275

DMUANF3	DI	DMUANF3
DMUANF3	DN	MLN8054
DMUANF3	MI	TTPS3C0
DMUANF3	MN	Aurora kinase A (AURKA)
DMUANF3	MT	DTT
DMUANF3	MA	Inhibitor
DMUANF3	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMUANF3	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMUANF3	DI	DMUANF3
DMUANF3	DN	MLN8054
DMUANF3	MI	DEJGDUW
DMUANF3	MN	Cytochrome P450 1A2 (CYP1A2)
DMUANF3	MT	DME
DMUANF3	MA	Metabolism
DMUANF3	RN	MLN8054 and Alisertib (MLN8237): discovery of selective oral aurora A inhibitors. ACS Med Chem Lett. 2015 Apr 22;6(6):630-4.
DMUANF3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26101564

DMUANF3	DI	DMUANF3
DMUANF3	DN	MLN8054
DMUANF3	MI	DE4LYSA
DMUANF3	MN	Cytochrome P450 3A4 (CYP3A4)
DMUANF3	MT	DME
DMUANF3	MA	Metabolism
DMUANF3	RN	MLN8054 and Alisertib (MLN8237): discovery of selective oral aurora A inhibitors. ACS Med Chem Lett. 2015 Apr 22;6(6):630-4.
DMUANF3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26101564

DMXQHZC	DI	DMXQHZC
DMXQHZC	DN	MM-151
DMXQHZC	MI	TTGKNB4
DMXQHZC	MN	Epidermal growth factor receptor (EGFR)
DMXQHZC	MT	DTT
DMXQHZC	MA	Antagonist
DMXQHZC	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMXQHZC	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMXQHZC	DI	DMXQHZC
DMXQHZC	DN	MM-151
DMXQHZC	MI	TTDC8N2
DMXQHZC	MN	Erbb3 tyrosine kinase receptor (Erbb-3)
DMXQHZC	MT	DTT
DMXQHZC	MA	Modulator
DMXQHZC	RN	MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther. 2014 Feb;13(2):410-25.
DMXQHZC	RU	https://pubmed.ncbi.nlm.nih.gov/24282274

DMYSJTR	DI	DMYSJTR
DMYSJTR	DN	MM-302
DMYSJTR	MI	TT6EO5L
DMYSJTR	MN	Erbb2 tyrosine kinase receptor (HER2)
DMYSJTR	MT	DTT
DMYSJTR	MA	Modulator
DMYSJTR	RN	Whole-body organ-level and kidney micro-dosimetric evaluations of (64)Cu-loaded HER2/ErbB2-targeted liposomal doxorubicin ((64)Cu-MM-302) in rodents and primates. EJNMMI Res. 2015 Apr 14;5:24.
DMYSJTR	RU	https://pubmed.ncbi.nlm.nih.gov/25918676

DMIMVEX	DI	DMIMVEX
DMIMVEX	DN	MMI-0100
DMIMVEX	MI	TTMUG9D
DMIMVEX	MN	MAPK-activated protein kinase 2 (MAPKAPK2)
DMIMVEX	MT	DTT
DMIMVEX	MA	Inhibitor
DMIMVEX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2094).
DMIMVEX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2094

DMAQJHO	DI	DMAQJHO
DMAQJHO	DN	Monohydroxyethylrutoside
DMAQJHO	MI	TTUDR0C
DMAQJHO	MN	Iron (Fe)
DMAQJHO	MT	DTT
DMAQJHO	MA	Modulator
DMAQJHO	RN	Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin. Clin Cancer Res. 1997 Oct;3(10):1747-54.
DMAQJHO	RU	https://pubmed.ncbi.nlm.nih.gov/9815559

DMM7TBO	DI	DMM7TBO
DMM7TBO	DN	MORAb-022
DMM7TBO	MI	TTNYZG2
DMM7TBO	MN	Granulocyte-macrophage colony-stimulating factor (CSF2)
DMM7TBO	MT	DTT
DMM7TBO	RN	Clinical pipeline report, company report or official report of Morphotek.
DMM7TBO	RU	http://www.morphotek.com/pipeline/MORAb-022.aspx

DMM7TBO	DI	DMM7TBO
DMM7TBO	DN	MORAb-022
DMM7TBO	MI	TT0T5HK
DMM7TBO	MN	Immunoglobulin gamma-1 heavy NIE (NIE)
DMM7TBO	MT	DTT
DMM7TBO	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMM7TBO	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMTUKW9	DI	DMTUKW9
DMTUKW9	DN	MORAb-066
DMTUKW9	MI	TT38MDJ
DMTUKW9	MN	Tissue factor (F3)
DMTUKW9	MT	DTT
DMTUKW9	RN	Clinical pipeline report, company report or official report of Morphotek.
DMTUKW9	RU	http://www.morphotek.com/pipeline/MORAb-066.aspx

DMJOMD4	DI	DMJOMD4
DMJOMD4	DN	MP-0112
DMJOMD4	MI	TTOHSBA
DMJOMD4	MN	Vascular endothelial growth factor A (VEGFA)
DMJOMD4	MT	DTT
DMJOMD4	MA	Inhibitor
DMJOMD4	RN	Treatment of exudative age-related macular degeneration with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study. Am J Ophthalmol. 2014 Oct;158(4):724-732.e2.
DMJOMD4	RU	https://pubmed.ncbi.nlm.nih.gov/24907435

DMQRNTG	DI	DMQRNTG
DMQRNTG	DN	MP-124
DMQRNTG	MI	TTEBCY8
DMQRNTG	MN	Poly [ADP-ribose] polymerase (PARP)
DMQRNTG	MT	DTT
DMQRNTG	MA	Modulator
DMQRNTG	RN	Company report (Mitsubishi Tanabe Pharma)
DMQRNTG	RU	http://www.mt-pharma-america.com/development.php

DM5VXWO	DI	DM5VXWO
DM5VXWO	DN	MP-157
DM5VXWO	MI	TTQVOEI
DM5VXWO	MN	Angiotensin II receptor type-2 (AGTR2)
DM5VXWO	MT	DTT
DM5VXWO	MA	Agonist
DM5VXWO	RN	As drug target reemerges, the question is to block or stimulate it. Nature Medicine. Spoonful of Medicine. 05 Feb 2014. Cassandra Willyard
DM5VXWO	RU	http://blogs.nature.com/spoonful/2014/02/as-drug-target-reemerges-the-question-is-to-block-or-stimulate-it.html

DME7JFM	DI	DME7JFM
DME7JFM	DN	MR1-1
DME7JFM	MI	TTGKNB4
DME7JFM	MN	Epidermal growth factor receptor (EGFR)
DME7JFM	MT	DTT
DME7JFM	MA	Modulator
DME7JFM	RN	A Phase I Study of Immunotoxin, MR1-1. Duke University report.
DME7JFM	RU	http://www.cancer.duke.edu/btc/modules/ClinicalTrials4/index.php?id=72

DMVNLGW	DI	DMVNLGW
DMVNLGW	DN	MR-1817
DMVNLGW	MI	TTMI6F5
DMVNLGW	MN	Transient receptor potential cation channel V1 (TRPV1)
DMVNLGW	MT	DTT
DMVNLGW	MA	Antagonist
DMVNLGW	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030745)
DMVNLGW	RU	http://adisinsight.springer.com/drugs/800030745

DMUVGMS	DI	DMUVGMS
DMUVGMS	DN	MRG-110
DMUVGMS	MI	TTIXJ2S
DMUVGMS	MN	microRNA hsa-miR-92 (MIR92)
DMUVGMS	MT	DTT
DMUVGMS	MA	Inhibitor
DMUVGMS	RN	Efficiency and Target Derepression of Anti-miR-92a: Results of a First in Human Study. Nucleic Acid Ther. 2020 Dec;30(6):335-345.
DMUVGMS	RU	https://pubmed.ncbi.nlm.nih.gov/32707001

DMFTAWU	DI	DMFTAWU
DMFTAWU	DN	mRNA-2416
DMFTAWU	MI	TTBW580
DMFTAWU	MN	TAX transcriptionally-activated glycoprotein 1 (OX40)
DMFTAWU	MT	DTT
DMFTAWU	MA	Replacement
DMFTAWU	RN	Clinical pipeline report, company report or official report of Moderna Therapeutics.
DMFTAWU	RU	https://www.modernatx.com/mrna-2416

DMUKBI2	DI	DMUKBI2
DMUKBI2	DN	mRNA-2752
DMUKBI2	MI	TTC1GLB
DMUKBI2	MN	Interleukin-23 (IL23)
DMUKBI2	MT	DTT
DMUKBI2	MA	Replacement
DMUKBI2	RN	Clinical pipeline report, company report or official report of Moderna Therapeutics.
DMUKBI2	RU	https://www.modernatx.com/mrna-2752

DMUKBI2	DI	DMUKBI2
DMUKBI2	DN	mRNA-2752
DMUKBI2	MI	TT8SLDN
DMUKBI2	MN	Interleukin-36 gamma (IL36G)
DMUKBI2	MT	DTT
DMUKBI2	MA	Replacement
DMUKBI2	RN	Clinical pipeline report, company report or official report of Moderna Therapeutics.
DMUKBI2	RU	https://www.modernatx.com/mrna-2752

DMUKBI2	DI	DMUKBI2
DMUKBI2	DN	mRNA-2752
DMUKBI2	MI	TTBW580
DMUKBI2	MN	TAX transcriptionally-activated glycoprotein 1 (OX40)
DMUKBI2	MT	DTT
DMUKBI2	MA	Replacement
DMUKBI2	RN	Clinical pipeline report, company report or official report of Moderna Therapeutics.
DMUKBI2	RU	https://www.modernatx.com/mrna-2752

DMM5N8P	DI	DMM5N8P
DMM5N8P	DN	MRX-2843
DMM5N8P	MI	TTGJCWZ
DMM5N8P	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMM5N8P	MT	DTT
DMM5N8P	MA	Inhibitor
DMM5N8P	RN	The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. JCI Insight. 2016 Mar;1(3):e85630.
DMM5N8P	RU	https://pubmed.ncbi.nlm.nih.gov/27158668

DMM5N8P	DI	DMM5N8P
DMM5N8P	DN	MRX-2843
DMM5N8P	MI	TTO7LKR
DMM5N8P	MN	Tyrosine-protein kinase Mer (MERTK)
DMM5N8P	MT	DTT
DMM5N8P	MA	Inhibitor
DMM5N8P	RN	The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. JCI Insight. 2016 Mar;1(3):e85630.
DMM5N8P	RU	https://pubmed.ncbi.nlm.nih.gov/27158668

DMWKDOQ	DI	DMWKDOQ
DMWKDOQ	DN	MRX34
DMWKDOQ	MI	TT96IGO
DMWKDOQ	MN	microRNA hsa-miR-34 (MIR34)
DMWKDOQ	MT	DTT
DMWKDOQ	MA	Modulator
DMWKDOQ	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMWKDOQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM7ER9J	DI	DM7ER9J
DM7ER9J	DN	MS-553
DM7ER9J	MI	TTYPXQF
DM7ER9J	MN	Protein kinase C beta (PRKCB)
DM7ER9J	MT	DTT
DM7ER9J	MA	Inhibitor
DM7ER9J	RN	ClinicalTrials.gov (NCT03492125) A Study Of The Selective PKC-beta Inhibitor MS- 553. U.S. National Institutes of Health.
DM7ER9J	RU	https://clinicaltrials.gov/ct2/show/NCT03492125

DMH8VXE	DI	DMH8VXE
DMH8VXE	DN	MSB2311
DMH8VXE	MI	TT8ZLTI
DMH8VXE	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMH8VXE	MT	DTT
DMH8VXE	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMH8VXE	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DM6XTZL	DI	DM6XTZL
DM6XTZL	DN	MSC-1
DM6XTZL	MI	TTGZ5WN
DM6XTZL	MN	Leukemia inhibitory factor (LIF)
DM6XTZL	MT	DTT
DM6XTZL	RN	National Cancer Institute Drug Dictionary (drug name MSC-1).
DM6XTZL	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-lif-monoclonal-antibody-msc-1

DM6XC8H	DI	DM6XC8H
DM6XC8H	DN	MSC110
DM6XC8H	MI	TT0IQER
DM6XC8H	MN	Macrophage colony-stimulating factor 1 (CSF1)
DM6XC8H	MT	DTT
DM6XC8H	MA	Inhibitor
DM6XC8H	RN	Colony-Stimulating Factor-1 Antibody Lacnotuzumab in a Phase 1 Healthy Volunteer Study and Mechanistic Investigation of Safety Outcomes. J Pharmacol Exp Ther. 2019 Jun;369(3):428-442.
DM6XC8H	RU	https://pubmed.ncbi.nlm.nih.gov/30894455

DMEP7HO	DI	DMEP7HO
DMEP7HO	DN	MSH-372
DMEP7HO	MI	TT84ETX
DMEP7HO	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMEP7HO	MT	DTT
DMEP7HO	MA	Inhibitor
DMEP7HO	RN	WO patent application no. 2004,0290,42, Pyrazole derivatives as reverse transcriptase inhibitors.
DMEP7HO	RU	http://www.google.com/patents/WO2004029042A1?cl=en

DM1N9YS	DI	DM1N9YS
DM1N9YS	DN	MSX-122
DM1N9YS	MI	TTBID49
DM1N9YS	MN	C-X-C chemokine receptor type 4 (CXCR4)
DM1N9YS	MT	DTT
DM1N9YS	MA	Antagonist
DM1N9YS	RN	Comparative evaluation of CC chemokine-induced migration of murine CD8alpha+ and CD8alpha- dendritic cells and their in vivo trafficking. J Leukoc Biol. 2004 Feb;75(2):275-85.
DM1N9YS	RU	https://pubmed.ncbi.nlm.nih.gov/14597730

DMPCUN5	DI	DMPCUN5
DMPCUN5	DN	MT-110
DMPCUN5	MI	TTZAT79
DMPCUN5	MN	T-cell surface glycoprotein CD3 epsilon (CD3E)
DMPCUN5	MT	DTT
DMPCUN5	RN	EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res. 2012 Jan 15;18(2):465-74.
DMPCUN5	RU	https://pubmed.ncbi.nlm.nih.gov/22096026

DMPCUN5	DI	DMPCUN5
DMPCUN5	DN	MT-110
DMPCUN5	MI	TTV3XPL
DMPCUN5	MN	T-cell surface glycoprotein CD3 gamma (CD3G)
DMPCUN5	MT	DTT
DMPCUN5	RN	EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res. 2012 Jan 15;18(2):465-74.
DMPCUN5	RU	https://pubmed.ncbi.nlm.nih.gov/22096026

DMPCUN5	DI	DMPCUN5
DMPCUN5	DN	MT-110
DMPCUN5	MI	TTZ8WH4
DMPCUN5	MN	Tumor-associated calcium signal transducer 1 (EPCAM)
DMPCUN5	MT	DTT
DMPCUN5	RN	EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res. 2012 Jan 15;18(2):465-74.
DMPCUN5	RU	https://pubmed.ncbi.nlm.nih.gov/22096026

DMT0EBU	DI	DMT0EBU
DMT0EBU	DN	MT-112
DMT0EBU	MI	TT9G4N0
DMT0EBU	MN	Glutamate carboxypeptidase II (GCPII)
DMT0EBU	MT	DTT
DMT0EBU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1606).
DMT0EBU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1606

DM5SN0A	DI	DM5SN0A
DM5SN0A	DN	MT-5111
DM5SN0A	MI	TT6EO5L
DM5SN0A	MN	Erbb2 tyrosine kinase receptor (HER2)
DM5SN0A	MT	DTT
DM5SN0A	MA	Inhibitor
DM5SN0A	RN	Clinical pipeline report, company report or official report of Molecular Templates.
DM5SN0A	RU	https://www.mtem.com/pipeline/mt-5111

DMG4QDT	DI	DMG4QDT
DMG4QDT	DN	MUC-1 dendritic cancer vaccine
DMG4QDT	MI	TTBHFYQ
DMG4QDT	MN	Mucin-1 (MUC1)
DMG4QDT	MT	DTT
DMG4QDT	RN	Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin. Int J Mol Med. 2003 Oct;12(4):493-502.
DMG4QDT	RU	https://pubmed.ncbi.nlm.nih.gov/12964025

DMAGCHE	DI	DMAGCHE
DMAGCHE	DN	Multi-envelope HIV vaccine
DMAGCHE	MI	TTBYP1X
DMAGCHE	MN	Human immunodeficiency virus Envelope glycoprotein gp120 (HIV gp120)
DMAGCHE	MT	DTT
DMAGCHE	RN	An assessment of the role of chimpanzees in AIDS vaccine research. Altern Lab Anim. 2008 Sep;36(4):381-428.
DMAGCHE	RU	https://pubmed.ncbi.nlm.nih.gov/18826331

DMAGCHE	DI	DMAGCHE
DMAGCHE	DN	Multi-envelope HIV vaccine
DMAGCHE	MI	TTG90S6
DMAGCHE	MN	Human immunodeficiency virus Glycoprotein 41 (HIV gp41)
DMAGCHE	MT	DTT
DMAGCHE	RN	An assessment of the role of chimpanzees in AIDS vaccine research. Altern Lab Anim. 2008 Sep;36(4):381-428.
DMAGCHE	RU	https://pubmed.ncbi.nlm.nih.gov/18826331

DM3JUXW	DI	DM3JUXW
DM3JUXW	DN	MVA HER-2 AutoVac
DM3JUXW	MI	TT6EO5L
DM3JUXW	MN	Erbb2 tyrosine kinase receptor (HER2)
DM3JUXW	MT	DTT
DM3JUXW	RN	Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. Ann Oncol. 2013 Jul;24(7):1740-8.
DM3JUXW	RU	https://pubmed.ncbi.nlm.nih.gov/23585514

DMFMW5C	DI	DMFMW5C
DMFMW5C	DN	MVA-BN Breast
DMFMW5C	MI	TTS78AZ
DMFMW5C	MN	Prostate specific antigen (KLK3)
DMFMW5C	MT	DTT
DMFMW5C	MA	Antagonist
DMFMW5C	RN	Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy. Cancer Res. 2011 Aug 1;71(15):5235-44.
DMFMW5C	RU	https://pubmed.ncbi.nlm.nih.gov/21670078

DM1FUAR	DI	DM1FUAR
DM1FUAR	DN	MV-CEA
DM1FUAR	MI	TTY6DTE
DM1FUAR	MN	Carcinoembryonic antigen CEA (CD66e)
DM1FUAR	MT	DTT
DM1FUAR	MA	Modulator
DM1FUAR	RN	Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res. 2010 Feb 1;70(3):875-82.
DM1FUAR	RU	https://pubmed.ncbi.nlm.nih.gov/20103634

DMEJ4C1	DI	DMEJ4C1
DMEJ4C1	DN	MVT-5873
DMEJ4C1	MI	TT80ARU
DMEJ4C1	MN	Ganglioside GD2 (GD2)
DMEJ4C1	MT	DTT
DMEJ4C1	MA	Modulator
DMEJ4C1	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMEJ4C1	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM5O4X9	DI	DM5O4X9
DM5O4X9	DN	Mycophenolic acid glucuronide
DM5O4X9	MI	DTI7UX6
DM5O4X9	MN	Breast cancer resistance protein (ABCG2)
DM5O4X9	MT	DTP
DM5O4X9	MA	Substrate
DM5O4X9	RN	Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther Drug Monit. 2008 Oct;30(5):559-64.
DM5O4X9	RU	http://www.ncbi.nlm.nih.gov/pubmed/18695635

DMHO6XP	DI	DMHO6XP
DMHO6XP	DN	MyoDys
DMHO6XP	MI	TT48MP6
DMHO6XP	MN	Dystrophin (DMD)
DMHO6XP	MT	DTT
DMHO6XP	MA	Modulator
DMHO6XP	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009280)
DMHO6XP	RU	http://adisinsight.springer.com/drugs/800009280

DM4ZN8M	DI	DM4ZN8M
DM4ZN8M	DN	N-803
DM4ZN8M	MI	TTJFA35
DM4ZN8M	MN	Interleukin-15 (IL15)
DM4ZN8M	MT	DTT
DM4ZN8M	MA	Agonist
DM4ZN8M	RN	The human IL-15 superagonist N-803 promotes migration of virus-specific CD8+ T and NK cells to B cell follicles but does not reverse latency in ART-suppressed, SHIV-infected macaques. PLoS Pathog. 2020 Mar 12;16(3):e1008339.
DM4ZN8M	RU	https://pubmed.ncbi.nlm.nih.gov/32163523

DM3PC0J	DI	DM3PC0J
DM3PC0J	DN	N-8295
DM3PC0J	MI	TTSHG0T
DM3PC0J	MN	Toll-like receptor 9 (TLR9)
DM3PC0J	MT	DTT
DM3PC0J	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019871)
DM3PC0J	RU	http://adisinsight.springer.com/drugs/800019871

DM3IT6R	DI	DM3IT6R
DM3IT6R	DN	N9-GP
DM3IT6R	MI	TTFEZ5Q
DM3IT6R	MN	Coagulation factor IX (F9)
DM3IT6R	MT	DTT
DM3IT6R	MA	Modulator
DM3IT6R	RN	Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood. 2011 Sep 8;118(10):2695-701.
DM3IT6R	RU	https://pubmed.ncbi.nlm.nih.gov/21555744

DM3E20L	DI	DM3E20L
DM3E20L	DN	Nagrestipen
DM3E20L	MI	TT8I4WB
DM3E20L	MN	Macrophage inflammatory protein 1-alpha (CCL3)
DM3E20L	MT	DTT
DM3E20L	MA	Modulator
DM3E20L	RN	Macrophage inflammatory protein derivative ECI301 enhances the alarmin-associated abscopal benefits of tumor radiotherapy. Cancer Res. 2014 Sep 15;74(18):5070-8.
DM3E20L	RU	https://pubmed.ncbi.nlm.nih.gov/25038226

DMMKZYV	DI	DMMKZYV
DMMKZYV	DN	Namitecan
DMMKZYV	MI	TTGTQHC
DMMKZYV	MN	DNA topoisomerase I (TOP1)
DMMKZYV	MT	DTT
DMMKZYV	MA	Inhibitor
DMMKZYV	RN	Namitecan: a hydrophilic camptothecin with a promising preclinical profile. Curr Med Chem. 2012;19(21):3488-501.
DMMKZYV	RU	https://pubmed.ncbi.nlm.nih.gov/22680917

DMHAZLM	DI	DMHAZLM
DMHAZLM	DN	Naringenin
DMHAZLM	MI	TTSZLWK
DMHAZLM	MN	Aromatase (CYP19A1)
DMHAZLM	MT	DTT
DMHAZLM	MA	Inhibitor
DMHAZLM	RN	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
DMHAZLM	RU	https://pubmed.ncbi.nlm.nih.gov/20413308

DMHAZLM	DI	DMHAZLM
DMHAZLM	DN	Naringenin
DMHAZLM	MI	DECV2ME
DMHAZLM	MN	Cytochrome P450 105D7 (cyp105)
DMHAZLM	MT	DME
DMHAZLM	MA	Metabolism
DMHAZLM	RN	The metagenome of Caracolus marginella gut microbiome using culture independent approaches and shotgun sequencing. Data Brief. 2017 Nov 22;16:501-505.
DMHAZLM	RU	https://pubmed.ncbi.nlm.nih.gov/29270447

DMHAZLM	DI	DMHAZLM
DMHAZLM	DN	Naringenin
DMHAZLM	MI	TTI84H7
DMHAZLM	MN	Cytochrome P450 1B1 (CYP1B1)
DMHAZLM	MT	DTT
DMHAZLM	MA	Inhibitor
DMHAZLM	RN	Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5.
DMHAZLM	RU	https://pubmed.ncbi.nlm.nih.gov/20696580

DMHAZLM	DI	DMHAZLM
DMHAZLM	DN	Naringenin
DMHAZLM	MI	TTIWB6L
DMHAZLM	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMHAZLM	MT	DTT
DMHAZLM	MA	Inhibitor
DMHAZLM	RN	Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries. J Med Chem. 2008 Jul 24;51(14):4188-99.
DMHAZLM	RU	https://pubmed.ncbi.nlm.nih.gov/18533708

DMHAZLM	DI	DMHAZLM
DMHAZLM	DN	Naringenin
DMHAZLM	MI	TTOM3J0
DMHAZLM	MN	Estrogen receptor beta (ESR2)
DMHAZLM	MT	DTT
DMHAZLM	MA	Inhibitor
DMHAZLM	RN	Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65.
DMHAZLM	RU	https://pubmed.ncbi.nlm.nih.gov/17149865

DMHAZLM	DI	DMHAZLM
DMHAZLM	DN	Naringenin
DMHAZLM	MI	TTV9A7R
DMHAZLM	MN	Lactoylglutathione lyase (GLO1)
DMHAZLM	MT	DTT
DMHAZLM	MA	Inhibitor
DMHAZLM	RN	Structure-activity relationship of human GLO I inhibitory natural flavonoids and their growth inhibitory effects. Bioorg Med Chem. 2008 Apr 1;16(7):3969-75.
DMHAZLM	RU	https://pubmed.ncbi.nlm.nih.gov/18258440

DMHAZLM	DI	DMHAZLM
DMHAZLM	DN	Naringenin
DMHAZLM	MI	DTUGYRD
DMHAZLM	MN	P-glycoprotein 1 (ABCB1)
DMHAZLM	MT	DTP
DMHAZLM	MA	Substrate
DMHAZLM	RN	Flavonoid permeability across an in situ model of the blood-brain barrier. Free Radic Biol Med. 2004 Mar 1;36(5):592-604.
DMHAZLM	RU	https://doi.org/10.1016/j.freeradbiomed.2003.11.023

DMZ2G69	DI	DMZ2G69
DMZ2G69	DN	Navicixizumab
DMZ2G69	MI	TTV23LH
DMZ2G69	MN	Delta-like protein 4 (DLL4)
DMZ2G69	MT	DTT
DMZ2G69	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZ2G69	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMZ2G69	DI	DMZ2G69
DMZ2G69	DN	Navicixizumab
DMZ2G69	MI	TTOHSBA
DMZ2G69	MN	Vascular endothelial growth factor A (VEGFA)
DMZ2G69	MT	DTT
DMZ2G69	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZ2G69	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMG0SWE	DI	DMG0SWE
DMG0SWE	DN	NBF-006
DMG0SWE	MI	TT48Z3K
DMG0SWE	MN	GSTP1 messenger RNA (GSTP1 mRNA)
DMG0SWE	MT	DTT
DMG0SWE	MA	Inhibitor
DMG0SWE	RN	Clinical pipeline report, company report or official report of Nitto Biopharma.
DMG0SWE	RU	https://www.nittobiopharma.com/index.php

DM5BQK3	DI	DM5BQK3
DM5BQK3	DN	NBI-34041
DM5BQK3	MI	TTIY658
DM5BQK3	MN	Corticotropin-releasing factor receptor 2 (CRHR2)
DM5BQK3	MT	DTT
DM5BQK3	MA	Antagonist
DM5BQK3	RN	Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36.
DM5BQK3	RU	https://pubmed.ncbi.nlm.nih.gov/16634704

DM5OWXA	DI	DM5OWXA
DM5OWXA	DN	NBM-BMX
DM5OWXA	MI	TTT6LFV
DM5OWXA	MN	Histone deacetylase 8 (HDAC8)
DM5OWXA	MT	DTT
DM5OWXA	MA	Inhibitor
DM5OWXA	RN	Clinical pipeline report, company report or official report of NatureWise Biotech & Medicals.
DM5OWXA	RU	https://www.naturewise.com.tw/#_index2

DMPHZI5	DI	DMPHZI5
DMPHZI5	DN	NBQX
DMPHZI5	MI	TTAN6JD
DMPHZI5	MN	Glutamate receptor AMPA (GRIA)
DMPHZI5	MT	DTT
DMPHZI5	MA	Inhibitor
DMPHZI5	RN	Synthesis and pharmacological characterization of N3-substituted willardiine derivatives: role of the substituent at the 5-position of the uracil r... J Med Chem. 2007 Apr 5;50(7):1558-70.
DMPHZI5	RU	https://pubmed.ncbi.nlm.nih.gov/17348638

DMPHZI5	DI	DMPHZI5
DMPHZI5	DN	NBQX
DMPHZI5	MI	TTVPQTF
DMPHZI5	MN	Glutamate receptor AMPA 1 (GRIA1)
DMPHZI5	MT	DTT
DMPHZI5	MA	Inhibitor
DMPHZI5	RN	Structural investigation of the 7-chloro-3-hydroxy-1H-quinazoline-2,4-dione scaffold to obtain AMPA and kainate receptor selective antagonists. Syn... J Med Chem. 2006 Oct 5;49(20):6015-26.
DMPHZI5	RU	https://pubmed.ncbi.nlm.nih.gov/17004715

DMPHZI5	DI	DMPHZI5
DMPHZI5	DN	NBQX
DMPHZI5	MI	TT0MYE2
DMPHZI5	MN	Glutamate receptor ionotropic kainate 1 (GRIK1)
DMPHZI5	MT	DTT
DMPHZI5	MA	Inhibitor
DMPHZI5	RN	4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with... Bioorg Med Chem Lett. 2000 May 15;10(10):1133-7.
DMPHZI5	RU	https://pubmed.ncbi.nlm.nih.gov/10843235

DMPHZI5	DI	DMPHZI5
DMPHZI5	DN	NBQX
DMPHZI5	MI	TTLD29N
DMPHZI5	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMPHZI5	MT	DTT
DMPHZI5	MA	Inhibitor
DMPHZI5	RN	Synthesis, ionotropic glutamate receptor binding affinity, and structure-activity relationships of a new set of 4,5-dihydro-8-heteroaryl-4-oxo-1,2,... J Med Chem. 2001 Sep 13;44(19):3157-65.
DMPHZI5	RU	https://pubmed.ncbi.nlm.nih.gov/11543685

DMPHZI5	DI	DMPHZI5
DMPHZI5	DN	NBQX
DMPHZI5	MI	TTKJEMQ
DMPHZI5	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMPHZI5	MT	DTT
DMPHZI5	MA	Inhibitor
DMPHZI5	RN	Synthesis, ionotropic glutamate receptor binding affinity, and structure-activity relationships of a new set of 4,5-dihydro-8-heteroaryl-4-oxo-1,2,... J Med Chem. 2001 Sep 13;44(19):3157-65.
DMPHZI5	RU	https://pubmed.ncbi.nlm.nih.gov/11543685

DMPHZI5	DI	DMPHZI5
DMPHZI5	DN	NBQX
DMPHZI5	MI	TTN9D8E
DMPHZI5	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMPHZI5	MT	DTT
DMPHZI5	MA	Inhibitor
DMPHZI5	RN	Synthesis, ionotropic glutamate receptor binding affinity, and structure-activity relationships of a new set of 4,5-dihydro-8-heteroaryl-4-oxo-1,2,... J Med Chem. 2001 Sep 13;44(19):3157-65.
DMPHZI5	RU	https://pubmed.ncbi.nlm.nih.gov/11543685

DMF3MN1	DI	DMF3MN1
DMF3MN1	DN	NBXT-001+Nobilis inhalation device
DMF3MN1	MI	TT9IK2Z
DMF3MN1	MN	N-methyl-D-aspartate receptor (NMDAR)
DMF3MN1	MT	DTT
DMF3MN1	MA	Antagonist
DMF3MN1	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMF3MN1	RU	http://phrma-docs.phrma.org/files/dmfile/MID-Update_Alzheimers-Disease_2017-Drug-List.pdf

DMM2SNG	DI	DMM2SNG
DMM2SNG	DN	NC-4016
DMM2SNG	MI	TTUTN1I
DMM2SNG	MN	Human Deoxyribonucleic acid (hDNA)
DMM2SNG	MT	DTT
DMM2SNG	MA	Inhibitor
DMM2SNG	RN	Effects of Treatment with Platinum Azidothymidine and Azidothymidine on Telomerase Activity and Bcl-2 Concentration in Hepatocellular Carcinoma- Induced Rats. Avicenna J Med Biotechnol. 2014 Oct-Dec;6(4): 200-209.
DMM2SNG	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224659/

DMUSPW5	DI	DMUSPW5
DMUSPW5	DN	NCO-48
DMUSPW5	MI	TTT4SY6
DMUSPW5	MN	Hepatitis B virus Polymerase (HBV P)
DMUSPW5	MT	DTT
DMUSPW5	MA	Inhibitor
DMUSPW5	RN	Safety, Tolerability and Pharmacokinetics of NCO-48 Fumarate in Healthy Subjects
DMUSPW5	RU	https://clinicaltrials.gov/ct2/show/NCT04309526

DMKJRQS	DI	DMKJRQS
DMKJRQS	DN	NCX-1015
DMKJRQS	MI	TTYRL6O
DMKJRQS	MN	Glucocorticoid receptor (NR3C1)
DMKJRQS	MT	DTT
DMKJRQS	MA	Modulator
DMKJRQS	RN	Glucocorticoid receptor nitration leads to enhanced anti-inflammatory effects of novel steroid ligands. J Immunol. 2003 Sep 15;171(6):3245-52.
DMKJRQS	RU	https://pubmed.ncbi.nlm.nih.gov/12960354

DMM7RC5	DI	DMM7RC5
DMM7RC5	DN	NCX-6560
DMM7RC5	MI	TTPADOQ
DMM7RC5	MN	HMG-CoA reductase (HMGCR)
DMM7RC5	MT	DTT
DMM7RC5	MA	Inhibitor
DMM7RC5	RN	Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003 Jul;2(7):517-26.
DMM7RC5	RU	https://pubmed.ncbi.nlm.nih.gov/12815379

DMVQAEK	DI	DMVQAEK
DMVQAEK	DN	ND-1.1
DMVQAEK	MI	TTF4CAM
DMVQAEK	MN	Influenza Hemagglutinin (Influ HA)
DMVQAEK	MT	DTT
DMVQAEK	RN	An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models. Clin Vaccine Immunol. 2013 Jan;20(1):85-94.
DMVQAEK	RU	https://pubmed.ncbi.nlm.nih.gov/23155123

DMUBTC6	DI	DMUBTC6
DMUBTC6	DN	ND7001
DMUBTC6	MI	TTJGW1Z
DMUBTC6	MN	Phosphodiesterase 2A (PDE2A)
DMUBTC6	MT	DTT
DMUBTC6	MA	Modulator
DMUBTC6	RN	Phosphodiesterase 2 inhibitors promote axonal outgrowth in organotypic slice co-cultures. Neurosignals. 2013;21(3-4):197-212.
DMUBTC6	RU	https://pubmed.ncbi.nlm.nih.gov/22947663

DM830EN	DI	DM830EN
DM830EN	DN	NEO-201
DM830EN	MI	TTA9CK4
DM830EN	MN	Biliary glycoprotein 1 (CEACAM1)
DM830EN	MT	DTT
DM830EN	MA	Inhibitor
DM830EN	RN	The Monoclonal Antibody NEO-201 Enhances Natural Killer Cell Cytotoxicity Against Tumor Cells Through Blockade of the Inhibitory CEACAM5/CEACAM1 Immune Checkpoint Pathway. Cancer Biother Radiopharm. 2020 Apr;35(3):190-198.
DM830EN	RU	https://pubmed.ncbi.nlm.nih.gov/31928422

DM830EN	DI	DM830EN
DM830EN	DN	NEO-201
DM830EN	MI	TTY6DTE
DM830EN	MN	Carcinoembryonic antigen CEA (CD66e)
DM830EN	MT	DTT
DM830EN	MA	Inhibitor
DM830EN	RN	The Monoclonal Antibody NEO-201 Enhances Natural Killer Cell Cytotoxicity Against Tumor Cells Through Blockade of the Inhibitory CEACAM5/CEACAM1 Immune Checkpoint Pathway. Cancer Biother Radiopharm. 2020 Apr;35(3):190-198.
DM830EN	RU	https://pubmed.ncbi.nlm.nih.gov/31928422

DMXTYWJ	DI	DMXTYWJ
DMXTYWJ	DN	Neovastat
DMXTYWJ	MI	TTXZ0KQ
DMXTYWJ	MN	Matrix metalloproteinase-12 (MMP-12)
DMXTYWJ	MT	DTT
DMXTYWJ	MA	Inhibitor
DMXTYWJ	RN	Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol. 2001 Dec;28(6):620-5.
DMXTYWJ	RU	https://pubmed.ncbi.nlm.nih.gov/11740820

DMXTYWJ	DI	DMXTYWJ
DMXTYWJ	DN	Neovastat
DMXTYWJ	MI	TTLM12X
DMXTYWJ	MN	Matrix metalloproteinase-2 (MMP-2)
DMXTYWJ	MT	DTT
DMXTYWJ	MA	Inhibitor
DMXTYWJ	RN	Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol. 2001 Dec;28(6):620-5.
DMXTYWJ	RU	https://pubmed.ncbi.nlm.nih.gov/11740820

DMXTYWJ	DI	DMXTYWJ
DMXTYWJ	DN	Neovastat
DMXTYWJ	MI	TT6X50U
DMXTYWJ	MN	Matrix metalloproteinase-9 (MMP-9)
DMXTYWJ	MT	DTT
DMXTYWJ	MA	Inhibitor
DMXTYWJ	RN	Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol. 2001 Dec;28(6):620-5.
DMXTYWJ	RU	https://pubmed.ncbi.nlm.nih.gov/11740820

DM59ZDN	DI	DM59ZDN
DM59ZDN	DN	Nesvacumab
DM59ZDN	MI	TTKLQTJ
DM59ZDN	MN	Angiopoietin-2 (ANGPT2)
DM59ZDN	MT	DTT
DM59ZDN	MA	Inhibitor
DM59ZDN	RN	Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease. Expert Opin Investig Drugs. 2019 Oct;28(10):861-869.
DM59ZDN	RU	https://pubmed.ncbi.nlm.nih.gov/31513439

DMNJTLC	DI	DMNJTLC
DMNJTLC	DN	Neu-2000
DMNJTLC	MI	TTN9D8E
DMNJTLC	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMNJTLC	MT	DTT
DMNJTLC	MA	Antagonist
DMNJTLC	RN	Neu2000, an NR2B-selective, moderate NMDA receptor antagonist and potent spin trapping molecule for stroke. Drug News Perspect. 2010 Nov;23(9):549-56.
DMNJTLC	RU	https://pubmed.ncbi.nlm.nih.gov/21152450

DMQK5ET	DI	DMQK5ET
DMQK5ET	DN	NG-350A
DMQK5ET	MI	TTN6Y9A
DMQK5ET	MN	CD40L receptor (CD40)
DMQK5ET	MT	DTT
DMQK5ET	MA	Agonist
DMQK5ET	RN	Clinical pipeline report, company report or official report of PsiOxus Therapeutics.
DMQK5ET	RU	https://psioxus.com/technology-products/ng-350a/

DMITVHM	DI	DMITVHM
DMITVHM	DN	NG-641
DMITVHM	MI	TTQOVYA
DMITVHM	MN	C-X-C motif chemokine 10 (CXCL10)
DMITVHM	MT	DTT
DMITVHM	RN	Clinical pipeline report, company report or official report of PsiOxus Therapeutics.
DMITVHM	RU	https://psioxus.com/technology-products/ng-641/

DMITVHM	DI	DMITVHM
DMITVHM	DN	NG-641
DMITVHM	MI	TTWE5PB
DMITVHM	MN	C-X-C motif chemokine 9 (CXCL9)
DMITVHM	MT	DTT
DMITVHM	RN	Clinical pipeline report, company report or official report of PsiOxus Therapeutics.
DMITVHM	RU	https://psioxus.com/technology-products/ng-641/

DMITVHM	DI	DMITVHM
DMITVHM	DN	NG-641
DMITVHM	MI	TT95SOA
DMITVHM	MN	Interferon alpha (IFNA)
DMITVHM	MT	DTT
DMITVHM	RN	Clinical pipeline report, company report or official report of PsiOxus Therapeutics.
DMITVHM	RU	https://psioxus.com/technology-products/ng-641/

DMITVHM	DI	DMITVHM
DMITVHM	DN	NG-641
DMITVHM	MI	TTGPQ0F
DMITVHM	MN	Prolyl endopeptidase FAP (FAP)
DMITVHM	MT	DTT
DMITVHM	RN	Clinical pipeline report, company report or official report of PsiOxus Therapeutics.
DMITVHM	RU	https://psioxus.com/technology-products/ng-641/

DMM1Y8F	DI	DMM1Y8F
DMM1Y8F	DN	NGD 94-1
DMM1Y8F	MI	TTE0A2F
DMM1Y8F	MN	Dopamine D4 receptor (D4R)
DMM1Y8F	MT	DTT
DMM1Y8F	MA	Antagonist
DMM1Y8F	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMM1Y8F	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMM1Y8F	DI	DMM1Y8F
DMM1Y8F	DN	NGD 94-1
DMM1Y8F	MI	TT729IR
DMM1Y8F	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DMM1Y8F	MT	DTT
DMM1Y8F	MA	Blocker
DMM1Y8F	RN	Differential inhibition of T-type calcium channels by neuroleptics. J Neurosci. 2002 Jan 15;22(2):396-403.
DMM1Y8F	RU	https://pubmed.ncbi.nlm.nih.gov/11784784

DMF21XQ	DI	DMF21XQ
DMF21XQ	DN	NGM120
DMF21XQ	MI	TTE61UB
DMF21XQ	MN	GDNF family receptor alpha-like (GFRAL)
DMF21XQ	MT	DTT
DMF21XQ	MA	Antagonist
DMF21XQ	RN	Clinical pipeline report, company report or official report of NGM Biopharmaceuticals.
DMF21XQ	RU	https://www.ngmbio.com/pipeline/

DMYNSRH	DI	DMYNSRH
DMYNSRH	DN	NGM313
DMYNSRH	MI	TTARBVH
DMYNSRH	MN	Beta-klotho (KLB)
DMYNSRH	MT	DTT
DMYNSRH	MA	Modulator
DMYNSRH	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMYNSRH	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMYNSRH	DI	DMYNSRH
DMYNSRH	DN	NGM313
DMYNSRH	MI	TTRLW2X
DMYNSRH	MN	Fibroblast growth factor receptor 1 (FGFR1)
DMYNSRH	MT	DTT
DMYNSRH	MA	Modulator
DMYNSRH	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMYNSRH	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMTVQH2	DI	DMTVQH2
DMTVQH2	DN	NGP 555
DMTVQH2	MI	TT9W8GU
DMTVQH2	MN	Gamma-secretase (GS)
DMTVQH2	MT	DTT
DMTVQH2	MA	Modulator
DMTVQH2	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMTVQH2	RU	http://phrma-docs.phrma.org/files/dmfile/MID-Update_Alzheimers-Disease_2017-Drug-List.pdf

DMU6CQ7	DI	DMU6CQ7
DMU6CQ7	DN	NHS-IL 12
DMU6CQ7	MI	TTGW72V
DMU6CQ7	MN	Interleukin-12 beta (IL12B)
DMU6CQ7	MT	DTT
DMU6CQ7	MA	Modulator
DMU6CQ7	RN	The immunocytokine NHS-IL12 as a potential cancer therapeutic. Oncotarget. 2014 Apr 15;5(7):1869-84.
DMU6CQ7	RU	https://pubmed.ncbi.nlm.nih.gov/24681847

DM31FOP	DI	DM31FOP
DM31FOP	DN	NI-0101
DM31FOP	MI	TTISGCA
DM31FOP	MN	Toll-like receptor 4 (TLR4)
DM31FOP	MT	DTT
DM31FOP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1754).
DM31FOP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1754

DM32VKQ	DI	DM32VKQ
DM32VKQ	DN	NI-0701
DM32VKQ	MI	TT9DWLC
DM32VKQ	MN	T-cell-specific protein RANTES (CCL5)
DM32VKQ	MT	DTT
DM32VKQ	MA	Inhibitor
DM32VKQ	RN	Handbook of Therapeutic Antibodies. Stefan D bel, Janice M. Reichert, 2014. Page(1021).
DM32VKQ	RU	https://books.google.com.hk/books?id=svHsBQAAQBAJ&pg=PA1021&lpg=PA1021&dq=%E2%80%9CNI-0701%E2%80%9D++RANTES&source=bl&ots=OSgek1U9gk&sig=gMuc7gZ8ZO4IH9EIdhuDhOrHTaU&hl=zh-CN&sa=X&ved=0CC8Q6AEwA2oVChMItuDj3InGyAIVzQmOCh0QPQ3H#v=onepage&q=%E2%80%9CNI-0701%E2%80%9D%20%20RANTES&f=false

DM8J3WE	DI	DM8J3WE
DM8J3WE	DN	Nibentan
DM8J3WE	MI	TT1VOHK
DM8J3WE	MN	Potassium channel unspecific (KC)
DM8J3WE	MT	DTT
DM8J3WE	MA	Blocker
DM8J3WE	RN	Nibentan -- a drug for pharmacological cardioversion of persistent atrial fibrillation. Kardiologiia. 2005;45(3):19-23.
DM8J3WE	RU	https://pubmed.ncbi.nlm.nih.gov/15821703

DMJBYSE	DI	DMJBYSE
DMJBYSE	DN	Nicotinamide riboside
DMJBYSE	MI	DEUATVX
DMJBYSE	MN	Quinone reductase 2 (NQO2)
DMJBYSE	MT	DME
DMJBYSE	MA	Metabolism
DMJBYSE	RN	Insights into the redox cycle of human quinone reductase 2. Free Radic Res. 2011 Oct;45(10):1184-95.
DMJBYSE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21762045

DM0PYEQ	DI	DM0PYEQ
DM0PYEQ	DN	NIP-004
DM0PYEQ	MI	TTIHYA4
DM0PYEQ	MN	Thrombopoietin receptor (MPL)
DM0PYEQ	MT	DTT
DM0PYEQ	MA	Agonist
DM0PYEQ	RN	A novel nonpeptidyl human c-Mpl activator stimulates human megakaryopoiesis and thrombopoiesis. Blood. 2006 Jun 1;107(11):4300-7.
DM0PYEQ	RU	https://pubmed.ncbi.nlm.nih.gov/16484588

DM4I02O	DI	DM4I02O
DM4I02O	DN	NJA-730
DM4I02O	MI	TT1ERKL
DM4I02O	MN	CD40 messenger RNA (CD40 mRNA)
DM4I02O	MT	DTT
DM4I02O	MA	Inhibitor
DM4I02O	RN	Clinical pipeline report, company report or official report of NapaJen Pharma.
DM4I02O	RU	https://www.napajen.com/en/study/nja-730/

DMSENTW	DI	DMSENTW
DMSENTW	DN	NJH395
DMSENTW	MI	TT6EO5L
DMSENTW	MN	Erbb2 tyrosine kinase receptor (HER2)
DMSENTW	MT	DTT
DMSENTW	RN	ClinicalTrials.gov (NCT03696771) Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer. U.S. National Institutes of Health.
DMSENTW	RU	https://clinicaltrials.gov/ct2/show/NCT03696771

DMGSDPL	DI	DMGSDPL
DMGSDPL	DN	NK-314
DMGSDPL	MI	TT0IHXV
DMGSDPL	MN	DNA topoisomerase II (TOP2)
DMGSDPL	MT	DTT
DMGSDPL	MA	Modulator
DMGSDPL	RN	NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform. J Biol Chem. 2008 Aug 29;283(35):23711-20.
DMGSDPL	RU	https://pubmed.ncbi.nlm.nih.gov/18596031

DM5AWK1	DI	DM5AWK1
DM5AWK1	DN	NKP-1339
DM5AWK1	MI	TTW26OG
DM5AWK1	MN	Endoplasmic reticulum chaperone BiP (HSPA5)
DM5AWK1	MT	DTT
DM5AWK1	MA	Inhibitor
DM5AWK1	RN	NKP-1339, a first-in-class anticancer drug showing mild side effects and activity in patients suffering from advanced refractory cancer. BMC Pharmacol Toxicol. 2012; 13(Suppl 1): A82.
DM5AWK1	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3506350/

DM5AWK1	DI	DM5AWK1
DM5AWK1	DN	NKP-1339
DM5AWK1	MI	TT0K6EO
DM5AWK1	MN	Stress-activated protein kinase JNK1 (JNK1)
DM5AWK1	MT	DTT
DM5AWK1	MA	Inhibitor
DM5AWK1	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1496).
DM5AWK1	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1496

DMDLJM1	DI	DMDLJM1
DMDLJM1	DN	NKR-2 CAR-T Cells
DMDLJM1	MI	TTLRN4A
DMDLJM1	MN	NKG2 D activating NK receptor (KLRK1)
DMDLJM1	MT	DTT
DMDLJM1	MA	CAR-T-Cell-Therapy
DMDLJM1	RN	ClinicalTrials.gov (NCT03612739) EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2
DMDLJM1	RU	https://clinicaltrials.gov/ct2/show/NCT03612739

DMR5ATX	DI	DMR5ATX
DMR5ATX	DN	NKR-2 cells
DMR5ATX	MI	TTLRN4A
DMR5ATX	MN	NKG2 D activating NK receptor (KLRK1)
DMR5ATX	MT	DTT
DMR5ATX	MA	CAR-T-Cell-Therapy
DMR5ATX	RN	ClinicalTrials.gov (NCT03310008) Dose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases
DMR5ATX	RU	https://clinicaltrials.gov/ct2/show/NCT03310008

DMI7ZK3	DI	DMI7ZK3
DMI7ZK3	DN	NKTT-120
DMI7ZK3	MI	TTA6ZER
DMI7ZK3	MN	Immunoglobulin G1k (IgG1k)
DMI7ZK3	MT	DTT
DMI7ZK3	RN	Advances in Sickle Cell Therapies in the Hydroxyurea Era. Mol Med. 2014; 20(Suppl 1): S37-S42.
DMI7ZK3	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4374518/

DMP9J5V	DI	DMP9J5V
DMP9J5V	DN	NLG802
DMP9J5V	MI	TTZJYKH
DMP9J5V	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMP9J5V	MT	DTT
DMP9J5V	MA	Inhibitor
DMP9J5V	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMP9J5V	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMYPWHD	DI	DMYPWHD
DMYPWHD	DN	NLG919
DMYPWHD	MI	TTV8N19
DMYPWHD	MN	Immune checkpoint (ICH)
DMYPWHD	MT	DTT
DMYPWHD	MA	Modulator
DMYPWHD	RN	Deal watch: Genentech dives deeper into the next wave of cancer immunotherapies. Nat Rev Drug Discov. 2014 Dec;13(12):879.
DMYPWHD	RU	https://pubmed.ncbi.nlm.nih.gov/25435209

DMPJMB7	DI	DMPJMB7
DMPJMB7	DN	NLX-101
DMPJMB7	MI	TTSQIFT
DMPJMB7	MN	5-HT 1A receptor (HTR1A)
DMPJMB7	MT	DTT
DMPJMB7	MA	Modulator
DMPJMB7	RN	In vivo electrophysiological and neurochemical effects of the selective 5-HT1A receptor agonist, F13640, at pre- and postsynaptic 5-HT1A receptors in the rat.Psychopharmacology (Berl).2012 May;221(2):261-72.
DMPJMB7	RU	https://www.ncbi.nlm.nih.gov/pubmed/22147258

DM5INE7	DI	DM5INE7
DM5INE7	DN	NM-3
DM5INE7	MI	TT9HKJA
DM5INE7	MN	Vascular endothelial growth factor (VEGF)
DM5INE7	MT	DTT
DM5INE7	MA	Inhibitor
DM5INE7	RN	2-(8-hydroxy-6-methoxy-1-oxo-1h-2-benzopyran-3-yl) propionic acid, an inhibitor of angiogenesis, ameliorates renal alterations in obese type 2 diabetic mice. Diabetes. 2006 May;55(5):1232-42.
DM5INE7	RU	https://pubmed.ncbi.nlm.nih.gov/16644677

DM2XIRW	DI	DM2XIRW
DM2XIRW	DN	NMS-03305293
DM2XIRW	MI	TTVDSZ0
DM2XIRW	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DM2XIRW	MT	DTT
DM2XIRW	MA	Inhibitor
DM2XIRW	RN	NMS-P293, a PARP-1 selective inhibitor with no trapping activity and high CNS penetration, possesses potent in vivo efficacy and represents a novel therapeutic option for brain localized metastases and glioblastoma. Cancer Res 2018;78(13 Suppl):Abstract nr 4843.
DM2XIRW	RU	https://cancerres.aacrjournals.org/content/78/13_Supplement/4843

DMDGCHR	DI	DMDGCHR
DMDGCHR	DN	NN-1218
DMDGCHR	MI	TTCBFJO
DMDGCHR	MN	Insulin receptor (INSR)
DMDGCHR	MT	DTT
DMDGCHR	MA	Modulator
DMDGCHR	RN	Ultrafast-Acting Insulins: State of the Art. J Diabetes Sci Technol. 2012 July; 6(4): 728-742.
DMDGCHR	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3440142/

DMRJEXM	DI	DMRJEXM
DMRJEXM	DN	NN-414
DMRJEXM	MI	TTP835K
DMRJEXM	MN	ATP-binding cassette transporter C8 (ABCC8)
DMRJEXM	MT	DTT
DMRJEXM	MA	Modulator
DMRJEXM	RN	Attenuation of hyperinsulinemia by NN414, a SUR1/Kir6.2 selective K-adenosine triphosphate channel opener, improves glucose tolerance and lipid profile in obese Zucker rats.Metabolism.2004 Apr;53(4):441-7.
DMRJEXM	RU	https://www.ncbi.nlm.nih.gov/pubmed/15045689

DMHVIZC	DI	DMHVIZC
DMHVIZC	DN	NN-7415
DMHVIZC	MI	TT068JH
DMHVIZC	MN	Tissue factor pathway inhibitor (TFPI)
DMHVIZC	MT	DTT
DMHVIZC	MA	Modulator
DMHVIZC	RN	Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial.J Thromb Haemost.2015 May;13(5):743-54.
DMHVIZC	RU	https://www.ncbi.nlm.nih.gov/pubmed/25641556

DMYXDB9	DI	DMYXDB9
DMYXDB9	DN	NN-8828
DMYXDB9	MI	TT9QEJ6
DMYXDB9	MN	Interleukin-21 (IL21)
DMYXDB9	MT	DTT
DMYXDB9	RN	Handbook of Therapeutic Antibodies. 2014. 1. Page(995).
DMYXDB9	RU	https://books.google.com.hk/books?id=svHsBQAAQBAJ&pg=PA995&lpg=PA995&dq=NN-8828++++++ANTI&source=bl&ots=OSgek3Ucgf&sig=8iYcf4GKsCAvCCC1QHsKqxZK3YQ&hl=zh-CN&sa=X&ved=0CEwQ6AEwBmoVChMIyrS7qtXGyAIVA0COCh20lgxt#v=onepage&q=NN-8828%20%20%20%20%20%20ANTI&f=false

DM1RBT8	DI	DM1RBT8
DM1RBT8	DN	NN-9926
DM1RBT8	MI	TTVIMDE
DM1RBT8	MN	Glucagon-like peptide 1 receptor (GLP1R)
DM1RBT8	MT	DTT
DM1RBT8	MA	Agonist
DM1RBT8	RN	Clinical pipeline report, company report or official report of Addex Pharmaceuticals.
DM1RBT8	RU	https://www.google.com.hk/url?sa=t&rct=j&q=&esrc=s&source=web&cd=6&ved=0CEkQFjAFahUKEwiqkvGZp7nIAhWRBo4KHcHbD4U&url=http%3a%2f%2fwww%2eedisoninvestmentresearch%2ecom%2f%3fACT%3d18%26ID%3d6480&usg=AFQjCNHEg3ua1DahAa3uYwDK0pG0MPee7Q

DMUPA7C	DI	DMUPA7C
DMUPA7C	DN	NOCICEPTIN
DMUPA7C	MI	TTNT7K8
DMUPA7C	MN	Nociceptin receptor (OPRL1)
DMUPA7C	MT	DTT
DMUPA7C	MA	Inhibitor
DMUPA7C	RN	Binding and in vitro activities of peptides with high affinity for the nociceptin/orphanin FQ receptor, ORL1. J Pharmacol Exp Ther. 1997 Nov;283(2):735-41.
DMUPA7C	RU	https://pubmed.ncbi.nlm.nih.gov/9353393

DMUPA7C	DI	DMUPA7C
DMUPA7C	DN	NOCICEPTIN
DMUPA7C	MI	TTKWM86
DMUPA7C	MN	Opioid receptor mu (MOP)
DMUPA7C	MT	DTT
DMUPA7C	MA	Inhibitor
DMUPA7C	RN	Synthesis and pharmacological evaluation of 1,2-dihydrospiro[isoquinoline-4(3H),4'-piperidin]-3-ones as nociceptin receptor agonists. J Med Chem. 2008 Feb 28;51(4):1058-62.
DMUPA7C	RU	https://pubmed.ncbi.nlm.nih.gov/18232652

DM2ILSJ	DI	DM2ILSJ
DM2ILSJ	DN	Norbuprenorphine
DM2ILSJ	MI	DTUGYRD
DM2ILSJ	MN	P-glycoprotein 1 (ABCB1)
DM2ILSJ	MT	DTP
DM2ILSJ	MA	Substrate
DM2ILSJ	RN	Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int J Neuropsychopharmacol. 2010 Aug;13(7):905-15.
DM2ILSJ	RU	https://doi.org/10.1017/S1461145709990848

DME2QUZ	DI	DME2QUZ
DME2QUZ	DN	NOV1501
DME2QUZ	MI	TTV23LH
DME2QUZ	MN	Delta-like protein 4 (DLL4)
DME2QUZ	MT	DTT
DME2QUZ	MA	Inhibitor
DME2QUZ	RN	Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer. BMB Rep. 2020 Nov;53(10):533-538.
DME2QUZ	RU	https://pubmed.ncbi.nlm.nih.gov/32580836

DME2QUZ	DI	DME2QUZ
DME2QUZ	DN	NOV1501
DME2QUZ	MI	TT9HKJA
DME2QUZ	MN	Vascular endothelial growth factor (VEGF)
DME2QUZ	MT	DTT
DME2QUZ	MA	Inhibitor
DME2QUZ	RN	Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer. BMB Rep. 2020 Nov;53(10):533-538.
DME2QUZ	RU	https://pubmed.ncbi.nlm.nih.gov/32580836

DMMYRHV	DI	DMMYRHV
DMMYRHV	DN	NOX-700
DMMYRHV	MI	TTUO9SZ
DMMYRHV	MN	Nitric oxide elimination (NOE)
DMMYRHV	MT	DTT
DMMYRHV	MA	Modulator
DMMYRHV	RN	Inhibition of nitrosylation, nitration, lymphocyte proliferation, and gene expression in acute and delayed cardiac allograft rejection by an orally active dithiocarbamate. J Cardiovasc Pharmacol. 2004 Apr;43(4):522-30.
DMMYRHV	RU	https://pubmed.ncbi.nlm.nih.gov/15085063

DMMKN4Q	DI	DMMKN4Q
DMMKN4Q	DN	NOX-A12
DMMKN4Q	MI	TT4UGTF
DMMKN4Q	MN	Stromal cell-derived factor 1 (CXCL12)
DMMKN4Q	MT	DTT
DMMKN4Q	MA	Inhibitor
DMMKN4Q	RN	SDF-1/CXCR4/CXCR7 is pivotal for vascular smooth muscle cell proliferation and chronic allograft vasculopathy. Transpl Int. 2015 Dec;28(12):1426-35.
DMMKN4Q	RU	https://pubmed.ncbi.nlm.nih.gov/26265085

DMHARE7	DI	DMHARE7
DMHARE7	DN	NP-500
DMHARE7	MI	TTZOPHG
DMHARE7	MN	Insulin (INS)
DMHARE7	MT	DTT
DMHARE7	MA	Modulator
DMHARE7	RN	Napo Receives Commitments for a Private Placement of Common Shares and Enters into Binding Letter of Intent for Intellectual Property License. Napo. JANUARY 08, 2007
DMHARE7	RU	http://www.prnewswire.com/news-releases/napo-receives-commitments-for-a-private-placement-of-common-shares-and-enters-into-binding-letter-of-intent-for-intellectual-property-license-53349492.html

DMZ72BD	DI	DMZ72BD
DMZ72BD	DN	NP-G2-044
DMZ72BD	MI	TTTRS9B
DMZ72BD	MN	Fascin (FSCN1)
DMZ72BD	MT	DTT
DMZ72BD	MA	Inhibitor
DMZ72BD	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZ72BD	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMFDBV5	DI	DMFDBV5
DMFDBV5	DN	NPT200-11
DMFDBV5	MI	TT08OSU
DMFDBV5	MN	Synuclein alpha (SNCA)
DMFDBV5	MT	DTT
DMFDBV5	MA	Inhibitor
DMFDBV5	RN	The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease. Sci Rep. 2018 Nov 1;8(1):16165.
DMFDBV5	RU	https://pubmed.ncbi.nlm.nih.gov/30385782

DMX8LY4	DI	DMX8LY4
DMX8LY4	DN	NS-8
DMX8LY4	MI	TT1VOHK
DMX8LY4	MN	Potassium channel unspecific (KC)
DMX8LY4	MT	DTT
DMX8LY4	MA	Agonist
DMX8LY4	RN	Stimulation of large-conductance calcium-activated potassium channels inhibits neurogenic contraction of human bladder from patients with urinary symptoms and reverses acetic acid-induced bladder hyperactivity in rats. Eur J Pharmacol. 2014 Jul 15;735:68-76.
DMX8LY4	RU	https://pubmed.ncbi.nlm.nih.gov/24747752

DMRAX19	DI	DMRAX19
DMRAX19	DN	NSC-14983
DMRAX19	MI	DEQ90PB
DMRAX19	MN	Dihydroorotase (pyrC)
DMRAX19	MT	DME
DMRAX19	MA	Metabolism
DMRAX19	RN	Enzyme elements involved in the interconversion of L-carbamylaspartate and L-dihydroorotate by dihydroorotase from Clostridium oroticum. Arch Biochem Biophys. 1985 Dec;243(2):447-53.
DMRAX19	RU	https://pubmed.ncbi.nlm.nih.gov/2867744

DM6093Y	DI	DM6093Y
DM6093Y	DN	NSC-172130
DM6093Y	MI	DECB0K3
DM6093Y	MN	Cytochrome P450 2D6 (CYP2D6)
DM6093Y	MT	DME
DM6093Y	MA	Metabolism
DM6093Y	RN	Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007 Jul;151(6):737-48.
DM6093Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17471183

DM96RD5	DI	DM96RD5
DM96RD5	DN	NSC-38348
DM96RD5	MI	DEJGDUW
DM96RD5	MN	Cytochrome P450 1A2 (CYP1A2)
DM96RD5	MT	DME
DM96RD5	MA	Metabolism
DM96RD5	RN	PharmGKB summary: caffeine pathway. Pharmacogenet Genomics. 2012 May;22(5):389-95.
DM96RD5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22293536

DMTYGWV	DI	DMTYGWV
DMTYGWV	DN	NSC-639829
DMTYGWV	MI	TTYFKSZ
DMTYGWV	MN	Tubulin beta (TUBB)
DMTYGWV	MT	DTT
DMTYGWV	MA	Modulator
DMTYGWV	RN	Solubilization of NSC-639829. Int J Pharm. 2001 Aug 28;225(1-2):41-7.
DMTYGWV	RU	https://pubmed.ncbi.nlm.nih.gov/11489553

DM5QHID	DI	DM5QHID
DM5QHID	DN	NSD-788
DM5QHID	MI	TTEX6LM
DM5QHID	MN	GABA(A) receptor gamma-3 (GABRG3)
DM5QHID	MT	DTT
DM5QHID	MA	Modulator
DM5QHID	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415).
DM5QHID	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415

DM1ITDN	DI	DM1ITDN
DM1ITDN	DN	NsG-0202
DM1ITDN	MI	TTDN3LF
DM1ITDN	MN	Nerve growth factor (NGF)
DM1ITDN	MT	DTT
DM1ITDN	MA	Modulator
DM1ITDN	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM1ITDN	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMSWJ6D	DI	DMSWJ6D
DMSWJ6D	DN	NU-206
DMSWJ6D	MI	TTI9HL4
DMSWJ6D	MN	Roof plate-specific spondin-1 (RSPO1)
DMSWJ6D	MT	DTT
DMSWJ6D	MA	Modulator
DMSWJ6D	RN	R-spondin1 and FOXL2 act into two distinct cellular types during goat ovarian differentiation.BMC Dev Biol.2008 Apr 2;8:36.
DMSWJ6D	RU	https://www.ncbi.nlm.nih.gov/pubmed/18384673

DMQ0F5P	DI	DMQ0F5P
DMQ0F5P	DN	NUC-3373
DMQ0F5P	MI	TT5FOMZ
DMQ0F5P	MN	Thymidylate synthase (TYMS)
DMQ0F5P	MT	DTT
DMQ0F5P	MA	Inhibitor
DMQ0F5P	RN	Clinical pipeline report, company report or official report of NuCana.
DMQ0F5P	RU	http://www.nucana.com/nuc3373.html

DMNF09S	DI	DMNF09S
DMNF09S	DN	NV-04
DMNF09S	MI	TTXPQW1
DMNF09S	MN	Hormone unspecific (HOM)
DMNF09S	MT	DTT
DMNF09S	MA	Modulator
DMNF09S	RN	US patent application no. 2011,0201,626, 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase.
DMNF09S	RU	https://www.google.com/patents/US20110201626

DMLKS7W	DI	DMLKS7W
DMLKS7W	DN	NV-5138
DMLKS7W	MI	TTX4GLS
DMLKS7W	MN	Mammalian target of rapamycin complex 1 (mTORC1)
DMLKS7W	MT	DTT
DMLKS7W	MA	Activator
DMLKS7W	RN	Sestrin modulator NV-5138 produces rapid antidepressant effects via direct mTORC1 activation. J Clin Invest. 2019 Apr 16;129(6):2542-2554.
DMLKS7W	RU	https://pubmed.ncbi.nlm.nih.gov/30990795

DM0UOA9	DI	DM0UOA9
DM0UOA9	DN	NV-52
DM0UOA9	MI	TTKNWZ4
DM0UOA9	MN	Thromboxane-A synthase (TBXAS1)
DM0UOA9	MT	DTT
DM0UOA9	MA	Inhibitor
DM0UOA9	RN	Phase Ib single- and multiple-dose pharmacokinetic study of oral NV-52 in healthy volunteers. Drugs R D. 2008;9(3):159-66.
DM0UOA9	RU	https://pubmed.ncbi.nlm.nih.gov/18457468

DM0EKUQ	DI	DM0EKUQ
DM0EKUQ	DN	NY-ESO-1 vaccine
DM0EKUQ	MI	TTE5ITK
DM0EKUQ	MN	Cancer/testis antigen 1 (NY-ESO-1)
DM0EKUQ	MT	DTT
DM0EKUQ	RN	Multiepitope CD8+ T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J Clin Invest. 2002 December 15; 110(12): 1813-1822.
DM0EKUQ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC151653/

DMWN2FP	DI	DMWN2FP
DMWN2FP	DN	NZV930
DMWN2FP	MI	TTK0O6Y
DMWN2FP	MN	Ecto-5'-nucleotidase (CD73)
DMWN2FP	MT	DTT
DMWN2FP	MA	Inhibitor
DMWN2FP	RN	Clinical pipeline report, company report or official report of Surface oncology.
DMWN2FP	RU	https://www.surfaceoncology.com/pipeline/the-srf373-nzv930-program/

DMPLV9G	DI	DMPLV9G
DMPLV9G	DN	OBP-801
DMPLV9G	MI	TTBH0VX
DMPLV9G	MN	Histone deacetylase (HDAC)
DMPLV9G	MT	DTT
DMPLV9G	MA	Inhibitor
DMPLV9G	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPLV9G	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMPLV9G	DI	DMPLV9G
DMPLV9G	DN	OBP-801
DMPLV9G	MI	TT6R7JZ
DMPLV9G	MN	Histone deacetylase 1 (HDAC1)
DMPLV9G	MT	DTT
DMPLV9G	MA	Inhibitor
DMPLV9G	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2658).
DMPLV9G	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2658

DMW4JRY	DI	DMW4JRY
DMW4JRY	DN	OBT076
DMW4JRY	MI	TTG180Q
DMW4JRY	MN	Lymphocyte antigen 75 (LY75)
DMW4JRY	MT	DTT
DMW4JRY	RN	MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid Tumors. Mol Cancer Ther. 2019 Sep;18(9):1533-1543.
DMW4JRY	RU	https://pubmed.ncbi.nlm.nih.gov/31227646

DMOSRFZ	DI	DMOSRFZ
DMOSRFZ	DN	OC-10X
DMOSRFZ	MI	TT9K83W
DMOSRFZ	MN	Tubulin receptor (TUBR)
DMOSRFZ	MT	DTT
DMOSRFZ	MA	Inhibitor
DMOSRFZ	RN	ClinicalTrials.gov (NCT01869933) Phase I Study Assessing the Ocular and Systemic Safety and Tolerability of OC-10X. U.S. National Institutes of Health.
DMOSRFZ	RU	https://clinicaltrials.gov/ct2/show/NCT01869933

DMZK1GW	DI	DMZK1GW
DMZK1GW	DN	OG987SC
DMZK1GW	MI	TTVIMDE
DMZK1GW	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMZK1GW	MT	DTT
DMZK1GW	MA	Modulator
DMZK1GW	RN	Clinical pipeline report, company report or official report of Novo Nordisk A/S.
DMZK1GW	RU	http://www.novonordisk.com/bin/getPDF.1866957.pdf

DMH0D5M	DI	DMH0D5M
DMH0D5M	DN	OI287GT
DMH0D5M	MI	TTZOPHG
DMH0D5M	MN	Insulin (INS)
DMH0D5M	MT	DTT
DMH0D5M	MA	Modulator
DMH0D5M	RN	Company report (Novonordisk)
DMH0D5M	RU	http://www.novonordisk.com/bin/getPDF.1698237.pdf

DMERDMV	DI	DMERDMV
DMERDMV	DN	OI362GT
DMERDMV	MI	TTZOPHG
DMERDMV	MN	Insulin (INS)
DMERDMV	MT	DTT
DMERDMV	MA	Modulator
DMERDMV	RN	Novo Nordisk increased operating profit in local currencies by 15% in the first quarter of 2014
DMERDMV	RU	https://www.novonordisk.com/bin/getPDF.1781915.pdf

DMSJWTE	DI	DMSJWTE
DMSJWTE	DN	OKI 179
DMSJWTE	MI	TTBH0VX
DMSJWTE	MN	Histone deacetylase (HDAC)
DMSJWTE	MT	DTT
DMSJWTE	MA	Inhibitor
DMSJWTE	RN	Clinical pipeline report, company report or official report of OnKure Therapeutics.
DMSJWTE	RU	http://onkuretherapeutics.com/pipeline/

DMLVNWO	DI	DMLVNWO
DMLVNWO	DN	Oleclumab
DMLVNWO	MI	TTK0O6Y
DMLVNWO	MN	Ecto-5'-nucleotidase (CD73)
DMLVNWO	MT	DTT
DMLVNWO	MA	Inhibitor
DMLVNWO	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMLVNWO	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM2THBX	DI	DM2THBX
DM2THBX	DN	OM-174
DM2THBX	MI	TTY7ZHS
DM2THBX	MN	Toll-like receptor 2 (TLR2)
DM2THBX	MT	DTT
DM2THBX	MA	Modulator
DM2THBX	RN	Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors. BMC Cancer. 2013 Apr 2;13:172.
DM2THBX	RU	https://pubmed.ncbi.nlm.nih.gov/23547558

DM2THBX	DI	DM2THBX
DM2THBX	DN	OM-174
DM2THBX	MI	TTISGCA
DM2THBX	MN	Toll-like receptor 4 (TLR4)
DM2THBX	MT	DTT
DM2THBX	MA	Modulator
DM2THBX	RN	Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors. BMC Cancer. 2013 Apr 2;13:172.
DM2THBX	RU	https://pubmed.ncbi.nlm.nih.gov/23547558

DMWHZEG	DI	DMWHZEG
DMWHZEG	DN	OMN-54
DMWHZEG	MI	TTPVYKI
DMWHZEG	MN	Signal transduction unspecific (ST)
DMWHZEG	MT	DTT
DMWHZEG	MA	Inhibitor
DMWHZEG	RN	Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient-derived, advanced prostate cancer tissue xenograft model. Mol Oncol. 2014 Mar;8(2):311-22.
DMWHZEG	RU	https://pubmed.ncbi.nlm.nih.gov/24388358

DMTFU8Q	DI	DMTFU8Q
DMTFU8Q	DN	OMP-131R10
DMTFU8Q	MI	TT7HJTF
DMTFU8Q	MN	R-spondin-3 (RSPO3)
DMTFU8Q	MT	DTT
DMTFU8Q	RN	Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organs. PLoS One. 2020 Mar 11;15(3):e0229445.
DMTFU8Q	RU	https://pubmed.ncbi.nlm.nih.gov/32160239

DMWK679	DI	DMWK679
DMWK679	DN	OMP-18R5
DMWK679	MI	TTUQMO5
DMWK679	MN	Frizzled-7 receptor (FZD7)
DMWK679	MT	DTT
DMWK679	MA	Inhibitor
DMWK679	RN	Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):11717-22.
DMWK679	RU	https://pubmed.ncbi.nlm.nih.gov/22753465

DMX1D0S	DI	DMX1D0S
DMX1D0S	DN	OMP-21M18
DMX1D0S	MI	TTV23LH
DMX1D0S	MN	Delta-like protein 4 (DLL4)
DMX1D0S	MT	DTT
DMX1D0S	MA	Modulator
DMX1D0S	RN	National Cancer Institute Drug Dictionary (drug id 614677).
DMX1D0S	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=614677

DMGWC86	DI	DMGWC86
DMGWC86	DN	OMP-52M51
DMGWC86	MI	TTB1STW
DMGWC86	MN	Notch-1 receptor (NOTCH1)
DMGWC86	MT	DTT
DMGWC86	RN	National Cancer Institute Drug Dictionary (drug id 741867).
DMGWC86	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=741867

DMO0JP1	DI	DMO0JP1
DMO0JP1	DN	OMS527
DMO0JP1	MI	TT1APCZ
DMO0JP1	MN	Phosphodiesterase 7 (PDE7)
DMO0JP1	MT	DTT
DMO0JP1	MA	Inhibitor
DMO0JP1	RN	Clinical pipeline report, company report or official report of Omeros.
DMO0JP1	RU	https://www.omeros.com/pipeline/

DMWYEDX	DI	DMWYEDX
DMWYEDX	DN	ON-01210.Na
DMWYEDX	MI	TTGQUFK
DMWYEDX	MN	PI3K/AKT/mTOR pathway (PAm pathway)
DMWYEDX	MT	DTT
DMWYEDX	MA	Inhibitor
DMWYEDX	RN	ON01210.Na (Ex-RAD ) mitigates radiation damage through activation of the AKT pathway. PLoS One. 2013;8(3):e58355.
DMWYEDX	RU	https://pubmed.ncbi.nlm.nih.gov/23505494

DM5VY23	DI	DM5VY23
DM5VY23	DN	ONC206
DM5VY23	MI	TTEX248
DM5VY23	MN	Dopamine D2 receptor (D2R)
DM5VY23	MT	DTT
DM5VY23	MA	Antagonist
DM5VY23	RN	ONC206, an Imipridone Derivative, Induces Cell Death Through Activation of the Integrated Stress Response in Serous Endometrial Cancer In Vitro. Front Oncol. 2020 Oct 20;10:577141.
DM5VY23	RU	https://pubmed.ncbi.nlm.nih.gov/33194693

DM8B40M	DI	DM8B40M
DM8B40M	DN	ONC-392
DM8B40M	MI	TTI2S1D
DM8B40M	MN	Cytotoxic T-lymphocyte protein 4 (CTLA-4)
DM8B40M	MT	DTT
DM8B40M	MA	Inhibitor
DM8B40M	RN	Clinical pipeline report, company report or official report of OncoImmune.
DM8B40M	RU	https://www.oncoc4.com/index.php/product-development/onc-392

DMC29LV	DI	DMC29LV
DMC29LV	DN	ONO-4059
DMC29LV	MI	TTGM6VW
DMC29LV	MN	Tyrosine-protein kinase BTK (ATK)
DMC29LV	MT	DTT
DMC29LV	MA	Modulator
DMC29LV	RN	ONO-4059, a novel oral Bruton's tyrosine kinase (Btk) inhibitor that demonstrates potent pharmacodynamic activity through Phosphorylated Btk (P-Btk) inhibition, in addition to effective anti-tumour activity in a TMD-8 (DLBCL) xenograft model. Cancer Research. 08/2013; 73(8 Supplement):2452-2452.
DMC29LV	RU	http://cancerres.aacrjournals.org/content/73/8_Supplement/2452

DMO4SD2	DI	DMO4SD2
DMO4SD2	DN	ONO-4232
DMO4SD2	MI	TT79WV3
DMO4SD2	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DMO4SD2	MT	DTT
DMO4SD2	MA	Agonist
DMO4SD2	RN	ONO-4232, an EP4-selective Agonist, Improves Left Ventricular Diastolic Dysfunction and Ameliorates Acute and Chronic Heart Failure in Animal Models. Circulation. 2012; 126: A15345.
DMO4SD2	RU	http://circ.ahajournals.org/cgi/content/meeting_abstract/126/21_MeetingAbstracts/A15345

DME63VK	DI	DME63VK
DME63VK	DN	ONO-4578
DME63VK	MI	TT79WV3
DME63VK	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DME63VK	MT	DTT
DME63VK	MA	Antagonist
DME63VK	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DME63VK	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMGBKCJ	DI	DMGBKCJ
DMGBKCJ	DN	ONO-7475
DMGBKCJ	MI	TTO7LKR
DMGBKCJ	MN	Tyrosine-protein kinase Mer (MERTK)
DMGBKCJ	MT	DTT
DMGBKCJ	MA	Inhibitor
DMGBKCJ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMGBKCJ	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMGBKCJ	DI	DMGBKCJ
DMGBKCJ	DN	ONO-7475
DMGBKCJ	MI	TTZPY6J
DMGBKCJ	MN	Tyrosine-protein kinase UFO (AXL)
DMGBKCJ	MT	DTT
DMGBKCJ	MA	Inhibitor
DMGBKCJ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMGBKCJ	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMUZFVH	DI	DMUZFVH
DMUZFVH	DN	ONT-10
DMUZFVH	MI	TTBHFYQ
DMUZFVH	MN	Mucin-1 (MUC1)
DMUZFVH	MT	DTT
DMUZFVH	RN	Clinical pipeline report, company report or official report of Oncothyreon.
DMUZFVH	RU	http://www.oncothyreon.com/product_pipeline/ont-10.html

DMBVZND	DI	DMBVZND
DMBVZND	DN	ONYX-015
DMBVZND	MI	TT7SBF5
DMBVZND	MN	Cellular tumor antigen p53 (TP53)
DMBVZND	MT	DTT
DMBVZND	MA	Modulator
DMBVZND	RN	Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell. 2004 Dec;6(6):611-23.
DMBVZND	RU	https://pubmed.ncbi.nlm.nih.gov/15607965

DMECVP9	DI	DMECVP9
DMECVP9	DN	OP-0595
DMECVP9	MI	TTHI19T
DMECVP9	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMECVP9	MT	DTT
DMECVP9	MA	Inhibitor
DMECVP9	RN	OP0595, a new diazabicyclooctane: mode of action as a serine -lactamase inhibitor, antibiotic and -lactam 'enhancer'. J Antimicrob Chemother. 2015 Oct;70(10):2779-86.
DMECVP9	RU	https://pubmed.ncbi.nlm.nih.gov/26089439

DM7YFW5	DI	DM7YFW5
DM7YFW5	DN	OPB-111077
DM7YFW5	MI	TTH8FZW
DM7YFW5	MN	Signal transducer and activator of transcription 3 (STAT3)
DM7YFW5	MT	DTT
DM7YFW5	MA	Inhibitor
DM7YFW5	RN	Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma. Cancer Res Treat. 2019 Apr;51(2):510-518.
DM7YFW5	RU	https://pubmed.ncbi.nlm.nih.gov/29898591

DM760FA	DI	DM760FA
DM760FA	DN	OPB-51602
DM760FA	MI	TTH8FZW
DM760FA	MN	Signal transducer and activator of transcription 3 (STAT3)
DM760FA	MT	DTT
DM760FA	MA	Inhibitor
DM760FA	RN	Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. Ann Oncol. 2015 May;26(5):998-1005.
DM760FA	RU	https://pubmed.ncbi.nlm.nih.gov/25609248

DMZWFKQ	DI	DMZWFKQ
DMZWFKQ	DN	OPC-14117
DMZWFKQ	MI	TTAD7UL
DMZWFKQ	MN	Superoxide anion (SPA)
DMZWFKQ	MT	DTT
DMZWFKQ	MA	Modulator
DMZWFKQ	RN	Evaluation of superoxide scavenging activity of OPC-14117 by electron spin resonance technique. Free Radic Res Commun. 1991;15(4):223-30.
DMZWFKQ	RU	https://pubmed.ncbi.nlm.nih.gov/1667773

DMLUYAJ	DI	DMLUYAJ
DMLUYAJ	DN	OPK-0018
DMLUYAJ	MI	TT4QPUL
DMLUYAJ	MN	Antithrombin-III (ATIII)
DMLUYAJ	MT	DTT
DMLUYAJ	MA	Antagonist
DMLUYAJ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2632).
DMLUYAJ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2632

DM3HOUX	DI	DM3HOUX
DM3HOUX	DN	OPL-CCL2-LPM
DM3HOUX	MI	TTFZYTO
DM3HOUX	MN	C-C chemokine receptor type 2 (CCR2)
DM3HOUX	MT	DTT
DM3HOUX	MA	Modulator
DM3HOUX	RN	Selective CCR2-targeted macrophage depletion ameliorates experimental mesangioproliferative glomerulonephritis. Clin Exp Immunol. 2009 February; 155(2): 295-303.
DM3HOUX	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2675261/

DMH6SNO	DI	DMH6SNO
DMH6SNO	DN	OP-R003
DMH6SNO	MI	TTT1V78
DMH6SNO	MN	Interleukin-6 (IL6)
DMH6SNO	MT	DTT
DMH6SNO	MA	Modulator
DMH6SNO	RN	A high-affinity fully human anti-IL-6 mAb (OP-R003-1, 1339) for the treatment of Multiple Myeloma
DMH6SNO	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2787636

DMBG534	DI	DMBG534
DMBG534	DN	Org-25435
DMBG534	MI	TTEX6LM
DMBG534	MN	GABA(A) receptor gamma-3 (GABRG3)
DMBG534	MT	DTT
DMBG534	MA	Modulator
DMBG534	RN	First administration to man of Org 25435, an intravenous anaesthetic: A Phase 1 Clinical Trial. BMC Anesthesiol. 2010 Jun 29;10:10.
DMBG534	RU	https://pubmed.ncbi.nlm.nih.gov/20587019

DME0WX2	DI	DME0WX2
DME0WX2	DN	Org-43902
DME0WX2	MI	TT2O4W9
DME0WX2	MN	Luteinizing hormone receptor (LHCGR)
DME0WX2	MT	DTT
DME0WX2	MA	Agonist
DME0WX2	RN	First evidence of ovulation induced by oral LH agonists in healthy female volunteers of reproductive age. J Clin Endocrinol Metab. 2013 Apr;98(4):1558-66.
DME0WX2	RU	https://pubmed.ncbi.nlm.nih.gov/23515453

DMR12S0	DI	DMR12S0
DMR12S0	DN	ORIC-101
DMR12S0	MI	TTOZRK6
DMR12S0	MN	Glucocorticoid receptor messenger RNA (GCR mRNA)
DMR12S0	MT	DTT
DMR12S0	MA	Antagonist
DMR12S0	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMR12S0	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMS8NM5	DI	DMS8NM5
DMS8NM5	DN	OS2966
DMS8NM5	MI	TTBVIQC
DMS8NM5	MN	Integrin beta-1 (ITGB1)
DMS8NM5	MT	DTT
DMS8NM5	MA	Inhibitor
DMS8NM5	RN	Convection-Enhanced Delivery of a First-in-Class Anti-beta1 Integrin Antibody for the Treatment of High-Grade Glioma Utilizing Real-Time Imaging. Pharmaceutics. 2020 Dec 30;13(1):40.
DMS8NM5	RU	https://pubmed.ncbi.nlm.nih.gov/33396712

DMF2CZ9	DI	DMF2CZ9
DMF2CZ9	DN	OSI-930
DMF2CZ9	MI	TTX41N9
DMF2CZ9	MN	Tyrosine-protein kinase Kit (KIT)
DMF2CZ9	MT	DTT
DMF2CZ9	MA	Modulator
DMF2CZ9	RN	OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance. Biochem Pharmacol. 2012 Sep 15;84(6):766-74.
DMF2CZ9	RU	https://pubmed.ncbi.nlm.nih.gov/22750060

DMF2CZ9	DI	DMF2CZ9
DMF2CZ9	DN	OSI-930
DMF2CZ9	MI	TTUTJGQ
DMF2CZ9	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMF2CZ9	MT	DTT
DMF2CZ9	MA	Modulator
DMF2CZ9	RN	OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance. Biochem Pharmacol. 2012 Sep 15;84(6):766-74.
DMF2CZ9	RU	https://pubmed.ncbi.nlm.nih.gov/22750060

DMI24RF	DI	DMI24RF
DMI24RF	DN	OT-82
DMI24RF	MI	TTD1WIG
DMI24RF	MN	Nicotinamide phosphoribosyltransferase (NAMPT)
DMI24RF	MT	DTT
DMI24RF	MA	Inhibitor
DMI24RF	RN	OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis. Leukemia. 2020 Jul;34(7):1828-1839.
DMI24RF	RU	https://pubmed.ncbi.nlm.nih.gov/31896781

DMWIEC1	DI	DMWIEC1
DMWIEC1	DN	OTSA-101-DTPA-90Y
DMWIEC1	MI	TTP1S2F
DMWIEC1	MN	Frizzled-10 (FZD10)
DMWIEC1	MT	DTT
DMWIEC1	RN	A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients. BMC Cancer. 2018 Jun 8;18(1):646.
DMWIEC1	RU	https://pubmed.ncbi.nlm.nih.gov/29884132

DMF5KNO	DI	DMF5KNO
DMF5KNO	DN	OTSSP167
DMF5KNO	MI	TT5MN2U
DMF5KNO	MN	Maternal embryonic leucine zipper kinase (MELK)
DMF5KNO	MT	DTT
DMF5KNO	MA	Inhibitor
DMF5KNO	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMF5KNO	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMF5KNO	DI	DMF5KNO
DMF5KNO	DN	OTSSP167
DMF5KNO	MI	TTBZOTY
DMF5KNO	MN	Tyrosine-protein kinase MELK (MELK)
DMF5KNO	MT	DTT
DMF5KNO	MA	Inhibitor
DMF5KNO	RN	Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer. Oncotarget. 2012 Dec;3(12):1629-40.
DMF5KNO	RU	https://pubmed.ncbi.nlm.nih.gov/23283305

DMN4LMT	DI	DMN4LMT
DMN4LMT	DN	Oxeglitazar
DMN4LMT	MI	TTJ584C
DMN4LMT	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMN4LMT	MT	DTT
DMN4LMT	MA	Modulator
DMN4LMT	RN	Therapeutic potential of aleglitazar, a new dual PPAR-alpha/gamma agonist: implications for cardiovascular disease in patients with diabetes mellitus. Am J Cardiovasc Drugs. 2010;10(4):209-16.
DMN4LMT	RU	https://pubmed.ncbi.nlm.nih.gov/20653327

DMN4LMT	DI	DMN4LMT
DMN4LMT	DN	Oxeglitazar
DMN4LMT	MI	TTZMAO3
DMN4LMT	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMN4LMT	MT	DTT
DMN4LMT	MA	Modulator
DMN4LMT	RN	Therapeutic potential of aleglitazar, a new dual PPAR-alpha/gamma agonist: implications for cardiovascular disease in patients with diabetes mellitus. Am J Cardiovasc Drugs. 2010;10(4):209-16.
DMN4LMT	RU	https://pubmed.ncbi.nlm.nih.gov/20653327

DMXZOI0	DI	DMXZOI0
DMXZOI0	DN	P11187
DMXZOI0	MI	TTB8FUC
DMXZOI0	MN	Free fatty acid receptor 1 (GPR40)
DMXZOI0	MT	DTT
DMXZOI0	MA	Modulator
DMXZOI0	RN	Treatment of Type 2 Diabetes by Free Fatty Acid Receptor Agonists. Front Endocrinol (Lausanne) 2014; 5: 137.
DMXZOI0	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4147718/

DMXHKYJ	DI	DMXHKYJ
DMXHKYJ	DN	P1446A-05
DMXHKYJ	MI	TT0PG8F
DMXHKYJ	MN	Cyclin-dependent kinase 4 (CDK4)
DMXHKYJ	MT	DTT
DMXHKYJ	MA	Inhibitor
DMXHKYJ	RN	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
DMXHKYJ	RU	https://pubmed.ncbi.nlm.nih.gov/19568282

DMJ3PNS	DI	DMJ3PNS
DMJ3PNS	DN	P-2745
DMJ3PNS	MI	TTP4520
DMJ3PNS	MN	TGF-beta receptor type I (TGFBR1)
DMJ3PNS	MT	DTT
DMJ3PNS	MA	Modulator
DMJ3PNS	RN	Novel potent inhibitor of Bcr-Abl mutated imatinib resistant chronic myeloid leukemia cell lines. Cancer Research. 06/2012; 72(8 Supplement):1822-1822.
DMJ3PNS	RU	http://cancerres.aacrjournals.org/content/72/8_Supplement/1822.short

DMIYQEM	DI	DMIYQEM
DMIYQEM	DN	P-7170
DMIYQEM	MI	TTHBTOP
DMIYQEM	MN	PI3-kinase gamma (PIK3CG)
DMIYQEM	MT	DTT
DMIYQEM	MA	Inhibitor
DMIYQEM	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2155).
DMIYQEM	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2155

DMNZQU5	DI	DMNZQU5
DMNZQU5	DN	P-7435
DMNZQU5	MI	TTF8P9I
DMNZQU5	MN	Diacylglycerol acyltransferase 1 (DGAT1)
DMNZQU5	MT	DTT
DMNZQU5	MA	Inhibitor
DMNZQU5	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033014)
DMNZQU5	RU	http://adisinsight.springer.com/drugs/800033014

DMYQUIP	DI	DMYQUIP
DMYQUIP	DN	PAC1
DMYQUIP	MI	TTPF2QI
DMYQUIP	MN	Caspase-3 (CASP3)
DMYQUIP	MT	DTT
DMYQUIP	MA	Activator
DMYQUIP	RN	Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy. Nat Chem Biol. 2006 Oct;2(10):543-50.
DMYQUIP	RU	https://pubmed.ncbi.nlm.nih.gov/16936720

DMX9AK6	DI	DMX9AK6
DMX9AK6	DN	PACAP38
DMX9AK6	MI	TTW4LYC
DMX9AK6	MN	Pituitary adenylate cyclase-activating 38 (PACAP-38)
DMX9AK6	MT	DTT
DMX9AK6	MA	Modulator
DMX9AK6	RN	Pituitary adenylate cyclase-activating polypeptides, PACAP-38 and PACAP-27, regulation of sympathetic neuron catecholamine, and neuropeptide Y expr... Ann N Y Acad Sci. 1996 Dec 26;805:204-16; discussion 217-8.
DMX9AK6	RU	https://pubmed.ncbi.nlm.nih.gov/8993404

DMXQ4NO	DI	DMXQ4NO
DMXQ4NO	DN	Palomid-529
DMXQ4NO	MI	TTX4GLS
DMXQ4NO	MN	Mammalian target of rapamycin complex 1 (mTORC1)
DMXQ4NO	MT	DTT
DMXQ4NO	MA	Inhibitor
DMXQ4NO	RN	Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2. Int J Cancer. 2013 Sep 1;133(5):1222-33.
DMXQ4NO	RU	https://pubmed.ncbi.nlm.nih.gov/23436212

DMXQ4NO	DI	DMXQ4NO
DMXQ4NO	DN	Palomid-529
DMXQ4NO	MI	TTWDKCL
DMXQ4NO	MN	Target of rapamycin complex 2 MAPKAP1 (MTORC2)
DMXQ4NO	MT	DTT
DMXQ4NO	MA	Inhibitor
DMXQ4NO	RN	Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2. Int J Cancer. 2013 Sep 1;133(5):1222-33.
DMXQ4NO	RU	https://pubmed.ncbi.nlm.nih.gov/23436212

DMY9LG1	DI	DMY9LG1
DMY9LG1	DN	PAN-90806
DMY9LG1	MI	TT9HKJA
DMY9LG1	MN	Vascular endothelial growth factor (VEGF)
DMY9LG1	MT	DTT
DMY9LG1	MA	Inhibitor
DMY9LG1	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMY9LG1	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMZSD3T	DI	DMZSD3T
DMZSD3T	DN	Patient-derived CD19- and CD22 specific CAR
DMZSD3T	MI	TTM6QSK
DMZSD3T	MN	B-cell receptor CD22 (CD22)
DMZSD3T	MT	DTT
DMZSD3T	MA	CAR-T-Cell-Therapy(Dual specific)
DMZSD3T	RN	ClinicalTrials.gov (NCT03330691) A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia and Lymphoma
DMZSD3T	RU	https://clinicaltrials.gov/ct2/show/NCT03330691

DMZSD3T	DI	DMZSD3T
DMZSD3T	DN	Patient-derived CD19- and CD22 specific CAR
DMZSD3T	MI	TTW640A
DMZSD3T	MN	B-lymphocyte surface antigen B4 (CD19)
DMZSD3T	MT	DTT
DMZSD3T	MA	CAR-T-Cell-Therapy(Dual specific)
DMZSD3T	RN	ClinicalTrials.gov (NCT03330691) A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia and Lymphoma
DMZSD3T	RU	https://clinicaltrials.gov/ct2/show/NCT03330691

DMFSMCB	DI	DMFSMCB
DMFSMCB	DN	Patritumab
DMFSMCB	MI	TTDC8N2
DMFSMCB	MN	Erbb3 tyrosine kinase receptor (Erbb-3)
DMFSMCB	MT	DTT
DMFSMCB	RN	Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Mar;73(3):511-6.
DMFSMCB	RU	https://pubmed.ncbi.nlm.nih.gov/24442032

DMDC9TB	DI	DMDC9TB
DMDC9TB	DN	P-BCMA-101 CAR-T cells
DMDC9TB	MI	TTZ3P4W
DMDC9TB	MN	B-cell maturation protein (TNFRSF17)
DMDC9TB	MT	DTT
DMDC9TB	MA	CAR-T-Cell-Therapy
DMDC9TB	RN	ClinicalTrials.gov (NCT03288493) P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)
DMDC9TB	RU	https://clinicaltrials.gov/ct2/show/NCT03288493

DMOPGXM	DI	DMOPGXM
DMOPGXM	DN	PBF-1129
DMOPGXM	MI	TTNE7KG
DMOPGXM	MN	Adenosine A2b receptor (ADORA2B)
DMOPGXM	MT	DTT
DMOPGXM	MA	Antagonist
DMOPGXM	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMOPGXM	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMBSQH9	DI	DMBSQH9
DMBSQH9	DN	PBF-999
DMBSQH9	MI	TTM2AOE
DMBSQH9	MN	Adenosine A2a receptor (ADORA2A)
DMBSQH9	MT	DTT
DMBSQH9	MA	Antagonist
DMBSQH9	RN	Clinical pipeline report, company report or official report of Palobiofarma.
DMBSQH9	RU	https://www.palobiofarma.com/pipeline-2/

DMBSQH9	DI	DMBSQH9
DMBSQH9	DN	PBF-999
DMBSQH9	MI	TTJW4LU
DMBSQH9	MN	Phosphodiesterase 10A (PDE10)
DMBSQH9	MT	DTT
DMBSQH9	MA	Inhibitor
DMBSQH9	RN	Clinical pipeline report, company report or official report of Palobiofarma.
DMBSQH9	RU	https://www.palobiofarma.com/pipeline-2/

DM0O2N4	DI	DM0O2N4
DM0O2N4	DN	pbi-shRNA EWS-FLI-Type 1
DM0O2N4	MI	TTHOM2S
DM0O2N4	MN	EWS-FLI1 fusion gene mRNA (EWS-FLI1 mRNA)
DM0O2N4	MT	DTT
DM0O2N4	MA	Inhibitor
DM0O2N4	RN	National Cancer Institute Drug Dictionary (drug id 780967).
DM0O2N4	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/780967

DM529QO	DI	DM529QO
DM529QO	DN	pbi-shRNA STMN1
DM529QO	MI	TT7W5OT
DM529QO	MN	STMN1 messenger RNA (STMN1 mRNA)
DM529QO	MT	DTT
DM529QO	MA	Inhibitor
DM529QO	RN	Clinical pipeline report, company report or official report of Gradalis.
DM529QO	RU	https://www.gradalisinc.com/product/development-pipeline

DMMR4E7	DI	DMMR4E7
DMMR4E7	DN	PBSVax
DMMR4E7	MI	TT3NH7G
DMMR4E7	MN	Human immunodeficiency virus Deoxyribonucleic acid (HIV DNA)
DMMR4E7	MT	DTT
DMMR4E7	MA	Modulator
DMMR4E7	RN	ClinicalTrials.gov (NCT01578889) Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults. U.S. National Institutes of Health.
DMMR4E7	RU	https://clinicaltrials.gov/ct2/show/NCT01578889

DM23K45	DI	DM23K45
DM23K45	DN	Pc4
DM23K45	MI	TTJGNVC
DM23K45	MN	Apoptosis regulator Bcl-2 (BCL-2)
DM23K45	MT	DTT
DM23K45	MA	Agonist
DM23K45	RN	Association between the photodynamic loss of Bcl-2 and the sensitivity to apoptosis caused by phthalocyanine photodynamic therapy. Photochem Photobiol. 2003 Jul;78(1):1-8.
DM23K45	RU	https://pubmed.ncbi.nlm.nih.gov/12929741

DMNHSI8	DI	DMNHSI8
DMNHSI8	DN	PCO371
DMNHSI8	MI	TTFPD47
DMNHSI8	MN	Parathyroid hormone 1 receptor (PTH1R)
DMNHSI8	MT	DTT
DMNHSI8	MA	Agonist
DMNHSI8	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMNHSI8	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DMH86KO	DI	DMH86KO
DMH86KO	DN	PCSK9 Adnectin
DMH86KO	MI	TTBRG7E
DMH86KO	MN	Proprotein convertase subtilisin/kexin type 9 (PCSK9)
DMH86KO	MT	DTT
DMH86KO	MA	Modulator
DMH86KO	RN	Pharmacologic profile of the Adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering. J Pharmacol Exp Ther. 2014 Aug;350(2):412-24.
DMH86KO	RU	https://pubmed.ncbi.nlm.nih.gov/24917546

DM74YO8	DI	DM74YO8
DM74YO8	DN	PDC-41
DM74YO8	MI	TTT2ZAR
DM74YO8	MN	Prostaglandin F2-alpha receptor (PTGFR)
DM74YO8	MT	DTT
DM74YO8	MA	Antagonist
DM74YO8	RN	THG113: a novel selective FP antagonist that delays preterm labor. Semin Perinatol. 2002 Dec;26(6):389-97.
DM74YO8	RU	https://pubmed.ncbi.nlm.nih.gov/12537309

DMLJHM2	DI	DMLJHM2
DMLJHM2	DN	PD-L1 t-haNK
DMLJHM2	MI	TT8ZLTI
DMLJHM2	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMLJHM2	MT	DTT
DMLJHM2	RN	ClinicalTrials.gov (NCT04050709) QUILT 3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers. U.S. National Institutes of Health.
DMLJHM2	RU	https://clinicaltrials.gov/ct2/show/NCT04050709

DM4CY2G	DI	DM4CY2G
DM4CY2G	DN	PEDF gene therapy
DM4CY2G	MI	TTR59S1
DM4CY2G	MN	Pigment epithelium-derived factor (SERPINF1)
DM4CY2G	MT	DTT
DM4CY2G	MA	Inhibitor
DM4CY2G	RN	Adenovector pigment epithelium-derived factor (AdPEDF) delivery for wet age-related macular degeneration. Retina. 2005 Dec;25(8 Suppl):S48-S49.
DM4CY2G	RU	https://pubmed.ncbi.nlm.nih.gov/16374334

DMB5JWX	DI	DMB5JWX
DMB5JWX	DN	Pegadricase
DMB5JWX	MI	TTZ1SWF
DMB5JWX	MN	Uric acid (URA)
DMB5JWX	MT	DTT
DMB5JWX	MA	Modulator
DMB5JWX	RN	Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies. J Rheumatol. 2002 Sep;29(9):1942-9.
DMB5JWX	RU	https://pubmed.ncbi.nlm.nih.gov/12233890

DMW7VGZ	DI	DMW7VGZ
DMW7VGZ	DN	PegCNTF
DMW7VGZ	MI	TTT2F9E
DMW7VGZ	MN	Ciliary neurotrophic factor receptor alpha (CNTFR)
DMW7VGZ	MT	DTT
DMW7VGZ	MA	Agonist
DMW7VGZ	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DMW7VGZ	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMW7VGZ	DI	DMW7VGZ
DMW7VGZ	DN	PegCNTF
DMW7VGZ	MI	TTQL5VC
DMW7VGZ	MN	Platelet-activating factor receptor (PTAFR)
DMW7VGZ	MT	DTT
DMW7VGZ	MA	Modulator
DMW7VGZ	RN	Sch 37370: a new drug combining antagonism of platelet-activating factor (PAF) with antagonism of histamine. Agents Actions Suppl. 1991;34:313-21.
DMW7VGZ	RU	https://pubmed.ncbi.nlm.nih.gov/1793070

DM0E37K	DI	DM0E37K
DM0E37K	DN	Pegdinetanib
DM0E37K	MI	TTUTJGQ
DM0E37K	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM0E37K	MT	DTT
DM0E37K	MA	Modulator
DM0E37K	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1813).
DM0E37K	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1813

DMQ4Z1P	DI	DMQ4Z1P
DMQ4Z1P	DN	Peginterferon beta
DMQ4Z1P	MI	TTRMX3V
DMQ4Z1P	MN	Janus kinase 2 (JAK-2)
DMQ4Z1P	MT	DTT
DMQ4Z1P	MA	Inhibitor
DMQ4Z1P	RN	Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders. Leukemia. 2008 Jul;22(7):1320-34.
DMQ4Z1P	RU	https://pubmed.ncbi.nlm.nih.gov/18528425

DMMEPKR	DI	DMMEPKR
DMMEPKR	DN	PEG-Interferon lambda (IL-29)
DMMEPKR	MI	TTM624L
DMMEPKR	MN	Interleukin-29 (IL29)
DMMEPKR	MT	DTT
DMMEPKR	MA	Agonist
DMMEPKR	RN	Preclinical and clinical development of pegylated interferon-lambda 1 in chronic hepatitis C. J Interferon Cytokine Res. 2010 Aug;30(8):591-5.
DMMEPKR	RU	https://pubmed.ncbi.nlm.nih.gov/20645873

DMHV58T	DI	DMHV58T
DMHV58T	DN	Peldesine
DMHV58T	MI	TTMCF1Y
DMHV58T	MN	Purine nucleoside phosphorylase (PNP)
DMHV58T	MT	DTT
DMHV58T	MA	Inhibitor
DMHV58T	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMHV58T	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMTEG6B	DI	DMTEG6B
DMTEG6B	DN	PENCLOMEDINE
DMTEG6B	MI	TTUTN1I
DMTEG6B	MN	Human Deoxyribonucleic acid (hDNA)
DMTEG6B	MT	DTT
DMTEG6B	MA	Modulator
DMTEG6B	RN	The alkylating agent penclomedine induces degeneration of purkinje cells in the rat cerebellum. Invest New Drugs. 2003 Aug;21(3):269-79.
DMTEG6B	RU	https://www.ncbi.nlm.nih.gov/pubmed/14578677

DM0BNLC	DI	DM0BNLC
DM0BNLC	DN	PENNVAX-6
DM0BNLC	MI	TTEC2T3
DM0BNLC	MN	Human immunodeficiency virus Envelope glycoprotein gp160 (HIV env)
DM0BNLC	MT	DTT
DM0BNLC	MA	Modulator
DM0BNLC	RN	Company report (Inovio)
DM0BNLC	RU	http://www.inovio.com/products/infectious-disease-vaccines/hiv/pennvax-g/

DMUTISK	DI	DMUTISK
DMUTISK	DN	Pennvax-B
DMUTISK	MI	TTUTN1I
DMUTISK	MN	Human Deoxyribonucleic acid (hDNA)
DMUTISK	MT	DTT
DMUTISK	RN	Synthetic consensus HIV-1 DNA induces potent cellular immune responses and synthesis of granzyme B, perforin in HIV infected individuals. Mol Ther. 2015 Mar;23(3):591-601.
DMUTISK	RU	https://pubmed.ncbi.nlm.nih.gov/25531694

DM7YX8G	DI	DM7YX8G
DM7YX8G	DN	Pennvax-G
DM7YX8G	MI	TTUTN1I
DM7YX8G	MN	Human Deoxyribonucleic acid (hDNA)
DM7YX8G	MT	DTT
DM7YX8G	RN	Synthetic consensus HIV-1 DNA induces potent cellular immune responses and synthesis of granzyme B, perforin in HIV infected individuals. Mol Ther. 2015 Mar;23(3):591-601.
DM7YX8G	RU	https://pubmed.ncbi.nlm.nih.gov/25531694

DMVYRH2	DI	DMVYRH2
DMVYRH2	DN	Perifosine
DMVYRH2	MI	TTHBTOP
DMVYRH2	MN	PI3-kinase gamma (PIK3CG)
DMVYRH2	MT	DTT
DMVYRH2	MA	Modulator
DMVYRH2	RN	Company report (Aezsinc)
DMVYRH2	RU	http://www.aezsinc.com/en/page.php?p=60&q=504

DM5PUO0	DI	DM5PUO0
DM5PUO0	DN	PF-00337210
DM5PUO0	MI	TTUTJGQ
DM5PUO0	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM5PUO0	MT	DTT
DM5PUO0	MA	Modulator
DM5PUO0	RN	Inhibition of VEGFR-2 Reverses Type 1 Diabetes in NOD Mice by Abrogating Insulitis and Restoring Islet Function. Diabetes. 2013 August; 62(8): 2870-2878.
DM5PUO0	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717875/

DM93LMS	DI	DM93LMS
DM93LMS	DN	PF-01247324
DM93LMS	MI	TT90XZ8
DM93LMS	MN	Voltage-gated sodium channel alpha Nav1.8 (SCN10A)
DM93LMS	MT	DTT
DM93LMS	MA	Blocker
DM93LMS	RN	Oral Administration of PF-01247324, a Subtype-Selective Nav1.8 Blocker, Reverses Cerebellar Deficits in a Mouse Model of Multiple Sclerosis. PLoS One. 2015; 10(3): e0119067.
DM93LMS	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352054/

DMLGD0V	DI	DMLGD0V
DMLGD0V	DN	PF-04776548
DMLGD0V	MI	TT5FNQT
DMLGD0V	MN	Human immunodeficiency virus Protease (HIV PR)
DMLGD0V	MT	DTT
DMLGD0V	MA	Modulator
DMLGD0V	RN	ClinicalTrials.gov (NCT01045317) A Study To Investigate The Clearance Of PF-04776548 From The Body Following A Very Low (Micro) Dose Of The Compound Using A Low Level Of Radiotracer To Help Quantify Expected Low Concentrations Of PF-04776548 In The Body. U.S. National Institutes of Health.
DMLGD0V	RU	https://clinicaltrials.gov/ct2/show/NCT01045317

DMDSCQG	DI	DMDSCQG
DMDSCQG	DN	PF-04840082
DMDSCQG	MI	TTE3RAC
DMDSCQG	MN	Dickkopf-related protein 1 (DKK1)
DMDSCQG	MT	DTT
DMDSCQG	MA	Modulator
DMDSCQG	RN	The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. J Pharmacol Exp Ther. 2010 Apr;333(1):2-13.
DMDSCQG	RU	https://pubmed.ncbi.nlm.nih.gov/20089807

DMZ8QRI	DI	DMZ8QRI
DMZ8QRI	DN	PF-04995274
DMZ8QRI	MI	TT07C3Y
DMZ8QRI	MN	5-HT 4 receptor (HTR4)
DMZ8QRI	MT	DTT
DMZ8QRI	MA	Agonist
DMZ8QRI	RN	Pharmacokinetics, safety and tolerability of PF04995274: A 5HT4 partial agonist being developed for the treatment of Alzheimer's disease. Alzheimer's and Dementia.
DMZ8QRI	RU	http://www.alzheimersanddementia.com/article/S1552-5260(11)02414-9/abstract

DMAEK3L	DI	DMAEK3L
DMAEK3L	DN	PF-05082566
DMAEK3L	MI	TTPW9LJ
DMAEK3L	MN	Co-stimulatory molecule 4-1BB (CD137)
DMAEK3L	MT	DTT
DMAEK3L	MA	Modulator
DMAEK3L	RN	Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity. Cancer Immunol Immunother. 2012 Oct;61(10):1721-33.
DMAEK3L	RU	https://pubmed.ncbi.nlm.nih.gov/22406983

DM4QPT0	DI	DM4QPT0
DM4QPT0	DN	PF-05105679
DM4QPT0	MI	TTXDKTO
DM4QPT0	MN	Long transient receptor potential channel 8 (TRPM8)
DM4QPT0	MT	DTT
DM4QPT0	MA	Modulator
DM4QPT0	RN	Inhibition of TRPM8 channels reduces pain in the cold pressor test in humans. J Pharmacol Exp Ther. 2014 Nov;351(2):259-69.
DM4QPT0	RU	https://pubmed.ncbi.nlm.nih.gov/25125580

DMUF6W9	DI	DMUF6W9
DMUF6W9	DN	PF-05186462
DMUF6W9	MI	TT4G2JS
DMUF6W9	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DMUF6W9	MT	DTT
DMUF6W9	MA	Inhibitor
DMUF6W9	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026875)
DMUF6W9	RU	http://adisinsight.springer.com/drugs/800026875

DM7B2JC	DI	DM7B2JC
DM7B2JC	DN	PF-05190457
DM7B2JC	MI	TTWDC17
DM7B2JC	MN	Growth hormone secretagogue receptor 1 (GHSR)
DM7B2JC	MT	DTT
DM7B2JC	MA	Modulator
DM7B2JC	RN	A gift for research. SciBX 7(6); doi:10.1038/scibx.2014.160. Feb. 13 2014
DM7B2JC	RU	http://www.nature.com/scibx/journal/v7/n6/full/scibx.2014.160.html

DM7OC9K	DI	DM7OC9K
DM7OC9K	DN	PF-05230905
DM7OC9K	MI	TTF8CQI
DM7OC9K	MN	Tumor necrosis factor (TNF)
DM7OC9K	MT	DTT
DM7OC9K	MA	Inhibitor
DM7OC9K	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033173)
DM7OC9K	RU	http://adisinsight.springer.com/drugs/800033173

DM7GSZL	DI	DM7GSZL
DM7GSZL	DN	PF-05230907
DM7GSZL	MI	TTGKNB4
DM7GSZL	MN	Epidermal growth factor receptor (EGFR)
DM7GSZL	MT	DTT
DM7GSZL	MA	Inhibitor
DM7GSZL	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7GSZL	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DMQYBSH	DI	DMQYBSH
DMQYBSH	DN	PF-05231023
DMQYBSH	MI	TTQ916P
DMQYBSH	MN	Fibroblast growth factor-21 (FGF21)
DMQYBSH	MT	DTT
DMQYBSH	RN	Mechanistic investigation of the preclinical pharmacokinetics and interspecies scaling of PF-05231023, a fibroblast growth factor 21-antibody protein conjugate. Drug Metab Dispos. 2015 Jun;43(6):803-11.
DMQYBSH	RU	https://pubmed.ncbi.nlm.nih.gov/25805881

DM2NTBL	DI	DM2NTBL
DM2NTBL	DN	PF-05241328
DM2NTBL	MI	TT4G2JS
DM2NTBL	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DM2NTBL	MT	DTT
DM2NTBL	MA	Inhibitor
DM2NTBL	RN	Recent progress in sodium channel modulators for pain. Bioorg Med Chem Lett. 2014 Aug 15;24(16):3690-9.
DM2NTBL	RU	https://pubmed.ncbi.nlm.nih.gov/25060923

DM5KBDY	DI	DM5KBDY
DM5KBDY	DN	PF-06263507
DM5KBDY	MI	TT70MLA
DM5KBDY	MN	Oncotrophoblast glycoprotein 5T4 (TPBG)
DM5KBDY	MT	DTT
DM5KBDY	RN	National Cancer Institute Drug Dictionary (drug id 751006).
DM5KBDY	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=751006

DMASKX9	DI	DMASKX9
DMASKX9	DN	PF-06342674
DMASKX9	MI	TTAWI51
DMASKX9	MN	Interleukin 7 receptor alpha (IL7R)
DMASKX9	MT	DTT
DMASKX9	MA	Antagonist
DMASKX9	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMASKX9	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMGB32Z	DI	DMGB32Z
DMGB32Z	DN	PF-06427878
DMGB32Z	MI	TTRHEQ4
DMGB32Z	MN	Diacylglycerol O-acyltransferase 2 (DGAT2)
DMGB32Z	MT	DTT
DMGB32Z	MA	Inhibitor
DMGB32Z	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMGB32Z	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DM9UZTO	DI	DM9UZTO
DM9UZTO	DN	PF-06444752
DM9UZTO	MI	TTYJQTF
DM9UZTO	MN	Immunoglobulin E (IgE)
DM9UZTO	MT	DTT
DM9UZTO	MA	Modulator
DM9UZTO	RN	ClinicalTrials.gov (NCT01723254) A Study To Assess The Safety And Tolerability Of Different Doses Of PF-06444753 And PF-06444752 In Subjects With Allergic Rhinitis. U.S. National Institutes of Health.
DM9UZTO	RU	https://clinicaltrials.gov/ct2/show/NCT01723254

DMNLK5Y	DI	DMNLK5Y
DMNLK5Y	DN	PF-06647020
DMNLK5Y	MI	TTXH2ZN
DMNLK5Y	MN	Inactive tyrosine-protein kinase 7 (PTK7)
DMNLK5Y	MT	DTT
DMNLK5Y	MA	Inhibitor
DMNLK5Y	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMNLK5Y	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMGUKRN	DI	DMGUKRN
DMGUKRN	DN	PF-06648671
DMGUKRN	MI	TT9W8GU
DMGUKRN	MN	Gamma-secretase (GS)
DMGUKRN	MT	DTT
DMGUKRN	MA	Modulator
DMGUKRN	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMGUKRN	RU	http://phrma-docs.phrma.org/files/dmfile/MID-Update_Alzheimers-Disease_2017-Drug-List.pdf

DM056JD	DI	DM056JD
DM056JD	DN	PF-06648671
DM056JD	MI	TT9W8GU
DM056JD	MN	Gamma-secretase (GS)
DM056JD	MT	DTT
DM056JD	MA	Modulator
DM056JD	RN	Pharmacokinetic and Pharmacodynamic Effects of a -Secretase Modulator, PF-06648671, on CSF Amyloid- Peptides in Randomized Phase I Studies. Clin Pharmacol Ther. 2020 Jan;107(1):211-220.
DM056JD	RU	https://pubmed.ncbi.nlm.nih.gov/31314925

DMK19V6	DI	DMK19V6
DMK19V6	DN	PF-06671008
DMK19V6	MI	TTARMD9
DMK19V6	MN	Placental cadherin (CDH3)
DMK19V6	MT	DTT
DMK19V6	MA	Immunomodulator 
DMK19V6	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMK19V6	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM2ZJ1C	DI	DM2ZJ1C
DM2ZJ1C	DN	PF-06747143
DM2ZJ1C	MI	TTBID49
DM2ZJ1C	MN	C-X-C chemokine receptor type 4 (CXCR4)
DM2ZJ1C	MT	DTT
DM2ZJ1C	MA	Antagonist
DM2ZJ1C	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM2ZJ1C	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMQUNRW	DI	DMQUNRW
DMQUNRW	DN	PF-06763809
DMQUNRW	MI	TTRX125
DMQUNRW	MN	Transcription factor unspecific (TF)
DMQUNRW	MT	DTT
DMQUNRW	MA	Inhibitor
DMQUNRW	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQUNRW	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMDE9I6	DI	DMDE9I6
DMDE9I6	DN	PF-06801591
DMDE9I6	MI	TTNBFWK
DMDE9I6	MN	Programmed cell death protein 1 (PD-1)
DMDE9I6	MT	DTT
DMDE9I6	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMDE9I6	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMSJOTL	DI	DMSJOTL
DMSJOTL	DN	PF-06817024
DMSJOTL	MI	TTFTSHD
DMSJOTL	MN	Cytokine unspecific (CYK)
DMSJOTL	MT	DTT
DMSJOTL	MA	Modulator
DMSJOTL	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMSJOTL	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DML3WT6	DI	DML3WT6
DML3WT6	DN	PF-06821497
DML3WT6	MI	TT9MZCQ
DML3WT6	MN	Enhancer of zeste homolog 2 (EZH2)
DML3WT6	MT	DTT
DML3WT6	MA	Inhibitor
DML3WT6	RN	Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497). J Med Chem. 2018 Feb 8;61(3):650-665.
DML3WT6	RU	https://pubmed.ncbi.nlm.nih.gov/29211475

DMRGVT9	DI	DMRGVT9
DMRGVT9	DN	PF-06826647
DMRGVT9	MI	TTBYWP2
DMRGVT9	MN	TYK2 tyrosine kinase (TYK2)
DMRGVT9	MT	DTT
DMRGVT9	MA	Inhibitor
DMRGVT9	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMRGVT9	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMOX6EJ	DI	DMOX6EJ
DMOX6EJ	DN	PF-06840003
DMOX6EJ	MI	TTZJYKH
DMOX6EJ	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMOX6EJ	MT	DTT
DMOX6EJ	MA	Inhibitor
DMOX6EJ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMOX6EJ	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMRZHV6	DI	DMRZHV6
DMRZHV6	DN	PF-06873600
DMRZHV6	MI	TTMBO1Z
DMRZHV6	MN	Cyclin-dependent kinase (CDK)
DMRZHV6	MT	DTT
DMRZHV6	MA	Inhibitor
DMRZHV6	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMRZHV6	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM7BOFR	DI	DM7BOFR
DM7BOFR	DN	PF-06939999
DM7BOFR	MI	TTR1D7X
DM7BOFR	MN	Protein arginine methyltransferase 5 (PRMT5)
DM7BOFR	MT	DTT
DM7BOFR	MA	Inhibitor
DM7BOFR	RN	National Cancer Institute Drug Dictionary (drug name PF-06939999).
DM7BOFR	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/protein-arginine-methyltransferase-5-inhibitor-pf-06939999

DMYP9WR	DI	DMYP9WR
DMYP9WR	DN	PF-06940434
DMYP9WR	MI	TT7B3HE
DMYP9WR	MN	Integrin alpha-V/beta-8 (ITGAV/B8)
DMYP9WR	MT	DTT
DMYP9WR	MA	Antagonist
DMYP9WR	RN	ClinicalTrials.gov (NCT04152018) Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.. U.S. National Institutes of Health.
DMYP9WR	RU	https://clinicaltrials.gov/ct2/show/NCT04152018

DMDQJEZ	DI	DMDQJEZ
DMDQJEZ	DN	PF-06952229
DMDQJEZ	MI	TTP4520
DMDQJEZ	MN	TGF-beta receptor type I (TGFBR1)
DMDQJEZ	MT	DTT
DMDQJEZ	MA	Inhibitor
DMDQJEZ	RN	Targeting the TGF pathway for cancer therapy. Pharmacol Ther. 2015 Mar;147:22-31.
DMDQJEZ	RU	https://pubmed.ncbi.nlm.nih.gov/25444759

DME3BJL	DI	DME3BJL
DME3BJL	DN	PF-07062119
DME3BJL	MI	TTLDPRG
DME3BJL	MN	Guanylyl cyclase C (GUCY2C)
DME3BJL	MT	DTT
DME3BJL	MA	Inhibitor
DME3BJL	RN	Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors. MAbs. Jan-Dec 2021;13(1):1850395.
DME3BJL	RU	https://pubmed.ncbi.nlm.nih.gov/33459147

DME3BJL	DI	DME3BJL
DME3BJL	DN	PF-07062119
DME3BJL	MI	TTUN7MC
DME3BJL	MN	T-cell surface glycoprotein CD3 (CD3)
DME3BJL	MT	DTT
DME3BJL	MA	Inhibitor
DME3BJL	RN	Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors. MAbs. Jan-Dec 2021;13(1):1850395.
DME3BJL	RU	https://pubmed.ncbi.nlm.nih.gov/33459147

DMMJZ2E	DI	DMMJZ2E
DMMJZ2E	DN	PF-07104091
DMMJZ2E	MI	TT7HF4W
DMMJZ2E	MN	Cyclin-dependent kinase 2 (CDK2)
DMMJZ2E	MT	DTT
DMMJZ2E	MA	Inhibitor
DMMJZ2E	RN	ClinicalTrials.gov (NCT04553133) PF-07104091 as a Single Agent and in Combination Therapy. U.S. National Institutes of Health.
DMMJZ2E	RU	https://clinicaltrials.gov/ct2/show/NCT04553133

DMPKO84	DI	DMPKO84
DMPKO84	DN	PF-07220060
DMPKO84	MI	TT0PG8F
DMPKO84	MN	Cyclin-dependent kinase 4 (CDK4)
DMPKO84	MT	DTT
DMPKO84	MA	Inhibitor
DMPKO84	RN	ClinicalTrials.gov (NCT04557449) Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4). U.S. National Institutes of Health.
DMPKO84	RU	https://clinicaltrials.gov/ct2/show/NCT04557449

DMSMNRQ	DI	DMSMNRQ
DMSMNRQ	DN	PF-07265807
DMSMNRQ	MI	TTO7LKR
DMSMNRQ	MN	Tyrosine-protein kinase Mer (MERTK)
DMSMNRQ	MT	DTT
DMSMNRQ	MA	Inhibitor
DMSMNRQ	RN	National Cancer Institute Drug Dictionary (drug name PF-07265807).
DMSMNRQ	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/axl-mer-inhibitor-pf-07265807

DMSMNRQ	DI	DMSMNRQ
DMSMNRQ	DN	PF-07265807
DMSMNRQ	MI	TTZPY6J
DMSMNRQ	MN	Tyrosine-protein kinase UFO (AXL)
DMSMNRQ	MT	DTT
DMSMNRQ	MA	Inhibitor
DMSMNRQ	RN	National Cancer Institute Drug Dictionary (drug name PF-07265807).
DMSMNRQ	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/axl-mer-inhibitor-pf-07265807

DMCOUHT	DI	DMCOUHT
DMCOUHT	DN	PF-2413873
DMCOUHT	MI	TTUV8G9
DMCOUHT	MN	Progesterone receptor (PGR)
DMCOUHT	MT	DTT
DMCOUHT	MA	Antagonist
DMCOUHT	RN	Unusual base-catalyzed exchange in the synthesis of deuterated PF-2413873. Journal of Labelled Compounds. 08/2009; 52(10):435 - 442.
DMCOUHT	RU	http://onlinelibrary.wiley.com/doi/10.1002/jlcr.1657/abstract

DMG2IE5	DI	DMG2IE5
DMG2IE5	DN	PF-3732010
DMG2IE5	MI	TTARMD9
DMG2IE5	MN	Placental cadherin (CDH3)
DMG2IE5	MT	DTT
DMG2IE5	RN	National Cancer Institute Drug Dictionary (drug id 580366).
DMG2IE5	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=580366

DM36PKZ	DI	DM36PKZ
DM36PKZ	DN	PF-3758309
DM36PKZ	MI	TT7Y3BZ
DM36PKZ	MN	PAK-4 protein kinase (PAK4)
DM36PKZ	MT	DTT
DM36PKZ	MA	Inhibitor
DM36PKZ	RN	Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proc Natl Acad Sci U S A. 2010 May 18;107(20):9446-51.
DM36PKZ	RU	https://pubmed.ncbi.nlm.nih.gov/20439741

DML0OCD	DI	DML0OCD
DML0OCD	DN	PF-3864086
DML0OCD	MI	TTMI6F5
DML0OCD	MN	Transient receptor potential cation channel V1 (TRPV1)
DML0OCD	MT	DTT
DML0OCD	MA	Antagonist
DML0OCD	RN	Clinical pipeline report, company report or official report of pfizer.
DML0OCD	RU	https://www.pfizer.com/files/investors/presentations/acr_102808_v2.pdf

DMU2A6D	DI	DMU2A6D
DMU2A6D	DN	PF-4217903
DMU2A6D	MI	TTNDSF4
DMU2A6D	MN	Proto-oncogene c-Met (MET)
DMU2A6D	MT	DTT
DMU2A6D	MA	Inhibitor
DMU2A6D	RN	Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitor. Mol Cancer Ther. 2012 Apr;11(4):1036-47.
DMU2A6D	RU	https://pubmed.ncbi.nlm.nih.gov/22389468

DMMETU8	DI	DMMETU8
DMMETU8	DN	PF-4418948
DMMETU8	MI	TT1ZAVI
DMMETU8	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DMMETU8	MT	DTT
DMMETU8	MA	Antagonist
DMMETU8	RN	Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
DMMETU8	RU	https://www.ncbi.nlm.nih.gov/pubmed/25772215

DM3427C	DI	DM3427C
DM3427C	DN	PF-4427429
DM3427C	MI	TTAFORY
DM3427C	MN	Calcitonin gene-related peptide (CALC)
DM3427C	MT	DTT
DM3427C	MA	Modulator
DM3427C	RN	Teva Announces Positive Results for TEV-48125 in Phase IIb Chronic Migraine Study Meeting Primary and Secondary Endpoints
DM3427C	RU	http://www.tevapharm.com/news/teva_announces_positive_results_for_tev_48125_in_phase_iib_chronic_migraine_study_meeting_primary_and_secondary_endpoints_02_15.aspx

DMYR7XP	DI	DMYR7XP
DMYR7XP	DN	PF-4455242
DMYR7XP	MI	TTQW87Y
DMYR7XP	MN	Opioid receptor kappa (OPRK1)
DMYR7XP	MT	DTT
DMYR7XP	MA	Modulator
DMYR7XP	RN	Design and discovery of a selective small molecule opioid antagonist (2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine, PF-4455242). J Med Chem. 2011 Aug 25;54(16):5868-77.
DMYR7XP	RU	https://pubmed.ncbi.nlm.nih.gov/21744827

DMKOE84	DI	DMKOE84
DMKOE84	DN	PF-4603629
DMKOE84	MI	TTVIMDE
DMKOE84	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMKOE84	MT	DTT
DMKOE84	MA	Modulator
DMKOE84	RN	Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results. Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):463-77.
DMKOE84	RU	https://pubmed.ncbi.nlm.nih.gov/19748064

DMSLE03	DI	DMSLE03
DMSLE03	DN	PF-562271
DMSLE03	MI	TTON5IT
DMSLE03	MN	Focal adhesion kinase 1 (FAK)
DMSLE03	MT	DTT
DMSLE03	MA	Inhibitor
DMSLE03	RN	Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Mol Cancer Ther. 2011 Nov;10(11):2135-45.
DMSLE03	RU	https://pubmed.ncbi.nlm.nih.gov/21903606

DMGLEM1	DI	DMGLEM1
DMGLEM1	DN	PF9601N
DMGLEM1	MI	TTGP7BY
DMGLEM1	MN	Monoamine oxidase type B (MAO-B)
DMGLEM1	MT	DTT
DMGLEM1	MA	Inhibitor
DMGLEM1	RN	Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42.
DMGLEM1	RU	https://pubmed.ncbi.nlm.nih.gov/18991661

DMLDZX1	DI	DMLDZX1
DMLDZX1	DN	PfAMA-1
DMLDZX1	MI	TTQZW34
DMLDZX1	MN	Plasmodium Apical membrane protein (Malaria AMA-1)
DMLDZX1	MT	DTT
DMLDZX1	RN	Plasmodium falciparum apical membrane antigen 1 (PfAMA-1) is translocated within micronemes along subpellicular microtubules during merozoite devel... J Cell Sci. 2003 Sep 15;116(Pt 18):3825-34.
DMLDZX1	RU	https://pubmed.ncbi.nlm.nih.gov/12902400

DM6ER9L	DI	DM6ER9L
DM6ER9L	DN	Pfizer 10
DM6ER9L	MI	TT4C8EA
DM6ER9L	MN	Dopamine D3 receptor (D3R)
DM6ER9L	MT	DTT
DM6ER9L	MA	Agonist
DM6ER9L	RN	Designing drugs for the treatment of female sexual dysfunction. Drug Discov Today. 2007 Sep;12(17-18):757-66.
DM6ER9L	RU	https://pubmed.ncbi.nlm.nih.gov/17826689

DMME5P8	DI	DMME5P8
DMME5P8	DN	Pfizer 4
DMME5P8	MI	TT5TKPM
DMME5P8	MN	Neutral endopeptidase (MME)
DMME5P8	MT	DTT
DMME5P8	MA	Inhibitor
DMME5P8	RN	Designing drugs for the treatment of female sexual dysfunction. Drug Discov Today. 2007 Sep;12(17-18):757-66.
DMME5P8	RU	https://pubmed.ncbi.nlm.nih.gov/17826689

DMIR21F	DI	DMIR21F
DMIR21F	DN	PFK-158
DMIR21F	MI	TTTHMQJ
DMIR21F	MN	Renal carcinoma antigen NY-REN-56 (PFKFB3)
DMIR21F	MT	DTT
DMIR21F	MA	Inhibitor
DMIR21F	RN	Discovery of a PFKFB3 inhibitor for phase I trial testing that synergizes with the B-Raf inhibitor vemurafenib. Cancer Metab. 2014; 2(Suppl 1): P14.
DMIR21F	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072985/

DM68D3O	DI	DM68D3O
DM68D3O	DN	PG-545
DM68D3O	MI	TTR7GJO
DM68D3O	MN	Heparanase (HPSE)
DM68D3O	MT	DTT
DM68D3O	MA	Modulator
DM68D3O	RN	PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. Br J Cancer. 2011 Feb 15;104(4):635-42.
DM68D3O	RU	https://pubmed.ncbi.nlm.nih.gov/21285983

DM2Y4FG	DI	DM2Y4FG
DM2Y4FG	DN	PHA-793887
DM2Y4FG	MI	TTH6V3D
DM2Y4FG	MN	Cyclin-dependent kinase 1 (CDK1)
DM2Y4FG	MT	DTT
DM2Y4FG	MA	Inhibitor
DM2Y4FG	RN	A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected h... Cell Cycle. 2011 Mar 15;10(6):963-70.
DM2Y4FG	RU	https://pubmed.ncbi.nlm.nih.gov/21368575

DM2Y4FG	DI	DM2Y4FG
DM2Y4FG	DN	PHA-793887
DM2Y4FG	MI	TT7HF4W
DM2Y4FG	MN	Cyclin-dependent kinase 2 (CDK2)
DM2Y4FG	MT	DTT
DM2Y4FG	MA	Inhibitor
DM2Y4FG	RN	A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected h... Cell Cycle. 2011 Mar 15;10(6):963-70.
DM2Y4FG	RU	https://pubmed.ncbi.nlm.nih.gov/21368575

DM2Y4FG	DI	DM2Y4FG
DM2Y4FG	DN	PHA-793887
DM2Y4FG	MI	TT0PG8F
DM2Y4FG	MN	Cyclin-dependent kinase 4 (CDK4)
DM2Y4FG	MT	DTT
DM2Y4FG	MA	Inhibitor
DM2Y4FG	RN	Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154.
DM2Y4FG	RU	https://pubmed.ncbi.nlm.nih.gov/21253554

DMUANF9	DI	DMUANF9
DMUANF9	DN	PHE-377
DMUANF9	MI	TTMI6F5
DMUANF9	MN	Transient receptor potential cation channel V1 (TRPV1)
DMUANF9	MT	DTT
DMUANF9	MA	Antagonist
DMUANF9	RN	Clinical pipeline report, company report or official report of Pharmeste.
DMUANF9	RU	http://www.pharmeste.com/home.asp?op=interna&id=1

DMBZ2QT	DI	DMBZ2QT
DMBZ2QT	DN	PHE885
DMBZ2QT	MI	TTZ3P4W
DMBZ2QT	MN	B-cell maturation protein (TNFRSF17)
DMBZ2QT	MT	DTT
DMBZ2QT	RN	ClinicalTrials.gov (NCT04318327) BCMA-directed CAR-T Cell Therapy in Adult Patients With Relapsed and/or Refractory Multiple Myeloma. U.S. National Institutes of Health.
DMBZ2QT	RU	https://clinicaltrials.gov/ct2/show/NCT04318327

DMERJ6V	DI	DMERJ6V
DMERJ6V	DN	PHX-1766
DMERJ6V	MI	TTRHUKY
DMERJ6V	MN	Hepatitis C virus Serine protease NS4A (HCV NS4A)
DMERJ6V	MT	DTT
DMERJ6V	MA	Modulator
DMERJ6V	RN	Pharmacokinetics and antiviral activity of PHX1766, a novel HCV protease inhibitor, using an accelerated Phase I study design. Antivir Ther. 2012;17(2):365-75.
DMERJ6V	RU	https://pubmed.ncbi.nlm.nih.gov/22293533

DMU26OE	DI	DMU26OE
DMU26OE	DN	PIM447
DMU26OE	MI	TTA7WGU
DMU26OE	MN	Serine/threonine-protein kinase pim (PIM)
DMU26OE	MT	DTT
DMU26OE	MA	Inhibitor
DMU26OE	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMU26OE	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMF3IBC	DI	DMF3IBC
DMF3IBC	DN	Plasma derived human butyrylcholinesterase
DMF3IBC	MI	TTEB0GD
DMF3IBC	MN	Cholinesterase (BCHE)
DMF3IBC	MT	DTT
DMF3IBC	MA	Modulator
DMF3IBC	RN	Acetylcholinesterase-Fc Fusion Protein (AChE-Fc): A Novel Potential Organophosphate Bioscavenger with Extended Plasma Half-Life. Bioconjug Chem. 2015 Aug 19;26(8):1753-8.
DMF3IBC	RU	https://pubmed.ncbi.nlm.nih.gov/26121420

DMBK9AM	DI	DMBK9AM
DMBK9AM	DN	PLX-4720
DMBK9AM	MI	TT0EOB8
DMBK9AM	MN	B-Raf messenger RNA (BRAF mRNA)
DMBK9AM	MT	DTT
DMBK9AM	MA	Inhibitor
DMBK9AM	RN	Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011 Oct 30;29(11):1046-51.
DMBK9AM	RU	https://pubmed.ncbi.nlm.nih.gov/22037378

DMBK9AM	DI	DMBK9AM
DMBK9AM	DN	PLX-4720
DMBK9AM	MI	TTUTJGQ
DMBK9AM	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMBK9AM	MT	DTT
DMBK9AM	MA	Inhibitor
DMBK9AM	RN	In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003 Jan;9(1):327-37.
DMBK9AM	RU	https://pubmed.ncbi.nlm.nih.gov/12538485

DMXLHVW	DI	DMXLHVW
DMXLHVW	DN	PLX51107
DMXLHVW	MI	TTE4BSY
DMXLHVW	MN	Bromodomain and extraterminal domain protein (BET)
DMXLHVW	MT	DTT
DMXLHVW	MA	Inhibitor
DMXLHVW	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMXLHVW	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMK4PWM	DI	DMK4PWM
DMK4PWM	DN	PLX-5622
DMK4PWM	MI	TTC70AJ
DMK4PWM	MN	Granulocyte colony-stimulating factor receptor (G-CSF-R)
DMK4PWM	MT	DTT
DMK4PWM	MA	Inhibitor
DMK4PWM	RN	Microglial Stimulation of Glioblastoma Invasion Involves Epidermal Growth Factor Receptor (EGFR) and Colony Stimulating Factor 1 Receptor (CSF-1R) Signaling. Mol Med. 2012; 18(1): 519-527.
DMK4PWM	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356419/

DMED2WN	DI	DMED2WN
DMED2WN	DN	PLX73086
DMED2WN	MI	TT0IQER
DMED2WN	MN	Macrophage colony-stimulating factor 1 (CSF1)
DMED2WN	MT	DTT
DMED2WN	MA	Antagonist
DMED2WN	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMED2WN	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM0IVGU	DI	DM0IVGU
DM0IVGU	DN	PLX7486
DM0IVGU	MI	TTC70AJ
DM0IVGU	MN	Granulocyte colony-stimulating factor receptor (G-CSF-R)
DM0IVGU	MT	DTT
DM0IVGU	MA	Inhibitor
DM0IVGU	RN	National Cancer Institute Drug Dictionary (drug id 747694).
DM0IVGU	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=747694

DM0IVGU	DI	DM0IVGU
DM0IVGU	DN	PLX7486
DM0IVGU	MI	TT7MRDV
DM0IVGU	MN	Macrophage colony-stimulating factor 1 receptor (CSF1R)
DM0IVGU	MT	DTT
DM0IVGU	MA	Inhibitor
DM0IVGU	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM0IVGU	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM0IVGU	DI	DM0IVGU
DM0IVGU	DN	PLX7486
DM0IVGU	MI	TTTDVOJ
DM0IVGU	MN	Tropomyosin-related kinase A (TrkA)
DM0IVGU	MT	DTT
DM0IVGU	MA	Inhibitor
DM0IVGU	RN	National Cancer Institute Drug Dictionary (drug id 747694).
DM0IVGU	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=747694

DMIS8BV	DI	DMIS8BV
DMIS8BV	DN	PMD-026
DMIS8BV	MI	TTMVQXO
DMIS8BV	MN	Ribosomal protein S6 kinase beta-2 (RPS6KB2)
DMIS8BV	MT	DTT
DMIS8BV	MA	Inhibitor
DMIS8BV	RN	ClinicalTrials.gov (NCT04115306) Phase 1/1b Study of Oral PMD-026 in Patients With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer. U.S. National Institutes of Health.
DMIS8BV	RU	https://clinicaltrials.gov/ct2/show/NCT04115306

DMY9XWB	DI	DMY9XWB
DMY9XWB	DN	PMI-005
DMY9XWB	MI	TTF8CQI
DMY9XWB	MN	Tumor necrosis factor (TNF)
DMY9XWB	MT	DTT
DMY9XWB	MA	Inhibitor
DMY9XWB	RN	US patent application no. 2008,0269,123, Methods for treating polycystic kidney disease (pkd) or other cyst forming diseases.
DMY9XWB	RU	https://www.google.com.ar/patents/US20080269123

DMQ82SH	DI	DMQ82SH
DMQ82SH	DN	PMZ-2123
DMQ82SH	MI	TTKRD0G
DMQ82SH	MN	Endothelin A receptor (EDNRA)
DMQ82SH	MT	DTT
DMQ82SH	MA	Antagonist
DMQ82SH	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQ82SH	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DM9B68S	DI	DM9B68S
DM9B68S	DN	POL-6014
DM9B68S	MI	TTPLTSQ
DM9B68S	MN	Neutrophil elastase (NE)
DM9B68S	MT	DTT
DM9B68S	MA	Inhibitor
DM9B68S	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2358).
DM9B68S	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2358

DMTOLI5	DI	DMTOLI5
DMTOLI5	DN	Pomaglumetad
DMTOLI5	MI	TTXJ47W
DMTOLI5	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMTOLI5	MT	DTT
DMTOLI5	MA	Modulator
DMTOLI5	RN	LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia. Curr Opin Investig Drugs. 2010 Jul;11(7):833-45.
DMTOLI5	RU	https://pubmed.ncbi.nlm.nih.gov/20571979

DMTOLI5	DI	DMTOLI5
DMTOLI5	DN	Pomaglumetad
DMTOLI5	MI	TT8A9EF
DMTOLI5	MN	Metabotropic glutamate receptor 3 (mGluR3)
DMTOLI5	MT	DTT
DMTOLI5	MA	Modulator
DMTOLI5	RN	LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia. Curr Opin Investig Drugs. 2010 Jul;11(7):833-45.
DMTOLI5	RU	https://pubmed.ncbi.nlm.nih.gov/20571979

DMCU54M	DI	DMCU54M
DMCU54M	DN	Posiphen R-phenserine
DMCU54M	MI	TT08OSU
DMCU54M	MN	Synuclein alpha (SNCA)
DMCU54M	MT	DTT
DMCU54M	MA	Modulator
DMCU54M	RN	The Anticholinesterase Phenserine and Its Enantiomer Posiphen as 5 ntranslated-Region-Directed Translation Blockers of the Parkinson's Alpha Synuclein Expression. Parkinson's Disease Volume 2012 (2012), Article ID 142372, Page(13).
DMCU54M	RU	http://www.hindawi.com/journals/pd/2012/142372/

DM2D7Z0	DI	DM2D7Z0
DM2D7Z0	DN	PPC-5650
DM2D7Z0	MI	TTRJYB6
DM2D7Z0	MN	Acid-sensing ion channel 1 (ASIC1)
DM2D7Z0	MT	DTT
DM2D7Z0	MA	Modulator
DM2D7Z0	RN	ClinicalTrials.gov (NCT01449487) Investigation of Efficacy and Safety of PPC-5650 to Experimental Induced Sensation and Pain in the Rectosigmoid. U.S. National Institutes of Health.
DM2D7Z0	RU	https://clinicaltrials.gov/ct2/show/NCT01449487

DMSAQBC	DI	DMSAQBC
DMSAQBC	DN	PPI-2458
DMSAQBC	MI	TTZL0OI
DMSAQBC	MN	Methionine aminopeptidase 2 (METAP2)
DMSAQBC	MT	DTT
DMSAQBC	MA	Inhibitor
DMSAQBC	RN	Metabolites of PPI-2458, a selective, irreversible inhibitor of methionine aminopeptidase-2: structure determination and in vivo activity. Drug Metab Dispos. 2013 Apr;41(4):814-26.
DMSAQBC	RU	https://pubmed.ncbi.nlm.nih.gov/23355637

DMEOJUN	DI	DMEOJUN
DMEOJUN	DN	PPI-383
DMEOJUN	MI	TTMVBWH
DMEOJUN	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMEOJUN	MT	DTT
DMEOJUN	MA	Inhibitor
DMEOJUN	RN	1173 IDENTIFICATION AND CHARACTERIZATION OF PPI-383, A NEXT GENERATION HCV NS5B NON-NUCLEOSIDE INHIBITOR WITH POTENT ACTIVITY AGAINST ALL MAJOR HCV GENOTYPES. Journal of Hepatology Volume 56, Supplement 2, April 2012, Pages S464.
DMEOJUN	RU	http://www.sciencedirect.com/science/article/pii/S0168827812611854

DMTOXLG	DI	DMTOXLG
DMTOXLG	DN	PPI-461
DMTOXLG	MI	TTCJ2X8
DMTOXLG	MN	Hepatitis C virus Non-structural 5A (HCV NS5A)
DMTOXLG	MT	DTT
DMTOXLG	MA	Modulator
DMTOXLG	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMTOXLG	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMOYUPM	DI	DMOYUPM
DMOYUPM	DN	PPL-100
DMOYUPM	MI	TT5FNQT
DMOYUPM	MN	Human immunodeficiency virus Protease (HIV PR)
DMOYUPM	MT	DTT
DMOYUPM	MA	Inhibitor
DMOYUPM	RN	Antiviral activity and cross-resistance profile of P-1946, a novel human immunodeficiency virus type 1 protease inhibitor. Antiviral Res. 2006 Jun;70(2):17-20.
DMOYUPM	RU	https://pubmed.ncbi.nlm.nih.gov/16473417

DMY2GDQ	DI	DMY2GDQ
DMY2GDQ	DN	P-PSMA-101
DMY2GDQ	MI	TTZ3P4W
DMY2GDQ	MN	B-cell maturation protein (TNFRSF17)
DMY2GDQ	MT	DTT
DMY2GDQ	RN	Clinical pipeline report, company report or official report of Poseida Therapeutics.
DMY2GDQ	RU	https://poseida.com/science/pipeline/#cart-therapies

DMHIS3M	DI	DMHIS3M
DMHIS3M	DN	PRAX-330
DMHIS3M	MI	TT54ERL
DMHIS3M	MN	Voltage-gated sodium channel alpha Nav1.6 (SCN8A)
DMHIS3M	MT	DTT
DMHIS3M	MA	Inhibitor
DMHIS3M	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMHIS3M	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMCUE71	DI	DMCUE71
DMCUE71	DN	PRGN-3005
DMCUE71	MI	TTC1PS3
DMCUE71	MN	Ovarian carcinoma antigen CA125 (MUC16)
DMCUE71	MT	DTT
DMCUE71	RN	Clinical pipeline report, company report or official report of Precigen.
DMCUE71	RU	https://precigen.com/pipeline/

DMR7BAO	DI	DMR7BAO
DMR7BAO	DN	PRN1371
DMR7BAO	MI	TT0LF7H
DMR7BAO	MN	Fibroblast growth factor receptor (FGFR)
DMR7BAO	MT	DTT
DMR7BAO	MA	Inhibitor
DMR7BAO	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMR7BAO	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMQNS51	DI	DMQNS51
DMQNS51	DN	PRN2246
DMQNS51	MI	TTGM6VW
DMQNS51	MN	Tyrosine-protein kinase BTK (ATK)
DMQNS51	MT	DTT
DMQNS51	MA	Inhibitor
DMQNS51	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQNS51	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMLKF3H	DI	DMLKF3H
DMLKF3H	DN	Prolanta
DMLKF3H	MI	TTBPXMA
DMLKF3H	MN	Prolactin receptor (PRLR)
DMLKF3H	MT	DTT
DMLKF3H	MA	Antagonist
DMLKF3H	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMLKF3H	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DME1Y9W	DI	DME1Y9W
DME1Y9W	DN	Protexia
DME1Y9W	MI	TTEB0GD
DME1Y9W	MN	Cholinesterase (BCHE)
DME1Y9W	MT	DTT
DME1Y9W	MA	Modulator
DME1Y9W	RN	In vitro and in vivo characterization of recombinant human butyrylcholinesterase (Protexia) as a potential nerve agent bioscavenger. Chem Biol Interact. 2005 Dec 15;157-158:363-5.
DME1Y9W	RU	https://pubmed.ncbi.nlm.nih.gov/16429486

DMBL7CW	DI	DMBL7CW
DMBL7CW	DN	PRT-062607
DMBL7CW	MI	TTOU65C
DMBL7CW	MN	Tyrosine-protein kinase SYK (SYK)
DMBL7CW	MT	DTT
DMBL7CW	MA	Inhibitor
DMBL7CW	RN	Advances in kinase inhibition: treating rheumatic diseases and beyond. Curr Opin Rheumatol. 2014 March; 26(2): 237-243.
DMBL7CW	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4106228/

DMIKE0O	DI	DMIKE0O
DMIKE0O	DN	PRT1419
DMIKE0O	MI	TTL53M6
DMIKE0O	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DMIKE0O	MT	DTT
DMIKE0O	MA	Inhibitor
DMIKE0O	RN	Clinical pipeline report, company report or official report of Prelude Therapeutics.
DMIKE0O	RU	https://preludetx.com/science/mcl1/prt1419/

DMHNZ3U	DI	DMHNZ3U
DMHNZ3U	DN	PRT543
DMHNZ3U	MI	TTR1D7X
DMHNZ3U	MN	Protein arginine methyltransferase 5 (PRMT5)
DMHNZ3U	MT	DTT
DMHNZ3U	MA	Inhibitor
DMHNZ3U	RN	Clinical pipeline report, company report or official report of Prelude Therapeutics.
DMHNZ3U	RU	https://preludetx.com/science/prmt5/prt543/

DMP5CLY	DI	DMP5CLY
DMP5CLY	DN	PRT6207
DMP5CLY	MI	TTOU65C
DMP5CLY	MN	Tyrosine-protein kinase SYK (SYK)
DMP5CLY	MT	DTT
DMP5CLY	MA	Modulator
DMP5CLY	RN	Advances in kinase inhibition: treating rheumatic diseases and beyond. Curr Opin Rheumatol. 2014 March; 26(2): 237-243.
DMP5CLY	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4106228/

DMW3MCX	DI	DMW3MCX
DMW3MCX	DN	PRT811
DMW3MCX	MI	TTR1D7X
DMW3MCX	MN	Protein arginine methyltransferase 5 (PRMT5)
DMW3MCX	MT	DTT
DMW3MCX	MA	Inhibitor
DMW3MCX	RN	Clinical pipeline report, company report or official report of Prelude Therapeutics.
DMW3MCX	RU	https://preludetx.com/science/prmt5/prt811/

DM5KI6X	DI	DM5KI6X
DM5KI6X	DN	PRX003
DM5KI6X	MI	TTD26RC
DM5KI6X	MN	Cell adhesion molecule (CADM)
DM5KI6X	MT	DTT
DM5KI6X	MA	Inhibitor
DM5KI6X	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM5KI6X	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DM5TLAP	DI	DM5TLAP
DM5TLAP	DN	PRX-07034
DM5TLAP	MI	TTJS8PY
DM5TLAP	MN	5-HT 6 receptor (HTR6)
DM5TLAP	MT	DTT
DM5TLAP	MA	Antagonist
DM5TLAP	RN	Low-dose prazosin in combination with 5-HT6 antagonist PRX-07034 has antipsychotic effects. Can J Physiol Pharmacol. 2015 Jan;93(1):13-21.
DM5TLAP	RU	https://pubmed.ncbi.nlm.nih.gov/25429515

DMWT8RI	DI	DMWT8RI
DMWT8RI	DN	PRX-105
DMWT8RI	MI	TT1RS9F
DMWT8RI	MN	Acetylcholinesterase (AChE)
DMWT8RI	MT	DTT
DMWT8RI	MA	Inhibitor
DMWT8RI	RN	Preclinical and first-in-human evaluation of PRX-105, a PEGylated, plant-derived, recombinant human acetylcholinesterase-R. Toxicol Appl Pharmacol. 2015 Sep 15;287(3):202-9.
DMWT8RI	RU	https://pubmed.ncbi.nlm.nih.gov/26051873

DM2594H	DI	DM2594H
DM2594H	DN	PS-178990
DM2594H	MI	TTS64P2
DM2594H	MN	Androgen receptor (AR)
DM2594H	MT	DTT
DM2594H	MA	Binder
DM2594H	RN	Selective androgen receptor modulators in preclinical and clinical development. Nucl Recept Signal. 2008; 6: e010.
DM2594H	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2602589/

DM75FWO	DI	DM75FWO
DM75FWO	DN	PSI-697
DM75FWO	MI	TTE5VG0
DM75FWO	MN	P-selectin (SELP)
DM75FWO	MT	DTT
DM75FWO	MA	Inhibitor
DM75FWO	RN	Effect of PSI-697, a novel P-selectin inhibitor, on platelet-monocyte aggregate formation in humans. J Am Heart Assoc. 2013 Jan 28;2(1):e006007.
DM75FWO	RU	https://pubmed.ncbi.nlm.nih.gov/23525448

DM5ZR4Q	DI	DM5ZR4Q
DM5ZR4Q	DN	PSI-938
DM5ZR4Q	MI	TTMVBWH
DM5ZR4Q	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DM5ZR4Q	MT	DTT
DM5ZR4Q	MA	Inhibitor
DM5ZR4Q	RN	2011 Pipeline of Pharmasset.
DM5ZR4Q	RU	http://www.pharmasset.com/pipeline/default.aspx

DM8Y1M9	DI	DM8Y1M9
DM8Y1M9	DN	PSMA CAR-T cell therapy
DM8Y1M9	MI	TT9G4N0
DM8Y1M9	MN	Glutamate carboxypeptidase II (GCPII)
DM8Y1M9	MT	DTT
DM8Y1M9	RN	Clinical pipeline report, company report or official report of Tmunity.
DM8Y1M9	RU	https://www.tmunity.com/pipeline

DMRHQTU	DI	DMRHQTU
DMRHQTU	DN	PSMA subunit vaccine
DMRHQTU	MI	TT9G4N0
DMRHQTU	MN	Glutamate carboxypeptidase II (GCPII)
DMRHQTU	MT	DTT
DMRHQTU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1606).
DMRHQTU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1606

DMOYX6W	DI	DMOYX6W
DMOYX6W	DN	PSMA-targeted tubulysin B conjugates
DMOYX6W	MI	TT9G4N0
DMOYX6W	MN	Glutamate carboxypeptidase II (GCPII)
DMOYX6W	MT	DTT
DMOYX6W	MA	Modulator
DMOYX6W	RN	Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand. Mol Pharm. 2009 May-Jun;6(3):780-9.
DMOYX6W	RU	https://pubmed.ncbi.nlm.nih.gov/19361233

DM03O8T	DI	DM03O8T
DM03O8T	DN	PSMA-VRP
DM03O8T	MI	TT9G4N0
DM03O8T	MN	Glutamate carboxypeptidase II (GCPII)
DM03O8T	MT	DTT
DM03O8T	RN	A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer. Vaccine. 2013 Jan 30;31(6):943-9.
DM03O8T	RU	https://pubmed.ncbi.nlm.nih.gov/23246260

DMB6M1P	DI	DMB6M1P
DMB6M1P	DN	PT-112
DMB6M1P	MI	TT84ETX
DMB6M1P	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMB6M1P	MT	DTT
DMB6M1P	MA	Inhibitor
DMB6M1P	RN	Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity r... J Med Chem. 1996 Oct 11;39(21):4261-74.
DMB6M1P	RU	https://pubmed.ncbi.nlm.nih.gov/8863804

DMWBA1S	DI	DMWBA1S
DMWBA1S	DN	PT-302
DMWBA1S	MI	TT84ETX
DMWBA1S	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMWBA1S	MT	DTT
DMWBA1S	MA	Inhibitor
DMWBA1S	RN	Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36.
DMWBA1S	RU	https://pubmed.ncbi.nlm.nih.gov/8523406

DMQNRGE	DI	DMQNRGE
DMQNRGE	DN	PTG-100
DMQNRGE	MI	TT4BT06
DMQNRGE	MN	Integrin alpha-4 (ITGA4)
DMQNRGE	MT	DTT
DMQNRGE	MA	Antagonist
DMQNRGE	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQNRGE	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMQNRGE	DI	DMQNRGE
DMQNRGE	DN	PTG-100
DMQNRGE	MI	TTLT9XQ
DMQNRGE	MN	Integrin beta-7 (ITGB7)
DMQNRGE	MT	DTT
DMQNRGE	MA	Antagonist
DMQNRGE	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQNRGE	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMRQ5YT	DI	DMRQ5YT
DMRQ5YT	DN	PTH(7-34) liposomal cream
DMRQ5YT	MI	TTEPJL5
DMRQ5YT	MN	Parathyroid hormone receptor (PTH2R)
DMRQ5YT	MT	DTT
DMRQ5YT	MA	Modulator
DMRQ5YT	RN	Differential effects of intermittent PTH(1-34) and PTH(7-34) on bone microarchitecture and aortic calcification in experimental renal failure. Bone. 2008 Dec;43(6):1022-30.
DMRQ5YT	RU	https://pubmed.ncbi.nlm.nih.gov/18761112

DMV5X8M	DI	DMV5X8M
DMV5X8M	DN	PTI-125
DMV5X8M	MI	TTSTRZY
DMV5X8M	MN	Filamin A (FLNA)
DMV5X8M	MT	DTT
DMV5X8M	MA	Inhibitor
DMV5X8M	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMV5X8M	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMNO91Q	DI	DMNO91Q
DMNO91Q	DN	PTI-202
DMNO91Q	MI	TTN4QDT
DMNO91Q	MN	Opioid receptor (OPR)
DMNO91Q	MT	DTT
DMNO91Q	MA	Modulator
DMNO91Q	RN	Clinical pipeline report, company report or official report of Pain Therapeutics, Inc.
DMNO91Q	RU	http://www.paintrials.com/pti-202.html

DM0A6N9	DI	DM0A6N9
DM0A6N9	DN	PTI-80
DM0A6N9	MI	TTS87KH
DM0A6N9	MN	Microtubule-associated protein tau (MAPT)
DM0A6N9	MT	DTT
DM0A6N9	MA	Inhibitor
DM0A6N9	RN	Biopharmaceutical Research Companies Are Developing More Than 430 Medicines for Top Chronic Diseases Affecting Older Americans. Pharmaceutical Research and Manufacturers of America report. 2014.
DM0A6N9	RU	http://www.phrma.org/sites/default/files/pdf/2014-meds-in-dev-older-americans.pdf

DMAWO5I	DI	DMAWO5I
DMAWO5I	DN	PTX-100
DMAWO5I	MI	TT4P2VW
DMAWO5I	MN	Geranylgeranyl transferase (GGTase)
DMAWO5I	MT	DTT
DMAWO5I	MA	Inhibitor
DMAWO5I	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMAWO5I	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM38F50	DI	DM38F50
DM38F50	DN	PTX-35
DM38F50	MI	TTDV6BQ
DM38F50	MN	Tumor necrosis factor receptor member 25 (TNFRSF25)
DM38F50	MT	DTT
DM38F50	MA	Agonist
DM38F50	RN	Clinical pipeline report, company report or official report of Pelican Therapeutics.
DM38F50	RU	https://www.pelicantherapeutics.com/products

DMJO0BP	DI	DMJO0BP
DMJO0BP	DN	PU3
DMJO0BP	MI	TT78R5H
DMJO0BP	MN	Heat shock protein 90 alpha (HSP90A)
DMJO0BP	MT	DTT
DMJO0BP	MA	Inhibitor
DMJO0BP	RN	Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008 Oct;8(7):761-82.
DMJO0BP	RU	https://pubmed.ncbi.nlm.nih.gov/18855578

DMKSU35	DI	DMKSU35
DMKSU35	DN	PU-AD
DMKSU35	MI	TT78R5H
DMKSU35	MN	Heat shock protein 90 alpha (HSP90A)
DMKSU35	MT	DTT
DMKSU35	MA	Inhibitor
DMKSU35	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMKSU35	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMIYHAW	DI	DMIYHAW
DMIYHAW	DN	PU-H71
DMIYHAW	MI	TTH5YN2
DMIYHAW	MN	Heat shock protein 90 beta (HSP90B)
DMIYHAW	MT	DTT
DMIYHAW	MA	Inhibitor
DMIYHAW	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMIYHAW	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMX5LB7	DI	DMX5LB7
DMX5LB7	DN	PUR0200
DMX5LB7	MI	TTOXS3C
DMX5LB7	MN	Muscarinic acetylcholine receptor (CHRM)
DMX5LB7	MT	DTT
DMX5LB7	MA	Modulator
DMX5LB7	RN	Clinical pipeline report, company report or official report of pulmatrix pipeline.
DMX5LB7	RU	http://pulmatrix.com/pipeline.html

DMJY15D	DI	DMJY15D
DMJY15D	DN	PWT-33597
DMJY15D	MI	TTEUNMR
DMJY15D	MN	PI3-kinase alpha (PIK3CA)
DMJY15D	MT	DTT
DMJY15D	MA	Modulator
DMJY15D	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMJY15D	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMJY15D	DI	DMJY15D
DMJY15D	DN	PWT-33597
DMJY15D	MI	TTCJG29
DMJY15D	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMJY15D	MT	DTT
DMJY15D	MA	Modulator
DMJY15D	RN	PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early phase clinical trials
DMJY15D	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3537862

DMWU682	DI	DMWU682
DMWU682	DN	PX-102
DMWU682	MI	TTS4UGC
DMWU682	MN	Farnesoid X-activated receptor (FXR)
DMWU682	MT	DTT
DMWU682	MA	Agonist
DMWU682	RN	An FXR Agonist Reduces Bile Acid Synthesis Independently of Increases in FGF19 in Healthy Volunteers. Gastroenterology. 2018 Oct;155(4):1012-1016.
DMWU682	RU	https://pubmed.ncbi.nlm.nih.gov/29928896

DM4AU8K	DI	DM4AU8K
DM4AU8K	DN	PX-478
DM4AU8K	MI	TTQHWNA
DM4AU8K	MN	Hypoxia-inducible factor 1 alpha (HIF-1A)
DM4AU8K	MT	DTT
DM4AU8K	MA	Inhibitor
DM4AU8K	RN	The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Mol Cancer Ther. 2009 Apr;8(4):947-58.
DM4AU8K	RU	https://pubmed.ncbi.nlm.nih.gov/19372568

DMVQJOS	DI	DMVQJOS
DMVQJOS	DN	PXS-25
DMVQJOS	MI	TTPNE41
DMVQJOS	MN	CI Man-6-P receptor (IGF2R)
DMVQJOS	MT	DTT
DMVQJOS	MA	Inhibitor
DMVQJOS	RN	Cation-independent mannose 6-phosphate receptor inhibitor (PXS25) inhibits fibrosis in human proximal tubular cells by inhibiting conversion of latent to active TGF-beta1. Am J Physiol Renal Physiol.2011 Jul;301(1):F84-93.
DMVQJOS	RU	https://pubmed.ncbi.nlm.nih.gov/21478477

DMW7K39	DI	DMW7K39
DMW7K39	DN	Pyrotinib
DMW7K39	MI	TTG96HZ
DMW7K39	MN	EGFR messenger RNA (EGFR mRNA)
DMW7K39	MT	DTT
DMW7K39	MA	Inhibitor
DMW7K39	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMW7K39	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMRGWDB	DI	DMRGWDB
DMRGWDB	DN	PZ01 CAR-T cells
DMRGWDB	MI	TTW640A
DMRGWDB	MN	B-lymphocyte surface antigen B4 (CD19)
DMRGWDB	MT	DTT
DMRGWDB	MA	CAR-T-Cell-Therapy
DMRGWDB	RN	ClinicalTrials.gov (NCT03281551) Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma
DMRGWDB	RU	https://clinicaltrials.gov/ct2/show/NCT03281551

DMP3QSA	DI	DMP3QSA
DMP3QSA	DN	Quinazoline derivative 9
DMP3QSA	MI	TTQFRP0
DMP3QSA	MN	MEK kinase kinase 2 (MAP4K2)
DMP3QSA	MT	DTT
DMP3QSA	MA	Inhibitor
DMP3QSA	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMP3QSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMP3QSA	DI	DMP3QSA
DMP3QSA	DN	Quinazoline derivative 9
DMP3QSA	MI	TTRHJA3
DMP3QSA	MN	SPS1/STE20-related protein kinase YSK4 (YSK4)
DMP3QSA	MT	DTT
DMP3QSA	MA	Inhibitor
DMP3QSA	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMP3QSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DM64U1Y	DI	DM64U1Y
DM64U1Y	DN	R-1663
DM64U1Y	MI	TTCIHJA
DM64U1Y	MN	Coagulation factor Xa (F10)
DM64U1Y	MT	DTT
DM64U1Y	MA	Inhibitor
DM64U1Y	RN	Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7.
DM64U1Y	RU	https://pubmed.ncbi.nlm.nih.gov/22844656

DMSKHIC	DI	DMSKHIC
DMSKHIC	DN	R4996
DMSKHIC	MI	TTLA931
DMSKHIC	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMSKHIC	MT	DTT
DMSKHIC	MA	Agonist
DMSKHIC	RN	Clinical pipeline report, company report or official report of Roche (2009).
DMSKHIC	RU	http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm

DM5XCRQ	DI	DM5XCRQ
DM5XCRQ	DN	R552
DM5XCRQ	MI	TTAIQSN
DM5XCRQ	MN	Receptor-interacting protein 1 (RIPK1)
DM5XCRQ	MT	DTT
DM5XCRQ	MA	Inhibitor
DM5XCRQ	RN	Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target. Nat Rev Drug Discov. 2020 Aug;19(8):553-571.
DM5XCRQ	RU	https://pubmed.ncbi.nlm.nih.gov/32669658

DMVA186	DI	DMVA186
DMVA186	DN	R7334
DMVA186	MI	TT48I1Y
DMVA186	MN	Placenta growth factor (PlGF)
DMVA186	MT	DTT
DMVA186	RN	Clinical pipeline report, company report or official report of Roche (2009).
DMVA186	RU	http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm

DME0CJ9	DI	DME0CJ9
DME0CJ9	DN	R763
DME0CJ9	MI	TTPS3C0
DME0CJ9	MN	Aurora kinase A (AURKA)
DME0CJ9	MT	DTT
DME0CJ9	MA	Inhibitor
DME0CJ9	RN	Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen. J Cancer Res Clin Oncol. 2010 Jan;136(1):99-113.
DME0CJ9	RU	https://pubmed.ncbi.nlm.nih.gov/19609559

DME0CJ9	DI	DME0CJ9
DME0CJ9	DN	R763
DME0CJ9	MI	TT5LS6T
DME0CJ9	MN	Aurora kinase B (AURKB)
DME0CJ9	MT	DTT
DME0CJ9	MA	Inhibitor
DME0CJ9	RN	Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen. J Cancer Res Clin Oncol. 2010 Jan;136(1):99-113.
DME0CJ9	RU	https://pubmed.ncbi.nlm.nih.gov/19609559

DM1N8PZ	DI	DM1N8PZ
DM1N8PZ	DN	rAAV1.tMCK.human-alpha-sarcoglycan
DM1N8PZ	MI	TTS9Q5V
DM1N8PZ	MN	Sarcoglycan alpha (SGCA)
DM1N8PZ	MT	DTT
DM1N8PZ	MA	Modulator
DM1N8PZ	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM1N8PZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMNVDI2	DI	DMNVDI2
DMNVDI2	DN	RAD-140
DMNVDI2	MI	TTS64P2
DMNVDI2	MN	Androgen receptor (AR)
DMNVDI2	MT	DTT
DMNVDI2	MA	Modulator
DMNVDI2	RN	Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140. ACS Med Chem Lett. 2010 Dec 2;2(2):124-9.
DMNVDI2	RU	https://pubmed.ncbi.nlm.nih.gov/24900290

DMIEJ0W	DI	DMIEJ0W
DMIEJ0W	DN	Radiolabelled-huA33
DMIEJ0W	MI	TT96HUR
DMIEJ0W	MN	Cell surface A33 antigen (GPA33)
DMIEJ0W	MT	DTT
DMIEJ0W	RN	(124)I-huA33 antibody PET of colorectal cancer. J Nucl Med. 2011 Aug;52(8):1173-80.
DMIEJ0W	RU	https://pubmed.ncbi.nlm.nih.gov/21764796

DM4VTX6	DI	DM4VTX6
DM4VTX6	DN	RASV-Sp
DM4VTX6	MI	TTHI19T
DM4VTX6	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DM4VTX6	MT	DTT
DM4VTX6	RN	WO patent application no. 2010,0456,20, Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae.
DM4VTX6	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20100422&CC=WO&NR=2010045620A1&KC=A1

DMAP6CS	DI	DMAP6CS
DMAP6CS	DN	RBN-2397
DMAP6CS	MI	TT2FRAN
DMAP6CS	MN	Protein mono-ADP-ribosyltransferase TIPARP (TIPARP)
DMAP6CS	MT	DTT
DMAP6CS	MA	Inhibitor
DMAP6CS	RN	Clinical pipeline report, company report or official report of Ribon Therapeutics.
DMAP6CS	RU	https://ribontx.com/rbn-2397/

DM25GIA	DI	DM25GIA
DM25GIA	DN	REC-01
DM25GIA	MI	TTDIGC1
DM25GIA	MN	Dipeptidyl peptidase 4 (DPP-4)
DM25GIA	MT	DTT
DM25GIA	MA	Inhibitor
DM25GIA	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM25GIA	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMHT5XV	DI	DMHT5XV
DMHT5XV	DN	REC-02
DMHT5XV	MI	TT4UGTF
DMHT5XV	MN	Stromal cell-derived factor 1 (CXCL12)
DMHT5XV	MT	DTT
DMHT5XV	MA	Modulator
DMHT5XV	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMHT5XV	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMK9Y71	DI	DMK9Y71
DMK9Y71	DN	Recombinant human Erbb3 fragment therapeutic tumor vaccine
DMK9Y71	MI	TT6EO5L
DMK9Y71	MN	Erbb2 tyrosine kinase receptor (HER2)
DMK9Y71	MT	DTT
DMK9Y71	RN	Clinical pipeline report, company report or official report of Zensun.
DMK9Y71	RU	http://www.zensunusa.com/research/

DMK9Y71	DI	DMK9Y71
DMK9Y71	DN	Recombinant human Erbb3 fragment therapeutic tumor vaccine
DMK9Y71	MI	TTDC8N2
DMK9Y71	MN	Erbb3 tyrosine kinase receptor (Erbb-3)
DMK9Y71	MT	DTT
DMK9Y71	RN	Clinical pipeline report, company report or official report of Zensun.
DMK9Y71	RU	http://www.zensunusa.com/research/

DMYBELW	DI	DMYBELW
DMYBELW	DN	REGN1193
DMYBELW	MI	TT9O6WS
DMYBELW	MN	Glucagon receptor (GCGR)
DMYBELW	MT	DTT
DMYBELW	MA	Blocker
DMYBELW	RN	A first-in-human pharmacodynamic and pharmacokinetic study of a fully human anti-glucagon receptor monoclonal antibody in normal healthy volunteers. Diabetes Obes Metab. 2018 Feb;20(2):283-291.
DMYBELW	RU	https://pubmed.ncbi.nlm.nih.gov/28755409

DME3VU8	DI	DME3VU8
DME3VU8	DN	REGN1400
DME3VU8	MI	TTDC8N2
DME3VU8	MN	Erbb3 tyrosine kinase receptor (Erbb-3)
DME3VU8	MT	DTT
DME3VU8	RN	J Clin Oncol 32:5s, 2014 (suppl; abstr 2516).
DME3VU8	RU	http://meetinglibrary.asco.org/content/131992-144

DM0E3ZG	DI	DM0E3ZG
DM0E3ZG	DN	REGN3048
DM0E3ZG	MI	TTZ3COY
DM0E3ZG	MN	COVID-19 spike glycoprotein (S)
DM0E3ZG	MT	DTT
DM0E3ZG	MA	Inhibitor
DM0E3ZG	RN	Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets. Antiviral Res. 2018 Aug;156:64-71.
DM0E3ZG	RU	https://pubmed.ncbi.nlm.nih.gov/29885377

DM7LIV2	DI	DM7LIV2
DM7LIV2	DN	REGN3051
DM7LIV2	MI	TTZ3COY
DM7LIV2	MN	COVID-19 spike glycoprotein (S)
DM7LIV2	MT	DTT
DM7LIV2	MA	Inhibitor
DM7LIV2	RN	Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets. Antiviral Res. 2018 Aug;156:64-71.
DM7LIV2	RU	https://pubmed.ncbi.nlm.nih.gov/29885377

DMWJ0IH	DI	DMWJ0IH
DMWJ0IH	DN	REGN-421
DMWJ0IH	MI	TTV23LH
DMWJ0IH	MN	Delta-like protein 4 (DLL4)
DMWJ0IH	MT	DTT
DMWJ0IH	RN	J Clin Oncol 31, 2013 (suppl; abstr 2502).
DMWJ0IH	RU	http://meetinglibrary.asco.org/content/113836-132

DM3720L	DI	DM3720L
DM3720L	DN	REGN5093
DM3720L	MI	TTNDSF4
DM3720L	MN	Proto-oncogene c-Met (MET)
DM3720L	MT	DTT
DM3720L	MA	Inhibitor
DM3720L	RN	Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals.
DM3720L	RU	https://www.regeneron.com/science/pipeline

DM0ZMNI	DI	DM0ZMNI
DM0ZMNI	DN	REGN6569
DM0ZMNI	MI	TTG6LA7
DM0ZMNI	MN	Activation-inducible TNFR family receptor (TNFRSF18)
DM0ZMNI	MT	DTT
DM0ZMNI	MA	Inhibitor
DM0ZMNI	RN	Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals.
DM0ZMNI	RU	https://www.regeneron.com/science/pipeline

DMHR7D4	DI	DMHR7D4
DMHR7D4	DN	REGN-910
DMHR7D4	MI	TTKLQTJ
DMHR7D4	MN	Angiopoietin-2 (ANGPT2)
DMHR7D4	MT	DTT
DMHR7D4	RN	Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res. 2013 Jan 1;73(1):108-18.
DMHR7D4	RU	https://pubmed.ncbi.nlm.nih.gov/23149917

DMZJH23	DI	DMZJH23
DMZJH23	DN	REP8839
DMZJH23	MI	TTOJ46K
DMZJH23	MN	Streptococcus Methionyl-tRNA synthetase (Stre-coc metG)
DMZJH23	MT	DTT
DMZJH23	MA	Inhibitor
DMZJH23	RN	Antibacterial activity of REP8839, a new antibiotic for topical use. Antimicrob Agents Chemother. 2005 Oct;49(10):4247-52.
DMZJH23	RU	https://pubmed.ncbi.nlm.nih.gov/16189105

DMZ8WAQ	DI	DMZ8WAQ
DMZ8WAQ	DN	Retroviral vector-transduced autologous T cells to express CD22-specific CARs
DMZ8WAQ	MI	TTM6QSK
DMZ8WAQ	MN	B-cell receptor CD22 (CD22)
DMZ8WAQ	MT	DTT
DMZ8WAQ	MA	CAR-T-Cell-Therapy
DMZ8WAQ	RN	ClinicalTrials.gov (NCT02721407) Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients
DMZ8WAQ	RU	https://clinicaltrials.gov/ct2/show/NCT02721407

DMLHIMO	DI	DMLHIMO
DMLHIMO	DN	REV-576
DMLHIMO	MI	TTKANGO
DMLHIMO	MN	Complement C5 (CO5)
DMLHIMO	MT	DTT
DMLHIMO	MA	Inhibitor
DMLHIMO	RN	Complement C5-inhibitor rEV576 (coversin) ameliorates in-vivo effects of antiphospholipid antibodies. Lupus. 2014 Oct;23(12):1324-6.
DMLHIMO	RU	https://pubmed.ncbi.nlm.nih.gov/25228739

DM7B650	DI	DM7B650
DM7B650	DN	RG-2833
DM7B650	MI	TT6R7JZ
DM7B650	MN	Histone deacetylase 1 (HDAC1)
DM7B650	MT	DTT
DM7B650	MA	Modulator
DM7B650	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM7B650	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM8GC65	DI	DM8GC65
DM8GC65	DN	RG3039
DM8GC65	MI	TTLSW9V
DM8GC65	MN	Scavenger decapping enzyme DcpS (DCPS)
DM8GC65	MT	DTT
DM8GC65	MA	Inhibitor
DM8GC65	RN	2011 Pipeline of Repligen.
DM8GC65	RU	http://www.repligen.com/products/pipeline

DM45HT6	DI	DM45HT6
DM45HT6	DN	RG6062
DM45HT6	MI	TTUE541
DM45HT6	MN	Leukocyte surface antigen Leu-16 (CD20)
DM45HT6	MT	DTT
DM45HT6	MA	Modulator
DM45HT6	RN	Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. J Clin Oncol. 2021 Jun 20;39(18):1959-1970.
DM45HT6	RU	https://pubmed.ncbi.nlm.nih.gov/33739857

DMO9BGI	DI	DMO9BGI
DMO9BGI	DN	RG6076
DMO9BGI	MI	TTPW9LJ
DMO9BGI	MN	Co-stimulatory molecule 4-1BB (CD137)
DMO9BGI	MT	DTT
DMO9BGI	RN	Clinical pipeline report, company report or official report of Roche.
DMO9BGI	RU	https://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm

DM9QNMB	DI	DM9QNMB
DM9QNMB	DN	RG6084
DM9QNMB	MI	TTFAOU7
DM9QNMB	MN	CD274 messenger RNA (CD274 mRNA)
DM9QNMB	MT	DTT
DM9QNMB	MA	Inhibitor
DM9QNMB	RN	Clinical pipeline report, company report or official report of Roche.
DM9QNMB	RU	https://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm

DM6TLPD	DI	DM6TLPD
DM6TLPD	DN	RG6115
DM6TLPD	MI	TTRJ1K4
DM6TLPD	MN	Toll-like receptor 7 (TLR7)
DM6TLPD	MT	DTT
DM6TLPD	MA	Agonist
DM6TLPD	RN	Clinical pipeline report, company report or official report of Roche.
DM6TLPD	RU	https://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm

DMX8YO1	DI	DMX8YO1
DMX8YO1	DN	RG6125
DMX8YO1	MI	TTRGWZC
DMX8YO1	MN	Osteoblast cadherin (CDH11)
DMX8YO1	MT	DTT
DMX8YO1	MA	Inhibitor
DMX8YO1	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMX8YO1	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMJFM3O	DI	DMJFM3O
DMJFM3O	DN	RG6139
DMJFM3O	MI	TTNVXAW
DMJFM3O	MN	Lymphocyte activation gene 3 protein (LAG3)
DMJFM3O	MT	DTT
DMJFM3O	MA	Inhibitor
DMJFM3O	RN	Clinical pipeline report, company report or official report of Genentech.
DMJFM3O	RU	https://www.genentechoncology.com/pipeline-molecules/pd-1-x-lag3.html

DMJFM3O	DI	DMJFM3O
DMJFM3O	DN	RG6139
DMJFM3O	MI	TTNBFWK
DMJFM3O	MN	Programmed cell death protein 1 (PD-1)
DMJFM3O	MT	DTT
DMJFM3O	MA	Inhibitor
DMJFM3O	RN	Clinical pipeline report, company report or official report of Genentech.
DMJFM3O	RU	https://www.genentechoncology.com/pipeline-molecules/pd-1-x-lag3.html

DMIHC4R	DI	DMIHC4R
DMIHC4R	DN	RG6146
DMIHC4R	MI	TTE4BSY
DMIHC4R	MN	Bromodomain and extraterminal domain protein (BET)
DMIHC4R	MT	DTT
DMIHC4R	MA	Inhibitor
DMIHC4R	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMIHC4R	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMSM0IJ	DI	DMSM0IJ
DMSM0IJ	DN	RG6279
DMSM0IJ	MI	TTNBFWK
DMSM0IJ	MN	Programmed cell death protein 1 (PD-1)
DMSM0IJ	MT	DTT
DMSM0IJ	RN	Clinical pipeline report, company report or official report of Roche.
DMSM0IJ	RU	https://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm

DMBRYZ7	DI	DMBRYZ7
DMBRYZ7	DN	RG6292
DMBRYZ7	MI	TT10Y9E
DMBRYZ7	MN	Interleukin 2 receptor alpha (IL2RA)
DMBRYZ7	MT	DTT
DMBRYZ7	MA	Inhibitor
DMBRYZ7	RN	Clinical pipeline report, company report or official report of Roche.
DMBRYZ7	RU	https://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm

DMEFUSJ	DI	DMEFUSJ
DMEFUSJ	DN	RG6296
DMEFUSJ	MI	TTZ3P4W
DMEFUSJ	MN	B-cell maturation protein (TNFRSF17)
DMEFUSJ	MT	DTT
DMEFUSJ	MA	Inhibitor
DMEFUSJ	RN	Clinical pipeline report, company report or official report of Genentech.
DMEFUSJ	RU	https://www.genentechoncology.com/pipeline-molecules/bcma-x-cd16a.html

DMEFUSJ	DI	DMEFUSJ
DMEFUSJ	DN	RG6296
DMEFUSJ	MI	TTIFOC0
DMEFUSJ	MN	Immunoglobulin gamma Fc receptor IIIA (FCGR3A)
DMEFUSJ	MT	DTT
DMEFUSJ	MA	Inhibitor
DMEFUSJ	RN	Clinical pipeline report, company report or official report of Genentech.
DMEFUSJ	RU	https://www.genentechoncology.com/pipeline-molecules/bcma-x-cd16a.html

DMSX5NJ	DI	DMSX5NJ
DMSX5NJ	DN	RG6330
DMSX5NJ	MI	TT3LH46
DMSX5NJ	MN	KRAS G12C mutant (KRAS G12C)
DMSX5NJ	MT	DTT
DMSX5NJ	MA	Inhibitor
DMSX5NJ	RN	Clinical pipeline report, company report or official report of Roche.
DMSX5NJ	RU	https://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm

DMOWYKS	DI	DMOWYKS
DMOWYKS	DN	RG6346
DMOWYKS	MI	TTSJVOI
DMOWYKS	MN	Hepatitis B virus Large envelope protein messenger RNA (HBV S mRNA)
DMOWYKS	MT	DTT
DMOWYKS	MA	Inhibitor
DMOWYKS	RN	Clinical pipeline report, company report or official report of Dicerna Pharmaceuticals.
DMOWYKS	RU	https://dicerna.com/pipeline/rg6346/

DMMWS3O	DI	DMMWS3O
DMMWS3O	DN	RG-7010
DMMWS3O	MI	TTHRID2
DMMWS3O	MN	Insulin-like growth factor I receptor (IGF1R)
DMMWS3O	MT	DTT
DMMWS3O	MA	Modulator
DMMWS3O	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031207)
DMMWS3O	RU	http://adisinsight.springer.com/drugs/800031207

DM2IDQ9	DI	DM2IDQ9
DM2IDQ9	DN	RG-7103
DM2IDQ9	MI	TT4O5P0
DM2IDQ9	MN	Helodermin-preferring VIP receptor (VIPR2)
DM2IDQ9	MT	DTT
DM2IDQ9	MA	Agonist
DM2IDQ9	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027925)
DM2IDQ9	RU	http://adisinsight.springer.com/drugs/800027925

DM6XVCO	DI	DM6XVCO
DM6XVCO	DN	RG7116
DM6XVCO	MI	TTDC8N2
DM6XVCO	MN	Erbb3 tyrosine kinase receptor (Erbb-3)
DM6XVCO	MT	DTT
DM6XVCO	MA	Modulator
DM6XVCO	RN	RG7116, a therapeutic antibody that binds the inactive HER3 receptor and is optimized for immune effector activation. Cancer Res. 2013 Aug 15;73(16):5183-94.
DM6XVCO	RU	https://pubmed.ncbi.nlm.nih.gov/23780344

DMTWSM2	DI	DMTWSM2
DMTWSM2	DN	RG7129
DMTWSM2	MI	TT8JRS7
DMTWSM2	MN	Beta-secretase (BACE)
DMTWSM2	MT	DTT
DMTWSM2	MA	Modulator
DMTWSM2	RN	BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimers Res Ther. 2014 Dec 24;6(9):89.
DMTWSM2	RU	https://pubmed.ncbi.nlm.nih.gov/25621019

DMYX4NP	DI	DMYX4NP
DMYX4NP	DN	RG7203
DMYX4NP	MI	TTJW4LU
DMYX4NP	MN	Phosphodiesterase 10A (PDE10)
DMYX4NP	MT	DTT
DMYX4NP	MA	Inhibitor
DMYX4NP	RN	Synaptic synopsis. SciBX 6(41); doi:10.1038/scibx.2013.1153. Oct. 24, 2013
DMYX4NP	RU	http://www.nature.com/scibx/journal/v6/n41/pdf/scibx.2013.1153.pdf?WT.ec_id=SCIBX-20131024

DMGFAVQ	DI	DMGFAVQ
DMGFAVQ	DN	RG7304
DMGFAVQ	MI	TT5TURO
DMGFAVQ	MN	A-Raf messenger RNA (ARAF mRNA)
DMGFAVQ	MT	DTT
DMGFAVQ	MA	Inhibitor
DMGFAVQ	RN	Clinical pipeline report, company report or official report of Roche.
DMGFAVQ	RU	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm

DMGFAVQ	DI	DMGFAVQ
DMGFAVQ	DN	RG7304
DMGFAVQ	MI	TT0EOB8
DMGFAVQ	MN	B-Raf messenger RNA (BRAF mRNA)
DMGFAVQ	MT	DTT
DMGFAVQ	MA	Inhibitor
DMGFAVQ	RN	Clinical pipeline report, company report or official report of Roche.
DMGFAVQ	RU	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm

DMGFAVQ	DI	DMGFAVQ
DMGFAVQ	DN	RG7304
DMGFAVQ	MI	TTZCRP3
DMGFAVQ	MN	ERK activator kinase (MEK)
DMGFAVQ	MT	DTT
DMGFAVQ	MA	Modulator
DMGFAVQ	RN	Clinical pipeline report, company report or official report of Roche.
DMGFAVQ	RU	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm

DMGFAVQ	DI	DMGFAVQ
DMGFAVQ	DN	RG7304
DMGFAVQ	MI	TTROQ37
DMGFAVQ	MN	MAPK/ERK kinase kinase (MAP3K)
DMGFAVQ	MT	DTT
DMGFAVQ	MA	Inhibitor
DMGFAVQ	RN	Clinical pipeline report, company report or official report of Roche.
DMGFAVQ	RU	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm

DMGFAVQ	DI	DMGFAVQ
DMGFAVQ	DN	RG7304
DMGFAVQ	MI	TT1EDJZ
DMGFAVQ	MN	Microtubule-associated protein (MAP)
DMGFAVQ	MT	DTT
DMGFAVQ	MA	Modulator
DMGFAVQ	RN	Clinical pipeline report, company report or official report of Roche.
DMGFAVQ	RU	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm

DMGFAVQ	DI	DMGFAVQ
DMGFAVQ	DN	RG7304
DMGFAVQ	MI	TTAN5W2
DMGFAVQ	MN	Raf messenger RNA (Raf mRNA)
DMGFAVQ	MT	DTT
DMGFAVQ	MA	Modulator
DMGFAVQ	RN	Clinical pipeline report, company report or official report of Roche.
DMGFAVQ	RU	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm

DMIW5NG	DI	DMIW5NG
DMIW5NG	DN	RG7342
DMIW5NG	MI	TTHS256
DMIW5NG	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMIW5NG	MT	DTT
DMIW5NG	MA	Agonist
DMIW5NG	RN	Clinical pipeline report, company report or official report of Roche.
DMIW5NG	RU	http://www.roche.com/irp2q14e-annex.pdf

DMOE5NQ	DI	DMOE5NQ
DMOE5NQ	DN	RG7347
DMOE5NQ	MI	TTIPJCB
DMOE5NQ	MN	Neuropilin-1 (NRP1)
DMOE5NQ	MT	DTT
DMOE5NQ	MA	Modulator
DMOE5NQ	RN	Neuropilin-1 as Therapeutic Target for Malignant Melanoma. Front Oncol. 2015; 5: 125.
DMOE5NQ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453476/

DMFDKS7	DI	DMFDKS7
DMFDKS7	DN	RG-7348
DMFDKS7	MI	TTMVBWH
DMFDKS7	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMFDKS7	MT	DTT
DMFDKS7	MA	Modulator
DMFDKS7	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMFDKS7	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMFGR98	DI	DMFGR98
DMFGR98	DN	RG-7351
DMFGR98	MI	TTIU98M
DMFGR98	MN	Trace amine-associated receptor-1 (TAAR1)
DMFGR98	MT	DTT
DMFGR98	MA	Agonist
DMFGR98	RN	Clinical pipeline report, company report or official report of Roche.
DMFGR98	RU	http://www.roche.com/roche_group_pipeline_2010-02-18.pdf

DM1NHEA	DI	DM1NHEA
DM1NHEA	DN	RG7450
DM1NHEA	MI	TT9E64S
DM1NHEA	MN	Metalloreductase STEAP1 (STEAP1)
DM1NHEA	MT	DTT
DM1NHEA	MA	Modulator
DM1NHEA	RN	Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development. Mar Drugs. 2014 January; 12(1): 255-278.
DM1NHEA	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3917273/

DM5OTGR	DI	DM5OTGR
DM5OTGR	DN	RG7461
DM5OTGR	MI	TTGPQ0F
DM5OTGR	MN	Prolyl endopeptidase FAP (FAP)
DM5OTGR	MT	DTT
DM5OTGR	MA	Antagonist
DM5OTGR	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM5OTGR	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMK6P9J	DI	DMK6P9J
DMK6P9J	DN	RG7741
DMK6P9J	MI	TTTU902
DMK6P9J	MN	Checkpoint kinase-1 (CHK1)
DMK6P9J	MT	DTT
DMK6P9J	MA	Modulator
DMK6P9J	RN	National Cancer Institute Drug Dictionary (drug id 730054).
DMK6P9J	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=730054

DMXBS6U	DI	DMXBS6U
DMXBS6U	DN	RG7775
DMXBS6U	MI	TT08GJW
DMXBS6U	MN	Ubiquitin-protein ligase E3 Mdm2 (MDM2)
DMXBS6U	MT	DTT
DMXBS6U	MA	Inhibitor
DMXBS6U	RN	Phase I clinical trail of RG7775 for treating Acute myelogenous leukemia. Roche.
DMXBS6U	RU	http://www.biocentury.com/products/rg7775

DMACLIH	DI	DMACLIH
DMACLIH	DN	RG7813
DMACLIH	MI	TTY6DTE
DMACLIH	MN	Carcinoembryonic antigen CEA (CD66e)
DMACLIH	MT	DTT
DMACLIH	MA	Inhibitor
DMACLIH	RN	Clinical pipeline report, company report or official report of Roche.
DMACLIH	RU	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm

DMD16JK	DI	DMD16JK
DMD16JK	DN	RG-7816
DMD16JK	MI	TTNZPQ1
DMD16JK	MN	GABA(A) receptor alpha-5 (GABRA5)
DMD16JK	MT	DTT
DMD16JK	MA	Modulator
DMD16JK	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMD16JK	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMRGHKN	DI	DMRGHKN
DMRGHKN	DN	RG7827
DMRGHKN	MI	TTPW9LJ
DMRGHKN	MN	Co-stimulatory molecule 4-1BB (CD137)
DMRGHKN	MT	DTT
DMRGHKN	MA	Agonist
DMRGHKN	RN	Clinical pipeline report, company report or official report of Roche.
DMRGHKN	RU	https://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm

DMCUBZO	DI	DMCUBZO
DMCUBZO	DN	RG7828
DMCUBZO	MI	TTUE541
DMCUBZO	MN	Leukocyte surface antigen Leu-16 (CD20)
DMCUBZO	MT	DTT
DMCUBZO	MA	Stimulator
DMCUBZO	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMCUBZO	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMGLXQ9	DI	DMGLXQ9
DMGLXQ9	DN	RG7854
DMGLXQ9	MI	TTRJ1K4
DMGLXQ9	MN	Toll-like receptor 7 (TLR7)
DMGLXQ9	MT	DTT
DMGLXQ9	MA	Agonist
DMGLXQ9	RN	Clinical pipeline report, company report or official report of Roche.
DMGLXQ9	RU	https://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm

DM2E5Z7	DI	DM2E5Z7
DM2E5Z7	DN	RG7882
DM2E5Z7	MI	TT4RXME
DM2E5Z7	MN	Mesothelin (MSLN)
DM2E5Z7	MT	DTT
DM2E5Z7	RN	Molecular Imaging As a Tool for Drug Development and Trial Design. JCO July 13, 2015 JCO.2015.61.6425
DM2E5Z7	RU	http://jco.ascopubs.org/content/early/2015/07/08/JCO.2015.61.6425.full

DM1R4MQ	DI	DM1R4MQ
DM1R4MQ	DN	RG7893
DM1R4MQ	MI	TT4G2JS
DM1R4MQ	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DM1R4MQ	MT	DTT
DM1R4MQ	MA	Inhibitor
DM1R4MQ	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800041740)
DM1R4MQ	RU	http://adisinsight.springer.com/drugs/800041740

DMKVIS5	DI	DMKVIS5
DMKVIS5	DN	RG7907
DMKVIS5	MI	TTM42UJ
DMKVIS5	MN	Hepatitis B virus Capsid protein (HBV C)
DMKVIS5	MT	DTT
DMKVIS5	MA	Inhibitor
DMKVIS5	RN	Clinical pipeline report, company report or official report of Roche.
DMKVIS5	RU	https://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm

DMEGOQP	DI	DMEGOQP
DMEGOQP	DN	RGB-286638
DMEGOQP	MI	TTH6V3D
DMEGOQP	MN	Cyclin-dependent kinase 1 (CDK1)
DMEGOQP	MT	DTT
DMEGOQP	MA	Inhibitor
DMEGOQP	RN	Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75.
DMEGOQP	RU	https://pubmed.ncbi.nlm.nih.gov/23807770

DMEGOQP	DI	DMEGOQP
DMEGOQP	DN	RGB-286638
DMEGOQP	MI	TT7HF4W
DMEGOQP	MN	Cyclin-dependent kinase 2 (CDK2)
DMEGOQP	MT	DTT
DMEGOQP	MA	Inhibitor
DMEGOQP	RN	Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75.
DMEGOQP	RU	https://pubmed.ncbi.nlm.nih.gov/23807770

DMEGOQP	DI	DMEGOQP
DMEGOQP	DN	RGB-286638
DMEGOQP	MI	TTMYWL7
DMEGOQP	MN	Cyclin-dependent kinase 3 (CDK3)
DMEGOQP	MT	DTT
DMEGOQP	MA	Inhibitor
DMEGOQP	RN	Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75.
DMEGOQP	RU	https://pubmed.ncbi.nlm.nih.gov/23807770

DMEGOQP	DI	DMEGOQP
DMEGOQP	DN	RGB-286638
DMEGOQP	MI	TT0PG8F
DMEGOQP	MN	Cyclin-dependent kinase 4 (CDK4)
DMEGOQP	MT	DTT
DMEGOQP	MA	Inhibitor
DMEGOQP	RN	Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154.
DMEGOQP	RU	https://pubmed.ncbi.nlm.nih.gov/21253554

DMEGOQP	DI	DMEGOQP
DMEGOQP	DN	RGB-286638
DMEGOQP	MI	TT1LVF2
DMEGOQP	MN	Cyclin-dependent kinase 9 (CDK9)
DMEGOQP	MT	DTT
DMEGOQP	MA	Inhibitor
DMEGOQP	RN	Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75.
DMEGOQP	RU	https://pubmed.ncbi.nlm.nih.gov/23807770

DMVJMF1	DI	DMVJMF1
DMVJMF1	DN	RGD-891
DMVJMF1	MI	TT38RM1
DMVJMF1	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DMVJMF1	MT	DTT
DMVJMF1	MA	Modulator
DMVJMF1	RN	Pharmacokinetics, pharmacodynamics, and safety of a platelet GPIIb/IIIa antagonist, RGD891, following intravenous administration in healthy male volunteers. J Clin Pharmacol. 2000 Nov;40(11):1245-56.
DMVJMF1	RU	https://pubmed.ncbi.nlm.nih.gov/11075310

DMQAIU1	DI	DMQAIU1
DMQAIU1	DN	RGLS4326
DMQAIU1	MI	TTMGJ19
DMQAIU1	MN	microRNA hsa-miR-17 (MIR17)
DMQAIU1	MT	DTT
DMQAIU1	MA	Inhibitor
DMQAIU1	RN	Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease. Nat Commun. 2019 Sep 12;10(1):4148.
DMQAIU1	RU	https://pubmed.ncbi.nlm.nih.gov/31515477

DMU87HW	DI	DMU87HW
DMU87HW	DN	RGX-111
DMU87HW	MI	TT0IUKX
DMU87HW	MN	Alpha-L-iduronidase (IDUA)
DMU87HW	MT	DTT
DMU87HW	MA	Replacement
DMU87HW	RN	Clinical pipeline report, company report or official report of REGENXBIO.
DMU87HW	RU	https://regenxbio.com/rgx-111/

DM8VGRX	DI	DM8VGRX
DM8VGRX	DN	RGX-202
DM8VGRX	MI	TTYUHB5
DM8VGRX	MN	Solute carrier family 6 member 8 (SLC6A8)
DM8VGRX	MT	DTT
DM8VGRX	MA	Inhibitor
DM8VGRX	RN	Clinical pipeline report, company report or official report of Rgenix.
DM8VGRX	RU	https://rgenix.com/rgx-202/

DMDM85L	DI	DMDM85L
DMDM85L	DN	RH 1
DMDM85L	MI	TTUTN1I
DMDM85L	MN	Human Deoxyribonucleic acid (hDNA)
DMDM85L	MT	DTT
DMDM85L	MA	Modulator
DMDM85L	RN	Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent RH1
DMDM85L	RU	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2612562

DM1HUA3	DI	DM1HUA3
DM1HUA3	DN	RHIgM12B7
DM1HUA3	MI	TTYOVWN
DM1HUA3	MN	Programmed cell death protein 2 (PD-2)
DM1HUA3	MT	DTT
DM1HUA3	RN	National Cancer Institute Drug Dictionary (drug id 593681).
DM1HUA3	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=593681

DM2A1DP	DI	DM2A1DP
DM2A1DP	DN	Ribavirin
DM2A1DP	MI	TT3GRLK
DM2A1DP	MN	HUMAN inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DM2A1DP	MT	DTT
DM2A1DP	MA	Inhibitor
DM2A1DP	RN	Proteomics of SARS-CoV-2-infected Host Cells Reveals Therapy Targets. Nature. 2020 May 14.  doi: 10.1038/s41586-020-2332-7.
DM2A1DP	RU	https://pubmed.ncbi.nlm.nih.gov/32408336

DM2A1DP	DI	DM2A1DP
DM2A1DP	DN	Ribavirin
DM2A1DP	MI	TTTU6X1
DM2A1DP	MN	HUMAN inosine-5'-monophosphate dehydrogenase 2 (IMPDH2)
DM2A1DP	MT	DTT
DM2A1DP	MA	Inhibitor
DM2A1DP	RN	Proteomics of SARS-CoV-2-infected Host Cells Reveals Therapy Targets. Nature. 2020 May 14.  doi: 10.1038/s41586-020-2332-7.
DM2A1DP	RU	https://pubmed.ncbi.nlm.nih.gov/32408336

DM2A1DP	DI	DM2A1DP
DM2A1DP	DN	Ribavirin
DM2A1DP	MI	TTOA6YT
DM2A1DP	MN	MERS-CoV RNA-directed RNA polymerase (RdRp)
DM2A1DP	MT	DTT
DM2A1DP	MA	Inhibitor
DM2A1DP	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DM2A1DP	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DM2A1DP	DI	DM2A1DP
DM2A1DP	DN	Ribavirin
DM2A1DP	MI	TTKXI53
DM2A1DP	MN	SARS-CoV RNA-directed RNA polymerase (RdRp)
DM2A1DP	MT	DTT
DM2A1DP	MA	Inhibitor
DM2A1DP	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DM2A1DP	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DMB9861	DI	DMB9861
DMB9861	DN	Rilapladib
DMB9861	MI	TT9V5JH
DMB9861	MN	Phospholipase A2 (PLA2G1B)
DMB9861	MT	DTT
DMB9861	MA	Modulator
DMB9861	RN	Effect of treatment for 12 weeks with rilapladib, a lipoprotein-associated phospholipase A2 inhibitor, on arterial inflammation as assessed with 18F-fluorodeoxyglucose-positron emission tomography imaging.J Am Coll Cardiol.2014 Jan 7-14;63(1):86-8.
DMB9861	RU	https://www.ncbi.nlm.nih.gov/pubmed/23973698

DMB9861	DI	DMB9861
DMB9861	DN	Rilapladib
DMB9861	MI	TTDNFMT
DMB9861	MN	Platelet-activating factor acetylhydrolase (PLA2G7)
DMB9861	MT	DTT
DMB9861	MA	Inhibitor
DMB9861	RN	Phospholipase A2 inhibitors. Curr Opin Lipidol. 2009 Aug;20(4):327-32.
DMB9861	RU	https://pubmed.ncbi.nlm.nih.gov/19550325

DMB9861	DI	DMB9861
DMB9861	DN	Rilapladib
DMB9861	MI	TTP3QRF
DMB9861	MN	Thymidine kinase 1 (TK1)
DMB9861	MT	DTT
DMB9861	MA	Inhibitor
DMB9861	RN	Trichomonas vaginalis thymidine kinase: purification, characterization and search for inhibitors. Biochem J. 1998 Aug 15;334 ( Pt 1):15-22.
DMB9861	RU	https://pubmed.ncbi.nlm.nih.gov/9693096

DMUT4YZ	DI	DMUT4YZ
DMUT4YZ	DN	RLY-1971
DMUT4YZ	MI	TT7WUAV
DMUT4YZ	MN	Protein-tyrosine phosphatase SHP-2 (PTPN11)
DMUT4YZ	MT	DTT
DMUT4YZ	MA	Inhibitor
DMUT4YZ	RN	Clinical pipeline report, company report or official report of Relay Therapeutics.
DMUT4YZ	RU	https://relaytx.com/pipeline/

DM3O52N	DI	DM3O52N
DM3O52N	DN	RLY-4008
DM3O52N	MI	TTGJVQM
DM3O52N	MN	Fibroblast growth factor receptor 2 (FGFR2)
DM3O52N	MT	DTT
DM3O52N	MA	Inhibitor
DM3O52N	RN	Clinical pipeline report, company report or official report of Relay Therapeutics.
DM3O52N	RU	https://relaytx.com/pipeline/

DMQ65YW	DI	DMQ65YW
DMQ65YW	DN	RO-09-4889
DMQ65YW	MI	TTZPS91
DMQ65YW	MN	Dihydrothymine dehydrogenase (DPYD)
DMQ65YW	MT	DTT
DMQ65YW	MA	Modulator
DMQ65YW	RN	Single ascending dose tolerability, pharmacokinetic-pharmacodynamic study of dihydropyrimidine dehydrogenase inhibitor Ro 09-4889. Clin Cancer Res. 2004 Apr 1;10(7):2327-35.
DMQ65YW	RU	https://pubmed.ncbi.nlm.nih.gov/15073108

DM95F8B	DI	DM95F8B
DM95F8B	DN	RO-14
DM95F8B	MI	TT4QPUL
DM95F8B	MN	Antithrombin-III (ATIII)
DM95F8B	MT	DTT
DM95F8B	MA	Modulator
DM95F8B	RN	Pharmacological effects and clinical applications of ultra low molecular weight heparins. Drug Discov Ther. 2014 Feb;8(1):1-10.
DM95F8B	RU	https://pubmed.ncbi.nlm.nih.gov/24647152

DM9PQ2N	DI	DM9PQ2N
DM9PQ2N	DN	RO-23-7553
DM9PQ2N	MI	TTK59TV
DM9PQ2N	MN	Vitamin D3 receptor (VDR)
DM9PQ2N	MT	DTT
DM9PQ2N	MA	Agonist
DM9PQ2N	RN	Three synthetic vitamin D analogues induce prostate-specific acid phosphatase and prostate-specific antigen while inhibiting the growth of human prostate cancer cells in a vitamin D receptor-dependent fashion. Clin Cancer Res. 1997 Aug;3(8):1331-8.
DM9PQ2N	RU	https://pubmed.ncbi.nlm.nih.gov/9815816

DML4C3Q	DI	DML4C3Q
DML4C3Q	DN	RO-5212054
DML4C3Q	MI	TTWCGQT
DML4C3Q	MN	Serine/threonine-protein kinase B-raf (BRAF)
DML4C3Q	MT	DTT
DML4C3Q	MA	Inhibitor
DML4C3Q	RN	National Cancer Institute Drug Dictionary (drug id 680347).
DML4C3Q	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=680347

DMVXQ5W	DI	DMVXQ5W
DMVXQ5W	DN	RO-5458640
DMVXQ5W	MI	TTBTDM1
DMVXQ5W	MN	TNF-related weak inducer of apoptosis (TWEAK)
DMVXQ5W	MT	DTT
DMVXQ5W	MA	Modulator
DMVXQ5W	RN	A novel llama antibody targeting Fn14 exhibits anti-metastatic activity in vivo. MAbs. 2014 January 1; 6(1): 297-308.
DMVXQ5W	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3929451/

DM7H6XI	DI	DM7H6XI
DM7H6XI	DN	RO6870810
DM7H6XI	MI	TTE4BSY
DM7H6XI	MN	Bromodomain and extraterminal domain protein (BET)
DM7H6XI	MT	DTT
DM7H6XI	MA	Inhibitor
DM7H6XI	RN	A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma. Br J Cancer. 2021 Feb;124(4):744-753.
DM7H6XI	RU	https://pubmed.ncbi.nlm.nih.gov/33311588

DMDRBNJ	DI	DMDRBNJ
DMDRBNJ	DN	ROCICLOVIR
DMDRBNJ	MI	TTIU7X1
DMDRBNJ	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMDRBNJ	MT	DTT
DMDRBNJ	MA	Modulator
DMDRBNJ	RN	Herpes simplex virus type 1 DNA polymerase. Mechanism of inhibition by acyclovir triphosphate. J Biol Chem. 1989 May 5;264(13):7405-11.
DMDRBNJ	RU	https://pubmed.ncbi.nlm.nih.gov/2540193

DM82KWY	DI	DM82KWY
DM82KWY	DN	Ronomilast
DM82KWY	MI	TTZ97H5
DM82KWY	MN	Phosphodiesterase 4A (PDE4A)
DM82KWY	MT	DTT
DM82KWY	MA	Inhibitor
DM82KWY	RN	Clinical pipeline report, company report or official report of Avarx.
DM82KWY	RU	http://www.avarx.com/AvaRx/SubDomains/bucket3609200049721832467/Listings/bucket3113046654580504235/Public.Listing.display.html

DM82KWY	DI	DM82KWY
DM82KWY	DN	Ronomilast
DM82KWY	MI	TTVIAT9
DM82KWY	MN	Phosphodiesterase 4B (PDE4B)
DM82KWY	MT	DTT
DM82KWY	MA	Inhibitor
DM82KWY	RN	Clinical pipeline report, company report or official report of Avarx.
DM82KWY	RU	http://www.avarx.com/AvaRx/SubDomains/bucket3609200049721832467/Listings/bucket3113046654580504235/Public.Listing.display.html

DM82KWY	DI	DM82KWY
DM82KWY	DN	Ronomilast
DM82KWY	MI	TTSKMI8
DM82KWY	MN	Phosphodiesterase 4D (PDE4D)
DM82KWY	MT	DTT
DM82KWY	MA	Inhibitor
DM82KWY	RN	Clinical pipeline report, company report or official report of Avarx.
DM82KWY	RU	http://www.avarx.com/AvaRx/SubDomains/bucket3609200049721832467/Listings/bucket3113046654580504235/Public.Listing.display.html

DM5EUIY	DI	DM5EUIY
DM5EUIY	DN	ROR1 CAR-specific Autologous T-Lymphocytes
DM5EUIY	MI	TTDEJAU
DM5EUIY	MN	Neurotrophic tyrosine kinase ROR1 (ROR1)
DM5EUIY	MT	DTT
DM5EUIY	MA	CAR-T-Cell-Therapy
DM5EUIY	RN	ClinicalTrials.gov (NCT02706392) Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
DM5EUIY	RU	https://clinicaltrials.gov/ct2/show/NCT02706392

DMIAK9P	DI	DMIAK9P
DMIAK9P	DN	ROR1R-CAR-T Cell
DMIAK9P	MI	TTDEJAU
DMIAK9P	MN	Neurotrophic tyrosine kinase ROR1 (ROR1)
DMIAK9P	MT	DTT
DMIAK9P	MA	CAR-T-Cell-Therapy
DMIAK9P	RN	ClinicalTrials.gov (NCT02194374) Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)
DMIAK9P	RU	https://clinicaltrials.gov/ct2/show/NCT02194374

DM9O3RY	DI	DM9O3RY
DM9O3RY	DN	Rosmantuzumab
DM9O3RY	MI	TT7HJTF
DM9O3RY	MN	R-spondin-3 (RSPO3)
DM9O3RY	MT	DTT
DM9O3RY	MA	Inhibitor
DM9O3RY	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9O3RY	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DME9UTO	DI	DME9UTO
DME9UTO	DN	RP4010
DME9UTO	MI	TTE76YK
DME9UTO	MN	Calcium-release activated calcium channel (CRACM)
DME9UTO	MT	DTT
DME9UTO	MA	Inhibitor
DME9UTO	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DME9UTO	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMHZ24N	DI	DMHZ24N
DMHZ24N	DN	RP-A501
DMHZ24N	MI	TTULDG7
DMHZ24N	MN	Lysosome-associated membrane glycoprotein 2 (LAMP2)
DMHZ24N	MT	DTT
DMHZ24N	MA	Replacement
DMHZ24N	RN	ClinicalTrials.gov (NCT03882437) Gene Therapy for Male Patients With Danon Disease (DD) Using RP-A501; AAV9.LAMP2B. U.S. National Institutes of Health.
DMHZ24N	RU	https://clinicaltrials.gov/ct2/show/NCT03882437

DMXKFOQ	DI	DMXKFOQ
DMXKFOQ	DN	RPI-78M
DMXKFOQ	MI	TTJSZTB
DMXKFOQ	MN	Nicotinic acetylcholine receptor (nAChR)
DMXKFOQ	MT	DTT
DMXKFOQ	MA	Antagonist
DMXKFOQ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMXKFOQ	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DM5OXPZ	DI	DM5OXPZ
DM5OXPZ	DN	RPI-MN
DM5OXPZ	MI	TTJSZTB
DM5OXPZ	MN	Nicotinic acetylcholine receptor (nAChR)
DM5OXPZ	MT	DTT
DM5OXPZ	MA	Antagonist
DM5OXPZ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM5OXPZ	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMA6JME	DI	DMA6JME
DMA6JME	DN	RTA 901
DMA6JME	MI	TTO7FVG
DMA6JME	MN	Heat shock protein 90 (HSP90)
DMA6JME	MT	DTT
DMA6JME	MA	Inhibitor
DMA6JME	RN	Clinical pipeline report, company report or official report of Reata Pharmaceuticals.
DMA6JME	RU	https://www.reatapharma.com/our-science/default.aspx

DM7C062	DI	DM7C062
DM7C062	DN	RTA-901
DM7C062	MI	TT78R5H
DM7C062	MN	Heat shock protein 90 alpha (HSP90A)
DM7C062	MT	DTT
DM7C062	MA	Modulator
DM7C062	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7C062	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMY8D5O	DI	DMY8D5O
DMY8D5O	DN	RTI-336
DMY8D5O	MI	TTVBI8W
DMY8D5O	MN	Dopamine transporter (DAT)
DMY8D5O	MT	DTT
DMY8D5O	MA	Modulator
DMY8D5O	RN	Development of the dopamine transporter selective RTI-336 as a pharmacotherapy for cocaine abuse.AAPS J.2006 Mar 24;8(1):E196-203.
DMY8D5O	RU	https://www.ncbi.nlm.nih.gov/pubmed/16584128

DM1B4CQ	DI	DM1B4CQ
DM1B4CQ	DN	RTL-1000
DM1B4CQ	MI	TTXQYT6
DM1B4CQ	MN	T-cells (T-cells)
DM1B4CQ	MT	DTT
DM1B4CQ	MA	Binder
DM1B4CQ	RN	RTL THERAPY FOR MULTIPLE SCLEROSIS: A Phase I Clinical Study. J Neuroimmunol. 2011 February; 231(1-2): 7-14.
DM1B4CQ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3026883/

DMYRPC8	DI	DMYRPC8
DMYRPC8	DN	RVSVIN HIV-1 gag vaccine
DMYRPC8	MI	TTFGZB6
DMYRPC8	MN	Human immunodeficiency virus GAG protein (HIV gag)
DMYRPC8	MT	DTT
DMYRPC8	RN	Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis. 2011 Nov;204 Suppl 3:S1075-81.
DMYRPC8	RU	https://pubmed.ncbi.nlm.nih.gov/21987744

DM0YCG3	DI	DM0YCG3
DM0YCG3	DN	RVT-103+RVT-104
DM0YCG3	MI	TTEB0GD
DM0YCG3	MN	Cholinesterase (BCHE)
DM0YCG3	MT	DTT
DM0YCG3	MA	Inhibitor
DM0YCG3	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM0YCG3	RU	http://phrma-docs.phrma.org/files/dmfile/MID-Update_Alzheimers-Disease_2017-Drug-List.pdf

DMJVCS1	DI	DMJVCS1
DMJVCS1	DN	RWJ-671818
DMJVCS1	MI	TT6L509
DMJVCS1	MN	Coagulation factor IIa (F2)
DMJVCS1	MT	DTT
DMJVCS1	MA	Modulator
DMJVCS1	RN	Discovery and clinical evaluation of 1-{N-[2-(amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RW... J Med Chem. 2010 Feb 25;53(4):1843-56.
DMJVCS1	RU	https://pubmed.ncbi.nlm.nih.gov/20102150

DM6YAGE	DI	DM6YAGE
DM6YAGE	DN	RWJ-67657
DM6YAGE	MI	TTVKILB
DM6YAGE	MN	Prostaglandin G/H synthase 2 (COX-2)
DM6YAGE	MT	DTT
DM6YAGE	MA	Inhibitor
DM6YAGE	RN	Monocyte intracellular cytokine production during human endotoxaemia with or without a second in vitro LPS challenge: effect of RWJ-67657, a p38 MAP-kinase inhibitor, on LPS-hyporesponsiveness. Clin Exp Immunol. 2002 Feb;127(2):337-43.
DM6YAGE	RU	https://pubmed.ncbi.nlm.nih.gov/11876759

DM4O07Q	DI	DM4O07Q
DM4O07Q	DN	RWJ-68023
DM4O07Q	MI	TT953CX
DM4O07Q	MN	Motilin receptor (MLNR)
DM4O07Q	MT	DTT
DM4O07Q	MA	Antagonist
DM4O07Q	RN	Effects of a nonpeptide motilin receptor antagonist on proximal gastric motor function. Br J Clin Pharmacol. 2004 Apr;57(4):393-401.
DM4O07Q	RU	https://pubmed.ncbi.nlm.nih.gov/15025736

DM4XETK	DI	DM4XETK
DM4XETK	DN	RX108
DM4XETK	MI	TTQ38E9
DM4XETK	MN	Sodium/potassium-transporting ATPase (SPT ATPase)
DM4XETK	MT	DTT
DM4XETK	MA	Inhibitor
DM4XETK	RN	ClinicalTrials.gov (NCT03646071) A Study of RX108 in Patients With Locally Advanced or Metastatic Solid Tumors. U.S. National Institutes of Health.
DM4XETK	RU	https://clinicaltrials.gov/ct2/show/NCT03646071

DM6NVTR	DI	DM6NVTR
DM6NVTR	DN	RXDX-106
DM6NVTR	MI	TTNDSF4
DM6NVTR	MN	Proto-oncogene c-Met (MET)
DM6NVTR	MT	DTT
DM6NVTR	MA	Inhibitor
DM6NVTR	RN	National Cancer Institute Drug Dictionary (drug name RXDX106).
DM6NVTR	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tam-c-met-inhibitor-rxdx-106

DM6NVTR	DI	DM6NVTR
DM6NVTR	DN	RXDX-106
DM6NVTR	MI	TTIEMFN
DM6NVTR	MN	TYRO3 tyrosine kinase receptor (TYRO3)
DM6NVTR	MT	DTT
DM6NVTR	MA	Inhibitor
DM6NVTR	RN	National Cancer Institute Drug Dictionary (drug name RXDX106).
DM6NVTR	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tam-c-met-inhibitor-rxdx-106

DM6NVTR	DI	DM6NVTR
DM6NVTR	DN	RXDX-106
DM6NVTR	MI	TTO7LKR
DM6NVTR	MN	Tyrosine-protein kinase Mer (MERTK)
DM6NVTR	MT	DTT
DM6NVTR	MA	Inhibitor
DM6NVTR	RN	National Cancer Institute Drug Dictionary (drug name RXDX106).
DM6NVTR	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tam-c-met-inhibitor-rxdx-106

DM6NVTR	DI	DM6NVTR
DM6NVTR	DN	RXDX-106
DM6NVTR	MI	TTZPY6J
DM6NVTR	MN	Tyrosine-protein kinase UFO (AXL)
DM6NVTR	MT	DTT
DM6NVTR	MA	Inhibitor
DM6NVTR	RN	National Cancer Institute Drug Dictionary (drug name RXDX106).
DM6NVTR	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tam-c-met-inhibitor-rxdx-106

DMYR1K8	DI	DMYR1K8
DMYR1K8	DN	S-17092-1
DMYR1K8	MI	TTNGKET
DMYR1K8	MN	Prolyl endopeptidase (PREP)
DMYR1K8	MT	DTT
DMYR1K8	MA	Inhibitor
DMYR1K8	RN	Effect of S 17092, a novel prolyl endopeptidase inhibitor, on substance P and alpha-melanocyte-stimulating hormone breakdown in the rat brain. J Neurochem. 2003 Mar;84(5):919-29.
DMYR1K8	RU	https://pubmed.ncbi.nlm.nih.gov/12603817

DMDQRWT	DI	DMDQRWT
DMDQRWT	DN	S-265744 LAP
DMDQRWT	MI	TT5FH9Y
DMDQRWT	MN	Human immunodeficiency virus Integrase (HIV IN)
DMDQRWT	MT	DTT
DMDQRWT	MA	Inhibitor
DMDQRWT	RN	Long-acting shot prevents infection with HIV analogue. Nature. doi:10.1038/nature.2014.14819. 04 March 2014
DMDQRWT	RU	http://www.nature.com/news/long-acting-shot-prevents-infection-with-hiv-analogue-1.14819

DM6XZRL	DI	DM6XZRL
DM6XZRL	DN	SA-5845
DM6XZRL	MI	TT5TPI6
DM6XZRL	MN	Opioid receptor sigma 1 (OPRS1)
DM6XZRL	MT	DTT
DM6XZRL	MA	Binder
DM6XZRL	RN	Tumor imaging with 2 sigma-receptor ligands, 18F-FE-SA5845 and 11C-SA4503: a feasibility study. J Nucl Med. 2004 Nov;45(11):1939-45.
DM6XZRL	RU	https://pubmed.ncbi.nlm.nih.gov/15534066

DMBGUDR	DI	DMBGUDR
DMBGUDR	DN	Safingol
DMBGUDR	MI	DE4LYSA
DMBGUDR	MN	Cytochrome P450 3A4 (CYP3A4)
DMBGUDR	MT	DME
DMBGUDR	MA	Metabolism
DMBGUDR	RN	Sex differences in rat hepatic cytolethality of the protein kinase C inhibitor safingol: role of biotransformation. Toxicol Appl Pharmacol. 1996 Apr;137(2):173-81.
DMBGUDR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8661342

DMBGUDR	DI	DMBGUDR
DMBGUDR	DN	Safingol
DMBGUDR	MI	TTYVX59
DMBGUDR	MN	Protein kinase C (PRKC)
DMBGUDR	MT	DTT
DMBGUDR	MA	Inhibitor
DMBGUDR	RN	The role of protein kinase C in the synergistic interaction of safingol and irinotecan in colon cancer cells. Int J Oncol. 2009 Dec;35(6):1463-71.
DMBGUDR	RU	https://pubmed.ncbi.nlm.nih.gov/19885570

DM1UIQP	DI	DM1UIQP
DM1UIQP	DN	SAFIRONIL
DM1UIQP	MI	TTNH25W
DM1UIQP	MN	Prolyl 4-hydroxylasesubunit alpha-1 (P4HA1)
DM1UIQP	MT	DTT
DM1UIQP	MA	Modulator
DM1UIQP	RN	Antifibrogenic therapies in chronic HCV infection. Curr Drug Targets Infect Disord. 2001 Aug;1(2):227-40.
DM1UIQP	RU	https://pubmed.ncbi.nlm.nih.gov/12455417

DMJ3HQY	DI	DMJ3HQY
DMJ3HQY	DN	Salvinorin A
DMJ3HQY	MI	DE6OQ3W
DMJ3HQY	MN	Cytochrome P450 1A1 (CYP1A1)
DMJ3HQY	MT	DME
DMJ3HQY	MA	Metabolism
DMJ3HQY	RN	Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen. Eur J Pharm Biopharm. 2009 Jun;72(2):471-7.
DMJ3HQY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19462483

DMJ3HQY	DI	DMJ3HQY
DMJ3HQY	DN	Salvinorin A
DMJ3HQY	MI	DEZMWRE
DMJ3HQY	MN	Cytochrome P450 2C18 (CYP2C18)
DMJ3HQY	MT	DME
DMJ3HQY	MA	Metabolism
DMJ3HQY	RN	Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen. Eur J Pharm Biopharm. 2009 Jun;72(2):471-7.
DMJ3HQY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19462483

DMJ3HQY	DI	DMJ3HQY
DMJ3HQY	DN	Salvinorin A
DMJ3HQY	MI	DECB0K3
DMJ3HQY	MN	Cytochrome P450 2D6 (CYP2D6)
DMJ3HQY	MT	DME
DMJ3HQY	MA	Metabolism
DMJ3HQY	RN	Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen. Eur J Pharm Biopharm. 2009 Jun;72(2):471-7.
DMJ3HQY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19462483

DMJ3HQY	DI	DMJ3HQY
DMJ3HQY	DN	Salvinorin A
DMJ3HQY	MI	DEVDYN7
DMJ3HQY	MN	Cytochrome P450 2E1 (CYP2E1)
DMJ3HQY	MT	DME
DMJ3HQY	MA	Metabolism
DMJ3HQY	RN	Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen. Eur J Pharm Biopharm. 2009 Jun;72(2):471-7.
DMJ3HQY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19462483

DMJ3HQY	DI	DMJ3HQY
DMJ3HQY	DN	Salvinorin A
DMJ3HQY	MI	TT27RFC
DMJ3HQY	MN	Opioid receptor delta (OPRD1)
DMJ3HQY	MT	DTT
DMJ3HQY	MA	Inhibitor
DMJ3HQY	RN	Herkinorin analogues with differential beta-arrestin-2 interactions. J Med Chem. 2008 Apr 24;51(8):2421-31.
DMJ3HQY	RU	https://pubmed.ncbi.nlm.nih.gov/18380425

DMJ3HQY	DI	DMJ3HQY
DMJ3HQY	DN	Salvinorin A
DMJ3HQY	MI	TTQW87Y
DMJ3HQY	MN	Opioid receptor kappa (OPRK1)
DMJ3HQY	MT	DTT
DMJ3HQY	MA	Inhibitor
DMJ3HQY	RN	Toward a structure-based model of salvinorin A recognition of the kappa-opioid receptor. J Med Chem. 2008 Mar 27;51(6):1824-30.
DMJ3HQY	RU	https://pubmed.ncbi.nlm.nih.gov/18293909

DMJ3HQY	DI	DMJ3HQY
DMJ3HQY	DN	Salvinorin A
DMJ3HQY	MI	TTKWM86
DMJ3HQY	MN	Opioid receptor mu (MOP)
DMJ3HQY	MT	DTT
DMJ3HQY	MA	Inhibitor
DMJ3HQY	RN	Herkinorin analogues with differential beta-arrestin-2 interactions. J Med Chem. 2008 Apr 24;51(8):2421-31.
DMJ3HQY	RU	https://pubmed.ncbi.nlm.nih.gov/18380425

DMJ3HQY	DI	DMJ3HQY
DMJ3HQY	DN	Salvinorin A
DMJ3HQY	MI	DEB3CV1
DMJ3HQY	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMJ3HQY	MT	DME
DMJ3HQY	MA	Metabolism
DMJ3HQY	RN	Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen. Eur J Pharm Biopharm. 2009 Jun;72(2):471-7.
DMJ3HQY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19462483

DMDHQYA	DI	DMDHQYA
DMDHQYA	DN	SAM-6
DMDHQYA	MI	TTW26OG
DMDHQYA	MN	Endoplasmic reticulum chaperone BiP (HSPA5)
DMDHQYA	MT	DTT
DMDHQYA	RN	A new tumor-specific variant of GRP78 as target for antibody-based therapy. Lab Invest. 2008 Apr;88(4):375-86.
DMDHQYA	RU	https://pubmed.ncbi.nlm.nih.gov/18268478

DMWU71N	DI	DMWU71N
DMWU71N	DN	SAN-134
DMWU71N	MI	TT1YWO5
DMWU71N	MN	Glucagon-like peptide 2 receptor (GLP2R)
DMWU71N	MT	DTT
DMWU71N	MA	Inhibitor
DMWU71N	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020865)
DMWU71N	RU	http://adisinsight.springer.com/drugs/800020865

DMQ9ZY0	DI	DMQ9ZY0
DMQ9ZY0	DN	SAR-104772
DMQ9ZY0	MI	TTP18AY
DMQ9ZY0	MN	Carboxypeptidase B2 (CPB2)
DMQ9ZY0	MT	DTT
DMQ9ZY0	MA	Inhibitor
DMQ9ZY0	RN	Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy . Journal of Thrombosis and Haemostasis Volume 7, Issue 12, pages 1962-1971, December 2009.
DMQ9ZY0	RU	http://onlinelibrary.wiley.com/doi/10.1111/j.1538-7836.2009.03596.x/full

DMRIH0S	DI	DMRIH0S
DMRIH0S	DN	SAR113244
DMRIH0S	MI	TTIW59R
DMRIH0S	MN	C-X-C chemokine receptor type 5 (CXCR5)
DMRIH0S	MT	DTT
DMRIH0S	MA	Modulator
DMRIH0S	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMRIH0S	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMZ1XR5	DI	DMZ1XR5
DMZ1XR5	DN	SAR-114137
DMZ1XR5	MI	TTDZN01
DMZ1XR5	MN	Cathepsin K (CTSK)
DMZ1XR5	MT	DTT
DMZ1XR5	MA	Inhibitor
DMZ1XR5	RN	From laboratory to pilot plant: the solid-state process development of a highly potent cathepsin S/K inhibitor. Eur J Pharm Biopharm. 2013 Apr;83(3):436-48.
DMZ1XR5	RU	https://pubmed.ncbi.nlm.nih.gov/23201054

DMZ1XR5	DI	DMZ1XR5
DMZ1XR5	DN	SAR-114137
DMZ1XR5	MI	TTUMQVO
DMZ1XR5	MN	Cathepsin S (CTSS)
DMZ1XR5	MT	DTT
DMZ1XR5	MA	Inhibitor
DMZ1XR5	RN	From laboratory to pilot plant: the solid-state process development of a highly potent cathepsin S/K inhibitor. Eur J Pharm Biopharm. 2013 Apr;83(3):436-48.
DMZ1XR5	RU	https://pubmed.ncbi.nlm.nih.gov/23201054

DMD2VRY	DI	DMD2VRY
DMD2VRY	DN	SAR-115740
DMD2VRY	MI	TTMI6F5
DMD2VRY	MN	Transient receptor potential cation channel V1 (TRPV1)
DMD2VRY	MT	DTT
DMD2VRY	MA	Antagonist
DMD2VRY	RN	Clinical pipeline report, company report or official report of Sanofi.
DMD2VRY	RU	https://ncats.nih.gov/files/SAR115740.pdf

DMKHM7O	DI	DMKHM7O
DMKHM7O	DN	SAR-126119
DMKHM7O	MI	TTP18AY
DMKHM7O	MN	Carboxypeptidase B2 (CPB2)
DMKHM7O	MT	DTT
DMKHM7O	MA	Inhibitor
DMKHM7O	RN	TAFIa inhibitors in the treatment of thrombosis. Curr Opin Drug Discov Devel. 2008 Jul;11(4):480-6.
DMKHM7O	RU	https://pubmed.ncbi.nlm.nih.gov/18600565

DMQ98MW	DI	DMQ98MW
DMQ98MW	DN	SAR164653
DMQ98MW	MI	TT5NILS
DMQ98MW	MN	Cathepsin A (CTSA)
DMQ98MW	MT	DTT
DMQ98MW	MA	Modulator
DMQ98MW	RN	Tolerability, safety and pharmacokinetics of the novel Cathepsin A inhibitor SAR164653 in healthy subjects.Clinical Pharmacology in Drug Development 05/2015.
DMQ98MW	RU	http://www.researchgate.net/publication/276150796_Tolerability_safety_and_pharmacokinetics_of_the_novel_Cathepsin_A_inhibitor_SAR164653_in_healthy_subjects

DMO8QY1	DI	DMO8QY1
DMO8QY1	DN	SAR-21609
DMO8QY1	MI	TTSHG0T
DMO8QY1	MN	Toll-like receptor 9 (TLR9)
DMO8QY1	MT	DTT
DMO8QY1	MA	Agonist
DMO8QY1	RN	Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012 August 1; 1(5): 699-716.
DMO8QY1	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3429574/

DMTFAGU	DI	DMTFAGU
DMTFAGU	DN	SAR228810
DMTFAGU	MI	TTE4KHA
DMTFAGU	MN	Amyloid beta A4 protein (APP)
DMTFAGU	MT	DTT
DMTFAGU	RN	SAR228810: An antiprotofibrillar beta-amyloid antibody designed to reduce risk of amyloid-related imaging abnormalities (ARIA). Alzheimer's & Dementia Volume 9, Issue 4, Supplement, July 2013, Pages P808-P809.
DMTFAGU	RU	http://www.sciencedirect.com/science/article/pii/S1552526013023352

DMUAJZD	DI	DMUAJZD
DMUAJZD	DN	SAR247799
DMUAJZD	MI	TT9JZCK
DMUAJZD	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMUAJZD	MT	DTT
DMUAJZD	MA	Agonist
DMUAJZD	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMUAJZD	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DM15PG9	DI	DM15PG9
DM15PG9	DN	SAR351034
DM15PG9	MI	TT2JWF6
DM15PG9	MN	Peroxisome proliferator-activated receptor delta (PPARD)
DM15PG9	MT	DTT
DM15PG9	MA	Modulator
DM15PG9	RN	Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development. Curr Diabetes Rev. 2015 March; 11(1): 17-31.
DM15PG9	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4428473/

DMA6O9R	DI	DMA6O9R
DMA6O9R	DN	SAR-389644
DMA6O9R	MI	TTNVEIR
DMA6O9R	MN	Prostaglandin D2 receptor (PTGDR)
DMA6O9R	MT	DTT
DMA6O9R	MA	Antagonist
DMA6O9R	RN	US patent application no. 2008,0300,217, Combination therapy with fumaric acid esters for the treatment of autoimmune and,or inflammatory disorders.
DMA6O9R	RU	http://www.google.com/patents/US20080300217

DMC1AZP	DI	DMC1AZP
DMC1AZP	DN	SAR-405838
DMC1AZP	MI	TT7SBF5
DMC1AZP	MN	Cellular tumor antigen p53 (TP53)
DMC1AZP	MT	DTT
DMC1AZP	MA	Modulator
DMC1AZP	RN	SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression. Cancer Res. 2014 Oct 15;74(20):5855-65.
DMC1AZP	RU	https://pubmed.ncbi.nlm.nih.gov/25145672

DM53IPE	DI	DM53IPE
DM53IPE	DN	SAR425899
DM53IPE	MI	TT0NUFM
DM53IPE	MN	Glucagon (GCG)
DM53IPE	MT	DTT
DM53IPE	MA	Agonist
DM53IPE	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM53IPE	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DM53IPE	DI	DM53IPE
DM53IPE	DN	SAR425899
DM53IPE	MI	TT9O6WS
DM53IPE	MN	Glucagon receptor (GCGR)
DM53IPE	MT	DTT
DM53IPE	MA	Modulator
DM53IPE	RN	Company report (Sanofi) (drug: LIXisenatide)
DM53IPE	RU	http://www.sanofi.com/Images/38980_IR_Call_ADA2015_FINAL.pdf

DM53IPE	DI	DM53IPE
DM53IPE	DN	SAR425899
DM53IPE	MI	TTVIMDE
DM53IPE	MN	Glucagon-like peptide 1 receptor (GLP1R)
DM53IPE	MT	DTT
DM53IPE	MA	Modulator
DM53IPE	RN	Company report (Sanofi) (drug: LIXisenatide)
DM53IPE	RU	http://www.sanofi.com/Images/38980_IR_Call_ADA2015_FINAL.pdf

DM7QO05	DI	DM7QO05
DM7QO05	DN	SAR438335
DM7QO05	MI	TTYMKBE
DM7QO05	MN	Gastric inhibitory polypeptide receptor (GIPR)
DM7QO05	MT	DTT
DM7QO05	MA	Agonist
DM7QO05	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7QO05	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DM7QO05	DI	DM7QO05
DM7QO05	DN	SAR438335
DM7QO05	MI	TTVIMDE
DM7QO05	MN	Glucagon-like peptide 1 receptor (GLP1R)
DM7QO05	MT	DTT
DM7QO05	MA	Agonist
DM7QO05	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7QO05	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DM5UXAB	DI	DM5UXAB
DM5UXAB	DN	SAR442085
DM5UXAB	MI	TTPURFN
DM5UXAB	MN	Cyclic ADP-ribose hydrolase 1 (CD38)
DM5UXAB	MT	DTT
DM5UXAB	MA	Inhibitor
DM5UXAB	RN	Clinical pipeline report, company report or official report of Sanofi.
DM5UXAB	RU	https://www.sanofi.com/en/science-and-innovation/research-and-development/rd-pipeline

DMXD5QP	DI	DMXD5QP
DMXD5QP	DN	SAR442257
DMXD5QP	MI	TTPURFN
DMXD5QP	MN	Cyclic ADP-ribose hydrolase 1 (CD38)
DMXD5QP	MT	DTT
DMXD5QP	MA	Inhibitor
DMXD5QP	RN	Clinical pipeline report, company report or official report of Sanofi.
DMXD5QP	RU	https://www.sanofi.com/en/science-and-innovation/research-and-development/rd-pipeline

DMXD5QP	DI	DMXD5QP
DMXD5QP	DN	SAR442257
DMXD5QP	MI	TTUN7MC
DMXD5QP	MN	T-cell surface glycoprotein CD3 (CD3)
DMXD5QP	MT	DTT
DMXD5QP	MA	Inhibitor
DMXD5QP	RN	Clinical pipeline report, company report or official report of Sanofi.
DMXD5QP	RU	https://www.sanofi.com/en/science-and-innovation/research-and-development/rd-pipeline

DMXD5QP	DI	DMXD5QP
DMXD5QP	DN	SAR442257
DMXD5QP	MI	TTQ13FT
DMXD5QP	MN	T-cell-specific surface glycoprotein CD28 (CD28)
DMXD5QP	MT	DTT
DMXD5QP	MA	Inhibitor
DMXD5QP	RN	Clinical pipeline report, company report or official report of Sanofi.
DMXD5QP	RU	https://www.sanofi.com/en/science-and-innovation/research-and-development/rd-pipeline

DMTAOPC	DI	DMTAOPC
DMTAOPC	DN	SAR442720
DMTAOPC	MI	TT7WUAV
DMTAOPC	MN	Protein-tyrosine phosphatase SHP-2 (PTPN11)
DMTAOPC	MT	DTT
DMTAOPC	MA	Inhibitor
DMTAOPC	RN	Clinical pipeline report, company report or official report of Revolution Medicines.
DMTAOPC	RU	https://www.revmed.com/pipeline/rmc-4630

DM6UN42	DI	DM6UN42
DM6UN42	DN	SAR444245
DM6UN42	MI	TTF89GD
DM6UN42	MN	Interleukin-2 (IL2)
DM6UN42	MT	DTT
DM6UN42	RN	Clinical pipeline report, company report or official report of Sanofi.
DM6UN42	RU	https://www.sanofi.com/en/media-room/press-releases/2020/2020-10-29-07-00-00

DMZ9YWG	DI	DMZ9YWG
DMZ9YWG	DN	SB 11285
DMZ9YWG	MI	TTT402Y
DMZ9YWG	MN	Stimulator of interferon genes protein (TMEM173)
DMZ9YWG	MT	DTT
DMZ9YWG	MA	Agonist
DMZ9YWG	RN	Clinical pipeline report, company report or official report of F-star Therapeutics.
DMZ9YWG	RU	https://www.f-star.com/pipeline/sb-11285/

DMXTKYR	DI	DMXTKYR
DMXTKYR	DN	SB-1578
DMXTKYR	MI	TTRMX3V
DMXTKYR	MN	Janus kinase 2 (JAK-2)
DMXTKYR	MT	DTT
DMXTKYR	MA	Inhibitor
DMXTKYR	RN	Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.
DMXTKYR	RU	https://pubmed.ncbi.nlm.nih.gov/24818516

DMLPB0X	DI	DMLPB0X
DMLPB0X	DN	SB-436811
DMLPB0X	MI	TTW5UDX
DMLPB0X	MN	Urotensin II receptor (UTS2R)
DMLPB0X	MT	DTT
DMLPB0X	MA	Inhibitor
DMLPB0X	RN	Urotensin-II receptor modulators as potential drugs. J Med Chem. 2010 Apr 8;53(7):2695-708.
DMLPB0X	RU	https://pubmed.ncbi.nlm.nih.gov/20043680

DMSZIP5	DI	DMSZIP5
DMSZIP5	DN	SB-639
DMSZIP5	MI	TT6R7JZ
DMSZIP5	MN	Histone deacetylase 1 (HDAC1)
DMSZIP5	MT	DTT
DMSZIP5	MA	Inhibitor
DMSZIP5	RN	Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92.
DMSZIP5	RU	https://pubmed.ncbi.nlm.nih.gov/17896917

DMXU2GS	DI	DMXU2GS
DMXU2GS	DN	SBS-1000
DMXU2GS	MI	TTZOPHG
DMXU2GS	MN	Insulin (INS)
DMXU2GS	MT	DTT
DMXU2GS	MA	Modulator
DMXU2GS	RN	Synergistic antihyperglycemic effects between plant-derived oleanolic acid and insulin in streptozotocin-induced diabetic rats. Ren Fail. 2010;32(7):832-9.
DMXU2GS	RU	https://pubmed.ncbi.nlm.nih.gov/20662697

DMHBD3T	DI	DMHBD3T
DMHBD3T	DN	SBT6050
DMHBD3T	MI	TT6EO5L
DMHBD3T	MN	Erbb2 tyrosine kinase receptor (HER2)
DMHBD3T	MT	DTT
DMHBD3T	RN	Clinical pipeline report, company report or official report of Silverback Therapeutics.
DMHBD3T	RU	https://silverbacktx.com/pipeline/#sbt6050

DMHBD3T	DI	DMHBD3T
DMHBD3T	DN	SBT6050
DMHBD3T	MI	TT8CWFK
DMHBD3T	MN	Toll-like receptor 8 (TLR8)
DMHBD3T	MT	DTT
DMHBD3T	MA	Agonist
DMHBD3T	RN	Clinical pipeline report, company report or official report of Silverback Therapeutics.
DMHBD3T	RU	https://silverbacktx.com/pipeline/#sbt6050

DM7GSLB	DI	DM7GSLB
DM7GSLB	DN	SC-20713
DM7GSLB	MI	DE4LYSA
DM7GSLB	MN	Cytochrome P450 3A4 (CYP3A4)
DM7GSLB	MT	DME
DM7GSLB	MA	Metabolism
DM7GSLB	RN	News and information in drug research: Ethynodiol diacetate.
DM7GSLB	RU	http://genelabs.com/drugsdb/details/ethynodiol-diacetate/

DMQ2K1V	DI	DMQ2K1V
DMQ2K1V	DN	SCH-442416
DMQ2K1V	MI	TTK25J1
DMQ2K1V	MN	Adenosine A1 receptor (ADORA1)
DMQ2K1V	MT	DTT
DMQ2K1V	MA	Inhibitor
DMQ2K1V	RN	Design, radiosynthesis, and biodistribution of a new potent and selective ligand for in vivo imaging of the adenosine A(2A) receptor system using p... J Med Chem. 2000 Nov 16;43(23):4359-62.
DMQ2K1V	RU	https://pubmed.ncbi.nlm.nih.gov/11087559

DMQ2K1V	DI	DMQ2K1V
DMQ2K1V	DN	SCH-442416
DMQ2K1V	MI	TTM2AOE
DMQ2K1V	MN	Adenosine A2a receptor (ADORA2A)
DMQ2K1V	MT	DTT
DMQ2K1V	MA	Inhibitor
DMQ2K1V	RN	Design, radiosynthesis, and biodistribution of a new potent and selective ligand for in vivo imaging of the adenosine A(2A) receptor system using p... J Med Chem. 2000 Nov 16;43(23):4359-62.
DMQ2K1V	RU	https://pubmed.ncbi.nlm.nih.gov/11087559

DMQ2K1V	DI	DMQ2K1V
DMQ2K1V	DN	SCH-442416
DMQ2K1V	MI	TTJFY5U
DMQ2K1V	MN	Adenosine A3 receptor (ADORA3)
DMQ2K1V	MT	DTT
DMQ2K1V	MA	Inhibitor
DMQ2K1V	RN	Synthesis and evaluation of 1,2,4-triazolo[1,5-c]pyrimidine derivatives as A2A receptor-selective antagonists. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5690-4.
DMQ2K1V	RU	https://pubmed.ncbi.nlm.nih.gov/20801028

DMDP6UF	DI	DMDP6UF
DMDP6UF	DN	SCH-721015
DMDP6UF	MI	TTSIUJ9
DMDP6UF	MN	Interferon-alpha 2 (IFNA2)
DMDP6UF	MT	DTT
DMDP6UF	MA	Modulator
DMDP6UF	RN	Toxicity and exposure of an adenovirus containing human interferon alpha-2b following intracystic administration in cynomolgus monkeys. Gene Ther. 2012 Jul;19(7):742-51.
DMDP6UF	RU	https://pubmed.ncbi.nlm.nih.gov/21900961

DM7A6R5	DI	DM7A6R5
DM7A6R5	DN	SCH-900117
DM7A6R5	MI	TTG0MT6
DM7A6R5	MN	Interleukin-17 (IL17)
DM7A6R5	MT	DTT
DM7A6R5	MA	Modulator
DM7A6R5	RN	Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012 Oct;11(10):763-76. 
DM7A6R5	RU	https://pubmed.ncbi.nlm.nih.gov/23023676

DMRD1IW	DI	DMRD1IW
DMRD1IW	DN	SCO-088
DMRD1IW	MI	TTS7G69
DMRD1IW	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMRD1IW	MT	DTT
DMRD1IW	MA	Inhibitor
DMRD1IW	RN	Clinical pipeline report, company report or official report of Sun Pharma Advanced Research Company.
DMRD1IW	RU	https://www.sparc.life/research-programs/sco-088

DMB1MZS	DI	DMB1MZS
DMB1MZS	DN	SCO-120
DMB1MZS	MI	TTZAYWL
DMB1MZS	MN	Estrogen receptor (ESR)
DMB1MZS	MT	DTT
DMB1MZS	MA	Degrader
DMB1MZS	RN	Clinical pipeline report, company report or official report of Sun Pharma Advanced Research Company.
DMB1MZS	RU	https://www.sparc.life/research-programs/sco-120

DMU0Q6L	DI	DMU0Q6L
DMU0Q6L	DN	SDX-7320
DMU0Q6L	MI	TTZL0OI
DMU0Q6L	MN	Methionine aminopeptidase 2 (METAP2)
DMU0Q6L	MT	DTT
DMU0Q6L	MA	Inhibitor
DMU0Q6L	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMU0Q6L	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMU9ZGN	DI	DMU9ZGN
DMU9ZGN	DN	SDZ-GPI-562
DMU9ZGN	MI	TT38RM1
DMU9ZGN	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DMU9ZGN	MT	DTT
DMU9ZGN	MA	Modulator
DMU9ZGN	RN	Heparin-induced thrombocytopenia: the role of platelet activation and therapeutic implications. Semin Thromb Hemost. 1999;25 Suppl 1:67-75.
DMU9ZGN	RU	https://www.ncbi.nlm.nih.gov/pubmed/10357155

DM8SINB	DI	DM8SINB
DM8SINB	DN	SDZ-LAV-694
DM8SINB	MI	TTML2WA
DM8SINB	MN	Tubulin (TUB)
DM8SINB	MT	DTT
DM8SINB	MA	Inhibitor
DM8SINB	RN	Recent Patents Reveal Microtubules as Persistent Promising Target for Novel Drug Development for Cancers. Recent Patents on Anti-Infective Drug Discovery 12/2009; 4(3):164-82.
DM8SINB	RU	http://www.researchgate.net/profile/Harish_Joshi/publication/26735183_Recent_patents_reveal_microtubules_as_persistent_promising_target_for_novel_drug_development_for_cancers/links/0deec5192b302d6e79000000.pdf

DML6QJN	DI	DML6QJN
DML6QJN	DN	SDZ-MKS-492
DML6QJN	MI	TTZCG4L
DML6QJN	MN	Phosphodiesterase 3 (PDE3)
DML6QJN	MT	DTT
DML6QJN	MA	Modulator
DML6QJN	RN	Effects of a cyclic nucleotide phosphodiesterase isoenzyme type III inhibitor, SDZ MKS 492 on airway responsiveness in beagles. Arerugi. 1993 Aug;42(8):920-5.
DML6QJN	RU	https://pubmed.ncbi.nlm.nih.gov/8250732

DMX94YF	DI	DMX94YF
DMX94YF	DN	SEA-CD70
DMX94YF	MI	TTNCIE0
DMX94YF	MN	CD70 antigen (CD27-L)
DMX94YF	MT	DTT
DMX94YF	MA	Inhibitor
DMX94YF	RN	Clinical pipeline report, company report or official report of Seagen.
DMX94YF	RU	https://www.seagen.com/science/pipeline

DM7GUH3	DI	DM7GUH3
DM7GUH3	DN	SEA-TGT
DM7GUH3	MI	TTWNL74
DM7GUH3	MN	V-set and immunoglobulin domain-containing protein 9 (TIGIT)
DM7GUH3	MT	DTT
DM7GUH3	MA	Inhibitor
DM7GUH3	RN	Clinical pipeline report, company report or official report of Seagen.
DM7GUH3	RU	https://www.seagen.com/science/pipeline

DMCP7SD	DI	DMCP7SD
DMCP7SD	DN	Seclidemstat
DMCP7SD	MI	TTNR0UQ
DMCP7SD	MN	Lysine-specific histone demethylase 1 (LSD)
DMCP7SD	MT	DTT
DMCP7SD	MA	Inhibitor
DMCP7SD	RN	Scaffolding LSD1 Inhibitors Impair NK Cell Metabolism and Cytotoxic Function Through Depletion of Glutathione. Front Immunol. 2020 Sep 17;11:2196.
DMCP7SD	RU	https://pubmed.ncbi.nlm.nih.gov/33042135

DMHCUZV	DI	DMHCUZV
DMHCUZV	DN	SEL120
DMHCUZV	MI	TTNABU9
DMHCUZV	MN	Cyclin-dependent kinase 19 (CDK19)
DMHCUZV	MT	DTT
DMHCUZV	MA	Inhibitor
DMHCUZV	RN	Clinical pipeline report, company report or official report of Ryvu Therapeutics.
DMHCUZV	RU	https://ryvu.com/pipeline/

DMHCUZV	DI	DMHCUZV
DMHCUZV	DN	SEL120
DMHCUZV	MI	TTBJR4L
DMHCUZV	MN	Cyclin-dependent kinase 8 (CDK8)
DMHCUZV	MT	DTT
DMHCUZV	MA	Inhibitor
DMHCUZV	RN	Clinical pipeline report, company report or official report of Ryvu Therapeutics.
DMHCUZV	RU	https://ryvu.com/pipeline/

DMF89ZT	DI	DMF89ZT
DMF89ZT	DN	SEP-228432
DMF89ZT	MI	TT3ROYC
DMF89ZT	MN	Serotonin transporter (SERT)
DMF89ZT	MT	DTT
DMF89ZT	MA	Inhibitor
DMF89ZT	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028715)
DMF89ZT	RU	http://adisinsight.springer.com/drugs/800028715

DMTZ983	DI	DMTZ983
DMTZ983	DN	SER-101
DMTZ983	MI	TT07C3Y
DMTZ983	MN	5-HT 4 receptor (HTR4)
DMTZ983	MT	DTT
DMTZ983	MA	Antagonist
DMTZ983	RN	Phase I clinical trail of SER101 (RO1160367) for treating heart failure leukemia. Roche.
DMTZ983	RU	http://www.biocentury.com/products/ser101

DMD2GKF	DI	DMD2GKF
DMD2GKF	DN	SFLT-01
DMD2GKF	MI	TT48I1Y
DMD2GKF	MN	Placenta growth factor (PlGF)
DMD2GKF	MT	DTT
DMD2GKF	MA	Modulator
DMD2GKF	RN	sFLT01: a novel fusion protein with antiangiogenic activity. Mol Cancer Ther. 2011 Mar;10(3):404-15.
DMD2GKF	RU	https://pubmed.ncbi.nlm.nih.gov/21252283

DMD2GKF	DI	DMD2GKF
DMD2GKF	DN	SFLT-01
DMD2GKF	MI	TTOHSBA
DMD2GKF	MN	Vascular endothelial growth factor A (VEGFA)
DMD2GKF	MT	DTT
DMD2GKF	MA	Modulator
DMD2GKF	RN	sFLT01: a novel fusion protein with antiangiogenic activity. Mol Cancer Ther. 2011 Mar;10(3):404-15.
DMD2GKF	RU	https://pubmed.ncbi.nlm.nih.gov/21252283

DMDAHEL	DI	DMDAHEL
DMDAHEL	DN	SGM-1019
DMDAHEL	MI	TT473XN
DMDAHEL	MN	P2X purinoceptor 7 (P2RX7)
DMDAHEL	MT	DTT
DMDAHEL	MA	Modulator
DMDAHEL	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMDAHEL	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMVBQ2L	DI	DMVBQ2L
DMVBQ2L	DN	SGN LIV1A
DMVBQ2L	MI	TTZN1CF
DMVBQ2L	MN	Solute carrier family 39 member 6 (SLC39A6)
DMVBQ2L	MT	DTT
DMVBQ2L	RN	SGN-LIV1A: a novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer. Mol Cancer Ther. 2014 Dec;13(12):2991-3000.
DMVBQ2L	RU	https://pubmed.ncbi.nlm.nih.gov/25253783

DMXA7W9	DI	DMXA7W9
DMXA7W9	DN	SGN-70
DMXA7W9	MI	TTNCIE0
DMXA7W9	MN	CD70 antigen (CD27-L)
DMXA7W9	MT	DTT
DMXA7W9	RN	2011 Pipeline of Seattle Genetics.
DMXA7W9	RU	http://www.seagen.com/product_pipeline.php

DMATJL9	DI	DMATJL9
DMATJL9	DN	SGN-B6A
DMATJL9	MI	TTKQSXZ
DMATJL9	MN	Integrin beta-6 (ITGB6)
DMATJL9	MT	DTT
DMATJL9	RN	Clinical pipeline report, company report or official report of Seagen.
DMATJL9	RU	https://www.seagen.com/science/pipeline

DMSVD2R	DI	DMSVD2R
DMSVD2R	DN	SGN-CD228A
DMSVD2R	MI	TT8OBT3
DMSVD2R	MN	Melanotransferrin (MELTF)
DMSVD2R	MT	DTT
DMSVD2R	RN	Clinical pipeline report, company report or official report of Seagen.
DMSVD2R	RU	https://www.seagen.com/science/pipeline

DMKW10G	DI	DMKW10G
DMKW10G	DN	SGN-CD30C
DMKW10G	MI	TT2GM5R
DMKW10G	MN	Lymphocyte activation antigen CD30 (TNFRSF8)
DMKW10G	MT	DTT
DMKW10G	RN	Clinical pipeline report, company report or official report of Seagen.
DMKW10G	RU	https://www.seagen.com/science/pipeline

DMMJ1PO	DI	DMMJ1PO
DMMJ1PO	DN	SGN-CD70A
DMMJ1PO	MI	TTNCIE0
DMMJ1PO	MN	CD70 antigen (CD27-L)
DMMJ1PO	MT	DTT
DMMJ1PO	RN	SGN-CD70A, a novel and highly potent anti-CD70 ADC, induces double-strand DNA breaks and is active in models of MDR+ renal cell carcinoma (RCC) and non-Hodgkin lymphoma (NHL). Cancer Research 10/2014; 74(19 Supplement):2647-2647.
DMMJ1PO	RU	http://cancerres.aacrjournals.org/content/74/19_Supplement/2647

DM3RSMF	DI	DM3RSMF
DM3RSMF	DN	Sgx523
DM3RSMF	MI	DEAWHS8
DM3RSMF	MN	Aldehyde oxidase (AOX1)
DM3RSMF	MT	DME
DM3RSMF	MA	Metabolism
DM3RSMF	RN	Species-specific metabolism of SGX523 by aldehyde oxidase and the toxicological implications. Drug Metab Dispos. 2010 Aug;38(8):1277-85.
DM3RSMF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20421447

DM3RSMF	DI	DM3RSMF
DM3RSMF	DN	Sgx523
DM3RSMF	MI	TTNDSF4
DM3RSMF	MN	Proto-oncogene c-Met (MET)
DM3RSMF	MT	DTT
DM3RSMF	MA	Inhibitor
DM3RSMF	RN	CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
DM3RSMF	RU	http://www.centerwatch.com/

DMO0CA8	DI	DMO0CA8
DMO0CA8	DN	SHP616
DMO0CA8	MI	TT7LRQH
DMO0CA8	MN	Complement C1s component (C1S)
DMO0CA8	MT	DTT
DMO0CA8	MA	Inhibitor
DMO0CA8	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMO0CA8	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMGFTAI	DI	DMGFTAI
DMGFTAI	DN	SHR0534
DMGFTAI	MI	TTB8FUC
DMGFTAI	MN	Free fatty acid receptor 1 (GPR40)
DMGFTAI	MT	DTT
DMGFTAI	MA	Agonist
DMGFTAI	RN	Targeting metabolic dysregulation for fibrosis therapy. Nat Rev Drug Discov. 2020 Jan;19(1):57-75.
DMGFTAI	RU	https://pubmed.ncbi.nlm.nih.gov/31548636

DMGFTAI	DI	DMGFTAI
DMGFTAI	DN	SHR0534
DMGFTAI	MI	TTG0MQD
DMGFTAI	MN	Inflammation-related GPCR EX33 (GPR84)
DMGFTAI	MT	DTT
DMGFTAI	MA	Agonist
DMGFTAI	RN	Targeting metabolic dysregulation for fibrosis therapy. Nat Rev Drug Discov. 2020 Jan;19(1):57-75.
DMGFTAI	RU	https://pubmed.ncbi.nlm.nih.gov/31548636

DMDSFEB	DI	DMDSFEB
DMDSFEB	DN	SI-B001
DMDSFEB	MI	TTGKNB4
DMDSFEB	MN	Epidermal growth factor receptor (EGFR)
DMDSFEB	MT	DTT
DMDSFEB	RN	Clinical pipeline report, company report or official report of SystImmune.
DMDSFEB	RU	https://systimmune.com/pipeline.html

DMDSFEB	DI	DMDSFEB
DMDSFEB	DN	SI-B001
DMDSFEB	MI	TTDC8N2
DMDSFEB	MN	Erbb3 tyrosine kinase receptor (Erbb-3)
DMDSFEB	MT	DTT
DMDSFEB	RN	Clinical pipeline report, company report or official report of SystImmune.
DMDSFEB	RU	https://systimmune.com/pipeline.html

DMJW5R0	DI	DMJW5R0
DMJW5R0	DN	SI-B003
DMJW5R0	MI	TTI2S1D
DMJW5R0	MN	Cytotoxic T-lymphocyte protein 4 (CTLA-4)
DMJW5R0	MT	DTT
DMJW5R0	RN	Clinical pipeline report, company report or official report of SystImmune.
DMJW5R0	RU	https://systimmune.com/pipeline.html

DMJW5R0	DI	DMJW5R0
DMJW5R0	DN	SI-B003
DMJW5R0	MI	TTNBFWK
DMJW5R0	MN	Programmed cell death protein 1 (PD-1)
DMJW5R0	MT	DTT
DMJW5R0	RN	Clinical pipeline report, company report or official report of SystImmune.
DMJW5R0	RU	https://systimmune.com/pipeline.html

DMFK7UR	DI	DMFK7UR
DMFK7UR	DN	Simotaxel
DMFK7UR	MI	TTYFKSZ
DMFK7UR	MN	Tubulin beta (TUBB)
DMFK7UR	MT	DTT
DMFK7UR	MA	Inhibitor
DMFK7UR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2640).
DMFK7UR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2640

DMG7XKP	DI	DMG7XKP
DMG7XKP	DN	SKF-105494
DMG7XKP	MI	TTYCILE
DMG7XKP	MN	Vasopressin receptor (VR)
DMG7XKP	MT	DTT
DMG7XKP	MA	Modulator
DMG7XKP	RN	Modulation of vasopressin antidiuretic action by alpha 2-adrenoceptors is species specific. Am J Physiol. 1991 Nov;261(5 Pt 2):R1242-6.
DMG7XKP	RU	https://pubmed.ncbi.nlm.nih.gov/1659234

DMUN7EQ	DI	DMUN7EQ
DMUN7EQ	DN	SKF-105809
DMUN7EQ	MI	TT2J34L
DMUN7EQ	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMUN7EQ	MT	DTT
DMUN7EQ	MA	Inhibitor
DMUN7EQ	RN	Analgetic activity of SK&amp;F 105809, a dual inhibitor of arachidonic acid metabolism. Agents Actions Suppl. 1991;32:113-7.
DMUN7EQ	RU	https://pubmed.ncbi.nlm.nih.gov/1906235

DMUN7EQ	DI	DMUN7EQ
DMUN7EQ	DN	SKF-105809
DMUN7EQ	MI	TTK0943
DMUN7EQ	MN	Prostaglandin G/H synthase (COX)
DMUN7EQ	MT	DTT
DMUN7EQ	MA	Modulator
DMUN7EQ	RN	Analgetic activity of SK&amp;F 105809, a dual inhibitor of arachidonic acid metabolism. Agents Actions Suppl. 1991;32:113-7.
DMUN7EQ	RU	https://pubmed.ncbi.nlm.nih.gov/1906235

DM4I92Z	DI	DM4I92Z
DM4I92Z	DN	SKI-G-801
DM4I92Z	MI	TTGJCWZ
DM4I92Z	MN	Fms-like tyrosine kinase 3 (FLT-3)
DM4I92Z	MT	DTT
DM4I92Z	MA	Inhibitor
DM4I92Z	RN	Clinical pipeline report, company report or official report of Genosco.
DM4I92Z	RU	http://genosco.com/pipeline/ski-g-801/

DMTSKXR	DI	DMTSKXR
DMTSKXR	DN	SKI-O-703
DMTSKXR	MI	TTOU65C
DMTSKXR	MN	Tyrosine-protein kinase SYK (SYK)
DMTSKXR	MT	DTT
DMTSKXR	MA	Inhibitor
DMTSKXR	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMTSKXR	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMW64UZ	DI	DMW64UZ
DMW64UZ	DN	SKL-10406
DMW64UZ	MI	TTJQOD7
DMW64UZ	MN	5-HT 2A receptor (HTR2A)
DMW64UZ	MT	DTT
DMW64UZ	MA	Binder
DMW64UZ	RN	Bi-directional modulation of BNST neurons by 5-HT: Molecular expression and functional properties of excitatory 5-HT receptor subtypes. Neuroscience. 2009 December 29; 164(4): 1776-1793.
DMW64UZ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2783788/

DMW64UZ	DI	DMW64UZ
DMW64UZ	DN	SKL-10406
DMW64UZ	MI	TTEX248
DMW64UZ	MN	Dopamine D2 receptor (D2R)
DMW64UZ	MT	DTT
DMW64UZ	MA	Binder
DMW64UZ	RN	Bi-directional modulation of BNST neurons by 5-HT: Molecular expression and functional properties of excitatory 5-HT receptor subtypes. Neuroscience. 2009 December 29; 164(4): 1776-1793.
DMW64UZ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2783788/

DM8YNI6	DI	DM8YNI6
DM8YNI6	DN	SKL-PSY
DM8YNI6	MI	TTSQIFT
DM8YNI6	MN	5-HT 1A receptor (HTR1A)
DM8YNI6	MT	DTT
DM8YNI6	MA	Modulator
DM8YNI6	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1).
DM8YNI6	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1

DMN3D72	DI	DMN3D72
DMN3D72	DN	SL-172154
DMN3D72	MI	TTN6Y9A
DMN3D72	MN	CD40L receptor (CD40)
DMN3D72	MT	DTT
DMN3D72	MA	Inhibitor
DMN3D72	RN	Clinical pipeline report, company report or official report of Shattuck Labs.
DMN3D72	RU	https://www.shattucklabs.com/pipeline/overview/

DMN3D72	DI	DMN3D72
DMN3D72	DN	SL-172154
DMN3D72	MI	TT28S46
DMN3D72	MN	Leukocyte surface antigen CD47 (CD47)
DMN3D72	MT	DTT
DMN3D72	MA	Inhibitor
DMN3D72	RN	Clinical pipeline report, company report or official report of Shattuck Labs.
DMN3D72	RU	https://www.shattucklabs.com/pipeline/overview/

DMIVGYK	DI	DMIVGYK
DMIVGYK	DN	SL-801
DMIVGYK	MI	TTCJUR4
DMIVGYK	MN	Exportin-1 (XPO1)
DMIVGYK	MT	DTT
DMIVGYK	MA	Inhibitor
DMIVGYK	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMIVGYK	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMVUL1H	DI	DMVUL1H
DMVUL1H	DN	Sleeping Beauty CAR-TCR
DMVUL1H	MI	TTW640A
DMVUL1H	MN	B-lymphocyte surface antigen B4 (CD19)
DMVUL1H	MT	DTT
DMVUL1H	RN	Clinical pipeline report, company report or official report of Ziopharm Oncology.
DMVUL1H	RU	https://ziopharm.com/pipeline/

DMIAOU6	DI	DMIAOU6
DMIAOU6	DN	SLN124
DMIAOU6	MI	TTNIUKC
DMIAOU6	MN	TMPRSS6 messenger RNA (TMPRSS6 mRNA)
DMIAOU6	MT	DTT
DMIAOU6	MA	Inhibitor
DMIAOU6	RN	SLN124, a GalNAc-siRNA Conjugate Targeting TMPRSS6, Efficiently Prevents Iron Overload in Hereditary Haemochromatosis Type 1. Hemasphere. 2019 Oct 1;3(6):e301.
DMIAOU6	RU	https://pubmed.ncbi.nlm.nih.gov/31976476

DM7WKTM	DI	DM7WKTM
DM7WKTM	DN	SLV-338
DM7WKTM	MI	TT1BGDH
DM7WKTM	MN	Endothelin-converting enzyme (ECE)
DM7WKTM	MT	DTT
DM7WKTM	MA	Modulator
DM7WKTM	RN	Renoprotective effects of combined endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 in acute and chronic experimental renal damage. Clin Lab. 2011;57(7-8):507-15.
DM7WKTM	RU	https://pubmed.ncbi.nlm.nih.gov/21888014

DM7WKTM	DI	DM7WKTM
DM7WKTM	DN	SLV-338
DM7WKTM	MI	TT5TKPM
DM7WKTM	MN	Neutral endopeptidase (MME)
DM7WKTM	MT	DTT
DM7WKTM	MA	Modulator
DM7WKTM	RN	Renoprotective effects of combined endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 in acute and chronic experimental renal damage. Clin Lab. 2011;57(7-8):507-15.
DM7WKTM	RU	https://pubmed.ncbi.nlm.nih.gov/21888014

DM491NI	DI	DM491NI
DM491NI	DN	SM04755
DM491NI	MI	TTFPSHI
DM491NI	MN	Wnt signaling pathway (Wnt pathway)
DM491NI	MT	DTT
DM491NI	MA	Modulator
DM491NI	RN	A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of SM04755 in Subjects with Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer.
DM491NI	RU	https://clinicaltrials.gov/ct2/show/NCT02191761?term=NCT02191761&rank=1

DM4KLNA	DI	DM4KLNA
DM4KLNA	DN	SM08502
DM4KLNA	MI	TTFPSHI
DM4KLNA	MN	Wnt signaling pathway (Wnt pathway)
DM4KLNA	MT	DTT
DM4KLNA	MA	Inhibitor
DM4KLNA	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM4KLNA	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM73YG5	DI	DM73YG5
DM73YG5	DN	SM09419
DM73YG5	MI	TT6K9BV
DM73YG5	MN	Cdc-like kinase (CLK)
DM73YG5	MT	DTT
DM73YG5	MA	Inhibitor
DM73YG5	RN	SM09419, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Inhibition of the Wnt Signaling Pathway and Antitumor Effects in FMS-like Tyrosine Kinase 3 (FLT3)-Mutant Acute Myeloid Leukemia Models. Blood; 2019,134 (Supplement_1):1377.
DM73YG5	RU	https://doi.org/10.1182/blood-2019-130500

DM8L1GJ	DI	DM8L1GJ
DM8L1GJ	DN	SNA-125
DM8L1GJ	MI	TTT7PJU
DM8L1GJ	MN	Janus kinase 3 (JAK-3)
DM8L1GJ	MT	DTT
DM8L1GJ	MA	Inhibitor
DM8L1GJ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM8L1GJ	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM8ZROW	DI	DM8ZROW
DM8ZROW	DN	SNDX-6352
DM8ZROW	MI	TT7MRDV
DM8ZROW	MN	Macrophage colony-stimulating factor 1 receptor (CSF1R)
DM8ZROW	MT	DTT
DM8ZROW	MA	Antagonist
DM8ZROW	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM8ZROW	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMEITAS	DI	DMEITAS
DMEITAS	DN	SNS-032
DMEITAS	MI	TT7HF4W
DMEITAS	MN	Cyclin-dependent kinase 2 (CDK2)
DMEITAS	MT	DTT
DMEITAS	MA	Inhibitor
DMEITAS	RN	Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45.
DMEITAS	RU	https://pubmed.ncbi.nlm.nih.gov/19234140

DMEITAS	DI	DMEITAS
DMEITAS	DN	SNS-032
DMEITAS	MI	TTQYF7G
DMEITAS	MN	Cyclin-dependent kinase 7 (CDK7)
DMEITAS	MT	DTT
DMEITAS	MA	Inhibitor
DMEITAS	RN	Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45.
DMEITAS	RU	https://pubmed.ncbi.nlm.nih.gov/19234140

DMEITAS	DI	DMEITAS
DMEITAS	DN	SNS-032
DMEITAS	MI	TT1LVF2
DMEITAS	MN	Cyclin-dependent kinase 9 (CDK9)
DMEITAS	MT	DTT
DMEITAS	MA	Inhibitor
DMEITAS	RN	Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45.
DMEITAS	RU	https://pubmed.ncbi.nlm.nih.gov/19234140

DMAC5F2	DI	DMAC5F2
DMAC5F2	DN	SNS-314
DMAC5F2	MI	TTPS3C0
DMAC5F2	MN	Aurora kinase A (AURKA)
DMAC5F2	MT	DTT
DMAC5F2	MA	Inhibitor
DMAC5F2	RN	SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemother Pharmacol. 2010 Mar;65(4):707-17.
DMAC5F2	RU	https://pubmed.ncbi.nlm.nih.gov/19649632

DMAC5F2	DI	DMAC5F2
DMAC5F2	DN	SNS-314
DMAC5F2	MI	TT5LS6T
DMAC5F2	MN	Aurora kinase B (AURKB)
DMAC5F2	MT	DTT
DMAC5F2	MA	Inhibitor
DMAC5F2	RN	SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemother Pharmacol. 2010 Mar;65(4):707-17.
DMAC5F2	RU	https://pubmed.ncbi.nlm.nih.gov/19649632

DMAC5F2	DI	DMAC5F2
DMAC5F2	DN	SNS-314
DMAC5F2	MI	TTLYXIT
DMAC5F2	MN	Aurora kinase C (AURKC)
DMAC5F2	MT	DTT
DMAC5F2	MA	Inhibitor
DMAC5F2	RN	SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemother Pharmacol. 2010 Mar;65(4):707-17.
DMAC5F2	RU	https://pubmed.ncbi.nlm.nih.gov/19649632

DMCGPU8	DI	DMCGPU8
DMCGPU8	DN	SNX281
DMCGPU8	MI	TTT402Y
DMCGPU8	MN	Stimulator of interferon genes protein (TMEM173)
DMCGPU8	MT	DTT
DMCGPU8	MA	Inhibitor
DMCGPU8	RN	Clinical pipeline report, company report or official report of Silicon Therapeutics.
DMCGPU8	RU	https://silicontx.com/therapeutics-and-pipeline/targets/sting-agonist/

DMB3WJF	DI	DMB3WJF
DMB3WJF	DN	Solulin
DMB3WJF	MI	TT6L509
DMB3WJF	MN	Coagulation factor IIa (F2)
DMB3WJF	MT	DTT
DMB3WJF	MA	Modulator
DMB3WJF	RN	The thrombomodulin analog Solulin promotes reperfusion and reduces infarct volume in a thrombotic stroke model. J Thromb Haemost. 2011 Jun;9(6):1174-82.
DMB3WJF	RU	https://pubmed.ncbi.nlm.nih.gov/21645225

DMB3YZJ	DI	DMB3YZJ
DMB3YZJ	DN	Sonepcizumab
DMB3YZJ	MI	TT9JZCK
DMB3YZJ	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMB3YZJ	MT	DTT
DMB3YZJ	RN	Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702.
DMB3YZJ	RU	https://pubmed.ncbi.nlm.nih.gov/23954895

DMBKL6O	DI	DMBKL6O
DMBKL6O	DN	SOR-C13
DMBKL6O	MI	TTBK14N
DMBKL6O	MN	Transient receptor potential cation channel V6 (TRPV6)
DMBKL6O	MT	DTT
DMBKL6O	MA	Inhibitor
DMBKL6O	RN	In vivo detection of human TRPV6-rich tumors with anti-cancer peptides derived from soricidin. PLoS One. 2013;8(3):e58866.
DMBKL6O	RU	https://pubmed.ncbi.nlm.nih.gov/23554944

DMAD6HS	DI	DMAD6HS
DMAD6HS	DN	SPC4955
DMAD6HS	MI	TT2718H
DMAD6HS	MN	Apolipoprotein B-100 (APOB)
DMAD6HS	MT	DTT
DMAD6HS	MA	Inhibitor
DMAD6HS	RN	2011 Pipeline of Santaris Pharma.
DMAD6HS	RU	http://www.santaris.com/product-pipeline

DMUPQ70	DI	DMUPQ70
DMUPQ70	DN	SPC5001
DMUPQ70	MI	TTBRG7E
DMUPQ70	MN	Proprotein convertase subtilisin/kexin type 9 (PCSK9)
DMUPQ70	MT	DTT
DMUPQ70	MA	Inhibitor
DMUPQ70	RN	2011 Pipeline of Santaris Pharma.
DMUPQ70	RU	http://www.santaris.com/product-pipeline

DMO1FTI	DI	DMO1FTI
DMO1FTI	DN	Sphingosine
DMO1FTI	MI	TTUAIKM
DMO1FTI	MN	Cholinephosphate cytidylyltransferase (PCYT1B)
DMO1FTI	MT	DTT
DMO1FTI	MA	Inhibitor
DMO1FTI	RN	Sphingosine inhibits the activity of rat liver CTP:phosphocholine cytidylyltransferase. J Biol Chem. 1990 Jul 15;265(20):11746-50.
DMO1FTI	RU	https://pubmed.ncbi.nlm.nih.gov/2164014

DMJCQKA	DI	DMJCQKA
DMJCQKA	DN	Sphingosine-1-Phosphate
DMJCQKA	MI	DTI7UX6
DMJCQKA	MN	Breast cancer resistance protein (ABCG2)
DMJCQKA	MT	DTP
DMJCQKA	MA	Substrate
DMJCQKA	RN	Estradiol induces export of sphingosine 1-phosphate from breast cancer cells via ABCC1 and ABCG2. J Biol Chem. 2010 Apr 2;285(14):10477-86.
DMJCQKA	RU	http://www.ncbi.nlm.nih.gov/pubmed/20110355

DMJCQKA	DI	DMJCQKA
DMJCQKA	DN	Sphingosine-1-Phosphate
DMJCQKA	MI	DTUGYRD
DMJCQKA	MN	P-glycoprotein 1 (ABCB1)
DMJCQKA	MT	DTP
DMJCQKA	MA	Substrate
DMJCQKA	RN	Lipid dependence of ABC transporter localization and function. Chem Phys Lipids. 2009 Oct;161(2):57-64.
DMJCQKA	RU	https://doi.org/10.1016/j.chemphyslip.2009.07.004

DMJCQKA	DI	DMJCQKA
DMJCQKA	DN	Sphingosine-1-Phosphate
DMJCQKA	MI	DE6WXTH
DMJCQKA	MN	Phospholipid phosphatase 1 (PLPP1)
DMJCQKA	MT	DME
DMJCQKA	MA	Metabolism
DMJCQKA	RN	Lipid phosphate phosphatase 3 regulates adipocyte sphingolipid synthesis, but not developmental adipogenesis or diet-induced obesity in mice. PLoS One. 2018 Jun 11;13(6):e0198063.
DMJCQKA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29889835

DMJCQKA	DI	DMJCQKA
DMJCQKA	DN	Sphingosine-1-Phosphate
DMJCQKA	MI	DT3Q1UO
DMJCQKA	MN	Protein spinster homolog 2 (SLC63A2)
DMJCQKA	MT	DTP
DMJCQKA	MA	Substrate
DMJCQKA	RN	The ABCs of membrane transporters in health and disease (SLC series): Introduction. Molecular Aspects of Medicine, 2013, 34(2-3):95-107. (GeneName=SLC63A2)
DMJCQKA	RU	http://slc.bioparadigms.org/protein?GeneName=SLC63A2

DMJCQKA	DI	DMJCQKA
DMJCQKA	DN	Sphingosine-1-Phosphate
DMJCQKA	MI	DELSNWC
DMJCQKA	MN	Sphingosine kinase 1 (SPHK1)
DMJCQKA	MT	DME
DMJCQKA	MA	Metabolism
DMJCQKA	RN	Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J Biol Chem. 2003 Nov 28;278(48):47408-15.
DMJCQKA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=13129923

DMJCQKA	DI	DMJCQKA
DMJCQKA	DN	Sphingosine-1-Phosphate
DMJCQKA	MI	DES1RUQ
DMJCQKA	MN	Sphingosine kinase 2 (SPHK2)
DMJCQKA	MT	DME
DMJCQKA	MA	Metabolism
DMJCQKA	RN	Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J Biol Chem. 2003 Nov 28;278(48):47408-15.
DMJCQKA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=13129923

DMJCQKA	DI	DMJCQKA
DMJCQKA	DN	Sphingosine-1-Phosphate
DMJCQKA	MI	TT9JZCK
DMJCQKA	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMJCQKA	MT	DTT
DMJCQKA	MA	Inhibitor
DMJCQKA	RN	Exploration of amino alcohol derivatives as novel, potent, and highly selective sphingosine-1-phosphate receptor subtype-1 agonists. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2520-4.
DMJCQKA	RU	https://pubmed.ncbi.nlm.nih.gov/20304639

DM5IPUS	DI	DM5IPUS
DM5IPUS	DN	SPI-014
DM5IPUS	MI	TT9W8GU
DM5IPUS	MN	Gamma-secretase (GS)
DM5IPUS	MT	DTT
DM5IPUS	MA	Modulator
DM5IPUS	RN	Modulation of gamma-secretase for the treatment of Alzheimer's disease. Int J Alzheimers Dis. 2012;2012:210756.
DM5IPUS	RU	https://pubmed.ncbi.nlm.nih.gov/23320246

DM8O2AQ	DI	DM8O2AQ
DM8O2AQ	DN	SPN-803
DM8O2AQ	MI	TT0EOB8
DM8O2AQ	MN	B-Raf messenger RNA (BRAF mRNA)
DM8O2AQ	MT	DTT
DM8O2AQ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1943).
DM8O2AQ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1943

DM8O2AQ	DI	DM8O2AQ
DM8O2AQ	DN	SPN-803
DM8O2AQ	MI	TTAN5W2
DM8O2AQ	MN	Raf messenger RNA (Raf mRNA)
DM8O2AQ	MT	DTT
DM8O2AQ	MA	Inhibitor
DM8O2AQ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2184).
DM8O2AQ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2184

DMO5760	DI	DMO5760
DMO5760	DN	SR13668
DMO5760	MI	TTAZ05C
DMO5760	MN	RAC-gamma serine/threonine-protein kinase (AKT3)
DMO5760	MT	DTT
DMO5760	MA	Modulator
DMO5760	RN	Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668. Cancer Prev Res (Phila). 2011 Mar;4(3):347-53.
DMO5760	RU	https://pubmed.ncbi.nlm.nih.gov/21372034

DMYRPBI	DI	DMYRPBI
DMYRPBI	DN	SR-4554
DMYRPBI	MI	TT5XVD6
DMYRPBI	MN	Intracellular nitroreductase (INR)
DMYRPBI	MT	DTT
DMYRPBI	MA	Modulator
DMYRPBI	RN	A phase I study of SR-4554 via intravenous administration for noninvasive investigation of tumor hypoxia by magnetic resonance spectroscopy in patients with malignancy. Clin Cancer Res. 2003 Nov 1;9(14):5101-12.
DMYRPBI	RU	https://pubmed.ncbi.nlm.nih.gov/14613987

DMQMO4N	DI	DMQMO4N
DMQMO4N	DN	SRF388
DMQMO4N	MI	TTC5LTG
DMQMO4N	MN	Interleukin-27 (IL27)
DMQMO4N	MT	DTT
DMQMO4N	RN	Clinical pipeline report, company report or official report of Surface oncology.
DMQMO4N	RU	https://www.surfaceoncology.com/pipeline-programs/

DMTK1BV	DI	DMTK1BV
DMTK1BV	DN	SRF617
DMTK1BV	MI	TTYM8DJ
DMTK1BV	MN	Ectonucleoside triphosphate diphosphohydrolase 1 (CD39)
DMTK1BV	MT	DTT
DMTK1BV	RN	Clinical pipeline report, company report or official report of Surface oncology.
DMTK1BV	RU	https://www.surfaceoncology.com/pipeline-programs/

DM0EWMT	DI	DM0EWMT
DM0EWMT	DN	SRK-181
DM0EWMT	MI	TTR9XHZ
DM0EWMT	MN	Transforming growth factor beta 1 (TGFB1)
DM0EWMT	MT	DTT
DM0EWMT	MA	Inhibitor
DM0EWMT	RN	Clinical pipeline report, company report or official report of Scholar Rock.
DM0EWMT	RU	https://scholarrock.com/our-pipeline/oncology/

DM7DAKX	DI	DM7DAKX
DM7DAKX	DN	SRT2379
DM7DAKX	MI	TTUF2HO
DM7DAKX	MN	NAD-dependent deacetylase sirtuin-1 (SIRT1)
DM7DAKX	MT	DTT
DM7DAKX	MA	Modulator
DM7DAKX	RN	SRT2379, a small-molecule SIRT1 activator, fails to reduce cytokine release in a human endotoxemia model. Critical Care 2013, 17(Suppl 4):P8.
DM7DAKX	RU	http://www.ccforum.com/content/17/S4/P8

DMRAXFH	DI	DMRAXFH
DMRAXFH	DN	SRT3025
DMRAXFH	MI	TTUF2HO
DMRAXFH	MN	NAD-dependent deacetylase sirtuin-1 (SIRT1)
DMRAXFH	MT	DTT
DMRAXFH	MA	Modulator
DMRAXFH	RN	The Sirt1 Activators SRT2183 and SRT3025 Inhibit RANKL-Induced Osteoclastogenesis in Bone Marrow-Derived Macrophages and Down-Regulate Sirt3 in Sirt1 Null Cells. PLoS One. 2015 Jul 30;10(7):e0134391.
DMRAXFH	RU	https://pubmed.ncbi.nlm.nih.gov/26226624

DMO1N8A	DI	DMO1N8A
DMO1N8A	DN	SRX-251
DMO1N8A	MI	TT4TFGN
DMO1N8A	MN	Vasopressin V1a receptor (V1AR)
DMO1N8A	MT	DTT
DMO1N8A	MA	Antagonist
DMO1N8A	RN	Orally active vasopressin V1a receptor antagonist, SRX251, selectively blocks aggressive behavior. Pharmacol Biochem Behav. 2006 Feb;83(2):169-74.
DMO1N8A	RU	https://pubmed.ncbi.nlm.nih.gov/16504276

DMSUFW6	DI	DMSUFW6
DMSUFW6	DN	SSR-125047
DMSUFW6	MI	TTFBNVI
DMSUFW6	MN	Aldose reductase (AKR1B1)
DMSUFW6	MT	DTT
DMSUFW6	MA	Inhibitor
DMSUFW6	RN	Aldose reductase inhibitors: an update. Ann Pharmacother. 1993 Jun;27(6):751-4.
DMSUFW6	RU	https://pubmed.ncbi.nlm.nih.gov/8329799

DMSUFW6	DI	DMSUFW6
DMSUFW6	DN	SSR-125047
DMSUFW6	MI	TT5TPI6
DMSUFW6	MN	Opioid receptor sigma 1 (OPRS1)
DMSUFW6	MT	DTT
DMSUFW6	MA	Binder
DMSUFW6	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMSUFW6	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMG6NI8	DI	DMG6NI8
DMG6NI8	DN	SSR-125329A
DMG6NI8	MI	TT5TPI6
DMG6NI8	MN	Opioid receptor sigma 1 (OPRS1)
DMG6NI8	MT	DTT
DMG6NI8	MA	Binder
DMG6NI8	RN	SSR125329A, a high affinity sigma receptor ligand with potent anti-inflammatory properties. Eur J Pharmacol. 2002 Dec 5;456(1-3):123-31.
DMG6NI8	RU	https://pubmed.ncbi.nlm.nih.gov/12450578

DMOJA7N	DI	DMOJA7N
DMOJA7N	DN	SSR-128428
DMOJA7N	MI	TT6L509
DMOJA7N	MN	Coagulation factor IIa (F2)
DMOJA7N	MT	DTT
DMOJA7N	MA	Modulator
DMOJA7N	RN	Company report (Sanofi) (drug: FY2008)
DMOJA7N	RU	http://en.sanofi.com/events/ceo_interview/docs/FY2008_EN_V5.pdf

DMOJA7N	DI	DMOJA7N
DMOJA7N	DN	SSR-128428
DMOJA7N	MI	TTCIHJA
DMOJA7N	MN	Coagulation factor Xa (F10)
DMOJA7N	MT	DTT
DMOJA7N	MA	Modulator
DMOJA7N	RN	Company report (Sanofi) (drug: FY2008)
DMOJA7N	RU	http://en.sanofi.com/events/ceo_interview/docs/FY2008_EN_V5.pdf

DMXQF1T	DI	DMXQF1T
DMXQF1T	DN	SSR-181507
DMXQF1T	MI	TTSQIFT
DMXQF1T	MN	5-HT 1A receptor (HTR1A)
DMXQF1T	MT	DTT
DMXQF1T	MA	Modulator
DMXQF1T	RN	SSR181507, a dopamine D receptor and 5-HT() receptor ligand: evidence for mixed anxiolytic- and antidepressant-like activities.Pharmacol Biochem Behav.2011 Jan;97(3):428-35.
DMXQF1T	RU	https://www.ncbi.nlm.nih.gov/pubmed/20920519

DMXQF1T	DI	DMXQF1T
DMXQF1T	DN	SSR-181507
DMXQF1T	MI	TTEX248
DMXQF1T	MN	Dopamine D2 receptor (D2R)
DMXQF1T	MT	DTT
DMXQF1T	MA	Modulator
DMXQF1T	RN	SSR181507, a dopamine D receptor and 5-HT() receptor ligand: evidence for mixed anxiolytic- and antidepressant-like activities.Pharmacol Biochem Behav.2011 Jan;97(3):428-35.
DMXQF1T	RU	https://www.ncbi.nlm.nih.gov/pubmed/20920519

DMX6V1L	DI	DMX6V1L
DMX6V1L	DN	ST-1141
DMX6V1L	MI	TTWDC17
DMX6V1L	MN	Growth hormone secretagogue receptor 1 (GHSR)
DMX6V1L	MT	DTT
DMX6V1L	MA	Agonist
DMX6V1L	RN	The Prokinetic Face of Ghrelin. International Journal of Peptides Volume 2010 (2010), Article ID 493614, Page(11).
DMX6V1L	RU	http://www.hindawi.com/journals/ijpep/2010/493614/

DMGPIV0	DI	DMGPIV0
DMGPIV0	DN	STA-5312
DMGPIV0	MI	TTYFKSZ
DMGPIV0	MN	Tubulin beta (TUBB)
DMGPIV0	MT	DTT
DMGPIV0	MA	Inhibitor
DMGPIV0	RN	Conjugated indole-imidazole derivatives displaying cytotoxicity against multidrug resistant cancer cell lines. Bioorganic & Medicinal Chemistry Letters. 11/2006; 16(19):5164-8.
DMGPIV0	RU	http://pubs.acs.org/doi/abs/10.1021/op6002852

DMDF29A	DI	DMDF29A
DMDF29A	DN	STM 434
DMDF29A	MI	TT9RV4P
DMDF29A	MN	Activin (ACT)
DMDF29A	MT	DTT
DMDF29A	MA	Inhibitor
DMDF29A	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMDF29A	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DMDF29A	DI	DMDF29A
DMDF29A	DN	STM 434
DMDF29A	MI	TTMQO60
DMDF29A	MN	Rho-associated protein kinase (ROCK)
DMDF29A	MT	DTT
DMDF29A	MA	Inhibitor
DMDF29A	RN	Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
DMDF29A	RU	https://www.ncbi.nlm.nih.gov/pubmed/28048944

DMXCJP8	DI	DMXCJP8
DMXCJP8	DN	STP1002
DMXCJP8	MI	TTKSAQZ
DMXCJP8	MN	Tankyrase (TNKS)
DMXCJP8	MT	DTT
DMXCJP8	MA	Inhibitor
DMXCJP8	RN	Design and development of a tankyrase inhibitor STP06-1002 as an anticancer therapeutic agent. Cancer Res 2017;77(13 Suppl):Abstract nr 5171.
DMXCJP8	RU	https://cancerres.aacrjournals.org/content/77/13_Supplement/5171

DMC5HXI	DI	DMC5HXI
DMC5HXI	DN	STRO-002
DMC5HXI	MI	TTVC37M
DMC5HXI	MN	Folate receptor alpha (FOLR1)
DMC5HXI	MT	DTT
DMC5HXI	RN	Clinical pipeline report, company report or official report of Sutro Biopharma.
DMC5HXI	RU	https://www.sutrobio.com/pipeline/

DMJAPRK	DI	DMJAPRK
DMJAPRK	DN	STX 64
DMJAPRK	MI	TTHM0R1
DMJAPRK	MN	Steryl-sulfatase (STS)
DMJAPRK	MT	DTT
DMJAPRK	MA	Inhibitor
DMJAPRK	RN	Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor. Clin Cancer Res. 2006 Mar 1;12(5):1585-92.
DMJAPRK	RU	https://pubmed.ncbi.nlm.nih.gov/16533785

DMMAS3K	DI	DMMAS3K
DMMAS3K	DN	SULFAMIDE
DMMAS3K	MI	TTUNARX
DMMAS3K	MN	Carbonic anhydrase (CA)
DMMAS3K	MT	DTT
DMMAS3K	MA	Inhibitor
DMMAS3K	RN	Carbonic anhydrase inhibitors: crystallographic and solution binding studies for the interaction of a boron-containing aromatic sulfamide with mamm... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3601-5.
DMMAS3K	RU	https://pubmed.ncbi.nlm.nih.gov/20472429

DMMAS3K	DI	DMMAS3K
DMMAS3K	DN	SULFAMIDE
DMMAS3K	MI	TTHQPL7
DMMAS3K	MN	Carbonic anhydrase I (CA-I)
DMMAS3K	MT	DTT
DMMAS3K	MA	Inhibitor
DMMAS3K	RN	Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5435-9.
DMMAS3K	RU	https://pubmed.ncbi.nlm.nih.gov/15454240

DMMAS3K	DI	DMMAS3K
DMMAS3K	DN	SULFAMIDE
DMMAS3K	MI	TTANPDJ
DMMAS3K	MN	Carbonic anhydrase II (CA-II)
DMMAS3K	MT	DTT
DMMAS3K	MA	Inhibitor
DMMAS3K	RN	Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5435-9.
DMMAS3K	RU	https://pubmed.ncbi.nlm.nih.gov/15454240

DMMAS3K	DI	DMMAS3K
DMMAS3K	DN	SULFAMIDE
DMMAS3K	MI	TTZHA0O
DMMAS3K	MN	Carbonic anhydrase IV (CA-IV)
DMMAS3K	MT	DTT
DMMAS3K	MA	Inhibitor
DMMAS3K	RN	Carbonic anhydrase inhibitors: crystallographic and solution binding studies for the interaction of a boron-containing aromatic sulfamide with mamm... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3601-5.
DMMAS3K	RU	https://pubmed.ncbi.nlm.nih.gov/20472429

DMMAS3K	DI	DMMAS3K
DMMAS3K	DN	SULFAMIDE
DMMAS3K	MI	TT2LVK8
DMMAS3K	MN	Carbonic anhydrase IX (CA-IX)
DMMAS3K	MT	DTT
DMMAS3K	MA	Inhibitor
DMMAS3K	RN	Carbonic anhydrase inhibitors. Inhibition of isozymes I, II, IV, V, and IX with anions isosteric and isoelectronic with sulfate, nitrate, and carbo... Bioorg Med Chem Lett. 2005 Feb 1;15(3):567-71.
DMMAS3K	RU	https://pubmed.ncbi.nlm.nih.gov/15664814

DMIF8RY	DI	DMIF8RY
DMIF8RY	DN	SUN-K0706
DMIF8RY	MI	TT6PKBN
DMIF8RY	MN	Proto-oncogene c-Src (SRC)
DMIF8RY	MT	DTT
DMIF8RY	MA	Inhibitor
DMIF8RY	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMIF8RY	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMDOSL0	DI	DMDOSL0
DMDOSL0	DN	SUN-N8075
DMDOSL0	MI	TTC0BEN
DMDOSL0	MN	Oxidative stress (OS)
DMDOSL0	MT	DTT
DMDOSL0	MA	Inhibitor
DMDOSL0	RN	Protective effect of SUN N8075, a free radical scavenger, against excessive light-induced retinal damage in mice. Biol Pharm Bull. 2014;37(3):424-30.
DMDOSL0	RU	https://pubmed.ncbi.nlm.nih.gov/24583861

DMTOUY9	DI	DMTOUY9
DMTOUY9	DN	Suramin
DMTOUY9	MI	TTZFDBT
DMTOUY9	MN	Follicle-stimulating hormone receptor (FSHR)
DMTOUY9	MT	DTT
DMTOUY9	MA	Antagonist
DMTOUY9	RN	Suramin: clinical uses and structure-activity relationships. Mini Rev Med Chem. 2008 Nov;8(13):1384-94.
DMTOUY9	RU	https://pubmed.ncbi.nlm.nih.gov/18991754

DMTOUY9	DI	DMTOUY9
DMTOUY9	DN	Suramin
DMTOUY9	MI	TTR7GJO
DMTOUY9	MN	Heparanase (HPSE)
DMTOUY9	MT	DTT
DMTOUY9	MA	Inhibitor
DMTOUY9	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1728).
DMTOUY9	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1728

DMZP671	DI	DMZP671
DMZP671	DN	SUVN 911
DMZP671	MI	TTL1ATN
DMZP671	MN	Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2)
DMZP671	MT	DTT
DMZP671	MA	Antagonist
DMZP671	RN	Discovery and Development of 3-(6-Chloropyridine-3-yloxymethyl)-2-azabicyclo[3.1.0]hexane Hydrochloride (SUVN-911): A Novel, Potent, Selective, and Orally Active Neuronal Nicotinic Acetylcholine alpha42 Receptor Antagonist for the Treatment of Depression. J Med Chem. 2020 Mar 26;63(6):2833-2853.
DMZP671	RU	https://pubmed.ncbi.nlm.nih.gov/32026697

DMLPBVF	DI	DMLPBVF
DMLPBVF	DN	SUVN-911
DMLPBVF	MI	TT5KPZR
DMLPBVF	MN	Neuronal acetylcholine receptor beta-2 (CHRNB2)
DMLPBVF	MT	DTT
DMLPBVF	MA	Antagonist
DMLPBVF	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMLPBVF	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DM6ZOD2	DI	DM6ZOD2
DM6ZOD2	DN	SUVN-D4010
DM6ZOD2	MI	TT07C3Y
DM6ZOD2	MN	5-HT 4 receptor (HTR4)
DM6ZOD2	MT	DTT
DM6ZOD2	MA	Agonist
DM6ZOD2	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM6ZOD2	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMHMG6X	DI	DMHMG6X
DMHMG6X	DN	SX-682
DMHMG6X	MI	TTMWT8Z
DMHMG6X	MN	C-X-C chemokine receptor type 1 (CXCR1)
DMHMG6X	MT	DTT
DMHMG6X	MA	Inhibitor
DMHMG6X	RN	Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models. Clin Cancer Res. 2020 Mar 15;26(6):1420-1431.
DMHMG6X	RU	https://pubmed.ncbi.nlm.nih.gov/31848188

DMHMG6X	DI	DMHMG6X
DMHMG6X	DN	SX-682
DMHMG6X	MI	TT30C9G
DMHMG6X	MN	C-X-C chemokine receptor type 2 (CXCR2)
DMHMG6X	MT	DTT
DMHMG6X	MA	Inhibitor
DMHMG6X	RN	Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models. Clin Cancer Res. 2020 Mar 15;26(6):1420-1431.
DMHMG6X	RU	https://pubmed.ncbi.nlm.nih.gov/31848188

DMK48PM	DI	DMK48PM
DMK48PM	DN	SY-1365
DMK48PM	MI	TTQYF7G
DMK48PM	MN	Cyclin-dependent kinase 7 (CDK7)
DMK48PM	MT	DTT
DMK48PM	MA	Inhibitor
DMK48PM	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMK48PM	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMH8UF0	DI	DMH8UF0
DMH8UF0	DN	SY-1425
DMH8UF0	MI	TTW38KT
DMH8UF0	MN	Retinoic acid receptor alpha (RARA)
DMH8UF0	MT	DTT
DMH8UF0	MA	Agonist
DMH8UF0	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMH8UF0	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMNW3LH	DI	DMNW3LH
DMNW3LH	DN	SY-5609
DMNW3LH	MI	TTQYF7G
DMNW3LH	MN	Cyclin-dependent kinase 7 (CDK7)
DMNW3LH	MT	DTT
DMNW3LH	MA	Inhibitor
DMNW3LH	RN	Clinical pipeline report, company report or official report of Syros Pharmaceuticals.
DMNW3LH	RU	https://www.syros.com/programs/sy-5609

DMVXLS5	DI	DMVXLS5
DMVXLS5	DN	Sym021
DMVXLS5	MI	TTNBFWK
DMVXLS5	MN	Programmed cell death protein 1 (PD-1)
DMVXLS5	MT	DTT
DMVXLS5	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMVXLS5	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMCK2YR	DI	DMCK2YR
DMCK2YR	DN	Sym022
DMCK2YR	MI	TTNVXAW
DMCK2YR	MN	Lymphocyte activation gene 3 protein (LAG3)
DMCK2YR	MT	DTT
DMCK2YR	MA	Inhibitor
DMCK2YR	RN	Clinical pipeline report, company report or official report of Symphogen.
DMCK2YR	RU	http://www.symphogen.com/pipeline/products/sym022/

DMV3L62	DI	DMV3L62
DMV3L62	DN	Sym023
DMV3L62	MI	TT1RWL7
DMV3L62	MN	Hepatitis A virus cellular receptor 2 (TIM3)
DMV3L62	MT	DTT
DMV3L62	MA	Inhibitor
DMV3L62	RN	Clinical pipeline report, company report or official report of Symphogen.
DMV3L62	RU	http://www.symphogen.com/pipeline/products/sym023/

DM0EZ69	DI	DM0EZ69
DM0EZ69	DN	SYN004
DM0EZ69	MI	TTGKNB4
DM0EZ69	MN	Epidermal growth factor receptor (EGFR)
DM0EZ69	MT	DTT
DM0EZ69	MA	Inhibitor
DM0EZ69	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM0EZ69	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMX05W8	DI	DMX05W8
DMX05W8	DN	SYN-1001
DMX05W8	MI	TTN4QDT
DMX05W8	MN	Opioid receptor (OPR)
DMX05W8	MT	DTT
DMX05W8	MA	Agonist
DMX05W8	RN	Improved brain uptake and pharmacological activity profile of morphine-6-glucuronide using a peptide vector-mediated strategy. J Pharmacol Exp Ther. 2005 May;313(2):712-9.
DMX05W8	RU	https://pubmed.ncbi.nlm.nih.gov/15647327

DM4UVTO	DI	DM4UVTO
DM4UVTO	DN	SYN125
DM4UVTO	MI	TTNBFWK
DM4UVTO	MN	Programmed cell death protein 1 (PD-1)
DM4UVTO	MT	DTT
DM4UVTO	RN	Clinical pipeline report, company report or official report of Symphogen.
DM4UVTO	RU	https://www.synermore.com/pipeline

DMZJNHM	DI	DMZJNHM
DMZJNHM	DN	SYNB1891
DMZJNHM	MI	TTT402Y
DMZJNHM	MN	Stimulator of interferon genes protein (TMEM173)
DMZJNHM	MT	DTT
DMZJNHM	MA	Agonist
DMZJNHM	RN	Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity. Nat Commun. 2020 Jun 1;11(1):2739.
DMZJNHM	RU	https://pubmed.ncbi.nlm.nih.gov/32483165

DM83E5B	DI	DM83E5B
DM83E5B	DN	Synthetic neutrophil inhibitor peptide
DM83E5B	MI	TTHQGFL
DM83E5B	MN	PMN apoptosis and chemotaxis (PMNAC)
DM83E5B	MT	DTT
DM83E5B	MA	Inhibitor
DM83E5B	RN	Attenuation of interleukin 8-induced nasal inflammation by an inhibitor peptide. Am J Respir Crit Care Med. 2001 Apr;163(5):1198-205.
DM83E5B	RU	https://pubmed.ncbi.nlm.nih.gov/11316659

DMH76KD	DI	DMH76KD
DMH76KD	DN	Syntropin
DMH76KD	MI	TTKMAZ6
DMH76KD	MN	Growth hormone receptor (GHR)
DMH76KD	MT	DTT
DMH76KD	MA	Modulator
DMH76KD	RN	Late feedback effects of hypothalamic-pituitary-adrenal axis hormones in healthy subjects. Psychoneuroendocrinology. 1998 May;23(4):371-83.
DMH76KD	RU	https://pubmed.ncbi.nlm.nih.gov/9695137

DMD23AX	DI	DMD23AX
DMD23AX	DN	Systebryl
DMD23AX	MI	TTE4KHA
DMD23AX	MN	Amyloid beta A4 protein (APP)
DMD23AX	MT	DTT
DMD23AX	MA	Inhibitor
DMD23AX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
DMD23AX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402

DMNE9Z0	DI	DMNE9Z0
DMNE9Z0	DN	T-0128
DMNE9Z0	MI	TTUTN1I
DMNE9Z0	MN	Human Deoxyribonucleic acid (hDNA)
DMNE9Z0	MT	DTT
DMNE9Z0	MA	Inhibitor
DMNE9Z0	RN	Complete regression of xenografted human carcinomas by camptothecin analogue-carboxymethyl dextran conjugate (T-0128). Cancer Res. 2000 Jun 1;60(11):2988-95.
DMNE9Z0	RU	https://pubmed.ncbi.nlm.nih.gov/10850447

DMV8IQW	DI	DMV8IQW
DMV8IQW	DN	Tafluposide
DMV8IQW	MI	TTGTQHC
DMV8IQW	MN	DNA topoisomerase I (TOP1)
DMV8IQW	MT	DTT
DMV8IQW	MA	Modulator
DMV8IQW	RN	Ex vivo effects of the dual topoisomerase inhibitor tafluposide (F 11782) on cells isolated from fresh tumor samples taken from patients with cancer. Anticancer Drugs. 2003 Jul;14(6):467-73.
DMV8IQW	RU	https://pubmed.ncbi.nlm.nih.gov/12853890

DMV8IQW	DI	DMV8IQW
DMV8IQW	DN	Tafluposide
DMV8IQW	MI	TT0IHXV
DMV8IQW	MN	DNA topoisomerase II (TOP2)
DMV8IQW	MT	DTT
DMV8IQW	MA	Modulator
DMV8IQW	RN	Ex vivo effects of the dual topoisomerase inhibitor tafluposide (F 11782) on cells isolated from fresh tumor samples taken from patients with cancer. Anticancer Drugs. 2003 Jul;14(6):467-73.
DMV8IQW	RU	https://pubmed.ncbi.nlm.nih.gov/12853890

DM6OKH4	DI	DM6OKH4
DM6OKH4	DN	TAK-020
DM6OKH4	MI	TTGM6VW
DM6OKH4	MN	Tyrosine-protein kinase BTK (ATK)
DM6OKH4	MT	DTT
DM6OKH4	MA	Inhibitor
DM6OKH4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM6OKH4	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DM0ZQ7J	DI	DM0ZQ7J
DM0ZQ7J	DN	TAK-041
DM0ZQ7J	MI	TTOL9B0
DM0ZQ7J	MN	G-protein-coupled receptor PGR3 (GPR139)
DM0ZQ7J	MT	DTT
DM0ZQ7J	MA	Agonist
DM0ZQ7J	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM0ZQ7J	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMX9EA0	DI	DMX9EA0
DMX9EA0	DN	TAK-058
DMX9EA0	MI	TTNXLKE
DMX9EA0	MN	5-HT 3 receptor (5HT3R)
DMX9EA0	MT	DTT
DMX9EA0	MA	Antagonist
DMX9EA0	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040805)
DMX9EA0	RU	http://adisinsight.springer.com/drugs/800040805

DMKUT08	DI	DMKUT08
DMKUT08	DN	TAK-071
DMKUT08	MI	TTZ9SOR
DMKUT08	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMKUT08	MT	DTT
DMKUT08	MA	Modulator
DMKUT08	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMKUT08	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMD79TX	DI	DMD79TX
DMD79TX	DN	TAK-102
DMD79TX	MI	TTJTSX4
DMD79TX	MN	Glypican-3 (GPC3)
DMD79TX	MT	DTT
DMD79TX	RN	ClinicalTrials.gov (NCT04405778) A Study of TAK-102 in Adult With Previously-Treated Solid Tumors. U.S. National Institutes of Health.
DMD79TX	RU	https://clinicaltrials.gov/ct2/show/NCT04405778

DMTXE19	DI	DMTXE19
DMTXE19	DN	TAK-114
DMTXE19	MI	TTH8FZW
DMTXE19	MN	Signal transducer and activator of transcription 3 (STAT3)
DMTXE19	MT	DTT
DMTXE19	MA	Modulator
DMTXE19	RN	Clinical pipeline report, company report or official report of Gastroenterology.
DMTXE19	RU	https://www.takeda.com/siteassets/system/investors/report/quarterlyannouncements/fy2014/takeda-ir-event--a-global-leader-in-gastroenterology-held-on-march-9-2015/qr2014_q3_p_en.pdf

DMYG704	DI	DMYG704
DMYG704	DN	TAK-137
DMYG704	MI	TTAN6JD
DMYG704	MN	Glutamate receptor AMPA (GRIA)
DMYG704	MT	DTT
DMYG704	MA	Modulator
DMYG704	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMYG704	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMRINBJ	DI	DMRINBJ
DMRINBJ	DN	TAK-169
DMRINBJ	MI	TTPURFN
DMRINBJ	MN	Cyclic ADP-ribose hydrolase 1 (CD38)
DMRINBJ	MT	DTT
DMRINBJ	MA	Inhibitor
DMRINBJ	RN	Clinical pipeline report, company report or official report of Molecular Templates.
DMRINBJ	RU	https://www.mtem.com/pipeline/tak-169

DMVYEFZ	DI	DMVYEFZ
DMVYEFZ	DN	TAK-202
DMVYEFZ	MI	TTFZYTO
DMVYEFZ	MN	C-C chemokine receptor type 2 (CCR2)
DMVYEFZ	MT	DTT
DMVYEFZ	MA	Antagonist
DMVYEFZ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMVYEFZ	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMW10HM	DI	DMW10HM
DMW10HM	DN	Tak-220
DMW10HM	MI	TT2CEJG
DMW10HM	MN	C-C chemokine receptor type 5 (CCR5)
DMW10HM	MT	DTT
DMW10HM	MA	Binder
DMW10HM	RN	Progress in targeting HIV-1 entry. Drug Discov Today. 2005 Aug 15;10(16):1085-94.
DMW10HM	RU	https://pubmed.ncbi.nlm.nih.gov/16182193

DM4GKV2	DI	DM4GKV2
DM4GKV2	DN	TAK-243
DM4GKV2	MI	TTU8HT1
DM4GKV2	MN	Ubiquitin-activating enzyme (UBA)
DM4GKV2	MT	DTT
DM4GKV2	MA	Inhibitor
DM4GKV2	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM4GKV2	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM1AKNI	DI	DM1AKNI
DM1AKNI	DN	TAK-252
DM1AKNI	MI	TTL31H0
DM1AKNI	MN	OX40L receptor (CD134)
DM1AKNI	MT	DTT
DM1AKNI	MA	Agonist
DM1AKNI	RN	Clinical pipeline report, company report or official report of Shattuck Labs.
DM1AKNI	RU	https://www.shattucklabs.com/pipeline/overview/

DM1AKNI	DI	DM1AKNI
DM1AKNI	DN	TAK-252
DM1AKNI	MI	TT8ZLTI
DM1AKNI	MN	Programmed cell death 1 ligand 1 (PD-L1)
DM1AKNI	MT	DTT
DM1AKNI	MA	Agonist
DM1AKNI	RN	Clinical pipeline report, company report or official report of Shattuck Labs.
DM1AKNI	RU	https://www.shattucklabs.com/pipeline/overview/

DM6KOBZ	DI	DM6KOBZ
DM6KOBZ	DN	TAK-285
DM6KOBZ	MI	TT6EO5L
DM6KOBZ	MN	Erbb2 tyrosine kinase receptor (HER2)
DM6KOBZ	MT	DTT
DM6KOBZ	MA	Inhibitor
DM6KOBZ	RN	Clinical pipeline report, company report or official report of Takeda (2009).
DM6KOBZ	RU	http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf

DMMWNQP	DI	DMMWNQP
DMMWNQP	DN	TAK-329
DMMWNQP	MI	TTDLNGZ
DMMWNQP	MN	Glucokinase (GCK)
DMMWNQP	MT	DTT
DMMWNQP	MA	Inhibitor
DMMWNQP	RN	Clinical pipeline report, company report or official report of Takeda.
DMMWNQP	RU	https://www.takeda.com/csr/reports/pdf/index/ar2011_16_en.pdf

DM7DFBL	DI	DM7DFBL
DM7DFBL	DN	TAK-441
DM7DFBL	MI	TT8J1S3
DM7DFBL	MN	Smoothened homolog (SMO)
DM7DFBL	MT	DTT
DM7DFBL	MA	Modulator
DM7DFBL	RN	TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling. Int J Cancer. 2013 Oct 15;133(8):1955-66.
DM7DFBL	RU	https://pubmed.ncbi.nlm.nih.gov/23564295

DMUXAP1	DI	DMUXAP1
DMUXAP1	DN	TAK-573
DMUXAP1	MI	TTPURFN
DMUXAP1	MN	Cyclic ADP-ribose hydrolase 1 (CD38)
DMUXAP1	MT	DTT
DMUXAP1	RN	Clinical pipeline report, company report or official report of Takeda.
DMUXAP1	RU	https://www.takeda.com/what-we-do/research-and-development/our-pipeline/

DMNFZOT	DI	DMNFZOT
DMNFZOT	DN	TAK-593
DMNFZOT	MI	TTI7421
DMNFZOT	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMNFZOT	MT	DTT
DMNFZOT	MA	Modulator
DMNFZOT	RN	Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism. Biochemistry. 2011 Feb 8;50(5):738-51. 
DMNFZOT	RU	https://www.ncbi.nlm.nih.gov/pubmed/21182308

DMNFZOT	DI	DMNFZOT
DMNFZOT	DN	TAK-593
DMNFZOT	MI	TTUTJGQ
DMNFZOT	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMNFZOT	MT	DTT
DMNFZOT	MA	Modulator
DMNFZOT	RN	Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism. Biochemistry. 2011 Feb 8;50(5):738-51. 
DMNFZOT	RU	https://www.ncbi.nlm.nih.gov/pubmed/21182308

DMQ8YKR	DI	DMQ8YKR
DMQ8YKR	DN	TAK-648
DMQ8YKR	MI	TTV5CGO
DMQ8YKR	MN	Phosphodiesterase 4 (PDE4)
DMQ8YKR	MT	DTT
DMQ8YKR	MA	Inhibitor
DMQ8YKR	RN	Pharmacokinetic/Pharmacodynamic Modeling of the PDE4 Inhibitor TAK-648 in Type 2 Diabetes: Early Translational Approaches for Human Dose Prediction. Clin Transl Sci. 2017 May;10(3):185-193.
DMQ8YKR	RU	https://pubmed.ncbi.nlm.nih.gov/28088839

DMCKF5J	DI	DMCKF5J
DMCKF5J	DN	TAK-676
DMCKF5J	MI	TTT402Y
DMCKF5J	MN	Stimulator of interferon genes protein (TMEM173)
DMCKF5J	MT	DTT
DMCKF5J	MA	Agonist
DMCKF5J	RN	National Cancer Institute Drug Dictionary (drug name TAK676).
DMCKF5J	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/sting-agonist-tak-676

DML3M0O	DI	DML3M0O
DML3M0O	DN	TAK-701
DML3M0O	MI	TT4V2JM
DML3M0O	MN	Hepatocyte growth factor (HGF)
DML3M0O	MT	DTT
DML3M0O	MA	Modulator
DML3M0O	RN	Targeting MET in cancer: rationale and progress.Nat Rev Cancer.2012 Jan 24;12(2):89-103.
DML3M0O	RU	https://www.ncbi.nlm.nih.gov/pubmed/22270953

DMC4RNA	DI	DMC4RNA
DMC4RNA	DN	TAK-733
DMC4RNA	MI	TTROQ37
DMC4RNA	MN	MAPK/ERK kinase kinase (MAP3K)
DMC4RNA	MT	DTT
DMC4RNA	MA	Modulator
DMC4RNA	RN	MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013; 6: 27.
DMC4RNA	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626705/

DMW43DL	DI	DMW43DL
DMW43DL	DN	TAK-828
DMW43DL	MI	TTGV6LY
DMW43DL	MN	Nuclear receptor ROR-gamma (RORG)
DMW43DL	MT	DTT
DMW43DL	MA	Agonist
DMW43DL	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMW43DL	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DM5KDGI	DI	DM5KDGI
DM5KDGI	DN	TAK-901
DM5KDGI	MI	TT5LS6T
DM5KDGI	MN	Aurora kinase B (AURKB)
DM5KDGI	MT	DTT
DM5KDGI	MA	Inhibitor
DM5KDGI	RN	Clinical pipeline report, company report or official report of Takeda (2009).
DM5KDGI	RU	http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf

DM1ALY9	DI	DM1ALY9
DM1ALY9	DN	TAK-931
DM1ALY9	MI	TTSMTDI
DM1ALY9	MN	CDC7-related kinase (CDC7)
DM1ALY9	MT	DTT
DM1ALY9	MA	Inhibitor
DM1ALY9	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM1ALY9	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMN4OGH	DI	DMN4OGH
DMN4OGH	DN	TAK-960
DMN4OGH	MI	TTIYVQP
DMN4OGH	MN	Polo-like kinase 1 (PLK1)
DMN4OGH	MT	DTT
DMN4OGH	MA	Modulator
DMN4OGH	RN	TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens. Mol Cancer Ther. 2012 Mar;11(3):700-9.
DMN4OGH	RU	https://pubmed.ncbi.nlm.nih.gov/22188812

DMSQZEP	DI	DMSQZEP
DMSQZEP	DN	TAR-200
DMSQZEP	MI	TTUBNVO
DMSQZEP	MN	DNA synthesis (DNA synth)
DMSQZEP	MT	DTT
DMSQZEP	MA	Inhibitor
DMSQZEP	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMSQZEP	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM5WDKY	DI	DM5WDKY
DM5WDKY	DN	TAS-103
DM5WDKY	MI	TT0IHXV
DM5WDKY	MN	DNA topoisomerase II (TOP2)
DM5WDKY	MT	DTT
DM5WDKY	MA	Modulator
DM5WDKY	RN	Mechanism of action of the dual topoisomerase-I and -II inhibitor TAS-103 and activity against (multi)drug resistant cells. Cancer Chemother Pharmacol. 2000;45(1):78-84.
DM5WDKY	RU	https://www.ncbi.nlm.nih.gov/pubmed/10647506

DM5WDKY	DI	DM5WDKY
DM5WDKY	DN	TAS-103
DM5WDKY	MI	DEYGVN4
DM5WDKY	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM5WDKY	MT	DME
DM5WDKY	MA	Metabolism
DM5WDKY	RN	Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer. J Clin Oncol. 2001 Apr 1;19(7):2084-90.
DM5WDKY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11283142

DMRX530	DI	DMRX530
DMRX530	DN	TAS-116
DMRX530	MI	TTH5YN2
DMRX530	MN	Heat shock protein 90 beta (HSP90B)
DMRX530	MT	DTT
DMRX530	MA	Inhibitor
DMRX530	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMRX530	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMJXBVP	DI	DMJXBVP
DMJXBVP	DN	TAS-119
DMJXBVP	MI	TTPS3C0
DMJXBVP	MN	Aurora kinase A (AURKA)
DMJXBVP	MT	DTT
DMJXBVP	MA	Inhibitor
DMJXBVP	RN	TAS-119, a selective Aurora A inhibitor, enhanced the antitumor efficacy of taxanes in multiple human tumor cell lines including paclitaxel-resistant cells. Molecular Cancer Therapeutics. 01/2014; 12(11_Supplement):A268-A268.
DMJXBVP	RU	http://mct.aacrjournals.org/content/12/11_Supplement/A268.short

DMHIA7Y	DI	DMHIA7Y
DMHIA7Y	DN	TAS-1440
DMHIA7Y	MI	TTNR0UQ
DMHIA7Y	MN	Lysine-specific histone demethylase 1 (LSD)
DMHIA7Y	MT	DTT
DMHIA7Y	MA	Inhibitor
DMHIA7Y	RN	Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
DMHIA7Y	RU	https://astx.com/tas1440-oral-lsd1-inhibitor-hematological-malignancies/

DMFG6ML	DI	DMFG6ML
DMFG6ML	DN	TAS3681
DMFG6ML	MI	TTS64P2
DMFG6ML	MN	Androgen receptor (AR)
DMFG6ML	MT	DTT
DMFG6ML	MA	Antagonist
DMFG6ML	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMFG6ML	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMKW4AJ	DI	DMKW4AJ
DMKW4AJ	DN	Tasidotin hydrochloride
DMKW4AJ	MI	TTYFKSZ
DMKW4AJ	MN	Tubulin beta (TUBB)
DMKW4AJ	MT	DTT
DMKW4AJ	MA	Binder
DMKW4AJ	RN	Intracellular activation and deactivation of tasidotin, an analog of dolastatin 15: correlation with cytotoxicity. Mol Pharmacol. 2009 Jan;75(1):218-26.
DMKW4AJ	RU	https://pubmed.ncbi.nlm.nih.gov/18927208

DM9CDPO	DI	DM9CDPO
DM9CDPO	DN	TBC-M4
DM9CDPO	MI	TTEC2T3
DM9CDPO	MN	Human immunodeficiency virus Envelope glycoprotein gp160 (HIV env)
DM9CDPO	MT	DTT
DM9CDPO	RN	A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res Hum Retroviruses. 2009 Nov;25(11):1107-16.
DM9CDPO	RU	https://pubmed.ncbi.nlm.nih.gov/19943789

DM9CDPO	DI	DM9CDPO
DM9CDPO	DN	TBC-M4
DM9CDPO	MI	TTFGZB6
DM9CDPO	MN	Human immunodeficiency virus GAG protein (HIV gag)
DM9CDPO	MT	DTT
DM9CDPO	RN	A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res Hum Retroviruses. 2009 Nov;25(11):1107-16.
DM9CDPO	RU	https://pubmed.ncbi.nlm.nih.gov/19943789

DM4W92J	DI	DM4W92J
DM4W92J	DN	TC-2216
DM4W92J	MI	TTL1ATN
DM4W92J	MN	Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2)
DM4W92J	MT	DTT
DM4W92J	MA	Modulator
DM4W92J	RN	TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity.CNS Neurosci Ther.2008 Winter;14(4):266-77.
DM4W92J	RU	https://www.ncbi.nlm.nih.gov/pubmed/19040552

DMJEBK8	DI	DMJEBK8
DMJEBK8	DN	TCD-717
DMJEBK8	MI	TT10AWB
DMJEBK8	MN	Choline kinase (CHKA)
DMJEBK8	MT	DTT
DMJEBK8	MA	Inhibitor
DMJEBK8	RN	National Cancer Institute Drug Dictionary (drug id 687183).
DMJEBK8	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=687183

DMV0AH8	DI	DMV0AH8
DMV0AH8	DN	TCN-P
DMV0AH8	MI	TTAZ05C
DMV0AH8	MN	RAC-gamma serine/threonine-protein kinase (AKT3)
DMV0AH8	MT	DTT
DMV0AH8	MA	Modulator
DMV0AH8	RN	Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT.Invest New Drugs.2011 Dec;29(6):1381-9.
DMV0AH8	RU	https://www.ncbi.nlm.nih.gov/pubmed/20644979

DMO8L6T	DI	DMO8L6T
DMO8L6T	DN	TD-0714
DMO8L6T	MI	TT5TKPM
DMO8L6T	MN	Neutral endopeptidase (MME)
DMO8L6T	MT	DTT
DMO8L6T	MA	Inhibitor
DMO8L6T	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMO8L6T	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMJG7AY	DI	DMJG7AY
DMJG7AY	DN	TD-1473
DMJG7AY	MI	TTJSQEF
DMJG7AY	MN	Tyrosine-protein kinase (PTK)
DMJG7AY	MT	DTT
DMJG7AY	MA	Inhibitor
DMJG7AY	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMJG7AY	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DM58J7E	DI	DM58J7E
DM58J7E	DN	Tedalinab
DM58J7E	MI	TTMSFAW
DM58J7E	MN	Cannabinoid receptor 2 (CB2)
DM58J7E	MT	DTT
DM58J7E	MA	Agonist
DM58J7E	RN	Cannabinoid CB2 receptor (CNR2). SciBX 3(46); doi:10.1038/scibx.2010.1384. Dec. 2 2010
DM58J7E	RU	http://www.nature.com/scibx/journal/v3/n46/full/scibx.2010.1384.html

DMV5LGJ	DI	DMV5LGJ
DMV5LGJ	DN	Tedatioxetine
DMV5LGJ	MI	TTWJBZ5
DMV5LGJ	MN	5-HT 2C receptor (HTR2C)
DMV5LGJ	MT	DTT
DMV5LGJ	MA	Modulator
DMV5LGJ	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMV5LGJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMV5LGJ	DI	DMV5LGJ
DMV5LGJ	DN	Tedatioxetine
DMV5LGJ	MI	TTNXLKE
DMV5LGJ	MN	5-HT 3 receptor (5HT3R)
DMV5LGJ	MT	DTT
DMV5LGJ	MA	Modulator
DMV5LGJ	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMV5LGJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMZG9U0	DI	DMZG9U0
DMZG9U0	DN	TeloB-Vax
DMZG9U0	MI	TTUJFD0
DMZG9U0	MN	Telomerase reverse transcriptase (TERT)
DMZG9U0	MT	DTT
DMZG9U0	MA	Modulator
DMZG9U0	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMZG9U0	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM7Q4EX	DI	DM7Q4EX
DM7Q4EX	DN	Temanogrel
DM7Q4EX	MI	TTJQOD7
DM7Q4EX	MN	5-HT 2A receptor (HTR2A)
DM7Q4EX	MT	DTT
DM7Q4EX	MA	Agonist
DM7Q4EX	RN	Clinical pipeline report, company report or official report of Arena Pharmaceuticals.
DM7Q4EX	RU	http://www.arenapharm.com/temanogrel

DM4UOY5	DI	DM4UOY5
DM4UOY5	DN	TEN010
DM4UOY5	MI	TTRA6BO
DM4UOY5	MN	Bromodomain-containing protein 4 (BRD4)
DM4UOY5	MT	DTT
DM4UOY5	MA	Modulator
DM4UOY5	RN	Targeting bromodomains: epigenetic readers of lysine acetylation.Nat Rev Drug Discov.2014 May;13(5):337-56.
DM4UOY5	RU	https://www.ncbi.nlm.nih.gov/pubmed/24751816

DMGJCDR	DI	DMGJCDR
DMGJCDR	DN	Teneligliptin
DMGJCDR	MI	DE4LYSA
DMGJCDR	MN	Cytochrome P450 3A4 (CYP3A4)
DMGJCDR	MT	DME
DMGJCDR	MA	Metabolism
DMGJCDR	RN	Effect of glimepiride on the pharmacokinetics of teneligliptin in healthy Korean subjects. J Clin Pharm Ther. 2019 Oct;44(5):720-725.
DMGJCDR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31094010

DMGJCDR	DI	DMGJCDR
DMGJCDR	DN	Teneligliptin
DMGJCDR	MI	TTDIGC1
DMGJCDR	MN	Dipeptidyl peptidase 4 (DPP-4)
DMGJCDR	MT	DTT
DMGJCDR	MA	Modulator
DMGJCDR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1612).
DMGJCDR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1612

DMC84Y9	DI	DMC84Y9
DMC84Y9	DN	Tepoditamab
DMC84Y9	MI	TT70N8V
DMC84Y9	MN	Myeloid inhibitory C-type lectin-like receptor (CD371)
DMC84Y9	MT	DTT
DMC84Y9	RN	MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis. Expert Opin Biol Ther. 2019 Jul;19(7):721-733.
DMC84Y9	RU	https://pubmed.ncbi.nlm.nih.gov/31286786

DMC84Y9	DI	DMC84Y9
DMC84Y9	DN	Tepoditamab
DMC84Y9	MI	TTUN7MC
DMC84Y9	MN	T-cell surface glycoprotein CD3 (CD3)
DMC84Y9	MT	DTT
DMC84Y9	RN	MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis. Expert Opin Biol Ther. 2019 Jul;19(7):721-733.
DMC84Y9	RU	https://pubmed.ncbi.nlm.nih.gov/31286786

DM3DUHL	DI	DM3DUHL
DM3DUHL	DN	TESTOSTERONE BUCICLATE
DM3DUHL	MI	TTS64P2
DM3DUHL	MN	Androgen receptor (AR)
DM3DUHL	MT	DTT
DM3DUHL	MA	Agonist
DM3DUHL	RN	Evidence for a role of testosterone-androgen receptor interactions in mediating masculine sexual behavior in male rats. Endocrinology. 1989 Feb;124(2):618-26.
DM3DUHL	RU	https://pubmed.ncbi.nlm.nih.gov/2912689

DMAOJBX	DI	DMAOJBX
DMAOJBX	DN	Tetrandrine
DMAOJBX	MI	TT5HONZ
DMAOJBX	MN	Calcium channel unspecific (CaC)
DMAOJBX	MT	DTT
DMAOJBX	MA	Antagonist
DMAOJBX	RN	Tetrandrine: a novel calcium channel antagonist inhibits type I calcium channels in neuroblastoma cells. Neuropharmacology. 1991 Dec;30(12A):1325-31.
DMAOJBX	RU	https://pubmed.ncbi.nlm.nih.gov/1787886

DMAOJBX	DI	DMAOJBX
DMAOJBX	DN	Tetrandrine
DMAOJBX	MI	DE4LYSA
DMAOJBX	MN	Cytochrome P450 3A4 (CYP3A4)
DMAOJBX	MT	DME
DMAOJBX	MA	Metabolism
DMAOJBX	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DMAOJBX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DMAOJBX	DI	DMAOJBX
DMAOJBX	DN	Tetrandrine
DMAOJBX	MI	DEIBDNY
DMAOJBX	MN	Cytochrome P450 3A5 (CYP3A5)
DMAOJBX	MT	DME
DMAOJBX	MA	Metabolism
DMAOJBX	RN	CYP3A5 mediates bioactivation and cytotoxicity of tetrandrine. Arch Toxicol. 2016 Jul;90(7):1737-48.
DMAOJBX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26302866

DMNDHKL	DI	DMNDHKL
DMNDHKL	DN	TG-1701
DMNDHKL	MI	TTGM6VW
DMNDHKL	MN	Tyrosine-protein kinase BTK (ATK)
DMNDHKL	MT	DTT
DMNDHKL	MA	Inhibitor
DMNDHKL	RN	Clinical pipeline report, company report or official report of TG Therapeutics.
DMNDHKL	RU	https://www.tgtherapeutics.com/our-pipeline/tg-1701/

DM3K4FY	DI	DM3K4FY
DM3K4FY	DN	TG-1801
DM3K4FY	MI	TTW640A
DM3K4FY	MN	B-lymphocyte surface antigen B4 (CD19)
DM3K4FY	MT	DTT
DM3K4FY	RN	Clinical pipeline report, company report or official report of TG Theraputics.
DM3K4FY	RU	https://www.tgtherapeutics.com/our-pipeline/tg-1801/

DM3K4FY	DI	DM3K4FY
DM3K4FY	DN	TG-1801
DM3K4FY	MI	TT28S46
DM3K4FY	MN	Leukocyte surface antigen CD47 (CD47)
DM3K4FY	MT	DTT
DM3K4FY	RN	Clinical pipeline report, company report or official report of TG Theraputics.
DM3K4FY	RU	https://www.tgtherapeutics.com/our-pipeline/tg-1801/

DMWBQ2Z	DI	DMWBQ2Z
DMWBQ2Z	DN	TGF-BR2 mab
DMWBQ2Z	MI	TTZE3P7
DMWBQ2Z	MN	TGF-beta receptor type II (TGFBR2)
DMWBQ2Z	MT	DTT
DMWBQ2Z	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1795).
DMWBQ2Z	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1795

DMC1HRA	DI	DMC1HRA
DMC1HRA	DN	Thiarabine
DMC1HRA	MI	TTUTN1I
DMC1HRA	MN	Human Deoxyribonucleic acid (hDNA)
DMC1HRA	MT	DTT
DMC1HRA	MA	Inhibitor
DMC1HRA	RN	Enzymology of Purine and Pyrimidine Antimetabolites Used in the Treatment of Cancer. Chem Rev. 2009 July; 109(7): 2880-2893.
DMC1HRA	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2827868/

DMOLFAU	DI	DMOLFAU
DMOLFAU	DN	Thiopilocarpine
DMOLFAU	MI	TTZ9SOR
DMOLFAU	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMOLFAU	MT	DTT
DMOLFAU	MA	Agonist
DMOLFAU	RN	SDZ ENS 163, a selective muscarinic M1 receptor agonist, facilitates the induction of long-term potentiation in rat hippocampal slices. Eur J Pharmacol. 1992 Nov 3;222(1):21-5.
DMOLFAU	RU	https://pubmed.ncbi.nlm.nih.gov/1468496

DMHRY8A	DI	DMHRY8A
DMHRY8A	DN	THR-687
DMHRY8A	MI	TTQFP08
DMHRY8A	MN	Integrin (ITG)
DMHRY8A	MT	DTT
DMHRY8A	MA	Antagonist
DMHRY8A	RN	The potent small molecule integrin antagonist THR-687 is a promising next-generation therapy for retinal vascular disorders. Exp Eye Res. 2019 Mar;180:43-52.
DMHRY8A	RU	https://pubmed.ncbi.nlm.nih.gov/30472075

DMO8SGD	DI	DMO8SGD
DMO8SGD	DN	Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy
DMO8SGD	MI	TTP3QRF
DMO8SGD	MN	Thymidine kinase 1 (TK1)
DMO8SGD	MT	DTT
DMO8SGD	MA	Modulator
DMO8SGD	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMO8SGD	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMSVO92	DI	DMSVO92
DMSVO92	DN	Tigapotide
DMSVO92	MI	TTYH1ZK
DMSVO92	MN	Beta-microseminoprotein (MSMB)
DMSVO92	MT	DTT
DMSVO92	MA	Inhibitor
DMSVO92	RN	National Cancer Institute Drug Dictionary (drug id 600185).
DMSVO92	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=600185

DMM3U2Q	DI	DMM3U2Q
DMM3U2Q	DN	TJ4309
DMM3U2Q	MI	TTK0O6Y
DMM3U2Q	MN	Ecto-5'-nucleotidase (CD73)
DMM3U2Q	MT	DTT
DMM3U2Q	RN	ClinicalTrials.gov (NCT04322006) A Phase I/II Study of TJ004309 for Advanced Solid Tumor. U.S. National Institutes of Health.
DMM3U2Q	RU	https://clinicaltrials.gov/ct2/show/NCT04322006

DMLUOVS	DI	DMLUOVS
DMLUOVS	DN	TJC4
DMLUOVS	MI	TT28S46
DMLUOVS	MN	Leukocyte surface antigen CD47 (CD47)
DMLUOVS	MT	DTT
DMLUOVS	RN	Clinical pipeline report, company report or official report of I-MAB Biopharma.
DMLUOVS	RU	https://i-mabbiopharma.com/en/Pipeline.aspx

DMTGLOY	DI	DMTGLOY
DMTGLOY	DN	TK216
DMTGLOY	MI	TT9AH0M
DMTGLOY	MN	Protein C-ets-2 (ETS2)
DMTGLOY	MT	DTT
DMTGLOY	MA	Inhibitor
DMTGLOY	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMTGLOY	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMCFGD4	DI	DMCFGD4
DMCFGD4	DN	TM38837
DMCFGD4	MI	TT6OEDT
DMCFGD4	MN	Cannabinoid receptor 1 (CB1)
DMCFGD4	MT	DTT
DMCFGD4	MA	Antagonist
DMCFGD4	RN	2011 Pipeline of 7TM Pharma.
DMCFGD4	RU	http://www.7tm.com/Pipeline.aspx

DMH3E5C	DI	DMH3E5C
DMH3E5C	DN	TMB-365
DMH3E5C	MI	TTN2JFW
DMH3E5C	MN	T-cell surface glycoprotein CD4 (CD4)
DMH3E5C	MT	DTT
DMH3E5C	RN	Clinical pipeline report, company report or official report of TaiMed Biologics.
DMH3E5C	RU	http://www.taimedbiologics.com/pipeline/36

DMYEALO	DI	DMYEALO
DMYEALO	DN	TMC-647055
DMYEALO	MI	TTMVBWH
DMYEALO	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMYEALO	MT	DTT
DMYEALO	MA	Inhibitor
DMYEALO	RN	WO patent application no. 2014,1522,75, Deuterium modified derivatives of the ns5b polymerase inhibitor tmc647055.
DMYEALO	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20140925&CC=WO&NR=2014152275A1&KC=A1

DMAOV7M	DI	DMAOV7M
DMAOV7M	DN	TMC649128
DMAOV7M	MI	TTMVBWH
DMAOV7M	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMAOV7M	MT	DTT
DMAOV7M	MA	Inhibitor
DMAOV7M	RN	Clinical pipeline report, company report or official report of Medivir (2011).
DMAOV7M	RU	http://www.medivir.se/v4/en/

DMAI0SH	DI	DMAI0SH
DMAI0SH	DN	TNB-383B
DMAI0SH	MI	TTZ3P4W
DMAI0SH	MN	B-cell maturation protein (TNFRSF17)
DMAI0SH	MT	DTT
DMAI0SH	RN	Clinical pipeline report, company report or official report of AbbVie.
DMAI0SH	RU	https://www.abbvie.com/our-science/pipeline/tnb-383b.html

DMAI0SH	DI	DMAI0SH
DMAI0SH	DN	TNB-383B
DMAI0SH	MI	TTUN7MC
DMAI0SH	MN	T-cell surface glycoprotein CD3 (CD3)
DMAI0SH	MT	DTT
DMAI0SH	RN	Clinical pipeline report, company report or official report of AbbVie.
DMAI0SH	RU	https://www.abbvie.com/our-science/pipeline/tnb-383b.html

DMSRICG	DI	DMSRICG
DMSRICG	DN	TNB-486
DMSRICG	MI	TTW640A
DMSRICG	MN	B-lymphocyte surface antigen B4 (CD19)
DMSRICG	MT	DTT
DMSRICG	RN	Clinical pipeline report, company report or official report of Teneobio.
DMSRICG	RU	https://teneobio.com/our-pipeline/

DMSRICG	DI	DMSRICG
DMSRICG	DN	TNB-486
DMSRICG	MI	TTUN7MC
DMSRICG	MN	T-cell surface glycoprotein CD3 (CD3)
DMSRICG	MT	DTT
DMSRICG	RN	Clinical pipeline report, company report or official report of Teneobio.
DMSRICG	RU	https://teneobio.com/our-pipeline/

DMHD6PA	DI	DMHD6PA
DMHD6PA	DN	TnMUC-1 CAR-T cell therapy
DMHD6PA	MI	TTBHFYQ
DMHD6PA	MN	Mucin-1 (MUC1)
DMHD6PA	MT	DTT
DMHD6PA	MA	Inhibitor
DMHD6PA	RN	ClinicalTrials.gov (NCT04025216) A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers. U.S. National Institutes of Health.
DMHD6PA	RU	https://clinicaltrials.gov/ct2/show/NCT04025216

DMZ60X4	DI	DMZ60X4
DMZ60X4	DN	TNO155
DMZ60X4	MI	TT7WUAV
DMZ60X4	MN	Protein-tyrosine phosphatase SHP-2 (PTPN11)
DMZ60X4	MT	DTT
DMZ60X4	MA	Inhibitor
DMZ60X4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZ60X4	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMSKF29	DI	DMSKF29
DMSKF29	DN	TNT009
DMSKF29	MI	TT7LRQH
DMSKF29	MN	Complement C1s component (C1S)
DMSKF29	MT	DTT
DMSKF29	MA	Inhibitor
DMSKF29	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMSKF29	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMD0NA1	DI	DMD0NA1
DMD0NA1	DN	TP 6076
DMD0NA1	MI	TTOVFH2
DMD0NA1	MN	Bacterial 30S ribosomal RNA (Bact 30S rRNA)
DMD0NA1	MT	DTT
DMD0NA1	MA	Inhibitor
DMD0NA1	RN	Clinical pipeline report, company report or official report of Tetraphase Pharmaceuticals.
DMD0NA1	RU	https://www.tphase.com/wp-content/uploads/2019/04/IDWeek-2018-TP-6076-Pipeline-FINAL-website.pdf

DMJVZBC	DI	DMJVZBC
DMJVZBC	DN	TP-0184
DMJVZBC	MI	TTJNBQA
DMJVZBC	MN	Activin receptor-like kinase 2 (ALK-2)
DMJVZBC	MT	DTT
DMJVZBC	MA	Inhibitor
DMJVZBC	RN	Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma.
DMJVZBC	RU	https://www.sdponcology.com/pipeline/

DMJVZBC	DI	DMJVZBC
DMJVZBC	DN	TP-0184
DMJVZBC	MI	TTP4520
DMJVZBC	MN	TGF-beta receptor type I (TGFBR1)
DMJVZBC	MT	DTT
DMJVZBC	MA	Inhibitor
DMJVZBC	RN	Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma.
DMJVZBC	RU	https://www.sdponcology.com/pipeline/

DM3Z07E	DI	DM3Z07E
DM3Z07E	DN	TP-1287
DM3Z07E	MI	TT1LVF2
DM3Z07E	MN	Cyclin-dependent kinase 9 (CDK9)
DM3Z07E	MT	DTT
DM3Z07E	MA	Inhibitor
DM3Z07E	RN	Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma.
DM3Z07E	RU	https://www.sdponcology.com/pipeline/

DMBTL2M	DI	DMBTL2M
DMBTL2M	DN	TP-1454
DMBTL2M	MI	TT4LOT8
DMBTL2M	MN	Pyruvate kinase M2 (PKM)
DMBTL2M	MT	DTT
DMBTL2M	MA	Activator
DMBTL2M	RN	Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma.
DMBTL2M	RU	https://www.ds-pharma.com/rd/clinical/pipeline.html

DM3PJSE	DI	DM3PJSE
DM3PJSE	DN	TP-271
DM3PJSE	MI	TTOVFH2
DM3PJSE	MN	Bacterial 30S ribosomal RNA (Bact 30S rRNA)
DM3PJSE	MT	DTT
DM3PJSE	MA	Inhibitor
DM3PJSE	RN	Clinical pipeline report, company report or official report of Tetraphase Pharmaceuticals.
DM3PJSE	RU	https://www.tphase.com/products/pipeline/

DMBQ6XY	DI	DMBQ6XY
DMBQ6XY	DN	TP-3654
DMBQ6XY	MI	TTA7WGU
DMBQ6XY	MN	Serine/threonine-protein kinase pim (PIM)
DMBQ6XY	MT	DTT
DMBQ6XY	MA	Inhibitor
DMBQ6XY	RN	Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma.
DMBQ6XY	RU	https://www.sdponcology.com/pipeline/

DM5RIT8	DI	DM5RIT8
DM5RIT8	DN	TP-6076
DM5RIT8	MI	TTOVFH2
DM5RIT8	MN	Bacterial 30S ribosomal RNA (Bact 30S rRNA)
DM5RIT8	MT	DTT
DM5RIT8	RN	Clinical pipeline report, company report or official report of Tetraphase Pharmaceuticals.
DM5RIT8	RU	https://www.tphase.com/wp-content/uploads/2019/04/IDWeek-2018-TP-6076-Pipeline-FINAL-website.pdf

DMG4U32	DI	DMG4U32
DMG4U32	DN	TPST-1120
DMG4U32	MI	TTJ584C
DMG4U32	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMG4U32	MT	DTT
DMG4U32	MA	Antagonist
DMG4U32	RN	Clinical pipeline report, company report or official report of Tempest Therapeutics.
DMG4U32	RU	https://www.tempesttx.com/pipeline/

DM3GSB2	DI	DM3GSB2
DM3GSB2	DN	TPST-1495
DM3GSB2	MI	TT1ZAVI
DM3GSB2	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DM3GSB2	MT	DTT
DM3GSB2	MA	Antagonist
DM3GSB2	RN	Clinical pipeline report, company report or official report of Tempest Therapeutics.
DM3GSB2	RU	https://www.tempesttx.com/pipeline/

DM3GSB2	DI	DM3GSB2
DM3GSB2	DN	TPST-1495
DM3GSB2	MI	TT79WV3
DM3GSB2	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DM3GSB2	MT	DTT
DM3GSB2	MA	Antagonist
DM3GSB2	RN	Clinical pipeline report, company report or official report of Tempest Therapeutics.
DM3GSB2	RU	https://www.tempesttx.com/pipeline/

DMC2IJN	DI	DMC2IJN
DMC2IJN	DN	TPX-0022
DMC2IJN	MI	TT7MRDV
DMC2IJN	MN	Macrophage colony-stimulating factor 1 receptor (CSF1R)
DMC2IJN	MT	DTT
DMC2IJN	MA	Inhibitor
DMC2IJN	RN	Clinical pipeline report, company report or official report of Turning Point Therapeutics.
DMC2IJN	RU	https://tptherapeutics.com/pipeline/tpx-0022/

DMC2IJN	DI	DMC2IJN
DMC2IJN	DN	TPX-0022
DMC2IJN	MI	TTNDSF4
DMC2IJN	MN	Proto-oncogene c-Met (MET)
DMC2IJN	MT	DTT
DMC2IJN	MA	Inhibitor
DMC2IJN	RN	Clinical pipeline report, company report or official report of Turning Point Therapeutics.
DMC2IJN	RU	https://tptherapeutics.com/pipeline/tpx-0022/

DMC2IJN	DI	DMC2IJN
DMC2IJN	DN	TPX-0022
DMC2IJN	MI	TT6PKBN
DMC2IJN	MN	Proto-oncogene c-Src (SRC)
DMC2IJN	MT	DTT
DMC2IJN	MA	Inhibitor
DMC2IJN	RN	Clinical pipeline report, company report or official report of Turning Point Therapeutics.
DMC2IJN	RU	https://tptherapeutics.com/pipeline/tpx-0022/

DMGC2AT	DI	DMGC2AT
DMGC2AT	DN	TR1801-ADC
DMGC2AT	MI	TTNDSF4
DMGC2AT	MN	Proto-oncogene c-Met (MET)
DMGC2AT	MT	DTT
DMGC2AT	RN	TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors. Mol Oncol. 2020 Jan;14(1):54-68.
DMGC2AT	RU	https://pubmed.ncbi.nlm.nih.gov/31736230

DMMRDUN	DI	DMMRDUN
DMMRDUN	DN	TrasGEX
DMMRDUN	MI	TT6EO5L
DMMRDUN	MN	Erbb2 tyrosine kinase receptor (HER2)
DMMRDUN	MT	DTT
DMMRDUN	RN	J Clin Oncol 32:5s, 2014 (suppl; abstr 2515).
DMMRDUN	RU	http://meetinglibrary.asco.org/content/131582-144

DM1DIVY	DI	DM1DIVY
DM1DIVY	DN	TRemelimumab + MEDI0562
DM1DIVY	MI	TTI2S1D
DM1DIVY	MN	Cytotoxic T-lymphocyte protein 4 (CTLA-4)
DM1DIVY	MT	DTT
DM1DIVY	MA	Agonist
DM1DIVY	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM1DIVY	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM1DIVY	DI	DM1DIVY
DM1DIVY	DN	TRemelimumab + MEDI0562
DM1DIVY	MI	TTL31H0
DM1DIVY	MN	OX40L receptor (CD134)
DM1DIVY	MT	DTT
DM1DIVY	MA	Agonist
DM1DIVY	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM1DIVY	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMQ7UN6	DI	DMQ7UN6
DMQ7UN6	DN	Trodusquemine
DMQ7UN6	MI	TTMS7KP
DMQ7UN6	MN	Protein-tyrosine phosphatase 1B (PTP1B)
DMQ7UN6	MT	DTT
DMQ7UN6	MA	Inhibitor
DMQ7UN6	RN	Inhibition of PTP1B by trodusquemine (MSI-1436) causes fat-specific weight loss in diet-induced obese mice. Obesity (Silver Spring). 2010 Aug;18(8):1516-23.
DMQ7UN6	RU	https://pubmed.ncbi.nlm.nih.gov/20075852

DMDSF0Q	DI	DMDSF0Q
DMDSF0Q	DN	TROVIRDINE HYDROCHLORIDE
DMDSF0Q	MI	TT84ETX
DMDSF0Q	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMDSF0Q	MT	DTT
DMDSF0Q	MA	Modulator
DMDSF0Q	RN	Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptases by the phenyl ethyl thiazolyl thiourea derivatives tr... Antiviral Res. 1995 Dec;28(4):331-42.
DMDSF0Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/8669892

DMSLQW2	DI	DMSLQW2
DMSLQW2	DN	TRPH-222
DMSLQW2	MI	TTM6QSK
DMSLQW2	MN	B-cell receptor CD22 (CD22)
DMSLQW2	MT	DTT
DMSLQW2	RN	Clinical pipeline report, company report or official report of Triphase Accelerator.
DMSLQW2	RU	http://triphaseco.com/trph-222/

DM2WZ86	DI	DM2WZ86
DM2WZ86	DN	TRV250
DM2WZ86	MI	TT27RFC
DM2WZ86	MN	Opioid receptor delta (OPRD1)
DM2WZ86	MT	DTT
DM2WZ86	MA	Modulator
DM2WZ86	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM2WZ86	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMHD8CF	DI	DMHD8CF
DMHD8CF	DN	TRV734
DMHD8CF	MI	TTKWM86
DMHD8CF	MN	Opioid receptor mu (MOP)
DMHD8CF	MT	DTT
DMHD8CF	MA	Agonist
DMHD8CF	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMHD8CF	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM9IDUH	DI	DM9IDUH
DM9IDUH	DN	TRX518
DM9IDUH	MI	TTG6LA7
DM9IDUH	MN	Activation-inducible TNFR family receptor (TNFRSF18)
DM9IDUH	MT	DTT
DM9IDUH	RN	Clinical pipeline report, company report or official report of Leap Therapeutics.
DM9IDUH	RU	https://www.leaptx.com/our-pipeline

DMVGN42	DI	DMVGN42
DMVGN42	DN	TRX-818
DMVGN42	MI	TTB8Y9K
DMVGN42	MN	Angiogenesis (AGG)
DMVGN42	MT	DTT
DMVGN42	MA	Inhibitor
DMVGN42	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMVGN42	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMNTVUK	DI	DMNTVUK
DMNTVUK	DN	TS01
DMNTVUK	MI	TT7LRQH
DMNTVUK	MN	Complement C1s component (C1S)
DMNTVUK	MT	DTT
DMNTVUK	MA	Modulator
DMNTVUK	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMNTVUK	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM56PFL	DI	DM56PFL
DM56PFL	DN	TSR-042
DM56PFL	MI	TTNBFWK
DM56PFL	MN	Programmed cell death protein 1 (PD-1)
DM56PFL	MT	DTT
DM56PFL	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DM56PFL	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMZ9EMO	DI	DMZ9EMO
DMZ9EMO	DN	TST001
DMZ9EMO	MI	TT6PKBX
DMZ9EMO	MN	Claudin-18 (CLDN18)
DMZ9EMO	MT	DTT
DMZ9EMO	RN	Clinical pipeline report, company report or official report of Transcenta.
DMZ9EMO	RU	http://www.transcenta.com/pipeline

DMT5AEF	DI	DMT5AEF
DMT5AEF	DN	TST-10088
DMT5AEF	MI	TTJ073B
DMT5AEF	MN	Ribosome (hRBS)
DMT5AEF	MT	DTT
DMT5AEF	MA	Immunomodulator (Immunostimulant)
DMT5AEF	RN	Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Nov;31(9):597-633.
DMT5AEF	RU	https://pubmed.ncbi.nlm.nih.gov/20094643

DMLDSX8	DI	DMLDSX8
DMLDSX8	DN	TT-30
DMLDSX8	MI	TTUW6OP
DMLDSX8	MN	Complement factor H (CFH)
DMLDSX8	MT	DTT
DMLDSX8	MA	Modulator
DMLDSX8	RN	The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. Blood. 2012 Jun 28;119(26):6307-16.
DMLDSX8	RU	https://pubmed.ncbi.nlm.nih.gov/22577173

DMLDSX8	DI	DMLDSX8
DMLDSX8	DN	TT-30
DMLDSX8	MI	TT0HUN7
DMLDSX8	MN	Complement receptor type 2 (CD21)
DMLDSX8	MT	DTT
DMLDSX8	MA	Modulator
DMLDSX8	RN	The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. Blood. 2012 Jun 28;119(26):6307-16.
DMLDSX8	RU	https://pubmed.ncbi.nlm.nih.gov/22577173

DM4QV8Y	DI	DM4QV8Y
DM4QV8Y	DN	TT-301
DM4QV8Y	MI	TTRYK0X
DM4QV8Y	MN	Interleukin-1 beta (IL1B)
DM4QV8Y	MT	DTT
DM4QV8Y	MA	Inhibitor
DM4QV8Y	RN	A Swell in the Armamentarium of Antiepileptic Drug Targets. Epilepsy Curr. 2011 Nov-Dec; 11(6): 172-176.
DM4QV8Y	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3220427/

DM7CHZ2	DI	DM7CHZ2
DM7CHZ2	DN	TTC-352
DM7CHZ2	MI	TTZAYWL
DM7CHZ2	MN	Estrogen receptor (ESR)
DM7CHZ2	MT	DTT
DM7CHZ2	MA	Agonist
DM7CHZ2	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7CHZ2	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM7E6V2	DI	DM7E6V2
DM7E6V2	DN	TTC-352
DM7E6V2	MI	TTZAYWL
DM7E6V2	MN	Estrogen receptor (ESR)
DM7E6V2	MT	DTT
DM7E6V2	MA	Agonist
DM7E6V2	RN	Clinical pipeline report, company report or official report of TTC Oncology.
DM7E6V2	RU	https://ttconcology.com/our-product/

DMDNPAV	DI	DMDNPAV
DMDNPAV	DN	TTI-621
DMDNPAV	MI	TT28S46
DMDNPAV	MN	Leukocyte surface antigen CD47 (CD47)
DMDNPAV	MT	DTT
DMDNPAV	MA	Inhibitor
DMDNPAV	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMDNPAV	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMOCQ4K	DI	DMOCQ4K
DMOCQ4K	DN	TTI-622
DMOCQ4K	MI	TT28S46
DMOCQ4K	MN	Leukocyte surface antigen CD47 (CD47)
DMOCQ4K	MT	DTT
DMOCQ4K	MA	Blocker
DMOCQ4K	RN	Clinical pipeline report, company report or official report of Trillium Therapeutics.
DMOCQ4K	RU	https://trilliumtherapeutics.com/pipeline/

DMCG01R	DI	DMCG01R
DMCG01R	DN	TTP-4000
DMCG01R	MI	TTMO9HF
DMCG01R	MN	Advanced glycosylation end product receptor (AGER)
DMCG01R	MT	DTT
DMCG01R	MA	Inhibitor
DMCG01R	RN	Receptor for advanced glycation end products: its role in Alzheimer's disease and other neurological diseases. Future Neurol. 2009; 4(2): 167-177.
DMCG01R	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2709862/

DMYFUOP	DI	DMYFUOP
DMYFUOP	DN	TTP-547
DMYFUOP	MI	TTDLNGZ
DMYFUOP	MN	Glucokinase (GCK)
DMYFUOP	MT	DTT
DMYFUOP	MA	Activator
DMYFUOP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2798).
DMYFUOP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2798

DM8H2AG	DI	DM8H2AG
DM8H2AG	DN	TTX-030
DM8H2AG	MI	TTYM8DJ
DM8H2AG	MN	Ectonucleoside triphosphate diphosphohydrolase 1 (CD39)
DM8H2AG	MT	DTT
DM8H2AG	MA	Inhibitor
DM8H2AG	RN	Clinical pipeline report, company report or official report of AbbVie.
DM8H2AG	RU	https://www.abbvie.com/our-science/pipeline/ttx-030.html

DM6GKYF	DI	DM6GKYF
DM6GKYF	DN	TTX-080
DM6GKYF	MI	TTLKFB3
DM6GKYF	MN	MHC class I antigen G (HLA-G)
DM6GKYF	MT	DTT
DM6GKYF	MA	Inhibitor
DM6GKYF	RN	Clinical pipeline report, company report or official report of Tizona Therapeutics.
DM6GKYF	RU	https://www.tizonatx.com/science/

DM36ONA	DI	DM36ONA
DM36ONA	DN	Turofexorate isopropyl
DM36ONA	MI	TTS4UGC
DM36ONA	MN	Farnesoid X-activated receptor (FXR)
DM36ONA	MT	DTT
DM36ONA	MA	Modulator
DM36ONA	RN	A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia. Am J Physiol Gastrointest Liver Physiol. 2009 Mar;296(3):G543-52.
DM36ONA	RU	https://pubmed.ncbi.nlm.nih.gov/19136377

DMZIK8R	DI	DMZIK8R
DMZIK8R	DN	TXA709
DMZIK8R	MI	TT4W1VJ
DMZIK8R	MN	Bacterial Celldivision protein FtsZ (Bact ftsZ)
DMZIK8R	MT	DTT
DMZIK8R	MA	Inhibitor
DMZIK8R	RN	Clinical pipeline report, company report or official report of TAXIS Pharmaceuticals.
DMZIK8R	RU	https://www.taxispharma.com/research-development/our-pipeline/

DMWOE62	DI	DMWOE62
DMWOE62	DN	U3-1565
DMWOE62	MI	TT15SL0
DMWOE62	MN	Proheparin-binding EGF-like growth factor (HBEGF)
DMWOE62	MT	DTT
DMWOE62	MA	Modulator
DMWOE62	RN	J Clin Oncol 31, 2013 (suppl; abstr 2519).
DMWOE62	RU	http://meetinglibrary.asco.org/content/111447-132

DM5XMHB	DI	DM5XMHB
DM5XMHB	DN	UC-781
DM5XMHB	MI	TT84ETX
DM5XMHB	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM5XMHB	MT	DTT
DM5XMHB	MA	Inhibitor
DM5XMHB	RN	The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells. J Virol. 2005 Sep;79(17):11179-86.
DM5XMHB	RU	https://pubmed.ncbi.nlm.nih.gov/16103169

DMG7FLI	DI	DMG7FLI
DMG7FLI	DN	UCART123
DMG7FLI	MI	TTENHJ0
DMG7FLI	MN	Interleukin 3 receptor alpha (IL3RA)
DMG7FLI	MT	DTT
DMG7FLI	MA	CAR-T-Cell-Therapy
DMG7FLI	RN	ClinicalTrials.gov (NCT03190278) Study Evaluating Safety and Efficacy of UCART123 in Patients With Acute Myeloid Leukemia
DMG7FLI	RU	https://clinicaltrials.gov/ct2/show/NCT03190278

DMARHU4	DI	DMARHU4
DMARHU4	DN	UCART-22
DMARHU4	MI	TTM6QSK
DMARHU4	MN	B-cell receptor CD22 (CD22)
DMARHU4	MT	DTT
DMARHU4	RN	Clinical pipeline report, company report or official report of Cellectis.
DMARHU4	RU	https://www.cellectis.com/en/products/product-candidates/

DM2Y4D7	DI	DM2Y4D7
DM2Y4D7	DN	UCARTCS1
DM2Y4D7	MI	TT7ILZ1
DM2Y4D7	MN	SLAM family member 7 SLAMF7 (CS1)
DM2Y4D7	MT	DTT
DM2Y4D7	RN	ClinicalTrials.gov (NCT04142619) Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01). U.S. National Institutes of Health.
DM2Y4D7	RU	https://clinicaltrials.gov/ct2/show/NCT04142619

DMSCXB7	DI	DMSCXB7
DMSCXB7	DN	UK-240455
DMSCXB7	MI	TTZ8EM9
DMSCXB7	MN	Glycine receptor (GlyR)
DMSCXB7	MT	DTT
DMSCXB7	MA	Modulator
DMSCXB7	RN	UK-315716/UK-240455. Pfizer. Curr Opin Investig Drugs. 2001 Dec;2(12):1737-9.
DMSCXB7	RU	https://pubmed.ncbi.nlm.nih.gov/11892937

DMI8795	DI	DMI8795
DMI8795	DN	UK-371800
DMI8795	MI	TTJ0IQB
DMI8795	MN	Phosphodiesterase 5A (PDE5A)
DMI8795	MT	DTT
DMI8795	MA	Inhibitor
DMI8795	RN	Highly potent and selective chiral inhibitors of PDE5: an illustration of Pfeiffer's rule. Bioorg Med Chem Lett. 2008 Dec 1;18(23):6033-6.
DMI8795	RU	https://pubmed.ncbi.nlm.nih.gov/18951784

DMFYKDX	DI	DMFYKDX
DMFYKDX	DN	UK-396082
DMFYKDX	MI	TTP18AY
DMFYKDX	MN	Carboxypeptidase B2 (CPB2)
DMFYKDX	MT	DTT
DMFYKDX	MA	Inhibitor
DMFYKDX	RN	Oxygenated analogues of UK-396082 as inhibitors of activated thrombin activatable fibrinolysis inhibitor. Bioorg Med Chem Lett. 2010 Jan 1;20(1):92-6.
DMFYKDX	RU	https://pubmed.ncbi.nlm.nih.gov/19954973

DMO8Z1D	DI	DMO8Z1D
DMO8Z1D	DN	UK-66914
DMO8Z1D	MI	TT1VOHK
DMO8Z1D	MN	Potassium channel unspecific (KC)
DMO8Z1D	MT	DTT
DMO8Z1D	MA	Blocker
DMO8Z1D	RN	Electrophysiologic properties of UK-66,914, a novel class III antiarrhythmic agent. J Cardiovasc Pharmacol. 1991 Mar;17(3):376-85.
DMO8Z1D	RU	https://pubmed.ncbi.nlm.nih.gov/1711597

DMHG7DZ	DI	DMHG7DZ
DMHG7DZ	DN	UltraCD40L
DMHG7DZ	MI	TTIJP3Q
DMHG7DZ	MN	TNF related activation protein (CD40LG)
DMHG7DZ	MT	DTT
DMHG7DZ	MA	Modulator
DMHG7DZ	RN	CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells. Cancer Immunol Immunother. 2013 February; 62(2): 347-357.
DMHG7DZ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3569584/

DMTLNGV	DI	DMTLNGV
DMTLNGV	DN	Umespirone
DMTLNGV	MI	TTSQIFT
DMTLNGV	MN	5-HT 1A receptor (HTR1A)
DMTLNGV	MT	DTT
DMTLNGV	MA	Antagonist
DMTLNGV	RN	The effects of umespirone as a potential anxiolytic and antipsychotic agent. Pharmacol Biochem Behav. 1991 Sep;40(1):89-96.
DMTLNGV	RU	https://pubmed.ncbi.nlm.nih.gov/1685786

DMTLNGV	DI	DMTLNGV
DMTLNGV	DN	Umespirone
DMTLNGV	MI	TTEX248
DMTLNGV	MN	Dopamine D2 receptor (D2R)
DMTLNGV	MT	DTT
DMTLNGV	MA	Antagonist
DMTLNGV	RN	The effects of umespirone as a potential anxiolytic and antipsychotic agent. Pharmacol Biochem Behav. 1991 Sep;40(1):89-96.
DMTLNGV	RU	https://pubmed.ncbi.nlm.nih.gov/1685786

DMI5UEB	DI	DMI5UEB
DMI5UEB	DN	Unacylated ghrelin
DMI5UEB	MI	TT1OCL0
DMI5UEB	MN	Ghrelin (GHRL)
DMI5UEB	MT	DTT
DMI5UEB	MA	Inhibitor
DMI5UEB	RN	Alize Pharma signs research collaboration and license option agreement with Lilly. Lyon, France, January 25, 2010.
DMI5UEB	RU	http://www.alz-pharma.com/actualite/alize-pharma-signs-research-collaboration-and-license-option-agreement-with-lilly

DMR38M4	DI	DMR38M4
DMR38M4	DN	UNBS-1450
DMR38M4	MI	TTWK8D0
DMR38M4	MN	Sodium pump subunit alpha-1 (ATP1A1)
DMR38M4	MT	DTT
DMR38M4	MA	Inhibitor
DMR38M4	RN	Early downregulation of Mcl-1 regulates apoptosis triggered by cardiac glycoside UNBS1450. Cell Death Dis. 2015 Jun 11;6:e1782.
DMR38M4	RU	https://pubmed.ncbi.nlm.nih.gov/26068790

DMIKV9W	DI	DMIKV9W
DMIKV9W	DN	Utomilumab
DMIKV9W	MI	TTPW9LJ
DMIKV9W	MN	Co-stimulatory molecule 4-1BB (CD137)
DMIKV9W	MT	DTT
DMIKV9W	MA	Agonist
DMIKV9W	RN	First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20 + Non-Hodgkin Lymphomas. Clin Cancer Res. 2020 Jun 1;26(11):2524-2534.
DMIKV9W	RU	https://pubmed.ncbi.nlm.nih.gov/32144134

DMJSX9N	DI	DMJSX9N
DMJSX9N	DN	V-24343
DMJSX9N	MI	TT6OEDT
DMJSX9N	MN	Cannabinoid receptor 1 (CB1)
DMJSX9N	MT	DTT
DMJSX9N	MA	Antagonist
DMJSX9N	RN	Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opin Emerg Drugs. 2009 Mar;14(1):43-65.
DMJSX9N	RU	https://pubmed.ncbi.nlm.nih.gov/19249987

DMYAIUB	DI	DMYAIUB
DMYAIUB	DN	Valortim
DMYAIUB	MI	TT3YGCD
DMYAIUB	MN	Bacterial Protective antigen (Bact pagA)
DMYAIUB	MT	DTT
DMYAIUB	RN	Phase I Study Evaluating the Safety and Pharmacokinetics of MDX-1303, a Fully Human Monoclonal Antibody against Bacillus anthracis Protective Antigen, in Healthy Volunteers. Clin Vaccine Immunol. 2011 December; 18(12): 2136-2142.
DMYAIUB	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3232684/

DM3ZW6A	DI	DM3ZW6A
DM3ZW6A	DN	VAN-10-4-eluting stent
DM3ZW6A	MI	TT1MG9E
DM3ZW6A	MN	Extracellular signal-regulated kinase 1 (ERK1)
DM3ZW6A	MT	DTT
DM3ZW6A	MA	Inhibitor
DM3ZW6A	RN	WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.
DM3ZW6A	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20131212&CC=WO&NR=2013185032A1&KC=A1

DM3ZW6A	DI	DM3ZW6A
DM3ZW6A	DN	VAN-10-4-eluting stent
DM3ZW6A	MI	TT4TQBX
DM3ZW6A	MN	Extracellular signal-regulated kinase 2 (ERK2)
DM3ZW6A	MT	DTT
DM3ZW6A	MA	Inhibitor
DM3ZW6A	RN	WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.
DM3ZW6A	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20131212&CC=WO&NR=2013185032A1&KC=A1

DMULRYC	DI	DMULRYC
DMULRYC	DN	VBY- 036
DMULRYC	MI	TTUMQVO
DMULRYC	MN	Cathepsin S (CTSS)
DMULRYC	MT	DTT
DMULRYC	MA	Inhibitor
DMULRYC	RN	Clinical pipeline report, company report or official report of ViroBay.
DMULRYC	RU	http://virobayinc.com/VBY-036.php

DMTKPH4	DI	DMTKPH4
DMTKPH4	DN	VBY- 891
DMTKPH4	MI	TTUMQVO
DMTKPH4	MN	Cathepsin S (CTSS)
DMTKPH4	MT	DTT
DMTKPH4	MA	Modulator
DMTKPH4	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2353).
DMTKPH4	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2353

DM4YIWK	DI	DM4YIWK
DM4YIWK	DN	VBY-129
DM4YIWK	MI	TTUMQVO
DM4YIWK	MN	Cathepsin S (CTSS)
DM4YIWK	MT	DTT
DM4YIWK	MA	Inhibitor
DM4YIWK	RN	Clinical pipeline report, company report or official report of ViroBay.
DM4YIWK	RU	http://www.virobayinc.com/VBY-129.php

DMU263R	DI	DMU263R
DMU263R	DN	VBY-376
DMU263R	MI	TTWXB3E
DMU263R	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DMU263R	MT	DTT
DMU263R	MA	Inhibitor
DMU263R	RN	Hepatitis C Virus NS3/4A Protease Inhibitors: A Light at the End of the Tunnel. Viruses. 2010 August; 2(8): 1752-1765.
DMU263R	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185733/

DMMKUOZ	DI	DMMKUOZ
DMMKUOZ	DN	VCH-286
DMMKUOZ	MI	TT2CEJG
DMMKUOZ	MN	C-C chemokine receptor type 5 (CCR5)
DMMKUOZ	MT	DTT
DMMKUOZ	MA	Antagonist
DMMKUOZ	RN	The Continuing Evolution of HIV-1 Therapy: Identification and Development of Novel Antiretroviral Agents Targeting Viral and Cellular Targets. Mol Biol Int. 2012;2012:401965.
DMMKUOZ	RU	https://pubmed.ncbi.nlm.nih.gov/22848825

DMS9EKG	DI	DMS9EKG
DMS9EKG	DN	VCL-1M01
DMS9EKG	MI	TTF89GD
DMS9EKG	MN	Interleukin-2 (IL2)
DMS9EKG	MT	DTT
DMS9EKG	MA	Modulator
DMS9EKG	RN	Interleukin-2 gene therapy in a patient with glioblastoma. Gene Ther. 1995 Mar;2(2):164-7.
DMS9EKG	RU	https://pubmed.ncbi.nlm.nih.gov/7719933

DMDSC63	DI	DMDSC63
DMDSC63	DN	VEL-0230
DMDSC63	MI	TTDZN01
DMDSC63	MN	Cathepsin K (CTSK)
DMDSC63	MT	DTT
DMDSC63	MA	Inhibitor
DMDSC63	RN	Discovery and parallel synthesis of a new class of cathepsin K inhibitors. Bioorg Med Chem Lett. 2001 Nov 19;11(22):2951-4.
DMDSC63	RU	https://pubmed.ncbi.nlm.nih.gov/11677133

DM9OEK1	DI	DM9OEK1
DM9OEK1	DN	Velpatasvir
DM9OEK1	MI	DTUGYRD
DM9OEK1	MN	P-glycoprotein 1 (ABCB1)
DM9OEK1	MT	DTP
DM9OEK1	MA	Substrate
DM9OEK1	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DM9OEK1	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DM9GC4R	DI	DM9GC4R
DM9GC4R	DN	VGX-100
DM9GC4R	MI	TT0QUFV
DM9GC4R	MN	Vascular endothelial growth factor C (VEGFC)
DM9GC4R	MT	DTT
DM9GC4R	MA	Modulator
DM9GC4R	RN	National Cancer Institute Drug Dictionary (drug id 724066).
DM9GC4R	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=724066

DMM1N5C	DI	DMM1N5C
DMM1N5C	DN	VGX-1027
DMM1N5C	MI	TTXT2VN
DMM1N5C	MN	NF-kappa-B-p38 signaling pathway (NFKB-p38 pathway)
DMM1N5C	MT	DTT
DMM1N5C	MA	Inhibitor
DMM1N5C	RN	Effects of the immunomodulator, VGX-1027, in endotoxin-induced uveitis in Lewis rats. Br J Pharmacol. 2008 Nov;155(5):722-30.
DMM1N5C	RU	https://pubmed.ncbi.nlm.nih.gov/18776919

DMGMEH7	DI	DMGMEH7
DMGMEH7	DN	VGX-3400
DMGMEH7	MI	TTF4CAM
DMGMEH7	MN	Influenza Hemagglutinin (Influ HA)
DMGMEH7	MT	DTT
DMGMEH7	RN	Clinical pipeline report, company report or official report of Inovio Pharmaceuticals.
DMGMEH7	RU	http://www.inovio.com/products/infectious-disease-vaccines/influenza/pandemic/

DMDFC2Y	DI	DMDFC2Y
DMDFC2Y	DN	VIC-1911
DMDFC2Y	MI	TTPS3C0
DMDFC2Y	MN	Aurora kinase A (AURKA)
DMDFC2Y	MT	DTT
DMDFC2Y	MA	Inhibitor
DMDFC2Y	RN	Clinical pipeline report, company report or official report of VITRAC Therapeutics.
DMDFC2Y	RU	https://vitractherapeutics.com/

DM6LQIU	DI	DM6LQIU
DM6LQIU	DN	VIR-2482
DM6LQIU	MI	TTF4CAM
DM6LQIU	MN	Influenza Hemagglutinin (Influ HA)
DM6LQIU	MT	DTT
DM6LQIU	RN	Clinical pipeline report, company report or official report of Vir Biotechnology.
DM6LQIU	RU	https://www.vir.bio/pipeline/

DMB3I04	DI	DMB3I04
DMB3I04	DN	VM-206
DMB3I04	MI	TT6EO5L
DMB3I04	MN	Erbb2 tyrosine kinase receptor (HER2)
DMB3I04	MT	DTT
DMB3I04	RN	WO patent application no. 2014,1441,21, Classification and actionability indices for lung cancer.
DMB3I04	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20140918&CC=WO&NR=2014144121A2&KC=A2

DM4AXPT	DI	DM4AXPT
DM4AXPT	DN	VMD-928
DM4AXPT	MI	TTTDVOJ
DM4AXPT	MN	Tropomyosin-related kinase A (TrkA)
DM4AXPT	MT	DTT
DM4AXPT	MA	Inhibitor
DM4AXPT	RN	ClinicalTrials.gov (NCT03556228) Oral TrkA Inhibitor VMD-928 for Treatment of Advanced Adult Solid Tumors or Lymphoma. U.S. National Institutes of Health.
DM4AXPT	RU	https://clinicaltrials.gov/ct2/show/NCT03556228

DMNZ6XH	DI	DMNZ6XH
DMNZ6XH	DN	VNRX-5133
DMNZ6XH	MI	TTHI19T
DMNZ6XH	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMNZ6XH	MT	DTT
DMNZ6XH	MA	Inhibitor
DMNZ6XH	RN	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo--lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections. J Med Chem. 2020 Mar 26;63(6):2789-2801.
DMNZ6XH	RU	https://pubmed.ncbi.nlm.nih.gov/31765155

DMDG30Q	DI	DMDG30Q
DMDG30Q	DN	VOB560
DMDG30Q	MI	TTJGNVC
DMDG30Q	MN	Apoptosis regulator Bcl-2 (BCL-2)
DMDG30Q	MT	DTT
DMDG30Q	MA	Inhibitor
DMDG30Q	RN	Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer. Cells. 2020 May 21;9(5):1287.
DMDG30Q	RU	https://pubmed.ncbi.nlm.nih.gov/32455818

DM215XO	DI	DM215XO
DM215XO	DN	Voxilaprevir
DM215XO	MI	DTUGYRD
DM215XO	MN	P-glycoprotein 1 (ABCB1)
DM215XO	MT	DTP
DM215XO	MA	Substrate
DM215XO	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DM215XO	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DM0S9OT	DI	DM0S9OT
DM0S9OT	DN	VRC07-523LS
DM0S9OT	MI	TTN2JFW
DM0S9OT	MN	T-cell surface glycoprotein CD4 (CD4)
DM0S9OT	MT	DTT
DM0S9OT	RN	Clinical pipeline report, company report or official report of TaiMed Biologics.
DM0S9OT	RU	http://www.taimedbiologics.com/pipeline/44

DMN9JCD	DI	DMN9JCD
DMN9JCD	DN	VS-4718
DMN9JCD	MI	TTON5IT
DMN9JCD	MN	Focal adhesion kinase 1 (FAK)
DMN9JCD	MT	DTT
DMN9JCD	MA	Inhibitor
DMN9JCD	RN	FAK Inhibition disrupts a beta5 integrin signaling axis controlling anchorage-independent ovarian carcinoma growth. Mol Cancer Ther. 2014 Aug;13(8):2050-61.
DMN9JCD	RU	https://pubmed.ncbi.nlm.nih.gov/24899686

DMMO3G5	DI	DMMO3G5
DMMO3G5	DN	VS-5584
DMMO3G5	MI	TTX4GLS
DMMO3G5	MN	Mammalian target of rapamycin complex 1 (mTORC1)
DMMO3G5	MT	DTT
DMMO3G5	MA	Inhibitor
DMMO3G5	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMMO3G5	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DMMO3G5	DI	DMMO3G5
DMMO3G5	DN	VS-5584
DMMO3G5	MI	TTHBTOP
DMMO3G5	MN	PI3-kinase gamma (PIK3CG)
DMMO3G5	MT	DTT
DMMO3G5	MA	Modulator
DMMO3G5	RN	VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer. Mol Cancer Ther. 2013 Feb;12(2):151-61.
DMMO3G5	RU	https://pubmed.ncbi.nlm.nih.gov/23270925

DMMO3G5	DI	DMMO3G5
DMMO3G5	DN	VS-5584
DMMO3G5	MI	TTCJG29
DMMO3G5	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMMO3G5	MT	DTT
DMMO3G5	MA	Modulator
DMMO3G5	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
DMMO3G5	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109

DMMO3G5	DI	DMMO3G5
DMMO3G5	DN	VS-5584
DMMO3G5	MI	TTWDKCL
DMMO3G5	MN	Target of rapamycin complex 2 MAPKAP1 (MTORC2)
DMMO3G5	MT	DTT
DMMO3G5	MA	Inhibitor
DMMO3G5	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMMO3G5	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DMQEOD6	DI	DMQEOD6
DMQEOD6	DN	VTP-27999
DMQEOD6	MI	TTB2MXP
DMQEOD6	MN	Angiotensinogenase renin (REN)
DMQEOD6	MT	DTT
DMQEOD6	MA	Inhibitor
DMQEOD6	RN	New Developments in the Pharmacological Treatment of Hypertension: Dead-End or a Glimmer at the Horizon . Curr Hypertens Rep. 2015; 17(6): 42.
DMQEOD6	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412646/

DM9W0B6	DI	DM9W0B6
DM9W0B6	DN	VTR-297
DM9W0B6	MI	TTBH0VX
DM9W0B6	MN	Histone deacetylase (HDAC)
DM9W0B6	MT	DTT
DM9W0B6	MA	Inhibitor
DM9W0B6	RN	Clinical pipeline report, company report or official report of Vanda Pharmaceuticals.
DM9W0B6	RU	https://vandapharmaceuticalsinc.gcs-web.com/news-releases/news-release-details/vanda-pharmaceuticals-reports-third-quarter-2019-financial

DM4ZIRK	DI	DM4ZIRK
DM4ZIRK	DN	VTX-1463
DM4ZIRK	MI	TT8CWFK
DM4ZIRK	MN	Toll-like receptor 8 (TLR8)
DM4ZIRK	MT	DTT
DM4ZIRK	MA	Agonist
DM4ZIRK	RN	VTX-1463, a novel TLR8 agonist for the treatment of allergic rhinitis. Expert Opin Investig Drugs. 2011 Jul;20(7):981-6.
DM4ZIRK	RU	https://pubmed.ncbi.nlm.nih.gov/21548830

DMC8J0G	DI	DMC8J0G
DMC8J0G	DN	VX-128
DMC8J0G	MI	TT90XZ8
DMC8J0G	MN	Voltage-gated sodium channel alpha Nav1.8 (SCN10A)
DMC8J0G	MT	DTT
DMC8J0G	MA	Inhibitor
DMC8J0G	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMC8J0G	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM8UTPJ	DI	DM8UTPJ
DM8UTPJ	DN	VX-500
DM8UTPJ	MI	TT5FNQT
DM8UTPJ	MN	Human immunodeficiency virus Protease (HIV PR)
DM8UTPJ	MT	DTT
DM8UTPJ	MA	Inhibitor
DM8UTPJ	RN	2011 Pipeline of Vertex.
DM8UTPJ	RU	http://www.vrtx.com/current-projects.html

DMAJ2T4	DI	DMAJ2T4
DMAJ2T4	DN	VX-916
DMAJ2T4	MI	TTMVBWH
DMAJ2T4	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMAJ2T4	MT	DTT
DMAJ2T4	MA	Inhibitor
DMAJ2T4	RN	2011 Pipeline of Vertex.
DMAJ2T4	RU	http://www.vrtx.com/current-projects.html

DMR9PCT	DI	DMR9PCT
DMR9PCT	DN	VX-970
DMR9PCT	MI	TT8ZYBQ
DMR9PCT	MN	Serine/threonine-protein kinase ATR (FRP1)
DMR9PCT	MT	DTT
DMR9PCT	MA	Inhibitor
DMR9PCT	RN	ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses. Cancer Res. 2014 Dec 1;74(23):6968-79.
DMR9PCT	RU	https://pubmed.ncbi.nlm.nih.gov/25269479

DMC9N7D	DI	DMC9N7D
DMC9N7D	DN	VYR 006
DMC9N7D	MI	TTYZVDJ
DMC9N7D	MN	Dihydrofolate reductase (DHFR)
DMC9N7D	MT	DTT
DMC9N7D	MA	Inhibitor
DMC9N7D	RN	Clinical pipeline report, company report or official report of Vyera Pharmaceuticals.
DMC9N7D	RU	https://www.vyera.com/news-center/vyera-pharmaceuticals-has-initiated-a-phase-1-study-of-a-new-dihydrofolate-reductase-inhibitor-designed-as-a-potential-treatment-for-toxoplasmosis

DMJ2R69	DI	DMJ2R69
DMJ2R69	DN	W-198
DMJ2R69	MI	TT3OT40
DMJ2R69	MN	Multidrug resistance protein 1 (ABCB1)
DMJ2R69	MT	DTT
DMJ2R69	MA	Modulator
DMJ2R69	RN	Mechanisms of tetrandrine and 5-bromotetrandrine in reversing multidrug resistance may relate to down-regulation of multidrug resistance associated protein 7 expression. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012 Jun;20(3):558-63.
DMJ2R69	RU	https://pubmed.ncbi.nlm.nih.gov/22739155

DMJQHTN	DI	DMJQHTN
DMJQHTN	DN	WCK-1152
DMJQHTN	MI	TTIXTO3
DMJQHTN	MN	Staphylococcus Topoisomerase IV (Stap-coc parC)
DMJQHTN	MT	DTT
DMJQHTN	MA	Modulator
DMJQHTN	RN	DOI: 10.1093/jac/dki361
DMJQHTN	RU	http://jac.oxfordjournals.org/content/56/6/1130.full.pdf

DM57FHW	DI	DM57FHW
DM57FHW	DN	WF-11605
DM57FHW	MI	TTTWGIX
DM57FHW	MN	Leukotriene receptor (LTR)
DM57FHW	MT	DTT
DM57FHW	MA	Modulator
DM57FHW	RN	WF11605, an antagonist of leukotriene B4 produced by a fungus. II. Structure determination. J Antibiot (Tokyo). 1992 May;45(5):704-8.
DM57FHW	RU	https://pubmed.ncbi.nlm.nih.gov/1320602

DM8RNSB	DI	DM8RNSB
DM8RNSB	DN	WP1220
DM8RNSB	MI	TTH8FZW
DM8RNSB	MN	Signal transducer and activator of transcription 3 (STAT3)
DM8RNSB	MT	DTT
DM8RNSB	MA	Inhibitor
DM8RNSB	RN	Clinical pipeline report, company report or official report of Moleculin Biotech.
DM8RNSB	RU	https://www.moleculin.com/technology/wp1220/

DM9PNR6	DI	DM9PNR6
DM9PNR6	DN	WST-057
DM9PNR6	MI	TTZ9SOR
DM9PNR6	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DM9PNR6	MT	DTT
DM9PNR6	MA	Antagonist
DM9PNR6	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9PNR6	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM7MS10	DI	DM7MS10
DM7MS10	DN	WVT078
DM7MS10	MI	TTZ3P4W
DM7MS10	MN	B-cell maturation protein (TNFRSF17)
DM7MS10	MT	DTT
DM7MS10	RN	ClinicalTrials.gov (NCT04123418) A Study of WVT078 in Patients With Multiple Myeloma (MM). U.S. National Institutes of Health.
DM7MS10	RU	https://clinicaltrials.gov/ct2/show/NCT04123418

DM7MS10	DI	DM7MS10
DM7MS10	DN	WVT078
DM7MS10	MI	TTUN7MC
DM7MS10	MN	T-cell surface glycoprotein CD3 (CD3)
DM7MS10	MT	DTT
DM7MS10	RN	ClinicalTrials.gov (NCT04123418) A Study of WVT078 in Patients With Multiple Myeloma (MM). U.S. National Institutes of Health.
DM7MS10	RU	https://clinicaltrials.gov/ct2/show/NCT04123418

DMFBOQ7	DI	DMFBOQ7
DMFBOQ7	DN	Xanthine
DMFBOQ7	MI	TTNE7KG
DMFBOQ7	MN	Adenosine A2b receptor (ADORA2B)
DMFBOQ7	MT	DTT
DMFBOQ7	MA	Antagonist
DMFBOQ7	RN	Role of adenosine in asthma. Drug Dev Res. 1996;39:333-6.
DMFBOQ7	RU	https://pubmed.ncbi.nlm.nih.gov/11542498

DMFBOQ7	DI	DMFBOQ7
DMFBOQ7	DN	Xanthine
DMFBOQ7	MI	DEJGDUW
DMFBOQ7	MN	Cytochrome P450 1A2 (CYP1A2)
DMFBOQ7	MT	DME
DMFBOQ7	MA	Metabolism
DMFBOQ7	RN	Rapid determination of five probe drugs and their metabolites in human plasma and urine by liquid chromatography/tandem mass spectrometry: application to cytochrome P450 phenotyping studies. Rapid Commun Mass Spectrom. 2004;18(23):2921-33.
DMFBOQ7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15529418

DMFBOQ7	DI	DMFBOQ7
DMFBOQ7	DN	Xanthine
DMFBOQ7	MI	DECG04O
DMFBOQ7	MN	Xanthine dehydrogenase/oxidase (XDH)
DMFBOQ7	MT	DME
DMFBOQ7	MA	Metabolism
DMFBOQ7	RN	Molecular characterization and taurine regulation of two novel CDOs (CDO1 and CDO2) from Carassius auratus. Comp Biochem Physiol B Biochem Mol Biol. 2019 Sep;235:54-61.
DMFBOQ7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31176866

DM1UIOA	DI	DM1UIOA
DM1UIOA	DN	XB-947
DM1UIOA	MI	TT4NVEM
DM1UIOA	MN	DNA topoisomerase II beta (TOP2B)
DM1UIOA	MT	DTT
DM1UIOA	MA	Modulator
DM1UIOA	RN	XK469, a selective topoisomerase IIbeta poison. Proc Natl Acad Sci U S A. 1999 October 12; 96(21): 12168-12173.
DM1UIOA	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC18430/

DMNKV3O	DI	DMNKV3O
DMNKV3O	DN	XEN007
DMNKV3O	MI	TTX4QDJ
DMNKV3O	MN	Voltage-gated calcium channel alpha Cav2.1 (CACNA1A)
DMNKV3O	MT	DTT
DMNKV3O	MA	Inhibitor
DMNKV3O	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMNKV3O	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMJVL57	DI	DMJVL57
DMJVL57	DN	XEN1101
DMJVL57	MI	TTIVDM3
DMJVL57	MN	Voltage-gated potassium channel Kv7.3 (KCNQ3)
DMJVL57	MT	DTT
DMJVL57	MA	Activator
DMJVL57	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMJVL57	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMRP9YF	DI	DMRP9YF
DMRP9YF	DN	XEN901
DMRP9YF	MI	TT54ERL
DMRP9YF	MN	Voltage-gated sodium channel alpha Nav1.6 (SCN8A)
DMRP9YF	MT	DTT
DMRP9YF	MA	Inhibitor
DMRP9YF	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMRP9YF	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMU0V45	DI	DMU0V45
DMU0V45	DN	XEN-D0101
DMU0V45	MI	TTW0CMT
DMU0V45	MN	Voltage-gated potassium channel Kv1.5 (KCNA5)
DMU0V45	MT	DTT
DMU0V45	MA	Modulator
DMU0V45	RN	Human electrophysiological and pharmacological properties of XEN-D0101: a novel atrial-selective Kv1.5/IKur inhibitor. J Cardiovasc Pharmacol. 2013 May;61(5):408-15.
DMU0V45	RU	https://pubmed.ncbi.nlm.nih.gov/23364608

DMR0U4V	DI	DMR0U4V
DMR0U4V	DN	XEN-D0103
DMR0U4V	MI	TTW0CMT
DMR0U4V	MN	Voltage-gated potassium channel Kv1.5 (KCNA5)
DMR0U4V	MT	DTT
DMR0U4V	MA	Inhibitor
DMR0U4V	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 542).
DMR0U4V	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=542

DMVYO41	DI	DMVYO41
DMVYO41	DN	XK-469
DMVYO41	MI	TT4NVEM
DMVYO41	MN	DNA topoisomerase II beta (TOP2B)
DMVYO41	MT	DTT
DMVYO41	MA	Modulator
DMVYO41	RN	A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469.Pharmacogenet Genomics.2014 Feb;24(2):129-32.
DMVYO41	RU	https://www.ncbi.nlm.nih.gov/pubmed/24300566

DMYSQHT	DI	DMYSQHT
DMYSQHT	DN	XL-041
DMYSQHT	MI	TTM1EQF
DMYSQHT	MN	Oxysterols receptor LXR (NR1H)
DMYSQHT	MT	DTT
DMYSQHT	MA	Modulator
DMYSQHT	RN	Emerging small molecule drugs. Handb Exp Pharmacol. 2015;224:617-30.
DMYSQHT	RU	https://pubmed.ncbi.nlm.nih.gov/25523004

DM3LRAC	DI	DM3LRAC
DM3LRAC	DN	XL092
DM3LRAC	MI	TTNDSF4
DM3LRAC	MN	Proto-oncogene c-Met (MET)
DM3LRAC	MT	DTT
DM3LRAC	MA	Inhibitor
DM3LRAC	RN	Clinical pipeline report, company report or official report of Exelixis.
DM3LRAC	RU	https://www.exelixis.com/pipeline/

DM3LRAC	DI	DM3LRAC
DM3LRAC	DN	XL092
DM3LRAC	MI	TTVJ1D8
DM3LRAC	MN	Vascular endothelial growth factor receptor (VEGFR)
DM3LRAC	MT	DTT
DM3LRAC	MA	Inhibitor
DM3LRAC	RN	Clinical pipeline report, company report or official report of Exelixis.
DM3LRAC	RU	https://www.exelixis.com/pipeline/

DME0F5W	DI	DME0F5W
DME0F5W	DN	XL418
DME0F5W	MI	TTAZ05C
DME0F5W	MN	RAC-gamma serine/threonine-protein kinase (AKT3)
DME0F5W	MT	DTT
DME0F5W	MA	Modulator
DME0F5W	RN	Targeting the phosphoinositide 3-kinase (PI3K) pathway in cancer
DME0F5W	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3142564

DME0F5W	DI	DME0F5W
DME0F5W	DN	XL418
DME0F5W	MI	TT7M3PI
DME0F5W	MN	Ribosomal protein S6 kinase (S6K)
DME0F5W	MT	DTT
DME0F5W	MA	Modulator
DME0F5W	RN	Targeting the phosphoinositide 3-kinase (PI3K) pathway in cancer
DME0F5W	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3142564

DMY93SW	DI	DMY93SW
DMY93SW	DN	XL550
DMY93SW	MI	TT26PHO
DMY93SW	MN	Mineralocorticoid receptor  (MR)
DMY93SW	MT	DTT
DMY93SW	MA	Antagonist
DMY93SW	RN	Clinical pipeline report, company report or official report of Exelixis (2011).
DMY93SW	RU	http://www.exelixis.com/pipeline

DM89NML	DI	DM89NML
DM89NML	DN	XL652/XL014
DM89NML	MI	TTM1EQF
DM89NML	MN	Oxysterols receptor LXR (NR1H)
DM89NML	MT	DTT
DM89NML	MA	Modulator
DM89NML	RN	Clinical pipeline report, company report or official report of Exelixis (2011).
DM89NML	RU	http://www.exelixis.com/pipeline

DMYS13R	DI	DMYS13R
DMYS13R	DN	XL999
DMYS13R	MI	TTUTJGQ
DMYS13R	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMYS13R	MT	DTT
DMYS13R	MA	Inhibitor
DMYS13R	RN	Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Mar;29(2):153-73.
DMYS13R	RU	https://pubmed.ncbi.nlm.nih.gov/17440629

DMXTOCE	DI	DMXTOCE
DMXTOCE	DN	XmAb13676
DMXTOCE	MI	TTUE541
DMXTOCE	MN	Leukocyte surface antigen Leu-16 (CD20)
DMXTOCE	MT	DTT
DMXTOCE	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMXTOCE	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMJIH83	DI	DMJIH83
DMJIH83	DN	XmAb20717
DMJIH83	MI	TTI2S1D
DMJIH83	MN	Cytotoxic T-lymphocyte protein 4 (CTLA-4)
DMJIH83	MT	DTT
DMJIH83	RN	Clinical pipeline report, company report or official report of Xencor.
DMJIH83	RU	https://xencor.com/pipeline/xmab20717/

DMJIH83	DI	DMJIH83
DMJIH83	DN	XmAb20717
DMJIH83	MI	TTNBFWK
DMJIH83	MN	Programmed cell death protein 1 (PD-1)
DMJIH83	MT	DTT
DMJIH83	RN	Clinical pipeline report, company report or official report of Xencor.
DMJIH83	RU	https://xencor.com/pipeline/xmab20717/

DMQB3HD	DI	DMQB3HD
DMQB3HD	DN	XmAb22841
DMQB3HD	MI	TTI2S1D
DMQB3HD	MN	Cytotoxic T-lymphocyte protein 4 (CTLA-4)
DMQB3HD	MT	DTT
DMQB3HD	RN	Clinical pipeline report, company report or official report of Xencor.
DMQB3HD	RU	https://xencor.com/pipeline/xmab22841/

DMQB3HD	DI	DMQB3HD
DMQB3HD	DN	XmAb22841
DMQB3HD	MI	TTNVXAW
DMQB3HD	MN	Lymphocyte activation gene 3 protein (LAG3)
DMQB3HD	MT	DTT
DMQB3HD	RN	Clinical pipeline report, company report or official report of Xencor.
DMQB3HD	RU	https://xencor.com/pipeline/xmab22841/

DMK9XUQ	DI	DMK9XUQ
DMK9XUQ	DN	XmAb23104
DMK9XUQ	MI	TTE5VP6
DMK9XUQ	MN	Inducible T-cell costimulator (ICOS)
DMK9XUQ	MT	DTT
DMK9XUQ	RN	Clinical pipeline report, company report or official report of Xencor.
DMK9XUQ	RU	https://xencor.com/pipeline/xmab23104/

DMK9XUQ	DI	DMK9XUQ
DMK9XUQ	DN	XmAb23104
DMK9XUQ	MI	TTNBFWK
DMK9XUQ	MN	Programmed cell death protein 1 (PD-1)
DMK9XUQ	MT	DTT
DMK9XUQ	RN	Clinical pipeline report, company report or official report of Xencor.
DMK9XUQ	RU	https://xencor.com/pipeline/xmab23104/

DM6V0KY	DI	DM6V0KY
DM6V0KY	DN	Xmab-2513
DM6V0KY	MI	TT2GM5R
DM6V0KY	MN	Lymphocyte activation antigen CD30 (TNFRSF8)
DM6V0KY	MT	DTT
DM6V0KY	RN	Phase I study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: Safety, pharmacokinetics (PK), immunogenicity, and efficacy. J Clin Oncol (Meeting Abstracts) May 2009 vol. 27 no. 15S 8531.
DM6V0KY	RU	http://meeting.ascopubs.org/cgi/content/abstract/27/15S/8531

DME7IVL	DI	DME7IVL
DME7IVL	DN	Xmab-7195
DME7IVL	MI	TTYJQTF
DME7IVL	MN	Immunoglobulin E (IgE)
DME7IVL	MT	DTT
DME7IVL	MA	Inhibitor
DME7IVL	RN	Clinical pipeline report, company report or official report of Xencor.
DME7IVL	RU	http://www.xencor.com/pipeline/xmab7195/

DM4MDCH	DI	DM4MDCH
DM4MDCH	DN	XMT-1001
DM4MDCH	MI	TTGTQHC
DM4MDCH	MN	DNA topoisomerase I (TOP1)
DM4MDCH	MT	DTT
DM4MDCH	MA	Inhibitor
DM4MDCH	RN	Pharmacokinetics and antitumor efficacy of XMT-1001, a novel, polymeric topoisomerase I inhibitor, in mice bearing HT-29 human colon carcinoma xenografts. Clin Cancer Res. 2012 May 1;18(9):2591-602.
DM4MDCH	RU	https://pubmed.ncbi.nlm.nih.gov/22392910

DMK0AW6	DI	DMK0AW6
DMK0AW6	DN	XOMA-3AB
DMK0AW6	MI	TTB52WU
DMK0AW6	MN	Bacterial Botulinum toxin A (Bact botA)
DMK0AW6	MT	DTT
DMK0AW6	RN	Clinical pipeline report, company report or official report of XOMA.
DMK0AW6	RU	http://www.xoma.com/content/pipeline/biodefense.htm

DMO9KZE	DI	DMO9KZE
DMO9KZE	DN	XR-5944
DMO9KZE	MI	TT0IHXV
DMO9KZE	MN	DNA topoisomerase II (TOP2)
DMO9KZE	MT	DTT
DMO9KZE	MA	Modulator
DMO9KZE	RN	Antitumor activity of XR5944, a novel and potent topoisomerase poison. Anticancer Drugs. 2001 Apr;12(4):359-67.
DMO9KZE	RU	https://pubmed.ncbi.nlm.nih.gov/11335793

DML3K9N	DI	DML3K9N
DML3K9N	DN	XTL-6865
DML3K9N	MI	TTDBG95
DML3K9N	MN	Hepatitis C virus Envelope glycoprotein E2 (HCV NS1)
DML3K9N	MT	DTT
DML3K9N	MA	Modulator
DML3K9N	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DML3K9N	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMKHVNE	DI	DMKHVNE
DMKHVNE	DN	YKP-1358
DMKHVNE	MI	TTJQOD7
DMKHVNE	MN	5-HT 2A receptor (HTR2A)
DMKHVNE	MT	DTT
DMKHVNE	MA	Modulator
DMKHVNE	RN	Modeling of brain D2 receptor occupancy-plasma concentration relationships with a novel antipsychotic, YKP1358, using serial PET scans in healthy volunteers. Clin Pharmacol Ther. 2007 Feb;81(2):252-8.
DMKHVNE	RU	https://pubmed.ncbi.nlm.nih.gov/17259948

DMKHVNE	DI	DMKHVNE
DMKHVNE	DN	YKP-1358
DMKHVNE	MI	TTEX248
DMKHVNE	MN	Dopamine D2 receptor (D2R)
DMKHVNE	MT	DTT
DMKHVNE	MA	Modulator
DMKHVNE	RN	Modeling of brain D2 receptor occupancy-plasma concentration relationships with a novel antipsychotic, YKP1358, using serial PET scans in healthy volunteers. Clin Pharmacol Ther. 2007 Feb;81(2):252-8.
DMKHVNE	RU	https://pubmed.ncbi.nlm.nih.gov/17259948

DMW2HS8	DI	DMW2HS8
DMW2HS8	DN	YM-116
DMW2HS8	MI	TTC8NQ2
DMW2HS8	MN	Lyase unspecific (LYA)
DMW2HS8	MT	DTT
DMW2HS8	MA	Inhibitor
DMW2HS8	RN	YM116, 2-(1H-imidazol-4-ylmethyl)-9H-carbazole, decreases adrenal androgen synthesis by inhibiting C17-20 lyase activity in NCI-H295 human adrenocortical carcinoma cells. Jpn J Pharmacol. 1999 Feb;79(2):213-20.
DMW2HS8	RU	https://pubmed.ncbi.nlm.nih.gov/10202857

DMNLY9R	DI	DMNLY9R
DMNLY9R	DN	YM-16151-4
DMNLY9R	MI	TTR6W5O
DMNLY9R	MN	Adrenergic receptor beta-1 (ADRB1)
DMNLY9R	MT	DTT
DMNLY9R	MA	Modulator
DMNLY9R	RN	Antianginal effects of YM-16151-4 in various experimental angina models. J Cardiovasc Pharmacol. 1993 May;21(5):701-8.
DMNLY9R	RU	https://pubmed.ncbi.nlm.nih.gov/7685438

DMNLY9R	DI	DMNLY9R
DMNLY9R	DN	YM-16151-4
DMNLY9R	MI	TT5HONZ
DMNLY9R	MN	Calcium channel unspecific (CaC)
DMNLY9R	MT	DTT
DMNLY9R	MA	Modulator
DMNLY9R	RN	Antianginal effects of YM-16151-4 in various experimental angina models. J Cardiovasc Pharmacol. 1993 May;21(5):701-8.
DMNLY9R	RU	https://pubmed.ncbi.nlm.nih.gov/7685438

DMS31YW	DI	DMS31YW
DMS31YW	DN	YM-57158
DMS31YW	MI	TTGKOY9
DMS31YW	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DMS31YW	MT	DTT
DMS31YW	MA	Modulator
DMS31YW	RN	In vitro pharmacologic profile of YM158, a new dual antagonist for LTD4 and TXA2 receptors. J Pharmacol Exp Ther. 1998 Nov;287(2):633-9.
DMS31YW	RU	https://pubmed.ncbi.nlm.nih.gov/9808690

DMS31YW	DI	DMS31YW
DMS31YW	DN	YM-57158
DMS31YW	MI	TT2O84V
DMS31YW	MN	Thromboxane A2 receptor (TBXA2R)
DMS31YW	MT	DTT
DMS31YW	MA	Modulator
DMS31YW	RN	In vitro pharmacologic profile of YM158, a new dual antagonist for LTD4 and TXA2 receptors. J Pharmacol Exp Ther. 1998 Nov;287(2):633-9.
DMS31YW	RU	https://pubmed.ncbi.nlm.nih.gov/9808690

DMCM0K6	DI	DMCM0K6
DMCM0K6	DN	YPEG-Somatropin
DMCM0K6	MI	TTT3YKH
DMCM0K6	MN	Somatotropin (GH1)
DMCM0K6	MT	DTT
DMCM0K6	MA	Modulator
DMCM0K6	RN	Somatropin therapy in adults with Prader-Willi syndrome. Treat Endocrinol. 2004;3(3):153-60.
DMCM0K6	RU	https://pubmed.ncbi.nlm.nih.gov/16026111

DM5BMIO	DI	DM5BMIO
DM5BMIO	DN	YTB323
DM5BMIO	MI	TTW640A
DM5BMIO	MN	B-lymphocyte surface antigen B4 (CD19)
DM5BMIO	MT	DTT
DM5BMIO	RN	Clinical pipeline report, company report or official report of Novartis.
DM5BMIO	RU	https://www.novartis.com/our-science/novartis-global-pipeline?search_api_views_fulltext=YTB323&field_pipeline_filing_date=All

DM1H75D	DI	DM1H75D
DM1H75D	DN	Z-100
DM1H75D	MI	TTV2CN0
DM1H75D	MN	Interferon receptor (IFNR)
DM1H75D	MT	DTT
DM1H75D	MA	Modulator
DM1H75D	RN	Inhibition of human immunodeficiency virus type 1 replication by Z-100, an immunomodulator extracted from human-type tubercle bacilli, in macrophages. J Gen Virol. 2004 Sep;85(Pt 9):2603-13.
DM1H75D	RU	https://pubmed.ncbi.nlm.nih.gov/15302954

DMZQP7N	DI	DMZQP7N
DMZQP7N	DN	ZD7114
DMZQP7N	MI	TTMXGCW
DMZQP7N	MN	Adrenergic receptor beta-3 (ADRB3)
DMZQP7N	MT	DTT
DMZQP7N	MA	Agonist
DMZQP7N	RN	Urinary tract toxicity in rats following administration of beta 3-adrenoceptor agonists. Toxicol Pathol. 1999 Mar-Apr;27(2):165-70.
DMZQP7N	RU	https://pubmed.ncbi.nlm.nih.gov/10207980

DM3KYO4	DI	DM3KYO4
DM3KYO4	DN	ZD-9379
DM3KYO4	MI	TTZ8EM9
DM3KYO4	MN	Glycine receptor (GlyR)
DM3KYO4	MT	DTT
DM3KYO4	MA	Modulator
DM3KYO4	RN	Neuroprotective potential of ionotropic glutamate receptor antagonists. Neurotox Res. 2002 Mar;4(2):119-26.
DM3KYO4	RU	https://pubmed.ncbi.nlm.nih.gov/12829411

DM2S04R	DI	DM2S04R
DM2S04R	DN	Zemab
DM2S04R	MI	TT6EO5L
DM2S04R	MN	Erbb2 tyrosine kinase receptor (HER2)
DM2S04R	MT	DTT
DM2S04R	RN	Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage between Components. Toxins (Basel) 2011 July; 3(7): 848-883.
DM2S04R	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202854/

DM72GZV	DI	DM72GZV
DM72GZV	DN	ZEN003694
DM72GZV	MI	TTE4BSY
DM72GZV	MN	Bromodomain and extraterminal domain protein (BET)
DM72GZV	MT	DTT
DM72GZV	MA	Inhibitor
DM72GZV	RN	Clinical pipeline report, company report or official report of Zenith Epigenetics.
DM72GZV	RU	https://www.zenithepigenetics.com/programs/pipeline

DM2LHPU	DI	DM2LHPU
DM2LHPU	DN	ZK-200775
DM2LHPU	MI	TTAN6JD
DM2LHPU	MN	Glutamate receptor AMPA (GRIA)
DM2LHPU	MT	DTT
DM2LHPU	MA	Inhibitor
DM2LHPU	RN	Synthesis of anticonvulsive AMPA antagonists: 4-oxo-10-substituted-imidaz. Bioorg Med Chem Lett. 2001 May 7;11(9):1205-10.
DM2LHPU	RU	https://pubmed.ncbi.nlm.nih.gov/11354378

DMTNUA4	DI	DMTNUA4
DMTNUA4	DN	ZL-1201
DMTNUA4	MI	TT28S46
DMTNUA4	MN	Leukocyte surface antigen CD47 (CD47)
DMTNUA4	MT	DTT
DMTNUA4	RN	Clinical pipeline report, company report or official report of ZAI Lab.
DMTNUA4	RU	http://www.zailaboratory.com/pipeline/list.aspx

DMX6AJ8	DI	DMX6AJ8
DMX6AJ8	DN	ZM-H1505R
DMX6AJ8	MI	TTM42UJ
DMX6AJ8	MN	Hepatitis B virus Capsid protein (HBV C)
DMX6AJ8	MT	DTT
DMX6AJ8	MA	Inhibitor
DMX6AJ8	RN	Clinical pipeline report, company report or official report of Shanghai Zhimeng Biopharma.
DMX6AJ8	RU	http://www.core-biopharma.com/pipeline.html

DMGTL8Z	DI	DMGTL8Z
DMGTL8Z	DN	ZP-1848
DMGTL8Z	MI	TT1YWO5
DMGTL8Z	MN	Glucagon-like peptide 2 receptor (GLP2R)
DMGTL8Z	MT	DTT
DMGTL8Z	MA	Modulator
DMGTL8Z	RN	US patent application no. 8,580,918, Peptidic glp-2 agonists.
DMGTL8Z	RU	http://www.google.com/patents/US8580918

DMRVDUM	DI	DMRVDUM
DMRVDUM	DN	ZP2929
DMRVDUM	MI	TT0NUFM
DMRVDUM	MN	Glucagon (GCG)
DMRVDUM	MT	DTT
DMRVDUM	MA	Agonist
DMRVDUM	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMRVDUM	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMRVDUM	DI	DMRVDUM
DMRVDUM	DN	ZP2929
DMRVDUM	MI	TT9O6WS
DMRVDUM	MN	Glucagon receptor (GCGR)
DMRVDUM	MT	DTT
DMRVDUM	MA	Modulator
DMRVDUM	RN	Company report (Zealandpharma)
DMRVDUM	RU	http://www.zealandpharma.com/product-pipeline/proprietary-pipeline/zp2929

DMRVDUM	DI	DMRVDUM
DMRVDUM	DN	ZP2929
DMRVDUM	MI	TTVIMDE
DMRVDUM	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMRVDUM	MT	DTT
DMRVDUM	MA	Modulator
DMRVDUM	RN	Company report (Zealandpharma)
DMRVDUM	RU	http://www.zealandpharma.com/product-pipeline/proprietary-pipeline/zp2929

DMVIMQX	DI	DMVIMQX
DMVIMQX	DN	ZSTK474
DMVIMQX	MI	TTHBTOP
DMVIMQX	MN	PI3-kinase gamma (PIK3CG)
DMVIMQX	MT	DTT
DMVIMQX	MA	Modulator
DMVIMQX	RN	Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer. Neoplasia. 2013 Oct;15(10):1172-83.
DMVIMQX	RU	https://pubmed.ncbi.nlm.nih.gov/24204196

DMO2WYX	DI	DMO2WYX
DMO2WYX	DN	ZT-1
DMO2WYX	MI	TT1RS9F
DMO2WYX	MN	Acetylcholinesterase (AChE)
DMO2WYX	MT	DTT
DMO2WYX	MA	Inhibitor
DMO2WYX	RN	A sensitive method for the determination of the novel cholinesterase inhibitor ZT-1 and its active metabolite huperzine A in rat blood using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2004;18(6):651-6.
DMO2WYX	RU	https://pubmed.ncbi.nlm.nih.gov/15052575

DMAU8L9	DI	DMAU8L9
DMAU8L9	DN	ZW49
DMAU8L9	MI	TT6EO5L
DMAU8L9	MN	Erbb2 tyrosine kinase receptor (HER2)
DMAU8L9	MT	DTT
DMAU8L9	MA	Inhibitor
DMAU8L9	RN	Clinical pipeline report, company report or official report of Zymeworks.
DMAU8L9	RU	https://www.zymeworks.com/pipeline#zw49

DMSLPTO	DI	DMSLPTO
DMSLPTO	DN	ZY01
DMSLPTO	MI	TT6OEDT
DMSLPTO	MN	Cannabinoid receptor 1 (CB1)
DMSLPTO	MT	DTT
DMSLPTO	MA	Antagonist
DMSLPTO	RN	2011 Pipeline of Zydus Cadila Group.
DMSLPTO	RU	http://www.zyduscadila.com/

DM796RI	DI	DM796RI
DM796RI	DN	ZYAN1
DM796RI	MI	TTJQFBG
DM796RI	MN	HIF-prolyl hydroxylase (HPH)
DM796RI	MT	DTT
DM796RI	MA	Inhibitor
DM796RI	RN	Pharmacological Characterization of ZYAN1, a Novel Prolyl Hydroxylase Inhibitor for the Treatment of Anemia. Drug Res (Stuttg). 2016 Feb;66(2):107-12.
DM796RI	RU	https://pubmed.ncbi.nlm.nih.gov/26367279

DMU2D0B	DI	DMU2D0B
DMU2D0B	DN	ZYDPLA 1
DMU2D0B	MI	TTDIGC1
DMU2D0B	MN	Dipeptidyl peptidase 4 (DPP-4)
DMU2D0B	MT	DTT
DMU2D0B	MA	Inhibitor
DMU2D0B	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMU2D0B	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DM4IG16	DI	DM4IG16
DM4IG16	DN	ZYGK-1
DM4IG16	MI	TTDLNGZ
DM4IG16	MN	Glucokinase (GCK)
DM4IG16	MT	DTT
DM4IG16	MA	Activator
DM4IG16	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2798).
DM4IG16	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2798

DMZ6042	DI	DMZ6042
DMZ6042	DN	ZYOG1
DMZ6042	MI	TTVIMDE
DMZ6042	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMZ6042	MT	DTT
DMZ6042	MA	Agonist
DMZ6042	RN	2011 Pipeline of Zydus Cadila Group.
DMZ6042	RU	http://www.zyduscadila.com/

DM1XOZK	DI	DM1XOZK
DM1XOZK	DN	ZYT-1
DM1XOZK	MI	TTGER3L
DM1XOZK	MN	Thyroid hormone receptor beta (THRB)
DM1XOZK	MT	DTT
DM1XOZK	MA	Modulator
DM1XOZK	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM1XOZK	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMX1ZQV	DI	DMX1ZQV
DMX1ZQV	DN	(S)-DRF-1042
DMX1ZQV	MI	TTGTQHC
DMX1ZQV	MN	DNA topoisomerase I (TOP1)
DMX1ZQV	MT	DTT
DMX1ZQV	MA	Inhibitor
DMX1ZQV	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2636).
DMX1ZQV	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2636

DMN2I3P	DI	DMN2I3P
DMN2I3P	DN	alpha-ketothiazole analogue 36
DMN2I3P	MI	TTDM4ZU
DMN2I3P	MN	Factor XI messenger RNA (F11 mRNA)
DMN2I3P	MT	DTT
DMN2I3P	MA	Inhibitor
DMN2I3P	RN	Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. Bioorg Med Chem. 2008 Feb 15;16(4):1562-95.
DMN2I3P	RU	https://pubmed.ncbi.nlm.nih.gov/18053726

DM6NVPT	DI	DM6NVPT
DM6NVPT	DN	Anti-CD19 Chimeric Antigen Receptor T Cells
DM6NVPT	MI	TTW640A
DM6NVPT	MN	B-lymphocyte surface antigen B4 (CD19)
DM6NVPT	MT	DTT
DM6NVPT	MA	CAR-T-Cell-Therapy
DM6NVPT	RN	ClinicalTrials.gov (NCT03624686) Production of Clinical-grade Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory B-cell Malignancies
DM6NVPT	RU	https://clinicaltrials.gov/ct2/show/NCT03624686

DM3M9OY	DI	DM3M9OY
DM3M9OY	DN	Anti-CD19/20-CAR vector-transduced T cells
DM3M9OY	MI	TTW640A
DM3M9OY	MN	B-lymphocyte surface antigen B4 (CD19)
DM3M9OY	MT	DTT
DM3M9OY	MA	CAR-T-Cell-Therapy(Dual specific)
DM3M9OY	RN	ClinicalTrials.gov (NCT03097770) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20
DM3M9OY	RU	https://clinicaltrials.gov/ct2/show/NCT03097770

DM3M9OY	DI	DM3M9OY
DM3M9OY	DN	Anti-CD19/20-CAR vector-transduced T cells
DM3M9OY	MI	TTUE541
DM3M9OY	MN	Leukocyte surface antigen Leu-16 (CD20)
DM3M9OY	MT	DTT
DM3M9OY	MA	CAR-T-Cell-Therapy(Dual specific)
DM3M9OY	RN	ClinicalTrials.gov (NCT03097770) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20
DM3M9OY	RU	https://clinicaltrials.gov/ct2/show/NCT03097770

DMGPTFL	DI	DMGPTFL
DMGPTFL	DN	AZ-4217
DMGPTFL	MI	TT8JRS7
DMGPTFL	MN	Beta-secretase (BACE)
DMGPTFL	MT	DTT
DMGPTFL	MA	Inhibitor
DMGPTFL	RN	AZ-4217: a high potency BACE inhibitor displaying acute central efficacy in different in vivo models and reduced amyloid deposition in Tg2576 mice. J Neurosci. 2013 Jun 12;33(24):10075-84.
DMGPTFL	RU	https://pubmed.ncbi.nlm.nih.gov/23761903

DMCEPKM	DI	DMCEPKM
DMCEPKM	DN	BCMA-CART
DMCEPKM	MI	TTZ3P4W
DMCEPKM	MN	B-cell maturation protein (TNFRSF17)
DMCEPKM	MT	DTT
DMCEPKM	MA	CAR-T-Cell-Therapy
DMCEPKM	RN	ClinicalTrials.gov (NCT03492268) Safety and Efficacy Evaluation of BCMA-CART for Treating Multiple Myeloma
DMCEPKM	RU	https://clinicaltrials.gov/ct2/show/NCT03492268

DMWXGRQ	DI	DMWXGRQ
DMWXGRQ	DN	BCMA-UCART
DMWXGRQ	MI	TTZ3P4W
DMWXGRQ	MN	B-cell maturation protein (TNFRSF17)
DMWXGRQ	MT	DTT
DMWXGRQ	MA	CAR-T-Cell-Therapy
DMWXGRQ	RN	ClinicalTrials.gov (NCT03752541) Efficacy and Safety Evaluation of BCMA-UCART
DMWXGRQ	RU	https://clinicaltrials.gov/ct2/show/NCT03752541

DM531SA	DI	DM531SA
DM531SA	DN	bimatoprost (free acid form)
DM531SA	MI	TTT2ZAR
DM531SA	MN	Prostaglandin F2-alpha receptor (PTGFR)
DM531SA	MT	DTT
DM531SA	MA	Agonist
DM531SA	RN	Replacement of the carboxylic acid group of prostaglandin f(2alpha) with a hydroxyl or methoxy substituent provides biologically unique compounds. Br J Pharmacol. 2000 Aug;130(8):1933-43.
DM531SA	RU	https://pubmed.ncbi.nlm.nih.gov/10952685

DMN2EI1	DI	DMN2EI1
DMN2EI1	DN	bis-triazole derivative 10
DMN2EI1	MI	TTP86E2
DMN2EI1	MN	Plasminogen (PLG)
DMN2EI1	MT	DTT
DMN2EI1	MA	Inhibitor
DMN2EI1	RN	A new strategy for the development of highly potent and selective plasmin inhibitors. J Med Chem. 2012 Feb 9;55(3):1171-80.
DMN2EI1	RU	https://pubmed.ncbi.nlm.nih.gov/22276953

DMLF2UY	DI	DMLF2UY
DMLF2UY	DN	CAR-BCMA T cell
DMLF2UY	MI	TTZ3P4W
DMLF2UY	MN	B-cell maturation protein (TNFRSF17)
DMLF2UY	MT	DTT
DMLF2UY	MA	CAR-T-Cell-Therapy
DMLF2UY	RN	ClinicalTrials.gov (NCT03302403) Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
DMLF2UY	RU	https://clinicaltrials.gov/ct2/show/NCT03302403

DMXU2D1	DI	DMXU2D1
DMXU2D1	DN	CAR-CD19 T cell
DMXU2D1	MI	TTW640A
DMXU2D1	MN	B-lymphocyte surface antigen B4 (CD19)
DMXU2D1	MT	DTT
DMXU2D1	MA	CAR-T-Cell-Therapy
DMXU2D1	RN	ClinicalTrials.gov (NCT03302403) Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
DMXU2D1	RU	https://clinicaltrials.gov/ct2/show/NCT03302403

DM6ZHTV	DI	DM6ZHTV
DM6ZHTV	DN	CAR-CLD18 T cell
DM6ZHTV	MI	TT6PKBX
DM6ZHTV	MN	Claudin-18 (CLDN18)
DM6ZHTV	MT	DTT
DM6ZHTV	MA	CAR-T-Cell-Therapy
DM6ZHTV	RN	ClinicalTrials.gov (NCT03302403) Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
DM6ZHTV	RU	https://clinicaltrials.gov/ct2/show/NCT03302403

DMBDT3V	DI	DMBDT3V
DMBDT3V	DN	CAR-GPC3 T cell
DMBDT3V	MI	TTJTSX4
DMBDT3V	MN	Glypican-3 (GPC3)
DMBDT3V	MT	DTT
DMBDT3V	MA	CAR-T-Cell-Therapy
DMBDT3V	RN	ClinicalTrials.gov (NCT03302403) Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
DMBDT3V	RU	https://clinicaltrials.gov/ct2/show/NCT03302403

DM0RX5E	DI	DM0RX5E
DM0RX5E	DN	CAR-GPC3 T cells
DM0RX5E	MI	TTJTSX4
DM0RX5E	MN	Glypican-3 (GPC3)
DM0RX5E	MT	DTT
DM0RX5E	MA	CAR-T-Cell-Therapy
DM0RX5E	RN	ClinicalTrials.gov (NCT03146234) CAR-GPC3 T Cells in Patients With Refractory Hepatocellular Carcinoma
DM0RX5E	RU	https://clinicaltrials.gov/ct2/show/NCT03146234

DMGW10M	DI	DMGW10M
DMGW10M	DN	CAR-T cells targeting BCMA
DMGW10M	MI	TTZ3P4W
DMGW10M	MN	B-cell maturation protein (TNFRSF17)
DMGW10M	MT	DTT
DMGW10M	MA	CAR-T-Cell-Therapy
DMGW10M	RN	ClinicalTrials.gov (NCT03473496) CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma
DMGW10M	RU	https://clinicaltrials.gov/ct2/show/NCT03473496

DMHBQYU	DI	DMHBQYU
DMHBQYU	DN	CAR-T cells targeting CD138
DMHBQYU	MI	TTYDSVG
DMHBQYU	MN	Syndecan-1 (SDC1)
DMHBQYU	MT	DTT
DMHBQYU	MA	CAR-T-Cell-Therapy
DMHBQYU	RN	ClinicalTrials.gov (NCT03473496) CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma
DMHBQYU	RU	https://clinicaltrials.gov/ct2/show/NCT03473496

DMH5C37	DI	DMH5C37
DMH5C37	DN	CAR-T cells targeting CD38
DMH5C37	MI	TTPURFN
DMH5C37	MN	Cyclic ADP-ribose hydrolase 1 (CD38)
DMH5C37	MT	DTT
DMH5C37	MA	CAR-T-Cell-Therapy
DMH5C37	RN	ClinicalTrials.gov (NCT03473457) CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia
DMH5C37	RU	https://clinicaltrials.gov/ct2/show/NCT03473457

DMAK1ME	DI	DMAK1ME
DMAK1ME	DN	CAR-T cells targeting CD56
DMAK1ME	MI	TTVXPHT
DMAK1ME	MN	Neural cell adhesion molecule 1 (NCAM1)
DMAK1ME	MT	DTT
DMAK1ME	MA	CAR-T-Cell-Therapy
DMAK1ME	RN	ClinicalTrials.gov (NCT03473457) CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia
DMAK1ME	RU	https://clinicaltrials.gov/ct2/show/NCT03473457

DMUEQ6C	DI	DMUEQ6C
DMUEQ6C	DN	CART-meso cells
DMUEQ6C	MI	TT4RXME
DMUEQ6C	MN	Mesothelin (MSLN)
DMUEQ6C	MT	DTT
DMUEQ6C	MA	CAR-T-Cell-Therapy
DMUEQ6C	RN	ClinicalTrials.gov (NCT03638193) Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer
DMUEQ6C	RU	https://clinicaltrials.gov/ct2/show/NCT03638193

DM2V6R7	DI	DM2V6R7
DM2V6R7	DN	CD19-CAR T Cells
DM2V6R7	MI	TTW640A
DM2V6R7	MN	B-lymphocyte surface antigen B4 (CD19)
DM2V6R7	MT	DTT
DM2V6R7	MA	CAR-T-Cell-Therapy
DM2V6R7	RN	ClinicalTrials.gov (NCT03423706) Clinical Studies of New Model Haploidentical Hematopoietic Stem Cell Transplantation
DM2V6R7	RU	https://clinicaltrials.gov/ct2/show/NCT03423706

DMF936G	DI	DMF936G
DMF936G	DN	CD19CART
DMF936G	MI	TTW640A
DMF936G	MN	B-lymphocyte surface antigen B4 (CD19)
DMF936G	MT	DTT
DMF936G	MA	CAR-T-Cell-Therapy
DMF936G	RN	ClinicalTrials.gov (NCT02813837) Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies
DMF936G	RU	https://clinicaltrials.gov/ct2/show/NCT02813837

DMLPAFG	DI	DMLPAFG
DMLPAFG	DN	CD19-targeted CAR-T cells
DMLPAFG	MI	TTW640A
DMLPAFG	MN	B-lymphocyte surface antigen B4 (CD19)
DMLPAFG	MT	DTT
DMLPAFG	MA	CAR-T-Cell-Therapy
DMLPAFG	RN	ClinicalTrials.gov (NCT03564977) CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation
DMLPAFG	RU	https://clinicaltrials.gov/ct2/show/NCT03564977

DMS87UT	DI	DMS87UT
DMS87UT	DN	CD19-targeted CAR-T cells
DMS87UT	MI	TTW640A
DMS87UT	MN	B-lymphocyte surface antigen B4 (CD19)
DMS87UT	MT	DTT
DMS87UT	MA	CAR-T-Cell-Therapy
DMS87UT	RN	ClinicalTrials.gov (NCT02728882) Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma
DMS87UT	RU	https://clinicaltrials.gov/ct2/show/NCT02728882

DM8VTF2	DI	DM8VTF2
DM8VTF2	DN	CD19-UCART
DM8VTF2	MI	TTW640A
DM8VTF2	MN	B-lymphocyte surface antigen B4 (CD19)
DM8VTF2	MT	DTT
DM8VTF2	MA	CAR-T-Cell-Therapy
DM8VTF2	RN	ClinicalTrials.gov (NCT03229876) Safety and Efficacy Evaluation of CD19-UCART
DM8VTF2	RU	https://clinicaltrials.gov/ct2/show/NCT03229876

DMXM19W	DI	DMXM19W
DMXM19W	DN	dequalinium
DMXM19W	MI	TT9R6BE
DMXM19W	MN	Calcium-activated potassium channel KCa2.1 (KCNN1)
DMXM19W	MT	DTT
DMXM19W	MA	Blocker (channel blocker)
DMXM19W	RN	Pharmacological characterization of small-conductance Ca(2+)-activated K(+) channels stably expressed in HEK 293 cells. Br J Pharmacol. 2000 Mar;129(5):991-9.
DMXM19W	RU	https://pubmed.ncbi.nlm.nih.gov/10696100

DMXM19W	DI	DMXM19W
DMXM19W	DN	dequalinium
DMXM19W	MI	TT2T5M0
DMXM19W	MN	Calcium-activated potassium channel KCa2.2 (KCNN2)
DMXM19W	MT	DTT
DMXM19W	MA	Blocker (channel blocker)
DMXM19W	RN	Block of rat brain recombinant SK channels by tricyclic antidepressants and related compounds. Eur J Pharmacol. 2000 Jul 28;401(1):1-7.
DMXM19W	RU	https://pubmed.ncbi.nlm.nih.gov/10915830

DMXM19W	DI	DMXM19W
DMXM19W	DN	dequalinium
DMXM19W	MI	TT9JH25
DMXM19W	MN	Calcium-activated potassium channel KCa2.3 (KCNN3)
DMXM19W	MT	DTT
DMXM19W	MA	Blocker (channel blocker)
DMXM19W	RN	Pharmacological characterisation of the human small conductance calcium-activated potassium channel hSK3 reveals sensitivity to tricyclic antidepressants and antipsychotic phenothiazines. Neuropharmacology. 2001 May;40(6):772-83.
DMXM19W	RU	https://pubmed.ncbi.nlm.nih.gov/11369031

DMXM19W	DI	DMXM19W
DMXM19W	DN	dequalinium
DMXM19W	MI	TTHIQMC
DMXM19W	MN	Cyclic nucleotide-gated channel alpha-1 (CNGA1)
DMXM19W	MT	DTT
DMXM19W	MA	Blocker (channel blocker)
DMXM19W	RN	Dequalinium: a novel, high-affinity blocker of CNGA1 channels. J Gen Physiol. 2003 Jan;121(1):37-47.
DMXM19W	RU	https://pubmed.ncbi.nlm.nih.gov/12508052

DMXM19W	DI	DMXM19W
DMXM19W	DN	dequalinium
DMXM19W	MI	TT8SJGB
DMXM19W	MN	Cyclic nucleotide-gated channel alpha-2 (CNGA2)
DMXM19W	MT	DTT
DMXM19W	MA	Blocker (channel blocker)
DMXM19W	RN	State-dependent block of CNG channels by dequalinium. J Gen Physiol. 2004 Mar;123(3):295-304.
DMXM19W	RU	https://pubmed.ncbi.nlm.nih.gov/14981138

DMV6RMB	DI	DMV6RMB
DMV6RMB	DN	EPCAM-targeted CAR-T cells
DMV6RMB	MI	TTZ8WH4
DMV6RMB	MN	Tumor-associated calcium signal transducer 1 (EPCAM)
DMV6RMB	MT	DTT
DMV6RMB	MA	CAR-T-Cell-Therapy
DMV6RMB	RN	ClinicalTrials.gov (NCT02725125) Study Evaluating the Efficacy and Safety With CAR-T for Stomach Cancer
DMV6RMB	RU	https://clinicaltrials.gov/ct2/show/NCT02725125

DM2N653	DI	DM2N653
DM2N653	DN	example 98 (WO2011020806)
DM2N653	MI	TT69DB8
DM2N653	MN	Beta-site APP-cleaving enzyme 2 (BACE2)
DM2N653	MT	DTT
DM2N653	MA	Inhibitor
DM2N653	RN	BACE2 as a new diabetes target: a patent review (2010 - 2012). Expert Opin Ther Pat. 2013 May;23(5):649-63.
DM2N653	RU	https://pubmed.ncbi.nlm.nih.gov/23506624

DM87BTM	DI	DM87BTM
DM87BTM	DN	GD2-targeted CAR-T cells
DM87BTM	MI	TT80ARU
DM87BTM	MN	Ganglioside GD2 (GD2)
DM87BTM	MT	DTT
DM87BTM	MA	CAR-T-Cell-Therapy
DM87BTM	RN	ClinicalTrials.gov (NCT02919046) Study Evaluating the Efficacy and Safety With CAR-T for Relapsed or Refractory Neuroblastoma in Children
DM87BTM	RU	https://clinicaltrials.gov/ct2/show/NCT02919046

DM7W6YN	DI	DM7W6YN
DM7W6YN	DN	GR148672X
DM7W6YN	MI	TTMF541
DM7W6YN	MN	Liver carboxylesterase (CES1)
DM7W6YN	MT	DTT
DM7W6YN	MA	Inhibitor
DM7W6YN	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2592).
DM7W6YN	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2592

DMCV5ND	DI	DMCV5ND
DMCV5ND	DN	GSK-264220A
DMCV5ND	MI	TTHSZXO
DMCV5ND	MN	Endothelial lipase (LIPG)
DMCV5ND	MT	DTT
DMCV5ND	MA	Inhibitor
DMCV5ND	RN	Discovery of potent, selective sulfonylfuran urea endothelial lipase inhibitors. Bioorg Med Chem Lett. 2009 Jan 1;19(1):27-30.
DMCV5ND	RU	https://pubmed.ncbi.nlm.nih.gov/19058966

DM5I2HL	DI	DM5I2HL
DM5I2HL	DN	GSK269962A
DM5I2HL	MI	TTZN7RP
DM5I2HL	MN	Rho-associated protein kinase 1 (ROCK1)
DM5I2HL	MT	DTT
DM5I2HL	MA	Inhibitor
DM5I2HL	RN	Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther. 2007 Jan;320(1):89-98.
DM5I2HL	RU	https://pubmed.ncbi.nlm.nih.gov/17018693

DM5I2HL	DI	DM5I2HL
DM5I2HL	DN	GSK269962A
DM5I2HL	MI	TTGWKQJ
DM5I2HL	MN	Rho-associated protein kinase 2 (ROCK2)
DM5I2HL	MT	DTT
DM5I2HL	MA	Inhibitor
DM5I2HL	RN	Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther. 2007 Jan;320(1):89-98.
DM5I2HL	RU	https://pubmed.ncbi.nlm.nih.gov/17018693

DM21Y8J	DI	DM21Y8J
DM21Y8J	DN	isatin sulfonamide 34
DM21Y8J	MI	TTM7Y45
DM21Y8J	MN	Caspase-7 (CASP7)
DM21Y8J	MT	DTT
DM21Y8J	MA	Inhibitor
DM21Y8J	RN	Potent and selective nonpeptide inhibitors of caspases 3 and 7. J Med Chem. 2001 Jun 7;44(12):2015-26.
DM21Y8J	RU	https://pubmed.ncbi.nlm.nih.gov/11384246

DM21Y8J	DI	DM21Y8J
DM21Y8J	DN	isatin sulfonamide 34
DM21Y8J	MI	TTB6T7O
DM21Y8J	MN	Caspase-9 (CASP9)
DM21Y8J	MT	DTT
DM21Y8J	MA	Inhibitor
DM21Y8J	RN	Potent and selective nonpeptide inhibitors of caspases 3 and 7. J Med Chem. 2001 Jun 7;44(12):2015-26.
DM21Y8J	RU	https://pubmed.ncbi.nlm.nih.gov/11384246

DMDU6GN	DI	DMDU6GN
DMDU6GN	DN	JNJ-479655
DMDU6GN	MI	TT473XN
DMDU6GN	MN	P2X purinoceptor 7 (P2RX7)
DMDU6GN	MT	DTT
DMDU6GN	MA	Antagonist
DMDU6GN	RN	Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567. Br J Pharmacol. 2013 Oct;170(3):624-40.
DMDU6GN	RU	https://pubmed.ncbi.nlm.nih.gov/23889535

DM2NZ6K	DI	DM2NZ6K
DM2NZ6K	DN	KGP94
DM2NZ6K	MI	TT36ETB
DM2NZ6K	MN	Cathepsin L (CTSL)
DM2NZ6K	MT	DTT
DM2NZ6K	MA	Inhibitor
DM2NZ6K	RN	Functionalized benzophenone, thiophene, pyridine, and fluorene thiosemicarbazone derivatives as inhibitors of cathepsin L. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6610-5.
DM2NZ6K	RU	https://pubmed.ncbi.nlm.nih.gov/20933415

DMR1NYF	DI	DMR1NYF
DMR1NYF	DN	KH064
DMR1NYF	MI	TTO8QRU
DMR1NYF	MN	Group IIA phospholipase A2 (GIIA sPLA2)
DMR1NYF	MT	DTT
DMR1NYF	MA	Inhibitor
DMR1NYF	RN	D-Tyrosine as a chiral precusor to potent inhibitors of human nonpancreatic secretory phospholipase A2 (IIa) with antiinflammatory activity. Chembiochem. 2003 Mar 3;4(2-3):181-5.
DMR1NYF	RU	https://pubmed.ncbi.nlm.nih.gov/12616631

DMWA5XP	DI	DMWA5XP
DMWA5XP	DN	KU-60019
DMWA5XP	MI	TTKBM7V
DMWA5XP	MN	ATM serine/threonine kinase (ATM)
DMWA5XP	MT	DTT
DMWA5XP	MA	Inhibitor
DMWA5XP	RN	Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol Cancer Ther. 2009 Oct;8(10):2894-902.
DMWA5XP	RU	https://pubmed.ncbi.nlm.nih.gov/19808981

DMCMOS8	DI	DMCMOS8
DMCMOS8	DN	L-Cysteine
DMCMOS8	MI	DESYL1F
DMCMOS8	MN	Glutamate-cysteine ligase catalytic (GCLC)
DMCMOS8	MT	DME
DMCMOS8	MA	Metabolism
DMCMOS8	RN	The enzymes of glutathione synthesis: gamma-glutamylcysteine synthetase. Adv Enzymol Relat Areas Mol Biol. 1999;73:209-67, xii.
DMCMOS8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10218110

DMCMOS8	DI	DMCMOS8
DMCMOS8	DN	L-Cysteine
DMCMOS8	MI	DEEBDFT
DMCMOS8	MN	Glutamate-cysteine ligase regulatory (GCLM)
DMCMOS8	MT	DME
DMCMOS8	MA	Metabolism
DMCMOS8	RN	The enzymes of glutathione synthesis: gamma-glutamylcysteine synthetase. Adv Enzymol Relat Areas Mol Biol. 1999;73:209-67, xii.
DMCMOS8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10218110

DMW15TC	DI	DMW15TC
DMW15TC	DN	methyl 5-[(4-tert-butylbenzoyl)amino]-2H-1,2,4-triazole-3-carboxylate
DMW15TC	MI	TTRJSMV
DMW15TC	MN	Factor XII messenger RNA (FA12 mRNA)
DMW15TC	MT	DTT
DMW15TC	MA	Inhibitor
DMW15TC	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2361).
DMW15TC	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2361

DMAPV6J	DI	DMAPV6J
DMAPV6J	DN	MK-0249
DMAPV6J	MI	TT9JNIC
DMAPV6J	MN	Histamine H3 receptor (H3R)
DMAPV6J	MT	DTT
DMAPV6J	MA	Agonist
DMAPV6J	RN	Synthesis, structure-activity relationships, and biological profiles of a quinazolinone class of histamine H3 receptor inverse agonists. J Med Chem. 2008 Aug 14;51(15):4780-9.
DMAPV6J	RU	https://pubmed.ncbi.nlm.nih.gov/18598020

DM3ADQW	DI	DM3ADQW
DM3ADQW	DN	NIA-114
DM3ADQW	MI	TT8WFXV
DM3ADQW	MN	Hydroxycarboxylic acid receptor 3 (HCAR3)
DM3ADQW	MT	DTT
DM3ADQW	MA	Agonist
DM3ADQW	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3ADQW	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DM3ADQW	DI	DM3ADQW
DM3ADQW	DN	NIA-114
DM3ADQW	MI	TTWNV8U
DM3ADQW	MN	Nicotinic acid receptor (HCAR2)
DM3ADQW	MT	DTT
DM3ADQW	MA	Agonist
DM3ADQW	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3ADQW	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMXFI90	DI	DMXFI90
DMXFI90	DN	oxazine 89
DMXFI90	MI	TT8JRS7
DMXFI90	MN	Beta-secretase (BACE)
DMXFI90	MT	DTT
DMXFI90	MA	Inhibitor
DMXFI90	RN	beta-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease. J Med Chem. 2013 May 23;56(10):3980-95.
DMXFI90	RU	https://pubmed.ncbi.nlm.nih.gov/23590342

DMO0892	DI	DMO0892
DMO0892	DN	PF-4708671
DMO0892	MI	TTG0U4H
DMO0892	MN	Ribosomal protein S6 kinase beta-1 (S6K1)
DMO0892	MT	DTT
DMO0892	MA	Inhibitor
DMO0892	RN	Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). Biochem J. 2010 Oct 15;431(2):245-55.
DMO0892	RU	https://pubmed.ncbi.nlm.nih.gov/20704563

DM4XAU7	DI	DM4XAU7
DM4XAU7	DN	PGF2alpha
DM4XAU7	MI	DTCSGPB
DM4XAU7	MN	Multidrug resistance-associated protein 4 (ABCC4)
DM4XAU7	MT	DTP
DM4XAU7	MA	Substrate
DM4XAU7	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM4XAU7	RU	https://doi.org/10.1007/s11095-012-0935-x

DM4XAU7	DI	DM4XAU7
DM4XAU7	DN	PGF2alpha
DM4XAU7	MI	DE9JFMC
DM4XAU7	MN	NADPH-dependent carbonyl reductase 1 (CBR1)
DM4XAU7	MT	DME
DM4XAU7	MA	Metabolism
DM4XAU7	RN	Metabolism of prostaglandins by the nonpregnant human uterus. J Clin Endocrinol Metab. 1983 Apr;56(4):678-85.
DM4XAU7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=6300160

DM4XAU7	DI	DM4XAU7
DM4XAU7	DN	PGF2alpha
DM4XAU7	MI	DTQ23VB
DM4XAU7	MN	Organic anion transporter 1 (SLC22A6)
DM4XAU7	MT	DTP
DM4XAU7	MA	Substrate
DM4XAU7	RN	Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
DM4XAU7	RU	http://www.ncbi.nlm.nih.gov/pubmed/11907186

DM4XAU7	DI	DM4XAU7
DM4XAU7	DN	PGF2alpha
DM4XAU7	MI	DT0OC1Q
DM4XAU7	MN	Organic anion transporter 2 (SLC22A7)
DM4XAU7	MT	DTP
DM4XAU7	MA	Substrate
DM4XAU7	RN	Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors. J Pharmacol Exp Ther. 2002 Jun;301(3):797-802.
DM4XAU7	RU	http://www.ncbi.nlm.nih.gov/pubmed/12023506

DM4XAU7	DI	DM4XAU7
DM4XAU7	DN	PGF2alpha
DM4XAU7	MI	DTVP67E
DM4XAU7	MN	Organic anion transporter 3 (SLC22A8)
DM4XAU7	MT	DTP
DM4XAU7	MA	Substrate
DM4XAU7	RN	Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
DM4XAU7	RU	http://www.ncbi.nlm.nih.gov/pubmed/11907186

DM4XAU7	DI	DM4XAU7
DM4XAU7	DN	PGF2alpha
DM4XAU7	MI	DT06JWZ
DM4XAU7	MN	Organic anion transporter 4 (SLC22A11)
DM4XAU7	MT	DTP
DM4XAU7	MA	Substrate
DM4XAU7	RN	Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
DM4XAU7	RU	http://www.ncbi.nlm.nih.gov/pubmed/11907186

DM4XAU7	DI	DM4XAU7
DM4XAU7	DN	PGF2alpha
DM4XAU7	MI	DT021JD
DM4XAU7	MN	Organic anion transporting polypeptide 2A1 (SLCO2A1)
DM4XAU7	MT	DTP
DM4XAU7	MA	Substrate
DM4XAU7	RN	Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT). J Clin Invest. 1996 Sep 1;98(5):1142-9.
DM4XAU7	RU	http://www.ncbi.nlm.nih.gov/pubmed/8787677

DM4XAU7	DI	DM4XAU7
DM4XAU7	DN	PGF2alpha
DM4XAU7	MI	DTVNRXW
DM4XAU7	MN	Organic anion transporting polypeptide 3A1 (SLCO3A1)
DM4XAU7	MT	DTP
DM4XAU7	MA	Substrate
DM4XAU7	RN	Molecular characterization of human and rat organic anion transporter OATP-D. Am J Physiol Renal Physiol. 2003 Dec;285(6):F1188-97.
DM4XAU7	RU	http://www.ncbi.nlm.nih.gov/pubmed/14631946

DM4XAU7	DI	DM4XAU7
DM4XAU7	DN	PGF2alpha
DM4XAU7	MI	DTT79CX
DM4XAU7	MN	Organic cation transporter 1 (SLC22A1)
DM4XAU7	MT	DTP
DM4XAU7	MA	Substrate
DM4XAU7	RN	Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
DM4XAU7	RU	http://www.ncbi.nlm.nih.gov/pubmed/11907186

DM4XAU7	DI	DM4XAU7
DM4XAU7	DN	PGF2alpha
DM4XAU7	MI	DT9IDPW
DM4XAU7	MN	Organic cation transporter 2 (SLC22A2)
DM4XAU7	MT	DTP
DM4XAU7	MA	Substrate
DM4XAU7	RN	Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
DM4XAU7	RU	http://www.ncbi.nlm.nih.gov/pubmed/11907186

DM4XAU7	DI	DM4XAU7
DM4XAU7	DN	PGF2alpha
DM4XAU7	MI	TTNVEIR
DM4XAU7	MN	Prostaglandin D2 receptor (PTGDR)
DM4XAU7	MT	DTT
DM4XAU7	MA	Agonist
DM4XAU7	RN	The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
DM4XAU7	RU	https://pubmed.ncbi.nlm.nih.gov/10634944

DM4XAU7	DI	DM4XAU7
DM4XAU7	DN	PGF2alpha
DM4XAU7	MI	TTQDMX5
DM4XAU7	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DM4XAU7	MT	DTT
DM4XAU7	MA	Agonist
DM4XAU7	RN	Expression and molecular pharmacology of the mouse CRTH2 receptor. J Pharmacol Exp Ther. 2003 Aug;306(2):463-70.
DM4XAU7	RU	https://pubmed.ncbi.nlm.nih.gov/12721327

DM4XAU7	DI	DM4XAU7
DM4XAU7	DN	PGF2alpha
DM4XAU7	MI	TTG1QMU
DM4XAU7	MN	Prostaglandin E2 receptor EP1 (PTGER1)
DM4XAU7	MT	DTT
DM4XAU7	MA	Agonist
DM4XAU7	RN	Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41.
DM4XAU7	RU	https://pubmed.ncbi.nlm.nih.gov/9537820

DM4XAU7	DI	DM4XAU7
DM4XAU7	DN	PGF2alpha
DM4XAU7	MI	TT1ZAVI
DM4XAU7	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DM4XAU7	MT	DTT
DM4XAU7	MA	Agonist
DM4XAU7	RN	Importance of the extracellular domain for prostaglandin EP(2) receptor function. Mol Pharmacol. 1999 Sep;56(3):545-51.
DM4XAU7	RU	https://pubmed.ncbi.nlm.nih.gov/10462542

DM4XAU7	DI	DM4XAU7
DM4XAU7	DN	PGF2alpha
DM4XAU7	MI	TTPNGDE
DM4XAU7	MN	Prostaglandin E2 receptor EP3 (PTGER3)
DM4XAU7	MT	DTT
DM4XAU7	MA	Agonist
DM4XAU7	RN	Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
DM4XAU7	RU	https://pubmed.ncbi.nlm.nih.gov/9313928

DM4XAU7	DI	DM4XAU7
DM4XAU7	DN	PGF2alpha
DM4XAU7	MI	TT79WV3
DM4XAU7	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DM4XAU7	MT	DTT
DM4XAU7	MA	Agonist
DM4XAU7	RN	Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41.
DM4XAU7	RU	https://pubmed.ncbi.nlm.nih.gov/9537820

DM4XAU7	DI	DM4XAU7
DM4XAU7	DN	PGF2alpha
DM4XAU7	MI	TTT2ZAR
DM4XAU7	MN	Prostaglandin F2-alpha receptor (PTGFR)
DM4XAU7	MT	DTT
DM4XAU7	MA	Agonist
DM4XAU7	RN	Identification by site-directed mutagenesis of amino acids contributing to ligand-binding specificity or signal transduction properties of the human FP prostanoid receptor. Biochem J. 2003 Apr 15;371(Pt 2):443-9.
DM4XAU7	RU	https://pubmed.ncbi.nlm.nih.gov/12519077

DM4XAU7	DI	DM4XAU7
DM4XAU7	DN	PGF2alpha
DM4XAU7	MI	TT2O84V
DM4XAU7	MN	Thromboxane A2 receptor (TBXA2R)
DM4XAU7	MT	DTT
DM4XAU7	MA	Agonist
DM4XAU7	RN	The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
DM4XAU7	RU	https://pubmed.ncbi.nlm.nih.gov/10634944

DMXE0F2	DI	DMXE0F2
DMXE0F2	DN	PMID10498202C1
DMXE0F2	MI	TTPT2QI
DMXE0F2	MN	Cathepsin D (CTSD)
DMXE0F2	MT	DTT
DMXE0F2	MA	Inhibitor
DMXE0F2	RN	Synthesis and structure activity relationships of novel small molecule cathepsin D inhibitors. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2531-6.
DMXE0F2	RU	https://pubmed.ncbi.nlm.nih.gov/10498202

DMJGFLD	DI	DMJGFLD
DMJGFLD	DN	PMID15026062C41
DMJGFLD	MI	TTLUQ8E
DMJGFLD	MN	Hormone sensitive lipase (LIPE)
DMJGFLD	MT	DTT
DMJGFLD	MA	Inhibitor
DMJGFLD	RN	Carbazates as potent inhibitors of hormone-sensitive lipase. Bioorg Med Chem Lett. 2004 Apr 5;14(7):1741-4.
DMJGFLD	RU	https://pubmed.ncbi.nlm.nih.gov/15026062

DMO1IHL	DI	DMO1IHL
DMO1IHL	DN	PMID17935984C1
DMO1IHL	MI	TTHY57M
DMO1IHL	MN	Matrix metalloproteinase-13 (MMP-13)
DMO1IHL	MT	DTT
DMO1IHL	MA	Inhibitor
DMO1IHL	RN	Potent, selective spiropyrrolidine pyrimidinetrione inhibitors of MMP-13. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6529-34.
DMO1IHL	RU	https://pubmed.ncbi.nlm.nih.gov/17935984

DMHPME3	DI	DMHPME3
DMHPME3	DN	PMID18163548C4
DMHPME3	MI	TTGY7WI
DMHPME3	MN	Urokinase-type plasminogen activator (PLAU)
DMHPME3	MT	DTT
DMHPME3	MA	Inhibitor
DMHPME3	RN	Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator. J Med Chem. 2008 Jan 24;51(2):183-6.
DMHPME3	RU	https://pubmed.ncbi.nlm.nih.gov/18163548

DM5UWH3	DI	DM5UWH3
DM5UWH3	DN	PMID22911925C2
DM5UWH3	MI	TT8JRS7
DM5UWH3	MN	Beta-secretase (BACE)
DM5UWH3	MT	DTT
DM5UWH3	MA	Inhibitor
DM5UWH3	RN	Establishing the relationship between in vitro potency, pharmacokinetic, and pharmacodynamic parameters in a series of orally available, hydroxyethylamine-derived beta-secretase inhibitors. J Pharmacol Exp Ther. 2012 Nov;343(2):460-7.
DM5UWH3	RU	https://pubmed.ncbi.nlm.nih.gov/22911925

DMX1IZ9	DI	DMX1IZ9
DMX1IZ9	DN	PMID23981898C11d 
DMX1IZ9	MI	TT8JRS7
DMX1IZ9	MN	Beta-secretase (BACE)
DMX1IZ9	MT	DTT
DMX1IZ9	MA	Inhibitor
DMX1IZ9	RN	Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective beta-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid beta-peptides. Bioorg Med Chem Lett. 2013 Oct 1;23(19):5300-6.
DMX1IZ9	RU	https://pubmed.ncbi.nlm.nih.gov/23981898

DMCM5GK	DI	DMCM5GK
DMCM5GK	DN	TAK-070
DMCM5GK	MI	TT8JRS7
DMCM5GK	MN	Beta-secretase (BACE)
DMCM5GK	MT	DTT
DMCM5GK	MA	Inhibitor
DMCM5GK	RN	A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease. J Neurosci. 2010 Aug 18;30(33):11157-66.
DMCM5GK	RU	https://pubmed.ncbi.nlm.nih.gov/20720123

DMGANIC	DI	DMGANIC
DMGANIC	DN	tamatinib
DMGANIC	MI	TT4DXQT
DMGANIC	MN	Proto-oncogene c-Ret (RET)
DMGANIC	MT	DTT
DMGANIC	MA	Inhibitor
DMGANIC	RN	Developmental toxicity associated with receptor tyrosine kinase Ret inhibition in reproductive toxicity testing. Birth Defects Res A Clin Mol Teratol. 2009 Feb;85(2):130-6.
DMGANIC	RU	https://pubmed.ncbi.nlm.nih.gov/19107952

DMGANIC	DI	DMGANIC
DMGANIC	DN	tamatinib
DMGANIC	MI	TTOU65C
DMGANIC	MN	Tyrosine-protein kinase SYK (SYK)
DMGANIC	MT	DTT
DMGANIC	MA	Inhibitor
DMGANIC	RN	Pharmacophore modeling study based on known spleen tyrosine kinase inhibitors together with virtual screening for identifying novel inhibitors. Bioorg Med Chem Lett. 2009 Apr 1;19(7):1944-9.
DMGANIC	RU	https://pubmed.ncbi.nlm.nih.gov/19254842

DMZO6CV	DI	DMZO6CV
DMZO6CV	DN	tiratricol
DMZO6CV	MI	TTTSEPU
DMZO6CV	MN	Thyroid hormone receptor alpha (THRA)
DMZO6CV	MT	DTT
DMZO6CV	MA	Agonist
DMZO6CV	RN	Binding of 3,5,3'-triiodothyronine (T3) and its analogs to the in vitro translational products of c-erbA protooncogenes: differences in the affinity of the alpha- and beta-forms for the acetic acid analog and failure of the human testis and kidney alpha-2 products to bind T3. Mol Endocrinol. 1990 Feb;4(2):227-34.
DMZO6CV	RU	https://pubmed.ncbi.nlm.nih.gov/2158622

DMZO6CV	DI	DMZO6CV
DMZO6CV	DN	tiratricol
DMZO6CV	MI	TTGER3L
DMZO6CV	MN	Thyroid hormone receptor beta (THRB)
DMZO6CV	MT	DTT
DMZO6CV	MA	Agonist
DMZO6CV	RN	Binding of 3,5,3'-triiodothyronine (T3) and its analogs to the in vitro translational products of c-erbA protooncogenes: differences in the affinity of the alpha- and beta-forms for the acetic acid analog and failure of the human testis and kidney alpha-2 products to bind T3. Mol Endocrinol. 1990 Feb;4(2):227-34.
DMZO6CV	RU	https://pubmed.ncbi.nlm.nih.gov/2158622

DMSRK2A	DI	DMSRK2A
DMSRK2A	DN	UK-356202
DMSRK2A	MI	TTGY7WI
DMSRK2A	MN	Urokinase-type plasminogen activator (PLAU)
DMSRK2A	MT	DTT
DMSRK2A	MA	Inhibitor
DMSRK2A	RN	Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-isoquinolinylguanidines. Bioorg Med Chem Lett. 2004 Jun 21;14(12):3227-30.
DMSRK2A	RU	https://pubmed.ncbi.nlm.nih.gov/15149680

DMOI0TN	DI	DMOI0TN
DMOI0TN	DN	VU0364739
DMOI0TN	MI	TTRLMKF
DMOI0TN	MN	Phospholipase D2 (PLD2)
DMOI0TN	MT	DTT
DMOI0TN	MA	Inhibitor
DMOI0TN	RN	Design, synthesis, and biological evaluation of halogenated N-(2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)benzamides: discovery of an isoform-selective small molecule phospholipase D2 inhibitor. J Med Chem. 2010 Sep 23;53(18):6706-19.
DMOI0TN	RU	https://pubmed.ncbi.nlm.nih.gov/20735042

DMMLQAS	DI	DMMLQAS
DMMLQAS	DN	(-)-deprenyl
DMMLQAS	MI	TT32XQJ
DMMLQAS	MN	Monoamine oxidase (MAO)
DMMLQAS	MT	DTT
DMMLQAS	MA	Inhibitor
DMMLQAS	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMMLQAS	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMGYZQ2	DI	DMGYZQ2
DMGYZQ2	DN	1-(biphenyl-4-yl-methyl)-1H-imidazole derivative 1
DMGYZQ2	MI	TTQVOEI
DMGYZQ2	MN	Angiotensin II receptor type-2 (AGTR2)
DMGYZQ2	MT	DTT
DMGYZQ2	MA	Agonist
DMGYZQ2	RN	PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
DMGYZQ2	RU	https://www.ncbi.nlm.nih.gov/pubmed/25416646

DMGYZQ2	DI	DMGYZQ2
DMGYZQ2	DN	1-(biphenyl-4-yl-methyl)-1H-imidazole derivative 1
DMGYZQ2	MI	TTZMAO3
DMGYZQ2	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMGYZQ2	MT	DTT
DMGYZQ2	MA	Agonist
DMGYZQ2	RN	PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
DMGYZQ2	RU	https://www.ncbi.nlm.nih.gov/pubmed/25416646

DMW5DC1	DI	DMW5DC1
DMW5DC1	DN	1,2,3,4-tetrahydroisoquinoline derivative 1
DMW5DC1	MI	TTGIZLN
DMW5DC1	MN	Keap1-Nrf2[dual DLG and ETGE] PPI (KEAP1-Nrf2 DLG and ETGE)
DMW5DC1	MT	DTT
DMW5DC1	MA	Modulator
DMW5DC1	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMW5DC1	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMW5DC1	DI	DMW5DC1
DMW5DC1	DN	1,2,3,4-tetrahydroisoquinoline derivative 1
DMW5DC1	MI	TTA6ZN2
DMW5DC1	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMW5DC1	MT	DTT
DMW5DC1	MA	Inhibitor
DMW5DC1	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMW5DC1	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMKHF39	DI	DMKHF39
DMKHF39	DN	1,2,3-triazole derivative 1
DMKHF39	MI	TT6OEDT
DMKHF39	MN	Cannabinoid receptor 1 (CB1)
DMKHF39	MT	DTT
DMKHF39	MA	Antagonist
DMKHF39	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMKHF39	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMFR23C	DI	DMFR23C
DMFR23C	DN	1,2,3-triazole derivative 2
DMFR23C	MI	TT6OEDT
DMFR23C	MN	Cannabinoid receptor 1 (CB1)
DMFR23C	MT	DTT
DMFR23C	MA	Antagonist
DMFR23C	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMFR23C	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMLAYG7	DI	DMLAYG7
DMLAYG7	DN	1,2,4,5-tetra-substituted imidazole derivative 1
DMLAYG7	MI	TT6OEDT
DMLAYG7	MN	Cannabinoid receptor 1 (CB1)
DMLAYG7	MT	DTT
DMLAYG7	MA	Antagonist
DMLAYG7	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMLAYG7	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMMCYI5	DI	DMMCYI5
DMMCYI5	DN	1,2,4,5-tetra-substituted imidazole derivative 2
DMMCYI5	MI	TT6OEDT
DMMCYI5	MN	Cannabinoid receptor 1 (CB1)
DMMCYI5	MT	DTT
DMMCYI5	MA	Antagonist
DMMCYI5	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMMCYI5	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMESOA8	DI	DMESOA8
DMESOA8	DN	1,2,4-oxadiazole derivative 1
DMESOA8	MI	TTNBFWK
DMESOA8	MN	Programmed cell death protein 1 (PD-1)
DMESOA8	MT	DTT
DMESOA8	MA	Inhibitor
DMESOA8	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMESOA8	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMA42SB	DI	DMA42SB
DMA42SB	DN	1,2,4-oxadiazole derivative 2
DMA42SB	MI	TTNBFWK
DMA42SB	MN	Programmed cell death protein 1 (PD-1)
DMA42SB	MT	DTT
DMA42SB	MA	Inhibitor
DMA42SB	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMA42SB	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMT6EDP	DI	DMT6EDP
DMT6EDP	DN	1,2,4-oxadiazole derivative 4
DMT6EDP	MI	TT23XQV
DMT6EDP	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMT6EDP	MT	DTT
DMT6EDP	MA	Inhibitor
DMT6EDP	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMT6EDP	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DM683R7	DI	DM683R7
DM683R7	DN	1,2,4-oxadiazole derivative 5
DM683R7	MI	TT23XQV
DM683R7	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DM683R7	MT	DTT
DM683R7	MA	Inhibitor
DM683R7	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DM683R7	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMFYKBJ	DI	DMFYKBJ
DMFYKBJ	DN	1,2,4-oxadiazole derivative 6
DMFYKBJ	MI	TT23XQV
DMFYKBJ	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMFYKBJ	MT	DTT
DMFYKBJ	MA	Inhibitor
DMFYKBJ	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMFYKBJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMBT4RJ	DI	DMBT4RJ
DMBT4RJ	DN	1,2,4-oxadiazole derivative 7
DMBT4RJ	MI	TT23XQV
DMBT4RJ	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMBT4RJ	MT	DTT
DMBT4RJ	MA	Inhibitor
DMBT4RJ	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMBT4RJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMQF62D	DI	DMQF62D
DMQF62D	DN	1,2,4-triazole [1,5-a]pyrimidin-7-yl derivative 1
DMQF62D	MI	TTJGW1Z
DMQF62D	MN	Phosphodiesterase 2A (PDE2A)
DMQF62D	MT	DTT
DMQF62D	MA	Inhibitor
DMQF62D	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMQF62D	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DM8KWQ9	DI	DM8KWQ9
DM8KWQ9	DN	1,2,4-triazole [1,5-a]pyrimidin-7-yl derivative 2
DM8KWQ9	MI	TTJGW1Z
DM8KWQ9	MN	Phosphodiesterase 2A (PDE2A)
DM8KWQ9	MT	DTT
DM8KWQ9	MA	Inhibitor
DM8KWQ9	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DM8KWQ9	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMR1QP4	DI	DMR1QP4
DMR1QP4	DN	1,2,4-triazole [1,5-a]pyrimidin-7-yl derivative 3
DMR1QP4	MI	TTJGW1Z
DMR1QP4	MN	Phosphodiesterase 2A (PDE2A)
DMR1QP4	MT	DTT
DMR1QP4	MA	Inhibitor
DMR1QP4	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMR1QP4	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMD9QW2	DI	DMD9QW2
DMD9QW2	DN	1,2,4-triazole [4,3-a]quinoxaline derivative 1
DMD9QW2	MI	TTJW4LU
DMD9QW2	MN	Phosphodiesterase 10A (PDE10)
DMD9QW2	MT	DTT
DMD9QW2	MA	Inhibitor
DMD9QW2	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMD9QW2	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMD9QW2	DI	DMD9QW2
DMD9QW2	DN	1,2,4-triazole [4,3-a]quinoxaline derivative 1
DMD9QW2	MI	TTJGW1Z
DMD9QW2	MN	Phosphodiesterase 2A (PDE2A)
DMD9QW2	MT	DTT
DMD9QW2	MA	Inhibitor
DMD9QW2	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMD9QW2	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DM3DIW9	DI	DM3DIW9
DM3DIW9	DN	1,2,4-triazole [4,3-a]quinoxaline derivative 2
DM3DIW9	MI	TTJW4LU
DM3DIW9	MN	Phosphodiesterase 10A (PDE10)
DM3DIW9	MT	DTT
DM3DIW9	MA	Inhibitor
DM3DIW9	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DM3DIW9	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DM3DIW9	DI	DM3DIW9
DM3DIW9	DN	1,2,4-triazole [4,3-a]quinoxaline derivative 2
DM3DIW9	MI	TTJGW1Z
DM3DIW9	MN	Phosphodiesterase 2A (PDE2A)
DM3DIW9	MT	DTT
DM3DIW9	MA	Inhibitor
DM3DIW9	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DM3DIW9	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMKXRYM	DI	DMKXRYM
DMKXRYM	DN	1,2,4-triazole [4,3-a]quinoxaline derivative 3
DMKXRYM	MI	TTJW4LU
DMKXRYM	MN	Phosphodiesterase 10A (PDE10)
DMKXRYM	MT	DTT
DMKXRYM	MA	Inhibitor
DMKXRYM	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMKXRYM	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMKXRYM	DI	DMKXRYM
DMKXRYM	DN	1,2,4-triazole [4,3-a]quinoxaline derivative 3
DMKXRYM	MI	TTJGW1Z
DMKXRYM	MN	Phosphodiesterase 2A (PDE2A)
DMKXRYM	MT	DTT
DMKXRYM	MA	Inhibitor
DMKXRYM	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMKXRYM	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DME8MN1	DI	DME8MN1
DME8MN1	DN	1,2,4-triazole derivative 1
DME8MN1	MI	TT6OEDT
DME8MN1	MN	Cannabinoid receptor 1 (CB1)
DME8MN1	MT	DTT
DME8MN1	MA	Antagonist
DME8MN1	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DME8MN1	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DM91Z8B	DI	DM91Z8B
DM91Z8B	DN	1,2,4-triazole derivative 2
DM91Z8B	MI	TT6OEDT
DM91Z8B	MN	Cannabinoid receptor 1 (CB1)
DM91Z8B	MT	DTT
DM91Z8B	MA	Antagonist
DM91Z8B	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DM91Z8B	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMU9XMV	DI	DMU9XMV
DMU9XMV	DN	1,2,4-triazole derivative 3
DMU9XMV	MI	TT5TPI6
DMU9XMV	MN	Opioid receptor sigma 1 (OPRS1)
DMU9XMV	MT	DTT
DMU9XMV	MA	Inhibitor
DMU9XMV	RN	Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578.
DMU9XMV	RU	https://www.ncbi.nlm.nih.gov/pubmed/28051882

DMHBJFN	DI	DMHBJFN
DMHBJFN	DN	1,2,4-triazole derivative 4
DMHBJFN	MI	TT5TPI6
DMHBJFN	MN	Opioid receptor sigma 1 (OPRS1)
DMHBJFN	MT	DTT
DMHBJFN	MA	Inhibitor
DMHBJFN	RN	Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578.
DMHBJFN	RU	https://www.ncbi.nlm.nih.gov/pubmed/28051882

DMIUPSA	DI	DMIUPSA
DMIUPSA	DN	1,2,4-triazolo[1,5a]pyridine derivative 1
DMIUPSA	MI	TTON5IT
DMIUPSA	MN	Focal adhesion kinase 1 (FAK)
DMIUPSA	MT	DTT
DMIUPSA	MA	Inhibitor
DMIUPSA	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMIUPSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMIUPSA	DI	DMIUPSA
DMIUPSA	DN	1,2,4-triazolo[1,5a]pyridine derivative 1
DMIUPSA	MI	TTRMX3V
DMIUPSA	MN	Janus kinase 2 (JAK-2)
DMIUPSA	MT	DTT
DMIUPSA	MA	Inhibitor
DMIUPSA	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMIUPSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMIUPSA	DI	DMIUPSA
DMIUPSA	DN	1,2,4-triazolo[1,5a]pyridine derivative 1
DMIUPSA	MI	TTT7PJU
DMIUPSA	MN	Janus kinase 3 (JAK-3)
DMIUPSA	MT	DTT
DMIUPSA	MA	Inhibitor
DMIUPSA	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMIUPSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMZFILT	DI	DMZFILT
DMZFILT	DN	1,2,4-triazolo[1,5a]pyridine derivative 2
DMZFILT	MI	TTPMQSO
DMZFILT	MN	ALK tyrosine kinase receptor (ALK)
DMZFILT	MT	DTT
DMZFILT	MA	Inhibitor
DMZFILT	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMZFILT	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMZFILT	DI	DMZFILT
DMZFILT	DN	1,2,4-triazolo[1,5a]pyridine derivative 2
DMZFILT	MI	TTRMX3V
DMZFILT	MN	Janus kinase 2 (JAK-2)
DMZFILT	MT	DTT
DMZFILT	MA	Inhibitor
DMZFILT	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMZFILT	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMMNVZ5	DI	DMMNVZ5
DMMNVZ5	DN	1,2,4-tri-substituted imidazoline derivative 1
DMMNVZ5	MI	TT6OEDT
DMMNVZ5	MN	Cannabinoid receptor 1 (CB1)
DMMNVZ5	MT	DTT
DMMNVZ5	MA	Antagonist
DMMNVZ5	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMMNVZ5	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMNH8GW	DI	DMNH8GW
DMNH8GW	DN	1,2-diamino cyclopentane-based derivative 1
DMNH8GW	MI	TT60Q8D
DMNH8GW	MN	Orexin receptor type 1 (HCRTR1)
DMNH8GW	MT	DTT
DMNH8GW	MA	Antagonist
DMNH8GW	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMNH8GW	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMNH8GW	DI	DMNH8GW
DMNH8GW	DN	1,2-diamino cyclopentane-based derivative 1
DMNH8GW	MI	TT9N02I
DMNH8GW	MN	Orexin receptor type 2 (HCRTR2)
DMNH8GW	MT	DTT
DMNH8GW	MA	Antagonist
DMNH8GW	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMNH8GW	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DM3ZF95	DI	DM3ZF95
DM3ZF95	DN	1,2-diamino cyclopentane-based derivative 10
DM3ZF95	MI	TT60Q8D
DM3ZF95	MN	Orexin receptor type 1 (HCRTR1)
DM3ZF95	MT	DTT
DM3ZF95	MA	Antagonist
DM3ZF95	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DM3ZF95	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DM3ZF95	DI	DM3ZF95
DM3ZF95	DN	1,2-diamino cyclopentane-based derivative 10
DM3ZF95	MI	TT9N02I
DM3ZF95	MN	Orexin receptor type 2 (HCRTR2)
DM3ZF95	MT	DTT
DM3ZF95	MA	Antagonist
DM3ZF95	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DM3ZF95	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMPZECW	DI	DMPZECW
DMPZECW	DN	1,2-diamino cyclopentane-based derivative 11
DMPZECW	MI	TT60Q8D
DMPZECW	MN	Orexin receptor type 1 (HCRTR1)
DMPZECW	MT	DTT
DMPZECW	MA	Antagonist
DMPZECW	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMPZECW	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMPZECW	DI	DMPZECW
DMPZECW	DN	1,2-diamino cyclopentane-based derivative 11
DMPZECW	MI	TT9N02I
DMPZECW	MN	Orexin receptor type 2 (HCRTR2)
DMPZECW	MT	DTT
DMPZECW	MA	Antagonist
DMPZECW	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMPZECW	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMWV53X	DI	DMWV53X
DMWV53X	DN	1,2-diamino cyclopentane-based derivative 12
DMWV53X	MI	TT60Q8D
DMWV53X	MN	Orexin receptor type 1 (HCRTR1)
DMWV53X	MT	DTT
DMWV53X	MA	Antagonist
DMWV53X	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMWV53X	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMWV53X	DI	DMWV53X
DMWV53X	DN	1,2-diamino cyclopentane-based derivative 12
DMWV53X	MI	TT9N02I
DMWV53X	MN	Orexin receptor type 2 (HCRTR2)
DMWV53X	MT	DTT
DMWV53X	MA	Antagonist
DMWV53X	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMWV53X	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DM10UX4	DI	DM10UX4
DM10UX4	DN	1,2-diamino cyclopentane-based derivative 13
DM10UX4	MI	TT60Q8D
DM10UX4	MN	Orexin receptor type 1 (HCRTR1)
DM10UX4	MT	DTT
DM10UX4	MA	Antagonist
DM10UX4	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DM10UX4	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DM10UX4	DI	DM10UX4
DM10UX4	DN	1,2-diamino cyclopentane-based derivative 13
DM10UX4	MI	TT9N02I
DM10UX4	MN	Orexin receptor type 2 (HCRTR2)
DM10UX4	MT	DTT
DM10UX4	MA	Antagonist
DM10UX4	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DM10UX4	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMTZDUV	DI	DMTZDUV
DMTZDUV	DN	1,2-diamino cyclopentane-based derivative 14
DMTZDUV	MI	TT60Q8D
DMTZDUV	MN	Orexin receptor type 1 (HCRTR1)
DMTZDUV	MT	DTT
DMTZDUV	MA	Antagonist
DMTZDUV	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMTZDUV	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMTZDUV	DI	DMTZDUV
DMTZDUV	DN	1,2-diamino cyclopentane-based derivative 14
DMTZDUV	MI	TT9N02I
DMTZDUV	MN	Orexin receptor type 2 (HCRTR2)
DMTZDUV	MT	DTT
DMTZDUV	MA	Antagonist
DMTZDUV	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMTZDUV	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMBY65W	DI	DMBY65W
DMBY65W	DN	1,2-diamino cyclopentane-based derivative 15
DMBY65W	MI	TT60Q8D
DMBY65W	MN	Orexin receptor type 1 (HCRTR1)
DMBY65W	MT	DTT
DMBY65W	MA	Antagonist
DMBY65W	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMBY65W	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMBY65W	DI	DMBY65W
DMBY65W	DN	1,2-diamino cyclopentane-based derivative 15
DMBY65W	MI	TT9N02I
DMBY65W	MN	Orexin receptor type 2 (HCRTR2)
DMBY65W	MT	DTT
DMBY65W	MA	Antagonist
DMBY65W	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMBY65W	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMHEX1Q	DI	DMHEX1Q
DMHEX1Q	DN	1,2-diamino cyclopentane-based derivative 16
DMHEX1Q	MI	TT60Q8D
DMHEX1Q	MN	Orexin receptor type 1 (HCRTR1)
DMHEX1Q	MT	DTT
DMHEX1Q	MA	Antagonist
DMHEX1Q	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMHEX1Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMHEX1Q	DI	DMHEX1Q
DMHEX1Q	DN	1,2-diamino cyclopentane-based derivative 16
DMHEX1Q	MI	TT9N02I
DMHEX1Q	MN	Orexin receptor type 2 (HCRTR2)
DMHEX1Q	MT	DTT
DMHEX1Q	MA	Antagonist
DMHEX1Q	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMHEX1Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMBC9UK	DI	DMBC9UK
DMBC9UK	DN	1,2-diamino cyclopentane-based derivative 17
DMBC9UK	MI	TT60Q8D
DMBC9UK	MN	Orexin receptor type 1 (HCRTR1)
DMBC9UK	MT	DTT
DMBC9UK	MA	Antagonist
DMBC9UK	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMBC9UK	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMBC9UK	DI	DMBC9UK
DMBC9UK	DN	1,2-diamino cyclopentane-based derivative 17
DMBC9UK	MI	TT9N02I
DMBC9UK	MN	Orexin receptor type 2 (HCRTR2)
DMBC9UK	MT	DTT
DMBC9UK	MA	Antagonist
DMBC9UK	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMBC9UK	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMCNQAF	DI	DMCNQAF
DMCNQAF	DN	1,2-diamino cyclopentane-based derivative 18
DMCNQAF	MI	TT60Q8D
DMCNQAF	MN	Orexin receptor type 1 (HCRTR1)
DMCNQAF	MT	DTT
DMCNQAF	MA	Antagonist
DMCNQAF	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMCNQAF	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMCNQAF	DI	DMCNQAF
DMCNQAF	DN	1,2-diamino cyclopentane-based derivative 18
DMCNQAF	MI	TT9N02I
DMCNQAF	MN	Orexin receptor type 2 (HCRTR2)
DMCNQAF	MT	DTT
DMCNQAF	MA	Antagonist
DMCNQAF	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMCNQAF	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMCBPI4	DI	DMCBPI4
DMCBPI4	DN	1,2-diamino cyclopentane-based derivative 19
DMCBPI4	MI	TT60Q8D
DMCBPI4	MN	Orexin receptor type 1 (HCRTR1)
DMCBPI4	MT	DTT
DMCBPI4	MA	Antagonist
DMCBPI4	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMCBPI4	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMCBPI4	DI	DMCBPI4
DMCBPI4	DN	1,2-diamino cyclopentane-based derivative 19
DMCBPI4	MI	TT9N02I
DMCBPI4	MN	Orexin receptor type 2 (HCRTR2)
DMCBPI4	MT	DTT
DMCBPI4	MA	Antagonist
DMCBPI4	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMCBPI4	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DM7RG5I	DI	DM7RG5I
DM7RG5I	DN	1,2-diamino cyclopentane-based derivative 2
DM7RG5I	MI	TT60Q8D
DM7RG5I	MN	Orexin receptor type 1 (HCRTR1)
DM7RG5I	MT	DTT
DM7RG5I	MA	Antagonist
DM7RG5I	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DM7RG5I	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DM7RG5I	DI	DM7RG5I
DM7RG5I	DN	1,2-diamino cyclopentane-based derivative 2
DM7RG5I	MI	TT9N02I
DM7RG5I	MN	Orexin receptor type 2 (HCRTR2)
DM7RG5I	MT	DTT
DM7RG5I	MA	Antagonist
DM7RG5I	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DM7RG5I	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DM9PHIK	DI	DM9PHIK
DM9PHIK	DN	1,2-diamino cyclopentane-based derivative 20
DM9PHIK	MI	TT60Q8D
DM9PHIK	MN	Orexin receptor type 1 (HCRTR1)
DM9PHIK	MT	DTT
DM9PHIK	MA	Antagonist
DM9PHIK	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DM9PHIK	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DM9PHIK	DI	DM9PHIK
DM9PHIK	DN	1,2-diamino cyclopentane-based derivative 20
DM9PHIK	MI	TT9N02I
DM9PHIK	MN	Orexin receptor type 2 (HCRTR2)
DM9PHIK	MT	DTT
DM9PHIK	MA	Antagonist
DM9PHIK	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DM9PHIK	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DM5Y1DC	DI	DM5Y1DC
DM5Y1DC	DN	1,2-diamino cyclopentane-based derivative 21
DM5Y1DC	MI	TT60Q8D
DM5Y1DC	MN	Orexin receptor type 1 (HCRTR1)
DM5Y1DC	MT	DTT
DM5Y1DC	MA	Antagonist
DM5Y1DC	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DM5Y1DC	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DM5Y1DC	DI	DM5Y1DC
DM5Y1DC	DN	1,2-diamino cyclopentane-based derivative 21
DM5Y1DC	MI	TT9N02I
DM5Y1DC	MN	Orexin receptor type 2 (HCRTR2)
DM5Y1DC	MT	DTT
DM5Y1DC	MA	Antagonist
DM5Y1DC	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DM5Y1DC	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMXRLI6	DI	DMXRLI6
DMXRLI6	DN	1,2-diamino cyclopentane-based derivative 22
DMXRLI6	MI	TT60Q8D
DMXRLI6	MN	Orexin receptor type 1 (HCRTR1)
DMXRLI6	MT	DTT
DMXRLI6	MA	Antagonist
DMXRLI6	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMXRLI6	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMXRLI6	DI	DMXRLI6
DMXRLI6	DN	1,2-diamino cyclopentane-based derivative 22
DMXRLI6	MI	TT9N02I
DMXRLI6	MN	Orexin receptor type 2 (HCRTR2)
DMXRLI6	MT	DTT
DMXRLI6	MA	Antagonist
DMXRLI6	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMXRLI6	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DM0HIQU	DI	DM0HIQU
DM0HIQU	DN	1,2-diamino cyclopentane-based derivative 23
DM0HIQU	MI	TT60Q8D
DM0HIQU	MN	Orexin receptor type 1 (HCRTR1)
DM0HIQU	MT	DTT
DM0HIQU	MA	Antagonist
DM0HIQU	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DM0HIQU	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DM0HIQU	DI	DM0HIQU
DM0HIQU	DN	1,2-diamino cyclopentane-based derivative 23
DM0HIQU	MI	TT9N02I
DM0HIQU	MN	Orexin receptor type 2 (HCRTR2)
DM0HIQU	MT	DTT
DM0HIQU	MA	Antagonist
DM0HIQU	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DM0HIQU	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMC26MT	DI	DMC26MT
DMC26MT	DN	1,2-diamino cyclopentane-based derivative 24
DMC26MT	MI	TT60Q8D
DMC26MT	MN	Orexin receptor type 1 (HCRTR1)
DMC26MT	MT	DTT
DMC26MT	MA	Antagonist
DMC26MT	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMC26MT	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMC26MT	DI	DMC26MT
DMC26MT	DN	1,2-diamino cyclopentane-based derivative 24
DMC26MT	MI	TT9N02I
DMC26MT	MN	Orexin receptor type 2 (HCRTR2)
DMC26MT	MT	DTT
DMC26MT	MA	Antagonist
DMC26MT	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMC26MT	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMEW0AT	DI	DMEW0AT
DMEW0AT	DN	1,2-diamino cyclopentane-based derivative 25
DMEW0AT	MI	TT60Q8D
DMEW0AT	MN	Orexin receptor type 1 (HCRTR1)
DMEW0AT	MT	DTT
DMEW0AT	MA	Antagonist
DMEW0AT	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMEW0AT	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMEW0AT	DI	DMEW0AT
DMEW0AT	DN	1,2-diamino cyclopentane-based derivative 25
DMEW0AT	MI	TT9N02I
DMEW0AT	MN	Orexin receptor type 2 (HCRTR2)
DMEW0AT	MT	DTT
DMEW0AT	MA	Antagonist
DMEW0AT	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMEW0AT	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMTFG4J	DI	DMTFG4J
DMTFG4J	DN	1,2-diamino cyclopentane-based derivative 26
DMTFG4J	MI	TT60Q8D
DMTFG4J	MN	Orexin receptor type 1 (HCRTR1)
DMTFG4J	MT	DTT
DMTFG4J	MA	Antagonist
DMTFG4J	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMTFG4J	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMTFG4J	DI	DMTFG4J
DMTFG4J	DN	1,2-diamino cyclopentane-based derivative 26
DMTFG4J	MI	TT9N02I
DMTFG4J	MN	Orexin receptor type 2 (HCRTR2)
DMTFG4J	MT	DTT
DMTFG4J	MA	Antagonist
DMTFG4J	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMTFG4J	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DM5LQJW	DI	DM5LQJW
DM5LQJW	DN	1,2-diamino cyclopentane-based derivative 27
DM5LQJW	MI	TT60Q8D
DM5LQJW	MN	Orexin receptor type 1 (HCRTR1)
DM5LQJW	MT	DTT
DM5LQJW	MA	Antagonist
DM5LQJW	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DM5LQJW	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DM5LQJW	DI	DM5LQJW
DM5LQJW	DN	1,2-diamino cyclopentane-based derivative 27
DM5LQJW	MI	TT9N02I
DM5LQJW	MN	Orexin receptor type 2 (HCRTR2)
DM5LQJW	MT	DTT
DM5LQJW	MA	Antagonist
DM5LQJW	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DM5LQJW	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMUTF17	DI	DMUTF17
DMUTF17	DN	1,2-diamino cyclopentane-based derivative 28
DMUTF17	MI	TT9BPT3
DMUTF17	MN	Orexin receptor (HCRTR)
DMUTF17	MT	DTT
DMUTF17	MA	Antagonist
DMUTF17	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMUTF17	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DM5FVH0	DI	DM5FVH0
DM5FVH0	DN	1,2-diamino cyclopentane-based derivative 29
DM5FVH0	MI	TT60Q8D
DM5FVH0	MN	Orexin receptor type 1 (HCRTR1)
DM5FVH0	MT	DTT
DM5FVH0	MA	Antagonist
DM5FVH0	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DM5FVH0	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DM5FVH0	DI	DM5FVH0
DM5FVH0	DN	1,2-diamino cyclopentane-based derivative 29
DM5FVH0	MI	TT9N02I
DM5FVH0	MN	Orexin receptor type 2 (HCRTR2)
DM5FVH0	MT	DTT
DM5FVH0	MA	Antagonist
DM5FVH0	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DM5FVH0	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DM143OK	DI	DM143OK
DM143OK	DN	1,2-diamino cyclopentane-based derivative 3
DM143OK	MI	TT60Q8D
DM143OK	MN	Orexin receptor type 1 (HCRTR1)
DM143OK	MT	DTT
DM143OK	MA	Antagonist
DM143OK	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DM143OK	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DM143OK	DI	DM143OK
DM143OK	DN	1,2-diamino cyclopentane-based derivative 3
DM143OK	MI	TT9N02I
DM143OK	MN	Orexin receptor type 2 (HCRTR2)
DM143OK	MT	DTT
DM143OK	MA	Antagonist
DM143OK	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DM143OK	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMZ4NJQ	DI	DMZ4NJQ
DMZ4NJQ	DN	1,2-diamino cyclopentane-based derivative 30
DMZ4NJQ	MI	TT60Q8D
DMZ4NJQ	MN	Orexin receptor type 1 (HCRTR1)
DMZ4NJQ	MT	DTT
DMZ4NJQ	MA	Antagonist
DMZ4NJQ	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMZ4NJQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMZ4NJQ	DI	DMZ4NJQ
DMZ4NJQ	DN	1,2-diamino cyclopentane-based derivative 30
DMZ4NJQ	MI	TT9N02I
DMZ4NJQ	MN	Orexin receptor type 2 (HCRTR2)
DMZ4NJQ	MT	DTT
DMZ4NJQ	MA	Antagonist
DMZ4NJQ	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMZ4NJQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMVZ5EP	DI	DMVZ5EP
DMVZ5EP	DN	1,2-diamino cyclopentane-based derivative 31
DMVZ5EP	MI	TT60Q8D
DMVZ5EP	MN	Orexin receptor type 1 (HCRTR1)
DMVZ5EP	MT	DTT
DMVZ5EP	MA	Antagonist
DMVZ5EP	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMVZ5EP	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMVZ5EP	DI	DMVZ5EP
DMVZ5EP	DN	1,2-diamino cyclopentane-based derivative 31
DMVZ5EP	MI	TT9N02I
DMVZ5EP	MN	Orexin receptor type 2 (HCRTR2)
DMVZ5EP	MT	DTT
DMVZ5EP	MA	Antagonist
DMVZ5EP	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMVZ5EP	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMQX8SD	DI	DMQX8SD
DMQX8SD	DN	1,2-diamino cyclopentane-based derivative 32
DMQX8SD	MI	TT60Q8D
DMQX8SD	MN	Orexin receptor type 1 (HCRTR1)
DMQX8SD	MT	DTT
DMQX8SD	MA	Antagonist
DMQX8SD	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMQX8SD	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMQX8SD	DI	DMQX8SD
DMQX8SD	DN	1,2-diamino cyclopentane-based derivative 32
DMQX8SD	MI	TT9N02I
DMQX8SD	MN	Orexin receptor type 2 (HCRTR2)
DMQX8SD	MT	DTT
DMQX8SD	MA	Antagonist
DMQX8SD	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMQX8SD	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMBOLSU	DI	DMBOLSU
DMBOLSU	DN	1,2-diamino cyclopentane-based derivative 33
DMBOLSU	MI	TT60Q8D
DMBOLSU	MN	Orexin receptor type 1 (HCRTR1)
DMBOLSU	MT	DTT
DMBOLSU	MA	Antagonist
DMBOLSU	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMBOLSU	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMBOLSU	DI	DMBOLSU
DMBOLSU	DN	1,2-diamino cyclopentane-based derivative 33
DMBOLSU	MI	TT9N02I
DMBOLSU	MN	Orexin receptor type 2 (HCRTR2)
DMBOLSU	MT	DTT
DMBOLSU	MA	Antagonist
DMBOLSU	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMBOLSU	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMVHL3W	DI	DMVHL3W
DMVHL3W	DN	1,2-diamino cyclopentane-based derivative 34
DMVHL3W	MI	TT60Q8D
DMVHL3W	MN	Orexin receptor type 1 (HCRTR1)
DMVHL3W	MT	DTT
DMVHL3W	MA	Antagonist
DMVHL3W	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMVHL3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMVHL3W	DI	DMVHL3W
DMVHL3W	DN	1,2-diamino cyclopentane-based derivative 34
DMVHL3W	MI	TT9N02I
DMVHL3W	MN	Orexin receptor type 2 (HCRTR2)
DMVHL3W	MT	DTT
DMVHL3W	MA	Antagonist
DMVHL3W	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMVHL3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMFBPSX	DI	DMFBPSX
DMFBPSX	DN	1,2-diamino cyclopentane-based derivative 4
DMFBPSX	MI	TT60Q8D
DMFBPSX	MN	Orexin receptor type 1 (HCRTR1)
DMFBPSX	MT	DTT
DMFBPSX	MA	Antagonist
DMFBPSX	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMFBPSX	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMFBPSX	DI	DMFBPSX
DMFBPSX	DN	1,2-diamino cyclopentane-based derivative 4
DMFBPSX	MI	TT9N02I
DMFBPSX	MN	Orexin receptor type 2 (HCRTR2)
DMFBPSX	MT	DTT
DMFBPSX	MA	Antagonist
DMFBPSX	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMFBPSX	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMCP15K	DI	DMCP15K
DMCP15K	DN	1,2-diamino cyclopentane-based derivative 5
DMCP15K	MI	TT60Q8D
DMCP15K	MN	Orexin receptor type 1 (HCRTR1)
DMCP15K	MT	DTT
DMCP15K	MA	Antagonist
DMCP15K	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMCP15K	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMCP15K	DI	DMCP15K
DMCP15K	DN	1,2-diamino cyclopentane-based derivative 5
DMCP15K	MI	TT9N02I
DMCP15K	MN	Orexin receptor type 2 (HCRTR2)
DMCP15K	MT	DTT
DMCP15K	MA	Antagonist
DMCP15K	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMCP15K	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMJ4ACP	DI	DMJ4ACP
DMJ4ACP	DN	1,2-diamino cyclopentane-based derivative 6
DMJ4ACP	MI	TT60Q8D
DMJ4ACP	MN	Orexin receptor type 1 (HCRTR1)
DMJ4ACP	MT	DTT
DMJ4ACP	MA	Antagonist
DMJ4ACP	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMJ4ACP	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMJ4ACP	DI	DMJ4ACP
DMJ4ACP	DN	1,2-diamino cyclopentane-based derivative 6
DMJ4ACP	MI	TT9N02I
DMJ4ACP	MN	Orexin receptor type 2 (HCRTR2)
DMJ4ACP	MT	DTT
DMJ4ACP	MA	Antagonist
DMJ4ACP	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMJ4ACP	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMHIV24	DI	DMHIV24
DMHIV24	DN	1,2-diamino cyclopentane-based derivative 7
DMHIV24	MI	TT60Q8D
DMHIV24	MN	Orexin receptor type 1 (HCRTR1)
DMHIV24	MT	DTT
DMHIV24	MA	Antagonist
DMHIV24	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMHIV24	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMHIV24	DI	DMHIV24
DMHIV24	DN	1,2-diamino cyclopentane-based derivative 7
DMHIV24	MI	TT9N02I
DMHIV24	MN	Orexin receptor type 2 (HCRTR2)
DMHIV24	MT	DTT
DMHIV24	MA	Antagonist
DMHIV24	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DMHIV24	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DM7JX8U	DI	DM7JX8U
DM7JX8U	DN	1,2-diamino cyclopentane-based derivative 8
DM7JX8U	MI	TT60Q8D
DM7JX8U	MN	Orexin receptor type 1 (HCRTR1)
DM7JX8U	MT	DTT
DM7JX8U	MA	Antagonist
DM7JX8U	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DM7JX8U	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DM7JX8U	DI	DM7JX8U
DM7JX8U	DN	1,2-diamino cyclopentane-based derivative 8
DM7JX8U	MI	TT9N02I
DM7JX8U	MN	Orexin receptor type 2 (HCRTR2)
DM7JX8U	MT	DTT
DM7JX8U	MA	Antagonist
DM7JX8U	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DM7JX8U	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DM7I8ZV	DI	DM7I8ZV
DM7I8ZV	DN	1,2-diamino cyclopentane-based derivative 9
DM7I8ZV	MI	TT60Q8D
DM7I8ZV	MN	Orexin receptor type 1 (HCRTR1)
DM7I8ZV	MT	DTT
DM7I8ZV	MA	Antagonist
DM7I8ZV	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DM7I8ZV	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DM7I8ZV	DI	DM7I8ZV
DM7I8ZV	DN	1,2-diamino cyclopentane-based derivative 9
DM7I8ZV	MI	TT9N02I
DM7I8ZV	MN	Orexin receptor type 2 (HCRTR2)
DM7I8ZV	MT	DTT
DM7I8ZV	MA	Antagonist
DM7I8ZV	RN	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
DM7I8ZV	RU	https://www.ncbi.nlm.nih.gov/pubmed/26593218

DMRFXMB	DI	DMRFXMB
DMRFXMB	DN	1,2-dihydroindazolo[4,3-bc][1,5]benzoxazepine derivative 1
DMRFXMB	MI	TTCZOF2
DMRFXMB	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMRFXMB	MT	DTT
DMRFXMB	MA	Inhibitor
DMRFXMB	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMRFXMB	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMJMCNP	DI	DMJMCNP
DMJMCNP	DN	1,3,4-oxadiazole derivative 1
DMJMCNP	MI	TTNBFWK
DMJMCNP	MN	Programmed cell death protein 1 (PD-1)
DMJMCNP	MT	DTT
DMJMCNP	MA	Inhibitor
DMJMCNP	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMJMCNP	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMH26EO	DI	DMH26EO
DMH26EO	DN	1,3,4-oxadiazole derivative 2
DMH26EO	MI	TTNBFWK
DMH26EO	MN	Programmed cell death protein 1 (PD-1)
DMH26EO	MT	DTT
DMH26EO	MA	Inhibitor
DMH26EO	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMH26EO	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMSR0X6	DI	DMSR0X6
DMSR0X6	DN	1,3,4-oxadiazole derivative 3
DMSR0X6	MI	TT23XQV
DMSR0X6	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMSR0X6	MT	DTT
DMSR0X6	MA	Inhibitor
DMSR0X6	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMSR0X6	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DM4GR2C	DI	DM4GR2C
DM4GR2C	DN	1,3,4-oxadiazole derivative 4
DM4GR2C	MI	TT23XQV
DM4GR2C	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DM4GR2C	MT	DTT
DM4GR2C	MA	Inhibitor
DM4GR2C	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DM4GR2C	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMI5VZN	DI	DMI5VZN
DMI5VZN	DN	1,3,4-oxadiazole derivative 5
DMI5VZN	MI	TT23XQV
DMI5VZN	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMI5VZN	MT	DTT
DMI5VZN	MA	Inhibitor
DMI5VZN	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMI5VZN	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMIEZ6L	DI	DMIEZ6L
DMIEZ6L	DN	1,3,4-oxadiazole derivative 6
DMIEZ6L	MI	TT23XQV
DMIEZ6L	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMIEZ6L	MT	DTT
DMIEZ6L	MA	Inhibitor
DMIEZ6L	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMIEZ6L	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMAB8QF	DI	DMAB8QF
DMAB8QF	DN	1,3,4-thiadiazole derivative 1
DMAB8QF	MI	TT23XQV
DMAB8QF	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMAB8QF	MT	DTT
DMAB8QF	MA	Inhibitor
DMAB8QF	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMAB8QF	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMXIG07	DI	DMXIG07
DMXIG07	DN	1,3,4-thiadiazole derivative 2
DMXIG07	MI	TT23XQV
DMXIG07	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMXIG07	MT	DTT
DMXIG07	MA	Inhibitor
DMXIG07	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMXIG07	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMLD7JU	DI	DMLD7JU
DMLD7JU	DN	1,3,5-triazine derivative 1
DMLD7JU	MI	TTMSFAW
DMLD7JU	MN	Cannabinoid receptor 2 (CB2)
DMLD7JU	MT	DTT
DMLD7JU	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DMLD7JU	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DMUS7O3	DI	DMUS7O3
DMUS7O3	DN	1,3-dihydroxy phenyl derivative 1
DMUS7O3	MI	TT23XQV
DMUS7O3	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMUS7O3	MT	DTT
DMUS7O3	MA	Inhibitor
DMUS7O3	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMUS7O3	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DM63NX5	DI	DM63NX5
DM63NX5	DN	1,3-dihydroxy phenyl derivative 2
DM63NX5	MI	TT23XQV
DM63NX5	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DM63NX5	MT	DTT
DM63NX5	MA	Inhibitor
DM63NX5	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DM63NX5	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMZY3HC	DI	DMZY3HC
DMZY3HC	DN	1,5-diphenylpyrrolidin-2-one derivative 1
DMZY3HC	MI	TT6OEDT
DMZY3HC	MN	Cannabinoid receptor 1 (CB1)
DMZY3HC	MT	DTT
DMZY3HC	MA	Antagonist
DMZY3HC	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMZY3HC	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMBR2Y9	DI	DMBR2Y9
DMBR2Y9	DN	1,5-diphenylpyrrolidin-2-one derivative 2
DMBR2Y9	MI	TT6OEDT
DMBR2Y9	MN	Cannabinoid receptor 1 (CB1)
DMBR2Y9	MT	DTT
DMBR2Y9	MA	Antagonist
DMBR2Y9	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMBR2Y9	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMEUO8G	DI	DMEUO8G
DMEUO8G	DN	1,5-di-substituted pyridine derivative 1
DMEUO8G	MI	TT7HF4W
DMEUO8G	MN	Cyclin-dependent kinase 2 (CDK2)
DMEUO8G	MT	DTT
DMEUO8G	MA	Inhibitor
DMEUO8G	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMEUO8G	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMEUO8G	DI	DMEUO8G
DMEUO8G	DN	1,5-di-substituted pyridine derivative 1
DMEUO8G	MI	TT1LVF2
DMEUO8G	MN	Cyclin-dependent kinase 9 (CDK9)
DMEUO8G	MT	DTT
DMEUO8G	MA	Inhibitor
DMEUO8G	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMEUO8G	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMUQ9CF	DI	DMUQ9CF
DMUQ9CF	DN	1,6-diazanaphthalenes and pyrido[2,3-d] pyrimidine derivative 1
DMUQ9CF	MI	TTIXKA4
DMUQ9CF	MN	Ribosomal protein S6 kinase alpha-1 (RSK1)
DMUQ9CF	MT	DTT
DMUQ9CF	MA	Inhibitor
DMUQ9CF	RN	Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78.
DMUQ9CF	RU	https://www.ncbi.nlm.nih.gov/pubmed/27410995

DMPZ0U8	DI	DMPZ0U8
DMPZ0U8	DN	1,6-diazanaphthalenes and pyrido[2,3-d] pyrimidine derivative 2
DMPZ0U8	MI	TTIXKA4
DMPZ0U8	MN	Ribosomal protein S6 kinase alpha-1 (RSK1)
DMPZ0U8	MT	DTT
DMPZ0U8	MA	Inhibitor
DMPZ0U8	RN	Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78.
DMPZ0U8	RU	https://www.ncbi.nlm.nih.gov/pubmed/27410995

DMF6W2Y	DI	DMF6W2Y
DMF6W2Y	DN	1,6-naphyridine-4-ketone fused heterocyclic derivative 1
DMF6W2Y	MI	TTOHSBA
DMF6W2Y	MN	Vascular endothelial growth factor A (VEGFA)
DMF6W2Y	MT	DTT
DMF6W2Y	MA	Inhibitor
DMF6W2Y	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMF6W2Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMHNPSO	DI	DMHNPSO
DMHNPSO	DN	1190312-92-5
DMHNPSO	MI	TTIG67W
DMHNPSO	MN	Lysine-specific demethylase 5A (KDM5A)
DMHNPSO	MT	DTT
DMHNPSO	MA	Inhibitor
DMHNPSO	RN	Histone demethylase inhibitors. US10174026.
DMHNPSO	RU	http://www.freepatentsonline.com/US10174026.html

DMJRK9D	DI	DMJRK9D
DMJRK9D	DN	1313212-89-3
DMJRK9D	MI	TTNAFOU
DMJRK9D	MN	Rotamase D (PPID)
DMJRK9D	MT	DTT
DMJRK9D	MA	Inhibitor
DMJRK9D	RN	Inhibitors of cyclophilins and uses thereof. US8901295.
DMJRK9D	RU	http://www.freepatentsonline.com/US8901295.html

DMM2N4T	DI	DMM2N4T
DMM2N4T	DN	1607004-34-1
DMM2N4T	MI	TTYG6BU
DMM2N4T	MN	Aggrecanase-1 (ADAMTS4)
DMM2N4T	MT	DTT
DMM2N4T	MA	Inhibitor
DMM2N4T	RN	Aggrecanase inhibitors. US9206139.
DMM2N4T	RU	http://www.freepatentsonline.com/US9206139.html

DMWNKQ8	DI	DMWNKQ8
DMWNKQ8	DN	1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 1
DMWNKQ8	MI	TTJGW1Z
DMWNKQ8	MN	Phosphodiesterase 2A (PDE2A)
DMWNKQ8	MT	DTT
DMWNKQ8	MA	Inhibitor
DMWNKQ8	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMWNKQ8	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMU6ST7	DI	DMU6ST7
DMU6ST7	DN	1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 2
DMU6ST7	MI	TTJGW1Z
DMU6ST7	MN	Phosphodiesterase 2A (PDE2A)
DMU6ST7	MT	DTT
DMU6ST7	MA	Inhibitor
DMU6ST7	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMU6ST7	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DM62K40	DI	DM62K40
DM62K40	DN	1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 3
DM62K40	MI	TTJW4LU
DM62K40	MN	Phosphodiesterase 10A (PDE10)
DM62K40	MT	DTT
DM62K40	MA	Inhibitor
DM62K40	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DM62K40	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DM62K40	DI	DM62K40
DM62K40	DN	1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 3
DM62K40	MI	TTJGW1Z
DM62K40	MN	Phosphodiesterase 2A (PDE2A)
DM62K40	MT	DTT
DM62K40	MA	Inhibitor
DM62K40	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DM62K40	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMQSTG9	DI	DMQSTG9
DMQSTG9	DN	1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 4
DMQSTG9	MI	TTJW4LU
DMQSTG9	MN	Phosphodiesterase 10A (PDE10)
DMQSTG9	MT	DTT
DMQSTG9	MA	Inhibitor
DMQSTG9	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMQSTG9	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMQSTG9	DI	DMQSTG9
DMQSTG9	DN	1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 4
DMQSTG9	MI	TTJGW1Z
DMQSTG9	MN	Phosphodiesterase 2A (PDE2A)
DMQSTG9	MT	DTT
DMQSTG9	MA	Inhibitor
DMQSTG9	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMQSTG9	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DM9E0ZD	DI	DM9E0ZD
DM9E0ZD	DN	1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 5
DM9E0ZD	MI	TTJW4LU
DM9E0ZD	MN	Phosphodiesterase 10A (PDE10)
DM9E0ZD	MT	DTT
DM9E0ZD	MA	Inhibitor
DM9E0ZD	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DM9E0ZD	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DM9E0ZD	DI	DM9E0ZD
DM9E0ZD	DN	1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 5
DM9E0ZD	MI	TTJGW1Z
DM9E0ZD	MN	Phosphodiesterase 2A (PDE2A)
DM9E0ZD	MT	DTT
DM9E0ZD	MA	Inhibitor
DM9E0ZD	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DM9E0ZD	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DM826JW	DI	DM826JW
DM826JW	DN	1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 6
DM826JW	MI	TTJW4LU
DM826JW	MN	Phosphodiesterase 10A (PDE10)
DM826JW	MT	DTT
DM826JW	MA	Inhibitor
DM826JW	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DM826JW	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DM826JW	DI	DM826JW
DM826JW	DN	1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 6
DM826JW	MI	TTJGW1Z
DM826JW	MN	Phosphodiesterase 2A (PDE2A)
DM826JW	MT	DTT
DM826JW	MA	Inhibitor
DM826JW	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DM826JW	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DML8RVS	DI	DML8RVS
DML8RVS	DN	1-Benzyl-3-bromo-1H-pyrrole-2,5-dione
DML8RVS	MI	TTWME23
DML8RVS	MN	Regulator of G-protein signaling 8 (RGS8)
DML8RVS	MT	DTT
DML8RVS	MA	Inhibitor
DML8RVS	RN	Small molecule inhibitors of RGS proteins. US8865750.
DML8RVS	RU	http://www.freepatentsonline.com/US8865750.html

DMWY9GM	DI	DMWY9GM
DMWY9GM	DN	1-Benzyl-3-p-tolyl-1H-pyrrole-2,5-dione
DMWY9GM	MI	TTWME23
DMWY9GM	MN	Regulator of G-protein signaling 8 (RGS8)
DMWY9GM	MT	DTT
DMWY9GM	MA	Inhibitor
DMWY9GM	RN	Small molecule inhibitors of RGS proteins. US8865750.
DMWY9GM	RU	http://www.freepatentsonline.com/US8865750.html

DMK75BT	DI	DMK75BT
DMK75BT	DN	1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 1
DMK75BT	MI	TTSXVID
DMK75BT	MN	Nuclear factor NF-kappa-B (NFKB)
DMK75BT	MT	DTT
DMK75BT	MA	Inhibitor
DMK75BT	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DMK75BT	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DMIWQZ5	DI	DMIWQZ5
DMIWQZ5	DN	1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 2
DMIWQZ5	MI	TTSXVID
DMIWQZ5	MN	Nuclear factor NF-kappa-B (NFKB)
DMIWQZ5	MT	DTT
DMIWQZ5	MA	Inhibitor
DMIWQZ5	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DMIWQZ5	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DMNXAUZ	DI	DMNXAUZ
DMNXAUZ	DN	1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 3
DMNXAUZ	MI	TTSXVID
DMNXAUZ	MN	Nuclear factor NF-kappa-B (NFKB)
DMNXAUZ	MT	DTT
DMNXAUZ	MA	Inhibitor
DMNXAUZ	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DMNXAUZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DMV2W9Z	DI	DMV2W9Z
DMV2W9Z	DN	1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 4
DMV2W9Z	MI	TTSXVID
DMV2W9Z	MN	Nuclear factor NF-kappa-B (NFKB)
DMV2W9Z	MT	DTT
DMV2W9Z	MA	Inhibitor
DMV2W9Z	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DMV2W9Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DMS5EHL	DI	DMS5EHL
DMS5EHL	DN	1-phenyl-1,3,4-triazole derivative 1
DMS5EHL	MI	TT956B0
DMS5EHL	MN	Keap1-Nrf2[DLG] PPI (KEAP1-Nrf2 DLG)
DMS5EHL	MT	DTT
DMS5EHL	MA	Modulator
DMS5EHL	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMS5EHL	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMS5EHL	DI	DMS5EHL
DMS5EHL	DN	1-phenyl-1,3,4-triazole derivative 1
DMS5EHL	MI	TTA6ZN2
DMS5EHL	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMS5EHL	MT	DTT
DMS5EHL	MA	Inhibitor
DMS5EHL	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMS5EHL	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMO7310	DI	DMO7310
DMO7310	DN	1-phenyl-1,3,4-triazole derivative 2
DMO7310	MI	TT956B0
DMO7310	MN	Keap1-Nrf2[DLG] PPI (KEAP1-Nrf2 DLG)
DMO7310	MT	DTT
DMO7310	MA	Modulator
DMO7310	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMO7310	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMO7310	DI	DMO7310
DMO7310	DN	1-phenyl-1,3,4-triazole derivative 2
DMO7310	MI	TTA6ZN2
DMO7310	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMO7310	MT	DTT
DMO7310	MA	Inhibitor
DMO7310	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMO7310	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMU8FC1	DI	DMU8FC1
DMU8FC1	DN	1-phenyl-1,3,4-triazole derivative 3
DMU8FC1	MI	TT956B0
DMU8FC1	MN	Keap1-Nrf2[DLG] PPI (KEAP1-Nrf2 DLG)
DMU8FC1	MT	DTT
DMU8FC1	MA	Modulator
DMU8FC1	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMU8FC1	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMU8FC1	DI	DMU8FC1
DMU8FC1	DN	1-phenyl-1,3,4-triazole derivative 3
DMU8FC1	MI	TTA6ZN2
DMU8FC1	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMU8FC1	MT	DTT
DMU8FC1	MA	Inhibitor
DMU8FC1	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMU8FC1	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMOY5EK	DI	DMOY5EK
DMOY5EK	DN	2-(substituted ethynyl)quinoline derivative 1
DMOY5EK	MI	TTHS256
DMOY5EK	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMOY5EK	MT	DTT
DMOY5EK	MA	Antagonist
DMOY5EK	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMOY5EK	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMPCYSW	DI	DMPCYSW
DMPCYSW	DN	2-(substituted ethynyl)quinoline derivative 2
DMPCYSW	MI	TTHS256
DMPCYSW	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMPCYSW	MT	DTT
DMPCYSW	MA	Antagonist
DMPCYSW	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMPCYSW	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMMF8A1	DI	DMMF8A1
DMMF8A1	DN	2-(substituted ethynyl)quinoline derivative 3
DMMF8A1	MI	TTHS256
DMMF8A1	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMMF8A1	MT	DTT
DMMF8A1	MA	Antagonist
DMMF8A1	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMMF8A1	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMTXZUF	DI	DMTXZUF
DMTXZUF	DN	2-(substituted ethynyl)quinoline derivative 4
DMTXZUF	MI	TTHS256
DMTXZUF	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMTXZUF	MT	DTT
DMTXZUF	MA	Antagonist
DMTXZUF	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMTXZUF	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMRTDOA	DI	DMRTDOA
DMRTDOA	DN	2,2-bipyridyl derivative 1
DMRTDOA	MI	TT0RGE9
DMRTDOA	MN	Lysine-specific demethylase 4 (KDM4)
DMRTDOA	MT	DTT
DMRTDOA	MA	Inhibitor
DMRTDOA	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMRTDOA	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMYLQZ1	DI	DMYLQZ1
DMYLQZ1	DN	2,2-bipyridyl derivative 2
DMYLQZ1	MI	TT0RGE9
DMYLQZ1	MN	Lysine-specific demethylase 4 (KDM4)
DMYLQZ1	MT	DTT
DMYLQZ1	MA	Inhibitor
DMYLQZ1	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMYLQZ1	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMPQF78	DI	DMPQF78
DMPQF78	DN	2,2-bipyridyl derivative 3
DMPQF78	MI	TT0RGE9
DMPQF78	MN	Lysine-specific demethylase 4 (KDM4)
DMPQF78	MT	DTT
DMPQF78	MA	Inhibitor
DMPQF78	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMPQF78	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMTYPBM	DI	DMTYPBM
DMTYPBM	DN	2,2-bipyridyl derivative 4
DMTYPBM	MI	TT0RGE9
DMTYPBM	MN	Lysine-specific demethylase 4 (KDM4)
DMTYPBM	MT	DTT
DMTYPBM	MA	Inhibitor
DMTYPBM	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMTYPBM	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMEJOPL	DI	DMEJOPL
DMEJOPL	DN	2,2-bipyridyl derivative 5
DMEJOPL	MI	TT0RGE9
DMEJOPL	MN	Lysine-specific demethylase 4 (KDM4)
DMEJOPL	MT	DTT
DMEJOPL	MA	Inhibitor
DMEJOPL	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMEJOPL	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMWRBSP	DI	DMWRBSP
DMWRBSP	DN	2,2-dimethylbenzopyran derivative 1
DMWRBSP	MI	TTUX68I
DMWRBSP	MN	Hypoxia-inducible factor 1 (HIF-1)
DMWRBSP	MT	DTT
DMWRBSP	MA	Inhibitor
DMWRBSP	RN	Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22.
DMWRBSP	RU	https://www.ncbi.nlm.nih.gov/pubmed/26882240

DM9XUYM	DI	DM9XUYM
DM9XUYM	DN	2,2-dimethylbenzopyran derivative 2
DM9XUYM	MI	TTUX68I
DM9XUYM	MN	Hypoxia-inducible factor 1 (HIF-1)
DM9XUYM	MT	DTT
DM9XUYM	MA	Inhibitor
DM9XUYM	RN	Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22.
DM9XUYM	RU	https://www.ncbi.nlm.nih.gov/pubmed/26882240

DMTCPSQ	DI	DMTCPSQ
DMTCPSQ	DN	2,2-dimethylbenzopyran derivative 3
DMTCPSQ	MI	TTUX68I
DMTCPSQ	MN	Hypoxia-inducible factor 1 (HIF-1)
DMTCPSQ	MT	DTT
DMTCPSQ	MA	Inhibitor
DMTCPSQ	RN	Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22.
DMTCPSQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26882240

DMD2KRW	DI	DMD2KRW
DMD2KRW	DN	2,3-diamino-benzo[b]thiophene derivative 1
DMD2KRW	MI	TTZJYKH
DMD2KRW	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMD2KRW	MT	DTT
DMD2KRW	MA	Inhibitor
DMD2KRW	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMD2KRW	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMD2KRW	DI	DMD2KRW
DMD2KRW	DN	2,3-diamino-benzo[b]thiophene derivative 1
DMD2KRW	MI	TTALN9W
DMD2KRW	MN	Indoleamine 2,3-dioxygenase 2 (IDO2)
DMD2KRW	MT	DTT
DMD2KRW	MA	Inhibitor
DMD2KRW	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMD2KRW	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMD2KRW	DI	DMD2KRW
DMD2KRW	DN	2,3-diamino-benzo[b]thiophene derivative 1
DMD2KRW	MI	TTXNCBV
DMD2KRW	MN	Tryptophan 2,3-dioxygenase (TDO)
DMD2KRW	MT	DTT
DMD2KRW	MA	Inhibitor
DMD2KRW	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMD2KRW	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMDYXKT	DI	DMDYXKT
DMDYXKT	DN	2,3-diamino-benzo[b]thiophene derivative 2
DMDYXKT	MI	TTZJYKH
DMDYXKT	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMDYXKT	MT	DTT
DMDYXKT	MA	Inhibitor
DMDYXKT	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMDYXKT	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMDYXKT	DI	DMDYXKT
DMDYXKT	DN	2,3-diamino-benzo[b]thiophene derivative 2
DMDYXKT	MI	TTALN9W
DMDYXKT	MN	Indoleamine 2,3-dioxygenase 2 (IDO2)
DMDYXKT	MT	DTT
DMDYXKT	MA	Inhibitor
DMDYXKT	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMDYXKT	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMDYXKT	DI	DMDYXKT
DMDYXKT	DN	2,3-diamino-benzo[b]thiophene derivative 2
DMDYXKT	MI	TTXNCBV
DMDYXKT	MN	Tryptophan 2,3-dioxygenase (TDO)
DMDYXKT	MT	DTT
DMDYXKT	MA	Inhibitor
DMDYXKT	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMDYXKT	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMR7QKL	DI	DMR7QKL
DMR7QKL	DN	2,3-diamino-benzo[b]thiophene derivative 3
DMR7QKL	MI	TTZJYKH
DMR7QKL	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMR7QKL	MT	DTT
DMR7QKL	MA	Inhibitor
DMR7QKL	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMR7QKL	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMR7QKL	DI	DMR7QKL
DMR7QKL	DN	2,3-diamino-benzo[b]thiophene derivative 3
DMR7QKL	MI	TTXNCBV
DMR7QKL	MN	Tryptophan 2,3-dioxygenase (TDO)
DMR7QKL	MT	DTT
DMR7QKL	MA	Inhibitor
DMR7QKL	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMR7QKL	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMEDFNC	DI	DMEDFNC
DMEDFNC	DN	2,3-diamino-benzo[b]thiophene derivative 4
DMEDFNC	MI	TTZJYKH
DMEDFNC	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMEDFNC	MT	DTT
DMEDFNC	MA	Inhibitor
DMEDFNC	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMEDFNC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMEDFNC	DI	DMEDFNC
DMEDFNC	DN	2,3-diamino-benzo[b]thiophene derivative 4
DMEDFNC	MI	TTALN9W
DMEDFNC	MN	Indoleamine 2,3-dioxygenase 2 (IDO2)
DMEDFNC	MT	DTT
DMEDFNC	MA	Inhibitor
DMEDFNC	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMEDFNC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMEDFNC	DI	DMEDFNC
DMEDFNC	DN	2,3-diamino-benzo[b]thiophene derivative 4
DMEDFNC	MI	TTXNCBV
DMEDFNC	MN	Tryptophan 2,3-dioxygenase (TDO)
DMEDFNC	MT	DTT
DMEDFNC	MA	Inhibitor
DMEDFNC	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMEDFNC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DM05WXD	DI	DM05WXD
DM05WXD	DN	2,3-diamino-benzo[b]thiophene derivative 5
DM05WXD	MI	TTZJYKH
DM05WXD	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DM05WXD	MT	DTT
DM05WXD	MA	Inhibitor
DM05WXD	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DM05WXD	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DM05WXD	DI	DM05WXD
DM05WXD	DN	2,3-diamino-benzo[b]thiophene derivative 5
DM05WXD	MI	TTALN9W
DM05WXD	MN	Indoleamine 2,3-dioxygenase 2 (IDO2)
DM05WXD	MT	DTT
DM05WXD	MA	Inhibitor
DM05WXD	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DM05WXD	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DM05WXD	DI	DM05WXD
DM05WXD	DN	2,3-diamino-benzo[b]thiophene derivative 5
DM05WXD	MI	TTXNCBV
DM05WXD	MN	Tryptophan 2,3-dioxygenase (TDO)
DM05WXD	MT	DTT
DM05WXD	MA	Inhibitor
DM05WXD	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DM05WXD	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMINE6V	DI	DMINE6V
DMINE6V	DN	2,3-diamino-benzo[b]thiophene derivative 6
DMINE6V	MI	TTZJYKH
DMINE6V	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMINE6V	MT	DTT
DMINE6V	MA	Inhibitor
DMINE6V	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMINE6V	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMINE6V	DI	DMINE6V
DMINE6V	DN	2,3-diamino-benzo[b]thiophene derivative 6
DMINE6V	MI	TTALN9W
DMINE6V	MN	Indoleamine 2,3-dioxygenase 2 (IDO2)
DMINE6V	MT	DTT
DMINE6V	MA	Inhibitor
DMINE6V	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMINE6V	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMINE6V	DI	DMINE6V
DMINE6V	DN	2,3-diamino-benzo[b]thiophene derivative 6
DMINE6V	MI	TTXNCBV
DMINE6V	MN	Tryptophan 2,3-dioxygenase (TDO)
DMINE6V	MT	DTT
DMINE6V	MA	Inhibitor
DMINE6V	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMINE6V	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMQVMNJ	DI	DMQVMNJ
DMQVMNJ	DN	2,3-diamino-benzo[b]thiophene derivative 7
DMQVMNJ	MI	TTZJYKH
DMQVMNJ	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMQVMNJ	MT	DTT
DMQVMNJ	MA	Inhibitor
DMQVMNJ	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMQVMNJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMQVMNJ	DI	DMQVMNJ
DMQVMNJ	DN	2,3-diamino-benzo[b]thiophene derivative 7
DMQVMNJ	MI	TTALN9W
DMQVMNJ	MN	Indoleamine 2,3-dioxygenase 2 (IDO2)
DMQVMNJ	MT	DTT
DMQVMNJ	MA	Inhibitor
DMQVMNJ	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMQVMNJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMQVMNJ	DI	DMQVMNJ
DMQVMNJ	DN	2,3-diamino-benzo[b]thiophene derivative 7
DMQVMNJ	MI	TTXNCBV
DMQVMNJ	MN	Tryptophan 2,3-dioxygenase (TDO)
DMQVMNJ	MT	DTT
DMQVMNJ	MA	Inhibitor
DMQVMNJ	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMQVMNJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DM5O8K0	DI	DM5O8K0
DM5O8K0	DN	2,3-diamino-benzo[b]thiophene derivative 8
DM5O8K0	MI	TTZJYKH
DM5O8K0	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DM5O8K0	MT	DTT
DM5O8K0	MA	Inhibitor
DM5O8K0	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DM5O8K0	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DM5O8K0	DI	DM5O8K0
DM5O8K0	DN	2,3-diamino-benzo[b]thiophene derivative 8
DM5O8K0	MI	TTALN9W
DM5O8K0	MN	Indoleamine 2,3-dioxygenase 2 (IDO2)
DM5O8K0	MT	DTT
DM5O8K0	MA	Inhibitor
DM5O8K0	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DM5O8K0	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DM5O8K0	DI	DM5O8K0
DM5O8K0	DN	2,3-diamino-benzo[b]thiophene derivative 8
DM5O8K0	MI	TTXNCBV
DM5O8K0	MN	Tryptophan 2,3-dioxygenase (TDO)
DM5O8K0	MT	DTT
DM5O8K0	MA	Inhibitor
DM5O8K0	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DM5O8K0	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMMFZKC	DI	DMMFZKC
DMMFZKC	DN	2-alkyloxy-3-phenylethynyl-4a,5-dihydropyrido[2,3-b]pyrazine derivative 1
DMMFZKC	MI	TT2F4OL
DMMFZKC	MN	Tissue transglutaminase (TG2)
DMMFZKC	MT	DTT
DMMFZKC	MA	Inhibitor
DMMFZKC	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DMMFZKC	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DMLXQET	DI	DMLXQET
DMLXQET	DN	2-cycloalkyl resorcinol cannabinoid ligand derivative 1
DMLXQET	MI	TT6OEDT
DMLXQET	MN	Cannabinoid receptor 1 (CB1)
DMLXQET	MT	DTT
DMLXQET	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DMLXQET	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DMLXQET	DI	DMLXQET
DMLXQET	DN	2-cycloalkyl resorcinol cannabinoid ligand derivative 1
DMLXQET	MI	TTMSFAW
DMLXQET	MN	Cannabinoid receptor 2 (CB2)
DMLXQET	MT	DTT
DMLXQET	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DMLXQET	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DMB65TO	DI	DMB65TO
DMB65TO	DN	2-cycloalkyl resorcinol cannabinoid ligand derivative 2
DMB65TO	MI	TT6OEDT
DMB65TO	MN	Cannabinoid receptor 1 (CB1)
DMB65TO	MT	DTT
DMB65TO	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DMB65TO	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DMB65TO	DI	DMB65TO
DMB65TO	DN	2-cycloalkyl resorcinol cannabinoid ligand derivative 2
DMB65TO	MI	TTMSFAW
DMB65TO	MN	Cannabinoid receptor 2 (CB2)
DMB65TO	MT	DTT
DMB65TO	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DMB65TO	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DMTJ1G8	DI	DMTJ1G8
DMTJ1G8	DN	2-cyclopropyl-4-substituted-phenoxy-quinoline derivative 1
DMTJ1G8	MI	TTPADOQ
DMTJ1G8	MN	HMG-CoA reductase (HMGCR)
DMTJ1G8	MT	DTT
DMTJ1G8	MA	Inhibitor
DMTJ1G8	RN	HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272.
DMTJ1G8	RU	https://www.ncbi.nlm.nih.gov/pubmed/27537201

DMHYIAV	DI	DMHYIAV
DMHYIAV	DN	2-ethyl-3-(4-hydroxy) benzoyl benzofuran derivative 1
DMHYIAV	MI	TTA592U
DMHYIAV	MN	Urate anion exchanger 1 (URAT1)
DMHYIAV	MT	DTT
DMHYIAV	MA	Inhibitor
DMHYIAV	RN	Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10.
DMHYIAV	RU	https://www.ncbi.nlm.nih.gov/pubmed/27414413

DMER2ZQ	DI	DMER2ZQ
DMER2ZQ	DN	2-hydroxybenzamide derivative 1
DMER2ZQ	MI	TT3Z6Y9
DMER2ZQ	MN	Cysteines of Keap1 (KEAP1 Cysteines)
DMER2ZQ	MT	DTT
DMER2ZQ	MA	Modulator
DMER2ZQ	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMER2ZQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMER2ZQ	DI	DMER2ZQ
DMER2ZQ	DN	2-hydroxybenzamide derivative 1
DMER2ZQ	MI	TTA6ZN2
DMER2ZQ	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMER2ZQ	MT	DTT
DMER2ZQ	MA	Activator
DMER2ZQ	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMER2ZQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM9FRN6	DI	DM9FRN6
DM9FRN6	DN	2-hydroxybenzamide derivative 2
DM9FRN6	MI	TT3Z6Y9
DM9FRN6	MN	Cysteines of Keap1 (KEAP1 Cysteines)
DM9FRN6	MT	DTT
DM9FRN6	MA	Modulator
DM9FRN6	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DM9FRN6	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM9FRN6	DI	DM9FRN6
DM9FRN6	DN	2-hydroxybenzamide derivative 2
DM9FRN6	MI	TTA6ZN2
DM9FRN6	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DM9FRN6	MT	DTT
DM9FRN6	MA	Activator
DM9FRN6	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DM9FRN6	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMI4KBC	DI	DMI4KBC
DMI4KBC	DN	2-PAM derivative 1
DMI4KBC	MI	TT1RS9F
DMI4KBC	MN	Acetylcholinesterase (AChE)
DMI4KBC	MT	DTT
DMI4KBC	MA	Reactivator
DMI4KBC	RN	Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476.
DMI4KBC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27967267

DMQ1FAH	DI	DMQ1FAH
DMQ1FAH	DN	2-piperidine thiazole derivative 1
DMQ1FAH	MI	TT3M2WO
DMQ1FAH	MN	Sphingosine kinase (SphK)
DMQ1FAH	MT	DTT
DMQ1FAH	MA	Inhibitor
DMQ1FAH	RN	Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416.
DMQ1FAH	RU	https://www.ncbi.nlm.nih.gov/pubmed/27539678

DMSJ1C0	DI	DMSJ1C0
DMSJ1C0	DN	2-piperidine thiazole derivative 2
DMSJ1C0	MI	TT3M2WO
DMSJ1C0	MN	Sphingosine kinase (SphK)
DMSJ1C0	MT	DTT
DMSJ1C0	MA	Inhibitor
DMSJ1C0	RN	Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416.
DMSJ1C0	RU	https://www.ncbi.nlm.nih.gov/pubmed/27539678

DMWXUS4	DI	DMWXUS4
DMWXUS4	DN	2-pyrazinone derivative 1
DMWXUS4	MI	TTPLTSQ
DMWXUS4	MN	Neutrophil elastase (NE)
DMWXUS4	MT	DTT
DMWXUS4	MA	Inhibitor
DMWXUS4	RN	Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
DMWXUS4	RU	https://www.ncbi.nlm.nih.gov/pubmed/26118988

DMLEH4U	DI	DMLEH4U
DMLEH4U	DN	2-pyrazinone derivative 2
DMLEH4U	MI	TTPLTSQ
DMLEH4U	MN	Neutrophil elastase (NE)
DMLEH4U	MT	DTT
DMLEH4U	MA	Inhibitor
DMLEH4U	RN	Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
DMLEH4U	RU	https://www.ncbi.nlm.nih.gov/pubmed/26118988

DME5WLD	DI	DME5WLD
DME5WLD	DN	2-pyrazinone derivative 3
DME5WLD	MI	TTPLTSQ
DME5WLD	MN	Neutrophil elastase (NE)
DME5WLD	MT	DTT
DME5WLD	MA	Inhibitor
DME5WLD	RN	Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
DME5WLD	RU	https://www.ncbi.nlm.nih.gov/pubmed/26118988

DMJRHS4	DI	DMJRHS4
DMJRHS4	DN	2-pyrazinone derivative 4
DMJRHS4	MI	TTPLTSQ
DMJRHS4	MN	Neutrophil elastase (NE)
DMJRHS4	MT	DTT
DMJRHS4	MA	Inhibitor
DMJRHS4	RN	Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
DMJRHS4	RU	https://www.ncbi.nlm.nih.gov/pubmed/26118988

DMBIRMA	DI	DMBIRMA
DMBIRMA	DN	2-pyrazinone derivative 5
DMBIRMA	MI	TTPLTSQ
DMBIRMA	MN	Neutrophil elastase (NE)
DMBIRMA	MT	DTT
DMBIRMA	MA	Inhibitor
DMBIRMA	RN	Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
DMBIRMA	RU	https://www.ncbi.nlm.nih.gov/pubmed/26118988

DMHIEBN	DI	DMHIEBN
DMHIEBN	DN	2-pyrazinone derivative 6
DMHIEBN	MI	TTPLTSQ
DMHIEBN	MN	Neutrophil elastase (NE)
DMHIEBN	MT	DTT
DMHIEBN	MA	Inhibitor
DMHIEBN	RN	Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
DMHIEBN	RU	https://www.ncbi.nlm.nih.gov/pubmed/26118988

DMTG6X9	DI	DMTG6X9
DMTG6X9	DN	2-pyrazinone derivative 7
DMTG6X9	MI	TTPLTSQ
DMTG6X9	MN	Neutrophil elastase (NE)
DMTG6X9	MT	DTT
DMTG6X9	MA	Inhibitor
DMTG6X9	RN	Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
DMTG6X9	RU	https://www.ncbi.nlm.nih.gov/pubmed/26118988

DM0DYAU	DI	DM0DYAU
DM0DYAU	DN	3-(6-allyloxy-2-naphthyl)-1-(4-piperidylmethyl)pyrazolo[3,4-d]pyrimidin-4-amine
DM0DYAU	MI	TT42OGM
DM0DYAU	MN	Hematopoietic cell kinase (HCK)
DM0DYAU	MT	DTT
DM0DYAU	MA	Inhibitor
DM0DYAU	RN	Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases. US9765037.
DM0DYAU	RU	http://www.freepatentsonline.com/US9765037.html

DM9YJWU	DI	DM9YJWU
DM9YJWU	DN	3-(phenoxymethyl) benzylamine derivative 1
DM9YJWU	MI	TTULVH8
DM9YJWU	MN	Tyrosinase (TYR)
DM9YJWU	MT	DTT
DM9YJWU	MA	Inhibitor
DM9YJWU	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DM9YJWU	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMGN9IX	DI	DMGN9IX
DMGN9IX	DN	3-(phenoxymethyl) benzylamine derivative 2
DMGN9IX	MI	TTULVH8
DMGN9IX	MN	Tyrosinase (TYR)
DMGN9IX	MT	DTT
DMGN9IX	MA	Inhibitor
DMGN9IX	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMGN9IX	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DM43EKN	DI	DM43EKN
DM43EKN	DN	3-(phenoxymethyl) benzylamine derivative 3
DM43EKN	MI	TTULVH8
DM43EKN	MN	Tyrosinase (TYR)
DM43EKN	MT	DTT
DM43EKN	MA	Inhibitor
DM43EKN	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DM43EKN	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DM58X6N	DI	DM58X6N
DM58X6N	DN	3-(phenoxymethyl) benzylamine derivative 4
DM58X6N	MI	TTULVH8
DM58X6N	MN	Tyrosinase (TYR)
DM58X6N	MT	DTT
DM58X6N	MA	Inhibitor
DM58X6N	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DM58X6N	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DM84HG2	DI	DM84HG2
DM84HG2	DN	3-(phenoxymethyl) benzylamine derivative 5
DM84HG2	MI	TTULVH8
DM84HG2	MN	Tyrosinase (TYR)
DM84HG2	MT	DTT
DM84HG2	MA	Inhibitor
DM84HG2	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DM84HG2	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DM0WBM3	DI	DM0WBM3
DM0WBM3	DN	3-(phenoxymethyl) benzylamine derivative 6
DM0WBM3	MI	TTULVH8
DM0WBM3	MN	Tyrosinase (TYR)
DM0WBM3	MT	DTT
DM0WBM3	MA	Inhibitor
DM0WBM3	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DM0WBM3	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DM4O3DW	DI	DM4O3DW
DM4O3DW	DN	3,4-Dihydroxybenzaldehyde
DM4O3DW	MI	TTGP7BY
DM4O3DW	MN	Monoamine oxidase type B (MAO-B)
DM4O3DW	MT	DTT
DM4O3DW	MA	Inhibitor
DM4O3DW	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DM4O3DW	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DM8L0MN	DI	DM8L0MN
DM8L0MN	DN	3-acylidene-2-oxoindole derivative 1
DM8L0MN	MI	TT2F4OL
DM8L0MN	MN	Tissue transglutaminase (TG2)
DM8L0MN	MT	DTT
DM8L0MN	MA	Inhibitor
DM8L0MN	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DM8L0MN	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DMJ98VG	DI	DMJ98VG
DMJ98VG	DN	3-acylidene-2-oxoindole derivative 2
DMJ98VG	MI	TT2F4OL
DMJ98VG	MN	Tissue transglutaminase (TG2)
DMJ98VG	MT	DTT
DMJ98VG	MA	Inhibitor
DMJ98VG	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DMJ98VG	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DMFDURZ	DI	DMFDURZ
DMFDURZ	DN	3-amino-5-benzyl-substituted indazole derivative 1
DMFDURZ	MI	TTKN7QR
DMFDURZ	MN	BDNF/NT-3 growth factors receptor (TrkB)
DMFDURZ	MT	DTT
DMFDURZ	MA	Inhibitor
DMFDURZ	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMFDURZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMFDURZ	DI	DMFDURZ
DMFDURZ	DN	3-amino-5-benzyl-substituted indazole derivative 1
DMFDURZ	MI	TTXABCW
DMFDURZ	MN	NT-3 growth factor receptor (TrkC)
DMFDURZ	MT	DTT
DMFDURZ	MA	Inhibitor
DMFDURZ	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMFDURZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMFDURZ	DI	DMFDURZ
DMFDURZ	DN	3-amino-5-benzyl-substituted indazole derivative 1
DMFDURZ	MI	TTTDVOJ
DMFDURZ	MN	Tropomyosin-related kinase A (TrkA)
DMFDURZ	MT	DTT
DMFDURZ	MA	Inhibitor
DMFDURZ	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMFDURZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMB6M3Y	DI	DMB6M3Y
DMB6M3Y	DN	3-benzyloxyphenyloxoacetic acid derivative 1
DMB6M3Y	MI	TTA592U
DMB6M3Y	MN	Urate anion exchanger 1 (URAT1)
DMB6M3Y	MT	DTT
DMB6M3Y	MA	Inhibitor
DMB6M3Y	RN	Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10.
DMB6M3Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/27414413

DM9GPKR	DI	DM9GPKR
DM9GPKR	DN	3-Hydroxy-2-butanone
DM9GPKR	MI	TTGP7BY
DM9GPKR	MN	Monoamine oxidase type B (MAO-B)
DM9GPKR	MT	DTT
DM9GPKR	MA	Inhibitor
DM9GPKR	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DM9GPKR	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMAR2OX	DI	DMAR2OX
DMAR2OX	DN	3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 1
DMAR2OX	MI	TTVDSZ0
DMAR2OX	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMAR2OX	MT	DTT
DMAR2OX	MA	Inhibitor
DMAR2OX	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DMAR2OX	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DMEVMU9	DI	DMEVMU9
DMEVMU9	DN	3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 2
DMEVMU9	MI	TTVDSZ0
DMEVMU9	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMEVMU9	MT	DTT
DMEVMU9	MA	Inhibitor
DMEVMU9	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DMEVMU9	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DMRQ74I	DI	DMRQ74I
DMRQ74I	DN	3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 3
DMRQ74I	MI	TTVDSZ0
DMRQ74I	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMRQ74I	MT	DTT
DMRQ74I	MA	Inhibitor
DMRQ74I	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DMRQ74I	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DM8Q19H	DI	DM8Q19H
DM8Q19H	DN	3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 4
DM8Q19H	MI	TTVDSZ0
DM8Q19H	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DM8Q19H	MT	DTT
DM8Q19H	MA	Inhibitor
DM8Q19H	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DM8Q19H	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DMXJ837	DI	DMXJ837
DMXJ837	DN	3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 5
DMXJ837	MI	TTVDSZ0
DMXJ837	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMXJ837	MT	DTT
DMXJ837	MA	Inhibitor
DMXJ837	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DMXJ837	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DMXMV6N	DI	DMXMV6N
DMXMV6N	DN	3-phenyl acrylic acid derivative 1
DMXMV6N	MI	TTZMAO3
DMXMV6N	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMXMV6N	MT	DTT
DMXMV6N	MA	Agonist
DMXMV6N	RN	PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
DMXMV6N	RU	https://www.ncbi.nlm.nih.gov/pubmed/25416646

DMB40HC	DI	DMB40HC
DMB40HC	DN	3-phenyl isoquinolin-1(2H) derivative 1
DMB40HC	MI	TTVDSZ0
DMB40HC	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMB40HC	MT	DTT
DMB40HC	MA	Inhibitor
DMB40HC	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DMB40HC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DMB40HC	DI	DMB40HC
DMB40HC	DN	3-phenyl isoquinolin-1(2H) derivative 1
DMB40HC	MI	TTQ4V96
DMB40HC	MN	Poly [ADP-ribose] polymerase 2 (PARP2)
DMB40HC	MT	DTT
DMB40HC	MA	Inhibitor
DMB40HC	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DMB40HC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DMB40HC	DI	DMB40HC
DMB40HC	DN	3-phenyl isoquinolin-1(2H) derivative 1
DMB40HC	MI	TTD8MEH
DMB40HC	MN	Poly [ADP-ribose] polymerase 3 (PARP3)
DMB40HC	MT	DTT
DMB40HC	MA	Inhibitor
DMB40HC	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DMB40HC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DMA749P	DI	DMA749P
DMA749P	DN	3-phenyl isoquinolin-1(2H) derivative 2
DMA749P	MI	TTVDSZ0
DMA749P	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMA749P	MT	DTT
DMA749P	MA	Inhibitor
DMA749P	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DMA749P	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DMW86YI	DI	DMW86YI
DMW86YI	DN	3-phenyl propanoic derivative 1
DMW86YI	MI	TTHQJI6
DMW86YI	MN	Keap1-Nrf2[ETGE] PPI (KEAP1-Nrf2 ETGE)
DMW86YI	MT	DTT
DMW86YI	MA	Modulator
DMW86YI	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMW86YI	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMW86YI	DI	DMW86YI
DMW86YI	DN	3-phenyl propanoic derivative 1
DMW86YI	MI	TTA6ZN2
DMW86YI	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMW86YI	MT	DTT
DMW86YI	MA	Inhibitor
DMW86YI	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMW86YI	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM17D30	DI	DM17D30
DM17D30	DN	3-phenyl propanoic derivative 2
DM17D30	MI	TTHQJI6
DM17D30	MN	Keap1-Nrf2[ETGE] PPI (KEAP1-Nrf2 ETGE)
DM17D30	MT	DTT
DM17D30	MA	Modulator
DM17D30	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DM17D30	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM17D30	DI	DM17D30
DM17D30	DN	3-phenyl propanoic derivative 2
DM17D30	MI	TTA6ZN2
DM17D30	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DM17D30	MT	DTT
DM17D30	MA	Inhibitor
DM17D30	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DM17D30	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM5GKS6	DI	DM5GKS6
DM5GKS6	DN	3-phenyl propanoic derivative 3
DM5GKS6	MI	TTGIZLN
DM5GKS6	MN	Keap1-Nrf2[dual DLG and ETGE] PPI (KEAP1-Nrf2 DLG and ETGE)
DM5GKS6	MT	DTT
DM5GKS6	MA	Modulator
DM5GKS6	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DM5GKS6	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM5GKS6	DI	DM5GKS6
DM5GKS6	DN	3-phenyl propanoic derivative 3
DM5GKS6	MI	TTA6ZN2
DM5GKS6	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DM5GKS6	MT	DTT
DM5GKS6	MA	Inhibitor
DM5GKS6	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DM5GKS6	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM3VB6G	DI	DM3VB6G
DM3VB6G	DN	3-phenyl pyrazole derivative 1
DM3VB6G	MI	TTJQOD7
DM3VB6G	MN	5-HT 2A receptor (HTR2A)
DM3VB6G	MT	DTT
DM3VB6G	MA	Antagonist
DM3VB6G	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DM3VB6G	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMB1JG2	DI	DMB1JG2
DMB1JG2	DN	3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivative 1
DMB1JG2	MI	TTOHSBA
DMB1JG2	MN	Vascular endothelial growth factor A (VEGFA)
DMB1JG2	MT	DTT
DMB1JG2	MA	Inhibitor
DMB1JG2	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMB1JG2	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMWCT04	DI	DMWCT04
DMWCT04	DN	3-substituted-1,2,4-oxadiazole derivative 1
DMWCT04	MI	TT23XQV
DMWCT04	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMWCT04	MT	DTT
DMWCT04	MA	Inhibitor
DMWCT04	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMWCT04	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMB3806	DI	DMB3806
DMB3806	DN	3-substituted-1,2,4-oxadiazole derivative 2
DMB3806	MI	TT23XQV
DMB3806	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMB3806	MT	DTT
DMB3806	MA	Inhibitor
DMB3806	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMB3806	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMKEOH8	DI	DMKEOH8
DMKEOH8	DN	3-substituted-2-furancarboxylic acid hydrazide derivative 1
DMKEOH8	MI	TT9O6WS
DMKEOH8	MN	Glucagon receptor (GCGR)
DMKEOH8	MT	DTT
DMKEOH8	MA	Antagonist
DMKEOH8	RN	Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30.
DMKEOH8	RU	https://www.ncbi.nlm.nih.gov/pubmed/25828189

DMLK29E	DI	DMLK29E
DMLK29E	DN	3-substituted-2-furancarboxylic acid hydrazide derivative 5
DMLK29E	MI	TT9O6WS
DMLK29E	MN	Glucagon receptor (GCGR)
DMLK29E	MT	DTT
DMLK29E	MA	Antagonist
DMLK29E	RN	Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30.
DMLK29E	RU	https://www.ncbi.nlm.nih.gov/pubmed/25828189

DMCJHK2	DI	DMCJHK2
DMCJHK2	DN	3ts4
DMCJHK2	MI	TTXLEG7
DMCJHK2	MN	Matrix metalloproteinase-10 (MMP-10)
DMCJHK2	MT	DTT
DMCJHK2	MA	Inhibitor
DMCJHK2	RN	Pseudodipeptides as MMP inhibitors. US8691753.
DMCJHK2	RU	http://www.freepatentsonline.com/US8691753.html

DME30O6	DI	DME30O6
DME30O6	DN	4-(2-cyclohexylethoxy) aniline derivative 1
DME30O6	MI	TTA6ZN2
DME30O6	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DME30O6	MT	DTT
DME30O6	MA	Inhibitor
DME30O6	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DME30O6	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM8F4QP	DI	DM8F4QP
DM8F4QP	DN	4-(2-cyclohexylethoxy) aniline derivative 2
DM8F4QP	MI	TTA6ZN2
DM8F4QP	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DM8F4QP	MT	DTT
DM8F4QP	MA	Inhibitor
DM8F4QP	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DM8F4QP	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMJU0SO	DI	DMJU0SO
DMJU0SO	DN	4-(2-cyclohexylethoxy) aniline derivative 3
DMJU0SO	MI	TTA6ZN2
DMJU0SO	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMJU0SO	MT	DTT
DMJU0SO	MA	Inhibitor
DMJU0SO	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMJU0SO	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMPULIC	DI	DMPULIC
DMPULIC	DN	4-(2-cyclohexylethoxy) aniline derivative 4
DMPULIC	MI	TTA6ZN2
DMPULIC	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMPULIC	MT	DTT
DMPULIC	MA	Inhibitor
DMPULIC	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMPULIC	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM7B81V	DI	DM7B81V
DM7B81V	DN	4-(thiazol-5-yl)-pyrimidine derivative 1
DM7B81V	MI	TT7HF4W
DM7B81V	MN	Cyclin-dependent kinase 2 (CDK2)
DM7B81V	MT	DTT
DM7B81V	MA	Inhibitor
DM7B81V	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DM7B81V	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DM7B81V	DI	DM7B81V
DM7B81V	DN	4-(thiazol-5-yl)-pyrimidine derivative 1
DM7B81V	MI	TT1LVF2
DM7B81V	MN	Cyclin-dependent kinase 9 (CDK9)
DM7B81V	MT	DTT
DM7B81V	MA	Inhibitor
DM7B81V	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DM7B81V	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMMQFCN	DI	DMMQFCN
DMMQFCN	DN	4-(thiazol-5-yl)-pyrimidine derivative 2
DMMQFCN	MI	TTH6V3D
DMMQFCN	MN	Cyclin-dependent kinase 1 (CDK1)
DMMQFCN	MT	DTT
DMMQFCN	MA	Inhibitor
DMMQFCN	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMMQFCN	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMMQFCN	DI	DMMQFCN
DMMQFCN	DN	4-(thiazol-5-yl)-pyrimidine derivative 2
DMMQFCN	MI	TT7HF4W
DMMQFCN	MN	Cyclin-dependent kinase 2 (CDK2)
DMMQFCN	MT	DTT
DMMQFCN	MA	Inhibitor
DMMQFCN	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMMQFCN	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMMQFCN	DI	DMMQFCN
DMMQFCN	DN	4-(thiazol-5-yl)-pyrimidine derivative 2
DMMQFCN	MI	TTL4Q97
DMMQFCN	MN	Cyclin-dependent kinase 5 (CDK5)
DMMQFCN	MT	DTT
DMMQFCN	MA	Inhibitor
DMMQFCN	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMMQFCN	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMMQFCN	DI	DMMQFCN
DMMQFCN	DN	4-(thiazol-5-yl)-pyrimidine derivative 2
DMMQFCN	MI	TT1LVF2
DMMQFCN	MN	Cyclin-dependent kinase 9 (CDK9)
DMMQFCN	MT	DTT
DMMQFCN	MA	Inhibitor
DMMQFCN	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMMQFCN	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMCISHW	DI	DMCISHW
DMCISHW	DN	4,5,6,7-tetrahydrofuro[3,4-c]pyridine-1(3H)-one derivative 1
DMCISHW	MI	TTV1C0Z
DMCISHW	MN	Neuropeptide S receptor (NPSR)
DMCISHW	MT	DTT
DMCISHW	MA	Antagonist
DMCISHW	RN	Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362.
DMCISHW	RU	https://www.ncbi.nlm.nih.gov/pubmed/27788040

DMPTRQD	DI	DMPTRQD
DMPTRQD	DN	4,5,6,7-tetrahydrofuro[3,4-c]pyridine-1(3H)-one derivative 2
DMPTRQD	MI	TTV1C0Z
DMPTRQD	MN	Neuropeptide S receptor (NPSR)
DMPTRQD	MT	DTT
DMPTRQD	MA	Antagonist
DMPTRQD	RN	Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362.
DMPTRQD	RU	https://www.ncbi.nlm.nih.gov/pubmed/27788040

DMFOBM9	DI	DMFOBM9
DMFOBM9	DN	4,5,6,7-tetrahydrofuro[3,4-c]pyridine-1(3H)-one derivative 3
DMFOBM9	MI	TTV1C0Z
DMFOBM9	MN	Neuropeptide S receptor (NPSR)
DMFOBM9	MT	DTT
DMFOBM9	MA	Antagonist
DMFOBM9	RN	Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362.
DMFOBM9	RU	https://www.ncbi.nlm.nih.gov/pubmed/27788040

DM6MCBU	DI	DM6MCBU
DM6MCBU	DN	4,5,6,7-tetrahydrofuro[3,4-c]pyridine-1(3H)-one derivative 4
DM6MCBU	MI	TTV1C0Z
DM6MCBU	MN	Neuropeptide S receptor (NPSR)
DM6MCBU	MT	DTT
DM6MCBU	MA	Antagonist
DM6MCBU	RN	Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362.
DM6MCBU	RU	https://www.ncbi.nlm.nih.gov/pubmed/27788040

DMMELYI	DI	DMMELYI
DMMELYI	DN	4-amino-3,5-di-substituted-thiazole derivative 1
DMMELYI	MI	TT7HF4W
DMMELYI	MN	Cyclin-dependent kinase 2 (CDK2)
DMMELYI	MT	DTT
DMMELYI	MA	Inhibitor
DMMELYI	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMMELYI	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMEMYDZ	DI	DMEMYDZ
DMEMYDZ	DN	4-aryl quinol derivative 1
DMEMYDZ	MI	TTR7UJ3
DMEMYDZ	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMEMYDZ	MT	DTT
DMEMYDZ	MA	Inhibitor
DMEMYDZ	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMEMYDZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DM7TW5Z	DI	DM7TW5Z
DM7TW5Z	DN	4-aryl quinol derivative 2
DM7TW5Z	MI	TTR7UJ3
DM7TW5Z	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DM7TW5Z	MT	DTT
DM7TW5Z	MA	Inhibitor
DM7TW5Z	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DM7TW5Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DM05V8Q	DI	DM05V8Q
DM05V8Q	DN	4-aryl quinol derivative 3
DM05V8Q	MI	TTR7UJ3
DM05V8Q	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DM05V8Q	MT	DTT
DM05V8Q	MA	Inhibitor
DM05V8Q	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DM05V8Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DM5IWX2	DI	DM5IWX2
DM5IWX2	DN	4-aryl quinol derivative 4
DM5IWX2	MI	TTR7UJ3
DM5IWX2	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DM5IWX2	MT	DTT
DM5IWX2	MA	Inhibitor
DM5IWX2	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DM5IWX2	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DMWB2YX	DI	DMWB2YX
DMWB2YX	DN	4-aryl quinol derivative 5
DMWB2YX	MI	TTR7UJ3
DMWB2YX	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMWB2YX	MT	DTT
DMWB2YX	MA	Inhibitor
DMWB2YX	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMWB2YX	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DMC3KTB	DI	DMC3KTB
DMC3KTB	DN	4-aryl quinol derivative 7
DMC3KTB	MI	TTR7UJ3
DMC3KTB	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMC3KTB	MT	DTT
DMC3KTB	MA	Inhibitor
DMC3KTB	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMC3KTB	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DMZDUNT	DI	DMZDUNT
DMZDUNT	DN	4-benzylidene-1-(cyclobutylo)piperidine derivative 1
DMZDUNT	MI	TT9JNIC
DMZDUNT	MN	Histamine H3 receptor (H3R)
DMZDUNT	MT	DTT
DMZDUNT	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DMZDUNT	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DMM9I1R	DI	DMM9I1R
DMM9I1R	DN	4-Carboxamido-isoindolinone derivative 1
DMM9I1R	MI	TTVDSZ0
DMM9I1R	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMM9I1R	MT	DTT
DMM9I1R	MA	Inhibitor
DMM9I1R	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DMM9I1R	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DM3EHSN	DI	DM3EHSN
DM3EHSN	DN	4-Carboxamido-isoindolinone derivative 2
DM3EHSN	MI	TTVDSZ0
DM3EHSN	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DM3EHSN	MT	DTT
DM3EHSN	MA	Inhibitor
DM3EHSN	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DM3EHSN	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DM43YA0	DI	DM43YA0
DM43YA0	DN	4-Carboxamido-isoindolinone derivative 3
DM43YA0	MI	TTVDSZ0
DM43YA0	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DM43YA0	MT	DTT
DM43YA0	MA	Inhibitor
DM43YA0	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DM43YA0	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DMTGEFW	DI	DMTGEFW
DMTGEFW	DN	4-Carboxamido-isoindolinone derivative 4
DMTGEFW	MI	TTVDSZ0
DMTGEFW	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMTGEFW	MT	DTT
DMTGEFW	MA	Inhibitor
DMTGEFW	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DMTGEFW	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DMIYVOC	DI	DMIYVOC
DMIYVOC	DN	4-Carboxamido-isoindolinone derivative 5
DMIYVOC	MI	TTVDSZ0
DMIYVOC	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMIYVOC	MT	DTT
DMIYVOC	MA	Inhibitor
DMIYVOC	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DMIYVOC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DM9L5KO	DI	DM9L5KO
DM9L5KO	DN	4-Hydroxy-2,5-dimethyl-3(2H)-furanone
DM9L5KO	MI	TTGP7BY
DM9L5KO	MN	Monoamine oxidase type B (MAO-B)
DM9L5KO	MT	DTT
DM9L5KO	MA	Inhibitor
DM9L5KO	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DM9L5KO	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DM471P5	DI	DM471P5
DM471P5	DN	4-hydroxybenzaldehyde
DM471P5	MI	TTT2LD9
DM471P5	MN	GABA transaminase (ABAT)
DM471P5	MT	DTT
DM471P5	MA	Inhibitor
DM471P5	RN	Inactivation of GABA transaminase by 3-chloro-1-(4-hydroxyphenyl)propan-1-one. Bioorg Med Chem Lett. 2009 Feb 1;19(3):731-4.
DM471P5	RU	https://pubmed.ncbi.nlm.nih.gov/19138517

DM471P5	DI	DM471P5
DM471P5	DN	4-hydroxybenzaldehyde
DM471P5	MI	TTGP7BY
DM471P5	MN	Monoamine oxidase type B (MAO-B)
DM471P5	MT	DTT
DM471P5	MA	Inhibitor
DM471P5	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DM471P5	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DM3WQNY	DI	DM3WQNY
DM3WQNY	DN	4-Hydroxybenzoicacid
DM3WQNY	MI	TTGP7BY
DM3WQNY	MN	Monoamine oxidase type B (MAO-B)
DM3WQNY	MT	DTT
DM3WQNY	MA	Inhibitor
DM3WQNY	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DM3WQNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMKDZMQ	DI	DMKDZMQ
DMKDZMQ	DN	4-Hydroxybenzylalcohol
DMKDZMQ	MI	TTGP7BY
DMKDZMQ	MN	Monoamine oxidase type B (MAO-B)
DMKDZMQ	MT	DTT
DMKDZMQ	MA	Inhibitor
DMKDZMQ	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMKDZMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMN6GTZ	DI	DMN6GTZ
DMN6GTZ	DN	4-Methoxybenzaldehyde
DMN6GTZ	MI	TTGP7BY
DMN6GTZ	MN	Monoamine oxidase type B (MAO-B)
DMN6GTZ	MT	DTT
DMN6GTZ	MA	Inhibitor
DMN6GTZ	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMN6GTZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMNTOZV	DI	DMNTOZV
DMNTOZV	DN	4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide derivative 1
DMNTOZV	MI	TT6OEDT
DMNTOZV	MN	Cannabinoid receptor 1 (CB1)
DMNTOZV	MT	DTT
DMNTOZV	MA	Antagonist
DMNTOZV	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMNTOZV	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMWFHKR	DI	DMWFHKR
DMWFHKR	DN	4-oxadiazole derivative 1
DMWFHKR	MI	TTO9X1H
DMWFHKR	MN	5-HT 7 receptor (HTR7)
DMWFHKR	MT	DTT
DMWFHKR	MA	Inhibitor
DMWFHKR	RN	Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
DMWFHKR	RU	https://www.ncbi.nlm.nih.gov/pubmed/25470667

DMN37BI	DI	DMN37BI
DMN37BI	DN	4-PAM derivative 1
DMN37BI	MI	TT1RS9F
DMN37BI	MN	Acetylcholinesterase (AChE)
DMN37BI	MT	DTT
DMN37BI	MA	Reactivator
DMN37BI	RN	Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476.
DMN37BI	RU	https://www.ncbi.nlm.nih.gov/pubmed/27967267

DMMBUGK	DI	DMMBUGK
DMMBUGK	DN	4-pyridone derivative 1
DMMBUGK	MI	TTPLTSQ
DMMBUGK	MN	Neutrophil elastase (NE)
DMMBUGK	MT	DTT
DMMBUGK	MA	Inhibitor
DMMBUGK	RN	Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
DMMBUGK	RU	https://www.ncbi.nlm.nih.gov/pubmed/26118988

DMS1O0G	DI	DMS1O0G
DMS1O0G	DN	4-pyridone derivative 2
DMS1O0G	MI	TTPLTSQ
DMS1O0G	MN	Neutrophil elastase (NE)
DMS1O0G	MT	DTT
DMS1O0G	MA	Inhibitor
DMS1O0G	RN	Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
DMS1O0G	RU	https://www.ncbi.nlm.nih.gov/pubmed/26118988

DMN2B87	DI	DMN2B87
DMN2B87	DN	5-azolone derivative 1
DMN2B87	MI	TTG5QB7
DMN2B87	MN	Calpain-2 (CAPN2)
DMN2B87	MT	DTT
DMN2B87	MA	Inhibitor
DMN2B87	RN	An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31.
DMN2B87	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399719

DMHXKFB	DI	DMHXKFB
DMHXKFB	DN	5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivative 1
DMHXKFB	MI	TT7HF4W
DMHXKFB	MN	Cyclin-dependent kinase 2 (CDK2)
DMHXKFB	MT	DTT
DMHXKFB	MA	Inhibitor
DMHXKFB	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMHXKFB	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMHXKFB	DI	DMHXKFB
DMHXKFB	DN	5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivative 1
DMHXKFB	MI	TT1LVF2
DMHXKFB	MN	Cyclin-dependent kinase 9 (CDK9)
DMHXKFB	MT	DTT
DMHXKFB	MA	Inhibitor
DMHXKFB	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMHXKFB	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMOIKB3	DI	DMOIKB3
DMOIKB3	DN	5-Hydrazino-1H-tetrazole
DMOIKB3	MI	TTLQUZS
DMOIKB3	MN	Cystathionine gamma-lyase (CTH)
DMOIKB3	MT	DTT
DMOIKB3	MA	Inhibitor
DMOIKB3	RN	Cystathionine--lyase (CSE) inhibitors. US9725426.
DMOIKB3	RU	http://www.freepatentsonline.com/US9725426.html

DM0VEBI	DI	DM0VEBI
DM0VEBI	DN	6,6-fused nitrogenous heterocyclic compound 1
DM0VEBI	MI	TT3PJMV
DM0VEBI	MN	Tyrosine-protein kinase ABL1 (ABL)
DM0VEBI	MT	DTT
DM0VEBI	MA	Inhibitor
DM0VEBI	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DM0VEBI	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMB1EAW	DI	DMB1EAW
DMB1EAW	DN	6,6-fused nitrogenous heterocyclic compound 2
DMB1EAW	MI	TT3PJMV
DMB1EAW	MN	Tyrosine-protein kinase ABL1 (ABL)
DMB1EAW	MT	DTT
DMB1EAW	MA	Inhibitor
DMB1EAW	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMB1EAW	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMX3VCO	DI	DMX3VCO
DMX3VCO	DN	6,6-fused nitrogenous heterocyclic compound 3
DMX3VCO	MI	TT3PJMV
DMX3VCO	MN	Tyrosine-protein kinase ABL1 (ABL)
DMX3VCO	MT	DTT
DMX3VCO	MA	Inhibitor
DMX3VCO	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMX3VCO	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMJL1MB	DI	DMJL1MB
DMJL1MB	DN	67S
DMJL1MB	MI	TTECBXN
DMJL1MB	MN	Oxysterols receptor LXR-alpha (NR1H3)
DMJL1MB	MT	DTT
DMJL1MB	MA	Inhibitor
DMJL1MB	RN	Piperazine derivatives as liver X receptor modulators. US10144715.
DMJL1MB	RU	http://www.freepatentsonline.com/US10144715.html

DMTXGYS	DI	DMTXGYS
DMTXGYS	DN	6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analog 1
DMTXGYS	MI	TTHS256
DMTXGYS	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMTXGYS	MT	DTT
DMTXGYS	MA	Modulator
DMTXGYS	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMTXGYS	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMFKTBM	DI	DMFKTBM
DMFKTBM	DN	6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analog 2
DMFKTBM	MI	TTHS256
DMFKTBM	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMFKTBM	MT	DTT
DMFKTBM	MA	Modulator
DMFKTBM	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMFKTBM	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMXMTLP	DI	DMXMTLP
DMXMTLP	DN	6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analog 3
DMXMTLP	MI	TTHS256
DMXMTLP	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMXMTLP	MT	DTT
DMXMTLP	MA	Modulator
DMXMTLP	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMXMTLP	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMN082G	DI	DMN082G
DMN082G	DN	6EP
DMN082G	MI	TTIG67W
DMN082G	MN	Lysine-specific demethylase 5A (KDM5A)
DMN082G	MT	DTT
DMN082G	MA	Inhibitor
DMN082G	RN	Histone demethylase inhibitors. US9714230.
DMN082G	RU	http://www.freepatentsonline.com/US9714230.html

DMV5XR7	DI	DMV5XR7
DMV5XR7	DN	6-Phenylquinazolin-4-amine
DMV5XR7	MI	TT6NI13
DMV5XR7	MN	MEK kinase kinase 4 (MAP4K4)
DMV5XR7	MT	DTT
DMV5XR7	MA	Inhibitor
DMV5XR7	RN	Aminoquinazoline and pyridopyrimidine derivatives. US9592235.
DMV5XR7	RU	http://www.freepatentsonline.com/US9592235.html

DMQL5B7	DI	DMQL5B7
DMQL5B7	DN	7-azaindole derivative 1
DMQL5B7	MI	TT0K6EO
DMQL5B7	MN	Stress-activated protein kinase JNK1 (JNK1)
DMQL5B7	MT	DTT
DMQL5B7	MA	Inhibitor
DMQL5B7	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMQL5B7	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMQL5B7	DI	DMQL5B7
DMQL5B7	DN	7-azaindole derivative 1
DMQL5B7	MI	TTHS0U8
DMQL5B7	MN	Stress-activated protein kinase JNK2 (JNK2)
DMQL5B7	MT	DTT
DMQL5B7	MA	Inhibitor
DMQL5B7	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMQL5B7	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMQL5B7	DI	DMQL5B7
DMQL5B7	DN	7-azaindole derivative 1
DMQL5B7	MI	TT056SO
DMQL5B7	MN	Stress-activated protein kinase JNK3 (JNK3)
DMQL5B7	MT	DTT
DMQL5B7	MA	Inhibitor
DMQL5B7	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMQL5B7	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMZRM2Q	DI	DMZRM2Q
DMZRM2Q	DN	7-azaindole derivative 2
DMZRM2Q	MI	TT0K6EO
DMZRM2Q	MN	Stress-activated protein kinase JNK1 (JNK1)
DMZRM2Q	MT	DTT
DMZRM2Q	MA	Inhibitor
DMZRM2Q	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMZRM2Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMZRM2Q	DI	DMZRM2Q
DMZRM2Q	DN	7-azaindole derivative 2
DMZRM2Q	MI	TTHS0U8
DMZRM2Q	MN	Stress-activated protein kinase JNK2 (JNK2)
DMZRM2Q	MT	DTT
DMZRM2Q	MA	Inhibitor
DMZRM2Q	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMZRM2Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMZRM2Q	DI	DMZRM2Q
DMZRM2Q	DN	7-azaindole derivative 2
DMZRM2Q	MI	TT056SO
DMZRM2Q	MN	Stress-activated protein kinase JNK3 (JNK3)
DMZRM2Q	MT	DTT
DMZRM2Q	MA	Inhibitor
DMZRM2Q	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMZRM2Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMQ7BV4	DI	DMQ7BV4
DMQ7BV4	DN	7-azaindole derivative 3
DMQ7BV4	MI	TT0K6EO
DMQ7BV4	MN	Stress-activated protein kinase JNK1 (JNK1)
DMQ7BV4	MT	DTT
DMQ7BV4	MA	Inhibitor
DMQ7BV4	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMQ7BV4	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMQ7BV4	DI	DMQ7BV4
DMQ7BV4	DN	7-azaindole derivative 3
DMQ7BV4	MI	TTHS0U8
DMQ7BV4	MN	Stress-activated protein kinase JNK2 (JNK2)
DMQ7BV4	MT	DTT
DMQ7BV4	MA	Inhibitor
DMQ7BV4	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMQ7BV4	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMQ7BV4	DI	DMQ7BV4
DMQ7BV4	DN	7-azaindole derivative 3
DMQ7BV4	MI	TT056SO
DMQ7BV4	MN	Stress-activated protein kinase JNK3 (JNK3)
DMQ7BV4	MT	DTT
DMQ7BV4	MA	Inhibitor
DMQ7BV4	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMQ7BV4	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMW3EMH	DI	DMW3EMH
DMW3EMH	DN	7-azaindole derivative 4
DMW3EMH	MI	TT056SO
DMW3EMH	MN	Stress-activated protein kinase JNK3 (JNK3)
DMW3EMH	MT	DTT
DMW3EMH	MA	Inhibitor
DMW3EMH	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMW3EMH	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMV3H98	DI	DMV3H98
DMV3H98	DN	7-azaindole derivative 5
DMV3H98	MI	TT0K6EO
DMV3H98	MN	Stress-activated protein kinase JNK1 (JNK1)
DMV3H98	MT	DTT
DMV3H98	MA	Inhibitor
DMV3H98	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMV3H98	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMV3H98	DI	DMV3H98
DMV3H98	DN	7-azaindole derivative 5
DMV3H98	MI	TTHS0U8
DMV3H98	MN	Stress-activated protein kinase JNK2 (JNK2)
DMV3H98	MT	DTT
DMV3H98	MA	Inhibitor
DMV3H98	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMV3H98	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMV3H98	DI	DMV3H98
DMV3H98	DN	7-azaindole derivative 5
DMV3H98	MI	TT056SO
DMV3H98	MN	Stress-activated protein kinase JNK3 (JNK3)
DMV3H98	MT	DTT
DMV3H98	MA	Inhibitor
DMV3H98	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMV3H98	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DM8X5GP	DI	DM8X5GP
DM8X5GP	DN	7-azaindole derivative 6
DM8X5GP	MI	TT056SO
DM8X5GP	MN	Stress-activated protein kinase JNK3 (JNK3)
DM8X5GP	MT	DTT
DM8X5GP	MA	Inhibitor
DM8X5GP	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DM8X5GP	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMB1WQZ	DI	DMB1WQZ
DMB1WQZ	DN	7-azaindole derivative 7
DMB1WQZ	MI	TT056SO
DMB1WQZ	MN	Stress-activated protein kinase JNK3 (JNK3)
DMB1WQZ	MT	DTT
DMB1WQZ	MA	Inhibitor
DMB1WQZ	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMB1WQZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMO1920	DI	DMO1920
DMO1920	DN	7-azaindole derivative 8
DMO1920	MI	TTVDSZ0
DMO1920	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMO1920	MT	DTT
DMO1920	MA	Inhibitor
DMO1920	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DMO1920	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DMAY4G1	DI	DMAY4G1
DMAY4G1	DN	7-azaindole derivative 9
DMAY4G1	MI	TTEBCY8
DMAY4G1	MN	Poly [ADP-ribose] polymerase (PARP)
DMAY4G1	MT	DTT
DMAY4G1	MA	Inhibitor
DMAY4G1	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DMAY4G1	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DMP04Z6	DI	DMP04Z6
DMP04Z6	DN	879325-11-8
DMP04Z6	MI	TTOJ9QL
DMP04Z6	MN	Endoplasmic reticulum to nucleus signaling 1 (ERN1)
DMP04Z6	MT	DTT
DMP04Z6	MA	Inhibitor
DMP04Z6	RN	IRE-1 inhibitors. US9040714.
DMP04Z6	RU	http://www.freepatentsonline.com/US9040714.html

DMPQ2L9	DI	DMPQ2L9
DMPQ2L9	DN	936563-93-8
DMPQ2L9	MI	TTX6F0Q
DMPQ2L9	MN	Tyrosine-protein kinase CSK (CSK)
DMPQ2L9	MT	DTT
DMPQ2L9	MA	Inhibitor
DMPQ2L9	RN	Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors. US9278100.
DMPQ2L9	RU	http://www.freepatentsonline.com/US9278100.html

DM9ESPR	DI	DM9ESPR
DM9ESPR	DN	A1-10436
DM9ESPR	MI	TT0C8BY
DM9ESPR	MN	Plasma retinol-binding protein (RBP4)
DM9ESPR	MT	DTT
DM9ESPR	MA	Inhibitor
DM9ESPR	RN	Derivatives of N-acyl-N-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes. US8853215.
DM9ESPR	RU	http://www.freepatentsonline.com/US8853215.html

DMJD1S6	DI	DMJD1S6
DMJD1S6	DN	A1-10438
DMJD1S6	MI	TT0C8BY
DMJD1S6	MN	Plasma retinol-binding protein (RBP4)
DMJD1S6	MT	DTT
DMJD1S6	MA	Inhibitor
DMJD1S6	RN	Derivatives of N-acyl-N-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes. US8853215.
DMJD1S6	RU	http://www.freepatentsonline.com/US8853215.html

DMFWYKE	DI	DMFWYKE
DMFWYKE	DN	AC1LCOK0
DMFWYKE	MI	TT3RMNA
DMFWYKE	MN	Chymotrypsin-C (CLCR)
DMFWYKE	MT	DTT
DMFWYKE	MA	Inhibitor
DMFWYKE	RN	Benzoxazinone derivatives for treatment of skin diseases. US9695194.
DMFWYKE	RU	http://www.freepatentsonline.com/US9695194.html

DMKTMCH	DI	DMKTMCH
DMKTMCH	DN	AC1LDDOQ
DMKTMCH	MI	TT3ZS42
DMKTMCH	MN	Phosphodiesterase 1B (PDE1B)
DMKTMCH	MT	DTT
DMKTMCH	MA	Inhibitor
DMKTMCH	RN	Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds. US10092575.
DMKTMCH	RU	http://www.freepatentsonline.com/US10092575.html

DMPOR3G	DI	DMPOR3G
DMPOR3G	DN	AC1LE05K
DMPOR3G	MI	TTOJ9QL
DMPOR3G	MN	Endoplasmic reticulum to nucleus signaling 1 (ERN1)
DMPOR3G	MT	DTT
DMPOR3G	MA	Inhibitor
DMPOR3G	RN	IRE-1 inhibitors. US9693992.
DMPOR3G	RU	http://www.freepatentsonline.com/US9693992.html

DMXI3O0	DI	DMXI3O0
DMXI3O0	DN	AC1LFGWU
DMXI3O0	MI	TTLKF5M
DMXI3O0	MN	NAD-dependent deacetylase sirtuin-2 (SIRT2)
DMXI3O0	MT	DTT
DMXI3O0	MA	Inhibitor
DMXI3O0	RN	Small molecule activators of NRF2 pathway. US9737525.
DMXI3O0	RU	http://www.freepatentsonline.com/US9737525.html

DMEVBZW	DI	DMEVBZW
DMEVBZW	DN	AC1LFXA6
DMEVBZW	MI	TT25MVL
DMEVBZW	MN	Serine protease hepsin (HPN)
DMEVBZW	MT	DTT
DMEVBZW	MA	Inhibitor
DMEVBZW	RN	Hepsin inhibitors. US9182402.
DMEVBZW	RU	http://www.freepatentsonline.com/US9182402.html

DM9Q0EC	DI	DM9Q0EC
DM9Q0EC	DN	AC1LJNG0
DM9Q0EC	MI	TT1NFO3
DM9Q0EC	MN	Bacterial Nicotinate-nucleotide adenylyltransferase (Bact nadD)
DM9Q0EC	MT	DTT
DM9Q0EC	MA	Inhibitor
DM9Q0EC	RN	Targeting NAD biosynthesis in bacterial pathogens. US8785499.
DM9Q0EC	RU	http://www.freepatentsonline.com/US8785499.html

DMVX9NK	DI	DMVX9NK
DMVX9NK	DN	AC1LOJYQ
DMVX9NK	MI	TTLKF5M
DMVX9NK	MN	NAD-dependent deacetylase sirtuin-2 (SIRT2)
DMVX9NK	MT	DTT
DMVX9NK	MA	Inhibitor
DMVX9NK	RN	Small molecule activators of NRF2 pathway. US9737525.
DMVX9NK	RU	http://www.freepatentsonline.com/US9737525.html

DMEW5LD	DI	DMEW5LD
DMEW5LD	DN	AC1M1SP5
DMEW5LD	MI	TTIS4OW
DMEW5LD	MN	Phosphodiesterase 8 (PDE8)
DMEW5LD	MT	DTT
DMEW5LD	MA	Inhibitor
DMEW5LD	RN	Inhibitors of phosphodiesterase 11 (PDE11). US9173884.
DMEW5LD	RU	http://www.freepatentsonline.com/US9173884.html

DM6293C	DI	DM6293C
DM6293C	DN	AC1MOZOL
DM6293C	MI	TT3ZS42
DM6293C	MN	Phosphodiesterase 1B (PDE1B)
DM6293C	MT	DTT
DM6293C	MA	Inhibitor
DM6293C	RN	Inhibitors of phosphodiesterase 11 (PDE11). US9173884.
DM6293C	RU	http://www.freepatentsonline.com/US9173884.html

DMO4YAB	DI	DMO4YAB
DMO4YAB	DN	Acrylamide compound 1
DMO4YAB	MI	TT9JNIC
DMO4YAB	MN	Histamine H3 receptor (H3R)
DMO4YAB	MT	DTT
DMO4YAB	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DMO4YAB	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DM7EOG4	DI	DM7EOG4
DM7EOG4	DN	Acrylamide compound 2
DM7EOG4	MI	TT9JNIC
DM7EOG4	MN	Histamine H3 receptor (H3R)
DM7EOG4	MT	DTT
DM7EOG4	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DM7EOG4	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DM7JARB	DI	DM7JARB
DM7JARB	DN	Acrylamide compound 3
DM7JARB	MI	TT9JNIC
DM7JARB	MN	Histamine H3 receptor (H3R)
DM7JARB	MT	DTT
DM7JARB	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DM7JARB	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DMZL6D8	DI	DMZL6D8
DMZL6D8	DN	Acrylamide compound 4
DMZL6D8	MI	TT9JNIC
DMZL6D8	MN	Histamine H3 receptor (H3R)
DMZL6D8	MT	DTT
DMZL6D8	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DMZL6D8	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DMXTUE1	DI	DMXTUE1
DMXTUE1	DN	Acyl oxymethyl acrylamide ester derivative 1
DMXTUE1	MI	TTR7UJ3
DMXTUE1	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMXTUE1	MT	DTT
DMXTUE1	MA	Inhibitor
DMXTUE1	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMXTUE1	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DMXTUE1	DI	DMXTUE1
DMXTUE1	DN	Acyl oxymethyl acrylamide ester derivative 1
DMXTUE1	MI	TTEP6RV
DMXTUE1	MN	Glutathione reductase (GR)
DMXTUE1	MT	DTT
DMXTUE1	MA	Inhibitor
DMXTUE1	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMXTUE1	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DMU8OIL	DI	DMU8OIL
DMU8OIL	DN	Acyl oxymethyl acrylamide ester derivative 2
DMU8OIL	MI	TTR7UJ3
DMU8OIL	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMU8OIL	MT	DTT
DMU8OIL	MA	Inhibitor
DMU8OIL	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMU8OIL	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DMX9J1C	DI	DMX9J1C
DMX9J1C	DN	Acyl piperidine derivative 1
DMX9J1C	MI	TTZJYKH
DMX9J1C	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMX9J1C	MT	DTT
DMX9J1C	MA	Inhibitor
DMX9J1C	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMX9J1C	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DM2FUIB	DI	DM2FUIB
DM2FUIB	DN	Acyl piperidine derivative 2
DM2FUIB	MI	TT2F4OL
DM2FUIB	MN	Tissue transglutaminase (TG2)
DM2FUIB	MT	DTT
DM2FUIB	MA	Inhibitor
DM2FUIB	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DM2FUIB	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DMIDUB4	DI	DMIDUB4
DMIDUB4	DN	Acyl piperidine derivative 3
DMIDUB4	MI	TT2F4OL
DMIDUB4	MN	Tissue transglutaminase (TG2)
DMIDUB4	MT	DTT
DMIDUB4	MA	Inhibitor
DMIDUB4	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DMIDUB4	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DMA1RVN	DI	DMA1RVN
DMA1RVN	DN	Ac-YVAD-cmk
DMA1RVN	MI	TTCQIBE
DMA1RVN	MN	Caspase-1 (CASP1)
DMA1RVN	MT	DTT
DMA1RVN	MA	Inhibitor
DMA1RVN	RN	Caspase inhibitors: a review of recently patented compounds (2013-2015).Expert Opin Ther Pat. 2018 Jan;28(1):47-59.
DMA1RVN	RU	https://www.ncbi.nlm.nih.gov/pubmed/28885866

DM7K256	DI	DM7K256
DM7K256	DN	Ac-YVAD-FMK
DM7K256	MI	TTCQIBE
DM7K256	MN	Caspase-1 (CASP1)
DM7K256	MT	DTT
DM7K256	MA	Inhibitor
DM7K256	RN	Caspase inhibitors: a review of recently patented compounds (2013-2015).Expert Opin Ther Pat. 2018 Jan;28(1):47-59.
DM7K256	RU	https://www.ncbi.nlm.nih.gov/pubmed/28885866

DMD94MP	DI	DMD94MP
DMD94MP	DN	Adamantyl derivative 1
DMD94MP	MI	TTMSFAW
DMD94MP	MN	Cannabinoid receptor 2 (CB2)
DMD94MP	MT	DTT
DMD94MP	MA	Agonist
DMD94MP	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DMD94MP	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DM2L83Y	DI	DM2L83Y
DM2L83Y	DN	AGGGWZCOULSEER-PYUWXLGESA-N
DM2L83Y	MI	TT5U49F
DM2L83Y	MN	PRKACA messenger RNA (PRKACA mRNA)
DM2L83Y	MT	DTT
DM2L83Y	MA	Inhibitor
DM2L83Y	RN	Purine derivatives. US8846696.
DM2L83Y	RU	http://www.freepatentsonline.com/US8846696.html

DM0P2U3	DI	DM0P2U3
DM0P2U3	DN	AKOS003197197
DM0P2U3	MI	TTLQUZS
DM0P2U3	MN	Cystathionine gamma-lyase (CTH)
DM0P2U3	MT	DTT
DM0P2U3	MA	Inhibitor
DM0P2U3	RN	Cystathionine--lyase (CSE) inhibitors. US9725426.
DM0P2U3	RU	http://www.freepatentsonline.com/US9725426.html

DMWHN1O	DI	DMWHN1O
DMWHN1O	DN	AKOS020330481
DMWHN1O	MI	TTIG67W
DMWHN1O	MN	Lysine-specific demethylase 5A (KDM5A)
DMWHN1O	MT	DTT
DMWHN1O	MA	Inhibitor
DMWHN1O	RN	Histone demethylase inhibitors. US9611221.
DMWHN1O	RU	http://www.freepatentsonline.com/US9611221.html

DMNIE4M	DI	DMNIE4M
DMNIE4M	DN	AKOS020330656
DMNIE4M	MI	TTIG67W
DMNIE4M	MN	Lysine-specific demethylase 5A (KDM5A)
DMNIE4M	MT	DTT
DMNIE4M	MA	Inhibitor
DMNIE4M	RN	Histone demethylase inhibitors. US10179769.
DMNIE4M	RU	http://www.freepatentsonline.com/US10179769.html

DMPXAGD	DI	DMPXAGD
DMPXAGD	DN	Alkaloid derivative 4
DMPXAGD	MI	TTUX68I
DMPXAGD	MN	Hypoxia-inducible factor 1 (HIF-1)
DMPXAGD	MT	DTT
DMPXAGD	MA	Inhibitor
DMPXAGD	RN	Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22.
DMPXAGD	RU	https://www.ncbi.nlm.nih.gov/pubmed/26882240

DMW57UB	DI	DMW57UB
DMW57UB	DN	Alkyl mannoside derivative 1
DMW57UB	MI	TTTCRU2
DMW57UB	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMW57UB	MT	DTT
DMW57UB	MA	Antagonist
DMW57UB	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMW57UB	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMHD51F	DI	DMHD51F
DMHD51F	DN	Alkyl mannoside derivative 10
DMHD51F	MI	TTTCRU2
DMHD51F	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMHD51F	MT	DTT
DMHD51F	MA	Antagonist
DMHD51F	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMHD51F	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMMNZ2U	DI	DMMNZ2U
DMMNZ2U	DN	Alkyl mannoside derivative 11
DMMNZ2U	MI	TTTCRU2
DMMNZ2U	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMMNZ2U	MT	DTT
DMMNZ2U	MA	Antagonist
DMMNZ2U	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMMNZ2U	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMX1OZF	DI	DMX1OZF
DMX1OZF	DN	Alkyl mannoside derivative 12
DMX1OZF	MI	TTTCRU2
DMX1OZF	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMX1OZF	MT	DTT
DMX1OZF	MA	Antagonist
DMX1OZF	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMX1OZF	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMNQUKP	DI	DMNQUKP
DMNQUKP	DN	Alkyl mannoside derivative 2
DMNQUKP	MI	TTTCRU2
DMNQUKP	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMNQUKP	MT	DTT
DMNQUKP	MA	Antagonist
DMNQUKP	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMNQUKP	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DML2B58	DI	DML2B58
DML2B58	DN	Alkyl mannoside derivative 3
DML2B58	MI	TTTCRU2
DML2B58	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DML2B58	MT	DTT
DML2B58	MA	Antagonist
DML2B58	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DML2B58	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMZR71O	DI	DMZR71O
DMZR71O	DN	Alkyl mannoside derivative 4
DMZR71O	MI	TTTCRU2
DMZR71O	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMZR71O	MT	DTT
DMZR71O	MA	Antagonist
DMZR71O	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMZR71O	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM04ZJ2	DI	DM04ZJ2
DM04ZJ2	DN	Alkyl mannoside derivative 5
DM04ZJ2	MI	TTTCRU2
DM04ZJ2	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM04ZJ2	MT	DTT
DM04ZJ2	MA	Antagonist
DM04ZJ2	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM04ZJ2	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMCIV32	DI	DMCIV32
DMCIV32	DN	Alkyl mannoside derivative 6
DMCIV32	MI	TTTCRU2
DMCIV32	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMCIV32	MT	DTT
DMCIV32	MA	Antagonist
DMCIV32	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMCIV32	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMBLSH1	DI	DMBLSH1
DMBLSH1	DN	Alkyl mannoside derivative 7
DMBLSH1	MI	TTTCRU2
DMBLSH1	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMBLSH1	MT	DTT
DMBLSH1	MA	Antagonist
DMBLSH1	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMBLSH1	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMZP1JT	DI	DMZP1JT
DMZP1JT	DN	Alkyl mannoside derivative 8
DMZP1JT	MI	TTTCRU2
DMZP1JT	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMZP1JT	MT	DTT
DMZP1JT	MA	Antagonist
DMZP1JT	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMZP1JT	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMV1QUX	DI	DMV1QUX
DMV1QUX	DN	Alkyl mannoside derivative 9
DMV1QUX	MI	TTTCRU2
DMV1QUX	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMV1QUX	MT	DTT
DMV1QUX	MA	Antagonist
DMV1QUX	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMV1QUX	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM06U3J	DI	DM06U3J
DM06U3J	DN	Alkyl sulfone derivative 1
DM06U3J	MI	TT7HF4W
DM06U3J	MN	Cyclin-dependent kinase 2 (CDK2)
DM06U3J	MT	DTT
DM06U3J	MA	Inhibitor
DM06U3J	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DM06U3J	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DM06U3J	DI	DM06U3J
DM06U3J	DN	Alkyl sulfone derivative 1
DM06U3J	MI	TT1LVF2
DM06U3J	MN	Cyclin-dependent kinase 9 (CDK9)
DM06U3J	MT	DTT
DM06U3J	MA	Inhibitor
DM06U3J	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DM06U3J	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMEZDQ4	DI	DMEZDQ4
DMEZDQ4	DN	Alkynyl-heteroaromatic ring compound 1
DMEZDQ4	MI	TTIV39N
DMEZDQ4	MN	Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I)
DMEZDQ4	MT	DTT
DMEZDQ4	MA	Inhibitor
DMEZDQ4	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMEZDQ4	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMK7DJ2	DI	DMK7DJ2
DMK7DJ2	DN	Alkynyl-substituted pyrimidinyl-pyrrole derivative 1
DMK7DJ2	MI	TTRMX3V
DMK7DJ2	MN	Janus kinase 2 (JAK-2)
DMK7DJ2	MT	DTT
DMK7DJ2	MA	Inhibitor
DMK7DJ2	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMK7DJ2	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMK7DJ2	DI	DMK7DJ2
DMK7DJ2	DN	Alkynyl-substituted pyrimidinyl-pyrrole derivative 1
DMK7DJ2	MI	TT1RWNJ
DMK7DJ2	MN	Tyrosine-protein kinase Lyn (JTK8)
DMK7DJ2	MT	DTT
DMK7DJ2	MA	Inhibitor
DMK7DJ2	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMK7DJ2	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMWX0QK	DI	DMWX0QK
DMWX0QK	DN	Alpha-substituted pirinixic acid and pirinixic acid ester derivative 1
DMWX0QK	MI	TTYLQ8V
DMWX0QK	MN	Prostaglandin E synthase (PTGES)
DMWX0QK	MT	DTT
DMWX0QK	MA	Inhibitor
DMWX0QK	RN	Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059.
DMWX0QK	RU	https://www.ncbi.nlm.nih.gov/pubmed/28627961

DMO64LA	DI	DMO64LA
DMO64LA	DN	Amide derivative 1
DMO64LA	MI	TT6OEDT
DMO64LA	MN	Cannabinoid receptor 1 (CB1)
DMO64LA	MT	DTT
DMO64LA	MA	Antagonist
DMO64LA	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMO64LA	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMBKIR0	DI	DMBKIR0
DMBKIR0	DN	Amide derivative 2
DMBKIR0	MI	TTZJYKH
DMBKIR0	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMBKIR0	MT	DTT
DMBKIR0	MA	Inhibitor
DMBKIR0	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMBKIR0	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DM1FUOY	DI	DM1FUOY
DM1FUOY	DN	amidepsines
DM1FUOY	MI	TTF8P9I
DM1FUOY	MN	Diacylglycerol acyltransferase 1 (DGAT1)
DM1FUOY	MT	DTT
DM1FUOY	MA	Inhibitor
DM1FUOY	RN	Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
DM1FUOY	RU	https://www.ncbi.nlm.nih.gov/pubmed/25470667

DMUPT9A	DI	DMUPT9A
DMUPT9A	DN	Amidine compound 1
DMUPT9A	MI	TTQR74A
DMUPT9A	MN	Proteinase activated receptor 2 (PAR2)
DMUPT9A	MT	DTT
DMUPT9A	MA	Antagonist
DMUPT9A	RN	Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
DMUPT9A	RU	https://www.ncbi.nlm.nih.gov/pubmed/26936077

DM2UWSX	DI	DM2UWSX
DM2UWSX	DN	Amidine compound 2
DM2UWSX	MI	TTQR74A
DM2UWSX	MN	Proteinase activated receptor 2 (PAR2)
DM2UWSX	MT	DTT
DM2UWSX	MA	Antagonist
DM2UWSX	RN	Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
DM2UWSX	RU	https://www.ncbi.nlm.nih.gov/pubmed/26936077

DMV0QJ4	DI	DMV0QJ4
DMV0QJ4	DN	Amidine compound 3
DMV0QJ4	MI	TTQR74A
DMV0QJ4	MN	Proteinase activated receptor 2 (PAR2)
DMV0QJ4	MT	DTT
DMV0QJ4	MA	Antagonist
DMV0QJ4	RN	Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
DMV0QJ4	RU	https://www.ncbi.nlm.nih.gov/pubmed/26936077

DM9EGVN	DI	DM9EGVN
DM9EGVN	DN	Amidine compound 4
DM9EGVN	MI	TTQR74A
DM9EGVN	MN	Proteinase activated receptor 2 (PAR2)
DM9EGVN	MT	DTT
DM9EGVN	MA	Antagonist
DM9EGVN	RN	Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
DM9EGVN	RU	https://www.ncbi.nlm.nih.gov/pubmed/26936077

DMMN8OY	DI	DMMN8OY
DMMN8OY	DN	Amidine compound 5
DMMN8OY	MI	TTQR74A
DMMN8OY	MN	Proteinase activated receptor 2 (PAR2)
DMMN8OY	MT	DTT
DMMN8OY	MA	Antagonist
DMMN8OY	RN	Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
DMMN8OY	RU	https://www.ncbi.nlm.nih.gov/pubmed/26936077

DMFNK0L	DI	DMFNK0L
DMFNK0L	DN	Amidine compound 6
DMFNK0L	MI	TTQR74A
DMFNK0L	MN	Proteinase activated receptor 2 (PAR2)
DMFNK0L	MT	DTT
DMFNK0L	MA	Antagonist
DMFNK0L	RN	Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
DMFNK0L	RU	https://www.ncbi.nlm.nih.gov/pubmed/26936077

DM8STUQ	DI	DM8STUQ
DM8STUQ	DN	Amidine oxime derivative 1
DM8STUQ	MI	TT1RS9F
DM8STUQ	MN	Acetylcholinesterase (AChE)
DM8STUQ	MT	DTT
DM8STUQ	MA	Reactivator
DM8STUQ	RN	Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476.
DM8STUQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27967267

DM5X92S	DI	DM5X92S
DM5X92S	DN	Amidopyrazole derivative 1
DM5X92S	MI	TTKFVXR
DM5X92S	MN	Renal carcinoma antigen NY-REN-64 (IRAK-4)
DM5X92S	MT	DTT
DM5X92S	MA	Inhibitor
DM5X92S	RN	Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32.
DM5X92S	RU	https://www.ncbi.nlm.nih.gov/pubmed/27310003

DMGO9WY	DI	DMGO9WY
DMGO9WY	DN	Amidopyrazole derivative 2
DMGO9WY	MI	TTKFVXR
DMGO9WY	MN	Renal carcinoma antigen NY-REN-64 (IRAK-4)
DMGO9WY	MT	DTT
DMGO9WY	MA	Inhibitor
DMGO9WY	RN	Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32.
DMGO9WY	RU	https://www.ncbi.nlm.nih.gov/pubmed/27310003

DMTHS3L	DI	DMTHS3L
DMTHS3L	DN	Amidopyrazole derivative 3
DMTHS3L	MI	TTKFVXR
DMTHS3L	MN	Renal carcinoma antigen NY-REN-64 (IRAK-4)
DMTHS3L	MT	DTT
DMTHS3L	MA	Inhibitor
DMTHS3L	RN	Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32.
DMTHS3L	RU	https://www.ncbi.nlm.nih.gov/pubmed/27310003

DMF6N7Z	DI	DMF6N7Z
DMF6N7Z	DN	Amidopyrazole derivative 4
DMF6N7Z	MI	TTKFVXR
DMF6N7Z	MN	Renal carcinoma antigen NY-REN-64 (IRAK-4)
DMF6N7Z	MT	DTT
DMF6N7Z	MA	Inhibitor
DMF6N7Z	RN	Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32.
DMF6N7Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/27310003

DMJ37V2	DI	DMJ37V2
DMJ37V2	DN	Amidopyrazole derivative 5
DMJ37V2	MI	TTKFVXR
DMJ37V2	MN	Renal carcinoma antigen NY-REN-64 (IRAK-4)
DMJ37V2	MT	DTT
DMJ37V2	MA	Inhibitor
DMJ37V2	RN	Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32.
DMJ37V2	RU	https://www.ncbi.nlm.nih.gov/pubmed/27310003

DMJZ1IG	DI	DMJZ1IG
DMJZ1IG	DN	Amidopyrazole derivative 6
DMJZ1IG	MI	TTKFVXR
DMJZ1IG	MN	Renal carcinoma antigen NY-REN-64 (IRAK-4)
DMJZ1IG	MT	DTT
DMJZ1IG	MA	Inhibitor
DMJZ1IG	RN	Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32.
DMJZ1IG	RU	https://www.ncbi.nlm.nih.gov/pubmed/27310003

DMQVZY5	DI	DMQVZY5
DMQVZY5	DN	Aminoarylpyridine derivative 1
DMQVZY5	MI	TT1LVF2
DMQVZY5	MN	Cyclin-dependent kinase 9 (CDK9)
DMQVZY5	MT	DTT
DMQVZY5	MA	Inhibitor
DMQVZY5	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMQVZY5	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMNI0M1	DI	DMNI0M1
DMNI0M1	DN	Aminoazetidine derivative 1
DMNI0M1	MI	TT6OEDT
DMNI0M1	MN	Cannabinoid receptor 1 (CB1)
DMNI0M1	MT	DTT
DMNI0M1	MA	Antagonist
DMNI0M1	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMNI0M1	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMHSNA5	DI	DMHSNA5
DMHSNA5	DN	Aminoazetidine derivative 2
DMHSNA5	MI	TT6OEDT
DMHSNA5	MN	Cannabinoid receptor 1 (CB1)
DMHSNA5	MT	DTT
DMHSNA5	MA	Antagonist
DMHSNA5	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMHSNA5	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMOQHA9	DI	DMOQHA9
DMOQHA9	DN	Aminoazetidine derivative 3
DMOQHA9	MI	TT6OEDT
DMOQHA9	MN	Cannabinoid receptor 1 (CB1)
DMOQHA9	MT	DTT
DMOQHA9	MA	Antagonist
DMOQHA9	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMOQHA9	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DM50E4Y	DI	DM50E4Y
DM50E4Y	DN	Aminoazetidine derivative 4
DM50E4Y	MI	TT6OEDT
DM50E4Y	MN	Cannabinoid receptor 1 (CB1)
DM50E4Y	MT	DTT
DM50E4Y	MA	Antagonist
DM50E4Y	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DM50E4Y	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMYPD4Z	DI	DMYPD4Z
DMYPD4Z	DN	Aminoazetidine derivative 5
DMYPD4Z	MI	TT6OEDT
DMYPD4Z	MN	Cannabinoid receptor 1 (CB1)
DMYPD4Z	MT	DTT
DMYPD4Z	MA	Antagonist
DMYPD4Z	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMYPD4Z	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DM3LNQG	DI	DM3LNQG
DM3LNQG	DN	Aminoazetidine derivative 7
DM3LNQG	MI	TT6OEDT
DM3LNQG	MN	Cannabinoid receptor 1 (CB1)
DM3LNQG	MT	DTT
DM3LNQG	MA	Antagonist
DM3LNQG	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DM3LNQG	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMLOIHD	DI	DMLOIHD
DMLOIHD	DN	Aminoazetidine derivative 8
DMLOIHD	MI	TT6OEDT
DMLOIHD	MN	Cannabinoid receptor 1 (CB1)
DMLOIHD	MT	DTT
DMLOIHD	MA	Antagonist
DMLOIHD	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMLOIHD	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMUASHT	DI	DMUASHT
DMUASHT	DN	Aminoazetidine derivative 9
DMUASHT	MI	TT6OEDT
DMUASHT	MN	Cannabinoid receptor 1 (CB1)
DMUASHT	MT	DTT
DMUASHT	MA	Antagonist
DMUASHT	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMUASHT	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DM1RQIU	DI	DM1RQIU
DM1RQIU	DN	Aminobenzoxazole analog 1
DM1RQIU	MI	TT473XN
DM1RQIU	MN	P2X purinoceptor 7 (P2RX7)
DM1RQIU	MT	DTT
DM1RQIU	MA	Antagonist
DM1RQIU	RN	P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267.
DM1RQIU	RU	https://www.ncbi.nlm.nih.gov/pubmed/27724045

DMYHRJD	DI	DMYHRJD
DMYHRJD	DN	Aminocyclopentenone compound 1
DMYHRJD	MI	TTRA6BO
DMYHRJD	MN	Bromodomain-containing protein 4 (BRD4)
DMYHRJD	MT	DTT
DMYHRJD	MA	Inhibitor
DMYHRJD	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMYHRJD	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMAYHNI	DI	DMAYHNI
DMAYHNI	DN	Aminocyclopentenone compound 2
DMAYHNI	MI	TTRA6BO
DMAYHNI	MN	Bromodomain-containing protein 4 (BRD4)
DMAYHNI	MT	DTT
DMAYHNI	MA	Inhibitor
DMAYHNI	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMAYHNI	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMFXK03	DI	DMFXK03
DMFXK03	DN	Aminocyclopentenone compound 3
DMFXK03	MI	TTRA6BO
DMFXK03	MN	Bromodomain-containing protein 4 (BRD4)
DMFXK03	MT	DTT
DMFXK03	MA	Inhibitor
DMFXK03	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMFXK03	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DM745TN	DI	DM745TN
DM745TN	DN	Aminocyclopentenone compound 4
DM745TN	MI	TTRA6BO
DM745TN	MN	Bromodomain-containing protein 4 (BRD4)
DM745TN	MT	DTT
DM745TN	MA	Inhibitor
DM745TN	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DM745TN	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMPW9ES	DI	DMPW9ES
DMPW9ES	DN	Aminocyclopentenone compound 5
DMPW9ES	MI	TTRA6BO
DMPW9ES	MN	Bromodomain-containing protein 4 (BRD4)
DMPW9ES	MT	DTT
DMPW9ES	MA	Inhibitor
DMPW9ES	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMPW9ES	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DM0NJFZ	DI	DM0NJFZ
DM0NJFZ	DN	Aminocyclopentenone compound 6
DM0NJFZ	MI	TTRA6BO
DM0NJFZ	MN	Bromodomain-containing protein 4 (BRD4)
DM0NJFZ	MT	DTT
DM0NJFZ	MA	Inhibitor
DM0NJFZ	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DM0NJFZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMDHGPN	DI	DMDHGPN
DMDHGPN	DN	Aminooxazole carboxamide derivative 1
DMDHGPN	MI	TT6DM01
DMDHGPN	MN	Janus kinase 1 (JAK-1)
DMDHGPN	MT	DTT
DMDHGPN	MA	Inhibitor
DMDHGPN	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMDHGPN	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMDHGPN	DI	DMDHGPN
DMDHGPN	DN	Aminooxazole carboxamide derivative 1
DMDHGPN	MI	TTRMX3V
DMDHGPN	MN	Janus kinase 2 (JAK-2)
DMDHGPN	MT	DTT
DMDHGPN	MA	Inhibitor
DMDHGPN	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMDHGPN	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMDHGPN	DI	DMDHGPN
DMDHGPN	DN	Aminooxazole carboxamide derivative 1
DMDHGPN	MI	TTT7PJU
DMDHGPN	MN	Janus kinase 3 (JAK-3)
DMDHGPN	MT	DTT
DMDHGPN	MA	Inhibitor
DMDHGPN	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMDHGPN	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMDHGPN	DI	DMDHGPN
DMDHGPN	DN	Aminooxazole carboxamide derivative 1
DMDHGPN	MI	TTBYWP2
DMDHGPN	MN	TYK2 tyrosine kinase (TYK2)
DMDHGPN	MT	DTT
DMDHGPN	MA	Inhibitor
DMDHGPN	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMDHGPN	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMFKTJL	DI	DMFKTJL
DMFKTJL	DN	Aminopiperidine derivative 1
DMFKTJL	MI	TTDIGC1
DMFKTJL	MN	Dipeptidyl peptidase 4 (DPP-4)
DMFKTJL	MT	DTT
DMFKTJL	MA	Inhibitor
DMFKTJL	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMFKTJL	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DM4JDHO	DI	DM4JDHO
DM4JDHO	DN	Aminopiperidine derivative 2
DM4JDHO	MI	TTDIGC1
DM4JDHO	MN	Dipeptidyl peptidase 4 (DPP-4)
DM4JDHO	MT	DTT
DM4JDHO	MA	Inhibitor
DM4JDHO	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DM4JDHO	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DMYE1A7	DI	DMYE1A7
DMYE1A7	DN	Aminopyridine derivative 1
DMYE1A7	MI	TTBYWP2
DMYE1A7	MN	TYK2 tyrosine kinase (TYK2)
DMYE1A7	MT	DTT
DMYE1A7	MA	Inhibitor
DMYE1A7	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMYE1A7	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMUGZNL	DI	DMUGZNL
DMUGZNL	DN	Aminopyridine derivative 2
DMUGZNL	MI	TTK0FEA
DMUGZNL	MN	Leucine-rich repeat kinase 2 (LRRK2)
DMUGZNL	MT	DTT
DMUGZNL	MA	Inhibitor
DMUGZNL	RN	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
DMUGZNL	RU	https://www.ncbi.nlm.nih.gov/pubmed/28117607

DMSLJE8	DI	DMSLJE8
DMSLJE8	DN	Aminopyridine derivative 3
DMSLJE8	MI	TTK0FEA
DMSLJE8	MN	Leucine-rich repeat kinase 2 (LRRK2)
DMSLJE8	MT	DTT
DMSLJE8	MA	Inhibitor
DMSLJE8	RN	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
DMSLJE8	RU	https://www.ncbi.nlm.nih.gov/pubmed/28117607

DMSLJE8	DI	DMSLJE8
DMSLJE8	DN	Aminopyridine derivative 3
DMSLJE8	MI	TT6AXLY
DMSLJE8	MN	Leucine-rich repeat kinase 2 G2019S mutant (LRRK2 G2019S)
DMSLJE8	MT	DTT
DMSLJE8	MA	Inhibitor
DMSLJE8	RN	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
DMSLJE8	RU	https://www.ncbi.nlm.nih.gov/pubmed/28117607

DMK1UJV	DI	DMK1UJV
DMK1UJV	DN	Aminopyrimidine derivative 1
DMK1UJV	MI	TTS7G69
DMK1UJV	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMK1UJV	MT	DTT
DMK1UJV	MA	Inhibitor
DMK1UJV	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMK1UJV	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DM2TF64	DI	DM2TF64
DM2TF64	DN	Aminopyrimidine derivative 10
DM2TF64	MI	TTH5TC2
DM2TF64	MN	NF-kappa-B-activating kinase (TBK1)
DM2TF64	MT	DTT
DM2TF64	MA	Inhibitor
DM2TF64	RN	TBK1 inhibitors: a review of patent literature (2011 - 2014).Expert Opin Ther Pat. 2015;25(12):1385-96.
DM2TF64	RU	https://www.ncbi.nlm.nih.gov/pubmed/26293650

DMKNITP	DI	DMKNITP
DMKNITP	DN	Aminopyrimidine derivative 2
DMKNITP	MI	TTS7G69
DMKNITP	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMKNITP	MT	DTT
DMKNITP	MA	Inhibitor
DMKNITP	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMKNITP	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMDP4GY	DI	DMDP4GY
DMDP4GY	DN	Aminopyrimidine derivative 3
DMDP4GY	MI	TTS7G69
DMDP4GY	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMDP4GY	MT	DTT
DMDP4GY	MA	Inhibitor
DMDP4GY	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMDP4GY	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMW039D	DI	DMW039D
DMW039D	DN	Aminopyrimidine derivative 4
DMW039D	MI	TTS7G69
DMW039D	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMW039D	MT	DTT
DMW039D	MA	Inhibitor
DMW039D	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMW039D	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DM5OZPV	DI	DM5OZPV
DM5OZPV	DN	Aminopyrimidine derivative 5
DM5OZPV	MI	TTBYWP2
DM5OZPV	MN	TYK2 tyrosine kinase (TYK2)
DM5OZPV	MT	DTT
DM5OZPV	MA	Inhibitor
DM5OZPV	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DM5OZPV	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMZF0DK	DI	DMZF0DK
DMZF0DK	DN	Aminopyrimidine derivative 6
DMZF0DK	MI	TTH5TC2
DMZF0DK	MN	NF-kappa-B-activating kinase (TBK1)
DMZF0DK	MT	DTT
DMZF0DK	MA	Inhibitor
DMZF0DK	RN	TBK1 inhibitors: a review of patent literature (2011 - 2014).Expert Opin Ther Pat. 2015;25(12):1385-96.
DMZF0DK	RU	https://www.ncbi.nlm.nih.gov/pubmed/26293650

DMW98RI	DI	DMW98RI
DMW98RI	DN	Aminopyrimidine derivative 7
DMW98RI	MI	TTH5TC2
DMW98RI	MN	NF-kappa-B-activating kinase (TBK1)
DMW98RI	MT	DTT
DMW98RI	MA	Inhibitor
DMW98RI	RN	TBK1 inhibitors: a review of patent literature (2011 - 2014).Expert Opin Ther Pat. 2015;25(12):1385-96.
DMW98RI	RU	https://www.ncbi.nlm.nih.gov/pubmed/26293650

DML83KW	DI	DML83KW
DML83KW	DN	Aminopyrimidine derivative 8
DML83KW	MI	TTH5TC2
DML83KW	MN	NF-kappa-B-activating kinase (TBK1)
DML83KW	MT	DTT
DML83KW	MA	Inhibitor
DML83KW	RN	TBK1 inhibitors: a review of patent literature (2011 - 2014).Expert Opin Ther Pat. 2015;25(12):1385-96.
DML83KW	RU	https://www.ncbi.nlm.nih.gov/pubmed/26293650

DM5VRXW	DI	DM5VRXW
DM5VRXW	DN	Aminopyrimidine derivative 9
DM5VRXW	MI	TTH5TC2
DM5VRXW	MN	NF-kappa-B-activating kinase (TBK1)
DM5VRXW	MT	DTT
DM5VRXW	MA	Inhibitor
DM5VRXW	RN	TBK1 inhibitors: a review of patent literature (2011 - 2014).Expert Opin Ther Pat. 2015;25(12):1385-96.
DM5VRXW	RU	https://www.ncbi.nlm.nih.gov/pubmed/26293650

DMW2LZ0	DI	DMW2LZ0
DMW2LZ0	DN	Aminotriazolopyridine derivative 1
DMW2LZ0	MI	TTKAWRQ
DMW2LZ0	MN	JAK-STAT signaling pathway (JAK-STAT pathway)
DMW2LZ0	MT	DTT
DMW2LZ0	MA	Inhibitor
DMW2LZ0	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMW2LZ0	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMW2LZ0	DI	DMW2LZ0
DMW2LZ0	DN	Aminotriazolopyridine derivative 1
DMW2LZ0	MI	TT6DM01
DMW2LZ0	MN	Janus kinase 1 (JAK-1)
DMW2LZ0	MT	DTT
DMW2LZ0	MA	Inhibitor
DMW2LZ0	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMW2LZ0	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMW2LZ0	DI	DMW2LZ0
DMW2LZ0	DN	Aminotriazolopyridine derivative 1
DMW2LZ0	MI	TTRMX3V
DMW2LZ0	MN	Janus kinase 2 (JAK-2)
DMW2LZ0	MT	DTT
DMW2LZ0	MA	Inhibitor
DMW2LZ0	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMW2LZ0	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMW2LZ0	DI	DMW2LZ0
DMW2LZ0	DN	Aminotriazolopyridine derivative 1
DMW2LZ0	MI	TTT7PJU
DMW2LZ0	MN	Janus kinase 3 (JAK-3)
DMW2LZ0	MT	DTT
DMW2LZ0	MA	Inhibitor
DMW2LZ0	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMW2LZ0	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMW2LZ0	DI	DMW2LZ0
DMW2LZ0	DN	Aminotriazolopyridine derivative 1
DMW2LZ0	MI	TTBYWP2
DMW2LZ0	MN	TYK2 tyrosine kinase (TYK2)
DMW2LZ0	MT	DTT
DMW2LZ0	MA	Inhibitor
DMW2LZ0	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMW2LZ0	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMW2LZ0	DI	DMW2LZ0
DMW2LZ0	DN	Aminotriazolopyridine derivative 1
DMW2LZ0	MI	TTJSQEF
DMW2LZ0	MN	Tyrosine-protein kinase (PTK)
DMW2LZ0	MT	DTT
DMW2LZ0	MA	Inhibitor
DMW2LZ0	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMW2LZ0	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DM2V31C	DI	DM2V31C
DM2V31C	DN	Ampicidin analog 1
DM2V31C	MI	TTBH0VX
DM2V31C	MN	Histone deacetylase (HDAC)
DM2V31C	MT	DTT
DM2V31C	MA	Inhibitor
DM2V31C	RN	Antiplasmodial drug targets: a patent review (2000 - 2013).Expert Opin Ther Pat. 2016;26(1):107-30.
DM2V31C	RU	https://www.ncbi.nlm.nih.gov/pubmed/26566576

DMZH8S9	DI	DMZH8S9
DMZH8S9	DN	Ampicidin analog 2
DMZH8S9	MI	TTBH0VX
DMZH8S9	MN	Histone deacetylase (HDAC)
DMZH8S9	MT	DTT
DMZH8S9	MA	Inhibitor
DMZH8S9	RN	Antiplasmodial drug targets: a patent review (2000 - 2013).Expert Opin Ther Pat. 2016;26(1):107-30.
DMZH8S9	RU	https://www.ncbi.nlm.nih.gov/pubmed/26566576

DMDSUGF	DI	DMDSUGF
DMDSUGF	DN	Aniline derivative 1
DMDSUGF	MI	TT7HF4W
DMDSUGF	MN	Cyclin-dependent kinase 2 (CDK2)
DMDSUGF	MT	DTT
DMDSUGF	MA	Inhibitor
DMDSUGF	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMDSUGF	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMDSUGF	DI	DMDSUGF
DMDSUGF	DN	Aniline derivative 1
DMDSUGF	MI	TTBH0VX
DMDSUGF	MN	Histone deacetylase (HDAC)
DMDSUGF	MT	DTT
DMDSUGF	MA	Inhibitor
DMDSUGF	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMDSUGF	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMY5J23	DI	DMY5J23
DMY5J23	DN	Antibodie derivative 1
DMY5J23	MI	TTOHSBA
DMY5J23	MN	Vascular endothelial growth factor A (VEGFA)
DMY5J23	MT	DTT
DMY5J23	MA	Blocker
DMY5J23	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMY5J23	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMGP5AR	DI	DMGP5AR
DMGP5AR	DN	Antibodie derivative 10
DMGP5AR	MI	TTUTJGQ
DMGP5AR	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMGP5AR	MT	DTT
DMGP5AR	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMGP5AR	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMPG3Y8	DI	DMPG3Y8
DMPG3Y8	DN	Antibodie derivative 11
DMPG3Y8	MI	TTOHSBA
DMPG3Y8	MN	Vascular endothelial growth factor A (VEGFA)
DMPG3Y8	MT	DTT
DMPG3Y8	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMPG3Y8	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMU7YC2	DI	DMU7YC2
DMU7YC2	DN	Antibodie derivative 2
DMU7YC2	MI	TTOHSBA
DMU7YC2	MN	Vascular endothelial growth factor A (VEGFA)
DMU7YC2	MT	DTT
DMU7YC2	MA	Binder
DMU7YC2	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMU7YC2	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMNPBRG	DI	DMNPBRG
DMNPBRG	DN	Antibodie derivative 3
DMNPBRG	MI	TTOHSBA
DMNPBRG	MN	Vascular endothelial growth factor A (VEGFA)
DMNPBRG	MT	DTT
DMNPBRG	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMNPBRG	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DM2WMGO	DI	DM2WMGO
DM2WMGO	DN	Antibodie derivative 4
DM2WMGO	MI	TTOHSBA
DM2WMGO	MN	Vascular endothelial growth factor A (VEGFA)
DM2WMGO	MT	DTT
DM2WMGO	MA	Inhibitor
DM2WMGO	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DM2WMGO	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMRTZE4	DI	DMRTZE4
DMRTZE4	DN	Antibodie derivative 5
DMRTZE4	MI	TTOUZN5
DMRTZE4	MN	Gremlin-1 (Gremlin-1)
DMRTZE4	MT	DTT
DMRTZE4	MA	Inhibitor
DMRTZE4	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMRTZE4	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMUG6YT	DI	DMUG6YT
DMUG6YT	DN	Antibodie derivative 6
DMUG6YT	MI	TTUTJGQ
DMUG6YT	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMUG6YT	MT	DTT
DMUG6YT	MA	Binder
DMUG6YT	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMUG6YT	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMJN37O	DI	DMJN37O
DMJN37O	DN	Antibodie derivative 7
DMJN37O	MI	TTOHSBA
DMJN37O	MN	Vascular endothelial growth factor A (VEGFA)
DMJN37O	MT	DTT
DMJN37O	MA	Binder
DMJN37O	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMJN37O	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DM0CEJM	DI	DM0CEJM
DM0CEJM	DN	Antibodie derivative 8
DM0CEJM	MI	TTOHSBA
DM0CEJM	MN	Vascular endothelial growth factor A (VEGFA)
DM0CEJM	MT	DTT
DM0CEJM	MA	Disrupter
DM0CEJM	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DM0CEJM	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMDRJ31	DI	DMDRJ31
DMDRJ31	DN	Antibodie derivative 9
DMDRJ31	MI	TTOHSBA
DMDRJ31	MN	Vascular endothelial growth factor A (VEGFA)
DMDRJ31	MT	DTT
DMDRJ31	MA	Stablizer
DMDRJ31	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMDRJ31	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMLQ8N1	DI	DMLQ8N1
DMLQ8N1	DN	AphanamgrandiolA
DMLQ8N1	MI	TT3WG5C
DMLQ8N1	MN	Monoamine oxidase type A (MAO-A)
DMLQ8N1	MT	DTT
DMLQ8N1	MA	Inhibitor
DMLQ8N1	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMLQ8N1	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DM7AXSM	DI	DM7AXSM
DM7AXSM	DN	Apogossypolone
DM7AXSM	MI	TTGT9C7
DM7AXSM	MN	Bcl-2-related protein A1 (BCL2A1)
DM7AXSM	MT	DTT
DM7AXSM	MA	Inhibitor
DM7AXSM	RN	Apogossypolone derivatives as anticancer agents. US8937193.
DM7AXSM	RU	http://www.freepatentsonline.com/US8937193.html

DMUPN01	DI	DMUPN01
DMUPN01	DN	AR-A014418
DMUPN01	MI	TTRZQE3
DMUPN01	MN	Glycogen synthase kinase-3 alpha (GSK-3A)
DMUPN01	MT	DTT
DMUPN01	RN	Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
DMUPN01	RU	https://www.ncbi.nlm.nih.gov/pubmed/27828716

DMUPN01	DI	DMUPN01
DMUPN01	DN	AR-A014418
DMUPN01	MI	TTRSMW9
DMUPN01	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMUPN01	MT	DTT
DMUPN01	MA	Inhibitor
DMUPN01	RN	Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models. Eur J Med Chem. 2009 Jun;44(6):2361-71.
DMUPN01	RU	https://pubmed.ncbi.nlm.nih.gov/18929433

DMGR6X1	DI	DMGR6X1
DMGR6X1	DN	Aromatic acetylene derivative 1
DMGR6X1	MI	TT23XQV
DMGR6X1	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMGR6X1	MT	DTT
DMGR6X1	MA	Inhibitor
DMGR6X1	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMGR6X1	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMXW0PV	DI	DMXW0PV
DMXW0PV	DN	Aromatic and heteroaryl compound 1
DMXW0PV	MI	TTUX68I
DMXW0PV	MN	Hypoxia-inducible factor 1 (HIF-1)
DMXW0PV	MT	DTT
DMXW0PV	MA	Inhibitor
DMXW0PV	RN	Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22.
DMXW0PV	RU	https://www.ncbi.nlm.nih.gov/pubmed/26882240

DMVLQ2P	DI	DMVLQ2P
DMVLQ2P	DN	Aromatic bicyclic compound 1
DMVLQ2P	MI	TTRMX3V
DMVLQ2P	MN	Janus kinase 2 (JAK-2)
DMVLQ2P	MT	DTT
DMVLQ2P	MA	Inhibitor
DMVLQ2P	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMVLQ2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMVLQ2P	DI	DMVLQ2P
DMVLQ2P	DN	Aromatic bicyclic compound 1
DMVLQ2P	MI	TT6PKBN
DMVLQ2P	MN	Proto-oncogene c-Src (SRC)
DMVLQ2P	MT	DTT
DMVLQ2P	MA	Inhibitor
DMVLQ2P	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMVLQ2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMKFV67	DI	DMKFV67
DMKFV67	DN	Aromatic bicyclic compound 2
DMKFV67	MI	TTRMX3V
DMKFV67	MN	Janus kinase 2 (JAK-2)
DMKFV67	MT	DTT
DMKFV67	MA	Inhibitor
DMKFV67	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMKFV67	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMKFV67	DI	DMKFV67
DMKFV67	DN	Aromatic bicyclic compound 2
DMKFV67	MI	TT6PKBN
DMKFV67	MN	Proto-oncogene c-Src (SRC)
DMKFV67	MT	DTT
DMKFV67	MA	Inhibitor
DMKFV67	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMKFV67	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMRXN94	DI	DMRXN94
DMRXN94	DN	Aromatic bicyclic compound 3
DMRXN94	MI	TTRMX3V
DMRXN94	MN	Janus kinase 2 (JAK-2)
DMRXN94	MT	DTT
DMRXN94	MA	Inhibitor
DMRXN94	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMRXN94	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMRXN94	DI	DMRXN94
DMRXN94	DN	Aromatic bicyclic compound 3
DMRXN94	MI	TT6PKBN
DMRXN94	MN	Proto-oncogene c-Src (SRC)
DMRXN94	MT	DTT
DMRXN94	MA	Inhibitor
DMRXN94	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMRXN94	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DM3E75P	DI	DM3E75P
DM3E75P	DN	Aromatic bicyclic compound 4
DM3E75P	MI	TTRMX3V
DM3E75P	MN	Janus kinase 2 (JAK-2)
DM3E75P	MT	DTT
DM3E75P	MA	Inhibitor
DM3E75P	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DM3E75P	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DM3E75P	DI	DM3E75P
DM3E75P	DN	Aromatic bicyclic compound 4
DM3E75P	MI	TT6PKBN
DM3E75P	MN	Proto-oncogene c-Src (SRC)
DM3E75P	MT	DTT
DM3E75P	MA	Inhibitor
DM3E75P	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DM3E75P	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMALF06	DI	DMALF06
DMALF06	DN	Aromatic bicyclic compound 5
DMALF06	MI	TTRMX3V
DMALF06	MN	Janus kinase 2 (JAK-2)
DMALF06	MT	DTT
DMALF06	MA	Inhibitor
DMALF06	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMALF06	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMALF06	DI	DMALF06
DMALF06	DN	Aromatic bicyclic compound 5
DMALF06	MI	TT6PKBN
DMALF06	MN	Proto-oncogene c-Src (SRC)
DMALF06	MT	DTT
DMALF06	MA	Inhibitor
DMALF06	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMALF06	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DM8L3KM	DI	DM8L3KM
DM8L3KM	DN	Aromatic bicyclic compound 6
DM8L3KM	MI	TTRMX3V
DM8L3KM	MN	Janus kinase 2 (JAK-2)
DM8L3KM	MT	DTT
DM8L3KM	MA	Inhibitor
DM8L3KM	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DM8L3KM	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DM8L3KM	DI	DM8L3KM
DM8L3KM	DN	Aromatic bicyclic compound 6
DM8L3KM	MI	TT6PKBN
DM8L3KM	MN	Proto-oncogene c-Src (SRC)
DM8L3KM	MT	DTT
DM8L3KM	MA	Inhibitor
DM8L3KM	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DM8L3KM	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMSRKON	DI	DMSRKON
DMSRKON	DN	Aromatic ethylene derivative 1
DMSRKON	MI	TT23XQV
DMSRKON	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMSRKON	MT	DTT
DMSRKON	MA	Inhibitor
DMSRKON	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMSRKON	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMJ8X7A	DI	DMJ8X7A
DMJ8X7A	DN	Aromatic hydrazine carboxyimidoamide derivative 1
DMJ8X7A	MI	TTULVH8
DMJ8X7A	MN	Tyrosinase (TYR)
DMJ8X7A	MT	DTT
DMJ8X7A	MA	Inhibitor
DMJ8X7A	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMJ8X7A	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMYH4D1	DI	DMYH4D1
DMYH4D1	DN	Aromatic hydrazine carboxyimidoamide derivative 2
DMYH4D1	MI	TTULVH8
DMYH4D1	MN	Tyrosinase (TYR)
DMYH4D1	MT	DTT
DMYH4D1	MA	Inhibitor
DMYH4D1	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMYH4D1	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DML63B7	DI	DML63B7
DML63B7	DN	Aromatic hydrazine carboxyimidoamide derivative 3
DML63B7	MI	TTULVH8
DML63B7	MN	Tyrosinase (TYR)
DML63B7	MT	DTT
DML63B7	MA	Inhibitor
DML63B7	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DML63B7	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMKE5PB	DI	DMKE5PB
DMKE5PB	DN	Aromatic hydrazine carboxyimidoamide derivative 4
DMKE5PB	MI	TTULVH8
DMKE5PB	MN	Tyrosinase (TYR)
DMKE5PB	MT	DTT
DMKE5PB	MA	Inhibitor
DMKE5PB	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMKE5PB	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DM4AM1E	DI	DM4AM1E
DM4AM1E	DN	Aromatic hydrazine carboxyimidoamide derivative 5
DM4AM1E	MI	TTULVH8
DM4AM1E	MN	Tyrosinase (TYR)
DM4AM1E	MT	DTT
DM4AM1E	MA	Inhibitor
DM4AM1E	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DM4AM1E	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DM8HDQT	DI	DM8HDQT
DM8HDQT	DN	Aromatic hydrazine carboxyimidoamide derivative 6
DM8HDQT	MI	TTULVH8
DM8HDQT	MN	Tyrosinase (TYR)
DM8HDQT	MT	DTT
DM8HDQT	MA	Inhibitor
DM8HDQT	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DM8HDQT	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMJX6DV	DI	DMJX6DV
DMJX6DV	DN	Aromatic ring compound 1
DMJX6DV	MI	TT9O6WS
DMJX6DV	MN	Glucagon receptor (GCGR)
DMJX6DV	MT	DTT
DMJX6DV	MA	Antagonist
DMJX6DV	RN	Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30.
DMJX6DV	RU	https://www.ncbi.nlm.nih.gov/pubmed/25828189

DMMAS3G	DI	DMMAS3G
DMMAS3G	DN	Aromatic ring compound 2
DMMAS3G	MI	TT9O6WS
DMMAS3G	MN	Glucagon receptor (GCGR)
DMMAS3G	MT	DTT
DMMAS3G	MA	Antagonist
DMMAS3G	RN	Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30.
DMMAS3G	RU	https://www.ncbi.nlm.nih.gov/pubmed/25828189

DM43APD	DI	DM43APD
DM43APD	DN	Aromatic ring compound 3
DM43APD	MI	TT9O6WS
DM43APD	MN	Glucagon receptor (GCGR)
DM43APD	MT	DTT
DM43APD	MA	Antagonist
DM43APD	RN	Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30.
DM43APD	RU	https://www.ncbi.nlm.nih.gov/pubmed/25828189

DMXGLST	DI	DMXGLST
DMXGLST	DN	Aromatic ring compound 4
DMXGLST	MI	TT9O6WS
DMXGLST	MN	Glucagon receptor (GCGR)
DMXGLST	MT	DTT
DMXGLST	MA	Antagonist
DMXGLST	RN	Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30.
DMXGLST	RU	https://www.ncbi.nlm.nih.gov/pubmed/25828189

DMSDRNQ	DI	DMSDRNQ
DMSDRNQ	DN	Aryl 1,2-diamine derivative 1
DMSDRNQ	MI	TTZJYKH
DMSDRNQ	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMSDRNQ	MT	DTT
DMSDRNQ	MA	Inhibitor
DMSDRNQ	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMSDRNQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DM417XY	DI	DM417XY
DM417XY	DN	Aryl alkanolamine derivative 1
DM417XY	MI	TT5TPI6
DM417XY	MN	Opioid receptor sigma 1 (OPRS1)
DM417XY	MT	DTT
DM417XY	MA	Antagonist
DM417XY	RN	Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578.
DM417XY	RU	https://www.ncbi.nlm.nih.gov/pubmed/28051882

DMUP0WH	DI	DMUP0WH
DMUP0WH	DN	Aryl alkanolamine derivative 2
DMUP0WH	MI	TT5TPI6
DMUP0WH	MN	Opioid receptor sigma 1 (OPRS1)
DMUP0WH	MT	DTT
DMUP0WH	MA	Antagonist
DMUP0WH	RN	Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578.
DMUP0WH	RU	https://www.ncbi.nlm.nih.gov/pubmed/28051882

DMA9B0V	DI	DMA9B0V
DMA9B0V	DN	Aryl azepine derivative 1
DMA9B0V	MI	TT9NXW4
DMA9B0V	MN	Sigma intracellular receptor 2 (TMEM97)
DMA9B0V	MT	DTT
DMA9B0V	MA	Ligand
DMA9B0V	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DMA9B0V	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DMI4XBC	DI	DMI4XBC
DMI4XBC	DN	Aryl azepine derivative 2
DMI4XBC	MI	TT9NXW4
DMI4XBC	MN	Sigma intracellular receptor 2 (TMEM97)
DMI4XBC	MT	DTT
DMI4XBC	MA	Ligand
DMI4XBC	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DMI4XBC	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DMGZHRT	DI	DMGZHRT
DMGZHRT	DN	Aryl carbamate analog 1
DMGZHRT	MI	TTUX68I
DMGZHRT	MN	Hypoxia-inducible factor 1 (HIF-1)
DMGZHRT	MT	DTT
DMGZHRT	MA	Inhibitor
DMGZHRT	RN	Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22.
DMGZHRT	RU	https://www.ncbi.nlm.nih.gov/pubmed/26882240

DMTZRCW	DI	DMTZRCW
DMTZRCW	DN	Aryl carboxamide derivative 1
DMTZRCW	MI	TTAXZ0K
DMTZRCW	MN	Voltage-gated sodium channel alpha Nav1.3 (SCN3A)
DMTZRCW	MT	DTT
DMTZRCW	MA	Inhibitor
DMTZRCW	RN	Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90.
DMTZRCW	RU	https://www.ncbi.nlm.nih.gov/pubmed/25539043

DMTZRCW	DI	DMTZRCW
DMTZRCW	DN	Aryl carboxamide derivative 1
DMTZRCW	MI	TTZOVE0
DMTZRCW	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DMTZRCW	MT	DTT
DMTZRCW	MA	Inhibitor
DMTZRCW	RN	Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90.
DMTZRCW	RU	https://www.ncbi.nlm.nih.gov/pubmed/25539043

DMTZRCW	DI	DMTZRCW
DMTZRCW	DN	Aryl carboxamide derivative 1
DMTZRCW	MI	TT4G2JS
DMTZRCW	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DMTZRCW	MT	DTT
DMTZRCW	MA	Inhibitor
DMTZRCW	RN	Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90.
DMTZRCW	RU	https://www.ncbi.nlm.nih.gov/pubmed/25539043

DM146TA	DI	DM146TA
DM146TA	DN	Aryl carboxamide derivative 2
DM146TA	MI	TTAXZ0K
DM146TA	MN	Voltage-gated sodium channel alpha Nav1.3 (SCN3A)
DM146TA	MT	DTT
DM146TA	MA	Inhibitor
DM146TA	RN	Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90.
DM146TA	RU	https://www.ncbi.nlm.nih.gov/pubmed/25539043

DM146TA	DI	DM146TA
DM146TA	DN	Aryl carboxamide derivative 2
DM146TA	MI	TTZOVE0
DM146TA	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DM146TA	MT	DTT
DM146TA	MA	Inhibitor
DM146TA	RN	Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90.
DM146TA	RU	https://www.ncbi.nlm.nih.gov/pubmed/25539043

DM146TA	DI	DM146TA
DM146TA	DN	Aryl carboxamide derivative 2
DM146TA	MI	TT4G2JS
DM146TA	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DM146TA	MT	DTT
DM146TA	MA	Inhibitor
DM146TA	RN	Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90.
DM146TA	RU	https://www.ncbi.nlm.nih.gov/pubmed/25539043

DM6FQ8L	DI	DM6FQ8L
DM6FQ8L	DN	Aryl carboxamide derivative 3
DM6FQ8L	MI	TTZOVE0
DM6FQ8L	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DM6FQ8L	MT	DTT
DM6FQ8L	MA	Inhibitor
DM6FQ8L	RN	Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90.
DM6FQ8L	RU	https://www.ncbi.nlm.nih.gov/pubmed/25539043

DMNBW8P	DI	DMNBW8P
DMNBW8P	DN	Aryl carboxamide derivative 4
DMNBW8P	MI	TT4G2JS
DMNBW8P	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DMNBW8P	MT	DTT
DMNBW8P	MA	Inhibitor
DMNBW8P	RN	Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90.
DMNBW8P	RU	https://www.ncbi.nlm.nih.gov/pubmed/25539043

DMZECH7	DI	DMZECH7
DMZECH7	DN	Aryl cyclopropylamine derivative 3
DMZECH7	MI	TTNR0UQ
DMZECH7	MN	Lysine-specific histone demethylase 1 (LSD)
DMZECH7	MT	DTT
DMZECH7	MA	Inhibitor
DMZECH7	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMZECH7	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DM0C1ZO	DI	DM0C1ZO
DM0C1ZO	DN	Aryl cyclopropylamine derivative 4
DM0C1ZO	MI	TTNR0UQ
DM0C1ZO	MN	Lysine-specific histone demethylase 1 (LSD)
DM0C1ZO	MT	DTT
DM0C1ZO	MA	Inhibitor
DM0C1ZO	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DM0C1ZO	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DM6CK7J	DI	DM6CK7J
DM6CK7J	DN	Aryl cyclopropylamine derivative 5
DM6CK7J	MI	TTNR0UQ
DM6CK7J	MN	Lysine-specific histone demethylase 1 (LSD)
DM6CK7J	MT	DTT
DM6CK7J	MA	Inhibitor
DM6CK7J	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DM6CK7J	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DM1TV6F	DI	DM1TV6F
DM1TV6F	DN	Aryl mannoside derivative 1
DM1TV6F	MI	TTTCRU2
DM1TV6F	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM1TV6F	MT	DTT
DM1TV6F	MA	Antagonist
DM1TV6F	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM1TV6F	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM251GL	DI	DM251GL
DM251GL	DN	Aryl mannoside derivative 10
DM251GL	MI	TTTCRU2
DM251GL	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM251GL	MT	DTT
DM251GL	MA	Antagonist
DM251GL	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM251GL	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMRVIPL	DI	DMRVIPL
DMRVIPL	DN	Aryl mannoside derivative 11
DMRVIPL	MI	TTTCRU2
DMRVIPL	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMRVIPL	MT	DTT
DMRVIPL	MA	Antagonist
DMRVIPL	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMRVIPL	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMOG8XT	DI	DMOG8XT
DMOG8XT	DN	Aryl mannoside derivative 12
DMOG8XT	MI	TTTCRU2
DMOG8XT	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMOG8XT	MT	DTT
DMOG8XT	MA	Antagonist
DMOG8XT	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMOG8XT	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM2W7JE	DI	DM2W7JE
DM2W7JE	DN	Aryl mannoside derivative 13
DM2W7JE	MI	TTTCRU2
DM2W7JE	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM2W7JE	MT	DTT
DM2W7JE	MA	Antagonist
DM2W7JE	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM2W7JE	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMR648Z	DI	DMR648Z
DMR648Z	DN	Aryl mannoside derivative 14
DMR648Z	MI	TTTCRU2
DMR648Z	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMR648Z	MT	DTT
DMR648Z	MA	Antagonist
DMR648Z	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMR648Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMQS8CF	DI	DMQS8CF
DMQS8CF	DN	Aryl mannoside derivative 15
DMQS8CF	MI	TTTCRU2
DMQS8CF	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMQS8CF	MT	DTT
DMQS8CF	MA	Antagonist
DMQS8CF	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMQS8CF	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMP6QEC	DI	DMP6QEC
DMP6QEC	DN	Aryl mannoside derivative 16
DMP6QEC	MI	TTTCRU2
DMP6QEC	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMP6QEC	MT	DTT
DMP6QEC	MA	Antagonist
DMP6QEC	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMP6QEC	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM0FSPQ	DI	DM0FSPQ
DM0FSPQ	DN	Aryl mannoside derivative 17
DM0FSPQ	MI	TTTCRU2
DM0FSPQ	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM0FSPQ	MT	DTT
DM0FSPQ	MA	Antagonist
DM0FSPQ	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM0FSPQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM0YUBR	DI	DM0YUBR
DM0YUBR	DN	Aryl mannoside derivative 18
DM0YUBR	MI	TTTCRU2
DM0YUBR	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM0YUBR	MT	DTT
DM0YUBR	MA	Antagonist
DM0YUBR	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM0YUBR	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM6K29H	DI	DM6K29H
DM6K29H	DN	Aryl mannoside derivative 19
DM6K29H	MI	TTTCRU2
DM6K29H	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM6K29H	MT	DTT
DM6K29H	MA	Antagonist
DM6K29H	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM6K29H	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM4S2U5	DI	DM4S2U5
DM4S2U5	DN	Aryl mannoside derivative 2
DM4S2U5	MI	TTTCRU2
DM4S2U5	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM4S2U5	MT	DTT
DM4S2U5	MA	Antagonist
DM4S2U5	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM4S2U5	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMZ2RV3	DI	DMZ2RV3
DMZ2RV3	DN	Aryl mannoside derivative 20
DMZ2RV3	MI	TTTCRU2
DMZ2RV3	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMZ2RV3	MT	DTT
DMZ2RV3	MA	Antagonist
DMZ2RV3	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMZ2RV3	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMJBY68	DI	DMJBY68
DMJBY68	DN	Aryl mannoside derivative 21
DMJBY68	MI	TTTCRU2
DMJBY68	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMJBY68	MT	DTT
DMJBY68	MA	Antagonist
DMJBY68	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMJBY68	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMJFDNB	DI	DMJFDNB
DMJFDNB	DN	Aryl mannoside derivative 22
DMJFDNB	MI	TTTCRU2
DMJFDNB	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMJFDNB	MT	DTT
DMJFDNB	MA	Antagonist
DMJFDNB	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMJFDNB	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMWUNRV	DI	DMWUNRV
DMWUNRV	DN	Aryl mannoside derivative 23
DMWUNRV	MI	TTTCRU2
DMWUNRV	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMWUNRV	MT	DTT
DMWUNRV	MA	Antagonist
DMWUNRV	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMWUNRV	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMF5XU8	DI	DMF5XU8
DMF5XU8	DN	Aryl mannoside derivative 3
DMF5XU8	MI	TTTCRU2
DMF5XU8	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMF5XU8	MT	DTT
DMF5XU8	MA	Antagonist
DMF5XU8	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMF5XU8	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMO19Y6	DI	DMO19Y6
DMO19Y6	DN	Aryl mannoside derivative 4
DMO19Y6	MI	TTTCRU2
DMO19Y6	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMO19Y6	MT	DTT
DMO19Y6	MA	Antagonist
DMO19Y6	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMO19Y6	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMMC31R	DI	DMMC31R
DMMC31R	DN	Aryl mannoside derivative 5
DMMC31R	MI	TTTCRU2
DMMC31R	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMMC31R	MT	DTT
DMMC31R	MA	Antagonist
DMMC31R	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMMC31R	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM5MIEC	DI	DM5MIEC
DM5MIEC	DN	Aryl mannoside derivative 6
DM5MIEC	MI	TTTCRU2
DM5MIEC	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM5MIEC	MT	DTT
DM5MIEC	MA	Antagonist
DM5MIEC	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM5MIEC	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM9YS40	DI	DM9YS40
DM9YS40	DN	Aryl mannoside derivative 7
DM9YS40	MI	TTTCRU2
DM9YS40	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM9YS40	MT	DTT
DM9YS40	MA	Antagonist
DM9YS40	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM9YS40	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMK6PFQ	DI	DMK6PFQ
DMK6PFQ	DN	Aryl mannoside derivative 8
DMK6PFQ	MI	TTTCRU2
DMK6PFQ	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMK6PFQ	MT	DTT
DMK6PFQ	MA	Antagonist
DMK6PFQ	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMK6PFQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMNSK7U	DI	DMNSK7U
DMNSK7U	DN	Aryl mannoside derivative 9
DMNSK7U	MI	TTTCRU2
DMNSK7U	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMNSK7U	MT	DTT
DMNSK7U	MA	Antagonist
DMNSK7U	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMNSK7U	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMBWH3O	DI	DMBWH3O
DMBWH3O	DN	Aryl methoxyacrylate derivative 1
DMBWH3O	MI	TTUX68I
DMBWH3O	MN	Hypoxia-inducible factor 1 (HIF-1)
DMBWH3O	MT	DTT
DMBWH3O	MA	Inhibitor
DMBWH3O	RN	Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22.
DMBWH3O	RU	https://www.ncbi.nlm.nih.gov/pubmed/26882240

DMNC0RX	DI	DMNC0RX
DMNC0RX	DN	Aryl methoxyacrylate derivative 2
DMNC0RX	MI	TTUX68I
DMNC0RX	MN	Hypoxia-inducible factor 1 (HIF-1)
DMNC0RX	MT	DTT
DMNC0RX	MA	Inhibitor
DMNC0RX	RN	Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22.
DMNC0RX	RU	https://www.ncbi.nlm.nih.gov/pubmed/26882240

DML1IXV	DI	DML1IXV
DML1IXV	DN	Aryl oxyanilide derivative 1
DML1IXV	MI	TTPTXIN
DML1IXV	MN	Translocator protein (TSPO)
DML1IXV	MT	DTT
DML1IXV	MA	Ligand
DML1IXV	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DML1IXV	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DM47V3I	DI	DM47V3I
DM47V3I	DN	Aryl oxyanilide derivative 2
DM47V3I	MI	TTPTXIN
DM47V3I	MN	Translocator protein (TSPO)
DM47V3I	MT	DTT
DM47V3I	MA	Ligand
DM47V3I	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DM47V3I	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMSGO7D	DI	DMSGO7D
DMSGO7D	DN	Aryl oxyanilide derivative 3
DMSGO7D	MI	TTPTXIN
DMSGO7D	MN	Translocator protein (TSPO)
DMSGO7D	MT	DTT
DMSGO7D	MA	Ligand
DMSGO7D	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMSGO7D	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DM9DJGU	DI	DM9DJGU
DM9DJGU	DN	Aryl piperazine derivative 1
DM9DJGU	MI	TTSQIFT
DM9DJGU	MN	5-HT 1A receptor (HTR1A)
DM9DJGU	MT	DTT
DM9DJGU	MA	Ligand
DM9DJGU	RN	5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
DM9DJGU	RU	https://www.ncbi.nlm.nih.gov/pubmed/30124346

DM9DJGU	DI	DM9DJGU
DM9DJGU	DN	Aryl piperazine derivative 1
DM9DJGU	MI	TTJQOD7
DM9DJGU	MN	5-HT 2A receptor (HTR2A)
DM9DJGU	MT	DTT
DM9DJGU	MA	Ligand
DM9DJGU	RN	5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
DM9DJGU	RU	https://www.ncbi.nlm.nih.gov/pubmed/30124346

DM9DJGU	DI	DM9DJGU
DM9DJGU	DN	Aryl piperazine derivative 1
DM9DJGU	MI	TTEX248
DM9DJGU	MN	Dopamine D2 receptor (D2R)
DM9DJGU	MT	DTT
DM9DJGU	MA	Ligand
DM9DJGU	RN	5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
DM9DJGU	RU	https://www.ncbi.nlm.nih.gov/pubmed/30124346

DM9DJGU	DI	DM9DJGU
DM9DJGU	DN	Aryl piperazine derivative 1
DM9DJGU	MI	TT4C8EA
DM9DJGU	MN	Dopamine D3 receptor (D3R)
DM9DJGU	MT	DTT
DM9DJGU	MA	Ligand
DM9DJGU	RN	5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
DM9DJGU	RU	https://www.ncbi.nlm.nih.gov/pubmed/30124346

DM5EGBY	DI	DM5EGBY
DM5EGBY	DN	Aryl piperazine derivative 10
DM5EGBY	MI	TTWJBZ5
DM5EGBY	MN	5-HT 2C receptor (HTR2C)
DM5EGBY	MT	DTT
DM5EGBY	MA	Agonist
DM5EGBY	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DM5EGBY	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMY8NEL	DI	DMY8NEL
DMY8NEL	DN	Aryl piperazine derivative 14
DMY8NEL	MI	TTWT5K7
DMY8NEL	MN	5-HT 1 receptor (5HT1R)
DMY8NEL	MT	DTT
DMY8NEL	MA	Agonist
DMY8NEL	RN	5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
DMY8NEL	RU	https://www.ncbi.nlm.nih.gov/pubmed/30124346

DMY8NEL	DI	DMY8NEL
DMY8NEL	DN	Aryl piperazine derivative 14
DMY8NEL	MI	TTSQIFT
DMY8NEL	MN	5-HT 1A receptor (HTR1A)
DMY8NEL	MT	DTT
DMY8NEL	MA	Agonist
DMY8NEL	RN	5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
DMY8NEL	RU	https://www.ncbi.nlm.nih.gov/pubmed/30124346

DMRK4IE	DI	DMRK4IE
DMRK4IE	DN	Aryl piperazine derivative 15
DMRK4IE	MI	TTWT5K7
DMRK4IE	MN	5-HT 1 receptor (5HT1R)
DMRK4IE	MT	DTT
DMRK4IE	MA	Agonist
DMRK4IE	RN	5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
DMRK4IE	RU	https://www.ncbi.nlm.nih.gov/pubmed/30124346

DMRK4IE	DI	DMRK4IE
DMRK4IE	DN	Aryl piperazine derivative 15
DMRK4IE	MI	TTSQIFT
DMRK4IE	MN	5-HT 1A receptor (HTR1A)
DMRK4IE	MT	DTT
DMRK4IE	MA	Agonist
DMRK4IE	RN	5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
DMRK4IE	RU	https://www.ncbi.nlm.nih.gov/pubmed/30124346

DM63XHT	DI	DM63XHT
DM63XHT	DN	Aryl piperazine derivative 16
DM63XHT	MI	TTWT5K7
DM63XHT	MN	5-HT 1 receptor (5HT1R)
DM63XHT	MT	DTT
DM63XHT	MA	Agonist
DM63XHT	RN	5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
DM63XHT	RU	https://www.ncbi.nlm.nih.gov/pubmed/30124346

DM63XHT	DI	DM63XHT
DM63XHT	DN	Aryl piperazine derivative 16
DM63XHT	MI	TTSQIFT
DM63XHT	MN	5-HT 1A receptor (HTR1A)
DM63XHT	MT	DTT
DM63XHT	MA	Agonist
DM63XHT	RN	5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
DM63XHT	RU	https://www.ncbi.nlm.nih.gov/pubmed/30124346

DMZ3DS5	DI	DMZ3DS5
DMZ3DS5	DN	Aryl piperazine derivative 6
DMZ3DS5	MI	TTSQIFT
DMZ3DS5	MN	5-HT 1A receptor (HTR1A)
DMZ3DS5	MT	DTT
DMZ3DS5	MA	Ligand
DMZ3DS5	RN	5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
DMZ3DS5	RU	https://www.ncbi.nlm.nih.gov/pubmed/30124346

DMZ3DS5	DI	DMZ3DS5
DMZ3DS5	DN	Aryl piperazine derivative 6
DMZ3DS5	MI	TTJQOD7
DMZ3DS5	MN	5-HT 2A receptor (HTR2A)
DMZ3DS5	MT	DTT
DMZ3DS5	MA	Ligand
DMZ3DS5	RN	5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
DMZ3DS5	RU	https://www.ncbi.nlm.nih.gov/pubmed/30124346

DMZ3DS5	DI	DMZ3DS5
DMZ3DS5	DN	Aryl piperazine derivative 6
DMZ3DS5	MI	TTEX248
DMZ3DS5	MN	Dopamine D2 receptor (D2R)
DMZ3DS5	MT	DTT
DMZ3DS5	MA	Ligand
DMZ3DS5	RN	5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
DMZ3DS5	RU	https://www.ncbi.nlm.nih.gov/pubmed/30124346

DMZ3DS5	DI	DMZ3DS5
DMZ3DS5	DN	Aryl piperazine derivative 6
DMZ3DS5	MI	TT4C8EA
DMZ3DS5	MN	Dopamine D3 receptor (D3R)
DMZ3DS5	MT	DTT
DMZ3DS5	MA	Ligand
DMZ3DS5	RN	5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
DMZ3DS5	RU	https://www.ncbi.nlm.nih.gov/pubmed/30124346

DM7BRIT	DI	DM7BRIT
DM7BRIT	DN	Aryl piperazine derivative 8
DM7BRIT	MI	TTWJBZ5
DM7BRIT	MN	5-HT 2C receptor (HTR2C)
DM7BRIT	MT	DTT
DM7BRIT	MA	Agonist
DM7BRIT	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DM7BRIT	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMLKNWF	DI	DMLKNWF
DMLKNWF	DN	Aryl piperazine derivative 9
DMLKNWF	MI	TTJQOD7
DMLKNWF	MN	5-HT 2A receptor (HTR2A)
DMLKNWF	MT	DTT
DMLKNWF	MA	Agonist
DMLKNWF	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMLKNWF	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMLKNWF	DI	DMLKNWF
DMLKNWF	DN	Aryl piperazine derivative 9
DMLKNWF	MI	TTWJBZ5
DMLKNWF	MN	5-HT 2C receptor (HTR2C)
DMLKNWF	MT	DTT
DMLKNWF	MA	Agonist
DMLKNWF	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMLKNWF	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DM3CVWU	DI	DM3CVWU
DM3CVWU	DN	Aryl pyrimidine derivative 1
DM3CVWU	MI	TT1LVF2
DM3CVWU	MN	Cyclin-dependent kinase 9 (CDK9)
DM3CVWU	MT	DTT
DM3CVWU	MA	Inhibitor
DM3CVWU	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DM3CVWU	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMU9Y4B	DI	DMU9Y4B
DMU9Y4B	DN	Aryl pyrimidine derivative 2
DMU9Y4B	MI	TTIY56R
DMU9Y4B	MN	Kynurenine 3-hydroxylase (KMO)
DMU9Y4B	MT	DTT
DMU9Y4B	MA	Inhibitor
DMU9Y4B	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMU9Y4B	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMXND26	DI	DMXND26
DMXND26	DN	Aryl pyrimidine derivative 3
DMXND26	MI	TTIY56R
DMXND26	MN	Kynurenine 3-hydroxylase (KMO)
DMXND26	MT	DTT
DMXND26	MA	Inhibitor
DMXND26	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMXND26	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMWSAL5	DI	DMWSAL5
DMWSAL5	DN	Aryl pyrimidine derivative 4
DMWSAL5	MI	TTIY56R
DMWSAL5	MN	Kynurenine 3-hydroxylase (KMO)
DMWSAL5	MT	DTT
DMWSAL5	MA	Inhibitor
DMWSAL5	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMWSAL5	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMEP9O8	DI	DMEP9O8
DMEP9O8	DN	Aryl pyrimidine derivative 5
DMEP9O8	MI	TTIY56R
DMEP9O8	MN	Kynurenine 3-hydroxylase (KMO)
DMEP9O8	MT	DTT
DMEP9O8	MA	Inhibitor
DMEP9O8	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMEP9O8	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMMF9U6	DI	DMMF9U6
DMMF9U6	DN	Aryl pyrimidine derivative 6
DMMF9U6	MI	TTIY56R
DMMF9U6	MN	Kynurenine 3-hydroxylase (KMO)
DMMF9U6	MT	DTT
DMMF9U6	MA	Inhibitor
DMMF9U6	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMMF9U6	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DM8FAW3	DI	DM8FAW3
DM8FAW3	DN	Aryl pyrimidine derivative 7
DM8FAW3	MI	TTIY56R
DM8FAW3	MN	Kynurenine 3-hydroxylase (KMO)
DM8FAW3	MT	DTT
DM8FAW3	MA	Inhibitor
DM8FAW3	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DM8FAW3	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DM7OA9E	DI	DM7OA9E
DM7OA9E	DN	Aryl pyrimidine derivative 8
DM7OA9E	MI	TTIY56R
DM7OA9E	MN	Kynurenine 3-hydroxylase (KMO)
DM7OA9E	MT	DTT
DM7OA9E	MA	Inhibitor
DM7OA9E	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DM7OA9E	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMBEYD1	DI	DMBEYD1
DMBEYD1	DN	Aryl pyrimidine derivative 9
DMBEYD1	MI	TTIY56R
DMBEYD1	MN	Kynurenine 3-hydroxylase (KMO)
DMBEYD1	MT	DTT
DMBEYD1	MA	Inhibitor
DMBEYD1	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMBEYD1	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMW7HKS	DI	DMW7HKS
DMW7HKS	DN	Aryl sulphoxide imine derivative 1
DMW7HKS	MI	TTZJYKH
DMW7HKS	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMW7HKS	MT	DTT
DMW7HKS	MA	Inhibitor
DMW7HKS	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMW7HKS	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DM0B9SP	DI	DM0B9SP
DM0B9SP	DN	Aryl urea derivative 1
DM0B9SP	MI	TTDP1UC
DM0B9SP	MN	Fatty acid amide hydrolase (FAAH)
DM0B9SP	MT	DTT
DM0B9SP	MA	Inhibitor
DM0B9SP	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DM0B9SP	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMQWJ12	DI	DMQWJ12
DMQWJ12	DN	Aryl urea derivative 2
DMQWJ12	MI	TTDP1UC
DMQWJ12	MN	Fatty acid amide hydrolase (FAAH)
DMQWJ12	MT	DTT
DMQWJ12	MA	Inhibitor
DMQWJ12	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMQWJ12	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DM1G7KI	DI	DM1G7KI
DM1G7KI	DN	Aryl urea derivative 3
DM1G7KI	MI	TTDP1UC
DM1G7KI	MN	Fatty acid amide hydrolase (FAAH)
DM1G7KI	MT	DTT
DM1G7KI	MA	Inhibitor
DM1G7KI	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DM1G7KI	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DM0HOJW	DI	DM0HOJW
DM0HOJW	DN	Aryl urea derivative 4
DM0HOJW	MI	TTDP1UC
DM0HOJW	MN	Fatty acid amide hydrolase (FAAH)
DM0HOJW	MT	DTT
DM0HOJW	MA	Inhibitor
DM0HOJW	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DM0HOJW	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DM54V1R	DI	DM54V1R
DM54V1R	DN	Aryl urea derivative 5
DM54V1R	MI	TTDP1UC
DM54V1R	MN	Fatty acid amide hydrolase (FAAH)
DM54V1R	MT	DTT
DM54V1R	MA	Inhibitor
DM54V1R	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DM54V1R	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMGM72Q	DI	DMGM72Q
DMGM72Q	DN	A-substituted phenylpropionic acid derivative 1
DMGM72Q	MI	TTZMAO3
DMGM72Q	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMGM72Q	MT	DTT
DMGM72Q	MA	Agonist
DMGM72Q	RN	PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
DMGM72Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/25416646

DMH5FEO	DI	DMH5FEO
DMH5FEO	DN	A-substituted phenylpropionic acid derivative 2
DMH5FEO	MI	TTZMAO3
DMH5FEO	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMH5FEO	MT	DTT
DMH5FEO	MA	Agonist
DMH5FEO	RN	PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
DMH5FEO	RU	https://www.ncbi.nlm.nih.gov/pubmed/25416646

DMRG1NL	DI	DMRG1NL
DMRG1NL	DN	Atorvastatin lactole derivative 1
DMRG1NL	MI	TTPADOQ
DMRG1NL	MN	HMG-CoA reductase (HMGCR)
DMRG1NL	MT	DTT
DMRG1NL	MA	Inhibitor
DMRG1NL	RN	HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272.
DMRG1NL	RU	https://www.ncbi.nlm.nih.gov/pubmed/27537201

DMVD5TA	DI	DMVD5TA
DMVD5TA	DN	Azachalcone derivative 1
DMVD5TA	MI	TT2F4OL
DMVD5TA	MN	Tissue transglutaminase (TG2)
DMVD5TA	MT	DTT
DMVD5TA	MA	Inhibitor
DMVD5TA	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DMVD5TA	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DMJWH4B	DI	DMJWH4B
DMJWH4B	DN	Azaindazole amide derivative 1
DMJWH4B	MI	TTKN7QR
DMJWH4B	MN	BDNF/NT-3 growth factors receptor (TrkB)
DMJWH4B	MT	DTT
DMJWH4B	MA	Inhibitor
DMJWH4B	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMJWH4B	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMJWH4B	DI	DMJWH4B
DMJWH4B	DN	Azaindazole amide derivative 1
DMJWH4B	MI	TTXABCW
DMJWH4B	MN	NT-3 growth factor receptor (TrkC)
DMJWH4B	MT	DTT
DMJWH4B	MA	Inhibitor
DMJWH4B	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMJWH4B	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMJWH4B	DI	DMJWH4B
DMJWH4B	DN	Azaindazole amide derivative 1
DMJWH4B	MI	TTTDVOJ
DMJWH4B	MN	Tropomyosin-related kinase A (TrkA)
DMJWH4B	MT	DTT
DMJWH4B	MA	Inhibitor
DMJWH4B	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMJWH4B	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DM3S0LI	DI	DM3S0LI
DM3S0LI	DN	Azaindazole derivative 1
DM3S0LI	MI	TTK0FEA
DM3S0LI	MN	Leucine-rich repeat kinase 2 (LRRK2)
DM3S0LI	MT	DTT
DM3S0LI	MA	Inhibitor
DM3S0LI	RN	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
DM3S0LI	RU	https://www.ncbi.nlm.nih.gov/pubmed/28117607

DMEYS3V	DI	DMEYS3V
DMEYS3V	DN	Azaindazole derivative 2
DMEYS3V	MI	TTK0FEA
DMEYS3V	MN	Leucine-rich repeat kinase 2 (LRRK2)
DMEYS3V	MT	DTT
DMEYS3V	MA	Inhibitor
DMEYS3V	RN	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
DMEYS3V	RU	https://www.ncbi.nlm.nih.gov/pubmed/28117607

DMOV9XA	DI	DMOV9XA
DMOV9XA	DN	Azaindazole derivative 3
DMOV9XA	MI	TTK0FEA
DMOV9XA	MN	Leucine-rich repeat kinase 2 (LRRK2)
DMOV9XA	MT	DTT
DMOV9XA	MA	Inhibitor
DMOV9XA	RN	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
DMOV9XA	RU	https://www.ncbi.nlm.nih.gov/pubmed/28117607

DMX3MNT	DI	DMX3MNT
DMX3MNT	DN	Azaindazole derivative 4
DMX3MNT	MI	TTK0FEA
DMX3MNT	MN	Leucine-rich repeat kinase 2 (LRRK2)
DMX3MNT	MT	DTT
DMX3MNT	MA	Inhibitor
DMX3MNT	RN	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
DMX3MNT	RU	https://www.ncbi.nlm.nih.gov/pubmed/28117607

DMSMXK3	DI	DMSMXK3
DMSMXK3	DN	Azaindole derivative 1
DMSMXK3	MI	TT3PJMV
DMSMXK3	MN	Tyrosine-protein kinase ABL1 (ABL)
DMSMXK3	MT	DTT
DMSMXK3	MA	Inhibitor
DMSMXK3	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMSMXK3	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMXBYHV	DI	DMXBYHV
DMXBYHV	DN	Azaindole derivative 2
DMXBYHV	MI	TT3PJMV
DMXBYHV	MN	Tyrosine-protein kinase ABL1 (ABL)
DMXBYHV	MT	DTT
DMXBYHV	MA	Inhibitor
DMXBYHV	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMXBYHV	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DM2EDOM	DI	DM2EDOM
DM2EDOM	DN	Azaindole derivative 3
DM2EDOM	MI	TT7RJY8
DM2EDOM	MN	Xanthine dehydrogenase/oxidase (XDH)
DM2EDOM	MT	DTT
DM2EDOM	MA	Inhibitor
DM2EDOM	RN	An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
DM2EDOM	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841045

DMCKSJ8	DI	DMCKSJ8
DMCKSJ8	DN	Azaindole derivative 4
DMCKSJ8	MI	TT7RJY8
DMCKSJ8	MN	Xanthine dehydrogenase/oxidase (XDH)
DMCKSJ8	MT	DTT
DMCKSJ8	MA	Inhibitor
DMCKSJ8	RN	An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
DMCKSJ8	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841045

DMD2BL3	DI	DMD2BL3
DMD2BL3	DN	Azaindole derivative 5
DMD2BL3	MI	TT7RJY8
DMD2BL3	MN	Xanthine dehydrogenase/oxidase (XDH)
DMD2BL3	MT	DTT
DMD2BL3	MA	Inhibitor
DMD2BL3	RN	An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
DMD2BL3	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841045

DMJBGHL	DI	DMJBGHL
DMJBGHL	DN	Azaindole derivative 6
DMJBGHL	MI	TT7RJY8
DMJBGHL	MN	Xanthine dehydrogenase/oxidase (XDH)
DMJBGHL	MT	DTT
DMJBGHL	MA	Inhibitor
DMJBGHL	RN	An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
DMJBGHL	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841045

DMA2JGU	DI	DMA2JGU
DMA2JGU	DN	Azaindole derivative 7
DMA2JGU	MI	TT7RJY8
DMA2JGU	MN	Xanthine dehydrogenase/oxidase (XDH)
DMA2JGU	MT	DTT
DMA2JGU	MA	Inhibitor
DMA2JGU	RN	An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
DMA2JGU	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841045

DMEUHCD	DI	DMEUHCD
DMEUHCD	DN	Aza-phenalene-3-ketone derivative 1
DMEUHCD	MI	TTEBCY8
DMEUHCD	MN	Poly [ADP-ribose] polymerase (PARP)
DMEUHCD	MT	DTT
DMEUHCD	MA	Inhibitor
DMEUHCD	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DMEUHCD	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DM76XH4	DI	DM76XH4
DM76XH4	DN	Azepan-4-one derivative 1
DM76XH4	MI	TTZC0KV
DM76XH4	MN	Zinc finger-containing ubiquitin peptidase 1 (ZUP1)
DM76XH4	MT	DTT
DM76XH4	MA	Inhibitor
DM76XH4	RN	Deubiquitinases (DUBs) and DUB inhibitors: a patent review.Expert Opin Ther Pat. 2015;25(10):1191-1208.
DM76XH4	RU	https://www.ncbi.nlm.nih.gov/pubmed/26077642

DM7O0MD	DI	DM7O0MD
DM7O0MD	DN	Azepan-4-one derivative 2
DM7O0MD	MI	TTZC0KV
DM7O0MD	MN	Zinc finger-containing ubiquitin peptidase 1 (ZUP1)
DM7O0MD	MT	DTT
DM7O0MD	MA	Inhibitor
DM7O0MD	RN	Deubiquitinases (DUBs) and DUB inhibitors: a patent review.Expert Opin Ther Pat. 2015;25(10):1191-1208.
DM7O0MD	RU	https://www.ncbi.nlm.nih.gov/pubmed/26077642

DMXEFUD	DI	DMXEFUD
DMXEFUD	DN	Azetidine derivative 1
DMXEFUD	MI	TT6OEDT
DMXEFUD	MN	Cannabinoid receptor 1 (CB1)
DMXEFUD	MT	DTT
DMXEFUD	MA	Antagonist
DMXEFUD	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMXEFUD	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMTB3KS	DI	DMTB3KS
DMTB3KS	DN	Azetidine derivative 2
DMTB3KS	MI	TTZCRP3
DMTB3KS	MN	ERK activator kinase (MEK)
DMTB3KS	MT	DTT
DMTB3KS	MA	Inhibitor
DMTB3KS	RN	MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906.
DMTB3KS	RU	https://www.ncbi.nlm.nih.gov/pubmed/28594589

DMIKSVG	DI	DMIKSVG
DMIKSVG	DN	Azetidine derivative 3
DMIKSVG	MI	TT6OEDT
DMIKSVG	MN	Cannabinoid receptor 1 (CB1)
DMIKSVG	MT	DTT
DMIKSVG	MA	Antagonist
DMIKSVG	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMIKSVG	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMXL2V9	DI	DMXL2V9
DMXL2V9	DN	Azetidine derivative 4
DMXL2V9	MI	TT6OEDT
DMXL2V9	MN	Cannabinoid receptor 1 (CB1)
DMXL2V9	MT	DTT
DMXL2V9	MA	Antagonist
DMXL2V9	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMXL2V9	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMJ9U0E	DI	DMJ9U0E
DMJ9U0E	DN	Azetidine derivative 5
DMJ9U0E	MI	TTZJYKH
DMJ9U0E	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMJ9U0E	MT	DTT
DMJ9U0E	MA	Inhibitor
DMJ9U0E	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMJ9U0E	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMH942E	DI	DMH942E
DMH942E	DN	Azetidine urea derivative 1
DMH942E	MI	TTDP1UC
DMH942E	MN	Fatty acid amide hydrolase (FAAH)
DMH942E	MT	DTT
DMH942E	MA	Inhibitor
DMH942E	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMH942E	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMJY8XI	DI	DMJY8XI
DMJY8XI	DN	Azetidine urea derivative 2
DMJY8XI	MI	TTDP1UC
DMJY8XI	MN	Fatty acid amide hydrolase (FAAH)
DMJY8XI	MT	DTT
DMJY8XI	MA	Inhibitor
DMJY8XI	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMJY8XI	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DM48PIO	DI	DM48PIO
DM48PIO	DN	Azetidine urea derivative 3
DM48PIO	MI	TTDP1UC
DM48PIO	MN	Fatty acid amide hydrolase (FAAH)
DM48PIO	MT	DTT
DM48PIO	MA	Inhibitor
DM48PIO	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DM48PIO	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMZX8Y0	DI	DMZX8Y0
DMZX8Y0	DN	Azetidine-1-carboxamide derivative 1
DMZX8Y0	MI	TT6OEDT
DMZX8Y0	MN	Cannabinoid receptor 1 (CB1)
DMZX8Y0	MT	DTT
DMZX8Y0	MA	Antagonist
DMZX8Y0	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMZX8Y0	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMONQ4L	DI	DMONQ4L
DMONQ4L	DN	Azetidine-1-carboxamide derivative 2
DMONQ4L	MI	TT6OEDT
DMONQ4L	MN	Cannabinoid receptor 1 (CB1)
DMONQ4L	MT	DTT
DMONQ4L	MA	Antagonist
DMONQ4L	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMONQ4L	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DM2UGK3	DI	DM2UGK3
DM2UGK3	DN	Azetidine-1-carboxamide derivative 3
DM2UGK3	MI	TT6OEDT
DM2UGK3	MN	Cannabinoid receptor 1 (CB1)
DM2UGK3	MT	DTT
DM2UGK3	MA	Antagonist
DM2UGK3	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DM2UGK3	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMRMED4	DI	DMRMED4
DMRMED4	DN	Azetidine-benzoxazin-3(4H)-one derivative 1
DMRMED4	MI	TTZ963I
DMRMED4	MN	Monoglyceride lipase (MAGL)
DMRMED4	MT	DTT
DMRMED4	MA	Inhibitor
DMRMED4	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMRMED4	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMMSPX7	DI	DMMSPX7
DMMSPX7	DN	Azetidine-benzoxazin-3(4H)-one derivative 2
DMMSPX7	MI	TTZ963I
DMMSPX7	MN	Monoglyceride lipase (MAGL)
DMMSPX7	MT	DTT
DMMSPX7	MA	Inhibitor
DMMSPX7	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMMSPX7	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMA430E	DI	DMA430E
DMA430E	DN	Azetidine-benzoxazin-3(4H)-one derivative 3
DMA430E	MI	TTZ963I
DMA430E	MN	Monoglyceride lipase (MAGL)
DMA430E	MT	DTT
DMA430E	MA	Inhibitor
DMA430E	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMA430E	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMMWK3E	DI	DMMWK3E
DMMWK3E	DN	Azetidinyl-piperazine derivative 1
DMMWK3E	MI	TTZ963I
DMMWK3E	MN	Monoglyceride lipase (MAGL)
DMMWK3E	MT	DTT
DMMWK3E	MA	Inhibitor
DMMWK3E	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMMWK3E	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DM0C48S	DI	DM0C48S
DM0C48S	DN	Azetidinyl-piperazine derivative 2
DM0C48S	MI	TTZ963I
DM0C48S	MN	Monoglyceride lipase (MAGL)
DM0C48S	MT	DTT
DM0C48S	MA	Inhibitor
DM0C48S	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DM0C48S	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DM3WHL2	DI	DM3WHL2
DM3WHL2	DN	Azetidinyl-piperazine derivative 3
DM3WHL2	MI	TTZ963I
DM3WHL2	MN	Monoglyceride lipase (MAGL)
DM3WHL2	MT	DTT
DM3WHL2	MA	Inhibitor
DM3WHL2	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DM3WHL2	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DM0IJYQ	DI	DM0IJYQ
DM0IJYQ	DN	Azetidinyl-piperidine derivative 1
DM0IJYQ	MI	TTZ963I
DM0IJYQ	MN	Monoglyceride lipase (MAGL)
DM0IJYQ	MT	DTT
DM0IJYQ	MA	Inhibitor
DM0IJYQ	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DM0IJYQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMNQLJU	DI	DMNQLJU
DMNQLJU	DN	Azetidinyl-piperidine derivative 2
DMNQLJU	MI	TTZ963I
DMNQLJU	MN	Monoglyceride lipase (MAGL)
DMNQLJU	MT	DTT
DMNQLJU	MA	Inhibitor
DMNQLJU	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMNQLJU	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DM2UDV8	DI	DM2UDV8
DM2UDV8	DN	Azetidinyl-piperidine derivative 3
DM2UDV8	MI	TTZ963I
DM2UDV8	MN	Monoglyceride lipase (MAGL)
DM2UDV8	MT	DTT
DM2UDV8	MA	Inhibitor
DM2UDV8	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DM2UDV8	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DM0E8YF	DI	DM0E8YF
DM0E8YF	DN	Azole benzene derivative 1
DM0E8YF	MI	TT7RJY8
DM0E8YF	MN	Xanthine dehydrogenase/oxidase (XDH)
DM0E8YF	MT	DTT
DM0E8YF	MA	Inhibitor
DM0E8YF	RN	An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
DM0E8YF	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841045

DMJG7M6	DI	DMJG7M6
DMJG7M6	DN	Azole benzene derivative 2
DMJG7M6	MI	TT7RJY8
DMJG7M6	MN	Xanthine dehydrogenase/oxidase (XDH)
DMJG7M6	MT	DTT
DMJG7M6	MA	Inhibitor
DMJG7M6	RN	An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
DMJG7M6	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841045

DMH8Q4T	DI	DMH8Q4T
DMH8Q4T	DN	Azole benzene derivative 3
DMH8Q4T	MI	TT7RJY8
DMH8Q4T	MN	Xanthine dehydrogenase/oxidase (XDH)
DMH8Q4T	MT	DTT
DMH8Q4T	MA	Inhibitor
DMH8Q4T	RN	An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
DMH8Q4T	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841045

DMDPHT1	DI	DMDPHT1
DMDPHT1	DN	Azole benzene derivative 4
DMDPHT1	MI	TT7RJY8
DMDPHT1	MN	Xanthine dehydrogenase/oxidase (XDH)
DMDPHT1	MT	DTT
DMDPHT1	MA	Inhibitor
DMDPHT1	RN	An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
DMDPHT1	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841045

DM76HXA	DI	DM76HXA
DM76HXA	DN	Azole derivative 1
DM76HXA	MI	TTDP1UC
DM76HXA	MN	Fatty acid amide hydrolase (FAAH)
DM76HXA	MT	DTT
DM76HXA	MA	Inhibitor
DM76HXA	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DM76HXA	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMOPNJ6	DI	DMOPNJ6
DMOPNJ6	DN	Azole derivative 2
DMOPNJ6	MI	TTDP1UC
DMOPNJ6	MN	Fatty acid amide hydrolase (FAAH)
DMOPNJ6	MT	DTT
DMOPNJ6	MA	Inhibitor
DMOPNJ6	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMOPNJ6	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMN9KTJ	DI	DMN9KTJ
DMN9KTJ	DN	Azole derivative 3
DMN9KTJ	MI	TTDP1UC
DMN9KTJ	MN	Fatty acid amide hydrolase (FAAH)
DMN9KTJ	MT	DTT
DMN9KTJ	MA	Inhibitor
DMN9KTJ	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMN9KTJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMOW01E	DI	DMOW01E
DMOW01E	DN	Azole derivative 4
DMOW01E	MI	TTDP1UC
DMOW01E	MN	Fatty acid amide hydrolase (FAAH)
DMOW01E	MT	DTT
DMOW01E	MA	Inhibitor
DMOW01E	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMOW01E	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DM36QM5	DI	DM36QM5
DM36QM5	DN	Azole derivative 5
DM36QM5	MI	TTDP1UC
DM36QM5	MN	Fatty acid amide hydrolase (FAAH)
DM36QM5	MT	DTT
DM36QM5	MA	Inhibitor
DM36QM5	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DM36QM5	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMTMJ7S	DI	DMTMJ7S
DMTMJ7S	DN	Azole derivative 6
DMTMJ7S	MI	TTF8P9I
DMTMJ7S	MN	Diacylglycerol acyltransferase 1 (DGAT1)
DMTMJ7S	MT	DTT
DMTMJ7S	MA	Inhibitor
DMTMJ7S	RN	Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
DMTMJ7S	RU	https://www.ncbi.nlm.nih.gov/pubmed/25470667

DMVUJGI	DI	DMVUJGI
DMVUJGI	DN	Azole derivative 7
DMVUJGI	MI	TTF8P9I
DMVUJGI	MN	Diacylglycerol acyltransferase 1 (DGAT1)
DMVUJGI	MT	DTT
DMVUJGI	MA	Inhibitor
DMVUJGI	RN	Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
DMVUJGI	RU	https://www.ncbi.nlm.nih.gov/pubmed/25470667

DM2DT6L	DI	DM2DT6L
DM2DT6L	DN	BB 0223767
DM2DT6L	MI	TTOJ9QL
DM2DT6L	MN	Endoplasmic reticulum to nucleus signaling 1 (ERN1)
DM2DT6L	MT	DTT
DM2DT6L	MA	Inhibitor
DM2DT6L	RN	IRE-1 inhibitors. US8614253.
DM2DT6L	RU	http://www.freepatentsonline.com/US8614253.html

DMTWIE2	DI	DMTWIE2
DMTWIE2	DN	BC11-28
DMTWIE2	MI	TTIS4OW
DMTWIE2	MN	Phosphodiesterase 8 (PDE8)
DMTWIE2	MT	DTT
DMTWIE2	MA	Inhibitor
DMTWIE2	RN	Inhibitors of phosphodiesterase 11 (PDE11). US9173884.
DMTWIE2	RU	http://www.freepatentsonline.com/US9173884.html

DMZD6IJ	DI	DMZD6IJ
DMZD6IJ	DN	BDBM108945
DMZD6IJ	MI	TTPKHTZ
DMZD6IJ	MN	Activin receptor type IB (ACVR1B)
DMZD6IJ	MT	DTT
DMZD6IJ	MA	Inhibitor
DMZD6IJ	RN	BMP inhibitors and methods of use thereof. US9682983.
DMZD6IJ	RU	http://www.freepatentsonline.com/US9682983.html

DMW5SD6	DI	DMW5SD6
DMW5SD6	DN	BDBM50011552
DMW5SD6	MI	TT6NI13
DMW5SD6	MN	MEK kinase kinase 4 (MAP4K4)
DMW5SD6	MT	DTT
DMW5SD6	MA	Inhibitor
DMW5SD6	RN	Aminoquinazoline and pyridopyrimidine derivatives. US9592235.
DMW5SD6	RU	http://www.freepatentsonline.com/US9592235.html

DMHNYQU	DI	DMHNYQU
DMHNYQU	DN	BDBM50011553
DMHNYQU	MI	TT6NI13
DMHNYQU	MN	MEK kinase kinase 4 (MAP4K4)
DMHNYQU	MT	DTT
DMHNYQU	MA	Inhibitor
DMHNYQU	RN	Aminoquinazoline and pyridopyrimidine derivatives. US9592235.
DMHNYQU	RU	http://www.freepatentsonline.com/US9592235.html

DMA7JB6	DI	DMA7JB6
DMA7JB6	DN	BDBM50054344
DMA7JB6	MI	TT369M5
DMA7JB6	MN	Protein-tyrosine phosphatase SHP-1 (PTPN6)
DMA7JB6	MT	DTT
DMA7JB6	MA	Inhibitor
DMA7JB6	RN	Hydroxyindole carboxylic acid based inhibitors for oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2). US9522881.
DMA7JB6	RU	http://www.freepatentsonline.com/US9522881.html

DMQ4TUE	DI	DMQ4TUE
DMQ4TUE	DN	BDBM50061601
DMQ4TUE	MI	TTCGOIN
DMQ4TUE	MN	PIM-3 protein kinase (PIM3)
DMQ4TUE	MT	DTT
DMQ4TUE	MA	Inhibitor
DMQ4TUE	RN	Azole compounds as PIM inhibitors. US9321756.
DMQ4TUE	RU	http://www.freepatentsonline.com/US9321756.html

DM3MRD9	DI	DM3MRD9
DM3MRD9	DN	BDBM50061608
DM3MRD9	MI	TTCGOIN
DM3MRD9	MN	PIM-3 protein kinase (PIM3)
DM3MRD9	MT	DTT
DM3MRD9	MA	Inhibitor
DM3MRD9	RN	Azole compounds as PIM inhibitors. US9321756.
DM3MRD9	RU	http://www.freepatentsonline.com/US9321756.html

DMM8IDC	DI	DMM8IDC
DMM8IDC	DN	BDBM50061612
DMM8IDC	MI	TTCGOIN
DMM8IDC	MN	PIM-3 protein kinase (PIM3)
DMM8IDC	MT	DTT
DMM8IDC	MA	Inhibitor
DMM8IDC	RN	Azole compounds as PIM inhibitors. US9321756.
DMM8IDC	RU	http://www.freepatentsonline.com/US9321756.html

DM4I829	DI	DM4I829
DM4I829	DN	BDBM50080408
DM4I829	MI	TTI1FPZ
DM4I829	MN	Epithelial discoidin domain receptor 1 (DDR1)
DM4I829	MT	DTT
DM4I829	MA	Inhibitor
DM4I829	RN	Quinazolinedione derivative. US9567304.
DM4I829	RU	http://www.freepatentsonline.com/US9567304.html

DMJNOB9	DI	DMJNOB9
DMJNOB9	DN	BDBM50080559
DMJNOB9	MI	TTDYP7I
DMJNOB9	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DMJNOB9	MT	DTT
DMJNOB9	MA	Inhibitor
DMJNOB9	RN	Pyridin-4-yl derivatives. US9617250.
DMJNOB9	RU	http://www.freepatentsonline.com/US9617250.html

DM3VNK0	DI	DM3VNK0
DM3VNK0	DN	BDBM50080563
DM3VNK0	MI	TTDYP7I
DM3VNK0	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DM3VNK0	MT	DTT
DM3VNK0	MA	Inhibitor
DM3VNK0	RN	Pyridin-4-yl derivatives. US9617250.
DM3VNK0	RU	http://www.freepatentsonline.com/US9617250.html

DMLJU5P	DI	DMLJU5P
DMLJU5P	DN	BDBM50080570
DMLJU5P	MI	TTDYP7I
DMLJU5P	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DMLJU5P	MT	DTT
DMLJU5P	MA	Inhibitor
DMLJU5P	RN	Pyridin-4-yl derivatives. US9617250.
DMLJU5P	RU	http://www.freepatentsonline.com/US9617250.html

DMS7ZLK	DI	DMS7ZLK
DMS7ZLK	DN	BDBM50158703
DMS7ZLK	MI	TTIG67W
DMS7ZLK	MN	Lysine-specific demethylase 5A (KDM5A)
DMS7ZLK	MT	DTT
DMS7ZLK	MA	Inhibitor
DMS7ZLK	RN	Histone demethylase inhibitors. US9714230.
DMS7ZLK	RU	http://www.freepatentsonline.com/US9714230.html

DMYJF70	DI	DMYJF70
DMYJF70	DN	BDBM50158755
DMYJF70	MI	TTIG67W
DMYJF70	MN	Lysine-specific demethylase 5A (KDM5A)
DMYJF70	MT	DTT
DMYJF70	MA	Inhibitor
DMYJF70	RN	Histone demethylase inhibitors. US10173996.
DMYJF70	RU	http://www.freepatentsonline.com/US10173996.html

DMU07MO	DI	DMU07MO
DMU07MO	DN	BDBM50158791
DMU07MO	MI	TTIG67W
DMU07MO	MN	Lysine-specific demethylase 5A (KDM5A)
DMU07MO	MT	DTT
DMU07MO	MA	Inhibitor
DMU07MO	RN	Histone demethylase inhibitors. US9725441.
DMU07MO	RU	http://www.freepatentsonline.com/US9725441.html

DMWJZU9	DI	DMWJZU9
DMWJZU9	DN	BDBM50158794
DMWJZU9	MI	TTIG67W
DMWJZU9	MN	Lysine-specific demethylase 5A (KDM5A)
DMWJZU9	MT	DTT
DMWJZU9	MA	Inhibitor
DMWJZU9	RN	Histone demethylase inhibitors. US10040779.
DMWJZU9	RU	http://www.freepatentsonline.com/US10040779.html

DMTWI1H	DI	DMTWI1H
DMTWI1H	DN	BDBM50158803
DMTWI1H	MI	TTIG67W
DMTWI1H	MN	Lysine-specific demethylase 5A (KDM5A)
DMTWI1H	MT	DTT
DMTWI1H	MA	Inhibitor
DMTWI1H	RN	Histone demethylase inhibitors. US9617242.
DMTWI1H	RU	http://www.freepatentsonline.com/US9617242.html

DMSTD28	DI	DMSTD28
DMSTD28	DN	BDBM50173306
DMSTD28	MI	TTAZ3MN
DMSTD28	MN	Beta-adrenergic receptor kinase 1 (ADRBK1)
DMSTD28	MT	DTT
DMSTD28	MA	Inhibitor
DMSTD28	RN	G protein-coupled receptor kinase 2 inhibitors and methods for use of the same. US10023564.
DMSTD28	RU	http://www.freepatentsonline.com/US10023564.html

DM7RTQP	DI	DM7RTQP
DM7RTQP	DN	BDBM50173323
DM7RTQP	MI	TTTCXO0
DM7RTQP	MN	G protein-coupled receptor kinase 5 (GRK5)
DM7RTQP	MT	DTT
DM7RTQP	MA	Inhibitor
DM7RTQP	RN	G protein-coupled receptor kinase 2 inhibitors and methods for use of the same. US10023564.
DM7RTQP	RU	http://www.freepatentsonline.com/US10023564.html

DMKEVDL	DI	DMKEVDL
DMKEVDL	DN	BDBM50173327
DMKEVDL	MI	TTTCXO0
DMKEVDL	MN	G protein-coupled receptor kinase 5 (GRK5)
DMKEVDL	MT	DTT
DMKEVDL	MA	Inhibitor
DMKEVDL	RN	G protein-coupled receptor kinase 2 inhibitors and methods for use of the same. US10023564.
DMKEVDL	RU	http://www.freepatentsonline.com/US10023564.html

DM1PU37	DI	DM1PU37
DM1PU37	DN	BDBM50173330
DM1PU37	MI	TTTCXO0
DM1PU37	MN	G protein-coupled receptor kinase 5 (GRK5)
DM1PU37	MT	DTT
DM1PU37	MA	Inhibitor
DM1PU37	RN	G protein-coupled receptor kinase 2 inhibitors and methods for use of the same. US10023564.
DM1PU37	RU	http://www.freepatentsonline.com/US10023564.html

DM52IQF	DI	DM52IQF
DM52IQF	DN	BDBM50177012
DM52IQF	MI	TTECBXN
DM52IQF	MN	Oxysterols receptor LXR-alpha (NR1H3)
DM52IQF	MT	DTT
DM52IQF	MA	Inhibitor
DM52IQF	RN	Piperazine derivatives as liver X receptor modulators. US10144715.
DM52IQF	RU	http://www.freepatentsonline.com/US10144715.html

DMEL28G	DI	DMEL28G
DMEL28G	DN	BDBM50177019
DMEL28G	MI	TTECBXN
DMEL28G	MN	Oxysterols receptor LXR-alpha (NR1H3)
DMEL28G	MT	DTT
DMEL28G	MA	Inhibitor
DMEL28G	RN	Piperazine derivatives as liver X receptor modulators. US10144715.
DMEL28G	RU	http://www.freepatentsonline.com/US10144715.html

DM7TASJ	DI	DM7TASJ
DM7TASJ	DN	BDBM50363773
DM7TASJ	MI	TTLKF5M
DM7TASJ	MN	NAD-dependent deacetylase sirtuin-2 (SIRT2)
DM7TASJ	MT	DTT
DM7TASJ	MA	Inhibitor
DM7TASJ	RN	Aroyl thiourea derivatives. US9365508.
DM7TASJ	RU	http://www.freepatentsonline.com/US9365508.html

DM46UPM	DI	DM46UPM
DM46UPM	DN	BDBM50363780
DM46UPM	MI	TTLKF5M
DM46UPM	MN	NAD-dependent deacetylase sirtuin-2 (SIRT2)
DM46UPM	MT	DTT
DM46UPM	MA	Inhibitor
DM46UPM	RN	Aroyl thiourea derivatives. US9365508.
DM46UPM	RU	http://www.freepatentsonline.com/US9365508.html

DMUQI15	DI	DMUQI15
DMUQI15	DN	BDBM50363782
DMUQI15	MI	TTLKF5M
DMUQI15	MN	NAD-dependent deacetylase sirtuin-2 (SIRT2)
DMUQI15	MT	DTT
DMUQI15	MA	Inhibitor
DMUQI15	RN	Aroyl thiourea derivatives. US9365508.
DMUQI15	RU	http://www.freepatentsonline.com/US9365508.html

DMPOVZ6	DI	DMPOVZ6
DMPOVZ6	DN	BDBM50379214
DMPOVZ6	MI	TTIET93
DMPOVZ6	MN	Activated CDC42 kinase 1 (ACK-1)
DMPOVZ6	MT	DTT
DMPOVZ6	MA	Inhibitor
DMPOVZ6	RN	Kinase modulators for the treatment of cancer. US9416123.
DMPOVZ6	RU	http://www.freepatentsonline.com/US9416123.html

DMQJ5S8	DI	DMQJ5S8
DMQJ5S8	DN	BDBM50382283
DMQJ5S8	MI	TTOYT5L
DMQJ5S8	MN	Dipeptidyl-peptidase 7 (DPP7)
DMQJ5S8	MT	DTT
DMQJ5S8	MA	Inhibitor
DMQJ5S8	RN	FAP inhibitors. US9346814.
DMQJ5S8	RU	http://www.freepatentsonline.com/US9346814.html

DM6DFTX	DI	DM6DFTX
DM6DFTX	DN	BDBM50434164
DM6DFTX	MI	TTOYT5L
DM6DFTX	MN	Dipeptidyl-peptidase 7 (DPP7)
DM6DFTX	MT	DTT
DM6DFTX	MA	Inhibitor
DM6DFTX	RN	FAP inhibitors. US9346814.
DM6DFTX	RU	http://www.freepatentsonline.com/US9346814.html

DMDTYJ9	DI	DMDTYJ9
DMDTYJ9	DN	BDBM50434165
DMDTYJ9	MI	TTOYT5L
DMDTYJ9	MN	Dipeptidyl-peptidase 7 (DPP7)
DMDTYJ9	MT	DTT
DMDTYJ9	MA	Inhibitor
DMDTYJ9	RN	FAP inhibitors. US9346814.
DMDTYJ9	RU	http://www.freepatentsonline.com/US9346814.html

DM9GLQB	DI	DM9GLQB
DM9GLQB	DN	BDBM50444058
DM9GLQB	MI	TTIEMFN
DM9GLQB	MN	TYRO3 tyrosine kinase receptor (TYRO3)
DM9GLQB	MT	DTT
DM9GLQB	MA	Inhibitor
DM9GLQB	RN	Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity. US9649309.
DM9GLQB	RU	http://www.freepatentsonline.com/US9649309.html

DMS0EMU	DI	DMS0EMU
DMS0EMU	DN	BDBM50444059
DMS0EMU	MI	TTIEMFN
DMS0EMU	MN	TYRO3 tyrosine kinase receptor (TYRO3)
DMS0EMU	MT	DTT
DMS0EMU	MA	Inhibitor
DMS0EMU	RN	Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity. US9649309.
DMS0EMU	RU	http://www.freepatentsonline.com/US9649309.html

DMR2UGC	DI	DMR2UGC
DMR2UGC	DN	BDBM50444062
DMR2UGC	MI	TTIEMFN
DMR2UGC	MN	TYRO3 tyrosine kinase receptor (TYRO3)
DMR2UGC	MT	DTT
DMR2UGC	MA	Inhibitor
DMR2UGC	RN	Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity. US9649309.
DMR2UGC	RU	http://www.freepatentsonline.com/US9649309.html

DMDOCTB	DI	DMDOCTB
DMDOCTB	DN	Benzamide derivative 1
DMDOCTB	MI	TT9NXW4
DMDOCTB	MN	Sigma intracellular receptor 2 (TMEM97)
DMDOCTB	MT	DTT
DMDOCTB	MA	Ligand
DMDOCTB	RN	Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578.
DMDOCTB	RU	https://www.ncbi.nlm.nih.gov/pubmed/28051882

DM9PKU2	DI	DM9PKU2
DM9PKU2	DN	Benzamide derivative 10
DM9PKU2	MI	TT5TPI6
DM9PKU2	MN	Opioid receptor sigma 1 (OPRS1)
DM9PKU2	MT	DTT
DM9PKU2	MA	Ligand
DM9PKU2	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DM9PKU2	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DM9PKU2	DI	DM9PKU2
DM9PKU2	DN	Benzamide derivative 10
DM9PKU2	MI	TT9NXW4
DM9PKU2	MN	Sigma intracellular receptor 2 (TMEM97)
DM9PKU2	MT	DTT
DM9PKU2	MA	Ligand
DM9PKU2	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DM9PKU2	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DM4V3Y5	DI	DM4V3Y5
DM4V3Y5	DN	Benzamide derivative 11
DM4V3Y5	MI	TT5TPI6
DM4V3Y5	MN	Opioid receptor sigma 1 (OPRS1)
DM4V3Y5	MT	DTT
DM4V3Y5	MA	Ligand
DM4V3Y5	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DM4V3Y5	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DM4V3Y5	DI	DM4V3Y5
DM4V3Y5	DN	Benzamide derivative 11
DM4V3Y5	MI	TT9NXW4
DM4V3Y5	MN	Sigma intracellular receptor 2 (TMEM97)
DM4V3Y5	MT	DTT
DM4V3Y5	MA	Ligand
DM4V3Y5	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DM4V3Y5	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DMS527F	DI	DMS527F
DMS527F	DN	Benzamide derivative 12
DMS527F	MI	TT473XN
DMS527F	MN	P2X purinoceptor 7 (P2RX7)
DMS527F	MT	DTT
DMS527F	MA	Antagonist
DMS527F	RN	P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267.
DMS527F	RU	https://www.ncbi.nlm.nih.gov/pubmed/27724045

DMYSH9J	DI	DMYSH9J
DMYSH9J	DN	Benzamide derivative 13
DMYSH9J	MI	TT473XN
DMYSH9J	MN	P2X purinoceptor 7 (P2RX7)
DMYSH9J	MT	DTT
DMYSH9J	MA	Antagonist
DMYSH9J	RN	P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267.
DMYSH9J	RU	https://www.ncbi.nlm.nih.gov/pubmed/27724045

DMP2LDC	DI	DMP2LDC
DMP2LDC	DN	Benzamide derivative 14
DMP2LDC	MI	TTYLQ8V
DMP2LDC	MN	Prostaglandin E synthase (PTGES)
DMP2LDC	MT	DTT
DMP2LDC	MA	Inhibitor
DMP2LDC	RN	Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059.
DMP2LDC	RU	https://www.ncbi.nlm.nih.gov/pubmed/28627961

DMAEBJ4	DI	DMAEBJ4
DMAEBJ4	DN	Benzamide derivative 15
DMAEBJ4	MI	TTYLQ8V
DMAEBJ4	MN	Prostaglandin E synthase (PTGES)
DMAEBJ4	MT	DTT
DMAEBJ4	MA	Inhibitor
DMAEBJ4	RN	Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059.
DMAEBJ4	RU	https://www.ncbi.nlm.nih.gov/pubmed/28627961

DMOAXKF	DI	DMOAXKF
DMOAXKF	DN	Benzamide derivative 16
DMOAXKF	MI	TTYLQ8V
DMOAXKF	MN	Prostaglandin E synthase (PTGES)
DMOAXKF	MT	DTT
DMOAXKF	MA	Inhibitor
DMOAXKF	RN	Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059.
DMOAXKF	RU	https://www.ncbi.nlm.nih.gov/pubmed/28627961

DMD7640	DI	DMD7640
DMD7640	DN	Benzamide derivative 18
DMD7640	MI	TTYLQ8V
DMD7640	MN	Prostaglandin E synthase (PTGES)
DMD7640	MT	DTT
DMD7640	MA	Inhibitor
DMD7640	RN	Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059.
DMD7640	RU	https://www.ncbi.nlm.nih.gov/pubmed/28627961

DM5YNTM	DI	DM5YNTM
DM5YNTM	DN	Benzamide derivative 19
DM5YNTM	MI	TTF8P9I
DM5YNTM	MN	Diacylglycerol acyltransferase 1 (DGAT1)
DM5YNTM	MT	DTT
DM5YNTM	MA	Inhibitor
DM5YNTM	RN	Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
DM5YNTM	RU	https://www.ncbi.nlm.nih.gov/pubmed/25470667

DM0UWNY	DI	DM0UWNY
DM0UWNY	DN	Benzamide derivative 2
DM0UWNY	MI	TT9NXW4
DM0UWNY	MN	Sigma intracellular receptor 2 (TMEM97)
DM0UWNY	MT	DTT
DM0UWNY	MA	Ligand
DM0UWNY	RN	Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578.
DM0UWNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/28051882

DMFY78L	DI	DMFY78L
DMFY78L	DN	Benzamide derivative 3
DMFY78L	MI	TT9NXW4
DMFY78L	MN	Sigma intracellular receptor 2 (TMEM97)
DMFY78L	MT	DTT
DMFY78L	MA	Ligand
DMFY78L	RN	Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578.
DMFY78L	RU	https://www.ncbi.nlm.nih.gov/pubmed/28051882

DMNKYL9	DI	DMNKYL9
DMNKYL9	DN	Benzamide derivative 4
DMNKYL9	MI	TT9NXW4
DMNKYL9	MN	Sigma intracellular receptor 2 (TMEM97)
DMNKYL9	MT	DTT
DMNKYL9	MA	Ligand
DMNKYL9	RN	Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578.
DMNKYL9	RU	https://www.ncbi.nlm.nih.gov/pubmed/28051882

DM6W0TM	DI	DM6W0TM
DM6W0TM	DN	Benzamide derivative 5
DM6W0TM	MI	TTA6ZN2
DM6W0TM	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DM6W0TM	MT	DTT
DM6W0TM	MA	Inhibitor
DM6W0TM	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DM6W0TM	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM80TDC	DI	DM80TDC
DM80TDC	DN	Benzamide derivative 6
DM80TDC	MI	TTA6ZN2
DM80TDC	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DM80TDC	MT	DTT
DM80TDC	MA	Inhibitor
DM80TDC	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DM80TDC	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM7UEJT	DI	DM7UEJT
DM7UEJT	DN	Benzamide derivative 7
DM7UEJT	MI	TT5TPI6
DM7UEJT	MN	Opioid receptor sigma 1 (OPRS1)
DM7UEJT	MT	DTT
DM7UEJT	MA	Ligand
DM7UEJT	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DM7UEJT	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DM7UEJT	DI	DM7UEJT
DM7UEJT	DN	Benzamide derivative 7
DM7UEJT	MI	TT9NXW4
DM7UEJT	MN	Sigma intracellular receptor 2 (TMEM97)
DM7UEJT	MT	DTT
DM7UEJT	MA	Ligand
DM7UEJT	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DM7UEJT	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DMAIJHC	DI	DMAIJHC
DMAIJHC	DN	Benzamide derivative 8
DMAIJHC	MI	TT5TPI6
DMAIJHC	MN	Opioid receptor sigma 1 (OPRS1)
DMAIJHC	MT	DTT
DMAIJHC	MA	Ligand
DMAIJHC	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DMAIJHC	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DMAIJHC	DI	DMAIJHC
DMAIJHC	DN	Benzamide derivative 8
DMAIJHC	MI	TT9NXW4
DMAIJHC	MN	Sigma intracellular receptor 2 (TMEM97)
DMAIJHC	MT	DTT
DMAIJHC	MA	Ligand
DMAIJHC	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DMAIJHC	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DMVFSJZ	DI	DMVFSJZ
DMVFSJZ	DN	Benzamide derivative 9
DMVFSJZ	MI	TT5TPI6
DMVFSJZ	MN	Opioid receptor sigma 1 (OPRS1)
DMVFSJZ	MT	DTT
DMVFSJZ	MA	Ligand
DMVFSJZ	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DMVFSJZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DMVFSJZ	DI	DMVFSJZ
DMVFSJZ	DN	Benzamide derivative 9
DMVFSJZ	MI	TT9NXW4
DMVFSJZ	MN	Sigma intracellular receptor 2 (TMEM97)
DMVFSJZ	MT	DTT
DMVFSJZ	MA	Ligand
DMVFSJZ	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DMVFSJZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DM4TOGU	DI	DM4TOGU
DM4TOGU	DN	Benzanilide compound 1
DM4TOGU	MI	TTUX68I
DM4TOGU	MN	Hypoxia-inducible factor 1 (HIF-1)
DM4TOGU	MT	DTT
DM4TOGU	MA	Inhibitor
DM4TOGU	RN	Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22.
DM4TOGU	RU	https://www.ncbi.nlm.nih.gov/pubmed/26882240

DMDM806	DI	DMDM806
DMDM806	DN	Benzanilide compound 2
DMDM806	MI	TTUX68I
DMDM806	MN	Hypoxia-inducible factor 1 (HIF-1)
DMDM806	MT	DTT
DMDM806	MA	Inhibitor
DMDM806	RN	Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22.
DMDM806	RU	https://www.ncbi.nlm.nih.gov/pubmed/26882240

DMA3BCU	DI	DMA3BCU
DMA3BCU	DN	Benzazepine derivative 1
DMA3BCU	MI	TTWJBZ5
DMA3BCU	MN	5-HT 2C receptor (HTR2C)
DMA3BCU	MT	DTT
DMA3BCU	MA	Agonist
DMA3BCU	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMA3BCU	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMKREJ2	DI	DMKREJ2
DMKREJ2	DN	Benzazepine derivative 2
DMKREJ2	MI	TTWJBZ5
DMKREJ2	MN	5-HT 2C receptor (HTR2C)
DMKREJ2	MT	DTT
DMKREJ2	MA	Agonist
DMKREJ2	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMKREJ2	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DM3BGEN	DI	DM3BGEN
DM3BGEN	DN	Benzazepine derivative 3
DM3BGEN	MI	TTWJBZ5
DM3BGEN	MN	5-HT 2C receptor (HTR2C)
DM3BGEN	MT	DTT
DM3BGEN	MA	Agonist
DM3BGEN	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DM3BGEN	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMM72LS	DI	DMM72LS
DMM72LS	DN	Benzazepine derivative 4
DMM72LS	MI	TTWJBZ5
DMM72LS	MN	5-HT 2C receptor (HTR2C)
DMM72LS	MT	DTT
DMM72LS	MA	Agonist
DMM72LS	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMM72LS	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DM6XRDH	DI	DM6XRDH
DM6XRDH	DN	Benzazepine derivative 5
DM6XRDH	MI	TTWJBZ5
DM6XRDH	MN	5-HT 2C receptor (HTR2C)
DM6XRDH	MT	DTT
DM6XRDH	MA	Agonist
DM6XRDH	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DM6XRDH	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMCGX5S	DI	DMCGX5S
DMCGX5S	DN	Benzazepine derivative 6
DMCGX5S	MI	TTWJBZ5
DMCGX5S	MN	5-HT 2C receptor (HTR2C)
DMCGX5S	MT	DTT
DMCGX5S	MA	Agonist
DMCGX5S	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMCGX5S	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DM6PMZC	DI	DM6PMZC
DM6PMZC	DN	Benzenamine derivative 1
DM6PMZC	MI	TTNR0UQ
DM6PMZC	MN	Lysine-specific histone demethylase 1 (LSD)
DM6PMZC	MT	DTT
DM6PMZC	MA	Inhibitor
DM6PMZC	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DM6PMZC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMDZ7QS	DI	DMDZ7QS
DMDZ7QS	DN	Benzenamine derivative 2
DMDZ7QS	MI	TTNR0UQ
DMDZ7QS	MN	Lysine-specific histone demethylase 1 (LSD)
DMDZ7QS	MT	DTT
DMDZ7QS	MA	Inhibitor
DMDZ7QS	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMDZ7QS	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DM8UXZ3	DI	DM8UXZ3
DM8UXZ3	DN	Benzenamine derivative 3
DM8UXZ3	MI	TTNR0UQ
DM8UXZ3	MN	Lysine-specific histone demethylase 1 (LSD)
DM8UXZ3	MT	DTT
DM8UXZ3	MA	Inhibitor
DM8UXZ3	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DM8UXZ3	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMQT7HV	DI	DMQT7HV
DMQT7HV	DN	Benzenamine derivative 4
DMQT7HV	MI	TTNR0UQ
DMQT7HV	MN	Lysine-specific histone demethylase 1 (LSD)
DMQT7HV	MT	DTT
DMQT7HV	MA	Inhibitor
DMQT7HV	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMQT7HV	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMB9VEH	DI	DMB9VEH
DMB9VEH	DN	Benzene sulfonamide derivative 1
DMB9VEH	MI	TTIY56R
DMB9VEH	MN	Kynurenine 3-hydroxylase (KMO)
DMB9VEH	MT	DTT
DMB9VEH	MA	Inhibitor
DMB9VEH	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMB9VEH	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DML9TF7	DI	DML9TF7
DML9TF7	DN	Benzene sulfonamide derivative 11
DML9TF7	MI	TT4G2JS
DML9TF7	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DML9TF7	MT	DTT
DML9TF7	MA	Inhibitor
DML9TF7	RN	Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90.
DML9TF7	RU	https://www.ncbi.nlm.nih.gov/pubmed/25539043

DMESKY1	DI	DMESKY1
DMESKY1	DN	Benzene sulfonamide derivative 12
DMESKY1	MI	TT4G2JS
DMESKY1	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DMESKY1	MT	DTT
DMESKY1	MA	Inhibitor
DMESKY1	RN	Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90.
DMESKY1	RU	https://www.ncbi.nlm.nih.gov/pubmed/25539043

DMFJTE9	DI	DMFJTE9
DMFJTE9	DN	Benzene sulfonamide derivative 15
DMFJTE9	MI	TT4G2JS
DMFJTE9	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DMFJTE9	MT	DTT
DMFJTE9	MA	Blocker
DMFJTE9	RN	Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90.
DMFJTE9	RU	https://www.ncbi.nlm.nih.gov/pubmed/25539043

DMATBZW	DI	DMATBZW
DMATBZW	DN	Benzene sulfonamide derivative 16
DMATBZW	MI	TTA592U
DMATBZW	MN	Urate anion exchanger 1 (URAT1)
DMATBZW	MT	DTT
DMATBZW	MA	Inhibitor
DMATBZW	RN	Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10.
DMATBZW	RU	https://www.ncbi.nlm.nih.gov/pubmed/27414413

DMUZQLR	DI	DMUZQLR
DMUZQLR	DN	Benzene sulfonamide derivative 2
DMUZQLR	MI	TTIY56R
DMUZQLR	MN	Kynurenine 3-hydroxylase (KMO)
DMUZQLR	MT	DTT
DMUZQLR	MA	Inhibitor
DMUZQLR	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMUZQLR	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMCQLJY	DI	DMCQLJY
DMCQLJY	DN	Benzene sulfonamide derivative 3
DMCQLJY	MI	TTIY56R
DMCQLJY	MN	Kynurenine 3-hydroxylase (KMO)
DMCQLJY	MT	DTT
DMCQLJY	MA	Inhibitor
DMCQLJY	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMCQLJY	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMXCUEG	DI	DMXCUEG
DMXCUEG	DN	Benzene sulfonamide derivative 4
DMXCUEG	MI	TTIY56R
DMXCUEG	MN	Kynurenine 3-hydroxylase (KMO)
DMXCUEG	MT	DTT
DMXCUEG	MA	Inhibitor
DMXCUEG	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMXCUEG	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMW4NXV	DI	DMW4NXV
DMW4NXV	DN	Benzene sulfonamide derivative 5
DMW4NXV	MI	TTIY56R
DMW4NXV	MN	Kynurenine 3-hydroxylase (KMO)
DMW4NXV	MT	DTT
DMW4NXV	MA	Inhibitor
DMW4NXV	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMW4NXV	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMD4UMP	DI	DMD4UMP
DMD4UMP	DN	Benzene sulfonamide derivative 6
DMD4UMP	MI	TTIY56R
DMD4UMP	MN	Kynurenine 3-hydroxylase (KMO)
DMD4UMP	MT	DTT
DMD4UMP	MA	Inhibitor
DMD4UMP	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMD4UMP	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DM0TKP2	DI	DM0TKP2
DM0TKP2	DN	Benzene sulfonamide derivative 7
DM0TKP2	MI	TTIY56R
DM0TKP2	MN	Kynurenine 3-hydroxylase (KMO)
DM0TKP2	MT	DTT
DM0TKP2	MA	Inhibitor
DM0TKP2	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DM0TKP2	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMATU1X	DI	DMATU1X
DMATU1X	DN	Benzene sulfonamide derivative 8
DMATU1X	MI	TTUX68I
DMATU1X	MN	Hypoxia-inducible factor 1 (HIF-1)
DMATU1X	MT	DTT
DMATU1X	MA	Inhibitor
DMATU1X	RN	Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22.
DMATU1X	RU	https://www.ncbi.nlm.nih.gov/pubmed/26882240

DMLET14	DI	DMLET14
DMLET14	DN	Benzene sulfonamide derivative 9
DMLET14	MI	TT4G2JS
DMLET14	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DMLET14	MT	DTT
DMLET14	MA	Blocker
DMLET14	RN	Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90.
DMLET14	RU	https://www.ncbi.nlm.nih.gov/pubmed/25539043

DM1IZA7	DI	DM1IZA7
DM1IZA7	DN	Benzimidazole
DM1IZA7	MI	TTSBVFO
DM1IZA7	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DM1IZA7	MT	DTT
DM1IZA7	MA	Inhibitor
DM1IZA7	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DM1IZA7	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DM2G83R	DI	DM2G83R
DM2G83R	DN	Benzimidazole and imadazopyridine carboximidamide compound 1
DM2G83R	MI	TTZJYKH
DM2G83R	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DM2G83R	MT	DTT
DM2G83R	MA	Inhibitor
DM2G83R	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DM2G83R	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMJ2CIY	DI	DMJ2CIY
DMJ2CIY	DN	Benzimidazole and imadazopyridine carboximidamide compound 2
DMJ2CIY	MI	TTZJYKH
DMJ2CIY	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMJ2CIY	MT	DTT
DMJ2CIY	MA	Inhibitor
DMJ2CIY	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMJ2CIY	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMIXERP	DI	DMIXERP
DMIXERP	DN	Benzimidazole and imidazopyridine derivative 1
DMIXERP	MI	TTCZOF2
DMIXERP	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMIXERP	MT	DTT
DMIXERP	MA	Inhibitor
DMIXERP	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMIXERP	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMB1L32	DI	DMB1L32
DMB1L32	DN	Benzimidazole carboxamide derivative 1
DMB1L32	MI	TTVDSZ0
DMB1L32	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMB1L32	MT	DTT
DMB1L32	MA	Inhibitor
DMB1L32	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DMB1L32	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DML8W16	DI	DML8W16
DML8W16	DN	Benzimidazole derivative 1
DML8W16	MI	TT6OEDT
DML8W16	MN	Cannabinoid receptor 1 (CB1)
DML8W16	MT	DTT
DML8W16	MA	Antagonist
DML8W16	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DML8W16	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DML3PE4	DI	DML3PE4
DML3PE4	DN	Benzimidazole derivative 10
DML3PE4	MI	TTQR74A
DML3PE4	MN	Proteinase activated receptor 2 (PAR2)
DML3PE4	MT	DTT
DML3PE4	MA	Antagonist
DML3PE4	RN	Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
DML3PE4	RU	https://www.ncbi.nlm.nih.gov/pubmed/26936077

DMGRD8B	DI	DMGRD8B
DMGRD8B	DN	Benzimidazole derivative 11
DMGRD8B	MI	TTYLQ8V
DMGRD8B	MN	Prostaglandin E synthase (PTGES)
DMGRD8B	MT	DTT
DMGRD8B	MA	Inhibitor
DMGRD8B	RN	Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059.
DMGRD8B	RU	https://www.ncbi.nlm.nih.gov/pubmed/28627961

DMOHERV	DI	DMOHERV
DMOHERV	DN	Benzimidazole derivative 12
DMOHERV	MI	TTYLQ8V
DMOHERV	MN	Prostaglandin E synthase (PTGES)
DMOHERV	MT	DTT
DMOHERV	MA	Inhibitor
DMOHERV	RN	Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059.
DMOHERV	RU	https://www.ncbi.nlm.nih.gov/pubmed/28627961

DMV4DQI	DI	DMV4DQI
DMV4DQI	DN	Benzimidazole derivative 13
DMV4DQI	MI	TTYLQ8V
DMV4DQI	MN	Prostaglandin E synthase (PTGES)
DMV4DQI	MT	DTT
DMV4DQI	MA	Inhibitor
DMV4DQI	RN	Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059.
DMV4DQI	RU	https://www.ncbi.nlm.nih.gov/pubmed/28627961

DMCY5M7	DI	DMCY5M7
DMCY5M7	DN	Benzimidazole derivative 14
DMCY5M7	MI	TTYLQ8V
DMCY5M7	MN	Prostaglandin E synthase (PTGES)
DMCY5M7	MT	DTT
DMCY5M7	MA	Inhibitor
DMCY5M7	RN	Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059.
DMCY5M7	RU	https://www.ncbi.nlm.nih.gov/pubmed/28627961

DMJ3AZ4	DI	DMJ3AZ4
DMJ3AZ4	DN	Benzimidazole derivative 15
DMJ3AZ4	MI	TTYLQ8V
DMJ3AZ4	MN	Prostaglandin E synthase (PTGES)
DMJ3AZ4	MT	DTT
DMJ3AZ4	MA	Inhibitor
DMJ3AZ4	RN	Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059.
DMJ3AZ4	RU	https://www.ncbi.nlm.nih.gov/pubmed/28627961

DMHEQDT	DI	DMHEQDT
DMHEQDT	DN	Benzimidazole derivative 16
DMHEQDT	MI	TTYLQ8V
DMHEQDT	MN	Prostaglandin E synthase (PTGES)
DMHEQDT	MT	DTT
DMHEQDT	MA	Inhibitor
DMHEQDT	RN	Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059.
DMHEQDT	RU	https://www.ncbi.nlm.nih.gov/pubmed/28627961

DM1DXME	DI	DM1DXME
DM1DXME	DN	Benzimidazole derivative 17
DM1DXME	MI	TTYLQ8V
DM1DXME	MN	Prostaglandin E synthase (PTGES)
DM1DXME	MT	DTT
DM1DXME	MA	Inhibitor
DM1DXME	RN	Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059.
DM1DXME	RU	https://www.ncbi.nlm.nih.gov/pubmed/28627961

DM4ZUDY	DI	DM4ZUDY
DM4ZUDY	DN	Benzimidazole derivative 2
DM4ZUDY	MI	TT6OEDT
DM4ZUDY	MN	Cannabinoid receptor 1 (CB1)
DM4ZUDY	MT	DTT
DM4ZUDY	MA	Antagonist
DM4ZUDY	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DM4ZUDY	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMY93WG	DI	DMY93WG
DMY93WG	DN	Benzimidazole derivative 3
DMY93WG	MI	TTULVH8
DMY93WG	MN	Tyrosinase (TYR)
DMY93WG	MT	DTT
DMY93WG	MA	Inhibitor
DMY93WG	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMY93WG	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DM9PL3F	DI	DM9PL3F
DM9PL3F	DN	Benzimidazole derivative 4
DM9PL3F	MI	TTULVH8
DM9PL3F	MN	Tyrosinase (TYR)
DM9PL3F	MT	DTT
DM9PL3F	MA	Inhibitor
DM9PL3F	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DM9PL3F	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMWOJLX	DI	DMWOJLX
DMWOJLX	DN	Benzimidazole derivative 5
DMWOJLX	MI	TTT7PJU
DMWOJLX	MN	Janus kinase 3 (JAK-3)
DMWOJLX	MT	DTT
DMWOJLX	MA	Inhibitor
DMWOJLX	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMWOJLX	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMV7TMB	DI	DMV7TMB
DMV7TMB	DN	Benzimidazole derivative 6
DMV7TMB	MI	TTPMQSO
DMV7TMB	MN	ALK tyrosine kinase receptor (ALK)
DMV7TMB	MT	DTT
DMV7TMB	MA	Inhibitor
DMV7TMB	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMV7TMB	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMV7TMB	DI	DMV7TMB
DMV7TMB	DN	Benzimidazole derivative 6
DMV7TMB	MI	TTTDVOJ
DMV7TMB	MN	Tropomyosin-related kinase A (TrkA)
DMV7TMB	MT	DTT
DMV7TMB	MA	Inhibitor
DMV7TMB	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMV7TMB	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMDK4RI	DI	DMDK4RI
DMDK4RI	DN	Benzimidazole derivative 7
DMDK4RI	MI	TT6DM01
DMDK4RI	MN	Janus kinase 1 (JAK-1)
DMDK4RI	MT	DTT
DMDK4RI	MA	Inhibitor
DMDK4RI	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMDK4RI	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMDK4RI	DI	DMDK4RI
DMDK4RI	DN	Benzimidazole derivative 7
DMDK4RI	MI	TTRMX3V
DMDK4RI	MN	Janus kinase 2 (JAK-2)
DMDK4RI	MT	DTT
DMDK4RI	MA	Inhibitor
DMDK4RI	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMDK4RI	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMDK4RI	DI	DMDK4RI
DMDK4RI	DN	Benzimidazole derivative 7
DMDK4RI	MI	TTT7PJU
DMDK4RI	MN	Janus kinase 3 (JAK-3)
DMDK4RI	MT	DTT
DMDK4RI	MA	Inhibitor
DMDK4RI	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMDK4RI	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMDK4RI	DI	DMDK4RI
DMDK4RI	DN	Benzimidazole derivative 7
DMDK4RI	MI	TTBYWP2
DMDK4RI	MN	TYK2 tyrosine kinase (TYK2)
DMDK4RI	MT	DTT
DMDK4RI	MA	Inhibitor
DMDK4RI	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMDK4RI	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMQ75BN	DI	DMQ75BN
DMQ75BN	DN	Benzimidazole derivative 8
DMQ75BN	MI	TTQR74A
DMQ75BN	MN	Proteinase activated receptor 2 (PAR2)
DMQ75BN	MT	DTT
DMQ75BN	MA	Antagonist
DMQ75BN	RN	Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
DMQ75BN	RU	https://www.ncbi.nlm.nih.gov/pubmed/26936077

DMHJ98M	DI	DMHJ98M
DMHJ98M	DN	Benzimidazole derivative 9
DMHJ98M	MI	TTQR74A
DMHJ98M	MN	Proteinase activated receptor 2 (PAR2)
DMHJ98M	MT	DTT
DMHJ98M	MA	Antagonist
DMHJ98M	RN	Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
DMHJ98M	RU	https://www.ncbi.nlm.nih.gov/pubmed/26936077

DMRZELF	DI	DMRZELF
DMRZELF	DN	Benzimidazolone acetamide derivative 1
DMRZELF	MI	TTPTXIN
DMRZELF	MN	Translocator protein (TSPO)
DMRZELF	MT	DTT
DMRZELF	MA	Ligand
DMRZELF	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMRZELF	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMD9VC1	DI	DMD9VC1
DMD9VC1	DN	Benzimidazolone acetamide derivative 2
DMD9VC1	MI	TTPTXIN
DMD9VC1	MN	Translocator protein (TSPO)
DMD9VC1	MT	DTT
DMD9VC1	MA	Ligand
DMD9VC1	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMD9VC1	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMF01AR	DI	DMF01AR
DMF01AR	DN	Benzisoselenazolone difluorocytidine derivative 1
DMF01AR	MI	TTR7UJ3
DMF01AR	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMF01AR	MT	DTT
DMF01AR	MA	Inhibitor
DMF01AR	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMF01AR	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DM4VXY1	DI	DM4VXY1
DM4VXY1	DN	Benzo(b)carbazol-11-one compound 1
DM4VXY1	MI	TT4DXQT
DM4VXY1	MN	Proto-oncogene c-Ret (RET)
DM4VXY1	MT	DTT
DM4VXY1	MA	Inhibitor
DM4VXY1	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DM4VXY1	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMGCHW9	DI	DMGCHW9
DMGCHW9	DN	Benzo(b)carbazol-11-one compound 2
DMGCHW9	MI	TT4DXQT
DMGCHW9	MN	Proto-oncogene c-Ret (RET)
DMGCHW9	MT	DTT
DMGCHW9	MA	Inhibitor
DMGCHW9	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMGCHW9	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMGCHW9	DI	DMGCHW9
DMGCHW9	DN	Benzo(b)carbazol-11-one compound 2
DMGCHW9	MI	TTY0WT7
DMGCHW9	MN	RET G691S mutant (RET G691S)
DMGCHW9	MT	DTT
DMGCHW9	MA	Inhibitor
DMGCHW9	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMGCHW9	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMGCHW9	DI	DMGCHW9
DMGCHW9	DN	Benzo(b)carbazol-11-one compound 2
DMGCHW9	MI	TT5XA6U
DMGCHW9	MN	RET M918T mutant (RET M918T)
DMGCHW9	MT	DTT
DMGCHW9	MA	Inhibitor
DMGCHW9	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMGCHW9	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMGCHW9	DI	DMGCHW9
DMGCHW9	DN	Benzo(b)carbazol-11-one compound 2
DMGCHW9	MI	TT8BF4A
DMGCHW9	MN	RET S891A mutant (RET S891A)
DMGCHW9	MT	DTT
DMGCHW9	MA	Inhibitor
DMGCHW9	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMGCHW9	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMGCHW9	DI	DMGCHW9
DMGCHW9	DN	Benzo(b)carbazol-11-one compound 2
DMGCHW9	MI	TT2RTDH
DMGCHW9	MN	RET V804L mutant (RET V804L)
DMGCHW9	MT	DTT
DMGCHW9	MA	Inhibitor
DMGCHW9	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMGCHW9	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMGCHW9	DI	DMGCHW9
DMGCHW9	DN	Benzo(b)carbazol-11-one compound 2
DMGCHW9	MI	TTQV3NX
DMGCHW9	MN	RET V804M mutant (RET V804M)
DMGCHW9	MT	DTT
DMGCHW9	MA	Inhibitor
DMGCHW9	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMGCHW9	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMGCHW9	DI	DMGCHW9
DMGCHW9	DN	Benzo(b)carbazol-11-one compound 2
DMGCHW9	MI	TTB0IO2
DMGCHW9	MN	RET Y791F mutant (RET Y791F)
DMGCHW9	MT	DTT
DMGCHW9	MA	Inhibitor
DMGCHW9	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMGCHW9	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMKXD2V	DI	DMKXD2V
DMKXD2V	DN	Benzo[d]oxazol-2(3H)-one derivative 1
DMKXD2V	MI	TTEX248
DMKXD2V	MN	Dopamine D2 receptor (D2R)
DMKXD2V	MT	DTT
DMKXD2V	MA	Ligand
DMKXD2V	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DMKXD2V	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DMKXD2V	DI	DMKXD2V
DMKXD2V	DN	Benzo[d]oxazol-2(3H)-one derivative 1
DMKXD2V	MI	TT9JNIC
DMKXD2V	MN	Histamine H3 receptor (H3R)
DMKXD2V	MT	DTT
DMKXD2V	MA	Inhibitor
DMKXD2V	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DMKXD2V	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DM47KWB	DI	DM47KWB
DM47KWB	DN	Benzo[d]oxazol-2(3H)-one derivative 2
DM47KWB	MI	TTEX248
DM47KWB	MN	Dopamine D2 receptor (D2R)
DM47KWB	MT	DTT
DM47KWB	MA	Ligand
DM47KWB	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DM47KWB	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DM47KWB	DI	DM47KWB
DM47KWB	DN	Benzo[d]oxazol-2(3H)-one derivative 2
DM47KWB	MI	TT9JNIC
DM47KWB	MN	Histamine H3 receptor (H3R)
DM47KWB	MT	DTT
DM47KWB	MA	Inhibitor
DM47KWB	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DM47KWB	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DM3Z5UQ	DI	DM3Z5UQ
DM3Z5UQ	DN	Benzo[d]oxazol-2(3H)-one derivative 3
DM3Z5UQ	MI	TTEX248
DM3Z5UQ	MN	Dopamine D2 receptor (D2R)
DM3Z5UQ	MT	DTT
DM3Z5UQ	MA	Ligand
DM3Z5UQ	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DM3Z5UQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DM3Z5UQ	DI	DM3Z5UQ
DM3Z5UQ	DN	Benzo[d]oxazol-2(3H)-one derivative 3
DM3Z5UQ	MI	TT9JNIC
DM3Z5UQ	MN	Histamine H3 receptor (H3R)
DM3Z5UQ	MT	DTT
DM3Z5UQ	MA	Inhibitor
DM3Z5UQ	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DM3Z5UQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DMNIPE6	DI	DMNIPE6
DMNIPE6	DN	Benzo[d]oxazole derivative 1
DMNIPE6	MI	TTA6ZN2
DMNIPE6	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMNIPE6	MT	DTT
DMNIPE6	MA	Inhibitor
DMNIPE6	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMNIPE6	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMR5V2A	DI	DMR5V2A
DMR5V2A	DN	Benzo[d]oxazole derivative 2
DMR5V2A	MI	TTA6ZN2
DMR5V2A	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMR5V2A	MT	DTT
DMR5V2A	MA	Inhibitor
DMR5V2A	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMR5V2A	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM712Y0	DI	DM712Y0
DM712Y0	DN	Benzo[d]oxazole derivative 3
DM712Y0	MI	TTA6ZN2
DM712Y0	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DM712Y0	MT	DTT
DM712Y0	MA	Inhibitor
DM712Y0	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DM712Y0	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM0RAC6	DI	DM0RAC6
DM0RAC6	DN	Benzo[d]oxazole derivative 4
DM0RAC6	MI	TTA6ZN2
DM0RAC6	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DM0RAC6	MT	DTT
DM0RAC6	MA	Inhibitor
DM0RAC6	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DM0RAC6	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMFXC5L	DI	DMFXC5L
DMFXC5L	DN	Benzodiazepine derivative 1
DMFXC5L	MI	TTPTXIN
DMFXC5L	MN	Translocator protein (TSPO)
DMFXC5L	MT	DTT
DMFXC5L	MA	Ligand
DMFXC5L	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMFXC5L	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DM5ZGNK	DI	DM5ZGNK
DM5ZGNK	DN	Benzodiazepine derivative 2
DM5ZGNK	MI	TTJGW1Z
DM5ZGNK	MN	Phosphodiesterase 2A (PDE2A)
DM5ZGNK	MT	DTT
DM5ZGNK	MA	Inhibitor
DM5ZGNK	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DM5ZGNK	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DM249KU	DI	DM249KU
DM249KU	DN	Benzodihydroisofuran derivative 1
DM249KU	MI	TTTJZ4M
DM249KU	MN	Prolylcarboxypeptidase (PRCP)
DM249KU	MT	DTT
DM249KU	MA	Inhibitor
DM249KU	RN	Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088.
DM249KU	RU	https://www.ncbi.nlm.nih.gov/pubmed/28699813

DMGK0FD	DI	DMGK0FD
DMGK0FD	DN	Benzodihydroisofuran derivative 2
DMGK0FD	MI	TTTJZ4M
DMGK0FD	MN	Prolylcarboxypeptidase (PRCP)
DMGK0FD	MT	DTT
DMGK0FD	MA	Inhibitor
DMGK0FD	RN	Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088.
DMGK0FD	RU	https://www.ncbi.nlm.nih.gov/pubmed/28699813

DMF6B1I	DI	DMF6B1I
DMF6B1I	DN	Benzodihydroisofuran derivative 3
DMF6B1I	MI	TTTJZ4M
DMF6B1I	MN	Prolylcarboxypeptidase (PRCP)
DMF6B1I	MT	DTT
DMF6B1I	MA	Inhibitor
DMF6B1I	RN	Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088.
DMF6B1I	RU	https://www.ncbi.nlm.nih.gov/pubmed/28699813

DM5IH2O	DI	DM5IH2O
DM5IH2O	DN	Benzodihydroisofuran derivative 4
DM5IH2O	MI	TTTJZ4M
DM5IH2O	MN	Prolylcarboxypeptidase (PRCP)
DM5IH2O	MT	DTT
DM5IH2O	MA	Inhibitor
DM5IH2O	RN	Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088.
DM5IH2O	RU	https://www.ncbi.nlm.nih.gov/pubmed/28699813

DM4198Z	DI	DM4198Z
DM4198Z	DN	Benzofurans derivative 1
DM4198Z	MI	TTA592U
DM4198Z	MN	Urate anion exchanger 1 (URAT1)
DM4198Z	MT	DTT
DM4198Z	MA	Inhibitor
DM4198Z	RN	Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10.
DM4198Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/27414413

DM3K25J	DI	DM3K25J
DM3K25J	DN	Benzoheterocyclic compound 1
DM3K25J	MI	TTZCRP3
DM3K25J	MN	ERK activator kinase (MEK)
DM3K25J	MT	DTT
DM3K25J	MA	Inhibitor
DM3K25J	RN	MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906.
DM3K25J	RU	https://www.ncbi.nlm.nih.gov/pubmed/28594589

DM5ZKR2	DI	DM5ZKR2
DM5ZKR2	DN	Benzoic acid derivative 1
DM5ZKR2	MI	TTA592U
DM5ZKR2	MN	Urate anion exchanger 1 (URAT1)
DM5ZKR2	MT	DTT
DM5ZKR2	MA	Inhibitor
DM5ZKR2	RN	Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10.
DM5ZKR2	RU	https://www.ncbi.nlm.nih.gov/pubmed/27414413

DMND8R0	DI	DMND8R0
DMND8R0	DN	Benzoic acid linked peptide analog 1
DMND8R0	MI	TTULVH8
DMND8R0	MN	Tyrosinase (TYR)
DMND8R0	MT	DTT
DMND8R0	MA	Inhibitor
DMND8R0	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMND8R0	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMUBG20	DI	DMUBG20
DMUBG20	DN	Benzoic acid linked peptide analog 2
DMUBG20	MI	TTULVH8
DMUBG20	MN	Tyrosinase (TYR)
DMUBG20	MT	DTT
DMUBG20	MA	Inhibitor
DMUBG20	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMUBG20	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DM42BU9	DI	DM42BU9
DM42BU9	DN	Benzoic acid linked peptide analog 3
DM42BU9	MI	TTULVH8
DM42BU9	MN	Tyrosinase (TYR)
DM42BU9	MT	DTT
DM42BU9	MA	Inhibitor
DM42BU9	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DM42BU9	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMNX5EU	DI	DMNX5EU
DMNX5EU	DN	Benzoic acid linked peptide analog 4
DMNX5EU	MI	TTULVH8
DMNX5EU	MN	Tyrosinase (TYR)
DMNX5EU	MT	DTT
DMNX5EU	MA	Inhibitor
DMNX5EU	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMNX5EU	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMNIZAR	DI	DMNIZAR
DMNIZAR	DN	Benzoic acid linked peptide analog 5
DMNIZAR	MI	TTULVH8
DMNIZAR	MN	Tyrosinase (TYR)
DMNIZAR	MT	DTT
DMNIZAR	MA	Inhibitor
DMNIZAR	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMNIZAR	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMTHKES	DI	DMTHKES
DMTHKES	DN	Benzoic acid linked peptide analog 6
DMTHKES	MI	TTULVH8
DMTHKES	MN	Tyrosinase (TYR)
DMTHKES	MT	DTT
DMTHKES	MA	Inhibitor
DMTHKES	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMTHKES	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMUJFCK	DI	DMUJFCK
DMUJFCK	DN	Benzoimidazole derivative 1
DMUJFCK	MI	TTZCRP3
DMUJFCK	MN	ERK activator kinase (MEK)
DMUJFCK	MT	DTT
DMUJFCK	MA	Inhibitor
DMUJFCK	RN	MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906.
DMUJFCK	RU	https://www.ncbi.nlm.nih.gov/pubmed/28594589

DMHX5VO	DI	DMHX5VO
DMHX5VO	DN	Benzoimidazole derivative 2
DMHX5VO	MI	TTZCRP3
DMHX5VO	MN	ERK activator kinase (MEK)
DMHX5VO	MT	DTT
DMHX5VO	MA	Inhibitor
DMHX5VO	RN	MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906.
DMHX5VO	RU	https://www.ncbi.nlm.nih.gov/pubmed/28594589

DMM9J34	DI	DMM9J34
DMM9J34	DN	Benzonaphthyridine derivative 1
DMM9J34	MI	TTCZOF2
DMM9J34	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMM9J34	MT	DTT
DMM9J34	MA	Inhibitor
DMM9J34	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMM9J34	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMB74LZ	DI	DMB74LZ
DMB74LZ	DN	Benzonaphthyridine derivative 2
DMB74LZ	MI	TTCZOF2
DMB74LZ	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMB74LZ	MT	DTT
DMB74LZ	MA	Inhibitor
DMB74LZ	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMB74LZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DM9FPK1	DI	DM9FPK1
DM9FPK1	DN	Benzothiazepine analog 1
DM9FPK1	MI	TTPTXIN
DM9FPK1	MN	Translocator protein (TSPO)
DM9FPK1	MT	DTT
DM9FPK1	MA	Ligand
DM9FPK1	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DM9FPK1	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMR6XF4	DI	DMR6XF4
DMR6XF4	DN	Benzothiazepine analog 10
DMR6XF4	MI	TTRA6BO
DMR6XF4	MN	Bromodomain-containing protein 4 (BRD4)
DMR6XF4	MT	DTT
DMR6XF4	MA	Inhibitor
DMR6XF4	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMR6XF4	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMVC51O	DI	DMVC51O
DMVC51O	DN	Benzothiazepine analog 11
DMVC51O	MI	TTRA6BO
DMVC51O	MN	Bromodomain-containing protein 4 (BRD4)
DMVC51O	MT	DTT
DMVC51O	MA	Inhibitor
DMVC51O	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMVC51O	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DM7XQ18	DI	DM7XQ18
DM7XQ18	DN	Benzothiazepine analog 12
DM7XQ18	MI	TTRA6BO
DM7XQ18	MN	Bromodomain-containing protein 4 (BRD4)
DM7XQ18	MT	DTT
DM7XQ18	MA	Inhibitor
DM7XQ18	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DM7XQ18	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMZ3NSJ	DI	DMZ3NSJ
DMZ3NSJ	DN	Benzothiazepine analog 2
DMZ3NSJ	MI	TTPTXIN
DMZ3NSJ	MN	Translocator protein (TSPO)
DMZ3NSJ	MT	DTT
DMZ3NSJ	MA	Ligand
DMZ3NSJ	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMZ3NSJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DM24NZG	DI	DM24NZG
DM24NZG	DN	Benzothiazepine analog 3
DM24NZG	MI	TTPTXIN
DM24NZG	MN	Translocator protein (TSPO)
DM24NZG	MT	DTT
DM24NZG	MA	Ligand
DM24NZG	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DM24NZG	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMV4OTD	DI	DMV4OTD
DMV4OTD	DN	Benzothiazepine analog 4
DMV4OTD	MI	TTPTXIN
DMV4OTD	MN	Translocator protein (TSPO)
DMV4OTD	MT	DTT
DMV4OTD	MA	Ligand
DMV4OTD	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMV4OTD	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMCH1WX	DI	DMCH1WX
DMCH1WX	DN	Benzothiazepine analog 5
DMCH1WX	MI	TTPTXIN
DMCH1WX	MN	Translocator protein (TSPO)
DMCH1WX	MT	DTT
DMCH1WX	MA	Ligand
DMCH1WX	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMCH1WX	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMB5KLD	DI	DMB5KLD
DMB5KLD	DN	Benzothiazepine analog 6
DMB5KLD	MI	TTPTXIN
DMB5KLD	MN	Translocator protein (TSPO)
DMB5KLD	MT	DTT
DMB5KLD	MA	Ligand
DMB5KLD	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMB5KLD	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DM25ZY4	DI	DM25ZY4
DM25ZY4	DN	Benzothiazepine analog 7
DM25ZY4	MI	TTPTXIN
DM25ZY4	MN	Translocator protein (TSPO)
DM25ZY4	MT	DTT
DM25ZY4	MA	Ligand
DM25ZY4	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DM25ZY4	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMAXDV5	DI	DMAXDV5
DMAXDV5	DN	Benzothiazepine analog 8
DMAXDV5	MI	TTPTXIN
DMAXDV5	MN	Translocator protein (TSPO)
DMAXDV5	MT	DTT
DMAXDV5	MA	Ligand
DMAXDV5	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMAXDV5	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMONDMG	DI	DMONDMG
DMONDMG	DN	Benzothiazepine analog 9
DMONDMG	MI	TTPTXIN
DMONDMG	MN	Translocator protein (TSPO)
DMONDMG	MT	DTT
DMONDMG	MA	Ligand
DMONDMG	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMONDMG	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMMVHY4	DI	DMMVHY4
DMMVHY4	DN	Benzothiazine derivative 1
DMMVHY4	MI	TT1LVF2
DMMVHY4	MN	Cyclin-dependent kinase 9 (CDK9)
DMMVHY4	MT	DTT
DMMVHY4	MA	Inhibitor
DMMVHY4	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMMVHY4	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMMVHY4	DI	DMMVHY4
DMMVHY4	DN	Benzothiazine derivative 1
DMMVHY4	MI	TTTN5QW
DMMVHY4	MN	Serine/threonine-protein kinase pim-1 (PIM1)
DMMVHY4	MT	DTT
DMMVHY4	MA	Inhibitor
DMMVHY4	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMMVHY4	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMJ51VZ	DI	DMJ51VZ
DMJ51VZ	DN	Benzothiazine-carboxamide compound 1
DMJ51VZ	MI	TTQR74A
DMJ51VZ	MN	Proteinase activated receptor 2 (PAR2)
DMJ51VZ	MT	DTT
DMJ51VZ	MA	Antagonist
DMJ51VZ	RN	Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
DMJ51VZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26936077

DMMP2RT	DI	DMMP2RT
DMMP2RT	DN	Benzothiazine-carboxamide compound 2
DMMP2RT	MI	TTQR74A
DMMP2RT	MN	Proteinase activated receptor 2 (PAR2)
DMMP2RT	MT	DTT
DMMP2RT	MA	Antagonist
DMMP2RT	RN	Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
DMMP2RT	RU	https://www.ncbi.nlm.nih.gov/pubmed/26936077

DMI31OD	DI	DMI31OD
DMI31OD	DN	Benzothiazine-carboxamide compound 3
DMI31OD	MI	TTQR74A
DMI31OD	MN	Proteinase activated receptor 2 (PAR2)
DMI31OD	MT	DTT
DMI31OD	MA	Antagonist
DMI31OD	RN	Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
DMI31OD	RU	https://www.ncbi.nlm.nih.gov/pubmed/26936077

DMSR918	DI	DMSR918
DMSR918	DN	Benzothiazine-carboxamide compound 4
DMSR918	MI	TTQR74A
DMSR918	MN	Proteinase activated receptor 2 (PAR2)
DMSR918	MT	DTT
DMSR918	MA	Antagonist
DMSR918	RN	Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
DMSR918	RU	https://www.ncbi.nlm.nih.gov/pubmed/26936077

DMM7N5E	DI	DMM7N5E
DMM7N5E	DN	Benzothiazine-carboxamide compound 5
DMM7N5E	MI	TTQR74A
DMM7N5E	MN	Proteinase activated receptor 2 (PAR2)
DMM7N5E	MT	DTT
DMM7N5E	MA	Antagonist
DMM7N5E	RN	Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
DMM7N5E	RU	https://www.ncbi.nlm.nih.gov/pubmed/26936077

DMW94IQ	DI	DMW94IQ
DMW94IQ	DN	Benzothiazine-carboxamide compound 6
DMW94IQ	MI	TTQR74A
DMW94IQ	MN	Proteinase activated receptor 2 (PAR2)
DMW94IQ	MT	DTT
DMW94IQ	MA	Antagonist
DMW94IQ	RN	Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
DMW94IQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26936077

DMHXFCQ	DI	DMHXFCQ
DMHXFCQ	DN	Benzothiazole analog 1
DMHXFCQ	MI	TTULVH8
DMHXFCQ	MN	Tyrosinase (TYR)
DMHXFCQ	MT	DTT
DMHXFCQ	MA	Inhibitor
DMHXFCQ	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMHXFCQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMUKNXF	DI	DMUKNXF
DMUKNXF	DN	Benzothiazole analog 2
DMUKNXF	MI	TTULVH8
DMUKNXF	MN	Tyrosinase (TYR)
DMUKNXF	MT	DTT
DMUKNXF	MA	Inhibitor
DMUKNXF	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMUKNXF	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMDLY38	DI	DMDLY38
DMDLY38	DN	Benzothiazole analog 3
DMDLY38	MI	TTULVH8
DMDLY38	MN	Tyrosinase (TYR)
DMDLY38	MT	DTT
DMDLY38	MA	Inhibitor
DMDLY38	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMDLY38	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMNDAT0	DI	DMNDAT0
DMNDAT0	DN	Benzothiazole analog 4
DMNDAT0	MI	TTULVH8
DMNDAT0	MN	Tyrosinase (TYR)
DMNDAT0	MT	DTT
DMNDAT0	MA	Inhibitor
DMNDAT0	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMNDAT0	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMN1J09	DI	DMN1J09
DMN1J09	DN	Benzothiazole analog 5
DMN1J09	MI	TTULVH8
DMN1J09	MN	Tyrosinase (TYR)
DMN1J09	MT	DTT
DMN1J09	MA	Inhibitor
DMN1J09	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMN1J09	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMJDC5T	DI	DMJDC5T
DMJDC5T	DN	Benzothiazoline derivative 1
DMJDC5T	MI	TTULVH8
DMJDC5T	MN	Tyrosinase (TYR)
DMJDC5T	MT	DTT
DMJDC5T	MA	Inhibitor
DMJDC5T	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMJDC5T	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMCO0ZS	DI	DMCO0ZS
DMCO0ZS	DN	Benzotriazole derivative 1
DMCO0ZS	MI	TT2F4OL
DMCO0ZS	MN	Tissue transglutaminase (TG2)
DMCO0ZS	MT	DTT
DMCO0ZS	MA	Inhibitor
DMCO0ZS	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DMCO0ZS	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DMIYXS8	DI	DMIYXS8
DMIYXS8	DN	Benzoxazepine analog 1
DMIYXS8	MI	TTPTXIN
DMIYXS8	MN	Translocator protein (TSPO)
DMIYXS8	MT	DTT
DMIYXS8	MA	Ligand
DMIYXS8	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMIYXS8	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DM4FHTG	DI	DM4FHTG
DM4FHTG	DN	Benzoxazinone derivative 2
DM4FHTG	MI	TT4319X
DM4FHTG	MN	Kallikrein-4 (KLK4)
DM4FHTG	MT	DTT
DM4FHTG	MA	Inhibitor
DM4FHTG	RN	Serine protease inhibitors to treat inflammation: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Feb;28(2):93-110.
DM4FHTG	RU	https://www.ncbi.nlm.nih.gov/pubmed/29171765

DM4FHTG	DI	DM4FHTG
DM4FHTG	DN	Benzoxazinone derivative 2
DM4FHTG	MI	TT5L2VC
DM4FHTG	MN	Kallikrein-related peptidase (KLK)
DM4FHTG	MT	DTT
DM4FHTG	MA	Inhibitor
DM4FHTG	RN	Serine protease inhibitors to treat inflammation: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Feb;28(2):93-110.
DM4FHTG	RU	https://www.ncbi.nlm.nih.gov/pubmed/29171765

DMY01FU	DI	DMY01FU
DMY01FU	DN	Benzoxazole derivative 1
DMY01FU	MI	TTDP1UC
DMY01FU	MN	Fatty acid amide hydrolase (FAAH)
DMY01FU	MT	DTT
DMY01FU	MA	Inhibitor
DMY01FU	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMY01FU	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMJBOL0	DI	DMJBOL0
DMJBOL0	DN	Benzoyl-piperidine derivative 1
DMJBOL0	MI	TTJQOD7
DMJBOL0	MN	5-HT 2A receptor (HTR2A)
DMJBOL0	MT	DTT
DMJBOL0	MA	Antagonist
DMJBOL0	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMJBOL0	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMFKX1M	DI	DMFKX1M
DMFKX1M	DN	Benzoyl-piperidine derivative 2
DMFKX1M	MI	TTJQOD7
DMFKX1M	MN	5-HT 2A receptor (HTR2A)
DMFKX1M	MT	DTT
DMFKX1M	MA	Antagonist
DMFKX1M	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMFKX1M	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMOU84B	DI	DMOU84B
DMOU84B	DN	Benzyl amine derivative 1
DMOU84B	MI	TT5L2VC
DMOU84B	MN	Kallikrein-related peptidase (KLK)
DMOU84B	MT	DTT
DMOU84B	MA	Inhibitor
DMOU84B	RN	Serine protease inhibitors to treat inflammation: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Feb;28(2):93-110.
DMOU84B	RU	https://www.ncbi.nlm.nih.gov/pubmed/29171765

DMFK7EL	DI	DMFK7EL
DMFK7EL	DN	Benzyl amine derivative 2
DMFK7EL	MI	TT5L2VC
DMFK7EL	MN	Kallikrein-related peptidase (KLK)
DMFK7EL	MT	DTT
DMFK7EL	MA	Inhibitor
DMFK7EL	RN	Serine protease inhibitors to treat inflammation: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Feb;28(2):93-110.
DMFK7EL	RU	https://www.ncbi.nlm.nih.gov/pubmed/29171765

DM6PTOX	DI	DM6PTOX
DM6PTOX	DN	Benzyl phenyl ether derivative 1
DM6PTOX	MI	TT23XQV
DM6PTOX	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DM6PTOX	MT	DTT
DM6PTOX	MA	Inhibitor
DM6PTOX	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DM6PTOX	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMMS4EI	DI	DMMS4EI
DMMS4EI	DN	Benzyl phenyl ether derivative 2
DMMS4EI	MI	TT23XQV
DMMS4EI	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMMS4EI	MT	DTT
DMMS4EI	MA	Inhibitor
DMMS4EI	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMMS4EI	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMIAB94	DI	DMIAB94
DMIAB94	DN	Benzyl pyrrolyloxoacetamide derivative 1
DMIAB94	MI	TTDP1UC
DMIAB94	MN	Fatty acid amide hydrolase (FAAH)
DMIAB94	MT	DTT
DMIAB94	MA	Inhibitor
DMIAB94	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMIAB94	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMHOLQF	DI	DMHOLQF
DMHOLQF	DN	Benzyl pyrrolyloxoacetamide derivative 2
DMHOLQF	MI	TTDP1UC
DMHOLQF	MN	Fatty acid amide hydrolase (FAAH)
DMHOLQF	MT	DTT
DMHOLQF	MA	Inhibitor
DMHOLQF	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMHOLQF	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMD7Z3H	DI	DMD7Z3H
DMD7Z3H	DN	Benzylcinnamate
DMD7Z3H	MI	TTGP7BY
DMD7Z3H	MN	Monoamine oxidase type B (MAO-B)
DMD7Z3H	MT	DTT
DMD7Z3H	MA	Inhibitor
DMD7Z3H	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMD7Z3H	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMZKTHL	DI	DMZKTHL
DMZKTHL	DN	Beta-cyclodextrin conjugate derivative 1
DMZKTHL	MI	TTTCRU2
DMZKTHL	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMZKTHL	MT	DTT
DMZKTHL	MA	Antagonist
DMZKTHL	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMZKTHL	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM9W1FO	DI	DM9W1FO
DM9W1FO	DN	Beta-cyclodextrin conjugate derivative 2
DM9W1FO	MI	TTTCRU2
DM9W1FO	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM9W1FO	MT	DTT
DM9W1FO	MA	Antagonist
DM9W1FO	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM9W1FO	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMQJF4P	DI	DMQJF4P
DMQJF4P	DN	Beta-cyclodextrin conjugate derivative 3
DMQJF4P	MI	TTTCRU2
DMQJF4P	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMQJF4P	MT	DTT
DMQJF4P	MA	Antagonist
DMQJF4P	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMQJF4P	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMO9RE8	DI	DMO9RE8
DMO9RE8	DN	Beta-cyclodextrin conjugate derivative 4
DMO9RE8	MI	TTTCRU2
DMO9RE8	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMO9RE8	MT	DTT
DMO9RE8	MA	Antagonist
DMO9RE8	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMO9RE8	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DML2B7G	DI	DML2B7G
DML2B7G	DN	Beta-cyclodextrin conjugate derivative 5
DML2B7G	MI	TTTCRU2
DML2B7G	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DML2B7G	MT	DTT
DML2B7G	MA	Antagonist
DML2B7G	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DML2B7G	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMMCDR7	DI	DMMCDR7
DMMCDR7	DN	Betais-sulfonylamino derivative 1
DMMCDR7	MI	TTYLQ8V
DMMCDR7	MN	Prostaglandin E synthase (PTGES)
DMMCDR7	MT	DTT
DMMCDR7	MA	Inhibitor
DMMCDR7	RN	Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059.
DMMCDR7	RU	https://www.ncbi.nlm.nih.gov/pubmed/28627961

DM5KTDY	DI	DM5KTDY
DM5KTDY	DN	Beta-naphthylacetic acids derivative 1
DM5KTDY	MI	TT5ZWB6
DM5KTDY	MN	Dihydrodiol dehydrogenase type I (AKR1C3)
DM5KTDY	MT	DTT
DM5KTDY	MA	Inhibitor; Antagonist; Blocker
DM5KTDY	RN	Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340.
DM5KTDY	RU	https://www.ncbi.nlm.nih.gov/pubmed/28895472

DM8D3FG	DI	DM8D3FG
DM8D3FG	DN	Beta-phe compound 1
DM8D3FG	MI	TTDIGC1
DM8D3FG	MN	Dipeptidyl peptidase 4 (DPP-4)
DM8D3FG	MT	DTT
DM8D3FG	MA	Inhibitor
DM8D3FG	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DM8D3FG	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DM786OD	DI	DM786OD
DM786OD	DN	Beta-phe compound 2
DM786OD	MI	TTDIGC1
DM786OD	MN	Dipeptidyl peptidase 4 (DPP-4)
DM786OD	MT	DTT
DM786OD	MA	Inhibitor
DM786OD	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DM786OD	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DM0G8XP	DI	DM0G8XP
DM0G8XP	DN	Beta-phe compound 3
DM0G8XP	MI	TTDIGC1
DM0G8XP	MN	Dipeptidyl peptidase 4 (DPP-4)
DM0G8XP	MT	DTT
DM0G8XP	MA	Inhibitor
DM0G8XP	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DM0G8XP	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DM79WI1	DI	DM79WI1
DM79WI1	DN	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 1
DM79WI1	MI	TTULVH8
DM79WI1	MN	Tyrosinase (TYR)
DM79WI1	MT	DTT
DM79WI1	MA	Inhibitor
DM79WI1	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DM79WI1	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMRXMCH	DI	DMRXMCH
DMRXMCH	DN	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 10
DMRXMCH	MI	TTULVH8
DMRXMCH	MN	Tyrosinase (TYR)
DMRXMCH	MT	DTT
DMRXMCH	MA	Inhibitor
DMRXMCH	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMRXMCH	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMVPR1D	DI	DMVPR1D
DMVPR1D	DN	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 11
DMVPR1D	MI	TTULVH8
DMVPR1D	MN	Tyrosinase (TYR)
DMVPR1D	MT	DTT
DMVPR1D	MA	Inhibitor
DMVPR1D	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMVPR1D	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMOHBCN	DI	DMOHBCN
DMOHBCN	DN	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 12
DMOHBCN	MI	TTULVH8
DMOHBCN	MN	Tyrosinase (TYR)
DMOHBCN	MT	DTT
DMOHBCN	MA	Inhibitor
DMOHBCN	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMOHBCN	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMKDBQG	DI	DMKDBQG
DMKDBQG	DN	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 13
DMKDBQG	MI	TTULVH8
DMKDBQG	MN	Tyrosinase (TYR)
DMKDBQG	MT	DTT
DMKDBQG	MA	Inhibitor
DMKDBQG	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMKDBQG	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMWUAXM	DI	DMWUAXM
DMWUAXM	DN	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 14
DMWUAXM	MI	TTULVH8
DMWUAXM	MN	Tyrosinase (TYR)
DMWUAXM	MT	DTT
DMWUAXM	MA	Inhibitor
DMWUAXM	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMWUAXM	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMAEQ0I	DI	DMAEQ0I
DMAEQ0I	DN	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 2
DMAEQ0I	MI	TTULVH8
DMAEQ0I	MN	Tyrosinase (TYR)
DMAEQ0I	MT	DTT
DMAEQ0I	MA	Inhibitor
DMAEQ0I	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMAEQ0I	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMGV8T9	DI	DMGV8T9
DMGV8T9	DN	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 3
DMGV8T9	MI	TTULVH8
DMGV8T9	MN	Tyrosinase (TYR)
DMGV8T9	MT	DTT
DMGV8T9	MA	Inhibitor
DMGV8T9	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMGV8T9	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMNQF9S	DI	DMNQF9S
DMNQF9S	DN	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 4
DMNQF9S	MI	TTULVH8
DMNQF9S	MN	Tyrosinase (TYR)
DMNQF9S	MT	DTT
DMNQF9S	MA	Inhibitor
DMNQF9S	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMNQF9S	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMBC48K	DI	DMBC48K
DMBC48K	DN	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 5
DMBC48K	MI	TTULVH8
DMBC48K	MN	Tyrosinase (TYR)
DMBC48K	MT	DTT
DMBC48K	MA	Inhibitor
DMBC48K	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMBC48K	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMK9XV8	DI	DMK9XV8
DMK9XV8	DN	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 6
DMK9XV8	MI	TTULVH8
DMK9XV8	MN	Tyrosinase (TYR)
DMK9XV8	MT	DTT
DMK9XV8	MA	Inhibitor
DMK9XV8	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMK9XV8	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMES41R	DI	DMES41R
DMES41R	DN	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 7
DMES41R	MI	TTULVH8
DMES41R	MN	Tyrosinase (TYR)
DMES41R	MT	DTT
DMES41R	MA	Inhibitor
DMES41R	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMES41R	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMRIPVG	DI	DMRIPVG
DMRIPVG	DN	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 8
DMRIPVG	MI	TTULVH8
DMRIPVG	MN	Tyrosinase (TYR)
DMRIPVG	MT	DTT
DMRIPVG	MA	Inhibitor
DMRIPVG	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMRIPVG	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DM7U20W	DI	DM7U20W
DM7U20W	DN	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 9
DM7U20W	MI	TTULVH8
DM7U20W	MN	Tyrosinase (TYR)
DM7U20W	MT	DTT
DM7U20W	MA	Inhibitor
DM7U20W	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DM7U20W	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMJG1ZS	DI	DMJG1ZS
DMJG1ZS	DN	Biaromatic compound 1
DMJG1ZS	MI	TTZMAO3
DMJG1ZS	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMJG1ZS	MT	DTT
DMJG1ZS	MA	Agonist
DMJG1ZS	RN	PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
DMJG1ZS	RU	https://www.ncbi.nlm.nih.gov/pubmed/25416646

DMHEAJQ	DI	DMHEAJQ
DMHEAJQ	DN	Biaryl compound 1
DMHEAJQ	MI	TT5YPJF
DMHEAJQ	MN	CD80-PD-L1 interaction (CD80/PD-L1 PPI)
DMHEAJQ	MT	DTT
DMHEAJQ	MA	Inhibitor
DMHEAJQ	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMHEAJQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMHEAJQ	DI	DMHEAJQ
DMHEAJQ	DN	Biaryl compound 1
DMHEAJQ	MI	TT23XQV
DMHEAJQ	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMHEAJQ	MT	DTT
DMHEAJQ	MA	Inhibitor
DMHEAJQ	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMHEAJQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMS8VYE	DI	DMS8VYE
DMS8VYE	DN	Biaryl compound 2
DMS8VYE	MI	TT5YPJF
DMS8VYE	MN	CD80-PD-L1 interaction (CD80/PD-L1 PPI)
DMS8VYE	MT	DTT
DMS8VYE	MA	Inhibitor
DMS8VYE	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMS8VYE	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMS8VYE	DI	DMS8VYE
DMS8VYE	DN	Biaryl compound 2
DMS8VYE	MI	TT23XQV
DMS8VYE	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMS8VYE	MT	DTT
DMS8VYE	MA	Inhibitor
DMS8VYE	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMS8VYE	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMX6YGS	DI	DMX6YGS
DMX6YGS	DN	Biaryl mannoside derivative 1
DMX6YGS	MI	TTTCRU2
DMX6YGS	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMX6YGS	MT	DTT
DMX6YGS	MA	Antagonist
DMX6YGS	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMX6YGS	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMPF37N	DI	DMPF37N
DMPF37N	DN	Biaryl mannoside derivative 10
DMPF37N	MI	TTTCRU2
DMPF37N	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMPF37N	MT	DTT
DMPF37N	MA	Antagonist
DMPF37N	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMPF37N	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMKES0G	DI	DMKES0G
DMKES0G	DN	Biaryl mannoside derivative 11
DMKES0G	MI	TTTCRU2
DMKES0G	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMKES0G	MT	DTT
DMKES0G	MA	Antagonist
DMKES0G	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMKES0G	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM5T29W	DI	DM5T29W
DM5T29W	DN	Biaryl mannoside derivative 12
DM5T29W	MI	TTTCRU2
DM5T29W	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM5T29W	MT	DTT
DM5T29W	MA	Antagonist
DM5T29W	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM5T29W	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM1Y8OM	DI	DM1Y8OM
DM1Y8OM	DN	Biaryl mannoside derivative 13
DM1Y8OM	MI	TTTCRU2
DM1Y8OM	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM1Y8OM	MT	DTT
DM1Y8OM	MA	Antagonist
DM1Y8OM	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM1Y8OM	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM4C5QY	DI	DM4C5QY
DM4C5QY	DN	Biaryl mannoside derivative 14
DM4C5QY	MI	TTTCRU2
DM4C5QY	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM4C5QY	MT	DTT
DM4C5QY	MA	Antagonist
DM4C5QY	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM4C5QY	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMKXT7H	DI	DMKXT7H
DMKXT7H	DN	Biaryl mannoside derivative 15
DMKXT7H	MI	TTTCRU2
DMKXT7H	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMKXT7H	MT	DTT
DMKXT7H	MA	Antagonist
DMKXT7H	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMKXT7H	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMP9742	DI	DMP9742
DMP9742	DN	Biaryl mannoside derivative 16
DMP9742	MI	TTTCRU2
DMP9742	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMP9742	MT	DTT
DMP9742	MA	Antagonist
DMP9742	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMP9742	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMIXV6G	DI	DMIXV6G
DMIXV6G	DN	Biaryl mannoside derivative 17
DMIXV6G	MI	TTTCRU2
DMIXV6G	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMIXV6G	MT	DTT
DMIXV6G	MA	Antagonist
DMIXV6G	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMIXV6G	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMHOPE0	DI	DMHOPE0
DMHOPE0	DN	Biaryl mannoside derivative 18
DMHOPE0	MI	TTTCRU2
DMHOPE0	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMHOPE0	MT	DTT
DMHOPE0	MA	Antagonist
DMHOPE0	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMHOPE0	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DME8DQ0	DI	DME8DQ0
DME8DQ0	DN	Biaryl mannoside derivative 19
DME8DQ0	MI	TTTCRU2
DME8DQ0	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DME8DQ0	MT	DTT
DME8DQ0	MA	Antagonist
DME8DQ0	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DME8DQ0	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMMB60X	DI	DMMB60X
DMMB60X	DN	Biaryl mannoside derivative 2
DMMB60X	MI	TTTCRU2
DMMB60X	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMMB60X	MT	DTT
DMMB60X	MA	Antagonist
DMMB60X	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMMB60X	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMNC5S0	DI	DMNC5S0
DMNC5S0	DN	Biaryl mannoside derivative 20
DMNC5S0	MI	TTTCRU2
DMNC5S0	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMNC5S0	MT	DTT
DMNC5S0	MA	Antagonist
DMNC5S0	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMNC5S0	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMGSLHN	DI	DMGSLHN
DMGSLHN	DN	Biaryl mannoside derivative 21
DMGSLHN	MI	TTTCRU2
DMGSLHN	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMGSLHN	MT	DTT
DMGSLHN	MA	Antagonist
DMGSLHN	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMGSLHN	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMYLVB3	DI	DMYLVB3
DMYLVB3	DN	Biaryl mannoside derivative 22
DMYLVB3	MI	TTTCRU2
DMYLVB3	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMYLVB3	MT	DTT
DMYLVB3	MA	Antagonist
DMYLVB3	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMYLVB3	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM2YVGH	DI	DM2YVGH
DM2YVGH	DN	Biaryl mannoside derivative 23
DM2YVGH	MI	TTTCRU2
DM2YVGH	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM2YVGH	MT	DTT
DM2YVGH	MA	Antagonist
DM2YVGH	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM2YVGH	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMF5TB4	DI	DMF5TB4
DMF5TB4	DN	Biaryl mannoside derivative 24
DMF5TB4	MI	TTTCRU2
DMF5TB4	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMF5TB4	MT	DTT
DMF5TB4	MA	Antagonist
DMF5TB4	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMF5TB4	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMRM3E9	DI	DMRM3E9
DMRM3E9	DN	Biaryl mannoside derivative 25
DMRM3E9	MI	TTTCRU2
DMRM3E9	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMRM3E9	MT	DTT
DMRM3E9	MA	Antagonist
DMRM3E9	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMRM3E9	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMYXLCJ	DI	DMYXLCJ
DMYXLCJ	DN	Biaryl mannoside derivative 26
DMYXLCJ	MI	TTTCRU2
DMYXLCJ	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMYXLCJ	MT	DTT
DMYXLCJ	MA	Antagonist
DMYXLCJ	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMYXLCJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMTDPHY	DI	DMTDPHY
DMTDPHY	DN	Biaryl mannoside derivative 27
DMTDPHY	MI	TTTCRU2
DMTDPHY	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMTDPHY	MT	DTT
DMTDPHY	MA	Antagonist
DMTDPHY	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMTDPHY	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMSNMZ2	DI	DMSNMZ2
DMSNMZ2	DN	Biaryl mannoside derivative 28
DMSNMZ2	MI	TTTCRU2
DMSNMZ2	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMSNMZ2	MT	DTT
DMSNMZ2	MA	Antagonist
DMSNMZ2	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMSNMZ2	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMCLTY3	DI	DMCLTY3
DMCLTY3	DN	Biaryl mannoside derivative 29
DMCLTY3	MI	TTTCRU2
DMCLTY3	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMCLTY3	MT	DTT
DMCLTY3	MA	Antagonist
DMCLTY3	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMCLTY3	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMAITK3	DI	DMAITK3
DMAITK3	DN	Biaryl mannoside derivative 3
DMAITK3	MI	TTTCRU2
DMAITK3	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMAITK3	MT	DTT
DMAITK3	MA	Antagonist
DMAITK3	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMAITK3	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMPLAWQ	DI	DMPLAWQ
DMPLAWQ	DN	Biaryl mannoside derivative 30
DMPLAWQ	MI	TTTCRU2
DMPLAWQ	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMPLAWQ	MT	DTT
DMPLAWQ	MA	Antagonist
DMPLAWQ	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMPLAWQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMMPJ3E	DI	DMMPJ3E
DMMPJ3E	DN	Biaryl mannoside derivative 31
DMMPJ3E	MI	TTTCRU2
DMMPJ3E	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMMPJ3E	MT	DTT
DMMPJ3E	MA	Antagonist
DMMPJ3E	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMMPJ3E	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMVF63N	DI	DMVF63N
DMVF63N	DN	Biaryl mannoside derivative 4
DMVF63N	MI	TTTCRU2
DMVF63N	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMVF63N	MT	DTT
DMVF63N	MA	Antagonist
DMVF63N	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMVF63N	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMRS1WG	DI	DMRS1WG
DMRS1WG	DN	Biaryl mannoside derivative 5
DMRS1WG	MI	TTTCRU2
DMRS1WG	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMRS1WG	MT	DTT
DMRS1WG	MA	Antagonist
DMRS1WG	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMRS1WG	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMEWA7U	DI	DMEWA7U
DMEWA7U	DN	Biaryl mannoside derivative 6
DMEWA7U	MI	TTTCRU2
DMEWA7U	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMEWA7U	MT	DTT
DMEWA7U	MA	Antagonist
DMEWA7U	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMEWA7U	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMD7053	DI	DMD7053
DMD7053	DN	Biaryl mannoside derivative 7
DMD7053	MI	TTTCRU2
DMD7053	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMD7053	MT	DTT
DMD7053	MA	Antagonist
DMD7053	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMD7053	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMWF2VG	DI	DMWF2VG
DMWF2VG	DN	Biaryl mannoside derivative 8
DMWF2VG	MI	TTTCRU2
DMWF2VG	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMWF2VG	MT	DTT
DMWF2VG	MA	Antagonist
DMWF2VG	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMWF2VG	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM1Q7AL	DI	DM1Q7AL
DM1Q7AL	DN	Biaryl mannoside derivative 9
DM1Q7AL	MI	TTTCRU2
DM1Q7AL	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM1Q7AL	MT	DTT
DM1Q7AL	MA	Antagonist
DM1Q7AL	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM1Q7AL	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMDK7LQ	DI	DMDK7LQ
DMDK7LQ	DN	Bicarboxylic and tricarboxylic ethynyl derivative 1
DMDK7LQ	MI	TTHS256
DMDK7LQ	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMDK7LQ	MT	DTT
DMDK7LQ	MA	Modulator
DMDK7LQ	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMDK7LQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMG9O7D	DI	DMG9O7D
DMG9O7D	DN	Bicarboxylic and tricarboxylic ethynyl derivative 2
DMG9O7D	MI	TTHS256
DMG9O7D	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMG9O7D	MT	DTT
DMG9O7D	MA	Modulator
DMG9O7D	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMG9O7D	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DM1KVTZ	DI	DM1KVTZ
DM1KVTZ	DN	Bicarboxylic and tricarboxylic ethynyl derivative 3
DM1KVTZ	MI	TTHS256
DM1KVTZ	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM1KVTZ	MT	DTT
DM1KVTZ	MA	Modulator
DM1KVTZ	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DM1KVTZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMOFI09	DI	DMOFI09
DMOFI09	DN	Bicyclic heteroaryl amide derivative 1
DMOFI09	MI	TT473XN
DMOFI09	MN	P2X purinoceptor 7 (P2RX7)
DMOFI09	MT	DTT
DMOFI09	MA	Antagonist
DMOFI09	RN	P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267.
DMOFI09	RU	https://www.ncbi.nlm.nih.gov/pubmed/27724045

DM69HL5	DI	DM69HL5
DM69HL5	DN	Bicyclic heteroaryl amide derivative 2
DM69HL5	MI	TT473XN
DM69HL5	MN	P2X purinoceptor 7 (P2RX7)
DM69HL5	MT	DTT
DM69HL5	MA	Antagonist
DM69HL5	RN	P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267.
DM69HL5	RU	https://www.ncbi.nlm.nih.gov/pubmed/27724045

DM0OYCX	DI	DM0OYCX
DM0OYCX	DN	Bicyclic heteroaryl amide derivative 3
DM0OYCX	MI	TT473XN
DM0OYCX	MN	P2X purinoceptor 7 (P2RX7)
DM0OYCX	MT	DTT
DM0OYCX	MA	Antagonist
DM0OYCX	RN	P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267.
DM0OYCX	RU	https://www.ncbi.nlm.nih.gov/pubmed/27724045

DMTBWC9	DI	DMTBWC9
DMTBWC9	DN	Bicyclic heteroaryl benzamide derivative 1
DMTBWC9	MI	TTTDVOJ
DMTBWC9	MN	Tropomyosin-related kinase A (TrkA)
DMTBWC9	MT	DTT
DMTBWC9	MA	Inhibitor
DMTBWC9	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMTBWC9	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DM5MT4R	DI	DM5MT4R
DM5MT4R	DN	Bicyclic heteroaryl benzamide derivative 2
DM5MT4R	MI	TTTDVOJ
DM5MT4R	MN	Tropomyosin-related kinase A (TrkA)
DM5MT4R	MT	DTT
DM5MT4R	MA	Inhibitor
DM5MT4R	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DM5MT4R	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DM54EV2	DI	DM54EV2
DM54EV2	DN	Bicyclic heteroaryl benzamide derivative 3
DM54EV2	MI	TTTDVOJ
DM54EV2	MN	Tropomyosin-related kinase A (TrkA)
DM54EV2	MT	DTT
DM54EV2	MA	Inhibitor
DM54EV2	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DM54EV2	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMUBDYG	DI	DMUBDYG
DMUBDYG	DN	Bicyclic heteroaryl benzamide derivative 4
DMUBDYG	MI	TTTDVOJ
DMUBDYG	MN	Tropomyosin-related kinase A (TrkA)
DMUBDYG	MT	DTT
DMUBDYG	MA	Inhibitor
DMUBDYG	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMUBDYG	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMFOVPT	DI	DMFOVPT
DMFOVPT	DN	Bicyclic heteroaryl benzamide derivative 5
DMFOVPT	MI	TTTDVOJ
DMFOVPT	MN	Tropomyosin-related kinase A (TrkA)
DMFOVPT	MT	DTT
DMFOVPT	MA	Inhibitor
DMFOVPT	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMFOVPT	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMQGYWV	DI	DMQGYWV
DMQGYWV	DN	Bicyclic heteroaryl benzamide derivative 6
DMQGYWV	MI	TTTDVOJ
DMQGYWV	MN	Tropomyosin-related kinase A (TrkA)
DMQGYWV	MT	DTT
DMQGYWV	MA	Inhibitor
DMQGYWV	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMQGYWV	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMM1LKF	DI	DMM1LKF
DMM1LKF	DN	Bicyclic heteroaryl benzamide derivative 7
DMM1LKF	MI	TTTDVOJ
DMM1LKF	MN	Tropomyosin-related kinase A (TrkA)
DMM1LKF	MT	DTT
DMM1LKF	MA	Inhibitor
DMM1LKF	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMM1LKF	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMVBQJ1	DI	DMVBQJ1
DMVBQJ1	DN	Bicyclic heteroaryl benzamide derivative 8
DMVBQJ1	MI	TTTDVOJ
DMVBQJ1	MN	Tropomyosin-related kinase A (TrkA)
DMVBQJ1	MT	DTT
DMVBQJ1	MA	Inhibitor
DMVBQJ1	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMVBQJ1	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMGONY4	DI	DMGONY4
DMGONY4	DN	Bicyclic heteroaryl benzamide derivative 9
DMGONY4	MI	TTTDVOJ
DMGONY4	MN	Tropomyosin-related kinase A (TrkA)
DMGONY4	MT	DTT
DMGONY4	MA	Inhibitor
DMGONY4	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMGONY4	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMB5XDM	DI	DMB5XDM
DMB5XDM	DN	Bicyclic heteroaryl carboxamide analog 1
DMB5XDM	MI	TTHS256
DMB5XDM	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMB5XDM	MT	DTT
DMB5XDM	MA	Modulator
DMB5XDM	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMB5XDM	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMKT7MD	DI	DMKT7MD
DMKT7MD	DN	Bicyclic heteroaryl carboxamide analog 2
DMKT7MD	MI	TTHS256
DMKT7MD	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMKT7MD	MT	DTT
DMKT7MD	MA	Modulator
DMKT7MD	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMKT7MD	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DM3QMA0	DI	DM3QMA0
DM3QMA0	DN	Bicyclic heteroaryl carboxamide analog 3
DM3QMA0	MI	TTHS256
DM3QMA0	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM3QMA0	MT	DTT
DM3QMA0	MA	Modulator
DM3QMA0	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DM3QMA0	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMWTCM8	DI	DMWTCM8
DMWTCM8	DN	Bicyclic hexapeptide derivative 1
DMWTCM8	MI	TT8J1S3
DMWTCM8	MN	Smoothened homolog (SMO)
DMWTCM8	MT	DTT
DMWTCM8	MA	Inhibitor
DMWTCM8	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMWTCM8	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMJP1IK	DI	DMJP1IK
DMJP1IK	DN	Bicyclic hexapeptide derivative 2
DMJP1IK	MI	TT8J1S3
DMJP1IK	MN	Smoothened homolog (SMO)
DMJP1IK	MT	DTT
DMJP1IK	MA	Inhibitor
DMJP1IK	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMJP1IK	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMAJ74C	DI	DMAJ74C
DMAJ74C	DN	Bicyclic pyrimidine derivative 1
DMAJ74C	MI	TTJOW1I
DMAJ74C	MN	Mannoside acetylglucosaminyltransferase 2 (MGAT2)
DMAJ74C	MT	DTT
DMAJ74C	MA	Inhibitor
DMAJ74C	RN	Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
DMAJ74C	RU	https://www.ncbi.nlm.nih.gov/pubmed/25470667

DMJP16K	DI	DMJP16K
DMJP16K	DN	Bicyclic pyrimidine derivative 2
DMJP16K	MI	TTDNFMT
DMJP16K	MN	Platelet-activating factor acetylhydrolase (PLA2G7)
DMJP16K	MT	DTT
DMJP16K	MA	Inhibitor
DMJP16K	RN	Inhibitors of phospholipase A2 and their therapeutic potential: an update on patents (2012-2016).Expert Opin Ther Pat. 2017 Feb;27(2):217-225.
DMJP16K	RU	https://www.ncbi.nlm.nih.gov/pubmed/27718763

DMGESCP	DI	DMGESCP
DMGESCP	DN	Bicyclo-heptan-2-amine derivative 1
DMGESCP	MI	TT9NXW4
DMGESCP	MN	Sigma intracellular receptor 2 (TMEM97)
DMGESCP	MT	DTT
DMGESCP	MA	Ligand
DMGESCP	RN	Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578.
DMGESCP	RU	https://www.ncbi.nlm.nih.gov/pubmed/28051882

DM9WUH5	DI	DM9WUH5
DM9WUH5	DN	Bicyclo-heptan-2-amine derivative 2
DM9WUH5	MI	TT9NXW4
DM9WUH5	MN	Sigma intracellular receptor 2 (TMEM97)
DM9WUH5	MT	DTT
DM9WUH5	MA	Ligand
DM9WUH5	RN	Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578.
DM9WUH5	RU	https://www.ncbi.nlm.nih.gov/pubmed/28051882

DM8ZRXE	DI	DM8ZRXE
DM8ZRXE	DN	Bicyclo-heptan-2-amine derivative 3
DM8ZRXE	MI	TT9NXW4
DM8ZRXE	MN	Sigma intracellular receptor 2 (TMEM97)
DM8ZRXE	MT	DTT
DM8ZRXE	MA	Ligand
DM8ZRXE	RN	Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578.
DM8ZRXE	RU	https://www.ncbi.nlm.nih.gov/pubmed/28051882

DMPRIS0	DI	DMPRIS0
DMPRIS0	DN	Bicyclo-heptan-2-amine derivative 4
DMPRIS0	MI	TT9NXW4
DMPRIS0	MN	Sigma intracellular receptor 2 (TMEM97)
DMPRIS0	MT	DTT
DMPRIS0	MA	Ligand
DMPRIS0	RN	Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578.
DMPRIS0	RU	https://www.ncbi.nlm.nih.gov/pubmed/28051882

DMB08D3	DI	DMB08D3
DMB08D3	DN	Bidentate ligands of Markush derivative 1
DMB08D3	MI	TTK0FEA
DMB08D3	MN	Leucine-rich repeat kinase 2 (LRRK2)
DMB08D3	MT	DTT
DMB08D3	MA	Inhibitor
DMB08D3	RN	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
DMB08D3	RU	https://www.ncbi.nlm.nih.gov/pubmed/28117607

DMB08D3	DI	DMB08D3
DMB08D3	DN	Bidentate ligands of Markush derivative 1
DMB08D3	MI	TTVOE6D
DMB08D3	MN	Mitogen-activated protein kinase (MAPK)
DMB08D3	MT	DTT
DMB08D3	MA	Inhibitor
DMB08D3	RN	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
DMB08D3	RU	https://www.ncbi.nlm.nih.gov/pubmed/28117607

DM2QNMC	DI	DM2QNMC
DM2QNMC	DN	Bidentate ligands of Markush derivative 2
DM2QNMC	MI	TTK0FEA
DM2QNMC	MN	Leucine-rich repeat kinase 2 (LRRK2)
DM2QNMC	MT	DTT
DM2QNMC	MA	Inhibitor
DM2QNMC	RN	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
DM2QNMC	RU	https://www.ncbi.nlm.nih.gov/pubmed/28117607

DM2QNMC	DI	DM2QNMC
DM2QNMC	DN	Bidentate ligands of Markush derivative 2
DM2QNMC	MI	TTVOE6D
DM2QNMC	MN	Mitogen-activated protein kinase (MAPK)
DM2QNMC	MT	DTT
DM2QNMC	MA	Inhibitor
DM2QNMC	RN	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
DM2QNMC	RU	https://www.ncbi.nlm.nih.gov/pubmed/28117607

DMPWKAH	DI	DMPWKAH
DMPWKAH	DN	Bidentate pyrazolopyrimidine acetamide analog 1
DMPWKAH	MI	TTPTXIN
DMPWKAH	MN	Translocator protein (TSPO)
DMPWKAH	MT	DTT
DMPWKAH	MA	Ligand
DMPWKAH	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMPWKAH	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DM6SPTJ	DI	DM6SPTJ
DM6SPTJ	DN	Bidentate pyrazolopyrimidine acetamide analog 2
DM6SPTJ	MI	TTPTXIN
DM6SPTJ	MN	Translocator protein (TSPO)
DM6SPTJ	MT	DTT
DM6SPTJ	MA	Ligand
DM6SPTJ	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DM6SPTJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMC7UHT	DI	DMC7UHT
DMC7UHT	DN	Bidentate pyrazolopyrimidine acetamide analog 3
DMC7UHT	MI	TTPTXIN
DMC7UHT	MN	Translocator protein (TSPO)
DMC7UHT	MT	DTT
DMC7UHT	MA	Ligand
DMC7UHT	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMC7UHT	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMKZLCQ	DI	DMKZLCQ
DMKZLCQ	DN	Bidentate pyrazolopyrimidine acetamide analog 4
DMKZLCQ	MI	TTPTXIN
DMKZLCQ	MN	Translocator protein (TSPO)
DMKZLCQ	MT	DTT
DMKZLCQ	MA	Ligand
DMKZLCQ	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMKZLCQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DM5WN0U	DI	DM5WN0U
DM5WN0U	DN	Binuclear gold(I) compound 1
DM5WN0U	MI	TTR7UJ3
DM5WN0U	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DM5WN0U	MT	DTT
DM5WN0U	MA	Inhibitor
DM5WN0U	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DM5WN0U	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DM5WAGC	DI	DM5WAGC
DM5WAGC	DN	Binuclear gold(I) compound 2
DM5WAGC	MI	TTR7UJ3
DM5WAGC	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DM5WAGC	MT	DTT
DM5WAGC	MA	Inhibitor
DM5WAGC	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DM5WAGC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DM94TKW	DI	DM94TKW
DM94TKW	DN	Binuclear gold(I) compound 3
DM94TKW	MI	TTR7UJ3
DM94TKW	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DM94TKW	MT	DTT
DM94TKW	MA	Inhibitor
DM94TKW	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DM94TKW	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DM1VYZ9	DI	DM1VYZ9
DM1VYZ9	DN	Biphenyl 1,2-diamine derivative 1
DM1VYZ9	MI	TTZJYKH
DM1VYZ9	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DM1VYZ9	MT	DTT
DM1VYZ9	MA	Modulator
DM1VYZ9	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DM1VYZ9	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DM6803W	DI	DM6803W
DM6803W	DN	Biphenyl carboxamidopropanoic acid derivative 1
DM6803W	MI	TT9O6WS
DM6803W	MN	Glucagon receptor (GCGR)
DM6803W	MT	DTT
DM6803W	MA	Antagonist
DM6803W	RN	Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30.
DM6803W	RU	https://www.ncbi.nlm.nih.gov/pubmed/25828189

DMQF2XN	DI	DMQF2XN
DMQF2XN	DN	Biphenyl carboxamidopropanoic acid derivative 2
DMQF2XN	MI	TT9O6WS
DMQF2XN	MN	Glucagon receptor (GCGR)
DMQF2XN	MT	DTT
DMQF2XN	MA	Antagonist
DMQF2XN	RN	Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30.
DMQF2XN	RU	https://www.ncbi.nlm.nih.gov/pubmed/25828189

DMLOVMP	DI	DMLOVMP
DMLOVMP	DN	Biphenyl carboxamidopropanoic acid derivative 3
DMLOVMP	MI	TT9O6WS
DMLOVMP	MN	Glucagon receptor (GCGR)
DMLOVMP	MT	DTT
DMLOVMP	MA	Antagonist
DMLOVMP	RN	Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30.
DMLOVMP	RU	https://www.ncbi.nlm.nih.gov/pubmed/25828189

DM715E8	DI	DM715E8
DM715E8	DN	Biphenyl carboxamidopropanoic acid derivative 4
DM715E8	MI	TT9O6WS
DM715E8	MN	Glucagon receptor (GCGR)
DM715E8	MT	DTT
DM715E8	MA	Antagonist
DM715E8	RN	Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30.
DM715E8	RU	https://www.ncbi.nlm.nih.gov/pubmed/25828189

DMPWFJN	DI	DMPWFJN
DMPWFJN	DN	Biphenyl carboxylic acid derivative 1
DMPWFJN	MI	TTL53M6
DMPWFJN	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DMPWFJN	MT	DTT
DMPWFJN	MA	Inhibitor
DMPWFJN	RN	Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
DMPWFJN	RU	https://www.ncbi.nlm.nih.gov/pubmed/27744724

DM6TXF4	DI	DM6TXF4
DM6TXF4	DN	Biphenyl carboxylic acid derivative 2
DM6TXF4	MI	TTL53M6
DM6TXF4	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DM6TXF4	MT	DTT
DM6TXF4	MA	Inhibitor
DM6TXF4	RN	Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
DM6TXF4	RU	https://www.ncbi.nlm.nih.gov/pubmed/27744724

DMG4WQB	DI	DMG4WQB
DMG4WQB	DN	Biphenyl derivative 1
DMG4WQB	MI	TTZJYKH
DMG4WQB	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMG4WQB	MT	DTT
DMG4WQB	MA	Inhibitor
DMG4WQB	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMG4WQB	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMJ4TZX	DI	DMJ4TZX
DMJ4TZX	DN	Biphenyl derivative 2
DMJ4TZX	MI	TTZJYKH
DMJ4TZX	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMJ4TZX	MT	DTT
DMJ4TZX	MA	Inhibitor
DMJ4TZX	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMJ4TZX	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMM3SWV	DI	DMM3SWV
DMM3SWV	DN	Biphenyl derivative 3
DMM3SWV	MI	TTZJYKH
DMM3SWV	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMM3SWV	MT	DTT
DMM3SWV	MA	Inhibitor
DMM3SWV	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMM3SWV	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMIPVYW	DI	DMIPVYW
DMIPVYW	DN	Biphenyl derivative 4
DMIPVYW	MI	TT9JNIC
DMIPVYW	MN	Histamine H3 receptor (H3R)
DMIPVYW	MT	DTT
DMIPVYW	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DMIPVYW	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DMS5UFX	DI	DMS5UFX
DMS5UFX	DN	Biphenyl mannoside derivative 1
DMS5UFX	MI	TTTCRU2
DMS5UFX	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMS5UFX	MT	DTT
DMS5UFX	MA	Antagonist
DMS5UFX	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMS5UFX	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMITLPW	DI	DMITLPW
DMITLPW	DN	Biphenyl mannoside derivative 10
DMITLPW	MI	TTTCRU2
DMITLPW	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMITLPW	MT	DTT
DMITLPW	MA	Antagonist
DMITLPW	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMITLPW	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMZF5XI	DI	DMZF5XI
DMZF5XI	DN	Biphenyl mannoside derivative 11
DMZF5XI	MI	TTTCRU2
DMZF5XI	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMZF5XI	MT	DTT
DMZF5XI	MA	Antagonist
DMZF5XI	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMZF5XI	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMU0YST	DI	DMU0YST
DMU0YST	DN	Biphenyl mannoside derivative 12
DMU0YST	MI	TTTCRU2
DMU0YST	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMU0YST	MT	DTT
DMU0YST	MA	Antagonist
DMU0YST	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMU0YST	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM83LTH	DI	DM83LTH
DM83LTH	DN	Biphenyl mannoside derivative 13
DM83LTH	MI	TTTCRU2
DM83LTH	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM83LTH	MT	DTT
DM83LTH	MA	Antagonist
DM83LTH	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM83LTH	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMMRTWG	DI	DMMRTWG
DMMRTWG	DN	Biphenyl mannoside derivative 14
DMMRTWG	MI	TTTCRU2
DMMRTWG	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMMRTWG	MT	DTT
DMMRTWG	MA	Antagonist
DMMRTWG	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMMRTWG	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM97BIQ	DI	DM97BIQ
DM97BIQ	DN	Biphenyl mannoside derivative 15
DM97BIQ	MI	TTTCRU2
DM97BIQ	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM97BIQ	MT	DTT
DM97BIQ	MA	Antagonist
DM97BIQ	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM97BIQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMECZVG	DI	DMECZVG
DMECZVG	DN	Biphenyl mannoside derivative 16
DMECZVG	MI	TTTCRU2
DMECZVG	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMECZVG	MT	DTT
DMECZVG	MA	Antagonist
DMECZVG	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMECZVG	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM7L8T5	DI	DM7L8T5
DM7L8T5	DN	Biphenyl mannoside derivative 17
DM7L8T5	MI	TTTCRU2
DM7L8T5	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM7L8T5	MT	DTT
DM7L8T5	MA	Antagonist
DM7L8T5	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM7L8T5	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM2GZ5Y	DI	DM2GZ5Y
DM2GZ5Y	DN	Biphenyl mannoside derivative 18
DM2GZ5Y	MI	TTTCRU2
DM2GZ5Y	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM2GZ5Y	MT	DTT
DM2GZ5Y	MA	Antagonist
DM2GZ5Y	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM2GZ5Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMGA0R6	DI	DMGA0R6
DMGA0R6	DN	Biphenyl mannoside derivative 19
DMGA0R6	MI	TTTCRU2
DMGA0R6	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMGA0R6	MT	DTT
DMGA0R6	MA	Antagonist
DMGA0R6	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMGA0R6	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMQB4DR	DI	DMQB4DR
DMQB4DR	DN	Biphenyl mannoside derivative 2
DMQB4DR	MI	TTTCRU2
DMQB4DR	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMQB4DR	MT	DTT
DMQB4DR	MA	Antagonist
DMQB4DR	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMQB4DR	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMDIYJ1	DI	DMDIYJ1
DMDIYJ1	DN	Biphenyl mannoside derivative 20
DMDIYJ1	MI	TTTCRU2
DMDIYJ1	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMDIYJ1	MT	DTT
DMDIYJ1	MA	Antagonist
DMDIYJ1	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMDIYJ1	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMTR6BX	DI	DMTR6BX
DMTR6BX	DN	Biphenyl mannoside derivative 21
DMTR6BX	MI	TTTCRU2
DMTR6BX	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMTR6BX	MT	DTT
DMTR6BX	MA	Antagonist
DMTR6BX	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMTR6BX	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMQGFKY	DI	DMQGFKY
DMQGFKY	DN	Biphenyl mannoside derivative 22
DMQGFKY	MI	TTTCRU2
DMQGFKY	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMQGFKY	MT	DTT
DMQGFKY	MA	Antagonist
DMQGFKY	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMQGFKY	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMC8OVU	DI	DMC8OVU
DMC8OVU	DN	Biphenyl mannoside derivative 23
DMC8OVU	MI	TTTCRU2
DMC8OVU	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMC8OVU	MT	DTT
DMC8OVU	MA	Antagonist
DMC8OVU	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMC8OVU	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMLUZ3K	DI	DMLUZ3K
DMLUZ3K	DN	Biphenyl mannoside derivative 24
DMLUZ3K	MI	TTTCRU2
DMLUZ3K	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMLUZ3K	MT	DTT
DMLUZ3K	MA	Antagonist
DMLUZ3K	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMLUZ3K	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMBWQ8L	DI	DMBWQ8L
DMBWQ8L	DN	Biphenyl mannoside derivative 25
DMBWQ8L	MI	TTTCRU2
DMBWQ8L	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMBWQ8L	MT	DTT
DMBWQ8L	MA	Antagonist
DMBWQ8L	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMBWQ8L	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM5Q4T2	DI	DM5Q4T2
DM5Q4T2	DN	Biphenyl mannoside derivative 26
DM5Q4T2	MI	TTTCRU2
DM5Q4T2	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM5Q4T2	MT	DTT
DM5Q4T2	MA	Antagonist
DM5Q4T2	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM5Q4T2	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMWQ6FJ	DI	DMWQ6FJ
DMWQ6FJ	DN	Biphenyl mannoside derivative 27
DMWQ6FJ	MI	TTTCRU2
DMWQ6FJ	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMWQ6FJ	MT	DTT
DMWQ6FJ	MA	Antagonist
DMWQ6FJ	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMWQ6FJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMMOTWK	DI	DMMOTWK
DMMOTWK	DN	Biphenyl mannoside derivative 28
DMMOTWK	MI	TTTCRU2
DMMOTWK	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMMOTWK	MT	DTT
DMMOTWK	MA	Antagonist
DMMOTWK	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMMOTWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM9H0Q3	DI	DM9H0Q3
DM9H0Q3	DN	Biphenyl mannoside derivative 29
DM9H0Q3	MI	TTTCRU2
DM9H0Q3	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM9H0Q3	MT	DTT
DM9H0Q3	MA	Antagonist
DM9H0Q3	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM9H0Q3	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMOKJEP	DI	DMOKJEP
DMOKJEP	DN	Biphenyl mannoside derivative 3
DMOKJEP	MI	TTTCRU2
DMOKJEP	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMOKJEP	MT	DTT
DMOKJEP	MA	Antagonist
DMOKJEP	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMOKJEP	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM81RIY	DI	DM81RIY
DM81RIY	DN	Biphenyl mannoside derivative 30
DM81RIY	MI	TTTCRU2
DM81RIY	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM81RIY	MT	DTT
DM81RIY	MA	Antagonist
DM81RIY	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM81RIY	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM0VR23	DI	DM0VR23
DM0VR23	DN	Biphenyl mannoside derivative 4
DM0VR23	MI	TTTCRU2
DM0VR23	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM0VR23	MT	DTT
DM0VR23	MA	Antagonist
DM0VR23	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM0VR23	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMOS03R	DI	DMOS03R
DMOS03R	DN	Biphenyl mannoside derivative 5
DMOS03R	MI	TTTCRU2
DMOS03R	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMOS03R	MT	DTT
DMOS03R	MA	Antagonist
DMOS03R	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMOS03R	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM93VEB	DI	DM93VEB
DM93VEB	DN	Biphenyl mannoside derivative 6
DM93VEB	MI	TTTCRU2
DM93VEB	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM93VEB	MT	DTT
DM93VEB	MA	Antagonist
DM93VEB	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM93VEB	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM46NRV	DI	DM46NRV
DM46NRV	DN	Biphenyl mannoside derivative 7
DM46NRV	MI	TTTCRU2
DM46NRV	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM46NRV	MT	DTT
DM46NRV	MA	Antagonist
DM46NRV	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM46NRV	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMZCWM5	DI	DMZCWM5
DMZCWM5	DN	Biphenyl mannoside derivative 8
DMZCWM5	MI	TTTCRU2
DMZCWM5	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMZCWM5	MT	DTT
DMZCWM5	MA	Antagonist
DMZCWM5	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMZCWM5	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMP52HJ	DI	DMP52HJ
DMP52HJ	DN	Biphenyl mannoside derivative 9
DMP52HJ	MI	TTTCRU2
DMP52HJ	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMP52HJ	MT	DTT
DMP52HJ	MA	Antagonist
DMP52HJ	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMP52HJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM6KGUB	DI	DM6KGUB
DM6KGUB	DN	Bipyrazole derivative 1
DM6KGUB	MI	TT6DM01
DM6KGUB	MN	Janus kinase 1 (JAK-1)
DM6KGUB	MT	DTT
DM6KGUB	MA	Inhibitor
DM6KGUB	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DM6KGUB	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMPUXL3	DI	DMPUXL3
DMPUXL3	DN	Bipyridine derivative 1
DMPUXL3	MI	TT1LVF2
DMPUXL3	MN	Cyclin-dependent kinase 9 (CDK9)
DMPUXL3	MT	DTT
DMPUXL3	MA	Inhibitor
DMPUXL3	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMPUXL3	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMQL34C	DI	DMQL34C
DMQL34C	DN	Bis-aminopyrimidine derivative 1
DMQL34C	MI	TT6DM01
DMQL34C	MN	Janus kinase 1 (JAK-1)
DMQL34C	MT	DTT
DMQL34C	MA	Inhibitor
DMQL34C	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMQL34C	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMQL34C	DI	DMQL34C
DMQL34C	DN	Bis-aminopyrimidine derivative 1
DMQL34C	MI	TTRMX3V
DMQL34C	MN	Janus kinase 2 (JAK-2)
DMQL34C	MT	DTT
DMQL34C	MA	Inhibitor
DMQL34C	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMQL34C	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMQL34C	DI	DMQL34C
DMQL34C	DN	Bis-aminopyrimidine derivative 1
DMQL34C	MI	TTT7PJU
DMQL34C	MN	Janus kinase 3 (JAK-3)
DMQL34C	MT	DTT
DMQL34C	MA	Inhibitor
DMQL34C	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMQL34C	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMQL34C	DI	DMQL34C
DMQL34C	DN	Bis-aminopyrimidine derivative 1
DMQL34C	MI	TTBYWP2
DMQL34C	MN	TYK2 tyrosine kinase (TYK2)
DMQL34C	MT	DTT
DMQL34C	MA	Inhibitor
DMQL34C	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMQL34C	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMJXNO1	DI	DMJXNO1
DMJXNO1	DN	Bis-aminopyrimidine derivative 2
DMJXNO1	MI	TT6DM01
DMJXNO1	MN	Janus kinase 1 (JAK-1)
DMJXNO1	MT	DTT
DMJXNO1	MA	Inhibitor
DMJXNO1	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMJXNO1	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMJXNO1	DI	DMJXNO1
DMJXNO1	DN	Bis-aminopyrimidine derivative 2
DMJXNO1	MI	TTRMX3V
DMJXNO1	MN	Janus kinase 2 (JAK-2)
DMJXNO1	MT	DTT
DMJXNO1	MA	Inhibitor
DMJXNO1	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMJXNO1	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMJXNO1	DI	DMJXNO1
DMJXNO1	DN	Bis-aminopyrimidine derivative 2
DMJXNO1	MI	TTT7PJU
DMJXNO1	MN	Janus kinase 3 (JAK-3)
DMJXNO1	MT	DTT
DMJXNO1	MA	Inhibitor
DMJXNO1	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMJXNO1	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMJXNO1	DI	DMJXNO1
DMJXNO1	DN	Bis-aminopyrimidine derivative 2
DMJXNO1	MI	TTBYWP2
DMJXNO1	MN	TYK2 tyrosine kinase (TYK2)
DMJXNO1	MT	DTT
DMJXNO1	MA	Inhibitor
DMJXNO1	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMJXNO1	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMUNSYX	DI	DMUNSYX
DMUNSYX	DN	Bis-aminopyrimidine derivative 3
DMUNSYX	MI	TT6DM01
DMUNSYX	MN	Janus kinase 1 (JAK-1)
DMUNSYX	MT	DTT
DMUNSYX	MA	Inhibitor
DMUNSYX	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMUNSYX	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMUNSYX	DI	DMUNSYX
DMUNSYX	DN	Bis-aminopyrimidine derivative 3
DMUNSYX	MI	TTRMX3V
DMUNSYX	MN	Janus kinase 2 (JAK-2)
DMUNSYX	MT	DTT
DMUNSYX	MA	Inhibitor
DMUNSYX	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMUNSYX	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMUNSYX	DI	DMUNSYX
DMUNSYX	DN	Bis-aminopyrimidine derivative 3
DMUNSYX	MI	TTT7PJU
DMUNSYX	MN	Janus kinase 3 (JAK-3)
DMUNSYX	MT	DTT
DMUNSYX	MA	Inhibitor
DMUNSYX	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMUNSYX	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMUNSYX	DI	DMUNSYX
DMUNSYX	DN	Bis-aminopyrimidine derivative 3
DMUNSYX	MI	TTBYWP2
DMUNSYX	MN	TYK2 tyrosine kinase (TYK2)
DMUNSYX	MT	DTT
DMUNSYX	MA	Inhibitor
DMUNSYX	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMUNSYX	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMO1ZIG	DI	DMO1ZIG
DMO1ZIG	DN	Bis-aminopyrimidine derivative 4
DMO1ZIG	MI	TT6DM01
DMO1ZIG	MN	Janus kinase 1 (JAK-1)
DMO1ZIG	MT	DTT
DMO1ZIG	MA	Inhibitor
DMO1ZIG	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMO1ZIG	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMO1ZIG	DI	DMO1ZIG
DMO1ZIG	DN	Bis-aminopyrimidine derivative 4
DMO1ZIG	MI	TTRMX3V
DMO1ZIG	MN	Janus kinase 2 (JAK-2)
DMO1ZIG	MT	DTT
DMO1ZIG	MA	Inhibitor
DMO1ZIG	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMO1ZIG	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMO1ZIG	DI	DMO1ZIG
DMO1ZIG	DN	Bis-aminopyrimidine derivative 4
DMO1ZIG	MI	TTT7PJU
DMO1ZIG	MN	Janus kinase 3 (JAK-3)
DMO1ZIG	MT	DTT
DMO1ZIG	MA	Inhibitor
DMO1ZIG	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMO1ZIG	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMO1ZIG	DI	DMO1ZIG
DMO1ZIG	DN	Bis-aminopyrimidine derivative 4
DMO1ZIG	MI	TTBYWP2
DMO1ZIG	MN	TYK2 tyrosine kinase (TYK2)
DMO1ZIG	MT	DTT
DMO1ZIG	MA	Inhibitor
DMO1ZIG	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMO1ZIG	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMWXLK1	DI	DMWXLK1
DMWXLK1	DN	Bis-aminopyrimidine derivative 5
DMWXLK1	MI	TTRMX3V
DMWXLK1	MN	Janus kinase 2 (JAK-2)
DMWXLK1	MT	DTT
DMWXLK1	MA	Inhibitor
DMWXLK1	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMWXLK1	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMWXLK1	DI	DMWXLK1
DMWXLK1	DN	Bis-aminopyrimidine derivative 5
DMWXLK1	MI	TTBYWP2
DMWXLK1	MN	TYK2 tyrosine kinase (TYK2)
DMWXLK1	MT	DTT
DMWXLK1	MA	Inhibitor
DMWXLK1	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMWXLK1	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMOR9ZA	DI	DMOR9ZA
DMOR9ZA	DN	Bis-indolylmaleimide derivative 1
DMOR9ZA	MI	TTCZOF2
DMOR9ZA	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMOR9ZA	MT	DTT
DMOR9ZA	MA	Inhibitor
DMOR9ZA	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMOR9ZA	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMLV9UR	DI	DMLV9UR
DMLV9UR	DN	Bis-sulfonamide derivative 1
DMLV9UR	MI	TTR7UJ3
DMLV9UR	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMLV9UR	MT	DTT
DMLV9UR	MA	Inhibitor
DMLV9UR	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMLV9UR	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DMR0ANI	DI	DMR0ANI
DMR0ANI	DN	Bis-sulfonamide derivative 2
DMR0ANI	MI	TTR7UJ3
DMR0ANI	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMR0ANI	MT	DTT
DMR0ANI	MA	Inhibitor
DMR0ANI	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMR0ANI	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DM6YQO3	DI	DM6YQO3
DM6YQO3	DN	BK3
DM6YQO3	MI	TT42OGM
DM6YQO3	MN	Hematopoietic cell kinase (HCK)
DM6YQO3	MT	DTT
DM6YQO3	MA	Inhibitor
DM6YQO3	RN	Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases. US9765037.
DM6YQO3	RU	http://www.freepatentsonline.com/US9765037.html

DMQD4X2	DI	DMQD4X2
DMQD4X2	DN	BK7
DMQD4X2	MI	TT42OGM
DMQD4X2	MN	Hematopoietic cell kinase (HCK)
DMQD4X2	MT	DTT
DMQD4X2	MA	Inhibitor
DMQD4X2	RN	Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases. US9765037.
DMQD4X2	RU	http://www.freepatentsonline.com/US9765037.html

DMMRXEQ	DI	DMMRXEQ
DMMRXEQ	DN	Boronic acid derivative 1
DMMRXEQ	MI	TTDP1UC
DMMRXEQ	MN	Fatty acid amide hydrolase (FAAH)
DMMRXEQ	MT	DTT
DMMRXEQ	MA	Inhibitor
DMMRXEQ	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMMRXEQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMLJH5T	DI	DMLJH5T
DMLJH5T	DN	Boronic acid derivative 2
DMLJH5T	MI	TTDP1UC
DMLJH5T	MN	Fatty acid amide hydrolase (FAAH)
DMLJH5T	MT	DTT
DMLJH5T	MA	Inhibitor
DMLJH5T	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMLJH5T	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMQ8X94	DI	DMQ8X94
DMQ8X94	DN	Boronic acid derivative 3
DMQ8X94	MI	TTDP1UC
DMQ8X94	MN	Fatty acid amide hydrolase (FAAH)
DMQ8X94	MT	DTT
DMQ8X94	MA	Inhibitor
DMQ8X94	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMQ8X94	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMVIFXR	DI	DMVIFXR
DMVIFXR	DN	Boronic acid derivative 4
DMVIFXR	MI	TTDP1UC
DMVIFXR	MN	Fatty acid amide hydrolase (FAAH)
DMVIFXR	MT	DTT
DMVIFXR	MA	Inhibitor
DMVIFXR	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMVIFXR	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMUCW9Y	DI	DMUCW9Y
DMUCW9Y	DN	Boronic acid derivative 5
DMUCW9Y	MI	TTDP1UC
DMUCW9Y	MN	Fatty acid amide hydrolase (FAAH)
DMUCW9Y	MT	DTT
DMUCW9Y	MA	Inhibitor
DMUCW9Y	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMUCW9Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMLMV4O	DI	DMLMV4O
DMLMV4O	DN	Boronic acid derivative 6
DMLMV4O	MI	TTDP1UC
DMLMV4O	MN	Fatty acid amide hydrolase (FAAH)
DMLMV4O	MT	DTT
DMLMV4O	MA	Inhibitor
DMLMV4O	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMLMV4O	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMCLB5D	DI	DMCLB5D
DMCLB5D	DN	Boswellia acid derivative 1
DMCLB5D	MI	TTYLQ8V
DMCLB5D	MN	Prostaglandin E synthase (PTGES)
DMCLB5D	MT	DTT
DMCLB5D	MA	Inhibitor
DMCLB5D	RN	Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059.
DMCLB5D	RU	https://www.ncbi.nlm.nih.gov/pubmed/28627961

DMMXQJU	DI	DMMXQJU
DMMXQJU	DN	Bromo benzyl ether derivative 1
DMMXQJU	MI	TT23XQV
DMMXQJU	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMMXQJU	MT	DTT
DMMXQJU	MA	Inhibitor
DMMXQJU	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMMXQJU	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMVBAUC	DI	DMVBAUC
DMVBAUC	DN	Bromo benzyl ether derivative 2
DMVBAUC	MI	TT23XQV
DMVBAUC	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMVBAUC	MT	DTT
DMVBAUC	MA	Inhibitor
DMVBAUC	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMVBAUC	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMVYNJZ	DI	DMVYNJZ
DMVYNJZ	DN	BUTAPROST
DMVYNJZ	MI	TTG1QMU
DMVYNJZ	MN	Prostaglandin E2 receptor EP1 (PTGER1)
DMVYNJZ	MT	DTT
DMVYNJZ	MA	Antagonist
DMVYNJZ	RN	Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
DMVYNJZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25772215

DMVYNJZ	DI	DMVYNJZ
DMVYNJZ	DN	BUTAPROST
DMVYNJZ	MI	TT1ZAVI
DMVYNJZ	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DMVYNJZ	MT	DTT
DMVYNJZ	MA	Antagonist
DMVYNJZ	RN	Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
DMVYNJZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25772215

DMVYNJZ	DI	DMVYNJZ
DMVYNJZ	DN	BUTAPROST
DMVYNJZ	MI	TTPNGDE
DMVYNJZ	MN	Prostaglandin E2 receptor EP3 (PTGER3)
DMVYNJZ	MT	DTT
DMVYNJZ	MA	Antagonist
DMVYNJZ	RN	Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
DMVYNJZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25772215

DMVYNJZ	DI	DMVYNJZ
DMVYNJZ	DN	BUTAPROST
DMVYNJZ	MI	TT79WV3
DMVYNJZ	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DMVYNJZ	MT	DTT
DMVYNJZ	MA	Antagonist
DMVYNJZ	RN	Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
DMVYNJZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25772215

DMVYNJZ	DI	DMVYNJZ
DMVYNJZ	DN	BUTAPROST
DMVYNJZ	MI	TTT2ZAR
DMVYNJZ	MN	Prostaglandin F2-alpha receptor (PTGFR)
DMVYNJZ	MT	DTT
DMVYNJZ	MA	Antagonist
DMVYNJZ	RN	Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
DMVYNJZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25772215

DMJPW7C	DI	DMJPW7C
DMJPW7C	DN	C06909
DMJPW7C	MI	TT5DOVB
DMJPW7C	MN	Cytomegalovirus Protease (CMV UL80)
DMJPW7C	MT	DTT
DMJPW7C	MA	Inhibitor
DMJPW7C	RN	Phosphonate compounds. US10071110.
DMJPW7C	RU	http://www.freepatentsonline.com/US10071110.html

DMW46GY	DI	DMW46GY
DMW46GY	DN	CAMBINOL
DMW46GY	MI	TTUF2HO
DMW46GY	MN	NAD-dependent deacetylase sirtuin-1 (SIRT1)
DMW46GY	MT	DTT
DMW46GY	MA	Inhibitor
DMW46GY	RN	Novel cambinol analogs as sirtuin inhibitors: synthesis, biological evaluation, and rationalization of activity. J Med Chem. 2009 May 14;52(9):2673-82.
DMW46GY	RU	https://pubmed.ncbi.nlm.nih.gov/19419202

DM81SYN	DI	DM81SYN
DM81SYN	DN	Cannabinoid quinone derivative 1
DM81SYN	MI	TTZMAO3
DM81SYN	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DM81SYN	MT	DTT
DM81SYN	MA	Ligand
DM81SYN	RN	PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
DM81SYN	RU	https://www.ncbi.nlm.nih.gov/pubmed/25416646

DMNDPEA	DI	DMNDPEA
DMNDPEA	DN	Carbamate derivative 1
DMNDPEA	MI	TTDP1UC
DMNDPEA	MN	Fatty acid amide hydrolase (FAAH)
DMNDPEA	MT	DTT
DMNDPEA	MA	Inhibitor
DMNDPEA	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMNDPEA	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMP98CL	DI	DMP98CL
DMP98CL	DN	Carbamate derivative 10
DMP98CL	MI	TTDP1UC
DMP98CL	MN	Fatty acid amide hydrolase (FAAH)
DMP98CL	MT	DTT
DMP98CL	MA	Inhibitor
DMP98CL	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMP98CL	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMP98CL	DI	DMP98CL
DMP98CL	DN	Carbamate derivative 10
DMP98CL	MI	TTZ963I
DMP98CL	MN	Monoglyceride lipase (MAGL)
DMP98CL	MT	DTT
DMP98CL	MA	Inhibitor
DMP98CL	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMP98CL	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DM3CF91	DI	DM3CF91
DM3CF91	DN	Carbamate derivative 11
DM3CF91	MI	TTZ963I
DM3CF91	MN	Monoglyceride lipase (MAGL)
DM3CF91	MT	DTT
DM3CF91	MA	Inhibitor
DM3CF91	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DM3CF91	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMMH27J	DI	DMMH27J
DMMH27J	DN	Carbamate derivative 12
DMMH27J	MI	TTZ963I
DMMH27J	MN	Monoglyceride lipase (MAGL)
DMMH27J	MT	DTT
DMMH27J	MA	Inhibitor
DMMH27J	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMMH27J	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMLH45M	DI	DMLH45M
DMLH45M	DN	Carbamate derivative 13
DMLH45M	MI	TTZ963I
DMLH45M	MN	Monoglyceride lipase (MAGL)
DMLH45M	MT	DTT
DMLH45M	MA	Inhibitor
DMLH45M	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMLH45M	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMZS0HT	DI	DMZS0HT
DMZS0HT	DN	Carbamate derivative 14
DMZS0HT	MI	TTZ963I
DMZS0HT	MN	Monoglyceride lipase (MAGL)
DMZS0HT	MT	DTT
DMZS0HT	MA	Inhibitor
DMZS0HT	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMZS0HT	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMOKC41	DI	DMOKC41
DMOKC41	DN	Carbamate derivative 15
DMOKC41	MI	TTZ963I
DMOKC41	MN	Monoglyceride lipase (MAGL)
DMOKC41	MT	DTT
DMOKC41	MA	Inhibitor
DMOKC41	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMOKC41	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMPLZSE	DI	DMPLZSE
DMPLZSE	DN	Carbamate derivative 16
DMPLZSE	MI	TTDP1UC
DMPLZSE	MN	Fatty acid amide hydrolase (FAAH)
DMPLZSE	MT	DTT
DMPLZSE	MA	Inhibitor
DMPLZSE	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMPLZSE	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMPLZSE	DI	DMPLZSE
DMPLZSE	DN	Carbamate derivative 16
DMPLZSE	MI	TTZ963I
DMPLZSE	MN	Monoglyceride lipase (MAGL)
DMPLZSE	MT	DTT
DMPLZSE	MA	Inhibitor
DMPLZSE	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMPLZSE	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMYSRPT	DI	DMYSRPT
DMYSRPT	DN	Carbamate derivative 17
DMYSRPT	MI	TTDP1UC
DMYSRPT	MN	Fatty acid amide hydrolase (FAAH)
DMYSRPT	MT	DTT
DMYSRPT	MA	Inhibitor
DMYSRPT	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMYSRPT	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMYSRPT	DI	DMYSRPT
DMYSRPT	DN	Carbamate derivative 17
DMYSRPT	MI	TTZ963I
DMYSRPT	MN	Monoglyceride lipase (MAGL)
DMYSRPT	MT	DTT
DMYSRPT	MA	Inhibitor
DMYSRPT	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMYSRPT	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMEWPQ6	DI	DMEWPQ6
DMEWPQ6	DN	Carbamate derivative 2
DMEWPQ6	MI	TTGX13H
DMEWPQ6	MN	Fatty-acid amide hydrolase 1 (FAAH1)
DMEWPQ6	MT	DTT
DMEWPQ6	MA	Inhibitor
DMEWPQ6	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMEWPQ6	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMEWPQ6	DI	DMEWPQ6
DMEWPQ6	DN	Carbamate derivative 2
DMEWPQ6	MI	TT8NGED
DMEWPQ6	MN	Prostaglandin G/H synthase 1 (COX-1)
DMEWPQ6	MT	DTT
DMEWPQ6	MA	Inhibitor
DMEWPQ6	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMEWPQ6	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMEWPQ6	DI	DMEWPQ6
DMEWPQ6	DN	Carbamate derivative 2
DMEWPQ6	MI	TTVKILB
DMEWPQ6	MN	Prostaglandin G/H synthase 2 (COX-2)
DMEWPQ6	MT	DTT
DMEWPQ6	MA	Inhibitor
DMEWPQ6	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMEWPQ6	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMO6NWD	DI	DMO6NWD
DMO6NWD	DN	Carbamate derivative 3
DMO6NWD	MI	TTDP1UC
DMO6NWD	MN	Fatty acid amide hydrolase (FAAH)
DMO6NWD	MT	DTT
DMO6NWD	MA	Inhibitor
DMO6NWD	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMO6NWD	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DM9MFDH	DI	DM9MFDH
DM9MFDH	DN	Carbamate derivative 4
DM9MFDH	MI	TTGX13H
DM9MFDH	MN	Fatty-acid amide hydrolase 1 (FAAH1)
DM9MFDH	MT	DTT
DM9MFDH	MA	Inhibitor
DM9MFDH	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DM9MFDH	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMHB5XG	DI	DMHB5XG
DMHB5XG	DN	Carbamate derivative 5
DMHB5XG	MI	TTGX13H
DMHB5XG	MN	Fatty-acid amide hydrolase 1 (FAAH1)
DMHB5XG	MT	DTT
DMHB5XG	MA	Inhibitor
DMHB5XG	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMHB5XG	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMMOSKZ	DI	DMMOSKZ
DMMOSKZ	DN	Carbamate derivative 6
DMMOSKZ	MI	TTGX13H
DMMOSKZ	MN	Fatty-acid amide hydrolase 1 (FAAH1)
DMMOSKZ	MT	DTT
DMMOSKZ	MA	Inhibitor
DMMOSKZ	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMMOSKZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMOPF9N	DI	DMOPF9N
DMOPF9N	DN	Carbamate derivative 7
DMOPF9N	MI	TTDP1UC
DMOPF9N	MN	Fatty acid amide hydrolase (FAAH)
DMOPF9N	MT	DTT
DMOPF9N	MA	Inhibitor
DMOPF9N	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMOPF9N	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMEAO42	DI	DMEAO42
DMEAO42	DN	Carbamate derivative 8
DMEAO42	MI	TTDP1UC
DMEAO42	MN	Fatty acid amide hydrolase (FAAH)
DMEAO42	MT	DTT
DMEAO42	MA	Inhibitor
DMEAO42	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMEAO42	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMW4B1U	DI	DMW4B1U
DMW4B1U	DN	Carbamate derivative 9
DMW4B1U	MI	TTDP1UC
DMW4B1U	MN	Fatty acid amide hydrolase (FAAH)
DMW4B1U	MT	DTT
DMW4B1U	MA	Inhibitor
DMW4B1U	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMW4B1U	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMW4B1U	DI	DMW4B1U
DMW4B1U	DN	Carbamate derivative 9
DMW4B1U	MI	TTZ963I
DMW4B1U	MN	Monoglyceride lipase (MAGL)
DMW4B1U	MT	DTT
DMW4B1U	MA	Inhibitor
DMW4B1U	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMW4B1U	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMXQTPJ	DI	DMXQTPJ
DMXQTPJ	DN	Carbamide derivative 1
DMXQTPJ	MI	TTDP1UC
DMXQTPJ	MN	Fatty acid amide hydrolase (FAAH)
DMXQTPJ	MT	DTT
DMXQTPJ	MA	Inhibitor
DMXQTPJ	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMXQTPJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMXQTPJ	DI	DMXQTPJ
DMXQTPJ	DN	Carbamide derivative 1
DMXQTPJ	MI	TTGX13H
DMXQTPJ	MN	Fatty-acid amide hydrolase 1 (FAAH1)
DMXQTPJ	MT	DTT
DMXQTPJ	MA	Inhibitor
DMXQTPJ	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMXQTPJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DM9O56W	DI	DM9O56W
DM9O56W	DN	Carbamide derivative 10
DM9O56W	MI	TTL7C8Q
DM9O56W	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DM9O56W	MT	DTT
DM9O56W	MA	Inhibitor
DM9O56W	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DM9O56W	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DMK7DJR	DI	DMK7DJR
DMK7DJR	DN	Carbamide derivative 11
DMK7DJR	MI	TTL7C8Q
DMK7DJR	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMK7DJR	MT	DTT
DMK7DJR	MA	Inhibitor
DMK7DJR	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DMK7DJR	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DMCAD64	DI	DMCAD64
DMCAD64	DN	Carbamide derivative 13
DMCAD64	MI	TTZJYKH
DMCAD64	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMCAD64	MT	DTT
DMCAD64	MA	Inhibitor
DMCAD64	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMCAD64	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMU04PM	DI	DMU04PM
DMU04PM	DN	Carbamide derivative 14
DMU04PM	MI	TTOHSBA
DMU04PM	MN	Vascular endothelial growth factor A (VEGFA)
DMU04PM	MT	DTT
DMU04PM	MA	Inhibitor
DMU04PM	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMU04PM	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DM2TDXW	DI	DM2TDXW
DM2TDXW	DN	Carbamide derivative 15
DM2TDXW	MI	TTOHSBA
DM2TDXW	MN	Vascular endothelial growth factor A (VEGFA)
DM2TDXW	MT	DTT
DM2TDXW	MA	Inhibitor
DM2TDXW	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DM2TDXW	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMLPOUR	DI	DMLPOUR
DMLPOUR	DN	Carbamide derivative 16
DMLPOUR	MI	TTOHSBA
DMLPOUR	MN	Vascular endothelial growth factor A (VEGFA)
DMLPOUR	MT	DTT
DMLPOUR	MA	Inhibitor
DMLPOUR	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMLPOUR	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMUF5AC	DI	DMUF5AC
DMUF5AC	DN	Carbamide derivative 17
DMUF5AC	MI	TTOHSBA
DMUF5AC	MN	Vascular endothelial growth factor A (VEGFA)
DMUF5AC	MT	DTT
DMUF5AC	MA	Inhibitor
DMUF5AC	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMUF5AC	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMZ37XI	DI	DMZ37XI
DMZ37XI	DN	Carbamide derivative 18
DMZ37XI	MI	TTOHSBA
DMZ37XI	MN	Vascular endothelial growth factor A (VEGFA)
DMZ37XI	MT	DTT
DMZ37XI	MA	Inhibitor
DMZ37XI	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMZ37XI	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMLDXOB	DI	DMLDXOB
DMLDXOB	DN	Carbamide derivative 19
DMLDXOB	MI	TTOHSBA
DMLDXOB	MN	Vascular endothelial growth factor A (VEGFA)
DMLDXOB	MT	DTT
DMLDXOB	MA	Inhibitor
DMLDXOB	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMLDXOB	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMW5GI3	DI	DMW5GI3
DMW5GI3	DN	Carbamide derivative 2
DMW5GI3	MI	TTO9X1H
DMW5GI3	MN	5-HT 7 receptor (HTR7)
DMW5GI3	MT	DTT
DMW5GI3	MA	Inhibitor
DMW5GI3	RN	Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
DMW5GI3	RU	https://www.ncbi.nlm.nih.gov/pubmed/25470667

DMYSWG1	DI	DMYSWG1
DMYSWG1	DN	Carbamide derivative 20
DMYSWG1	MI	TTOHSBA
DMYSWG1	MN	Vascular endothelial growth factor A (VEGFA)
DMYSWG1	MT	DTT
DMYSWG1	MA	Inhibitor
DMYSWG1	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMYSWG1	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMD03J5	DI	DMD03J5
DMD03J5	DN	Carbamide derivative 21
DMD03J5	MI	TTOHSBA
DMD03J5	MN	Vascular endothelial growth factor A (VEGFA)
DMD03J5	MT	DTT
DMD03J5	MA	Inhibitor
DMD03J5	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMD03J5	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMC3TJI	DI	DMC3TJI
DMC3TJI	DN	Carbamide derivative 22
DMC3TJI	MI	TTOHSBA
DMC3TJI	MN	Vascular endothelial growth factor A (VEGFA)
DMC3TJI	MT	DTT
DMC3TJI	MA	Inhibitor
DMC3TJI	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMC3TJI	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DM0IRPO	DI	DM0IRPO
DM0IRPO	DN	Carbamide derivative 23
DM0IRPO	MI	TTOHSBA
DM0IRPO	MN	Vascular endothelial growth factor A (VEGFA)
DM0IRPO	MT	DTT
DM0IRPO	MA	Inhibitor
DM0IRPO	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DM0IRPO	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMD6Y73	DI	DMD6Y73
DMD6Y73	DN	Carbamide derivative 24
DMD6Y73	MI	TTDP1UC
DMD6Y73	MN	Fatty acid amide hydrolase (FAAH)
DMD6Y73	MT	DTT
DMD6Y73	MA	Inhibitor
DMD6Y73	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMD6Y73	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMD6Y73	DI	DMD6Y73
DMD6Y73	DN	Carbamide derivative 24
DMD6Y73	MI	TTZ963I
DMD6Y73	MN	Monoglyceride lipase (MAGL)
DMD6Y73	MT	DTT
DMD6Y73	MA	Inhibitor
DMD6Y73	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMD6Y73	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DM8ONCL	DI	DM8ONCL
DM8ONCL	DN	Carbamide derivative 25
DM8ONCL	MI	TTDP1UC
DM8ONCL	MN	Fatty acid amide hydrolase (FAAH)
DM8ONCL	MT	DTT
DM8ONCL	MA	Inhibitor
DM8ONCL	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DM8ONCL	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DM8ONCL	DI	DM8ONCL
DM8ONCL	DN	Carbamide derivative 25
DM8ONCL	MI	TTZ963I
DM8ONCL	MN	Monoglyceride lipase (MAGL)
DM8ONCL	MT	DTT
DM8ONCL	MA	Inhibitor
DM8ONCL	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DM8ONCL	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMDU9XF	DI	DMDU9XF
DMDU9XF	DN	Carbamide derivative 26
DMDU9XF	MI	TTDP1UC
DMDU9XF	MN	Fatty acid amide hydrolase (FAAH)
DMDU9XF	MT	DTT
DMDU9XF	MA	Inhibitor
DMDU9XF	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMDU9XF	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMDU9XF	DI	DMDU9XF
DMDU9XF	DN	Carbamide derivative 26
DMDU9XF	MI	TTZ963I
DMDU9XF	MN	Monoglyceride lipase (MAGL)
DMDU9XF	MT	DTT
DMDU9XF	MA	Inhibitor
DMDU9XF	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMDU9XF	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DM4ISCQ	DI	DM4ISCQ
DM4ISCQ	DN	Carbamide derivative 3
DM4ISCQ	MI	TTF8P9I
DM4ISCQ	MN	Diacylglycerol acyltransferase 1 (DGAT1)
DM4ISCQ	MT	DTT
DM4ISCQ	MA	Inhibitor
DM4ISCQ	RN	Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
DM4ISCQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25470667

DM5V2D9	DI	DM5V2D9
DM5V2D9	DN	Carbamide derivative 4
DM5V2D9	MI	TTL7C8Q
DM5V2D9	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DM5V2D9	MT	DTT
DM5V2D9	MA	Inhibitor
DM5V2D9	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DM5V2D9	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DM951HL	DI	DM951HL
DM951HL	DN	Carbamide derivative 5
DM951HL	MI	TTL7C8Q
DM951HL	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DM951HL	MT	DTT
DM951HL	MA	Inhibitor
DM951HL	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DM951HL	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DMORBE3	DI	DMORBE3
DMORBE3	DN	Carbamide derivative 6
DMORBE3	MI	TTL7C8Q
DMORBE3	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMORBE3	MT	DTT
DMORBE3	MA	Inhibitor
DMORBE3	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DMORBE3	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DMWKXN4	DI	DMWKXN4
DMWKXN4	DN	Carbamide derivative 7
DMWKXN4	MI	TTL7C8Q
DMWKXN4	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMWKXN4	MT	DTT
DMWKXN4	MA	Inhibitor
DMWKXN4	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DMWKXN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DMZ3FJO	DI	DMZ3FJO
DMZ3FJO	DN	Carbamide derivative 8
DMZ3FJO	MI	TTL7C8Q
DMZ3FJO	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMZ3FJO	MT	DTT
DMZ3FJO	MA	Inhibitor
DMZ3FJO	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DMZ3FJO	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DMY06VC	DI	DMY06VC
DMY06VC	DN	Carbamide derivative 9
DMY06VC	MI	TTL7C8Q
DMY06VC	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMY06VC	MT	DTT
DMY06VC	MA	Inhibitor
DMY06VC	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DMY06VC	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DM0EBS8	DI	DM0EBS8
DM0EBS8	DN	Carbamoyl oxime derivative 1
DM0EBS8	MI	TTGX13H
DM0EBS8	MN	Fatty-acid amide hydrolase 1 (FAAH1)
DM0EBS8	MT	DTT
DM0EBS8	MA	Inhibitor
DM0EBS8	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DM0EBS8	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DM3B5RS	DI	DM3B5RS
DM3B5RS	DN	Carbazole-3-carboxamide analog 1
DM3B5RS	MI	TT6OEDT
DM3B5RS	MN	Cannabinoid receptor 1 (CB1)
DM3B5RS	MT	DTT
DM3B5RS	MA	Agonist
DM3B5RS	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DM3B5RS	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DM3B5RS	DI	DM3B5RS
DM3B5RS	DN	Carbazole-3-carboxamide analog 1
DM3B5RS	MI	TTMSFAW
DM3B5RS	MN	Cannabinoid receptor 2 (CB2)
DM3B5RS	MT	DTT
DM3B5RS	MA	Agonist
DM3B5RS	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DM3B5RS	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DM5GEBH	DI	DM5GEBH
DM5GEBH	DN	Carboxamide derivative 1
DM5GEBH	MI	TT6OEDT
DM5GEBH	MN	Cannabinoid receptor 1 (CB1)
DM5GEBH	MT	DTT
DM5GEBH	MA	Antagonist
DM5GEBH	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DM5GEBH	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DM5WMO9	DI	DM5WMO9
DM5WMO9	DN	Carboxamide derivative 10
DM5WMO9	MI	TTG5QB7
DM5WMO9	MN	Calpain-2 (CAPN2)
DM5WMO9	MT	DTT
DM5WMO9	MA	Inhibitor
DM5WMO9	RN	An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31.
DM5WMO9	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399719

DM1DN94	DI	DM1DN94
DM1DN94	DN	Carboxamide derivative 11
DM1DN94	MI	TTG5QB7
DM1DN94	MN	Calpain-2 (CAPN2)
DM1DN94	MT	DTT
DM1DN94	MA	Inhibitor
DM1DN94	RN	An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31.
DM1DN94	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399719

DMU5GKC	DI	DMU5GKC
DMU5GKC	DN	Carboxamide derivative 4
DMU5GKC	MI	TTPMQSO
DMU5GKC	MN	ALK tyrosine kinase receptor (ALK)
DMU5GKC	MT	DTT
DMU5GKC	MA	Inhibitor
DMU5GKC	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMU5GKC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMU5GKC	DI	DMU5GKC
DMU5GKC	DN	Carboxamide derivative 4
DMU5GKC	MI	TTGJCWZ
DMU5GKC	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMU5GKC	MT	DTT
DMU5GKC	MA	Inhibitor
DMU5GKC	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMU5GKC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMU5GKC	DI	DMU5GKC
DMU5GKC	DN	Carboxamide derivative 4
DMU5GKC	MI	TT4DXQT
DMU5GKC	MN	Proto-oncogene c-Ret (RET)
DMU5GKC	MT	DTT
DMU5GKC	MA	Inhibitor
DMU5GKC	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMU5GKC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMU5GKC	DI	DMU5GKC
DMU5GKC	DN	Carboxamide derivative 4
DMU5GKC	MI	TTSZ6Y3
DMU5GKC	MN	Proto-oncogene c-Ros (ROS1)
DMU5GKC	MT	DTT
DMU5GKC	MA	Inhibitor
DMU5GKC	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMU5GKC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DM149WN	DI	DM149WN
DM149WN	DN	Carboxamide derivative 5
DM149WN	MI	TTG5QB7
DM149WN	MN	Calpain-2 (CAPN2)
DM149WN	MT	DTT
DM149WN	MA	Inhibitor
DM149WN	RN	An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31.
DM149WN	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399719

DM6GZW4	DI	DM6GZW4
DM6GZW4	DN	Carboxamide derivative 6
DM6GZW4	MI	TTG5QB7
DM6GZW4	MN	Calpain-2 (CAPN2)
DM6GZW4	MT	DTT
DM6GZW4	MA	Inhibitor
DM6GZW4	RN	An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31.
DM6GZW4	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399719

DM8TQS4	DI	DM8TQS4
DM8TQS4	DN	Carboxamide derivative 7
DM8TQS4	MI	TTG5QB7
DM8TQS4	MN	Calpain-2 (CAPN2)
DM8TQS4	MT	DTT
DM8TQS4	MA	Inhibitor
DM8TQS4	RN	An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31.
DM8TQS4	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399719

DM6HI34	DI	DM6HI34
DM6HI34	DN	Carboxamide derivative 8
DM6HI34	MI	TTG5QB7
DM6HI34	MN	Calpain-2 (CAPN2)
DM6HI34	MT	DTT
DM6HI34	MA	Inhibitor
DM6HI34	RN	An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31.
DM6HI34	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399719

DMVISYC	DI	DMVISYC
DMVISYC	DN	Carboxamide derivative 9
DMVISYC	MI	TTG5QB7
DMVISYC	MN	Calpain-2 (CAPN2)
DMVISYC	MT	DTT
DMVISYC	MA	Inhibitor
DMVISYC	RN	An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31.
DMVISYC	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399719

DM86E2P	DI	DM86E2P
DM86E2P	DN	Carboxylic acid derivative 1
DM86E2P	MI	TTYLQ8V
DM86E2P	MN	Prostaglandin E synthase (PTGES)
DM86E2P	MT	DTT
DM86E2P	MA	Inhibitor
DM86E2P	RN	Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059.
DM86E2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/28627961

DM7INA1	DI	DM7INA1
DM7INA1	DN	Central azetidine derivative 1
DM7INA1	MI	TTHS256
DM7INA1	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM7INA1	MT	DTT
DM7INA1	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DM7INA1	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DM2BLJ6	DI	DM2BLJ6
DM2BLJ6	DN	Central azetidine derivative 2
DM2BLJ6	MI	TTHS256
DM2BLJ6	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM2BLJ6	MT	DTT
DM2BLJ6	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DM2BLJ6	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMSMBCO	DI	DMSMBCO
DMSMBCO	DN	Chalcone derivative 1
DMSMBCO	MI	TT3Z6Y9
DMSMBCO	MN	Cysteines of Keap1 (KEAP1 Cysteines)
DMSMBCO	MT	DTT
DMSMBCO	MA	Modulator
DMSMBCO	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMSMBCO	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMSMBCO	DI	DMSMBCO
DMSMBCO	DN	Chalcone derivative 1
DMSMBCO	MI	TTA6ZN2
DMSMBCO	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMSMBCO	MT	DTT
DMSMBCO	MA	Activator
DMSMBCO	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMSMBCO	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMG84D3	DI	DMG84D3
DMG84D3	DN	Chalcone derivative 2
DMG84D3	MI	TT3Z6Y9
DMG84D3	MN	Cysteines of Keap1 (KEAP1 Cysteines)
DMG84D3	MT	DTT
DMG84D3	MA	Modulator
DMG84D3	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMG84D3	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMG84D3	DI	DMG84D3
DMG84D3	DN	Chalcone derivative 2
DMG84D3	MI	TTA6ZN2
DMG84D3	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMG84D3	MT	DTT
DMG84D3	MA	Activator
DMG84D3	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMG84D3	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMFS7C3	DI	DMFS7C3
DMFS7C3	DN	Chalcone derivative 3
DMFS7C3	MI	TT3Z6Y9
DMFS7C3	MN	Cysteines of Keap1 (KEAP1 Cysteines)
DMFS7C3	MT	DTT
DMFS7C3	MA	Modulator
DMFS7C3	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMFS7C3	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMFS7C3	DI	DMFS7C3
DMFS7C3	DN	Chalcone derivative 3
DMFS7C3	MI	TTA6ZN2
DMFS7C3	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMFS7C3	MT	DTT
DMFS7C3	MA	Activator
DMFS7C3	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMFS7C3	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM45COR	DI	DM45COR
DM45COR	DN	Chalcone derivative 4
DM45COR	MI	TT3Z6Y9
DM45COR	MN	Cysteines of Keap1 (KEAP1 Cysteines)
DM45COR	MT	DTT
DM45COR	MA	Modulator
DM45COR	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DM45COR	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM45COR	DI	DM45COR
DM45COR	DN	Chalcone derivative 4
DM45COR	MI	TTA6ZN2
DM45COR	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DM45COR	MT	DTT
DM45COR	MA	Activator
DM45COR	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DM45COR	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMJZGT8	DI	DMJZGT8
DMJZGT8	DN	Chalcone derivative 5
DMJZGT8	MI	TT2F4OL
DMJZGT8	MN	Tissue transglutaminase (TG2)
DMJZGT8	MT	DTT
DMJZGT8	MA	Inhibitor
DMJZGT8	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DMJZGT8	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DMB8MNU	DI	DMB8MNU
DMB8MNU	DN	CHIR-99021
DMB8MNU	MI	TTH6V3D
DMB8MNU	MN	Cyclin-dependent kinase 1 (CDK1)
DMB8MNU	MT	DTT
DMB8MNU	MA	Inhibitor
DMB8MNU	RN	Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95.
DMB8MNU	RU	https://pubmed.ncbi.nlm.nih.gov/12606497

DMB8MNU	DI	DMB8MNU
DMB8MNU	DN	CHIR-99021
DMB8MNU	MI	TT4TQBX
DMB8MNU	MN	Extracellular signal-regulated kinase 2 (ERK2)
DMB8MNU	MT	DTT
DMB8MNU	MA	Inhibitor
DMB8MNU	RN	Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95.
DMB8MNU	RU	https://pubmed.ncbi.nlm.nih.gov/12606497

DMB8MNU	DI	DMB8MNU
DMB8MNU	DN	CHIR-99021
DMB8MNU	MI	TTRZQE3
DMB8MNU	MN	Glycogen synthase kinase-3 alpha (GSK-3A)
DMB8MNU	MT	DTT
DMB8MNU	MA	Inhibitor
DMB8MNU	RN	Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
DMB8MNU	RU	https://www.ncbi.nlm.nih.gov/pubmed/27828716

DMB8MNU	DI	DMB8MNU
DMB8MNU	DN	CHIR-99021
DMB8MNU	MI	TTRSMW9
DMB8MNU	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMB8MNU	MT	DTT
DMB8MNU	MA	Inhibitor
DMB8MNU	RN	Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95.
DMB8MNU	RU	https://pubmed.ncbi.nlm.nih.gov/12606497

DMW4J0P	DI	DMW4J0P
DMW4J0P	DN	Chloroacetyl ester derivative 1
DMW4J0P	MI	TT2F4OL
DMW4J0P	MN	Tissue transglutaminase (TG2)
DMW4J0P	MT	DTT
DMW4J0P	MA	Inhibitor
DMW4J0P	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DMW4J0P	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DMR39ZY	DI	DMR39ZY
DMR39ZY	DN	Chlorobenzamide derivative 1
DMR39ZY	MI	TT473XN
DMR39ZY	MN	P2X purinoceptor 7 (P2RX7)
DMR39ZY	MT	DTT
DMR39ZY	MA	Antagonist
DMR39ZY	RN	P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267.
DMR39ZY	RU	https://www.ncbi.nlm.nih.gov/pubmed/27724045

DMKS7O3	DI	DMKS7O3
DMKS7O3	DN	Chlorobenzamide derivative 2
DMKS7O3	MI	TT473XN
DMKS7O3	MN	P2X purinoceptor 7 (P2RX7)
DMKS7O3	MT	DTT
DMKS7O3	MA	Antagonist
DMKS7O3	RN	P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267.
DMKS7O3	RU	https://www.ncbi.nlm.nih.gov/pubmed/27724045

DM7SOZN	DI	DM7SOZN
DM7SOZN	DN	Chromene derivative 1
DM7SOZN	MI	TTWJBZ5
DM7SOZN	MN	5-HT 2C receptor (HTR2C)
DM7SOZN	MT	DTT
DM7SOZN	MA	Agonist
DM7SOZN	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DM7SOZN	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMINXMY	DI	DMINXMY
DMINXMY	DN	CID 138805970
DMINXMY	MI	TT3KYWB
DMINXMY	MN	Ribosomal protein S6 kinase alpha-6 (RSK6)
DMINXMY	MT	DTT
DMINXMY	MA	Inhibitor
DMINXMY	RN	Substituted tetrahydropyrido[3,2:4,5]pyrrolo[1,2-a]pyrazine-2-carboxamides as RSK inhibitors. US9771366.
DMINXMY	RU	http://www.freepatentsonline.com/US9771366.html

DMITX1G	DI	DMITX1G
DMITX1G	DN	Citalopram derivative 1
DMITX1G	MI	TTTIBOJ
DMITX1G	MN	Histamine H1 receptor (H1R)
DMITX1G	MT	DTT
DMITX1G	MA	Inhibitor
DMITX1G	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DMITX1G	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DMITX1G	DI	DMITX1G
DMITX1G	DN	Citalopram derivative 1
DMITX1G	MI	TT3ROYC
DMITX1G	MN	Serotonin transporter (SERT)
DMITX1G	MT	DTT
DMITX1G	MA	Inhibitor
DMITX1G	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DMITX1G	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DMV6H95	DI	DMV6H95
DMV6H95	DN	C-linked disaccharide biphenyl mannoside derivative 1
DMV6H95	MI	TTTCRU2
DMV6H95	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMV6H95	MT	DTT
DMV6H95	MA	Antagonist
DMV6H95	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMV6H95	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMJT1WG	DI	DMJT1WG
DMJT1WG	DN	C-linked disaccharide biphenyl mannoside derivative 2
DMJT1WG	MI	TTTCRU2
DMJT1WG	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMJT1WG	MT	DTT
DMJT1WG	MA	Antagonist
DMJT1WG	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMJT1WG	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMY10T2	DI	DMY10T2
DMY10T2	DN	C-linked disaccharide biphenyl mannoside derivative 3
DMY10T2	MI	TTTCRU2
DMY10T2	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMY10T2	MT	DTT
DMY10T2	MA	Antagonist
DMY10T2	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMY10T2	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMRLE65	DI	DMRLE65
DMRLE65	DN	C-linked disaccharide biphenyl mannoside derivative 4
DMRLE65	MI	TTTCRU2
DMRLE65	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMRLE65	MT	DTT
DMRLE65	MA	Antagonist
DMRLE65	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMRLE65	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMUG7E9	DI	DMUG7E9
DMUG7E9	DN	C-linked disaccharide biphenyl mannoside derivative 5
DMUG7E9	MI	TTTCRU2
DMUG7E9	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMUG7E9	MT	DTT
DMUG7E9	MA	Antagonist
DMUG7E9	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMUG7E9	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMUILMD	DI	DMUILMD
DMUILMD	DN	C-linked disaccharide biphenyl mannoside derivative 6
DMUILMD	MI	TTTCRU2
DMUILMD	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMUILMD	MT	DTT
DMUILMD	MA	Antagonist
DMUILMD	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMUILMD	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMWYJF6	DI	DMWYJF6
DMWYJF6	DN	Complex heterocyclic compound 1
DMWYJF6	MI	TTSCIM2
DMWYJF6	MN	Extracellular lysophospholipase D (E-NPP2)
DMWYJF6	MT	DTT
DMWYJF6	MA	Inhibitor
DMWYJF6	RN	Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829.
DMWYJF6	RU	https://www.ncbi.nlm.nih.gov/pubmed/28447479

DMLZMIG	DI	DMLZMIG
DMLZMIG	DN	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1
DMLZMIG	MI	TTOHSBA
DMLZMIG	MN	Vascular endothelial growth factor A (VEGFA)
DMLZMIG	MT	DTT
DMLZMIG	MA	Inhibitor
DMLZMIG	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMLZMIG	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DM3ZGBH	DI	DM3ZGBH
DM3ZGBH	DN	Coumaricacid
DM3ZGBH	MI	TTGP7BY
DM3ZGBH	MN	Monoamine oxidase type B (MAO-B)
DM3ZGBH	MT	DTT
DM3ZGBH	MA	Inhibitor
DM3ZGBH	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DM3ZGBH	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMI1BKA	DI	DMI1BKA
DMI1BKA	DN	Coumarin/resveratrol hybrid derivative 1
DMI1BKA	MI	TTGP7BY
DMI1BKA	MN	Monoamine oxidase type B (MAO-B)
DMI1BKA	MT	DTT
DMI1BKA	MA	Inhibitor
DMI1BKA	RN	MAO inhibitors and their wider applications: a patent review.Expert Opin Ther Pat. 2018 Mar;28(3):211-226.
DMI1BKA	RU	https://www.ncbi.nlm.nih.gov/pubmed/29324067

DMK12OT	DI	DMK12OT
DMK12OT	DN	Coumarin/resveratrol hybrid derivative 2
DMK12OT	MI	TTGP7BY
DMK12OT	MN	Monoamine oxidase type B (MAO-B)
DMK12OT	MT	DTT
DMK12OT	MA	Inhibitor
DMK12OT	RN	MAO inhibitors and their wider applications: a patent review.Expert Opin Ther Pat. 2018 Mar;28(3):211-226.
DMK12OT	RU	https://www.ncbi.nlm.nih.gov/pubmed/29324067

DMXP073	DI	DMXP073
DMXP073	DN	CQ7
DMXP073	MI	TTV298Y
DMXP073	MN	Calmodulin-dependent kinase II (CAMKK2)
DMXP073	MT	DTT
DMXP073	MA	Inhibitor
DMXP073	RN	Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof. US9623028.
DMXP073	RU	http://www.freepatentsonline.com/US9623028.html

DMBV5Z0	DI	DMBV5Z0
DMBV5Z0	DN	CRWCYVOHVXAEMF-LBPRGKRZSA-N
DMBV5Z0	MI	TTOYT5L
DMBV5Z0	MN	Dipeptidyl-peptidase 7 (DPP7)
DMBV5Z0	MT	DTT
DMBV5Z0	MA	Inhibitor
DMBV5Z0	RN	FAP inhibitors. US9346814.
DMBV5Z0	RU	http://www.freepatentsonline.com/US9346814.html

DM76Q10	DI	DM76Q10
DM76Q10	DN	Crystalline anhydrous toluene derivative 1
DM76Q10	MI	TTZMAO3
DM76Q10	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DM76Q10	MT	DTT
DM76Q10	MA	Agonist
DM76Q10	RN	PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
DM76Q10	RU	https://www.ncbi.nlm.nih.gov/pubmed/25416646

DM5BFJO	DI	DM5BFJO
DM5BFJO	DN	CS-W011402
DM5BFJO	MI	TT6A59G
DM5BFJO	MN	Phosphodiesterase 4C (PDE4C)
DM5BFJO	MT	DTT
DM5BFJO	MA	Inhibitor
DM5BFJO	RN	Imidazopyridazine compounds. US9598421.
DM5BFJO	RU	http://www.freepatentsonline.com/US9598421.html

DM4765M	DI	DM4765M
DM4765M	DN	Curcumin analog 1
DM4765M	MI	TTRMX3V
DM4765M	MN	Janus kinase 2 (JAK-2)
DM4765M	MT	DTT
DM4765M	MA	Inhibitor
DM4765M	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DM4765M	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DM4765M	DI	DM4765M
DM4765M	DN	Curcumin analog 1
DM4765M	MI	TTH8FZW
DM4765M	MN	Signal transducer and activator of transcription 3 (STAT3)
DM4765M	MT	DTT
DM4765M	MA	Inhibitor
DM4765M	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DM4765M	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMZ8S6X	DI	DMZ8S6X
DMZ8S6X	DN	Curcumin analog 2
DMZ8S6X	MI	TTRMX3V
DMZ8S6X	MN	Janus kinase 2 (JAK-2)
DMZ8S6X	MT	DTT
DMZ8S6X	MA	Inhibitor
DMZ8S6X	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMZ8S6X	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMZ8S6X	DI	DMZ8S6X
DMZ8S6X	DN	Curcumin analog 2
DMZ8S6X	MI	TTH8FZW
DMZ8S6X	MN	Signal transducer and activator of transcription 3 (STAT3)
DMZ8S6X	MT	DTT
DMZ8S6X	MA	Inhibitor
DMZ8S6X	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMZ8S6X	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMMX1ZE	DI	DMMX1ZE
DMMX1ZE	DN	Cyano(dimethyl)methyl isoxazoles and [1,3,4]-thiadiazoles derivative 1
DMMX1ZE	MI	TT6OEDT
DMMX1ZE	MN	Cannabinoid receptor 1 (CB1)
DMMX1ZE	MT	DTT
DMMX1ZE	MA	Agonist
DMMX1ZE	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DMMX1ZE	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DMMX1ZE	DI	DMMX1ZE
DMMX1ZE	DN	Cyano(dimethyl)methyl isoxazoles and [1,3,4]-thiadiazoles derivative 1
DMMX1ZE	MI	TTMSFAW
DMMX1ZE	MN	Cannabinoid receptor 2 (CB2)
DMMX1ZE	MT	DTT
DMMX1ZE	MA	Agonist
DMMX1ZE	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DMMX1ZE	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DM6GTDM	DI	DM6GTDM
DM6GTDM	DN	Cyano(dimethyl)methyl isoxazoles and [1,3,4]-thiadiazoles derivative 2
DM6GTDM	MI	TT6OEDT
DM6GTDM	MN	Cannabinoid receptor 1 (CB1)
DM6GTDM	MT	DTT
DM6GTDM	MA	Agonist
DM6GTDM	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DM6GTDM	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DM6GTDM	DI	DM6GTDM
DM6GTDM	DN	Cyano(dimethyl)methyl isoxazoles and [1,3,4]-thiadiazoles derivative 2
DM6GTDM	MI	TTMSFAW
DM6GTDM	MN	Cannabinoid receptor 2 (CB2)
DM6GTDM	MT	DTT
DM6GTDM	MA	Agonist
DM6GTDM	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DM6GTDM	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DMD198F	DI	DMD198F
DMD198F	DN	Cyanomethyl pypazole carboxamide derivative 1
DMD198F	MI	TT6DM01
DMD198F	MN	Janus kinase 1 (JAK-1)
DMD198F	MT	DTT
DMD198F	MA	Inhibitor
DMD198F	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMD198F	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMD198F	DI	DMD198F
DMD198F	DN	Cyanomethyl pypazole carboxamide derivative 1
DMD198F	MI	TTRMX3V
DMD198F	MN	Janus kinase 2 (JAK-2)
DMD198F	MT	DTT
DMD198F	MA	Inhibitor
DMD198F	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMD198F	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMSVMUT	DI	DMSVMUT
DMSVMUT	DN	Cyclic compound 1
DMSVMUT	MI	TTNBFWK
DMSVMUT	MN	Programmed cell death protein 1 (PD-1)
DMSVMUT	MT	DTT
DMSVMUT	MA	Inhibitor
DMSVMUT	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMSVMUT	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMGRBAJ	DI	DMGRBAJ
DMGRBAJ	DN	Cyclic compound 2
DMGRBAJ	MI	TTNBFWK
DMGRBAJ	MN	Programmed cell death protein 1 (PD-1)
DMGRBAJ	MT	DTT
DMGRBAJ	MA	Inhibitor
DMGRBAJ	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMGRBAJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMVOEN7	DI	DMVOEN7
DMVOEN7	DN	Cyclic compound 3
DMVOEN7	MI	TTNBFWK
DMVOEN7	MN	Programmed cell death protein 1 (PD-1)
DMVOEN7	MT	DTT
DMVOEN7	MA	Inhibitor
DMVOEN7	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMVOEN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DM2BZI0	DI	DM2BZI0
DM2BZI0	DN	Cyclic cyanoethypypazole derivative 1
DM2BZI0	MI	TT6DM01
DM2BZI0	MN	Janus kinase 1 (JAK-1)
DM2BZI0	MT	DTT
DM2BZI0	MA	Inhibitor
DM2BZI0	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DM2BZI0	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DM2BZI0	DI	DM2BZI0
DM2BZI0	DN	Cyclic cyanoethypypazole derivative 1
DM2BZI0	MI	TTRMX3V
DM2BZI0	MN	Janus kinase 2 (JAK-2)
DM2BZI0	MT	DTT
DM2BZI0	MA	Inhibitor
DM2BZI0	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DM2BZI0	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DM0K62M	DI	DM0K62M
DM0K62M	DN	Cyclic hydroxamate derivative 1
DM0K62M	MI	TTZJYKH
DM0K62M	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DM0K62M	MT	DTT
DM0K62M	MA	Inhibitor
DM0K62M	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DM0K62M	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DM1ZIPN	DI	DM1ZIPN
DM1ZIPN	DN	Cyclic octapeptide derivative 1
DM1ZIPN	MI	TTUX68I
DM1ZIPN	MN	Hypoxia-inducible factor 1 (HIF-1)
DM1ZIPN	MT	DTT
DM1ZIPN	MA	Inhibitor
DM1ZIPN	RN	Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22.
DM1ZIPN	RU	https://www.ncbi.nlm.nih.gov/pubmed/26882240

DM78NOU	DI	DM78NOU
DM78NOU	DN	Cyclic peptide derivative 1
DM78NOU	MI	TTNR0UQ
DM78NOU	MN	Lysine-specific histone demethylase 1 (LSD)
DM78NOU	MT	DTT
DM78NOU	MA	Inhibitor
DM78NOU	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DM78NOU	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DM78NOU	DI	DM78NOU
DM78NOU	DN	Cyclic peptide derivative 1
DM78NOU	MI	TT3WG5C
DM78NOU	MN	Monoamine oxidase type A (MAO-A)
DM78NOU	MT	DTT
DM78NOU	MA	Inhibitor
DM78NOU	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DM78NOU	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DM78NOU	DI	DM78NOU
DM78NOU	DN	Cyclic peptide derivative 1
DM78NOU	MI	TTGP7BY
DM78NOU	MN	Monoamine oxidase type B (MAO-B)
DM78NOU	MT	DTT
DM78NOU	MA	Inhibitor
DM78NOU	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DM78NOU	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMV2UQ5	DI	DMV2UQ5
DMV2UQ5	DN	Cyclic peptidomimetic derivative 1
DMV2UQ5	MI	TT23XQV
DMV2UQ5	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMV2UQ5	MT	DTT
DMV2UQ5	MA	Inhibitor
DMV2UQ5	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMV2UQ5	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMWH3FP	DI	DMWH3FP
DMWH3FP	DN	Cyclic peptidomimetic derivative 2
DMWH3FP	MI	TT23XQV
DMWH3FP	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMWH3FP	MT	DTT
DMWH3FP	MA	Inhibitor
DMWH3FP	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMWH3FP	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMI7KG4	DI	DMI7KG4
DMI7KG4	DN	Cyclic peptidomimetic derivative 3
DMI7KG4	MI	TT23XQV
DMI7KG4	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMI7KG4	MT	DTT
DMI7KG4	MA	Inhibitor
DMI7KG4	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMI7KG4	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMJMWDV	DI	DMJMWDV
DMJMWDV	DN	Cyclic sulfonamide derivative 1
DMJMWDV	MI	TT8J1S3
DMJMWDV	MN	Smoothened homolog (SMO)
DMJMWDV	MT	DTT
DMJMWDV	MA	Inhibitor
DMJMWDV	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMJMWDV	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMXSZ5B	DI	DMXSZ5B
DMXSZ5B	DN	Cyclic sulfonamide derivative 2
DMXSZ5B	MI	TT8J1S3
DMXSZ5B	MN	Smoothened homolog (SMO)
DMXSZ5B	MT	DTT
DMXSZ5B	MA	Inhibitor
DMXSZ5B	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMXSZ5B	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMBANT7	DI	DMBANT7
DMBANT7	DN	Cyclic sulfonamide derivative 3
DMBANT7	MI	TT8J1S3
DMBANT7	MN	Smoothened homolog (SMO)
DMBANT7	MT	DTT
DMBANT7	MA	Inhibitor
DMBANT7	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMBANT7	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMWAU49	DI	DMWAU49
DMWAU49	DN	Cyclic sulfonamide derivative 4
DMWAU49	MI	TT8J1S3
DMWAU49	MN	Smoothened homolog (SMO)
DMWAU49	MT	DTT
DMWAU49	MA	Inhibitor
DMWAU49	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMWAU49	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMXMGSP	DI	DMXMGSP
DMXMGSP	DN	Cycloalkyl acid derivative 1
DMXMGSP	MI	TTA592U
DMXMGSP	MN	Urate anion exchanger 1 (URAT1)
DMXMGSP	MT	DTT
DMXMGSP	MA	Inhibitor
DMXMGSP	RN	Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10.
DMXMGSP	RU	https://www.ncbi.nlm.nih.gov/pubmed/27414413

DM09LY3	DI	DM09LY3
DM09LY3	DN	Cycloalkyl acid derivative 2
DM09LY3	MI	TTA592U
DM09LY3	MN	Urate anion exchanger 1 (URAT1)
DM09LY3	MT	DTT
DM09LY3	MA	Inhibitor
DM09LY3	RN	Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10.
DM09LY3	RU	https://www.ncbi.nlm.nih.gov/pubmed/27414413

DM3RK0S	DI	DM3RK0S
DM3RK0S	DN	Cycloalkyl nitrile pyrazole carboxamide derivative 1
DM3RK0S	MI	TT6DM01
DM3RK0S	MN	Janus kinase 1 (JAK-1)
DM3RK0S	MT	DTT
DM3RK0S	MA	Inhibitor
DM3RK0S	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DM3RK0S	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DM3RK0S	DI	DM3RK0S
DM3RK0S	DN	Cycloalkyl nitrile pyrazole carboxamide derivative 1
DM3RK0S	MI	TTRMX3V
DM3RK0S	MN	Janus kinase 2 (JAK-2)
DM3RK0S	MT	DTT
DM3RK0S	MA	Inhibitor
DM3RK0S	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DM3RK0S	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMD3LK1	DI	DMD3LK1
DMD3LK1	DN	Cycloalkyl nitrile pyrazolo pyridone derivative 1
DMD3LK1	MI	TT6DM01
DMD3LK1	MN	Janus kinase 1 (JAK-1)
DMD3LK1	MT	DTT
DMD3LK1	MA	Inhibitor
DMD3LK1	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMD3LK1	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMD3LK1	DI	DMD3LK1
DMD3LK1	DN	Cycloalkyl nitrile pyrazolo pyridone derivative 1
DMD3LK1	MI	TTRMX3V
DMD3LK1	MN	Janus kinase 2 (JAK-2)
DMD3LK1	MT	DTT
DMD3LK1	MA	Inhibitor
DMD3LK1	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMD3LK1	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMW4JB0	DI	DMW4JB0
DMW4JB0	DN	Cycloalkyl nitrile pyrazolo pyridone derivative 2
DMW4JB0	MI	TT6DM01
DMW4JB0	MN	Janus kinase 1 (JAK-1)
DMW4JB0	MT	DTT
DMW4JB0	MA	Inhibitor
DMW4JB0	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMW4JB0	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMW4JB0	DI	DMW4JB0
DMW4JB0	DN	Cycloalkyl nitrile pyrazolo pyridone derivative 2
DMW4JB0	MI	TTRMX3V
DMW4JB0	MN	Janus kinase 2 (JAK-2)
DMW4JB0	MT	DTT
DMW4JB0	MA	Inhibitor
DMW4JB0	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMW4JB0	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMN3WID	DI	DMN3WID
DMN3WID	DN	Cyclohexane carboxamide derivative 1
DMN3WID	MI	TTTJZ4M
DMN3WID	MN	Prolylcarboxypeptidase (PRCP)
DMN3WID	MT	DTT
DMN3WID	MA	Inhibitor
DMN3WID	RN	Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088.
DMN3WID	RU	https://www.ncbi.nlm.nih.gov/pubmed/28699813

DM1A0WU	DI	DM1A0WU
DM1A0WU	DN	Cyclohexane carboxamide derivative 2
DM1A0WU	MI	TTTJZ4M
DM1A0WU	MN	Prolylcarboxypeptidase (PRCP)
DM1A0WU	MT	DTT
DM1A0WU	MA	Inhibitor
DM1A0WU	RN	Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088.
DM1A0WU	RU	https://www.ncbi.nlm.nih.gov/pubmed/28699813

DMQLZUW	DI	DMQLZUW
DMQLZUW	DN	Cyclohexane carboxamide derivative 3
DMQLZUW	MI	TTTJZ4M
DMQLZUW	MN	Prolylcarboxypeptidase (PRCP)
DMQLZUW	MT	DTT
DMQLZUW	MA	Inhibitor
DMQLZUW	RN	Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088.
DMQLZUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/28699813

DMRBI5X	DI	DMRBI5X
DMRBI5X	DN	Cyclohexyl azetidine derivative 1
DMRBI5X	MI	TT6DM01
DMRBI5X	MN	Janus kinase 1 (JAK-1)
DMRBI5X	MT	DTT
DMRBI5X	MA	Inhibitor
DMRBI5X	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMRBI5X	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMORFPT	DI	DMORFPT
DMORFPT	DN	Cyclohexyl carbamate derivative 1
DMORFPT	MI	TTULVH8
DMORFPT	MN	Tyrosinase (TYR)
DMORFPT	MT	DTT
DMORFPT	MA	Inhibitor
DMORFPT	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMORFPT	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DM6VPIR	DI	DM6VPIR
DM6VPIR	DN	Cyclohexyl carbamate derivative 2
DM6VPIR	MI	TTULVH8
DM6VPIR	MN	Tyrosinase (TYR)
DM6VPIR	MT	DTT
DM6VPIR	MA	Inhibitor
DM6VPIR	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DM6VPIR	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMVIZTY	DI	DMVIZTY
DMVIZTY	DN	Cyclohexyl carbamate derivative 3
DMVIZTY	MI	TTULVH8
DMVIZTY	MN	Tyrosinase (TYR)
DMVIZTY	MT	DTT
DMVIZTY	MA	Inhibitor
DMVIZTY	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMVIZTY	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMLD49W	DI	DMLD49W
DMLD49W	DN	Cyclohexyl carbamate derivative 4
DMLD49W	MI	TTULVH8
DMLD49W	MN	Tyrosinase (TYR)
DMLD49W	MT	DTT
DMLD49W	MA	Inhibitor
DMLD49W	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMLD49W	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMS68DP	DI	DMS68DP
DMS68DP	DN	Cyclohexyl carbamate derivative 5
DMS68DP	MI	TTULVH8
DMS68DP	MN	Tyrosinase (TYR)
DMS68DP	MT	DTT
DMS68DP	MA	Inhibitor
DMS68DP	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMS68DP	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMSD2TN	DI	DMSD2TN
DMSD2TN	DN	Cyclohexyl carbamate derivative 6
DMSD2TN	MI	TTULVH8
DMSD2TN	MN	Tyrosinase (TYR)
DMSD2TN	MT	DTT
DMSD2TN	MA	Inhibitor
DMSD2TN	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMSD2TN	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DM2URPE	DI	DM2URPE
DM2URPE	DN	Cyclohexyl carbamate derivative 7
DM2URPE	MI	TTULVH8
DM2URPE	MN	Tyrosinase (TYR)
DM2URPE	MT	DTT
DM2URPE	MA	Inhibitor
DM2URPE	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DM2URPE	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMB9DEO	DI	DMB9DEO
DMB9DEO	DN	Cyclohexyl carbamate derivative 8
DMB9DEO	MI	TTULVH8
DMB9DEO	MN	Tyrosinase (TYR)
DMB9DEO	MT	DTT
DMB9DEO	MA	Inhibitor
DMB9DEO	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMB9DEO	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMI2T1D	DI	DMI2T1D
DMI2T1D	DN	Cyclohexyl-ethyl-substituted diaza and triaza-tricyclic compound 1
DMI2T1D	MI	TTZJYKH
DMI2T1D	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMI2T1D	MT	DTT
DMI2T1D	MA	Antagonist
DMI2T1D	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMI2T1D	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMKM6BY	DI	DMKM6BY
DMKM6BY	DN	Cyclopenta[d]pyrimidine derivative 1
DMKM6BY	MI	TTKN7QR
DMKM6BY	MN	BDNF/NT-3 growth factors receptor (TrkB)
DMKM6BY	MT	DTT
DMKM6BY	MA	Inhibitor
DMKM6BY	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMKM6BY	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMKM6BY	DI	DMKM6BY
DMKM6BY	DN	Cyclopenta[d]pyrimidine derivative 1
DMKM6BY	MI	TTXABCW
DMKM6BY	MN	NT-3 growth factor receptor (TrkC)
DMKM6BY	MT	DTT
DMKM6BY	MA	Inhibitor
DMKM6BY	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMKM6BY	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMH7PGC	DI	DMH7PGC
DMH7PGC	DN	Cyclopentane carboxamide derivative 1
DMH7PGC	MI	TTTJZ4M
DMH7PGC	MN	Prolylcarboxypeptidase (PRCP)
DMH7PGC	MT	DTT
DMH7PGC	MA	Inhibitor
DMH7PGC	RN	Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088.
DMH7PGC	RU	https://www.ncbi.nlm.nih.gov/pubmed/28699813

DMYP5FK	DI	DMYP5FK
DMYP5FK	DN	Cyclopentane carboxamide derivative 2
DMYP5FK	MI	TTTJZ4M
DMYP5FK	MN	Prolylcarboxypeptidase (PRCP)
DMYP5FK	MT	DTT
DMYP5FK	MA	Inhibitor
DMYP5FK	RN	Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088.
DMYP5FK	RU	https://www.ncbi.nlm.nih.gov/pubmed/28699813

DMNXBPQ	DI	DMNXBPQ
DMNXBPQ	DN	Cyclopropane 1-carboxylic acid derivative 1
DMNXBPQ	MI	TTIY56R
DMNXBPQ	MN	Kynurenine 3-hydroxylase (KMO)
DMNXBPQ	MT	DTT
DMNXBPQ	MA	Inhibitor
DMNXBPQ	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMNXBPQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DM3M169	DI	DM3M169
DM3M169	DN	Cyclopropane 1-carboxylic acid derivative 10
DM3M169	MI	TTIY56R
DM3M169	MN	Kynurenine 3-hydroxylase (KMO)
DM3M169	MT	DTT
DM3M169	MA	Inhibitor
DM3M169	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DM3M169	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMSXB58	DI	DMSXB58
DMSXB58	DN	Cyclopropane 1-carboxylic acid derivative 2
DMSXB58	MI	TTIY56R
DMSXB58	MN	Kynurenine 3-hydroxylase (KMO)
DMSXB58	MT	DTT
DMSXB58	MA	Inhibitor
DMSXB58	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMSXB58	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DM6K59I	DI	DM6K59I
DM6K59I	DN	Cyclopropane 1-carboxylic acid derivative 3
DM6K59I	MI	TTIY56R
DM6K59I	MN	Kynurenine 3-hydroxylase (KMO)
DM6K59I	MT	DTT
DM6K59I	MA	Inhibitor
DM6K59I	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DM6K59I	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DM8PVN3	DI	DM8PVN3
DM8PVN3	DN	Cyclopropane 1-carboxylic acid derivative 4
DM8PVN3	MI	TTIY56R
DM8PVN3	MN	Kynurenine 3-hydroxylase (KMO)
DM8PVN3	MT	DTT
DM8PVN3	MA	Inhibitor
DM8PVN3	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DM8PVN3	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMCSIYG	DI	DMCSIYG
DMCSIYG	DN	Cyclopropane 1-carboxylic acid derivative 5
DMCSIYG	MI	TTIY56R
DMCSIYG	MN	Kynurenine 3-hydroxylase (KMO)
DMCSIYG	MT	DTT
DMCSIYG	MA	Inhibitor
DMCSIYG	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMCSIYG	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DM0OMBW	DI	DM0OMBW
DM0OMBW	DN	Cyclopropane 1-carboxylic acid derivative 6
DM0OMBW	MI	TTIY56R
DM0OMBW	MN	Kynurenine 3-hydroxylase (KMO)
DM0OMBW	MT	DTT
DM0OMBW	MA	Inhibitor
DM0OMBW	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DM0OMBW	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DM4RTMO	DI	DM4RTMO
DM4RTMO	DN	Cyclopropane 1-carboxylic acid derivative 7
DM4RTMO	MI	TTIY56R
DM4RTMO	MN	Kynurenine 3-hydroxylase (KMO)
DM4RTMO	MT	DTT
DM4RTMO	MA	Inhibitor
DM4RTMO	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DM4RTMO	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DM4P9HL	DI	DM4P9HL
DM4P9HL	DN	Cyclopropane 1-carboxylic acid derivative 8
DM4P9HL	MI	TTIY56R
DM4P9HL	MN	Kynurenine 3-hydroxylase (KMO)
DM4P9HL	MT	DTT
DM4P9HL	MA	Inhibitor
DM4P9HL	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DM4P9HL	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMLH9AQ	DI	DMLH9AQ
DMLH9AQ	DN	Cyclopropane 1-carboxylic acid derivative 9
DMLH9AQ	MI	TTIY56R
DMLH9AQ	MN	Kynurenine 3-hydroxylase (KMO)
DMLH9AQ	MT	DTT
DMLH9AQ	MA	Inhibitor
DMLH9AQ	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMLH9AQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMXN361	DI	DMXN361
DMXN361	DN	Cyclopropylamine derivative 1
DMXN361	MI	TTNR0UQ
DMXN361	MN	Lysine-specific histone demethylase 1 (LSD)
DMXN361	MT	DTT
DMXN361	MA	Inhibitor
DMXN361	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMXN361	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMZ5WN8	DI	DMZ5WN8
DMZ5WN8	DN	Cyclopropylamine derivative 10
DMZ5WN8	MI	TTNR0UQ
DMZ5WN8	MN	Lysine-specific histone demethylase 1 (LSD)
DMZ5WN8	MT	DTT
DMZ5WN8	MA	Inhibitor
DMZ5WN8	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMZ5WN8	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMZ5WN8	DI	DMZ5WN8
DMZ5WN8	DN	Cyclopropylamine derivative 10
DMZ5WN8	MI	TT32XQJ
DMZ5WN8	MN	Monoamine oxidase (MAO)
DMZ5WN8	MT	DTT
DMZ5WN8	MA	Inhibitor
DMZ5WN8	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMZ5WN8	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMMJ0YN	DI	DMMJ0YN
DMMJ0YN	DN	Cyclopropylamine derivative 11
DMMJ0YN	MI	TTNR0UQ
DMMJ0YN	MN	Lysine-specific histone demethylase 1 (LSD)
DMMJ0YN	MT	DTT
DMMJ0YN	MA	Inhibitor
DMMJ0YN	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMMJ0YN	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMMJ0YN	DI	DMMJ0YN
DMMJ0YN	DN	Cyclopropylamine derivative 11
DMMJ0YN	MI	TT32XQJ
DMMJ0YN	MN	Monoamine oxidase (MAO)
DMMJ0YN	MT	DTT
DMMJ0YN	MA	Inhibitor
DMMJ0YN	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMMJ0YN	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMV4I0K	DI	DMV4I0K
DMV4I0K	DN	Cyclopropylamine derivative 12
DMV4I0K	MI	TTNR0UQ
DMV4I0K	MN	Lysine-specific histone demethylase 1 (LSD)
DMV4I0K	MT	DTT
DMV4I0K	MA	Inhibitor
DMV4I0K	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMV4I0K	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMV4I0K	DI	DMV4I0K
DMV4I0K	DN	Cyclopropylamine derivative 12
DMV4I0K	MI	TT32XQJ
DMV4I0K	MN	Monoamine oxidase (MAO)
DMV4I0K	MT	DTT
DMV4I0K	MA	Inhibitor
DMV4I0K	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMV4I0K	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMXNVD4	DI	DMXNVD4
DMXNVD4	DN	Cyclopropylamine derivative 13
DMXNVD4	MI	TTNR0UQ
DMXNVD4	MN	Lysine-specific histone demethylase 1 (LSD)
DMXNVD4	MT	DTT
DMXNVD4	MA	Inhibitor
DMXNVD4	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMXNVD4	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMXNVD4	DI	DMXNVD4
DMXNVD4	DN	Cyclopropylamine derivative 13
DMXNVD4	MI	TT32XQJ
DMXNVD4	MN	Monoamine oxidase (MAO)
DMXNVD4	MT	DTT
DMXNVD4	MA	Inhibitor
DMXNVD4	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMXNVD4	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DM6E9L4	DI	DM6E9L4
DM6E9L4	DN	Cyclopropylamine derivative 3
DM6E9L4	MI	TTNR0UQ
DM6E9L4	MN	Lysine-specific histone demethylase 1 (LSD)
DM6E9L4	MT	DTT
DM6E9L4	MA	Inhibitor
DM6E9L4	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DM6E9L4	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMOCF4Y	DI	DMOCF4Y
DMOCF4Y	DN	Cyclopropylamine derivative 4
DMOCF4Y	MI	TTNR0UQ
DMOCF4Y	MN	Lysine-specific histone demethylase 1 (LSD)
DMOCF4Y	MT	DTT
DMOCF4Y	MA	Inhibitor
DMOCF4Y	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMOCF4Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DM5BCGD	DI	DM5BCGD
DM5BCGD	DN	Cyclopropylamine derivative 5
DM5BCGD	MI	TTNR0UQ
DM5BCGD	MN	Lysine-specific histone demethylase 1 (LSD)
DM5BCGD	MT	DTT
DM5BCGD	MA	Inhibitor
DM5BCGD	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DM5BCGD	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMB2RKC	DI	DMB2RKC
DMB2RKC	DN	Cyclopropylamine derivative 6
DMB2RKC	MI	TTNR0UQ
DMB2RKC	MN	Lysine-specific histone demethylase 1 (LSD)
DMB2RKC	MT	DTT
DMB2RKC	MA	Inhibitor
DMB2RKC	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMB2RKC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DM3X4PJ	DI	DM3X4PJ
DM3X4PJ	DN	Cyclopropylamine derivative 7
DM3X4PJ	MI	TTNR0UQ
DM3X4PJ	MN	Lysine-specific histone demethylase 1 (LSD)
DM3X4PJ	MT	DTT
DM3X4PJ	MA	Inhibitor
DM3X4PJ	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DM3X4PJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMA89WQ	DI	DMA89WQ
DMA89WQ	DN	Cyclopropylamine derivative 8
DMA89WQ	MI	TTNR0UQ
DMA89WQ	MN	Lysine-specific histone demethylase 1 (LSD)
DMA89WQ	MT	DTT
DMA89WQ	MA	Inhibitor
DMA89WQ	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMA89WQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMX7YAL	DI	DMX7YAL
DMX7YAL	DN	Cyclopropylamine derivative 9
DMX7YAL	MI	TTNR0UQ
DMX7YAL	MN	Lysine-specific histone demethylase 1 (LSD)
DMX7YAL	MT	DTT
DMX7YAL	MA	Inhibitor
DMX7YAL	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMX7YAL	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMX7YAL	DI	DMX7YAL
DMX7YAL	DN	Cyclopropylamine derivative 9
DMX7YAL	MI	TT32XQJ
DMX7YAL	MN	Monoamine oxidase (MAO)
DMX7YAL	MT	DTT
DMX7YAL	MA	Inhibitor
DMX7YAL	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMX7YAL	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DM0YTGS	DI	DM0YTGS
DM0YTGS	DN	Cyclopropyl-spiro piperidine derivative 1
DM0YTGS	MI	TT4G2JS
DM0YTGS	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DM0YTGS	MT	DTT
DM0YTGS	MA	Blocker
DM0YTGS	RN	Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90.
DM0YTGS	RU	https://www.ncbi.nlm.nih.gov/pubmed/25539043

DMM0R65	DI	DMM0R65
DMM0R65	DN	Cyclopropyl-spiro piperidine derivative 2
DMM0R65	MI	TT4G2JS
DMM0R65	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DMM0R65	MT	DTT
DMM0R65	MA	Blocker
DMM0R65	RN	Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90.
DMM0R65	RU	https://www.ncbi.nlm.nih.gov/pubmed/25539043

DM0IZW8	DI	DM0IZW8
DM0IZW8	DN	Cyclopropyl-spiro piperidine derivative 3
DM0IZW8	MI	TT4G2JS
DM0IZW8	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DM0IZW8	MT	DTT
DM0IZW8	MA	Blocker
DM0IZW8	RN	Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90.
DM0IZW8	RU	https://www.ncbi.nlm.nih.gov/pubmed/25539043

DM2ZWSM	DI	DM2ZWSM
DM2ZWSM	DN	Cyclopropyl-spiro piperidine derivative 4
DM2ZWSM	MI	TT4G2JS
DM2ZWSM	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DM2ZWSM	MT	DTT
DM2ZWSM	MA	Blocker
DM2ZWSM	RN	Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90.
DM2ZWSM	RU	https://www.ncbi.nlm.nih.gov/pubmed/25539043

DMXKUMJ	DI	DMXKUMJ
DMXKUMJ	DN	Decyle nelycorine dibromo salt derivative 1
DMXKUMJ	MI	TT1RS9F
DMXKUMJ	MN	Acetylcholinesterase (AChE)
DMXKUMJ	MT	DTT
DMXKUMJ	MA	Inhibitor
DMXKUMJ	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DMXKUMJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DMXKUMJ	DI	DMXKUMJ
DMXKUMJ	DN	Decyle nelycorine dibromo salt derivative 1
DMXKUMJ	MI	TTEB0GD
DMXKUMJ	MN	Cholinesterase (BCHE)
DMXKUMJ	MT	DTT
DMXKUMJ	MA	Inhibitor
DMXKUMJ	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DMXKUMJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DM3Q9OX	DI	DM3Q9OX
DM3Q9OX	DN	Deuterated 3-cyanoquinoline derivative 1
DM3Q9OX	MI	TTS7G69
DM3Q9OX	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DM3Q9OX	MT	DTT
DM3Q9OX	MA	Inhibitor
DM3Q9OX	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DM3Q9OX	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DM3Q9OX	DI	DM3Q9OX
DM3Q9OX	DN	Deuterated 3-cyanoquinoline derivative 1
DM3Q9OX	MI	TT6PKBN
DM3Q9OX	MN	Proto-oncogene c-Src (SRC)
DM3Q9OX	MT	DTT
DM3Q9OX	MA	Inhibitor
DM3Q9OX	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DM3Q9OX	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DM02V5Q	DI	DM02V5Q
DM02V5Q	DN	Diamidothiazole derivative 1
DM02V5Q	MI	TTCY4SB
DM02V5Q	MN	Aurora kinase (AURK)
DM02V5Q	MT	DTT
DM02V5Q	MA	Inhibitor
DM02V5Q	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DM02V5Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DM02V5Q	DI	DM02V5Q
DM02V5Q	DN	Diamidothiazole derivative 1
DM02V5Q	MI	TTTU902
DM02V5Q	MN	Checkpoint kinase-1 (CHK1)
DM02V5Q	MT	DTT
DM02V5Q	MA	Inhibitor
DM02V5Q	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DM02V5Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DM02V5Q	DI	DM02V5Q
DM02V5Q	DN	Diamidothiazole derivative 1
DM02V5Q	MI	TT7HF4W
DM02V5Q	MN	Cyclin-dependent kinase 2 (CDK2)
DM02V5Q	MT	DTT
DM02V5Q	MA	Inhibitor
DM02V5Q	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DM02V5Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DM02V5Q	DI	DM02V5Q
DM02V5Q	DN	Diamidothiazole derivative 1
DM02V5Q	MI	TTIDAPM
DM02V5Q	MN	ERK activator kinase 1 (MEK1)
DM02V5Q	MT	DTT
DM02V5Q	MA	Inhibitor
DM02V5Q	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DM02V5Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMUG69Q	DI	DMUG69Q
DMUG69Q	DN	Diamine derivative 1
DMUG69Q	MI	TTULVH8
DMUG69Q	MN	Tyrosinase (TYR)
DMUG69Q	MT	DTT
DMUG69Q	MA	Inhibitor
DMUG69Q	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMUG69Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMQEYTJ	DI	DMQEYTJ
DMQEYTJ	DN	Diamine derivative 2
DMQEYTJ	MI	TTULVH8
DMQEYTJ	MN	Tyrosinase (TYR)
DMQEYTJ	MT	DTT
DMQEYTJ	MA	Inhibitor
DMQEYTJ	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMQEYTJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMSYX4U	DI	DMSYX4U
DMSYX4U	DN	Diamine derivative 3
DMSYX4U	MI	TTULVH8
DMSYX4U	MN	Tyrosinase (TYR)
DMSYX4U	MT	DTT
DMSYX4U	MA	Inhibitor
DMSYX4U	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMSYX4U	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMPUH4Z	DI	DMPUH4Z
DMPUH4Z	DN	Diaminopyridine analog 4
DMPUH4Z	MI	TTKFVXR
DMPUH4Z	MN	Renal carcinoma antigen NY-REN-64 (IRAK-4)
DMPUH4Z	MT	DTT
DMPUH4Z	MA	Inhibitor
DMPUH4Z	RN	Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32.
DMPUH4Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/27310003

DM5B0F3	DI	DM5B0F3
DM5B0F3	DN	Diaminopyridine analog 5
DM5B0F3	MI	TTKFVXR
DM5B0F3	MN	Renal carcinoma antigen NY-REN-64 (IRAK-4)
DM5B0F3	MT	DTT
DM5B0F3	MA	Inhibitor
DM5B0F3	RN	Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32.
DM5B0F3	RU	https://www.ncbi.nlm.nih.gov/pubmed/27310003

DM06MJH	DI	DM06MJH
DM06MJH	DN	Diaryl amine derivative 1
DM06MJH	MI	TT7HF4W
DM06MJH	MN	Cyclin-dependent kinase 2 (CDK2)
DM06MJH	MT	DTT
DM06MJH	MA	Inhibitor
DM06MJH	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DM06MJH	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DM06MJH	DI	DM06MJH
DM06MJH	DN	Diaryl amine derivative 1
DM06MJH	MI	TT1LVF2
DM06MJH	MN	Cyclin-dependent kinase 9 (CDK9)
DM06MJH	MT	DTT
DM06MJH	MA	Inhibitor
DM06MJH	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DM06MJH	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMRBYAV	DI	DMRBYAV
DMRBYAV	DN	Diaryl amine derivative 2
DMRBYAV	MI	TT6R7JZ
DMRBYAV	MN	Histone deacetylase 1 (HDAC1)
DMRBYAV	MT	DTT
DMRBYAV	MA	Inhibitor
DMRBYAV	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMRBYAV	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMRBYAV	DI	DMRBYAV
DMRBYAV	DN	Diaryl amine derivative 2
DMRBYAV	MI	TT5ZKDI
DMRBYAV	MN	Histone deacetylase 6 (HDAC6)
DMRBYAV	MT	DTT
DMRBYAV	MA	Inhibitor
DMRBYAV	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMRBYAV	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMLBN1T	DI	DMLBN1T
DMLBN1T	DN	Diaryl amine derivative 3
DMLBN1T	MI	TT6R7JZ
DMLBN1T	MN	Histone deacetylase 1 (HDAC1)
DMLBN1T	MT	DTT
DMLBN1T	MA	Inhibitor
DMLBN1T	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMLBN1T	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMLBN1T	DI	DMLBN1T
DMLBN1T	DN	Diaryl amine derivative 3
DMLBN1T	MI	TT5ZKDI
DMLBN1T	MN	Histone deacetylase 6 (HDAC6)
DMLBN1T	MT	DTT
DMLBN1T	MA	Inhibitor
DMLBN1T	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMLBN1T	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMZL6AX	DI	DMZL6AX
DMZL6AX	DN	Diaryl amine derivative 4
DMZL6AX	MI	TT4YWTO
DMZL6AX	MN	Histone deacetylase 3 (HDAC3)
DMZL6AX	MT	DTT
DMZL6AX	MA	Inhibitor
DMZL6AX	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMZL6AX	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMZL6AX	DI	DMZL6AX
DMZL6AX	DN	Diaryl amine derivative 4
DMZL6AX	MI	TT5ZKDI
DMZL6AX	MN	Histone deacetylase 6 (HDAC6)
DMZL6AX	MT	DTT
DMZL6AX	MA	Inhibitor
DMZL6AX	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMZL6AX	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMIQOY7	DI	DMIQOY7
DMIQOY7	DN	Diaryl morpholine derivative 1
DMIQOY7	MI	TT6OEDT
DMIQOY7	MN	Cannabinoid receptor 1 (CB1)
DMIQOY7	MT	DTT
DMIQOY7	MA	Antagonist
DMIQOY7	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMIQOY7	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMERQ7V	DI	DMERQ7V
DMERQ7V	DN	Diaryl piperazine derivative 1
DMERQ7V	MI	TT6OEDT
DMERQ7V	MN	Cannabinoid receptor 1 (CB1)
DMERQ7V	MT	DTT
DMERQ7V	MA	Antagonist
DMERQ7V	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMERQ7V	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMDOB20	DI	DMDOB20
DMDOB20	DN	Diaryl piperazine derivative 2
DMDOB20	MI	TT6OEDT
DMDOB20	MN	Cannabinoid receptor 1 (CB1)
DMDOB20	MT	DTT
DMDOB20	MA	Antagonist
DMDOB20	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMDOB20	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMXFNOD	DI	DMXFNOD
DMXFNOD	DN	Diarylamine and arylheteroarylamine pyrazole derivative 1
DMXFNOD	MI	TTJQOD7
DMXFNOD	MN	5-HT 2A receptor (HTR2A)
DMXFNOD	MT	DTT
DMXFNOD	MA	Agonist
DMXFNOD	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMXFNOD	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DM6NR9Y	DI	DM6NR9Y
DM6NR9Y	DN	Diarylamine and arylheteroarylamine pyrazole derivative 2
DM6NR9Y	MI	TTJQOD7
DM6NR9Y	MN	5-HT 2A receptor (HTR2A)
DM6NR9Y	MT	DTT
DM6NR9Y	MA	Agonist
DM6NR9Y	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DM6NR9Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMLZ1UB	DI	DMLZ1UB
DMLZ1UB	DN	Diarylamine and arylheteroarylamine pyrazole derivative 3
DMLZ1UB	MI	TTJQOD7
DMLZ1UB	MN	5-HT 2A receptor (HTR2A)
DMLZ1UB	MT	DTT
DMLZ1UB	MA	Agonist
DMLZ1UB	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMLZ1UB	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DM9YD0Q	DI	DM9YD0Q
DM9YD0Q	DN	Diazepinone derivative 1
DM9YD0Q	MI	TTHS256
DM9YD0Q	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM9YD0Q	MT	DTT
DM9YD0Q	MA	Modulator
DM9YD0Q	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DM9YD0Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMLQ7PG	DI	DMLQ7PG
DMLQ7PG	DN	Diazepinone derivative 2
DMLQ7PG	MI	TTHS256
DMLQ7PG	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMLQ7PG	MT	DTT
DMLQ7PG	MA	Modulator
DMLQ7PG	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMLQ7PG	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMPTZ69	DI	DMPTZ69
DMPTZ69	DN	Diazepinone derivative 3
DMPTZ69	MI	TTHS256
DMPTZ69	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMPTZ69	MT	DTT
DMPTZ69	MA	Modulator
DMPTZ69	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMPTZ69	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DM389YD	DI	DM389YD
DM389YD	DN	Diazepinone derivative 4
DM389YD	MI	TTHS256
DM389YD	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM389YD	MT	DTT
DM389YD	MA	Modulator
DM389YD	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DM389YD	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DM2U1QH	DI	DM2U1QH
DM2U1QH	DN	Diazepinone derivative 5
DM2U1QH	MI	TTHS256
DM2U1QH	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM2U1QH	MT	DTT
DM2U1QH	MA	Modulator
DM2U1QH	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DM2U1QH	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMRM5I1	DI	DMRM5I1
DMRM5I1	DN	Dibenzo [c,f]-[2,7]naphthyridine derivative 1
DMRM5I1	MI	TTCZOF2
DMRM5I1	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMRM5I1	MT	DTT
DMRM5I1	MA	Inhibitor
DMRM5I1	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMRM5I1	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMUNFAT	DI	DMUNFAT
DMUNFAT	DN	Dihydrobenzoxazine and tetrahydroquinoxaline sulfonamide derivative 1
DMUNFAT	MI	TTZOVE0
DMUNFAT	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DMUNFAT	MT	DTT
DMUNFAT	MA	Blocker
DMUNFAT	RN	Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90.
DMUNFAT	RU	https://www.ncbi.nlm.nih.gov/pubmed/25539043

DMUNFAT	DI	DMUNFAT
DMUNFAT	DN	Dihydrobenzoxazine and tetrahydroquinoxaline sulfonamide derivative 1
DMUNFAT	MI	TT4G2JS
DMUNFAT	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DMUNFAT	MT	DTT
DMUNFAT	MA	Blocker
DMUNFAT	RN	Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90.
DMUNFAT	RU	https://www.ncbi.nlm.nih.gov/pubmed/25539043

DMC3IN2	DI	DMC3IN2
DMC3IN2	DN	Dihydrodiazepinocarbazolone derivative 1
DMC3IN2	MI	TTVDSZ0
DMC3IN2	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMC3IN2	MT	DTT
DMC3IN2	MA	Inhibitor
DMC3IN2	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DMC3IN2	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DMC3IN2	DI	DMC3IN2
DMC3IN2	DN	Dihydrodiazepinocarbazolone derivative 1
DMC3IN2	MI	TTQ4V96
DMC3IN2	MN	Poly [ADP-ribose] polymerase 2 (PARP2)
DMC3IN2	MT	DTT
DMC3IN2	MA	Inhibitor
DMC3IN2	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DMC3IN2	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DM1R0FJ	DI	DM1R0FJ
DM1R0FJ	DN	Dihydrodiazepinocarbazolone derivative 2
DM1R0FJ	MI	TTEBCY8
DM1R0FJ	MN	Poly [ADP-ribose] polymerase (PARP)
DM1R0FJ	MT	DTT
DM1R0FJ	MA	Inhibitor
DM1R0FJ	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DM1R0FJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DM5UPGZ	DI	DM5UPGZ
DM5UPGZ	DN	Dihydroisoquinoline carboxamide analog 1
DM5UPGZ	MI	TT473XN
DM5UPGZ	MN	P2X purinoceptor 7 (P2RX7)
DM5UPGZ	MT	DTT
DM5UPGZ	MA	Antagonist
DM5UPGZ	RN	P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267.
DM5UPGZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27724045

DMQRECT	DI	DMQRECT
DMQRECT	DN	Dihydroisoxazole derivative 1
DMQRECT	MI	TT2F4OL
DMQRECT	MN	Tissue transglutaminase (TG2)
DMQRECT	MT	DTT
DMQRECT	MA	Inhibitor
DMQRECT	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DMQRECT	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DMLTZKX	DI	DMLTZKX
DMLTZKX	DN	Dihydroisoxazole derivative 2
DMLTZKX	MI	TT2F4OL
DMLTZKX	MN	Tissue transglutaminase (TG2)
DMLTZKX	MT	DTT
DMLTZKX	MA	Inhibitor
DMLTZKX	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DMLTZKX	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DM16M4A	DI	DM16M4A
DM16M4A	DN	Dihydropyridine compound 1
DM16M4A	MI	TT4DXQT
DM16M4A	MN	Proto-oncogene c-Ret (RET)
DM16M4A	MT	DTT
DM16M4A	MA	Inhibitor
DM16M4A	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DM16M4A	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DM6RGOY	DI	DM6RGOY
DM6RGOY	DN	Dihydropyridine compound 2
DM6RGOY	MI	TT4DXQT
DM6RGOY	MN	Proto-oncogene c-Ret (RET)
DM6RGOY	MT	DTT
DM6RGOY	MA	Inhibitor
DM6RGOY	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DM6RGOY	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMR3AVK	DI	DMR3AVK
DMR3AVK	DN	Dihydropyridine compound 3
DMR3AVK	MI	TT4DXQT
DMR3AVK	MN	Proto-oncogene c-Ret (RET)
DMR3AVK	MT	DTT
DMR3AVK	MA	Inhibitor
DMR3AVK	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMR3AVK	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMIFZLG	DI	DMIFZLG
DMIFZLG	DN	Dihydropyridine compound 4
DMIFZLG	MI	TT4DXQT
DMIFZLG	MN	Proto-oncogene c-Ret (RET)
DMIFZLG	MT	DTT
DMIFZLG	MA	Inhibitor
DMIFZLG	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMIFZLG	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMC41TK	DI	DMC41TK
DMC41TK	DN	Dihydropyridine compound 5
DMC41TK	MI	TT4DXQT
DMC41TK	MN	Proto-oncogene c-Ret (RET)
DMC41TK	MT	DTT
DMC41TK	MA	Inhibitor
DMC41TK	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMC41TK	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMEXT6J	DI	DMEXT6J
DMEXT6J	DN	Dihydropyridine compound 6
DMEXT6J	MI	TT4DXQT
DMEXT6J	MN	Proto-oncogene c-Ret (RET)
DMEXT6J	MT	DTT
DMEXT6J	MA	Inhibitor
DMEXT6J	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMEXT6J	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMWIYFQ	DI	DMWIYFQ
DMWIYFQ	DN	Dihydropyrido phthalazinone derivative 1
DMWIYFQ	MI	TTVDSZ0
DMWIYFQ	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMWIYFQ	MT	DTT
DMWIYFQ	MA	Inhibitor
DMWIYFQ	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DMWIYFQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DMR4PQN	DI	DMR4PQN
DMR4PQN	DN	Dihydropyrido phthalazinone derivative 2
DMR4PQN	MI	TTVDSZ0
DMR4PQN	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMR4PQN	MT	DTT
DMR4PQN	MA	Inhibitor
DMR4PQN	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DMR4PQN	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DMMFBI3	DI	DMMFBI3
DMMFBI3	DN	Dihydropyrido phthalazinone derivative 3
DMMFBI3	MI	TTEBCY8
DMMFBI3	MN	Poly [ADP-ribose] polymerase (PARP)
DMMFBI3	MT	DTT
DMMFBI3	MA	Inhibitor
DMMFBI3	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DMMFBI3	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DMWEJ6U	DI	DMWEJ6U
DMWEJ6U	DN	Dihydropyrido phthalazinone derivative 4
DMWEJ6U	MI	TTEBCY8
DMWEJ6U	MN	Poly [ADP-ribose] polymerase (PARP)
DMWEJ6U	MT	DTT
DMWEJ6U	MA	Inhibitor
DMWEJ6U	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DMWEJ6U	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DM8S7NQ	DI	DM8S7NQ
DM8S7NQ	DN	Dihydropyrido pyrazinone compound 1
DM8S7NQ	MI	TTE4BSY
DM8S7NQ	MN	Bromodomain and extraterminal domain protein (BET)
DM8S7NQ	MT	DTT
DM8S7NQ	MA	Inhibitor
DM8S7NQ	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DM8S7NQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMOTG2Y	DI	DMOTG2Y
DMOTG2Y	DN	Dihydropyrido pyrazinone compound 2
DMOTG2Y	MI	TTIYVQP
DMOTG2Y	MN	Polo-like kinase 1 (PLK1)
DMOTG2Y	MT	DTT
DMOTG2Y	MA	Inhibitor
DMOTG2Y	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMOTG2Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DM3PEUN	DI	DM3PEUN
DM3PEUN	DN	Dihydropyrido pyrazinone compound 3
DM3PEUN	MI	TTIYVQP
DM3PEUN	MN	Polo-like kinase 1 (PLK1)
DM3PEUN	MT	DTT
DM3PEUN	MA	Inhibitor
DM3PEUN	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DM3PEUN	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMSTC9Z	DI	DMSTC9Z
DMSTC9Z	DN	Dihydropyrido pyrimidine derivative 1
DMSTC9Z	MI	TTSCIM2
DMSTC9Z	MN	Extracellular lysophospholipase D (E-NPP2)
DMSTC9Z	MT	DTT
DMSTC9Z	MA	Inhibitor
DMSTC9Z	RN	Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829.
DMSTC9Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/28447479

DMA25XH	DI	DMA25XH
DMA25XH	DN	Dihydropyrimidinone derivative 1
DMA25XH	MI	TTPLTSQ
DMA25XH	MN	Neutrophil elastase (NE)
DMA25XH	MT	DTT
DMA25XH	MA	Inhibitor
DMA25XH	RN	Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
DMA25XH	RU	https://www.ncbi.nlm.nih.gov/pubmed/26118988

DM5Y13R	DI	DM5Y13R
DM5Y13R	DN	Dihydropyrimidinone derivative 2
DM5Y13R	MI	TTPLTSQ
DM5Y13R	MN	Neutrophil elastase (NE)
DM5Y13R	MT	DTT
DM5Y13R	MA	Inhibitor
DM5Y13R	RN	Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
DM5Y13R	RU	https://www.ncbi.nlm.nih.gov/pubmed/26118988

DMA1S6Q	DI	DMA1S6Q
DMA1S6Q	DN	Dihydropyrimidinone derivative 3
DMA1S6Q	MI	TTJOW1I
DMA1S6Q	MN	Mannoside acetylglucosaminyltransferase 2 (MGAT2)
DMA1S6Q	MT	DTT
DMA1S6Q	MA	Inhibitor
DMA1S6Q	RN	Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
DMA1S6Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/25470667

DMNEKOZ	DI	DMNEKOZ
DMNEKOZ	DN	Dihydropyrimidinone derivative 4
DMNEKOZ	MI	TTJOW1I
DMNEKOZ	MN	Mannoside acetylglucosaminyltransferase 2 (MGAT2)
DMNEKOZ	MT	DTT
DMNEKOZ	MA	Inhibitor
DMNEKOZ	RN	Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
DMNEKOZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25470667

DMHGE1T	DI	DMHGE1T
DMHGE1T	DN	Dihydropyrrolopyrazole derivative 1
DMHGE1T	MI	TTDIGC1
DMHGE1T	MN	Dipeptidyl peptidase 4 (DPP-4)
DMHGE1T	MT	DTT
DMHGE1T	MA	Inhibitor
DMHGE1T	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMHGE1T	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DMUJ3XK	DI	DMUJ3XK
DMUJ3XK	DN	Dihydrothieno [2,3-e]indazole derivative 1
DMUJ3XK	MI	TTRPDBG
DMUJ3XK	MN	Inhibitor of nuclear factor kappa-B kinase (IKK)
DMUJ3XK	MT	DTT
DMUJ3XK	MA	Inhibitor
DMUJ3XK	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DMUJ3XK	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DM0D3HU	DI	DM0D3HU
DM0D3HU	DN	Dihydrothieno [2,3-e]indazole derivative 2
DM0D3HU	MI	TTRPDBG
DM0D3HU	MN	Inhibitor of nuclear factor kappa-B kinase (IKK)
DM0D3HU	MT	DTT
DM0D3HU	MA	Inhibitor
DM0D3HU	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DM0D3HU	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DM85VQR	DI	DM85VQR
DM85VQR	DN	Dihydrothieno [2,3-e]indazole derivative 3
DM85VQR	MI	TTRPDBG
DM85VQR	MN	Inhibitor of nuclear factor kappa-B kinase (IKK)
DM85VQR	MT	DTT
DM85VQR	MA	Inhibitor
DM85VQR	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DM85VQR	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DMR4LPO	DI	DMR4LPO
DMR4LPO	DN	Dihydrothieno [2,3-e]indazole derivative 4
DMR4LPO	MI	TTRPDBG
DMR4LPO	MN	Inhibitor of nuclear factor kappa-B kinase (IKK)
DMR4LPO	MT	DTT
DMR4LPO	MA	Inhibitor
DMR4LPO	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DMR4LPO	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DMAH1EP	DI	DMAH1EP
DMAH1EP	DN	Dihydroxyfumaric acid derivative 1
DMAH1EP	MI	TTULVH8
DMAH1EP	MN	Tyrosinase (TYR)
DMAH1EP	MT	DTT
DMAH1EP	MA	Inhibitor
DMAH1EP	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMAH1EP	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMZ4B3W	DI	DMZ4B3W
DMZ4B3W	DN	Dimethoxybenzylidene-2-thio-imidazole-4-one derivative 1
DMZ4B3W	MI	TTF2LRI
DMZ4B3W	MN	Cathepsin B (CTSB)
DMZ4B3W	MT	DTT
DMZ4B3W	MA	Inhibitor
DMZ4B3W	RN	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
DMZ4B3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/27998201

DM2OTJS	DI	DM2OTJS
DM2OTJS	DN	Dipeptide analog 1
DM2OTJS	MI	TTEAD9J
DM2OTJS	MN	Proteasome beta-8 (PS beta-8)
DM2OTJS	MT	DTT
DM2OTJS	MA	Inhibitor
DM2OTJS	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DM2OTJS	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DM2OTJS	DI	DM2OTJS
DM2OTJS	DN	Dipeptide analog 1
DM2OTJS	MI	TTOUSTQ
DM2OTJS	MN	Proteasome beta-9 (PS beta-9)
DM2OTJS	MT	DTT
DM2OTJS	MA	Inhibitor
DM2OTJS	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DM2OTJS	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMMAF2S	DI	DMMAF2S
DMMAF2S	DN	Dipeptide analog 2
DMMAF2S	MI	TT2F4OL
DMMAF2S	MN	Tissue transglutaminase (TG2)
DMMAF2S	MT	DTT
DMMAF2S	MA	Inhibitor
DMMAF2S	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DMMAF2S	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DM6RLTV	DI	DM6RLTV
DM6RLTV	DN	Dipeptide analog 3
DM6RLTV	MI	TT2F4OL
DM6RLTV	MN	Tissue transglutaminase (TG2)
DM6RLTV	MT	DTT
DM6RLTV	MA	Inhibitor
DM6RLTV	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DM6RLTV	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DMXOPIJ	DI	DMXOPIJ
DMXOPIJ	DN	Dipeptide analog 4
DMXOPIJ	MI	TT2F4OL
DMXOPIJ	MN	Tissue transglutaminase (TG2)
DMXOPIJ	MT	DTT
DMXOPIJ	MA	Inhibitor
DMXOPIJ	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DMXOPIJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DM2DYMS	DI	DM2DYMS
DM2DYMS	DN	Diphenyl purine derivative 1
DM2DYMS	MI	TT6OEDT
DM2DYMS	MN	Cannabinoid receptor 1 (CB1)
DM2DYMS	MT	DTT
DM2DYMS	MA	Antagonist
DM2DYMS	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DM2DYMS	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMG8MCJ	DI	DMG8MCJ
DMG8MCJ	DN	Diphenyl purine derivative 2
DMG8MCJ	MI	TT6OEDT
DMG8MCJ	MN	Cannabinoid receptor 1 (CB1)
DMG8MCJ	MT	DTT
DMG8MCJ	MA	Antagonist
DMG8MCJ	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMG8MCJ	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMY5CFW	DI	DMY5CFW
DMY5CFW	DN	Diphenyl purine derivative 3
DMY5CFW	MI	TT6OEDT
DMY5CFW	MN	Cannabinoid receptor 1 (CB1)
DMY5CFW	MT	DTT
DMY5CFW	MA	Antagonist
DMY5CFW	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMY5CFW	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMP3JF4	DI	DMP3JF4
DMP3JF4	DN	Diphenyl purine derivative 4
DMP3JF4	MI	TT6OEDT
DMP3JF4	MN	Cannabinoid receptor 1 (CB1)
DMP3JF4	MT	DTT
DMP3JF4	MA	Antagonist
DMP3JF4	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMP3JF4	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMC2T4H	DI	DMC2T4H
DMC2T4H	DN	Diphenyl purine derivative 5
DMC2T4H	MI	TT6OEDT
DMC2T4H	MN	Cannabinoid receptor 1 (CB1)
DMC2T4H	MT	DTT
DMC2T4H	MA	Antagonist
DMC2T4H	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMC2T4H	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DM3OCXI	DI	DM3OCXI
DM3OCXI	DN	Di-substituted piperidine derivative 1
DM3OCXI	MI	TTEB0GD
DM3OCXI	MN	Cholinesterase (BCHE)
DM3OCXI	MT	DTT
DM3OCXI	MA	Inhibitor
DM3OCXI	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DM3OCXI	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DM23XQL	DI	DM23XQL
DM23XQL	DN	Di-substituted piperidine derivative 2
DM23XQL	MI	TT1RS9F
DM23XQL	MN	Acetylcholinesterase (AChE)
DM23XQL	MT	DTT
DM23XQL	MA	Inhibitor
DM23XQL	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DM23XQL	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DM23XQL	DI	DM23XQL
DM23XQL	DN	Di-substituted piperidine derivative 2
DM23XQL	MI	TTEB0GD
DM23XQL	MN	Cholinesterase (BCHE)
DM23XQL	MT	DTT
DM23XQL	MA	Inhibitor
DM23XQL	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DM23XQL	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DM2IBX9	DI	DM2IBX9
DM2IBX9	DN	Di-substituted piperidine derivative 3
DM2IBX9	MI	TTEB0GD
DM2IBX9	MN	Cholinesterase (BCHE)
DM2IBX9	MT	DTT
DM2IBX9	MA	Inhibitor
DM2IBX9	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DM2IBX9	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DMTYL68	DI	DMTYL68
DMTYL68	DN	Disulfide compound 1
DMTYL68	MI	TTR7UJ3
DMTYL68	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMTYL68	MT	DTT
DMTYL68	MA	Inhibitor
DMTYL68	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMTYL68	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DM6ON31	DI	DM6ON31
DM6ON31	DN	Disulfide compound 2
DM6ON31	MI	TTR7UJ3
DM6ON31	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DM6ON31	MT	DTT
DM6ON31	MA	Inhibitor
DM6ON31	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DM6ON31	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DMOEFD3	DI	DMOEFD3
DMOEFD3	DN	Disulfiram analog 1
DMOEFD3	MI	TTZHPB8
DMOEFD3	MN	Lysine-specific demethylase 4A (KDM4A)
DMOEFD3	MT	DTT
DMOEFD3	MA	Inhibitor
DMOEFD3	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMOEFD3	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMOMGU5	DI	DMOMGU5
DMOMGU5	DN	Disulfiram analog 2
DMOMGU5	MI	TTZHPB8
DMOMGU5	MN	Lysine-specific demethylase 4A (KDM4A)
DMOMGU5	MT	DTT
DMOMGU5	MA	Inhibitor
DMOMGU5	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMOMGU5	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMYQHER	DI	DMYQHER
DMYQHER	DN	Diterpene triepoxide derivative 1
DMYQHER	MI	TTLPJWH
DMYQHER	MN	Thioredoxin reductase (PRDX5)
DMYQHER	MT	DTT
DMYQHER	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMYQHER	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DMAZOH4	DI	DMAZOH4
DMAZOH4	DN	Diterpenoid derivative 1
DMAZOH4	MI	TT3Z6Y9
DMAZOH4	MN	Cysteines of Keap1 (KEAP1 Cysteines)
DMAZOH4	MT	DTT
DMAZOH4	MA	Modulator
DMAZOH4	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMAZOH4	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMAZOH4	DI	DMAZOH4
DMAZOH4	DN	Diterpenoid derivative 1
DMAZOH4	MI	TTA6ZN2
DMAZOH4	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMAZOH4	MT	DTT
DMAZOH4	MA	Activator
DMAZOH4	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMAZOH4	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMKT19M	DI	DMKT19M
DMKT19M	DN	Diterpenoid derivative 2
DMKT19M	MI	TT3Z6Y9
DMKT19M	MN	Cysteines of Keap1 (KEAP1 Cysteines)
DMKT19M	MT	DTT
DMKT19M	MA	Modulator
DMKT19M	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMKT19M	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMKT19M	DI	DMKT19M
DMKT19M	DN	Diterpenoid derivative 2
DMKT19M	MI	TTA6ZN2
DMKT19M	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMKT19M	MT	DTT
DMKT19M	MA	Activator
DMKT19M	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMKT19M	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM6BU7N	DI	DM6BU7N
DM6BU7N	DN	Doramapimod
DM6BU7N	MI	TT42OGM
DM6BU7N	MN	Hematopoietic cell kinase (HCK)
DM6BU7N	MT	DTT
DM6BU7N	MA	Inhibitor
DM6BU7N	RN	Respiratory formulations and compounds for use therein. US8933228.
DM6BU7N	RU	http://www.freepatentsonline.com/US8933228.html

DM2HLGC	DI	DM2HLGC
DM2HLGC	DN	DZ9
DM2HLGC	MI	TT1NFO3
DM2HLGC	MN	Bacterial Nicotinate-nucleotide adenylyltransferase (Bact nadD)
DM2HLGC	MT	DTT
DM2HLGC	MA	Inhibitor
DM2HLGC	RN	Targeting NAD biosynthesis in bacterial pathogens. US8785499.
DM2HLGC	RU	http://www.freepatentsonline.com/US8785499.html

DM5UM8I	DI	DM5UM8I
DM5UM8I	DN	EEA
DM5UM8I	MI	TTXLEG7
DM5UM8I	MN	Matrix metalloproteinase-10 (MMP-10)
DM5UM8I	MT	DTT
DM5UM8I	MA	Inhibitor
DM5UM8I	RN	Pseudodipeptides as MMP inhibitors. US8691753.
DM5UM8I	RU	http://www.freepatentsonline.com/US8691753.html

DMR9IE5	DI	DMR9IE5
DMR9IE5	DN	EEC
DMR9IE5	MI	TTXLEG7
DMR9IE5	MN	Matrix metalloproteinase-10 (MMP-10)
DMR9IE5	MT	DTT
DMR9IE5	MA	Inhibitor
DMR9IE5	RN	Pseudodipeptides as MMP inhibitors. US8691753.
DMR9IE5	RU	http://www.freepatentsonline.com/US8691753.html

DMQF1UM	DI	DMQF1UM
DMQF1UM	DN	Egonol compound 1
DMQF1UM	MI	TT1RS9F
DMQF1UM	MN	Acetylcholinesterase (AChE)
DMQF1UM	MT	DTT
DMQF1UM	MA	Inhibitor
DMQF1UM	RN	Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476.
DMQF1UM	RU	https://www.ncbi.nlm.nih.gov/pubmed/27967267

DMQF1UM	DI	DMQF1UM
DMQF1UM	DN	Egonol compound 1
DMQF1UM	MI	TTEB0GD
DMQF1UM	MN	Cholinesterase (BCHE)
DMQF1UM	MT	DTT
DMQF1UM	MA	Inhibitor
DMQF1UM	RN	Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476.
DMQF1UM	RU	https://www.ncbi.nlm.nih.gov/pubmed/27967267

DMNBAZH	DI	DMNBAZH
DMNBAZH	DN	Enol carbamate derivative 1
DMNBAZH	MI	TTDP1UC
DMNBAZH	MN	Fatty acid amide hydrolase (FAAH)
DMNBAZH	MT	DTT
DMNBAZH	MA	Inhibitor
DMNBAZH	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMNBAZH	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMJSIN8	DI	DMJSIN8
DMJSIN8	DN	Enzoxazolinone sulfonamide derivative 1
DMJSIN8	MI	TT4G2JS
DMJSIN8	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DMJSIN8	MT	DTT
DMJSIN8	MA	Blocker
DMJSIN8	RN	Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90.
DMJSIN8	RU	https://www.ncbi.nlm.nih.gov/pubmed/25539043

DMU8LPN	DI	DMU8LPN
DMU8LPN	DN	Epoxysuccinate derivative 1
DMU8LPN	MI	TTG5QB7
DMU8LPN	MN	Calpain-2 (CAPN2)
DMU8LPN	MT	DTT
DMU8LPN	MA	Inhibitor
DMU8LPN	RN	An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31.
DMU8LPN	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399719

DMYF39U	DI	DMYF39U
DMYF39U	DN	Epoxysuccinate derivative 10
DMYF39U	MI	TTG5QB7
DMYF39U	MN	Calpain-2 (CAPN2)
DMYF39U	MT	DTT
DMYF39U	MA	Inhibitor
DMYF39U	RN	An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31.
DMYF39U	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399719

DMEV9O3	DI	DMEV9O3
DMEV9O3	DN	Epoxysuccinate derivative 2
DMEV9O3	MI	TTG5QB7
DMEV9O3	MN	Calpain-2 (CAPN2)
DMEV9O3	MT	DTT
DMEV9O3	MA	Inhibitor
DMEV9O3	RN	An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31.
DMEV9O3	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399719

DMMETW5	DI	DMMETW5
DMMETW5	DN	Epoxysuccinate derivative 3
DMMETW5	MI	TTG5QB7
DMMETW5	MN	Calpain-2 (CAPN2)
DMMETW5	MT	DTT
DMMETW5	MA	Inhibitor
DMMETW5	RN	An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31.
DMMETW5	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399719

DMCF6M8	DI	DMCF6M8
DMCF6M8	DN	Epoxysuccinate derivative 4
DMCF6M8	MI	TTG5QB7
DMCF6M8	MN	Calpain-2 (CAPN2)
DMCF6M8	MT	DTT
DMCF6M8	MA	Inhibitor
DMCF6M8	RN	An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31.
DMCF6M8	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399719

DM37MCN	DI	DM37MCN
DM37MCN	DN	Epoxysuccinate derivative 5
DM37MCN	MI	TTG5QB7
DM37MCN	MN	Calpain-2 (CAPN2)
DM37MCN	MT	DTT
DM37MCN	MA	Inhibitor
DM37MCN	RN	An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31.
DM37MCN	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399719

DMQM6ZS	DI	DMQM6ZS
DMQM6ZS	DN	Epoxysuccinate derivative 6
DMQM6ZS	MI	TTG5QB7
DMQM6ZS	MN	Calpain-2 (CAPN2)
DMQM6ZS	MT	DTT
DMQM6ZS	MA	Inhibitor
DMQM6ZS	RN	An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31.
DMQM6ZS	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399719

DMTSPVF	DI	DMTSPVF
DMTSPVF	DN	Epoxysuccinate derivative 7
DMTSPVF	MI	TTG5QB7
DMTSPVF	MN	Calpain-2 (CAPN2)
DMTSPVF	MT	DTT
DMTSPVF	MA	Inhibitor
DMTSPVF	RN	An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31.
DMTSPVF	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399719

DMQTVPC	DI	DMQTVPC
DMQTVPC	DN	Epoxysuccinate derivative 8
DMQTVPC	MI	TTG5QB7
DMQTVPC	MN	Calpain-2 (CAPN2)
DMQTVPC	MT	DTT
DMQTVPC	MA	Inhibitor
DMQTVPC	RN	An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31.
DMQTVPC	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399719

DM49FU0	DI	DM49FU0
DM49FU0	DN	Epoxysuccinate derivative 9
DM49FU0	MI	TTG5QB7
DM49FU0	MN	Calpain-2 (CAPN2)
DM49FU0	MT	DTT
DM49FU0	MA	Inhibitor
DM49FU0	RN	An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31.
DM49FU0	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399719

DM7XYRA	DI	DM7XYRA
DM7XYRA	DN	Eptastatin derivative 1
DM7XYRA	MI	TTPADOQ
DM7XYRA	MN	HMG-CoA reductase (HMGCR)
DM7XYRA	MT	DTT
DM7XYRA	MA	Inhibitor
DM7XYRA	RN	HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272.
DM7XYRA	RU	https://www.ncbi.nlm.nih.gov/pubmed/27537201

DMLOBAQ	DI	DMLOBAQ
DMLOBAQ	DN	Ethinyl-pyrazole derivative 1
DMLOBAQ	MI	TTXJ47W
DMLOBAQ	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMLOBAQ	MT	DTT
DMLOBAQ	MA	Antagonist
DMLOBAQ	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DMLOBAQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DMA3PE7	DI	DMA3PE7
DMA3PE7	DN	Ethinyl-pyrazole derivative 2
DMA3PE7	MI	TTXJ47W
DMA3PE7	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMA3PE7	MT	DTT
DMA3PE7	MA	Antagonist
DMA3PE7	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DMA3PE7	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DM87DOX	DI	DM87DOX
DM87DOX	DN	Ethinyl-pyrazole derivative 3
DM87DOX	MI	TTXJ47W
DM87DOX	MN	Metabotropic glutamate receptor 2 (mGluR2)
DM87DOX	MT	DTT
DM87DOX	MA	Antagonist
DM87DOX	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DM87DOX	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DMTBG39	DI	DMTBG39
DMTBG39	DN	Ethylaminopyrimidine derivative 1
DMTBG39	MI	TTDP1UC
DMTBG39	MN	Fatty acid amide hydrolase (FAAH)
DMTBG39	MT	DTT
DMTBG39	MA	Inhibitor
DMTBG39	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMTBG39	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMTBG39	DI	DMTBG39
DMTBG39	DN	Ethylaminopyrimidine derivative 1
DMTBG39	MI	TTGX13H
DMTBG39	MN	Fatty-acid amide hydrolase 1 (FAAH1)
DMTBG39	MT	DTT
DMTBG39	MA	Inhibitor
DMTBG39	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMTBG39	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DM9WMJ1	DI	DM9WMJ1
DM9WMJ1	DN	Ethylvanillin
DM9WMJ1	MI	TTGP7BY
DM9WMJ1	MN	Monoamine oxidase type B (MAO-B)
DM9WMJ1	MT	DTT
DM9WMJ1	MA	Inhibitor
DM9WMJ1	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DM9WMJ1	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMWXKRZ	DI	DMWXKRZ
DMWXKRZ	DN	Ethynyl compound 1
DMWXKRZ	MI	TTHS256
DMWXKRZ	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMWXKRZ	MT	DTT
DMWXKRZ	MA	Modulator
DMWXKRZ	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMWXKRZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMJDG37	DI	DMJDG37
DMJDG37	DN	Ethynyl compound 2
DMJDG37	MI	TTHS256
DMJDG37	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMJDG37	MT	DTT
DMJDG37	MA	Modulator
DMJDG37	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMJDG37	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMD9PZQ	DI	DMD9PZQ
DMD9PZQ	DN	Ethynyl compound 3
DMD9PZQ	MI	TTHS256
DMD9PZQ	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMD9PZQ	MT	DTT
DMD9PZQ	MA	Modulator
DMD9PZQ	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMD9PZQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMLDMO8	DI	DMLDMO8
DMLDMO8	DN	Ethynyl compound 4
DMLDMO8	MI	TTHS256
DMLDMO8	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMLDMO8	MT	DTT
DMLDMO8	MA	Modulator
DMLDMO8	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMLDMO8	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DM53ZPE	DI	DM53ZPE
DM53ZPE	DN	Ethynyl compound 5
DM53ZPE	MI	TTHS256
DM53ZPE	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM53ZPE	MT	DTT
DM53ZPE	MA	Modulator
DM53ZPE	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DM53ZPE	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMDOEFC	DI	DMDOEFC
DMDOEFC	DN	Ethynyl compound 6
DMDOEFC	MI	TTHS256
DMDOEFC	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMDOEFC	MT	DTT
DMDOEFC	MA	Modulator
DMDOEFC	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMDOEFC	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMPUG2M	DI	DMPUG2M
DMPUG2M	DN	Ethynyl compound 7
DMPUG2M	MI	TTHS256
DMPUG2M	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMPUG2M	MT	DTT
DMPUG2M	MA	Modulator
DMPUG2M	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMPUG2M	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DM7US1H	DI	DM7US1H
DM7US1H	DN	Eugenol
DM7US1H	MI	TTKPW01
DM7US1H	MN	Androgen receptor messenger RNA (AR mRNA)
DM7US1H	MT	DTT
DM7US1H	MA	Inhibitor
DM7US1H	RN	Effect of essential oils, such as raspberry ketone and its derivatives, on antiandrogenic activity based on in vitro reporter gene assay. Bioorg Med Chem Lett. 2010 Apr 1;20(7):2111-4.
DM7US1H	RU	https://pubmed.ncbi.nlm.nih.gov/20226658

DM7US1H	DI	DM7US1H
DM7US1H	DN	Eugenol
DM7US1H	MI	TTGP7BY
DM7US1H	MN	Monoamine oxidase type B (MAO-B)
DM7US1H	MT	DTT
DM7US1H	MA	Inhibitor
DM7US1H	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DM7US1H	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DM7US1H	DI	DM7US1H
DM7US1H	DN	Eugenol
DM7US1H	MI	DEYGVN4
DM7US1H	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM7US1H	MT	DME
DM7US1H	MA	Metabolism
DM7US1H	RN	Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Biol Chem. 2004 Jan 9;279(2):1429-41.
DM7US1H	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14557274

DM7US1H	DI	DM7US1H
DM7US1H	DN	Eugenol
DM7US1H	MI	DEZO4N3
DM7US1H	MN	UDP-glucuronosyltransferase 1A7 (UGT1A7)
DM7US1H	MT	DME
DM7US1H	MA	Metabolism
DM7US1H	RN	Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Biol Chem. 2004 Jan 9;279(2):1429-41.
DM7US1H	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14557274

DM7US1H	DI	DM7US1H
DM7US1H	DN	Eugenol
DM7US1H	MI	DE2GB8N
DM7US1H	MN	UDP-glucuronosyltransferase 1A8 (UGT1A8)
DM7US1H	MT	DME
DM7US1H	MA	Metabolism
DM7US1H	RN	Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Biol Chem. 2004 Jan 9;279(2):1429-41.
DM7US1H	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14557274

DM7US1H	DI	DM7US1H
DM7US1H	DN	Eugenol
DM7US1H	MI	DE85D2P
DM7US1H	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DM7US1H	MT	DME
DM7US1H	MA	Metabolism
DM7US1H	RN	Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Biol Chem. 2004 Jan 9;279(2):1429-41.
DM7US1H	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14557274

DMJC7NF	DI	DMJC7NF
DMJC7NF	DN	Ferulic Acid
DMJC7NF	MI	TTUNARX
DMJC7NF	MN	Carbonic anhydrase (CA)
DMJC7NF	MT	DTT
DMJC7NF	MA	Inhibitor
DMJC7NF	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DMJC7NF	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DMJC7NF	DI	DMJC7NF
DMJC7NF	DN	Ferulic Acid
DMJC7NF	MI	TTHQPL7
DMJC7NF	MN	Carbonic anhydrase I (CA-I)
DMJC7NF	MT	DTT
DMJC7NF	MA	Inhibitor
DMJC7NF	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DMJC7NF	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DMJC7NF	DI	DMJC7NF
DMJC7NF	DN	Ferulic Acid
DMJC7NF	MI	TTANPDJ
DMJC7NF	MN	Carbonic anhydrase II (CA-II)
DMJC7NF	MT	DTT
DMJC7NF	MA	Inhibitor
DMJC7NF	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DMJC7NF	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DMJC7NF	DI	DMJC7NF
DMJC7NF	DN	Ferulic Acid
DMJC7NF	MI	TTZHA0O
DMJC7NF	MN	Carbonic anhydrase IV (CA-IV)
DMJC7NF	MT	DTT
DMJC7NF	MA	Inhibitor
DMJC7NF	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DMJC7NF	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DMJC7NF	DI	DMJC7NF
DMJC7NF	DN	Ferulic Acid
DMJC7NF	MI	TT2LVK8
DMJC7NF	MN	Carbonic anhydrase IX (CA-IX)
DMJC7NF	MT	DTT
DMJC7NF	MA	Inhibitor
DMJC7NF	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DMJC7NF	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DMJC7NF	DI	DMJC7NF
DMJC7NF	DN	Ferulic Acid
DMJC7NF	MI	TTCFSPE
DMJC7NF	MN	Carbonic anhydrase VI (CA-VI)
DMJC7NF	MT	DTT
DMJC7NF	MA	Inhibitor
DMJC7NF	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DMJC7NF	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DMJC7NF	DI	DMJC7NF
DMJC7NF	DN	Ferulic Acid
DMJC7NF	MI	TTSYM0R
DMJC7NF	MN	Carbonic anhydrase XII (CA-XII)
DMJC7NF	MT	DTT
DMJC7NF	MA	Inhibitor
DMJC7NF	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DMJC7NF	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DMJC7NF	DI	DMJC7NF
DMJC7NF	DN	Ferulic Acid
DMJC7NF	MI	TTEYTKG
DMJC7NF	MN	Carbonic anhydrase XIV (CA-XIV)
DMJC7NF	MT	DTT
DMJC7NF	MA	Inhibitor
DMJC7NF	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DMJC7NF	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DMJC7NF	DI	DMJC7NF
DMJC7NF	DN	Ferulic Acid
DMJC7NF	MI	TTGP7BY
DMJC7NF	MN	Monoamine oxidase type B (MAO-B)
DMJC7NF	MT	DTT
DMJC7NF	MA	Inhibitor
DMJC7NF	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMJC7NF	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMPFAST	DI	DMPFAST
DMPFAST	DN	Five membered heterocyclic benzamide derivative 1
DMPFAST	MI	TTTDVOJ
DMPFAST	MN	Tropomyosin-related kinase A (TrkA)
DMPFAST	MT	DTT
DMPFAST	MA	Inhibitor
DMPFAST	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMPFAST	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DM4U63E	DI	DM4U63E
DM4U63E	DN	Five membered heterocyclic benzamide derivative 2
DM4U63E	MI	TTTDVOJ
DM4U63E	MN	Tropomyosin-related kinase A (TrkA)
DM4U63E	MT	DTT
DM4U63E	MA	Inhibitor
DM4U63E	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DM4U63E	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMUS4Z0	DI	DMUS4Z0
DMUS4Z0	DN	Five membered heterocyclic benzamide derivative 3
DMUS4Z0	MI	TTTDVOJ
DMUS4Z0	MN	Tropomyosin-related kinase A (TrkA)
DMUS4Z0	MT	DTT
DMUS4Z0	MA	Inhibitor
DMUS4Z0	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMUS4Z0	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DM7SK5Q	DI	DM7SK5Q
DM7SK5Q	DN	Five-and-six-membered heterocyclic compound 1
DM7SK5Q	MI	TT6DM01
DM7SK5Q	MN	Janus kinase 1 (JAK-1)
DM7SK5Q	MT	DTT
DM7SK5Q	MA	Inhibitor
DM7SK5Q	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DM7SK5Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DM7SK5Q	DI	DM7SK5Q
DM7SK5Q	DN	Five-and-six-membered heterocyclic compound 1
DM7SK5Q	MI	TTRMX3V
DM7SK5Q	MN	Janus kinase 2 (JAK-2)
DM7SK5Q	MT	DTT
DM7SK5Q	MA	Inhibitor
DM7SK5Q	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DM7SK5Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DM7SK5Q	DI	DM7SK5Q
DM7SK5Q	DN	Five-and-six-membered heterocyclic compound 1
DM7SK5Q	MI	TTT7PJU
DM7SK5Q	MN	Janus kinase 3 (JAK-3)
DM7SK5Q	MT	DTT
DM7SK5Q	MA	Inhibitor
DM7SK5Q	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DM7SK5Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMO8UKD	DI	DMO8UKD
DMO8UKD	DN	Five-membered heteroaromatic compound 1
DMO8UKD	MI	TTZJYKH
DMO8UKD	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMO8UKD	MT	DTT
DMO8UKD	MA	Inhibitor
DMO8UKD	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMO8UKD	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DM1QH8Z	DI	DM1QH8Z
DM1QH8Z	DN	Five-membered heteroaromatic compound 2
DM1QH8Z	MI	TTZJYKH
DM1QH8Z	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DM1QH8Z	MT	DTT
DM1QH8Z	MA	Inhibitor
DM1QH8Z	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DM1QH8Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMS0P9E	DI	DMS0P9E
DMS0P9E	DN	Five-membered heteroaromatic compound 3
DMS0P9E	MI	TTZJYKH
DMS0P9E	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMS0P9E	MT	DTT
DMS0P9E	MA	Inhibitor
DMS0P9E	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMS0P9E	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMCQP0B	DI	DMCQP0B
DMCQP0B	DN	Flavonoid derivative 1
DMCQP0B	MI	TTH8FZW
DMCQP0B	MN	Signal transducer and activator of transcription 3 (STAT3)
DMCQP0B	MT	DTT
DMCQP0B	MA	Inhibitor
DMCQP0B	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMCQP0B	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMWZARV	DI	DMWZARV
DMWZARV	DN	Flavonoid derivative 2
DMWZARV	MI	TTH8FZW
DMWZARV	MN	Signal transducer and activator of transcription 3 (STAT3)
DMWZARV	MT	DTT
DMWZARV	MA	Inhibitor
DMWZARV	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMWZARV	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMT7ZEL	DI	DMT7ZEL
DMT7ZEL	DN	Flavonoid derivative 3
DMT7ZEL	MI	TTH8FZW
DMT7ZEL	MN	Signal transducer and activator of transcription 3 (STAT3)
DMT7ZEL	MT	DTT
DMT7ZEL	MA	Inhibitor
DMT7ZEL	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMT7ZEL	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMMOSVD	DI	DMMOSVD
DMMOSVD	DN	Flavonoid derivative 4
DMMOSVD	MI	TTH8FZW
DMMOSVD	MN	Signal transducer and activator of transcription 3 (STAT3)
DMMOSVD	MT	DTT
DMMOSVD	MA	Inhibitor
DMMOSVD	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMMOSVD	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMTWAJX	DI	DMTWAJX
DMTWAJX	DN	Flavonoid derivative 5
DMTWAJX	MI	TTH8FZW
DMTWAJX	MN	Signal transducer and activator of transcription 3 (STAT3)
DMTWAJX	MT	DTT
DMTWAJX	MA	Inhibitor
DMTWAJX	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMTWAJX	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DM0E38G	DI	DM0E38G
DM0E38G	DN	Flavonoid derivative 6
DM0E38G	MI	TTV8CRH
DM0E38G	MN	Lysine-specific demethylase 4C (KDM4C)
DM0E38G	MT	DTT
DM0E38G	MA	Inhibitor
DM0E38G	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DM0E38G	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DM6A9UR	DI	DM6A9UR
DM6A9UR	DN	Flavonoid derivative 7
DM6A9UR	MI	TTL4Q97
DM6A9UR	MN	Cyclin-dependent kinase 5 (CDK5)
DM6A9UR	MT	DTT
DM6A9UR	MA	Inhibitor
DM6A9UR	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DM6A9UR	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DM4O9T3	DI	DM4O9T3
DM4O9T3	DN	Flavonoid derivative 8
DM4O9T3	MI	TTJ584C
DM4O9T3	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DM4O9T3	MT	DTT
DM4O9T3	MA	Agonist
DM4O9T3	RN	PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
DM4O9T3	RU	https://www.ncbi.nlm.nih.gov/pubmed/25416646

DM4O9T3	DI	DM4O9T3
DM4O9T3	DN	Flavonoid derivative 8
DM4O9T3	MI	TTZMAO3
DM4O9T3	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DM4O9T3	MT	DTT
DM4O9T3	MA	Agonist
DM4O9T3	RN	PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
DM4O9T3	RU	https://www.ncbi.nlm.nih.gov/pubmed/25416646

DMXL3A5	DI	DMXL3A5
DMXL3A5	DN	Flavopiridol analog 1
DMXL3A5	MI	TT7HF4W
DMXL3A5	MN	Cyclin-dependent kinase 2 (CDK2)
DMXL3A5	MT	DTT
DMXL3A5	MA	Inhibitor
DMXL3A5	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMXL3A5	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMXL3A5	DI	DMXL3A5
DMXL3A5	DN	Flavopiridol analog 1
DMXL3A5	MI	TT1LVF2
DMXL3A5	MN	Cyclin-dependent kinase 9 (CDK9)
DMXL3A5	MT	DTT
DMXL3A5	MA	Inhibitor
DMXL3A5	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMXL3A5	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMGOSN2	DI	DMGOSN2
DMGOSN2	DN	Fluorinated compound 1
DMGOSN2	MI	TT7HF4W
DMGOSN2	MN	Cyclin-dependent kinase 2 (CDK2)
DMGOSN2	MT	DTT
DMGOSN2	MA	Inhibitor
DMGOSN2	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMGOSN2	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMQOGHN	DI	DMQOGHN
DMQOGHN	DN	Fluorinated donepezil derivative 1
DMQOGHN	MI	TT1RS9F
DMQOGHN	MN	Acetylcholinesterase (AChE)
DMQOGHN	MT	DTT
DMQOGHN	MA	Inhibitor
DMQOGHN	RN	Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476.
DMQOGHN	RU	https://www.ncbi.nlm.nih.gov/pubmed/27967267

DMV1SCA	DI	DMV1SCA
DMV1SCA	DN	Fluorinated donepezil derivative 2
DMV1SCA	MI	TT1RS9F
DMV1SCA	MN	Acetylcholinesterase (AChE)
DMV1SCA	MT	DTT
DMV1SCA	MA	Inhibitor
DMV1SCA	RN	Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476.
DMV1SCA	RU	https://www.ncbi.nlm.nih.gov/pubmed/27967267

DMTS8O9	DI	DMTS8O9
DMTS8O9	DN	Fluorophenyl-substituted heterocyclic amide analog 1
DMTS8O9	MI	TT473XN
DMTS8O9	MN	P2X purinoceptor 7 (P2RX7)
DMTS8O9	MT	DTT
DMTS8O9	MA	Antagonist
DMTS8O9	RN	P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267.
DMTS8O9	RU	https://www.ncbi.nlm.nih.gov/pubmed/27724045

DM2QXVW	DI	DM2QXVW
DM2QXVW	DN	Furopyridine derivative 1
DM2QXVW	MI	TT6OEDT
DM2QXVW	MN	Cannabinoid receptor 1 (CB1)
DM2QXVW	MT	DTT
DM2QXVW	MA	Antagonist
DM2QXVW	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DM2QXVW	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMEU3J9	DI	DMEU3J9
DMEU3J9	DN	Furopyridine derivative 2
DMEU3J9	MI	TT6OEDT
DMEU3J9	MN	Cannabinoid receptor 1 (CB1)
DMEU3J9	MT	DTT
DMEU3J9	MA	Antagonist
DMEU3J9	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMEU3J9	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DM4EUFL	DI	DM4EUFL
DM4EUFL	DN	Fused aromatic compound 1
DM4EUFL	MI	TTZMAO3
DM4EUFL	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DM4EUFL	MT	DTT
DM4EUFL	MA	Agonist
DM4EUFL	RN	PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
DM4EUFL	RU	https://www.ncbi.nlm.nih.gov/pubmed/25416646

DMFAM8B	DI	DMFAM8B
DMFAM8B	DN	Fused aryl carbocycle derivative 1
DMFAM8B	MI	TT9NXW4
DMFAM8B	MN	Sigma intracellular receptor 2 (TMEM97)
DMFAM8B	MT	DTT
DMFAM8B	MA	Ligand
DMFAM8B	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DMFAM8B	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DMAQBJP	DI	DMAQBJP
DMAQBJP	DN	Fused aryl carbocycle derivative 2
DMAQBJP	MI	TT9NXW4
DMAQBJP	MN	Sigma intracellular receptor 2 (TMEM97)
DMAQBJP	MT	DTT
DMAQBJP	MA	Ligand
DMAQBJP	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DMAQBJP	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DM5I4CA	DI	DM5I4CA
DM5I4CA	DN	Fused aryl carbocycle derivative 3
DM5I4CA	MI	TT9NXW4
DM5I4CA	MN	Sigma intracellular receptor 2 (TMEM97)
DM5I4CA	MT	DTT
DM5I4CA	MA	Ligand
DM5I4CA	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DM5I4CA	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DMOU8T3	DI	DMOU8T3
DMOU8T3	DN	Fused aryl carbocycle derivative 4
DMOU8T3	MI	TT9NXW4
DMOU8T3	MN	Sigma intracellular receptor 2 (TMEM97)
DMOU8T3	MT	DTT
DMOU8T3	MA	Ligand
DMOU8T3	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DMOU8T3	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DMPBMEU	DI	DMPBMEU
DMPBMEU	DN	Fused aryl carbocycle derivative 8
DMPBMEU	MI	TT9NXW4
DMPBMEU	MN	Sigma intracellular receptor 2 (TMEM97)
DMPBMEU	MT	DTT
DMPBMEU	MA	Ligand
DMPBMEU	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DMPBMEU	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DMQ2X6O	DI	DMQ2X6O
DMQ2X6O	DN	Fused aryl carbocycle derivative 9
DMQ2X6O	MI	TT9NXW4
DMQ2X6O	MN	Sigma intracellular receptor 2 (TMEM97)
DMQ2X6O	MT	DTT
DMQ2X6O	MA	Ligand
DMQ2X6O	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DMQ2X6O	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DMKLO2H	DI	DMKLO2H
DMKLO2H	DN	Fused benzoheterocycle amide derivative 1
DMKLO2H	MI	TTKFVXR
DMKLO2H	MN	Renal carcinoma antigen NY-REN-64 (IRAK-4)
DMKLO2H	MT	DTT
DMKLO2H	MA	Inhibitor
DMKLO2H	RN	Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32.
DMKLO2H	RU	https://www.ncbi.nlm.nih.gov/pubmed/27310003

DM9NMHS	DI	DM9NMHS
DM9NMHS	DN	Fused benzoheterocycle amide derivative 2
DM9NMHS	MI	TTKFVXR
DM9NMHS	MN	Renal carcinoma antigen NY-REN-64 (IRAK-4)
DM9NMHS	MT	DTT
DM9NMHS	MA	Inhibitor
DM9NMHS	RN	Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32.
DM9NMHS	RU	https://www.ncbi.nlm.nih.gov/pubmed/27310003

DMVU9RG	DI	DMVU9RG
DMVU9RG	DN	Fused heterocyclic compound 1
DMVU9RG	MI	TT7RJY8
DMVU9RG	MN	Xanthine dehydrogenase/oxidase (XDH)
DMVU9RG	MT	DTT
DMVU9RG	MA	Inhibitor
DMVU9RG	RN	An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
DMVU9RG	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841045

DMALDZ6	DI	DMALDZ6
DMALDZ6	DN	Fused heterocyclic compound 10
DMALDZ6	MI	TT7RJY8
DMALDZ6	MN	Xanthine dehydrogenase/oxidase (XDH)
DMALDZ6	MT	DTT
DMALDZ6	MA	Inhibitor
DMALDZ6	RN	An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
DMALDZ6	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841045

DMJC4UZ	DI	DMJC4UZ
DMJC4UZ	DN	Fused heterocyclic compound 11
DMJC4UZ	MI	TT7RJY8
DMJC4UZ	MN	Xanthine dehydrogenase/oxidase (XDH)
DMJC4UZ	MT	DTT
DMJC4UZ	MA	Inhibitor
DMJC4UZ	RN	An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
DMJC4UZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841045

DMSYD6Z	DI	DMSYD6Z
DMSYD6Z	DN	Fused heterocyclic compound 12
DMSYD6Z	MI	TTA592U
DMSYD6Z	MN	Urate anion exchanger 1 (URAT1)
DMSYD6Z	MT	DTT
DMSYD6Z	MA	Inhibitor
DMSYD6Z	RN	Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10.
DMSYD6Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/27414413

DM361J8	DI	DM361J8
DM361J8	DN	Fused heterocyclic compound 2
DM361J8	MI	TT7RJY8
DM361J8	MN	Xanthine dehydrogenase/oxidase (XDH)
DM361J8	MT	DTT
DM361J8	MA	Inhibitor
DM361J8	RN	An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
DM361J8	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841045

DM2QVHY	DI	DM2QVHY
DM2QVHY	DN	Fused heterocyclic compound 3
DM2QVHY	MI	TT7RJY8
DM2QVHY	MN	Xanthine dehydrogenase/oxidase (XDH)
DM2QVHY	MT	DTT
DM2QVHY	MA	Inhibitor
DM2QVHY	RN	An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
DM2QVHY	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841045

DMHTS5G	DI	DMHTS5G
DMHTS5G	DN	Fused heterocyclic compound 4
DMHTS5G	MI	TT7RJY8
DMHTS5G	MN	Xanthine dehydrogenase/oxidase (XDH)
DMHTS5G	MT	DTT
DMHTS5G	MA	Inhibitor
DMHTS5G	RN	An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
DMHTS5G	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841045

DM10CGB	DI	DM10CGB
DM10CGB	DN	Fused heterocyclic compound 5
DM10CGB	MI	TT7RJY8
DM10CGB	MN	Xanthine dehydrogenase/oxidase (XDH)
DM10CGB	MT	DTT
DM10CGB	MA	Inhibitor
DM10CGB	RN	An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
DM10CGB	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841045

DM9DC3U	DI	DM9DC3U
DM9DC3U	DN	Fused heterocyclic compound 6
DM9DC3U	MI	TT7RJY8
DM9DC3U	MN	Xanthine dehydrogenase/oxidase (XDH)
DM9DC3U	MT	DTT
DM9DC3U	MA	Inhibitor
DM9DC3U	RN	An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
DM9DC3U	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841045

DMGNWJD	DI	DMGNWJD
DMGNWJD	DN	Fused heterocyclic compound 7
DMGNWJD	MI	TT7RJY8
DMGNWJD	MN	Xanthine dehydrogenase/oxidase (XDH)
DMGNWJD	MT	DTT
DMGNWJD	MA	Inhibitor
DMGNWJD	RN	An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
DMGNWJD	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841045

DMO8JE7	DI	DMO8JE7
DMO8JE7	DN	Fused heterocyclic compound 8
DMO8JE7	MI	TT7RJY8
DMO8JE7	MN	Xanthine dehydrogenase/oxidase (XDH)
DMO8JE7	MT	DTT
DMO8JE7	MA	Inhibitor
DMO8JE7	RN	An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
DMO8JE7	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841045

DM25IMA	DI	DM25IMA
DM25IMA	DN	Fused heterocyclic compound 9
DM25IMA	MI	TT7RJY8
DM25IMA	MN	Xanthine dehydrogenase/oxidase (XDH)
DM25IMA	MT	DTT
DM25IMA	MA	Inhibitor
DM25IMA	RN	An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
DM25IMA	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841045

DMPHL3J	DI	DMPHL3J
DMPHL3J	DN	Fused ring compound 1
DMPHL3J	MI	TTZMAO3
DMPHL3J	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMPHL3J	MT	DTT
DMPHL3J	MA	Agonist
DMPHL3J	RN	PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
DMPHL3J	RU	https://www.ncbi.nlm.nih.gov/pubmed/25416646

DMV7IX4	DI	DMV7IX4
DMV7IX4	DN	Fused thiophene derivative 1
DMV7IX4	MI	TTK0FEA
DMV7IX4	MN	Leucine-rich repeat kinase 2 (LRRK2)
DMV7IX4	MT	DTT
DMV7IX4	MA	Inhibitor
DMV7IX4	RN	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
DMV7IX4	RU	https://www.ncbi.nlm.nih.gov/pubmed/28117607

DMV7IX4	DI	DMV7IX4
DMV7IX4	DN	Fused thiophene derivative 1
DMV7IX4	MI	TTC7A6G
DMV7IX4	MN	Leucine-rich repeat kinase 2 S935 phosphorylation (LRRK2 pS935)
DMV7IX4	MT	DTT
DMV7IX4	MA	Inhibitor
DMV7IX4	RN	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
DMV7IX4	RU	https://www.ncbi.nlm.nih.gov/pubmed/28117607

DM4Z72S	DI	DM4Z72S
DM4Z72S	DN	Fused triazoloamino-phenyl analog 1
DM4Z72S	MI	TT473XN
DM4Z72S	MN	P2X purinoceptor 7 (P2RX7)
DM4Z72S	MT	DTT
DM4Z72S	MA	Antagonist
DM4Z72S	RN	P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267.
DM4Z72S	RU	https://www.ncbi.nlm.nih.gov/pubmed/27724045

DM5BVCS	DI	DM5BVCS
DM5BVCS	DN	Galantamine analog 1
DM5BVCS	MI	TT1RS9F
DM5BVCS	MN	Acetylcholinesterase (AChE)
DM5BVCS	MT	DTT
DM5BVCS	MA	Inhibitor
DM5BVCS	RN	Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476.
DM5BVCS	RU	https://www.ncbi.nlm.nih.gov/pubmed/27967267

DMK6RFS	DI	DMK6RFS
DMK6RFS	DN	Geminally-substituted cyanoethylpypazolo pyridone derivative 1
DMK6RFS	MI	TT6DM01
DMK6RFS	MN	Janus kinase 1 (JAK-1)
DMK6RFS	MT	DTT
DMK6RFS	MA	Inhibitor
DMK6RFS	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMK6RFS	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMK6RFS	DI	DMK6RFS
DMK6RFS	DN	Geminally-substituted cyanoethylpypazolo pyridone derivative 1
DMK6RFS	MI	TTRMX3V
DMK6RFS	MN	Janus kinase 2 (JAK-2)
DMK6RFS	MT	DTT
DMK6RFS	MA	Inhibitor
DMK6RFS	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMK6RFS	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMB2INX	DI	DMB2INX
DMB2INX	DN	Geminally-substituted cyanoethylpypazolo pyridone derivative 2
DMB2INX	MI	TT6DM01
DMB2INX	MN	Janus kinase 1 (JAK-1)
DMB2INX	MT	DTT
DMB2INX	MA	Inhibitor
DMB2INX	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMB2INX	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMB2INX	DI	DMB2INX
DMB2INX	DN	Geminally-substituted cyanoethylpypazolo pyridone derivative 2
DMB2INX	MI	TTRMX3V
DMB2INX	MN	Janus kinase 2 (JAK-2)
DMB2INX	MT	DTT
DMB2INX	MA	Inhibitor
DMB2INX	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMB2INX	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMT1EH9	DI	DMT1EH9
DMT1EH9	DN	Gold-complexed thiosaccharide derivative 1
DMT1EH9	MI	TTH8FZW
DMT1EH9	MN	Signal transducer and activator of transcription 3 (STAT3)
DMT1EH9	MT	DTT
DMT1EH9	MA	Inhibitor
DMT1EH9	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMT1EH9	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DM9U4OZ	DI	DM9U4OZ
DM9U4OZ	DN	Gold-complexed thiosaccharide derivative 2
DM9U4OZ	MI	TTH8FZW
DM9U4OZ	MN	Signal transducer and activator of transcription 3 (STAT3)
DM9U4OZ	MT	DTT
DM9U4OZ	MA	Inhibitor
DM9U4OZ	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DM9U4OZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMMOGL8	DI	DMMOGL8
DMMOGL8	DN	Gold-complexed thiosaccharide derivative 3
DMMOGL8	MI	TTH8FZW
DMMOGL8	MN	Signal transducer and activator of transcription 3 (STAT3)
DMMOGL8	MT	DTT
DMMOGL8	MA	Inhibitor
DMMOGL8	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMMOGL8	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMVAKUI	DI	DMVAKUI
DMVAKUI	DN	Golden phosphorous acetyletic compound 1
DMVAKUI	MI	TTR7UJ3
DMVAKUI	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMVAKUI	MT	DTT
DMVAKUI	MA	Inhibitor
DMVAKUI	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMVAKUI	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DMVAKUI	DI	DMVAKUI
DMVAKUI	DN	Golden phosphorous acetyletic compound 1
DMVAKUI	MI	TTEP6RV
DMVAKUI	MN	Glutathione reductase (GR)
DMVAKUI	MT	DTT
DMVAKUI	MA	Inhibitor
DMVAKUI	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMVAKUI	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DMYJ15A	DI	DMYJ15A
DMYJ15A	DN	Golden phosphorous acetyletic compound 2
DMYJ15A	MI	TTR7UJ3
DMYJ15A	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMYJ15A	MT	DTT
DMYJ15A	MA	Inhibitor
DMYJ15A	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMYJ15A	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DMYJ15A	DI	DMYJ15A
DMYJ15A	DN	Golden phosphorous acetyletic compound 2
DMYJ15A	MI	TTEP6RV
DMYJ15A	MN	Glutathione reductase (GR)
DMYJ15A	MT	DTT
DMYJ15A	MA	Inhibitor
DMYJ15A	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMYJ15A	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DMRUCK8	DI	DMRUCK8
DMRUCK8	DN	Golden phosphorous acetyletic compound 3
DMRUCK8	MI	TTR7UJ3
DMRUCK8	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMRUCK8	MT	DTT
DMRUCK8	MA	Inhibitor
DMRUCK8	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMRUCK8	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DMFHC0O	DI	DMFHC0O
DMFHC0O	DN	GypensapogeninA
DMFHC0O	MI	TT3WG5C
DMFHC0O	MN	Monoamine oxidase type A (MAO-A)
DMFHC0O	MT	DTT
DMFHC0O	MA	Inhibitor
DMFHC0O	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMFHC0O	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMX4ET5	DI	DMX4ET5
DMX4ET5	DN	GypensapogeninB
DMX4ET5	MI	TT3WG5C
DMX4ET5	MN	Monoamine oxidase type A (MAO-A)
DMX4ET5	MT	DTT
DMX4ET5	MA	Inhibitor
DMX4ET5	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMX4ET5	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMM78UR	DI	DMM78UR
DMM78UR	DN	H3K7T
DMM78UR	MI	TTSCO7R
DMM78UR	MN	NAD-dependent deacetylase sirtuin (SIRT)
DMM78UR	MT	DTT
DMM78UR	MA	Inhibitor
DMM78UR	RN	Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15.
DMM78UR	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435179

DMPA5WD	DI	DMPA5WD
DMPA5WD	DN	Harmine
DMPA5WD	MI	TTSBVFO
DMPA5WD	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DMPA5WD	MT	DTT
DMPA5WD	MA	Inhibitor
DMPA5WD	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMPA5WD	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMPA5WD	DI	DMPA5WD
DMPA5WD	DN	Harmine
DMPA5WD	MI	TT84OS6
DMPA5WD	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 2 (DYRK2)
DMPA5WD	MT	DTT
DMPA5WD	MA	Inhibitor
DMPA5WD	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMPA5WD	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMPA5WD	DI	DMPA5WD
DMPA5WD	DN	Harmine
DMPA5WD	MI	TTV4EX0
DMPA5WD	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 3 (DYRK3)
DMPA5WD	MT	DTT
DMPA5WD	MA	Inhibitor
DMPA5WD	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMPA5WD	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMPA5WD	DI	DMPA5WD
DMPA5WD	DN	Harmine
DMPA5WD	MI	TT3WG5C
DMPA5WD	MN	Monoamine oxidase type A (MAO-A)
DMPA5WD	MT	DTT
DMPA5WD	MA	Inhibitor
DMPA5WD	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMPA5WD	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMI732U	DI	DMI732U
DMI732U	DN	Heteroaromatic ring derivative 1
DMI732U	MI	TTSCIM2
DMI732U	MN	Extracellular lysophospholipase D (E-NPP2)
DMI732U	MT	DTT
DMI732U	MA	Inhibitor
DMI732U	RN	Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829.
DMI732U	RU	https://www.ncbi.nlm.nih.gov/pubmed/28447479

DM5YD4W	DI	DM5YD4W
DM5YD4W	DN	Heteroaromatic ring derivative 2
DM5YD4W	MI	TTSCIM2
DM5YD4W	MN	Extracellular lysophospholipase D (E-NPP2)
DM5YD4W	MT	DTT
DM5YD4W	MA	Inhibitor
DM5YD4W	RN	Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829.
DM5YD4W	RU	https://www.ncbi.nlm.nih.gov/pubmed/28447479

DMKJL5T	DI	DMKJL5T
DMKJL5T	DN	Heteroaromatic ring derivative 3
DMKJL5T	MI	TTSCIM2
DMKJL5T	MN	Extracellular lysophospholipase D (E-NPP2)
DMKJL5T	MT	DTT
DMKJL5T	MA	Inhibitor
DMKJL5T	RN	Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829.
DMKJL5T	RU	https://www.ncbi.nlm.nih.gov/pubmed/28447479

DM9IL5Q	DI	DM9IL5Q
DM9IL5Q	DN	Heteroaromatic ring derivative 4
DM9IL5Q	MI	TTSCIM2
DM9IL5Q	MN	Extracellular lysophospholipase D (E-NPP2)
DM9IL5Q	MT	DTT
DM9IL5Q	MA	Inhibitor
DM9IL5Q	RN	Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829.
DM9IL5Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/28447479

DMDOQKY	DI	DMDOQKY
DMDOQKY	DN	Heteroaryl-azepine derivative 1
DMDOQKY	MI	TTWJBZ5
DMDOQKY	MN	5-HT 2C receptor (HTR2C)
DMDOQKY	MT	DTT
DMDOQKY	MA	Agonist
DMDOQKY	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMDOQKY	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMMZ8LE	DI	DMMZ8LE
DMMZ8LE	DN	Heteroaryl-azepine derivative 10
DMMZ8LE	MI	TTWJBZ5
DMMZ8LE	MN	5-HT 2C receptor (HTR2C)
DMMZ8LE	MT	DTT
DMMZ8LE	MA	Agonist
DMMZ8LE	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMMZ8LE	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DM5BF6H	DI	DM5BF6H
DM5BF6H	DN	Heteroaryl-azepine derivative 11
DM5BF6H	MI	TTWJBZ5
DM5BF6H	MN	5-HT 2C receptor (HTR2C)
DM5BF6H	MT	DTT
DM5BF6H	MA	Agonist
DM5BF6H	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DM5BF6H	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMOG72B	DI	DMOG72B
DMOG72B	DN	Heteroaryl-azepine derivative 12
DMOG72B	MI	TTWJBZ5
DMOG72B	MN	5-HT 2C receptor (HTR2C)
DMOG72B	MT	DTT
DMOG72B	MA	Agonist
DMOG72B	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMOG72B	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DME86DP	DI	DME86DP
DME86DP	DN	Heteroaryl-azepine derivative 13
DME86DP	MI	TTWJBZ5
DME86DP	MN	5-HT 2C receptor (HTR2C)
DME86DP	MT	DTT
DME86DP	MA	Agonist
DME86DP	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DME86DP	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMG1TIF	DI	DMG1TIF
DMG1TIF	DN	Heteroaryl-azepine derivative 14
DMG1TIF	MI	TTWJBZ5
DMG1TIF	MN	5-HT 2C receptor (HTR2C)
DMG1TIF	MT	DTT
DMG1TIF	MA	Agonist
DMG1TIF	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMG1TIF	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMS3WEJ	DI	DMS3WEJ
DMS3WEJ	DN	Heteroaryl-azepine derivative 15
DMS3WEJ	MI	TTWJBZ5
DMS3WEJ	MN	5-HT 2C receptor (HTR2C)
DMS3WEJ	MT	DTT
DMS3WEJ	MA	Agonist
DMS3WEJ	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMS3WEJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMDFL6B	DI	DMDFL6B
DMDFL6B	DN	Heteroaryl-azepine derivative 2
DMDFL6B	MI	TTWJBZ5
DMDFL6B	MN	5-HT 2C receptor (HTR2C)
DMDFL6B	MT	DTT
DMDFL6B	MA	Agonist
DMDFL6B	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMDFL6B	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMG14E3	DI	DMG14E3
DMG14E3	DN	Heteroaryl-azepine derivative 3
DMG14E3	MI	TTWJBZ5
DMG14E3	MN	5-HT 2C receptor (HTR2C)
DMG14E3	MT	DTT
DMG14E3	MA	Agonist
DMG14E3	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMG14E3	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMZVLH2	DI	DMZVLH2
DMZVLH2	DN	Heteroaryl-azepine derivative 4
DMZVLH2	MI	TTWJBZ5
DMZVLH2	MN	5-HT 2C receptor (HTR2C)
DMZVLH2	MT	DTT
DMZVLH2	MA	Agonist
DMZVLH2	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMZVLH2	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMON5RD	DI	DMON5RD
DMON5RD	DN	Heteroaryl-azepine derivative 5
DMON5RD	MI	TTWJBZ5
DMON5RD	MN	5-HT 2C receptor (HTR2C)
DMON5RD	MT	DTT
DMON5RD	MA	Agonist
DMON5RD	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMON5RD	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DM3O7UG	DI	DM3O7UG
DM3O7UG	DN	Heteroaryl-azepine derivative 6
DM3O7UG	MI	TTWJBZ5
DM3O7UG	MN	5-HT 2C receptor (HTR2C)
DM3O7UG	MT	DTT
DM3O7UG	MA	Agonist
DM3O7UG	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DM3O7UG	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMS6HOG	DI	DMS6HOG
DMS6HOG	DN	Heteroaryl-azepine derivative 7
DMS6HOG	MI	TTWJBZ5
DMS6HOG	MN	5-HT 2C receptor (HTR2C)
DMS6HOG	MT	DTT
DMS6HOG	MA	Agonist
DMS6HOG	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMS6HOG	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMBJH8N	DI	DMBJH8N
DMBJH8N	DN	Heteroaryl-azepine derivative 8
DMBJH8N	MI	TTWJBZ5
DMBJH8N	MN	5-HT 2C receptor (HTR2C)
DMBJH8N	MT	DTT
DMBJH8N	MA	Agonist
DMBJH8N	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMBJH8N	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMUZR3X	DI	DMUZR3X
DMUZR3X	DN	Heteroaryl-azepine derivative 9
DMUZR3X	MI	TTWJBZ5
DMUZR3X	MN	5-HT 2C receptor (HTR2C)
DMUZR3X	MT	DTT
DMUZR3X	MA	Agonist
DMUZR3X	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMUZR3X	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMPRF1K	DI	DMPRF1K
DMPRF1K	DN	Heteroaryl-carboxamide derivative 1
DMPRF1K	MI	TTCZOF2
DMPRF1K	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMPRF1K	MT	DTT
DMPRF1K	MA	Inhibitor
DMPRF1K	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMPRF1K	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMVTARK	DI	DMVTARK
DMVTARK	DN	Heteroaryl-carboxamide derivative 10
DMVTARK	MI	TTCZOF2
DMVTARK	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMVTARK	MT	DTT
DMVTARK	MA	Inhibitor
DMVTARK	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMVTARK	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DM1CWU7	DI	DM1CWU7
DM1CWU7	DN	Heteroaryl-carboxamide derivative 11
DM1CWU7	MI	TT5L2VC
DM1CWU7	MN	Kallikrein-related peptidase (KLK)
DM1CWU7	MT	DTT
DM1CWU7	MA	Inhibitor
DM1CWU7	RN	Serine protease inhibitors to treat inflammation: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Feb;28(2):93-110.
DM1CWU7	RU	https://www.ncbi.nlm.nih.gov/pubmed/29171765

DMGEFIW	DI	DMGEFIW
DMGEFIW	DN	Heteroaryl-carboxamide derivative 2
DMGEFIW	MI	TTCZOF2
DMGEFIW	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMGEFIW	MT	DTT
DMGEFIW	MA	Inhibitor
DMGEFIW	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMGEFIW	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMBGTNM	DI	DMBGTNM
DMBGTNM	DN	Heteroaryl-carboxamide derivative 3
DMBGTNM	MI	TTCZOF2
DMBGTNM	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMBGTNM	MT	DTT
DMBGTNM	MA	Inhibitor
DMBGTNM	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMBGTNM	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMHUIXR	DI	DMHUIXR
DMHUIXR	DN	Heteroaryl-carboxamide derivative 4
DMHUIXR	MI	TTCZOF2
DMHUIXR	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMHUIXR	MT	DTT
DMHUIXR	MA	Inhibitor
DMHUIXR	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMHUIXR	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMMX6V4	DI	DMMX6V4
DMMX6V4	DN	Heteroaryl-carboxamide derivative 5
DMMX6V4	MI	TTCZOF2
DMMX6V4	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMMX6V4	MT	DTT
DMMX6V4	MA	Inhibitor
DMMX6V4	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMMX6V4	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DM9IPDU	DI	DM9IPDU
DM9IPDU	DN	Heteroaryl-carboxamide derivative 6
DM9IPDU	MI	TTCZOF2
DM9IPDU	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DM9IPDU	MT	DTT
DM9IPDU	MA	Inhibitor
DM9IPDU	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DM9IPDU	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMOAYEV	DI	DMOAYEV
DMOAYEV	DN	Heteroaryl-carboxamide derivative 7
DMOAYEV	MI	TTCZOF2
DMOAYEV	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMOAYEV	MT	DTT
DMOAYEV	MA	Inhibitor
DMOAYEV	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMOAYEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMJTN91	DI	DMJTN91
DMJTN91	DN	Heteroaryl-carboxamide derivative 8
DMJTN91	MI	TTCZOF2
DMJTN91	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMJTN91	MT	DTT
DMJTN91	MA	Inhibitor
DMJTN91	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMJTN91	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMI627Z	DI	DMI627Z
DMI627Z	DN	Heteroaryl-carboxamide derivative 9
DMI627Z	MI	TTCZOF2
DMI627Z	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMI627Z	MT	DTT
DMI627Z	MA	Inhibitor
DMI627Z	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMI627Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMRF58Q	DI	DMRF58Q
DMRF58Q	DN	Heteroaryl-cyclopropylamine derivative 1
DMRF58Q	MI	TTNR0UQ
DMRF58Q	MN	Lysine-specific histone demethylase 1 (LSD)
DMRF58Q	MT	DTT
DMRF58Q	MA	Inhibitor
DMRF58Q	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMRF58Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMRF58Q	DI	DMRF58Q
DMRF58Q	DN	Heteroaryl-cyclopropylamine derivative 1
DMRF58Q	MI	TT3WG5C
DMRF58Q	MN	Monoamine oxidase type A (MAO-A)
DMRF58Q	MT	DTT
DMRF58Q	MA	Inhibitor
DMRF58Q	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMRF58Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMRF58Q	DI	DMRF58Q
DMRF58Q	DN	Heteroaryl-cyclopropylamine derivative 1
DMRF58Q	MI	TTGP7BY
DMRF58Q	MN	Monoamine oxidase type B (MAO-B)
DMRF58Q	MT	DTT
DMRF58Q	MA	Inhibitor
DMRF58Q	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMRF58Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DM9NE5T	DI	DM9NE5T
DM9NE5T	DN	Heteroaryl-cyclopropylamine derivative 2
DM9NE5T	MI	TTNR0UQ
DM9NE5T	MN	Lysine-specific histone demethylase 1 (LSD)
DM9NE5T	MT	DTT
DM9NE5T	MA	Inhibitor
DM9NE5T	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DM9NE5T	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMH9EQ1	DI	DMH9EQ1
DMH9EQ1	DN	Heteroaryl-cyclopropylamine derivative 3
DMH9EQ1	MI	TTNR0UQ
DMH9EQ1	MN	Lysine-specific histone demethylase 1 (LSD)
DMH9EQ1	MT	DTT
DMH9EQ1	MA	Inhibitor
DMH9EQ1	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMH9EQ1	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMH9EQ1	DI	DMH9EQ1
DMH9EQ1	DN	Heteroaryl-cyclopropylamine derivative 3
DMH9EQ1	MI	TTGP7BY
DMH9EQ1	MN	Monoamine oxidase type B (MAO-B)
DMH9EQ1	MT	DTT
DMH9EQ1	MA	Inhibitor
DMH9EQ1	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMH9EQ1	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMMU01R	DI	DMMU01R
DMMU01R	DN	Heteroaryl-cyclopropylamine derivative 4
DMMU01R	MI	TTZHPB8
DMMU01R	MN	Lysine-specific demethylase 4A (KDM4A)
DMMU01R	MT	DTT
DMMU01R	MA	Inhibitor
DMMU01R	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMMU01R	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMMU01R	DI	DMMU01R
DMMU01R	DN	Heteroaryl-cyclopropylamine derivative 4
DMMU01R	MI	TTNR0UQ
DMMU01R	MN	Lysine-specific histone demethylase 1 (LSD)
DMMU01R	MT	DTT
DMMU01R	MA	Inhibitor
DMMU01R	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMMU01R	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DM9LQCH	DI	DM9LQCH
DM9LQCH	DN	Heteroaryl-pyrazole derivative 1
DM9LQCH	MI	TTXJ47W
DM9LQCH	MN	Metabotropic glutamate receptor 2 (mGluR2)
DM9LQCH	MT	DTT
DM9LQCH	MA	Antagonist
DM9LQCH	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DM9LQCH	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DMIG0TQ	DI	DMIG0TQ
DMIG0TQ	DN	Heteroaryl-pyrazole derivative 2
DMIG0TQ	MI	TTXJ47W
DMIG0TQ	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMIG0TQ	MT	DTT
DMIG0TQ	MA	Antagonist
DMIG0TQ	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DMIG0TQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DMO45G3	DI	DMO45G3
DMO45G3	DN	Heteroaryl-pyrazole derivative 3
DMO45G3	MI	TTXJ47W
DMO45G3	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMO45G3	MT	DTT
DMO45G3	MA	Antagonist
DMO45G3	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DMO45G3	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DM2BM1L	DI	DM2BM1L
DM2BM1L	DN	Heteroaryl-substituted urea derivative 1
DM2BM1L	MI	TTDP1UC
DM2BM1L	MN	Fatty acid amide hydrolase (FAAH)
DM2BM1L	MT	DTT
DM2BM1L	MA	Inhibitor
DM2BM1L	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DM2BM1L	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMHFQLC	DI	DMHFQLC
DMHFQLC	DN	Heteroaryl-substituted urea derivative 2
DMHFQLC	MI	TTDP1UC
DMHFQLC	MN	Fatty acid amide hydrolase (FAAH)
DMHFQLC	MT	DTT
DMHFQLC	MA	Inhibitor
DMHFQLC	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMHFQLC	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DM8PHBG	DI	DM8PHBG
DM8PHBG	DN	Heterocycle-containing compound 1
DM8PHBG	MI	TT9O6WS
DM8PHBG	MN	Glucagon receptor (GCGR)
DM8PHBG	MT	DTT
DM8PHBG	MA	Antagonist
DM8PHBG	RN	Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30.
DM8PHBG	RU	https://www.ncbi.nlm.nih.gov/pubmed/25828189

DM2KVMT	DI	DM2KVMT
DM2KVMT	DN	Heterocycle-containing compound 2
DM2KVMT	MI	TT9O6WS
DM2KVMT	MN	Glucagon receptor (GCGR)
DM2KVMT	MT	DTT
DM2KVMT	MA	Antagonist
DM2KVMT	RN	Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30.
DM2KVMT	RU	https://www.ncbi.nlm.nih.gov/pubmed/25828189

DMHMTF7	DI	DMHMTF7
DMHMTF7	DN	Heterocycle-containing compound 3
DMHMTF7	MI	TT9O6WS
DMHMTF7	MN	Glucagon receptor (GCGR)
DMHMTF7	MT	DTT
DMHMTF7	MA	Antagonist
DMHMTF7	RN	Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30.
DMHMTF7	RU	https://www.ncbi.nlm.nih.gov/pubmed/25828189

DM6IRJL	DI	DM6IRJL
DM6IRJL	DN	Heterocycle-containing compound 4
DM6IRJL	MI	TT9O6WS
DM6IRJL	MN	Glucagon receptor (GCGR)
DM6IRJL	MT	DTT
DM6IRJL	MA	Antagonist
DM6IRJL	RN	Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30.
DM6IRJL	RU	https://www.ncbi.nlm.nih.gov/pubmed/25828189

DM6EY5Z	DI	DM6EY5Z
DM6EY5Z	DN	Heterocycle-containing compound 5
DM6EY5Z	MI	TT9O6WS
DM6EY5Z	MN	Glucagon receptor (GCGR)
DM6EY5Z	MT	DTT
DM6EY5Z	MA	Antagonist
DM6EY5Z	RN	Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30.
DM6EY5Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/25828189

DMJ5X46	DI	DMJ5X46
DMJ5X46	DN	Heterocyclic derivative 1
DMJ5X46	MI	TTHS256
DMJ5X46	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMJ5X46	MT	DTT
DMJ5X46	MA	Modulator
DMJ5X46	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMJ5X46	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMN580F	DI	DMN580F
DMN580F	DN	Heterocyclic derivative 10
DMN580F	MI	TTCZOF2
DMN580F	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMN580F	MT	DTT
DMN580F	MA	Inhibitor
DMN580F	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMN580F	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMUOI92	DI	DMUOI92
DMUOI92	DN	Heterocyclic derivative 11
DMUOI92	MI	TTCZOF2
DMUOI92	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMUOI92	MT	DTT
DMUOI92	MA	Inhibitor
DMUOI92	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMUOI92	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMQJW9R	DI	DMQJW9R
DMQJW9R	DN	Heterocyclic derivative 12
DMQJW9R	MI	TTCZOF2
DMQJW9R	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMQJW9R	MT	DTT
DMQJW9R	MA	Inhibitor
DMQJW9R	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMQJW9R	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMWOBHM	DI	DMWOBHM
DMWOBHM	DN	Heterocyclic derivative 13
DMWOBHM	MI	TTCZOF2
DMWOBHM	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMWOBHM	MT	DTT
DMWOBHM	MA	Inhibitor
DMWOBHM	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMWOBHM	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMJ0WVR	DI	DMJ0WVR
DMJ0WVR	DN	Heterocyclic derivative 14
DMJ0WVR	MI	TTCZOF2
DMJ0WVR	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMJ0WVR	MT	DTT
DMJ0WVR	MA	Inhibitor
DMJ0WVR	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMJ0WVR	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMWZNDO	DI	DMWZNDO
DMWZNDO	DN	Heterocyclic derivative 15
DMWZNDO	MI	TTCZOF2
DMWZNDO	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMWZNDO	MT	DTT
DMWZNDO	MA	Inhibitor
DMWZNDO	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMWZNDO	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DM6NJV7	DI	DM6NJV7
DM6NJV7	DN	Heterocyclic derivative 16
DM6NJV7	MI	TTCZOF2
DM6NJV7	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DM6NJV7	MT	DTT
DM6NJV7	MA	Inhibitor
DM6NJV7	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DM6NJV7	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMD1K7E	DI	DMD1K7E
DMD1K7E	DN	Heterocyclic derivative 17
DMD1K7E	MI	TTCZOF2
DMD1K7E	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMD1K7E	MT	DTT
DMD1K7E	MA	Inhibitor
DMD1K7E	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMD1K7E	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMFUEDL	DI	DMFUEDL
DMFUEDL	DN	Heterocyclic derivative 18
DMFUEDL	MI	TTCZOF2
DMFUEDL	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMFUEDL	MT	DTT
DMFUEDL	MA	Inhibitor
DMFUEDL	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMFUEDL	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMNG0WH	DI	DMNG0WH
DMNG0WH	DN	Heterocyclic derivative 19
DMNG0WH	MI	TTCZOF2
DMNG0WH	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMNG0WH	MT	DTT
DMNG0WH	MA	Inhibitor
DMNG0WH	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMNG0WH	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DM2QCBF	DI	DM2QCBF
DM2QCBF	DN	Heterocyclic derivative 2
DM2QCBF	MI	TTHS256
DM2QCBF	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM2QCBF	MT	DTT
DM2QCBF	MA	Modulator
DM2QCBF	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DM2QCBF	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DM56T1P	DI	DM56T1P
DM56T1P	DN	Heterocyclic derivative 26
DM56T1P	MI	TTIXKA4
DM56T1P	MN	Ribosomal protein S6 kinase alpha-1 (RSK1)
DM56T1P	MT	DTT
DM56T1P	MA	Inhibitor
DM56T1P	RN	Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78.
DM56T1P	RU	https://www.ncbi.nlm.nih.gov/pubmed/27410995

DMCD0MS	DI	DMCD0MS
DMCD0MS	DN	Heterocyclic derivative 3
DMCD0MS	MI	TTHS256
DMCD0MS	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMCD0MS	MT	DTT
DMCD0MS	MA	Modulator
DMCD0MS	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMCD0MS	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DM7VP8M	DI	DM7VP8M
DM7VP8M	DN	Heterocyclic derivative 4
DM7VP8M	MI	TTCZOF2
DM7VP8M	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DM7VP8M	MT	DTT
DM7VP8M	MA	Inhibitor
DM7VP8M	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DM7VP8M	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMWJDEO	DI	DMWJDEO
DMWJDEO	DN	Heterocyclic derivative 5
DMWJDEO	MI	TTCZOF2
DMWJDEO	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMWJDEO	MT	DTT
DMWJDEO	MA	Inhibitor
DMWJDEO	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMWJDEO	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DM6HWN3	DI	DM6HWN3
DM6HWN3	DN	Heterocyclic derivative 6
DM6HWN3	MI	TTCZOF2
DM6HWN3	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DM6HWN3	MT	DTT
DM6HWN3	MA	Inhibitor
DM6HWN3	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DM6HWN3	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMU6LS4	DI	DMU6LS4
DMU6LS4	DN	Heterocyclic derivative 7
DMU6LS4	MI	TTCZOF2
DMU6LS4	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMU6LS4	MT	DTT
DMU6LS4	MA	Inhibitor
DMU6LS4	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMU6LS4	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMKPSIA	DI	DMKPSIA
DMKPSIA	DN	Heterocyclic derivative 8
DMKPSIA	MI	TTCZOF2
DMKPSIA	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMKPSIA	MT	DTT
DMKPSIA	MA	Inhibitor
DMKPSIA	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMKPSIA	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMY4LB7	DI	DMY4LB7
DMY4LB7	DN	Heterocyclic derivative 9
DMY4LB7	MI	TTCZOF2
DMY4LB7	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMY4LB7	MT	DTT
DMY4LB7	MA	Inhibitor
DMY4LB7	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMY4LB7	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMA91IJ	DI	DMA91IJ
DMA91IJ	DN	Heterocyclic-carboxamide derivative 1
DMA91IJ	MI	TTCZOF2
DMA91IJ	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMA91IJ	MT	DTT
DMA91IJ	MA	Inhibitor
DMA91IJ	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMA91IJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMSQK50	DI	DMSQK50
DMSQK50	DN	Heterocyclic-carboxamide derivative 2
DMSQK50	MI	TTCZOF2
DMSQK50	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMSQK50	MT	DTT
DMSQK50	MA	Inhibitor
DMSQK50	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMSQK50	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMEGK3Q	DI	DMEGK3Q
DMEGK3Q	DN	Heterocyclic-fused piperazine derivative 1
DMEGK3Q	MI	TT473XN
DMEGK3Q	MN	P2X purinoceptor 7 (P2RX7)
DMEGK3Q	MT	DTT
DMEGK3Q	MA	Antagonist
DMEGK3Q	RN	P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267.
DMEGK3Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/27724045

DMJEX3D	DI	DMJEX3D
DMJEX3D	DN	Heterocyclic-substituted 3-alkyl azetidine derivative 1
DMJEX3D	MI	TT6OEDT
DMJEX3D	MN	Cannabinoid receptor 1 (CB1)
DMJEX3D	MT	DTT
DMJEX3D	MA	Antagonist
DMJEX3D	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMJEX3D	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMEX7PV	DI	DMEX7PV
DMEX7PV	DN	Heterocyclic-substituted 3-alkyl azetidine derivative 2
DMEX7PV	MI	TT6OEDT
DMEX7PV	MN	Cannabinoid receptor 1 (CB1)
DMEX7PV	MT	DTT
DMEX7PV	MA	Antagonist
DMEX7PV	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMEX7PV	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMO1Y30	DI	DMO1Y30
DMO1Y30	DN	Heterocyclic-substituted 3-alkyl azetidine derivative 3
DMO1Y30	MI	TT6OEDT
DMO1Y30	MN	Cannabinoid receptor 1 (CB1)
DMO1Y30	MT	DTT
DMO1Y30	MA	Antagonist
DMO1Y30	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMO1Y30	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMNJVR6	DI	DMNJVR6
DMNJVR6	DN	Heterocyclic-tetracyclic tetrahydrofuran derivative 1
DMNJVR6	MI	TTYSN63
DMNJVR6	MN	5-HT 2 receptor (5HT2R)
DMNJVR6	MT	DTT
DMNJVR6	MA	Antagonist
DMNJVR6	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMNJVR6	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMC1ZIX	DI	DMC1ZIX
DMC1ZIX	DN	Hexahydro azepinone derivative 1
DMC1ZIX	MI	TTMQO60
DMC1ZIX	MN	Rho-associated protein kinase (ROCK)
DMC1ZIX	MT	DTT
DMC1ZIX	MA	Inhibitor
DMC1ZIX	RN	Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
DMC1ZIX	RU	https://www.ncbi.nlm.nih.gov/pubmed/28048944

DMT2Z0I	DI	DMT2Z0I
DMT2Z0I	DN	Hexahydro naphthalene derivative 1
DMT2Z0I	MI	TTPADOQ
DMT2Z0I	MN	HMG-CoA reductase (HMGCR)
DMT2Z0I	MT	DTT
DMT2Z0I	MA	Inhibitor
DMT2Z0I	RN	HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272.
DMT2Z0I	RU	https://www.ncbi.nlm.nih.gov/pubmed/27537201

DMFG9HP	DI	DMFG9HP
DMFG9HP	DN	Hexahydro naphthalene derivative 2
DMFG9HP	MI	TTPADOQ
DMFG9HP	MN	HMG-CoA reductase (HMGCR)
DMFG9HP	MT	DTT
DMFG9HP	MA	Inhibitor
DMFG9HP	RN	HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272.
DMFG9HP	RU	https://www.ncbi.nlm.nih.gov/pubmed/27537201

DM1KT4I	DI	DM1KT4I
DM1KT4I	DN	Hexahydro naphthalene derivative 3
DM1KT4I	MI	TTPADOQ
DM1KT4I	MN	HMG-CoA reductase (HMGCR)
DM1KT4I	MT	DTT
DM1KT4I	MA	Inhibitor
DM1KT4I	RN	HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272.
DM1KT4I	RU	https://www.ncbi.nlm.nih.gov/pubmed/27537201

DM4VNWX	DI	DM4VNWX
DM4VNWX	DN	Hexahydro quinoline derivative 1
DM4VNWX	MI	TTZJYKH
DM4VNWX	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DM4VNWX	MT	DTT
DM4VNWX	MA	Inhibitor
DM4VNWX	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DM4VNWX	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMU5JC0	DI	DMU5JC0
DMU5JC0	DN	HouttuynoidA
DMU5JC0	MI	TT3WG5C
DMU5JC0	MN	Monoamine oxidase type A (MAO-A)
DMU5JC0	MT	DTT
DMU5JC0	MA	Inhibitor
DMU5JC0	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMU5JC0	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMFIG8C	DI	DMFIG8C
DMFIG8C	DN	Hydoxyamidine derivative 1
DMFIG8C	MI	TTZJYKH
DMFIG8C	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMFIG8C	MT	DTT
DMFIG8C	MA	Inhibitor
DMFIG8C	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMFIG8C	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMUA740	DI	DMUA740
DMUA740	DN	Hydrazide derivative 1
DMUA740	MI	TT6OEDT
DMUA740	MN	Cannabinoid receptor 1 (CB1)
DMUA740	MT	DTT
DMUA740	MA	Antagonist
DMUA740	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMUA740	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DM3U79M	DI	DM3U79M
DM3U79M	DN	Hydrazide derivative 3
DM3U79M	MI	TTK0FEA
DM3U79M	MN	Leucine-rich repeat kinase 2 (LRRK2)
DM3U79M	MT	DTT
DM3U79M	MA	Inhibitor
DM3U79M	RN	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
DM3U79M	RU	https://www.ncbi.nlm.nih.gov/pubmed/28117607

DM1HI8Q	DI	DM1HI8Q
DM1HI8Q	DN	Hydrazide derivative 4
DM1HI8Q	MI	TTK0FEA
DM1HI8Q	MN	Leucine-rich repeat kinase 2 (LRRK2)
DM1HI8Q	MT	DTT
DM1HI8Q	MA	Inhibitor
DM1HI8Q	RN	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
DM1HI8Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/28117607

DM6RLVB	DI	DM6RLVB
DM6RLVB	DN	Hydrazide derivative 5
DM6RLVB	MI	TTK0FEA
DM6RLVB	MN	Leucine-rich repeat kinase 2 (LRRK2)
DM6RLVB	MT	DTT
DM6RLVB	MA	Inhibitor
DM6RLVB	RN	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
DM6RLVB	RU	https://www.ncbi.nlm.nih.gov/pubmed/28117607

DMEQBTO	DI	DMEQBTO
DMEQBTO	DN	Hydrazinoacetic acid
DMEQBTO	MI	TTLQUZS
DMEQBTO	MN	Cystathionine gamma-lyase (CTH)
DMEQBTO	MT	DTT
DMEQBTO	MA	Inhibitor
DMEQBTO	RN	Cystathionine--lyase (CSE) inhibitors. US9725426.
DMEQBTO	RU	http://www.freepatentsonline.com/US9725426.html

DMGATHZ	DI	DMGATHZ
DMGATHZ	DN	Hydroxamate analog 1
DMGATHZ	MI	TTZHPB8
DMGATHZ	MN	Lysine-specific demethylase 4A (KDM4A)
DMGATHZ	MT	DTT
DMGATHZ	MA	Inhibitor
DMGATHZ	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMGATHZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMGATHZ	DI	DMGATHZ
DMGATHZ	DN	Hydroxamate analog 1
DMGATHZ	MI	TTV8CRH
DMGATHZ	MN	Lysine-specific demethylase 4C (KDM4C)
DMGATHZ	MT	DTT
DMGATHZ	MA	Inhibitor
DMGATHZ	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMGATHZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMBMG1S	DI	DMBMG1S
DMBMG1S	DN	Hydroxamate analog 2
DMBMG1S	MI	TT0RGE9
DMBMG1S	MN	Lysine-specific demethylase 4 (KDM4)
DMBMG1S	MT	DTT
DMBMG1S	MA	Inhibitor
DMBMG1S	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMBMG1S	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMDQYJ1	DI	DMDQYJ1
DMDQYJ1	DN	Hydroxamate analog 3
DMDQYJ1	MI	TT0RGE9
DMDQYJ1	MN	Lysine-specific demethylase 4 (KDM4)
DMDQYJ1	MT	DTT
DMDQYJ1	MA	Inhibitor
DMDQYJ1	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMDQYJ1	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMBHIL2	DI	DMBHIL2
DMBHIL2	DN	Hydroxy amidine derivative 1
DMBHIL2	MI	TTZJYKH
DMBHIL2	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMBHIL2	MT	DTT
DMBHIL2	MA	Inhibitor
DMBHIL2	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMBHIL2	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DM7SUFJ	DI	DM7SUFJ
DM7SUFJ	DN	Hydroxy amidine derivative 2
DM7SUFJ	MI	TTZJYKH
DM7SUFJ	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DM7SUFJ	MT	DTT
DM7SUFJ	MA	Inhibitor
DM7SUFJ	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DM7SUFJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMAJFDT	DI	DMAJFDT
DMAJFDT	DN	Hydroxyqunoline analog 1
DMAJFDT	MI	TTWAQBO
DMAJFDT	MN	Lysine-specific demethylase 4E (KDM4E)
DMAJFDT	MT	DTT
DMAJFDT	MA	Inhibitor
DMAJFDT	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMAJFDT	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMX3TZ7	DI	DMX3TZ7
DMX3TZ7	DN	Hydroxyqunoline analog 2
DMX3TZ7	MI	TTWAQBO
DMX3TZ7	MN	Lysine-specific demethylase 4E (KDM4E)
DMX3TZ7	MT	DTT
DMX3TZ7	MA	Inhibitor
DMX3TZ7	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMX3TZ7	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMCMKIL	DI	DMCMKIL
DMCMKIL	DN	Hydroxyqunoline analog 3
DMCMKIL	MI	TTWAQBO
DMCMKIL	MN	Lysine-specific demethylase 4E (KDM4E)
DMCMKIL	MT	DTT
DMCMKIL	MA	Inhibitor
DMCMKIL	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMCMKIL	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMGQMCZ	DI	DMGQMCZ
DMGQMCZ	DN	Hydroxyqunoline analog 4
DMGQMCZ	MI	TTWAQBO
DMGQMCZ	MN	Lysine-specific demethylase 4E (KDM4E)
DMGQMCZ	MT	DTT
DMGQMCZ	MA	Inhibitor
DMGQMCZ	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMGQMCZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DM5QAKR	DI	DM5QAKR
DM5QAKR	DN	Hydroxyqunoline analog 5
DM5QAKR	MI	TTWAQBO
DM5QAKR	MN	Lysine-specific demethylase 4E (KDM4E)
DM5QAKR	MT	DTT
DM5QAKR	MA	Inhibitor
DM5QAKR	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DM5QAKR	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMMFI5G	DI	DMMFI5G
DMMFI5G	DN	Hypersulfated disaccharide compound 1
DMMFI5G	MI	TTPLTSQ
DMMFI5G	MN	Neutrophil elastase (NE)
DMMFI5G	MT	DTT
DMMFI5G	MA	Inhibitor
DMMFI5G	RN	Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
DMMFI5G	RU	https://www.ncbi.nlm.nih.gov/pubmed/26118988

DMMJTUW	DI	DMMJTUW
DMMJTUW	DN	Imatinib and nilotinib derivative 1
DMMJTUW	MI	TTUNARX
DMMJTUW	MN	Carbonic anhydrase (CA)
DMMJTUW	MT	DTT
DMMJTUW	MA	Inhibitor
DMMJTUW	RN	Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).Expert Opin Ther Pat. 2018 Oct;28(10):729-740.
DMMJTUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/30074415

DM34NZ8	DI	DM34NZ8
DM34NZ8	DN	Imatinib and nilotinib derivative 2
DM34NZ8	MI	TTUNARX
DM34NZ8	MN	Carbonic anhydrase (CA)
DM34NZ8	MT	DTT
DM34NZ8	MA	Inhibitor
DM34NZ8	RN	Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).Expert Opin Ther Pat. 2018 Oct;28(10):729-740.
DM34NZ8	RU	https://www.ncbi.nlm.nih.gov/pubmed/30074415

DMWUFKO	DI	DMWUFKO
DMWUFKO	DN	Imidamide derivative 1
DMWUFKO	MI	TT3M2WO
DMWUFKO	MN	Sphingosine kinase (SphK)
DMWUFKO	MT	DTT
DMWUFKO	MA	Inhibitor
DMWUFKO	RN	Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416.
DMWUFKO	RU	https://www.ncbi.nlm.nih.gov/pubmed/27539678

DMWABOJ	DI	DMWABOJ
DMWABOJ	DN	Imidazo [1,2-a]pyridine compound 1
DMWABOJ	MI	TTUX68I
DMWABOJ	MN	Hypoxia-inducible factor 1 (HIF-1)
DMWABOJ	MT	DTT
DMWABOJ	MA	Inhibitor
DMWABOJ	RN	Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22.
DMWABOJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26882240

DM01RXU	DI	DM01RXU
DM01RXU	DN	Imidazo bicyclic iminium derivative 1
DM01RXU	MI	TTJOMH6
DM01RXU	MN	Zinc finger protein GLI1 (Gli1)
DM01RXU	MT	DTT
DM01RXU	MA	Inhibitor
DM01RXU	RN	Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35.
DM01RXU	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666870

DMA7DI6	DI	DMA7DI6
DMA7DI6	DN	Imidazo bicyclic iminium derivative 2
DMA7DI6	MI	TTJOMH6
DMA7DI6	MN	Zinc finger protein GLI1 (Gli1)
DMA7DI6	MT	DTT
DMA7DI6	MA	Inhibitor
DMA7DI6	RN	Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35.
DMA7DI6	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666870

DMENYZ0	DI	DMENYZ0
DMENYZ0	DN	Imidazo bicyclic iminium derivative 3
DMENYZ0	MI	TT8J1S3
DMENYZ0	MN	Smoothened homolog (SMO)
DMENYZ0	MT	DTT
DMENYZ0	MA	Inhibitor
DMENYZ0	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMENYZ0	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMHRV8J	DI	DMHRV8J
DMHRV8J	DN	Imidazo bicyclic iminium derivative 4
DMHRV8J	MI	TT8J1S3
DMHRV8J	MN	Smoothened homolog (SMO)
DMHRV8J	MT	DTT
DMHRV8J	MA	Inhibitor
DMHRV8J	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMHRV8J	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMS8GIU	DI	DMS8GIU
DMS8GIU	DN	Imidazo bicyclic iminium derivative 5
DMS8GIU	MI	TT8J1S3
DMS8GIU	MN	Smoothened homolog (SMO)
DMS8GIU	MT	DTT
DMS8GIU	MA	Inhibitor
DMS8GIU	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMS8GIU	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMEP5MJ	DI	DMEP5MJ
DMEP5MJ	DN	Imidazo bicyclic iminium derivative 6
DMEP5MJ	MI	TT8J1S3
DMEP5MJ	MN	Smoothened homolog (SMO)
DMEP5MJ	MT	DTT
DMEP5MJ	MA	Inhibitor
DMEP5MJ	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMEP5MJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DM0Y4X8	DI	DM0Y4X8
DM0Y4X8	DN	Imidazo bicyclic iminium derivative 7
DM0Y4X8	MI	TT8J1S3
DM0Y4X8	MN	Smoothened homolog (SMO)
DM0Y4X8	MT	DTT
DM0Y4X8	MA	Inhibitor
DM0Y4X8	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DM0Y4X8	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMBMFPC	DI	DMBMFPC
DMBMFPC	DN	Imidazo bicyclic iminium derivative 8
DMBMFPC	MI	TT8J1S3
DMBMFPC	MN	Smoothened homolog (SMO)
DMBMFPC	MT	DTT
DMBMFPC	MA	Inhibitor
DMBMFPC	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMBMFPC	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMQXCT1	DI	DMQXCT1
DMQXCT1	DN	Imidazo bicyclic iminium derivative 9
DMQXCT1	MI	TT8J1S3
DMQXCT1	MN	Smoothened homolog (SMO)
DMQXCT1	MT	DTT
DMQXCT1	MA	Inhibitor
DMQXCT1	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMQXCT1	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DM34ZCG	DI	DM34ZCG
DM34ZCG	DN	Imidazo cyclohexylamine derivative 1
DM34ZCG	MI	TTDIGC1
DM34ZCG	MN	Dipeptidyl peptidase 4 (DPP-4)
DM34ZCG	MT	DTT
DM34ZCG	MA	Inhibitor
DM34ZCG	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DM34ZCG	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DMKPAN3	DI	DMKPAN3
DMKPAN3	DN	Imidazo cyclohexylamine derivative 2
DMKPAN3	MI	TTDIGC1
DMKPAN3	MN	Dipeptidyl peptidase 4 (DPP-4)
DMKPAN3	MT	DTT
DMKPAN3	MA	Inhibitor
DMKPAN3	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMKPAN3	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DMCQBZK	DI	DMCQBZK
DMCQBZK	DN	Imidazo cyclohexylamine derivative 3
DMCQBZK	MI	TTDIGC1
DMCQBZK	MN	Dipeptidyl peptidase 4 (DPP-4)
DMCQBZK	MT	DTT
DMCQBZK	MA	Inhibitor
DMCQBZK	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMCQBZK	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DM1JXKY	DI	DM1JXKY
DM1JXKY	DN	Imidazo isoindole derivative 1
DM1JXKY	MI	TTZJYKH
DM1JXKY	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DM1JXKY	MT	DTT
DM1JXKY	MA	Inhibitor
DM1JXKY	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DM1JXKY	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMCXHGW	DI	DMCXHGW
DMCXHGW	DN	Imidazo pyridine derivative 1
DMCXHGW	MI	TTTDVOJ
DMCXHGW	MN	Tropomyosin-related kinase A (TrkA)
DMCXHGW	MT	DTT
DMCXHGW	MA	Inhibitor
DMCXHGW	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMCXHGW	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMC49SV	DI	DMC49SV
DMC49SV	DN	Imidazo pyridine derivative 2
DMC49SV	MI	TTDIGC1
DMC49SV	MN	Dipeptidyl peptidase 4 (DPP-4)
DMC49SV	MT	DTT
DMC49SV	MA	Inhibitor
DMC49SV	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMC49SV	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DMPCLZB	DI	DMPCLZB
DMPCLZB	DN	Imidazo pyridine derivative 3
DMPCLZB	MI	TT0PG8F
DMPCLZB	MN	Cyclin-dependent kinase 4 (CDK4)
DMPCLZB	MT	DTT
DMPCLZB	MA	Inhibitor
DMPCLZB	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMPCLZB	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DM3YMHP	DI	DM3YMHP
DM3YMHP	DN	Imidazo pyridine derivative 4
DM3YMHP	MI	TTV1C0Z
DM3YMHP	MN	Neuropeptide S receptor (NPSR)
DM3YMHP	MT	DTT
DM3YMHP	MA	Antagonist
DM3YMHP	RN	Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362.
DM3YMHP	RU	https://www.ncbi.nlm.nih.gov/pubmed/27788040

DMOVJ35	DI	DMOVJ35
DMOVJ35	DN	Imidazo pyridine derivative 5
DMOVJ35	MI	TTV1C0Z
DMOVJ35	MN	Neuropeptide S receptor (NPSR)
DMOVJ35	MT	DTT
DMOVJ35	MA	Antagonist
DMOVJ35	RN	Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362.
DMOVJ35	RU	https://www.ncbi.nlm.nih.gov/pubmed/27788040

DMG6W3O	DI	DMG6W3O
DMG6W3O	DN	Imidazo pyridine derivative 6
DMG6W3O	MI	TTV1C0Z
DMG6W3O	MN	Neuropeptide S receptor (NPSR)
DMG6W3O	MT	DTT
DMG6W3O	MA	Antagonist
DMG6W3O	RN	Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362.
DMG6W3O	RU	https://www.ncbi.nlm.nih.gov/pubmed/27788040

DMGDMWA	DI	DMGDMWA
DMGDMWA	DN	Imidazo quinoline derivative 1
DMGDMWA	MI	TTCZOF2
DMGDMWA	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMGDMWA	MT	DTT
DMGDMWA	MA	Inhibitor
DMGDMWA	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMGDMWA	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMLVY7A	DI	DMLVY7A
DMLVY7A	DN	Imidazo triazine derivative 1
DMLVY7A	MI	TTJGW1Z
DMLVY7A	MN	Phosphodiesterase 2A (PDE2A)
DMLVY7A	MT	DTT
DMLVY7A	MA	Inhibitor
DMLVY7A	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMLVY7A	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMZFG68	DI	DMZFG68
DMZFG68	DN	Imidazo triazine derivative 2
DMZFG68	MI	TTJGW1Z
DMZFG68	MN	Phosphodiesterase 2A (PDE2A)
DMZFG68	MT	DTT
DMZFG68	MA	Inhibitor
DMZFG68	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMZFG68	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DM142HI	DI	DM142HI
DM142HI	DN	Imidazo triazine derivative 3
DM142HI	MI	TTJGW1Z
DM142HI	MN	Phosphodiesterase 2A (PDE2A)
DM142HI	MT	DTT
DM142HI	MA	Inhibitor
DM142HI	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DM142HI	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMZTS2O	DI	DMZTS2O
DMZTS2O	DN	Imidazo triazine derivative 4
DMZTS2O	MI	TTJGW1Z
DMZTS2O	MN	Phosphodiesterase 2A (PDE2A)
DMZTS2O	MT	DTT
DMZTS2O	MA	Inhibitor
DMZTS2O	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMZTS2O	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DM18P4N	DI	DM18P4N
DM18P4N	DN	Imidazo triazine derivative 5
DM18P4N	MI	TTJGW1Z
DM18P4N	MN	Phosphodiesterase 2A (PDE2A)
DM18P4N	MT	DTT
DM18P4N	MA	Inhibitor
DM18P4N	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DM18P4N	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DM5NEQ2	DI	DM5NEQ2
DM5NEQ2	DN	Imidazo[1,2-a]pyridine derivative 1
DM5NEQ2	MI	TTHS256
DM5NEQ2	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM5NEQ2	MT	DTT
DM5NEQ2	MA	Modulator
DM5NEQ2	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DM5NEQ2	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DM654Z0	DI	DM654Z0
DM654Z0	DN	Imidazo[1,2-b]pyridazine acetamide derivative 1
DM654Z0	MI	TTPTXIN
DM654Z0	MN	Translocator protein (TSPO)
DM654Z0	MT	DTT
DM654Z0	MA	Ligand
DM654Z0	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DM654Z0	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMVX7YB	DI	DMVX7YB
DMVX7YB	DN	Imidazo[1,2-b]pyridazine acetamide derivative 2
DMVX7YB	MI	TTPTXIN
DMVX7YB	MN	Translocator protein (TSPO)
DMVX7YB	MT	DTT
DMVX7YB	MA	Ligand
DMVX7YB	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMVX7YB	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMARLZ6	DI	DMARLZ6
DMARLZ6	DN	Imidazo[1,2-b]pyridazine acetamide derivative 3
DMARLZ6	MI	TTPTXIN
DMARLZ6	MN	Translocator protein (TSPO)
DMARLZ6	MT	DTT
DMARLZ6	MA	Ligand
DMARLZ6	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMARLZ6	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DM5J09E	DI	DM5J09E
DM5J09E	DN	Imidazo[1,2-b]pyridazine acetamide derivative 4
DM5J09E	MI	TTPTXIN
DM5J09E	MN	Translocator protein (TSPO)
DM5J09E	MT	DTT
DM5J09E	MA	Ligand
DM5J09E	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DM5J09E	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMGWYJR	DI	DMGWYJR
DMGWYJR	DN	Imidazo[1,2-b]pyridazine acetamide derivative 5
DMGWYJR	MI	TTPTXIN
DMGWYJR	MN	Translocator protein (TSPO)
DMGWYJR	MT	DTT
DMGWYJR	MA	Ligand
DMGWYJR	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMGWYJR	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DM73ESA	DI	DM73ESA
DM73ESA	DN	Imidazo[1,2-b]pyridazine acetamide derivative 6
DM73ESA	MI	TTPTXIN
DM73ESA	MN	Translocator protein (TSPO)
DM73ESA	MT	DTT
DM73ESA	MA	Ligand
DM73ESA	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DM73ESA	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMQLJU2	DI	DMQLJU2
DMQLJU2	DN	Imidazo[1,2-b]pyridazine acetamide derivative 7
DMQLJU2	MI	TTPTXIN
DMQLJU2	MN	Translocator protein (TSPO)
DMQLJU2	MT	DTT
DMQLJU2	MA	Ligand
DMQLJU2	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMQLJU2	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMULTAI	DI	DMULTAI
DMULTAI	DN	Imidazo[1,2-b]pyridazine derivative 1
DMULTAI	MI	TTSZ6Y3
DMULTAI	MN	Proto-oncogene c-Ros (ROS1)
DMULTAI	MT	DTT
DMULTAI	MA	Inhibitor
DMULTAI	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMULTAI	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMULTAI	DI	DMULTAI
DMULTAI	DN	Imidazo[1,2-b]pyridazine derivative 1
DMULTAI	MI	TTTDVOJ
DMULTAI	MN	Tropomyosin-related kinase A (TrkA)
DMULTAI	MT	DTT
DMULTAI	MA	Inhibitor
DMULTAI	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMULTAI	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DM1JYNW	DI	DM1JYNW
DM1JYNW	DN	Imidazo[1,2-b]pyridazine derivative 2
DM1JYNW	MI	TTSZ6Y3
DM1JYNW	MN	Proto-oncogene c-Ros (ROS1)
DM1JYNW	MT	DTT
DM1JYNW	MA	Inhibitor
DM1JYNW	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DM1JYNW	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DM1JYNW	DI	DM1JYNW
DM1JYNW	DN	Imidazo[1,2-b]pyridazine derivative 2
DM1JYNW	MI	TTTDVOJ
DM1JYNW	MN	Tropomyosin-related kinase A (TrkA)
DM1JYNW	MT	DTT
DM1JYNW	MA	Inhibitor
DM1JYNW	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DM1JYNW	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMPDTG0	DI	DMPDTG0
DMPDTG0	DN	Imidazo[1,2-b]pyridazine derivative 3
DMPDTG0	MI	TTSZ6Y3
DMPDTG0	MN	Proto-oncogene c-Ros (ROS1)
DMPDTG0	MT	DTT
DMPDTG0	MA	Inhibitor
DMPDTG0	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMPDTG0	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMPDTG0	DI	DMPDTG0
DMPDTG0	DN	Imidazo[1,2-b]pyridazine derivative 3
DMPDTG0	MI	TTTDVOJ
DMPDTG0	MN	Tropomyosin-related kinase A (TrkA)
DMPDTG0	MT	DTT
DMPDTG0	MA	Inhibitor
DMPDTG0	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMPDTG0	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DM2DL4I	DI	DM2DL4I
DM2DL4I	DN	Imidazo[1,2-b]pyridazine derivative 4
DM2DL4I	MI	TTTDVOJ
DM2DL4I	MN	Tropomyosin-related kinase A (TrkA)
DM2DL4I	MT	DTT
DM2DL4I	MA	Inhibitor
DM2DL4I	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DM2DL4I	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMK8V7A	DI	DMK8V7A
DMK8V7A	DN	Imidazo[1,2-b]pyridazine derivative 5
DMK8V7A	MI	TTTDVOJ
DMK8V7A	MN	Tropomyosin-related kinase A (TrkA)
DMK8V7A	MT	DTT
DMK8V7A	MA	Inhibitor
DMK8V7A	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMK8V7A	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMSIRC2	DI	DMSIRC2
DMSIRC2	DN	Imidazo[1,2-b]pyridazine derivative 6
DMSIRC2	MI	TTTDVOJ
DMSIRC2	MN	Tropomyosin-related kinase A (TrkA)
DMSIRC2	MT	DTT
DMSIRC2	MA	Inhibitor
DMSIRC2	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMSIRC2	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMDQLUP	DI	DMDQLUP
DMDQLUP	DN	Imidazo[1,2-b]pyridazine derivative 7
DMDQLUP	MI	TTTDVOJ
DMDQLUP	MN	Tropomyosin-related kinase A (TrkA)
DMDQLUP	MT	DTT
DMDQLUP	MA	Inhibitor
DMDQLUP	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMDQLUP	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMFIP0D	DI	DMFIP0D
DMFIP0D	DN	Imidazo[1,5-a]pyridine derivative 1
DMFIP0D	MI	TTZJYKH
DMFIP0D	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMFIP0D	MT	DTT
DMFIP0D	MA	Inhibitor
DMFIP0D	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMFIP0D	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMU3PAR	DI	DMU3PAR
DMU3PAR	DN	Imidazo[1,5-a]pyridine derivative 2
DMU3PAR	MI	TTZJYKH
DMU3PAR	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMU3PAR	MT	DTT
DMU3PAR	MA	Inhibitor
DMU3PAR	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMU3PAR	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DM4KBZQ	DI	DM4KBZQ
DM4KBZQ	DN	Imidazo[4,5-c]pyridine derivative 1
DM4KBZQ	MI	TTKAWRQ
DM4KBZQ	MN	JAK-STAT signaling pathway (JAK-STAT pathway)
DM4KBZQ	MT	DTT
DM4KBZQ	MA	Inhibitor
DM4KBZQ	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DM4KBZQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DM4KBZQ	DI	DM4KBZQ
DM4KBZQ	DN	Imidazo[4,5-c]pyridine derivative 1
DM4KBZQ	MI	TT6DM01
DM4KBZQ	MN	Janus kinase 1 (JAK-1)
DM4KBZQ	MT	DTT
DM4KBZQ	MA	Inhibitor
DM4KBZQ	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DM4KBZQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DM4KBZQ	DI	DM4KBZQ
DM4KBZQ	DN	Imidazo[4,5-c]pyridine derivative 1
DM4KBZQ	MI	TTT7PJU
DM4KBZQ	MN	Janus kinase 3 (JAK-3)
DM4KBZQ	MT	DTT
DM4KBZQ	MA	Inhibitor
DM4KBZQ	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DM4KBZQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DM4KBZQ	DI	DM4KBZQ
DM4KBZQ	DN	Imidazo[4,5-c]pyridine derivative 1
DM4KBZQ	MI	TTBYWP2
DM4KBZQ	MN	TYK2 tyrosine kinase (TYK2)
DM4KBZQ	MT	DTT
DM4KBZQ	MA	Inhibitor
DM4KBZQ	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DM4KBZQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DM4KBZQ	DI	DM4KBZQ
DM4KBZQ	DN	Imidazo[4,5-c]pyridine derivative 1
DM4KBZQ	MI	TTJSQEF
DM4KBZQ	MN	Tyrosine-protein kinase (PTK)
DM4KBZQ	MT	DTT
DM4KBZQ	MA	Inhibitor
DM4KBZQ	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DM4KBZQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMFDRJT	DI	DMFDRJT
DMFDRJT	DN	Imidazo[4,5-c]pyridine derivative 2
DMFDRJT	MI	TTKAWRQ
DMFDRJT	MN	JAK-STAT signaling pathway (JAK-STAT pathway)
DMFDRJT	MT	DTT
DMFDRJT	MA	Inhibitor
DMFDRJT	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMFDRJT	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMFDRJT	DI	DMFDRJT
DMFDRJT	DN	Imidazo[4,5-c]pyridine derivative 2
DMFDRJT	MI	TT6DM01
DMFDRJT	MN	Janus kinase 1 (JAK-1)
DMFDRJT	MT	DTT
DMFDRJT	MA	Inhibitor
DMFDRJT	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMFDRJT	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMFDRJT	DI	DMFDRJT
DMFDRJT	DN	Imidazo[4,5-c]pyridine derivative 2
DMFDRJT	MI	TTRMX3V
DMFDRJT	MN	Janus kinase 2 (JAK-2)
DMFDRJT	MT	DTT
DMFDRJT	MA	Inhibitor
DMFDRJT	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMFDRJT	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMFDRJT	DI	DMFDRJT
DMFDRJT	DN	Imidazo[4,5-c]pyridine derivative 2
DMFDRJT	MI	TTT7PJU
DMFDRJT	MN	Janus kinase 3 (JAK-3)
DMFDRJT	MT	DTT
DMFDRJT	MA	Inhibitor
DMFDRJT	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMFDRJT	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMFDRJT	DI	DMFDRJT
DMFDRJT	DN	Imidazo[4,5-c]pyridine derivative 2
DMFDRJT	MI	TTBYWP2
DMFDRJT	MN	TYK2 tyrosine kinase (TYK2)
DMFDRJT	MT	DTT
DMFDRJT	MA	Inhibitor
DMFDRJT	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMFDRJT	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMFDRJT	DI	DMFDRJT
DMFDRJT	DN	Imidazo[4,5-c]pyridine derivative 2
DMFDRJT	MI	TTJSQEF
DMFDRJT	MN	Tyrosine-protein kinase (PTK)
DMFDRJT	MT	DTT
DMFDRJT	MA	Inhibitor
DMFDRJT	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMFDRJT	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMUB4QL	DI	DMUB4QL
DMUB4QL	DN	Imidazo[5,1-c][1,2,4]benzotriazine derivative 1
DMUB4QL	MI	TTJW4LU
DMUB4QL	MN	Phosphodiesterase 10A (PDE10)
DMUB4QL	MT	DTT
DMUB4QL	MA	Inhibitor
DMUB4QL	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMUB4QL	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMUB4QL	DI	DMUB4QL
DMUB4QL	DN	Imidazo[5,1-c][1,2,4]benzotriazine derivative 1
DMUB4QL	MI	TTJGW1Z
DMUB4QL	MN	Phosphodiesterase 2A (PDE2A)
DMUB4QL	MT	DTT
DMUB4QL	MA	Inhibitor
DMUB4QL	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMUB4QL	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMB8AJP	DI	DMB8AJP
DMB8AJP	DN	Imidazo[5,1-c][1,2,4]benzotriazine derivative 2
DMB8AJP	MI	TTJW4LU
DMB8AJP	MN	Phosphodiesterase 10A (PDE10)
DMB8AJP	MT	DTT
DMB8AJP	MA	Inhibitor
DMB8AJP	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMB8AJP	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMB8AJP	DI	DMB8AJP
DMB8AJP	DN	Imidazo[5,1-c][1,2,4]benzotriazine derivative 2
DMB8AJP	MI	TTJGW1Z
DMB8AJP	MN	Phosphodiesterase 2A (PDE2A)
DMB8AJP	MT	DTT
DMB8AJP	MA	Inhibitor
DMB8AJP	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMB8AJP	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMYX684	DI	DMYX684
DMYX684	DN	Imidazo[5,1-c][1,2,4]benzotriazine derivative 3
DMYX684	MI	TTJW4LU
DMYX684	MN	Phosphodiesterase 10A (PDE10)
DMYX684	MT	DTT
DMYX684	MA	Inhibitor
DMYX684	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMYX684	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMYX684	DI	DMYX684
DMYX684	DN	Imidazo[5,1-c][1,2,4]benzotriazine derivative 3
DMYX684	MI	TTJGW1Z
DMYX684	MN	Phosphodiesterase 2A (PDE2A)
DMYX684	MT	DTT
DMYX684	MA	Inhibitor
DMYX684	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMYX684	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMWF4S7	DI	DMWF4S7
DMWF4S7	DN	Imidazo[5,1-c][1,2,4]benzotriazine derivative 4
DMWF4S7	MI	TTJW4LU
DMWF4S7	MN	Phosphodiesterase 10A (PDE10)
DMWF4S7	MT	DTT
DMWF4S7	MA	Inhibitor
DMWF4S7	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMWF4S7	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMWF4S7	DI	DMWF4S7
DMWF4S7	DN	Imidazo[5,1-c][1,2,4]benzotriazine derivative 4
DMWF4S7	MI	TTJGW1Z
DMWF4S7	MN	Phosphodiesterase 2A (PDE2A)
DMWF4S7	MT	DTT
DMWF4S7	MA	Inhibitor
DMWF4S7	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMWF4S7	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMQBH81	DI	DMQBH81
DMQBH81	DN	Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 1
DMQBH81	MI	TTJW4LU
DMQBH81	MN	Phosphodiesterase 10A (PDE10)
DMQBH81	MT	DTT
DMQBH81	MA	Inhibitor
DMQBH81	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMQBH81	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMQBH81	DI	DMQBH81
DMQBH81	DN	Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 1
DMQBH81	MI	TTJGW1Z
DMQBH81	MN	Phosphodiesterase 2A (PDE2A)
DMQBH81	MT	DTT
DMQBH81	MA	Inhibitor
DMQBH81	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMQBH81	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMS3ROL	DI	DMS3ROL
DMS3ROL	DN	Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 2
DMS3ROL	MI	TTJW4LU
DMS3ROL	MN	Phosphodiesterase 10A (PDE10)
DMS3ROL	MT	DTT
DMS3ROL	MA	Inhibitor
DMS3ROL	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMS3ROL	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMS3ROL	DI	DMS3ROL
DMS3ROL	DN	Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 2
DMS3ROL	MI	TTJGW1Z
DMS3ROL	MN	Phosphodiesterase 2A (PDE2A)
DMS3ROL	MT	DTT
DMS3ROL	MA	Inhibitor
DMS3ROL	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMS3ROL	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMZ61T8	DI	DMZ61T8
DMZ61T8	DN	Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 3
DMZ61T8	MI	TTJW4LU
DMZ61T8	MN	Phosphodiesterase 10A (PDE10)
DMZ61T8	MT	DTT
DMZ61T8	MA	Inhibitor
DMZ61T8	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMZ61T8	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMZ61T8	DI	DMZ61T8
DMZ61T8	DN	Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 3
DMZ61T8	MI	TTJGW1Z
DMZ61T8	MN	Phosphodiesterase 2A (PDE2A)
DMZ61T8	MT	DTT
DMZ61T8	MA	Inhibitor
DMZ61T8	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMZ61T8	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMKR5ZO	DI	DMKR5ZO
DMKR5ZO	DN	Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 4
DMKR5ZO	MI	TTJW4LU
DMKR5ZO	MN	Phosphodiesterase 10A (PDE10)
DMKR5ZO	MT	DTT
DMKR5ZO	MA	Inhibitor
DMKR5ZO	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMKR5ZO	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMKR5ZO	DI	DMKR5ZO
DMKR5ZO	DN	Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 4
DMKR5ZO	MI	TTJGW1Z
DMKR5ZO	MN	Phosphodiesterase 2A (PDE2A)
DMKR5ZO	MT	DTT
DMKR5ZO	MA	Inhibitor
DMKR5ZO	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMKR5ZO	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DM7UAKH	DI	DM7UAKH
DM7UAKH	DN	Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 5
DM7UAKH	MI	TTJW4LU
DM7UAKH	MN	Phosphodiesterase 10A (PDE10)
DM7UAKH	MT	DTT
DM7UAKH	MA	Inhibitor
DM7UAKH	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DM7UAKH	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DM7UAKH	DI	DM7UAKH
DM7UAKH	DN	Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 5
DM7UAKH	MI	TTJGW1Z
DM7UAKH	MN	Phosphodiesterase 2A (PDE2A)
DM7UAKH	MT	DTT
DM7UAKH	MA	Inhibitor
DM7UAKH	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DM7UAKH	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMKRUAN	DI	DMKRUAN
DMKRUAN	DN	Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 6
DMKRUAN	MI	TTJW4LU
DMKRUAN	MN	Phosphodiesterase 10A (PDE10)
DMKRUAN	MT	DTT
DMKRUAN	MA	Inhibitor
DMKRUAN	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMKRUAN	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMKRUAN	DI	DMKRUAN
DMKRUAN	DN	Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 6
DMKRUAN	MI	TTJGW1Z
DMKRUAN	MN	Phosphodiesterase 2A (PDE2A)
DMKRUAN	MT	DTT
DMKRUAN	MA	Inhibitor
DMKRUAN	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMKRUAN	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMINBJM	DI	DMINBJM
DMINBJM	DN	Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 7
DMINBJM	MI	TTJW4LU
DMINBJM	MN	Phosphodiesterase 10A (PDE10)
DMINBJM	MT	DTT
DMINBJM	MA	Inhibitor
DMINBJM	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMINBJM	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMINBJM	DI	DMINBJM
DMINBJM	DN	Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 7
DMINBJM	MI	TTJGW1Z
DMINBJM	MN	Phosphodiesterase 2A (PDE2A)
DMINBJM	MT	DTT
DMINBJM	MA	Inhibitor
DMINBJM	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMINBJM	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DM42EST	DI	DM42EST
DM42EST	DN	Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 8
DM42EST	MI	TTJW4LU
DM42EST	MN	Phosphodiesterase 10A (PDE10)
DM42EST	MT	DTT
DM42EST	MA	Inhibitor
DM42EST	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DM42EST	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DM42EST	DI	DM42EST
DM42EST	DN	Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 8
DM42EST	MI	TTJGW1Z
DM42EST	MN	Phosphodiesterase 2A (PDE2A)
DM42EST	MT	DTT
DM42EST	MA	Inhibitor
DM42EST	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DM42EST	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DM0SOKJ	DI	DM0SOKJ
DM0SOKJ	DN	Imidazole benzamide derivative 1
DM0SOKJ	MI	TTYLQ8V
DM0SOKJ	MN	Prostaglandin E synthase (PTGES)
DM0SOKJ	MT	DTT
DM0SOKJ	MA	Inhibitor
DM0SOKJ	RN	Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059.
DM0SOKJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28627961

DM14KHX	DI	DM14KHX
DM14KHX	DN	Imidazole derivative 1
DM14KHX	MI	TT6OEDT
DM14KHX	MN	Cannabinoid receptor 1 (CB1)
DM14KHX	MT	DTT
DM14KHX	MA	Antagonist
DM14KHX	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DM14KHX	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMI7W3K	DI	DMI7W3K
DMI7W3K	DN	Imidazole derivative 10
DMI7W3K	MI	TTN9T81
DMI7W3K	MN	Arachidonate 15-lipoxygenase (15-LOX)
DMI7W3K	MT	DTT
DMI7W3K	MA	Inhibitor
DMI7W3K	RN	15-Lipoxygenase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):65-88.
DMI7W3K	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560362

DMTJ0DP	DI	DMTJ0DP
DMTJ0DP	DN	Imidazole derivative 11
DMTJ0DP	MI	TTN9T81
DMTJ0DP	MN	Arachidonate 15-lipoxygenase (15-LOX)
DMTJ0DP	MT	DTT
DMTJ0DP	MA	Inhibitor
DMTJ0DP	RN	15-Lipoxygenase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):65-88.
DMTJ0DP	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560362

DM8GCVO	DI	DM8GCVO
DM8GCVO	DN	Imidazole derivative 2
DM8GCVO	MI	TT6OEDT
DM8GCVO	MN	Cannabinoid receptor 1 (CB1)
DM8GCVO	MT	DTT
DM8GCVO	MA	Antagonist
DM8GCVO	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DM8GCVO	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMV1ER2	DI	DMV1ER2
DMV1ER2	DN	Imidazole derivative 3
DMV1ER2	MI	TT6OEDT
DMV1ER2	MN	Cannabinoid receptor 1 (CB1)
DMV1ER2	MT	DTT
DMV1ER2	MA	Antagonist
DMV1ER2	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMV1ER2	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMPGMX2	DI	DMPGMX2
DMPGMX2	DN	Imidazole derivative 4
DMPGMX2	MI	TT6OEDT
DMPGMX2	MN	Cannabinoid receptor 1 (CB1)
DMPGMX2	MT	DTT
DMPGMX2	MA	Antagonist
DMPGMX2	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMPGMX2	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMVSXUM	DI	DMVSXUM
DMVSXUM	DN	Imidazole derivative 5
DMVSXUM	MI	TT6OEDT
DMVSXUM	MN	Cannabinoid receptor 1 (CB1)
DMVSXUM	MT	DTT
DMVSXUM	MA	Antagonist
DMVSXUM	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMVSXUM	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMOXHZJ	DI	DMOXHZJ
DMOXHZJ	DN	Imidazole derivative 6
DMOXHZJ	MI	TT6OEDT
DMOXHZJ	MN	Cannabinoid receptor 1 (CB1)
DMOXHZJ	MT	DTT
DMOXHZJ	MA	Antagonist
DMOXHZJ	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMOXHZJ	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMLPQ7E	DI	DMLPQ7E
DMLPQ7E	DN	Imidazole derivative 7
DMLPQ7E	MI	TT6OEDT
DMLPQ7E	MN	Cannabinoid receptor 1 (CB1)
DMLPQ7E	MT	DTT
DMLPQ7E	MA	Antagonist
DMLPQ7E	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMLPQ7E	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMK9P7S	DI	DMK9P7S
DMK9P7S	DN	Imidazole derivative 8
DMK9P7S	MI	TTTJZ4M
DMK9P7S	MN	Prolylcarboxypeptidase (PRCP)
DMK9P7S	MT	DTT
DMK9P7S	MA	Inhibitor
DMK9P7S	RN	Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088.
DMK9P7S	RU	https://www.ncbi.nlm.nih.gov/pubmed/28699813

DMSV42L	DI	DMSV42L
DMSV42L	DN	Imidazole derivative 9
DMSV42L	MI	TTTJZ4M
DMSV42L	MN	Prolylcarboxypeptidase (PRCP)
DMSV42L	MT	DTT
DMSV42L	MA	Inhibitor
DMSV42L	RN	Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088.
DMSV42L	RU	https://www.ncbi.nlm.nih.gov/pubmed/28699813

DM7UMW2	DI	DM7UMW2
DM7UMW2	DN	Imidazoleisoindoles derivative 1
DM7UMW2	MI	TTZJYKH
DM7UMW2	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DM7UMW2	MT	DTT
DM7UMW2	MA	Inhibitor
DM7UMW2	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DM7UMW2	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMRJKIQ	DI	DMRJKIQ
DMRJKIQ	DN	Imidazoleisoindoles derivative 2
DMRJKIQ	MI	TTZJYKH
DMRJKIQ	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMRJKIQ	MT	DTT
DMRJKIQ	MA	Inhibitor
DMRJKIQ	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMRJKIQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMECJDM	DI	DMECJDM
DMECJDM	DN	Imidazolidine derivative 1
DMECJDM	MI	TT473XN
DMECJDM	MN	P2X purinoceptor 7 (P2RX7)
DMECJDM	MT	DTT
DMECJDM	MA	Antagonist
DMECJDM	RN	P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267.
DMECJDM	RU	https://www.ncbi.nlm.nih.gov/pubmed/27724045

DMUFSQ2	DI	DMUFSQ2
DMUFSQ2	DN	Imidazolidine-2,4-dione derivative 1
DMUFSQ2	MI	TT6OEDT
DMUFSQ2	MN	Cannabinoid receptor 1 (CB1)
DMUFSQ2	MT	DTT
DMUFSQ2	MA	Antagonist
DMUFSQ2	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMUFSQ2	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMVMD2O	DI	DMVMD2O
DMVMD2O	DN	Imidazolidine-2,4-dione derivative 2
DMVMD2O	MI	TT6OEDT
DMVMD2O	MN	Cannabinoid receptor 1 (CB1)
DMVMD2O	MT	DTT
DMVMD2O	MA	Antagonist
DMVMD2O	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMVMD2O	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DM847I2	DI	DM847I2
DM847I2	DN	Imidazolyl urea derivative 1
DM847I2	MI	TTDP1UC
DM847I2	MN	Fatty acid amide hydrolase (FAAH)
DM847I2	MT	DTT
DM847I2	MA	Inhibitor
DM847I2	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DM847I2	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMEY6L8	DI	DMEY6L8
DMEY6L8	DN	Imidazopyridazine derivative 1
DMEY6L8	MI	TT6DM01
DMEY6L8	MN	Janus kinase 1 (JAK-1)
DMEY6L8	MT	DTT
DMEY6L8	MA	Inhibitor
DMEY6L8	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMEY6L8	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMEY6L8	DI	DMEY6L8
DMEY6L8	DN	Imidazopyridazine derivative 1
DMEY6L8	MI	TTT7PJU
DMEY6L8	MN	Janus kinase 3 (JAK-3)
DMEY6L8	MT	DTT
DMEY6L8	MA	Inhibitor
DMEY6L8	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMEY6L8	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMZORKY	DI	DMZORKY
DMZORKY	DN	Imidazopyridazine derivative 2
DMZORKY	MI	TT6DM01
DMZORKY	MN	Janus kinase 1 (JAK-1)
DMZORKY	MT	DTT
DMZORKY	MA	Inhibitor
DMZORKY	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMZORKY	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMZORKY	DI	DMZORKY
DMZORKY	DN	Imidazopyridazine derivative 2
DMZORKY	MI	TTT7PJU
DMZORKY	MN	Janus kinase 3 (JAK-3)
DMZORKY	MT	DTT
DMZORKY	MA	Inhibitor
DMZORKY	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMZORKY	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMXVOP3	DI	DMXVOP3
DMXVOP3	DN	Imidazopyridazine derivative 3
DMXVOP3	MI	TTQR74A
DMXVOP3	MN	Proteinase activated receptor 2 (PAR2)
DMXVOP3	MT	DTT
DMXVOP3	MA	Antagonist
DMXVOP3	RN	Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
DMXVOP3	RU	https://www.ncbi.nlm.nih.gov/pubmed/26936077

DMIAJMO	DI	DMIAJMO
DMIAJMO	DN	Imidazopyridazine derivative 4
DMIAJMO	MI	TTQR74A
DMIAJMO	MN	Proteinase activated receptor 2 (PAR2)
DMIAJMO	MT	DTT
DMIAJMO	MA	Antagonist
DMIAJMO	RN	Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
DMIAJMO	RU	https://www.ncbi.nlm.nih.gov/pubmed/26936077

DM9SXYH	DI	DM9SXYH
DM9SXYH	DN	Imidazopyridazine derivative 5
DM9SXYH	MI	TTQR74A
DM9SXYH	MN	Proteinase activated receptor 2 (PAR2)
DM9SXYH	MT	DTT
DM9SXYH	MA	Antagonist
DM9SXYH	RN	Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
DM9SXYH	RU	https://www.ncbi.nlm.nih.gov/pubmed/26936077

DM5F1LR	DI	DM5F1LR
DM5F1LR	DN	Imidazopyridazine derivative 6
DM5F1LR	MI	TTQR74A
DM5F1LR	MN	Proteinase activated receptor 2 (PAR2)
DM5F1LR	MT	DTT
DM5F1LR	MA	Antagonist
DM5F1LR	RN	Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
DM5F1LR	RU	https://www.ncbi.nlm.nih.gov/pubmed/26936077

DM5X160	DI	DM5X160
DM5X160	DN	Imidazopyridazine derivative 7
DM5X160	MI	TTQR74A
DM5X160	MN	Proteinase activated receptor 2 (PAR2)
DM5X160	MT	DTT
DM5X160	MA	Antagonist
DM5X160	RN	Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
DM5X160	RU	https://www.ncbi.nlm.nih.gov/pubmed/26936077

DMF7NXJ	DI	DMF7NXJ
DMF7NXJ	DN	Imidazopyridazine derivative 8
DMF7NXJ	MI	TTQR74A
DMF7NXJ	MN	Proteinase activated receptor 2 (PAR2)
DMF7NXJ	MT	DTT
DMF7NXJ	MA	Antagonist
DMF7NXJ	RN	Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
DMF7NXJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26936077

DMO41ZB	DI	DMO41ZB
DMO41ZB	DN	Imidazopyridine acetamide analog 1
DMO41ZB	MI	TTPTXIN
DMO41ZB	MN	Translocator protein (TSPO)
DMO41ZB	MT	DTT
DMO41ZB	MA	Ligand
DMO41ZB	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMO41ZB	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMIKMBO	DI	DMIKMBO
DMIKMBO	DN	Imidazopyridine acetamide analog 2
DMIKMBO	MI	TTPTXIN
DMIKMBO	MN	Translocator protein (TSPO)
DMIKMBO	MT	DTT
DMIKMBO	MA	Ligand
DMIKMBO	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMIKMBO	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMZ08LD	DI	DMZ08LD
DMZ08LD	DN	Imidazopyridine acetamide analog 3
DMZ08LD	MI	TTPTXIN
DMZ08LD	MN	Translocator protein (TSPO)
DMZ08LD	MT	DTT
DMZ08LD	MA	Ligand
DMZ08LD	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMZ08LD	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMPHK87	DI	DMPHK87
DMPHK87	DN	Imidazopyridine acetamide analog 4
DMPHK87	MI	TTPTXIN
DMPHK87	MN	Translocator protein (TSPO)
DMPHK87	MT	DTT
DMPHK87	MA	Ligand
DMPHK87	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMPHK87	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMMFCRU	DI	DMMFCRU
DMMFCRU	DN	Imidazopyridine acetamide analog 5
DMMFCRU	MI	TTPTXIN
DMMFCRU	MN	Translocator protein (TSPO)
DMMFCRU	MT	DTT
DMMFCRU	MA	Ligand
DMMFCRU	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMMFCRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DME7M5R	DI	DME7M5R
DME7M5R	DN	Imidazopyridine acetamide analog 6
DME7M5R	MI	TTPTXIN
DME7M5R	MN	Translocator protein (TSPO)
DME7M5R	MT	DTT
DME7M5R	MA	Ligand
DME7M5R	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DME7M5R	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMQDA3I	DI	DMQDA3I
DMQDA3I	DN	Imidazopyridine acetamide analog 7
DMQDA3I	MI	TTPTXIN
DMQDA3I	MN	Translocator protein (TSPO)
DMQDA3I	MT	DTT
DMQDA3I	MA	Ligand
DMQDA3I	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMQDA3I	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMTUS0Y	DI	DMTUS0Y
DMTUS0Y	DN	Imidazopyridine and triazolopyridine compound 1
DMTUS0Y	MI	TTHS256
DMTUS0Y	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMTUS0Y	MT	DTT
DMTUS0Y	MA	Modulator
DMTUS0Y	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMTUS0Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMYCLAM	DI	DMYCLAM
DMYCLAM	DN	Imidazopyridine and triazolopyridine compound 2
DMYCLAM	MI	TTHS256
DMYCLAM	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMYCLAM	MT	DTT
DMYCLAM	MA	Modulator
DMYCLAM	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMYCLAM	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMWU8VM	DI	DMWU8VM
DMWU8VM	DN	Imidazopyridine and triazolopyridine compound 3
DMWU8VM	MI	TTHS256
DMWU8VM	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMWU8VM	MT	DTT
DMWU8VM	MA	Modulator
DMWU8VM	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMWU8VM	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMI1OWK	DI	DMI1OWK
DMI1OWK	DN	Imidazopyridine and triazolopyridine compound 4
DMI1OWK	MI	TTHS256
DMI1OWK	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMI1OWK	MT	DTT
DMI1OWK	MA	Modulator
DMI1OWK	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMI1OWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DM8EB57	DI	DM8EB57
DM8EB57	DN	Imidazopyridine derivative 1
DM8EB57	MI	TTPTXIN
DM8EB57	MN	Translocator protein (TSPO)
DM8EB57	MT	DTT
DM8EB57	MA	Ligand
DM8EB57	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DM8EB57	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DM9FRV7	DI	DM9FRV7
DM9FRV7	DN	Imidazopyridine derivative 2
DM9FRV7	MI	TTPTXIN
DM9FRV7	MN	Translocator protein (TSPO)
DM9FRV7	MT	DTT
DM9FRV7	MA	Ligand
DM9FRV7	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DM9FRV7	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMJCSL3	DI	DMJCSL3
DMJCSL3	DN	Imidazopyridine derivative 3
DMJCSL3	MI	TTBYWP2
DMJCSL3	MN	TYK2 tyrosine kinase (TYK2)
DMJCSL3	MT	DTT
DMJCSL3	MA	Inhibitor
DMJCSL3	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMJCSL3	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMP2AXV	DI	DMP2AXV
DMP2AXV	DN	Imidazopyridine derivative 4
DMP2AXV	MI	TTT7PJU
DMP2AXV	MN	Janus kinase 3 (JAK-3)
DMP2AXV	MT	DTT
DMP2AXV	MA	Inhibitor
DMP2AXV	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMP2AXV	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMP2AXV	DI	DMP2AXV
DMP2AXV	DN	Imidazopyridine derivative 4
DMP2AXV	MI	TTGM6VW
DMP2AXV	MN	Tyrosine-protein kinase BTK (ATK)
DMP2AXV	MT	DTT
DMP2AXV	MA	Inhibitor
DMP2AXV	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMP2AXV	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMUKBGD	DI	DMUKBGD
DMUKBGD	DN	Imidazopyridine derivative 5
DMUKBGD	MI	TTYLQ8V
DMUKBGD	MN	Prostaglandin E synthase (PTGES)
DMUKBGD	MT	DTT
DMUKBGD	MA	Inhibitor
DMUKBGD	RN	Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059.
DMUKBGD	RU	https://www.ncbi.nlm.nih.gov/pubmed/28627961

DMA0V4F	DI	DMA0V4F
DMA0V4F	DN	Imidazopyridine derivative 6
DMA0V4F	MI	TTYLQ8V
DMA0V4F	MN	Prostaglandin E synthase (PTGES)
DMA0V4F	MT	DTT
DMA0V4F	MA	Inhibitor
DMA0V4F	RN	Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059.
DMA0V4F	RU	https://www.ncbi.nlm.nih.gov/pubmed/28627961

DMI3XPJ	DI	DMI3XPJ
DMI3XPJ	DN	Imidazopyridine derivative 7
DMI3XPJ	MI	TTYLQ8V
DMI3XPJ	MN	Prostaglandin E synthase (PTGES)
DMI3XPJ	MT	DTT
DMI3XPJ	MA	Inhibitor
DMI3XPJ	RN	Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059.
DMI3XPJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28627961

DMWN17V	DI	DMWN17V
DMWN17V	DN	Imidazopyrimidinone derivative 1
DMWN17V	MI	TTSCIM2
DMWN17V	MN	Extracellular lysophospholipase D (E-NPP2)
DMWN17V	MT	DTT
DMWN17V	MA	Inhibitor
DMWN17V	RN	Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829.
DMWN17V	RU	https://www.ncbi.nlm.nih.gov/pubmed/28447479

DMX34PU	DI	DMX34PU
DMX34PU	DN	Imidazotriazinone derivative 1
DMX34PU	MI	TTJGW1Z
DMX34PU	MN	Phosphodiesterase 2A (PDE2A)
DMX34PU	MT	DTT
DMX34PU	MA	Inhibitor
DMX34PU	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMX34PU	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMBURAZ	DI	DMBURAZ
DMBURAZ	DN	IncarviatoneA
DMBURAZ	MI	TT3WG5C
DMBURAZ	MN	Monoamine oxidase type A (MAO-A)
DMBURAZ	MT	DTT
DMBURAZ	MA	Inhibitor
DMBURAZ	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMBURAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMA6BCH	DI	DMA6BCH
DMA6BCH	DN	Indandione derivative 1
DMA6BCH	MI	TTV1C0Z
DMA6BCH	MN	Neuropeptide S receptor (NPSR)
DMA6BCH	MT	DTT
DMA6BCH	MA	Antagonist
DMA6BCH	RN	Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362.
DMA6BCH	RU	https://www.ncbi.nlm.nih.gov/pubmed/27788040

DMVR04K	DI	DMVR04K
DMVR04K	DN	Indandione derivative 2
DMVR04K	MI	TTV1C0Z
DMVR04K	MN	Neuropeptide S receptor (NPSR)
DMVR04K	MT	DTT
DMVR04K	MA	Antagonist
DMVR04K	RN	Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362.
DMVR04K	RU	https://www.ncbi.nlm.nih.gov/pubmed/27788040

DM0TURE	DI	DM0TURE
DM0TURE	DN	Indandione derivative 3
DM0TURE	MI	TTV1C0Z
DM0TURE	MN	Neuropeptide S receptor (NPSR)
DM0TURE	MT	DTT
DM0TURE	MA	Antagonist
DM0TURE	RN	Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362.
DM0TURE	RU	https://www.ncbi.nlm.nih.gov/pubmed/27788040

DMQPTEJ	DI	DMQPTEJ
DMQPTEJ	DN	Indanone and indandione derivative 1
DMQPTEJ	MI	TTV1C0Z
DMQPTEJ	MN	Neuropeptide S receptor (NPSR)
DMQPTEJ	MT	DTT
DMQPTEJ	MA	Antagonist
DMQPTEJ	RN	Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362.
DMQPTEJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27788040

DMKUT6S	DI	DMKUT6S
DMKUT6S	DN	Indazole amide derivative 1
DMKUT6S	MI	TTKFVXR
DMKUT6S	MN	Renal carcinoma antigen NY-REN-64 (IRAK-4)
DMKUT6S	MT	DTT
DMKUT6S	MA	Inhibitor
DMKUT6S	RN	Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32.
DMKUT6S	RU	https://www.ncbi.nlm.nih.gov/pubmed/27310003

DMRPT5O	DI	DMRPT5O
DMRPT5O	DN	Indazole amide derivative 2
DMRPT5O	MI	TTKFVXR
DMRPT5O	MN	Renal carcinoma antigen NY-REN-64 (IRAK-4)
DMRPT5O	MT	DTT
DMRPT5O	MA	Inhibitor
DMRPT5O	RN	Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32.
DMRPT5O	RU	https://www.ncbi.nlm.nih.gov/pubmed/27310003

DME8JTW	DI	DME8JTW
DME8JTW	DN	Indazole derivative 1
DME8JTW	MI	TTCZOF2
DME8JTW	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DME8JTW	MT	DTT
DME8JTW	MA	Inhibitor
DME8JTW	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DME8JTW	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMV7AX9	DI	DMV7AX9
DMV7AX9	DN	Indazole derivative 2
DMV7AX9	MI	TTZJYKH
DMV7AX9	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMV7AX9	MT	DTT
DMV7AX9	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMV7AX9	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMVUWLK	DI	DMVUWLK
DMVUWLK	DN	Indazole derivative 3
DMVUWLK	MI	TTZJYKH
DMVUWLK	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMVUWLK	MT	DTT
DMVUWLK	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMVUWLK	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMVUWLK	DI	DMVUWLK
DMVUWLK	DN	Indazole derivative 3
DMVUWLK	MI	TTXNCBV
DMVUWLK	MN	Tryptophan 2,3-dioxygenase (TDO)
DMVUWLK	MT	DTT
DMVUWLK	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMVUWLK	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMJ2CRO	DI	DMJ2CRO
DMJ2CRO	DN	Indazole derivative 4
DMJ2CRO	MI	TTZJYKH
DMJ2CRO	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMJ2CRO	MT	DTT
DMJ2CRO	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMJ2CRO	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMM1I8R	DI	DMM1I8R
DMM1I8R	DN	Indazole derivative 5
DMM1I8R	MI	TTZJTWA
DMM1I8R	MN	ABL T315I mutant (ABL T315I)
DMM1I8R	MT	DTT
DMM1I8R	MA	Inhibitor
DMM1I8R	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMM1I8R	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMM1I8R	DI	DMM1I8R
DMM1I8R	DN	Indazole derivative 5
DMM1I8R	MI	TTIV39N
DMM1I8R	MN	Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I)
DMM1I8R	MT	DTT
DMM1I8R	MA	Inhibitor
DMM1I8R	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMM1I8R	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMGO1CB	DI	DMGO1CB
DMGO1CB	DN	Indazole derivative 6
DMGO1CB	MI	TTRZQE3
DMGO1CB	MN	Glycogen synthase kinase-3 alpha (GSK-3A)
DMGO1CB	MT	DTT
DMGO1CB	MA	Inhibitor
DMGO1CB	RN	Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
DMGO1CB	RU	https://www.ncbi.nlm.nih.gov/pubmed/27828716

DMHJDU6	DI	DMHJDU6
DMHJDU6	DN	Indazoletriazolephenyl derivative 1
DMHJDU6	MI	TTXAJWN
DMHJDU6	MN	IL-1 receptor-associated kinase 1 (IRAK1)
DMHJDU6	MT	DTT
DMHJDU6	MA	Inhibitor
DMHJDU6	RN	Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32.
DMHJDU6	RU	https://www.ncbi.nlm.nih.gov/pubmed/27310003

DMHJDU6	DI	DMHJDU6
DMHJDU6	DN	Indazoletriazolephenyl derivative 1
DMHJDU6	MI	TTKFVXR
DMHJDU6	MN	Renal carcinoma antigen NY-REN-64 (IRAK-4)
DMHJDU6	MT	DTT
DMHJDU6	MA	Inhibitor
DMHJDU6	RN	Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32.
DMHJDU6	RU	https://www.ncbi.nlm.nih.gov/pubmed/27310003

DMWZLK6	DI	DMWZLK6
DMWZLK6	DN	Indazoletriazolephenyl derivative 2
DMWZLK6	MI	TTXAJWN
DMWZLK6	MN	IL-1 receptor-associated kinase 1 (IRAK1)
DMWZLK6	MT	DTT
DMWZLK6	MA	Inhibitor
DMWZLK6	RN	Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32.
DMWZLK6	RU	https://www.ncbi.nlm.nih.gov/pubmed/27310003

DMWZLK6	DI	DMWZLK6
DMWZLK6	DN	Indazoletriazolephenyl derivative 2
DMWZLK6	MI	TTKFVXR
DMWZLK6	MN	Renal carcinoma antigen NY-REN-64 (IRAK-4)
DMWZLK6	MT	DTT
DMWZLK6	MA	Inhibitor
DMWZLK6	RN	Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32.
DMWZLK6	RU	https://www.ncbi.nlm.nih.gov/pubmed/27310003

DMR2GW1	DI	DMR2GW1
DMR2GW1	DN	Indazolyl-thiadiazolamine derivative 1
DMR2GW1	MI	TTGWKQJ
DMR2GW1	MN	Rho-associated protein kinase 2 (ROCK2)
DMR2GW1	MT	DTT
DMR2GW1	MA	Inhibitor
DMR2GW1	RN	Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
DMR2GW1	RU	https://www.ncbi.nlm.nih.gov/pubmed/28048944

DMB8673	DI	DMB8673
DMB8673	DN	Indirubin derivative 1
DMB8673	MI	TTLRFIH
DMB8673	MN	Signal transducer and activator of transcription 5 (STAT5)
DMB8673	MT	DTT
DMB8673	MA	Inhibitor
DMB8673	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMB8673	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMLX183	DI	DMLX183
DMLX183	DN	Indirubin derivative 2
DMLX183	MI	TTRZQE3
DMLX183	MN	Glycogen synthase kinase-3 alpha (GSK-3A)
DMLX183	MT	DTT
DMLX183	MA	Inhibitor
DMLX183	RN	Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
DMLX183	RU	https://www.ncbi.nlm.nih.gov/pubmed/27828716

DM5F8J1	DI	DM5F8J1
DM5F8J1	DN	Indol-5-ol derivative 1
DM5F8J1	MI	TT3PJMV
DM5F8J1	MN	Tyrosine-protein kinase ABL1 (ABL)
DM5F8J1	MT	DTT
DM5F8J1	MA	Inhibitor
DM5F8J1	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DM5F8J1	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMS0169	DI	DMS0169
DMS0169	DN	Indole and benzimidazole derivative 1
DMS0169	MI	TTN9T81
DMS0169	MN	Arachidonate 15-lipoxygenase (15-LOX)
DMS0169	MT	DTT
DMS0169	RN	15-Lipoxygenase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):65-88.
DMS0169	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560362

DMLHGC9	DI	DMLHGC9
DMLHGC9	DN	Indole carboxamide derivative 1
DMLHGC9	MI	TT473XN
DMLHGC9	MN	P2X purinoceptor 7 (P2RX7)
DMLHGC9	MT	DTT
DMLHGC9	MA	Antagonist
DMLHGC9	RN	P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267.
DMLHGC9	RU	https://www.ncbi.nlm.nih.gov/pubmed/27724045

DMIGS81	DI	DMIGS81
DMIGS81	DN	Indole-based analog 1
DMIGS81	MI	TTL53M6
DMIGS81	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DMIGS81	MT	DTT
DMIGS81	MA	Inhibitor
DMIGS81	RN	Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
DMIGS81	RU	https://www.ncbi.nlm.nih.gov/pubmed/27744724

DMAM6YC	DI	DMAM6YC
DMAM6YC	DN	Indole-based analog 10
DMAM6YC	MI	TTPTXIN
DMAM6YC	MN	Translocator protein (TSPO)
DMAM6YC	MT	DTT
DMAM6YC	MA	Ligand
DMAM6YC	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366.
DMAM6YC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27599163

DMVRX7S	DI	DMVRX7S
DMVRX7S	DN	Indole-based analog 11
DMVRX7S	MI	TT7HF4W
DMVRX7S	MN	Cyclin-dependent kinase 2 (CDK2)
DMVRX7S	MT	DTT
DMVRX7S	MA	Inhibitor
DMVRX7S	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMVRX7S	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMVRX7S	DI	DMVRX7S
DMVRX7S	DN	Indole-based analog 11
DMVRX7S	MI	TTBH0VX
DMVRX7S	MN	Histone deacetylase (HDAC)
DMVRX7S	MT	DTT
DMVRX7S	MA	Inhibitor
DMVRX7S	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMVRX7S	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DM1CNRH	DI	DM1CNRH
DM1CNRH	DN	Indole-based analog 12
DM1CNRH	MI	TTMBO1Z
DM1CNRH	MN	Cyclin-dependent kinase (CDK)
DM1CNRH	MT	DTT
DM1CNRH	MA	Inhibitor
DM1CNRH	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DM1CNRH	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMV7DFM	DI	DMV7DFM
DMV7DFM	DN	Indole-based analog 13
DMV7DFM	MI	TTH6V3D
DMV7DFM	MN	Cyclin-dependent kinase 1 (CDK1)
DMV7DFM	MT	DTT
DMV7DFM	MA	Inhibitor
DMV7DFM	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMV7DFM	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMV7DFM	DI	DMV7DFM
DMV7DFM	DN	Indole-based analog 13
DMV7DFM	MI	TT7HF4W
DMV7DFM	MN	Cyclin-dependent kinase 2 (CDK2)
DMV7DFM	MT	DTT
DMV7DFM	MA	Inhibitor
DMV7DFM	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMV7DFM	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMV7DFM	DI	DMV7DFM
DMV7DFM	DN	Indole-based analog 13
DMV7DFM	MI	TT0PG8F
DMV7DFM	MN	Cyclin-dependent kinase 4 (CDK4)
DMV7DFM	MT	DTT
DMV7DFM	MA	Inhibitor
DMV7DFM	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMV7DFM	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMV7DFM	DI	DMV7DFM
DMV7DFM	DN	Indole-based analog 13
DMV7DFM	MI	TT1LVF2
DMV7DFM	MN	Cyclin-dependent kinase 9 (CDK9)
DMV7DFM	MT	DTT
DMV7DFM	MA	Inhibitor
DMV7DFM	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMV7DFM	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMQURWZ	DI	DMQURWZ
DMQURWZ	DN	Indole-based analog 14
DMQURWZ	MI	TTUM2ZR
DMQURWZ	MN	Ribosomal protein S6 kinase alpha-3 (RSK3)
DMQURWZ	MT	DTT
DMQURWZ	MA	Inhibitor
DMQURWZ	RN	Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78.
DMQURWZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27410995

DM0NEVC	DI	DM0NEVC
DM0NEVC	DN	Indole-based analog 2
DM0NEVC	MI	TTJGNVC
DM0NEVC	MN	Apoptosis regulator Bcl-2 (BCL-2)
DM0NEVC	MT	DTT
DM0NEVC	MA	Inhibitor
DM0NEVC	RN	Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
DM0NEVC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27744724

DM0NEVC	DI	DM0NEVC
DM0NEVC	DN	Indole-based analog 2
DM0NEVC	MI	TTU1E82
DM0NEVC	MN	Apoptosis regulator Bcl-xL (BCL-xL)
DM0NEVC	MT	DTT
DM0NEVC	MA	Inhibitor
DM0NEVC	RN	Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
DM0NEVC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27744724

DM0NEVC	DI	DM0NEVC
DM0NEVC	DN	Indole-based analog 2
DM0NEVC	MI	TTL53M6
DM0NEVC	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DM0NEVC	MT	DTT
DM0NEVC	MA	Inhibitor
DM0NEVC	RN	Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
DM0NEVC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27744724

DMTEYQJ	DI	DMTEYQJ
DMTEYQJ	DN	Indole-based analog 3
DMTEYQJ	MI	TTJGNVC
DMTEYQJ	MN	Apoptosis regulator Bcl-2 (BCL-2)
DMTEYQJ	MT	DTT
DMTEYQJ	MA	Inhibitor
DMTEYQJ	RN	Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
DMTEYQJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27744724

DMTEYQJ	DI	DMTEYQJ
DMTEYQJ	DN	Indole-based analog 3
DMTEYQJ	MI	TTU1E82
DMTEYQJ	MN	Apoptosis regulator Bcl-xL (BCL-xL)
DMTEYQJ	MT	DTT
DMTEYQJ	MA	Inhibitor
DMTEYQJ	RN	Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
DMTEYQJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27744724

DMTEYQJ	DI	DMTEYQJ
DMTEYQJ	DN	Indole-based analog 3
DMTEYQJ	MI	TTL53M6
DMTEYQJ	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DMTEYQJ	MT	DTT
DMTEYQJ	MA	Inhibitor
DMTEYQJ	RN	Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
DMTEYQJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27744724

DM5JUR2	DI	DM5JUR2
DM5JUR2	DN	Indole-based analog 5
DM5JUR2	MI	TTPTXIN
DM5JUR2	MN	Translocator protein (TSPO)
DM5JUR2	MT	DTT
DM5JUR2	MA	Ligand
DM5JUR2	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366.
DM5JUR2	RU	https://www.ncbi.nlm.nih.gov/pubmed/27599163

DMFI2H6	DI	DMFI2H6
DMFI2H6	DN	Indole-based analog 9
DMFI2H6	MI	TTPTXIN
DMFI2H6	MN	Translocator protein (TSPO)
DMFI2H6	MT	DTT
DMFI2H6	MA	Ligand
DMFI2H6	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366.
DMFI2H6	RU	https://www.ncbi.nlm.nih.gov/pubmed/27599163

DMJ41UI	DI	DMJ41UI
DMJ41UI	DN	Indoline derivative 1
DMJ41UI	MI	TT1RS9F
DMJ41UI	MN	Acetylcholinesterase (AChE)
DMJ41UI	MT	DTT
DMJ41UI	MA	Inhibitor
DMJ41UI	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DMJ41UI	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DMJ41UI	DI	DMJ41UI
DMJ41UI	DN	Indoline derivative 1
DMJ41UI	MI	TTEB0GD
DMJ41UI	MN	Cholinesterase (BCHE)
DMJ41UI	MT	DTT
DMJ41UI	MA	Inhibitor
DMJ41UI	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DMJ41UI	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DMTPGRO	DI	DMTPGRO
DMTPGRO	DN	Indoline derivative 10
DMTPGRO	MI	TT5OU0D
DMTPGRO	MN	PRKR-like endoplasmic reticulum kinase (PERK)
DMTPGRO	MT	DTT
DMTPGRO	MA	Inhibitor
DMTPGRO	RN	Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48.
DMTPGRO	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646439

DM6JR3X	DI	DM6JR3X
DM6JR3X	DN	Indoline derivative 11
DM6JR3X	MI	TT5OU0D
DM6JR3X	MN	PRKR-like endoplasmic reticulum kinase (PERK)
DM6JR3X	MT	DTT
DM6JR3X	MA	Inhibitor
DM6JR3X	RN	Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48.
DM6JR3X	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646439

DMJURBM	DI	DMJURBM
DMJURBM	DN	Indoline derivative 12
DMJURBM	MI	TTOHSBA
DMJURBM	MN	Vascular endothelial growth factor A (VEGFA)
DMJURBM	MT	DTT
DMJURBM	MA	Inhibitor
DMJURBM	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMJURBM	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DM982GD	DI	DM982GD
DM982GD	DN	Indoline derivative 13
DM982GD	MI	TTOHSBA
DM982GD	MN	Vascular endothelial growth factor A (VEGFA)
DM982GD	MT	DTT
DM982GD	MA	Inhibitor
DM982GD	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DM982GD	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DM8DHRN	DI	DM8DHRN
DM8DHRN	DN	Indoline derivative 14
DM8DHRN	MI	TTOHSBA
DM8DHRN	MN	Vascular endothelial growth factor A (VEGFA)
DM8DHRN	MT	DTT
DM8DHRN	MA	Inhibitor
DM8DHRN	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DM8DHRN	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMRFEH4	DI	DMRFEH4
DMRFEH4	DN	Indoline derivative 15
DMRFEH4	MI	TTOHSBA
DMRFEH4	MN	Vascular endothelial growth factor A (VEGFA)
DMRFEH4	MT	DTT
DMRFEH4	MA	Inhibitor
DMRFEH4	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMRFEH4	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DM9AGBT	DI	DM9AGBT
DM9AGBT	DN	Indoline derivative 16
DM9AGBT	MI	TTOHSBA
DM9AGBT	MN	Vascular endothelial growth factor A (VEGFA)
DM9AGBT	MT	DTT
DM9AGBT	MA	Inhibitor
DM9AGBT	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DM9AGBT	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMXSFJ8	DI	DMXSFJ8
DMXSFJ8	DN	Indoline derivative 17
DMXSFJ8	MI	TTOHSBA
DMXSFJ8	MN	Vascular endothelial growth factor A (VEGFA)
DMXSFJ8	MT	DTT
DMXSFJ8	MA	Inhibitor
DMXSFJ8	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMXSFJ8	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMX640D	DI	DMX640D
DMX640D	DN	Indoline derivative 18
DMX640D	MI	TTOHSBA
DMX640D	MN	Vascular endothelial growth factor A (VEGFA)
DMX640D	MT	DTT
DMX640D	MA	Inhibitor
DMX640D	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMX640D	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMOHITL	DI	DMOHITL
DMOHITL	DN	Indoline derivative 19
DMOHITL	MI	TTOHSBA
DMOHITL	MN	Vascular endothelial growth factor A (VEGFA)
DMOHITL	MT	DTT
DMOHITL	MA	Inhibitor
DMOHITL	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMOHITL	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMASXR5	DI	DMASXR5
DMASXR5	DN	Indoline derivative 2
DMASXR5	MI	TT5OU0D
DMASXR5	MN	PRKR-like endoplasmic reticulum kinase (PERK)
DMASXR5	MT	DTT
DMASXR5	MA	Inhibitor
DMASXR5	RN	Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48.
DMASXR5	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646439

DM4JNLQ	DI	DM4JNLQ
DM4JNLQ	DN	Indoline derivative 20
DM4JNLQ	MI	TTOHSBA
DM4JNLQ	MN	Vascular endothelial growth factor A (VEGFA)
DM4JNLQ	MT	DTT
DM4JNLQ	MA	Inhibitor
DM4JNLQ	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DM4JNLQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DM3YPX1	DI	DM3YPX1
DM3YPX1	DN	Indoline derivative 21
DM3YPX1	MI	TTOHSBA
DM3YPX1	MN	Vascular endothelial growth factor A (VEGFA)
DM3YPX1	MT	DTT
DM3YPX1	MA	Inhibitor
DM3YPX1	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DM3YPX1	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DM20YBJ	DI	DM20YBJ
DM20YBJ	DN	Indoline derivative 3
DM20YBJ	MI	TT5OU0D
DM20YBJ	MN	PRKR-like endoplasmic reticulum kinase (PERK)
DM20YBJ	MT	DTT
DM20YBJ	MA	Inhibitor
DM20YBJ	RN	Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48.
DM20YBJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646439

DMU5KWC	DI	DMU5KWC
DMU5KWC	DN	Indoline derivative 6
DMU5KWC	MI	TT5OU0D
DMU5KWC	MN	PRKR-like endoplasmic reticulum kinase (PERK)
DMU5KWC	MT	DTT
DMU5KWC	MA	Inhibitor
DMU5KWC	RN	Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48.
DMU5KWC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646439

DMXS46Y	DI	DMXS46Y
DMXS46Y	DN	Indoline derivative 7
DMXS46Y	MI	TT5OU0D
DMXS46Y	MN	PRKR-like endoplasmic reticulum kinase (PERK)
DMXS46Y	MT	DTT
DMXS46Y	MA	Inhibitor
DMXS46Y	RN	Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48.
DMXS46Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646439

DMS8KMB	DI	DMS8KMB
DMS8KMB	DN	Indoline derivative 8
DMS8KMB	MI	TT5OU0D
DMS8KMB	MN	PRKR-like endoplasmic reticulum kinase (PERK)
DMS8KMB	MT	DTT
DMS8KMB	MA	Inhibitor
DMS8KMB	RN	Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48.
DMS8KMB	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646439

DMCORT3	DI	DMCORT3
DMCORT3	DN	Indoline derivative 9
DMCORT3	MI	TT5OU0D
DMCORT3	MN	PRKR-like endoplasmic reticulum kinase (PERK)
DMCORT3	MT	DTT
DMCORT3	MA	Inhibitor
DMCORT3	RN	Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48.
DMCORT3	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646439

DMTC129	DI	DMTC129
DMTC129	DN	Indolinone derivative 1
DMTC129	MI	TTCZOF2
DMTC129	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMTC129	MT	DTT
DMTC129	MA	Inhibitor
DMTC129	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMTC129	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DM4GZBI	DI	DM4GZBI
DM4GZBI	DN	Indolizine derivative 1
DM4GZBI	MI	TTN9T81
DM4GZBI	MN	Arachidonate 15-lipoxygenase (15-LOX)
DM4GZBI	MT	DTT
DM4GZBI	MA	Inhibitor
DM4GZBI	RN	Inhibitors of phospholipase A2 and their therapeutic potential: an update on patents (2012-2016).Expert Opin Ther Pat. 2017 Feb;27(2):217-225.
DM4GZBI	RU	https://www.ncbi.nlm.nih.gov/pubmed/27718763

DM4GZBI	DI	DM4GZBI
DM4GZBI	DN	Indolizine derivative 1
DM4GZBI	MI	TTDNFMT
DM4GZBI	MN	Platelet-activating factor acetylhydrolase (PLA2G7)
DM4GZBI	MT	DTT
DM4GZBI	MA	Inhibitor
DM4GZBI	RN	Inhibitors of phospholipase A2 and their therapeutic potential: an update on patents (2012-2016).Expert Opin Ther Pat. 2017 Feb;27(2):217-225.
DM4GZBI	RU	https://www.ncbi.nlm.nih.gov/pubmed/27718763

DM3E5V6	DI	DM3E5V6
DM3E5V6	DN	Indomethacin analog 1
DM3E5V6	MI	TT5ZWB6
DM3E5V6	MN	Dihydrodiol dehydrogenase type I (AKR1C3)
DM3E5V6	MT	DTT
DM3E5V6	MA	Inhibitor; Antagonist; Blocker
DM3E5V6	RN	Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340.
DM3E5V6	RU	https://www.ncbi.nlm.nih.gov/pubmed/28895472

DMKFPJ7	DI	DMKFPJ7
DMKFPJ7	DN	Indomethacin analog 2
DMKFPJ7	MI	TT5ZWB6
DMKFPJ7	MN	Dihydrodiol dehydrogenase type I (AKR1C3)
DMKFPJ7	MT	DTT
DMKFPJ7	MA	Inhibitor; Antagonist; Blocker
DMKFPJ7	RN	Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340.
DMKFPJ7	RU	https://www.ncbi.nlm.nih.gov/pubmed/28895472

DM53JXE	DI	DM53JXE
DM53JXE	DN	Indomethacin analog 3
DM53JXE	MI	TT5ZWB6
DM53JXE	MN	Dihydrodiol dehydrogenase type I (AKR1C3)
DM53JXE	MT	DTT
DM53JXE	MA	Inhibitor; Antagonist; Blocker
DM53JXE	RN	Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340.
DM53JXE	RU	https://www.ncbi.nlm.nih.gov/pubmed/28895472

DMI3YO7	DI	DMI3YO7
DMI3YO7	DN	Iodophenyl-N-methyl-N-fluoroalkyl-3-isoquinoline carboxamide derivative 1
DMI3YO7	MI	TTPTXIN
DMI3YO7	MN	Translocator protein (TSPO)
DMI3YO7	MT	DTT
DMI3YO7	MA	Ligand
DMI3YO7	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMI3YO7	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DM8LNXQ	DI	DM8LNXQ
DM8LNXQ	DN	Iodophenyl-N-methyl-N-fluoroalkyl-3-isoquinoline carboxamide derivative 2
DM8LNXQ	MI	TTPTXIN
DM8LNXQ	MN	Translocator protein (TSPO)
DM8LNXQ	MT	DTT
DM8LNXQ	MA	Ligand
DM8LNXQ	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DM8LNXQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DM39H1F	DI	DM39H1F
DM39H1F	DN	Iodophenyl-N-methyl-N-fluoroalkyl-3-isoquinoline carboxamide derivative 3
DM39H1F	MI	TTPTXIN
DM39H1F	MN	Translocator protein (TSPO)
DM39H1F	MT	DTT
DM39H1F	MA	Ligand
DM39H1F	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DM39H1F	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMDBK6O	DI	DMDBK6O
DMDBK6O	DN	Isochroman-4-ketone derivative 1
DMDBK6O	MI	TT1RS9F
DMDBK6O	MN	Acetylcholinesterase (AChE)
DMDBK6O	MT	DTT
DMDBK6O	MA	Inhibitor
DMDBK6O	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DMDBK6O	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DMDBK6O	DI	DMDBK6O
DMDBK6O	DN	Isochroman-4-ketone derivative 1
DMDBK6O	MI	TTEB0GD
DMDBK6O	MN	Cholinesterase (BCHE)
DMDBK6O	MT	DTT
DMDBK6O	MA	Inhibitor
DMDBK6O	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DMDBK6O	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DMMCWH9	DI	DMMCWH9
DMMCWH9	DN	Isoflavone derivative 1
DMMCWH9	MI	TT8J1S3
DMMCWH9	MN	Smoothened homolog (SMO)
DMMCWH9	MT	DTT
DMMCWH9	MA	Inhibitor
DMMCWH9	RN	Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35.
DMMCWH9	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666870

DMMCWH9	DI	DMMCWH9
DMMCWH9	DN	Isoflavone derivative 1
DMMCWH9	MI	TTJOMH6
DMMCWH9	MN	Zinc finger protein GLI1 (Gli1)
DMMCWH9	MT	DTT
DMMCWH9	MA	Inhibitor
DMMCWH9	RN	Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35.
DMMCWH9	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666870

DMTWAH3	DI	DMTWAH3
DMTWAH3	DN	Isoflavone derivative 2
DMTWAH3	MI	TT8J1S3
DMTWAH3	MN	Smoothened homolog (SMO)
DMTWAH3	MT	DTT
DMTWAH3	MA	Inhibitor
DMTWAH3	RN	Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35.
DMTWAH3	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666870

DMTWAH3	DI	DMTWAH3
DMTWAH3	DN	Isoflavone derivative 2
DMTWAH3	MI	TTJOMH6
DMTWAH3	MN	Zinc finger protein GLI1 (Gli1)
DMTWAH3	MT	DTT
DMTWAH3	MA	Inhibitor
DMTWAH3	RN	Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35.
DMTWAH3	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666870

DMYFKR2	DI	DMYFKR2
DMYFKR2	DN	Isoflavone derivative 3
DMYFKR2	MI	TT8J1S3
DMYFKR2	MN	Smoothened homolog (SMO)
DMYFKR2	MT	DTT
DMYFKR2	MA	Inhibitor
DMYFKR2	RN	Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35.
DMYFKR2	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666870

DMYFKR2	DI	DMYFKR2
DMYFKR2	DN	Isoflavone derivative 3
DMYFKR2	MI	TTJOMH6
DMYFKR2	MN	Zinc finger protein GLI1 (Gli1)
DMYFKR2	MT	DTT
DMYFKR2	MA	Inhibitor
DMYFKR2	RN	Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35.
DMYFKR2	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666870

DMYRU7I	DI	DMYRU7I
DMYRU7I	DN	Isoflavone derivative 4
DMYRU7I	MI	TT8J1S3
DMYRU7I	MN	Smoothened homolog (SMO)
DMYRU7I	MT	DTT
DMYRU7I	MA	Inhibitor
DMYRU7I	RN	Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35.
DMYRU7I	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666870

DMYRU7I	DI	DMYRU7I
DMYRU7I	DN	Isoflavone derivative 4
DMYRU7I	MI	TTJOMH6
DMYRU7I	MN	Zinc finger protein GLI1 (Gli1)
DMYRU7I	MT	DTT
DMYRU7I	MA	Inhibitor
DMYRU7I	RN	Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35.
DMYRU7I	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666870

DM2GL47	DI	DM2GL47
DM2GL47	DN	Isoflavone derivative 5
DM2GL47	MI	TT8J1S3
DM2GL47	MN	Smoothened homolog (SMO)
DM2GL47	MT	DTT
DM2GL47	MA	Inhibitor
DM2GL47	RN	Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35.
DM2GL47	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666870

DM2GL47	DI	DM2GL47
DM2GL47	DN	Isoflavone derivative 5
DM2GL47	MI	TTJOMH6
DM2GL47	MN	Zinc finger protein GLI1 (Gli1)
DM2GL47	MT	DTT
DM2GL47	MA	Inhibitor
DM2GL47	RN	Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35.
DM2GL47	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666870

DM2ZYVL	DI	DM2ZYVL
DM2ZYVL	DN	Isoflavone derivative 6
DM2ZYVL	MI	TT8J1S3
DM2ZYVL	MN	Smoothened homolog (SMO)
DM2ZYVL	MT	DTT
DM2ZYVL	MA	Inhibitor
DM2ZYVL	RN	Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35.
DM2ZYVL	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666870

DM2ZYVL	DI	DM2ZYVL
DM2ZYVL	DN	Isoflavone derivative 6
DM2ZYVL	MI	TTJOMH6
DM2ZYVL	MN	Zinc finger protein GLI1 (Gli1)
DM2ZYVL	MT	DTT
DM2ZYVL	MA	Inhibitor
DM2ZYVL	RN	Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35.
DM2ZYVL	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666870

DMNCHBL	DI	DMNCHBL
DMNCHBL	DN	Isoflavone derivative 7
DMNCHBL	MI	TT8J1S3
DMNCHBL	MN	Smoothened homolog (SMO)
DMNCHBL	MT	DTT
DMNCHBL	MA	Inhibitor
DMNCHBL	RN	Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35.
DMNCHBL	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666870

DMNCHBL	DI	DMNCHBL
DMNCHBL	DN	Isoflavone derivative 7
DMNCHBL	MI	TTJOMH6
DMNCHBL	MN	Zinc finger protein GLI1 (Gli1)
DMNCHBL	MT	DTT
DMNCHBL	MA	Inhibitor
DMNCHBL	RN	Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35.
DMNCHBL	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666870

DMN0XJQ	DI	DMN0XJQ
DMN0XJQ	DN	Isoflavone derivative 8
DMN0XJQ	MI	TT8J1S3
DMN0XJQ	MN	Smoothened homolog (SMO)
DMN0XJQ	MT	DTT
DMN0XJQ	MA	Inhibitor
DMN0XJQ	RN	Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35.
DMN0XJQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666870

DMN0XJQ	DI	DMN0XJQ
DMN0XJQ	DN	Isoflavone derivative 8
DMN0XJQ	MI	TTJOMH6
DMN0XJQ	MN	Zinc finger protein GLI1 (Gli1)
DMN0XJQ	MT	DTT
DMN0XJQ	MA	Inhibitor
DMN0XJQ	RN	Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35.
DMN0XJQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666870

DMA78MD	DI	DMA78MD
DMA78MD	DN	Isoflavone derivative 9
DMA78MD	MI	TT8J1S3
DMA78MD	MN	Smoothened homolog (SMO)
DMA78MD	MT	DTT
DMA78MD	MA	Inhibitor
DMA78MD	RN	Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35.
DMA78MD	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666870

DMA78MD	DI	DMA78MD
DMA78MD	DN	Isoflavone derivative 9
DMA78MD	MI	TTJOMH6
DMA78MD	MN	Zinc finger protein GLI1 (Gli1)
DMA78MD	MT	DTT
DMA78MD	MA	Inhibitor
DMA78MD	RN	Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35.
DMA78MD	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666870

DMWTU8X	DI	DMWTU8X
DMWTU8X	DN	Isoindole 1,3-dione analog 1
DMWTU8X	MI	TT473XN
DMWTU8X	MN	P2X purinoceptor 7 (P2RX7)
DMWTU8X	MT	DTT
DMWTU8X	MA	Antagonist
DMWTU8X	RN	P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267.
DMWTU8X	RU	https://www.ncbi.nlm.nih.gov/pubmed/27724045

DMD19QC	DI	DMD19QC
DMD19QC	DN	Isoindoline derivative 1
DMD19QC	MI	TT5TPI6
DMD19QC	MN	Opioid receptor sigma 1 (OPRS1)
DMD19QC	MT	DTT
DMD19QC	MA	Ligand
DMD19QC	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DMD19QC	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DMD19QC	DI	DMD19QC
DMD19QC	DN	Isoindoline derivative 1
DMD19QC	MI	TT9NXW4
DMD19QC	MN	Sigma intracellular receptor 2 (TMEM97)
DMD19QC	MT	DTT
DMD19QC	MA	Ligand
DMD19QC	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DMD19QC	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DMD19QC	DI	DMD19QC
DMD19QC	DN	Isoindoline derivative 1
DMD19QC	MI	TTQ6VDM
DMD19QC	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMD19QC	MT	DTT
DMD19QC	MA	Ligand
DMD19QC	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DMD19QC	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DMTE0S3	DI	DMTE0S3
DMTE0S3	DN	Isoindoline derivative 2
DMTE0S3	MI	TT5TPI6
DMTE0S3	MN	Opioid receptor sigma 1 (OPRS1)
DMTE0S3	MT	DTT
DMTE0S3	MA	Ligand
DMTE0S3	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DMTE0S3	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DMTE0S3	DI	DMTE0S3
DMTE0S3	DN	Isoindoline derivative 2
DMTE0S3	MI	TT9NXW4
DMTE0S3	MN	Sigma intracellular receptor 2 (TMEM97)
DMTE0S3	MT	DTT
DMTE0S3	MA	Ligand
DMTE0S3	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DMTE0S3	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DMTE0S3	DI	DMTE0S3
DMTE0S3	DN	Isoindoline derivative 2
DMTE0S3	MI	TTQ6VDM
DMTE0S3	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMTE0S3	MT	DTT
DMTE0S3	MA	Ligand
DMTE0S3	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DMTE0S3	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DM2MYL9	DI	DM2MYL9
DM2MYL9	DN	Isoindoline derivative 3
DM2MYL9	MI	TT5TPI6
DM2MYL9	MN	Opioid receptor sigma 1 (OPRS1)
DM2MYL9	MT	DTT
DM2MYL9	MA	Ligand
DM2MYL9	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DM2MYL9	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DM2MYL9	DI	DM2MYL9
DM2MYL9	DN	Isoindoline derivative 3
DM2MYL9	MI	TT9NXW4
DM2MYL9	MN	Sigma intracellular receptor 2 (TMEM97)
DM2MYL9	MT	DTT
DM2MYL9	MA	Ligand
DM2MYL9	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DM2MYL9	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DM2MYL9	DI	DM2MYL9
DM2MYL9	DN	Isoindoline derivative 3
DM2MYL9	MI	TTQ6VDM
DM2MYL9	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DM2MYL9	MT	DTT
DM2MYL9	MA	Ligand
DM2MYL9	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DM2MYL9	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DMP1NKI	DI	DMP1NKI
DMP1NKI	DN	Isoindoline derivative 4
DMP1NKI	MI	TT5TPI6
DMP1NKI	MN	Opioid receptor sigma 1 (OPRS1)
DMP1NKI	MT	DTT
DMP1NKI	MA	Ligand
DMP1NKI	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DMP1NKI	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DMP1NKI	DI	DMP1NKI
DMP1NKI	DN	Isoindoline derivative 4
DMP1NKI	MI	TT9NXW4
DMP1NKI	MN	Sigma intracellular receptor 2 (TMEM97)
DMP1NKI	MT	DTT
DMP1NKI	MA	Ligand
DMP1NKI	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DMP1NKI	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DMP1NKI	DI	DMP1NKI
DMP1NKI	DN	Isoindoline derivative 4
DMP1NKI	MI	TTQ6VDM
DMP1NKI	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMP1NKI	MT	DTT
DMP1NKI	MA	Ligand
DMP1NKI	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DMP1NKI	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DMIUTQW	DI	DMIUTQW
DMIUTQW	DN	Isoindoline derivative 5
DMIUTQW	MI	TT5TPI6
DMIUTQW	MN	Opioid receptor sigma 1 (OPRS1)
DMIUTQW	MT	DTT
DMIUTQW	MA	Ligand
DMIUTQW	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DMIUTQW	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DMIUTQW	DI	DMIUTQW
DMIUTQW	DN	Isoindoline derivative 5
DMIUTQW	MI	TT9NXW4
DMIUTQW	MN	Sigma intracellular receptor 2 (TMEM97)
DMIUTQW	MT	DTT
DMIUTQW	MA	Ligand
DMIUTQW	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DMIUTQW	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DMIUTQW	DI	DMIUTQW
DMIUTQW	DN	Isoindoline derivative 5
DMIUTQW	MI	TTQ6VDM
DMIUTQW	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMIUTQW	MT	DTT
DMIUTQW	MA	Ligand
DMIUTQW	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DMIUTQW	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DMIYUAN	DI	DMIYUAN
DMIYUAN	DN	Isoquinoline 1,3-dione derivative 1
DMIYUAN	MI	TTH6V3D
DMIYUAN	MN	Cyclin-dependent kinase 1 (CDK1)
DMIYUAN	MT	DTT
DMIYUAN	MA	Inhibitor
DMIYUAN	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMIYUAN	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMIYUAN	DI	DMIYUAN
DMIYUAN	DN	Isoquinoline 1,3-dione derivative 1
DMIYUAN	MI	TT7HF4W
DMIYUAN	MN	Cyclin-dependent kinase 2 (CDK2)
DMIYUAN	MT	DTT
DMIYUAN	MA	Inhibitor
DMIYUAN	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMIYUAN	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMIYUAN	DI	DMIYUAN
DMIYUAN	DN	Isoquinoline 1,3-dione derivative 1
DMIYUAN	MI	TT0PG8F
DMIYUAN	MN	Cyclin-dependent kinase 4 (CDK4)
DMIYUAN	MT	DTT
DMIYUAN	MA	Inhibitor
DMIYUAN	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMIYUAN	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMIYUAN	DI	DMIYUAN
DMIYUAN	DN	Isoquinoline 1,3-dione derivative 1
DMIYUAN	MI	TTO0FDJ
DMIYUAN	MN	Cyclin-dependent kinase 6 (CDK6)
DMIYUAN	MT	DTT
DMIYUAN	MA	Inhibitor
DMIYUAN	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMIYUAN	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMOAY3Q	DI	DMOAY3Q
DMOAY3Q	DN	Isoquinoline carboxamide derivative 1
DMOAY3Q	MI	TTPTXIN
DMOAY3Q	MN	Translocator protein (TSPO)
DMOAY3Q	MT	DTT
DMOAY3Q	MA	Ligand
DMOAY3Q	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMOAY3Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMR0Y3K	DI	DMR0Y3K
DMR0Y3K	DN	Isoquinoline derivative 1
DMR0Y3K	MI	TTMSFAW
DMR0Y3K	MN	Cannabinoid receptor 2 (CB2)
DMR0Y3K	MT	DTT
DMR0Y3K	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DMR0Y3K	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DMRHBLD	DI	DMRHBLD
DMRHBLD	DN	Isoquinoline derivative 2
DMRHBLD	MI	TTMSFAW
DMRHBLD	MN	Cannabinoid receptor 2 (CB2)
DMRHBLD	MT	DTT
DMRHBLD	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DMRHBLD	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DM4R1MK	DI	DM4R1MK
DM4R1MK	DN	Isoquinoline derivative 3
DM4R1MK	MI	TTMSFAW
DM4R1MK	MN	Cannabinoid receptor 2 (CB2)
DM4R1MK	MT	DTT
DM4R1MK	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DM4R1MK	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DMB5F8Q	DI	DMB5F8Q
DMB5F8Q	DN	Isoquinoline derivative 4
DMB5F8Q	MI	TTMQO60
DMB5F8Q	MN	Rho-associated protein kinase (ROCK)
DMB5F8Q	MT	DTT
DMB5F8Q	MA	Inhibitor
DMB5F8Q	RN	Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
DMB5F8Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/28048944

DMNJ2R9	DI	DMNJ2R9
DMNJ2R9	DN	Isoquinoline derivative 5
DMNJ2R9	MI	TTMQO60
DMNJ2R9	MN	Rho-associated protein kinase (ROCK)
DMNJ2R9	MT	DTT
DMNJ2R9	MA	Inhibitor
DMNJ2R9	RN	Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
DMNJ2R9	RU	https://www.ncbi.nlm.nih.gov/pubmed/28048944

DMM5BDS	DI	DMM5BDS
DMM5BDS	DN	Isoquinoline sulfonamide derivative 1
DMM5BDS	MI	TTMQO60
DMM5BDS	MN	Rho-associated protein kinase (ROCK)
DMM5BDS	MT	DTT
DMM5BDS	MA	Inhibitor
DMM5BDS	RN	Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
DMM5BDS	RU	https://www.ncbi.nlm.nih.gov/pubmed/28048944

DMQVYL0	DI	DMQVYL0
DMQVYL0	DN	Isoquinoline sulfonamide derivative 2
DMQVYL0	MI	TTMQO60
DMQVYL0	MN	Rho-associated protein kinase (ROCK)
DMQVYL0	MT	DTT
DMQVYL0	MA	Inhibitor
DMQVYL0	RN	Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
DMQVYL0	RU	https://www.ncbi.nlm.nih.gov/pubmed/28048944

DMC5F3H	DI	DMC5F3H
DMC5F3H	DN	Isoquinoline sulfonyl derivative 1
DMC5F3H	MI	TTMQO60
DMC5F3H	MN	Rho-associated protein kinase (ROCK)
DMC5F3H	MT	DTT
DMC5F3H	MA	Inhibitor
DMC5F3H	RN	Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
DMC5F3H	RU	https://www.ncbi.nlm.nih.gov/pubmed/28048944

DMT5E7M	DI	DMT5E7M
DMT5E7M	DN	Isoquinoline sulfonyl derivative 2
DMT5E7M	MI	TTMQO60
DMT5E7M	MN	Rho-associated protein kinase (ROCK)
DMT5E7M	MT	DTT
DMT5E7M	MA	Inhibitor
DMT5E7M	RN	Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
DMT5E7M	RU	https://www.ncbi.nlm.nih.gov/pubmed/28048944

DMHIAVW	DI	DMHIAVW
DMHIAVW	DN	Isoquinoline sulfonyl derivative 3
DMHIAVW	MI	TTMQO60
DMHIAVW	MN	Rho-associated protein kinase (ROCK)
DMHIAVW	MT	DTT
DMHIAVW	MA	Inhibitor
DMHIAVW	RN	Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
DMHIAVW	RU	https://www.ncbi.nlm.nih.gov/pubmed/28048944

DMW6R0H	DI	DMW6R0H
DMW6R0H	DN	Isoquinolone derivative 1
DMW6R0H	MI	TT5ZWB6
DMW6R0H	MN	Dihydrodiol dehydrogenase type I (AKR1C3)
DMW6R0H	MT	DTT
DMW6R0H	MA	Inhibitor; Antagonist; Blocker
DMW6R0H	RN	Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340.
DMW6R0H	RU	https://www.ncbi.nlm.nih.gov/pubmed/28895472

DMP2QDM	DI	DMP2QDM
DMP2QDM	DN	Isosteric imidazolyl pyrimidine derivative 1
DMP2QDM	MI	TT7HF4W
DMP2QDM	MN	Cyclin-dependent kinase 2 (CDK2)
DMP2QDM	MT	DTT
DMP2QDM	MA	Inhibitor
DMP2QDM	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMP2QDM	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMP2QDM	DI	DMP2QDM
DMP2QDM	DN	Isosteric imidazolyl pyrimidine derivative 1
DMP2QDM	MI	TT6R7JZ
DMP2QDM	MN	Histone deacetylase 1 (HDAC1)
DMP2QDM	MT	DTT
DMP2QDM	MA	Inhibitor
DMP2QDM	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMP2QDM	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMLSUH3	DI	DMLSUH3
DMLSUH3	DN	Isothiazolidine derivative 1
DMLSUH3	MI	TT473XN
DMLSUH3	MN	P2X purinoceptor 7 (P2RX7)
DMLSUH3	MT	DTT
DMLSUH3	MA	Antagonist
DMLSUH3	RN	P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267.
DMLSUH3	RU	https://www.ncbi.nlm.nih.gov/pubmed/27724045

DMHAJCM	DI	DMHAJCM
DMHAJCM	DN	Isothiazolone derivative 1
DMHAJCM	MI	TTN9T81
DMHAJCM	MN	Arachidonate 15-lipoxygenase (15-LOX)
DMHAJCM	MT	DTT
DMHAJCM	MA	Inhibitor
DMHAJCM	RN	15-Lipoxygenase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):65-88.
DMHAJCM	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560362

DMK31M6	DI	DMK31M6
DMK31M6	DN	Isothiocyanate derivative 1
DMK31M6	MI	TT2F4OL
DMK31M6	MN	Tissue transglutaminase (TG2)
DMK31M6	MT	DTT
DMK31M6	MA	Inhibitor
DMK31M6	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DMK31M6	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DMUMPZX	DI	DMUMPZX
DMUMPZX	DN	Isoxazole derivative 1
DMUMPZX	MI	TT6DM01
DMUMPZX	MN	Janus kinase 1 (JAK-1)
DMUMPZX	MT	DTT
DMUMPZX	MA	Inhibitor
DMUMPZX	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMUMPZX	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMUMPZX	DI	DMUMPZX
DMUMPZX	DN	Isoxazole derivative 1
DMUMPZX	MI	TTRMX3V
DMUMPZX	MN	Janus kinase 2 (JAK-2)
DMUMPZX	MT	DTT
DMUMPZX	MA	Inhibitor
DMUMPZX	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMUMPZX	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMUMPZX	DI	DMUMPZX
DMUMPZX	DN	Isoxazole derivative 1
DMUMPZX	MI	TTT7PJU
DMUMPZX	MN	Janus kinase 3 (JAK-3)
DMUMPZX	MT	DTT
DMUMPZX	MA	Inhibitor
DMUMPZX	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMUMPZX	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMT842O	DI	DMT842O
DMT842O	DN	Isoxazole derivative 2
DMT842O	MI	TT6DM01
DMT842O	MN	Janus kinase 1 (JAK-1)
DMT842O	MT	DTT
DMT842O	MA	Inhibitor
DMT842O	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMT842O	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMT842O	DI	DMT842O
DMT842O	DN	Isoxazole derivative 2
DMT842O	MI	TTRMX3V
DMT842O	MN	Janus kinase 2 (JAK-2)
DMT842O	MT	DTT
DMT842O	MA	Inhibitor
DMT842O	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMT842O	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMT842O	DI	DMT842O
DMT842O	DN	Isoxazole derivative 2
DMT842O	MI	TTT7PJU
DMT842O	MN	Janus kinase 3 (JAK-3)
DMT842O	MT	DTT
DMT842O	MA	Inhibitor
DMT842O	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMT842O	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DM5CXQT	DI	DM5CXQT
DM5CXQT	DN	Isoxazole-based bicyclic compound 1
DM5CXQT	MI	TTE4BSY
DM5CXQT	MN	Bromodomain and extraterminal domain protein (BET)
DM5CXQT	MT	DTT
DM5CXQT	MA	Inhibitor
DM5CXQT	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DM5CXQT	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMAYKZ9	DI	DMAYKZ9
DMAYKZ9	DN	Isoxazole-based bicyclic compound 10
DMAYKZ9	MI	TTE4BSY
DMAYKZ9	MN	Bromodomain and extraterminal domain protein (BET)
DMAYKZ9	MT	DTT
DMAYKZ9	MA	Inhibitor
DMAYKZ9	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMAYKZ9	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DM1G8SM	DI	DM1G8SM
DM1G8SM	DN	Isoxazole-based bicyclic compound 11
DM1G8SM	MI	TTE4BSY
DM1G8SM	MN	Bromodomain and extraterminal domain protein (BET)
DM1G8SM	MT	DTT
DM1G8SM	MA	Inhibitor
DM1G8SM	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DM1G8SM	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMVA8KL	DI	DMVA8KL
DMVA8KL	DN	Isoxazole-based bicyclic compound 12
DMVA8KL	MI	TTE4BSY
DMVA8KL	MN	Bromodomain and extraterminal domain protein (BET)
DMVA8KL	MT	DTT
DMVA8KL	MA	Inhibitor
DMVA8KL	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMVA8KL	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DM7OBVT	DI	DM7OBVT
DM7OBVT	DN	Isoxazole-based bicyclic compound 13
DM7OBVT	MI	TTE4BSY
DM7OBVT	MN	Bromodomain and extraterminal domain protein (BET)
DM7OBVT	MT	DTT
DM7OBVT	MA	Inhibitor
DM7OBVT	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DM7OBVT	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMS3CDT	DI	DMS3CDT
DMS3CDT	DN	Isoxazole-based bicyclic compound 14
DMS3CDT	MI	TTE4BSY
DMS3CDT	MN	Bromodomain and extraterminal domain protein (BET)
DMS3CDT	MT	DTT
DMS3CDT	MA	Inhibitor
DMS3CDT	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMS3CDT	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMPXK1C	DI	DMPXK1C
DMPXK1C	DN	Isoxazole-based bicyclic compound 15
DMPXK1C	MI	TTE4BSY
DMPXK1C	MN	Bromodomain and extraterminal domain protein (BET)
DMPXK1C	MT	DTT
DMPXK1C	MA	Inhibitor
DMPXK1C	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMPXK1C	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DM614F8	DI	DM614F8
DM614F8	DN	Isoxazole-based bicyclic compound 16
DM614F8	MI	TTE4BSY
DM614F8	MN	Bromodomain and extraterminal domain protein (BET)
DM614F8	MT	DTT
DM614F8	MA	Inhibitor
DM614F8	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DM614F8	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DM2SUCK	DI	DM2SUCK
DM2SUCK	DN	Isoxazole-based bicyclic compound 17
DM2SUCK	MI	TTE4BSY
DM2SUCK	MN	Bromodomain and extraterminal domain protein (BET)
DM2SUCK	MT	DTT
DM2SUCK	MA	Inhibitor
DM2SUCK	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DM2SUCK	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DME8CQA	DI	DME8CQA
DME8CQA	DN	Isoxazole-based bicyclic compound 18
DME8CQA	MI	TTE4BSY
DME8CQA	MN	Bromodomain and extraterminal domain protein (BET)
DME8CQA	MT	DTT
DME8CQA	MA	Inhibitor
DME8CQA	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DME8CQA	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DM01FD3	DI	DM01FD3
DM01FD3	DN	Isoxazole-based bicyclic compound 19
DM01FD3	MI	TTE4BSY
DM01FD3	MN	Bromodomain and extraterminal domain protein (BET)
DM01FD3	MT	DTT
DM01FD3	MA	Inhibitor
DM01FD3	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DM01FD3	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMYLR2S	DI	DMYLR2S
DMYLR2S	DN	Isoxazole-based bicyclic compound 2
DMYLR2S	MI	TTE4BSY
DMYLR2S	MN	Bromodomain and extraterminal domain protein (BET)
DMYLR2S	MT	DTT
DMYLR2S	MA	Inhibitor
DMYLR2S	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMYLR2S	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMWMRKJ	DI	DMWMRKJ
DMWMRKJ	DN	Isoxazole-based bicyclic compound 3
DMWMRKJ	MI	TTE4BSY
DMWMRKJ	MN	Bromodomain and extraterminal domain protein (BET)
DMWMRKJ	MT	DTT
DMWMRKJ	MA	Inhibitor
DMWMRKJ	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMWMRKJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMNI0PH	DI	DMNI0PH
DMNI0PH	DN	Isoxazole-based bicyclic compound 4
DMNI0PH	MI	TTE4BSY
DMNI0PH	MN	Bromodomain and extraterminal domain protein (BET)
DMNI0PH	MT	DTT
DMNI0PH	MA	Inhibitor
DMNI0PH	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMNI0PH	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMT46PS	DI	DMT46PS
DMT46PS	DN	Isoxazole-based bicyclic compound 5
DMT46PS	MI	TTE4BSY
DMT46PS	MN	Bromodomain and extraterminal domain protein (BET)
DMT46PS	MT	DTT
DMT46PS	MA	Inhibitor
DMT46PS	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMT46PS	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMKSNZG	DI	DMKSNZG
DMKSNZG	DN	Isoxazole-based bicyclic compound 6
DMKSNZG	MI	TTE4BSY
DMKSNZG	MN	Bromodomain and extraterminal domain protein (BET)
DMKSNZG	MT	DTT
DMKSNZG	MA	Inhibitor
DMKSNZG	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMKSNZG	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DM3T840	DI	DM3T840
DM3T840	DN	Isoxazole-based bicyclic compound 7
DM3T840	MI	TTE4BSY
DM3T840	MN	Bromodomain and extraterminal domain protein (BET)
DM3T840	MT	DTT
DM3T840	MA	Inhibitor
DM3T840	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DM3T840	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DM3IV7K	DI	DM3IV7K
DM3IV7K	DN	Isoxazole-based bicyclic compound 8
DM3IV7K	MI	TTE4BSY
DM3IV7K	MN	Bromodomain and extraterminal domain protein (BET)
DM3IV7K	MT	DTT
DM3IV7K	MA	Inhibitor
DM3IV7K	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DM3IV7K	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMWA7RB	DI	DMWA7RB
DMWA7RB	DN	Isoxazole-based bicyclic compound 9
DMWA7RB	MI	TTE4BSY
DMWA7RB	MN	Bromodomain and extraterminal domain protein (BET)
DMWA7RB	MT	DTT
DMWA7RB	MA	Inhibitor
DMWA7RB	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMWA7RB	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMRML9B	DI	DMRML9B
DMRML9B	DN	Isoxazoles and isoxazoline derivative 1
DMRML9B	MI	TTIY56R
DMRML9B	MN	Kynurenine 3-hydroxylase (KMO)
DMRML9B	MT	DTT
DMRML9B	MA	Inhibitor
DMRML9B	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMRML9B	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMKCYSD	DI	DMKCYSD
DMKCYSD	DN	Isoxazoles and isoxazoline derivative 2
DMKCYSD	MI	TTIY56R
DMKCYSD	MN	Kynurenine 3-hydroxylase (KMO)
DMKCYSD	MT	DTT
DMKCYSD	MA	Inhibitor
DMKCYSD	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMKCYSD	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMULJOS	DI	DMULJOS
DMULJOS	DN	Isoxazoles and isoxazoline derivative 3
DMULJOS	MI	TTIY56R
DMULJOS	MN	Kynurenine 3-hydroxylase (KMO)
DMULJOS	MT	DTT
DMULJOS	MA	Inhibitor
DMULJOS	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMULJOS	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMW3JZV	DI	DMW3JZV
DMW3JZV	DN	Isoxazoles and isoxazoline derivative 4
DMW3JZV	MI	TTIY56R
DMW3JZV	MN	Kynurenine 3-hydroxylase (KMO)
DMW3JZV	MT	DTT
DMW3JZV	MA	Inhibitor
DMW3JZV	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMW3JZV	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMCWFU1	DI	DMCWFU1
DMCWFU1	DN	Isoxazoles and isoxazoline derivative 5
DMCWFU1	MI	TTIY56R
DMCWFU1	MN	Kynurenine 3-hydroxylase (KMO)
DMCWFU1	MT	DTT
DMCWFU1	MA	Inhibitor
DMCWFU1	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMCWFU1	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMIKBV5	DI	DMIKBV5
DMIKBV5	DN	Isoxazoles and isoxazoline derivative 6
DMIKBV5	MI	TTIY56R
DMIKBV5	MN	Kynurenine 3-hydroxylase (KMO)
DMIKBV5	MT	DTT
DMIKBV5	MA	Inhibitor
DMIKBV5	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMIKBV5	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMLR8MS	DI	DMLR8MS
DMLR8MS	DN	Isoxazoline derivative 1
DMLR8MS	MI	TTDP1UC
DMLR8MS	MN	Fatty acid amide hydrolase (FAAH)
DMLR8MS	MT	DTT
DMLR8MS	MA	Inhibitor
DMLR8MS	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMLR8MS	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMK5M8Q	DI	DMK5M8Q
DMK5M8Q	DN	Isoxazoline derivative 2
DMK5M8Q	MI	TTDP1UC
DMK5M8Q	MN	Fatty acid amide hydrolase (FAAH)
DMK5M8Q	MT	DTT
DMK5M8Q	MA	Inhibitor
DMK5M8Q	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMK5M8Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMBVDHK	DI	DMBVDHK
DMBVDHK	DN	Isoxazoline derivative 3
DMBVDHK	MI	TTDP1UC
DMBVDHK	MN	Fatty acid amide hydrolase (FAAH)
DMBVDHK	MT	DTT
DMBVDHK	MA	Inhibitor
DMBVDHK	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMBVDHK	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DM01DG4	DI	DM01DG4
DM01DG4	DN	Isoxazoline derivative 4
DM01DG4	MI	TTDP1UC
DM01DG4	MN	Fatty acid amide hydrolase (FAAH)
DM01DG4	MT	DTT
DM01DG4	MA	Inhibitor
DM01DG4	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DM01DG4	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMER7QX	DI	DMER7QX
DMER7QX	DN	JCXGHZCWAHCYGY-UHFFFAOYSA-N
DMER7QX	MI	TTDYP7I
DMER7QX	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DMER7QX	MT	DTT
DMER7QX	MA	Inhibitor
DMER7QX	RN	6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (S1P) receptor for the treatment of multiple sclerosis. US9150519.
DMER7QX	RU	http://www.freepatentsonline.com/US9150519.html

DMS3HNM	DI	DMS3HNM
DMS3HNM	DN	Jte 013
DMS3HNM	MI	TTVSMOH
DMS3HNM	MN	Sphingosine-1-phosphate receptor 2 (S1PR2)
DMS3HNM	MT	DTT
DMS3HNM	MA	Inhibitor
DMS3HNM	RN	Sphingosine 1-phosphate receptor antagonists. US9663511.
DMS3HNM	RU	http://www.freepatentsonline.com/US9663511.html

DMGTSCP	DI	DMGTSCP
DMGTSCP	DN	JWH-015
DMGTSCP	MI	TTMSFAW
DMGTSCP	MN	Cannabinoid receptor 2 (CB2)
DMGTSCP	MT	DTT
DMGTSCP	MA	Agonist
DMGTSCP	RN	Posttraining activation of CB1 cannabinoid receptors in the CA1 region of the dorsal hippocampus impairs object recognition long-term memory. Neurobiol Learn Mem. 2008 Sep;90(2):374-81.
DMGTSCP	RU	https://pubmed.ncbi.nlm.nih.gov/18524639

DM7UK5E	DI	DM7UK5E
DM7UK5E	DN	KadcoccitoneA
DM7UK5E	MI	TT3WG5C
DM7UK5E	MN	Monoamine oxidase type A (MAO-A)
DM7UK5E	MT	DTT
DM7UK5E	MA	Inhibitor
DM7UK5E	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DM7UK5E	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMAGVXW	DI	DMAGVXW
DMAGVXW	DN	KENPAULLONE
DMAGVXW	MI	TTH6V3D
DMAGVXW	MN	Cyclin-dependent kinase 1 (CDK1)
DMAGVXW	MT	DTT
DMAGVXW	MA	Inhibitor
DMAGVXW	RN	Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay. Eur J Med Chem. 2010 Sep;45(9):4316-30.
DMAGVXW	RU	https://pubmed.ncbi.nlm.nih.gov/20638755

DMAGVXW	DI	DMAGVXW
DMAGVXW	DN	KENPAULLONE
DMAGVXW	MI	TTL4Q97
DMAGVXW	MN	Cyclin-dependent kinase 5 (CDK5)
DMAGVXW	MT	DTT
DMAGVXW	MA	Inhibitor
DMAGVXW	RN	1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.
DMAGVXW	RU	https://pubmed.ncbi.nlm.nih.gov/14698171

DMAGVXW	DI	DMAGVXW
DMAGVXW	DN	KENPAULLONE
DMAGVXW	MI	TT9P6OW
DMAGVXW	MN	G2/mitotic-specific cyclin B1 (CCNB1)
DMAGVXW	MT	DTT
DMAGVXW	MA	Inhibitor
DMAGVXW	RN	Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay. Eur J Med Chem. 2010 Sep;45(9):4316-30.
DMAGVXW	RU	https://pubmed.ncbi.nlm.nih.gov/20638755

DMAGVXW	DI	DMAGVXW
DMAGVXW	DN	KENPAULLONE
DMAGVXW	MI	TTRZQE3
DMAGVXW	MN	Glycogen synthase kinase-3 alpha (GSK-3A)
DMAGVXW	MT	DTT
DMAGVXW	MA	Inhibitor
DMAGVXW	RN	Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
DMAGVXW	RU	https://www.ncbi.nlm.nih.gov/pubmed/27828716

DMAGVXW	DI	DMAGVXW
DMAGVXW	DN	KENPAULLONE
DMAGVXW	MI	TTRSMW9
DMAGVXW	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMAGVXW	MT	DTT
DMAGVXW	MA	Inhibitor
DMAGVXW	RN	1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.
DMAGVXW	RU	https://pubmed.ncbi.nlm.nih.gov/14698171

DMAGVXW	DI	DMAGVXW
DMAGVXW	DN	KENPAULLONE
DMAGVXW	MI	TTSFWA7
DMAGVXW	MN	Plasmodium CDK Pfmrk (Malaria Pfmrk)
DMAGVXW	MT	DTT
DMAGVXW	MA	Inhibitor
DMAGVXW	RN	A three-dimensional in silico pharmacophore model for inhibition of Plasmodium falciparum cyclin-dependent kinases and discovery of different class... J Med Chem. 2004 Oct 21;47(22):5418-26.
DMAGVXW	RU	https://pubmed.ncbi.nlm.nih.gov/15481979

DM1ZK7E	DI	DM1ZK7E
DM1ZK7E	DN	Ketoheterocycle derivative 1
DM1ZK7E	MI	TTDP1UC
DM1ZK7E	MN	Fatty acid amide hydrolase (FAAH)
DM1ZK7E	MT	DTT
DM1ZK7E	MA	Inhibitor
DM1ZK7E	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DM1ZK7E	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DM3KW2A	DI	DM3KW2A
DM3KW2A	DN	Ketoheterocycle derivative 2
DM3KW2A	MI	TTDP1UC
DM3KW2A	MN	Fatty acid amide hydrolase (FAAH)
DM3KW2A	MT	DTT
DM3KW2A	MA	Inhibitor
DM3KW2A	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DM3KW2A	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMFHD05	DI	DMFHD05
DMFHD05	DN	Ketoheterocycle derivative 3
DMFHD05	MI	TTDP1UC
DMFHD05	MN	Fatty acid amide hydrolase (FAAH)
DMFHD05	MT	DTT
DMFHD05	MA	Inhibitor
DMFHD05	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMFHD05	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DM2LQXY	DI	DM2LQXY
DM2LQXY	DN	Ketoheterocycle derivative 4
DM2LQXY	MI	TTDP1UC
DM2LQXY	MN	Fatty acid amide hydrolase (FAAH)
DM2LQXY	MT	DTT
DM2LQXY	MA	Inhibitor
DM2LQXY	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DM2LQXY	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMRY7KV	DI	DMRY7KV
DMRY7KV	DN	KRDULPYOVRWKMA-UHFFFAOYSA-N
DMRY7KV	MI	TTIEMFN
DMRY7KV	MN	TYRO3 tyrosine kinase receptor (TYRO3)
DMRY7KV	MT	DTT
DMRY7KV	MA	Inhibitor
DMRY7KV	RN	Pyrrolopyrimidine derivatives as TAM inhibitors. US10053465.
DMRY7KV	RU	http://www.freepatentsonline.com/US10053465.html

DMDYKPC	DI	DMDYKPC
DMDYKPC	DN	Lactam derivative 1
DMDYKPC	MI	TTF8P9I
DMDYKPC	MN	Diacylglycerol acyltransferase 1 (DGAT1)
DMDYKPC	MT	DTT
DMDYKPC	MA	Inhibitor
DMDYKPC	RN	Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
DMDYKPC	RU	https://www.ncbi.nlm.nih.gov/pubmed/25470667

DMT58QE	DI	DMT58QE
DMT58QE	DN	Lactam derivative 2
DMT58QE	MI	TTF8P9I
DMT58QE	MN	Diacylglycerol acyltransferase 1 (DGAT1)
DMT58QE	MT	DTT
DMT58QE	MA	Inhibitor
DMT58QE	RN	Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
DMT58QE	RU	https://www.ncbi.nlm.nih.gov/pubmed/25470667

DMD0XIL	DI	DMD0XIL
DMD0XIL	DN	Lactam derivative 3
DMD0XIL	MI	TTF8P9I
DMD0XIL	MN	Diacylglycerol acyltransferase 1 (DGAT1)
DMD0XIL	MT	DTT
DMD0XIL	MA	Inhibitor
DMD0XIL	RN	Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
DMD0XIL	RU	https://www.ncbi.nlm.nih.gov/pubmed/25470667

DMJ3ZAI	DI	DMJ3ZAI
DMJ3ZAI	DN	Lactam derivative 4
DMJ3ZAI	MI	TTF8P9I
DMJ3ZAI	MN	Diacylglycerol acyltransferase 1 (DGAT1)
DMJ3ZAI	MT	DTT
DMJ3ZAI	MA	Inhibitor
DMJ3ZAI	RN	Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
DMJ3ZAI	RU	https://www.ncbi.nlm.nih.gov/pubmed/25470667

DMX5FYZ	DI	DMX5FYZ
DMX5FYZ	DN	Lactam derivative 5
DMX5FYZ	MI	TTF8P9I
DMX5FYZ	MN	Diacylglycerol acyltransferase 1 (DGAT1)
DMX5FYZ	MT	DTT
DMX5FYZ	MA	Inhibitor
DMX5FYZ	RN	Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
DMX5FYZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25470667

DMWC3P5	DI	DMWC3P5
DMWC3P5	DN	Lactol derivative 1
DMWC3P5	MI	TTPADOQ
DMWC3P5	MN	HMG-CoA reductase (HMGCR)
DMWC3P5	MT	DTT
DMWC3P5	MA	Inhibitor
DMWC3P5	RN	HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272.
DMWC3P5	RU	https://www.ncbi.nlm.nih.gov/pubmed/27537201

DMP3GRA	DI	DMP3GRA
DMP3GRA	DN	Lactol derivative 2
DMP3GRA	MI	TTPADOQ
DMP3GRA	MN	HMG-CoA reductase (HMGCR)
DMP3GRA	MT	DTT
DMP3GRA	MA	Inhibitor
DMP3GRA	RN	HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272.
DMP3GRA	RU	https://www.ncbi.nlm.nih.gov/pubmed/27537201

DMCULK7	DI	DMCULK7
DMCULK7	DN	Lazabemide
DMCULK7	MI	TT32XQJ
DMCULK7	MN	Monoamine oxidase (MAO)
DMCULK7	MT	DTT
DMCULK7	MA	Inhibitor
DMCULK7	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMCULK7	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMCULK7	DI	DMCULK7
DMCULK7	DN	Lazabemide
DMCULK7	MI	TTGP7BY
DMCULK7	MN	Monoamine oxidase type B (MAO-B)
DMCULK7	MT	DTT
DMCULK7	MA	Inhibitor
DMCULK7	RN	The activity of MAO A and B in rat renal cells and tubules. Life Sci. 1998;62(8):727-37.
DMCULK7	RU	https://pubmed.ncbi.nlm.nih.gov/9489509

DM189D7	DI	DM189D7
DM189D7	DN	Lazabemide analog 1
DM189D7	MI	TTGP7BY
DM189D7	MN	Monoamine oxidase type B (MAO-B)
DM189D7	MT	DTT
DM189D7	MA	Inhibitor
DM189D7	RN	MAO inhibitors and their wider applications: a patent review.Expert Opin Ther Pat. 2018 Mar;28(3):211-226.
DM189D7	RU	https://www.ncbi.nlm.nih.gov/pubmed/29324067

DM1STAD	DI	DM1STAD
DM1STAD	DN	L-piperazino-3-phenyl-indane derivative 1
DM1STAD	MI	TTJQOD7
DM1STAD	MN	5-HT 2A receptor (HTR2A)
DM1STAD	MT	DTT
DM1STAD	MA	Antagonist
DM1STAD	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DM1STAD	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DM1STAD	DI	DM1STAD
DM1STAD	DN	L-piperazino-3-phenyl-indane derivative 1
DM1STAD	MI	TTEX248
DM1STAD	MN	Dopamine D2 receptor (D2R)
DM1STAD	MT	DTT
DM1STAD	MA	Antagonist
DM1STAD	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DM1STAD	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DM1STAD	DI	DM1STAD
DM1STAD	DN	L-piperazino-3-phenyl-indane derivative 1
DM1STAD	MI	TTWFZ1N
DM1STAD	MN	Dopamine receptor (DR)
DM1STAD	MT	DTT
DM1STAD	MA	Antagonist
DM1STAD	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DM1STAD	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMGKQXP	DI	DMGKQXP
DMGKQXP	DN	Lycorine dimer salt derivative 1
DMGKQXP	MI	TT1RS9F
DMGKQXP	MN	Acetylcholinesterase (AChE)
DMGKQXP	MT	DTT
DMGKQXP	MA	Inhibitor
DMGKQXP	RN	Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476.
DMGKQXP	RU	https://www.ncbi.nlm.nih.gov/pubmed/27967267

DMN7I9C	DI	DMN7I9C
DMN7I9C	DN	Macrocycle derivative 1
DMN7I9C	MI	TT5YPJF
DMN7I9C	MN	CD80-PD-L1 interaction (CD80/PD-L1 PPI)
DMN7I9C	MT	DTT
DMN7I9C	MA	Inhibitor
DMN7I9C	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMN7I9C	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMN7I9C	DI	DMN7I9C
DMN7I9C	DN	Macrocycle derivative 1
DMN7I9C	MI	TT23XQV
DMN7I9C	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMN7I9C	MT	DTT
DMN7I9C	MA	Inhibitor
DMN7I9C	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMN7I9C	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DM1KBSV	DI	DM1KBSV
DM1KBSV	DN	Macrocycle derivative 13
DM1KBSV	MI	TTKN7QR
DM1KBSV	MN	BDNF/NT-3 growth factors receptor (TrkB)
DM1KBSV	MT	DTT
DM1KBSV	MA	Inhibitor
DM1KBSV	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DM1KBSV	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMXSRPH	DI	DMXSRPH
DMXSRPH	DN	Macrocycle derivative 14
DMXSRPH	MI	TTBJR4L
DMXSRPH	MN	Cyclin-dependent kinase 8 (CDK8)
DMXSRPH	MT	DTT
DMXSRPH	MA	Inhibitor
DMXSRPH	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMXSRPH	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DM5OEQZ	DI	DM5OEQZ
DM5OEQZ	DN	Macrocycle derivative 2
DM5OEQZ	MI	TT5YPJF
DM5OEQZ	MN	CD80-PD-L1 interaction (CD80/PD-L1 PPI)
DM5OEQZ	MT	DTT
DM5OEQZ	MA	Inhibitor
DM5OEQZ	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DM5OEQZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DM5OEQZ	DI	DM5OEQZ
DM5OEQZ	DN	Macrocycle derivative 2
DM5OEQZ	MI	TT23XQV
DM5OEQZ	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DM5OEQZ	MT	DTT
DM5OEQZ	MA	Inhibitor
DM5OEQZ	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DM5OEQZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMYGFTI	DI	DMYGFTI
DMYGFTI	DN	Macrocycle derivative 3
DMYGFTI	MI	TT5YPJF
DMYGFTI	MN	CD80-PD-L1 interaction (CD80/PD-L1 PPI)
DMYGFTI	MT	DTT
DMYGFTI	MA	Inhibitor
DMYGFTI	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMYGFTI	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMYGFTI	DI	DMYGFTI
DMYGFTI	DN	Macrocycle derivative 3
DMYGFTI	MI	TT23XQV
DMYGFTI	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMYGFTI	MT	DTT
DMYGFTI	MA	Inhibitor
DMYGFTI	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMYGFTI	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMOQBN4	DI	DMOQBN4
DMOQBN4	DN	Macrocycle derivative 4
DMOQBN4	MI	TT5YPJF
DMOQBN4	MN	CD80-PD-L1 interaction (CD80/PD-L1 PPI)
DMOQBN4	MT	DTT
DMOQBN4	MA	Inhibitor
DMOQBN4	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMOQBN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMOQBN4	DI	DMOQBN4
DMOQBN4	DN	Macrocycle derivative 4
DMOQBN4	MI	TT23XQV
DMOQBN4	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMOQBN4	MT	DTT
DMOQBN4	MA	Inhibitor
DMOQBN4	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMOQBN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMK3UJY	DI	DMK3UJY
DMK3UJY	DN	Macrocycle derivative 5
DMK3UJY	MI	TT5YPJF
DMK3UJY	MN	CD80-PD-L1 interaction (CD80/PD-L1 PPI)
DMK3UJY	MT	DTT
DMK3UJY	MA	Inhibitor
DMK3UJY	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMK3UJY	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMK3UJY	DI	DMK3UJY
DMK3UJY	DN	Macrocycle derivative 5
DMK3UJY	MI	TT23XQV
DMK3UJY	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMK3UJY	MT	DTT
DMK3UJY	MA	Inhibitor
DMK3UJY	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMK3UJY	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMQ84KW	DI	DMQ84KW
DMQ84KW	DN	Macrocycle derivative 6
DMQ84KW	MI	TT5YPJF
DMQ84KW	MN	CD80-PD-L1 interaction (CD80/PD-L1 PPI)
DMQ84KW	MT	DTT
DMQ84KW	MA	Inhibitor
DMQ84KW	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMQ84KW	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMQ84KW	DI	DMQ84KW
DMQ84KW	DN	Macrocycle derivative 6
DMQ84KW	MI	TT23XQV
DMQ84KW	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMQ84KW	MT	DTT
DMQ84KW	MA	Inhibitor
DMQ84KW	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMQ84KW	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMP2JF0	DI	DMP2JF0
DMP2JF0	DN	Macrocycle derivative 7
DMP2JF0	MI	TT5YPJF
DMP2JF0	MN	CD80-PD-L1 interaction (CD80/PD-L1 PPI)
DMP2JF0	MT	DTT
DMP2JF0	MA	Inhibitor
DMP2JF0	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMP2JF0	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMP2JF0	DI	DMP2JF0
DMP2JF0	DN	Macrocycle derivative 7
DMP2JF0	MI	TT23XQV
DMP2JF0	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMP2JF0	MT	DTT
DMP2JF0	MA	Inhibitor
DMP2JF0	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMP2JF0	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMOMTBE	DI	DMOMTBE
DMOMTBE	DN	Macrocycle derivative 8
DMOMTBE	MI	TT5YPJF
DMOMTBE	MN	CD80-PD-L1 interaction (CD80/PD-L1 PPI)
DMOMTBE	MT	DTT
DMOMTBE	MA	Inhibitor
DMOMTBE	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMOMTBE	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMOMTBE	DI	DMOMTBE
DMOMTBE	DN	Macrocycle derivative 8
DMOMTBE	MI	TT23XQV
DMOMTBE	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMOMTBE	MT	DTT
DMOMTBE	MA	Inhibitor
DMOMTBE	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMOMTBE	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMARU0E	DI	DMARU0E
DMARU0E	DN	Macrocycle derivative 9
DMARU0E	MI	TT5YPJF
DMARU0E	MN	CD80-PD-L1 interaction (CD80/PD-L1 PPI)
DMARU0E	MT	DTT
DMARU0E	MA	Inhibitor
DMARU0E	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMARU0E	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMARU0E	DI	DMARU0E
DMARU0E	DN	Macrocycle derivative 9
DMARU0E	MI	TT23XQV
DMARU0E	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMARU0E	MT	DTT
DMARU0E	MA	Inhibitor
DMARU0E	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMARU0E	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMS65IT	DI	DMS65IT
DMS65IT	DN	Macrocyclic peptide analog 1
DMS65IT	MI	TT23XQV
DMS65IT	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMS65IT	MT	DTT
DMS65IT	MA	Inhibitor
DMS65IT	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMS65IT	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMOGLBZ	DI	DMOGLBZ
DMOGLBZ	DN	Macrocyclic peptide analog 2
DMOGLBZ	MI	TT23XQV
DMOGLBZ	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMOGLBZ	MT	DTT
DMOGLBZ	MA	Inhibitor
DMOGLBZ	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMOGLBZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMV172W	DI	DMV172W
DMV172W	DN	Macrocyclic peptide analog 3
DMV172W	MI	TT23XQV
DMV172W	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMV172W	MT	DTT
DMV172W	MA	Inhibitor
DMV172W	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMV172W	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DM0ON7S	DI	DM0ON7S
DM0ON7S	DN	Macrolactam derivative 1
DM0ON7S	MI	TTKFVXR
DM0ON7S	MN	Renal carcinoma antigen NY-REN-64 (IRAK-4)
DM0ON7S	MT	DTT
DM0ON7S	MA	Inhibitor
DM0ON7S	RN	Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32.
DM0ON7S	RU	https://www.ncbi.nlm.nih.gov/pubmed/27310003

DME72VA	DI	DME72VA
DME72VA	DN	Macrolactam derivative 2
DME72VA	MI	TTKFVXR
DME72VA	MN	Renal carcinoma antigen NY-REN-64 (IRAK-4)
DME72VA	MT	DTT
DME72VA	MA	Inhibitor
DME72VA	RN	Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32.
DME72VA	RU	https://www.ncbi.nlm.nih.gov/pubmed/27310003

DMFNGUV	DI	DMFNGUV
DMFNGUV	DN	Macrolactam derivative 3
DMFNGUV	MI	TTKFVXR
DMFNGUV	MN	Renal carcinoma antigen NY-REN-64 (IRAK-4)
DMFNGUV	MT	DTT
DMFNGUV	MA	Inhibitor
DMFNGUV	RN	Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32.
DMFNGUV	RU	https://www.ncbi.nlm.nih.gov/pubmed/27310003

DM5AXHF	DI	DM5AXHF
DM5AXHF	DN	Macrolactam derivative 4
DM5AXHF	MI	TTKFVXR
DM5AXHF	MN	Renal carcinoma antigen NY-REN-64 (IRAK-4)
DM5AXHF	MT	DTT
DM5AXHF	MA	Inhibitor
DM5AXHF	RN	Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32.
DM5AXHF	RU	https://www.ncbi.nlm.nih.gov/pubmed/27310003

DMINM8F	DI	DMINM8F
DMINM8F	DN	Maleimides derivative 1
DMINM8F	MI	TTRZQE3
DMINM8F	MN	Glycogen synthase kinase-3 alpha (GSK-3A)
DMINM8F	MT	DTT
DMINM8F	MA	Inhibitor
DMINM8F	RN	Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
DMINM8F	RU	https://www.ncbi.nlm.nih.gov/pubmed/27828716

DMUVYWE	DI	DMUVYWE
DMUVYWE	DN	Maleimides derivative 2
DMUVYWE	MI	TTRZQE3
DMUVYWE	MN	Glycogen synthase kinase-3 alpha (GSK-3A)
DMUVYWE	MT	DTT
DMUVYWE	RN	Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
DMUVYWE	RU	https://www.ncbi.nlm.nih.gov/pubmed/27828716

DMEFQND	DI	DMEFQND
DMEFQND	DN	Maleimides derivative 3
DMEFQND	MI	TTRZQE3
DMEFQND	MN	Glycogen synthase kinase-3 alpha (GSK-3A)
DMEFQND	MT	DTT
DMEFQND	MA	Inhibitor
DMEFQND	RN	Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
DMEFQND	RU	https://www.ncbi.nlm.nih.gov/pubmed/27828716

DMIE7U3	DI	DMIE7U3
DMIE7U3	DN	Mannoside derivative 1
DMIE7U3	MI	TTTCRU2
DMIE7U3	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMIE7U3	MT	DTT
DMIE7U3	MA	Antagonist
DMIE7U3	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMIE7U3	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMZYRHN	DI	DMZYRHN
DMZYRHN	DN	Mannoside derivative 10
DMZYRHN	MI	TTTCRU2
DMZYRHN	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMZYRHN	MT	DTT
DMZYRHN	MA	Antagonist
DMZYRHN	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMZYRHN	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM8I051	DI	DM8I051
DM8I051	DN	Mannoside derivative 11
DM8I051	MI	TTTCRU2
DM8I051	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM8I051	MT	DTT
DM8I051	MA	Antagonist
DM8I051	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM8I051	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM4QUY0	DI	DM4QUY0
DM4QUY0	DN	Mannoside derivative 12
DM4QUY0	MI	TTTCRU2
DM4QUY0	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM4QUY0	MT	DTT
DM4QUY0	MA	Antagonist
DM4QUY0	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM4QUY0	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM0U7P9	DI	DM0U7P9
DM0U7P9	DN	Mannoside derivative 13
DM0U7P9	MI	TTTCRU2
DM0U7P9	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM0U7P9	MT	DTT
DM0U7P9	MA	Antagonist
DM0U7P9	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM0U7P9	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMFEQD2	DI	DMFEQD2
DMFEQD2	DN	Mannoside derivative 2
DMFEQD2	MI	TTTCRU2
DMFEQD2	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMFEQD2	MT	DTT
DMFEQD2	MA	Antagonist
DMFEQD2	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMFEQD2	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMPF2UG	DI	DMPF2UG
DMPF2UG	DN	Mannoside derivative 3
DMPF2UG	MI	TTTCRU2
DMPF2UG	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMPF2UG	MT	DTT
DMPF2UG	MA	Antagonist
DMPF2UG	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMPF2UG	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMZBY73	DI	DMZBY73
DMZBY73	DN	Mannoside derivative 4
DMZBY73	MI	TTTCRU2
DMZBY73	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMZBY73	MT	DTT
DMZBY73	MA	Antagonist
DMZBY73	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMZBY73	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMMXNY8	DI	DMMXNY8
DMMXNY8	DN	Mannoside derivative 5
DMMXNY8	MI	TTTCRU2
DMMXNY8	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMMXNY8	MT	DTT
DMMXNY8	MA	Antagonist
DMMXNY8	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMMXNY8	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMCM3NW	DI	DMCM3NW
DMCM3NW	DN	Mannoside derivative 6
DMCM3NW	MI	TTTCRU2
DMCM3NW	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMCM3NW	MT	DTT
DMCM3NW	MA	Antagonist
DMCM3NW	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMCM3NW	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMOUT1F	DI	DMOUT1F
DMOUT1F	DN	Mannoside derivative 7
DMOUT1F	MI	TTTCRU2
DMOUT1F	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMOUT1F	MT	DTT
DMOUT1F	MA	Antagonist
DMOUT1F	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMOUT1F	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMKTJAH	DI	DMKTJAH
DMKTJAH	DN	Mannoside derivative 8
DMKTJAH	MI	TTTCRU2
DMKTJAH	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMKTJAH	MT	DTT
DMKTJAH	MA	Antagonist
DMKTJAH	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMKTJAH	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMIKZXD	DI	DMIKZXD
DMIKZXD	DN	Mannoside derivative 9
DMIKZXD	MI	TTTCRU2
DMIKZXD	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMIKZXD	MT	DTT
DMIKZXD	MA	Antagonist
DMIKZXD	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMIKZXD	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMMCS9P	DI	DMMCS9P
DMMCS9P	DN	Matairesinol derivative 1
DMMCS9P	MI	TTUX68I
DMMCS9P	MN	Hypoxia-inducible factor 1 (HIF-1)
DMMCS9P	MT	DTT
DMMCS9P	MA	Inhibitor
DMMCS9P	RN	Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22.
DMMCS9P	RU	https://www.ncbi.nlm.nih.gov/pubmed/26882240

DMUOW3T	DI	DMUOW3T
DMUOW3T	DN	Metal complex derivative 1
DMUOW3T	MI	TTR7UJ3
DMUOW3T	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMUOW3T	MT	DTT
DMUOW3T	MA	Inhibitor
DMUOW3T	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMUOW3T	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DM0BTH8	DI	DM0BTH8
DM0BTH8	DN	Metal complex derivative 2
DM0BTH8	MI	TTR7UJ3
DM0BTH8	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DM0BTH8	MT	DTT
DM0BTH8	MA	Inhibitor
DM0BTH8	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DM0BTH8	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DM31BMP	DI	DM31BMP
DM31BMP	DN	Metal complex derivative 3
DM31BMP	MI	TTR7UJ3
DM31BMP	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DM31BMP	MT	DTT
DM31BMP	MA	Inhibitor
DM31BMP	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DM31BMP	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DM9BYJ0	DI	DM9BYJ0
DM9BYJ0	DN	Methyl 2-amino-4-phenylthiophene-3-carboxylate
DM9BYJ0	MI	TTUWGRA
DM9BYJ0	MN	Protein kinase C zeta (PRKCZ)
DM9BYJ0	MT	DTT
DM9BYJ0	MA	Inhibitor
DM9BYJ0	RN	Compounds, formulations, and methods of protein kinase C inhibition. US8889672.
DM9BYJ0	RU	http://www.freepatentsonline.com/US8889672.html

DMUNME2	DI	DMUNME2
DMUNME2	DN	Methylbenzenesulfonamide derivative 1
DMUNME2	MI	TTOHFIY
DMUNME2	MN	Sphingosine kinase 1 (SPHK1)
DMUNME2	MT	DTT
DMUNME2	MA	Inhibitor
DMUNME2	RN	Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416.
DMUNME2	RU	https://www.ncbi.nlm.nih.gov/pubmed/27539678

DM5PS6K	DI	DM5PS6K
DM5PS6K	DN	Methyl-piperidine compound 1
DM5PS6K	MI	TTYLQ8V
DM5PS6K	MN	Prostaglandin E synthase (PTGES)
DM5PS6K	MT	DTT
DM5PS6K	MA	Inhibitor
DM5PS6K	RN	Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059.
DM5PS6K	RU	https://www.ncbi.nlm.nih.gov/pubmed/28627961

DMHVZ4M	DI	DMHVZ4M
DMHVZ4M	DN	Methylsulfonylbenzamide derivative 2
DMHVZ4M	MI	TT4G2JS
DMHVZ4M	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DMHVZ4M	MT	DTT
DMHVZ4M	MA	Inhibitor
DMHVZ4M	RN	Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90.
DMHVZ4M	RU	https://www.ncbi.nlm.nih.gov/pubmed/25539043

DM8UOY6	DI	DM8UOY6
DM8UOY6	DN	MHHFJYABEVJNEG-UHFFFAOYSA-N
DM8UOY6	MI	TTDYP7I
DM8UOY6	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DM8UOY6	MT	DTT
DM8UOY6	MA	Inhibitor
DM8UOY6	RN	6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (S1P) receptor for the treatment of multiple sclerosis. US9150519.
DM8UOY6	RU	http://www.freepatentsonline.com/US9150519.html

DMNEY58	DI	DMNEY58
DMNEY58	DN	ML272
DMNEY58	MI	TT3T17P
DMNEY58	MN	Phospholipase D1 (PLD1)
DMNEY58	MT	DTT
DMNEY58	MA	Inhibitor
DMNEY58	RN	Antiviral therapies with phospholipase D inhibitors. US9453017.
DMNEY58	RU	http://www.freepatentsonline.com/US9453017.html

DMRWNAY	DI	DMRWNAY
DMRWNAY	DN	Monoamine derivative 1
DMRWNAY	MI	TTULVH8
DMRWNAY	MN	Tyrosinase (TYR)
DMRWNAY	MT	DTT
DMRWNAY	MA	Inhibitor
DMRWNAY	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMRWNAY	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMAZ6DI	DI	DMAZ6DI
DMAZ6DI	DN	Monoamine derivative 2
DMAZ6DI	MI	TTULVH8
DMAZ6DI	MN	Tyrosinase (TYR)
DMAZ6DI	MT	DTT
DMAZ6DI	MA	Inhibitor
DMAZ6DI	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMAZ6DI	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DM4I75L	DI	DM4I75L
DM4I75L	DN	Monoamine derivative 3
DM4I75L	MI	TTULVH8
DM4I75L	MN	Tyrosinase (TYR)
DM4I75L	MT	DTT
DM4I75L	MA	Inhibitor
DM4I75L	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DM4I75L	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMYFKP2	DI	DMYFKP2
DMYFKP2	DN	Monoamine derivative 4
DMYFKP2	MI	TTULVH8
DMYFKP2	MN	Tyrosinase (TYR)
DMYFKP2	MT	DTT
DMYFKP2	MA	Inhibitor
DMYFKP2	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMYFKP2	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DM3PF60	DI	DM3PF60
DM3PF60	DN	Monoamine derivative 5
DM3PF60	MI	TTULVH8
DM3PF60	MN	Tyrosinase (TYR)
DM3PF60	MT	DTT
DM3PF60	MA	Inhibitor
DM3PF60	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DM3PF60	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMCI6YH	DI	DMCI6YH
DMCI6YH	DN	Monoaryl-1,2-diamine derivative 1
DMCI6YH	MI	TTZJYKH
DMCI6YH	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMCI6YH	MT	DTT
DMCI6YH	MA	Inhibitor
DMCI6YH	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMCI6YH	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMXUNZ1	DI	DMXUNZ1
DMXUNZ1	DN	Monoaryl-1,2-diamine derivative 2
DMXUNZ1	MI	TTZJYKH
DMXUNZ1	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMXUNZ1	MT	DTT
DMXUNZ1	MA	Inhibitor
DMXUNZ1	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMXUNZ1	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMAXKPC	DI	DMAXKPC
DMAXKPC	DN	Monoaryl-1,2-diamine derivative 3
DMAXKPC	MI	TTZJYKH
DMAXKPC	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMAXKPC	MT	DTT
DMAXKPC	MA	Modulator
DMAXKPC	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMAXKPC	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMD8AKH	DI	DMD8AKH
DMD8AKH	DN	Monoaryl-1,2-diamine derivative 4
DMD8AKH	MI	TTZJYKH
DMD8AKH	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMD8AKH	MT	DTT
DMD8AKH	MA	Modulator
DMD8AKH	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMD8AKH	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMJ8YZK	DI	DMJ8YZK
DMJ8YZK	DN	Monofluorine derivative 1
DMJ8YZK	MI	TTZJYKH
DMJ8YZK	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMJ8YZK	MT	DTT
DMJ8YZK	MA	Antagonist
DMJ8YZK	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMJ8YZK	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMNGQ3I	DI	DMNGQ3I
DMNGQ3I	DN	MRL20
DMNGQ3I	MI	TTZMAO3
DMNGQ3I	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMNGQ3I	MT	DTT
DMNGQ3I	MA	Agonist
DMNGQ3I	RN	PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
DMNGQ3I	RU	https://www.ncbi.nlm.nih.gov/pubmed/25416646

DM8NS7U	DI	DM8NS7U
DM8NS7U	DN	MRL24
DM8NS7U	MI	TTZMAO3
DM8NS7U	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DM8NS7U	MT	DTT
DM8NS7U	MA	Agonist
DM8NS7U	RN	PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
DM8NS7U	RU	https://www.ncbi.nlm.nih.gov/pubmed/25416646

DMOZTUE	DI	DMOZTUE
DMOZTUE	DN	Mycophenolic acid/nucleotide derivative 1
DMOZTUE	MI	TTL7C8Q
DMOZTUE	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMOZTUE	MT	DTT
DMOZTUE	MA	Inhibitor
DMOZTUE	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DMOZTUE	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DMHD8RK	DI	DMHD8RK
DMHD8RK	DN	Mycophenolic acid/nucleotide derivative 10
DMHD8RK	MI	TTL7C8Q
DMHD8RK	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMHD8RK	MT	DTT
DMHD8RK	MA	Inhibitor
DMHD8RK	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DMHD8RK	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DMXWOAG	DI	DMXWOAG
DMXWOAG	DN	Mycophenolic acid/nucleotide derivative 11
DMXWOAG	MI	TTL7C8Q
DMXWOAG	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMXWOAG	MT	DTT
DMXWOAG	MA	Inhibitor
DMXWOAG	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DMXWOAG	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DM47L9Q	DI	DM47L9Q
DM47L9Q	DN	Mycophenolic acid/nucleotide derivative 12
DM47L9Q	MI	TTL7C8Q
DM47L9Q	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DM47L9Q	MT	DTT
DM47L9Q	MA	Inhibitor
DM47L9Q	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DM47L9Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DMAT9NE	DI	DMAT9NE
DMAT9NE	DN	Mycophenolic acid/nucleotide derivative 2
DMAT9NE	MI	TTL7C8Q
DMAT9NE	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMAT9NE	MT	DTT
DMAT9NE	MA	Inhibitor
DMAT9NE	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DMAT9NE	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DM5UX7B	DI	DM5UX7B
DM5UX7B	DN	Mycophenolic acid/nucleotide derivative 3
DM5UX7B	MI	TTL7C8Q
DM5UX7B	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DM5UX7B	MT	DTT
DM5UX7B	MA	Inhibitor
DM5UX7B	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DM5UX7B	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DMEHMKY	DI	DMEHMKY
DMEHMKY	DN	Mycophenolic acid/nucleotide derivative 4
DMEHMKY	MI	TTL7C8Q
DMEHMKY	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMEHMKY	MT	DTT
DMEHMKY	MA	Inhibitor
DMEHMKY	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DMEHMKY	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DM74UP5	DI	DM74UP5
DM74UP5	DN	Mycophenolic acid/nucleotide derivative 5
DM74UP5	MI	TTL7C8Q
DM74UP5	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DM74UP5	MT	DTT
DM74UP5	MA	Inhibitor
DM74UP5	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DM74UP5	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DMGFORB	DI	DMGFORB
DMGFORB	DN	Mycophenolic acid/nucleotide derivative 6
DMGFORB	MI	TTL7C8Q
DMGFORB	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMGFORB	MT	DTT
DMGFORB	MA	Inhibitor
DMGFORB	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DMGFORB	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DMC27TO	DI	DMC27TO
DMC27TO	DN	Mycophenolic acid/nucleotide derivative 7
DMC27TO	MI	TTL7C8Q
DMC27TO	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMC27TO	MT	DTT
DMC27TO	MA	Inhibitor
DMC27TO	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DMC27TO	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DMWGIJS	DI	DMWGIJS
DMWGIJS	DN	Mycophenolic acid/nucleotide derivative 8
DMWGIJS	MI	TTL7C8Q
DMWGIJS	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMWGIJS	MT	DTT
DMWGIJS	MA	Inhibitor
DMWGIJS	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DMWGIJS	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DMYQTLK	DI	DMYQTLK
DMYQTLK	DN	Mycophenolic acid/nucleotide derivative 9
DMYQTLK	MI	TTL7C8Q
DMYQTLK	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMYQTLK	MT	DTT
DMYQTLK	MA	Inhibitor
DMYQTLK	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DMYQTLK	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DMA8BLZ	DI	DMA8BLZ
DMA8BLZ	DN	MyriberineA
DMA8BLZ	MI	TT3WG5C
DMA8BLZ	MN	Monoamine oxidase type A (MAO-A)
DMA8BLZ	MT	DTT
DMA8BLZ	MA	Inhibitor
DMA8BLZ	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMA8BLZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMH7T8C	DI	DMH7T8C
DMH7T8C	DN	N-(2-phenylcyclopropyl) amino acid derivative 1
DMH7T8C	MI	TTZHPB8
DMH7T8C	MN	Lysine-specific demethylase 4A (KDM4A)
DMH7T8C	MT	DTT
DMH7T8C	MA	Inhibitor
DMH7T8C	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMH7T8C	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMH7T8C	DI	DMH7T8C
DMH7T8C	DN	N-(2-phenylcyclopropyl) amino acid derivative 1
DMH7T8C	MI	TTNR0UQ
DMH7T8C	MN	Lysine-specific histone demethylase 1 (LSD)
DMH7T8C	MT	DTT
DMH7T8C	MA	Inhibitor
DMH7T8C	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMH7T8C	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMH7T8C	DI	DMH7T8C
DMH7T8C	DN	N-(2-phenylcyclopropyl) amino acid derivative 1
DMH7T8C	MI	TTGP7BY
DMH7T8C	MN	Monoamine oxidase type B (MAO-B)
DMH7T8C	MT	DTT
DMH7T8C	MA	Inhibitor
DMH7T8C	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMH7T8C	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DM6YV3O	DI	DM6YV3O
DM6YV3O	DN	N-(2-phenylcyclopropyl) amino acid derivative 2
DM6YV3O	MI	TTNR0UQ
DM6YV3O	MN	Lysine-specific histone demethylase 1 (LSD)
DM6YV3O	MT	DTT
DM6YV3O	MA	Inhibitor
DM6YV3O	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DM6YV3O	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DM6YV3O	DI	DM6YV3O
DM6YV3O	DN	N-(2-phenylcyclopropyl) amino acid derivative 2
DM6YV3O	MI	TT32XQJ
DM6YV3O	MN	Monoamine oxidase (MAO)
DM6YV3O	MT	DTT
DM6YV3O	MA	Inhibitor
DM6YV3O	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DM6YV3O	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMFBRSL	DI	DMFBRSL
DMFBRSL	DN	N-(2-phenylcyclopropyl) amino acid derivative 3
DMFBRSL	MI	TTNR0UQ
DMFBRSL	MN	Lysine-specific histone demethylase 1 (LSD)
DMFBRSL	MT	DTT
DMFBRSL	MA	Inhibitor
DMFBRSL	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMFBRSL	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMFBRSL	DI	DMFBRSL
DMFBRSL	DN	N-(2-phenylcyclopropyl) amino acid derivative 3
DMFBRSL	MI	TT3WG5C
DMFBRSL	MN	Monoamine oxidase type A (MAO-A)
DMFBRSL	MT	DTT
DMFBRSL	MA	Inhibitor
DMFBRSL	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMFBRSL	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMFBRSL	DI	DMFBRSL
DMFBRSL	DN	N-(2-phenylcyclopropyl) amino acid derivative 3
DMFBRSL	MI	TTGP7BY
DMFBRSL	MN	Monoamine oxidase type B (MAO-B)
DMFBRSL	MT	DTT
DMFBRSL	MA	Inhibitor
DMFBRSL	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMFBRSL	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DM6TYM0	DI	DM6TYM0
DM6TYM0	DN	N-(arylalkyl)-1H-indole-2-sulfonic acid amide derivative 1
DM6TYM0	MI	TT6OEDT
DM6TYM0	MN	Cannabinoid receptor 1 (CB1)
DM6TYM0	MT	DTT
DM6TYM0	MA	Antagonist
DM6TYM0	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DM6TYM0	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DM2MPN0	DI	DM2MPN0
DM2MPN0	DN	N-(arylalkyl)-1H-indole-2-sulfonic acid amide derivative 2
DM2MPN0	MI	TT6OEDT
DM2MPN0	MN	Cannabinoid receptor 1 (CB1)
DM2MPN0	MT	DTT
DM2MPN0	MA	Antagonist
DM2MPN0	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DM2MPN0	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DM8GJA7	DI	DM8GJA7
DM8GJA7	DN	N-(arylamino)sulfonamide derivative 1
DM8GJA7	MI	TTZCRP3
DM8GJA7	MN	ERK activator kinase (MEK)
DM8GJA7	MT	DTT
DM8GJA7	MA	Inhibitor
DM8GJA7	RN	MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906.
DM8GJA7	RU	https://www.ncbi.nlm.nih.gov/pubmed/28594589

DMGQWKH	DI	DMGQWKH
DMGQWKH	DN	N-(benzimidazole/indole) benzoic acid derivative 1
DMGQWKH	MI	TT5ZWB6
DMGQWKH	MN	Dihydrodiol dehydrogenase type I (AKR1C3)
DMGQWKH	MT	DTT
DMGQWKH	MA	Inhibitor
DMGQWKH	RN	Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340.
DMGQWKH	RU	https://www.ncbi.nlm.nih.gov/pubmed/28895472

DMOPUFM	DI	DMOPUFM
DMOPUFM	DN	N-(benzimidazole/indole) benzoic acid derivative 2
DMOPUFM	MI	TT5ZWB6
DMOPUFM	MN	Dihydrodiol dehydrogenase type I (AKR1C3)
DMOPUFM	MT	DTT
DMOPUFM	MA	Inhibitor
DMOPUFM	RN	Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340.
DMOPUFM	RU	https://www.ncbi.nlm.nih.gov/pubmed/28895472

DM541QW	DI	DM541QW
DM541QW	DN	N-(benzimidazolylcarbonyl)-piperidine derivative 1
DM541QW	MI	TT5ZWB6
DM541QW	MN	Dihydrodiol dehydrogenase type I (AKR1C3)
DM541QW	MT	DTT
DM541QW	MA	Inhibitor
DM541QW	RN	Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340.
DM541QW	RU	https://www.ncbi.nlm.nih.gov/pubmed/28895472

DM0OMAL	DI	DM0OMAL
DM0OMAL	DN	N-(cyanomethyl)-4-(2-(phenylamino)pyrimidin-4-yl)benzamide derivative 1
DM0OMAL	MI	TT6DM01
DM0OMAL	MN	Janus kinase 1 (JAK-1)
DM0OMAL	MT	DTT
DM0OMAL	MA	Inhibitor
DM0OMAL	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DM0OMAL	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DM0OMAL	DI	DM0OMAL
DM0OMAL	DN	N-(cyanomethyl)-4-(2-(phenylamino)pyrimidin-4-yl)benzamide derivative 1
DM0OMAL	MI	TTRMX3V
DM0OMAL	MN	Janus kinase 2 (JAK-2)
DM0OMAL	MT	DTT
DM0OMAL	MA	Inhibitor
DM0OMAL	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DM0OMAL	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DM0OMAL	DI	DM0OMAL
DM0OMAL	DN	N-(cyanomethyl)-4-(2-(phenylamino)pyrimidin-4-yl)benzamide derivative 1
DM0OMAL	MI	TTT7PJU
DM0OMAL	MN	Janus kinase 3 (JAK-3)
DM0OMAL	MT	DTT
DM0OMAL	MA	Inhibitor
DM0OMAL	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DM0OMAL	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMARHJ9	DI	DMARHJ9
DMARHJ9	DN	N-(indolylcarbonyl)-piperidine derivative 1
DMARHJ9	MI	TT5ZWB6
DMARHJ9	MN	Dihydrodiol dehydrogenase type I (AKR1C3)
DMARHJ9	MT	DTT
DMARHJ9	MA	Inhibitor
DMARHJ9	RN	Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340.
DMARHJ9	RU	https://www.ncbi.nlm.nih.gov/pubmed/28895472

DM310ES	DI	DM310ES
DM310ES	DN	N-(naphthylamino)-benzoate derivative 1
DM310ES	MI	TT5ZWB6
DM310ES	MN	Dihydrodiol dehydrogenase type I (AKR1C3)
DM310ES	MT	DTT
DM310ES	MA	Inhibitor; Antagonist; Blocker
DM310ES	RN	Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340.
DM310ES	RU	https://www.ncbi.nlm.nih.gov/pubmed/28895472

DMNIWVG	DI	DMNIWVG
DMNIWVG	DN	N-(phenylamino)-benzoate derivative 1
DMNIWVG	MI	TT5ZWB6
DMNIWVG	MN	Dihydrodiol dehydrogenase type I (AKR1C3)
DMNIWVG	MT	DTT
DMNIWVG	MA	Inhibitor; Antagonist; Blocker
DMNIWVG	RN	Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340.
DMNIWVG	RU	https://www.ncbi.nlm.nih.gov/pubmed/28895472

DM0ZJX7	DI	DM0ZJX7
DM0ZJX7	DN	N-(phenylpyrazolyl)benzamide derivative 1
DM0ZJX7	MI	TTTDVOJ
DM0ZJX7	MN	Tropomyosin-related kinase A (TrkA)
DM0ZJX7	MT	DTT
DM0ZJX7	MA	Inhibitor
DM0ZJX7	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DM0ZJX7	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DM305UL	DI	DM305UL
DM305UL	DN	N-(pyridin-2-yl)pyridine methylsulfone derivative 1
DM305UL	MI	TT7HF4W
DM305UL	MN	Cyclin-dependent kinase 2 (CDK2)
DM305UL	MT	DTT
DM305UL	MA	Inhibitor
DM305UL	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DM305UL	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DM305UL	DI	DM305UL
DM305UL	DN	N-(pyridin-2-yl)pyridine methylsulfone derivative 1
DM305UL	MI	TT1LVF2
DM305UL	MN	Cyclin-dependent kinase 9 (CDK9)
DM305UL	MT	DTT
DM305UL	MA	Inhibitor
DM305UL	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DM305UL	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMRE2I3	DI	DMRE2I3
DMRE2I3	DN	N-(pyridin-2-yl)pyrimidin-4-amine derivative 1
DMRE2I3	MI	TT1LVF2
DMRE2I3	MN	Cyclin-dependent kinase 9 (CDK9)
DMRE2I3	MT	DTT
DMRE2I3	MA	Inhibitor
DMRE2I3	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMRE2I3	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMTZ6K9	DI	DMTZ6K9
DMTZ6K9	DN	N-(pyridin-2-yl)pyrimidin-4-amine derivative 2
DMTZ6K9	MI	TT7HF4W
DMTZ6K9	MN	Cyclin-dependent kinase 2 (CDK2)
DMTZ6K9	MT	DTT
DMTZ6K9	MA	Inhibitor
DMTZ6K9	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMTZ6K9	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMTZ6K9	DI	DMTZ6K9
DMTZ6K9	DN	N-(pyridin-2-yl)pyrimidin-4-amine derivative 2
DMTZ6K9	MI	TT1LVF2
DMTZ6K9	MN	Cyclin-dependent kinase 9 (CDK9)
DMTZ6K9	MT	DTT
DMTZ6K9	MA	Inhibitor
DMTZ6K9	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMTZ6K9	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMA85UD	DI	DMA85UD
DMA85UD	DN	N-(pyridinepyrroylylcarbonyl)-piperidine derivative 1
DMA85UD	MI	TT5ZWB6
DMA85UD	MN	Dihydrodiol dehydrogenase type I (AKR1C3)
DMA85UD	MT	DTT
DMA85UD	MA	Inhibitor
DMA85UD	RN	Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340.
DMA85UD	RU	https://www.ncbi.nlm.nih.gov/pubmed/28895472

DMSD4G0	DI	DMSD4G0
DMSD4G0	DN	N,N-bis(5-pyrazoyl)urea derivative 1
DMSD4G0	MI	TTTDVOJ
DMSD4G0	MN	Tropomyosin-related kinase A (TrkA)
DMSD4G0	MT	DTT
DMSD4G0	MA	Inhibitor
DMSD4G0	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMSD4G0	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMEXPAU	DI	DMEXPAU
DMEXPAU	DN	N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 1
DMEXPAU	MI	TTMSFAW
DMEXPAU	MN	Cannabinoid receptor 2 (CB2)
DMEXPAU	MT	DTT
DMEXPAU	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DMEXPAU	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DMD4CU5	DI	DMD4CU5
DMD4CU5	DN	N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 2
DMD4CU5	MI	TT6OEDT
DMD4CU5	MN	Cannabinoid receptor 1 (CB1)
DMD4CU5	MT	DTT
DMD4CU5	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DMD4CU5	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DMD4CU5	DI	DMD4CU5
DMD4CU5	DN	N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 2
DMD4CU5	MI	TTMSFAW
DMD4CU5	MN	Cannabinoid receptor 2 (CB2)
DMD4CU5	MT	DTT
DMD4CU5	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DMD4CU5	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DMM78VS	DI	DMM78VS
DMM78VS	DN	N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 3
DMM78VS	MI	TT6OEDT
DMM78VS	MN	Cannabinoid receptor 1 (CB1)
DMM78VS	MT	DTT
DMM78VS	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DMM78VS	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DMM78VS	DI	DMM78VS
DMM78VS	DN	N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 3
DMM78VS	MI	TTMSFAW
DMM78VS	MN	Cannabinoid receptor 2 (CB2)
DMM78VS	MT	DTT
DMM78VS	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DMM78VS	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DM6R34M	DI	DM6R34M
DM6R34M	DN	N-{4
DM6R34M	MI	TTCGOIN
DM6R34M	MN	PIM-3 protein kinase (PIM3)
DM6R34M	MT	DTT
DM6R34M	MA	Inhibitor
DM6R34M	RN	Kinase inhibitors and methods of their use. US8592455.
DM6R34M	RU	http://www.freepatentsonline.com/US8592455.html

DMRHVWA	DI	DMRHVWA
DMRHVWA	DN	N6-cyclopropyllydine derivative 1
DMRHVWA	MI	TTNR0UQ
DMRHVWA	MN	Lysine-specific histone demethylase 1 (LSD)
DMRHVWA	MT	DTT
DMRHVWA	MA	Inhibitor
DMRHVWA	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMRHVWA	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DM5GCUR	DI	DM5GCUR
DM5GCUR	DN	N-acylpiperidine ether derivative 1
DM5GCUR	MI	TTTDVOJ
DM5GCUR	MN	Tropomyosin-related kinase A (TrkA)
DM5GCUR	MT	DTT
DM5GCUR	MA	Inhibitor
DM5GCUR	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DM5GCUR	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DM02RQ4	DI	DM02RQ4
DM02RQ4	DN	N-acylpiperidine ether derivative 2
DM02RQ4	MI	TTTDVOJ
DM02RQ4	MN	Tropomyosin-related kinase A (TrkA)
DM02RQ4	MT	DTT
DM02RQ4	MA	Inhibitor
DM02RQ4	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DM02RQ4	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMXWE5R	DI	DMXWE5R
DMXWE5R	DN	N-acylpiperidine ether derivative 3
DMXWE5R	MI	TTTDVOJ
DMXWE5R	MN	Tropomyosin-related kinase A (TrkA)
DMXWE5R	MT	DTT
DMXWE5R	MA	Inhibitor
DMXWE5R	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMXWE5R	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMBUQDR	DI	DMBUQDR
DMBUQDR	DN	N-acylpiperidine ether derivative 4
DMBUQDR	MI	TTTDVOJ
DMBUQDR	MN	Tropomyosin-related kinase A (TrkA)
DMBUQDR	MT	DTT
DMBUQDR	MA	Inhibitor
DMBUQDR	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMBUQDR	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMQ2MKT	DI	DMQ2MKT
DMQ2MKT	DN	N-acylpiperidine ether derivative 5
DMQ2MKT	MI	TTTDVOJ
DMQ2MKT	MN	Tropomyosin-related kinase A (TrkA)
DMQ2MKT	MT	DTT
DMQ2MKT	MA	Inhibitor
DMQ2MKT	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMQ2MKT	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMAS01P	DI	DMAS01P
DMAS01P	DN	N-acylpiperidine ether derivative 6
DMAS01P	MI	TTTDVOJ
DMAS01P	MN	Tropomyosin-related kinase A (TrkA)
DMAS01P	MT	DTT
DMAS01P	MA	Inhibitor
DMAS01P	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMAS01P	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMCJR4N	DI	DMCJR4N
DMCJR4N	DN	N-acylpiperidine ether derivative 7
DMCJR4N	MI	TTTDVOJ
DMCJR4N	MN	Tropomyosin-related kinase A (TrkA)
DMCJR4N	MT	DTT
DMCJR4N	MA	Inhibitor
DMCJR4N	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMCJR4N	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMQ4ULC	DI	DMQ4ULC
DMQ4ULC	DN	N-acylpyrrolidine ether derivative 1
DMQ4ULC	MI	TTTDVOJ
DMQ4ULC	MN	Tropomyosin-related kinase A (TrkA)
DMQ4ULC	MT	DTT
DMQ4ULC	MA	Inhibitor
DMQ4ULC	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMQ4ULC	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMK4Y71	DI	DMK4Y71
DMK4Y71	DN	N-acylpyrrolidine ether derivative 2
DMK4Y71	MI	TTTDVOJ
DMK4Y71	MN	Tropomyosin-related kinase A (TrkA)
DMK4Y71	MT	DTT
DMK4Y71	MA	Inhibitor
DMK4Y71	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMK4Y71	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMU2WGL	DI	DMU2WGL
DMU2WGL	DN	N-alkyl-4-oxazolecar boxamide derivative 1
DMU2WGL	MI	TTDP1UC
DMU2WGL	MN	Fatty acid amide hydrolase (FAAH)
DMU2WGL	MT	DTT
DMU2WGL	MA	Inhibitor
DMU2WGL	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMU2WGL	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMR6YAD	DI	DMR6YAD
DMR6YAD	DN	N-alkyl-4-oxazolecar boxamide derivative 2
DMR6YAD	MI	TTDP1UC
DMR6YAD	MN	Fatty acid amide hydrolase (FAAH)
DMR6YAD	MT	DTT
DMR6YAD	MA	Inhibitor
DMR6YAD	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMR6YAD	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMXPBL5	DI	DMXPBL5
DMXPBL5	DN	N-alkylamide derivative 1
DMXPBL5	MI	TTHS256
DMXPBL5	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMXPBL5	MT	DTT
DMXPBL5	MA	Modulator
DMXPBL5	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMXPBL5	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DM568TX	DI	DM568TX
DM568TX	DN	N-alkylamide derivative 2
DM568TX	MI	TTHS256
DM568TX	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM568TX	MT	DTT
DM568TX	MA	Modulator
DM568TX	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DM568TX	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMWLPEB	DI	DMWLPEB
DMWLPEB	DN	Naphthalene derivative 1
DMWLPEB	MI	TTGIZLN
DMWLPEB	MN	Keap1-Nrf2[dual DLG and ETGE] PPI (KEAP1-Nrf2 DLG and ETGE)
DMWLPEB	MT	DTT
DMWLPEB	MA	Modulator
DMWLPEB	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMWLPEB	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMWLPEB	DI	DMWLPEB
DMWLPEB	DN	Naphthalene derivative 1
DMWLPEB	MI	TTA6ZN2
DMWLPEB	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMWLPEB	MT	DTT
DMWLPEB	MA	Inhibitor
DMWLPEB	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMWLPEB	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMTGIP7	DI	DMTGIP7
DMTGIP7	DN	Naphthyridine and isoquinoline derivative 1
DMTGIP7	MI	TTH6V3D
DMTGIP7	MN	Cyclin-dependent kinase 1 (CDK1)
DMTGIP7	MT	DTT
DMTGIP7	MA	Inhibitor
DMTGIP7	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMTGIP7	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMTGIP7	DI	DMTGIP7
DMTGIP7	DN	Naphthyridine and isoquinoline derivative 1
DMTGIP7	MI	TT7HF4W
DMTGIP7	MN	Cyclin-dependent kinase 2 (CDK2)
DMTGIP7	MT	DTT
DMTGIP7	MA	Inhibitor
DMTGIP7	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMTGIP7	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMTGIP7	DI	DMTGIP7
DMTGIP7	DN	Naphthyridine and isoquinoline derivative 1
DMTGIP7	MI	TTL4Q97
DMTGIP7	MN	Cyclin-dependent kinase 5 (CDK5)
DMTGIP7	MT	DTT
DMTGIP7	MA	Inhibitor
DMTGIP7	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMTGIP7	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMQHAU1	DI	DMQHAU1
DMQHAU1	DN	N-arylmethyl-N-phenyl cyclic urea derivative 1
DMQHAU1	MI	TTTDVOJ
DMQHAU1	MN	Tropomyosin-related kinase A (TrkA)
DMQHAU1	MT	DTT
DMQHAU1	MA	Inhibitor
DMQHAU1	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMQHAU1	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMWVQDA	DI	DMWVQDA
DMWVQDA	DN	N-arylmethyl-N-phenyl cyclic urea derivative 2
DMWVQDA	MI	TTTDVOJ
DMWVQDA	MN	Tropomyosin-related kinase A (TrkA)
DMWVQDA	MT	DTT
DMWVQDA	MA	Inhibitor
DMWVQDA	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMWVQDA	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMEU12W	DI	DMEU12W
DMEU12W	DN	NCGC00381656-01
DMEU12W	MI	TTIG67W
DMEU12W	MN	Lysine-specific demethylase 5A (KDM5A)
DMEU12W	MT	DTT
DMEU12W	MA	Inhibitor
DMEU12W	RN	Histone demethylase inhibitors. US9738637.
DMEU12W	RU	http://www.freepatentsonline.com/US9738637.html

DM6TMXL	DI	DM6TMXL
DM6TMXL	DN	N-containing heterocyclic derivative 1
DM6TMXL	MI	TTJOW1I
DM6TMXL	MN	Mannoside acetylglucosaminyltransferase 2 (MGAT2)
DM6TMXL	MT	DTT
DM6TMXL	MA	Inhibitor
DM6TMXL	RN	Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
DM6TMXL	RU	https://www.ncbi.nlm.nih.gov/pubmed/25470667

DMW1PL7	DI	DMW1PL7
DMW1PL7	DN	NG7
DMW1PL7	MI	TTI1FPZ
DMW1PL7	MN	Epithelial discoidin domain receptor 1 (DDR1)
DMW1PL7	MT	DTT
DMW1PL7	MA	Inhibitor
DMW1PL7	RN	Fused 2-aminothiazole compounds. US8765747.
DMW1PL7	RU	http://www.freepatentsonline.com/US8765747.html

DMW2LD5	DI	DMW2LD5
DMW2LD5	DN	Nicotinyl hydroxamic acid derivative 1
DMW2LD5	MI	TTULVH8
DMW2LD5	MN	Tyrosinase (TYR)
DMW2LD5	MT	DTT
DMW2LD5	MA	Inhibitor
DMW2LD5	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMW2LD5	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMXDSYU	DI	DMXDSYU
DMXDSYU	DN	Nitrogen mustard derivative 1
DMXDSYU	MI	TT7HF4W
DMXDSYU	MN	Cyclin-dependent kinase 2 (CDK2)
DMXDSYU	MT	DTT
DMXDSYU	MA	Inhibitor
DMXDSYU	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMXDSYU	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMXDSYU	DI	DMXDSYU
DMXDSYU	DN	Nitrogen mustard derivative 1
DMXDSYU	MI	TTMYWL7
DMXDSYU	MN	Cyclin-dependent kinase 3 (CDK3)
DMXDSYU	MT	DTT
DMXDSYU	MA	Inhibitor
DMXDSYU	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMXDSYU	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMXDSYU	DI	DMXDSYU
DMXDSYU	DN	Nitrogen mustard derivative 1
DMXDSYU	MI	TT1LVF2
DMXDSYU	MN	Cyclin-dependent kinase 9 (CDK9)
DMXDSYU	MT	DTT
DMXDSYU	MA	Inhibitor
DMXDSYU	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMXDSYU	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMD7OW0	DI	DMD7OW0
DMD7OW0	DN	Nitrogen/sulfur-substituted estrene derivative 1
DMD7OW0	MI	TT5ZWB6
DMD7OW0	MN	Dihydrodiol dehydrogenase type I (AKR1C3)
DMD7OW0	MT	DTT
DMD7OW0	MA	Inhibitor
DMD7OW0	RN	Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340.
DMD7OW0	RU	https://www.ncbi.nlm.nih.gov/pubmed/28895472

DMIVK7D	DI	DMIVK7D
DMIVK7D	DN	N-methylmethanesulfonamide derivative 1
DMIVK7D	MI	TT6DM01
DMIVK7D	MN	Janus kinase 1 (JAK-1)
DMIVK7D	MT	DTT
DMIVK7D	MA	Inhibitor
DMIVK7D	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMIVK7D	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMIVK7D	DI	DMIVK7D
DMIVK7D	DN	N-methylmethanesulfonamide derivative 1
DMIVK7D	MI	TTT7PJU
DMIVK7D	MN	Janus kinase 3 (JAK-3)
DMIVK7D	MT	DTT
DMIVK7D	MA	Inhibitor
DMIVK7D	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMIVK7D	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMIVK7D	DI	DMIVK7D
DMIVK7D	DN	N-methylmethanesulfonamide derivative 1
DMIVK7D	MI	TTBYWP2
DMIVK7D	MN	TYK2 tyrosine kinase (TYK2)
DMIVK7D	MT	DTT
DMIVK7D	MA	Inhibitor
DMIVK7D	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMIVK7D	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMCVBPF	DI	DMCVBPF
DMCVBPF	DN	N-naphtyl-N-benzylurea derivative 1
DMCVBPF	MI	TTRZQE3
DMCVBPF	MN	Glycogen synthase kinase-3 alpha (GSK-3A)
DMCVBPF	MT	DTT
DMCVBPF	MA	Inhibitor
DMCVBPF	RN	Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
DMCVBPF	RU	https://www.ncbi.nlm.nih.gov/pubmed/27828716

DM2P509	DI	DM2P509
DM2P509	DN	N-oxalyl-D-tyrosine derivative 1
DM2P509	MI	TTWAQBO
DM2P509	MN	Lysine-specific demethylase 4E (KDM4E)
DM2P509	MT	DTT
DM2P509	MA	Inhibitor
DM2P509	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DM2P509	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMWSZMC	DI	DMWSZMC
DMWSZMC	DN	N-oxalyl-D-tyrosine derivative 2
DMWSZMC	MI	TTWAQBO
DMWSZMC	MN	Lysine-specific demethylase 4E (KDM4E)
DMWSZMC	MT	DTT
DMWSZMC	MA	Inhibitor
DMWSZMC	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMWSZMC	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DM7XS9G	DI	DM7XS9G
DM7XS9G	DN	N-oxalyl-D-tyrosine derivative 3
DM7XS9G	MI	TTWAQBO
DM7XS9G	MN	Lysine-specific demethylase 4E (KDM4E)
DM7XS9G	MT	DTT
DM7XS9G	MA	Inhibitor
DM7XS9G	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DM7XS9G	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMUE7R5	DI	DMUE7R5
DMUE7R5	DN	N-oxalyl-D-tyrosine derivative 4
DMUE7R5	MI	TTWAQBO
DMUE7R5	MN	Lysine-specific demethylase 4E (KDM4E)
DMUE7R5	MT	DTT
DMUE7R5	MA	Inhibitor
DMUE7R5	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMUE7R5	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DM673GR	DI	DM673GR
DM673GR	DN	N-oxalyl-D-tyrosine derivative 5
DM673GR	MI	TTWAQBO
DM673GR	MN	Lysine-specific demethylase 4E (KDM4E)
DM673GR	MT	DTT
DM673GR	MA	Inhibitor
DM673GR	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DM673GR	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DM106SU	DI	DM106SU
DM106SU	DN	N-oxalyl-D-tyrosine derivative 6
DM106SU	MI	TTWAQBO
DM106SU	MN	Lysine-specific demethylase 4E (KDM4E)
DM106SU	MT	DTT
DM106SU	MA	Inhibitor
DM106SU	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DM106SU	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DM13K8R	DI	DM13K8R
DM13K8R	DN	N-oxalyl-D-tyrosine derivative 7
DM13K8R	MI	TTWAQBO
DM13K8R	MN	Lysine-specific demethylase 4E (KDM4E)
DM13K8R	MT	DTT
DM13K8R	MA	Inhibitor
DM13K8R	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DM13K8R	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMNV0OA	DI	DMNV0OA
DMNV0OA	DN	N-oxalyl-D-tyrosine derivative 8
DMNV0OA	MI	TTWAQBO
DMNV0OA	MN	Lysine-specific demethylase 4E (KDM4E)
DMNV0OA	MT	DTT
DMNV0OA	MA	Inhibitor
DMNV0OA	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMNV0OA	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMTMYJ6	DI	DMTMYJ6
DMTMYJ6	DN	N-oxalyl-D-tyrosine derivative 9
DMTMYJ6	MI	TTWAQBO
DMTMYJ6	MN	Lysine-specific demethylase 4E (KDM4E)
DMTMYJ6	MT	DTT
DMTMYJ6	MA	Inhibitor
DMTMYJ6	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMTMYJ6	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMUHFLQ	DI	DMUHFLQ
DMUHFLQ	DN	N-oxalylglycine derivative 1
DMUHFLQ	MI	TT0RGE9
DMUHFLQ	MN	Lysine-specific demethylase 4 (KDM4)
DMUHFLQ	MT	DTT
DMUHFLQ	MA	Inhibitor
DMUHFLQ	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMUHFLQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMDJC96	DI	DMDJC96
DMDJC96	DN	N-oxalylglycine derivative 2
DMDJC96	MI	TT0RGE9
DMDJC96	MN	Lysine-specific demethylase 4 (KDM4)
DMDJC96	MT	DTT
DMDJC96	MA	Inhibitor
DMDJC96	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMDJC96	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMQF0RY	DI	DMQF0RY
DMQF0RY	DN	N-oxalylglycine derivative 3
DMQF0RY	MI	TT0RGE9
DMQF0RY	MN	Lysine-specific demethylase 4 (KDM4)
DMQF0RY	MT	DTT
DMQF0RY	MA	Inhibitor
DMQF0RY	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMQF0RY	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DM9A8L5	DI	DM9A8L5
DM9A8L5	DN	N-phenyl-5-phenyl-pyrazolin-3-yl amide derivative 1
DM9A8L5	MI	TT6OEDT
DM9A8L5	MN	Cannabinoid receptor 1 (CB1)
DM9A8L5	MT	DTT
DM9A8L5	MA	Antagonist
DM9A8L5	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DM9A8L5	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DM8T2LV	DI	DM8T2LV
DM8T2LV	DN	N-phenyl-5-phenyl-pyrazolin-3-yl amide derivative 2
DM8T2LV	MI	TT6OEDT
DM8T2LV	MN	Cannabinoid receptor 1 (CB1)
DM8T2LV	MT	DTT
DM8T2LV	MA	Antagonist
DM8T2LV	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DM8T2LV	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMEH0RC	DI	DMEH0RC
DMEH0RC	DN	N-phenyl-5-phenyl-pyrazolin-3-yl amide derivative 3
DMEH0RC	MI	TT6OEDT
DMEH0RC	MN	Cannabinoid receptor 1 (CB1)
DMEH0RC	MT	DTT
DMEH0RC	MA	Antagonist
DMEH0RC	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMEH0RC	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMMDYAV	DI	DMMDYAV
DMMDYAV	DN	N-phenyl-pyridine-2-carboxamide derivative 1
DMMDYAV	MI	TT23XQV
DMMDYAV	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMMDYAV	MT	DTT
DMMDYAV	MA	Inhibitor
DMMDYAV	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMMDYAV	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DM6OG2Y	DI	DM6OG2Y
DM6OG2Y	DN	N-phenyl-pyridine-2-carboxamide derivative 2
DM6OG2Y	MI	TT23XQV
DM6OG2Y	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DM6OG2Y	MT	DTT
DM6OG2Y	MA	Inhibitor
DM6OG2Y	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DM6OG2Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMAV8LM	DI	DMAV8LM
DMAV8LM	DN	N-phenyl-pyrimidin-4-amine derivative 1
DMAV8LM	MI	TT7HF4W
DMAV8LM	MN	Cyclin-dependent kinase 2 (CDK2)
DMAV8LM	MT	DTT
DMAV8LM	MA	Inhibitor
DMAV8LM	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMAV8LM	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMAV8LM	DI	DMAV8LM
DMAV8LM	DN	N-phenyl-pyrimidin-4-amine derivative 1
DMAV8LM	MI	TT1LVF2
DMAV8LM	MN	Cyclin-dependent kinase 9 (CDK9)
DMAV8LM	MT	DTT
DMAV8LM	MA	Inhibitor
DMAV8LM	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMAV8LM	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMLSK97	DI	DMLSK97
DMLSK97	DN	N-quinolin-benzene sulphonamide derivative 1
DMLSK97	MI	TTSXVID
DMLSK97	MN	Nuclear factor NF-kappa-B (NFKB)
DMLSK97	MT	DTT
DMLSK97	MA	Inhibitor
DMLSK97	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DMLSK97	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DMH65CX	DI	DMH65CX
DMH65CX	DN	N-quinolin-benzene sulphonamide derivative 2
DMH65CX	MI	TTSXVID
DMH65CX	MN	Nuclear factor NF-kappa-B (NFKB)
DMH65CX	MT	DTT
DMH65CX	MA	Inhibitor
DMH65CX	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DMH65CX	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DMU65YX	DI	DMU65YX
DMU65YX	DN	N-quinolin-benzene sulphonamide derivative 3
DMU65YX	MI	TTSXVID
DMU65YX	MN	Nuclear factor NF-kappa-B (NFKB)
DMU65YX	MT	DTT
DMU65YX	MA	Inhibitor
DMU65YX	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DMU65YX	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DMEYKXL	DI	DMEYKXL
DMEYKXL	DN	NSC-87877
DMEYKXL	MI	TT369M5
DMEYKXL	MN	Protein-tyrosine phosphatase SHP-1 (PTPN6)
DMEYKXL	MT	DTT
DMEYKXL	MA	Inhibitor
DMEYKXL	RN	Inhibition of Shp2/PTPN11 protein tyrosine phosphatase by NSC-87877, NSC-117199 and their analogs. US8987474.
DMEYKXL	RU	http://www.freepatentsonline.com/US8987474.html

DMEYKXL	DI	DMEYKXL
DMEYKXL	DN	NSC-87877
DMEYKXL	MI	TT7WUAV
DMEYKXL	MN	Protein-tyrosine phosphatase SHP-2 (PTPN11)
DMEYKXL	MT	DTT
DMEYKXL	MA	Inhibitor
DMEYKXL	RN	Inhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2 (Shp2) based on oxindole scaffolds. J Med Chem. 2008 Aug 28;51(16):4948-56.
DMEYKXL	RU	https://pubmed.ncbi.nlm.nih.gov/18680359

DMSU80N	DI	DMSU80N
DMSU80N	DN	N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl-phenylcarbamate analog 1
DMSU80N	MI	TT9NXW4
DMSU80N	MN	Sigma intracellular receptor 2 (TMEM97)
DMSU80N	MT	DTT
DMSU80N	MA	Ligand
DMSU80N	RN	Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578.
DMSU80N	RU	https://www.ncbi.nlm.nih.gov/pubmed/28051882

DMPW1GI	DI	DMPW1GI
DMPW1GI	DN	N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl-phenylcarbamate analog 2
DMPW1GI	MI	TT9NXW4
DMPW1GI	MN	Sigma intracellular receptor 2 (TMEM97)
DMPW1GI	MT	DTT
DMPW1GI	MA	Ligand
DMPW1GI	RN	Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578.
DMPW1GI	RU	https://www.ncbi.nlm.nih.gov/pubmed/28051882

DMZF9TM	DI	DMZF9TM
DMZF9TM	DN	N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl-phenylcarbamate analog 3
DMZF9TM	MI	TT9NXW4
DMZF9TM	MN	Sigma intracellular receptor 2 (TMEM97)
DMZF9TM	MT	DTT
DMZF9TM	MA	Ligand
DMZF9TM	RN	Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578.
DMZF9TM	RU	https://www.ncbi.nlm.nih.gov/pubmed/28051882

DMHTVGM	DI	DMHTVGM
DMHTVGM	DN	N-substituted pyrazole derivative 1
DMHTVGM	MI	TTXJ47W
DMHTVGM	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMHTVGM	MT	DTT
DMHTVGM	MA	Antagonist
DMHTVGM	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DMHTVGM	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DMQWODI	DI	DMQWODI
DMQWODI	DN	N-substituted pyrazole derivative 2
DMQWODI	MI	TTXJ47W
DMQWODI	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMQWODI	MT	DTT
DMQWODI	MA	Antagonist
DMQWODI	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DMQWODI	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DM5TIFH	DI	DM5TIFH
DM5TIFH	DN	N-substituted pyrazole derivative 3
DM5TIFH	MI	TTXJ47W
DM5TIFH	MN	Metabotropic glutamate receptor 2 (mGluR2)
DM5TIFH	MT	DTT
DM5TIFH	MA	Antagonist
DM5TIFH	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DM5TIFH	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DM0ECWR	DI	DM0ECWR
DM0ECWR	DN	Octahydro-pyrrolo[3,4-c]-pyrrole derivative 1
DM0ECWR	MI	TTSCIM2
DM0ECWR	MN	Extracellular lysophospholipase D (E-NPP2)
DM0ECWR	MT	DTT
DM0ECWR	MA	Inhibitor
DM0ECWR	RN	Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829.
DM0ECWR	RU	https://www.ncbi.nlm.nih.gov/pubmed/28447479

DMZIALN	DI	DMZIALN
DMZIALN	DN	Olenolic acid acetate derivative 1
DMZIALN	MI	TTSXVID
DMZIALN	MN	Nuclear factor NF-kappa-B (NFKB)
DMZIALN	MT	DTT
DMZIALN	MA	Inhibitor
DMZIALN	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DMZIALN	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DM74T5L	DI	DM74T5L
DM74T5L	DN	Oligooxopiperazine derivative 1
DM74T5L	MI	TTUX68I
DM74T5L	MN	Hypoxia-inducible factor 1 (HIF-1)
DM74T5L	MT	DTT
DM74T5L	MA	Inhibitor
DM74T5L	RN	Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22.
DM74T5L	RU	https://www.ncbi.nlm.nih.gov/pubmed/26882240

DM7Y2RL	DI	DM7Y2RL
DM7Y2RL	DN	Oxazole derivative 1
DM7Y2RL	MI	TTN7R6K
DM7Y2RL	MN	Signal transducer and activator of transcription 1 (STAT1)
DM7Y2RL	MT	DTT
DM7Y2RL	MA	Inhibitor
DM7Y2RL	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DM7Y2RL	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DM7Y2RL	DI	DM7Y2RL
DM7Y2RL	DN	Oxazole derivative 1
DM7Y2RL	MI	TTH8FZW
DM7Y2RL	MN	Signal transducer and activator of transcription 3 (STAT3)
DM7Y2RL	MT	DTT
DM7Y2RL	MA	Inhibitor
DM7Y2RL	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DM7Y2RL	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMPZ81S	DI	DMPZ81S
DMPZ81S	DN	Oxazolo[3,4-a]pyrazine derivative 1
DMPZ81S	MI	TTV1C0Z
DMPZ81S	MN	Neuropeptide S receptor (NPSR)
DMPZ81S	MT	DTT
DMPZ81S	MA	Antagonist
DMPZ81S	RN	Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362.
DMPZ81S	RU	https://www.ncbi.nlm.nih.gov/pubmed/27788040

DM28E0A	DI	DM28E0A
DM28E0A	DN	Oxazolo[3,4-a]pyrazine derivative 2
DM28E0A	MI	TTV1C0Z
DM28E0A	MN	Neuropeptide S receptor (NPSR)
DM28E0A	MT	DTT
DM28E0A	MA	Antagonist
DM28E0A	RN	Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362.
DM28E0A	RU	https://www.ncbi.nlm.nih.gov/pubmed/27788040

DM1LPKH	DI	DM1LPKH
DM1LPKH	DN	Oxazolo[3,4-a]pyrazine derivative 3
DM1LPKH	MI	TTV1C0Z
DM1LPKH	MN	Neuropeptide S receptor (NPSR)
DM1LPKH	MT	DTT
DM1LPKH	MA	Antagonist
DM1LPKH	RN	Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362.
DM1LPKH	RU	https://www.ncbi.nlm.nih.gov/pubmed/27788040

DM1B74D	DI	DM1B74D
DM1B74D	DN	Oxazolo[3,4-a]pyrazine derivative 4
DM1B74D	MI	TTV1C0Z
DM1B74D	MN	Neuropeptide S receptor (NPSR)
DM1B74D	MT	DTT
DM1B74D	MA	Antagonist
DM1B74D	RN	Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362.
DM1B74D	RU	https://www.ncbi.nlm.nih.gov/pubmed/27788040

DMC5G76	DI	DMC5G76
DMC5G76	DN	Oxazolo[3,4-a]pyrazine derivative 5
DMC5G76	MI	TTV1C0Z
DMC5G76	MN	Neuropeptide S receptor (NPSR)
DMC5G76	MT	DTT
DMC5G76	MA	Antagonist
DMC5G76	RN	Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362.
DMC5G76	RU	https://www.ncbi.nlm.nih.gov/pubmed/27788040

DM5DC9A	DI	DM5DC9A
DM5DC9A	DN	Oxazolo[3,4-a]pyrazine derivative 6
DM5DC9A	MI	TTV1C0Z
DM5DC9A	MN	Neuropeptide S receptor (NPSR)
DM5DC9A	MT	DTT
DM5DC9A	MA	Antagonist
DM5DC9A	RN	Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362.
DM5DC9A	RU	https://www.ncbi.nlm.nih.gov/pubmed/27788040

DMEX5VK	DI	DMEX5VK
DMEX5VK	DN	Oxazolo[3,4-a]pyrazine derivative 7
DMEX5VK	MI	TTV1C0Z
DMEX5VK	MN	Neuropeptide S receptor (NPSR)
DMEX5VK	MT	DTT
DMEX5VK	MA	Antagonist
DMEX5VK	RN	Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362.
DMEX5VK	RU	https://www.ncbi.nlm.nih.gov/pubmed/27788040

DMZM6FW	DI	DMZM6FW
DMZM6FW	DN	Oxazolyl methylthiothiazole derivative 1
DMZM6FW	MI	TTH6V3D
DMZM6FW	MN	Cyclin-dependent kinase 1 (CDK1)
DMZM6FW	MT	DTT
DMZM6FW	MA	Inhibitor
DMZM6FW	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMZM6FW	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMZM6FW	DI	DMZM6FW
DMZM6FW	DN	Oxazolyl methylthiothiazole derivative 1
DMZM6FW	MI	TT7HF4W
DMZM6FW	MN	Cyclin-dependent kinase 2 (CDK2)
DMZM6FW	MT	DTT
DMZM6FW	MA	Inhibitor
DMZM6FW	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMZM6FW	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMZM6FW	DI	DMZM6FW
DMZM6FW	DN	Oxazolyl methylthiothiazole derivative 1
DMZM6FW	MI	TTMYWL7
DMZM6FW	MN	Cyclin-dependent kinase 3 (CDK3)
DMZM6FW	MT	DTT
DMZM6FW	MA	Inhibitor
DMZM6FW	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMZM6FW	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMZM6FW	DI	DMZM6FW
DMZM6FW	DN	Oxazolyl methylthiothiazole derivative 1
DMZM6FW	MI	TT0PG8F
DMZM6FW	MN	Cyclin-dependent kinase 4 (CDK4)
DMZM6FW	MT	DTT
DMZM6FW	MA	Inhibitor
DMZM6FW	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMZM6FW	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMZM6FW	DI	DMZM6FW
DMZM6FW	DN	Oxazolyl methylthiothiazole derivative 1
DMZM6FW	MI	TTO0FDJ
DMZM6FW	MN	Cyclin-dependent kinase 6 (CDK6)
DMZM6FW	MT	DTT
DMZM6FW	MA	Inhibitor
DMZM6FW	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMZM6FW	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMZM6FW	DI	DMZM6FW
DMZM6FW	DN	Oxazolyl methylthiothiazole derivative 1
DMZM6FW	MI	TTQYF7G
DMZM6FW	MN	Cyclin-dependent kinase 7 (CDK7)
DMZM6FW	MT	DTT
DMZM6FW	MA	Inhibitor
DMZM6FW	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMZM6FW	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMZM6FW	DI	DMZM6FW
DMZM6FW	DN	Oxazolyl methylthiothiazole derivative 1
DMZM6FW	MI	TT1LVF2
DMZM6FW	MN	Cyclin-dependent kinase 9 (CDK9)
DMZM6FW	MT	DTT
DMZM6FW	MA	Inhibitor
DMZM6FW	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMZM6FW	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMZM6FW	DI	DMZM6FW
DMZM6FW	DN	Oxazolyl methylthiothiazole derivative 1
DMZM6FW	MI	TTBH0VX
DMZM6FW	MN	Histone deacetylase (HDAC)
DMZM6FW	MT	DTT
DMZM6FW	MA	Inhibitor
DMZM6FW	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMZM6FW	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMSB09X	DI	DMSB09X
DMSB09X	DN	Oxetane 3,3-dicarboxamide compound 1
DMSB09X	MI	TTOHSBA
DMSB09X	MN	Vascular endothelial growth factor A (VEGFA)
DMSB09X	MT	DTT
DMSB09X	MA	Inhibitor
DMSB09X	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMSB09X	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMMCTAK	DI	DMMCTAK
DMMCTAK	DN	Oxetane 3,3-dicarboxamide compound 2
DMMCTAK	MI	TTOHSBA
DMMCTAK	MN	Vascular endothelial growth factor A (VEGFA)
DMMCTAK	MT	DTT
DMMCTAK	MA	Inhibitor
DMMCTAK	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMMCTAK	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMWUYIB	DI	DMWUYIB
DMWUYIB	DN	Oxime derivative 1
DMWUYIB	MI	TTEB0GD
DMWUYIB	MN	Cholinesterase (BCHE)
DMWUYIB	MT	DTT
DMWUYIB	MA	Reactivator
DMWUYIB	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DMWUYIB	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DMMSVW5	DI	DMMSVW5
DMMSVW5	DN	Oxindole derivative 1
DMMSVW5	MI	TTJGW1Z
DMMSVW5	MN	Phosphodiesterase 2A (PDE2A)
DMMSVW5	MT	DTT
DMMSVW5	MA	Inhibitor
DMMSVW5	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMMSVW5	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DM6ZYMC	DI	DM6ZYMC
DM6ZYMC	DN	Oxindole derivative 2
DM6ZYMC	MI	TTK0FEA
DM6ZYMC	MN	Leucine-rich repeat kinase 2 (LRRK2)
DM6ZYMC	MT	DTT
DM6ZYMC	MA	Inhibitor
DM6ZYMC	RN	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
DM6ZYMC	RU	https://www.ncbi.nlm.nih.gov/pubmed/28117607

DM0ENF3	DI	DM0ENF3
DM0ENF3	DN	Oxindole derivative 3
DM0ENF3	MI	TTK0FEA
DM0ENF3	MN	Leucine-rich repeat kinase 2 (LRRK2)
DM0ENF3	MT	DTT
DM0ENF3	MA	Inhibitor
DM0ENF3	RN	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
DM0ENF3	RU	https://www.ncbi.nlm.nih.gov/pubmed/28117607

DM0ENF3	DI	DM0ENF3
DM0ENF3	DN	Oxindole derivative 3
DM0ENF3	MI	TT6AXLY
DM0ENF3	MN	Leucine-rich repeat kinase 2 G2019S mutant (LRRK2 G2019S)
DM0ENF3	MT	DTT
DM0ENF3	MA	Inhibitor
DM0ENF3	RN	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
DM0ENF3	RU	https://www.ncbi.nlm.nih.gov/pubmed/28117607

DM3U58I	DI	DM3U58I
DM3U58I	DN	Oxindole derivative 4
DM3U58I	MI	TTK0FEA
DM3U58I	MN	Leucine-rich repeat kinase 2 (LRRK2)
DM3U58I	MT	DTT
DM3U58I	MA	Inhibitor
DM3U58I	RN	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
DM3U58I	RU	https://www.ncbi.nlm.nih.gov/pubmed/28117607

DM3U58I	DI	DM3U58I
DM3U58I	DN	Oxindole derivative 4
DM3U58I	MI	TT6AXLY
DM3U58I	MN	Leucine-rich repeat kinase 2 G2019S mutant (LRRK2 G2019S)
DM3U58I	MT	DTT
DM3U58I	MA	Inhibitor
DM3U58I	RN	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
DM3U58I	RU	https://www.ncbi.nlm.nih.gov/pubmed/28117607

DM1SH5R	DI	DM1SH5R
DM1SH5R	DN	Oxotetrahydro-2-H-furo[3.2-b]pyrrol-4(5-H)-yl derivative 1
DM1SH5R	MI	TTDZN01
DM1SH5R	MN	Cathepsin K (CTSK)
DM1SH5R	MT	DTT
DM1SH5R	MA	Inhibitor
DM1SH5R	RN	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
DM1SH5R	RU	https://www.ncbi.nlm.nih.gov/pubmed/27998201

DM1SH5R	DI	DM1SH5R
DM1SH5R	DN	Oxotetrahydro-2-H-furo[3.2-b]pyrrol-4(5-H)-yl derivative 1
DM1SH5R	MI	TTUMQVO
DM1SH5R	MN	Cathepsin S (CTSS)
DM1SH5R	MT	DTT
DM1SH5R	MA	Inhibitor
DM1SH5R	RN	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
DM1SH5R	RU	https://www.ncbi.nlm.nih.gov/pubmed/27998201

DM0RI7F	DI	DM0RI7F
DM0RI7F	DN	Palbociclib/ribociclib analog 1
DM0RI7F	MI	TT7HF4W
DM0RI7F	MN	Cyclin-dependent kinase 2 (CDK2)
DM0RI7F	MT	DTT
DM0RI7F	MA	Inhibitor
DM0RI7F	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DM0RI7F	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DM0RI7F	DI	DM0RI7F
DM0RI7F	DN	Palbociclib/ribociclib analog 1
DM0RI7F	MI	TT0PG8F
DM0RI7F	MN	Cyclin-dependent kinase 4 (CDK4)
DM0RI7F	MT	DTT
DM0RI7F	MA	Inhibitor
DM0RI7F	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DM0RI7F	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DM859ZQ	DI	DM859ZQ
DM859ZQ	DN	Palmarumycin derivative 1
DM859ZQ	MI	TTR7UJ3
DM859ZQ	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DM859ZQ	MT	DTT
DM859ZQ	MA	Inhibitor
DM859ZQ	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DM859ZQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DMRLWZI	DI	DMRLWZI
DMRLWZI	DN	Palmarumycin derivative 2
DMRLWZI	MI	TTR7UJ3
DMRLWZI	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMRLWZI	MT	DTT
DMRLWZI	MA	Inhibitor
DMRLWZI	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMRLWZI	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DM198BY	DI	DM198BY
DM198BY	DN	Palmarumycin derivative 3
DM198BY	MI	TTR7UJ3
DM198BY	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DM198BY	MT	DTT
DM198BY	MA	Inhibitor
DM198BY	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DM198BY	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DMZGI0R	DI	DMZGI0R
DMZGI0R	DN	Palmarumycin derivative 4
DMZGI0R	MI	TTR7UJ3
DMZGI0R	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMZGI0R	MT	DTT
DMZGI0R	MA	Inhibitor
DMZGI0R	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMZGI0R	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DM231WS	DI	DM231WS
DM231WS	DN	P-coumaric acid derivative 1
DM231WS	MI	TTULVH8
DM231WS	MN	Tyrosinase (TYR)
DM231WS	MT	DTT
DM231WS	MA	Inhibitor
DM231WS	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DM231WS	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMFTZBY	DI	DMFTZBY
DMFTZBY	DN	P-coumaric acid derivative 2
DMFTZBY	MI	TTULVH8
DMFTZBY	MN	Tyrosinase (TYR)
DMFTZBY	MT	DTT
DMFTZBY	MA	Inhibitor
DMFTZBY	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMFTZBY	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMFE4IY	DI	DMFE4IY
DMFE4IY	DN	P-coumaric acid derivative 3
DMFE4IY	MI	TTULVH8
DMFE4IY	MN	Tyrosinase (TYR)
DMFE4IY	MT	DTT
DMFE4IY	MA	Inhibitor
DMFE4IY	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMFE4IY	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DM5WQP3	DI	DM5WQP3
DM5WQP3	DN	P-coumaric acid derivative 4
DM5WQP3	MI	TTULVH8
DM5WQP3	MN	Tyrosinase (TYR)
DM5WQP3	MT	DTT
DM5WQP3	MA	Inhibitor
DM5WQP3	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DM5WQP3	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMFKGZ7	DI	DMFKGZ7
DMFKGZ7	DN	P-coumaric acid derivative 5
DMFKGZ7	MI	TTULVH8
DMFKGZ7	MN	Tyrosinase (TYR)
DMFKGZ7	MT	DTT
DMFKGZ7	MA	Inhibitor
DMFKGZ7	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMFKGZ7	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMF4YGC	DI	DMF4YGC
DMF4YGC	DN	P-coumaric acid derivative 6
DMF4YGC	MI	TTULVH8
DMF4YGC	MN	Tyrosinase (TYR)
DMF4YGC	MT	DTT
DMF4YGC	MA	Inhibitor
DMF4YGC	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMF4YGC	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMF3LIX	DI	DMF3LIX
DMF3LIX	DN	Peptide analog 1
DMF3LIX	MI	TT23XQV
DMF3LIX	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMF3LIX	MT	DTT
DMF3LIX	MA	Inhibitor
DMF3LIX	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMF3LIX	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMYKOAM	DI	DMYKOAM
DMYKOAM	DN	Peptide analog 10
DMYKOAM	MI	TTSJMN8
DMYKOAM	MN	Immunoproteasome complex (IP)
DMYKOAM	MT	DTT
DMYKOAM	MA	Inhibitor
DMYKOAM	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMYKOAM	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DML9C64	DI	DML9C64
DML9C64	DN	Peptide analog 11
DML9C64	MI	TT68GPI
DML9C64	MN	Proteasome beta-5 (PS beta-5)
DML9C64	MT	DTT
DML9C64	MA	Inhibitor
DML9C64	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DML9C64	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DML9C64	DI	DML9C64
DML9C64	DN	Peptide analog 11
DML9C64	MI	TTEAD9J
DML9C64	MN	Proteasome beta-8 (PS beta-8)
DML9C64	MT	DTT
DML9C64	MA	Inhibitor
DML9C64	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DML9C64	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMSJHV3	DI	DMSJHV3
DMSJHV3	DN	Peptide analog 12
DMSJHV3	MI	TTSJMN8
DMSJHV3	MN	Immunoproteasome complex (IP)
DMSJHV3	MT	DTT
DMSJHV3	MA	Inhibitor
DMSJHV3	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMSJHV3	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMWI6V3	DI	DMWI6V3
DMWI6V3	DN	Peptide analog 13
DMWI6V3	MI	TT68GPI
DMWI6V3	MN	Proteasome beta-5 (PS beta-5)
DMWI6V3	MT	DTT
DMWI6V3	MA	Inhibitor
DMWI6V3	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMWI6V3	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMWI6V3	DI	DMWI6V3
DMWI6V3	DN	Peptide analog 13
DMWI6V3	MI	TTEAD9J
DMWI6V3	MN	Proteasome beta-8 (PS beta-8)
DMWI6V3	MT	DTT
DMWI6V3	MA	Inhibitor
DMWI6V3	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMWI6V3	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMN97QF	DI	DMN97QF
DMN97QF	DN	Peptide analog 14
DMN97QF	MI	TTOUSTQ
DMN97QF	MN	Proteasome beta-9 (PS beta-9)
DMN97QF	MT	DTT
DMN97QF	MA	Inhibitor
DMN97QF	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMN97QF	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DM0K5Q1	DI	DM0K5Q1
DM0K5Q1	DN	Peptide analog 15
DM0K5Q1	MI	TTSJMN8
DM0K5Q1	MN	Immunoproteasome complex (IP)
DM0K5Q1	MT	DTT
DM0K5Q1	MA	Inhibitor
DM0K5Q1	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DM0K5Q1	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMKJ27D	DI	DMKJ27D
DMKJ27D	DN	Peptide analog 16
DMKJ27D	MI	TTSJMN8
DMKJ27D	MN	Immunoproteasome complex (IP)
DMKJ27D	MT	DTT
DMKJ27D	MA	Inhibitor
DMKJ27D	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMKJ27D	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMJ91EM	DI	DMJ91EM
DMJ91EM	DN	Peptide analog 17
DMJ91EM	MI	TT68GPI
DMJ91EM	MN	Proteasome beta-5 (PS beta-5)
DMJ91EM	MT	DTT
DMJ91EM	MA	Inhibitor
DMJ91EM	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMJ91EM	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMJ91EM	DI	DMJ91EM
DMJ91EM	DN	Peptide analog 17
DMJ91EM	MI	TTEAD9J
DMJ91EM	MN	Proteasome beta-8 (PS beta-8)
DMJ91EM	MT	DTT
DMJ91EM	MA	Inhibitor
DMJ91EM	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMJ91EM	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMF1TR6	DI	DMF1TR6
DMF1TR6	DN	Peptide analog 18
DMF1TR6	MI	TTSJMN8
DMF1TR6	MN	Immunoproteasome complex (IP)
DMF1TR6	MT	DTT
DMF1TR6	MA	Inhibitor
DMF1TR6	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMF1TR6	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMLIVT6	DI	DMLIVT6
DMLIVT6	DN	Peptide analog 19
DMLIVT6	MI	TT68GPI
DMLIVT6	MN	Proteasome beta-5 (PS beta-5)
DMLIVT6	MT	DTT
DMLIVT6	MA	Inhibitor
DMLIVT6	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMLIVT6	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMLIVT6	DI	DMLIVT6
DMLIVT6	DN	Peptide analog 19
DMLIVT6	MI	TTEAD9J
DMLIVT6	MN	Proteasome beta-8 (PS beta-8)
DMLIVT6	MT	DTT
DMLIVT6	MA	Inhibitor
DMLIVT6	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMLIVT6	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMYFUM6	DI	DMYFUM6
DMYFUM6	DN	Peptide analog 2
DMYFUM6	MI	TT23XQV
DMYFUM6	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMYFUM6	MT	DTT
DMYFUM6	MA	Inhibitor
DMYFUM6	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMYFUM6	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DM2L9KI	DI	DM2L9KI
DM2L9KI	DN	Peptide analog 20
DM2L9KI	MI	TTSJMN8
DM2L9KI	MN	Immunoproteasome complex (IP)
DM2L9KI	MT	DTT
DM2L9KI	MA	Inhibitor
DM2L9KI	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DM2L9KI	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMJDFS1	DI	DMJDFS1
DMJDFS1	DN	Peptide analog 21
DMJDFS1	MI	TT8EPLT
DMJDFS1	MN	Proteasome beta-1 (PS beta-1)
DMJDFS1	MT	DTT
DMJDFS1	MA	Inhibitor
DMJDFS1	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMJDFS1	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMJDFS1	DI	DMJDFS1
DMJDFS1	DN	Peptide analog 21
DMJDFS1	MI	TTPNACM
DMJDFS1	MN	Proteasome beta-10 (PS beta-10)
DMJDFS1	MT	DTT
DMJDFS1	MA	Inhibitor
DMJDFS1	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMJDFS1	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMJDFS1	DI	DMJDFS1
DMJDFS1	DN	Peptide analog 21
DMJDFS1	MI	TT49BVC
DMJDFS1	MN	Proteasome beta-2 (PS beta-2)
DMJDFS1	MT	DTT
DMJDFS1	MA	Inhibitor
DMJDFS1	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMJDFS1	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMJDFS1	DI	DMJDFS1
DMJDFS1	DN	Peptide analog 21
DMJDFS1	MI	TT68GPI
DMJDFS1	MN	Proteasome beta-5 (PS beta-5)
DMJDFS1	MT	DTT
DMJDFS1	MA	Inhibitor
DMJDFS1	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMJDFS1	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMJDFS1	DI	DMJDFS1
DMJDFS1	DN	Peptide analog 21
DMJDFS1	MI	TTEAD9J
DMJDFS1	MN	Proteasome beta-8 (PS beta-8)
DMJDFS1	MT	DTT
DMJDFS1	MA	Inhibitor
DMJDFS1	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMJDFS1	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMJDFS1	DI	DMJDFS1
DMJDFS1	DN	Peptide analog 21
DMJDFS1	MI	TTOUSTQ
DMJDFS1	MN	Proteasome beta-9 (PS beta-9)
DMJDFS1	MT	DTT
DMJDFS1	MA	Inhibitor
DMJDFS1	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMJDFS1	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMTLO1E	DI	DMTLO1E
DMTLO1E	DN	Peptide analog 22
DMTLO1E	MI	TTSJMN8
DMTLO1E	MN	Immunoproteasome complex (IP)
DMTLO1E	MT	DTT
DMTLO1E	MA	Inhibitor
DMTLO1E	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMTLO1E	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMDU21R	DI	DMDU21R
DMDU21R	DN	Peptide analog 23
DMDU21R	MI	TT8EPLT
DMDU21R	MN	Proteasome beta-1 (PS beta-1)
DMDU21R	MT	DTT
DMDU21R	MA	Inhibitor
DMDU21R	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMDU21R	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMDU21R	DI	DMDU21R
DMDU21R	DN	Peptide analog 23
DMDU21R	MI	TTPNACM
DMDU21R	MN	Proteasome beta-10 (PS beta-10)
DMDU21R	MT	DTT
DMDU21R	MA	Inhibitor
DMDU21R	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMDU21R	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMDU21R	DI	DMDU21R
DMDU21R	DN	Peptide analog 23
DMDU21R	MI	TT49BVC
DMDU21R	MN	Proteasome beta-2 (PS beta-2)
DMDU21R	MT	DTT
DMDU21R	MA	Inhibitor
DMDU21R	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMDU21R	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMDU21R	DI	DMDU21R
DMDU21R	DN	Peptide analog 23
DMDU21R	MI	TT68GPI
DMDU21R	MN	Proteasome beta-5 (PS beta-5)
DMDU21R	MT	DTT
DMDU21R	MA	Inhibitor
DMDU21R	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMDU21R	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMDU21R	DI	DMDU21R
DMDU21R	DN	Peptide analog 23
DMDU21R	MI	TTEAD9J
DMDU21R	MN	Proteasome beta-8 (PS beta-8)
DMDU21R	MT	DTT
DMDU21R	MA	Inhibitor
DMDU21R	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMDU21R	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMDU21R	DI	DMDU21R
DMDU21R	DN	Peptide analog 23
DMDU21R	MI	TTOUSTQ
DMDU21R	MN	Proteasome beta-9 (PS beta-9)
DMDU21R	MT	DTT
DMDU21R	MA	Inhibitor
DMDU21R	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMDU21R	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DM904T7	DI	DM904T7
DM904T7	DN	Peptide analog 24
DM904T7	MI	TTSJMN8
DM904T7	MN	Immunoproteasome complex (IP)
DM904T7	MT	DTT
DM904T7	MA	Inhibitor
DM904T7	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DM904T7	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMFBQHZ	DI	DMFBQHZ
DMFBQHZ	DN	Peptide analog 25
DMFBQHZ	MI	TT68GPI
DMFBQHZ	MN	Proteasome beta-5 (PS beta-5)
DMFBQHZ	MT	DTT
DMFBQHZ	MA	Inhibitor
DMFBQHZ	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMFBQHZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMFBQHZ	DI	DMFBQHZ
DMFBQHZ	DN	Peptide analog 25
DMFBQHZ	MI	TTEAD9J
DMFBQHZ	MN	Proteasome beta-8 (PS beta-8)
DMFBQHZ	MT	DTT
DMFBQHZ	MA	Inhibitor
DMFBQHZ	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMFBQHZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DM8FGZB	DI	DM8FGZB
DM8FGZB	DN	Peptide analog 26
DM8FGZB	MI	TTSJMN8
DM8FGZB	MN	Immunoproteasome complex (IP)
DM8FGZB	MT	DTT
DM8FGZB	MA	Inhibitor
DM8FGZB	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DM8FGZB	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DML4XJ2	DI	DML4XJ2
DML4XJ2	DN	Peptide analog 27
DML4XJ2	MI	TT68GPI
DML4XJ2	MN	Proteasome beta-5 (PS beta-5)
DML4XJ2	MT	DTT
DML4XJ2	MA	Inhibitor
DML4XJ2	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DML4XJ2	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DML4XJ2	DI	DML4XJ2
DML4XJ2	DN	Peptide analog 27
DML4XJ2	MI	TTEAD9J
DML4XJ2	MN	Proteasome beta-8 (PS beta-8)
DML4XJ2	MT	DTT
DML4XJ2	MA	Inhibitor
DML4XJ2	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DML4XJ2	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMHT4PF	DI	DMHT4PF
DMHT4PF	DN	Peptide analog 28
DMHT4PF	MI	TT68GPI
DMHT4PF	MN	Proteasome beta-5 (PS beta-5)
DMHT4PF	MT	DTT
DMHT4PF	MA	Inhibitor
DMHT4PF	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMHT4PF	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMHT4PF	DI	DMHT4PF
DMHT4PF	DN	Peptide analog 28
DMHT4PF	MI	TTEAD9J
DMHT4PF	MN	Proteasome beta-8 (PS beta-8)
DMHT4PF	MT	DTT
DMHT4PF	MA	Inhibitor
DMHT4PF	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMHT4PF	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DM1NMR6	DI	DM1NMR6
DM1NMR6	DN	Peptide analog 29
DM1NMR6	MI	TTSJMN8
DM1NMR6	MN	Immunoproteasome complex (IP)
DM1NMR6	MT	DTT
DM1NMR6	MA	Inhibitor
DM1NMR6	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DM1NMR6	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMYMJV3	DI	DMYMJV3
DMYMJV3	DN	Peptide analog 3
DMYMJV3	MI	TT23XQV
DMYMJV3	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMYMJV3	MT	DTT
DMYMJV3	MA	Inhibitor
DMYMJV3	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMYMJV3	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMYEJV0	DI	DMYEJV0
DMYEJV0	DN	Peptide analog 30
DMYEJV0	MI	TTSJMN8
DMYEJV0	MN	Immunoproteasome complex (IP)
DMYEJV0	MT	DTT
DMYEJV0	MA	Inhibitor
DMYEJV0	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMYEJV0	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMS9O6I	DI	DMS9O6I
DMS9O6I	DN	Peptide analog 31
DMS9O6I	MI	TT68GPI
DMS9O6I	MN	Proteasome beta-5 (PS beta-5)
DMS9O6I	MT	DTT
DMS9O6I	MA	Inhibitor
DMS9O6I	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMS9O6I	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMS9O6I	DI	DMS9O6I
DMS9O6I	DN	Peptide analog 31
DMS9O6I	MI	TTEAD9J
DMS9O6I	MN	Proteasome beta-8 (PS beta-8)
DMS9O6I	MT	DTT
DMS9O6I	MA	Inhibitor
DMS9O6I	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMS9O6I	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMGQ1PK	DI	DMGQ1PK
DMGQ1PK	DN	Peptide analog 32
DMGQ1PK	MI	TTSJMN8
DMGQ1PK	MN	Immunoproteasome complex (IP)
DMGQ1PK	MT	DTT
DMGQ1PK	MA	Inhibitor
DMGQ1PK	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMGQ1PK	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DML5P6O	DI	DML5P6O
DML5P6O	DN	Peptide analog 33
DML5P6O	MI	TT68GPI
DML5P6O	MN	Proteasome beta-5 (PS beta-5)
DML5P6O	MT	DTT
DML5P6O	MA	Inhibitor
DML5P6O	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DML5P6O	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DML5P6O	DI	DML5P6O
DML5P6O	DN	Peptide analog 33
DML5P6O	MI	TTEAD9J
DML5P6O	MN	Proteasome beta-8 (PS beta-8)
DML5P6O	MT	DTT
DML5P6O	MA	Inhibitor
DML5P6O	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DML5P6O	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMG4EOP	DI	DMG4EOP
DMG4EOP	DN	Peptide analog 34
DMG4EOP	MI	TT68GPI
DMG4EOP	MN	Proteasome beta-5 (PS beta-5)
DMG4EOP	MT	DTT
DMG4EOP	MA	Inhibitor
DMG4EOP	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMG4EOP	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMG4EOP	DI	DMG4EOP
DMG4EOP	DN	Peptide analog 34
DMG4EOP	MI	TTEAD9J
DMG4EOP	MN	Proteasome beta-8 (PS beta-8)
DMG4EOP	MT	DTT
DMG4EOP	MA	Inhibitor
DMG4EOP	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMG4EOP	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMSOQG7	DI	DMSOQG7
DMSOQG7	DN	Peptide analog 35
DMSOQG7	MI	TTSJMN8
DMSOQG7	MN	Immunoproteasome complex (IP)
DMSOQG7	MT	DTT
DMSOQG7	MA	Inhibitor
DMSOQG7	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMSOQG7	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMB4LNI	DI	DMB4LNI
DMB4LNI	DN	Peptide analog 36
DMB4LNI	MI	TTPNACM
DMB4LNI	MN	Proteasome beta-10 (PS beta-10)
DMB4LNI	MT	DTT
DMB4LNI	MA	Inhibitor
DMB4LNI	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMB4LNI	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMB4LNI	DI	DMB4LNI
DMB4LNI	DN	Peptide analog 36
DMB4LNI	MI	TT49BVC
DMB4LNI	MN	Proteasome beta-2 (PS beta-2)
DMB4LNI	MT	DTT
DMB4LNI	MA	Inhibitor
DMB4LNI	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMB4LNI	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMB4LNI	DI	DMB4LNI
DMB4LNI	DN	Peptide analog 36
DMB4LNI	MI	TT68GPI
DMB4LNI	MN	Proteasome beta-5 (PS beta-5)
DMB4LNI	MT	DTT
DMB4LNI	MA	Inhibitor
DMB4LNI	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMB4LNI	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMVX71N	DI	DMVX71N
DMVX71N	DN	Peptide analog 37
DMVX71N	MI	TTPNACM
DMVX71N	MN	Proteasome beta-10 (PS beta-10)
DMVX71N	MT	DTT
DMVX71N	MA	Inhibitor
DMVX71N	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMVX71N	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMVX71N	DI	DMVX71N
DMVX71N	DN	Peptide analog 37
DMVX71N	MI	TT49BVC
DMVX71N	MN	Proteasome beta-2 (PS beta-2)
DMVX71N	MT	DTT
DMVX71N	MA	Inhibitor
DMVX71N	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMVX71N	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMVX71N	DI	DMVX71N
DMVX71N	DN	Peptide analog 37
DMVX71N	MI	TT68GPI
DMVX71N	MN	Proteasome beta-5 (PS beta-5)
DMVX71N	MT	DTT
DMVX71N	MA	Inhibitor
DMVX71N	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMVX71N	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DM9FL81	DI	DM9FL81
DM9FL81	DN	Peptide analog 38
DM9FL81	MI	TTPNACM
DM9FL81	MN	Proteasome beta-10 (PS beta-10)
DM9FL81	MT	DTT
DM9FL81	MA	Inhibitor
DM9FL81	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DM9FL81	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DM9FL81	DI	DM9FL81
DM9FL81	DN	Peptide analog 38
DM9FL81	MI	TT49BVC
DM9FL81	MN	Proteasome beta-2 (PS beta-2)
DM9FL81	MT	DTT
DM9FL81	MA	Inhibitor
DM9FL81	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DM9FL81	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DM9FL81	DI	DM9FL81
DM9FL81	DN	Peptide analog 38
DM9FL81	MI	TT68GPI
DM9FL81	MN	Proteasome beta-5 (PS beta-5)
DM9FL81	MT	DTT
DM9FL81	MA	Inhibitor
DM9FL81	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DM9FL81	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMYJOTP	DI	DMYJOTP
DMYJOTP	DN	Peptide analog 39
DMYJOTP	MI	TT8EPLT
DMYJOTP	MN	Proteasome beta-1 (PS beta-1)
DMYJOTP	MT	DTT
DMYJOTP	MA	Inhibitor
DMYJOTP	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMYJOTP	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMYJOTP	DI	DMYJOTP
DMYJOTP	DN	Peptide analog 39
DMYJOTP	MI	TT49BVC
DMYJOTP	MN	Proteasome beta-2 (PS beta-2)
DMYJOTP	MT	DTT
DMYJOTP	MA	Inhibitor
DMYJOTP	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMYJOTP	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMYJOTP	DI	DMYJOTP
DMYJOTP	DN	Peptide analog 39
DMYJOTP	MI	TT68GPI
DMYJOTP	MN	Proteasome beta-5 (PS beta-5)
DMYJOTP	MT	DTT
DMYJOTP	MA	Inhibitor
DMYJOTP	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMYJOTP	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DM5KEVG	DI	DM5KEVG
DM5KEVG	DN	Peptide analog 4
DM5KEVG	MI	TT23XQV
DM5KEVG	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DM5KEVG	MT	DTT
DM5KEVG	MA	Inhibitor
DM5KEVG	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DM5KEVG	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DM12VO9	DI	DM12VO9
DM12VO9	DN	Peptide analog 40
DM12VO9	MI	TTSJMN8
DM12VO9	MN	Immunoproteasome complex (IP)
DM12VO9	MT	DTT
DM12VO9	MA	Inhibitor
DM12VO9	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DM12VO9	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DM96KXE	DI	DM96KXE
DM96KXE	DN	Peptide analog 41
DM96KXE	MI	TT8EPLT
DM96KXE	MN	Proteasome beta-1 (PS beta-1)
DM96KXE	MT	DTT
DM96KXE	MA	Inhibitor
DM96KXE	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DM96KXE	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DM96KXE	DI	DM96KXE
DM96KXE	DN	Peptide analog 41
DM96KXE	MI	TT49BVC
DM96KXE	MN	Proteasome beta-2 (PS beta-2)
DM96KXE	MT	DTT
DM96KXE	MA	Inhibitor
DM96KXE	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DM96KXE	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DM96KXE	DI	DM96KXE
DM96KXE	DN	Peptide analog 41
DM96KXE	MI	TT68GPI
DM96KXE	MN	Proteasome beta-5 (PS beta-5)
DM96KXE	MT	DTT
DM96KXE	MA	Inhibitor
DM96KXE	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DM96KXE	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DM96KXE	DI	DM96KXE
DM96KXE	DN	Peptide analog 41
DM96KXE	MI	TTEAD9J
DM96KXE	MN	Proteasome beta-8 (PS beta-8)
DM96KXE	MT	DTT
DM96KXE	MA	Inhibitor
DM96KXE	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DM96KXE	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DM96KXE	DI	DM96KXE
DM96KXE	DN	Peptide analog 41
DM96KXE	MI	TTOUSTQ
DM96KXE	MN	Proteasome beta-9 (PS beta-9)
DM96KXE	MT	DTT
DM96KXE	MA	Inhibitor
DM96KXE	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DM96KXE	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMF1MZ4	DI	DMF1MZ4
DMF1MZ4	DN	Peptide analog 42
DMF1MZ4	MI	TTSJMN8
DMF1MZ4	MN	Immunoproteasome complex (IP)
DMF1MZ4	MT	DTT
DMF1MZ4	MA	Inhibitor
DMF1MZ4	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMF1MZ4	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMYMPF9	DI	DMYMPF9
DMYMPF9	DN	Peptide analog 43
DMYMPF9	MI	TTSJMN8
DMYMPF9	MN	Immunoproteasome complex (IP)
DMYMPF9	MT	DTT
DMYMPF9	MA	Inhibitor
DMYMPF9	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMYMPF9	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMOJDQF	DI	DMOJDQF
DMOJDQF	DN	Peptide analog 44
DMOJDQF	MI	TTDIGC1
DMOJDQF	MN	Dipeptidyl peptidase 4 (DPP-4)
DMOJDQF	MT	DTT
DMOJDQF	MA	Inhibitor
DMOJDQF	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMOJDQF	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DMGA3U8	DI	DMGA3U8
DMGA3U8	DN	Peptide analog 45
DMGA3U8	MI	TTDIGC1
DMGA3U8	MN	Dipeptidyl peptidase 4 (DPP-4)
DMGA3U8	MT	DTT
DMGA3U8	MA	Inhibitor
DMGA3U8	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMGA3U8	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DMC48AX	DI	DMC48AX
DMC48AX	DN	Peptide analog 46
DMC48AX	MI	TTDIGC1
DMC48AX	MN	Dipeptidyl peptidase 4 (DPP-4)
DMC48AX	MT	DTT
DMC48AX	MA	Inhibitor
DMC48AX	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMC48AX	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DM7U8WD	DI	DM7U8WD
DM7U8WD	DN	Peptide analog 47
DM7U8WD	MI	TTDIGC1
DM7U8WD	MN	Dipeptidyl peptidase 4 (DPP-4)
DM7U8WD	MT	DTT
DM7U8WD	MA	Inhibitor
DM7U8WD	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DM7U8WD	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DMM2WA4	DI	DMM2WA4
DMM2WA4	DN	Peptide analog 48
DMM2WA4	MI	TTDIGC1
DMM2WA4	MN	Dipeptidyl peptidase 4 (DPP-4)
DMM2WA4	MT	DTT
DMM2WA4	MA	Inhibitor
DMM2WA4	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMM2WA4	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DMP5SA2	DI	DMP5SA2
DMP5SA2	DN	Peptide analog 49
DMP5SA2	MI	TTDIGC1
DMP5SA2	MN	Dipeptidyl peptidase 4 (DPP-4)
DMP5SA2	MT	DTT
DMP5SA2	MA	Inhibitor
DMP5SA2	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMP5SA2	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DM8B13I	DI	DM8B13I
DM8B13I	DN	Peptide analog 5
DM8B13I	MI	TT23XQV
DM8B13I	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DM8B13I	MT	DTT
DM8B13I	MA	Inhibitor
DM8B13I	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DM8B13I	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMM8K7R	DI	DMM8K7R
DMM8K7R	DN	Peptide analog 50
DMM8K7R	MI	TTDIGC1
DMM8K7R	MN	Dipeptidyl peptidase 4 (DPP-4)
DMM8K7R	MT	DTT
DMM8K7R	MA	Inhibitor
DMM8K7R	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMM8K7R	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DM1D7CE	DI	DM1D7CE
DM1D7CE	DN	Peptide analog 51
DM1D7CE	MI	TTDIGC1
DM1D7CE	MN	Dipeptidyl peptidase 4 (DPP-4)
DM1D7CE	MT	DTT
DM1D7CE	MA	Inhibitor
DM1D7CE	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DM1D7CE	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DMDG5T9	DI	DMDG5T9
DMDG5T9	DN	Peptide analog 52
DMDG5T9	MI	TT2F4OL
DMDG5T9	MN	Tissue transglutaminase (TG2)
DMDG5T9	MT	DTT
DMDG5T9	MA	Inhibitor
DMDG5T9	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DMDG5T9	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DM9FJXS	DI	DM9FJXS
DM9FJXS	DN	Peptide analog 53
DM9FJXS	MI	TT2F4OL
DM9FJXS	MN	Tissue transglutaminase (TG2)
DM9FJXS	MT	DTT
DM9FJXS	MA	Inhibitor
DM9FJXS	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DM9FJXS	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DMZVB5U	DI	DMZVB5U
DMZVB5U	DN	Peptide analog 54
DMZVB5U	MI	TT2F4OL
DMZVB5U	MN	Tissue transglutaminase (TG2)
DMZVB5U	MT	DTT
DMZVB5U	MA	Inhibitor
DMZVB5U	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DMZVB5U	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DMVLP8H	DI	DMVLP8H
DMVLP8H	DN	Peptide analog 55
DMVLP8H	MI	TTQAJF1
DMVLP8H	MN	Cathepsin G (CTSG)
DMVLP8H	MT	DTT
DMVLP8H	MA	Inhibitor
DMVLP8H	RN	Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
DMVLP8H	RU	https://www.ncbi.nlm.nih.gov/pubmed/26118988

DMVLP8H	DI	DMVLP8H
DMVLP8H	DN	Peptide analog 55
DMVLP8H	MI	TTPLTSQ
DMVLP8H	MN	Neutrophil elastase (NE)
DMVLP8H	MT	DTT
DMVLP8H	MA	Inhibitor
DMVLP8H	RN	Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
DMVLP8H	RU	https://www.ncbi.nlm.nih.gov/pubmed/26118988

DMBCFJU	DI	DMBCFJU
DMBCFJU	DN	Peptide analog 56
DMBCFJU	MI	TTQAJF1
DMBCFJU	MN	Cathepsin G (CTSG)
DMBCFJU	MT	DTT
DMBCFJU	MA	Inhibitor
DMBCFJU	RN	Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
DMBCFJU	RU	https://www.ncbi.nlm.nih.gov/pubmed/26118988

DMBCFJU	DI	DMBCFJU
DMBCFJU	DN	Peptide analog 56
DMBCFJU	MI	TTPLTSQ
DMBCFJU	MN	Neutrophil elastase (NE)
DMBCFJU	MT	DTT
DMBCFJU	MA	Inhibitor
DMBCFJU	RN	Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
DMBCFJU	RU	https://www.ncbi.nlm.nih.gov/pubmed/26118988

DM6IQWE	DI	DM6IQWE
DM6IQWE	DN	Peptide analog 57
DM6IQWE	MI	TTQAJF1
DM6IQWE	MN	Cathepsin G (CTSG)
DM6IQWE	MT	DTT
DM6IQWE	MA	Inhibitor
DM6IQWE	RN	Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
DM6IQWE	RU	https://www.ncbi.nlm.nih.gov/pubmed/26118988

DM6IQWE	DI	DM6IQWE
DM6IQWE	DN	Peptide analog 57
DM6IQWE	MI	TTPLTSQ
DM6IQWE	MN	Neutrophil elastase (NE)
DM6IQWE	MT	DTT
DM6IQWE	MA	Inhibitor
DM6IQWE	RN	Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
DM6IQWE	RU	https://www.ncbi.nlm.nih.gov/pubmed/26118988

DM7X62M	DI	DM7X62M
DM7X62M	DN	Peptide analog 58
DM7X62M	MI	TTQAJF1
DM7X62M	MN	Cathepsin G (CTSG)
DM7X62M	MT	DTT
DM7X62M	MA	Inhibitor
DM7X62M	RN	Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
DM7X62M	RU	https://www.ncbi.nlm.nih.gov/pubmed/26118988

DM7X62M	DI	DM7X62M
DM7X62M	DN	Peptide analog 58
DM7X62M	MI	TTPLTSQ
DM7X62M	MN	Neutrophil elastase (NE)
DM7X62M	MT	DTT
DM7X62M	MA	Inhibitor
DM7X62M	RN	Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
DM7X62M	RU	https://www.ncbi.nlm.nih.gov/pubmed/26118988

DMZAMNX	DI	DMZAMNX
DMZAMNX	DN	Peptide analog 59
DMZAMNX	MI	TTQAJF1
DMZAMNX	MN	Cathepsin G (CTSG)
DMZAMNX	MT	DTT
DMZAMNX	MA	Inhibitor
DMZAMNX	RN	Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
DMZAMNX	RU	https://www.ncbi.nlm.nih.gov/pubmed/26118988

DMZAMNX	DI	DMZAMNX
DMZAMNX	DN	Peptide analog 59
DMZAMNX	MI	TTPLTSQ
DMZAMNX	MN	Neutrophil elastase (NE)
DMZAMNX	MT	DTT
DMZAMNX	MA	Inhibitor
DMZAMNX	RN	Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
DMZAMNX	RU	https://www.ncbi.nlm.nih.gov/pubmed/26118988

DM68M0G	DI	DM68M0G
DM68M0G	DN	Peptide analog 6
DM68M0G	MI	TT23XQV
DM68M0G	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DM68M0G	MT	DTT
DM68M0G	MA	Inhibitor
DM68M0G	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DM68M0G	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMMSTNA	DI	DMMSTNA
DMMSTNA	DN	Peptide analog 60
DMMSTNA	MI	TTQAJF1
DMMSTNA	MN	Cathepsin G (CTSG)
DMMSTNA	MT	DTT
DMMSTNA	MA	Inhibitor
DMMSTNA	RN	Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
DMMSTNA	RU	https://www.ncbi.nlm.nih.gov/pubmed/26118988

DMMSTNA	DI	DMMSTNA
DMMSTNA	DN	Peptide analog 60
DMMSTNA	MI	TTPLTSQ
DMMSTNA	MN	Neutrophil elastase (NE)
DMMSTNA	MT	DTT
DMMSTNA	MA	Inhibitor
DMMSTNA	RN	Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
DMMSTNA	RU	https://www.ncbi.nlm.nih.gov/pubmed/26118988

DM45JMT	DI	DM45JMT
DM45JMT	DN	Peptide analog 61
DM45JMT	MI	TTQAJF1
DM45JMT	MN	Cathepsin G (CTSG)
DM45JMT	MT	DTT
DM45JMT	MA	Inhibitor
DM45JMT	RN	Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
DM45JMT	RU	https://www.ncbi.nlm.nih.gov/pubmed/26118988

DM45JMT	DI	DM45JMT
DM45JMT	DN	Peptide analog 61
DM45JMT	MI	TTPLTSQ
DM45JMT	MN	Neutrophil elastase (NE)
DM45JMT	MT	DTT
DM45JMT	MA	Inhibitor
DM45JMT	RN	Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
DM45JMT	RU	https://www.ncbi.nlm.nih.gov/pubmed/26118988

DM28NK0	DI	DM28NK0
DM28NK0	DN	Peptide analog 62
DM28NK0	MI	TTQAJF1
DM28NK0	MN	Cathepsin G (CTSG)
DM28NK0	MT	DTT
DM28NK0	MA	Inhibitor
DM28NK0	RN	Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
DM28NK0	RU	https://www.ncbi.nlm.nih.gov/pubmed/26118988

DM28NK0	DI	DM28NK0
DM28NK0	DN	Peptide analog 62
DM28NK0	MI	TTPLTSQ
DM28NK0	MN	Neutrophil elastase (NE)
DM28NK0	MT	DTT
DM28NK0	MA	Inhibitor
DM28NK0	RN	Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
DM28NK0	RU	https://www.ncbi.nlm.nih.gov/pubmed/26118988

DMGC7NW	DI	DMGC7NW
DMGC7NW	DN	Peptide analog 63
DMGC7NW	MI	TTPLTSQ
DMGC7NW	MN	Neutrophil elastase (NE)
DMGC7NW	MT	DTT
DMGC7NW	MA	Inhibitor
DMGC7NW	RN	Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
DMGC7NW	RU	https://www.ncbi.nlm.nih.gov/pubmed/26118988

DM1G2J5	DI	DM1G2J5
DM1G2J5	DN	Peptide analog 64
DM1G2J5	MI	TTPLTSQ
DM1G2J5	MN	Neutrophil elastase (NE)
DM1G2J5	MT	DTT
DM1G2J5	MA	Inhibitor
DM1G2J5	RN	Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
DM1G2J5	RU	https://www.ncbi.nlm.nih.gov/pubmed/26118988

DMAJLM1	DI	DMAJLM1
DMAJLM1	DN	Peptide analog 65
DMAJLM1	MI	TTPLTSQ
DMAJLM1	MN	Neutrophil elastase (NE)
DMAJLM1	MT	DTT
DMAJLM1	MA	Inhibitor
DMAJLM1	RN	Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
DMAJLM1	RU	https://www.ncbi.nlm.nih.gov/pubmed/26118988

DMW502M	DI	DMW502M
DMW502M	DN	Peptide analog 66
DMW502M	MI	TTPLTSQ
DMW502M	MN	Neutrophil elastase (NE)
DMW502M	MT	DTT
DMW502M	MA	Inhibitor
DMW502M	RN	Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
DMW502M	RU	https://www.ncbi.nlm.nih.gov/pubmed/26118988

DMJ8QTX	DI	DMJ8QTX
DMJ8QTX	DN	Peptide analog 67
DMJ8QTX	MI	TTPLTSQ
DMJ8QTX	MN	Neutrophil elastase (NE)
DMJ8QTX	MT	DTT
DMJ8QTX	MA	Inhibitor
DMJ8QTX	RN	Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
DMJ8QTX	RU	https://www.ncbi.nlm.nih.gov/pubmed/26118988

DMFG2KT	DI	DMFG2KT
DMFG2KT	DN	Peptide analog 68
DMFG2KT	MI	TTPLTSQ
DMFG2KT	MN	Neutrophil elastase (NE)
DMFG2KT	MT	DTT
DMFG2KT	MA	Inhibitor
DMFG2KT	RN	Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
DMFG2KT	RU	https://www.ncbi.nlm.nih.gov/pubmed/26118988

DM2OXW3	DI	DM2OXW3
DM2OXW3	DN	Peptide analog 69
DM2OXW3	MI	TTPLTSQ
DM2OXW3	MN	Neutrophil elastase (NE)
DM2OXW3	MT	DTT
DM2OXW3	MA	Inhibitor
DM2OXW3	RN	Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
DM2OXW3	RU	https://www.ncbi.nlm.nih.gov/pubmed/26118988

DMKYOLV	DI	DMKYOLV
DMKYOLV	DN	Peptide analog 7
DMKYOLV	MI	TTH8FZW
DMKYOLV	MN	Signal transducer and activator of transcription 3 (STAT3)
DMKYOLV	MT	DTT
DMKYOLV	MA	Inhibitor
DMKYOLV	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMKYOLV	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMN43Q5	DI	DMN43Q5
DMN43Q5	DN	Peptide analog 70
DMN43Q5	MI	TTQAJF1
DMN43Q5	MN	Cathepsin G (CTSG)
DMN43Q5	MT	DTT
DMN43Q5	MA	Inhibitor
DMN43Q5	RN	Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
DMN43Q5	RU	https://www.ncbi.nlm.nih.gov/pubmed/26118988

DMN43Q5	DI	DMN43Q5
DMN43Q5	DN	Peptide analog 70
DMN43Q5	MI	TTPLTSQ
DMN43Q5	MN	Neutrophil elastase (NE)
DMN43Q5	MT	DTT
DMN43Q5	MA	Inhibitor
DMN43Q5	RN	Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
DMN43Q5	RU	https://www.ncbi.nlm.nih.gov/pubmed/26118988

DMSEKZG	DI	DMSEKZG
DMSEKZG	DN	Peptide analog 71
DMSEKZG	MI	TTQR74A
DMSEKZG	MN	Proteinase activated receptor 2 (PAR2)
DMSEKZG	MT	DTT
DMSEKZG	MA	Agonist
DMSEKZG	RN	Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
DMSEKZG	RU	https://www.ncbi.nlm.nih.gov/pubmed/26936077

DMXU71M	DI	DMXU71M
DMXU71M	DN	Peptide analog 72
DMXU71M	MI	TTQR74A
DMXU71M	MN	Proteinase activated receptor 2 (PAR2)
DMXU71M	MT	DTT
DMXU71M	MA	Agonist
DMXU71M	RN	Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
DMXU71M	RU	https://www.ncbi.nlm.nih.gov/pubmed/26936077

DMFG7A8	DI	DMFG7A8
DMFG7A8	DN	Peptide analog 8
DMFG7A8	MI	TTN7R6K
DMFG7A8	MN	Signal transducer and activator of transcription 1 (STAT1)
DMFG7A8	MT	DTT
DMFG7A8	MA	Inhibitor
DMFG7A8	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMFG7A8	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DM953EV	DI	DM953EV
DM953EV	DN	Peptide analog 9
DM953EV	MI	TTSJMN8
DM953EV	MN	Immunoproteasome complex (IP)
DM953EV	MT	DTT
DM953EV	MA	Inhibitor
DM953EV	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DM953EV	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMMP9N7	DI	DMMP9N7
DMMP9N7	DN	Peptidomimetic analog 1
DMMP9N7	MI	TTH8FZW
DMMP9N7	MN	Signal transducer and activator of transcription 3 (STAT3)
DMMP9N7	MT	DTT
DMMP9N7	MA	Inhibitor
DMMP9N7	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMMP9N7	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMN2VZW	DI	DMN2VZW
DMN2VZW	DN	Peptidomimetic analog 2
DMN2VZW	MI	TTH8FZW
DMN2VZW	MN	Signal transducer and activator of transcription 3 (STAT3)
DMN2VZW	MT	DTT
DMN2VZW	MA	Inhibitor
DMN2VZW	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMN2VZW	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMPWS9N	DI	DMPWS9N
DMPWS9N	DN	Peptidomimetic analog 3
DMPWS9N	MI	TTH8FZW
DMPWS9N	MN	Signal transducer and activator of transcription 3 (STAT3)
DMPWS9N	MT	DTT
DMPWS9N	MA	Inhibitor
DMPWS9N	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMPWS9N	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DM9Q0JS	DI	DM9Q0JS
DM9Q0JS	DN	Peptidomimetic analog 4
DM9Q0JS	MI	TTH8FZW
DM9Q0JS	MN	Signal transducer and activator of transcription 3 (STAT3)
DM9Q0JS	MT	DTT
DM9Q0JS	MA	Inhibitor
DM9Q0JS	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DM9Q0JS	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMF0DE2	DI	DMF0DE2
DMF0DE2	DN	Peptidomimetic analog 5
DMF0DE2	MI	TTN7R6K
DMF0DE2	MN	Signal transducer and activator of transcription 1 (STAT1)
DMF0DE2	MT	DTT
DMF0DE2	MA	Inhibitor
DMF0DE2	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMF0DE2	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMF0DE2	DI	DMF0DE2
DMF0DE2	DN	Peptidomimetic analog 5
DMF0DE2	MI	TTH8FZW
DMF0DE2	MN	Signal transducer and activator of transcription 3 (STAT3)
DMF0DE2	MT	DTT
DMF0DE2	MA	Inhibitor
DMF0DE2	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMF0DE2	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMSUD5X	DI	DMSUD5X
DMSUD5X	DN	Peptidomimetic analog 6
DMSUD5X	MI	TTQR74A
DMSUD5X	MN	Proteinase activated receptor 2 (PAR2)
DMSUD5X	MT	DTT
DMSUD5X	MA	Agonist
DMSUD5X	RN	Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
DMSUD5X	RU	https://www.ncbi.nlm.nih.gov/pubmed/26936077

DM15TMH	DI	DM15TMH
DM15TMH	DN	Peptidomimetic analog 7
DM15TMH	MI	TTUX68I
DM15TMH	MN	Hypoxia-inducible factor 1 (HIF-1)
DM15TMH	MT	DTT
DM15TMH	MA	Inhibitor
DM15TMH	RN	Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22.
DM15TMH	RU	https://www.ncbi.nlm.nih.gov/pubmed/26882240

DM0PBJT	DI	DM0PBJT
DM0PBJT	DN	Phenoxypiperidine derivative 1
DM0PBJT	MI	TT9JNIC
DM0PBJT	MN	Histamine H3 receptor (H3R)
DM0PBJT	MT	DTT
DM0PBJT	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DM0PBJT	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DMC5G8P	DI	DMC5G8P
DMC5G8P	DN	Phenoxypiperidine derivative 2
DMC5G8P	MI	TT9JNIC
DMC5G8P	MN	Histamine H3 receptor (H3R)
DMC5G8P	MT	DTT
DMC5G8P	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DMC5G8P	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DMVYP8K	DI	DMVYP8K
DMVYP8K	DN	Phenylalanine derivative 1
DMVYP8K	MI	TT36ETB
DMVYP8K	MN	Cathepsin L (CTSL)
DMVYP8K	MT	DTT
DMVYP8K	MA	Inhibitor
DMVYP8K	RN	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
DMVYP8K	RU	https://www.ncbi.nlm.nih.gov/pubmed/27998201

DMVYP8K	DI	DMVYP8K
DMVYP8K	DN	Phenylalanine derivative 1
DMVYP8K	MI	TTUMQVO
DMVYP8K	MN	Cathepsin S (CTSS)
DMVYP8K	MT	DTT
DMVYP8K	MA	Inhibitor
DMVYP8K	RN	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
DMVYP8K	RU	https://www.ncbi.nlm.nih.gov/pubmed/27998201

DMEO9QB	DI	DMEO9QB
DMEO9QB	DN	Phenylate derivative 1
DMEO9QB	MI	TT23XQV
DMEO9QB	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMEO9QB	MT	DTT
DMEO9QB	MA	Inhibitor
DMEO9QB	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMEO9QB	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMG0ZSY	DI	DMG0ZSY
DMG0ZSY	DN	Phenylate derivative 2
DMG0ZSY	MI	TT23XQV
DMG0ZSY	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMG0ZSY	MT	DTT
DMG0ZSY	MA	Inhibitor
DMG0ZSY	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMG0ZSY	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DM1BIY4	DI	DM1BIY4
DM1BIY4	DN	Phenylmethanesulfonamide derivative 1
DM1BIY4	MI	TTJOW1I
DM1BIY4	MN	Mannoside acetylglucosaminyltransferase 2 (MGAT2)
DM1BIY4	MT	DTT
DM1BIY4	MA	Inhibitor
DM1BIY4	RN	Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
DM1BIY4	RU	https://www.ncbi.nlm.nih.gov/pubmed/25470667

DMTEJRB	DI	DMTEJRB
DMTEJRB	DN	Phenylpropionic acid derivative 1
DMTEJRB	MI	TTZMAO3
DMTEJRB	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMTEJRB	MT	DTT
DMTEJRB	MA	Agonist
DMTEJRB	RN	PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
DMTEJRB	RU	https://www.ncbi.nlm.nih.gov/pubmed/25416646

DMVCKZT	DI	DMVCKZT
DMVCKZT	DN	Phenylpropylamine derivative 1
DMVCKZT	MI	TT5TPI6
DMVCKZT	MN	Opioid receptor sigma 1 (OPRS1)
DMVCKZT	MT	DTT
DMVCKZT	MA	Ligand
DMVCKZT	RN	Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578.
DMVCKZT	RU	https://www.ncbi.nlm.nih.gov/pubmed/28051882

DMTDIA6	DI	DMTDIA6
DMTDIA6	DN	Phenylpropylamine derivative 2
DMTDIA6	MI	TT5TPI6
DMTDIA6	MN	Opioid receptor sigma 1 (OPRS1)
DMTDIA6	MT	DTT
DMTDIA6	MA	Ligand
DMTDIA6	RN	Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578.
DMTDIA6	RU	https://www.ncbi.nlm.nih.gov/pubmed/28051882

DMH3FUR	DI	DMH3FUR
DMH3FUR	DN	Phenylpropylamine derivative 3
DMH3FUR	MI	TT5TPI6
DMH3FUR	MN	Opioid receptor sigma 1 (OPRS1)
DMH3FUR	MT	DTT
DMH3FUR	MA	Ligand
DMH3FUR	RN	Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578.
DMH3FUR	RU	https://www.ncbi.nlm.nih.gov/pubmed/28051882

DM0R653	DI	DM0R653
DM0R653	DN	Phenylpropylamine derivative 4
DM0R653	MI	TT5TPI6
DM0R653	MN	Opioid receptor sigma 1 (OPRS1)
DM0R653	MT	DTT
DM0R653	MA	Ligand
DM0R653	RN	Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578.
DM0R653	RU	https://www.ncbi.nlm.nih.gov/pubmed/28051882

DMU0S2W	DI	DMU0S2W
DMU0S2W	DN	Phenylpropylamine derivative 5
DMU0S2W	MI	TT5TPI6
DMU0S2W	MN	Opioid receptor sigma 1 (OPRS1)
DMU0S2W	MT	DTT
DMU0S2W	MA	Ligand
DMU0S2W	RN	Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578.
DMU0S2W	RU	https://www.ncbi.nlm.nih.gov/pubmed/28051882

DMLSWKR	DI	DMLSWKR
DMLSWKR	DN	Phenylpurine acetamide analog 1
DMLSWKR	MI	TTPTXIN
DMLSWKR	MN	Translocator protein (TSPO)
DMLSWKR	MT	DTT
DMLSWKR	MA	Ligand
DMLSWKR	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMLSWKR	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMMGBLC	DI	DMMGBLC
DMMGBLC	DN	Phenylpurine acetamide analog 2
DMMGBLC	MI	TTPTXIN
DMMGBLC	MN	Translocator protein (TSPO)
DMMGBLC	MT	DTT
DMMGBLC	MA	Ligand
DMMGBLC	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMMGBLC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMVHLQM	DI	DMVHLQM
DMVHLQM	DN	Phenylpyridine derivative 1
DMVHLQM	MI	TT1LVF2
DMVHLQM	MN	Cyclin-dependent kinase 9 (CDK9)
DMVHLQM	MT	DTT
DMVHLQM	MA	Inhibitor
DMVHLQM	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMVHLQM	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMTRPE6	DI	DMTRPE6
DMTRPE6	DN	Phenylpyridine derivative 2
DMTRPE6	MI	TT1LVF2
DMTRPE6	MN	Cyclin-dependent kinase 9 (CDK9)
DMTRPE6	MT	DTT
DMTRPE6	MA	Inhibitor
DMTRPE6	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMTRPE6	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMDT5JI	DI	DMDT5JI
DMDT5JI	DN	Phenylpyridine derivative 3
DMDT5JI	MI	TTQVOEI
DMDT5JI	MN	Angiotensin II receptor type-2 (AGTR2)
DMDT5JI	MT	DTT
DMDT5JI	MA	Agonist
DMDT5JI	RN	PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
DMDT5JI	RU	https://www.ncbi.nlm.nih.gov/pubmed/25416646

DMDT5JI	DI	DMDT5JI
DMDT5JI	DN	Phenylpyridine derivative 3
DMDT5JI	MI	TTZMAO3
DMDT5JI	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMDT5JI	MT	DTT
DMDT5JI	MA	Agonist
DMDT5JI	RN	PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
DMDT5JI	RU	https://www.ncbi.nlm.nih.gov/pubmed/25416646

DMPAI5C	DI	DMPAI5C
DMPAI5C	DN	Phenylpyrrolidinone derivative 1
DMPAI5C	MI	TT5OU0D
DMPAI5C	MN	PRKR-like endoplasmic reticulum kinase (PERK)
DMPAI5C	MT	DTT
DMPAI5C	MA	Inhibitor
DMPAI5C	RN	Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48.
DMPAI5C	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646439

DMF3NCO	DI	DMF3NCO
DMF3NCO	DN	Phenylpyrrolidinone derivative 2
DMF3NCO	MI	TT5OU0D
DMF3NCO	MN	PRKR-like endoplasmic reticulum kinase (PERK)
DMF3NCO	MT	DTT
DMF3NCO	MA	Inhibitor
DMF3NCO	RN	Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48.
DMF3NCO	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646439

DMPZKQN	DI	DMPZKQN
DMPZKQN	DN	Phenylpyrrolidinone derivative 3
DMPZKQN	MI	TT5OU0D
DMPZKQN	MN	PRKR-like endoplasmic reticulum kinase (PERK)
DMPZKQN	MT	DTT
DMPZKQN	MA	Inhibitor
DMPZKQN	RN	Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48.
DMPZKQN	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646439

DMSX47Q	DI	DMSX47Q
DMSX47Q	DN	Phenylpyrrolidinone derivative 4
DMSX47Q	MI	TT5OU0D
DMSX47Q	MN	PRKR-like endoplasmic reticulum kinase (PERK)
DMSX47Q	MT	DTT
DMSX47Q	MA	Inhibitor
DMSX47Q	RN	Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48.
DMSX47Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646439

DMZSTLH	DI	DMZSTLH
DMZSTLH	DN	Phenylpyrrolidinone derivative 5
DMZSTLH	MI	TT5OU0D
DMZSTLH	MN	PRKR-like endoplasmic reticulum kinase (PERK)
DMZSTLH	MT	DTT
DMZSTLH	MA	Inhibitor
DMZSTLH	RN	Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48.
DMZSTLH	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646439

DM9NOP3	DI	DM9NOP3
DM9NOP3	DN	Phenylsulfonyl derivative 1
DM9NOP3	MI	TT9JNIC
DM9NOP3	MN	Histamine H3 receptor (H3R)
DM9NOP3	MT	DTT
DM9NOP3	MA	Inhibitor
DM9NOP3	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DM9NOP3	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DM63128	DI	DM63128
DM63128	DN	Phenylsulfonyl derivative 2
DM63128	MI	TT9JNIC
DM63128	MN	Histamine H3 receptor (H3R)
DM63128	MT	DTT
DM63128	MA	Inhibitor
DM63128	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DM63128	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DME6FLN	DI	DME6FLN
DME6FLN	DN	Phenylsulfonyl derivative 3
DME6FLN	MI	TT9JNIC
DME6FLN	MN	Histamine H3 receptor (H3R)
DME6FLN	MT	DTT
DME6FLN	MA	Inhibitor
DME6FLN	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DME6FLN	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DM1HYW4	DI	DM1HYW4
DM1HYW4	DN	Phenylsulfonyl derivative 4
DM1HYW4	MI	TT9JNIC
DM1HYW4	MN	Histamine H3 receptor (H3R)
DM1HYW4	MT	DTT
DM1HYW4	MA	Inhibitor
DM1HYW4	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DM1HYW4	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DMTHXUC	DI	DMTHXUC
DMTHXUC	DN	Phenylthioacetate derivative 1
DMTHXUC	MI	TTA592U
DMTHXUC	MN	Urate anion exchanger 1 (URAT1)
DMTHXUC	MT	DTT
DMTHXUC	MA	Inhibitor
DMTHXUC	RN	Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10.
DMTHXUC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27414413

DMZPHN5	DI	DMZPHN5
DMZPHN5	DN	Phthalazine derivative 1
DMZPHN5	MI	TTEBCY8
DMZPHN5	MN	Poly [ADP-ribose] polymerase (PARP)
DMZPHN5	MT	DTT
DMZPHN5	MA	Inhibitor
DMZPHN5	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DMZPHN5	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DMODTSC	DI	DMODTSC
DMODTSC	DN	Phthalazine derivative 2
DMODTSC	MI	TTEBCY8
DMODTSC	MN	Poly [ADP-ribose] polymerase (PARP)
DMODTSC	MT	DTT
DMODTSC	MA	Inhibitor
DMODTSC	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DMODTSC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DMA1OEF	DI	DMA1OEF
DMA1OEF	DN	Phthalazine derivative 3
DMA1OEF	MI	TTVDSZ0
DMA1OEF	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMA1OEF	MT	DTT
DMA1OEF	MA	Inhibitor
DMA1OEF	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DMA1OEF	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DMD2R1H	DI	DMD2R1H
DMD2R1H	DN	Phthalazine ketone derivative 1
DMD2R1H	MI	TTVDSZ0
DMD2R1H	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMD2R1H	MT	DTT
DMD2R1H	MA	Inhibitor
DMD2R1H	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DMD2R1H	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DM07C1I	DI	DM07C1I
DM07C1I	DN	Phthalazine ketone derivative 2
DM07C1I	MI	TTVDSZ0
DM07C1I	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DM07C1I	MT	DTT
DM07C1I	MA	Inhibitor
DM07C1I	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DM07C1I	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DMIWY93	DI	DMIWY93
DMIWY93	DN	Phthalazine ketone derivative 3
DMIWY93	MI	TTVDSZ0
DMIWY93	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMIWY93	MT	DTT
DMIWY93	MA	Inhibitor
DMIWY93	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DMIWY93	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DMNA941	DI	DMNA941
DMNA941	DN	Phthalazinone derivative 1
DMNA941	MI	TTYLQ8V
DMNA941	MN	Prostaglandin E synthase (PTGES)
DMNA941	MT	DTT
DMNA941	MA	Inhibitor
DMNA941	RN	Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059.
DMNA941	RU	https://www.ncbi.nlm.nih.gov/pubmed/28627961

DM5H3R8	DI	DM5H3R8
DM5H3R8	DN	PhyllanthoidA
DM5H3R8	MI	TT3WG5C
DM5H3R8	MN	Monoamine oxidase type A (MAO-A)
DM5H3R8	MT	DTT
DM5H3R8	MA	Inhibitor
DM5H3R8	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DM5H3R8	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMM9F8D	DI	DMM9F8D
DMM9F8D	DN	Phytocannabinoid/aminoalkylindole derivative 1
DMM9F8D	MI	TT6OEDT
DMM9F8D	MN	Cannabinoid receptor 1 (CB1)
DMM9F8D	MT	DTT
DMM9F8D	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DMM9F8D	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DMM9F8D	DI	DMM9F8D
DMM9F8D	DN	Phytocannabinoid/aminoalkylindole derivative 1
DMM9F8D	MI	TTMSFAW
DMM9F8D	MN	Cannabinoid receptor 2 (CB2)
DMM9F8D	MT	DTT
DMM9F8D	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DMM9F8D	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DMOXJ7Q	DI	DMOXJ7Q
DMOXJ7Q	DN	Phytocannabinoid/aminoalkylindole derivative 2
DMOXJ7Q	MI	TT6OEDT
DMOXJ7Q	MN	Cannabinoid receptor 1 (CB1)
DMOXJ7Q	MT	DTT
DMOXJ7Q	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DMOXJ7Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DMOXJ7Q	DI	DMOXJ7Q
DMOXJ7Q	DN	Phytocannabinoid/aminoalkylindole derivative 2
DMOXJ7Q	MI	TTMSFAW
DMOXJ7Q	MN	Cannabinoid receptor 2 (CB2)
DMOXJ7Q	MT	DTT
DMOXJ7Q	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DMOXJ7Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DMUP4DX	DI	DMUP4DX
DMUP4DX	DN	Picolinamido propanoic acid derivative 1
DMUP4DX	MI	TT9O6WS
DMUP4DX	MN	Glucagon receptor (GCGR)
DMUP4DX	MT	DTT
DMUP4DX	MA	Antagonist
DMUP4DX	RN	Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30.
DMUP4DX	RU	https://www.ncbi.nlm.nih.gov/pubmed/25828189

DMR74ET	DI	DMR74ET
DMR74ET	DN	Picolinamido propanoic acid derivative 2
DMR74ET	MI	TT9O6WS
DMR74ET	MN	Glucagon receptor (GCGR)
DMR74ET	MT	DTT
DMR74ET	MA	Antagonist
DMR74ET	RN	Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30.
DMR74ET	RU	https://www.ncbi.nlm.nih.gov/pubmed/25828189

DMP1RV5	DI	DMP1RV5
DMP1RV5	DN	Picolinamido propanoic acid derivative 3
DMP1RV5	MI	TT9O6WS
DMP1RV5	MN	Glucagon receptor (GCGR)
DMP1RV5	MT	DTT
DMP1RV5	MA	Antagonist
DMP1RV5	RN	Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30.
DMP1RV5	RU	https://www.ncbi.nlm.nih.gov/pubmed/25828189

DMCIXD4	DI	DMCIXD4
DMCIXD4	DN	Piperazine carbamate/urea derivative 1
DMCIXD4	MI	TT9JNIC
DMCIXD4	MN	Histamine H3 receptor (H3R)
DMCIXD4	MT	DTT
DMCIXD4	MA	Ligand
DMCIXD4	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DMCIXD4	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DMCG6BE	DI	DMCG6BE
DMCG6BE	DN	Piperazine carbamate/urea derivative 2
DMCG6BE	MI	TT9JNIC
DMCG6BE	MN	Histamine H3 receptor (H3R)
DMCG6BE	MT	DTT
DMCG6BE	MA	Ligand
DMCG6BE	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DMCG6BE	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DM2R468	DI	DM2R468
DM2R468	DN	Piperazine carbamate/urea derivative 3
DM2R468	MI	TT9JNIC
DM2R468	MN	Histamine H3 receptor (H3R)
DM2R468	MT	DTT
DM2R468	MA	Ligand
DM2R468	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DM2R468	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DM75J4T	DI	DM75J4T
DM75J4T	DN	Piperazine carbamate/urea derivative 4
DM75J4T	MI	TT9JNIC
DM75J4T	MN	Histamine H3 receptor (H3R)
DM75J4T	MT	DTT
DM75J4T	MA	Ligand
DM75J4T	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DM75J4T	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DMJ80IZ	DI	DMJ80IZ
DMJ80IZ	DN	Piperazine carbamate/urea derivative 5
DMJ80IZ	MI	TT9JNIC
DMJ80IZ	MN	Histamine H3 receptor (H3R)
DMJ80IZ	MT	DTT
DMJ80IZ	MA	Ligand
DMJ80IZ	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DMJ80IZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DMZEPU3	DI	DMZEPU3
DMZEPU3	DN	Piperazine carbamate/urea derivative 6
DMZEPU3	MI	TT9JNIC
DMZEPU3	MN	Histamine H3 receptor (H3R)
DMZEPU3	MT	DTT
DMZEPU3	MA	Ligand
DMZEPU3	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DMZEPU3	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DM067UC	DI	DM067UC
DM067UC	DN	Piperazine carbamate/urea derivative 7
DM067UC	MI	TT9JNIC
DM067UC	MN	Histamine H3 receptor (H3R)
DM067UC	MT	DTT
DM067UC	MA	Ligand
DM067UC	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DM067UC	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DMZSYU4	DI	DMZSYU4
DMZSYU4	DN	Piperazine carbamic compound 1
DMZSYU4	MI	TTDP1UC
DMZSYU4	MN	Fatty acid amide hydrolase (FAAH)
DMZSYU4	MT	DTT
DMZSYU4	MA	Inhibitor
DMZSYU4	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMZSYU4	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMZSYU4	DI	DMZSYU4
DMZSYU4	DN	Piperazine carbamic compound 1
DMZSYU4	MI	TTSINOV
DMZSYU4	MN	Monoacylglycerol lipase ABHD6 (ABHD6)
DMZSYU4	MT	DTT
DMZSYU4	MA	Inhibitor
DMZSYU4	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMZSYU4	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMZSYU4	DI	DMZSYU4
DMZSYU4	DN	Piperazine carbamic compound 1
DMZSYU4	MI	TTZ963I
DMZSYU4	MN	Monoglyceride lipase (MAGL)
DMZSYU4	MT	DTT
DMZSYU4	MA	Inhibitor
DMZSYU4	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMZSYU4	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMMQ0ZO	DI	DMMQ0ZO
DMMQ0ZO	DN	Piperazine carbamic compound 2
DMMQ0ZO	MI	TTDP1UC
DMMQ0ZO	MN	Fatty acid amide hydrolase (FAAH)
DMMQ0ZO	MT	DTT
DMMQ0ZO	MA	Inhibitor
DMMQ0ZO	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMMQ0ZO	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMMQ0ZO	DI	DMMQ0ZO
DMMQ0ZO	DN	Piperazine carbamic compound 2
DMMQ0ZO	MI	TTSINOV
DMMQ0ZO	MN	Monoacylglycerol lipase ABHD6 (ABHD6)
DMMQ0ZO	MT	DTT
DMMQ0ZO	MA	Inhibitor
DMMQ0ZO	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMMQ0ZO	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMMQ0ZO	DI	DMMQ0ZO
DMMQ0ZO	DN	Piperazine carbamic compound 2
DMMQ0ZO	MI	TTZ963I
DMMQ0ZO	MN	Monoglyceride lipase (MAGL)
DMMQ0ZO	MT	DTT
DMMQ0ZO	MA	Inhibitor
DMMQ0ZO	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMMQ0ZO	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DM8IU1G	DI	DM8IU1G
DM8IU1G	DN	Piperazine carbamic compound 3
DM8IU1G	MI	TTZ963I
DM8IU1G	MN	Monoglyceride lipase (MAGL)
DM8IU1G	MT	DTT
DM8IU1G	MA	Inhibitor
DM8IU1G	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DM8IU1G	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMKZUO4	DI	DMKZUO4
DMKZUO4	DN	Piperazine carbamic compound 4
DMKZUO4	MI	TTSINOV
DMKZUO4	MN	Monoacylglycerol lipase ABHD6 (ABHD6)
DMKZUO4	MT	DTT
DMKZUO4	MA	Inhibitor
DMKZUO4	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMKZUO4	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMKZUO4	DI	DMKZUO4
DMKZUO4	DN	Piperazine carbamic compound 4
DMKZUO4	MI	TTZ963I
DMKZUO4	MN	Monoglyceride lipase (MAGL)
DMKZUO4	MT	DTT
DMKZUO4	MA	Inhibitor
DMKZUO4	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMKZUO4	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMXH65Z	DI	DMXH65Z
DMXH65Z	DN	Piperazine carbamic compound 5
DMXH65Z	MI	TTSINOV
DMXH65Z	MN	Monoacylglycerol lipase ABHD6 (ABHD6)
DMXH65Z	MT	DTT
DMXH65Z	MA	Inhibitor
DMXH65Z	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMXH65Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMXH65Z	DI	DMXH65Z
DMXH65Z	DN	Piperazine carbamic compound 5
DMXH65Z	MI	TTZ963I
DMXH65Z	MN	Monoglyceride lipase (MAGL)
DMXH65Z	MT	DTT
DMXH65Z	MA	Inhibitor
DMXH65Z	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMXH65Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMJ7F1Q	DI	DMJ7F1Q
DMJ7F1Q	DN	Piperazine derivative 1
DMJ7F1Q	MI	TT6OEDT
DMJ7F1Q	MN	Cannabinoid receptor 1 (CB1)
DMJ7F1Q	MT	DTT
DMJ7F1Q	MA	Antagonist
DMJ7F1Q	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMJ7F1Q	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DM4JZ2T	DI	DM4JZ2T
DM4JZ2T	DN	Piperazine derivative 2
DM4JZ2T	MI	TT6OEDT
DM4JZ2T	MN	Cannabinoid receptor 1 (CB1)
DM4JZ2T	MT	DTT
DM4JZ2T	MA	Antagonist
DM4JZ2T	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DM4JZ2T	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DM8MZR6	DI	DM8MZR6
DM8MZR6	DN	Piperazine derivative 3
DM8MZR6	MI	TTJQOD7
DM8MZR6	MN	5-HT 2A receptor (HTR2A)
DM8MZR6	MT	DTT
DM8MZR6	MA	Antagonist
DM8MZR6	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DM8MZR6	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DM2XGNY	DI	DM2XGNY
DM2XGNY	DN	Piperazine derivative 4
DM2XGNY	MI	TTJQOD7
DM2XGNY	MN	5-HT 2A receptor (HTR2A)
DM2XGNY	MT	DTT
DM2XGNY	MA	Antagonist
DM2XGNY	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DM2XGNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMDFUBH	DI	DMDFUBH
DMDFUBH	DN	Piperazine derivative 5
DMDFUBH	MI	TTQR74A
DMDFUBH	MN	Proteinase activated receptor 2 (PAR2)
DMDFUBH	MT	DTT
DMDFUBH	MA	Antagonist
DMDFUBH	RN	Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
DMDFUBH	RU	https://www.ncbi.nlm.nih.gov/pubmed/26936077

DMDL3A5	DI	DMDL3A5
DMDL3A5	DN	Piperazine derivative 6
DMDL3A5	MI	TT473XN
DMDL3A5	MN	P2X purinoceptor 7 (P2RX7)
DMDL3A5	MT	DTT
DMDL3A5	MA	Antagonist
DMDL3A5	RN	P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267.
DMDL3A5	RU	https://www.ncbi.nlm.nih.gov/pubmed/27724045

DM9Y4ZV	DI	DM9Y4ZV
DM9Y4ZV	DN	Piperazine derivative 7
DM9Y4ZV	MI	TT5TPI6
DM9Y4ZV	MN	Opioid receptor sigma 1 (OPRS1)
DM9Y4ZV	MT	DTT
DM9Y4ZV	MA	Ligand
DM9Y4ZV	RN	Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578.
DM9Y4ZV	RU	https://www.ncbi.nlm.nih.gov/pubmed/28051882

DM9Y4ZV	DI	DM9Y4ZV
DM9Y4ZV	DN	Piperazine derivative 7
DM9Y4ZV	MI	TT9NXW4
DM9Y4ZV	MN	Sigma intracellular receptor 2 (TMEM97)
DM9Y4ZV	MT	DTT
DM9Y4ZV	MA	Ligand
DM9Y4ZV	RN	Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578.
DM9Y4ZV	RU	https://www.ncbi.nlm.nih.gov/pubmed/28051882

DM1XUVB	DI	DM1XUVB
DM1XUVB	DN	Piperazine derivative 8
DM1XUVB	MI	TTSCIM2
DM1XUVB	MN	Extracellular lysophospholipase D (E-NPP2)
DM1XUVB	MT	DTT
DM1XUVB	RN	Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829.
DM1XUVB	RU	https://www.ncbi.nlm.nih.gov/pubmed/28447479

DMEWAQ9	DI	DMEWAQ9
DMEWAQ9	DN	Piperazine urea derivative 1
DMEWAQ9	MI	TTDP1UC
DMEWAQ9	MN	Fatty acid amide hydrolase (FAAH)
DMEWAQ9	MT	DTT
DMEWAQ9	MA	Inhibitor
DMEWAQ9	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMEWAQ9	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DM5OCM7	DI	DM5OCM7
DM5OCM7	DN	Piperazine urea derivative 2
DM5OCM7	MI	TTGX13H
DM5OCM7	MN	Fatty-acid amide hydrolase 1 (FAAH1)
DM5OCM7	MT	DTT
DM5OCM7	MA	Inhibitor
DM5OCM7	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DM5OCM7	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMNAJWQ	DI	DMNAJWQ
DMNAJWQ	DN	Piperazine urea derivative 3
DMNAJWQ	MI	TTQR74A
DMNAJWQ	MN	Proteinase activated receptor 2 (PAR2)
DMNAJWQ	MT	DTT
DMNAJWQ	MA	Antagonist
DMNAJWQ	RN	Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
DMNAJWQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26936077

DM3K7IM	DI	DM3K7IM
DM3K7IM	DN	Piperazine urea derivative 4
DM3K7IM	MI	TTQR74A
DM3K7IM	MN	Proteinase activated receptor 2 (PAR2)
DM3K7IM	MT	DTT
DM3K7IM	MA	Antagonist
DM3K7IM	RN	Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
DM3K7IM	RU	https://www.ncbi.nlm.nih.gov/pubmed/26936077

DM7WOD9	DI	DM7WOD9
DM7WOD9	DN	Piperazinyl methyl quinazolinone derivative 1
DM7WOD9	MI	TT9NXW4
DM7WOD9	MN	Sigma intracellular receptor 2 (TMEM97)
DM7WOD9	MT	DTT
DM7WOD9	MA	Ligand
DM7WOD9	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DM7WOD9	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DM913KS	DI	DM913KS
DM913KS	DN	Piperazinyl methyl quinazolinone derivative 2
DM913KS	MI	TT9NXW4
DM913KS	MN	Sigma intracellular receptor 2 (TMEM97)
DM913KS	MT	DTT
DM913KS	MA	Ligand
DM913KS	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DM913KS	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DMYH4AZ	DI	DMYH4AZ
DMYH4AZ	DN	Piperazinyl methyl quinazolinone derivative 3
DMYH4AZ	MI	TT9NXW4
DMYH4AZ	MN	Sigma intracellular receptor 2 (TMEM97)
DMYH4AZ	MT	DTT
DMYH4AZ	MA	Ligand
DMYH4AZ	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DMYH4AZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DM3LKTE	DI	DM3LKTE
DM3LKTE	DN	Piperazinyl norbenzomorphane compound 1
DM3LKTE	MI	TT9NXW4
DM3LKTE	MN	Sigma intracellular receptor 2 (TMEM97)
DM3LKTE	MT	DTT
DM3LKTE	MA	Ligand
DM3LKTE	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DM3LKTE	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DMD2CX1	DI	DMD2CX1
DMD2CX1	DN	Piperazinyl norbenzomorphane compound 2
DMD2CX1	MI	TT9NXW4
DMD2CX1	MN	Sigma intracellular receptor 2 (TMEM97)
DMD2CX1	MT	DTT
DMD2CX1	MA	Ligand
DMD2CX1	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DMD2CX1	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DMZYJKG	DI	DMZYJKG
DMZYJKG	DN	Piperazinyl norbenzomorphane compound 3
DMZYJKG	MI	TT9NXW4
DMZYJKG	MN	Sigma intracellular receptor 2 (TMEM97)
DMZYJKG	MT	DTT
DMZYJKG	MA	Ligand
DMZYJKG	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DMZYJKG	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DMRSCJ7	DI	DMRSCJ7
DMRSCJ7	DN	Piperazinyl norbenzomorphane compound 4
DMRSCJ7	MI	TT9NXW4
DMRSCJ7	MN	Sigma intracellular receptor 2 (TMEM97)
DMRSCJ7	MT	DTT
DMRSCJ7	MA	Ligand
DMRSCJ7	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DMRSCJ7	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DMY8QIG	DI	DMY8QIG
DMY8QIG	DN	Piperidine carboxamide derivative 1
DMY8QIG	MI	TTYLQ8V
DMY8QIG	MN	Prostaglandin E synthase (PTGES)
DMY8QIG	MT	DTT
DMY8QIG	MA	Inhibitor
DMY8QIG	RN	Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059.
DMY8QIG	RU	https://www.ncbi.nlm.nih.gov/pubmed/28627961

DMHN5KW	DI	DMHN5KW
DMHN5KW	DN	Piperidine derivative 1
DMHN5KW	MI	TTTIBOJ
DMHN5KW	MN	Histamine H1 receptor (H1R)
DMHN5KW	MT	DTT
DMHN5KW	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DMHN5KW	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DMHN5KW	DI	DMHN5KW
DMHN5KW	DN	Piperidine derivative 1
DMHN5KW	MI	TT9JNIC
DMHN5KW	MN	Histamine H3 receptor (H3R)
DMHN5KW	MT	DTT
DMHN5KW	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DMHN5KW	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DMHN5KW	DI	DMHN5KW
DMHN5KW	DN	Piperidine derivative 1
DMHN5KW	MI	TT3ROYC
DMHN5KW	MN	Serotonin transporter (SERT)
DMHN5KW	MT	DTT
DMHN5KW	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DMHN5KW	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DMHXMB4	DI	DMHXMB4
DMHXMB4	DN	Piperidine derivative 2
DMHXMB4	MI	TTQR74A
DMHXMB4	MN	Proteinase activated receptor 2 (PAR2)
DMHXMB4	MT	DTT
DMHXMB4	MA	Antagonist
DMHXMB4	RN	Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
DMHXMB4	RU	https://www.ncbi.nlm.nih.gov/pubmed/26936077

DM80XRM	DI	DM80XRM
DM80XRM	DN	Piperidine derivative 3
DM80XRM	MI	TTQR74A
DM80XRM	MN	Proteinase activated receptor 2 (PAR2)
DM80XRM	MT	DTT
DM80XRM	MA	Antagonist
DM80XRM	RN	Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
DM80XRM	RU	https://www.ncbi.nlm.nih.gov/pubmed/26936077

DM6C5DR	DI	DM6C5DR
DM6C5DR	DN	Piperidine derivative 4
DM6C5DR	MI	TT5TPI6
DM6C5DR	MN	Opioid receptor sigma 1 (OPRS1)
DM6C5DR	MT	DTT
DM6C5DR	MA	Ligand
DM6C5DR	RN	Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578.
DM6C5DR	RU	https://www.ncbi.nlm.nih.gov/pubmed/28051882

DMQ0VK4	DI	DMQ0VK4
DMQ0VK4	DN	Piperidine derivative 5
DMQ0VK4	MI	TT5TPI6
DMQ0VK4	MN	Opioid receptor sigma 1 (OPRS1)
DMQ0VK4	MT	DTT
DMQ0VK4	MA	Ligand
DMQ0VK4	RN	Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578.
DMQ0VK4	RU	https://www.ncbi.nlm.nih.gov/pubmed/28051882

DMQ0VK4	DI	DMQ0VK4
DMQ0VK4	DN	Piperidine derivative 5
DMQ0VK4	MI	TT9NXW4
DMQ0VK4	MN	Sigma intracellular receptor 2 (TMEM97)
DMQ0VK4	MT	DTT
DMQ0VK4	MA	Ligand
DMQ0VK4	RN	Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578.
DMQ0VK4	RU	https://www.ncbi.nlm.nih.gov/pubmed/28051882

DM0GCTY	DI	DM0GCTY
DM0GCTY	DN	Piperidine derivative 6
DM0GCTY	MI	TT5TPI6
DM0GCTY	MN	Opioid receptor sigma 1 (OPRS1)
DM0GCTY	MT	DTT
DM0GCTY	MA	Ligand
DM0GCTY	RN	Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578.
DM0GCTY	RU	https://www.ncbi.nlm.nih.gov/pubmed/28051882

DM0GCTY	DI	DM0GCTY
DM0GCTY	DN	Piperidine derivative 6
DM0GCTY	MI	TT9NXW4
DM0GCTY	MN	Sigma intracellular receptor 2 (TMEM97)
DM0GCTY	MT	DTT
DM0GCTY	MA	Ligand
DM0GCTY	RN	Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578.
DM0GCTY	RU	https://www.ncbi.nlm.nih.gov/pubmed/28051882

DMAM50X	DI	DMAM50X
DMAM50X	DN	Piperidinone derivative 1
DMAM50X	MI	TT473XN
DMAM50X	MN	P2X purinoceptor 7 (P2RX7)
DMAM50X	MT	DTT
DMAM50X	MA	Antagonist
DMAM50X	RN	P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267.
DMAM50X	RU	https://www.ncbi.nlm.nih.gov/pubmed/27724045

DMWAYXP	DI	DMWAYXP
DMWAYXP	DN	Piperidinyl pyrazole derivative 1
DMWAYXP	MI	TTTJZ4M
DMWAYXP	MN	Prolylcarboxypeptidase (PRCP)
DMWAYXP	MT	DTT
DMWAYXP	MA	Inhibitor
DMWAYXP	RN	Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088.
DMWAYXP	RU	https://www.ncbi.nlm.nih.gov/pubmed/28699813

DM21S5G	DI	DM21S5G
DM21S5G	DN	Piperidinyl pyrazole derivative 2
DM21S5G	MI	TTTJZ4M
DM21S5G	MN	Prolylcarboxypeptidase (PRCP)
DM21S5G	MT	DTT
DM21S5G	MA	Inhibitor
DM21S5G	RN	Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088.
DM21S5G	RU	https://www.ncbi.nlm.nih.gov/pubmed/28699813

DMX2V0W	DI	DMX2V0W
DMX2V0W	DN	Piperidinyl pyrazole derivative 3
DMX2V0W	MI	TTTJZ4M
DMX2V0W	MN	Prolylcarboxypeptidase (PRCP)
DMX2V0W	MT	DTT
DMX2V0W	MA	Inhibitor
DMX2V0W	RN	Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088.
DMX2V0W	RU	https://www.ncbi.nlm.nih.gov/pubmed/28699813

DMS8NFJ	DI	DMS8NFJ
DMS8NFJ	DN	Piperidinyl pyrazole derivative 4
DMS8NFJ	MI	TTTJZ4M
DMS8NFJ	MN	Prolylcarboxypeptidase (PRCP)
DMS8NFJ	MT	DTT
DMS8NFJ	MA	Inhibitor
DMS8NFJ	RN	Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088.
DMS8NFJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28699813

DMTSX7J	DI	DMTSX7J
DMTSX7J	DN	Piperidinyl triazole derivative 1
DMTSX7J	MI	TTTJZ4M
DMTSX7J	MN	Prolylcarboxypeptidase (PRCP)
DMTSX7J	MT	DTT
DMTSX7J	MA	Inhibitor
DMTSX7J	RN	Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088.
DMTSX7J	RU	https://www.ncbi.nlm.nih.gov/pubmed/28699813

DM2FZPE	DI	DM2FZPE
DM2FZPE	DN	Piperidinyl triazole derivative 2
DM2FZPE	MI	TTTJZ4M
DM2FZPE	MN	Prolylcarboxypeptidase (PRCP)
DM2FZPE	MT	DTT
DM2FZPE	MA	Inhibitor
DM2FZPE	RN	Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088.
DM2FZPE	RU	https://www.ncbi.nlm.nih.gov/pubmed/28699813

DM0J2TE	DI	DM0J2TE
DM0J2TE	DN	Piperidinyl triazole derivative 3
DM0J2TE	MI	TTTJZ4M
DM0J2TE	MN	Prolylcarboxypeptidase (PRCP)
DM0J2TE	MT	DTT
DM0J2TE	MA	Inhibitor
DM0J2TE	RN	Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088.
DM0J2TE	RU	https://www.ncbi.nlm.nih.gov/pubmed/28699813

DMOQJMU	DI	DMOQJMU
DMOQJMU	DN	Piperidinyl triazole derivative 4
DMOQJMU	MI	TTTJZ4M
DMOQJMU	MN	Prolylcarboxypeptidase (PRCP)
DMOQJMU	MT	DTT
DMOQJMU	MA	Inhibitor
DMOQJMU	RN	Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088.
DMOQJMU	RU	https://www.ncbi.nlm.nih.gov/pubmed/28699813

DM4QVD0	DI	DM4QVD0
DM4QVD0	DN	Piperidinyl triazole derivative 5
DM4QVD0	MI	TTTJZ4M
DM4QVD0	MN	Prolylcarboxypeptidase (PRCP)
DM4QVD0	MT	DTT
DM4QVD0	MA	Inhibitor
DM4QVD0	RN	Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088.
DM4QVD0	RU	https://www.ncbi.nlm.nih.gov/pubmed/28699813

DMG5HI1	DI	DMG5HI1
DMG5HI1	DN	Piperidinyl triazole derivative 6
DMG5HI1	MI	TTTJZ4M
DMG5HI1	MN	Prolylcarboxypeptidase (PRCP)
DMG5HI1	MT	DTT
DMG5HI1	MA	Inhibitor
DMG5HI1	RN	Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088.
DMG5HI1	RU	https://www.ncbi.nlm.nih.gov/pubmed/28699813

DME26SY	DI	DME26SY
DME26SY	DN	Piperonal
DME26SY	MI	TTGP7BY
DME26SY	MN	Monoamine oxidase type B (MAO-B)
DME26SY	MT	DTT
DME26SY	MA	Inhibitor
DME26SY	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DME26SY	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMFZ9Q3	DI	DMFZ9Q3
DMFZ9Q3	DN	Pitavastatin derivative 1
DMFZ9Q3	MI	TTPADOQ
DMFZ9Q3	MN	HMG-CoA reductase (HMGCR)
DMFZ9Q3	MT	DTT
DMFZ9Q3	MA	Inhibitor
DMFZ9Q3	RN	HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272.
DMFZ9Q3	RU	https://www.ncbi.nlm.nih.gov/pubmed/27537201

DM8OYI4	DI	DM8OYI4
DM8OYI4	DN	Platinum IV complexe 1
DM8OYI4	MI	TTN7R6K
DM8OYI4	MN	Signal transducer and activator of transcription 1 (STAT1)
DM8OYI4	MT	DTT
DM8OYI4	MA	Inhibitor
DM8OYI4	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DM8OYI4	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DM8OYI4	DI	DM8OYI4
DM8OYI4	DN	Platinum IV complexe 1
DM8OYI4	MI	TTH8FZW
DM8OYI4	MN	Signal transducer and activator of transcription 3 (STAT3)
DM8OYI4	MT	DTT
DM8OYI4	MA	Inhibitor
DM8OYI4	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DM8OYI4	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DM8OYI4	DI	DM8OYI4
DM8OYI4	DN	Platinum IV complexe 1
DM8OYI4	MI	TTLRFIH
DM8OYI4	MN	Signal transducer and activator of transcription 5 (STAT5)
DM8OYI4	MT	DTT
DM8OYI4	MA	Inhibitor
DM8OYI4	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DM8OYI4	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMRXKJZ	DI	DMRXKJZ
DMRXKJZ	DN	PMID25399719-Compound-17
DMRXKJZ	MI	TTG5QB7
DMRXKJZ	MN	Calpain-2 (CAPN2)
DMRXKJZ	MT	DTT
DMRXKJZ	MA	Inhibitor
DMRXKJZ	RN	An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31.
DMRXKJZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399719

DMRXKJZ	DI	DMRXKJZ
DMRXKJZ	DN	PMID25399719-Compound-17
DMRXKJZ	MI	TTDZN01
DMRXKJZ	MN	Cathepsin K (CTSK)
DMRXKJZ	MT	DTT
DMRXKJZ	MA	Inhibitor
DMRXKJZ	RN	An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31.
DMRXKJZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399719

DMRXKJZ	DI	DMRXKJZ
DMRXKJZ	DN	PMID25399719-Compound-17
DMRXKJZ	MI	TT36ETB
DMRXKJZ	MN	Cathepsin L (CTSL)
DMRXKJZ	MT	DTT
DMRXKJZ	MA	Inhibitor
DMRXKJZ	RN	An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31.
DMRXKJZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399719

DMRXKJZ	DI	DMRXKJZ
DMRXKJZ	DN	PMID25399719-Compound-17
DMRXKJZ	MI	TTUMQVO
DMRXKJZ	MN	Cathepsin S (CTSS)
DMRXKJZ	MT	DTT
DMRXKJZ	MA	Inhibitor
DMRXKJZ	RN	An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31.
DMRXKJZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399719

DM23NEX	DI	DM23NEX
DM23NEX	DN	PMID25399762-Compound-Figure1-Aphanamixoid A
DM23NEX	MI	TT3WG5C
DM23NEX	MN	Monoamine oxidase type A (MAO-A)
DM23NEX	MT	DTT
DM23NEX	MA	Inhibitor
DM23NEX	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DM23NEX	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMRHNOY	DI	DMRHNOY
DMRHNOY	DN	PMID25399762-Compound-Figure1-Chukrasone A
DMRHNOY	MI	TT3WG5C
DMRHNOY	MN	Monoamine oxidase type A (MAO-A)
DMRHNOY	MT	DTT
DMRHNOY	MA	Inhibitor
DMRHNOY	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMRHNOY	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DM0K4XE	DI	DM0K4XE
DM0K4XE	DN	PMID25399762-Compound-Figure1-Chukrasone B
DM0K4XE	MI	TT3WG5C
DM0K4XE	MN	Monoamine oxidase type A (MAO-A)
DM0K4XE	MT	DTT
DM0K4XE	MA	Inhibitor
DM0K4XE	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DM0K4XE	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMDX1MK	DI	DMDX1MK
DMDX1MK	DN	PMID25399762-Compound-Figure1-Eryngiolide A
DMDX1MK	MI	TT3WG5C
DMDX1MK	MN	Monoamine oxidase type A (MAO-A)
DMDX1MK	MT	DTT
DMDX1MK	MA	Inhibitor
DMDX1MK	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMDX1MK	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMSYGHO	DI	DMSYGHO
DMSYGHO	DN	PMID25399762-Compound-Figure1-Neonectrolide A
DMSYGHO	MI	TT3WG5C
DMSYGHO	MN	Monoamine oxidase type A (MAO-A)
DMSYGHO	MT	DTT
DMSYGHO	MA	Inhibitor
DMSYGHO	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMSYGHO	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMRIEH3	DI	DMRIEH3
DMRIEH3	DN	PMID25399762-Compound-Figure1-Sarcaboside A
DMRIEH3	MI	TT3WG5C
DMRIEH3	MN	Monoamine oxidase type A (MAO-A)
DMRIEH3	MT	DTT
DMRIEH3	MA	Inhibitor
DMRIEH3	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMRIEH3	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMDL6TG	DI	DMDL6TG
DMDL6TG	DN	PMID25399762-Compound-Figure1-Sarcaboside B
DMDL6TG	MI	TT3WG5C
DMDL6TG	MN	Monoamine oxidase type A (MAO-A)
DMDL6TG	MT	DTT
DMDL6TG	MA	Inhibitor
DMDL6TG	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMDL6TG	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMG1EKV	DI	DMG1EKV
DMG1EKV	DN	PMID25399762-Compound-Figure2-Artoxanthochromane
DMG1EKV	MI	TT3WG5C
DMG1EKV	MN	Monoamine oxidase type A (MAO-A)
DMG1EKV	MT	DTT
DMG1EKV	MA	Inhibitor
DMG1EKV	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMG1EKV	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMYJ0I8	DI	DMYJ0I8
DMYJ0I8	DN	PMID25399762-Compound-Figure2-Spirooliganone B
DMYJ0I8	MI	TT3WG5C
DMYJ0I8	MN	Monoamine oxidase type A (MAO-A)
DMYJ0I8	MT	DTT
DMYJ0I8	MA	Inhibitor
DMYJ0I8	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMYJ0I8	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMP5Y19	DI	DMP5Y19
DMP5Y19	DN	PMID25399762-Compound-Figure3-Aspeverin
DMP5Y19	MI	TT3WG5C
DMP5Y19	MN	Monoamine oxidase type A (MAO-A)
DMP5Y19	MT	DTT
DMP5Y19	MA	Inhibitor
DMP5Y19	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMP5Y19	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DM9KTRA	DI	DM9KTRA
DM9KTRA	DN	PMID25399762-Compound-Figure3-Fluevirosine A
DM9KTRA	MI	TT3WG5C
DM9KTRA	MN	Monoamine oxidase type A (MAO-A)
DM9KTRA	MT	DTT
DM9KTRA	MA	Inhibitor
DM9KTRA	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DM9KTRA	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMBSP1G	DI	DMBSP1G
DMBSP1G	DN	PMID25399762-Compound-Figure3-Lycojaponicumin A
DMBSP1G	MI	TT3WG5C
DMBSP1G	MN	Monoamine oxidase type A (MAO-A)
DMBSP1G	MT	DTT
DMBSP1G	MA	Inhibitor
DMBSP1G	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMBSP1G	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMKP64Z	DI	DMKP64Z
DMKP64Z	DN	PMID25399762-Compound-Figure3-Lycojaponicumin B
DMKP64Z	MI	TT3WG5C
DMKP64Z	MN	Monoamine oxidase type A (MAO-A)
DMKP64Z	MT	DTT
DMKP64Z	MA	Inhibitor
DMKP64Z	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMKP64Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DM7NUT2	DI	DM7NUT2
DM7NUT2	DN	PMID25399762-Compound-Figure3-Lycojaponicumin C
DM7NUT2	MI	TT3WG5C
DM7NUT2	MN	Monoamine oxidase type A (MAO-A)
DM7NUT2	MT	DTT
DM7NUT2	MA	Inhibitor
DM7NUT2	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DM7NUT2	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMLAS7K	DI	DMLAS7K
DMLAS7K	DN	PMID25399762-Compound-Table 5-8
DMLAS7K	MI	TT3WG5C
DMLAS7K	MN	Monoamine oxidase type A (MAO-A)
DMLAS7K	MT	DTT
DMLAS7K	MA	Inhibitor
DMLAS7K	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMLAS7K	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DM18FP4	DI	DM18FP4
DM18FP4	DN	PMID25399762-Compound-Table 5-O-methyl-M30
DM18FP4	MI	TT3WG5C
DM18FP4	MN	Monoamine oxidase type A (MAO-A)
DM18FP4	MT	DTT
DM18FP4	MA	Inhibitor
DM18FP4	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DM18FP4	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DM4UM03	DI	DM4UM03
DM4UM03	DN	PMID25399762-Compound-Table 6-10
DM4UM03	MI	TTNR0UQ
DM4UM03	MN	Lysine-specific histone demethylase 1 (LSD)
DM4UM03	MT	DTT
DM4UM03	MA	Inhibitor
DM4UM03	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DM4UM03	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DM4UM03	DI	DM4UM03
DM4UM03	DN	PMID25399762-Compound-Table 6-10
DM4UM03	MI	TTGP7BY
DM4UM03	MN	Monoamine oxidase type B (MAO-B)
DM4UM03	MT	DTT
DM4UM03	MA	Inhibitor
DM4UM03	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DM4UM03	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMYGTU2	DI	DMYGTU2
DMYGTU2	DN	PMID25399762-Compound-Table 6-11
DMYGTU2	MI	TTNR0UQ
DMYGTU2	MN	Lysine-specific histone demethylase 1 (LSD)
DMYGTU2	MT	DTT
DMYGTU2	MA	Inhibitor
DMYGTU2	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMYGTU2	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMYGTU2	DI	DMYGTU2
DMYGTU2	DN	PMID25399762-Compound-Table 6-11
DMYGTU2	MI	TTGP7BY
DMYGTU2	MN	Monoamine oxidase type B (MAO-B)
DMYGTU2	MT	DTT
DMYGTU2	MA	Inhibitor
DMYGTU2	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMYGTU2	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMZ07RP	DI	DMZ07RP
DMZ07RP	DN	PMID25399762-Compound-Table 6-12
DMZ07RP	MI	TTNR0UQ
DMZ07RP	MN	Lysine-specific histone demethylase 1 (LSD)
DMZ07RP	MT	DTT
DMZ07RP	MA	Inhibitor
DMZ07RP	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMZ07RP	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMZ07RP	DI	DMZ07RP
DMZ07RP	DN	PMID25399762-Compound-Table 6-12
DMZ07RP	MI	TTGP7BY
DMZ07RP	MN	Monoamine oxidase type B (MAO-B)
DMZ07RP	MT	DTT
DMZ07RP	MA	Inhibitor
DMZ07RP	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMZ07RP	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DM6LR42	DI	DM6LR42
DM6LR42	DN	PMID25399762-Compound-Table 6-13
DM6LR42	MI	TTNR0UQ
DM6LR42	MN	Lysine-specific histone demethylase 1 (LSD)
DM6LR42	MT	DTT
DM6LR42	MA	Inhibitor
DM6LR42	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DM6LR42	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DM6LR42	DI	DM6LR42
DM6LR42	DN	PMID25399762-Compound-Table 6-13
DM6LR42	MI	TTGP7BY
DM6LR42	MN	Monoamine oxidase type B (MAO-B)
DM6LR42	MT	DTT
DM6LR42	MA	Inhibitor
DM6LR42	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DM6LR42	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMZHB9Y	DI	DMZHB9Y
DMZHB9Y	DN	PMID25399762-Compound-Table 6-14
DMZHB9Y	MI	TTNR0UQ
DMZHB9Y	MN	Lysine-specific histone demethylase 1 (LSD)
DMZHB9Y	MT	DTT
DMZHB9Y	MA	Inhibitor
DMZHB9Y	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMZHB9Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMZHB9Y	DI	DMZHB9Y
DMZHB9Y	DN	PMID25399762-Compound-Table 6-14
DMZHB9Y	MI	TTGP7BY
DMZHB9Y	MN	Monoamine oxidase type B (MAO-B)
DMZHB9Y	MT	DTT
DMZHB9Y	MA	Inhibitor
DMZHB9Y	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMZHB9Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMCHWSF	DI	DMCHWSF
DMCHWSF	DN	PMID25399762-Compound-Table 6-15
DMCHWSF	MI	TTNR0UQ
DMCHWSF	MN	Lysine-specific histone demethylase 1 (LSD)
DMCHWSF	MT	DTT
DMCHWSF	MA	Inhibitor
DMCHWSF	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMCHWSF	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMCHWSF	DI	DMCHWSF
DMCHWSF	DN	PMID25399762-Compound-Table 6-15
DMCHWSF	MI	TTGP7BY
DMCHWSF	MN	Monoamine oxidase type B (MAO-B)
DMCHWSF	MT	DTT
DMCHWSF	MA	Inhibitor
DMCHWSF	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMCHWSF	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMDWIPG	DI	DMDWIPG
DMDWIPG	DN	PMID25399762-Compound-Table 6-9
DMDWIPG	MI	TTNR0UQ
DMDWIPG	MN	Lysine-specific histone demethylase 1 (LSD)
DMDWIPG	MT	DTT
DMDWIPG	MA	Inhibitor
DMDWIPG	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMDWIPG	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMDWIPG	DI	DMDWIPG
DMDWIPG	DN	PMID25399762-Compound-Table 6-9
DMDWIPG	MI	TTGP7BY
DMDWIPG	MN	Monoamine oxidase type B (MAO-B)
DMDWIPG	MT	DTT
DMDWIPG	MA	Inhibitor
DMDWIPG	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMDWIPG	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMSL3MB	DI	DMSL3MB
DMSL3MB	DN	PMID25399762-Compound-Table 7-Vanillic acid
DMSL3MB	MI	TTGP7BY
DMSL3MB	MN	Monoamine oxidase type B (MAO-B)
DMSL3MB	MT	DTT
DMSL3MB	MA	Inhibitor
DMSL3MB	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMSL3MB	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DM759MJ	DI	DM759MJ
DM759MJ	DN	PMID25399762-Compound-Table 7-Vanillyl alcohol
DM759MJ	MI	TTGP7BY
DM759MJ	MN	Monoamine oxidase type B (MAO-B)
DM759MJ	MT	DTT
DM759MJ	MA	Inhibitor
DM759MJ	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DM759MJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DM4J2SM	DI	DM4J2SM
DM4J2SM	DN	PMID25399762-Compound-Table 7-Veratraldehyde
DM4J2SM	MI	TTGP7BY
DM4J2SM	MN	Monoamine oxidase type B (MAO-B)
DM4J2SM	MT	DTT
DM4J2SM	MA	Inhibitor
DM4J2SM	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DM4J2SM	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMMP7HX	DI	DMMP7HX
DMMP7HX	DN	PMID25399762-Compound-Table1-C1
DMMP7HX	MI	TTGP7BY
DMMP7HX	MN	Monoamine oxidase type B (MAO-B)
DMMP7HX	MT	DTT
DMMP7HX	MA	Inhibitor
DMMP7HX	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMMP7HX	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMWY5XT	DI	DMWY5XT
DMWY5XT	DN	PMID25399762-Compound-Table1-C10
DMWY5XT	MI	TTGP7BY
DMWY5XT	MN	Monoamine oxidase type B (MAO-B)
DMWY5XT	MT	DTT
DMWY5XT	MA	Inhibitor
DMWY5XT	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMWY5XT	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMVASXW	DI	DMVASXW
DMVASXW	DN	PMID25399762-Compound-Table1-C11
DMVASXW	MI	TTGP7BY
DMVASXW	MN	Monoamine oxidase type B (MAO-B)
DMVASXW	MT	DTT
DMVASXW	MA	Inhibitor
DMVASXW	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMVASXW	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMF9X6P	DI	DMF9X6P
DMF9X6P	DN	PMID25399762-Compound-Table1-C12
DMF9X6P	MI	TTGP7BY
DMF9X6P	MN	Monoamine oxidase type B (MAO-B)
DMF9X6P	MT	DTT
DMF9X6P	MA	Inhibitor
DMF9X6P	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMF9X6P	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMD80Q6	DI	DMD80Q6
DMD80Q6	DN	PMID25399762-Compound-Table1-C13
DMD80Q6	MI	TTGP7BY
DMD80Q6	MN	Monoamine oxidase type B (MAO-B)
DMD80Q6	MT	DTT
DMD80Q6	MA	Inhibitor
DMD80Q6	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMD80Q6	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DM7960M	DI	DM7960M
DM7960M	DN	PMID25399762-Compound-Table1-C14
DM7960M	MI	TTGP7BY
DM7960M	MN	Monoamine oxidase type B (MAO-B)
DM7960M	MT	DTT
DM7960M	MA	Inhibitor
DM7960M	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DM7960M	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMR0P1U	DI	DMR0P1U
DMR0P1U	DN	PMID25399762-Compound-Table1-C15
DMR0P1U	MI	TTGP7BY
DMR0P1U	MN	Monoamine oxidase type B (MAO-B)
DMR0P1U	MT	DTT
DMR0P1U	MA	Inhibitor
DMR0P1U	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMR0P1U	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMYTEAC	DI	DMYTEAC
DMYTEAC	DN	PMID25399762-Compound-Table1-C16
DMYTEAC	MI	TTGP7BY
DMYTEAC	MN	Monoamine oxidase type B (MAO-B)
DMYTEAC	MT	DTT
DMYTEAC	MA	Inhibitor
DMYTEAC	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMYTEAC	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMNMU3R	DI	DMNMU3R
DMNMU3R	DN	PMID25399762-Compound-Table1-C17
DMNMU3R	MI	TTGP7BY
DMNMU3R	MN	Monoamine oxidase type B (MAO-B)
DMNMU3R	MT	DTT
DMNMU3R	MA	Inhibitor
DMNMU3R	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMNMU3R	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DM2ZUVH	DI	DM2ZUVH
DM2ZUVH	DN	PMID25399762-Compound-Table1-C18
DM2ZUVH	MI	TTGP7BY
DM2ZUVH	MN	Monoamine oxidase type B (MAO-B)
DM2ZUVH	MT	DTT
DM2ZUVH	MA	Inhibitor
DM2ZUVH	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DM2ZUVH	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMMO3F1	DI	DMMO3F1
DMMO3F1	DN	PMID25399762-Compound-Table1-C19
DMMO3F1	MI	TTGP7BY
DMMO3F1	MN	Monoamine oxidase type B (MAO-B)
DMMO3F1	MT	DTT
DMMO3F1	MA	Inhibitor
DMMO3F1	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMMO3F1	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMPFLGO	DI	DMPFLGO
DMPFLGO	DN	PMID25399762-Compound-Table1-C2
DMPFLGO	MI	TTGP7BY
DMPFLGO	MN	Monoamine oxidase type B (MAO-B)
DMPFLGO	MT	DTT
DMPFLGO	MA	Inhibitor
DMPFLGO	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMPFLGO	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMITNWZ	DI	DMITNWZ
DMITNWZ	DN	PMID25399762-Compound-Table1-C20
DMITNWZ	MI	TTGP7BY
DMITNWZ	MN	Monoamine oxidase type B (MAO-B)
DMITNWZ	MT	DTT
DMITNWZ	MA	Inhibitor
DMITNWZ	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMITNWZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMMFILA	DI	DMMFILA
DMMFILA	DN	PMID25399762-Compound-Table1-C21
DMMFILA	MI	TTGP7BY
DMMFILA	MN	Monoamine oxidase type B (MAO-B)
DMMFILA	MT	DTT
DMMFILA	MA	Inhibitor
DMMFILA	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMMFILA	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMBE0R2	DI	DMBE0R2
DMBE0R2	DN	PMID25399762-Compound-Table1-C22
DMBE0R2	MI	TTGP7BY
DMBE0R2	MN	Monoamine oxidase type B (MAO-B)
DMBE0R2	MT	DTT
DMBE0R2	MA	Inhibitor
DMBE0R2	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMBE0R2	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMF89PY	DI	DMF89PY
DMF89PY	DN	PMID25399762-Compound-Table1-C23
DMF89PY	MI	TTGP7BY
DMF89PY	MN	Monoamine oxidase type B (MAO-B)
DMF89PY	MT	DTT
DMF89PY	MA	Inhibitor
DMF89PY	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMF89PY	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMJK296	DI	DMJK296
DMJK296	DN	PMID25399762-Compound-Table1-C24
DMJK296	MI	TTGP7BY
DMJK296	MN	Monoamine oxidase type B (MAO-B)
DMJK296	MT	DTT
DMJK296	MA	Inhibitor
DMJK296	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMJK296	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMHT41B	DI	DMHT41B
DMHT41B	DN	PMID25399762-Compound-Table1-C25
DMHT41B	MI	TTGP7BY
DMHT41B	MN	Monoamine oxidase type B (MAO-B)
DMHT41B	MT	DTT
DMHT41B	MA	Inhibitor
DMHT41B	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMHT41B	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMXAKNH	DI	DMXAKNH
DMXAKNH	DN	PMID25399762-Compound-Table1-C3
DMXAKNH	MI	TTGP7BY
DMXAKNH	MN	Monoamine oxidase type B (MAO-B)
DMXAKNH	MT	DTT
DMXAKNH	MA	Inhibitor
DMXAKNH	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMXAKNH	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMJCVBM	DI	DMJCVBM
DMJCVBM	DN	PMID25399762-Compound-Table1-C4
DMJCVBM	MI	TTGP7BY
DMJCVBM	MN	Monoamine oxidase type B (MAO-B)
DMJCVBM	MT	DTT
DMJCVBM	MA	Inhibitor
DMJCVBM	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMJCVBM	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMEJNUG	DI	DMEJNUG
DMEJNUG	DN	PMID25399762-Compound-Table1-C5
DMEJNUG	MI	TTGP7BY
DMEJNUG	MN	Monoamine oxidase type B (MAO-B)
DMEJNUG	MT	DTT
DMEJNUG	MA	Inhibitor
DMEJNUG	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMEJNUG	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMY3UKC	DI	DMY3UKC
DMY3UKC	DN	PMID25399762-Compound-Table1-C6
DMY3UKC	MI	TTGP7BY
DMY3UKC	MN	Monoamine oxidase type B (MAO-B)
DMY3UKC	MT	DTT
DMY3UKC	MA	Inhibitor
DMY3UKC	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMY3UKC	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMQJV3L	DI	DMQJV3L
DMQJV3L	DN	PMID25399762-Compound-Table1-C7
DMQJV3L	MI	TTGP7BY
DMQJV3L	MN	Monoamine oxidase type B (MAO-B)
DMQJV3L	MT	DTT
DMQJV3L	MA	Inhibitor
DMQJV3L	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMQJV3L	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMRCPKV	DI	DMRCPKV
DMRCPKV	DN	PMID25399762-Compound-Table1-C8
DMRCPKV	MI	TTGP7BY
DMRCPKV	MN	Monoamine oxidase type B (MAO-B)
DMRCPKV	MT	DTT
DMRCPKV	MA	Inhibitor
DMRCPKV	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMRCPKV	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMVMT26	DI	DMVMT26
DMVMT26	DN	PMID25399762-Compound-Table1-C9
DMVMT26	MI	TTGP7BY
DMVMT26	MN	Monoamine oxidase type B (MAO-B)
DMVMT26	MT	DTT
DMVMT26	MA	Inhibitor
DMVMT26	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMVMT26	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMJETVH	DI	DMJETVH
DMJETVH	DN	PMID25416646-Compound-Figure2-J
DMJETVH	MI	TTZMAO3
DMJETVH	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMJETVH	MT	DTT
DMJETVH	MA	Agonist
DMJETVH	RN	PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
DMJETVH	RU	https://www.ncbi.nlm.nih.gov/pubmed/25416646

DMNTAYK	DI	DMNTAYK
DMNTAYK	DN	PMID25416646-Compound-Figure2-K
DMNTAYK	MI	TTZMAO3
DMNTAYK	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMNTAYK	MT	DTT
DMNTAYK	MA	Agonist
DMNTAYK	RN	PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
DMNTAYK	RU	https://www.ncbi.nlm.nih.gov/pubmed/25416646

DMLDPGY	DI	DMLDPGY
DMLDPGY	DN	PMID25416646-Compound-Figure2-N
DMLDPGY	MI	TTZMAO3
DMLDPGY	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMLDPGY	MT	DTT
DMLDPGY	MA	Agonist
DMLDPGY	RN	PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
DMLDPGY	RU	https://www.ncbi.nlm.nih.gov/pubmed/25416646

DM9OHAN	DI	DM9OHAN
DM9OHAN	DN	PMID25416646-Compound-Figure5-A
DM9OHAN	MI	TTJ584C
DM9OHAN	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DM9OHAN	MT	DTT
DM9OHAN	MA	Agonist
DM9OHAN	RN	PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
DM9OHAN	RU	https://www.ncbi.nlm.nih.gov/pubmed/25416646

DM9OHAN	DI	DM9OHAN
DM9OHAN	DN	PMID25416646-Compound-Figure5-A
DM9OHAN	MI	TTZMAO3
DM9OHAN	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DM9OHAN	MT	DTT
DM9OHAN	MA	Agonist
DM9OHAN	RN	PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
DM9OHAN	RU	https://www.ncbi.nlm.nih.gov/pubmed/25416646

DM17FKL	DI	DM17FKL
DM17FKL	DN	PMID25416646-Compound-Figure5-C
DM17FKL	MI	TT2JWF6
DM17FKL	MN	Peroxisome proliferator-activated receptor delta (PPARD)
DM17FKL	MT	DTT
DM17FKL	MA	Agonist
DM17FKL	RN	PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
DM17FKL	RU	https://www.ncbi.nlm.nih.gov/pubmed/25416646

DM17FKL	DI	DM17FKL
DM17FKL	DN	PMID25416646-Compound-Figure5-C
DM17FKL	MI	TTZMAO3
DM17FKL	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DM17FKL	MT	DTT
DM17FKL	MA	Agonist
DM17FKL	RN	PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
DM17FKL	RU	https://www.ncbi.nlm.nih.gov/pubmed/25416646

DMYO7VH	DI	DMYO7VH
DMYO7VH	DN	PMID25416646-Compound-Figure5-E
DMYO7VH	MI	TTQVOEI
DMYO7VH	MN	Angiotensin II receptor type-2 (AGTR2)
DMYO7VH	MT	DTT
DMYO7VH	MA	Agonist
DMYO7VH	RN	PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
DMYO7VH	RU	https://www.ncbi.nlm.nih.gov/pubmed/25416646

DMYO7VH	DI	DMYO7VH
DMYO7VH	DN	PMID25416646-Compound-Figure5-E
DMYO7VH	MI	TTZMAO3
DMYO7VH	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMYO7VH	MT	DTT
DMYO7VH	MA	Agonist
DMYO7VH	RN	PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
DMYO7VH	RU	https://www.ncbi.nlm.nih.gov/pubmed/25416646

DMCJTU1	DI	DMCJTU1
DMCJTU1	DN	PMID25416646-Compound-Figure5-H
DMCJTU1	MI	TTJ584C
DMCJTU1	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMCJTU1	MT	DTT
DMCJTU1	MA	Agonist
DMCJTU1	RN	PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
DMCJTU1	RU	https://www.ncbi.nlm.nih.gov/pubmed/25416646

DMCJTU1	DI	DMCJTU1
DMCJTU1	DN	PMID25416646-Compound-Figure5-H
DMCJTU1	MI	TTZMAO3
DMCJTU1	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMCJTU1	MT	DTT
DMCJTU1	MA	Agonist
DMCJTU1	RN	PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
DMCJTU1	RU	https://www.ncbi.nlm.nih.gov/pubmed/25416646

DMMRUVT	DI	DMMRUVT
DMMRUVT	DN	PMID25435179-Compound-EP20142759295NP-1
DMMRUVT	MI	TTSCO7R
DMMRUVT	MN	NAD-dependent deacetylase sirtuin (SIRT)
DMMRUVT	MT	DTT
DMMRUVT	MA	Inhibitor
DMMRUVT	RN	Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15.
DMMRUVT	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435179

DMXJT8R	DI	DMXJT8R
DMXJT8R	DN	PMID25435179-Compound-US2012165330(I)
DMXJT8R	MI	TTSCO7R
DMXJT8R	MN	NAD-dependent deacetylase sirtuin (SIRT)
DMXJT8R	MT	DTT
DMXJT8R	MA	Inhibitor
DMXJT8R	RN	Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15.
DMXJT8R	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435179

DMMRT0Q	DI	DMMRT0Q
DMMRT0Q	DN	PMID25435179-Compound-WO2012006391H3K9TSu
DMMRT0Q	MI	TTSCO7R
DMMRT0Q	MN	NAD-dependent deacetylase sirtuin (SIRT)
DMMRT0Q	MT	DTT
DMMRT0Q	MA	Inhibitor
DMMRT0Q	RN	Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15.
DMMRT0Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435179

DM2F1T0	DI	DM2F1T0
DM2F1T0	DN	PMID25435179-Compound-WO2012106509CAY10602
DM2F1T0	MI	TTUF2HO
DM2F1T0	MN	NAD-dependent deacetylase sirtuin-1 (SIRT1)
DM2F1T0	MT	DTT
DM2F1T0	MA	Inhibitor
DM2F1T0	RN	Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15.
DM2F1T0	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435179

DMLAH39	DI	DMLAH39
DMLAH39	DN	PMID25435179-Compound-WO2012106509Salermide
DMLAH39	MI	TTUF2HO
DMLAH39	MN	NAD-dependent deacetylase sirtuin-1 (SIRT1)
DMLAH39	MT	DTT
DMLAH39	MA	Inhibitor
DMLAH39	RN	Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15.
DMLAH39	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435179

DMBSOED	DI	DMBSOED
DMBSOED	DN	PMID25435179-Compound-WO2012106509Tenovin-6
DMBSOED	MI	TTUF2HO
DMBSOED	MN	NAD-dependent deacetylase sirtuin-1 (SIRT1)
DMBSOED	MT	DTT
DMBSOED	MA	Inhibitor
DMBSOED	RN	Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15.
DMBSOED	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435179

DM79BFU	DI	DM79BFU
DM79BFU	DN	PMID25435179-Compound-WO2012149608USYDS1
DM79BFU	MI	TTSCO7R
DM79BFU	MN	NAD-dependent deacetylase sirtuin (SIRT)
DM79BFU	MT	DTT
DM79BFU	MA	Inhibitor
DM79BFU	RN	Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15.
DM79BFU	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435179

DMIHRG4	DI	DMIHRG4
DMIHRG4	DN	PMID25435179-Compound-WO2013059587(V, 1st set)
DMIHRG4	MI	TTSCO7R
DMIHRG4	MN	NAD-dependent deacetylase sirtuin (SIRT)
DMIHRG4	MT	DTT
DMIHRG4	MA	Inhibitor
DMIHRG4	RN	Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15.
DMIHRG4	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435179

DM7YJ4L	DI	DM7YJ4L
DM7YJ4L	DN	PMID25435179-Compound-WO2013059587(VI, 2nd set)
DM7YJ4L	MI	TTSCO7R
DM7YJ4L	MN	NAD-dependent deacetylase sirtuin (SIRT)
DM7YJ4L	MT	DTT
DM7YJ4L	MA	Inhibitor
DM7YJ4L	RN	Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15.
DM7YJ4L	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435179

DMLUWCD	DI	DMLUWCD
DMLUWCD	DN	PMID25435179-Compound-WO2013059594(III)
DMLUWCD	MI	TTSCO7R
DMLUWCD	MN	NAD-dependent deacetylase sirtuin (SIRT)
DMLUWCD	MT	DTT
DMLUWCD	MA	Inhibitor
DMLUWCD	RN	Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15.
DMLUWCD	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435179

DMK90ED	DI	DMK90ED
DMK90ED	DN	PMID25435179-Compound-WO2013059594(IV)
DMK90ED	MI	TTSCO7R
DMK90ED	MN	NAD-dependent deacetylase sirtuin (SIRT)
DMK90ED	MT	DTT
DMK90ED	MA	Inhibitor
DMK90ED	RN	Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15.
DMK90ED	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435179

DMXC3UP	DI	DMXC3UP
DMXC3UP	DN	PMID25435179-Compound-WO2014110399Splitomycin
DMXC3UP	MI	TTSCO7R
DMXC3UP	MN	NAD-dependent deacetylase sirtuin (SIRT)
DMXC3UP	MT	DTT
DMXC3UP	MA	Inhibitor
DMXC3UP	RN	Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15.
DMXC3UP	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435179

DM12QO7	DI	DM12QO7
DM12QO7	DN	PMID25435285-Compound-10
DM12QO7	MI	TTXJ47W
DM12QO7	MN	Metabotropic glutamate receptor 2 (mGluR2)
DM12QO7	MT	DTT
DM12QO7	MA	Antagonist
DM12QO7	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DM12QO7	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DMHBWNS	DI	DMHBWNS
DMHBWNS	DN	PMID25435285-Compound-15
DMHBWNS	MI	TTXJ47W
DMHBWNS	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMHBWNS	MT	DTT
DMHBWNS	MA	Antagonist
DMHBWNS	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DMHBWNS	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DMHBWNS	DI	DMHBWNS
DMHBWNS	DN	PMID25435285-Compound-15
DMHBWNS	MI	TT8A9EF
DMHBWNS	MN	Metabotropic glutamate receptor 3 (mGluR3)
DMHBWNS	MT	DTT
DMHBWNS	MA	Antagonist
DMHBWNS	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DMHBWNS	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DMKFX2G	DI	DMKFX2G
DMKFX2G	DN	PMID25435285-Compound-16
DMKFX2G	MI	TTXJ47W
DMKFX2G	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMKFX2G	MT	DTT
DMKFX2G	MA	Antagonist
DMKFX2G	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DMKFX2G	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DMKFX2G	DI	DMKFX2G
DMKFX2G	DN	PMID25435285-Compound-16
DMKFX2G	MI	TT8A9EF
DMKFX2G	MN	Metabotropic glutamate receptor 3 (mGluR3)
DMKFX2G	MT	DTT
DMKFX2G	MA	Antagonist
DMKFX2G	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DMKFX2G	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DMG9FYH	DI	DMG9FYH
DMG9FYH	DN	PMID25435285-Compound-20
DMG9FYH	MI	TTXJ47W
DMG9FYH	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMG9FYH	MT	DTT
DMG9FYH	MA	Antagonist
DMG9FYH	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DMG9FYH	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DMG9FYH	DI	DMG9FYH
DMG9FYH	DN	PMID25435285-Compound-20
DMG9FYH	MI	TT8A9EF
DMG9FYH	MN	Metabotropic glutamate receptor 3 (mGluR3)
DMG9FYH	MT	DTT
DMG9FYH	MA	Antagonist
DMG9FYH	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DMG9FYH	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DM27U1F	DI	DM27U1F
DM27U1F	DN	PMID25435285-Compound-22
DM27U1F	MI	TTXJ47W
DM27U1F	MN	Metabotropic glutamate receptor 2 (mGluR2)
DM27U1F	MT	DTT
DM27U1F	MA	Antagonist
DM27U1F	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DM27U1F	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DM27U1F	DI	DM27U1F
DM27U1F	DN	PMID25435285-Compound-22
DM27U1F	MI	TT8A9EF
DM27U1F	MN	Metabotropic glutamate receptor 3 (mGluR3)
DM27U1F	MT	DTT
DM27U1F	MA	Antagonist
DM27U1F	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DM27U1F	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DMIVJMO	DI	DMIVJMO
DMIVJMO	DN	PMID25435285-Compound-25
DMIVJMO	MI	TTXJ47W
DMIVJMO	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMIVJMO	MT	DTT
DMIVJMO	MA	Antagonist
DMIVJMO	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DMIVJMO	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DMTJHAK	DI	DMTJHAK
DMTJHAK	DN	PMID25435285-Compound-26
DMTJHAK	MI	TTXJ47W
DMTJHAK	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMTJHAK	MT	DTT
DMTJHAK	MA	Antagonist
DMTJHAK	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DMTJHAK	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DMTYHCU	DI	DMTYHCU
DMTYHCU	DN	PMID25435285-Compound-37
DMTYHCU	MI	TTXJ47W
DMTYHCU	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMTYHCU	MT	DTT
DMTYHCU	MA	Antagonist
DMTYHCU	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DMTYHCU	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DMSIKM2	DI	DMSIKM2
DMSIKM2	DN	PMID25435285-Compound-38
DMSIKM2	MI	TTXJ47W
DMSIKM2	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMSIKM2	MT	DTT
DMSIKM2	MA	Antagonist
DMSIKM2	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DMSIKM2	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DMG2ES1	DI	DMG2ES1
DMG2ES1	DN	PMID25435285-Compound-39
DMG2ES1	MI	TTXJ47W
DMG2ES1	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMG2ES1	MT	DTT
DMG2ES1	MA	Antagonist
DMG2ES1	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DMG2ES1	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DMW2C19	DI	DMW2C19
DMW2C19	DN	PMID25435285-Compound-40
DMW2C19	MI	TTXJ47W
DMW2C19	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMW2C19	MT	DTT
DMW2C19	MA	Antagonist
DMW2C19	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DMW2C19	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DMJ5LGA	DI	DMJ5LGA
DMJ5LGA	DN	PMID25435285-Compound-41
DMJ5LGA	MI	TTXJ47W
DMJ5LGA	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMJ5LGA	MT	DTT
DMJ5LGA	MA	Antagonist
DMJ5LGA	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DMJ5LGA	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DMTN79G	DI	DMTN79G
DMTN79G	DN	PMID25435285-Compound-42
DMTN79G	MI	TTXJ47W
DMTN79G	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMTN79G	MT	DTT
DMTN79G	MA	Antagonist
DMTN79G	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DMTN79G	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DMEGJ73	DI	DMEGJ73
DMEGJ73	DN	PMID25435285-Compound-43
DMEGJ73	MI	TTXJ47W
DMEGJ73	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMEGJ73	MT	DTT
DMEGJ73	MA	Antagonist
DMEGJ73	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DMEGJ73	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DM4K3AU	DI	DM4K3AU
DM4K3AU	DN	PMID25435285-Compound-44
DM4K3AU	MI	TTXJ47W
DM4K3AU	MN	Metabotropic glutamate receptor 2 (mGluR2)
DM4K3AU	MT	DTT
DM4K3AU	MA	Antagonist
DM4K3AU	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DM4K3AU	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DM74WSJ	DI	DM74WSJ
DM74WSJ	DN	PMID25435285-Compound-45
DM74WSJ	MI	TTXJ47W
DM74WSJ	MN	Metabotropic glutamate receptor 2 (mGluR2)
DM74WSJ	MT	DTT
DM74WSJ	MA	Antagonist
DM74WSJ	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DM74WSJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DMC6HPV	DI	DMC6HPV
DMC6HPV	DN	PMID25435285-Compound-46
DMC6HPV	MI	TTXJ47W
DMC6HPV	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMC6HPV	MT	DTT
DMC6HPV	MA	Antagonist
DMC6HPV	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DMC6HPV	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DM92F1C	DI	DM92F1C
DM92F1C	DN	PMID25435285-Compound-47
DM92F1C	MI	TTXJ47W
DM92F1C	MN	Metabotropic glutamate receptor 2 (mGluR2)
DM92F1C	MT	DTT
DM92F1C	MA	Antagonist
DM92F1C	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DM92F1C	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DM7G51M	DI	DM7G51M
DM7G51M	DN	PMID25435285-Compound-49
DM7G51M	MI	TTXJ47W
DM7G51M	MN	Metabotropic glutamate receptor 2 (mGluR2)
DM7G51M	MT	DTT
DM7G51M	MA	Antagonist
DM7G51M	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DM7G51M	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DML48NA	DI	DML48NA
DML48NA	DN	PMID25435285-Compound-50
DML48NA	MI	TTXJ47W
DML48NA	MN	Metabotropic glutamate receptor 2 (mGluR2)
DML48NA	MT	DTT
DML48NA	MA	Antagonist
DML48NA	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DML48NA	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DM2VZG6	DI	DM2VZG6
DM2VZG6	DN	PMID25435285-Compound-51
DM2VZG6	MI	TTXJ47W
DM2VZG6	MN	Metabotropic glutamate receptor 2 (mGluR2)
DM2VZG6	MT	DTT
DM2VZG6	MA	Antagonist
DM2VZG6	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DM2VZG6	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DMXD8L1	DI	DMXD8L1
DMXD8L1	DN	PMID25435285-Compound-52
DMXD8L1	MI	TTXJ47W
DMXD8L1	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMXD8L1	MT	DTT
DMXD8L1	MA	Antagonist
DMXD8L1	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DMXD8L1	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DMSRYIP	DI	DMSRYIP
DMSRYIP	DN	PMID25435285-Compound-53
DMSRYIP	MI	TTXJ47W
DMSRYIP	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMSRYIP	MT	DTT
DMSRYIP	MA	Antagonist
DMSRYIP	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DMSRYIP	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DMSKCEH	DI	DMSKCEH
DMSKCEH	DN	PMID25468267-Compound-46
DMSKCEH	MI	TTZHPB8
DMSKCEH	MN	Lysine-specific demethylase 4A (KDM4A)
DMSKCEH	MT	DTT
DMSKCEH	MA	Inhibitor
DMSKCEH	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMSKCEH	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMSKCEH	DI	DMSKCEH
DMSKCEH	DN	PMID25468267-Compound-46
DMSKCEH	MI	TTV8CRH
DMSKCEH	MN	Lysine-specific demethylase 4C (KDM4C)
DMSKCEH	MT	DTT
DMSKCEH	MA	Inhibitor
DMSKCEH	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMSKCEH	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMSKCEH	DI	DMSKCEH
DMSKCEH	DN	PMID25468267-Compound-46
DMSKCEH	MI	TTWAQBO
DMSKCEH	MN	Lysine-specific demethylase 4E (KDM4E)
DMSKCEH	MT	DTT
DMSKCEH	MA	Inhibitor
DMSKCEH	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMSKCEH	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMG2JEK	DI	DMG2JEK
DMG2JEK	DN	PMID25468267-Compound-47
DMG2JEK	MI	TTV8CRH
DMG2JEK	MN	Lysine-specific demethylase 4C (KDM4C)
DMG2JEK	MT	DTT
DMG2JEK	MA	Inhibitor
DMG2JEK	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMG2JEK	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMBPT9Z	DI	DMBPT9Z
DMBPT9Z	DN	PMID25468267-Compound-48
DMBPT9Z	MI	TT0RGE9
DMBPT9Z	MN	Lysine-specific demethylase 4 (KDM4)
DMBPT9Z	MT	DTT
DMBPT9Z	MA	Inhibitor
DMBPT9Z	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMBPT9Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DM2HG9U	DI	DM2HG9U
DM2HG9U	DN	PMID25468267-Compound-49
DM2HG9U	MI	TT0RGE9
DM2HG9U	MN	Lysine-specific demethylase 4 (KDM4)
DM2HG9U	MT	DTT
DM2HG9U	MA	Inhibitor
DM2HG9U	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DM2HG9U	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMIVJ2W	DI	DMIVJ2W
DMIVJ2W	DN	PMID25468267-Compound-50
DMIVJ2W	MI	TT0RGE9
DMIVJ2W	MN	Lysine-specific demethylase 4 (KDM4)
DMIVJ2W	MT	DTT
DMIVJ2W	MA	Inhibitor
DMIVJ2W	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMIVJ2W	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMNPC0H	DI	DMNPC0H
DMNPC0H	DN	PMID25468267-Compound-51
DMNPC0H	MI	TT0RGE9
DMNPC0H	MN	Lysine-specific demethylase 4 (KDM4)
DMNPC0H	MT	DTT
DMNPC0H	MA	Inhibitor
DMNPC0H	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMNPC0H	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMAH1G7	DI	DMAH1G7
DMAH1G7	DN	PMID25468267-Compound-52
DMAH1G7	MI	TT0RGE9
DMAH1G7	MN	Lysine-specific demethylase 4 (KDM4)
DMAH1G7	MT	DTT
DMAH1G7	MA	Inhibitor
DMAH1G7	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMAH1G7	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMONWYI	DI	DMONWYI
DMONWYI	DN	PMID25468267-Compound-53
DMONWYI	MI	TT0RGE9
DMONWYI	MN	Lysine-specific demethylase 4 (KDM4)
DMONWYI	MT	DTT
DMONWYI	MA	Inhibitor
DMONWYI	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMONWYI	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMI93AX	DI	DMI93AX
DMI93AX	DN	PMID25468267-Compound-54
DMI93AX	MI	TT0RGE9
DMI93AX	MN	Lysine-specific demethylase 4 (KDM4)
DMI93AX	MT	DTT
DMI93AX	MA	Inhibitor
DMI93AX	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMI93AX	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMIXQRY	DI	DMIXQRY
DMIXQRY	DN	PMID25468267-Compound-55
DMIXQRY	MI	TTV8CRH
DMIXQRY	MN	Lysine-specific demethylase 4C (KDM4C)
DMIXQRY	MT	DTT
DMIXQRY	MA	Inhibitor
DMIXQRY	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMIXQRY	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMAI19Z	DI	DMAI19Z
DMAI19Z	DN	PMID25468267-Compound-56
DMAI19Z	MI	TTV8CRH
DMAI19Z	MN	Lysine-specific demethylase 4C (KDM4C)
DMAI19Z	MT	DTT
DMAI19Z	MA	Inhibitor
DMAI19Z	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMAI19Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DM6EN54	DI	DM6EN54
DM6EN54	DN	PMID25470667-Compound-AZD3988
DM6EN54	MI	TTF8P9I
DM6EN54	MN	Diacylglycerol acyltransferase 1 (DGAT1)
DM6EN54	MT	DTT
DM6EN54	MA	Inhibitor
DM6EN54	RN	Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
DM6EN54	RU	https://www.ncbi.nlm.nih.gov/pubmed/25470667

DMY3140	DI	DMY3140
DMY3140	DN	PMID25470667-Compound-BAY744113
DMY3140	MI	TTF8P9I
DMY3140	MN	Diacylglycerol acyltransferase 1 (DGAT1)
DMY3140	MT	DTT
DMY3140	MA	Inhibitor
DMY3140	RN	Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
DMY3140	RU	https://www.ncbi.nlm.nih.gov/pubmed/25470667

DMMVQW8	DI	DMMVQW8
DMMVQW8	DN	PMID25470667-Compound-Figure4-1A
DMMVQW8	MI	TTF8P9I
DMMVQW8	MN	Diacylglycerol acyltransferase 1 (DGAT1)
DMMVQW8	MT	DTT
DMMVQW8	MA	Inhibitor
DMMVQW8	RN	Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
DMMVQW8	RU	https://www.ncbi.nlm.nih.gov/pubmed/25470667

DMMVQW8	DI	DMMVQW8
DMMVQW8	DN	PMID25470667-Compound-Figure4-1A
DMMVQW8	MI	TTRHEQ4
DMMVQW8	MN	Diacylglycerol O-acyltransferase 2 (DGAT2)
DMMVQW8	MT	DTT
DMMVQW8	MA	Inhibitor
DMMVQW8	RN	Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
DMMVQW8	RU	https://www.ncbi.nlm.nih.gov/pubmed/25470667

DME40TS	DI	DME40TS
DME40TS	DN	PMID25470667-Compound-GO-CoA-Tat
DME40TS	MI	TTSYOWR
DME40TS	MN	Ghrelin O acyltransferase (GOAT)
DME40TS	MT	DTT
DME40TS	MA	Inhibitor
DME40TS	RN	Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
DME40TS	RU	https://www.ncbi.nlm.nih.gov/pubmed/25470667

DMYZ2UA	DI	DMYZ2UA
DMYZ2UA	DN	PMID25470667-Compound-K-604
DMYZ2UA	MI	TTK3C21
DMYZ2UA	MN	Acetoacetyl-CoA thiolase (ACAT1)
DMYZ2UA	MT	DTT
DMYZ2UA	MA	Inhibitor
DMYZ2UA	RN	Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
DMYZ2UA	RU	https://www.ncbi.nlm.nih.gov/pubmed/25470667

DM0OBAW	DI	DM0OBAW
DM0OBAW	DN	PMID25470667-Compound-PF-04620110
DM0OBAW	MI	TTF8P9I
DM0OBAW	MN	Diacylglycerol acyltransferase 1 (DGAT1)
DM0OBAW	MT	DTT
DM0OBAW	MA	Inhibitor
DM0OBAW	RN	Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
DM0OBAW	RU	https://www.ncbi.nlm.nih.gov/pubmed/25470667

DMCF2G7	DI	DMCF2G7
DMCF2G7	DN	PMID25470667-Compound-roselipins
DMCF2G7	MI	TTRHEQ4
DMCF2G7	MN	Diacylglycerol O-acyltransferase 2 (DGAT2)
DMCF2G7	MT	DTT
DMCF2G7	MA	Inhibitor
DMCF2G7	RN	Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
DMCF2G7	RU	https://www.ncbi.nlm.nih.gov/pubmed/25470667

DMQB4LE	DI	DMQB4LE
DMQB4LE	DN	PMID25482888-Compound-11
DMQB4LE	MI	TTDIGC1
DMQB4LE	MN	Dipeptidyl peptidase 4 (DPP-4)
DMQB4LE	MT	DTT
DMQB4LE	MA	Inhibitor
DMQB4LE	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMQB4LE	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DM8JIDR	DI	DM8JIDR
DM8JIDR	DN	PMID25482888-Compound-12
DM8JIDR	MI	TTDIGC1
DM8JIDR	MN	Dipeptidyl peptidase 4 (DPP-4)
DM8JIDR	MT	DTT
DM8JIDR	MA	Inhibitor
DM8JIDR	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DM8JIDR	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DMBS2FT	DI	DMBS2FT
DMBS2FT	DN	PMID25482888-Compound-13
DMBS2FT	MI	TTDIGC1
DMBS2FT	MN	Dipeptidyl peptidase 4 (DPP-4)
DMBS2FT	MT	DTT
DMBS2FT	MA	Inhibitor
DMBS2FT	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMBS2FT	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DMC82UR	DI	DMC82UR
DMC82UR	DN	PMID25482888-Compound-14
DMC82UR	MI	TTDIGC1
DMC82UR	MN	Dipeptidyl peptidase 4 (DPP-4)
DMC82UR	MT	DTT
DMC82UR	MA	Inhibitor
DMC82UR	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMC82UR	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DMO913H	DI	DMO913H
DMO913H	DN	PMID25482888-Compound-15
DMO913H	MI	TTDIGC1
DMO913H	MN	Dipeptidyl peptidase 4 (DPP-4)
DMO913H	MT	DTT
DMO913H	MA	Inhibitor
DMO913H	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMO913H	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DMIFVXE	DI	DMIFVXE
DMIFVXE	DN	PMID25482888-Compound-16
DMIFVXE	MI	TTDIGC1
DMIFVXE	MN	Dipeptidyl peptidase 4 (DPP-4)
DMIFVXE	MT	DTT
DMIFVXE	MA	Inhibitor
DMIFVXE	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMIFVXE	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DMY4AJ7	DI	DMY4AJ7
DMY4AJ7	DN	PMID25482888-Compound-17
DMY4AJ7	MI	TTDIGC1
DMY4AJ7	MN	Dipeptidyl peptidase 4 (DPP-4)
DMY4AJ7	MT	DTT
DMY4AJ7	MA	Inhibitor
DMY4AJ7	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMY4AJ7	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DM0W5UA	DI	DM0W5UA
DM0W5UA	DN	PMID25482888-Compound-18
DM0W5UA	MI	TTDIGC1
DM0W5UA	MN	Dipeptidyl peptidase 4 (DPP-4)
DM0W5UA	MT	DTT
DM0W5UA	MA	Inhibitor
DM0W5UA	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DM0W5UA	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DM2W9AP	DI	DM2W9AP
DM2W9AP	DN	PMID25482888-Compound-21
DM2W9AP	MI	TTDIGC1
DM2W9AP	MN	Dipeptidyl peptidase 4 (DPP-4)
DM2W9AP	MT	DTT
DM2W9AP	MA	Inhibitor
DM2W9AP	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DM2W9AP	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DMX5R9N	DI	DMX5R9N
DMX5R9N	DN	PMID25482888-Compound-34
DMX5R9N	MI	TTDIGC1
DMX5R9N	MN	Dipeptidyl peptidase 4 (DPP-4)
DMX5R9N	MT	DTT
DMX5R9N	MA	Inhibitor
DMX5R9N	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMX5R9N	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DMMZO8Y	DI	DMMZO8Y
DMMZO8Y	DN	PMID25482888-Compound-37
DMMZO8Y	MI	TTDIGC1
DMMZO8Y	MN	Dipeptidyl peptidase 4 (DPP-4)
DMMZO8Y	MT	DTT
DMMZO8Y	MA	Inhibitor
DMMZO8Y	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMMZO8Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DMJOPEL	DI	DMJOPEL
DMJOPEL	DN	PMID25482888-Compound-38
DMJOPEL	MI	TTDIGC1
DMJOPEL	MN	Dipeptidyl peptidase 4 (DPP-4)
DMJOPEL	MT	DTT
DMJOPEL	MA	Inhibitor
DMJOPEL	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMJOPEL	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DMMLJ5E	DI	DMMLJ5E
DMMLJ5E	DN	PMID25482888-Compound-50
DMMLJ5E	MI	TTDIGC1
DMMLJ5E	MN	Dipeptidyl peptidase 4 (DPP-4)
DMMLJ5E	MT	DTT
DMMLJ5E	MA	Inhibitor
DMMLJ5E	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMMLJ5E	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DMDLPB7	DI	DMDLPB7
DMDLPB7	DN	PMID25482888-Compound-52
DMDLPB7	MI	TTDIGC1
DMDLPB7	MN	Dipeptidyl peptidase 4 (DPP-4)
DMDLPB7	MT	DTT
DMDLPB7	MA	Inhibitor
DMDLPB7	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMDLPB7	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DMB3DMR	DI	DMB3DMR
DMB3DMR	DN	PMID25482888-Compound-56
DMB3DMR	MI	TTDIGC1
DMB3DMR	MN	Dipeptidyl peptidase 4 (DPP-4)
DMB3DMR	MT	DTT
DMB3DMR	MA	Inhibitor
DMB3DMR	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMB3DMR	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DM03UK2	DI	DM03UK2
DM03UK2	DN	PMID25482888-Compound-6
DM03UK2	MI	TTDIGC1
DM03UK2	MN	Dipeptidyl peptidase 4 (DPP-4)
DM03UK2	MT	DTT
DM03UK2	MA	Inhibitor
DM03UK2	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DM03UK2	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DMPY8NU	DI	DMPY8NU
DMPY8NU	DN	PMID25482888-Compound-69
DMPY8NU	MI	TTDIGC1
DMPY8NU	MN	Dipeptidyl peptidase 4 (DPP-4)
DMPY8NU	MT	DTT
DMPY8NU	MA	Inhibitor
DMPY8NU	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMPY8NU	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DMEYLM2	DI	DMEYLM2
DMEYLM2	DN	PMID25482888-Compound-70
DMEYLM2	MI	TTDIGC1
DMEYLM2	MN	Dipeptidyl peptidase 4 (DPP-4)
DMEYLM2	MT	DTT
DMEYLM2	MA	Inhibitor
DMEYLM2	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMEYLM2	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DMZB140	DI	DMZB140
DMZB140	DN	PMID25482888-Compound-71
DMZB140	MI	TTDIGC1
DMZB140	MN	Dipeptidyl peptidase 4 (DPP-4)
DMZB140	MT	DTT
DMZB140	MA	Inhibitor
DMZB140	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMZB140	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DMQOVKF	DI	DMQOVKF
DMQOVKF	DN	PMID25482888-Compound-72
DMQOVKF	MI	TTDIGC1
DMQOVKF	MN	Dipeptidyl peptidase 4 (DPP-4)
DMQOVKF	MT	DTT
DMQOVKF	MA	Inhibitor
DMQOVKF	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMQOVKF	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DME0XS4	DI	DME0XS4
DME0XS4	DN	PMID25514969-Compound-10
DME0XS4	MI	TT4EB85
DME0XS4	MN	Cholesterol 24-hydroxylase (CYP46A1)
DME0XS4	MT	DTT
DME0XS4	MA	Inhibitor
DME0XS4	RN	Imidazo[1,2-a]pyridines as cholesterol 24-hydroxylase (CYP46A1) inhibitors: a patent evaluation (WO2014061676).Expert Opin Ther Pat. 2015 Mar;25(3):373-7.
DME0XS4	RU	https://www.ncbi.nlm.nih.gov/pubmed/25514969

DMUPL0W	DI	DMUPL0W
DMUPL0W	DN	PMID25514969-Compound-11
DMUPL0W	MI	TT4EB85
DMUPL0W	MN	Cholesterol 24-hydroxylase (CYP46A1)
DMUPL0W	MT	DTT
DMUPL0W	MA	Inhibitor
DMUPL0W	RN	Imidazo[1,2-a]pyridines as cholesterol 24-hydroxylase (CYP46A1) inhibitors: a patent evaluation (WO2014061676).Expert Opin Ther Pat. 2015 Mar;25(3):373-7.
DMUPL0W	RU	https://www.ncbi.nlm.nih.gov/pubmed/25514969

DMOE5N0	DI	DMOE5N0
DMOE5N0	DN	PMID25514969-Compound-12
DMOE5N0	MI	TT4EB85
DMOE5N0	MN	Cholesterol 24-hydroxylase (CYP46A1)
DMOE5N0	MT	DTT
DMOE5N0	MA	Inhibitor
DMOE5N0	RN	Imidazo[1,2-a]pyridines as cholesterol 24-hydroxylase (CYP46A1) inhibitors: a patent evaluation (WO2014061676).Expert Opin Ther Pat. 2015 Mar;25(3):373-7.
DMOE5N0	RU	https://www.ncbi.nlm.nih.gov/pubmed/25514969

DMQB03U	DI	DMQB03U
DMQB03U	DN	PMID25514969-Compound-13
DMQB03U	MI	TT4EB85
DMQB03U	MN	Cholesterol 24-hydroxylase (CYP46A1)
DMQB03U	MT	DTT
DMQB03U	MA	Inhibitor
DMQB03U	RN	Imidazo[1,2-a]pyridines as cholesterol 24-hydroxylase (CYP46A1) inhibitors: a patent evaluation (WO2014061676).Expert Opin Ther Pat. 2015 Mar;25(3):373-7.
DMQB03U	RU	https://www.ncbi.nlm.nih.gov/pubmed/25514969

DM2NVLZ	DI	DM2NVLZ
DM2NVLZ	DN	PMID25514969-Compound-8
DM2NVLZ	MI	TT4EB85
DM2NVLZ	MN	Cholesterol 24-hydroxylase (CYP46A1)
DM2NVLZ	MT	DTT
DM2NVLZ	MA	Inhibitor
DM2NVLZ	RN	Imidazo[1,2-a]pyridines as cholesterol 24-hydroxylase (CYP46A1) inhibitors: a patent evaluation (WO2014061676).Expert Opin Ther Pat. 2015 Mar;25(3):373-7.
DM2NVLZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25514969

DMAEZB1	DI	DMAEZB1
DMAEZB1	DN	PMID25514969-Compound-9
DMAEZB1	MI	TT4EB85
DMAEZB1	MN	Cholesterol 24-hydroxylase (CYP46A1)
DMAEZB1	MT	DTT
DMAEZB1	MA	Inhibitor
DMAEZB1	RN	Imidazo[1,2-a]pyridines as cholesterol 24-hydroxylase (CYP46A1) inhibitors: a patent evaluation (WO2014061676).Expert Opin Ther Pat. 2015 Mar;25(3):373-7.
DMAEZB1	RU	https://www.ncbi.nlm.nih.gov/pubmed/25514969

DMC6S0W	DI	DMC6S0W
DMC6S0W	DN	PMID25514969-Compound-Figure2-2
DMC6S0W	MI	TT4EB85
DMC6S0W	MN	Cholesterol 24-hydroxylase (CYP46A1)
DMC6S0W	MT	DTT
DMC6S0W	MA	Inhibitor
DMC6S0W	RN	Imidazo[1,2-a]pyridines as cholesterol 24-hydroxylase (CYP46A1) inhibitors: a patent evaluation (WO2014061676).Expert Opin Ther Pat. 2015 Mar;25(3):373-7.
DMC6S0W	RU	https://www.ncbi.nlm.nih.gov/pubmed/25514969

DMUYVOP	DI	DMUYVOP
DMUYVOP	DN	PMID25514969-Compound-Figure2-3
DMUYVOP	MI	TT4EB85
DMUYVOP	MN	Cholesterol 24-hydroxylase (CYP46A1)
DMUYVOP	MT	DTT
DMUYVOP	MA	Inhibitor
DMUYVOP	RN	Imidazo[1,2-a]pyridines as cholesterol 24-hydroxylase (CYP46A1) inhibitors: a patent evaluation (WO2014061676).Expert Opin Ther Pat. 2015 Mar;25(3):373-7.
DMUYVOP	RU	https://www.ncbi.nlm.nih.gov/pubmed/25514969

DMXSAN7	DI	DMXSAN7
DMXSAN7	DN	PMID25514969-Compound-Figure2-4
DMXSAN7	MI	TT4EB85
DMXSAN7	MN	Cholesterol 24-hydroxylase (CYP46A1)
DMXSAN7	MT	DTT
DMXSAN7	MA	Inhibitor
DMXSAN7	RN	Imidazo[1,2-a]pyridines as cholesterol 24-hydroxylase (CYP46A1) inhibitors: a patent evaluation (WO2014061676).Expert Opin Ther Pat. 2015 Mar;25(3):373-7.
DMXSAN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/25514969

DM7D12Y	DI	DM7D12Y
DM7D12Y	DN	PMID25514969-Compound-Figure3
DM7D12Y	MI	TT4EB85
DM7D12Y	MN	Cholesterol 24-hydroxylase (CYP46A1)
DM7D12Y	MT	DTT
DM7D12Y	MA	Inhibitor
DM7D12Y	RN	Imidazo[1,2-a]pyridines as cholesterol 24-hydroxylase (CYP46A1) inhibitors: a patent evaluation (WO2014061676).Expert Opin Ther Pat. 2015 Mar;25(3):373-7.
DM7D12Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/25514969

DMRJ30G	DI	DMRJ30G
DMRJ30G	DN	PMID25522065-Compound-10
DMRJ30G	MI	TTX4RTB
DMRJ30G	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMRJ30G	MT	DTT
DMRJ30G	MA	Antagonist
DMRJ30G	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DMRJ30G	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DM410Z6	DI	DM410Z6
DM410Z6	DN	PMID25522065-Compound-11
DM410Z6	MI	TTX4RTB
DM410Z6	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DM410Z6	MT	DTT
DM410Z6	MA	Antagonist
DM410Z6	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DM410Z6	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DMVKO9C	DI	DMVKO9C
DMVKO9C	DN	PMID25522065-Compound-12
DMVKO9C	MI	TTX4RTB
DMVKO9C	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMVKO9C	MT	DTT
DMVKO9C	MA	Antagonist
DMVKO9C	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DMVKO9C	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DM92HZG	DI	DM92HZG
DM92HZG	DN	PMID25522065-Compound-13
DM92HZG	MI	TTX4RTB
DM92HZG	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DM92HZG	MT	DTT
DM92HZG	MA	Antagonist
DM92HZG	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DM92HZG	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DMGZER5	DI	DMGZER5
DMGZER5	DN	PMID25522065-Compound-14
DMGZER5	MI	TTX4RTB
DMGZER5	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMGZER5	MT	DTT
DMGZER5	MA	Antagonist
DMGZER5	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DMGZER5	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DMZMQFW	DI	DMZMQFW
DMZMQFW	DN	PMID25522065-Compound-15
DMZMQFW	MI	TTX4RTB
DMZMQFW	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMZMQFW	MT	DTT
DMZMQFW	MA	Antagonist
DMZMQFW	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DMZMQFW	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DMAN3BT	DI	DMAN3BT
DMAN3BT	DN	PMID25522065-Compound-16
DMAN3BT	MI	TTX4RTB
DMAN3BT	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMAN3BT	MT	DTT
DMAN3BT	MA	Antagonist
DMAN3BT	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DMAN3BT	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DM7X6HR	DI	DM7X6HR
DM7X6HR	DN	PMID25522065-Compound-17
DM7X6HR	MI	TTX4RTB
DM7X6HR	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DM7X6HR	MT	DTT
DM7X6HR	MA	Antagonist
DM7X6HR	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DM7X6HR	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DMTPJI8	DI	DMTPJI8
DMTPJI8	DN	PMID25522065-Compound-18
DMTPJI8	MI	TTX4RTB
DMTPJI8	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMTPJI8	MT	DTT
DMTPJI8	MA	Antagonist
DMTPJI8	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DMTPJI8	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DMP4VYQ	DI	DMP4VYQ
DMP4VYQ	DN	PMID25522065-Compound-19
DMP4VYQ	MI	TTX4RTB
DMP4VYQ	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMP4VYQ	MT	DTT
DMP4VYQ	MA	Antagonist
DMP4VYQ	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DMP4VYQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DM3I6OF	DI	DM3I6OF
DM3I6OF	DN	PMID25522065-Compound-2
DM3I6OF	MI	TTX4RTB
DM3I6OF	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DM3I6OF	MT	DTT
DM3I6OF	MA	Antagonist
DM3I6OF	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DM3I6OF	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DMG5J9Z	DI	DMG5J9Z
DMG5J9Z	DN	PMID25522065-Compound-20
DMG5J9Z	MI	TTX4RTB
DMG5J9Z	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMG5J9Z	MT	DTT
DMG5J9Z	MA	Antagonist
DMG5J9Z	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DMG5J9Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DMRZMH5	DI	DMRZMH5
DMRZMH5	DN	PMID25522065-Compound-21
DMRZMH5	MI	TTX4RTB
DMRZMH5	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMRZMH5	MT	DTT
DMRZMH5	MA	Antagonist
DMRZMH5	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DMRZMH5	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DM1N5UH	DI	DM1N5UH
DM1N5UH	DN	PMID25522065-Compound-22
DM1N5UH	MI	TTX4RTB
DM1N5UH	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DM1N5UH	MT	DTT
DM1N5UH	MA	Antagonist
DM1N5UH	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DM1N5UH	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DMHSGPU	DI	DMHSGPU
DMHSGPU	DN	PMID25522065-Compound-23
DMHSGPU	MI	TTX4RTB
DMHSGPU	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMHSGPU	MT	DTT
DMHSGPU	MA	Antagonist
DMHSGPU	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DMHSGPU	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DM9MLQ6	DI	DM9MLQ6
DM9MLQ6	DN	PMID25522065-Compound-24
DM9MLQ6	MI	TTX4RTB
DM9MLQ6	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DM9MLQ6	MT	DTT
DM9MLQ6	MA	Antagonist
DM9MLQ6	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DM9MLQ6	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DMUM3YW	DI	DMUM3YW
DMUM3YW	DN	PMID25522065-Compound-25
DMUM3YW	MI	TTX4RTB
DMUM3YW	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMUM3YW	MT	DTT
DMUM3YW	MA	Antagonist
DMUM3YW	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DMUM3YW	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DMY07NA	DI	DMY07NA
DMY07NA	DN	PMID25522065-Compound-26
DMY07NA	MI	TTX4RTB
DMY07NA	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMY07NA	MT	DTT
DMY07NA	MA	Antagonist
DMY07NA	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DMY07NA	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DMXN4KB	DI	DMXN4KB
DMXN4KB	DN	PMID25522065-Compound-27
DMXN4KB	MI	TTX4RTB
DMXN4KB	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMXN4KB	MT	DTT
DMXN4KB	MA	Antagonist
DMXN4KB	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DMXN4KB	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DMB93QU	DI	DMB93QU
DMB93QU	DN	PMID25522065-Compound-28
DMB93QU	MI	TTX4RTB
DMB93QU	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMB93QU	MT	DTT
DMB93QU	MA	Antagonist
DMB93QU	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DMB93QU	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DMBNAK9	DI	DMBNAK9
DMBNAK9	DN	PMID25522065-Compound-29
DMBNAK9	MI	TTX4RTB
DMBNAK9	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMBNAK9	MT	DTT
DMBNAK9	MA	Antagonist
DMBNAK9	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DMBNAK9	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DM54DXT	DI	DM54DXT
DM54DXT	DN	PMID25522065-Compound-3
DM54DXT	MI	TTX4RTB
DM54DXT	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DM54DXT	MT	DTT
DM54DXT	MA	Antagonist
DM54DXT	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DM54DXT	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DMMOV67	DI	DMMOV67
DMMOV67	DN	PMID25522065-Compound-30
DMMOV67	MI	TTX4RTB
DMMOV67	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMMOV67	MT	DTT
DMMOV67	MA	Antagonist
DMMOV67	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DMMOV67	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DMEMBOW	DI	DMEMBOW
DMEMBOW	DN	PMID25522065-Compound-31
DMEMBOW	MI	TTX4RTB
DMEMBOW	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMEMBOW	MT	DTT
DMEMBOW	MA	Antagonist
DMEMBOW	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DMEMBOW	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DM5H3YA	DI	DM5H3YA
DM5H3YA	DN	PMID25522065-Compound-32
DM5H3YA	MI	TTX4RTB
DM5H3YA	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DM5H3YA	MT	DTT
DM5H3YA	MA	Antagonist
DM5H3YA	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DM5H3YA	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DMYMJIW	DI	DMYMJIW
DMYMJIW	DN	PMID25522065-Compound-33
DMYMJIW	MI	TTX4RTB
DMYMJIW	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMYMJIW	MT	DTT
DMYMJIW	MA	Antagonist
DMYMJIW	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DMYMJIW	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DMZDIRQ	DI	DMZDIRQ
DMZDIRQ	DN	PMID25522065-Compound-34
DMZDIRQ	MI	TTX4RTB
DMZDIRQ	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMZDIRQ	MT	DTT
DMZDIRQ	MA	Antagonist
DMZDIRQ	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DMZDIRQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DM1JAFV	DI	DM1JAFV
DM1JAFV	DN	PMID25522065-Compound-35
DM1JAFV	MI	TTX4RTB
DM1JAFV	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DM1JAFV	MT	DTT
DM1JAFV	MA	Antagonist
DM1JAFV	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DM1JAFV	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DMNISGE	DI	DMNISGE
DMNISGE	DN	PMID25522065-Compound-36
DMNISGE	MI	TTX4RTB
DMNISGE	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMNISGE	MT	DTT
DMNISGE	MA	Antagonist
DMNISGE	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DMNISGE	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DMH3CK0	DI	DMH3CK0
DMH3CK0	DN	PMID25522065-Compound-37
DMH3CK0	MI	TTX4RTB
DMH3CK0	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMH3CK0	MT	DTT
DMH3CK0	MA	Antagonist
DMH3CK0	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DMH3CK0	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DMQLBAJ	DI	DMQLBAJ
DMQLBAJ	DN	PMID25522065-Compound-38
DMQLBAJ	MI	TTX4RTB
DMQLBAJ	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMQLBAJ	MT	DTT
DMQLBAJ	MA	Antagonist
DMQLBAJ	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DMQLBAJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DM5YMQH	DI	DM5YMQH
DM5YMQH	DN	PMID25522065-Compound-39
DM5YMQH	MI	TTX4RTB
DM5YMQH	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DM5YMQH	MT	DTT
DM5YMQH	MA	Antagonist
DM5YMQH	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DM5YMQH	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DM84U7F	DI	DM84U7F
DM84U7F	DN	PMID25522065-Compound-4
DM84U7F	MI	TTX4RTB
DM84U7F	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DM84U7F	MT	DTT
DM84U7F	MA	Antagonist
DM84U7F	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DM84U7F	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DMCIQ01	DI	DMCIQ01
DMCIQ01	DN	PMID25522065-Compound-40
DMCIQ01	MI	TTX4RTB
DMCIQ01	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMCIQ01	MT	DTT
DMCIQ01	MA	Antagonist
DMCIQ01	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DMCIQ01	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DMWALOT	DI	DMWALOT
DMWALOT	DN	PMID25522065-Compound-41
DMWALOT	MI	TTX4RTB
DMWALOT	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMWALOT	MT	DTT
DMWALOT	MA	Antagonist
DMWALOT	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DMWALOT	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DMAUO6C	DI	DMAUO6C
DMAUO6C	DN	PMID25522065-Compound-42
DMAUO6C	MI	TTX4RTB
DMAUO6C	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMAUO6C	MT	DTT
DMAUO6C	MA	Antagonist
DMAUO6C	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DMAUO6C	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DMS1FKC	DI	DMS1FKC
DMS1FKC	DN	PMID25522065-Compound-43
DMS1FKC	MI	TTX4RTB
DMS1FKC	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMS1FKC	MT	DTT
DMS1FKC	MA	Antagonist
DMS1FKC	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DMS1FKC	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DMJKOFB	DI	DMJKOFB
DMJKOFB	DN	PMID25522065-Compound-44
DMJKOFB	MI	TTX4RTB
DMJKOFB	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMJKOFB	MT	DTT
DMJKOFB	MA	Antagonist
DMJKOFB	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DMJKOFB	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DMONJLT	DI	DMONJLT
DMONJLT	DN	PMID25522065-Compound-45
DMONJLT	MI	TTX4RTB
DMONJLT	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMONJLT	MT	DTT
DMONJLT	MA	Antagonist
DMONJLT	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DMONJLT	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DMBH97R	DI	DMBH97R
DMBH97R	DN	PMID25522065-Compound-46
DMBH97R	MI	TTX4RTB
DMBH97R	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMBH97R	MT	DTT
DMBH97R	MA	Antagonist
DMBH97R	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DMBH97R	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DMXRI5J	DI	DMXRI5J
DMXRI5J	DN	PMID25522065-Compound-47
DMXRI5J	MI	TTX4RTB
DMXRI5J	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMXRI5J	MT	DTT
DMXRI5J	MA	Antagonist
DMXRI5J	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DMXRI5J	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DMHI4L6	DI	DMHI4L6
DMHI4L6	DN	PMID25522065-Compound-48
DMHI4L6	MI	TTX4RTB
DMHI4L6	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMHI4L6	MT	DTT
DMHI4L6	MA	Antagonist
DMHI4L6	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DMHI4L6	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DMNI03Z	DI	DMNI03Z
DMNI03Z	DN	PMID25522065-Compound-49
DMNI03Z	MI	TTX4RTB
DMNI03Z	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMNI03Z	MT	DTT
DMNI03Z	MA	Antagonist
DMNI03Z	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DMNI03Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DMA8G6B	DI	DMA8G6B
DMA8G6B	DN	PMID25522065-Compound-5
DMA8G6B	MI	TTX4RTB
DMA8G6B	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMA8G6B	MT	DTT
DMA8G6B	MA	Antagonist
DMA8G6B	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DMA8G6B	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DMBWA0V	DI	DMBWA0V
DMBWA0V	DN	PMID25522065-Compound-50
DMBWA0V	MI	TTX4RTB
DMBWA0V	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMBWA0V	MT	DTT
DMBWA0V	MA	Antagonist
DMBWA0V	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DMBWA0V	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DMEU48I	DI	DMEU48I
DMEU48I	DN	PMID25522065-Compound-51
DMEU48I	MI	TTX4RTB
DMEU48I	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMEU48I	MT	DTT
DMEU48I	MA	Antagonist
DMEU48I	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DMEU48I	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DMU1PEZ	DI	DMU1PEZ
DMU1PEZ	DN	PMID25522065-Compound-6
DMU1PEZ	MI	TTX4RTB
DMU1PEZ	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMU1PEZ	MT	DTT
DMU1PEZ	MA	Antagonist
DMU1PEZ	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DMU1PEZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DMYZMX6	DI	DMYZMX6
DMYZMX6	DN	PMID25522065-Compound-7
DMYZMX6	MI	TTX4RTB
DMYZMX6	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMYZMX6	MT	DTT
DMYZMX6	MA	Antagonist
DMYZMX6	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DMYZMX6	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DMJMCKD	DI	DMJMCKD
DMJMCKD	DN	PMID25522065-Compound-8
DMJMCKD	MI	TTX4RTB
DMJMCKD	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMJMCKD	MT	DTT
DMJMCKD	MA	Antagonist
DMJMCKD	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DMJMCKD	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DMAMRPW	DI	DMAMRPW
DMAMRPW	DN	PMID25522065-Compound-9
DMAMRPW	MI	TTX4RTB
DMAMRPW	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMAMRPW	MT	DTT
DMAMRPW	MA	Antagonist
DMAMRPW	RN	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
DMAMRPW	RU	https://www.ncbi.nlm.nih.gov/pubmed/25522065

DM4GQJH	DI	DM4GQJH
DM4GQJH	DN	PMID25553724-Compound-EP20132578214 2
DM4GQJH	MI	TTSXVID
DM4GQJH	MN	Nuclear factor NF-kappa-B (NFKB)
DM4GQJH	MT	DTT
DM4GQJH	MA	Inhibitor
DM4GQJH	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DM4GQJH	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DMM3QEW	DI	DMM3QEW
DMM3QEW	DN	PMID25553724-Compound-US2011000295210
DMM3QEW	MI	TTSXVID
DMM3QEW	MN	Nuclear factor NF-kappa-B (NFKB)
DMM3QEW	MT	DTT
DMM3QEW	MA	Inhibitor
DMM3QEW	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DMM3QEW	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DMZCO6J	DI	DMZCO6J
DMZCO6J	DN	PMID25553724-Compound-US2011788838110
DMZCO6J	MI	TTSXVID
DMZCO6J	MN	Nuclear factor NF-kappa-B (NFKB)
DMZCO6J	MT	DTT
DMZCO6J	MA	Inhibitor
DMZCO6J	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DMZCO6J	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DMH4DMY	DI	DMH4DMY
DMH4DMY	DN	PMID25553724-Compound-US2011796857710
DMH4DMY	MI	TTSXVID
DMH4DMY	MN	Nuclear factor NF-kappa-B (NFKB)
DMH4DMY	MT	DTT
DMH4DMY	MA	Inhibitor
DMH4DMY	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DMH4DMY	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DMIZ64O	DI	DMIZ64O
DMIZ64O	DN	PMID25553724-Compound-US2011799419010
DMIZ64O	MI	TTSXVID
DMIZ64O	MN	Nuclear factor NF-kappa-B (NFKB)
DMIZ64O	MT	DTT
DMIZ64O	MA	Inhibitor
DMIZ64O	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DMIZ64O	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DMZ96CG	DI	DMZ96CG
DMZ96CG	DN	PMID25553724-Compound-US2011801300410
DMZ96CG	MI	TTSXVID
DMZ96CG	MN	Nuclear factor NF-kappa-B (NFKB)
DMZ96CG	MT	DTT
DMZ96CG	MA	Inhibitor
DMZ96CG	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DMZ96CG	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DMCDHZT	DI	DMCDHZT
DMCDHZT	DN	PMID25553724-Compound-US2011803494010
DMCDHZT	MI	TTSXVID
DMCDHZT	MN	Nuclear factor NF-kappa-B (NFKB)
DMCDHZT	MT	DTT
DMCDHZT	MA	Inhibitor
DMCDHZT	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DMCDHZT	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DMIAV5M	DI	DMIAV5M
DMIAV5M	DN	PMID25553724-Compound-US2011806744710
DMIAV5M	MI	TTSXVID
DMIAV5M	MN	Nuclear factor NF-kappa-B (NFKB)
DMIAV5M	MT	DTT
DMIAV5M	MA	Inhibitor
DMIAV5M	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DMIAV5M	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DM9KAF1	DI	DM9KAF1
DM9KAF1	DN	PMID25553724-Compound-US2012810604610
DM9KAF1	MI	TTSXVID
DM9KAF1	MN	Nuclear factor NF-kappa-B (NFKB)
DM9KAF1	MT	DTT
DM9KAF1	MA	Inhibitor
DM9KAF1	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DM9KAF1	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DMS7RYP	DI	DMS7RYP
DMS7RYP	DN	PMID25553724-Compound-US2012819831110
DMS7RYP	MI	TTSXVID
DMS7RYP	MN	Nuclear factor NF-kappa-B (NFKB)
DMS7RYP	MT	DTT
DMS7RYP	MA	Inhibitor
DMS7RYP	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DMS7RYP	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DMDQ6H7	DI	DMDQ6H7
DMDQ6H7	DN	PMID25553724-Compound-US2012820715110
DMDQ6H7	MI	TTSXVID
DMDQ6H7	MN	Nuclear factor NF-kappa-B (NFKB)
DMDQ6H7	MT	DTT
DMDQ6H7	MA	Inhibitor
DMDQ6H7	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DMDQ6H7	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DMCUMSV	DI	DMCUMSV
DMCUMSV	DN	PMID25553724-Compound-US2012830453910
DMCUMSV	MI	TTSXVID
DMCUMSV	MN	Nuclear factor NF-kappa-B (NFKB)
DMCUMSV	MT	DTT
DMCUMSV	MA	Inhibitor
DMCUMSV	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DMCUMSV	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DMFCE51	DI	DMFCE51
DMFCE51	DN	PMID25553724-Compound-US2012832440110
DMFCE51	MI	TTSXVID
DMFCE51	MN	Nuclear factor NF-kappa-B (NFKB)
DMFCE51	MT	DTT
DMFCE51	MA	Inhibitor
DMFCE51	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DMFCE51	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DMUBZO3	DI	DMUBZO3
DMUBZO3	DN	PMID25553724-Compound-US20130116324 2
DMUBZO3	MI	TTSXVID
DMUBZO3	MN	Nuclear factor NF-kappa-B (NFKB)
DMUBZO3	MT	DTT
DMUBZO3	MA	Inhibitor
DMUBZO3	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DMUBZO3	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DMYGB2O	DI	DMYGB2O
DMYGB2O	DN	PMID25553724-Compound-US20130237529 35
DMYGB2O	MI	TTBP3XA
DMYGB2O	MN	Polyubiquitin-C (UBC)
DMYGB2O	MT	DTT
DMYGB2O	MA	Inhibitor
DMYGB2O	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DMYGB2O	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DM9NGDI	DI	DM9NGDI
DM9NGDI	DN	PMID25553724-Compound-US20130237529 36
DM9NGDI	MI	TTBP3XA
DM9NGDI	MN	Polyubiquitin-C (UBC)
DM9NGDI	MT	DTT
DM9NGDI	MA	Inhibitor
DM9NGDI	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DM9NGDI	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DMV7SQH	DI	DMV7SQH
DMV7SQH	DN	PMID25553724-Compound-US20138552206 4
DMV7SQH	MI	TTSXVID
DMV7SQH	MN	Nuclear factor NF-kappa-B (NFKB)
DMV7SQH	MT	DTT
DMV7SQH	MA	Inhibitor
DMV7SQH	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DMV7SQH	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DMRVE7Z	DI	DMRVE7Z
DMRVE7Z	DN	PMID25553724-Compound-US20138552206 5
DMRVE7Z	MI	TTSXVID
DMRVE7Z	MN	Nuclear factor NF-kappa-B (NFKB)
DMRVE7Z	MT	DTT
DMRVE7Z	MA	Inhibitor
DMRVE7Z	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DMRVE7Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DM5ATIV	DI	DM5ATIV
DM5ATIV	DN	PMID25553724-Compound-WO2011127048 31
DM5ATIV	MI	TTSXVID
DM5ATIV	MN	Nuclear factor NF-kappa-B (NFKB)
DM5ATIV	MT	DTT
DM5ATIV	MA	Modulator
DM5ATIV	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DM5ATIV	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DMH3NOZ	DI	DMH3NOZ
DMH3NOZ	DN	PMID25553724-Compound-WO2011127048 32
DMH3NOZ	MI	TTSXVID
DMH3NOZ	MN	Nuclear factor NF-kappa-B (NFKB)
DMH3NOZ	MT	DTT
DMH3NOZ	MA	Modulator
DMH3NOZ	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DMH3NOZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DMH7496	DI	DMH7496
DMH7496	DN	PMID25553724-Compound-WO2011127048 33
DMH7496	MI	TTSXVID
DMH7496	MN	Nuclear factor NF-kappa-B (NFKB)
DMH7496	MT	DTT
DMH7496	MA	Modulator
DMH7496	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DMH7496	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DM4YE8W	DI	DM4YE8W
DM4YE8W	DN	PMID25553724-Compound-WO2011127048 34
DM4YE8W	MI	TTSXVID
DM4YE8W	MN	Nuclear factor NF-kappa-B (NFKB)
DM4YE8W	MT	DTT
DM4YE8W	MA	Modulator
DM4YE8W	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DM4YE8W	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DMPQ175	DI	DMPQ175
DMPQ175	DN	PMID25553724-Compound-WO2011152671 2
DMPQ175	MI	TTSXVID
DMPQ175	MN	Nuclear factor NF-kappa-B (NFKB)
DMPQ175	MT	DTT
DMPQ175	MA	Inhibitor
DMPQ175	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DMPQ175	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DMPFMSJ	DI	DMPFMSJ
DMPFMSJ	DN	PMID25553724-Compound-WO2013082253 31
DMPFMSJ	MI	TTSXVID
DMPFMSJ	MN	Nuclear factor NF-kappa-B (NFKB)
DMPFMSJ	MT	DTT
DMPFMSJ	MA	Modulator
DMPFMSJ	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DMPFMSJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DMXYSO1	DI	DMXYSO1
DMXYSO1	DN	PMID25553724-Compound-WO2013082253 32
DMXYSO1	MI	TTSXVID
DMXYSO1	MN	Nuclear factor NF-kappa-B (NFKB)
DMXYSO1	MT	DTT
DMXYSO1	MA	Modulator
DMXYSO1	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DMXYSO1	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DMR1YH9	DI	DMR1YH9
DMR1YH9	DN	PMID25553724-Compound-WO2013082253 33
DMR1YH9	MI	TTSXVID
DMR1YH9	MN	Nuclear factor NF-kappa-B (NFKB)
DMR1YH9	MT	DTT
DMR1YH9	MA	Modulator
DMR1YH9	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DMR1YH9	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DML1U69	DI	DML1U69
DML1U69	DN	PMID25553724-Compound-WO2013082253 34
DML1U69	MI	TTSXVID
DML1U69	MN	Nuclear factor NF-kappa-B (NFKB)
DML1U69	MT	DTT
DML1U69	MA	Modulator
DML1U69	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DML1U69	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DMA2IMQ	DI	DMA2IMQ
DMA2IMQ	DN	PMID25623274-Compound-WO2014132220C1
DMA2IMQ	MI	TTI2WET
DMA2IMQ	MN	Platelet-derived growth factor receptor (PDGFR)
DMA2IMQ	MT	DTT
DMA2IMQ	MA	Inhibitor
DMA2IMQ	RN	Evaluation of WO-2014132220, selective PDGFR inhibitors for the treatment of pulmonary arterial hypertension.Expert Opin Ther Pat. 2015 Apr;25(4):493-9.
DMA2IMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25623274

DMXEZWP	DI	DMXEZWP
DMXEZWP	DN	PMID25623274-Compound-WO2014132220C2
DMXEZWP	MI	TTI2WET
DMXEZWP	MN	Platelet-derived growth factor receptor (PDGFR)
DMXEZWP	MT	DTT
DMXEZWP	MA	Inhibitor
DMXEZWP	RN	Evaluation of WO-2014132220, selective PDGFR inhibitors for the treatment of pulmonary arterial hypertension.Expert Opin Ther Pat. 2015 Apr;25(4):493-9.
DMXEZWP	RU	https://www.ncbi.nlm.nih.gov/pubmed/25623274

DM8POGS	DI	DM8POGS
DM8POGS	DN	PMID25656651-Compound-10
DM8POGS	MI	TTS7G69
DM8POGS	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DM8POGS	MT	DTT
DM8POGS	MA	Inhibitor
DM8POGS	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DM8POGS	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DM5ECH2	DI	DM5ECH2
DM5ECH2	DN	PMID25656651-Compound-11a
DM5ECH2	MI	TTS7G69
DM5ECH2	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DM5ECH2	MT	DTT
DM5ECH2	MA	Inhibitor
DM5ECH2	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DM5ECH2	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMP580J	DI	DMP580J
DMP580J	DN	PMID25656651-Compound-11b
DMP580J	MI	TTS7G69
DMP580J	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMP580J	MT	DTT
DMP580J	MA	Inhibitor
DMP580J	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMP580J	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMAYINQ	DI	DMAYINQ
DMAYINQ	DN	PMID25656651-Compound-11c
DMAYINQ	MI	TTS7G69
DMAYINQ	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMAYINQ	MT	DTT
DMAYINQ	MA	Inhibitor
DMAYINQ	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMAYINQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DM0C9YL	DI	DM0C9YL
DM0C9YL	DN	PMID25656651-Compound-15a
DM0C9YL	MI	TTS7G69
DM0C9YL	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DM0C9YL	MT	DTT
DM0C9YL	MA	Inhibitor
DM0C9YL	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DM0C9YL	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMJ4DRI	DI	DMJ4DRI
DMJ4DRI	DN	PMID25656651-Compound-15b
DMJ4DRI	MI	TTS7G69
DMJ4DRI	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMJ4DRI	MT	DTT
DMJ4DRI	MA	Inhibitor
DMJ4DRI	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMJ4DRI	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMNK2DQ	DI	DMNK2DQ
DMNK2DQ	DN	PMID25656651-Compound-15c
DMNK2DQ	MI	TTS7G69
DMNK2DQ	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMNK2DQ	MT	DTT
DMNK2DQ	MA	Inhibitor
DMNK2DQ	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMNK2DQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DM9XRYU	DI	DM9XRYU
DM9XRYU	DN	PMID25656651-Compound-16a
DM9XRYU	MI	TTS7G69
DM9XRYU	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DM9XRYU	MT	DTT
DM9XRYU	MA	Inhibitor
DM9XRYU	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DM9XRYU	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DM5EHK2	DI	DM5EHK2
DM5EHK2	DN	PMID25656651-Compound-16b
DM5EHK2	MI	TTS7G69
DM5EHK2	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DM5EHK2	MT	DTT
DM5EHK2	MA	Inhibitor
DM5EHK2	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DM5EHK2	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMAIVEN	DI	DMAIVEN
DMAIVEN	DN	PMID25656651-Compound-18
DMAIVEN	MI	TTS7G69
DMAIVEN	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMAIVEN	MT	DTT
DMAIVEN	MA	Inhibitor
DMAIVEN	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMAIVEN	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMSNUVZ	DI	DMSNUVZ
DMSNUVZ	DN	PMID25656651-Compound-19a
DMSNUVZ	MI	TTS7G69
DMSNUVZ	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMSNUVZ	MT	DTT
DMSNUVZ	MA	Inhibitor
DMSNUVZ	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMSNUVZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMSNUVZ	DI	DMSNUVZ
DMSNUVZ	DN	PMID25656651-Compound-19a
DMSNUVZ	MI	TTIV39N
DMSNUVZ	MN	Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I)
DMSNUVZ	MT	DTT
DMSNUVZ	MA	Inhibitor
DMSNUVZ	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMSNUVZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMI1Z7D	DI	DMI1Z7D
DMI1Z7D	DN	PMID25656651-Compound-19b
DMI1Z7D	MI	TTS7G69
DMI1Z7D	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMI1Z7D	MT	DTT
DMI1Z7D	MA	Inhibitor
DMI1Z7D	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMI1Z7D	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMI1Z7D	DI	DMI1Z7D
DMI1Z7D	DN	PMID25656651-Compound-19b
DMI1Z7D	MI	TTIV39N
DMI1Z7D	MN	Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I)
DMI1Z7D	MT	DTT
DMI1Z7D	MA	Inhibitor
DMI1Z7D	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMI1Z7D	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DM7R2X0	DI	DM7R2X0
DM7R2X0	DN	PMID25656651-Compound-20a
DM7R2X0	MI	TTS7G69
DM7R2X0	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DM7R2X0	MT	DTT
DM7R2X0	MA	Inhibitor
DM7R2X0	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DM7R2X0	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMLUFB2	DI	DMLUFB2
DMLUFB2	DN	PMID25656651-Compound-20b
DMLUFB2	MI	TTS7G69
DMLUFB2	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMLUFB2	MT	DTT
DMLUFB2	MA	Inhibitor
DMLUFB2	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMLUFB2	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMCKAON	DI	DMCKAON
DMCKAON	DN	PMID25656651-Compound-21a
DMCKAON	MI	TTS7G69
DMCKAON	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMCKAON	MT	DTT
DMCKAON	MA	Inhibitor
DMCKAON	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMCKAON	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMCKAON	DI	DMCKAON
DMCKAON	DN	PMID25656651-Compound-21a
DMCKAON	MI	TTI7421
DMCKAON	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMCKAON	MT	DTT
DMCKAON	MA	Inhibitor
DMCKAON	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMCKAON	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMCKAON	DI	DMCKAON
DMCKAON	DN	PMID25656651-Compound-21a
DMCKAON	MI	TTX41N9
DMCKAON	MN	Tyrosine-protein kinase Kit (KIT)
DMCKAON	MT	DTT
DMCKAON	MA	Inhibitor
DMCKAON	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMCKAON	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMVABXI	DI	DMVABXI
DMVABXI	DN	PMID25656651-Compound-21b
DMVABXI	MI	TTS7G69
DMVABXI	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMVABXI	MT	DTT
DMVABXI	MA	Inhibitor
DMVABXI	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMVABXI	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMVABXI	DI	DMVABXI
DMVABXI	DN	PMID25656651-Compound-21b
DMVABXI	MI	TTI7421
DMVABXI	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMVABXI	MT	DTT
DMVABXI	MA	Inhibitor
DMVABXI	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMVABXI	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMVABXI	DI	DMVABXI
DMVABXI	DN	PMID25656651-Compound-21b
DMVABXI	MI	TTX41N9
DMVABXI	MN	Tyrosine-protein kinase Kit (KIT)
DMVABXI	MT	DTT
DMVABXI	MA	Inhibitor
DMVABXI	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMVABXI	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMZUB3D	DI	DMZUB3D
DMZUB3D	DN	PMID25656651-Compound-23a
DMZUB3D	MI	TTS7G69
DMZUB3D	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMZUB3D	MT	DTT
DMZUB3D	MA	Inhibitor
DMZUB3D	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMZUB3D	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMTOFGH	DI	DMTOFGH
DMTOFGH	DN	PMID25656651-Compound-23b
DMTOFGH	MI	TTS7G69
DMTOFGH	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMTOFGH	MT	DTT
DMTOFGH	MA	Inhibitor
DMTOFGH	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMTOFGH	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMLTR9E	DI	DMLTR9E
DMLTR9E	DN	PMID25656651-Compound-23c
DMLTR9E	MI	TTS7G69
DMLTR9E	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMLTR9E	MT	DTT
DMLTR9E	MA	Inhibitor
DMLTR9E	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMLTR9E	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMAYSNQ	DI	DMAYSNQ
DMAYSNQ	DN	PMID25656651-Compound-25
DMAYSNQ	MI	TTS7G69
DMAYSNQ	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMAYSNQ	MT	DTT
DMAYSNQ	MA	Inhibitor
DMAYSNQ	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMAYSNQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMXM98J	DI	DMXM98J
DMXM98J	DN	PMID25656651-Compound-26a
DMXM98J	MI	TTS7G69
DMXM98J	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMXM98J	MT	DTT
DMXM98J	MA	Inhibitor
DMXM98J	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMXM98J	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMWG95Z	DI	DMWG95Z
DMWG95Z	DN	PMID25656651-Compound-26b
DMWG95Z	MI	TTS7G69
DMWG95Z	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMWG95Z	MT	DTT
DMWG95Z	MA	Inhibitor
DMWG95Z	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMWG95Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMR7A58	DI	DMR7A58
DMR7A58	DN	PMID25656651-Compound-26c
DMR7A58	MI	TTS7G69
DMR7A58	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMR7A58	MT	DTT
DMR7A58	MA	Inhibitor
DMR7A58	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMR7A58	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMXK43O	DI	DMXK43O
DMXK43O	DN	PMID25656651-Compound-27
DMXK43O	MI	TTS7G69
DMXK43O	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMXK43O	MT	DTT
DMXK43O	MA	Inhibitor
DMXK43O	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMXK43O	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DM06LDV	DI	DM06LDV
DM06LDV	DN	PMID25656651-Compound-28a
DM06LDV	MI	TT3PJMV
DM06LDV	MN	Tyrosine-protein kinase ABL1 (ABL)
DM06LDV	MT	DTT
DM06LDV	MA	Inhibitor
DM06LDV	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DM06LDV	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMKB7XV	DI	DMKB7XV
DMKB7XV	DN	PMID25656651-Compound-28b
DMKB7XV	MI	TT3PJMV
DMKB7XV	MN	Tyrosine-protein kinase ABL1 (ABL)
DMKB7XV	MT	DTT
DMKB7XV	MA	Inhibitor
DMKB7XV	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMKB7XV	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMCEST4	DI	DMCEST4
DMCEST4	DN	PMID25656651-Compound-29a
DMCEST4	MI	TTS7G69
DMCEST4	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMCEST4	MT	DTT
DMCEST4	MA	Inhibitor
DMCEST4	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMCEST4	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMBKRY7	DI	DMBKRY7
DMBKRY7	DN	PMID25656651-Compound-29b
DMBKRY7	MI	TTS7G69
DMBKRY7	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMBKRY7	MT	DTT
DMBKRY7	MA	Inhibitor
DMBKRY7	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMBKRY7	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMVMSQ2	DI	DMVMSQ2
DMVMSQ2	DN	PMID25656651-Compound-30a
DMVMSQ2	MI	TTS7G69
DMVMSQ2	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMVMSQ2	MT	DTT
DMVMSQ2	MA	Inhibitor
DMVMSQ2	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMVMSQ2	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMEJMPD	DI	DMEJMPD
DMEJMPD	DN	PMID25656651-Compound-30b
DMEJMPD	MI	TTS7G69
DMEJMPD	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMEJMPD	MT	DTT
DMEJMPD	MA	Inhibitor
DMEJMPD	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMEJMPD	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMSVQMO	DI	DMSVQMO
DMSVQMO	DN	PMID25656651-Compound-31a
DMSVQMO	MI	TTIV39N
DMSVQMO	MN	Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I)
DMSVQMO	MT	DTT
DMSVQMO	MA	Inhibitor
DMSVQMO	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMSVQMO	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DM6TGUR	DI	DM6TGUR
DM6TGUR	DN	PMID25656651-Compound-31b
DM6TGUR	MI	TTIV39N
DM6TGUR	MN	Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I)
DM6TGUR	MT	DTT
DM6TGUR	MA	Inhibitor
DM6TGUR	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DM6TGUR	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMDJGPC	DI	DMDJGPC
DMDJGPC	DN	PMID25656651-Compound-31c
DMDJGPC	MI	TTIV39N
DMDJGPC	MN	Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I)
DMDJGPC	MT	DTT
DMDJGPC	MA	Inhibitor
DMDJGPC	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMDJGPC	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMCRA2U	DI	DMCRA2U
DMCRA2U	DN	PMID25656651-Compound-33a
DMCRA2U	MI	TT3PJMV
DMCRA2U	MN	Tyrosine-protein kinase ABL1 (ABL)
DMCRA2U	MT	DTT
DMCRA2U	MA	Inhibitor
DMCRA2U	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMCRA2U	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMU8ZI3	DI	DMU8ZI3
DMU8ZI3	DN	PMID25656651-Compound-33b
DMU8ZI3	MI	TT3PJMV
DMU8ZI3	MN	Tyrosine-protein kinase ABL1 (ABL)
DMU8ZI3	MT	DTT
DMU8ZI3	MA	Inhibitor
DMU8ZI3	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMU8ZI3	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMWOR8B	DI	DMWOR8B
DMWOR8B	DN	PMID25656651-Compound-34a
DMWOR8B	MI	TT3PJMV
DMWOR8B	MN	Tyrosine-protein kinase ABL1 (ABL)
DMWOR8B	MT	DTT
DMWOR8B	MA	Inhibitor
DMWOR8B	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMWOR8B	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMBD706	DI	DMBD706
DMBD706	DN	PMID25656651-Compound-34b
DMBD706	MI	TT3PJMV
DMBD706	MN	Tyrosine-protein kinase ABL1 (ABL)
DMBD706	MT	DTT
DMBD706	MA	Inhibitor
DMBD706	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMBD706	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMG5I41	DI	DMG5I41
DMG5I41	DN	PMID25656651-Compound-34c
DMG5I41	MI	TT3PJMV
DMG5I41	MN	Tyrosine-protein kinase ABL1 (ABL)
DMG5I41	MT	DTT
DMG5I41	MA	Inhibitor
DMG5I41	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMG5I41	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMNXVY9	DI	DMNXVY9
DMNXVY9	DN	PMID25656651-Compound-36a
DMNXVY9	MI	TTS7G69
DMNXVY9	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMNXVY9	MT	DTT
DMNXVY9	MA	Inhibitor
DMNXVY9	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMNXVY9	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMNXVY9	DI	DMNXVY9
DMNXVY9	DN	PMID25656651-Compound-36a
DMNXVY9	MI	TTIV39N
DMNXVY9	MN	Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I)
DMNXVY9	MT	DTT
DMNXVY9	MA	Inhibitor
DMNXVY9	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMNXVY9	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMHYDM7	DI	DMHYDM7
DMHYDM7	DN	PMID25656651-Compound-36b
DMHYDM7	MI	TTS7G69
DMHYDM7	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMHYDM7	MT	DTT
DMHYDM7	MA	Inhibitor
DMHYDM7	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMHYDM7	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMHYDM7	DI	DMHYDM7
DMHYDM7	DN	PMID25656651-Compound-36b
DMHYDM7	MI	TTIV39N
DMHYDM7	MN	Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I)
DMHYDM7	MT	DTT
DMHYDM7	MA	Inhibitor
DMHYDM7	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMHYDM7	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMOGKSW	DI	DMOGKSW
DMOGKSW	DN	PMID25656651-Compound-36c
DMOGKSW	MI	TTS7G69
DMOGKSW	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMOGKSW	MT	DTT
DMOGKSW	MA	Inhibitor
DMOGKSW	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMOGKSW	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMOGKSW	DI	DMOGKSW
DMOGKSW	DN	PMID25656651-Compound-36c
DMOGKSW	MI	TTIV39N
DMOGKSW	MN	Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I)
DMOGKSW	MT	DTT
DMOGKSW	MA	Inhibitor
DMOGKSW	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMOGKSW	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMKMY4I	DI	DMKMY4I
DMKMY4I	DN	PMID25656651-Compound-36d
DMKMY4I	MI	TTS7G69
DMKMY4I	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMKMY4I	MT	DTT
DMKMY4I	MA	Inhibitor
DMKMY4I	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMKMY4I	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMKMY4I	DI	DMKMY4I
DMKMY4I	DN	PMID25656651-Compound-36d
DMKMY4I	MI	TTIV39N
DMKMY4I	MN	Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I)
DMKMY4I	MT	DTT
DMKMY4I	MA	Inhibitor
DMKMY4I	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMKMY4I	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DM0P4F3	DI	DM0P4F3
DM0P4F3	DN	PMID25656651-Compound-37a
DM0P4F3	MI	TTS7G69
DM0P4F3	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DM0P4F3	MT	DTT
DM0P4F3	MA	Inhibitor
DM0P4F3	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DM0P4F3	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DM0P4F3	DI	DM0P4F3
DM0P4F3	DN	PMID25656651-Compound-37a
DM0P4F3	MI	TTIV39N
DM0P4F3	MN	Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I)
DM0P4F3	MT	DTT
DM0P4F3	MA	Inhibitor
DM0P4F3	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DM0P4F3	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMX98YV	DI	DMX98YV
DMX98YV	DN	PMID25656651-Compound-37b
DMX98YV	MI	TTS7G69
DMX98YV	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMX98YV	MT	DTT
DMX98YV	MA	Inhibitor
DMX98YV	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMX98YV	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMX98YV	DI	DMX98YV
DMX98YV	DN	PMID25656651-Compound-37b
DMX98YV	MI	TTIV39N
DMX98YV	MN	Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I)
DMX98YV	MT	DTT
DMX98YV	MA	Inhibitor
DMX98YV	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMX98YV	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DM684IK	DI	DM684IK
DM684IK	DN	PMID25656651-Compound-37c
DM684IK	MI	TTS7G69
DM684IK	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DM684IK	MT	DTT
DM684IK	MA	Inhibitor
DM684IK	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DM684IK	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DM684IK	DI	DM684IK
DM684IK	DN	PMID25656651-Compound-37c
DM684IK	MI	TTIV39N
DM684IK	MN	Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I)
DM684IK	MT	DTT
DM684IK	MA	Inhibitor
DM684IK	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DM684IK	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMECOY7	DI	DMECOY7
DMECOY7	DN	PMID25656651-Compound-38
DMECOY7	MI	TTS7G69
DMECOY7	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMECOY7	MT	DTT
DMECOY7	MA	Inhibitor
DMECOY7	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMECOY7	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMLGD52	DI	DMLGD52
DMLGD52	DN	PMID25656651-Compound-40
DMLGD52	MI	TTS7G69
DMLGD52	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMLGD52	MT	DTT
DMLGD52	MA	Inhibitor
DMLGD52	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMLGD52	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMTUA6E	DI	DMTUA6E
DMTUA6E	DN	PMID25656651-Compound-42
DMTUA6E	MI	TTZJTWA
DMTUA6E	MN	ABL T315I mutant (ABL T315I)
DMTUA6E	MT	DTT
DMTUA6E	MA	Inhibitor
DMTUA6E	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMTUA6E	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMTUA6E	DI	DMTUA6E
DMTUA6E	DN	PMID25656651-Compound-42
DMTUA6E	MI	TT3PJMV
DMTUA6E	MN	Tyrosine-protein kinase ABL1 (ABL)
DMTUA6E	MT	DTT
DMTUA6E	MA	Inhibitor
DMTUA6E	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMTUA6E	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DM7XQUT	DI	DM7XQUT
DM7XQUT	DN	PMID25656651-Compound-46
DM7XQUT	MI	TT3PJMV
DM7XQUT	MN	Tyrosine-protein kinase ABL1 (ABL)
DM7XQUT	MT	DTT
DM7XQUT	MA	Inhibitor
DM7XQUT	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DM7XQUT	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMAI95U	DI	DMAI95U
DMAI95U	DN	PMID25656651-Compound-5
DMAI95U	MI	TTS7G69
DMAI95U	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMAI95U	MT	DTT
DMAI95U	MA	Inhibitor
DMAI95U	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMAI95U	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMK3TMD	DI	DMK3TMD
DMK3TMD	DN	PMID25656651-Compound-7
DMK3TMD	MI	TTS7G69
DMK3TMD	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMK3TMD	MT	DTT
DMK3TMD	MA	Inhibitor
DMK3TMD	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMK3TMD	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMEL1WX	DI	DMEL1WX
DMEL1WX	DN	PMID25666693-Compound-1
DMEL1WX	MI	TTMI6F5
DMEL1WX	MN	Transient receptor potential cation channel V1 (TRPV1)
DMEL1WX	MT	DTT
DMEL1WX	MA	Antagonist
DMEL1WX	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMEL1WX	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMQP3TD	DI	DMQP3TD
DMQP3TD	DN	PMID25666693-Compound-10
DMQP3TD	MI	TTMI6F5
DMQP3TD	MN	Transient receptor potential cation channel V1 (TRPV1)
DMQP3TD	MT	DTT
DMQP3TD	MA	Antagonist
DMQP3TD	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMQP3TD	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMYTZFP	DI	DMYTZFP
DMYTZFP	DN	PMID25666693-Compound-100
DMYTZFP	MI	TTMI6F5
DMYTZFP	MN	Transient receptor potential cation channel V1 (TRPV1)
DMYTZFP	MT	DTT
DMYTZFP	MA	Antagonist
DMYTZFP	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMYTZFP	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMNOD4A	DI	DMNOD4A
DMNOD4A	DN	PMID25666693-Compound-101
DMNOD4A	MI	TTMI6F5
DMNOD4A	MN	Transient receptor potential cation channel V1 (TRPV1)
DMNOD4A	MT	DTT
DMNOD4A	MA	Antagonist
DMNOD4A	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMNOD4A	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM0OY5D	DI	DM0OY5D
DM0OY5D	DN	PMID25666693-Compound-102
DM0OY5D	MI	TTMI6F5
DM0OY5D	MN	Transient receptor potential cation channel V1 (TRPV1)
DM0OY5D	MT	DTT
DM0OY5D	MA	Antagonist
DM0OY5D	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM0OY5D	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM8DZA6	DI	DM8DZA6
DM8DZA6	DN	PMID25666693-Compound-103
DM8DZA6	MI	TTMI6F5
DM8DZA6	MN	Transient receptor potential cation channel V1 (TRPV1)
DM8DZA6	MT	DTT
DM8DZA6	MA	Antagonist
DM8DZA6	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM8DZA6	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMYCT5B	DI	DMYCT5B
DMYCT5B	DN	PMID25666693-Compound-104
DMYCT5B	MI	TTMI6F5
DMYCT5B	MN	Transient receptor potential cation channel V1 (TRPV1)
DMYCT5B	MT	DTT
DMYCT5B	MA	Antagonist
DMYCT5B	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMYCT5B	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMV509A	DI	DMV509A
DMV509A	DN	PMID25666693-Compound-105
DMV509A	MI	TTMI6F5
DMV509A	MN	Transient receptor potential cation channel V1 (TRPV1)
DMV509A	MT	DTT
DMV509A	MA	Antagonist
DMV509A	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMV509A	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMEG8CB	DI	DMEG8CB
DMEG8CB	DN	PMID25666693-Compound-106
DMEG8CB	MI	TTMI6F5
DMEG8CB	MN	Transient receptor potential cation channel V1 (TRPV1)
DMEG8CB	MT	DTT
DMEG8CB	MA	Antagonist
DMEG8CB	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMEG8CB	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMB2RML	DI	DMB2RML
DMB2RML	DN	PMID25666693-Compound-107
DMB2RML	MI	TTMI6F5
DMB2RML	MN	Transient receptor potential cation channel V1 (TRPV1)
DMB2RML	MT	DTT
DMB2RML	MA	Antagonist
DMB2RML	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMB2RML	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMN0FCA	DI	DMN0FCA
DMN0FCA	DN	PMID25666693-Compound-108
DMN0FCA	MI	TTMI6F5
DMN0FCA	MN	Transient receptor potential cation channel V1 (TRPV1)
DMN0FCA	MT	DTT
DMN0FCA	MA	Antagonist
DMN0FCA	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMN0FCA	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMWGIS7	DI	DMWGIS7
DMWGIS7	DN	PMID25666693-Compound-109
DMWGIS7	MI	TTMI6F5
DMWGIS7	MN	Transient receptor potential cation channel V1 (TRPV1)
DMWGIS7	MT	DTT
DMWGIS7	MA	Antagonist
DMWGIS7	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMWGIS7	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM9HOM6	DI	DM9HOM6
DM9HOM6	DN	PMID25666693-Compound-11
DM9HOM6	MI	TTMI6F5
DM9HOM6	MN	Transient receptor potential cation channel V1 (TRPV1)
DM9HOM6	MT	DTT
DM9HOM6	MA	Antagonist
DM9HOM6	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM9HOM6	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMNGD2S	DI	DMNGD2S
DMNGD2S	DN	PMID25666693-Compound-110
DMNGD2S	MI	TTMI6F5
DMNGD2S	MN	Transient receptor potential cation channel V1 (TRPV1)
DMNGD2S	MT	DTT
DMNGD2S	MA	Antagonist
DMNGD2S	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMNGD2S	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMNKW1E	DI	DMNKW1E
DMNKW1E	DN	PMID25666693-Compound-111
DMNKW1E	MI	TTMI6F5
DMNKW1E	MN	Transient receptor potential cation channel V1 (TRPV1)
DMNKW1E	MT	DTT
DMNKW1E	MA	Antagonist
DMNKW1E	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMNKW1E	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMQOSH5	DI	DMQOSH5
DMQOSH5	DN	PMID25666693-Compound-112
DMQOSH5	MI	TTMI6F5
DMQOSH5	MN	Transient receptor potential cation channel V1 (TRPV1)
DMQOSH5	MT	DTT
DMQOSH5	MA	Antagonist
DMQOSH5	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMQOSH5	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM02O5V	DI	DM02O5V
DM02O5V	DN	PMID25666693-Compound-113
DM02O5V	MI	TTMI6F5
DM02O5V	MN	Transient receptor potential cation channel V1 (TRPV1)
DM02O5V	MT	DTT
DM02O5V	MA	Antagonist
DM02O5V	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM02O5V	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMA9YDK	DI	DMA9YDK
DMA9YDK	DN	PMID25666693-Compound-114
DMA9YDK	MI	TTMI6F5
DMA9YDK	MN	Transient receptor potential cation channel V1 (TRPV1)
DMA9YDK	MT	DTT
DMA9YDK	MA	Antagonist
DMA9YDK	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMA9YDK	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMF5ODZ	DI	DMF5ODZ
DMF5ODZ	DN	PMID25666693-Compound-115
DMF5ODZ	MI	TTMI6F5
DMF5ODZ	MN	Transient receptor potential cation channel V1 (TRPV1)
DMF5ODZ	MT	DTT
DMF5ODZ	MA	Antagonist
DMF5ODZ	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMF5ODZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMNEBXL	DI	DMNEBXL
DMNEBXL	DN	PMID25666693-Compound-116
DMNEBXL	MI	TTMI6F5
DMNEBXL	MN	Transient receptor potential cation channel V1 (TRPV1)
DMNEBXL	MT	DTT
DMNEBXL	MA	Antagonist
DMNEBXL	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMNEBXL	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMN9LDH	DI	DMN9LDH
DMN9LDH	DN	PMID25666693-Compound-117
DMN9LDH	MI	TTMI6F5
DMN9LDH	MN	Transient receptor potential cation channel V1 (TRPV1)
DMN9LDH	MT	DTT
DMN9LDH	MA	Antagonist
DMN9LDH	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMN9LDH	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMBIQMS	DI	DMBIQMS
DMBIQMS	DN	PMID25666693-Compound-118
DMBIQMS	MI	TTMI6F5
DMBIQMS	MN	Transient receptor potential cation channel V1 (TRPV1)
DMBIQMS	MT	DTT
DMBIQMS	MA	Antagonist
DMBIQMS	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMBIQMS	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMD0WIA	DI	DMD0WIA
DMD0WIA	DN	PMID25666693-Compound-119
DMD0WIA	MI	TTMI6F5
DMD0WIA	MN	Transient receptor potential cation channel V1 (TRPV1)
DMD0WIA	MT	DTT
DMD0WIA	MA	Antagonist
DMD0WIA	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMD0WIA	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMVSFNE	DI	DMVSFNE
DMVSFNE	DN	PMID25666693-Compound-12
DMVSFNE	MI	TTMI6F5
DMVSFNE	MN	Transient receptor potential cation channel V1 (TRPV1)
DMVSFNE	MT	DTT
DMVSFNE	MA	Antagonist
DMVSFNE	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMVSFNE	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMVREIM	DI	DMVREIM
DMVREIM	DN	PMID25666693-Compound-120
DMVREIM	MI	TTMI6F5
DMVREIM	MN	Transient receptor potential cation channel V1 (TRPV1)
DMVREIM	MT	DTT
DMVREIM	MA	Antagonist
DMVREIM	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMVREIM	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMC1QDB	DI	DMC1QDB
DMC1QDB	DN	PMID25666693-Compound-121
DMC1QDB	MI	TTMI6F5
DMC1QDB	MN	Transient receptor potential cation channel V1 (TRPV1)
DMC1QDB	MT	DTT
DMC1QDB	MA	Antagonist
DMC1QDB	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMC1QDB	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMR63O2	DI	DMR63O2
DMR63O2	DN	PMID25666693-Compound-122
DMR63O2	MI	TTMI6F5
DMR63O2	MN	Transient receptor potential cation channel V1 (TRPV1)
DMR63O2	MT	DTT
DMR63O2	MA	Antagonist
DMR63O2	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMR63O2	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM9358G	DI	DM9358G
DM9358G	DN	PMID25666693-Compound-123
DM9358G	MI	TTMI6F5
DM9358G	MN	Transient receptor potential cation channel V1 (TRPV1)
DM9358G	MT	DTT
DM9358G	MA	Antagonist
DM9358G	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM9358G	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM6ODU7	DI	DM6ODU7
DM6ODU7	DN	PMID25666693-Compound-124
DM6ODU7	MI	TTMI6F5
DM6ODU7	MN	Transient receptor potential cation channel V1 (TRPV1)
DM6ODU7	MT	DTT
DM6ODU7	MA	Antagonist
DM6ODU7	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM6ODU7	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMR0WM1	DI	DMR0WM1
DMR0WM1	DN	PMID25666693-Compound-125
DMR0WM1	MI	TTMI6F5
DMR0WM1	MN	Transient receptor potential cation channel V1 (TRPV1)
DMR0WM1	MT	DTT
DMR0WM1	MA	Antagonist
DMR0WM1	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMR0WM1	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMKN72Y	DI	DMKN72Y
DMKN72Y	DN	PMID25666693-Compound-126
DMKN72Y	MI	TTMI6F5
DMKN72Y	MN	Transient receptor potential cation channel V1 (TRPV1)
DMKN72Y	MT	DTT
DMKN72Y	MA	Antagonist
DMKN72Y	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMKN72Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMCE6MB	DI	DMCE6MB
DMCE6MB	DN	PMID25666693-Compound-127
DMCE6MB	MI	TTMI6F5
DMCE6MB	MN	Transient receptor potential cation channel V1 (TRPV1)
DMCE6MB	MT	DTT
DMCE6MB	MA	Antagonist
DMCE6MB	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMCE6MB	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM6QHGV	DI	DM6QHGV
DM6QHGV	DN	PMID25666693-Compound-128
DM6QHGV	MI	TTMI6F5
DM6QHGV	MN	Transient receptor potential cation channel V1 (TRPV1)
DM6QHGV	MT	DTT
DM6QHGV	MA	Antagonist
DM6QHGV	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM6QHGV	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM74NBY	DI	DM74NBY
DM74NBY	DN	PMID25666693-Compound-129
DM74NBY	MI	TTMI6F5
DM74NBY	MN	Transient receptor potential cation channel V1 (TRPV1)
DM74NBY	MT	DTT
DM74NBY	MA	Antagonist
DM74NBY	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM74NBY	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMI0YWU	DI	DMI0YWU
DMI0YWU	DN	PMID25666693-Compound-13
DMI0YWU	MI	TTMI6F5
DMI0YWU	MN	Transient receptor potential cation channel V1 (TRPV1)
DMI0YWU	MT	DTT
DMI0YWU	MA	Antagonist
DMI0YWU	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMI0YWU	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMIX1K0	DI	DMIX1K0
DMIX1K0	DN	PMID25666693-Compound-130
DMIX1K0	MI	TTMI6F5
DMIX1K0	MN	Transient receptor potential cation channel V1 (TRPV1)
DMIX1K0	MT	DTT
DMIX1K0	MA	Antagonist
DMIX1K0	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMIX1K0	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DML7SYH	DI	DML7SYH
DML7SYH	DN	PMID25666693-Compound-131
DML7SYH	MI	TTMI6F5
DML7SYH	MN	Transient receptor potential cation channel V1 (TRPV1)
DML7SYH	MT	DTT
DML7SYH	MA	Antagonist
DML7SYH	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DML7SYH	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMHQM8W	DI	DMHQM8W
DMHQM8W	DN	PMID25666693-Compound-132
DMHQM8W	MI	TTMI6F5
DMHQM8W	MN	Transient receptor potential cation channel V1 (TRPV1)
DMHQM8W	MT	DTT
DMHQM8W	MA	Antagonist
DMHQM8W	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMHQM8W	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMHEPR3	DI	DMHEPR3
DMHEPR3	DN	PMID25666693-Compound-133
DMHEPR3	MI	TTMI6F5
DMHEPR3	MN	Transient receptor potential cation channel V1 (TRPV1)
DMHEPR3	MT	DTT
DMHEPR3	MA	Antagonist
DMHEPR3	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMHEPR3	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM2WJKR	DI	DM2WJKR
DM2WJKR	DN	PMID25666693-Compound-134
DM2WJKR	MI	TTMI6F5
DM2WJKR	MN	Transient receptor potential cation channel V1 (TRPV1)
DM2WJKR	MT	DTT
DM2WJKR	MA	Antagonist
DM2WJKR	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM2WJKR	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMYZVPD	DI	DMYZVPD
DMYZVPD	DN	PMID25666693-Compound-135
DMYZVPD	MI	TTMI6F5
DMYZVPD	MN	Transient receptor potential cation channel V1 (TRPV1)
DMYZVPD	MT	DTT
DMYZVPD	MA	Antagonist
DMYZVPD	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMYZVPD	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMPY1QC	DI	DMPY1QC
DMPY1QC	DN	PMID25666693-Compound-136
DMPY1QC	MI	TTMI6F5
DMPY1QC	MN	Transient receptor potential cation channel V1 (TRPV1)
DMPY1QC	MT	DTT
DMPY1QC	MA	Antagonist
DMPY1QC	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMPY1QC	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMZ7LAO	DI	DMZ7LAO
DMZ7LAO	DN	PMID25666693-Compound-137
DMZ7LAO	MI	TTMI6F5
DMZ7LAO	MN	Transient receptor potential cation channel V1 (TRPV1)
DMZ7LAO	MT	DTT
DMZ7LAO	MA	Antagonist
DMZ7LAO	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMZ7LAO	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMJLFEN	DI	DMJLFEN
DMJLFEN	DN	PMID25666693-Compound-138
DMJLFEN	MI	TTMI6F5
DMJLFEN	MN	Transient receptor potential cation channel V1 (TRPV1)
DMJLFEN	MT	DTT
DMJLFEN	MA	Antagonist
DMJLFEN	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMJLFEN	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMLMEPI	DI	DMLMEPI
DMLMEPI	DN	PMID25666693-Compound-139
DMLMEPI	MI	TTMI6F5
DMLMEPI	MN	Transient receptor potential cation channel V1 (TRPV1)
DMLMEPI	MT	DTT
DMLMEPI	MA	Antagonist
DMLMEPI	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMLMEPI	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM3D4RI	DI	DM3D4RI
DM3D4RI	DN	PMID25666693-Compound-14
DM3D4RI	MI	TTMI6F5
DM3D4RI	MN	Transient receptor potential cation channel V1 (TRPV1)
DM3D4RI	MT	DTT
DM3D4RI	MA	Antagonist
DM3D4RI	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM3D4RI	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMVQU9T	DI	DMVQU9T
DMVQU9T	DN	PMID25666693-Compound-140
DMVQU9T	MI	TTMI6F5
DMVQU9T	MN	Transient receptor potential cation channel V1 (TRPV1)
DMVQU9T	MT	DTT
DMVQU9T	MA	Antagonist
DMVQU9T	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMVQU9T	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMQGTYE	DI	DMQGTYE
DMQGTYE	DN	PMID25666693-Compound-141
DMQGTYE	MI	TTMI6F5
DMQGTYE	MN	Transient receptor potential cation channel V1 (TRPV1)
DMQGTYE	MT	DTT
DMQGTYE	MA	Antagonist
DMQGTYE	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMQGTYE	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMFKN1O	DI	DMFKN1O
DMFKN1O	DN	PMID25666693-Compound-142
DMFKN1O	MI	TTMI6F5
DMFKN1O	MN	Transient receptor potential cation channel V1 (TRPV1)
DMFKN1O	MT	DTT
DMFKN1O	MA	Antagonist
DMFKN1O	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMFKN1O	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMJP0NB	DI	DMJP0NB
DMJP0NB	DN	PMID25666693-Compound-143
DMJP0NB	MI	TTMI6F5
DMJP0NB	MN	Transient receptor potential cation channel V1 (TRPV1)
DMJP0NB	MT	DTT
DMJP0NB	MA	Antagonist
DMJP0NB	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMJP0NB	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMCXELD	DI	DMCXELD
DMCXELD	DN	PMID25666693-Compound-144
DMCXELD	MI	TTMI6F5
DMCXELD	MN	Transient receptor potential cation channel V1 (TRPV1)
DMCXELD	MT	DTT
DMCXELD	MA	Antagonist
DMCXELD	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMCXELD	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMP89E4	DI	DMP89E4
DMP89E4	DN	PMID25666693-Compound-145
DMP89E4	MI	TTMI6F5
DMP89E4	MN	Transient receptor potential cation channel V1 (TRPV1)
DMP89E4	MT	DTT
DMP89E4	MA	Antagonist
DMP89E4	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMP89E4	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMLE5BK	DI	DMLE5BK
DMLE5BK	DN	PMID25666693-Compound-146
DMLE5BK	MI	TTMI6F5
DMLE5BK	MN	Transient receptor potential cation channel V1 (TRPV1)
DMLE5BK	MT	DTT
DMLE5BK	MA	Antagonist
DMLE5BK	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMLE5BK	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMG1SYN	DI	DMG1SYN
DMG1SYN	DN	PMID25666693-Compound-147
DMG1SYN	MI	TTMI6F5
DMG1SYN	MN	Transient receptor potential cation channel V1 (TRPV1)
DMG1SYN	MT	DTT
DMG1SYN	MA	Antagonist
DMG1SYN	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMG1SYN	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM0EYON	DI	DM0EYON
DM0EYON	DN	PMID25666693-Compound-148
DM0EYON	MI	TTMI6F5
DM0EYON	MN	Transient receptor potential cation channel V1 (TRPV1)
DM0EYON	MT	DTT
DM0EYON	MA	Antagonist
DM0EYON	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM0EYON	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMPU19H	DI	DMPU19H
DMPU19H	DN	PMID25666693-Compound-149
DMPU19H	MI	TTMI6F5
DMPU19H	MN	Transient receptor potential cation channel V1 (TRPV1)
DMPU19H	MT	DTT
DMPU19H	MA	Antagonist
DMPU19H	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMPU19H	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM1G6AE	DI	DM1G6AE
DM1G6AE	DN	PMID25666693-Compound-15
DM1G6AE	MI	TTMI6F5
DM1G6AE	MN	Transient receptor potential cation channel V1 (TRPV1)
DM1G6AE	MT	DTT
DM1G6AE	MA	Antagonist
DM1G6AE	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM1G6AE	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMHMEFY	DI	DMHMEFY
DMHMEFY	DN	PMID25666693-Compound-150
DMHMEFY	MI	TTMI6F5
DMHMEFY	MN	Transient receptor potential cation channel V1 (TRPV1)
DMHMEFY	MT	DTT
DMHMEFY	MA	Antagonist
DMHMEFY	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMHMEFY	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM5CY86	DI	DM5CY86
DM5CY86	DN	PMID25666693-Compound-151
DM5CY86	MI	TTMI6F5
DM5CY86	MN	Transient receptor potential cation channel V1 (TRPV1)
DM5CY86	MT	DTT
DM5CY86	MA	Antagonist
DM5CY86	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM5CY86	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM27154	DI	DM27154
DM27154	DN	PMID25666693-Compound-152
DM27154	MI	TTMI6F5
DM27154	MN	Transient receptor potential cation channel V1 (TRPV1)
DM27154	MT	DTT
DM27154	MA	Antagonist
DM27154	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM27154	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM1FTV6	DI	DM1FTV6
DM1FTV6	DN	PMID25666693-Compound-153
DM1FTV6	MI	TTMI6F5
DM1FTV6	MN	Transient receptor potential cation channel V1 (TRPV1)
DM1FTV6	MT	DTT
DM1FTV6	MA	Antagonist
DM1FTV6	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM1FTV6	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMKNU0Z	DI	DMKNU0Z
DMKNU0Z	DN	PMID25666693-Compound-154
DMKNU0Z	MI	TTMI6F5
DMKNU0Z	MN	Transient receptor potential cation channel V1 (TRPV1)
DMKNU0Z	MT	DTT
DMKNU0Z	MA	Antagonist
DMKNU0Z	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMKNU0Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMZLB07	DI	DMZLB07
DMZLB07	DN	PMID25666693-Compound-155
DMZLB07	MI	TTMI6F5
DMZLB07	MN	Transient receptor potential cation channel V1 (TRPV1)
DMZLB07	MT	DTT
DMZLB07	MA	Antagonist
DMZLB07	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMZLB07	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMTVAUP	DI	DMTVAUP
DMTVAUP	DN	PMID25666693-Compound-156
DMTVAUP	MI	TTMI6F5
DMTVAUP	MN	Transient receptor potential cation channel V1 (TRPV1)
DMTVAUP	MT	DTT
DMTVAUP	MA	Antagonist
DMTVAUP	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMTVAUP	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DME8LUY	DI	DME8LUY
DME8LUY	DN	PMID25666693-Compound-157
DME8LUY	MI	TTMI6F5
DME8LUY	MN	Transient receptor potential cation channel V1 (TRPV1)
DME8LUY	MT	DTT
DME8LUY	MA	Antagonist
DME8LUY	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DME8LUY	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM2BTCU	DI	DM2BTCU
DM2BTCU	DN	PMID25666693-Compound-158
DM2BTCU	MI	TTMI6F5
DM2BTCU	MN	Transient receptor potential cation channel V1 (TRPV1)
DM2BTCU	MT	DTT
DM2BTCU	MA	Antagonist
DM2BTCU	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM2BTCU	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM74OGS	DI	DM74OGS
DM74OGS	DN	PMID25666693-Compound-159
DM74OGS	MI	TTMI6F5
DM74OGS	MN	Transient receptor potential cation channel V1 (TRPV1)
DM74OGS	MT	DTT
DM74OGS	MA	Antagonist
DM74OGS	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM74OGS	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM6SL9D	DI	DM6SL9D
DM6SL9D	DN	PMID25666693-Compound-16
DM6SL9D	MI	TTMI6F5
DM6SL9D	MN	Transient receptor potential cation channel V1 (TRPV1)
DM6SL9D	MT	DTT
DM6SL9D	MA	Antagonist
DM6SL9D	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM6SL9D	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM2KTAB	DI	DM2KTAB
DM2KTAB	DN	PMID25666693-Compound-160
DM2KTAB	MI	TTMI6F5
DM2KTAB	MN	Transient receptor potential cation channel V1 (TRPV1)
DM2KTAB	MT	DTT
DM2KTAB	MA	Antagonist
DM2KTAB	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM2KTAB	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM06IWA	DI	DM06IWA
DM06IWA	DN	PMID25666693-Compound-161
DM06IWA	MI	TTMI6F5
DM06IWA	MN	Transient receptor potential cation channel V1 (TRPV1)
DM06IWA	MT	DTT
DM06IWA	MA	Antagonist
DM06IWA	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM06IWA	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMXS5WY	DI	DMXS5WY
DMXS5WY	DN	PMID25666693-Compound-162
DMXS5WY	MI	TTMI6F5
DMXS5WY	MN	Transient receptor potential cation channel V1 (TRPV1)
DMXS5WY	MT	DTT
DMXS5WY	MA	Antagonist
DMXS5WY	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMXS5WY	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMRK1W7	DI	DMRK1W7
DMRK1W7	DN	PMID25666693-Compound-17
DMRK1W7	MI	TTMI6F5
DMRK1W7	MN	Transient receptor potential cation channel V1 (TRPV1)
DMRK1W7	MT	DTT
DMRK1W7	MA	Antagonist
DMRK1W7	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMRK1W7	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMKU6C3	DI	DMKU6C3
DMKU6C3	DN	PMID25666693-Compound-18
DMKU6C3	MI	TTMI6F5
DMKU6C3	MN	Transient receptor potential cation channel V1 (TRPV1)
DMKU6C3	MT	DTT
DMKU6C3	MA	Antagonist
DMKU6C3	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMKU6C3	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM63UM8	DI	DM63UM8
DM63UM8	DN	PMID25666693-Compound-19
DM63UM8	MI	TTMI6F5
DM63UM8	MN	Transient receptor potential cation channel V1 (TRPV1)
DM63UM8	MT	DTT
DM63UM8	MA	Antagonist
DM63UM8	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM63UM8	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMERD39	DI	DMERD39
DMERD39	DN	PMID25666693-Compound-2
DMERD39	MI	TTMI6F5
DMERD39	MN	Transient receptor potential cation channel V1 (TRPV1)
DMERD39	MT	DTT
DMERD39	MA	Antagonist
DMERD39	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMERD39	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM3I90D	DI	DM3I90D
DM3I90D	DN	PMID25666693-Compound-20
DM3I90D	MI	TTMI6F5
DM3I90D	MN	Transient receptor potential cation channel V1 (TRPV1)
DM3I90D	MT	DTT
DM3I90D	MA	Antagonist
DM3I90D	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM3I90D	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMUXO47	DI	DMUXO47
DMUXO47	DN	PMID25666693-Compound-21
DMUXO47	MI	TTMI6F5
DMUXO47	MN	Transient receptor potential cation channel V1 (TRPV1)
DMUXO47	MT	DTT
DMUXO47	MA	Antagonist
DMUXO47	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMUXO47	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMHPW3X	DI	DMHPW3X
DMHPW3X	DN	PMID25666693-Compound-22
DMHPW3X	MI	TTMI6F5
DMHPW3X	MN	Transient receptor potential cation channel V1 (TRPV1)
DMHPW3X	MT	DTT
DMHPW3X	MA	Antagonist
DMHPW3X	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMHPW3X	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMJ3YDT	DI	DMJ3YDT
DMJ3YDT	DN	PMID25666693-Compound-23
DMJ3YDT	MI	TTMI6F5
DMJ3YDT	MN	Transient receptor potential cation channel V1 (TRPV1)
DMJ3YDT	MT	DTT
DMJ3YDT	MA	Antagonist
DMJ3YDT	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMJ3YDT	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMUMYKX	DI	DMUMYKX
DMUMYKX	DN	PMID25666693-Compound-24
DMUMYKX	MI	TTMI6F5
DMUMYKX	MN	Transient receptor potential cation channel V1 (TRPV1)
DMUMYKX	MT	DTT
DMUMYKX	MA	Antagonist
DMUMYKX	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMUMYKX	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMI8CB3	DI	DMI8CB3
DMI8CB3	DN	PMID25666693-Compound-25
DMI8CB3	MI	TTMI6F5
DMI8CB3	MN	Transient receptor potential cation channel V1 (TRPV1)
DMI8CB3	MT	DTT
DMI8CB3	MA	Antagonist
DMI8CB3	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMI8CB3	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMQBFI2	DI	DMQBFI2
DMQBFI2	DN	PMID25666693-Compound-26
DMQBFI2	MI	TTMI6F5
DMQBFI2	MN	Transient receptor potential cation channel V1 (TRPV1)
DMQBFI2	MT	DTT
DMQBFI2	MA	Antagonist
DMQBFI2	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMQBFI2	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMKHO8T	DI	DMKHO8T
DMKHO8T	DN	PMID25666693-Compound-27
DMKHO8T	MI	TTMI6F5
DMKHO8T	MN	Transient receptor potential cation channel V1 (TRPV1)
DMKHO8T	MT	DTT
DMKHO8T	MA	Antagonist
DMKHO8T	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMKHO8T	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM7T962	DI	DM7T962
DM7T962	DN	PMID25666693-Compound-28
DM7T962	MI	TTMI6F5
DM7T962	MN	Transient receptor potential cation channel V1 (TRPV1)
DM7T962	MT	DTT
DM7T962	MA	Antagonist
DM7T962	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM7T962	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM02D1B	DI	DM02D1B
DM02D1B	DN	PMID25666693-Compound-29
DM02D1B	MI	TTMI6F5
DM02D1B	MN	Transient receptor potential cation channel V1 (TRPV1)
DM02D1B	MT	DTT
DM02D1B	MA	Antagonist
DM02D1B	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM02D1B	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMN692C	DI	DMN692C
DMN692C	DN	PMID25666693-Compound-3
DMN692C	MI	TTMI6F5
DMN692C	MN	Transient receptor potential cation channel V1 (TRPV1)
DMN692C	MT	DTT
DMN692C	MA	Antagonist
DMN692C	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMN692C	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMC3DT7	DI	DMC3DT7
DMC3DT7	DN	PMID25666693-Compound-30
DMC3DT7	MI	TTMI6F5
DMC3DT7	MN	Transient receptor potential cation channel V1 (TRPV1)
DMC3DT7	MT	DTT
DMC3DT7	MA	Antagonist
DMC3DT7	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMC3DT7	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM853Y7	DI	DM853Y7
DM853Y7	DN	PMID25666693-Compound-31
DM853Y7	MI	TTMI6F5
DM853Y7	MN	Transient receptor potential cation channel V1 (TRPV1)
DM853Y7	MT	DTT
DM853Y7	MA	Antagonist
DM853Y7	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM853Y7	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM58Z4M	DI	DM58Z4M
DM58Z4M	DN	PMID25666693-Compound-32
DM58Z4M	MI	TTMI6F5
DM58Z4M	MN	Transient receptor potential cation channel V1 (TRPV1)
DM58Z4M	MT	DTT
DM58Z4M	MA	Antagonist
DM58Z4M	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM58Z4M	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMW7981	DI	DMW7981
DMW7981	DN	PMID25666693-Compound-33
DMW7981	MI	TTMI6F5
DMW7981	MN	Transient receptor potential cation channel V1 (TRPV1)
DMW7981	MT	DTT
DMW7981	MA	Antagonist
DMW7981	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMW7981	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMWGAQU	DI	DMWGAQU
DMWGAQU	DN	PMID25666693-Compound-34
DMWGAQU	MI	TTMI6F5
DMWGAQU	MN	Transient receptor potential cation channel V1 (TRPV1)
DMWGAQU	MT	DTT
DMWGAQU	MA	Antagonist
DMWGAQU	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMWGAQU	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMG9CPH	DI	DMG9CPH
DMG9CPH	DN	PMID25666693-Compound-35
DMG9CPH	MI	TTMI6F5
DMG9CPH	MN	Transient receptor potential cation channel V1 (TRPV1)
DMG9CPH	MT	DTT
DMG9CPH	MA	Antagonist
DMG9CPH	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMG9CPH	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMWVR81	DI	DMWVR81
DMWVR81	DN	PMID25666693-Compound-36
DMWVR81	MI	TTMI6F5
DMWVR81	MN	Transient receptor potential cation channel V1 (TRPV1)
DMWVR81	MT	DTT
DMWVR81	MA	Antagonist
DMWVR81	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMWVR81	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMSR218	DI	DMSR218
DMSR218	DN	PMID25666693-Compound-37
DMSR218	MI	TTMI6F5
DMSR218	MN	Transient receptor potential cation channel V1 (TRPV1)
DMSR218	MT	DTT
DMSR218	MA	Antagonist
DMSR218	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMSR218	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMBW36Y	DI	DMBW36Y
DMBW36Y	DN	PMID25666693-Compound-38
DMBW36Y	MI	TTMI6F5
DMBW36Y	MN	Transient receptor potential cation channel V1 (TRPV1)
DMBW36Y	MT	DTT
DMBW36Y	MA	Antagonist
DMBW36Y	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMBW36Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DML3KHF	DI	DML3KHF
DML3KHF	DN	PMID25666693-Compound-39
DML3KHF	MI	TTMI6F5
DML3KHF	MN	Transient receptor potential cation channel V1 (TRPV1)
DML3KHF	MT	DTT
DML3KHF	MA	Antagonist
DML3KHF	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DML3KHF	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMBD9S5	DI	DMBD9S5
DMBD9S5	DN	PMID25666693-Compound-4
DMBD9S5	MI	TTMI6F5
DMBD9S5	MN	Transient receptor potential cation channel V1 (TRPV1)
DMBD9S5	MT	DTT
DMBD9S5	MA	Antagonist
DMBD9S5	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMBD9S5	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM58QW1	DI	DM58QW1
DM58QW1	DN	PMID25666693-Compound-40
DM58QW1	MI	TTMI6F5
DM58QW1	MN	Transient receptor potential cation channel V1 (TRPV1)
DM58QW1	MT	DTT
DM58QW1	MA	Antagonist
DM58QW1	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM58QW1	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DML76MF	DI	DML76MF
DML76MF	DN	PMID25666693-Compound-41
DML76MF	MI	TTMI6F5
DML76MF	MN	Transient receptor potential cation channel V1 (TRPV1)
DML76MF	MT	DTT
DML76MF	MA	Antagonist
DML76MF	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DML76MF	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM6I49E	DI	DM6I49E
DM6I49E	DN	PMID25666693-Compound-42
DM6I49E	MI	TTMI6F5
DM6I49E	MN	Transient receptor potential cation channel V1 (TRPV1)
DM6I49E	MT	DTT
DM6I49E	MA	Antagonist
DM6I49E	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM6I49E	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMTN25V	DI	DMTN25V
DMTN25V	DN	PMID25666693-Compound-43
DMTN25V	MI	TTMI6F5
DMTN25V	MN	Transient receptor potential cation channel V1 (TRPV1)
DMTN25V	MT	DTT
DMTN25V	MA	Antagonist
DMTN25V	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMTN25V	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM0I72B	DI	DM0I72B
DM0I72B	DN	PMID25666693-Compound-44
DM0I72B	MI	TTMI6F5
DM0I72B	MN	Transient receptor potential cation channel V1 (TRPV1)
DM0I72B	MT	DTT
DM0I72B	MA	Antagonist
DM0I72B	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM0I72B	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMVDKXY	DI	DMVDKXY
DMVDKXY	DN	PMID25666693-Compound-45
DMVDKXY	MI	TTMI6F5
DMVDKXY	MN	Transient receptor potential cation channel V1 (TRPV1)
DMVDKXY	MT	DTT
DMVDKXY	MA	Antagonist
DMVDKXY	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMVDKXY	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM0MEXT	DI	DM0MEXT
DM0MEXT	DN	PMID25666693-Compound-46
DM0MEXT	MI	TTMI6F5
DM0MEXT	MN	Transient receptor potential cation channel V1 (TRPV1)
DM0MEXT	MT	DTT
DM0MEXT	MA	Antagonist
DM0MEXT	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM0MEXT	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMHBN5M	DI	DMHBN5M
DMHBN5M	DN	PMID25666693-Compound-47
DMHBN5M	MI	TTMI6F5
DMHBN5M	MN	Transient receptor potential cation channel V1 (TRPV1)
DMHBN5M	MT	DTT
DMHBN5M	MA	Antagonist
DMHBN5M	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMHBN5M	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMEVL0S	DI	DMEVL0S
DMEVL0S	DN	PMID25666693-Compound-48
DMEVL0S	MI	TTMI6F5
DMEVL0S	MN	Transient receptor potential cation channel V1 (TRPV1)
DMEVL0S	MT	DTT
DMEVL0S	MA	Antagonist
DMEVL0S	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMEVL0S	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM67DEG	DI	DM67DEG
DM67DEG	DN	PMID25666693-Compound-49
DM67DEG	MI	TTMI6F5
DM67DEG	MN	Transient receptor potential cation channel V1 (TRPV1)
DM67DEG	MT	DTT
DM67DEG	MA	Antagonist
DM67DEG	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM67DEG	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM53PBG	DI	DM53PBG
DM53PBG	DN	PMID25666693-Compound-5
DM53PBG	MI	TTMI6F5
DM53PBG	MN	Transient receptor potential cation channel V1 (TRPV1)
DM53PBG	MT	DTT
DM53PBG	MA	Antagonist
DM53PBG	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM53PBG	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM4GUZO	DI	DM4GUZO
DM4GUZO	DN	PMID25666693-Compound-50
DM4GUZO	MI	TTMI6F5
DM4GUZO	MN	Transient receptor potential cation channel V1 (TRPV1)
DM4GUZO	MT	DTT
DM4GUZO	MA	Antagonist
DM4GUZO	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM4GUZO	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM3KSV9	DI	DM3KSV9
DM3KSV9	DN	PMID25666693-Compound-51
DM3KSV9	MI	TTMI6F5
DM3KSV9	MN	Transient receptor potential cation channel V1 (TRPV1)
DM3KSV9	MT	DTT
DM3KSV9	MA	Antagonist
DM3KSV9	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM3KSV9	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMQPOGC	DI	DMQPOGC
DMQPOGC	DN	PMID25666693-Compound-52
DMQPOGC	MI	TTMI6F5
DMQPOGC	MN	Transient receptor potential cation channel V1 (TRPV1)
DMQPOGC	MT	DTT
DMQPOGC	MA	Antagonist
DMQPOGC	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMQPOGC	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMKCARH	DI	DMKCARH
DMKCARH	DN	PMID25666693-Compound-53
DMKCARH	MI	TTMI6F5
DMKCARH	MN	Transient receptor potential cation channel V1 (TRPV1)
DMKCARH	MT	DTT
DMKCARH	MA	Antagonist
DMKCARH	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMKCARH	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMLW95Y	DI	DMLW95Y
DMLW95Y	DN	PMID25666693-Compound-54
DMLW95Y	MI	TTMI6F5
DMLW95Y	MN	Transient receptor potential cation channel V1 (TRPV1)
DMLW95Y	MT	DTT
DMLW95Y	MA	Antagonist
DMLW95Y	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMLW95Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMPE7M8	DI	DMPE7M8
DMPE7M8	DN	PMID25666693-Compound-55
DMPE7M8	MI	TTMI6F5
DMPE7M8	MN	Transient receptor potential cation channel V1 (TRPV1)
DMPE7M8	MT	DTT
DMPE7M8	MA	Antagonist
DMPE7M8	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMPE7M8	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM82BAM	DI	DM82BAM
DM82BAM	DN	PMID25666693-Compound-56
DM82BAM	MI	TTMI6F5
DM82BAM	MN	Transient receptor potential cation channel V1 (TRPV1)
DM82BAM	MT	DTT
DM82BAM	MA	Antagonist
DM82BAM	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM82BAM	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMQRFXT	DI	DMQRFXT
DMQRFXT	DN	PMID25666693-Compound-57
DMQRFXT	MI	TTMI6F5
DMQRFXT	MN	Transient receptor potential cation channel V1 (TRPV1)
DMQRFXT	MT	DTT
DMQRFXT	MA	Antagonist
DMQRFXT	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMQRFXT	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMJEH0F	DI	DMJEH0F
DMJEH0F	DN	PMID25666693-Compound-58
DMJEH0F	MI	TTMI6F5
DMJEH0F	MN	Transient receptor potential cation channel V1 (TRPV1)
DMJEH0F	MT	DTT
DMJEH0F	MA	Antagonist
DMJEH0F	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMJEH0F	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMLI1YR	DI	DMLI1YR
DMLI1YR	DN	PMID25666693-Compound-59
DMLI1YR	MI	TTMI6F5
DMLI1YR	MN	Transient receptor potential cation channel V1 (TRPV1)
DMLI1YR	MT	DTT
DMLI1YR	MA	Antagonist
DMLI1YR	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMLI1YR	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMC5W1Y	DI	DMC5W1Y
DMC5W1Y	DN	PMID25666693-Compound-6
DMC5W1Y	MI	TTMI6F5
DMC5W1Y	MN	Transient receptor potential cation channel V1 (TRPV1)
DMC5W1Y	MT	DTT
DMC5W1Y	MA	Antagonist
DMC5W1Y	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMC5W1Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM2C58A	DI	DM2C58A
DM2C58A	DN	PMID25666693-Compound-60
DM2C58A	MI	TTMI6F5
DM2C58A	MN	Transient receptor potential cation channel V1 (TRPV1)
DM2C58A	MT	DTT
DM2C58A	MA	Antagonist
DM2C58A	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM2C58A	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM0B578	DI	DM0B578
DM0B578	DN	PMID25666693-Compound-61
DM0B578	MI	TTMI6F5
DM0B578	MN	Transient receptor potential cation channel V1 (TRPV1)
DM0B578	MT	DTT
DM0B578	MA	Antagonist
DM0B578	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM0B578	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMDMFJG	DI	DMDMFJG
DMDMFJG	DN	PMID25666693-Compound-62
DMDMFJG	MI	TTMI6F5
DMDMFJG	MN	Transient receptor potential cation channel V1 (TRPV1)
DMDMFJG	MT	DTT
DMDMFJG	MA	Antagonist
DMDMFJG	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMDMFJG	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM6DFAK	DI	DM6DFAK
DM6DFAK	DN	PMID25666693-Compound-63
DM6DFAK	MI	TTMI6F5
DM6DFAK	MN	Transient receptor potential cation channel V1 (TRPV1)
DM6DFAK	MT	DTT
DM6DFAK	MA	Antagonist
DM6DFAK	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM6DFAK	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMDWH8T	DI	DMDWH8T
DMDWH8T	DN	PMID25666693-Compound-64
DMDWH8T	MI	TTMI6F5
DMDWH8T	MN	Transient receptor potential cation channel V1 (TRPV1)
DMDWH8T	MT	DTT
DMDWH8T	MA	Antagonist
DMDWH8T	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMDWH8T	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM1A0GT	DI	DM1A0GT
DM1A0GT	DN	PMID25666693-Compound-65
DM1A0GT	MI	TTMI6F5
DM1A0GT	MN	Transient receptor potential cation channel V1 (TRPV1)
DM1A0GT	MT	DTT
DM1A0GT	MA	Antagonist
DM1A0GT	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM1A0GT	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMD13OS	DI	DMD13OS
DMD13OS	DN	PMID25666693-Compound-66
DMD13OS	MI	TTMI6F5
DMD13OS	MN	Transient receptor potential cation channel V1 (TRPV1)
DMD13OS	MT	DTT
DMD13OS	MA	Antagonist
DMD13OS	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMD13OS	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMPV9L2	DI	DMPV9L2
DMPV9L2	DN	PMID25666693-Compound-67
DMPV9L2	MI	TTMI6F5
DMPV9L2	MN	Transient receptor potential cation channel V1 (TRPV1)
DMPV9L2	MT	DTT
DMPV9L2	MA	Antagonist
DMPV9L2	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMPV9L2	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM87HTO	DI	DM87HTO
DM87HTO	DN	PMID25666693-Compound-68
DM87HTO	MI	TTMI6F5
DM87HTO	MN	Transient receptor potential cation channel V1 (TRPV1)
DM87HTO	MT	DTT
DM87HTO	MA	Antagonist
DM87HTO	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM87HTO	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMIPFO3	DI	DMIPFO3
DMIPFO3	DN	PMID25666693-Compound-69
DMIPFO3	MI	TTMI6F5
DMIPFO3	MN	Transient receptor potential cation channel V1 (TRPV1)
DMIPFO3	MT	DTT
DMIPFO3	MA	Antagonist
DMIPFO3	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMIPFO3	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMNTVFH	DI	DMNTVFH
DMNTVFH	DN	PMID25666693-Compound-7
DMNTVFH	MI	TTMI6F5
DMNTVFH	MN	Transient receptor potential cation channel V1 (TRPV1)
DMNTVFH	MT	DTT
DMNTVFH	MA	Antagonist
DMNTVFH	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMNTVFH	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMEPYGQ	DI	DMEPYGQ
DMEPYGQ	DN	PMID25666693-Compound-70
DMEPYGQ	MI	TTMI6F5
DMEPYGQ	MN	Transient receptor potential cation channel V1 (TRPV1)
DMEPYGQ	MT	DTT
DMEPYGQ	MA	Antagonist
DMEPYGQ	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMEPYGQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM4VAQ3	DI	DM4VAQ3
DM4VAQ3	DN	PMID25666693-Compound-71
DM4VAQ3	MI	TTMI6F5
DM4VAQ3	MN	Transient receptor potential cation channel V1 (TRPV1)
DM4VAQ3	MT	DTT
DM4VAQ3	MA	Antagonist
DM4VAQ3	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM4VAQ3	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMW8XD2	DI	DMW8XD2
DMW8XD2	DN	PMID25666693-Compound-72
DMW8XD2	MI	TTMI6F5
DMW8XD2	MN	Transient receptor potential cation channel V1 (TRPV1)
DMW8XD2	MT	DTT
DMW8XD2	MA	Antagonist
DMW8XD2	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMW8XD2	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM9LZJ5	DI	DM9LZJ5
DM9LZJ5	DN	PMID25666693-Compound-73
DM9LZJ5	MI	TTMI6F5
DM9LZJ5	MN	Transient receptor potential cation channel V1 (TRPV1)
DM9LZJ5	MT	DTT
DM9LZJ5	MA	Antagonist
DM9LZJ5	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM9LZJ5	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM80E3F	DI	DM80E3F
DM80E3F	DN	PMID25666693-Compound-74
DM80E3F	MI	TTMI6F5
DM80E3F	MN	Transient receptor potential cation channel V1 (TRPV1)
DM80E3F	MT	DTT
DM80E3F	MA	Antagonist
DM80E3F	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM80E3F	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMNATSQ	DI	DMNATSQ
DMNATSQ	DN	PMID25666693-Compound-75
DMNATSQ	MI	TTMI6F5
DMNATSQ	MN	Transient receptor potential cation channel V1 (TRPV1)
DMNATSQ	MT	DTT
DMNATSQ	MA	Antagonist
DMNATSQ	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMNATSQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMYH429	DI	DMYH429
DMYH429	DN	PMID25666693-Compound-76
DMYH429	MI	TTMI6F5
DMYH429	MN	Transient receptor potential cation channel V1 (TRPV1)
DMYH429	MT	DTT
DMYH429	MA	Antagonist
DMYH429	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMYH429	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM05D48	DI	DM05D48
DM05D48	DN	PMID25666693-Compound-77
DM05D48	MI	TTMI6F5
DM05D48	MN	Transient receptor potential cation channel V1 (TRPV1)
DM05D48	MT	DTT
DM05D48	MA	Antagonist
DM05D48	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM05D48	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMQI1YN	DI	DMQI1YN
DMQI1YN	DN	PMID25666693-Compound-78
DMQI1YN	MI	TTMI6F5
DMQI1YN	MN	Transient receptor potential cation channel V1 (TRPV1)
DMQI1YN	MT	DTT
DMQI1YN	MA	Antagonist
DMQI1YN	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMQI1YN	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMTQ26G	DI	DMTQ26G
DMTQ26G	DN	PMID25666693-Compound-79
DMTQ26G	MI	TTMI6F5
DMTQ26G	MN	Transient receptor potential cation channel V1 (TRPV1)
DMTQ26G	MT	DTT
DMTQ26G	MA	Antagonist
DMTQ26G	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMTQ26G	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMZQ6HC	DI	DMZQ6HC
DMZQ6HC	DN	PMID25666693-Compound-8
DMZQ6HC	MI	TTMI6F5
DMZQ6HC	MN	Transient receptor potential cation channel V1 (TRPV1)
DMZQ6HC	MT	DTT
DMZQ6HC	MA	Antagonist
DMZQ6HC	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMZQ6HC	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMB56LS	DI	DMB56LS
DMB56LS	DN	PMID25666693-Compound-80
DMB56LS	MI	TTMI6F5
DMB56LS	MN	Transient receptor potential cation channel V1 (TRPV1)
DMB56LS	MT	DTT
DMB56LS	MA	Antagonist
DMB56LS	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMB56LS	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM5ZELW	DI	DM5ZELW
DM5ZELW	DN	PMID25666693-Compound-81
DM5ZELW	MI	TTMI6F5
DM5ZELW	MN	Transient receptor potential cation channel V1 (TRPV1)
DM5ZELW	MT	DTT
DM5ZELW	MA	Antagonist
DM5ZELW	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM5ZELW	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM1MZ70	DI	DM1MZ70
DM1MZ70	DN	PMID25666693-Compound-82
DM1MZ70	MI	TTMI6F5
DM1MZ70	MN	Transient receptor potential cation channel V1 (TRPV1)
DM1MZ70	MT	DTT
DM1MZ70	MA	Antagonist
DM1MZ70	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM1MZ70	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM2ZVXD	DI	DM2ZVXD
DM2ZVXD	DN	PMID25666693-Compound-83
DM2ZVXD	MI	TTMI6F5
DM2ZVXD	MN	Transient receptor potential cation channel V1 (TRPV1)
DM2ZVXD	MT	DTT
DM2ZVXD	MA	Antagonist
DM2ZVXD	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM2ZVXD	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM4QYIJ	DI	DM4QYIJ
DM4QYIJ	DN	PMID25666693-Compound-84
DM4QYIJ	MI	TTMI6F5
DM4QYIJ	MN	Transient receptor potential cation channel V1 (TRPV1)
DM4QYIJ	MT	DTT
DM4QYIJ	MA	Antagonist
DM4QYIJ	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM4QYIJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMGVU7M	DI	DMGVU7M
DMGVU7M	DN	PMID25666693-Compound-85
DMGVU7M	MI	TTMI6F5
DMGVU7M	MN	Transient receptor potential cation channel V1 (TRPV1)
DMGVU7M	MT	DTT
DMGVU7M	MA	Antagonist
DMGVU7M	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMGVU7M	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMFZ3S4	DI	DMFZ3S4
DMFZ3S4	DN	PMID25666693-Compound-86
DMFZ3S4	MI	TTMI6F5
DMFZ3S4	MN	Transient receptor potential cation channel V1 (TRPV1)
DMFZ3S4	MT	DTT
DMFZ3S4	MA	Antagonist
DMFZ3S4	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMFZ3S4	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMAV4XY	DI	DMAV4XY
DMAV4XY	DN	PMID25666693-Compound-87
DMAV4XY	MI	TTMI6F5
DMAV4XY	MN	Transient receptor potential cation channel V1 (TRPV1)
DMAV4XY	MT	DTT
DMAV4XY	MA	Antagonist
DMAV4XY	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMAV4XY	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMT9EJL	DI	DMT9EJL
DMT9EJL	DN	PMID25666693-Compound-88
DMT9EJL	MI	TTMI6F5
DMT9EJL	MN	Transient receptor potential cation channel V1 (TRPV1)
DMT9EJL	MT	DTT
DMT9EJL	MA	Antagonist
DMT9EJL	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMT9EJL	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM6RQKH	DI	DM6RQKH
DM6RQKH	DN	PMID25666693-Compound-89
DM6RQKH	MI	TTMI6F5
DM6RQKH	MN	Transient receptor potential cation channel V1 (TRPV1)
DM6RQKH	MT	DTT
DM6RQKH	MA	Antagonist
DM6RQKH	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM6RQKH	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM8A4B5	DI	DM8A4B5
DM8A4B5	DN	PMID25666693-Compound-9
DM8A4B5	MI	TTMI6F5
DM8A4B5	MN	Transient receptor potential cation channel V1 (TRPV1)
DM8A4B5	MT	DTT
DM8A4B5	MA	Antagonist
DM8A4B5	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM8A4B5	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM26NQE	DI	DM26NQE
DM26NQE	DN	PMID25666693-Compound-90
DM26NQE	MI	TTMI6F5
DM26NQE	MN	Transient receptor potential cation channel V1 (TRPV1)
DM26NQE	MT	DTT
DM26NQE	MA	Antagonist
DM26NQE	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM26NQE	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMXU3IE	DI	DMXU3IE
DMXU3IE	DN	PMID25666693-Compound-91
DMXU3IE	MI	TTMI6F5
DMXU3IE	MN	Transient receptor potential cation channel V1 (TRPV1)
DMXU3IE	MT	DTT
DMXU3IE	MA	Antagonist
DMXU3IE	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMXU3IE	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMRGOZ8	DI	DMRGOZ8
DMRGOZ8	DN	PMID25666693-Compound-92
DMRGOZ8	MI	TTMI6F5
DMRGOZ8	MN	Transient receptor potential cation channel V1 (TRPV1)
DMRGOZ8	MT	DTT
DMRGOZ8	MA	Antagonist
DMRGOZ8	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMRGOZ8	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMM5EI4	DI	DMM5EI4
DMM5EI4	DN	PMID25666693-Compound-93
DMM5EI4	MI	TTMI6F5
DMM5EI4	MN	Transient receptor potential cation channel V1 (TRPV1)
DMM5EI4	MT	DTT
DMM5EI4	MA	Antagonist
DMM5EI4	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMM5EI4	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMHREX9	DI	DMHREX9
DMHREX9	DN	PMID25666693-Compound-94
DMHREX9	MI	TTMI6F5
DMHREX9	MN	Transient receptor potential cation channel V1 (TRPV1)
DMHREX9	MT	DTT
DMHREX9	MA	Antagonist
DMHREX9	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMHREX9	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMFNB1T	DI	DMFNB1T
DMFNB1T	DN	PMID25666693-Compound-95
DMFNB1T	MI	TTMI6F5
DMFNB1T	MN	Transient receptor potential cation channel V1 (TRPV1)
DMFNB1T	MT	DTT
DMFNB1T	MA	Antagonist
DMFNB1T	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMFNB1T	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DME3NTB	DI	DME3NTB
DME3NTB	DN	PMID25666693-Compound-96
DME3NTB	MI	TTMI6F5
DME3NTB	MN	Transient receptor potential cation channel V1 (TRPV1)
DME3NTB	MT	DTT
DME3NTB	MA	Antagonist
DME3NTB	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DME3NTB	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMHJOP7	DI	DMHJOP7
DMHJOP7	DN	PMID25666693-Compound-97
DMHJOP7	MI	TTMI6F5
DMHJOP7	MN	Transient receptor potential cation channel V1 (TRPV1)
DMHJOP7	MT	DTT
DMHJOP7	MA	Antagonist
DMHJOP7	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMHJOP7	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DM2ZR8M	DI	DM2ZR8M
DM2ZR8M	DN	PMID25666693-Compound-98
DM2ZR8M	MI	TTMI6F5
DM2ZR8M	MN	Transient receptor potential cation channel V1 (TRPV1)
DM2ZR8M	MT	DTT
DM2ZR8M	MA	Antagonist
DM2ZR8M	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DM2ZR8M	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMOISDH	DI	DMOISDH
DMOISDH	DN	PMID25666693-Compound-99
DMOISDH	MI	TTMI6F5
DMOISDH	MN	Transient receptor potential cation channel V1 (TRPV1)
DMOISDH	MT	DTT
DMOISDH	MA	Antagonist
DMOISDH	RN	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
DMOISDH	RU	https://www.ncbi.nlm.nih.gov/pubmed/25666693

DMDZT7Y	DI	DMDZT7Y
DMDZT7Y	DN	PMID25684022-Compound-EP20041486488
DMDZT7Y	MI	TTCZOF2
DMDZT7Y	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMDZT7Y	MT	DTT
DMDZT7Y	MA	Inhibitor
DMDZT7Y	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMDZT7Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMR4MSH	DI	DMR4MSH
DMR4MSH	DN	PMID25684022-Compound-US20120277229 39(1.1)
DMR4MSH	MI	TTCZOF2
DMR4MSH	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMR4MSH	MT	DTT
DMR4MSH	MA	Inhibitor
DMR4MSH	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMR4MSH	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMR3J9A	DI	DMR3J9A
DMR3J9A	DN	PMID25684022-Compound-US20120277229 40(1.2)
DMR3J9A	MI	TTCZOF2
DMR3J9A	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMR3J9A	MT	DTT
DMR3J9A	MA	Inhibitor
DMR3J9A	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMR3J9A	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DM7V6E0	DI	DM7V6E0
DM7V6E0	DN	PMID25684022-Compound-US20120277229 41(1.3)
DM7V6E0	MI	TTCZOF2
DM7V6E0	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DM7V6E0	MT	DTT
DM7V6E0	MA	Inhibitor
DM7V6E0	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DM7V6E0	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMUQ04C	DI	DMUQ04C
DMUQ04C	DN	PMID25684022-Compound-US20120277229 44(1.4)
DMUQ04C	MI	TTCZOF2
DMUQ04C	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMUQ04C	MT	DTT
DMUQ04C	MA	Inhibitor
DMUQ04C	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMUQ04C	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMEIA6Y	DI	DMEIA6Y
DMEIA6Y	DN	PMID25684022-Compound-US20120277229 45(1.5)
DMEIA6Y	MI	TTCZOF2
DMEIA6Y	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMEIA6Y	MT	DTT
DMEIA6Y	MA	Inhibitor
DMEIA6Y	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMEIA6Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMDHJMU	DI	DMDHJMU
DMDHJMU	DN	PMID25684022-Compound-US20130053382 35(1-11)
DMDHJMU	MI	TTCZOF2
DMDHJMU	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMDHJMU	MT	DTT
DMDHJMU	MA	Inhibitor
DMDHJMU	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMDHJMU	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DM40FVN	DI	DM40FVN
DM40FVN	DN	PMID25684022-Compound-US20130053382 36(3-5)
DM40FVN	MI	TTCZOF2
DM40FVN	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DM40FVN	MT	DTT
DM40FVN	MA	Inhibitor
DM40FVN	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DM40FVN	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMY7Z85	DI	DMY7Z85
DMY7Z85	DN	PMID25684022-Compound-US20130053382 37(4-6)
DMY7Z85	MI	TTCZOF2
DMY7Z85	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMY7Z85	MT	DTT
DMY7Z85	MA	Inhibitor
DMY7Z85	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMY7Z85	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMHLQ2T	DI	DMHLQ2T
DMHLQ2T	DN	PMID25684022-Compound-US20130053382 38(5-7)
DMHLQ2T	MI	TTCZOF2
DMHLQ2T	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMHLQ2T	MT	DTT
DMHLQ2T	MA	Inhibitor
DMHLQ2T	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMHLQ2T	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DM809AX	DI	DM809AX
DM809AX	DN	PMID25684022-Compound-WO2004087707
DM809AX	MI	TTCZOF2
DM809AX	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DM809AX	MT	DTT
DM809AX	MA	Inhibitor
DM809AX	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DM809AX	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMV7PNF	DI	DMV7PNF
DMV7PNF	DN	PMID25684022-Compound-WO2006015124
DMV7PNF	MI	TTCZOF2
DMV7PNF	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMV7PNF	MT	DTT
DMV7PNF	MA	Inhibitor
DMV7PNF	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMV7PNF	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMDMJYL	DI	DMDMJYL
DMDMJYL	DN	PMID25684022-Compound-WO2008005457
DMDMJYL	MI	TTCZOF2
DMDMJYL	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMDMJYL	MT	DTT
DMDMJYL	MA	Inhibitor
DMDMJYL	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMDMJYL	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMKJ1HC	DI	DMKJ1HC
DMKJ1HC	DN	PMID25684022-Compound-WO2008079988
DMKJ1HC	MI	TTCZOF2
DMKJ1HC	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMKJ1HC	MT	DTT
DMKJ1HC	MA	Inhibitor
DMKJ1HC	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMKJ1HC	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DM8L5JR	DI	DM8L5JR
DM8L5JR	DN	PMID25684022-Compound-WO2008107444
DM8L5JR	MI	TTCZOF2
DM8L5JR	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DM8L5JR	MT	DTT
DM8L5JR	MA	Inhibitor
DM8L5JR	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DM8L5JR	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMTP02Q	DI	DMTP02Q
DMTP02Q	DN	PMID25684022-Compound-WO2009153313
DMTP02Q	MI	TTCZOF2
DMTP02Q	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMTP02Q	MT	DTT
DMTP02Q	MA	Inhibitor
DMTP02Q	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMTP02Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DM37FDV	DI	DM37FDV
DM37FDV	DN	PMID25684022-Compound-WO2010127754
DM37FDV	MI	TTCZOF2
DM37FDV	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DM37FDV	MT	DTT
DM37FDV	MA	Inhibitor
DM37FDV	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DM37FDV	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DM3IZ0H	DI	DM3IZ0H
DM3IZ0H	DN	PMID25684022-Compound-WO2011137219 35(1-11)
DM3IZ0H	MI	TTCZOF2
DM3IZ0H	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DM3IZ0H	MT	DTT
DM3IZ0H	MA	Inhibitor
DM3IZ0H	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DM3IZ0H	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMAQHI5	DI	DMAQHI5
DMAQHI5	DN	PMID25684022-Compound-WO2011137219 36(3-5)
DMAQHI5	MI	TTCZOF2
DMAQHI5	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMAQHI5	MT	DTT
DMAQHI5	MA	Inhibitor
DMAQHI5	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMAQHI5	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMSQ5J8	DI	DMSQ5J8
DMSQ5J8	DN	PMID25684022-Compound-WO2011137219 37(4-6)
DMSQ5J8	MI	TTCZOF2
DMSQ5J8	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMSQ5J8	MT	DTT
DMSQ5J8	MA	Inhibitor
DMSQ5J8	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMSQ5J8	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DM4NXBK	DI	DM4NXBK
DM4NXBK	DN	PMID25684022-Compound-WO2011137219 38(5-7)
DM4NXBK	MI	TTCZOF2
DM4NXBK	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DM4NXBK	MT	DTT
DM4NXBK	MA	Inhibitor
DM4NXBK	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DM4NXBK	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMSDRA4	DI	DMSDRA4
DMSDRA4	DN	PMID25684022-Compound-WO2012135799 42(1.4)
DMSDRA4	MI	TTCZOF2
DMSDRA4	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMSDRA4	MT	DTT
DMSDRA4	MA	Inhibitor
DMSDRA4	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMSDRA4	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMHI3O1	DI	DMHI3O1
DMHI3O1	DN	PMID25684022-Compound-WO2012135799 43(1.5)
DMHI3O1	MI	TTCZOF2
DMHI3O1	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMHI3O1	MT	DTT
DMHI3O1	MA	Inhibitor
DMHI3O1	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMHI3O1	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMZ73D9	DI	DMZ73D9
DMZ73D9	DN	PMID25726713-Compound-10
DMZ73D9	MI	TT8J1S3
DMZ73D9	MN	Smoothened homolog (SMO)
DMZ73D9	MT	DTT
DMZ73D9	MA	Inhibitor
DMZ73D9	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMZ73D9	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMN42OT	DI	DMN42OT
DMN42OT	DN	PMID25726713-Compound-11
DMN42OT	MI	TT8J1S3
DMN42OT	MN	Smoothened homolog (SMO)
DMN42OT	MT	DTT
DMN42OT	MA	Inhibitor
DMN42OT	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMN42OT	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMD3AHN	DI	DMD3AHN
DMD3AHN	DN	PMID25726713-Compound-12
DMD3AHN	MI	TT8J1S3
DMD3AHN	MN	Smoothened homolog (SMO)
DMD3AHN	MT	DTT
DMD3AHN	MA	Inhibitor
DMD3AHN	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMD3AHN	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DM8LZ60	DI	DM8LZ60
DM8LZ60	DN	PMID25726713-Compound-13
DM8LZ60	MI	TT8J1S3
DM8LZ60	MN	Smoothened homolog (SMO)
DM8LZ60	MT	DTT
DM8LZ60	MA	Inhibitor
DM8LZ60	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DM8LZ60	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DM6ORB9	DI	DM6ORB9
DM6ORB9	DN	PMID25726713-Compound-14
DM6ORB9	MI	TT8J1S3
DM6ORB9	MN	Smoothened homolog (SMO)
DM6ORB9	MT	DTT
DM6ORB9	MA	Inhibitor
DM6ORB9	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DM6ORB9	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DM67WM4	DI	DM67WM4
DM67WM4	DN	PMID25726713-Compound-15
DM67WM4	MI	TT8J1S3
DM67WM4	MN	Smoothened homolog (SMO)
DM67WM4	MT	DTT
DM67WM4	MA	Inhibitor
DM67WM4	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DM67WM4	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DM3BOZP	DI	DM3BOZP
DM3BOZP	DN	PMID25726713-Compound-16
DM3BOZP	MI	TT8J1S3
DM3BOZP	MN	Smoothened homolog (SMO)
DM3BOZP	MT	DTT
DM3BOZP	MA	Inhibitor
DM3BOZP	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DM3BOZP	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DM9MFUN	DI	DM9MFUN
DM9MFUN	DN	PMID25726713-Compound-17
DM9MFUN	MI	TTW6JVU
DM9MFUN	MN	Smoothened D473H mutant (SMO D473H)
DM9MFUN	MT	DTT
DM9MFUN	MA	Antagonist
DM9MFUN	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DM9MFUN	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DM9MFUN	DI	DM9MFUN
DM9MFUN	DN	PMID25726713-Compound-17
DM9MFUN	MI	TT8J1S3
DM9MFUN	MN	Smoothened homolog (SMO)
DM9MFUN	MT	DTT
DM9MFUN	MA	Antagonist
DM9MFUN	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DM9MFUN	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMP7C5L	DI	DMP7C5L
DMP7C5L	DN	PMID25726713-Compound-18
DMP7C5L	MI	TT8J1S3
DMP7C5L	MN	Smoothened homolog (SMO)
DMP7C5L	MT	DTT
DMP7C5L	MA	Antagonist
DMP7C5L	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMP7C5L	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMQJZLI	DI	DMQJZLI
DMQJZLI	DN	PMID25726713-Compound-19
DMQJZLI	MI	TT8J1S3
DMQJZLI	MN	Smoothened homolog (SMO)
DMQJZLI	MT	DTT
DMQJZLI	MA	Inhibitor
DMQJZLI	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMQJZLI	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMZOG9S	DI	DMZOG9S
DMZOG9S	DN	PMID25726713-Compound-20
DMZOG9S	MI	TT8J1S3
DMZOG9S	MN	Smoothened homolog (SMO)
DMZOG9S	MT	DTT
DMZOG9S	MA	Inhibitor
DMZOG9S	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMZOG9S	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMB0DS5	DI	DMB0DS5
DMB0DS5	DN	PMID25726713-Compound-21
DMB0DS5	MI	TT8J1S3
DMB0DS5	MN	Smoothened homolog (SMO)
DMB0DS5	MT	DTT
DMB0DS5	MA	Inhibitor
DMB0DS5	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMB0DS5	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMJUHXB	DI	DMJUHXB
DMJUHXB	DN	PMID25726713-Compound-22
DMJUHXB	MI	TT8J1S3
DMJUHXB	MN	Smoothened homolog (SMO)
DMJUHXB	MT	DTT
DMJUHXB	MA	Inhibitor
DMJUHXB	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMJUHXB	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMEXNOP	DI	DMEXNOP
DMEXNOP	DN	PMID25726713-Compound-23
DMEXNOP	MI	TT8J1S3
DMEXNOP	MN	Smoothened homolog (SMO)
DMEXNOP	MT	DTT
DMEXNOP	MA	Inhibitor
DMEXNOP	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMEXNOP	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMMFK2Q	DI	DMMFK2Q
DMMFK2Q	DN	PMID25726713-Compound-24
DMMFK2Q	MI	TT8J1S3
DMMFK2Q	MN	Smoothened homolog (SMO)
DMMFK2Q	MT	DTT
DMMFK2Q	MA	Inhibitor
DMMFK2Q	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMMFK2Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMLCPWT	DI	DMLCPWT
DMLCPWT	DN	PMID25726713-Compound-25
DMLCPWT	MI	TT8J1S3
DMLCPWT	MN	Smoothened homolog (SMO)
DMLCPWT	MT	DTT
DMLCPWT	MA	Inhibitor
DMLCPWT	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMLCPWT	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMJ8MXZ	DI	DMJ8MXZ
DMJ8MXZ	DN	PMID25726713-Compound-26
DMJ8MXZ	MI	TT8J1S3
DMJ8MXZ	MN	Smoothened homolog (SMO)
DMJ8MXZ	MT	DTT
DMJ8MXZ	MA	Inhibitor
DMJ8MXZ	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMJ8MXZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMTL73W	DI	DMTL73W
DMTL73W	DN	PMID25726713-Compound-27
DMTL73W	MI	TT8J1S3
DMTL73W	MN	Smoothened homolog (SMO)
DMTL73W	MT	DTT
DMTL73W	MA	Inhibitor
DMTL73W	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMTL73W	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMYM60P	DI	DMYM60P
DMYM60P	DN	PMID25726713-Compound-28
DMYM60P	MI	TT8J1S3
DMYM60P	MN	Smoothened homolog (SMO)
DMYM60P	MT	DTT
DMYM60P	MA	Inhibitor
DMYM60P	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMYM60P	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DM3QU80	DI	DM3QU80
DM3QU80	DN	PMID25726713-Compound-29
DM3QU80	MI	TT8J1S3
DM3QU80	MN	Smoothened homolog (SMO)
DM3QU80	MT	DTT
DM3QU80	MA	Inhibitor
DM3QU80	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DM3QU80	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMFBHAC	DI	DMFBHAC
DMFBHAC	DN	PMID25726713-Compound-30
DMFBHAC	MI	TT8J1S3
DMFBHAC	MN	Smoothened homolog (SMO)
DMFBHAC	MT	DTT
DMFBHAC	MA	Inhibitor
DMFBHAC	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMFBHAC	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMN13BI	DI	DMN13BI
DMN13BI	DN	PMID25726713-Compound-31
DMN13BI	MI	TT8J1S3
DMN13BI	MN	Smoothened homolog (SMO)
DMN13BI	MT	DTT
DMN13BI	MA	Inhibitor
DMN13BI	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMN13BI	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMIFH8T	DI	DMIFH8T
DMIFH8T	DN	PMID25726713-Compound-32
DMIFH8T	MI	TT8J1S3
DMIFH8T	MN	Smoothened homolog (SMO)
DMIFH8T	MT	DTT
DMIFH8T	MA	Inhibitor
DMIFH8T	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMIFH8T	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMEQ9BN	DI	DMEQ9BN
DMEQ9BN	DN	PMID25726713-Compound-33
DMEQ9BN	MI	TT8J1S3
DMEQ9BN	MN	Smoothened homolog (SMO)
DMEQ9BN	MT	DTT
DMEQ9BN	MA	Inhibitor
DMEQ9BN	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMEQ9BN	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMCXDKS	DI	DMCXDKS
DMCXDKS	DN	PMID25726713-Compound-34
DMCXDKS	MI	TT8J1S3
DMCXDKS	MN	Smoothened homolog (SMO)
DMCXDKS	MT	DTT
DMCXDKS	MA	Inhibitor
DMCXDKS	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMCXDKS	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMYCABN	DI	DMYCABN
DMYCABN	DN	PMID25726713-Compound-35
DMYCABN	MI	TT8J1S3
DMYCABN	MN	Smoothened homolog (SMO)
DMYCABN	MT	DTT
DMYCABN	MA	Inhibitor
DMYCABN	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMYCABN	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMYPT63	DI	DMYPT63
DMYPT63	DN	PMID25726713-Compound-36
DMYPT63	MI	TT8J1S3
DMYPT63	MN	Smoothened homolog (SMO)
DMYPT63	MT	DTT
DMYPT63	MA	Inhibitor
DMYPT63	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMYPT63	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMGXOJK	DI	DMGXOJK
DMGXOJK	DN	PMID25726713-Compound-37
DMGXOJK	MI	TT8J1S3
DMGXOJK	MN	Smoothened homolog (SMO)
DMGXOJK	MT	DTT
DMGXOJK	MA	Inhibitor
DMGXOJK	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMGXOJK	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DM4XJST	DI	DM4XJST
DM4XJST	DN	PMID25726713-Compound-38
DM4XJST	MI	TT8J1S3
DM4XJST	MN	Smoothened homolog (SMO)
DM4XJST	MT	DTT
DM4XJST	MA	Inhibitor
DM4XJST	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DM4XJST	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMVL25C	DI	DMVL25C
DMVL25C	DN	PMID25726713-Compound-39
DMVL25C	MI	TT8J1S3
DMVL25C	MN	Smoothened homolog (SMO)
DMVL25C	MT	DTT
DMVL25C	MA	Inhibitor
DMVL25C	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMVL25C	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DM5E2B3	DI	DM5E2B3
DM5E2B3	DN	PMID25726713-Compound-42
DM5E2B3	MI	TT8J1S3
DM5E2B3	MN	Smoothened homolog (SMO)
DM5E2B3	MT	DTT
DM5E2B3	MA	Inhibitor
DM5E2B3	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DM5E2B3	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DME9QCM	DI	DME9QCM
DME9QCM	DN	PMID25726713-Compound-43
DME9QCM	MI	TT8J1S3
DME9QCM	MN	Smoothened homolog (SMO)
DME9QCM	MT	DTT
DME9QCM	MA	Inhibitor
DME9QCM	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DME9QCM	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMEFA20	DI	DMEFA20
DMEFA20	DN	PMID25726713-Compound-44
DMEFA20	MI	TT8J1S3
DMEFA20	MN	Smoothened homolog (SMO)
DMEFA20	MT	DTT
DMEFA20	MA	Inhibitor
DMEFA20	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMEFA20	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMR8OVI	DI	DMR8OVI
DMR8OVI	DN	PMID25726713-Compound-45
DMR8OVI	MI	TT8J1S3
DMR8OVI	MN	Smoothened homolog (SMO)
DMR8OVI	MT	DTT
DMR8OVI	MA	Inhibitor
DMR8OVI	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMR8OVI	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DM27DQP	DI	DM27DQP
DM27DQP	DN	PMID25726713-Compound-46
DM27DQP	MI	TT8J1S3
DM27DQP	MN	Smoothened homolog (SMO)
DM27DQP	MT	DTT
DM27DQP	MA	Inhibitor
DM27DQP	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DM27DQP	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMXE5KM	DI	DMXE5KM
DMXE5KM	DN	PMID25726713-Compound-47
DMXE5KM	MI	TT0PG8F
DMXE5KM	MN	Cyclin-dependent kinase 4 (CDK4)
DMXE5KM	MT	DTT
DMXE5KM	MA	Inhibitor
DMXE5KM	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMXE5KM	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMXE5KM	DI	DMXE5KM
DMXE5KM	DN	PMID25726713-Compound-47
DMXE5KM	MI	TTO0FDJ
DMXE5KM	MN	Cyclin-dependent kinase 6 (CDK6)
DMXE5KM	MT	DTT
DMXE5KM	MA	Inhibitor
DMXE5KM	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMXE5KM	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMXE5KM	DI	DMXE5KM
DMXE5KM	DN	PMID25726713-Compound-47
DMXE5KM	MI	TTCJG29
DMXE5KM	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMXE5KM	MT	DTT
DMXE5KM	MA	Inhibitor
DMXE5KM	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMXE5KM	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMXE5KM	DI	DMXE5KM
DMXE5KM	DN	PMID25726713-Compound-47
DMXE5KM	MI	TT8J1S3
DMXE5KM	MN	Smoothened homolog (SMO)
DMXE5KM	MT	DTT
DMXE5KM	MA	Inhibitor
DMXE5KM	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMXE5KM	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMSIOUA	DI	DMSIOUA
DMSIOUA	DN	PMID25726713-Compound-48
DMSIOUA	MI	TT0PG8F
DMSIOUA	MN	Cyclin-dependent kinase 4 (CDK4)
DMSIOUA	MT	DTT
DMSIOUA	MA	Inhibitor
DMSIOUA	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMSIOUA	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMSIOUA	DI	DMSIOUA
DMSIOUA	DN	PMID25726713-Compound-48
DMSIOUA	MI	TTO0FDJ
DMSIOUA	MN	Cyclin-dependent kinase 6 (CDK6)
DMSIOUA	MT	DTT
DMSIOUA	MA	Inhibitor
DMSIOUA	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMSIOUA	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMSIOUA	DI	DMSIOUA
DMSIOUA	DN	PMID25726713-Compound-48
DMSIOUA	MI	TTCJG29
DMSIOUA	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMSIOUA	MT	DTT
DMSIOUA	MA	Inhibitor
DMSIOUA	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMSIOUA	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMSIOUA	DI	DMSIOUA
DMSIOUA	DN	PMID25726713-Compound-48
DMSIOUA	MI	TT8J1S3
DMSIOUA	MN	Smoothened homolog (SMO)
DMSIOUA	MT	DTT
DMSIOUA	MA	Inhibitor
DMSIOUA	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMSIOUA	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DM2CT4G	DI	DM2CT4G
DM2CT4G	DN	PMID25726713-Compound-49
DM2CT4G	MI	TT0PG8F
DM2CT4G	MN	Cyclin-dependent kinase 4 (CDK4)
DM2CT4G	MT	DTT
DM2CT4G	MA	Inhibitor
DM2CT4G	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DM2CT4G	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DM2CT4G	DI	DM2CT4G
DM2CT4G	DN	PMID25726713-Compound-49
DM2CT4G	MI	TTO0FDJ
DM2CT4G	MN	Cyclin-dependent kinase 6 (CDK6)
DM2CT4G	MT	DTT
DM2CT4G	MA	Inhibitor
DM2CT4G	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DM2CT4G	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DM2CT4G	DI	DM2CT4G
DM2CT4G	DN	PMID25726713-Compound-49
DM2CT4G	MI	TTCJG29
DM2CT4G	MN	Serine/threonine-protein kinase mTOR (mTOR)
DM2CT4G	MT	DTT
DM2CT4G	MA	Inhibitor
DM2CT4G	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DM2CT4G	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DM2CT4G	DI	DM2CT4G
DM2CT4G	DN	PMID25726713-Compound-49
DM2CT4G	MI	TT8J1S3
DM2CT4G	MN	Smoothened homolog (SMO)
DM2CT4G	MT	DTT
DM2CT4G	MA	Inhibitor
DM2CT4G	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DM2CT4G	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DM3BDFV	DI	DM3BDFV
DM3BDFV	DN	PMID25726713-Compound-50
DM3BDFV	MI	TT0PG8F
DM3BDFV	MN	Cyclin-dependent kinase 4 (CDK4)
DM3BDFV	MT	DTT
DM3BDFV	MA	Inhibitor
DM3BDFV	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DM3BDFV	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DM3BDFV	DI	DM3BDFV
DM3BDFV	DN	PMID25726713-Compound-50
DM3BDFV	MI	TTO0FDJ
DM3BDFV	MN	Cyclin-dependent kinase 6 (CDK6)
DM3BDFV	MT	DTT
DM3BDFV	MA	Inhibitor
DM3BDFV	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DM3BDFV	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DM3BDFV	DI	DM3BDFV
DM3BDFV	DN	PMID25726713-Compound-50
DM3BDFV	MI	TTCJG29
DM3BDFV	MN	Serine/threonine-protein kinase mTOR (mTOR)
DM3BDFV	MT	DTT
DM3BDFV	MA	Inhibitor
DM3BDFV	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DM3BDFV	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DM3BDFV	DI	DM3BDFV
DM3BDFV	DN	PMID25726713-Compound-50
DM3BDFV	MI	TT8J1S3
DM3BDFV	MN	Smoothened homolog (SMO)
DM3BDFV	MT	DTT
DM3BDFV	MA	Inhibitor
DM3BDFV	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DM3BDFV	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMF0OW4	DI	DMF0OW4
DMF0OW4	DN	PMID25726713-Compound-51
DMF0OW4	MI	TT0PG8F
DMF0OW4	MN	Cyclin-dependent kinase 4 (CDK4)
DMF0OW4	MT	DTT
DMF0OW4	MA	Inhibitor
DMF0OW4	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMF0OW4	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMF0OW4	DI	DMF0OW4
DMF0OW4	DN	PMID25726713-Compound-51
DMF0OW4	MI	TTO0FDJ
DMF0OW4	MN	Cyclin-dependent kinase 6 (CDK6)
DMF0OW4	MT	DTT
DMF0OW4	MA	Inhibitor
DMF0OW4	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMF0OW4	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMF0OW4	DI	DMF0OW4
DMF0OW4	DN	PMID25726713-Compound-51
DMF0OW4	MI	TTCJG29
DMF0OW4	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMF0OW4	MT	DTT
DMF0OW4	MA	Inhibitor
DMF0OW4	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMF0OW4	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMF0OW4	DI	DMF0OW4
DMF0OW4	DN	PMID25726713-Compound-51
DMF0OW4	MI	TT8J1S3
DMF0OW4	MN	Smoothened homolog (SMO)
DMF0OW4	MT	DTT
DMF0OW4	MA	Inhibitor
DMF0OW4	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMF0OW4	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMUHEP8	DI	DMUHEP8
DMUHEP8	DN	PMID25726713-Compound-56
DMUHEP8	MI	TT8J1S3
DMUHEP8	MN	Smoothened homolog (SMO)
DMUHEP8	MT	DTT
DMUHEP8	MA	Inhibitor
DMUHEP8	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMUHEP8	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMMZHB1	DI	DMMZHB1
DMMZHB1	DN	PMID25726713-Compound-57
DMMZHB1	MI	TT8J1S3
DMMZHB1	MN	Smoothened homolog (SMO)
DMMZHB1	MT	DTT
DMMZHB1	MA	Inhibitor
DMMZHB1	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMMZHB1	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMPDX3L	DI	DMPDX3L
DMPDX3L	DN	PMID25726713-Compound-58
DMPDX3L	MI	TT8J1S3
DMPDX3L	MN	Smoothened homolog (SMO)
DMPDX3L	MT	DTT
DMPDX3L	MA	Inhibitor
DMPDX3L	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMPDX3L	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMBF1OG	DI	DMBF1OG
DMBF1OG	DN	PMID25726713-Compound-59
DMBF1OG	MI	TT8J1S3
DMBF1OG	MN	Smoothened homolog (SMO)
DMBF1OG	MT	DTT
DMBF1OG	MA	Inhibitor
DMBF1OG	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMBF1OG	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMR8HSU	DI	DMR8HSU
DMR8HSU	DN	PMID25726713-Compound-60
DMR8HSU	MI	TT8J1S3
DMR8HSU	MN	Smoothened homolog (SMO)
DMR8HSU	MT	DTT
DMR8HSU	MA	Inhibitor
DMR8HSU	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMR8HSU	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMYXK7I	DI	DMYXK7I
DMYXK7I	DN	PMID25726713-Compound-61
DMYXK7I	MI	TT8J1S3
DMYXK7I	MN	Smoothened homolog (SMO)
DMYXK7I	MT	DTT
DMYXK7I	MA	Inhibitor
DMYXK7I	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMYXK7I	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMXNLTR	DI	DMXNLTR
DMXNLTR	DN	PMID25726713-Compound-62
DMXNLTR	MI	TT8J1S3
DMXNLTR	MN	Smoothened homolog (SMO)
DMXNLTR	MT	DTT
DMXNLTR	MA	Inhibitor
DMXNLTR	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMXNLTR	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMT0QLO	DI	DMT0QLO
DMT0QLO	DN	PMID25726713-Compound-63
DMT0QLO	MI	TT8J1S3
DMT0QLO	MN	Smoothened homolog (SMO)
DMT0QLO	MT	DTT
DMT0QLO	MA	Inhibitor
DMT0QLO	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMT0QLO	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DM6A8TS	DI	DM6A8TS
DM6A8TS	DN	PMID25726713-Compound-64
DM6A8TS	MI	TT8J1S3
DM6A8TS	MN	Smoothened homolog (SMO)
DM6A8TS	MT	DTT
DM6A8TS	MA	Inhibitor
DM6A8TS	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DM6A8TS	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DM048C1	DI	DM048C1
DM048C1	DN	PMID25747044-Compound-miRNA
DM048C1	MI	TTLUW5B
DM048C1	MN	Laminin receptor 37/67kDa (LRP/LR)
DM048C1	MT	DTT
DM048C1	MA	Inhibitor
DM048C1	RN	Novel patented therapeutic approaches targeting the 37/67 kDa laminin receptor for treatment of cancer and Alzheimer's disease.Expert Opin Ther Pat. 2015 May;25(5):567-82.
DM048C1	RU	https://www.ncbi.nlm.nih.gov/pubmed/25747044

DMVWF6I	DI	DMVWF6I
DMVWF6I	DN	PMID25772215-Compound-EP20082149552C9
DMVWF6I	MI	TT1ZAVI
DMVWF6I	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DMVWF6I	MT	DTT
DMVWF6I	MA	Antagonist
DMVWF6I	RN	Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
DMVWF6I	RU	https://www.ncbi.nlm.nih.gov/pubmed/25772215

DM48YKE	DI	DM48YKE
DM48YKE	DN	PMID25772215-Compound-EP2149552diaminopyrimidines
DM48YKE	MI	TT1ZAVI
DM48YKE	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DM48YKE	MT	DTT
DM48YKE	MA	Antagonist
DM48YKE	RN	Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
DM48YKE	RU	https://www.ncbi.nlm.nih.gov/pubmed/25772215

DM7EKZ6	DI	DM7EKZ6
DM7EKZ6	DN	PMID25772215-Compound-US02014179750M1
DM7EKZ6	MI	TT1ZAVI
DM7EKZ6	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DM7EKZ6	MT	DTT
DM7EKZ6	MA	Antagonist
DM7EKZ6	RN	Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
DM7EKZ6	RU	https://www.ncbi.nlm.nih.gov/pubmed/25772215

DMC50F3	DI	DMC50F3
DMC50F3	DN	PMID25772215-Compound-US02014179750M2
DMC50F3	MI	TT1ZAVI
DMC50F3	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DMC50F3	MT	DTT
DMC50F3	MA	Antagonist
DMC50F3	RN	Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
DMC50F3	RU	https://www.ncbi.nlm.nih.gov/pubmed/25772215

DMJA1XC	DI	DMJA1XC
DMJA1XC	DN	PMID25772215-Compound-US02014179750M3
DMJA1XC	MI	TT1ZAVI
DMJA1XC	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DMJA1XC	MT	DTT
DMJA1XC	MA	Antagonist
DMJA1XC	RN	Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
DMJA1XC	RU	https://www.ncbi.nlm.nih.gov/pubmed/25772215

DMWD1FP	DI	DMWD1FP
DMWD1FP	DN	PMID25772215-Compound-US02014179750TG6-10-1
DMWD1FP	MI	TT1ZAVI
DMWD1FP	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DMWD1FP	MT	DTT
DMWD1FP	MA	Antagonist
DMWD1FP	RN	Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
DMWD1FP	RU	https://www.ncbi.nlm.nih.gov/pubmed/25772215

DMRLZD2	DI	DMRLZD2
DMRLZD2	DN	PMID25772215-Compound-US02014179750TG6-129
DMRLZD2	MI	TT1ZAVI
DMRLZD2	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DMRLZD2	MT	DTT
DMRLZD2	MA	Antagonist
DMRLZD2	RN	Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
DMRLZD2	RU	https://www.ncbi.nlm.nih.gov/pubmed/25772215

DMB87WZ	DI	DMB87WZ
DMB87WZ	DN	PMID25772215-Compound-US02014179750TG7-112-2
DMB87WZ	MI	TT1ZAVI
DMB87WZ	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DMB87WZ	MT	DTT
DMB87WZ	MA	Antagonist
DMB87WZ	RN	Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
DMB87WZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25772215

DMORK8H	DI	DMORK8H
DMORK8H	DN	PMID25772215-Compound-US02014179750TG7-170
DMORK8H	MI	TT1ZAVI
DMORK8H	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DMORK8H	MT	DTT
DMORK8H	MA	Antagonist
DMORK8H	RN	Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
DMORK8H	RU	https://www.ncbi.nlm.nih.gov/pubmed/25772215

DM9I4EV	DI	DM9I4EV
DM9I4EV	DN	PMID25772215-Compound-US02014179750TG7-74
DM9I4EV	MI	TT1ZAVI
DM9I4EV	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DM9I4EV	MT	DTT
DM9I4EV	MA	Antagonist
DM9I4EV	RN	Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
DM9I4EV	RU	https://www.ncbi.nlm.nih.gov/pubmed/25772215

DMRTZC4	DI	DMRTZC4
DMRTZC4	DN	PMID25772215-Compound-US02014179750TG7-76
DMRTZC4	MI	TT1ZAVI
DMRTZC4	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DMRTZC4	MT	DTT
DMRTZC4	MA	Antagonist
DMRTZC4	RN	Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
DMRTZC4	RU	https://www.ncbi.nlm.nih.gov/pubmed/25772215

DM8IL6Y	DI	DM8IL6Y
DM8IL6Y	DN	PMID25772215-Compound-US02014179750TG8-15
DM8IL6Y	MI	TT1ZAVI
DM8IL6Y	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DM8IL6Y	MT	DTT
DM8IL6Y	MA	Antagonist
DM8IL6Y	RN	Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
DM8IL6Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/25772215

DMD3CB4	DI	DMD3CB4
DMD3CB4	DN	PMID25772215-Compound-WO2012177618M4
DMD3CB4	MI	TT1ZAVI
DMD3CB4	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DMD3CB4	MT	DTT
DMD3CB4	MA	Antagonist
DMD3CB4	RN	Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
DMD3CB4	RU	https://www.ncbi.nlm.nih.gov/pubmed/25772215

DMWUK9X	DI	DMWUK9X
DMWUK9X	DN	PMID25772215-Compound-WO2012177618M5
DMWUK9X	MI	TT1ZAVI
DMWUK9X	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DMWUK9X	MT	DTT
DMWUK9X	MA	Antagonist
DMWUK9X	RN	Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
DMWUK9X	RU	https://www.ncbi.nlm.nih.gov/pubmed/25772215

DMDCZVI	DI	DMDCZVI
DMDCZVI	DN	PMID25772215-Compound-WO2012177618M6
DMDCZVI	MI	TT1ZAVI
DMDCZVI	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DMDCZVI	MT	DTT
DMDCZVI	MA	Antagonist
DMDCZVI	RN	Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
DMDCZVI	RU	https://www.ncbi.nlm.nih.gov/pubmed/25772215

DMGHSR9	DI	DMGHSR9
DMGHSR9	DN	PMID25776143-Compound-1
DMGHSR9	MI	TT4TFGN
DMGHSR9	MN	Vasopressin V1a receptor (V1AR)
DMGHSR9	MT	DTT
DMGHSR9	MA	Agonist
DMGHSR9	RN	Vasopressin V1a and V1b receptor modulators: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jun;25(6):711-22.
DMGHSR9	RU	https://www.ncbi.nlm.nih.gov/pubmed/25776143

DMTZRFP	DI	DMTZRFP
DMTZRFP	DN	PMID25776143-Compound-2
DMTZRFP	MI	TT4TFGN
DMTZRFP	MN	Vasopressin V1a receptor (V1AR)
DMTZRFP	MT	DTT
DMTZRFP	MA	Agonist
DMTZRFP	RN	Vasopressin V1a and V1b receptor modulators: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jun;25(6):711-22.
DMTZRFP	RU	https://www.ncbi.nlm.nih.gov/pubmed/25776143

DMCULI1	DI	DMCULI1
DMCULI1	DN	PMID25776143-Compound-3
DMCULI1	MI	TT4TFGN
DMCULI1	MN	Vasopressin V1a receptor (V1AR)
DMCULI1	MT	DTT
DMCULI1	MA	Inhibitor
DMCULI1	RN	Vasopressin V1a and V1b receptor modulators: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jun;25(6):711-22.
DMCULI1	RU	https://www.ncbi.nlm.nih.gov/pubmed/25776143

DMMVETJ	DI	DMMVETJ
DMMVETJ	DN	PMID25776143-Compound-4
DMMVETJ	MI	TT4TFGN
DMMVETJ	MN	Vasopressin V1a receptor (V1AR)
DMMVETJ	MT	DTT
DMMVETJ	MA	Inhibitor
DMMVETJ	RN	Vasopressin V1a and V1b receptor modulators: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jun;25(6):711-22.
DMMVETJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25776143

DM7QIMN	DI	DM7QIMN
DM7QIMN	DN	PMID25776143-Compound-7
DM7QIMN	MI	TT4TFGN
DM7QIMN	MN	Vasopressin V1a receptor (V1AR)
DM7QIMN	MT	DTT
DM7QIMN	MA	Antagonist
DM7QIMN	RN	Vasopressin V1a and V1b receptor modulators: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jun;25(6):711-22.
DM7QIMN	RU	https://www.ncbi.nlm.nih.gov/pubmed/25776143

DMUKFJ0	DI	DMUKFJ0
DMUKFJ0	DN	PMID25776143-Compound-8
DMUKFJ0	MI	TT4TFGN
DMUKFJ0	MN	Vasopressin V1a receptor (V1AR)
DMUKFJ0	MT	DTT
DMUKFJ0	MA	Antagonist
DMUKFJ0	RN	Vasopressin V1a and V1b receptor modulators: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jun;25(6):711-22.
DMUKFJ0	RU	https://www.ncbi.nlm.nih.gov/pubmed/25776143

DMEC1TR	DI	DMEC1TR
DMEC1TR	DN	PMID25828189-Compound-19
DMEC1TR	MI	TT9O6WS
DMEC1TR	MN	Glucagon receptor (GCGR)
DMEC1TR	MT	DTT
DMEC1TR	MA	Antagonist
DMEC1TR	RN	Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30.
DMEC1TR	RU	https://www.ncbi.nlm.nih.gov/pubmed/25828189

DM7D0CT	DI	DM7D0CT
DM7D0CT	DN	PMID25828189-Compound-21
DM7D0CT	MI	TT9O6WS
DM7D0CT	MN	Glucagon receptor (GCGR)
DM7D0CT	MT	DTT
DM7D0CT	MA	Antagonist
DM7D0CT	RN	Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30.
DM7D0CT	RU	https://www.ncbi.nlm.nih.gov/pubmed/25828189

DMC2O0Q	DI	DMC2O0Q
DMC2O0Q	DN	PMID25828189-Compound-22
DMC2O0Q	MI	TT9O6WS
DMC2O0Q	MN	Glucagon receptor (GCGR)
DMC2O0Q	MT	DTT
DMC2O0Q	MA	Antagonist
DMC2O0Q	RN	Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30.
DMC2O0Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/25828189

DMYPT2H	DI	DMYPT2H
DMYPT2H	DN	PMID25980951-Compound-1
DMYPT2H	MI	TTQ5LRD
DMYPT2H	MN	Cellular inhibitor of apoptosis 1 (BIRC2)
DMYPT2H	MT	DTT
DMYPT2H	MA	Antagonist
DMYPT2H	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMYPT2H	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMYPT2H	DI	DMYPT2H
DMYPT2H	DN	PMID25980951-Compound-1
DMYPT2H	MI	TTIRY6K
DMYPT2H	MN	Cellular inhibitor of apoptosis 2 (BIRC3)
DMYPT2H	MT	DTT
DMYPT2H	MA	Antagonist
DMYPT2H	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMYPT2H	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMYPT2H	DI	DMYPT2H
DMYPT2H	DN	PMID25980951-Compound-1
DMYPT2H	MI	TTR7B60
DMYPT2H	MN	X-linked inhibitor of apoptosis protein (XIAP)
DMYPT2H	MT	DTT
DMYPT2H	MA	Antagonist
DMYPT2H	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMYPT2H	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DME3ZJO	DI	DME3ZJO
DME3ZJO	DN	PMID25980951-Compound-10
DME3ZJO	MI	TTR7B60
DME3ZJO	MN	X-linked inhibitor of apoptosis protein (XIAP)
DME3ZJO	MT	DTT
DME3ZJO	MA	Antagonist
DME3ZJO	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DME3ZJO	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMZ9LSY	DI	DMZ9LSY
DMZ9LSY	DN	PMID25980951-Compound-11
DMZ9LSY	MI	TTR7B60
DMZ9LSY	MN	X-linked inhibitor of apoptosis protein (XIAP)
DMZ9LSY	MT	DTT
DMZ9LSY	MA	Antagonist
DMZ9LSY	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMZ9LSY	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMG8K1P	DI	DMG8K1P
DMG8K1P	DN	PMID25980951-Compound-12
DMG8K1P	MI	TTR7B60
DMG8K1P	MN	X-linked inhibitor of apoptosis protein (XIAP)
DMG8K1P	MT	DTT
DMG8K1P	MA	Antagonist
DMG8K1P	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMG8K1P	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMGHR4D	DI	DMGHR4D
DMGHR4D	DN	PMID25980951-Compound-13
DMGHR4D	MI	TTR7B60
DMGHR4D	MN	X-linked inhibitor of apoptosis protein (XIAP)
DMGHR4D	MT	DTT
DMGHR4D	MA	Antagonist
DMGHR4D	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMGHR4D	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DM637IC	DI	DM637IC
DM637IC	DN	PMID25980951-Compound-14
DM637IC	MI	TTR7B60
DM637IC	MN	X-linked inhibitor of apoptosis protein (XIAP)
DM637IC	MT	DTT
DM637IC	MA	Antagonist
DM637IC	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DM637IC	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMB2MIT	DI	DMB2MIT
DMB2MIT	DN	PMID25980951-Compound-15
DMB2MIT	MI	TTR7B60
DMB2MIT	MN	X-linked inhibitor of apoptosis protein (XIAP)
DMB2MIT	MT	DTT
DMB2MIT	MA	Antagonist
DMB2MIT	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMB2MIT	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DM1J3LE	DI	DM1J3LE
DM1J3LE	DN	PMID25980951-Compound-16
DM1J3LE	MI	TTQ5LRD
DM1J3LE	MN	Cellular inhibitor of apoptosis 1 (BIRC2)
DM1J3LE	MT	DTT
DM1J3LE	MA	Antagonist
DM1J3LE	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DM1J3LE	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMSC8B6	DI	DMSC8B6
DMSC8B6	DN	PMID25980951-Compound-17
DMSC8B6	MI	TTQ5LRD
DMSC8B6	MN	Cellular inhibitor of apoptosis 1 (BIRC2)
DMSC8B6	MT	DTT
DMSC8B6	MA	Antagonist
DMSC8B6	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMSC8B6	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMC3NHJ	DI	DMC3NHJ
DMC3NHJ	DN	PMID25980951-Compound-18
DMC3NHJ	MI	TTQ5LRD
DMC3NHJ	MN	Cellular inhibitor of apoptosis 1 (BIRC2)
DMC3NHJ	MT	DTT
DMC3NHJ	MA	Antagonist
DMC3NHJ	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMC3NHJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMGIV0M	DI	DMGIV0M
DMGIV0M	DN	PMID25980951-Compound-19
DMGIV0M	MI	TTQ5LRD
DMGIV0M	MN	Cellular inhibitor of apoptosis 1 (BIRC2)
DMGIV0M	MT	DTT
DMGIV0M	MA	Antagonist
DMGIV0M	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMGIV0M	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMGIV0M	DI	DMGIV0M
DMGIV0M	DN	PMID25980951-Compound-19
DMGIV0M	MI	TTR7B60
DMGIV0M	MN	X-linked inhibitor of apoptosis protein (XIAP)
DMGIV0M	MT	DTT
DMGIV0M	MA	Antagonist
DMGIV0M	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMGIV0M	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMM45AC	DI	DMM45AC
DMM45AC	DN	PMID25980951-Compound-20
DMM45AC	MI	TTQ5LRD
DMM45AC	MN	Cellular inhibitor of apoptosis 1 (BIRC2)
DMM45AC	MT	DTT
DMM45AC	MA	Antagonist
DMM45AC	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMM45AC	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMM45AC	DI	DMM45AC
DMM45AC	DN	PMID25980951-Compound-20
DMM45AC	MI	TTR7B60
DMM45AC	MN	X-linked inhibitor of apoptosis protein (XIAP)
DMM45AC	MT	DTT
DMM45AC	MA	Antagonist
DMM45AC	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMM45AC	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMIE0MR	DI	DMIE0MR
DMIE0MR	DN	PMID25980951-Compound-21
DMIE0MR	MI	TTQ5LRD
DMIE0MR	MN	Cellular inhibitor of apoptosis 1 (BIRC2)
DMIE0MR	MT	DTT
DMIE0MR	MA	Antagonist
DMIE0MR	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMIE0MR	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMIE0MR	DI	DMIE0MR
DMIE0MR	DN	PMID25980951-Compound-21
DMIE0MR	MI	TTR7B60
DMIE0MR	MN	X-linked inhibitor of apoptosis protein (XIAP)
DMIE0MR	MT	DTT
DMIE0MR	MA	Antagonist
DMIE0MR	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMIE0MR	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DM6OEHK	DI	DM6OEHK
DM6OEHK	DN	PMID25980951-Compound-22
DM6OEHK	MI	TTQ5LRD
DM6OEHK	MN	Cellular inhibitor of apoptosis 1 (BIRC2)
DM6OEHK	MT	DTT
DM6OEHK	MA	Antagonist
DM6OEHK	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DM6OEHK	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DM6OEHK	DI	DM6OEHK
DM6OEHK	DN	PMID25980951-Compound-22
DM6OEHK	MI	TTR7B60
DM6OEHK	MN	X-linked inhibitor of apoptosis protein (XIAP)
DM6OEHK	MT	DTT
DM6OEHK	MA	Antagonist
DM6OEHK	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DM6OEHK	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMK9DH7	DI	DMK9DH7
DMK9DH7	DN	PMID25980951-Compound-26
DMK9DH7	MI	TTR7B60
DMK9DH7	MN	X-linked inhibitor of apoptosis protein (XIAP)
DMK9DH7	MT	DTT
DMK9DH7	MA	Antagonist
DMK9DH7	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMK9DH7	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMXAH9F	DI	DMXAH9F
DMXAH9F	DN	PMID25980951-Compound-27
DMXAH9F	MI	TTQ5LRD
DMXAH9F	MN	Cellular inhibitor of apoptosis 1 (BIRC2)
DMXAH9F	MT	DTT
DMXAH9F	MA	Antagonist
DMXAH9F	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMXAH9F	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMXAH9F	DI	DMXAH9F
DMXAH9F	DN	PMID25980951-Compound-27
DMXAH9F	MI	TTIRY6K
DMXAH9F	MN	Cellular inhibitor of apoptosis 2 (BIRC3)
DMXAH9F	MT	DTT
DMXAH9F	MA	Antagonist
DMXAH9F	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMXAH9F	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMXAH9F	DI	DMXAH9F
DMXAH9F	DN	PMID25980951-Compound-27
DMXAH9F	MI	TTR7B60
DMXAH9F	MN	X-linked inhibitor of apoptosis protein (XIAP)
DMXAH9F	MT	DTT
DMXAH9F	MA	Antagonist
DMXAH9F	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMXAH9F	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMV0EIA	DI	DMV0EIA
DMV0EIA	DN	PMID25980951-Compound-28
DMV0EIA	MI	TTR7B60
DMV0EIA	MN	X-linked inhibitor of apoptosis protein (XIAP)
DMV0EIA	MT	DTT
DMV0EIA	MA	Antagonist
DMV0EIA	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMV0EIA	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DM5WIX3	DI	DM5WIX3
DM5WIX3	DN	PMID25980951-Compound-29
DM5WIX3	MI	TTR7B60
DM5WIX3	MN	X-linked inhibitor of apoptosis protein (XIAP)
DM5WIX3	MT	DTT
DM5WIX3	MA	Antagonist
DM5WIX3	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DM5WIX3	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMPSWXU	DI	DMPSWXU
DMPSWXU	DN	PMID25980951-Compound-3
DMPSWXU	MI	TTQ5LRD
DMPSWXU	MN	Cellular inhibitor of apoptosis 1 (BIRC2)
DMPSWXU	MT	DTT
DMPSWXU	MA	Antagonist
DMPSWXU	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMPSWXU	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMPSWXU	DI	DMPSWXU
DMPSWXU	DN	PMID25980951-Compound-3
DMPSWXU	MI	TTR7B60
DMPSWXU	MN	X-linked inhibitor of apoptosis protein (XIAP)
DMPSWXU	MT	DTT
DMPSWXU	MA	Antagonist
DMPSWXU	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMPSWXU	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMXCSHE	DI	DMXCSHE
DMXCSHE	DN	PMID25980951-Compound-30
DMXCSHE	MI	TTR7B60
DMXCSHE	MN	X-linked inhibitor of apoptosis protein (XIAP)
DMXCSHE	MT	DTT
DMXCSHE	MA	Antagonist
DMXCSHE	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMXCSHE	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMC1Y2T	DI	DMC1Y2T
DMC1Y2T	DN	PMID25980951-Compound-31
DMC1Y2T	MI	TTR7B60
DMC1Y2T	MN	X-linked inhibitor of apoptosis protein (XIAP)
DMC1Y2T	MT	DTT
DMC1Y2T	MA	Antagonist
DMC1Y2T	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMC1Y2T	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMXETA8	DI	DMXETA8
DMXETA8	DN	PMID25980951-Compound-32
DMXETA8	MI	TTR7B60
DMXETA8	MN	X-linked inhibitor of apoptosis protein (XIAP)
DMXETA8	MT	DTT
DMXETA8	MA	Antagonist
DMXETA8	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMXETA8	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMYO9UD	DI	DMYO9UD
DMYO9UD	DN	PMID25980951-Compound-33
DMYO9UD	MI	TTR7B60
DMYO9UD	MN	X-linked inhibitor of apoptosis protein (XIAP)
DMYO9UD	MT	DTT
DMYO9UD	MA	Antagonist
DMYO9UD	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMYO9UD	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMBD4K9	DI	DMBD4K9
DMBD4K9	DN	PMID25980951-Compound-36
DMBD4K9	MI	TTQ5LRD
DMBD4K9	MN	Cellular inhibitor of apoptosis 1 (BIRC2)
DMBD4K9	MT	DTT
DMBD4K9	MA	Antagonist
DMBD4K9	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMBD4K9	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMBD4K9	DI	DMBD4K9
DMBD4K9	DN	PMID25980951-Compound-36
DMBD4K9	MI	TTR7B60
DMBD4K9	MN	X-linked inhibitor of apoptosis protein (XIAP)
DMBD4K9	MT	DTT
DMBD4K9	MA	Antagonist
DMBD4K9	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMBD4K9	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMHP6J2	DI	DMHP6J2
DMHP6J2	DN	PMID25980951-Compound-37
DMHP6J2	MI	TTQ5LRD
DMHP6J2	MN	Cellular inhibitor of apoptosis 1 (BIRC2)
DMHP6J2	MT	DTT
DMHP6J2	MA	Antagonist
DMHP6J2	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMHP6J2	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMHP6J2	DI	DMHP6J2
DMHP6J2	DN	PMID25980951-Compound-37
DMHP6J2	MI	TTR7B60
DMHP6J2	MN	X-linked inhibitor of apoptosis protein (XIAP)
DMHP6J2	MT	DTT
DMHP6J2	MA	Antagonist
DMHP6J2	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMHP6J2	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMEUBDA	DI	DMEUBDA
DMEUBDA	DN	PMID25980951-Compound-38
DMEUBDA	MI	TTQ5LRD
DMEUBDA	MN	Cellular inhibitor of apoptosis 1 (BIRC2)
DMEUBDA	MT	DTT
DMEUBDA	MA	Antagonist
DMEUBDA	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMEUBDA	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMEUBDA	DI	DMEUBDA
DMEUBDA	DN	PMID25980951-Compound-38
DMEUBDA	MI	TTR7B60
DMEUBDA	MN	X-linked inhibitor of apoptosis protein (XIAP)
DMEUBDA	MT	DTT
DMEUBDA	MA	Antagonist
DMEUBDA	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMEUBDA	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMEZ3QV	DI	DMEZ3QV
DMEZ3QV	DN	PMID25980951-Compound-39
DMEZ3QV	MI	TTR7B60
DMEZ3QV	MN	X-linked inhibitor of apoptosis protein (XIAP)
DMEZ3QV	MT	DTT
DMEZ3QV	MA	Antagonist
DMEZ3QV	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMEZ3QV	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DM9RZSH	DI	DM9RZSH
DM9RZSH	DN	PMID25980951-Compound-4
DM9RZSH	MI	TTQ5LRD
DM9RZSH	MN	Cellular inhibitor of apoptosis 1 (BIRC2)
DM9RZSH	MT	DTT
DM9RZSH	MA	Antagonist
DM9RZSH	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DM9RZSH	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DM9RZSH	DI	DM9RZSH
DM9RZSH	DN	PMID25980951-Compound-4
DM9RZSH	MI	TTR7B60
DM9RZSH	MN	X-linked inhibitor of apoptosis protein (XIAP)
DM9RZSH	MT	DTT
DM9RZSH	MA	Antagonist
DM9RZSH	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DM9RZSH	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMJOD8I	DI	DMJOD8I
DMJOD8I	DN	PMID25980951-Compound-40
DMJOD8I	MI	TTR7B60
DMJOD8I	MN	X-linked inhibitor of apoptosis protein (XIAP)
DMJOD8I	MT	DTT
DMJOD8I	MA	Antagonist
DMJOD8I	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMJOD8I	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMNROIP	DI	DMNROIP
DMNROIP	DN	PMID25980951-Compound-41
DMNROIP	MI	TTQ5LRD
DMNROIP	MN	Cellular inhibitor of apoptosis 1 (BIRC2)
DMNROIP	MT	DTT
DMNROIP	MA	Antagonist
DMNROIP	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMNROIP	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMNROIP	DI	DMNROIP
DMNROIP	DN	PMID25980951-Compound-41
DMNROIP	MI	TTR7B60
DMNROIP	MN	X-linked inhibitor of apoptosis protein (XIAP)
DMNROIP	MT	DTT
DMNROIP	MA	Antagonist
DMNROIP	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMNROIP	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DM8XESD	DI	DM8XESD
DM8XESD	DN	PMID25980951-Compound-42
DM8XESD	MI	TTQ5LRD
DM8XESD	MN	Cellular inhibitor of apoptosis 1 (BIRC2)
DM8XESD	MT	DTT
DM8XESD	MA	Antagonist
DM8XESD	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DM8XESD	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DM8XESD	DI	DM8XESD
DM8XESD	DN	PMID25980951-Compound-42
DM8XESD	MI	TTR7B60
DM8XESD	MN	X-linked inhibitor of apoptosis protein (XIAP)
DM8XESD	MT	DTT
DM8XESD	MA	Antagonist
DM8XESD	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DM8XESD	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMTJRCS	DI	DMTJRCS
DMTJRCS	DN	PMID25980951-Compound-43
DMTJRCS	MI	TTQ5LRD
DMTJRCS	MN	Cellular inhibitor of apoptosis 1 (BIRC2)
DMTJRCS	MT	DTT
DMTJRCS	MA	Antagonist
DMTJRCS	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMTJRCS	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMTJRCS	DI	DMTJRCS
DMTJRCS	DN	PMID25980951-Compound-43
DMTJRCS	MI	TTIRY6K
DMTJRCS	MN	Cellular inhibitor of apoptosis 2 (BIRC3)
DMTJRCS	MT	DTT
DMTJRCS	MA	Antagonist
DMTJRCS	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMTJRCS	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMTJRCS	DI	DMTJRCS
DMTJRCS	DN	PMID25980951-Compound-43
DMTJRCS	MI	TTR7B60
DMTJRCS	MN	X-linked inhibitor of apoptosis protein (XIAP)
DMTJRCS	MT	DTT
DMTJRCS	MA	Antagonist
DMTJRCS	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMTJRCS	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMS5896	DI	DMS5896
DMS5896	DN	PMID25980951-Compound-44
DMS5896	MI	TTQ5LRD
DMS5896	MN	Cellular inhibitor of apoptosis 1 (BIRC2)
DMS5896	MT	DTT
DMS5896	MA	Antagonist
DMS5896	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMS5896	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMS5896	DI	DMS5896
DMS5896	DN	PMID25980951-Compound-44
DMS5896	MI	TTIRY6K
DMS5896	MN	Cellular inhibitor of apoptosis 2 (BIRC3)
DMS5896	MT	DTT
DMS5896	MA	Antagonist
DMS5896	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMS5896	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMS5896	DI	DMS5896
DMS5896	DN	PMID25980951-Compound-44
DMS5896	MI	TTR7B60
DMS5896	MN	X-linked inhibitor of apoptosis protein (XIAP)
DMS5896	MT	DTT
DMS5896	MA	Antagonist
DMS5896	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMS5896	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DM1EU06	DI	DM1EU06
DM1EU06	DN	PMID25980951-Compound-45
DM1EU06	MI	TTR7B60
DM1EU06	MN	X-linked inhibitor of apoptosis protein (XIAP)
DM1EU06	MT	DTT
DM1EU06	MA	Antagonist
DM1EU06	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DM1EU06	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMB3IZT	DI	DMB3IZT
DMB3IZT	DN	PMID25980951-Compound-5
DMB3IZT	MI	TTQ5LRD
DMB3IZT	MN	Cellular inhibitor of apoptosis 1 (BIRC2)
DMB3IZT	MT	DTT
DMB3IZT	MA	Antagonist
DMB3IZT	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMB3IZT	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMB3IZT	DI	DMB3IZT
DMB3IZT	DN	PMID25980951-Compound-5
DMB3IZT	MI	TTR7B60
DMB3IZT	MN	X-linked inhibitor of apoptosis protein (XIAP)
DMB3IZT	MT	DTT
DMB3IZT	MA	Antagonist
DMB3IZT	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMB3IZT	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMVSW5N	DI	DMVSW5N
DMVSW5N	DN	PMID25980951-Compound-6
DMVSW5N	MI	TTQ5LRD
DMVSW5N	MN	Cellular inhibitor of apoptosis 1 (BIRC2)
DMVSW5N	MT	DTT
DMVSW5N	MA	Antagonist
DMVSW5N	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMVSW5N	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMVSW5N	DI	DMVSW5N
DMVSW5N	DN	PMID25980951-Compound-6
DMVSW5N	MI	TTHZ8TA
DMVSW5N	MN	Melanoma inhibitor of apoptosis protein (ML-IAP)
DMVSW5N	MT	DTT
DMVSW5N	MA	Antagonist
DMVSW5N	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMVSW5N	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMVSW5N	DI	DMVSW5N
DMVSW5N	DN	PMID25980951-Compound-6
DMVSW5N	MI	TTR7B60
DMVSW5N	MN	X-linked inhibitor of apoptosis protein (XIAP)
DMVSW5N	MT	DTT
DMVSW5N	MA	Antagonist
DMVSW5N	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMVSW5N	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMF8V5J	DI	DMF8V5J
DMF8V5J	DN	PMID25980951-Compound-7
DMF8V5J	MI	TTQ5LRD
DMF8V5J	MN	Cellular inhibitor of apoptosis 1 (BIRC2)
DMF8V5J	MT	DTT
DMF8V5J	MA	Antagonist
DMF8V5J	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMF8V5J	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DMF8V5J	DI	DMF8V5J
DMF8V5J	DN	PMID25980951-Compound-7
DMF8V5J	MI	TTR7B60
DMF8V5J	MN	X-linked inhibitor of apoptosis protein (XIAP)
DMF8V5J	MT	DTT
DMF8V5J	MA	Antagonist
DMF8V5J	RN	Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
DMF8V5J	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980951

DM89LF0	DI	DM89LF0
DM89LF0	DN	PMID25991433-Compound-A1
DM89LF0	MI	TTH6V3D
DM89LF0	MN	Cyclin-dependent kinase 1 (CDK1)
DM89LF0	MT	DTT
DM89LF0	MA	Inhibitor
DM89LF0	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DM89LF0	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DM89LF0	DI	DM89LF0
DM89LF0	DN	PMID25991433-Compound-A1
DM89LF0	MI	TT7HF4W
DM89LF0	MN	Cyclin-dependent kinase 2 (CDK2)
DM89LF0	MT	DTT
DM89LF0	MA	Inhibitor
DM89LF0	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DM89LF0	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DM89LF0	DI	DM89LF0
DM89LF0	DN	PMID25991433-Compound-A1
DM89LF0	MI	TT0PG8F
DM89LF0	MN	Cyclin-dependent kinase 4 (CDK4)
DM89LF0	MT	DTT
DM89LF0	MA	Inhibitor
DM89LF0	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DM89LF0	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DM89LF0	DI	DM89LF0
DM89LF0	DN	PMID25991433-Compound-A1
DM89LF0	MI	TTQBR95
DM89LF0	MN	Stress-activated protein kinase 2a (p38 alpha)
DM89LF0	MT	DTT
DM89LF0	MA	Inhibitor
DM89LF0	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DM89LF0	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DM89LF0	DI	DM89LF0
DM89LF0	DN	PMID25991433-Compound-A1
DM89LF0	MI	TT0K6EO
DM89LF0	MN	Stress-activated protein kinase JNK1 (JNK1)
DM89LF0	MT	DTT
DM89LF0	MA	Inhibitor
DM89LF0	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DM89LF0	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DM89LF0	DI	DM89LF0
DM89LF0	DN	PMID25991433-Compound-A1
DM89LF0	MI	TTHS0U8
DM89LF0	MN	Stress-activated protein kinase JNK2 (JNK2)
DM89LF0	MT	DTT
DM89LF0	MA	Inhibitor
DM89LF0	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DM89LF0	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DM89LF0	DI	DM89LF0
DM89LF0	DN	PMID25991433-Compound-A1
DM89LF0	MI	TT056SO
DM89LF0	MN	Stress-activated protein kinase JNK3 (JNK3)
DM89LF0	MT	DTT
DM89LF0	MA	Inhibitor
DM89LF0	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DM89LF0	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DM39NBT	DI	DM39NBT
DM39NBT	DN	PMID25991433-Compound-A10
DM39NBT	MI	TT0K6EO
DM39NBT	MN	Stress-activated protein kinase JNK1 (JNK1)
DM39NBT	MT	DTT
DM39NBT	MA	Inhibitor
DM39NBT	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DM39NBT	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DM39NBT	DI	DM39NBT
DM39NBT	DN	PMID25991433-Compound-A10
DM39NBT	MI	TTHS0U8
DM39NBT	MN	Stress-activated protein kinase JNK2 (JNK2)
DM39NBT	MT	DTT
DM39NBT	MA	Inhibitor
DM39NBT	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DM39NBT	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMD59C2	DI	DMD59C2
DMD59C2	DN	PMID25991433-Compound-A11
DMD59C2	MI	TT0K6EO
DMD59C2	MN	Stress-activated protein kinase JNK1 (JNK1)
DMD59C2	MT	DTT
DMD59C2	MA	Inhibitor
DMD59C2	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMD59C2	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMD59C2	DI	DMD59C2
DMD59C2	DN	PMID25991433-Compound-A11
DMD59C2	MI	TTHS0U8
DMD59C2	MN	Stress-activated protein kinase JNK2 (JNK2)
DMD59C2	MT	DTT
DMD59C2	MA	Inhibitor
DMD59C2	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMD59C2	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMX7MHC	DI	DMX7MHC
DMX7MHC	DN	PMID25991433-Compound-A2
DMX7MHC	MI	TT0K6EO
DMX7MHC	MN	Stress-activated protein kinase JNK1 (JNK1)
DMX7MHC	MT	DTT
DMX7MHC	MA	Inhibitor
DMX7MHC	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMX7MHC	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMX7MHC	DI	DMX7MHC
DMX7MHC	DN	PMID25991433-Compound-A2
DMX7MHC	MI	TTHS0U8
DMX7MHC	MN	Stress-activated protein kinase JNK2 (JNK2)
DMX7MHC	MT	DTT
DMX7MHC	MA	Inhibitor
DMX7MHC	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMX7MHC	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMJ1X53	DI	DMJ1X53
DMJ1X53	DN	PMID25991433-Compound-A3
DMJ1X53	MI	TT0K6EO
DMJ1X53	MN	Stress-activated protein kinase JNK1 (JNK1)
DMJ1X53	MT	DTT
DMJ1X53	MA	Inhibitor
DMJ1X53	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMJ1X53	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMJ1X53	DI	DMJ1X53
DMJ1X53	DN	PMID25991433-Compound-A3
DMJ1X53	MI	TTHS0U8
DMJ1X53	MN	Stress-activated protein kinase JNK2 (JNK2)
DMJ1X53	MT	DTT
DMJ1X53	MA	Inhibitor
DMJ1X53	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMJ1X53	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DM5YD1K	DI	DM5YD1K
DM5YD1K	DN	PMID25991433-Compound-A5
DM5YD1K	MI	TT0K6EO
DM5YD1K	MN	Stress-activated protein kinase JNK1 (JNK1)
DM5YD1K	MT	DTT
DM5YD1K	MA	Inhibitor
DM5YD1K	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DM5YD1K	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DM5YD1K	DI	DM5YD1K
DM5YD1K	DN	PMID25991433-Compound-A5
DM5YD1K	MI	TTHS0U8
DM5YD1K	MN	Stress-activated protein kinase JNK2 (JNK2)
DM5YD1K	MT	DTT
DM5YD1K	MA	Inhibitor
DM5YD1K	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DM5YD1K	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMFSB9Y	DI	DMFSB9Y
DMFSB9Y	DN	PMID25991433-Compound-A6
DMFSB9Y	MI	TT0K6EO
DMFSB9Y	MN	Stress-activated protein kinase JNK1 (JNK1)
DMFSB9Y	MT	DTT
DMFSB9Y	MA	Inhibitor
DMFSB9Y	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMFSB9Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMFSB9Y	DI	DMFSB9Y
DMFSB9Y	DN	PMID25991433-Compound-A6
DMFSB9Y	MI	TTHS0U8
DMFSB9Y	MN	Stress-activated protein kinase JNK2 (JNK2)
DMFSB9Y	MT	DTT
DMFSB9Y	MA	Inhibitor
DMFSB9Y	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMFSB9Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DM2ISDH	DI	DM2ISDH
DM2ISDH	DN	PMID25991433-Compound-A7
DM2ISDH	MI	TT0K6EO
DM2ISDH	MN	Stress-activated protein kinase JNK1 (JNK1)
DM2ISDH	MT	DTT
DM2ISDH	MA	Inhibitor
DM2ISDH	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DM2ISDH	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DM2ISDH	DI	DM2ISDH
DM2ISDH	DN	PMID25991433-Compound-A7
DM2ISDH	MI	TTHS0U8
DM2ISDH	MN	Stress-activated protein kinase JNK2 (JNK2)
DM2ISDH	MT	DTT
DM2ISDH	MA	Inhibitor
DM2ISDH	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DM2ISDH	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMHG4WD	DI	DMHG4WD
DMHG4WD	DN	PMID25991433-Compound-A8
DMHG4WD	MI	TT0K6EO
DMHG4WD	MN	Stress-activated protein kinase JNK1 (JNK1)
DMHG4WD	MT	DTT
DMHG4WD	MA	Inhibitor
DMHG4WD	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMHG4WD	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMHG4WD	DI	DMHG4WD
DMHG4WD	DN	PMID25991433-Compound-A8
DMHG4WD	MI	TTHS0U8
DMHG4WD	MN	Stress-activated protein kinase JNK2 (JNK2)
DMHG4WD	MT	DTT
DMHG4WD	MA	Inhibitor
DMHG4WD	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMHG4WD	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMPYCIM	DI	DMPYCIM
DMPYCIM	DN	PMID25991433-Compound-A9
DMPYCIM	MI	TT0K6EO
DMPYCIM	MN	Stress-activated protein kinase JNK1 (JNK1)
DMPYCIM	MT	DTT
DMPYCIM	MA	Inhibitor
DMPYCIM	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMPYCIM	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMPYCIM	DI	DMPYCIM
DMPYCIM	DN	PMID25991433-Compound-A9
DMPYCIM	MI	TTHS0U8
DMPYCIM	MN	Stress-activated protein kinase JNK2 (JNK2)
DMPYCIM	MT	DTT
DMPYCIM	MA	Inhibitor
DMPYCIM	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMPYCIM	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMJTO69	DI	DMJTO69
DMJTO69	DN	PMID25991433-Compound-B1
DMJTO69	MI	TTVOE6D
DMJTO69	MN	Mitogen-activated protein kinase (MAPK)
DMJTO69	MT	DTT
DMJTO69	MA	Inhibitor
DMJTO69	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMJTO69	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMTYQOF	DI	DMTYQOF
DMTYQOF	DN	PMID25991433-Compound-B2
DMTYQOF	MI	TTVOE6D
DMTYQOF	MN	Mitogen-activated protein kinase (MAPK)
DMTYQOF	MT	DTT
DMTYQOF	MA	Inhibitor
DMTYQOF	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMTYQOF	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMWSGV2	DI	DMWSGV2
DMWSGV2	DN	PMID25991433-Compound-B3
DMWSGV2	MI	TTVOE6D
DMWSGV2	MN	Mitogen-activated protein kinase (MAPK)
DMWSGV2	MT	DTT
DMWSGV2	MA	Inhibitor
DMWSGV2	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMWSGV2	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DM3KWFQ	DI	DM3KWFQ
DM3KWFQ	DN	PMID25991433-Compound-C1
DM3KWFQ	MI	TTHS0U8
DM3KWFQ	MN	Stress-activated protein kinase JNK2 (JNK2)
DM3KWFQ	MT	DTT
DM3KWFQ	MA	Inhibitor
DM3KWFQ	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DM3KWFQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMOAU09	DI	DMOAU09
DMOAU09	DN	PMID25991433-Compound-C2
DMOAU09	MI	TTVOE6D
DMOAU09	MN	Mitogen-activated protein kinase (MAPK)
DMOAU09	MT	DTT
DMOAU09	MA	Inhibitor
DMOAU09	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMOAU09	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMSKWBE	DI	DMSKWBE
DMSKWBE	DN	PMID25991433-Compound-C3
DMSKWBE	MI	TTVOE6D
DMSKWBE	MN	Mitogen-activated protein kinase (MAPK)
DMSKWBE	MT	DTT
DMSKWBE	MA	Inhibitor
DMSKWBE	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMSKWBE	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMXSK8Y	DI	DMXSK8Y
DMXSK8Y	DN	PMID25991433-Compound-D1
DMXSK8Y	MI	TT0K6EO
DMXSK8Y	MN	Stress-activated protein kinase JNK1 (JNK1)
DMXSK8Y	MT	DTT
DMXSK8Y	MA	Inhibitor
DMXSK8Y	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMXSK8Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMXSK8Y	DI	DMXSK8Y
DMXSK8Y	DN	PMID25991433-Compound-D1
DMXSK8Y	MI	TTHS0U8
DMXSK8Y	MN	Stress-activated protein kinase JNK2 (JNK2)
DMXSK8Y	MT	DTT
DMXSK8Y	MA	Inhibitor
DMXSK8Y	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMXSK8Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMLWSNA	DI	DMLWSNA
DMLWSNA	DN	PMID25991433-Compound-D2
DMLWSNA	MI	TT0K6EO
DMLWSNA	MN	Stress-activated protein kinase JNK1 (JNK1)
DMLWSNA	MT	DTT
DMLWSNA	MA	Inhibitor
DMLWSNA	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMLWSNA	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMLWSNA	DI	DMLWSNA
DMLWSNA	DN	PMID25991433-Compound-D2
DMLWSNA	MI	TTHS0U8
DMLWSNA	MN	Stress-activated protein kinase JNK2 (JNK2)
DMLWSNA	MT	DTT
DMLWSNA	MA	Inhibitor
DMLWSNA	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMLWSNA	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMKWFVP	DI	DMKWFVP
DMKWFVP	DN	PMID25991433-Compound-E1
DMKWFVP	MI	TT0K6EO
DMKWFVP	MN	Stress-activated protein kinase JNK1 (JNK1)
DMKWFVP	MT	DTT
DMKWFVP	MA	Inhibitor
DMKWFVP	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMKWFVP	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DM8YR1V	DI	DM8YR1V
DM8YR1V	DN	PMID25991433-Compound-E2
DM8YR1V	MI	TT0K6EO
DM8YR1V	MN	Stress-activated protein kinase JNK1 (JNK1)
DM8YR1V	MT	DTT
DM8YR1V	MA	Inhibitor
DM8YR1V	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DM8YR1V	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DM62XNE	DI	DM62XNE
DM62XNE	DN	PMID25991433-Compound-E3
DM62XNE	MI	TT0K6EO
DM62XNE	MN	Stress-activated protein kinase JNK1 (JNK1)
DM62XNE	MT	DTT
DM62XNE	MA	Inhibitor
DM62XNE	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DM62XNE	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DM1VHYX	DI	DM1VHYX
DM1VHYX	DN	PMID25991433-Compound-E4
DM1VHYX	MI	TT0K6EO
DM1VHYX	MN	Stress-activated protein kinase JNK1 (JNK1)
DM1VHYX	MT	DTT
DM1VHYX	MA	Inhibitor
DM1VHYX	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DM1VHYX	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DM2ZCTW	DI	DM2ZCTW
DM2ZCTW	DN	PMID25991433-Compound-E5
DM2ZCTW	MI	TT0K6EO
DM2ZCTW	MN	Stress-activated protein kinase JNK1 (JNK1)
DM2ZCTW	MT	DTT
DM2ZCTW	MA	Inhibitor
DM2ZCTW	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DM2ZCTW	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DM536JN	DI	DM536JN
DM536JN	DN	PMID25991433-Compound-Eb
DM536JN	MI	TT0K6EO
DM536JN	MN	Stress-activated protein kinase JNK1 (JNK1)
DM536JN	MT	DTT
DM536JN	MA	Inhibitor
DM536JN	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DM536JN	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMFS2YL	DI	DMFS2YL
DMFS2YL	DN	PMID25991433-Compound-F1
DMFS2YL	MI	TTVOE6D
DMFS2YL	MN	Mitogen-activated protein kinase (MAPK)
DMFS2YL	MT	DTT
DMFS2YL	MA	Inhibitor
DMFS2YL	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMFS2YL	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DM37VIQ	DI	DM37VIQ
DM37VIQ	DN	PMID25991433-Compound-F2
DM37VIQ	MI	TTQBR95
DM37VIQ	MN	Stress-activated protein kinase 2a (p38 alpha)
DM37VIQ	MT	DTT
DM37VIQ	MA	Inhibitor
DM37VIQ	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DM37VIQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DM37VIQ	DI	DM37VIQ
DM37VIQ	DN	PMID25991433-Compound-F2
DM37VIQ	MI	TT0K6EO
DM37VIQ	MN	Stress-activated protein kinase JNK1 (JNK1)
DM37VIQ	MT	DTT
DM37VIQ	MA	Inhibitor
DM37VIQ	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DM37VIQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DM37VIQ	DI	DM37VIQ
DM37VIQ	DN	PMID25991433-Compound-F2
DM37VIQ	MI	TTHS0U8
DM37VIQ	MN	Stress-activated protein kinase JNK2 (JNK2)
DM37VIQ	MT	DTT
DM37VIQ	MA	Inhibitor
DM37VIQ	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DM37VIQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DM37VIQ	DI	DM37VIQ
DM37VIQ	DN	PMID25991433-Compound-F2
DM37VIQ	MI	TT056SO
DM37VIQ	MN	Stress-activated protein kinase JNK3 (JNK3)
DM37VIQ	MT	DTT
DM37VIQ	MA	Inhibitor
DM37VIQ	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DM37VIQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMHS3ZW	DI	DMHS3ZW
DMHS3ZW	DN	PMID25991433-Compound-G1
DMHS3ZW	MI	TT0K6EO
DMHS3ZW	MN	Stress-activated protein kinase JNK1 (JNK1)
DMHS3ZW	MT	DTT
DMHS3ZW	MA	Inhibitor
DMHS3ZW	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMHS3ZW	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMU3XBH	DI	DMU3XBH
DMU3XBH	DN	PMID25991433-Compound-G2
DMU3XBH	MI	TT0K6EO
DMU3XBH	MN	Stress-activated protein kinase JNK1 (JNK1)
DMU3XBH	MT	DTT
DMU3XBH	MA	Inhibitor
DMU3XBH	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMU3XBH	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMACWQY	DI	DMACWQY
DMACWQY	DN	PMID25991433-Compound-G4
DMACWQY	MI	TT0K6EO
DMACWQY	MN	Stress-activated protein kinase JNK1 (JNK1)
DMACWQY	MT	DTT
DMACWQY	MA	Inhibitor
DMACWQY	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMACWQY	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMRJ1KY	DI	DMRJ1KY
DMRJ1KY	DN	PMID25991433-Compound-G5
DMRJ1KY	MI	TT0K6EO
DMRJ1KY	MN	Stress-activated protein kinase JNK1 (JNK1)
DMRJ1KY	MT	DTT
DMRJ1KY	MA	Inhibitor
DMRJ1KY	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMRJ1KY	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DM0Q37R	DI	DM0Q37R
DM0Q37R	DN	PMID25991433-Compound-H1
DM0Q37R	MI	TT0K6EO
DM0Q37R	MN	Stress-activated protein kinase JNK1 (JNK1)
DM0Q37R	MT	DTT
DM0Q37R	MA	Inhibitor
DM0Q37R	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DM0Q37R	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMZ9BTN	DI	DMZ9BTN
DMZ9BTN	DN	PMID25991433-Compound-H2
DMZ9BTN	MI	TT0K6EO
DMZ9BTN	MN	Stress-activated protein kinase JNK1 (JNK1)
DMZ9BTN	MT	DTT
DMZ9BTN	MA	Inhibitor
DMZ9BTN	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMZ9BTN	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMQKLX0	DI	DMQKLX0
DMQKLX0	DN	PMID25991433-Compound-H3
DMQKLX0	MI	TT0K6EO
DMQKLX0	MN	Stress-activated protein kinase JNK1 (JNK1)
DMQKLX0	MT	DTT
DMQKLX0	MA	Inhibitor
DMQKLX0	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMQKLX0	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMQGUMN	DI	DMQGUMN
DMQGUMN	DN	PMID25991433-Compound-J1
DMQGUMN	MI	TTVOE6D
DMQGUMN	MN	Mitogen-activated protein kinase (MAPK)
DMQGUMN	MT	DTT
DMQGUMN	MA	Inhibitor
DMQGUMN	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMQGUMN	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMZSOCK	DI	DMZSOCK
DMZSOCK	DN	PMID25991433-Compound-J2
DMZSOCK	MI	TT0K6EO
DMZSOCK	MN	Stress-activated protein kinase JNK1 (JNK1)
DMZSOCK	MT	DTT
DMZSOCK	MA	Inhibitor
DMZSOCK	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMZSOCK	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMZSOCK	DI	DMZSOCK
DMZSOCK	DN	PMID25991433-Compound-J2
DMZSOCK	MI	TTHS0U8
DMZSOCK	MN	Stress-activated protein kinase JNK2 (JNK2)
DMZSOCK	MT	DTT
DMZSOCK	MA	Inhibitor
DMZSOCK	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMZSOCK	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMZSOCK	DI	DMZSOCK
DMZSOCK	DN	PMID25991433-Compound-J2
DMZSOCK	MI	TT056SO
DMZSOCK	MN	Stress-activated protein kinase JNK3 (JNK3)
DMZSOCK	MT	DTT
DMZSOCK	MA	Inhibitor
DMZSOCK	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMZSOCK	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DM17P3F	DI	DM17P3F
DM17P3F	DN	PMID25991433-Compound-J3
DM17P3F	MI	TT0K6EO
DM17P3F	MN	Stress-activated protein kinase JNK1 (JNK1)
DM17P3F	MT	DTT
DM17P3F	MA	Inhibitor
DM17P3F	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DM17P3F	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DM17P3F	DI	DM17P3F
DM17P3F	DN	PMID25991433-Compound-J3
DM17P3F	MI	TTHS0U8
DM17P3F	MN	Stress-activated protein kinase JNK2 (JNK2)
DM17P3F	MT	DTT
DM17P3F	MA	Inhibitor
DM17P3F	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DM17P3F	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DM17P3F	DI	DM17P3F
DM17P3F	DN	PMID25991433-Compound-J3
DM17P3F	MI	TT056SO
DM17P3F	MN	Stress-activated protein kinase JNK3 (JNK3)
DM17P3F	MT	DTT
DM17P3F	MA	Inhibitor
DM17P3F	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DM17P3F	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMU75ZX	DI	DMU75ZX
DMU75ZX	DN	PMID25991433-Compound-J5
DMU75ZX	MI	TT0K6EO
DMU75ZX	MN	Stress-activated protein kinase JNK1 (JNK1)
DMU75ZX	MT	DTT
DMU75ZX	MA	Inhibitor
DMU75ZX	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMU75ZX	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMU75ZX	DI	DMU75ZX
DMU75ZX	DN	PMID25991433-Compound-J5
DMU75ZX	MI	TTHS0U8
DMU75ZX	MN	Stress-activated protein kinase JNK2 (JNK2)
DMU75ZX	MT	DTT
DMU75ZX	MA	Inhibitor
DMU75ZX	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMU75ZX	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMU75ZX	DI	DMU75ZX
DMU75ZX	DN	PMID25991433-Compound-J5
DMU75ZX	MI	TT056SO
DMU75ZX	MN	Stress-activated protein kinase JNK3 (JNK3)
DMU75ZX	MT	DTT
DMU75ZX	MA	Inhibitor
DMU75ZX	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMU75ZX	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMOWULJ	DI	DMOWULJ
DMOWULJ	DN	PMID25991433-Compound-J6
DMOWULJ	MI	TTVOE6D
DMOWULJ	MN	Mitogen-activated protein kinase (MAPK)
DMOWULJ	MT	DTT
DMOWULJ	MA	Inhibitor
DMOWULJ	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMOWULJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMLT8PA	DI	DMLT8PA
DMLT8PA	DN	PMID25991433-Compound-K1
DMLT8PA	MI	TT0K6EO
DMLT8PA	MN	Stress-activated protein kinase JNK1 (JNK1)
DMLT8PA	MT	DTT
DMLT8PA	MA	Inhibitor
DMLT8PA	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMLT8PA	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMBS4LE	DI	DMBS4LE
DMBS4LE	DN	PMID25991433-Compound-K2
DMBS4LE	MI	TT0K6EO
DMBS4LE	MN	Stress-activated protein kinase JNK1 (JNK1)
DMBS4LE	MT	DTT
DMBS4LE	MA	Inhibitor
DMBS4LE	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMBS4LE	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DM5U8WT	DI	DM5U8WT
DM5U8WT	DN	PMID25991433-Compound-L
DM5U8WT	MI	TTVOE6D
DM5U8WT	MN	Mitogen-activated protein kinase (MAPK)
DM5U8WT	MT	DTT
DM5U8WT	MA	Inhibitor
DM5U8WT	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DM5U8WT	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DM2135Y	DI	DM2135Y
DM2135Y	DN	PMID25991433-Compound-L1
DM2135Y	MI	TT3ZIJL
DM2135Y	MN	JNK-interacting protein peptide (pepJIP)
DM2135Y	MT	DTT
DM2135Y	MA	Inhibitor
DM2135Y	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DM2135Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DM2135Y	DI	DM2135Y
DM2135Y	DN	PMID25991433-Compound-L1
DM2135Y	MI	TTQBR95
DM2135Y	MN	Stress-activated protein kinase 2a (p38 alpha)
DM2135Y	MT	DTT
DM2135Y	MA	Inhibitor
DM2135Y	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DM2135Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DM2135Y	DI	DM2135Y
DM2135Y	DN	PMID25991433-Compound-L1
DM2135Y	MI	TT0K6EO
DM2135Y	MN	Stress-activated protein kinase JNK1 (JNK1)
DM2135Y	MT	DTT
DM2135Y	MA	Inhibitor
DM2135Y	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DM2135Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DM58UO9	DI	DM58UO9
DM58UO9	DN	PMID25991433-Compound-L2
DM58UO9	MI	TT3ZIJL
DM58UO9	MN	JNK-interacting protein peptide (pepJIP)
DM58UO9	MT	DTT
DM58UO9	MA	Inhibitor
DM58UO9	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DM58UO9	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DM58UO9	DI	DM58UO9
DM58UO9	DN	PMID25991433-Compound-L2
DM58UO9	MI	TTVOE6D
DM58UO9	MN	Mitogen-activated protein kinase (MAPK)
DM58UO9	MT	DTT
DM58UO9	MA	Inhibitor
DM58UO9	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DM58UO9	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DM58UO9	DI	DM58UO9
DM58UO9	DN	PMID25991433-Compound-L2
DM58UO9	MI	TTQBR95
DM58UO9	MN	Stress-activated protein kinase 2a (p38 alpha)
DM58UO9	MT	DTT
DM58UO9	MA	Inhibitor
DM58UO9	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DM58UO9	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DM3LWUR	DI	DM3LWUR
DM3LWUR	DN	PMID25991433-Compound-L3
DM3LWUR	MI	TT3ZIJL
DM3LWUR	MN	JNK-interacting protein peptide (pepJIP)
DM3LWUR	MT	DTT
DM3LWUR	MA	Inhibitor
DM3LWUR	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DM3LWUR	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DM3LWUR	DI	DM3LWUR
DM3LWUR	DN	PMID25991433-Compound-L3
DM3LWUR	MI	TTVOE6D
DM3LWUR	MN	Mitogen-activated protein kinase (MAPK)
DM3LWUR	MT	DTT
DM3LWUR	MA	Inhibitor
DM3LWUR	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DM3LWUR	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DM3LWUR	DI	DM3LWUR
DM3LWUR	DN	PMID25991433-Compound-L3
DM3LWUR	MI	TTQBR95
DM3LWUR	MN	Stress-activated protein kinase 2a (p38 alpha)
DM3LWUR	MT	DTT
DM3LWUR	MA	Inhibitor
DM3LWUR	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DM3LWUR	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMN27QB	DI	DMN27QB
DMN27QB	DN	PMID25991433-Compound-N1
DMN27QB	MI	TTXKZ8Q
DMN27QB	MN	JNK-interacting protein 1 peptide (pepJIP1)
DMN27QB	MT	DTT
DMN27QB	MA	Inhibitor
DMN27QB	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMN27QB	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMN27QB	DI	DMN27QB
DMN27QB	DN	PMID25991433-Compound-N1
DMN27QB	MI	TT0K6EO
DMN27QB	MN	Stress-activated protein kinase JNK1 (JNK1)
DMN27QB	MT	DTT
DMN27QB	MA	Inhibitor
DMN27QB	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMN27QB	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMXY4BE	DI	DMXY4BE
DMXY4BE	DN	PMID25991433-Compound-N2
DMXY4BE	MI	TTVOE6D
DMXY4BE	MN	Mitogen-activated protein kinase (MAPK)
DMXY4BE	MT	DTT
DMXY4BE	MA	Inhibitor
DMXY4BE	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMXY4BE	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMLHC5V	DI	DMLHC5V
DMLHC5V	DN	PMID25991433-Compound-N3
DMLHC5V	MI	TT3ZIJL
DMLHC5V	MN	JNK-interacting protein peptide (pepJIP)
DMLHC5V	MT	DTT
DMLHC5V	MA	Inhibitor
DMLHC5V	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMLHC5V	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMLHC5V	DI	DMLHC5V
DMLHC5V	DN	PMID25991433-Compound-N3
DMLHC5V	MI	TT0K6EO
DMLHC5V	MN	Stress-activated protein kinase JNK1 (JNK1)
DMLHC5V	MT	DTT
DMLHC5V	MA	Inhibitor
DMLHC5V	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMLHC5V	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMH073T	DI	DMH073T
DMH073T	DN	PMID25991433-Compound-O1
DMH073T	MI	TTR2TXZ
DMH073T	MN	Jun N terminal kinase (JNK)
DMH073T	MT	DTT
DMH073T	MA	Inhibitor
DMH073T	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMH073T	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMTROIQ	DI	DMTROIQ
DMTROIQ	DN	PMID25991433-Compound-O2
DMTROIQ	MI	TTQBR95
DMTROIQ	MN	Stress-activated protein kinase 2a (p38 alpha)
DMTROIQ	MT	DTT
DMTROIQ	MA	Inhibitor
DMTROIQ	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMTROIQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMVOWS5	DI	DMVOWS5
DMVOWS5	DN	PMID25991433-Compound-O3
DMVOWS5	MI	TT0K6EO
DMVOWS5	MN	Stress-activated protein kinase JNK1 (JNK1)
DMVOWS5	MT	DTT
DMVOWS5	MA	Inhibitor
DMVOWS5	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMVOWS5	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMVOWS5	DI	DMVOWS5
DMVOWS5	DN	PMID25991433-Compound-O3
DMVOWS5	MI	TTHS0U8
DMVOWS5	MN	Stress-activated protein kinase JNK2 (JNK2)
DMVOWS5	MT	DTT
DMVOWS5	MA	Inhibitor
DMVOWS5	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMVOWS5	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMVOWS5	DI	DMVOWS5
DMVOWS5	DN	PMID25991433-Compound-O3
DMVOWS5	MI	TT056SO
DMVOWS5	MN	Stress-activated protein kinase JNK3 (JNK3)
DMVOWS5	MT	DTT
DMVOWS5	MA	Inhibitor
DMVOWS5	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMVOWS5	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMD8AX6	DI	DMD8AX6
DMD8AX6	DN	PMID25991433-Compound-P1
DMD8AX6	MI	TT0K6EO
DMD8AX6	MN	Stress-activated protein kinase JNK1 (JNK1)
DMD8AX6	MT	DTT
DMD8AX6	MA	Inhibitor
DMD8AX6	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMD8AX6	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMD8AX6	DI	DMD8AX6
DMD8AX6	DN	PMID25991433-Compound-P1
DMD8AX6	MI	TTHS0U8
DMD8AX6	MN	Stress-activated protein kinase JNK2 (JNK2)
DMD8AX6	MT	DTT
DMD8AX6	MA	Inhibitor
DMD8AX6	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMD8AX6	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMD8AX6	DI	DMD8AX6
DMD8AX6	DN	PMID25991433-Compound-P1
DMD8AX6	MI	TT056SO
DMD8AX6	MN	Stress-activated protein kinase JNK3 (JNK3)
DMD8AX6	MT	DTT
DMD8AX6	MA	Inhibitor
DMD8AX6	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMD8AX6	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMEGS7U	DI	DMEGS7U
DMEGS7U	DN	PMID25991433-Compound-P2
DMEGS7U	MI	TTVOE6D
DMEGS7U	MN	Mitogen-activated protein kinase (MAPK)
DMEGS7U	MT	DTT
DMEGS7U	MA	Inhibitor
DMEGS7U	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMEGS7U	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMAFZLP	DI	DMAFZLP
DMAFZLP	DN	PMID25991433-Compound-P3
DMAFZLP	MI	TTVOE6D
DMAFZLP	MN	Mitogen-activated protein kinase (MAPK)
DMAFZLP	MT	DTT
DMAFZLP	MA	Inhibitor
DMAFZLP	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMAFZLP	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMVF1D6	DI	DMVF1D6
DMVF1D6	DN	PMID25991433-Compound-P4
DMVF1D6	MI	TT0K6EO
DMVF1D6	MN	Stress-activated protein kinase JNK1 (JNK1)
DMVF1D6	MT	DTT
DMVF1D6	MA	Inhibitor
DMVF1D6	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMVF1D6	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMVF1D6	DI	DMVF1D6
DMVF1D6	DN	PMID25991433-Compound-P4
DMVF1D6	MI	TTHS0U8
DMVF1D6	MN	Stress-activated protein kinase JNK2 (JNK2)
DMVF1D6	MT	DTT
DMVF1D6	MA	Inhibitor
DMVF1D6	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMVF1D6	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMVF1D6	DI	DMVF1D6
DMVF1D6	DN	PMID25991433-Compound-P4
DMVF1D6	MI	TT056SO
DMVF1D6	MN	Stress-activated protein kinase JNK3 (JNK3)
DMVF1D6	MT	DTT
DMVF1D6	MA	Inhibitor
DMVF1D6	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMVF1D6	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DM6FCS9	DI	DM6FCS9
DM6FCS9	DN	PMID25991433-Compound-P5
DM6FCS9	MI	TT0K6EO
DM6FCS9	MN	Stress-activated protein kinase JNK1 (JNK1)
DM6FCS9	MT	DTT
DM6FCS9	MA	Inhibitor
DM6FCS9	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DM6FCS9	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DM6FCS9	DI	DM6FCS9
DM6FCS9	DN	PMID25991433-Compound-P5
DM6FCS9	MI	TTHS0U8
DM6FCS9	MN	Stress-activated protein kinase JNK2 (JNK2)
DM6FCS9	MT	DTT
DM6FCS9	MA	Inhibitor
DM6FCS9	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DM6FCS9	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DM6FCS9	DI	DM6FCS9
DM6FCS9	DN	PMID25991433-Compound-P5
DM6FCS9	MI	TT056SO
DM6FCS9	MN	Stress-activated protein kinase JNK3 (JNK3)
DM6FCS9	MT	DTT
DM6FCS9	MA	Inhibitor
DM6FCS9	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DM6FCS9	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMNDVC9	DI	DMNDVC9
DMNDVC9	DN	PMID25991433-Compound-P6
DMNDVC9	MI	TT0K6EO
DMNDVC9	MN	Stress-activated protein kinase JNK1 (JNK1)
DMNDVC9	MT	DTT
DMNDVC9	MA	Inhibitor
DMNDVC9	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMNDVC9	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMNDVC9	DI	DMNDVC9
DMNDVC9	DN	PMID25991433-Compound-P6
DMNDVC9	MI	TTHS0U8
DMNDVC9	MN	Stress-activated protein kinase JNK2 (JNK2)
DMNDVC9	MT	DTT
DMNDVC9	MA	Inhibitor
DMNDVC9	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMNDVC9	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMNDVC9	DI	DMNDVC9
DMNDVC9	DN	PMID25991433-Compound-P6
DMNDVC9	MI	TT056SO
DMNDVC9	MN	Stress-activated protein kinase JNK3 (JNK3)
DMNDVC9	MT	DTT
DMNDVC9	MA	Inhibitor
DMNDVC9	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMNDVC9	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMEMSB2	DI	DMEMSB2
DMEMSB2	DN	PMID25991433-Compound-Q1
DMEMSB2	MI	TTR2TXZ
DMEMSB2	MN	Jun N terminal kinase (JNK)
DMEMSB2	MT	DTT
DMEMSB2	MA	Inhibitor
DMEMSB2	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMEMSB2	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMEMSB2	DI	DMEMSB2
DMEMSB2	DN	PMID25991433-Compound-Q1
DMEMSB2	MI	TTVOE6D
DMEMSB2	MN	Mitogen-activated protein kinase (MAPK)
DMEMSB2	MT	DTT
DMEMSB2	MA	Inhibitor
DMEMSB2	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMEMSB2	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DMAIKJV	DI	DMAIKJV
DMAIKJV	DN	PMID25991433-Compound-Q2
DMAIKJV	MI	TTVOE6D
DMAIKJV	MN	Mitogen-activated protein kinase (MAPK)
DMAIKJV	MT	DTT
DMAIKJV	MA	Inhibitor
DMAIKJV	RN	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
DMAIKJV	RU	https://www.ncbi.nlm.nih.gov/pubmed/25991433

DM8FQJB	DI	DM8FQJB
DM8FQJB	DN	PMID26004420-Compound-U2014S0288042A
DM8FQJB	MI	TTJ13ST
DM8FQJB	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DM8FQJB	MT	DTT
DM8FQJB	MA	Inhibitor
DM8FQJB	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DM8FQJB	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DM8RJTQ	DI	DM8RJTQ
DM8RJTQ	DN	PMID26004420-Compound-U2014S0288042C
DM8RJTQ	MI	TTJ13ST
DM8RJTQ	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DM8RJTQ	MT	DTT
DM8RJTQ	MA	Inhibitor
DM8RJTQ	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DM8RJTQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DMVQSYT	DI	DMVQSYT
DMVQSYT	DN	PMID26004420-Compound-US20140031349A
DMVQSYT	MI	TTJ13ST
DMVQSYT	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DMVQSYT	MT	DTT
DMVQSYT	MA	Inhibitor
DMVQSYT	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DMVQSYT	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DM3M1NB	DI	DM3M1NB
DM3M1NB	DN	PMID26004420-Compound-US20140031349B
DM3M1NB	MI	TTJ13ST
DM3M1NB	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DM3M1NB	MT	DTT
DM3M1NB	MA	Inhibitor
DM3M1NB	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DM3M1NB	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DMDP8J0	DI	DMDP8J0
DMDP8J0	DN	PMID26004420-Compound-US20140031349C
DMDP8J0	MI	TTJ13ST
DMDP8J0	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DMDP8J0	MT	DTT
DMDP8J0	MA	Inhibitor
DMDP8J0	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DMDP8J0	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DMUD7IB	DI	DMUD7IB
DMUD7IB	DN	PMID26004420-Compound-US20140031349D
DMUD7IB	MI	TTJ13ST
DMUD7IB	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DMUD7IB	MT	DTT
DMUD7IB	MA	Inhibitor
DMUD7IB	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DMUD7IB	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DMIXVNQ	DI	DMIXVNQ
DMIXVNQ	DN	PMID26004420-Compound-US20140142115A
DMIXVNQ	MI	TTJ13ST
DMIXVNQ	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DMIXVNQ	MT	DTT
DMIXVNQ	MA	Inhibitor
DMIXVNQ	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DMIXVNQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DM07DC6	DI	DM07DC6
DM07DC6	DN	PMID26004420-Compound-US20140142115B
DM07DC6	MI	TTJ13ST
DM07DC6	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DM07DC6	MT	DTT
DM07DC6	MA	Inhibitor
DM07DC6	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DM07DC6	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DMQ7Z5F	DI	DMQ7Z5F
DMQ7Z5F	DN	PMID26004420-Compound-US20140142115C
DMQ7Z5F	MI	TTJ13ST
DMQ7Z5F	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DMQ7Z5F	MT	DTT
DMQ7Z5F	MA	Inhibitor
DMQ7Z5F	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DMQ7Z5F	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DMQ5AIT	DI	DMQ5AIT
DMQ5AIT	DN	PMID26004420-Compound-US20140275020D
DMQ5AIT	MI	TTJ13ST
DMQ5AIT	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DMQ5AIT	MT	DTT
DMQ5AIT	MA	Inhibitor
DMQ5AIT	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DMQ5AIT	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DMH7JKI	DI	DMH7JKI
DMH7JKI	DN	PMID26004420-Compound-US20140275020E
DMH7JKI	MI	TTJ13ST
DMH7JKI	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DMH7JKI	MT	DTT
DMH7JKI	MA	Inhibitor
DMH7JKI	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DMH7JKI	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DMH8M1D	DI	DMH8M1D
DMH8M1D	DN	PMID26004420-Compound-US20140309213A
DMH8M1D	MI	TTJ13ST
DMH8M1D	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DMH8M1D	MT	DTT
DMH8M1D	MA	Inhibitor
DMH8M1D	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DMH8M1D	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DM0P4TA	DI	DM0P4TA
DM0P4TA	DN	PMID26004420-Compound-US20140309213B
DM0P4TA	MI	TTJ13ST
DM0P4TA	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DM0P4TA	MT	DTT
DM0P4TA	MA	Inhibitor
DM0P4TA	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DM0P4TA	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DM4M2TU	DI	DM4M2TU
DM4M2TU	DN	PMID26004420-Compound-US20140336177D
DM4M2TU	MI	TTJ13ST
DM4M2TU	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DM4M2TU	MT	DTT
DM4M2TU	MA	Inhibitor
DM4M2TU	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DM4M2TU	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DMCRJO1	DI	DMCRJO1
DMCRJO1	DN	PMID26004420-Compound-US20140336177E
DMCRJO1	MI	TTJ13ST
DMCRJO1	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DMCRJO1	MT	DTT
DMCRJO1	MA	Inhibitor
DMCRJO1	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DMCRJO1	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DM37GMQ	DI	DM37GMQ
DM37GMQ	DN	PMID26004420-Compound-WO2010129379A
DM37GMQ	MI	TTJ13ST
DM37GMQ	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DM37GMQ	MT	DTT
DM37GMQ	MA	Inhibitor
DM37GMQ	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DM37GMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DM62A1H	DI	DM62A1H
DM62A1H	DN	PMID26004420-Compound-WO2010129379B
DM62A1H	MI	TTJ13ST
DM62A1H	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DM62A1H	MT	DTT
DM62A1H	MA	Inhibitor
DM62A1H	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DM62A1H	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DMV3X64	DI	DMV3X64
DMV3X64	DN	PMID26004420-Compound-WO2010129379C
DMV3X64	MI	TTJ13ST
DMV3X64	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DMV3X64	MT	DTT
DMV3X64	MA	Inhibitor
DMV3X64	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DMV3X64	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DMR9B2D	DI	DMR9B2D
DMR9B2D	DN	PMID26004420-Compound-WO2012058116A
DMR9B2D	MI	TTJ13ST
DMR9B2D	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DMR9B2D	MT	DTT
DMR9B2D	MA	Inhibitor
DMR9B2D	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DMR9B2D	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DMD41UF	DI	DMD41UF
DMD41UF	DN	PMID26004420-Compound-WO2012058116B
DMD41UF	MI	TTJ13ST
DMD41UF	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DMD41UF	MT	DTT
DMD41UF	MA	Inhibitor
DMD41UF	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DMD41UF	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DM2Y64W	DI	DM2Y64W
DM2Y64W	DN	PMID26004420-Compound-WO2012058116C
DM2Y64W	MI	TTJ13ST
DM2Y64W	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DM2Y64W	MT	DTT
DM2Y64W	MA	Inhibitor
DM2Y64W	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DM2Y64W	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DMUX0SG	DI	DMUX0SG
DMUX0SG	DN	PMID26004420-Compound-WO2012058134A
DMUX0SG	MI	TTJ13ST
DMUX0SG	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DMUX0SG	MT	DTT
DMUX0SG	MA	Inhibitor
DMUX0SG	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DMUX0SG	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DMGVXCL	DI	DMGVXCL
DMGVXCL	DN	PMID26004420-Compound-WO2012058134B
DMGVXCL	MI	TTJ13ST
DMGVXCL	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DMGVXCL	MT	DTT
DMGVXCL	MA	Inhibitor
DMGVXCL	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DMGVXCL	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DM9AJVK	DI	DM9AJVK
DM9AJVK	DN	PMID26004420-Compound-WO2012058134C
DM9AJVK	MI	TTJ13ST
DM9AJVK	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DM9AJVK	MT	DTT
DM9AJVK	MA	Inhibitor
DM9AJVK	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DM9AJVK	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DMIV92A	DI	DMIV92A
DMIV92A	DN	PMID26004420-Compound-WO2013028474A
DMIV92A	MI	TTJ13ST
DMIV92A	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DMIV92A	MT	DTT
DMIV92A	MA	Inhibitor
DMIV92A	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DMIV92A	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DMCP0WF	DI	DMCP0WF
DMCP0WF	DN	PMID26004420-Compound-WO2013028474B
DMCP0WF	MI	TTJ13ST
DMCP0WF	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DMCP0WF	MT	DTT
DMCP0WF	MA	Inhibitor
DMCP0WF	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DMCP0WF	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DMTCPNY	DI	DMTCPNY
DMTCPNY	DN	PMID26004420-Compound-WO2013028474C
DMTCPNY	MI	TTJ13ST
DMTCPNY	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DMTCPNY	MT	DTT
DMTCPNY	MA	Inhibitor
DMTCPNY	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DMTCPNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DMT7GQ1	DI	DMT7GQ1
DMT7GQ1	DN	PMID26004420-Compound-WO2013039802A
DMT7GQ1	MI	TTJ13ST
DMT7GQ1	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DMT7GQ1	MT	DTT
DMT7GQ1	MA	Inhibitor
DMT7GQ1	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DMT7GQ1	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DMP130R	DI	DMP130R
DMP130R	DN	PMID26004420-Compound-WO2013039802B
DMP130R	MI	TTJ13ST
DMP130R	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DMP130R	MT	DTT
DMP130R	MA	Inhibitor
DMP130R	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DMP130R	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DMV7ISR	DI	DMV7ISR
DMV7ISR	DN	PMID26004420-Compound-WO2013039802C
DMV7ISR	MI	TTJ13ST
DMV7ISR	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DMV7ISR	MT	DTT
DMV7ISR	MA	Inhibitor
DMV7ISR	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DMV7ISR	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DMH7E38	DI	DMH7E38
DMH7E38	DN	PMID26004420-Compound-WO2013062892D
DMH7E38	MI	TTJ13ST
DMH7E38	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DMH7E38	MT	DTT
DMH7E38	MA	Inhibitor
DMH7E38	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DMH7E38	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DMMHLA9	DI	DMMHLA9
DMMHLA9	DN	PMID26004420-Compound-WO2013062892E
DMMHLA9	MI	TTJ13ST
DMMHLA9	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DMMHLA9	MT	DTT
DMMHLA9	MA	Inhibitor
DMMHLA9	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DMMHLA9	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DM5N9M4	DI	DM5N9M4
DM5N9M4	DN	PMID26004420-Compound-WO2013062900A
DM5N9M4	MI	TTJ13ST
DM5N9M4	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DM5N9M4	MT	DTT
DM5N9M4	MA	Inhibitor
DM5N9M4	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DM5N9M4	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DMIM8UF	DI	DMIM8UF
DMIM8UF	DN	PMID26004420-Compound-WO2013062900B
DMIM8UF	MI	TTJ13ST
DMIM8UF	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DMIM8UF	MT	DTT
DMIM8UF	MA	Inhibitor
DMIM8UF	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DMIM8UF	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DMDZHAB	DI	DMDZHAB
DMDZHAB	DN	PMID26004420-Compound-WO2013062900C
DMDZHAB	MI	TTJ13ST
DMDZHAB	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DMDZHAB	MT	DTT
DMDZHAB	MA	Inhibitor
DMDZHAB	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DMDZHAB	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DMRDUS9	DI	DMRDUS9
DMRDUS9	DN	PMID26004420-Compound-WO2014015495A
DMRDUS9	MI	TTJ13ST
DMRDUS9	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DMRDUS9	MT	DTT
DMRDUS9	MA	Inhibitor
DMRDUS9	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DMRDUS9	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DMLH637	DI	DMLH637
DMLH637	DN	PMID26004420-Compound-WO2014015495B
DMLH637	MI	TTJ13ST
DMLH637	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DMLH637	MT	DTT
DMLH637	MA	Inhibitor
DMLH637	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DMLH637	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DMHA18O	DI	DMHA18O
DMHA18O	DN	PMID26004420-Compound-WO2014015495C
DMHA18O	MI	TTJ13ST
DMHA18O	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DMHA18O	MT	DTT
DMHA18O	MA	Inhibitor
DMHA18O	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DMHA18O	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DM3QO5R	DI	DM3QO5R
DM3QO5R	DN	PMID26004420-Compound-WO2014015495D
DM3QO5R	MI	TTJ13ST
DM3QO5R	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DM3QO5R	MT	DTT
DM3QO5R	MA	Inhibitor
DM3QO5R	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DM3QO5R	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DMY6JAB	DI	DMY6JAB
DMY6JAB	DN	PMID26004420-Compound-WO2014085210A
DMY6JAB	MI	TTJ13ST
DMY6JAB	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DMY6JAB	MT	DTT
DMY6JAB	MA	Inhibitor
DMY6JAB	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DMY6JAB	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DMTD0RK	DI	DMTD0RK
DMTD0RK	DN	PMID26004420-Compound-WO2014085210B
DMTD0RK	MI	TTJ13ST
DMTD0RK	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DMTD0RK	MT	DTT
DMTD0RK	MA	Inhibitor
DMTD0RK	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DMTD0RK	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DMKC6SA	DI	DMKC6SA
DMKC6SA	DN	PMID26004420-Compound-WO2014085210C
DMKC6SA	MI	TTJ13ST
DMKC6SA	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DMKC6SA	MT	DTT
DMKC6SA	MA	Inhibitor
DMKC6SA	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DMKC6SA	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DMJIZWR	DI	DMJIZWR
DMJIZWR	DN	PMID26004420-Compound-WO2014099633D
DMJIZWR	MI	TTJ13ST
DMJIZWR	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DMJIZWR	MT	DTT
DMJIZWR	MA	Inhibitor
DMJIZWR	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DMJIZWR	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DMSPG8Y	DI	DMSPG8Y
DMSPG8Y	DN	PMID26004420-Compound-WO2014099633E
DMSPG8Y	MI	TTJ13ST
DMSPG8Y	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DMSPG8Y	MT	DTT
DMSPG8Y	MA	Inhibitor
DMSPG8Y	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DMSPG8Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DM59INV	DI	DM59INV
DM59INV	DN	PMID26004420-Compound-WO2014126944A
DM59INV	MI	TTJ13ST
DM59INV	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DM59INV	MT	DTT
DM59INV	MA	Inhibitor
DM59INV	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DM59INV	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DMH0LBI	DI	DMH0LBI
DMH0LBI	DN	PMID26004420-Compound-WO2014126944B
DMH0LBI	MI	TTJ13ST
DMH0LBI	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DMH0LBI	MT	DTT
DMH0LBI	MA	Inhibitor
DMH0LBI	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DMH0LBI	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DMN1B3F	DI	DMN1B3F
DMN1B3F	DN	PMID26004420-Compound-WO2014150132A
DMN1B3F	MI	TTJ13ST
DMN1B3F	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DMN1B3F	MT	DTT
DMN1B3F	MA	Inhibitor
DMN1B3F	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DMN1B3F	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DMJX8WY	DI	DMJX8WY
DMJX8WY	DN	PMID26004420-Compound-WO2014150132B
DMJX8WY	MI	TTJ13ST
DMJX8WY	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DMJX8WY	MT	DTT
DMJX8WY	MA	Inhibitor
DMJX8WY	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DMJX8WY	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DM2FDCT	DI	DM2FDCT
DM2FDCT	DN	PMID26004420-Compound-WO2014150132C
DM2FDCT	MI	TTJ13ST
DM2FDCT	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DM2FDCT	MT	DTT
DM2FDCT	MA	Inhibitor
DM2FDCT	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DM2FDCT	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DMI30GA	DI	DMI30GA
DMI30GA	DN	PMID26004420-Compound-WO2015017305D
DMI30GA	MI	TTJ13ST
DMI30GA	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DMI30GA	MT	DTT
DMI30GA	MA	Inhibitor
DMI30GA	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DMI30GA	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DMV4HQ5	DI	DMV4HQ5
DMV4HQ5	DN	PMID26004420-Compound-WO2015017305E
DMV4HQ5	MI	TTJ13ST
DMV4HQ5	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DMV4HQ5	MT	DTT
DMV4HQ5	MA	Inhibitor
DMV4HQ5	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DMV4HQ5	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DMLV6IY	DI	DMLV6IY
DMLV6IY	DN	PMID26004420-Compound-WO2015017305F
DMLV6IY	MI	TTJ13ST
DMLV6IY	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DMLV6IY	MT	DTT
DMLV6IY	MA	Inhibitor
DMLV6IY	RN	Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51.
DMLV6IY	RU	https://www.ncbi.nlm.nih.gov/pubmed/26004420

DMENX90	DI	DMENX90
DMENX90	DN	PMID26077642-Compound-Figure3A
DMENX90	MI	TTVSYP9
DMENX90	MN	Ubiquitin carboxyl-terminal hydrolase 14 (USP14)
DMENX90	MT	DTT
DMENX90	MA	Inhibitor
DMENX90	RN	Deubiquitinases (DUBs) and DUB inhibitors: a patent review.Expert Opin Ther Pat. 2015;25(10):1191-1208.
DMENX90	RU	https://www.ncbi.nlm.nih.gov/pubmed/26077642

DMENX90	DI	DMENX90
DMENX90	DN	PMID26077642-Compound-Figure3A
DMENX90	MI	TTSX29Z
DMENX90	MN	Ubiquitin C-terminal hydrolase UCH37 (UCHL5)
DMENX90	MT	DTT
DMENX90	MA	Inhibitor
DMENX90	RN	Deubiquitinases (DUBs) and DUB inhibitors: a patent review.Expert Opin Ther Pat. 2015;25(10):1191-1208.
DMENX90	RU	https://www.ncbi.nlm.nih.gov/pubmed/26077642

DM9A8PN	DI	DM9A8PN
DM9A8PN	DN	PMID26077642-Compound-Figure3G
DM9A8PN	MI	TTZC0KV
DM9A8PN	MN	Zinc finger-containing ubiquitin peptidase 1 (ZUP1)
DM9A8PN	MT	DTT
DM9A8PN	MA	Inhibitor
DM9A8PN	RN	Deubiquitinases (DUBs) and DUB inhibitors: a patent review.Expert Opin Ther Pat. 2015;25(10):1191-1208.
DM9A8PN	RU	https://www.ncbi.nlm.nih.gov/pubmed/26077642

DMQYWBR	DI	DMQYWBR
DMQYWBR	DN	PMID26077642-Compound-Figure3H
DMQYWBR	MI	TTZC0KV
DMQYWBR	MN	Zinc finger-containing ubiquitin peptidase 1 (ZUP1)
DMQYWBR	MT	DTT
DMQYWBR	MA	Inhibitor
DMQYWBR	RN	Deubiquitinases (DUBs) and DUB inhibitors: a patent review.Expert Opin Ther Pat. 2015;25(10):1191-1208.
DMQYWBR	RU	https://www.ncbi.nlm.nih.gov/pubmed/26077642

DMS9KCF	DI	DMS9KCF
DMS9KCF	DN	PMID26077642-Compound-Vif1
DMS9KCF	MI	TTXU3EQ
DMS9KCF	MN	Herpesvirus ubiquitin-specific protease (HAUSP)
DMS9KCF	MT	DTT
DMS9KCF	MA	Inhibitor
DMS9KCF	RN	Deubiquitinases (DUBs) and DUB inhibitors: a patent review.Expert Opin Ther Pat. 2015;25(10):1191-1208.
DMS9KCF	RU	https://www.ncbi.nlm.nih.gov/pubmed/26077642

DMYXIS7	DI	DMYXIS7
DMYXIS7	DN	PMID26077642-Compound-Vif2
DMYXIS7	MI	TTXU3EQ
DMYXIS7	MN	Herpesvirus ubiquitin-specific protease (HAUSP)
DMYXIS7	MT	DTT
DMYXIS7	MA	Inhibitor
DMYXIS7	RN	Deubiquitinases (DUBs) and DUB inhibitors: a patent review.Expert Opin Ther Pat. 2015;25(10):1191-1208.
DMYXIS7	RU	https://www.ncbi.nlm.nih.gov/pubmed/26077642

DM2PUBI	DI	DM2PUBI
DM2PUBI	DN	PMID26099857-Compound-WO2011037610Formula(I)
DM2PUBI	MI	TTKVTQO
DM2PUBI	MN	Prostaglandin transporter (SLC21A2)
DM2PUBI	MT	DTT
DM2PUBI	MA	Inhibitor
DM2PUBI	RN	Treatment of obesity and pulmonary arterial hypertension with inhibitors of the prostaglandin transporter: evaluation of patent WO2014/204895A1.Expert Opin Ther Pat. 2015;25(9):1069-77.
DM2PUBI	RU	https://www.ncbi.nlm.nih.gov/pubmed/26099857

DMXVCHZ	DI	DMXVCHZ
DMXVCHZ	DN	PMID26161698-Compound-10
DMXVCHZ	MI	TTMBO1Z
DMXVCHZ	MN	Cyclin-dependent kinase (CDK)
DMXVCHZ	MT	DTT
DMXVCHZ	MA	Inhibitor
DMXVCHZ	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMXVCHZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMB92RA	DI	DMB92RA
DMB92RA	DN	PMID26161698-Compound-17
DMB92RA	MI	TTMYWL7
DMB92RA	MN	Cyclin-dependent kinase 3 (CDK3)
DMB92RA	MT	DTT
DMB92RA	MA	Inhibitor
DMB92RA	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMB92RA	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMB92RA	DI	DMB92RA
DMB92RA	DN	PMID26161698-Compound-17
DMB92RA	MI	TT0PG8F
DMB92RA	MN	Cyclin-dependent kinase 4 (CDK4)
DMB92RA	MT	DTT
DMB92RA	MA	Inhibitor
DMB92RA	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMB92RA	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DM6JVR5	DI	DM6JVR5
DM6JVR5	DN	PMID26161698-Compound-18
DM6JVR5	MI	TTL4Q97
DM6JVR5	MN	Cyclin-dependent kinase 5 (CDK5)
DM6JVR5	MT	DTT
DM6JVR5	MA	Inhibitor
DM6JVR5	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DM6JVR5	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DM6JVR5	DI	DM6JVR5
DM6JVR5	DN	PMID26161698-Compound-18
DM6JVR5	MI	TTRSMW9
DM6JVR5	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DM6JVR5	MT	DTT
DM6JVR5	MA	Inhibitor
DM6JVR5	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DM6JVR5	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DM4AFHY	DI	DM4AFHY
DM4AFHY	DN	PMID26161698-Compound-25
DM4AFHY	MI	TT7HF4W
DM4AFHY	MN	Cyclin-dependent kinase 2 (CDK2)
DM4AFHY	MT	DTT
DM4AFHY	MA	Inhibitor
DM4AFHY	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DM4AFHY	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DM4AFHY	DI	DM4AFHY
DM4AFHY	DN	PMID26161698-Compound-25
DM4AFHY	MI	TT1LVF2
DM4AFHY	MN	Cyclin-dependent kinase 9 (CDK9)
DM4AFHY	MT	DTT
DM4AFHY	MA	Inhibitor
DM4AFHY	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DM4AFHY	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMRIWKV	DI	DMRIWKV
DMRIWKV	DN	PMID26161698-Compound-32
DMRIWKV	MI	TT1LVF2
DMRIWKV	MN	Cyclin-dependent kinase 9 (CDK9)
DMRIWKV	MT	DTT
DMRIWKV	MA	Inhibitor
DMRIWKV	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMRIWKV	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMTIM1E	DI	DMTIM1E
DMTIM1E	DN	PMID26161698-Compound-34
DMTIM1E	MI	TTQYF7G
DMTIM1E	MN	Cyclin-dependent kinase 7 (CDK7)
DMTIM1E	MT	DTT
DMTIM1E	MA	Inhibitor
DMTIM1E	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMTIM1E	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DM8UPO3	DI	DM8UPO3
DM8UPO3	DN	PMID26161698-Compound-44
DM8UPO3	MI	TTSMTDI
DM8UPO3	MN	CDC7-related kinase (CDC7)
DM8UPO3	MT	DTT
DM8UPO3	MA	Inhibitor
DM8UPO3	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DM8UPO3	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DM8UPO3	DI	DM8UPO3
DM8UPO3	DN	PMID26161698-Compound-44
DM8UPO3	MI	TTMBO1Z
DM8UPO3	MN	Cyclin-dependent kinase (CDK)
DM8UPO3	MT	DTT
DM8UPO3	MA	Inhibitor
DM8UPO3	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DM8UPO3	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMF9C4I	DI	DMF9C4I
DMF9C4I	DN	PMID26161824-Compound-68
DMF9C4I	MI	TT6OEDT
DMF9C4I	MN	Cannabinoid receptor 1 (CB1)
DMF9C4I	MT	DTT
DMF9C4I	MA	Antagonist
DMF9C4I	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMF9C4I	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMKOSN5	DI	DMKOSN5
DMKOSN5	DN	PMID26161824-Compound-69
DMKOSN5	MI	TT6OEDT
DMKOSN5	MN	Cannabinoid receptor 1 (CB1)
DMKOSN5	MT	DTT
DMKOSN5	MA	Antagonist
DMKOSN5	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMKOSN5	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMHXT12	DI	DMHXT12
DMHXT12	DN	PMID26293650-Compound-34
DMHXT12	MI	TTH5TC2
DMHXT12	MN	NF-kappa-B-activating kinase (TBK1)
DMHXT12	MT	DTT
DMHXT12	MA	Inhibitor
DMHXT12	RN	TBK1 inhibitors: a review of patent literature (2011 - 2014).Expert Opin Ther Pat. 2015;25(12):1385-96.
DMHXT12	RU	https://www.ncbi.nlm.nih.gov/pubmed/26293650

DMPG8MF	DI	DMPG8MF
DMPG8MF	DN	PMID26293650-Compound-35
DMPG8MF	MI	TTH5TC2
DMPG8MF	MN	NF-kappa-B-activating kinase (TBK1)
DMPG8MF	MT	DTT
DMPG8MF	MA	Inhibitor
DMPG8MF	RN	TBK1 inhibitors: a review of patent literature (2011 - 2014).Expert Opin Ther Pat. 2015;25(12):1385-96.
DMPG8MF	RU	https://www.ncbi.nlm.nih.gov/pubmed/26293650

DMP8RQ4	DI	DMP8RQ4
DMP8RQ4	DN	PMID26394986-Compound-10
DMP8RQ4	MI	TTN7R6K
DMP8RQ4	MN	Signal transducer and activator of transcription 1 (STAT1)
DMP8RQ4	MT	DTT
DMP8RQ4	MA	Inhibitor
DMP8RQ4	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMP8RQ4	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMP8RQ4	DI	DMP8RQ4
DMP8RQ4	DN	PMID26394986-Compound-10
DMP8RQ4	MI	TTH8FZW
DMP8RQ4	MN	Signal transducer and activator of transcription 3 (STAT3)
DMP8RQ4	MT	DTT
DMP8RQ4	MA	Inhibitor
DMP8RQ4	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMP8RQ4	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMP8RQ4	DI	DMP8RQ4
DMP8RQ4	DN	PMID26394986-Compound-10
DMP8RQ4	MI	TTLRFIH
DMP8RQ4	MN	Signal transducer and activator of transcription 5 (STAT5)
DMP8RQ4	MT	DTT
DMP8RQ4	MA	Inhibitor
DMP8RQ4	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMP8RQ4	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMWMZE4	DI	DMWMZE4
DMWMZE4	DN	PMID26394986-Compound-11
DMWMZE4	MI	TTH8FZW
DMWMZE4	MN	Signal transducer and activator of transcription 3 (STAT3)
DMWMZE4	MT	DTT
DMWMZE4	MA	Inhibitor
DMWMZE4	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMWMZE4	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMTSQXE	DI	DMTSQXE
DMTSQXE	DN	PMID26394986-Compound-12
DMTSQXE	MI	TTH8FZW
DMTSQXE	MN	Signal transducer and activator of transcription 3 (STAT3)
DMTSQXE	MT	DTT
DMTSQXE	MA	Inhibitor
DMTSQXE	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMTSQXE	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMBUZHO	DI	DMBUZHO
DMBUZHO	DN	PMID26394986-Compound-13
DMBUZHO	MI	TTH8FZW
DMBUZHO	MN	Signal transducer and activator of transcription 3 (STAT3)
DMBUZHO	MT	DTT
DMBUZHO	MA	Inhibitor
DMBUZHO	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMBUZHO	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMF9J0Y	DI	DMF9J0Y
DMF9J0Y	DN	PMID26394986-Compound-20
DMF9J0Y	MI	TTH8FZW
DMF9J0Y	MN	Signal transducer and activator of transcription 3 (STAT3)
DMF9J0Y	MT	DTT
DMF9J0Y	MA	Inhibitor
DMF9J0Y	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMF9J0Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMLMQD4	DI	DMLMQD4
DMLMQD4	DN	PMID26394986-Compound-21
DMLMQD4	MI	TTH8FZW
DMLMQD4	MN	Signal transducer and activator of transcription 3 (STAT3)
DMLMQD4	MT	DTT
DMLMQD4	MA	Inhibitor
DMLMQD4	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMLMQD4	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DM43Z1G	DI	DM43Z1G
DM43Z1G	DN	PMID26394986-Compound-22
DM43Z1G	MI	TTH8FZW
DM43Z1G	MN	Signal transducer and activator of transcription 3 (STAT3)
DM43Z1G	MT	DTT
DM43Z1G	MA	Inhibitor
DM43Z1G	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DM43Z1G	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DM2E6M7	DI	DM2E6M7
DM2E6M7	DN	PMID26394986-Compound-42
DM2E6M7	MI	TTH8FZW
DM2E6M7	MN	Signal transducer and activator of transcription 3 (STAT3)
DM2E6M7	MT	DTT
DM2E6M7	MA	Inhibitor
DM2E6M7	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DM2E6M7	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DM1HIEZ	DI	DM1HIEZ
DM1HIEZ	DN	PMID26394986-Compound-43
DM1HIEZ	MI	TTH8FZW
DM1HIEZ	MN	Signal transducer and activator of transcription 3 (STAT3)
DM1HIEZ	MT	DTT
DM1HIEZ	MA	Inhibitor
DM1HIEZ	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DM1HIEZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMOJ52P	DI	DMOJ52P
DMOJ52P	DN	PMID26394986-Compound-44
DMOJ52P	MI	TTH8FZW
DMOJ52P	MN	Signal transducer and activator of transcription 3 (STAT3)
DMOJ52P	MT	DTT
DMOJ52P	MA	Inhibitor
DMOJ52P	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMOJ52P	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DML5I9K	DI	DML5I9K
DML5I9K	DN	PMID26394986-Compound-50
DML5I9K	MI	TTH8FZW
DML5I9K	MN	Signal transducer and activator of transcription 3 (STAT3)
DML5I9K	MT	DTT
DML5I9K	MA	Inhibitor
DML5I9K	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DML5I9K	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMV6GIC	DI	DMV6GIC
DMV6GIC	DN	PMID26394986-Compound-51
DMV6GIC	MI	TTH8FZW
DMV6GIC	MN	Signal transducer and activator of transcription 3 (STAT3)
DMV6GIC	MT	DTT
DMV6GIC	MA	Inhibitor
DMV6GIC	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMV6GIC	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMSZWAM	DI	DMSZWAM
DMSZWAM	DN	PMID26394986-Compound-52
DMSZWAM	MI	TTH8FZW
DMSZWAM	MN	Signal transducer and activator of transcription 3 (STAT3)
DMSZWAM	MT	DTT
DMSZWAM	MA	Inhibitor
DMSZWAM	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMSZWAM	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMS6EDU	DI	DMS6EDU
DMS6EDU	DN	PMID26394986-Compound-53
DMS6EDU	MI	TTH8FZW
DMS6EDU	MN	Signal transducer and activator of transcription 3 (STAT3)
DMS6EDU	MT	DTT
DMS6EDU	MA	Inhibitor
DMS6EDU	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMS6EDU	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMY8FZA	DI	DMY8FZA
DMY8FZA	DN	PMID26394986-Compound-54
DMY8FZA	MI	TTH8FZW
DMY8FZA	MN	Signal transducer and activator of transcription 3 (STAT3)
DMY8FZA	MT	DTT
DMY8FZA	MA	Inhibitor
DMY8FZA	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMY8FZA	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMPNJ4X	DI	DMPNJ4X
DMPNJ4X	DN	PMID26394986-Compound-56
DMPNJ4X	MI	TTLRFIH
DMPNJ4X	MN	Signal transducer and activator of transcription 5 (STAT5)
DMPNJ4X	MT	DTT
DMPNJ4X	MA	Inhibitor
DMPNJ4X	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMPNJ4X	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMILUT8	DI	DMILUT8
DMILUT8	DN	PMID26394986-Compound-57
DMILUT8	MI	TTLRFIH
DMILUT8	MN	Signal transducer and activator of transcription 5 (STAT5)
DMILUT8	MT	DTT
DMILUT8	MA	Inhibitor
DMILUT8	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMILUT8	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMNEGA0	DI	DMNEGA0
DMNEGA0	DN	PMID26394986-Compound-Figure16
DMNEGA0	MI	TTH8FZW
DMNEGA0	MN	Signal transducer and activator of transcription 3 (STAT3)
DMNEGA0	MT	DTT
DMNEGA0	MA	Inhibitor
DMNEGA0	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMNEGA0	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMEGBHP	DI	DMEGBHP
DMEGBHP	DN	PMID26394986-Compound-Figure17
DMEGBHP	MI	TTH8FZW
DMEGBHP	MN	Signal transducer and activator of transcription 3 (STAT3)
DMEGBHP	MT	DTT
DMEGBHP	MA	Inhibitor
DMEGBHP	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMEGBHP	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMNOJGW	DI	DMNOJGW
DMNOJGW	DN	PMID26413912-Compound-84
DMNOJGW	MI	TTDP1UC
DMNOJGW	MN	Fatty acid amide hydrolase (FAAH)
DMNOJGW	MT	DTT
DMNOJGW	MA	Inhibitor
DMNOJGW	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMNOJGW	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMNOJGW	DI	DMNOJGW
DMNOJGW	DN	PMID26413912-Compound-84
DMNOJGW	MI	TTGX13H
DMNOJGW	MN	Fatty-acid amide hydrolase 1 (FAAH1)
DMNOJGW	MT	DTT
DMNOJGW	MA	Inhibitor
DMNOJGW	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMNOJGW	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DM9V13U	DI	DM9V13U
DM9V13U	DN	PMID26560362-Compound-90
DM9V13U	MI	TTN9T81
DM9V13U	MN	Arachidonate 15-lipoxygenase (15-LOX)
DM9V13U	MT	DTT
DM9V13U	MA	Inhibitor
DM9V13U	RN	15-Lipoxygenase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):65-88.
DM9V13U	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560362

DMSI7F2	DI	DMSI7F2
DMSI7F2	DN	PMID26560530-Compound-1
DMSI7F2	MI	TT2F4OL
DMSI7F2	MN	Tissue transglutaminase (TG2)
DMSI7F2	MT	DTT
DMSI7F2	MA	Inhibitor
DMSI7F2	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DMSI7F2	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DMZ5UST	DI	DMZ5UST
DMZ5UST	DN	PMID26560530-Compound-11
DMZ5UST	MI	TT2F4OL
DMZ5UST	MN	Tissue transglutaminase (TG2)
DMZ5UST	MT	DTT
DMZ5UST	MA	Inhibitor
DMZ5UST	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DMZ5UST	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DMA8JGP	DI	DMA8JGP
DMA8JGP	DN	PMID26560530-Compound-12
DMA8JGP	MI	TT2F4OL
DMA8JGP	MN	Tissue transglutaminase (TG2)
DMA8JGP	MT	DTT
DMA8JGP	MA	Inhibitor
DMA8JGP	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DMA8JGP	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DMKF26Z	DI	DMKF26Z
DMKF26Z	DN	PMID26560530-Compound-13
DMKF26Z	MI	TTXI2RA
DMKF26Z	MN	Coagulation factor XIIIA (F13A1)
DMKF26Z	MT	DTT
DMKF26Z	MA	Inhibitor
DMKF26Z	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DMKF26Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DMKF26Z	DI	DMKF26Z
DMKF26Z	DN	PMID26560530-Compound-13
DMKF26Z	MI	TT2F4OL
DMKF26Z	MN	Tissue transglutaminase (TG2)
DMKF26Z	MT	DTT
DMKF26Z	MA	Inhibitor
DMKF26Z	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DMKF26Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DM52MIK	DI	DM52MIK
DM52MIK	DN	PMID26560530-Compound-14
DM52MIK	MI	TT2F4OL
DM52MIK	MN	Tissue transglutaminase (TG2)
DM52MIK	MT	DTT
DM52MIK	MA	Inhibitor
DM52MIK	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DM52MIK	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DM1ZSEI	DI	DM1ZSEI
DM1ZSEI	DN	PMID26560530-Compound-15
DM1ZSEI	MI	TT2F4OL
DM1ZSEI	MN	Tissue transglutaminase (TG2)
DM1ZSEI	MT	DTT
DM1ZSEI	MA	Inhibitor
DM1ZSEI	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DM1ZSEI	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DM8UI4Z	DI	DM8UI4Z
DM8UI4Z	DN	PMID26560530-Compound-16
DM8UI4Z	MI	TT2F4OL
DM8UI4Z	MN	Tissue transglutaminase (TG2)
DM8UI4Z	MT	DTT
DM8UI4Z	MA	Inhibitor
DM8UI4Z	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DM8UI4Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DMITU83	DI	DMITU83
DMITU83	DN	PMID26560530-Compound-17
DMITU83	MI	TT2F4OL
DMITU83	MN	Tissue transglutaminase (TG2)
DMITU83	MT	DTT
DMITU83	MA	Inhibitor
DMITU83	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DMITU83	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DMK39S5	DI	DMK39S5
DMK39S5	DN	PMID26560530-Compound-18
DMK39S5	MI	TT2F4OL
DMK39S5	MN	Tissue transglutaminase (TG2)
DMK39S5	MT	DTT
DMK39S5	MA	Inhibitor
DMK39S5	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DMK39S5	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DMC7AXQ	DI	DMC7AXQ
DMC7AXQ	DN	PMID26560530-Compound-2
DMC7AXQ	MI	TT2F4OL
DMC7AXQ	MN	Tissue transglutaminase (TG2)
DMC7AXQ	MT	DTT
DMC7AXQ	MA	Inhibitor
DMC7AXQ	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DMC7AXQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DMDS2CU	DI	DMDS2CU
DMDS2CU	DN	PMID26560530-Compound-23
DMDS2CU	MI	TT2F4OL
DMDS2CU	MN	Tissue transglutaminase (TG2)
DMDS2CU	MT	DTT
DMDS2CU	MA	Inhibitor
DMDS2CU	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DMDS2CU	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DMWCM2I	DI	DMWCM2I
DMWCM2I	DN	PMID26560530-Compound-24
DMWCM2I	MI	TT2F4OL
DMWCM2I	MN	Tissue transglutaminase (TG2)
DMWCM2I	MT	DTT
DMWCM2I	MA	Inhibitor
DMWCM2I	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DMWCM2I	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DMZ43OM	DI	DMZ43OM
DMZ43OM	DN	PMID26560530-Compound-25
DMZ43OM	MI	TT2F4OL
DMZ43OM	MN	Tissue transglutaminase (TG2)
DMZ43OM	MT	DTT
DMZ43OM	MA	Inhibitor
DMZ43OM	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DMZ43OM	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DMVEQ2P	DI	DMVEQ2P
DMVEQ2P	DN	PMID26560530-Compound-26
DMVEQ2P	MI	TT2F4OL
DMVEQ2P	MN	Tissue transglutaminase (TG2)
DMVEQ2P	MT	DTT
DMVEQ2P	MA	Inhibitor
DMVEQ2P	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DMVEQ2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DM8WP3D	DI	DM8WP3D
DM8WP3D	DN	PMID26560530-Compound-27
DM8WP3D	MI	TT2F4OL
DM8WP3D	MN	Tissue transglutaminase (TG2)
DM8WP3D	MT	DTT
DM8WP3D	MA	Inhibitor
DM8WP3D	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DM8WP3D	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DM92OT0	DI	DM92OT0
DM92OT0	DN	PMID26560530-Compound-3
DM92OT0	MI	TT2F4OL
DM92OT0	MN	Tissue transglutaminase (TG2)
DM92OT0	MT	DTT
DM92OT0	MA	Inhibitor
DM92OT0	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DM92OT0	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DM74GUB	DI	DM74GUB
DM74GUB	DN	PMID26560530-Compound-31
DM74GUB	MI	TT2F4OL
DM74GUB	MN	Tissue transglutaminase (TG2)
DM74GUB	MT	DTT
DM74GUB	MA	Inhibitor
DM74GUB	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DM74GUB	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DM2QWXF	DI	DM2QWXF
DM2QWXF	DN	PMID26560530-Compound-32
DM2QWXF	MI	TT2F4OL
DM2QWXF	MN	Tissue transglutaminase (TG2)
DM2QWXF	MT	DTT
DM2QWXF	MA	Inhibitor
DM2QWXF	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DM2QWXF	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DMUL84D	DI	DMUL84D
DMUL84D	DN	PMID26560530-Compound-33
DMUL84D	MI	TT2F4OL
DMUL84D	MN	Tissue transglutaminase (TG2)
DMUL84D	MT	DTT
DMUL84D	MA	Inhibitor
DMUL84D	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DMUL84D	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DMLGZPO	DI	DMLGZPO
DMLGZPO	DN	PMID26560530-Compound-34
DMLGZPO	MI	TT2F4OL
DMLGZPO	MN	Tissue transglutaminase (TG2)
DMLGZPO	MT	DTT
DMLGZPO	MA	Inhibitor
DMLGZPO	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DMLGZPO	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DMO36RL	DI	DMO36RL
DMO36RL	DN	PMID26560530-Compound-35
DMO36RL	MI	TT2F4OL
DMO36RL	MN	Tissue transglutaminase (TG2)
DMO36RL	MT	DTT
DMO36RL	MA	Inhibitor
DMO36RL	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DMO36RL	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DMEZLBQ	DI	DMEZLBQ
DMEZLBQ	DN	PMID26560530-Compound-4
DMEZLBQ	MI	TT2F4OL
DMEZLBQ	MN	Tissue transglutaminase (TG2)
DMEZLBQ	MT	DTT
DMEZLBQ	MA	Inhibitor
DMEZLBQ	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DMEZLBQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DMTOJCG	DI	DMTOJCG
DMTOJCG	DN	PMID26560530-Compound-46
DMTOJCG	MI	TT2F4OL
DMTOJCG	MN	Tissue transglutaminase (TG2)
DMTOJCG	MT	DTT
DMTOJCG	MA	Inhibitor
DMTOJCG	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DMTOJCG	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DMWC1IY	DI	DMWC1IY
DMWC1IY	DN	PMID26560530-Compound-47
DMWC1IY	MI	TT2F4OL
DMWC1IY	MN	Tissue transglutaminase (TG2)
DMWC1IY	MT	DTT
DMWC1IY	MA	Inhibitor
DMWC1IY	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DMWC1IY	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DMXV0CK	DI	DMXV0CK
DMXV0CK	DN	PMID26560530-Compound-48
DMXV0CK	MI	TT2F4OL
DMXV0CK	MN	Tissue transglutaminase (TG2)
DMXV0CK	MT	DTT
DMXV0CK	MA	Inhibitor
DMXV0CK	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DMXV0CK	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DMST6C2	DI	DMST6C2
DMST6C2	DN	PMID26560530-Compound-49
DMST6C2	MI	TT2F4OL
DMST6C2	MN	Tissue transglutaminase (TG2)
DMST6C2	MT	DTT
DMST6C2	MA	Inhibitor
DMST6C2	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DMST6C2	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DM6G2WJ	DI	DM6G2WJ
DM6G2WJ	DN	PMID26560530-Compound-5
DM6G2WJ	MI	TT2F4OL
DM6G2WJ	MN	Tissue transglutaminase (TG2)
DM6G2WJ	MT	DTT
DM6G2WJ	MA	Inhibitor
DM6G2WJ	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DM6G2WJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DMHZ8N1	DI	DMHZ8N1
DMHZ8N1	DN	PMID26560530-Compound-50
DMHZ8N1	MI	TT2F4OL
DMHZ8N1	MN	Tissue transglutaminase (TG2)
DMHZ8N1	MT	DTT
DMHZ8N1	MA	Inhibitor
DMHZ8N1	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DMHZ8N1	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DM2X4R0	DI	DM2X4R0
DM2X4R0	DN	PMID26560530-Compound-54
DM2X4R0	MI	TT2F4OL
DM2X4R0	MN	Tissue transglutaminase (TG2)
DM2X4R0	MT	DTT
DM2X4R0	MA	Inhibitor
DM2X4R0	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DM2X4R0	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DMMHL2C	DI	DMMHL2C
DMMHL2C	DN	PMID26560530-Compound-6
DMMHL2C	MI	TT2F4OL
DMMHL2C	MN	Tissue transglutaminase (TG2)
DMMHL2C	MT	DTT
DMMHL2C	MA	Inhibitor
DMMHL2C	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DMMHL2C	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DMRAXD1	DI	DMRAXD1
DMRAXD1	DN	PMID26560530-Compound-7
DMRAXD1	MI	TT2F4OL
DMRAXD1	MN	Tissue transglutaminase (TG2)
DMRAXD1	MT	DTT
DMRAXD1	MA	Inhibitor
DMRAXD1	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DMRAXD1	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DMN6TG7	DI	DMN6TG7
DMN6TG7	DN	PMID26560530-Compound-8
DMN6TG7	MI	TT2F4OL
DMN6TG7	MN	Tissue transglutaminase (TG2)
DMN6TG7	MT	DTT
DMN6TG7	MA	Inhibitor
DMN6TG7	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DMN6TG7	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DMBYTSI	DI	DMBYTSI
DMBYTSI	DN	PMID26609882-Compound-34
DMBYTSI	MI	TTJQOD7
DMBYTSI	MN	5-HT 2A receptor (HTR2A)
DMBYTSI	MT	DTT
DMBYTSI	MA	Antagonist
DMBYTSI	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMBYTSI	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DM8OLYQ	DI	DM8OLYQ
DM8OLYQ	DN	PMID26609882-Compound-35
DM8OLYQ	MI	TTJQOD7
DM8OLYQ	MN	5-HT 2A receptor (HTR2A)
DM8OLYQ	MT	DTT
DM8OLYQ	MA	Antagonist
DM8OLYQ	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DM8OLYQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMFT3RM	DI	DMFT3RM
DMFT3RM	DN	PMID26609882-Compound-36
DMFT3RM	MI	TTJQOD7
DMFT3RM	MN	5-HT 2A receptor (HTR2A)
DMFT3RM	MT	DTT
DMFT3RM	MA	Antagonist
DMFT3RM	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMFT3RM	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMD3T1Q	DI	DMD3T1Q
DMD3T1Q	DN	PMID26609882-Compound-58
DMD3T1Q	MI	TTWJBZ5
DMD3T1Q	MN	5-HT 2C receptor (HTR2C)
DMD3T1Q	MT	DTT
DMD3T1Q	MA	Antagonist
DMD3T1Q	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMD3T1Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DM6C45G	DI	DM6C45G
DM6C45G	DN	PMID26609882-Compound-83
DM6C45G	MI	TTWJBZ5
DM6C45G	MN	5-HT 2C receptor (HTR2C)
DM6C45G	MT	DTT
DM6C45G	MA	Agonist
DM6C45G	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DM6C45G	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMOJVK6	DI	DMOJVK6
DMOJVK6	DN	PMID26651364-Compound-105
DMOJVK6	MI	TTTCRU2
DMOJVK6	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMOJVK6	MT	DTT
DMOJVK6	MA	Antagonist
DMOJVK6	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMOJVK6	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMQZJDF	DI	DMQZJDF
DMQZJDF	DN	PMID26651364-Compound-106
DMQZJDF	MI	TTTCRU2
DMQZJDF	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMQZJDF	MT	DTT
DMQZJDF	MA	Antagonist
DMQZJDF	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMQZJDF	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMMZ1WL	DI	DMMZ1WL
DMMZ1WL	DN	PMID26651364-Compound-107
DMMZ1WL	MI	TTTCRU2
DMMZ1WL	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMMZ1WL	MT	DTT
DMMZ1WL	MA	Antagonist
DMMZ1WL	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMMZ1WL	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMA7D3K	DI	DMA7D3K
DMA7D3K	DN	PMID26651364-Compound-108
DMA7D3K	MI	TTTCRU2
DMA7D3K	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMA7D3K	MT	DTT
DMA7D3K	MA	Antagonist
DMA7D3K	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMA7D3K	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM01IWV	DI	DM01IWV
DM01IWV	DN	PMID26651364-Compound-109
DM01IWV	MI	TTTCRU2
DM01IWV	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM01IWV	MT	DTT
DM01IWV	MA	Antagonist
DM01IWV	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM01IWV	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMTPBNY	DI	DMTPBNY
DMTPBNY	DN	PMID26651364-Compound-10a
DMTPBNY	MI	TTTCRU2
DMTPBNY	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMTPBNY	MT	DTT
DMTPBNY	MA	Antagonist
DMTPBNY	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMTPBNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM16ANH	DI	DM16ANH
DM16ANH	DN	PMID26651364-Compound-10b
DM16ANH	MI	TTTCRU2
DM16ANH	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM16ANH	MT	DTT
DM16ANH	MA	Antagonist
DM16ANH	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM16ANH	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMCRNWA	DI	DMCRNWA
DMCRNWA	DN	PMID26651364-Compound-10c
DMCRNWA	MI	TTTCRU2
DMCRNWA	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMCRNWA	MT	DTT
DMCRNWA	MA	Antagonist
DMCRNWA	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMCRNWA	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMGIV3C	DI	DMGIV3C
DMGIV3C	DN	PMID26651364-Compound-10d
DMGIV3C	MI	TTTCRU2
DMGIV3C	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMGIV3C	MT	DTT
DMGIV3C	MA	Antagonist
DMGIV3C	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMGIV3C	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMPA3IX	DI	DMPA3IX
DMPA3IX	DN	PMID26651364-Compound-110
DMPA3IX	MI	TTTCRU2
DMPA3IX	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMPA3IX	MT	DTT
DMPA3IX	MA	Antagonist
DMPA3IX	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMPA3IX	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMY9R58	DI	DMY9R58
DMY9R58	DN	PMID26651364-Compound-111
DMY9R58	MI	TTTCRU2
DMY9R58	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMY9R58	MT	DTT
DMY9R58	MA	Antagonist
DMY9R58	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMY9R58	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM1LIRP	DI	DM1LIRP
DM1LIRP	DN	PMID26651364-Compound-112
DM1LIRP	MI	TTTCRU2
DM1LIRP	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM1LIRP	MT	DTT
DM1LIRP	MA	Antagonist
DM1LIRP	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM1LIRP	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM6OQKM	DI	DM6OQKM
DM6OQKM	DN	PMID26651364-Compound-113
DM6OQKM	MI	TTTCRU2
DM6OQKM	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM6OQKM	MT	DTT
DM6OQKM	MA	Antagonist
DM6OQKM	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM6OQKM	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM5GHJA	DI	DM5GHJA
DM5GHJA	DN	PMID26651364-Compound-114
DM5GHJA	MI	TTTCRU2
DM5GHJA	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM5GHJA	MT	DTT
DM5GHJA	MA	Antagonist
DM5GHJA	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM5GHJA	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMHIA26	DI	DMHIA26
DMHIA26	DN	PMID26651364-Compound-115
DMHIA26	MI	TTTCRU2
DMHIA26	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMHIA26	MT	DTT
DMHIA26	MA	Antagonist
DMHIA26	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMHIA26	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMJ3201	DI	DMJ3201
DMJ3201	DN	PMID26651364-Compound-116
DMJ3201	MI	TTTCRU2
DMJ3201	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMJ3201	MT	DTT
DMJ3201	MA	Antagonist
DMJ3201	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMJ3201	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM6LXHS	DI	DM6LXHS
DM6LXHS	DN	PMID26651364-Compound-117a
DM6LXHS	MI	TTTCRU2
DM6LXHS	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM6LXHS	MT	DTT
DM6LXHS	MA	Antagonist
DM6LXHS	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM6LXHS	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMUQSM1	DI	DMUQSM1
DMUQSM1	DN	PMID26651364-Compound-117b
DMUQSM1	MI	TTTCRU2
DMUQSM1	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMUQSM1	MT	DTT
DMUQSM1	MA	Antagonist
DMUQSM1	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMUQSM1	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM6ZRV4	DI	DM6ZRV4
DM6ZRV4	DN	PMID26651364-Compound-118
DM6ZRV4	MI	TTTCRU2
DM6ZRV4	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM6ZRV4	MT	DTT
DM6ZRV4	MA	Antagonist
DM6ZRV4	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM6ZRV4	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMONAZI	DI	DMONAZI
DMONAZI	DN	PMID26651364-Compound-119
DMONAZI	MI	TTTCRU2
DMONAZI	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMONAZI	MT	DTT
DMONAZI	MA	Antagonist
DMONAZI	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMONAZI	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMGBFK3	DI	DMGBFK3
DMGBFK3	DN	PMID26651364-Compound-11b
DMGBFK3	MI	TTTCRU2
DMGBFK3	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMGBFK3	MT	DTT
DMGBFK3	MA	Antagonist
DMGBFK3	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMGBFK3	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM76WBP	DI	DM76WBP
DM76WBP	DN	PMID26651364-Compound-11c
DM76WBP	MI	TTTCRU2
DM76WBP	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM76WBP	MT	DTT
DM76WBP	MA	Antagonist
DM76WBP	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM76WBP	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMZTBEQ	DI	DMZTBEQ
DMZTBEQ	DN	PMID26651364-Compound-120
DMZTBEQ	MI	TTTCRU2
DMZTBEQ	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMZTBEQ	MT	DTT
DMZTBEQ	MA	Antagonist
DMZTBEQ	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMZTBEQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM4ZG0Q	DI	DM4ZG0Q
DM4ZG0Q	DN	PMID26651364-Compound-121
DM4ZG0Q	MI	TTTCRU2
DM4ZG0Q	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM4ZG0Q	MT	DTT
DM4ZG0Q	MA	Antagonist
DM4ZG0Q	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM4ZG0Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMVFTIL	DI	DMVFTIL
DMVFTIL	DN	PMID26651364-Compound-122
DMVFTIL	MI	TTTCRU2
DMVFTIL	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMVFTIL	MT	DTT
DMVFTIL	MA	Antagonist
DMVFTIL	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMVFTIL	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMR0E5W	DI	DMR0E5W
DMR0E5W	DN	PMID26651364-Compound-123
DMR0E5W	MI	TTTCRU2
DMR0E5W	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMR0E5W	MT	DTT
DMR0E5W	MA	Antagonist
DMR0E5W	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMR0E5W	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM6VER5	DI	DM6VER5
DM6VER5	DN	PMID26651364-Compound-124
DM6VER5	MI	TTTCRU2
DM6VER5	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM6VER5	MT	DTT
DM6VER5	MA	Antagonist
DM6VER5	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM6VER5	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMINUDB	DI	DMINUDB
DMINUDB	DN	PMID26651364-Compound-125
DMINUDB	MI	TTTCRU2
DMINUDB	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMINUDB	MT	DTT
DMINUDB	MA	Antagonist
DMINUDB	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMINUDB	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMSTKH6	DI	DMSTKH6
DMSTKH6	DN	PMID26651364-Compound-126a
DMSTKH6	MI	TTTCRU2
DMSTKH6	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMSTKH6	MT	DTT
DMSTKH6	MA	Antagonist
DMSTKH6	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMSTKH6	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM2I1QZ	DI	DM2I1QZ
DM2I1QZ	DN	PMID26651364-Compound-126b
DM2I1QZ	MI	TTTCRU2
DM2I1QZ	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM2I1QZ	MT	DTT
DM2I1QZ	MA	Antagonist
DM2I1QZ	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM2I1QZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM80PI1	DI	DM80PI1
DM80PI1	DN	PMID26651364-Compound-126c
DM80PI1	MI	TTTCRU2
DM80PI1	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM80PI1	MT	DTT
DM80PI1	MA	Antagonist
DM80PI1	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM80PI1	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMEN8RA	DI	DMEN8RA
DMEN8RA	DN	PMID26651364-Compound-127
DMEN8RA	MI	TTTCRU2
DMEN8RA	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMEN8RA	MT	DTT
DMEN8RA	MA	Antagonist
DMEN8RA	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMEN8RA	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM4W0BX	DI	DM4W0BX
DM4W0BX	DN	PMID26651364-Compound-128
DM4W0BX	MI	TTTCRU2
DM4W0BX	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM4W0BX	MT	DTT
DM4W0BX	MA	Antagonist
DM4W0BX	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM4W0BX	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMY0HP1	DI	DMY0HP1
DMY0HP1	DN	PMID26651364-Compound-4
DMY0HP1	MI	TTTCRU2
DMY0HP1	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMY0HP1	MT	DTT
DMY0HP1	MA	Antagonist
DMY0HP1	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMY0HP1	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMLBZGO	DI	DMLBZGO
DMLBZGO	DN	PMID26651364-Compound-45
DMLBZGO	MI	TTTCRU2
DMLBZGO	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMLBZGO	MT	DTT
DMLBZGO	MA	Antagonist
DMLBZGO	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMLBZGO	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMQFDU8	DI	DMQFDU8
DMQFDU8	DN	PMID26651364-Compound-46
DMQFDU8	MI	TTTCRU2
DMQFDU8	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMQFDU8	MT	DTT
DMQFDU8	MA	Antagonist
DMQFDU8	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMQFDU8	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM4S5PB	DI	DM4S5PB
DM4S5PB	DN	PMID26651364-Compound-47
DM4S5PB	MI	TTTCRU2
DM4S5PB	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM4S5PB	MT	DTT
DM4S5PB	MA	Antagonist
DM4S5PB	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM4S5PB	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMHXFGU	DI	DMHXFGU
DMHXFGU	DN	PMID26651364-Compound-48
DMHXFGU	MI	TTTCRU2
DMHXFGU	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMHXFGU	MT	DTT
DMHXFGU	MA	Antagonist
DMHXFGU	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMHXFGU	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMMV5A9	DI	DMMV5A9
DMMV5A9	DN	PMID26651364-Compound-49
DMMV5A9	MI	TTTCRU2
DMMV5A9	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMMV5A9	MT	DTT
DMMV5A9	MA	Antagonist
DMMV5A9	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMMV5A9	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMH7XL3	DI	DMH7XL3
DMH7XL3	DN	PMID26651364-Compound-5
DMH7XL3	MI	TTTCRU2
DMH7XL3	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMH7XL3	MT	DTT
DMH7XL3	MA	Antagonist
DMH7XL3	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMH7XL3	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM6GFYR	DI	DM6GFYR
DM6GFYR	DN	PMID26651364-Compound-50
DM6GFYR	MI	TTTCRU2
DM6GFYR	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM6GFYR	MT	DTT
DM6GFYR	MA	Antagonist
DM6GFYR	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM6GFYR	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM01GVE	DI	DM01GVE
DM01GVE	DN	PMID26651364-Compound-5a
DM01GVE	MI	TTTCRU2
DM01GVE	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM01GVE	MT	DTT
DM01GVE	MA	Antagonist
DM01GVE	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM01GVE	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMLHJ1E	DI	DMLHJ1E
DMLHJ1E	DN	PMID26651364-Compound-5b
DMLHJ1E	MI	TTTCRU2
DMLHJ1E	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMLHJ1E	MT	DTT
DMLHJ1E	MA	Antagonist
DMLHJ1E	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMLHJ1E	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMDQTA2	DI	DMDQTA2
DMDQTA2	DN	PMID26651364-Compound-5c
DMDQTA2	MI	TTTCRU2
DMDQTA2	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMDQTA2	MT	DTT
DMDQTA2	MA	Antagonist
DMDQTA2	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMDQTA2	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMF6Z5I	DI	DMF6Z5I
DMF6Z5I	DN	PMID26651364-Compound-5d
DMF6Z5I	MI	TTTCRU2
DMF6Z5I	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMF6Z5I	MT	DTT
DMF6Z5I	MA	Antagonist
DMF6Z5I	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMF6Z5I	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM9TJR5	DI	DM9TJR5
DM9TJR5	DN	PMID26651364-Compound-5e
DM9TJR5	MI	TTTCRU2
DM9TJR5	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM9TJR5	MT	DTT
DM9TJR5	MA	Antagonist
DM9TJR5	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM9TJR5	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMAZIY6	DI	DMAZIY6
DMAZIY6	DN	PMID26651364-Compound-5f
DMAZIY6	MI	TTTCRU2
DMAZIY6	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMAZIY6	MT	DTT
DMAZIY6	MA	Antagonist
DMAZIY6	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMAZIY6	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMSW0HB	DI	DMSW0HB
DMSW0HB	DN	PMID26651364-Compound-5g
DMSW0HB	MI	TTTCRU2
DMSW0HB	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMSW0HB	MT	DTT
DMSW0HB	MA	Antagonist
DMSW0HB	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMSW0HB	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM8HAJ3	DI	DM8HAJ3
DM8HAJ3	DN	PMID26651364-Compound-6a
DM8HAJ3	MI	TTTCRU2
DM8HAJ3	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM8HAJ3	MT	DTT
DM8HAJ3	MA	Antagonist
DM8HAJ3	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM8HAJ3	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMBINOJ	DI	DMBINOJ
DMBINOJ	DN	PMID26651364-Compound-6b
DMBINOJ	MI	TTTCRU2
DMBINOJ	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMBINOJ	MT	DTT
DMBINOJ	MA	Antagonist
DMBINOJ	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMBINOJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMPF86L	DI	DMPF86L
DMPF86L	DN	PMID26651364-Compound-6c
DMPF86L	MI	TTTCRU2
DMPF86L	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMPF86L	MT	DTT
DMPF86L	MA	Antagonist
DMPF86L	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMPF86L	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM9J57W	DI	DM9J57W
DM9J57W	DN	PMID26651364-Compound-6d
DM9J57W	MI	TTTCRU2
DM9J57W	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM9J57W	MT	DTT
DM9J57W	MA	Antagonist
DM9J57W	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM9J57W	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM4LF0X	DI	DM4LF0X
DM4LF0X	DN	PMID26651364-Compound-6e
DM4LF0X	MI	TTTCRU2
DM4LF0X	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM4LF0X	MT	DTT
DM4LF0X	MA	Antagonist
DM4LF0X	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM4LF0X	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMQMBY9	DI	DMQMBY9
DMQMBY9	DN	PMID26651364-Compound-7a
DMQMBY9	MI	TTTCRU2
DMQMBY9	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMQMBY9	MT	DTT
DMQMBY9	MA	Antagonist
DMQMBY9	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMQMBY9	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM3LCIM	DI	DM3LCIM
DM3LCIM	DN	PMID26651364-Compound-7b
DM3LCIM	MI	TTTCRU2
DM3LCIM	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM3LCIM	MT	DTT
DM3LCIM	MA	Antagonist
DM3LCIM	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM3LCIM	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMGCUJB	DI	DMGCUJB
DMGCUJB	DN	PMID26651364-Compound-7c
DMGCUJB	MI	TTTCRU2
DMGCUJB	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMGCUJB	MT	DTT
DMGCUJB	MA	Antagonist
DMGCUJB	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMGCUJB	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM89VQT	DI	DM89VQT
DM89VQT	DN	PMID26651364-Compound-7d
DM89VQT	MI	TTTCRU2
DM89VQT	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM89VQT	MT	DTT
DM89VQT	MA	Antagonist
DM89VQT	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM89VQT	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM2SZ0B	DI	DM2SZ0B
DM2SZ0B	DN	PMID26651364-Compound-7e
DM2SZ0B	MI	TTTCRU2
DM2SZ0B	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM2SZ0B	MT	DTT
DM2SZ0B	MA	Antagonist
DM2SZ0B	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM2SZ0B	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM1M3WF	DI	DM1M3WF
DM1M3WF	DN	PMID26651364-Compound-8a
DM1M3WF	MI	TTTCRU2
DM1M3WF	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM1M3WF	MT	DTT
DM1M3WF	MA	Antagonist
DM1M3WF	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM1M3WF	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMYVU36	DI	DMYVU36
DMYVU36	DN	PMID26651364-Compound-8b
DMYVU36	MI	TTTCRU2
DMYVU36	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMYVU36	MT	DTT
DMYVU36	MA	Antagonist
DMYVU36	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMYVU36	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DME7UNT	DI	DME7UNT
DME7UNT	DN	PMID26651364-Compound-8c
DME7UNT	MI	TTTCRU2
DME7UNT	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DME7UNT	MT	DTT
DME7UNT	MA	Antagonist
DME7UNT	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DME7UNT	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMSO2F8	DI	DMSO2F8
DMSO2F8	DN	PMID26651364-Compound-8d
DMSO2F8	MI	TTTCRU2
DMSO2F8	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMSO2F8	MT	DTT
DMSO2F8	MA	Antagonist
DMSO2F8	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMSO2F8	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMAXWPS	DI	DMAXWPS
DMAXWPS	DN	PMID26651364-Compound-9a
DMAXWPS	MI	TTTCRU2
DMAXWPS	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMAXWPS	MT	DTT
DMAXWPS	MA	Antagonist
DMAXWPS	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMAXWPS	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM6HTU0	DI	DM6HTU0
DM6HTU0	DN	PMID26651364-Compound-9b
DM6HTU0	MI	TTTCRU2
DM6HTU0	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM6HTU0	MT	DTT
DM6HTU0	MA	Antagonist
DM6HTU0	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM6HTU0	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM49V8G	DI	DM49V8G
DM49V8G	DN	PMID26651364-Compound-9c
DM49V8G	MI	TTTCRU2
DM49V8G	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM49V8G	MT	DTT
DM49V8G	MA	Antagonist
DM49V8G	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM49V8G	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMF0L3E	DI	DMF0L3E
DMF0L3E	DN	PMID26651364-Compound-9d
DMF0L3E	MI	TTTCRU2
DMF0L3E	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMF0L3E	MT	DTT
DMF0L3E	MA	Antagonist
DMF0L3E	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMF0L3E	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DM9FIKD	DI	DM9FIKD
DM9FIKD	DN	PMID26651364-Compound-9e
DM9FIKD	MI	TTTCRU2
DM9FIKD	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM9FIKD	MT	DTT
DM9FIKD	MA	Antagonist
DM9FIKD	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DM9FIKD	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMF1MV6	DI	DMF1MV6
DMF1MV6	DN	PMID26651364-Compound-9f
DMF1MV6	MI	TTTCRU2
DMF1MV6	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMF1MV6	MT	DTT
DMF1MV6	MA	Antagonist
DMF1MV6	RN	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
DMF1MV6	RU	https://www.ncbi.nlm.nih.gov/pubmed/26651364

DMMGQ7Z	DI	DMMGQ7Z
DMMGQ7Z	DN	PMID26666870-Compound-16
DMMGQ7Z	MI	TTJOMH6
DMMGQ7Z	MN	Zinc finger protein GLI1 (Gli1)
DMMGQ7Z	MT	DTT
DMMGQ7Z	MA	Inhibitor
DMMGQ7Z	RN	Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35.
DMMGQ7Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666870

DMWJXRO	DI	DMWJXRO
DMWJXRO	DN	PMID26666989-Compound-Figure11Ala down
DMWJXRO	MI	TT8BUGW
DMWJXRO	MN	Glycogen phosphorylase (PYG)
DMWJXRO	MT	DTT
DMWJXRO	MA	Inhibitor
DMWJXRO	RN	Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212.
DMWJXRO	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666989

DMGU914	DI	DMGU914
DMGU914	DN	PMID26666989-Compound-Figure11Ala up
DMGU914	MI	TT8BUGW
DMGU914	MN	Glycogen phosphorylase (PYG)
DMGU914	MT	DTT
DMGU914	MA	Inhibitor
DMGU914	RN	Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212.
DMGU914	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666989

DMA59QF	DI	DMA59QF
DMA59QF	DN	PMID26666989-Compound-Figure11topright
DMA59QF	MI	TT8BUGW
DMA59QF	MN	Glycogen phosphorylase (PYG)
DMA59QF	MT	DTT
DMA59QF	MA	Inhibitor
DMA59QF	RN	Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212.
DMA59QF	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666989

DMGIPDH	DI	DMGIPDH
DMGIPDH	DN	PMID26666989-Compound-Figure12bottommiddle01
DMGIPDH	MI	TT8BUGW
DMGIPDH	MN	Glycogen phosphorylase (PYG)
DMGIPDH	MT	DTT
DMGIPDH	MA	Inhibitor
DMGIPDH	RN	Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212.
DMGIPDH	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666989

DM2VHJ7	DI	DM2VHJ7
DM2VHJ7	DN	PMID26666989-Compound-Figure12bottommiddle02
DM2VHJ7	MI	TT8BUGW
DM2VHJ7	MN	Glycogen phosphorylase (PYG)
DM2VHJ7	MT	DTT
DM2VHJ7	MA	Inhibitor
DM2VHJ7	RN	Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212.
DM2VHJ7	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666989

DMDLVXU	DI	DMDLVXU
DMDLVXU	DN	PMID26666989-Compound-Figure12bottomright
DMDLVXU	MI	TT8BUGW
DMDLVXU	MN	Glycogen phosphorylase (PYG)
DMDLVXU	MT	DTT
DMDLVXU	MA	Inhibitor
DMDLVXU	RN	Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212.
DMDLVXU	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666989

DMF5LNK	DI	DMF5LNK
DMF5LNK	DN	PMID26666989-Compound-Figure12left
DMF5LNK	MI	TT8BUGW
DMF5LNK	MN	Glycogen phosphorylase (PYG)
DMF5LNK	MT	DTT
DMF5LNK	MA	Inhibitor
DMF5LNK	RN	Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212.
DMF5LNK	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666989

DMEUSGR	DI	DMEUSGR
DMEUSGR	DN	PMID26666989-Compound-Figure12topmiddile
DMEUSGR	MI	TT8BUGW
DMEUSGR	MN	Glycogen phosphorylase (PYG)
DMEUSGR	MT	DTT
DMEUSGR	MA	Inhibitor
DMEUSGR	RN	Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212.
DMEUSGR	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666989

DMISJDH	DI	DMISJDH
DMISJDH	DN	PMID26666989-Compound-Figure9bottomright
DMISJDH	MI	TT8BUGW
DMISJDH	MN	Glycogen phosphorylase (PYG)
DMISJDH	MT	DTT
DMISJDH	MA	Inhibitor
DMISJDH	RN	Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212.
DMISJDH	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666989

DM0NM1Y	DI	DM0NM1Y
DM0NM1Y	DN	PMID26666989-Compound-Figure9left01
DM0NM1Y	MI	TT8BUGW
DM0NM1Y	MN	Glycogen phosphorylase (PYG)
DM0NM1Y	MT	DTT
DM0NM1Y	MA	Inhibitor
DM0NM1Y	RN	Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212.
DM0NM1Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666989

DM7L6WS	DI	DM7L6WS
DM7L6WS	DN	PMID26666989-Compound-Figure9left02
DM7L6WS	MI	TT8BUGW
DM7L6WS	MN	Glycogen phosphorylase (PYG)
DM7L6WS	MT	DTT
DM7L6WS	MA	Inhibitor
DM7L6WS	RN	Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212.
DM7L6WS	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666989

DM4MA2X	DI	DM4MA2X
DM4MA2X	DN	PMID26666989-Compound-Figure9middle01
DM4MA2X	MI	TT8BUGW
DM4MA2X	MN	Glycogen phosphorylase (PYG)
DM4MA2X	MT	DTT
DM4MA2X	MA	Inhibitor
DM4MA2X	RN	Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212.
DM4MA2X	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666989

DM2ANJ7	DI	DM2ANJ7
DM2ANJ7	DN	PMID26666989-Compound-Figure9middle02
DM2ANJ7	MI	TT8BUGW
DM2ANJ7	MN	Glycogen phosphorylase (PYG)
DM2ANJ7	MT	DTT
DM2ANJ7	MA	Inhibitor
DM2ANJ7	RN	Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212.
DM2ANJ7	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666989

DMOPR7A	DI	DMOPR7A
DMOPR7A	DN	PMID26666989-Compound-Figure9middle03
DMOPR7A	MI	TT8BUGW
DMOPR7A	MN	Glycogen phosphorylase (PYG)
DMOPR7A	MT	DTT
DMOPR7A	MA	Inhibitor
DMOPR7A	RN	Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212.
DMOPR7A	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666989

DMNWRA0	DI	DMNWRA0
DMNWRA0	DN	PMID26666989-Compound-Figure9middle04
DMNWRA0	MI	TT8BUGW
DMNWRA0	MN	Glycogen phosphorylase (PYG)
DMNWRA0	MT	DTT
DMNWRA0	MA	Inhibitor
DMNWRA0	RN	Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212.
DMNWRA0	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666989

DMN73KO	DI	DMN73KO
DMN73KO	DN	PMID26666989-Compound-Figure9middle05
DMN73KO	MI	TT8BUGW
DMN73KO	MN	Glycogen phosphorylase (PYG)
DMN73KO	MT	DTT
DMN73KO	MA	Inhibitor
DMN73KO	RN	Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212.
DMN73KO	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666989

DMYKPHX	DI	DMYKPHX
DMYKPHX	DN	PMID26666989-Compound-Figure9middle06
DMYKPHX	MI	TT8BUGW
DMYKPHX	MN	Glycogen phosphorylase (PYG)
DMYKPHX	MT	DTT
DMYKPHX	MA	Inhibitor
DMYKPHX	RN	Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212.
DMYKPHX	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666989

DMA02ED	DI	DMA02ED
DMA02ED	DN	PMID26666989-Compound-Figure9middle07
DMA02ED	MI	TT8BUGW
DMA02ED	MN	Glycogen phosphorylase (PYG)
DMA02ED	MT	DTT
DMA02ED	MA	Inhibitor
DMA02ED	RN	Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212.
DMA02ED	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666989

DM8KF15	DI	DM8KF15
DM8KF15	DN	PMID26666989-Compound-Figure9middle08
DM8KF15	MI	TT8BUGW
DM8KF15	MN	Glycogen phosphorylase (PYG)
DM8KF15	MT	DTT
DM8KF15	MA	Inhibitor
DM8KF15	RN	Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212.
DM8KF15	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666989

DMB4SH8	DI	DMB4SH8
DMB4SH8	DN	PMID26666989-Compound-Figure9middle10
DMB4SH8	MI	TT8BUGW
DMB4SH8	MN	Glycogen phosphorylase (PYG)
DMB4SH8	MT	DTT
DMB4SH8	MA	Inhibitor
DMB4SH8	RN	Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212.
DMB4SH8	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666989

DMT6CNM	DI	DMT6CNM
DMT6CNM	DN	PMID26666989-Compound-Figure9middle11
DMT6CNM	MI	TT8BUGW
DMT6CNM	MN	Glycogen phosphorylase (PYG)
DMT6CNM	MT	DTT
DMT6CNM	MA	Inhibitor
DMT6CNM	RN	Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212.
DMT6CNM	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666989

DMX612V	DI	DMX612V
DMX612V	DN	PMID26666989-Compound-Figure9middle12
DMX612V	MI	TT8BUGW
DMX612V	MN	Glycogen phosphorylase (PYG)
DMX612V	MT	DTT
DMX612V	MA	Inhibitor
DMX612V	RN	Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212.
DMX612V	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666989

DMKZTVR	DI	DMKZTVR
DMKZTVR	DN	PMID26666989-Compound-Figure9middle13
DMKZTVR	MI	TT8BUGW
DMKZTVR	MN	Glycogen phosphorylase (PYG)
DMKZTVR	MT	DTT
DMKZTVR	MA	Inhibitor
DMKZTVR	RN	Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212.
DMKZTVR	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666989

DMVS1TU	DI	DMVS1TU
DMVS1TU	DN	PMID26666989-Compound-Figure9topright01
DMVS1TU	MI	TT8BUGW
DMVS1TU	MN	Glycogen phosphorylase (PYG)
DMVS1TU	MT	DTT
DMVS1TU	MA	Inhibitor
DMVS1TU	RN	Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212.
DMVS1TU	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666989

DMJ3GX6	DI	DMJ3GX6
DMJ3GX6	DN	PMID26666989-Compound-Figure9toprightR02
DMJ3GX6	MI	TT8BUGW
DMJ3GX6	MN	Glycogen phosphorylase (PYG)
DMJ3GX6	MT	DTT
DMJ3GX6	MA	Inhibitor
DMJ3GX6	RN	Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212.
DMJ3GX6	RU	https://www.ncbi.nlm.nih.gov/pubmed/26666989

DMOJ936	DI	DMOJ936
DMOJ936	DN	PMID26815044-Compound-114
DMOJ936	MI	TTULVH8
DMOJ936	MN	Tyrosinase (TYR)
DMOJ936	MT	DTT
DMOJ936	MA	Inhibitor
DMOJ936	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMOJ936	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DM8SWHO	DI	DM8SWHO
DM8SWHO	DN	PMID26815044-Compound-115
DM8SWHO	MI	TTULVH8
DM8SWHO	MN	Tyrosinase (TYR)
DM8SWHO	MT	DTT
DM8SWHO	MA	Inhibitor
DM8SWHO	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DM8SWHO	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMDUXRT	DI	DMDUXRT
DMDUXRT	DN	PMID26815044-Compound-116
DMDUXRT	MI	TTULVH8
DMDUXRT	MN	Tyrosinase (TYR)
DMDUXRT	MT	DTT
DMDUXRT	MA	Inhibitor
DMDUXRT	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMDUXRT	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DM2GON6	DI	DM2GON6
DM2GON6	DN	PMID26815044-Compound-117
DM2GON6	MI	TTULVH8
DM2GON6	MN	Tyrosinase (TYR)
DM2GON6	MT	DTT
DM2GON6	MA	Inhibitor
DM2GON6	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DM2GON6	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMC28VB	DI	DMC28VB
DMC28VB	DN	PMID26815044-Compound-118
DMC28VB	MI	TTULVH8
DMC28VB	MN	Tyrosinase (TYR)
DMC28VB	MT	DTT
DMC28VB	MA	Inhibitor
DMC28VB	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMC28VB	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMMNXA1	DI	DMMNXA1
DMMNXA1	DN	PMID26815044-Compound-121
DMMNXA1	MI	TTULVH8
DMMNXA1	MN	Tyrosinase (TYR)
DMMNXA1	MT	DTT
DMMNXA1	MA	Inhibitor
DMMNXA1	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMMNXA1	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DM1HAGJ	DI	DM1HAGJ
DM1HAGJ	DN	PMID26815044-Compound-122
DM1HAGJ	MI	TTULVH8
DM1HAGJ	MN	Tyrosinase (TYR)
DM1HAGJ	MT	DTT
DM1HAGJ	MA	Inhibitor
DM1HAGJ	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DM1HAGJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMFTE3Y	DI	DMFTE3Y
DMFTE3Y	DN	PMID26815044-Compound-123
DMFTE3Y	MI	TTULVH8
DMFTE3Y	MN	Tyrosinase (TYR)
DMFTE3Y	MT	DTT
DMFTE3Y	MA	Inhibitor
DMFTE3Y	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMFTE3Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DM25WGP	DI	DM25WGP
DM25WGP	DN	PMID26815044-Compound-124
DM25WGP	MI	TTULVH8
DM25WGP	MN	Tyrosinase (TYR)
DM25WGP	MT	DTT
DM25WGP	MA	Inhibitor
DM25WGP	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DM25WGP	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DM6EFIN	DI	DM6EFIN
DM6EFIN	DN	PMID26815044-Compound-125
DM6EFIN	MI	TTULVH8
DM6EFIN	MN	Tyrosinase (TYR)
DM6EFIN	MT	DTT
DM6EFIN	MA	Inhibitor
DM6EFIN	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DM6EFIN	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMMJK0L	DI	DMMJK0L
DMMJK0L	DN	PMID26815044-Compound-126
DMMJK0L	MI	TTULVH8
DMMJK0L	MN	Tyrosinase (TYR)
DMMJK0L	MT	DTT
DMMJK0L	MA	Inhibitor
DMMJK0L	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMMJK0L	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMO97LR	DI	DMO97LR
DMO97LR	DN	PMID26815044-Compound-127
DMO97LR	MI	TTULVH8
DMO97LR	MN	Tyrosinase (TYR)
DMO97LR	MT	DTT
DMO97LR	MA	Inhibitor
DMO97LR	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMO97LR	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMH8E7S	DI	DMH8E7S
DMH8E7S	DN	PMID26815044-Compound-30
DMH8E7S	MI	TTULVH8
DMH8E7S	MN	Tyrosinase (TYR)
DMH8E7S	MT	DTT
DMH8E7S	MA	Inhibitor
DMH8E7S	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMH8E7S	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMBINQ9	DI	DMBINQ9
DMBINQ9	DN	PMID26815044-Compound-31
DMBINQ9	MI	TTULVH8
DMBINQ9	MN	Tyrosinase (TYR)
DMBINQ9	MT	DTT
DMBINQ9	MA	Inhibitor
DMBINQ9	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMBINQ9	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMN5H3C	DI	DMN5H3C
DMN5H3C	DN	PMID26815044-Compound-32
DMN5H3C	MI	TTULVH8
DMN5H3C	MN	Tyrosinase (TYR)
DMN5H3C	MT	DTT
DMN5H3C	MA	Inhibitor
DMN5H3C	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMN5H3C	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMM3FJO	DI	DMM3FJO
DMM3FJO	DN	PMID26815044-Compound-47
DMM3FJO	MI	TTULVH8
DMM3FJO	MN	Tyrosinase (TYR)
DMM3FJO	MT	DTT
DMM3FJO	MA	Inhibitor
DMM3FJO	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMM3FJO	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMJ1Z7U	DI	DMJ1Z7U
DMJ1Z7U	DN	PMID26815044-Compound-48
DMJ1Z7U	MI	TTULVH8
DMJ1Z7U	MN	Tyrosinase (TYR)
DMJ1Z7U	MT	DTT
DMJ1Z7U	MA	Inhibitor
DMJ1Z7U	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMJ1Z7U	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMD9WRS	DI	DMD9WRS
DMD9WRS	DN	PMID26815044-Compound-49
DMD9WRS	MI	TTULVH8
DMD9WRS	MN	Tyrosinase (TYR)
DMD9WRS	MT	DTT
DMD9WRS	MA	Inhibitor
DMD9WRS	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMD9WRS	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMYI1SX	DI	DMYI1SX
DMYI1SX	DN	PMID26815044-Compound-50
DMYI1SX	MI	TTULVH8
DMYI1SX	MN	Tyrosinase (TYR)
DMYI1SX	MT	DTT
DMYI1SX	MA	Inhibitor
DMYI1SX	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMYI1SX	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMQGTJ5	DI	DMQGTJ5
DMQGTJ5	DN	PMID26815044-Compound-51
DMQGTJ5	MI	TTULVH8
DMQGTJ5	MN	Tyrosinase (TYR)
DMQGTJ5	MT	DTT
DMQGTJ5	MA	Inhibitor
DMQGTJ5	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMQGTJ5	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMN4C2O	DI	DMN4C2O
DMN4C2O	DN	PMID26815044-Compound-52
DMN4C2O	MI	TTULVH8
DMN4C2O	MN	Tyrosinase (TYR)
DMN4C2O	MT	DTT
DMN4C2O	MA	Inhibitor
DMN4C2O	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMN4C2O	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMEKBOG	DI	DMEKBOG
DMEKBOG	DN	PMID26815044-Compound-64
DMEKBOG	MI	TTULVH8
DMEKBOG	MN	Tyrosinase (TYR)
DMEKBOG	MT	DTT
DMEKBOG	MA	Inhibitor
DMEKBOG	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMEKBOG	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMV46DG	DI	DMV46DG
DMV46DG	DN	PMID26815044-Compound-93
DMV46DG	MI	TTULVH8
DMV46DG	MN	Tyrosinase (TYR)
DMV46DG	MT	DTT
DMV46DG	MA	Inhibitor
DMV46DG	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMV46DG	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMI3QLT	DI	DMI3QLT
DMI3QLT	DN	PMID26815044-Compound-H
DMI3QLT	MI	TTULVH8
DMI3QLT	MN	Tyrosinase (TYR)
DMI3QLT	MT	DTT
DMI3QLT	MA	Inhibitor
DMI3QLT	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMI3QLT	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMZISDR	DI	DMZISDR
DMZISDR	DN	PMID26815044-Compound-I
DMZISDR	MI	TTULVH8
DMZISDR	MN	Tyrosinase (TYR)
DMZISDR	MT	DTT
DMZISDR	MA	Inhibitor
DMZISDR	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMZISDR	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMPAE8N	DI	DMPAE8N
DMPAE8N	DN	PMID26882240-Compound-1
DMPAE8N	MI	TT9MZCQ
DMPAE8N	MN	Enhancer of zeste homolog 2 (EZH2)
DMPAE8N	MT	DTT
DMPAE8N	MA	Inhibitor
DMPAE8N	RN	Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22.
DMPAE8N	RU	https://www.ncbi.nlm.nih.gov/pubmed/26882240

DMPAE8N	DI	DMPAE8N
DMPAE8N	DN	PMID26882240-Compound-1
DMPAE8N	MI	TTUX68I
DMPAE8N	MN	Hypoxia-inducible factor 1 (HIF-1)
DMPAE8N	MT	DTT
DMPAE8N	MA	Inhibitor
DMPAE8N	RN	Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22.
DMPAE8N	RU	https://www.ncbi.nlm.nih.gov/pubmed/26882240

DMQVZ01	DI	DMQVZ01
DMQVZ01	DN	PMID26882240-Compound-14
DMQVZ01	MI	TTUX68I
DMQVZ01	MN	Hypoxia-inducible factor 1 (HIF-1)
DMQVZ01	MT	DTT
DMQVZ01	MA	Inhibitor
DMQVZ01	RN	Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22.
DMQVZ01	RU	https://www.ncbi.nlm.nih.gov/pubmed/26882240

DMZ12V4	DI	DMZ12V4
DMZ12V4	DN	PMID26882240-Compound-15
DMZ12V4	MI	TTUX68I
DMZ12V4	MN	Hypoxia-inducible factor 1 (HIF-1)
DMZ12V4	MT	DTT
DMZ12V4	MA	Inhibitor
DMZ12V4	RN	Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22.
DMZ12V4	RU	https://www.ncbi.nlm.nih.gov/pubmed/26882240

DMX7Y52	DI	DMX7Y52
DMX7Y52	DN	PMID26882240-Compound-2
DMX7Y52	MI	TTUX68I
DMX7Y52	MN	Hypoxia-inducible factor 1 (HIF-1)
DMX7Y52	MT	DTT
DMX7Y52	MA	Inhibitor
DMX7Y52	RN	Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22.
DMX7Y52	RU	https://www.ncbi.nlm.nih.gov/pubmed/26882240

DMFZM3X	DI	DMFZM3X
DMFZM3X	DN	PMID26882240-Compound-3
DMFZM3X	MI	TTUX68I
DMFZM3X	MN	Hypoxia-inducible factor 1 (HIF-1)
DMFZM3X	MT	DTT
DMFZM3X	MA	Inhibitor
DMFZM3X	RN	Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22.
DMFZM3X	RU	https://www.ncbi.nlm.nih.gov/pubmed/26882240

DMJS4RP	DI	DMJS4RP
DMJS4RP	DN	PMID26882240-Compound-32
DMJS4RP	MI	TTUX68I
DMJS4RP	MN	Hypoxia-inducible factor 1 (HIF-1)
DMJS4RP	MT	DTT
DMJS4RP	MA	Inhibitor
DMJS4RP	RN	Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22.
DMJS4RP	RU	https://www.ncbi.nlm.nih.gov/pubmed/26882240

DMS4RLZ	DI	DMS4RLZ
DMS4RLZ	DN	PMID26882240-Compound-4
DMS4RLZ	MI	TTUX68I
DMS4RLZ	MN	Hypoxia-inducible factor 1 (HIF-1)
DMS4RLZ	MT	DTT
DMS4RLZ	MA	Inhibitor
DMS4RLZ	RN	Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22.
DMS4RLZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26882240

DM61NOP	DI	DM61NOP
DM61NOP	DN	PMID26882240-Compound-6
DM61NOP	MI	TTUX68I
DM61NOP	MN	Hypoxia-inducible factor 1 (HIF-1)
DM61NOP	MT	DTT
DM61NOP	MA	Inhibitor
DM61NOP	RN	Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22.
DM61NOP	RU	https://www.ncbi.nlm.nih.gov/pubmed/26882240

DMOX8E3	DI	DMOX8E3
DMOX8E3	DN	PMID26882240-Compound-7
DMOX8E3	MI	TTUX68I
DMOX8E3	MN	Hypoxia-inducible factor 1 (HIF-1)
DMOX8E3	MT	DTT
DMOX8E3	MA	Inhibitor
DMOX8E3	RN	Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22.
DMOX8E3	RU	https://www.ncbi.nlm.nih.gov/pubmed/26882240

DMWJRY7	DI	DMWJRY7
DMWJRY7	DN	PMID26882240-Compound-8
DMWJRY7	MI	TTUX68I
DMWJRY7	MN	Hypoxia-inducible factor 1 (HIF-1)
DMWJRY7	MT	DTT
DMWJRY7	MA	Inhibitor
DMWJRY7	RN	Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22.
DMWJRY7	RU	https://www.ncbi.nlm.nih.gov/pubmed/26882240

DMEJ107	DI	DMEJ107
DMEJ107	DN	PMID26924192-Compound-102
DMEJ107	MI	TT7CPI5
DMEJ107	MN	Bromodomain testis-specific protein (BRDT)
DMEJ107	MT	DTT
DMEJ107	MA	Inhibitor
DMEJ107	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMEJ107	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMEJ107	DI	DMEJ107
DMEJ107	DN	PMID26924192-Compound-102
DMEJ107	MI	TTDP48B
DMEJ107	MN	Bromodomain-containing protein 2 (BRD2)
DMEJ107	MT	DTT
DMEJ107	MA	Inhibitor
DMEJ107	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMEJ107	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMEJ107	DI	DMEJ107
DMEJ107	DN	PMID26924192-Compound-102
DMEJ107	MI	TTHE657
DMEJ107	MN	Bromodomain-containing protein 3 (BRD3)
DMEJ107	MT	DTT
DMEJ107	MA	Inhibitor
DMEJ107	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMEJ107	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMEJ107	DI	DMEJ107
DMEJ107	DN	PMID26924192-Compound-102
DMEJ107	MI	TTRA6BO
DMEJ107	MN	Bromodomain-containing protein 4 (BRD4)
DMEJ107	MT	DTT
DMEJ107	MA	Inhibitor
DMEJ107	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMEJ107	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMWOCP7	DI	DMWOCP7
DMWOCP7	DN	PMID26924192-Compound-103
DMWOCP7	MI	TT7CPI5
DMWOCP7	MN	Bromodomain testis-specific protein (BRDT)
DMWOCP7	MT	DTT
DMWOCP7	MA	Inhibitor
DMWOCP7	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMWOCP7	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMWOCP7	DI	DMWOCP7
DMWOCP7	DN	PMID26924192-Compound-103
DMWOCP7	MI	TTDP48B
DMWOCP7	MN	Bromodomain-containing protein 2 (BRD2)
DMWOCP7	MT	DTT
DMWOCP7	MA	Inhibitor
DMWOCP7	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMWOCP7	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMWOCP7	DI	DMWOCP7
DMWOCP7	DN	PMID26924192-Compound-103
DMWOCP7	MI	TTHE657
DMWOCP7	MN	Bromodomain-containing protein 3 (BRD3)
DMWOCP7	MT	DTT
DMWOCP7	MA	Inhibitor
DMWOCP7	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMWOCP7	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMWOCP7	DI	DMWOCP7
DMWOCP7	DN	PMID26924192-Compound-103
DMWOCP7	MI	TTRA6BO
DMWOCP7	MN	Bromodomain-containing protein 4 (BRD4)
DMWOCP7	MT	DTT
DMWOCP7	MA	Inhibitor
DMWOCP7	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMWOCP7	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DM346EU	DI	DM346EU
DM346EU	DN	PMID26924192-Compound-104
DM346EU	MI	TT7CPI5
DM346EU	MN	Bromodomain testis-specific protein (BRDT)
DM346EU	MT	DTT
DM346EU	MA	Inhibitor
DM346EU	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DM346EU	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DM346EU	DI	DM346EU
DM346EU	DN	PMID26924192-Compound-104
DM346EU	MI	TTDP48B
DM346EU	MN	Bromodomain-containing protein 2 (BRD2)
DM346EU	MT	DTT
DM346EU	MA	Inhibitor
DM346EU	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DM346EU	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DM346EU	DI	DM346EU
DM346EU	DN	PMID26924192-Compound-104
DM346EU	MI	TTHE657
DM346EU	MN	Bromodomain-containing protein 3 (BRD3)
DM346EU	MT	DTT
DM346EU	MA	Inhibitor
DM346EU	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DM346EU	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DM346EU	DI	DM346EU
DM346EU	DN	PMID26924192-Compound-104
DM346EU	MI	TTRA6BO
DM346EU	MN	Bromodomain-containing protein 4 (BRD4)
DM346EU	MT	DTT
DM346EU	MA	Inhibitor
DM346EU	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DM346EU	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMAWLGI	DI	DMAWLGI
DMAWLGI	DN	PMID26924192-Compound-105
DMAWLGI	MI	TT7CPI5
DMAWLGI	MN	Bromodomain testis-specific protein (BRDT)
DMAWLGI	MT	DTT
DMAWLGI	MA	Inhibitor
DMAWLGI	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMAWLGI	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMAWLGI	DI	DMAWLGI
DMAWLGI	DN	PMID26924192-Compound-105
DMAWLGI	MI	TTDP48B
DMAWLGI	MN	Bromodomain-containing protein 2 (BRD2)
DMAWLGI	MT	DTT
DMAWLGI	MA	Inhibitor
DMAWLGI	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMAWLGI	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMAWLGI	DI	DMAWLGI
DMAWLGI	DN	PMID26924192-Compound-105
DMAWLGI	MI	TTHE657
DMAWLGI	MN	Bromodomain-containing protein 3 (BRD3)
DMAWLGI	MT	DTT
DMAWLGI	MA	Inhibitor
DMAWLGI	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMAWLGI	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMAWLGI	DI	DMAWLGI
DMAWLGI	DN	PMID26924192-Compound-105
DMAWLGI	MI	TTRA6BO
DMAWLGI	MN	Bromodomain-containing protein 4 (BRD4)
DMAWLGI	MT	DTT
DMAWLGI	MA	Inhibitor
DMAWLGI	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMAWLGI	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DM9HRZJ	DI	DM9HRZJ
DM9HRZJ	DN	PMID26924192-Compound-106
DM9HRZJ	MI	TTDP48B
DM9HRZJ	MN	Bromodomain-containing protein 2 (BRD2)
DM9HRZJ	MT	DTT
DM9HRZJ	MA	Inhibitor
DM9HRZJ	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DM9HRZJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMHAOF1	DI	DMHAOF1
DMHAOF1	DN	PMID26924192-Compound-20
DMHAOF1	MI	TTRA6BO
DMHAOF1	MN	Bromodomain-containing protein 4 (BRD4)
DMHAOF1	MT	DTT
DMHAOF1	MA	Inhibitor
DMHAOF1	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMHAOF1	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DM4MZ29	DI	DM4MZ29
DM4MZ29	DN	PMID26924192-Compound-21
DM4MZ29	MI	TTRA6BO
DM4MZ29	MN	Bromodomain-containing protein 4 (BRD4)
DM4MZ29	MT	DTT
DM4MZ29	MA	Inhibitor
DM4MZ29	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DM4MZ29	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMX964E	DI	DMX964E
DMX964E	DN	PMID26924192-Compound-22
DMX964E	MI	TTRA6BO
DMX964E	MN	Bromodomain-containing protein 4 (BRD4)
DMX964E	MT	DTT
DMX964E	MA	Inhibitor
DMX964E	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMX964E	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DME60LY	DI	DME60LY
DME60LY	DN	PMID26924192-Compound-23
DME60LY	MI	TTRA6BO
DME60LY	MN	Bromodomain-containing protein 4 (BRD4)
DME60LY	MT	DTT
DME60LY	MA	Inhibitor
DME60LY	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DME60LY	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMDN5Q4	DI	DMDN5Q4
DMDN5Q4	DN	PMID26924192-Compound-24
DMDN5Q4	MI	TTRA6BO
DMDN5Q4	MN	Bromodomain-containing protein 4 (BRD4)
DMDN5Q4	MT	DTT
DMDN5Q4	MA	Inhibitor
DMDN5Q4	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMDN5Q4	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMEL7XA	DI	DMEL7XA
DMEL7XA	DN	PMID26924192-Compound-25
DMEL7XA	MI	TTRA6BO
DMEL7XA	MN	Bromodomain-containing protein 4 (BRD4)
DMEL7XA	MT	DTT
DMEL7XA	MA	Inhibitor
DMEL7XA	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMEL7XA	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMWXNIJ	DI	DMWXNIJ
DMWXNIJ	DN	PMID26924192-Compound-30
DMWXNIJ	MI	TTRA6BO
DMWXNIJ	MN	Bromodomain-containing protein 4 (BRD4)
DMWXNIJ	MT	DTT
DMWXNIJ	MA	Inhibitor
DMWXNIJ	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMWXNIJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMWXNIJ	DI	DMWXNIJ
DMWXNIJ	DN	PMID26924192-Compound-30
DMWXNIJ	MI	TTU6FSC
DMWXNIJ	MN	Extracellular signal-regulated kinase 5 (ERK5)
DMWXNIJ	MT	DTT
DMWXNIJ	MA	Inhibitor
DMWXNIJ	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMWXNIJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMIFV58	DI	DMIFV58
DMIFV58	DN	PMID26924192-Compound-31
DMIFV58	MI	TTRA6BO
DMIFV58	MN	Bromodomain-containing protein 4 (BRD4)
DMIFV58	MT	DTT
DMIFV58	MA	Inhibitor
DMIFV58	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMIFV58	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DM0JSOZ	DI	DM0JSOZ
DM0JSOZ	DN	PMID26924192-Compound-32
DM0JSOZ	MI	TTRA6BO
DM0JSOZ	MN	Bromodomain-containing protein 4 (BRD4)
DM0JSOZ	MT	DTT
DM0JSOZ	MA	Inhibitor
DM0JSOZ	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DM0JSOZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DM0JSOZ	DI	DM0JSOZ
DM0JSOZ	DN	PMID26924192-Compound-32
DM0JSOZ	MI	TTU6FSC
DM0JSOZ	MN	Extracellular signal-regulated kinase 5 (ERK5)
DM0JSOZ	MT	DTT
DM0JSOZ	MA	Inhibitor
DM0JSOZ	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DM0JSOZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DM9NWXM	DI	DM9NWXM
DM9NWXM	DN	PMID26924192-Compound-33
DM9NWXM	MI	TTRA6BO
DM9NWXM	MN	Bromodomain-containing protein 4 (BRD4)
DM9NWXM	MT	DTT
DM9NWXM	MA	Inhibitor
DM9NWXM	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DM9NWXM	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DM9NWXM	DI	DM9NWXM
DM9NWXM	DN	PMID26924192-Compound-33
DM9NWXM	MI	TTU6FSC
DM9NWXM	MN	Extracellular signal-regulated kinase 5 (ERK5)
DM9NWXM	MT	DTT
DM9NWXM	MA	Inhibitor
DM9NWXM	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DM9NWXM	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMTVZWM	DI	DMTVZWM
DMTVZWM	DN	PMID26924192-Compound-50
DMTVZWM	MI	TTE4BSY
DMTVZWM	MN	Bromodomain and extraterminal domain protein (BET)
DMTVZWM	MT	DTT
DMTVZWM	MA	Inhibitor
DMTVZWM	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMTVZWM	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMB2MH3	DI	DMB2MH3
DMB2MH3	DN	PMID26924192-Compound-51
DMB2MH3	MI	TTE4BSY
DMB2MH3	MN	Bromodomain and extraterminal domain protein (BET)
DMB2MH3	MT	DTT
DMB2MH3	MA	Inhibitor
DMB2MH3	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMB2MH3	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMFU6JR	DI	DMFU6JR
DMFU6JR	DN	PMID26924192-Compound-52
DMFU6JR	MI	TTE4BSY
DMFU6JR	MN	Bromodomain and extraterminal domain protein (BET)
DMFU6JR	MT	DTT
DMFU6JR	MA	Inhibitor
DMFU6JR	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMFU6JR	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMFN1AR	DI	DMFN1AR
DMFN1AR	DN	PMID26924192-Compound-53
DMFN1AR	MI	TTE4BSY
DMFN1AR	MN	Bromodomain and extraterminal domain protein (BET)
DMFN1AR	MT	DTT
DMFN1AR	MA	Inhibitor
DMFN1AR	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMFN1AR	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMODT8F	DI	DMODT8F
DMODT8F	DN	PMID26924192-Compound-54
DMODT8F	MI	TTE4BSY
DMODT8F	MN	Bromodomain and extraterminal domain protein (BET)
DMODT8F	MT	DTT
DMODT8F	MA	Inhibitor
DMODT8F	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMODT8F	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMGWQVT	DI	DMGWQVT
DMGWQVT	DN	PMID26924192-Compound-55
DMGWQVT	MI	TTE4BSY
DMGWQVT	MN	Bromodomain and extraterminal domain protein (BET)
DMGWQVT	MT	DTT
DMGWQVT	MA	Inhibitor
DMGWQVT	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMGWQVT	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DM6YGLT	DI	DM6YGLT
DM6YGLT	DN	PMID26924192-Compound-56
DM6YGLT	MI	TTE4BSY
DM6YGLT	MN	Bromodomain and extraterminal domain protein (BET)
DM6YGLT	MT	DTT
DM6YGLT	MA	Inhibitor
DM6YGLT	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DM6YGLT	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DM3NXP8	DI	DM3NXP8
DM3NXP8	DN	PMID26924192-Compound-57
DM3NXP8	MI	TTE4BSY
DM3NXP8	MN	Bromodomain and extraterminal domain protein (BET)
DM3NXP8	MT	DTT
DM3NXP8	MA	Inhibitor
DM3NXP8	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DM3NXP8	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMXK6LV	DI	DMXK6LV
DMXK6LV	DN	PMID26936077-Compound-13
DMXK6LV	MI	TTQR74A
DMXK6LV	MN	Proteinase activated receptor 2 (PAR2)
DMXK6LV	MT	DTT
DMXK6LV	MA	Antagonist
DMXK6LV	RN	Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
DMXK6LV	RU	https://www.ncbi.nlm.nih.gov/pubmed/26936077

DMIZL8D	DI	DMIZL8D
DMIZL8D	DN	PMID26936077-Compound-34
DMIZL8D	MI	TTQR74A
DMIZL8D	MN	Proteinase activated receptor 2 (PAR2)
DMIZL8D	MT	DTT
DMIZL8D	MA	Antagonist
DMIZL8D	RN	Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
DMIZL8D	RU	https://www.ncbi.nlm.nih.gov/pubmed/26936077

DMD0HAT	DI	DMD0HAT
DMD0HAT	DN	PMID27019002-Compound-13
DMD0HAT	MI	TTNR0UQ
DMD0HAT	MN	Lysine-specific histone demethylase 1 (LSD)
DMD0HAT	MT	DTT
DMD0HAT	MA	Inhibitor
DMD0HAT	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMD0HAT	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMZ9T8H	DI	DMZ9T8H
DMZ9T8H	DN	PMID27019002-Compound-16
DMZ9T8H	MI	TTNR0UQ
DMZ9T8H	MN	Lysine-specific histone demethylase 1 (LSD)
DMZ9T8H	MT	DTT
DMZ9T8H	MA	Inhibitor
DMZ9T8H	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMZ9T8H	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DM7JASU	DI	DM7JASU
DM7JASU	DN	PMID27019002-Compound-17
DM7JASU	MI	TTNR0UQ
DM7JASU	MN	Lysine-specific histone demethylase 1 (LSD)
DM7JASU	MT	DTT
DM7JASU	MA	Inhibitor
DM7JASU	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DM7JASU	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DM7JASU	DI	DM7JASU
DM7JASU	DN	PMID27019002-Compound-17
DM7JASU	MI	TT32XQJ
DM7JASU	MN	Monoamine oxidase (MAO)
DM7JASU	MT	DTT
DM7JASU	MA	Inhibitor
DM7JASU	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DM7JASU	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMRX748	DI	DMRX748
DMRX748	DN	PMID27019002-Compound-20a
DMRX748	MI	TTNR0UQ
DMRX748	MN	Lysine-specific histone demethylase 1 (LSD)
DMRX748	MT	DTT
DMRX748	MA	Inhibitor
DMRX748	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMRX748	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMRX748	DI	DMRX748
DMRX748	DN	PMID27019002-Compound-20a
DMRX748	MI	TT32XQJ
DMRX748	MN	Monoamine oxidase (MAO)
DMRX748	MT	DTT
DMRX748	MA	Inhibitor
DMRX748	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMRX748	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMYRV8I	DI	DMYRV8I
DMYRV8I	DN	PMID27019002-Compound-20b
DMYRV8I	MI	TTNR0UQ
DMYRV8I	MN	Lysine-specific histone demethylase 1 (LSD)
DMYRV8I	MT	DTT
DMYRV8I	MA	Inhibitor
DMYRV8I	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMYRV8I	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMC6AF2	DI	DMC6AF2
DMC6AF2	DN	PMID27019002-Compound-21a
DMC6AF2	MI	TTNR0UQ
DMC6AF2	MN	Lysine-specific histone demethylase 1 (LSD)
DMC6AF2	MT	DTT
DMC6AF2	MA	Inhibitor
DMC6AF2	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMC6AF2	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMMC31N	DI	DMMC31N
DMMC31N	DN	PMID27019002-Compound-21b
DMMC31N	MI	TTZHPB8
DMMC31N	MN	Lysine-specific demethylase 4A (KDM4A)
DMMC31N	MT	DTT
DMMC31N	MA	Inhibitor
DMMC31N	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMMC31N	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMMC31N	DI	DMMC31N
DMMC31N	DN	PMID27019002-Compound-21b
DMMC31N	MI	TTNR0UQ
DMMC31N	MN	Lysine-specific histone demethylase 1 (LSD)
DMMC31N	MT	DTT
DMMC31N	MA	Inhibitor
DMMC31N	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMMC31N	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMWZOKP	DI	DMWZOKP
DMWZOKP	DN	PMID27019002-Compound-21c
DMWZOKP	MI	TTZHPB8
DMWZOKP	MN	Lysine-specific demethylase 4A (KDM4A)
DMWZOKP	MT	DTT
DMWZOKP	MA	Inhibitor
DMWZOKP	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMWZOKP	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMWZOKP	DI	DMWZOKP
DMWZOKP	DN	PMID27019002-Compound-21c
DMWZOKP	MI	TTNR0UQ
DMWZOKP	MN	Lysine-specific histone demethylase 1 (LSD)
DMWZOKP	MT	DTT
DMWZOKP	MA	Inhibitor
DMWZOKP	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMWZOKP	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DM1R6GA	DI	DM1R6GA
DM1R6GA	DN	PMID27019002-Compound-28
DM1R6GA	MI	TTNR0UQ
DM1R6GA	MN	Lysine-specific histone demethylase 1 (LSD)
DM1R6GA	MT	DTT
DM1R6GA	MA	Inhibitor
DM1R6GA	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DM1R6GA	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DM954C8	DI	DM954C8
DM954C8	DN	PMID27019002-Compound-28a
DM954C8	MI	TTNR0UQ
DM954C8	MN	Lysine-specific histone demethylase 1 (LSD)
DM954C8	MT	DTT
DM954C8	MA	Inhibitor
DM954C8	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DM954C8	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMRWGHN	DI	DMRWGHN
DMRWGHN	DN	PMID27019002-Compound-31a
DMRWGHN	MI	TTNR0UQ
DMRWGHN	MN	Lysine-specific histone demethylase 1 (LSD)
DMRWGHN	MT	DTT
DMRWGHN	MA	Inhibitor
DMRWGHN	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMRWGHN	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMJ1K4Y	DI	DMJ1K4Y
DMJ1K4Y	DN	PMID27019002-Compound-31b
DMJ1K4Y	MI	TTNR0UQ
DMJ1K4Y	MN	Lysine-specific histone demethylase 1 (LSD)
DMJ1K4Y	MT	DTT
DMJ1K4Y	MA	Inhibitor
DMJ1K4Y	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMJ1K4Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMMB6XC	DI	DMMB6XC
DMMB6XC	DN	PMID27019002-Compound-37a
DMMB6XC	MI	TTNR0UQ
DMMB6XC	MN	Lysine-specific histone demethylase 1 (LSD)
DMMB6XC	MT	DTT
DMMB6XC	MA	Inhibitor
DMMB6XC	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMMB6XC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMCIT5A	DI	DMCIT5A
DMCIT5A	DN	PMID27019002-Compound-37b
DMCIT5A	MI	TTNR0UQ
DMCIT5A	MN	Lysine-specific histone demethylase 1 (LSD)
DMCIT5A	MT	DTT
DMCIT5A	MA	Inhibitor
DMCIT5A	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMCIT5A	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMVLXRB	DI	DMVLXRB
DMVLXRB	DN	PMID27019002-Compound-41
DMVLXRB	MI	TTNR0UQ
DMVLXRB	MN	Lysine-specific histone demethylase 1 (LSD)
DMVLXRB	MT	DTT
DMVLXRB	MA	Inhibitor
DMVLXRB	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMVLXRB	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DM42VUQ	DI	DM42VUQ
DM42VUQ	DN	PMID27019002-Compound-42a
DM42VUQ	MI	TTNR0UQ
DM42VUQ	MN	Lysine-specific histone demethylase 1 (LSD)
DM42VUQ	MT	DTT
DM42VUQ	MA	Inhibitor
DM42VUQ	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DM42VUQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMHJBRO	DI	DMHJBRO
DMHJBRO	DN	PMID27019002-Compound-42b
DMHJBRO	MI	TTNR0UQ
DMHJBRO	MN	Lysine-specific histone demethylase 1 (LSD)
DMHJBRO	MT	DTT
DMHJBRO	MA	Inhibitor
DMHJBRO	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMHJBRO	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMMOVGU	DI	DMMOVGU
DMMOVGU	DN	PMID27019002-Compound-43a
DMMOVGU	MI	TTNR0UQ
DMMOVGU	MN	Lysine-specific histone demethylase 1 (LSD)
DMMOVGU	MT	DTT
DMMOVGU	MA	Inhibitor
DMMOVGU	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMMOVGU	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMIMFND	DI	DMIMFND
DMIMFND	DN	PMID27019002-Compound-43b
DMIMFND	MI	TTNR0UQ
DMIMFND	MN	Lysine-specific histone demethylase 1 (LSD)
DMIMFND	MT	DTT
DMIMFND	MA	Inhibitor
DMIMFND	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMIMFND	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DM72TBJ	DI	DM72TBJ
DM72TBJ	DN	PMID27019002-Compound-43c
DM72TBJ	MI	TTNR0UQ
DM72TBJ	MN	Lysine-specific histone demethylase 1 (LSD)
DM72TBJ	MT	DTT
DM72TBJ	MA	Inhibitor
DM72TBJ	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DM72TBJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DM5HUCR	DI	DM5HUCR
DM5HUCR	DN	PMID27019002-Compound-44
DM5HUCR	MI	TTNR0UQ
DM5HUCR	MN	Lysine-specific histone demethylase 1 (LSD)
DM5HUCR	MT	DTT
DM5HUCR	MA	Inhibitor
DM5HUCR	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DM5HUCR	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DM3G6YV	DI	DM3G6YV
DM3G6YV	DN	PMID27019002-Compound-45
DM3G6YV	MI	TTNR0UQ
DM3G6YV	MN	Lysine-specific histone demethylase 1 (LSD)
DM3G6YV	MT	DTT
DM3G6YV	MA	Inhibitor
DM3G6YV	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DM3G6YV	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMQPU7K	DI	DMQPU7K
DMQPU7K	DN	PMID27019002-Compound-46
DMQPU7K	MI	TTNR0UQ
DMQPU7K	MN	Lysine-specific histone demethylase 1 (LSD)
DMQPU7K	MT	DTT
DMQPU7K	MA	Inhibitor
DMQPU7K	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMQPU7K	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMQPU7K	DI	DMQPU7K
DMQPU7K	DN	PMID27019002-Compound-46
DMQPU7K	MI	TT8VP2T
DMQPU7K	MN	Lysine-specific histone demethylase 1B (KDM1B)
DMQPU7K	MT	DTT
DMQPU7K	MA	Inhibitor
DMQPU7K	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMQPU7K	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMRLWP9	DI	DMRLWP9
DMRLWP9	DN	PMID27019002-Compound-47
DMRLWP9	MI	TTNR0UQ
DMRLWP9	MN	Lysine-specific histone demethylase 1 (LSD)
DMRLWP9	MT	DTT
DMRLWP9	MA	Inhibitor
DMRLWP9	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMRLWP9	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMRLWP9	DI	DMRLWP9
DMRLWP9	DN	PMID27019002-Compound-47
DMRLWP9	MI	TT8VP2T
DMRLWP9	MN	Lysine-specific histone demethylase 1B (KDM1B)
DMRLWP9	MT	DTT
DMRLWP9	MA	Inhibitor
DMRLWP9	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMRLWP9	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMIO8J3	DI	DMIO8J3
DMIO8J3	DN	PMID27019002-Compound-48
DMIO8J3	MI	TTNR0UQ
DMIO8J3	MN	Lysine-specific histone demethylase 1 (LSD)
DMIO8J3	MT	DTT
DMIO8J3	MA	Inhibitor
DMIO8J3	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMIO8J3	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMIO8J3	DI	DMIO8J3
DMIO8J3	DN	PMID27019002-Compound-48
DMIO8J3	MI	TT8VP2T
DMIO8J3	MN	Lysine-specific histone demethylase 1B (KDM1B)
DMIO8J3	MT	DTT
DMIO8J3	MA	Inhibitor
DMIO8J3	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMIO8J3	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMP6WCX	DI	DMP6WCX
DMP6WCX	DN	PMID27019002-Compound-49
DMP6WCX	MI	TTNR0UQ
DMP6WCX	MN	Lysine-specific histone demethylase 1 (LSD)
DMP6WCX	MT	DTT
DMP6WCX	MA	Inhibitor
DMP6WCX	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMP6WCX	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DM4D75L	DI	DM4D75L
DM4D75L	DN	PMID27019002-Compound-50
DM4D75L	MI	TTNR0UQ
DM4D75L	MN	Lysine-specific histone demethylase 1 (LSD)
DM4D75L	MT	DTT
DM4D75L	MA	Inhibitor
DM4D75L	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DM4D75L	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMB0S52	DI	DMB0S52
DMB0S52	DN	PMID27019002-Compound-7
DMB0S52	MI	TTNR0UQ
DMB0S52	MN	Lysine-specific histone demethylase 1 (LSD)
DMB0S52	MT	DTT
DMB0S52	MA	Inhibitor
DMB0S52	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMB0S52	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMW2N5D	DI	DMW2N5D
DMW2N5D	DN	PMID27109571-Compound-1
DMW2N5D	MI	TTMY6L1
DMW2N5D	MN	Fatty acid-binding protein (FABP)
DMW2N5D	MT	DTT
DMW2N5D	MA	Inhibitor
DMW2N5D	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMW2N5D	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMW60HU	DI	DMW60HU
DMW60HU	DN	PMID27109571-Compound-10
DMW60HU	MI	TTHWMFZ
DMW60HU	MN	Fatty acid-binding protein 4 (FABP4)
DMW60HU	MT	DTT
DMW60HU	MA	Inhibitor
DMW60HU	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMW60HU	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMMI4KQ	DI	DMMI4KQ
DMMI4KQ	DN	PMID27109571-Compound-11
DMMI4KQ	MI	TTHWMFZ
DMMI4KQ	MN	Fatty acid-binding protein 4 (FABP4)
DMMI4KQ	MT	DTT
DMMI4KQ	MA	Inhibitor
DMMI4KQ	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMMI4KQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DM6HWBK	DI	DM6HWBK
DM6HWBK	DN	PMID27109571-Compound-12
DM6HWBK	MI	TTHWMFZ
DM6HWBK	MN	Fatty acid-binding protein 4 (FABP4)
DM6HWBK	MT	DTT
DM6HWBK	MA	Inhibitor
DM6HWBK	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DM6HWBK	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DM6HWBK	DI	DM6HWBK
DM6HWBK	DN	PMID27109571-Compound-12
DM6HWBK	MI	TTNT2S6
DM6HWBK	MN	Fatty acid-binding protein 5 (FABP5)
DM6HWBK	MT	DTT
DM6HWBK	MA	Inhibitor
DM6HWBK	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DM6HWBK	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMUKOGJ	DI	DMUKOGJ
DMUKOGJ	DN	PMID27109571-Compound-13
DMUKOGJ	MI	TTHWMFZ
DMUKOGJ	MN	Fatty acid-binding protein 4 (FABP4)
DMUKOGJ	MT	DTT
DMUKOGJ	MA	Inhibitor
DMUKOGJ	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMUKOGJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMUKOGJ	DI	DMUKOGJ
DMUKOGJ	DN	PMID27109571-Compound-13
DMUKOGJ	MI	TTNT2S6
DMUKOGJ	MN	Fatty acid-binding protein 5 (FABP5)
DMUKOGJ	MT	DTT
DMUKOGJ	MA	Inhibitor
DMUKOGJ	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMUKOGJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMVY6B9	DI	DMVY6B9
DMVY6B9	DN	PMID27109571-Compound-14
DMVY6B9	MI	TTHWMFZ
DMVY6B9	MN	Fatty acid-binding protein 4 (FABP4)
DMVY6B9	MT	DTT
DMVY6B9	MA	Inhibitor
DMVY6B9	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMVY6B9	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMVY6B9	DI	DMVY6B9
DMVY6B9	DN	PMID27109571-Compound-14
DMVY6B9	MI	TTNT2S6
DMVY6B9	MN	Fatty acid-binding protein 5 (FABP5)
DMVY6B9	MT	DTT
DMVY6B9	MA	Inhibitor
DMVY6B9	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMVY6B9	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMUR3FY	DI	DMUR3FY
DMUR3FY	DN	PMID27109571-Compound-15
DMUR3FY	MI	TTHWMFZ
DMUR3FY	MN	Fatty acid-binding protein 4 (FABP4)
DMUR3FY	MT	DTT
DMUR3FY	MA	Inhibitor
DMUR3FY	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMUR3FY	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMUR3FY	DI	DMUR3FY
DMUR3FY	DN	PMID27109571-Compound-15
DMUR3FY	MI	TTNT2S6
DMUR3FY	MN	Fatty acid-binding protein 5 (FABP5)
DMUR3FY	MT	DTT
DMUR3FY	MA	Inhibitor
DMUR3FY	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMUR3FY	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMZI25U	DI	DMZI25U
DMZI25U	DN	PMID27109571-Compound-16
DMZI25U	MI	TTHWMFZ
DMZI25U	MN	Fatty acid-binding protein 4 (FABP4)
DMZI25U	MT	DTT
DMZI25U	MA	Inhibitor
DMZI25U	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMZI25U	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMZI25U	DI	DMZI25U
DMZI25U	DN	PMID27109571-Compound-16
DMZI25U	MI	TTNT2S6
DMZI25U	MN	Fatty acid-binding protein 5 (FABP5)
DMZI25U	MT	DTT
DMZI25U	MA	Inhibitor
DMZI25U	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMZI25U	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMBETU6	DI	DMBETU6
DMBETU6	DN	PMID27109571-Compound-17
DMBETU6	MI	TTHWMFZ
DMBETU6	MN	Fatty acid-binding protein 4 (FABP4)
DMBETU6	MT	DTT
DMBETU6	MA	Inhibitor
DMBETU6	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMBETU6	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMBETU6	DI	DMBETU6
DMBETU6	DN	PMID27109571-Compound-17
DMBETU6	MI	TTNT2S6
DMBETU6	MN	Fatty acid-binding protein 5 (FABP5)
DMBETU6	MT	DTT
DMBETU6	MA	Inhibitor
DMBETU6	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMBETU6	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DM4S5ME	DI	DM4S5ME
DM4S5ME	DN	PMID27109571-Compound-18
DM4S5ME	MI	TTHWMFZ
DM4S5ME	MN	Fatty acid-binding protein 4 (FABP4)
DM4S5ME	MT	DTT
DM4S5ME	MA	Inhibitor
DM4S5ME	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DM4S5ME	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DM4S5ME	DI	DM4S5ME
DM4S5ME	DN	PMID27109571-Compound-18
DM4S5ME	MI	TTNT2S6
DM4S5ME	MN	Fatty acid-binding protein 5 (FABP5)
DM4S5ME	MT	DTT
DM4S5ME	MA	Inhibitor
DM4S5ME	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DM4S5ME	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMIJGLB	DI	DMIJGLB
DMIJGLB	DN	PMID27109571-Compound-19
DMIJGLB	MI	TTHWMFZ
DMIJGLB	MN	Fatty acid-binding protein 4 (FABP4)
DMIJGLB	MT	DTT
DMIJGLB	MA	Inhibitor
DMIJGLB	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMIJGLB	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMIJGLB	DI	DMIJGLB
DMIJGLB	DN	PMID27109571-Compound-19
DMIJGLB	MI	TTNT2S6
DMIJGLB	MN	Fatty acid-binding protein 5 (FABP5)
DMIJGLB	MT	DTT
DMIJGLB	MA	Inhibitor
DMIJGLB	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMIJGLB	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMTD1X8	DI	DMTD1X8
DMTD1X8	DN	PMID27109571-Compound-2
DMTD1X8	MI	TTMY6L1
DMTD1X8	MN	Fatty acid-binding protein (FABP)
DMTD1X8	MT	DTT
DMTD1X8	MA	Inhibitor
DMTD1X8	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMTD1X8	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMQU9XP	DI	DMQU9XP
DMQU9XP	DN	PMID27109571-Compound-20
DMQU9XP	MI	TTHWMFZ
DMQU9XP	MN	Fatty acid-binding protein 4 (FABP4)
DMQU9XP	MT	DTT
DMQU9XP	MA	Inhibitor
DMQU9XP	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMQU9XP	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMQU9XP	DI	DMQU9XP
DMQU9XP	DN	PMID27109571-Compound-20
DMQU9XP	MI	TTNT2S6
DMQU9XP	MN	Fatty acid-binding protein 5 (FABP5)
DMQU9XP	MT	DTT
DMQU9XP	MA	Inhibitor
DMQU9XP	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMQU9XP	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DM0R5Y8	DI	DM0R5Y8
DM0R5Y8	DN	PMID27109571-Compound-21
DM0R5Y8	MI	TTHWMFZ
DM0R5Y8	MN	Fatty acid-binding protein 4 (FABP4)
DM0R5Y8	MT	DTT
DM0R5Y8	MA	Inhibitor
DM0R5Y8	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DM0R5Y8	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DM0R5Y8	DI	DM0R5Y8
DM0R5Y8	DN	PMID27109571-Compound-21
DM0R5Y8	MI	TTNT2S6
DM0R5Y8	MN	Fatty acid-binding protein 5 (FABP5)
DM0R5Y8	MT	DTT
DM0R5Y8	MA	Inhibitor
DM0R5Y8	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DM0R5Y8	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMC52VP	DI	DMC52VP
DMC52VP	DN	PMID27109571-Compound-22
DMC52VP	MI	TTHWMFZ
DMC52VP	MN	Fatty acid-binding protein 4 (FABP4)
DMC52VP	MT	DTT
DMC52VP	MA	Inhibitor
DMC52VP	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMC52VP	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMC52VP	DI	DMC52VP
DMC52VP	DN	PMID27109571-Compound-22
DMC52VP	MI	TTNT2S6
DMC52VP	MN	Fatty acid-binding protein 5 (FABP5)
DMC52VP	MT	DTT
DMC52VP	MA	Inhibitor
DMC52VP	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMC52VP	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DML49UI	DI	DML49UI
DML49UI	DN	PMID27109571-Compound-23
DML49UI	MI	TTHWMFZ
DML49UI	MN	Fatty acid-binding protein 4 (FABP4)
DML49UI	MT	DTT
DML49UI	MA	Inhibitor
DML49UI	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DML49UI	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DML49UI	DI	DML49UI
DML49UI	DN	PMID27109571-Compound-23
DML49UI	MI	TTNT2S6
DML49UI	MN	Fatty acid-binding protein 5 (FABP5)
DML49UI	MT	DTT
DML49UI	MA	Inhibitor
DML49UI	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DML49UI	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMPHTC0	DI	DMPHTC0
DMPHTC0	DN	PMID27109571-Compound-24
DMPHTC0	MI	TTHWMFZ
DMPHTC0	MN	Fatty acid-binding protein 4 (FABP4)
DMPHTC0	MT	DTT
DMPHTC0	MA	Inhibitor
DMPHTC0	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMPHTC0	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMPHTC0	DI	DMPHTC0
DMPHTC0	DN	PMID27109571-Compound-24
DMPHTC0	MI	TTNT2S6
DMPHTC0	MN	Fatty acid-binding protein 5 (FABP5)
DMPHTC0	MT	DTT
DMPHTC0	MA	Inhibitor
DMPHTC0	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMPHTC0	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DM435GR	DI	DM435GR
DM435GR	DN	PMID27109571-Compound-25
DM435GR	MI	TTHWMFZ
DM435GR	MN	Fatty acid-binding protein 4 (FABP4)
DM435GR	MT	DTT
DM435GR	MA	Inhibitor
DM435GR	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DM435GR	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DM435GR	DI	DM435GR
DM435GR	DN	PMID27109571-Compound-25
DM435GR	MI	TTNT2S6
DM435GR	MN	Fatty acid-binding protein 5 (FABP5)
DM435GR	MT	DTT
DM435GR	MA	Inhibitor
DM435GR	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DM435GR	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMJCL53	DI	DMJCL53
DMJCL53	DN	PMID27109571-Compound-26
DMJCL53	MI	TTHWMFZ
DMJCL53	MN	Fatty acid-binding protein 4 (FABP4)
DMJCL53	MT	DTT
DMJCL53	MA	Inhibitor
DMJCL53	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMJCL53	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMJCL53	DI	DMJCL53
DMJCL53	DN	PMID27109571-Compound-26
DMJCL53	MI	TTNT2S6
DMJCL53	MN	Fatty acid-binding protein 5 (FABP5)
DMJCL53	MT	DTT
DMJCL53	MA	Inhibitor
DMJCL53	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMJCL53	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMXRTH4	DI	DMXRTH4
DMXRTH4	DN	PMID27109571-Compound-27
DMXRTH4	MI	TTHWMFZ
DMXRTH4	MN	Fatty acid-binding protein 4 (FABP4)
DMXRTH4	MT	DTT
DMXRTH4	MA	Inhibitor
DMXRTH4	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMXRTH4	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMXRTH4	DI	DMXRTH4
DMXRTH4	DN	PMID27109571-Compound-27
DMXRTH4	MI	TTNT2S6
DMXRTH4	MN	Fatty acid-binding protein 5 (FABP5)
DMXRTH4	MT	DTT
DMXRTH4	MA	Inhibitor
DMXRTH4	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMXRTH4	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMTZVY3	DI	DMTZVY3
DMTZVY3	DN	PMID27109571-Compound-28
DMTZVY3	MI	TTHWMFZ
DMTZVY3	MN	Fatty acid-binding protein 4 (FABP4)
DMTZVY3	MT	DTT
DMTZVY3	MA	Inhibitor
DMTZVY3	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMTZVY3	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMTZVY3	DI	DMTZVY3
DMTZVY3	DN	PMID27109571-Compound-28
DMTZVY3	MI	TTNT2S6
DMTZVY3	MN	Fatty acid-binding protein 5 (FABP5)
DMTZVY3	MT	DTT
DMTZVY3	MA	Inhibitor
DMTZVY3	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMTZVY3	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMDMEHQ	DI	DMDMEHQ
DMDMEHQ	DN	PMID27109571-Compound-29
DMDMEHQ	MI	TTHWMFZ
DMDMEHQ	MN	Fatty acid-binding protein 4 (FABP4)
DMDMEHQ	MT	DTT
DMDMEHQ	MA	Inhibitor
DMDMEHQ	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMDMEHQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMDMEHQ	DI	DMDMEHQ
DMDMEHQ	DN	PMID27109571-Compound-29
DMDMEHQ	MI	TTNT2S6
DMDMEHQ	MN	Fatty acid-binding protein 5 (FABP5)
DMDMEHQ	MT	DTT
DMDMEHQ	MA	Inhibitor
DMDMEHQ	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMDMEHQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMDXMH9	DI	DMDXMH9
DMDXMH9	DN	PMID27109571-Compound-3
DMDXMH9	MI	TTMY6L1
DMDXMH9	MN	Fatty acid-binding protein (FABP)
DMDXMH9	MT	DTT
DMDXMH9	MA	Inhibitor
DMDXMH9	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMDXMH9	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DM24FSP	DI	DM24FSP
DM24FSP	DN	PMID27109571-Compound-30
DM24FSP	MI	TTHWMFZ
DM24FSP	MN	Fatty acid-binding protein 4 (FABP4)
DM24FSP	MT	DTT
DM24FSP	MA	Inhibitor
DM24FSP	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DM24FSP	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DM24FSP	DI	DM24FSP
DM24FSP	DN	PMID27109571-Compound-30
DM24FSP	MI	TTNT2S6
DM24FSP	MN	Fatty acid-binding protein 5 (FABP5)
DM24FSP	MT	DTT
DM24FSP	MA	Inhibitor
DM24FSP	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DM24FSP	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMU690T	DI	DMU690T
DMU690T	DN	PMID27109571-Compound-31
DMU690T	MI	TTHWMFZ
DMU690T	MN	Fatty acid-binding protein 4 (FABP4)
DMU690T	MT	DTT
DMU690T	MA	Inhibitor
DMU690T	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMU690T	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMU690T	DI	DMU690T
DMU690T	DN	PMID27109571-Compound-31
DMU690T	MI	TTNT2S6
DMU690T	MN	Fatty acid-binding protein 5 (FABP5)
DMU690T	MT	DTT
DMU690T	MA	Inhibitor
DMU690T	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMU690T	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DM4IS6Q	DI	DM4IS6Q
DM4IS6Q	DN	PMID27109571-Compound-32
DM4IS6Q	MI	TTMY6L1
DM4IS6Q	MN	Fatty acid-binding protein (FABP)
DM4IS6Q	MT	DTT
DM4IS6Q	MA	Inhibitor
DM4IS6Q	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DM4IS6Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMGR2JC	DI	DMGR2JC
DMGR2JC	DN	PMID27109571-Compound-33
DMGR2JC	MI	TTMY6L1
DMGR2JC	MN	Fatty acid-binding protein (FABP)
DMGR2JC	MT	DTT
DMGR2JC	MA	Inhibitor
DMGR2JC	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMGR2JC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DM5OXUK	DI	DM5OXUK
DM5OXUK	DN	PMID27109571-Compound-34
DM5OXUK	MI	TTMY6L1
DM5OXUK	MN	Fatty acid-binding protein (FABP)
DM5OXUK	MT	DTT
DM5OXUK	MA	Inhibitor
DM5OXUK	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DM5OXUK	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMGV4PT	DI	DMGV4PT
DMGV4PT	DN	PMID27109571-Compound-35
DMGV4PT	MI	TTMY6L1
DMGV4PT	MN	Fatty acid-binding protein (FABP)
DMGV4PT	MT	DTT
DMGV4PT	MA	Inhibitor
DMGV4PT	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMGV4PT	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMCJ48G	DI	DMCJ48G
DMCJ48G	DN	PMID27109571-Compound-36
DMCJ48G	MI	TTMY6L1
DMCJ48G	MN	Fatty acid-binding protein (FABP)
DMCJ48G	MT	DTT
DMCJ48G	MA	Inhibitor
DMCJ48G	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMCJ48G	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMJCAOD	DI	DMJCAOD
DMJCAOD	DN	PMID27109571-Compound-37
DMJCAOD	MI	TTMY6L1
DMJCAOD	MN	Fatty acid-binding protein (FABP)
DMJCAOD	MT	DTT
DMJCAOD	MA	Inhibitor
DMJCAOD	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMJCAOD	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMRQHDF	DI	DMRQHDF
DMRQHDF	DN	PMID27109571-Compound-38
DMRQHDF	MI	TTMY6L1
DMRQHDF	MN	Fatty acid-binding protein (FABP)
DMRQHDF	MT	DTT
DMRQHDF	MA	Inhibitor
DMRQHDF	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMRQHDF	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMBHJDR	DI	DMBHJDR
DMBHJDR	DN	PMID27109571-Compound-39
DMBHJDR	MI	TTMY6L1
DMBHJDR	MN	Fatty acid-binding protein (FABP)
DMBHJDR	MT	DTT
DMBHJDR	MA	Inhibitor
DMBHJDR	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMBHJDR	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMYRG0Q	DI	DMYRG0Q
DMYRG0Q	DN	PMID27109571-Compound-4
DMYRG0Q	MI	TTMY6L1
DMYRG0Q	MN	Fatty acid-binding protein (FABP)
DMYRG0Q	MT	DTT
DMYRG0Q	MA	Inhibitor
DMYRG0Q	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMYRG0Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMQ83EV	DI	DMQ83EV
DMQ83EV	DN	PMID27109571-Compound-40
DMQ83EV	MI	TTMY6L1
DMQ83EV	MN	Fatty acid-binding protein (FABP)
DMQ83EV	MT	DTT
DMQ83EV	MA	Inhibitor
DMQ83EV	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMQ83EV	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMY4IAV	DI	DMY4IAV
DMY4IAV	DN	PMID27109571-Compound-41
DMY4IAV	MI	TTMY6L1
DMY4IAV	MN	Fatty acid-binding protein (FABP)
DMY4IAV	MT	DTT
DMY4IAV	MA	Inhibitor
DMY4IAV	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMY4IAV	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMZOI3K	DI	DMZOI3K
DMZOI3K	DN	PMID27109571-Compound-42
DMZOI3K	MI	TTMY6L1
DMZOI3K	MN	Fatty acid-binding protein (FABP)
DMZOI3K	MT	DTT
DMZOI3K	MA	Inhibitor
DMZOI3K	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMZOI3K	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMYZ42W	DI	DMYZ42W
DMYZ42W	DN	PMID27109571-Compound-43
DMYZ42W	MI	TTMY6L1
DMYZ42W	MN	Fatty acid-binding protein (FABP)
DMYZ42W	MT	DTT
DMYZ42W	MA	Inhibitor
DMYZ42W	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMYZ42W	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DM3AUZS	DI	DM3AUZS
DM3AUZS	DN	PMID27109571-Compound-44
DM3AUZS	MI	TTMY6L1
DM3AUZS	MN	Fatty acid-binding protein (FABP)
DM3AUZS	MT	DTT
DM3AUZS	MA	Inhibitor
DM3AUZS	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DM3AUZS	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMOZKAH	DI	DMOZKAH
DMOZKAH	DN	PMID27109571-Compound-5
DMOZKAH	MI	TTMY6L1
DMOZKAH	MN	Fatty acid-binding protein (FABP)
DMOZKAH	MT	DTT
DMOZKAH	MA	Inhibitor
DMOZKAH	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMOZKAH	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMPHMTR	DI	DMPHMTR
DMPHMTR	DN	PMID27109571-Compound-6
DMPHMTR	MI	TTMY6L1
DMPHMTR	MN	Fatty acid-binding protein (FABP)
DMPHMTR	MT	DTT
DMPHMTR	MA	Inhibitor
DMPHMTR	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMPHMTR	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DM8GYCD	DI	DM8GYCD
DM8GYCD	DN	PMID27109571-Compound-7
DM8GYCD	MI	TTHWMFZ
DM8GYCD	MN	Fatty acid-binding protein 4 (FABP4)
DM8GYCD	MT	DTT
DM8GYCD	MA	Inhibitor
DM8GYCD	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DM8GYCD	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMTKFX7	DI	DMTKFX7
DMTKFX7	DN	PMID27109571-Compound-8
DMTKFX7	MI	TTHWMFZ
DMTKFX7	MN	Fatty acid-binding protein 4 (FABP4)
DMTKFX7	MT	DTT
DMTKFX7	MA	Inhibitor
DMTKFX7	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMTKFX7	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMWM03O	DI	DMWM03O
DMWM03O	DN	PMID27109571-Compound-9
DMWM03O	MI	TTHWMFZ
DMWM03O	MN	Fatty acid-binding protein 4 (FABP4)
DMWM03O	MT	DTT
DMWM03O	MA	Inhibitor
DMWM03O	RN	Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.
DMWM03O	RU	https://www.ncbi.nlm.nih.gov/pubmed/27109571

DMBWLSA	DI	DMBWLSA
DMBWLSA	DN	PMID27172114-Compound-30
DMBWLSA	MI	TTZJYKH
DMBWLSA	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMBWLSA	MT	DTT
DMBWLSA	MA	Inhibitor
DMBWLSA	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMBWLSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMBWLSA	DI	DMBWLSA
DMBWLSA	DN	PMID27172114-Compound-30
DMBWLSA	MI	TTALN9W
DMBWLSA	MN	Indoleamine 2,3-dioxygenase 2 (IDO2)
DMBWLSA	MT	DTT
DMBWLSA	MA	Inhibitor
DMBWLSA	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMBWLSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMBWLSA	DI	DMBWLSA
DMBWLSA	DN	PMID27172114-Compound-30
DMBWLSA	MI	TTXNCBV
DMBWLSA	MN	Tryptophan 2,3-dioxygenase (TDO)
DMBWLSA	MT	DTT
DMBWLSA	MA	Inhibitor
DMBWLSA	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMBWLSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMTIQYD	DI	DMTIQYD
DMTIQYD	DN	PMID27172114-Compound-47
DMTIQYD	MI	TTIY56R
DMTIQYD	MN	Kynurenine 3-hydroxylase (KMO)
DMTIQYD	MT	DTT
DMTIQYD	MA	Inhibitor
DMTIQYD	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMTIQYD	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMSXJVY	DI	DMSXJVY
DMSXJVY	DN	PMID27172114-Compound-49
DMSXJVY	MI	TTIY56R
DMSXJVY	MN	Kynurenine 3-hydroxylase (KMO)
DMSXJVY	MT	DTT
DMSXJVY	MA	Inhibitor
DMSXJVY	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMSXJVY	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DM84RES	DI	DM84RES
DM84RES	DN	PMID27215781-Compound-1
DM84RES	MI	TT6OEDT
DM84RES	MN	Cannabinoid receptor 1 (CB1)
DM84RES	MT	DTT
DM84RES	MA	Agonist
DM84RES	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DM84RES	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DMIX90M	DI	DMIX90M
DMIX90M	DN	PMID27215781-Compound-11
DMIX90M	MI	TTMSFAW
DMIX90M	MN	Cannabinoid receptor 2 (CB2)
DMIX90M	MT	DTT
DMIX90M	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DMIX90M	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DMR9GLW	DI	DMR9GLW
DMR9GLW	DN	PMID27215781-Compound-12
DMR9GLW	MI	TTMSFAW
DMR9GLW	MN	Cannabinoid receptor 2 (CB2)
DMR9GLW	MT	DTT
DMR9GLW	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DMR9GLW	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DMNKH07	DI	DMNKH07
DMNKH07	DN	PMID27215781-Compound-13
DMNKH07	MI	TTMSFAW
DMNKH07	MN	Cannabinoid receptor 2 (CB2)
DMNKH07	MT	DTT
DMNKH07	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DMNKH07	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DMYMTSL	DI	DMYMTSL
DMYMTSL	DN	PMID27215781-Compound-19
DMYMTSL	MI	TTMSFAW
DMYMTSL	MN	Cannabinoid receptor 2 (CB2)
DMYMTSL	MT	DTT
DMYMTSL	MA	Agonist
DMYMTSL	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DMYMTSL	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DMBOX0K	DI	DMBOX0K
DMBOX0K	DN	PMID27215781-Compound-2
DMBOX0K	MI	TT6OEDT
DMBOX0K	MN	Cannabinoid receptor 1 (CB1)
DMBOX0K	MT	DTT
DMBOX0K	MA	Agonist
DMBOX0K	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DMBOX0K	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DMBOX0K	DI	DMBOX0K
DMBOX0K	DN	PMID27215781-Compound-2
DMBOX0K	MI	TTMSFAW
DMBOX0K	MN	Cannabinoid receptor 2 (CB2)
DMBOX0K	MT	DTT
DMBOX0K	MA	Agonist
DMBOX0K	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DMBOX0K	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DMKZF8E	DI	DMKZF8E
DMKZF8E	DN	PMID27215781-Compound-25
DMKZF8E	MI	TTMSFAW
DMKZF8E	MN	Cannabinoid receptor 2 (CB2)
DMKZF8E	MT	DTT
DMKZF8E	MA	Agonist
DMKZF8E	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DMKZF8E	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DMTJHC2	DI	DMTJHC2
DMTJHC2	DN	PMID27215781-Compound-27
DMTJHC2	MI	TTMSFAW
DMTJHC2	MN	Cannabinoid receptor 2 (CB2)
DMTJHC2	MT	DTT
DMTJHC2	MA	Agonist
DMTJHC2	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DMTJHC2	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DM9ZF3P	DI	DM9ZF3P
DM9ZF3P	DN	PMID27215781-Compound-28
DM9ZF3P	MI	TTMSFAW
DM9ZF3P	MN	Cannabinoid receptor 2 (CB2)
DM9ZF3P	MT	DTT
DM9ZF3P	MA	Agonist
DM9ZF3P	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DM9ZF3P	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DMDJM1Y	DI	DMDJM1Y
DMDJM1Y	DN	PMID27215781-Compound-29
DMDJM1Y	MI	TTMSFAW
DMDJM1Y	MN	Cannabinoid receptor 2 (CB2)
DMDJM1Y	MT	DTT
DMDJM1Y	MA	Agonist
DMDJM1Y	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DMDJM1Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DM7USO9	DI	DM7USO9
DM7USO9	DN	PMID27215781-Compound-30
DM7USO9	MI	TTMSFAW
DM7USO9	MN	Cannabinoid receptor 2 (CB2)
DM7USO9	MT	DTT
DM7USO9	MA	Agonist
DM7USO9	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DM7USO9	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DMJMO72	DI	DMJMO72
DMJMO72	DN	PMID27215781-Compound-31
DMJMO72	MI	TTMSFAW
DMJMO72	MN	Cannabinoid receptor 2 (CB2)
DMJMO72	MT	DTT
DMJMO72	MA	Agonist
DMJMO72	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DMJMO72	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DM7IYRM	DI	DM7IYRM
DM7IYRM	DN	PMID27215781-Compound-32
DM7IYRM	MI	TTMSFAW
DM7IYRM	MN	Cannabinoid receptor 2 (CB2)
DM7IYRM	MT	DTT
DM7IYRM	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DM7IYRM	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DMX4W2R	DI	DMX4W2R
DMX4W2R	DN	PMID27215781-Compound-33
DMX4W2R	MI	TTMSFAW
DMX4W2R	MN	Cannabinoid receptor 2 (CB2)
DMX4W2R	MT	DTT
DMX4W2R	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DMX4W2R	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DMTAZBC	DI	DMTAZBC
DMTAZBC	DN	PMID27215781-Compound-34
DMTAZBC	MI	TTMSFAW
DMTAZBC	MN	Cannabinoid receptor 2 (CB2)
DMTAZBC	MT	DTT
DMTAZBC	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DMTAZBC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DM0L68P	DI	DM0L68P
DM0L68P	DN	PMID27215781-Compound-37
DM0L68P	MI	TT6OEDT
DM0L68P	MN	Cannabinoid receptor 1 (CB1)
DM0L68P	MT	DTT
DM0L68P	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DM0L68P	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DM0L68P	DI	DM0L68P
DM0L68P	DN	PMID27215781-Compound-37
DM0L68P	MI	TTMSFAW
DM0L68P	MN	Cannabinoid receptor 2 (CB2)
DM0L68P	MT	DTT
DM0L68P	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DM0L68P	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DMRU0BL	DI	DMRU0BL
DMRU0BL	DN	PMID27215781-Compound-4
DMRU0BL	MI	TTMSFAW
DMRU0BL	MN	Cannabinoid receptor 2 (CB2)
DMRU0BL	MT	DTT
DMRU0BL	MA	Agonist
DMRU0BL	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DMRU0BL	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DM0NYK3	DI	DM0NYK3
DM0NYK3	DN	PMID27321640-Compound-58
DM0NYK3	MI	TTJW4LU
DM0NYK3	MN	Phosphodiesterase 10A (PDE10)
DM0NYK3	MT	DTT
DM0NYK3	MA	Inhibitor
DM0NYK3	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DM0NYK3	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DM0NYK3	DI	DM0NYK3
DM0NYK3	DN	PMID27321640-Compound-58
DM0NYK3	MI	TTJGW1Z
DM0NYK3	MN	Phosphodiesterase 2A (PDE2A)
DM0NYK3	MT	DTT
DM0NYK3	MA	Inhibitor
DM0NYK3	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DM0NYK3	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DM41B5O	DI	DM41B5O
DM41B5O	DN	PMID27321640-Compound-59
DM41B5O	MI	TTJW4LU
DM41B5O	MN	Phosphodiesterase 10A (PDE10)
DM41B5O	MT	DTT
DM41B5O	MA	Inhibitor
DM41B5O	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DM41B5O	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DM41B5O	DI	DM41B5O
DM41B5O	DN	PMID27321640-Compound-59
DM41B5O	MI	TTJGW1Z
DM41B5O	MN	Phosphodiesterase 2A (PDE2A)
DM41B5O	MT	DTT
DM41B5O	MA	Inhibitor
DM41B5O	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DM41B5O	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMHWV67	DI	DMHWV67
DMHWV67	DN	PMID27321640-Compound-74
DMHWV67	MI	TTJGW1Z
DMHWV67	MN	Phosphodiesterase 2A (PDE2A)
DMHWV67	MT	DTT
DMHWV67	MA	Inhibitor
DMHWV67	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMHWV67	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DM2P5J9	DI	DM2P5J9
DM2P5J9	DN	PMID27321640-Compound-75
DM2P5J9	MI	TTJGW1Z
DM2P5J9	MN	Phosphodiesterase 2A (PDE2A)
DM2P5J9	MT	DTT
DM2P5J9	MA	Inhibitor
DM2P5J9	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DM2P5J9	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DM40LIN	DI	DM40LIN
DM40LIN	DN	PMID27321640-Compound-76
DM40LIN	MI	TTJGW1Z
DM40LIN	MN	Phosphodiesterase 2A (PDE2A)
DM40LIN	MT	DTT
DM40LIN	MA	Inhibitor
DM40LIN	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DM40LIN	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMYUP6G	DI	DMYUP6G
DMYUP6G	DN	PMID27336223-Compound-10
DMYUP6G	MI	TTISP28
DMYUP6G	MN	Retinoic acid receptor beta (RARB)
DMYUP6G	MT	DTT
DMYUP6G	MA	Agonist
DMYUP6G	RN	Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review.Expert Opin Ther Pat. 2016 Aug;26(8):957-71.
DMYUP6G	RU	https://www.ncbi.nlm.nih.gov/pubmed/27336223

DMBN6KU	DI	DMBN6KU
DMBN6KU	DN	PMID27336223-Compound-11
DMBN6KU	MI	TT1Q3IE
DMBN6KU	MN	Retinoic acid receptor gamma (RARG)
DMBN6KU	MT	DTT
DMBN6KU	MA	Agonist
DMBN6KU	RN	Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review.Expert Opin Ther Pat. 2016 Aug;26(8):957-71.
DMBN6KU	RU	https://www.ncbi.nlm.nih.gov/pubmed/27336223

DMT4P7K	DI	DMT4P7K
DMT4P7K	DN	PMID27336223-Compound-12
DMT4P7K	MI	TT1Q3IE
DMT4P7K	MN	Retinoic acid receptor gamma (RARG)
DMT4P7K	MT	DTT
DMT4P7K	MA	Agonist
DMT4P7K	RN	Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review.Expert Opin Ther Pat. 2016 Aug;26(8):957-71.
DMT4P7K	RU	https://www.ncbi.nlm.nih.gov/pubmed/27336223

DMSZLYD	DI	DMSZLYD
DMSZLYD	DN	PMID27336223-Compound-13
DMSZLYD	MI	TT1Q3IE
DMSZLYD	MN	Retinoic acid receptor gamma (RARG)
DMSZLYD	MT	DTT
DMSZLYD	MA	Agonist
DMSZLYD	RN	Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review.Expert Opin Ther Pat. 2016 Aug;26(8):957-71.
DMSZLYD	RU	https://www.ncbi.nlm.nih.gov/pubmed/27336223

DMC41MA	DI	DMC41MA
DMC41MA	DN	PMID27336223-Compound-14
DMC41MA	MI	TT1Q3IE
DMC41MA	MN	Retinoic acid receptor gamma (RARG)
DMC41MA	MT	DTT
DMC41MA	MA	Agonist
DMC41MA	RN	Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review.Expert Opin Ther Pat. 2016 Aug;26(8):957-71.
DMC41MA	RU	https://www.ncbi.nlm.nih.gov/pubmed/27336223

DMIYCFE	DI	DMIYCFE
DMIYCFE	DN	PMID27336223-Compound-15
DMIYCFE	MI	TT1Q3IE
DMIYCFE	MN	Retinoic acid receptor gamma (RARG)
DMIYCFE	MT	DTT
DMIYCFE	MA	Agonist
DMIYCFE	RN	Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review.Expert Opin Ther Pat. 2016 Aug;26(8):957-71.
DMIYCFE	RU	https://www.ncbi.nlm.nih.gov/pubmed/27336223

DMJFSOM	DI	DMJFSOM
DMJFSOM	DN	PMID27336223-Compound-4
DMJFSOM	MI	TTW38KT
DMJFSOM	MN	Retinoic acid receptor alpha (RARA)
DMJFSOM	MT	DTT
DMJFSOM	MA	Agonist
DMJFSOM	RN	Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review.Expert Opin Ther Pat. 2016 Aug;26(8):957-71.
DMJFSOM	RU	https://www.ncbi.nlm.nih.gov/pubmed/27336223

DM6E50A	DI	DM6E50A
DM6E50A	DN	PMID27336223-Compound-5
DM6E50A	MI	TTW38KT
DM6E50A	MN	Retinoic acid receptor alpha (RARA)
DM6E50A	MT	DTT
DM6E50A	MA	Agonist
DM6E50A	RN	Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review.Expert Opin Ther Pat. 2016 Aug;26(8):957-71.
DM6E50A	RU	https://www.ncbi.nlm.nih.gov/pubmed/27336223

DM9QM6I	DI	DM9QM6I
DM9QM6I	DN	PMID27336223-Compound-7
DM9QM6I	MI	TTISP28
DM9QM6I	MN	Retinoic acid receptor beta (RARB)
DM9QM6I	MT	DTT
DM9QM6I	MA	Agonist
DM9QM6I	RN	Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review.Expert Opin Ther Pat. 2016 Aug;26(8):957-71.
DM9QM6I	RU	https://www.ncbi.nlm.nih.gov/pubmed/27336223

DM460D1	DI	DM460D1
DM460D1	DN	PMID27336223-Compound-8
DM460D1	MI	TTISP28
DM460D1	MN	Retinoic acid receptor beta (RARB)
DM460D1	MT	DTT
DM460D1	MA	Agonist
DM460D1	RN	Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review.Expert Opin Ther Pat. 2016 Aug;26(8):957-71.
DM460D1	RU	https://www.ncbi.nlm.nih.gov/pubmed/27336223

DM6V13W	DI	DM6V13W
DM6V13W	DN	PMID27336223-Compound-9
DM6V13W	MI	TT1Q3IE
DM6V13W	MN	Retinoic acid receptor gamma (RARG)
DM6V13W	MT	DTT
DM6V13W	MA	Agonist
DM6V13W	RN	Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review.Expert Opin Ther Pat. 2016 Aug;26(8):957-71.
DM6V13W	RU	https://www.ncbi.nlm.nih.gov/pubmed/27336223

DMTQRVC	DI	DMTQRVC
DMTQRVC	DN	PMID27376512-Compound-asCEBP-1
DMTQRVC	MI	TT6S2FE
DMTQRVC	MN	DNA [cytosine-5]-methyltransferase 1 (DNMT1)
DMTQRVC	MT	DTT
DMTQRVC	MA	Inhibitor
DMTQRVC	RN	DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
DMTQRVC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27376512

DMLAY8B	DI	DMLAY8B
DMLAY8B	DN	PMID27376512-Compound-asCEBP-1HPE
DMLAY8B	MI	TT6S2FE
DMLAY8B	MN	DNA [cytosine-5]-methyltransferase 1 (DNMT1)
DMLAY8B	MT	DTT
DMLAY8B	MA	Inhibitor
DMLAY8B	RN	DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
DMLAY8B	RU	https://www.ncbi.nlm.nih.gov/pubmed/27376512

DMJUL1A	DI	DMJUL1A
DMJUL1A	DN	PMID27376512-Compound-asCEBP-2
DMJUL1A	MI	TT6S2FE
DMJUL1A	MN	DNA [cytosine-5]-methyltransferase 1 (DNMT1)
DMJUL1A	MT	DTT
DMJUL1A	MA	Inhibitor
DMJUL1A	RN	DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
DMJUL1A	RU	https://www.ncbi.nlm.nih.gov/pubmed/27376512

DM9QEIV	DI	DM9QEIV
DM9QEIV	DN	PMID27376512-Compound-asCEBP-2HPE
DM9QEIV	MI	TT6S2FE
DM9QEIV	MN	DNA [cytosine-5]-methyltransferase 1 (DNMT1)
DM9QEIV	MT	DTT
DM9QEIV	MA	Inhibitor
DM9QEIV	RN	DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
DM9QEIV	RU	https://www.ncbi.nlm.nih.gov/pubmed/27376512

DMBFUTL	DI	DMBFUTL
DMBFUTL	DN	PMID27376512-Compound-CROs
DMBFUTL	MI	TTHVCUP
DMBFUTL	MN	DNA [cytosine-5]-methyltransferase (DNMT)
DMBFUTL	MT	DTT
DMBFUTL	MA	Inhibitor
DMBFUTL	RN	DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
DMBFUTL	RU	https://www.ncbi.nlm.nih.gov/pubmed/27376512

DMP59OX	DI	DMP59OX
DMP59OX	DN	PMID27376512-Compound-Figure2aExample1
DMP59OX	MI	TTJUALD
DMP59OX	MN	DNA [cytosine-5]-methyltransferase 3A (DNMT3A)
DMP59OX	MT	DTT
DMP59OX	MA	Inhibitor
DMP59OX	RN	DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
DMP59OX	RU	https://www.ncbi.nlm.nih.gov/pubmed/27376512

DMP59OX	DI	DMP59OX
DMP59OX	DN	PMID27376512-Compound-Figure2aExample1
DMP59OX	MI	TT3FDAV
DMP59OX	MN	DNA [cytosine-5]-methyltransferase 3-like (DNMT3L)
DMP59OX	MT	DTT
DMP59OX	MA	Inhibitor
DMP59OX	RN	DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
DMP59OX	RU	https://www.ncbi.nlm.nih.gov/pubmed/27376512

DMZIKN6	DI	DMZIKN6
DMZIKN6	DN	PMID27376512-Compound-Figure3CG
DMZIKN6	MI	TTJUALD
DMZIKN6	MN	DNA [cytosine-5]-methyltransferase 3A (DNMT3A)
DMZIKN6	MT	DTT
DMZIKN6	MA	Inhibitor
DMZIKN6	RN	DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
DMZIKN6	RU	https://www.ncbi.nlm.nih.gov/pubmed/27376512

DMIS4H0	DI	DMIS4H0
DMIS4H0	DN	PMID27376512-Compound-Figure3CM
DMIS4H0	MI	TTJUALD
DMIS4H0	MN	DNA [cytosine-5]-methyltransferase 3A (DNMT3A)
DMIS4H0	MT	DTT
DMIS4H0	MA	Inhibitor
DMIS4H0	RN	DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
DMIS4H0	RU	https://www.ncbi.nlm.nih.gov/pubmed/27376512

DMP7DL6	DI	DMP7DL6
DMP7DL6	DN	PMID27376512-Compound-Figure3CN
DMP7DL6	MI	TTJUALD
DMP7DL6	MN	DNA [cytosine-5]-methyltransferase 3A (DNMT3A)
DMP7DL6	MT	DTT
DMP7DL6	MA	Inhibitor
DMP7DL6	RN	DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
DMP7DL6	RU	https://www.ncbi.nlm.nih.gov/pubmed/27376512

DM67VNW	DI	DM67VNW
DM67VNW	DN	PMID27376512-Compound-miR-155-5p
DM67VNW	MI	TT6S2FE
DM67VNW	MN	DNA [cytosine-5]-methyltransferase 1 (DNMT1)
DM67VNW	MT	DTT
DM67VNW	MA	Inhibitor
DM67VNW	RN	DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
DM67VNW	RU	https://www.ncbi.nlm.nih.gov/pubmed/27376512

DM1MVQD	DI	DM1MVQD
DM1MVQD	DN	PMID27376512-Compound-MTC-422 
DM1MVQD	MI	TT6S2FE
DM1MVQD	MN	DNA [cytosine-5]-methyltransferase 1 (DNMT1)
DM1MVQD	MT	DTT
DM1MVQD	MA	Inhibitor
DM1MVQD	RN	DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
DM1MVQD	RU	https://www.ncbi.nlm.nih.gov/pubmed/27376512

DM1MVQD	DI	DM1MVQD
DM1MVQD	DN	PMID27376512-Compound-MTC-422 
DM1MVQD	MI	TTJUALD
DM1MVQD	MN	DNA [cytosine-5]-methyltransferase 3A (DNMT3A)
DM1MVQD	MT	DTT
DM1MVQD	MA	Inhibitor
DM1MVQD	RN	DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
DM1MVQD	RU	https://www.ncbi.nlm.nih.gov/pubmed/27376512

DM1MVQD	DI	DM1MVQD
DM1MVQD	DN	PMID27376512-Compound-MTC-422 
DM1MVQD	MI	TT6VZ78
DM1MVQD	MN	DNA [cytosine-5]-methyltransferase 3B (DNMT3B)
DM1MVQD	MT	DTT
DM1MVQD	MA	Inhibitor
DM1MVQD	RN	DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
DM1MVQD	RU	https://www.ncbi.nlm.nih.gov/pubmed/27376512

DM9RSDX	DI	DM9RSDX
DM9RSDX	DN	PMID27376512-Compound-MTC-423
DM9RSDX	MI	TT6S2FE
DM9RSDX	MN	DNA [cytosine-5]-methyltransferase 1 (DNMT1)
DM9RSDX	MT	DTT
DM9RSDX	MA	Inhibitor
DM9RSDX	RN	DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
DM9RSDX	RU	https://www.ncbi.nlm.nih.gov/pubmed/27376512

DM9RSDX	DI	DM9RSDX
DM9RSDX	DN	PMID27376512-Compound-MTC-423
DM9RSDX	MI	TTJUALD
DM9RSDX	MN	DNA [cytosine-5]-methyltransferase 3A (DNMT3A)
DM9RSDX	MT	DTT
DM9RSDX	MA	Inhibitor
DM9RSDX	RN	DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
DM9RSDX	RU	https://www.ncbi.nlm.nih.gov/pubmed/27376512

DM9RSDX	DI	DM9RSDX
DM9RSDX	DN	PMID27376512-Compound-MTC-423
DM9RSDX	MI	TT6VZ78
DM9RSDX	MN	DNA [cytosine-5]-methyltransferase 3B (DNMT3B)
DM9RSDX	MT	DTT
DM9RSDX	MA	Inhibitor
DM9RSDX	RN	DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
DM9RSDX	RU	https://www.ncbi.nlm.nih.gov/pubmed/27376512

DMGNRZU	DI	DMGNRZU
DMGNRZU	DN	PMID27376512-Compound-MTC-424
DMGNRZU	MI	TT6S2FE
DMGNRZU	MN	DNA [cytosine-5]-methyltransferase 1 (DNMT1)
DMGNRZU	MT	DTT
DMGNRZU	MA	Inhibitor
DMGNRZU	RN	DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
DMGNRZU	RU	https://www.ncbi.nlm.nih.gov/pubmed/27376512

DMGNRZU	DI	DMGNRZU
DMGNRZU	DN	PMID27376512-Compound-MTC-424
DMGNRZU	MI	TTJUALD
DMGNRZU	MN	DNA [cytosine-5]-methyltransferase 3A (DNMT3A)
DMGNRZU	MT	DTT
DMGNRZU	MA	Inhibitor
DMGNRZU	RN	DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
DMGNRZU	RU	https://www.ncbi.nlm.nih.gov/pubmed/27376512

DMGNRZU	DI	DMGNRZU
DMGNRZU	DN	PMID27376512-Compound-MTC-424
DMGNRZU	MI	TT6VZ78
DMGNRZU	MN	DNA [cytosine-5]-methyltransferase 3B (DNMT3B)
DMGNRZU	MT	DTT
DMGNRZU	MA	Inhibitor
DMGNRZU	RN	DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
DMGNRZU	RU	https://www.ncbi.nlm.nih.gov/pubmed/27376512

DMWXEZD	DI	DMWXEZD
DMWXEZD	DN	PMID27376512-Compound-MTC-427
DMWXEZD	MI	TT6S2FE
DMWXEZD	MN	DNA [cytosine-5]-methyltransferase 1 (DNMT1)
DMWXEZD	MT	DTT
DMWXEZD	MA	Inhibitor
DMWXEZD	RN	DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
DMWXEZD	RU	https://www.ncbi.nlm.nih.gov/pubmed/27376512

DMWXEZD	DI	DMWXEZD
DMWXEZD	DN	PMID27376512-Compound-MTC-427
DMWXEZD	MI	TTJUALD
DMWXEZD	MN	DNA [cytosine-5]-methyltransferase 3A (DNMT3A)
DMWXEZD	MT	DTT
DMWXEZD	MA	Inhibitor
DMWXEZD	RN	DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
DMWXEZD	RU	https://www.ncbi.nlm.nih.gov/pubmed/27376512

DMWXEZD	DI	DMWXEZD
DMWXEZD	DN	PMID27376512-Compound-MTC-427
DMWXEZD	MI	TT6VZ78
DMWXEZD	MN	DNA [cytosine-5]-methyltransferase 3B (DNMT3B)
DMWXEZD	MT	DTT
DMWXEZD	MA	Inhibitor
DMWXEZD	RN	DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
DMWXEZD	RU	https://www.ncbi.nlm.nih.gov/pubmed/27376512

DM7OS5E	DI	DM7OS5E
DM7OS5E	DN	PMID27376512-Compound-MTC-433
DM7OS5E	MI	TT6S2FE
DM7OS5E	MN	DNA [cytosine-5]-methyltransferase 1 (DNMT1)
DM7OS5E	MT	DTT
DM7OS5E	MA	Inhibitor
DM7OS5E	RN	DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
DM7OS5E	RU	https://www.ncbi.nlm.nih.gov/pubmed/27376512

DM70CTE	DI	DM70CTE
DM70CTE	DN	PMID27376512-Compound-MTC-434
DM70CTE	MI	TTHVCUP
DM70CTE	MN	DNA [cytosine-5]-methyltransferase (DNMT)
DM70CTE	MT	DTT
DM70CTE	MA	Inhibitor
DM70CTE	RN	DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
DM70CTE	RU	https://www.ncbi.nlm.nih.gov/pubmed/27376512

DM5K4YF	DI	DM5K4YF
DM5K4YF	DN	PMID27376512-Compound-PG-11047
DM5K4YF	MI	TTHVCUP
DM5K4YF	MN	DNA [cytosine-5]-methyltransferase (DNMT)
DM5K4YF	MT	DTT
DM5K4YF	MA	Inhibitor
DM5K4YF	RN	DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
DM5K4YF	RU	https://www.ncbi.nlm.nih.gov/pubmed/27376512

DM5K4YF	DI	DM5K4YF
DM5K4YF	DN	PMID27376512-Compound-PG-11047
DM5K4YF	MI	TTBH0VX
DM5K4YF	MN	Histone deacetylase (HDAC)
DM5K4YF	MT	DTT
DM5K4YF	MA	Inhibitor
DM5K4YF	RN	DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
DM5K4YF	RU	https://www.ncbi.nlm.nih.gov/pubmed/27376512

DM3U7RN	DI	DM3U7RN
DM3U7RN	DN	PMID27376512-Compound-PG-11048
DM3U7RN	MI	TTHVCUP
DM3U7RN	MN	DNA [cytosine-5]-methyltransferase (DNMT)
DM3U7RN	MT	DTT
DM3U7RN	MA	Inhibitor
DM3U7RN	RN	DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
DM3U7RN	RU	https://www.ncbi.nlm.nih.gov/pubmed/27376512

DM3U7RN	DI	DM3U7RN
DM3U7RN	DN	PMID27376512-Compound-PG-11048
DM3U7RN	MI	TTBH0VX
DM3U7RN	MN	Histone deacetylase (HDAC)
DM3U7RN	MT	DTT
DM3U7RN	MA	Inhibitor
DM3U7RN	RN	DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
DM3U7RN	RU	https://www.ncbi.nlm.nih.gov/pubmed/27376512

DMIFTUN	DI	DMIFTUN
DMIFTUN	DN	PMID27376512-Compound-Table1Example11
DMIFTUN	MI	TT6S2FE
DMIFTUN	MN	DNA [cytosine-5]-methyltransferase 1 (DNMT1)
DMIFTUN	MT	DTT
DMIFTUN	MA	Inhibitor
DMIFTUN	RN	DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
DMIFTUN	RU	https://www.ncbi.nlm.nih.gov/pubmed/27376512

DMM3VA8	DI	DMM3VA8
DMM3VA8	DN	PMID27376512-Compound-Table1Example16
DMM3VA8	MI	TT6S2FE
DMM3VA8	MN	DNA [cytosine-5]-methyltransferase 1 (DNMT1)
DMM3VA8	MT	DTT
DMM3VA8	MA	Inhibitor
DMM3VA8	RN	DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
DMM3VA8	RU	https://www.ncbi.nlm.nih.gov/pubmed/27376512

DM5RX9D	DI	DM5RX9D
DM5RX9D	DN	PMID27376512-Compound-Table1Example30
DM5RX9D	MI	TT6S2FE
DM5RX9D	MN	DNA [cytosine-5]-methyltransferase 1 (DNMT1)
DM5RX9D	MT	DTT
DM5RX9D	MA	Inhibitor
DM5RX9D	RN	DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
DM5RX9D	RU	https://www.ncbi.nlm.nih.gov/pubmed/27376512

DMFJG7P	DI	DMFJG7P
DMFJG7P	DN	PMID27376512-Compound-Table1Example4
DMFJG7P	MI	TT6S2FE
DMFJG7P	MN	DNA [cytosine-5]-methyltransferase 1 (DNMT1)
DMFJG7P	MT	DTT
DMFJG7P	MA	Inhibitor
DMFJG7P	RN	DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
DMFJG7P	RU	https://www.ncbi.nlm.nih.gov/pubmed/27376512

DM4Q6XZ	DI	DM4Q6XZ
DM4Q6XZ	DN	PMID27376512-Compound-Table1Example5
DM4Q6XZ	MI	TT6S2FE
DM4Q6XZ	MN	DNA [cytosine-5]-methyltransferase 1 (DNMT1)
DM4Q6XZ	MT	DTT
DM4Q6XZ	MA	Inhibitor
DM4Q6XZ	RN	DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
DM4Q6XZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27376512

DMKU7GD	DI	DMKU7GD
DMKU7GD	DN	PMID27376512-Compound-Table1Example8
DMKU7GD	MI	TT6S2FE
DMKU7GD	MN	DNA [cytosine-5]-methyltransferase 1 (DNMT1)
DMKU7GD	MT	DTT
DMKU7GD	MA	Inhibitor
DMKU7GD	RN	DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
DMKU7GD	RU	https://www.ncbi.nlm.nih.gov/pubmed/27376512

DMD4CIU	DI	DMD4CIU
DMD4CIU	DN	PMID27387065-Compound-6
DMD4CIU	MI	TTK25J1
DMD4CIU	MN	Adenosine A1 receptor (ADORA1)
DMD4CIU	MT	DTT
DMD4CIU	MA	Agonist
DMD4CIU	RN	Carbonic anhydrase inhibitors: a review on the progress of patent literature (2011-2016).Expert Opin Ther Pat. 2016 Aug;26(8):947-56.
DMD4CIU	RU	https://www.ncbi.nlm.nih.gov/pubmed/27387065

DMDQMZT	DI	DMDQMZT
DMDQMZT	DN	PMID27410995-Compound-Figure3c
DMDQMZT	MI	TTG0U4H
DMDQMZT	MN	Ribosomal protein S6 kinase beta-1 (S6K1)
DMDQMZT	MT	DTT
DMDQMZT	MA	Inhibitor
DMDQMZT	RN	Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78.
DMDQMZT	RU	https://www.ncbi.nlm.nih.gov/pubmed/27410995

DMJRZLB	DI	DMJRZLB
DMJRZLB	DN	PMID27410995-Compound-Figure3j
DMJRZLB	MI	TTUM2ZR
DMJRZLB	MN	Ribosomal protein S6 kinase alpha-3 (RSK3)
DMJRZLB	MT	DTT
DMJRZLB	MA	Inhibitor
DMJRZLB	RN	Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78.
DMJRZLB	RU	https://www.ncbi.nlm.nih.gov/pubmed/27410995

DMJRZLB	DI	DMJRZLB
DMJRZLB	DN	PMID27410995-Compound-Figure3j
DMJRZLB	MI	TT9ABMF
DMJRZLB	MN	Serine/threonine-protein kinase Chk2 (RAD53)
DMJRZLB	MT	DTT
DMJRZLB	MA	Inhibitor
DMJRZLB	RN	Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78.
DMJRZLB	RU	https://www.ncbi.nlm.nih.gov/pubmed/27410995

DMJ0QLB	DI	DMJ0QLB
DMJ0QLB	DN	PMID27410995-Compound-Figure3k
DMJ0QLB	MI	TT7M3PI
DMJ0QLB	MN	Ribosomal protein S6 kinase (S6K)
DMJ0QLB	MT	DTT
DMJ0QLB	MA	Activator
DMJ0QLB	RN	Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78.
DMJ0QLB	RU	https://www.ncbi.nlm.nih.gov/pubmed/27410995

DMUG9X0	DI	DMUG9X0
DMUG9X0	DN	PMID27414413-Compound-Figure6right
DMUG9X0	MI	TTA592U
DMUG9X0	MN	Urate anion exchanger 1 (URAT1)
DMUG9X0	MT	DTT
DMUG9X0	MA	Inhibitor
DMUG9X0	RN	Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10.
DMUG9X0	RU	https://www.ncbi.nlm.nih.gov/pubmed/27414413

DMTZNSM	DI	DMTZNSM
DMTZNSM	DN	PMID27414413-Compound-Figure8right
DMTZNSM	MI	TTA592U
DMTZNSM	MN	Urate anion exchanger 1 (URAT1)
DMTZNSM	MT	DTT
DMTZNSM	MA	Inhibitor
DMTZNSM	RN	Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10.
DMTZNSM	RU	https://www.ncbi.nlm.nih.gov/pubmed/27414413

DM5LOST	DI	DM5LOST
DM5LOST	DN	PMID27454349-Compound-100
DM5LOST	MI	TTK59TV
DM5LOST	MN	Vitamin D3 receptor (VDR)
DM5LOST	MT	DTT
DM5LOST	MA	Agonist
DM5LOST	RN	Vitamin D receptor 2016: novel ligands and structural insights.Expert Opin Ther Pat. 2016 Nov;26(11):1291-1306.
DM5LOST	RU	https://www.ncbi.nlm.nih.gov/pubmed/27454349

DMQIYM6	DI	DMQIYM6
DMQIYM6	DN	PMID27454349-Compound-101
DMQIYM6	MI	TTK59TV
DMQIYM6	MN	Vitamin D3 receptor (VDR)
DMQIYM6	MT	DTT
DMQIYM6	MA	Agonist
DMQIYM6	RN	Vitamin D receptor 2016: novel ligands and structural insights.Expert Opin Ther Pat. 2016 Nov;26(11):1291-1306.
DMQIYM6	RU	https://www.ncbi.nlm.nih.gov/pubmed/27454349

DMEGRMX	DI	DMEGRMX
DMEGRMX	DN	PMID27454349-Compound-102
DMEGRMX	MI	TTK59TV
DMEGRMX	MN	Vitamin D3 receptor (VDR)
DMEGRMX	MT	DTT
DMEGRMX	MA	Agonist
DMEGRMX	RN	Vitamin D receptor 2016: novel ligands and structural insights.Expert Opin Ther Pat. 2016 Nov;26(11):1291-1306.
DMEGRMX	RU	https://www.ncbi.nlm.nih.gov/pubmed/27454349

DMAN7CG	DI	DMAN7CG
DMAN7CG	DN	PMID27454349-Compound-91
DMAN7CG	MI	TTK59TV
DMAN7CG	MN	Vitamin D3 receptor (VDR)
DMAN7CG	MT	DTT
DMAN7CG	MA	Agonist
DMAN7CG	RN	Vitamin D receptor 2016: novel ligands and structural insights.Expert Opin Ther Pat. 2016 Nov;26(11):1291-1306.
DMAN7CG	RU	https://www.ncbi.nlm.nih.gov/pubmed/27454349

DMOEYVT	DI	DMOEYVT
DMOEYVT	DN	PMID27454349-Compound-92
DMOEYVT	MI	TTK59TV
DMOEYVT	MN	Vitamin D3 receptor (VDR)
DMOEYVT	MT	DTT
DMOEYVT	MA	Agonist
DMOEYVT	RN	Vitamin D receptor 2016: novel ligands and structural insights.Expert Opin Ther Pat. 2016 Nov;26(11):1291-1306.
DMOEYVT	RU	https://www.ncbi.nlm.nih.gov/pubmed/27454349

DMCTMB1	DI	DMCTMB1
DMCTMB1	DN	PMID27454349-Compound-93
DMCTMB1	MI	TTK59TV
DMCTMB1	MN	Vitamin D3 receptor (VDR)
DMCTMB1	MT	DTT
DMCTMB1	MA	Agonist
DMCTMB1	RN	Vitamin D receptor 2016: novel ligands and structural insights.Expert Opin Ther Pat. 2016 Nov;26(11):1291-1306.
DMCTMB1	RU	https://www.ncbi.nlm.nih.gov/pubmed/27454349

DMK0SIM	DI	DMK0SIM
DMK0SIM	DN	PMID27454349-Compound-94
DMK0SIM	MI	TTK59TV
DMK0SIM	MN	Vitamin D3 receptor (VDR)
DMK0SIM	MT	DTT
DMK0SIM	MA	Agonist
DMK0SIM	RN	Vitamin D receptor 2016: novel ligands and structural insights.Expert Opin Ther Pat. 2016 Nov;26(11):1291-1306.
DMK0SIM	RU	https://www.ncbi.nlm.nih.gov/pubmed/27454349

DM17KL2	DI	DM17KL2
DM17KL2	DN	PMID27454349-Compound-95
DM17KL2	MI	TTK59TV
DM17KL2	MN	Vitamin D3 receptor (VDR)
DM17KL2	MT	DTT
DM17KL2	MA	Agonist
DM17KL2	RN	Vitamin D receptor 2016: novel ligands and structural insights.Expert Opin Ther Pat. 2016 Nov;26(11):1291-1306.
DM17KL2	RU	https://www.ncbi.nlm.nih.gov/pubmed/27454349

DMW0TM1	DI	DMW0TM1
DMW0TM1	DN	PMID27454349-Compound-96
DMW0TM1	MI	TTK59TV
DMW0TM1	MN	Vitamin D3 receptor (VDR)
DMW0TM1	MT	DTT
DMW0TM1	MA	Agonist
DMW0TM1	RN	Vitamin D receptor 2016: novel ligands and structural insights.Expert Opin Ther Pat. 2016 Nov;26(11):1291-1306.
DMW0TM1	RU	https://www.ncbi.nlm.nih.gov/pubmed/27454349

DMEXV6L	DI	DMEXV6L
DMEXV6L	DN	PMID27454349-Compound-97
DMEXV6L	MI	TTK59TV
DMEXV6L	MN	Vitamin D3 receptor (VDR)
DMEXV6L	MT	DTT
DMEXV6L	MA	Agonist
DMEXV6L	RN	Vitamin D receptor 2016: novel ligands and structural insights.Expert Opin Ther Pat. 2016 Nov;26(11):1291-1306.
DMEXV6L	RU	https://www.ncbi.nlm.nih.gov/pubmed/27454349

DMZKYMI	DI	DMZKYMI
DMZKYMI	DN	PMID27454349-Compound-98
DMZKYMI	MI	TTK59TV
DMZKYMI	MN	Vitamin D3 receptor (VDR)
DMZKYMI	MT	DTT
DMZKYMI	MA	Agonist
DMZKYMI	RN	Vitamin D receptor 2016: novel ligands and structural insights.Expert Opin Ther Pat. 2016 Nov;26(11):1291-1306.
DMZKYMI	RU	https://www.ncbi.nlm.nih.gov/pubmed/27454349

DMH0CQU	DI	DMH0CQU
DMH0CQU	DN	PMID27454349-Compound-99
DMH0CQU	MI	TTK59TV
DMH0CQU	MN	Vitamin D3 receptor (VDR)
DMH0CQU	MT	DTT
DMH0CQU	MA	Agonist
DMH0CQU	RN	Vitamin D receptor 2016: novel ligands and structural insights.Expert Opin Ther Pat. 2016 Nov;26(11):1291-1306.
DMH0CQU	RU	https://www.ncbi.nlm.nih.gov/pubmed/27454349

DM9C4XH	DI	DM9C4XH
DM9C4XH	DN	PMID27537201-Compound-Figure11
DM9C4XH	MI	TTPADOQ
DM9C4XH	MN	HMG-CoA reductase (HMGCR)
DM9C4XH	MT	DTT
DM9C4XH	MA	Inhibitor
DM9C4XH	RN	HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272.
DM9C4XH	RU	https://www.ncbi.nlm.nih.gov/pubmed/27537201

DMPDTHQ	DI	DMPDTHQ
DMPDTHQ	DN	PMID27537201-Compound-Figure13b
DMPDTHQ	MI	TTPADOQ
DMPDTHQ	MN	HMG-CoA reductase (HMGCR)
DMPDTHQ	MT	DTT
DMPDTHQ	MA	Inhibitor
DMPDTHQ	RN	HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272.
DMPDTHQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27537201

DMWZ1PD	DI	DMWZ1PD
DMWZ1PD	DN	PMID27537201-Compound-Figure13c
DMWZ1PD	MI	TTPADOQ
DMWZ1PD	MN	HMG-CoA reductase (HMGCR)
DMWZ1PD	MT	DTT
DMWZ1PD	MA	Inhibitor
DMWZ1PD	RN	HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272.
DMWZ1PD	RU	https://www.ncbi.nlm.nih.gov/pubmed/27537201

DMVBJKH	DI	DMVBJKH
DMVBJKH	DN	PMID27537201-Compound-Figure15a
DMVBJKH	MI	TTPADOQ
DMVBJKH	MN	HMG-CoA reductase (HMGCR)
DMVBJKH	MT	DTT
DMVBJKH	MA	Inhibitor
DMVBJKH	RN	HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272.
DMVBJKH	RU	https://www.ncbi.nlm.nih.gov/pubmed/27537201

DMZ6N2J	DI	DMZ6N2J
DMZ6N2J	DN	PMID27537201-Compound-Figure15b
DMZ6N2J	MI	TTPADOQ
DMZ6N2J	MN	HMG-CoA reductase (HMGCR)
DMZ6N2J	MT	DTT
DMZ6N2J	MA	Inhibitor
DMZ6N2J	RN	HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272.
DMZ6N2J	RU	https://www.ncbi.nlm.nih.gov/pubmed/27537201

DMWKVZD	DI	DMWKVZD
DMWKVZD	DN	PMID27537201-Compound-Figure17
DMWKVZD	MI	TTPADOQ
DMWKVZD	MN	HMG-CoA reductase (HMGCR)
DMWKVZD	MT	DTT
DMWKVZD	MA	Inhibitor
DMWKVZD	RN	HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272.
DMWKVZD	RU	https://www.ncbi.nlm.nih.gov/pubmed/27537201

DM61SR0	DI	DM61SR0
DM61SR0	DN	PMID27539678-Compound-10
DM61SR0	MI	TTOHFIY
DM61SR0	MN	Sphingosine kinase 1 (SPHK1)
DM61SR0	MT	DTT
DM61SR0	MA	Inhibitor
DM61SR0	RN	Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416.
DM61SR0	RU	https://www.ncbi.nlm.nih.gov/pubmed/27539678

DMIKAJC	DI	DMIKAJC
DMIKAJC	DN	PMID27539678-Compound-11
DMIKAJC	MI	TTOHFIY
DMIKAJC	MN	Sphingosine kinase 1 (SPHK1)
DMIKAJC	MT	DTT
DMIKAJC	MA	Inhibitor
DMIKAJC	RN	Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416.
DMIKAJC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27539678

DMNIKTA	DI	DMNIKTA
DMNIKTA	DN	PMID27539678-Compound-12
DMNIKTA	MI	TTOHFIY
DMNIKTA	MN	Sphingosine kinase 1 (SPHK1)
DMNIKTA	MT	DTT
DMNIKTA	MA	Inhibitor
DMNIKTA	RN	Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416.
DMNIKTA	RU	https://www.ncbi.nlm.nih.gov/pubmed/27539678

DM1J2V8	DI	DM1J2V8
DM1J2V8	DN	PMID27539678-Compound-13
DM1J2V8	MI	TTOHFIY
DM1J2V8	MN	Sphingosine kinase 1 (SPHK1)
DM1J2V8	MT	DTT
DM1J2V8	MA	Inhibitor
DM1J2V8	RN	Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416.
DM1J2V8	RU	https://www.ncbi.nlm.nih.gov/pubmed/27539678

DMZ02LA	DI	DMZ02LA
DMZ02LA	DN	PMID27539678-Compound-14
DMZ02LA	MI	TTOHFIY
DMZ02LA	MN	Sphingosine kinase 1 (SPHK1)
DMZ02LA	MT	DTT
DMZ02LA	MA	Inhibitor
DMZ02LA	RN	Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416.
DMZ02LA	RU	https://www.ncbi.nlm.nih.gov/pubmed/27539678

DMMDJH8	DI	DMMDJH8
DMMDJH8	DN	PMID27539678-Compound-16
DMMDJH8	MI	TTOHFIY
DMMDJH8	MN	Sphingosine kinase 1 (SPHK1)
DMMDJH8	MT	DTT
DMMDJH8	MA	Inhibitor
DMMDJH8	RN	Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416.
DMMDJH8	RU	https://www.ncbi.nlm.nih.gov/pubmed/27539678

DMVG7A5	DI	DMVG7A5
DMVG7A5	DN	PMID27539678-Compound-17
DMVG7A5	MI	TTOHFIY
DMVG7A5	MN	Sphingosine kinase 1 (SPHK1)
DMVG7A5	MT	DTT
DMVG7A5	MA	Inhibitor
DMVG7A5	RN	Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416.
DMVG7A5	RU	https://www.ncbi.nlm.nih.gov/pubmed/27539678

DMRNBP3	DI	DMRNBP3
DMRNBP3	DN	PMID27539678-Compound-3
DMRNBP3	MI	TT3M2WO
DMRNBP3	MN	Sphingosine kinase (SphK)
DMRNBP3	MT	DTT
DMRNBP3	MA	Inhibitor
DMRNBP3	RN	Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416.
DMRNBP3	RU	https://www.ncbi.nlm.nih.gov/pubmed/27539678

DMJ8BAS	DI	DMJ8BAS
DMJ8BAS	DN	PMID27539678-Compound-4
DMJ8BAS	MI	TT3M2WO
DMJ8BAS	MN	Sphingosine kinase (SphK)
DMJ8BAS	MT	DTT
DMJ8BAS	MA	Inhibitor
DMJ8BAS	RN	Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416.
DMJ8BAS	RU	https://www.ncbi.nlm.nih.gov/pubmed/27539678

DMBKNDE	DI	DMBKNDE
DMBKNDE	DN	PMID27539678-Compound-6
DMBKNDE	MI	TTOHFIY
DMBKNDE	MN	Sphingosine kinase 1 (SPHK1)
DMBKNDE	MT	DTT
DMBKNDE	MA	Inhibitor
DMBKNDE	RN	Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416.
DMBKNDE	RU	https://www.ncbi.nlm.nih.gov/pubmed/27539678

DMQAC4K	DI	DMQAC4K
DMQAC4K	DN	PMID27539678-Compound-7
DMQAC4K	MI	TTOHFIY
DMQAC4K	MN	Sphingosine kinase 1 (SPHK1)
DMQAC4K	MT	DTT
DMQAC4K	MA	Inhibitor
DMQAC4K	RN	Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416.
DMQAC4K	RU	https://www.ncbi.nlm.nih.gov/pubmed/27539678

DMHWUEV	DI	DMHWUEV
DMHWUEV	DN	PMID27539678-Compound-8
DMHWUEV	MI	TT3M2WO
DMHWUEV	MN	Sphingosine kinase (SphK)
DMHWUEV	MT	DTT
DMHWUEV	MA	Inhibitor
DMHWUEV	RN	Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416.
DMHWUEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/27539678

DM0Y5NU	DI	DM0Y5NU
DM0Y5NU	DN	PMID27539678-Compound-9
DM0Y5NU	MI	TTOHFIY
DM0Y5NU	MN	Sphingosine kinase 1 (SPHK1)
DM0Y5NU	MT	DTT
DM0Y5NU	MA	Inhibitor
DM0Y5NU	RN	Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416.
DM0Y5NU	RU	https://www.ncbi.nlm.nih.gov/pubmed/27539678

DM5OQBR	DI	DM5OQBR
DM5OQBR	DN	PMID27551786-Compound-106
DM5OQBR	MI	TT26PHO
DM5OQBR	MN	Mineralocorticoid receptor  (MR)
DM5OQBR	MT	DTT
DM5OQBR	MA	Antagonist
DM5OQBR	RN	Mineralocorticoid receptor antagonists: a patent evaluation of US20150284376A1.Expert Opin Ther Pat. 2016 Sep 14:1-4.
DM5OQBR	RU	https://www.ncbi.nlm.nih.gov/pubmed/27551786

DM4IZUH	DI	DM4IZUH
DM4IZUH	DN	PMID27551786-Compound-138
DM4IZUH	MI	TT26PHO
DM4IZUH	MN	Mineralocorticoid receptor  (MR)
DM4IZUH	MT	DTT
DM4IZUH	MA	Antagonist
DM4IZUH	RN	Mineralocorticoid receptor antagonists: a patent evaluation of US20150284376A1.Expert Opin Ther Pat. 2016 Sep 14:1-4.
DM4IZUH	RU	https://www.ncbi.nlm.nih.gov/pubmed/27551786

DMA7H63	DI	DMA7H63
DMA7H63	DN	PMID27551786-Compound-I
DMA7H63	MI	TT26PHO
DMA7H63	MN	Mineralocorticoid receptor  (MR)
DMA7H63	MT	DTT
DMA7H63	MA	Antagonist
DMA7H63	RN	Mineralocorticoid receptor antagonists: a patent evaluation of US20150284376A1.Expert Opin Ther Pat. 2016 Sep 14:1-4.
DMA7H63	RU	https://www.ncbi.nlm.nih.gov/pubmed/27551786

DMJADXV	DI	DMJADXV
DMJADXV	DN	PMID27551786-Compound-II
DMJADXV	MI	TT26PHO
DMJADXV	MN	Mineralocorticoid receptor  (MR)
DMJADXV	MT	DTT
DMJADXV	MA	Antagonist
DMJADXV	RN	Mineralocorticoid receptor antagonists: a patent evaluation of US20150284376A1.Expert Opin Ther Pat. 2016 Sep 14:1-4.
DMJADXV	RU	https://www.ncbi.nlm.nih.gov/pubmed/27551786

DMBQ981	DI	DMBQ981
DMBQ981	DN	PMID27551786-Compound-III
DMBQ981	MI	TT26PHO
DMBQ981	MN	Mineralocorticoid receptor  (MR)
DMBQ981	MT	DTT
DMBQ981	MA	Antagonist
DMBQ981	RN	Mineralocorticoid receptor antagonists: a patent evaluation of US20150284376A1.Expert Opin Ther Pat. 2016 Sep 14:1-4.
DMBQ981	RU	https://www.ncbi.nlm.nih.gov/pubmed/27551786

DM7IB8L	DI	DM7IB8L
DM7IB8L	DN	PMID27551786-Compound-IV
DM7IB8L	MI	TT26PHO
DM7IB8L	MN	Mineralocorticoid receptor  (MR)
DM7IB8L	MT	DTT
DM7IB8L	MA	Antagonist
DM7IB8L	RN	Mineralocorticoid receptor antagonists: a patent evaluation of US20150284376A1.Expert Opin Ther Pat. 2016 Sep 14:1-4.
DM7IB8L	RU	https://www.ncbi.nlm.nih.gov/pubmed/27551786

DM5KARO	DI	DM5KARO
DM5KARO	DN	PMID27599163-Compound-52
DM5KARO	MI	TTPTXIN
DM5KARO	MN	Translocator protein (TSPO)
DM5KARO	MT	DTT
DM5KARO	MA	Ligand
DM5KARO	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366.
DM5KARO	RU	https://www.ncbi.nlm.nih.gov/pubmed/27599163

DMYCQR4	DI	DMYCQR4
DMYCQR4	DN	PMID27599163-Compound-75
DMYCQR4	MI	TTPTXIN
DMYCQR4	MN	Translocator protein (TSPO)
DMYCQR4	MT	DTT
DMYCQR4	MA	Ligand
DMYCQR4	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366.
DMYCQR4	RU	https://www.ncbi.nlm.nih.gov/pubmed/27599163

DMODPFU	DI	DMODPFU
DMODPFU	DN	PMID27599163-Compound-76
DMODPFU	MI	TTPTXIN
DMODPFU	MN	Translocator protein (TSPO)
DMODPFU	MT	DTT
DMODPFU	MA	Ligand
DMODPFU	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366.
DMODPFU	RU	https://www.ncbi.nlm.nih.gov/pubmed/27599163

DM2TNH4	DI	DM2TNH4
DM2TNH4	DN	PMID27599163-Compound-77
DM2TNH4	MI	TTPTXIN
DM2TNH4	MN	Translocator protein (TSPO)
DM2TNH4	MT	DTT
DM2TNH4	MA	Ligand
DM2TNH4	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366.
DM2TNH4	RU	https://www.ncbi.nlm.nih.gov/pubmed/27599163

DMZC58R	DI	DMZC58R
DMZC58R	DN	PMID27599163-Compound-78
DMZC58R	MI	TTPTXIN
DMZC58R	MN	Translocator protein (TSPO)
DMZC58R	MT	DTT
DMZC58R	MA	Ligand
DMZC58R	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366.
DMZC58R	RU	https://www.ncbi.nlm.nih.gov/pubmed/27599163

DMVUWYB	DI	DMVUWYB
DMVUWYB	DN	PMID27599163-Compound-79
DMVUWYB	MI	TTPTXIN
DMVUWYB	MN	Translocator protein (TSPO)
DMVUWYB	MT	DTT
DMVUWYB	MA	Ligand
DMVUWYB	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366.
DMVUWYB	RU	https://www.ncbi.nlm.nih.gov/pubmed/27599163

DMZ5QC4	DI	DMZ5QC4
DMZ5QC4	DN	PMID27599163-Compound-81
DMZ5QC4	MI	TTPTXIN
DMZ5QC4	MN	Translocator protein (TSPO)
DMZ5QC4	MT	DTT
DMZ5QC4	MA	Ligand
DMZ5QC4	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366.
DMZ5QC4	RU	https://www.ncbi.nlm.nih.gov/pubmed/27599163

DMO74I9	DI	DMO74I9
DMO74I9	DN	PMID27599163-Compound-82
DMO74I9	MI	TTPTXIN
DMO74I9	MN	Translocator protein (TSPO)
DMO74I9	MT	DTT
DMO74I9	MA	Ligand
DMO74I9	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366.
DMO74I9	RU	https://www.ncbi.nlm.nih.gov/pubmed/27599163

DM5RBFC	DI	DM5RBFC
DM5RBFC	DN	PMID27607364-Compound-10
DM5RBFC	MI	TTPTXIN
DM5RBFC	MN	Translocator protein (TSPO)
DM5RBFC	MT	DTT
DM5RBFC	MA	Ligand
DM5RBFC	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DM5RBFC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMMF4XO	DI	DMMF4XO
DMMF4XO	DN	PMID27607364-Compound-141
DMMF4XO	MI	TTPTXIN
DMMF4XO	MN	Translocator protein (TSPO)
DMMF4XO	MT	DTT
DMMF4XO	MA	Ligand
DMMF4XO	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMMF4XO	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DM0F6VU	DI	DM0F6VU
DM0F6VU	DN	PMID27607364-Compound-162
DM0F6VU	MI	TTPTXIN
DM0F6VU	MN	Translocator protein (TSPO)
DM0F6VU	MT	DTT
DM0F6VU	MA	Ligand
DM0F6VU	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DM0F6VU	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMKBZDP	DI	DMKBZDP
DMKBZDP	DN	PMID27607364-Compound-4
DMKBZDP	MI	TTPTXIN
DMKBZDP	MN	Translocator protein (TSPO)
DMKBZDP	MT	DTT
DMKBZDP	MA	Ligand
DMKBZDP	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMKBZDP	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMXJVW4	DI	DMXJVW4
DMXJVW4	DN	PMID27607364-Compound-58
DMXJVW4	MI	TTPTXIN
DMXJVW4	MN	Translocator protein (TSPO)
DMXJVW4	MT	DTT
DMXJVW4	MA	Ligand
DMXJVW4	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMXJVW4	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMLY7I3	DI	DMLY7I3
DMLY7I3	DN	PMID27607364-Compound-59
DMLY7I3	MI	TTPTXIN
DMLY7I3	MN	Translocator protein (TSPO)
DMLY7I3	MT	DTT
DMLY7I3	MA	Ligand
DMLY7I3	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMLY7I3	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DM584EP	DI	DM584EP
DM584EP	DN	PMID27607364-Compound-60
DM584EP	MI	TTPTXIN
DM584EP	MN	Translocator protein (TSPO)
DM584EP	MT	DTT
DM584EP	MA	Ligand
DM584EP	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DM584EP	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMWE6NZ	DI	DMWE6NZ
DMWE6NZ	DN	PMID27607364-Compound-61
DMWE6NZ	MI	TTPTXIN
DMWE6NZ	MN	Translocator protein (TSPO)
DMWE6NZ	MT	DTT
DMWE6NZ	MA	Ligand
DMWE6NZ	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMWE6NZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMXGT2A	DI	DMXGT2A
DMXGT2A	DN	PMID27607364-Compound-62
DMXGT2A	MI	TTPTXIN
DMXGT2A	MN	Translocator protein (TSPO)
DMXGT2A	MT	DTT
DMXGT2A	MA	Ligand
DMXGT2A	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMXGT2A	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMVTPHY	DI	DMVTPHY
DMVTPHY	DN	PMID27607364-Compound-63
DMVTPHY	MI	TTPTXIN
DMVTPHY	MN	Translocator protein (TSPO)
DMVTPHY	MT	DTT
DMVTPHY	MA	Ligand
DMVTPHY	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMVTPHY	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMZSI15	DI	DMZSI15
DMZSI15	DN	PMID27607364-Compound-64
DMZSI15	MI	TTPTXIN
DMZSI15	MN	Translocator protein (TSPO)
DMZSI15	MT	DTT
DMZSI15	MA	Ligand
DMZSI15	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMZSI15	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DM9NEFG	DI	DM9NEFG
DM9NEFG	DN	PMID27607364-Compound-65
DM9NEFG	MI	TTPTXIN
DM9NEFG	MN	Translocator protein (TSPO)
DM9NEFG	MT	DTT
DM9NEFG	MA	Ligand
DM9NEFG	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DM9NEFG	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMTJ0LB	DI	DMTJ0LB
DMTJ0LB	DN	PMID27724045-Compound-14
DMTJ0LB	MI	TT473XN
DMTJ0LB	MN	P2X purinoceptor 7 (P2RX7)
DMTJ0LB	MT	DTT
DMTJ0LB	MA	Antagonist
DMTJ0LB	RN	P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267.
DMTJ0LB	RU	https://www.ncbi.nlm.nih.gov/pubmed/27724045

DMVN5BD	DI	DMVN5BD
DMVN5BD	DN	PMID27724045-Compound-15
DMVN5BD	MI	TT473XN
DMVN5BD	MN	P2X purinoceptor 7 (P2RX7)
DMVN5BD	MT	DTT
DMVN5BD	MA	Antagonist
DMVN5BD	RN	P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267.
DMVN5BD	RU	https://www.ncbi.nlm.nih.gov/pubmed/27724045

DM4W72V	DI	DM4W72V
DM4W72V	DN	PMID27724045-Compound-17
DM4W72V	MI	TT473XN
DM4W72V	MN	P2X purinoceptor 7 (P2RX7)
DM4W72V	MT	DTT
DM4W72V	MA	Antagonist
DM4W72V	RN	P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267.
DM4W72V	RU	https://www.ncbi.nlm.nih.gov/pubmed/27724045

DMVDBHT	DI	DMVDBHT
DMVDBHT	DN	PMID27724045-Compound-19
DMVDBHT	MI	TT473XN
DMVDBHT	MN	P2X purinoceptor 7 (P2RX7)
DMVDBHT	MT	DTT
DMVDBHT	MA	Antagonist
DMVDBHT	RN	P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267.
DMVDBHT	RU	https://www.ncbi.nlm.nih.gov/pubmed/27724045

DMKTQX8	DI	DMKTQX8
DMKTQX8	DN	PMID27724045-Compound-29
DMKTQX8	MI	TT473XN
DMKTQX8	MN	P2X purinoceptor 7 (P2RX7)
DMKTQX8	MT	DTT
DMKTQX8	MA	Antagonist
DMKTQX8	RN	P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267.
DMKTQX8	RU	https://www.ncbi.nlm.nih.gov/pubmed/27724045

DMOS7ZP	DI	DMOS7ZP
DMOS7ZP	DN	PMID27724045-Compound-33
DMOS7ZP	MI	TT473XN
DMOS7ZP	MN	P2X purinoceptor 7 (P2RX7)
DMOS7ZP	MT	DTT
DMOS7ZP	MA	Antagonist
DMOS7ZP	RN	P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267.
DMOS7ZP	RU	https://www.ncbi.nlm.nih.gov/pubmed/27724045

DMFKS2P	DI	DMFKS2P
DMFKS2P	DN	PMID27744724-Compound-10
DMFKS2P	MI	TTJGNVC
DMFKS2P	MN	Apoptosis regulator Bcl-2 (BCL-2)
DMFKS2P	MT	DTT
DMFKS2P	MA	Inhibitor
DMFKS2P	RN	Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
DMFKS2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/27744724

DMFKS2P	DI	DMFKS2P
DMFKS2P	DN	PMID27744724-Compound-10
DMFKS2P	MI	TTU1E82
DMFKS2P	MN	Apoptosis regulator Bcl-xL (BCL-xL)
DMFKS2P	MT	DTT
DMFKS2P	MA	Inhibitor
DMFKS2P	RN	Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
DMFKS2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/27744724

DMFKS2P	DI	DMFKS2P
DMFKS2P	DN	PMID27744724-Compound-10
DMFKS2P	MI	TTL53M6
DMFKS2P	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DMFKS2P	MT	DTT
DMFKS2P	MA	Inhibitor
DMFKS2P	RN	Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
DMFKS2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/27744724

DMCFOXP	DI	DMCFOXP
DMCFOXP	DN	PMID27744724-Compound-13
DMCFOXP	MI	TTL53M6
DMCFOXP	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DMCFOXP	MT	DTT
DMCFOXP	MA	Inhibitor
DMCFOXP	RN	Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
DMCFOXP	RU	https://www.ncbi.nlm.nih.gov/pubmed/27744724

DM73S2C	DI	DM73S2C
DM73S2C	DN	PMID27744724-Compound-18
DM73S2C	MI	TTJGNVC
DM73S2C	MN	Apoptosis regulator Bcl-2 (BCL-2)
DM73S2C	MT	DTT
DM73S2C	MA	Inhibitor
DM73S2C	RN	Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
DM73S2C	RU	https://www.ncbi.nlm.nih.gov/pubmed/27744724

DM73S2C	DI	DM73S2C
DM73S2C	DN	PMID27744724-Compound-18
DM73S2C	MI	TTQ79W8
DM73S2C	MN	Apoptosis regulator Bcl-W (BCL-W)
DM73S2C	MT	DTT
DM73S2C	MA	Inhibitor
DM73S2C	RN	Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
DM73S2C	RU	https://www.ncbi.nlm.nih.gov/pubmed/27744724

DM73S2C	DI	DM73S2C
DM73S2C	DN	PMID27744724-Compound-18
DM73S2C	MI	TTU1E82
DM73S2C	MN	Apoptosis regulator Bcl-xL (BCL-xL)
DM73S2C	MT	DTT
DM73S2C	MA	Inhibitor
DM73S2C	RN	Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
DM73S2C	RU	https://www.ncbi.nlm.nih.gov/pubmed/27744724

DM73S2C	DI	DM73S2C
DM73S2C	DN	PMID27744724-Compound-18
DM73S2C	MI	TTL53M6
DM73S2C	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DM73S2C	MT	DTT
DM73S2C	MA	Inhibitor
DM73S2C	RN	Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
DM73S2C	RU	https://www.ncbi.nlm.nih.gov/pubmed/27744724

DM214WA	DI	DM214WA
DM214WA	DN	PMID27744724-Compound-19
DM214WA	MI	TTL53M6
DM214WA	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DM214WA	MT	DTT
DM214WA	MA	Inhibitor
DM214WA	RN	Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
DM214WA	RU	https://www.ncbi.nlm.nih.gov/pubmed/27744724

DMD0T6S	DI	DMD0T6S
DMD0T6S	DN	PMID27744724-Compound-20
DMD0T6S	MI	TTL53M6
DMD0T6S	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DMD0T6S	MT	DTT
DMD0T6S	MA	Inhibitor
DMD0T6S	RN	Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
DMD0T6S	RU	https://www.ncbi.nlm.nih.gov/pubmed/27744724

DM18UA5	DI	DM18UA5
DM18UA5	DN	PMID27744724-Compound-21
DM18UA5	MI	TTJGNVC
DM18UA5	MN	Apoptosis regulator Bcl-2 (BCL-2)
DM18UA5	MT	DTT
DM18UA5	MA	Inhibitor
DM18UA5	RN	Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
DM18UA5	RU	https://www.ncbi.nlm.nih.gov/pubmed/27744724

DM18UA5	DI	DM18UA5
DM18UA5	DN	PMID27744724-Compound-21
DM18UA5	MI	TTU1E82
DM18UA5	MN	Apoptosis regulator Bcl-xL (BCL-xL)
DM18UA5	MT	DTT
DM18UA5	MA	Inhibitor
DM18UA5	RN	Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
DM18UA5	RU	https://www.ncbi.nlm.nih.gov/pubmed/27744724

DM18UA5	DI	DM18UA5
DM18UA5	DN	PMID27744724-Compound-21
DM18UA5	MI	TTL53M6
DM18UA5	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DM18UA5	MT	DTT
DM18UA5	MA	Inhibitor
DM18UA5	RN	Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
DM18UA5	RU	https://www.ncbi.nlm.nih.gov/pubmed/27744724

DMM6FOW	DI	DMM6FOW
DMM6FOW	DN	PMID27744724-Compound-22
DMM6FOW	MI	TTL53M6
DMM6FOW	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DMM6FOW	MT	DTT
DMM6FOW	MA	Inhibitor
DMM6FOW	RN	Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
DMM6FOW	RU	https://www.ncbi.nlm.nih.gov/pubmed/27744724

DMXA70C	DI	DMXA70C
DMXA70C	DN	PMID27744724-Compound-23
DMXA70C	MI	TTL53M6
DMXA70C	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DMXA70C	MT	DTT
DMXA70C	MA	Inhibitor
DMXA70C	RN	Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
DMXA70C	RU	https://www.ncbi.nlm.nih.gov/pubmed/27744724

DM8GOH3	DI	DM8GOH3
DM8GOH3	DN	PMID27744724-Compound-26
DM8GOH3	MI	TTU1E82
DM8GOH3	MN	Apoptosis regulator Bcl-xL (BCL-xL)
DM8GOH3	MT	DTT
DM8GOH3	MA	Inhibitor
DM8GOH3	RN	Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
DM8GOH3	RU	https://www.ncbi.nlm.nih.gov/pubmed/27744724

DM8GOH3	DI	DM8GOH3
DM8GOH3	DN	PMID27744724-Compound-26
DM8GOH3	MI	TTL53M6
DM8GOH3	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DM8GOH3	MT	DTT
DM8GOH3	MA	Inhibitor
DM8GOH3	RN	Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
DM8GOH3	RU	https://www.ncbi.nlm.nih.gov/pubmed/27744724

DMV6MLC	DI	DMV6MLC
DMV6MLC	DN	PMID27744724-Compound-27
DMV6MLC	MI	TTU1E82
DMV6MLC	MN	Apoptosis regulator Bcl-xL (BCL-xL)
DMV6MLC	MT	DTT
DMV6MLC	MA	Inhibitor
DMV6MLC	RN	Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
DMV6MLC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27744724

DMV6MLC	DI	DMV6MLC
DMV6MLC	DN	PMID27744724-Compound-27
DMV6MLC	MI	TTL53M6
DMV6MLC	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DMV6MLC	MT	DTT
DMV6MLC	MA	Inhibitor
DMV6MLC	RN	Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
DMV6MLC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27744724

DMB018S	DI	DMB018S
DMB018S	DN	PMID27744724-Compound-28
DMB018S	MI	TTL53M6
DMB018S	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DMB018S	MT	DTT
DMB018S	MA	Inhibitor
DMB018S	RN	Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
DMB018S	RU	https://www.ncbi.nlm.nih.gov/pubmed/27744724

DM2GDXH	DI	DM2GDXH
DM2GDXH	DN	PMID27744724-Compound-29
DM2GDXH	MI	TTL53M6
DM2GDXH	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DM2GDXH	MT	DTT
DM2GDXH	MA	Inhibitor
DM2GDXH	RN	Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
DM2GDXH	RU	https://www.ncbi.nlm.nih.gov/pubmed/27744724

DMWKYU4	DI	DMWKYU4
DMWKYU4	DN	PMID27744724-Compound-3
DMWKYU4	MI	TTL53M6
DMWKYU4	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DMWKYU4	MT	DTT
DMWKYU4	MA	Inhibitor
DMWKYU4	RN	Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
DMWKYU4	RU	https://www.ncbi.nlm.nih.gov/pubmed/27744724

DMV1WND	DI	DMV1WND
DMV1WND	DN	PMID27744724-Compound-4
DMV1WND	MI	TTL53M6
DMV1WND	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DMV1WND	MT	DTT
DMV1WND	MA	Inhibitor
DMV1WND	RN	Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
DMV1WND	RU	https://www.ncbi.nlm.nih.gov/pubmed/27744724

DM6UTAQ	DI	DM6UTAQ
DM6UTAQ	DN	PMID27744724-Compound-5
DM6UTAQ	MI	TTL53M6
DM6UTAQ	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DM6UTAQ	MT	DTT
DM6UTAQ	MA	Inhibitor
DM6UTAQ	RN	Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
DM6UTAQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27744724

DMV7P4N	DI	DMV7P4N
DMV7P4N	DN	PMID27744724-Compound-6
DMV7P4N	MI	TTL53M6
DMV7P4N	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DMV7P4N	MT	DTT
DMV7P4N	MA	Inhibitor
DMV7P4N	RN	Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
DMV7P4N	RU	https://www.ncbi.nlm.nih.gov/pubmed/27744724

DMT2W97	DI	DMT2W97
DMT2W97	DN	PMID27744724-Compound-Fomula2
DMT2W97	MI	TTL53M6
DMT2W97	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DMT2W97	MT	DTT
DMT2W97	MA	Inhibitor
DMT2W97	RN	Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
DMT2W97	RU	https://www.ncbi.nlm.nih.gov/pubmed/27744724

DMFAGOZ	DI	DMFAGOZ
DMFAGOZ	DN	PMID27774822-Compound-Figure10Compound12
DMFAGOZ	MI	TTJNBQA
DMFAGOZ	MN	Activin receptor-like kinase 2 (ALK-2)
DMFAGOZ	MT	DTT
DMFAGOZ	MA	Inhibitor
DMFAGOZ	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMFAGOZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMFAGOZ	DI	DMFAGOZ
DMFAGOZ	DN	PMID27774822-Compound-Figure10Compound12
DMFAGOZ	MI	TTRMX3V
DMFAGOZ	MN	Janus kinase 2 (JAK-2)
DMFAGOZ	MT	DTT
DMFAGOZ	MA	Inhibitor
DMFAGOZ	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMFAGOZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMMJVTW	DI	DMMJVTW
DMMJVTW	DN	PMID27774822-Compound-Figure10Compound4
DMMJVTW	MI	TTJNBQA
DMMJVTW	MN	Activin receptor-like kinase 2 (ALK-2)
DMMJVTW	MT	DTT
DMMJVTW	MA	Inhibitor
DMMJVTW	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMMJVTW	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMMJVTW	DI	DMMJVTW
DMMJVTW	DN	PMID27774822-Compound-Figure10Compound4
DMMJVTW	MI	TTRMX3V
DMMJVTW	MN	Janus kinase 2 (JAK-2)
DMMJVTW	MT	DTT
DMMJVTW	MA	Inhibitor
DMMJVTW	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMMJVTW	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DM3M6SE	DI	DM3M6SE
DM3M6SE	DN	PMID27774822-Compound-Figure10CompoundA
DM3M6SE	MI	TTJSQEF
DM3M6SE	MN	Tyrosine-protein kinase (PTK)
DM3M6SE	MT	DTT
DM3M6SE	MA	Inhibitor
DM3M6SE	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DM3M6SE	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMCTXPQ	DI	DMCTXPQ
DMCTXPQ	DN	PMID27774822-Compound-Figure10Example1
DMCTXPQ	MI	TTRMX3V
DMCTXPQ	MN	Janus kinase 2 (JAK-2)
DMCTXPQ	MT	DTT
DMCTXPQ	MA	Inhibitor
DMCTXPQ	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMCTXPQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMCTXPQ	DI	DMCTXPQ
DMCTXPQ	DN	PMID27774822-Compound-Figure10Example1
DMCTXPQ	MI	TTT7PJU
DMCTXPQ	MN	Janus kinase 3 (JAK-3)
DMCTXPQ	MT	DTT
DMCTXPQ	MA	Inhibitor
DMCTXPQ	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMCTXPQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMCTXPQ	DI	DMCTXPQ
DMCTXPQ	DN	PMID27774822-Compound-Figure10Example1
DMCTXPQ	MI	TTJSQEF
DMCTXPQ	MN	Tyrosine-protein kinase (PTK)
DMCTXPQ	MT	DTT
DMCTXPQ	MA	Inhibitor
DMCTXPQ	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMCTXPQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMNXYZP	DI	DMNXYZP
DMNXYZP	DN	PMID27774822-Compound-Figure10Example19
DMNXYZP	MI	TTRMX3V
DMNXYZP	MN	Janus kinase 2 (JAK-2)
DMNXYZP	MT	DTT
DMNXYZP	MA	Inhibitor
DMNXYZP	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMNXYZP	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMNXYZP	DI	DMNXYZP
DMNXYZP	DN	PMID27774822-Compound-Figure10Example19
DMNXYZP	MI	TTT7PJU
DMNXYZP	MN	Janus kinase 3 (JAK-3)
DMNXYZP	MT	DTT
DMNXYZP	MA	Inhibitor
DMNXYZP	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMNXYZP	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMAHFXV	DI	DMAHFXV
DMAHFXV	DN	PMID27774822-Compound-Figure11Example5
DMAHFXV	MI	TT6DM01
DMAHFXV	MN	Janus kinase 1 (JAK-1)
DMAHFXV	MT	DTT
DMAHFXV	MA	Inhibitor
DMAHFXV	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMAHFXV	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMAHFXV	DI	DMAHFXV
DMAHFXV	DN	PMID27774822-Compound-Figure11Example5
DMAHFXV	MI	TTRMX3V
DMAHFXV	MN	Janus kinase 2 (JAK-2)
DMAHFXV	MT	DTT
DMAHFXV	MA	Inhibitor
DMAHFXV	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMAHFXV	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMAHFXV	DI	DMAHFXV
DMAHFXV	DN	PMID27774822-Compound-Figure11Example5
DMAHFXV	MI	TTT7PJU
DMAHFXV	MN	Janus kinase 3 (JAK-3)
DMAHFXV	MT	DTT
DMAHFXV	MA	Inhibitor
DMAHFXV	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMAHFXV	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMAHFXV	DI	DMAHFXV
DMAHFXV	DN	PMID27774822-Compound-Figure11Example5
DMAHFXV	MI	TTBYWP2
DMAHFXV	MN	TYK2 tyrosine kinase (TYK2)
DMAHFXV	MT	DTT
DMAHFXV	MA	Inhibitor
DMAHFXV	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMAHFXV	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMCL19N	DI	DMCL19N
DMCL19N	DN	PMID27774822-Compound-Figure1Example20
DMCL19N	MI	TT6DM01
DMCL19N	MN	Janus kinase 1 (JAK-1)
DMCL19N	MT	DTT
DMCL19N	MA	Inhibitor
DMCL19N	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMCL19N	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMCL19N	DI	DMCL19N
DMCL19N	DN	PMID27774822-Compound-Figure1Example20
DMCL19N	MI	TTRMX3V
DMCL19N	MN	Janus kinase 2 (JAK-2)
DMCL19N	MT	DTT
DMCL19N	MA	Inhibitor
DMCL19N	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMCL19N	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMCL19N	DI	DMCL19N
DMCL19N	DN	PMID27774822-Compound-Figure1Example20
DMCL19N	MI	TTT7PJU
DMCL19N	MN	Janus kinase 3 (JAK-3)
DMCL19N	MT	DTT
DMCL19N	MA	Inhibitor
DMCL19N	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMCL19N	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DM86M7D	DI	DM86M7D
DM86M7D	DN	PMID27774822-Compound-Figure2Example1-1left
DM86M7D	MI	TTRMX3V
DM86M7D	MN	Janus kinase 2 (JAK-2)
DM86M7D	MT	DTT
DM86M7D	MA	Inhibitor
DM86M7D	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DM86M7D	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DM86M7D	DI	DM86M7D
DM86M7D	DN	PMID27774822-Compound-Figure2Example1-1left
DM86M7D	MI	TTT7PJU
DM86M7D	MN	Janus kinase 3 (JAK-3)
DM86M7D	MT	DTT
DM86M7D	MA	Inhibitor
DM86M7D	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DM86M7D	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DM2YPLF	DI	DM2YPLF
DM2YPLF	DN	PMID27774822-Compound-Figure2Example1-1right
DM2YPLF	MI	TTRMX3V
DM2YPLF	MN	Janus kinase 2 (JAK-2)
DM2YPLF	MT	DTT
DM2YPLF	MA	Inhibitor
DM2YPLF	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DM2YPLF	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DM2YPLF	DI	DM2YPLF
DM2YPLF	DN	PMID27774822-Compound-Figure2Example1-1right
DM2YPLF	MI	TTT7PJU
DM2YPLF	MN	Janus kinase 3 (JAK-3)
DM2YPLF	MT	DTT
DM2YPLF	MA	Inhibitor
DM2YPLF	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DM2YPLF	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMEHIS4	DI	DMEHIS4
DMEHIS4	DN	PMID27774822-Compound-Figure2Example4-3
DMEHIS4	MI	TTT7PJU
DMEHIS4	MN	Janus kinase 3 (JAK-3)
DMEHIS4	MT	DTT
DMEHIS4	MA	Inhibitor
DMEHIS4	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMEHIS4	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMOENP4	DI	DMOENP4
DMOENP4	DN	PMID27774822-Compound-Figure3CompoundI-165
DMOENP4	MI	TTRMX3V
DMOENP4	MN	Janus kinase 2 (JAK-2)
DMOENP4	MT	DTT
DMOENP4	MA	Inhibitor
DMOENP4	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMOENP4	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMOENP4	DI	DMOENP4
DMOENP4	DN	PMID27774822-Compound-Figure3CompoundI-165
DMOENP4	MI	TTBYWP2
DMOENP4	MN	TYK2 tyrosine kinase (TYK2)
DMOENP4	MT	DTT
DMOENP4	MA	Inhibitor
DMOENP4	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMOENP4	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMCD19T	DI	DMCD19T
DMCD19T	DN	PMID27774822-Compound-Figure6Example2
DMCD19T	MI	TTT7PJU
DMCD19T	MN	Janus kinase 3 (JAK-3)
DMCD19T	MT	DTT
DMCD19T	MA	Inhibitor
DMCD19T	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMCD19T	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DM3FY85	DI	DM3FY85
DM3FY85	DN	PMID27774822-Compound-Figure6Example3
DM3FY85	MI	TTT7PJU
DM3FY85	MN	Janus kinase 3 (JAK-3)
DM3FY85	MT	DTT
DM3FY85	MA	Inhibitor
DM3FY85	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DM3FY85	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMF5IWB	DI	DMF5IWB
DMF5IWB	DN	PMID27774822-Compound-Figure7Example63
DMF5IWB	MI	TT6DM01
DMF5IWB	MN	Janus kinase 1 (JAK-1)
DMF5IWB	MT	DTT
DMF5IWB	MA	Inhibitor
DMF5IWB	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMF5IWB	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMF5IWB	DI	DMF5IWB
DMF5IWB	DN	PMID27774822-Compound-Figure7Example63
DMF5IWB	MI	TTRMX3V
DMF5IWB	MN	Janus kinase 2 (JAK-2)
DMF5IWB	MT	DTT
DMF5IWB	MA	Inhibitor
DMF5IWB	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMF5IWB	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMRHZF3	DI	DMRHZF3
DMRHZF3	DN	PMID27774822-Compound-Figure8Example5
DMRHZF3	MI	TTRMX3V
DMRHZF3	MN	Janus kinase 2 (JAK-2)
DMRHZF3	MT	DTT
DMRHZF3	MA	Inhibitor
DMRHZF3	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMRHZF3	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMRHZF3	DI	DMRHZF3
DMRHZF3	DN	PMID27774822-Compound-Figure8Example5
DMRHZF3	MI	TTT7PJU
DMRHZF3	MN	Janus kinase 3 (JAK-3)
DMRHZF3	MT	DTT
DMRHZF3	MA	Inhibitor
DMRHZF3	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMRHZF3	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMSHIT2	DI	DMSHIT2
DMSHIT2	DN	PMID27774822-Compound-Figure9Example15
DMSHIT2	MI	TTBYWP2
DMSHIT2	MN	TYK2 tyrosine kinase (TYK2)
DMSHIT2	MT	DTT
DMSHIT2	MA	Inhibitor
DMSHIT2	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMSHIT2	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMH1W8F	DI	DMH1W8F
DMH1W8F	DN	PMID27774824-Compound-Figure11Example1up
DMH1W8F	MI	TTKAWRQ
DMH1W8F	MN	JAK-STAT signaling pathway (JAK-STAT pathway)
DMH1W8F	MT	DTT
DMH1W8F	MA	Inhibitor
DMH1W8F	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMH1W8F	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMH1W8F	DI	DMH1W8F
DMH1W8F	DN	PMID27774824-Compound-Figure11Example1up
DMH1W8F	MI	TT6DM01
DMH1W8F	MN	Janus kinase 1 (JAK-1)
DMH1W8F	MT	DTT
DMH1W8F	MA	Inhibitor
DMH1W8F	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMH1W8F	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMH1W8F	DI	DMH1W8F
DMH1W8F	DN	PMID27774824-Compound-Figure11Example1up
DMH1W8F	MI	TTRMX3V
DMH1W8F	MN	Janus kinase 2 (JAK-2)
DMH1W8F	MT	DTT
DMH1W8F	MA	Inhibitor
DMH1W8F	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMH1W8F	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMH1W8F	DI	DMH1W8F
DMH1W8F	DN	PMID27774824-Compound-Figure11Example1up
DMH1W8F	MI	TTT7PJU
DMH1W8F	MN	Janus kinase 3 (JAK-3)
DMH1W8F	MT	DTT
DMH1W8F	MA	Inhibitor
DMH1W8F	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMH1W8F	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMH1W8F	DI	DMH1W8F
DMH1W8F	DN	PMID27774824-Compound-Figure11Example1up
DMH1W8F	MI	TTBYWP2
DMH1W8F	MN	TYK2 tyrosine kinase (TYK2)
DMH1W8F	MT	DTT
DMH1W8F	MA	Inhibitor
DMH1W8F	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMH1W8F	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMH1W8F	DI	DMH1W8F
DMH1W8F	DN	PMID27774824-Compound-Figure11Example1up
DMH1W8F	MI	TTJSQEF
DMH1W8F	MN	Tyrosine-protein kinase (PTK)
DMH1W8F	MT	DTT
DMH1W8F	MA	Inhibitor
DMH1W8F	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMH1W8F	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMAGKNJ	DI	DMAGKNJ
DMAGKNJ	DN	PMID27774824-Compound-Figure12Example1
DMAGKNJ	MI	TTT7PJU
DMAGKNJ	MN	Janus kinase 3 (JAK-3)
DMAGKNJ	MT	DTT
DMAGKNJ	MA	Inhibitor
DMAGKNJ	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMAGKNJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMAGKNJ	DI	DMAGKNJ
DMAGKNJ	DN	PMID27774824-Compound-Figure12Example1
DMAGKNJ	MI	TTGM6VW
DMAGKNJ	MN	Tyrosine-protein kinase BTK (ATK)
DMAGKNJ	MT	DTT
DMAGKNJ	MA	Inhibitor
DMAGKNJ	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMAGKNJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMYOSIA	DI	DMYOSIA
DMYOSIA	DN	PMID27774824-Compound-Figure12Example10
DMYOSIA	MI	TTT7PJU
DMYOSIA	MN	Janus kinase 3 (JAK-3)
DMYOSIA	MT	DTT
DMYOSIA	MA	Inhibitor
DMYOSIA	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMYOSIA	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMYOSIA	DI	DMYOSIA
DMYOSIA	DN	PMID27774824-Compound-Figure12Example10
DMYOSIA	MI	TTGM6VW
DMYOSIA	MN	Tyrosine-protein kinase BTK (ATK)
DMYOSIA	MT	DTT
DMYOSIA	MA	Inhibitor
DMYOSIA	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMYOSIA	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMNIZD7	DI	DMNIZD7
DMNIZD7	DN	PMID27774824-Compound-Figure12Example61
DMNIZD7	MI	TTT7PJU
DMNIZD7	MN	Janus kinase 3 (JAK-3)
DMNIZD7	MT	DTT
DMNIZD7	MA	Inhibitor
DMNIZD7	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMNIZD7	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMNIZD7	DI	DMNIZD7
DMNIZD7	DN	PMID27774824-Compound-Figure12Example61
DMNIZD7	MI	TTGM6VW
DMNIZD7	MN	Tyrosine-protein kinase BTK (ATK)
DMNIZD7	MT	DTT
DMNIZD7	MA	Inhibitor
DMNIZD7	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMNIZD7	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMQHYMJ	DI	DMQHYMJ
DMQHYMJ	DN	PMID27774824-Compound-Figure2Example4
DMQHYMJ	MI	TT6DM01
DMQHYMJ	MN	Janus kinase 1 (JAK-1)
DMQHYMJ	MT	DTT
DMQHYMJ	MA	Inhibitor
DMQHYMJ	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMQHYMJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMQHYMJ	DI	DMQHYMJ
DMQHYMJ	DN	PMID27774824-Compound-Figure2Example4
DMQHYMJ	MI	TTRMX3V
DMQHYMJ	MN	Janus kinase 2 (JAK-2)
DMQHYMJ	MT	DTT
DMQHYMJ	MA	Inhibitor
DMQHYMJ	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMQHYMJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMQHYMJ	DI	DMQHYMJ
DMQHYMJ	DN	PMID27774824-Compound-Figure2Example4
DMQHYMJ	MI	TTT7PJU
DMQHYMJ	MN	Janus kinase 3 (JAK-3)
DMQHYMJ	MT	DTT
DMQHYMJ	MA	Inhibitor
DMQHYMJ	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMQHYMJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMYZ6XQ	DI	DMYZ6XQ
DMYZ6XQ	DN	PMID27774824-Compound-Figure3Example18
DMYZ6XQ	MI	TT6DM01
DMYZ6XQ	MN	Janus kinase 1 (JAK-1)
DMYZ6XQ	MT	DTT
DMYZ6XQ	MA	Inhibitor
DMYZ6XQ	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMYZ6XQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMYZ6XQ	DI	DMYZ6XQ
DMYZ6XQ	DN	PMID27774824-Compound-Figure3Example18
DMYZ6XQ	MI	TTRMX3V
DMYZ6XQ	MN	Janus kinase 2 (JAK-2)
DMYZ6XQ	MT	DTT
DMYZ6XQ	MA	Inhibitor
DMYZ6XQ	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMYZ6XQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMYZ6XQ	DI	DMYZ6XQ
DMYZ6XQ	DN	PMID27774824-Compound-Figure3Example18
DMYZ6XQ	MI	TTT7PJU
DMYZ6XQ	MN	Janus kinase 3 (JAK-3)
DMYZ6XQ	MT	DTT
DMYZ6XQ	MA	Inhibitor
DMYZ6XQ	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMYZ6XQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMYZ6XQ	DI	DMYZ6XQ
DMYZ6XQ	DN	PMID27774824-Compound-Figure3Example18
DMYZ6XQ	MI	TTBYWP2
DMYZ6XQ	MN	TYK2 tyrosine kinase (TYK2)
DMYZ6XQ	MT	DTT
DMYZ6XQ	MA	Inhibitor
DMYZ6XQ	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMYZ6XQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMXDOGK	DI	DMXDOGK
DMXDOGK	DN	PMID27774824-Compound-Figure3Example7
DMXDOGK	MI	TTT7PJU
DMXDOGK	MN	Janus kinase 3 (JAK-3)
DMXDOGK	MT	DTT
DMXDOGK	MA	Inhibitor
DMXDOGK	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMXDOGK	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMXDOGK	DI	DMXDOGK
DMXDOGK	DN	PMID27774824-Compound-Figure3Example7
DMXDOGK	MI	TT3C80U
DMXDOGK	MN	T-cell-specific kinase (ITK)
DMXDOGK	MT	DTT
DMXDOGK	MA	Inhibitor
DMXDOGK	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMXDOGK	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMDZKXC	DI	DMDZKXC
DMDZKXC	DN	PMID27774824-Compound-Figure5Example13
DMDZKXC	MI	TTT7PJU
DMDZKXC	MN	Janus kinase 3 (JAK-3)
DMDZKXC	MT	DTT
DMDZKXC	MA	Inhibitor
DMDZKXC	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMDZKXC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DM1CM7S	DI	DM1CM7S
DM1CM7S	DN	PMID27774824-Compound-Figure6Example12
DM1CM7S	MI	TT6DM01
DM1CM7S	MN	Janus kinase 1 (JAK-1)
DM1CM7S	MT	DTT
DM1CM7S	MA	Inhibitor
DM1CM7S	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DM1CM7S	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DM1CM7S	DI	DM1CM7S
DM1CM7S	DN	PMID27774824-Compound-Figure6Example12
DM1CM7S	MI	TTRMX3V
DM1CM7S	MN	Janus kinase 2 (JAK-2)
DM1CM7S	MT	DTT
DM1CM7S	MA	Inhibitor
DM1CM7S	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DM1CM7S	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DM1CM7S	DI	DM1CM7S
DM1CM7S	DN	PMID27774824-Compound-Figure6Example12
DM1CM7S	MI	TTT7PJU
DM1CM7S	MN	Janus kinase 3 (JAK-3)
DM1CM7S	MT	DTT
DM1CM7S	MA	Inhibitor
DM1CM7S	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DM1CM7S	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DM1CM7S	DI	DM1CM7S
DM1CM7S	DN	PMID27774824-Compound-Figure6Example12
DM1CM7S	MI	TTBYWP2
DM1CM7S	MN	TYK2 tyrosine kinase (TYK2)
DM1CM7S	MT	DTT
DM1CM7S	MA	Inhibitor
DM1CM7S	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DM1CM7S	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMB18V5	DI	DMB18V5
DMB18V5	DN	PMID27774824-Compound-Figure6Example6
DMB18V5	MI	TT6DM01
DMB18V5	MN	Janus kinase 1 (JAK-1)
DMB18V5	MT	DTT
DMB18V5	MA	Inhibitor
DMB18V5	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMB18V5	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMB18V5	DI	DMB18V5
DMB18V5	DN	PMID27774824-Compound-Figure6Example6
DMB18V5	MI	TTRMX3V
DMB18V5	MN	Janus kinase 2 (JAK-2)
DMB18V5	MT	DTT
DMB18V5	MA	Inhibitor
DMB18V5	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMB18V5	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMT85AH	DI	DMT85AH
DMT85AH	DN	PMID27774824-Compound-Figure7Example10
DMT85AH	MI	TT6DM01
DMT85AH	MN	Janus kinase 1 (JAK-1)
DMT85AH	MT	DTT
DMT85AH	MA	Inhibitor
DMT85AH	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMT85AH	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMT85AH	DI	DMT85AH
DMT85AH	DN	PMID27774824-Compound-Figure7Example10
DMT85AH	MI	TTRMX3V
DMT85AH	MN	Janus kinase 2 (JAK-2)
DMT85AH	MT	DTT
DMT85AH	MA	Inhibitor
DMT85AH	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMT85AH	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DM6OCSJ	DI	DM6OCSJ
DM6OCSJ	DN	PMID27774824-Compound-Figure8Example22
DM6OCSJ	MI	TTRMX3V
DM6OCSJ	MN	Janus kinase 2 (JAK-2)
DM6OCSJ	MT	DTT
DM6OCSJ	MA	Inhibitor
DM6OCSJ	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DM6OCSJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DM1VOPH	DI	DM1VOPH
DM1VOPH	DN	PMID27774824-Compound-Figure8Example99
DM1VOPH	MI	TTRMX3V
DM1VOPH	MN	Janus kinase 2 (JAK-2)
DM1VOPH	MT	DTT
DM1VOPH	MA	Inhibitor
DM1VOPH	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DM1VOPH	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMXAV42	DI	DMXAV42
DMXAV42	DN	PMID27774824-Compound-Figure9Example2down
DMXAV42	MI	TTZ04AF
DMXAV42	MN	EGFR T790M mutant (EGFR T790M)
DMXAV42	MT	DTT
DMXAV42	MA	Inhibitor
DMXAV42	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMXAV42	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMXAV42	DI	DMXAV42
DMXAV42	DN	PMID27774824-Compound-Figure9Example2down
DMXAV42	MI	TT6DM01
DMXAV42	MN	Janus kinase 1 (JAK-1)
DMXAV42	MT	DTT
DMXAV42	MA	Inhibitor
DMXAV42	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMXAV42	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMXAV42	DI	DMXAV42
DMXAV42	DN	PMID27774824-Compound-Figure9Example2down
DMXAV42	MI	TTRMX3V
DMXAV42	MN	Janus kinase 2 (JAK-2)
DMXAV42	MT	DTT
DMXAV42	MA	Inhibitor
DMXAV42	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMXAV42	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMXAV42	DI	DMXAV42
DMXAV42	DN	PMID27774824-Compound-Figure9Example2down
DMXAV42	MI	TTT7PJU
DMXAV42	MN	Janus kinase 3 (JAK-3)
DMXAV42	MT	DTT
DMXAV42	MA	Inhibitor
DMXAV42	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMXAV42	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMXAV42	DI	DMXAV42
DMXAV42	DN	PMID27774824-Compound-Figure9Example2down
DMXAV42	MI	TTBYWP2
DMXAV42	MN	TYK2 tyrosine kinase (TYK2)
DMXAV42	MT	DTT
DMXAV42	MA	Inhibitor
DMXAV42	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMXAV42	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMXAV42	DI	DMXAV42
DMXAV42	DN	PMID27774824-Compound-Figure9Example2down
DMXAV42	MI	TT3PJMV
DMXAV42	MN	Tyrosine-protein kinase ABL1 (ABL)
DMXAV42	MT	DTT
DMXAV42	MA	Inhibitor
DMXAV42	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMXAV42	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DME3TMS	DI	DME3TMS
DME3TMS	DN	PMID27774824-Compound-Figure9Example2up
DME3TMS	MI	TT6DM01
DME3TMS	MN	Janus kinase 1 (JAK-1)
DME3TMS	MT	DTT
DME3TMS	MA	Inhibitor
DME3TMS	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DME3TMS	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DME3TMS	DI	DME3TMS
DME3TMS	DN	PMID27774824-Compound-Figure9Example2up
DME3TMS	MI	TTRMX3V
DME3TMS	MN	Janus kinase 2 (JAK-2)
DME3TMS	MT	DTT
DME3TMS	MA	Inhibitor
DME3TMS	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DME3TMS	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DME3TMS	DI	DME3TMS
DME3TMS	DN	PMID27774824-Compound-Figure9Example2up
DME3TMS	MI	TTT7PJU
DME3TMS	MN	Janus kinase 3 (JAK-3)
DME3TMS	MT	DTT
DME3TMS	MA	Inhibitor
DME3TMS	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DME3TMS	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DME3TMS	DI	DME3TMS
DME3TMS	DN	PMID27774824-Compound-Figure9Example2up
DME3TMS	MI	TTBYWP2
DME3TMS	MN	TYK2 tyrosine kinase (TYK2)
DME3TMS	MT	DTT
DME3TMS	MA	Inhibitor
DME3TMS	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DME3TMS	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DME3TMS	DI	DME3TMS
DME3TMS	DN	PMID27774824-Compound-Figure9Example2up
DME3TMS	MI	TT3PJMV
DME3TMS	MN	Tyrosine-protein kinase ABL1 (ABL)
DME3TMS	MT	DTT
DME3TMS	MA	Inhibitor
DME3TMS	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DME3TMS	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMHPK31	DI	DMHPK31
DMHPK31	DN	PMID27788040-Compound-5
DMHPK31	MI	TTV1C0Z
DMHPK31	MN	Neuropeptide S receptor (NPSR)
DMHPK31	MT	DTT
DMHPK31	MA	Antagonist
DMHPK31	RN	Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362.
DMHPK31	RU	https://www.ncbi.nlm.nih.gov/pubmed/27788040

DMW3X1I	DI	DMW3X1I
DMW3X1I	DN	PMID27788040-Compound-5a
DMW3X1I	MI	TTV1C0Z
DMW3X1I	MN	Neuropeptide S receptor (NPSR)
DMW3X1I	MT	DTT
DMW3X1I	MA	Antagonist
DMW3X1I	RN	Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362.
DMW3X1I	RU	https://www.ncbi.nlm.nih.gov/pubmed/27788040

DMPQKXR	DI	DMPQKXR
DMPQKXR	DN	PMID27788040-Compound-5b
DMPQKXR	MI	TTV1C0Z
DMPQKXR	MN	Neuropeptide S receptor (NPSR)
DMPQKXR	MT	DTT
DMPQKXR	MA	Antagonist
DMPQKXR	RN	Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362.
DMPQKXR	RU	https://www.ncbi.nlm.nih.gov/pubmed/27788040

DMK72JS	DI	DMK72JS
DMK72JS	DN	PMID27788040-Compound-5c
DMK72JS	MI	TTV1C0Z
DMK72JS	MN	Neuropeptide S receptor (NPSR)
DMK72JS	MT	DTT
DMK72JS	MA	Antagonist
DMK72JS	RN	Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362.
DMK72JS	RU	https://www.ncbi.nlm.nih.gov/pubmed/27788040

DMHX8OF	DI	DMHX8OF
DMHX8OF	DN	PMID27788040-Compound-6
DMHX8OF	MI	TTV1C0Z
DMHX8OF	MN	Neuropeptide S receptor (NPSR)
DMHX8OF	MT	DTT
DMHX8OF	MA	Antagonist
DMHX8OF	RN	Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362.
DMHX8OF	RU	https://www.ncbi.nlm.nih.gov/pubmed/27788040

DM4QA6X	DI	DM4QA6X
DM4QA6X	DN	PMID27788040-Compound-6a
DM4QA6X	MI	TTV1C0Z
DM4QA6X	MN	Neuropeptide S receptor (NPSR)
DM4QA6X	MT	DTT
DM4QA6X	MA	Antagonist
DM4QA6X	RN	Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362.
DM4QA6X	RU	https://www.ncbi.nlm.nih.gov/pubmed/27788040

DMD3U96	DI	DMD3U96
DMD3U96	DN	PMID27788040-Compound-6b
DMD3U96	MI	TTV1C0Z
DMD3U96	MN	Neuropeptide S receptor (NPSR)
DMD3U96	MT	DTT
DMD3U96	MA	Antagonist
DMD3U96	RN	Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362.
DMD3U96	RU	https://www.ncbi.nlm.nih.gov/pubmed/27788040

DMNRU35	DI	DMNRU35
DMNRU35	DN	PMID27788040-Compound-6c
DMNRU35	MI	TTV1C0Z
DMNRU35	MN	Neuropeptide S receptor (NPSR)
DMNRU35	MT	DTT
DMNRU35	MA	Antagonist
DMNRU35	RN	Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362.
DMNRU35	RU	https://www.ncbi.nlm.nih.gov/pubmed/27788040

DM3G21F	DI	DM3G21F
DM3G21F	DN	PMID27828716-Compound-15
DM3G21F	MI	TTRZQE3
DM3G21F	MN	Glycogen synthase kinase-3 alpha (GSK-3A)
DM3G21F	MT	DTT
DM3G21F	MA	Inhibitor
DM3G21F	RN	Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
DM3G21F	RU	https://www.ncbi.nlm.nih.gov/pubmed/27828716

DM9VXY7	DI	DM9VXY7
DM9VXY7	DN	PMID27828716-Compound-16
DM9VXY7	MI	TTRZQE3
DM9VXY7	MN	Glycogen synthase kinase-3 alpha (GSK-3A)
DM9VXY7	MT	DTT
DM9VXY7	MA	Inhibitor
DM9VXY7	RN	Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
DM9VXY7	RU	https://www.ncbi.nlm.nih.gov/pubmed/27828716

DMR7V9E	DI	DMR7V9E
DMR7V9E	DN	PMID27828716-Compound-17
DMR7V9E	MI	TTRZQE3
DMR7V9E	MN	Glycogen synthase kinase-3 alpha (GSK-3A)
DMR7V9E	MT	DTT
DMR7V9E	MA	Inhibitor
DMR7V9E	RN	Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
DMR7V9E	RU	https://www.ncbi.nlm.nih.gov/pubmed/27828716

DMNR6KL	DI	DMNR6KL
DMNR6KL	DN	PMID27828716-Compound-18
DMNR6KL	MI	TTRZQE3
DMNR6KL	MN	Glycogen synthase kinase-3 alpha (GSK-3A)
DMNR6KL	MT	DTT
DMNR6KL	MA	Inhibitor
DMNR6KL	RN	Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
DMNR6KL	RU	https://www.ncbi.nlm.nih.gov/pubmed/27828716

DM8V7QH	DI	DM8V7QH
DM8V7QH	DN	PMID27828716-Compound-19
DM8V7QH	MI	TTRZQE3
DM8V7QH	MN	Glycogen synthase kinase-3 alpha (GSK-3A)
DM8V7QH	MT	DTT
DM8V7QH	MA	Inhibitor
DM8V7QH	RN	Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
DM8V7QH	RU	https://www.ncbi.nlm.nih.gov/pubmed/27828716

DMDA3PN	DI	DMDA3PN
DMDA3PN	DN	PMID27828716-Compound-20
DMDA3PN	MI	TTRZQE3
DMDA3PN	MN	Glycogen synthase kinase-3 alpha (GSK-3A)
DMDA3PN	MT	DTT
DMDA3PN	MA	Inhibitor
DMDA3PN	RN	Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
DMDA3PN	RU	https://www.ncbi.nlm.nih.gov/pubmed/27828716

DMO1NAR	DI	DMO1NAR
DMO1NAR	DN	PMID27828716-Compound-21
DMO1NAR	MI	TTRZQE3
DMO1NAR	MN	Glycogen synthase kinase-3 alpha (GSK-3A)
DMO1NAR	MT	DTT
DMO1NAR	MA	Inhibitor
DMO1NAR	RN	Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
DMO1NAR	RU	https://www.ncbi.nlm.nih.gov/pubmed/27828716

DMUM5L6	DI	DMUM5L6
DMUM5L6	DN	PMID27828716-Compound-BIO-acetoxime
DMUM5L6	MI	TTRZQE3
DMUM5L6	MN	Glycogen synthase kinase-3 alpha (GSK-3A)
DMUM5L6	MT	DTT
DMUM5L6	MA	Inhibitor
DMUM5L6	RN	Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
DMUM5L6	RU	https://www.ncbi.nlm.nih.gov/pubmed/27828716

DMY9WHZ	DI	DMY9WHZ
DMY9WHZ	DN	PMID27841036-Compound-23
DMY9WHZ	MI	TTEBCY8
DMY9WHZ	MN	Poly [ADP-ribose] polymerase (PARP)
DMY9WHZ	MT	DTT
DMY9WHZ	MA	Inhibitor
DMY9WHZ	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DMY9WHZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DM9VMJ3	DI	DM9VMJ3
DM9VMJ3	DN	PMID27841036-Compound-24
DM9VMJ3	MI	TTEBCY8
DM9VMJ3	MN	Poly [ADP-ribose] polymerase (PARP)
DM9VMJ3	MT	DTT
DM9VMJ3	MA	Inhibitor
DM9VMJ3	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DM9VMJ3	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DMGXI95	DI	DMGXI95
DMGXI95	DN	PMID27841036-Compound-33
DMGXI95	MI	TTVDSZ0
DMGXI95	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMGXI95	MT	DTT
DMGXI95	MA	Inhibitor
DMGXI95	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DMGXI95	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DMHIV2L	DI	DMHIV2L
DMHIV2L	DN	PMID27841036-Compound-36
DMHIV2L	MI	TTEBCY8
DMHIV2L	MN	Poly [ADP-ribose] polymerase (PARP)
DMHIV2L	MT	DTT
DMHIV2L	MA	Inhibitor
DMHIV2L	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DMHIV2L	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DM1KJAQ	DI	DM1KJAQ
DM1KJAQ	DN	PMID27841036-Compound-38
DM1KJAQ	MI	TTEBCY8
DM1KJAQ	MN	Poly [ADP-ribose] polymerase (PARP)
DM1KJAQ	MT	DTT
DM1KJAQ	MA	Inhibitor
DM1KJAQ	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DM1KJAQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DM3FAIS	DI	DM3FAIS
DM3FAIS	DN	PMID27841036-Compound-V
DM3FAIS	MI	TTEBCY8
DM3FAIS	MN	Poly [ADP-ribose] polymerase (PARP)
DM3FAIS	MT	DTT
DM3FAIS	MA	Inhibitor
DM3FAIS	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DM3FAIS	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DM1HPY7	DI	DM1HPY7
DM1HPY7	DN	PMID27841036-Compound-XI
DM1HPY7	MI	TTEBCY8
DM1HPY7	MN	Poly [ADP-ribose] polymerase (PARP)
DM1HPY7	MT	DTT
DM1HPY7	MA	Inhibitor
DM1HPY7	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DM1HPY7	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DM9K5BZ	DI	DM9K5BZ
DM9K5BZ	DN	PMID27841036-Compound-XVII
DM9K5BZ	MI	TTEBCY8
DM9K5BZ	MN	Poly [ADP-ribose] polymerase (PARP)
DM9K5BZ	MT	DTT
DM9K5BZ	MA	Inhibitor
DM9K5BZ	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DM9K5BZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DME2IHD	DI	DME2IHD
DME2IHD	DN	PMID27841045-Compound-129
DME2IHD	MI	TT7RJY8
DME2IHD	MN	Xanthine dehydrogenase/oxidase (XDH)
DME2IHD	MT	DTT
DME2IHD	MA	Inhibitor
DME2IHD	RN	An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
DME2IHD	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841045

DM2AVEG	DI	DM2AVEG
DM2AVEG	DN	PMID27841045-Compound-130
DM2AVEG	MI	TT7RJY8
DM2AVEG	MN	Xanthine dehydrogenase/oxidase (XDH)
DM2AVEG	MT	DTT
DM2AVEG	MA	Inhibitor
DM2AVEG	RN	An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
DM2AVEG	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841045

DMIKTVL	DI	DMIKTVL
DMIKTVL	DN	PMID27841045-Compound-131
DMIKTVL	MI	TT7RJY8
DMIKTVL	MN	Xanthine dehydrogenase/oxidase (XDH)
DMIKTVL	MT	DTT
DMIKTVL	MA	Inhibitor
DMIKTVL	RN	An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
DMIKTVL	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841045

DMCQB93	DI	DMCQB93
DMCQB93	DN	PMID27841045-Compound-132
DMCQB93	MI	TT7RJY8
DMCQB93	MN	Xanthine dehydrogenase/oxidase (XDH)
DMCQB93	MT	DTT
DMCQB93	MA	Inhibitor
DMCQB93	RN	An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
DMCQB93	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841045

DMXPO6T	DI	DMXPO6T
DMXPO6T	DN	PMID27841045-Compound-133
DMXPO6T	MI	TT7RJY8
DMXPO6T	MN	Xanthine dehydrogenase/oxidase (XDH)
DMXPO6T	MT	DTT
DMXPO6T	MA	Inhibitor
DMXPO6T	RN	An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
DMXPO6T	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841045

DMY3U7N	DI	DMY3U7N
DMY3U7N	DN	PMID27841045-Compound-134
DMY3U7N	MI	TT7RJY8
DMY3U7N	MN	Xanthine dehydrogenase/oxidase (XDH)
DMY3U7N	MT	DTT
DMY3U7N	MA	Inhibitor
DMY3U7N	RN	An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
DMY3U7N	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841045

DMVR9TJ	DI	DMVR9TJ
DMVR9TJ	DN	PMID27841045-Compound-135
DMVR9TJ	MI	TT7RJY8
DMVR9TJ	MN	Xanthine dehydrogenase/oxidase (XDH)
DMVR9TJ	MT	DTT
DMVR9TJ	MA	Inhibitor
DMVR9TJ	RN	An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
DMVR9TJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841045

DM0KR8E	DI	DM0KR8E
DM0KR8E	DN	PMID27841045-Compound-136
DM0KR8E	MI	TT7RJY8
DM0KR8E	MN	Xanthine dehydrogenase/oxidase (XDH)
DM0KR8E	MT	DTT
DM0KR8E	MA	Inhibitor
DM0KR8E	RN	An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
DM0KR8E	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841045

DML25WY	DI	DML25WY
DML25WY	DN	PMID27841045-Compound-137
DML25WY	MI	TT7RJY8
DML25WY	MN	Xanthine dehydrogenase/oxidase (XDH)
DML25WY	MT	DTT
DML25WY	MA	Inhibitor
DML25WY	RN	An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
DML25WY	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841045

DMR7MBY	DI	DMR7MBY
DMR7MBY	DN	PMID27841045-Compound-143
DMR7MBY	MI	TT7RJY8
DMR7MBY	MN	Xanthine dehydrogenase/oxidase (XDH)
DMR7MBY	MT	DTT
DMR7MBY	MA	Inhibitor
DMR7MBY	RN	An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
DMR7MBY	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841045

DMR43JE	DI	DMR43JE
DMR43JE	DN	PMID27841045-Compound-144
DMR43JE	MI	TT7RJY8
DMR43JE	MN	Xanthine dehydrogenase/oxidase (XDH)
DMR43JE	MT	DTT
DMR43JE	MA	Inhibitor
DMR43JE	RN	An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
DMR43JE	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841045

DMAJRP1	DI	DMAJRP1
DMAJRP1	DN	PMID27841045-Compound-145
DMAJRP1	MI	TT7RJY8
DMAJRP1	MN	Xanthine dehydrogenase/oxidase (XDH)
DMAJRP1	MT	DTT
DMAJRP1	MA	Inhibitor
DMAJRP1	RN	An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
DMAJRP1	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841045

DM675SX	DI	DM675SX
DM675SX	DN	PMID27841045-Compound-155
DM675SX	MI	TT7RJY8
DM675SX	MN	Xanthine dehydrogenase/oxidase (XDH)
DM675SX	MT	DTT
DM675SX	MA	Inhibitor
DM675SX	RN	An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
DM675SX	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841045

DML4AVX	DI	DML4AVX
DML4AVX	DN	PMID27841045-Compound-156
DML4AVX	MI	TT7RJY8
DML4AVX	MN	Xanthine dehydrogenase/oxidase (XDH)
DML4AVX	MT	DTT
DML4AVX	MA	Inhibitor
DML4AVX	RN	An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
DML4AVX	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841045

DM7EXNI	DI	DM7EXNI
DM7EXNI	DN	PMID27841045-Compound-157
DM7EXNI	MI	TT7RJY8
DM7EXNI	MN	Xanthine dehydrogenase/oxidase (XDH)
DM7EXNI	MT	DTT
DM7EXNI	MA	Inhibitor
DM7EXNI	RN	An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
DM7EXNI	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841045

DMBNHI7	DI	DMBNHI7
DMBNHI7	DN	PMID27967267-Compound-12
DMBNHI7	MI	TT1RS9F
DMBNHI7	MN	Acetylcholinesterase (AChE)
DMBNHI7	MT	DTT
DMBNHI7	MA	Inhibitor
DMBNHI7	RN	Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476.
DMBNHI7	RU	https://www.ncbi.nlm.nih.gov/pubmed/27967267

DMY5UB8	DI	DMY5UB8
DMY5UB8	DN	PMID27967267-Compound-13
DMY5UB8	MI	TT1RS9F
DMY5UB8	MN	Acetylcholinesterase (AChE)
DMY5UB8	MT	DTT
DMY5UB8	MA	Inhibitor
DMY5UB8	RN	Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476.
DMY5UB8	RU	https://www.ncbi.nlm.nih.gov/pubmed/27967267

DMGI5Z8	DI	DMGI5Z8
DMGI5Z8	DN	PMID27967267-Compound-14
DMGI5Z8	MI	TT1RS9F
DMGI5Z8	MN	Acetylcholinesterase (AChE)
DMGI5Z8	MT	DTT
DMGI5Z8	MA	Inhibitor
DMGI5Z8	RN	Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476.
DMGI5Z8	RU	https://www.ncbi.nlm.nih.gov/pubmed/27967267

DMEW46T	DI	DMEW46T
DMEW46T	DN	PMID27967267-Compound-15
DMEW46T	MI	TT1RS9F
DMEW46T	MN	Acetylcholinesterase (AChE)
DMEW46T	MT	DTT
DMEW46T	MA	Inhibitor
DMEW46T	RN	Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476.
DMEW46T	RU	https://www.ncbi.nlm.nih.gov/pubmed/27967267

DMO0QME	DI	DMO0QME
DMO0QME	DN	PMID27967267-Compound-27
DMO0QME	MI	TT1RS9F
DMO0QME	MN	Acetylcholinesterase (AChE)
DMO0QME	MT	DTT
DMO0QME	RN	Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476.
DMO0QME	RU	https://www.ncbi.nlm.nih.gov/pubmed/27967267

DMVM31E	DI	DMVM31E
DMVM31E	DN	PMID27967267-Compound-28
DMVM31E	MI	TT1RS9F
DMVM31E	MN	Acetylcholinesterase (AChE)
DMVM31E	MT	DTT
DMVM31E	RN	Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476.
DMVM31E	RU	https://www.ncbi.nlm.nih.gov/pubmed/27967267

DM7JIF0	DI	DM7JIF0
DM7JIF0	DN	PMID27967267-Compound-3
DM7JIF0	MI	TT1RS9F
DM7JIF0	MN	Acetylcholinesterase (AChE)
DM7JIF0	MT	DTT
DM7JIF0	MA	Inhibitor
DM7JIF0	RN	Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476.
DM7JIF0	RU	https://www.ncbi.nlm.nih.gov/pubmed/27967267

DM7CWZ4	DI	DM7CWZ4
DM7CWZ4	DN	PMID27967267-Compound-36
DM7CWZ4	MI	TT1RS9F
DM7CWZ4	MN	Acetylcholinesterase (AChE)
DM7CWZ4	MT	DTT
DM7CWZ4	RN	Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476.
DM7CWZ4	RU	https://www.ncbi.nlm.nih.gov/pubmed/27967267

DMQOAJP	DI	DMQOAJP
DMQOAJP	DN	PMID27967267-Compound-39
DMQOAJP	MI	TT1RS9F
DMQOAJP	MN	Acetylcholinesterase (AChE)
DMQOAJP	MT	DTT
DMQOAJP	MA	Inhibitor
DMQOAJP	RN	Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476.
DMQOAJP	RU	https://www.ncbi.nlm.nih.gov/pubmed/27967267

DM68KPS	DI	DM68KPS
DM68KPS	DN	PMID27967267-Compound-42
DM68KPS	MI	TT1RS9F
DM68KPS	MN	Acetylcholinesterase (AChE)
DM68KPS	MT	DTT
DM68KPS	MA	Inhibitor
DM68KPS	RN	Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476.
DM68KPS	RU	https://www.ncbi.nlm.nih.gov/pubmed/27967267

DM12X0P	DI	DM12X0P
DM12X0P	DN	PMID27967267-Compound-43
DM12X0P	MI	TT1RS9F
DM12X0P	MN	Acetylcholinesterase (AChE)
DM12X0P	MT	DTT
DM12X0P	MA	Inhibitor
DM12X0P	RN	Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476.
DM12X0P	RU	https://www.ncbi.nlm.nih.gov/pubmed/27967267

DMEXATH	DI	DMEXATH
DMEXATH	DN	PMID27967267-Compound-47
DMEXATH	MI	TT1RS9F
DMEXATH	MN	Acetylcholinesterase (AChE)
DMEXATH	MT	DTT
DMEXATH	MA	Reactivator
DMEXATH	RN	Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476.
DMEXATH	RU	https://www.ncbi.nlm.nih.gov/pubmed/27967267

DM81A50	DI	DM81A50
DM81A50	DN	PMID27967267-Compound-48
DM81A50	MI	TT1RS9F
DM81A50	MN	Acetylcholinesterase (AChE)
DM81A50	MT	DTT
DM81A50	MA	Reactivator
DM81A50	RN	Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476.
DM81A50	RU	https://www.ncbi.nlm.nih.gov/pubmed/27967267

DMQTRFX	DI	DMQTRFX
DMQTRFX	DN	PMID27967267-Compound-49
DMQTRFX	MI	TT1RS9F
DMQTRFX	MN	Acetylcholinesterase (AChE)
DMQTRFX	MT	DTT
DMQTRFX	MA	Reactivator
DMQTRFX	RN	Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476.
DMQTRFX	RU	https://www.ncbi.nlm.nih.gov/pubmed/27967267

DMNH891	DI	DMNH891
DMNH891	DN	PMID27967267-Compound-51
DMNH891	MI	TT1RS9F
DMNH891	MN	Acetylcholinesterase (AChE)
DMNH891	MT	DTT
DMNH891	MA	Reactivator
DMNH891	RN	Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476.
DMNH891	RU	https://www.ncbi.nlm.nih.gov/pubmed/27967267

DMRH7ZY	DI	DMRH7ZY
DMRH7ZY	DN	PMID27967267-Compound-52
DMRH7ZY	MI	TT1RS9F
DMRH7ZY	MN	Acetylcholinesterase (AChE)
DMRH7ZY	MT	DTT
DMRH7ZY	MA	Reactivator
DMRH7ZY	RN	Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476.
DMRH7ZY	RU	https://www.ncbi.nlm.nih.gov/pubmed/27967267

DMAN71J	DI	DMAN71J
DMAN71J	DN	PMID27967267-Compound-7
DMAN71J	MI	TT1RS9F
DMAN71J	MN	Acetylcholinesterase (AChE)
DMAN71J	MT	DTT
DMAN71J	MA	Inhibitor
DMAN71J	RN	Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476.
DMAN71J	RU	https://www.ncbi.nlm.nih.gov/pubmed/27967267

DM7TLDW	DI	DM7TLDW
DM7TLDW	DN	PMID27967267-Compound-neostenine
DM7TLDW	MI	TT1RS9F
DM7TLDW	MN	Acetylcholinesterase (AChE)
DM7TLDW	MT	DTT
DM7TLDW	MA	Inhibitor
DM7TLDW	RN	Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476.
DM7TLDW	RU	https://www.ncbi.nlm.nih.gov/pubmed/27967267

DM3CPJQ	DI	DM3CPJQ
DM3CPJQ	DN	PMID27967267-Compound-neotuberostemonine
DM3CPJQ	MI	TT1RS9F
DM3CPJQ	MN	Acetylcholinesterase (AChE)
DM3CPJQ	MT	DTT
DM3CPJQ	MA	Inhibitor
DM3CPJQ	RN	Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476.
DM3CPJQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27967267

DM2K54D	DI	DM2K54D
DM2K54D	DN	PMID27967267-Compound-stenine
DM2K54D	MI	TT1RS9F
DM2K54D	MN	Acetylcholinesterase (AChE)
DM2K54D	MT	DTT
DM2K54D	MA	Inhibitor
DM2K54D	RN	Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476.
DM2K54D	RU	https://www.ncbi.nlm.nih.gov/pubmed/27967267

DMTI5E3	DI	DMTI5E3
DMTI5E3	DN	PMID27977313-Compound-17
DMTI5E3	MI	TTR7UJ3
DMTI5E3	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMTI5E3	MT	DTT
DMTI5E3	MA	Inhibitor
DMTI5E3	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMTI5E3	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DMIA3GH	DI	DMIA3GH
DMIA3GH	DN	PMID27977313-Compound-18
DMIA3GH	MI	TTR7UJ3
DMIA3GH	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMIA3GH	MT	DTT
DMIA3GH	MA	Inhibitor
DMIA3GH	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMIA3GH	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DM5JSI3	DI	DM5JSI3
DM5JSI3	DN	PMID27977313-Compound-19
DM5JSI3	MI	TTR7UJ3
DM5JSI3	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DM5JSI3	MT	DTT
DM5JSI3	MA	Inhibitor
DM5JSI3	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DM5JSI3	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DMVYO09	DI	DMVYO09
DMVYO09	DN	PMID27977313-Compound-27
DMVYO09	MI	TTR7UJ3
DMVYO09	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMVYO09	MT	DTT
DMVYO09	MA	Inhibitor
DMVYO09	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMVYO09	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DM67NBI	DI	DM67NBI
DM67NBI	DN	PMID27977313-Compound-28
DM67NBI	MI	TTR7UJ3
DM67NBI	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DM67NBI	MT	DTT
DM67NBI	MA	Inhibitor
DM67NBI	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DM67NBI	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DMIF7KG	DI	DMIF7KG
DMIF7KG	DN	PMID27977313-Compound-29
DMIF7KG	MI	TTR7UJ3
DMIF7KG	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMIF7KG	MT	DTT
DMIF7KG	MA	Inhibitor
DMIF7KG	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMIF7KG	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DMWHAKG	DI	DMWHAKG
DMWHAKG	DN	PMID27977313-Compound-30
DMWHAKG	MI	TTR7UJ3
DMWHAKG	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMWHAKG	MT	DTT
DMWHAKG	MA	Inhibitor
DMWHAKG	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMWHAKG	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DMBL5J9	DI	DMBL5J9
DMBL5J9	DN	PMID27977313-Compound-31
DMBL5J9	MI	TTR7UJ3
DMBL5J9	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMBL5J9	MT	DTT
DMBL5J9	MA	Inhibitor
DMBL5J9	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMBL5J9	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DMZNM52	DI	DMZNM52
DMZNM52	DN	PMID27977313-Compound-32
DMZNM52	MI	TTR7UJ3
DMZNM52	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMZNM52	MT	DTT
DMZNM52	MA	Inhibitor
DMZNM52	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMZNM52	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DM0LB21	DI	DM0LB21
DM0LB21	DN	PMID27977313-Compound-39
DM0LB21	MI	TTR7UJ3
DM0LB21	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DM0LB21	MT	DTT
DM0LB21	MA	Inhibitor
DM0LB21	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DM0LB21	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DML4C6D	DI	DML4C6D
DML4C6D	DN	PMID27977313-Compound-42
DML4C6D	MI	TTR7UJ3
DML4C6D	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DML4C6D	MT	DTT
DML4C6D	MA	Inhibitor
DML4C6D	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DML4C6D	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DMTFLVN	DI	DMTFLVN
DMTFLVN	DN	PMID27977313-Compound-43
DMTFLVN	MI	TTR7UJ3
DMTFLVN	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMTFLVN	MT	DTT
DMTFLVN	MA	Inhibitor
DMTFLVN	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMTFLVN	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DM9S2UP	DI	DM9S2UP
DM9S2UP	DN	PMID27977313-Compound-44
DM9S2UP	MI	TTR7UJ3
DM9S2UP	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DM9S2UP	MT	DTT
DM9S2UP	MA	Inhibitor
DM9S2UP	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DM9S2UP	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DMSZ0GE	DI	DMSZ0GE
DMSZ0GE	DN	PMID27977313-Compound-45
DMSZ0GE	MI	TTR7UJ3
DMSZ0GE	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMSZ0GE	MT	DTT
DMSZ0GE	MA	Inhibitor
DMSZ0GE	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMSZ0GE	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DMGF04T	DI	DMGF04T
DMGF04T	DN	PMID27977313-Compound-46
DMGF04T	MI	TTR7UJ3
DMGF04T	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMGF04T	MT	DTT
DMGF04T	MA	Inhibitor
DMGF04T	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMGF04T	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DMI61KF	DI	DMI61KF
DMI61KF	DN	PMID27977313-Compound-47
DMI61KF	MI	TTR7UJ3
DMI61KF	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMI61KF	MT	DTT
DMI61KF	MA	Inhibitor
DMI61KF	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMI61KF	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DM4EFRL	DI	DM4EFRL
DM4EFRL	DN	PMID27977313-Compound-48
DM4EFRL	MI	TTR7UJ3
DM4EFRL	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DM4EFRL	MT	DTT
DM4EFRL	MA	Inhibitor
DM4EFRL	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DM4EFRL	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DMTUNW4	DI	DMTUNW4
DMTUNW4	DN	PMID27977313-Compound-5
DMTUNW4	MI	TTR7UJ3
DMTUNW4	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMTUNW4	MT	DTT
DMTUNW4	MA	Inhibitor
DMTUNW4	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMTUNW4	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DMCUAO9	DI	DMCUAO9
DMCUAO9	DN	PMID27977313-Compound-6
DMCUAO9	MI	TTR7UJ3
DMCUAO9	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMCUAO9	MT	DTT
DMCUAO9	MA	Inhibitor
DMCUAO9	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMCUAO9	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DMWIMN9	DI	DMWIMN9
DMWIMN9	DN	PMID27977313-Compound-7
DMWIMN9	MI	TTR7UJ3
DMWIMN9	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMWIMN9	MT	DTT
DMWIMN9	MA	Inhibitor
DMWIMN9	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMWIMN9	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DMYFV3D	DI	DMYFV3D
DMYFV3D	DN	PMID27977313-Compound-8
DMYFV3D	MI	TTR7UJ3
DMYFV3D	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMYFV3D	MT	DTT
DMYFV3D	MA	Inhibitor
DMYFV3D	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMYFV3D	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DMJ6CI5	DI	DMJ6CI5
DMJ6CI5	DN	PMID27977313-Compound-Figure4b
DMJ6CI5	MI	TTR7UJ3
DMJ6CI5	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMJ6CI5	MT	DTT
DMJ6CI5	MA	Inhibitor
DMJ6CI5	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMJ6CI5	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DMICBFK	DI	DMICBFK
DMICBFK	DN	PMID27977313-Compound-Figure6C
DMICBFK	MI	TTR7UJ3
DMICBFK	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMICBFK	MT	DTT
DMICBFK	MA	Inhibitor
DMICBFK	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMICBFK	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DM5QH4C	DI	DM5QH4C
DM5QH4C	DN	PMID27998201-Compound-1
DM5QH4C	MI	TT36ETB
DM5QH4C	MN	Cathepsin L (CTSL)
DM5QH4C	MT	DTT
DM5QH4C	MA	Inhibitor
DM5QH4C	RN	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
DM5QH4C	RU	https://www.ncbi.nlm.nih.gov/pubmed/27998201

DMVXTIL	DI	DMVXTIL
DMVXTIL	DN	PMID27998201-Compound-10
DMVXTIL	MI	TTDZN01
DMVXTIL	MN	Cathepsin K (CTSK)
DMVXTIL	MT	DTT
DMVXTIL	MA	Inhibitor
DMVXTIL	RN	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
DMVXTIL	RU	https://www.ncbi.nlm.nih.gov/pubmed/27998201

DMTV5NU	DI	DMTV5NU
DMTV5NU	DN	PMID27998201-Compound-11
DMTV5NU	MI	TTF2LRI
DMTV5NU	MN	Cathepsin B (CTSB)
DMTV5NU	MT	DTT
DMTV5NU	MA	Inhibitor
DMTV5NU	RN	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
DMTV5NU	RU	https://www.ncbi.nlm.nih.gov/pubmed/27998201

DM8QZNC	DI	DM8QZNC
DM8QZNC	DN	PMID27998201-Compound-12
DM8QZNC	MI	TTF2LRI
DM8QZNC	MN	Cathepsin B (CTSB)
DM8QZNC	MT	DTT
DM8QZNC	MA	Inhibitor
DM8QZNC	RN	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
DM8QZNC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27998201

DM8QZNC	DI	DM8QZNC
DM8QZNC	DN	PMID27998201-Compound-12
DM8QZNC	MI	TTJOKD1
DM8QZNC	MN	Cathepsin F (CTSF)
DM8QZNC	MT	DTT
DM8QZNC	MA	Inhibitor
DM8QZNC	RN	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
DM8QZNC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27998201

DM8QZNC	DI	DM8QZNC
DM8QZNC	DN	PMID27998201-Compound-12
DM8QZNC	MI	TTDZN01
DM8QZNC	MN	Cathepsin K (CTSK)
DM8QZNC	MT	DTT
DM8QZNC	MA	Inhibitor
DM8QZNC	RN	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
DM8QZNC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27998201

DM8QZNC	DI	DM8QZNC
DM8QZNC	DN	PMID27998201-Compound-12
DM8QZNC	MI	TT36ETB
DM8QZNC	MN	Cathepsin L (CTSL)
DM8QZNC	MT	DTT
DM8QZNC	MA	Inhibitor
DM8QZNC	RN	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
DM8QZNC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27998201

DM8QZNC	DI	DM8QZNC
DM8QZNC	DN	PMID27998201-Compound-12
DM8QZNC	MI	TTUMQVO
DM8QZNC	MN	Cathepsin S (CTSS)
DM8QZNC	MT	DTT
DM8QZNC	MA	Inhibitor
DM8QZNC	RN	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
DM8QZNC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27998201

DM8QZNC	DI	DM8QZNC
DM8QZNC	DN	PMID27998201-Compound-12
DM8QZNC	MI	TTSD9T1
DM8QZNC	MN	Cathepsin V (CTSV)
DM8QZNC	MT	DTT
DM8QZNC	MA	Inhibitor
DM8QZNC	RN	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
DM8QZNC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27998201

DMZHIM8	DI	DMZHIM8
DMZHIM8	DN	PMID27998201-Compound-13
DMZHIM8	MI	TTF2LRI
DMZHIM8	MN	Cathepsin B (CTSB)
DMZHIM8	MT	DTT
DMZHIM8	MA	Inhibitor
DMZHIM8	RN	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
DMZHIM8	RU	https://www.ncbi.nlm.nih.gov/pubmed/27998201

DMOB8LU	DI	DMOB8LU
DMOB8LU	DN	PMID27998201-Compound-15
DMOB8LU	MI	TTDZN01
DMOB8LU	MN	Cathepsin K (CTSK)
DMOB8LU	MT	DTT
DMOB8LU	MA	Inhibitor
DMOB8LU	RN	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
DMOB8LU	RU	https://www.ncbi.nlm.nih.gov/pubmed/27998201

DMOB8LU	DI	DMOB8LU
DMOB8LU	DN	PMID27998201-Compound-15
DMOB8LU	MI	TTUMQVO
DMOB8LU	MN	Cathepsin S (CTSS)
DMOB8LU	MT	DTT
DMOB8LU	MA	Inhibitor
DMOB8LU	RN	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
DMOB8LU	RU	https://www.ncbi.nlm.nih.gov/pubmed/27998201

DMAZVHJ	DI	DMAZVHJ
DMAZVHJ	DN	PMID27998201-Compound-17
DMAZVHJ	MI	TTF2LRI
DMAZVHJ	MN	Cathepsin B (CTSB)
DMAZVHJ	MT	DTT
DMAZVHJ	MA	Inhibitor
DMAZVHJ	RN	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
DMAZVHJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27998201

DMAZVHJ	DI	DMAZVHJ
DMAZVHJ	DN	PMID27998201-Compound-17
DMAZVHJ	MI	TT36ETB
DMAZVHJ	MN	Cathepsin L (CTSL)
DMAZVHJ	MT	DTT
DMAZVHJ	MA	Inhibitor
DMAZVHJ	RN	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
DMAZVHJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27998201

DMAZVHJ	DI	DMAZVHJ
DMAZVHJ	DN	PMID27998201-Compound-17
DMAZVHJ	MI	TTUMQVO
DMAZVHJ	MN	Cathepsin S (CTSS)
DMAZVHJ	MT	DTT
DMAZVHJ	MA	Inhibitor
DMAZVHJ	RN	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
DMAZVHJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27998201

DM67RMX	DI	DM67RMX
DM67RMX	DN	PMID27998201-Compound-19
DM67RMX	MI	TT36ETB
DM67RMX	MN	Cathepsin L (CTSL)
DM67RMX	MT	DTT
DM67RMX	MA	Inhibitor
DM67RMX	RN	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
DM67RMX	RU	https://www.ncbi.nlm.nih.gov/pubmed/27998201

DMMAE3C	DI	DMMAE3C
DMMAE3C	DN	PMID27998201-Compound-2
DMMAE3C	MI	TTF2LRI
DMMAE3C	MN	Cathepsin B (CTSB)
DMMAE3C	MT	DTT
DMMAE3C	MA	Inhibitor
DMMAE3C	RN	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
DMMAE3C	RU	https://www.ncbi.nlm.nih.gov/pubmed/27998201

DMS9QA7	DI	DMS9QA7
DMS9QA7	DN	PMID27998201-Compound-22
DMS9QA7	MI	TTF2LRI
DMS9QA7	MN	Cathepsin B (CTSB)
DMS9QA7	MT	DTT
DMS9QA7	MA	Inhibitor
DMS9QA7	RN	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
DMS9QA7	RU	https://www.ncbi.nlm.nih.gov/pubmed/27998201

DM25BNZ	DI	DM25BNZ
DM25BNZ	DN	PMID27998201-Compound-24
DM25BNZ	MI	TTF2LRI
DM25BNZ	MN	Cathepsin B (CTSB)
DM25BNZ	MT	DTT
DM25BNZ	MA	Inhibitor
DM25BNZ	RN	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
DM25BNZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27998201

DMVZ0ND	DI	DMVZ0ND
DMVZ0ND	DN	PMID27998201-Compound-5
DMVZ0ND	MI	TTF2LRI
DMVZ0ND	MN	Cathepsin B (CTSB)
DMVZ0ND	MT	DTT
DMVZ0ND	MA	Inhibitor
DMVZ0ND	RN	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
DMVZ0ND	RU	https://www.ncbi.nlm.nih.gov/pubmed/27998201

DMVZ0ND	DI	DMVZ0ND
DMVZ0ND	DN	PMID27998201-Compound-5
DMVZ0ND	MI	TTJOKD1
DMVZ0ND	MN	Cathepsin F (CTSF)
DMVZ0ND	MT	DTT
DMVZ0ND	MA	Inhibitor
DMVZ0ND	RN	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
DMVZ0ND	RU	https://www.ncbi.nlm.nih.gov/pubmed/27998201

DMVZ0ND	DI	DMVZ0ND
DMVZ0ND	DN	PMID27998201-Compound-5
DMVZ0ND	MI	TTDZN01
DMVZ0ND	MN	Cathepsin K (CTSK)
DMVZ0ND	MT	DTT
DMVZ0ND	MA	Inhibitor
DMVZ0ND	RN	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
DMVZ0ND	RU	https://www.ncbi.nlm.nih.gov/pubmed/27998201

DMVZ0ND	DI	DMVZ0ND
DMVZ0ND	DN	PMID27998201-Compound-5
DMVZ0ND	MI	TT36ETB
DMVZ0ND	MN	Cathepsin L (CTSL)
DMVZ0ND	MT	DTT
DMVZ0ND	MA	Inhibitor
DMVZ0ND	RN	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
DMVZ0ND	RU	https://www.ncbi.nlm.nih.gov/pubmed/27998201

DMVZ0ND	DI	DMVZ0ND
DMVZ0ND	DN	PMID27998201-Compound-5
DMVZ0ND	MI	TTUMQVO
DMVZ0ND	MN	Cathepsin S (CTSS)
DMVZ0ND	MT	DTT
DMVZ0ND	MA	Inhibitor
DMVZ0ND	RN	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
DMVZ0ND	RU	https://www.ncbi.nlm.nih.gov/pubmed/27998201

DM0LGTY	DI	DM0LGTY
DM0LGTY	DN	PMID27998201-Compound-6
DM0LGTY	MI	TT36ETB
DM0LGTY	MN	Cathepsin L (CTSL)
DM0LGTY	MT	DTT
DM0LGTY	MA	Inhibitor
DM0LGTY	RN	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
DM0LGTY	RU	https://www.ncbi.nlm.nih.gov/pubmed/27998201

DM0LGTY	DI	DM0LGTY
DM0LGTY	DN	PMID27998201-Compound-6
DM0LGTY	MI	TTUMQVO
DM0LGTY	MN	Cathepsin S (CTSS)
DM0LGTY	MT	DTT
DM0LGTY	MA	Inhibitor
DM0LGTY	RN	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
DM0LGTY	RU	https://www.ncbi.nlm.nih.gov/pubmed/27998201

DMU4QYR	DI	DMU4QYR
DMU4QYR	DN	PMID27998201-Compound-7
DMU4QYR	MI	TT36ETB
DMU4QYR	MN	Cathepsin L (CTSL)
DMU4QYR	MT	DTT
DMU4QYR	MA	Inhibitor
DMU4QYR	RN	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
DMU4QYR	RU	https://www.ncbi.nlm.nih.gov/pubmed/27998201

DMU4QYR	DI	DMU4QYR
DMU4QYR	DN	PMID27998201-Compound-7
DMU4QYR	MI	TTUMQVO
DMU4QYR	MN	Cathepsin S (CTSS)
DMU4QYR	MT	DTT
DMU4QYR	MA	Inhibitor
DMU4QYR	RN	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
DMU4QYR	RU	https://www.ncbi.nlm.nih.gov/pubmed/27998201

DMZK0SY	DI	DMZK0SY
DMZK0SY	DN	PMID27998201-Compound-8
DMZK0SY	MI	TTDZN01
DMZK0SY	MN	Cathepsin K (CTSK)
DMZK0SY	MT	DTT
DMZK0SY	MA	Inhibitor
DMZK0SY	RN	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
DMZK0SY	RU	https://www.ncbi.nlm.nih.gov/pubmed/27998201

DM1JOZN	DI	DM1JOZN
DM1JOZN	DN	PMID27998201-Compound-9
DM1JOZN	MI	TTF2LRI
DM1JOZN	MN	Cathepsin B (CTSB)
DM1JOZN	MT	DTT
DM1JOZN	MA	Inhibitor
DM1JOZN	RN	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
DM1JOZN	RU	https://www.ncbi.nlm.nih.gov/pubmed/27998201

DM1JOZN	DI	DM1JOZN
DM1JOZN	DN	PMID27998201-Compound-9
DM1JOZN	MI	TTDZN01
DM1JOZN	MN	Cathepsin K (CTSK)
DM1JOZN	MT	DTT
DM1JOZN	MA	Inhibitor
DM1JOZN	RN	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
DM1JOZN	RU	https://www.ncbi.nlm.nih.gov/pubmed/27998201

DM1JOZN	DI	DM1JOZN
DM1JOZN	DN	PMID27998201-Compound-9
DM1JOZN	MI	TT36ETB
DM1JOZN	MN	Cathepsin L (CTSL)
DM1JOZN	MT	DTT
DM1JOZN	MA	Inhibitor
DM1JOZN	RN	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
DM1JOZN	RU	https://www.ncbi.nlm.nih.gov/pubmed/27998201

DM1JOZN	DI	DM1JOZN
DM1JOZN	DN	PMID27998201-Compound-9
DM1JOZN	MI	TTUMQVO
DM1JOZN	MN	Cathepsin S (CTSS)
DM1JOZN	MT	DTT
DM1JOZN	MA	Inhibitor
DM1JOZN	RN	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
DM1JOZN	RU	https://www.ncbi.nlm.nih.gov/pubmed/27998201

DMQ6WEN	DI	DMQ6WEN
DMQ6WEN	DN	PMID28048944-Compound-11
DMQ6WEN	MI	TTGWKQJ
DMQ6WEN	MN	Rho-associated protein kinase 2 (ROCK2)
DMQ6WEN	MT	DTT
DMQ6WEN	MA	Inhibitor
DMQ6WEN	RN	Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
DMQ6WEN	RU	https://www.ncbi.nlm.nih.gov/pubmed/28048944

DMPT3V9	DI	DMPT3V9
DMPT3V9	DN	PMID28048944-Compound-19
DMPT3V9	MI	TTZN7RP
DMPT3V9	MN	Rho-associated protein kinase 1 (ROCK1)
DMPT3V9	MT	DTT
DMPT3V9	MA	Inhibitor
DMPT3V9	RN	Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
DMPT3V9	RU	https://www.ncbi.nlm.nih.gov/pubmed/28048944

DMPT3V9	DI	DMPT3V9
DMPT3V9	DN	PMID28048944-Compound-19
DMPT3V9	MI	TTGWKQJ
DMPT3V9	MN	Rho-associated protein kinase 2 (ROCK2)
DMPT3V9	MT	DTT
DMPT3V9	MA	Inhibitor
DMPT3V9	RN	Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
DMPT3V9	RU	https://www.ncbi.nlm.nih.gov/pubmed/28048944

DM9ZXOP	DI	DM9ZXOP
DM9ZXOP	DN	PMID28048944-Compound-2
DM9ZXOP	MI	TTZN7RP
DM9ZXOP	MN	Rho-associated protein kinase 1 (ROCK1)
DM9ZXOP	MT	DTT
DM9ZXOP	MA	Inhibitor
DM9ZXOP	RN	Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
DM9ZXOP	RU	https://www.ncbi.nlm.nih.gov/pubmed/28048944

DM9ZXOP	DI	DM9ZXOP
DM9ZXOP	DN	PMID28048944-Compound-2
DM9ZXOP	MI	TTGWKQJ
DM9ZXOP	MN	Rho-associated protein kinase 2 (ROCK2)
DM9ZXOP	MT	DTT
DM9ZXOP	MA	Inhibitor
DM9ZXOP	RN	Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
DM9ZXOP	RU	https://www.ncbi.nlm.nih.gov/pubmed/28048944

DM19BQ6	DI	DM19BQ6
DM19BQ6	DN	PMID28048944-Compound-20
DM19BQ6	MI	TTZN7RP
DM19BQ6	MN	Rho-associated protein kinase 1 (ROCK1)
DM19BQ6	MT	DTT
DM19BQ6	MA	Inhibitor
DM19BQ6	RN	Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
DM19BQ6	RU	https://www.ncbi.nlm.nih.gov/pubmed/28048944

DMPNG9C	DI	DMPNG9C
DMPNG9C	DN	PMID28048944-Compound-21
DMPNG9C	MI	TTZN7RP
DMPNG9C	MN	Rho-associated protein kinase 1 (ROCK1)
DMPNG9C	MT	DTT
DMPNG9C	MA	Inhibitor
DMPNG9C	RN	Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
DMPNG9C	RU	https://www.ncbi.nlm.nih.gov/pubmed/28048944

DM1BN74	DI	DM1BN74
DM1BN74	DN	PMID28048944-Compound-3
DM1BN74	MI	TTZN7RP
DM1BN74	MN	Rho-associated protein kinase 1 (ROCK1)
DM1BN74	MT	DTT
DM1BN74	MA	Inhibitor
DM1BN74	RN	Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
DM1BN74	RU	https://www.ncbi.nlm.nih.gov/pubmed/28048944

DM1BN74	DI	DM1BN74
DM1BN74	DN	PMID28048944-Compound-3
DM1BN74	MI	TTGWKQJ
DM1BN74	MN	Rho-associated protein kinase 2 (ROCK2)
DM1BN74	MT	DTT
DM1BN74	MA	Inhibitor
DM1BN74	RN	Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
DM1BN74	RU	https://www.ncbi.nlm.nih.gov/pubmed/28048944

DMJAUWG	DI	DMJAUWG
DMJAUWG	DN	PMID28048944-Compound-4
DMJAUWG	MI	TTZN7RP
DMJAUWG	MN	Rho-associated protein kinase 1 (ROCK1)
DMJAUWG	MT	DTT
DMJAUWG	MA	Inhibitor
DMJAUWG	RN	Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
DMJAUWG	RU	https://www.ncbi.nlm.nih.gov/pubmed/28048944

DMJAUWG	DI	DMJAUWG
DMJAUWG	DN	PMID28048944-Compound-4
DMJAUWG	MI	TTGWKQJ
DMJAUWG	MN	Rho-associated protein kinase 2 (ROCK2)
DMJAUWG	MT	DTT
DMJAUWG	MA	Inhibitor
DMJAUWG	RN	Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
DMJAUWG	RU	https://www.ncbi.nlm.nih.gov/pubmed/28048944

DMAB987	DI	DMAB987
DMAB987	DN	PMID28048944-Compound-5
DMAB987	MI	TTZN7RP
DMAB987	MN	Rho-associated protein kinase 1 (ROCK1)
DMAB987	MT	DTT
DMAB987	MA	Inhibitor
DMAB987	RN	Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
DMAB987	RU	https://www.ncbi.nlm.nih.gov/pubmed/28048944

DMAB987	DI	DMAB987
DMAB987	DN	PMID28048944-Compound-5
DMAB987	MI	TTGWKQJ
DMAB987	MN	Rho-associated protein kinase 2 (ROCK2)
DMAB987	MT	DTT
DMAB987	MA	Inhibitor
DMAB987	RN	Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
DMAB987	RU	https://www.ncbi.nlm.nih.gov/pubmed/28048944

DM5RCBV	DI	DM5RCBV
DM5RCBV	DN	PMID28048944-Compound-6
DM5RCBV	MI	TTZN7RP
DM5RCBV	MN	Rho-associated protein kinase 1 (ROCK1)
DM5RCBV	MT	DTT
DM5RCBV	MA	Inhibitor
DM5RCBV	RN	Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
DM5RCBV	RU	https://www.ncbi.nlm.nih.gov/pubmed/28048944

DM5RCBV	DI	DM5RCBV
DM5RCBV	DN	PMID28048944-Compound-6
DM5RCBV	MI	TTGWKQJ
DM5RCBV	MN	Rho-associated protein kinase 2 (ROCK2)
DM5RCBV	MT	DTT
DM5RCBV	MA	Inhibitor
DM5RCBV	RN	Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
DM5RCBV	RU	https://www.ncbi.nlm.nih.gov/pubmed/28048944

DMXZ368	DI	DMXZ368
DMXZ368	DN	PMID28048944-Compound-7
DMXZ368	MI	TTZN7RP
DMXZ368	MN	Rho-associated protein kinase 1 (ROCK1)
DMXZ368	MT	DTT
DMXZ368	MA	Inhibitor
DMXZ368	RN	Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
DMXZ368	RU	https://www.ncbi.nlm.nih.gov/pubmed/28048944

DMXZ368	DI	DMXZ368
DMXZ368	DN	PMID28048944-Compound-7
DMXZ368	MI	TTGWKQJ
DMXZ368	MN	Rho-associated protein kinase 2 (ROCK2)
DMXZ368	MT	DTT
DMXZ368	MA	Inhibitor
DMXZ368	RN	Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
DMXZ368	RU	https://www.ncbi.nlm.nih.gov/pubmed/28048944

DMRANS2	DI	DMRANS2
DMRANS2	DN	PMID28051882-Compound-Figure9
DMRANS2	MI	TT9NXW4
DMRANS2	MN	Sigma intracellular receptor 2 (TMEM97)
DMRANS2	MT	DTT
DMRANS2	MA	Ligand
DMRANS2	RN	Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578.
DMRANS2	RU	https://www.ncbi.nlm.nih.gov/pubmed/28051882

DMLNA8P	DI	DMLNA8P
DMLNA8P	DN	PMID28051882-Compound-XI
DMLNA8P	MI	TT9NXW4
DMLNA8P	MN	Sigma intracellular receptor 2 (TMEM97)
DMLNA8P	MT	DTT
DMLNA8P	MA	Ligand
DMLNA8P	RN	Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578.
DMLNA8P	RU	https://www.ncbi.nlm.nih.gov/pubmed/28051882

DM1RN89	DI	DM1RN89
DM1RN89	DN	PMID28051882-Compound-XIV
DM1RN89	MI	TT5TPI6
DM1RN89	MN	Opioid receptor sigma 1 (OPRS1)
DM1RN89	MT	DTT
DM1RN89	MA	Ligand
DM1RN89	RN	Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578.
DM1RN89	RU	https://www.ncbi.nlm.nih.gov/pubmed/28051882

DM1RN89	DI	DM1RN89
DM1RN89	DN	PMID28051882-Compound-XIV
DM1RN89	MI	TT9NXW4
DM1RN89	MN	Sigma intracellular receptor 2 (TMEM97)
DM1RN89	MT	DTT
DM1RN89	MA	Ligand
DM1RN89	RN	Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578.
DM1RN89	RU	https://www.ncbi.nlm.nih.gov/pubmed/28051882

DMG2PCZ	DI	DMG2PCZ
DMG2PCZ	DN	PMID28067079-Compound-95
DMG2PCZ	MI	TTHS256
DMG2PCZ	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMG2PCZ	MT	DTT
DMG2PCZ	MA	Modulator
DMG2PCZ	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMG2PCZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMCUX42	DI	DMCUX42
DMCUX42	DN	PMID28067079-Compound-97
DMCUX42	MI	TTHS256
DMCUX42	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMCUX42	MT	DTT
DMCUX42	MA	Modulator
DMCUX42	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMCUX42	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMLKP1O	DI	DMLKP1O
DMLKP1O	DN	PMID28067079-Compound-98
DMLKP1O	MI	TTHS256
DMLKP1O	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMLKP1O	MT	DTT
DMLKP1O	MA	Modulator
DMLKP1O	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMLKP1O	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMQW470	DI	DMQW470
DMQW470	DN	PMID28074661-Compound-US20100022547C80
DMQW470	MI	TTL7C8Q
DMQW470	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMQW470	MT	DTT
DMQW470	MA	Inhibitor
DMQW470	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DMQW470	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DMM9E1U	DI	DMM9E1U
DMM9E1U	DN	PMID28074661-Compound-US20100022547C81
DMM9E1U	MI	TTL7C8Q
DMM9E1U	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMM9E1U	MT	DTT
DMM9E1U	MA	Inhibitor
DMM9E1U	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DMM9E1U	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DM94MT3	DI	DM94MT3
DM94MT3	DN	PMID28074661-Compound-US20100022547C82
DM94MT3	MI	TTL7C8Q
DM94MT3	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DM94MT3	MT	DTT
DM94MT3	MA	Inhibitor
DM94MT3	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DM94MT3	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DM18LO7	DI	DM18LO7
DM18LO7	DN	PMID28074661-Compound-US20100022547C83
DM18LO7	MI	TTL7C8Q
DM18LO7	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DM18LO7	MT	DTT
DM18LO7	MA	Inhibitor
DM18LO7	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DM18LO7	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DMONEJ4	DI	DMONEJ4
DMONEJ4	DN	PMID28074661-Compound-US20100022547C86
DMONEJ4	MI	TTL7C8Q
DMONEJ4	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMONEJ4	MT	DTT
DMONEJ4	MA	Inhibitor
DMONEJ4	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DMONEJ4	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DM8E702	DI	DM8E702
DM8E702	DN	PMID28074661-Compound-US20100022547C87
DM8E702	MI	TTL7C8Q
DM8E702	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DM8E702	MT	DTT
DM8E702	MA	Inhibitor
DM8E702	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DM8E702	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DMNUR8E	DI	DMNUR8E
DMNUR8E	DN	PMID28074661-Compound-US20100022547C88
DMNUR8E	MI	TTL7C8Q
DMNUR8E	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMNUR8E	MT	DTT
DMNUR8E	MA	Inhibitor
DMNUR8E	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DMNUR8E	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DM75QVW	DI	DM75QVW
DM75QVW	DN	PMID28074661-Compound-US20120264760C80
DM75QVW	MI	TTL7C8Q
DM75QVW	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DM75QVW	MT	DTT
DM75QVW	MA	Inhibitor
DM75QVW	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DM75QVW	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DMH249S	DI	DMH249S
DMH249S	DN	PMID28074661-Compound-US20120264760C81
DMH249S	MI	TTL7C8Q
DMH249S	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMH249S	MT	DTT
DMH249S	MA	Inhibitor
DMH249S	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DMH249S	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DM18PRU	DI	DM18PRU
DM18PRU	DN	PMID28074661-Compound-US20120264760C82
DM18PRU	MI	TTL7C8Q
DM18PRU	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DM18PRU	MT	DTT
DM18PRU	MA	Inhibitor
DM18PRU	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DM18PRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DMD7AU3	DI	DMD7AU3
DMD7AU3	DN	PMID28074661-Compound-US20120264760C83
DMD7AU3	MI	TTL7C8Q
DMD7AU3	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMD7AU3	MT	DTT
DMD7AU3	MA	Inhibitor
DMD7AU3	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DMD7AU3	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DMKFEO4	DI	DMKFEO4
DMKFEO4	DN	PMID28074661-Compound-US20120264760C86
DMKFEO4	MI	TTL7C8Q
DMKFEO4	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMKFEO4	MT	DTT
DMKFEO4	MA	Inhibitor
DMKFEO4	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DMKFEO4	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DM85XKT	DI	DM85XKT
DM85XKT	DN	PMID28074661-Compound-US20120264760C87
DM85XKT	MI	TTL7C8Q
DM85XKT	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DM85XKT	MT	DTT
DM85XKT	MA	Inhibitor
DM85XKT	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DM85XKT	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DMIKRCM	DI	DMIKRCM
DMIKRCM	DN	PMID28074661-Compound-US20120264760C88
DMIKRCM	MI	TTL7C8Q
DMIKRCM	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMIKRCM	MT	DTT
DMIKRCM	MA	Inhibitor
DMIKRCM	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DMIKRCM	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DMEJ4LW	DI	DMEJ4LW
DMEJ4LW	DN	PMID28074661-Compound-US20128202889C90
DMEJ4LW	MI	TTL7C8Q
DMEJ4LW	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMEJ4LW	MT	DTT
DMEJ4LW	MA	Inhibitor
DMEJ4LW	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DMEJ4LW	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DM1QUN0	DI	DM1QUN0
DM1QUN0	DN	PMID28074661-Compound-US20158969342C84
DM1QUN0	MI	TTL7C8Q
DM1QUN0	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DM1QUN0	MT	DTT
DM1QUN0	MA	Inhibitor
DM1QUN0	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DM1QUN0	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DMMYH82	DI	DMMYH82
DMMYH82	DN	PMID28074661-Compound-US20169447134C85
DMMYH82	MI	TTL7C8Q
DMMYH82	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMMYH82	MT	DTT
DMMYH82	MA	Inhibitor
DMMYH82	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DMMYH82	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DMFORUW	DI	DMFORUW
DMFORUW	DN	PMID28074661-Compound-WO2009018344C78
DMFORUW	MI	TTL7C8Q
DMFORUW	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMFORUW	MT	DTT
DMFORUW	MA	Inhibitor
DMFORUW	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DMFORUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DM64QNL	DI	DM64QNL
DM64QNL	DN	PMID28074661-Compound-WO2009018344C79
DM64QNL	MI	TTL7C8Q
DM64QNL	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DM64QNL	MT	DTT
DM64QNL	MA	Inhibitor
DM64QNL	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DM64QNL	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DMC4TQL	DI	DMC4TQL
DMC4TQL	DN	PMID28092474-Compound-32
DMC4TQL	MI	TTBH0VX
DMC4TQL	MN	Histone deacetylase (HDAC)
DMC4TQL	MT	DTT
DMC4TQL	MA	Inhibitor
DMC4TQL	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMC4TQL	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMGZ61E	DI	DMGZ61E
DMGZ61E	DN	PMID28092474-Compound-32a
DMGZ61E	MI	TT6R7JZ
DMGZ61E	MN	Histone deacetylase 1 (HDAC1)
DMGZ61E	MT	DTT
DMGZ61E	MA	Inhibitor
DMGZ61E	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMGZ61E	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMGZ61E	DI	DMGZ61E
DMGZ61E	DN	PMID28092474-Compound-32a
DMGZ61E	MI	TT5ZKDI
DMGZ61E	MN	Histone deacetylase 6 (HDAC6)
DMGZ61E	MT	DTT
DMGZ61E	MA	Inhibitor
DMGZ61E	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMGZ61E	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMT2B5A	DI	DMT2B5A
DMT2B5A	DN	PMID28092474-Compound-32b
DMT2B5A	MI	TT6R7JZ
DMT2B5A	MN	Histone deacetylase 1 (HDAC1)
DMT2B5A	MT	DTT
DMT2B5A	MA	Inhibitor
DMT2B5A	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMT2B5A	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMT2B5A	DI	DMT2B5A
DMT2B5A	DN	PMID28092474-Compound-32b
DMT2B5A	MI	TT5ZKDI
DMT2B5A	MN	Histone deacetylase 6 (HDAC6)
DMT2B5A	MT	DTT
DMT2B5A	MA	Inhibitor
DMT2B5A	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMT2B5A	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMGA3XL	DI	DMGA3XL
DMGA3XL	DN	PMID28092474-Compound-32c
DMGA3XL	MI	TT6R7JZ
DMGA3XL	MN	Histone deacetylase 1 (HDAC1)
DMGA3XL	MT	DTT
DMGA3XL	MA	Inhibitor
DMGA3XL	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMGA3XL	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMGA3XL	DI	DMGA3XL
DMGA3XL	DN	PMID28092474-Compound-32c
DMGA3XL	MI	TT5ZKDI
DMGA3XL	MN	Histone deacetylase 6 (HDAC6)
DMGA3XL	MT	DTT
DMGA3XL	MA	Inhibitor
DMGA3XL	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMGA3XL	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMW21U4	DI	DMW21U4
DMW21U4	DN	PMID28092474-Compound-32d
DMW21U4	MI	TT6R7JZ
DMW21U4	MN	Histone deacetylase 1 (HDAC1)
DMW21U4	MT	DTT
DMW21U4	MA	Inhibitor
DMW21U4	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMW21U4	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMW21U4	DI	DMW21U4
DMW21U4	DN	PMID28092474-Compound-32d
DMW21U4	MI	TT5ZKDI
DMW21U4	MN	Histone deacetylase 6 (HDAC6)
DMW21U4	MT	DTT
DMW21U4	MA	Inhibitor
DMW21U4	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMW21U4	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DM8NHQS	DI	DM8NHQS
DM8NHQS	DN	PMID28092474-Compound-32e
DM8NHQS	MI	TT6R7JZ
DM8NHQS	MN	Histone deacetylase 1 (HDAC1)
DM8NHQS	MT	DTT
DM8NHQS	MA	Inhibitor
DM8NHQS	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DM8NHQS	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DM8NHQS	DI	DM8NHQS
DM8NHQS	DN	PMID28092474-Compound-32e
DM8NHQS	MI	TT5ZKDI
DM8NHQS	MN	Histone deacetylase 6 (HDAC6)
DM8NHQS	MT	DTT
DM8NHQS	MA	Inhibitor
DM8NHQS	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DM8NHQS	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMEIZ6Y	DI	DMEIZ6Y
DMEIZ6Y	DN	PMID28092474-Compound-32f
DMEIZ6Y	MI	TT6R7JZ
DMEIZ6Y	MN	Histone deacetylase 1 (HDAC1)
DMEIZ6Y	MT	DTT
DMEIZ6Y	MA	Inhibitor
DMEIZ6Y	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMEIZ6Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMEIZ6Y	DI	DMEIZ6Y
DMEIZ6Y	DN	PMID28092474-Compound-32f
DMEIZ6Y	MI	TT5ZKDI
DMEIZ6Y	MN	Histone deacetylase 6 (HDAC6)
DMEIZ6Y	MT	DTT
DMEIZ6Y	MA	Inhibitor
DMEIZ6Y	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMEIZ6Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMTKLEP	DI	DMTKLEP
DMTKLEP	DN	PMID28092474-Compound-32g
DMTKLEP	MI	TT6R7JZ
DMTKLEP	MN	Histone deacetylase 1 (HDAC1)
DMTKLEP	MT	DTT
DMTKLEP	MA	Inhibitor
DMTKLEP	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMTKLEP	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMTKLEP	DI	DMTKLEP
DMTKLEP	DN	PMID28092474-Compound-32g
DMTKLEP	MI	TT5ZKDI
DMTKLEP	MN	Histone deacetylase 6 (HDAC6)
DMTKLEP	MT	DTT
DMTKLEP	MA	Inhibitor
DMTKLEP	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMTKLEP	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DME1WHT	DI	DME1WHT
DME1WHT	DN	PMID28092474-Compound-32h
DME1WHT	MI	TT6R7JZ
DME1WHT	MN	Histone deacetylase 1 (HDAC1)
DME1WHT	MT	DTT
DME1WHT	MA	Inhibitor
DME1WHT	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DME1WHT	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DME1WHT	DI	DME1WHT
DME1WHT	DN	PMID28092474-Compound-32h
DME1WHT	MI	TT5ZKDI
DME1WHT	MN	Histone deacetylase 6 (HDAC6)
DME1WHT	MT	DTT
DME1WHT	MA	Inhibitor
DME1WHT	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DME1WHT	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMN3ZEF	DI	DMN3ZEF
DMN3ZEF	DN	PMID28092474-Compound-32i
DMN3ZEF	MI	TT6R7JZ
DMN3ZEF	MN	Histone deacetylase 1 (HDAC1)
DMN3ZEF	MT	DTT
DMN3ZEF	MA	Inhibitor
DMN3ZEF	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMN3ZEF	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMN3ZEF	DI	DMN3ZEF
DMN3ZEF	DN	PMID28092474-Compound-32i
DMN3ZEF	MI	TT5ZKDI
DMN3ZEF	MN	Histone deacetylase 6 (HDAC6)
DMN3ZEF	MT	DTT
DMN3ZEF	MA	Inhibitor
DMN3ZEF	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMN3ZEF	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMSGWTX	DI	DMSGWTX
DMSGWTX	DN	PMID28092474-Compound-32j
DMSGWTX	MI	TT6R7JZ
DMSGWTX	MN	Histone deacetylase 1 (HDAC1)
DMSGWTX	MT	DTT
DMSGWTX	MA	Inhibitor
DMSGWTX	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMSGWTX	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMSGWTX	DI	DMSGWTX
DMSGWTX	DN	PMID28092474-Compound-32j
DMSGWTX	MI	TT5ZKDI
DMSGWTX	MN	Histone deacetylase 6 (HDAC6)
DMSGWTX	MT	DTT
DMSGWTX	MA	Inhibitor
DMSGWTX	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMSGWTX	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMHSJ65	DI	DMHSJ65
DMHSJ65	DN	PMID28092474-Compound-32k
DMHSJ65	MI	TT6R7JZ
DMHSJ65	MN	Histone deacetylase 1 (HDAC1)
DMHSJ65	MT	DTT
DMHSJ65	MA	Inhibitor
DMHSJ65	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMHSJ65	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMHSJ65	DI	DMHSJ65
DMHSJ65	DN	PMID28092474-Compound-32k
DMHSJ65	MI	TT5ZKDI
DMHSJ65	MN	Histone deacetylase 6 (HDAC6)
DMHSJ65	MT	DTT
DMHSJ65	MA	Inhibitor
DMHSJ65	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMHSJ65	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMSP5IA	DI	DMSP5IA
DMSP5IA	DN	PMID28092474-Compound-32l
DMSP5IA	MI	TT6R7JZ
DMSP5IA	MN	Histone deacetylase 1 (HDAC1)
DMSP5IA	MT	DTT
DMSP5IA	MA	Inhibitor
DMSP5IA	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMSP5IA	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMSP5IA	DI	DMSP5IA
DMSP5IA	DN	PMID28092474-Compound-32l
DMSP5IA	MI	TT5ZKDI
DMSP5IA	MN	Histone deacetylase 6 (HDAC6)
DMSP5IA	MT	DTT
DMSP5IA	MA	Inhibitor
DMSP5IA	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMSP5IA	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMADMWB	DI	DMADMWB
DMADMWB	DN	PMID28092474-Compound-32m
DMADMWB	MI	TT6R7JZ
DMADMWB	MN	Histone deacetylase 1 (HDAC1)
DMADMWB	MT	DTT
DMADMWB	MA	Inhibitor
DMADMWB	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMADMWB	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMADMWB	DI	DMADMWB
DMADMWB	DN	PMID28092474-Compound-32m
DMADMWB	MI	TT5ZKDI
DMADMWB	MN	Histone deacetylase 6 (HDAC6)
DMADMWB	MT	DTT
DMADMWB	MA	Inhibitor
DMADMWB	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMADMWB	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMJO3RW	DI	DMJO3RW
DMJO3RW	DN	PMID28092474-Compound-32n
DMJO3RW	MI	TT6R7JZ
DMJO3RW	MN	Histone deacetylase 1 (HDAC1)
DMJO3RW	MT	DTT
DMJO3RW	MA	Inhibitor
DMJO3RW	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMJO3RW	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMJO3RW	DI	DMJO3RW
DMJO3RW	DN	PMID28092474-Compound-32n
DMJO3RW	MI	TT5ZKDI
DMJO3RW	MN	Histone deacetylase 6 (HDAC6)
DMJO3RW	MT	DTT
DMJO3RW	MA	Inhibitor
DMJO3RW	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMJO3RW	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMV9BQN	DI	DMV9BQN
DMV9BQN	DN	PMID28092474-Compound-32o
DMV9BQN	MI	TT6R7JZ
DMV9BQN	MN	Histone deacetylase 1 (HDAC1)
DMV9BQN	MT	DTT
DMV9BQN	MA	Inhibitor
DMV9BQN	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMV9BQN	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMV9BQN	DI	DMV9BQN
DMV9BQN	DN	PMID28092474-Compound-32o
DMV9BQN	MI	TT5ZKDI
DMV9BQN	MN	Histone deacetylase 6 (HDAC6)
DMV9BQN	MT	DTT
DMV9BQN	MA	Inhibitor
DMV9BQN	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMV9BQN	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DM4ZO21	DI	DM4ZO21
DM4ZO21	DN	PMID28092474-Compound-32p
DM4ZO21	MI	TT6R7JZ
DM4ZO21	MN	Histone deacetylase 1 (HDAC1)
DM4ZO21	MT	DTT
DM4ZO21	MA	Inhibitor
DM4ZO21	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DM4ZO21	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DM4ZO21	DI	DM4ZO21
DM4ZO21	DN	PMID28092474-Compound-32p
DM4ZO21	MI	TT5ZKDI
DM4ZO21	MN	Histone deacetylase 6 (HDAC6)
DM4ZO21	MT	DTT
DM4ZO21	MA	Inhibitor
DM4ZO21	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DM4ZO21	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMEASZY	DI	DMEASZY
DMEASZY	DN	PMID28092474-Compound-32q
DMEASZY	MI	TT6R7JZ
DMEASZY	MN	Histone deacetylase 1 (HDAC1)
DMEASZY	MT	DTT
DMEASZY	MA	Inhibitor
DMEASZY	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMEASZY	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMEASZY	DI	DMEASZY
DMEASZY	DN	PMID28092474-Compound-32q
DMEASZY	MI	TT5ZKDI
DMEASZY	MN	Histone deacetylase 6 (HDAC6)
DMEASZY	MT	DTT
DMEASZY	MA	Inhibitor
DMEASZY	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMEASZY	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMLTKMS	DI	DMLTKMS
DMLTKMS	DN	PMID28092474-Compound-32r
DMLTKMS	MI	TT6R7JZ
DMLTKMS	MN	Histone deacetylase 1 (HDAC1)
DMLTKMS	MT	DTT
DMLTKMS	MA	Inhibitor
DMLTKMS	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMLTKMS	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMLTKMS	DI	DMLTKMS
DMLTKMS	DN	PMID28092474-Compound-32r
DMLTKMS	MI	TT5ZKDI
DMLTKMS	MN	Histone deacetylase 6 (HDAC6)
DMLTKMS	MT	DTT
DMLTKMS	MA	Inhibitor
DMLTKMS	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMLTKMS	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMS103B	DI	DMS103B
DMS103B	DN	PMID28092474-Compound-32s
DMS103B	MI	TT6R7JZ
DMS103B	MN	Histone deacetylase 1 (HDAC1)
DMS103B	MT	DTT
DMS103B	MA	Inhibitor
DMS103B	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMS103B	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMS103B	DI	DMS103B
DMS103B	DN	PMID28092474-Compound-32s
DMS103B	MI	TT5ZKDI
DMS103B	MN	Histone deacetylase 6 (HDAC6)
DMS103B	MT	DTT
DMS103B	MA	Inhibitor
DMS103B	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMS103B	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DM2JF0T	DI	DM2JF0T
DM2JF0T	DN	PMID28092474-Compound-32t
DM2JF0T	MI	TT6R7JZ
DM2JF0T	MN	Histone deacetylase 1 (HDAC1)
DM2JF0T	MT	DTT
DM2JF0T	MA	Inhibitor
DM2JF0T	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DM2JF0T	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DM2JF0T	DI	DM2JF0T
DM2JF0T	DN	PMID28092474-Compound-32t
DM2JF0T	MI	TT5ZKDI
DM2JF0T	MN	Histone deacetylase 6 (HDAC6)
DM2JF0T	MT	DTT
DM2JF0T	MA	Inhibitor
DM2JF0T	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DM2JF0T	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DM805ZN	DI	DM805ZN
DM805ZN	DN	PMID28092474-Compound-32u
DM805ZN	MI	TT6R7JZ
DM805ZN	MN	Histone deacetylase 1 (HDAC1)
DM805ZN	MT	DTT
DM805ZN	MA	Inhibitor
DM805ZN	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DM805ZN	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DM805ZN	DI	DM805ZN
DM805ZN	DN	PMID28092474-Compound-32u
DM805ZN	MI	TT5ZKDI
DM805ZN	MN	Histone deacetylase 6 (HDAC6)
DM805ZN	MT	DTT
DM805ZN	MA	Inhibitor
DM805ZN	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DM805ZN	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMHV3ES	DI	DMHV3ES
DMHV3ES	DN	PMID28092474-Compound-32v
DMHV3ES	MI	TT6R7JZ
DMHV3ES	MN	Histone deacetylase 1 (HDAC1)
DMHV3ES	MT	DTT
DMHV3ES	MA	Inhibitor
DMHV3ES	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMHV3ES	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMHV3ES	DI	DMHV3ES
DMHV3ES	DN	PMID28092474-Compound-32v
DMHV3ES	MI	TT5ZKDI
DMHV3ES	MN	Histone deacetylase 6 (HDAC6)
DMHV3ES	MT	DTT
DMHV3ES	MA	Inhibitor
DMHV3ES	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMHV3ES	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DML79XQ	DI	DML79XQ
DML79XQ	DN	PMID28092474-Compound-32x
DML79XQ	MI	TT6R7JZ
DML79XQ	MN	Histone deacetylase 1 (HDAC1)
DML79XQ	MT	DTT
DML79XQ	MA	Inhibitor
DML79XQ	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DML79XQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DML79XQ	DI	DML79XQ
DML79XQ	DN	PMID28092474-Compound-32x
DML79XQ	MI	TT5ZKDI
DML79XQ	MN	Histone deacetylase 6 (HDAC6)
DML79XQ	MT	DTT
DML79XQ	MA	Inhibitor
DML79XQ	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DML79XQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMLR03U	DI	DMLR03U
DMLR03U	DN	PMID28092474-Compound-32y
DMLR03U	MI	TT6R7JZ
DMLR03U	MN	Histone deacetylase 1 (HDAC1)
DMLR03U	MT	DTT
DMLR03U	MA	Inhibitor
DMLR03U	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMLR03U	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMLR03U	DI	DMLR03U
DMLR03U	DN	PMID28092474-Compound-32y
DMLR03U	MI	TT5ZKDI
DMLR03U	MN	Histone deacetylase 6 (HDAC6)
DMLR03U	MT	DTT
DMLR03U	MA	Inhibitor
DMLR03U	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMLR03U	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMEPWGH	DI	DMEPWGH
DMEPWGH	DN	PMID28092474-Compound-32z
DMEPWGH	MI	TT6R7JZ
DMEPWGH	MN	Histone deacetylase 1 (HDAC1)
DMEPWGH	MT	DTT
DMEPWGH	MA	Inhibitor
DMEPWGH	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMEPWGH	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMEPWGH	DI	DMEPWGH
DMEPWGH	DN	PMID28092474-Compound-32z
DMEPWGH	MI	TT5ZKDI
DMEPWGH	MN	Histone deacetylase 6 (HDAC6)
DMEPWGH	MT	DTT
DMEPWGH	MA	Inhibitor
DMEPWGH	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMEPWGH	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMRE6GP	DI	DMRE6GP
DMRE6GP	DN	PMID28092474-Compound-33
DMRE6GP	MI	TTBH0VX
DMRE6GP	MN	Histone deacetylase (HDAC)
DMRE6GP	MT	DTT
DMRE6GP	MA	Inhibitor
DMRE6GP	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMRE6GP	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DM7GH4Y	DI	DM7GH4Y
DM7GH4Y	DN	PMID28092474-Compound-33a
DM7GH4Y	MI	TT6R7JZ
DM7GH4Y	MN	Histone deacetylase 1 (HDAC1)
DM7GH4Y	MT	DTT
DM7GH4Y	MA	Inhibitor
DM7GH4Y	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DM7GH4Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DM7GH4Y	DI	DM7GH4Y
DM7GH4Y	DN	PMID28092474-Compound-33a
DM7GH4Y	MI	TT5ZKDI
DM7GH4Y	MN	Histone deacetylase 6 (HDAC6)
DM7GH4Y	MT	DTT
DM7GH4Y	MA	Inhibitor
DM7GH4Y	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DM7GH4Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMIJQZV	DI	DMIJQZV
DMIJQZV	DN	PMID28092474-Compound-33b
DMIJQZV	MI	TT6R7JZ
DMIJQZV	MN	Histone deacetylase 1 (HDAC1)
DMIJQZV	MT	DTT
DMIJQZV	MA	Inhibitor
DMIJQZV	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMIJQZV	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMIJQZV	DI	DMIJQZV
DMIJQZV	DN	PMID28092474-Compound-33b
DMIJQZV	MI	TT5ZKDI
DMIJQZV	MN	Histone deacetylase 6 (HDAC6)
DMIJQZV	MT	DTT
DMIJQZV	MA	Inhibitor
DMIJQZV	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMIJQZV	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DM51JP6	DI	DM51JP6
DM51JP6	DN	PMID28092474-Compound-33c
DM51JP6	MI	TT6R7JZ
DM51JP6	MN	Histone deacetylase 1 (HDAC1)
DM51JP6	MT	DTT
DM51JP6	MA	Inhibitor
DM51JP6	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DM51JP6	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DM51JP6	DI	DM51JP6
DM51JP6	DN	PMID28092474-Compound-33c
DM51JP6	MI	TT5ZKDI
DM51JP6	MN	Histone deacetylase 6 (HDAC6)
DM51JP6	MT	DTT
DM51JP6	MA	Inhibitor
DM51JP6	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DM51JP6	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMW38MK	DI	DMW38MK
DMW38MK	DN	PMID28092474-Compound-33d
DMW38MK	MI	TT6R7JZ
DMW38MK	MN	Histone deacetylase 1 (HDAC1)
DMW38MK	MT	DTT
DMW38MK	MA	Inhibitor
DMW38MK	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMW38MK	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMW38MK	DI	DMW38MK
DMW38MK	DN	PMID28092474-Compound-33d
DMW38MK	MI	TT5ZKDI
DMW38MK	MN	Histone deacetylase 6 (HDAC6)
DMW38MK	MT	DTT
DMW38MK	MA	Inhibitor
DMW38MK	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMW38MK	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMGTSXL	DI	DMGTSXL
DMGTSXL	DN	PMID28092474-Compound-33e
DMGTSXL	MI	TT6R7JZ
DMGTSXL	MN	Histone deacetylase 1 (HDAC1)
DMGTSXL	MT	DTT
DMGTSXL	MA	Inhibitor
DMGTSXL	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMGTSXL	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMGTSXL	DI	DMGTSXL
DMGTSXL	DN	PMID28092474-Compound-33e
DMGTSXL	MI	TT5ZKDI
DMGTSXL	MN	Histone deacetylase 6 (HDAC6)
DMGTSXL	MT	DTT
DMGTSXL	MA	Inhibitor
DMGTSXL	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMGTSXL	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMA360M	DI	DMA360M
DMA360M	DN	PMID28092474-Compound-33f
DMA360M	MI	TT6R7JZ
DMA360M	MN	Histone deacetylase 1 (HDAC1)
DMA360M	MT	DTT
DMA360M	MA	Inhibitor
DMA360M	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMA360M	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMA360M	DI	DMA360M
DMA360M	DN	PMID28092474-Compound-33f
DMA360M	MI	TT5ZKDI
DMA360M	MN	Histone deacetylase 6 (HDAC6)
DMA360M	MT	DTT
DMA360M	MA	Inhibitor
DMA360M	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMA360M	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DM18DY6	DI	DM18DY6
DM18DY6	DN	PMID28092474-Compound-33g
DM18DY6	MI	TT6R7JZ
DM18DY6	MN	Histone deacetylase 1 (HDAC1)
DM18DY6	MT	DTT
DM18DY6	MA	Inhibitor
DM18DY6	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DM18DY6	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DM18DY6	DI	DM18DY6
DM18DY6	DN	PMID28092474-Compound-33g
DM18DY6	MI	TT5ZKDI
DM18DY6	MN	Histone deacetylase 6 (HDAC6)
DM18DY6	MT	DTT
DM18DY6	MA	Inhibitor
DM18DY6	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DM18DY6	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DM1DN6V	DI	DM1DN6V
DM1DN6V	DN	PMID28092474-Compound-33h
DM1DN6V	MI	TT6R7JZ
DM1DN6V	MN	Histone deacetylase 1 (HDAC1)
DM1DN6V	MT	DTT
DM1DN6V	MA	Inhibitor
DM1DN6V	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DM1DN6V	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DM1DN6V	DI	DM1DN6V
DM1DN6V	DN	PMID28092474-Compound-33h
DM1DN6V	MI	TT5ZKDI
DM1DN6V	MN	Histone deacetylase 6 (HDAC6)
DM1DN6V	MT	DTT
DM1DN6V	MA	Inhibitor
DM1DN6V	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DM1DN6V	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DM16E95	DI	DM16E95
DM16E95	DN	PMID28092474-Compound-33i
DM16E95	MI	TT6R7JZ
DM16E95	MN	Histone deacetylase 1 (HDAC1)
DM16E95	MT	DTT
DM16E95	MA	Inhibitor
DM16E95	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DM16E95	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DM16E95	DI	DM16E95
DM16E95	DN	PMID28092474-Compound-33i
DM16E95	MI	TT5ZKDI
DM16E95	MN	Histone deacetylase 6 (HDAC6)
DM16E95	MT	DTT
DM16E95	MA	Inhibitor
DM16E95	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DM16E95	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMNTRIZ	DI	DMNTRIZ
DMNTRIZ	DN	PMID28092474-Compound-33j
DMNTRIZ	MI	TT6R7JZ
DMNTRIZ	MN	Histone deacetylase 1 (HDAC1)
DMNTRIZ	MT	DTT
DMNTRIZ	MA	Inhibitor
DMNTRIZ	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMNTRIZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMNTRIZ	DI	DMNTRIZ
DMNTRIZ	DN	PMID28092474-Compound-33j
DMNTRIZ	MI	TT5ZKDI
DMNTRIZ	MN	Histone deacetylase 6 (HDAC6)
DMNTRIZ	MT	DTT
DMNTRIZ	MA	Inhibitor
DMNTRIZ	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMNTRIZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMF2ZNT	DI	DMF2ZNT
DMF2ZNT	DN	PMID28092474-Compound-33k
DMF2ZNT	MI	TT6R7JZ
DMF2ZNT	MN	Histone deacetylase 1 (HDAC1)
DMF2ZNT	MT	DTT
DMF2ZNT	MA	Inhibitor
DMF2ZNT	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMF2ZNT	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMF2ZNT	DI	DMF2ZNT
DMF2ZNT	DN	PMID28092474-Compound-33k
DMF2ZNT	MI	TT5ZKDI
DMF2ZNT	MN	Histone deacetylase 6 (HDAC6)
DMF2ZNT	MT	DTT
DMF2ZNT	MA	Inhibitor
DMF2ZNT	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMF2ZNT	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMPJSB2	DI	DMPJSB2
DMPJSB2	DN	PMID28092474-Compound-33l
DMPJSB2	MI	TT6R7JZ
DMPJSB2	MN	Histone deacetylase 1 (HDAC1)
DMPJSB2	MT	DTT
DMPJSB2	MA	Inhibitor
DMPJSB2	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMPJSB2	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMPJSB2	DI	DMPJSB2
DMPJSB2	DN	PMID28092474-Compound-33l
DMPJSB2	MI	TT5ZKDI
DMPJSB2	MN	Histone deacetylase 6 (HDAC6)
DMPJSB2	MT	DTT
DMPJSB2	MA	Inhibitor
DMPJSB2	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMPJSB2	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMXSPT9	DI	DMXSPT9
DMXSPT9	DN	PMID28092474-Compound-33m
DMXSPT9	MI	TT6R7JZ
DMXSPT9	MN	Histone deacetylase 1 (HDAC1)
DMXSPT9	MT	DTT
DMXSPT9	MA	Inhibitor
DMXSPT9	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMXSPT9	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMXSPT9	DI	DMXSPT9
DMXSPT9	DN	PMID28092474-Compound-33m
DMXSPT9	MI	TT5ZKDI
DMXSPT9	MN	Histone deacetylase 6 (HDAC6)
DMXSPT9	MT	DTT
DMXSPT9	MA	Inhibitor
DMXSPT9	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMXSPT9	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DM6DJZ7	DI	DM6DJZ7
DM6DJZ7	DN	PMID28092474-Compound-33o
DM6DJZ7	MI	TT6R7JZ
DM6DJZ7	MN	Histone deacetylase 1 (HDAC1)
DM6DJZ7	MT	DTT
DM6DJZ7	MA	Inhibitor
DM6DJZ7	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DM6DJZ7	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DM6DJZ7	DI	DM6DJZ7
DM6DJZ7	DN	PMID28092474-Compound-33o
DM6DJZ7	MI	TT5ZKDI
DM6DJZ7	MN	Histone deacetylase 6 (HDAC6)
DM6DJZ7	MT	DTT
DM6DJZ7	MA	Inhibitor
DM6DJZ7	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DM6DJZ7	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMI8ZBK	DI	DMI8ZBK
DMI8ZBK	DN	PMID28092474-Compound-33p
DMI8ZBK	MI	TT6R7JZ
DMI8ZBK	MN	Histone deacetylase 1 (HDAC1)
DMI8ZBK	MT	DTT
DMI8ZBK	MA	Inhibitor
DMI8ZBK	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMI8ZBK	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMI8ZBK	DI	DMI8ZBK
DMI8ZBK	DN	PMID28092474-Compound-33p
DMI8ZBK	MI	TT5ZKDI
DMI8ZBK	MN	Histone deacetylase 6 (HDAC6)
DMI8ZBK	MT	DTT
DMI8ZBK	MA	Inhibitor
DMI8ZBK	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMI8ZBK	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DM6JRCW	DI	DM6JRCW
DM6JRCW	DN	PMID28092474-Compound-34
DM6JRCW	MI	TTBH0VX
DM6JRCW	MN	Histone deacetylase (HDAC)
DM6JRCW	MT	DTT
DM6JRCW	MA	Inhibitor
DM6JRCW	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DM6JRCW	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMXQE7C	DI	DMXQE7C
DMXQE7C	DN	PMID28092474-Compound-34a
DMXQE7C	MI	TT6R7JZ
DMXQE7C	MN	Histone deacetylase 1 (HDAC1)
DMXQE7C	MT	DTT
DMXQE7C	MA	Inhibitor
DMXQE7C	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMXQE7C	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMXQE7C	DI	DMXQE7C
DMXQE7C	DN	PMID28092474-Compound-34a
DMXQE7C	MI	TT5ZKDI
DMXQE7C	MN	Histone deacetylase 6 (HDAC6)
DMXQE7C	MT	DTT
DMXQE7C	MA	Inhibitor
DMXQE7C	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMXQE7C	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DM6X2CO	DI	DM6X2CO
DM6X2CO	DN	PMID28092474-Compound-34b
DM6X2CO	MI	TT6R7JZ
DM6X2CO	MN	Histone deacetylase 1 (HDAC1)
DM6X2CO	MT	DTT
DM6X2CO	MA	Inhibitor
DM6X2CO	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DM6X2CO	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DM6X2CO	DI	DM6X2CO
DM6X2CO	DN	PMID28092474-Compound-34b
DM6X2CO	MI	TT5ZKDI
DM6X2CO	MN	Histone deacetylase 6 (HDAC6)
DM6X2CO	MT	DTT
DM6X2CO	MA	Inhibitor
DM6X2CO	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DM6X2CO	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMMI7DY	DI	DMMI7DY
DMMI7DY	DN	PMID28092474-Compound-34c
DMMI7DY	MI	TT6R7JZ
DMMI7DY	MN	Histone deacetylase 1 (HDAC1)
DMMI7DY	MT	DTT
DMMI7DY	MA	Inhibitor
DMMI7DY	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMMI7DY	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMMI7DY	DI	DMMI7DY
DMMI7DY	DN	PMID28092474-Compound-34c
DMMI7DY	MI	TT5ZKDI
DMMI7DY	MN	Histone deacetylase 6 (HDAC6)
DMMI7DY	MT	DTT
DMMI7DY	MA	Inhibitor
DMMI7DY	RN	Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
DMMI7DY	RU	https://www.ncbi.nlm.nih.gov/pubmed/28092474

DMAXS57	DI	DMAXS57
DMAXS57	DN	PMID28117607-Compound-20
DMAXS57	MI	TTK0FEA
DMAXS57	MN	Leucine-rich repeat kinase 2 (LRRK2)
DMAXS57	MT	DTT
DMAXS57	MA	Inhibitor
DMAXS57	RN	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
DMAXS57	RU	https://www.ncbi.nlm.nih.gov/pubmed/28117607

DMS8OTG	DI	DMS8OTG
DMS8OTG	DN	PMID28117607-Compound-21
DMS8OTG	MI	TTK0FEA
DMS8OTG	MN	Leucine-rich repeat kinase 2 (LRRK2)
DMS8OTG	MT	DTT
DMS8OTG	MA	Inhibitor
DMS8OTG	RN	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
DMS8OTG	RU	https://www.ncbi.nlm.nih.gov/pubmed/28117607

DMVIY73	DI	DMVIY73
DMVIY73	DN	PMID28117607-Compound-4
DMVIY73	MI	TTK0FEA
DMVIY73	MN	Leucine-rich repeat kinase 2 (LRRK2)
DMVIY73	MT	DTT
DMVIY73	MA	Inhibitor
DMVIY73	RN	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
DMVIY73	RU	https://www.ncbi.nlm.nih.gov/pubmed/28117607

DMPBNFM	DI	DMPBNFM
DMPBNFM	DN	PMID28117607-Compound-5
DMPBNFM	MI	TTK0FEA
DMPBNFM	MN	Leucine-rich repeat kinase 2 (LRRK2)
DMPBNFM	MT	DTT
DMPBNFM	MA	Inhibitor
DMPBNFM	RN	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
DMPBNFM	RU	https://www.ncbi.nlm.nih.gov/pubmed/28117607

DM68B1R	DI	DM68B1R
DM68B1R	DN	PMID28117607-Compound-6
DM68B1R	MI	TTK0FEA
DM68B1R	MN	Leucine-rich repeat kinase 2 (LRRK2)
DM68B1R	MT	DTT
DM68B1R	MA	Inhibitor
DM68B1R	RN	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
DM68B1R	RU	https://www.ncbi.nlm.nih.gov/pubmed/28117607

DMJZREU	DI	DMJZREU
DMJZREU	DN	PMID28117607-Compound-7
DMJZREU	MI	TTK0FEA
DMJZREU	MN	Leucine-rich repeat kinase 2 (LRRK2)
DMJZREU	MT	DTT
DMJZREU	MA	Inhibitor
DMJZREU	RN	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
DMJZREU	RU	https://www.ncbi.nlm.nih.gov/pubmed/28117607

DMBHRUP	DI	DMBHRUP
DMBHRUP	DN	PMID28270010-Compound-Figure16-a
DMBHRUP	MI	TTTDVOJ
DMBHRUP	MN	Tropomyosin-related kinase A (TrkA)
DMBHRUP	MT	DTT
DMBHRUP	MA	Inhibitor
DMBHRUP	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMBHRUP	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMAIRL2	DI	DMAIRL2
DMAIRL2	DN	PMID28270010-Compound-Figure16-b-1
DMAIRL2	MI	TTTDVOJ
DMAIRL2	MN	Tropomyosin-related kinase A (TrkA)
DMAIRL2	MT	DTT
DMAIRL2	MA	Inhibitor
DMAIRL2	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMAIRL2	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DM6YLMB	DI	DM6YLMB
DM6YLMB	DN	PMID28270010-Compound-Figure16-b-2
DM6YLMB	MI	TTTDVOJ
DM6YLMB	MN	Tropomyosin-related kinase A (TrkA)
DM6YLMB	MT	DTT
DM6YLMB	MA	Inhibitor
DM6YLMB	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DM6YLMB	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMPOI27	DI	DMPOI27
DMPOI27	DN	PMID28270010-Compound-Figure17-1
DMPOI27	MI	TTTDVOJ
DMPOI27	MN	Tropomyosin-related kinase A (TrkA)
DMPOI27	MT	DTT
DMPOI27	MA	Inhibitor
DMPOI27	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMPOI27	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DM7QLX8	DI	DM7QLX8
DM7QLX8	DN	PMID28270010-Compound-Figure17-2
DM7QLX8	MI	TTTDVOJ
DM7QLX8	MN	Tropomyosin-related kinase A (TrkA)
DM7QLX8	MT	DTT
DM7QLX8	MA	Inhibitor
DM7QLX8	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DM7QLX8	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DME0TUJ	DI	DME0TUJ
DME0TUJ	DN	PMID28270010-Compound-Figure17-3
DME0TUJ	MI	TTTDVOJ
DME0TUJ	MN	Tropomyosin-related kinase A (TrkA)
DME0TUJ	MT	DTT
DME0TUJ	MA	Inhibitor
DME0TUJ	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DME0TUJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DM6IYAT	DI	DM6IYAT
DM6IYAT	DN	PMID28270010-Compound-Figure21-b
DM6IYAT	MI	TTPMQSO
DM6IYAT	MN	ALK tyrosine kinase receptor (ALK)
DM6IYAT	MT	DTT
DM6IYAT	MA	Inhibitor
DM6IYAT	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DM6IYAT	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DM6IYAT	DI	DM6IYAT
DM6IYAT	DN	PMID28270010-Compound-Figure21-b
DM6IYAT	MI	TTSZ6Y3
DM6IYAT	MN	Proto-oncogene c-Ros (ROS1)
DM6IYAT	MT	DTT
DM6IYAT	MA	Inhibitor
DM6IYAT	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DM6IYAT	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMNTQL5	DI	DMNTQL5
DMNTQL5	DN	PMID28270010-Compound-Figure24-a
DMNTQL5	MI	TT7MRDV
DMNTQL5	MN	Macrophage colony-stimulating factor 1 receptor (CSF1R)
DMNTQL5	MT	DTT
DMNTQL5	MA	Inhibitor
DMNTQL5	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMNTQL5	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMNTQL5	DI	DMNTQL5
DMNTQL5	DN	PMID28270010-Compound-Figure24-a
DMNTQL5	MI	TTTDVOJ
DMNTQL5	MN	Tropomyosin-related kinase A (TrkA)
DMNTQL5	MT	DTT
DMNTQL5	MA	Inhibitor
DMNTQL5	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMNTQL5	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DM0QHLK	DI	DM0QHLK
DM0QHLK	DN	PMID28270010-Compound-Figure24-b
DM0QHLK	MI	TTKN7QR
DM0QHLK	MN	BDNF/NT-3 growth factors receptor (TrkB)
DM0QHLK	MT	DTT
DM0QHLK	MA	Inhibitor
DM0QHLK	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DM0QHLK	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DM0QHLK	DI	DM0QHLK
DM0QHLK	DN	PMID28270010-Compound-Figure24-b
DM0QHLK	MI	TTXABCW
DM0QHLK	MN	NT-3 growth factor receptor (TrkC)
DM0QHLK	MT	DTT
DM0QHLK	MA	Inhibitor
DM0QHLK	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DM0QHLK	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DM0QHLK	DI	DM0QHLK
DM0QHLK	DN	PMID28270010-Compound-Figure24-b
DM0QHLK	MI	TTTDVOJ
DM0QHLK	MN	Tropomyosin-related kinase A (TrkA)
DM0QHLK	MT	DTT
DM0QHLK	MA	Inhibitor
DM0QHLK	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DM0QHLK	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DM2YAPJ	DI	DM2YAPJ
DM2YAPJ	DN	PMID28270010-Compound-Figure5-1
DM2YAPJ	MI	TTKN7QR
DM2YAPJ	MN	BDNF/NT-3 growth factors receptor (TrkB)
DM2YAPJ	MT	DTT
DM2YAPJ	MA	Inhibitor
DM2YAPJ	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DM2YAPJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DM2YAPJ	DI	DM2YAPJ
DM2YAPJ	DN	PMID28270010-Compound-Figure5-1
DM2YAPJ	MI	TTXABCW
DM2YAPJ	MN	NT-3 growth factor receptor (TrkC)
DM2YAPJ	MT	DTT
DM2YAPJ	MA	Inhibitor
DM2YAPJ	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DM2YAPJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DM2YAPJ	DI	DM2YAPJ
DM2YAPJ	DN	PMID28270010-Compound-Figure5-1
DM2YAPJ	MI	TTTDVOJ
DM2YAPJ	MN	Tropomyosin-related kinase A (TrkA)
DM2YAPJ	MT	DTT
DM2YAPJ	MA	Inhibitor
DM2YAPJ	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DM2YAPJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMK3GRZ	DI	DMK3GRZ
DMK3GRZ	DN	PMID28270010-Compound-Figure5-2
DMK3GRZ	MI	TTKN7QR
DMK3GRZ	MN	BDNF/NT-3 growth factors receptor (TrkB)
DMK3GRZ	MT	DTT
DMK3GRZ	MA	Inhibitor
DMK3GRZ	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMK3GRZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMK3GRZ	DI	DMK3GRZ
DMK3GRZ	DN	PMID28270010-Compound-Figure5-2
DMK3GRZ	MI	TTXABCW
DMK3GRZ	MN	NT-3 growth factor receptor (TrkC)
DMK3GRZ	MT	DTT
DMK3GRZ	MA	Inhibitor
DMK3GRZ	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMK3GRZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMK3GRZ	DI	DMK3GRZ
DMK3GRZ	DN	PMID28270010-Compound-Figure5-2
DMK3GRZ	MI	TTTDVOJ
DMK3GRZ	MN	Tropomyosin-related kinase A (TrkA)
DMK3GRZ	MT	DTT
DMK3GRZ	MA	Inhibitor
DMK3GRZ	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMK3GRZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMSOT1R	DI	DMSOT1R
DMSOT1R	DN	PMID28270010-Compound-Figure5-3
DMSOT1R	MI	TTKN7QR
DMSOT1R	MN	BDNF/NT-3 growth factors receptor (TrkB)
DMSOT1R	MT	DTT
DMSOT1R	MA	Inhibitor
DMSOT1R	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMSOT1R	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMSOT1R	DI	DMSOT1R
DMSOT1R	DN	PMID28270010-Compound-Figure5-3
DMSOT1R	MI	TTXABCW
DMSOT1R	MN	NT-3 growth factor receptor (TrkC)
DMSOT1R	MT	DTT
DMSOT1R	MA	Inhibitor
DMSOT1R	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMSOT1R	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMSOT1R	DI	DMSOT1R
DMSOT1R	DN	PMID28270010-Compound-Figure5-3
DMSOT1R	MI	TTTDVOJ
DMSOT1R	MN	Tropomyosin-related kinase A (TrkA)
DMSOT1R	MT	DTT
DMSOT1R	MA	Inhibitor
DMSOT1R	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMSOT1R	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DM437ZC	DI	DM437ZC
DM437ZC	DN	PMID28270021-Compound-WO2010077680 103
DM437ZC	MI	TTTDVOJ
DM437ZC	MN	Tropomyosin-related kinase A (TrkA)
DM437ZC	MT	DTT
DM437ZC	MA	Antagonist
DM437ZC	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DM437ZC	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMNUA21	DI	DMNUA21
DMNUA21	DN	PMID28270021-Compound-WO2010077680 109
DMNUA21	MI	TTTDVOJ
DMNUA21	MN	Tropomyosin-related kinase A (TrkA)
DMNUA21	MT	DTT
DMNUA21	MA	Antagonist
DMNUA21	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMNUA21	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMQAZMC	DI	DMQAZMC
DMQAZMC	DN	PMID28270021-Compound-WO2010077680 201
DMQAZMC	MI	TTTDVOJ
DMQAZMC	MN	Tropomyosin-related kinase A (TrkA)
DMQAZMC	MT	DTT
DMQAZMC	MA	Antagonist
DMQAZMC	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMQAZMC	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DM6VAS2	DI	DM6VAS2
DM6VAS2	DN	PMID28270021-Compound-WO2010077680 481
DM6VAS2	MI	TTTDVOJ
DM6VAS2	MN	Tropomyosin-related kinase A (TrkA)
DM6VAS2	MT	DTT
DM6VAS2	MA	Antagonist
DM6VAS2	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DM6VAS2	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMQ9CBS	DI	DMQ9CBS
DMQ9CBS	DN	PMID28270021-Compound-WO2010077680 495
DMQ9CBS	MI	TTTDVOJ
DMQ9CBS	MN	Tropomyosin-related kinase A (TrkA)
DMQ9CBS	MT	DTT
DMQ9CBS	MA	Antagonist
DMQ9CBS	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMQ9CBS	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DM6TJU0	DI	DM6TJU0
DM6TJU0	DN	PMID28270021-Compound-WO2010077680 803
DM6TJU0	MI	TTTDVOJ
DM6TJU0	MN	Tropomyosin-related kinase A (TrkA)
DM6TJU0	MT	DTT
DM6TJU0	MA	Antagonist
DM6TJU0	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DM6TJU0	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DM47FNS	DI	DM47FNS
DM47FNS	DN	PMID28270021-Compound-WO2010077680 811
DM47FNS	MI	TTTDVOJ
DM47FNS	MN	Tropomyosin-related kinase A (TrkA)
DM47FNS	MT	DTT
DM47FNS	MA	Antagonist
DM47FNS	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DM47FNS	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMVS7CJ	DI	DMVS7CJ
DMVS7CJ	DN	PMID28270021-Compound-WO2013009582Example16
DMVS7CJ	MI	TTTDVOJ
DMVS7CJ	MN	Tropomyosin-related kinase A (TrkA)
DMVS7CJ	MT	DTT
DMVS7CJ	MA	Inhibitor
DMVS7CJ	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMVS7CJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMQK4IX	DI	DMQK4IX
DMQK4IX	DN	PMID28270021-Compound-WO2013009582Example76
DMQK4IX	MI	TTTDVOJ
DMQK4IX	MN	Tropomyosin-related kinase A (TrkA)
DMQK4IX	MT	DTT
DMQK4IX	MA	Inhibitor
DMQK4IX	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMQK4IX	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DM2XKTB	DI	DM2XKTB
DM2XKTB	DN	PMID28270021-Compound-WO2013161919Example85-117
DM2XKTB	MI	TTTDVOJ
DM2XKTB	MN	Tropomyosin-related kinase A (TrkA)
DM2XKTB	MT	DTT
DM2XKTB	MA	Inhibitor
DM2XKTB	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DM2XKTB	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMO02EL	DI	DMO02EL
DMO02EL	DN	PMID28270021-Compound-WO2014078408Example1
DMO02EL	MI	TTTDVOJ
DMO02EL	MN	Tropomyosin-related kinase A (TrkA)
DMO02EL	MT	DTT
DMO02EL	MA	Inhibitor
DMO02EL	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMO02EL	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMVCBSK	DI	DMVCBSK
DMVCBSK	DN	PMID28270021-Compound-WO2014078408Example26
DMVCBSK	MI	TTTDVOJ
DMVCBSK	MN	Tropomyosin-related kinase A (TrkA)
DMVCBSK	MT	DTT
DMVCBSK	MA	Inhibitor
DMVCBSK	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMVCBSK	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMKO4ZH	DI	DMKO4ZH
DMKO4ZH	DN	PMID28270021-Compound-WO2014129431Example8-1
DMKO4ZH	MI	TTTDVOJ
DMKO4ZH	MN	Tropomyosin-related kinase A (TrkA)
DMKO4ZH	MT	DTT
DMKO4ZH	MA	Inhibitor
DMKO4ZH	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMKO4ZH	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMA04P6	DI	DMA04P6
DMA04P6	DN	PMID28270021-Compound-WO2014152663 701
DMA04P6	MI	TTTDVOJ
DMA04P6	MN	Tropomyosin-related kinase A (TrkA)
DMA04P6	MT	DTT
DMA04P6	MA	Inhibitor
DMA04P6	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMA04P6	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DM16URY	DI	DM16URY
DM16URY	DN	PMID28270021-Compound-WO2015042088Example11
DM16URY	MI	TTTDVOJ
DM16URY	MN	Tropomyosin-related kinase A (TrkA)
DM16URY	MT	DTT
DM16URY	MA	Inhibitor
DM16URY	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DM16URY	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMOZHGU	DI	DMOZHGU
DMOZHGU	DN	PMID28270021-Compound-WO2015042088Example12
DMOZHGU	MI	TTTDVOJ
DMOZHGU	MN	Tropomyosin-related kinase A (TrkA)
DMOZHGU	MT	DTT
DMOZHGU	MA	Inhibitor
DMOZHGU	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMOZHGU	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DM6KXOQ	DI	DM6KXOQ
DM6KXOQ	DN	PMID28270021-Compound-WO2015042088Example4
DM6KXOQ	MI	TTKN7QR
DM6KXOQ	MN	BDNF/NT-3 growth factors receptor (TrkB)
DM6KXOQ	MT	DTT
DM6KXOQ	MA	Inhibitor
DM6KXOQ	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DM6KXOQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DM6KXOQ	DI	DM6KXOQ
DM6KXOQ	DN	PMID28270021-Compound-WO2015042088Example4
DM6KXOQ	MI	TTXABCW
DM6KXOQ	MN	NT-3 growth factor receptor (TrkC)
DM6KXOQ	MT	DTT
DM6KXOQ	MA	Inhibitor
DM6KXOQ	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DM6KXOQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DM6KXOQ	DI	DM6KXOQ
DM6KXOQ	DN	PMID28270021-Compound-WO2015042088Example4
DM6KXOQ	MI	TTTDVOJ
DM6KXOQ	MN	Tropomyosin-related kinase A (TrkA)
DM6KXOQ	MT	DTT
DM6KXOQ	MA	Inhibitor
DM6KXOQ	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DM6KXOQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMD5QEL	DI	DMD5QEL
DMD5QEL	DN	PMID28270021-Compound-WO2016054807Example1
DMD5QEL	MI	TTKN7QR
DMD5QEL	MN	BDNF/NT-3 growth factors receptor (TrkB)
DMD5QEL	MT	DTT
DMD5QEL	MA	Inhibitor
DMD5QEL	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMD5QEL	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMD5QEL	DI	DMD5QEL
DMD5QEL	DN	PMID28270021-Compound-WO2016054807Example1
DMD5QEL	MI	TTXABCW
DMD5QEL	MN	NT-3 growth factor receptor (TrkC)
DMD5QEL	MT	DTT
DMD5QEL	MA	Inhibitor
DMD5QEL	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMD5QEL	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMD5QEL	DI	DMD5QEL
DMD5QEL	DN	PMID28270021-Compound-WO2016054807Example1
DMD5QEL	MI	TTTDVOJ
DMD5QEL	MN	Tropomyosin-related kinase A (TrkA)
DMD5QEL	MT	DTT
DMD5QEL	MA	Inhibitor
DMD5QEL	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMD5QEL	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMW2ZRM	DI	DMW2ZRM
DMW2ZRM	DN	PMID28270021-Compound-WO2016054807Example112
DMW2ZRM	MI	TTTDVOJ
DMW2ZRM	MN	Tropomyosin-related kinase A (TrkA)
DMW2ZRM	MT	DTT
DMW2ZRM	MA	Inhibitor
DMW2ZRM	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMW2ZRM	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMREZ9I	DI	DMREZ9I
DMREZ9I	DN	PMID28270021-Compound-WO2016054807Example71
DMREZ9I	MI	TTTDVOJ
DMREZ9I	MN	Tropomyosin-related kinase A (TrkA)
DMREZ9I	MT	DTT
DMREZ9I	MA	Inhibitor
DMREZ9I	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMREZ9I	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMPI86D	DI	DMPI86D
DMPI86D	DN	PMID28270021-Compound-WO2016054807Example80
DMPI86D	MI	TTTDVOJ
DMPI86D	MN	Tropomyosin-related kinase A (TrkA)
DMPI86D	MT	DTT
DMPI86D	MA	Inhibitor
DMPI86D	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMPI86D	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DM9ADSN	DI	DM9ADSN
DM9ADSN	DN	PMID28270021-Compound-WO2016054807Example82
DM9ADSN	MI	TTTDVOJ
DM9ADSN	MN	Tropomyosin-related kinase A (TrkA)
DM9ADSN	MT	DTT
DM9ADSN	MA	Inhibitor
DM9ADSN	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DM9ADSN	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMSEIL0	DI	DMSEIL0
DMSEIL0	DN	PMID28350212-Compound-1
DMSEIL0	MI	TTZS04O
DMSEIL0	MN	Gamma-secretase subunit APH-1A/1B (APH-1)
DMSEIL0	MT	DTT
DMSEIL0	MA	Inhibitor
DMSEIL0	RN	Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866.
DMSEIL0	RU	https://www.ncbi.nlm.nih.gov/pubmed/28350212

DME72ZH	DI	DME72ZH
DME72ZH	DN	PMID28350212-Compound-12
DME72ZH	MI	TTZS04O
DME72ZH	MN	Gamma-secretase subunit APH-1A/1B (APH-1)
DME72ZH	MT	DTT
DME72ZH	MA	Inhibitor
DME72ZH	RN	Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866.
DME72ZH	RU	https://www.ncbi.nlm.nih.gov/pubmed/28350212

DMPWYL8	DI	DMPWYL8
DMPWYL8	DN	PMID28350212-Compound-13
DMPWYL8	MI	TTZS04O
DMPWYL8	MN	Gamma-secretase subunit APH-1A/1B (APH-1)
DMPWYL8	MT	DTT
DMPWYL8	MA	Inhibitor
DMPWYL8	RN	Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866.
DMPWYL8	RU	https://www.ncbi.nlm.nih.gov/pubmed/28350212

DMSFL5B	DI	DMSFL5B
DMSFL5B	DN	PMID28350212-Compound-15
DMSFL5B	MI	TTZS04O
DMSFL5B	MN	Gamma-secretase subunit APH-1A/1B (APH-1)
DMSFL5B	MT	DTT
DMSFL5B	MA	Inhibitor
DMSFL5B	RN	Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866.
DMSFL5B	RU	https://www.ncbi.nlm.nih.gov/pubmed/28350212

DMA1RP9	DI	DMA1RP9
DMA1RP9	DN	PMID28350212-Compound-16
DMA1RP9	MI	TTZS04O
DMA1RP9	MN	Gamma-secretase subunit APH-1A/1B (APH-1)
DMA1RP9	MT	DTT
DMA1RP9	MA	Inhibitor
DMA1RP9	RN	Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866.
DMA1RP9	RU	https://www.ncbi.nlm.nih.gov/pubmed/28350212

DMH8GC6	DI	DMH8GC6
DMH8GC6	DN	PMID28350212-Compound-18
DMH8GC6	MI	TTZS04O
DMH8GC6	MN	Gamma-secretase subunit APH-1A/1B (APH-1)
DMH8GC6	MT	DTT
DMH8GC6	MA	Inhibitor
DMH8GC6	RN	Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866.
DMH8GC6	RU	https://www.ncbi.nlm.nih.gov/pubmed/28350212

DMI4US6	DI	DMI4US6
DMI4US6	DN	PMID28350212-Compound-19
DMI4US6	MI	TTZS04O
DMI4US6	MN	Gamma-secretase subunit APH-1A/1B (APH-1)
DMI4US6	MT	DTT
DMI4US6	MA	Inhibitor
DMI4US6	RN	Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866.
DMI4US6	RU	https://www.ncbi.nlm.nih.gov/pubmed/28350212

DMM5G7S	DI	DMM5G7S
DMM5G7S	DN	PMID28350212-Compound-20
DMM5G7S	MI	TTZS04O
DMM5G7S	MN	Gamma-secretase subunit APH-1A/1B (APH-1)
DMM5G7S	MT	DTT
DMM5G7S	MA	Inhibitor
DMM5G7S	RN	Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866.
DMM5G7S	RU	https://www.ncbi.nlm.nih.gov/pubmed/28350212

DMFTGZC	DI	DMFTGZC
DMFTGZC	DN	PMID28350212-Compound-21
DMFTGZC	MI	TTZS04O
DMFTGZC	MN	Gamma-secretase subunit APH-1A/1B (APH-1)
DMFTGZC	MT	DTT
DMFTGZC	MA	Inhibitor
DMFTGZC	RN	Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866.
DMFTGZC	RU	https://www.ncbi.nlm.nih.gov/pubmed/28350212

DMKXZYC	DI	DMKXZYC
DMKXZYC	DN	PMID28350212-Compound-22
DMKXZYC	MI	TTZS04O
DMKXZYC	MN	Gamma-secretase subunit APH-1A/1B (APH-1)
DMKXZYC	MT	DTT
DMKXZYC	MA	Inhibitor
DMKXZYC	RN	Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866.
DMKXZYC	RU	https://www.ncbi.nlm.nih.gov/pubmed/28350212

DM3MVW1	DI	DM3MVW1
DM3MVW1	DN	PMID28350212-Compound-23
DM3MVW1	MI	TTZS04O
DM3MVW1	MN	Gamma-secretase subunit APH-1A/1B (APH-1)
DM3MVW1	MT	DTT
DM3MVW1	MA	Inhibitor
DM3MVW1	RN	Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866.
DM3MVW1	RU	https://www.ncbi.nlm.nih.gov/pubmed/28350212

DMPJH6L	DI	DMPJH6L
DMPJH6L	DN	PMID28350212-Compound-24
DMPJH6L	MI	TTZS04O
DMPJH6L	MN	Gamma-secretase subunit APH-1A/1B (APH-1)
DMPJH6L	MT	DTT
DMPJH6L	MA	Inhibitor
DMPJH6L	RN	Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866.
DMPJH6L	RU	https://www.ncbi.nlm.nih.gov/pubmed/28350212

DML2VUC	DI	DML2VUC
DML2VUC	DN	PMID28350212-Compound-25
DML2VUC	MI	TTZS04O
DML2VUC	MN	Gamma-secretase subunit APH-1A/1B (APH-1)
DML2VUC	MT	DTT
DML2VUC	MA	Inhibitor
DML2VUC	RN	Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866.
DML2VUC	RU	https://www.ncbi.nlm.nih.gov/pubmed/28350212

DMF1ZJ3	DI	DMF1ZJ3
DMF1ZJ3	DN	PMID28350212-Compound-30
DMF1ZJ3	MI	TTZS04O
DMF1ZJ3	MN	Gamma-secretase subunit APH-1A/1B (APH-1)
DMF1ZJ3	MT	DTT
DMF1ZJ3	MA	Inhibitor
DMF1ZJ3	RN	Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866.
DMF1ZJ3	RU	https://www.ncbi.nlm.nih.gov/pubmed/28350212

DMSKE2O	DI	DMSKE2O
DMSKE2O	DN	PMID28350212-Compound-35
DMSKE2O	MI	TTZS04O
DMSKE2O	MN	Gamma-secretase subunit APH-1A/1B (APH-1)
DMSKE2O	MT	DTT
DMSKE2O	MA	Inhibitor
DMSKE2O	RN	Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866.
DMSKE2O	RU	https://www.ncbi.nlm.nih.gov/pubmed/28350212

DM7ULWD	DI	DM7ULWD
DM7ULWD	DN	PMID28350212-Compound-36
DM7ULWD	MI	TTZS04O
DM7ULWD	MN	Gamma-secretase subunit APH-1A/1B (APH-1)
DM7ULWD	MT	DTT
DM7ULWD	MA	Inhibitor
DM7ULWD	RN	Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866.
DM7ULWD	RU	https://www.ncbi.nlm.nih.gov/pubmed/28350212

DMUBSFV	DI	DMUBSFV
DMUBSFV	DN	PMID28350212-Compound-7
DMUBSFV	MI	TTZS04O
DMUBSFV	MN	Gamma-secretase subunit APH-1A/1B (APH-1)
DMUBSFV	MT	DTT
DMUBSFV	MA	Inhibitor
DMUBSFV	RN	Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866.
DMUBSFV	RU	https://www.ncbi.nlm.nih.gov/pubmed/28350212

DMR0PUA	DI	DMR0PUA
DMR0PUA	DN	PMID28394193-Compound-10
DMR0PUA	MI	TTJBYRU
DMR0PUA	MN	EZH2 Y641F mutant (EZH2 Y641F)
DMR0PUA	MT	DTT
DMR0PUA	MA	Inhibitor
DMR0PUA	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DMR0PUA	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DMJ23AL	DI	DMJ23AL
DMJ23AL	DN	PMID28394193-Compound-11
DMJ23AL	MI	TTJBYRU
DMJ23AL	MN	EZH2 Y641F mutant (EZH2 Y641F)
DMJ23AL	MT	DTT
DMJ23AL	MA	Inhibitor
DMJ23AL	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DMJ23AL	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DMA7H9T	DI	DMA7H9T
DMA7H9T	DN	PMID28394193-Compound-12
DMA7H9T	MI	TT9MZCQ
DMA7H9T	MN	Enhancer of zeste homolog 2 (EZH2)
DMA7H9T	MT	DTT
DMA7H9T	MA	Inhibitor
DMA7H9T	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DMA7H9T	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DMA7H9T	DI	DMA7H9T
DMA7H9T	DN	PMID28394193-Compound-12
DMA7H9T	MI	TTJBYRU
DMA7H9T	MN	EZH2 Y641F mutant (EZH2 Y641F)
DMA7H9T	MT	DTT
DMA7H9T	MA	Inhibitor
DMA7H9T	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DMA7H9T	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DMGZ9MW	DI	DMGZ9MW
DMGZ9MW	DN	PMID28394193-Compound-13
DMGZ9MW	MI	TT9MZCQ
DMGZ9MW	MN	Enhancer of zeste homolog 2 (EZH2)
DMGZ9MW	MT	DTT
DMGZ9MW	MA	Inhibitor
DMGZ9MW	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DMGZ9MW	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DMGZ9MW	DI	DMGZ9MW
DMGZ9MW	DN	PMID28394193-Compound-13
DMGZ9MW	MI	TTJBYRU
DMGZ9MW	MN	EZH2 Y641F mutant (EZH2 Y641F)
DMGZ9MW	MT	DTT
DMGZ9MW	MA	Inhibitor
DMGZ9MW	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DMGZ9MW	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DM6T2FM	DI	DM6T2FM
DM6T2FM	DN	PMID28394193-Compound-14
DM6T2FM	MI	TT9MZCQ
DM6T2FM	MN	Enhancer of zeste homolog 2 (EZH2)
DM6T2FM	MT	DTT
DM6T2FM	MA	Inhibitor
DM6T2FM	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DM6T2FM	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DM6T2FM	DI	DM6T2FM
DM6T2FM	DN	PMID28394193-Compound-14
DM6T2FM	MI	TTJBYRU
DM6T2FM	MN	EZH2 Y641F mutant (EZH2 Y641F)
DM6T2FM	MT	DTT
DM6T2FM	MA	Inhibitor
DM6T2FM	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DM6T2FM	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DMXMP92	DI	DMXMP92
DMXMP92	DN	PMID28394193-Compound-15
DMXMP92	MI	TT9MZCQ
DMXMP92	MN	Enhancer of zeste homolog 2 (EZH2)
DMXMP92	MT	DTT
DMXMP92	MA	Inhibitor
DMXMP92	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DMXMP92	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DMQDRUT	DI	DMQDRUT
DMQDRUT	DN	PMID28394193-Compound-16
DMQDRUT	MI	TT9MZCQ
DMQDRUT	MN	Enhancer of zeste homolog 2 (EZH2)
DMQDRUT	MT	DTT
DMQDRUT	MA	Inhibitor
DMQDRUT	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DMQDRUT	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DMPR9GA	DI	DMPR9GA
DMPR9GA	DN	PMID28394193-Compound-17
DMPR9GA	MI	TT9MZCQ
DMPR9GA	MN	Enhancer of zeste homolog 2 (EZH2)
DMPR9GA	MT	DTT
DMPR9GA	MA	Inhibitor
DMPR9GA	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DMPR9GA	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DMIBZ2H	DI	DMIBZ2H
DMIBZ2H	DN	PMID28394193-Compound-18
DMIBZ2H	MI	TT9MZCQ
DMIBZ2H	MN	Enhancer of zeste homolog 2 (EZH2)
DMIBZ2H	MT	DTT
DMIBZ2H	MA	Inhibitor
DMIBZ2H	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DMIBZ2H	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DM4ZAE8	DI	DM4ZAE8
DM4ZAE8	DN	PMID28394193-Compound-19
DM4ZAE8	MI	TT9MZCQ
DM4ZAE8	MN	Enhancer of zeste homolog 2 (EZH2)
DM4ZAE8	MT	DTT
DM4ZAE8	MA	Inhibitor
DM4ZAE8	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DM4ZAE8	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DMC5NR0	DI	DMC5NR0
DMC5NR0	DN	PMID28394193-Compound-20
DMC5NR0	MI	TT9MZCQ
DMC5NR0	MN	Enhancer of zeste homolog 2 (EZH2)
DMC5NR0	MT	DTT
DMC5NR0	MA	Inhibitor
DMC5NR0	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DMC5NR0	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DMLD8K3	DI	DMLD8K3
DMLD8K3	DN	PMID28394193-Compound-21
DMLD8K3	MI	TT9MZCQ
DMLD8K3	MN	Enhancer of zeste homolog 2 (EZH2)
DMLD8K3	MT	DTT
DMLD8K3	MA	Inhibitor
DMLD8K3	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DMLD8K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DM8PJ3F	DI	DM8PJ3F
DM8PJ3F	DN	PMID28394193-Compound-22
DM8PJ3F	MI	TT9MZCQ
DM8PJ3F	MN	Enhancer of zeste homolog 2 (EZH2)
DM8PJ3F	MT	DTT
DM8PJ3F	MA	Inhibitor
DM8PJ3F	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DM8PJ3F	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DMNHCMY	DI	DMNHCMY
DMNHCMY	DN	PMID28394193-Compound-23
DMNHCMY	MI	TT9MZCQ
DMNHCMY	MN	Enhancer of zeste homolog 2 (EZH2)
DMNHCMY	MT	DTT
DMNHCMY	MA	Inhibitor
DMNHCMY	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DMNHCMY	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DMYCVWZ	DI	DMYCVWZ
DMYCVWZ	DN	PMID28394193-Compound-24
DMYCVWZ	MI	TT9MZCQ
DMYCVWZ	MN	Enhancer of zeste homolog 2 (EZH2)
DMYCVWZ	MT	DTT
DMYCVWZ	MA	Inhibitor
DMYCVWZ	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DMYCVWZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DMPIXAO	DI	DMPIXAO
DMPIXAO	DN	PMID28394193-Compound-25
DMPIXAO	MI	TT9MZCQ
DMPIXAO	MN	Enhancer of zeste homolog 2 (EZH2)
DMPIXAO	MT	DTT
DMPIXAO	MA	Inhibitor
DMPIXAO	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DMPIXAO	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DMNWCUJ	DI	DMNWCUJ
DMNWCUJ	DN	PMID28394193-Compound-26
DMNWCUJ	MI	TT9MZCQ
DMNWCUJ	MN	Enhancer of zeste homolog 2 (EZH2)
DMNWCUJ	MT	DTT
DMNWCUJ	MA	Inhibitor
DMNWCUJ	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DMNWCUJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DM2KVDH	DI	DM2KVDH
DM2KVDH	DN	PMID28394193-Compound-27
DM2KVDH	MI	TT9MZCQ
DM2KVDH	MN	Enhancer of zeste homolog 2 (EZH2)
DM2KVDH	MT	DTT
DM2KVDH	MA	Inhibitor
DM2KVDH	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DM2KVDH	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DMC24OL	DI	DMC24OL
DMC24OL	DN	PMID28394193-Compound-28
DMC24OL	MI	TT9MZCQ
DMC24OL	MN	Enhancer of zeste homolog 2 (EZH2)
DMC24OL	MT	DTT
DMC24OL	MA	Inhibitor
DMC24OL	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DMC24OL	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DMBVI7L	DI	DMBVI7L
DMBVI7L	DN	PMID28394193-Compound-29
DMBVI7L	MI	TT9MZCQ
DMBVI7L	MN	Enhancer of zeste homolog 2 (EZH2)
DMBVI7L	MT	DTT
DMBVI7L	MA	Inhibitor
DMBVI7L	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DMBVI7L	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DMGEZT8	DI	DMGEZT8
DMGEZT8	DN	PMID28394193-Compound-30
DMGEZT8	MI	TT9MZCQ
DMGEZT8	MN	Enhancer of zeste homolog 2 (EZH2)
DMGEZT8	MT	DTT
DMGEZT8	MA	Inhibitor
DMGEZT8	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DMGEZT8	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DMJ02N1	DI	DMJ02N1
DMJ02N1	DN	PMID28394193-Compound-31
DMJ02N1	MI	TT9MZCQ
DMJ02N1	MN	Enhancer of zeste homolog 2 (EZH2)
DMJ02N1	MT	DTT
DMJ02N1	MA	Inhibitor
DMJ02N1	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DMJ02N1	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DM628MP	DI	DM628MP
DM628MP	DN	PMID28394193-Compound-32
DM628MP	MI	TT9MZCQ
DM628MP	MN	Enhancer of zeste homolog 2 (EZH2)
DM628MP	MT	DTT
DM628MP	MA	Inhibitor
DM628MP	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DM628MP	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DMEOHX2	DI	DMEOHX2
DMEOHX2	DN	PMID28394193-Compound-33
DMEOHX2	MI	TT9MZCQ
DMEOHX2	MN	Enhancer of zeste homolog 2 (EZH2)
DMEOHX2	MT	DTT
DMEOHX2	MA	Inhibitor
DMEOHX2	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DMEOHX2	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DMB7WNP	DI	DMB7WNP
DMB7WNP	DN	PMID28394193-Compound-34
DMB7WNP	MI	TT9MZCQ
DMB7WNP	MN	Enhancer of zeste homolog 2 (EZH2)
DMB7WNP	MT	DTT
DMB7WNP	MA	Inhibitor
DMB7WNP	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DMB7WNP	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DMV1AGC	DI	DMV1AGC
DMV1AGC	DN	PMID28394193-Compound-35
DMV1AGC	MI	TT9MZCQ
DMV1AGC	MN	Enhancer of zeste homolog 2 (EZH2)
DMV1AGC	MT	DTT
DMV1AGC	MA	Inhibitor
DMV1AGC	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DMV1AGC	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DM658HJ	DI	DM658HJ
DM658HJ	DN	PMID28394193-Compound-36
DM658HJ	MI	TT9MZCQ
DM658HJ	MN	Enhancer of zeste homolog 2 (EZH2)
DM658HJ	MT	DTT
DM658HJ	MA	Inhibitor
DM658HJ	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DM658HJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DM73CA5	DI	DM73CA5
DM73CA5	DN	PMID28394193-Compound-37
DM73CA5	MI	TT9MZCQ
DM73CA5	MN	Enhancer of zeste homolog 2 (EZH2)
DM73CA5	MT	DTT
DM73CA5	MA	Inhibitor
DM73CA5	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DM73CA5	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DM25PMQ	DI	DM25PMQ
DM25PMQ	DN	PMID28394193-Compound-38
DM25PMQ	MI	TT9MZCQ
DM25PMQ	MN	Enhancer of zeste homolog 2 (EZH2)
DM25PMQ	MT	DTT
DM25PMQ	MA	Inhibitor
DM25PMQ	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DM25PMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DM2NS5T	DI	DM2NS5T
DM2NS5T	DN	PMID28394193-Compound-39
DM2NS5T	MI	TT9MZCQ
DM2NS5T	MN	Enhancer of zeste homolog 2 (EZH2)
DM2NS5T	MT	DTT
DM2NS5T	MA	Inhibitor
DM2NS5T	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DM2NS5T	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DMO5479	DI	DMO5479
DMO5479	DN	PMID28394193-Compound-40
DMO5479	MI	TT9MZCQ
DMO5479	MN	Enhancer of zeste homolog 2 (EZH2)
DMO5479	MT	DTT
DMO5479	MA	Inhibitor
DMO5479	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DMO5479	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DMYLVTQ	DI	DMYLVTQ
DMYLVTQ	DN	PMID28394193-Compound-41
DMYLVTQ	MI	TT9MZCQ
DMYLVTQ	MN	Enhancer of zeste homolog 2 (EZH2)
DMYLVTQ	MT	DTT
DMYLVTQ	MA	Inhibitor
DMYLVTQ	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DMYLVTQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DMLI7TG	DI	DMLI7TG
DMLI7TG	DN	PMID28394193-Compound-42
DMLI7TG	MI	TT9MZCQ
DMLI7TG	MN	Enhancer of zeste homolog 2 (EZH2)
DMLI7TG	MT	DTT
DMLI7TG	MA	Inhibitor
DMLI7TG	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DMLI7TG	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DMASV8I	DI	DMASV8I
DMASV8I	DN	PMID28394193-Compound-43
DMASV8I	MI	TT9MZCQ
DMASV8I	MN	Enhancer of zeste homolog 2 (EZH2)
DMASV8I	MT	DTT
DMASV8I	MA	Inhibitor
DMASV8I	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DMASV8I	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DME6FWY	DI	DME6FWY
DME6FWY	DN	PMID28394193-Compound-44
DME6FWY	MI	TT9MZCQ
DME6FWY	MN	Enhancer of zeste homolog 2 (EZH2)
DME6FWY	MT	DTT
DME6FWY	MA	Inhibitor
DME6FWY	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DME6FWY	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DMZJXPF	DI	DMZJXPF
DMZJXPF	DN	PMID28394193-Compound-45
DMZJXPF	MI	TT9MZCQ
DMZJXPF	MN	Enhancer of zeste homolog 2 (EZH2)
DMZJXPF	MT	DTT
DMZJXPF	MA	Inhibitor
DMZJXPF	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DMZJXPF	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DMZJXPF	DI	DMZJXPF
DMZJXPF	DN	PMID28394193-Compound-45
DMZJXPF	MI	TTJW2UQ
DMZJXPF	MN	EZH2 Y641N mutant (EZH2 Y641N)
DMZJXPF	MT	DTT
DMZJXPF	MA	Inhibitor
DMZJXPF	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DMZJXPF	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DMYMPNA	DI	DMYMPNA
DMYMPNA	DN	PMID28394193-Compound-46
DMYMPNA	MI	TT9MZCQ
DMYMPNA	MN	Enhancer of zeste homolog 2 (EZH2)
DMYMPNA	MT	DTT
DMYMPNA	MA	Inhibitor
DMYMPNA	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DMYMPNA	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DMYMPNA	DI	DMYMPNA
DMYMPNA	DN	PMID28394193-Compound-46
DMYMPNA	MI	TTJW2UQ
DMYMPNA	MN	EZH2 Y641N mutant (EZH2 Y641N)
DMYMPNA	MT	DTT
DMYMPNA	MA	Inhibitor
DMYMPNA	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DMYMPNA	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DM7UDIM	DI	DM7UDIM
DM7UDIM	DN	PMID28394193-Compound-47
DM7UDIM	MI	TT9MZCQ
DM7UDIM	MN	Enhancer of zeste homolog 2 (EZH2)
DM7UDIM	MT	DTT
DM7UDIM	MA	Inhibitor
DM7UDIM	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DM7UDIM	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DMEU4Y1	DI	DMEU4Y1
DMEU4Y1	DN	PMID28394193-Compound-49
DMEU4Y1	MI	TT9MZCQ
DMEU4Y1	MN	Enhancer of zeste homolog 2 (EZH2)
DMEU4Y1	MT	DTT
DMEU4Y1	MA	Inhibitor
DMEU4Y1	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DMEU4Y1	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DM4NVTB	DI	DM4NVTB
DM4NVTB	DN	PMID28394193-Compound-50
DM4NVTB	MI	TT9MZCQ
DM4NVTB	MN	Enhancer of zeste homolog 2 (EZH2)
DM4NVTB	MT	DTT
DM4NVTB	MA	Inhibitor
DM4NVTB	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DM4NVTB	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DM0KPQ9	DI	DM0KPQ9
DM0KPQ9	DN	PMID28394193-Compound-51
DM0KPQ9	MI	TT9MZCQ
DM0KPQ9	MN	Enhancer of zeste homolog 2 (EZH2)
DM0KPQ9	MT	DTT
DM0KPQ9	MA	Inhibitor
DM0KPQ9	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DM0KPQ9	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DM2I9HY	DI	DM2I9HY
DM2I9HY	DN	PMID28394193-Compound-52
DM2I9HY	MI	TT9MZCQ
DM2I9HY	MN	Enhancer of zeste homolog 2 (EZH2)
DM2I9HY	MT	DTT
DM2I9HY	MA	Inhibitor
DM2I9HY	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DM2I9HY	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DMXMRQP	DI	DMXMRQP
DMXMRQP	DN	PMID28394193-Compound-53
DMXMRQP	MI	TT9MZCQ
DMXMRQP	MN	Enhancer of zeste homolog 2 (EZH2)
DMXMRQP	MT	DTT
DMXMRQP	MA	Inhibitor
DMXMRQP	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DMXMRQP	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DMMQ3UG	DI	DMMQ3UG
DMMQ3UG	DN	PMID28394193-Compound-54
DMMQ3UG	MI	TT9MZCQ
DMMQ3UG	MN	Enhancer of zeste homolog 2 (EZH2)
DMMQ3UG	MT	DTT
DMMQ3UG	MA	Inhibitor
DMMQ3UG	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DMMQ3UG	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DM2FPHZ	DI	DM2FPHZ
DM2FPHZ	DN	PMID28394193-Compound-55
DM2FPHZ	MI	TT9MZCQ
DM2FPHZ	MN	Enhancer of zeste homolog 2 (EZH2)
DM2FPHZ	MT	DTT
DM2FPHZ	MA	Inhibitor
DM2FPHZ	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DM2FPHZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DM2FPHZ	DI	DM2FPHZ
DM2FPHZ	DN	PMID28394193-Compound-55
DM2FPHZ	MI	TTJW2UQ
DM2FPHZ	MN	EZH2 Y641N mutant (EZH2 Y641N)
DM2FPHZ	MT	DTT
DM2FPHZ	MA	Inhibitor
DM2FPHZ	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DM2FPHZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DMQRFZK	DI	DMQRFZK
DMQRFZK	DN	PMID28394193-Compound-56
DMQRFZK	MI	TT9MZCQ
DMQRFZK	MN	Enhancer of zeste homolog 2 (EZH2)
DMQRFZK	MT	DTT
DMQRFZK	MA	Inhibitor
DMQRFZK	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DMQRFZK	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DMQRFZK	DI	DMQRFZK
DMQRFZK	DN	PMID28394193-Compound-56
DMQRFZK	MI	TTJW2UQ
DMQRFZK	MN	EZH2 Y641N mutant (EZH2 Y641N)
DMQRFZK	MT	DTT
DMQRFZK	MA	Inhibitor
DMQRFZK	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DMQRFZK	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DM4Y3US	DI	DM4Y3US
DM4Y3US	DN	PMID28394193-Compound-57
DM4Y3US	MI	TT9MZCQ
DM4Y3US	MN	Enhancer of zeste homolog 2 (EZH2)
DM4Y3US	MT	DTT
DM4Y3US	MA	Inhibitor
DM4Y3US	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DM4Y3US	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DM4Y3US	DI	DM4Y3US
DM4Y3US	DN	PMID28394193-Compound-57
DM4Y3US	MI	TTJW2UQ
DM4Y3US	MN	EZH2 Y641N mutant (EZH2 Y641N)
DM4Y3US	MT	DTT
DM4Y3US	MA	Inhibitor
DM4Y3US	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DM4Y3US	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DMXK2GA	DI	DMXK2GA
DMXK2GA	DN	PMID28394193-Compound-Figure3bI
DMXK2GA	MI	TT9MZCQ
DMXK2GA	MN	Enhancer of zeste homolog 2 (EZH2)
DMXK2GA	MT	DTT
DMXK2GA	MA	Inhibitor
DMXK2GA	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DMXK2GA	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DML6PE0	DI	DML6PE0
DML6PE0	DN	PMID28394193-Compound-Figure3bII
DML6PE0	MI	TT9MZCQ
DML6PE0	MN	Enhancer of zeste homolog 2 (EZH2)
DML6PE0	MT	DTT
DML6PE0	MA	Inhibitor
DML6PE0	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DML6PE0	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DMUI385	DI	DMUI385
DMUI385	DN	PMID28394193-Compound-Figure3bIII
DMUI385	MI	TT9MZCQ
DMUI385	MN	Enhancer of zeste homolog 2 (EZH2)
DMUI385	MT	DTT
DMUI385	MA	Inhibitor
DMUI385	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DMUI385	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DMKVRTM	DI	DMKVRTM
DMKVRTM	DN	PMID28394193-Compound-Figure5aVIII
DMKVRTM	MI	TT9MZCQ
DMKVRTM	MN	Enhancer of zeste homolog 2 (EZH2)
DMKVRTM	MT	DTT
DMKVRTM	MA	Inhibitor
DMKVRTM	RN	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
DMKVRTM	RU	https://www.ncbi.nlm.nih.gov/pubmed/28394193

DMA7OEF	DI	DMA7OEF
DMA7OEF	DN	PMID28447479-Compound-10
DMA7OEF	MI	TTSCIM2
DMA7OEF	MN	Extracellular lysophospholipase D (E-NPP2)
DMA7OEF	MT	DTT
DMA7OEF	MA	Inhibitor
DMA7OEF	RN	Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829.
DMA7OEF	RU	https://www.ncbi.nlm.nih.gov/pubmed/28447479

DMOYMWZ	DI	DMOYMWZ
DMOYMWZ	DN	PMID28447479-Compound-11
DMOYMWZ	MI	TTSCIM2
DMOYMWZ	MN	Extracellular lysophospholipase D (E-NPP2)
DMOYMWZ	MT	DTT
DMOYMWZ	MA	Inhibitor
DMOYMWZ	RN	Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829.
DMOYMWZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28447479

DMA91X2	DI	DMA91X2
DMA91X2	DN	PMID28447479-Compound-14
DMA91X2	MI	TTSCIM2
DMA91X2	MN	Extracellular lysophospholipase D (E-NPP2)
DMA91X2	MT	DTT
DMA91X2	MA	Inhibitor
DMA91X2	RN	Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829.
DMA91X2	RU	https://www.ncbi.nlm.nih.gov/pubmed/28447479

DMWSL5G	DI	DMWSL5G
DMWSL5G	DN	PMID28447479-Compound-20
DMWSL5G	MI	TTSCIM2
DMWSL5G	MN	Extracellular lysophospholipase D (E-NPP2)
DMWSL5G	MT	DTT
DMWSL5G	MA	Inhibitor
DMWSL5G	RN	Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829.
DMWSL5G	RU	https://www.ncbi.nlm.nih.gov/pubmed/28447479

DM8PET6	DI	DM8PET6
DM8PET6	DN	PMID28447479-Compound-21
DM8PET6	MI	TTSCIM2
DM8PET6	MN	Extracellular lysophospholipase D (E-NPP2)
DM8PET6	MT	DTT
DM8PET6	MA	Inhibitor
DM8PET6	RN	Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829.
DM8PET6	RU	https://www.ncbi.nlm.nih.gov/pubmed/28447479

DMRCM1O	DI	DMRCM1O
DMRCM1O	DN	PMID28447479-Compound-22
DMRCM1O	MI	TTSCIM2
DMRCM1O	MN	Extracellular lysophospholipase D (E-NPP2)
DMRCM1O	MT	DTT
DMRCM1O	RN	Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829.
DMRCM1O	RU	https://www.ncbi.nlm.nih.gov/pubmed/28447479

DMM0BVE	DI	DMM0BVE
DMM0BVE	DN	PMID28447479-Compound-23
DMM0BVE	MI	TTSCIM2
DMM0BVE	MN	Extracellular lysophospholipase D (E-NPP2)
DMM0BVE	MT	DTT
DMM0BVE	RN	Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829.
DMM0BVE	RU	https://www.ncbi.nlm.nih.gov/pubmed/28447479

DMDOVIZ	DI	DMDOVIZ
DMDOVIZ	DN	PMID28447479-Compound-24
DMDOVIZ	MI	TTSCIM2
DMDOVIZ	MN	Extracellular lysophospholipase D (E-NPP2)
DMDOVIZ	MT	DTT
DMDOVIZ	RN	Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829.
DMDOVIZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28447479

DMJZSWF	DI	DMJZSWF
DMJZSWF	DN	PMID28447479-Compound-26
DMJZSWF	MI	TTSCIM2
DMJZSWF	MN	Extracellular lysophospholipase D (E-NPP2)
DMJZSWF	MT	DTT
DMJZSWF	MA	Agonist
DMJZSWF	RN	Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829.
DMJZSWF	RU	https://www.ncbi.nlm.nih.gov/pubmed/28447479

DMVZPIO	DI	DMVZPIO
DMVZPIO	DN	PMID28447479-Compound-27
DMVZPIO	MI	TTSCIM2
DMVZPIO	MN	Extracellular lysophospholipase D (E-NPP2)
DMVZPIO	MT	DTT
DMVZPIO	MA	Agonist
DMVZPIO	RN	Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829.
DMVZPIO	RU	https://www.ncbi.nlm.nih.gov/pubmed/28447479

DMUBM1Y	DI	DMUBM1Y
DMUBM1Y	DN	PMID28447479-Compound-4
DMUBM1Y	MI	TTSCIM2
DMUBM1Y	MN	Extracellular lysophospholipase D (E-NPP2)
DMUBM1Y	MT	DTT
DMUBM1Y	MA	Inhibitor
DMUBM1Y	RN	Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829.
DMUBM1Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/28447479

DMD9W6H	DI	DMD9W6H
DMD9W6H	DN	PMID28454500-Compound-10
DMD9W6H	MI	TT3Z6Y9
DMD9W6H	MN	Cysteines of Keap1 (KEAP1 Cysteines)
DMD9W6H	MT	DTT
DMD9W6H	MA	Modulator
DMD9W6H	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMD9W6H	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMD9W6H	DI	DMD9W6H
DMD9W6H	DN	PMID28454500-Compound-10
DMD9W6H	MI	TTA6ZN2
DMD9W6H	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMD9W6H	MT	DTT
DMD9W6H	MA	Activator
DMD9W6H	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMD9W6H	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM1ZFC9	DI	DM1ZFC9
DM1ZFC9	DN	PMID28454500-Compound-11
DM1ZFC9	MI	TT3Z6Y9
DM1ZFC9	MN	Cysteines of Keap1 (KEAP1 Cysteines)
DM1ZFC9	MT	DTT
DM1ZFC9	MA	Modulator
DM1ZFC9	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DM1ZFC9	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM1ZFC9	DI	DM1ZFC9
DM1ZFC9	DN	PMID28454500-Compound-11
DM1ZFC9	MI	TTA6ZN2
DM1ZFC9	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DM1ZFC9	MT	DTT
DM1ZFC9	MA	Activator
DM1ZFC9	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DM1ZFC9	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMUY4LS	DI	DMUY4LS
DMUY4LS	DN	PMID28454500-Compound-12
DMUY4LS	MI	TT3Z6Y9
DMUY4LS	MN	Cysteines of Keap1 (KEAP1 Cysteines)
DMUY4LS	MT	DTT
DMUY4LS	MA	Modulator
DMUY4LS	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMUY4LS	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMUY4LS	DI	DMUY4LS
DMUY4LS	DN	PMID28454500-Compound-12
DMUY4LS	MI	TTA6ZN2
DMUY4LS	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMUY4LS	MT	DTT
DMUY4LS	MA	Activator
DMUY4LS	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMUY4LS	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM7SIVA	DI	DM7SIVA
DM7SIVA	DN	PMID28454500-Compound-13
DM7SIVA	MI	TT3Z6Y9
DM7SIVA	MN	Cysteines of Keap1 (KEAP1 Cysteines)
DM7SIVA	MT	DTT
DM7SIVA	MA	Modulator
DM7SIVA	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DM7SIVA	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM7SIVA	DI	DM7SIVA
DM7SIVA	DN	PMID28454500-Compound-13
DM7SIVA	MI	TTA6ZN2
DM7SIVA	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DM7SIVA	MT	DTT
DM7SIVA	MA	Activator
DM7SIVA	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DM7SIVA	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMAGVHX	DI	DMAGVHX
DMAGVHX	DN	PMID28454500-Compound-3
DMAGVHX	MI	TT3Z6Y9
DMAGVHX	MN	Cysteines of Keap1 (KEAP1 Cysteines)
DMAGVHX	MT	DTT
DMAGVHX	MA	Modulator
DMAGVHX	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMAGVHX	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMAGVHX	DI	DMAGVHX
DMAGVHX	DN	PMID28454500-Compound-3
DMAGVHX	MI	TTA6ZN2
DMAGVHX	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMAGVHX	MT	DTT
DMAGVHX	MA	Activator
DMAGVHX	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMAGVHX	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMAIGJP	DI	DMAIGJP
DMAIGJP	DN	PMID28454500-Compound-32
DMAIGJP	MI	TT3Z6Y9
DMAIGJP	MN	Cysteines of Keap1 (KEAP1 Cysteines)
DMAIGJP	MT	DTT
DMAIGJP	MA	Modulator
DMAIGJP	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMAIGJP	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMAIGJP	DI	DMAIGJP
DMAIGJP	DN	PMID28454500-Compound-32
DMAIGJP	MI	TTA6ZN2
DMAIGJP	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMAIGJP	MT	DTT
DMAIGJP	MA	Activator
DMAIGJP	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMAIGJP	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMYXQU3	DI	DMYXQU3
DMYXQU3	DN	PMID28454500-Compound-33
DMYXQU3	MI	TT3Z6Y9
DMYXQU3	MN	Cysteines of Keap1 (KEAP1 Cysteines)
DMYXQU3	MT	DTT
DMYXQU3	MA	Modulator
DMYXQU3	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMYXQU3	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMYXQU3	DI	DMYXQU3
DMYXQU3	DN	PMID28454500-Compound-33
DMYXQU3	MI	TTA6ZN2
DMYXQU3	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMYXQU3	MT	DTT
DMYXQU3	MA	Activator
DMYXQU3	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMYXQU3	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMN2910	DI	DMN2910
DMN2910	DN	PMID28454500-Compound-34
DMN2910	MI	TT3Z6Y9
DMN2910	MN	Cysteines of Keap1 (KEAP1 Cysteines)
DMN2910	MT	DTT
DMN2910	MA	Modulator
DMN2910	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMN2910	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMN2910	DI	DMN2910
DMN2910	DN	PMID28454500-Compound-34
DMN2910	MI	TTA6ZN2
DMN2910	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMN2910	MT	DTT
DMN2910	MA	Activator
DMN2910	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMN2910	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM2OM4Z	DI	DM2OM4Z
DM2OM4Z	DN	PMID28454500-Compound-35
DM2OM4Z	MI	TT3Z6Y9
DM2OM4Z	MN	Cysteines of Keap1 (KEAP1 Cysteines)
DM2OM4Z	MT	DTT
DM2OM4Z	MA	Modulator
DM2OM4Z	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DM2OM4Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM2OM4Z	DI	DM2OM4Z
DM2OM4Z	DN	PMID28454500-Compound-35
DM2OM4Z	MI	TTA6ZN2
DM2OM4Z	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DM2OM4Z	MT	DTT
DM2OM4Z	MA	Activator
DM2OM4Z	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DM2OM4Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM5RZWG	DI	DM5RZWG
DM5RZWG	DN	PMID28454500-Compound-36
DM5RZWG	MI	TT3Z6Y9
DM5RZWG	MN	Cysteines of Keap1 (KEAP1 Cysteines)
DM5RZWG	MT	DTT
DM5RZWG	MA	Modulator
DM5RZWG	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DM5RZWG	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM5RZWG	DI	DM5RZWG
DM5RZWG	DN	PMID28454500-Compound-36
DM5RZWG	MI	TTA6ZN2
DM5RZWG	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DM5RZWG	MT	DTT
DM5RZWG	MA	Activator
DM5RZWG	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DM5RZWG	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM83P6H	DI	DM83P6H
DM83P6H	DN	PMID28454500-Compound-37
DM83P6H	MI	TT3Z6Y9
DM83P6H	MN	Cysteines of Keap1 (KEAP1 Cysteines)
DM83P6H	MT	DTT
DM83P6H	MA	Modulator
DM83P6H	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DM83P6H	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM83P6H	DI	DM83P6H
DM83P6H	DN	PMID28454500-Compound-37
DM83P6H	MI	TTA6ZN2
DM83P6H	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DM83P6H	MT	DTT
DM83P6H	MA	Activator
DM83P6H	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DM83P6H	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM9TVWJ	DI	DM9TVWJ
DM9TVWJ	DN	PMID28454500-Compound-40
DM9TVWJ	MI	TT3Z6Y9
DM9TVWJ	MN	Cysteines of Keap1 (KEAP1 Cysteines)
DM9TVWJ	MT	DTT
DM9TVWJ	MA	Modulator
DM9TVWJ	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DM9TVWJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM9TVWJ	DI	DM9TVWJ
DM9TVWJ	DN	PMID28454500-Compound-40
DM9TVWJ	MI	TTA6ZN2
DM9TVWJ	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DM9TVWJ	MT	DTT
DM9TVWJ	MA	Activator
DM9TVWJ	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DM9TVWJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMGAW81	DI	DMGAW81
DMGAW81	DN	PMID28454500-Compound-41
DMGAW81	MI	TT3Z6Y9
DMGAW81	MN	Cysteines of Keap1 (KEAP1 Cysteines)
DMGAW81	MT	DTT
DMGAW81	MA	Modulator
DMGAW81	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMGAW81	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMGAW81	DI	DMGAW81
DMGAW81	DN	PMID28454500-Compound-41
DMGAW81	MI	TTA6ZN2
DMGAW81	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMGAW81	MT	DTT
DMGAW81	MA	Activator
DMGAW81	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMGAW81	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM5NJDK	DI	DM5NJDK
DM5NJDK	DN	PMID28454500-Compound-49
DM5NJDK	MI	TT3Z6Y9
DM5NJDK	MN	Cysteines of Keap1 (KEAP1 Cysteines)
DM5NJDK	MT	DTT
DM5NJDK	MA	Modulator
DM5NJDK	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DM5NJDK	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM5NJDK	DI	DM5NJDK
DM5NJDK	DN	PMID28454500-Compound-49
DM5NJDK	MI	TTA6ZN2
DM5NJDK	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DM5NJDK	MT	DTT
DM5NJDK	MA	Activator
DM5NJDK	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DM5NJDK	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMQPKCD	DI	DMQPKCD
DMQPKCD	DN	PMID28454500-Compound-50
DMQPKCD	MI	TT3Z6Y9
DMQPKCD	MN	Cysteines of Keap1 (KEAP1 Cysteines)
DMQPKCD	MT	DTT
DMQPKCD	MA	Modulator
DMQPKCD	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMQPKCD	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMQPKCD	DI	DMQPKCD
DMQPKCD	DN	PMID28454500-Compound-50
DMQPKCD	MI	TTA6ZN2
DMQPKCD	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMQPKCD	MT	DTT
DMQPKCD	MA	Activator
DMQPKCD	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMQPKCD	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMTK9M6	DI	DMTK9M6
DMTK9M6	DN	PMID28454500-Compound-57
DMTK9M6	MI	TTGIZLN
DMTK9M6	MN	Keap1-Nrf2[dual DLG and ETGE] PPI (KEAP1-Nrf2 DLG and ETGE)
DMTK9M6	MT	DTT
DMTK9M6	MA	Modulator
DMTK9M6	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMTK9M6	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMTK9M6	DI	DMTK9M6
DMTK9M6	DN	PMID28454500-Compound-57
DMTK9M6	MI	TTA6ZN2
DMTK9M6	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMTK9M6	MT	DTT
DMTK9M6	MA	Inhibitor
DMTK9M6	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMTK9M6	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMDEHYR	DI	DMDEHYR
DMDEHYR	DN	PMID28454500-Compound-58
DMDEHYR	MI	TTGIZLN
DMDEHYR	MN	Keap1-Nrf2[dual DLG and ETGE] PPI (KEAP1-Nrf2 DLG and ETGE)
DMDEHYR	MT	DTT
DMDEHYR	MA	Modulator
DMDEHYR	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMDEHYR	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMDEHYR	DI	DMDEHYR
DMDEHYR	DN	PMID28454500-Compound-58
DMDEHYR	MI	TTA6ZN2
DMDEHYR	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMDEHYR	MT	DTT
DMDEHYR	MA	Inhibitor
DMDEHYR	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMDEHYR	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMQWPSF	DI	DMQWPSF
DMQWPSF	DN	PMID28454500-Compound-59
DMQWPSF	MI	TTGIZLN
DMQWPSF	MN	Keap1-Nrf2[dual DLG and ETGE] PPI (KEAP1-Nrf2 DLG and ETGE)
DMQWPSF	MT	DTT
DMQWPSF	MA	Modulator
DMQWPSF	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMQWPSF	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMQWPSF	DI	DMQWPSF
DMQWPSF	DN	PMID28454500-Compound-59
DMQWPSF	MI	TTA6ZN2
DMQWPSF	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMQWPSF	MT	DTT
DMQWPSF	MA	Inhibitor
DMQWPSF	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMQWPSF	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM1I9JC	DI	DM1I9JC
DM1I9JC	DN	PMID28454500-Compound-60
DM1I9JC	MI	TTGIZLN
DM1I9JC	MN	Keap1-Nrf2[dual DLG and ETGE] PPI (KEAP1-Nrf2 DLG and ETGE)
DM1I9JC	MT	DTT
DM1I9JC	MA	Modulator
DM1I9JC	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DM1I9JC	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM1I9JC	DI	DM1I9JC
DM1I9JC	DN	PMID28454500-Compound-60
DM1I9JC	MI	TTA6ZN2
DM1I9JC	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DM1I9JC	MT	DTT
DM1I9JC	MA	Inhibitor
DM1I9JC	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DM1I9JC	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM6BQFA	DI	DM6BQFA
DM6BQFA	DN	PMID28454500-Compound-8
DM6BQFA	MI	TT3Z6Y9
DM6BQFA	MN	Cysteines of Keap1 (KEAP1 Cysteines)
DM6BQFA	MT	DTT
DM6BQFA	MA	Modulator
DM6BQFA	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DM6BQFA	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM6BQFA	DI	DM6BQFA
DM6BQFA	DN	PMID28454500-Compound-8
DM6BQFA	MI	TTA6ZN2
DM6BQFA	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DM6BQFA	MT	DTT
DM6BQFA	MA	Activator
DM6BQFA	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DM6BQFA	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM3HR7F	DI	DM3HR7F
DM3HR7F	DN	PMID28454500-Compound-9
DM3HR7F	MI	TT3Z6Y9
DM3HR7F	MN	Cysteines of Keap1 (KEAP1 Cysteines)
DM3HR7F	MT	DTT
DM3HR7F	MA	Modulator
DM3HR7F	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DM3HR7F	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM3HR7F	DI	DM3HR7F
DM3HR7F	DN	PMID28454500-Compound-9
DM3HR7F	MI	TTA6ZN2
DM3HR7F	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DM3HR7F	MT	DTT
DM3HR7F	MA	Activator
DM3HR7F	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DM3HR7F	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMJ1KFO	DI	DMJ1KFO
DMJ1KFO	DN	PMID28454500-Compound-91
DMJ1KFO	MI	TTA6ZN2
DMJ1KFO	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMJ1KFO	MT	DTT
DMJ1KFO	MA	Inhibitor
DMJ1KFO	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMJ1KFO	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM1RS4X	DI	DM1RS4X
DM1RS4X	DN	PMID28454500-Compound-92
DM1RS4X	MI	TTA6ZN2
DM1RS4X	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DM1RS4X	MT	DTT
DM1RS4X	MA	Inhibitor
DM1RS4X	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DM1RS4X	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMMDK6B	DI	DMMDK6B
DMMDK6B	DN	PMID28454500-Compound-93
DMMDK6B	MI	TTA6ZN2
DMMDK6B	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMMDK6B	MT	DTT
DMMDK6B	MA	Inhibitor
DMMDK6B	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMMDK6B	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM5Q962	DI	DM5Q962
DM5Q962	DN	PMID28454500-Compound-94
DM5Q962	MI	TTA6ZN2
DM5Q962	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DM5Q962	MT	DTT
DM5Q962	MA	Inhibitor
DM5Q962	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DM5Q962	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM9L2VR	DI	DM9L2VR
DM9L2VR	DN	PMID28454500-Compound-95
DM9L2VR	MI	TTA6ZN2
DM9L2VR	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DM9L2VR	MT	DTT
DM9L2VR	MA	Inhibitor
DM9L2VR	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DM9L2VR	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM2A75P	DI	DM2A75P
DM2A75P	DN	PMID28454500-Compound-96
DM2A75P	MI	TTA6ZN2
DM2A75P	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DM2A75P	MT	DTT
DM2A75P	MA	Inhibitor
DM2A75P	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DM2A75P	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMHV75N	DI	DMHV75N
DMHV75N	DN	PMID28460551-Compound-1
DMHV75N	MI	TT8FYO9
DMHV75N	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMHV75N	MT	DTT
DMHV75N	MA	Inhibitor
DMHV75N	RN	Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761.
DMHV75N	RU	https://www.ncbi.nlm.nih.gov/pubmed/28460551

DM4DOUB	DI	DM4DOUB
DM4DOUB	DN	PMID28460551-Compound-2
DM4DOUB	MI	TTI7421
DM4DOUB	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM4DOUB	MT	DTT
DM4DOUB	MA	Inhibitor
DM4DOUB	RN	Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761.
DM4DOUB	RU	https://www.ncbi.nlm.nih.gov/pubmed/28460551

DMA1FRM	DI	DMA1FRM
DMA1FRM	DN	PMID28460551-Compound-3
DMA1FRM	MI	TTFJ8Q1
DMA1FRM	MN	Protein kinase C alpha (PRKCA)
DMA1FRM	MT	DTT
DMA1FRM	MA	Inhibitor
DMA1FRM	RN	Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761.
DMA1FRM	RU	https://www.ncbi.nlm.nih.gov/pubmed/28460551

DMT7U1O	DI	DMT7U1O
DMT7U1O	DN	PMID28460551-Compound-6
DMT7U1O	MI	TT6PKBN
DMT7U1O	MN	Proto-oncogene c-Src (SRC)
DMT7U1O	MT	DTT
DMT7U1O	MA	Inhibitor
DMT7U1O	RN	Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761.
DMT7U1O	RU	https://www.ncbi.nlm.nih.gov/pubmed/28460551

DMT7U1O	DI	DMT7U1O
DMT7U1O	DN	PMID28460551-Compound-6
DMT7U1O	MI	TTWTSCV
DMT7U1O	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DMT7U1O	MT	DTT
DMT7U1O	MA	Inhibitor
DMT7U1O	RN	Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761.
DMT7U1O	RU	https://www.ncbi.nlm.nih.gov/pubmed/28460551

DMLZV70	DI	DMLZV70
DMLZV70	DN	PMID28594589-Compound-TABLE3C1
DMLZV70	MI	TTZCRP3
DMLZV70	MN	ERK activator kinase (MEK)
DMLZV70	MT	DTT
DMLZV70	MA	Inhibitor
DMLZV70	RN	MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906.
DMLZV70	RU	https://www.ncbi.nlm.nih.gov/pubmed/28594589

DMPK7IU	DI	DMPK7IU
DMPK7IU	DN	PMID28594589-Compound-TABLE3C12
DMPK7IU	MI	TTZCRP3
DMPK7IU	MN	ERK activator kinase (MEK)
DMPK7IU	MT	DTT
DMPK7IU	MA	Inhibitor
DMPK7IU	RN	MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906.
DMPK7IU	RU	https://www.ncbi.nlm.nih.gov/pubmed/28594589

DM4KWVF	DI	DM4KWVF
DM4KWVF	DN	PMID28594589-Compound-TABLE3C14
DM4KWVF	MI	TTZCRP3
DM4KWVF	MN	ERK activator kinase (MEK)
DM4KWVF	MT	DTT
DM4KWVF	MA	Inhibitor
DM4KWVF	RN	MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906.
DM4KWVF	RU	https://www.ncbi.nlm.nih.gov/pubmed/28594589

DMVYG0U	DI	DMVYG0U
DMVYG0U	DN	PMID28594589-Compound-TABLE3C2
DMVYG0U	MI	TTZCRP3
DMVYG0U	MN	ERK activator kinase (MEK)
DMVYG0U	MT	DTT
DMVYG0U	MA	Inhibitor
DMVYG0U	RN	MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906.
DMVYG0U	RU	https://www.ncbi.nlm.nih.gov/pubmed/28594589

DMBTZ8I	DI	DMBTZ8I
DMBTZ8I	DN	PMID28621580-Compound-WO2013036866C66
DMBTZ8I	MI	TTOHSBA
DMBTZ8I	MN	Vascular endothelial growth factor A (VEGFA)
DMBTZ8I	MT	DTT
DMBTZ8I	MA	Inhibitor
DMBTZ8I	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMBTZ8I	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DM15OKA	DI	DM15OKA
DM15OKA	DN	PMID28621580-Compound-WO2013112959C68
DM15OKA	MI	TTOHSBA
DM15OKA	MN	Vascular endothelial growth factor A (VEGFA)
DM15OKA	MT	DTT
DM15OKA	MA	Inhibitor
DM15OKA	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DM15OKA	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMR58TX	DI	DMR58TX
DMR58TX	DN	PMID28621580-Compound-WO2014079545C69
DMR58TX	MI	TTOHSBA
DMR58TX	MN	Vascular endothelial growth factor A (VEGFA)
DMR58TX	MT	DTT
DMR58TX	MA	Inhibitor
DMR58TX	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMR58TX	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMX96FI	DI	DMX96FI
DMX96FI	DN	PMID28621580-Compound-WO2015089220C70
DMX96FI	MI	TTOHSBA
DMX96FI	MN	Vascular endothelial growth factor A (VEGFA)
DMX96FI	MT	DTT
DMX96FI	MA	Inhibitor
DMX96FI	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMX96FI	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DM36P7T	DI	DM36P7T
DM36P7T	DN	PMID28627961-Compound-22
DM36P7T	MI	TTYLQ8V
DM36P7T	MN	Prostaglandin E synthase (PTGES)
DM36P7T	MT	DTT
DM36P7T	MA	Inhibitor
DM36P7T	RN	Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059.
DM36P7T	RU	https://www.ncbi.nlm.nih.gov/pubmed/28627961

DMRLU8I	DI	DMRLU8I
DMRLU8I	DN	PMID28627961-Compound-30
DMRLU8I	MI	TTYLQ8V
DMRLU8I	MN	Prostaglandin E synthase (PTGES)
DMRLU8I	MT	DTT
DMRLU8I	MA	Inhibitor
DMRLU8I	RN	Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059.
DMRLU8I	RU	https://www.ncbi.nlm.nih.gov/pubmed/28627961

DMLGYXW	DI	DMLGYXW
DMLGYXW	DN	PMID28627961-Compound-31
DMLGYXW	MI	TTYLQ8V
DMLGYXW	MN	Prostaglandin E synthase (PTGES)
DMLGYXW	MT	DTT
DMLGYXW	MA	Inhibitor
DMLGYXW	RN	Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059.
DMLGYXW	RU	https://www.ncbi.nlm.nih.gov/pubmed/28627961

DM5IZKD	DI	DM5IZKD
DM5IZKD	DN	PMID28627961-Compound-32
DM5IZKD	MI	TTYLQ8V
DM5IZKD	MN	Prostaglandin E synthase (PTGES)
DM5IZKD	MT	DTT
DM5IZKD	MA	Inhibitor
DM5IZKD	RN	Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059.
DM5IZKD	RU	https://www.ncbi.nlm.nih.gov/pubmed/28627961

DMWV4YE	DI	DMWV4YE
DMWV4YE	DN	PMID28627961-Compound-33
DMWV4YE	MI	TTYLQ8V
DMWV4YE	MN	Prostaglandin E synthase (PTGES)
DMWV4YE	MT	DTT
DMWV4YE	MA	Inhibitor
DMWV4YE	RN	Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059.
DMWV4YE	RU	https://www.ncbi.nlm.nih.gov/pubmed/28627961

DMODL3P	DI	DMODL3P
DMODL3P	DN	PMID28627961-Compound-41
DMODL3P	MI	TTYLQ8V
DMODL3P	MN	Prostaglandin E synthase (PTGES)
DMODL3P	MT	DTT
DMODL3P	MA	Inhibitor
DMODL3P	RN	Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059.
DMODL3P	RU	https://www.ncbi.nlm.nih.gov/pubmed/28627961

DM7ATLP	DI	DM7ATLP
DM7ATLP	DN	PMID28627961-Compound-44
DM7ATLP	MI	TTYLQ8V
DM7ATLP	MN	Prostaglandin E synthase (PTGES)
DM7ATLP	MT	DTT
DM7ATLP	MA	Inhibitor
DM7ATLP	RN	Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059.
DM7ATLP	RU	https://www.ncbi.nlm.nih.gov/pubmed/28627961

DMBN3X4	DI	DMBN3X4
DMBN3X4	DN	PMID28766366-Compound-Scheme11
DMBN3X4	MI	TTSBVFO
DMBN3X4	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DMBN3X4	MT	DTT
DMBN3X4	MA	Inhibitor
DMBN3X4	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMBN3X4	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMMJ5SN	DI	DMMJ5SN
DMMJ5SN	DN	PMID28766366-Compound-Scheme12-1
DMMJ5SN	MI	TTSBVFO
DMMJ5SN	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DMMJ5SN	MT	DTT
DMMJ5SN	MA	Inhibitor
DMMJ5SN	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMMJ5SN	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DM3BA1L	DI	DM3BA1L
DM3BA1L	DN	PMID28766366-Compound-Scheme12-2
DM3BA1L	MI	TTSBVFO
DM3BA1L	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DM3BA1L	MT	DTT
DM3BA1L	MA	Inhibitor
DM3BA1L	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DM3BA1L	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DM4V3AY	DI	DM4V3AY
DM4V3AY	DN	PMID28766366-Compound-Scheme12-3
DM4V3AY	MI	TTSBVFO
DM4V3AY	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DM4V3AY	MT	DTT
DM4V3AY	MA	Inhibitor
DM4V3AY	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DM4V3AY	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DM5BG6L	DI	DM5BG6L
DM5BG6L	DN	PMID28766366-Compound-Scheme12-4
DM5BG6L	MI	TTSBVFO
DM5BG6L	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DM5BG6L	MT	DTT
DM5BG6L	MA	Inhibitor
DM5BG6L	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DM5BG6L	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMLQCYV	DI	DMLQCYV
DMLQCYV	DN	PMID28766366-Compound-Scheme13INDY
DMLQCYV	MI	TTSBVFO
DMLQCYV	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DMLQCYV	MT	DTT
DMLQCYV	MA	Inhibitor
DMLQCYV	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMLQCYV	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMBQ0RN	DI	DMBQ0RN
DMBQ0RN	DN	PMID28766366-Compound-Scheme14BINDY
DMBQ0RN	MI	TTSBVFO
DMBQ0RN	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DMBQ0RN	MT	DTT
DMBQ0RN	MA	Inhibitor
DMBQ0RN	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMBQ0RN	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMBQ0RN	DI	DMBQ0RN
DMBQ0RN	DN	PMID28766366-Compound-Scheme14BINDY
DMBQ0RN	MI	TTYGQ8A
DMBQ0RN	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B)
DMBQ0RN	MT	DTT
DMBQ0RN	MA	Inhibitor
DMBQ0RN	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMBQ0RN	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMBQ0RN	DI	DMBQ0RN
DMBQ0RN	DN	PMID28766366-Compound-Scheme14BINDY
DMBQ0RN	MI	TT84OS6
DMBQ0RN	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 2 (DYRK2)
DMBQ0RN	MT	DTT
DMBQ0RN	MA	Inhibitor
DMBQ0RN	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMBQ0RN	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMVG275	DI	DMVG275
DMVG275	DN	PMID28766366-Compound-Scheme15-1
DMVG275	MI	TTSBVFO
DMVG275	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DMVG275	MT	DTT
DMVG275	MA	Inhibitor
DMVG275	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMVG275	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMU8ENF	DI	DMU8ENF
DMU8ENF	DN	PMID28766366-Compound-Scheme15-2
DMU8ENF	MI	TTSBVFO
DMU8ENF	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DMU8ENF	MT	DTT
DMU8ENF	MA	Inhibitor
DMU8ENF	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMU8ENF	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMA423P	DI	DMA423P
DMA423P	DN	PMID28766366-Compound-Scheme15-3
DMA423P	MI	TTSBVFO
DMA423P	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DMA423P	MT	DTT
DMA423P	MA	Inhibitor
DMA423P	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMA423P	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMQ5UEA	DI	DMQ5UEA
DMQ5UEA	DN	PMID28766366-Compound-Scheme16DMAT
DMQ5UEA	MI	TTSBVFO
DMQ5UEA	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DMQ5UEA	MT	DTT
DMQ5UEA	MA	Inhibitor
DMQ5UEA	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMQ5UEA	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMQ5UEA	DI	DMQ5UEA
DMQ5UEA	DN	PMID28766366-Compound-Scheme16DMAT
DMQ5UEA	MI	TT84OS6
DMQ5UEA	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 2 (DYRK2)
DMQ5UEA	MT	DTT
DMQ5UEA	MA	Inhibitor
DMQ5UEA	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMQ5UEA	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMBQ21J	DI	DMBQ21J
DMBQ21J	DN	PMID28766366-Compound-Scheme18
DMBQ21J	MI	TTSBVFO
DMBQ21J	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DMBQ21J	MT	DTT
DMBQ21J	MA	Inhibitor
DMBQ21J	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMBQ21J	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMHIUWX	DI	DMHIUWX
DMHIUWX	DN	PMID28766366-Compound-Scheme1WO2011135259
DMHIUWX	MI	TTSBVFO
DMHIUWX	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DMHIUWX	MT	DTT
DMHIUWX	MA	Inhibitor
DMHIUWX	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMHIUWX	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMWTRUK	DI	DMWTRUK
DMWTRUK	DN	PMID28766366-Compound-Scheme21Left
DMWTRUK	MI	TTSBVFO
DMWTRUK	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DMWTRUK	MT	DTT
DMWTRUK	MA	Inhibitor
DMWTRUK	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMWTRUK	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMWTRUK	DI	DMWTRUK
DMWTRUK	DN	PMID28766366-Compound-Scheme21Left
DMWTRUK	MI	TTYGQ8A
DMWTRUK	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B)
DMWTRUK	MT	DTT
DMWTRUK	MA	Inhibitor
DMWTRUK	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMWTRUK	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMWTRUK	DI	DMWTRUK
DMWTRUK	DN	PMID28766366-Compound-Scheme21Left
DMWTRUK	MI	TT84OS6
DMWTRUK	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 2 (DYRK2)
DMWTRUK	MT	DTT
DMWTRUK	MA	Inhibitor
DMWTRUK	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMWTRUK	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMWTRUK	DI	DMWTRUK
DMWTRUK	DN	PMID28766366-Compound-Scheme21Left
DMWTRUK	MI	TTV4EX0
DMWTRUK	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 3 (DYRK3)
DMWTRUK	MT	DTT
DMWTRUK	MA	Inhibitor
DMWTRUK	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMWTRUK	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMF3X40	DI	DMF3X40
DMF3X40	DN	PMID28766366-Compound-Scheme21Right
DMF3X40	MI	TTSBVFO
DMF3X40	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DMF3X40	MT	DTT
DMF3X40	MA	Inhibitor
DMF3X40	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMF3X40	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMF3X40	DI	DMF3X40
DMF3X40	DN	PMID28766366-Compound-Scheme21Right
DMF3X40	MI	TTYGQ8A
DMF3X40	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B)
DMF3X40	MT	DTT
DMF3X40	MA	Inhibitor
DMF3X40	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMF3X40	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMF3X40	DI	DMF3X40
DMF3X40	DN	PMID28766366-Compound-Scheme21Right
DMF3X40	MI	TT84OS6
DMF3X40	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 2 (DYRK2)
DMF3X40	MT	DTT
DMF3X40	MA	Inhibitor
DMF3X40	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMF3X40	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMF3X40	DI	DMF3X40
DMF3X40	DN	PMID28766366-Compound-Scheme21Right
DMF3X40	MI	TTV4EX0
DMF3X40	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 3 (DYRK3)
DMF3X40	MT	DTT
DMF3X40	MA	Inhibitor
DMF3X40	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMF3X40	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMD8N5O	DI	DMD8N5O
DMD8N5O	DN	PMID28766366-Compound-Scheme22Middle
DMD8N5O	MI	TTXZCO0
DMD8N5O	MN	Microtubule-associated protein tau phosphorylation (MAPT p)
DMD8N5O	MT	DTT
DMD8N5O	MA	Inhibitor
DMD8N5O	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMD8N5O	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMRLSKV	DI	DMRLSKV
DMRLSKV	DN	PMID28766366-Compound-Scheme23MPPDerivatives
DMRLSKV	MI	TTSBVFO
DMRLSKV	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DMRLSKV	MT	DTT
DMRLSKV	MA	Inhibitor
DMRLSKV	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMRLSKV	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMBWAV7	DI	DMBWAV7
DMBWAV7	DN	PMID28766366-Compound-Scheme24-11H-pyrido[4,3-a]carbazole
DMBWAV7	MI	TTSBVFO
DMBWAV7	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DMBWAV7	MT	DTT
DMBWAV7	MA	Inhibitor
DMBWAV7	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMBWAV7	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMNKRSZ	DI	DMNKRSZ
DMNKRSZ	DN	PMID28766366-Compound-Scheme24Paprotrain
DMNKRSZ	MI	TTSBVFO
DMNKRSZ	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DMNKRSZ	MT	DTT
DMNKRSZ	MA	Inhibitor
DMNKRSZ	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMNKRSZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DM7OGWH	DI	DM7OGWH
DM7OGWH	DN	PMID28766366-Compound-Scheme25-2
DM7OGWH	MI	TTSBVFO
DM7OGWH	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DM7OGWH	MT	DTT
DM7OGWH	MA	Inhibitor
DM7OGWH	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DM7OGWH	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DM7OGWH	DI	DM7OGWH
DM7OGWH	DN	PMID28766366-Compound-Scheme25-2
DM7OGWH	MI	TTYGQ8A
DM7OGWH	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B)
DM7OGWH	MT	DTT
DM7OGWH	MA	Inhibitor
DM7OGWH	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DM7OGWH	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMGVT5Y	DI	DMGVT5Y
DMGVT5Y	DN	PMID28766366-Compound-Scheme25-3
DMGVT5Y	MI	TTSBVFO
DMGVT5Y	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DMGVT5Y	MT	DTT
DMGVT5Y	MA	Inhibitor
DMGVT5Y	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMGVT5Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMGVT5Y	DI	DMGVT5Y
DMGVT5Y	DN	PMID28766366-Compound-Scheme25-3
DMGVT5Y	MI	TTYGQ8A
DMGVT5Y	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B)
DMGVT5Y	MT	DTT
DMGVT5Y	MA	Inhibitor
DMGVT5Y	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMGVT5Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMOD9BY	DI	DMOD9BY
DMOD9BY	DN	PMID28766366-Compound-Scheme25-4
DMOD9BY	MI	TTSBVFO
DMOD9BY	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DMOD9BY	MT	DTT
DMOD9BY	MA	Inhibitor
DMOD9BY	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMOD9BY	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMOD9BY	DI	DMOD9BY
DMOD9BY	DN	PMID28766366-Compound-Scheme25-4
DMOD9BY	MI	TTYGQ8A
DMOD9BY	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B)
DMOD9BY	MT	DTT
DMOD9BY	MA	Inhibitor
DMOD9BY	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMOD9BY	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DM3Q1FT	DI	DM3Q1FT
DM3Q1FT	DN	PMID28766366-Compound-Scheme27LeucettamineB
DM3Q1FT	MI	TTSBVFO
DM3Q1FT	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DM3Q1FT	MT	DTT
DM3Q1FT	MA	Inhibitor
DM3Q1FT	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DM3Q1FT	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMLX26R	DI	DMLX26R
DMLX26R	DN	PMID28766366-Compound-Scheme27LeucettineL41
DMLX26R	MI	TTSBVFO
DMLX26R	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DMLX26R	MT	DTT
DMLX26R	MA	Inhibitor
DMLX26R	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMLX26R	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMPVZ6W	DI	DMPVZ6W
DMPVZ6W	DN	PMID28766366-Compound-Scheme27LeucettineL41derivatives
DMPVZ6W	MI	TTSBVFO
DMPVZ6W	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DMPVZ6W	MT	DTT
DMPVZ6W	MA	Inhibitor
DMPVZ6W	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMPVZ6W	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMO4Q95	DI	DMO4Q95
DMO4Q95	DN	PMID28766366-Compound-Scheme2WO2012/098065bottom
DMO4Q95	MI	TTSBVFO
DMO4Q95	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DMO4Q95	MT	DTT
DMO4Q95	MA	Inhibitor
DMO4Q95	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMO4Q95	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMO4Q95	DI	DMO4Q95
DMO4Q95	DN	PMID28766366-Compound-Scheme2WO2012/098065bottom
DMO4Q95	MI	TTYGQ8A
DMO4Q95	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B)
DMO4Q95	MT	DTT
DMO4Q95	MA	Inhibitor
DMO4Q95	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMO4Q95	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMVJDRI	DI	DMVJDRI
DMVJDRI	DN	PMID28766366-Compound-Scheme2WO2012/098065upper
DMVJDRI	MI	TTSBVFO
DMVJDRI	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DMVJDRI	MT	DTT
DMVJDRI	MA	Inhibitor
DMVJDRI	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMVJDRI	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMVJDRI	DI	DMVJDRI
DMVJDRI	DN	PMID28766366-Compound-Scheme2WO2012/098065upper
DMVJDRI	MI	TTYGQ8A
DMVJDRI	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B)
DMVJDRI	MT	DTT
DMVJDRI	MA	Inhibitor
DMVJDRI	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMVJDRI	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMDXIU9	DI	DMDXIU9
DMDXIU9	DN	PMID28766366-Compound-Scheme4Bottom
DMDXIU9	MI	TTSBVFO
DMDXIU9	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DMDXIU9	MT	DTT
DMDXIU9	MA	Inhibitor
DMDXIU9	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMDXIU9	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMDXIU9	DI	DMDXIU9
DMDXIU9	DN	PMID28766366-Compound-Scheme4Bottom
DMDXIU9	MI	TTYGQ8A
DMDXIU9	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B)
DMDXIU9	MT	DTT
DMDXIU9	MA	Inhibitor
DMDXIU9	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMDXIU9	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMPH4JV	DI	DMPH4JV
DMPH4JV	DN	PMID28766366-Compound-Scheme4Upper
DMPH4JV	MI	TTSBVFO
DMPH4JV	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DMPH4JV	MT	DTT
DMPH4JV	MA	Inhibitor
DMPH4JV	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMPH4JV	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMPH4JV	DI	DMPH4JV
DMPH4JV	DN	PMID28766366-Compound-Scheme4Upper
DMPH4JV	MI	TTYGQ8A
DMPH4JV	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B)
DMPH4JV	MT	DTT
DMPH4JV	MA	Inhibitor
DMPH4JV	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMPH4JV	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMO6KZ5	DI	DMO6KZ5
DMO6KZ5	DN	PMID28766366-Compound-Scheme5
DMO6KZ5	MI	TTSBVFO
DMO6KZ5	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DMO6KZ5	MT	DTT
DMO6KZ5	MA	Inhibitor
DMO6KZ5	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMO6KZ5	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMO6KZ5	DI	DMO6KZ5
DMO6KZ5	DN	PMID28766366-Compound-Scheme5
DMO6KZ5	MI	TTYGQ8A
DMO6KZ5	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B)
DMO6KZ5	MT	DTT
DMO6KZ5	MA	Inhibitor
DMO6KZ5	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMO6KZ5	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMJOG3W	DI	DMJOG3W
DMJOG3W	DN	PMID28766366-Compound-Scheme6Pyrrolo[2,3-d]pyrimidines
DMJOG3W	MI	TTSBVFO
DMJOG3W	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DMJOG3W	MT	DTT
DMJOG3W	MA	Inhibitor
DMJOG3W	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMJOG3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMQV6R0	DI	DMQV6R0
DMQV6R0	DN	PMID28766366-Compound-Scheme7WO2012/098070bottom
DMQV6R0	MI	TTSBVFO
DMQV6R0	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DMQV6R0	MT	DTT
DMQV6R0	MA	Inhibitor
DMQV6R0	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMQV6R0	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMQV6R0	DI	DMQV6R0
DMQV6R0	DN	PMID28766366-Compound-Scheme7WO2012/098070bottom
DMQV6R0	MI	TTYGQ8A
DMQV6R0	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B)
DMQV6R0	MT	DTT
DMQV6R0	MA	Inhibitor
DMQV6R0	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMQV6R0	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMGAQR5	DI	DMGAQR5
DMGAQR5	DN	PMID28766366-Compound-Scheme7WO2012/098070upper
DMGAQR5	MI	TTSBVFO
DMGAQR5	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DMGAQR5	MT	DTT
DMGAQR5	MA	Inhibitor
DMGAQR5	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMGAQR5	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMGAQR5	DI	DMGAQR5
DMGAQR5	DN	PMID28766366-Compound-Scheme7WO2012/098070upper
DMGAQR5	MI	TTYGQ8A
DMGAQR5	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B)
DMGAQR5	MT	DTT
DMGAQR5	MA	Inhibitor
DMGAQR5	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMGAQR5	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMSX09A	DI	DMSX09A
DMSX09A	DN	PMID28766366-Compound-Scheme8NCGC-00010037
DMSX09A	MI	TTSBVFO
DMSX09A	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DMSX09A	MT	DTT
DMSX09A	MA	Inhibitor
DMSX09A	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMSX09A	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMDUSN5	DI	DMDUSN5
DMDUSN5	DN	PMID28766366-Compound-Scheme8NCGC-00185981
DMDUSN5	MI	TTSBVFO
DMDUSN5	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DMDUSN5	MT	DTT
DMDUSN5	MA	Inhibitor
DMDUSN5	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMDUSN5	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMUWZD9	DI	DMUWZD9
DMUWZD9	DN	PMID28766366-Compound-Scheme8NCGC-00189310
DMUWZD9	MI	TTSBVFO
DMUWZD9	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DMUWZD9	MT	DTT
DMUWZD9	MA	Inhibitor
DMUWZD9	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMUWZD9	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMMZGC8	DI	DMMZGC8
DMMZGC8	DN	PMID28766366-Compound-Scheme9EHT1610
DMMZGC8	MI	TTSBVFO
DMMZGC8	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DMMZGC8	MT	DTT
DMMZGC8	MA	Inhibitor
DMMZGC8	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMMZGC8	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMMZGC8	DI	DMMZGC8
DMMZGC8	DN	PMID28766366-Compound-Scheme9EHT1610
DMMZGC8	MI	TTYGQ8A
DMMZGC8	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B)
DMMZGC8	MT	DTT
DMMZGC8	MA	Inhibitor
DMMZGC8	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMMZGC8	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMVBPML	DI	DMVBPML
DMVBPML	DN	PMID28766366-Compound-Scheme9EHT3356
DMVBPML	MI	TTSBVFO
DMVBPML	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DMVBPML	MT	DTT
DMVBPML	MA	Inhibitor
DMVBPML	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMVBPML	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMVBPML	DI	DMVBPML
DMVBPML	DN	PMID28766366-Compound-Scheme9EHT3356
DMVBPML	MI	TTYGQ8A
DMVBPML	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B)
DMVBPML	MT	DTT
DMVBPML	MA	Inhibitor
DMVBPML	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMVBPML	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DM0O18N	DI	DM0O18N
DM0O18N	DN	PMID28766366-Compound-Scheme9EHT5372
DM0O18N	MI	TTSBVFO
DM0O18N	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DM0O18N	MT	DTT
DM0O18N	MA	Inhibitor
DM0O18N	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DM0O18N	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DM0O18N	DI	DM0O18N
DM0O18N	DN	PMID28766366-Compound-Scheme9EHT5372
DM0O18N	MI	TTYGQ8A
DM0O18N	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B)
DM0O18N	MT	DTT
DM0O18N	MA	Inhibitor
DM0O18N	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DM0O18N	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMVY6PX	DI	DMVY6PX
DMVY6PX	DN	PMID28766366-Compound-Scheme9EHT6840
DMVY6PX	MI	TTSBVFO
DMVY6PX	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DMVY6PX	MT	DTT
DMVY6PX	MA	Inhibitor
DMVY6PX	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMVY6PX	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMVY6PX	DI	DMVY6PX
DMVY6PX	DN	PMID28766366-Compound-Scheme9EHT6840
DMVY6PX	MI	TTYGQ8A
DMVY6PX	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B)
DMVY6PX	MT	DTT
DMVY6PX	MA	Inhibitor
DMVY6PX	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMVY6PX	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DM7RPKM	DI	DM7RPKM
DM7RPKM	DN	PMID28766366-Compound-Scheme9EHT9851
DM7RPKM	MI	TTSBVFO
DM7RPKM	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DM7RPKM	MT	DTT
DM7RPKM	MA	Inhibitor
DM7RPKM	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DM7RPKM	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DM7RPKM	DI	DM7RPKM
DM7RPKM	DN	PMID28766366-Compound-Scheme9EHT9851
DM7RPKM	MI	TTYGQ8A
DM7RPKM	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B)
DM7RPKM	MT	DTT
DM7RPKM	MA	Inhibitor
DM7RPKM	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DM7RPKM	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DMQJF15	DI	DMQJF15
DMQJF15	DN	PMID28870136-Compound-36
DMQJF15	MI	TTK0O6Y
DMQJF15	MN	Ecto-5'-nucleotidase (CD73)
DMQJF15	MT	DTT
DMQJF15	MA	Inhibitor
DMQJF15	RN	Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
DMQJF15	RU	https://www.ncbi.nlm.nih.gov/pubmed/28870136

DMAPMG2	DI	DMAPMG2
DMAPMG2	DN	PMID28870136-Compound-37
DMAPMG2	MI	TTK0O6Y
DMAPMG2	MN	Ecto-5'-nucleotidase (CD73)
DMAPMG2	MT	DTT
DMAPMG2	MA	Inhibitor
DMAPMG2	RN	Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
DMAPMG2	RU	https://www.ncbi.nlm.nih.gov/pubmed/28870136

DM67XSL	DI	DM67XSL
DM67XSL	DN	PMID28870136-Compound-38
DM67XSL	MI	TTK0O6Y
DM67XSL	MN	Ecto-5'-nucleotidase (CD73)
DM67XSL	MT	DTT
DM67XSL	MA	Inhibitor
DM67XSL	RN	Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
DM67XSL	RU	https://www.ncbi.nlm.nih.gov/pubmed/28870136

DMU18W6	DI	DMU18W6
DMU18W6	DN	PMID28870136-Compound-39
DMU18W6	MI	TTK0O6Y
DMU18W6	MN	Ecto-5'-nucleotidase (CD73)
DMU18W6	MT	DTT
DMU18W6	MA	Inhibitor
DMU18W6	RN	Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
DMU18W6	RU	https://www.ncbi.nlm.nih.gov/pubmed/28870136

DMJP0AG	DI	DMJP0AG
DMJP0AG	DN	PMID28870136-Compound-40
DMJP0AG	MI	TTK0O6Y
DMJP0AG	MN	Ecto-5'-nucleotidase (CD73)
DMJP0AG	MT	DTT
DMJP0AG	MA	Inhibitor
DMJP0AG	RN	Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
DMJP0AG	RU	https://www.ncbi.nlm.nih.gov/pubmed/28870136

DMSWM9Q	DI	DMSWM9Q
DMSWM9Q	DN	PMID28870136-Compound-41
DMSWM9Q	MI	TTK0O6Y
DMSWM9Q	MN	Ecto-5'-nucleotidase (CD73)
DMSWM9Q	MT	DTT
DMSWM9Q	MA	Inhibitor
DMSWM9Q	RN	Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
DMSWM9Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/28870136

DMV0R2X	DI	DMV0R2X
DMV0R2X	DN	PMID28870136-Compound-42
DMV0R2X	MI	TTK0O6Y
DMV0R2X	MN	Ecto-5'-nucleotidase (CD73)
DMV0R2X	MT	DTT
DMV0R2X	MA	Inhibitor
DMV0R2X	RN	Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
DMV0R2X	RU	https://www.ncbi.nlm.nih.gov/pubmed/28870136

DMWGV8N	DI	DMWGV8N
DMWGV8N	DN	PMID28870136-Compound-43
DMWGV8N	MI	TTK0O6Y
DMWGV8N	MN	Ecto-5'-nucleotidase (CD73)
DMWGV8N	MT	DTT
DMWGV8N	MA	Inhibitor
DMWGV8N	RN	Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
DMWGV8N	RU	https://www.ncbi.nlm.nih.gov/pubmed/28870136

DMNOAQB	DI	DMNOAQB
DMNOAQB	DN	PMID28870136-Compound-44
DMNOAQB	MI	TTK0O6Y
DMNOAQB	MN	Ecto-5'-nucleotidase (CD73)
DMNOAQB	MT	DTT
DMNOAQB	MA	Inhibitor
DMNOAQB	RN	Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
DMNOAQB	RU	https://www.ncbi.nlm.nih.gov/pubmed/28870136

DM1QHV0	DI	DM1QHV0
DM1QHV0	DN	PMID28870136-Compound-45
DM1QHV0	MI	TTK0O6Y
DM1QHV0	MN	Ecto-5'-nucleotidase (CD73)
DM1QHV0	MT	DTT
DM1QHV0	MA	Inhibitor
DM1QHV0	RN	Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
DM1QHV0	RU	https://www.ncbi.nlm.nih.gov/pubmed/28870136

DM4FD7C	DI	DM4FD7C
DM4FD7C	DN	PMID28870136-Compound-46
DM4FD7C	MI	TTK0O6Y
DM4FD7C	MN	Ecto-5'-nucleotidase (CD73)
DM4FD7C	MT	DTT
DM4FD7C	MA	Inhibitor
DM4FD7C	RN	Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
DM4FD7C	RU	https://www.ncbi.nlm.nih.gov/pubmed/28870136

DMYWBRX	DI	DMYWBRX
DMYWBRX	DN	PMID28870136-Compound-47
DMYWBRX	MI	TTK0O6Y
DMYWBRX	MN	Ecto-5'-nucleotidase (CD73)
DMYWBRX	MT	DTT
DMYWBRX	MA	Inhibitor
DMYWBRX	RN	Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
DMYWBRX	RU	https://www.ncbi.nlm.nih.gov/pubmed/28870136

DMPIM9L	DI	DMPIM9L
DMPIM9L	DN	PMID28870136-Compound-48
DMPIM9L	MI	TTK0O6Y
DMPIM9L	MN	Ecto-5'-nucleotidase (CD73)
DMPIM9L	MT	DTT
DMPIM9L	MA	Inhibitor
DMPIM9L	RN	Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
DMPIM9L	RU	https://www.ncbi.nlm.nih.gov/pubmed/28870136

DMTUC9E	DI	DMTUC9E
DMTUC9E	DN	PMID28870136-Compound-49
DMTUC9E	MI	TTK0O6Y
DMTUC9E	MN	Ecto-5'-nucleotidase (CD73)
DMTUC9E	MT	DTT
DMTUC9E	MA	Inhibitor
DMTUC9E	RN	Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
DMTUC9E	RU	https://www.ncbi.nlm.nih.gov/pubmed/28870136

DM42OYU	DI	DM42OYU
DM42OYU	DN	PMID28870136-Compound-50
DM42OYU	MI	TTK0O6Y
DM42OYU	MN	Ecto-5'-nucleotidase (CD73)
DM42OYU	MT	DTT
DM42OYU	MA	Inhibitor
DM42OYU	RN	Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
DM42OYU	RU	https://www.ncbi.nlm.nih.gov/pubmed/28870136

DMU3MQB	DI	DMU3MQB
DMU3MQB	DN	PMID28870136-Compound-51
DMU3MQB	MI	TTK0O6Y
DMU3MQB	MN	Ecto-5'-nucleotidase (CD73)
DMU3MQB	MT	DTT
DMU3MQB	MA	Inhibitor
DMU3MQB	RN	Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
DMU3MQB	RU	https://www.ncbi.nlm.nih.gov/pubmed/28870136

DMFDERP	DI	DMFDERP
DMFDERP	DN	PMID28870136-Compound-52
DMFDERP	MI	TTK0O6Y
DMFDERP	MN	Ecto-5'-nucleotidase (CD73)
DMFDERP	MT	DTT
DMFDERP	MA	Inhibitor
DMFDERP	RN	Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
DMFDERP	RU	https://www.ncbi.nlm.nih.gov/pubmed/28870136

DMLEWY6	DI	DMLEWY6
DMLEWY6	DN	PMID28870136-Compound-53
DMLEWY6	MI	TTK0O6Y
DMLEWY6	MN	Ecto-5'-nucleotidase (CD73)
DMLEWY6	MT	DTT
DMLEWY6	MA	Inhibitor
DMLEWY6	RN	Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
DMLEWY6	RU	https://www.ncbi.nlm.nih.gov/pubmed/28870136

DM6HOES	DI	DM6HOES
DM6HOES	DN	PMID28870136-Compound-54
DM6HOES	MI	TTK0O6Y
DM6HOES	MN	Ecto-5'-nucleotidase (CD73)
DM6HOES	MT	DTT
DM6HOES	MA	Inhibitor
DM6HOES	RN	Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
DM6HOES	RU	https://www.ncbi.nlm.nih.gov/pubmed/28870136

DMVRJZX	DI	DMVRJZX
DMVRJZX	DN	PMID28870136-Compound-55
DMVRJZX	MI	TTK0O6Y
DMVRJZX	MN	Ecto-5'-nucleotidase (CD73)
DMVRJZX	MT	DTT
DMVRJZX	MA	Inhibitor
DMVRJZX	RN	Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
DMVRJZX	RU	https://www.ncbi.nlm.nih.gov/pubmed/28870136

DMK0RTV	DI	DMK0RTV
DMK0RTV	DN	PMID28870136-Compound-56
DMK0RTV	MI	TTK0O6Y
DMK0RTV	MN	Ecto-5'-nucleotidase (CD73)
DMK0RTV	MT	DTT
DMK0RTV	MA	Inhibitor
DMK0RTV	RN	Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
DMK0RTV	RU	https://www.ncbi.nlm.nih.gov/pubmed/28870136

DME3HLC	DI	DME3HLC
DME3HLC	DN	PMID28870136-Compound-57
DME3HLC	MI	TTK0O6Y
DME3HLC	MN	Ecto-5'-nucleotidase (CD73)
DME3HLC	MT	DTT
DME3HLC	MA	Inhibitor
DME3HLC	RN	Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
DME3HLC	RU	https://www.ncbi.nlm.nih.gov/pubmed/28870136

DMQIUD9	DI	DMQIUD9
DMQIUD9	DN	PMID28870136-Compound-58
DMQIUD9	MI	TTK0O6Y
DMQIUD9	MN	Ecto-5'-nucleotidase (CD73)
DMQIUD9	MT	DTT
DMQIUD9	MA	Inhibitor
DMQIUD9	RN	Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
DMQIUD9	RU	https://www.ncbi.nlm.nih.gov/pubmed/28870136

DMHP90Q	DI	DMHP90Q
DMHP90Q	DN	PMID28870136-Compound-59
DMHP90Q	MI	TTK0O6Y
DMHP90Q	MN	Ecto-5'-nucleotidase (CD73)
DMHP90Q	MT	DTT
DMHP90Q	MA	Inhibitor
DMHP90Q	RN	Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
DMHP90Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/28870136

DM39QU8	DI	DM39QU8
DM39QU8	DN	PMID28870136-Compound-60
DM39QU8	MI	TTK0O6Y
DM39QU8	MN	Ecto-5'-nucleotidase (CD73)
DM39QU8	MT	DTT
DM39QU8	MA	Inhibitor
DM39QU8	RN	Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
DM39QU8	RU	https://www.ncbi.nlm.nih.gov/pubmed/28870136

DMFNU9D	DI	DMFNU9D
DMFNU9D	DN	PMID28870136-Compound-61
DMFNU9D	MI	TTK0O6Y
DMFNU9D	MN	Ecto-5'-nucleotidase (CD73)
DMFNU9D	MT	DTT
DMFNU9D	MA	Inhibitor
DMFNU9D	RN	Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
DMFNU9D	RU	https://www.ncbi.nlm.nih.gov/pubmed/28870136

DMNKXJ2	DI	DMNKXJ2
DMNKXJ2	DN	PMID28870136-Compound-62
DMNKXJ2	MI	TTK0O6Y
DMNKXJ2	MN	Ecto-5'-nucleotidase (CD73)
DMNKXJ2	MT	DTT
DMNKXJ2	MA	Inhibitor
DMNKXJ2	RN	Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
DMNKXJ2	RU	https://www.ncbi.nlm.nih.gov/pubmed/28870136

DM26WNY	DI	DM26WNY
DM26WNY	DN	PMID28870136-Compound-63
DM26WNY	MI	TTK0O6Y
DM26WNY	MN	Ecto-5'-nucleotidase (CD73)
DM26WNY	MT	DTT
DM26WNY	MA	Inhibitor
DM26WNY	RN	Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
DM26WNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/28870136

DMBKSVH	DI	DMBKSVH
DMBKSVH	DN	PMID28870136-Compound-64
DMBKSVH	MI	TTK0O6Y
DMBKSVH	MN	Ecto-5'-nucleotidase (CD73)
DMBKSVH	MT	DTT
DMBKSVH	MA	Inhibitor
DMBKSVH	RN	Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
DMBKSVH	RU	https://www.ncbi.nlm.nih.gov/pubmed/28870136

DMF5K9J	DI	DMF5K9J
DMF5K9J	DN	PMID28870136-Compound-65
DMF5K9J	MI	TTK0O6Y
DMF5K9J	MN	Ecto-5'-nucleotidase (CD73)
DMF5K9J	MT	DTT
DMF5K9J	MA	Inhibitor
DMF5K9J	RN	Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
DMF5K9J	RU	https://www.ncbi.nlm.nih.gov/pubmed/28870136

DME3YRI	DI	DME3YRI
DME3YRI	DN	PMID28870136-Compound-67
DME3YRI	MI	TTK0O6Y
DME3YRI	MN	Ecto-5'-nucleotidase (CD73)
DME3YRI	MT	DTT
DME3YRI	MA	Inhibitor
DME3YRI	RN	Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
DME3YRI	RU	https://www.ncbi.nlm.nih.gov/pubmed/28870136

DMFTM8X	DI	DMFTM8X
DMFTM8X	DN	PMID28870136-Compound-68
DMFTM8X	MI	TTK0O6Y
DMFTM8X	MN	Ecto-5'-nucleotidase (CD73)
DMFTM8X	MT	DTT
DMFTM8X	MA	Inhibitor
DMFTM8X	RN	Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
DMFTM8X	RU	https://www.ncbi.nlm.nih.gov/pubmed/28870136

DMVCQKB	DI	DMVCQKB
DMVCQKB	DN	PMID28870136-Compound-69
DMVCQKB	MI	TTK0O6Y
DMVCQKB	MN	Ecto-5'-nucleotidase (CD73)
DMVCQKB	MT	DTT
DMVCQKB	MA	Inhibitor
DMVCQKB	RN	Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
DMVCQKB	RU	https://www.ncbi.nlm.nih.gov/pubmed/28870136

DMECU90	DI	DMECU90
DMECU90	DN	PMID28906174-Compound-figure1g
DMECU90	MI	TTSCIUP
DMECU90	MN	Oxytocin receptor (OTR)
DMECU90	MT	DTT
DMECU90	MA	Antagonist
DMECU90	RN	A patent review of oxytocin receptor antagonists 2013-2017.Expert Opin Ther Pat. 2017 Dec;27(12):1287-1290.
DMECU90	RU	https://www.ncbi.nlm.nih.gov/pubmed/28906174

DMECU90	DI	DMECU90
DMECU90	DN	PMID28906174-Compound-figure1g
DMECU90	MI	TT4TFGN
DMECU90	MN	Vasopressin V1a receptor (V1AR)
DMECU90	MT	DTT
DMECU90	MA	Antagonist
DMECU90	RN	A patent review of oxytocin receptor antagonists 2013-2017.Expert Opin Ther Pat. 2017 Dec;27(12):1287-1290.
DMECU90	RU	https://www.ncbi.nlm.nih.gov/pubmed/28906174

DMLMHR5	DI	DMLMHR5
DMLMHR5	DN	PMID29053063-Compound-11c
DMLMHR5	MI	TTSINOV
DMLMHR5	MN	Monoacylglycerol lipase ABHD6 (ABHD6)
DMLMHR5	MT	DTT
DMLMHR5	MA	Inhibitor
DMLMHR5	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMLMHR5	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMLMHR5	DI	DMLMHR5
DMLMHR5	DN	PMID29053063-Compound-11c
DMLMHR5	MI	TTZ963I
DMLMHR5	MN	Monoglyceride lipase (MAGL)
DMLMHR5	MT	DTT
DMLMHR5	MA	Inhibitor
DMLMHR5	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMLMHR5	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMDRK68	DI	DMDRK68
DMDRK68	DN	PMID29053063-Compound-11d
DMDRK68	MI	TTDP1UC
DMDRK68	MN	Fatty acid amide hydrolase (FAAH)
DMDRK68	MT	DTT
DMDRK68	MA	Inhibitor
DMDRK68	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMDRK68	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMDRK68	DI	DMDRK68
DMDRK68	DN	PMID29053063-Compound-11d
DMDRK68	MI	TTSINOV
DMDRK68	MN	Monoacylglycerol lipase ABHD6 (ABHD6)
DMDRK68	MT	DTT
DMDRK68	MA	Inhibitor
DMDRK68	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMDRK68	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMDRK68	DI	DMDRK68
DMDRK68	DN	PMID29053063-Compound-11d
DMDRK68	MI	TTZ963I
DMDRK68	MN	Monoglyceride lipase (MAGL)
DMDRK68	MT	DTT
DMDRK68	MA	Inhibitor
DMDRK68	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMDRK68	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMBR72X	DI	DMBR72X
DMBR72X	DN	PMID29053063-Compound-14
DMBR72X	MI	TTDP1UC
DMBR72X	MN	Fatty acid amide hydrolase (FAAH)
DMBR72X	MT	DTT
DMBR72X	MA	Inhibitor
DMBR72X	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMBR72X	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMBR72X	DI	DMBR72X
DMBR72X	DN	PMID29053063-Compound-14
DMBR72X	MI	TTZ963I
DMBR72X	MN	Monoglyceride lipase (MAGL)
DMBR72X	MT	DTT
DMBR72X	MA	Inhibitor
DMBR72X	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMBR72X	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DM07U5R	DI	DM07U5R
DM07U5R	DN	PMID29053063-Compound-15
DM07U5R	MI	TTRQ6UD
DM07U5R	MN	Diacylglycerol lipase alpha (DAGLA)
DM07U5R	MT	DTT
DM07U5R	MA	Inhibitor
DM07U5R	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DM07U5R	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DM07U5R	DI	DM07U5R
DM07U5R	DN	PMID29053063-Compound-15
DM07U5R	MI	TTDP1UC
DM07U5R	MN	Fatty acid amide hydrolase (FAAH)
DM07U5R	MT	DTT
DM07U5R	MA	Inhibitor
DM07U5R	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DM07U5R	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DM07U5R	DI	DM07U5R
DM07U5R	DN	PMID29053063-Compound-15
DM07U5R	MI	TTZ963I
DM07U5R	MN	Monoglyceride lipase (MAGL)
DM07U5R	MT	DTT
DM07U5R	MA	Inhibitor
DM07U5R	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DM07U5R	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMRHPN0	DI	DMRHPN0
DMRHPN0	DN	PMID29053063-Compound-17
DMRHPN0	MI	TTZ963I
DMRHPN0	MN	Monoglyceride lipase (MAGL)
DMRHPN0	MT	DTT
DMRHPN0	MA	Inhibitor
DMRHPN0	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMRHPN0	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DM8RAK0	DI	DM8RAK0
DM8RAK0	DN	PMID29053063-Compound-4
DM8RAK0	MI	TTZ963I
DM8RAK0	MN	Monoglyceride lipase (MAGL)
DM8RAK0	MT	DTT
DM8RAK0	MA	Inhibitor
DM8RAK0	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DM8RAK0	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DM2P05S	DI	DM2P05S
DM2P05S	DN	PMID29053063-Compound-5
DM2P05S	MI	TTZ963I
DM2P05S	MN	Monoglyceride lipase (MAGL)
DM2P05S	MT	DTT
DM2P05S	MA	Inhibitor
DM2P05S	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DM2P05S	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMTOHNQ	DI	DMTOHNQ
DMTOHNQ	DN	PMID29053063-Compound-7a
DMTOHNQ	MI	TTZ963I
DMTOHNQ	MN	Monoglyceride lipase (MAGL)
DMTOHNQ	MT	DTT
DMTOHNQ	MA	Inhibitor
DMTOHNQ	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMTOHNQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMDJ6O8	DI	DMDJ6O8
DMDJ6O8	DN	PMID29053063-Compound-7b
DMDJ6O8	MI	TTZ963I
DMDJ6O8	MN	Monoglyceride lipase (MAGL)
DMDJ6O8	MT	DTT
DMDJ6O8	MA	Inhibitor
DMDJ6O8	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMDJ6O8	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMNZO7V	DI	DMNZO7V
DMNZO7V	DN	PMID29053063-Compound-7c
DMNZO7V	MI	TTZ963I
DMNZO7V	MN	Monoglyceride lipase (MAGL)
DMNZO7V	MT	DTT
DMNZO7V	MA	Inhibitor
DMNZO7V	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMNZO7V	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMUNXAR	DI	DMUNXAR
DMUNXAR	DN	PMID29053063-Compound-7d
DMUNXAR	MI	TTZ963I
DMUNXAR	MN	Monoglyceride lipase (MAGL)
DMUNXAR	MT	DTT
DMUNXAR	MA	Inhibitor
DMUNXAR	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMUNXAR	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DM6XYFB	DI	DM6XYFB
DM6XYFB	DN	PMID29053063-Compound-7e
DM6XYFB	MI	TTZ963I
DM6XYFB	MN	Monoglyceride lipase (MAGL)
DM6XYFB	MT	DTT
DM6XYFB	MA	Inhibitor
DM6XYFB	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DM6XYFB	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMIQ263	DI	DMIQ263
DMIQ263	DN	PMID29053063-Compound-7f
DMIQ263	MI	TTZ963I
DMIQ263	MN	Monoglyceride lipase (MAGL)
DMIQ263	MT	DTT
DMIQ263	MA	Inhibitor
DMIQ263	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMIQ263	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMFWXPS	DI	DMFWXPS
DMFWXPS	DN	PMID29130358-Compound-Figure10(2a)
DMFWXPS	MI	TTMX39J
DMFWXPS	MN	Matrix metalloproteinase-1 (MMP-1)
DMFWXPS	MT	DTT
DMFWXPS	MA	Inhibitor
DMFWXPS	RN	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
DMFWXPS	RU	https://www.ncbi.nlm.nih.gov/pubmed/29130358

DMFWXPS	DI	DMFWXPS
DMFWXPS	DN	PMID29130358-Compound-Figure10(2a)
DMFWXPS	MI	TTLM12X
DMFWXPS	MN	Matrix metalloproteinase-2 (MMP-2)
DMFWXPS	MT	DTT
DMFWXPS	MA	Inhibitor
DMFWXPS	RN	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
DMFWXPS	RU	https://www.ncbi.nlm.nih.gov/pubmed/29130358

DMFWXPS	DI	DMFWXPS
DMFWXPS	DN	PMID29130358-Compound-Figure10(2a)
DMFWXPS	MI	TTUZ2L5
DMFWXPS	MN	Matrix metalloproteinase-3 (MMP-3)
DMFWXPS	MT	DTT
DMFWXPS	MA	Inhibitor
DMFWXPS	RN	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
DMFWXPS	RU	https://www.ncbi.nlm.nih.gov/pubmed/29130358

DMSME2B	DI	DMSME2B
DMSME2B	DN	PMID29130358-Compound-Figure11(3)
DMSME2B	MI	TTLM12X
DMSME2B	MN	Matrix metalloproteinase-2 (MMP-2)
DMSME2B	MT	DTT
DMSME2B	MA	Inhibitor
DMSME2B	RN	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
DMSME2B	RU	https://www.ncbi.nlm.nih.gov/pubmed/29130358

DMSME2B	DI	DMSME2B
DMSME2B	DN	PMID29130358-Compound-Figure11(3)
DMSME2B	MI	TTULVH8
DMSME2B	MN	Tyrosinase (TYR)
DMSME2B	MT	DTT
DMSME2B	MA	Inhibitor
DMSME2B	RN	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
DMSME2B	RU	https://www.ncbi.nlm.nih.gov/pubmed/29130358

DMDFPIO	DI	DMDFPIO
DMDFPIO	DN	PMID29130358-Compound-Figure13(4)
DMDFPIO	MI	TTLM12X
DMDFPIO	MN	Matrix metalloproteinase-2 (MMP-2)
DMDFPIO	MT	DTT
DMDFPIO	MA	Inhibitor
DMDFPIO	RN	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
DMDFPIO	RU	https://www.ncbi.nlm.nih.gov/pubmed/29130358

DMDFPIO	DI	DMDFPIO
DMDFPIO	DN	PMID29130358-Compound-Figure13(4)
DMDFPIO	MI	TT6X50U
DMDFPIO	MN	Matrix metalloproteinase-9 (MMP-9)
DMDFPIO	MT	DTT
DMDFPIO	MA	Inhibitor
DMDFPIO	RN	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
DMDFPIO	RU	https://www.ncbi.nlm.nih.gov/pubmed/29130358

DMB6KS9	DI	DMB6KS9
DMB6KS9	DN	PMID29130358-Compound-Figure14(5)
DMB6KS9	MI	TTXPTJE
DMB6KS9	MN	Gelatinase (GEL)
DMB6KS9	MT	DTT
DMB6KS9	MA	Inhibitor
DMB6KS9	RN	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
DMB6KS9	RU	https://www.ncbi.nlm.nih.gov/pubmed/29130358

DMFMJIN	DI	DMFMJIN
DMFMJIN	DN	PMID29130358-Compound-Figure14(6)
DMFMJIN	MI	TTXPTJE
DMFMJIN	MN	Gelatinase (GEL)
DMFMJIN	MT	DTT
DMFMJIN	MA	Inhibitor
DMFMJIN	RN	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
DMFMJIN	RU	https://www.ncbi.nlm.nih.gov/pubmed/29130358

DM85ETX	DI	DM85ETX
DM85ETX	DN	PMID29130358-Compound-Figure15(7)
DM85ETX	MI	TTXPTJE
DM85ETX	MN	Gelatinase (GEL)
DM85ETX	MT	DTT
DM85ETX	MA	Inhibitor
DM85ETX	RN	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
DM85ETX	RU	https://www.ncbi.nlm.nih.gov/pubmed/29130358

DML8FUD	DI	DML8FUD
DML8FUD	DN	PMID29130358-Compound-Figure15(8)
DML8FUD	MI	TTXPTJE
DML8FUD	MN	Gelatinase (GEL)
DML8FUD	MT	DTT
DML8FUD	MA	Inhibitor
DML8FUD	RN	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
DML8FUD	RU	https://www.ncbi.nlm.nih.gov/pubmed/29130358

DMKX5R8	DI	DMKX5R8
DMKX5R8	DN	PMID29130358-Compound-Figure16(9a)
DMKX5R8	MI	TTHY57M
DMKX5R8	MN	Matrix metalloproteinase-13 (MMP-13)
DMKX5R8	MT	DTT
DMKX5R8	MA	Inhibitor
DMKX5R8	RN	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
DMKX5R8	RU	https://www.ncbi.nlm.nih.gov/pubmed/29130358

DMKX5R8	DI	DMKX5R8
DMKX5R8	DN	PMID29130358-Compound-Figure16(9a)
DMKX5R8	MI	TTLM12X
DMKX5R8	MN	Matrix metalloproteinase-2 (MMP-2)
DMKX5R8	MT	DTT
DMKX5R8	MA	Inhibitor
DMKX5R8	RN	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
DMKX5R8	RU	https://www.ncbi.nlm.nih.gov/pubmed/29130358

DMPAQLZ	DI	DMPAQLZ
DMPAQLZ	DN	PMID29130358-Compound-Figure16(9b)
DMPAQLZ	MI	TTHY57M
DMPAQLZ	MN	Matrix metalloproteinase-13 (MMP-13)
DMPAQLZ	MT	DTT
DMPAQLZ	MA	Inhibitor
DMPAQLZ	RN	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
DMPAQLZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29130358

DMPAQLZ	DI	DMPAQLZ
DMPAQLZ	DN	PMID29130358-Compound-Figure16(9b)
DMPAQLZ	MI	TTLM12X
DMPAQLZ	MN	Matrix metalloproteinase-2 (MMP-2)
DMPAQLZ	MT	DTT
DMPAQLZ	MA	Inhibitor
DMPAQLZ	RN	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
DMPAQLZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29130358

DM0ZRI9	DI	DM0ZRI9
DM0ZRI9	DN	PMID29130358-Compound-Figure16(9c)
DM0ZRI9	MI	TTHY57M
DM0ZRI9	MN	Matrix metalloproteinase-13 (MMP-13)
DM0ZRI9	MT	DTT
DM0ZRI9	MA	Inhibitor
DM0ZRI9	RN	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
DM0ZRI9	RU	https://www.ncbi.nlm.nih.gov/pubmed/29130358

DM0ZRI9	DI	DM0ZRI9
DM0ZRI9	DN	PMID29130358-Compound-Figure16(9c)
DM0ZRI9	MI	TTLM12X
DM0ZRI9	MN	Matrix metalloproteinase-2 (MMP-2)
DM0ZRI9	MT	DTT
DM0ZRI9	MA	Inhibitor
DM0ZRI9	RN	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
DM0ZRI9	RU	https://www.ncbi.nlm.nih.gov/pubmed/29130358

DMVA15O	DI	DMVA15O
DMVA15O	DN	PMID29130358-Compound-Figure17(10)
DMVA15O	MI	TTXZ0KQ
DMVA15O	MN	Matrix metalloproteinase-12 (MMP-12)
DMVA15O	MT	DTT
DMVA15O	MA	Inhibitor
DMVA15O	RN	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
DMVA15O	RU	https://www.ncbi.nlm.nih.gov/pubmed/29130358

DMVA15O	DI	DMVA15O
DMVA15O	DN	PMID29130358-Compound-Figure17(10)
DMVA15O	MI	TT6X50U
DMVA15O	MN	Matrix metalloproteinase-9 (MMP-9)
DMVA15O	MT	DTT
DMVA15O	MA	Inhibitor
DMVA15O	RN	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
DMVA15O	RU	https://www.ncbi.nlm.nih.gov/pubmed/29130358

DMSZA9L	DI	DMSZA9L
DMSZA9L	DN	PMID29130358-Compound-Figure17(11)
DMSZA9L	MI	TTXZ0KQ
DMSZA9L	MN	Matrix metalloproteinase-12 (MMP-12)
DMSZA9L	MT	DTT
DMSZA9L	MA	Inhibitor
DMSZA9L	RN	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
DMSZA9L	RU	https://www.ncbi.nlm.nih.gov/pubmed/29130358

DMSZA9L	DI	DMSZA9L
DMSZA9L	DN	PMID29130358-Compound-Figure17(11)
DMSZA9L	MI	TT6X50U
DMSZA9L	MN	Matrix metalloproteinase-9 (MMP-9)
DMSZA9L	MT	DTT
DMSZA9L	MA	Inhibitor
DMSZA9L	RN	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
DMSZA9L	RU	https://www.ncbi.nlm.nih.gov/pubmed/29130358

DMML4PA	DI	DMML4PA
DMML4PA	DN	PMID29130358-Compound-Figure17(12)
DMML4PA	MI	TTXZ0KQ
DMML4PA	MN	Matrix metalloproteinase-12 (MMP-12)
DMML4PA	MT	DTT
DMML4PA	MA	Inhibitor
DMML4PA	RN	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
DMML4PA	RU	https://www.ncbi.nlm.nih.gov/pubmed/29130358

DMML4PA	DI	DMML4PA
DMML4PA	DN	PMID29130358-Compound-Figure17(12)
DMML4PA	MI	TT6X50U
DMML4PA	MN	Matrix metalloproteinase-9 (MMP-9)
DMML4PA	MT	DTT
DMML4PA	MA	Inhibitor
DMML4PA	RN	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
DMML4PA	RU	https://www.ncbi.nlm.nih.gov/pubmed/29130358

DM2QRIW	DI	DM2QRIW
DM2QRIW	DN	PMID29130358-Compound-Figure17(13)
DM2QRIW	MI	TT6X50U
DM2QRIW	MN	Matrix metalloproteinase-9 (MMP-9)
DM2QRIW	MT	DTT
DM2QRIW	MA	Inhibitor
DM2QRIW	RN	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
DM2QRIW	RU	https://www.ncbi.nlm.nih.gov/pubmed/29130358

DM7WXJ9	DI	DM7WXJ9
DM7WXJ9	DN	PMID29130358-Compound-Figure18(14)
DM7WXJ9	MI	TTHY57M
DM7WXJ9	MN	Matrix metalloproteinase-13 (MMP-13)
DM7WXJ9	MT	DTT
DM7WXJ9	MA	Inhibitor
DM7WXJ9	RN	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
DM7WXJ9	RU	https://www.ncbi.nlm.nih.gov/pubmed/29130358

DM7WXJ9	DI	DM7WXJ9
DM7WXJ9	DN	PMID29130358-Compound-Figure18(14)
DM7WXJ9	MI	TTLM12X
DM7WXJ9	MN	Matrix metalloproteinase-2 (MMP-2)
DM7WXJ9	MT	DTT
DM7WXJ9	MA	Inhibitor
DM7WXJ9	RN	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
DM7WXJ9	RU	https://www.ncbi.nlm.nih.gov/pubmed/29130358

DMHIBTZ	DI	DMHIBTZ
DMHIBTZ	DN	PMID29130358-Compound-Figure18(14a)
DMHIBTZ	MI	TTMX39J
DMHIBTZ	MN	Matrix metalloproteinase-1 (MMP-1)
DMHIBTZ	MT	DTT
DMHIBTZ	MA	Inhibitor
DMHIBTZ	RN	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
DMHIBTZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29130358

DMHIBTZ	DI	DMHIBTZ
DMHIBTZ	DN	PMID29130358-Compound-Figure18(14a)
DMHIBTZ	MI	TTHY57M
DMHIBTZ	MN	Matrix metalloproteinase-13 (MMP-13)
DMHIBTZ	MT	DTT
DMHIBTZ	MA	Inhibitor
DMHIBTZ	RN	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
DMHIBTZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29130358

DMHIBTZ	DI	DMHIBTZ
DMHIBTZ	DN	PMID29130358-Compound-Figure18(14a)
DMHIBTZ	MI	TTLM12X
DMHIBTZ	MN	Matrix metalloproteinase-2 (MMP-2)
DMHIBTZ	MT	DTT
DMHIBTZ	MA	Inhibitor
DMHIBTZ	RN	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
DMHIBTZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29130358

DMHIBTZ	DI	DMHIBTZ
DMHIBTZ	DN	PMID29130358-Compound-Figure18(14a)
DMHIBTZ	MI	TT6X50U
DMHIBTZ	MN	Matrix metalloproteinase-9 (MMP-9)
DMHIBTZ	MT	DTT
DMHIBTZ	MA	Inhibitor
DMHIBTZ	RN	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
DMHIBTZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29130358

DMMX5I6	DI	DMMX5I6
DMMX5I6	DN	PMID29130358-Compound-Figure9(1)
DMMX5I6	MI	TTXPTJE
DMMX5I6	MN	Gelatinase (GEL)
DMMX5I6	MT	DTT
DMMX5I6	MA	Inhibitor
DMMX5I6	RN	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
DMMX5I6	RU	https://www.ncbi.nlm.nih.gov/pubmed/29130358

DMTJEU5	DI	DMTJEU5
DMTJEU5	DN	PMID29130358-Compound-LonimacranthoideVI
DMTJEU5	MI	TTVKILB
DMTJEU5	MN	Prostaglandin G/H synthase 2 (COX-2)
DMTJEU5	MT	DTT
DMTJEU5	MA	Inhibitor
DMTJEU5	RN	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
DMTJEU5	RU	https://www.ncbi.nlm.nih.gov/pubmed/29130358

DMOGIAU	DI	DMOGIAU
DMOGIAU	DN	PMID29130358-Compound-LonimacranthoideVII
DMOGIAU	MI	TTLM12X
DMOGIAU	MN	Matrix metalloproteinase-2 (MMP-2)
DMOGIAU	MT	DTT
DMOGIAU	MA	Inhibitor
DMOGIAU	RN	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
DMOGIAU	RU	https://www.ncbi.nlm.nih.gov/pubmed/29130358

DMOGIAU	DI	DMOGIAU
DMOGIAU	DN	PMID29130358-Compound-LonimacranthoideVII
DMOGIAU	MI	TT6X50U
DMOGIAU	MN	Matrix metalloproteinase-9 (MMP-9)
DMOGIAU	MT	DTT
DMOGIAU	MA	Inhibitor
DMOGIAU	RN	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
DMOGIAU	RU	https://www.ncbi.nlm.nih.gov/pubmed/29130358

DMC64XQ	DI	DMC64XQ
DMC64XQ	DN	PMID29130358-Compound-SB-3CT
DMC64XQ	MI	TTLM12X
DMC64XQ	MN	Matrix metalloproteinase-2 (MMP-2)
DMC64XQ	MT	DTT
DMC64XQ	MA	Inhibitor
DMC64XQ	RN	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
DMC64XQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29130358

DMC64XQ	DI	DMC64XQ
DMC64XQ	DN	PMID29130358-Compound-SB-3CT
DMC64XQ	MI	TT6X50U
DMC64XQ	MN	Matrix metalloproteinase-9 (MMP-9)
DMC64XQ	MT	DTT
DMC64XQ	MA	Inhibitor
DMC64XQ	RN	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
DMC64XQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29130358

DMDN4KP	DI	DMDN4KP
DMDN4KP	DN	PMID29166791-Compound-AMPCP
DMDN4KP	MI	TTK0O6Y
DMDN4KP	MN	Ecto-5'-nucleotidase (CD73)
DMDN4KP	MT	DTT
DMDN4KP	MA	Inhibitor
DMDN4KP	RN	Evaluation of WO2017098421: GSK's benzothiazine compounds as CD73 inhibitor filings.Expert Opin Ther Pat. 2018 Feb;28(2):167-171.
DMDN4KP	RU	https://www.ncbi.nlm.nih.gov/pubmed/29166791

DM0DAR1	DI	DM0DAR1
DM0DAR1	DN	PMID29324067-Compound-25
DM0DAR1	MI	TT3WG5C
DM0DAR1	MN	Monoamine oxidase type A (MAO-A)
DM0DAR1	MT	DTT
DM0DAR1	MA	Inhibitor
DM0DAR1	RN	MAO inhibitors and their wider applications: a patent review.Expert Opin Ther Pat. 2018 Mar;28(3):211-226.
DM0DAR1	RU	https://www.ncbi.nlm.nih.gov/pubmed/29324067

DMPXZYN	DI	DMPXZYN
DMPXZYN	DN	PMID29324067-Compound-38
DMPXZYN	MI	TTGP7BY
DMPXZYN	MN	Monoamine oxidase type B (MAO-B)
DMPXZYN	MT	DTT
DMPXZYN	MA	Inhibitor
DMPXZYN	RN	MAO inhibitors and their wider applications: a patent review.Expert Opin Ther Pat. 2018 Mar;28(3):211-226.
DMPXZYN	RU	https://www.ncbi.nlm.nih.gov/pubmed/29324067

DM69A05	DI	DM69A05
DM69A05	DN	PMID29324067-Compound-40
DM69A05	MI	TTGP7BY
DM69A05	MN	Monoamine oxidase type B (MAO-B)
DM69A05	MT	DTT
DM69A05	MA	Inhibitor
DM69A05	RN	MAO inhibitors and their wider applications: a patent review.Expert Opin Ther Pat. 2018 Mar;28(3):211-226.
DM69A05	RU	https://www.ncbi.nlm.nih.gov/pubmed/29324067

DMTOA1Q	DI	DMTOA1Q
DMTOA1Q	DN	PMID29334795-Compound-21
DMTOA1Q	MI	TT9JNIC
DMTOA1Q	MN	Histamine H3 receptor (H3R)
DMTOA1Q	MT	DTT
DMTOA1Q	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DMTOA1Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DM8N10A	DI	DM8N10A
DM8N10A	DN	PMID29334795-Compound-22
DM8N10A	MI	TT9JNIC
DM8N10A	MN	Histamine H3 receptor (H3R)
DM8N10A	MT	DTT
DM8N10A	MA	Agonis; Inverse agonist
DM8N10A	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DM8N10A	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DM3VL64	DI	DM3VL64
DM3VL64	DN	PMID29334795-Compound-23
DM3VL64	MI	TT9JNIC
DM3VL64	MN	Histamine H3 receptor (H3R)
DM3VL64	MT	DTT
DM3VL64	MA	Inverse agonist
DM3VL64	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DM3VL64	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DMTUQV0	DI	DMTUQV0
DMTUQV0	DN	PMID29334795-Compound-24
DMTUQV0	MI	TT9JNIC
DMTUQV0	MN	Histamine H3 receptor (H3R)
DMTUQV0	MT	DTT
DMTUQV0	MA	Inverse agonist
DMTUQV0	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DMTUQV0	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DMGEWVP	DI	DMGEWVP
DMGEWVP	DN	PMID29334795-Compound-25
DMGEWVP	MI	TT9JNIC
DMGEWVP	MN	Histamine H3 receptor (H3R)
DMGEWVP	MT	DTT
DMGEWVP	MA	Inverse agonist
DMGEWVP	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DMGEWVP	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DM1SWYU	DI	DM1SWYU
DM1SWYU	DN	PMID29334795-Compound-28
DM1SWYU	MI	TT9JNIC
DM1SWYU	MN	Histamine H3 receptor (H3R)
DM1SWYU	MT	DTT
DM1SWYU	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DM1SWYU	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DMM30LJ	DI	DMM30LJ
DMM30LJ	DN	PMID29334795-Compound-55
DMM30LJ	MI	TT9JNIC
DMM30LJ	MN	Histamine H3 receptor (H3R)
DMM30LJ	MT	DTT
DMM30LJ	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DMM30LJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DMS9Q3U	DI	DMS9Q3U
DMS9Q3U	DN	PMID29334795-Compound-56
DMS9Q3U	MI	TT9JNIC
DMS9Q3U	MN	Histamine H3 receptor (H3R)
DMS9Q3U	MT	DTT
DMS9Q3U	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DMS9Q3U	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DMGO1PA	DI	DMGO1PA
DMGO1PA	DN	PMID29334795-Compound-57
DMGO1PA	MI	TT9JNIC
DMGO1PA	MN	Histamine H3 receptor (H3R)
DMGO1PA	MT	DTT
DMGO1PA	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DMGO1PA	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DMB8GHJ	DI	DMB8GHJ
DMB8GHJ	DN	PMID29334795-Compound-58
DMB8GHJ	MI	TT9JNIC
DMB8GHJ	MN	Histamine H3 receptor (H3R)
DMB8GHJ	MT	DTT
DMB8GHJ	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DMB8GHJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DM9H3LI	DI	DM9H3LI
DM9H3LI	DN	PMID29334795-Compound-61
DM9H3LI	MI	TTTIBOJ
DM9H3LI	MN	Histamine H1 receptor (H1R)
DM9H3LI	MT	DTT
DM9H3LI	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DM9H3LI	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DM9H3LI	DI	DM9H3LI
DM9H3LI	DN	PMID29334795-Compound-61
DM9H3LI	MI	TT9JNIC
DM9H3LI	MN	Histamine H3 receptor (H3R)
DM9H3LI	MT	DTT
DM9H3LI	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DM9H3LI	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DM9H3LI	DI	DM9H3LI
DM9H3LI	DN	PMID29334795-Compound-61
DM9H3LI	MI	TT3ROYC
DM9H3LI	MN	Serotonin transporter (SERT)
DM9H3LI	MT	DTT
DM9H3LI	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DM9H3LI	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DMKAFPC	DI	DMKAFPC
DMKAFPC	DN	PMID29334795-Compound-62
DMKAFPC	MI	TTEX248
DMKAFPC	MN	Dopamine D2 receptor (D2R)
DMKAFPC	MT	DTT
DMKAFPC	MA	Ligand
DMKAFPC	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DMKAFPC	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DMKAFPC	DI	DMKAFPC
DMKAFPC	DN	PMID29334795-Compound-62
DMKAFPC	MI	TT9JNIC
DMKAFPC	MN	Histamine H3 receptor (H3R)
DMKAFPC	MT	DTT
DMKAFPC	MA	Inhibitor
DMKAFPC	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DMKAFPC	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DMQOF53	DI	DMQOF53
DMQOF53	DN	PMID29334795-Compound-66
DMQOF53	MI	TTEX248
DMQOF53	MN	Dopamine D2 receptor (D2R)
DMQOF53	MT	DTT
DMQOF53	MA	Ligand
DMQOF53	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DMQOF53	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DMQOF53	DI	DMQOF53
DMQOF53	DN	PMID29334795-Compound-66
DMQOF53	MI	TT9JNIC
DMQOF53	MN	Histamine H3 receptor (H3R)
DMQOF53	MT	DTT
DMQOF53	MA	Inhibitor
DMQOF53	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DMQOF53	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DMC95N7	DI	DMC95N7
DMC95N7	DN	PMID29334795-Compound-67
DMC95N7	MI	TTEX248
DMC95N7	MN	Dopamine D2 receptor (D2R)
DMC95N7	MT	DTT
DMC95N7	MA	Ligand
DMC95N7	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DMC95N7	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DMC95N7	DI	DMC95N7
DMC95N7	DN	PMID29334795-Compound-67
DMC95N7	MI	TT9JNIC
DMC95N7	MN	Histamine H3 receptor (H3R)
DMC95N7	MT	DTT
DMC95N7	MA	Inhibitor
DMC95N7	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DMC95N7	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DMDJFUX	DI	DMDJFUX
DMDJFUX	DN	PMID29338548-Compound-13
DMDJFUX	MI	TTHJTF7
DMDJFUX	MN	Glycine transporter GlyT-1 (SLC6A9)
DMDJFUX	MT	DTT
DMDJFUX	MA	Inhibitor
DMDJFUX	RN	Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210.
DMDJFUX	RU	https://www.ncbi.nlm.nih.gov/pubmed/29338548

DMXIO9A	DI	DMXIO9A
DMXIO9A	DN	PMID29338548-Compound-14
DMXIO9A	MI	TTHJTF7
DMXIO9A	MN	Glycine transporter GlyT-1 (SLC6A9)
DMXIO9A	MT	DTT
DMXIO9A	MA	Inhibitor
DMXIO9A	RN	Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210.
DMXIO9A	RU	https://www.ncbi.nlm.nih.gov/pubmed/29338548

DM6J0Z8	DI	DM6J0Z8
DM6J0Z8	DN	PMID29338548-Compound-15
DM6J0Z8	MI	TTHJTF7
DM6J0Z8	MN	Glycine transporter GlyT-1 (SLC6A9)
DM6J0Z8	MT	DTT
DM6J0Z8	MA	Inhibitor
DM6J0Z8	RN	Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210.
DM6J0Z8	RU	https://www.ncbi.nlm.nih.gov/pubmed/29338548

DMQNVUB	DI	DMQNVUB
DMQNVUB	DN	PMID29338548-Compound-16
DMQNVUB	MI	TTHJTF7
DMQNVUB	MN	Glycine transporter GlyT-1 (SLC6A9)
DMQNVUB	MT	DTT
DMQNVUB	MA	Inhibitor
DMQNVUB	RN	Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210.
DMQNVUB	RU	https://www.ncbi.nlm.nih.gov/pubmed/29338548

DMFXCPQ	DI	DMFXCPQ
DMFXCPQ	DN	PMID29338548-Compound-17
DMFXCPQ	MI	TTHJTF7
DMFXCPQ	MN	Glycine transporter GlyT-1 (SLC6A9)
DMFXCPQ	MT	DTT
DMFXCPQ	MA	Inhibitor
DMFXCPQ	RN	Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210.
DMFXCPQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29338548

DM0XA3D	DI	DM0XA3D
DM0XA3D	DN	PMID29338548-Compound-18
DM0XA3D	MI	TTHJTF7
DM0XA3D	MN	Glycine transporter GlyT-1 (SLC6A9)
DM0XA3D	MT	DTT
DM0XA3D	MA	Inhibitor
DM0XA3D	RN	Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210.
DM0XA3D	RU	https://www.ncbi.nlm.nih.gov/pubmed/29338548

DMKHTE1	DI	DMKHTE1
DMKHTE1	DN	PMID29338548-Compound-19
DMKHTE1	MI	TTHJTF7
DMKHTE1	MN	Glycine transporter GlyT-1 (SLC6A9)
DMKHTE1	MT	DTT
DMKHTE1	MA	Inhibitor
DMKHTE1	RN	Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210.
DMKHTE1	RU	https://www.ncbi.nlm.nih.gov/pubmed/29338548

DMZ3EHV	DI	DMZ3EHV
DMZ3EHV	DN	PMID29338548-Compound-20
DMZ3EHV	MI	TTHJTF7
DMZ3EHV	MN	Glycine transporter GlyT-1 (SLC6A9)
DMZ3EHV	MT	DTT
DMZ3EHV	MA	Inhibitor
DMZ3EHV	RN	Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210.
DMZ3EHV	RU	https://www.ncbi.nlm.nih.gov/pubmed/29338548

DMRTBKC	DI	DMRTBKC
DMRTBKC	DN	PMID29338548-Compound-21
DMRTBKC	MI	TTHJTF7
DMRTBKC	MN	Glycine transporter GlyT-1 (SLC6A9)
DMRTBKC	MT	DTT
DMRTBKC	MA	Inhibitor
DMRTBKC	RN	Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210.
DMRTBKC	RU	https://www.ncbi.nlm.nih.gov/pubmed/29338548

DMT3AL5	DI	DMT3AL5
DMT3AL5	DN	PMID29338548-Compound-22
DMT3AL5	MI	TTHJTF7
DMT3AL5	MN	Glycine transporter GlyT-1 (SLC6A9)
DMT3AL5	MT	DTT
DMT3AL5	MA	Inhibitor
DMT3AL5	RN	Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210.
DMT3AL5	RU	https://www.ncbi.nlm.nih.gov/pubmed/29338548

DMTA3D8	DI	DMTA3D8
DMTA3D8	DN	PMID29338548-Compound-23
DMTA3D8	MI	TTHJTF7
DMTA3D8	MN	Glycine transporter GlyT-1 (SLC6A9)
DMTA3D8	MT	DTT
DMTA3D8	MA	Inhibitor
DMTA3D8	RN	Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210.
DMTA3D8	RU	https://www.ncbi.nlm.nih.gov/pubmed/29338548

DMWRGOX	DI	DMWRGOX
DMWRGOX	DN	PMID29338548-Compound-24
DMWRGOX	MI	TTHJTF7
DMWRGOX	MN	Glycine transporter GlyT-1 (SLC6A9)
DMWRGOX	MT	DTT
DMWRGOX	MA	Inhibitor
DMWRGOX	RN	Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210.
DMWRGOX	RU	https://www.ncbi.nlm.nih.gov/pubmed/29338548

DM83LWC	DI	DM83LWC
DM83LWC	DN	PMID29338548-Compound-25
DM83LWC	MI	TTHJTF7
DM83LWC	MN	Glycine transporter GlyT-1 (SLC6A9)
DM83LWC	MT	DTT
DM83LWC	MA	Inhibitor
DM83LWC	RN	Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210.
DM83LWC	RU	https://www.ncbi.nlm.nih.gov/pubmed/29338548

DMT2D5H	DI	DMT2D5H
DMT2D5H	DN	PMID29338548-Compound-26
DMT2D5H	MI	TTHJTF7
DMT2D5H	MN	Glycine transporter GlyT-1 (SLC6A9)
DMT2D5H	MT	DTT
DMT2D5H	MA	Inhibitor
DMT2D5H	RN	Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210.
DMT2D5H	RU	https://www.ncbi.nlm.nih.gov/pubmed/29338548

DMNW37Y	DI	DMNW37Y
DMNW37Y	DN	PMID29338548-Compound-27
DMNW37Y	MI	TTHJTF7
DMNW37Y	MN	Glycine transporter GlyT-1 (SLC6A9)
DMNW37Y	MT	DTT
DMNW37Y	MA	Inhibitor
DMNW37Y	RN	Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210.
DMNW37Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/29338548

DMNBT3K	DI	DMNBT3K
DMNBT3K	DN	PMID29338548-Compound-28
DMNBT3K	MI	TTHJTF7
DMNBT3K	MN	Glycine transporter GlyT-1 (SLC6A9)
DMNBT3K	MT	DTT
DMNBT3K	MA	Inhibitor
DMNBT3K	RN	Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210.
DMNBT3K	RU	https://www.ncbi.nlm.nih.gov/pubmed/29338548

DMUGC53	DI	DMUGC53
DMUGC53	DN	PMID29338548-Compound-29
DMUGC53	MI	TTHJTF7
DMUGC53	MN	Glycine transporter GlyT-1 (SLC6A9)
DMUGC53	MT	DTT
DMUGC53	MA	Inhibitor
DMUGC53	RN	Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210.
DMUGC53	RU	https://www.ncbi.nlm.nih.gov/pubmed/29338548

DM8JK2D	DI	DM8JK2D
DM8JK2D	DN	PMID29338548-Compound-30
DM8JK2D	MI	TTHJTF7
DM8JK2D	MN	Glycine transporter GlyT-1 (SLC6A9)
DM8JK2D	MT	DTT
DM8JK2D	MA	Inhibitor
DM8JK2D	RN	Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210.
DM8JK2D	RU	https://www.ncbi.nlm.nih.gov/pubmed/29338548

DMWMPE2	DI	DMWMPE2
DMWMPE2	DN	PMID29338548-Compound-31
DMWMPE2	MI	TTHJTF7
DMWMPE2	MN	Glycine transporter GlyT-1 (SLC6A9)
DMWMPE2	MT	DTT
DMWMPE2	MA	Inhibitor
DMWMPE2	RN	Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210.
DMWMPE2	RU	https://www.ncbi.nlm.nih.gov/pubmed/29338548

DM4Q5SW	DI	DM4Q5SW
DM4Q5SW	DN	PMID29338548-Compound-33
DM4Q5SW	MI	TTHJTF7
DM4Q5SW	MN	Glycine transporter GlyT-1 (SLC6A9)
DM4Q5SW	MT	DTT
DM4Q5SW	MA	Inhibitor
DM4Q5SW	RN	Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210.
DM4Q5SW	RU	https://www.ncbi.nlm.nih.gov/pubmed/29338548

DM839NQ	DI	DM839NQ
DM839NQ	DN	PMID29338548-Compound-34
DM839NQ	MI	TTHJTF7
DM839NQ	MN	Glycine transporter GlyT-1 (SLC6A9)
DM839NQ	MT	DTT
DM839NQ	MA	Inhibitor
DM839NQ	RN	Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210.
DM839NQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29338548

DMG675B	DI	DMG675B
DMG675B	DN	PMID29338548-Compound-36
DMG675B	MI	TTHJTF7
DMG675B	MN	Glycine transporter GlyT-1 (SLC6A9)
DMG675B	MT	DTT
DMG675B	MA	Inhibitor
DMG675B	RN	Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210.
DMG675B	RU	https://www.ncbi.nlm.nih.gov/pubmed/29338548

DMAM0US	DI	DMAM0US
DMAM0US	DN	PMID29338548-Compound-37
DMAM0US	MI	TTHJTF7
DMAM0US	MN	Glycine transporter GlyT-1 (SLC6A9)
DMAM0US	MT	DTT
DMAM0US	MA	Inhibitor
DMAM0US	RN	Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210.
DMAM0US	RU	https://www.ncbi.nlm.nih.gov/pubmed/29338548

DM6BKQ8	DI	DM6BKQ8
DM6BKQ8	DN	PMID29338548-Compound-38
DM6BKQ8	MI	TTHJTF7
DM6BKQ8	MN	Glycine transporter GlyT-1 (SLC6A9)
DM6BKQ8	MT	DTT
DM6BKQ8	MA	Inhibitor
DM6BKQ8	RN	Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210.
DM6BKQ8	RU	https://www.ncbi.nlm.nih.gov/pubmed/29338548

DM69Y7R	DI	DM69Y7R
DM69Y7R	DN	PMID29338548-Compound-39
DM69Y7R	MI	TTHJTF7
DM69Y7R	MN	Glycine transporter GlyT-1 (SLC6A9)
DM69Y7R	MT	DTT
DM69Y7R	MA	Inhibitor
DM69Y7R	RN	Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210.
DM69Y7R	RU	https://www.ncbi.nlm.nih.gov/pubmed/29338548

DMLAHC1	DI	DMLAHC1
DMLAHC1	DN	PMID29338548-Compound-40
DMLAHC1	MI	TTHJTF7
DMLAHC1	MN	Glycine transporter GlyT-1 (SLC6A9)
DMLAHC1	MT	DTT
DMLAHC1	MA	Inhibitor
DMLAHC1	RN	Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210.
DMLAHC1	RU	https://www.ncbi.nlm.nih.gov/pubmed/29338548

DM2L7ES	DI	DM2L7ES
DM2L7ES	DN	PMID29338548-Compound-41
DM2L7ES	MI	TTHJTF7
DM2L7ES	MN	Glycine transporter GlyT-1 (SLC6A9)
DM2L7ES	MT	DTT
DM2L7ES	MA	Inhibitor
DM2L7ES	RN	Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210.
DM2L7ES	RU	https://www.ncbi.nlm.nih.gov/pubmed/29338548

DMJYQLC	DI	DMJYQLC
DMJYQLC	DN	PMID29338548-Compound-44
DMJYQLC	MI	TTHJTF7
DMJYQLC	MN	Glycine transporter GlyT-1 (SLC6A9)
DMJYQLC	MT	DTT
DMJYQLC	MA	Inhibitor
DMJYQLC	RN	Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210.
DMJYQLC	RU	https://www.ncbi.nlm.nih.gov/pubmed/29338548

DMO4JYK	DI	DMO4JYK
DMO4JYK	DN	PMID29338548-Compound-45
DMO4JYK	MI	TTHJTF7
DMO4JYK	MN	Glycine transporter GlyT-1 (SLC6A9)
DMO4JYK	MT	DTT
DMO4JYK	MA	Inhibitor
DMO4JYK	RN	Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210.
DMO4JYK	RU	https://www.ncbi.nlm.nih.gov/pubmed/29338548

DMRKIA1	DI	DMRKIA1
DMRKIA1	DN	PMID29338548-Compound-46
DMRKIA1	MI	TTHJTF7
DMRKIA1	MN	Glycine transporter GlyT-1 (SLC6A9)
DMRKIA1	MT	DTT
DMRKIA1	MA	Inhibitor
DMRKIA1	RN	Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210.
DMRKIA1	RU	https://www.ncbi.nlm.nih.gov/pubmed/29338548

DMHBOK6	DI	DMHBOK6
DMHBOK6	DN	PMID29338548-Compound-47
DMHBOK6	MI	TTHJTF7
DMHBOK6	MN	Glycine transporter GlyT-1 (SLC6A9)
DMHBOK6	MT	DTT
DMHBOK6	MA	Inhibitor
DMHBOK6	RN	Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210.
DMHBOK6	RU	https://www.ncbi.nlm.nih.gov/pubmed/29338548

DMDRJHO	DI	DMDRJHO
DMDRJHO	DN	PMID29338548-Compound-48
DMDRJHO	MI	TTHJTF7
DMDRJHO	MN	Glycine transporter GlyT-1 (SLC6A9)
DMDRJHO	MT	DTT
DMDRJHO	MA	Inhibitor
DMDRJHO	RN	Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210.
DMDRJHO	RU	https://www.ncbi.nlm.nih.gov/pubmed/29338548

DM1NJ3U	DI	DM1NJ3U
DM1NJ3U	DN	PMID29338548-Compound-49
DM1NJ3U	MI	TTHJTF7
DM1NJ3U	MN	Glycine transporter GlyT-1 (SLC6A9)
DM1NJ3U	MT	DTT
DM1NJ3U	MA	Inhibitor
DM1NJ3U	RN	Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210.
DM1NJ3U	RU	https://www.ncbi.nlm.nih.gov/pubmed/29338548

DM7EW5U	DI	DM7EW5U
DM7EW5U	DN	PMID29473428-Compound-10
DM7EW5U	MI	TTZJYKH
DM7EW5U	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DM7EW5U	MT	DTT
DM7EW5U	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DM7EW5U	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DM5MXFK	DI	DM5MXFK
DM5MXFK	DN	PMID29473428-Compound-11
DM5MXFK	MI	TTZJYKH
DM5MXFK	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DM5MXFK	MT	DTT
DM5MXFK	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DM5MXFK	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMCB0D6	DI	DMCB0D6
DMCB0D6	DN	PMID29473428-Compound-14
DMCB0D6	MI	TTZJYKH
DMCB0D6	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMCB0D6	MT	DTT
DMCB0D6	MA	Inhibitor
DMCB0D6	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMCB0D6	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DM571JP	DI	DM571JP
DM571JP	DN	PMID29473428-Compound-15
DM571JP	MI	TTZJYKH
DM571JP	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DM571JP	MT	DTT
DM571JP	MA	Inhibitor
DM571JP	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DM571JP	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DM21QCE	DI	DM21QCE
DM21QCE	DN	PMID29473428-Compound-16
DM21QCE	MI	TTZJYKH
DM21QCE	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DM21QCE	MT	DTT
DM21QCE	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DM21QCE	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMI04GC	DI	DMI04GC
DMI04GC	DN	PMID29473428-Compound-17
DMI04GC	MI	TTZJYKH
DMI04GC	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMI04GC	MT	DTT
DMI04GC	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMI04GC	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMZGNWO	DI	DMZGNWO
DMZGNWO	DN	PMID29473428-Compound-21
DMZGNWO	MI	TTZJYKH
DMZGNWO	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMZGNWO	MT	DTT
DMZGNWO	MA	Inhibitor
DMZGNWO	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMZGNWO	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMCNSZD	DI	DMCNSZD
DMCNSZD	DN	PMID29473428-Compound-22
DMCNSZD	MI	TTZJYKH
DMCNSZD	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMCNSZD	MT	DTT
DMCNSZD	MA	Inhibitor
DMCNSZD	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMCNSZD	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMBMTUV	DI	DMBMTUV
DMBMTUV	DN	PMID29473428-Compound-29
DMBMTUV	MI	TTZJYKH
DMBMTUV	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMBMTUV	MT	DTT
DMBMTUV	MA	Inhibitor
DMBMTUV	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMBMTUV	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMZA3FL	DI	DMZA3FL
DMZA3FL	DN	PMID29473428-Compound-33
DMZA3FL	MI	TTZJYKH
DMZA3FL	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMZA3FL	MT	DTT
DMZA3FL	MA	Inhibitor
DMZA3FL	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMZA3FL	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DM7BRPI	DI	DM7BRPI
DM7BRPI	DN	PMID29473428-Compound-34
DM7BRPI	MI	TTZJYKH
DM7BRPI	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DM7BRPI	MT	DTT
DM7BRPI	MA	Inhibitor
DM7BRPI	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DM7BRPI	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMKRUPW	DI	DMKRUPW
DMKRUPW	DN	PMID29473428-Compound-39
DMKRUPW	MI	TTZJYKH
DMKRUPW	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMKRUPW	MT	DTT
DMKRUPW	MA	Antagonist
DMKRUPW	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMKRUPW	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DM9KVOD	DI	DM9KVOD
DM9KVOD	DN	PMID29473428-Compound-4
DM9KVOD	MI	TTZJYKH
DM9KVOD	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DM9KVOD	MT	DTT
DM9KVOD	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DM9KVOD	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DM4AOIR	DI	DM4AOIR
DM4AOIR	DN	PMID29473428-Compound-41
DM4AOIR	MI	TTZJYKH
DM4AOIR	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DM4AOIR	MT	DTT
DM4AOIR	MA	Antagonist
DM4AOIR	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DM4AOIR	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMQ8EYV	DI	DMQ8EYV
DMQ8EYV	DN	PMID29473428-Compound-43
DMQ8EYV	MI	TTZJYKH
DMQ8EYV	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMQ8EYV	MT	DTT
DMQ8EYV	MA	Inhibitor
DMQ8EYV	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMQ8EYV	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMCLJ0M	DI	DMCLJ0M
DMCLJ0M	DN	PMID29473428-Compound-47
DMCLJ0M	MI	TTZJYKH
DMCLJ0M	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMCLJ0M	MT	DTT
DMCLJ0M	MA	Inhibitor
DMCLJ0M	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMCLJ0M	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMAYT2E	DI	DMAYT2E
DMAYT2E	DN	PMID29473428-Compound-48
DMAYT2E	MI	TTZJYKH
DMAYT2E	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMAYT2E	MT	DTT
DMAYT2E	MA	Inhibitor
DMAYT2E	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMAYT2E	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMXUVDH	DI	DMXUVDH
DMXUVDH	DN	PMID29473428-Compound-50
DMXUVDH	MI	TTZJYKH
DMXUVDH	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMXUVDH	MT	DTT
DMXUVDH	MA	Inhibitor
DMXUVDH	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMXUVDH	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMSXKP6	DI	DMSXKP6
DMSXKP6	DN	PMID29473428-Compound-52
DMSXKP6	MI	TTZJYKH
DMSXKP6	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMSXKP6	MT	DTT
DMSXKP6	MA	Inhibitor
DMSXKP6	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMSXKP6	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMOASLQ	DI	DMOASLQ
DMOASLQ	DN	PMID29473428-Compound-53
DMOASLQ	MI	TTZJYKH
DMOASLQ	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMOASLQ	MT	DTT
DMOASLQ	MA	Inhibitor
DMOASLQ	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMOASLQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMKIS26	DI	DMKIS26
DMKIS26	DN	PMID29473428-Compound-54
DMKIS26	MI	TTZJYKH
DMKIS26	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMKIS26	MT	DTT
DMKIS26	MA	Inhibitor
DMKIS26	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMKIS26	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMVP7DL	DI	DMVP7DL
DMVP7DL	DN	PMID29473428-Compound-58
DMVP7DL	MI	TTZJYKH
DMVP7DL	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMVP7DL	MT	DTT
DMVP7DL	MA	Inhibitor
DMVP7DL	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMVP7DL	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMJYUN2	DI	DMJYUN2
DMJYUN2	DN	PMID29473428-Compound-59
DMJYUN2	MI	TTZJYKH
DMJYUN2	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMJYUN2	MT	DTT
DMJYUN2	MA	Inhibitor
DMJYUN2	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMJYUN2	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMOVPWD	DI	DMOVPWD
DMOVPWD	DN	PMID29473428-Compound-6
DMOVPWD	MI	TTZJYKH
DMOVPWD	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMOVPWD	MT	DTT
DMOVPWD	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMOVPWD	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMRKWPQ	DI	DMRKWPQ
DMRKWPQ	DN	PMID29473428-Compound-60
DMRKWPQ	MI	TTZJYKH
DMRKWPQ	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMRKWPQ	MT	DTT
DMRKWPQ	MA	Inhibitor
DMRKWPQ	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMRKWPQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMMV5KI	DI	DMMV5KI
DMMV5KI	DN	PMID29473428-Compound-70
DMMV5KI	MI	TTZJYKH
DMMV5KI	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMMV5KI	MT	DTT
DMMV5KI	MA	Inhibitor
DMMV5KI	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMMV5KI	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DML5G6D	DI	DML5G6D
DML5G6D	DN	PMID29473428-Compound-71
DML5G6D	MI	TTZJYKH
DML5G6D	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DML5G6D	MT	DTT
DML5G6D	MA	Inhibitor
DML5G6D	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DML5G6D	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMJOBUZ	DI	DMJOBUZ
DMJOBUZ	DN	PMID29473428-Compound-72
DMJOBUZ	MI	TTZJYKH
DMJOBUZ	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMJOBUZ	MT	DTT
DMJOBUZ	MA	Inhibitor
DMJOBUZ	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMJOBUZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DM8PZ46	DI	DM8PZ46
DM8PZ46	DN	PMID29473428-Compound-76
DM8PZ46	MI	TTZJYKH
DM8PZ46	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DM8PZ46	MT	DTT
DM8PZ46	MA	Inhibitor
DM8PZ46	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DM8PZ46	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DM8PZ46	DI	DM8PZ46
DM8PZ46	DN	PMID29473428-Compound-76
DM8PZ46	MI	TTXNCBV
DM8PZ46	MN	Tryptophan 2,3-dioxygenase (TDO)
DM8PZ46	MT	DTT
DM8PZ46	MA	Inhibitor
DM8PZ46	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DM8PZ46	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DM8VBU2	DI	DM8VBU2
DM8VBU2	DN	PMID29473428-Compound-80
DM8VBU2	MI	TTZJYKH
DM8VBU2	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DM8VBU2	MT	DTT
DM8VBU2	MA	Inhibitor
DM8VBU2	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DM8VBU2	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMDKT9X	DI	DMDKT9X
DMDKT9X	DN	PMID29649907-Compound-1
DMDKT9X	MI	TTS4UGC
DMDKT9X	MN	Farnesoid X-activated receptor (FXR)
DMDKT9X	MT	DTT
DMDKT9X	MA	Agonist
DMDKT9X	RN	Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
DMDKT9X	RU	https://www.ncbi.nlm.nih.gov/pubmed/29649907

DMNE9AX	DI	DMNE9AX
DMNE9AX	DN	PMID29649907-Compound-10
DMNE9AX	MI	TTS4UGC
DMNE9AX	MN	Farnesoid X-activated receptor (FXR)
DMNE9AX	MT	DTT
DMNE9AX	MA	Agonist
DMNE9AX	RN	Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
DMNE9AX	RU	https://www.ncbi.nlm.nih.gov/pubmed/29649907

DMSC9MH	DI	DMSC9MH
DMSC9MH	DN	PMID29649907-Compound-11
DMSC9MH	MI	TTS4UGC
DMSC9MH	MN	Farnesoid X-activated receptor (FXR)
DMSC9MH	MT	DTT
DMSC9MH	MA	Agonist
DMSC9MH	RN	Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
DMSC9MH	RU	https://www.ncbi.nlm.nih.gov/pubmed/29649907

DMBHT2E	DI	DMBHT2E
DMBHT2E	DN	PMID29649907-Compound-12
DMBHT2E	MI	TTS4UGC
DMBHT2E	MN	Farnesoid X-activated receptor (FXR)
DMBHT2E	MT	DTT
DMBHT2E	MA	Agonist
DMBHT2E	RN	Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
DMBHT2E	RU	https://www.ncbi.nlm.nih.gov/pubmed/29649907

DMLBQUS	DI	DMLBQUS
DMLBQUS	DN	PMID29649907-Compound-13
DMLBQUS	MI	TTS4UGC
DMLBQUS	MN	Farnesoid X-activated receptor (FXR)
DMLBQUS	MT	DTT
DMLBQUS	MA	Agonist
DMLBQUS	RN	Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
DMLBQUS	RU	https://www.ncbi.nlm.nih.gov/pubmed/29649907

DMQAV30	DI	DMQAV30
DMQAV30	DN	PMID29649907-Compound-14
DMQAV30	MI	TTS4UGC
DMQAV30	MN	Farnesoid X-activated receptor (FXR)
DMQAV30	MT	DTT
DMQAV30	MA	Agonist
DMQAV30	RN	Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
DMQAV30	RU	https://www.ncbi.nlm.nih.gov/pubmed/29649907

DMMIKFU	DI	DMMIKFU
DMMIKFU	DN	PMID29649907-Compound-15
DMMIKFU	MI	TTS4UGC
DMMIKFU	MN	Farnesoid X-activated receptor (FXR)
DMMIKFU	MT	DTT
DMMIKFU	MA	Agonist
DMMIKFU	RN	Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
DMMIKFU	RU	https://www.ncbi.nlm.nih.gov/pubmed/29649907

DMBVOZK	DI	DMBVOZK
DMBVOZK	DN	PMID29649907-Compound-18
DMBVOZK	MI	TTS4UGC
DMBVOZK	MN	Farnesoid X-activated receptor (FXR)
DMBVOZK	MT	DTT
DMBVOZK	MA	Agonist
DMBVOZK	RN	Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
DMBVOZK	RU	https://www.ncbi.nlm.nih.gov/pubmed/29649907

DMFL38V	DI	DMFL38V
DMFL38V	DN	PMID29649907-Compound-19
DMFL38V	MI	TTS4UGC
DMFL38V	MN	Farnesoid X-activated receptor (FXR)
DMFL38V	MT	DTT
DMFL38V	MA	Agonist
DMFL38V	RN	Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
DMFL38V	RU	https://www.ncbi.nlm.nih.gov/pubmed/29649907

DMM4TBH	DI	DMM4TBH
DMM4TBH	DN	PMID29649907-Compound-2
DMM4TBH	MI	TTS4UGC
DMM4TBH	MN	Farnesoid X-activated receptor (FXR)
DMM4TBH	MT	DTT
DMM4TBH	MA	Agonist
DMM4TBH	RN	Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
DMM4TBH	RU	https://www.ncbi.nlm.nih.gov/pubmed/29649907

DMGNW34	DI	DMGNW34
DMGNW34	DN	PMID29649907-Compound-20
DMGNW34	MI	TTS4UGC
DMGNW34	MN	Farnesoid X-activated receptor (FXR)
DMGNW34	MT	DTT
DMGNW34	MA	Agonist
DMGNW34	RN	Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
DMGNW34	RU	https://www.ncbi.nlm.nih.gov/pubmed/29649907

DMES0UY	DI	DMES0UY
DMES0UY	DN	PMID29649907-Compound-21
DMES0UY	MI	TTS4UGC
DMES0UY	MN	Farnesoid X-activated receptor (FXR)
DMES0UY	MT	DTT
DMES0UY	MA	Agonist
DMES0UY	RN	Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
DMES0UY	RU	https://www.ncbi.nlm.nih.gov/pubmed/29649907

DMXW108	DI	DMXW108
DMXW108	DN	PMID29649907-Compound-22
DMXW108	MI	TTS4UGC
DMXW108	MN	Farnesoid X-activated receptor (FXR)
DMXW108	MT	DTT
DMXW108	MA	Agonist
DMXW108	RN	Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
DMXW108	RU	https://www.ncbi.nlm.nih.gov/pubmed/29649907

DMW7T45	DI	DMW7T45
DMW7T45	DN	PMID29649907-Compound-23
DMW7T45	MI	TTS4UGC
DMW7T45	MN	Farnesoid X-activated receptor (FXR)
DMW7T45	MT	DTT
DMW7T45	MA	Agonist
DMW7T45	RN	Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
DMW7T45	RU	https://www.ncbi.nlm.nih.gov/pubmed/29649907

DMUHNS7	DI	DMUHNS7
DMUHNS7	DN	PMID29649907-Compound-24
DMUHNS7	MI	TTS4UGC
DMUHNS7	MN	Farnesoid X-activated receptor (FXR)
DMUHNS7	MT	DTT
DMUHNS7	MA	Agonist
DMUHNS7	RN	Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
DMUHNS7	RU	https://www.ncbi.nlm.nih.gov/pubmed/29649907

DMALOEW	DI	DMALOEW
DMALOEW	DN	PMID29649907-Compound-25
DMALOEW	MI	TTS4UGC
DMALOEW	MN	Farnesoid X-activated receptor (FXR)
DMALOEW	MT	DTT
DMALOEW	MA	Agonist
DMALOEW	RN	Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
DMALOEW	RU	https://www.ncbi.nlm.nih.gov/pubmed/29649907

DM6O78C	DI	DM6O78C
DM6O78C	DN	PMID29649907-Compound-26
DM6O78C	MI	TTS4UGC
DM6O78C	MN	Farnesoid X-activated receptor (FXR)
DM6O78C	MT	DTT
DM6O78C	MA	Agonist
DM6O78C	RN	Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
DM6O78C	RU	https://www.ncbi.nlm.nih.gov/pubmed/29649907

DMQDGZL	DI	DMQDGZL
DMQDGZL	DN	PMID29649907-Compound-27
DMQDGZL	MI	TTS4UGC
DMQDGZL	MN	Farnesoid X-activated receptor (FXR)
DMQDGZL	MT	DTT
DMQDGZL	MA	Agonist
DMQDGZL	RN	Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
DMQDGZL	RU	https://www.ncbi.nlm.nih.gov/pubmed/29649907

DMYMKZC	DI	DMYMKZC
DMYMKZC	DN	PMID29649907-Compound-28
DMYMKZC	MI	TTS4UGC
DMYMKZC	MN	Farnesoid X-activated receptor (FXR)
DMYMKZC	MT	DTT
DMYMKZC	MA	Agonist
DMYMKZC	RN	Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
DMYMKZC	RU	https://www.ncbi.nlm.nih.gov/pubmed/29649907

DMEVZIK	DI	DMEVZIK
DMEVZIK	DN	PMID29649907-Compound-29
DMEVZIK	MI	TTS4UGC
DMEVZIK	MN	Farnesoid X-activated receptor (FXR)
DMEVZIK	MT	DTT
DMEVZIK	MA	Agonist
DMEVZIK	RN	Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
DMEVZIK	RU	https://www.ncbi.nlm.nih.gov/pubmed/29649907

DMPVSG9	DI	DMPVSG9
DMPVSG9	DN	PMID29649907-Compound-3
DMPVSG9	MI	TTS4UGC
DMPVSG9	MN	Farnesoid X-activated receptor (FXR)
DMPVSG9	MT	DTT
DMPVSG9	MA	Agonist
DMPVSG9	RN	Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
DMPVSG9	RU	https://www.ncbi.nlm.nih.gov/pubmed/29649907

DM0SY7Q	DI	DM0SY7Q
DM0SY7Q	DN	PMID29649907-Compound-30
DM0SY7Q	MI	TTS4UGC
DM0SY7Q	MN	Farnesoid X-activated receptor (FXR)
DM0SY7Q	MT	DTT
DM0SY7Q	MA	Agonist
DM0SY7Q	RN	Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
DM0SY7Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/29649907

DME6H8Q	DI	DME6H8Q
DME6H8Q	DN	PMID29649907-Compound-31
DME6H8Q	MI	TTS4UGC
DME6H8Q	MN	Farnesoid X-activated receptor (FXR)
DME6H8Q	MT	DTT
DME6H8Q	MA	Agonist
DME6H8Q	RN	Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
DME6H8Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/29649907

DM7E9HA	DI	DM7E9HA
DM7E9HA	DN	PMID29649907-Compound-32
DM7E9HA	MI	TTS4UGC
DM7E9HA	MN	Farnesoid X-activated receptor (FXR)
DM7E9HA	MT	DTT
DM7E9HA	MA	Agonist
DM7E9HA	RN	Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
DM7E9HA	RU	https://www.ncbi.nlm.nih.gov/pubmed/29649907

DM39HCU	DI	DM39HCU
DM39HCU	DN	PMID29649907-Compound-33
DM39HCU	MI	TTS4UGC
DM39HCU	MN	Farnesoid X-activated receptor (FXR)
DM39HCU	MT	DTT
DM39HCU	MA	Agonist
DM39HCU	RN	Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
DM39HCU	RU	https://www.ncbi.nlm.nih.gov/pubmed/29649907

DMUDKE0	DI	DMUDKE0
DMUDKE0	DN	PMID29649907-Compound-34
DMUDKE0	MI	TTS4UGC
DMUDKE0	MN	Farnesoid X-activated receptor (FXR)
DMUDKE0	MT	DTT
DMUDKE0	MA	Agonist
DMUDKE0	RN	Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
DMUDKE0	RU	https://www.ncbi.nlm.nih.gov/pubmed/29649907

DMSWJPO	DI	DMSWJPO
DMSWJPO	DN	PMID29649907-Compound-35
DMSWJPO	MI	TTS4UGC
DMSWJPO	MN	Farnesoid X-activated receptor (FXR)
DMSWJPO	MT	DTT
DMSWJPO	MA	Agonist
DMSWJPO	RN	Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
DMSWJPO	RU	https://www.ncbi.nlm.nih.gov/pubmed/29649907

DMP5KEW	DI	DMP5KEW
DMP5KEW	DN	PMID29649907-Compound-36
DMP5KEW	MI	TTS4UGC
DMP5KEW	MN	Farnesoid X-activated receptor (FXR)
DMP5KEW	MT	DTT
DMP5KEW	MA	Agonist
DMP5KEW	RN	Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
DMP5KEW	RU	https://www.ncbi.nlm.nih.gov/pubmed/29649907

DM8WKYT	DI	DM8WKYT
DM8WKYT	DN	PMID29649907-Compound-37
DM8WKYT	MI	TTS4UGC
DM8WKYT	MN	Farnesoid X-activated receptor (FXR)
DM8WKYT	MT	DTT
DM8WKYT	MA	Agonist
DM8WKYT	RN	Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
DM8WKYT	RU	https://www.ncbi.nlm.nih.gov/pubmed/29649907

DMMP09F	DI	DMMP09F
DMMP09F	DN	PMID29649907-Compound-38
DMMP09F	MI	TTS4UGC
DMMP09F	MN	Farnesoid X-activated receptor (FXR)
DMMP09F	MT	DTT
DMMP09F	MA	Agonist
DMMP09F	RN	Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
DMMP09F	RU	https://www.ncbi.nlm.nih.gov/pubmed/29649907

DMI3ELU	DI	DMI3ELU
DMI3ELU	DN	PMID29649907-Compound-39
DMI3ELU	MI	TTS4UGC
DMI3ELU	MN	Farnesoid X-activated receptor (FXR)
DMI3ELU	MT	DTT
DMI3ELU	MA	Agonist
DMI3ELU	RN	Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
DMI3ELU	RU	https://www.ncbi.nlm.nih.gov/pubmed/29649907

DMO45VP	DI	DMO45VP
DMO45VP	DN	PMID29649907-Compound-4
DMO45VP	MI	TTS4UGC
DMO45VP	MN	Farnesoid X-activated receptor (FXR)
DMO45VP	MT	DTT
DMO45VP	MA	Agonist
DMO45VP	RN	Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
DMO45VP	RU	https://www.ncbi.nlm.nih.gov/pubmed/29649907

DMS6UD2	DI	DMS6UD2
DMS6UD2	DN	PMID29649907-Compound-40
DMS6UD2	MI	TTS4UGC
DMS6UD2	MN	Farnesoid X-activated receptor (FXR)
DMS6UD2	MT	DTT
DMS6UD2	MA	Agonist
DMS6UD2	RN	Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
DMS6UD2	RU	https://www.ncbi.nlm.nih.gov/pubmed/29649907

DM26IRH	DI	DM26IRH
DM26IRH	DN	PMID29649907-Compound-41
DM26IRH	MI	TTS4UGC
DM26IRH	MN	Farnesoid X-activated receptor (FXR)
DM26IRH	MT	DTT
DM26IRH	MA	Agonist
DM26IRH	RN	Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
DM26IRH	RU	https://www.ncbi.nlm.nih.gov/pubmed/29649907

DMSAD9B	DI	DMSAD9B
DMSAD9B	DN	PMID29649907-Compound-42
DMSAD9B	MI	TTS4UGC
DMSAD9B	MN	Farnesoid X-activated receptor (FXR)
DMSAD9B	MT	DTT
DMSAD9B	MA	Agonist
DMSAD9B	RN	Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
DMSAD9B	RU	https://www.ncbi.nlm.nih.gov/pubmed/29649907

DMBA2S3	DI	DMBA2S3
DMBA2S3	DN	PMID29649907-Compound-44
DMBA2S3	MI	TTS4UGC
DMBA2S3	MN	Farnesoid X-activated receptor (FXR)
DMBA2S3	MT	DTT
DMBA2S3	MA	Antagonist
DMBA2S3	RN	Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
DMBA2S3	RU	https://www.ncbi.nlm.nih.gov/pubmed/29649907

DMDWSIE	DI	DMDWSIE
DMDWSIE	DN	PMID29649907-Compound-5
DMDWSIE	MI	TTS4UGC
DMDWSIE	MN	Farnesoid X-activated receptor (FXR)
DMDWSIE	MT	DTT
DMDWSIE	MA	Agonist
DMDWSIE	RN	Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
DMDWSIE	RU	https://www.ncbi.nlm.nih.gov/pubmed/29649907

DMV2D5M	DI	DMV2D5M
DMV2D5M	DN	PMID29649907-Compound-8
DMV2D5M	MI	TTS4UGC
DMV2D5M	MN	Farnesoid X-activated receptor (FXR)
DMV2D5M	MT	DTT
DMV2D5M	MA	Agonist
DMV2D5M	RN	Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
DMV2D5M	RU	https://www.ncbi.nlm.nih.gov/pubmed/29649907

DMV2D5M	DI	DMV2D5M
DMV2D5M	DN	PMID29649907-Compound-8
DMV2D5M	MI	TTSDVTR
DMV2D5M	MN	G-protein coupled bile acid receptor 1 (GPBAR1)
DMV2D5M	MT	DTT
DMV2D5M	MA	Agonist
DMV2D5M	RN	Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
DMV2D5M	RU	https://www.ncbi.nlm.nih.gov/pubmed/29649907

DMA6H4W	DI	DMA6H4W
DMA6H4W	DN	PMID29649907-Compound-9
DMA6H4W	MI	TTS4UGC
DMA6H4W	MN	Farnesoid X-activated receptor (FXR)
DMA6H4W	MT	DTT
DMA6H4W	MA	Agonist
DMA6H4W	RN	Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
DMA6H4W	RU	https://www.ncbi.nlm.nih.gov/pubmed/29649907

DMA0RI8	DI	DMA0RI8
DMA0RI8	DN	PMID29649907-Compound-INT767
DMA0RI8	MI	TTS4UGC
DMA0RI8	MN	Farnesoid X-activated receptor (FXR)
DMA0RI8	MT	DTT
DMA0RI8	MA	Agonist
DMA0RI8	RN	Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
DMA0RI8	RU	https://www.ncbi.nlm.nih.gov/pubmed/29649907

DMA0RI8	DI	DMA0RI8
DMA0RI8	DN	PMID29649907-Compound-INT767
DMA0RI8	MI	TTSDVTR
DMA0RI8	MN	G-protein coupled bile acid receptor 1 (GPBAR1)
DMA0RI8	MT	DTT
DMA0RI8	MA	Agonist
DMA0RI8	RN	Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
DMA0RI8	RU	https://www.ncbi.nlm.nih.gov/pubmed/29649907

DMNKABH	DI	DMNKABH
DMNKABH	DN	PMID29671355-Compound-11
DMNKABH	MI	TT6R7JZ
DMNKABH	MN	Histone deacetylase 1 (HDAC1)
DMNKABH	MT	DTT
DMNKABH	MA	Inhibitor
DMNKABH	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMNKABH	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMNKABH	DI	DMNKABH
DMNKABH	DN	PMID29671355-Compound-11
DMNKABH	MI	TTSHTOI
DMNKABH	MN	Histone deacetylase 2 (HDAC2)
DMNKABH	MT	DTT
DMNKABH	MA	Inhibitor
DMNKABH	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMNKABH	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMNKABH	DI	DMNKABH
DMNKABH	DN	PMID29671355-Compound-11
DMNKABH	MI	TT4YWTO
DMNKABH	MN	Histone deacetylase 3 (HDAC3)
DMNKABH	MT	DTT
DMNKABH	MA	Inhibitor
DMNKABH	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMNKABH	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMNKABH	DI	DMNKABH
DMNKABH	DN	PMID29671355-Compound-11
DMNKABH	MI	TT5ZKDI
DMNKABH	MN	Histone deacetylase 6 (HDAC6)
DMNKABH	MT	DTT
DMNKABH	MA	Inhibitor
DMNKABH	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMNKABH	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMBQOW4	DI	DMBQOW4
DMBQOW4	DN	PMID29671355-Compound-12
DMBQOW4	MI	TTTQGH8
DMBQOW4	MN	Histone deacetylase 4 (HDAC4)
DMBQOW4	MT	DTT
DMBQOW4	MA	Inhibitor
DMBQOW4	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMBQOW4	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMALXYR	DI	DMALXYR
DMALXYR	DN	PMID29671355-Compound-13
DMALXYR	MI	TT6R7JZ
DMALXYR	MN	Histone deacetylase 1 (HDAC1)
DMALXYR	MT	DTT
DMALXYR	MA	Inhibitor
DMALXYR	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMALXYR	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMALXYR	DI	DMALXYR
DMALXYR	DN	PMID29671355-Compound-13
DMALXYR	MI	TT5ZKDI
DMALXYR	MN	Histone deacetylase 6 (HDAC6)
DMALXYR	MT	DTT
DMALXYR	MA	Inhibitor
DMALXYR	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMALXYR	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMALXYR	DI	DMALXYR
DMALXYR	DN	PMID29671355-Compound-13
DMALXYR	MI	TTT6LFV
DMALXYR	MN	Histone deacetylase 8 (HDAC8)
DMALXYR	MT	DTT
DMALXYR	MA	Inhibitor
DMALXYR	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMALXYR	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM8UMQH	DI	DM8UMQH
DM8UMQH	DN	PMID29671355-Compound-14
DM8UMQH	MI	TT5ZKDI
DM8UMQH	MN	Histone deacetylase 6 (HDAC6)
DM8UMQH	MT	DTT
DM8UMQH	MA	Inhibitor
DM8UMQH	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM8UMQH	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMAEPD4	DI	DMAEPD4
DMAEPD4	DN	PMID29671355-Compound-15
DMAEPD4	MI	TT5ZKDI
DMAEPD4	MN	Histone deacetylase 6 (HDAC6)
DMAEPD4	MT	DTT
DMAEPD4	MA	Inhibitor
DMAEPD4	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMAEPD4	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM2C6ZF	DI	DM2C6ZF
DM2C6ZF	DN	PMID29671355-Compound-16
DM2C6ZF	MI	TT5ZKDI
DM2C6ZF	MN	Histone deacetylase 6 (HDAC6)
DM2C6ZF	MT	DTT
DM2C6ZF	MA	Inhibitor
DM2C6ZF	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM2C6ZF	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMUY53P	DI	DMUY53P
DMUY53P	DN	PMID29671355-Compound-18
DMUY53P	MI	TT6R7JZ
DMUY53P	MN	Histone deacetylase 1 (HDAC1)
DMUY53P	MT	DTT
DMUY53P	MA	Inhibitor
DMUY53P	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMUY53P	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMUY53P	DI	DMUY53P
DMUY53P	DN	PMID29671355-Compound-18
DMUY53P	MI	TT5ZKDI
DMUY53P	MN	Histone deacetylase 6 (HDAC6)
DMUY53P	MT	DTT
DMUY53P	MA	Inhibitor
DMUY53P	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMUY53P	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM9LMNB	DI	DM9LMNB
DM9LMNB	DN	PMID29671355-Compound-19
DM9LMNB	MI	TT6R7JZ
DM9LMNB	MN	Histone deacetylase 1 (HDAC1)
DM9LMNB	MT	DTT
DM9LMNB	MA	Inhibitor
DM9LMNB	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM9LMNB	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM9LMNB	DI	DM9LMNB
DM9LMNB	DN	PMID29671355-Compound-19
DM9LMNB	MI	TT5ZKDI
DM9LMNB	MN	Histone deacetylase 6 (HDAC6)
DM9LMNB	MT	DTT
DM9LMNB	MA	Inhibitor
DM9LMNB	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM9LMNB	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMPJN0M	DI	DMPJN0M
DMPJN0M	DN	PMID29671355-Compound-21
DMPJN0M	MI	TT6R7JZ
DMPJN0M	MN	Histone deacetylase 1 (HDAC1)
DMPJN0M	MT	DTT
DMPJN0M	MA	Inhibitor
DMPJN0M	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMPJN0M	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMPJN0M	DI	DMPJN0M
DMPJN0M	DN	PMID29671355-Compound-21
DMPJN0M	MI	TTYHPU6
DMPJN0M	MN	Histone deacetylase 10 (HDAC10)
DMPJN0M	MT	DTT
DMPJN0M	MA	Inhibitor
DMPJN0M	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMPJN0M	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMPJN0M	DI	DMPJN0M
DMPJN0M	DN	PMID29671355-Compound-21
DMPJN0M	MI	TT8K17W
DMPJN0M	MN	Histone deacetylase 11 (HDAC11)
DMPJN0M	MT	DTT
DMPJN0M	MA	Inhibitor
DMPJN0M	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMPJN0M	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMPJN0M	DI	DMPJN0M
DMPJN0M	DN	PMID29671355-Compound-21
DMPJN0M	MI	TTSHTOI
DMPJN0M	MN	Histone deacetylase 2 (HDAC2)
DMPJN0M	MT	DTT
DMPJN0M	MA	Inhibitor
DMPJN0M	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMPJN0M	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMPJN0M	DI	DMPJN0M
DMPJN0M	DN	PMID29671355-Compound-21
DMPJN0M	MI	TT4YWTO
DMPJN0M	MN	Histone deacetylase 3 (HDAC3)
DMPJN0M	MT	DTT
DMPJN0M	MA	Inhibitor
DMPJN0M	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMPJN0M	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMPJN0M	DI	DMPJN0M
DMPJN0M	DN	PMID29671355-Compound-21
DMPJN0M	MI	TTTQGH8
DMPJN0M	MN	Histone deacetylase 4 (HDAC4)
DMPJN0M	MT	DTT
DMPJN0M	MA	Inhibitor
DMPJN0M	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMPJN0M	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMPJN0M	DI	DMPJN0M
DMPJN0M	DN	PMID29671355-Compound-21
DMPJN0M	MI	TT5ZKDI
DMPJN0M	MN	Histone deacetylase 6 (HDAC6)
DMPJN0M	MT	DTT
DMPJN0M	MA	Inhibitor
DMPJN0M	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMPJN0M	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMPJN0M	DI	DMPJN0M
DMPJN0M	DN	PMID29671355-Compound-21
DMPJN0M	MI	TTMUEK1
DMPJN0M	MN	Histone deacetylase 7 (HDAC7)
DMPJN0M	MT	DTT
DMPJN0M	MA	Inhibitor
DMPJN0M	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMPJN0M	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMPJN0M	DI	DMPJN0M
DMPJN0M	DN	PMID29671355-Compound-21
DMPJN0M	MI	TTT6LFV
DMPJN0M	MN	Histone deacetylase 8 (HDAC8)
DMPJN0M	MT	DTT
DMPJN0M	MA	Inhibitor
DMPJN0M	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMPJN0M	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMPJN0M	DI	DMPJN0M
DMPJN0M	DN	PMID29671355-Compound-21
DMPJN0M	MI	TT8M4E1
DMPJN0M	MN	Histone deacetylase 9 (HDAC9)
DMPJN0M	MT	DTT
DMPJN0M	MA	Inhibitor
DMPJN0M	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMPJN0M	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMRGV83	DI	DMRGV83
DMRGV83	DN	PMID29671355-Compound-22
DMRGV83	MI	TT6R7JZ
DMRGV83	MN	Histone deacetylase 1 (HDAC1)
DMRGV83	MT	DTT
DMRGV83	MA	Inhibitor
DMRGV83	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMRGV83	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMRGV83	DI	DMRGV83
DMRGV83	DN	PMID29671355-Compound-22
DMRGV83	MI	TT5ZKDI
DMRGV83	MN	Histone deacetylase 6 (HDAC6)
DMRGV83	MT	DTT
DMRGV83	MA	Inhibitor
DMRGV83	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMRGV83	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMUBOEX	DI	DMUBOEX
DMUBOEX	DN	PMID29671355-Compound-23
DMUBOEX	MI	TT6R7JZ
DMUBOEX	MN	Histone deacetylase 1 (HDAC1)
DMUBOEX	MT	DTT
DMUBOEX	MA	Inhibitor
DMUBOEX	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMUBOEX	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMUBOEX	DI	DMUBOEX
DMUBOEX	DN	PMID29671355-Compound-23
DMUBOEX	MI	TT8K17W
DMUBOEX	MN	Histone deacetylase 11 (HDAC11)
DMUBOEX	MT	DTT
DMUBOEX	MA	Inhibitor
DMUBOEX	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMUBOEX	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMUBOEX	DI	DMUBOEX
DMUBOEX	DN	PMID29671355-Compound-23
DMUBOEX	MI	TTSHTOI
DMUBOEX	MN	Histone deacetylase 2 (HDAC2)
DMUBOEX	MT	DTT
DMUBOEX	MA	Inhibitor
DMUBOEX	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMUBOEX	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMUBOEX	DI	DMUBOEX
DMUBOEX	DN	PMID29671355-Compound-23
DMUBOEX	MI	TTTQGH8
DMUBOEX	MN	Histone deacetylase 4 (HDAC4)
DMUBOEX	MT	DTT
DMUBOEX	MA	Inhibitor
DMUBOEX	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMUBOEX	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMUBOEX	DI	DMUBOEX
DMUBOEX	DN	PMID29671355-Compound-23
DMUBOEX	MI	TTUELN5
DMUBOEX	MN	Histone deacetylase 5 (HDAC5)
DMUBOEX	MT	DTT
DMUBOEX	MA	Inhibitor
DMUBOEX	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMUBOEX	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMUBOEX	DI	DMUBOEX
DMUBOEX	DN	PMID29671355-Compound-23
DMUBOEX	MI	TT5ZKDI
DMUBOEX	MN	Histone deacetylase 6 (HDAC6)
DMUBOEX	MT	DTT
DMUBOEX	MA	Inhibitor
DMUBOEX	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMUBOEX	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMUBOEX	DI	DMUBOEX
DMUBOEX	DN	PMID29671355-Compound-23
DMUBOEX	MI	TTT6LFV
DMUBOEX	MN	Histone deacetylase 8 (HDAC8)
DMUBOEX	MT	DTT
DMUBOEX	MA	Inhibitor
DMUBOEX	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMUBOEX	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMCIGJ1	DI	DMCIGJ1
DMCIGJ1	DN	PMID29671355-Compound-24
DMCIGJ1	MI	TT6R7JZ
DMCIGJ1	MN	Histone deacetylase 1 (HDAC1)
DMCIGJ1	MT	DTT
DMCIGJ1	MA	Inhibitor
DMCIGJ1	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMCIGJ1	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMCIGJ1	DI	DMCIGJ1
DMCIGJ1	DN	PMID29671355-Compound-24
DMCIGJ1	MI	TT5ZKDI
DMCIGJ1	MN	Histone deacetylase 6 (HDAC6)
DMCIGJ1	MT	DTT
DMCIGJ1	MA	Inhibitor
DMCIGJ1	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMCIGJ1	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMPV0KZ	DI	DMPV0KZ
DMPV0KZ	DN	PMID29671355-Compound-25
DMPV0KZ	MI	TT6R7JZ
DMPV0KZ	MN	Histone deacetylase 1 (HDAC1)
DMPV0KZ	MT	DTT
DMPV0KZ	MA	Inhibitor
DMPV0KZ	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMPV0KZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMPV0KZ	DI	DMPV0KZ
DMPV0KZ	DN	PMID29671355-Compound-25
DMPV0KZ	MI	TTYHPU6
DMPV0KZ	MN	Histone deacetylase 10 (HDAC10)
DMPV0KZ	MT	DTT
DMPV0KZ	MA	Inhibitor
DMPV0KZ	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMPV0KZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMPV0KZ	DI	DMPV0KZ
DMPV0KZ	DN	PMID29671355-Compound-25
DMPV0KZ	MI	TT8K17W
DMPV0KZ	MN	Histone deacetylase 11 (HDAC11)
DMPV0KZ	MT	DTT
DMPV0KZ	MA	Inhibitor
DMPV0KZ	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMPV0KZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMPV0KZ	DI	DMPV0KZ
DMPV0KZ	DN	PMID29671355-Compound-25
DMPV0KZ	MI	TTSHTOI
DMPV0KZ	MN	Histone deacetylase 2 (HDAC2)
DMPV0KZ	MT	DTT
DMPV0KZ	MA	Inhibitor
DMPV0KZ	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMPV0KZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMPV0KZ	DI	DMPV0KZ
DMPV0KZ	DN	PMID29671355-Compound-25
DMPV0KZ	MI	TT4YWTO
DMPV0KZ	MN	Histone deacetylase 3 (HDAC3)
DMPV0KZ	MT	DTT
DMPV0KZ	MA	Inhibitor
DMPV0KZ	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMPV0KZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMPV0KZ	DI	DMPV0KZ
DMPV0KZ	DN	PMID29671355-Compound-25
DMPV0KZ	MI	TTTQGH8
DMPV0KZ	MN	Histone deacetylase 4 (HDAC4)
DMPV0KZ	MT	DTT
DMPV0KZ	MA	Inhibitor
DMPV0KZ	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMPV0KZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMPV0KZ	DI	DMPV0KZ
DMPV0KZ	DN	PMID29671355-Compound-25
DMPV0KZ	MI	TTUELN5
DMPV0KZ	MN	Histone deacetylase 5 (HDAC5)
DMPV0KZ	MT	DTT
DMPV0KZ	MA	Inhibitor
DMPV0KZ	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMPV0KZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMPV0KZ	DI	DMPV0KZ
DMPV0KZ	DN	PMID29671355-Compound-25
DMPV0KZ	MI	TT5ZKDI
DMPV0KZ	MN	Histone deacetylase 6 (HDAC6)
DMPV0KZ	MT	DTT
DMPV0KZ	MA	Inhibitor
DMPV0KZ	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMPV0KZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMPV0KZ	DI	DMPV0KZ
DMPV0KZ	DN	PMID29671355-Compound-25
DMPV0KZ	MI	TTMUEK1
DMPV0KZ	MN	Histone deacetylase 7 (HDAC7)
DMPV0KZ	MT	DTT
DMPV0KZ	MA	Inhibitor
DMPV0KZ	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMPV0KZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMPV0KZ	DI	DMPV0KZ
DMPV0KZ	DN	PMID29671355-Compound-25
DMPV0KZ	MI	TTT6LFV
DMPV0KZ	MN	Histone deacetylase 8 (HDAC8)
DMPV0KZ	MT	DTT
DMPV0KZ	MA	Inhibitor
DMPV0KZ	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMPV0KZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMPV0KZ	DI	DMPV0KZ
DMPV0KZ	DN	PMID29671355-Compound-25
DMPV0KZ	MI	TT8M4E1
DMPV0KZ	MN	Histone deacetylase 9 (HDAC9)
DMPV0KZ	MT	DTT
DMPV0KZ	MA	Inhibitor
DMPV0KZ	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMPV0KZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM5K6MG	DI	DM5K6MG
DM5K6MG	DN	PMID29671355-Compound-26
DM5K6MG	MI	TT6R7JZ
DM5K6MG	MN	Histone deacetylase 1 (HDAC1)
DM5K6MG	MT	DTT
DM5K6MG	MA	Inhibitor
DM5K6MG	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM5K6MG	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM5K6MG	DI	DM5K6MG
DM5K6MG	DN	PMID29671355-Compound-26
DM5K6MG	MI	TT5ZKDI
DM5K6MG	MN	Histone deacetylase 6 (HDAC6)
DM5K6MG	MT	DTT
DM5K6MG	MA	Inhibitor
DM5K6MG	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM5K6MG	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMP7S9E	DI	DMP7S9E
DMP7S9E	DN	PMID29671355-Compound-27
DMP7S9E	MI	TT6R7JZ
DMP7S9E	MN	Histone deacetylase 1 (HDAC1)
DMP7S9E	MT	DTT
DMP7S9E	MA	Inhibitor
DMP7S9E	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMP7S9E	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMP7S9E	DI	DMP7S9E
DMP7S9E	DN	PMID29671355-Compound-27
DMP7S9E	MI	TT5ZKDI
DMP7S9E	MN	Histone deacetylase 6 (HDAC6)
DMP7S9E	MT	DTT
DMP7S9E	MA	Inhibitor
DMP7S9E	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMP7S9E	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMLXSHW	DI	DMLXSHW
DMLXSHW	DN	PMID29671355-Compound-28
DMLXSHW	MI	TT6R7JZ
DMLXSHW	MN	Histone deacetylase 1 (HDAC1)
DMLXSHW	MT	DTT
DMLXSHW	MA	Inhibitor
DMLXSHW	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMLXSHW	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMLXSHW	DI	DMLXSHW
DMLXSHW	DN	PMID29671355-Compound-28
DMLXSHW	MI	TT5ZKDI
DMLXSHW	MN	Histone deacetylase 6 (HDAC6)
DMLXSHW	MT	DTT
DMLXSHW	MA	Inhibitor
DMLXSHW	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMLXSHW	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM3H78D	DI	DM3H78D
DM3H78D	DN	PMID29671355-Compound-31
DM3H78D	MI	TT6R7JZ
DM3H78D	MN	Histone deacetylase 1 (HDAC1)
DM3H78D	MT	DTT
DM3H78D	MA	Inhibitor
DM3H78D	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM3H78D	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM3H78D	DI	DM3H78D
DM3H78D	DN	PMID29671355-Compound-31
DM3H78D	MI	TTSHTOI
DM3H78D	MN	Histone deacetylase 2 (HDAC2)
DM3H78D	MT	DTT
DM3H78D	MA	Inhibitor
DM3H78D	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM3H78D	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM3H78D	DI	DM3H78D
DM3H78D	DN	PMID29671355-Compound-31
DM3H78D	MI	TT4YWTO
DM3H78D	MN	Histone deacetylase 3 (HDAC3)
DM3H78D	MT	DTT
DM3H78D	MA	Inhibitor
DM3H78D	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM3H78D	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM3H78D	DI	DM3H78D
DM3H78D	DN	PMID29671355-Compound-31
DM3H78D	MI	TTTQGH8
DM3H78D	MN	Histone deacetylase 4 (HDAC4)
DM3H78D	MT	DTT
DM3H78D	MA	Inhibitor
DM3H78D	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM3H78D	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM3H78D	DI	DM3H78D
DM3H78D	DN	PMID29671355-Compound-31
DM3H78D	MI	TTUELN5
DM3H78D	MN	Histone deacetylase 5 (HDAC5)
DM3H78D	MT	DTT
DM3H78D	MA	Inhibitor
DM3H78D	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM3H78D	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM3H78D	DI	DM3H78D
DM3H78D	DN	PMID29671355-Compound-31
DM3H78D	MI	TT5ZKDI
DM3H78D	MN	Histone deacetylase 6 (HDAC6)
DM3H78D	MT	DTT
DM3H78D	MA	Inhibitor
DM3H78D	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM3H78D	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM3H78D	DI	DM3H78D
DM3H78D	DN	PMID29671355-Compound-31
DM3H78D	MI	TTMUEK1
DM3H78D	MN	Histone deacetylase 7 (HDAC7)
DM3H78D	MT	DTT
DM3H78D	MA	Inhibitor
DM3H78D	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM3H78D	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM3H78D	DI	DM3H78D
DM3H78D	DN	PMID29671355-Compound-31
DM3H78D	MI	TTT6LFV
DM3H78D	MN	Histone deacetylase 8 (HDAC8)
DM3H78D	MT	DTT
DM3H78D	MA	Inhibitor
DM3H78D	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM3H78D	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM3H78D	DI	DM3H78D
DM3H78D	DN	PMID29671355-Compound-31
DM3H78D	MI	TT8M4E1
DM3H78D	MN	Histone deacetylase 9 (HDAC9)
DM3H78D	MT	DTT
DM3H78D	MA	Inhibitor
DM3H78D	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM3H78D	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMQJ3TC	DI	DMQJ3TC
DMQJ3TC	DN	PMID29671355-Compound-36
DMQJ3TC	MI	TT8K17W
DMQJ3TC	MN	Histone deacetylase 11 (HDAC11)
DMQJ3TC	MT	DTT
DMQJ3TC	MA	Inhibitor
DMQJ3TC	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMQJ3TC	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMQJ3TC	DI	DMQJ3TC
DMQJ3TC	DN	PMID29671355-Compound-36
DMQJ3TC	MI	TTT6LFV
DMQJ3TC	MN	Histone deacetylase 8 (HDAC8)
DMQJ3TC	MT	DTT
DMQJ3TC	MA	Inhibitor
DMQJ3TC	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMQJ3TC	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMJ1O5R	DI	DMJ1O5R
DMJ1O5R	DN	PMID29671355-Compound-37
DMJ1O5R	MI	TTT6LFV
DMJ1O5R	MN	Histone deacetylase 8 (HDAC8)
DMJ1O5R	MT	DTT
DMJ1O5R	MA	Inhibitor
DMJ1O5R	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMJ1O5R	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMYATB5	DI	DMYATB5
DMYATB5	DN	PMID29671355-Compound-38a
DMYATB5	MI	TT6R7JZ
DMYATB5	MN	Histone deacetylase 1 (HDAC1)
DMYATB5	MT	DTT
DMYATB5	MA	Inhibitor
DMYATB5	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMYATB5	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMYATB5	DI	DMYATB5
DMYATB5	DN	PMID29671355-Compound-38a
DMYATB5	MI	TT5ZKDI
DMYATB5	MN	Histone deacetylase 6 (HDAC6)
DMYATB5	MT	DTT
DMYATB5	MA	Inhibitor
DMYATB5	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMYATB5	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMYXE4J	DI	DMYXE4J
DMYXE4J	DN	PMID29671355-Compound-38b
DMYXE4J	MI	TT6R7JZ
DMYXE4J	MN	Histone deacetylase 1 (HDAC1)
DMYXE4J	MT	DTT
DMYXE4J	MA	Inhibitor
DMYXE4J	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMYXE4J	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMYXE4J	DI	DMYXE4J
DMYXE4J	DN	PMID29671355-Compound-38b
DMYXE4J	MI	TT5ZKDI
DMYXE4J	MN	Histone deacetylase 6 (HDAC6)
DMYXE4J	MT	DTT
DMYXE4J	MA	Inhibitor
DMYXE4J	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMYXE4J	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM6EJ93	DI	DM6EJ93
DM6EJ93	DN	PMID29671355-Compound-39
DM6EJ93	MI	TT6R7JZ
DM6EJ93	MN	Histone deacetylase 1 (HDAC1)
DM6EJ93	MT	DTT
DM6EJ93	MA	Inhibitor
DM6EJ93	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM6EJ93	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM6EJ93	DI	DM6EJ93
DM6EJ93	DN	PMID29671355-Compound-39
DM6EJ93	MI	TT5ZKDI
DM6EJ93	MN	Histone deacetylase 6 (HDAC6)
DM6EJ93	MT	DTT
DM6EJ93	MA	Inhibitor
DM6EJ93	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM6EJ93	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMXY103	DI	DMXY103
DMXY103	DN	PMID29671355-Compound-42
DMXY103	MI	TT6R7JZ
DMXY103	MN	Histone deacetylase 1 (HDAC1)
DMXY103	MT	DTT
DMXY103	MA	Inhibitor
DMXY103	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMXY103	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMVPMWJ	DI	DMVPMWJ
DMVPMWJ	DN	PMID29671355-Compound-43
DMVPMWJ	MI	TT6R7JZ
DMVPMWJ	MN	Histone deacetylase 1 (HDAC1)
DMVPMWJ	MT	DTT
DMVPMWJ	MA	Inhibitor
DMVPMWJ	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMVPMWJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMVPMWJ	DI	DMVPMWJ
DMVPMWJ	DN	PMID29671355-Compound-43
DMVPMWJ	MI	TTYHPU6
DMVPMWJ	MN	Histone deacetylase 10 (HDAC10)
DMVPMWJ	MT	DTT
DMVPMWJ	MA	Inhibitor
DMVPMWJ	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMVPMWJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMVPMWJ	DI	DMVPMWJ
DMVPMWJ	DN	PMID29671355-Compound-43
DMVPMWJ	MI	TT8K17W
DMVPMWJ	MN	Histone deacetylase 11 (HDAC11)
DMVPMWJ	MT	DTT
DMVPMWJ	MA	Inhibitor
DMVPMWJ	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMVPMWJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMVPMWJ	DI	DMVPMWJ
DMVPMWJ	DN	PMID29671355-Compound-43
DMVPMWJ	MI	TTSHTOI
DMVPMWJ	MN	Histone deacetylase 2 (HDAC2)
DMVPMWJ	MT	DTT
DMVPMWJ	MA	Inhibitor
DMVPMWJ	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMVPMWJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMVPMWJ	DI	DMVPMWJ
DMVPMWJ	DN	PMID29671355-Compound-43
DMVPMWJ	MI	TT4YWTO
DMVPMWJ	MN	Histone deacetylase 3 (HDAC3)
DMVPMWJ	MT	DTT
DMVPMWJ	MA	Inhibitor
DMVPMWJ	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMVPMWJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMVPMWJ	DI	DMVPMWJ
DMVPMWJ	DN	PMID29671355-Compound-43
DMVPMWJ	MI	TTTQGH8
DMVPMWJ	MN	Histone deacetylase 4 (HDAC4)
DMVPMWJ	MT	DTT
DMVPMWJ	MA	Inhibitor
DMVPMWJ	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMVPMWJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMVPMWJ	DI	DMVPMWJ
DMVPMWJ	DN	PMID29671355-Compound-43
DMVPMWJ	MI	TTUELN5
DMVPMWJ	MN	Histone deacetylase 5 (HDAC5)
DMVPMWJ	MT	DTT
DMVPMWJ	MA	Inhibitor
DMVPMWJ	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMVPMWJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMVPMWJ	DI	DMVPMWJ
DMVPMWJ	DN	PMID29671355-Compound-43
DMVPMWJ	MI	TT5ZKDI
DMVPMWJ	MN	Histone deacetylase 6 (HDAC6)
DMVPMWJ	MT	DTT
DMVPMWJ	MA	Inhibitor
DMVPMWJ	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMVPMWJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMVPMWJ	DI	DMVPMWJ
DMVPMWJ	DN	PMID29671355-Compound-43
DMVPMWJ	MI	TTMUEK1
DMVPMWJ	MN	Histone deacetylase 7 (HDAC7)
DMVPMWJ	MT	DTT
DMVPMWJ	MA	Inhibitor
DMVPMWJ	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMVPMWJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMVPMWJ	DI	DMVPMWJ
DMVPMWJ	DN	PMID29671355-Compound-43
DMVPMWJ	MI	TTT6LFV
DMVPMWJ	MN	Histone deacetylase 8 (HDAC8)
DMVPMWJ	MT	DTT
DMVPMWJ	MA	Inhibitor
DMVPMWJ	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMVPMWJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMVPMWJ	DI	DMVPMWJ
DMVPMWJ	DN	PMID29671355-Compound-43
DMVPMWJ	MI	TT8M4E1
DMVPMWJ	MN	Histone deacetylase 9 (HDAC9)
DMVPMWJ	MT	DTT
DMVPMWJ	MA	Inhibitor
DMVPMWJ	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMVPMWJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM80A3V	DI	DM80A3V
DM80A3V	DN	PMID29671355-Compound-44
DM80A3V	MI	TT6R7JZ
DM80A3V	MN	Histone deacetylase 1 (HDAC1)
DM80A3V	MT	DTT
DM80A3V	MA	Inhibitor
DM80A3V	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM80A3V	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM80A3V	DI	DM80A3V
DM80A3V	DN	PMID29671355-Compound-44
DM80A3V	MI	TTYHPU6
DM80A3V	MN	Histone deacetylase 10 (HDAC10)
DM80A3V	MT	DTT
DM80A3V	MA	Inhibitor
DM80A3V	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM80A3V	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM80A3V	DI	DM80A3V
DM80A3V	DN	PMID29671355-Compound-44
DM80A3V	MI	TT8K17W
DM80A3V	MN	Histone deacetylase 11 (HDAC11)
DM80A3V	MT	DTT
DM80A3V	MA	Inhibitor
DM80A3V	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM80A3V	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM80A3V	DI	DM80A3V
DM80A3V	DN	PMID29671355-Compound-44
DM80A3V	MI	TTSHTOI
DM80A3V	MN	Histone deacetylase 2 (HDAC2)
DM80A3V	MT	DTT
DM80A3V	MA	Inhibitor
DM80A3V	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM80A3V	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM80A3V	DI	DM80A3V
DM80A3V	DN	PMID29671355-Compound-44
DM80A3V	MI	TT4YWTO
DM80A3V	MN	Histone deacetylase 3 (HDAC3)
DM80A3V	MT	DTT
DM80A3V	MA	Inhibitor
DM80A3V	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM80A3V	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM80A3V	DI	DM80A3V
DM80A3V	DN	PMID29671355-Compound-44
DM80A3V	MI	TT5ZKDI
DM80A3V	MN	Histone deacetylase 6 (HDAC6)
DM80A3V	MT	DTT
DM80A3V	MA	Inhibitor
DM80A3V	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM80A3V	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM80A3V	DI	DM80A3V
DM80A3V	DN	PMID29671355-Compound-44
DM80A3V	MI	TTT6LFV
DM80A3V	MN	Histone deacetylase 8 (HDAC8)
DM80A3V	MT	DTT
DM80A3V	MA	Inhibitor
DM80A3V	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM80A3V	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM5LYKR	DI	DM5LYKR
DM5LYKR	DN	PMID29671355-Compound-45a
DM5LYKR	MI	TTTQGH8
DM5LYKR	MN	Histone deacetylase 4 (HDAC4)
DM5LYKR	MT	DTT
DM5LYKR	MA	Inhibitor
DM5LYKR	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM5LYKR	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM5LYKR	DI	DM5LYKR
DM5LYKR	DN	PMID29671355-Compound-45a
DM5LYKR	MI	TTUELN5
DM5LYKR	MN	Histone deacetylase 5 (HDAC5)
DM5LYKR	MT	DTT
DM5LYKR	MA	Inhibitor
DM5LYKR	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM5LYKR	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM5LYKR	DI	DM5LYKR
DM5LYKR	DN	PMID29671355-Compound-45a
DM5LYKR	MI	TTMUEK1
DM5LYKR	MN	Histone deacetylase 7 (HDAC7)
DM5LYKR	MT	DTT
DM5LYKR	MA	Inhibitor
DM5LYKR	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM5LYKR	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM5LYKR	DI	DM5LYKR
DM5LYKR	DN	PMID29671355-Compound-45a
DM5LYKR	MI	TT8M4E1
DM5LYKR	MN	Histone deacetylase 9 (HDAC9)
DM5LYKR	MT	DTT
DM5LYKR	MA	Inhibitor
DM5LYKR	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM5LYKR	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM5I1QV	DI	DM5I1QV
DM5I1QV	DN	PMID29671355-Compound-47a
DM5I1QV	MI	TTTQGH8
DM5I1QV	MN	Histone deacetylase 4 (HDAC4)
DM5I1QV	MT	DTT
DM5I1QV	MA	Inhibitor
DM5I1QV	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM5I1QV	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMBUJ39	DI	DMBUJ39
DMBUJ39	DN	PMID29671355-Compound-47b
DMBUJ39	MI	TTTQGH8
DMBUJ39	MN	Histone deacetylase 4 (HDAC4)
DMBUJ39	MT	DTT
DMBUJ39	MA	Inhibitor
DMBUJ39	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMBUJ39	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMAH982	DI	DMAH982
DMAH982	DN	PMID29671355-Compound-47c
DMAH982	MI	TTTQGH8
DMAH982	MN	Histone deacetylase 4 (HDAC4)
DMAH982	MT	DTT
DMAH982	MA	Inhibitor
DMAH982	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMAH982	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMPA9OY	DI	DMPA9OY
DMPA9OY	DN	PMID29671355-Compound-47d
DMPA9OY	MI	TTTQGH8
DMPA9OY	MN	Histone deacetylase 4 (HDAC4)
DMPA9OY	MT	DTT
DMPA9OY	MA	Inhibitor
DMPA9OY	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMPA9OY	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMLDFVN	DI	DMLDFVN
DMLDFVN	DN	PMID29671355-Compound-50
DMLDFVN	MI	TTTQGH8
DMLDFVN	MN	Histone deacetylase 4 (HDAC4)
DMLDFVN	MT	DTT
DMLDFVN	MA	Inhibitor
DMLDFVN	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMLDFVN	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMEUZM3	DI	DMEUZM3
DMEUZM3	DN	PMID29671355-Compound-52
DMEUZM3	MI	TTTQGH8
DMEUZM3	MN	Histone deacetylase 4 (HDAC4)
DMEUZM3	MT	DTT
DMEUZM3	MA	Inhibitor
DMEUZM3	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMEUZM3	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMCRWV3	DI	DMCRWV3
DMCRWV3	DN	PMID29671355-Compound-53
DMCRWV3	MI	TTBH0VX
DMCRWV3	MN	Histone deacetylase (HDAC)
DMCRWV3	MT	DTT
DMCRWV3	MA	Inhibitor
DMCRWV3	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMCRWV3	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMJV1SY	DI	DMJV1SY
DMJV1SY	DN	PMID29671355-Compound-55
DMJV1SY	MI	TT6R7JZ
DMJV1SY	MN	Histone deacetylase 1 (HDAC1)
DMJV1SY	MT	DTT
DMJV1SY	MA	Inhibitor
DMJV1SY	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMJV1SY	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMJV1SY	DI	DMJV1SY
DMJV1SY	DN	PMID29671355-Compound-55
DMJV1SY	MI	TTSHTOI
DMJV1SY	MN	Histone deacetylase 2 (HDAC2)
DMJV1SY	MT	DTT
DMJV1SY	MA	Inhibitor
DMJV1SY	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMJV1SY	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMJV1SY	DI	DMJV1SY
DMJV1SY	DN	PMID29671355-Compound-55
DMJV1SY	MI	TT4YWTO
DMJV1SY	MN	Histone deacetylase 3 (HDAC3)
DMJV1SY	MT	DTT
DMJV1SY	MA	Inhibitor
DMJV1SY	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMJV1SY	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM0VBMI	DI	DM0VBMI
DM0VBMI	DN	PMID29671355-Compound-56
DM0VBMI	MI	TT6R7JZ
DM0VBMI	MN	Histone deacetylase 1 (HDAC1)
DM0VBMI	MT	DTT
DM0VBMI	MA	Inhibitor
DM0VBMI	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM0VBMI	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM0VBMI	DI	DM0VBMI
DM0VBMI	DN	PMID29671355-Compound-56
DM0VBMI	MI	TTYHPU6
DM0VBMI	MN	Histone deacetylase 10 (HDAC10)
DM0VBMI	MT	DTT
DM0VBMI	MA	Inhibitor
DM0VBMI	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM0VBMI	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM0VBMI	DI	DM0VBMI
DM0VBMI	DN	PMID29671355-Compound-56
DM0VBMI	MI	TTSHTOI
DM0VBMI	MN	Histone deacetylase 2 (HDAC2)
DM0VBMI	MT	DTT
DM0VBMI	MA	Inhibitor
DM0VBMI	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM0VBMI	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM0VBMI	DI	DM0VBMI
DM0VBMI	DN	PMID29671355-Compound-56
DM0VBMI	MI	TT4YWTO
DM0VBMI	MN	Histone deacetylase 3 (HDAC3)
DM0VBMI	MT	DTT
DM0VBMI	MA	Inhibitor
DM0VBMI	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM0VBMI	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM0VBMI	DI	DM0VBMI
DM0VBMI	DN	PMID29671355-Compound-56
DM0VBMI	MI	TTTQGH8
DM0VBMI	MN	Histone deacetylase 4 (HDAC4)
DM0VBMI	MT	DTT
DM0VBMI	MA	Inhibitor
DM0VBMI	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM0VBMI	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM0VBMI	DI	DM0VBMI
DM0VBMI	DN	PMID29671355-Compound-56
DM0VBMI	MI	TT5ZKDI
DM0VBMI	MN	Histone deacetylase 6 (HDAC6)
DM0VBMI	MT	DTT
DM0VBMI	MA	Inhibitor
DM0VBMI	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM0VBMI	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM0VBMI	DI	DM0VBMI
DM0VBMI	DN	PMID29671355-Compound-56
DM0VBMI	MI	TTMUEK1
DM0VBMI	MN	Histone deacetylase 7 (HDAC7)
DM0VBMI	MT	DTT
DM0VBMI	MA	Inhibitor
DM0VBMI	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM0VBMI	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM0VBMI	DI	DM0VBMI
DM0VBMI	DN	PMID29671355-Compound-56
DM0VBMI	MI	TTT6LFV
DM0VBMI	MN	Histone deacetylase 8 (HDAC8)
DM0VBMI	MT	DTT
DM0VBMI	MA	Inhibitor
DM0VBMI	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM0VBMI	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM57N3Y	DI	DM57N3Y
DM57N3Y	DN	PMID29671355-Compound-57
DM57N3Y	MI	TT6R7JZ
DM57N3Y	MN	Histone deacetylase 1 (HDAC1)
DM57N3Y	MT	DTT
DM57N3Y	MA	Inhibitor
DM57N3Y	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM57N3Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM57N3Y	DI	DM57N3Y
DM57N3Y	DN	PMID29671355-Compound-57
DM57N3Y	MI	TT4YWTO
DM57N3Y	MN	Histone deacetylase 3 (HDAC3)
DM57N3Y	MT	DTT
DM57N3Y	MA	Inhibitor
DM57N3Y	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM57N3Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM2F0CQ	DI	DM2F0CQ
DM2F0CQ	DN	PMID29671355-Compound-59
DM2F0CQ	MI	TT6R7JZ
DM2F0CQ	MN	Histone deacetylase 1 (HDAC1)
DM2F0CQ	MT	DTT
DM2F0CQ	MA	Inhibitor
DM2F0CQ	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM2F0CQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM2F0CQ	DI	DM2F0CQ
DM2F0CQ	DN	PMID29671355-Compound-59
DM2F0CQ	MI	TTSHTOI
DM2F0CQ	MN	Histone deacetylase 2 (HDAC2)
DM2F0CQ	MT	DTT
DM2F0CQ	MA	Inhibitor
DM2F0CQ	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM2F0CQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM2F0CQ	DI	DM2F0CQ
DM2F0CQ	DN	PMID29671355-Compound-59
DM2F0CQ	MI	TT4YWTO
DM2F0CQ	MN	Histone deacetylase 3 (HDAC3)
DM2F0CQ	MT	DTT
DM2F0CQ	MA	Inhibitor
DM2F0CQ	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM2F0CQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMXH1G3	DI	DMXH1G3
DMXH1G3	DN	PMID29671355-Compound-61
DMXH1G3	MI	TT6R7JZ
DMXH1G3	MN	Histone deacetylase 1 (HDAC1)
DMXH1G3	MT	DTT
DMXH1G3	MA	Inhibitor
DMXH1G3	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMXH1G3	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMXH1G3	DI	DMXH1G3
DMXH1G3	DN	PMID29671355-Compound-61
DMXH1G3	MI	TTSHTOI
DMXH1G3	MN	Histone deacetylase 2 (HDAC2)
DMXH1G3	MT	DTT
DMXH1G3	MA	Inhibitor
DMXH1G3	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMXH1G3	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMXH1G3	DI	DMXH1G3
DMXH1G3	DN	PMID29671355-Compound-61
DMXH1G3	MI	TT4YWTO
DMXH1G3	MN	Histone deacetylase 3 (HDAC3)
DMXH1G3	MT	DTT
DMXH1G3	MA	Inhibitor
DMXH1G3	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMXH1G3	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMXH1G3	DI	DMXH1G3
DMXH1G3	DN	PMID29671355-Compound-61
DMXH1G3	MI	TTTQGH8
DMXH1G3	MN	Histone deacetylase 4 (HDAC4)
DMXH1G3	MT	DTT
DMXH1G3	MA	Inhibitor
DMXH1G3	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMXH1G3	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMXH1G3	DI	DMXH1G3
DMXH1G3	DN	PMID29671355-Compound-61
DMXH1G3	MI	TT5ZKDI
DMXH1G3	MN	Histone deacetylase 6 (HDAC6)
DMXH1G3	MT	DTT
DMXH1G3	MA	Inhibitor
DMXH1G3	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMXH1G3	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMXH1G3	DI	DMXH1G3
DMXH1G3	DN	PMID29671355-Compound-61
DMXH1G3	MI	TTT6LFV
DMXH1G3	MN	Histone deacetylase 8 (HDAC8)
DMXH1G3	MT	DTT
DMXH1G3	MA	Inhibitor
DMXH1G3	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMXH1G3	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMWRS34	DI	DMWRS34
DMWRS34	DN	PMID29671355-Compound-62
DMWRS34	MI	TT6R7JZ
DMWRS34	MN	Histone deacetylase 1 (HDAC1)
DMWRS34	MT	DTT
DMWRS34	MA	Inhibitor
DMWRS34	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMWRS34	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMWRS34	DI	DMWRS34
DMWRS34	DN	PMID29671355-Compound-62
DMWRS34	MI	TTYHPU6
DMWRS34	MN	Histone deacetylase 10 (HDAC10)
DMWRS34	MT	DTT
DMWRS34	MA	Inhibitor
DMWRS34	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMWRS34	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMWRS34	DI	DMWRS34
DMWRS34	DN	PMID29671355-Compound-62
DMWRS34	MI	TT8K17W
DMWRS34	MN	Histone deacetylase 11 (HDAC11)
DMWRS34	MT	DTT
DMWRS34	MA	Inhibitor
DMWRS34	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMWRS34	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMWRS34	DI	DMWRS34
DMWRS34	DN	PMID29671355-Compound-62
DMWRS34	MI	TTSHTOI
DMWRS34	MN	Histone deacetylase 2 (HDAC2)
DMWRS34	MT	DTT
DMWRS34	MA	Inhibitor
DMWRS34	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMWRS34	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMWRS34	DI	DMWRS34
DMWRS34	DN	PMID29671355-Compound-62
DMWRS34	MI	TT4YWTO
DMWRS34	MN	Histone deacetylase 3 (HDAC3)
DMWRS34	MT	DTT
DMWRS34	MA	Inhibitor
DMWRS34	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMWRS34	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMWRS34	DI	DMWRS34
DMWRS34	DN	PMID29671355-Compound-62
DMWRS34	MI	TTTQGH8
DMWRS34	MN	Histone deacetylase 4 (HDAC4)
DMWRS34	MT	DTT
DMWRS34	MA	Inhibitor
DMWRS34	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMWRS34	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMWRS34	DI	DMWRS34
DMWRS34	DN	PMID29671355-Compound-62
DMWRS34	MI	TTUELN5
DMWRS34	MN	Histone deacetylase 5 (HDAC5)
DMWRS34	MT	DTT
DMWRS34	MA	Inhibitor
DMWRS34	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMWRS34	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMWRS34	DI	DMWRS34
DMWRS34	DN	PMID29671355-Compound-62
DMWRS34	MI	TT5ZKDI
DMWRS34	MN	Histone deacetylase 6 (HDAC6)
DMWRS34	MT	DTT
DMWRS34	MA	Inhibitor
DMWRS34	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMWRS34	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMWRS34	DI	DMWRS34
DMWRS34	DN	PMID29671355-Compound-62
DMWRS34	MI	TTMUEK1
DMWRS34	MN	Histone deacetylase 7 (HDAC7)
DMWRS34	MT	DTT
DMWRS34	MA	Inhibitor
DMWRS34	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMWRS34	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMWRS34	DI	DMWRS34
DMWRS34	DN	PMID29671355-Compound-62
DMWRS34	MI	TTT6LFV
DMWRS34	MN	Histone deacetylase 8 (HDAC8)
DMWRS34	MT	DTT
DMWRS34	MA	Inhibitor
DMWRS34	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMWRS34	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMWRS34	DI	DMWRS34
DMWRS34	DN	PMID29671355-Compound-62
DMWRS34	MI	TT8M4E1
DMWRS34	MN	Histone deacetylase 9 (HDAC9)
DMWRS34	MT	DTT
DMWRS34	MA	Inhibitor
DMWRS34	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMWRS34	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMY3Q58	DI	DMY3Q58
DMY3Q58	DN	PMID29671355-Compound-65a
DMY3Q58	MI	TT6R7JZ
DMY3Q58	MN	Histone deacetylase 1 (HDAC1)
DMY3Q58	MT	DTT
DMY3Q58	MA	Inhibitor
DMY3Q58	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMY3Q58	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMY3Q58	DI	DMY3Q58
DMY3Q58	DN	PMID29671355-Compound-65a
DMY3Q58	MI	TT5ZKDI
DMY3Q58	MN	Histone deacetylase 6 (HDAC6)
DMY3Q58	MT	DTT
DMY3Q58	MA	Inhibitor
DMY3Q58	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMY3Q58	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM1RPL4	DI	DM1RPL4
DM1RPL4	DN	PMID29671355-Compound-67
DM1RPL4	MI	TT6R7JZ
DM1RPL4	MN	Histone deacetylase 1 (HDAC1)
DM1RPL4	MT	DTT
DM1RPL4	MA	Inhibitor
DM1RPL4	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM1RPL4	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM1RPL4	DI	DM1RPL4
DM1RPL4	DN	PMID29671355-Compound-67
DM1RPL4	MI	TTSHTOI
DM1RPL4	MN	Histone deacetylase 2 (HDAC2)
DM1RPL4	MT	DTT
DM1RPL4	MA	Inhibitor
DM1RPL4	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM1RPL4	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM1RPL4	DI	DM1RPL4
DM1RPL4	DN	PMID29671355-Compound-67
DM1RPL4	MI	TT4YWTO
DM1RPL4	MN	Histone deacetylase 3 (HDAC3)
DM1RPL4	MT	DTT
DM1RPL4	MA	Inhibitor
DM1RPL4	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM1RPL4	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM1RPL4	DI	DM1RPL4
DM1RPL4	DN	PMID29671355-Compound-67
DM1RPL4	MI	TTTQGH8
DM1RPL4	MN	Histone deacetylase 4 (HDAC4)
DM1RPL4	MT	DTT
DM1RPL4	MA	Inhibitor
DM1RPL4	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM1RPL4	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM1RPL4	DI	DM1RPL4
DM1RPL4	DN	PMID29671355-Compound-67
DM1RPL4	MI	TTUELN5
DM1RPL4	MN	Histone deacetylase 5 (HDAC5)
DM1RPL4	MT	DTT
DM1RPL4	MA	Inhibitor
DM1RPL4	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM1RPL4	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM1RPL4	DI	DM1RPL4
DM1RPL4	DN	PMID29671355-Compound-67
DM1RPL4	MI	TT5ZKDI
DM1RPL4	MN	Histone deacetylase 6 (HDAC6)
DM1RPL4	MT	DTT
DM1RPL4	MA	Inhibitor
DM1RPL4	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM1RPL4	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM1RPL4	DI	DM1RPL4
DM1RPL4	DN	PMID29671355-Compound-67
DM1RPL4	MI	TTMUEK1
DM1RPL4	MN	Histone deacetylase 7 (HDAC7)
DM1RPL4	MT	DTT
DM1RPL4	MA	Inhibitor
DM1RPL4	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM1RPL4	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM1RPL4	DI	DM1RPL4
DM1RPL4	DN	PMID29671355-Compound-67
DM1RPL4	MI	TTT6LFV
DM1RPL4	MN	Histone deacetylase 8 (HDAC8)
DM1RPL4	MT	DTT
DM1RPL4	MA	Inhibitor
DM1RPL4	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM1RPL4	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMLGBR6	DI	DMLGBR6
DMLGBR6	DN	PMID29671355-Compound-68b
DMLGBR6	MI	TTTQGH8
DMLGBR6	MN	Histone deacetylase 4 (HDAC4)
DMLGBR6	MT	DTT
DMLGBR6	MA	Inhibitor
DMLGBR6	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMLGBR6	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMLGBR6	DI	DMLGBR6
DMLGBR6	DN	PMID29671355-Compound-68b
DMLGBR6	MI	TTT6LFV
DMLGBR6	MN	Histone deacetylase 8 (HDAC8)
DMLGBR6	MT	DTT
DMLGBR6	MA	Inhibitor
DMLGBR6	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMLGBR6	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMU61XP	DI	DMU61XP
DMU61XP	DN	PMID29671355-Compound-69
DMU61XP	MI	TTBH0VX
DMU61XP	MN	Histone deacetylase (HDAC)
DMU61XP	MT	DTT
DMU61XP	MA	Inhibitor
DMU61XP	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMU61XP	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM394WH	DI	DM394WH
DM394WH	DN	PMID29671355-Compound-70
DM394WH	MI	TTTQGH8
DM394WH	MN	Histone deacetylase 4 (HDAC4)
DM394WH	MT	DTT
DM394WH	MA	Inhibitor
DM394WH	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM394WH	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMUAC1T	DI	DMUAC1T
DMUAC1T	DN	PMID29671355-Compound-71a
DMUAC1T	MI	TTTQGH8
DMUAC1T	MN	Histone deacetylase 4 (HDAC4)
DMUAC1T	MT	DTT
DMUAC1T	MA	Inhibitor
DMUAC1T	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMUAC1T	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM8VG4Q	DI	DM8VG4Q
DM8VG4Q	DN	PMID29671355-Compound-71b
DM8VG4Q	MI	TTTQGH8
DM8VG4Q	MN	Histone deacetylase 4 (HDAC4)
DM8VG4Q	MT	DTT
DM8VG4Q	MA	Inhibitor
DM8VG4Q	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM8VG4Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMICDV6	DI	DMICDV6
DMICDV6	DN	PMID29671355-Compound-72a
DMICDV6	MI	TTTQGH8
DMICDV6	MN	Histone deacetylase 4 (HDAC4)
DMICDV6	MT	DTT
DMICDV6	MA	Inhibitor
DMICDV6	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMICDV6	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM08OV7	DI	DM08OV7
DM08OV7	DN	PMID29671355-Compound-72b
DM08OV7	MI	TTTQGH8
DM08OV7	MN	Histone deacetylase 4 (HDAC4)
DM08OV7	MT	DTT
DM08OV7	MA	Inhibitor
DM08OV7	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM08OV7	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMCNF36	DI	DMCNF36
DMCNF36	DN	PMID29671355-Compound-73
DMCNF36	MI	TT6R7JZ
DMCNF36	MN	Histone deacetylase 1 (HDAC1)
DMCNF36	MT	DTT
DMCNF36	MA	Inhibitor
DMCNF36	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMCNF36	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMCNF36	DI	DMCNF36
DMCNF36	DN	PMID29671355-Compound-73
DMCNF36	MI	TT5ZKDI
DMCNF36	MN	Histone deacetylase 6 (HDAC6)
DMCNF36	MT	DTT
DMCNF36	MA	Inhibitor
DMCNF36	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMCNF36	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMCNF36	DI	DMCNF36
DMCNF36	DN	PMID29671355-Compound-73
DMCNF36	MI	TT8M4E1
DMCNF36	MN	Histone deacetylase 9 (HDAC9)
DMCNF36	MT	DTT
DMCNF36	MA	Inhibitor
DMCNF36	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMCNF36	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM49YTU	DI	DM49YTU
DM49YTU	DN	PMID29671355-Compound-74
DM49YTU	MI	TTSHTOI
DM49YTU	MN	Histone deacetylase 2 (HDAC2)
DM49YTU	MT	DTT
DM49YTU	MA	Inhibitor
DM49YTU	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM49YTU	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM49YTU	DI	DM49YTU
DM49YTU	DN	PMID29671355-Compound-74
DM49YTU	MI	TT5ZKDI
DM49YTU	MN	Histone deacetylase 6 (HDAC6)
DM49YTU	MT	DTT
DM49YTU	MA	Inhibitor
DM49YTU	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM49YTU	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM7YQJK	DI	DM7YQJK
DM7YQJK	DN	PMID29671355-Compound-8
DM7YQJK	MI	TT6R7JZ
DM7YQJK	MN	Histone deacetylase 1 (HDAC1)
DM7YQJK	MT	DTT
DM7YQJK	MA	Inhibitor
DM7YQJK	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM7YQJK	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM7YQJK	DI	DM7YQJK
DM7YQJK	DN	PMID29671355-Compound-8
DM7YQJK	MI	TTYHPU6
DM7YQJK	MN	Histone deacetylase 10 (HDAC10)
DM7YQJK	MT	DTT
DM7YQJK	MA	Inhibitor
DM7YQJK	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM7YQJK	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM7YQJK	DI	DM7YQJK
DM7YQJK	DN	PMID29671355-Compound-8
DM7YQJK	MI	TTSHTOI
DM7YQJK	MN	Histone deacetylase 2 (HDAC2)
DM7YQJK	MT	DTT
DM7YQJK	MA	Inhibitor
DM7YQJK	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM7YQJK	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM7YQJK	DI	DM7YQJK
DM7YQJK	DN	PMID29671355-Compound-8
DM7YQJK	MI	TT4YWTO
DM7YQJK	MN	Histone deacetylase 3 (HDAC3)
DM7YQJK	MT	DTT
DM7YQJK	MA	Inhibitor
DM7YQJK	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM7YQJK	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DM7YQJK	DI	DM7YQJK
DM7YQJK	DN	PMID29671355-Compound-8
DM7YQJK	MI	TT5ZKDI
DM7YQJK	MN	Histone deacetylase 6 (HDAC6)
DM7YQJK	MT	DTT
DM7YQJK	MA	Inhibitor
DM7YQJK	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DM7YQJK	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMXL96M	DI	DMXL96M
DMXL96M	DN	PMID29671355-Compound-9
DMXL96M	MI	TT6R7JZ
DMXL96M	MN	Histone deacetylase 1 (HDAC1)
DMXL96M	MT	DTT
DMXL96M	MA	Inhibitor
DMXL96M	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMXL96M	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMXL96M	DI	DMXL96M
DMXL96M	DN	PMID29671355-Compound-9
DMXL96M	MI	TTSHTOI
DMXL96M	MN	Histone deacetylase 2 (HDAC2)
DMXL96M	MT	DTT
DMXL96M	MA	Inhibitor
DMXL96M	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMXL96M	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMXL96M	DI	DMXL96M
DMXL96M	DN	PMID29671355-Compound-9
DMXL96M	MI	TT4YWTO
DMXL96M	MN	Histone deacetylase 3 (HDAC3)
DMXL96M	MT	DTT
DMXL96M	MA	Inhibitor
DMXL96M	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMXL96M	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMXL96M	DI	DMXL96M
DMXL96M	DN	PMID29671355-Compound-9
DMXL96M	MI	TT5ZKDI
DMXL96M	MN	Histone deacetylase 6 (HDAC6)
DMXL96M	MT	DTT
DMXL96M	MA	Inhibitor
DMXL96M	RN	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
DMXL96M	RU	https://www.ncbi.nlm.nih.gov/pubmed/29671355

DMZBHR9	DI	DMZBHR9
DMZBHR9	DN	PMID29757691-Compound-10
DMZBHR9	MI	TT1RS9F
DMZBHR9	MN	Acetylcholinesterase (AChE)
DMZBHR9	MT	DTT
DMZBHR9	MA	Inhibitor
DMZBHR9	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DMZBHR9	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DMZBHR9	DI	DMZBHR9
DMZBHR9	DN	PMID29757691-Compound-10
DMZBHR9	MI	TTEB0GD
DMZBHR9	MN	Cholinesterase (BCHE)
DMZBHR9	MT	DTT
DMZBHR9	MA	Inhibitor
DMZBHR9	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DMZBHR9	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DMEUC04	DI	DMEUC04
DMEUC04	DN	PMID29757691-Compound-2a
DMEUC04	MI	TT1RS9F
DMEUC04	MN	Acetylcholinesterase (AChE)
DMEUC04	MT	DTT
DMEUC04	MA	Inhibitor
DMEUC04	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DMEUC04	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DMEUC04	DI	DMEUC04
DMEUC04	DN	PMID29757691-Compound-2a
DMEUC04	MI	TTEB0GD
DMEUC04	MN	Cholinesterase (BCHE)
DMEUC04	MT	DTT
DMEUC04	MA	Inhibitor
DMEUC04	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DMEUC04	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DMBRQP1	DI	DMBRQP1
DMBRQP1	DN	PMID29757691-Compound-2a-i
DMBRQP1	MI	TT1RS9F
DMBRQP1	MN	Acetylcholinesterase (AChE)
DMBRQP1	MT	DTT
DMBRQP1	MA	Inhibitor
DMBRQP1	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DMBRQP1	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DMBRQP1	DI	DMBRQP1
DMBRQP1	DN	PMID29757691-Compound-2a-i
DMBRQP1	MI	TTEB0GD
DMBRQP1	MN	Cholinesterase (BCHE)
DMBRQP1	MT	DTT
DMBRQP1	MA	Inhibitor
DMBRQP1	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DMBRQP1	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DMFD9UZ	DI	DMFD9UZ
DMFD9UZ	DN	PMID29757691-Compound-4
DMFD9UZ	MI	TT1RS9F
DMFD9UZ	MN	Acetylcholinesterase (AChE)
DMFD9UZ	MT	DTT
DMFD9UZ	MA	Inhibitor
DMFD9UZ	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DMFD9UZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DMFD9UZ	DI	DMFD9UZ
DMFD9UZ	DN	PMID29757691-Compound-4
DMFD9UZ	MI	TT3WG5C
DMFD9UZ	MN	Monoamine oxidase type A (MAO-A)
DMFD9UZ	MT	DTT
DMFD9UZ	MA	Inhibitor
DMFD9UZ	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DMFD9UZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DMFD9UZ	DI	DMFD9UZ
DMFD9UZ	DN	PMID29757691-Compound-4
DMFD9UZ	MI	TTGP7BY
DMFD9UZ	MN	Monoamine oxidase type B (MAO-B)
DMFD9UZ	MT	DTT
DMFD9UZ	MA	Inhibitor
DMFD9UZ	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DMFD9UZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DM7TPBF	DI	DM7TPBF
DM7TPBF	DN	PMID29757691-Compound-7
DM7TPBF	MI	TT1RS9F
DM7TPBF	MN	Acetylcholinesterase (AChE)
DM7TPBF	MT	DTT
DM7TPBF	MA	Inhibitor
DM7TPBF	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DM7TPBF	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DM7TPBF	DI	DM7TPBF
DM7TPBF	DN	PMID29757691-Compound-7
DM7TPBF	MI	TTEB0GD
DM7TPBF	MN	Cholinesterase (BCHE)
DM7TPBF	MT	DTT
DM7TPBF	MA	Inhibitor
DM7TPBF	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DM7TPBF	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DM5IFBV	DI	DM5IFBV
DM5IFBV	DN	PMID29757691-Compound-8a
DM5IFBV	MI	TT1RS9F
DM5IFBV	MN	Acetylcholinesterase (AChE)
DM5IFBV	MT	DTT
DM5IFBV	MA	Inhibitor
DM5IFBV	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DM5IFBV	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DM5IFBV	DI	DM5IFBV
DM5IFBV	DN	PMID29757691-Compound-8a
DM5IFBV	MI	TTEB0GD
DM5IFBV	MN	Cholinesterase (BCHE)
DM5IFBV	MT	DTT
DM5IFBV	MA	Inhibitor
DM5IFBV	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DM5IFBV	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DMEOZKF	DI	DMEOZKF
DMEOZKF	DN	PMID29757691-Compound-8b
DMEOZKF	MI	TT1RS9F
DMEOZKF	MN	Acetylcholinesterase (AChE)
DMEOZKF	MT	DTT
DMEOZKF	MA	Inhibitor
DMEOZKF	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DMEOZKF	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DMEOZKF	DI	DMEOZKF
DMEOZKF	DN	PMID29757691-Compound-8b
DMEOZKF	MI	TTEB0GD
DMEOZKF	MN	Cholinesterase (BCHE)
DMEOZKF	MT	DTT
DMEOZKF	MA	Inhibitor
DMEOZKF	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DMEOZKF	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DMHL7SW	DI	DMHL7SW
DMHL7SW	DN	PMID29757691-Compound-8c
DMHL7SW	MI	TT1RS9F
DMHL7SW	MN	Acetylcholinesterase (AChE)
DMHL7SW	MT	DTT
DMHL7SW	MA	Inhibitor
DMHL7SW	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DMHL7SW	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DMHL7SW	DI	DMHL7SW
DMHL7SW	DN	PMID29757691-Compound-8c
DMHL7SW	MI	TTEB0GD
DMHL7SW	MN	Cholinesterase (BCHE)
DMHL7SW	MT	DTT
DMHL7SW	MA	Inhibitor
DMHL7SW	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DMHL7SW	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DM6PDEH	DI	DM6PDEH
DM6PDEH	DN	PMID29757691-Compound-8d
DM6PDEH	MI	TT1RS9F
DM6PDEH	MN	Acetylcholinesterase (AChE)
DM6PDEH	MT	DTT
DM6PDEH	MA	Inhibitor
DM6PDEH	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DM6PDEH	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DM6PDEH	DI	DM6PDEH
DM6PDEH	DN	PMID29757691-Compound-8d
DM6PDEH	MI	TTEB0GD
DM6PDEH	MN	Cholinesterase (BCHE)
DM6PDEH	MT	DTT
DM6PDEH	MA	Inhibitor
DM6PDEH	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DM6PDEH	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DMCZ3SH	DI	DMCZ3SH
DMCZ3SH	DN	PMID29865878-Compound-38
DMCZ3SH	MI	TTSJMN8
DMCZ3SH	MN	Immunoproteasome complex (IP)
DMCZ3SH	MT	DTT
DMCZ3SH	MA	Inhibitor
DMCZ3SH	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMCZ3SH	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMSCWZF	DI	DMSCWZF
DMSCWZF	DN	PMID29865878-Compound-39
DMSCWZF	MI	TTSJMN8
DMSCWZF	MN	Immunoproteasome complex (IP)
DMSCWZF	MT	DTT
DMSCWZF	MA	Inhibitor
DMSCWZF	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMSCWZF	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMGXUNA	DI	DMGXUNA
DMGXUNA	DN	PMID29865878-Compound-40
DMGXUNA	MI	TTSJMN8
DMGXUNA	MN	Immunoproteasome complex (IP)
DMGXUNA	MT	DTT
DMGXUNA	MA	Inhibitor
DMGXUNA	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMGXUNA	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMSAO52	DI	DMSAO52
DMSAO52	DN	PMID29865878-Compound-41
DMSAO52	MI	TTSJMN8
DMSAO52	MN	Immunoproteasome complex (IP)
DMSAO52	MT	DTT
DMSAO52	MA	Inhibitor
DMSAO52	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMSAO52	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMY2PTU	DI	DMY2PTU
DMY2PTU	DN	PMID29865878-Compound-42
DMY2PTU	MI	TTSJMN8
DMY2PTU	MN	Immunoproteasome complex (IP)
DMY2PTU	MT	DTT
DMY2PTU	MA	Inhibitor
DMY2PTU	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMY2PTU	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMQUE6D	DI	DMQUE6D
DMQUE6D	DN	PMID29865878-Compound-43
DMQUE6D	MI	TT68GPI
DMQUE6D	MN	Proteasome beta-5 (PS beta-5)
DMQUE6D	MT	DTT
DMQUE6D	MA	Inhibitor
DMQUE6D	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMQUE6D	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMQUE6D	DI	DMQUE6D
DMQUE6D	DN	PMID29865878-Compound-43
DMQUE6D	MI	TTEAD9J
DMQUE6D	MN	Proteasome beta-8 (PS beta-8)
DMQUE6D	MT	DTT
DMQUE6D	MA	Inhibitor
DMQUE6D	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMQUE6D	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMRTQ4I	DI	DMRTQ4I
DMRTQ4I	DN	PMID29865878-Compound-44
DMRTQ4I	MI	TT68GPI
DMRTQ4I	MN	Proteasome beta-5 (PS beta-5)
DMRTQ4I	MT	DTT
DMRTQ4I	MA	Inhibitor
DMRTQ4I	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMRTQ4I	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMRTQ4I	DI	DMRTQ4I
DMRTQ4I	DN	PMID29865878-Compound-44
DMRTQ4I	MI	TTEAD9J
DMRTQ4I	MN	Proteasome beta-8 (PS beta-8)
DMRTQ4I	MT	DTT
DMRTQ4I	MA	Inhibitor
DMRTQ4I	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMRTQ4I	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DM462XZ	DI	DM462XZ
DM462XZ	DN	PMID29865878-Compound-45
DM462XZ	MI	TTSJMN8
DM462XZ	MN	Immunoproteasome complex (IP)
DM462XZ	MT	DTT
DM462XZ	MA	Inhibitor
DM462XZ	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DM462XZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMP3MXK	DI	DMP3MXK
DMP3MXK	DN	PMID29865878-Compound-46
DMP3MXK	MI	TT8EPLT
DMP3MXK	MN	Proteasome beta-1 (PS beta-1)
DMP3MXK	MT	DTT
DMP3MXK	MA	Inhibitor
DMP3MXK	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMP3MXK	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMP3MXK	DI	DMP3MXK
DMP3MXK	DN	PMID29865878-Compound-46
DMP3MXK	MI	TT68GPI
DMP3MXK	MN	Proteasome beta-5 (PS beta-5)
DMP3MXK	MT	DTT
DMP3MXK	MA	Inhibitor
DMP3MXK	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMP3MXK	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMP3MXK	DI	DMP3MXK
DMP3MXK	DN	PMID29865878-Compound-46
DMP3MXK	MI	TTEAD9J
DMP3MXK	MN	Proteasome beta-8 (PS beta-8)
DMP3MXK	MT	DTT
DMP3MXK	MA	Inhibitor
DMP3MXK	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMP3MXK	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMP3MXK	DI	DMP3MXK
DMP3MXK	DN	PMID29865878-Compound-46
DMP3MXK	MI	TTOUSTQ
DMP3MXK	MN	Proteasome beta-9 (PS beta-9)
DMP3MXK	MT	DTT
DMP3MXK	MA	Inhibitor
DMP3MXK	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMP3MXK	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMX31I2	DI	DMX31I2
DMX31I2	DN	PMID29865878-Compound-47
DMX31I2	MI	TTSJMN8
DMX31I2	MN	Immunoproteasome complex (IP)
DMX31I2	MT	DTT
DMX31I2	MA	Inhibitor
DMX31I2	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMX31I2	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMVQTR2	DI	DMVQTR2
DMVQTR2	DN	PMID29865878-Compound-48
DMVQTR2	MI	TT8EPLT
DMVQTR2	MN	Proteasome beta-1 (PS beta-1)
DMVQTR2	MT	DTT
DMVQTR2	MA	Inhibitor
DMVQTR2	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMVQTR2	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMVQTR2	DI	DMVQTR2
DMVQTR2	DN	PMID29865878-Compound-48
DMVQTR2	MI	TT68GPI
DMVQTR2	MN	Proteasome beta-5 (PS beta-5)
DMVQTR2	MT	DTT
DMVQTR2	MA	Inhibitor
DMVQTR2	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMVQTR2	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMVQTR2	DI	DMVQTR2
DMVQTR2	DN	PMID29865878-Compound-48
DMVQTR2	MI	TTEAD9J
DMVQTR2	MN	Proteasome beta-8 (PS beta-8)
DMVQTR2	MT	DTT
DMVQTR2	MA	Inhibitor
DMVQTR2	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMVQTR2	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMVQTR2	DI	DMVQTR2
DMVQTR2	DN	PMID29865878-Compound-48
DMVQTR2	MI	TTOUSTQ
DMVQTR2	MN	Proteasome beta-9 (PS beta-9)
DMVQTR2	MT	DTT
DMVQTR2	MA	Inhibitor
DMVQTR2	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMVQTR2	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMK0GTV	DI	DMK0GTV
DMK0GTV	DN	PMID29865878-Compound-49
DMK0GTV	MI	TT8EPLT
DMK0GTV	MN	Proteasome beta-1 (PS beta-1)
DMK0GTV	MT	DTT
DMK0GTV	MA	Inhibitor
DMK0GTV	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMK0GTV	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMK0GTV	DI	DMK0GTV
DMK0GTV	DN	PMID29865878-Compound-49
DMK0GTV	MI	TT68GPI
DMK0GTV	MN	Proteasome beta-5 (PS beta-5)
DMK0GTV	MT	DTT
DMK0GTV	MA	Inhibitor
DMK0GTV	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMK0GTV	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMK0GTV	DI	DMK0GTV
DMK0GTV	DN	PMID29865878-Compound-49
DMK0GTV	MI	TTEAD9J
DMK0GTV	MN	Proteasome beta-8 (PS beta-8)
DMK0GTV	MT	DTT
DMK0GTV	MA	Inhibitor
DMK0GTV	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMK0GTV	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMK0GTV	DI	DMK0GTV
DMK0GTV	DN	PMID29865878-Compound-49
DMK0GTV	MI	TTOUSTQ
DMK0GTV	MN	Proteasome beta-9 (PS beta-9)
DMK0GTV	MT	DTT
DMK0GTV	MA	Inhibitor
DMK0GTV	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMK0GTV	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMZ8BJX	DI	DMZ8BJX
DMZ8BJX	DN	PMID29865878-Compound-50
DMZ8BJX	MI	TTSJMN8
DMZ8BJX	MN	Immunoproteasome complex (IP)
DMZ8BJX	MT	DTT
DMZ8BJX	MA	Inhibitor
DMZ8BJX	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMZ8BJX	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DM0LXT2	DI	DM0LXT2
DM0LXT2	DN	PMID29865878-Compound-51
DM0LXT2	MI	TT8EPLT
DM0LXT2	MN	Proteasome beta-1 (PS beta-1)
DM0LXT2	MT	DTT
DM0LXT2	MA	Inhibitor
DM0LXT2	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DM0LXT2	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DM0LXT2	DI	DM0LXT2
DM0LXT2	DN	PMID29865878-Compound-51
DM0LXT2	MI	TT68GPI
DM0LXT2	MN	Proteasome beta-5 (PS beta-5)
DM0LXT2	MT	DTT
DM0LXT2	MA	Inhibitor
DM0LXT2	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DM0LXT2	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DM0LXT2	DI	DM0LXT2
DM0LXT2	DN	PMID29865878-Compound-51
DM0LXT2	MI	TTEAD9J
DM0LXT2	MN	Proteasome beta-8 (PS beta-8)
DM0LXT2	MT	DTT
DM0LXT2	MA	Inhibitor
DM0LXT2	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DM0LXT2	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DM0LXT2	DI	DM0LXT2
DM0LXT2	DN	PMID29865878-Compound-51
DM0LXT2	MI	TTOUSTQ
DM0LXT2	MN	Proteasome beta-9 (PS beta-9)
DM0LXT2	MT	DTT
DM0LXT2	MA	Inhibitor
DM0LXT2	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DM0LXT2	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DM47M2U	DI	DM47M2U
DM47M2U	DN	PMID29865878-Compound-52
DM47M2U	MI	TTSJMN8
DM47M2U	MN	Immunoproteasome complex (IP)
DM47M2U	MT	DTT
DM47M2U	MA	Inhibitor
DM47M2U	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DM47M2U	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DM6JV1W	DI	DM6JV1W
DM6JV1W	DN	PMID29865878-Compound-53
DM6JV1W	MI	TT8EPLT
DM6JV1W	MN	Proteasome beta-1 (PS beta-1)
DM6JV1W	MT	DTT
DM6JV1W	MA	Inhibitor
DM6JV1W	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DM6JV1W	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DM6JV1W	DI	DM6JV1W
DM6JV1W	DN	PMID29865878-Compound-53
DM6JV1W	MI	TT68GPI
DM6JV1W	MN	Proteasome beta-5 (PS beta-5)
DM6JV1W	MT	DTT
DM6JV1W	MA	Inhibitor
DM6JV1W	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DM6JV1W	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DM6JV1W	DI	DM6JV1W
DM6JV1W	DN	PMID29865878-Compound-53
DM6JV1W	MI	TTEAD9J
DM6JV1W	MN	Proteasome beta-8 (PS beta-8)
DM6JV1W	MT	DTT
DM6JV1W	MA	Inhibitor
DM6JV1W	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DM6JV1W	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DM6JV1W	DI	DM6JV1W
DM6JV1W	DN	PMID29865878-Compound-53
DM6JV1W	MI	TTOUSTQ
DM6JV1W	MN	Proteasome beta-9 (PS beta-9)
DM6JV1W	MT	DTT
DM6JV1W	MA	Inhibitor
DM6JV1W	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DM6JV1W	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMED71P	DI	DMED71P
DMED71P	DN	PMID29865878-Compound-54
DMED71P	MI	TTSJMN8
DMED71P	MN	Immunoproteasome complex (IP)
DMED71P	MT	DTT
DMED71P	MA	Inhibitor
DMED71P	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMED71P	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMY52ZB	DI	DMY52ZB
DMY52ZB	DN	PMID29865878-Compound-55
DMY52ZB	MI	TT8EPLT
DMY52ZB	MN	Proteasome beta-1 (PS beta-1)
DMY52ZB	MT	DTT
DMY52ZB	MA	Inhibitor
DMY52ZB	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMY52ZB	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMY52ZB	DI	DMY52ZB
DMY52ZB	DN	PMID29865878-Compound-55
DMY52ZB	MI	TT68GPI
DMY52ZB	MN	Proteasome beta-5 (PS beta-5)
DMY52ZB	MT	DTT
DMY52ZB	MA	Inhibitor
DMY52ZB	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMY52ZB	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMY52ZB	DI	DMY52ZB
DMY52ZB	DN	PMID29865878-Compound-55
DMY52ZB	MI	TTEAD9J
DMY52ZB	MN	Proteasome beta-8 (PS beta-8)
DMY52ZB	MT	DTT
DMY52ZB	MA	Inhibitor
DMY52ZB	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMY52ZB	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMY52ZB	DI	DMY52ZB
DMY52ZB	DN	PMID29865878-Compound-55
DMY52ZB	MI	TTOUSTQ
DMY52ZB	MN	Proteasome beta-9 (PS beta-9)
DMY52ZB	MT	DTT
DMY52ZB	MA	Inhibitor
DMY52ZB	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMY52ZB	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DM45QW1	DI	DM45QW1
DM45QW1	DN	PMID29865878-Compound-56
DM45QW1	MI	TTSJMN8
DM45QW1	MN	Immunoproteasome complex (IP)
DM45QW1	MT	DTT
DM45QW1	MA	Inhibitor
DM45QW1	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DM45QW1	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DM3VQ1Y	DI	DM3VQ1Y
DM3VQ1Y	DN	PMID29865878-Compound-57
DM3VQ1Y	MI	TTEAD9J
DM3VQ1Y	MN	Proteasome beta-8 (PS beta-8)
DM3VQ1Y	MT	DTT
DM3VQ1Y	MA	Inhibitor
DM3VQ1Y	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DM3VQ1Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMO108N	DI	DMO108N
DMO108N	DN	PMID29865878-Compound-58
DMO108N	MI	TTEAD9J
DMO108N	MN	Proteasome beta-8 (PS beta-8)
DMO108N	MT	DTT
DMO108N	MA	Inhibitor
DMO108N	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMO108N	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMM73VG	DI	DMM73VG
DMM73VG	DN	PMID29865878-Compound-59
DMM73VG	MI	TTEAD9J
DMM73VG	MN	Proteasome beta-8 (PS beta-8)
DMM73VG	MT	DTT
DMM73VG	MA	Inhibitor
DMM73VG	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMM73VG	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMPQX8R	DI	DMPQX8R
DMPQX8R	DN	PMID29865878-Compound-60
DMPQX8R	MI	TTSJMN8
DMPQX8R	MN	Immunoproteasome complex (IP)
DMPQX8R	MT	DTT
DMPQX8R	MA	Inhibitor
DMPQX8R	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMPQX8R	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMG7VF1	DI	DMG7VF1
DMG7VF1	DN	PMID29865878-Compound-61
DMG7VF1	MI	TTEAD9J
DMG7VF1	MN	Proteasome beta-8 (PS beta-8)
DMG7VF1	MT	DTT
DMG7VF1	MA	Inhibitor
DMG7VF1	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMG7VF1	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DML47KS	DI	DML47KS
DML47KS	DN	PMID29865878-Compound-62
DML47KS	MI	TTEAD9J
DML47KS	MN	Proteasome beta-8 (PS beta-8)
DML47KS	MT	DTT
DML47KS	MA	Inhibitor
DML47KS	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DML47KS	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMEM2I8	DI	DMEM2I8
DMEM2I8	DN	PMID29865878-Compound-63
DMEM2I8	MI	TTEAD9J
DMEM2I8	MN	Proteasome beta-8 (PS beta-8)
DMEM2I8	MT	DTT
DMEM2I8	MA	Inhibitor
DMEM2I8	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMEM2I8	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DM1U6H2	DI	DM1U6H2
DM1U6H2	DN	PMID29865878-Compound-64
DM1U6H2	MI	TTEAD9J
DM1U6H2	MN	Proteasome beta-8 (PS beta-8)
DM1U6H2	MT	DTT
DM1U6H2	MA	Inhibitor
DM1U6H2	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DM1U6H2	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMX1E6O	DI	DMX1E6O
DMX1E6O	DN	PMID29865878-Compound-8
DMX1E6O	MI	TT68GPI
DMX1E6O	MN	Proteasome beta-5 (PS beta-5)
DMX1E6O	MT	DTT
DMX1E6O	MA	Inhibitor
DMX1E6O	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMX1E6O	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DMX1E6O	DI	DMX1E6O
DMX1E6O	DN	PMID29865878-Compound-8
DMX1E6O	MI	TTEAD9J
DMX1E6O	MN	Proteasome beta-8 (PS beta-8)
DMX1E6O	MT	DTT
DMX1E6O	MA	Inhibitor
DMX1E6O	RN	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
DMX1E6O	RU	https://www.ncbi.nlm.nih.gov/pubmed/29865878

DM7K3A0	DI	DM7K3A0
DM7K3A0	DN	PMID30074415-Compound-12
DM7K3A0	MI	TT2LVK8
DM7K3A0	MN	Carbonic anhydrase IX (CA-IX)
DM7K3A0	MT	DTT
DM7K3A0	MA	Inhibitor
DM7K3A0	RN	Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).Expert Opin Ther Pat. 2018 Oct;28(10):729-740.
DM7K3A0	RU	https://www.ncbi.nlm.nih.gov/pubmed/30074415

DM06PX4	DI	DM06PX4
DM06PX4	DN	PMID30074415-Compound-19
DM06PX4	MI	TTUNARX
DM06PX4	MN	Carbonic anhydrase (CA)
DM06PX4	MT	DTT
DM06PX4	MA	Inhibitor
DM06PX4	RN	Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).Expert Opin Ther Pat. 2018 Oct;28(10):729-740.
DM06PX4	RU	https://www.ncbi.nlm.nih.gov/pubmed/30074415

DMX9LGW	DI	DMX9LGW
DMX9LGW	DN	PMID30074415-Compound-20
DMX9LGW	MI	TTUNARX
DMX9LGW	MN	Carbonic anhydrase (CA)
DMX9LGW	MT	DTT
DMX9LGW	MA	Inhibitor
DMX9LGW	RN	Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).Expert Opin Ther Pat. 2018 Oct;28(10):729-740.
DMX9LGW	RU	https://www.ncbi.nlm.nih.gov/pubmed/30074415

DM3NPOU	DI	DM3NPOU
DM3NPOU	DN	PMID30074415-Compound-21
DM3NPOU	MI	TTUNARX
DM3NPOU	MN	Carbonic anhydrase (CA)
DM3NPOU	MT	DTT
DM3NPOU	MA	Inhibitor
DM3NPOU	RN	Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).Expert Opin Ther Pat. 2018 Oct;28(10):729-740.
DM3NPOU	RU	https://www.ncbi.nlm.nih.gov/pubmed/30074415

DM2G8DN	DI	DM2G8DN
DM2G8DN	DN	PMID30074415-Compound-GS3
DM2G8DN	MI	TT2LVK8
DM2G8DN	MN	Carbonic anhydrase IX (CA-IX)
DM2G8DN	MT	DTT
DM2G8DN	MA	Inhibitor
DM2G8DN	RN	Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).Expert Opin Ther Pat. 2018 Oct;28(10):729-740.
DM2G8DN	RU	https://www.ncbi.nlm.nih.gov/pubmed/30074415

DMY37VQ	DI	DMY37VQ
DMY37VQ	DN	PMID30107136-Compound-Example1
DMY37VQ	MI	TT8ZLTI
DMY37VQ	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMY37VQ	MT	DTT
DMY37VQ	MA	Inhibitor
DMY37VQ	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMY37VQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMD65GU	DI	DMD65GU
DMD65GU	DN	PMID30107136-Compound-Example11
DMD65GU	MI	TT5YPJF
DMD65GU	MN	CD80-PD-L1 interaction (CD80/PD-L1 PPI)
DMD65GU	MT	DTT
DMD65GU	MA	Inhibitor
DMD65GU	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMD65GU	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMD65GU	DI	DMD65GU
DMD65GU	DN	PMID30107136-Compound-Example11
DMD65GU	MI	TT23XQV
DMD65GU	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMD65GU	MT	DTT
DMD65GU	MA	Inhibitor
DMD65GU	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMD65GU	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMN2K10	DI	DMN2K10
DMN2K10	DN	PMID30107136-Compound-Example12
DMN2K10	MI	TT5YPJF
DMN2K10	MN	CD80-PD-L1 interaction (CD80/PD-L1 PPI)
DMN2K10	MT	DTT
DMN2K10	MA	Inhibitor
DMN2K10	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMN2K10	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMN2K10	DI	DMN2K10
DMN2K10	DN	PMID30107136-Compound-Example12
DMN2K10	MI	TT23XQV
DMN2K10	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMN2K10	MT	DTT
DMN2K10	MA	Inhibitor
DMN2K10	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMN2K10	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DM4CN9K	DI	DM4CN9K
DM4CN9K	DN	PMID30107136-Compound-Example13
DM4CN9K	MI	TT23XQV
DM4CN9K	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DM4CN9K	MT	DTT
DM4CN9K	MA	Inhibitor
DM4CN9K	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DM4CN9K	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMAUFS7	DI	DMAUFS7
DMAUFS7	DN	PMID30107136-Compound-Example14
DMAUFS7	MI	TT23XQV
DMAUFS7	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMAUFS7	MT	DTT
DMAUFS7	MA	Inhibitor
DMAUFS7	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMAUFS7	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMYHQ0S	DI	DMYHQ0S
DMYHQ0S	DN	PMID30107136-Compound-Example15
DMYHQ0S	MI	TTNBFWK
DMYHQ0S	MN	Programmed cell death protein 1 (PD-1)
DMYHQ0S	MT	DTT
DMYHQ0S	MA	Inhibitor
DMYHQ0S	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMYHQ0S	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DM6EKIV	DI	DM6EKIV
DM6EKIV	DN	PMID30107136-Compound-Example16
DM6EKIV	MI	TTNBFWK
DM6EKIV	MN	Programmed cell death protein 1 (PD-1)
DM6EKIV	MT	DTT
DM6EKIV	MA	Inhibitor
DM6EKIV	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DM6EKIV	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DM9HMB4	DI	DM9HMB4
DM9HMB4	DN	PMID30107136-Compound-Example2
DM9HMB4	MI	TT8ZLTI
DM9HMB4	MN	Programmed cell death 1 ligand 1 (PD-L1)
DM9HMB4	MT	DTT
DM9HMB4	MA	Inhibitor
DM9HMB4	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DM9HMB4	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMDCN43	DI	DMDCN43
DMDCN43	DN	PMID30107136-Compound-Example3
DMDCN43	MI	TT23XQV
DMDCN43	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMDCN43	MT	DTT
DMDCN43	MA	Inhibitor
DMDCN43	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMDCN43	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMRKLTE	DI	DMRKLTE
DMRKLTE	DN	PMID30107136-Compound-Example4
DMRKLTE	MI	TT23XQV
DMRKLTE	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMRKLTE	MT	DTT
DMRKLTE	MA	Inhibitor
DMRKLTE	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMRKLTE	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMQPIK4	DI	DMQPIK4
DMQPIK4	DN	PMID30107136-Compound-Example41
DMQPIK4	MI	TT23XQV
DMQPIK4	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMQPIK4	MT	DTT
DMQPIK4	MA	Inhibitor
DMQPIK4	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMQPIK4	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DM95FIN	DI	DM95FIN
DM95FIN	DN	PMID30107136-Compound-Example42
DM95FIN	MI	TT23XQV
DM95FIN	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DM95FIN	MT	DTT
DM95FIN	MA	Inhibitor
DM95FIN	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DM95FIN	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMJSH0F	DI	DMJSH0F
DMJSH0F	DN	PMID30107136-Compound-Example43
DMJSH0F	MI	TT23XQV
DMJSH0F	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMJSH0F	MT	DTT
DMJSH0F	MA	Inhibitor
DMJSH0F	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMJSH0F	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DM8KAIY	DI	DM8KAIY
DM8KAIY	DN	PMID30107136-Compound-Example44
DM8KAIY	MI	TT23XQV
DM8KAIY	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DM8KAIY	MT	DTT
DM8KAIY	MA	Inhibitor
DM8KAIY	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DM8KAIY	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMC075A	DI	DMC075A
DMC075A	DN	PMID30107136-Compound-Example45
DMC075A	MI	TT23XQV
DMC075A	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMC075A	MT	DTT
DMC075A	MA	Inhibitor
DMC075A	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMC075A	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMYFSAD	DI	DMYFSAD
DMYFSAD	DN	PMID30107136-Compound-Example46
DMYFSAD	MI	TT23XQV
DMYFSAD	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMYFSAD	MT	DTT
DMYFSAD	MA	Inhibitor
DMYFSAD	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMYFSAD	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DM1TCBQ	DI	DM1TCBQ
DM1TCBQ	DN	PMID30107136-Compound-Example47
DM1TCBQ	MI	TT23XQV
DM1TCBQ	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DM1TCBQ	MT	DTT
DM1TCBQ	MA	Inhibitor
DM1TCBQ	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DM1TCBQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMH57FG	DI	DMH57FG
DMH57FG	DN	PMID30107136-Compound-Example48
DMH57FG	MI	TT23XQV
DMH57FG	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMH57FG	MT	DTT
DMH57FG	MA	Inhibitor
DMH57FG	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMH57FG	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DM4D1WK	DI	DM4D1WK
DM4D1WK	DN	PMID30107136-Compound-Example49
DM4D1WK	MI	TT23XQV
DM4D1WK	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DM4D1WK	MT	DTT
DM4D1WK	MA	Inhibitor
DM4D1WK	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DM4D1WK	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMV15GM	DI	DMV15GM
DMV15GM	DN	PMID30107136-Compound-Example50
DMV15GM	MI	TT23XQV
DMV15GM	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMV15GM	MT	DTT
DMV15GM	MA	Inhibitor
DMV15GM	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMV15GM	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DM08CBJ	DI	DM08CBJ
DM08CBJ	DN	PMID30107136-Compound-Example51
DM08CBJ	MI	TT23XQV
DM08CBJ	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DM08CBJ	MT	DTT
DM08CBJ	MA	Inhibitor
DM08CBJ	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DM08CBJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMJ1C0A	DI	DMJ1C0A
DMJ1C0A	DN	PMID30107136-Compound-Example52
DMJ1C0A	MI	TT23XQV
DMJ1C0A	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMJ1C0A	MT	DTT
DMJ1C0A	MA	Inhibitor
DMJ1C0A	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMJ1C0A	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DM39FDV	DI	DM39FDV
DM39FDV	DN	PMID30107136-Compound-Example53
DM39FDV	MI	TT23XQV
DM39FDV	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DM39FDV	MT	DTT
DM39FDV	MA	Inhibitor
DM39FDV	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DM39FDV	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DM9DL1E	DI	DM9DL1E
DM9DL1E	DN	PMID30107136-Compound-Example54
DM9DL1E	MI	TT23XQV
DM9DL1E	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DM9DL1E	MT	DTT
DM9DL1E	MA	Inhibitor
DM9DL1E	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DM9DL1E	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMZXC0D	DI	DMZXC0D
DMZXC0D	DN	PMID30107136-Compound-Example57
DMZXC0D	MI	TT23XQV
DMZXC0D	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMZXC0D	MT	DTT
DMZXC0D	MA	Inhibitor
DMZXC0D	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMZXC0D	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DM3AY9K	DI	DM3AY9K
DM3AY9K	DN	PMID30107136-Compound-Example58
DM3AY9K	MI	TT23XQV
DM3AY9K	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DM3AY9K	MT	DTT
DM3AY9K	MA	Inhibitor
DM3AY9K	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DM3AY9K	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DM6XWL9	DI	DM6XWL9
DM6XWL9	DN	PMID30107136-Compound-Example59
DM6XWL9	MI	TT23XQV
DM6XWL9	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DM6XWL9	MT	DTT
DM6XWL9	MA	Inhibitor
DM6XWL9	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DM6XWL9	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMUZ85A	DI	DMUZ85A
DMUZ85A	DN	PMID30107136-Compound-Example60
DMUZ85A	MI	TT23XQV
DMUZ85A	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMUZ85A	MT	DTT
DMUZ85A	MA	Inhibitor
DMUZ85A	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMUZ85A	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMS42KH	DI	DMS42KH
DMS42KH	DN	PMID30107136-Compound-Example7
DMS42KH	MI	TT23XQV
DMS42KH	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMS42KH	MT	DTT
DMS42KH	MA	Inhibitor
DMS42KH	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMS42KH	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMBIK28	DI	DMBIK28
DMBIK28	DN	PMID30107136-Compound-Example8
DMBIK28	MI	TT23XQV
DMBIK28	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMBIK28	MT	DTT
DMBIK28	MA	Inhibitor
DMBIK28	RN	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
DMBIK28	RU	https://www.ncbi.nlm.nih.gov/pubmed/30107136

DMHTJVA	DI	DMHTJVA
DMHTJVA	DN	PMID30124346-Compound-13TABLE4
DMHTJVA	MI	TTSQIFT
DMHTJVA	MN	5-HT 1A receptor (HTR1A)
DMHTJVA	MT	DTT
DMHTJVA	MA	Agonist
DMHTJVA	RN	5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
DMHTJVA	RU	https://www.ncbi.nlm.nih.gov/pubmed/30124346

DMHTJVA	DI	DMHTJVA
DMHTJVA	DN	PMID30124346-Compound-13TABLE4
DMHTJVA	MI	TTJQOD7
DMHTJVA	MN	5-HT 2A receptor (HTR2A)
DMHTJVA	MT	DTT
DMHTJVA	MA	Ligand
DMHTJVA	RN	5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
DMHTJVA	RU	https://www.ncbi.nlm.nih.gov/pubmed/30124346

DMHTJVA	DI	DMHTJVA
DMHTJVA	DN	PMID30124346-Compound-13TABLE4
DMHTJVA	MI	TTJS8PY
DMHTJVA	MN	5-HT 6 receptor (HTR6)
DMHTJVA	MT	DTT
DMHTJVA	MA	Ligand
DMHTJVA	RN	5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
DMHTJVA	RU	https://www.ncbi.nlm.nih.gov/pubmed/30124346

DMHTJVA	DI	DMHTJVA
DMHTJVA	DN	PMID30124346-Compound-13TABLE4
DMHTJVA	MI	TTO9X1H
DMHTJVA	MN	5-HT 7 receptor (HTR7)
DMHTJVA	MT	DTT
DMHTJVA	MA	Ligand
DMHTJVA	RN	5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
DMHTJVA	RU	https://www.ncbi.nlm.nih.gov/pubmed/30124346

DMHTJVA	DI	DMHTJVA
DMHTJVA	DN	PMID30124346-Compound-13TABLE4
DMHTJVA	MI	TTEX248
DMHTJVA	MN	Dopamine D2 receptor (D2R)
DMHTJVA	MT	DTT
DMHTJVA	MA	Ligand
DMHTJVA	RN	5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
DMHTJVA	RU	https://www.ncbi.nlm.nih.gov/pubmed/30124346

DM2G3VE	DI	DM2G3VE
DM2G3VE	DN	PMID30124346-Compound-34TABLE4
DM2G3VE	MI	TTSQIFT
DM2G3VE	MN	5-HT 1A receptor (HTR1A)
DM2G3VE	MT	DTT
DM2G3VE	MA	Ligand
DM2G3VE	RN	5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
DM2G3VE	RU	https://www.ncbi.nlm.nih.gov/pubmed/30124346

DM2G3VE	DI	DM2G3VE
DM2G3VE	DN	PMID30124346-Compound-34TABLE4
DM2G3VE	MI	TTJQOD7
DM2G3VE	MN	5-HT 2A receptor (HTR2A)
DM2G3VE	MT	DTT
DM2G3VE	MA	Ligand
DM2G3VE	RN	5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
DM2G3VE	RU	https://www.ncbi.nlm.nih.gov/pubmed/30124346

DM2G3VE	DI	DM2G3VE
DM2G3VE	DN	PMID30124346-Compound-34TABLE4
DM2G3VE	MI	TTJS8PY
DM2G3VE	MN	5-HT 6 receptor (HTR6)
DM2G3VE	MT	DTT
DM2G3VE	MA	Ligand
DM2G3VE	RN	5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
DM2G3VE	RU	https://www.ncbi.nlm.nih.gov/pubmed/30124346

DM2G3VE	DI	DM2G3VE
DM2G3VE	DN	PMID30124346-Compound-34TABLE4
DM2G3VE	MI	TTO9X1H
DM2G3VE	MN	5-HT 7 receptor (HTR7)
DM2G3VE	MT	DTT
DM2G3VE	MA	Ligand
DM2G3VE	RN	5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
DM2G3VE	RU	https://www.ncbi.nlm.nih.gov/pubmed/30124346

DM2G3VE	DI	DM2G3VE
DM2G3VE	DN	PMID30124346-Compound-34TABLE4
DM2G3VE	MI	TTEX248
DM2G3VE	MN	Dopamine D2 receptor (D2R)
DM2G3VE	MT	DTT
DM2G3VE	MA	Ligand
DM2G3VE	RN	5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
DM2G3VE	RU	https://www.ncbi.nlm.nih.gov/pubmed/30124346

DM3QX0R	DI	DM3QX0R
DM3QX0R	DN	PMID30124346-Compound-60TABLE5
DM3QX0R	MI	TTSQIFT
DM3QX0R	MN	5-HT 1A receptor (HTR1A)
DM3QX0R	MT	DTT
DM3QX0R	MA	Ligand
DM3QX0R	RN	5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
DM3QX0R	RU	https://www.ncbi.nlm.nih.gov/pubmed/30124346

DM3QX0R	DI	DM3QX0R
DM3QX0R	DN	PMID30124346-Compound-60TABLE5
DM3QX0R	MI	TTVIREA
DM3QX0R	MN	Adrenergic receptor (ADR)
DM3QX0R	MT	DTT
DM3QX0R	MA	Ligand
DM3QX0R	RN	5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
DM3QX0R	RU	https://www.ncbi.nlm.nih.gov/pubmed/30124346

DM3QX0R	DI	DM3QX0R
DM3QX0R	DN	PMID30124346-Compound-60TABLE5
DM3QX0R	MI	TTEX248
DM3QX0R	MN	Dopamine D2 receptor (D2R)
DM3QX0R	MT	DTT
DM3QX0R	MA	Ligand
DM3QX0R	RN	5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
DM3QX0R	RU	https://www.ncbi.nlm.nih.gov/pubmed/30124346

DMJMTNL	DI	DMJMTNL
DMJMTNL	DN	PMID30124346-Compound-LDT66
DMJMTNL	MI	TTSQIFT
DMJMTNL	MN	5-HT 1A receptor (HTR1A)
DMJMTNL	MT	DTT
DMJMTNL	RN	5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
DMJMTNL	RU	https://www.ncbi.nlm.nih.gov/pubmed/30124346

DMJMTNL	DI	DMJMTNL
DMJMTNL	DN	PMID30124346-Compound-LDT66
DMJMTNL	MI	TTNGILX
DMJMTNL	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMJMTNL	MT	DTT
DMJMTNL	RN	5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
DMJMTNL	RU	https://www.ncbi.nlm.nih.gov/pubmed/30124346

DMJMTNL	DI	DMJMTNL
DMJMTNL	DN	PMID30124346-Compound-LDT66
DMJMTNL	MI	TT34BHT
DMJMTNL	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMJMTNL	MT	DTT
DMJMTNL	RN	5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
DMJMTNL	RU	https://www.ncbi.nlm.nih.gov/pubmed/30124346

DM5MUNG	DI	DM5MUNG
DM5MUNG	DN	PMID30124346-Compound-LDT8
DM5MUNG	MI	TTSQIFT
DM5MUNG	MN	5-HT 1A receptor (HTR1A)
DM5MUNG	MT	DTT
DM5MUNG	MA	Antagonist
DM5MUNG	RN	5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
DM5MUNG	RU	https://www.ncbi.nlm.nih.gov/pubmed/30124346

DM5MUNG	DI	DM5MUNG
DM5MUNG	DN	PMID30124346-Compound-LDT8
DM5MUNG	MI	TTJQOD7
DM5MUNG	MN	5-HT 2A receptor (HTR2A)
DM5MUNG	MT	DTT
DM5MUNG	MA	Antagonist
DM5MUNG	RN	5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
DM5MUNG	RU	https://www.ncbi.nlm.nih.gov/pubmed/30124346

DM5MUNG	DI	DM5MUNG
DM5MUNG	DN	PMID30124346-Compound-LDT8
DM5MUNG	MI	TTNGILX
DM5MUNG	MN	Adrenergic receptor alpha-1A (ADRA1A)
DM5MUNG	MT	DTT
DM5MUNG	MA	Antagonist
DM5MUNG	RN	5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
DM5MUNG	RU	https://www.ncbi.nlm.nih.gov/pubmed/30124346

DM5MUNG	DI	DM5MUNG
DM5MUNG	DN	PMID30124346-Compound-LDT8
DM5MUNG	MI	TT34BHT
DM5MUNG	MN	Adrenergic receptor alpha-1D (ADRA1D)
DM5MUNG	MT	DTT
DM5MUNG	MA	Antagonist
DM5MUNG	RN	5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
DM5MUNG	RU	https://www.ncbi.nlm.nih.gov/pubmed/30124346

DMQU10C	DI	DMQU10C
DMQU10C	DN	PMID30185082-Compound-14
DMQU10C	MI	TT9NXW4
DMQU10C	MN	Sigma intracellular receptor 2 (TMEM97)
DMQU10C	MT	DTT
DMQU10C	MA	Ligand
DMQU10C	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DMQU10C	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DMYFLT1	DI	DMYFLT1
DMYFLT1	DN	PMID30185082-Compound-27
DMYFLT1	MI	TT9NXW4
DMYFLT1	MN	Sigma intracellular receptor 2 (TMEM97)
DMYFLT1	MT	DTT
DMYFLT1	MA	Ligand
DMYFLT1	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DMYFLT1	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DMI0WHE	DI	DMI0WHE
DMI0WHE	DN	PMID30185082-Compound-28
DMI0WHE	MI	TT9NXW4
DMI0WHE	MN	Sigma intracellular receptor 2 (TMEM97)
DMI0WHE	MT	DTT
DMI0WHE	MA	Ligand
DMI0WHE	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DMI0WHE	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DM9GX0F	DI	DM9GX0F
DM9GX0F	DN	PMID30185082-Compound-53
DM9GX0F	MI	TT9NXW4
DM9GX0F	MN	Sigma intracellular receptor 2 (TMEM97)
DM9GX0F	MT	DTT
DM9GX0F	MA	Ligand
DM9GX0F	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DM9GX0F	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DMKP14O	DI	DMKP14O
DMKP14O	DN	PMID30185082-Compound-54
DMKP14O	MI	TT9NXW4
DMKP14O	MN	Sigma intracellular receptor 2 (TMEM97)
DMKP14O	MT	DTT
DMKP14O	MA	Ligand
DMKP14O	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DMKP14O	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DMW8V4R	DI	DMW8V4R
DMW8V4R	DN	PMID30185082-Compound-55
DMW8V4R	MI	TT9NXW4
DMW8V4R	MN	Sigma intracellular receptor 2 (TMEM97)
DMW8V4R	MT	DTT
DMW8V4R	MA	Ligand
DMW8V4R	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DMW8V4R	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DMLGKYI	DI	DMLGKYI
DMLGKYI	DN	PMID30185082-Compound-56
DMLGKYI	MI	TT9NXW4
DMLGKYI	MN	Sigma intracellular receptor 2 (TMEM97)
DMLGKYI	MT	DTT
DMLGKYI	MA	Ligand
DMLGKYI	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DMLGKYI	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DMNDF1Z	DI	DMNDF1Z
DMNDF1Z	DN	PMID30185082-Compound-57
DMNDF1Z	MI	TT5TPI6
DMNDF1Z	MN	Opioid receptor sigma 1 (OPRS1)
DMNDF1Z	MT	DTT
DMNDF1Z	MA	Ligand
DMNDF1Z	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DMNDF1Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DMNDF1Z	DI	DMNDF1Z
DMNDF1Z	DN	PMID30185082-Compound-57
DMNDF1Z	MI	TT9NXW4
DMNDF1Z	MN	Sigma intracellular receptor 2 (TMEM97)
DMNDF1Z	MT	DTT
DMNDF1Z	MA	Ligand
DMNDF1Z	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DMNDF1Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DMW2S0J	DI	DMW2S0J
DMW2S0J	DN	PMID30185082-Compound-63
DMW2S0J	MI	TT9NXW4
DMW2S0J	MN	Sigma intracellular receptor 2 (TMEM97)
DMW2S0J	MT	DTT
DMW2S0J	MA	Ligand
DMW2S0J	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DMW2S0J	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DMKD470	DI	DMKD470
DMKD470	DN	PMID30185082-Compound-64
DMKD470	MI	TT5TPI6
DMKD470	MN	Opioid receptor sigma 1 (OPRS1)
DMKD470	MT	DTT
DMKD470	MA	Ligand
DMKD470	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DMKD470	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DMKD470	DI	DMKD470
DMKD470	DN	PMID30185082-Compound-64
DMKD470	MI	TT9NXW4
DMKD470	MN	Sigma intracellular receptor 2 (TMEM97)
DMKD470	MT	DTT
DMKD470	MA	Ligand
DMKD470	RN	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
DMKD470	RU	https://www.ncbi.nlm.nih.gov/pubmed/30185082

DME0RJ2	DI	DME0RJ2
DME0RJ2	DN	PMID30259754-Compound-INT-767
DME0RJ2	MI	TTS4UGC
DME0RJ2	MN	Farnesoid X-activated receptor (FXR)
DME0RJ2	MT	DTT
DME0RJ2	MA	Agonist
DME0RJ2	RN	FXR modulators for enterohepatic and metabolic diseases.Expert Opin Ther Pat. 2018 Nov;28(11):765-782.
DME0RJ2	RU	https://www.ncbi.nlm.nih.gov/pubmed/30259754

DMZ5CDY	DI	DMZ5CDY
DMZ5CDY	DN	PMID30259754-Compound-LY2562175
DMZ5CDY	MI	TTS4UGC
DMZ5CDY	MN	Farnesoid X-activated receptor (FXR)
DMZ5CDY	MT	DTT
DMZ5CDY	MA	Agonist
DMZ5CDY	RN	FXR modulators for enterohepatic and metabolic diseases.Expert Opin Ther Pat. 2018 Nov;28(11):765-782.
DMZ5CDY	RU	https://www.ncbi.nlm.nih.gov/pubmed/30259754

DM78IN5	DI	DM78IN5
DM78IN5	DN	PMID30259754-Compound-Px-102
DM78IN5	MI	TTS4UGC
DM78IN5	MN	Farnesoid X-activated receptor (FXR)
DM78IN5	MT	DTT
DM78IN5	MA	Agonist
DM78IN5	RN	FXR modulators for enterohepatic and metabolic diseases.Expert Opin Ther Pat. 2018 Nov;28(11):765-782.
DM78IN5	RU	https://www.ncbi.nlm.nih.gov/pubmed/30259754

DMVP16K	DI	DMVP16K
DMVP16K	DN	PMID30259754-Compound-pyrrole[2,3-d]azepines
DMVP16K	MI	TTS4UGC
DMVP16K	MN	Farnesoid X-activated receptor (FXR)
DMVP16K	MT	DTT
DMVP16K	MA	Agonist
DMVP16K	RN	FXR modulators for enterohepatic and metabolic diseases.Expert Opin Ther Pat. 2018 Nov;28(11):765-782.
DMVP16K	RU	https://www.ncbi.nlm.nih.gov/pubmed/30259754

DMDKSJQ	DI	DMDKSJQ
DMDKSJQ	DN	PMID30259754-Compound-WAY-362450
DMDKSJQ	MI	TTS4UGC
DMDKSJQ	MN	Farnesoid X-activated receptor (FXR)
DMDKSJQ	MT	DTT
DMDKSJQ	MA	Agonist
DMDKSJQ	RN	FXR modulators for enterohepatic and metabolic diseases.Expert Opin Ther Pat. 2018 Nov;28(11):765-782.
DMDKSJQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/30259754

DM52MKV	DI	DM52MKV
DM52MKV	DN	PMID30273516-Compound-1
DM52MKV	MI	TTCW0KX
DM52MKV	MN	Glutaminase (GLS)
DM52MKV	MT	DTT
DM52MKV	MA	Inhibitor
DM52MKV	RN	Glutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):823-835.
DM52MKV	RU	https://www.ncbi.nlm.nih.gov/pubmed/30273516

DMIWEZH	DI	DMIWEZH
DMIWEZH	DN	PMID30273516-Compound-12
DMIWEZH	MI	TTCW0KX
DMIWEZH	MN	Glutaminase (GLS)
DMIWEZH	MT	DTT
DMIWEZH	MA	Inhibitor
DMIWEZH	RN	Glutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):823-835.
DMIWEZH	RU	https://www.ncbi.nlm.nih.gov/pubmed/30273516

DMK9TJP	DI	DMK9TJP
DMK9TJP	DN	PMID30273516-Compound-13
DMK9TJP	MI	TTCW0KX
DMK9TJP	MN	Glutaminase (GLS)
DMK9TJP	MT	DTT
DMK9TJP	MA	Inhibitor
DMK9TJP	RN	Glutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):823-835.
DMK9TJP	RU	https://www.ncbi.nlm.nih.gov/pubmed/30273516

DMURZHA	DI	DMURZHA
DMURZHA	DN	PMID30273516-Compound-14
DMURZHA	MI	TTCW0KX
DMURZHA	MN	Glutaminase (GLS)
DMURZHA	MT	DTT
DMURZHA	MA	Inhibitor
DMURZHA	RN	Glutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):823-835.
DMURZHA	RU	https://www.ncbi.nlm.nih.gov/pubmed/30273516

DMSD647	DI	DMSD647
DMSD647	DN	PMID30273516-Compound-15
DMSD647	MI	TTCW0KX
DMSD647	MN	Glutaminase (GLS)
DMSD647	MT	DTT
DMSD647	MA	Inhibitor
DMSD647	RN	Glutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):823-835.
DMSD647	RU	https://www.ncbi.nlm.nih.gov/pubmed/30273516

DMVZA0U	DI	DMVZA0U
DMVZA0U	DN	PMID30273516-Compound-22a
DMVZA0U	MI	TTCW0KX
DMVZA0U	MN	Glutaminase (GLS)
DMVZA0U	MT	DTT
DMVZA0U	MA	Inhibitor
DMVZA0U	RN	Glutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):823-835.
DMVZA0U	RU	https://www.ncbi.nlm.nih.gov/pubmed/30273516

DMZ5O3K	DI	DMZ5O3K
DMZ5O3K	DN	PMID30273516-Compound-22b
DMZ5O3K	MI	TTCW0KX
DMZ5O3K	MN	Glutaminase (GLS)
DMZ5O3K	MT	DTT
DMZ5O3K	MA	Inhibitor
DMZ5O3K	RN	Glutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):823-835.
DMZ5O3K	RU	https://www.ncbi.nlm.nih.gov/pubmed/30273516

DM8NBJV	DI	DM8NBJV
DM8NBJV	DN	PMID30273516-Compound-37
DM8NBJV	MI	TTCW0KX
DM8NBJV	MN	Glutaminase (GLS)
DM8NBJV	MT	DTT
DM8NBJV	MA	Inhibitor
DM8NBJV	RN	Glutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):823-835.
DM8NBJV	RU	https://www.ncbi.nlm.nih.gov/pubmed/30273516

DMRPJBF	DI	DMRPJBF
DMRPJBF	DN	PMID30273516-Compound-38
DMRPJBF	MI	TTCW0KX
DMRPJBF	MN	Glutaminase (GLS)
DMRPJBF	MT	DTT
DMRPJBF	MA	Inhibitor
DMRPJBF	RN	Glutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):823-835.
DMRPJBF	RU	https://www.ncbi.nlm.nih.gov/pubmed/30273516

DMBF3ZE	DI	DMBF3ZE
DMBF3ZE	DN	PMID30273516-Compound-39
DMBF3ZE	MI	TTCW0KX
DMBF3ZE	MN	Glutaminase (GLS)
DMBF3ZE	MT	DTT
DMBF3ZE	MA	Inhibitor
DMBF3ZE	RN	Glutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):823-835.
DMBF3ZE	RU	https://www.ncbi.nlm.nih.gov/pubmed/30273516

DM5N8YJ	DI	DM5N8YJ
DM5N8YJ	DN	PMID30273516-Compound-40
DM5N8YJ	MI	TTCW0KX
DM5N8YJ	MN	Glutaminase (GLS)
DM5N8YJ	MT	DTT
DM5N8YJ	MA	Inhibitor
DM5N8YJ	RN	Glutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):823-835.
DM5N8YJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/30273516

DM5UBMJ	DI	DM5UBMJ
DM5UBMJ	DN	PMID30273516-Compound-41
DM5UBMJ	MI	TTCW0KX
DM5UBMJ	MN	Glutaminase (GLS)
DM5UBMJ	MT	DTT
DM5UBMJ	MA	Inhibitor
DM5UBMJ	RN	Glutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):823-835.
DM5UBMJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/30273516

DMM83WL	DI	DMM83WL
DMM83WL	DN	PMID30280939-Compound-US20170128558
DMM83WL	MI	TTOK0LR
DMM83WL	MN	Toll-like receptor (TLR)
DMM83WL	MT	DTT
DMM83WL	MA	Agonist
DMM83WL	RN	Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):837-847.
DMM83WL	RU	https://www.ncbi.nlm.nih.gov/pubmed/30280939

DMPVW2Q	DI	DMPVW2Q
DMPVW2Q	DN	PMID30280939-Compound-US20179642901
DMPVW2Q	MI	TTOK0LR
DMPVW2Q	MN	Toll-like receptor (TLR)
DMPVW2Q	MT	DTT
DMPVW2Q	MA	Agonist
DMPVW2Q	RN	Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):837-847.
DMPVW2Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/30280939

DM6VP5K	DI	DM6VP5K
DM6VP5K	DN	PMID30280939-Compound-WO2005070959
DM6VP5K	MI	TTOK0LR
DM6VP5K	MN	Toll-like receptor (TLR)
DM6VP5K	MT	DTT
DM6VP5K	MA	Immune response agent
DM6VP5K	RN	Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):837-847.
DM6VP5K	RU	https://www.ncbi.nlm.nih.gov/pubmed/30280939

DMLVSEK	DI	DMLVSEK
DMLVSEK	DN	PMID30280939-Compound-WO200606195
DMLVSEK	MI	TTOK0LR
DMLVSEK	MN	Toll-like receptor (TLR)
DMLVSEK	MT	DTT
DMLVSEK	MA	Agonist
DMLVSEK	RN	Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):837-847.
DMLVSEK	RU	https://www.ncbi.nlm.nih.gov/pubmed/30280939

DM7DG0M	DI	DM7DG0M
DM7DG0M	DN	PMID30280939-Compound-WO2008009652
DM7DG0M	MI	TTOK0LR
DM7DG0M	MN	Toll-like receptor (TLR)
DM7DG0M	MT	DTT
DM7DG0M	MA	Agonist
DM7DG0M	RN	Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):837-847.
DM7DG0M	RU	https://www.ncbi.nlm.nih.gov/pubmed/30280939

DMXRHCJ	DI	DMXRHCJ
DMXRHCJ	DN	PMID30280939-Compound-WO2009082440
DMXRHCJ	MI	TTOK0LR
DMXRHCJ	MN	Toll-like receptor (TLR)
DMXRHCJ	MT	DTT
DMXRHCJ	MA	Agonist
DMXRHCJ	RN	Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):837-847.
DMXRHCJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/30280939

DMRB7LI	DI	DMRB7LI
DMRB7LI	DN	PMID30280939-Compound-WO2013119856
DMRB7LI	MI	TTOK0LR
DMRB7LI	MN	Toll-like receptor (TLR)
DMRB7LI	MT	DTT
DMRB7LI	MA	Agonist
DMRB7LI	RN	Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):837-847.
DMRB7LI	RU	https://www.ncbi.nlm.nih.gov/pubmed/30280939

DMUKIEJ	DI	DMUKIEJ
DMUKIEJ	DN	PMID30280939-Compound-WO2013148426
DMUKIEJ	MI	TTOK0LR
DMUKIEJ	MN	Toll-like receptor (TLR)
DMUKIEJ	MT	DTT
DMUKIEJ	MA	Agonist
DMUKIEJ	RN	Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):837-847.
DMUKIEJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/30280939

DM4Z2KY	DI	DM4Z2KY
DM4Z2KY	DN	PMID30280939-Compound-WO2013148427
DM4Z2KY	MI	TTOK0LR
DM4Z2KY	MN	Toll-like receptor (TLR)
DM4Z2KY	MT	DTT
DM4Z2KY	MA	Agonist
DM4Z2KY	RN	Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):837-847.
DM4Z2KY	RU	https://www.ncbi.nlm.nih.gov/pubmed/30280939

DM4ILAK	DI	DM4ILAK
DM4ILAK	DN	PMID30280939-Compound-WO2015035128
DM4ILAK	MI	TTOK0LR
DM4ILAK	MN	Toll-like receptor (TLR)
DM4ILAK	MT	DTT
DM4ILAK	MA	Agonist
DM4ILAK	RN	Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):837-847.
DM4ILAK	RU	https://www.ncbi.nlm.nih.gov/pubmed/30280939

DM5K3DF	DI	DM5K3DF
DM5K3DF	DN	PMID30280939-Compound-WO2015091734
DM5K3DF	MI	TTOK0LR
DM5K3DF	MN	Toll-like receptor (TLR)
DM5K3DF	MT	DTT
DM5K3DF	MA	Agonist
DM5K3DF	RN	Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):837-847.
DM5K3DF	RU	https://www.ncbi.nlm.nih.gov/pubmed/30280939

DMGCE3Z	DI	DMGCE3Z
DMGCE3Z	DN	PMID30280939-Compound-WO2015150568
DMGCE3Z	MI	TTOK0LR
DMGCE3Z	MN	Toll-like receptor (TLR)
DMGCE3Z	MT	DTT
DMGCE3Z	MA	Agonist
DMGCE3Z	RN	Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):837-847.
DMGCE3Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/30280939

DMSWI67	DI	DMSWI67
DMSWI67	DN	Polycyclic compound 1
DMSWI67	MI	TTYLQ8V
DMSWI67	MN	Prostaglandin E synthase (PTGES)
DMSWI67	MT	DTT
DMSWI67	MA	Inhibitor
DMSWI67	RN	Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059.
DMSWI67	RU	https://www.ncbi.nlm.nih.gov/pubmed/28627961

DMPHCJ5	DI	DMPHCJ5
DMPHCJ5	DN	Polyhydroxy benzamide derivative 1
DMPHCJ5	MI	TTULVH8
DMPHCJ5	MN	Tyrosinase (TYR)
DMPHCJ5	MT	DTT
DMPHCJ5	MA	Inhibitor
DMPHCJ5	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMPHCJ5	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DM0BRNU	DI	DM0BRNU
DM0BRNU	DN	Polyhydroxy benzamide derivative 2
DM0BRNU	MI	TTULVH8
DM0BRNU	MN	Tyrosinase (TYR)
DM0BRNU	MT	DTT
DM0BRNU	MA	Inhibitor
DM0BRNU	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DM0BRNU	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMCLZWS	DI	DMCLZWS
DMCLZWS	DN	Polyhydroxy benzamide derivative 3
DMCLZWS	MI	TTULVH8
DMCLZWS	MN	Tyrosinase (TYR)
DMCLZWS	MT	DTT
DMCLZWS	MA	Inhibitor
DMCLZWS	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMCLZWS	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DM6QBV2	DI	DM6QBV2
DM6QBV2	DN	Polyhydroxy benzamide derivative 4
DM6QBV2	MI	TTULVH8
DM6QBV2	MN	Tyrosinase (TYR)
DM6QBV2	MT	DTT
DM6QBV2	MA	Inhibitor
DM6QBV2	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DM6QBV2	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMZC6AI	DI	DMZC6AI
DMZC6AI	DN	Polyhydroxy benzamide derivative 5
DMZC6AI	MI	TTULVH8
DMZC6AI	MN	Tyrosinase (TYR)
DMZC6AI	MT	DTT
DMZC6AI	MA	Inhibitor
DMZC6AI	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMZC6AI	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMDLS54	DI	DMDLS54
DMDLS54	DN	Poly-substituted azoles statin lactone derivative 1
DMDLS54	MI	TTPADOQ
DMDLS54	MN	HMG-CoA reductase (HMGCR)
DMDLS54	MT	DTT
DMDLS54	MA	Inhibitor
DMDLS54	RN	HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272.
DMDLS54	RU	https://www.ncbi.nlm.nih.gov/pubmed/27537201

DM5G3CN	DI	DM5G3CN
DM5G3CN	DN	Poly-substituted azoles statin lactone derivative 2
DM5G3CN	MI	TTPADOQ
DM5G3CN	MN	HMG-CoA reductase (HMGCR)
DM5G3CN	MT	DTT
DM5G3CN	MA	Inhibitor
DM5G3CN	RN	HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272.
DM5G3CN	RU	https://www.ncbi.nlm.nih.gov/pubmed/27537201

DMQJ38W	DI	DMQJ38W
DMQJ38W	DN	Poly-substituted miazine derivative 1
DMQJ38W	MI	TTPADOQ
DMQJ38W	MN	HMG-CoA reductase (HMGCR)
DMQJ38W	MT	DTT
DMQJ38W	MA	Inhibitor
DMQJ38W	RN	HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272.
DMQJ38W	RU	https://www.ncbi.nlm.nih.gov/pubmed/27537201

DMH2AYV	DI	DMH2AYV
DMH2AYV	DN	Proline amide derivative 1
DMH2AYV	MI	TTTJZ4M
DMH2AYV	MN	Prolylcarboxypeptidase (PRCP)
DMH2AYV	MT	DTT
DMH2AYV	MA	Inhibitor
DMH2AYV	RN	Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088.
DMH2AYV	RU	https://www.ncbi.nlm.nih.gov/pubmed/28699813

DME57SJ	DI	DME57SJ
DME57SJ	DN	P-toluenesulfonate derivative 1
DME57SJ	MI	TTZCRP3
DME57SJ	MN	ERK activator kinase (MEK)
DME57SJ	MT	DTT
DME57SJ	MA	Inhibitor
DME57SJ	RN	MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906.
DME57SJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28594589

DM92SWJ	DI	DM92SWJ
DM92SWJ	DN	Purin-6-one derivative 1
DM92SWJ	MI	TTJGW1Z
DM92SWJ	MN	Phosphodiesterase 2A (PDE2A)
DM92SWJ	MT	DTT
DM92SWJ	MA	Inhibitor
DM92SWJ	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DM92SWJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMB65Z4	DI	DMB65Z4
DMB65Z4	DN	Purine derivative 1
DMB65Z4	MI	TT6OEDT
DMB65Z4	MN	Cannabinoid receptor 1 (CB1)
DMB65Z4	MT	DTT
DMB65Z4	MA	Antagonist
DMB65Z4	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMB65Z4	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMNRG0P	DI	DMNRG0P
DMNRG0P	DN	Purine derivative 2
DMNRG0P	MI	TT6OEDT
DMNRG0P	MN	Cannabinoid receptor 1 (CB1)
DMNRG0P	MT	DTT
DMNRG0P	MA	Antagonist
DMNRG0P	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMNRG0P	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMPI2S9	DI	DMPI2S9
DMPI2S9	DN	Purine derivative 3
DMPI2S9	MI	TT6OEDT
DMPI2S9	MN	Cannabinoid receptor 1 (CB1)
DMPI2S9	MT	DTT
DMPI2S9	MA	Antagonist
DMPI2S9	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMPI2S9	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMYD5SQ	DI	DMYD5SQ
DMYD5SQ	DN	Purine derivative 4
DMYD5SQ	MI	TTMBO1Z
DMYD5SQ	MN	Cyclin-dependent kinase (CDK)
DMYD5SQ	MT	DTT
DMYD5SQ	MA	Inhibitor
DMYD5SQ	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMYD5SQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMMVG2O	DI	DMMVG2O
DMMVG2O	DN	Pyrano[2,3-b]pyridine derivative 1
DMMVG2O	MI	TT6OEDT
DMMVG2O	MN	Cannabinoid receptor 1 (CB1)
DMMVG2O	MT	DTT
DMMVG2O	MA	Antagonist
DMMVG2O	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMMVG2O	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMOJ8P1	DI	DMOJ8P1
DMOJ8P1	DN	Pyrano[2,3-b]pyridine derivative 2
DMOJ8P1	MI	TT6OEDT
DMOJ8P1	MN	Cannabinoid receptor 1 (CB1)
DMOJ8P1	MT	DTT
DMOJ8P1	MA	Antagonist
DMOJ8P1	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMOJ8P1	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DM3RAU4	DI	DM3RAU4
DM3RAU4	DN	Pyrazine carboxamide derivative 1
DM3RAU4	MI	TTF8P9I
DM3RAU4	MN	Diacylglycerol acyltransferase 1 (DGAT1)
DM3RAU4	MT	DTT
DM3RAU4	MA	Inhibitor
DM3RAU4	RN	Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
DM3RAU4	RU	https://www.ncbi.nlm.nih.gov/pubmed/25470667

DMP1MDV	DI	DMP1MDV
DMP1MDV	DN	Pyrazino[2,1-a]isoquinolin derivative 1
DMP1MDV	MI	TT3Z6Y9
DMP1MDV	MN	Cysteines of Keap1 (KEAP1 Cysteines)
DMP1MDV	MT	DTT
DMP1MDV	MA	Modulator
DMP1MDV	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMP1MDV	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMP1MDV	DI	DMP1MDV
DMP1MDV	DN	Pyrazino[2,1-a]isoquinolin derivative 1
DMP1MDV	MI	TTA6ZN2
DMP1MDV	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMP1MDV	MT	DTT
DMP1MDV	MA	Activator
DMP1MDV	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMP1MDV	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMYXKQ3	DI	DMYXKQ3
DMYXKQ3	DN	Pyrazino[2,1-a]isoquinolin derivative 2
DMYXKQ3	MI	TT3Z6Y9
DMYXKQ3	MN	Cysteines of Keap1 (KEAP1 Cysteines)
DMYXKQ3	MT	DTT
DMYXKQ3	MA	Modulator
DMYXKQ3	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMYXKQ3	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMYXKQ3	DI	DMYXKQ3
DMYXKQ3	DN	Pyrazino[2,1-a]isoquinolin derivative 2
DMYXKQ3	MI	TTA6ZN2
DMYXKQ3	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMYXKQ3	MT	DTT
DMYXKQ3	MA	Activator
DMYXKQ3	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMYXKQ3	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMXYU3I	DI	DMXYU3I
DMXYU3I	DN	Pyrazino[2,1-a]isoquinolin derivative 3
DMXYU3I	MI	TT3Z6Y9
DMXYU3I	MN	Cysteines of Keap1 (KEAP1 Cysteines)
DMXYU3I	MT	DTT
DMXYU3I	MA	Modulator
DMXYU3I	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMXYU3I	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMXYU3I	DI	DMXYU3I
DMXYU3I	DN	Pyrazino[2,1-a]isoquinolin derivative 3
DMXYU3I	MI	TTA6ZN2
DMXYU3I	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMXYU3I	MT	DTT
DMXYU3I	MA	Activator
DMXYU3I	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMXYU3I	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMKTNBC	DI	DMKTNBC
DMKTNBC	DN	Pyrazino[2,1-a]isoquinolin derivative 4
DMKTNBC	MI	TT3Z6Y9
DMKTNBC	MN	Cysteines of Keap1 (KEAP1 Cysteines)
DMKTNBC	MT	DTT
DMKTNBC	MA	Modulator
DMKTNBC	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMKTNBC	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMKTNBC	DI	DMKTNBC
DMKTNBC	DN	Pyrazino[2,1-a]isoquinolin derivative 4
DMKTNBC	MI	TTA6ZN2
DMKTNBC	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMKTNBC	MT	DTT
DMKTNBC	MA	Activator
DMKTNBC	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMKTNBC	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMUXQST	DI	DMUXQST
DMUXQST	DN	Pyrazinylpyridine derivative 1
DMUXQST	MI	TT1LVF2
DMUXQST	MN	Cyclin-dependent kinase 9 (CDK9)
DMUXQST	MT	DTT
DMUXQST	MA	Inhibitor
DMUXQST	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMUXQST	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DM05S2X	DI	DM05S2X
DM05S2X	DN	Pyrazole and benzimidazole derivative 1
DM05S2X	MI	TTRZQE3
DM05S2X	MN	Glycogen synthase kinase-3 alpha (GSK-3A)
DM05S2X	MT	DTT
DM05S2X	MA	Inhibitor
DM05S2X	RN	Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
DM05S2X	RU	https://www.ncbi.nlm.nih.gov/pubmed/27828716

DMKTFJ2	DI	DMKTFJ2
DMKTFJ2	DN	Pyrazole and thiophene derivative 1
DMKTFJ2	MI	TTRA6BO
DMKTFJ2	MN	Bromodomain-containing protein 4 (BRD4)
DMKTFJ2	MT	DTT
DMKTFJ2	MA	Inhibitor
DMKTFJ2	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMKTFJ2	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMD51HM	DI	DMD51HM
DMD51HM	DN	Pyrazole and thiophene derivative 2
DMD51HM	MI	TTRA6BO
DMD51HM	MN	Bromodomain-containing protein 4 (BRD4)
DMD51HM	MT	DTT
DMD51HM	MA	Inhibitor
DMD51HM	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMD51HM	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMIKUN9	DI	DMIKUN9
DMIKUN9	DN	Pyrazole and thiophene derivative 3
DMIKUN9	MI	TTRA6BO
DMIKUN9	MN	Bromodomain-containing protein 4 (BRD4)
DMIKUN9	MT	DTT
DMIKUN9	MA	Inhibitor
DMIKUN9	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMIKUN9	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMDETKY	DI	DMDETKY
DMDETKY	DN	Pyrazole and thiophene derivative 4
DMDETKY	MI	TTRA6BO
DMDETKY	MN	Bromodomain-containing protein 4 (BRD4)
DMDETKY	MT	DTT
DMDETKY	MA	Inhibitor
DMDETKY	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMDETKY	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DM3R9PL	DI	DM3R9PL
DM3R9PL	DN	Pyrazole derivative 1
DM3R9PL	MI	TT6OEDT
DM3R9PL	MN	Cannabinoid receptor 1 (CB1)
DM3R9PL	MT	DTT
DM3R9PL	MA	Antagonist
DM3R9PL	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DM3R9PL	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMH7PGU	DI	DMH7PGU
DMH7PGU	DN	Pyrazole derivative 11
DMH7PGU	MI	TT6OEDT
DMH7PGU	MN	Cannabinoid receptor 1 (CB1)
DMH7PGU	MT	DTT
DMH7PGU	MA	Antagonist
DMH7PGU	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMH7PGU	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DM7LFNG	DI	DM7LFNG
DM7LFNG	DN	Pyrazole derivative 12
DM7LFNG	MI	TT6OEDT
DM7LFNG	MN	Cannabinoid receptor 1 (CB1)
DM7LFNG	MT	DTT
DM7LFNG	MA	Antagonist
DM7LFNG	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DM7LFNG	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DM5S3L0	DI	DM5S3L0
DM5S3L0	DN	Pyrazole derivative 13
DM5S3L0	MI	TT6OEDT
DM5S3L0	MN	Cannabinoid receptor 1 (CB1)
DM5S3L0	MT	DTT
DM5S3L0	MA	Antagonist
DM5S3L0	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DM5S3L0	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMEDXW9	DI	DMEDXW9
DMEDXW9	DN	Pyrazole derivative 14
DMEDXW9	MI	TT6OEDT
DMEDXW9	MN	Cannabinoid receptor 1 (CB1)
DMEDXW9	MT	DTT
DMEDXW9	MA	Antagonist
DMEDXW9	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMEDXW9	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMJCX8M	DI	DMJCX8M
DMJCX8M	DN	Pyrazole derivative 15
DMJCX8M	MI	TT6OEDT
DMJCX8M	MN	Cannabinoid receptor 1 (CB1)
DMJCX8M	MT	DTT
DMJCX8M	MA	Antagonist
DMJCX8M	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMJCX8M	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DM5A8F3	DI	DM5A8F3
DM5A8F3	DN	Pyrazole derivative 16
DM5A8F3	MI	TT6OEDT
DM5A8F3	MN	Cannabinoid receptor 1 (CB1)
DM5A8F3	MT	DTT
DM5A8F3	MA	Antagonist
DM5A8F3	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DM5A8F3	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DM7F9V4	DI	DM7F9V4
DM7F9V4	DN	Pyrazole derivative 17
DM7F9V4	MI	TT6OEDT
DM7F9V4	MN	Cannabinoid receptor 1 (CB1)
DM7F9V4	MT	DTT
DM7F9V4	MA	Antagonist
DM7F9V4	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DM7F9V4	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMVZ8KD	DI	DMVZ8KD
DMVZ8KD	DN	Pyrazole derivative 18
DMVZ8KD	MI	TT6OEDT
DMVZ8KD	MN	Cannabinoid receptor 1 (CB1)
DMVZ8KD	MT	DTT
DMVZ8KD	MA	Antagonist
DMVZ8KD	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMVZ8KD	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMM7OR3	DI	DMM7OR3
DMM7OR3	DN	Pyrazole derivative 19
DMM7OR3	MI	TT6OEDT
DMM7OR3	MN	Cannabinoid receptor 1 (CB1)
DMM7OR3	MT	DTT
DMM7OR3	MA	Antagonist
DMM7OR3	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMM7OR3	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMIS97T	DI	DMIS97T
DMIS97T	DN	Pyrazole derivative 2
DMIS97T	MI	TT6OEDT
DMIS97T	MN	Cannabinoid receptor 1 (CB1)
DMIS97T	MT	DTT
DMIS97T	MA	Antagonist
DMIS97T	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMIS97T	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DM2HO1S	DI	DM2HO1S
DM2HO1S	DN	Pyrazole derivative 20
DM2HO1S	MI	TT6OEDT
DM2HO1S	MN	Cannabinoid receptor 1 (CB1)
DM2HO1S	MT	DTT
DM2HO1S	MA	Antagonist
DM2HO1S	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DM2HO1S	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMUPNHA	DI	DMUPNHA
DMUPNHA	DN	Pyrazole derivative 21
DMUPNHA	MI	TT6OEDT
DMUPNHA	MN	Cannabinoid receptor 1 (CB1)
DMUPNHA	MT	DTT
DMUPNHA	MA	Antagonist
DMUPNHA	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMUPNHA	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMCS08K	DI	DMCS08K
DMCS08K	DN	Pyrazole derivative 22
DMCS08K	MI	TT6OEDT
DMCS08K	MN	Cannabinoid receptor 1 (CB1)
DMCS08K	MT	DTT
DMCS08K	MA	Antagonist
DMCS08K	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMCS08K	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMH2LFS	DI	DMH2LFS
DMH2LFS	DN	Pyrazole derivative 23
DMH2LFS	MI	TT6OEDT
DMH2LFS	MN	Cannabinoid receptor 1 (CB1)
DMH2LFS	MT	DTT
DMH2LFS	MA	Antagonist
DMH2LFS	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMH2LFS	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMVX2D0	DI	DMVX2D0
DMVX2D0	DN	Pyrazole derivative 24
DMVX2D0	MI	TT6OEDT
DMVX2D0	MN	Cannabinoid receptor 1 (CB1)
DMVX2D0	MT	DTT
DMVX2D0	MA	Antagonist
DMVX2D0	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMVX2D0	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMM2RYG	DI	DMM2RYG
DMM2RYG	DN	Pyrazole derivative 25
DMM2RYG	MI	TT6OEDT
DMM2RYG	MN	Cannabinoid receptor 1 (CB1)
DMM2RYG	MT	DTT
DMM2RYG	MA	Antagonist
DMM2RYG	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMM2RYG	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMX92ZK	DI	DMX92ZK
DMX92ZK	DN	Pyrazole derivative 26
DMX92ZK	MI	TT6OEDT
DMX92ZK	MN	Cannabinoid receptor 1 (CB1)
DMX92ZK	MT	DTT
DMX92ZK	MA	Antagonist
DMX92ZK	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMX92ZK	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMDB5FH	DI	DMDB5FH
DMDB5FH	DN	Pyrazole derivative 27
DMDB5FH	MI	TT6OEDT
DMDB5FH	MN	Cannabinoid receptor 1 (CB1)
DMDB5FH	MT	DTT
DMDB5FH	MA	Antagonist
DMDB5FH	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMDB5FH	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMYEFW1	DI	DMYEFW1
DMYEFW1	DN	Pyrazole derivative 28
DMYEFW1	MI	TT6OEDT
DMYEFW1	MN	Cannabinoid receptor 1 (CB1)
DMYEFW1	MT	DTT
DMYEFW1	MA	Antagonist
DMYEFW1	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMYEFW1	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DM7DTYS	DI	DM7DTYS
DM7DTYS	DN	Pyrazole derivative 29
DM7DTYS	MI	TT6OEDT
DM7DTYS	MN	Cannabinoid receptor 1 (CB1)
DM7DTYS	MT	DTT
DM7DTYS	MA	Antagonist
DM7DTYS	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DM7DTYS	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMX2NQW	DI	DMX2NQW
DMX2NQW	DN	Pyrazole derivative 3
DMX2NQW	MI	TT6OEDT
DMX2NQW	MN	Cannabinoid receptor 1 (CB1)
DMX2NQW	MT	DTT
DMX2NQW	MA	Antagonist
DMX2NQW	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMX2NQW	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMT1DJP	DI	DMT1DJP
DMT1DJP	DN	Pyrazole derivative 30
DMT1DJP	MI	TT6OEDT
DMT1DJP	MN	Cannabinoid receptor 1 (CB1)
DMT1DJP	MT	DTT
DMT1DJP	MA	Antagonist
DMT1DJP	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMT1DJP	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMDTQCG	DI	DMDTQCG
DMDTQCG	DN	Pyrazole derivative 31
DMDTQCG	MI	TT6OEDT
DMDTQCG	MN	Cannabinoid receptor 1 (CB1)
DMDTQCG	MT	DTT
DMDTQCG	MA	Antagonist
DMDTQCG	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMDTQCG	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMU59IJ	DI	DMU59IJ
DMU59IJ	DN	Pyrazole derivative 32
DMU59IJ	MI	TT6OEDT
DMU59IJ	MN	Cannabinoid receptor 1 (CB1)
DMU59IJ	MT	DTT
DMU59IJ	MA	Antagonist
DMU59IJ	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMU59IJ	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMUNLK8	DI	DMUNLK8
DMUNLK8	DN	Pyrazole derivative 33
DMUNLK8	MI	TT6OEDT
DMUNLK8	MN	Cannabinoid receptor 1 (CB1)
DMUNLK8	MT	DTT
DMUNLK8	MA	Antagonist
DMUNLK8	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMUNLK8	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMRH2EJ	DI	DMRH2EJ
DMRH2EJ	DN	Pyrazole derivative 34
DMRH2EJ	MI	TT6OEDT
DMRH2EJ	MN	Cannabinoid receptor 1 (CB1)
DMRH2EJ	MT	DTT
DMRH2EJ	MA	Antagonist
DMRH2EJ	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMRH2EJ	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DM6KROX	DI	DM6KROX
DM6KROX	DN	Pyrazole derivative 35
DM6KROX	MI	TT6OEDT
DM6KROX	MN	Cannabinoid receptor 1 (CB1)
DM6KROX	MT	DTT
DM6KROX	MA	Antagonist
DM6KROX	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DM6KROX	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMSDVI1	DI	DMSDVI1
DMSDVI1	DN	Pyrazole derivative 36
DMSDVI1	MI	TT6OEDT
DMSDVI1	MN	Cannabinoid receptor 1 (CB1)
DMSDVI1	MT	DTT
DMSDVI1	MA	Antagonist
DMSDVI1	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMSDVI1	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMZJ5FN	DI	DMZJ5FN
DMZJ5FN	DN	Pyrazole derivative 37
DMZJ5FN	MI	TT6OEDT
DMZJ5FN	MN	Cannabinoid receptor 1 (CB1)
DMZJ5FN	MT	DTT
DMZJ5FN	MA	Antagonist
DMZJ5FN	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMZJ5FN	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMPVDSC	DI	DMPVDSC
DMPVDSC	DN	Pyrazole derivative 38
DMPVDSC	MI	TT6OEDT
DMPVDSC	MN	Cannabinoid receptor 1 (CB1)
DMPVDSC	MT	DTT
DMPVDSC	MA	Antagonist
DMPVDSC	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMPVDSC	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMMGWKE	DI	DMMGWKE
DMMGWKE	DN	Pyrazole derivative 39
DMMGWKE	MI	TT6OEDT
DMMGWKE	MN	Cannabinoid receptor 1 (CB1)
DMMGWKE	MT	DTT
DMMGWKE	MA	Antagonist
DMMGWKE	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMMGWKE	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DM2DK1E	DI	DM2DK1E
DM2DK1E	DN	Pyrazole derivative 4
DM2DK1E	MI	TT6OEDT
DM2DK1E	MN	Cannabinoid receptor 1 (CB1)
DM2DK1E	MT	DTT
DM2DK1E	MA	Antagonist
DM2DK1E	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DM2DK1E	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DM7CMV6	DI	DM7CMV6
DM7CMV6	DN	Pyrazole derivative 40
DM7CMV6	MI	TT6OEDT
DM7CMV6	MN	Cannabinoid receptor 1 (CB1)
DM7CMV6	MT	DTT
DM7CMV6	MA	Antagonist
DM7CMV6	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DM7CMV6	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMDGSKH	DI	DMDGSKH
DMDGSKH	DN	Pyrazole derivative 5
DMDGSKH	MI	TT6OEDT
DMDGSKH	MN	Cannabinoid receptor 1 (CB1)
DMDGSKH	MT	DTT
DMDGSKH	MA	Antagonist
DMDGSKH	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMDGSKH	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMMIOZ5	DI	DMMIOZ5
DMMIOZ5	DN	Pyrazole derivative 53
DMMIOZ5	MI	TT6OEDT
DMMIOZ5	MN	Cannabinoid receptor 1 (CB1)
DMMIOZ5	MT	DTT
DMMIOZ5	MA	Antagonist
DMMIOZ5	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMMIOZ5	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DM9PNTF	DI	DM9PNTF
DM9PNTF	DN	Pyrazole derivative 54
DM9PNTF	MI	TT6OEDT
DM9PNTF	MN	Cannabinoid receptor 1 (CB1)
DM9PNTF	MT	DTT
DM9PNTF	MA	Antagonist
DM9PNTF	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DM9PNTF	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMZ3J78	DI	DMZ3J78
DMZ3J78	DN	Pyrazole derivative 57
DMZ3J78	MI	TT6OEDT
DMZ3J78	MN	Cannabinoid receptor 1 (CB1)
DMZ3J78	MT	DTT
DMZ3J78	MA	Antagonist
DMZ3J78	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMZ3J78	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMZIOW0	DI	DMZIOW0
DMZIOW0	DN	Pyrazole derivative 58
DMZIOW0	MI	TT6OEDT
DMZIOW0	MN	Cannabinoid receptor 1 (CB1)
DMZIOW0	MT	DTT
DMZIOW0	MA	Antagonist
DMZIOW0	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMZIOW0	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMXZC8K	DI	DMXZC8K
DMXZC8K	DN	Pyrazole derivative 59
DMXZC8K	MI	TT6OEDT
DMXZC8K	MN	Cannabinoid receptor 1 (CB1)
DMXZC8K	MT	DTT
DMXZC8K	MA	Antagonist
DMXZC8K	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMXZC8K	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMIDN6T	DI	DMIDN6T
DMIDN6T	DN	Pyrazole derivative 6
DMIDN6T	MI	TT6OEDT
DMIDN6T	MN	Cannabinoid receptor 1 (CB1)
DMIDN6T	MT	DTT
DMIDN6T	MA	Antagonist
DMIDN6T	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMIDN6T	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMQ08BM	DI	DMQ08BM
DMQ08BM	DN	Pyrazole derivative 60
DMQ08BM	MI	TT6OEDT
DMQ08BM	MN	Cannabinoid receptor 1 (CB1)
DMQ08BM	MT	DTT
DMQ08BM	MA	Antagonist
DMQ08BM	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMQ08BM	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMO6M1Q	DI	DMO6M1Q
DMO6M1Q	DN	Pyrazole derivative 61
DMO6M1Q	MI	TTCZOF2
DMO6M1Q	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMO6M1Q	MT	DTT
DMO6M1Q	MA	Inhibitor
DMO6M1Q	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMO6M1Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMN53R0	DI	DMN53R0
DMN53R0	DN	Pyrazole derivative 62
DMN53R0	MI	TTH8FZW
DMN53R0	MN	Signal transducer and activator of transcription 3 (STAT3)
DMN53R0	MT	DTT
DMN53R0	MA	Inhibitor
DMN53R0	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMN53R0	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMTVAJ0	DI	DMTVAJ0
DMTVAJ0	DN	Pyrazole derivative 63
DMTVAJ0	MI	TTH8FZW
DMTVAJ0	MN	Signal transducer and activator of transcription 3 (STAT3)
DMTVAJ0	MT	DTT
DMTVAJ0	MA	Inhibitor
DMTVAJ0	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMTVAJ0	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMXAURE	DI	DMXAURE
DMXAURE	DN	Pyrazole derivative 64
DMXAURE	MI	TTH8FZW
DMXAURE	MN	Signal transducer and activator of transcription 3 (STAT3)
DMXAURE	MT	DTT
DMXAURE	MA	Inhibitor
DMXAURE	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMXAURE	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMYTLRJ	DI	DMYTLRJ
DMYTLRJ	DN	Pyrazole derivative 65
DMYTLRJ	MI	TTH8FZW
DMYTLRJ	MN	Signal transducer and activator of transcription 3 (STAT3)
DMYTLRJ	MT	DTT
DMYTLRJ	MA	Inhibitor
DMYTLRJ	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMYTLRJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMBYWJI	DI	DMBYWJI
DMBYWJI	DN	Pyrazole derivative 66
DMBYWJI	MI	TTH8FZW
DMBYWJI	MN	Signal transducer and activator of transcription 3 (STAT3)
DMBYWJI	MT	DTT
DMBYWJI	MA	Inhibitor
DMBYWJI	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMBYWJI	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMNZUHX	DI	DMNZUHX
DMNZUHX	DN	Pyrazole derivative 67
DMNZUHX	MI	TTJQOD7
DMNZUHX	MN	5-HT 2A receptor (HTR2A)
DMNZUHX	MT	DTT
DMNZUHX	MA	Antagonist
DMNZUHX	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMNZUHX	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMVY0JT	DI	DMVY0JT
DMVY0JT	DN	Pyrazole derivative 68
DMVY0JT	MI	TTJQOD7
DMVY0JT	MN	5-HT 2A receptor (HTR2A)
DMVY0JT	MT	DTT
DMVY0JT	MA	Antagonist
DMVY0JT	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMVY0JT	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMKCJE1	DI	DMKCJE1
DMKCJE1	DN	Pyrazole derivative 69
DMKCJE1	MI	TTJQOD7
DMKCJE1	MN	5-HT 2A receptor (HTR2A)
DMKCJE1	MT	DTT
DMKCJE1	MA	Antagonist
DMKCJE1	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMKCJE1	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMYKU0T	DI	DMYKU0T
DMYKU0T	DN	Pyrazole derivative 7
DMYKU0T	MI	TT6OEDT
DMYKU0T	MN	Cannabinoid receptor 1 (CB1)
DMYKU0T	MT	DTT
DMYKU0T	MA	Antagonist
DMYKU0T	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMYKU0T	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMR6VIG	DI	DMR6VIG
DMR6VIG	DN	Pyrazole derivative 70
DMR6VIG	MI	TTJQOD7
DMR6VIG	MN	5-HT 2A receptor (HTR2A)
DMR6VIG	MT	DTT
DMR6VIG	MA	Antagonist
DMR6VIG	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMR6VIG	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMSNY3W	DI	DMSNY3W
DMSNY3W	DN	Pyrazole derivative 71
DMSNY3W	MI	TTJQOD7
DMSNY3W	MN	5-HT 2A receptor (HTR2A)
DMSNY3W	MT	DTT
DMSNY3W	MA	Antagonist
DMSNY3W	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMSNY3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMWFTCN	DI	DMWFTCN
DMWFTCN	DN	Pyrazole derivative 72
DMWFTCN	MI	TTJQOD7
DMWFTCN	MN	5-HT 2A receptor (HTR2A)
DMWFTCN	MT	DTT
DMWFTCN	MA	Antagonist
DMWFTCN	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMWFTCN	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMFARIK	DI	DMFARIK
DMFARIK	DN	Pyrazole derivative 73
DMFARIK	MI	TTJQOD7
DMFARIK	MN	5-HT 2A receptor (HTR2A)
DMFARIK	MT	DTT
DMFARIK	MA	Antagonist
DMFARIK	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMFARIK	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DM70QPF	DI	DM70QPF
DM70QPF	DN	Pyrazole derivative 74
DM70QPF	MI	TTJQOD7
DM70QPF	MN	5-HT 2A receptor (HTR2A)
DM70QPF	MT	DTT
DM70QPF	MA	Antagonist
DM70QPF	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DM70QPF	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMAB2EN	DI	DMAB2EN
DMAB2EN	DN	Pyrazole derivative 75
DMAB2EN	MI	TTJQOD7
DMAB2EN	MN	5-HT 2A receptor (HTR2A)
DMAB2EN	MT	DTT
DMAB2EN	MA	Antagonist
DMAB2EN	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMAB2EN	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DM6Y27J	DI	DM6Y27J
DM6Y27J	DN	Pyrazole derivative 76
DM6Y27J	MI	TTXJ47W
DM6Y27J	MN	Metabotropic glutamate receptor 2 (mGluR2)
DM6Y27J	MT	DTT
DM6Y27J	MA	Antagonist
DM6Y27J	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DM6Y27J	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DM5E1ZJ	DI	DM5E1ZJ
DM5E1ZJ	DN	Pyrazole derivative 77
DM5E1ZJ	MI	TTXJ47W
DM5E1ZJ	MN	Metabotropic glutamate receptor 2 (mGluR2)
DM5E1ZJ	MT	DTT
DM5E1ZJ	MA	Antagonist
DM5E1ZJ	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DM5E1ZJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DMMCHOW	DI	DMMCHOW
DMMCHOW	DN	Pyrazole derivative 78
DMMCHOW	MI	TTXJ47W
DMMCHOW	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMMCHOW	MT	DTT
DMMCHOW	MA	Antagonist
DMMCHOW	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DMMCHOW	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DM9JHYL	DI	DM9JHYL
DM9JHYL	DN	Pyrazole derivative 79
DM9JHYL	MI	TTXJ47W
DM9JHYL	MN	Metabotropic glutamate receptor 2 (mGluR2)
DM9JHYL	MT	DTT
DM9JHYL	MA	Antagonist
DM9JHYL	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DM9JHYL	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DMMRTAL	DI	DMMRTAL
DMMRTAL	DN	Pyrazole derivative 8
DMMRTAL	MI	TT6OEDT
DMMRTAL	MN	Cannabinoid receptor 1 (CB1)
DMMRTAL	MT	DTT
DMMRTAL	MA	Antagonist
DMMRTAL	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMMRTAL	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMQ3TGM	DI	DMQ3TGM
DMQ3TGM	DN	Pyrazole derivative 80
DMQ3TGM	MI	TTDP1UC
DMQ3TGM	MN	Fatty acid amide hydrolase (FAAH)
DMQ3TGM	MT	DTT
DMQ3TGM	MA	Inhibitor
DMQ3TGM	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMQ3TGM	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMQ3TGM	DI	DMQ3TGM
DMQ3TGM	DN	Pyrazole derivative 80
DMQ3TGM	MI	TTSINOV
DMQ3TGM	MN	Monoacylglycerol lipase ABHD6 (ABHD6)
DMQ3TGM	MT	DTT
DMQ3TGM	MA	Inhibitor
DMQ3TGM	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMQ3TGM	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMQ3TGM	DI	DMQ3TGM
DMQ3TGM	DN	Pyrazole derivative 80
DMQ3TGM	MI	TTZ963I
DMQ3TGM	MN	Monoglyceride lipase (MAGL)
DMQ3TGM	MT	DTT
DMQ3TGM	MA	Inhibitor
DMQ3TGM	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMQ3TGM	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMWT437	DI	DMWT437
DMWT437	DN	Pyrazole derivative 81
DMWT437	MI	TTDP1UC
DMWT437	MN	Fatty acid amide hydrolase (FAAH)
DMWT437	MT	DTT
DMWT437	MA	Inhibitor
DMWT437	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMWT437	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMWT437	DI	DMWT437
DMWT437	DN	Pyrazole derivative 81
DMWT437	MI	TTSINOV
DMWT437	MN	Monoacylglycerol lipase ABHD6 (ABHD6)
DMWT437	MT	DTT
DMWT437	MA	Inhibitor
DMWT437	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMWT437	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMWT437	DI	DMWT437
DMWT437	DN	Pyrazole derivative 81
DMWT437	MI	TTZ963I
DMWT437	MN	Monoglyceride lipase (MAGL)
DMWT437	MT	DTT
DMWT437	MA	Inhibitor
DMWT437	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMWT437	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMETCI3	DI	DMETCI3
DMETCI3	DN	Pyrazole derivative 82
DMETCI3	MI	TTDP1UC
DMETCI3	MN	Fatty acid amide hydrolase (FAAH)
DMETCI3	MT	DTT
DMETCI3	MA	Inhibitor
DMETCI3	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMETCI3	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMETCI3	DI	DMETCI3
DMETCI3	DN	Pyrazole derivative 82
DMETCI3	MI	TTSINOV
DMETCI3	MN	Monoacylglycerol lipase ABHD6 (ABHD6)
DMETCI3	MT	DTT
DMETCI3	MA	Inhibitor
DMETCI3	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMETCI3	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMETCI3	DI	DMETCI3
DMETCI3	DN	Pyrazole derivative 82
DMETCI3	MI	TTZ963I
DMETCI3	MN	Monoglyceride lipase (MAGL)
DMETCI3	MT	DTT
DMETCI3	MA	Inhibitor
DMETCI3	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMETCI3	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMMGLOA	DI	DMMGLOA
DMMGLOA	DN	Pyrazole derivative 83
DMMGLOA	MI	TTDP1UC
DMMGLOA	MN	Fatty acid amide hydrolase (FAAH)
DMMGLOA	MT	DTT
DMMGLOA	MA	Inhibitor
DMMGLOA	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMMGLOA	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMMGLOA	DI	DMMGLOA
DMMGLOA	DN	Pyrazole derivative 83
DMMGLOA	MI	TTZ963I
DMMGLOA	MN	Monoglyceride lipase (MAGL)
DMMGLOA	MT	DTT
DMMGLOA	MA	Inhibitor
DMMGLOA	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMMGLOA	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DME8Q0F	DI	DME8Q0F
DME8Q0F	DN	Pyrazole derivative 84
DME8Q0F	MI	TTDP1UC
DME8Q0F	MN	Fatty acid amide hydrolase (FAAH)
DME8Q0F	MT	DTT
DME8Q0F	MA	Inhibitor
DME8Q0F	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DME8Q0F	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DME8Q0F	DI	DME8Q0F
DME8Q0F	DN	Pyrazole derivative 84
DME8Q0F	MI	TTZ963I
DME8Q0F	MN	Monoglyceride lipase (MAGL)
DME8Q0F	MT	DTT
DME8Q0F	MA	Inhibitor
DME8Q0F	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DME8Q0F	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMNBCKI	DI	DMNBCKI
DMNBCKI	DN	Pyrazole derivative 85
DMNBCKI	MI	TTZ963I
DMNBCKI	MN	Monoglyceride lipase (MAGL)
DMNBCKI	MT	DTT
DMNBCKI	MA	Inhibitor
DMNBCKI	RN	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
DMNBCKI	RU	https://www.ncbi.nlm.nih.gov/pubmed/29053063

DMW3PJV	DI	DMW3PJV
DMW3PJV	DN	Pyrazole derivative 86
DMW3PJV	MI	TT5TPI6
DMW3PJV	MN	Opioid receptor sigma 1 (OPRS1)
DMW3PJV	MT	DTT
DMW3PJV	MA	Inhibitor
DMW3PJV	RN	Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578.
DMW3PJV	RU	https://www.ncbi.nlm.nih.gov/pubmed/28051882

DMGZUAY	DI	DMGZUAY
DMGZUAY	DN	Pyrazole derivative 87
DMGZUAY	MI	TTSCIM2
DMGZUAY	MN	Extracellular lysophospholipase D (E-NPP2)
DMGZUAY	MT	DTT
DMGZUAY	MA	Inhibitor
DMGZUAY	RN	Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829.
DMGZUAY	RU	https://www.ncbi.nlm.nih.gov/pubmed/28447479

DMVX7YT	DI	DMVX7YT
DMVX7YT	DN	Pyrazole N-1 aryl and heteroaryl derivative 1
DMVX7YT	MI	TTKFVXR
DMVX7YT	MN	Renal carcinoma antigen NY-REN-64 (IRAK-4)
DMVX7YT	MT	DTT
DMVX7YT	MA	Inhibitor
DMVX7YT	RN	Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32.
DMVX7YT	RU	https://www.ncbi.nlm.nih.gov/pubmed/27310003

DMVQXZJ	DI	DMVQXZJ
DMVQXZJ	DN	Pyrazole-3-carboxamide derivative 1
DMVQXZJ	MI	TT0K1SC
DMVQXZJ	MN	5-HT 2B receptor (HTR2B)
DMVQXZJ	MT	DTT
DMVQXZJ	MA	Antagonist
DMVQXZJ	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMVQXZJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMGS2ET	DI	DMGS2ET
DMGS2ET	DN	Pyrazoline derivative 1
DMGS2ET	MI	TT6OEDT
DMGS2ET	MN	Cannabinoid receptor 1 (CB1)
DMGS2ET	MT	DTT
DMGS2ET	MA	Antagonist
DMGS2ET	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMGS2ET	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMCZORA	DI	DMCZORA
DMCZORA	DN	Pyrazoline derivative 10
DMCZORA	MI	TT6OEDT
DMCZORA	MN	Cannabinoid receptor 1 (CB1)
DMCZORA	MT	DTT
DMCZORA	MA	Antagonist
DMCZORA	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMCZORA	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMAB3YG	DI	DMAB3YG
DMAB3YG	DN	Pyrazoline derivative 11
DMAB3YG	MI	TT6OEDT
DMAB3YG	MN	Cannabinoid receptor 1 (CB1)
DMAB3YG	MT	DTT
DMAB3YG	MA	Antagonist
DMAB3YG	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMAB3YG	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMOA8E4	DI	DMOA8E4
DMOA8E4	DN	Pyrazoline derivative 2
DMOA8E4	MI	TT6OEDT
DMOA8E4	MN	Cannabinoid receptor 1 (CB1)
DMOA8E4	MT	DTT
DMOA8E4	MA	Antagonist
DMOA8E4	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMOA8E4	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMGH0LQ	DI	DMGH0LQ
DMGH0LQ	DN	Pyrazoline derivative 3
DMGH0LQ	MI	TT6OEDT
DMGH0LQ	MN	Cannabinoid receptor 1 (CB1)
DMGH0LQ	MT	DTT
DMGH0LQ	MA	Antagonist
DMGH0LQ	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMGH0LQ	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMRT7I8	DI	DMRT7I8
DMRT7I8	DN	Pyrazoline derivative 4
DMRT7I8	MI	TT6OEDT
DMRT7I8	MN	Cannabinoid receptor 1 (CB1)
DMRT7I8	MT	DTT
DMRT7I8	MA	Antagonist
DMRT7I8	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMRT7I8	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMEGS9U	DI	DMEGS9U
DMEGS9U	DN	Pyrazoline derivative 5
DMEGS9U	MI	TT6OEDT
DMEGS9U	MN	Cannabinoid receptor 1 (CB1)
DMEGS9U	MT	DTT
DMEGS9U	MA	Antagonist
DMEGS9U	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMEGS9U	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMOK7CW	DI	DMOK7CW
DMOK7CW	DN	Pyrazolo[1,5-a]-1,3,5-triazine derivative 1
DMOK7CW	MI	TTH6V3D
DMOK7CW	MN	Cyclin-dependent kinase 1 (CDK1)
DMOK7CW	MT	DTT
DMOK7CW	MA	Inhibitor
DMOK7CW	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMOK7CW	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMOK7CW	DI	DMOK7CW
DMOK7CW	DN	Pyrazolo[1,5-a]-1,3,5-triazine derivative 1
DMOK7CW	MI	TT7HF4W
DMOK7CW	MN	Cyclin-dependent kinase 2 (CDK2)
DMOK7CW	MT	DTT
DMOK7CW	MA	Inhibitor
DMOK7CW	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMOK7CW	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMOK7CW	DI	DMOK7CW
DMOK7CW	DN	Pyrazolo[1,5-a]-1,3,5-triazine derivative 1
DMOK7CW	MI	TTL4Q97
DMOK7CW	MN	Cyclin-dependent kinase 5 (CDK5)
DMOK7CW	MT	DTT
DMOK7CW	MA	Inhibitor
DMOK7CW	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMOK7CW	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMOK7CW	DI	DMOK7CW
DMOK7CW	DN	Pyrazolo[1,5-a]-1,3,5-triazine derivative 1
DMOK7CW	MI	TT1LVF2
DMOK7CW	MN	Cyclin-dependent kinase 9 (CDK9)
DMOK7CW	MT	DTT
DMOK7CW	MA	Inhibitor
DMOK7CW	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMOK7CW	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMH1W89	DI	DMH1W89
DMH1W89	DN	Pyrazolo[1,5-a]pyridine derivative 1
DMH1W89	MI	TTTDVOJ
DMH1W89	MN	Tropomyosin-related kinase A (TrkA)
DMH1W89	MT	DTT
DMH1W89	MA	Inhibitor
DMH1W89	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMH1W89	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMLS827	DI	DMLS827
DMLS827	DN	Pyrazolo[1,5-a]pyridine derivative 2
DMLS827	MI	TTTDVOJ
DMLS827	MN	Tropomyosin-related kinase A (TrkA)
DMLS827	MT	DTT
DMLS827	MA	Inhibitor
DMLS827	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMLS827	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DM0FPMV	DI	DM0FPMV
DM0FPMV	DN	Pyrazolo[1,5-a]pyrimidine derivative 1
DM0FPMV	MI	TT6OEDT
DM0FPMV	MN	Cannabinoid receptor 1 (CB1)
DM0FPMV	MT	DTT
DM0FPMV	MA	Antagonist
DM0FPMV	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DM0FPMV	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DM07GEK	DI	DM07GEK
DM07GEK	DN	Pyrazolo[1,5-a]pyrimidine derivative 10
DM07GEK	MI	TT6OEDT
DM07GEK	MN	Cannabinoid receptor 1 (CB1)
DM07GEK	MT	DTT
DM07GEK	MA	Antagonist
DM07GEK	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DM07GEK	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DM0O4WR	DI	DM0O4WR
DM0O4WR	DN	Pyrazolo[1,5-a]pyrimidine derivative 11
DM0O4WR	MI	TT6OEDT
DM0O4WR	MN	Cannabinoid receptor 1 (CB1)
DM0O4WR	MT	DTT
DM0O4WR	MA	Antagonist
DM0O4WR	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DM0O4WR	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMMLDUI	DI	DMMLDUI
DMMLDUI	DN	Pyrazolo[1,5-a]pyrimidine derivative 12
DMMLDUI	MI	TT6OEDT
DMMLDUI	MN	Cannabinoid receptor 1 (CB1)
DMMLDUI	MT	DTT
DMMLDUI	MA	Antagonist
DMMLDUI	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMMLDUI	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMR5O7T	DI	DMR5O7T
DMR5O7T	DN	Pyrazolo[1,5-a]pyrimidine derivative 13
DMR5O7T	MI	TT6OEDT
DMR5O7T	MN	Cannabinoid receptor 1 (CB1)
DMR5O7T	MT	DTT
DMR5O7T	MA	Antagonist
DMR5O7T	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMR5O7T	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMB6EFV	DI	DMB6EFV
DMB6EFV	DN	Pyrazolo[1,5-a]pyrimidine derivative 14
DMB6EFV	MI	TTTDVOJ
DMB6EFV	MN	Tropomyosin-related kinase A (TrkA)
DMB6EFV	MT	DTT
DMB6EFV	MA	Inhibitor
DMB6EFV	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMB6EFV	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMAZI3D	DI	DMAZI3D
DMAZI3D	DN	Pyrazolo[1,5-a]pyrimidine derivative 15
DMAZI3D	MI	TTTDVOJ
DMAZI3D	MN	Tropomyosin-related kinase A (TrkA)
DMAZI3D	MT	DTT
DMAZI3D	MA	Inhibitor
DMAZI3D	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMAZI3D	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMTYN2D	DI	DMTYN2D
DMTYN2D	DN	Pyrazolo[1,5-a]pyrimidine derivative 16
DMTYN2D	MI	TTTDVOJ
DMTYN2D	MN	Tropomyosin-related kinase A (TrkA)
DMTYN2D	MT	DTT
DMTYN2D	MA	Inhibitor
DMTYN2D	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMTYN2D	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMNIER3	DI	DMNIER3
DMNIER3	DN	Pyrazolo[1,5-a]pyrimidine derivative 17
DMNIER3	MI	TTTDVOJ
DMNIER3	MN	Tropomyosin-related kinase A (TrkA)
DMNIER3	MT	DTT
DMNIER3	MA	Inhibitor
DMNIER3	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMNIER3	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMVEP6Y	DI	DMVEP6Y
DMVEP6Y	DN	Pyrazolo[1,5-a]pyrimidine derivative 18
DMVEP6Y	MI	TTTDVOJ
DMVEP6Y	MN	Tropomyosin-related kinase A (TrkA)
DMVEP6Y	MT	DTT
DMVEP6Y	MA	Inhibitor
DMVEP6Y	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMVEP6Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMFV36A	DI	DMFV36A
DMFV36A	DN	Pyrazolo[1,5-a]pyrimidine derivative 19
DMFV36A	MI	TTTDVOJ
DMFV36A	MN	Tropomyosin-related kinase A (TrkA)
DMFV36A	MT	DTT
DMFV36A	MA	Inhibitor
DMFV36A	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMFV36A	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMO3MJ7	DI	DMO3MJ7
DMO3MJ7	DN	Pyrazolo[1,5-a]pyrimidine derivative 2
DMO3MJ7	MI	TT6OEDT
DMO3MJ7	MN	Cannabinoid receptor 1 (CB1)
DMO3MJ7	MT	DTT
DMO3MJ7	MA	Antagonist
DMO3MJ7	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMO3MJ7	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMJLU8R	DI	DMJLU8R
DMJLU8R	DN	Pyrazolo[1,5-a]pyrimidine derivative 20
DMJLU8R	MI	TTTDVOJ
DMJLU8R	MN	Tropomyosin-related kinase A (TrkA)
DMJLU8R	MT	DTT
DMJLU8R	MA	Inhibitor
DMJLU8R	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMJLU8R	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMWNZTI	DI	DMWNZTI
DMWNZTI	DN	Pyrazolo[1,5-a]pyrimidine derivative 21
DMWNZTI	MI	TTTDVOJ
DMWNZTI	MN	Tropomyosin-related kinase A (TrkA)
DMWNZTI	MT	DTT
DMWNZTI	MA	Inhibitor
DMWNZTI	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMWNZTI	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMG5CXB	DI	DMG5CXB
DMG5CXB	DN	Pyrazolo[1,5-a]pyrimidine derivative 22
DMG5CXB	MI	TTTDVOJ
DMG5CXB	MN	Tropomyosin-related kinase A (TrkA)
DMG5CXB	MT	DTT
DMG5CXB	MA	Inhibitor
DMG5CXB	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMG5CXB	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMQVLP8	DI	DMQVLP8
DMQVLP8	DN	Pyrazolo[1,5-a]pyrimidine derivative 23
DMQVLP8	MI	TTTDVOJ
DMQVLP8	MN	Tropomyosin-related kinase A (TrkA)
DMQVLP8	MT	DTT
DMQVLP8	MA	Inhibitor
DMQVLP8	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMQVLP8	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMT4ZP9	DI	DMT4ZP9
DMT4ZP9	DN	Pyrazolo[1,5-a]pyrimidine derivative 24
DMT4ZP9	MI	TTTDVOJ
DMT4ZP9	MN	Tropomyosin-related kinase A (TrkA)
DMT4ZP9	MT	DTT
DMT4ZP9	MA	Inhibitor
DMT4ZP9	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMT4ZP9	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMKE7YO	DI	DMKE7YO
DMKE7YO	DN	Pyrazolo[1,5-a]pyrimidine derivative 25
DMKE7YO	MI	TTTDVOJ
DMKE7YO	MN	Tropomyosin-related kinase A (TrkA)
DMKE7YO	MT	DTT
DMKE7YO	MA	Inhibitor
DMKE7YO	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMKE7YO	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMGZ59Q	DI	DMGZ59Q
DMGZ59Q	DN	Pyrazolo[1,5-a]pyrimidine derivative 26
DMGZ59Q	MI	TTTDVOJ
DMGZ59Q	MN	Tropomyosin-related kinase A (TrkA)
DMGZ59Q	MT	DTT
DMGZ59Q	MA	Inhibitor
DMGZ59Q	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMGZ59Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DM9OXAB	DI	DM9OXAB
DM9OXAB	DN	Pyrazolo[1,5-a]pyrimidine derivative 27
DM9OXAB	MI	TTTDVOJ
DM9OXAB	MN	Tropomyosin-related kinase A (TrkA)
DM9OXAB	MT	DTT
DM9OXAB	MA	Inhibitor
DM9OXAB	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DM9OXAB	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMG1RNL	DI	DMG1RNL
DMG1RNL	DN	Pyrazolo[1,5-a]pyrimidine derivative 28
DMG1RNL	MI	TTF8P9I
DMG1RNL	MN	Diacylglycerol acyltransferase 1 (DGAT1)
DMG1RNL	MT	DTT
DMG1RNL	MA	Inhibitor
DMG1RNL	RN	Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
DMG1RNL	RU	https://www.ncbi.nlm.nih.gov/pubmed/25470667

DMCT6QW	DI	DMCT6QW
DMCT6QW	DN	Pyrazolo[1,5-a]pyrimidine derivative 29
DMCT6QW	MI	TTF8P9I
DMCT6QW	MN	Diacylglycerol acyltransferase 1 (DGAT1)
DMCT6QW	MT	DTT
DMCT6QW	MA	Inhibitor
DMCT6QW	RN	Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
DMCT6QW	RU	https://www.ncbi.nlm.nih.gov/pubmed/25470667

DMHTV47	DI	DMHTV47
DMHTV47	DN	Pyrazolo[1,5-a]pyrimidine derivative 3
DMHTV47	MI	TT6OEDT
DMHTV47	MN	Cannabinoid receptor 1 (CB1)
DMHTV47	MT	DTT
DMHTV47	MA	Antagonist
DMHTV47	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMHTV47	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMCAVF0	DI	DMCAVF0
DMCAVF0	DN	Pyrazolo[1,5-a]pyrimidine derivative 4
DMCAVF0	MI	TT6OEDT
DMCAVF0	MN	Cannabinoid receptor 1 (CB1)
DMCAVF0	MT	DTT
DMCAVF0	MA	Antagonist
DMCAVF0	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMCAVF0	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DM3UBG2	DI	DM3UBG2
DM3UBG2	DN	Pyrazolo[1,5-a]pyrimidine derivative 5
DM3UBG2	MI	TT6OEDT
DM3UBG2	MN	Cannabinoid receptor 1 (CB1)
DM3UBG2	MT	DTT
DM3UBG2	MA	Antagonist
DM3UBG2	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DM3UBG2	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DM5E1KS	DI	DM5E1KS
DM5E1KS	DN	Pyrazolo[1,5-a]pyrimidine derivative 6
DM5E1KS	MI	TT6OEDT
DM5E1KS	MN	Cannabinoid receptor 1 (CB1)
DM5E1KS	MT	DTT
DM5E1KS	MA	Antagonist
DM5E1KS	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DM5E1KS	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMFUSPR	DI	DMFUSPR
DMFUSPR	DN	Pyrazolo[1,5-a]pyrimidine derivative 7
DMFUSPR	MI	TT6OEDT
DMFUSPR	MN	Cannabinoid receptor 1 (CB1)
DMFUSPR	MT	DTT
DMFUSPR	MA	Antagonist
DMFUSPR	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMFUSPR	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMTQNYZ	DI	DMTQNYZ
DMTQNYZ	DN	Pyrazolo[1,5-a]pyrimidine derivative 8
DMTQNYZ	MI	TT6OEDT
DMTQNYZ	MN	Cannabinoid receptor 1 (CB1)
DMTQNYZ	MT	DTT
DMTQNYZ	MA	Antagonist
DMTQNYZ	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMTQNYZ	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMXAW2S	DI	DMXAW2S
DMXAW2S	DN	Pyrazolo[1,5-a]pyrimidine derivative 9
DMXAW2S	MI	TT6OEDT
DMXAW2S	MN	Cannabinoid receptor 1 (CB1)
DMXAW2S	MT	DTT
DMXAW2S	MA	Antagonist
DMXAW2S	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMXAW2S	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMQHCDZ	DI	DMQHCDZ
DMQHCDZ	DN	Pyrazolo[3,4-c]pyridine derivative 1
DMQHCDZ	MI	TTSCIM2
DMQHCDZ	MN	Extracellular lysophospholipase D (E-NPP2)
DMQHCDZ	MT	DTT
DMQHCDZ	MA	Inhibitor
DMQHCDZ	RN	Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829.
DMQHCDZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28447479

DMT57C4	DI	DMT57C4
DMT57C4	DN	Pyrazolo[3,4-d]pyrimidine derivative 1
DMT57C4	MI	TTJGW1Z
DMT57C4	MN	Phosphodiesterase 2A (PDE2A)
DMT57C4	MT	DTT
DMT57C4	MA	Inhibitor
DMT57C4	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMT57C4	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMO054V	DI	DMO054V
DMO054V	DN	Pyrazolo[3,4-d]pyrimidine derivative 2
DMO054V	MI	TTJGW1Z
DMO054V	MN	Phosphodiesterase 2A (PDE2A)
DMO054V	MT	DTT
DMO054V	MA	Inhibitor
DMO054V	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMO054V	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMRKVP9	DI	DMRKVP9
DMRKVP9	DN	Pyrazolo[3,4-d]pyrimidine derivative 3
DMRKVP9	MI	TTJGW1Z
DMRKVP9	MN	Phosphodiesterase 2A (PDE2A)
DMRKVP9	MT	DTT
DMRKVP9	MA	Inhibitor
DMRKVP9	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMRKVP9	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMGFAS6	DI	DMGFAS6
DMGFAS6	DN	Pyrazolo[3,4-d]pyrimidine derivative 4
DMGFAS6	MI	TTJGW1Z
DMGFAS6	MN	Phosphodiesterase 2A (PDE2A)
DMGFAS6	MT	DTT
DMGFAS6	MA	Inhibitor
DMGFAS6	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMGFAS6	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMIH0F4	DI	DMIH0F4
DMIH0F4	DN	Pyrazolo[3,4-d]pyrimidine derivative 5
DMIH0F4	MI	TT4DXQT
DMIH0F4	MN	Proto-oncogene c-Ret (RET)
DMIH0F4	MT	DTT
DMIH0F4	MA	Inhibitor
DMIH0F4	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMIH0F4	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMCTWVY	DI	DMCTWVY
DMCTWVY	DN	Pyrazolo[3,4-d]pyrimidine derivative 6
DMCTWVY	MI	TT4DXQT
DMCTWVY	MN	Proto-oncogene c-Ret (RET)
DMCTWVY	MT	DTT
DMCTWVY	MA	Inhibitor
DMCTWVY	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMCTWVY	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DM4GF58	DI	DM4GF58
DM4GF58	DN	Pyrazolo[3,4-d]pyrimidine derivative 7
DM4GF58	MI	TT4DXQT
DM4GF58	MN	Proto-oncogene c-Ret (RET)
DM4GF58	MT	DTT
DM4GF58	MA	Inhibitor
DM4GF58	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DM4GF58	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DM89GKE	DI	DM89GKE
DM89GKE	DN	Pyrazolo[3,4-d]pyrimidine derivative 8
DM89GKE	MI	TT4DXQT
DM89GKE	MN	Proto-oncogene c-Ret (RET)
DM89GKE	MT	DTT
DM89GKE	MA	Inhibitor
DM89GKE	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DM89GKE	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMHRUIZ	DI	DMHRUIZ
DMHRUIZ	DN	Pyrazolo[4,3-c]pyridine derivative 1
DMHRUIZ	MI	TTTDVOJ
DMHRUIZ	MN	Tropomyosin-related kinase A (TrkA)
DMHRUIZ	MT	DTT
DMHRUIZ	MA	Inhibitor
DMHRUIZ	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMHRUIZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMCDFLQ	DI	DMCDFLQ
DMCDFLQ	DN	Pyrazolo[4,3-c]pyridine derivative 2
DMCDFLQ	MI	TTNDSC3
DMCDFLQ	MN	B lymphocyte kinase (BLK)
DMCDFLQ	MT	DTT
DMCDFLQ	MA	Inhibitor
DMCDFLQ	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMCDFLQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMCDFLQ	DI	DMCDFLQ
DMCDFLQ	DN	Pyrazolo[4,3-c]pyridine derivative 2
DMCDFLQ	MI	TT6DM01
DMCDFLQ	MN	Janus kinase 1 (JAK-1)
DMCDFLQ	MT	DTT
DMCDFLQ	MA	Inhibitor
DMCDFLQ	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMCDFLQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMCDFLQ	DI	DMCDFLQ
DMCDFLQ	DN	Pyrazolo[4,3-c]pyridine derivative 2
DMCDFLQ	MI	TTRMX3V
DMCDFLQ	MN	Janus kinase 2 (JAK-2)
DMCDFLQ	MT	DTT
DMCDFLQ	MA	Inhibitor
DMCDFLQ	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMCDFLQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMCDFLQ	DI	DMCDFLQ
DMCDFLQ	DN	Pyrazolo[4,3-c]pyridine derivative 2
DMCDFLQ	MI	TTT7PJU
DMCDFLQ	MN	Janus kinase 3 (JAK-3)
DMCDFLQ	MT	DTT
DMCDFLQ	MA	Inhibitor
DMCDFLQ	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMCDFLQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMCDFLQ	DI	DMCDFLQ
DMCDFLQ	DN	Pyrazolo[4,3-c]pyridine derivative 2
DMCDFLQ	MI	TT3C80U
DMCDFLQ	MN	T-cell-specific kinase (ITK)
DMCDFLQ	MT	DTT
DMCDFLQ	MA	Inhibitor
DMCDFLQ	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMCDFLQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMCDFLQ	DI	DMCDFLQ
DMCDFLQ	DN	Pyrazolo[4,3-c]pyridine derivative 2
DMCDFLQ	MI	TTBYWP2
DMCDFLQ	MN	TYK2 tyrosine kinase (TYK2)
DMCDFLQ	MT	DTT
DMCDFLQ	MA	Inhibitor
DMCDFLQ	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMCDFLQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMCDFLQ	DI	DMCDFLQ
DMCDFLQ	DN	Pyrazolo[4,3-c]pyridine derivative 2
DMCDFLQ	MI	TTGM6VW
DMCDFLQ	MN	Tyrosine-protein kinase BTK (ATK)
DMCDFLQ	MT	DTT
DMCDFLQ	MA	Inhibitor
DMCDFLQ	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMCDFLQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMCDFLQ	DI	DMCDFLQ
DMCDFLQ	DN	Pyrazolo[4,3-c]pyridine derivative 2
DMCDFLQ	MI	TT1ZV49
DMCDFLQ	MN	Tyrosine-protein kinase Tec (PSCTK4)
DMCDFLQ	MT	DTT
DMCDFLQ	MA	Inhibitor
DMCDFLQ	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMCDFLQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMTM82B	DI	DMTM82B
DMTM82B	DN	Pyrazolo[4,3-h]quinazoline-3-carboxamide derivative 1
DMTM82B	MI	TTTDVOJ
DMTM82B	MN	Tropomyosin-related kinase A (TrkA)
DMTM82B	MT	DTT
DMTM82B	MA	Inhibitor
DMTM82B	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMTM82B	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMRN2QI	DI	DMRN2QI
DMRN2QI	DN	Pyrazolodiazepine derivative 1
DMRN2QI	MI	TT2F4OL
DMRN2QI	MN	Tissue transglutaminase (TG2)
DMRN2QI	MT	DTT
DMRN2QI	MA	Inhibitor
DMRN2QI	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DMRN2QI	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DMKYX7J	DI	DMKYX7J
DMKYX7J	DN	Pyrazolodihydropyridine derivative 1
DMKYX7J	MI	TTRZQE3
DMKYX7J	MN	Glycogen synthase kinase-3 alpha (GSK-3A)
DMKYX7J	MT	DTT
DMKYX7J	MA	Inhibitor
DMKYX7J	RN	Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
DMKYX7J	RU	https://www.ncbi.nlm.nih.gov/pubmed/27828716

DMY03RZ	DI	DMY03RZ
DMY03RZ	DN	Pyrazolopyridine derivative 1
DMY03RZ	MI	TTT7PJU
DMY03RZ	MN	Janus kinase 3 (JAK-3)
DMY03RZ	MT	DTT
DMY03RZ	MA	Inhibitor
DMY03RZ	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMY03RZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMCJVLR	DI	DMCJVLR
DMCJVLR	DN	Pyrazolopyridine derivative 2
DMCJVLR	MI	TTT7PJU
DMCJVLR	MN	Janus kinase 3 (JAK-3)
DMCJVLR	MT	DTT
DMCJVLR	MA	Inhibitor
DMCJVLR	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMCJVLR	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DM2VQ4P	DI	DM2VQ4P
DM2VQ4P	DN	Pyrazolopyridine derivative 3
DM2VQ4P	MI	TT6DM01
DM2VQ4P	MN	Janus kinase 1 (JAK-1)
DM2VQ4P	MT	DTT
DM2VQ4P	MA	Inhibitor
DM2VQ4P	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DM2VQ4P	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DM2VQ4P	DI	DM2VQ4P
DM2VQ4P	DN	Pyrazolopyridine derivative 3
DM2VQ4P	MI	TTRMX3V
DM2VQ4P	MN	Janus kinase 2 (JAK-2)
DM2VQ4P	MT	DTT
DM2VQ4P	MA	Inhibitor
DM2VQ4P	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DM2VQ4P	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DM2VQ4P	DI	DM2VQ4P
DM2VQ4P	DN	Pyrazolopyridine derivative 3
DM2VQ4P	MI	TTT7PJU
DM2VQ4P	MN	Janus kinase 3 (JAK-3)
DM2VQ4P	MT	DTT
DM2VQ4P	MA	Inhibitor
DM2VQ4P	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DM2VQ4P	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DM2VQ4P	DI	DM2VQ4P
DM2VQ4P	DN	Pyrazolopyridine derivative 3
DM2VQ4P	MI	TTBYWP2
DM2VQ4P	MN	TYK2 tyrosine kinase (TYK2)
DM2VQ4P	MT	DTT
DM2VQ4P	MA	Inhibitor
DM2VQ4P	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DM2VQ4P	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMX7RWV	DI	DMX7RWV
DMX7RWV	DN	Pyrazolopyridine derivative 4
DMX7RWV	MI	TT6DM01
DMX7RWV	MN	Janus kinase 1 (JAK-1)
DMX7RWV	MT	DTT
DMX7RWV	MA	Inhibitor
DMX7RWV	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMX7RWV	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMX7RWV	DI	DMX7RWV
DMX7RWV	DN	Pyrazolopyridine derivative 4
DMX7RWV	MI	TTRMX3V
DMX7RWV	MN	Janus kinase 2 (JAK-2)
DMX7RWV	MT	DTT
DMX7RWV	MA	Inhibitor
DMX7RWV	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMX7RWV	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMX7RWV	DI	DMX7RWV
DMX7RWV	DN	Pyrazolopyridine derivative 4
DMX7RWV	MI	TTT7PJU
DMX7RWV	MN	Janus kinase 3 (JAK-3)
DMX7RWV	MT	DTT
DMX7RWV	MA	Inhibitor
DMX7RWV	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMX7RWV	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMTZCLG	DI	DMTZCLG
DMTZCLG	DN	Pyrazolopyridine derivative 5
DMTZCLG	MI	TTBYWP2
DMTZCLG	MN	TYK2 tyrosine kinase (TYK2)
DMTZCLG	MT	DTT
DMTZCLG	MA	Inhibitor
DMTZCLG	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMTZCLG	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DM5OH8D	DI	DM5OH8D
DM5OH8D	DN	Pyrazolopyridine derivative 6
DM5OH8D	MI	TTRMX3V
DM5OH8D	MN	Janus kinase 2 (JAK-2)
DM5OH8D	MT	DTT
DM5OH8D	MA	Inhibitor
DM5OH8D	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DM5OH8D	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DM5OH8D	DI	DM5OH8D
DM5OH8D	DN	Pyrazolopyridine derivative 6
DM5OH8D	MI	TTT7PJU
DM5OH8D	MN	Janus kinase 3 (JAK-3)
DM5OH8D	MT	DTT
DM5OH8D	MA	Inhibitor
DM5OH8D	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DM5OH8D	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMCTQ9O	DI	DMCTQ9O
DMCTQ9O	DN	Pyrazolopyridine derivative 7
DMCTQ9O	MI	TTRMX3V
DMCTQ9O	MN	Janus kinase 2 (JAK-2)
DMCTQ9O	MT	DTT
DMCTQ9O	MA	Inhibitor
DMCTQ9O	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMCTQ9O	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMCTQ9O	DI	DMCTQ9O
DMCTQ9O	DN	Pyrazolopyridine derivative 7
DMCTQ9O	MI	TTT7PJU
DMCTQ9O	MN	Janus kinase 3 (JAK-3)
DMCTQ9O	MT	DTT
DMCTQ9O	MA	Inhibitor
DMCTQ9O	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMCTQ9O	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMSR5FO	DI	DMSR5FO
DMSR5FO	DN	Pyrazolopyridines and imidazopyridine derivative 1
DMSR5FO	MI	TTCZOF2
DMSR5FO	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMSR5FO	MT	DTT
DMSR5FO	MA	Inhibitor
DMSR5FO	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMSR5FO	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMRAS8L	DI	DMRAS8L
DMRAS8L	DN	Pyrazolopyrimidine acetamide analog 1
DMRAS8L	MI	TTPTXIN
DMRAS8L	MN	Translocator protein (TSPO)
DMRAS8L	MT	DTT
DMRAS8L	MA	Ligand
DMRAS8L	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMRAS8L	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMK7F3A	DI	DMK7F3A
DMK7F3A	DN	Pyrazolopyrimidine acetamide analog 2
DMK7F3A	MI	TTPTXIN
DMK7F3A	MN	Translocator protein (TSPO)
DMK7F3A	MT	DTT
DMK7F3A	MA	Ligand
DMK7F3A	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMK7F3A	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DM6TB4Z	DI	DM6TB4Z
DM6TB4Z	DN	Pyrazolopyrimidine and thienopyrimidine amide derivative 1
DM6TB4Z	MI	TTXAJWN
DM6TB4Z	MN	IL-1 receptor-associated kinase 1 (IRAK1)
DM6TB4Z	MT	DTT
DM6TB4Z	MA	Inhibitor
DM6TB4Z	RN	Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32.
DM6TB4Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/27310003

DM6TB4Z	DI	DM6TB4Z
DM6TB4Z	DN	Pyrazolopyrimidine and thienopyrimidine amide derivative 1
DM6TB4Z	MI	TTKFVXR
DM6TB4Z	MN	Renal carcinoma antigen NY-REN-64 (IRAK-4)
DM6TB4Z	MT	DTT
DM6TB4Z	MA	Inhibitor
DM6TB4Z	RN	Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32.
DM6TB4Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/27310003

DMFUNH4	DI	DMFUNH4
DMFUNH4	DN	Pyrazolopyrimidine and thienopyrimidine amide derivative 2
DMFUNH4	MI	TTXAJWN
DMFUNH4	MN	IL-1 receptor-associated kinase 1 (IRAK1)
DMFUNH4	MT	DTT
DMFUNH4	MA	Inhibitor
DMFUNH4	RN	Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32.
DMFUNH4	RU	https://www.ncbi.nlm.nih.gov/pubmed/27310003

DMFUNH4	DI	DMFUNH4
DMFUNH4	DN	Pyrazolopyrimidine and thienopyrimidine amide derivative 2
DMFUNH4	MI	TTKFVXR
DMFUNH4	MN	Renal carcinoma antigen NY-REN-64 (IRAK-4)
DMFUNH4	MT	DTT
DMFUNH4	MA	Inhibitor
DMFUNH4	RN	Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32.
DMFUNH4	RU	https://www.ncbi.nlm.nih.gov/pubmed/27310003

DMHO3NB	DI	DMHO3NB
DMHO3NB	DN	Pyrazolopyrimidine derivative 1
DMHO3NB	MI	TTHS256
DMHO3NB	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMHO3NB	MT	DTT
DMHO3NB	MA	Modulator
DMHO3NB	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMHO3NB	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMZEP5X	DI	DMZEP5X
DMZEP5X	DN	Pyrazolopyrimidine derivative 2
DMZEP5X	MI	TTHS256
DMZEP5X	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMZEP5X	MT	DTT
DMZEP5X	MA	Modulator
DMZEP5X	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMZEP5X	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMI0J7D	DI	DMI0J7D
DMI0J7D	DN	Pyrazolopyrimidine derivative 3
DMI0J7D	MI	TTHS256
DMI0J7D	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMI0J7D	MT	DTT
DMI0J7D	MA	Modulator
DMI0J7D	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMI0J7D	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DM7XSHK	DI	DM7XSHK
DM7XSHK	DN	Pyrazolopyrimidine derivative 4
DM7XSHK	MI	TTHS256
DM7XSHK	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM7XSHK	MT	DTT
DM7XSHK	MA	Modulator
DM7XSHK	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DM7XSHK	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMVUSF3	DI	DMVUSF3
DMVUSF3	DN	Pyrazolopyrimidine derivative 5
DMVUSF3	MI	TTHS256
DMVUSF3	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMVUSF3	MT	DTT
DMVUSF3	MA	Modulator
DMVUSF3	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMVUSF3	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMG8V31	DI	DMG8V31
DMG8V31	DN	Pyrazolopyrimidine derivative 6
DMG8V31	MI	TTHS256
DMG8V31	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMG8V31	MT	DTT
DMG8V31	MA	Modulator
DMG8V31	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMG8V31	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMTD3C1	DI	DMTD3C1
DMTD3C1	DN	Pyrazolo-triazine derivative 1
DMTD3C1	MI	TTQYF7G
DMTD3C1	MN	Cyclin-dependent kinase 7 (CDK7)
DMTD3C1	MT	DTT
DMTD3C1	MA	Inhibitor
DMTD3C1	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMTD3C1	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DML6V78	DI	DML6V78
DML6V78	DN	Pyrazolo-triazine derivative 2
DML6V78	MI	TT7HF4W
DML6V78	MN	Cyclin-dependent kinase 2 (CDK2)
DML6V78	MT	DTT
DML6V78	MA	Inhibitor
DML6V78	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DML6V78	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DML6V78	DI	DML6V78
DML6V78	DN	Pyrazolo-triazine derivative 2
DML6V78	MI	TTQYF7G
DML6V78	MN	Cyclin-dependent kinase 7 (CDK7)
DML6V78	MT	DTT
DML6V78	MA	Inhibitor
DML6V78	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DML6V78	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMKJ3PC	DI	DMKJ3PC
DMKJ3PC	DN	Pyridazin-3(2H)-one derivative 1
DMKJ3PC	MI	TT9JNIC
DMKJ3PC	MN	Histamine H3 receptor (H3R)
DMKJ3PC	MT	DTT
DMKJ3PC	MA	Inverse agonist
DMKJ3PC	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DMKJ3PC	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DMF7MEB	DI	DMF7MEB
DMF7MEB	DN	Pyridazinone derivative 1
DMF7MEB	MI	TT473XN
DMF7MEB	MN	P2X purinoceptor 7 (P2RX7)
DMF7MEB	MT	DTT
DMF7MEB	MA	Antagonist
DMF7MEB	RN	P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267.
DMF7MEB	RU	https://www.ncbi.nlm.nih.gov/pubmed/27724045

DM3GU7K	DI	DM3GU7K
DM3GU7K	DN	Pyridic ketone derivative 1
DM3GU7K	MI	TTIDAPM
DM3GU7K	MN	ERK activator kinase 1 (MEK1)
DM3GU7K	MT	DTT
DM3GU7K	MA	Inhibitor
DM3GU7K	RN	MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906.
DM3GU7K	RU	https://www.ncbi.nlm.nih.gov/pubmed/28594589

DM3GU7K	DI	DM3GU7K
DM3GU7K	DN	Pyridic ketone derivative 1
DM3GU7K	MI	TTTW2NY
DM3GU7K	MN	ERK activator kinase 2 (MEK2)
DM3GU7K	MT	DTT
DM3GU7K	MA	Inhibitor
DM3GU7K	RN	MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906.
DM3GU7K	RU	https://www.ncbi.nlm.nih.gov/pubmed/28594589

DMGEYJW	DI	DMGEYJW
DMGEYJW	DN	Pyridine and pyrimidine derivative 1
DMGEYJW	MI	TTSCIM2
DMGEYJW	MN	Extracellular lysophospholipase D (E-NPP2)
DMGEYJW	MT	DTT
DMGEYJW	MA	Inhibitor
DMGEYJW	RN	Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829.
DMGEYJW	RU	https://www.ncbi.nlm.nih.gov/pubmed/28447479

DMSGF8T	DI	DMSGF8T
DMSGF8T	DN	Pyridine derivative 1
DMSGF8T	MI	TTZJYKH
DMSGF8T	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMSGF8T	MT	DTT
DMSGF8T	MA	Inhibitor
DMSGF8T	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMSGF8T	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMVL2G3	DI	DMVL2G3
DMVL2G3	DN	Pyridine derivative 10
DMVL2G3	MI	TTOHSBA
DMVL2G3	MN	Vascular endothelial growth factor A (VEGFA)
DMVL2G3	MT	DTT
DMVL2G3	MA	Inhibitor
DMVL2G3	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMVL2G3	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMF9VMW	DI	DMF9VMW
DMF9VMW	DN	Pyridine derivative 11
DMF9VMW	MI	TTOHSBA
DMF9VMW	MN	Vascular endothelial growth factor A (VEGFA)
DMF9VMW	MT	DTT
DMF9VMW	MA	Inhibitor
DMF9VMW	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMF9VMW	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DM8KBHX	DI	DM8KBHX
DM8KBHX	DN	Pyridine derivative 12
DM8KBHX	MI	TTHS256
DM8KBHX	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM8KBHX	MT	DTT
DM8KBHX	MA	Modulator
DM8KBHX	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DM8KBHX	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMX8RGH	DI	DMX8RGH
DMX8RGH	DN	Pyridine derivative 13
DMX8RGH	MI	TTHS256
DMX8RGH	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMX8RGH	MT	DTT
DMX8RGH	MA	Modulator
DMX8RGH	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMX8RGH	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DM7JCM6	DI	DM7JCM6
DM7JCM6	DN	Pyridine derivative 14
DM7JCM6	MI	TTHS256
DM7JCM6	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM7JCM6	MT	DTT
DM7JCM6	MA	Modulator
DM7JCM6	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DM7JCM6	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMGBR43	DI	DMGBR43
DMGBR43	DN	Pyridine derivative 15
DMGBR43	MI	TTHS256
DMGBR43	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMGBR43	MT	DTT
DMGBR43	MA	Modulator
DMGBR43	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMGBR43	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMICZLS	DI	DMICZLS
DMICZLS	DN	Pyridine derivative 16
DMICZLS	MI	TTHS256
DMICZLS	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMICZLS	MT	DTT
DMICZLS	MA	Modulator
DMICZLS	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMICZLS	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMLC5WA	DI	DMLC5WA
DMLC5WA	DN	Pyridine derivative 17
DMLC5WA	MI	TTHS256
DMLC5WA	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMLC5WA	MT	DTT
DMLC5WA	MA	Modulator
DMLC5WA	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMLC5WA	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMBZMYT	DI	DMBZMYT
DMBZMYT	DN	Pyridine derivative 18
DMBZMYT	MI	TTGJCWZ
DMBZMYT	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMBZMYT	MT	DTT
DMBZMYT	MA	Inhibitor
DMBZMYT	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMBZMYT	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMBZMYT	DI	DMBZMYT
DMBZMYT	DN	Pyridine derivative 18
DMBZMYT	MI	TT7MRDV
DMBZMYT	MN	Macrophage colony-stimulating factor 1 receptor (CSF1R)
DMBZMYT	MT	DTT
DMBZMYT	MA	Inhibitor
DMBZMYT	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMBZMYT	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMBZMYT	DI	DMBZMYT
DMBZMYT	DN	Pyridine derivative 18
DMBZMYT	MI	TT8FYO9
DMBZMYT	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMBZMYT	MT	DTT
DMBZMYT	MA	Inhibitor
DMBZMYT	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMBZMYT	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMBZMYT	DI	DMBZMYT
DMBZMYT	DN	Pyridine derivative 18
DMBZMYT	MI	TTI7421
DMBZMYT	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMBZMYT	MT	DTT
DMBZMYT	MA	Inhibitor
DMBZMYT	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMBZMYT	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMBZMYT	DI	DMBZMYT
DMBZMYT	DN	Pyridine derivative 18
DMBZMYT	MI	TT4DXQT
DMBZMYT	MN	Proto-oncogene c-Ret (RET)
DMBZMYT	MT	DTT
DMBZMYT	MA	Inhibitor
DMBZMYT	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMBZMYT	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMBZMYT	DI	DMBZMYT
DMBZMYT	DN	Pyridine derivative 18
DMBZMYT	MI	TT6PKBN
DMBZMYT	MN	Proto-oncogene c-Src (SRC)
DMBZMYT	MT	DTT
DMBZMYT	MA	Inhibitor
DMBZMYT	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMBZMYT	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMBZMYT	DI	DMBZMYT
DMBZMYT	DN	Pyridine derivative 18
DMBZMYT	MI	TTX41N9
DMBZMYT	MN	Tyrosine-protein kinase Kit (KIT)
DMBZMYT	MT	DTT
DMBZMYT	MA	Inhibitor
DMBZMYT	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMBZMYT	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMBZMYT	DI	DMBZMYT
DMBZMYT	DN	Pyridine derivative 18
DMBZMYT	MI	TTUTJGQ
DMBZMYT	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMBZMYT	MT	DTT
DMBZMYT	MA	Inhibitor
DMBZMYT	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMBZMYT	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMXYT40	DI	DMXYT40
DMXYT40	DN	Pyridine derivative 19
DMXYT40	MI	TT7MRDV
DMXYT40	MN	Macrophage colony-stimulating factor 1 receptor (CSF1R)
DMXYT40	MT	DTT
DMXYT40	MA	Inhibitor
DMXYT40	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMXYT40	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMXYT40	DI	DMXYT40
DMXYT40	DN	Pyridine derivative 19
DMXYT40	MI	TT8FYO9
DMXYT40	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMXYT40	MT	DTT
DMXYT40	MA	Inhibitor
DMXYT40	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMXYT40	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMXYT40	DI	DMXYT40
DMXYT40	DN	Pyridine derivative 19
DMXYT40	MI	TT4DXQT
DMXYT40	MN	Proto-oncogene c-Ret (RET)
DMXYT40	MT	DTT
DMXYT40	MA	Inhibitor
DMXYT40	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMXYT40	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMXYT40	DI	DMXYT40
DMXYT40	DN	Pyridine derivative 19
DMXYT40	MI	TTX41N9
DMXYT40	MN	Tyrosine-protein kinase Kit (KIT)
DMXYT40	MT	DTT
DMXYT40	MA	Inhibitor
DMXYT40	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMXYT40	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMGSUIV	DI	DMGSUIV
DMGSUIV	DN	Pyridine derivative 2
DMGSUIV	MI	TTOHSBA
DMGSUIV	MN	Vascular endothelial growth factor A (VEGFA)
DMGSUIV	MT	DTT
DMGSUIV	MA	Inhibitor
DMGSUIV	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMGSUIV	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMAOF0W	DI	DMAOF0W
DMAOF0W	DN	Pyridine derivative 20
DMAOF0W	MI	TT7MRDV
DMAOF0W	MN	Macrophage colony-stimulating factor 1 receptor (CSF1R)
DMAOF0W	MT	DTT
DMAOF0W	MA	Inhibitor
DMAOF0W	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMAOF0W	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMAOF0W	DI	DMAOF0W
DMAOF0W	DN	Pyridine derivative 20
DMAOF0W	MI	TT8FYO9
DMAOF0W	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMAOF0W	MT	DTT
DMAOF0W	MA	Inhibitor
DMAOF0W	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMAOF0W	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMAOF0W	DI	DMAOF0W
DMAOF0W	DN	Pyridine derivative 20
DMAOF0W	MI	TT4DXQT
DMAOF0W	MN	Proto-oncogene c-Ret (RET)
DMAOF0W	MT	DTT
DMAOF0W	MA	Inhibitor
DMAOF0W	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMAOF0W	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMAOF0W	DI	DMAOF0W
DMAOF0W	DN	Pyridine derivative 20
DMAOF0W	MI	TTX41N9
DMAOF0W	MN	Tyrosine-protein kinase Kit (KIT)
DMAOF0W	MT	DTT
DMAOF0W	MA	Inhibitor
DMAOF0W	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMAOF0W	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMF3907	DI	DMF3907
DMF3907	DN	Pyridine derivative 21
DMF3907	MI	TT7MRDV
DMF3907	MN	Macrophage colony-stimulating factor 1 receptor (CSF1R)
DMF3907	MT	DTT
DMF3907	MA	Inhibitor
DMF3907	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMF3907	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMF3907	DI	DMF3907
DMF3907	DN	Pyridine derivative 21
DMF3907	MI	TT8FYO9
DMF3907	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMF3907	MT	DTT
DMF3907	MA	Inhibitor
DMF3907	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMF3907	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMF3907	DI	DMF3907
DMF3907	DN	Pyridine derivative 21
DMF3907	MI	TT4DXQT
DMF3907	MN	Proto-oncogene c-Ret (RET)
DMF3907	MT	DTT
DMF3907	MA	Inhibitor
DMF3907	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMF3907	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMF3907	DI	DMF3907
DMF3907	DN	Pyridine derivative 21
DMF3907	MI	TTX41N9
DMF3907	MN	Tyrosine-protein kinase Kit (KIT)
DMF3907	MT	DTT
DMF3907	MA	Inhibitor
DMF3907	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMF3907	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMSIERF	DI	DMSIERF
DMSIERF	DN	Pyridine derivative 22
DMSIERF	MI	TT7MRDV
DMSIERF	MN	Macrophage colony-stimulating factor 1 receptor (CSF1R)
DMSIERF	MT	DTT
DMSIERF	MA	Inhibitor
DMSIERF	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMSIERF	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMSIERF	DI	DMSIERF
DMSIERF	DN	Pyridine derivative 22
DMSIERF	MI	TT8FYO9
DMSIERF	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMSIERF	MT	DTT
DMSIERF	MA	Inhibitor
DMSIERF	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMSIERF	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMSIERF	DI	DMSIERF
DMSIERF	DN	Pyridine derivative 22
DMSIERF	MI	TT4DXQT
DMSIERF	MN	Proto-oncogene c-Ret (RET)
DMSIERF	MT	DTT
DMSIERF	MA	Inhibitor
DMSIERF	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMSIERF	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMSIERF	DI	DMSIERF
DMSIERF	DN	Pyridine derivative 22
DMSIERF	MI	TTX41N9
DMSIERF	MN	Tyrosine-protein kinase Kit (KIT)
DMSIERF	MT	DTT
DMSIERF	MA	Inhibitor
DMSIERF	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMSIERF	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMFALQN	DI	DMFALQN
DMFALQN	DN	Pyridine derivative 3
DMFALQN	MI	TTOHSBA
DMFALQN	MN	Vascular endothelial growth factor A (VEGFA)
DMFALQN	MT	DTT
DMFALQN	MA	Inhibitor
DMFALQN	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMFALQN	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DM6N8T3	DI	DM6N8T3
DM6N8T3	DN	Pyridine derivative 4
DM6N8T3	MI	TTOHSBA
DM6N8T3	MN	Vascular endothelial growth factor A (VEGFA)
DM6N8T3	MT	DTT
DM6N8T3	MA	Inhibitor
DM6N8T3	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DM6N8T3	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMXP6W1	DI	DMXP6W1
DMXP6W1	DN	Pyridine derivative 5
DMXP6W1	MI	TTOHSBA
DMXP6W1	MN	Vascular endothelial growth factor A (VEGFA)
DMXP6W1	MT	DTT
DMXP6W1	MA	Inhibitor
DMXP6W1	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMXP6W1	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DM8NBM0	DI	DM8NBM0
DM8NBM0	DN	Pyridine derivative 6
DM8NBM0	MI	TTOHSBA
DM8NBM0	MN	Vascular endothelial growth factor A (VEGFA)
DM8NBM0	MT	DTT
DM8NBM0	MA	Inhibitor
DM8NBM0	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DM8NBM0	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMYT1QN	DI	DMYT1QN
DMYT1QN	DN	Pyridine derivative 7
DMYT1QN	MI	TTOHSBA
DMYT1QN	MN	Vascular endothelial growth factor A (VEGFA)
DMYT1QN	MT	DTT
DMYT1QN	MA	Inhibitor
DMYT1QN	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMYT1QN	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMITVUY	DI	DMITVUY
DMITVUY	DN	Pyridine derivative 8
DMITVUY	MI	TTOHSBA
DMITVUY	MN	Vascular endothelial growth factor A (VEGFA)
DMITVUY	MT	DTT
DMITVUY	MA	Inhibitor
DMITVUY	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMITVUY	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMVF1BI	DI	DMVF1BI
DMVF1BI	DN	Pyridine derivative 9
DMVF1BI	MI	TTOHSBA
DMVF1BI	MN	Vascular endothelial growth factor A (VEGFA)
DMVF1BI	MT	DTT
DMVF1BI	MA	Inhibitor
DMVF1BI	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMVF1BI	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMJNE4V	DI	DMJNE4V
DMJNE4V	DN	Pyridine-2,4-dicarboxylic acid analog 1
DMJNE4V	MI	TTWAQBO
DMJNE4V	MN	Lysine-specific demethylase 4E (KDM4E)
DMJNE4V	MT	DTT
DMJNE4V	MA	Inhibitor
DMJNE4V	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMJNE4V	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMCNWPI	DI	DMCNWPI
DMCNWPI	DN	Pyridine-2,4-dicarboxylic acid analog 2
DMCNWPI	MI	TTWAQBO
DMCNWPI	MN	Lysine-specific demethylase 4E (KDM4E)
DMCNWPI	MT	DTT
DMCNWPI	MA	Inhibitor
DMCNWPI	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMCNWPI	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DM4XAGS	DI	DM4XAGS
DM4XAGS	DN	Pyridine-2,4-dicarboxylic acid analog 3
DM4XAGS	MI	TTWAQBO
DM4XAGS	MN	Lysine-specific demethylase 4E (KDM4E)
DM4XAGS	MT	DTT
DM4XAGS	MA	Inhibitor
DM4XAGS	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DM4XAGS	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMGPCSR	DI	DMGPCSR
DMGPCSR	DN	Pyridine-2,4-dicarboxylic acid analog 4
DMGPCSR	MI	TTWAQBO
DMGPCSR	MN	Lysine-specific demethylase 4E (KDM4E)
DMGPCSR	MT	DTT
DMGPCSR	MA	Inhibitor
DMGPCSR	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMGPCSR	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMZSTCQ	DI	DMZSTCQ
DMZSTCQ	DN	Pyridine-2,4-dicarboxylic acid derivative 1
DMZSTCQ	MI	TT0RGE9
DMZSTCQ	MN	Lysine-specific demethylase 4 (KDM4)
DMZSTCQ	MT	DTT
DMZSTCQ	MA	Inhibitor
DMZSTCQ	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMZSTCQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMGCMF5	DI	DMGCMF5
DMGCMF5	DN	Pyridine-2,4-dicarboxylic acid derivative 2
DMGCMF5	MI	TT0RGE9
DMGCMF5	MN	Lysine-specific demethylase 4 (KDM4)
DMGCMF5	MT	DTT
DMGCMF5	MA	Inhibitor
DMGCMF5	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMGCMF5	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMCUP4L	DI	DMCUP4L
DMCUP4L	DN	Pyridine-2,4-dicarboxylic acid derivative 3
DMCUP4L	MI	TT0RGE9
DMCUP4L	MN	Lysine-specific demethylase 4 (KDM4)
DMCUP4L	MT	DTT
DMCUP4L	MA	Inhibitor
DMCUP4L	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMCUP4L	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DM9KOYX	DI	DM9KOYX
DM9KOYX	DN	Pyridine-amide derivative 1
DM9KOYX	MI	TTF8P9I
DM9KOYX	MN	Diacylglycerol acyltransferase 1 (DGAT1)
DM9KOYX	MT	DTT
DM9KOYX	MA	Inhibitor
DM9KOYX	RN	Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
DM9KOYX	RU	https://www.ncbi.nlm.nih.gov/pubmed/25470667

DM25M8D	DI	DM25M8D
DM25M8D	DN	Pyridine-carboximide derivative 1
DM25M8D	MI	TTF8P9I
DM25M8D	MN	Diacylglycerol acyltransferase 1 (DGAT1)
DM25M8D	MT	DTT
DM25M8D	MA	Inhibitor
DM25M8D	RN	Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
DM25M8D	RU	https://www.ncbi.nlm.nih.gov/pubmed/25470667

DMHXWZB	DI	DMHXWZB
DMHXWZB	DN	Pyridine-carboximide derivative 2
DMHXWZB	MI	TTF8P9I
DMHXWZB	MN	Diacylglycerol acyltransferase 1 (DGAT1)
DMHXWZB	MT	DTT
DMHXWZB	MA	Inhibitor
DMHXWZB	RN	Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
DMHXWZB	RU	https://www.ncbi.nlm.nih.gov/pubmed/25470667

DMKQFTY	DI	DMKQFTY
DMKQFTY	DN	Pyridino tricyclic compound 1
DMKQFTY	MI	TTZJYKH
DMKQFTY	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMKQFTY	MT	DTT
DMKQFTY	MA	Inhibitor
DMKQFTY	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMKQFTY	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DM3F4KS	DI	DM3F4KS
DM3F4KS	DN	Pyridinone carboxamide derivative 1
DM3F4KS	MI	TTCZOF2
DM3F4KS	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DM3F4KS	MT	DTT
DM3F4KS	MA	Inhibitor
DM3F4KS	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DM3F4KS	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DM2GR5Q	DI	DM2GR5Q
DM2GR5Q	DN	Pyridinone compound 1
DM2GR5Q	MI	TTZCRP3
DM2GR5Q	MN	ERK activator kinase (MEK)
DM2GR5Q	MT	DTT
DM2GR5Q	MA	Inhibitor
DM2GR5Q	RN	MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906.
DM2GR5Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/28594589

DMK5YJI	DI	DMK5YJI
DMK5YJI	DN	Pyrido/pyrrolo-fused pyrimidine derivative 1
DMK5YJI	MI	TTSCIM2
DMK5YJI	MN	Extracellular lysophospholipase D (E-NPP2)
DMK5YJI	MT	DTT
DMK5YJI	MA	Inhibitor
DMK5YJI	RN	Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829.
DMK5YJI	RU	https://www.ncbi.nlm.nih.gov/pubmed/28447479

DMHKRVL	DI	DMHKRVL
DMHKRVL	DN	Pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 1
DMHKRVL	MI	TTJW4LU
DMHKRVL	MN	Phosphodiesterase 10A (PDE10)
DMHKRVL	MT	DTT
DMHKRVL	MA	Inhibitor
DMHKRVL	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMHKRVL	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMHKRVL	DI	DMHKRVL
DMHKRVL	DN	Pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 1
DMHKRVL	MI	TTJGW1Z
DMHKRVL	MN	Phosphodiesterase 2A (PDE2A)
DMHKRVL	MT	DTT
DMHKRVL	MA	Inhibitor
DMHKRVL	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMHKRVL	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMUO25Y	DI	DMUO25Y
DMUO25Y	DN	Pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 2
DMUO25Y	MI	TTJW4LU
DMUO25Y	MN	Phosphodiesterase 10A (PDE10)
DMUO25Y	MT	DTT
DMUO25Y	MA	Inhibitor
DMUO25Y	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMUO25Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMUO25Y	DI	DMUO25Y
DMUO25Y	DN	Pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 2
DMUO25Y	MI	TTJGW1Z
DMUO25Y	MN	Phosphodiesterase 2A (PDE2A)
DMUO25Y	MT	DTT
DMUO25Y	MA	Inhibitor
DMUO25Y	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMUO25Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMAEYNT	DI	DMAEYNT
DMAEYNT	DN	Pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 3
DMAEYNT	MI	TTJW4LU
DMAEYNT	MN	Phosphodiesterase 10A (PDE10)
DMAEYNT	MT	DTT
DMAEYNT	MA	Inhibitor
DMAEYNT	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMAEYNT	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMAEYNT	DI	DMAEYNT
DMAEYNT	DN	Pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 3
DMAEYNT	MI	TTJGW1Z
DMAEYNT	MN	Phosphodiesterase 2A (PDE2A)
DMAEYNT	MT	DTT
DMAEYNT	MA	Inhibitor
DMAEYNT	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMAEYNT	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMF0XI3	DI	DMF0XI3
DMF0XI3	DN	Pyrido[1,2-a]indole-1.-carboxylic acid analog 1
DMF0XI3	MI	TTV8CRH
DMF0XI3	MN	Lysine-specific demethylase 4C (KDM4C)
DMF0XI3	MT	DTT
DMF0XI3	MA	Inhibitor
DMF0XI3	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMF0XI3	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMWMV48	DI	DMWMV48
DMWMV48	DN	Pyrido[1,2-a]indole-1.-carboxylic acid analog 2
DMWMV48	MI	TTV8CRH
DMWMV48	MN	Lysine-specific demethylase 4C (KDM4C)
DMWMV48	MT	DTT
DMWMV48	MA	Inhibitor
DMWMV48	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMWMV48	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMCLKBY	DI	DMCLKBY
DMCLKBY	DN	Pyrido[1,2-a]indole-1.-carboxylic acid analog 3
DMCLKBY	MI	TTV8CRH
DMCLKBY	MN	Lysine-specific demethylase 4C (KDM4C)
DMCLKBY	MT	DTT
DMCLKBY	MA	Inhibitor
DMCLKBY	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMCLKBY	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DM09FOQ	DI	DM09FOQ
DM09FOQ	DN	Pyrido[1,2-a]indole-1.-carboxylic acid analog 4
DM09FOQ	MI	TTV8CRH
DM09FOQ	MN	Lysine-specific demethylase 4C (KDM4C)
DM09FOQ	MT	DTT
DM09FOQ	MA	Inhibitor
DM09FOQ	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DM09FOQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMO3QDW	DI	DMO3QDW
DMO3QDW	DN	Pyrido[1,2-a]indole-1.-carboxylic acid analog 5
DMO3QDW	MI	TTV8CRH
DMO3QDW	MN	Lysine-specific demethylase 4C (KDM4C)
DMO3QDW	MT	DTT
DMO3QDW	MA	Inhibitor
DMO3QDW	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMO3QDW	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMRQ1ZB	DI	DMRQ1ZB
DMRQ1ZB	DN	Pyrido[1,2-a]indole-1.-carboxylic acid analog 6
DMRQ1ZB	MI	TTV8CRH
DMRQ1ZB	MN	Lysine-specific demethylase 4C (KDM4C)
DMRQ1ZB	MT	DTT
DMRQ1ZB	MA	Inhibitor
DMRQ1ZB	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMRQ1ZB	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMXY3F0	DI	DMXY3F0
DMXY3F0	DN	Pyrido[1,2-a]indole-1.-carboxylic acid analog 7
DMXY3F0	MI	TTV8CRH
DMXY3F0	MN	Lysine-specific demethylase 4C (KDM4C)
DMXY3F0	MT	DTT
DMXY3F0	MA	Inhibitor
DMXY3F0	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMXY3F0	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMHZLSO	DI	DMHZLSO
DMHZLSO	DN	Pyrido[2,3-d]pyrimidine derivative 1
DMHZLSO	MI	TT6OEDT
DMHZLSO	MN	Cannabinoid receptor 1 (CB1)
DMHZLSO	MT	DTT
DMHZLSO	MA	Antagonist
DMHZLSO	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMHZLSO	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMSM53I	DI	DMSM53I
DMSM53I	DN	Pyrido[2,3-d]pyrimidine derivative 2
DMSM53I	MI	TT6OEDT
DMSM53I	MN	Cannabinoid receptor 1 (CB1)
DMSM53I	MT	DTT
DMSM53I	MA	Antagonist
DMSM53I	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMSM53I	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMM8CL4	DI	DMM8CL4
DMM8CL4	DN	Pyrido[2,3-d]pyrimidine-2,4-diamine derivative 1
DMM8CL4	MI	TTJGW1Z
DMM8CL4	MN	Phosphodiesterase 2A (PDE2A)
DMM8CL4	MT	DTT
DMM8CL4	MA	Inhibitor
DMM8CL4	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMM8CL4	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMRHAU4	DI	DMRHAU4
DMRHAU4	DN	Pyrido[3,2-d]pyrimidine derivative 2
DMRHAU4	MI	TTTDVOJ
DMRHAU4	MN	Tropomyosin-related kinase A (TrkA)
DMRHAU4	MT	DTT
DMRHAU4	MA	Inhibitor
DMRHAU4	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMRHAU4	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DM6D1XR	DI	DM6D1XR
DM6D1XR	DN	Pyrido[3,2-d]pyrimidine derivative 3
DM6D1XR	MI	TTTDVOJ
DM6D1XR	MN	Tropomyosin-related kinase A (TrkA)
DM6D1XR	MT	DTT
DM6D1XR	MA	Inhibitor
DM6D1XR	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DM6D1XR	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMC8935	DI	DMC8935
DMC8935	DN	Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 1
DMC8935	MI	TTJW4LU
DMC8935	MN	Phosphodiesterase 10A (PDE10)
DMC8935	MT	DTT
DMC8935	MA	Inhibitor
DMC8935	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMC8935	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMC8935	DI	DMC8935
DMC8935	DN	Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 1
DMC8935	MI	TTJGW1Z
DMC8935	MN	Phosphodiesterase 2A (PDE2A)
DMC8935	MT	DTT
DMC8935	MA	Inhibitor
DMC8935	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMC8935	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMC8935	DI	DMC8935
DMC8935	DN	Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 1
DMC8935	MI	TTQ6VDM
DMC8935	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMC8935	MT	DTT
DMC8935	MA	Inhibitor
DMC8935	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMC8935	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DM4CSBD	DI	DM4CSBD
DM4CSBD	DN	Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 2
DM4CSBD	MI	TTJW4LU
DM4CSBD	MN	Phosphodiesterase 10A (PDE10)
DM4CSBD	MT	DTT
DM4CSBD	MA	Inhibitor
DM4CSBD	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DM4CSBD	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DM4CSBD	DI	DM4CSBD
DM4CSBD	DN	Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 2
DM4CSBD	MI	TTJGW1Z
DM4CSBD	MN	Phosphodiesterase 2A (PDE2A)
DM4CSBD	MT	DTT
DM4CSBD	MA	Inhibitor
DM4CSBD	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DM4CSBD	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DM4CSBD	DI	DM4CSBD
DM4CSBD	DN	Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 2
DM4CSBD	MI	TTQ6VDM
DM4CSBD	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DM4CSBD	MT	DTT
DM4CSBD	MA	Inhibitor
DM4CSBD	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DM4CSBD	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMOTGEK	DI	DMOTGEK
DMOTGEK	DN	Pyrido[4,3-d]pyrimidin-5(6H)-one derivative 1
DMOTGEK	MI	TTCZOF2
DMOTGEK	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMOTGEK	MT	DTT
DMOTGEK	MA	Inhibitor
DMOTGEK	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMOTGEK	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMP6TUQ	DI	DMP6TUQ
DMP6TUQ	DN	Pyridoindole derivative 1
DMP6TUQ	MI	TTS7G69
DMP6TUQ	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMP6TUQ	MT	DTT
DMP6TUQ	MA	Inhibitor
DMP6TUQ	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMP6TUQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMIXK7Y	DI	DMIXK7Y
DMIXK7Y	DN	Pyridoindole derivative 2
DMIXK7Y	MI	TTS7G69
DMIXK7Y	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMIXK7Y	MT	DTT
DMIXK7Y	MA	Inhibitor
DMIXK7Y	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMIXK7Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMONCT1	DI	DMONCT1
DMONCT1	DN	Pyridoindole derivative 3
DMONCT1	MI	TTS7G69
DMONCT1	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMONCT1	MT	DTT
DMONCT1	MA	Inhibitor
DMONCT1	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMONCT1	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMTZK6V	DI	DMTZK6V
DMTZK6V	DN	Pyridopyrimidine derivative 1
DMTZK6V	MI	TTZCRP3
DMTZK6V	MN	ERK activator kinase (MEK)
DMTZK6V	MT	DTT
DMTZK6V	MA	Inhibitor
DMTZK6V	RN	MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906.
DMTZK6V	RU	https://www.ncbi.nlm.nih.gov/pubmed/28594589

DMZ6TSD	DI	DMZ6TSD
DMZ6TSD	DN	Pyridopyrimidinone derivative 1
DMZ6TSD	MI	TTK0FEA
DMZ6TSD	MN	Leucine-rich repeat kinase 2 (LRRK2)
DMZ6TSD	MT	DTT
DMZ6TSD	MA	Inhibitor
DMZ6TSD	RN	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
DMZ6TSD	RU	https://www.ncbi.nlm.nih.gov/pubmed/28117607

DMUF63N	DI	DMUF63N
DMUF63N	DN	Pyridopyrimidinone derivative 2
DMUF63N	MI	TTK0FEA
DMUF63N	MN	Leucine-rich repeat kinase 2 (LRRK2)
DMUF63N	MT	DTT
DMUF63N	MA	Inhibitor
DMUF63N	RN	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
DMUF63N	RU	https://www.ncbi.nlm.nih.gov/pubmed/28117607

DMHSDUR	DI	DMHSDUR
DMHSDUR	DN	Pyridopyrimidinone derivative 3
DMHSDUR	MI	TTK0FEA
DMHSDUR	MN	Leucine-rich repeat kinase 2 (LRRK2)
DMHSDUR	MT	DTT
DMHSDUR	MA	Inhibitor
DMHSDUR	RN	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
DMHSDUR	RU	https://www.ncbi.nlm.nih.gov/pubmed/28117607

DM71UYI	DI	DM71UYI
DM71UYI	DN	Pyridotriazolopyrimidine derivative 1
DM71UYI	MI	TT6OEDT
DM71UYI	MN	Cannabinoid receptor 1 (CB1)
DM71UYI	MT	DTT
DM71UYI	MA	Antagonist
DM71UYI	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DM71UYI	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DM0VOY9	DI	DM0VOY9
DM0VOY9	DN	Pyridotriazolopyrimidine derivative 2
DM0VOY9	MI	TT6OEDT
DM0VOY9	MN	Cannabinoid receptor 1 (CB1)
DM0VOY9	MT	DTT
DM0VOY9	MA	Antagonist
DM0VOY9	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DM0VOY9	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMYVCTD	DI	DMYVCTD
DMYVCTD	DN	Pyridotriazolopyrimidine derivative 3
DMYVCTD	MI	TT6OEDT
DMYVCTD	MN	Cannabinoid receptor 1 (CB1)
DMYVCTD	MT	DTT
DMYVCTD	MA	Antagonist
DMYVCTD	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMYVCTD	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMUTE5S	DI	DMUTE5S
DMUTE5S	DN	Pyridyl compound 1
DMUTE5S	MI	TT3Z6Y9
DMUTE5S	MN	Cysteines of Keap1 (KEAP1 Cysteines)
DMUTE5S	MT	DTT
DMUTE5S	MA	Modulator
DMUTE5S	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMUTE5S	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMUTE5S	DI	DMUTE5S
DMUTE5S	DN	Pyridyl compound 1
DMUTE5S	MI	TTA6ZN2
DMUTE5S	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMUTE5S	MT	DTT
DMUTE5S	MA	Activator
DMUTE5S	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMUTE5S	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMD6GNO	DI	DMD6GNO
DMD6GNO	DN	Pyrimidine benzenesulfonamide derivative 1
DMD6GNO	MI	TTIY56R
DMD6GNO	MN	Kynurenine 3-hydroxylase (KMO)
DMD6GNO	MT	DTT
DMD6GNO	MA	Inhibitor
DMD6GNO	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMD6GNO	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMVQ4NS	DI	DMVQ4NS
DMVQ4NS	DN	Pyrimidine benzenesulfonamide derivative 2
DMVQ4NS	MI	TTIY56R
DMVQ4NS	MN	Kynurenine 3-hydroxylase (KMO)
DMVQ4NS	MT	DTT
DMVQ4NS	MA	Inhibitor
DMVQ4NS	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMVQ4NS	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMJ71Q0	DI	DMJ71Q0
DMJ71Q0	DN	Pyrimidine benzenesulfonamide derivative 3
DMJ71Q0	MI	TTIY56R
DMJ71Q0	MN	Kynurenine 3-hydroxylase (KMO)
DMJ71Q0	MT	DTT
DMJ71Q0	MA	Inhibitor
DMJ71Q0	RN	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
DMJ71Q0	RU	https://www.ncbi.nlm.nih.gov/pubmed/27172114

DMN9VQM	DI	DMN9VQM
DMN9VQM	DN	Pyrimidine derivative 1
DMN9VQM	MI	TTAXZ0K
DMN9VQM	MN	Voltage-gated sodium channel alpha Nav1.3 (SCN3A)
DMN9VQM	MT	DTT
DMN9VQM	MA	Blocker
DMN9VQM	RN	Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90.
DMN9VQM	RU	https://www.ncbi.nlm.nih.gov/pubmed/25539043

DMN9VQM	DI	DMN9VQM
DMN9VQM	DN	Pyrimidine derivative 1
DMN9VQM	MI	TT4G2JS
DMN9VQM	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DMN9VQM	MT	DTT
DMN9VQM	MA	Blocker
DMN9VQM	RN	Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90.
DMN9VQM	RU	https://www.ncbi.nlm.nih.gov/pubmed/25539043

DMBEZUY	DI	DMBEZUY
DMBEZUY	DN	Pyrimidine derivative 10
DMBEZUY	MI	TTOHSBA
DMBEZUY	MN	Vascular endothelial growth factor A (VEGFA)
DMBEZUY	MT	DTT
DMBEZUY	MA	Inhibitor
DMBEZUY	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMBEZUY	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMJ4QD5	DI	DMJ4QD5
DMJ4QD5	DN	Pyrimidine derivative 11
DMJ4QD5	MI	TTOHSBA
DMJ4QD5	MN	Vascular endothelial growth factor A (VEGFA)
DMJ4QD5	MT	DTT
DMJ4QD5	MA	Inhibitor
DMJ4QD5	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMJ4QD5	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMMBFQH	DI	DMMBFQH
DMMBFQH	DN	Pyrimidine derivative 12
DMMBFQH	MI	TTUTJGQ
DMMBFQH	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMMBFQH	MT	DTT
DMMBFQH	MA	Inhibitor
DMMBFQH	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMMBFQH	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMASGR1	DI	DMASGR1
DMASGR1	DN	Pyrimidine derivative 13
DMASGR1	MI	TTUTJGQ
DMASGR1	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMASGR1	MT	DTT
DMASGR1	MA	Inhibitor
DMASGR1	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMASGR1	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DM7B2XG	DI	DM7B2XG
DM7B2XG	DN	Pyrimidine derivative 14
DM7B2XG	MI	TTUTJGQ
DM7B2XG	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM7B2XG	MT	DTT
DM7B2XG	MA	Inhibitor
DM7B2XG	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DM7B2XG	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMV2Y84	DI	DMV2Y84
DMV2Y84	DN	Pyrimidine derivative 15
DMV2Y84	MI	TTDCBX5
DMV2Y84	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DMV2Y84	MT	DTT
DMV2Y84	MA	Inhibitor
DMV2Y84	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMV2Y84	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DM3GYPD	DI	DM3GYPD
DM3GYPD	DN	Pyrimidine derivative 16
DM3GYPD	MI	TTNR0UQ
DM3GYPD	MN	Lysine-specific histone demethylase 1 (LSD)
DM3GYPD	MT	DTT
DM3GYPD	MA	Inhibitor
DM3GYPD	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DM3GYPD	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DM7YA9Z	DI	DM7YA9Z
DM7YA9Z	DN	Pyrimidine derivative 17
DM7YA9Z	MI	TTNR0UQ
DM7YA9Z	MN	Lysine-specific histone demethylase 1 (LSD)
DM7YA9Z	MT	DTT
DM7YA9Z	MA	Inhibitor
DM7YA9Z	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DM7YA9Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMIZTKS	DI	DMIZTKS
DMIZTKS	DN	Pyrimidine derivative 18
DMIZTKS	MI	TTNR0UQ
DMIZTKS	MN	Lysine-specific histone demethylase 1 (LSD)
DMIZTKS	MT	DTT
DMIZTKS	MA	Inhibitor
DMIZTKS	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMIZTKS	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMLPO0K	DI	DMLPO0K
DMLPO0K	DN	Pyrimidine derivative 19
DMLPO0K	MI	TT8J1S3
DMLPO0K	MN	Smoothened homolog (SMO)
DMLPO0K	MT	DTT
DMLPO0K	MA	Inhibitor
DMLPO0K	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMLPO0K	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMS8OR3	DI	DMS8OR3
DMS8OR3	DN	Pyrimidine derivative 2
DMS8OR3	MI	TTYLQ8V
DMS8OR3	MN	Prostaglandin E synthase (PTGES)
DMS8OR3	MT	DTT
DMS8OR3	MA	Inhibitor
DMS8OR3	RN	Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059.
DMS8OR3	RU	https://www.ncbi.nlm.nih.gov/pubmed/28627961

DMQUEDK	DI	DMQUEDK
DMQUEDK	DN	Pyrimidine derivative 20
DMQUEDK	MI	TT8J1S3
DMQUEDK	MN	Smoothened homolog (SMO)
DMQUEDK	MT	DTT
DMQUEDK	MA	Inhibitor
DMQUEDK	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMQUEDK	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMELA2F	DI	DMELA2F
DMELA2F	DN	Pyrimidine derivative 21
DMELA2F	MI	TT8J1S3
DMELA2F	MN	Smoothened homolog (SMO)
DMELA2F	MT	DTT
DMELA2F	MA	Inhibitor
DMELA2F	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMELA2F	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DMN64AK	DI	DMN64AK
DMN64AK	DN	Pyrimidine derivative 22
DMN64AK	MI	TT8J1S3
DMN64AK	MN	Smoothened homolog (SMO)
DMN64AK	MT	DTT
DMN64AK	MA	Inhibitor
DMN64AK	RN	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
DMN64AK	RU	https://www.ncbi.nlm.nih.gov/pubmed/25726713

DM5MLQU	DI	DM5MLQU
DM5MLQU	DN	Pyrimidine derivative 23
DM5MLQU	MI	TTJQOD7
DM5MLQU	MN	5-HT 2A receptor (HTR2A)
DM5MLQU	MT	DTT
DM5MLQU	MA	Antagonist
DM5MLQU	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DM5MLQU	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DM5MLQU	DI	DM5MLQU
DM5MLQU	DN	Pyrimidine derivative 23
DM5MLQU	MI	TT0K1SC
DM5MLQU	MN	5-HT 2B receptor (HTR2B)
DM5MLQU	MT	DTT
DM5MLQU	MA	Antagonist
DM5MLQU	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DM5MLQU	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DM5MLQU	DI	DM5MLQU
DM5MLQU	DN	Pyrimidine derivative 23
DM5MLQU	MI	TTWJBZ5
DM5MLQU	MN	5-HT 2C receptor (HTR2C)
DM5MLQU	MT	DTT
DM5MLQU	MA	Antagonist
DM5MLQU	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DM5MLQU	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMOQ726	DI	DMOQ726
DMOQ726	DN	Pyrimidine derivative 24
DMOQ726	MI	TTJQOD7
DMOQ726	MN	5-HT 2A receptor (HTR2A)
DMOQ726	MT	DTT
DMOQ726	MA	Antagonist
DMOQ726	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMOQ726	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMOQ726	DI	DMOQ726
DMOQ726	DN	Pyrimidine derivative 24
DMOQ726	MI	TT0K1SC
DMOQ726	MN	5-HT 2B receptor (HTR2B)
DMOQ726	MT	DTT
DMOQ726	MA	Antagonist
DMOQ726	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMOQ726	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMOQ726	DI	DMOQ726
DMOQ726	DN	Pyrimidine derivative 24
DMOQ726	MI	TTWJBZ5
DMOQ726	MN	5-HT 2C receptor (HTR2C)
DMOQ726	MT	DTT
DMOQ726	MA	Antagonist
DMOQ726	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMOQ726	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DM51MFS	DI	DM51MFS
DM51MFS	DN	Pyrimidine derivative 25
DM51MFS	MI	TTJQOD7
DM51MFS	MN	5-HT 2A receptor (HTR2A)
DM51MFS	MT	DTT
DM51MFS	MA	Antagonist
DM51MFS	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DM51MFS	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DM51MFS	DI	DM51MFS
DM51MFS	DN	Pyrimidine derivative 25
DM51MFS	MI	TT0K1SC
DM51MFS	MN	5-HT 2B receptor (HTR2B)
DM51MFS	MT	DTT
DM51MFS	MA	Antagonist
DM51MFS	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DM51MFS	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DM51MFS	DI	DM51MFS
DM51MFS	DN	Pyrimidine derivative 25
DM51MFS	MI	TTWJBZ5
DM51MFS	MN	5-HT 2C receptor (HTR2C)
DM51MFS	MT	DTT
DM51MFS	MA	Antagonist
DM51MFS	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DM51MFS	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DM90WKN	DI	DM90WKN
DM90WKN	DN	Pyrimidine derivative 26
DM90WKN	MI	TTJQOD7
DM90WKN	MN	5-HT 2A receptor (HTR2A)
DM90WKN	MT	DTT
DM90WKN	MA	Antagonist
DM90WKN	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DM90WKN	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DM90WKN	DI	DM90WKN
DM90WKN	DN	Pyrimidine derivative 26
DM90WKN	MI	TT0K1SC
DM90WKN	MN	5-HT 2B receptor (HTR2B)
DM90WKN	MT	DTT
DM90WKN	MA	Antagonist
DM90WKN	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DM90WKN	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DM90WKN	DI	DM90WKN
DM90WKN	DN	Pyrimidine derivative 26
DM90WKN	MI	TTWJBZ5
DM90WKN	MN	5-HT 2C receptor (HTR2C)
DM90WKN	MT	DTT
DM90WKN	MA	Antagonist
DM90WKN	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DM90WKN	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMIQSDW	DI	DMIQSDW
DMIQSDW	DN	Pyrimidine derivative 27
DMIQSDW	MI	TTJQOD7
DMIQSDW	MN	5-HT 2A receptor (HTR2A)
DMIQSDW	MT	DTT
DMIQSDW	MA	Antagonist
DMIQSDW	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMIQSDW	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMIQSDW	DI	DMIQSDW
DMIQSDW	DN	Pyrimidine derivative 27
DMIQSDW	MI	TT0K1SC
DMIQSDW	MN	5-HT 2B receptor (HTR2B)
DMIQSDW	MT	DTT
DMIQSDW	MA	Antagonist
DMIQSDW	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMIQSDW	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMIQSDW	DI	DMIQSDW
DMIQSDW	DN	Pyrimidine derivative 27
DMIQSDW	MI	TTWJBZ5
DMIQSDW	MN	5-HT 2C receptor (HTR2C)
DMIQSDW	MT	DTT
DMIQSDW	MA	Antagonist
DMIQSDW	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMIQSDW	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DM1D2AS	DI	DM1D2AS
DM1D2AS	DN	Pyrimidine derivative 28
DM1D2AS	MI	TTJQOD7
DM1D2AS	MN	5-HT 2A receptor (HTR2A)
DM1D2AS	MT	DTT
DM1D2AS	MA	Antagonist
DM1D2AS	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DM1D2AS	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DM1D2AS	DI	DM1D2AS
DM1D2AS	DN	Pyrimidine derivative 28
DM1D2AS	MI	TT0K1SC
DM1D2AS	MN	5-HT 2B receptor (HTR2B)
DM1D2AS	MT	DTT
DM1D2AS	MA	Antagonist
DM1D2AS	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DM1D2AS	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DM1D2AS	DI	DM1D2AS
DM1D2AS	DN	Pyrimidine derivative 28
DM1D2AS	MI	TTWJBZ5
DM1D2AS	MN	5-HT 2C receptor (HTR2C)
DM1D2AS	MT	DTT
DM1D2AS	MA	Antagonist
DM1D2AS	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DM1D2AS	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMVOYJ8	DI	DMVOYJ8
DMVOYJ8	DN	Pyrimidine derivative 29
DMVOYJ8	MI	TTJQOD7
DMVOYJ8	MN	5-HT 2A receptor (HTR2A)
DMVOYJ8	MT	DTT
DMVOYJ8	MA	Antagonist
DMVOYJ8	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMVOYJ8	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMVOYJ8	DI	DMVOYJ8
DMVOYJ8	DN	Pyrimidine derivative 29
DMVOYJ8	MI	TT0K1SC
DMVOYJ8	MN	5-HT 2B receptor (HTR2B)
DMVOYJ8	MT	DTT
DMVOYJ8	MA	Antagonist
DMVOYJ8	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMVOYJ8	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMVOYJ8	DI	DMVOYJ8
DMVOYJ8	DN	Pyrimidine derivative 29
DMVOYJ8	MI	TTWJBZ5
DMVOYJ8	MN	5-HT 2C receptor (HTR2C)
DMVOYJ8	MT	DTT
DMVOYJ8	MA	Antagonist
DMVOYJ8	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMVOYJ8	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMC3E8M	DI	DMC3E8M
DMC3E8M	DN	Pyrimidine derivative 3
DMC3E8M	MI	TTCZOF2
DMC3E8M	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMC3E8M	MT	DTT
DMC3E8M	MA	Inhibitor
DMC3E8M	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMC3E8M	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMTQBUD	DI	DMTQBUD
DMTQBUD	DN	Pyrimidine derivative 30
DMTQBUD	MI	TTDIGC1
DMTQBUD	MN	Dipeptidyl peptidase 4 (DPP-4)
DMTQBUD	MT	DTT
DMTQBUD	MA	Inhibitor
DMTQBUD	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMTQBUD	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DMOJTLU	DI	DMOJTLU
DMOJTLU	DN	Pyrimidine derivative 31
DMOJTLU	MI	TTDIGC1
DMOJTLU	MN	Dipeptidyl peptidase 4 (DPP-4)
DMOJTLU	MT	DTT
DMOJTLU	MA	Inhibitor
DMOJTLU	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMOJTLU	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DMCUQFG	DI	DMCUQFG
DMCUQFG	DN	Pyrimidine derivative 32
DMCUQFG	MI	TTDIGC1
DMCUQFG	MN	Dipeptidyl peptidase 4 (DPP-4)
DMCUQFG	MT	DTT
DMCUQFG	MA	Inhibitor
DMCUQFG	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMCUQFG	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DMWL5V0	DI	DMWL5V0
DMWL5V0	DN	Pyrimidine derivative 33
DMWL5V0	MI	TTDIGC1
DMWL5V0	MN	Dipeptidyl peptidase 4 (DPP-4)
DMWL5V0	MT	DTT
DMWL5V0	MA	Inhibitor
DMWL5V0	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMWL5V0	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DM4192V	DI	DM4192V
DM4192V	DN	Pyrimidine derivative 34
DM4192V	MI	TTPLTSQ
DM4192V	MN	Neutrophil elastase (NE)
DM4192V	MT	DTT
DM4192V	MA	Inhibitor
DM4192V	RN	Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
DM4192V	RU	https://www.ncbi.nlm.nih.gov/pubmed/26118988

DM8K6IS	DI	DM8K6IS
DM8K6IS	DN	Pyrimidine derivative 4
DM8K6IS	MI	TTUTJGQ
DM8K6IS	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM8K6IS	MT	DTT
DM8K6IS	MA	Inhibitor
DM8K6IS	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DM8K6IS	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMNET19	DI	DMNET19
DMNET19	DN	Pyrimidine derivative 5
DMNET19	MI	TTOHSBA
DMNET19	MN	Vascular endothelial growth factor A (VEGFA)
DMNET19	MT	DTT
DMNET19	MA	Inhibitor
DMNET19	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMNET19	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMBAHYO	DI	DMBAHYO
DMBAHYO	DN	Pyrimidine derivative 6
DMBAHYO	MI	TTOHSBA
DMBAHYO	MN	Vascular endothelial growth factor A (VEGFA)
DMBAHYO	MT	DTT
DMBAHYO	MA	Inhibitor
DMBAHYO	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMBAHYO	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMF6DUT	DI	DMF6DUT
DMF6DUT	DN	Pyrimidine derivative 7
DMF6DUT	MI	TTOHSBA
DMF6DUT	MN	Vascular endothelial growth factor A (VEGFA)
DMF6DUT	MT	DTT
DMF6DUT	MA	Inhibitor
DMF6DUT	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMF6DUT	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMVW25O	DI	DMVW25O
DMVW25O	DN	Pyrimidine derivative 8
DMVW25O	MI	TTOHSBA
DMVW25O	MN	Vascular endothelial growth factor A (VEGFA)
DMVW25O	MT	DTT
DMVW25O	MA	Inhibitor
DMVW25O	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMVW25O	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMV6U9Y	DI	DMV6U9Y
DMV6U9Y	DN	Pyrimidine derivative 9
DMV6U9Y	MI	TTOHSBA
DMV6U9Y	MN	Vascular endothelial growth factor A (VEGFA)
DMV6U9Y	MT	DTT
DMV6U9Y	MA	Inhibitor
DMV6U9Y	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMV6U9Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMT6O1N	DI	DMT6O1N
DMT6O1N	DN	Pyrimidine-4(3H)-one derivative 1
DMT6O1N	MI	TTJOW1I
DMT6O1N	MN	Mannoside acetylglucosaminyltransferase 2 (MGAT2)
DMT6O1N	MT	DTT
DMT6O1N	MA	Inhibitor
DMT6O1N	RN	Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
DMT6O1N	RU	https://www.ncbi.nlm.nih.gov/pubmed/25470667

DML4OYQ	DI	DML4OYQ
DML4OYQ	DN	Pyrimidinedione derivative 1
DML4OYQ	MI	TTDIGC1
DML4OYQ	MN	Dipeptidyl peptidase 4 (DPP-4)
DML4OYQ	MT	DTT
DML4OYQ	MA	Inhibitor
DML4OYQ	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DML4OYQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DM1I7Z6	DI	DM1I7Z6
DM1I7Z6	DN	Pyrimidinone derivative 1
DM1I7Z6	MI	TTCZOF2
DM1I7Z6	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DM1I7Z6	MT	DTT
DM1I7Z6	MA	Inhibitor
DM1I7Z6	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DM1I7Z6	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMDQNKW	DI	DMDQNKW
DMDQNKW	DN	Pyrimidinone derivative 4
DMDQNKW	MI	TTPLTSQ
DMDQNKW	MN	Neutrophil elastase (NE)
DMDQNKW	MT	DTT
DMDQNKW	MA	Inhibitor
DMDQNKW	RN	Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
DMDQNKW	RU	https://www.ncbi.nlm.nih.gov/pubmed/26118988

DMLFY57	DI	DMLFY57
DMLFY57	DN	Pyrimidinone derivative 5
DMLFY57	MI	TTSCIM2
DMLFY57	MN	Extracellular lysophospholipase D (E-NPP2)
DMLFY57	MT	DTT
DMLFY57	MA	Inhibitor
DMLFY57	RN	Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829.
DMLFY57	RU	https://www.ncbi.nlm.nih.gov/pubmed/28447479

DMYKHQ8	DI	DMYKHQ8
DMYKHQ8	DN	Pyrimidinyl compound 1
DMYKHQ8	MI	TTH5TC2
DMYKHQ8	MN	NF-kappa-B-activating kinase (TBK1)
DMYKHQ8	MT	DTT
DMYKHQ8	MA	Inhibitor
DMYKHQ8	RN	TBK1 inhibitors: a review of patent literature (2011 - 2014).Expert Opin Ther Pat. 2015;25(12):1385-96.
DMYKHQ8	RU	https://www.ncbi.nlm.nih.gov/pubmed/26293650

DM9TW5O	DI	DM9TW5O
DM9TW5O	DN	Pyrimidinyl compound 2
DM9TW5O	MI	TTH5TC2
DM9TW5O	MN	NF-kappa-B-activating kinase (TBK1)
DM9TW5O	MT	DTT
DM9TW5O	MA	Inhibitor
DM9TW5O	RN	TBK1 inhibitors: a review of patent literature (2011 - 2014).Expert Opin Ther Pat. 2015;25(12):1385-96.
DM9TW5O	RU	https://www.ncbi.nlm.nih.gov/pubmed/26293650

DMOE2FZ	DI	DMOE2FZ
DMOE2FZ	DN	Pyrimidinyl compound 3
DMOE2FZ	MI	TTH5TC2
DMOE2FZ	MN	NF-kappa-B-activating kinase (TBK1)
DMOE2FZ	MT	DTT
DMOE2FZ	MA	Inhibitor
DMOE2FZ	RN	TBK1 inhibitors: a review of patent literature (2011 - 2014).Expert Opin Ther Pat. 2015;25(12):1385-96.
DMOE2FZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26293650

DM53O9Y	DI	DM53O9Y
DM53O9Y	DN	Pyrimidinyl compound 4
DM53O9Y	MI	TTH5TC2
DM53O9Y	MN	NF-kappa-B-activating kinase (TBK1)
DM53O9Y	MT	DTT
DM53O9Y	MA	Inhibitor
DM53O9Y	RN	TBK1 inhibitors: a review of patent literature (2011 - 2014).Expert Opin Ther Pat. 2015;25(12):1385-96.
DM53O9Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/26293650

DMCKBGM	DI	DMCKBGM
DMCKBGM	DN	Pyrimidinyl compound 5
DMCKBGM	MI	TTH5TC2
DMCKBGM	MN	NF-kappa-B-activating kinase (TBK1)
DMCKBGM	MT	DTT
DMCKBGM	MA	Inhibitor
DMCKBGM	RN	TBK1 inhibitors: a review of patent literature (2011 - 2014).Expert Opin Ther Pat. 2015;25(12):1385-96.
DMCKBGM	RU	https://www.ncbi.nlm.nih.gov/pubmed/26293650

DML2E8S	DI	DML2E8S
DML2E8S	DN	Pyrimidinyl compound 6
DML2E8S	MI	TTH5TC2
DML2E8S	MN	NF-kappa-B-activating kinase (TBK1)
DML2E8S	MT	DTT
DML2E8S	MA	Inhibitor
DML2E8S	RN	TBK1 inhibitors: a review of patent literature (2011 - 2014).Expert Opin Ther Pat. 2015;25(12):1385-96.
DML2E8S	RU	https://www.ncbi.nlm.nih.gov/pubmed/26293650

DMMYW2L	DI	DMMYW2L
DMMYW2L	DN	Pyrimidinyl compound 7
DMMYW2L	MI	TTH5TC2
DMMYW2L	MN	NF-kappa-B-activating kinase (TBK1)
DMMYW2L	MT	DTT
DMMYW2L	MA	Inhibitor
DMMYW2L	RN	TBK1 inhibitors: a review of patent literature (2011 - 2014).Expert Opin Ther Pat. 2015;25(12):1385-96.
DMMYW2L	RU	https://www.ncbi.nlm.nih.gov/pubmed/26293650

DMZ83P1	DI	DMZ83P1
DMZ83P1	DN	Pyrimidinyl ethylenediamine derivative 1
DMZ83P1	MI	TTDP1UC
DMZ83P1	MN	Fatty acid amide hydrolase (FAAH)
DMZ83P1	MT	DTT
DMZ83P1	MA	Inhibitor
DMZ83P1	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMZ83P1	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMZ83P1	DI	DMZ83P1
DMZ83P1	DN	Pyrimidinyl ethylenediamine derivative 1
DMZ83P1	MI	TTGX13H
DMZ83P1	MN	Fatty-acid amide hydrolase 1 (FAAH1)
DMZ83P1	MT	DTT
DMZ83P1	MA	Inhibitor
DMZ83P1	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMZ83P1	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DM72T58	DI	DM72T58
DM72T58	DN	Pyrimidinyl pyrazolamine derivative 1
DM72T58	MI	TTS7G69
DM72T58	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DM72T58	MT	DTT
DM72T58	MA	Inhibitor
DM72T58	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DM72T58	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DM6O2Q9	DI	DM6O2Q9
DM6O2Q9	DN	Pyrimido[4,5-d] pyrimidines and pyrido[4,3-d] pyrimidine derivative 1
DM6O2Q9	MI	TTG0U4H
DM6O2Q9	MN	Ribosomal protein S6 kinase beta-1 (S6K1)
DM6O2Q9	MT	DTT
DM6O2Q9	MA	Inhibitor
DM6O2Q9	RN	Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78.
DM6O2Q9	RU	https://www.ncbi.nlm.nih.gov/pubmed/27410995

DMB5UF7	DI	DMB5UF7
DMB5UF7	DN	Pyrimido-indole derivative 1
DMB5UF7	MI	TTE4BSY
DMB5UF7	MN	Bromodomain and extraterminal domain protein (BET)
DMB5UF7	MT	DTT
DMB5UF7	MA	Inhibitor
DMB5UF7	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMB5UF7	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DM3REN5	DI	DM3REN5
DM3REN5	DN	Pyrimido-indole derivative 2
DM3REN5	MI	TTE4BSY
DM3REN5	MN	Bromodomain and extraterminal domain protein (BET)
DM3REN5	MT	DTT
DM3REN5	MA	Inhibitor
DM3REN5	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DM3REN5	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DM53LGD	DI	DM53LGD
DM53LGD	DN	Pyrimido-indole derivative 3
DM53LGD	MI	TTE4BSY
DM53LGD	MN	Bromodomain and extraterminal domain protein (BET)
DM53LGD	MT	DTT
DM53LGD	MA	Inhibitor
DM53LGD	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DM53LGD	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DM32N7D	DI	DM32N7D
DM32N7D	DN	Pyrimidopyridazinone derivative 1
DM32N7D	MI	TTRMX3V
DM32N7D	MN	Janus kinase 2 (JAK-2)
DM32N7D	MT	DTT
DM32N7D	MA	Inhibitor
DM32N7D	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DM32N7D	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DM32N7D	DI	DM32N7D
DM32N7D	DN	Pyrimidopyridazinone derivative 1
DM32N7D	MI	TTOU65C
DM32N7D	MN	Tyrosine-protein kinase SYK (SYK)
DM32N7D	MT	DTT
DM32N7D	MA	Inhibitor
DM32N7D	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DM32N7D	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMD1RT0	DI	DMD1RT0
DMD1RT0	DN	Pyrimidopyridazinone derivative 2
DMD1RT0	MI	TT6DM01
DMD1RT0	MN	Janus kinase 1 (JAK-1)
DMD1RT0	MT	DTT
DMD1RT0	MA	Inhibitor
DMD1RT0	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMD1RT0	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMD1RT0	DI	DMD1RT0
DMD1RT0	DN	Pyrimidopyridazinone derivative 2
DMD1RT0	MI	TTRMX3V
DMD1RT0	MN	Janus kinase 2 (JAK-2)
DMD1RT0	MT	DTT
DMD1RT0	MA	Inhibitor
DMD1RT0	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMD1RT0	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMD1RT0	DI	DMD1RT0
DMD1RT0	DN	Pyrimidopyridazinone derivative 2
DMD1RT0	MI	TTT7PJU
DMD1RT0	MN	Janus kinase 3 (JAK-3)
DMD1RT0	MT	DTT
DMD1RT0	MA	Inhibitor
DMD1RT0	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMD1RT0	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMD1RT0	DI	DMD1RT0
DMD1RT0	DN	Pyrimidopyridazinone derivative 2
DMD1RT0	MI	TTOU65C
DMD1RT0	MN	Tyrosine-protein kinase SYK (SYK)
DMD1RT0	MT	DTT
DMD1RT0	MA	Inhibitor
DMD1RT0	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMD1RT0	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DM0RC1Z	DI	DM0RC1Z
DM0RC1Z	DN	Pyrrole derivative 1
DM0RC1Z	MI	TT6OEDT
DM0RC1Z	MN	Cannabinoid receptor 1 (CB1)
DM0RC1Z	MT	DTT
DM0RC1Z	MA	Antagonist
DM0RC1Z	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DM0RC1Z	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMMNKFX	DI	DMMNKFX
DMMNKFX	DN	Pyrrole derivative 2
DMMNKFX	MI	TT6OEDT
DMMNKFX	MN	Cannabinoid receptor 1 (CB1)
DMMNKFX	MT	DTT
DMMNKFX	MA	Antagonist
DMMNKFX	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMMNKFX	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMFV64B	DI	DMFV64B
DMFV64B	DN	Pyrrole derivative 3
DMFV64B	MI	TT6OEDT
DMFV64B	MN	Cannabinoid receptor 1 (CB1)
DMFV64B	MT	DTT
DMFV64B	MA	Antagonist
DMFV64B	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMFV64B	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMQDL43	DI	DMQDL43
DMQDL43	DN	Pyrrole derivative 4
DMQDL43	MI	TT6OEDT
DMQDL43	MN	Cannabinoid receptor 1 (CB1)
DMQDL43	MT	DTT
DMQDL43	MA	Antagonist
DMQDL43	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMQDL43	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMJUMC6	DI	DMJUMC6
DMJUMC6	DN	Pyrrole derivative 5
DMJUMC6	MI	TT6OEDT
DMJUMC6	MN	Cannabinoid receptor 1 (CB1)
DMJUMC6	MT	DTT
DMJUMC6	MA	Antagonist
DMJUMC6	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMJUMC6	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DM875RE	DI	DM875RE
DM875RE	DN	Pyrrole derivative 6
DM875RE	MI	TT6OEDT
DM875RE	MN	Cannabinoid receptor 1 (CB1)
DM875RE	MT	DTT
DM875RE	MA	Antagonist
DM875RE	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DM875RE	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMZCERW	DI	DMZCERW
DMZCERW	DN	Pyrrole derivative 7
DMZCERW	MI	TT6DM01
DMZCERW	MN	Janus kinase 1 (JAK-1)
DMZCERW	MT	DTT
DMZCERW	MA	Inhibitor
DMZCERW	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMZCERW	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMZCERW	DI	DMZCERW
DMZCERW	DN	Pyrrole derivative 7
DMZCERW	MI	TTRMX3V
DMZCERW	MN	Janus kinase 2 (JAK-2)
DMZCERW	MT	DTT
DMZCERW	MA	Inhibitor
DMZCERW	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMZCERW	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMZCERW	DI	DMZCERW
DMZCERW	DN	Pyrrole derivative 7
DMZCERW	MI	TTBYWP2
DMZCERW	MN	TYK2 tyrosine kinase (TYK2)
DMZCERW	MT	DTT
DMZCERW	MA	Inhibitor
DMZCERW	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMZCERW	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DM1A0VB	DI	DM1A0VB
DM1A0VB	DN	Pyrrole six-membered heteroaryl ring derivative 1
DM1A0VB	MI	TT6DM01
DM1A0VB	MN	Janus kinase 1 (JAK-1)
DM1A0VB	MT	DTT
DM1A0VB	MA	Inhibitor
DM1A0VB	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DM1A0VB	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DM1A0VB	DI	DM1A0VB
DM1A0VB	DN	Pyrrole six-membered heteroaryl ring derivative 1
DM1A0VB	MI	TTRMX3V
DM1A0VB	MN	Janus kinase 2 (JAK-2)
DM1A0VB	MT	DTT
DM1A0VB	MA	Inhibitor
DM1A0VB	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DM1A0VB	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DM1A0VB	DI	DM1A0VB
DM1A0VB	DN	Pyrrole six-membered heteroaryl ring derivative 1
DM1A0VB	MI	TTT7PJU
DM1A0VB	MN	Janus kinase 3 (JAK-3)
DM1A0VB	MT	DTT
DM1A0VB	MA	Inhibitor
DM1A0VB	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DM1A0VB	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMJK98Z	DI	DMJK98Z
DMJK98Z	DN	Pyrrolidine carboxamide derivative 1
DMJK98Z	MI	TTQHWNA
DMJK98Z	MN	Hypoxia-inducible factor 1 alpha (HIF-1A)
DMJK98Z	MT	DTT
DMJK98Z	MA	Inhibitor
DMJK98Z	RN	Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22.
DMJK98Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/26882240

DMJK98Z	DI	DMJK98Z
DMJK98Z	DN	Pyrrolidine carboxamide derivative 1
DMJK98Z	MI	TTEMWSD
DMJK98Z	MN	von Hippel-Lindau disease tumor suppressor (VHL)
DMJK98Z	MT	DTT
DMJK98Z	MA	Inhibitor
DMJK98Z	RN	Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22.
DMJK98Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/26882240

DMKDX6W	DI	DMKDX6W
DMKDX6W	DN	Pyrrolidine carboxamide derivative 2
DMKDX6W	MI	TTTJZ4M
DMKDX6W	MN	Prolylcarboxypeptidase (PRCP)
DMKDX6W	MT	DTT
DMKDX6W	MA	Inhibitor
DMKDX6W	RN	Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088.
DMKDX6W	RU	https://www.ncbi.nlm.nih.gov/pubmed/28699813

DMXALJE	DI	DMXALJE
DMXALJE	DN	Pyrrolidine derivative 1
DMXALJE	MI	TTHS256
DMXALJE	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMXALJE	MT	DTT
DMXALJE	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMXALJE	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMCQN5M	DI	DMCQN5M
DMCQN5M	DN	Pyrrolidine derivative 10
DMCQN5M	MI	TTSCIUP
DMCQN5M	MN	Oxytocin receptor (OTR)
DMCQN5M	MT	DTT
DMCQN5M	MA	Antagonist
DMCQN5M	RN	A patent review of oxytocin receptor antagonists 2013-2017.Expert Opin Ther Pat. 2017 Dec;27(12):1287-1290.
DMCQN5M	RU	https://www.ncbi.nlm.nih.gov/pubmed/28906174

DMIHRV9	DI	DMIHRV9
DMIHRV9	DN	Pyrrolidine derivative 11
DMIHRV9	MI	TTSCIUP
DMIHRV9	MN	Oxytocin receptor (OTR)
DMIHRV9	MT	DTT
DMIHRV9	MA	Antagonist
DMIHRV9	RN	A patent review of oxytocin receptor antagonists 2013-2017.Expert Opin Ther Pat. 2017 Dec;27(12):1287-1290.
DMIHRV9	RU	https://www.ncbi.nlm.nih.gov/pubmed/28906174

DMXO8R5	DI	DMXO8R5
DMXO8R5	DN	Pyrrolidine derivative 12
DMXO8R5	MI	TTSCIUP
DMXO8R5	MN	Oxytocin receptor (OTR)
DMXO8R5	MT	DTT
DMXO8R5	MA	Antagonist
DMXO8R5	RN	A patent review of oxytocin receptor antagonists 2013-2017.Expert Opin Ther Pat. 2017 Dec;27(12):1287-1290.
DMXO8R5	RU	https://www.ncbi.nlm.nih.gov/pubmed/28906174

DM3VA8P	DI	DM3VA8P
DM3VA8P	DN	Pyrrolidine derivative 13
DM3VA8P	MI	TTSCIUP
DM3VA8P	MN	Oxytocin receptor (OTR)
DM3VA8P	MT	DTT
DM3VA8P	MA	Antagonist
DM3VA8P	RN	A patent review of oxytocin receptor antagonists 2013-2017.Expert Opin Ther Pat. 2017 Dec;27(12):1287-1290.
DM3VA8P	RU	https://www.ncbi.nlm.nih.gov/pubmed/28906174

DM3VA8P	DI	DM3VA8P
DM3VA8P	DN	Pyrrolidine derivative 13
DM3VA8P	MI	TT4TFGN
DM3VA8P	MN	Vasopressin V1a receptor (V1AR)
DM3VA8P	MT	DTT
DM3VA8P	MA	Antagonist
DM3VA8P	RN	A patent review of oxytocin receptor antagonists 2013-2017.Expert Opin Ther Pat. 2017 Dec;27(12):1287-1290.
DM3VA8P	RU	https://www.ncbi.nlm.nih.gov/pubmed/28906174

DM5WA29	DI	DM5WA29
DM5WA29	DN	Pyrrolidine derivative 2
DM5WA29	MI	TTHS256
DM5WA29	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM5WA29	MT	DTT
DM5WA29	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DM5WA29	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMHM8WJ	DI	DMHM8WJ
DMHM8WJ	DN	Pyrrolidine derivative 3
DMHM8WJ	MI	TTHS256
DMHM8WJ	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMHM8WJ	MT	DTT
DMHM8WJ	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMHM8WJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMZ2HBL	DI	DMZ2HBL
DMZ2HBL	DN	Pyrrolidine derivative 4
DMZ2HBL	MI	TTHS256
DMZ2HBL	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMZ2HBL	MT	DTT
DMZ2HBL	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMZ2HBL	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DM5NKXO	DI	DM5NKXO
DM5NKXO	DN	Pyrrolidine derivative 5
DM5NKXO	MI	TTHS256
DM5NKXO	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM5NKXO	MT	DTT
DM5NKXO	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DM5NKXO	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMJ3ZP2	DI	DMJ3ZP2
DMJ3ZP2	DN	Pyrrolidine derivative 6
DMJ3ZP2	MI	TT9O6WS
DMJ3ZP2	MN	Glucagon receptor (GCGR)
DMJ3ZP2	MT	DTT
DMJ3ZP2	MA	Antagonist
DMJ3ZP2	RN	Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30.
DMJ3ZP2	RU	https://www.ncbi.nlm.nih.gov/pubmed/25828189

DMIOJD6	DI	DMIOJD6
DMIOJD6	DN	Pyrrolidine derivative 7
DMIOJD6	MI	TT9O6WS
DMIOJD6	MN	Glucagon receptor (GCGR)
DMIOJD6	MT	DTT
DMIOJD6	MA	Antagonist
DMIOJD6	RN	Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30.
DMIOJD6	RU	https://www.ncbi.nlm.nih.gov/pubmed/25828189

DMWPXJ5	DI	DMWPXJ5
DMWPXJ5	DN	Pyrrolidine derivative 8
DMWPXJ5	MI	TT9O6WS
DMWPXJ5	MN	Glucagon receptor (GCGR)
DMWPXJ5	MT	DTT
DMWPXJ5	MA	Antagonist
DMWPXJ5	RN	Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30.
DMWPXJ5	RU	https://www.ncbi.nlm.nih.gov/pubmed/25828189

DMZK658	DI	DMZK658
DMZK658	DN	Pyrrolidine derivative 9
DMZK658	MI	TTSCIUP
DMZK658	MN	Oxytocin receptor (OTR)
DMZK658	MT	DTT
DMZK658	MA	Antagonist
DMZK658	RN	A patent review of oxytocin receptor antagonists 2013-2017.Expert Opin Ther Pat. 2017 Dec;27(12):1287-1290.
DMZK658	RU	https://www.ncbi.nlm.nih.gov/pubmed/28906174

DM7DF6Z	DI	DM7DF6Z
DM7DF6Z	DN	Pyrrolidinyl urea derivative 1
DM7DF6Z	MI	TTDP1UC
DM7DF6Z	MN	Fatty acid amide hydrolase (FAAH)
DM7DF6Z	MT	DTT
DM7DF6Z	MA	Inhibitor
DM7DF6Z	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DM7DF6Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMV6YXJ	DI	DMV6YXJ
DMV6YXJ	DN	Pyrrolidinyl urea derivative 10
DMV6YXJ	MI	TTTDVOJ
DMV6YXJ	MN	Tropomyosin-related kinase A (TrkA)
DMV6YXJ	MT	DTT
DMV6YXJ	MA	Inhibitor
DMV6YXJ	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMV6YXJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMWKSF3	DI	DMWKSF3
DMWKSF3	DN	Pyrrolidinyl urea derivative 11
DMWKSF3	MI	TTTDVOJ
DMWKSF3	MN	Tropomyosin-related kinase A (TrkA)
DMWKSF3	MT	DTT
DMWKSF3	MA	Inhibitor
DMWKSF3	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMWKSF3	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMJ6IE5	DI	DMJ6IE5
DMJ6IE5	DN	Pyrrolidinyl urea derivative 12
DMJ6IE5	MI	TTTDVOJ
DMJ6IE5	MN	Tropomyosin-related kinase A (TrkA)
DMJ6IE5	MT	DTT
DMJ6IE5	MA	Inhibitor
DMJ6IE5	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMJ6IE5	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DM3VL82	DI	DM3VL82
DM3VL82	DN	Pyrrolidinyl urea derivative 13
DM3VL82	MI	TTTDVOJ
DM3VL82	MN	Tropomyosin-related kinase A (TrkA)
DM3VL82	MT	DTT
DM3VL82	MA	Inhibitor
DM3VL82	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DM3VL82	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMYFP95	DI	DMYFP95
DMYFP95	DN	Pyrrolidinyl urea derivative 2
DMYFP95	MI	TTTDVOJ
DMYFP95	MN	Tropomyosin-related kinase A (TrkA)
DMYFP95	MT	DTT
DMYFP95	MA	Inhibitor
DMYFP95	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMYFP95	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMFDLHN	DI	DMFDLHN
DMFDLHN	DN	Pyrrolidinyl urea derivative 3
DMFDLHN	MI	TTTDVOJ
DMFDLHN	MN	Tropomyosin-related kinase A (TrkA)
DMFDLHN	MT	DTT
DMFDLHN	MA	Inhibitor
DMFDLHN	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMFDLHN	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DM8SZKU	DI	DM8SZKU
DM8SZKU	DN	Pyrrolidinyl urea derivative 4
DM8SZKU	MI	TTTDVOJ
DM8SZKU	MN	Tropomyosin-related kinase A (TrkA)
DM8SZKU	MT	DTT
DM8SZKU	MA	Inhibitor
DM8SZKU	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DM8SZKU	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMU51T4	DI	DMU51T4
DMU51T4	DN	Pyrrolidinyl urea derivative 5
DMU51T4	MI	TTTDVOJ
DMU51T4	MN	Tropomyosin-related kinase A (TrkA)
DMU51T4	MT	DTT
DMU51T4	MA	Inhibitor
DMU51T4	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMU51T4	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DM01GEB	DI	DM01GEB
DM01GEB	DN	Pyrrolidinyl urea derivative 6
DM01GEB	MI	TTTDVOJ
DM01GEB	MN	Tropomyosin-related kinase A (TrkA)
DM01GEB	MT	DTT
DM01GEB	MA	Inhibitor
DM01GEB	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DM01GEB	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMYADJP	DI	DMYADJP
DMYADJP	DN	Pyrrolidinyl urea derivative 7
DMYADJP	MI	TTTDVOJ
DMYADJP	MN	Tropomyosin-related kinase A (TrkA)
DMYADJP	MT	DTT
DMYADJP	MA	Inhibitor
DMYADJP	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMYADJP	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMW2JG8	DI	DMW2JG8
DMW2JG8	DN	Pyrrolidinyl urea derivative 8
DMW2JG8	MI	TTTDVOJ
DMW2JG8	MN	Tropomyosin-related kinase A (TrkA)
DMW2JG8	MT	DTT
DMW2JG8	MA	Inhibitor
DMW2JG8	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMW2JG8	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMO1I4W	DI	DMO1I4W
DMO1I4W	DN	Pyrrolidinyl urea derivative 9
DMO1I4W	MI	TTTDVOJ
DMO1I4W	MN	Tropomyosin-related kinase A (TrkA)
DMO1I4W	MT	DTT
DMO1I4W	MA	Inhibitor
DMO1I4W	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMO1I4W	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DM5RCW8	DI	DM5RCW8
DM5RCW8	DN	Pyrrolo[1,2-c]pyrazole derivative 1
DM5RCW8	MI	TTZJYKH
DM5RCW8	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DM5RCW8	MT	DTT
DM5RCW8	MA	Inhibitor
DM5RCW8	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DM5RCW8	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMI0AW7	DI	DMI0AW7
DMI0AW7	DN	Pyrrolo[1,2-f]triazine derivative 1
DMI0AW7	MI	TTDIGC1
DMI0AW7	MN	Dipeptidyl peptidase 4 (DPP-4)
DMI0AW7	MT	DTT
DMI0AW7	MA	Inhibitor
DMI0AW7	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMI0AW7	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DM7DU9P	DI	DM7DU9P
DM7DU9P	DN	Pyrrolo[1,2-f]triazine derivative 2
DM7DU9P	MI	TTDIGC1
DM7DU9P	MN	Dipeptidyl peptidase 4 (DPP-4)
DM7DU9P	MT	DTT
DM7DU9P	MA	Inhibitor
DM7DU9P	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DM7DU9P	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DMWXZBF	DI	DMWXZBF
DMWXZBF	DN	Pyrrolo[2,3-b]pyridine carboxamide derivative 1
DMWXZBF	MI	TTS7G69
DMWXZBF	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMWXZBF	MT	DTT
DMWXZBF	MA	Inhibitor
DMWXZBF	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMWXZBF	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMVKCQU	DI	DMVKCQU
DMVKCQU	DN	Pyrrolo[2,3-b]pyridine derivative 1
DMVKCQU	MI	TTTDVOJ
DMVKCQU	MN	Tropomyosin-related kinase A (TrkA)
DMVKCQU	MT	DTT
DMVKCQU	MA	Inhibitor
DMVKCQU	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMVKCQU	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DM7IPWB	DI	DM7IPWB
DM7IPWB	DN	Pyrrolo[2,3-b]pyridine derivative 2
DM7IPWB	MI	TTTDVOJ
DM7IPWB	MN	Tropomyosin-related kinase A (TrkA)
DM7IPWB	MT	DTT
DM7IPWB	MA	Inhibitor
DM7IPWB	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DM7IPWB	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMCYOL7	DI	DMCYOL7
DMCYOL7	DN	Pyrrolo[2,3-b]pyridine derivative 3
DMCYOL7	MI	TTTDVOJ
DMCYOL7	MN	Tropomyosin-related kinase A (TrkA)
DMCYOL7	MT	DTT
DMCYOL7	MA	Inhibitor
DMCYOL7	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMCYOL7	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMJBTZG	DI	DMJBTZG
DMJBTZG	DN	Pyrrolo[2,3-b]pyridine derivative 4
DMJBTZG	MI	TTIV39N
DMJBTZG	MN	Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I)
DMJBTZG	MT	DTT
DMJBTZG	MA	Inhibitor
DMJBTZG	RN	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
DMJBTZG	RU	https://www.ncbi.nlm.nih.gov/pubmed/25656651

DMYUEA6	DI	DMYUEA6
DMYUEA6	DN	Pyrrolo[2,3-d]pyrimidine derivative 1
DMYUEA6	MI	TTIXKA4
DMYUEA6	MN	Ribosomal protein S6 kinase alpha-1 (RSK1)
DMYUEA6	MT	DTT
DMYUEA6	MA	Inhibitor
DMYUEA6	RN	Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78.
DMYUEA6	RU	https://www.ncbi.nlm.nih.gov/pubmed/27410995

DMRWG2E	DI	DMRWG2E
DMRWG2E	DN	Pyrrolo[2,3-d]pyrimidine derivative 10
DMRWG2E	MI	TTH6V3D
DMRWG2E	MN	Cyclin-dependent kinase 1 (CDK1)
DMRWG2E	MT	DTT
DMRWG2E	MA	Inhibitor
DMRWG2E	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMRWG2E	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMRWG2E	DI	DMRWG2E
DMRWG2E	DN	Pyrrolo[2,3-d]pyrimidine derivative 10
DMRWG2E	MI	TT0PG8F
DMRWG2E	MN	Cyclin-dependent kinase 4 (CDK4)
DMRWG2E	MT	DTT
DMRWG2E	MA	Inhibitor
DMRWG2E	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMRWG2E	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DM983CY	DI	DM983CY
DM983CY	DN	Pyrrolo[2,3-d]pyrimidine derivative 11
DM983CY	MI	TT6DM01
DM983CY	MN	Janus kinase 1 (JAK-1)
DM983CY	MT	DTT
DM983CY	MA	Inhibitor
DM983CY	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DM983CY	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DM983CY	DI	DM983CY
DM983CY	DN	Pyrrolo[2,3-d]pyrimidine derivative 11
DM983CY	MI	TTRMX3V
DM983CY	MN	Janus kinase 2 (JAK-2)
DM983CY	MT	DTT
DM983CY	MA	Inhibitor
DM983CY	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DM983CY	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMYTV49	DI	DMYTV49
DMYTV49	DN	Pyrrolo[2,3-d]pyrimidine derivative 12
DMYTV49	MI	TTGM6VW
DMYTV49	MN	Tyrosine-protein kinase BTK (ATK)
DMYTV49	MT	DTT
DMYTV49	MA	Inhibitor
DMYTV49	RN	Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318.
DMYTV49	RU	https://www.ncbi.nlm.nih.gov/pubmed/28705083

DMTGELI	DI	DMTGELI
DMTGELI	DN	Pyrrolo[2,3-d]pyrimidine derivative 13
DMTGELI	MI	TTGM6VW
DMTGELI	MN	Tyrosine-protein kinase BTK (ATK)
DMTGELI	MT	DTT
DMTGELI	MA	Inhibitor
DMTGELI	RN	Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318.
DMTGELI	RU	https://www.ncbi.nlm.nih.gov/pubmed/28705083

DMK4LOH	DI	DMK4LOH
DMK4LOH	DN	Pyrrolo[2,3-d]pyrimidine derivative 14
DMK4LOH	MI	TTGM6VW
DMK4LOH	MN	Tyrosine-protein kinase BTK (ATK)
DMK4LOH	MT	DTT
DMK4LOH	MA	Inhibitor
DMK4LOH	RN	Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318.
DMK4LOH	RU	https://www.ncbi.nlm.nih.gov/pubmed/28705083

DMZ4PLC	DI	DMZ4PLC
DMZ4PLC	DN	Pyrrolo[2,3-d]pyrimidine derivative 15
DMZ4PLC	MI	TTGM6VW
DMZ4PLC	MN	Tyrosine-protein kinase BTK (ATK)
DMZ4PLC	MT	DTT
DMZ4PLC	MA	Inhibitor
DMZ4PLC	RN	Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318.
DMZ4PLC	RU	https://www.ncbi.nlm.nih.gov/pubmed/28705083

DM1GYZQ	DI	DM1GYZQ
DM1GYZQ	DN	Pyrrolo[2,3-d]pyrimidine derivative 16
DM1GYZQ	MI	TTGM6VW
DM1GYZQ	MN	Tyrosine-protein kinase BTK (ATK)
DM1GYZQ	MT	DTT
DM1GYZQ	MA	Inhibitor
DM1GYZQ	RN	Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318.
DM1GYZQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28705083

DMXWVN2	DI	DMXWVN2
DMXWVN2	DN	Pyrrolo[2,3-d]pyrimidine derivative 17
DMXWVN2	MI	TTGM6VW
DMXWVN2	MN	Tyrosine-protein kinase BTK (ATK)
DMXWVN2	MT	DTT
DMXWVN2	MA	Inhibitor
DMXWVN2	RN	Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318.
DMXWVN2	RU	https://www.ncbi.nlm.nih.gov/pubmed/28705083

DMSXH8K	DI	DMSXH8K
DMSXH8K	DN	Pyrrolo[2,3-d]pyrimidine derivative 18
DMSXH8K	MI	TTGM6VW
DMSXH8K	MN	Tyrosine-protein kinase BTK (ATK)
DMSXH8K	MT	DTT
DMSXH8K	MA	Inhibitor
DMSXH8K	RN	Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318.
DMSXH8K	RU	https://www.ncbi.nlm.nih.gov/pubmed/28705083

DMC9TGM	DI	DMC9TGM
DMC9TGM	DN	Pyrrolo[2,3-d]pyrimidine derivative 19
DMC9TGM	MI	TTGM6VW
DMC9TGM	MN	Tyrosine-protein kinase BTK (ATK)
DMC9TGM	MT	DTT
DMC9TGM	MA	Inhibitor
DMC9TGM	RN	Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318.
DMC9TGM	RU	https://www.ncbi.nlm.nih.gov/pubmed/28705083

DMJFYK1	DI	DMJFYK1
DMJFYK1	DN	Pyrrolo[2,3-d]pyrimidine derivative 2
DMJFYK1	MI	TTIXKA4
DMJFYK1	MN	Ribosomal protein S6 kinase alpha-1 (RSK1)
DMJFYK1	MT	DTT
DMJFYK1	MA	Inhibitor
DMJFYK1	RN	Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78.
DMJFYK1	RU	https://www.ncbi.nlm.nih.gov/pubmed/27410995

DM2E7DJ	DI	DM2E7DJ
DM2E7DJ	DN	Pyrrolo[2,3-d]pyrimidine derivative 20
DM2E7DJ	MI	TTGM6VW
DM2E7DJ	MN	Tyrosine-protein kinase BTK (ATK)
DM2E7DJ	MT	DTT
DM2E7DJ	MA	Inhibitor
DM2E7DJ	RN	Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318.
DM2E7DJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28705083

DM9S07A	DI	DM9S07A
DM9S07A	DN	Pyrrolo[2,3-d]pyrimidine derivative 21
DM9S07A	MI	TTGM6VW
DM9S07A	MN	Tyrosine-protein kinase BTK (ATK)
DM9S07A	MT	DTT
DM9S07A	MA	Inhibitor
DM9S07A	RN	Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318.
DM9S07A	RU	https://www.ncbi.nlm.nih.gov/pubmed/28705083

DMHWNSD	DI	DMHWNSD
DMHWNSD	DN	Pyrrolo[2,3-d]pyrimidine derivative 22
DMHWNSD	MI	TTGM6VW
DMHWNSD	MN	Tyrosine-protein kinase BTK (ATK)
DMHWNSD	MT	DTT
DMHWNSD	MA	Inhibitor
DMHWNSD	RN	Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318.
DMHWNSD	RU	https://www.ncbi.nlm.nih.gov/pubmed/28705083

DMTMWKX	DI	DMTMWKX
DMTMWKX	DN	Pyrrolo[2,3-d]pyrimidine derivative 23
DMTMWKX	MI	TTGM6VW
DMTMWKX	MN	Tyrosine-protein kinase BTK (ATK)
DMTMWKX	MT	DTT
DMTMWKX	MA	Inhibitor
DMTMWKX	RN	Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318.
DMTMWKX	RU	https://www.ncbi.nlm.nih.gov/pubmed/28705083

DMZQF9R	DI	DMZQF9R
DMZQF9R	DN	Pyrrolo[2,3-d]pyrimidine derivative 24
DMZQF9R	MI	TTGKNB4
DMZQF9R	MN	Epidermal growth factor receptor (EGFR)
DMZQF9R	MT	DTT
DMZQF9R	MA	Inhibitor
DMZQF9R	RN	Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318.
DMZQF9R	RU	https://www.ncbi.nlm.nih.gov/pubmed/28705083

DMWU3O4	DI	DMWU3O4
DMWU3O4	DN	Pyrrolo[2,3-d]pyrimidine derivative 25
DMWU3O4	MI	TTGM6VW
DMWU3O4	MN	Tyrosine-protein kinase BTK (ATK)
DMWU3O4	MT	DTT
DMWU3O4	MA	Inhibitor
DMWU3O4	RN	Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318.
DMWU3O4	RU	https://www.ncbi.nlm.nih.gov/pubmed/28705083

DMX1ANB	DI	DMX1ANB
DMX1ANB	DN	Pyrrolo[2,3-d]pyrimidine derivative 26
DMX1ANB	MI	TTGM6VW
DMX1ANB	MN	Tyrosine-protein kinase BTK (ATK)
DMX1ANB	MT	DTT
DMX1ANB	MA	Inhibitor
DMX1ANB	RN	Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318.
DMX1ANB	RU	https://www.ncbi.nlm.nih.gov/pubmed/28705083

DMCZJ1W	DI	DMCZJ1W
DMCZJ1W	DN	Pyrrolo[2,3-d]pyrimidine derivative 27
DMCZJ1W	MI	TTGM6VW
DMCZJ1W	MN	Tyrosine-protein kinase BTK (ATK)
DMCZJ1W	MT	DTT
DMCZJ1W	MA	Inhibitor
DMCZJ1W	RN	Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318.
DMCZJ1W	RU	https://www.ncbi.nlm.nih.gov/pubmed/28705083

DMXRJI2	DI	DMXRJI2
DMXRJI2	DN	Pyrrolo[2,3-d]pyrimidine derivative 28
DMXRJI2	MI	TTGBPJE
DMXRJI2	MN	PI3-kinase delta (PIK3CD)
DMXRJI2	MT	DTT
DMXRJI2	MA	Inhibitor
DMXRJI2	RN	Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318.
DMXRJI2	RU	https://www.ncbi.nlm.nih.gov/pubmed/28705083

DMXRJI2	DI	DMXRJI2
DMXRJI2	DN	Pyrrolo[2,3-d]pyrimidine derivative 28
DMXRJI2	MI	TTGM6VW
DMXRJI2	MN	Tyrosine-protein kinase BTK (ATK)
DMXRJI2	MT	DTT
DMXRJI2	MA	Inhibitor
DMXRJI2	RN	Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318.
DMXRJI2	RU	https://www.ncbi.nlm.nih.gov/pubmed/28705083

DM6IJRG	DI	DM6IJRG
DM6IJRG	DN	Pyrrolo[2,3-d]pyrimidine derivative 29
DM6IJRG	MI	TTGM6VW
DM6IJRG	MN	Tyrosine-protein kinase BTK (ATK)
DM6IJRG	MT	DTT
DM6IJRG	MA	Inhibitor
DM6IJRG	RN	Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318.
DM6IJRG	RU	https://www.ncbi.nlm.nih.gov/pubmed/28705083

DMTX1G4	DI	DMTX1G4
DMTX1G4	DN	Pyrrolo[2,3-d]pyrimidine derivative 3
DMTX1G4	MI	TTTDVOJ
DMTX1G4	MN	Tropomyosin-related kinase A (TrkA)
DMTX1G4	MT	DTT
DMTX1G4	MA	Inhibitor
DMTX1G4	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMTX1G4	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DM57W29	DI	DM57W29
DM57W29	DN	Pyrrolo[2,3-d]pyrimidine derivative 30
DM57W29	MI	TTGM6VW
DM57W29	MN	Tyrosine-protein kinase BTK (ATK)
DM57W29	MT	DTT
DM57W29	MA	Inhibitor
DM57W29	RN	Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318.
DM57W29	RU	https://www.ncbi.nlm.nih.gov/pubmed/28705083

DMA9PM4	DI	DMA9PM4
DMA9PM4	DN	Pyrrolo[2,3-d]pyrimidine derivative 31
DMA9PM4	MI	TTGM6VW
DMA9PM4	MN	Tyrosine-protein kinase BTK (ATK)
DMA9PM4	MT	DTT
DMA9PM4	MA	Inhibitor
DMA9PM4	RN	Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318.
DMA9PM4	RU	https://www.ncbi.nlm.nih.gov/pubmed/28705083

DMQGI0R	DI	DMQGI0R
DMQGI0R	DN	Pyrrolo[2,3-d]pyrimidine derivative 32
DMQGI0R	MI	TTGM6VW
DMQGI0R	MN	Tyrosine-protein kinase BTK (ATK)
DMQGI0R	MT	DTT
DMQGI0R	MA	Inhibitor
DMQGI0R	RN	Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318.
DMQGI0R	RU	https://www.ncbi.nlm.nih.gov/pubmed/28705083

DM6BTMX	DI	DM6BTMX
DM6BTMX	DN	Pyrrolo[2,3-d]pyrimidine derivative 33
DM6BTMX	MI	TTGM6VW
DM6BTMX	MN	Tyrosine-protein kinase BTK (ATK)
DM6BTMX	MT	DTT
DM6BTMX	MA	Inhibitor
DM6BTMX	RN	Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318.
DM6BTMX	RU	https://www.ncbi.nlm.nih.gov/pubmed/28705083

DMXU08A	DI	DMXU08A
DMXU08A	DN	Pyrrolo[2,3-d]pyrimidine derivative 35
DMXU08A	MI	TTUM2ZR
DMXU08A	MN	Ribosomal protein S6 kinase alpha-3 (RSK3)
DMXU08A	MT	DTT
DMXU08A	MA	Inhibitor
DMXU08A	RN	Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78.
DMXU08A	RU	https://www.ncbi.nlm.nih.gov/pubmed/27410995

DME0WSR	DI	DME0WSR
DME0WSR	DN	Pyrrolo[2,3-d]pyrimidine derivative 4
DME0WSR	MI	TTKN7QR
DME0WSR	MN	BDNF/NT-3 growth factors receptor (TrkB)
DME0WSR	MT	DTT
DME0WSR	MA	Inhibitor
DME0WSR	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DME0WSR	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DME0WSR	DI	DME0WSR
DME0WSR	DN	Pyrrolo[2,3-d]pyrimidine derivative 4
DME0WSR	MI	TTXABCW
DME0WSR	MN	NT-3 growth factor receptor (TrkC)
DME0WSR	MT	DTT
DME0WSR	MA	Inhibitor
DME0WSR	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DME0WSR	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DME0WSR	DI	DME0WSR
DME0WSR	DN	Pyrrolo[2,3-d]pyrimidine derivative 4
DME0WSR	MI	TTTDVOJ
DME0WSR	MN	Tropomyosin-related kinase A (TrkA)
DME0WSR	MT	DTT
DME0WSR	MA	Inhibitor
DME0WSR	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DME0WSR	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DM3D1L6	DI	DM3D1L6
DM3D1L6	DN	Pyrrolo[2,3-d]pyrimidine derivative 6
DM3D1L6	MI	TT6DM01
DM3D1L6	MN	Janus kinase 1 (JAK-1)
DM3D1L6	MT	DTT
DM3D1L6	MA	Inhibitor
DM3D1L6	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DM3D1L6	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DM3D1L6	DI	DM3D1L6
DM3D1L6	DN	Pyrrolo[2,3-d]pyrimidine derivative 6
DM3D1L6	MI	TTRMX3V
DM3D1L6	MN	Janus kinase 2 (JAK-2)
DM3D1L6	MT	DTT
DM3D1L6	MA	Inhibitor
DM3D1L6	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DM3D1L6	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DM3D1L6	DI	DM3D1L6
DM3D1L6	DN	Pyrrolo[2,3-d]pyrimidine derivative 6
DM3D1L6	MI	TTT7PJU
DM3D1L6	MN	Janus kinase 3 (JAK-3)
DM3D1L6	MT	DTT
DM3D1L6	MA	Inhibitor
DM3D1L6	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DM3D1L6	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DM3D1L6	DI	DM3D1L6
DM3D1L6	DN	Pyrrolo[2,3-d]pyrimidine derivative 6
DM3D1L6	MI	TTBYWP2
DM3D1L6	MN	TYK2 tyrosine kinase (TYK2)
DM3D1L6	MT	DTT
DM3D1L6	MA	Inhibitor
DM3D1L6	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DM3D1L6	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DM30Y8M	DI	DM30Y8M
DM30Y8M	DN	Pyrrolo[2,3-d]pyrimidine derivative 7
DM30Y8M	MI	TT6DM01
DM30Y8M	MN	Janus kinase 1 (JAK-1)
DM30Y8M	MT	DTT
DM30Y8M	MA	Inhibitor
DM30Y8M	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DM30Y8M	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DM30Y8M	DI	DM30Y8M
DM30Y8M	DN	Pyrrolo[2,3-d]pyrimidine derivative 7
DM30Y8M	MI	TTRMX3V
DM30Y8M	MN	Janus kinase 2 (JAK-2)
DM30Y8M	MT	DTT
DM30Y8M	MA	Inhibitor
DM30Y8M	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DM30Y8M	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DM30Y8M	DI	DM30Y8M
DM30Y8M	DN	Pyrrolo[2,3-d]pyrimidine derivative 7
DM30Y8M	MI	TTT7PJU
DM30Y8M	MN	Janus kinase 3 (JAK-3)
DM30Y8M	MT	DTT
DM30Y8M	MA	Inhibitor
DM30Y8M	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DM30Y8M	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DM30Y8M	DI	DM30Y8M
DM30Y8M	DN	Pyrrolo[2,3-d]pyrimidine derivative 7
DM30Y8M	MI	TTBYWP2
DM30Y8M	MN	TYK2 tyrosine kinase (TYK2)
DM30Y8M	MT	DTT
DM30Y8M	MA	Inhibitor
DM30Y8M	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DM30Y8M	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMAW6KU	DI	DMAW6KU
DMAW6KU	DN	Pyrrolo[2,3-d]pyrimidine derivative 8
DMAW6KU	MI	TT6DM01
DMAW6KU	MN	Janus kinase 1 (JAK-1)
DMAW6KU	MT	DTT
DMAW6KU	MA	Inhibitor
DMAW6KU	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMAW6KU	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMAW6KU	DI	DMAW6KU
DMAW6KU	DN	Pyrrolo[2,3-d]pyrimidine derivative 8
DMAW6KU	MI	TTRMX3V
DMAW6KU	MN	Janus kinase 2 (JAK-2)
DMAW6KU	MT	DTT
DMAW6KU	MA	Inhibitor
DMAW6KU	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMAW6KU	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMAW6KU	DI	DMAW6KU
DMAW6KU	DN	Pyrrolo[2,3-d]pyrimidine derivative 8
DMAW6KU	MI	TTT7PJU
DMAW6KU	MN	Janus kinase 3 (JAK-3)
DMAW6KU	MT	DTT
DMAW6KU	MA	Inhibitor
DMAW6KU	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMAW6KU	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMAW6KU	DI	DMAW6KU
DMAW6KU	DN	Pyrrolo[2,3-d]pyrimidine derivative 8
DMAW6KU	MI	TTBYWP2
DMAW6KU	MN	TYK2 tyrosine kinase (TYK2)
DMAW6KU	MT	DTT
DMAW6KU	MA	Inhibitor
DMAW6KU	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMAW6KU	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DM0HU5O	DI	DM0HU5O
DM0HU5O	DN	Pyrrolo[2,3-d]pyrimidine derivative 9
DM0HU5O	MI	TTH6V3D
DM0HU5O	MN	Cyclin-dependent kinase 1 (CDK1)
DM0HU5O	MT	DTT
DM0HU5O	MA	Inhibitor
DM0HU5O	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DM0HU5O	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DM0HU5O	DI	DM0HU5O
DM0HU5O	DN	Pyrrolo[2,3-d]pyrimidine derivative 9
DM0HU5O	MI	TT7HF4W
DM0HU5O	MN	Cyclin-dependent kinase 2 (CDK2)
DM0HU5O	MT	DTT
DM0HU5O	MA	Inhibitor
DM0HU5O	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DM0HU5O	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DM0HU5O	DI	DM0HU5O
DM0HU5O	DN	Pyrrolo[2,3-d]pyrimidine derivative 9
DM0HU5O	MI	TT0PG8F
DM0HU5O	MN	Cyclin-dependent kinase 4 (CDK4)
DM0HU5O	MT	DTT
DM0HU5O	MA	Inhibitor
DM0HU5O	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DM0HU5O	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMKF8HI	DI	DMKF8HI
DMKF8HI	DN	Pyrrolo[3,2-c]pyridine derivative 1
DMKF8HI	MI	TTTDVOJ
DMKF8HI	MN	Tropomyosin-related kinase A (TrkA)
DMKF8HI	MT	DTT
DMKF8HI	MA	Inhibitor
DMKF8HI	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMKF8HI	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMS4I6B	DI	DMS4I6B
DMS4I6B	DN	Pyrrolo-benzo-diazine derivative 1
DMS4I6B	MI	TT4G2JS
DMS4I6B	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DMS4I6B	MT	DTT
DMS4I6B	MA	Blocker
DMS4I6B	RN	Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90.
DMS4I6B	RU	https://www.ncbi.nlm.nih.gov/pubmed/25539043

DMP8I02	DI	DMP8I02
DMP8I02	DN	Pyrrolo-pyrazine derivative 1
DMP8I02	MI	TTT7PJU
DMP8I02	MN	Janus kinase 3 (JAK-3)
DMP8I02	MT	DTT
DMP8I02	MA	Inhibitor
DMP8I02	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMP8I02	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMO9Q8J	DI	DMO9Q8J
DMO9Q8J	DN	Pyrrolo-pyrazine derivative 2
DMO9Q8J	MI	TTT7PJU
DMO9Q8J	MN	Janus kinase 3 (JAK-3)
DMO9Q8J	MT	DTT
DMO9Q8J	MA	Inhibitor
DMO9Q8J	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMO9Q8J	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMLM6DT	DI	DMLM6DT
DMLM6DT	DN	Pyrrolo-pyrazine derivative 3
DMLM6DT	MI	TTT7PJU
DMLM6DT	MN	Janus kinase 3 (JAK-3)
DMLM6DT	MT	DTT
DMLM6DT	MA	Inhibitor
DMLM6DT	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMLM6DT	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMLM6DT	DI	DMLM6DT
DMLM6DT	DN	Pyrrolo-pyrazine derivative 3
DMLM6DT	MI	TTOU65C
DMLM6DT	MN	Tyrosine-protein kinase SYK (SYK)
DMLM6DT	MT	DTT
DMLM6DT	MA	Inhibitor
DMLM6DT	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMLM6DT	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMD1S92	DI	DMD1S92
DMD1S92	DN	Pyrrolo-pyrazine derivative 4
DMD1S92	MI	TTT7PJU
DMD1S92	MN	Janus kinase 3 (JAK-3)
DMD1S92	MT	DTT
DMD1S92	MA	Inhibitor
DMD1S92	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMD1S92	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMD1S92	DI	DMD1S92
DMD1S92	DN	Pyrrolo-pyrazine derivative 4
DMD1S92	MI	TTOU65C
DMD1S92	MN	Tyrosine-protein kinase SYK (SYK)
DMD1S92	MT	DTT
DMD1S92	MA	Inhibitor
DMD1S92	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMD1S92	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMQ2U54	DI	DMQ2U54
DMQ2U54	DN	Pyrrolo-pyridazine derivative 1
DMQ2U54	MI	TTK0FEA
DMQ2U54	MN	Leucine-rich repeat kinase 2 (LRRK2)
DMQ2U54	MT	DTT
DMQ2U54	MA	Inhibitor
DMQ2U54	RN	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
DMQ2U54	RU	https://www.ncbi.nlm.nih.gov/pubmed/28117607

DM9K5CI	DI	DM9K5CI
DM9K5CI	DN	Pyrrolo-pyridine derivative 1
DM9K5CI	MI	TTK0FEA
DM9K5CI	MN	Leucine-rich repeat kinase 2 (LRRK2)
DM9K5CI	MT	DTT
DM9K5CI	MA	Inhibitor
DM9K5CI	RN	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
DM9K5CI	RU	https://www.ncbi.nlm.nih.gov/pubmed/28117607

DMVNY5I	DI	DMVNY5I
DMVNY5I	DN	Pyrrolo-pyridine derivative 2
DMVNY5I	MI	TTK0FEA
DMVNY5I	MN	Leucine-rich repeat kinase 2 (LRRK2)
DMVNY5I	MT	DTT
DMVNY5I	MA	Inhibitor
DMVNY5I	RN	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
DMVNY5I	RU	https://www.ncbi.nlm.nih.gov/pubmed/28117607

DMVNY5I	DI	DMVNY5I
DMVNY5I	DN	Pyrrolo-pyridine derivative 2
DMVNY5I	MI	TT6AXLY
DMVNY5I	MN	Leucine-rich repeat kinase 2 G2019S mutant (LRRK2 G2019S)
DMVNY5I	MT	DTT
DMVNY5I	MA	Inhibitor
DMVNY5I	RN	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
DMVNY5I	RU	https://www.ncbi.nlm.nih.gov/pubmed/28117607

DMSNQEJ	DI	DMSNQEJ
DMSNQEJ	DN	Pyrrolo-pyridine derivative 3
DMSNQEJ	MI	TT6DM01
DMSNQEJ	MN	Janus kinase 1 (JAK-1)
DMSNQEJ	MT	DTT
DMSNQEJ	MA	Inhibitor
DMSNQEJ	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMSNQEJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMSNQEJ	DI	DMSNQEJ
DMSNQEJ	DN	Pyrrolo-pyridine derivative 3
DMSNQEJ	MI	TTRMX3V
DMSNQEJ	MN	Janus kinase 2 (JAK-2)
DMSNQEJ	MT	DTT
DMSNQEJ	MA	Inhibitor
DMSNQEJ	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMSNQEJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMSNQEJ	DI	DMSNQEJ
DMSNQEJ	DN	Pyrrolo-pyridine derivative 3
DMSNQEJ	MI	TTT7PJU
DMSNQEJ	MN	Janus kinase 3 (JAK-3)
DMSNQEJ	MT	DTT
DMSNQEJ	MA	Inhibitor
DMSNQEJ	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMSNQEJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMK820T	DI	DMK820T
DMK820T	DN	Pyrrolo-pyridinone derivative 1
DMK820T	MI	TT4DXQT
DMK820T	MN	Proto-oncogene c-Ret (RET)
DMK820T	MT	DTT
DMK820T	MA	Inhibitor
DMK820T	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMK820T	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DM5G67X	DI	DM5G67X
DM5G67X	DN	Pyrrolo-pyridinone derivative 2
DM5G67X	MI	TT4DXQT
DM5G67X	MN	Proto-oncogene c-Ret (RET)
DM5G67X	MT	DTT
DM5G67X	MA	Inhibitor
DM5G67X	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DM5G67X	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DME1Q3W	DI	DME1Q3W
DME1Q3W	DN	Pyrrolo-pyridinone derivative 3
DME1Q3W	MI	TT4DXQT
DME1Q3W	MN	Proto-oncogene c-Ret (RET)
DME1Q3W	MT	DTT
DME1Q3W	MA	Inhibitor
DME1Q3W	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DME1Q3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DM2EVJR	DI	DM2EVJR
DM2EVJR	DN	Pyrrolo-pyridinone derivative 4
DM2EVJR	MI	TT4DXQT
DM2EVJR	MN	Proto-oncogene c-Ret (RET)
DM2EVJR	MT	DTT
DM2EVJR	MA	Inhibitor
DM2EVJR	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DM2EVJR	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMK2FSY	DI	DMK2FSY
DMK2FSY	DN	Pyrrolo-pyridinone derivative 5
DMK2FSY	MI	TTAXZ0K
DMK2FSY	MN	Voltage-gated sodium channel alpha Nav1.3 (SCN3A)
DMK2FSY	MT	DTT
DMK2FSY	MA	Inhibitor
DMK2FSY	RN	Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90.
DMK2FSY	RU	https://www.ncbi.nlm.nih.gov/pubmed/25539043

DMK2FSY	DI	DMK2FSY
DMK2FSY	DN	Pyrrolo-pyridinone derivative 5
DMK2FSY	MI	TT4G2JS
DMK2FSY	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DMK2FSY	MT	DTT
DMK2FSY	MA	Inhibitor
DMK2FSY	RN	Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90.
DMK2FSY	RU	https://www.ncbi.nlm.nih.gov/pubmed/25539043

DMXGNP8	DI	DMXGNP8
DMXGNP8	DN	Pyrrolo-pyridinone derivative 6
DMXGNP8	MI	TTAXZ0K
DMXGNP8	MN	Voltage-gated sodium channel alpha Nav1.3 (SCN3A)
DMXGNP8	MT	DTT
DMXGNP8	MA	Inhibitor
DMXGNP8	RN	Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90.
DMXGNP8	RU	https://www.ncbi.nlm.nih.gov/pubmed/25539043

DMXGNP8	DI	DMXGNP8
DMXGNP8	DN	Pyrrolo-pyridinone derivative 6
DMXGNP8	MI	TT4G2JS
DMXGNP8	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DMXGNP8	MT	DTT
DMXGNP8	MA	Inhibitor
DMXGNP8	RN	Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90.
DMXGNP8	RU	https://www.ncbi.nlm.nih.gov/pubmed/25539043

DMR6QCE	DI	DMR6QCE
DMR6QCE	DN	Pyrrolo-pyridone derivative 1
DMR6QCE	MI	TT6DM01
DMR6QCE	MN	Janus kinase 1 (JAK-1)
DMR6QCE	MT	DTT
DMR6QCE	MA	Inhibitor
DMR6QCE	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMR6QCE	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMR6QCE	DI	DMR6QCE
DMR6QCE	DN	Pyrrolo-pyridone derivative 1
DMR6QCE	MI	TTRMX3V
DMR6QCE	MN	Janus kinase 2 (JAK-2)
DMR6QCE	MT	DTT
DMR6QCE	MA	Inhibitor
DMR6QCE	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMR6QCE	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMCZ8UV	DI	DMCZ8UV
DMCZ8UV	DN	Pyrrolo-pyridone derivative 2
DMCZ8UV	MI	TT6DM01
DMCZ8UV	MN	Janus kinase 1 (JAK-1)
DMCZ8UV	MT	DTT
DMCZ8UV	MA	Inhibitor
DMCZ8UV	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMCZ8UV	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMCZ8UV	DI	DMCZ8UV
DMCZ8UV	DN	Pyrrolo-pyridone derivative 2
DMCZ8UV	MI	TTRMX3V
DMCZ8UV	MN	Janus kinase 2 (JAK-2)
DMCZ8UV	MT	DTT
DMCZ8UV	MA	Inhibitor
DMCZ8UV	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMCZ8UV	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMUIK3W	DI	DMUIK3W
DMUIK3W	DN	Pyrrolo-pyridone derivative 3
DMUIK3W	MI	TT6DM01
DMUIK3W	MN	Janus kinase 1 (JAK-1)
DMUIK3W	MT	DTT
DMUIK3W	MA	Inhibitor
DMUIK3W	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMUIK3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMUIK3W	DI	DMUIK3W
DMUIK3W	DN	Pyrrolo-pyridone derivative 3
DMUIK3W	MI	TTBYWP2
DMUIK3W	MN	TYK2 tyrosine kinase (TYK2)
DMUIK3W	MT	DTT
DMUIK3W	MA	Inhibitor
DMUIK3W	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMUIK3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMEVXT0	DI	DMEVXT0
DMEVXT0	DN	Pyrrolo-pyrimidine derivative 1
DMEVXT0	MI	TTK0FEA
DMEVXT0	MN	Leucine-rich repeat kinase 2 (LRRK2)
DMEVXT0	MT	DTT
DMEVXT0	MA	Inhibitor
DMEVXT0	RN	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
DMEVXT0	RU	https://www.ncbi.nlm.nih.gov/pubmed/28117607

DMR0ZU6	DI	DMR0ZU6
DMR0ZU6	DN	Pyrrolo-pyrimidine derivative 10
DMR0ZU6	MI	TTK0FEA
DMR0ZU6	MN	Leucine-rich repeat kinase 2 (LRRK2)
DMR0ZU6	MT	DTT
DMR0ZU6	MA	Inhibitor
DMR0ZU6	RN	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
DMR0ZU6	RU	https://www.ncbi.nlm.nih.gov/pubmed/28117607

DMEIDC0	DI	DMEIDC0
DMEIDC0	DN	Pyrrolo-pyrimidine derivative 11
DMEIDC0	MI	TTK0FEA
DMEIDC0	MN	Leucine-rich repeat kinase 2 (LRRK2)
DMEIDC0	MT	DTT
DMEIDC0	MA	Inhibitor
DMEIDC0	RN	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
DMEIDC0	RU	https://www.ncbi.nlm.nih.gov/pubmed/28117607

DMEHYBJ	DI	DMEHYBJ
DMEHYBJ	DN	Pyrrolo-pyrimidine derivative 2
DMEHYBJ	MI	TT4DXQT
DMEHYBJ	MN	Proto-oncogene c-Ret (RET)
DMEHYBJ	MT	DTT
DMEHYBJ	MA	Inhibitor
DMEHYBJ	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMEHYBJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMKHWN9	DI	DMKHWN9
DMKHWN9	DN	Pyrrolo-pyrimidine derivative 3
DMKHWN9	MI	TT4DXQT
DMKHWN9	MN	Proto-oncogene c-Ret (RET)
DMKHWN9	MT	DTT
DMKHWN9	MA	Inhibitor
DMKHWN9	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMKHWN9	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMITK03	DI	DMITK03
DMITK03	DN	Pyrrolo-pyrimidine derivative 4
DMITK03	MI	TT4DXQT
DMITK03	MN	Proto-oncogene c-Ret (RET)
DMITK03	MT	DTT
DMITK03	MA	Inhibitor
DMITK03	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMITK03	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMVA95G	DI	DMVA95G
DMVA95G	DN	Pyrrolo-pyrimidine derivative 5
DMVA95G	MI	TT4DXQT
DMVA95G	MN	Proto-oncogene c-Ret (RET)
DMVA95G	MT	DTT
DMVA95G	MA	Inhibitor
DMVA95G	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMVA95G	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMGYT81	DI	DMGYT81
DMGYT81	DN	Pyrrolo-pyrimidine derivative 6
DMGYT81	MI	TT4DXQT
DMGYT81	MN	Proto-oncogene c-Ret (RET)
DMGYT81	MT	DTT
DMGYT81	MA	Inhibitor
DMGYT81	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMGYT81	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMZH27I	DI	DMZH27I
DMZH27I	DN	Pyrrolo-pyrimidine derivative 8
DMZH27I	MI	TTK0FEA
DMZH27I	MN	Leucine-rich repeat kinase 2 (LRRK2)
DMZH27I	MT	DTT
DMZH27I	MA	Inhibitor
DMZH27I	RN	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
DMZH27I	RU	https://www.ncbi.nlm.nih.gov/pubmed/28117607

DMJEV86	DI	DMJEV86
DMJEV86	DN	Pyrrolo-pyrimidine derivative 9
DMJEV86	MI	TTK0FEA
DMJEV86	MN	Leucine-rich repeat kinase 2 (LRRK2)
DMJEV86	MT	DTT
DMJEV86	MA	Inhibitor
DMJEV86	RN	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
DMJEV86	RU	https://www.ncbi.nlm.nih.gov/pubmed/28117607

DMN4SE5	DI	DMN4SE5
DMN4SE5	DN	Pyrrolo-pyrrolone derivative 1
DMN4SE5	MI	TTDP48B
DMN4SE5	MN	Bromodomain-containing protein 2 (BRD2)
DMN4SE5	MT	DTT
DMN4SE5	MA	Inhibitor
DMN4SE5	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMN4SE5	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMN4SE5	DI	DMN4SE5
DMN4SE5	DN	Pyrrolo-pyrrolone derivative 1
DMN4SE5	MI	TTHE657
DMN4SE5	MN	Bromodomain-containing protein 3 (BRD3)
DMN4SE5	MT	DTT
DMN4SE5	MA	Inhibitor
DMN4SE5	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMN4SE5	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMN4SE5	DI	DMN4SE5
DMN4SE5	DN	Pyrrolo-pyrrolone derivative 1
DMN4SE5	MI	TTRA6BO
DMN4SE5	MN	Bromodomain-containing protein 4 (BRD4)
DMN4SE5	MT	DTT
DMN4SE5	MA	Inhibitor
DMN4SE5	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMN4SE5	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DM8VYMA	DI	DM8VYMA
DM8VYMA	DN	Pyrrolo-pyrrolone derivative 2
DM8VYMA	MI	TTRA6BO
DM8VYMA	MN	Bromodomain-containing protein 4 (BRD4)
DM8VYMA	MT	DTT
DM8VYMA	MA	Inhibitor
DM8VYMA	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DM8VYMA	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMHGPU1	DI	DMHGPU1
DMHGPU1	DN	Pyrrolo-pyrrolone derivative 3
DMHGPU1	MI	TTRA6BO
DMHGPU1	MN	Bromodomain-containing protein 4 (BRD4)
DMHGPU1	MT	DTT
DMHGPU1	MA	Inhibitor
DMHGPU1	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMHGPU1	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMFJBZI	DI	DMFJBZI
DMFJBZI	DN	Pyrrolo-pyrrolone derivative 4
DMFJBZI	MI	TTRA6BO
DMFJBZI	MN	Bromodomain-containing protein 4 (BRD4)
DMFJBZI	MT	DTT
DMFJBZI	MA	Inhibitor
DMFJBZI	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMFJBZI	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMMX0N5	DI	DMMX0N5
DMMX0N5	DN	Pyrrolo-pyrrolone derivative 5
DMMX0N5	MI	TTRA6BO
DMMX0N5	MN	Bromodomain-containing protein 4 (BRD4)
DMMX0N5	MT	DTT
DMMX0N5	MA	Inhibitor
DMMX0N5	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMMX0N5	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMBW208	DI	DMBW208
DMBW208	DN	Pyrrolo-pyrrolone derivative 6
DMBW208	MI	TTFRCTK
DMBW208	MN	CREB-binding protein (CREBBP)
DMBW208	MT	DTT
DMBW208	MA	Inhibitor
DMBW208	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMBW208	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DM4DJA7	DI	DM4DJA7
DM4DJA7	DN	QCPOIDRINIAUKU-SRBBEKPSSA-N
DM4DJA7	MI	TTXHWA7
DM4DJA7	MN	Ubiquitin-activating enzyme E1 (UBAE1)
DM4DJA7	MT	DTT
DM4DJA7	MA	Inhibitor
DM4DJA7	RN	Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme. US10202389.
DM4DJA7	RU	http://www.freepatentsonline.com/US10202389.html

DMH86F2	DI	DMH86F2
DMH86F2	DN	Quinazoline alkaloid derivative 1
DMH86F2	MI	TT1RS9F
DMH86F2	MN	Acetylcholinesterase (AChE)
DMH86F2	MT	DTT
DMH86F2	MA	Inhibitor
DMH86F2	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DMH86F2	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DMH86F2	DI	DMH86F2
DMH86F2	DN	Quinazoline alkaloid derivative 1
DMH86F2	MI	TTEB0GD
DMH86F2	MN	Cholinesterase (BCHE)
DMH86F2	MT	DTT
DMH86F2	MA	Inhibitor
DMH86F2	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DMH86F2	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DMOBFAU	DI	DMOBFAU
DMOBFAU	DN	Quinazoline derivative 1
DMOBFAU	MI	TTDIGC1
DMOBFAU	MN	Dipeptidyl peptidase 4 (DPP-4)
DMOBFAU	MT	DTT
DMOBFAU	MA	Inhibitor
DMOBFAU	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMOBFAU	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DMZ3ORT	DI	DMZ3ORT
DMZ3ORT	DN	Quinazoline derivative 10
DMZ3ORT	MI	TTQR74A
DMZ3ORT	MN	Proteinase activated receptor 2 (PAR2)
DMZ3ORT	MT	DTT
DMZ3ORT	MA	Antagonist
DMZ3ORT	RN	Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
DMZ3ORT	RU	https://www.ncbi.nlm.nih.gov/pubmed/26936077

DMAH435	DI	DMAH435
DMAH435	DN	Quinazoline derivative 11
DMAH435	MI	TTQR74A
DMAH435	MN	Proteinase activated receptor 2 (PAR2)
DMAH435	MT	DTT
DMAH435	MA	Antagonist
DMAH435	RN	Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
DMAH435	RU	https://www.ncbi.nlm.nih.gov/pubmed/26936077

DMVKZU2	DI	DMVKZU2
DMVKZU2	DN	Quinazoline derivative 12
DMVKZU2	MI	TTQR74A
DMVKZU2	MN	Proteinase activated receptor 2 (PAR2)
DMVKZU2	MT	DTT
DMVKZU2	MA	Antagonist
DMVKZU2	RN	Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
DMVKZU2	RU	https://www.ncbi.nlm.nih.gov/pubmed/26936077

DMFU6OD	DI	DMFU6OD
DMFU6OD	DN	Quinazoline derivative 13
DMFU6OD	MI	TTQR74A
DMFU6OD	MN	Proteinase activated receptor 2 (PAR2)
DMFU6OD	MT	DTT
DMFU6OD	MA	Antagonist
DMFU6OD	RN	Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
DMFU6OD	RU	https://www.ncbi.nlm.nih.gov/pubmed/26936077

DMHLJA7	DI	DMHLJA7
DMHLJA7	DN	Quinazoline derivative 14
DMHLJA7	MI	TT4DXQT
DMHLJA7	MN	Proto-oncogene c-Ret (RET)
DMHLJA7	MT	DTT
DMHLJA7	MA	Inhibitor
DMHLJA7	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMHLJA7	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMD965S	DI	DMD965S
DMD965S	DN	Quinazoline derivative 15
DMD965S	MI	TT4DXQT
DMD965S	MN	Proto-oncogene c-Ret (RET)
DMD965S	MT	DTT
DMD965S	MA	Inhibitor
DMD965S	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMD965S	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMD965S	DI	DMD965S
DMD965S	DN	Quinazoline derivative 15
DMD965S	MI	TTUTJGQ
DMD965S	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMD965S	MT	DTT
DMD965S	MA	Inhibitor
DMD965S	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMD965S	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMQ704Z	DI	DMQ704Z
DMQ704Z	DN	Quinazoline derivative 16
DMQ704Z	MI	TT4DXQT
DMQ704Z	MN	Proto-oncogene c-Ret (RET)
DMQ704Z	MT	DTT
DMQ704Z	MA	Inhibitor
DMQ704Z	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMQ704Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMQ704Z	DI	DMQ704Z
DMQ704Z	DN	Quinazoline derivative 16
DMQ704Z	MI	TTUTJGQ
DMQ704Z	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMQ704Z	MT	DTT
DMQ704Z	MA	Inhibitor
DMQ704Z	RN	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
DMQ704Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646564

DMGECO2	DI	DMGECO2
DMGECO2	DN	Quinazoline derivative 2
DMGECO2	MI	TTPTXIN
DMGECO2	MN	Translocator protein (TSPO)
DMGECO2	MT	DTT
DMGECO2	MA	Ligand
DMGECO2	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMGECO2	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMF05GL	DI	DMF05GL
DMF05GL	DN	Quinazoline derivative 3
DMF05GL	MI	TTPTXIN
DMF05GL	MN	Translocator protein (TSPO)
DMF05GL	MT	DTT
DMF05GL	MA	Ligand
DMF05GL	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMF05GL	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMJIDLU	DI	DMJIDLU
DMJIDLU	DN	Quinazoline derivative 4
DMJIDLU	MI	TTPTXIN
DMJIDLU	MN	Translocator protein (TSPO)
DMJIDLU	MT	DTT
DMJIDLU	MA	Ligand
DMJIDLU	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMJIDLU	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMEIH73	DI	DMEIH73
DMEIH73	DN	Quinazoline derivative 5
DMEIH73	MI	TTPTXIN
DMEIH73	MN	Translocator protein (TSPO)
DMEIH73	MT	DTT
DMEIH73	MA	Ligand
DMEIH73	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMEIH73	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMKZ6MD	DI	DMKZ6MD
DMKZ6MD	DN	Quinazoline derivative 6
DMKZ6MD	MI	TTPTXIN
DMKZ6MD	MN	Translocator protein (TSPO)
DMKZ6MD	MT	DTT
DMKZ6MD	MA	Ligand
DMKZ6MD	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMKZ6MD	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMIBRE5	DI	DMIBRE5
DMIBRE5	DN	Quinazoline derivative 7
DMIBRE5	MI	TTPTXIN
DMIBRE5	MN	Translocator protein (TSPO)
DMIBRE5	MT	DTT
DMIBRE5	MA	Ligand
DMIBRE5	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMIBRE5	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMSD04W	DI	DMSD04W
DMSD04W	DN	Quinazolinedione derivative 1
DMSD04W	MI	TTVDSZ0
DMSD04W	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMSD04W	MT	DTT
DMSD04W	MA	Inhibitor
DMSD04W	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DMSD04W	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DM3TVI6	DI	DM3TVI6
DM3TVI6	DN	Quinazolinedione derivative 2
DM3TVI6	MI	TTVDSZ0
DM3TVI6	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DM3TVI6	MT	DTT
DM3TVI6	MA	Inhibitor
DM3TVI6	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DM3TVI6	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DMZ5GIH	DI	DMZ5GIH
DMZ5GIH	DN	Quinazolinedione derivative 3
DMZ5GIH	MI	TTVDSZ0
DMZ5GIH	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMZ5GIH	MT	DTT
DMZ5GIH	MA	Inhibitor
DMZ5GIH	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DMZ5GIH	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DME24BI	DI	DME24BI
DME24BI	DN	Quinazolines and azaquinazoline derivative 1
DME24BI	MI	TTZCRP3
DME24BI	MN	ERK activator kinase (MEK)
DME24BI	MT	DTT
DME24BI	MA	Inhibitor
DME24BI	RN	MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906.
DME24BI	RU	https://www.ncbi.nlm.nih.gov/pubmed/28594589

DMSU1PC	DI	DMSU1PC
DMSU1PC	DN	Quinazolinone derivative 1
DMSU1PC	MI	TTL7C8Q
DMSU1PC	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMSU1PC	MT	DTT
DMSU1PC	MA	Inhibitor
DMSU1PC	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DMSU1PC	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DM0XVQY	DI	DM0XVQY
DM0XVQY	DN	Quinazolinone derivative 2
DM0XVQY	MI	TTL7C8Q
DM0XVQY	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DM0XVQY	MT	DTT
DM0XVQY	MA	Inhibitor
DM0XVQY	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DM0XVQY	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DMDRIZF	DI	DMDRIZF
DMDRIZF	DN	Quinazolinone derivative 3
DMDRIZF	MI	TTE4BSY
DMDRIZF	MN	Bromodomain and extraterminal domain protein (BET)
DMDRIZF	MT	DTT
DMDRIZF	MA	Inhibitor
DMDRIZF	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMDRIZF	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DM8WH97	DI	DM8WH97
DM8WH97	DN	Quinazolinone derivative 4
DM8WH97	MI	TTE4BSY
DM8WH97	MN	Bromodomain and extraterminal domain protein (BET)
DM8WH97	MT	DTT
DM8WH97	MA	Inhibitor
DM8WH97	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DM8WH97	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMXOKH3	DI	DMXOKH3
DMXOKH3	DN	Quinazolinone derivative 5
DMXOKH3	MI	TTE4BSY
DMXOKH3	MN	Bromodomain and extraterminal domain protein (BET)
DMXOKH3	MT	DTT
DMXOKH3	MA	Inhibitor
DMXOKH3	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMXOKH3	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMKDTO4	DI	DMKDTO4
DMKDTO4	DN	Quinoline and quinazoline derivative 1
DMKDTO4	MI	TTUTJGQ
DMKDTO4	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMKDTO4	MT	DTT
DMKDTO4	MA	Inhibitor
DMKDTO4	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMKDTO4	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DM6E1N4	DI	DM6E1N4
DM6E1N4	DN	Quinoline and quinazoline derivative 10
DM6E1N4	MI	TTOHSBA
DM6E1N4	MN	Vascular endothelial growth factor A (VEGFA)
DM6E1N4	MT	DTT
DM6E1N4	MA	Inhibitor
DM6E1N4	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DM6E1N4	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DM9PSI3	DI	DM9PSI3
DM9PSI3	DN	Quinoline and quinazoline derivative 2
DM9PSI3	MI	TTOHSBA
DM9PSI3	MN	Vascular endothelial growth factor A (VEGFA)
DM9PSI3	MT	DTT
DM9PSI3	MA	Inhibitor
DM9PSI3	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DM9PSI3	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMGY4WO	DI	DMGY4WO
DMGY4WO	DN	Quinoline and quinazoline derivative 3
DMGY4WO	MI	TTOHSBA
DMGY4WO	MN	Vascular endothelial growth factor A (VEGFA)
DMGY4WO	MT	DTT
DMGY4WO	MA	Inhibitor
DMGY4WO	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMGY4WO	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DM5VCQP	DI	DM5VCQP
DM5VCQP	DN	Quinoline and quinazoline derivative 4
DM5VCQP	MI	TTOHSBA
DM5VCQP	MN	Vascular endothelial growth factor A (VEGFA)
DM5VCQP	MT	DTT
DM5VCQP	MA	Inhibitor
DM5VCQP	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DM5VCQP	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DM7RQ2G	DI	DM7RQ2G
DM7RQ2G	DN	Quinoline and quinazoline derivative 5
DM7RQ2G	MI	TTOHSBA
DM7RQ2G	MN	Vascular endothelial growth factor A (VEGFA)
DM7RQ2G	MT	DTT
DM7RQ2G	MA	Inhibitor
DM7RQ2G	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DM7RQ2G	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMZ2TB5	DI	DMZ2TB5
DMZ2TB5	DN	Quinoline and quinazoline derivative 6
DMZ2TB5	MI	TTOHSBA
DMZ2TB5	MN	Vascular endothelial growth factor A (VEGFA)
DMZ2TB5	MT	DTT
DMZ2TB5	MA	Inhibitor
DMZ2TB5	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMZ2TB5	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMMJEWB	DI	DMMJEWB
DMMJEWB	DN	Quinoline and quinazoline derivative 7
DMMJEWB	MI	TTOHSBA
DMMJEWB	MN	Vascular endothelial growth factor A (VEGFA)
DMMJEWB	MT	DTT
DMMJEWB	MA	Inhibitor
DMMJEWB	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMMJEWB	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMW3JH0	DI	DMW3JH0
DMW3JH0	DN	Quinoline and quinazoline derivative 8
DMW3JH0	MI	TTOHSBA
DMW3JH0	MN	Vascular endothelial growth factor A (VEGFA)
DMW3JH0	MT	DTT
DMW3JH0	MA	Inhibitor
DMW3JH0	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMW3JH0	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMBL86O	DI	DMBL86O
DMBL86O	DN	Quinoline and quinazoline derivative 9
DMBL86O	MI	TTOHSBA
DMBL86O	MN	Vascular endothelial growth factor A (VEGFA)
DMBL86O	MT	DTT
DMBL86O	MA	Inhibitor
DMBL86O	RN	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
DMBL86O	RU	https://www.ncbi.nlm.nih.gov/pubmed/28621580

DMW5YJB	DI	DMW5YJB
DMW5YJB	DN	Quinoline carboxamide derivative 1
DMW5YJB	MI	TTH8FZW
DMW5YJB	MN	Signal transducer and activator of transcription 3 (STAT3)
DMW5YJB	MT	DTT
DMW5YJB	MA	Inhibitor
DMW5YJB	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMW5YJB	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMZTQVF	DI	DMZTQVF
DMZTQVF	DN	Quinoline carboxamide derivative 10
DMZTQVF	MI	TTPTXIN
DMZTQVF	MN	Translocator protein (TSPO)
DMZTQVF	MT	DTT
DMZTQVF	MA	Ligand
DMZTQVF	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMZTQVF	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DM9XQBG	DI	DM9XQBG
DM9XQBG	DN	Quinoline carboxamide derivative 2
DM9XQBG	MI	TTH8FZW
DM9XQBG	MN	Signal transducer and activator of transcription 3 (STAT3)
DM9XQBG	MT	DTT
DM9XQBG	MA	Inhibitor
DM9XQBG	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DM9XQBG	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMCAS85	DI	DMCAS85
DMCAS85	DN	Quinoline carboxamide derivative 3
DMCAS85	MI	TTH8FZW
DMCAS85	MN	Signal transducer and activator of transcription 3 (STAT3)
DMCAS85	MT	DTT
DMCAS85	MA	Inhibitor
DMCAS85	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMCAS85	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMVUNYD	DI	DMVUNYD
DMVUNYD	DN	Quinoline carboxamide derivative 4
DMVUNYD	MI	TTPTXIN
DMVUNYD	MN	Translocator protein (TSPO)
DMVUNYD	MT	DTT
DMVUNYD	MA	Ligand
DMVUNYD	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMVUNYD	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DM14029	DI	DM14029
DM14029	DN	Quinoline carboxamide derivative 5
DM14029	MI	TTPTXIN
DM14029	MN	Translocator protein (TSPO)
DM14029	MT	DTT
DM14029	MA	Ligand
DM14029	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DM14029	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMQ9ATN	DI	DMQ9ATN
DMQ9ATN	DN	Quinoline carboxamide derivative 6
DMQ9ATN	MI	TTPTXIN
DMQ9ATN	MN	Translocator protein (TSPO)
DMQ9ATN	MT	DTT
DMQ9ATN	MA	Ligand
DMQ9ATN	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DMQ9ATN	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DM8AG0Z	DI	DM8AG0Z
DM8AG0Z	DN	Quinoline carboxamide derivative 7
DM8AG0Z	MI	TTPTXIN
DM8AG0Z	MN	Translocator protein (TSPO)
DM8AG0Z	MT	DTT
DM8AG0Z	MA	Ligand
DM8AG0Z	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DM8AG0Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DM3IXYL	DI	DM3IXYL
DM3IXYL	DN	Quinoline carboxamide derivative 8
DM3IXYL	MI	TTPTXIN
DM3IXYL	MN	Translocator protein (TSPO)
DM3IXYL	MT	DTT
DM3IXYL	MA	Ligand
DM3IXYL	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DM3IXYL	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DM7YFBT	DI	DM7YFBT
DM7YFBT	DN	Quinoline carboxamide derivative 9
DM7YFBT	MI	TTPTXIN
DM7YFBT	MN	Translocator protein (TSPO)
DM7YFBT	MT	DTT
DM7YFBT	MA	Ligand
DM7YFBT	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
DM7YFBT	RU	https://www.ncbi.nlm.nih.gov/pubmed/27607364

DMRY2HL	DI	DMRY2HL
DMRY2HL	DN	Quinoline derivative 1
DMRY2HL	MI	TTPADOQ
DMRY2HL	MN	HMG-CoA reductase (HMGCR)
DMRY2HL	MT	DTT
DMRY2HL	MA	Inhibitor
DMRY2HL	RN	HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272.
DMRY2HL	RU	https://www.ncbi.nlm.nih.gov/pubmed/27537201

DM6GSCV	DI	DM6GSCV
DM6GSCV	DN	Quinoline derivative 10
DM6GSCV	MI	TT473XN
DM6GSCV	MN	P2X purinoceptor 7 (P2RX7)
DM6GSCV	MT	DTT
DM6GSCV	MA	Antagonist
DM6GSCV	RN	P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267.
DM6GSCV	RU	https://www.ncbi.nlm.nih.gov/pubmed/27724045

DMH02JL	DI	DMH02JL
DMH02JL	DN	Quinoline derivative 11
DMH02JL	MI	TT473XN
DMH02JL	MN	P2X purinoceptor 7 (P2RX7)
DMH02JL	MT	DTT
DMH02JL	MA	Antagonist
DMH02JL	RN	P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267.
DMH02JL	RU	https://www.ncbi.nlm.nih.gov/pubmed/27724045

DMH02JL	DI	DMH02JL
DMH02JL	DN	Quinoline derivative 11
DMH02JL	MI	TTQ6VDM
DMH02JL	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMH02JL	MT	DTT
DMH02JL	MA	Antagonist
DMH02JL	RN	P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267.
DMH02JL	RU	https://www.ncbi.nlm.nih.gov/pubmed/27724045

DM9FXE7	DI	DM9FXE7
DM9FXE7	DN	Quinoline derivative 12
DM9FXE7	MI	TT473XN
DM9FXE7	MN	P2X purinoceptor 7 (P2RX7)
DM9FXE7	MT	DTT
DM9FXE7	MA	Antagonist
DM9FXE7	RN	P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267.
DM9FXE7	RU	https://www.ncbi.nlm.nih.gov/pubmed/27724045

DM9FXE7	DI	DM9FXE7
DM9FXE7	DN	Quinoline derivative 12
DM9FXE7	MI	TTQ6VDM
DM9FXE7	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DM9FXE7	MT	DTT
DM9FXE7	MA	Antagonist
DM9FXE7	RN	P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267.
DM9FXE7	RU	https://www.ncbi.nlm.nih.gov/pubmed/27724045

DMAH4P8	DI	DMAH4P8
DMAH4P8	DN	Quinoline derivative 13
DMAH4P8	MI	TT473XN
DMAH4P8	MN	P2X purinoceptor 7 (P2RX7)
DMAH4P8	MT	DTT
DMAH4P8	MA	Antagonist
DMAH4P8	RN	P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267.
DMAH4P8	RU	https://www.ncbi.nlm.nih.gov/pubmed/27724045

DMAH4P8	DI	DMAH4P8
DMAH4P8	DN	Quinoline derivative 13
DMAH4P8	MI	TTQ6VDM
DMAH4P8	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMAH4P8	MT	DTT
DMAH4P8	MA	Antagonist
DMAH4P8	RN	P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267.
DMAH4P8	RU	https://www.ncbi.nlm.nih.gov/pubmed/27724045

DMSRB8M	DI	DMSRB8M
DMSRB8M	DN	Quinoline derivative 14
DMSRB8M	MI	TTRZQE3
DMSRB8M	MN	Glycogen synthase kinase-3 alpha (GSK-3A)
DMSRB8M	MT	DTT
DMSRB8M	MA	Inhibitor
DMSRB8M	RN	Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
DMSRB8M	RU	https://www.ncbi.nlm.nih.gov/pubmed/27828716

DM7HD0T	DI	DM7HD0T
DM7HD0T	DN	Quinoline derivative 15
DM7HD0T	MI	TTRZQE3
DM7HD0T	MN	Glycogen synthase kinase-3 alpha (GSK-3A)
DM7HD0T	MT	DTT
DM7HD0T	MA	Inhibitor
DM7HD0T	RN	Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
DM7HD0T	RU	https://www.ncbi.nlm.nih.gov/pubmed/27828716

DMTHG87	DI	DMTHG87
DMTHG87	DN	Quinoline derivative 16
DMTHG87	MI	TTPADOQ
DMTHG87	MN	HMG-CoA reductase (HMGCR)
DMTHG87	MT	DTT
DMTHG87	MA	Inhibitor
DMTHG87	RN	HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272.
DMTHG87	RU	https://www.ncbi.nlm.nih.gov/pubmed/27537201

DMKULV8	DI	DMKULV8
DMKULV8	DN	Quinoline derivative 17
DMKULV8	MI	TTPADOQ
DMKULV8	MN	HMG-CoA reductase (HMGCR)
DMKULV8	MT	DTT
DMKULV8	MA	Inhibitor
DMKULV8	RN	HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272.
DMKULV8	RU	https://www.ncbi.nlm.nih.gov/pubmed/27537201

DMSG71Z	DI	DMSG71Z
DMSG71Z	DN	Quinoline derivative 18
DMSG71Z	MI	TTSCO7R
DMSG71Z	MN	NAD-dependent deacetylase sirtuin (SIRT)
DMSG71Z	MT	DTT
DMSG71Z	MA	Inhibitor
DMSG71Z	RN	Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15.
DMSG71Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435179

DM0MLI9	DI	DM0MLI9
DM0MLI9	DN	Quinoline derivative 19
DM0MLI9	MI	TTSCO7R
DM0MLI9	MN	NAD-dependent deacetylase sirtuin (SIRT)
DM0MLI9	MT	DTT
DM0MLI9	MA	Inhibitor
DM0MLI9	RN	Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15.
DM0MLI9	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435179

DMNO2BP	DI	DMNO2BP
DMNO2BP	DN	Quinoline derivative 2
DMNO2BP	MI	TT0K1SC
DMNO2BP	MN	5-HT 2B receptor (HTR2B)
DMNO2BP	MT	DTT
DMNO2BP	MA	Antagonist
DMNO2BP	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMNO2BP	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMNO2BP	DI	DMNO2BP
DMNO2BP	DN	Quinoline derivative 2
DMNO2BP	MI	TTWJBZ5
DMNO2BP	MN	5-HT 2C receptor (HTR2C)
DMNO2BP	MT	DTT
DMNO2BP	MA	Agonist
DMNO2BP	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMNO2BP	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMNXCZT	DI	DMNXCZT
DMNXCZT	DN	Quinoline derivative 20
DMNXCZT	MI	TTSCO7R
DMNXCZT	MN	NAD-dependent deacetylase sirtuin (SIRT)
DMNXCZT	MT	DTT
DMNXCZT	MA	Inhibitor
DMNXCZT	RN	Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15.
DMNXCZT	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435179

DMDV6EY	DI	DMDV6EY
DMDV6EY	DN	Quinoline derivative 3
DMDV6EY	MI	TTXJ47W
DMDV6EY	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMDV6EY	MT	DTT
DMDV6EY	MA	Antagonist
DMDV6EY	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DMDV6EY	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DMPB4L6	DI	DMPB4L6
DMPB4L6	DN	Quinoline derivative 4
DMPB4L6	MI	TTXJ47W
DMPB4L6	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMPB4L6	MT	DTT
DMPB4L6	MA	Antagonist
DMPB4L6	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DMPB4L6	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DMS1TOX	DI	DMS1TOX
DMS1TOX	DN	Quinoline derivative 5
DMS1TOX	MI	TTXJ47W
DMS1TOX	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMS1TOX	MT	DTT
DMS1TOX	MA	Antagonist
DMS1TOX	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DMS1TOX	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DMVBPGI	DI	DMVBPGI
DMVBPGI	DN	Quinoline derivative 6
DMVBPGI	MI	TTXJ47W
DMVBPGI	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMVBPGI	MT	DTT
DMVBPGI	MA	Antagonist
DMVBPGI	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DMVBPGI	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DM56I8H	DI	DM56I8H
DM56I8H	DN	Quinoline derivative 7
DM56I8H	MI	TTXJ47W
DM56I8H	MN	Metabotropic glutamate receptor 2 (mGluR2)
DM56I8H	MT	DTT
DM56I8H	MA	Antagonist
DM56I8H	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DM56I8H	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DMLIW1X	DI	DMLIW1X
DMLIW1X	DN	Quinoline derivative 8
DMLIW1X	MI	TTXJ47W
DMLIW1X	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMLIW1X	MT	DTT
DMLIW1X	MA	Antagonist
DMLIW1X	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DMLIW1X	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DMIC86N	DI	DMIC86N
DMIC86N	DN	Quinoline derivative 9
DMIC86N	MI	TTXJ47W
DMIC86N	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMIC86N	MT	DTT
DMIC86N	MA	Antagonist
DMIC86N	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DMIC86N	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DMENZPR	DI	DMENZPR
DMENZPR	DN	Quinolinyl compound 1
DMENZPR	MI	TT9O6WS
DMENZPR	MN	Glucagon receptor (GCGR)
DMENZPR	MT	DTT
DMENZPR	MA	Antagonist
DMENZPR	RN	Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30.
DMENZPR	RU	https://www.ncbi.nlm.nih.gov/pubmed/25828189

DMGLK92	DI	DMGLK92
DMGLK92	DN	Quinolinyl compound 2
DMGLK92	MI	TT9O6WS
DMGLK92	MN	Glucagon receptor (GCGR)
DMGLK92	MT	DTT
DMGLK92	MA	Antagonist
DMGLK92	RN	Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30.
DMGLK92	RU	https://www.ncbi.nlm.nih.gov/pubmed/25828189

DMCIKR3	DI	DMCIKR3
DMCIKR3	DN	Quinolinyl pyrazinyl urea derivative 1
DMCIKR3	MI	TTRZQE3
DMCIKR3	MN	Glycogen synthase kinase-3 alpha (GSK-3A)
DMCIKR3	MT	DTT
DMCIKR3	MA	Inhibitor
DMCIKR3	RN	Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
DMCIKR3	RU	https://www.ncbi.nlm.nih.gov/pubmed/27828716

DMKJN9G	DI	DMKJN9G
DMKJN9G	DN	Quinolinyl pyrazinyl urea derivative 2
DMKJN9G	MI	TTRZQE3
DMKJN9G	MN	Glycogen synthase kinase-3 alpha (GSK-3A)
DMKJN9G	MT	DTT
DMKJN9G	MA	Inhibitor
DMKJN9G	RN	Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
DMKJN9G	RU	https://www.ncbi.nlm.nih.gov/pubmed/27828716

DME6P7T	DI	DME6P7T
DME6P7T	DN	Quinolone derivative 1
DME6P7T	MI	TTL7C8Q
DME6P7T	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DME6P7T	MT	DTT
DME6P7T	MA	Inhibitor
DME6P7T	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DME6P7T	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DMENQ5O	DI	DMENQ5O
DMENQ5O	DN	Quinoxaline derivative 1
DMENQ5O	MI	TTSXVID
DMENQ5O	MN	Nuclear factor NF-kappa-B (NFKB)
DMENQ5O	MT	DTT
DMENQ5O	MA	Inhibitor
DMENQ5O	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DMENQ5O	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DM031YW	DI	DM031YW
DM031YW	DN	Quinoxaline derivative 2
DM031YW	MI	TTSXVID
DM031YW	MN	Nuclear factor NF-kappa-B (NFKB)
DM031YW	MT	DTT
DM031YW	MA	Inhibitor
DM031YW	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DM031YW	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DMLZRAI	DI	DMLZRAI
DMLZRAI	DN	Quinoxaline derivative 3
DMLZRAI	MI	TTSXVID
DMLZRAI	MN	Nuclear factor NF-kappa-B (NFKB)
DMLZRAI	MT	DTT
DMLZRAI	MA	Inhibitor
DMLZRAI	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DMLZRAI	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DMS3PRT	DI	DMS3PRT
DMS3PRT	DN	Quinoxaline derivative 4
DMS3PRT	MI	TTSXVID
DMS3PRT	MN	Nuclear factor NF-kappa-B (NFKB)
DMS3PRT	MT	DTT
DMS3PRT	MA	Inhibitor
DMS3PRT	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DMS3PRT	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DM8EY2G	DI	DM8EY2G
DM8EY2G	DN	Quinoxaline derivative 5
DM8EY2G	MI	TTSXVID
DM8EY2G	MN	Nuclear factor NF-kappa-B (NFKB)
DM8EY2G	MT	DTT
DM8EY2G	MA	Inhibitor
DM8EY2G	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DM8EY2G	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DMBRX8D	DI	DMBRX8D
DMBRX8D	DN	Quinoxaline derivative 6
DMBRX8D	MI	TTSXVID
DMBRX8D	MN	Nuclear factor NF-kappa-B (NFKB)
DMBRX8D	MT	DTT
DMBRX8D	MA	Inhibitor
DMBRX8D	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DMBRX8D	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DMG4FYP	DI	DMG4FYP
DMG4FYP	DN	Resorcinol compound 1
DMG4FYP	MI	TTULVH8
DMG4FYP	MN	Tyrosinase (TYR)
DMG4FYP	MT	DTT
DMG4FYP	MA	Inhibitor
DMG4FYP	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMG4FYP	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMPA26U	DI	DMPA26U
DMPA26U	DN	Resorcinol compound 10
DMPA26U	MI	TTULVH8
DMPA26U	MN	Tyrosinase (TYR)
DMPA26U	MT	DTT
DMPA26U	MA	Inhibitor
DMPA26U	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMPA26U	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMGDLPZ	DI	DMGDLPZ
DMGDLPZ	DN	Resorcinol compound 11
DMGDLPZ	MI	TTULVH8
DMGDLPZ	MN	Tyrosinase (TYR)
DMGDLPZ	MT	DTT
DMGDLPZ	MA	Inhibitor
DMGDLPZ	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMGDLPZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMEMT3I	DI	DMEMT3I
DMEMT3I	DN	Resorcinol compound 12
DMEMT3I	MI	TTULVH8
DMEMT3I	MN	Tyrosinase (TYR)
DMEMT3I	MT	DTT
DMEMT3I	MA	Inhibitor
DMEMT3I	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMEMT3I	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMVARUE	DI	DMVARUE
DMVARUE	DN	Resorcinol compound 13
DMVARUE	MI	TTULVH8
DMVARUE	MN	Tyrosinase (TYR)
DMVARUE	MT	DTT
DMVARUE	MA	Inhibitor
DMVARUE	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMVARUE	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DM6XFA5	DI	DM6XFA5
DM6XFA5	DN	Resorcinol compound 14
DM6XFA5	MI	TTULVH8
DM6XFA5	MN	Tyrosinase (TYR)
DM6XFA5	MT	DTT
DM6XFA5	MA	Inhibitor
DM6XFA5	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DM6XFA5	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMSLYVT	DI	DMSLYVT
DMSLYVT	DN	Resorcinol compound 15
DMSLYVT	MI	TTULVH8
DMSLYVT	MN	Tyrosinase (TYR)
DMSLYVT	MT	DTT
DMSLYVT	MA	Inhibitor
DMSLYVT	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMSLYVT	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMFDXBJ	DI	DMFDXBJ
DMFDXBJ	DN	Resorcinol compound 16
DMFDXBJ	MI	TTULVH8
DMFDXBJ	MN	Tyrosinase (TYR)
DMFDXBJ	MT	DTT
DMFDXBJ	MA	Inhibitor
DMFDXBJ	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMFDXBJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMFR4S0	DI	DMFR4S0
DMFR4S0	DN	Resorcinol compound 17
DMFR4S0	MI	TTULVH8
DMFR4S0	MN	Tyrosinase (TYR)
DMFR4S0	MT	DTT
DMFR4S0	MA	Inhibitor
DMFR4S0	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMFR4S0	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DM64R2K	DI	DM64R2K
DM64R2K	DN	Resorcinol compound 18
DM64R2K	MI	TTULVH8
DM64R2K	MN	Tyrosinase (TYR)
DM64R2K	MT	DTT
DM64R2K	MA	Inhibitor
DM64R2K	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DM64R2K	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMJIZPQ	DI	DMJIZPQ
DMJIZPQ	DN	Resorcinol compound 19
DMJIZPQ	MI	TTULVH8
DMJIZPQ	MN	Tyrosinase (TYR)
DMJIZPQ	MT	DTT
DMJIZPQ	MA	Inhibitor
DMJIZPQ	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMJIZPQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMGDQYW	DI	DMGDQYW
DMGDQYW	DN	Resorcinol compound 2
DMGDQYW	MI	TTULVH8
DMGDQYW	MN	Tyrosinase (TYR)
DMGDQYW	MT	DTT
DMGDQYW	MA	Inhibitor
DMGDQYW	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMGDQYW	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DME4OGJ	DI	DME4OGJ
DME4OGJ	DN	Resorcinol compound 20
DME4OGJ	MI	TTULVH8
DME4OGJ	MN	Tyrosinase (TYR)
DME4OGJ	MT	DTT
DME4OGJ	MA	Inhibitor
DME4OGJ	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DME4OGJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DM8EQPJ	DI	DM8EQPJ
DM8EQPJ	DN	Resorcinol compound 21
DM8EQPJ	MI	TTULVH8
DM8EQPJ	MN	Tyrosinase (TYR)
DM8EQPJ	MT	DTT
DM8EQPJ	MA	Inhibitor
DM8EQPJ	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DM8EQPJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMSW3GB	DI	DMSW3GB
DMSW3GB	DN	Resorcinol compound 22
DMSW3GB	MI	TTULVH8
DMSW3GB	MN	Tyrosinase (TYR)
DMSW3GB	MT	DTT
DMSW3GB	MA	Inhibitor
DMSW3GB	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMSW3GB	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMU3APC	DI	DMU3APC
DMU3APC	DN	Resorcinol compound 23
DMU3APC	MI	TTULVH8
DMU3APC	MN	Tyrosinase (TYR)
DMU3APC	MT	DTT
DMU3APC	MA	Inhibitor
DMU3APC	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMU3APC	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DM2IKDL	DI	DM2IKDL
DM2IKDL	DN	Resorcinol compound 24
DM2IKDL	MI	TTULVH8
DM2IKDL	MN	Tyrosinase (TYR)
DM2IKDL	MT	DTT
DM2IKDL	MA	Inhibitor
DM2IKDL	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DM2IKDL	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMEZUN7	DI	DMEZUN7
DMEZUN7	DN	Resorcinol compound 25
DMEZUN7	MI	TTULVH8
DMEZUN7	MN	Tyrosinase (TYR)
DMEZUN7	MT	DTT
DMEZUN7	MA	Inhibitor
DMEZUN7	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMEZUN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMT21JG	DI	DMT21JG
DMT21JG	DN	Resorcinol compound 26
DMT21JG	MI	TTULVH8
DMT21JG	MN	Tyrosinase (TYR)
DMT21JG	MT	DTT
DMT21JG	MA	Inhibitor
DMT21JG	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMT21JG	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DM71R3T	DI	DM71R3T
DM71R3T	DN	Resorcinol compound 27
DM71R3T	MI	TTULVH8
DM71R3T	MN	Tyrosinase (TYR)
DM71R3T	MT	DTT
DM71R3T	MA	Inhibitor
DM71R3T	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DM71R3T	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMCHLAN	DI	DMCHLAN
DMCHLAN	DN	Resorcinol compound 28
DMCHLAN	MI	TTULVH8
DMCHLAN	MN	Tyrosinase (TYR)
DMCHLAN	MT	DTT
DMCHLAN	MA	Inhibitor
DMCHLAN	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMCHLAN	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DML7ONU	DI	DML7ONU
DML7ONU	DN	Resorcinol compound 29
DML7ONU	MI	TTULVH8
DML7ONU	MN	Tyrosinase (TYR)
DML7ONU	MT	DTT
DML7ONU	MA	Inhibitor
DML7ONU	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DML7ONU	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMPTK0G	DI	DMPTK0G
DMPTK0G	DN	Resorcinol compound 3
DMPTK0G	MI	TTULVH8
DMPTK0G	MN	Tyrosinase (TYR)
DMPTK0G	MT	DTT
DMPTK0G	MA	Inhibitor
DMPTK0G	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMPTK0G	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMMTVN4	DI	DMMTVN4
DMMTVN4	DN	Resorcinol compound 30
DMMTVN4	MI	TTULVH8
DMMTVN4	MN	Tyrosinase (TYR)
DMMTVN4	MT	DTT
DMMTVN4	MA	Inhibitor
DMMTVN4	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMMTVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMSPCLD	DI	DMSPCLD
DMSPCLD	DN	Resorcinol compound 31
DMSPCLD	MI	TTULVH8
DMSPCLD	MN	Tyrosinase (TYR)
DMSPCLD	MT	DTT
DMSPCLD	MA	Inhibitor
DMSPCLD	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMSPCLD	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DM2RPYB	DI	DM2RPYB
DM2RPYB	DN	Resorcinol compound 32
DM2RPYB	MI	TTULVH8
DM2RPYB	MN	Tyrosinase (TYR)
DM2RPYB	MT	DTT
DM2RPYB	MA	Inhibitor
DM2RPYB	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DM2RPYB	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMLJYS1	DI	DMLJYS1
DMLJYS1	DN	Resorcinol compound 33
DMLJYS1	MI	TTULVH8
DMLJYS1	MN	Tyrosinase (TYR)
DMLJYS1	MT	DTT
DMLJYS1	MA	Inhibitor
DMLJYS1	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMLJYS1	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMQF90E	DI	DMQF90E
DMQF90E	DN	Resorcinol compound 34
DMQF90E	MI	TTULVH8
DMQF90E	MN	Tyrosinase (TYR)
DMQF90E	MT	DTT
DMQF90E	MA	Inhibitor
DMQF90E	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMQF90E	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMIM9EY	DI	DMIM9EY
DMIM9EY	DN	Resorcinol compound 4
DMIM9EY	MI	TTULVH8
DMIM9EY	MN	Tyrosinase (TYR)
DMIM9EY	MT	DTT
DMIM9EY	MA	Inhibitor
DMIM9EY	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMIM9EY	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMQ5TYK	DI	DMQ5TYK
DMQ5TYK	DN	Resorcinol compound 5
DMQ5TYK	MI	TTULVH8
DMQ5TYK	MN	Tyrosinase (TYR)
DMQ5TYK	MT	DTT
DMQ5TYK	MA	Inhibitor
DMQ5TYK	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMQ5TYK	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DM809YH	DI	DM809YH
DM809YH	DN	Resorcinol compound 6
DM809YH	MI	TTULVH8
DM809YH	MN	Tyrosinase (TYR)
DM809YH	MT	DTT
DM809YH	MA	Inhibitor
DM809YH	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DM809YH	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DM031RU	DI	DM031RU
DM031RU	DN	Resorcinol compound 7
DM031RU	MI	TTULVH8
DM031RU	MN	Tyrosinase (TYR)
DM031RU	MT	DTT
DM031RU	MA	Inhibitor
DM031RU	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DM031RU	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMLF53V	DI	DMLF53V
DMLF53V	DN	Resorcinol compound 8
DMLF53V	MI	TTULVH8
DMLF53V	MN	Tyrosinase (TYR)
DMLF53V	MT	DTT
DMLF53V	MA	Inhibitor
DMLF53V	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMLF53V	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMCJO0R	DI	DMCJO0R
DMCJO0R	DN	Resorcinol compound 9
DMCJO0R	MI	TTULVH8
DMCJO0R	MN	Tyrosinase (TYR)
DMCJO0R	MT	DTT
DMCJO0R	MA	Inhibitor
DMCJO0R	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMCJO0R	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMUB7RV	DI	DMUB7RV
DMUB7RV	DN	Ring-fused compound 1
DMUB7RV	MI	TTA592U
DMUB7RV	MN	Urate anion exchanger 1 (URAT1)
DMUB7RV	MT	DTT
DMUB7RV	MA	Inhibitor
DMUB7RV	RN	Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10.
DMUB7RV	RU	https://www.ncbi.nlm.nih.gov/pubmed/27414413

DMD1G3Z	DI	DMD1G3Z
DMD1G3Z	DN	Roscovitine derivative 1
DMD1G3Z	MI	TTH6V3D
DMD1G3Z	MN	Cyclin-dependent kinase 1 (CDK1)
DMD1G3Z	MT	DTT
DMD1G3Z	MA	Inhibitor
DMD1G3Z	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMD1G3Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMD1G3Z	DI	DMD1G3Z
DMD1G3Z	DN	Roscovitine derivative 1
DMD1G3Z	MI	TT7HF4W
DMD1G3Z	MN	Cyclin-dependent kinase 2 (CDK2)
DMD1G3Z	MT	DTT
DMD1G3Z	MA	Inhibitor
DMD1G3Z	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMD1G3Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMD1G3Z	DI	DMD1G3Z
DMD1G3Z	DN	Roscovitine derivative 1
DMD1G3Z	MI	TTL4Q97
DMD1G3Z	MN	Cyclin-dependent kinase 5 (CDK5)
DMD1G3Z	MT	DTT
DMD1G3Z	MA	Inhibitor
DMD1G3Z	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMD1G3Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMD1G3Z	DI	DMD1G3Z
DMD1G3Z	DN	Roscovitine derivative 1
DMD1G3Z	MI	TTQYF7G
DMD1G3Z	MN	Cyclin-dependent kinase 7 (CDK7)
DMD1G3Z	MT	DTT
DMD1G3Z	MA	Inhibitor
DMD1G3Z	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMD1G3Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMD1G3Z	DI	DMD1G3Z
DMD1G3Z	DN	Roscovitine derivative 1
DMD1G3Z	MI	TT1LVF2
DMD1G3Z	MN	Cyclin-dependent kinase 9 (CDK9)
DMD1G3Z	MT	DTT
DMD1G3Z	MA	Inhibitor
DMD1G3Z	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DMD1G3Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DM41ZW9	DI	DM41ZW9
DM41ZW9	DN	Ruxolitinib derivative 1
DM41ZW9	MI	TTJSQEF
DM41ZW9	MN	Tyrosine-protein kinase (PTK)
DM41ZW9	MT	DTT
DM41ZW9	MA	Inhibitor
DM41ZW9	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DM41ZW9	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMSJWZ3	DI	DMSJWZ3
DMSJWZ3	DN	Ruxolitinib derivative 2
DMSJWZ3	MI	TT6DM01
DMSJWZ3	MN	Janus kinase 1 (JAK-1)
DMSJWZ3	MT	DTT
DMSJWZ3	MA	Inhibitor
DMSJWZ3	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMSJWZ3	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMSJWZ3	DI	DMSJWZ3
DMSJWZ3	DN	Ruxolitinib derivative 2
DMSJWZ3	MI	TTRMX3V
DMSJWZ3	MN	Janus kinase 2 (JAK-2)
DMSJWZ3	MT	DTT
DMSJWZ3	MA	Inhibitor
DMSJWZ3	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMSJWZ3	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMSJWZ3	DI	DMSJWZ3
DMSJWZ3	DN	Ruxolitinib derivative 2
DMSJWZ3	MI	TTT7PJU
DMSJWZ3	MN	Janus kinase 3 (JAK-3)
DMSJWZ3	MT	DTT
DMSJWZ3	MA	Inhibitor
DMSJWZ3	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMSJWZ3	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMB79QJ	DI	DMB79QJ
DMB79QJ	DN	Salicylic acid derivative 1
DMB79QJ	MI	TTH8FZW
DMB79QJ	MN	Signal transducer and activator of transcription 3 (STAT3)
DMB79QJ	MT	DTT
DMB79QJ	MA	Inhibitor
DMB79QJ	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMB79QJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMD8C9S	DI	DMD8C9S
DMD8C9S	DN	Salicylic acid derivative 2
DMD8C9S	MI	TTH8FZW
DMD8C9S	MN	Signal transducer and activator of transcription 3 (STAT3)
DMD8C9S	MT	DTT
DMD8C9S	MA	Inhibitor
DMD8C9S	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMD8C9S	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DM4OGKH	DI	DM4OGKH
DM4OGKH	DN	Salicylic acid derivative 3
DM4OGKH	MI	TTH8FZW
DM4OGKH	MN	Signal transducer and activator of transcription 3 (STAT3)
DM4OGKH	MT	DTT
DM4OGKH	MA	Inhibitor
DM4OGKH	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DM4OGKH	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DM4MAHK	DI	DM4MAHK
DM4MAHK	DN	Salicylic acid derivative 4
DM4MAHK	MI	TTH8FZW
DM4MAHK	MN	Signal transducer and activator of transcription 3 (STAT3)
DM4MAHK	MT	DTT
DM4MAHK	MA	Inhibitor
DM4MAHK	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DM4MAHK	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DM3OZ0F	DI	DM3OZ0F
DM3OZ0F	DN	Salicylic acid derivative 5
DM3OZ0F	MI	TTH8FZW
DM3OZ0F	MN	Signal transducer and activator of transcription 3 (STAT3)
DM3OZ0F	MT	DTT
DM3OZ0F	MA	Inhibitor
DM3OZ0F	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DM3OZ0F	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMLBEPW	DI	DMLBEPW
DMLBEPW	DN	Salicylic acid derivative 6
DMLBEPW	MI	TTH8FZW
DMLBEPW	MN	Signal transducer and activator of transcription 3 (STAT3)
DMLBEPW	MT	DTT
DMLBEPW	MA	Inhibitor
DMLBEPW	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMLBEPW	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMJFHVN	DI	DMJFHVN
DMJFHVN	DN	Salicylic acid derivative 7
DMJFHVN	MI	TTH8FZW
DMJFHVN	MN	Signal transducer and activator of transcription 3 (STAT3)
DMJFHVN	MT	DTT
DMJFHVN	MA	Inhibitor
DMJFHVN	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DMJFHVN	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DM2MQD0	DI	DM2MQD0
DM2MQD0	DN	SB19065
DM2MQD0	MI	TT42OGM
DM2MQD0	MN	Hematopoietic cell kinase (HCK)
DM2MQD0	MT	DTT
DM2MQD0	MA	Inhibitor
DM2MQD0	RN	Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases and pharmaceutical composition containing same. US9062066.
DM2MQD0	RU	http://www.freepatentsonline.com/US9062066.html

DMKQ0GE	DI	DMKQ0GE
DMKQ0GE	DN	SCHEMBL15198145
DMKQ0GE	MI	TTXHWA7
DMKQ0GE	MN	Ubiquitin-activating enzyme E1 (UBAE1)
DMKQ0GE	MT	DTT
DMKQ0GE	MA	Inhibitor
DMKQ0GE	RN	Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme. US10202389.
DMKQ0GE	RU	http://www.freepatentsonline.com/US10202389.html

DMHPQI2	DI	DMHPQI2
DMHPQI2	DN	SCHEMBL15198146
DMHPQI2	MI	TTXHWA7
DMHPQI2	MN	Ubiquitin-activating enzyme E1 (UBAE1)
DMHPQI2	MT	DTT
DMHPQI2	MA	Inhibitor
DMHPQI2	RN	Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme. US10202389.
DMHPQI2	RU	http://www.freepatentsonline.com/US10202389.html

DMK0T9E	DI	DMK0T9E
DMK0T9E	DN	SCHEMBL15295829
DMK0T9E	MI	TTVSMOH
DMK0T9E	MN	Sphingosine-1-phosphate receptor 2 (S1PR2)
DMK0T9E	MT	DTT
DMK0T9E	MA	Inhibitor
DMK0T9E	RN	Sphingosine 1-phosphate receptor antagonists. US9663511.
DMK0T9E	RU	http://www.freepatentsonline.com/US9663511.html

DM3OB4T	DI	DM3OB4T
DM3OB4T	DN	SCHEMBL16322760
DM3OB4T	MI	TT78309
DM3OB4T	MN	BUB1 mitotic checkpoint serine/threonine kinase (BUB1)
DM3OB4T	MT	DTT
DM3OB4T	MA	Inhibitor
DM3OB4T	RN	Substituted benzylpyrazoles. US9765058.
DM3OB4T	RU	http://www.freepatentsonline.com/US9765058.html

DMQARW2	DI	DMQARW2
DMQARW2	DN	SCHEMBL16365841
DMQARW2	MI	TT78309
DMQARW2	MN	BUB1 mitotic checkpoint serine/threonine kinase (BUB1)
DMQARW2	MT	DTT
DMQARW2	MA	Inhibitor
DMQARW2	RN	Substituted benzylpyrazoles. US9765058.
DMQARW2	RU	http://www.freepatentsonline.com/US9765058.html

DMC7PTY	DI	DMC7PTY
DMC7PTY	DN	SCHEMBL17766424
DMC7PTY	MI	TT78309
DMC7PTY	MN	BUB1 mitotic checkpoint serine/threonine kinase (BUB1)
DMC7PTY	MT	DTT
DMC7PTY	MA	Inhibitor
DMC7PTY	RN	Substituted benzylpyrazoles. US9765058.
DMC7PTY	RU	http://www.freepatentsonline.com/US9765058.html

DMQD6IL	DI	DMQD6IL
DMQD6IL	DN	Schiff base compound 1
DMQD6IL	MI	TT3WG5C
DMQD6IL	MN	Monoamine oxidase type A (MAO-A)
DMQD6IL	MT	DTT
DMQD6IL	RN	MAO inhibitors and their wider applications: a patent review.Expert Opin Ther Pat. 2018 Mar;28(3):211-226.
DMQD6IL	RU	https://www.ncbi.nlm.nih.gov/pubmed/29324067

DMQD6IL	DI	DMQD6IL
DMQD6IL	DN	Schiff base compound 1
DMQD6IL	MI	TTGP7BY
DMQD6IL	MN	Monoamine oxidase type B (MAO-B)
DMQD6IL	MT	DTT
DMQD6IL	RN	MAO inhibitors and their wider applications: a patent review.Expert Opin Ther Pat. 2018 Mar;28(3):211-226.
DMQD6IL	RU	https://www.ncbi.nlm.nih.gov/pubmed/29324067

DMWD20L	DI	DMWD20L
DMWD20L	DN	Schiff base compound 2
DMWD20L	MI	TTGP7BY
DMWD20L	MN	Monoamine oxidase type B (MAO-B)
DMWD20L	MT	DTT
DMWD20L	RN	MAO inhibitors and their wider applications: a patent review.Expert Opin Ther Pat. 2018 Mar;28(3):211-226.
DMWD20L	RU	https://www.ncbi.nlm.nih.gov/pubmed/29324067

DMEDNTJ	DI	DMEDNTJ
DMEDNTJ	DN	Secondary and tertiary (hetero)arylamide derivative 1
DMEDNTJ	MI	TTGP7BY
DMEDNTJ	MN	Monoamine oxidase type B (MAO-B)
DMEDNTJ	MT	DTT
DMEDNTJ	MA	Inhibitor
DMEDNTJ	RN	MAO inhibitors and their wider applications: a patent review.Expert Opin Ther Pat. 2018 Mar;28(3):211-226.
DMEDNTJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/29324067

DMIES9B	DI	DMIES9B
DMIES9B	DN	Secondary and tertiary (hetero)arylamide derivative 2
DMIES9B	MI	TT3WG5C
DMIES9B	MN	Monoamine oxidase type A (MAO-A)
DMIES9B	MT	DTT
DMIES9B	MA	Inhibitor
DMIES9B	RN	MAO inhibitors and their wider applications: a patent review.Expert Opin Ther Pat. 2018 Mar;28(3):211-226.
DMIES9B	RU	https://www.ncbi.nlm.nih.gov/pubmed/29324067

DM9C5Z8	DI	DM9C5Z8
DM9C5Z8	DN	Selenium compound 1
DM9C5Z8	MI	TTZHPB8
DM9C5Z8	MN	Lysine-specific demethylase 4A (KDM4A)
DM9C5Z8	MT	DTT
DM9C5Z8	MA	Inhibitor
DM9C5Z8	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DM9C5Z8	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMLWIJ7	DI	DMLWIJ7
DMLWIJ7	DN	Selenium compound 2
DMLWIJ7	MI	TTZHPB8
DMLWIJ7	MN	Lysine-specific demethylase 4A (KDM4A)
DMLWIJ7	MT	DTT
DMLWIJ7	MA	Inhibitor
DMLWIJ7	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMLWIJ7	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMQ5AJ6	DI	DMQ5AJ6
DMQ5AJ6	DN	Selenium compound 3
DMQ5AJ6	MI	TTZHPB8
DMQ5AJ6	MN	Lysine-specific demethylase 4A (KDM4A)
DMQ5AJ6	MT	DTT
DMQ5AJ6	MA	Inhibitor
DMQ5AJ6	RN	KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.
DMQ5AJ6	RU	https://www.ncbi.nlm.nih.gov/pubmed/25468267

DMYFK85	DI	DMYFK85
DMYFK85	DN	Six-membered heterocyclic benzamide derivative 1
DMYFK85	MI	TTTDVOJ
DMYFK85	MN	Tropomyosin-related kinase A (TrkA)
DMYFK85	MT	DTT
DMYFK85	MA	Inhibitor
DMYFK85	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMYFK85	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMX6AKV	DI	DMX6AKV
DMX6AKV	DN	Six-membered heterocyclic benzamide derivative 2
DMX6AKV	MI	TTTDVOJ
DMX6AKV	MN	Tropomyosin-related kinase A (TrkA)
DMX6AKV	MT	DTT
DMX6AKV	MA	Inhibitor
DMX6AKV	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMX6AKV	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMEGVD4	DI	DMEGVD4
DMEGVD4	DN	Six-membered heterocyclic benzamide derivative 3
DMEGVD4	MI	TTTDVOJ
DMEGVD4	MN	Tropomyosin-related kinase A (TrkA)
DMEGVD4	MT	DTT
DMEGVD4	MA	Inhibitor
DMEGVD4	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMEGVD4	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMB0D1H	DI	DMB0D1H
DMB0D1H	DN	Six-membered heterocyclic benzamide derivative 4
DMB0D1H	MI	TTTDVOJ
DMB0D1H	MN	Tropomyosin-related kinase A (TrkA)
DMB0D1H	MT	DTT
DMB0D1H	MA	Inhibitor
DMB0D1H	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMB0D1H	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DM0GTUH	DI	DM0GTUH
DM0GTUH	DN	Six-membered heterocyclic benzamide derivative 5
DM0GTUH	MI	TTTDVOJ
DM0GTUH	MN	Tropomyosin-related kinase A (TrkA)
DM0GTUH	MT	DTT
DM0GTUH	MA	Inhibitor
DM0GTUH	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DM0GTUH	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMZU96C	DI	DMZU96C
DMZU96C	DN	Six-membered heterocyclic benzamide derivative 6
DMZU96C	MI	TTTDVOJ
DMZU96C	MN	Tropomyosin-related kinase A (TrkA)
DMZU96C	MT	DTT
DMZU96C	MA	Inhibitor
DMZU96C	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMZU96C	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DM15AFI	DI	DM15AFI
DM15AFI	DN	Six-membered heterocyclic benzamide derivative 7
DM15AFI	MI	TTTDVOJ
DM15AFI	MN	Tropomyosin-related kinase A (TrkA)
DM15AFI	MT	DTT
DM15AFI	MA	Inhibitor
DM15AFI	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DM15AFI	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMJF6S0	DI	DMJF6S0
DMJF6S0	DN	Sphinx
DMJF6S0	MI	TTU3WV6
DMJF6S0	MN	SRSF protein kinase 1 (SRPK1)
DMJF6S0	MT	DTT
DMJF6S0	MA	Inhibitor
DMJF6S0	RN	Piperazine derivatives for treating disorders. US9695160.
DMJF6S0	RU	http://www.freepatentsonline.com/US9695160.html

DM8XJTH	DI	DM8XJTH
DM8XJTH	DN	SPHINX scaffold, 3
DM8XJTH	MI	TTU3WV6
DM8XJTH	MN	SRSF protein kinase 1 (SRPK1)
DM8XJTH	MT	DTT
DM8XJTH	MA	Inhibitor
DM8XJTH	RN	Piperazine derivatives for treating disorders. US9695160.
DM8XJTH	RU	http://www.freepatentsonline.com/US9695160.html

DM4R7OQ	DI	DM4R7OQ
DM4R7OQ	DN	Spirocyclic diamine urea derivative 1
DM4R7OQ	MI	TTDP1UC
DM4R7OQ	MN	Fatty acid amide hydrolase (FAAH)
DM4R7OQ	MT	DTT
DM4R7OQ	MA	Inhibitor
DM4R7OQ	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DM4R7OQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMH5N78	DI	DMH5N78
DMH5N78	DN	Spirocyclic diamine urea derivative 2
DMH5N78	MI	TTDP1UC
DMH5N78	MN	Fatty acid amide hydrolase (FAAH)
DMH5N78	MT	DTT
DMH5N78	MA	Inhibitor
DMH5N78	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMH5N78	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMCPVRU	DI	DMCPVRU
DMCPVRU	DN	Spiroimidazolone derivative 1
DMCPVRU	MI	TT9O6WS
DMCPVRU	MN	Glucagon receptor (GCGR)
DMCPVRU	MT	DTT
DMCPVRU	MA	Antagonist
DMCPVRU	RN	Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30.
DMCPVRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/25828189

DM3EAHB	DI	DM3EAHB
DM3EAHB	DN	Spiroimidazolone derivative 2
DM3EAHB	MI	TT9O6WS
DM3EAHB	MN	Glucagon receptor (GCGR)
DM3EAHB	MT	DTT
DM3EAHB	MA	Antagonist
DM3EAHB	RN	Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30.
DM3EAHB	RU	https://www.ncbi.nlm.nih.gov/pubmed/25828189

DM02J8N	DI	DM02J8N
DM02J8N	DN	Spiroimidazolone derivative 3
DM02J8N	MI	TT9O6WS
DM02J8N	MN	Glucagon receptor (GCGR)
DM02J8N	MT	DTT
DM02J8N	MA	Antagonist
DM02J8N	RN	Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30.
DM02J8N	RU	https://www.ncbi.nlm.nih.gov/pubmed/25828189

DMXIHPT	DI	DMXIHPT
DMXIHPT	DN	Spiroimidazolone derivative 4
DMXIHPT	MI	TT9O6WS
DMXIHPT	MN	Glucagon receptor (GCGR)
DMXIHPT	MT	DTT
DMXIHPT	MA	Antagonist
DMXIHPT	RN	Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30.
DMXIHPT	RU	https://www.ncbi.nlm.nih.gov/pubmed/25828189

DM5A62X	DI	DM5A62X
DM5A62X	DN	Spiroimidazolone derivative 5
DM5A62X	MI	TT9O6WS
DM5A62X	MN	Glucagon receptor (GCGR)
DM5A62X	MT	DTT
DM5A62X	MA	Antagonist
DM5A62X	RN	Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30.
DM5A62X	RU	https://www.ncbi.nlm.nih.gov/pubmed/25828189

DMJN5CI	DI	DMJN5CI
DMJN5CI	DN	Spiroimidazolone derivative 6
DMJN5CI	MI	TT9O6WS
DMJN5CI	MN	Glucagon receptor (GCGR)
DMJN5CI	MT	DTT
DMJN5CI	MA	Antagonist
DMJN5CI	RN	Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30.
DMJN5CI	RU	https://www.ncbi.nlm.nih.gov/pubmed/25828189

DM5A4TP	DI	DM5A4TP
DM5A4TP	DN	Spiroimidazolone derivative 7
DM5A4TP	MI	TT9O6WS
DM5A4TP	MN	Glucagon receptor (GCGR)
DM5A4TP	MT	DTT
DM5A4TP	MA	Antagonist
DM5A4TP	RN	Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30.
DM5A4TP	RU	https://www.ncbi.nlm.nih.gov/pubmed/25828189

DMK5G7D	DI	DMK5G7D
DMK5G7D	DN	Spirolaxine derivative 1
DMK5G7D	MI	TTZMAO3
DMK5G7D	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMK5G7D	MT	DTT
DMK5G7D	MA	Agonist
DMK5G7D	RN	PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
DMK5G7D	RU	https://www.ncbi.nlm.nih.gov/pubmed/25416646

DMYJL2Z	DI	DMYJL2Z
DMYJL2Z	DN	Spiroquinolone derivative 1
DMYJL2Z	MI	TTRZQE3
DMYJL2Z	MN	Glycogen synthase kinase-3 alpha (GSK-3A)
DMYJL2Z	MT	DTT
DMYJL2Z	MA	Inhibitor
DMYJL2Z	RN	Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
DMYJL2Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/27828716

DMB0NVQ	DI	DMB0NVQ
DMB0NVQ	DN	Steroid derivative 1
DMB0NVQ	MI	TTUX68I
DMB0NVQ	MN	Hypoxia-inducible factor 1 (HIF-1)
DMB0NVQ	MT	DTT
DMB0NVQ	MA	Inhibitor
DMB0NVQ	RN	Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22.
DMB0NVQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26882240

DMQ0RGB	DI	DMQ0RGB
DMQ0RGB	DN	Steroid derivative 2
DMQ0RGB	MI	TTUX68I
DMQ0RGB	MN	Hypoxia-inducible factor 1 (HIF-1)
DMQ0RGB	MT	DTT
DMQ0RGB	MA	Inhibitor
DMQ0RGB	RN	Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22.
DMQ0RGB	RU	https://www.ncbi.nlm.nih.gov/pubmed/26882240

DMETIKC	DI	DMETIKC
DMETIKC	DN	Steroid derivative 3
DMETIKC	MI	TTUX68I
DMETIKC	MN	Hypoxia-inducible factor 1 (HIF-1)
DMETIKC	MT	DTT
DMETIKC	MA	Inhibitor
DMETIKC	RN	Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22.
DMETIKC	RU	https://www.ncbi.nlm.nih.gov/pubmed/26882240

DMJPYVS	DI	DMJPYVS
DMJPYVS	DN	Steroid derivative 4
DMJPYVS	MI	TTUX68I
DMJPYVS	MN	Hypoxia-inducible factor 1 (HIF-1)
DMJPYVS	MT	DTT
DMJPYVS	MA	Inhibitor
DMJPYVS	RN	Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22.
DMJPYVS	RU	https://www.ncbi.nlm.nih.gov/pubmed/26882240

DMHLA5V	DI	DMHLA5V
DMHLA5V	DN	Steroidal carboxamide derivative 1
DMHLA5V	MI	TT9JNIC
DMHLA5V	MN	Histamine H3 receptor (H3R)
DMHLA5V	MT	DTT
DMHLA5V	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DMHLA5V	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DM5U36G	DI	DM5U36G
DM5U36G	DN	Sterol derivative 1
DM5U36G	MI	TTPADOQ
DM5U36G	MN	HMG-CoA reductase (HMGCR)
DM5U36G	MT	DTT
DM5U36G	MA	Inhibitor
DM5U36G	RN	HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272.
DM5U36G	RU	https://www.ncbi.nlm.nih.gov/pubmed/27537201

DME1B23	DI	DME1B23
DME1B23	DN	Sterol derivative 2
DME1B23	MI	TTPADOQ
DME1B23	MN	HMG-CoA reductase (HMGCR)
DME1B23	MT	DTT
DME1B23	MA	Inhibitor
DME1B23	RN	HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272.
DME1B23	RU	https://www.ncbi.nlm.nih.gov/pubmed/27537201

DMOT1FQ	DI	DMOT1FQ
DMOT1FQ	DN	Sterol derivative 3
DMOT1FQ	MI	TTPADOQ
DMOT1FQ	MN	HMG-CoA reductase (HMGCR)
DMOT1FQ	MT	DTT
DMOT1FQ	MA	Inhibitor
DMOT1FQ	RN	HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272.
DMOT1FQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27537201

DM6KPYL	DI	DM6KPYL
DM6KPYL	DN	STK296197
DM6KPYL	MI	TT3RMNA
DM6KPYL	MN	Chymotrypsin-C (CLCR)
DM6KPYL	MT	DTT
DM6KPYL	MA	Inhibitor
DM6KPYL	RN	Benzoxazinone derivatives for treatment of skin diseases. US9695194.
DM6KPYL	RU	http://www.freepatentsonline.com/US9695194.html

DM19GAY	DI	DM19GAY
DM19GAY	DN	STK696827
DM19GAY	MI	TT1NFO3
DM19GAY	MN	Bacterial Nicotinate-nucleotide adenylyltransferase (Bact nadD)
DM19GAY	MT	DTT
DM19GAY	MA	Inhibitor
DM19GAY	RN	Targeting NAD biosynthesis in bacterial pathogens. US8785499.
DM19GAY	RU	http://www.freepatentsonline.com/US8785499.html

DMTXDSG	DI	DMTXDSG
DMTXDSG	DN	Succinamide derivative 1
DMTXDSG	MI	TTA592U
DMTXDSG	MN	Urate anion exchanger 1 (URAT1)
DMTXDSG	MT	DTT
DMTXDSG	MA	Inhibitor
DMTXDSG	RN	Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10.
DMTXDSG	RU	https://www.ncbi.nlm.nih.gov/pubmed/27414413

DMQ0VK9	DI	DMQ0VK9
DMQ0VK9	DN	Sulfamic acid ester derivative 1
DMQ0VK9	MI	TTZJYKH
DMQ0VK9	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMQ0VK9	MT	DTT
DMQ0VK9	MA	Inhibitor
DMQ0VK9	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMQ0VK9	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMO7ZRW	DI	DMO7ZRW
DMO7ZRW	DN	Sulfamoylamide derivative 1
DMO7ZRW	MI	TTZJYKH
DMO7ZRW	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMO7ZRW	MT	DTT
DMO7ZRW	MA	Inhibitor
DMO7ZRW	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMO7ZRW	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMTX21L	DI	DMTX21L
DMTX21L	DN	Sulfonamide derivative 1
DMTX21L	MI	TT6OEDT
DMTX21L	MN	Cannabinoid receptor 1 (CB1)
DMTX21L	MT	DTT
DMTX21L	MA	Antagonist
DMTX21L	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMTX21L	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMA32GJ	DI	DMA32GJ
DMA32GJ	DN	Sulfonamide derivative 10
DMA32GJ	MI	TTA592U
DMA32GJ	MN	Urate anion exchanger 1 (URAT1)
DMA32GJ	MT	DTT
DMA32GJ	MA	Inhibitor
DMA32GJ	RN	Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10.
DMA32GJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27414413

DMJBR86	DI	DMJBR86
DMJBR86	DN	Sulfonamide derivative 11
DMJBR86	MI	TTA592U
DMJBR86	MN	Urate anion exchanger 1 (URAT1)
DMJBR86	MT	DTT
DMJBR86	MA	Inhibitor
DMJBR86	RN	Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10.
DMJBR86	RU	https://www.ncbi.nlm.nih.gov/pubmed/27414413

DMXEL56	DI	DMXEL56
DMXEL56	DN	Sulfonamide derivative 12
DMXEL56	MI	TT2LVK8
DMXEL56	MN	Carbonic anhydrase IX (CA-IX)
DMXEL56	MT	DTT
DMXEL56	MA	Inhibitor
DMXEL56	RN	Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).Expert Opin Ther Pat. 2018 Oct;28(10):729-740.
DMXEL56	RU	https://www.ncbi.nlm.nih.gov/pubmed/30074415

DM5CUSJ	DI	DM5CUSJ
DM5CUSJ	DN	Sulfonamide derivative 15
DM5CUSJ	MI	TTZS04O
DM5CUSJ	MN	Gamma-secretase subunit APH-1A/1B (APH-1)
DM5CUSJ	MT	DTT
DM5CUSJ	MA	Inhibitor
DM5CUSJ	RN	Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761.
DM5CUSJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28460551

DMTFNGM	DI	DMTFNGM
DMTFNGM	DN	Sulfonamide derivative 16
DMTFNGM	MI	TT5ZKDI
DMTFNGM	MN	Histone deacetylase 6 (HDAC6)
DMTFNGM	MT	DTT
DMTFNGM	MA	Inhibitor
DMTFNGM	RN	Sulfonamide inhibitors: a patent review 2013-present.Expert Opin Ther Pat. 2018 Jul;28(7):541-549.
DMTFNGM	RU	https://www.ncbi.nlm.nih.gov/pubmed/29886770

DMIQ1PL	DI	DMIQ1PL
DMIQ1PL	DN	Sulfonamide derivative 17
DMIQ1PL	MI	TT3M2WO
DMIQ1PL	MN	Sphingosine kinase (SphK)
DMIQ1PL	MT	DTT
DMIQ1PL	MA	Inhibitor
DMIQ1PL	RN	Sulfonamide inhibitors: a patent review 2013-present.Expert Opin Ther Pat. 2018 Jul;28(7):541-549.
DMIQ1PL	RU	https://www.ncbi.nlm.nih.gov/pubmed/29886770

DMHTJ7N	DI	DMHTJ7N
DMHTJ7N	DN	Sulfonamide derivative 18
DMHTJ7N	MI	TTZMAO3
DMHTJ7N	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMHTJ7N	MT	DTT
DMHTJ7N	MA	Agonist
DMHTJ7N	RN	PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
DMHTJ7N	RU	https://www.ncbi.nlm.nih.gov/pubmed/25416646

DMD51AV	DI	DMD51AV
DMD51AV	DN	Sulfonamide derivative 6
DMD51AV	MI	TTZJYKH
DMD51AV	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMD51AV	MT	DTT
DMD51AV	MA	Inhibitor
DMD51AV	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMD51AV	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMN5YUK	DI	DMN5YUK
DMN5YUK	DN	Sulfonamide derivative 7
DMN5YUK	MI	TTZJYKH
DMN5YUK	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMN5YUK	MT	DTT
DMN5YUK	MA	Inhibitor
DMN5YUK	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMN5YUK	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DMOXIZC	DI	DMOXIZC
DMOXIZC	DN	Sulfonamide derivative 8
DMOXIZC	MI	TTZJYKH
DMOXIZC	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMOXIZC	MT	DTT
DMOXIZC	MA	Inhibitor
DMOXIZC	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMOXIZC	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DM2RZL8	DI	DM2RZL8
DM2RZL8	DN	Sulfonamide derivative 9
DM2RZL8	MI	TT2F4OL
DM2RZL8	MN	Tissue transglutaminase (TG2)
DM2RZL8	MT	DTT
DM2RZL8	MA	Inhibitor
DM2RZL8	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DM2RZL8	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DMP9Z34	DI	DMP9Z34
DMP9Z34	DN	Sulfonamide-thiadiazole derivative 1
DMP9Z34	MI	TT2LVK8
DMP9Z34	MN	Carbonic anhydrase IX (CA-IX)
DMP9Z34	MT	DTT
DMP9Z34	MA	Inhibitor
DMP9Z34	RN	Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).Expert Opin Ther Pat. 2018 Oct;28(10):729-740.
DMP9Z34	RU	https://www.ncbi.nlm.nih.gov/pubmed/30074415

DMZAE78	DI	DMZAE78
DMZAE78	DN	Sulfonamide-thiadiazole derivative 2
DMZAE78	MI	TT2LVK8
DMZAE78	MN	Carbonic anhydrase IX (CA-IX)
DMZAE78	MT	DTT
DMZAE78	MA	Inhibitor
DMZAE78	RN	Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).Expert Opin Ther Pat. 2018 Oct;28(10):729-740.
DMZAE78	RU	https://www.ncbi.nlm.nih.gov/pubmed/30074415

DMCO8JD	DI	DMCO8JD
DMCO8JD	DN	Sulfonylated piperazine derivative 1
DMCO8JD	MI	TT6OEDT
DMCO8JD	MN	Cannabinoid receptor 1 (CB1)
DMCO8JD	MT	DTT
DMCO8JD	MA	Antagonist
DMCO8JD	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMCO8JD	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMZYPV3	DI	DMZYPV3
DMZYPV3	DN	Sulfonylated piperazine derivative 2
DMZYPV3	MI	TT6OEDT
DMZYPV3	MN	Cannabinoid receptor 1 (CB1)
DMZYPV3	MT	DTT
DMZYPV3	MA	Antagonist
DMZYPV3	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMZYPV3	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMOJAZ9	DI	DMOJAZ9
DMOJAZ9	DN	Sulfonylated piperazine derivative 3
DMOJAZ9	MI	TT6OEDT
DMOJAZ9	MN	Cannabinoid receptor 1 (CB1)
DMOJAZ9	MT	DTT
DMOJAZ9	MA	Antagonist
DMOJAZ9	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMOJAZ9	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMZW2XP	DI	DMZW2XP
DMZW2XP	DN	Sulfonylated piperazine derivative 4
DMZW2XP	MI	TT6OEDT
DMZW2XP	MN	Cannabinoid receptor 1 (CB1)
DMZW2XP	MT	DTT
DMZW2XP	MA	Antagonist
DMZW2XP	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMZW2XP	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DM65NBS	DI	DM65NBS
DM65NBS	DN	Sulfonylated piperazine derivative 5
DM65NBS	MI	TT6OEDT
DM65NBS	MN	Cannabinoid receptor 1 (CB1)
DM65NBS	MT	DTT
DM65NBS	MA	Antagonist
DM65NBS	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DM65NBS	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMHO29Y	DI	DMHO29Y
DMHO29Y	DN	T83193
DMHO29Y	MI	TTT2LD9
DMHO29Y	MN	GABA transaminase (ABAT)
DMHO29Y	MT	DTT
DMHO29Y	MA	Inhibitor
DMHO29Y	RN	Inhibition of GABA shunt enzymes' activity by 4-hydroxybenzaldehyde derivatives. Bioorg Med Chem Lett. 2006 Feb;16(3):592-5.
DMHO29Y	RU	https://pubmed.ncbi.nlm.nih.gov/16290145

DMHO29Y	DI	DMHO29Y
DMHO29Y	DN	T83193
DMHO29Y	MI	TTGP7BY
DMHO29Y	MN	Monoamine oxidase type B (MAO-B)
DMHO29Y	MT	DTT
DMHO29Y	MA	Inhibitor
DMHO29Y	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMHO29Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMHO29Y	DI	DMHO29Y
DMHO29Y	DN	T83193
DMHO29Y	MI	TTJUWVB
DMHO29Y	MN	Succinate-semialdehyde dehydrogenase (ALDH5A1)
DMHO29Y	MT	DTT
DMHO29Y	MA	Inhibitor
DMHO29Y	RN	Inhibition of GABA shunt enzymes' activity by 4-hydroxybenzaldehyde derivatives. Bioorg Med Chem Lett. 2006 Feb;16(3):592-5.
DMHO29Y	RU	https://pubmed.ncbi.nlm.nih.gov/16290145

DM86BDS	DI	DM86BDS
DM86BDS	DN	T8361
DM86BDS	MI	TTOJ9QL
DM86BDS	MN	Endoplasmic reticulum to nucleus signaling 1 (ERN1)
DM86BDS	MT	DTT
DM86BDS	MA	Inhibitor
DM86BDS	RN	IRE-1 inhibitors. US8614253.
DM86BDS	RU	http://www.freepatentsonline.com/US8614253.html

DMX41ZF	DI	DMX41ZF
DMX41ZF	DN	T863
DMX41ZF	MI	TTF8P9I
DMX41ZF	MN	Diacylglycerol acyltransferase 1 (DGAT1)
DMX41ZF	MT	DTT
DMX41ZF	MA	Inhibitor
DMX41ZF	RN	Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
DMX41ZF	RU	https://www.ncbi.nlm.nih.gov/pubmed/25470667

DMFOKRW	DI	DMFOKRW
DMFOKRW	DN	Tacrine heterodimer derivative 1
DMFOKRW	MI	TT1RS9F
DMFOKRW	MN	Acetylcholinesterase (AChE)
DMFOKRW	MT	DTT
DMFOKRW	MA	Inhibitor
DMFOKRW	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DMFOKRW	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DMFOKRW	DI	DMFOKRW
DMFOKRW	DN	Tacrine heterodimer derivative 1
DMFOKRW	MI	TTEB0GD
DMFOKRW	MN	Cholinesterase (BCHE)
DMFOKRW	MT	DTT
DMFOKRW	MA	Inhibitor
DMFOKRW	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DMFOKRW	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DMJ04RQ	DI	DMJ04RQ
DMJ04RQ	DN	Tacrine-caffeic acid hybrid derivative 1
DMJ04RQ	MI	TT1RS9F
DMJ04RQ	MN	Acetylcholinesterase (AChE)
DMJ04RQ	MT	DTT
DMJ04RQ	MA	Inhibitor
DMJ04RQ	RN	Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476.
DMJ04RQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27967267

DMMVPSY	DI	DMMVPSY
DMMVPSY	DN	Tacrine-caffeic acid hybrid derivative 2
DMMVPSY	MI	TT1RS9F
DMMVPSY	MN	Acetylcholinesterase (AChE)
DMMVPSY	MT	DTT
DMMVPSY	MA	Inhibitor
DMMVPSY	RN	Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476.
DMMVPSY	RU	https://www.ncbi.nlm.nih.gov/pubmed/27967267

DM6YBTR	DI	DM6YBTR
DM6YBTR	DN	Tacrine-coumarin hybrid derivative 1
DM6YBTR	MI	TT3WG5C
DM6YBTR	MN	Monoamine oxidase type A (MAO-A)
DM6YBTR	MT	DTT
DM6YBTR	RN	MAO inhibitors and their wider applications: a patent review.Expert Opin Ther Pat. 2018 Mar;28(3):211-226.
DM6YBTR	RU	https://www.ncbi.nlm.nih.gov/pubmed/29324067

DM6YBTR	DI	DM6YBTR
DM6YBTR	DN	Tacrine-coumarin hybrid derivative 1
DM6YBTR	MI	TTGP7BY
DM6YBTR	MN	Monoamine oxidase type B (MAO-B)
DM6YBTR	MT	DTT
DM6YBTR	RN	MAO inhibitors and their wider applications: a patent review.Expert Opin Ther Pat. 2018 Mar;28(3):211-226.
DM6YBTR	RU	https://www.ncbi.nlm.nih.gov/pubmed/29324067

DMK0S4I	DI	DMK0S4I
DMK0S4I	DN	Tacrine-dihydropyridine hybrid derivative 1
DMK0S4I	MI	TT1RS9F
DMK0S4I	MN	Acetylcholinesterase (AChE)
DMK0S4I	MT	DTT
DMK0S4I	RN	Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476.
DMK0S4I	RU	https://www.ncbi.nlm.nih.gov/pubmed/27967267

DMQ3K5B	DI	DMQ3K5B
DMQ3K5B	DN	Tacrine-indole hybrid derivative 1
DMQ3K5B	MI	TT1RS9F
DMQ3K5B	MN	Acetylcholinesterase (AChE)
DMQ3K5B	MT	DTT
DMQ3K5B	MA	Inhibitor
DMQ3K5B	RN	Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476.
DMQ3K5B	RU	https://www.ncbi.nlm.nih.gov/pubmed/27967267

DMH9N2T	DI	DMH9N2T
DMH9N2T	DN	Tacrine-indole hybrid derivative 2
DMH9N2T	MI	TT1RS9F
DMH9N2T	MN	Acetylcholinesterase (AChE)
DMH9N2T	MT	DTT
DMH9N2T	MA	Inhibitor
DMH9N2T	RN	Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476.
DMH9N2T	RU	https://www.ncbi.nlm.nih.gov/pubmed/27967267

DMUTKNW	DI	DMUTKNW
DMUTKNW	DN	Tacrine-indole hybrid derivative 3
DMUTKNW	MI	TT1RS9F
DMUTKNW	MN	Acetylcholinesterase (AChE)
DMUTKNW	MT	DTT
DMUTKNW	MA	Inhibitor
DMUTKNW	RN	Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476.
DMUTKNW	RU	https://www.ncbi.nlm.nih.gov/pubmed/27967267

DMNGY8R	DI	DMNGY8R
DMNGY8R	DN	Tacrine-phenothiazine hybrid derivative 1
DMNGY8R	MI	TT1RS9F
DMNGY8R	MN	Acetylcholinesterase (AChE)
DMNGY8R	MT	DTT
DMNGY8R	MA	Inhibitor
DMNGY8R	RN	Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476.
DMNGY8R	RU	https://www.ncbi.nlm.nih.gov/pubmed/27967267

DMK5HAC	DI	DMK5HAC
DMK5HAC	DN	Tarizine derivative 1
DMK5HAC	MI	TT4G2JS
DMK5HAC	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DMK5HAC	MT	DTT
DMK5HAC	MA	Inhibitor
DMK5HAC	RN	Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90.
DMK5HAC	RU	https://www.ncbi.nlm.nih.gov/pubmed/25539043

DMQKOMR	DI	DMQKOMR
DMQKOMR	DN	Tarnylcypromine derivative 1
DMQKOMR	MI	TTNR0UQ
DMQKOMR	MN	Lysine-specific histone demethylase 1 (LSD)
DMQKOMR	MT	DTT
DMQKOMR	MA	Inhibitor
DMQKOMR	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMQKOMR	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMEJR2F	DI	DMEJR2F
DMEJR2F	DN	Tarnylcypromine derivative 2
DMEJR2F	MI	TTNR0UQ
DMEJR2F	MN	Lysine-specific histone demethylase 1 (LSD)
DMEJR2F	MT	DTT
DMEJR2F	MA	Inhibitor
DMEJR2F	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMEJR2F	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMEJR2F	DI	DMEJR2F
DMEJR2F	DN	Tarnylcypromine derivative 2
DMEJR2F	MI	TT8VP2T
DMEJR2F	MN	Lysine-specific histone demethylase 1B (KDM1B)
DMEJR2F	MT	DTT
DMEJR2F	MA	Inhibitor
DMEJR2F	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMEJR2F	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMEJR2F	DI	DMEJR2F
DMEJR2F	DN	Tarnylcypromine derivative 2
DMEJR2F	MI	TT3WG5C
DMEJR2F	MN	Monoamine oxidase type A (MAO-A)
DMEJR2F	MT	DTT
DMEJR2F	MA	Inhibitor
DMEJR2F	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMEJR2F	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMEJR2F	DI	DMEJR2F
DMEJR2F	DN	Tarnylcypromine derivative 2
DMEJR2F	MI	TTGP7BY
DMEJR2F	MN	Monoamine oxidase type B (MAO-B)
DMEJR2F	MT	DTT
DMEJR2F	MA	Inhibitor
DMEJR2F	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMEJR2F	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMKJOMC	DI	DMKJOMC
DMKJOMC	DN	Tarnylcypromine derivative 3
DMKJOMC	MI	TTNR0UQ
DMKJOMC	MN	Lysine-specific histone demethylase 1 (LSD)
DMKJOMC	MT	DTT
DMKJOMC	MA	Inhibitor
DMKJOMC	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMKJOMC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMKJOMC	DI	DMKJOMC
DMKJOMC	DN	Tarnylcypromine derivative 3
DMKJOMC	MI	TT8VP2T
DMKJOMC	MN	Lysine-specific histone demethylase 1B (KDM1B)
DMKJOMC	MT	DTT
DMKJOMC	MA	Inhibitor
DMKJOMC	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMKJOMC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMKJOMC	DI	DMKJOMC
DMKJOMC	DN	Tarnylcypromine derivative 3
DMKJOMC	MI	TT3WG5C
DMKJOMC	MN	Monoamine oxidase type A (MAO-A)
DMKJOMC	MT	DTT
DMKJOMC	MA	Inhibitor
DMKJOMC	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMKJOMC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMKJOMC	DI	DMKJOMC
DMKJOMC	DN	Tarnylcypromine derivative 3
DMKJOMC	MI	TTGP7BY
DMKJOMC	MN	Monoamine oxidase type B (MAO-B)
DMKJOMC	MT	DTT
DMKJOMC	MA	Inhibitor
DMKJOMC	RN	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
DMKJOMC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27019002

DMG6Q45	DI	DMG6Q45
DMG6Q45	DN	TDZD-8
DMG6Q45	MI	TTRZQE3
DMG6Q45	MN	Glycogen synthase kinase-3 alpha (GSK-3A)
DMG6Q45	MT	DTT
DMG6Q45	MA	Inhibitor
DMG6Q45	RN	Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
DMG6Q45	RU	https://www.ncbi.nlm.nih.gov/pubmed/27828716

DMG6Q45	DI	DMG6Q45
DMG6Q45	DN	TDZD-8
DMG6Q45	MI	TTRSMW9
DMG6Q45	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMG6Q45	MT	DTT
DMG6Q45	MA	Inhibitor
DMG6Q45	RN	Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3beta inhibitors through virtual screening. Bioorg Med Chem Lett. 2012 Dec 1;22(23):7232-6.
DMG6Q45	RU	https://pubmed.ncbi.nlm.nih.gov/23099099

DMFMZCW	DI	DMFMZCW
DMFMZCW	DN	Terpyridineplatinum(II) complexe 1
DMFMZCW	MI	TTR7UJ3
DMFMZCW	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMFMZCW	MT	DTT
DMFMZCW	MA	Inhibitor
DMFMZCW	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMFMZCW	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DMLUYR0	DI	DMLUYR0
DMLUYR0	DN	Terpyridineplatinum(II) complexe 2
DMLUYR0	MI	TTR7UJ3
DMLUYR0	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMLUYR0	MT	DTT
DMLUYR0	MA	Inhibitor
DMLUYR0	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMLUYR0	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DM54EFD	DI	DM54EFD
DM54EFD	DN	Terpyridineplatinum(II) complexe 3
DM54EFD	MI	TTR7UJ3
DM54EFD	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DM54EFD	MT	DTT
DM54EFD	MA	Inhibitor
DM54EFD	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DM54EFD	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DM54EFD	DI	DM54EFD
DM54EFD	DN	Terpyridineplatinum(II) complexe 3
DM54EFD	MI	TTEP6RV
DM54EFD	MN	Glutathione reductase (GR)
DM54EFD	MT	DTT
DM54EFD	MA	Inhibitor
DM54EFD	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DM54EFD	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DMOV86T	DI	DMOV86T
DMOV86T	DN	Terpyridineplatinum(II) complexe 4
DMOV86T	MI	TTR7UJ3
DMOV86T	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMOV86T	MT	DTT
DMOV86T	MA	Inhibitor
DMOV86T	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMOV86T	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DMOV86T	DI	DMOV86T
DMOV86T	DN	Terpyridineplatinum(II) complexe 4
DMOV86T	MI	TTEP6RV
DMOV86T	MN	Glutathione reductase (GR)
DMOV86T	MT	DTT
DMOV86T	MA	Inhibitor
DMOV86T	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMOV86T	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DMI4MJ2	DI	DMI4MJ2
DMI4MJ2	DN	Terpyridineplatinum(II) complexe 5
DMI4MJ2	MI	TTR7UJ3
DMI4MJ2	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMI4MJ2	MT	DTT
DMI4MJ2	MA	Inhibitor
DMI4MJ2	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMI4MJ2	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DMS3YPJ	DI	DMS3YPJ
DMS3YPJ	DN	Tetra/penta-cyclic pyridophthalazinone derivative 1
DMS3YPJ	MI	TTEBCY8
DMS3YPJ	MN	Poly [ADP-ribose] polymerase (PARP)
DMS3YPJ	MT	DTT
DMS3YPJ	MA	Inhibitor
DMS3YPJ	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DMS3YPJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DMLRY53	DI	DMLRY53
DMLRY53	DN	Tetra-azabenzo[e]azulene derivative 1
DMLRY53	MI	TT4TFGN
DMLRY53	MN	Vasopressin V1a receptor (V1AR)
DMLRY53	MT	DTT
DMLRY53	MA	Inhibitor
DMLRY53	RN	Vasopressin V1a and V1b receptor modulators: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jun;25(6):711-22.
DMLRY53	RU	https://www.ncbi.nlm.nih.gov/pubmed/25776143

DMUEI4N	DI	DMUEI4N
DMUEI4N	DN	Tetra-azabenzo[e]azulene derivative 2
DMUEI4N	MI	TT4TFGN
DMUEI4N	MN	Vasopressin V1a receptor (V1AR)
DMUEI4N	MT	DTT
DMUEI4N	MA	Inhibitor
DMUEI4N	RN	Vasopressin V1a and V1b receptor modulators: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jun;25(6):711-22.
DMUEI4N	RU	https://www.ncbi.nlm.nih.gov/pubmed/25776143

DMS1GJD	DI	DMS1GJD
DMS1GJD	DN	Tetra-cyclic compound 1
DMS1GJD	MI	TTJSQEF
DMS1GJD	MN	Tyrosine-protein kinase (PTK)
DMS1GJD	MT	DTT
DMS1GJD	MA	Inhibitor
DMS1GJD	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMS1GJD	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMX2EFL	DI	DMX2EFL
DMX2EFL	DN	Tetra-cyclic pyridophthalazinone derivative 1
DMX2EFL	MI	TTVDSZ0
DMX2EFL	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMX2EFL	MT	DTT
DMX2EFL	MA	Inhibitor
DMX2EFL	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DMX2EFL	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DMX2EFL	DI	DMX2EFL
DMX2EFL	DN	Tetra-cyclic pyridophthalazinone derivative 1
DMX2EFL	MI	TTQ4V96
DMX2EFL	MN	Poly [ADP-ribose] polymerase 2 (PARP2)
DMX2EFL	MT	DTT
DMX2EFL	MA	Inhibitor
DMX2EFL	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DMX2EFL	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DMUXNKG	DI	DMUXNKG
DMUXNKG	DN	Tetra-hydro-1H-1,2,6-triazaazulene derivative 1
DMUXNKG	MI	TT6OEDT
DMUXNKG	MN	Cannabinoid receptor 1 (CB1)
DMUXNKG	MT	DTT
DMUXNKG	MA	Antagonist
DMUXNKG	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMUXNKG	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DMVTZ6S	DI	DMVTZ6S
DMVTZ6S	DN	Tetra-hydro-1H-1,2,6-triazaazulene derivative 2
DMVTZ6S	MI	TT6OEDT
DMVTZ6S	MN	Cannabinoid receptor 1 (CB1)
DMVTZ6S	MT	DTT
DMVTZ6S	MA	Antagonist
DMVTZ6S	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMVTZ6S	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DM5MVLG	DI	DM5MVLG
DM5MVLG	DN	Tetra-hydro-carboline derivative 1
DM5MVLG	MI	TTSCIM2
DM5MVLG	MN	Extracellular lysophospholipase D (E-NPP2)
DM5MVLG	MT	DTT
DM5MVLG	MA	Inhibitor
DM5MVLG	RN	Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829.
DM5MVLG	RU	https://www.ncbi.nlm.nih.gov/pubmed/28447479

DMXTL7V	DI	DMXTL7V
DMXTL7V	DN	Tetra-hydro-carboline derivative 2
DMXTL7V	MI	TTSCIM2
DMXTL7V	MN	Extracellular lysophospholipase D (E-NPP2)
DMXTL7V	MT	DTT
DMXTL7V	MA	Inhibitor
DMXTL7V	RN	Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829.
DMXTL7V	RU	https://www.ncbi.nlm.nih.gov/pubmed/28447479

DM3W5SM	DI	DM3W5SM
DM3W5SM	DN	Tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 1
DM3W5SM	MI	TTXJ47W
DM3W5SM	MN	Metabotropic glutamate receptor 2 (mGluR2)
DM3W5SM	MT	DTT
DM3W5SM	MA	Antagonist
DM3W5SM	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DM3W5SM	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DMB1T6S	DI	DMB1T6S
DMB1T6S	DN	Tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 2
DMB1T6S	MI	TTXJ47W
DMB1T6S	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMB1T6S	MT	DTT
DMB1T6S	MA	Antagonist
DMB1T6S	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DMB1T6S	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DM71LVY	DI	DM71LVY
DM71LVY	DN	Tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 3
DM71LVY	MI	TTXJ47W
DM71LVY	MN	Metabotropic glutamate receptor 2 (mGluR2)
DM71LVY	MT	DTT
DM71LVY	MA	Antagonist
DM71LVY	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DM71LVY	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DMLMXT6	DI	DMLMXT6
DMLMXT6	DN	Tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 4
DMLMXT6	MI	TTXJ47W
DMLMXT6	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMLMXT6	MT	DTT
DMLMXT6	MA	Antagonist
DMLMXT6	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DMLMXT6	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DM7C0R8	DI	DM7C0R8
DM7C0R8	DN	Tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 5
DM7C0R8	MI	TTXJ47W
DM7C0R8	MN	Metabotropic glutamate receptor 2 (mGluR2)
DM7C0R8	MT	DTT
DM7C0R8	MA	Antagonist
DM7C0R8	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DM7C0R8	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DMCE3J0	DI	DMCE3J0
DMCE3J0	DN	Tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 6
DMCE3J0	MI	TTXJ47W
DMCE3J0	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMCE3J0	MT	DTT
DMCE3J0	MA	Antagonist
DMCE3J0	RN	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
DMCE3J0	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435285

DML86IO	DI	DML86IO
DML86IO	DN	Tetra-hydro-isoquinoline derivative 1
DML86IO	MI	TT1RS9F
DML86IO	MN	Acetylcholinesterase (AChE)
DML86IO	MT	DTT
DML86IO	MA	Inhibitor
DML86IO	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DML86IO	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DML86IO	DI	DML86IO
DML86IO	DN	Tetra-hydro-isoquinoline derivative 1
DML86IO	MI	TTEB0GD
DML86IO	MN	Cholinesterase (BCHE)
DML86IO	MT	DTT
DML86IO	MA	Inhibitor
DML86IO	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DML86IO	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DML86IO	DI	DML86IO
DML86IO	DN	Tetra-hydro-isoquinoline derivative 1
DML86IO	MI	TT3WG5C
DML86IO	MN	Monoamine oxidase type A (MAO-A)
DML86IO	MT	DTT
DML86IO	MA	Inhibitor
DML86IO	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DML86IO	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DML86IO	DI	DML86IO
DML86IO	DN	Tetra-hydro-isoquinoline derivative 1
DML86IO	MI	TTGP7BY
DML86IO	MN	Monoamine oxidase type B (MAO-B)
DML86IO	MT	DTT
DML86IO	MA	Inhibitor
DML86IO	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DML86IO	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DM5CKVF	DI	DM5CKVF
DM5CKVF	DN	Tetra-hydro-isoquinoline derivative 2
DM5CKVF	MI	TT1RS9F
DM5CKVF	MN	Acetylcholinesterase (AChE)
DM5CKVF	MT	DTT
DM5CKVF	MA	Inhibitor
DM5CKVF	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DM5CKVF	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DM5CKVF	DI	DM5CKVF
DM5CKVF	DN	Tetra-hydro-isoquinoline derivative 2
DM5CKVF	MI	TTEB0GD
DM5CKVF	MN	Cholinesterase (BCHE)
DM5CKVF	MT	DTT
DM5CKVF	MA	Inhibitor
DM5CKVF	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DM5CKVF	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DM5CKVF	DI	DM5CKVF
DM5CKVF	DN	Tetra-hydro-isoquinoline derivative 2
DM5CKVF	MI	TT3WG5C
DM5CKVF	MN	Monoamine oxidase type A (MAO-A)
DM5CKVF	MT	DTT
DM5CKVF	MA	Inhibitor
DM5CKVF	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DM5CKVF	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DM5CKVF	DI	DM5CKVF
DM5CKVF	DN	Tetra-hydro-isoquinoline derivative 2
DM5CKVF	MI	TTGP7BY
DM5CKVF	MN	Monoamine oxidase type B (MAO-B)
DM5CKVF	MT	DTT
DM5CKVF	MA	Inhibitor
DM5CKVF	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DM5CKVF	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DMCZA45	DI	DMCZA45
DMCZA45	DN	Tetra-hydro-isoquinoline derivative 3
DMCZA45	MI	TT1RS9F
DMCZA45	MN	Acetylcholinesterase (AChE)
DMCZA45	MT	DTT
DMCZA45	MA	Inhibitor
DMCZA45	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DMCZA45	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DMCZA45	DI	DMCZA45
DMCZA45	DN	Tetra-hydro-isoquinoline derivative 3
DMCZA45	MI	TTEB0GD
DMCZA45	MN	Cholinesterase (BCHE)
DMCZA45	MT	DTT
DMCZA45	MA	Inhibitor
DMCZA45	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DMCZA45	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DMCZA45	DI	DMCZA45
DMCZA45	DN	Tetra-hydro-isoquinoline derivative 3
DMCZA45	MI	TT3WG5C
DMCZA45	MN	Monoamine oxidase type A (MAO-A)
DMCZA45	MT	DTT
DMCZA45	MA	Inhibitor
DMCZA45	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DMCZA45	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DMCZA45	DI	DMCZA45
DMCZA45	DN	Tetra-hydro-isoquinoline derivative 3
DMCZA45	MI	TTGP7BY
DMCZA45	MN	Monoamine oxidase type B (MAO-B)
DMCZA45	MT	DTT
DMCZA45	MA	Inhibitor
DMCZA45	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DMCZA45	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DMDV0MP	DI	DMDV0MP
DMDV0MP	DN	Tetra-hydro-isoquinoline derivative 4
DMDV0MP	MI	TT1RS9F
DMDV0MP	MN	Acetylcholinesterase (AChE)
DMDV0MP	MT	DTT
DMDV0MP	MA	Inhibitor
DMDV0MP	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DMDV0MP	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DMDV0MP	DI	DMDV0MP
DMDV0MP	DN	Tetra-hydro-isoquinoline derivative 4
DMDV0MP	MI	TTEB0GD
DMDV0MP	MN	Cholinesterase (BCHE)
DMDV0MP	MT	DTT
DMDV0MP	MA	Inhibitor
DMDV0MP	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DMDV0MP	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DMDV0MP	DI	DMDV0MP
DMDV0MP	DN	Tetra-hydro-isoquinoline derivative 4
DMDV0MP	MI	TT3WG5C
DMDV0MP	MN	Monoamine oxidase type A (MAO-A)
DMDV0MP	MT	DTT
DMDV0MP	MA	Inhibitor
DMDV0MP	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DMDV0MP	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DMDV0MP	DI	DMDV0MP
DMDV0MP	DN	Tetra-hydro-isoquinoline derivative 4
DMDV0MP	MI	TTGP7BY
DMDV0MP	MN	Monoamine oxidase type B (MAO-B)
DMDV0MP	MT	DTT
DMDV0MP	MA	Inhibitor
DMDV0MP	RN	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
DMDV0MP	RU	https://www.ncbi.nlm.nih.gov/pubmed/29757691

DMURYO0	DI	DMURYO0
DMURYO0	DN	Tetra-hydro-naphthalene derivative 1
DMURYO0	MI	TTDP1UC
DMURYO0	MN	Fatty acid amide hydrolase (FAAH)
DMURYO0	MT	DTT
DMURYO0	MA	Inhibitor
DMURYO0	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMURYO0	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMEBGZJ	DI	DMEBGZJ
DMEBGZJ	DN	Tetra-hydro-naphthalene derivative 2
DMEBGZJ	MI	TTDP1UC
DMEBGZJ	MN	Fatty acid amide hydrolase (FAAH)
DMEBGZJ	MT	DTT
DMEBGZJ	MA	Inhibitor
DMEBGZJ	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMEBGZJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMVBZKF	DI	DMVBZKF
DMVBZKF	DN	Tetra-hydro-naphthalene derivative 3
DMVBZKF	MI	TTDP1UC
DMVBZKF	MN	Fatty acid amide hydrolase (FAAH)
DMVBZKF	MT	DTT
DMVBZKF	MA	Inhibitor
DMVBZKF	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMVBZKF	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DM5YSTU	DI	DM5YSTU
DM5YSTU	DN	Tetra-hydro-naphthyridine derivative 1
DM5YSTU	MI	TTDP1UC
DM5YSTU	MN	Fatty acid amide hydrolase (FAAH)
DM5YSTU	MT	DTT
DM5YSTU	MA	Inhibitor
DM5YSTU	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DM5YSTU	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DM72MDA	DI	DM72MDA
DM72MDA	DN	Tetra-hydro-oxazolopyridine derivative 1
DM72MDA	MI	TTHS256
DM72MDA	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM72MDA	MT	DTT
DM72MDA	MA	Modulator
DM72MDA	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DM72MDA	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DM72MDA	DI	DM72MDA
DM72MDA	DN	Tetra-hydro-oxazolopyridine derivative 1
DM72MDA	MI	TTGP7BY
DM72MDA	MN	Monoamine oxidase type B (MAO-B)
DM72MDA	MT	DTT
DM72MDA	MA	Modulator
DM72MDA	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DM72MDA	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMP65Z4	DI	DMP65Z4
DMP65Z4	DN	Tetra-hydro-oxazolopyridine derivative 2
DMP65Z4	MI	TTHS256
DMP65Z4	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMP65Z4	MT	DTT
DMP65Z4	MA	Modulator
DMP65Z4	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMP65Z4	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMP65Z4	DI	DMP65Z4
DMP65Z4	DN	Tetra-hydro-oxazolopyridine derivative 2
DMP65Z4	MI	TTGP7BY
DMP65Z4	MN	Monoamine oxidase type B (MAO-B)
DMP65Z4	MT	DTT
DMP65Z4	MA	Modulator
DMP65Z4	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMP65Z4	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMQYKT2	DI	DMQYKT2
DMQYKT2	DN	Tetra-hydro-oxazolopyridine derivative 3
DMQYKT2	MI	TTHS256
DMQYKT2	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMQYKT2	MT	DTT
DMQYKT2	MA	Modulator
DMQYKT2	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMQYKT2	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DM21J83	DI	DM21J83
DM21J83	DN	Tetra-hydro-oxazolopyridine derivative 4
DM21J83	MI	TTHS256
DM21J83	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM21J83	MT	DTT
DM21J83	MA	Modulator
DM21J83	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DM21J83	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMQGA1I	DI	DMQGA1I
DMQGA1I	DN	Tetra-hydro-oxazolopyridine derivative 5
DMQGA1I	MI	TTHS256
DMQGA1I	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMQGA1I	MT	DTT
DMQGA1I	MA	Modulator
DMQGA1I	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMQGA1I	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMLW7YO	DI	DMLW7YO
DMLW7YO	DN	Tetra-hydro-oxazolopyridine derivative 6
DMLW7YO	MI	TTHS256
DMLW7YO	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMLW7YO	MT	DTT
DMLW7YO	MA	Modulator
DMLW7YO	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMLW7YO	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DM3HVCZ	DI	DM3HVCZ
DM3HVCZ	DN	Tetra-hydro-pyrazolopyrazine derivative 1
DM3HVCZ	MI	TTHS256
DM3HVCZ	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM3HVCZ	MT	DTT
DM3HVCZ	MA	Modulator
DM3HVCZ	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DM3HVCZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMQ027F	DI	DMQ027F
DMQ027F	DN	Tetra-hydro-pyrazolopyrazine derivative 2
DMQ027F	MI	TTHS256
DMQ027F	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMQ027F	MT	DTT
DMQ027F	MA	Modulator
DMQ027F	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMQ027F	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMKGJ1S	DI	DMKGJ1S
DMKGJ1S	DN	Tetra-hydro-pyrazolopyrazine derivative 3
DMKGJ1S	MI	TTHS256
DMKGJ1S	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMKGJ1S	MT	DTT
DMKGJ1S	MA	Modulator
DMKGJ1S	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMKGJ1S	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMRMTF6	DI	DMRMTF6
DMRMTF6	DN	Tetra-hydro-pyrazolopyrazine derivative 4
DMRMTF6	MI	TTHS256
DMRMTF6	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMRMTF6	MT	DTT
DMRMTF6	MA	Modulator
DMRMTF6	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMRMTF6	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMAM7Y2	DI	DMAM7Y2
DMAM7Y2	DN	Tetra-hydro-pyrazolopyrazine derivative 5
DMAM7Y2	MI	TTHS256
DMAM7Y2	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMAM7Y2	MT	DTT
DMAM7Y2	MA	Modulator
DMAM7Y2	RN	mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
DMAM7Y2	RU	https://www.ncbi.nlm.nih.gov/pubmed/28067079

DMM06K5	DI	DMM06K5
DMM06K5	DN	Tetra-hydro-pyrrolopyrimidinedione derivative 1
DMM06K5	MI	TTPLTSQ
DMM06K5	MN	Neutrophil elastase (NE)
DMM06K5	MT	DTT
DMM06K5	MA	Inhibitor
DMM06K5	RN	Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
DMM06K5	RU	https://www.ncbi.nlm.nih.gov/pubmed/26118988

DMM92KW	DI	DMM92KW
DMM92KW	DN	Tetra-hydro-quinoline derivative 1
DMM92KW	MI	TTVDSZ0
DMM92KW	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMM92KW	MT	DTT
DMM92KW	MA	Inhibitor
DMM92KW	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DMM92KW	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DMEKO71	DI	DMEKO71
DMEKO71	DN	Tetra-hydro-quinoline derivative 2
DMEKO71	MI	TTE4BSY
DMEKO71	MN	Bromodomain and extraterminal domain protein (BET)
DMEKO71	MT	DTT
DMEKO71	MA	Inhibitor
DMEKO71	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMEKO71	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMAWY4L	DI	DMAWY4L
DMAWY4L	DN	Tetra-hydro-quinoline derivative 3
DMAWY4L	MI	TTE4BSY
DMAWY4L	MN	Bromodomain and extraterminal domain protein (BET)
DMAWY4L	MT	DTT
DMAWY4L	MA	Inhibitor
DMAWY4L	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMAWY4L	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMMC3AG	DI	DMMC3AG
DMMC3AG	DN	Tetra-hydro-quinoline derivative 4
DMMC3AG	MI	TTE4BSY
DMMC3AG	MN	Bromodomain and extraterminal domain protein (BET)
DMMC3AG	MT	DTT
DMMC3AG	MA	Inhibitor
DMMC3AG	RN	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
DMMC3AG	RU	https://www.ncbi.nlm.nih.gov/pubmed/26924192

DMI6VG9	DI	DMI6VG9
DMI6VG9	DN	Tetra-hydro-triazolopyrimidine derivative 2
DMI6VG9	MI	TTPLTSQ
DMI6VG9	MN	Neutrophil elastase (NE)
DMI6VG9	MT	DTT
DMI6VG9	MA	Inhibitor
DMI6VG9	RN	Serine protease inhibitors to treat inflammation: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Feb;28(2):93-110.
DMI6VG9	RU	https://www.ncbi.nlm.nih.gov/pubmed/29171765

DMEG5YO	DI	DMEG5YO
DMEG5YO	DN	Tetra-substituted urea derivative 1
DMEG5YO	MI	TTDP1UC
DMEG5YO	MN	Fatty acid amide hydrolase (FAAH)
DMEG5YO	MT	DTT
DMEG5YO	MA	Inhibitor
DMEG5YO	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMEG5YO	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMKXZUA	DI	DMKXZUA
DMKXZUA	DN	Tetra-substituted urea derivative 2
DMKXZUA	MI	TTDP1UC
DMKXZUA	MN	Fatty acid amide hydrolase (FAAH)
DMKXZUA	MT	DTT
DMKXZUA	MA	Inhibitor
DMKXZUA	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DMKXZUA	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DM52683	DI	DM52683
DM52683	DN	Tetrazole acetic acid derivative 1
DM52683	MI	TTA592U
DM52683	MN	Urate anion exchanger 1 (URAT1)
DM52683	MT	DTT
DM52683	MA	Inhibitor
DM52683	RN	Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10.
DM52683	RU	https://www.ncbi.nlm.nih.gov/pubmed/27414413

DM1AGSD	DI	DM1AGSD
DM1AGSD	DN	Tetrazole derivative 1
DM1AGSD	MI	TT473XN
DM1AGSD	MN	P2X purinoceptor 7 (P2RX7)
DM1AGSD	MT	DTT
DM1AGSD	MA	Antagonist
DM1AGSD	RN	P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267.
DM1AGSD	RU	https://www.ncbi.nlm.nih.gov/pubmed/27724045

DM2D4WQ	DI	DM2D4WQ
DM2D4WQ	DN	Tetrazolyl urea derivative 1
DM2D4WQ	MI	TTDP1UC
DM2D4WQ	MN	Fatty acid amide hydrolase (FAAH)
DM2D4WQ	MT	DTT
DM2D4WQ	MA	Inhibitor
DM2D4WQ	RN	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
DM2D4WQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26413912

DMP4HR2	DI	DMP4HR2
DMP4HR2	DN	TG003
DMP4HR2	MI	TTE6YDG
DMP4HR2	MN	CDC-like kinase 1 (CLK1)
DMP4HR2	MT	DTT
DMP4HR2	MA	Inhibitor
DMP4HR2	RN	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
DMP4HR2	RU	https://pubmed.ncbi.nlm.nih.gov/18077363

DMP4HR2	DI	DMP4HR2
DMP4HR2	DN	TG003
DMP4HR2	MI	TT85TPS
DMP4HR2	MN	CDC-like kinase 2 (CLK2)
DMP4HR2	MT	DTT
DMP4HR2	MA	Inhibitor
DMP4HR2	RN	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
DMP4HR2	RU	https://pubmed.ncbi.nlm.nih.gov/18077363

DMP4HR2	DI	DMP4HR2
DMP4HR2	DN	TG003
DMP4HR2	MI	TTSBVFO
DMP4HR2	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DMP4HR2	MT	DTT
DMP4HR2	MA	Inhibitor
DMP4HR2	RN	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
DMP4HR2	RU	https://www.ncbi.nlm.nih.gov/pubmed/28766366

DM1L3ZA	DI	DM1L3ZA
DM1L3ZA	DN	Thiadiazolidindione derivative 1
DM1L3ZA	MI	TTRZQE3
DM1L3ZA	MN	Glycogen synthase kinase-3 alpha (GSK-3A)
DM1L3ZA	MT	DTT
DM1L3ZA	MA	Inhibitor
DM1L3ZA	RN	Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
DM1L3ZA	RU	https://www.ncbi.nlm.nih.gov/pubmed/27828716

DM5AUL0	DI	DM5AUL0
DM5AUL0	DN	Thiadiazolidindione derivative 2
DM5AUL0	MI	TTRZQE3
DM5AUL0	MN	Glycogen synthase kinase-3 alpha (GSK-3A)
DM5AUL0	MT	DTT
DM5AUL0	MA	Inhibitor
DM5AUL0	RN	Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
DM5AUL0	RU	https://www.ncbi.nlm.nih.gov/pubmed/27828716

DMNTZ93	DI	DMNTZ93
DMNTZ93	DN	Thiadiazolidindione derivative 3
DMNTZ93	MI	TTRZQE3
DMNTZ93	MN	Glycogen synthase kinase-3 alpha (GSK-3A)
DMNTZ93	MT	DTT
DMNTZ93	MA	Inhibitor
DMNTZ93	RN	Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
DMNTZ93	RU	https://www.ncbi.nlm.nih.gov/pubmed/27828716

DMX93AI	DI	DMX93AI
DMX93AI	DN	Thiadiazolyl carboxamide derivative 1
DMX93AI	MI	TTTDVOJ
DMX93AI	MN	Tropomyosin-related kinase A (TrkA)
DMX93AI	MT	DTT
DMX93AI	MA	Inhibitor
DMX93AI	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMX93AI	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMW62LX	DI	DMW62LX
DMW62LX	DN	Thiazole carboxamide derivative 1
DMW62LX	MI	TTCZOF2
DMW62LX	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMW62LX	MT	DTT
DMW62LX	MA	Inhibitor
DMW62LX	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMW62LX	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMWKI89	DI	DMWKI89
DMWKI89	DN	Thiazole carboxamide derivative 10
DMWKI89	MI	TTCZOF2
DMWKI89	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMWKI89	MT	DTT
DMWKI89	MA	Inhibitor
DMWKI89	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMWKI89	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DM0Q3HF	DI	DM0Q3HF
DM0Q3HF	DN	Thiazole carboxamide derivative 11
DM0Q3HF	MI	TTCZOF2
DM0Q3HF	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DM0Q3HF	MT	DTT
DM0Q3HF	MA	Inhibitor
DM0Q3HF	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DM0Q3HF	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMG0H73	DI	DMG0H73
DMG0H73	DN	Thiazole carboxamide derivative 12
DMG0H73	MI	TTCZOF2
DMG0H73	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMG0H73	MT	DTT
DMG0H73	MA	Inhibitor
DMG0H73	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMG0H73	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMHQCEJ	DI	DMHQCEJ
DMHQCEJ	DN	Thiazole carboxamide derivative 13
DMHQCEJ	MI	TTCZOF2
DMHQCEJ	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMHQCEJ	MT	DTT
DMHQCEJ	MA	Inhibitor
DMHQCEJ	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMHQCEJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMMKNP7	DI	DMMKNP7
DMMKNP7	DN	Thiazole carboxamide derivative 14
DMMKNP7	MI	TTCZOF2
DMMKNP7	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMMKNP7	MT	DTT
DMMKNP7	MA	Inhibitor
DMMKNP7	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMMKNP7	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMCH1DL	DI	DMCH1DL
DMCH1DL	DN	Thiazole carboxamide derivative 15
DMCH1DL	MI	TTCZOF2
DMCH1DL	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMCH1DL	MT	DTT
DMCH1DL	MA	Inhibitor
DMCH1DL	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMCH1DL	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMJQBVH	DI	DMJQBVH
DMJQBVH	DN	Thiazole carboxamide derivative 16
DMJQBVH	MI	TTCZOF2
DMJQBVH	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMJQBVH	MT	DTT
DMJQBVH	MA	Inhibitor
DMJQBVH	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMJQBVH	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMPMN92	DI	DMPMN92
DMPMN92	DN	Thiazole carboxamide derivative 17
DMPMN92	MI	TTCZOF2
DMPMN92	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMPMN92	MT	DTT
DMPMN92	MA	Inhibitor
DMPMN92	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMPMN92	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DM987MK	DI	DM987MK
DM987MK	DN	Thiazole carboxamide derivative 18
DM987MK	MI	TTCZOF2
DM987MK	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DM987MK	MT	DTT
DM987MK	MA	Inhibitor
DM987MK	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DM987MK	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMW59Q4	DI	DMW59Q4
DMW59Q4	DN	Thiazole carboxamide derivative 19
DMW59Q4	MI	TTCZOF2
DMW59Q4	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMW59Q4	MT	DTT
DMW59Q4	MA	Inhibitor
DMW59Q4	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMW59Q4	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMLIRGM	DI	DMLIRGM
DMLIRGM	DN	Thiazole carboxamide derivative 2
DMLIRGM	MI	TTCZOF2
DMLIRGM	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMLIRGM	MT	DTT
DMLIRGM	MA	Inhibitor
DMLIRGM	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMLIRGM	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMORSH9	DI	DMORSH9
DMORSH9	DN	Thiazole carboxamide derivative 20
DMORSH9	MI	TTCZOF2
DMORSH9	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMORSH9	MT	DTT
DMORSH9	MA	Inhibitor
DMORSH9	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMORSH9	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMTJBCG	DI	DMTJBCG
DMTJBCG	DN	Thiazole carboxamide derivative 21
DMTJBCG	MI	TTCZOF2
DMTJBCG	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMTJBCG	MT	DTT
DMTJBCG	MA	Inhibitor
DMTJBCG	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMTJBCG	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DM6WTR2	DI	DM6WTR2
DM6WTR2	DN	Thiazole carboxamide derivative 22
DM6WTR2	MI	TTCZOF2
DM6WTR2	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DM6WTR2	MT	DTT
DM6WTR2	MA	Inhibitor
DM6WTR2	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DM6WTR2	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMMO6JY	DI	DMMO6JY
DMMO6JY	DN	Thiazole carboxamide derivative 23
DMMO6JY	MI	TTCZOF2
DMMO6JY	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMMO6JY	MT	DTT
DMMO6JY	MA	Inhibitor
DMMO6JY	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMMO6JY	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMZ6YB0	DI	DMZ6YB0
DMZ6YB0	DN	Thiazole carboxamide derivative 24
DMZ6YB0	MI	TTCZOF2
DMZ6YB0	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMZ6YB0	MT	DTT
DMZ6YB0	MA	Inhibitor
DMZ6YB0	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMZ6YB0	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMLRTFX	DI	DMLRTFX
DMLRTFX	DN	Thiazole carboxamide derivative 25
DMLRTFX	MI	TTCZOF2
DMLRTFX	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMLRTFX	MT	DTT
DMLRTFX	MA	Inhibitor
DMLRTFX	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMLRTFX	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DM8DHZ4	DI	DM8DHZ4
DM8DHZ4	DN	Thiazole carboxamide derivative 26
DM8DHZ4	MI	TTCZOF2
DM8DHZ4	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DM8DHZ4	MT	DTT
DM8DHZ4	MA	Inhibitor
DM8DHZ4	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DM8DHZ4	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMV30QO	DI	DMV30QO
DMV30QO	DN	Thiazole carboxamide derivative 27
DMV30QO	MI	TTCZOF2
DMV30QO	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMV30QO	MT	DTT
DMV30QO	MA	Inhibitor
DMV30QO	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMV30QO	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMGEIZV	DI	DMGEIZV
DMGEIZV	DN	Thiazole carboxamide derivative 28
DMGEIZV	MI	TTCZOF2
DMGEIZV	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMGEIZV	MT	DTT
DMGEIZV	MA	Inhibitor
DMGEIZV	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMGEIZV	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMCRVO5	DI	DMCRVO5
DMCRVO5	DN	Thiazole carboxamide derivative 29
DMCRVO5	MI	TTCZOF2
DMCRVO5	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMCRVO5	MT	DTT
DMCRVO5	MA	Inhibitor
DMCRVO5	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMCRVO5	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMLRA3C	DI	DMLRA3C
DMLRA3C	DN	Thiazole carboxamide derivative 3
DMLRA3C	MI	TTCZOF2
DMLRA3C	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMLRA3C	MT	DTT
DMLRA3C	MA	Inhibitor
DMLRA3C	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMLRA3C	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMEOKCB	DI	DMEOKCB
DMEOKCB	DN	Thiazole carboxamide derivative 30
DMEOKCB	MI	TTCZOF2
DMEOKCB	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMEOKCB	MT	DTT
DMEOKCB	MA	Inhibitor
DMEOKCB	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMEOKCB	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMI3X14	DI	DMI3X14
DMI3X14	DN	Thiazole carboxamide derivative 4
DMI3X14	MI	TTCZOF2
DMI3X14	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMI3X14	MT	DTT
DMI3X14	MA	Inhibitor
DMI3X14	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMI3X14	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DM2H95E	DI	DM2H95E
DM2H95E	DN	Thiazole carboxamide derivative 5
DM2H95E	MI	TTCZOF2
DM2H95E	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DM2H95E	MT	DTT
DM2H95E	MA	Inhibitor
DM2H95E	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DM2H95E	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMWHCOE	DI	DMWHCOE
DMWHCOE	DN	Thiazole carboxamide derivative 6
DMWHCOE	MI	TTCZOF2
DMWHCOE	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMWHCOE	MT	DTT
DMWHCOE	MA	Inhibitor
DMWHCOE	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMWHCOE	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMLBK8V	DI	DMLBK8V
DMLBK8V	DN	Thiazole carboxamide derivative 7
DMLBK8V	MI	TTCZOF2
DMLBK8V	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMLBK8V	MT	DTT
DMLBK8V	MA	Inhibitor
DMLBK8V	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMLBK8V	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMVOTKN	DI	DMVOTKN
DMVOTKN	DN	Thiazole carboxamide derivative 8
DMVOTKN	MI	TTCZOF2
DMVOTKN	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMVOTKN	MT	DTT
DMVOTKN	MA	Inhibitor
DMVOTKN	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMVOTKN	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DM5P04R	DI	DM5P04R
DM5P04R	DN	Thiazole carboxamide derivative 9
DM5P04R	MI	TTCZOF2
DM5P04R	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DM5P04R	MT	DTT
DM5P04R	MA	Inhibitor
DM5P04R	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DM5P04R	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DM2WDXV	DI	DM2WDXV
DM2WDXV	DN	Thiazole derivative 1
DM2WDXV	MI	TTULVH8
DM2WDXV	MN	Tyrosinase (TYR)
DM2WDXV	MT	DTT
DM2WDXV	MA	Inhibitor
DM2WDXV	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DM2WDXV	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DM8ZXBS	DI	DM8ZXBS
DM8ZXBS	DN	Thiazole derivative 2
DM8ZXBS	MI	TTA6ZN2
DM8ZXBS	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DM8ZXBS	MT	DTT
DM8ZXBS	MA	Inhibitor
DM8ZXBS	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DM8ZXBS	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMKU51G	DI	DMKU51G
DMKU51G	DN	Thiazole derivative 3
DMKU51G	MI	TTA6ZN2
DMKU51G	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMKU51G	MT	DTT
DMKU51G	MA	Inhibitor
DMKU51G	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMKU51G	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM5UQK6	DI	DM5UQK6
DM5UQK6	DN	Thiazole derivative 4
DM5UQK6	MI	TTTDVOJ
DM5UQK6	MN	Tropomyosin-related kinase A (TrkA)
DM5UQK6	MT	DTT
DM5UQK6	MA	Inhibitor
DM5UQK6	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DM5UQK6	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMESAUL	DI	DMESAUL
DMESAUL	DN	Thiazole derivative 5
DMESAUL	MI	TT473XN
DMESAUL	MN	P2X purinoceptor 7 (P2RX7)
DMESAUL	MT	DTT
DMESAUL	MA	Antagonist
DMESAUL	RN	P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267.
DMESAUL	RU	https://www.ncbi.nlm.nih.gov/pubmed/27724045

DMCPV0D	DI	DMCPV0D
DMCPV0D	DN	Thiazole-fused cycloalkyl carboxamide derivative 1
DMCPV0D	MI	TT473XN
DMCPV0D	MN	P2X purinoceptor 7 (P2RX7)
DMCPV0D	MT	DTT
DMCPV0D	MA	Antagonist
DMCPV0D	RN	P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267.
DMCPV0D	RU	https://www.ncbi.nlm.nih.gov/pubmed/27724045

DM05VO6	DI	DM05VO6
DM05VO6	DN	Thiazolidine derivative 1
DM05VO6	MI	TTULVH8
DM05VO6	MN	Tyrosinase (TYR)
DM05VO6	MT	DTT
DM05VO6	MA	Inhibitor
DM05VO6	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DM05VO6	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DM73GNJ	DI	DM73GNJ
DM73GNJ	DN	Thiazolidine derivative 2
DM73GNJ	MI	TTULVH8
DM73GNJ	MN	Tyrosinase (TYR)
DM73GNJ	MT	DTT
DM73GNJ	MA	Inhibitor
DM73GNJ	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DM73GNJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMXFGTZ	DI	DMXFGTZ
DMXFGTZ	DN	Thiazolidine derivative 3
DMXFGTZ	MI	TTULVH8
DMXFGTZ	MN	Tyrosinase (TYR)
DMXFGTZ	MT	DTT
DMXFGTZ	MA	Inhibitor
DMXFGTZ	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMXFGTZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMLBA4D	DI	DMLBA4D
DMLBA4D	DN	Thiazolidine dione crystalline derivative 1
DMLBA4D	MI	TTZMAO3
DMLBA4D	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMLBA4D	MT	DTT
DMLBA4D	MA	Agonist
DMLBA4D	RN	PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
DMLBA4D	RU	https://www.ncbi.nlm.nih.gov/pubmed/25416646

DM86HU3	DI	DM86HU3
DM86HU3	DN	Thiazoline derivative 1
DM86HU3	MI	TTULVH8
DM86HU3	MN	Tyrosinase (TYR)
DM86HU3	MT	DTT
DM86HU3	MA	Inhibitor
DM86HU3	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DM86HU3	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMXRE1V	DI	DMXRE1V
DMXRE1V	DN	Thiazoline derivative 2
DMXRE1V	MI	TTULVH8
DMXRE1V	MN	Tyrosinase (TYR)
DMXRE1V	MT	DTT
DMXRE1V	MA	Inhibitor
DMXRE1V	RN	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
DMXRE1V	RU	https://www.ncbi.nlm.nih.gov/pubmed/26815044

DMAFE5R	DI	DMAFE5R
DMAFE5R	DN	Thiazolopyridine derivative 1
DMAFE5R	MI	TTBYWP2
DMAFE5R	MN	TYK2 tyrosine kinase (TYK2)
DMAFE5R	MT	DTT
DMAFE5R	MA	Inhibitor
DMAFE5R	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMAFE5R	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMLUPV1	DI	DMLUPV1
DMLUPV1	DN	Thieno[2,3-c]pyridine derivative 1
DMLUPV1	MI	TTZJYKH
DMLUPV1	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMLUPV1	MT	DTT
DMLUPV1	MA	Inhibitor
DMLUPV1	RN	A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
DMLUPV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/29473428

DM1C8MA	DI	DM1C8MA
DM1C8MA	DN	Thieno[3,2-c]pyridine-7-carboxamide derivative 1
DM1C8MA	MI	TTCZOF2
DM1C8MA	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DM1C8MA	MT	DTT
DM1C8MA	MA	Inhibitor
DM1C8MA	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DM1C8MA	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMOWFA5	DI	DMOWFA5
DMOWFA5	DN	Thieno[3,2-c]pyridine-7-carboxamide derivative 2
DMOWFA5	MI	TTCZOF2
DMOWFA5	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMOWFA5	MT	DTT
DMOWFA5	MA	Inhibitor
DMOWFA5	RN	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
DMOWFA5	RU	https://www.ncbi.nlm.nih.gov/pubmed/25684022

DMZP6KR	DI	DMZP6KR
DMZP6KR	DN	Thiomorpholine derivative 1
DMZP6KR	MI	TTDIGC1
DMZP6KR	MN	Dipeptidyl peptidase 4 (DPP-4)
DMZP6KR	MT	DTT
DMZP6KR	MA	Inhibitor
DMZP6KR	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMZP6KR	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DMZP6KR	DI	DMZP6KR
DMZP6KR	DN	Thiomorpholine derivative 1
DMZP6KR	MI	TTJGLZF
DMZP6KR	MN	Dipeptidyl peptidase 8 (DPP-8)
DMZP6KR	MT	DTT
DMZP6KR	MA	Inhibitor
DMZP6KR	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMZP6KR	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DMZP6KR	DI	DMZP6KR
DMZP6KR	DN	Thiomorpholine derivative 1
DMZP6KR	MI	TTNDUL7
DMZP6KR	MN	Dipeptidyl peptidase 9 (DPP-9)
DMZP6KR	MT	DTT
DMZP6KR	MA	Inhibitor
DMZP6KR	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMZP6KR	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DMWOK1D	DI	DMWOK1D
DMWOK1D	DN	Thiomorpholine derivative 2
DMWOK1D	MI	TTDIGC1
DMWOK1D	MN	Dipeptidyl peptidase 4 (DPP-4)
DMWOK1D	MT	DTT
DMWOK1D	MA	Inhibitor
DMWOK1D	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMWOK1D	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DMWOK1D	DI	DMWOK1D
DMWOK1D	DN	Thiomorpholine derivative 2
DMWOK1D	MI	TTJGLZF
DMWOK1D	MN	Dipeptidyl peptidase 8 (DPP-8)
DMWOK1D	MT	DTT
DMWOK1D	MA	Inhibitor
DMWOK1D	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMWOK1D	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DMWOK1D	DI	DMWOK1D
DMWOK1D	DN	Thiomorpholine derivative 2
DMWOK1D	MI	TTNDUL7
DMWOK1D	MN	Dipeptidyl peptidase 9 (DPP-9)
DMWOK1D	MT	DTT
DMWOK1D	MA	Inhibitor
DMWOK1D	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMWOK1D	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DM6QHO0	DI	DM6QHO0
DM6QHO0	DN	Tihoacetate derivative 1
DM6QHO0	MI	TTA592U
DM6QHO0	MN	Urate anion exchanger 1 (URAT1)
DM6QHO0	MT	DTT
DM6QHO0	MA	Inhibitor
DM6QHO0	RN	Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10.
DM6QHO0	RU	https://www.ncbi.nlm.nih.gov/pubmed/27414413

DM5UI73	DI	DM5UI73
DM5UI73	DN	Tihotungstate derivative 1
DM5UI73	MI	TTSXVID
DM5UI73	MN	Nuclear factor NF-kappa-B (NFKB)
DM5UI73	MT	DTT
DM5UI73	MA	Inhibitor
DM5UI73	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DM5UI73	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DMGR6IJ	DI	DMGR6IJ
DMGR6IJ	DN	Tihourea derivative 1
DMGR6IJ	MI	TTSXVID
DMGR6IJ	MN	Nuclear factor NF-kappa-B (NFKB)
DMGR6IJ	MT	DTT
DMGR6IJ	MA	Inhibitor
DMGR6IJ	RN	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
DMGR6IJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25553724

DMHR43K	DI	DMHR43K
DMHR43K	DN	Tlouidine sulfonamide derivative 1
DMHR43K	MI	TTUX68I
DMHR43K	MN	Hypoxia-inducible factor 1 (HIF-1)
DMHR43K	MT	DTT
DMHR43K	MA	Inhibitor
DMHR43K	RN	Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22.
DMHR43K	RU	https://www.ncbi.nlm.nih.gov/pubmed/26882240

DM6KJLG	DI	DM6KJLG
DM6KJLG	DN	Trepenoid derivative 1
DM6KJLG	MI	TT3Z6Y9
DM6KJLG	MN	Cysteines of Keap1 (KEAP1 Cysteines)
DM6KJLG	MT	DTT
DM6KJLG	MA	Modulator
DM6KJLG	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DM6KJLG	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM6KJLG	DI	DM6KJLG
DM6KJLG	DN	Trepenoid derivative 1
DM6KJLG	MI	TTA6ZN2
DM6KJLG	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DM6KJLG	MT	DTT
DM6KJLG	MA	Activator
DM6KJLG	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DM6KJLG	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DM9QB2S	DI	DM9QB2S
DM9QB2S	DN	Triazole derivative 1
DM9QB2S	MI	TT2F4OL
DM9QB2S	MN	Tissue transglutaminase (TG2)
DM9QB2S	MT	DTT
DM9QB2S	MA	Inhibitor
DM9QB2S	RN	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
DM9QB2S	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560530

DM7KNXH	DI	DM7KNXH
DM7KNXH	DN	Triazole derivative 2
DM7KNXH	MI	TT473XN
DM7KNXH	MN	P2X purinoceptor 7 (P2RX7)
DM7KNXH	MT	DTT
DM7KNXH	MA	Antagonist
DM7KNXH	RN	P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267.
DM7KNXH	RU	https://www.ncbi.nlm.nih.gov/pubmed/27724045

DMZR0TH	DI	DMZR0TH
DMZR0TH	DN	Triazole derivative 3
DMZR0TH	MI	TTN9T81
DMZR0TH	MN	Arachidonate 15-lipoxygenase (15-LOX)
DMZR0TH	MT	DTT
DMZR0TH	MA	Inhibitor
DMZR0TH	RN	15-Lipoxygenase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):65-88.
DMZR0TH	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560362

DMCFEAS	DI	DMCFEAS
DMCFEAS	DN	Triazole derivative 4
DMCFEAS	MI	TTSCIUP
DMCFEAS	MN	Oxytocin receptor (OTR)
DMCFEAS	MT	DTT
DMCFEAS	MA	Antagonist
DMCFEAS	RN	A patent review of oxytocin receptor antagonists 2013-2017.Expert Opin Ther Pat. 2017 Dec;27(12):1287-1290.
DMCFEAS	RU	https://www.ncbi.nlm.nih.gov/pubmed/28906174

DMA83QK	DI	DMA83QK
DMA83QK	DN	Triazole derivative 5
DMA83QK	MI	TTSCIUP
DMA83QK	MN	Oxytocin receptor (OTR)
DMA83QK	MT	DTT
DMA83QK	MA	Antagonist
DMA83QK	RN	A patent review of oxytocin receptor antagonists 2013-2017.Expert Opin Ther Pat. 2017 Dec;27(12):1287-1290.
DMA83QK	RU	https://www.ncbi.nlm.nih.gov/pubmed/28906174

DMU15FW	DI	DMU15FW
DMU15FW	DN	Triazole derivative 6
DMU15FW	MI	TTSCIUP
DMU15FW	MN	Oxytocin receptor (OTR)
DMU15FW	MT	DTT
DMU15FW	MA	Antagonist
DMU15FW	RN	A patent review of oxytocin receptor antagonists 2013-2017.Expert Opin Ther Pat. 2017 Dec;27(12):1287-1290.
DMU15FW	RU	https://www.ncbi.nlm.nih.gov/pubmed/28906174

DMRK4AT	DI	DMRK4AT
DMRK4AT	DN	Triazole derivative 7
DMRK4AT	MI	TTSCIUP
DMRK4AT	MN	Oxytocin receptor (OTR)
DMRK4AT	MT	DTT
DMRK4AT	MA	Antagonist
DMRK4AT	RN	A patent review of oxytocin receptor antagonists 2013-2017.Expert Opin Ther Pat. 2017 Dec;27(12):1287-1290.
DMRK4AT	RU	https://www.ncbi.nlm.nih.gov/pubmed/28906174

DMCWES7	DI	DMCWES7
DMCWES7	DN	Triazole gold complexe 1
DMCWES7	MI	TTR7UJ3
DMCWES7	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMCWES7	MT	DTT
DMCWES7	MA	Inhibitor
DMCWES7	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMCWES7	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DMJON7D	DI	DMJON7D
DMJON7D	DN	Triazole gold complexe 2
DMJON7D	MI	TTR7UJ3
DMJON7D	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMJON7D	MT	DTT
DMJON7D	MA	Inhibitor
DMJON7D	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DMJON7D	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DM5TILQ	DI	DM5TILQ
DM5TILQ	DN	Triazole gold complexe 3
DM5TILQ	MI	TTR7UJ3
DM5TILQ	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DM5TILQ	MT	DTT
DM5TILQ	MA	Inhibitor
DM5TILQ	RN	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
DM5TILQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/27977313

DMPRGLZ	DI	DMPRGLZ
DMPRGLZ	DN	Triazole piperazine derivative 1
DMPRGLZ	MI	TTDIGC1
DMPRGLZ	MN	Dipeptidyl peptidase 4 (DPP-4)
DMPRGLZ	MT	DTT
DMPRGLZ	MA	Inhibitor
DMPRGLZ	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMPRGLZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DM8LFGS	DI	DM8LFGS
DM8LFGS	DN	Triazole propanedioic acid derivative 1
DM8LFGS	MI	TTA592U
DM8LFGS	MN	Urate anion exchanger 1 (URAT1)
DM8LFGS	MT	DTT
DM8LFGS	MA	Inhibitor
DM8LFGS	RN	Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10.
DM8LFGS	RU	https://www.ncbi.nlm.nih.gov/pubmed/27414413

DM34MCP	DI	DM34MCP
DM34MCP	DN	Triazolo[4,3-b]pyridazine derivative 1
DM34MCP	MI	TTSCO7R
DM34MCP	MN	NAD-dependent deacetylase sirtuin (SIRT)
DM34MCP	MT	DTT
DM34MCP	MA	Inhibitor
DM34MCP	RN	Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15.
DM34MCP	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435179

DMMJ1FN	DI	DMMJ1FN
DMMJ1FN	DN	Triazolo[4,3-b]pyridazine derivative 2
DMMJ1FN	MI	TTTDVOJ
DMMJ1FN	MN	Tropomyosin-related kinase A (TrkA)
DMMJ1FN	MT	DTT
DMMJ1FN	MA	Inhibitor
DMMJ1FN	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMMJ1FN	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DM79KEX	DI	DM79KEX
DM79KEX	DN	Triazolo-benzodiazepine derivative 1
DM79KEX	MI	TT9JNIC
DM79KEX	MN	Histamine H3 receptor (H3R)
DM79KEX	MT	DTT
DM79KEX	MA	Ligand
DM79KEX	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DM79KEX	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DMQSCHA	DI	DMQSCHA
DMQSCHA	DN	Triazolo-benzodiazepine derivative 2
DMQSCHA	MI	TT9JNIC
DMQSCHA	MN	Histamine H3 receptor (H3R)
DMQSCHA	MT	DTT
DMQSCHA	MA	Ligand
DMQSCHA	RN	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
DMQSCHA	RU	https://www.ncbi.nlm.nih.gov/pubmed/29334795

DMU9A7V	DI	DMU9A7V
DMU9A7V	DN	Triazolo-phthalazine derivative 1
DMU9A7V	MI	TTJGW1Z
DMU9A7V	MN	Phosphodiesterase 2A (PDE2A)
DMU9A7V	MT	DTT
DMU9A7V	MA	Inhibitor
DMU9A7V	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMU9A7V	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DM1KHGY	DI	DM1KHGY
DM1KHGY	DN	Triazolo-pyrazinone derivative 1
DM1KHGY	MI	TT473XN
DM1KHGY	MN	P2X purinoceptor 7 (P2RX7)
DM1KHGY	MT	DTT
DM1KHGY	MA	Antagonist
DM1KHGY	RN	P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267.
DM1KHGY	RU	https://www.ncbi.nlm.nih.gov/pubmed/27724045

DM0Q9VY	DI	DM0Q9VY
DM0Q9VY	DN	Triazolo-pyridine derivative 1
DM0Q9VY	MI	TT6DM01
DM0Q9VY	MN	Janus kinase 1 (JAK-1)
DM0Q9VY	MT	DTT
DM0Q9VY	MA	Inhibitor
DM0Q9VY	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DM0Q9VY	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DM0Q9VY	DI	DM0Q9VY
DM0Q9VY	DN	Triazolo-pyridine derivative 1
DM0Q9VY	MI	TTRMX3V
DM0Q9VY	MN	Janus kinase 2 (JAK-2)
DM0Q9VY	MT	DTT
DM0Q9VY	MA	Inhibitor
DM0Q9VY	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DM0Q9VY	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMXPQ24	DI	DMXPQ24
DMXPQ24	DN	Triazolo-pyridine derivative 2
DMXPQ24	MI	TTJW4LU
DMXPQ24	MN	Phosphodiesterase 10A (PDE10)
DMXPQ24	MT	DTT
DMXPQ24	MA	Inhibitor
DMXPQ24	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMXPQ24	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMXPQ24	DI	DMXPQ24
DMXPQ24	DN	Triazolo-pyridine derivative 2
DMXPQ24	MI	TTJGW1Z
DMXPQ24	MN	Phosphodiesterase 2A (PDE2A)
DMXPQ24	MT	DTT
DMXPQ24	MA	Inhibitor
DMXPQ24	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMXPQ24	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMQL1TV	DI	DMQL1TV
DMQL1TV	DN	Triazolo-pyridine derivative 3
DMQL1TV	MI	TTJW4LU
DMQL1TV	MN	Phosphodiesterase 10A (PDE10)
DMQL1TV	MT	DTT
DMQL1TV	MA	Inhibitor
DMQL1TV	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMQL1TV	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMQL1TV	DI	DMQL1TV
DMQL1TV	DN	Triazolo-pyridine derivative 3
DMQL1TV	MI	TTJGW1Z
DMQL1TV	MN	Phosphodiesterase 2A (PDE2A)
DMQL1TV	MT	DTT
DMQL1TV	MA	Inhibitor
DMQL1TV	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMQL1TV	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DM5ZQKS	DI	DM5ZQKS
DM5ZQKS	DN	Triazolo-pyridine derivative 4
DM5ZQKS	MI	TTJW4LU
DM5ZQKS	MN	Phosphodiesterase 10A (PDE10)
DM5ZQKS	MT	DTT
DM5ZQKS	MA	Inhibitor
DM5ZQKS	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DM5ZQKS	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DM5ZQKS	DI	DM5ZQKS
DM5ZQKS	DN	Triazolo-pyridine derivative 4
DM5ZQKS	MI	TTJGW1Z
DM5ZQKS	MN	Phosphodiesterase 2A (PDE2A)
DM5ZQKS	MT	DTT
DM5ZQKS	MA	Inhibitor
DM5ZQKS	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DM5ZQKS	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DM1R205	DI	DM1R205
DM1R205	DN	Triazolo-pyridine derivative 5
DM1R205	MI	TTJW4LU
DM1R205	MN	Phosphodiesterase 10A (PDE10)
DM1R205	MT	DTT
DM1R205	MA	Inhibitor
DM1R205	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DM1R205	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DM1R205	DI	DM1R205
DM1R205	DN	Triazolo-pyridine derivative 5
DM1R205	MI	TTJGW1Z
DM1R205	MN	Phosphodiesterase 2A (PDE2A)
DM1R205	MT	DTT
DM1R205	MA	Inhibitor
DM1R205	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DM1R205	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMX4WFP	DI	DMX4WFP
DMX4WFP	DN	Triazolo-pyridine derivative 6
DMX4WFP	MI	TTJW4LU
DMX4WFP	MN	Phosphodiesterase 10A (PDE10)
DMX4WFP	MT	DTT
DMX4WFP	MA	Inhibitor
DMX4WFP	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMX4WFP	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMX4WFP	DI	DMX4WFP
DMX4WFP	DN	Triazolo-pyridine derivative 6
DMX4WFP	MI	TTJGW1Z
DMX4WFP	MN	Phosphodiesterase 2A (PDE2A)
DMX4WFP	MT	DTT
DMX4WFP	MA	Inhibitor
DMX4WFP	RN	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
DMX4WFP	RU	https://www.ncbi.nlm.nih.gov/pubmed/27321640

DMJN72E	DI	DMJN72E
DMJN72E	DN	Triazolo-pyrimidinedione derivative 1
DMJN72E	MI	TTDIGC1
DMJN72E	MN	Dipeptidyl peptidase 4 (DPP-4)
DMJN72E	MT	DTT
DMJN72E	MA	Inhibitor
DMJN72E	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMJN72E	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DMLGNB2	DI	DMLGNB2
DMLGNB2	DN	Triazolo-pyrimidinedione derivative 2
DMLGNB2	MI	TTDIGC1
DMLGNB2	MN	Dipeptidyl peptidase 4 (DPP-4)
DMLGNB2	MT	DTT
DMLGNB2	MA	Inhibitor
DMLGNB2	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMLGNB2	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DMYEDJI	DI	DMYEDJI
DMYEDJI	DN	Tricyclic 5-quinolone derivative 1
DMYEDJI	MI	TTRZQE3
DMYEDJI	MN	Glycogen synthase kinase-3 alpha (GSK-3A)
DMYEDJI	MT	DTT
DMYEDJI	MA	Inhibitor
DMYEDJI	RN	Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
DMYEDJI	RU	https://www.ncbi.nlm.nih.gov/pubmed/27828716

DM5SD9E	DI	DM5SD9E
DM5SD9E	DN	Tricyclic benzimidazole derivative 1
DM5SD9E	MI	TTH6V3D
DM5SD9E	MN	Cyclin-dependent kinase 1 (CDK1)
DM5SD9E	MT	DTT
DM5SD9E	MA	Inhibitor
DM5SD9E	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DM5SD9E	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DM5SD9E	DI	DM5SD9E
DM5SD9E	DN	Tricyclic benzimidazole derivative 1
DM5SD9E	MI	TTL4Q97
DM5SD9E	MN	Cyclin-dependent kinase 5 (CDK5)
DM5SD9E	MT	DTT
DM5SD9E	MA	Inhibitor
DM5SD9E	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DM5SD9E	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DM5SD9E	DI	DM5SD9E
DM5SD9E	DN	Tricyclic benzimidazole derivative 1
DM5SD9E	MI	TTQYF7G
DM5SD9E	MN	Cyclin-dependent kinase 7 (CDK7)
DM5SD9E	MT	DTT
DM5SD9E	MA	Inhibitor
DM5SD9E	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DM5SD9E	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DM5SD9E	DI	DM5SD9E
DM5SD9E	DN	Tricyclic benzimidazole derivative 1
DM5SD9E	MI	TTBJR4L
DM5SD9E	MN	Cyclin-dependent kinase 8 (CDK8)
DM5SD9E	MT	DTT
DM5SD9E	MA	Inhibitor
DM5SD9E	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DM5SD9E	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DM5SD9E	DI	DM5SD9E
DM5SD9E	DN	Tricyclic benzimidazole derivative 1
DM5SD9E	MI	TT1LVF2
DM5SD9E	MN	Cyclin-dependent kinase 9 (CDK9)
DM5SD9E	MT	DTT
DM5SD9E	MA	Inhibitor
DM5SD9E	RN	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
DM5SD9E	RU	https://www.ncbi.nlm.nih.gov/pubmed/26161698

DMLBR4F	DI	DMLBR4F
DMLBR4F	DN	Tricyclic compound 1
DMLBR4F	MI	TT6DM01
DMLBR4F	MN	Janus kinase 1 (JAK-1)
DMLBR4F	MT	DTT
DMLBR4F	MA	Inhibitor
DMLBR4F	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMLBR4F	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMLBR4F	DI	DMLBR4F
DMLBR4F	DN	Tricyclic compound 1
DMLBR4F	MI	TTRMX3V
DMLBR4F	MN	Janus kinase 2 (JAK-2)
DMLBR4F	MT	DTT
DMLBR4F	MA	Inhibitor
DMLBR4F	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMLBR4F	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMLBR4F	DI	DMLBR4F
DMLBR4F	DN	Tricyclic compound 1
DMLBR4F	MI	TTT7PJU
DMLBR4F	MN	Janus kinase 3 (JAK-3)
DMLBR4F	MT	DTT
DMLBR4F	MA	Inhibitor
DMLBR4F	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMLBR4F	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMV1RQX	DI	DMV1RQX
DMV1RQX	DN	Tricyclic compound 10
DMV1RQX	MI	TTAIQSN
DMV1RQX	MN	Receptor-interacting protein 1 (RIPK1)
DMV1RQX	MT	DTT
DMV1RQX	MA	Inhibitor
DMV1RQX	RN	Necroptosis inhibitors as therapeutic targets in inflammation mediated disorders - a review of the current literature and patents.Expert Opin Ther Pat. 2016 Nov;26(11):1239-1256.
DMV1RQX	RU	https://www.ncbi.nlm.nih.gov/pubmed/27568917

DMJAZ7D	DI	DMJAZ7D
DMJAZ7D	DN	Tricyclic compound 11
DMJAZ7D	MI	TT6DM01
DMJAZ7D	MN	Janus kinase 1 (JAK-1)
DMJAZ7D	MT	DTT
DMJAZ7D	MA	Inhibitor
DMJAZ7D	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMJAZ7D	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMJAZ7D	DI	DMJAZ7D
DMJAZ7D	DN	Tricyclic compound 11
DMJAZ7D	MI	TTRMX3V
DMJAZ7D	MN	Janus kinase 2 (JAK-2)
DMJAZ7D	MT	DTT
DMJAZ7D	MA	Inhibitor
DMJAZ7D	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMJAZ7D	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMJAZ7D	DI	DMJAZ7D
DMJAZ7D	DN	Tricyclic compound 11
DMJAZ7D	MI	TTT7PJU
DMJAZ7D	MN	Janus kinase 3 (JAK-3)
DMJAZ7D	MT	DTT
DMJAZ7D	MA	Inhibitor
DMJAZ7D	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMJAZ7D	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMJAZ7D	DI	DMJAZ7D
DMJAZ7D	DN	Tricyclic compound 11
DMJAZ7D	MI	TTBYWP2
DMJAZ7D	MN	TYK2 tyrosine kinase (TYK2)
DMJAZ7D	MT	DTT
DMJAZ7D	MA	Inhibitor
DMJAZ7D	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMJAZ7D	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMJAWOI	DI	DMJAWOI
DMJAWOI	DN	Tricyclic compound 2
DMJAWOI	MI	TTT7PJU
DMJAWOI	MN	Janus kinase 3 (JAK-3)
DMJAWOI	MT	DTT
DMJAWOI	MA	Inhibitor
DMJAWOI	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DMJAWOI	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DM9K7P0	DI	DM9K7P0
DM9K7P0	DN	Tricyclic compound 3
DM9K7P0	MI	TT6DM01
DM9K7P0	MN	Janus kinase 1 (JAK-1)
DM9K7P0	MT	DTT
DM9K7P0	MA	Inhibitor
DM9K7P0	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DM9K7P0	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMEIG16	DI	DMEIG16
DMEIG16	DN	Tricyclic compound 4
DMEIG16	MI	TTGWKQJ
DMEIG16	MN	Rho-associated protein kinase 2 (ROCK2)
DMEIG16	MT	DTT
DMEIG16	MA	Inhibitor
DMEIG16	RN	Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
DMEIG16	RU	https://www.ncbi.nlm.nih.gov/pubmed/28048944

DMLPMS7	DI	DMLPMS7
DMLPMS7	DN	Tricyclic compound 5
DMLPMS7	MI	TTGWKQJ
DMLPMS7	MN	Rho-associated protein kinase 2 (ROCK2)
DMLPMS7	MT	DTT
DMLPMS7	MA	Inhibitor
DMLPMS7	RN	Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
DMLPMS7	RU	https://www.ncbi.nlm.nih.gov/pubmed/28048944

DMMJ81G	DI	DMMJ81G
DMMJ81G	DN	Tricyclic compound 6
DMMJ81G	MI	TTGWKQJ
DMMJ81G	MN	Rho-associated protein kinase 2 (ROCK2)
DMMJ81G	MT	DTT
DMMJ81G	MA	Inhibitor
DMMJ81G	RN	Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
DMMJ81G	RU	https://www.ncbi.nlm.nih.gov/pubmed/28048944

DME84S5	DI	DME84S5
DME84S5	DN	Tricyclic compound 7
DME84S5	MI	TTGWKQJ
DME84S5	MN	Rho-associated protein kinase 2 (ROCK2)
DME84S5	MT	DTT
DME84S5	MA	Inhibitor
DME84S5	RN	Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
DME84S5	RU	https://www.ncbi.nlm.nih.gov/pubmed/28048944

DMZI8GK	DI	DMZI8GK
DMZI8GK	DN	Tricyclic compound 8
DMZI8GK	MI	TTAIQSN
DMZI8GK	MN	Receptor-interacting protein 1 (RIPK1)
DMZI8GK	MT	DTT
DMZI8GK	MA	Inhibitor
DMZI8GK	RN	Necroptosis inhibitors as therapeutic targets in inflammation mediated disorders - a review of the current literature and patents.Expert Opin Ther Pat. 2016 Nov;26(11):1239-1256.
DMZI8GK	RU	https://www.ncbi.nlm.nih.gov/pubmed/27568917

DMF5E6U	DI	DMF5E6U
DMF5E6U	DN	Tricyclic compound 9
DMF5E6U	MI	TTAIQSN
DMF5E6U	MN	Receptor-interacting protein 1 (RIPK1)
DMF5E6U	MT	DTT
DMF5E6U	MA	Inhibitor
DMF5E6U	RN	Necroptosis inhibitors as therapeutic targets in inflammation mediated disorders - a review of the current literature and patents.Expert Opin Ther Pat. 2016 Nov;26(11):1239-1256.
DMF5E6U	RU	https://www.ncbi.nlm.nih.gov/pubmed/27568917

DMXLJH4	DI	DMXLJH4
DMXLJH4	DN	Tricyclic heterocycle derivative 1
DMXLJH4	MI	TT6DM01
DMXLJH4	MN	Janus kinase 1 (JAK-1)
DMXLJH4	MT	DTT
DMXLJH4	MA	Inhibitor
DMXLJH4	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMXLJH4	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMXLJH4	DI	DMXLJH4
DMXLJH4	DN	Tricyclic heterocycle derivative 1
DMXLJH4	MI	TTRMX3V
DMXLJH4	MN	Janus kinase 2 (JAK-2)
DMXLJH4	MT	DTT
DMXLJH4	MA	Inhibitor
DMXLJH4	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMXLJH4	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMXLJH4	DI	DMXLJH4
DMXLJH4	DN	Tricyclic heterocycle derivative 1
DMXLJH4	MI	TTT7PJU
DMXLJH4	MN	Janus kinase 3 (JAK-3)
DMXLJH4	MT	DTT
DMXLJH4	MA	Inhibitor
DMXLJH4	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMXLJH4	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMXLJH4	DI	DMXLJH4
DMXLJH4	DN	Tricyclic heterocycle derivative 1
DMXLJH4	MI	TTBYWP2
DMXLJH4	MN	TYK2 tyrosine kinase (TYK2)
DMXLJH4	MT	DTT
DMXLJH4	MA	Inhibitor
DMXLJH4	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMXLJH4	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DM1W02D	DI	DM1W02D
DM1W02D	DN	Tricyclic heterocycle derivative 2
DM1W02D	MI	TTRMX3V
DM1W02D	MN	Janus kinase 2 (JAK-2)
DM1W02D	MT	DTT
DM1W02D	MA	Inhibitor
DM1W02D	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DM1W02D	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DM1W02D	DI	DM1W02D
DM1W02D	DN	Tricyclic heterocycle derivative 2
DM1W02D	MI	TTT7PJU
DM1W02D	MN	Janus kinase 3 (JAK-3)
DM1W02D	MT	DTT
DM1W02D	MA	Inhibitor
DM1W02D	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
DM1W02D	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774824

DMJNCD6	DI	DMJNCD6
DMJNCD6	DN	Tricyclic heterocycle derivative 3
DMJNCD6	MI	TTZC0KV
DMJNCD6	MN	Zinc finger-containing ubiquitin peptidase 1 (ZUP1)
DMJNCD6	MT	DTT
DMJNCD6	MA	Inhibitor
DMJNCD6	RN	Deubiquitinases (DUBs) and DUB inhibitors: a patent review.Expert Opin Ther Pat. 2015;25(10):1191-1208.
DMJNCD6	RU	https://www.ncbi.nlm.nih.gov/pubmed/26077642

DM9XBL4	DI	DM9XBL4
DM9XBL4	DN	Tricyclic heterocycle derivative 4
DM9XBL4	MI	TTVSYP9
DM9XBL4	MN	Ubiquitin carboxyl-terminal hydrolase 14 (USP14)
DM9XBL4	MT	DTT
DM9XBL4	MA	Inhibitor
DM9XBL4	RN	Deubiquitinases (DUBs) and DUB inhibitors: a patent review.Expert Opin Ther Pat. 2015;25(10):1191-1208.
DM9XBL4	RU	https://www.ncbi.nlm.nih.gov/pubmed/26077642

DMG1ESV	DI	DMG1ESV
DMG1ESV	DN	Tricyclic heterocycle derivative 5
DMG1ESV	MI	TT6DM01
DMG1ESV	MN	Janus kinase 1 (JAK-1)
DMG1ESV	MT	DTT
DMG1ESV	MA	Inhibitor
DMG1ESV	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMG1ESV	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMG1ESV	DI	DMG1ESV
DMG1ESV	DN	Tricyclic heterocycle derivative 5
DMG1ESV	MI	TTRMX3V
DMG1ESV	MN	Janus kinase 2 (JAK-2)
DMG1ESV	MT	DTT
DMG1ESV	MA	Inhibitor
DMG1ESV	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMG1ESV	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMG1ESV	DI	DMG1ESV
DMG1ESV	DN	Tricyclic heterocycle derivative 5
DMG1ESV	MI	TTT7PJU
DMG1ESV	MN	Janus kinase 3 (JAK-3)
DMG1ESV	MT	DTT
DMG1ESV	MA	Inhibitor
DMG1ESV	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMG1ESV	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMG1ESV	DI	DMG1ESV
DMG1ESV	DN	Tricyclic heterocycle derivative 5
DMG1ESV	MI	TTBYWP2
DMG1ESV	MN	TYK2 tyrosine kinase (TYK2)
DMG1ESV	MT	DTT
DMG1ESV	MA	Inhibitor
DMG1ESV	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMG1ESV	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMQJK70	DI	DMQJK70
DMQJK70	DN	Tricyclic heterocycle derivative 6
DMQJK70	MI	TTDIGC1
DMQJK70	MN	Dipeptidyl peptidase 4 (DPP-4)
DMQJK70	MT	DTT
DMQJK70	MA	Inhibitor
DMQJK70	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMQJK70	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DM4HBWU	DI	DM4HBWU
DM4HBWU	DN	Tricyclic indole compound 1
DM4HBWU	MI	TTPTXIN
DM4HBWU	MN	Translocator protein (TSPO)
DM4HBWU	MT	DTT
DM4HBWU	MA	Ligand
DM4HBWU	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366.
DM4HBWU	RU	https://www.ncbi.nlm.nih.gov/pubmed/27599163

DMK1QTH	DI	DMK1QTH
DMK1QTH	DN	Tricyclic indole compound 10
DMK1QTH	MI	TTPTXIN
DMK1QTH	MN	Translocator protein (TSPO)
DMK1QTH	MT	DTT
DMK1QTH	MA	Ligand
DMK1QTH	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366.
DMK1QTH	RU	https://www.ncbi.nlm.nih.gov/pubmed/27599163

DML724H	DI	DML724H
DML724H	DN	Tricyclic indole compound 11
DML724H	MI	TTPTXIN
DML724H	MN	Translocator protein (TSPO)
DML724H	MT	DTT
DML724H	MA	Ligand
DML724H	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366.
DML724H	RU	https://www.ncbi.nlm.nih.gov/pubmed/27599163

DMEZQ29	DI	DMEZQ29
DMEZQ29	DN	Tricyclic indole compound 12
DMEZQ29	MI	TTPTXIN
DMEZQ29	MN	Translocator protein (TSPO)
DMEZQ29	MT	DTT
DMEZQ29	MA	Ligand
DMEZQ29	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366.
DMEZQ29	RU	https://www.ncbi.nlm.nih.gov/pubmed/27599163

DMS6XT4	DI	DMS6XT4
DMS6XT4	DN	Tricyclic indole compound 13
DMS6XT4	MI	TTVDSZ0
DMS6XT4	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMS6XT4	MT	DTT
DMS6XT4	MA	Inhibitor
DMS6XT4	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DMS6XT4	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DMXVNSR	DI	DMXVNSR
DMXVNSR	DN	Tricyclic indole compound 14
DMXVNSR	MI	TTPTXIN
DMXVNSR	MN	Translocator protein (TSPO)
DMXVNSR	MT	DTT
DMXVNSR	MA	Ligand
DMXVNSR	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366.
DMXVNSR	RU	https://www.ncbi.nlm.nih.gov/pubmed/27599163

DMHRY63	DI	DMHRY63
DMHRY63	DN	Tricyclic indole compound 2
DMHRY63	MI	TTPTXIN
DMHRY63	MN	Translocator protein (TSPO)
DMHRY63	MT	DTT
DMHRY63	MA	Ligand
DMHRY63	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366.
DMHRY63	RU	https://www.ncbi.nlm.nih.gov/pubmed/27599163

DM5B92W	DI	DM5B92W
DM5B92W	DN	Tricyclic indole compound 3
DM5B92W	MI	TTPTXIN
DM5B92W	MN	Translocator protein (TSPO)
DM5B92W	MT	DTT
DM5B92W	MA	Ligand
DM5B92W	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366.
DM5B92W	RU	https://www.ncbi.nlm.nih.gov/pubmed/27599163

DMUZ4L3	DI	DMUZ4L3
DMUZ4L3	DN	Tricyclic indole compound 4
DMUZ4L3	MI	TTPTXIN
DMUZ4L3	MN	Translocator protein (TSPO)
DMUZ4L3	MT	DTT
DMUZ4L3	MA	Ligand
DMUZ4L3	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366.
DMUZ4L3	RU	https://www.ncbi.nlm.nih.gov/pubmed/27599163

DMX5YG9	DI	DMX5YG9
DMX5YG9	DN	Tricyclic indole compound 5
DMX5YG9	MI	TTPTXIN
DMX5YG9	MN	Translocator protein (TSPO)
DMX5YG9	MT	DTT
DMX5YG9	MA	Ligand
DMX5YG9	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366.
DMX5YG9	RU	https://www.ncbi.nlm.nih.gov/pubmed/27599163

DMXAS8P	DI	DMXAS8P
DMXAS8P	DN	Tricyclic indole compound 6
DMXAS8P	MI	TTPTXIN
DMXAS8P	MN	Translocator protein (TSPO)
DMXAS8P	MT	DTT
DMXAS8P	MA	Ligand
DMXAS8P	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366.
DMXAS8P	RU	https://www.ncbi.nlm.nih.gov/pubmed/27599163

DMFQSU8	DI	DMFQSU8
DMFQSU8	DN	Tricyclic indole compound 7
DMFQSU8	MI	TTPTXIN
DMFQSU8	MN	Translocator protein (TSPO)
DMFQSU8	MT	DTT
DMFQSU8	MA	Ligand
DMFQSU8	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366.
DMFQSU8	RU	https://www.ncbi.nlm.nih.gov/pubmed/27599163

DMYAUVM	DI	DMYAUVM
DMYAUVM	DN	Tricyclic indole compound 8
DMYAUVM	MI	TTPTXIN
DMYAUVM	MN	Translocator protein (TSPO)
DMYAUVM	MT	DTT
DMYAUVM	MA	Ligand
DMYAUVM	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366.
DMYAUVM	RU	https://www.ncbi.nlm.nih.gov/pubmed/27599163

DMVA7BC	DI	DMVA7BC
DMVA7BC	DN	Tricyclic indole compound 9
DMVA7BC	MI	TTPTXIN
DMVA7BC	MN	Translocator protein (TSPO)
DMVA7BC	MT	DTT
DMVA7BC	MA	Ligand
DMVA7BC	RN	Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366.
DMVA7BC	RU	https://www.ncbi.nlm.nih.gov/pubmed/27599163

DM6QSND	DI	DM6QSND
DM6QSND	DN	Tricyclic isoxazoloquinazoline derivative 1
DM6QSND	MI	TT5OU0D
DM6QSND	MN	PRKR-like endoplasmic reticulum kinase (PERK)
DM6QSND	MT	DTT
DM6QSND	MA	Inhibitor
DM6QSND	RN	Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48.
DM6QSND	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646439

DMH4TY1	DI	DMH4TY1
DMH4TY1	DN	Tricyclic isoxazoloquinazoline derivative 2
DMH4TY1	MI	TTP7EGM
DMH4TY1	MN	Dual specificity protein kinase TTK (MPS1)
DMH4TY1	MT	DTT
DMH4TY1	MA	Inhibitor
DMH4TY1	RN	Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48.
DMH4TY1	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646439

DMH4TY1	DI	DMH4TY1
DMH4TY1	DN	Tricyclic isoxazoloquinazoline derivative 2
DMH4TY1	MI	TT5OU0D
DMH4TY1	MN	PRKR-like endoplasmic reticulum kinase (PERK)
DMH4TY1	MT	DTT
DMH4TY1	MA	Inhibitor
DMH4TY1	RN	Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48.
DMH4TY1	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646439

DML2PWF	DI	DML2PWF
DML2PWF	DN	Tricyclic isoxazoloquinazoline derivative 3
DML2PWF	MI	TTP7EGM
DML2PWF	MN	Dual specificity protein kinase TTK (MPS1)
DML2PWF	MT	DTT
DML2PWF	MA	Inhibitor
DML2PWF	RN	Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48.
DML2PWF	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646439

DML2PWF	DI	DML2PWF
DML2PWF	DN	Tricyclic isoxazoloquinazoline derivative 3
DML2PWF	MI	TT5OU0D
DML2PWF	MN	PRKR-like endoplasmic reticulum kinase (PERK)
DML2PWF	MT	DTT
DML2PWF	MA	Inhibitor
DML2PWF	RN	Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48.
DML2PWF	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646439

DM8VIM4	DI	DM8VIM4
DM8VIM4	DN	Tricyclic isoxazoloquinazoline derivative 4
DM8VIM4	MI	TTP7EGM
DM8VIM4	MN	Dual specificity protein kinase TTK (MPS1)
DM8VIM4	MT	DTT
DM8VIM4	MA	Inhibitor
DM8VIM4	RN	Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48.
DM8VIM4	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646439

DM8VIM4	DI	DM8VIM4
DM8VIM4	DN	Tricyclic isoxazoloquinazoline derivative 4
DM8VIM4	MI	TT5OU0D
DM8VIM4	MN	PRKR-like endoplasmic reticulum kinase (PERK)
DM8VIM4	MT	DTT
DM8VIM4	MA	Inhibitor
DM8VIM4	RN	Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48.
DM8VIM4	RU	https://www.ncbi.nlm.nih.gov/pubmed/27646439

DM94NZF	DI	DM94NZF
DM94NZF	DN	Tricyclic phytocannabinoid derivative 1
DM94NZF	MI	TT6OEDT
DM94NZF	MN	Cannabinoid receptor 1 (CB1)
DM94NZF	MT	DTT
DM94NZF	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DM94NZF	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DM94NZF	DI	DM94NZF
DM94NZF	DN	Tricyclic phytocannabinoid derivative 1
DM94NZF	MI	TTMSFAW
DM94NZF	MN	Cannabinoid receptor 2 (CB2)
DM94NZF	MT	DTT
DM94NZF	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DM94NZF	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DM7YVQL	DI	DM7YVQL
DM7YVQL	DN	Tricyclic phytocannabinoid derivative 2
DM7YVQL	MI	TT6OEDT
DM7YVQL	MN	Cannabinoid receptor 1 (CB1)
DM7YVQL	MT	DTT
DM7YVQL	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DM7YVQL	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DM7YVQL	DI	DM7YVQL
DM7YVQL	DN	Tricyclic phytocannabinoid derivative 2
DM7YVQL	MI	TTMSFAW
DM7YVQL	MN	Cannabinoid receptor 2 (CB2)
DM7YVQL	MT	DTT
DM7YVQL	RN	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
DM7YVQL	RU	https://www.ncbi.nlm.nih.gov/pubmed/27215781

DMGY3OR	DI	DMGY3OR
DMGY3OR	DN	Tricyclic pyrrolidine derivative 1
DMGY3OR	MI	TTWJBZ5
DMGY3OR	MN	5-HT 2C receptor (HTR2C)
DMGY3OR	MT	DTT
DMGY3OR	MA	Agonist
DMGY3OR	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMGY3OR	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMRD1XJ	DI	DMRD1XJ
DMRD1XJ	DN	Tricyclic pyrrolidine derivative 2
DMRD1XJ	MI	TTWJBZ5
DMRD1XJ	MN	5-HT 2C receptor (HTR2C)
DMRD1XJ	MT	DTT
DMRD1XJ	MA	Agonist
DMRD1XJ	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMRD1XJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMK2V6H	DI	DMK2V6H
DMK2V6H	DN	Tricyclic pyrrolidine derivative 3
DMK2V6H	MI	TTWJBZ5
DMK2V6H	MN	5-HT 2C receptor (HTR2C)
DMK2V6H	MT	DTT
DMK2V6H	MA	Agonist
DMK2V6H	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DMK2V6H	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DM0JYWT	DI	DM0JYWT
DM0JYWT	DN	Tricyclic pyrrolidine derivative 4
DM0JYWT	MI	TTWJBZ5
DM0JYWT	MN	5-HT 2C receptor (HTR2C)
DM0JYWT	MT	DTT
DM0JYWT	MA	Agonist
DM0JYWT	RN	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
DM0JYWT	RU	https://www.ncbi.nlm.nih.gov/pubmed/26609882

DMFIXW4	DI	DMFIXW4
DMFIXW4	DN	Tricyclic pyrrolopyridine compound 1
DMFIXW4	MI	TT6DM01
DMFIXW4	MN	Janus kinase 1 (JAK-1)
DMFIXW4	MT	DTT
DMFIXW4	MA	Inhibitor
DMFIXW4	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMFIXW4	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMFIXW4	DI	DMFIXW4
DMFIXW4	DN	Tricyclic pyrrolopyridine compound 1
DMFIXW4	MI	TTRMX3V
DMFIXW4	MN	Janus kinase 2 (JAK-2)
DMFIXW4	MT	DTT
DMFIXW4	MA	Inhibitor
DMFIXW4	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMFIXW4	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMFIXW4	DI	DMFIXW4
DMFIXW4	DN	Tricyclic pyrrolopyridine compound 1
DMFIXW4	MI	TTT7PJU
DMFIXW4	MN	Janus kinase 3 (JAK-3)
DMFIXW4	MT	DTT
DMFIXW4	MA	Inhibitor
DMFIXW4	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMFIXW4	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMFIXW4	DI	DMFIXW4
DMFIXW4	DN	Tricyclic pyrrolopyridine compound 1
DMFIXW4	MI	TTBYWP2
DMFIXW4	MN	TYK2 tyrosine kinase (TYK2)
DMFIXW4	MT	DTT
DMFIXW4	MA	Inhibitor
DMFIXW4	RN	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
DMFIXW4	RU	https://www.ncbi.nlm.nih.gov/pubmed/27774822

DMZTPUA	DI	DMZTPUA
DMZTPUA	DN	Triptolidenol analog 1
DMZTPUA	MI	TTUX68I
DMZTPUA	MN	Hypoxia-inducible factor 1 (HIF-1)
DMZTPUA	MT	DTT
DMZTPUA	MA	Inhibitor
DMZTPUA	RN	Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22.
DMZTPUA	RU	https://www.ncbi.nlm.nih.gov/pubmed/26882240

DMEQ3RD	DI	DMEQ3RD
DMEQ3RD	DN	Tri-substituted benzene derivative 1
DMEQ3RD	MI	TTN9T81
DMEQ3RD	MN	Arachidonate 15-lipoxygenase (15-LOX)
DMEQ3RD	MT	DTT
DMEQ3RD	MA	Inhibitor
DMEQ3RD	RN	15-Lipoxygenase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):65-88.
DMEQ3RD	RU	https://www.ncbi.nlm.nih.gov/pubmed/26560362

DM7NTO9	DI	DM7NTO9
DM7NTO9	DN	Tri-substituted purine derivative 1
DM7NTO9	MI	TTH8FZW
DM7NTO9	MN	Signal transducer and activator of transcription 3 (STAT3)
DM7NTO9	MT	DTT
DM7NTO9	MA	Inhibitor
DM7NTO9	RN	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
DM7NTO9	RU	https://www.ncbi.nlm.nih.gov/pubmed/26394986

DMHGRTX	DI	DMHGRTX
DMHGRTX	DN	Tri-substituted urea derivative 1
DMHGRTX	MI	TTTDVOJ
DMHGRTX	MN	Tropomyosin-related kinase A (TrkA)
DMHGRTX	MT	DTT
DMHGRTX	MA	Inhibitor
DMHGRTX	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMHGRTX	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMUVPR8	DI	DMUVPR8
DMUVPR8	DN	Tri-substituted urea derivative 2
DMUVPR8	MI	TTTDVOJ
DMUVPR8	MN	Tropomyosin-related kinase A (TrkA)
DMUVPR8	MT	DTT
DMUVPR8	MA	Inhibitor
DMUVPR8	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
DMUVPR8	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270021

DMLJ2HE	DI	DMLJ2HE
DMLJ2HE	DN	Undecylenic acid derivative 1
DMLJ2HE	MI	TT1WBIJ
DMLJ2HE	MN	Calpain-1 (CAPN1)
DMLJ2HE	MT	DTT
DMLJ2HE	RN	An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31.
DMLJ2HE	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399719

DMUD7H8	DI	DMUD7H8
DMUD7H8	DN	Unii-I92MU0V408
DMUD7H8	MI	TT42OGM
DMUD7H8	MN	Hematopoietic cell kinase (HCK)
DMUD7H8	MT	DTT
DMUD7H8	MA	Inhibitor
DMUD7H8	RN	Respiratory formulations and compounds for use therein. US8933228.
DMUD7H8	RU	http://www.freepatentsonline.com/US8933228.html

DMUHSAZ	DI	DMUHSAZ
DMUHSAZ	DN	Unii-R228S06soh
DMUHSAZ	MI	TTVSMOH
DMUHSAZ	MN	Sphingosine-1-phosphate receptor 2 (S1PR2)
DMUHSAZ	MT	DTT
DMUHSAZ	MA	Inhibitor
DMUHSAZ	RN	Sphingosine 1-phosphate receptor antagonists. US9663511.
DMUHSAZ	RU	http://www.freepatentsonline.com/US9663511.html

DM5SX8T	DI	DM5SX8T
DM5SX8T	DN	Uracil derivative 1
DM5SX8T	MI	TTPLTSQ
DM5SX8T	MN	Neutrophil elastase (NE)
DM5SX8T	MT	DTT
DM5SX8T	MA	Inhibitor
DM5SX8T	RN	Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
DM5SX8T	RU	https://www.ncbi.nlm.nih.gov/pubmed/26118988

DMEQFXZ	DI	DMEQFXZ
DMEQFXZ	DN	Urea and carbamate bioisostere derivative 1
DMEQFXZ	MI	TTTB4UP
DMEQFXZ	MN	Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2)
DMEQFXZ	MT	DTT
DMEQFXZ	MA	Inhibitor
DMEQFXZ	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DMEQFXZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DMWNR8I	DI	DMWNR8I
DMWNR8I	DN	Urea and carbamate bioisostere derivative 10
DMWNR8I	MI	TTL7C8Q
DMWNR8I	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMWNR8I	MT	DTT
DMWNR8I	MA	Inhibitor
DMWNR8I	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DMWNR8I	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DMAP6YS	DI	DMAP6YS
DMAP6YS	DN	Urea and carbamate bioisostere derivative 11
DMAP6YS	MI	TTL7C8Q
DMAP6YS	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMAP6YS	MT	DTT
DMAP6YS	MA	Inhibitor
DMAP6YS	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DMAP6YS	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DM6BJEW	DI	DM6BJEW
DM6BJEW	DN	Urea and carbamate bioisostere derivative 13
DM6BJEW	MI	TTL7C8Q
DM6BJEW	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DM6BJEW	MT	DTT
DM6BJEW	MA	Inhibitor
DM6BJEW	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DM6BJEW	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DMDP09N	DI	DMDP09N
DMDP09N	DN	Urea and carbamate bioisostere derivative 14
DMDP09N	MI	TTL7C8Q
DMDP09N	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMDP09N	MT	DTT
DMDP09N	MA	Inhibitor
DMDP09N	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DMDP09N	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DM3SQUD	DI	DM3SQUD
DM3SQUD	DN	Urea and carbamate bioisostere derivative 15
DM3SQUD	MI	TTL7C8Q
DM3SQUD	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DM3SQUD	MT	DTT
DM3SQUD	MA	Inhibitor
DM3SQUD	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DM3SQUD	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DMRLC4X	DI	DMRLC4X
DMRLC4X	DN	Urea and carbamate bioisostere derivative 16
DMRLC4X	MI	TTL7C8Q
DMRLC4X	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMRLC4X	MT	DTT
DMRLC4X	MA	Inhibitor
DMRLC4X	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DMRLC4X	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DM7PSB1	DI	DM7PSB1
DM7PSB1	DN	Urea and carbamate bioisostere derivative 18
DM7PSB1	MI	TTL7C8Q
DM7PSB1	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DM7PSB1	MT	DTT
DM7PSB1	MA	Inhibitor
DM7PSB1	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DM7PSB1	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DMRTJSC	DI	DMRTJSC
DMRTJSC	DN	Urea and carbamate bioisostere derivative 2
DMRTJSC	MI	TTL7C8Q
DMRTJSC	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMRTJSC	MT	DTT
DMRTJSC	MA	Inhibitor
DMRTJSC	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DMRTJSC	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DMPXVWE	DI	DMPXVWE
DMPXVWE	DN	Urea and carbamate bioisostere derivative 3
DMPXVWE	MI	TTL7C8Q
DMPXVWE	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMPXVWE	MT	DTT
DMPXVWE	MA	Inhibitor
DMPXVWE	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DMPXVWE	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DM5GZNS	DI	DM5GZNS
DM5GZNS	DN	Urea and carbamate bioisostere derivative 4
DM5GZNS	MI	TTL7C8Q
DM5GZNS	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DM5GZNS	MT	DTT
DM5GZNS	MA	Inhibitor
DM5GZNS	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DM5GZNS	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DM02ZM4	DI	DM02ZM4
DM02ZM4	DN	Urea and carbamate bioisostere derivative 5
DM02ZM4	MI	TTL7C8Q
DM02ZM4	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DM02ZM4	MT	DTT
DM02ZM4	MA	Inhibitor
DM02ZM4	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DM02ZM4	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DMP29I0	DI	DMP29I0
DMP29I0	DN	Urea and carbamate bioisostere derivative 6
DMP29I0	MI	TTL7C8Q
DMP29I0	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMP29I0	MT	DTT
DMP29I0	MA	Inhibitor
DMP29I0	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DMP29I0	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DM2GPLQ	DI	DM2GPLQ
DM2GPLQ	DN	Urea and carbamate bioisostere derivative 7
DM2GPLQ	MI	TTL7C8Q
DM2GPLQ	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DM2GPLQ	MT	DTT
DM2GPLQ	MA	Inhibitor
DM2GPLQ	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DM2GPLQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DMIYD41	DI	DMIYD41
DMIYD41	DN	Urea and carbamate bioisostere derivative 9
DMIYD41	MI	TTL7C8Q
DMIYD41	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMIYD41	MT	DTT
DMIYD41	MA	Inhibitor
DMIYD41	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DMIYD41	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DMN51XF	DI	DMN51XF
DMN51XF	DN	Ureido-phenyl-substituted triazine derivative 1
DMN51XF	MI	TTTDVOJ
DMN51XF	MN	Tropomyosin-related kinase A (TrkA)
DMN51XF	MT	DTT
DMN51XF	MA	Inhibitor
DMN51XF	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMN51XF	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMR0JDW	DI	DMR0JDW
DMR0JDW	DN	Ureido-phenyl-substituted triazine derivative 2
DMR0JDW	MI	TTTDVOJ
DMR0JDW	MN	Tropomyosin-related kinase A (TrkA)
DMR0JDW	MT	DTT
DMR0JDW	MA	Inhibitor
DMR0JDW	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMR0JDW	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMVCWXD	DI	DMVCWXD
DMVCWXD	DN	US10022354, Example 151
DMVCWXD	MI	TTIG67W
DMVCWXD	MN	Lysine-specific demethylase 5A (KDM5A)
DMVCWXD	MT	DTT
DMVCWXD	MA	Inhibitor
DMVCWXD	RN	IRE-1 inhibitors
DMVCWXD	RU	http://www.freepatentsonline.com/US10022354.html

DMGDZLP	DI	DMGDZLP
DMGDZLP	DN	US10022354, Example 152
DMGDZLP	MI	TTIG67W
DMGDZLP	MN	Lysine-specific demethylase 5A (KDM5A)
DMGDZLP	MT	DTT
DMGDZLP	MA	Inhibitor
DMGDZLP	RN	IRE-1 inhibitors
DMGDZLP	RU	http://www.freepatentsonline.com/US10022354.html

DMIAGPX	DI	DMIAGPX
DMIAGPX	DN	US10022354, Example 5
DMIAGPX	MI	TTIG67W
DMIAGPX	MN	Lysine-specific demethylase 5A (KDM5A)
DMIAGPX	MT	DTT
DMIAGPX	MA	Inhibitor
DMIAGPX	RN	IRE-1 inhibitors
DMIAGPX	RU	http://www.freepatentsonline.com/US10022354.html

DMU21PD	DI	DMU21PD
DMU21PD	DN	US10023583, Example 13
DMU21PD	MI	TTY2KP7
DMU21PD	MN	Leucyl-cysteinyl aminopeptidase (LNPEP)
DMU21PD	MT	DTT
DMU21PD	MA	Inhibitor
DMU21PD	RN	Bicyclic pyridine compound. US10023583.
DMU21PD	RU	http://www.freepatentsonline.com/US10023583.html

DM5LK6O	DI	DM5LK6O
DM5LK6O	DN	US10023583, Example 24
DM5LK6O	MI	TTY2KP7
DM5LK6O	MN	Leucyl-cysteinyl aminopeptidase (LNPEP)
DM5LK6O	MT	DTT
DM5LK6O	MA	Inhibitor
DM5LK6O	RN	Bicyclic pyridine compound. US10023583.
DM5LK6O	RU	http://www.freepatentsonline.com/US10023583.html

DMZR10T	DI	DMZR10T
DMZR10T	DN	US10023583, Example 5
DMZR10T	MI	TTY2KP7
DMZR10T	MN	Leucyl-cysteinyl aminopeptidase (LNPEP)
DMZR10T	MT	DTT
DMZR10T	MA	Inhibitor
DMZR10T	RN	Bicyclic pyridine compound. US10023583.
DMZR10T	RU	http://www.freepatentsonline.com/US10023583.html

DM40KU8	DI	DM40KU8
DM40KU8	DN	US10023583, Example 8
DM40KU8	MI	TTY2KP7
DM40KU8	MN	Leucyl-cysteinyl aminopeptidase (LNPEP)
DM40KU8	MT	DTT
DM40KU8	MA	Inhibitor
DM40KU8	RN	Bicyclic pyridine compound. US10023583.
DM40KU8	RU	http://www.freepatentsonline.com/US10023583.html

DMG4T13	DI	DMG4T13
DMG4T13	DN	US10030004, Compound 11a
DMG4T13	MI	TTPKHTZ
DMG4T13	MN	Activin receptor type IB (ACVR1B)
DMG4T13	MT	DTT
DMG4T13	MA	Inhibitor
DMG4T13	RN	Compounds and methods of use. US10030004.
DMG4T13	RU	http://www.freepatentsonline.com/US10030004.html

DM0RAPC	DI	DM0RAPC
DM0RAPC	DN	US10030004, Compound 19
DM0RAPC	MI	TTPKHTZ
DM0RAPC	MN	Activin receptor type IB (ACVR1B)
DM0RAPC	MT	DTT
DM0RAPC	MA	Inhibitor
DM0RAPC	RN	Compounds and methods of use. US10030004.
DM0RAPC	RU	http://www.freepatentsonline.com/US10030004.html

DMD0GN6	DI	DMD0GN6
DMD0GN6	DN	US10030004, Compound 33
DMD0GN6	MI	TTPKHTZ
DMD0GN6	MN	Activin receptor type IB (ACVR1B)
DMD0GN6	MT	DTT
DMD0GN6	MA	Inhibitor
DMD0GN6	RN	Compounds and methods of use. US10030004.
DMD0GN6	RU	http://www.freepatentsonline.com/US10030004.html

DMLJV01	DI	DMLJV01
DMLJV01	DN	US10034861, Example 1
DMLJV01	MI	TT3ZS42
DMLJV01	MN	Phosphodiesterase 1B (PDE1B)
DMLJV01	MT	DTT
DMLJV01	MA	Inhibitor
DMLJV01	RN	1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors. US10034861.
DMLJV01	RU	http://www.freepatentsonline.com/US10034861.html

DM27SFD	DI	DM27SFD
DM27SFD	DN	US10034861, Example 164
DM27SFD	MI	TT3ZS42
DM27SFD	MN	Phosphodiesterase 1B (PDE1B)
DM27SFD	MT	DTT
DM27SFD	MA	Inhibitor
DM27SFD	RN	1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors. US10034861.
DM27SFD	RU	http://www.freepatentsonline.com/US10034861.html

DMD8FS5	DI	DMD8FS5
DMD8FS5	DN	US10034861, Example 165
DMD8FS5	MI	TT3ZS42
DMD8FS5	MN	Phosphodiesterase 1B (PDE1B)
DMD8FS5	MT	DTT
DMD8FS5	MA	Inhibitor
DMD8FS5	RN	1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors. US10034861.
DMD8FS5	RU	http://www.freepatentsonline.com/US10034861.html

DM28XHN	DI	DM28XHN
DM28XHN	DN	US10035778, Example 1
DM28XHN	MI	TTIF29E
DM28XHN	MN	Integrin beta-8 (ITGB8)
DM28XHN	MT	DTT
DM28XHN	MA	Inhibitor
DM28XHN	RN	Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists. US10035778.
DM28XHN	RU	http://www.freepatentsonline.com/US10035778.html

DMBN6W2	DI	DMBN6W2
DMBN6W2	DN	US10035778, Example 12
DMBN6W2	MI	TTIF29E
DMBN6W2	MN	Integrin beta-8 (ITGB8)
DMBN6W2	MT	DTT
DMBN6W2	MA	Inhibitor
DMBN6W2	RN	Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists. US10035778.
DMBN6W2	RU	http://www.freepatentsonline.com/US10035778.html

DMJ53DR	DI	DMJ53DR
DMJ53DR	DN	US10035778, Example 16
DMJ53DR	MI	TTIF29E
DMJ53DR	MN	Integrin beta-8 (ITGB8)
DMJ53DR	MT	DTT
DMJ53DR	MA	Inhibitor
DMJ53DR	RN	Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists. US10035778.
DMJ53DR	RU	http://www.freepatentsonline.com/US10035778.html

DMLMV1Y	DI	DMLMV1Y
DMLMV1Y	DN	US10040779, Example 1
DMLMV1Y	MI	TTIG67W
DMLMV1Y	MN	Lysine-specific demethylase 5A (KDM5A)
DMLMV1Y	MT	DTT
DMLMV1Y	MA	Inhibitor
DMLMV1Y	RN	Histone demethylase inhibitors. US10040779.
DMLMV1Y	RU	http://www.freepatentsonline.com/US10040779.html

DMWDGCH	DI	DMWDGCH
DMWDGCH	DN	US10040779, Example 4
DMWDGCH	MI	TTIG67W
DMWDGCH	MN	Lysine-specific demethylase 5A (KDM5A)
DMWDGCH	MT	DTT
DMWDGCH	MA	Inhibitor
DMWDGCH	RN	Histone demethylase inhibitors. US10040779.
DMWDGCH	RU	http://www.freepatentsonline.com/US10040779.html

DMPM8VB	DI	DMPM8VB
DMPM8VB	DN	US10053465, 12
DMPM8VB	MI	TTIEMFN
DMPM8VB	MN	TYRO3 tyrosine kinase receptor (TYRO3)
DMPM8VB	MT	DTT
DMPM8VB	MA	Inhibitor
DMPM8VB	RN	Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors. US9708333.
DMPM8VB	RU	http://www.freepatentsonline.com/US9708333.html

DMV7BF2	DI	DMV7BF2
DMV7BF2	DN	US10053465, 5
DMV7BF2	MI	TTIEMFN
DMV7BF2	MN	TYRO3 tyrosine kinase receptor (TYRO3)
DMV7BF2	MT	DTT
DMV7BF2	MA	Inhibitor
DMV7BF2	RN	Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors. US9708333.
DMV7BF2	RU	http://www.freepatentsonline.com/US9708333.html

DM42XWO	DI	DM42XWO
DM42XWO	DN	US10053465, 8
DM42XWO	MI	TTIEMFN
DM42XWO	MN	TYRO3 tyrosine kinase receptor (TYRO3)
DM42XWO	MT	DTT
DM42XWO	MA	Inhibitor
DM42XWO	RN	Pyrrolopyrimidine derivatives as TAM inhibitors. US10053465.
DM42XWO	RU	http://www.freepatentsonline.com/US10053465.html

DMBD95S	DI	DMBD95S
DMBD95S	DN	US10059720, Example 80
DMBD95S	MI	TTY2KP7
DMBD95S	MN	Leucyl-cysteinyl aminopeptidase (LNPEP)
DMBD95S	MT	DTT
DMBD95S	MA	Inhibitor
DMBD95S	RN	Pyridine derivative. US10059720.
DMBD95S	RU	http://www.freepatentsonline.com/US10059720.html

DMJ6GU9	DI	DMJ6GU9
DMJ6GU9	DN	US10059720, Example 82
DMJ6GU9	MI	TTY2KP7
DMJ6GU9	MN	Leucyl-cysteinyl aminopeptidase (LNPEP)
DMJ6GU9	MT	DTT
DMJ6GU9	MA	Inhibitor
DMJ6GU9	RN	Pyridine derivative. US10059720.
DMJ6GU9	RU	http://www.freepatentsonline.com/US10059720.html

DMKLVE4	DI	DMKLVE4
DMKLVE4	DN	US10059720, Example 84
DMKLVE4	MI	TTY2KP7
DMKLVE4	MN	Leucyl-cysteinyl aminopeptidase (LNPEP)
DMKLVE4	MT	DTT
DMKLVE4	MA	Inhibitor
DMKLVE4	RN	Pyridine derivative. US10059720.
DMKLVE4	RU	http://www.freepatentsonline.com/US10059720.html

DMBWJK4	DI	DMBWJK4
DMBWJK4	DN	US10065972, Example 281
DMBWJK4	MI	TTT3IXG
DMBWJK4	MN	Kynurenine oxoglutarate transaminase II (AADAT)
DMBWJK4	MT	DTT
DMBWJK4	MA	Inhibitor
DMBWJK4	RN	Bicyclic or tricyclic heterocyclic compound. US10065972.
DMBWJK4	RU	http://www.freepatentsonline.com/US10065972.html

DMT8WVZ	DI	DMT8WVZ
DMT8WVZ	DN	US10065972, Example 396
DMT8WVZ	MI	TTT3IXG
DMT8WVZ	MN	Kynurenine oxoglutarate transaminase II (AADAT)
DMT8WVZ	MT	DTT
DMT8WVZ	MA	Inhibitor
DMT8WVZ	RN	Bicyclic or tricyclic heterocyclic compound. US10065972.
DMT8WVZ	RU	http://www.freepatentsonline.com/US10065972.html

DM9QCTJ	DI	DM9QCTJ
DM9QCTJ	DN	US10065972, Example 560
DM9QCTJ	MI	TTT3IXG
DM9QCTJ	MN	Kynurenine oxoglutarate transaminase II (AADAT)
DM9QCTJ	MT	DTT
DM9QCTJ	MA	Inhibitor
DM9QCTJ	RN	Bicyclic or tricyclic heterocyclic compound. US10065972.
DM9QCTJ	RU	http://www.freepatentsonline.com/US10065972.html

DM95YLX	DI	DM95YLX
DM95YLX	DN	US10071110, Compound cCDV
DM95YLX	MI	TT5DOVB
DM95YLX	MN	Cytomegalovirus Protease (CMV UL80)
DM95YLX	MT	DTT
DM95YLX	MA	Inhibitor
DM95YLX	RN	Phosphonate compounds. US10071110.
DM95YLX	RU	http://www.freepatentsonline.com/US10071110.html

DMOZ84C	DI	DMOZ84C
DMOZ84C	DN	US10077269, Example 6
DMOZ84C	MI	TT6A59G
DMOZ84C	MN	Phosphodiesterase 4C (PDE4C)
DMOZ84C	MT	DTT
DMOZ84C	MA	Inhibitor
DMOZ84C	RN	Imidazopyridazine compounds. US9598421.
DMOZ84C	RU	http://www.freepatentsonline.com/US9598421.html

DM3BDHN	DI	DM3BDHN
DM3BDHN	DN	US10081632, Compound 25
DM3BDHN	MI	TT3KYWB
DM3BDHN	MN	Ribosomal protein S6 kinase alpha-6 (RSK6)
DM3BDHN	MT	DTT
DM3BDHN	MA	Inhibitor
DM3BDHN	RN	Substituted tetrahydropyrido[3,2:4,5]pyrrolo[1,2-a]pyrazine-2-carboxamides as RSK inhibitors. US9771366.
DM3BDHN	RU	http://www.freepatentsonline.com/US9771366.html

DMM6WAB	DI	DMM6WAB
DMM6WAB	DN	US10087167, Compound 3002
DMM6WAB	MI	TTQFZWR
DMM6WAB	MN	Hepatitis C virus Core protein messenger RNA (HCV Core mRNA)
DMM6WAB	MT	DTT
DMM6WAB	MA	Inhibitor
DMM6WAB	RN	Benzofurans substituted with secondary benzamide as HCV inhibitors. US10087167.
DMM6WAB	RU	http://www.freepatentsonline.com/US10087167.html

DMITOY6	DI	DMITOY6
DMITOY6	DN	US10087167, Compound 3003
DMITOY6	MI	TTQFZWR
DMITOY6	MN	Hepatitis C virus Core protein messenger RNA (HCV Core mRNA)
DMITOY6	MT	DTT
DMITOY6	MA	Inhibitor
DMITOY6	RN	Benzofurans substituted with secondary benzamide as HCV inhibitors. US10087167.
DMITOY6	RU	http://www.freepatentsonline.com/US10087167.html

DMAP1DN	DI	DMAP1DN
DMAP1DN	DN	US10087167, Compound 4001
DMAP1DN	MI	TTQFZWR
DMAP1DN	MN	Hepatitis C virus Core protein messenger RNA (HCV Core mRNA)
DMAP1DN	MT	DTT
DMAP1DN	MA	Inhibitor
DMAP1DN	RN	Benzofurans substituted with secondary benzamide as HCV inhibitors. US10087167.
DMAP1DN	RU	http://www.freepatentsonline.com/US10087167.html

DMU8CAD	DI	DMU8CAD
DMU8CAD	DN	US10092575, Example 101
DMU8CAD	MI	TT3ZS42
DMU8CAD	MN	Phosphodiesterase 1B (PDE1B)
DMU8CAD	MT	DTT
DMU8CAD	MA	Inhibitor
DMU8CAD	RN	Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds. US10092575.
DMU8CAD	RU	http://www.freepatentsonline.com/US10092575.html

DMT47DF	DI	DMT47DF
DMT47DF	DN	US10092575, Example 141
DMT47DF	MI	TT3ZS42
DMT47DF	MN	Phosphodiesterase 1B (PDE1B)
DMT47DF	MT	DTT
DMT47DF	MA	Inhibitor
DMT47DF	RN	Therapeutic thiophene-, furan-, and pyridine-fused azolopyrimidin-5-(6h)-ones. US10105367.
DMT47DF	RU	http://www.freepatentsonline.com/US10105367.html

DM7MNE2	DI	DM7MNE2
DM7MNE2	DN	US10092575, Example 158
DM7MNE2	MI	TT3ZS42
DM7MNE2	MN	Phosphodiesterase 1B (PDE1B)
DM7MNE2	MT	DTT
DM7MNE2	MA	Inhibitor
DM7MNE2	RN	Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds. US10092575.
DM7MNE2	RU	http://www.freepatentsonline.com/US10092575.html

DMJKS4X	DI	DMJKS4X
DMJKS4X	DN	US10100051, Compound 1
DMJKS4X	MI	TT9ISBX
DMJKS4X	MN	HIF-prolyl hydroxylase 2 (HPH-2)
DMJKS4X	MT	DTT
DMJKS4X	MA	Inhibitor
DMJKS4X	RN	Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, preparation method thereof and pharmaceutical use thereof. US10100051.
DMJKS4X	RU	http://www.freepatentsonline.com/US10100051.html

DMQ7ODW	DI	DMQ7ODW
DMQ7ODW	DN	US10100051, Compound 10
DMQ7ODW	MI	TT9ISBX
DMQ7ODW	MN	HIF-prolyl hydroxylase 2 (HPH-2)
DMQ7ODW	MT	DTT
DMQ7ODW	MA	Inhibitor
DMQ7ODW	RN	Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, preparation method thereof and pharmaceutical use thereof. US10100051.
DMQ7ODW	RU	http://www.freepatentsonline.com/US10100051.html

DM2DEOA	DI	DM2DEOA
DM2DEOA	DN	US10100051, Compound 11
DM2DEOA	MI	TT9ISBX
DM2DEOA	MN	HIF-prolyl hydroxylase 2 (HPH-2)
DM2DEOA	MT	DTT
DM2DEOA	MA	Inhibitor
DM2DEOA	RN	Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, preparation method thereof and pharmaceutical use thereof. US10100051.
DM2DEOA	RU	http://www.freepatentsonline.com/US10100051.html

DMWESZ1	DI	DMWESZ1
DMWESZ1	DN	US10100051, Compound 2
DMWESZ1	MI	TT9ISBX
DMWESZ1	MN	HIF-prolyl hydroxylase 2 (HPH-2)
DMWESZ1	MT	DTT
DMWESZ1	MA	Inhibitor
DMWESZ1	RN	Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, preparation method thereof and pharmaceutical use thereof. US10100051.
DMWESZ1	RU	http://www.freepatentsonline.com/US10100051.html

DMEVGR6	DI	DMEVGR6
DMEVGR6	DN	US10149841, Compound 1
DMEVGR6	MI	TT9ISBX
DMEVGR6	MN	HIF-prolyl hydroxylase 2 (HPH-2)
DMEVGR6	MT	DTT
DMEVGR6	MA	Inhibitor
DMEVGR6	RN	Compound of 3-hydroxyl pyridine, preparation method thereof and pharmaceutical use thereof. US10149841.
DMEVGR6	RU	http://www.freepatentsonline.com/US10149841.html

DMYSI9J	DI	DMYSI9J
DMYSI9J	DN	US10149841, Compound 19
DMYSI9J	MI	TT9ISBX
DMYSI9J	MN	HIF-prolyl hydroxylase 2 (HPH-2)
DMYSI9J	MT	DTT
DMYSI9J	MA	Inhibitor
DMYSI9J	RN	Compound of 3-hydroxyl pyridine, preparation method thereof and pharmaceutical use thereof. US10149841.
DMYSI9J	RU	http://www.freepatentsonline.com/US10149841.html

DMBS50K	DI	DMBS50K
DMBS50K	DN	US10149841, Compound 5
DMBS50K	MI	TT9ISBX
DMBS50K	MN	HIF-prolyl hydroxylase 2 (HPH-2)
DMBS50K	MT	DTT
DMBS50K	MA	Inhibitor
DMBS50K	RN	Compound of 3-hydroxyl pyridine, preparation method thereof and pharmaceutical use thereof. US10149841.
DMBS50K	RU	http://www.freepatentsonline.com/US10149841.html

DMS415A	DI	DMS415A
DMS415A	DN	US10149841, Compound 9
DMS415A	MI	TT9ISBX
DMS415A	MN	HIF-prolyl hydroxylase 2 (HPH-2)
DMS415A	MT	DTT
DMS415A	MA	Inhibitor
DMS415A	RN	Compound of 3-hydroxyl pyridine, preparation method thereof and pharmaceutical use thereof. US10149841.
DMS415A	RU	http://www.freepatentsonline.com/US10149841.html

DME2AZG	DI	DME2AZG
DME2AZG	DN	US10150740, Example 1
DME2AZG	MI	TTQFZWR
DME2AZG	MN	Hepatitis C virus Core protein messenger RNA (HCV Core mRNA)
DME2AZG	MT	DTT
DME2AZG	MA	Inhibitor
DME2AZG	RN	6,7-dihydropyrido[2,1-A]phthalazin-2-ones for the treatment and prophylaxis of hepatitis B virus infection. US10150740.
DME2AZG	RU	http://www.freepatentsonline.com/US10150740.html

DMKM93Q	DI	DMKM93Q
DMKM93Q	DN	US10150740, Example 4
DMKM93Q	MI	TTQFZWR
DMKM93Q	MN	Hepatitis C virus Core protein messenger RNA (HCV Core mRNA)
DMKM93Q	MT	DTT
DMKM93Q	MA	Inhibitor
DMKM93Q	RN	6,7-dihydropyrido[2,1-A]phthalazin-2-ones for the treatment and prophylaxis of hepatitis B virus infection. US10150740.
DMKM93Q	RU	http://www.freepatentsonline.com/US10150740.html

DM1VPLU	DI	DM1VPLU
DM1VPLU	DN	US10150740, Example 9
DM1VPLU	MI	TTQFZWR
DM1VPLU	MN	Hepatitis C virus Core protein messenger RNA (HCV Core mRNA)
DM1VPLU	MT	DTT
DM1VPLU	MA	Inhibitor
DM1VPLU	RN	6,7-dihydropyrido[2,1-A]phthalazin-2-ones for the treatment and prophylaxis of hepatitis B virus infection. US10150740.
DM1VPLU	RU	http://www.freepatentsonline.com/US10150740.html

DMVMNP1	DI	DMVMNP1
DMVMNP1	DN	US10166249, Example 695
DMVMNP1	MI	TTDYP7I
DMVMNP1	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DMVMNP1	MT	DTT
DMVMNP1	MA	Inhibitor
DMVMNP1	RN	Substituted bicyclic compounds. US10166249.
DMVMNP1	RU	http://www.freepatentsonline.com/US10166249.html

DMSYRI3	DI	DMSYRI3
DMSYRI3	DN	US10174026, Example 2
DMSYRI3	MI	TTIG67W
DMSYRI3	MN	Lysine-specific demethylase 5A (KDM5A)
DMSYRI3	MT	DTT
DMSYRI3	MA	Inhibitor
DMSYRI3	RN	Histone demethylase inhibitors. US10174026.
DMSYRI3	RU	http://www.freepatentsonline.com/US10174026.html

DMJKTYW	DI	DMJKTYW
DMJKTYW	DN	US10174026, Example 99
DMJKTYW	MI	TTIG67W
DMJKTYW	MN	Lysine-specific demethylase 5A (KDM5A)
DMJKTYW	MT	DTT
DMJKTYW	MA	Inhibitor
DMJKTYW	RN	Histone demethylase inhibitors. US10174026.
DMJKTYW	RU	http://www.freepatentsonline.com/US10174026.html

DMGTBO3	DI	DMGTBO3
DMGTBO3	DN	US10179791, Compound 171
DMGTBO3	MI	TTDYP7I
DMGTBO3	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DMGTBO3	MT	DTT
DMGTBO3	MA	Inhibitor
DMGTBO3	RN	Spiro-cyclic amine derivatives as S1P modulators. US10179791.
DMGTBO3	RU	http://www.freepatentsonline.com/US10179791.html

DMRHQLF	DI	DMRHQLF
DMRHQLF	DN	US10179791, Compound 176
DMRHQLF	MI	TTDYP7I
DMRHQLF	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DMRHQLF	MT	DTT
DMRHQLF	MA	Inhibitor
DMRHQLF	RN	Spiro-cyclic amine derivatives as S1P modulators. US10179791.
DMRHQLF	RU	http://www.freepatentsonline.com/US10179791.html

DMLZBRM	DI	DMLZBRM
DMLZBRM	DN	US10179791, Compound 296
DMLZBRM	MI	TTDYP7I
DMLZBRM	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DMLZBRM	MT	DTT
DMLZBRM	MA	Inhibitor
DMLZBRM	RN	Spiro-cyclic amine derivatives as S1P modulators. US10179791.
DMLZBRM	RU	http://www.freepatentsonline.com/US10179791.html

DMAE6CK	DI	DMAE6CK
DMAE6CK	DN	US20160326143, 28
DMAE6CK	MI	TTW7OTG
DMAE6CK	MN	Leukotriene C4 synthase (LTC4S)
DMAE6CK	MT	DTT
DMAE6CK	MA	Inhibitor
DMAE6CK	RN	COMPOUNDS AND USES. US20160326143.
DMAE6CK	RU	http://www.freepatentsonline.com/US20160326143.html

DML5KXB	DI	DML5KXB
DML5KXB	DN	US20160326143, 3
DML5KXB	MI	TTW7OTG
DML5KXB	MN	Leukotriene C4 synthase (LTC4S)
DML5KXB	MT	DTT
DML5KXB	MA	Inhibitor
DML5KXB	RN	COMPOUNDS AND USES. US20160326143.
DML5KXB	RU	http://www.freepatentsonline.com/US20160326143.html

DMUDE89	DI	DMUDE89
DMUDE89	DN	US20160326143, 38
DMUDE89	MI	TTW7OTG
DMUDE89	MN	Leukotriene C4 synthase (LTC4S)
DMUDE89	MT	DTT
DMUDE89	MA	Inhibitor
DMUDE89	RN	Compounds and uses. US9657001.
DMUDE89	RU	http://www.freepatentsonline.com/US9657001.html

DM2DU7R	DI	DM2DU7R
DM2DU7R	DN	US20160326143, 50
DM2DU7R	MI	TTW7OTG
DM2DU7R	MN	Leukotriene C4 synthase (LTC4S)
DM2DU7R	MT	DTT
DM2DU7R	MA	Inhibitor
DM2DU7R	RN	Compounds and uses. US9657001.
DM2DU7R	RU	http://www.freepatentsonline.com/US9657001.html

DMH7JVA	DI	DMH7JVA
DMH7JVA	DN	US8470836, 2
DMH7JVA	MI	TTOYT5L
DMH7JVA	MN	Dipeptidyl-peptidase 7 (DPP7)
DMH7JVA	MT	DTT
DMH7JVA	MA	Inhibitor
DMH7JVA	RN	Dipeptidyl peptidase-IV inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent. US8470836.
DMH7JVA	RU	http://www.freepatentsonline.com/US8470836.html

DMYR10P	DI	DMYR10P
DMYR10P	DN	US8470836, 5
DMYR10P	MI	TTOYT5L
DMYR10P	MN	Dipeptidyl-peptidase 7 (DPP7)
DMYR10P	MT	DTT
DMYR10P	MA	Inhibitor
DMYR10P	RN	Dipeptidyl peptidase-IV inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent. US8470836.
DMYR10P	RU	http://www.freepatentsonline.com/US8470836.html

DMVYQXH	DI	DMVYQXH
DMVYQXH	DN	US8470836, 6
DMVYQXH	MI	TTOYT5L
DMVYQXH	MN	Dipeptidyl-peptidase 7 (DPP7)
DMVYQXH	MT	DTT
DMVYQXH	MA	Inhibitor
DMVYQXH	RN	Dipeptidyl peptidase-IV inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent. US8470836.
DMVYQXH	RU	http://www.freepatentsonline.com/US8470836.html

DMM4GLH	DI	DMM4GLH
DMM4GLH	DN	US8470836, 8
DMM4GLH	MI	TTOYT5L
DMM4GLH	MN	Dipeptidyl-peptidase 7 (DPP7)
DMM4GLH	MT	DTT
DMM4GLH	MA	Inhibitor
DMM4GLH	RN	Dipeptidyl peptidase-IV inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent. US8470836.
DMM4GLH	RU	http://www.freepatentsonline.com/US8470836.html

DMFEUMZ	DI	DMFEUMZ
DMFEUMZ	DN	US8481586, 15
DMFEUMZ	MI	TTCGOIN
DMFEUMZ	MN	PIM-3 protein kinase (PIM3)
DMFEUMZ	MT	DTT
DMFEUMZ	MA	Inhibitor
DMFEUMZ	RN	Pyrrolo[2,3-a] carbazoles and use thereof as PIM kinase inhibitors. US8481586.
DMFEUMZ	RU	http://www.freepatentsonline.com/US8481586.html

DM6U3ZR	DI	DM6U3ZR
DM6U3ZR	DN	US8481586, 40
DM6U3ZR	MI	TTCGOIN
DM6U3ZR	MN	PIM-3 protein kinase (PIM3)
DM6U3ZR	MT	DTT
DM6U3ZR	MA	Inhibitor
DM6U3ZR	RN	Pyrrolo[2,3-a] carbazoles and use thereof as PIM kinase inhibitors. US8481586.
DM6U3ZR	RU	http://www.freepatentsonline.com/US8481586.html

DM5W0A2	DI	DM5W0A2
DM5W0A2	DN	US8481586, 5
DM5W0A2	MI	TTCGOIN
DM5W0A2	MN	PIM-3 protein kinase (PIM3)
DM5W0A2	MT	DTT
DM5W0A2	MA	Inhibitor
DM5W0A2	RN	Pyrrolo[2,3-a] carbazoles and use thereof as PIM kinase inhibitors. US8481586.
DM5W0A2	RU	http://www.freepatentsonline.com/US8481586.html

DMV6FL8	DI	DMV6FL8
DMV6FL8	DN	US8481733, 106
DMV6FL8	MI	TTIET93
DMV6FL8	MN	Activated CDC42 kinase 1 (ACK-1)
DMV6FL8	MT	DTT
DMV6FL8	MA	Inhibitor
DMV6FL8	RN	Substituted imidazopyr- and imidazotri-azines. US8481733.
DMV6FL8	RU	http://www.freepatentsonline.com/US8481733.html

DMZQIKL	DI	DMZQIKL
DMZQIKL	DN	US8481733, 118
DMZQIKL	MI	TTIET93
DMZQIKL	MN	Activated CDC42 kinase 1 (ACK-1)
DMZQIKL	MT	DTT
DMZQIKL	MA	Inhibitor
DMZQIKL	RN	Substituted imidazopyr- and imidazotri-azines. US8481733.
DMZQIKL	RU	http://www.freepatentsonline.com/US8481733.html

DM36R21	DI	DM36R21
DM36R21	DN	US8481733, 95
DM36R21	MI	TTIET93
DM36R21	MN	Activated CDC42 kinase 1 (ACK-1)
DM36R21	MT	DTT
DM36R21	MA	Inhibitor
DM36R21	RN	Substituted imidazopyr- and imidazotri-azines. US8481733.
DM36R21	RU	http://www.freepatentsonline.com/US8481733.html

DMCJH4F	DI	DMCJH4F
DMCJH4F	DN	US8524917, 10
DMCJH4F	MI	TTDYP7I
DMCJH4F	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DMCJH4F	MT	DTT
DMCJH4F	MA	Inhibitor
DMCJH4F	RN	6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity. US8524917.
DMCJH4F	RU	http://www.freepatentsonline.com/US8524917.html

DMETY0U	DI	DMETY0U
DMETY0U	DN	US8524917, 11
DMETY0U	MI	TTDYP7I
DMETY0U	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DMETY0U	MT	DTT
DMETY0U	MA	Inhibitor
DMETY0U	RN	S1P3 receptor inhibitors for treating pain. US8563594.
DMETY0U	RU	http://www.freepatentsonline.com/US8563594.html

DMZ2ECB	DI	DMZ2ECB
DMZ2ECB	DN	US8524917, 12
DMZ2ECB	MI	TTDYP7I
DMZ2ECB	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DMZ2ECB	MT	DTT
DMZ2ECB	MA	Inhibitor
DMZ2ECB	RN	S1P3 receptor inhibitors for treating pain. US8563594.
DMZ2ECB	RU	http://www.freepatentsonline.com/US8563594.html

DMRPD8U	DI	DMRPD8U
DMRPD8U	DN	US8524917, 60
DMRPD8U	MI	TTDYP7I
DMRPD8U	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DMRPD8U	MT	DTT
DMRPD8U	MA	Inhibitor
DMRPD8U	RN	6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity. US8524917.
DMRPD8U	RU	http://www.freepatentsonline.com/US8524917.html

DMF9LNO	DI	DMF9LNO
DMF9LNO	DN	US8536181, A41
DMF9LNO	MI	TT9ISBX
DMF9LNO	MN	HIF-prolyl hydroxylase 2 (HPH-2)
DMF9LNO	MT	DTT
DMF9LNO	MA	Inhibitor
DMF9LNO	RN	Prolyl hydroxylase inhibitors. US8536181.
DMF9LNO	RU	http://www.freepatentsonline.com/US8536181.html

DMZNF59	DI	DMZNF59
DMZNF59	DN	US8536181, C14
DMZNF59	MI	TT9ISBX
DMZNF59	MN	HIF-prolyl hydroxylase 2 (HPH-2)
DMZNF59	MT	DTT
DMZNF59	MA	Inhibitor
DMZNF59	RN	Prolyl hydroxylase inhibitors. US8536181.
DMZNF59	RU	http://www.freepatentsonline.com/US8536181.html

DMRTL63	DI	DMRTL63
DMRTL63	DN	US8536181, C17
DMRTL63	MI	TT9ISBX
DMRTL63	MN	HIF-prolyl hydroxylase 2 (HPH-2)
DMRTL63	MT	DTT
DMRTL63	MA	Inhibitor
DMRTL63	RN	Methods for increasing the stabilization of hypoxia inducible factor-1 alpha. US8778412.
DMRTL63	RU	http://www.freepatentsonline.com/US8778412.html

DMAM51Z	DI	DMAM51Z
DMAM51Z	DN	US8536181, C35
DMAM51Z	MI	TT9ISBX
DMAM51Z	MN	HIF-prolyl hydroxylase 2 (HPH-2)
DMAM51Z	MT	DTT
DMAM51Z	MA	Inhibitor
DMAM51Z	RN	Prolyl hydroxylase inhibitors. US8536181.
DMAM51Z	RU	http://www.freepatentsonline.com/US8536181.html

DMQRO6G	DI	DMQRO6G
DMQRO6G	DN	US8546370, 102
DMQRO6G	MI	TTUMHT8
DMQRO6G	MN	Tyrosine-protein kinase ZAP-70 (ZAP-70)
DMQRO6G	MT	DTT
DMQRO6G	MA	Inhibitor
DMQRO6G	RN	Compounds and compositions as kinase inhibitors. US8546370.
DMQRO6G	RU	http://www.freepatentsonline.com/US8546370.html

DM2K6YU	DI	DM2K6YU
DM2K6YU	DN	US8546370, 11
DM2K6YU	MI	TTUMHT8
DM2K6YU	MN	Tyrosine-protein kinase ZAP-70 (ZAP-70)
DM2K6YU	MT	DTT
DM2K6YU	MA	Inhibitor
DM2K6YU	RN	Compounds and compositions as kinase inhibitors. US8546370.
DM2K6YU	RU	http://www.freepatentsonline.com/US8546370.html

DMGIJZA	DI	DMGIJZA
DMGIJZA	DN	US8546370, 17
DMGIJZA	MI	TTUMHT8
DMGIJZA	MN	Tyrosine-protein kinase ZAP-70 (ZAP-70)
DMGIJZA	MT	DTT
DMGIJZA	MA	Inhibitor
DMGIJZA	RN	Compounds and compositions as kinase inhibitors. US8546370.
DMGIJZA	RU	http://www.freepatentsonline.com/US8546370.html

DMDP87V	DI	DMDP87V
DMDP87V	DN	US8563594, 152
DMDP87V	MI	TTDYP7I
DMDP87V	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DMDP87V	MT	DTT
DMDP87V	MA	Inhibitor
DMDP87V	RN	S1P3 receptor inhibitors for treating pain. US8563594.
DMDP87V	RU	http://www.freepatentsonline.com/US8563594.html

DMZV6YT	DI	DMZV6YT
DMZV6YT	DN	US8569313, Inhibitor 14
DMZV6YT	MI	TTPRO7W
DMZV6YT	MN	Suppressor of tumorigenicity 14 protein (ST14)
DMZV6YT	MT	DTT
DMZV6YT	MA	Inhibitor
DMZV6YT	RN	Meta-substituted phenyl sulfonyl amides of secondary amino acid amides, the production thereof, and use thereof as matriptase inhibitors. US8569313.
DMZV6YT	RU	http://www.freepatentsonline.com/US8569313.html

DMTMG02	DI	DMTMG02
DMTMG02	DN	US8569313, Inhibitor 15
DMTMG02	MI	TTPRO7W
DMTMG02	MN	Suppressor of tumorigenicity 14 protein (ST14)
DMTMG02	MT	DTT
DMTMG02	MA	Inhibitor
DMTMG02	RN	Meta-substituted phenyl sulfonyl amides of secondary amino acid amides, the production thereof, and use thereof as matriptase inhibitors. US8569313.
DMTMG02	RU	http://www.freepatentsonline.com/US8569313.html

DMXTCGM	DI	DMXTCGM
DMXTCGM	DN	US8569313, Inhibitor 18
DMXTCGM	MI	TTPRO7W
DMXTCGM	MN	Suppressor of tumorigenicity 14 protein (ST14)
DMXTCGM	MT	DTT
DMXTCGM	MA	Inhibitor
DMXTCGM	RN	Meta-substituted phenyl sulfonyl amides of secondary amino acid amides, the production thereof, and use thereof as matriptase inhibitors. US8569313.
DMXTCGM	RU	http://www.freepatentsonline.com/US8569313.html

DMLXG43	DI	DMLXG43
DMLXG43	DN	US8569313, Inhibitor 19
DMLXG43	MI	TTPRO7W
DMLXG43	MN	Suppressor of tumorigenicity 14 protein (ST14)
DMLXG43	MT	DTT
DMLXG43	MA	Inhibitor
DMLXG43	RN	Meta-substituted phenyl sulfonyl amides of secondary amino acid amides, the production thereof, and use thereof as matriptase inhibitors. US8569313.
DMLXG43	RU	http://www.freepatentsonline.com/US8569313.html

DMKLJ6O	DI	DMKLJ6O
DMKLJ6O	DN	US8586571, 12
DMKLJ6O	MI	TT0C8BY
DMKLJ6O	MN	Plasma retinol-binding protein (RBP4)
DMKLJ6O	MT	DTT
DMKLJ6O	MA	Inhibitor
DMKLJ6O	RN	Heterocyclic compound. US8586571.
DMKLJ6O	RU	http://www.freepatentsonline.com/US8586571.html

DMX3A0O	DI	DMX3A0O
DMX3A0O	DN	US8586571, 36
DMX3A0O	MI	TT0C8BY
DMX3A0O	MN	Plasma retinol-binding protein (RBP4)
DMX3A0O	MT	DTT
DMX3A0O	MA	Inhibitor
DMX3A0O	RN	Heterocyclic compound. US8586571.
DMX3A0O	RU	http://www.freepatentsonline.com/US8586571.html

DM1N74R	DI	DM1N74R
DM1N74R	DN	US8586571, 6
DM1N74R	MI	TT0C8BY
DM1N74R	MN	Plasma retinol-binding protein (RBP4)
DM1N74R	MT	DTT
DM1N74R	MA	Inhibitor
DM1N74R	RN	Heterocyclic compound. US8586571.
DM1N74R	RU	http://www.freepatentsonline.com/US8586571.html

DM29KS1	DI	DM29KS1
DM29KS1	DN	US8592431, 181
DM29KS1	MI	TTLJKZ0
DM29KS1	MN	Acetyl-CoA transporter (SLC33A1)
DM29KS1	MT	DTT
DM29KS1	MA	Inhibitor
DM29KS1	RN	Fused ring compound and use thereof. US8592431.
DM29KS1	RU	http://www.freepatentsonline.com/US8592431.html

DM1K5HS	DI	DM1K5HS
DM1K5HS	DN	US8592431, 185
DM1K5HS	MI	TTLJKZ0
DM1K5HS	MN	Acetyl-CoA transporter (SLC33A1)
DM1K5HS	MT	DTT
DM1K5HS	MA	Inhibitor
DM1K5HS	RN	Fused ring compound and use thereof. US8592431.
DM1K5HS	RU	http://www.freepatentsonline.com/US8592431.html

DMAPGBF	DI	DMAPGBF
DMAPGBF	DN	US8592431, 457
DMAPGBF	MI	TTLJKZ0
DMAPGBF	MN	Acetyl-CoA transporter (SLC33A1)
DMAPGBF	MT	DTT
DMAPGBF	MA	Inhibitor
DMAPGBF	RN	Fused ring compound and use thereof. US8592431.
DMAPGBF	RU	http://www.freepatentsonline.com/US8592431.html

DMY8U6J	DI	DMY8U6J
DMY8U6J	DN	US8592455, 3
DMY8U6J	MI	TTCGOIN
DMY8U6J	MN	PIM-3 protein kinase (PIM3)
DMY8U6J	MT	DTT
DMY8U6J	MA	Inhibitor
DMY8U6J	RN	Kinase inhibitors and methods of their use. US8592455.
DMY8U6J	RU	http://www.freepatentsonline.com/US8592455.html

DMTE8QO	DI	DMTE8QO
DMTE8QO	DN	US8592455, 90
DMTE8QO	MI	TTCGOIN
DMTE8QO	MN	PIM-3 protein kinase (PIM3)
DMTE8QO	MT	DTT
DMTE8QO	MA	Inhibitor
DMTE8QO	RN	Kinase inhibitors and methods of their use. US8592455.
DMTE8QO	RU	http://www.freepatentsonline.com/US8592455.html

DM0YD3Z	DI	DM0YD3Z
DM0YD3Z	DN	US8598172, 1
DM0YD3Z	MI	TT976FS
DM0YD3Z	MN	Polo-like kinase 2 (PLK2)
DM0YD3Z	MT	DTT
DM0YD3Z	MA	Inhibitor
DM0YD3Z	RN	Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors. US8598172.
DM0YD3Z	RU	http://www.freepatentsonline.com/US8598172.html

DM9YI3K	DI	DM9YI3K
DM9YI3K	DN	US8598210, Table XV, 1
DM9YI3K	MI	TT9ISBX
DM9YI3K	MN	HIF-prolyl hydroxylase 2 (HPH-2)
DM9YI3K	MT	DTT
DM9YI3K	MA	Inhibitor
DM9YI3K	RN	Prolyl hydroxylase inhibitors and methods of use. US8598210.
DM9YI3K	RU	http://www.freepatentsonline.com/US8598210.html

DMDK98P	DI	DMDK98P
DMDK98P	DN	US8598210, Table XV, 2
DMDK98P	MI	TT9ISBX
DMDK98P	MN	HIF-prolyl hydroxylase 2 (HPH-2)
DMDK98P	MT	DTT
DMDK98P	MA	Inhibitor
DMDK98P	RN	Prolyl hydroxylase inhibitors and methods of use. US9598370.
DMDK98P	RU	http://www.freepatentsonline.com/US9598370.html

DM3XWMO	DI	DM3XWMO
DM3XWMO	DN	US8598210, Table XV, 4
DM3XWMO	MI	TT9ISBX
DM3XWMO	MN	HIF-prolyl hydroxylase 2 (HPH-2)
DM3XWMO	MT	DTT
DM3XWMO	MA	Inhibitor
DM3XWMO	RN	Prolyl hydroxylase inhibitors and methods of use. US8598210.
DM3XWMO	RU	http://www.freepatentsonline.com/US8598210.html

DMEU5ST	DI	DMEU5ST
DMEU5ST	DN	US8598210, Table XV, 5
DMEU5ST	MI	TT9ISBX
DMEU5ST	MN	HIF-prolyl hydroxylase 2 (HPH-2)
DMEU5ST	MT	DTT
DMEU5ST	MA	Inhibitor
DMEU5ST	RN	Prolyl hydroxylase inhibitors and method of use. US8722895.
DMEU5ST	RU	http://www.freepatentsonline.com/US8722895.html

DM5CULA	DI	DM5CULA
DM5CULA	DN	US8609715, A-1
DM5CULA	MI	TTXL0GC
DM5CULA	MN	Enteropeptidase (TMPRSS15)
DM5CULA	MT	DTT
DM5CULA	MA	Inhibitor
DM5CULA	RN	Heteroarylcarboxylic acid ester derivative. US8609715.
DM5CULA	RU	http://www.freepatentsonline.com/US8609715.html

DMY9SFE	DI	DMY9SFE
DMY9SFE	DN	US8609715, A-26
DMY9SFE	MI	TTXL0GC
DMY9SFE	MN	Enteropeptidase (TMPRSS15)
DMY9SFE	MT	DTT
DMY9SFE	MA	Inhibitor
DMY9SFE	RN	Heteroarylcarboxylic acid ester derivative. US8609715.
DMY9SFE	RU	http://www.freepatentsonline.com/US8609715.html

DMU26R7	DI	DMU26R7
DMU26R7	DN	US8609715, B-61
DMU26R7	MI	TTXL0GC
DMU26R7	MN	Enteropeptidase (TMPRSS15)
DMU26R7	MT	DTT
DMU26R7	MA	Inhibitor
DMU26R7	RN	Heteroarylcarboxylic acid ester derivative. US8609715.
DMU26R7	RU	http://www.freepatentsonline.com/US8609715.html

DMJKFVU	DI	DMJKFVU
DMJKFVU	DN	US8614253, 29-1
DMJKFVU	MI	TTOJ9QL
DMJKFVU	MN	Endoplasmic reticulum to nucleus signaling 1 (ERN1)
DMJKFVU	MT	DTT
DMJKFVU	MA	Inhibitor
DMJKFVU	RN	IRE-1 inhibitors. US9241942.
DMJKFVU	RU	http://www.freepatentsonline.com/US9241942.html

DMVI83P	DI	DMVI83P
DMVI83P	DN	US8614253, 29-19
DMVI83P	MI	TTOJ9QL
DMVI83P	MN	Endoplasmic reticulum to nucleus signaling 1 (ERN1)
DMVI83P	MT	DTT
DMVI83P	MA	Inhibitor
DMVI83P	RN	IRE-1 inhibitors. US9493435.
DMVI83P	RU	http://www.freepatentsonline.com/US9493435.html

DMRSP2M	DI	DMRSP2M
DMRSP2M	DN	US8614253, 32-4
DMRSP2M	MI	TTOJ9QL
DMRSP2M	MN	Endoplasmic reticulum to nucleus signaling 1 (ERN1)
DMRSP2M	MT	DTT
DMRSP2M	MA	Inhibitor
DMRSP2M	RN	IRE-1 inhibitors. US9493435.
DMRSP2M	RU	http://www.freepatentsonline.com/US9493435.html

DMSQODK	DI	DMSQODK
DMSQODK	DN	US8614253, 32-5
DMSQODK	MI	TTOJ9QL
DMSQODK	MN	Endoplasmic reticulum to nucleus signaling 1 (ERN1)
DMSQODK	MT	DTT
DMSQODK	MA	Inhibitor
DMSQODK	RN	IRE-1 inhibitors. US8614253.
DMSQODK	RU	http://www.freepatentsonline.com/US8614253.html

DM4G3OC	DI	DM4G3OC
DM4G3OC	DN	US8669361, 102
DM4G3OC	MI	TTCGOIN
DM4G3OC	MN	PIM-3 protein kinase (PIM3)
DM4G3OC	MT	DTT
DM4G3OC	MA	Inhibitor
DM4G3OC	RN	Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use. US9573943.
DM4G3OC	RU	http://www.freepatentsonline.com/US9573943.html

DMC67G4	DI	DMC67G4
DMC67G4	DN	US8669361, 103
DMC67G4	MI	TTCGOIN
DMC67G4	MN	PIM-3 protein kinase (PIM3)
DMC67G4	MT	DTT
DMC67G4	MA	Inhibitor
DMC67G4	RN	Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use. US8669361.
DMC67G4	RU	http://www.freepatentsonline.com/US8669361.html

DMIZWM6	DI	DMIZWM6
DMIZWM6	DN	US8669361, 105
DMIZWM6	MI	TTCGOIN
DMIZWM6	MN	PIM-3 protein kinase (PIM3)
DMIZWM6	MT	DTT
DMIZWM6	MA	Inhibitor
DMIZWM6	RN	Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use. US8669361.
DMIZWM6	RU	http://www.freepatentsonline.com/US8669361.html

DMF8MIB	DI	DMF8MIB
DMF8MIB	DN	US8669361, 107
DMF8MIB	MI	TTCGOIN
DMF8MIB	MN	PIM-3 protein kinase (PIM3)
DMF8MIB	MT	DTT
DMF8MIB	MA	Inhibitor
DMF8MIB	RN	Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use. US8669361.
DMF8MIB	RU	http://www.freepatentsonline.com/US8669361.html

DMKYNB0	DI	DMKYNB0
DMKYNB0	DN	US8703720, 15
DMKYNB0	MI	TTO3NYT
DMKYNB0	MN	Galectin-1 (LGALS1)
DMKYNB0	MT	DTT
DMKYNB0	MA	Inhibitor
DMKYNB0	RN	Galactoside inhibitors of galectins. US8703720.
DMKYNB0	RU	http://www.freepatentsonline.com/US8703720.html

DMFGIPR	DI	DMFGIPR
DMFGIPR	DN	US8703720, Reference Compound 1
DMFGIPR	MI	TTO3NYT
DMFGIPR	MN	Galectin-1 (LGALS1)
DMFGIPR	MT	DTT
DMFGIPR	MA	Inhibitor
DMFGIPR	RN	Galactoside inhibitors of galectins. US8703720.
DMFGIPR	RU	http://www.freepatentsonline.com/US8703720.html

DM536FO	DI	DM536FO
DM536FO	DN	US8703720, Reference Compound 2
DM536FO	MI	TTO3NYT
DM536FO	MN	Galectin-1 (LGALS1)
DM536FO	MT	DTT
DM536FO	MA	Inhibitor
DM536FO	RN	Galactoside inhibitors of galectins. US8703720.
DM536FO	RU	http://www.freepatentsonline.com/US8703720.html

DMCNAM9	DI	DMCNAM9
DMCNAM9	DN	US8710232, 1
DMCNAM9	MI	TT4UJX5
DMCNAM9	MN	Carboxypeptidase B1 (CPB1)
DMCNAM9	MT	DTT
DMCNAM9	MA	Inhibitor
DMCNAM9	RN	Imidazole derivatives used as TAFIa inhibitors. US8710232.
DMCNAM9	RU	http://www.freepatentsonline.com/US8710232.html

DMCNS9T	DI	DMCNS9T
DMCNS9T	DN	US8710232, 7
DMCNS9T	MI	TT4UJX5
DMCNS9T	MN	Carboxypeptidase B1 (CPB1)
DMCNS9T	MT	DTT
DMCNS9T	MA	Inhibitor
DMCNS9T	RN	Imidazole derivatives used as TAFIa inhibitors. US8710232.
DMCNS9T	RU	http://www.freepatentsonline.com/US8710232.html

DM1MQ7J	DI	DM1MQ7J
DM1MQ7J	DN	US8710232, 8
DM1MQ7J	MI	TT4UJX5
DM1MQ7J	MN	Carboxypeptidase B1 (CPB1)
DM1MQ7J	MT	DTT
DM1MQ7J	MA	Inhibitor
DM1MQ7J	RN	Imidazole derivatives used as TAFIa inhibitors. US8710232.
DM1MQ7J	RU	http://www.freepatentsonline.com/US8710232.html

DMU9YPV	DI	DMU9YPV
DMU9YPV	DN	US8741907-compound-3
DMU9YPV	MI	TTN34SQ
DMU9YPV	MN	Phosphodiesterase 3B (PDE3B)
DMU9YPV	MT	DTT
DMU9YPV	MA	Inhibitor
DMU9YPV	RN	Selective phosphodiesterase 9A inhibitors as medicaments for improving cognitive processes. US9067945.
DMU9YPV	RU	http://www.freepatentsonline.com/US9067945.html

DMSYD3X	DI	DMSYD3X
DMSYD3X	DN	US8754233, (4-Benzothiazol-2-yl-1H-pyrazol-3-yl)-[2-(1H-imidazol-4-yl)-ethyl]-amine
DMSYD3X	MI	TT7ALZG
DMSYD3X	MN	Integrin-linked protein kinase 1 (ILK)
DMSYD3X	MT	DTT
DMSYD3X	MA	Inhibitor
DMSYD3X	RN	Pyrazolylbenzothiazole derivatives and their use as therapeutic agents. US8754233.
DMSYD3X	RU	http://www.freepatentsonline.com/US8754233.html

DMJPQNH	DI	DMJPQNH
DMJPQNH	DN	US8754233, 2-(3-Amino-1H-pyrazol-4-yl)-5-fluoro-benzothiazole-6-sulfonic acid amide
DMJPQNH	MI	TT7ALZG
DMJPQNH	MN	Integrin-linked protein kinase 1 (ILK)
DMJPQNH	MT	DTT
DMJPQNH	MA	Inhibitor
DMJPQNH	RN	Pyrazolylbenzothiazole derivatives and their use as therapeutic agents. US8754233.
DMJPQNH	RU	http://www.freepatentsonline.com/US8754233.html

DMJY0CD	DI	DMJY0CD
DMJY0CD	DN	US8754233, 4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-(2-fluoro-phenyl)-2H-pyrazol-3-ylamine
DMJY0CD	MI	TT7ALZG
DMJY0CD	MN	Integrin-linked protein kinase 1 (ILK)
DMJY0CD	MT	DTT
DMJY0CD	MA	Inhibitor
DMJY0CD	RN	Pyrazolylbenzothiazole derivatives and their use as therapeutic agents. US8754233.
DMJY0CD	RU	http://www.freepatentsonline.com/US8754233.html

DMRHNIL	DI	DMRHNIL
DMRHNIL	DN	US8759338, 1
DMRHNIL	MI	TTCGOIN
DMRHNIL	MN	PIM-3 protein kinase (PIM3)
DMRHNIL	MT	DTT
DMRHNIL	MA	Inhibitor
DMRHNIL	RN	Heterocyclic kinase inhibitors. US8759338.
DMRHNIL	RU	http://www.freepatentsonline.com/US8759338.html

DMXHN1V	DI	DMXHN1V
DMXHN1V	DN	US8759338, 12
DMXHN1V	MI	TTCGOIN
DMXHN1V	MN	PIM-3 protein kinase (PIM3)
DMXHN1V	MT	DTT
DMXHN1V	MA	Inhibitor
DMXHN1V	RN	Heterocyclic kinase inhibitors. US8759338.
DMXHN1V	RU	http://www.freepatentsonline.com/US8759338.html

DMSBRHJ	DI	DMSBRHJ
DMSBRHJ	DN	US8759338, 2
DMSBRHJ	MI	TTCGOIN
DMSBRHJ	MN	PIM-3 protein kinase (PIM3)
DMSBRHJ	MT	DTT
DMSBRHJ	MA	Inhibitor
DMSBRHJ	RN	Heterocyclic kinase inhibitors. US8759338.
DMSBRHJ	RU	http://www.freepatentsonline.com/US8759338.html

DM2J8IS	DI	DM2J8IS
DM2J8IS	DN	US8772478, 1
DM2J8IS	MI	TTQICM2
DM2J8IS	MN	ADAM metallopeptidase 33 (ADAM33)
DM2J8IS	MT	DTT
DM2J8IS	MA	Inhibitor
DM2J8IS	RN	Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics. US8772478.
DM2J8IS	RU	http://www.freepatentsonline.com/US8772478.html

DMFJD5L	DI	DMFJD5L
DMFJD5L	DN	US8772478, 2
DMFJD5L	MI	TTQICM2
DMFJD5L	MN	ADAM metallopeptidase 33 (ADAM33)
DMFJD5L	MT	DTT
DMFJD5L	MA	Inhibitor
DMFJD5L	RN	Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics. US8772478.
DMFJD5L	RU	http://www.freepatentsonline.com/US8772478.html

DMN4FRE	DI	DMN4FRE
DMN4FRE	DN	US8772478, 3
DMN4FRE	MI	TTQICM2
DMN4FRE	MN	ADAM metallopeptidase 33 (ADAM33)
DMN4FRE	MT	DTT
DMN4FRE	MA	Inhibitor
DMN4FRE	RN	Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics. US8772478.
DMN4FRE	RU	http://www.freepatentsonline.com/US8772478.html

DMHI6RZ	DI	DMHI6RZ
DMHI6RZ	DN	US8772478, 5
DMHI6RZ	MI	TTQICM2
DMHI6RZ	MN	ADAM metallopeptidase 33 (ADAM33)
DMHI6RZ	MT	DTT
DMHI6RZ	MA	Inhibitor
DMHI6RZ	RN	Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics. US8772478.
DMHI6RZ	RU	http://www.freepatentsonline.com/US8772478.html

DMUPRX2	DI	DMUPRX2
DMUPRX2	DN	US8791257, 17
DMUPRX2	MI	TTR93NU
DMUPRX2	MN	Casein kinase II alpha prime (CSNK2A2)
DMUPRX2	MT	DTT
DMUPRX2	MA	Inhibitor
DMUPRX2	RN	Substituted pyrrolotriazines as protein kinase inhibitors. US8791257.
DMUPRX2	RU	http://www.freepatentsonline.com/US8791257.html

DMAEHCP	DI	DMAEHCP
DMAEHCP	DN	US8791257, 38
DMAEHCP	MI	TTR93NU
DMAEHCP	MN	Casein kinase II alpha prime (CSNK2A2)
DMAEHCP	MT	DTT
DMAEHCP	MA	Inhibitor
DMAEHCP	RN	Substituted pyrrolotriazines as protein kinase inhibitors. US8791257.
DMAEHCP	RU	http://www.freepatentsonline.com/US8791257.html

DMIQO8N	DI	DMIQO8N
DMIQO8N	DN	US8791257, 4
DMIQO8N	MI	TTR93NU
DMIQO8N	MN	Casein kinase II alpha prime (CSNK2A2)
DMIQO8N	MT	DTT
DMIQO8N	MA	Inhibitor
DMIQO8N	RN	Substituted pyrrolotriazines as protein kinase inhibitors. US8791257.
DMIQO8N	RU	http://www.freepatentsonline.com/US8791257.html

DMWKDET	DI	DMWKDET
DMWKDET	DN	US8829193, 1
DMWKDET	MI	TTCGOIN
DMWKDET	MN	PIM-3 protein kinase (PIM3)
DMWKDET	MT	DTT
DMWKDET	MA	Inhibitor
DMWKDET	RN	PIM kinase inhibitors and methods of their use. US8829193.
DMWKDET	RU	http://www.freepatentsonline.com/US8829193.html

DMBIAQD	DI	DMBIAQD
DMBIAQD	DN	US8829193, 2
DMBIAQD	MI	TTCGOIN
DMBIAQD	MN	PIM-3 protein kinase (PIM3)
DMBIAQD	MT	DTT
DMBIAQD	MA	Inhibitor
DMBIAQD	RN	PIM kinase inhibitors and methods of their use. US8829193.
DMBIAQD	RU	http://www.freepatentsonline.com/US8829193.html

DM5ZGK3	DI	DM5ZGK3
DM5ZGK3	DN	US8829193, 3
DM5ZGK3	MI	TTCGOIN
DM5ZGK3	MN	PIM-3 protein kinase (PIM3)
DM5ZGK3	MT	DTT
DM5ZGK3	MA	Inhibitor
DM5ZGK3	RN	PIM kinase inhibitors and methods of their use. US8829193.
DM5ZGK3	RU	http://www.freepatentsonline.com/US8829193.html

DMRUTJZ	DI	DMRUTJZ
DMRUTJZ	DN	US8846654, 11
DMRUTJZ	MI	TTIS4OW
DMRUTJZ	MN	Phosphodiesterase 8 (PDE8)
DMRUTJZ	MT	DTT
DMRUTJZ	MA	Inhibitor
DMRUTJZ	RN	Therapeutic applications in the cardiovascular field of quinazolinedione derivatives. US8846654.
DMRUTJZ	RU	http://www.freepatentsonline.com/US8846654.html

DMML258	DI	DMML258
DMML258	DN	US8846654, 251
DMML258	MI	TTIS4OW
DMML258	MN	Phosphodiesterase 8 (PDE8)
DMML258	MT	DTT
DMML258	MA	Inhibitor
DMML258	RN	Therapeutic applications in the cardiovascular field of quinazolinedione derivatives. US8846654.
DMML258	RU	http://www.freepatentsonline.com/US8846654.html

DMP3RCH	DI	DMP3RCH
DMP3RCH	DN	US8846654, 294
DMP3RCH	MI	TTIS4OW
DMP3RCH	MN	Phosphodiesterase 8 (PDE8)
DMP3RCH	MT	DTT
DMP3RCH	MA	Inhibitor
DMP3RCH	RN	Therapeutic applications in the cardiovascular field of quinazolinedione derivatives. US8846654.
DMP3RCH	RU	http://www.freepatentsonline.com/US8846654.html

DMX8NLB	DI	DMX8NLB
DMX8NLB	DN	US8853215, 3
DMX8NLB	MI	TT0C8BY
DMX8NLB	MN	Plasma retinol-binding protein (RBP4)
DMX8NLB	MT	DTT
DMX8NLB	MA	Inhibitor
DMX8NLB	RN	Derivatives of N-acyl-N-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes. US8853215.
DMX8NLB	RU	http://www.freepatentsonline.com/US8853215.html

DMDN8P1	DI	DMDN8P1
DMDN8P1	DN	US8877733, 27
DMDN8P1	MI	TTQFZWR
DMDN8P1	MN	Hepatitis C virus Core protein messenger RNA (HCV Core mRNA)
DMDN8P1	MT	DTT
DMDN8P1	MA	Inhibitor
DMDN8P1	RN	1-substituted pyrimidine N-nucleoside analogs for antiviral treatment. US8877733.
DMDN8P1	RU	http://www.freepatentsonline.com/US8877733.html

DMLY3RE	DI	DMLY3RE
DMLY3RE	DN	US8877733, 28
DMLY3RE	MI	TTQFZWR
DMLY3RE	MN	Hepatitis C virus Core protein messenger RNA (HCV Core mRNA)
DMLY3RE	MT	DTT
DMLY3RE	MA	Inhibitor
DMLY3RE	RN	1-substituted pyrimidine N-nucleoside analogs for antiviral treatment. US8877733.
DMLY3RE	RU	http://www.freepatentsonline.com/US8877733.html

DM8B1Q4	DI	DM8B1Q4
DM8B1Q4	DN	US8889672, 252-036-001
DM8B1Q4	MI	TTUWGRA
DM8B1Q4	MN	Protein kinase C zeta (PRKCZ)
DM8B1Q4	MT	DTT
DM8B1Q4	MA	Inhibitor
DM8B1Q4	RN	Compounds, formulations, and methods of protein kinase C inhibition. US8889672.
DM8B1Q4	RU	http://www.freepatentsonline.com/US8889672.html

DMKXRJ4	DI	DMKXRJ4
DMKXRJ4	DN	US8889696, 39
DMKXRJ4	MI	TTUWGRA
DMKXRJ4	MN	Protein kinase C zeta (PRKCZ)
DMKXRJ4	MT	DTT
DMKXRJ4	MA	Inhibitor
DMKXRJ4	RN	Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof. US8889696.
DMKXRJ4	RU	http://www.freepatentsonline.com/US8889696.html

DMSYUHK	DI	DMSYUHK
DMSYUHK	DN	US8889696, Staurosporine
DMSYUHK	MI	TTCGOIN
DMSYUHK	MN	PIM-3 protein kinase (PIM3)
DMSYUHK	MT	DTT
DMSYUHK	MA	Inhibitor
DMSYUHK	RN	Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof. US8889696.
DMSYUHK	RU	http://www.freepatentsonline.com/US8889696.html

DMEAUJT	DI	DMEAUJT
DMEAUJT	DN	US8901295, F609
DMEAUJT	MI	TTNAFOU
DMEAUJT	MN	Rotamase D (PPID)
DMEAUJT	MT	DTT
DMEAUJT	MA	Inhibitor
DMEAUJT	RN	Inhibitors of cyclophilins and uses thereof. US8901295.
DMEAUJT	RU	http://www.freepatentsonline.com/US8901295.html

DMPICE1	DI	DMPICE1
DMPICE1	DN	US8901295, F673
DMPICE1	MI	TTNAFOU
DMPICE1	MN	Rotamase D (PPID)
DMPICE1	MT	DTT
DMPICE1	MA	Inhibitor
DMPICE1	RN	Inhibitors of cyclophilins and uses thereof. US8901295.
DMPICE1	RU	http://www.freepatentsonline.com/US8901295.html

DM34KXF	DI	DM34KXF
DM34KXF	DN	US8921389, 1
DM34KXF	MI	TT9ISBX
DM34KXF	MN	HIF-prolyl hydroxylase 2 (HPH-2)
DM34KXF	MT	DTT
DM34KXF	MA	Inhibitor
DM34KXF	RN	Naphthyridine derivatives as inhibitors of Hypoxia inducible factor (HIF) hydroxylase. US9695170.
DM34KXF	RU	http://www.freepatentsonline.com/US9695170.html

DM8NE12	DI	DM8NE12
DM8NE12	DN	US8921389, 123
DM8NE12	MI	TT9ISBX
DM8NE12	MN	HIF-prolyl hydroxylase 2 (HPH-2)
DM8NE12	MT	DTT
DM8NE12	MA	Inhibitor
DM8NE12	RN	Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase. US8921389.
DM8NE12	RU	http://www.freepatentsonline.com/US8921389.html

DMX7KDR	DI	DMX7KDR
DMX7KDR	DN	US8921389, 2
DMX7KDR	MI	TT9ISBX
DMX7KDR	MN	HIF-prolyl hydroxylase 2 (HPH-2)
DMX7KDR	MT	DTT
DMX7KDR	MA	Inhibitor
DMX7KDR	RN	Naphthyridine derivatives as inhibitors of Hypoxia inducible factor (HIF) hydroxylase. US9695170.
DMX7KDR	RU	http://www.freepatentsonline.com/US9695170.html

DME1A80	DI	DME1A80
DME1A80	DN	US8921389, 210
DME1A80	MI	TT9ISBX
DME1A80	MN	HIF-prolyl hydroxylase 2 (HPH-2)
DME1A80	MT	DTT
DME1A80	MA	Inhibitor
DME1A80	RN	Naphthyridine derivatives as inhibitors of Hypoxia inducible factor (HIF) hydroxylase. US9695170.
DME1A80	RU	http://www.freepatentsonline.com/US9695170.html

DMIY68N	DI	DMIY68N
DMIY68N	DN	US8921389, 22
DMIY68N	MI	TT9ISBX
DMIY68N	MN	HIF-prolyl hydroxylase 2 (HPH-2)
DMIY68N	MT	DTT
DMIY68N	MA	Inhibitor
DMIY68N	RN	Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase. US8921389.
DMIY68N	RU	http://www.freepatentsonline.com/US8921389.html

DMG3T7E	DI	DMG3T7E
DMG3T7E	DN	US8933095, 1
DMG3T7E	MI	TTT3IXG
DMG3T7E	MN	Kynurenine oxoglutarate transaminase II (AADAT)
DMG3T7E	MT	DTT
DMG3T7E	MA	Inhibitor
DMG3T7E	RN	KAT II inhibitors. US8933095.
DMG3T7E	RU	http://www.freepatentsonline.com/US8933095.html

DMZUNJ4	DI	DMZUNJ4
DMZUNJ4	DN	US8933095, 14
DMZUNJ4	MI	TTT3IXG
DMZUNJ4	MN	Kynurenine oxoglutarate transaminase II (AADAT)
DMZUNJ4	MT	DTT
DMZUNJ4	MA	Inhibitor
DMZUNJ4	RN	KAT II inhibitors. US8598200.
DMZUNJ4	RU	http://www.freepatentsonline.com/US8598200.html

DMRN5F4	DI	DMRN5F4
DMRN5F4	DN	US8933095, 16
DMRN5F4	MI	TTT3IXG
DMRN5F4	MN	Kynurenine oxoglutarate transaminase II (AADAT)
DMRN5F4	MT	DTT
DMRN5F4	MA	Inhibitor
DMRN5F4	RN	KAT II inhibitors. US8933095.
DMRN5F4	RU	http://www.freepatentsonline.com/US8933095.html

DMOZ4FS	DI	DMOZ4FS
DMOZ4FS	DN	US8933095, 18
DMOZ4FS	MI	TTT3IXG
DMOZ4FS	MN	Kynurenine oxoglutarate transaminase II (AADAT)
DMOZ4FS	MT	DTT
DMOZ4FS	MA	Inhibitor
DMOZ4FS	RN	KAT II inhibitors. US8598200.
DMOZ4FS	RU	http://www.freepatentsonline.com/US8598200.html

DMPNCOL	DI	DMPNCOL
DMPNCOL	DN	US8933228, 3
DMPNCOL	MI	TT42OGM
DMPNCOL	MN	Hematopoietic cell kinase (HCK)
DMPNCOL	MT	DTT
DMPNCOL	MA	Inhibitor
DMPNCOL	RN	Respiratory formulations and compounds for use therein. US8933228.
DMPNCOL	RU	http://www.freepatentsonline.com/US8933228.html

DMKEX51	DI	DMKEX51
DMKEX51	DN	US8933228, Ref 2
DMKEX51	MI	TT42OGM
DMKEX51	MN	Hematopoietic cell kinase (HCK)
DMKEX51	MT	DTT
DMKEX51	MA	Inhibitor
DMKEX51	RN	1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as P38 MAP knase inhibitors. US9724347.
DMKEX51	RU	http://www.freepatentsonline.com/US9724347.html

DM6EMYB	DI	DM6EMYB
DM6EMYB	DN	US8937193-compound-6b
DM6EMYB	MI	TTGT9C7
DM6EMYB	MN	Bcl-2-related protein A1 (BCL2A1)
DM6EMYB	MT	DTT
DM6EMYB	MA	Inhibitor
DM6EMYB	RN	Apogossypolone derivatives as anticancer agents. US8937193.
DM6EMYB	RU	http://www.freepatentsonline.com/US8937193.html

DMHZJEA	DI	DMHZJEA
DMHZJEA	DN	US8937193-compound-7
DMHZJEA	MI	TTGT9C7
DMHZJEA	MN	Bcl-2-related protein A1 (BCL2A1)
DMHZJEA	MT	DTT
DMHZJEA	MA	Inhibitor
DMHZJEA	RN	Apogossypolone derivatives as anticancer agents. US8937193.
DMHZJEA	RU	http://www.freepatentsonline.com/US8937193.html

DM3PU57	DI	DM3PU57
DM3PU57	DN	US8940736, 23
DM3PU57	MI	TTR93NU
DM3PU57	MN	Casein kinase II alpha prime (CSNK2A2)
DM3PU57	MT	DTT
DM3PU57	MA	Inhibitor
DM3PU57	RN	Imidazotriazinecarbonitriles useful as kinase inhibitors. US8940736.
DM3PU57	RU	http://www.freepatentsonline.com/US8940736.html

DMXY4SP	DI	DMXY4SP
DMXY4SP	DN	US8940736, 6
DMXY4SP	MI	TTR93NU
DMXY4SP	MN	Casein kinase II alpha prime (CSNK2A2)
DMXY4SP	MT	DTT
DMXY4SP	MA	Inhibitor
DMXY4SP	RN	Imidazotriazinecarbonitriles useful as kinase inhibitors. US8940736.
DMXY4SP	RU	http://www.freepatentsonline.com/US8940736.html

DM9KSVI	DI	DM9KSVI
DM9KSVI	DN	US8940736, 7
DM9KSVI	MI	TTR93NU
DM9KSVI	MN	Casein kinase II alpha prime (CSNK2A2)
DM9KSVI	MT	DTT
DM9KSVI	MA	Inhibitor
DM9KSVI	RN	Imidazotriazinecarbonitriles useful as kinase inhibitors. US8940736.
DM9KSVI	RU	http://www.freepatentsonline.com/US8940736.html

DM4S5DF	DI	DM4S5DF
DM4S5DF	DN	US8975409, Comparative compound B
DM4S5DF	MI	TTVSMOH
DM4S5DF	MN	Sphingosine-1-phosphate receptor 2 (S1PR2)
DM4S5DF	MT	DTT
DM4S5DF	MA	Inhibitor
DM4S5DF	RN	Phenyl derivative. US8975409.
DM4S5DF	RU	http://www.freepatentsonline.com/US8975409.html

DMVB42P	DI	DMVB42P
DMVB42P	DN	US8975409, Example 13
DMVB42P	MI	TTVSMOH
DMVB42P	MN	Sphingosine-1-phosphate receptor 2 (S1PR2)
DMVB42P	MT	DTT
DMVB42P	MA	Inhibitor
DMVB42P	RN	Phenyl derivative. US8975409.
DMVB42P	RU	http://www.freepatentsonline.com/US8975409.html

DMJQOAE	DI	DMJQOAE
DMJQOAE	DN	US8975409, Example 9(3)
DMJQOAE	MI	TTVSMOH
DMJQOAE	MN	Sphingosine-1-phosphate receptor 2 (S1PR2)
DMJQOAE	MT	DTT
DMJQOAE	MA	Inhibitor
DMJQOAE	RN	Phenyl derivative. US8975409.
DMJQOAE	RU	http://www.freepatentsonline.com/US8975409.html

DM4MRP9	DI	DM4MRP9
DM4MRP9	DN	US8987457, 117
DM4MRP9	MI	TTCGOIN
DM4MRP9	MN	PIM-3 protein kinase (PIM3)
DM4MRP9	MT	DTT
DM4MRP9	MA	Inhibitor
DM4MRP9	RN	Ring-substituted N-pyridinyl amides as kinase inhibitors. US8987457.
DM4MRP9	RU	http://www.freepatentsonline.com/US8987457.html

DMAGNEH	DI	DMAGNEH
DMAGNEH	DN	US8987457, 15
DMAGNEH	MI	TTCGOIN
DMAGNEH	MN	PIM-3 protein kinase (PIM3)
DMAGNEH	MT	DTT
DMAGNEH	MA	Inhibitor
DMAGNEH	RN	Ring-substituted N-pyridinyl amides as kinase inhibitors. US8987457.
DMAGNEH	RU	http://www.freepatentsonline.com/US8987457.html

DM0O8WS	DI	DM0O8WS
DM0O8WS	DN	US8987457, 198
DM0O8WS	MI	TTCGOIN
DM0O8WS	MN	PIM-3 protein kinase (PIM3)
DM0O8WS	MT	DTT
DM0O8WS	MA	Inhibitor
DM0O8WS	RN	Ring-substituted N-pyridinyl amides as kinase inhibitors. US8987457.
DM0O8WS	RU	http://www.freepatentsonline.com/US8987457.html

DMBF1C0	DI	DMBF1C0
DMBF1C0	DN	US9006244, E1
DMBF1C0	MI	TTECBXN
DMBF1C0	MN	Oxysterols receptor LXR-alpha (NR1H3)
DMBF1C0	MT	DTT
DMBF1C0	MA	Inhibitor
DMBF1C0	RN	Liver X receptor modulators. US9006244.
DMBF1C0	RU	http://www.freepatentsonline.com/US9006244.html

DMPDF9B	DI	DMPDF9B
DMPDF9B	DN	US9006244, E2a
DMPDF9B	MI	TTECBXN
DMPDF9B	MN	Oxysterols receptor LXR-alpha (NR1H3)
DMPDF9B	MT	DTT
DMPDF9B	MA	Inhibitor
DMPDF9B	RN	Liver X receptor modulators. US9006244.
DMPDF9B	RU	http://www.freepatentsonline.com/US9006244.html

DMP0TBO	DI	DMP0TBO
DMP0TBO	DN	US9006244, E2b
DMP0TBO	MI	TTECBXN
DMP0TBO	MN	Oxysterols receptor LXR-alpha (NR1H3)
DMP0TBO	MT	DTT
DMP0TBO	MA	Inhibitor
DMP0TBO	RN	Liver X receptor modulators. US9006244.
DMP0TBO	RU	http://www.freepatentsonline.com/US9006244.html

DMPGY0M	DI	DMPGY0M
DMPGY0M	DN	US9024044, 1
DMPGY0M	MI	TTXL0GC
DMPGY0M	MN	Enteropeptidase (TMPRSS15)
DMPGY0M	MT	DTT
DMPGY0M	MA	Inhibitor
DMPGY0M	RN	Heteroarylcarboxylic acid ester derivative. US9227949.
DMPGY0M	RU	http://www.freepatentsonline.com/US9227949.html

DMWRXS8	DI	DMWRXS8
DMWRXS8	DN	US9024044, 2
DMWRXS8	MI	TTXL0GC
DMWRXS8	MN	Enteropeptidase (TMPRSS15)
DMWRXS8	MT	DTT
DMWRXS8	MA	Inhibitor
DMWRXS8	RN	Heteroarylcarboxylic acid ester derivative. US9655879.
DMWRXS8	RU	http://www.freepatentsonline.com/US9655879.html

DMKNDMB	DI	DMKNDMB
DMKNDMB	DN	US9024044, 3
DMKNDMB	MI	TTXL0GC
DMKNDMB	MN	Enteropeptidase (TMPRSS15)
DMKNDMB	MT	DTT
DMKNDMB	MA	Inhibitor
DMKNDMB	RN	Heteroarylcarboxylic acid ester derivative. US9024044.
DMKNDMB	RU	http://www.freepatentsonline.com/US9024044.html

DMANFK8	DI	DMANFK8
DMANFK8	DN	US9024044, 4
DMANFK8	MI	TTXL0GC
DMANFK8	MN	Enteropeptidase (TMPRSS15)
DMANFK8	MT	DTT
DMANFK8	MA	Inhibitor
DMANFK8	RN	Heteroarylcarboxylic acid ester derivative. US9655879.
DMANFK8	RU	http://www.freepatentsonline.com/US9655879.html

DMZKGOX	DI	DMZKGOX
DMZKGOX	DN	US9024044, 62
DMZKGOX	MI	TTXL0GC
DMZKGOX	MN	Enteropeptidase (TMPRSS15)
DMZKGOX	MT	DTT
DMZKGOX	MA	Inhibitor
DMZKGOX	RN	Heteroarylcarboxylic acid ester derivative. US9024044.
DMZKGOX	RU	http://www.freepatentsonline.com/US9024044.html

DMDELNU	DI	DMDELNU
DMDELNU	DN	US9040714, 155
DMDELNU	MI	TTOJ9QL
DMDELNU	MN	Endoplasmic reticulum to nucleus signaling 1 (ERN1)
DMDELNU	MT	DTT
DMDELNU	MA	Inhibitor
DMDELNU	RN	IRE-1 inhibitors. US9040714.
DMDELNU	RU	http://www.freepatentsonline.com/US9040714.html

DM53Z4I	DI	DM53Z4I
DM53Z4I	DN	US9040714, 7
DM53Z4I	MI	TTOJ9QL
DM53Z4I	MN	Endoplasmic reticulum to nucleus signaling 1 (ERN1)
DM53Z4I	MT	DTT
DM53Z4I	MA	Inhibitor
DM53Z4I	RN	IRE-1 inhibitors. US9040714.
DM53Z4I	RU	http://www.freepatentsonline.com/US9040714.html

DM2Z43I	DI	DM2Z43I
DM2Z43I	DN	US9073931, E1
DM2Z43I	MI	TTECBXN
DM2Z43I	MN	Oxysterols receptor LXR-alpha (NR1H3)
DM2Z43I	MT	DTT
DM2Z43I	MA	Inhibitor
DM2Z43I	RN	Liver X receptor modulators. US9073931.
DM2Z43I	RU	http://www.freepatentsonline.com/US9073931.html

DMK9FJG	DI	DMK9FJG
DMK9FJG	DN	US9073931, E2
DMK9FJG	MI	TTECBXN
DMK9FJG	MN	Oxysterols receptor LXR-alpha (NR1H3)
DMK9FJG	MT	DTT
DMK9FJG	MA	Inhibitor
DMK9FJG	RN	Liver X receptor modulators. US9073931.
DMK9FJG	RU	http://www.freepatentsonline.com/US9073931.html

DMCYM8P	DI	DMCYM8P
DMCYM8P	DN	US9073931, E3
DMCYM8P	MI	TTECBXN
DMCYM8P	MN	Oxysterols receptor LXR-alpha (NR1H3)
DMCYM8P	MT	DTT
DMCYM8P	MA	Inhibitor
DMCYM8P	RN	Liver X receptor modulators. US9073931.
DMCYM8P	RU	http://www.freepatentsonline.com/US9073931.html

DMZD1L5	DI	DMZD1L5
DMZD1L5	DN	US9073936, 1
DMZD1L5	MI	TT3ZS42
DMZD1L5	MN	Phosphodiesterase 1B (PDE1B)
DMZD1L5	MT	DTT
DMZD1L5	MA	Inhibitor
DMZD1L5	RN	Organic compounds. US9598426.
DMZD1L5	RU	http://www.freepatentsonline.com/US9598426.html

DMZH3MX	DI	DMZH3MX
DMZH3MX	DN	US9073936, 2
DMZH3MX	MI	TT3ZS42
DMZH3MX	MN	Phosphodiesterase 1B (PDE1B)
DMZH3MX	MT	DTT
DMZH3MX	MA	Inhibitor
DMZH3MX	RN	Organic compounds. US9598426.
DMZH3MX	RU	http://www.freepatentsonline.com/US9598426.html

DMS9W6O	DI	DMS9W6O
DMS9W6O	DN	US9073936, 3
DMS9W6O	MI	TT3ZS42
DMS9W6O	MN	Phosphodiesterase 1B (PDE1B)
DMS9W6O	MT	DTT
DMS9W6O	MA	Inhibitor
DMS9W6O	RN	Organic compounds. US9598426.
DMS9W6O	RU	http://www.freepatentsonline.com/US9598426.html

DM8UOKE	DI	DM8UOKE
DM8UOKE	DN	US9096594, 3
DM8UOKE	MI	TTFQEMX
DM8UOKE	MN	Casein kinase I alpha (CSNK1A1)
DM8UOKE	MT	DTT
DM8UOKE	MA	Inhibitor
DM8UOKE	RN	Kinase inhibitors and methods of use thereof. US9096594.
DM8UOKE	RU	http://www.freepatentsonline.com/US9096594.html

DMPT2ZS	DI	DMPT2ZS
DMPT2ZS	DN	US9108950, 1
DMPT2ZS	MI	TT42OGM
DMPT2ZS	MN	Hematopoietic cell kinase (HCK)
DMPT2ZS	MT	DTT
DMPT2ZS	MA	Inhibitor
DMPT2ZS	RN	1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as p38 MAP kinase inhibitors. US9108950.
DMPT2ZS	RU	http://www.freepatentsonline.com/US9108950.html

DMKLYCV	DI	DMKLYCV
DMKLYCV	DN	US9127005, P0L
DMKLYCV	MI	TT3T17P
DMKLYCV	MN	Phospholipase D1 (PLD1)
DMKLYCV	MT	DTT
DMKLYCV	MA	Inhibitor
DMKLYCV	RN	Isoform selective phospholipase D inhibitors. US9127005.
DMKLYCV	RU	http://www.freepatentsonline.com/US9127005.html

DM3R7BT	DI	DM3R7BT
DM3R7BT	DN	US9127005, P2B
DM3R7BT	MI	TT3T17P
DM3R7BT	MN	Phospholipase D1 (PLD1)
DM3R7BT	MT	DTT
DM3R7BT	MA	Inhibitor
DM3R7BT	RN	Isoform selective phospholipase D inhibitors. US9127005.
DM3R7BT	RU	http://www.freepatentsonline.com/US9127005.html

DMMT98V	DI	DMMT98V
DMMT98V	DN	US9127005, P2C
DMMT98V	MI	TT3T17P
DMMT98V	MN	Phospholipase D1 (PLD1)
DMMT98V	MT	DTT
DMMT98V	MA	Inhibitor
DMMT98V	RN	Isoform selective phospholipase D inhibitors. US9127005.
DMMT98V	RU	http://www.freepatentsonline.com/US9127005.html

DM9RIF4	DI	DM9RIF4
DM9RIF4	DN	US9132129, Cpd002
DM9RIF4	MI	TTH9LDP
DM9RIF4	MN	PC4 and SFRS1-interacting protein (PSIP1)
DM9RIF4	MT	DTT
DM9RIF4	MA	Inhibitor
DM9RIF4	RN	Antiviral compounds. US9132129.
DM9RIF4	RU	http://www.freepatentsonline.com/US9132129.html

DMG18XH	DI	DMG18XH
DMG18XH	DN	US9132129, Cpd023
DMG18XH	MI	TTH9LDP
DMG18XH	MN	PC4 and SFRS1-interacting protein (PSIP1)
DMG18XH	MT	DTT
DMG18XH	MA	Inhibitor
DMG18XH	RN	Antiviral compounds. US9132129.
DMG18XH	RU	http://www.freepatentsonline.com/US9132129.html

DM17YHP	DI	DM17YHP
DM17YHP	DN	US9132129, Cpd047
DM17YHP	MI	TTH9LDP
DM17YHP	MN	PC4 and SFRS1-interacting protein (PSIP1)
DM17YHP	MT	DTT
DM17YHP	MA	Inhibitor
DM17YHP	RN	Antiviral compounds. US9132129.
DM17YHP	RU	http://www.freepatentsonline.com/US9132129.html

DMT6HXB	DI	DMT6HXB
DMT6HXB	DN	US9156852, 1
DMT6HXB	MI	TTU98HG
DMT6HXB	MN	Discoidin domain-containing receptor 2 (DDR2)
DMT6HXB	MT	DTT
DMT6HXB	MA	Inhibitor
DMT6HXB	RN	Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases. US9156852.
DMT6HXB	RU	http://www.freepatentsonline.com/US9156852.html

DMZ1RMA	DI	DMZ1RMA
DMZ1RMA	DN	US9156852, 105
DMZ1RMA	MI	TTU98HG
DMZ1RMA	MN	Discoidin domain-containing receptor 2 (DDR2)
DMZ1RMA	MT	DTT
DMZ1RMA	MA	Inhibitor
DMZ1RMA	RN	Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases. US9156852.
DMZ1RMA	RU	http://www.freepatentsonline.com/US9156852.html

DMFSOQY	DI	DMFSOQY
DMFSOQY	DN	US9156852, 38
DMFSOQY	MI	TTU98HG
DMFSOQY	MN	Discoidin domain-containing receptor 2 (DDR2)
DMFSOQY	MT	DTT
DMFSOQY	MA	Inhibitor
DMFSOQY	RN	Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases. US9156852.
DMFSOQY	RU	http://www.freepatentsonline.com/US9156852.html

DM1K5T0	DI	DM1K5T0
DM1K5T0	DN	US9156852, 83
DM1K5T0	MI	TTI1FPZ
DM1K5T0	MN	Epithelial discoidin domain receptor 1 (DDR1)
DM1K5T0	MT	DTT
DM1K5T0	MA	Inhibitor
DM1K5T0	RN	Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases. US9156852.
DM1K5T0	RU	http://www.freepatentsonline.com/US9156852.html

DMOKG3Q	DI	DMOKG3Q
DMOKG3Q	DN	US9181182, 34
DMOKG3Q	MI	TTDYP7I
DMOKG3Q	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DMOKG3Q	MT	DTT
DMOKG3Q	MA	Inhibitor
DMOKG3Q	RN	S1P receptors modulators. US9181182.
DMOKG3Q	RU	http://www.freepatentsonline.com/US9181182.html

DM3QIF4	DI	DM3QIF4
DM3QIF4	DN	US9181182, 40
DM3QIF4	MI	TTDYP7I
DM3QIF4	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DM3QIF4	MT	DTT
DM3QIF4	MA	Inhibitor
DM3QIF4	RN	S1P receptors modulators. US9181182.
DM3QIF4	RU	http://www.freepatentsonline.com/US9181182.html

DM4OHB5	DI	DM4OHB5
DM4OHB5	DN	US9181182, 47
DM4OHB5	MI	TTDYP7I
DM4OHB5	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DM4OHB5	MT	DTT
DM4OHB5	MA	Inhibitor
DM4OHB5	RN	S1P receptors modulators. US9181182.
DM4OHB5	RU	http://www.freepatentsonline.com/US9181182.html

DMVFBHD	DI	DMVFBHD
DMVFBHD	DN	US9187437, 24
DMVFBHD	MI	TTDYP7I
DMVFBHD	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DMVFBHD	MT	DTT
DMVFBHD	MA	Inhibitor
DMVFBHD	RN	Substituted oxadiazole compounds. US9187437.
DMVFBHD	RU	http://www.freepatentsonline.com/US9187437.html

DM2ULB8	DI	DM2ULB8
DM2ULB8	DN	US9187437, 38
DM2ULB8	MI	TTDYP7I
DM2ULB8	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DM2ULB8	MT	DTT
DM2ULB8	MA	Inhibitor
DM2ULB8	RN	Substituted oxadiazole compounds. US9187437.
DM2ULB8	RU	http://www.freepatentsonline.com/US9187437.html

DMEHSR7	DI	DMEHSR7
DMEHSR7	DN	US9187437, 8
DMEHSR7	MI	TTDYP7I
DMEHSR7	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DMEHSR7	MT	DTT
DMEHSR7	MA	Inhibitor
DMEHSR7	RN	Substituted oxadiazole compounds. US9187437.
DMEHSR7	RU	http://www.freepatentsonline.com/US9187437.html

DMCLHX5	DI	DMCLHX5
DMCLHX5	DN	US9200020, Table 3 compound 8
DMCLHX5	MI	TTBL49X
DMCLHX5	MN	Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ)
DMCLHX5	MT	DTT
DMCLHX5	MA	Inhibitor
DMCLHX5	RN	6-oxopurine phosphoribosyltransferase inhibitors. US9200020.
DMCLHX5	RU	http://www.freepatentsonline.com/US9200020.html

DMEARS2	DI	DMEARS2
DMEARS2	DN	US9200020, Table 3, Compound 1B
DMEARS2	MI	TTBL49X
DMEARS2	MN	Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ)
DMEARS2	MT	DTT
DMEARS2	MA	Inhibitor
DMEARS2	RN	6-oxopurine phosphoribosyltransferase inhibitors. US9200020.
DMEARS2	RU	http://www.freepatentsonline.com/US9200020.html

DMXFB5Z	DI	DMXFB5Z
DMXFB5Z	DN	US9200020, Table 3, Compound 2B
DMXFB5Z	MI	TTBL49X
DMXFB5Z	MN	Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ)
DMXFB5Z	MT	DTT
DMXFB5Z	MA	Inhibitor
DMXFB5Z	RN	6-oxopurine phosphoribosyltransferase inhibitors. US9200020.
DMXFB5Z	RU	http://www.freepatentsonline.com/US9200020.html

DM3NE8J	DI	DM3NE8J
DM3NE8J	DN	US9206139, 4
DM3NE8J	MI	TTYG6BU
DM3NE8J	MN	Aggrecanase-1 (ADAMTS4)
DM3NE8J	MT	DTT
DM3NE8J	MA	Inhibitor
DM3NE8J	RN	Aggrecanase inhibitors. US9206139.
DM3NE8J	RU	http://www.freepatentsonline.com/US9206139.html

DMB4JS7	DI	DMB4JS7
DMB4JS7	DN	US9206139, 5
DMB4JS7	MI	TTYG6BU
DMB4JS7	MN	Aggrecanase-1 (ADAMTS4)
DMB4JS7	MT	DTT
DMB4JS7	MA	Inhibitor
DMB4JS7	RN	Aggrecanase inhibitors. US9206139.
DMB4JS7	RU	http://www.freepatentsonline.com/US9206139.html

DMD803F	DI	DMD803F
DMD803F	DN	US9216972, 132
DMD803F	MI	TTDYP7I
DMD803F	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DMD803F	MT	DTT
DMD803F	MA	Inhibitor
DMD803F	RN	Tricyclic heterocyclic compounds. US9216972.
DMD803F	RU	http://www.freepatentsonline.com/US9216972.html

DM7AHQE	DI	DM7AHQE
DM7AHQE	DN	US9216972, 61
DM7AHQE	MI	TTDYP7I
DM7AHQE	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DM7AHQE	MT	DTT
DM7AHQE	MA	Inhibitor
DM7AHQE	RN	Tricyclic heterocyclic compounds. US9216972.
DM7AHQE	RU	http://www.freepatentsonline.com/US9216972.html

DMXR5SZ	DI	DMXR5SZ
DMXR5SZ	DN	US9216972, 67
DMXR5SZ	MI	TTDYP7I
DMXR5SZ	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DMXR5SZ	MT	DTT
DMXR5SZ	MA	Inhibitor
DMXR5SZ	RN	Tricyclic heterocyclic compounds. US9216972.
DMXR5SZ	RU	http://www.freepatentsonline.com/US9216972.html

DMKLCZF	DI	DMKLCZF
DMKLCZF	DN	US9216972, 94
DMKLCZF	MI	TTDYP7I
DMKLCZF	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DMKLCZF	MT	DTT
DMKLCZF	MA	Inhibitor
DMKLCZF	RN	Tricyclic heterocyclic compounds. US9216972.
DMKLCZF	RU	http://www.freepatentsonline.com/US9216972.html

DMSXG78	DI	DMSXG78
DMSXG78	DN	US9217012, 10
DMSXG78	MI	TT405FP
DMSXG78	MN	FAP-1 messenger RNA (PTPN13 mRNA)
DMSXG78	MT	DTT
DMSXG78	MA	Inhibitor
DMSXG78	RN	Inhibitors of protein tyrosine phosphatases. US9217012.
DMSXG78	RU	http://www.freepatentsonline.com/US9217012.html

DM8GW54	DI	DM8GW54
DM8GW54	DN	US9241942, 32-12
DM8GW54	MI	TTOJ9QL
DM8GW54	MN	Endoplasmic reticulum to nucleus signaling 1 (ERN1)
DM8GW54	MT	DTT
DM8GW54	MA	Inhibitor
DM8GW54	RN	IRE-1 inhibitors. US9493435.
DM8GW54	RU	http://www.freepatentsonline.com/US9493435.html

DMYUDCE	DI	DMYUDCE
DMYUDCE	DN	US9266828, B
DMYUDCE	MI	TTH9WF6
DMYUDCE	MN	Dibasic-processing enzyme (Furin)
DMYUDCE	MT	DTT
DMYUDCE	MA	Inhibitor
DMYUDCE	RN	Inhibitors of Furin and other pro-protein convertases. US9266828.
DMYUDCE	RU	http://www.freepatentsonline.com/US9266828.html

DMQEL1W	DI	DMQEL1W
DMQEL1W	DN	US9266828, C
DMQEL1W	MI	TTH9WF6
DMQEL1W	MN	Dibasic-processing enzyme (Furin)
DMQEL1W	MT	DTT
DMQEL1W	MA	Inhibitor
DMQEL1W	RN	Inhibitors of Furin and other pro-protein convertases. US9266828.
DMQEL1W	RU	http://www.freepatentsonline.com/US9266828.html

DMYUL2X	DI	DMYUL2X
DMYUL2X	DN	US9266828, E
DMYUL2X	MI	TTH9WF6
DMYUL2X	MN	Dibasic-processing enzyme (Furin)
DMYUL2X	MT	DTT
DMYUL2X	MA	Inhibitor
DMYUL2X	RN	Inhibitors of Furin and other pro-protein convertases. US9266828.
DMYUL2X	RU	http://www.freepatentsonline.com/US9266828.html

DM0GOCZ	DI	DM0GOCZ
DM0GOCZ	DN	US9340511, 2
DM0GOCZ	MI	TT9ISBX
DM0GOCZ	MN	HIF-prolyl hydroxylase 2 (HPH-2)
DM0GOCZ	MT	DTT
DM0GOCZ	MA	Inhibitor
DM0GOCZ	RN	Process for making isoquinoline compounds. US9708269.
DM0GOCZ	RU	http://www.freepatentsonline.com/US9708269.html

DMFQERG	DI	DMFQERG
DMFQERG	DN	US9340511, 5
DMFQERG	MI	TT9ISBX
DMFQERG	MN	HIF-prolyl hydroxylase 2 (HPH-2)
DMFQERG	MT	DTT
DMFQERG	MA	Inhibitor
DMFQERG	RN	Process for making isoquinoline compounds. US9708269.
DMFQERG	RU	http://www.freepatentsonline.com/US9708269.html

DMRL0WA	DI	DMRL0WA
DMRL0WA	DN	US9340511, 6
DMRL0WA	MI	TT9ISBX
DMRL0WA	MN	HIF-prolyl hydroxylase 2 (HPH-2)
DMRL0WA	MT	DTT
DMRL0WA	MA	Inhibitor
DMRL0WA	RN	Process for making isoquinoline compounds. US9340511.
DMRL0WA	RU	http://www.freepatentsonline.com/US9340511.html

DMC0PUI	DI	DMC0PUI
DMC0PUI	DN	US9340511, 7
DMC0PUI	MI	TT9ISBX
DMC0PUI	MN	HIF-prolyl hydroxylase 2 (HPH-2)
DMC0PUI	MT	DTT
DMC0PUI	MA	Inhibitor
DMC0PUI	RN	Process for making isoquinoline compounds. US9708269.
DMC0PUI	RU	http://www.freepatentsonline.com/US9708269.html

DM5E9RH	DI	DM5E9RH
DM5E9RH	DN	US9340574, 7
DM5E9RH	MI	TTWMKXP
DM5E9RH	MN	Protein-tyrosine phosphatase eta (HPTP)
DM5E9RH	MT	DTT
DM5E9RH	MA	Inhibitor
DM5E9RH	RN	Inhibitors of protein tyrosine phosphatases. US9340574.
DM5E9RH	RU	http://www.freepatentsonline.com/US9340574.html

DMSLBT3	DI	DMSLBT3
DMSLBT3	DN	US9346821, A-20
DMSLBT3	MI	TTXL0GC
DMSLBT3	MN	Enteropeptidase (TMPRSS15)
DMSLBT3	MT	DTT
DMSLBT3	MA	Inhibitor
DMSLBT3	RN	Heterocyclic carboxylic acid ester derivative. US9346821.
DMSLBT3	RU	http://www.freepatentsonline.com/US9346821.html

DMR6P8T	DI	DMR6P8T
DMR6P8T	DN	US9346821, B-13
DMR6P8T	MI	TTXL0GC
DMR6P8T	MN	Enteropeptidase (TMPRSS15)
DMR6P8T	MT	DTT
DMR6P8T	MA	Inhibitor
DMR6P8T	RN	Heterocyclic carboxylic acid ester derivative. US9346821.
DMR6P8T	RU	http://www.freepatentsonline.com/US9346821.html

DMQ1LGV	DI	DMQ1LGV
DMQ1LGV	DN	US9346821, B-42
DMQ1LGV	MI	TTXL0GC
DMQ1LGV	MN	Enteropeptidase (TMPRSS15)
DMQ1LGV	MT	DTT
DMQ1LGV	MA	Inhibitor
DMQ1LGV	RN	Heterocyclic carboxylic acid ester derivative. US9346821.
DMQ1LGV	RU	http://www.freepatentsonline.com/US9346821.html

DMWG98Z	DI	DMWG98Z
DMWG98Z	DN	US9353089, 135
DMWG98Z	MI	TTXMNHO
DMWG98Z	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMWG98Z	MT	DTT
DMWG98Z	MA	Inhibitor
DMWG98Z	RN	Compositions and methods for the treatment of malaria. US9353089.
DMWG98Z	RU	http://www.freepatentsonline.com/US9353089.html

DMB4MJ0	DI	DMB4MJ0
DMB4MJ0	DN	US9353089, 327
DMB4MJ0	MI	TTXMNHO
DMB4MJ0	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMB4MJ0	MT	DTT
DMB4MJ0	MA	Inhibitor
DMB4MJ0	RN	Compositions and methods for the treatment of malaria. US9353089.
DMB4MJ0	RU	http://www.freepatentsonline.com/US9353089.html

DMK02LS	DI	DMK02LS
DMK02LS	DN	US9353089, 330
DMK02LS	MI	TTXMNHO
DMK02LS	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMK02LS	MT	DTT
DMK02LS	MA	Inhibitor
DMK02LS	RN	Compositions and methods for the treatment of malaria. US9353089.
DMK02LS	RU	http://www.freepatentsonline.com/US9353089.html

DMA3OI4	DI	DMA3OI4
DMA3OI4	DN	US9359293, TA
DMA3OI4	MI	TTLKF5M
DMA3OI4	MN	NAD-dependent deacetylase sirtuin-2 (SIRT2)
DMA3OI4	MT	DTT
DMA3OI4	MA	Inhibitor
DMA3OI4	RN	Methods of treatment using modulators of SIRT2. US9359293.
DMA3OI4	RU	http://www.freepatentsonline.com/US9359293.html

DMRQ2G4	DI	DMRQ2G4
DMRQ2G4	DN	US9359293, TB
DMRQ2G4	MI	TTLKF5M
DMRQ2G4	MN	NAD-dependent deacetylase sirtuin-2 (SIRT2)
DMRQ2G4	MT	DTT
DMRQ2G4	MA	Inhibitor
DMRQ2G4	RN	Methods of treatment using modulators of SIRT2. US9359293.
DMRQ2G4	RU	http://www.freepatentsonline.com/US9359293.html

DM0NIB5	DI	DM0NIB5
DM0NIB5	DN	US9359293, TM
DM0NIB5	MI	TTLKF5M
DM0NIB5	MN	NAD-dependent deacetylase sirtuin-2 (SIRT2)
DM0NIB5	MT	DTT
DM0NIB5	MA	Inhibitor
DM0NIB5	RN	Methods of treatment using modulators of SIRT2. US9359293.
DM0NIB5	RU	http://www.freepatentsonline.com/US9359293.html

DMSA86Y	DI	DMSA86Y
DMSA86Y	DN	US9365572, 5
DMSA86Y	MI	TTYXEPL
DMSA86Y	MN	Ribosomal protein S6 kinase alpha-5 (RSK5)
DMSA86Y	MT	DTT
DMSA86Y	MA	Inhibitor
DMSA86Y	RN	PI3K and/or mTOR inhibitor. US9365572.
DMSA86Y	RU	http://www.freepatentsonline.com/US9365572.html

DMVL57U	DI	DMVL57U
DMVL57U	DN	US9388139, 12
DMVL57U	MI	TTN34SQ
DMVL57U	MN	Phosphodiesterase 3B (PDE3B)
DMVL57U	MT	DTT
DMVL57U	MA	Inhibitor
DMVL57U	RN	Derivatives of celeboxib, use thereof and preparation thereof. US9388139.
DMVL57U	RU	http://www.freepatentsonline.com/US9388139.html

DMMFC0V	DI	DMMFC0V
DMMFC0V	DN	US9409892, 136
DMMFC0V	MI	TT9ISBX
DMMFC0V	MN	HIF-prolyl hydroxylase 2 (HPH-2)
DMMFC0V	MT	DTT
DMMFC0V	MA	Inhibitor
DMMFC0V	RN	4-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitors. US9409892.
DMMFC0V	RU	http://www.freepatentsonline.com/US9409892.html

DMZJTSP	DI	DMZJTSP
DMZJTSP	DN	US9409892, 148
DMZJTSP	MI	TT9ISBX
DMZJTSP	MN	HIF-prolyl hydroxylase 2 (HPH-2)
DMZJTSP	MT	DTT
DMZJTSP	MA	Inhibitor
DMZJTSP	RN	4-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitors. US9409892.
DMZJTSP	RU	http://www.freepatentsonline.com/US9409892.html

DMHF2OX	DI	DMHF2OX
DMHF2OX	DN	US9409892, 19
DMHF2OX	MI	TT9ISBX
DMHF2OX	MN	HIF-prolyl hydroxylase 2 (HPH-2)
DMHF2OX	MT	DTT
DMHF2OX	MA	Inhibitor
DMHF2OX	RN	4-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitors. US9409892.
DMHF2OX	RU	http://www.freepatentsonline.com/US9409892.html

DMWAL5Q	DI	DMWAL5Q
DMWAL5Q	DN	US9409892, 59
DMWAL5Q	MI	TT9ISBX
DMWAL5Q	MN	HIF-prolyl hydroxylase 2 (HPH-2)
DMWAL5Q	MT	DTT
DMWAL5Q	MA	Inhibitor
DMWAL5Q	RN	4-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitors. US9409892.
DMWAL5Q	RU	http://www.freepatentsonline.com/US9409892.html

DMV4AHL	DI	DMV4AHL
DMV4AHL	DN	US9422240, 1-282
DMV4AHL	MI	TT9ISBX
DMV4AHL	MN	HIF-prolyl hydroxylase 2 (HPH-2)
DMV4AHL	MT	DTT
DMV4AHL	MA	Inhibitor
DMV4AHL	RN	Partially saturated nitrogen-containing heterocyclic compound. US9422240.
DMV4AHL	RU	http://www.freepatentsonline.com/US9422240.html

DM0S2UK	DI	DM0S2UK
DM0S2UK	DN	US9422240, 1-286
DM0S2UK	MI	TT9ISBX
DM0S2UK	MN	HIF-prolyl hydroxylase 2 (HPH-2)
DM0S2UK	MT	DTT
DM0S2UK	MA	Inhibitor
DM0S2UK	RN	Partially saturated nitrogen-containing heterocyclic compound. US9422240.
DM0S2UK	RU	http://www.freepatentsonline.com/US9422240.html

DMST6IF	DI	DMST6IF
DMST6IF	DN	US9422240, 1-297
DMST6IF	MI	TT9ISBX
DMST6IF	MN	HIF-prolyl hydroxylase 2 (HPH-2)
DMST6IF	MT	DTT
DMST6IF	MA	Inhibitor
DMST6IF	RN	Partially saturated nitrogen-containing heterocyclic compound. US9422240.
DMST6IF	RU	http://www.freepatentsonline.com/US9422240.html

DMH7DL5	DI	DMH7DL5
DMH7DL5	DN	US9422240, 1-298
DMH7DL5	MI	TT9ISBX
DMH7DL5	MN	HIF-prolyl hydroxylase 2 (HPH-2)
DMH7DL5	MT	DTT
DMH7DL5	MA	Inhibitor
DMH7DL5	RN	Partially saturated nitrogen-containing heterocyclic compound. US9422240.
DMH7DL5	RU	http://www.freepatentsonline.com/US9422240.html

DMS842X	DI	DMS842X
DMS842X	DN	US9434725, 113
DMS842X	MI	TTCGOIN
DMS842X	MN	PIM-3 protein kinase (PIM3)
DMS842X	MT	DTT
DMS842X	MA	Inhibitor
DMS842X	RN	5-azaindazole compounds and methods of use. US9434725.
DMS842X	RU	http://www.freepatentsonline.com/US9434725.html

DM6Z01B	DI	DM6Z01B
DM6Z01B	DN	US9434725, 285
DM6Z01B	MI	TTCGOIN
DM6Z01B	MN	PIM-3 protein kinase (PIM3)
DM6Z01B	MT	DTT
DM6Z01B	MA	Inhibitor
DM6Z01B	RN	5-azaindazole compounds and methods of use. US9434725.
DM6Z01B	RU	http://www.freepatentsonline.com/US9434725.html

DM316FB	DI	DM316FB
DM316FB	DN	US9434725, 315
DM316FB	MI	TTCGOIN
DM316FB	MN	PIM-3 protein kinase (PIM3)
DM316FB	MT	DTT
DM316FB	MA	Inhibitor
DM316FB	RN	5-azaindazole compounds and methods of use. US9434725.
DM316FB	RU	http://www.freepatentsonline.com/US9434725.html

DMIT0H3	DI	DMIT0H3
DMIT0H3	DN	US9434727, 120
DMIT0H3	MI	TT0C8BY
DMIT0H3	MN	Plasma retinol-binding protein (RBP4)
DMIT0H3	MT	DTT
DMIT0H3	MA	Inhibitor
DMIT0H3	RN	Substituted 4-phenylpiperidines, their preparation and use. US9434727.
DMIT0H3	RU	http://www.freepatentsonline.com/US9434727.html

DMC812I	DI	DMC812I
DMC812I	DN	US9434727, 153
DMC812I	MI	TT0C8BY
DMC812I	MN	Plasma retinol-binding protein (RBP4)
DMC812I	MT	DTT
DMC812I	MA	Inhibitor
DMC812I	RN	Substituted 4-phenylpiperidines, their preparation and use. US9434727.
DMC812I	RU	http://www.freepatentsonline.com/US9434727.html

DMLPWK3	DI	DMLPWK3
DMLPWK3	DN	US9434727, 40
DMLPWK3	MI	TT0C8BY
DMLPWK3	MN	Plasma retinol-binding protein (RBP4)
DMLPWK3	MT	DTT
DMLPWK3	MA	Inhibitor
DMLPWK3	RN	Substituted 4-phenylpiperidines, their preparation and use. US9777010.
DMLPWK3	RU	http://www.freepatentsonline.com/US9777010.html

DM9HQXC	DI	DM9HQXC
DM9HQXC	DN	US9434727, 63
DM9HQXC	MI	TT0C8BY
DM9HQXC	MN	Plasma retinol-binding protein (RBP4)
DM9HQXC	MT	DTT
DM9HQXC	MA	Inhibitor
DM9HQXC	RN	Substituted 4-phenylpiperidines, their preparation and use. US9434727.
DM9HQXC	RU	http://www.freepatentsonline.com/US9434727.html

DMCJG8Z	DI	DMCJG8Z
DMCJG8Z	DN	US9434727, 93
DMCJG8Z	MI	TT0C8BY
DMCJG8Z	MN	Plasma retinol-binding protein (RBP4)
DMCJG8Z	MT	DTT
DMCJG8Z	MA	Inhibitor
DMCJG8Z	RN	Substituted 4-phenylpiperidines, their preparation and use. US10072016.
DMCJG8Z	RU	http://www.freepatentsonline.com/US10072016.html

DMVQ3IX	DI	DMVQ3IX
DMVQ3IX	DN	US9453017, 1
DMVQ3IX	MI	TT3T17P
DMVQ3IX	MN	Phospholipase D1 (PLD1)
DMVQ3IX	MT	DTT
DMVQ3IX	MA	Inhibitor
DMVQ3IX	RN	Antiviral therapies with phospholipase D inhibitors. US9453017.
DMVQ3IX	RU	http://www.freepatentsonline.com/US9453017.html

DMPH05Y	DI	DMPH05Y
DMPH05Y	DN	US9453017, 2
DMPH05Y	MI	TT3T17P
DMPH05Y	MN	Phospholipase D1 (PLD1)
DMPH05Y	MT	DTT
DMPH05Y	MA	Inhibitor
DMPH05Y	RN	Antiviral therapies with phospholipase D inhibitors. US9453017.
DMPH05Y	RU	http://www.freepatentsonline.com/US9453017.html

DMGPDEF	DI	DMGPDEF
DMGPDEF	DN	US9475795, 19
DMGPDEF	MI	TTB9CIL
DMGPDEF	MN	Prokineticin receptor-1 (PROKR1)
DMGPDEF	MT	DTT
DMGPDEF	MA	Inhibitor
DMGPDEF	RN	Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases. US9475795.
DMGPDEF	RU	http://www.freepatentsonline.com/US9475795.html

DM0ZDL3	DI	DM0ZDL3
DM0ZDL3	DN	US9475795, 80
DM0ZDL3	MI	TTB9CIL
DM0ZDL3	MN	Prokineticin receptor-1 (PROKR1)
DM0ZDL3	MT	DTT
DM0ZDL3	MA	Inhibitor
DM0ZDL3	RN	Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases. US9475795.
DM0ZDL3	RU	http://www.freepatentsonline.com/US9475795.html

DMR6ODL	DI	DMR6ODL
DMR6ODL	DN	US9475795, 89
DMR6ODL	MI	TTB9CIL
DMR6ODL	MN	Prokineticin receptor-1 (PROKR1)
DMR6ODL	MT	DTT
DMR6ODL	MA	Inhibitor
DMR6ODL	RN	Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases. US9475795.
DMR6ODL	RU	http://www.freepatentsonline.com/US9475795.html

DM4MJ3U	DI	DM4MJ3U
DM4MJ3U	DN	US9493447, 1001
DM4MJ3U	MI	TTIS4OW
DM4MJ3U	MN	Phosphodiesterase 8 (PDE8)
DM4MJ3U	MT	DTT
DM4MJ3U	MA	Inhibitor
DM4MJ3U	RN	Optically active PDE10 inhibitor. US9493447.
DM4MJ3U	RU	http://www.freepatentsonline.com/US9493447.html

DMC1YR5	DI	DMC1YR5
DMC1YR5	DN	US9493490, C
DMC1YR5	MI	TTAZ3MN
DMC1YR5	MN	Beta-adrenergic receptor kinase 1 (ADRBK1)
DMC1YR5	MT	DTT
DMC1YR5	MA	Inhibitor
DMC1YR5	RN	Boron-containing small molecules. US9493490.
DMC1YR5	RU	http://www.freepatentsonline.com/US9493490.html

DMUVC25	DI	DMUVC25
DMUVC25	DN	US9493490, D
DMUVC25	MI	TTAZ3MN
DMUVC25	MN	Beta-adrenergic receptor kinase 1 (ADRBK1)
DMUVC25	MT	DTT
DMUVC25	MA	Inhibitor
DMUVC25	RN	Boron-containing small molecules. US9493490.
DMUVC25	RU	http://www.freepatentsonline.com/US9493490.html

DMFCIGE	DI	DMFCIGE
DMFCIGE	DN	US9493490, E
DMFCIGE	MI	TTAZ3MN
DMFCIGE	MN	Beta-adrenergic receptor kinase 1 (ADRBK1)
DMFCIGE	MT	DTT
DMFCIGE	MA	Inhibitor
DMFCIGE	RN	Boron-containing small molecules. US9493490.
DMFCIGE	RU	http://www.freepatentsonline.com/US9493490.html

DMJDTSN	DI	DMJDTSN
DMJDTSN	DN	US9493490, L
DMJDTSN	MI	TTAZ3MN
DMJDTSN	MN	Beta-adrenergic receptor kinase 1 (ADRBK1)
DMJDTSN	MT	DTT
DMJDTSN	MA	Inhibitor
DMJDTSN	RN	Boron-containing small molecules. US9493490.
DMJDTSN	RU	http://www.freepatentsonline.com/US9493490.html

DMR1Z3I	DI	DMR1Z3I
DMR1Z3I	DN	US9522888, 412
DMR1Z3I	MI	TTDYP7I
DMR1Z3I	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DMR1Z3I	MT	DTT
DMR1Z3I	MA	Inhibitor
DMR1Z3I	RN	Substituted bicyclic compounds. US10166249.
DMR1Z3I	RU	http://www.freepatentsonline.com/US10166249.html

DM6UXZK	DI	DM6UXZK
DM6UXZK	DN	US9522888, 575
DM6UXZK	MI	TTDYP7I
DM6UXZK	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DM6UXZK	MT	DTT
DM6UXZK	MA	Inhibitor
DM6UXZK	RN	Substituted bicyclic compounds. US9522888.
DM6UXZK	RU	http://www.freepatentsonline.com/US9522888.html

DMG0QZ1	DI	DMG0QZ1
DMG0QZ1	DN	US9522888, 618
DMG0QZ1	MI	TTDYP7I
DMG0QZ1	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DMG0QZ1	MT	DTT
DMG0QZ1	MA	Inhibitor
DMG0QZ1	RN	Substituted bicyclic compounds. US10166249.
DMG0QZ1	RU	http://www.freepatentsonline.com/US10166249.html

DMTRZI7	DI	DMTRZI7
DMTRZI7	DN	US9522888, 695
DMTRZI7	MI	TTDYP7I
DMTRZI7	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DMTRZI7	MT	DTT
DMTRZI7	MA	Inhibitor
DMTRZI7	RN	Substituted bicyclic compounds. US9522888.
DMTRZI7	RU	http://www.freepatentsonline.com/US9522888.html

DM81MV6	DI	DM81MV6
DM81MV6	DN	US9567304, Compound F-54
DM81MV6	MI	TTI1FPZ
DM81MV6	MN	Epithelial discoidin domain receptor 1 (DDR1)
DM81MV6	MT	DTT
DM81MV6	MA	Inhibitor
DM81MV6	RN	Quinazolinedione derivative. US9567304.
DM81MV6	RU	http://www.freepatentsonline.com/US9567304.html

DMCGUNB	DI	DMCGUNB
DMCGUNB	DN	US9567304, Compound N-9
DMCGUNB	MI	TTI1FPZ
DMCGUNB	MN	Epithelial discoidin domain receptor 1 (DDR1)
DMCGUNB	MT	DTT
DMCGUNB	MA	Inhibitor
DMCGUNB	RN	Quinazolinedione derivative. US9567304.
DMCGUNB	RU	http://www.freepatentsonline.com/US9567304.html

DMJ76RC	DI	DMJ76RC
DMJ76RC	DN	US9580418, Example 11
DMJ76RC	MI	TTCGOIN
DMJ76RC	MN	PIM-3 protein kinase (PIM3)
DMJ76RC	MT	DTT
DMJ76RC	MA	Inhibitor
DMJ76RC	RN	Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors. US9580418.
DMJ76RC	RU	http://www.freepatentsonline.com/US9580418.html

DMGH9B3	DI	DMGH9B3
DMGH9B3	DN	US9580418, Example 8
DMGH9B3	MI	TTCGOIN
DMGH9B3	MN	PIM-3 protein kinase (PIM3)
DMGH9B3	MT	DTT
DMGH9B3	MA	Inhibitor
DMGH9B3	RN	Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors. US9580418.
DMGH9B3	RU	http://www.freepatentsonline.com/US9580418.html

DMERWUQ	DI	DMERWUQ
DMERWUQ	DN	US9586942, 16
DMERWUQ	MI	TTYJRN5
DMERWUQ	MN	N-acetylglucosaminyltransferase I (NAGAT1)
DMERWUQ	MT	DTT
DMERWUQ	MA	Inhibitor
DMERWUQ	RN	Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy. US9586942.
DMERWUQ	RU	http://www.freepatentsonline.com/US9586942.html

DMZ745J	DI	DMZ745J
DMZ745J	DN	US9586942, 2
DMZ745J	MI	TTYJRN5
DMZ745J	MN	N-acetylglucosaminyltransferase I (NAGAT1)
DMZ745J	MT	DTT
DMZ745J	MA	Inhibitor
DMZ745J	RN	Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy. US9586942.
DMZ745J	RU	http://www.freepatentsonline.com/US9586942.html

DMRXCYF	DI	DMRXCYF
DMRXCYF	DN	US9586942, 3*
DMRXCYF	MI	TTYJRN5
DMRXCYF	MN	N-acetylglucosaminyltransferase I (NAGAT1)
DMRXCYF	MT	DTT
DMRXCYF	MA	Inhibitor
DMRXCYF	RN	Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy. US9586942.
DMRXCYF	RU	http://www.freepatentsonline.com/US9586942.html

DM2RE91	DI	DM2RE91
DM2RE91	DN	US9586945, 1
DM2RE91	MI	TTYJRN5
DM2RE91	MN	N-acetylglucosaminyltransferase I (NAGAT1)
DM2RE91	MT	DTT
DM2RE91	MA	Inhibitor
DM2RE91	RN	Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy. US9586945.
DM2RE91	RU	http://www.freepatentsonline.com/US9586945.html

DMKZC4V	DI	DMKZC4V
DMKZC4V	DN	US9586945, 19a
DMKZC4V	MI	TTYJRN5
DMKZC4V	MN	N-acetylglucosaminyltransferase I (NAGAT1)
DMKZC4V	MT	DTT
DMKZC4V	MA	Inhibitor
DMKZC4V	RN	Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy. US9586945.
DMKZC4V	RU	http://www.freepatentsonline.com/US9586945.html

DM6A8XJ	DI	DM6A8XJ
DM6A8XJ	DN	US9586945, 5
DM6A8XJ	MI	TTYJRN5
DM6A8XJ	MN	N-acetylglucosaminyltransferase I (NAGAT1)
DM6A8XJ	MT	DTT
DM6A8XJ	MA	Inhibitor
DM6A8XJ	RN	Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy. US9586945.
DM6A8XJ	RU	http://www.freepatentsonline.com/US9586945.html

DMRVQ5Z	DI	DMRVQ5Z
DMRVQ5Z	DN	US9598431, 1
DMRVQ5Z	MI	TTGB2LZ
DMRVQ5Z	MN	RAR-related orphan receptor-beta (RORB)
DMRVQ5Z	MT	DTT
DMRVQ5Z	MA	Inhibitor
DMRVQ5Z	RN	Compounds useful for inhibiting ROR-gamma-t. US9598431.
DMRVQ5Z	RU	http://www.freepatentsonline.com/US9598431.html

DMILY1P	DI	DMILY1P
DMILY1P	DN	US9598431, 2
DMILY1P	MI	TTGB2LZ
DMILY1P	MN	RAR-related orphan receptor-beta (RORB)
DMILY1P	MT	DTT
DMILY1P	MA	Inhibitor
DMILY1P	RN	Compounds useful for inhibiting ROR-gamma-t. US9598431.
DMILY1P	RU	http://www.freepatentsonline.com/US9598431.html

DMRC4O7	DI	DMRC4O7
DMRC4O7	DN	US9598431, 3
DMRC4O7	MI	TT1TYN7
DMRC4O7	MN	Nuclear receptor ROR-alpha (RORA)
DMRC4O7	MT	DTT
DMRC4O7	MA	Inhibitor
DMRC4O7	RN	Compounds useful for inhibiting ROR-gamma-t. US9598431.
DMRC4O7	RU	http://www.freepatentsonline.com/US9598431.html

DMXGF56	DI	DMXGF56
DMXGF56	DN	US9598431, 5
DMXGF56	MI	TTGB2LZ
DMXGF56	MN	RAR-related orphan receptor-beta (RORB)
DMXGF56	MT	DTT
DMXGF56	MA	Inhibitor
DMXGF56	RN	Compounds useful for inhibiting ROR-gamma-t. US9598431.
DMXGF56	RU	http://www.freepatentsonline.com/US9598431.html

DMSD354	DI	DMSD354
DMSD354	DN	US9611221, Example 9
DMSD354	MI	TTIG67W
DMSD354	MN	Lysine-specific demethylase 5A (KDM5A)
DMSD354	MT	DTT
DMSD354	MA	Inhibitor
DMSD354	RN	Histone demethylase inhibitors. US9611221.
DMSD354	RU	http://www.freepatentsonline.com/US9611221.html

DM89LKQ	DI	DM89LKQ
DM89LKQ	DN	US9617250, Example 1 Example 204 of D1
DM89LKQ	MI	TTDYP7I
DM89LKQ	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DM89LKQ	MT	DTT
DM89LKQ	MA	Inhibitor
DM89LKQ	RN	Pyridin-4-yl derivatives. US9617250.
DM89LKQ	RU	http://www.freepatentsonline.com/US9617250.html

DM6F7M2	DI	DM6F7M2
DM6F7M2	DN	US9623028, Compound 101
DM6F7M2	MI	TTV298Y
DM6F7M2	MN	Calmodulin-dependent kinase II (CAMKK2)
DM6F7M2	MT	DTT
DM6F7M2	MA	Inhibitor
DM6F7M2	RN	Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof. US9623028.
DM6F7M2	RU	http://www.freepatentsonline.com/US9623028.html

DMMSHX4	DI	DMMSHX4
DMMSHX4	DN	US9623028, Compound 79
DMMSHX4	MI	TTV298Y
DMMSHX4	MN	Calmodulin-dependent kinase II (CAMKK2)
DMMSHX4	MT	DTT
DMMSHX4	MA	Inhibitor
DMMSHX4	RN	Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof. US9623028.
DMMSHX4	RU	http://www.freepatentsonline.com/US9623028.html

DMR3Z49	DI	DMR3Z49
DMR3Z49	DN	US9650366, 12
DMR3Z49	MI	TTXEZJ4
DMR3Z49	MN	Tyrosine-protein kinase EIF2AK2 (p68)
DMR3Z49	MT	DTT
DMR3Z49	MA	Inhibitor
DMR3Z49	RN	Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors. US9650366.
DMR3Z49	RU	http://www.freepatentsonline.com/US9650366.html

DM9HZ03	DI	DM9HZ03
DM9HZ03	DN	US9650366, 2
DM9HZ03	MI	TTXEZJ4
DM9HZ03	MN	Tyrosine-protein kinase EIF2AK2 (p68)
DM9HZ03	MT	DTT
DM9HZ03	MA	Inhibitor
DM9HZ03	RN	Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors. US9650366.
DM9HZ03	RU	http://www.freepatentsonline.com/US9650366.html

DMUCIPE	DI	DMUCIPE
DMUCIPE	DN	US9650366, 9
DMUCIPE	MI	TTXEZJ4
DMUCIPE	MN	Tyrosine-protein kinase EIF2AK2 (p68)
DMUCIPE	MT	DTT
DMUCIPE	MA	Inhibitor
DMUCIPE	RN	Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors. US9650366.
DMUCIPE	RU	http://www.freepatentsonline.com/US9650366.html

DMXU8DI	DI	DMXU8DI
DMXU8DI	DN	US9656955, Example 351
DMXU8DI	MI	TTYJRN5
DMXU8DI	MN	N-acetylglucosaminyltransferase I (NAGAT1)
DMXU8DI	MT	DTT
DMXU8DI	MA	Inhibitor
DMXU8DI	RN	Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy. US9656955.
DMXU8DI	RU	http://www.freepatentsonline.com/US9656955.html

DMC3Q9O	DI	DMC3Q9O
DMC3Q9O	DN	US9656955, Example 540
DMC3Q9O	MI	TTYJRN5
DMC3Q9O	MN	N-acetylglucosaminyltransferase I (NAGAT1)
DMC3Q9O	MT	DTT
DMC3Q9O	MA	Inhibitor
DMC3Q9O	RN	Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy. US9656955.
DMC3Q9O	RU	http://www.freepatentsonline.com/US9656955.html

DMKS7D9	DI	DMKS7D9
DMKS7D9	DN	US9656955, Example 652
DMKS7D9	MI	TTYJRN5
DMKS7D9	MN	N-acetylglucosaminyltransferase I (NAGAT1)
DMKS7D9	MT	DTT
DMKS7D9	MA	Inhibitor
DMKS7D9	RN	Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy. US9656955.
DMKS7D9	RU	http://www.freepatentsonline.com/US9656955.html

DM9JCL2	DI	DM9JCL2
DM9JCL2	DN	US9670220, 33
DM9JCL2	MI	TTDYP7I
DM9JCL2	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DM9JCL2	MT	DTT
DM9JCL2	MA	Inhibitor
DM9JCL2	RN	Fused heterocyclic derivatives as S1P modulators. US9670220.
DM9JCL2	RU	http://www.freepatentsonline.com/US9670220.html

DMNZD8T	DI	DMNZD8T
DMNZD8T	DN	US9670220, 76
DMNZD8T	MI	TTDYP7I
DMNZD8T	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DMNZD8T	MT	DTT
DMNZD8T	MA	Inhibitor
DMNZD8T	RN	Fused heterocyclic derivatives as S1P modulators. US9670220.
DMNZD8T	RU	http://www.freepatentsonline.com/US9670220.html

DMZG1HO	DI	DMZG1HO
DMZG1HO	DN	US9670220, 77
DMZG1HO	MI	TTDYP7I
DMZG1HO	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DMZG1HO	MT	DTT
DMZG1HO	MA	Inhibitor
DMZG1HO	RN	Fused heterocyclic derivatives as S1P modulators. US9670220.
DMZG1HO	RU	http://www.freepatentsonline.com/US9670220.html

DM6EQVT	DI	DM6EQVT
DM6EQVT	DN	US9682983, 1
DM6EQVT	MI	TTPKHTZ
DM6EQVT	MN	Activin receptor type IB (ACVR1B)
DM6EQVT	MT	DTT
DM6EQVT	MA	Inhibitor
DM6EQVT	RN	BMP inhibitors and methods of use thereof. US9682983.
DM6EQVT	RU	http://www.freepatentsonline.com/US9682983.html

DM6R1YP	DI	DM6R1YP
DM6R1YP	DN	US9682983, 33
DM6R1YP	MI	TTPKHTZ
DM6R1YP	MN	Activin receptor type IB (ACVR1B)
DM6R1YP	MT	DTT
DM6R1YP	MA	Inhibitor
DM6R1YP	RN	BMP inhibitors and methods of use thereof. US9682983.
DM6R1YP	RU	http://www.freepatentsonline.com/US9682983.html

DMVGQXK	DI	DMVGQXK
DMVGQXK	DN	US9682991, 2
DMVGQXK	MI	TTCGOIN
DMVGQXK	MN	PIM-3 protein kinase (PIM3)
DMVGQXK	MT	DTT
DMVGQXK	MA	Inhibitor
DMVGQXK	RN	Tricyclic compounds for use as kinase inhibitors. US9682991.
DMVGQXK	RU	http://www.freepatentsonline.com/US9682991.html

DMGTIP6	DI	DMGTIP6
DMGTIP6	DN	US9682991, 23
DMGTIP6	MI	TTCGOIN
DMGTIP6	MN	PIM-3 protein kinase (PIM3)
DMGTIP6	MT	DTT
DMGTIP6	MA	Inhibitor
DMGTIP6	RN	Tricyclic compounds for use as kinase inhibitors. US9682991.
DMGTIP6	RU	http://www.freepatentsonline.com/US9682991.html

DM7SQKD	DI	DM7SQKD
DM7SQKD	DN	US9682991, 7
DM7SQKD	MI	TTCGOIN
DM7SQKD	MN	PIM-3 protein kinase (PIM3)
DM7SQKD	MT	DTT
DM7SQKD	MA	Inhibitor
DM7SQKD	RN	Tricyclic compounds for use as kinase inhibitors. US9682991.
DM7SQKD	RU	http://www.freepatentsonline.com/US9682991.html

DMMCNVO	DI	DMMCNVO
DMMCNVO	DN	US9694002, 129
DMMCNVO	MI	TTANOZH
DMMCNVO	MN	SCN1A messenger RNA (SCN1A mRNA)
DMMCNVO	MT	DTT
DMMCNVO	MA	Inhibitor
DMMCNVO	RN	Substituted benzamides and methods of use thereof. US9694002.
DMMCNVO	RU	http://www.freepatentsonline.com/US9694002.html

DMV1OR0	DI	DMV1OR0
DMV1OR0	DN	US9694002, 495
DMV1OR0	MI	TTANOZH
DMV1OR0	MN	SCN1A messenger RNA (SCN1A mRNA)
DMV1OR0	MT	DTT
DMV1OR0	MA	Inhibitor
DMV1OR0	RN	Substituted benzamides and methods of use thereof. US9694002.
DMV1OR0	RU	http://www.freepatentsonline.com/US9694002.html

DM804T5	DI	DM804T5
DM804T5	DN	US9694002, 59
DM804T5	MI	TTANOZH
DM804T5	MN	SCN1A messenger RNA (SCN1A mRNA)
DM804T5	MT	DTT
DM804T5	MA	Inhibitor
DM804T5	RN	Substituted benzamides and methods of use thereof. US9694002.
DM804T5	RU	http://www.freepatentsonline.com/US9694002.html

DMZF3AQ	DI	DMZF3AQ
DMZF3AQ	DN	US9695118, 4
DMZF3AQ	MI	TTI1FPZ
DMZF3AQ	MN	Epithelial discoidin domain receptor 1 (DDR1)
DMZF3AQ	MT	DTT
DMZF3AQ	MA	Inhibitor
DMZF3AQ	RN	Benzamide derivative. US9695118.
DMZF3AQ	RU	http://www.freepatentsonline.com/US9695118.html

DMAD3VL	DI	DMAD3VL
DMAD3VL	DN	US9695118, 8
DMAD3VL	MI	TTI1FPZ
DMAD3VL	MN	Epithelial discoidin domain receptor 1 (DDR1)
DMAD3VL	MT	DTT
DMAD3VL	MA	Inhibitor
DMAD3VL	RN	Benzamide derivative. US9695118.
DMAD3VL	RU	http://www.freepatentsonline.com/US9695118.html

DMSI09Y	DI	DMSI09Y
DMSI09Y	DN	US9707205, 40
DMSI09Y	MI	TTDYP7I
DMSI09Y	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DMSI09Y	MT	DTT
DMSI09Y	MA	Inhibitor
DMSI09Y	RN	S1P receptors modulators and their use thereof. US9707205.
DMSI09Y	RU	http://www.freepatentsonline.com/US9707205.html

DMEB59T	DI	DMEB59T
DMEB59T	DN	US9714230, 12
DMEB59T	MI	TTIG67W
DMEB59T	MN	Lysine-specific demethylase 5A (KDM5A)
DMEB59T	MT	DTT
DMEB59T	MA	Inhibitor
DMEB59T	RN	Histone demethylase inhibitors. US9714230.
DMEB59T	RU	http://www.freepatentsonline.com/US9714230.html

DMPZS16	DI	DMPZS16
DMPZS16	DN	US9714230, 46
DMPZS16	MI	TTIG67W
DMPZS16	MN	Lysine-specific demethylase 5A (KDM5A)
DMPZS16	MT	DTT
DMPZS16	MA	Inhibitor
DMPZS16	RN	Histone demethylase inhibitors. US9604961.
DMPZS16	RU	http://www.freepatentsonline.com/US9604961.html

DMOVEZF	DI	DMOVEZF
DMOVEZF	DN	VAPBGCRAUJRZPO-UHFFFAOYSA-N
DMOVEZF	MI	TTI1FPZ
DMOVEZF	MN	Epithelial discoidin domain receptor 1 (DDR1)
DMOVEZF	MT	DTT
DMOVEZF	MA	Inhibitor
DMOVEZF	RN	Benzamide derivative. US9695118.
DMOVEZF	RU	http://www.freepatentsonline.com/US9695118.html

DMH9ION	DI	DMH9ION
DMH9ION	DN	VFEDEOUBYBLDKN-AAFJCEBUSA-N
DMH9ION	MI	TT5U49F
DMH9ION	MN	PRKACA messenger RNA (PRKACA mRNA)
DMH9ION	MT	DTT
DMH9ION	MA	Inhibitor
DMH9ION	RN	Purine derivatives. US8846696.
DMH9ION	RU	http://www.freepatentsonline.com/US8846696.html

DMTMFNK	DI	DMTMFNK
DMTMFNK	DN	Vinyl sulfone derivative 1
DMTMFNK	MI	TT3Z6Y9
DMTMFNK	MN	Cysteines of Keap1 (KEAP1 Cysteines)
DMTMFNK	MT	DTT
DMTMFNK	MA	Modulator
DMTMFNK	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMTMFNK	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DMTMFNK	DI	DMTMFNK
DMTMFNK	DN	Vinyl sulfone derivative 1
DMTMFNK	MI	TTA6ZN2
DMTMFNK	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMTMFNK	MT	DTT
DMTMFNK	MA	Activator
DMTMFNK	RN	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
DMTMFNK	RU	https://www.ncbi.nlm.nih.gov/pubmed/28454500

DML32R8	DI	DML32R8
DML32R8	DN	VX-148
DML32R8	MI	TTL7C8Q
DML32R8	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DML32R8	MT	DTT
DML32R8	MA	Inhibitor
DML32R8	RN	Characterization of pharmacological efficacy of VX-148, a new, potent immunosuppressive inosine 5'-monophosphate dehydrogenase inhibitor. J Pharmacol Exp Ther. 2002 Sep;302(3):1272-7.
DML32R8	RU	https://pubmed.ncbi.nlm.nih.gov/12183689

DMIULVJ	DI	DMIULVJ
DMIULVJ	DN	Xanthine derivative 1
DMIULVJ	MI	TTDIGC1
DMIULVJ	MN	Dipeptidyl peptidase 4 (DPP-4)
DMIULVJ	MT	DTT
DMIULVJ	MA	Inhibitor
DMIULVJ	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMIULVJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DMNXJ8G	DI	DMNXJ8G
DMNXJ8G	DN	Xanthine/amino piperidine compound 1
DMNXJ8G	MI	TTDIGC1
DMNXJ8G	MN	Dipeptidyl peptidase 4 (DPP-4)
DMNXJ8G	MT	DTT
DMNXJ8G	MA	Inhibitor
DMNXJ8G	RN	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
DMNXJ8G	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482888

DM5Q93Y	DI	DM5Q93Y
DM5Q93Y	DN	XHPNYYOUZWOWNT-PYUWXLGESA-N
DM5Q93Y	MI	TT5U49F
DM5Q93Y	MN	PRKACA messenger RNA (PRKACA mRNA)
DM5Q93Y	MT	DTT
DM5Q93Y	MA	Inhibitor
DM5Q93Y	RN	Purine derivatives. US8846696.
DM5Q93Y	RU	http://www.freepatentsonline.com/US8846696.html

DMHAVYS	DI	DMHAVYS
DMHAVYS	DN	Y-9680
DMHAVYS	MI	TTUWGRA
DMHAVYS	MN	Protein kinase C zeta (PRKCZ)
DMHAVYS	MT	DTT
DMHAVYS	MA	Inhibitor
DMHAVYS	RN	Compounds, formulations, and methods of protein kinase C inhibition. US8889672.
DMHAVYS	RU	http://www.freepatentsonline.com/US8889672.html

DMA91FM	DI	DMA91FM
DMA91FM	DN	YYDJCLCSBYCSCO-UHFFFAOYSA-N
DMA91FM	MI	TTDYP7I
DMA91FM	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DMA91FM	MT	DTT
DMA91FM	MA	Inhibitor
DMA91FM	RN	6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (S1P) receptor for the treatment of multiple sclerosis. US9150519.
DMA91FM	RU	http://www.freepatentsonline.com/US9150519.html

DMUOZEJ	DI	DMUOZEJ
DMUOZEJ	DN	Z223457004
DMUOZEJ	MI	TT3RMNA
DMUOZEJ	MN	Chymotrypsin-C (CLCR)
DMUOZEJ	MT	DTT
DMUOZEJ	MA	Inhibitor
DMUOZEJ	RN	Benzoxazinone derivatives for treatment of skin diseases. US9695194.
DMUOZEJ	RU	http://www.freepatentsonline.com/US9695194.html

DMRBFUA	DI	DMRBFUA
DMRBFUA	DN	Z90308237
DMRBFUA	MI	TT3RMNA
DMRBFUA	MN	Chymotrypsin-C (CLCR)
DMRBFUA	MT	DTT
DMRBFUA	MA	Inhibitor
DMRBFUA	RN	Benzoxazinone derivatives for treatment of skin diseases. US9695194.
DMRBFUA	RU	http://www.freepatentsonline.com/US9695194.html

DMLZDAK	DI	DMLZDAK
DMLZDAK	DN	ZINC19658740
DMLZDAK	MI	TTB9CIL
DMLZDAK	MN	Prokineticin receptor-1 (PROKR1)
DMLZDAK	MT	DTT
DMLZDAK	MA	Inhibitor
DMLZDAK	RN	Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases. US10167273.
DMLZDAK	RU	http://www.freepatentsonline.com/US10167273.html

DMYCH0G	DI	DMYCH0G
DMYCH0G	DN	ZINC584606052
DMYCH0G	MI	TT6A59G
DMYCH0G	MN	Phosphodiesterase 4C (PDE4C)
DMYCH0G	MT	DTT
DMYCH0G	MA	Inhibitor
DMYCH0G	RN	Imidazopyridazine compounds. US9598421.
DMYCH0G	RU	http://www.freepatentsonline.com/US9598421.html

DMW9P6U	DI	DMW9P6U
DMW9P6U	DN	ZINC915379
DMW9P6U	MI	TTLKF5M
DMW9P6U	MN	NAD-dependent deacetylase sirtuin-2 (SIRT2)
DMW9P6U	MT	DTT
DMW9P6U	MA	Inhibitor
DMW9P6U	RN	Small molecule activators of NRF2 pathway. US9737525.
DMW9P6U	RU	http://www.freepatentsonline.com/US9737525.html

DMR0F4H	DI	DMR0F4H
DMR0F4H	DN	ZINC959121
DMR0F4H	MI	TTU3WV6
DMR0F4H	MN	SRSF protein kinase 1 (SRPK1)
DMR0F4H	MT	DTT
DMR0F4H	MA	Inhibitor
DMR0F4H	RN	Piperazine derivatives for treating disorders. US9695160.
DMR0F4H	RU	http://www.freepatentsonline.com/US9695160.html

DM3OPBR	DI	DM3OPBR
DM3OPBR	DN	ZNFTXQFGUIKQQE-UHFFFAOYSA-N
DM3OPBR	MI	TTDYP7I
DM3OPBR	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DM3OPBR	MT	DTT
DM3OPBR	MA	Inhibitor
DM3OPBR	RN	6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (S1P) receptor for the treatment of multiple sclerosis. US9150519.
DM3OPBR	RU	http://www.freepatentsonline.com/US9150519.html

DMXYA5K	DI	DMXYA5K
DMXYA5K	DN	Agomelatine
DMXYA5K	MI	DEJGDUW
DMXYA5K	MN	Cytochrome P450 1A2 (CYP1A2)
DMXYA5K	MT	DME
DMXYA5K	MA	Metabolism
DMXYA5K	RN	Does celecoxib inhibit agomelatine metabolism via CYP2C9 or CYP1A2? Drug Des Devel Ther. 2018 Jul 11;12:2169-2172.
DMXYA5K	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30034221

DMXYA5K	DI	DMXYA5K
DMXYA5K	DN	Agomelatine
DMXYA5K	MI	TT0WAIE
DMXYA5K	MN	Melatonin receptor type 1A (MTNR1A)
DMXYA5K	MT	DTT
DMXYA5K	MA	Agonist
DMXYA5K	RN	Melatonin receptor agonists: SAR and applications to the treatment of sleep-wake disorders. Curr Top Med Chem. 2008;8(11):954-68.
DMXYA5K	RU	https://pubmed.ncbi.nlm.nih.gov/18673165

DMYJ8Z3	DI	DMYJ8Z3
DMYJ8Z3	DN	Alprenolol
DMYJ8Z3	MI	TTR6W5O
DMYJ8Z3	MN	Adrenergic receptor beta-1 (ADRB1)
DMYJ8Z3	MT	DTT
DMYJ8Z3	MA	Antagonist
DMYJ8Z3	RN	Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation. Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14555-60.
DMYJ8Z3	RU	https://pubmed.ncbi.nlm.nih.gov/18787115

DMYJ8Z3	DI	DMYJ8Z3
DMYJ8Z3	DN	Alprenolol
DMYJ8Z3	MI	DECB0K3
DMYJ8Z3	MN	Cytochrome P450 2D6 (CYP2D6)
DMYJ8Z3	MT	DME
DMYJ8Z3	MA	Metabolism
DMYJ8Z3	RN	Influence of the CYP2D6 isoenzyme in patients treated with venlafaxine for major depressive disorder: clinical and economic consequences. PLoS One. 2014 Nov 4;9(11):e90453.
DMYJ8Z3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25369508

DMYJ8Z3	DI	DMYJ8Z3
DMYJ8Z3	DN	Alprenolol
DMYJ8Z3	MI	DTUGYRD
DMYJ8Z3	MN	P-glycoprotein 1 (ABCB1)
DMYJ8Z3	MT	DTP
DMYJ8Z3	MA	Substrate
DMYJ8Z3	RN	A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26.
DMYJ8Z3	RU	https://doi.org/10.1007/s00210-008-0345-0

DMGVNJ7	DI	DMGVNJ7
DMGVNJ7	DN	Amineptine
DMGVNJ7	MI	TTVBI8W
DMGVNJ7	MN	Dopamine transporter (DAT)
DMGVNJ7	MT	DTT
DMGVNJ7	MA	Inhibitor
DMGVNJ7	RN	Amineptine in the treatment of amphetamine withdrawal: a placebo-controlled, randomised, double-blind study. J Med Assoc Thai. 1997 Sep;80(9):587-92.
DMGVNJ7	RU	https://pubmed.ncbi.nlm.nih.gov/9347672

DMQ9RBV	DI	DMQ9RBV
DMQ9RBV	DN	Aminopterin
DMQ9RBV	MI	TT9SL3Q
DMQ9RBV	MN	Polypeptide deformylase (PDF)
DMQ9RBV	MT	DTT
DMQ9RBV	MA	Inhibitor
DMQ9RBV	RN	Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer. 2003 Feb 20;103(5):587-99.
DMQ9RBV	RU	https://pubmed.ncbi.nlm.nih.gov/12494465

DM2HN6Q	DI	DM2HN6Q
DM2HN6Q	DN	Astemizole
DM2HN6Q	MI	DECB0K3
DM2HN6Q	MN	Cytochrome P450 2D6 (CYP2D6)
DM2HN6Q	MT	DME
DM2HN6Q	MA	Metabolism
DM2HN6Q	RN	Involvement of multiple human cytochromes P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine. Br J Clin Pharmacol. 2001 Feb;51(2):133-42.
DM2HN6Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11259984

DM2HN6Q	DI	DM2HN6Q
DM2HN6Q	DN	Astemizole
DM2HN6Q	MI	DERSX5P
DM2HN6Q	MN	Cytochrome P450 2J2 (CYP2J2)
DM2HN6Q	MT	DME
DM2HN6Q	MA	Metabolism
DM2HN6Q	RN	Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity. Drug Metab Dispos. 2012 May;40(5):943-51.
DM2HN6Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22328583

DM2HN6Q	DI	DM2HN6Q
DM2HN6Q	DN	Astemizole
DM2HN6Q	MI	DE4LYSA
DM2HN6Q	MN	Cytochrome P450 3A4 (CYP3A4)
DM2HN6Q	MT	DME
DM2HN6Q	MA	Metabolism
DM2HN6Q	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM2HN6Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM2HN6Q	DI	DM2HN6Q
DM2HN6Q	DN	Astemizole
DM2HN6Q	MI	DEIBDNY
DM2HN6Q	MN	Cytochrome P450 3A5 (CYP3A5)
DM2HN6Q	MT	DME
DM2HN6Q	MA	Metabolism
DM2HN6Q	RN	Drug Interactions Flockhart Table
DM2HN6Q	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM2HN6Q	DI	DM2HN6Q
DM2HN6Q	DN	Astemizole
DM2HN6Q	MI	DERD86B
DM2HN6Q	MN	Cytochrome P450 3A7 (CYP3A7)
DM2HN6Q	MT	DME
DM2HN6Q	MA	Metabolism
DM2HN6Q	RN	Drug Interactions Flockhart Table
DM2HN6Q	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM2HN6Q	DI	DM2HN6Q
DM2HN6Q	DN	Astemizole
DM2HN6Q	MI	TTTIBOJ
DM2HN6Q	MN	Histamine H1 receptor (H1R)
DM2HN6Q	MT	DTT
DM2HN6Q	MA	Antagonist
DM2HN6Q	RN	Histamine H1 receptor induces cytosolic calcium increase and aquaporin translocation in human salivary gland cells. J Pharmacol Exp Ther. 2009 Aug;330(2):403-12.
DM2HN6Q	RU	https://pubmed.ncbi.nlm.nih.gov/19443731

DM2HN6Q	DI	DM2HN6Q
DM2HN6Q	DN	Astemizole
DM2HN6Q	MI	DTUGYRD
DM2HN6Q	MN	P-glycoprotein 1 (ABCB1)
DM2HN6Q	MT	DTP
DM2HN6Q	MA	Substrate
DM2HN6Q	RN	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
DM2HN6Q	RU	https://doi.org/10.1016/j.addr.2011.12.008

DM0J92L	DI	DM0J92L
DM0J92L	DN	Benactyzine
DM0J92L	MI	TTH18TF
DM0J92L	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DM0J92L	MT	DTT
DM0J92L	MA	Antagonist
DM0J92L	RN	The muscarinic antagonists aprophen and benactyzine are noncompetitive inhibitors of the nicotinic acetylcholine receptor. Mol Pharmacol. 1987 Nov;32(5):678-85.
DM0J92L	RU	https://pubmed.ncbi.nlm.nih.gov/3683366

DM5ZOX8	DI	DM5ZOX8
DM5ZOX8	DN	Benoxaprofen
DM5ZOX8	MI	TTK3C21
DM5ZOX8	MN	Acetoacetyl-CoA thiolase (ACAT1)
DM5ZOX8	MT	DTT
DM5ZOX8	MA	Inhibitor
DM5ZOX8	RN	Inhibition of lyso-PAF: acetyl-CoA acetyltransferase by salicylates and other compounds. Prostaglandins. 1988 Jun;35(6):939-44.
DM5ZOX8	RU	https://pubmed.ncbi.nlm.nih.gov/2903520

DMJMHNL	DI	DMJMHNL
DMJMHNL	DN	Bethanidine
DMJMHNL	MI	TTR6W5O
DMJMHNL	MN	Adrenergic receptor beta-1 (ADRB1)
DMJMHNL	MT	DTT
DMJMHNL	MA	Antagonist
DMJMHNL	RN	Withdrawal syndromes and the cessation of antihypertensive therapy. Arch Intern Med. 1981 Aug;141(9):1125-7.
DMJMHNL	RU	https://pubmed.ncbi.nlm.nih.gov/6114720

DMPJKRL	DI	DMPJKRL
DMPJKRL	DN	Bithionol
DMPJKRL	MI	TTG5QB7
DMPJKRL	MN	Calpain-2 (CAPN2)
DMPJKRL	MT	DTT
DMPJKRL	MA	Inhibitor
DMPJKRL	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMPJKRL	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMPJKRL	DI	DMPJKRL
DMPJKRL	DN	Bithionol
DMPJKRL	MI	TTZAYWL
DMPJKRL	MN	Estrogen receptor (ESR)
DMPJKRL	MT	DTT
DMPJKRL	MA	Inhibitor
DMPJKRL	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMPJKRL	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMPJKRL	DI	DMPJKRL
DMPJKRL	DN	Bithionol
DMPJKRL	MI	TTOM3J0
DMPJKRL	MN	Estrogen receptor beta (ESR2)
DMPJKRL	MT	DTT
DMPJKRL	MA	Inhibitor
DMPJKRL	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMPJKRL	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMPJKRL	DI	DMPJKRL
DMPJKRL	DN	Bithionol
DMPJKRL	MI	TTL53M6
DMPJKRL	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DMPJKRL	MT	DTT
DMPJKRL	MA	Inhibitor
DMPJKRL	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMPJKRL	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMBQYO0	DI	DMBQYO0
DMBQYO0	DN	Casopitant
DMBQYO0	MI	TTZPO1L
DMBQYO0	MN	Substance-P receptor (TACR1)
DMBQYO0	MT	DTT
DMBQYO0	MA	Antagonist
DMBQYO0	RN	Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
DMBQYO0	RU	https://pubmed.ncbi.nlm.nih.gov/18172433

DM4Y95F	DI	DM4Y95F
DM4Y95F	DN	Cephaloridine
DM4Y95F	MI	DET9I1W
DM4Y95F	MN	Beta-lactamase (blaB)
DM4Y95F	MT	DME
DM4Y95F	MA	Metabolism
DM4Y95F	RN	Purification and characterization of a new beta-lactamase from Bacteroides uniformis. Antimicrob Agents Chemother. 1995 Jul;39(7):1458-61.
DM4Y95F	RU	https://pubmed.ncbi.nlm.nih.gov/7492085

DM4Y95F	DI	DM4Y95F
DM4Y95F	DN	Cephaloridine
DM4Y95F	MI	DEKGVS4
DM4Y95F	MN	Beta-lactamase (blaB)
DM4Y95F	MT	DME
DM4Y95F	MA	Metabolism
DM4Y95F	RN	Characterization of the penA and penR genes of Burkholderia cepacia 249 which encode the chromosomal class A penicillinase and its LysR-type transcriptional regulator. Antimicrob Agents Chemother. 1997 Nov;41(11):2399-405.
DM4Y95F	RU	https://pubmed.ncbi.nlm.nih.gov/9371340

DM4Y95F	DI	DM4Y95F
DM4Y95F	DN	Cephaloridine
DM4Y95F	MI	DES5XRU
DM4Y95F	MN	Cytochrome P450 2C8 (CYP2C8)
DM4Y95F	MT	DME
DM4Y95F	MA	Metabolism
DM4Y95F	RN	Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther. 2004 Oct;311(1):228-36.
DM4Y95F	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15194707

DM4Y95F	DI	DM4Y95F
DM4Y95F	DN	Cephaloridine
DM4Y95F	MI	DTVP67E
DM4Y95F	MN	Organic anion transporter 3 (SLC22A8)
DM4Y95F	MT	DTP
DM4Y95F	MA	Substrate
DM4Y95F	RN	Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. Biochem Pharmacol. 2005 Oct 1;70(7):1104-13.
DM4Y95F	RU	http://www.ncbi.nlm.nih.gov/pubmed/16098483

DM4Y95F	DI	DM4Y95F
DM4Y95F	DN	Cephaloridine
DM4Y95F	MI	DT9G7XN
DM4Y95F	MN	Peptide transporter 1 (SLC15A1)
DM4Y95F	MT	DTP
DM4Y95F	MA	Substrate
DM4Y95F	RN	Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res. 1999 Jan;16(1):55-61.
DM4Y95F	RU	https://doi.org/10.1023/A:1018814627484

DMSV2WZ	DI	DMSV2WZ
DMSV2WZ	DN	Chlorotrianisene
DMSV2WZ	MI	TTZAYWL
DMSV2WZ	MN	Estrogen receptor (ESR)
DMSV2WZ	MT	DTT
DMSV2WZ	MA	Binder
DMSV2WZ	RN	Inactivation of the uterine estrogen receptor binding of estradiol during P-450 catalyzed metabolism of chlorotrianisene (TACE). Speculation that TACE antiestrogenic activity involves covalent binding to the estrogen receptor. FEBS Lett. 1990 Feb 12;261(1):59-62.
DMSV2WZ	RU	https://pubmed.ncbi.nlm.nih.gov/2307235

DM746BZ	DI	DM746BZ
DM746BZ	DN	Clioquinol
DM746BZ	MI	TTUNARX
DM746BZ	MN	Carbonic anhydrase (CA)
DM746BZ	MT	DTT
DM746BZ	MA	Inhibitor
DM746BZ	RN	Carbonic anhydrase inhibitors: Inhibition of the new membrane-associated isoform XV with phenols. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3593-6.
DM746BZ	RU	https://pubmed.ncbi.nlm.nih.gov/18501600

DM746BZ	DI	DM746BZ
DM746BZ	DN	Clioquinol
DM746BZ	MI	TTQW87Y
DM746BZ	MN	Opioid receptor kappa (OPRK1)
DM746BZ	MT	DTT
DM746BZ	MA	Inhibitor
DM746BZ	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DM746BZ	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DM746BZ	DI	DM746BZ
DM746BZ	DN	Clioquinol
DM746BZ	MI	DEYWLRK
DM746BZ	MN	Sulfotransferase 1A1 (SULT1A1)
DM746BZ	MT	DME
DM746BZ	MA	Metabolism
DM746BZ	RN	Clioquinol is sulfated by human jejunum cytosol and SULT1A3, a human-specific dopamine sulfotransferase. Toxicol Lett. 2011 Oct 10;206(2):229-33.
DM746BZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21820498

DMJ7YDS	DI	DMJ7YDS
DMJ7YDS	DN	Dexfenfluramine
DMJ7YDS	MI	DEJGDUW
DMJ7YDS	MN	Cytochrome P450 1A2 (CYP1A2)
DMJ7YDS	MT	DME
DMJ7YDS	MA	Metabolism
DMJ7YDS	RN	Appetite suppressant drugs as inhibitors of human cytochromes P450: in vitro inhibition of P450-2D6 by D- and L-fenfluramine, but not phentermine. J Clin Psychopharmacol. 1998 Aug;18(4):338-41.
DMJ7YDS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9690701

DMJ7YDS	DI	DMJ7YDS
DMJ7YDS	DN	Dexfenfluramine
DMJ7YDS	MI	DECB0K3
DMJ7YDS	MN	Cytochrome P450 2D6 (CYP2D6)
DMJ7YDS	MT	DME
DMJ7YDS	MA	Metabolism
DMJ7YDS	RN	Metabolism of dexfenfluramine in human liver microsomes and by recombinant enzymes: role of CYP2D6 and 1A2. Pharmacogenetics. 1998 Oct;8(5):423-32.
DMJ7YDS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9825834

DMJ7YDS	DI	DMJ7YDS
DMJ7YDS	DN	Dexfenfluramine
DMJ7YDS	MI	TT3ROYC
DMJ7YDS	MN	Serotonin transporter (SERT)
DMJ7YDS	MT	DTT
DMJ7YDS	MA	Inhibitor
DMJ7YDS	RN	Serotonergic drugs : effects on appetite expression and use for the treatment of obesity. Drugs. 2007;67(1):27-55.
DMJ7YDS	RU	https://pubmed.ncbi.nlm.nih.gov/17209663

DMRZ5D7	DI	DMRZ5D7
DMRZ5D7	DN	Droxicam
DMRZ5D7	MI	TTK0943
DMRZ5D7	MN	Prostaglandin G/H synthase (COX)
DMRZ5D7	MT	DTT
DMRZ5D7	MA	Modulator
DMRZ5D7	RN	Pharmacokinetic profile of droxicam. Eur J Rheumatol Inflamm. 1991;11(4):10-4.
DMRZ5D7	RU	https://pubmed.ncbi.nlm.nih.gov/1365484

DMV5KR3	DI	DMV5KR3
DMV5KR3	DN	Ebrotidine
DMV5KR3	MI	TTQHJ1K
DMV5KR3	MN	Histamine H2 receptor (H2R)
DMV5KR3	MT	DTT
DMV5KR3	MA	Modulator
DMV5KR3	RN	Histamine H2-receptor antagonist action of ebrotidine. Effects on gastric acid secretion, gastrin levels and NSAID-induced gastrotoxicity in the rat. Arzneimittelforschung. 1997 Apr;47(4A):439-46.
DMV5KR3	RU	https://pubmed.ncbi.nlm.nih.gov/9205740

DMK0GHV	DI	DMK0GHV
DMK0GHV	DN	Encainide
DMK0GHV	MI	DECB0K3
DMK0GHV	MN	Cytochrome P450 2D6 (CYP2D6)
DMK0GHV	MT	DME
DMK0GHV	MA	Metabolism
DMK0GHV	RN	Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet. 2000 Feb;38(2):111-80.
DMK0GHV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10709776

DMK0GHV	DI	DMK0GHV
DMK0GHV	DN	Encainide
DMK0GHV	MI	TTZOVE0
DMK0GHV	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DMK0GHV	MT	DTT
DMK0GHV	MA	Blocker
DMK0GHV	RN	From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials. Am J Cardiol. 1996 Aug 29;78(4A):28-33.
DMK0GHV	RU	https://pubmed.ncbi.nlm.nih.gov/8780326

DM67PWD	DI	DM67PWD
DM67PWD	DN	Etilefrine
DM67PWD	MI	TTVIREA
DM67PWD	MN	Adrenergic receptor (ADR)
DM67PWD	MT	DTT
DM67PWD	MA	Modulator
DM67PWD	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DM67PWD	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM67PWD	DI	DM67PWD
DM67PWD	DN	Etilefrine
DM67PWD	MI	DT6201N
DM67PWD	MN	Organic cation transporter 3 (SLC22A3)
DM67PWD	MT	DTP
DM67PWD	MA	Substrate
DM67PWD	RN	Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol. 2005 Dec 5;70(12):1851-60.
DM67PWD	RU	http://www.ncbi.nlm.nih.gov/pubmed/16263091

DMVG9YN	DI	DMVG9YN
DMVG9YN	DN	Fencamfamine
DMVG9YN	MI	TTEX248
DMVG9YN	MN	Dopamine D2 receptor (D2R)
DMVG9YN	MT	DTT
DMVG9YN	MA	Agonist
DMVG9YN	RN	Dopamine uptake inhibiting versus dopamine releasing properties of fencamfamine: an in vitro study. Biochem Pharmacol. 1983 Aug 1;32(15):2329-31.
DMVG9YN	RU	https://pubmed.ncbi.nlm.nih.gov/6136281

DMH6NG5	DI	DMH6NG5
DMH6NG5	DN	Fendiline
DMH6NG5	MI	TT0K1SC
DMH6NG5	MN	5-HT 2B receptor (HTR2B)
DMH6NG5	MT	DTT
DMH6NG5	MA	Inhibitor
DMH6NG5	RN	Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify no... J Med Chem. 2010 Nov 11;53(21):7573-86.
DMH6NG5	RU	https://pubmed.ncbi.nlm.nih.gov/20958049

DMH6NG5	DI	DMH6NG5
DMH6NG5	DN	Fendiline
DMH6NG5	MI	DE4LYSA
DMH6NG5	MN	Cytochrome P450 3A4 (CYP3A4)
DMH6NG5	MT	DME
DMH6NG5	MA	Metabolism
DMH6NG5	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DMH6NG5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DMY9P37	DI	DMY9P37
DMY9P37	DN	Flupenthixol
DMY9P37	MI	TTEX248
DMY9P37	MN	Dopamine D2 receptor (D2R)
DMY9P37	MT	DTT
DMY9P37	MA	Antagonist
DMY9P37	RN	A role for medial prefrontal dopaminergic innervation in instrumental conditioning. J Neurosci. 2009 May 20;29(20):6599-606.
DMY9P37	RU	https://pubmed.ncbi.nlm.nih.gov/19458230

DMWIDJK	DI	DMWIDJK
DMWIDJK	DN	FORMESTANE
DMWIDJK	MI	TTSZLWK
DMWIDJK	MN	Aromatase (CYP19A1)
DMWIDJK	MT	DTT
DMWIDJK	MA	Inhibitor
DMWIDJK	RN	The taiwaniaquinoids: a review. J Nat Prod. 2010 Feb 26;73(2):284-98.
DMWIDJK	RU	https://pubmed.ncbi.nlm.nih.gov/20102168

DM9AGWQ	DI	DM9AGWQ
DM9AGWQ	DN	HEXESTROL
DM9AGWQ	MI	TTZAYWL
DM9AGWQ	MN	Estrogen receptor (ESR)
DM9AGWQ	MT	DTT
DM9AGWQ	MA	Inhibitor
DM9AGWQ	RN	Bone targeted drugs 2. synthesis of estrogens with hydroxyapatite affinity, Bioorg. Med. Chem. Lett. 6(9):1047-1050 (1996).
DM9AGWQ	RU	http://www.sciencedirect.com/science/article/pii/0960894X96001655

DM9AGWQ	DI	DM9AGWQ
DM9AGWQ	DN	HEXESTROL
DM9AGWQ	MI	TTOM3J0
DM9AGWQ	MN	Estrogen receptor beta (ESR2)
DM9AGWQ	MT	DTT
DM9AGWQ	MA	Inhibitor
DM9AGWQ	RN	Bone targeted drugs 2. synthesis of estrogens with hydroxyapatite affinity, Bioorg. Med. Chem. Lett. 6(9):1047-1050 (1996).
DM9AGWQ	RU	http://www.sciencedirect.com/science/article/pii/0960894X96001655

DMSO2T9	DI	DMSO2T9
DMSO2T9	DN	Ibuproxam
DMSO2T9	MI	TT2J34L
DMSO2T9	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMSO2T9	MT	DTT
DMSO2T9	MA	Inhibitor
DMSO2T9	RN	In vivo characterization of hydroxamic acid inhibitors of 5-lipoxygenase. J Med Chem. 1987 Nov;30(11):2121-6.
DMSO2T9	RU	https://pubmed.ncbi.nlm.nih.gov/3669019

DM5QSKN	DI	DM5QSKN
DM5QSKN	DN	INDOPROFEN
DM5QSKN	MI	TTMWT8Z
DM5QSKN	MN	C-X-C chemokine receptor type 1 (CXCR1)
DM5QSKN	MT	DTT
DM5QSKN	MA	Inhibitor
DM5QSKN	RN	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
DM5QSKN	RU	https://pubmed.ncbi.nlm.nih.gov/15974585

DM5QSKN	DI	DM5QSKN
DM5QSKN	DN	INDOPROFEN
DM5QSKN	MI	TT30C9G
DM5QSKN	MN	C-X-C chemokine receptor type 2 (CXCR2)
DM5QSKN	MT	DTT
DM5QSKN	MA	Inhibitor
DM5QSKN	RN	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
DM5QSKN	RU	https://pubmed.ncbi.nlm.nih.gov/15974585

DM5QSKN	DI	DM5QSKN
DM5QSKN	DN	INDOPROFEN
DM5QSKN	MI	TTIV96N
DM5QSKN	MN	Fatty acid-binding protein 1 (FABP1)
DM5QSKN	MT	DTT
DM5QSKN	MA	Inhibitor
DM5QSKN	RN	Characterization of the drug binding specificity of rat liver fatty acid binding protein. J Med Chem. 2008 Jul 10;51(13):3755-64.
DM5QSKN	RU	https://pubmed.ncbi.nlm.nih.gov/18533710

DM5QSKN	DI	DM5QSKN
DM5QSKN	DN	INDOPROFEN
DM5QSKN	MI	TT8NGED
DM5QSKN	MN	Prostaglandin G/H synthase 1 (COX-1)
DM5QSKN	MT	DTT
DM5QSKN	MA	Inhibitor
DM5QSKN	RN	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
DM5QSKN	RU	https://pubmed.ncbi.nlm.nih.gov/15974585

DM5QSKN	DI	DM5QSKN
DM5QSKN	DN	INDOPROFEN
DM5QSKN	MI	TTVKILB
DM5QSKN	MN	Prostaglandin G/H synthase 2 (COX-2)
DM5QSKN	MT	DTT
DM5QSKN	MA	Inhibitor
DM5QSKN	RN	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
DM5QSKN	RU	https://pubmed.ncbi.nlm.nih.gov/15974585

DMNSJFD	DI	DMNSJFD
DMNSJFD	DN	Indoramin
DMNSJFD	MI	TT34BHT
DMNSJFD	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMNSJFD	MT	DTT
DMNSJFD	MA	Inhibitor
DMNSJFD	RN	Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem. 1995 Sep 1;38(18):3415-44.
DMNSJFD	RU	https://pubmed.ncbi.nlm.nih.gov/7658428

DMNSJFD	DI	DMNSJFD
DMNSJFD	DN	Indoramin
DMNSJFD	MI	TTWM4TY
DMNSJFD	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMNSJFD	MT	DTT
DMNSJFD	MA	Inhibitor
DMNSJFD	RN	Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem. 1995 Sep 1;38(18):3415-44.
DMNSJFD	RU	https://pubmed.ncbi.nlm.nih.gov/7658428

DMNSJFD	DI	DMNSJFD
DMNSJFD	DN	Indoramin
DMNSJFD	MI	TT2NUT5
DMNSJFD	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMNSJFD	MT	DTT
DMNSJFD	MA	Inhibitor
DMNSJFD	RN	Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem. 1995 Sep 1;38(18):3415-44.
DMNSJFD	RU	https://pubmed.ncbi.nlm.nih.gov/7658428

DMNSJFD	DI	DMNSJFD
DMNSJFD	DN	Indoramin
DMNSJFD	MI	DECB0K3
DMNSJFD	MN	Cytochrome P450 2D6 (CYP2D6)
DMNSJFD	MT	DME
DMNSJFD	MA	Metabolism
DMNSJFD	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMNSJFD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMGTBC7	DI	DMGTBC7
DMGTBC7	DN	ISIS 2922
DMGTBC7	MI	TTS92NQ
DMGTBC7	MN	Cytomegalovirus DNA polymerase messenger RNA (CMV DNA polymerase mRNA)
DMGTBC7	MT	DTT
DMGTBC7	RN	US patent application no. 5,442,049, Oligonucleotides for modulating the effects of cytomegalovirus infections.
DMGTBC7	RU	http://www.patentbuddy.com/Patent/5442049?ft=true&sr=true

DMMS2J5	DI	DMMS2J5
DMMS2J5	DN	Isoxicam
DMMS2J5	MI	DTUGYRD
DMMS2J5	MN	P-glycoprotein 1 (ABCB1)
DMMS2J5	MT	DTP
DMMS2J5	MA	Substrate
DMMS2J5	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMMS2J5	RU	https://doi.org/10.1007/s11095-012-0935-x

DMACMLO	DI	DMACMLO
DMACMLO	DN	LYSERGIC ACID DIETHYLAMIDE
DMACMLO	MI	TTSQIFT
DMACMLO	MN	5-HT 1A receptor (HTR1A)
DMACMLO	MT	DTT
DMACMLO	MA	Inhibitor
DMACMLO	RN	Stereoselective LSD-like activity in a series of d-lysergic acid amides of (R)- and (S)-2-aminoalkanes. J Med Chem. 1995 Mar 17;38(6):958-66.
DMACMLO	RU	https://pubmed.ncbi.nlm.nih.gov/7699712

DMACMLO	DI	DMACMLO
DMACMLO	DN	LYSERGIC ACID DIETHYLAMIDE
DMACMLO	MI	TTJQOD7
DMACMLO	MN	5-HT 2A receptor (HTR2A)
DMACMLO	MT	DTT
DMACMLO	MA	Inhibitor
DMACMLO	RN	C-(4,5,6-trimethoxyindan-1-yl)methanamine: a mescaline analogue designed using a homology model of the 5-HT2A receptor. J Med Chem. 2006 Jul 13;49(14):4269-74.
DMACMLO	RU	https://pubmed.ncbi.nlm.nih.gov/16821786

DM79GRO	DI	DM79GRO
DM79GRO	DN	Metamizole
DM79GRO	MI	TT8NGED
DM79GRO	MN	Prostaglandin G/H synthase 1 (COX-1)
DM79GRO	MT	DTT
DM79GRO	MA	Inhibitor
DM79GRO	RN	Mechanisms of action of paracetamol and related analgesics. Inflammopharmacology. 2003;11(4):401-13.
DM79GRO	RU	https://pubmed.ncbi.nlm.nih.gov/15035793

DM79GRO	DI	DM79GRO
DM79GRO	DN	Metamizole
DM79GRO	MI	DEZV4AP
DM79GRO	MN	RNA cytidine acetyltransferase (hALP)
DM79GRO	MT	DME
DM79GRO	MA	Metabolism
DM79GRO	RN	N-acetyltransferase 2 polymorphisms and susceptibility to infant leukemia with maternal exposure to dipyrone during pregnancy. Cancer Epidemiol Biomarkers Prev. 2010 Dec;19(12):3037-43.
DM79GRO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20884738

DMW9NY0	DI	DMW9NY0
DMW9NY0	DN	Methaqualone
DMW9NY0	MI	DE4LYSA
DMW9NY0	MN	Cytochrome P450 3A4 (CYP3A4)
DMW9NY0	MT	DME
DMW9NY0	MA	Metabolism
DMW9NY0	RN	Assessment of the stereoselective metabolism of methaqualone in man by capillary electrophoresis. Electrophoresis. 2003 Aug;24(15):2598-607.
DMW9NY0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12900872

DMCP2TS	DI	DMCP2TS
DMCP2TS	DN	Nomifensine
DMCP2TS	MI	TTEX248
DMCP2TS	MN	Dopamine D2 receptor (D2R)
DMCP2TS	MT	DTT
DMCP2TS	MA	Antagonist
DMCP2TS	RN	Pharmacologically induced, subsecond dopamine transients in the caudate-putamen of the anesthetized rat. Synapse. 2007 Jan;61(1):37-9.
DMCP2TS	RU	https://pubmed.ncbi.nlm.nih.gov/17068772

DMDKXYC	DI	DMDKXYC
DMDKXYC	DN	Parabis
DMDKXYC	MI	DTI7UX6
DMDKXYC	MN	Breast cancer resistance protein (ABCG2)
DMDKXYC	MT	DTP
DMDKXYC	MA	Substrate
DMDKXYC	RN	Human and rat ABC transporter efflux of bisphenol a and bisphenol a glucuronide: interspecies comparison and implications for pharmacokinetic assessment. Toxicol Sci. 2012 Aug;128(2):317-25.
DMDKXYC	RU	https://doi.org/10.1093/toxsci/kfs167

DMRQAM0	DI	DMRQAM0
DMRQAM0	DN	Phenacetin
DMRQAM0	MI	DEKP5HX
DMRQAM0	MN	Cholesterol 24-hydroxylase (CYP46A1)
DMRQAM0	MT	DME
DMRQAM0	MA	Metabolism
DMRQAM0	RN	Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain. Biochemistry. 2003 Dec 9;42(48):14284-92.
DMRQAM0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14640697

DMRQAM0	DI	DMRQAM0
DMRQAM0	DN	Phenacetin
DMRQAM0	MI	DE6OQ3W
DMRQAM0	MN	Cytochrome P450 1A1 (CYP1A1)
DMRQAM0	MT	DME
DMRQAM0	MA	Metabolism
DMRQAM0	RN	Identification of CYP3A4 as the enzyme involved in the mono-N-dealkylation of disopyramide enantiomers in humans. Drug Metab Dispos. 2000 Aug;28(8):937-44.
DMRQAM0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10901704

DMRQAM0	DI	DMRQAM0
DMRQAM0	DN	Phenacetin
DMRQAM0	MI	DEJGDUW
DMRQAM0	MN	Cytochrome P450 1A2 (CYP1A2)
DMRQAM0	MT	DME
DMRQAM0	MA	Metabolism
DMRQAM0	RN	CYP2A13 metabolizes the substrates of human CYP1A2, phenacetin, and theophylline. Drug Metab Dispos. 2007 Mar;35(3):335-9.
DMRQAM0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17178771

DMRQAM0	DI	DMRQAM0
DMRQAM0	DN	Phenacetin
DMRQAM0	MI	DEXZA9U
DMRQAM0	MN	Cytochrome P450 2A13 (CYP2A13)
DMRQAM0	MT	DME
DMRQAM0	MA	Metabolism
DMRQAM0	RN	CYP2A13 metabolizes the substrates of human CYP1A2, phenacetin, and theophylline. Drug Metab Dispos. 2007 Mar;35(3):335-9.
DMRQAM0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17178771

DMRQAM0	DI	DMRQAM0
DMRQAM0	DN	Phenacetin
DMRQAM0	MI	DEJVYAZ
DMRQAM0	MN	Cytochrome P450 2A6 (CYP2A6)
DMRQAM0	MT	DME
DMRQAM0	MA	Metabolism
DMRQAM0	RN	Activation of phenacetin O-deethylase activity by alpha-naphthoflavone in human liver microsomes. Xenobiotica. 1999 Sep;29(9):885-98.
DMRQAM0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10548449

DMRQAM0	DI	DMRQAM0
DMRQAM0	DN	Phenacetin
DMRQAM0	MI	DE5IED8
DMRQAM0	MN	Cytochrome P450 2C9 (CYP2C9)
DMRQAM0	MT	DME
DMRQAM0	MA	Metabolism
DMRQAM0	RN	Activation of phenacetin O-deethylase activity by alpha-naphthoflavone in human liver microsomes. Xenobiotica. 1999 Sep;29(9):885-98.
DMRQAM0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10548449

DMRQAM0	DI	DMRQAM0
DMRQAM0	DN	Phenacetin
DMRQAM0	MI	DECB0K3
DMRQAM0	MN	Cytochrome P450 2D6 (CYP2D6)
DMRQAM0	MT	DME
DMRQAM0	MA	Metabolism
DMRQAM0	RN	Human cytochromes P450 mediating phenacetin O-deethylation in vitro: validation of the high affinity component as an index of CYP1A2 activity. J Pharm Sci. 1998 Dec;87(12):1502-7.
DMRQAM0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10189256

DMRQAM0	DI	DMRQAM0
DMRQAM0	DN	Phenacetin
DMRQAM0	MI	DEVDYN7
DMRQAM0	MN	Cytochrome P450 2E1 (CYP2E1)
DMRQAM0	MT	DME
DMRQAM0	MA	Metabolism
DMRQAM0	RN	Involvement of CYP2E1 as A low-affinity enzyme in phenacetin O-deethylation in human liver microsomes. Drug Metab Dispos. 1999 Aug;27(8):860-5.
DMRQAM0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10421611

DMRQAM0	DI	DMRQAM0
DMRQAM0	DN	Phenacetin
DMRQAM0	MI	DE4LYSA
DMRQAM0	MN	Cytochrome P450 3A4 (CYP3A4)
DMRQAM0	MT	DME
DMRQAM0	MA	Metabolism
DMRQAM0	RN	Involvement of CYP2E1 as A low-affinity enzyme in phenacetin O-deethylation in human liver microsomes. Drug Metab Dispos. 1999 Aug;27(8):860-5.
DMRQAM0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10421611

DMRQAM0	DI	DMRQAM0
DMRQAM0	DN	Phenacetin
DMRQAM0	MI	TTL7C8Q
DMRQAM0	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMRQAM0	MT	DTT
DMRQAM0	MA	Inhibitor
DMRQAM0	RN	A potent "fat base" nucleotide inhibitor of IMP dehydrogenase. Biochemistry. 1998 Aug 25;37(34):11949-52.
DMRQAM0	RU	https://pubmed.ncbi.nlm.nih.gov/9718319

DMRQAM0	DI	DMRQAM0
DMRQAM0	DN	Phenacetin
DMRQAM0	MI	DEGTFWK
DMRQAM0	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMRQAM0	MT	DME
DMRQAM0	MA	Metabolism
DMRQAM0	RN	Activation of phenacetin O-deethylase activity by alpha-naphthoflavone in human liver microsomes. Xenobiotica. 1999 Sep;29(9):885-98.
DMRQAM0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10548449

DMRQAM0	DI	DMRQAM0
DMRQAM0	DN	Phenacetin
DMRQAM0	MI	TT8NGED
DMRQAM0	MN	Prostaglandin G/H synthase 1 (COX-1)
DMRQAM0	MT	DTT
DMRQAM0	MA	Inhibitor
DMRQAM0	RN	Direct toxicity of nonsteroidal antiinflammatory drugs for renal medullary cells. Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5317-22.
DMRQAM0	RU	https://pubmed.ncbi.nlm.nih.gov/11320259

DMQ52JG	DI	DMQ52JG
DMQ52JG	DN	Phenformin
DMQ52JG	MI	TTLAFZV
DMQ52JG	MN	AMP-activated protein kinase (AMPK)
DMQ52JG	MT	DTT
DMQ52JG	MA	Activator
DMQ52JG	RN	Complementary regulation of TBC1D1 and AS160 by growth factors, insulin and AMPK activators. Biochem J. 2008 Jan 15;409(2):449-59.
DMQ52JG	RU	https://pubmed.ncbi.nlm.nih.gov/17995453

DMQ52JG	DI	DMQ52JG
DMQ52JG	DN	Phenformin
DMQ52JG	MI	DECB0K3
DMQ52JG	MN	Cytochrome P450 2D6 (CYP2D6)
DMQ52JG	MT	DME
DMQ52JG	MA	Metabolism
DMQ52JG	RN	Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Mol Pharmacol. 1991 Jul;40(1):63-8.
DMQ52JG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1857341

DMQ52JG	DI	DMQ52JG
DMQ52JG	DN	Phenformin
DMQ52JG	MI	DTT79CX
DMQ52JG	MN	Organic cation transporter 1 (SLC22A1)
DMQ52JG	MT	DTP
DMQ52JG	MA	Substrate
DMQ52JG	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMQ52JG	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DM5SICT	DI	DM5SICT
DM5SICT	DN	Phenolphthalein
DM5SICT	MI	DTFI42L
DM5SICT	MN	Multidrug resistance-associated protein 2 (ABCC2)
DM5SICT	MT	DTP
DM5SICT	MA	Substrate
DM5SICT	RN	Biliary excretion of phenolphthalein sulfate in rats. Pharmacology. 2003 Aug;68(4):177-82.
DM5SICT	RU	http://www.ncbi.nlm.nih.gov/pubmed/12837971

DM5SICT	DI	DM5SICT
DM5SICT	DN	Phenolphthalein
DM5SICT	MI	DEYGVN4
DM5SICT	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM5SICT	MT	DME
DM5SICT	MA	Metabolism
DM5SICT	RN	Inhibition of UDP-glucuronyltransferase activity in rat liver microsomes by pyrimidine derivatives. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1995 Nov;112(3):321-5.
DM5SICT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8838685

DMTFK3O	DI	DMTFK3O
DMTFK3O	DN	Phenylpropanolamine
DMTFK3O	MI	TTG28O6
DMTFK3O	MN	Adrenergic receptor Alpha-1 (ADRA1)
DMTFK3O	MT	DTT
DMTFK3O	MA	Agonist
DMTFK3O	RN	Synthesis and structure-activity studies on N-[5-(1H-imidazol-4-yl)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide, an imidazole-containing alpha(1A)-adrenoceptor agonist. J Med Chem. 2004 Jun 3;47(12):3220-35.
DMTFK3O	RU	https://pubmed.ncbi.nlm.nih.gov/15163201

DMGQF3R	DI	DMGQF3R
DMGQF3R	DN	Remoxipride
DMGQF3R	MI	DECB0K3
DMGQF3R	MN	Cytochrome P450 2D6 (CYP2D6)
DMGQF3R	MT	DME
DMGQF3R	MA	Metabolism
DMGQF3R	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMGQF3R	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMGQF3R	DI	DMGQF3R
DMGQF3R	DN	Remoxipride
DMGQF3R	MI	TTEX248
DMGQF3R	MN	Dopamine D2 receptor (D2R)
DMGQF3R	MT	DTT
DMGQF3R	MA	Antagonist
DMGQF3R	RN	Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38.
DMGQF3R	RU	https://pubmed.ncbi.nlm.nih.gov/11873706

DMVMIK2	DI	DMVMIK2
DMVMIK2	DN	Roxithromycin
DMVMIK2	MI	TTUWYEA
DMVMIK2	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DMVMIK2	MT	DTT
DMVMIK2	MA	Inhibitor
DMVMIK2	RN	Molecular insights into 14-membered macrolides using the MM-PBSA method. J Chem Inf Model. 2009 Jun;49(6):1558-67.
DMVMIK2	RU	https://pubmed.ncbi.nlm.nih.gov/19469526

DMVMIK2	DI	DMVMIK2
DMVMIK2	DN	Roxithromycin
DMVMIK2	MI	DE4LYSA
DMVMIK2	MN	Cytochrome P450 3A4 (CYP3A4)
DMVMIK2	MT	DME
DMVMIK2	MA	Metabolism
DMVMIK2	RN	Hepatic veno-occlusive disease associated with immunosuppressive cyclophosphamide dosing and roxithromycin. Ann Pharmacother. 2006 Apr;40(4):767-70.
DMVMIK2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16595573

DMVMIK2	DI	DMVMIK2
DMVMIK2	DN	Roxithromycin
DMVMIK2	MI	DTUGYRD
DMVMIK2	MN	P-glycoprotein 1 (ABCB1)
DMVMIK2	MT	DTP
DMVMIK2	MA	Substrate
DMVMIK2	RN	Differences in assessment of macrolide interaction with human MDR1 (ABCB1, P-gp) using rhodamine-123 efflux, ATPase activity and cellular accumulation assays. Eur J Pharm Sci. 2010 Sep 11;41(1):86-95.
DMVMIK2	RU	https://doi.org/10.1016/j.ejps.2010.05.016

DMMP65N	DI	DMMP65N
DMMP65N	DN	Sertindole
DMMP65N	MI	DECB0K3
DMMP65N	MN	Cytochrome P450 2D6 (CYP2D6)
DMMP65N	MT	DME
DMMP65N	MA	Metabolism
DMMP65N	RN	Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007 Jan;100(1):4-22.
DMMP65N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17214606

DMMP65N	DI	DMMP65N
DMMP65N	DN	Sertindole
DMMP65N	MI	DE4LYSA
DMMP65N	MN	Cytochrome P450 3A4 (CYP3A4)
DMMP65N	MT	DME
DMMP65N	MA	Metabolism
DMMP65N	RN	Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007 Jan;100(1):4-22.
DMMP65N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17214606

DMMP65N	DI	DMMP65N
DMMP65N	DN	Sertindole
DMMP65N	MI	TTEX248
DMMP65N	MN	Dopamine D2 receptor (D2R)
DMMP65N	MT	DTT
DMMP65N	MA	Antagonist
DMMP65N	RN	Effect of sertindole on extracellular dopamine, acetylcholine, and glutamate in the medial prefrontal cortex of conscious rats: a comparison with r... Psychopharmacology (Berl). 2009 Sep;206(1):39-49.
DMMP65N	RU	https://pubmed.ncbi.nlm.nih.gov/19506838

DMKM5HB	DI	DMKM5HB
DMKM5HB	DN	Sitaxsentan
DMKM5HB	MI	DE5IED8
DMKM5HB	MN	Cytochrome P450 2C9 (CYP2C9)
DMKM5HB	MT	DME
DMKM5HB	MA	Metabolism
DMKM5HB	RN	Interaction of acenocoumarol and sitaxentan in pulmonary arterial hypertension. Eur J Clin Invest. 2009 Jun;39 Suppl 2:14-8.
DMKM5HB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19335742

DMKM5HB	DI	DMKM5HB
DMKM5HB	DN	Sitaxsentan
DMKM5HB	MI	TTKRD0G
DMKM5HB	MN	Endothelin A receptor (EDNRA)
DMKM5HB	MT	DTT
DMKM5HB	MA	Antagonist
DMKM5HB	RN	Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
DMKM5HB	RU	https://pubmed.ncbi.nlm.nih.gov/17064221

DMBCK2S	DI	DMBCK2S
DMBCK2S	DN	Sulfametopyrazine
DMBCK2S	MI	TT4ILYC
DMBCK2S	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMBCK2S	MT	DTT
DMBCK2S	MA	Inhibitor
DMBCK2S	RN	Plasmodium falciparum dihydrofolate reductase Val-16 and Thr-108 mutation associated with in vivo resistance to antifolate drug: a case study. Indian J Malariol. 2001 Sep-Dec;38(3-4):76-83.
DMBCK2S	RU	https://pubmed.ncbi.nlm.nih.gov/12125519

DMFR79T	DI	DMFR79T
DMFR79T	DN	TBC 11251 (TBC)
DMFR79T	MI	TTKRD0G
DMFR79T	MN	Endothelin A receptor (EDNRA)
DMFR79T	MT	DTT
DMFR79T	MA	Antagonist
DMFR79T	RN	Systemic administration of the endothelin-A receptor antagonist TBC 11251 attenuates cerebral vasospasm after experimental subarachnoid hemorrhage:... Neurosurgery. 1998 Dec;43(6):1409-17; discussion 1417-8.
DMFR79T	RU	https://pubmed.ncbi.nlm.nih.gov/9848855

DM3TON2	DI	DM3TON2
DM3TON2	DN	Temafloxacin
DM3TON2	MI	TTN6J5F
DM3TON2	MN	Bacterial DNA gyrase (Bact gyrase)
DM3TON2	MT	DTT
DM3TON2	MA	Modulator
DM3TON2	RN	Mechanisms and frequency of resistance to temafloxacin. Am J Med. 1991 Dec 30;91(6A):27S-30S.
DM3TON2	RU	https://pubmed.ncbi.nlm.nih.gov/1662892

DM3TON2	DI	DM3TON2
DM3TON2	DN	Temafloxacin
DM3TON2	MI	DEJGDUW
DM3TON2	MN	Cytochrome P450 1A2 (CYP1A2)
DM3TON2	MT	DME
DM3TON2	MA	Metabolism
DM3TON2	RN	Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro. Antimicrob Agents Chemother. 1992 May;36(5):942-8.
DM3TON2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1510417

DM4KLPT	DI	DM4KLPT
DM4KLPT	DN	Terfenadine
DM4KLPT	MI	DE5IED8
DM4KLPT	MN	Cytochrome P450 2C9 (CYP2C9)
DM4KLPT	MT	DME
DM4KLPT	MA	Metabolism
DM4KLPT	RN	Effects of serum albumin and liver cytosol on CYP2C9- and CYP3A4-mediated drug metabolism. Drug Metab Pharmacokinet. 2002;17(6):522-31.
DM4KLPT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15618707

DM4KLPT	DI	DM4KLPT
DM4KLPT	DN	Terfenadine
DM4KLPT	MI	DECB0K3
DM4KLPT	MN	Cytochrome P450 2D6 (CYP2D6)
DM4KLPT	MT	DME
DM4KLPT	MA	Metabolism
DM4KLPT	RN	Metabolism of epinastine, a histamine H1 receptor antagonist, in human liver microsomes in comparison with that of terfenadine. Res Commun Mol Pathol Pharmacol. 1997 Dec;98(3):273-92.
DM4KLPT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9485522

DM4KLPT	DI	DM4KLPT
DM4KLPT	DN	Terfenadine
DM4KLPT	MI	DE4LYSA
DM4KLPT	MN	Cytochrome P450 3A4 (CYP3A4)
DM4KLPT	MT	DME
DM4KLPT	MA	Metabolism
DM4KLPT	RN	Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet. 2005;44(3):279-304.
DM4KLPT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15762770

DM4KLPT	DI	DM4KLPT
DM4KLPT	DN	Terfenadine
DM4KLPT	MI	DEIBDNY
DM4KLPT	MN	Cytochrome P450 3A5 (CYP3A5)
DM4KLPT	MT	DME
DM4KLPT	MA	Metabolism
DM4KLPT	RN	Drug Interactions Flockhart Table
DM4KLPT	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM4KLPT	DI	DM4KLPT
DM4KLPT	DN	Terfenadine
DM4KLPT	MI	DERD86B
DM4KLPT	MN	Cytochrome P450 3A7 (CYP3A7)
DM4KLPT	MT	DME
DM4KLPT	MA	Metabolism
DM4KLPT	RN	Drug Interactions Flockhart Table
DM4KLPT	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM4KLPT	DI	DM4KLPT
DM4KLPT	DN	Terfenadine
DM4KLPT	MI	TTTIBOJ
DM4KLPT	MN	Histamine H1 receptor (H1R)
DM4KLPT	MT	DTT
DM4KLPT	MA	Antagonist
DM4KLPT	RN	Small mouse cholangiocytes proliferate in response to H1 histamine receptor stimulation by activation of the IP3/CaMK I/CREB pathway. Am J Physiol Cell Physiol. 2008 Aug;295(2):C499-513.
DM4KLPT	RU	https://pubmed.ncbi.nlm.nih.gov/18508907

DM4KLPT	DI	DM4KLPT
DM4KLPT	DN	Terfenadine
DM4KLPT	MI	DTUGYRD
DM4KLPT	MN	P-glycoprotein 1 (ABCB1)
DM4KLPT	MT	DTP
DM4KLPT	MA	Substrate
DM4KLPT	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM4KLPT	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMLFSTR	DI	DMLFSTR
DMLFSTR	DN	Ticrynafen
DMLFSTR	MI	DE5IED8
DMLFSTR	MN	Cytochrome P450 2C9 (CYP2C9)
DMLFSTR	MT	DME
DMLFSTR	MA	Metabolism
DMLFSTR	RN	Cytochrome P450 enzymes and UDP-glucuronosyltransferases as hepatocellular autoantigens. Mol Biol Rep. 1996;23(3-4):235-42.
DMLFSTR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9112234

DMABRJL	DI	DMABRJL
DMABRJL	DN	Ximelagatran
DMABRJL	MI	TT6L509
DMABRJL	MN	Coagulation factor IIa (F2)
DMABRJL	MT	DTT
DMABRJL	MA	Inhibitor
DMABRJL	RN	Ximelagatran increases membrane fluidity and changes membrane lipid composition in primary human hepatocytes. Toxicol In Vitro. 2009 Oct;23(7):1305-10.
DMABRJL	RU	https://pubmed.ncbi.nlm.nih.gov/19616086

DMABRJL	DI	DMABRJL
DMABRJL	DN	Ximelagatran
DMABRJL	MI	DE5IED8
DMABRJL	MN	Cytochrome P450 2C9 (CYP2C9)
DMABRJL	MT	DME
DMABRJL	MA	Metabolism
DMABRJL	RN	Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet. 2005;44(12):1227-46.
DMABRJL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16372822

DMABRJL	DI	DMABRJL
DMABRJL	DN	Ximelagatran
DMABRJL	MI	DTUGYRD
DMABRJL	MN	P-glycoprotein 1 (ABCB1)
DMABRJL	MT	DTP
DMABRJL	MA	Substrate
DMABRJL	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMABRJL	RU	https://doi.org/10.1007/s11095-012-0935-x

DMNI3U2	DI	DMNI3U2
DMNI3U2	DN	ZIMELIDINE
DMNI3U2	MI	TT3ROYC
DMNI3U2	MN	Serotonin transporter (SERT)
DMNI3U2	MT	DTT
DMNI3U2	MA	Inhibitor
DMNI3U2	RN	Nontricyclic antidepressant agents derived from cis- and trans-1-amino-4-aryltetralins. J Med Chem. 1984 Nov;27(11):1508-15.
DMNI3U2	RU	https://pubmed.ncbi.nlm.nih.gov/6492080

DM7APNJ	DI	DM7APNJ
DM7APNJ	DN	Zomepirac
DM7APNJ	MI	DE4LYSA
DM7APNJ	MN	Cytochrome P450 3A4 (CYP3A4)
DM7APNJ	MT	DME
DM7APNJ	MA	Metabolism
DM7APNJ	RN	Evidence for the bioactivation of zomepirac and tolmetin by an oxidative pathway: identification of glutathione adducts in vitro in human liver microsomes and in vivo in rats. Drug Metab Dispos. 2006 Jan;34(1):145-51.
DM7APNJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16251255

DM7APNJ	DI	DM7APNJ
DM7APNJ	DN	Zomepirac
DM7APNJ	MI	TTK0943
DM7APNJ	MN	Prostaglandin G/H synthase (COX)
DM7APNJ	MT	DTT
DM7APNJ	MA	Modulator
DM7APNJ	RN	Effect of preischemia cyclooxygenase inhibition by zomepirac sodium on reflow, cerebral autoregulation, and EEG recovery in the cat after global ischemia. J Cereb Blood Flow Metab. 1986 Dec;6(6):691-702.
DM7APNJ	RU	https://pubmed.ncbi.nlm.nih.gov/3098746

DMEQ3IW	DI	DMEQ3IW
DMEQ3IW	DN	(S)-amisulpride
DMEQ3IW	MI	TTEX248
DMEQ3IW	MN	Dopamine D2 receptor (D2R)
DMEQ3IW	MT	DTT
DMEQ3IW	MA	Antagonist
DMEQ3IW	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMEQ3IW	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMPL2KM	DI	DMPL2KM
DMPL2KM	DN	GW-501516
DMPL2KM	MI	TT2JWF6
DMPL2KM	MN	Peroxisome proliferator-activated receptor delta (PPARD)
DMPL2KM	MT	DTT
DMPL2KM	MA	Modulator
DMPL2KM	RN	Lipid effects of peroxisome proliferator-activated receptor- agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome.Arterioscler Thromb Vasc Biol.2012 Sep;32(9):2289-94.
DMPL2KM	RU	https://www.ncbi.nlm.nih.gov/pubmed/22814748

DMTF9YV	DI	DMTF9YV
DMTF9YV	DN	AE-0047
DMTF9YV	MI	TT5HONZ
DMTF9YV	MN	Calcium channel unspecific (CaC)
DMTF9YV	MT	DTT
DMTF9YV	MA	Modulator
DMTF9YV	RN	AE0047-mediated calcium channel blocking in vascular smooth muscles. Gen Pharmacol. 1997 Sep;29(3):337-43.
DMTF9YV	RU	https://pubmed.ncbi.nlm.nih.gov/9378237

DM7BN1A	DI	DM7BN1A
DM7BN1A	DN	Bermoprofen
DM7BN1A	MI	TTK0943
DM7BN1A	MN	Prostaglandin G/H synthase (COX)
DM7BN1A	MT	DTT
DM7BN1A	MA	Modulator
DM7BN1A	RN	Prolongation of antipyretic action and reduction of gastric ulcerogenicity in the rat by controlled-release granules of bermoprofen, a new nonsteroidal anti-inflammatory drug. J Pharm Sci. 1991 Sep;80(9):876-80.
DM7BN1A	RU	https://pubmed.ncbi.nlm.nih.gov/1800712

DM6E5VA	DI	DM6E5VA
DM6E5VA	DN	Clinprost
DM6E5VA	MI	TTOFYT1
DM6E5VA	MN	Prostacyclin receptor (PTGIR)
DM6E5VA	MT	DTT
DM6E5VA	MA	Modulator
DM6E5VA	RN	Protective effect of a prostaglandin I2 analog, TEI-7165, on ischemic neuronal damage in gerbils. Brain Res. 1997 Sep 26;769(2):321-8.
DM6E5VA	RU	https://pubmed.ncbi.nlm.nih.gov/9374201

DM3OUWC	DI	DM3OUWC
DM3OUWC	DN	Domitroban
DM3OUWC	MI	TT2O84V
DM3OUWC	MN	Thromboxane A2 receptor (TBXA2R)
DM3OUWC	MT	DTT
DM3OUWC	MA	Antagonist
DM3OUWC	RN	The effect of a novel thromboxane A2 (TXA2) receptor antagonist (S-1452) on the antigen-induced bronchoconstriction and airway hyperresponsiveness in guinea pigs. Prostaglandins Leukot Essent Fatty Acids. 1993 May;48(5):343-9.
DM3OUWC	RU	https://pubmed.ncbi.nlm.nih.gov/7686675

DMFOEVQ	DI	DMFOEVQ
DMFOEVQ	DN	Ecabapide
DMFOEVQ	MI	TT2NUT5
DMFOEVQ	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMFOEVQ	MT	DTT
DMFOEVQ	MA	Modulator
DMFOEVQ	RN	Identification of major biliary and urinary metabolites of ecabapide in rats. Xenobiotica. 1996 Sep;26(9):983-94.
DMFOEVQ	RU	https://pubmed.ncbi.nlm.nih.gov/8893045

DMKQI7S	DI	DMKQI7S
DMKQI7S	DN	EMITEFUR
DMKQI7S	MI	TTU6BFZ
DMKQI7S	MN	Candida Thymidylate synthase (Candi TMP1)
DMKQI7S	MT	DTT
DMKQI7S	MA	Inhibitor
DMKQI7S	RN	Antitumor activity of fluoropyrimidines and thymidylate synthetase inhibition. Jpn J Cancer Res. 1991 Apr;82(4):476-82.
DMKQI7S	RU	https://pubmed.ncbi.nlm.nih.gov/1904428

DML1Y49	DI	DML1Y49
DML1Y49	DN	Epanolol
DML1Y49	MI	TTMXGCW
DML1Y49	MN	Adrenergic receptor beta-3 (ADRB3)
DML1Y49	MT	DTT
DML1Y49	MA	Modulator
DML1Y49	RN	Pharmacokinetics of epanolol after acute and chronic oral dosing in elderly patients with stable angina pectoris. Br J Clin Pharmacol. 1990 Mar;29(3):333-7.
DML1Y49	RU	https://pubmed.ncbi.nlm.nih.gov/1968755

DML1Y49	DI	DML1Y49
DML1Y49	DN	Epanolol
DML1Y49	MI	DECB0K3
DML1Y49	MN	Cytochrome P450 2D6 (CYP2D6)
DML1Y49	MT	DME
DML1Y49	MA	Metabolism
DML1Y49	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DML1Y49	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DM05MCO	DI	DM05MCO
DM05MCO	DN	Inaperisone
DM05MCO	MI	TTJSZTB
DM05MCO	MN	Nicotinic acetylcholine receptor (nAChR)
DM05MCO	MT	DTT
DM05MCO	MA	Modulator
DM05MCO	RN	Inhibitory effect of inaperisone hydrochloride (inaperisone), a new centrally acting muscle relaxant, on the micturition reflex. Eur J Pharmacol. 1992 Mar 31;213(3):409-15.
DM05MCO	RU	https://pubmed.ncbi.nlm.nih.gov/1618281

DM1B8NU	DI	DM1B8NU
DM1B8NU	DN	Isbogrel
DM1B8NU	MI	TT2GVH5
DM1B8NU	MN	Isomerase unspecific (IsoM)
DM1B8NU	MT	DTT
DM1B8NU	MA	Modulator
DM1B8NU	RN	Beneficial effect of CV-4151 (Isbogrel), a thromboxane A2 synthase inhibitor, in a rat middle cerebral artery thrombosis model. Thromb Res. 1995 Jul 1;79(1):95-107.
DM1B8NU	RU	https://pubmed.ncbi.nlm.nih.gov/7495108

DMXZ4BK	DI	DMXZ4BK
DMXZ4BK	DN	LAS-41001
DMXZ4BK	MI	TTOD7B3
DMXZ4BK	MN	Retinoic acid receptor (RAR)
DMXZ4BK	MT	DTT
DMXZ4BK	MA	Modulator
DMXZ4BK	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027956)
DMXZ4BK	RU	http://adisinsight.springer.com/drugs/800027956

DMBKNJT	DI	DMBKNJT
DMBKNJT	DN	LEMINOPRAZOLE
DMBKNJT	MI	TTLOKXP
DMBKNJT	MN	Gastric H(+)/K(+) ATPase (Proton pump)
DMBKNJT	MT	DTT
DMBKNJT	MA	Modulator
DMBKNJT	RN	Vasoinhibitory effect of leminoprazole, a H+,K(+)-ATPase inhibitor, on rat aortic rings. Gen Pharmacol. 1996 Jan;27(1):117-21.
DMBKNJT	RU	https://www.ncbi.nlm.nih.gov/pubmed/8742507

DMNS4TK	DI	DMNS4TK
DMNS4TK	DN	Levcromakalim
DMNS4TK	MI	TT1VOHK
DMNS4TK	MN	Potassium channel unspecific (KC)
DMNS4TK	MT	DTT
DMNS4TK	MA	Modulator
DMNS4TK	RN	The potassium channel opener levcromakalim causes expansive remodelling of experimental vein grafts. J Vasc Surg. 2006 Jul;44(1):159-65.
DMNS4TK	RU	https://www.ncbi.nlm.nih.gov/pubmed/16828441

DMFGMD9	DI	DMFGMD9
DMFGMD9	DN	LUBELUZOLE
DMFGMD9	MI	TTRK8B9
DMFGMD9	MN	Sodium channel unspecific (NaC)
DMFGMD9	MT	DTT
DMFGMD9	MA	Inhibitor
DMFGMD9	RN	Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37.
DMFGMD9	RU	https://pubmed.ncbi.nlm.nih.gov/11170622

DMFGMD9	DI	DMFGMD9
DMFGMD9	DN	LUBELUZOLE
DMFGMD9	MI	TTZOVE0
DMFGMD9	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DMFGMD9	MT	DTT
DMFGMD9	MA	Inhibitor
DMFGMD9	RN	Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37.
DMFGMD9	RU	https://pubmed.ncbi.nlm.nih.gov/11170622

DMEQDHP	DI	DMEQDHP
DMEQDHP	DN	Meluadrine
DMEQDHP	MI	TT2CJVK
DMEQDHP	MN	Adrenergic receptor beta-2 (ADRB2)
DMEQDHP	MT	DTT
DMEQDHP	MA	Modulator
DMEQDHP	RN	Effects of meluadrine tartrate and ritodrine hydrochloride on oxytocin-induced uterine contraction, uterine arterial blood flow and maternal cardiovascular function in pregnant goats. Jpn J Pharmacol. 2002 Oct;90(2):107-13.
DMEQDHP	RU	https://pubmed.ncbi.nlm.nih.gov/12419879

DM9ADLQ	DI	DM9ADLQ
DM9ADLQ	DN	Monatepil maleate
DM9ADLQ	MI	TT5HONZ
DM9ADLQ	MN	Calcium channel unspecific (CaC)
DM9ADLQ	MT	DTT
DM9ADLQ	MA	Modulator
DM9ADLQ	RN	Antihypertensive, antiatherosclerotic, and plasma lipid-lowering effects of monatepil, a novel calcium antagonist with alpha 1-adrenoceptor-blocking activity in experimental animals. Am J Hypertens. 1994 Oct;7(10 Pt 2):131S-40S.
DM9ADLQ	RU	https://pubmed.ncbi.nlm.nih.gov/7826563

DM31OGZ	DI	DM31OGZ
DM31OGZ	DN	MONTIRELIN TETRAHYDRATE
DM31OGZ	MI	TT4J8MF
DM31OGZ	MN	Thyrotropin-releasing hormone receptor (TRHR)
DM31OGZ	MT	DTT
DM31OGZ	MA	Modulator
DM31OGZ	RN	Montirelin hydrate (NS-3), a TRH analog, improved the disturbance of consciousness caused by head concussion and pentobarbital in mice. Nihon Yakurigaku Zasshi. 1996 May;107(5):237-45.
DM31OGZ	RU	https://pubmed.ncbi.nlm.nih.gov/8690305

DMXF0NS	DI	DMXF0NS
DMXF0NS	DN	Norastemizole
DMXF0NS	MI	TTTIBOJ
DMXF0NS	MN	Histamine H1 receptor (H1R)
DMXF0NS	MT	DTT
DMXF0NS	MA	Modulator
DMXF0NS	RN	Effect of tecastemizole on pulmonary and cutaneous allergic inflammatory responses. Clin Exp Allergy. 2007 Jun;37(6):909-17.
DMXF0NS	RU	https://www.ncbi.nlm.nih.gov/pubmed/17517105

DMUH0KO	DI	DMUH0KO
DMUH0KO	DN	Palonidipine hydrochloride
DMUH0KO	MI	TT5HONZ
DMUH0KO	MN	Calcium channel unspecific (CaC)
DMUH0KO	MT	DTT
DMUH0KO	MA	Modulator
DMUH0KO	RN	Effect of palonidipine hydrochloride (TC-81), a novel calcium antagonist, on the canine coronary artery. Nihon Yakurigaku Zasshi. 1993 Jul;102(1):23-33.
DMUH0KO	RU	https://pubmed.ncbi.nlm.nih.gov/8335285

DMP6BG4	DI	DMP6BG4
DMP6BG4	DN	Pirazolac
DMP6BG4	MI	TTK0943
DMP6BG4	MN	Prostaglandin G/H synthase (COX)
DMP6BG4	MT	DTT
DMP6BG4	MA	Modulator
DMP6BG4	RN	Differential dosing study of pirazolac, a new non-steroidal anti-inflammatory agent, in patients with rheumatoid arthritis. Curr Med Res Opin. 1985;9(8):542-7.
DMP6BG4	RU	https://pubmed.ncbi.nlm.nih.gov/3896664

DMD8K3B	DI	DMD8K3B
DMD8K3B	DN	PW-2101
DMD8K3B	MI	TTMXGCW
DMD8K3B	MN	Adrenergic receptor beta-3 (ADRB3)
DMD8K3B	MT	DTT
DMD8K3B	MA	Antagonist
DMD8K3B	RN	PW 2101 Penwest discontinued, USA (hypertension) Penwest non-approvable, USA (hypertension), R & D Focus Drug News. July 11, 2005
DMD8K3B	RU	http://business.highbeam.com/436989/article-1G1-133855652/pw-2101-penwest-discontinued-usa

DM4LSJ2	DI	DM4LSJ2
DM4LSJ2	DN	Satigrel
DM4LSJ2	MI	TTKNWZ4
DM4LSJ2	MN	Thromboxane-A synthase (TBXAS1)
DM4LSJ2	MT	DTT
DM4LSJ2	MA	Modulator
DM4LSJ2	RN	Mechanisms of satigrel (E5510), a new anti-platelet drug, in inhibiting human platelet aggregation. Selectivity and potency against prostaglandin H synthases isozyme activities and phosphodiesterase isoform activities. Biol Pharm Bull. 1996 Jun;19(6):828-33.
DM4LSJ2	RU	https://pubmed.ncbi.nlm.nih.gov/8799481

DMYBPJ1	DI	DMYBPJ1
DMYBPJ1	DN	Semotiadil
DMYBPJ1	MI	TT5HONZ
DMYBPJ1	MN	Calcium channel unspecific (CaC)
DMYBPJ1	MT	DTT
DMYBPJ1	MA	Blocker
DMYBPJ1	RN	Thyroid hypertrophic effect of semotiadil fumarate, a new calcium antagonist, in rats. J Toxicol Sci. 2000 May;25(2):121-30.
DMYBPJ1	RU	https://pubmed.ncbi.nlm.nih.gov/10845190

DMC14HL	DI	DMC14HL
DMC14HL	DN	Suriclone
DMC14HL	MI	TTEX6LM
DMC14HL	MN	GABA(A) receptor gamma-3 (GABRG3)
DMC14HL	MT	DTT
DMC14HL	MA	Modulator
DMC14HL	RN	The effect of cyclopyrrolones on GABAA receptor function is different from that of benzodiazepines. Naunyn Schmiedebergs Arch Pharmacol. 1994 Sep;350(3):294-300.
DMC14HL	RU	https://www.ncbi.nlm.nih.gov/pubmed/7824046

DM6PVWS	DI	DM6PVWS
DM6PVWS	DN	Telenzepine
DM6PVWS	MI	TTOXS3C
DM6PVWS	MN	Muscarinic acetylcholine receptor (CHRM)
DM6PVWS	MT	DTT
DM6PVWS	MA	Antagonist
DM6PVWS	RN	The existence of stable enantiomers of telenzepine and their stereoselective interaction with muscarinic receptor subtypes. Mol Pharmacol. 1989 Apr;35(4):477-83.
DM6PVWS	RU	https://pubmed.ncbi.nlm.nih.gov/2704371

DM6PVWS	DI	DM6PVWS
DM6PVWS	DN	Telenzepine
DM6PVWS	MI	TTZ9SOR
DM6PVWS	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DM6PVWS	MT	DTT
DM6PVWS	MA	Modulator
DM6PVWS	RN	Effect of telenzepine, an M1-selective muscarinic receptor antagonist, in patients with nocturnal asthma. Pulm Pharmacol. 1994 Apr;7(2):91-7.
DM6PVWS	RU	https://pubmed.ncbi.nlm.nih.gov/8081076

DMUM3CP	DI	DMUM3CP
DMUM3CP	DN	15(S)-hydroxyeicosatetraenoic acid (ophthalmic, dry eye), Alcon
DMUM3CP	MI	TTHBUXE
DMUM3CP	MN	Mucin (MUC)
DMUM3CP	MT	DTT
DMUM3CP	MA	Modulator
DMUM3CP	RN	15(S)-hydroxyeicosatetraenoic acid (15-HETE), a product of arachidonic acid peroxidation, is an active component of hemozoin toxicity to monocytes. Parassitologia. 1999 Sep;41(1-3):199-202.
DMUM3CP	RU	https://pubmed.ncbi.nlm.nih.gov/10697856

DM0GMJ6	DI	DM0GMJ6
DM0GMJ6	DN	2085-P
DM0GMJ6	MI	TTHI19T
DM0GMJ6	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DM0GMJ6	MT	DTT
DM0GMJ6	MA	Modulator
DM0GMJ6	RN	US patent application no. 2004,0023,290, Novel therapeutic agents that modulate enzymatic processes.
DM0GMJ6	RU	http://www.google.com/patents/US20040023290

DM09GSW	DI	DM09GSW
DM09GSW	DN	Abafungin
DM09GSW	MI	TTTSOUD
DM09GSW	MN	Candida Cytochrome P450 51 (Candi ERG11)
DM09GSW	MT	DTT
DM09GSW	MA	Inhibitor
DM09GSW	RN	Upregulation of sterol C14-demethylase expression in Trypanosoma cruzi treated with sterol biosynthesis inhibitors. Mol Biochem Parasitol. 2005 Nov;144(1):68-75.
DM09GSW	RU	https://pubmed.ncbi.nlm.nih.gov/16165233

DMAENDF	DI	DMAENDF
DMAENDF	DN	Abetimus sodium
DMAENDF	MI	TTUTN1I
DMAENDF	MN	Human Deoxyribonucleic acid (hDNA)
DMAENDF	MT	DTT
DMAENDF	MA	Inhibitor
DMAENDF	RN	Emergence of targeted immune therapies for systemic lupus. Expert Opin Emerg Drugs. 2005 Feb;10(1):53-65.
DMAENDF	RU	https://pubmed.ncbi.nlm.nih.gov/15757403

DMNKZ61	DI	DMNKZ61
DMNKZ61	DN	Ablukast
DMNKZ61	MI	TTGKOY9
DMNKZ61	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DMNKZ61	MT	DTT
DMNKZ61	MA	Modulator
DMNKZ61	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMNKZ61	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMKM543	DI	DMKM543
DMKM543	DN	Acecainide
DMKM543	MI	TT1VOHK
DMKM543	MN	Potassium channel unspecific (KC)
DMKM543	MT	DTT
DMKM543	MA	Opener
DMKM543	RN	Acecainide (N-acetylprocainamide). A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiac arrhythmias. Drugs. 1990 May;39(5):720-40.
DMKM543	RU	https://pubmed.ncbi.nlm.nih.gov/1693889

DMKM543	DI	DMKM543
DMKM543	DN	Acecainide
DMKM543	MI	TTZOVE0
DMKM543	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DMKM543	MT	DTT
DMKM543	MA	Blocker
DMKM543	RN	Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine. Pharmacol Biochem Behav. 1998 Feb;59(2):305-12.
DMKM543	RU	https://pubmed.ncbi.nlm.nih.gov/9476974

DMPQZ80	DI	DMPQZ80
DMPQZ80	DN	Acivicin
DMPQZ80	MI	TTN12BZ
DMPQZ80	MN	CTP synthase (CTPS1)
DMPQZ80	MT	DTT
DMPQZ80	MA	Inhibitor
DMPQZ80	RN	Synergistic effects with inhibitors of de novo pyrimidine synthesis, acivicin, and N-(phosphonacetyl)-L-aspartic acid. Cancer Res. 1981 Sep;41(9 Pt 1):3419-23.
DMPQZ80	RU	https://pubmed.ncbi.nlm.nih.gov/7260907

DMPQZ80	DI	DMPQZ80
DMPQZ80	DN	Acivicin
DMPQZ80	MI	TT5XOKS
DMPQZ80	MN	Leishmania Carbamoyl-phosphate synthase (Leishm CPS)
DMPQZ80	MT	DTT
DMPQZ80	MA	Inhibitor
DMPQZ80	RN	Acivicin: a highly active potential chemotherapeutic agent against visceral leishmaniasis. Biochem Biophys Res Commun. 1990 Jul 31;170(2):426-32.
DMPQZ80	RU	https://pubmed.ncbi.nlm.nih.gov/2383250

DMTG18I	DI	DMTG18I
DMTG18I	DN	Aleglitazar
DMTG18I	MI	DES5XRU
DMTG18I	MN	Cytochrome P450 2C8 (CYP2C8)
DMTG18I	MT	DME
DMTG18I	MA	Metabolism
DMTG18I	RN	Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: an analysis of the AleCardio trial. Diabetes Obes Metab. 2020 Jan;22(1):30-38.
DMTG18I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31468659

DMTG18I	DI	DMTG18I
DMTG18I	DN	Aleglitazar
DMTG18I	MI	TTJ584C
DMTG18I	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMTG18I	MT	DTT
DMTG18I	MA	Agonist
DMTG18I	RN	Clinical pipeline report, company report or official report of Roche (2009).
DMTG18I	RU	http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm

DMV2Y6L	DI	DMV2Y6L
DMV2Y6L	DN	Alinidine
DMV2Y6L	MI	TT1VOHK
DMV2Y6L	MN	Potassium channel unspecific (KC)
DMV2Y6L	MT	DTT
DMV2Y6L	MA	Blocker
DMV2Y6L	RN	Decrease in bradycardic effect of AQ-A 39 and alinidine in guinea-pig sinoatrial node depolarized by high external K+-concentration. Naunyn Schmiedebergs Arch Pharmacol. 1984 Dec;328(2):210-3.
DMV2Y6L	RU	https://pubmed.ncbi.nlm.nih.gov/6527706

DMV3PEA	DI	DMV3PEA
DMV3PEA	DN	Almokalant
DMV3PEA	MI	TT1VOHK
DMV3PEA	MN	Potassium channel unspecific (KC)
DMV3PEA	MT	DTT
DMV3PEA	MA	Modulator
DMV3PEA	RN	Effect of almokalant, a selective potassium channel blocker, on the termination and inducibility of paroxysmal supraventricular tachycardias: a study in patients with Wolff-Parkinson-White syndrome and atrioventricular nodal reentrant tachycardia.Almokalant PSVT Study Group.J Cardiovasc Pharmacol.1995 Aug;26(2):198-206.
DMV3PEA	RU	https://www.ncbi.nlm.nih.gov/pubmed/7475043

DMFE3CT	DI	DMFE3CT
DMFE3CT	DN	Alniditan
DMFE3CT	MI	TTK8CXU
DMFE3CT	MN	5-HT 1B receptor (HTR1B)
DMFE3CT	MT	DTT
DMFE3CT	MA	Agonist
DMFE3CT	RN	Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines. Br J Pharmacol. 1998 Apr;123(8):1655-65.
DMFE3CT	RU	https://pubmed.ncbi.nlm.nih.gov/9605573

DMFE3CT	DI	DMFE3CT
DMFE3CT	DN	Alniditan
DMFE3CT	MI	TT6MSOK
DMFE3CT	MN	5-HT 1D receptor (HTR1D)
DMFE3CT	MT	DTT
DMFE3CT	MA	Agonist
DMFE3CT	RN	Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines. Br J Pharmacol. 1998 Apr;123(8):1655-65.
DMFE3CT	RU	https://pubmed.ncbi.nlm.nih.gov/9605573

DMGW07M	DI	DMGW07M
DMGW07M	DN	Aloxistatin
DMGW07M	MI	TTG5QB7
DMGW07M	MN	Calpain-2 (CAPN2)
DMGW07M	MT	DTT
DMGW07M	MA	Inhibitor
DMGW07M	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMGW07M	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMGW07M	DI	DMGW07M
DMGW07M	DN	Aloxistatin
DMGW07M	MI	TTQAJF1
DMGW07M	MN	Cathepsin G (CTSG)
DMGW07M	MT	DTT
DMGW07M	MA	Inhibitor
DMGW07M	RN	Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing. J Biol Chem. 2007 Jul 20;282(29):20836-46.
DMGW07M	RU	https://pubmed.ncbi.nlm.nih.gov/17535802

DMPS14M	DI	DMPS14M
DMPS14M	DN	Amibegron
DMPS14M	MI	TTMXGCW
DMPS14M	MN	Adrenergic receptor beta-3 (ADRB3)
DMPS14M	MT	DTT
DMPS14M	MA	Agonist
DMPS14M	RN	Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
DMPS14M	RU	https://pubmed.ncbi.nlm.nih.gov/18172433

DMNEM2C	DI	DMNEM2C
DMNEM2C	DN	Anipamil
DMNEM2C	MI	TT5HONZ
DMNEM2C	MN	Calcium channel unspecific (CaC)
DMNEM2C	MT	DTT
DMNEM2C	MA	Modulator
DMNEM2C	RN	Effects of the novel calcium channel blocker, anipamil, on the isolated rabbit heart. Comparison with verapamil and gallopamil. Naunyn Schmiedebergs Arch Pharmacol. 1992 Sep;346(3):339-44.
DMNEM2C	RU	https://pubmed.ncbi.nlm.nih.gov/1383837

DM8XO3B	DI	DM8XO3B
DM8XO3B	DN	ARANOSE
DM8XO3B	MI	TTUTN1I
DM8XO3B	MN	Human Deoxyribonucleic acid (hDNA)
DM8XO3B	MT	DTT
DM8XO3B	MA	Binder
DM8XO3B	RN	Alternative DNA loops regulate the arabinose operon in Escherichia coli. Proc Natl Acad Sci U S A. 1988 Aug;85(15):5444-8.
DM8XO3B	RU	https://pubmed.ncbi.nlm.nih.gov/3041410

DM4BV2W	DI	DM4BV2W
DM4BV2W	DN	Asoprisnil
DM4BV2W	MI	TTUV8G9
DM4BV2W	MN	Progesterone receptor (PGR)
DM4BV2W	MT	DTT
DM4BV2W	MA	Modulator
DM4BV2W	RN	New drugs in development for the treatment of endometriosis. Expert Opin Investig Drugs. 2008 Aug;17(8):1187-202.
DM4BV2W	RU	https://pubmed.ncbi.nlm.nih.gov/18616415

DMPTG39	DI	DMPTG39
DMPTG39	DN	Ataprost
DMPTG39	MI	TTOFYT1
DMPTG39	MN	Prostacyclin receptor (PTGIR)
DMPTG39	MT	DTT
DMPTG39	MA	Modulator
DMPTG39	RN	Pharmacokinetics of intravenous ataprost alfadex, a new prostaglandin I2 analog in healthy volunteers. Int J Clin Pharmacol Ther Toxicol. 1993 Aug;31(8):373-5.
DMPTG39	RU	https://pubmed.ncbi.nlm.nih.gov/8225681

DMFG4OM	DI	DMFG4OM
DMFG4OM	DN	Avasimibe
DMFG4OM	MI	TTMF541
DMFG4OM	MN	Liver carboxylesterase (CES1)
DMFG4OM	MT	DTT
DMFG4OM	MA	Inhibitor
DMFG4OM	RN	New advances in lipid-modifying therapies for reducing cardiovascular risk. Cardiology. 2002;97(2):59-66.
DMFG4OM	RU	https://pubmed.ncbi.nlm.nih.gov/11978950

DM3SE2N	DI	DM3SE2N
DM3SE2N	DN	Avitriptan
DM3SE2N	MI	TT6MSOK
DM3SE2N	MN	5-HT 1D receptor (HTR1D)
DM3SE2N	MT	DTT
DM3SE2N	MA	Agonist
DM3SE2N	RN	Safety trial with the 5HT1B/1D agonist avitriptan (BMS-180048) in patients with migraine who have experienced pressure, tightness, and/or pain in the chest, neck, and/or throat following sumatriptan.Cephalalgia. 1998 Oct;18(8):546-51.
DM3SE2N	RU	https://pubmed.ncbi.nlm.nih.gov/9827246

DMT5O8I	DI	DMT5O8I
DMT5O8I	DN	Axokine
DMT5O8I	MI	TTY84UG
DMT5O8I	MN	Acetyl-CoA carboxylase 2 (ACACB)
DMT5O8I	MT	DTT
DMT5O8I	MA	Inhibitor
DMT5O8I	RN	Obesity: pathophysiology and clinical management. Curr Med Chem. 2009;16(4):506-21.
DMT5O8I	RU	https://pubmed.ncbi.nlm.nih.gov/19199918

DM7G8T0	DI	DM7G8T0
DM7G8T0	DN	Azithromycin/chloroquine
DM7G8T0	MI	TTUWYEA
DM7G8T0	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DM7G8T0	MT	DTT
DM7G8T0	MA	Binder
DM7G8T0	RN	Pfizer. Product Development Pipeline. March 31 2009.
DM7G8T0	RU	http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf

DM7G8T0	DI	DM7G8T0
DM7G8T0	DN	Azithromycin/chloroquine
DM7G8T0	MI	DTFI42L
DM7G8T0	MN	Multidrug resistance-associated protein 2 (ABCC2)
DM7G8T0	MT	DTP
DM7G8T0	MA	Substrate
DM7G8T0	RN	Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin. Antimicrob Agents Chemother. 2004 Mar;48(3):809-14.
DM7G8T0	RU	http://www.ncbi.nlm.nih.gov/pubmed/14982769

DM7G8T0	DI	DM7G8T0
DM7G8T0	DN	Azithromycin/chloroquine
DM7G8T0	MI	DTUGYRD
DM7G8T0	MN	P-glycoprotein 1 (ABCB1)
DM7G8T0	MT	DTP
DM7G8T0	MA	Substrate
DM7G8T0	RN	Resveratrol modifies biliary secretion of cholephilic compounds in sham-operated and cholestatic rats. World J Gastroenterol. 2017 Nov 21;23(43):7678-7692.
DM7G8T0	RU	http://www.ncbi.nlm.nih.gov/pubmed/29209109

DMAMFXC	DI	DMAMFXC
DMAMFXC	DN	BCG65-E7
DMAMFXC	MI	TTD24Y0
DMAMFXC	MN	Toll-like receptor 3 (TLR3)
DMAMFXC	MT	DTT
DMAMFXC	MA	Agonist
DMAMFXC	RN	Serological response to an HPV16 E7 based therapeutic vaccine in women with high-grade cervical dysplasia. Gynecol Oncol. 2010 Feb;116(2):208-12.
DMAMFXC	RU	https://pubmed.ncbi.nlm.nih.gov/19555999

DMRQV8I	DI	DMRQV8I
DMRQV8I	DN	Becatecarin
DMRQV8I	MI	DTI7UX6
DMRQV8I	MN	Breast cancer resistance protein (ABCG2)
DMRQV8I	MT	DTP
DMRQV8I	MA	Substrate
DMRQV8I	RN	Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cells. Cancer Chemother Pharmacol. 2009 Aug;64(3):575-83.
DMRQV8I	RU	https://doi.org/10.1007/s00280-008-0908-2

DMRQV8I	DI	DMRQV8I
DMRQV8I	DN	Becatecarin
DMRQV8I	MI	TTGTQHC
DMRQV8I	MN	DNA topoisomerase I (TOP1)
DMRQV8I	MT	DTT
DMRQV8I	MA	Modulator
DMRQV8I	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMRQV8I	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMZIV6D	DI	DMZIV6D
DMZIV6D	DN	Befloxatone
DMZIV6D	MI	DTI7UX6
DMZIV6D	MN	Breast cancer resistance protein (ABCG2)
DMZIV6D	MT	DTP
DMZIV6D	MA	Substrate
DMZIV6D	RN	Transport of selected PET radiotracers by human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2): an in vitro screening. J Nucl Med. 2011 Mar;52(3):415-23.
DMZIV6D	RU	https://doi.org/10.2967/jnumed.110.079608

DMZIV6D	DI	DMZIV6D
DMZIV6D	DN	Befloxatone
DMZIV6D	MI	TT3WG5C
DMZIV6D	MN	Monoamine oxidase type A (MAO-A)
DMZIV6D	MT	DTT
DMZIV6D	MA	Inhibitor
DMZIV6D	RN	Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. II. Pharmacological profile. J Pharmacol Exp Ther. 1996 Apr;277(1):265-77.
DMZIV6D	RU	https://pubmed.ncbi.nlm.nih.gov/8613929

DMSPJX9	DI	DMSPJX9
DMSPJX9	DN	BEMESETRON
DMSPJX9	MI	TTPC4TU
DMSPJX9	MN	5-HT 3A receptor (HTR3A)
DMSPJX9	MT	DTT
DMSPJX9	MA	Inhibitor
DMSPJX9	RN	Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships. J Med Chem. 1992 Jan 24;35(2):310-9.
DMSPJX9	RU	https://pubmed.ncbi.nlm.nih.gov/1732548

DMSPJX9	DI	DMSPJX9
DMSPJX9	DN	BEMESETRON
DMSPJX9	MI	TTR6K75
DMSPJX9	MN	5-HT 3B receptor (HTR3B)
DMSPJX9	MT	DTT
DMSPJX9	MA	Inhibitor
DMSPJX9	RN	Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships. J Med Chem. 1992 Jan 24;35(2):310-9.
DMSPJX9	RU	https://pubmed.ncbi.nlm.nih.gov/1732548

DMSPJX9	DI	DMSPJX9
DMSPJX9	DN	BEMESETRON
DMSPJX9	MI	TTJFY5U
DMSPJX9	MN	Adenosine A3 receptor (ADORA3)
DMSPJX9	MT	DTT
DMSPJX9	MA	Inhibitor
DMSPJX9	RN	2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96.
DMSPJX9	RU	https://pubmed.ncbi.nlm.nih.gov/16250647

DMIEB8Y	DI	DMIEB8Y
DMIEB8Y	DN	Bevasiranib
DMIEB8Y	MI	TTOHSBA
DMIEB8Y	MN	Vascular endothelial growth factor A (VEGFA)
DMIEB8Y	MT	DTT
DMIEB8Y	MA	Modulator
DMIEB8Y	RN	Bevasiranib for the Treatment of Wet, Age-Related Macular Degeneration
DMIEB8Y	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661434

DM47ZHW	DI	DM47ZHW
DM47ZHW	DN	Bidisomide
DM47ZHW	MI	TTRK8B9
DM47ZHW	MN	Sodium channel unspecific (NaC)
DM47ZHW	MT	DTT
DM47ZHW	MA	Modulator
DM47ZHW	RN	Bidisomide (SC-40230), a new antiarrhythmic agent: initial study of tolerability and pharmacokinetics. Clin Pharmacol Ther. 1992 Apr;51(4):371-8.
DM47ZHW	RU	https://pubmed.ncbi.nlm.nih.gov/1563207

DMOQIMS	DI	DMOQIMS
DMOQIMS	DN	Bifeprunox
DMOQIMS	MI	TTSQIFT
DMOQIMS	MN	5-HT 1A receptor (HTR1A)
DMOQIMS	MT	DTT
DMOQIMS	MA	Modulator
DMOQIMS	RN	Bifeprunox: a partial agonist at dopamine D2 and serotonin 1A receptors, influences nicotine-seeking behaviour in response to drug-associated stimuli in rats.Addict Biol.2012 Mar;17(2):274-86.
DMOQIMS	RU	https://www.ncbi.nlm.nih.gov/pubmed/21521422

DMOQIMS	DI	DMOQIMS
DMOQIMS	DN	Bifeprunox
DMOQIMS	MI	TTEX248
DMOQIMS	MN	Dopamine D2 receptor (D2R)
DMOQIMS	MT	DTT
DMOQIMS	MA	Modulator
DMOQIMS	RN	Bifeprunox: a partial agonist at dopamine D2 and serotonin 1A receptors, influences nicotine-seeking behaviour in response to drug-associated stimuli in rats.Addict Biol.2012 Mar;17(2):274-86.
DMOQIMS	RU	https://www.ncbi.nlm.nih.gov/pubmed/21521422

DMLXHZR	DI	DMLXHZR
DMLXHZR	DN	BL-1832
DMLXHZR	MI	TTZPO1L
DMLXHZR	MN	Substance-P receptor (TACR1)
DMLXHZR	MT	DTT
DMLXHZR	MA	Antagonist
DMLXHZR	RN	WO patent application no. 2006,0132,05, Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation.
DMLXHZR	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20060209&CC=WO&NR=2006013205A1&KC=A1

DMKSFPE	DI	DMKSFPE
DMKSFPE	DN	BMS 275291
DMKSFPE	MI	TTMX39J
DMKSFPE	MN	Matrix metalloproteinase-1 (MMP-1)
DMKSFPE	MT	DTT
DMKSFPE	MA	Inhibitor
DMKSFPE	RN	Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium. Cancer. 2008 Mar 1;112(5):1083-8.
DMKSFPE	RU	https://pubmed.ncbi.nlm.nih.gov/18224669

DMKSFPE	DI	DMKSFPE
DMKSFPE	DN	BMS 275291
DMKSFPE	MI	TTLM12X
DMKSFPE	MN	Matrix metalloproteinase-2 (MMP-2)
DMKSFPE	MT	DTT
DMKSFPE	MA	Inhibitor
DMKSFPE	RN	Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium. Cancer. 2008 Mar 1;112(5):1083-8.
DMKSFPE	RU	https://pubmed.ncbi.nlm.nih.gov/18224669

DMKSFPE	DI	DMKSFPE
DMKSFPE	DN	BMS 275291
DMKSFPE	MI	TTMTWOS
DMKSFPE	MN	Matrix metalloproteinase-7 (MMP-7)
DMKSFPE	MT	DTT
DMKSFPE	MA	Inhibitor
DMKSFPE	RN	Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium. Cancer. 2008 Mar 1;112(5):1083-8.
DMKSFPE	RU	https://pubmed.ncbi.nlm.nih.gov/18224669

DM0HR5W	DI	DM0HR5W
DM0HR5W	DN	BMS-181100
DM0HR5W	MI	TTSQIFT
DM0HR5W	MN	5-HT 1A receptor (HTR1A)
DM0HR5W	MT	DTT
DM0HR5W	MA	Modulator
DM0HR5W	RN	BMY 14802, a sigma receptor ligand for the treatment of schizophrenia. Neuropsychopharmacology. 1994 Feb;10(1):37-40.
DM0HR5W	RU	https://www.ncbi.nlm.nih.gov/pubmed/7910021

DM0HR5W	DI	DM0HR5W
DM0HR5W	DN	BMS-181100
DM0HR5W	MI	TT5TPI6
DM0HR5W	MN	Opioid receptor sigma 1 (OPRS1)
DM0HR5W	MT	DTT
DM0HR5W	MA	Modulator
DM0HR5W	RN	BMY 14802, a sigma receptor ligand for the treatment of schizophrenia. Neuropsychopharmacology. 1994 Feb;10(1):37-40.
DM0HR5W	RU	https://www.ncbi.nlm.nih.gov/pubmed/7910021

DMFZNLH	DI	DMFZNLH
DMFZNLH	DN	BMS-204352
DMFZNLH	MI	TT1VOHK
DMFZNLH	MN	Potassium channel unspecific (KC)
DMFZNLH	MT	DTT
DMFZNLH	MA	Modulator
DMFZNLH	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMFZNLH	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMZK70E	DI	DMZK70E
DMZK70E	DN	BN 50730
DMZK70E	MI	TTQL5VC
DMZK70E	MN	Platelet-activating factor receptor (PTAFR)
DMZK70E	MT	DTT
DMZK70E	MA	Modulator
DMZK70E	RN	Platelet-activating factor antagonist BN 50730 attenuates hypoxic-ischemic brain injury in neonatal rats. Pediatr Res. 2001 Jun;49(6):804-11.
DMZK70E	RU	https://www.ncbi.nlm.nih.gov/pubmed/11385142

DMMT1YQ	DI	DMMT1YQ
DMMT1YQ	DN	Bropirimine
DMMT1YQ	MI	TTG9CFY
DMMT1YQ	MN	Bacterial Dihydroneopterinaldolase (Bact folB)
DMMT1YQ	MT	DTT
DMMT1YQ	MA	Inhibitor
DMMT1YQ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMMT1YQ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMMT1YQ	DI	DMMT1YQ
DMMT1YQ	DN	Bropirimine
DMMT1YQ	MI	DEJGDUW
DMMT1YQ	MN	Cytochrome P450 1A2 (CYP1A2)
DMMT1YQ	MT	DME
DMMT1YQ	MA	Metabolism
DMMT1YQ	RN	Human biotransformation of bropirimine. Characterization of the major bropirimine oxidative metabolites formed in vitro. Drug Metab Dispos. 1998 Oct;26(10):1048-51.
DMMT1YQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9763414

DMMT1YQ	DI	DMMT1YQ
DMMT1YQ	DN	Bropirimine
DMMT1YQ	MI	TTV2CN0
DMMT1YQ	MN	Interferon receptor (IFNR)
DMMT1YQ	MT	DTT
DMMT1YQ	MA	Modulator
DMMT1YQ	RN	Comparison between circulating interferon and drug levels following administration of 2-amino-5-bromo-6-phenyl-4(3H)-pyrimidinone (ABPP) to different animal species. J Interferon Res. 1982;2(3):317-27.
DMMT1YQ	RU	https://pubmed.ncbi.nlm.nih.gov/6182250

DMRA6H5	DI	DMRA6H5
DMRA6H5	DN	Broxaterol
DMRA6H5	MI	TT2CJVK
DMRA6H5	MN	Adrenergic receptor beta-2 (ADRB2)
DMRA6H5	MT	DTT
DMRA6H5	MA	Modulator
DMRA6H5	RN	Broxaterol, a new beta 2-adrenoceptor agonist compared to salbutamol in asthmatics, oral and inhalation treatment. Respiration. 1989;55 Suppl 2:15-9.
DMRA6H5	RU	https://pubmed.ncbi.nlm.nih.gov/2572036

DM4HGMX	DI	DM4HGMX
DM4HGMX	DN	CDP571
DM4HGMX	MI	TTF8CQI
DM4HGMX	MN	Tumor necrosis factor (TNF)
DM4HGMX	MT	DTT
DM4HGMX	MA	Modulator
DM4HGMX	RN	CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo... Aliment Pharmacol Ther. 2006 Mar 1;23(5):617-28.
DM4HGMX	RU	https://www.ncbi.nlm.nih.gov/pubmed/16480401

DMANMXZ	DI	DMANMXZ
DMANMXZ	DN	CEFCANEL DALOXATE HYDROCHLORIDE
DMANMXZ	MI	TTJP4SM
DMANMXZ	MN	Bacterial Penicillin binding protein (Bact PBP)
DMANMXZ	MT	DTT
DMANMXZ	MA	Modulator
DMANMXZ	RN	Pharmacokinetics of oral cefcanel daloxate hydrochloride in healthy volunteers and patients with various degrees of impaired renal function. J Antimicrob Chemother. 1994 Feb;33(2):281-8.
DMANMXZ	RU	https://pubmed.ncbi.nlm.nih.gov/8182009

DMEMUQP	DI	DMEMUQP
DMEMUQP	DN	CEFETECOL
DMEMUQP	MI	TTJP4SM
DMEMUQP	MN	Bacterial Penicillin binding protein (Bact PBP)
DMEMUQP	MT	DTT
DMEMUQP	MA	Modulator
DMEMUQP	RN	Antibacterial activities in vitro and in vivo and pharmacokinetics of cefquinome (HR 111V), a new broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1991 Jan;35(1):14-9.
DMEMUQP	RU	https://pubmed.ncbi.nlm.nih.gov/2014969

DMRYC08	DI	DMRYC08
DMRYC08	DN	CGP71683A
DMRYC08	MI	TTY6EWA
DMRYC08	MN	Neuropeptide Y receptor type 5 (NPY5R)
DMRYC08	MT	DTT
DMRYC08	MA	Antagonist
DMRYC08	RN	Neuropeptide Y-induced enhancement of the evoked release of newly synthesized dopamine in rat striatum: mediation by Y2 receptors. Neuropharmacology. 2007 May;52(6):1396-402.
DMRYC08	RU	https://pubmed.ncbi.nlm.nih.gov/17382974

DMHSM7I	DI	DMHSM7I
DMHSM7I	DN	Cilomilast
DMHSM7I	MI	TTV5CGO
DMHSM7I	MN	Phosphodiesterase 4 (PDE4)
DMHSM7I	MT	DTT
DMHSM7I	MA	Inhibitor
DMHSM7I	RN	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
DMHSM7I	RU	https://pubmed.ncbi.nlm.nih.gov/16634702

DMHSM7I	DI	DMHSM7I
DMHSM7I	DN	Cilomilast
DMHSM7I	MI	TTZ97H5
DMHSM7I	MN	Phosphodiesterase 4A (PDE4A)
DMHSM7I	MT	DTT
DMHSM7I	MA	Inhibitor
DMHSM7I	RN	Emerging drugs for asthma. Expert Opin Emerg Drugs. 2008 Dec;13(4):643-53.
DMHSM7I	RU	https://pubmed.ncbi.nlm.nih.gov/19046132

DMOU173	DI	DMOU173
DMOU173	DN	CP-945598
DMOU173	MI	TT6OEDT
DMOU173	MN	Cannabinoid receptor 1 (CB1)
DMOU173	MT	DTT
DMOU173	MA	Antagonist
DMOU173	RN	Pfizer. Product Development Pipeline. March 31 2009.
DMOU173	RU	http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf

DM753RT	DI	DM753RT
DM753RT	DN	CVT-124
DM753RT	MI	TTK25J1
DM753RT	MN	Adenosine A1 receptor (ADORA1)
DM753RT	MT	DTT
DM753RT	MA	Antagonist
DM753RT	RN	CV Therapeutics. Company report from CV Therapeutics, Inc. CV Therapeutics. 2009.
DM753RT	RU	http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/11-08-2007/0004700893&EDATE=

DMHSLVO	DI	DMHSLVO
DMHSLVO	DN	DA-7101
DMHSLVO	MI	TTHI19T
DMHSLVO	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMHSLVO	MT	DTT
DMHSLVO	MA	Inhibitor
DMHSLVO	RN	Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
DMHSLVO	RU	https://pubmed.ncbi.nlm.nih.gov/15934867

DMNQIKV	DI	DMNQIKV
DMNQIKV	DN	DALTROBAN
DMNQIKV	MI	TT2O84V
DMNQIKV	MN	Thromboxane A2 receptor (TBXA2R)
DMNQIKV	MT	DTT
DMNQIKV	MA	Inhibitor
DMNQIKV	RN	Synthesis and thromboxane A2/prostaglandin H2 receptor antagonistic activity of phenol derivatives. J Med Chem. 1992 Jun 12;35(12):2202-9.
DMNQIKV	RU	https://pubmed.ncbi.nlm.nih.gov/1535377

DMZ38EN	DI	DMZ38EN
DMZ38EN	DN	Dalvastatin
DMZ38EN	MI	TTPADOQ
DMZ38EN	MN	HMG-CoA reductase (HMGCR)
DMZ38EN	MT	DTT
DMZ38EN	MA	Inhibitor
DMZ38EN	RN	RG 12561 (dalvastatin): a novel synthetic inhibitor of HMG-CoA reductase and cholesterol-lowering agent. Pharmacology. 1993;46(1):13-22.
DMZ38EN	RU	https://pubmed.ncbi.nlm.nih.gov/8434028

DMSWLA3	DI	DMSWLA3
DMSWLA3	DN	Darapladib
DMSWLA3	MI	TT9V5JH
DMSWLA3	MN	Phospholipase A2 (PLA2G1B)
DMSWLA3	MT	DTT
DMSWLA3	MA	Modulator
DMSWLA3	RN	Darapladib, a reversible lipoprotein-associated phospholipase A2 inhibitor, for the oral treatment of atherosclerosis and coronary artery disease. IDrugs. 2009 Oct;12(10):648-55.
DMSWLA3	RU	https://www.ncbi.nlm.nih.gov/pubmed/19790016

DMC40SD	DI	DMC40SD
DMC40SD	DN	Darexaban maleate
DMC40SD	MI	TTCIHJA
DMC40SD	MN	Coagulation factor Xa (F10)
DMC40SD	MT	DTT
DMC40SD	MA	Inhibitor
DMC40SD	RN	The pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P-glycoprotein and CYP3A4. Br J Clin Pharmacol. 2013 Feb;75(2):440-9.
DMC40SD	RU	https://pubmed.ncbi.nlm.nih.gov/22642721

DMEMF60	DI	DMEMF60
DMEMF60	DN	Delequamine hydrochloride
DMEMF60	MI	TT2NUT5
DMEMF60	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMEMF60	MT	DTT
DMEMF60	MA	Modulator
DMEMF60	RN	Modulation of sexual behaviour in the rat by a potent and selective alpha 2-adrenoceptor antagonist, delequamine (RS-15385-197). Br J Pharmacol. 1996 May;118(1):63-72.
DMEMF60	RU	https://pubmed.ncbi.nlm.nih.gov/8733577

DMXKWAL	DI	DMXKWAL
DMXKWAL	DN	Deligoparin sodium
DMXKWAL	MI	TT4QPUL
DMXKWAL	MN	Antithrombin-III (ATIII)
DMXKWAL	MT	DTT
DMXKWAL	MA	Modulator
DMXKWAL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2632).
DMXKWAL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2632

DM8DUZT	DI	DM8DUZT
DM8DUZT	DN	Deramciclane
DM8DUZT	MI	TTJQOD7
DM8DUZT	MN	5-HT 2A receptor (HTR2A)
DM8DUZT	MT	DTT
DM8DUZT	MA	Modulator
DM8DUZT	RN	Deramciclane, a putative anxiolytic drug, is a serotonin 5-HT2C receptor inverse agonist but fails to induce 5-HT2C receptor down-regulation. Psychopharmacology (Berl). 1998 Mar;136(2):99-104.
DM8DUZT	RU	https://pubmed.ncbi.nlm.nih.gov/9551765

DM8DUZT	DI	DM8DUZT
DM8DUZT	DN	Deramciclane
DM8DUZT	MI	TTWJBZ5
DM8DUZT	MN	5-HT 2C receptor (HTR2C)
DM8DUZT	MT	DTT
DM8DUZT	MA	Modulator
DM8DUZT	RN	Deramciclane, a putative anxiolytic drug, is a serotonin 5-HT2C receptor inverse agonist but fails to induce 5-HT2C receptor down-regulation. Psychopharmacology (Berl). 1998 Mar;136(2):99-104.
DM8DUZT	RU	https://pubmed.ncbi.nlm.nih.gov/9551765

DM8DUZT	DI	DM8DUZT
DM8DUZT	DN	Deramciclane
DM8DUZT	MI	DEVDYN7
DM8DUZT	MN	Cytochrome P450 2E1 (CYP2E1)
DM8DUZT	MT	DME
DM8DUZT	MA	Metabolism
DM8DUZT	RN	Role of CYP2E1 in deramciclane metabolism. Drug Metab Dispos. 2005 Nov;33(11):1717-22.
DM8DUZT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15932955

DMO3AJS	DI	DMO3AJS
DMO3AJS	DN	DG031
DMO3AJS	MI	TTDMBF5
DMO3AJS	MN	Arachidonate 5-lipoxygenase activating protein (FLAP)
DMO3AJS	MT	DTT
DMO3AJS	MA	Inhibitor
DMO3AJS	RN	BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol. 2007 Sep;58(3):583-8.
DMO3AJS	RU	https://pubmed.ncbi.nlm.nih.gov/17928652

DMX2SHT	DI	DMX2SHT
DMX2SHT	DN	Dianicline
DMX2SHT	MI	TTL1ATN
DMX2SHT	MN	Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2)
DMX2SHT	MT	DTT
DMX2SHT	MA	Modulator
DMX2SHT	RN	Dianicline, a novel 42 nicotinic acetylcholine receptor partial agonist, for smoking cessation: a randomized placebo-controlled clinical trial.Nicotine Tob Res.2011 Jan;13(1):1-6.
DMX2SHT	RU	https://www.ncbi.nlm.nih.gov/pubmed/21041839

DMWMHU7	DI	DMWMHU7
DMWMHU7	DN	Dofequidar fumarate
DMWMHU7	MI	TTJUXV6
DMWMHU7	MN	Multidrug resistance protein 3 (ABCB4)
DMWMHU7	MT	DTT
DMWMHU7	MA	Modulator
DMWMHU7	RN	Reversal of multidrug resistance by a novel quinoline derivative, MS-209. Cancer Chemother Pharmacol. 1995;35(4):271-7.
DMWMHU7	RU	https://pubmed.ncbi.nlm.nih.gov/7828268

DMJOM31	DI	DMJOM31
DMJOM31	DN	ELGODIPINE HYDROCHLORIDE
DMJOM31	MI	TT5HONZ
DMJOM31	MN	Calcium channel unspecific (CaC)
DMJOM31	MT	DTT
DMJOM31	MA	Agonist
DMJOM31	RN	The calcium channel blocker amlodipine exerts its anti-proliferative action via p21(Waf1/Cip1) gene activation. FASEB J. 2004 Oct;18(13):1516-23.
DMJOM31	RU	https://pubmed.ncbi.nlm.nih.gov/15466360

DM38CIV	DI	DM38CIV
DM38CIV	DN	ELTANOLONE
DM38CIV	MI	TT1MPAY
DM38CIV	MN	GABA(A) receptor alpha-1 (GABRA1)
DM38CIV	MT	DTT
DM38CIV	MA	Inhibitor
DM38CIV	RN	Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (... J Med Chem. 2005 Apr 21;48(8):3051-9.
DM38CIV	RU	https://pubmed.ncbi.nlm.nih.gov/15828844

DM38CIV	DI	DM38CIV
DM38CIV	DN	ELTANOLONE
DM38CIV	MI	TTZA1NY
DM38CIV	MN	GABA(A) receptor beta-2 (GABRB2)
DM38CIV	MT	DTT
DM38CIV	MA	Inhibitor
DM38CIV	RN	Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (... J Med Chem. 2005 Apr 21;48(8):3051-9.
DM38CIV	RU	https://pubmed.ncbi.nlm.nih.gov/15828844

DM38CIV	DI	DM38CIV
DM38CIV	DN	ELTANOLONE
DM38CIV	MI	TT06RH5
DM38CIV	MN	GABA(A) receptor gamma-2 (GABRG2)
DM38CIV	MT	DTT
DM38CIV	MA	Inhibitor
DM38CIV	RN	Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (... J Med Chem. 2005 Apr 21;48(8):3051-9.
DM38CIV	RU	https://pubmed.ncbi.nlm.nih.gov/15828844

DM38CIV	DI	DM38CIV
DM38CIV	DN	ELTANOLONE
DM38CIV	MI	TTNJYV2
DM38CIV	MN	Gamma-aminobutyric acid receptor (GAR)
DM38CIV	MT	DTT
DM38CIV	MA	Inhibitor
DM38CIV	RN	Neurosteroid analogues. 11. Alternative ring system scaffolds: gamma-aminobutyric acid receptor modulation and anesthetic actions of benz[f]indenes. J Med Chem. 2006 Jul 27;49(15):4595-605.
DM38CIV	RU	https://pubmed.ncbi.nlm.nih.gov/16854065

DM5JUW0	DI	DM5JUW0
DM5JUW0	DN	EM-800
DM5JUW0	MI	TTZAYWL
DM5JUW0	MN	Estrogen receptor (ESR)
DM5JUW0	MT	DTT
DM5JUW0	MA	Antagonist
DM5JUW0	RN	EM-800, a novel antiestrogen, acts as a pure antagonist of the transcriptional functions of estrogen receptors alpha and beta. Endocrinology. 1998 Jan;139(1):111-8.
DM5JUW0	RU	https://pubmed.ncbi.nlm.nih.gov/9421405

DM5JUW0	DI	DM5JUW0
DM5JUW0	DN	EM-800
DM5JUW0	MI	TTOM3J0
DM5JUW0	MN	Estrogen receptor beta (ESR2)
DM5JUW0	MT	DTT
DM5JUW0	MA	Antagonist
DM5JUW0	RN	EM-800, a novel antiestrogen, acts as a pure antagonist of the transcriptional functions of estrogen receptors alpha and beta. Endocrinology. 1998 Jan;139(1):111-8.
DM5JUW0	RU	https://pubmed.ncbi.nlm.nih.gov/9421405

DMCU1WO	DI	DMCU1WO
DMCU1WO	DN	Eperezolid
DMCU1WO	MI	TTUWYEA
DMCU1WO	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DMCU1WO	MT	DTT
DMCU1WO	MA	Modulator
DMCU1WO	RN	The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin.
DMCU1WO	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC164081

DMM5ZX6	DI	DMM5ZX6
DMM5ZX6	DN	Epothilone B
DMM5ZX6	MI	DE4LYSA
DMM5ZX6	MN	Cytochrome P450 3A4 (CYP3A4)
DMM5ZX6	MT	DME
DMM5ZX6	MA	Metabolism
DMM5ZX6	RN	The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development. Clin Cancer Res. 2008 May 1;14(9):2701-9.
DMM5ZX6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18451235

DMM5ZX6	DI	DMM5ZX6
DMM5ZX6	DN	Epothilone B
DMM5ZX6	MI	TTML2WA
DMM5ZX6	MN	Tubulin (TUB)
DMM5ZX6	MT	DTT
DMM5ZX6	MA	Inhibitor
DMM5ZX6	RN	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
DMM5ZX6	RU	https://pubmed.ncbi.nlm.nih.gov/19249983

DM3OUT0	DI	DM3OUT0
DM3OUT0	DN	Etarotene
DM3OUT0	MI	TT4PTJ7
DM3OUT0	MN	Ribonuclease P protein (RPP)
DM3OUT0	MT	DTT
DM3OUT0	MA	Modulator
DM3OUT0	RN	Retinoids inhibit human epidermal keratinocyte RNase P activity. Biol Chem. 2003 Mar;384(3):457-62.
DM3OUT0	RU	https://pubmed.ncbi.nlm.nih.gov/12715896

DMF93U1	DI	DMF93U1
DMF93U1	DN	Etilevodopa
DMF93U1	MI	DECB0K3
DMF93U1	MN	Cytochrome P450 2D6 (CYP2D6)
DMF93U1	MT	DME
DMF93U1	MA	Metabolism
DMF93U1	RN	Identification of cytochrome P450 enzymes involved in the metabolism of 4'-methoxy-alpha-pyrrolidinopropiophenone (MOPPP), a designer drug, in human liver microsomes. Xenobiotica. 2003 Oct;33(10):989-98.
DMF93U1	RU	http://www.ncbi.nlm.nih.gov/pubmed/14555336

DM159U2	DI	DM159U2
DM159U2	DN	Evernimicin
DM159U2	MI	TTUWYEA
DM159U2	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DM159U2	MT	DTT
DM159U2	MA	Modulator
DM159U2	RN	Evernimicin binds exclusively to the 50S ribosomal subunit and inhibits translation in cell-free systems derived from both gram-positive and gram-n... Antimicrob Agents Chemother. 2000 May;44(5):1121-6.
DM159U2	RU	https://www.ncbi.nlm.nih.gov/pubmed/10770739

DMOIP7R	DI	DMOIP7R
DMOIP7R	DN	Flesinoxan
DMOIP7R	MI	TTSQIFT
DMOIP7R	MN	5-HT 1A receptor (HTR1A)
DMOIP7R	MT	DTT
DMOIP7R	MA	Agonist
DMOIP7R	RN	Effect of sustained administration of the 5-HT1A receptor agonist flesinoxan on rat 5-HT neurotransmission. Eur Neuropsychopharmacol. 1999 Sep;9(5):427-40.
DMOIP7R	RU	https://pubmed.ncbi.nlm.nih.gov/10523050

DMOIP7R	DI	DMOIP7R
DMOIP7R	DN	Flesinoxan
DMOIP7R	MI	DTUGYRD
DMOIP7R	MN	P-glycoprotein 1 (ABCB1)
DMOIP7R	MT	DTP
DMOIP7R	MA	Substrate
DMOIP7R	RN	Active efflux of the 5-HT(1A) receptor agonist flesinoxan via P-glycoprotein at the blood-brain barrier. Eur J Pharm Sci. 2001 Aug;14(1):81-6.
DMOIP7R	RU	https://doi.org/10.1016/S0928-0987(01)00150-6

DMN1O7E	DI	DMN1O7E
DMN1O7E	DN	FLUPAROXAN
DMN1O7E	MI	TT2NUT5
DMN1O7E	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMN1O7E	MT	DTT
DMN1O7E	MA	Modulator
DMN1O7E	RN	The pharmacology of fluparoxan: a selective alpha 2-adrenoceptor antagonist. Br J Pharmacol. 1991 Apr;102(4):887-95.
DMN1O7E	RU	https://pubmed.ncbi.nlm.nih.gov/1677298

DML1DGP	DI	DML1DGP
DML1DGP	DN	FOROPAFANT
DML1DGP	MI	TTQL5VC
DML1DGP	MN	Platelet-activating factor receptor (PTAFR)
DML1DGP	MT	DTT
DML1DGP	MA	Antagonist
DML1DGP	RN	Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist. J Pharmacol Exp Ther. 1991 Oct;259(1):44-51.
DML1DGP	RU	https://pubmed.ncbi.nlm.nih.gov/1656029

DME94QF	DI	DME94QF
DME94QF	DN	Furnidipine
DME94QF	MI	TTXHYV6
DME94QF	MN	Voltage-gated L-type calcium channel (L-CaC)
DME94QF	MT	DTT
DME94QF	MA	Modulator
DME94QF	RN	Q-type Ca2+ channels are located closer to secretory sites than L-type channels: functional evidence in chromaffin cells. Pflugers Arch. 1998 Mar;435(4):472-8.
DME94QF	RU	https://www.ncbi.nlm.nih.gov/pubmed/9446693

DMNSE2I	DI	DMNSE2I
DMNSE2I	DN	Galocitabine
DMNSE2I	MI	TTU6BFZ
DMNSE2I	MN	Candida Thymidylate synthase (Candi TMP1)
DMNSE2I	MT	DTT
DMNSE2I	MA	Inhibitor
DMNSE2I	RN	The role of thymidylate synthase in cellular regulation. Adv Enzyme Regul. 1996;36:143-63.
DMNSE2I	RU	https://pubmed.ncbi.nlm.nih.gov/8869745

DMJ4KQS	DI	DMJ4KQS
DMJ4KQS	DN	GW-406381
DMJ4KQS	MI	TTVKILB
DMJ4KQS	MN	Prostaglandin G/H synthase 2 (COX-2)
DMJ4KQS	MT	DTT
DMJ4KQS	MA	Inhibitor
DMJ4KQS	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DMJ4KQS	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DMG6TS2	DI	DMG6TS2
DMG6TS2	DN	GW873140
DMG6TS2	MI	TT2CEJG
DMG6TS2	MN	C-C chemokine receptor type 5 (CCR5)
DMG6TS2	MT	DTT
DMG6TS2	MA	Binder
DMG6TS2	RN	In vitro and clinical investigation of the relationship between CCR5 receptor occupancy and anti-HIV activity of Aplaviroc. J Clin Pharmacol. 2008 Oct;48(10):1179-88.
DMG6TS2	RU	https://pubmed.ncbi.nlm.nih.gov/18676693

DMG6TS2	DI	DMG6TS2
DMG6TS2	DN	GW873140
DMG6TS2	MI	DE4LYSA
DMG6TS2	MN	Cytochrome P450 3A4 (CYP3A4)
DMG6TS2	MT	DME
DMG6TS2	MA	Metabolism
DMG6TS2	RN	Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrob Agents Chemother. 2008 Mar;52(3):858-65.
DMG6TS2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18070967

DMG6TS2	DI	DMG6TS2
DMG6TS2	DN	GW873140
DMG6TS2	MI	DEGTFWK
DMG6TS2	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMG6TS2	MT	DME
DMG6TS2	MA	Metabolism
DMG6TS2	RN	Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrob Agents Chemother. 2008 Mar;52(3):858-65.
DMG6TS2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18070967

DMWB23S	DI	DMWB23S
DMWB23S	DN	H1N1 influenza vaccine
DMWB23S	MI	TT3J5ZI
DMWB23S	MN	Cell mediated immunity response (CMIR)
DMWB23S	MT	DTT
DMWB23S	RN	Risk factors affecting seroconversion after influenza A/H1N1 vaccination in hemodialysis patients. BMC Nephrol. 2012 Dec 3;13:165.
DMWB23S	RU	https://pubmed.ncbi.nlm.nih.gov/23206898

DMX3IRE	DI	DMX3IRE
DMX3IRE	DN	HBP-347
DMX3IRE	MI	TT78R5H
DMX3IRE	MN	Heat shock protein 90 alpha (HSP90A)
DMX3IRE	MT	DTT
DMX3IRE	MA	Modulator
DMX3IRE	RN	US patent application no. 2013,0023,420, Susceptibility to hsp90-inhibitors.
DMX3IRE	RU	http://www.google.com/patents/US20130023420

DMGYKDN	DI	DMGYKDN
DMGYKDN	DN	Hemoximer
DMGYKDN	MI	TTQO71U
DMGYKDN	MN	Hemoglobin (HB)
DMGYKDN	MT	DTT
DMGYKDN	MA	Antagonist
DMGYKDN	RN	Effect of NaBH4 Concentration and Reaction Time on Physical Properties of Glutaraldehyde-Polymerized Hemoglobin. Biotechnology Progress. 05/2004; 20(3):946-52.
DMGYKDN	RU	http://onlinelibrary.wiley.com/doi/10.1021/bp0499754/abstract

DMRXUY7	DI	DMRXUY7
DMRXUY7	DN	Idoxifene
DMRXUY7	MI	TTZAYWL
DMRXUY7	MN	Estrogen receptor (ESR)
DMRXUY7	MT	DTT
DMRXUY7	MA	Modulator
DMRXUY7	RN	Idoxifene: a novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats. Endocrinology. 1998 Dec;139(12):5224-34.
DMRXUY7	RU	https://pubmed.ncbi.nlm.nih.gov/9832463

DM3SKAC	DI	DM3SKAC
DM3SKAC	DN	Idraparinux
DM3SKAC	MI	TTCIHJA
DM3SKAC	MN	Coagulation factor Xa (F10)
DM3SKAC	MT	DTT
DM3SKAC	MA	Inhibitor
DM3SKAC	RN	Pharma & Vaccines. Product Development Pipeline. April 29 2009.
DM3SKAC	RU	http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf

DMDEL2W	DI	DMDEL2W
DMDEL2W	DN	Iferanserin-Ventrus
DMDEL2W	MI	TTJQOD7
DMDEL2W	MN	5-HT 2A receptor (HTR2A)
DMDEL2W	MT	DTT
DMDEL2W	MA	Modulator
DMDEL2W	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 6).
DMDEL2W	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=6

DM8KSMX	DI	DM8KSMX
DM8KSMX	DN	IMIRESTAT
DM8KSMX	MI	TTFBNVI
DM8KSMX	MN	Aldose reductase (AKR1B1)
DM8KSMX	MT	DTT
DM8KSMX	MA	Inhibitor
DM8KSMX	RN	Spiro[fluoreneisothiazolidin]one dioxides: new aldose reductase and L-hexonate dehydrogenase inhibitors. J Med Chem. 1991 Nov;34(11):3229-34.
DM8KSMX	RU	https://pubmed.ncbi.nlm.nih.gov/1956041

DMTHMEI	DI	DMTHMEI
DMTHMEI	DN	INS 316
DMTHMEI	MI	TTYXPCO
DMTHMEI	MN	P2Y purinoceptor 11 (P2RY11)
DMTHMEI	MT	DTT
DMTHMEI	MA	Agonist
DMTHMEI	RN	Characterization of a Ca2+ response to both UTP and ATP at human P2Y11 receptors: evidence for agonist-specific signaling. Mol Pharmacol. 2003 Jun;63(6):1356-63.
DMTHMEI	RU	https://pubmed.ncbi.nlm.nih.gov/12761346

DMTHMEI	DI	DMTHMEI
DMTHMEI	DN	INS 316
DMTHMEI	MI	TTOZHQC
DMTHMEI	MN	P2Y purinoceptor 2 (P2RY2)
DMTHMEI	MT	DTT
DMTHMEI	MA	Modulator
DMTHMEI	RN	Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study. Pediatr Pulmonol. 2001 Aug;32(2):122-8.
DMTHMEI	RU	https://pubmed.ncbi.nlm.nih.gov/11477729

DMTHMEI	DI	DMTHMEI
DMTHMEI	DN	INS 316
DMTHMEI	MI	TT24DGP
DMTHMEI	MN	P2Y purinoceptor 4 (P2RY4)
DMTHMEI	MT	DTT
DMTHMEI	MA	Agonist
DMTHMEI	RN	ATP, an agonist at the rat P2Y(4) receptor, is an antagonist at the human P2Y(4) receptor. Mol Pharmacol. 2000 May;57(5):926-31.
DMTHMEI	RU	https://pubmed.ncbi.nlm.nih.gov/10779375

DMTHMEI	DI	DMTHMEI
DMTHMEI	DN	INS 316
DMTHMEI	MI	TTNVSKA
DMTHMEI	MN	P2Y purinoceptor 6 (P2RY6)
DMTHMEI	MT	DTT
DMTHMEI	MA	Agonist
DMTHMEI	RN	Cloning, functional expression and tissue distribution of the human P2Y6 receptor. Biochem Biophys Res Commun. 1996 May 15;222(2):303-8.
DMTHMEI	RU	https://pubmed.ncbi.nlm.nih.gov/8670200

DMVL8PB	DI	DMVL8PB
DMVL8PB	DN	IoGen
DMVL8PB	MI	TTZAYWL
DMVL8PB	MN	Estrogen receptor (ESR)
DMVL8PB	MT	DTT
DMVL8PB	MA	Modulator
DMVL8PB	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620).
DMVL8PB	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=620

DM7SA9J	DI	DM7SA9J
DM7SA9J	DN	IR-103
DM7SA9J	MI	TTSHG0T
DM7SA9J	MN	Toll-like receptor 9 (TLR9)
DM7SA9J	MT	DTT
DM7SA9J	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1759).
DM7SA9J	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1759

DMUYQH8	DI	DMUYQH8
DMUYQH8	DN	IRX-4310
DMUYQH8	MI	TTOD7B3
DMUYQH8	MN	Retinoic acid receptor (RAR)
DMUYQH8	MT	DTT
DMUYQH8	MA	Antagonist
DMUYQH8	RN	An antagonist of retinoic acid receptors more effectively inhibits growth of human prostate cancer cells than normal prostate epithelium. Br J Cancer. 2004 Aug 2;91(3):580-8.
DMUYQH8	RU	https://pubmed.ncbi.nlm.nih.gov/15266311

DM1AFPW	DI	DM1AFPW
DM1AFPW	DN	KC-764
DM1AFPW	MI	TTK0943
DM1AFPW	MN	Prostaglandin G/H synthase (COX)
DM1AFPW	MT	DTT
DM1AFPW	MA	Modulator
DM1AFPW	RN	Clinical and preclinical pharmacology of KC-764, a novel antiplatelet agent. Nihon Rinsho. 1992 Feb;50(2):379-84.
DM1AFPW	RU	https://pubmed.ncbi.nlm.nih.gov/1613994

DMZMFX6	DI	DMZMFX6
DMZMFX6	DN	KU-1257
DMZMFX6	MI	TTQHJ1K
DMZMFX6	MN	Histamine H2 receptor (H2R)
DMZMFX6	MT	DTT
DMZMFX6	MA	Antagonist
DMZMFX6	RN	Pharmacological profiles of the new histamine H2-receptor antagonist N-ethyl-N'-[3-[3-(piperidinomethyl)phenoxy] propyl] urea. Arzneimittelforschung. 1993 Feb;43(2):129-33.
DMZMFX6	RU	https://pubmed.ncbi.nlm.nih.gov/8096132

DMQZ6SE	DI	DMQZ6SE
DMQZ6SE	DN	KW-2149
DMQZ6SE	MI	TTUTN1I
DMQZ6SE	MN	Human Deoxyribonucleic acid (hDNA)
DMQZ6SE	MT	DTT
DMQZ6SE	MA	Binder
DMQZ6SE	RN	KW-2149 (7-N-[2-[gamma-L-glutamylamino]ethyldithioethyl] mitomycin C): DNA interactions and drug uptake following serum activation. Biochem Pharmacol. 1998 Jun 1;55(11):1777-83.
DMQZ6SE	RU	https://pubmed.ncbi.nlm.nih.gov/9714295

DMXWRGF	DI	DMXWRGF
DMXWRGF	DN	L-759274
DMXWRGF	MI	TTZPO1L
DMXWRGF	MN	Substance-P receptor (TACR1)
DMXWRGF	MT	DTT
DMXWRGF	MA	Antagonist
DMXWRGF	RN	Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
DMXWRGF	RU	https://pubmed.ncbi.nlm.nih.gov/18172433

DM7RGFW	DI	DM7RGFW
DM7RGFW	DN	Lamectacin
DM7RGFW	MI	TTEX248
DM7RGFW	MN	Dopamine D2 receptor (D2R)
DM7RGFW	MT	DTT
DM7RGFW	MA	Antagonist
DM7RGFW	RN	Emerging drugs for bipolar disorder. Expert Opin Emerg Drugs. 2006 Nov;11(4):621-34.
DM7RGFW	RU	https://pubmed.ncbi.nlm.nih.gov/17064222

DMHR1A7	DI	DMHR1A7
DMHR1A7	DN	LAMIFIBAN
DMHR1A7	MI	TT38RM1
DMHR1A7	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DMHR1A7	MT	DTT
DMHR1A7	MA	Modulator
DMHR1A7	RN	Lamifiban. Drugs. 1999 Feb;57(2):215-21; discussion 222-3.
DMHR1A7	RU	https://www.ncbi.nlm.nih.gov/pubmed/10188762

DMJY9CW	DI	DMJY9CW
DMJY9CW	DN	Lapaquistat acetate
DMJY9CW	MI	TTFQEO5
DMJY9CW	MN	Squalene synthetase (FDFT1)
DMJY9CW	MT	DTT
DMJY9CW	MA	Inhibitor
DMJY9CW	RN	Lapaquistat acetate, a squalene synthase inhibitor, changes macrophage/lipid-rich coronary plaques of hypercholesterolaemic rabbits into fibrous le... Br J Pharmacol. 2008 Jul;154(5):949-57.
DMJY9CW	RU	https://pubmed.ncbi.nlm.nih.gov/18587443

DM8CEDR	DI	DM8CEDR
DM8CEDR	DN	Laropiprant+niacin
DM8CEDR	MI	TTNVEIR
DM8CEDR	MN	Prostaglandin D2 receptor (PTGDR)
DM8CEDR	MT	DTT
DM8CEDR	MA	Antagonist
DM8CEDR	RN	Emerging antidyslipidemic drugs. Expert Opin Emerg Drugs. 2008 Jun;13(2):363-81.
DM8CEDR	RU	https://pubmed.ncbi.nlm.nih.gov/18537526

DMCM239	DI	DMCM239
DMCM239	DN	Larotaxel
DMCM239	MI	TTML2WA
DMCM239	MN	Tubulin (TUB)
DMCM239	MT	DTT
DMCM239	MA	Inhibitor
DMCM239	RN	Pharma & Vaccines. Product Development Pipeline. April 29 2009.
DMCM239	RU	http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf

DMKMTR7	DI	DMKMTR7
DMKMTR7	DN	LDI-200
DMKMTR7	MI	TT2O4W9
DMKMTR7	MN	Luteinizing hormone receptor (LHCGR)
DMKMTR7	MT	DTT
DMKMTR7	MA	Modulator
DMKMTR7	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 254).
DMKMTR7	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=254

DMN9KJ2	DI	DMN9KJ2
DMN9KJ2	DN	Lenercept
DMN9KJ2	MI	TTZXH48
DMN9KJ2	MN	TNF receptor (TNFR)
DMN9KJ2	MT	DTT
DMN9KJ2	MA	Modulator
DMN9KJ2	RN	Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controll... Crit Care Med. 2001 Mar;29(3):503-10.
DMN9KJ2	RU	https://www.ncbi.nlm.nih.gov/pubmed/11373411

DMWUS8N	DI	DMWUS8N
DMWUS8N	DN	Licarbazepine
DMWUS8N	MI	TTRK8B9
DMWUS8N	MN	Sodium channel unspecific (NaC)
DMWUS8N	MT	DTT
DMWUS8N	MA	Blocker
DMWUS8N	RN	Emerging drugs for bipolar disorder. Expert Opin Emerg Drugs. 2006 Nov;11(4):621-34.
DMWUS8N	RU	https://pubmed.ncbi.nlm.nih.gov/17064222

DM8OMI6	DI	DM8OMI6
DM8OMI6	DN	Lobucavir
DM8OMI6	MI	TT84ETX
DM8OMI6	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM8OMI6	MT	DTT
DM8OMI6	MA	Modulator
DM8OMI6	RN	Antiviral efficacy of lobucavir (BMS-180194), a cyclobutyl-guanosine nucleoside analogue, in the woodchuck (Marmota monax) model of chronic hepatit... Antiviral Res. 2000 Dec;48(3):197-203.
DM8OMI6	RU	https://www.ncbi.nlm.nih.gov/pubmed/11164506

DMHE804	DI	DMHE804
DMHE804	DN	LOTRAFIBAN
DMHE804	MI	TT38RM1
DMHE804	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DMHE804	MT	DTT
DMHE804	MA	Modulator
DMHE804	RN	Lotrafiban: an oral platelet glycoprotein IIb/IIIa blocker.Expert Opin Investig Drugs.2000 Nov;9(11):2673-87.
DMHE804	RU	https://www.ncbi.nlm.nih.gov/pubmed/11060829

DM2KITF	DI	DM2KITF
DM2KITF	DN	LY335979
DM2KITF	MI	TT3OT40
DM2KITF	MN	Multidrug resistance protein 1 (ABCB1)
DM2KITF	MT	DTT
DM2KITF	MA	Modulator
DM2KITF	RN	A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxoru... Clin Cancer Res. 2004 May 15;10(10):3265-72.
DM2KITF	RU	https://www.ncbi.nlm.nih.gov/pubmed/15161679

DM2KITF	DI	DM2KITF
DM2KITF	DN	LY335979
DM2KITF	MI	TTJUXV6
DM2KITF	MN	Multidrug resistance protein 3 (ABCB4)
DM2KITF	MT	DTT
DM2KITF	MA	Modulator
DM2KITF	RN	A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxoru... Clin Cancer Res. 2004 May 15;10(10):3265-72.
DM2KITF	RU	https://www.ncbi.nlm.nih.gov/pubmed/15161679

DMSC4K1	DI	DMSC4K1
DMSC4K1	DN	LY-544344
DMSC4K1	MI	TTXJ47W
DMSC4K1	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMSC4K1	MT	DTT
DMSC4K1	MA	Agonist
DMSC4K1	RN	Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
DMSC4K1	RU	https://pubmed.ncbi.nlm.nih.gov/16377242

DMSC4K1	DI	DMSC4K1
DMSC4K1	DN	LY-544344
DMSC4K1	MI	TT8A9EF
DMSC4K1	MN	Metabotropic glutamate receptor 3 (mGluR3)
DMSC4K1	MT	DTT
DMSC4K1	MA	Agonist
DMSC4K1	RN	Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
DMSC4K1	RU	https://pubmed.ncbi.nlm.nih.gov/16377242

DMUR3VP	DI	DMUR3VP
DMUR3VP	DN	MDL-11939
DMUR3VP	MI	TTJQOD7
DMUR3VP	MN	5-HT 2A receptor (HTR2A)
DMUR3VP	MT	DTT
DMUR3VP	MA	Inhibitor
DMUR3VP	RN	Ketanserin analogues: structure-affinity relationships for 5-HT2 and 5-HT1C serotonin receptor binding. J Med Chem. 1992 Dec 25;35(26):4903-10.
DMUR3VP	RU	https://pubmed.ncbi.nlm.nih.gov/1479590

DMAZ28C	DI	DMAZ28C
DMAZ28C	DN	Metazosin
DMAZ28C	MI	TTG28O6
DMAZ28C	MN	Adrenergic receptor Alpha-1 (ADRA1)
DMAZ28C	MT	DTT
DMAZ28C	MA	Antagonist
DMAZ28C	RN	Metazosin tablets (Kenosin) in the treatment of chronic congestive heart failure. Cas Lek Cesk. 1995 Sep 20;134(18):590-3.
DMAZ28C	RU	https://pubmed.ncbi.nlm.nih.gov/7489576

DM9FJ7N	DI	DM9FJ7N
DM9FJ7N	DN	Midafotel
DM9FJ7N	MI	TT9IK2Z
DM9FJ7N	MN	N-methyl-D-aspartate receptor (NMDAR)
DM9FJ7N	MT	DTT
DM9FJ7N	MA	Modulator
DM9FJ7N	RN	D-CPP-ene (SDZ EAA 494), a potent and competitive N-methyl-D-aspartate (NMDA) antagonist: effect on spontaneous activity and NMDA-induced depolarizations in the rat neocortical slice preparation, compared with other CPP derivatives and MK-801. Neurosci Lett. 1990 Jun 8;113(3):315-21.
DM9FJ7N	RU	https://pubmed.ncbi.nlm.nih.gov/2166255

DMPCY8K	DI	DMPCY8K
DMPCY8K	DN	Milameline
DMPCY8K	MI	TTOXS3C
DMPCY8K	MN	Muscarinic acetylcholine receptor (CHRM)
DMPCY8K	MT	DTT
DMPCY8K	MA	Modulator
DMPCY8K	RN	Milameline (CI-979/RU35926): a muscarinic receptor agonist with cognition-activating properties: biochemical and in vivo characterization. J Pharmacol Exp Ther. 1999 Nov;291(2):812-22.
DMPCY8K	RU	https://pubmed.ncbi.nlm.nih.gov/10525104

DM86XJG	DI	DM86XJG
DM86XJG	DN	MINALRESTAT
DM86XJG	MI	TTFBNVI
DM86XJG	MN	Aldose reductase (AKR1B1)
DM86XJG	MT	DTT
DM86XJG	MA	Modulator
DM86XJG	RN	Minalrestat, an aldose reductase inhibitor, corrects the impaired microvascular reactivity in diabetes. J Pharmacol Exp Ther. 2003 Mar;304(3):1236-42.
DM86XJG	RU	https://www.ncbi.nlm.nih.gov/pubmed/12604701

DMMZO8X	DI	DMMZO8X
DMMZO8X	DN	Miproxifene
DMMZO8X	MI	TTZAYWL
DMMZO8X	MN	Estrogen receptor (ESR)
DMMZO8X	MT	DTT
DMMZO8X	MA	Modulator
DMMZO8X	RN	Estrogen agonistic/antagonistic effects of miproxifene phosphate (TAT-59)Shibata J1, Toko T, Saito H, Lykkesfeldt AE, Fujioka A, Sato K, Hashimoto A, Wierzba K, Yamada Y.Author information1Hanno Research Center, Taiho Pharmaceutical Co., Ltd., 1-27 Misugidai, Hanno-City, Saitama, 357-8527, Japan.Erratum inCancer Chemother Pharmacol 2000;46(2):172. AbstractPURPOSE: We evaluated miproxifene phosphate (TAT-59) to elucidate its efficacy in antiestrogen therapy for breast cancer patients and to assess its tissue-selective estrogenic/antiestrogenic activity.METHODS: Using DP-TAT-59, a major and active metabolite of TAT-59, an in vitro cell growth inhibition test was performed. Antitumor activity was determined using TAT-59 against human tumor xenografts of the MCF-7 and the Br-10 cell lines andMCF-7-derived tamoxifen-resistant cell lines, R-27 and FST-1. The antitumor activity of DP-TAT-59 and DM-DP-TAT-59, major metabolites of TAT-59 found in human blood following a TAT-59 dose, was also examined after intravenous administration to experimental animals. The residual estrogenic activity of TAT-59, evaluated in terms of bone and lipid metabolism in ovariectomized rats, was then comparedwith that of tamoxifen.RESULTS: DP-TAT-59 significantly inhibited the proliferation of estrogen receptor-positive MCF-7 and T-47D tumor cells in the presence of 1 nM estradiol. TAT-59, given to mice bearing MCF-7 or Br-10 xenografts, at the dose level of 5 mg/kg, exerted a significant growth inhibitory effect that was stronger than that of tamoxifen. Moreover, R-27 and FST-1 tumors, which show a resistance to tamoxifen, responded strongly to TAT-59, suggesting that TAT-59 might be effective against tumors resistant to tamoxifen. The metabolites of TAT-59, DP-TAT-59 and DM-DP-TAT-59, showed similar antitumor activity. Both TAT-59 and tamoxifen suppressed the decrease in bone density and reduced the blood cholesterol levels in ovariectomized rats, suggesting that the estrogenic activity of TAT-59 is comparable to that of tamoxifen.CONCLUSIONS: On the basis of the above results, one may expect TAT-59 to become an effective drug in patients with tumors less sensitive to tamoxifen, while its estrogenic activity as determined by bone and lipid metabolism is similar to that of tamoxifen.PMID: 10663628 [PubMed - indexed for MEDLINE] ShareMeSH Terms, SubstancesMeSH TermsAnimalsAntineoplastic Agents, Hormonal/pharmacologyBreast Neoplasms/pathology*Cell Division/drug effectsDrug Screening Assays, AntitumorEstradiol/pharmacologyEstrogen Antagonists/pharmacology*FemaleHumansLipid MetabolismMiceMice, Inbred BALB CRatsRats, Sprague-DawleyReceptors, Estrogen/physiologyTamoxifen/analogs &amp; derivatives*Tamoxifen/pharmacologyTransplantation, HeterologousTumor Cells, Cultured/drug effectsSubstancesAntineoplastic Agents, HormonalEstrogen AntagonistsReceptors, EstrogenTamoxifenTAT 59EstradiolLinkOut - more resourcesOther Literature SourcesAccess more work from the authors - ResearchGateMedicalBreast Cancer - MedlinePlus Health InformationMiscellaneousESTRADIOL - Hazardous Substances Data BankTAMOXIFEN - Hazardous Substances Data BankPubMed Commons home Cancer Chemother Pharmacol. 2000;45(2):133-41.
DMMZO8X	RU	https://pubmed.ncbi.nlm.nih.gov/10663628

DMXT36M	DI	DMXT36M
DMXT36M	DN	Mivazerol
DMXT36M	MI	TTQ8AFT
DMXT36M	MN	Adrenergic receptor Alpha-2 (ADRA2)
DMXT36M	MT	DTT
DMXT36M	MA	Agonist
DMXT36M	RN	Alpha-2 and imidazoline receptor agonists. Their pharmacology and therapeutic role. Anaesthesia. 1999 Feb;54(2):146-65.
DMXT36M	RU	https://pubmed.ncbi.nlm.nih.gov/10215710

DMJ59A4	DI	DMJ59A4
DMJ59A4	DN	MOFEGILINE
DMJ59A4	MI	TTGP7BY
DMJ59A4	MN	Monoamine oxidase type B (MAO-B)
DMJ59A4	MT	DTT
DMJ59A4	MA	Modulator
DMJ59A4	RN	Structural and mechanistic studies of mofegiline inhibition of recombinant human monoamine oxidase B. J Med Chem. 2008 Dec 25;51(24):8019-26.
DMJ59A4	RU	https://pubmed.ncbi.nlm.nih.gov/19053775

DMZAL8C	DI	DMZAL8C
DMZAL8C	DN	Motesanib
DMZAL8C	MI	TTI2WET
DMZAL8C	MN	Platelet-derived growth factor receptor (PDGFR)
DMZAL8C	MT	DTT
DMZAL8C	MA	Inhibitor
DMZAL8C	RN	Clinical pipeline report, company report or official report of Amgen (2009).
DMZAL8C	RU	http://www.amgen.com/science/pipe.jsp

DMZAL8C	DI	DMZAL8C
DMZAL8C	DN	Motesanib
DMZAL8C	MI	TTX41N9
DMZAL8C	MN	Tyrosine-protein kinase Kit (KIT)
DMZAL8C	MT	DTT
DMZAL8C	MA	Inhibitor
DMZAL8C	RN	Clinical pipeline report, company report or official report of Amgen (2009).
DMZAL8C	RU	http://www.amgen.com/science/pipe.jsp

DMZAL8C	DI	DMZAL8C
DMZAL8C	DN	Motesanib
DMZAL8C	MI	TTUTJGQ
DMZAL8C	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMZAL8C	MT	DTT
DMZAL8C	MA	Inhibitor
DMZAL8C	RN	Clinical pipeline report, company report or official report of Amgen (2009).
DMZAL8C	RU	http://www.amgen.com/science/pipe.jsp

DMYQZBT	DI	DMYQZBT
DMYQZBT	DN	MR-889
DMYQZBT	MI	TTPLTSQ
DMYQZBT	MN	Neutrophil elastase (NE)
DMYQZBT	MT	DTT
DMYQZBT	MA	Inhibitor
DMYQZBT	RN	Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs. 2002 Jul;11(7):965-80.
DMYQZBT	RU	https://pubmed.ncbi.nlm.nih.gov/12084007

DMNX0JH	DI	DMNX0JH
DMNX0JH	DN	N-0861
DMNX0JH	MI	TTK25J1
DMNX0JH	MN	Adenosine A1 receptor (ADORA1)
DMNX0JH	MT	DTT
DMNX0JH	MA	Antagonist
DMNX0JH	RN	N-0861 selectively antagonizes adenosine A1 receptors in vivo. Eur J Pharmacol. 1992 May 27;216(1):9-16.
DMNX0JH	RU	https://pubmed.ncbi.nlm.nih.gov/1526257

DMXHWK6	DI	DMXHWK6
DMXHWK6	DN	Neutralase
DMXHWK6	MI	TTR7GJO
DMXHWK6	MN	Heparanase (HPSE)
DMXHWK6	MT	DTT
DMXHWK6	MA	Modulator
DMXHWK6	RN	Heparanase neutralizes the anticoagulation properties of heparin and low-molecular-weight heparin. J Thromb Haemost. 2006 Mar;4(3):560-5.
DMXHWK6	RU	https://pubmed.ncbi.nlm.nih.gov/16460439

DMJL5TR	DI	DMJL5TR
DMJL5TR	DN	NOLOMIROLE HYDROCHLORIDE
DMJL5TR	MI	TT2NUT5
DMJL5TR	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMJL5TR	MT	DTT
DMJL5TR	MA	Modulator
DMJL5TR	RN	Effect of nolomirole on monocrotaline-induced heart failure. Pharmacol Res. 2004 Jan;49(1):1-5.
DMJL5TR	RU	https://pubmed.ncbi.nlm.nih.gov/14597145

DMJL5TR	DI	DMJL5TR
DMJL5TR	DN	NOLOMIROLE HYDROCHLORIDE
DMJL5TR	MI	TTEX248
DMJL5TR	MN	Dopamine D2 receptor (D2R)
DMJL5TR	MT	DTT
DMJL5TR	MA	Agonist
DMJL5TR	RN	Effect of nolomirole on monocrotaline-induced heart failure. Pharmacol Res. 2004 Jan;49(1):1-5.
DMJL5TR	RU	https://pubmed.ncbi.nlm.nih.gov/14597145

DMMDY27	DI	DMMDY27
DMMDY27	DN	Nuleusin
DMMDY27	MI	TTF89GD
DMMDY27	MN	Interleukin-2 (IL2)
DMMDY27	MT	DTT
DMMDY27	MA	Agonist
DMMDY27	RN	Expression, purification and characterization of recombinant human interleukin-2-serum albumin (rhIL-2-HSA) fusion protein in Pichia pastoris. Protein Expr Purif. 2012 Jul;84(1):154-60.
DMMDY27	RU	https://pubmed.ncbi.nlm.nih.gov/22609631

DMQN3JX	DI	DMQN3JX
DMQN3JX	DN	Ocinaplon
DMQN3JX	MI	TTEX6LM
DMQN3JX	MN	GABA(A) receptor gamma-3 (GABRG3)
DMQN3JX	MT	DTT
DMQN3JX	MA	Modulator
DMQN3JX	RN	Discriminative stimulus properties of GABAA receptor positive allosteric modulators TPA023, ocinaplon and NG2-73 in rats trained to discriminate chlordiazepoxide or zolpidem. Eur J Pharmacol. 2011 Oct 1;668(1-2):190-3.
DMQN3JX	RU	https://pubmed.ncbi.nlm.nih.gov/21762686

DM0O2HP	DI	DM0O2HP
DM0O2HP	DN	OLAMUFLOXACIN MESILATE
DM0O2HP	MI	TTN6J5F
DM0O2HP	MN	Bacterial DNA gyrase (Bact gyrase)
DM0O2HP	MT	DTT
DM0O2HP	MA	Modulator
DM0O2HP	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM0O2HP	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM1RKWV	DI	DM1RKWV
DM1RKWV	DN	ONO-3805
DM1RKWV	MI	TT2A0DR
DM1RKWV	MN	Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A)
DM1RKWV	MT	DTT
DM1RKWV	MA	Modulator
DM1RKWV	RN	Significant role of 5 alpha-reductase on feedback effects of androgen in rat anterior pituitary cells demonstrated with a nonsteroidal 5 alpha-redu... J Androl. 1994 Nov-Dec;15(6):521-7.
DM1RKWV	RU	https://www.ncbi.nlm.nih.gov/pubmed/7721654

DMEDLXJ	DI	DMEDLXJ
DMEDLXJ	DN	ORBOFIBAN
DMEDLXJ	MI	TT38RM1
DMEDLXJ	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DMEDLXJ	MT	DTT
DMEDLXJ	MA	Modulator
DMEDLXJ	RN	Orbofiban: an orally active GPIIb/IIIa platelet receptor antagonist. Med Res Rev. 2001 May;21(3):211-26.
DMEDLXJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/11301411

DMVRA8N	DI	DMVRA8N
DMVRA8N	DN	Org-2766
DMVRA8N	MI	TTEDJN4
DMVRA8N	MN	Low-affinity nerve growth factor receptor (NGFR)
DMVRA8N	MT	DTT
DMVRA8N	MA	Modulator
DMVRA8N	RN	Effects of the ACTH4-9 analog Org2766 on brain plasticity: modulation of excitatory neurotransmission. Psychoneuroendocrinology. 1992 Aug;17(4):315-25.
DMVRA8N	RU	https://pubmed.ncbi.nlm.nih.gov/1332099

DMN7TL8	DI	DMN7TL8
DMN7TL8	DN	Osutidine
DMN7TL8	MI	TTQHJ1K
DMN7TL8	MN	Histamine H2 receptor (H2R)
DMN7TL8	MT	DTT
DMN7TL8	MA	Antagonist
DMN7TL8	RN	Effects of osutidine (T-593) and its enantiomers on gastric mucosal hemodynamics and mucosal integrity in anesthetized rats. Arzneimittelforschung. 2001 Jan;51(1):46-50.
DMN7TL8	RU	https://pubmed.ncbi.nlm.nih.gov/11215325

DMGOPMK	DI	DMGOPMK
DMGOPMK	DN	Otamixaban
DMGOPMK	MI	TTCIHJA
DMGOPMK	MN	Coagulation factor Xa (F10)
DMGOPMK	MT	DTT
DMGOPMK	MA	Inhibitor
DMGOPMK	RN	Pharma & Vaccines. Product Development Pipeline. April 29 2009.
DMGOPMK	RU	http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf

DMWPT8J	DI	DMWPT8J
DMWPT8J	DN	Oxibendazole
DMWPT8J	MI	TTORYTW
DMWPT8J	MN	Polymerase unspecific (POL)
DMWPT8J	MT	DTT
DMWPT8J	MA	Inhibitor
DMWPT8J	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMWPT8J	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMPEHBJ	DI	DMPEHBJ
DMPEHBJ	DN	OX-NLA
DMPEHBJ	MI	TT7CXIM
DMPEHBJ	MN	Histamine receptor (HR)
DMPEHBJ	MT	DTT
DMPEHBJ	MA	Antagonist
DMPEHBJ	RN	Clinical pipeline report, company report or official report of Orexo.
DMPEHBJ	RU	http://www.orexo.com/Portfolio/OX-NLA/

DMFNLDY	DI	DMFNLDY
DMFNLDY	DN	P-1
DMFNLDY	MI	TTSXVID
DMFNLDY	MN	Nuclear factor NF-kappa-B (NFKB)
DMFNLDY	MT	DTT
DMFNLDY	MA	Modulator
DMFNLDY	RN	Chinese herbal medicine for atopic eczema. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD002291.
DMFNLDY	RU	https://pubmed.ncbi.nlm.nih.gov/15495031

DM1FST8	DI	DM1FST8
DM1FST8	DN	Pazinaclone
DM1FST8	MI	TTEX6LM
DM1FST8	MN	GABA(A) receptor gamma-3 (GABRG3)
DM1FST8	MT	DTT
DM1FST8	MA	Modulator
DM1FST8	RN	The benzodiazepine binding site of GABA(A) receptors as a target for the development of novel anxiolytics. Expert Opin Investig Drugs. 2005 May;14(5):601-18.
DM1FST8	RU	https://pubmed.ncbi.nlm.nih.gov/15926867

DM4IM0G	DI	DM4IM0G
DM4IM0G	DN	Pexelizumab
DM4IM0G	MI	TTKANGO
DM4IM0G	MN	Complement C5 (CO5)
DM4IM0G	MT	DTT
DM4IM0G	RN	Pexelizumab reduces death and myocardial infarction in higher risk cardiac surgical patients. Ann Thorac Surg. 2006 Aug;82(2):486-92.
DM4IM0G	RU	https://pubmed.ncbi.nlm.nih.gov/16863750

DMXEU14	DI	DMXEU14
DMXEU14	DN	PF-1913539
DMXEU14	MI	TTM2AOE
DMXEU14	MN	Adenosine A2a receptor (ADORA2A)
DMXEU14	MT	DTT
DMXEU14	MA	Antagonist
DMXEU14	RN	Blockade of A2A adenosine receptors prevents basic fibroblast growth factor-induced reactive astrogliosis in rat striatal primary astrocytes. Glia. 2003 Aug;43(2):190-4.
DMXEU14	RU	https://pubmed.ncbi.nlm.nih.gov/12838511

DMXEU14	DI	DMXEU14
DMXEU14	DN	PF-1913539
DMXEU14	MI	TTNE7KG
DMXEU14	MN	Adenosine A2b receptor (ADORA2B)
DMXEU14	MT	DTT
DMXEU14	MA	Antagonist
DMXEU14	RN	Differences in the order of potency for agonists but not antagonists at human and rat adenosine A2A receptors. Biochem Pharmacol. 1999 Jan 1;57(1):65-75.
DMXEU14	RU	https://pubmed.ncbi.nlm.nih.gov/9920286

DMXEU14	DI	DMXEU14
DMXEU14	DN	PF-1913539
DMXEU14	MI	TTVBPDM
DMXEU14	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMXEU14	MT	DTT
DMXEU14	MA	Antagonist
DMXEU14	RN	Pfizer. Product Development Pipeline. March 31 2009.
DMXEU14	RU	http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf

DMXSTRM	DI	DMXSTRM
DMXSTRM	DN	Pibutidine
DMXSTRM	MI	TTQHJ1K
DMXSTRM	MN	Histamine H2 receptor (H2R)
DMXSTRM	MT	DTT
DMXSTRM	MA	Modulator
DMXSTRM	RN	Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors. Mol Pharmacol. 1995 Oct;48(4):774-82.
DMXSTRM	RU	https://pubmed.ncbi.nlm.nih.gov/7476906

DMQXJDM	DI	DMQXJDM
DMQXJDM	DN	Piroximone
DMQXJDM	MI	TTUST1O
DMQXJDM	MN	Phosphodiesterase (PDE)
DMQXJDM	MT	DTT
DMQXJDM	MA	Inhibitor
DMQXJDM	RN	Circulatory effects of the PDE-inhibitors piroximone and enoximone. Br J Clin Pharmacol. 1993 Oct;36(4):309-14.
DMQXJDM	RU	https://pubmed.ncbi.nlm.nih.gov/12959308

DMDZBIQ	DI	DMDZBIQ
DMDZBIQ	DN	PMI-001
DMDZBIQ	MI	TTF89GD
DMDZBIQ	MN	Interleukin-2 (IL2)
DMDZBIQ	MT	DTT
DMDZBIQ	MA	Inhibitor
DMDZBIQ	RN	Development of a botanical anti-arthritis drug, PMI-001. SBIR.STTR America's Seed Fund.
DMDZBIQ	RU	https://www.sbir.gov/sbirsearch/detail/275638

DMDZBIQ	DI	DMDZBIQ
DMDZBIQ	DN	PMI-001
DMDZBIQ	MI	TTVKILB
DMDZBIQ	MN	Prostaglandin G/H synthase 2 (COX-2)
DMDZBIQ	MT	DTT
DMDZBIQ	MA	Inhibitor
DMDZBIQ	RN	Development of a botanical anti-arthritis drug, PMI-001. SBIR.STTR America's Seed Fund.
DMDZBIQ	RU	https://www.sbir.gov/sbirsearch/detail/275638

DM04ZUW	DI	DM04ZUW
DM04ZUW	DN	Ponalrestat
DM04ZUW	MI	TTFBNVI
DM04ZUW	MN	Aldose reductase (AKR1B1)
DM04ZUW	MT	DTT
DM04ZUW	MA	Inhibitor
DM04ZUW	RN	Ponalrestat, an aldose reductase inhibitor, inhibits cachexia syndrome induced by colon26 adenocarcinoma in mice. Anticancer Res. 1999 Sep-Oct;19(5B):4105-11.
DM04ZUW	RU	https://pubmed.ncbi.nlm.nih.gov/10628361

DM04ZUW	DI	DM04ZUW
DM04ZUW	DN	Ponalrestat
DM04ZUW	MI	TTN7Y4P
DM04ZUW	MN	Sodium/glucose cotransporter 2 (SLC5A4)
DM04ZUW	MT	DTT
DM04ZUW	MA	Blocker
DM04ZUW	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009).
DM04ZUW	RU	http://www.isispharm.com/Pipeline/index.htm

DML6EWH	DI	DML6EWH
DML6EWH	DN	Posatirelin
DML6EWH	MI	TT4J8MF
DML6EWH	MN	Thyrotropin-releasing hormone receptor (TRHR)
DML6EWH	MT	DTT
DML6EWH	MA	Modulator
DML6EWH	RN	TRH analogs at Gedeon Richter Ltd.: highlights of experimental and clinical efficacy of posatirelin. Acta Pharm Hung. 2002;72(1):62-8.
DML6EWH	RU	https://pubmed.ncbi.nlm.nih.gov/12426788

DMI02PF	DI	DMI02PF
DMI02PF	DN	PRINOMIDE TROMETHAMINE
DMI02PF	MI	TTVKILB
DMI02PF	MN	Prostaglandin G/H synthase 2 (COX-2)
DMI02PF	MT	DTT
DMI02PF	MA	Inhibitor
DMI02PF	RN	Dexketoprofene, selective cox-1 inhibitor nsaids, without gastrointestinal injury in rats. Acta Gastroenterol Latinoam. 2002 May;32(1):17-20.
DMI02PF	RU	https://pubmed.ncbi.nlm.nih.gov/12136686

DMW9H7M	DI	DMW9H7M
DMW9H7M	DN	Propiram fumarate
DMW9H7M	MI	TTN4QDT
DMW9H7M	MN	Opioid receptor (OPR)
DMW9H7M	MT	DTT
DMW9H7M	MA	Modulator
DMW9H7M	RN	The relative analgesic efficacy of propiram fumarate, codeine, aspirin, and placebo in post-impaction dental pain. J Clin Pharmacol. 1984 Jan;24(1):35-42.
DMW9H7M	RU	https://pubmed.ncbi.nlm.nih.gov/6368614

DMB069L	DI	DMB069L
DMB069L	DN	PUMAPRAZOLE
DMB069L	MI	TTLOKXP
DMB069L	MN	Gastric H(+)/K(+) ATPase (Proton pump)
DMB069L	MT	DTT
DMB069L	MA	Modulator
DMB069L	RN	Effects of pumaprazole (BY841), a novel reversible proton pump antagonist, and of omeprazole, on intragastric acidity before and after cure of Heli... Aliment Pharmacol Ther. 1999 Jan;13(1):27-34.
DMB069L	RU	https://www.ncbi.nlm.nih.gov/pubmed/9892876

DMO9XTJ	DI	DMO9XTJ
DMO9XTJ	DN	Quinelorane
DMO9XTJ	MI	TT4C8EA
DMO9XTJ	MN	Dopamine D3 receptor (D3R)
DMO9XTJ	MT	DTT
DMO9XTJ	MA	Modulator
DMO9XTJ	RN	Quinelorane, a dopamine D3/D2 receptor agonist, reduces prepulse inhibition of startle and ventral pallidal GABA efflux: time course studies.Pharmacol Biochem Behav.2008 Oct;90(4):686-90.
DMO9XTJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/18579193

DMNTURD	DI	DMNTURD
DMNTURD	DN	Ranagengliotucel-T
DMNTURD	MI	TTI0KH6
DMNTURD	MN	TGF beta-2 messenger RNA (TGFB2 mRNA)
DMNTURD	MT	DTT
DMNTURD	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017210)
DMNTURD	RU	http://adisinsight.springer.com/drugs/800017210

DMAINU1	DI	DMAINU1
DMAINU1	DN	RB-006
DMAINU1	MI	TTFEZ5Q
DMAINU1	MN	Coagulation factor IX (F9)
DMAINU1	MT	DTT
DMAINU1	MA	Inhibitor
DMAINU1	RN	In-vitro evaluation of anti-factor IXa aptamer on thrombin generation, clotting time, and viscoelastometry. Thromb Haemost. 2009 May;101(5):827-33.
DMAINU1	RU	https://pubmed.ncbi.nlm.nih.gov/19404534

DMXV28I	DI	DMXV28I
DMXV28I	DN	RG-12915
DMXV28I	MI	TTNXLKE
DMXV28I	MN	5-HT 3 receptor (5HT3R)
DMXV28I	MT	DTT
DMXV28I	MA	Antagonist
DMXV28I	RN	Cataractogenesis in rats induced by in utero exposure to RG 12915, a 5-HT3 antagonist. Fundam Appl Toxicol. 1995 Sep;27(2):270-6.
DMXV28I	RU	https://pubmed.ncbi.nlm.nih.gov/8529823

DMCV0BZ	DI	DMCV0BZ
DMCV0BZ	DN	RhTPO
DMCV0BZ	MI	TTIHYA4
DMCV0BZ	MN	Thrombopoietin receptor (MPL)
DMCV0BZ	MT	DTT
DMCV0BZ	MA	Agonist
DMCV0BZ	RN	Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54.
DMCV0BZ	RU	https://pubmed.ncbi.nlm.nih.gov/18537519

DMBKN4P	DI	DMBKN4P
DMBKN4P	DN	Riferminogene pecaplasmid
DMBKN4P	MI	TTMY81X
DMBKN4P	MN	Heparin-binding growth factor 1 (FGF1)
DMBKN4P	MT	DTT
DMBKN4P	MA	Modulator
DMBKN4P	RN	Riferminogene pecaplasmide. Am J Cardiovasc Drugs. 2010;10(5):343-6.
DMBKN4P	RU	https://pubmed.ncbi.nlm.nih.gov/20860417

DM0X36Y	DI	DM0X36Y
DM0X36Y	DN	Ritanserin
DM0X36Y	MI	TTYSN63
DM0X36Y	MN	5-HT 2 receptor (5HT2R)
DM0X36Y	MT	DTT
DM0X36Y	MA	Antagonist
DM0X36Y	RN	Characterization of contractile 5-hydroxytryptamine receptor subtypes in the in situ autoperfused kidney in the anaesthetized rat. Eur J Pharmacol. 2008 Sep 11;592(1-3):133-7.
DM0X36Y	RU	https://pubmed.ncbi.nlm.nih.gov/18644367

DM0X36Y	DI	DM0X36Y
DM0X36Y	DN	Ritanserin
DM0X36Y	MI	TTJQOD7
DM0X36Y	MN	5-HT 2A receptor (HTR2A)
DM0X36Y	MT	DTT
DM0X36Y	MA	Antagonist
DM0X36Y	RN	Characterization of contractile 5-hydroxytryptamine receptor subtypes in the in situ autoperfused kidney in the anaesthetized rat. Eur J Pharmacol. 2008 Sep 11;592(1-3):133-7.
DM0X36Y	RU	https://pubmed.ncbi.nlm.nih.gov/18644367

DM0X36Y	DI	DM0X36Y
DM0X36Y	DN	Ritanserin
DM0X36Y	MI	TT0K1SC
DM0X36Y	MN	5-HT 2B receptor (HTR2B)
DM0X36Y	MT	DTT
DM0X36Y	MA	Antagonist
DM0X36Y	RN	p-Chloroamphetamine, a serotonin-releasing drug, elicited in rats a hyperglycemia mediated by the 5-HT1A and 5-HT2B/2C receptors. Eur J Pharmacol. 1998 Oct 23;359(2-3):185-90.
DM0X36Y	RU	https://pubmed.ncbi.nlm.nih.gov/9832390

DM0X36Y	DI	DM0X36Y
DM0X36Y	DN	Ritanserin
DM0X36Y	MI	TTWJBZ5
DM0X36Y	MN	5-HT 2C receptor (HTR2C)
DM0X36Y	MT	DTT
DM0X36Y	MA	Antagonist
DM0X36Y	RN	Characterization of contractile 5-hydroxytryptamine receptor subtypes in the in situ autoperfused kidney in the anaesthetized rat. Eur J Pharmacol. 2008 Sep 11;592(1-3):133-7.
DM0X36Y	RU	https://pubmed.ncbi.nlm.nih.gov/18644367

DM0X36Y	DI	DM0X36Y
DM0X36Y	DN	Ritanserin
DM0X36Y	MI	TT85JO3
DM0X36Y	MN	5-HT receptor (5HTR)
DM0X36Y	MT	DTT
DM0X36Y	MA	Antagonist
DM0X36Y	RN	Combined treatment of portal hypertension with ritanserin and propranolol in conscious and unrestrained cirrhotic rats. Hepatology. 1992 May;15(5):878-82.
DM0X36Y	RU	https://pubmed.ncbi.nlm.nih.gov/1568730

DM0X36Y	DI	DM0X36Y
DM0X36Y	DN	Ritanserin
DM0X36Y	MI	TT4FDG6
DM0X36Y	MN	Voltage-gated calcium channel alpha Cav2.2 (CACNA1B)
DM0X36Y	MT	DTT
DM0X36Y	MA	Blocker
DM0X36Y	RN	N,N-dialkyl-dipeptidylamines as novel N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Mar 22;9(6):907-12.
DM0X36Y	RU	https://pubmed.ncbi.nlm.nih.gov/10206559

DM8M1X0	DI	DM8M1X0
DM8M1X0	DN	Ro-16-6028
DM8M1X0	MI	TTPTXIN
DM8M1X0	MN	Translocator protein (TSPO)
DM8M1X0	MT	DTT
DM8M1X0	MA	Modulator
DM8M1X0	RN	Bretazenil, a benzodiazepine receptor partial agonist, as an adjunct in the prophylactic treatment of OP poisoning. J Appl Toxicol. 2001 Dec;21 Suppl 1:S115-9.
DM8M1X0	RU	https://www.ncbi.nlm.nih.gov/pubmed/11920931

DMOVJ60	DI	DMOVJ60
DMOVJ60	DN	RPAF-AH
DMOVJ60	MI	TTDNFMT
DMOVJ60	MN	Platelet-activating factor acetylhydrolase (PLA2G7)
DMOVJ60	MT	DTT
DMOVJ60	MA	Modulator
DMOVJ60	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006777)
DMOVJ60	RU	http://adisinsight.springer.com/drugs/800006777

DMPUED3	DI	DMPUED3
DMPUED3	DN	S-12968
DMPUED3	MI	TT5HONZ
DMPUED3	MN	Calcium channel unspecific (CaC)
DMPUED3	MT	DTT
DMPUED3	MA	Blocker
DMPUED3	RN	(+)-S-12967 and (-)-S-12968: 1,4-dihydropyridine stereoisomers with calcium channel agonistic and antagonistic properties in rat resistance arteries. Br J Pharmacol. 1991 Jul;103(3):1703-8.
DMPUED3	RU	https://pubmed.ncbi.nlm.nih.gov/1933134

DMSW051	DI	DMSW051
DMSW051	DN	Sabeluzole
DMSW051	MI	DECB0K3
DMSW051	MN	Cytochrome P450 2D6 (CYP2D6)
DMSW051	MT	DME
DMSW051	MA	Metabolism
DMSW051	RN	Pharmacokinetics of sabeluzole and dextromethorphan oxidation capacity in patients with severe hepatic dysfunction and healthy volunteers. Br J Clin Pharmacol. 2001 Feb;51(2):164-8.
DMSW051	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11259989

DM3KC81	DI	DM3KC81
DM3KC81	DN	Sanfetrinem
DM3KC81	MI	TTJP4SM
DM3KC81	MN	Bacterial Penicillin binding protein (Bact PBP)
DM3KC81	MT	DTT
DM3KC81	MA	Modulator
DM3KC81	RN	Entry of Sanfetrinem into Human Polymorphonuclear Granulocytes and Its Cell-Associated Activity against Intracellular, Penicillin-Resistant Streptococcus pneumoniae
DM3KC81	RU	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC105677

DMSRJY3	DI	DMSRJY3
DMSRJY3	DN	Saredutant
DMSRJY3	MI	TTYO0A3
DMSRJY3	MN	Substance-K receptor (TACR2)
DMSRJY3	MT	DTT
DMSRJY3	MA	Antagonist
DMSRJY3	RN	Characterization of species-related differences in the pharmacology of tachykinin NK receptors 1, 2 and 3. Biochem Pharmacol. 2009 May 1;77(9):1522-30.
DMSRJY3	RU	https://pubmed.ncbi.nlm.nih.gov/19426690

DMCJLD1	DI	DMCJLD1
DMCJLD1	DN	SCH 727965
DMCJLD1	MI	TTH6V3D
DMCJLD1	MN	Cyclin-dependent kinase 1 (CDK1)
DMCJLD1	MT	DTT
DMCJLD1	MA	Inhibitor
DMCJLD1	RN	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
DMCJLD1	RU	https://pubmed.ncbi.nlm.nih.gov/19568282

DMCJLD1	DI	DMCJLD1
DMCJLD1	DN	SCH 727965
DMCJLD1	MI	TT7HF4W
DMCJLD1	MN	Cyclin-dependent kinase 2 (CDK2)
DMCJLD1	MT	DTT
DMCJLD1	MA	Inhibitor
DMCJLD1	RN	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
DMCJLD1	RU	https://pubmed.ncbi.nlm.nih.gov/19568282

DMCJLD1	DI	DMCJLD1
DMCJLD1	DN	SCH 727965
DMCJLD1	MI	TT1LVF2
DMCJLD1	MN	Cyclin-dependent kinase 9 (CDK9)
DMCJLD1	MT	DTT
DMCJLD1	MA	Inhibitor
DMCJLD1	RN	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
DMCJLD1	RU	https://pubmed.ncbi.nlm.nih.gov/19568282

DMIHQZ8	DI	DMIHQZ8
DMIHQZ8	DN	Segard
DMIHQZ8	MI	TTF8CQI
DMIHQZ8	MN	Tumor necrosis factor (TNF)
DMIHQZ8	MT	DTT
DMIHQZ8	RN	Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study. Crit Care Med. 2001 Apr;29(4):765-9.
DMIHQZ8	RU	https://pubmed.ncbi.nlm.nih.gov/11373466

DM3IJMN	DI	DM3IJMN
DM3IJMN	DN	Seletracetam
DM3IJMN	MI	DE4LYSA
DM3IJMN	MN	Cytochrome P450 3A4 (CYP3A4)
DM3IJMN	MT	DME
DM3IJMN	MA	Metabolism
DM3IJMN	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DM3IJMN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DM3IJMN	DI	DM3IJMN
DM3IJMN	DN	Seletracetam
DM3IJMN	MI	TTT3P91
DM3IJMN	MN	Synaptic vesicle glycoprotein 2A (SV2A)
DM3IJMN	MT	DTT
DM3IJMN	MA	Binder
DM3IJMN	RN	Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.
DM3IJMN	RU	https://pubmed.ncbi.nlm.nih.gov/17874969

DM3FLIX	DI	DM3FLIX
DM3FLIX	DN	Selfotel
DM3FLIX	MI	TT9IK2Z
DM3FLIX	MN	N-methyl-D-aspartate receptor (NMDAR)
DM3FLIX	MT	DTT
DM3FLIX	MA	Antagonist
DM3FLIX	RN	Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2003 Jan;3(1):9-20.
DM3FLIX	RU	https://pubmed.ncbi.nlm.nih.gov/12507405

DMRBYH8	DI	DMRBYH8
DMRBYH8	DN	Sepimostat mesylate
DMRBYH8	MI	TTEMV5X
DMRBYH8	MN	Serine protease unspecific (SP)
DMRBYH8	MT	DTT
DMRBYH8	MA	Modulator
DMRBYH8	RN	Effect of FUT-187, oral serine protease inhibitor, on inflammation in the gastric remnant. Gan To Kagaku Ryoho. 1996 Dec;23(14):1971-9.
DMRBYH8	RU	https://pubmed.ncbi.nlm.nih.gov/8978806

DMPNTDL	DI	DMPNTDL
DMPNTDL	DN	Seratrodast
DMPNTDL	MI	DEPKLMQ
DMPNTDL	MN	Cytochrome P450 2B6 (CYP2B6)
DMPNTDL	MT	DME
DMPNTDL	MA	Metabolism
DMPNTDL	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMPNTDL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMPNTDL	DI	DMPNTDL
DMPNTDL	DN	Seratrodast
DMPNTDL	MI	DES5XRU
DMPNTDL	MN	Cytochrome P450 2C8 (CYP2C8)
DMPNTDL	MT	DME
DMPNTDL	MA	Metabolism
DMPNTDL	RN	Identification of cytochromes P450 involved in the human liver microsomal metabolism of the thromboxane A2 inhibitor seratrodast (ABT-001). Drug Metab Dispos. 1997 Jan;25(1):110-5.
DMPNTDL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9010637

DMPNTDL	DI	DMPNTDL
DMPNTDL	DN	Seratrodast
DMPNTDL	MI	DE5IED8
DMPNTDL	MN	Cytochrome P450 2C9 (CYP2C9)
DMPNTDL	MT	DME
DMPNTDL	MA	Metabolism
DMPNTDL	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMPNTDL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMPNTDL	DI	DMPNTDL
DMPNTDL	DN	Seratrodast
DMPNTDL	MI	DE4LYSA
DMPNTDL	MN	Cytochrome P450 3A4 (CYP3A4)
DMPNTDL	MT	DME
DMPNTDL	MA	Metabolism
DMPNTDL	RN	Identification of cytochromes P450 involved in the human liver microsomal metabolism of the thromboxane A2 inhibitor seratrodast (ABT-001). Drug Metab Dispos. 1997 Jan;25(1):110-5.
DMPNTDL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9010637

DMPNTDL	DI	DMPNTDL
DMPNTDL	DN	Seratrodast
DMPNTDL	MI	DEGTFWK
DMPNTDL	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMPNTDL	MT	DME
DMPNTDL	MA	Metabolism
DMPNTDL	RN	Identification of cytochromes P450 involved in the human liver microsomal metabolism of the thromboxane A2 inhibitor seratrodast (ABT-001). Drug Metab Dispos. 1997 Jan;25(1):110-5.
DMPNTDL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9010637

DMPNTDL	DI	DMPNTDL
DMPNTDL	DN	Seratrodast
DMPNTDL	MI	DE073H6
DMPNTDL	MN	Prostaglandin G/H synthase 1 (COX-1)
DMPNTDL	MT	DME
DMPNTDL	MA	Metabolism
DMPNTDL	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMPNTDL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMPNTDL	DI	DMPNTDL
DMPNTDL	DN	Seratrodast
DMPNTDL	MI	TT2O84V
DMPNTDL	MN	Thromboxane A2 receptor (TBXA2R)
DMPNTDL	MT	DTT
DMPNTDL	MA	Antagonist
DMPNTDL	RN	Thromboxane A2 inhibition: therapeutic potential in bronchial asthma. Am J Respir Med. 2002;1(1):11-7.
DMPNTDL	RU	https://pubmed.ncbi.nlm.nih.gov/14720071

DMPNTDL	DI	DMPNTDL
DMPNTDL	DN	Seratrodast
DMPNTDL	MI	DE85D2P
DMPNTDL	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMPNTDL	MT	DME
DMPNTDL	MA	Metabolism
DMPNTDL	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMPNTDL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMYQT2V	DI	DMYQT2V
DMYQT2V	DN	Sibenadet
DMYQT2V	MI	TT2CJVK
DMYQT2V	MN	Adrenergic receptor beta-2 (ADRB2)
DMYQT2V	MT	DTT
DMYQT2V	MA	Modulator
DMYQT2V	RN	The role of the novel D2/beta2-agonist, Viozan (sibenadet HCl), in the treatment of symptoms of chronic obstructive pulmonary disease: results of a... Respir Med. 2003 Jan;97 Suppl A:S23-33.
DMYQT2V	RU	https://www.ncbi.nlm.nih.gov/pubmed/12564608

DMYQT2V	DI	DMYQT2V
DMYQT2V	DN	Sibenadet
DMYQT2V	MI	TTEX248
DMYQT2V	MN	Dopamine D2 receptor (D2R)
DMYQT2V	MT	DTT
DMYQT2V	MA	Modulator
DMYQT2V	RN	The role of the novel D2/beta2-agonist, Viozan (sibenadet HCl), in the treatment of symptoms of chronic obstructive pulmonary disease: results of a... Respir Med. 2003 Jan;97 Suppl A:S23-33.
DMYQT2V	RU	https://www.ncbi.nlm.nih.gov/pubmed/12564608

DMZU1TV	DI	DMZU1TV
DMZU1TV	DN	SIBRAFIBAN
DMZU1TV	MI	TT38RM1
DMZU1TV	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DMZU1TV	MT	DTT
DMZU1TV	MA	Modulator
DMZU1TV	RN	Pharmacokinetics and pharmacodynamics of sibrafiban, an orally administered GP IIb/IIIa antagonist, following coadministration of aspirin and heparin. J Clin Pharmacol. 2000 May;40(5):488-95.
DMZU1TV	RU	https://www.ncbi.nlm.nih.gov/pubmed/10806602

DM0T2QV	DI	DM0T2QV
DM0T2QV	DN	Sitimagene ceradenovec
DM0T2QV	MI	TTP3QRF
DM0T2QV	MN	Thymidine kinase 1 (TK1)
DM0T2QV	MT	DTT
DM0T2QV	MA	Modulator
DM0T2QV	RN	Sitimagene ceradenovec: a gene-based drug for the treatment of operable high-grade glioma. Future Oncol. 2010 Nov;6(11):1691-710.
DM0T2QV	RU	https://pubmed.ncbi.nlm.nih.gov/21142657

DMXW1Y3	DI	DMXW1Y3
DMXW1Y3	DN	SKF-96067
DMXW1Y3	MI	TTLOKXP
DMXW1Y3	MN	Gastric H(+)/K(+) ATPase (Proton pump)
DMXW1Y3	MT	DTT
DMXW1Y3	MA	Modulator
DMXW1Y3	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMXW1Y3	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMMG47P	DI	DMMG47P
DMMG47P	DN	SUN-09
DMMG47P	MI	TTDCVZW
DMMG47P	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMMG47P	MT	DTT
DMMG47P	MA	Modulator
DMMG47P	RN	The effects of the GABA agonist, baclofen, on sleep and breathing. Eur Respir J. 1995 Feb;8(2):230-4.
DMMG47P	RU	https://www.ncbi.nlm.nih.gov/pubmed/7758556

DM6M8ZX	DI	DM6M8ZX
DM6M8ZX	DN	Sunepitron
DM6M8ZX	MI	TTSQIFT
DM6M8ZX	MN	5-HT 1A receptor (HTR1A)
DM6M8ZX	MT	DTT
DM6M8ZX	MA	Inhibitor
DM6M8ZX	RN	An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment o... J Med Chem. 2006 Jun 1;49(11):3116-35.
DM6M8ZX	RU	https://pubmed.ncbi.nlm.nih.gov/16722631

DM6M8ZX	DI	DM6M8ZX
DM6M8ZX	DN	Sunepitron
DM6M8ZX	MI	TTNGILX
DM6M8ZX	MN	Adrenergic receptor alpha-1A (ADRA1A)
DM6M8ZX	MT	DTT
DM6M8ZX	MA	Inhibitor
DM6M8ZX	RN	An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment o... J Med Chem. 2006 Jun 1;49(11):3116-35.
DM6M8ZX	RU	https://pubmed.ncbi.nlm.nih.gov/16722631

DM6M8ZX	DI	DM6M8ZX
DM6M8ZX	DN	Sunepitron
DM6M8ZX	MI	TTBRKXS
DM6M8ZX	MN	Adrenergic receptor alpha-1B (ADRA1B)
DM6M8ZX	MT	DTT
DM6M8ZX	MA	Inhibitor
DM6M8ZX	RN	An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment o... J Med Chem. 2006 Jun 1;49(11):3116-35.
DM6M8ZX	RU	https://pubmed.ncbi.nlm.nih.gov/16722631

DM6M8ZX	DI	DM6M8ZX
DM6M8ZX	DN	Sunepitron
DM6M8ZX	MI	TT34BHT
DM6M8ZX	MN	Adrenergic receptor alpha-1D (ADRA1D)
DM6M8ZX	MT	DTT
DM6M8ZX	MA	Inhibitor
DM6M8ZX	RN	An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment o... J Med Chem. 2006 Jun 1;49(11):3116-35.
DM6M8ZX	RU	https://pubmed.ncbi.nlm.nih.gov/16722631

DMVB9XC	DI	DMVB9XC
DMVB9XC	DN	Tanomastat
DMVB9XC	MI	TTLM12X
DMVB9XC	MN	Matrix metalloproteinase-2 (MMP-2)
DMVB9XC	MT	DTT
DMVB9XC	MA	Inhibitor
DMVB9XC	RN	Radiation therapy and biological compounds for consolidation therapy in advanced ovarian cancer. Int J Gynecol Cancer. 2008 Mar-Apr;18 Suppl 1:44-6.
DMVB9XC	RU	https://pubmed.ncbi.nlm.nih.gov/18336400

DMA4WY5	DI	DMA4WY5
DMA4WY5	DN	Taprostene
DMA4WY5	MI	TT9B4N3
DMA4WY5	MN	Prostaglandin receptor (PTGR)
DMA4WY5	MT	DTT
DMA4WY5	MA	Modulator
DMA4WY5	RN	Partial agonism of taprostene at prostanoid IP receptors in vascular preparations from guinea-pig, rat, and mouse. J Cardiovasc Pharmacol. 2004 Jun;43(6):795-807.
DMA4WY5	RU	https://pubmed.ncbi.nlm.nih.gov/15167273

DM5G9W0	DI	DM5G9W0
DM5G9W0	DN	Taranabant
DM5G9W0	MI	TT6OEDT
DM5G9W0	MN	Cannabinoid receptor 1 (CB1)
DM5G9W0	MT	DTT
DM5G9W0	MA	Antagonist
DM5G9W0	RN	Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Pract Res Clin Endocrinol Metab. 2009 Feb;23(1):133-44.
DM5G9W0	RU	https://pubmed.ncbi.nlm.nih.gov/19285266

DM9T6MS	DI	DM9T6MS
DM9T6MS	DN	Tecadenoson
DM9T6MS	MI	TTK25J1
DM9T6MS	MN	Adenosine A1 receptor (ADORA1)
DM9T6MS	MT	DTT
DM9T6MS	MA	Agonist
DM9T6MS	RN	CV Therapeutics. Company report from CV Therapeutics, Inc. CV Therapeutics. 2009.
DM9T6MS	RU	http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/11-08-2007/0004700893&EDATE=

DM9T6MS	DI	DM9T6MS
DM9T6MS	DN	Tecadenoson
DM9T6MS	MI	DTXD1TQ
DM9T6MS	MN	Equilibrative nucleoside transporter 1 (SLC29A1)
DM9T6MS	MT	DTP
DM9T6MS	MA	Substrate
DM9T6MS	RN	Transport of A1 adenosine receptor agonist tecadenoson by human and mouse nucleoside transporters: evidence for blood-brain barrier transport by murine equilibrative nucleoside transporter 1 mENT1. Drug Metab Dispos. 2013 Apr;41(4):916-22.
DM9T6MS	RU	http://www.ncbi.nlm.nih.gov/pubmed/23388705

DM9T6MS	DI	DM9T6MS
DM9T6MS	DN	Tecadenoson
DM9T6MS	MI	TTYVX59
DM9T6MS	MN	Protein kinase C (PRKC)
DM9T6MS	MT	DTT
DM9T6MS	MA	Binder
DM9T6MS	RN	Protein kinase C as a molecular target for cancer prevention by selenocompounds. Nutr Cancer. 2001;40(1):55-63.
DM9T6MS	RU	https://pubmed.ncbi.nlm.nih.gov/11799924

DMYF1DN	DI	DMYF1DN
DMYF1DN	DN	Terutroban sodium
DMYF1DN	MI	TT2O84V
DMYF1DN	MN	Thromboxane A2 receptor (TBXA2R)
DMYF1DN	MT	DTT
DMYF1DN	MA	Antagonist
DMYF1DN	RN	Terutroban and endothelial TP receptors in atherogenesis. Med Sci (Paris). 2006 Apr;22(4):437-43.
DMYF1DN	RU	https://pubmed.ncbi.nlm.nih.gov/16597416

DMWNXES	DI	DMWNXES
DMWNXES	DN	Thrombomodulin
DMWNXES	MI	TTAPV67
DMWNXES	MN	Thrombomodulin (THBD)
DMWNXES	MT	DTT
DMWNXES	MA	Modulator
DMWNXES	RN	Thrombomodulin. Nihon Yakurigaku Zasshi. 2000 Nov;116(5):283-9.
DMWNXES	RU	https://pubmed.ncbi.nlm.nih.gov/11215378

DME5QDP	DI	DME5QDP
DME5QDP	DN	TIOSPIRONE
DME5QDP	MI	TTSQIFT
DME5QDP	MN	5-HT 1A receptor (HTR1A)
DME5QDP	MT	DTT
DME5QDP	MA	Inhibitor
DME5QDP	RN	Synthesis and biological activity of the putative metabolites of the atypical antipsychotic agent tiospirone. J Med Chem. 1991 Nov;34(11):3316-28.
DME5QDP	RU	https://pubmed.ncbi.nlm.nih.gov/1683407

DME5QDP	DI	DME5QDP
DME5QDP	DN	TIOSPIRONE
DME5QDP	MI	TTJQOD7
DME5QDP	MN	5-HT 2A receptor (HTR2A)
DME5QDP	MT	DTT
DME5QDP	MA	Inhibitor
DME5QDP	RN	3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J Med Chem. 1996 Jan 5;39(1):143-8.
DME5QDP	RU	https://pubmed.ncbi.nlm.nih.gov/8568801

DME5QDP	DI	DME5QDP
DME5QDP	DN	TIOSPIRONE
DME5QDP	MI	TTNGILX
DME5QDP	MN	Adrenergic receptor alpha-1A (ADRA1A)
DME5QDP	MT	DTT
DME5QDP	MA	Inhibitor
DME5QDP	RN	3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J Med Chem. 1996 Jan 5;39(1):143-8.
DME5QDP	RU	https://pubmed.ncbi.nlm.nih.gov/8568801

DME5QDP	DI	DME5QDP
DME5QDP	DN	TIOSPIRONE
DME5QDP	MI	TTBRKXS
DME5QDP	MN	Adrenergic receptor alpha-1B (ADRA1B)
DME5QDP	MT	DTT
DME5QDP	MA	Inhibitor
DME5QDP	RN	3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J Med Chem. 1996 Jan 5;39(1):143-8.
DME5QDP	RU	https://pubmed.ncbi.nlm.nih.gov/8568801

DME5QDP	DI	DME5QDP
DME5QDP	DN	TIOSPIRONE
DME5QDP	MI	TT34BHT
DME5QDP	MN	Adrenergic receptor alpha-1D (ADRA1D)
DME5QDP	MT	DTT
DME5QDP	MA	Inhibitor
DME5QDP	RN	3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J Med Chem. 1996 Jan 5;39(1):143-8.
DME5QDP	RU	https://pubmed.ncbi.nlm.nih.gov/8568801

DME5QDP	DI	DME5QDP
DME5QDP	DN	TIOSPIRONE
DME5QDP	MI	TTEX248
DME5QDP	MN	Dopamine D2 receptor (D2R)
DME5QDP	MT	DTT
DME5QDP	MA	Inhibitor
DME5QDP	RN	3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J Med Chem. 1996 Jan 5;39(1):143-8.
DME5QDP	RU	https://pubmed.ncbi.nlm.nih.gov/8568801

DM7RNPJ	DI	DM7RNPJ
DM7RNPJ	DN	Trenonacog alfa
DM7RNPJ	MI	TTFEZ5Q
DM7RNPJ	MN	Coagulation factor IX (F9)
DM7RNPJ	MT	DTT
DM7RNPJ	MA	Modulator
DM7RNPJ	RN	Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis.Haemophilia.2012 Nov;18(6):881-7.
DM7RNPJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/22764744

DMOVBSF	DI	DMOVBSF
DMOVBSF	DN	Tresperimus
DMOVBSF	MI	DE6SOC5
DMOVBSF	MN	Copper amine oxidase (AOC3)
DMOVBSF	MT	DME
DMOVBSF	MA	Metabolism
DMOVBSF	RN	Metabolism of tresperimus by rat aorta semicarbazide-sensitive amine oxidase (SSAO). Fundam Clin Pharmacol. 2002 Dec;16(6):461-70.
DMOVBSF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12685504

DMXRU9M	DI	DMXRU9M
DMXRU9M	DN	Valspodar
DMXRU9M	MI	TTCIHJA
DMXRU9M	MN	Coagulation factor Xa (F10)
DMXRU9M	MT	DTT
DMXRU9M	MA	Inhibitor
DMXRU9M	RN	Non-hemostatic activity of coagulation factor Xa: potential implications for various diseases. Curr Opin Pharmacol. 2001 Apr;1(2):169-75.
DMXRU9M	RU	https://pubmed.ncbi.nlm.nih.gov/11714092

DMXRU9M	DI	DMXRU9M
DMXRU9M	DN	Valspodar
DMXRU9M	MI	TT0JLSD
DMXRU9M	MN	Multidrug resistance protein (MDR)
DMXRU9M	MT	DTT
DMXRU9M	MA	Modulator
DMXRU9M	RN	Intracellular levels of two cyclosporin derivatives valspodar (PSC 833) and cyclosporin a closely associated with multidrug resistance-modulating activity in sublines of human colorectal adenocarcinoma HCT-15. Jpn J Cancer Res. 2001 Oct;92(10):1116-26.
DMXRU9M	RU	https://pubmed.ncbi.nlm.nih.gov/11676863

DMXRU9M	DI	DMXRU9M
DMXRU9M	DN	Valspodar
DMXRU9M	MI	DTUGYRD
DMXRU9M	MN	P-glycoprotein 1 (ABCB1)
DMXRU9M	MT	DTP
DMXRU9M	MA	Substrate
DMXRU9M	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMXRU9M	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMUB0EC	DI	DMUB0EC
DMUB0EC	DN	VELNACRINE
DMUB0EC	MI	TT1RS9F
DMUB0EC	MN	Acetylcholinesterase (AChE)
DMUB0EC	MT	DTT
DMUB0EC	MA	Inhibitor
DMUB0EC	RN	Synthesis and biological activity of putative mono-hydroxylated metabolites of velnacrine, Bioorg. Med. Chem. Lett. 2(8):865-870 (1992).
DMUB0EC	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805466

DMFJORV	DI	DMFJORV
DMFJORV	DN	Verpasep caltespen
DMFJORV	MI	TTVQGI2
DMFJORV	MN	Mycobacterium Heat shock protein 65 (MycB groL2)
DMFJORV	MT	DTT
DMFJORV	RN	Activity of HspE7, a novel immunotherapy, in patients with anogenital warts. Dis Colon Rectum. 2002 Apr;45(4):502-7.
DMFJORV	RU	https://pubmed.ncbi.nlm.nih.gov/12006932

DMBRYT8	DI	DMBRYT8
DMBRYT8	DN	XEMILOFIBAN
DMBRYT8	MI	TT38RM1
DMBRYT8	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DMBRYT8	MT	DTT
DMBRYT8	MA	Modulator
DMBRYT8	RN	Glycoprotein IIb/IIIa receptor number and occupancy during chronic administration of an oral antagonist. J Pharmacol Exp Ther. 2000 Nov;295(2):670-6.
DMBRYT8	RU	https://www.ncbi.nlm.nih.gov/pubmed/11046104

DMBRYT8	DI	DMBRYT8
DMBRYT8	DN	XEMILOFIBAN
DMBRYT8	MI	TTJA1ZO
DMBRYT8	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMBRYT8	MT	DTT
DMBRYT8	MA	Inhibitor
DMBRYT8	RN	Potent, orally active GPIIb/IIIa antagonists containing a nipecotic acid subunit. Structure-activity studies leading to the discovery of RWJ-53308. J Med Chem. 1999 Dec 16;42(25):5254-65.
DMBRYT8	RU	https://pubmed.ncbi.nlm.nih.gov/10602710

DM3EZ68	DI	DM3EZ68
DM3EZ68	DN	Y-23684
DM3EZ68	MI	TTEX6LM
DM3EZ68	MN	GABA(A) receptor gamma-3 (GABRG3)
DM3EZ68	MT	DTT
DM3EZ68	MA	Modulator
DM3EZ68	RN	The pharmacological properties of Y-23684, a benzodiazepine receptor partial agonist. Br J Pharmacol. 1994 Apr;111(4):1170-8.
DM3EZ68	RU	https://pubmed.ncbi.nlm.nih.gov/7913372

DMFEN6T	DI	DMFEN6T
DMFEN6T	DN	YM533
DMFEN6T	MI	TTOFYT1
DMFEN6T	MN	Prostacyclin receptor (PTGIR)
DMFEN6T	MT	DTT
DMFEN6T	MA	Modulator
DMFEN6T	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 345).
DMFEN6T	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=345

DM51FVE	DI	DM51FVE
DM51FVE	DN	Zamifenacin
DM51FVE	MI	TTQ13Z5
DM51FVE	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DM51FVE	MT	DTT
DM51FVE	MA	Antagonist
DM51FVE	RN	Drug treatment options for irritable bowel syndrome: managing for success. Drugs Aging. 2001;18(3):201-11.
DM51FVE	RU	https://pubmed.ncbi.nlm.nih.gov/11302287

DMTCP8H	DI	DMTCP8H
DMTCP8H	DN	Zanapezil
DMTCP8H	MI	TT1RS9F
DMTCP8H	MN	Acetylcholinesterase (AChE)
DMTCP8H	MT	DTT
DMTCP8H	MA	Inhibitor
DMTCP8H	RN	Effect of oral administration of zanapezil (TAK-147) for 21 days on acetylcholine and monoamines levels in the ventral hippocampus of freely moving rats. Br J Pharmacol. 2005 Aug;145(8):1035-44.
DMTCP8H	RU	https://pubmed.ncbi.nlm.nih.gov/15951830

DMIK6C9	DI	DMIK6C9
DMIK6C9	DN	Zibotentan
DMIK6C9	MI	TTKRD0G
DMIK6C9	MN	Endothelin A receptor (EDNRA)
DMIK6C9	MT	DTT
DMIK6C9	MA	Antagonist
DMIK6C9	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DMIK6C9	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DM6R3WC	DI	DM6R3WC
DM6R3WC	DN	BAY 86-6150
DM6R3WC	MI	TTF0EGX
DM6R3WC	MN	Coagulation factor VII (F7)
DM6R3WC	MT	DTT
DM6R3WC	MA	Modulator
DM6R3WC	RN	Bayer HealthCare and Maxygen Announce Hematology Agreement. U.S. Securities and Exchange Commission. July 2, 2008.
DM6R3WC	RU	http://www.sec.gov/Archives/edgar/data/1068796/000095013408012286/f41954exv99w1.htm

DMTR50E	DI	DMTR50E
DMTR50E	DN	Ilepatril
DMTR50E	MI	TTL69WB
DMTR50E	MN	Angiotensin-converting enzyme (ACE)
DMTR50E	MT	DTT
DMTR50E	MA	Modulator
DMTR50E	RN	Ilepatril (AVE-7688), a vasopeptidase inhibitor for the treatment of hypertension. Curr Opin Investig Drugs. 2008 Mar;9(3):301-9.
DMTR50E	RU	https://pubmed.ncbi.nlm.nih.gov/18311667

DMTR50E	DI	DMTR50E
DMTR50E	DN	Ilepatril
DMTR50E	MI	TT5TKPM
DMTR50E	MN	Neutral endopeptidase (MME)
DMTR50E	MT	DTT
DMTR50E	MA	Modulator
DMTR50E	RN	Ilepatril (AVE-7688), a vasopeptidase inhibitor for the treatment of hypertension. Curr Opin Investig Drugs. 2008 Mar;9(3):301-9.
DMTR50E	RU	https://pubmed.ncbi.nlm.nih.gov/18311667

DMMT4PB	DI	DMMT4PB
DMMT4PB	DN	Osanetant
DMMT4PB	MI	TTBPGLU
DMMT4PB	MN	Neuromedin-K receptor (TACR3)
DMMT4PB	MT	DTT
DMMT4PB	MA	Antagonist
DMMT4PB	RN	Pharmacological characterization of senktide-induced tail whips. Neuropharmacology. 2010 Jan;58(1):259-67.
DMMT4PB	RU	https://pubmed.ncbi.nlm.nih.gov/19540857

DMLQVTJ	DI	DMLQVTJ
DMLQVTJ	DN	Octopamine
DMLQVTJ	MI	TTCIHJA
DMLQVTJ	MN	Coagulation factor Xa (F10)
DMLQVTJ	MT	DTT
DMLQVTJ	MA	Inhibitor
DMLQVTJ	RN	Description of the chemical and pharmacological characteristics of a new hemisynthetic ultra-low-molecular-weight heparin, AVE5026. J Thromb Haemost. 2009 Jul;7(7):1143-51.
DMLQVTJ	RU	https://pubmed.ncbi.nlm.nih.gov/19422447

DMLQVTJ	DI	DMLQVTJ
DMLQVTJ	DN	Octopamine
DMLQVTJ	MI	DECB0K3
DMLQVTJ	MN	Cytochrome P450 2D6 (CYP2D6)
DMLQVTJ	MT	DME
DMLQVTJ	MA	Metabolism
DMLQVTJ	RN	Dopamine formation from tyramine by CYP2D6. Biochem Biophys Res Commun. 1998 Aug 28;249(3):838-43.
DMLQVTJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9731223

DMLQVTJ	DI	DMLQVTJ
DMLQVTJ	DN	Octopamine
DMLQVTJ	MI	DE4LYSA
DMLQVTJ	MN	Cytochrome P450 3A4 (CYP3A4)
DMLQVTJ	MT	DME
DMLQVTJ	MA	Metabolism
DMLQVTJ	RN	Seville (sour) orange juice: synephrine content and cardiovascular effects in normotensive adults. J Clin Pharmacol. 2001 Oct;41(10):1059-63.
DMLQVTJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11583473

DMLQVTJ	DI	DMLQVTJ
DMLQVTJ	DN	Octopamine
DMLQVTJ	MI	DEIBDNY
DMLQVTJ	MN	Cytochrome P450 3A5 (CYP3A5)
DMLQVTJ	MT	DME
DMLQVTJ	MA	Metabolism
DMLQVTJ	RN	Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases. J Anal Toxicol. 2005 Oct;29(7):590-8.
DMLQVTJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16419387

DMLQVTJ	DI	DMLQVTJ
DMLQVTJ	DN	Octopamine
DMLQVTJ	MI	DEZV4AP
DMLQVTJ	MN	RNA cytidine acetyltransferase (hALP)
DMLQVTJ	MT	DME
DMLQVTJ	MA	Metabolism
DMLQVTJ	RN	[N-acetylation of biogenic amines in Drosophila virilis]. Genetika. 1997 Jun;33(6):788-92.
DMLQVTJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9289416

DMQV4C3	DI	DMQV4C3
DMQV4C3	DN	4030W92
DMQV4C3	MI	TTRK8B9
DMQV4C3	MN	Sodium channel unspecific (NaC)
DMQV4C3	MT	DTT
DMQV4C3	MA	Modulator
DMQV4C3	RN	Lack of effect of two oral sodium channel antagonists, lamotrigine and 4030W92, on intradermal capsaicin-induced hyperalgesia model. Pharmacol Biochem Behav. 2004 Jun;78(2):349-55.
DMQV4C3	RU	https://pubmed.ncbi.nlm.nih.gov/15219777

DMUXMGN	DI	DMUXMGN
DMUXMGN	DN	4991W93
DMUXMGN	MI	TTRK8B9
DMUXMGN	MN	Sodium channel unspecific (NaC)
DMUXMGN	MT	DTT
DMUXMGN	MA	Modulator
DMUXMGN	RN	CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol. 2010 Oct;6(10):573-82.
DMUXMGN	RU	https://pubmed.ncbi.nlm.nih.gov/20820195

DMYOG98	DI	DMYOG98
DMYOG98	DN	534U87
DMYOG98	MI	TTRK8B9
DMYOG98	MN	Sodium channel unspecific (NaC)
DMYOG98	MT	DTT
DMYOG98	MA	Modulator
DMYOG98	RN	The anticonvulsant BW534U87 depresses epileptiform activity in rat hippocampal slices by an adenosine-dependent mechanism and through inhibition of voltage-gated Na+ channels. Br J Pharmacol. 1999 Nov;128(5):1011-20.
DMYOG98	RU	https://pubmed.ncbi.nlm.nih.gov/10556938

DMG0I6L	DI	DMG0I6L
DMG0I6L	DN	97-139
DMG0I6L	MI	TTKRD0G
DMG0I6L	MN	Endothelin A receptor (EDNRA)
DMG0I6L	MT	DTT
DMG0I6L	MA	Antagonist
DMG0I6L	RN	S-0139 (Shionogi). Curr Opin Investig Drugs. 2002 Jul;3(7):1051-6.
DMG0I6L	RU	https://pubmed.ncbi.nlm.nih.gov/12186266

DMSGY5M	DI	DMSGY5M
DMSGY5M	DN	99mTc-ciprofloxacin
DMSGY5M	MI	TTN6J5F
DMSGY5M	MN	Bacterial DNA gyrase (Bact gyrase)
DMSGY5M	MT	DTT
DMSGY5M	MA	Inhibitor
DMSGY5M	RN	Binding of ciprofloxacin labelled with technetium Tc 99m versus 99mTc-pertechnetate to a live and killed equine isolate of Escherichia coli. Can J Vet Res. 2005 October; 69(4): 272-277.
DMSGY5M	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1250239/

DMEG240	DI	DMEG240
DMEG240	DN	A-437203
DMEG240	MI	TT4C8EA
DMEG240	MN	Dopamine D3 receptor (D3R)
DMEG240	MT	DTT
DMEG240	MA	Modulator
DMEG240	RN	Association of dopamine-related genetic loci to dopamine D3 receptor antagonist ABT-925 clinical response.Transl Psychiatry.2013 Apr 9;3:e245.
DMEG240	RU	https://www.ncbi.nlm.nih.gov/pubmed/23571810

DMX56G4	DI	DMX56G4
DMX56G4	DN	A-5021
DMX56G4	MI	TTF1HYB
DMX56G4	MN	Herpesvirus DNA polymerase (KSHV DNAP)
DMX56G4	MT	DTT
DMX56G4	MA	Modulator
DMX56G4	RN	Mode of action of (1'S,2'R)-9-[[1',2'-bis(hydroxymethyl) cycloprop-1'-yl]methyl]guanine (A-5021) against herpes simplex virus type 1 and type 2 and varicella-zoster virus. Antimicrob Agents Chemother. 1998 Aug;42(8):2095-102.
DMX56G4	RU	https://pubmed.ncbi.nlm.nih.gov/9687413

DMF4MRD	DI	DMF4MRD
DMF4MRD	DN	A-75925
DMF4MRD	MI	TT5FNQT
DMF4MRD	MN	Human immunodeficiency virus Protease (HIV PR)
DMF4MRD	MT	DTT
DMF4MRD	MA	Inhibitor
DMF4MRD	RN	Solvation studies of DMP323 and A76928 bound to HIV protease: analysis of water sites using grand canonical Monte Carlo simulations. Protein Sci. 1998 Mar;7(3):573-9.
DMF4MRD	RU	https://pubmed.ncbi.nlm.nih.gov/9541388

DM7VSBH	DI	DM7VSBH
DM7VSBH	DN	A-86719.1
DM7VSBH	MI	TTN6J5F
DM7VSBH	MN	Bacterial DNA gyrase (Bact gyrase)
DM7VSBH	MT	DTT
DM7VSBH	MA	Modulator
DM7VSBH	RN	Efficacy of ABT-719, a 2-pyridone antimicrobial, against enterococci, Escherichia coli, and Pseudomonas aeruginosa in experimental murine pyeloneph... J Antimicrob Chemother. 1996 Oct;38(4):641-53.
DM7VSBH	RU	https://www.ncbi.nlm.nih.gov/pubmed/8937959

DMB5TH3	DI	DMB5TH3
DMB5TH3	DN	AA-193
DMB5TH3	MI	TTIF3GB
DMB5TH3	MN	Glucose transporter type 9 (GLUT9)
DMB5TH3	MT	DTT
DMB5TH3	MA	Modulator
DMB5TH3	RN	Uricosurics inhibit urate transporter in rat renal brush border membrane vesicles. Eur J Pharmacol. 1990 Oct 23;187(3):303-12.
DMB5TH3	RU	https://pubmed.ncbi.nlm.nih.gov/2073918

DM78623	DI	DM78623
DM78623	DN	AA-2379
DM78623	MI	TTUST1O
DM78623	MN	Phosphodiesterase (PDE)
DM78623	MT	DTT
DM78623	MA	Inhibitor
DM78623	RN	Inhibitory effects of methyl 7-butyl-4,5,6,7-tetrahydro-3-methylamino-4,6-dioxo-5-propyl- 2H-pyrazolo[3,4-d]pyrimidine-2-carboxylate (AA-2379) on lysosomal enzyme and arachidonic acid release from rat polymorphonuclear leukocytes and its mode of action. Agents Actions. 1989 Nov;28(3-4):248-55.
DM78623	RU	https://pubmed.ncbi.nlm.nih.gov/2556899

DM8DT7U	DI	DM8DT7U
DM8DT7U	DN	ABT-089
DM8DT7U	MI	TTL1ATN
DM8DT7U	MN	Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2)
DM8DT7U	MT	DTT
DM8DT7U	MA	Modulator
DM8DT7U	RN	Selectivity of ABT-089 for alpha4beta2* and alpha6beta2* nicotinic acetylcholine receptors in brain.Biochem Pharmacol.2009 Oct 1;78(7):795-802.
DM8DT7U	RU	https://www.ncbi.nlm.nih.gov/pubmed/19481067

DMNP72I	DI	DMNP72I
DMNP72I	DN	ABT-418
DMNP72I	MI	TT4H1MQ
DMNP72I	MN	Neuronal acetylcholine receptor alpha-4 (CHRNA4)
DMNP72I	MT	DTT
DMNP72I	MA	Agonist
DMNP72I	RN	(S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization. J Pharmacol Exp Ther. 1994 Jul;270(1):319-28.
DMNP72I	RU	https://pubmed.ncbi.nlm.nih.gov/7913497

DMNP72I	DI	DMNP72I
DMNP72I	DN	ABT-418
DMNP72I	MI	TT5KPZR
DMNP72I	MN	Neuronal acetylcholine receptor beta-2 (CHRNB2)
DMNP72I	MT	DTT
DMNP72I	MA	Agonist
DMNP72I	RN	Nicotine, brain nicotinic receptors, and neuropsychiatric disorders. Arch Med Res. 2000 Mar-Apr;31(2):131-44.
DMNP72I	RU	https://pubmed.ncbi.nlm.nih.gov/10880717

DMNP72I	DI	DMNP72I
DMNP72I	DN	ABT-418
DMNP72I	MI	TTJSZTB
DMNP72I	MN	Nicotinic acetylcholine receptor (nAChR)
DMNP72I	MT	DTT
DMNP72I	MA	Agonist
DMNP72I	RN	Enhancement of sustained attention performance by the nicotinic acetylcholine receptor agonist ABT-418 in intact but not basal forebrain-lesioned rats. Psychopharmacology (Berl). 1999 May;144(2):175-82.
DMNP72I	RU	https://pubmed.ncbi.nlm.nih.gov/10394999

DMGMBCW	DI	DMGMBCW
DMGMBCW	DN	ABT-594
DMGMBCW	MI	TT4H1MQ
DMGMBCW	MN	Neuronal acetylcholine receptor alpha-4 (CHRNA4)
DMGMBCW	MT	DTT
DMGMBCW	MA	Agonist
DMGMBCW	RN	The nicotinic acetylcholine receptor agonist ABT-594 increases FGF-2 expression in various rat brain regions. Neuroreport. 1999 Dec 16;10(18):3909-13.
DMGMBCW	RU	https://pubmed.ncbi.nlm.nih.gov/10716232

DMGMBCW	DI	DMGMBCW
DMGMBCW	DN	ABT-594
DMGMBCW	MI	TT5KPZR
DMGMBCW	MN	Neuronal acetylcholine receptor beta-2 (CHRNB2)
DMGMBCW	MT	DTT
DMGMBCW	MA	Agonist
DMGMBCW	RN	The nicotinic acetylcholine receptor agonist ABT-594 increases FGF-2 expression in various rat brain regions. Neuroreport. 1999 Dec 16;10(18):3909-13.
DMGMBCW	RU	https://pubmed.ncbi.nlm.nih.gov/10716232

DMGMBCW	DI	DMGMBCW
DMGMBCW	DN	ABT-594
DMGMBCW	MI	TTJSZTB
DMGMBCW	MN	Nicotinic acetylcholine receptor (nAChR)
DMGMBCW	MT	DTT
DMGMBCW	MA	Agonist
DMGMBCW	RN	ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors: II. In vivo characterization. J Pharmacol Exp Ther. 1998 May;285(2):787-94.
DMGMBCW	RU	https://pubmed.ncbi.nlm.nih.gov/9580627

DMDQVY4	DI	DMDQVY4
DMDQVY4	DN	ABT-724
DMDQVY4	MI	TTE0A2F
DMDQVY4	MN	Dopamine D4 receptor (D4R)
DMDQVY4	MT	DTT
DMDQVY4	MA	Agonist
DMDQVY4	RN	Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats. Proc Natl Acad Sci U S A. 2004 April 27; 101(17): 6758-6763.
DMDQVY4	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC404118/

DMM02XV	DI	DMM02XV
DMM02XV	DN	AD-5467
DMM02XV	MI	TTFBNVI
DMM02XV	MN	Aldose reductase (AKR1B1)
DMM02XV	MT	DTT
DMM02XV	MA	Inhibitor
DMM02XV	RN	Studies on antidiabetic agents. IX. A new aldose reductase inhibitor, AD-5467, and related 1,4-benzoxazine and 1,4-benzothiazine derivatives: synthesis and biological activity. Chem Pharm Bull (Tokyo). 1990 May;38(5):1238-45.
DMM02XV	RU	https://pubmed.ncbi.nlm.nih.gov/2118427

DMTOCV7	DI	DMTOCV7
DMTOCV7	DN	Adaprolol maleate-SME
DMTOCV7	MI	TTMXGCW
DMTOCV7	MN	Adrenergic receptor beta-3 (ADRB3)
DMTOCV7	MT	DTT
DMTOCV7	MA	Modulator
DMTOCV7	RN	Synthesis and pharmacological activity of adaprolol enantiomers: a new soft drug for treating glaucoma. J Ocul Pharmacol Ther. 1996 Summer;12(2):115-22.
DMTOCV7	RU	https://pubmed.ncbi.nlm.nih.gov/8773927

DMMKFUP	DI	DMMKFUP
DMMKFUP	DN	Adatanserin
DMMKFUP	MI	TTSQIFT
DMMKFUP	MN	5-HT 1A receptor (HTR1A)
DMMKFUP	MT	DTT
DMMKFUP	MA	Agonist
DMMKFUP	RN	Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
DMMKFUP	RU	https://pubmed.ncbi.nlm.nih.gov/18172433

DMMKFUP	DI	DMMKFUP
DMMKFUP	DN	Adatanserin
DMMKFUP	MI	TTJQOD7
DMMKFUP	MN	5-HT 2A receptor (HTR2A)
DMMKFUP	MT	DTT
DMMKFUP	MA	Antagonist
DMMKFUP	RN	Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
DMMKFUP	RU	https://pubmed.ncbi.nlm.nih.gov/18172433

DMPFQLX	DI	DMPFQLX
DMPFQLX	DN	ADL 10-0101
DMPFQLX	MI	TTQW87Y
DMPFQLX	MN	Opioid receptor kappa (OPRK1)
DMPFQLX	MT	DTT
DMPFQLX	MA	Agonist
DMPFQLX	RN	Analgesia from a peripherally active kappa-opioid receptor agonist in patients with chronic pancreatitis. Pain. 2003 Jan;101(1-2):89-95.
DMPFQLX	RU	https://pubmed.ncbi.nlm.nih.gov/12507703

DMQM54P	DI	DMQM54P
DMQM54P	DN	ADL-5945
DMQM54P	MI	TTKWM86
DMQM54P	MN	Opioid receptor mu (MOP)
DMQM54P	MT	DTT
DMQM54P	MA	Antagonist
DMQM54P	RN	Novel opioid antagonists for opioid-induced bowel dysfunction. Expert Opin Investig Drugs. 2011 Aug;20(8):1047-56.
DMQM54P	RU	https://pubmed.ncbi.nlm.nih.gov/21663526

DMJ8ZFR	DI	DMJ8ZFR
DMJ8ZFR	DN	ADOZELESIN
DMJ8ZFR	MI	TTUTN1I
DMJ8ZFR	MN	Human Deoxyribonucleic acid (hDNA)
DMJ8ZFR	MT	DTT
DMJ8ZFR	MA	Binder
DMJ8ZFR	RN	Mapping of DNA alkylation sites induced by adozelesin and bizelesin in human cells by ligation-mediated polymerase chain reaction. Biochemistry. 1994 May 17;33(19):6024-30.
DMJ8ZFR	RU	https://pubmed.ncbi.nlm.nih.gov/8180230

DMS8JIU	DI	DMS8JIU
DMS8JIU	DN	ADROGOLIDE HYDROCHLORIDE
DMS8JIU	MI	TTZFYLI
DMS8JIU	MN	Dopamine D1 receptor (D1R)
DMS8JIU	MT	DTT
DMS8JIU	MA	Agonist
DMS8JIU	RN	Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data. CNS Drug Rev. 2001 Fall;7(3):305-16.
DMS8JIU	RU	https://pubmed.ncbi.nlm.nih.gov/11607045

DMZS2M4	DI	DMZS2M4
DMZS2M4	DN	ADX-10061
DMZS2M4	MI	TTZFYLI
DMZS2M4	MN	Dopamine D1 receptor (D1R)
DMZS2M4	MT	DTT
DMZS2M4	MA	Antagonist
DMZS2M4	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001476)
DMZS2M4	RU	http://adisinsight.springer.com/drugs/800001476

DMZ7WKN	DI	DMZ7WKN
DMZ7WKN	DN	Adyvia
DMZ7WKN	MI	TTHBTOP
DMZ7WKN	MN	PI3-kinase gamma (PIK3CG)
DMZ7WKN	MT	DTT
DMZ7WKN	MA	Modulator
DMZ7WKN	RN	Insulinotropic agent ID-1101 (4-hydroxyisoleucine) activates insulin signaling in rat.Am J Physiol Endocrinol Metab.2004 Sep;287(3):E463-71.
DMZ7WKN	RU	https://www.ncbi.nlm.nih.gov/pubmed/15082420

DMRWSKX	DI	DMRWSKX
DMRWSKX	DN	Afegostat
DMRWSKX	MI	TT1B5PU
DMRWSKX	MN	Glucosylceramidase (GBA)
DMRWSKX	MT	DTT
DMRWSKX	MA	Inhibitor
DMRWSKX	RN	Lysosomes as a therapeutic target. Nat Rev Drug Discov. 2019 Dec;18(12):923-948.
DMRWSKX	RU	https://pubmed.ncbi.nlm.nih.gov/31477883

DMSF5VK	DI	DMSF5VK
DMSF5VK	DN	Affitope AD-02
DMSF5VK	MI	TTE4KHA
DMSF5VK	MN	Amyloid beta A4 protein (APP)
DMSF5VK	MT	DTT
DMSF5VK	RN	Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward. Expert Rev Clin Immunol. 2014 Mar;10(3):405-19.
DMSF5VK	RU	https://pubmed.ncbi.nlm.nih.gov/24490853

DM497SK	DI	DM497SK
DM497SK	DN	Agatolimod
DM497SK	MI	TTSHG0T
DM497SK	MN	Toll-like receptor 9 (TLR9)
DM497SK	MT	DTT
DM497SK	MA	Agonist
DM497SK	RN	Pfizer. Product Development Pipeline. March 31 2009.
DM497SK	RU	http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf

DMZRW5E	DI	DMZRW5E
DMZRW5E	DN	AGN211745
DMZRW5E	MI	TTPFN62
DMZRW5E	MN	VEGFR2 messenger RNA (VEGFR2 mRNA)
DMZRW5E	MT	DTT
DMZRW5E	RN	Teaming up to tackle RNAi delivery challenge. Nat Rev Drug Discov. 2009 Jul;8(7):525-6.
DMZRW5E	RU	https://pubmed.ncbi.nlm.nih.gov/19568274

DME6OXB	DI	DME6OXB
DME6OXB	DN	AKL-0707
DME6OXB	MI	TTG4R8V
DME6OXB	MN	Growth hormone-releasing hormone receptor (GHRHR)
DME6OXB	MT	DTT
DME6OXB	MA	Agonist
DME6OXB	RN	A super-agonist of growth hormone-releasing hormone causes rapid improvement of nutritional status in patients with chronic kidney disease. Kidney Int. 2010 Mar;77(5):450-8.
DME6OXB	RU	https://pubmed.ncbi.nlm.nih.gov/20016461

DM6IPWN	DI	DM6IPWN
DM6IPWN	DN	AKP-020
DM6IPWN	MI	TTCBFJO
DM6IPWN	MN	Insulin receptor (INSR)
DM6IPWN	MT	DTT
DM6IPWN	MA	Enhancer
DM6IPWN	RN	Effect of vanadium on insulin and leptin in Zucker diabetic fatty rats. Mol Cell Biochem. 2001 Feb;218(1-2):93-6.
DM6IPWN	RU	https://pubmed.ncbi.nlm.nih.gov/11330843

DMT5KBF	DI	DMT5KBF
DMT5KBF	DN	ALNESPIRONE
DMT5KBF	MI	TTSQIFT
DMT5KBF	MN	5-HT 1A receptor (HTR1A)
DMT5KBF	MT	DTT
DMT5KBF	MA	Agonist
DMT5KBF	RN	Chronic alnespirone-induced desensitization of somatodendritic 5-HT1A autoreceptors in the rat dorsal raphe nucleus. Eur J Pharmacol. 1999 Jan 22;365(2-3):165-73.
DMT5KBF	RU	https://pubmed.ncbi.nlm.nih.gov/9988099

DMIKLRN	DI	DMIKLRN
DMIKLRN	DN	ALPRENOXIME HYDROCHLORIDE
DMIKLRN	MI	TTMXGCW
DMIKLRN	MN	Adrenergic receptor beta-3 (ADRB3)
DMIKLRN	MT	DTT
DMIKLRN	MA	Modulator
DMIKLRN	RN	Improved delivery through biological membranes. LVI. Pharmacological evaluation of alprenoxime--a new potential antiglaucoma agent. Pharm Res. 1991 Nov;8(11):1389-95.
DMIKLRN	RU	https://pubmed.ncbi.nlm.nih.gov/1798675

DMIAXCZ	DI	DMIAXCZ
DMIAXCZ	DN	Alrestatin
DMIAXCZ	MI	TTFBNVI
DMIAXCZ	MN	Aldose reductase (AKR1B1)
DMIAXCZ	MT	DTT
DMIAXCZ	MA	Inhibitor
DMIAXCZ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMIAXCZ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMEKHX0	DI	DMEKHX0
DMEKHX0	DN	ALS 2-0426
DMEKHX0	MI	TTDIGC1
DMEKHX0	MN	Dipeptidyl peptidase 4 (DPP-4)
DMEKHX0	MT	DTT
DMEKHX0	MA	Inhibitor
DMEKHX0	RN	Novel Pharmacological Approaches to the Treatment of Type 2 Diabetes. Pharmacological Reviews April 2012 vol. 64 no. 2 188-237.
DMEKHX0	RU	http://pharmrev.aspetjournals.org/content/64/2/188.full

DMAQNBW	DI	DMAQNBW
DMAQNBW	DN	AM103
DMAQNBW	MI	TTDMBF5
DMAQNBW	MN	Arachidonate 5-lipoxygenase activating protein (FLAP)
DMAQNBW	MT	DTT
DMAQNBW	MA	Inhibitor
DMAQNBW	RN	AM103 Experimental Treatment for Respiratory Diseases. Amira Pharmaceuticals/GSK. 2009.
DMAQNBW	RU	http://www.drugdevelopment-technology.com/projects/am103/

DMF8KH7	DI	DMF8KH7
DMF8KH7	DN	AM336
DMF8KH7	MI	TT5HONZ
DMF8KH7	MN	Calcium channel unspecific (CaC)
DMF8KH7	MT	DTT
DMF8KH7	MA	Modulator
DMF8KH7	RN	Intravenous injection of leconotide, an omega conotoxin: synergistic antihyperalgesic effects with morphine in a rat model of bone cancer pain.Pain Med.2011 Jun;12(6):923-41.
DMF8KH7	RU	https://www.ncbi.nlm.nih.gov/pubmed/21539704

DMA57O4	DI	DMA57O4
DMA57O4	DN	Ambasilide
DMA57O4	MI	TT1VOHK
DMA57O4	MN	Potassium channel unspecific (KC)
DMA57O4	MT	DTT
DMA57O4	MA	Blocker
DMA57O4	RN	Ambasilide prolongs the action potential and blocks multiple potassium currents in human atrium. J Cardiovasc Pharmacol. 1999 May;33(5):762-71.
DMA57O4	RU	https://pubmed.ncbi.nlm.nih.gov/10226864

DMRY9V8	DI	DMRY9V8
DMRY9V8	DN	AMESERGIDE
DMRY9V8	MI	TTJQOD7
DMRY9V8	MN	5-HT 2A receptor (HTR2A)
DMRY9V8	MT	DTT
DMRY9V8	MA	Antagonist
DMRY9V8	RN	Effects of the serotonin antagonist amesergide on reproduction in female rats. Reprod Toxicol. 1993 Nov-Dec;7(6):607-12.
DMRY9V8	RU	https://pubmed.ncbi.nlm.nih.gov/8118111

DMMUS8X	DI	DMMUS8X
DMMUS8X	DN	AMG 108
DMMUS8X	MI	TT51DEV
DMMUS8X	MN	Interleukin 1 receptor type 2 (IL1R2)
DMMUS8X	MT	DTT
DMMUS8X	MA	Antagonist
DMMUS8X	RN	Clinical pipeline report, company report or official report of Amgen (2009).
DMMUS8X	RU	http://www.amgen.com/science/pipe.jsp

DM4RFT8	DI	DM4RFT8
DM4RFT8	DN	Amifloxacin
DM4RFT8	MI	TT0IHXV
DM4RFT8	MN	DNA topoisomerase II (TOP2)
DM4RFT8	MT	DTT
DM4RFT8	MA	Inhibitor
DM4RFT8	RN	Activity of fluoroquinolone antibiotics against Plasmodium falciparum in vitro. Antimicrob Agents Chemother. 1988 Aug;32(8):1182-6.
DM4RFT8	RU	https://pubmed.ncbi.nlm.nih.gov/2847647

DMGL0Q2	DI	DMGL0Q2
DMGL0Q2	DN	AN-9
DMGL0Q2	MI	TT6R7JZ
DMGL0Q2	MN	Histone deacetylase 1 (HDAC1)
DMGL0Q2	MT	DTT
DMGL0Q2	MA	Inhibitor
DMGL0Q2	RN	Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006 Sep;5(9):769-84.
DMGL0Q2	RU	https://pubmed.ncbi.nlm.nih.gov/16955068

DMBQLS5	DI	DMBQLS5
DMBQLS5	DN	Angiozyme
DMBQLS5	MI	TT2Q6G1
DMBQLS5	MN	Vascular endothelial growth factor receptor 1 (FLT-1)
DMBQLS5	MT	DTT
DMBQLS5	MA	Modulator
DMBQLS5	RN	An open-label, phase 2 trial of RPI.4610 (Angiozyme) in the treatment of metastatic breast cancer.Cancer.2012 Sep 1;118(17):4098-104.
DMBQLS5	RU	https://www.ncbi.nlm.nih.gov/pubmed/22281842

DMEO6PR	DI	DMEO6PR
DMEO6PR	DN	Antide
DMEO6PR	MI	TT8R70G
DMEO6PR	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMEO6PR	MT	DTT
DMEO6PR	MA	Antagonist
DMEO6PR	RN	Antide (Nal-Lys GnRH antagonist) suppression of pituitary-testicular function and sexual behavior in group-living rhesus monkeys. Physiol Behav. 1991 Aug;50(2):429-35.
DMEO6PR	RU	https://pubmed.ncbi.nlm.nih.gov/1745690

DMGDPSI	DI	DMGDPSI
DMGDPSI	DN	AOD-9604
DMGDPSI	MI	TTKMAZ6
DMGDPSI	MN	Growth hormone receptor (GHR)
DMGDPSI	MT	DTT
DMGDPSI	MA	Agonist
DMGDPSI	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DMGDPSI	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMWDCG7	DI	DMWDCG7
DMWDCG7	DN	AP-521
DMWDCG7	MI	TTSQIFT
DMWDCG7	MN	5-HT 1A receptor (HTR1A)
DMWDCG7	MT	DTT
DMWDCG7	MA	Agonist
DMWDCG7	RN	The effects of AP521, a novel anxiolytic drug, in three anxiety models and on serotonergic neural transmission in rats. J Pharmacol Sci. 2015 Jan;127(1):109-16.
DMWDCG7	RU	https://pubmed.ncbi.nlm.nih.gov/25704026

DMWKJCB	DI	DMWKJCB
DMWKJCB	DN	AP-5346
DMWKJCB	MI	TTUTN1I
DMWKJCB	MN	Human Deoxyribonucleic acid (hDNA)
DMWKJCB	MT	DTT
DMWKJCB	MA	Inhibitor
DMWKJCB	RN	Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2248-54.
DMWKJCB	RU	https://pubmed.ncbi.nlm.nih.gov/16609041

DM8IB6K	DI	DM8IB6K
DM8IB6K	DN	APC-2059
DM8IB6K	MI	TTM1TDX
DM8IB6K	MN	Tryptase alpha/beta-1 (Tryptase)
DM8IB6K	MT	DTT
DM8IB6K	MA	Inhibitor
DM8IB6K	RN	Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): an open-label pilot study. Aliment Pharmacol Ther. 2002 Mar;16(3):407-13.
DM8IB6K	RU	https://pubmed.ncbi.nlm.nih.gov/11876693

DM02DNQ	DI	DM02DNQ
DM02DNQ	DN	APC-366
DM02DNQ	MI	TTM1TDX
DM02DNQ	MN	Tryptase alpha/beta-1 (Tryptase)
DM02DNQ	MT	DTT
DM02DNQ	MA	Inhibitor
DM02DNQ	RN	Inhibitors of tryptase for the treatment of mast cell-mediated diseases. Curr Pharm Des. 1998 Oct;4(5):381-96.
DM02DNQ	RU	https://pubmed.ncbi.nlm.nih.gov/10197050

DMR3Q82	DI	DMR3Q82
DMR3Q82	DN	Apricoxib
DMR3Q82	MI	TTVKILB
DMR3Q82	MN	Prostaglandin G/H synthase 2 (COX-2)
DMR3Q82	MT	DTT
DMR3Q82	MA	Inhibitor
DMR3Q82	RN	Apricoxib, a COX-2 inhibitor for the potential treatment of pain and cancer. IDrugs. 2009 Nov;12(11):711-22.
DMR3Q82	RU	https://pubmed.ncbi.nlm.nih.gov/19844858

DMML5WB	DI	DMML5WB
DMML5WB	DN	AR-D-111421
DMML5WB	MI	TTZC9FV
DMML5WB	MN	Vasoactive intestinal polypeptide receptor (VIPR)
DMML5WB	MT	DTT
DMML5WB	MA	Modulator
DMML5WB	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013264)
DMML5WB	RU	http://adisinsight.springer.com/drugs/800013264

DMBTG8J	DI	DMBTG8J
DMBTG8J	DN	AR-H047108
DMBTG8J	MI	TTLOKXP
DMBTG8J	MN	Gastric H(+)/K(+) ATPase (Proton pump)
DMBTG8J	MT	DTT
DMBTG8J	MA	Modulator
DMBTG8J	RN	Early stellate cell activation and veno-occlusive-disease (VOD)-like hepatotoxicity in dogs treated with AR-H047108, an imidazopyridine proton pump inhibitor.Toxicol Pathol.2008 Jul;36(5):727-37.
DMBTG8J	RU	https://www.ncbi.nlm.nih.gov/pubmed/18648100

DMNGQM0	DI	DMNGQM0
DMNGQM0	DN	Arm036
DMNGQM0	MI	TTU5CIX
DMNGQM0	MN	Ryanodine receptor 1 (RYR1)
DMNGQM0	MT	DTT
DMNGQM0	MA	Modulator
DMNGQM0	RN	The Ryanodine Receptor Stabilizer S44121 / Arm036 Improves Peripheral and Respiratory Muscle Function in a Mouse Model of Heart Failure. Circulation. 2014; 130: A13726.
DMNGQM0	RU	http://circ.ahajournals.org/content/130/Suppl_2/A13726.abstract

DMS0LCZ	DI	DMS0LCZ
DMS0LCZ	DN	ARX-201
DMS0LCZ	MI	TTT3YKH
DMS0LCZ	MN	Somatotropin (GH1)
DMS0LCZ	MT	DTT
DMS0LCZ	MA	Modulator
DMS0LCZ	RN	Company report (Avarx)
DMS0LCZ	RU	http://www.avarx.com/search/showOpportunityDetails?asset_id=1309

DMC2WI7	DI	DMC2WI7
DMC2WI7	DN	AS-35
DMC2WI7	MI	TTGKOY9
DMC2WI7	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DMC2WI7	MT	DTT
DMC2WI7	MA	Modulator
DMC2WI7	RN	Inhibition of radiolabeled leukotriene-binding by AS-35 in guinea pig lung membrane fraction. Jpn J Pharmacol. 1992 Apr;58(4):357-64.
DMC2WI7	RU	https://www.ncbi.nlm.nih.gov/pubmed/1405033

DMC2WI7	DI	DMC2WI7
DMC2WI7	DN	AS-35
DMC2WI7	MI	TT0PZR5
DMC2WI7	MN	Leukotriene CysLT2 receptor (CYSLTR2)
DMC2WI7	MT	DTT
DMC2WI7	MA	Modulator
DMC2WI7	RN	Inhibition of radiolabeled leukotriene-binding by AS-35 in guinea pig lung membrane fraction. Jpn J Pharmacol. 1992 Apr;58(4):357-64.
DMC2WI7	RU	https://www.ncbi.nlm.nih.gov/pubmed/1405033

DM10XWU	DI	DM10XWU
DM10XWU	DN	Atipamezole
DM10XWU	MI	TTQ8AFT
DM10XWU	MN	Adrenergic receptor Alpha-2 (ADRA2)
DM10XWU	MT	DTT
DM10XWU	MA	Antagonist
DM10XWU	RN	Low doses of alpha 2-adrenoceptor antagonists augment spinal morphine analgesia and inhibit development of acute and chronic tolerance. Br J Pharmacol. 2008 Dec;155(8):1264-78.
DM10XWU	RU	https://pubmed.ncbi.nlm.nih.gov/18806811

DMZEMG6	DI	DMZEMG6
DMZEMG6	DN	Atiratecan
DMZEMG6	MI	TTGTQHC
DMZEMG6	MN	DNA topoisomerase I (TOP1)
DMZEMG6	MT	DTT
DMZEMG6	MA	Inhibitor
DMZEMG6	RN	Method development and validation of the simultaneous determination of a novel topoisomerase 1 inhibitor, the prodrug, and the active metabolite in human plasma using column-switching LC-MS/MS, and its application in a clinical trial. J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Nov 15;879(30):3415-22.
DMZEMG6	RU	https://pubmed.ncbi.nlm.nih.gov/21975380

DM7OE9F	DI	DM7OE9F
DM7OE9F	DN	Atocalcitol
DM7OE9F	MI	TTK59TV
DM7OE9F	MN	Vitamin D3 receptor (VDR)
DM7OE9F	MT	DTT
DM7OE9F	MA	Agonist
DM7OE9F	RN	Elocalcitol, a vitamin D3 analog for the potential treatment of benign prostatic hyperplasia, overactive bladder and male infertility. IDrugs. 2009 Jun;12(6):381-93.
DM7OE9F	RU	https://pubmed.ncbi.nlm.nih.gov/19517319

DMWJ245	DI	DMWJ245
DMWJ245	DN	ATX-201
DMWJ245	MI	TTML2WA
DMWJ245	MN	Tubulin (TUB)
DMWJ245	MT	DTT
DMWJ245	MA	Inhibitor
DMWJ245	RN	Clinical pipeline report, company report or official report of Kythera Biopharmaceuticals.
DMWJ245	RU	http://www.kythera.com/kythera-biopharmaceuticals-announces-discontinuation-of-actinic-keratosis-clinical-program/

DMWA957	DI	DMWA957
DMWA957	DN	Avarofloxacin
DMWA957	MI	TTIXTO3
DMWA957	MN	Staphylococcus Topoisomerase IV (Stap-coc parC)
DMWA957	MT	DTT
DMWA957	MA	Modulator
DMWA957	RN	Antistaphylococcal activities of the new fluoroquinolone JNJ-Q2. Antimicrob Agents Chemother. 2011 Dec;55(12):5512-21.
DMWA957	RU	https://pubmed.ncbi.nlm.nih.gov/21911562

DMRYK1C	DI	DMRYK1C
DMRYK1C	DN	AVE-0847
DMRYK1C	MI	TTJ584C
DMRYK1C	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMRYK1C	MT	DTT
DMRYK1C	MA	Modulator
DMRYK1C	RN	DOI: 10.1038/scibx.2012.669
DMRYK1C	RU	http://www.nature.com/scibx/journal/v5/n26/fig_tab/scibx.2012.669_T1.html

DMRYK1C	DI	DMRYK1C
DMRYK1C	DN	AVE-0847
DMRYK1C	MI	TTZMAO3
DMRYK1C	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMRYK1C	MT	DTT
DMRYK1C	MA	Modulator
DMRYK1C	RN	DOI: 10.1038/scibx.2012.669
DMRYK1C	RU	http://www.nature.com/scibx/journal/v5/n26/fig_tab/scibx.2012.669_T1.html

DMXNK0J	DI	DMXNK0J
DMXNK0J	DN	AVE1625
DMXNK0J	MI	TT6OEDT
DMXNK0J	MN	Cannabinoid receptor 1 (CB1)
DMXNK0J	MT	DTT
DMXNK0J	MA	Antagonist
DMXNK0J	RN	Pharma & Vaccines. Product Development Pipeline. April 29 2009.
DMXNK0J	RU	http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf

DMUQ6IL	DI	DMUQ6IL
DMUQ6IL	DN	AVE-1642
DMUQ6IL	MI	TTHRID2
DMUQ6IL	MN	Insulin-like growth factor I receptor (IGF1R)
DMUQ6IL	MT	DTT
DMUQ6IL	RN	Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growthfactor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. Clin Cancer Res. 2009 Sep 1;15(17):5445-56.
DMUQ6IL	RU	https://pubmed.ncbi.nlm.nih.gov/19706799

DMCX6MD	DI	DMCX6MD
DMCX6MD	DN	AVE-8134
DMCX6MD	MI	TTJ584C
DMCX6MD	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMCX6MD	MT	DTT
DMCX6MD	MA	Agonist
DMCX6MD	RN	The peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats. Acta Pharmacol Sin. 2009 Jul;30(7):935-46.
DMCX6MD	RU	https://pubmed.ncbi.nlm.nih.gov/19503102

DMFCOZL	DI	DMFCOZL
DMFCOZL	DN	AVN 397
DMFCOZL	MI	TTJS8PY
DMFCOZL	MN	5-HT 6 receptor (HTR6)
DMFCOZL	MT	DTT
DMFCOZL	MA	Antagonist
DMFCOZL	RN	Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. Curr Opin Investig Drugs. 2010 January; 11(1): 80-91.
DMFCOZL	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3346261/

DM2I8NT	DI	DM2I8NT
DM2I8NT	DN	Avosentan
DM2I8NT	MI	TTKRD0G
DM2I8NT	MN	Endothelin A receptor (EDNRA)
DM2I8NT	MT	DTT
DM2I8NT	MA	Antagonist
DM2I8NT	RN	Agents in development for the treatment of diabetic nephropathy. Expert Opin Emerg Drugs. 2008 Sep;13(3):447-63.
DM2I8NT	RU	https://pubmed.ncbi.nlm.nih.gov/18764722

DM8NA4M	DI	DM8NA4M
DM8NA4M	DN	AVT-02 UE
DM8NA4M	MI	TTN7R6K
DM8NA4M	MN	Signal transducer and activator of transcription 1 (STAT1)
DM8NA4M	MT	DTT
DM8NA4M	MA	Inhibitor
DM8NA4M	RN	Avontec Announces Results of a Multiple Dose Clinical Phase I Study with Its Drug Candidate AVT-02 UE Ointment After Topical Treatment in Male Healthy Volunteers. Avontec. 2008.
DM8NA4M	RU	http://www.drugs.com/clinical_trials/avontec-announces-results-multiple-clinical-phase-study-candidate-avt-02-ue-ointment-after-topical-4866.html

DMV1ES3	DI	DMV1ES3
DMV1ES3	DN	AZALANSTAT
DMV1ES3	MI	TTTSOUD
DMV1ES3	MN	Candida Cytochrome P450 51 (Candi ERG11)
DMV1ES3	MT	DTT
DMV1ES3	MA	Modulator
DMV1ES3	RN	Azalanstat (RS-21607), a lanosterol 14 alpha-demethylase inhibitor with cholesterol-lowering activity. Biochem Pharmacol. 1995 Aug 8;50(4):529-44.
DMV1ES3	RU	https://www.ncbi.nlm.nih.gov/pubmed/7646560

DM4B7CM	DI	DM4B7CM
DM4B7CM	DN	AZD0328
DM4B7CM	MI	TTLA931
DM4B7CM	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DM4B7CM	MT	DTT
DM4B7CM	MA	Modulator
DM4B7CM	RN	Ultra-low exposure to -7 nicotinic acetylcholine receptor partial agonists elicits an improvement in cognition that corresponds with an increase in -7 receptor expression in rodents: implications for low dose clinical efficacy.Neuroscience.2011 Jul 14;186:76-87.
DM4B7CM	RU	https://www.ncbi.nlm.nih.gov/pubmed/21550383

DMA9Q2V	DI	DMA9Q2V
DMA9Q2V	DN	AZD0837
DMA9Q2V	MI	TT6L509
DMA9Q2V	MN	Coagulation factor IIa (F2)
DMA9Q2V	MT	DTT
DMA9Q2V	MA	Inhibitor
DMA9Q2V	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DMA9Q2V	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DML3RSF	DI	DML3RSF
DML3RSF	DN	AZD1236
DML3RSF	MI	TTXZ0KQ
DML3RSF	MN	Matrix metalloproteinase-12 (MMP-12)
DML3RSF	MT	DTT
DML3RSF	MA	Inhibitor
DML3RSF	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DML3RSF	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DMFAG8W	DI	DMFAG8W
DMFAG8W	DN	AZD1386
DMFAG8W	MI	TTMI6F5
DMFAG8W	MN	Transient receptor potential cation channel V1 (TRPV1)
DMFAG8W	MT	DTT
DMFAG8W	MA	Blocker
DMFAG8W	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DMFAG8W	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DMHP6OY	DI	DMHP6OY
DMHP6OY	DN	AZD2066
DMHP6OY	MI	TTHS256
DMHP6OY	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMHP6OY	MT	DTT
DMHP6OY	MA	Antagonist
DMHP6OY	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DMHP6OY	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DM1TDWI	DI	DM1TDWI
DM1TDWI	DN	AZD2207
DM1TDWI	MI	TT6OEDT
DM1TDWI	MN	Cannabinoid receptor 1 (CB1)
DM1TDWI	MT	DTT
DM1TDWI	MA	Antagonist
DM1TDWI	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DM1TDWI	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DM9OPDE	DI	DM9OPDE
DM9OPDE	DN	AZD2516
DM9OPDE	MI	TTHS256
DM9OPDE	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM9OPDE	MT	DTT
DM9OPDE	MA	Antagonist
DM9OPDE	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DM9OPDE	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DMT5ZK3	DI	DMT5ZK3
DMT5ZK3	DN	AZD3355
DMT5ZK3	MI	TTDCVZW
DMT5ZK3	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMT5ZK3	MT	DTT
DMT5ZK3	MA	Modulator
DMT5ZK3	RN	Efficacy and safety of lesogaberan in gastro-oesophageal reflux disease: a randomised controlled trial.Gut.2013 Sep;62(9):1248-55.
DMT5ZK3	RU	https://www.ncbi.nlm.nih.gov/pubmed/22730470

DM4K085	DI	DM4K085
DM4K085	DN	AZD-3778
DM4K085	MI	TTQR8Z6
DM4K085	MN	Chemokine receptor (CHR)
DM4K085	MT	DTT
DM4K085	MA	Modulator
DM4K085	RN	New Drugs and Targets for Asthma and COPD. Trevor T. Hansel, Peter J. Barnes. 2010. Page(304).
DM4K085	RU	https://books.google.com.hk/books?id=aHipG471tVgC&pg=PT318&lpg=PT318&dq=%22AZD-3778%22&source=bl&ots=y_RqGG2ANK&sig=reQ4tfDvvdsUNpDF8vYyquoyO9Q&hl=zh-CN&sa=X&ved=0CD0Q6AEwBGoVChMI98D7zdG_yAIVSBiOCh0hpweg#v=onepage&q=%22AZD-3778%22&f=false

DM3VFKM	DI	DM3VFKM
DM3VFKM	DN	AZD4818
DM3VFKM	MI	TTC24WT
DM3VFKM	MN	C-C chemokine receptor type 1 (CCR1)
DM3VFKM	MT	DTT
DM3VFKM	MA	Antagonist
DM3VFKM	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DM3VFKM	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DME8KQW	DI	DME8KQW
DME8KQW	DN	AZD-5423
DME8KQW	MI	TTYRL6O
DME8KQW	MN	Glucocorticoid receptor (NR3C1)
DME8KQW	MT	DTT
DME8KQW	MA	Agonist
DME8KQW	RN	A nonsteroidal glucocorticoid receptor agonist inhibits allergen-induced late asthmatic responses. Am J Respir Crit Care Med. 2015 Jan 15;191(2):161-7.
DME8KQW	RU	https://pubmed.ncbi.nlm.nih.gov/25473939

DMVZSRG	DI	DMVZSRG
DMVZSRG	DN	AZD6370
DMVZSRG	MI	TTDLNGZ
DMVZSRG	MN	Glucokinase (GCK)
DMVZSRG	MT	DTT
DMVZSRG	MA	Activator
DMVZSRG	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DMVZSRG	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DMHZ3DE	DI	DMHZ3DE
DMHZ3DE	DN	AZD6765
DMHZ3DE	MI	TT9IK2Z
DMHZ3DE	MN	N-methyl-D-aspartate receptor (NMDAR)
DMHZ3DE	MT	DTT
DMHZ3DE	MA	Antagonist
DMHZ3DE	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DMHZ3DE	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DMEQ2N1	DI	DMEQ2N1
DMEQ2N1	DN	AZD8529
DMEQ2N1	MI	TTVBPDM
DMEQ2N1	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMEQ2N1	MT	DTT
DMEQ2N1	MA	Agonist
DMEQ2N1	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DMEQ2N1	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DMHA5ME	DI	DMHA5ME
DMHA5ME	DN	AZD-9684
DMHA5ME	MI	TTP18AY
DMHA5ME	MN	Carboxypeptidase B2 (CPB2)
DMHA5ME	MT	DTT
DMHA5ME	MA	Inhibitor
DMHA5ME	RN	Clinical pipeline report, company report or official report of AstraZeneca.
DMHA5ME	RU	http://www.astrazeneca.com.au/research/cardiovascular?itemId=396161

DMHA5ME	DI	DMHA5ME
DMHA5ME	DN	AZD-9684
DMHA5ME	MI	TTMT0HG
DMHA5ME	MN	Neuronal acetylcholine receptor alpha-2/alpha-3 (CHRNA2/A3)
DMHA5ME	MT	DTT
DMHA5ME	MA	Antagonist
DMHA5ME	RN	Blockade and activation of the human neuronal nicotinic acetylcholine receptors by atracurium and laudanosine. Anesthesiology. 2001 Apr;94(4):643-51.
DMHA5ME	RU	https://pubmed.ncbi.nlm.nih.gov/11379686

DMHA5ME	DI	DMHA5ME
DMHA5ME	DN	AZD-9684
DMHA5ME	MI	TTLA931
DMHA5ME	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMHA5ME	MT	DTT
DMHA5ME	MA	Antagonist
DMHA5ME	RN	Blockade and activation of the human neuronal nicotinic acetylcholine receptors by atracurium and laudanosine. Anesthesiology. 2001 Apr;94(4):643-51.
DMHA5ME	RU	https://pubmed.ncbi.nlm.nih.gov/11379686

DMHA5ME	DI	DMHA5ME
DMHA5ME	DN	AZD-9684
DMHA5ME	MI	TT5KPZR
DMHA5ME	MN	Neuronal acetylcholine receptor beta-2 (CHRNB2)
DMHA5ME	MT	DTT
DMHA5ME	MA	Antagonist
DMHA5ME	RN	Blockade and activation of the human neuronal nicotinic acetylcholine receptors by atracurium and laudanosine. Anesthesiology. 2001 Apr;94(4):643-51.
DMHA5ME	RU	https://pubmed.ncbi.nlm.nih.gov/11379686

DM04CIK	DI	DM04CIK
DM04CIK	DN	AZT-P-DDI
DM04CIK	MI	TT84ETX
DM04CIK	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM04CIK	MT	DTT
DM04CIK	MA	Inhibitor
DM04CIK	RN	Antiviral activities of nucleotide heterodimers against human immunodeficiency virus type 1 in vitro. Antiviral Res. 1996 Jun;31(1-2):115-20.
DM04CIK	RU	https://pubmed.ncbi.nlm.nih.gov/8793015

DM06JTL	DI	DM06JTL
DM06JTL	DN	Balicatib
DM06JTL	MI	TTDZN01
DM06JTL	MN	Cathepsin K (CTSK)
DM06JTL	MT	DTT
DM06JTL	MA	Inhibitor
DM06JTL	RN	Current and future treatments of bone metastases. Expert Opin Emerg Drugs. 2008 Dec;13(4):609-27.
DM06JTL	RU	https://pubmed.ncbi.nlm.nih.gov/19046130

DMPMKUF	DI	DMPMKUF
DMPMKUF	DN	BAM-1110
DMPMKUF	MI	TTZFYLI
DMPMKUF	MN	Dopamine D1 receptor (D1R)
DMPMKUF	MT	DTT
DMPMKUF	MA	Modulator
DMPMKUF	RN	Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinso... J Pharmacol Exp Ther. 1998 Jul;286(1):228-33.
DMPMKUF	RU	https://www.ncbi.nlm.nih.gov/pubmed/9655864

DMPMKUF	DI	DMPMKUF
DMPMKUF	DN	BAM-1110
DMPMKUF	MI	TTEX248
DMPMKUF	MN	Dopamine D2 receptor (D2R)
DMPMKUF	MT	DTT
DMPMKUF	MA	Modulator
DMPMKUF	RN	Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinso... J Pharmacol Exp Ther. 1998 Jul;286(1):228-33.
DMPMKUF	RU	https://www.ncbi.nlm.nih.gov/pubmed/9655864

DMV2DIW	DI	DMV2DIW
DMV2DIW	DN	BAY 10-00394
DMV2DIW	MI	TTH6V3D
DMV2DIW	MN	Cyclin-dependent kinase 1 (CDK1)
DMV2DIW	MT	DTT
DMV2DIW	MA	Inhibitor
DMV2DIW	RN	National Cancer Institute Drug Dictionary (drug id 770319).
DMV2DIW	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=770319

DMV2DIW	DI	DMV2DIW
DMV2DIW	DN	BAY 10-00394
DMV2DIW	MI	TT7HF4W
DMV2DIW	MN	Cyclin-dependent kinase 2 (CDK2)
DMV2DIW	MT	DTT
DMV2DIW	MA	Inhibitor
DMV2DIW	RN	National Cancer Institute Drug Dictionary (drug id 770319).
DMV2DIW	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=770319

DMV2DIW	DI	DMV2DIW
DMV2DIW	DN	BAY 10-00394
DMV2DIW	MI	TT0PG8F
DMV2DIW	MN	Cyclin-dependent kinase 4 (CDK4)
DMV2DIW	MT	DTT
DMV2DIW	MA	Inhibitor
DMV2DIW	RN	Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154.
DMV2DIW	RU	https://pubmed.ncbi.nlm.nih.gov/21253554

DMV2DIW	DI	DMV2DIW
DMV2DIW	DN	BAY 10-00394
DMV2DIW	MI	TT1LVF2
DMV2DIW	MN	Cyclin-dependent kinase 9 (CDK9)
DMV2DIW	MT	DTT
DMV2DIW	MA	Inhibitor
DMV2DIW	RN	National Cancer Institute Drug Dictionary (drug id 770319).
DMV2DIW	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=770319

DMCZKG0	DI	DMCZKG0
DMCZKG0	DN	BAY-Y-3118
DMCZKG0	MI	TTN6J5F
DMCZKG0	MN	Bacterial DNA gyrase (Bact gyrase)
DMCZKG0	MT	DTT
DMCZKG0	MA	Modulator
DMCZKG0	RN	Bay Y 3118, a new quinolone derivative, rapidly eradicates Listeria monocytogenes from infected mice and L929 cells.
DMCZKG0	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC284583

DMR569L	DI	DMR569L
DMR569L	DN	BBR-3438
DMR569L	MI	TTUTN1I
DMR569L	MN	Human Deoxyribonucleic acid (hDNA)
DMR569L	MT	DTT
DMR569L	MA	Binder
DMR569L	RN	A novel 9-aza-anthrapyrazole effective against human prostatic carcinoma xenografts. Oncology. 2001;61(3):234-42.
DMR569L	RU	https://pubmed.ncbi.nlm.nih.gov/11574780

DM6ANFC	DI	DM6ANFC
DM6ANFC	DN	BCH-2687
DM6ANFC	MI	TTKWM86
DM6ANFC	MN	Opioid receptor mu (MOP)
DM6ANFC	MT	DTT
DM6ANFC	MA	Agonist
DM6ANFC	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009073)
DM6ANFC	RU	http://adisinsight.springer.com/drugs/800009073

DMPIJE7	DI	DMPIJE7
DMPIJE7	DN	Becampanel
DMPIJE7	MI	TTAN6JD
DMPIJE7	MN	Glutamate receptor AMPA (GRIA)
DMPIJE7	MT	DTT
DMPIJE7	MA	Antagonist
DMPIJE7	RN	Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.
DMPIJE7	RU	https://pubmed.ncbi.nlm.nih.gov/17874969

DMEQL9U	DI	DMEQL9U
DMEQL9U	DN	Benzydamine
DMEQL9U	MI	DE6OQ3W
DMEQL9U	MN	Cytochrome P450 1A1 (CYP1A1)
DMEQL9U	MT	DME
DMEQL9U	MA	Metabolism
DMEQL9U	RN	In vitro evaluation of potential in vivo probes for human flavin-containing monooxygenase (FMO): metabolism of benzydamine and caffeine by FMO and P450 isoforms. Br J Clin Pharmacol. 2000 Oct;50(4):311-4.
DMEQL9U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11012553

DMEQL9U	DI	DMEQL9U
DMEQL9U	DN	Benzydamine
DMEQL9U	MI	DEJGDUW
DMEQL9U	MN	Cytochrome P450 1A2 (CYP1A2)
DMEQL9U	MT	DME
DMEQL9U	MA	Metabolism
DMEQL9U	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMEQL9U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMEQL9U	DI	DMEQL9U
DMEQL9U	DN	Benzydamine
DMEQL9U	MI	DECB0K3
DMEQL9U	MN	Cytochrome P450 2D6 (CYP2D6)
DMEQL9U	MT	DME
DMEQL9U	MA	Metabolism
DMEQL9U	RN	In vitro evaluation of potential in vivo probes for human flavin-containing monooxygenase (FMO): metabolism of benzydamine and caffeine by FMO and P450 isoforms. Br J Clin Pharmacol. 2000 Oct;50(4):311-4.
DMEQL9U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11012553

DMEQL9U	DI	DMEQL9U
DMEQL9U	DN	Benzydamine
DMEQL9U	MI	DEVDYN7
DMEQL9U	MN	Cytochrome P450 2E1 (CYP2E1)
DMEQL9U	MT	DME
DMEQL9U	MA	Metabolism
DMEQL9U	RN	Characterization of moclobemide N-oxidation in human liver microsomes. Xenobiotica. 2001 Jul;31(7):387-97.
DMEQL9U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11531003

DMEQL9U	DI	DMEQL9U
DMEQL9U	DN	Benzydamine
DMEQL9U	MI	DE4LYSA
DMEQL9U	MN	Cytochrome P450 3A4 (CYP3A4)
DMEQL9U	MT	DME
DMEQL9U	MA	Metabolism
DMEQL9U	RN	In vitro evaluation of potential in vivo probes for human flavin-containing monooxygenase (FMO): metabolism of benzydamine and caffeine by FMO and P450 isoforms. Br J Clin Pharmacol. 2000 Oct;50(4):311-4.
DMEQL9U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11012553

DMEQL9U	DI	DMEQL9U
DMEQL9U	DN	Benzydamine
DMEQL9U	MI	DEGAZ8O
DMEQL9U	MN	Dimethylaniline oxidase 4 (FMO4)
DMEQL9U	MT	DME
DMEQL9U	MA	Metabolism
DMEQL9U	RN	In vitro evaluation of potential in vivo probes for human flavin-containing monooxygenase (FMO): metabolism of benzydamine and caffeine by FMO and P450 isoforms. Br J Clin Pharmacol. 2000 Oct;50(4):311-4.
DMEQL9U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11012553

DMEQL9U	DI	DMEQL9U
DMEQL9U	DN	Benzydamine
DMEQL9U	MI	DEGTFWK
DMEQL9U	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMEQL9U	MT	DME
DMEQL9U	MA	Metabolism
DMEQL9U	RN	Characterization of moclobemide N-oxidation in human liver microsomes. Xenobiotica. 2001 Jul;31(7):387-97.
DMEQL9U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11531003

DMEQL9U	DI	DMEQL9U
DMEQL9U	DN	Benzydamine
DMEQL9U	MI	TTK0943
DMEQL9U	MN	Prostaglandin G/H synthase (COX)
DMEQL9U	MT	DTT
DMEQL9U	MA	Inhibitor
DMEQL9U	RN	Emerging drugs for chemotherapy-induced mucositis. Expert Opin Emerg Drugs. 2008 Sep;13(3):511-22.
DMEQL9U	RU	https://pubmed.ncbi.nlm.nih.gov/18764726

DMEK6J0	DI	DMEK6J0
DMEK6J0	DN	Bervastatin
DMEK6J0	MI	TTPADOQ
DMEK6J0	MN	HMG-CoA reductase (HMGCR)
DMEK6J0	MT	DTT
DMEK6J0	MA	Inhibitor
DMEK6J0	RN	Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia. Clin Cardiol. 2003 Jan;26(1):18-24.
DMEK6J0	RU	https://pubmed.ncbi.nlm.nih.gov/12539808

DMTE3UV	DI	DMTE3UV
DMTE3UV	DN	BI 1467335
DMTE3UV	MI	TT7HC21
DMTE3UV	MN	Membrane copper amine oxidase (AOC3)
DMTE3UV	MT	DTT
DMTE3UV	MA	Inhibitor
DMTE3UV	RN	Clinical pipeline report, company report or official report of Boehringer Ingelheim.
DMTE3UV	RU	https://www.boehringer-ingelheim.us/press-release/boehringer-ingelheim-discontinues-development-bi-1467335-diabetic-retinopathy

DMGWFZJ	DI	DMGWFZJ
DMGWFZJ	DN	BIBR-363
DMGWFZJ	MI	TTGN1ZA
DMGWFZJ	MN	Angiotensin II receptor (AGTR)
DMGWFZJ	MT	DTT
DMGWFZJ	MA	Modulator
DMGWFZJ	RN	Evaluation of the angiotensin challenge methodology for assessing the pharmacodynamic profile of antihypertensive drugs acting on the renin-angiotensin system. Br J Clin Pharmacol. 1999 October; 48(4): 594-604.
DMGWFZJ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014379/

DMIZ59O	DI	DMIZ59O
DMIZ59O	DN	BIM-23268
DMIZ59O	MI	TTOMNR9
DMIZ59O	MN	Somatostatin receptor (SSTR)
DMIZ59O	MT	DTT
DMIZ59O	MA	Modulator
DMIZ59O	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMIZ59O	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMOP95G	DI	DMOP95G
DMOP95G	DN	Bimoclomol
DMOP95G	MI	TTHYBIX
DMOP95G	MN	Heat shock protein 70 (HSP70)
DMOP95G	MT	DTT
DMOP95G	MA	Modulator
DMOP95G	RN	Bimoclomol elevates heat shock protein 70 and cytoprotects rat neonatal cardiomyocytes. Eur J Pharmacol. 2002 Jan 18;435(1):73-7.
DMOP95G	RU	https://pubmed.ncbi.nlm.nih.gov/11790380

DM65JCM	DI	DM65JCM
DM65JCM	DN	Biricodar
DM65JCM	MI	TT3OT40
DM65JCM	MN	Multidrug resistance protein 1 (ABCB1)
DM65JCM	MT	DTT
DM65JCM	MA	Modulator
DM65JCM	RN	ClinicalTrials.gov (NCT00003847) VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With Recurrent Small Cell Lung Cancer. U.S. National Institutes of Health.
DM65JCM	RU	https://clinicaltrials.gov/ct2/show/NCT00003847

DMBIQL2	DI	DMBIQL2
DMBIQL2	DN	BISNAFIDE MESILATE
DMBIQL2	MI	TTUTN1I
DMBIQL2	MN	Human Deoxyribonucleic acid (hDNA)
DMBIQL2	MT	DTT
DMBIQL2	MA	Inhibitor
DMBIQL2	RN	DNA sequence recognition by bispyrazinonaphthalimides antitumor agents. Biochemistry. 2003 Oct 14;42(40):11751-61.
DMBIQL2	RU	https://pubmed.ncbi.nlm.nih.gov/14529286

DMQ6CYE	DI	DMQ6CYE
DMQ6CYE	DN	BIWB-1
DMQ6CYE	MI	TTF89GD
DMQ6CYE	MN	Interleukin-2 (IL2)
DMQ6CYE	MT	DTT
DMQ6CYE	RN	WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.
DMQ6CYE	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20131212&CC=WO&NR=2013185032A1&KC=A1

DM7ZI8A	DI	DM7ZI8A
DM7ZI8A	DN	BM-17.0744
DM7ZI8A	MI	TTJ584C
DM7ZI8A	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DM7ZI8A	MT	DTT
DM7ZI8A	MA	Activator
DM7ZI8A	RN	Cardiac function and metabolism in Type 2 diabetic mice after treatment with BM 17.0744, a novel PPAR-alpha activator. Am J Physiol Heart Circ Physiol. 2002 Sep;283(3):H949-57.
DM7ZI8A	RU	https://pubmed.ncbi.nlm.nih.gov/12181123

DMVBGIT	DI	DMVBGIT
DMVBGIT	DN	BMS-180448
DMVBGIT	MI	TT1VOHK
DMVBGIT	MN	Potassium channel unspecific (KC)
DMVBGIT	MT	DTT
DMVBGIT	MA	Agonist
DMVBGIT	RN	The novel cardioprotective agent BMS-180448 activates a potassium conductance in cardiac and vascular smooth muscle. Naunyn Schmiedebergs Arch Pharmacol. 1996 Oct;354(4):444-51.
DMVBGIT	RU	https://pubmed.ncbi.nlm.nih.gov/8897447

DMT4VSE	DI	DMT4VSE
DMT4VSE	DN	BMS-181101
DMT4VSE	MI	TT6MSOK
DMT4VSE	MN	5-HT 1D receptor (HTR1D)
DMT4VSE	MT	DTT
DMT4VSE	MA	Antagonist
DMT4VSE	RN	Sensitive triple-quadrupole mass spectrometric assay for the determination of BMS-181885, a 5-HT1 agonist, in human plasma following solid phase extraction. Biomed Chromatogr. 1999 Oct;13(6):425-30.
DMT4VSE	RU	https://pubmed.ncbi.nlm.nih.gov/10477901

DMT4VSE	DI	DMT4VSE
DMT4VSE	DN	BMS-181101
DMT4VSE	MI	DECB0K3
DMT4VSE	MN	Cytochrome P450 2D6 (CYP2D6)
DMT4VSE	MT	DME
DMT4VSE	MA	Metabolism
DMT4VSE	RN	Pharmacokinetic assessment of the sites of first-pass metabolism of BMS-181101, an antidepressant agent, in rats. J Pharm Pharmacol. 1998 Mar;50(3):275-8.
DMT4VSE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9600718

DMT4VSE	DI	DMT4VSE
DMT4VSE	DN	BMS-181101
DMT4VSE	MI	DE4LYSA
DMT4VSE	MN	Cytochrome P450 3A4 (CYP3A4)
DMT4VSE	MT	DME
DMT4VSE	MA	Metabolism
DMT4VSE	RN	Pharmacokinetic assessment of the sites of first-pass metabolism of BMS-181101, an antidepressant agent, in rats. J Pharm Pharmacol. 1998 Mar;50(3):275-8.
DMT4VSE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9600718

DMGPHTJ	DI	DMGPHTJ
DMGPHTJ	DN	BMS-181168
DMGPHTJ	MI	TTH18TF
DMGPHTJ	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMGPHTJ	MT	DTT
DMGPHTJ	MA	Modulator
DMGPHTJ	RN	Efficacy and safety of BMY 21,502 in Alzheimer disease. Ann Pharmacother. 1996 Dec;30(12):1376-80.
DMGPHTJ	RU	https://pubmed.ncbi.nlm.nih.gov/8968446

DMP8SIV	DI	DMP8SIV
DMP8SIV	DN	BMS-187745
DMP8SIV	MI	TTFQEO5
DMP8SIV	MN	Squalene synthetase (FDFT1)
DMP8SIV	MT	DTT
DMP8SIV	MA	Inhibitor
DMP8SIV	RN	Phosphonosulfonates are potent, selective inhibitors of dehydrosqualene synthase and staphyloxanthin biosynthesis in Staphylococcus aureus. J Med Chem. 2009 Feb 26;52(4):976-88.
DMP8SIV	RU	https://pubmed.ncbi.nlm.nih.gov/19191557

DMODK2J	DI	DMODK2J
DMODK2J	DN	BMS-193884
DMODK2J	MI	TTKRD0G
DMODK2J	MN	Endothelin A receptor (EDNRA)
DMODK2J	MT	DTT
DMODK2J	MA	Modulator
DMODK2J	RN	Vasodilator effects of the endothelin ETA receptor selective antagonist BMS-193884 in healthy men
DMODK2J	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884878

DMRPU10	DI	DMRPU10
DMRPU10	DN	BMS-488043
DMRPU10	MI	DE4LYSA
DMRPU10	MN	Cytochrome P450 3A4 (CYP3A4)
DMRPU10	MT	DME
DMRPU10	MA	Metabolism
DMRPU10	RN	Antiviral activity, pharmacokinetics, and safety of BMS-488043, a novel oral small-molecule HIV-1 attachment inhibitor, in HIV-1-infected subjects. Antimicrob Agents Chemother. 2011 Feb;55(2):722-8.
DMRPU10	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21078951

DMRPU10	DI	DMRPU10
DMRPU10	DN	BMS-488043
DMRPU10	MI	TTBYP1X
DMRPU10	MN	Human immunodeficiency virus Envelope glycoprotein gp120 (HIV gp120)
DMRPU10	MT	DTT
DMRPU10	MA	Modulator
DMRPU10	RN	The investigations on HIV-1 gp120 bound with BMS-488043 by using docking and molecular dynamics simulations.J Mol Model.2013 Feb;19(2):905-17.
DMRPU10	RU	https://www.ncbi.nlm.nih.gov/pubmed/23086459

DMS2IC9	DI	DMS2IC9
DMS2IC9	DN	BMS-587101
DMS2IC9	MI	TT48WR6
DMS2IC9	MN	Integrin alpha-L (ITGAL)
DMS2IC9	MT	DTT
DMS2IC9	MA	Inhibitor
DMS2IC9	RN	Small molecule antagonist of leukocyte function associated antigen-1 (LFA-1): structure-activity relationships leading to the identification of 6-(... J Med Chem. 2010 May 13;53(9):3814-30.
DMS2IC9	RU	https://pubmed.ncbi.nlm.nih.gov/20405922

DMS2IC9	DI	DMS2IC9
DMS2IC9	DN	BMS-587101
DMS2IC9	MI	TTIJWR7
DMS2IC9	MN	Integrin beta-2 (ITGB2)
DMS2IC9	MT	DTT
DMS2IC9	MA	Inhibitor
DMS2IC9	RN	Discovery and development of 5-[(5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-yl-methyl]-3-thioph... J Med Chem. 2006 Nov 30;49(24):6946-9.
DMS2IC9	RU	https://pubmed.ncbi.nlm.nih.gov/17125246

DM2NBXR	DI	DM2NBXR
DM2NBXR	DN	BMY-21950
DM2NBXR	MI	TTPADOQ
DM2NBXR	MN	HMG-CoA reductase (HMGCR)
DM2NBXR	MT	DTT
DM2NBXR	MA	Inhibitor
DM2NBXR	RN	Selective inhibition of cholesterol synthesis in liver versus extrahepatic tissues by HMG-CoA reductase inhibitors. J Lipid Res. 1990 Jul;31(7):1271-82.
DM2NBXR	RU	https://pubmed.ncbi.nlm.nih.gov/2401858

DMMJDYI	DI	DMMJDYI
DMMJDYI	DN	BMY-30123
DMMJDYI	MI	TTOD7B3
DMMJDYI	MN	Retinoic acid receptor (RAR)
DMMJDYI	MT	DTT
DMMJDYI	MA	Modulator
DMMJDYI	RN	The pharmacology of a novel topical retinoid, BMY 30123: comparison with tretinoin. J Pharm Pharmacol. 1992 May;44(5):379-86.
DMMJDYI	RU	https://pubmed.ncbi.nlm.nih.gov/1359051

DMA4UCP	DI	DMA4UCP
DMA4UCP	DN	BMY-30129
DMA4UCP	MI	TT9V5JH
DMA4UCP	MN	Phospholipase A2 (PLA2G1B)
DMA4UCP	MT	DTT
DMA4UCP	MA	Inhibitor
DMA4UCP	RN	Inhibitor of phospholipase A2 blocks eicosanoid and platelet activating factor biosynthesis and has topical anti-inflammatory activity. J Pharmacol Exp Ther. 1994 Nov;271(2):852-9.
DMA4UCP	RU	https://pubmed.ncbi.nlm.nih.gov/7965805

DMC35T1	DI	DMC35T1
DMC35T1	DN	BN50727
DMC35T1	MI	TTQL5VC
DMC35T1	MN	Platelet-activating factor receptor (PTAFR)
DMC35T1	MT	DTT
DMC35T1	MA	Modulator
DMC35T1	RN	Platelet-activating factor preferentially stimulates the phospholipase A2/cyclooxygenase cascade in the rabbit cornea. Curr Eye Res. 1995 Sep;14(9):769-75.
DMC35T1	RU	https://www.ncbi.nlm.nih.gov/pubmed/8529415

DMK0PVC	DI	DMK0PVC
DMK0PVC	DN	BOF-4272
DMK0PVC	MI	TT7RJY8
DMK0PVC	MN	Xanthine dehydrogenase/oxidase (XDH)
DMK0PVC	MT	DTT
DMK0PVC	MA	Inhibitor
DMK0PVC	RN	Enantioselective uptake of BOF-4272, a xanthine oxidase inhibitor with a chiral sulfoxide, by isolated rat hepatocytes. Yakugaku Zasshi. 2001 Dec;121(12):989-94.
DMK0PVC	RU	https://pubmed.ncbi.nlm.nih.gov/11766411

DMI3T64	DI	DMI3T64
DMI3T64	DN	BP-2.94
DMI3T64	MI	TT9JNIC
DMI3T64	MN	Histamine H3 receptor (H3R)
DMI3T64	MT	DTT
DMI3T64	MA	Modulator
DMI3T64	RN	Sleep and waking during acute histamine H3 agonist BP 2.94 or H3 antagonist carboperamide (MR 16155) administration in rats. Neuropsychopharmacology. 1996 Jul;15(1):31-5.
DMI3T64	RU	https://pubmed.ncbi.nlm.nih.gov/8797189

DMAQ6DS	DI	DMAQ6DS
DMAQ6DS	DN	BP-897
DMAQ6DS	MI	TT4C8EA
DMAQ6DS	MN	Dopamine D3 receptor (D3R)
DMAQ6DS	MT	DTT
DMAQ6DS	MA	Modulator
DMAQ6DS	RN	BP 897, a selective dopamine D3 receptor ligand with therapeutic potential for the treatment of cocaine-addiction.CNS Drug Rev.2003 Summer;9(2):141-58.
DMAQ6DS	RU	https://www.ncbi.nlm.nih.gov/pubmed/12847556

DMFN1WI	DI	DMFN1WI
DMFN1WI	DN	BR3-Fc
DMFN1WI	MI	TTWMIDN
DMFN1WI	MN	B-cell-activating factor (TNFSF13B)
DMFN1WI	MT	DTT
DMFN1WI	MA	Inhibitor
DMFN1WI	RN	Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54.
DMFN1WI	RU	https://pubmed.ncbi.nlm.nih.gov/18537519

DMRVH2S	DI	DMRVH2S
DMRVH2S	DN	Brecanavir
DMRVH2S	MI	TT5FNQT
DMRVH2S	MN	Human immunodeficiency virus Protease (HIV PR)
DMRVH2S	MT	DTT
DMRVH2S	MA	Modulator
DMRVH2S	RN	Safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus type 1 protease inhibitor, following repeat administration with and without ritonavir in healthy adult subjects.Antimicrob Agents Chemother.2007 Apr;51(4):1202-8.
DMRVH2S	RU	https://www.ncbi.nlm.nih.gov/pubmed/17261626

DMRKBIU	DI	DMRKBIU
DMRKBIU	DN	BRL-32872A
DMRKBIU	MI	TT5HONZ
DMRKBIU	MN	Calcium channel unspecific (CaC)
DMRKBIU	MT	DTT
DMRKBIU	MA	Modulator
DMRKBIU	RN	Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile... J Pharmacol Exp Ther. 1996 Feb;276(2):637-46.
DMRKBIU	RU	https://www.ncbi.nlm.nih.gov/pubmed/8632331

DMRKBIU	DI	DMRKBIU
DMRKBIU	DN	BRL-32872A
DMRKBIU	MI	TT1VOHK
DMRKBIU	MN	Potassium channel unspecific (KC)
DMRKBIU	MT	DTT
DMRKBIU	MA	Modulator
DMRKBIU	RN	Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile... J Pharmacol Exp Ther. 1996 Feb;276(2):637-46.
DMRKBIU	RU	https://www.ncbi.nlm.nih.gov/pubmed/8632331

DMIHSOG	DI	DMIHSOG
DMIHSOG	DN	BRL-46470
DMIHSOG	MI	TTNXLKE
DMIHSOG	MN	5-HT 3 receptor (5HT3R)
DMIHSOG	MT	DTT
DMIHSOG	MA	Modulator
DMIHSOG	RN	Evidence that the atypical 5-HT3 receptor ligand, [3H]-BRL46470, labels additional 5-HT3 binding sites compared to [3H]-granisetron. Br J Pharmacol. 1995 Sep;116(2):1781-8.
DMIHSOG	RU	https://www.ncbi.nlm.nih.gov/pubmed/8528560

DM0WG4U	DI	DM0WG4U
DM0WG4U	DN	BRL-55834
DM0WG4U	MI	TT1VOHK
DM0WG4U	MN	Potassium channel unspecific (KC)
DM0WG4U	MT	DTT
DM0WG4U	MA	Opener
DM0WG4U	RN	Comparison of the airways relaxant and hypotensive potencies of the potassium channel activators BRL 55834 and levcromakalim (BRL 38227) in vivo in guinea-pigs and rats. Br J Pharmacol. 1993 Aug;109(4):1133-9.
DM0WG4U	RU	https://pubmed.ncbi.nlm.nih.gov/8401925

DMV3Y8R	DI	DMV3Y8R
DMV3Y8R	DN	BRL-61063
DMV3Y8R	MI	TTK25J1
DMV3Y8R	MN	Adenosine A1 receptor (ADORA1)
DMV3Y8R	MT	DTT
DMV3Y8R	MA	Inhibitor
DMV3Y8R	RN	Inhibition of cyclic nucleotide phosphodiesterase by derivatives of 1,3-bis(cyclopropylmethyl)xanthine. J Med Chem. 1994 Feb 18;37(4):476-85.
DMV3Y8R	RU	https://pubmed.ncbi.nlm.nih.gov/8120866

DMV3Y8R	DI	DMV3Y8R
DMV3Y8R	DN	BRL-61063
DMV3Y8R	MI	TTJ0IQB
DMV3Y8R	MN	Phosphodiesterase 5A (PDE5A)
DMV3Y8R	MT	DTT
DMV3Y8R	MA	Inhibitor
DMV3Y8R	RN	Inhibition of cyclic nucleotide phosphodiesterase by derivatives of 1,3-bis(cyclopropylmethyl)xanthine. J Med Chem. 1994 Feb 18;37(4):476-85.
DMV3Y8R	RU	https://pubmed.ncbi.nlm.nih.gov/8120866

DMTEQ0G	DI	DMTEQ0G
DMTEQ0G	DN	Brofaromine
DMTEQ0G	MI	DECB0K3
DMTEQ0G	MN	Cytochrome P450 2D6 (CYP2D6)
DMTEQ0G	MT	DME
DMTEQ0G	MA	Metabolism
DMTEQ0G	RN	Role of cytochrome P4502D6 in the metabolism of brofaromine. A new selective MAO-A inhibitor. Eur J Clin Pharmacol. 1993;45(3):265-9.
DMTEQ0G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8276052

DMTEQ0G	DI	DMTEQ0G
DMTEQ0G	DN	Brofaromine
DMTEQ0G	MI	TT3WG5C
DMTEQ0G	MN	Monoamine oxidase type A (MAO-A)
DMTEQ0G	MT	DTT
DMTEQ0G	MA	Modulator
DMTEQ0G	RN	Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors. J Neural Transm Suppl. 1989;28:5-20.
DMTEQ0G	RU	https://pubmed.ncbi.nlm.nih.gov/2677242

DM54K2P	DI	DM54K2P
DM54K2P	DN	BTS-67582
DM54K2P	MI	TTEF5MJ
DM54K2P	MN	ATP-binding cassette transporter C9 (ABCC9)
DM54K2P	MT	DTT
DM54K2P	MA	Modulator
DM54K2P	RN	BTS-67582 (Knoll Pharmaceuticals Co). IDrugs. 1999 Apr;2(4):355-9.
DM54K2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/16158354

DM43JK0	DI	DM43JK0
DM43JK0	DN	BVT-115959
DM43JK0	MI	TTM2AOE
DM43JK0	MN	Adenosine A2a receptor (ADORA2A)
DM43JK0	MT	DTT
DM43JK0	MA	Agonist
DM43JK0	RN	Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta. 2011 May;1808(5):1290-308.
DM43JK0	RU	https://pubmed.ncbi.nlm.nih.gov/21185259

DMI2LFG	DI	DMI2LFG
DMI2LFG	DN	BW-773U82
DMI2LFG	MI	TT0IHXV
DMI2LFG	MN	DNA topoisomerase II (TOP2)
DMI2LFG	MT	DTT
DMI2LFG	MA	Modulator
DMI2LFG	RN	Correlation of cytotoxicity and protein-associated DNA strand breaks for 2-(arylmethylamino)-1,3-propanediols. Anticancer Drug Des. 1998 Oct;13(7):825-35.
DMI2LFG	RU	https://pubmed.ncbi.nlm.nih.gov/9807165

DM8ZFS3	DI	DM8ZFS3
DM8ZFS3	DN	BY-1949
DM8ZFS3	MI	TT5WKM8
DM8ZFS3	MN	ATP phosphatase (ATPase)
DM8ZFS3	MT	DTT
DM8ZFS3	MA	Modulator
DM8ZFS3	RN	An activation of synaptosomal Na+,K(+)-ATPase by a novel dibenzoxazepine derivative (BY-1949) in the rat brain: its functional role in the neurotransmitter uptake systems. J Neurochem. 1992 Jan;58(1):362-8.
DM8ZFS3	RU	https://pubmed.ncbi.nlm.nih.gov/1345768

DMHJ3SN	DI	DMHJ3SN
DMHJ3SN	DN	Cadrofloxacin
DMHJ3SN	MI	TTN6J5F
DMHJ3SN	MN	Bacterial DNA gyrase (Bact gyrase)
DMHJ3SN	MT	DTT
DMHJ3SN	MA	Modulator
DMHJ3SN	RN	Hydrophilicity of quinolones is not an exclusive factor for decreased activity in efflux-mediated resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother. 1996 Aug;40(8):1835-42.
DMHJ3SN	RU	https://pubmed.ncbi.nlm.nih.gov/8843290

DMS3ECJ	DI	DMS3ECJ
DMS3ECJ	DN	Camobucol
DMS3ECJ	MI	TTF8CQI
DMS3ECJ	MN	Tumor necrosis factor (TNF)
DMS3ECJ	MT	DTT
DMS3ECJ	MA	Inhibitor
DMS3ECJ	RN	AGIX-4207 [2-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]acetic acid], a novel ... J Pharmacol Exp Ther. 2005 May;313(2):492-501.
DMS3ECJ	RU	https://pubmed.ncbi.nlm.nih.gov/15701708

DMNOLHT	DI	DMNOLHT
DMNOLHT	DN	Caracemide
DMNOLHT	MI	TT1RS9F
DMNOLHT	MN	Acetylcholinesterase (AChE)
DMNOLHT	MT	DTT
DMNOLHT	MA	Inhibitor
DMNOLHT	RN	Biochemical pharmacology of N-acetyl-N-(methylcarbamoyloxy)-N'-methylurea (caracemide; NSC-253272). Biochem Pharmacol. 1986 Aug 15;35(16):2781-7.
DMNOLHT	RU	https://pubmed.ncbi.nlm.nih.gov/3527174

DMV2DY3	DI	DMV2DY3
DMV2DY3	DN	CARIPORIDE
DMV2DY3	MI	TTGSEFH
DMV2DY3	MN	Sodium/hydrogen exchanger 1 (SLC9A1)
DMV2DY3	MT	DTT
DMV2DY3	MA	Inhibitor
DMV2DY3	RN	Synthesis and bioactivity of substituted indan-1-ylideneaminoguanidine derivatives. Eur J Med Chem. 2009 Sep;44(9):3771-6.
DMV2DY3	RU	https://pubmed.ncbi.nlm.nih.gov/19482383

DMV2DY3	DI	DMV2DY3
DMV2DY3	DN	CARIPORIDE
DMV2DY3	MI	TTFZVPO
DMV2DY3	MN	Sodium/hydrogen exchanger 3 (SLC9A3)
DMV2DY3	MT	DTT
DMV2DY3	MA	Inhibitor
DMV2DY3	RN	Bicyclic acylguanidine Na+/H+ antiporter inhibitors. J Med Chem. 1998 Sep 10;41(19):3736-47.
DMV2DY3	RU	https://pubmed.ncbi.nlm.nih.gov/9733499

DM5DI1G	DI	DM5DI1G
DM5DI1G	DN	CARZELESIN
DM5DI1G	MI	TTUTN1I
DM5DI1G	MN	Human Deoxyribonucleic acid (hDNA)
DM5DI1G	MT	DTT
DM5DI1G	MA	Binder
DM5DI1G	RN	Sequence selectivity of DNA alkylation by adozelesin and carzelesin. Arch Pharm Res. 1998 Aug;21(4):385-90.
DM5DI1G	RU	https://pubmed.ncbi.nlm.nih.gov/9875464

DMPZFDE	DI	DMPZFDE
DMPZFDE	DN	CASTANOSPERMINE
DMPZFDE	MI	TTQRL1H
DMPZFDE	MN	Glucosidase unspecific (GAN)
DMPZFDE	MT	DTT
DMPZFDE	MA	Modulator
DMPZFDE	RN	Castanospermine inhibits alpha-glucosidase activities and alters glycogen distribution in animals. Proc Natl Acad Sci U S A. 1985 Jan;82(1):93-7.
DMPZFDE	RU	https://pubmed.ncbi.nlm.nih.gov/3881759

DMVP4YK	DI	DMVP4YK
DMVP4YK	DN	CB1954
DMVP4YK	MI	DEEHWOG
DMVP4YK	MN	Azoreductase (azoR)
DMVP4YK	MT	DME
DMVP4YK	MA	Metabolism
DMVP4YK	RN	Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954. Biochem Pharmacol. 2010 Mar 1;79(5):678-87.
DMVP4YK	RU	https://pubmed.ncbi.nlm.nih.gov/19852945

DMVP4YK	DI	DMVP4YK
DMVP4YK	DN	CB1954
DMVP4YK	MI	DE07EIQ
DMVP4YK	MN	General stress protein 14 (ywrO)
DMVP4YK	MT	DME
DMVP4YK	MA	Metabolism
DMVP4YK	RN	Bacillus amyloliquefaciens orthologue of Bacillus subtilis ywrO encodes a nitroreductase enzyme which activates the prodrug CB 1954. Microbiology. 2002 Jan;148(Pt 1):297-306.
DMVP4YK	RU	https://pubmed.ncbi.nlm.nih.gov/11782522

DMVP4YK	DI	DMVP4YK
DMVP4YK	DN	CB1954
DMVP4YK	MI	DE1FR8H
DMVP4YK	MN	N-ethylmaleimide reductase (nemA)
DMVP4YK	MT	DME
DMVP4YK	MA	Metabolism
DMVP4YK	RN	Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954. Biochem Pharmacol. 2010 Mar 1;79(5):678-87.
DMVP4YK	RU	https://pubmed.ncbi.nlm.nih.gov/19852945

DMVP4YK	DI	DMVP4YK
DMVP4YK	DN	CB1954
DMVP4YK	MI	DEDPI65
DMVP4YK	MN	Oxygen-insensitive NADPH nitroreductase A (nfsA)
DMVP4YK	MT	DME
DMVP4YK	MA	Metabolism
DMVP4YK	RN	Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954. Biochem Pharmacol. 2010 Mar 1;79(5):678-87.
DMVP4YK	RU	https://pubmed.ncbi.nlm.nih.gov/19852945

DMVP4YK	DI	DMVP4YK
DMVP4YK	DN	CB1954
DMVP4YK	MI	DE0QLUZ
DMVP4YK	MN	Oxygen-insensitive NADPH nitroreductase B (nfsB)
DMVP4YK	MT	DME
DMVP4YK	MA	Metabolism
DMVP4YK	RN	Conversion of NfsB, a minor Escherichia coli nitroreductase, to a flavin reductase similar in biochemical properties to FRase I, the major flavin reductase in Vibrio fischeri, by a single amino acid substitution. J Bacteriol. 1996 Aug;178(15):4731-3.
DMVP4YK	RU	https://pubmed.ncbi.nlm.nih.gov/8755909

DMVP4YK	DI	DMVP4YK
DMVP4YK	DN	CB1954
DMVP4YK	MI	DENP5RY
DMVP4YK	MN	Quinone reductase 1 (NQO1)
DMVP4YK	MT	DME
DMVP4YK	MA	Metabolism
DMVP4YK	RN	Gene Therapy of the Central Nervous System. Charter 22 - Prodrug-Activation Gene Therapy. 2006, Pages 291-301
DMVP4YK	RU	https://www.sciencedirect.com/science/article/pii/B978012397632150023X

DMVP4YK	DI	DMVP4YK
DMVP4YK	DN	CB1954
DMVP4YK	MI	TTJLP0R
DMVP4YK	MN	Quinone reductase 2 (NQO2)
DMVP4YK	MT	DTT
DMVP4YK	MA	Inhibitor
DMVP4YK	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMVP4YK	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM2FAH0	DI	DM2FAH0
DM2FAH0	DN	CBF-BS2
DM2FAH0	MI	TTKN8W0
DM2FAH0	MN	Glucose-6-phosphate dehydrogenase (G6PD)
DM2FAH0	MT	DTT
DM2FAH0	MA	Modulator
DM2FAH0	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007279)
DM2FAH0	RU	http://adisinsight.springer.com/drugs/800007279

DM9P7Z2	DI	DM9P7Z2
DM9P7Z2	DN	CD-349
DM9P7Z2	MI	TT5HONZ
DM9P7Z2	MN	Calcium channel unspecific (CaC)
DM9P7Z2	MT	DTT
DM9P7Z2	MA	Modulator
DM9P7Z2	RN	A new Ca-antagonist, CD-349, binding to the Ca-channel of rat myocardium and brain and hog coronary artery. Jpn J Pharmacol. 1988 Dec;48(4):453-62.
DM9P7Z2	RU	https://pubmed.ncbi.nlm.nih.gov/2854176

DMUPJW4	DI	DMUPJW4
DMUPJW4	DN	CDP840
DMUPJW4	MI	TTZ97H5
DMUPJW4	MN	Phosphodiesterase 4A (PDE4A)
DMUPJW4	MT	DTT
DMUPJW4	MA	Inhibitor
DMUPJW4	RN	Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly... Bioorg Med Chem Lett. 2005 Dec 1;15(23):5241-6.
DMUPJW4	RU	https://pubmed.ncbi.nlm.nih.gov/16168647

DMUPJW4	DI	DMUPJW4
DMUPJW4	DN	CDP840
DMUPJW4	MI	TTVIAT9
DMUPJW4	MN	Phosphodiesterase 4B (PDE4B)
DMUPJW4	MT	DTT
DMUPJW4	MA	Inhibitor
DMUPJW4	RN	Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly... Bioorg Med Chem Lett. 2005 Dec 1;15(23):5241-6.
DMUPJW4	RU	https://pubmed.ncbi.nlm.nih.gov/16168647

DMUPJW4	DI	DMUPJW4
DMUPJW4	DN	CDP840
DMUPJW4	MI	TTSKMI8
DMUPJW4	MN	Phosphodiesterase 4D (PDE4D)
DMUPJW4	MT	DTT
DMUPJW4	MA	Inhibitor
DMUPJW4	RN	Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly... Bioorg Med Chem Lett. 2005 Dec 1;15(23):5241-6.
DMUPJW4	RU	https://pubmed.ncbi.nlm.nih.gov/16168647

DMWHQM3	DI	DMWHQM3
DMWHQM3	DN	CDP-850
DMWHQM3	MI	TTE5VG0
DMWHQM3	MN	P-selectin (SELP)
DMWHQM3	MT	DTT
DMWHQM3	RN	WO patent application no. 2001,0276,21, Competitive inhibition elisa for antibody detection.
DMWHQM3	RU	http://www.google.com/patents/WO2001027621A2?cl=en

DMEI0LJ	DI	DMEI0LJ
DMEI0LJ	DN	CDP-860
DMEI0LJ	MI	TTI7421
DMEI0LJ	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMEI0LJ	MT	DTT
DMEI0LJ	MA	Modulator
DMEI0LJ	RN	Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated w... J Clin Oncol. 2005 Feb 10;23(5):973-81.
DMEI0LJ	RU	https://pubmed.ncbi.nlm.nih.gov/15466784

DM746L8	DI	DM746L8
DM746L8	DN	CE-1037
DM746L8	MI	TTPLTSQ
DM746L8	MN	Neutrophil elastase (NE)
DM746L8	MT	DTT
DM746L8	MA	Inhibitor
DM746L8	RN	Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs. 2002 Jul;11(7):965-80.
DM746L8	RU	https://pubmed.ncbi.nlm.nih.gov/12084007

DMXO49B	DI	DMXO49B
DMXO49B	DN	CE-326597
DMXO49B	MI	TTCG0AL
DMXO49B	MN	Cholecystokinin receptor type A (CCKAR)
DMXO49B	MT	DTT
DMXO49B	MA	Agonist
DMXO49B	RN	Obesity Pharmacotherapy: Current Perspectives and Future Directions. Curr Cardiol Rev. 2013 February; 9(1): 33-54.
DMXO49B	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584306/

DMIR4FB	DI	DMIR4FB
DMIR4FB	DN	CEMADOTIN HYDROCHLORIDE
DMIR4FB	MI	TTYFKSZ
DMIR4FB	MN	Tubulin beta (TUBB)
DMIR4FB	MT	DTT
DMIR4FB	MA	Modulator
DMIR4FB	RN	Suppression of microtubule dynamics by binding of cemadotin to tubulin: possible mechanism for its antitumor action. Biochemistry. 1998 Dec 15;37(50):17571-8.
DMIR4FB	RU	https://pubmed.ncbi.nlm.nih.gov/9860873

DMG62H1	DI	DMG62H1
DMG62H1	DN	CereCRIB
DMG62H1	MI	TTN4QDT
DMG62H1	MN	Opioid receptor (OPR)
DMG62H1	MT	DTT
DMG62H1	MA	Modulator
DMG62H1	RN	US patent application no. 5,874,099, Methods for making immunoisolatary implantable vehicles with a biocompatible jacket and a biocompatible matrix core.
DMG62H1	RU	http://www.google.co.ug/patents/US5874099

DMFBNI6	DI	DMFBNI6
DMFBNI6	DN	Ceronapril
DMFBNI6	MI	TTL69WB
DMFBNI6	MN	Angiotensin-converting enzyme (ACE)
DMFBNI6	MT	DTT
DMFBNI6	MA	Inhibitor
DMFBNI6	RN	Radioimmunoassay for ceronapril, a new angiotensin-converting enzyme inhibitor, and its application to a pharmacokinetic study in healthy male volunteers. Ther Drug Monit. 1992 Jun;14(3):209-19.
DMFBNI6	RU	https://pubmed.ncbi.nlm.nih.gov/1412607

DMFBNI6	DI	DMFBNI6
DMFBNI6	DN	Ceronapril
DMFBNI6	MI	DT9G7XN
DMFBNI6	MN	Peptide transporter 1 (SLC15A1)
DMFBNI6	MT	DTP
DMFBNI6	MA	Substrate
DMFBNI6	RN	Pharmaceutical and pharmacological importance of peptide transporters. J Pharm Pharmacol. 2008 May;60(5):543-85.
DMFBNI6	RU	https://doi.org/10.1211/jpp.60.5.0002

DMUG5OB	DI	DMUG5OB
DMUG5OB	DN	CETi-1
DMUG5OB	MI	TTFQAYR
DMUG5OB	MN	Cholesteryl ester transfer protein (CETP)
DMUG5OB	MT	DTT
DMUG5OB	RN	CETi-1. AVANT. Curr Opin Investig Drugs. 2004 Mar;5(3):334-8.
DMUG5OB	RU	https://pubmed.ncbi.nlm.nih.gov/15083601

DMHK8IM	DI	DMHK8IM
DMHK8IM	DN	CFC-222
DMHK8IM	MI	TTN6J5F
DMHK8IM	MN	Bacterial DNA gyrase (Bact gyrase)
DMHK8IM	MT	DTT
DMHK8IM	MA	Modulator
DMHK8IM	RN	Fluoroquinolone resistance in Mycoplasma gallisepticum: DNA gyrase as primary target of enrofloxacin and impact of mutations in topoisomerases on r... J Antimicrob Chemother. 2002 Oct;50(4):589-92.
DMHK8IM	RU	https://www.ncbi.nlm.nih.gov/pubmed/12356806

DMBJQU6	DI	DMBJQU6
DMBJQU6	DN	CGP-49823
DMBJQU6	MI	TTZPO1L
DMBJQU6	MN	Substance-P receptor (TACR1)
DMBJQU6	MT	DTT
DMBJQU6	MA	Antagonist
DMBJQU6	RN	The potency of the novel tachykinin receptor antagonist CGP49823 at rat and gerbil motoneurones in vitro. Eur J Pharmacol. 1998 Jan 26;342(2-3):203-8.
DMBJQU6	RU	https://pubmed.ncbi.nlm.nih.gov/9548386

DMCRPKS	DI	DMCRPKS
DMCRPKS	DN	CGRP
DMCRPKS	MI	TTAFORY
DMCRPKS	MN	Calcitonin gene-related peptide (CALC)
DMCRPKS	MT	DTT
DMCRPKS	MA	Modulator
DMCRPKS	RN	Calcitonin gene-related peptide as inflammatory mediator.Pulm Pharmacol Ther.2003;16(3):121-30.
DMCRPKS	RU	https://www.ncbi.nlm.nih.gov/pubmed/12749828

DM2OWCV	DI	DM2OWCV
DM2OWCV	DN	CGS-25462
DM2OWCV	MI	TT5TKPM
DM2OWCV	MN	Neutral endopeptidase (MME)
DM2OWCV	MT	DTT
DM2OWCV	MA	Modulator
DM2OWCV	RN	Quantitative analytical methods for the determination of a new hypertension drug, CGS 25462, and its metabolites (CGS 25659 and CGS 24592) in human plasma by high-performance liquid chromatography. JChromatogr B Biomed Sci Appl. 1998 Mar 20;706(2):287-94.
DM2OWCV	RU	https://pubmed.ncbi.nlm.nih.gov/9551815

DM03XVA	DI	DM03XVA
DM03XVA	DN	CI-1018
DM03XVA	MI	TTZ97H5
DM03XVA	MN	Phosphodiesterase 4A (PDE4A)
DM03XVA	MT	DTT
DM03XVA	MA	Inhibitor
DM03XVA	RN	New substituted triaza-benzo[cd]azulen-9-ones as promising phosphodiesterase-4 inhibitors. Bioorg Med Chem Lett. 2004 Jun 21;14(12):3303-6.
DM03XVA	RU	https://pubmed.ncbi.nlm.nih.gov/15149695

DM03XVA	DI	DM03XVA
DM03XVA	DN	CI-1018
DM03XVA	MI	TTVIAT9
DM03XVA	MN	Phosphodiesterase 4B (PDE4B)
DM03XVA	MT	DTT
DM03XVA	MA	Inhibitor
DM03XVA	RN	New substituted triaza-benzo[cd]azulen-9-ones as promising phosphodiesterase-4 inhibitors. Bioorg Med Chem Lett. 2004 Jun 21;14(12):3303-6.
DM03XVA	RU	https://pubmed.ncbi.nlm.nih.gov/15149695

DM03XVA	DI	DM03XVA
DM03XVA	DN	CI-1018
DM03XVA	MI	TTSKMI8
DM03XVA	MN	Phosphodiesterase 4D (PDE4D)
DM03XVA	MT	DTT
DM03XVA	MA	Inhibitor
DM03XVA	RN	New substituted triaza-benzo[cd]azulen-9-ones as promising phosphodiesterase-4 inhibitors. Bioorg Med Chem Lett. 2004 Jun 21;14(12):3303-6.
DM03XVA	RU	https://pubmed.ncbi.nlm.nih.gov/15149695

DMADPQX	DI	DMADPQX
DMADPQX	DN	CI-930
DMADPQX	MI	TT06AWU
DMADPQX	MN	Phosphodiesterase 3A (PDE3A)
DMADPQX	MT	DTT
DMADPQX	MA	Inhibitor
DMADPQX	RN	Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazi... J Med Chem. 1989 Feb;32(2):342-50.
DMADPQX	RU	https://pubmed.ncbi.nlm.nih.gov/2536438

DMN4QSW	DI	DMN4QSW
DMN4QSW	DN	CI-949
DMN4QSW	MI	TTN53ZF
DMN4QSW	MN	Leukotriene B4 receptor 1 (LTB4R)
DMN4QSW	MT	DTT
DMN4QSW	MA	Modulator
DMN4QSW	RN	Inhibition of histamine, leukotriene C4/D4, and thromboxane B2 release from human leukocytes and human chopped lung mast cells by the allergic mediator release inhibitor, CI-949. J Allergy Clin Immunol. 1990 Dec;86(6 Pt 1):902-8.
DMN4QSW	RU	https://pubmed.ncbi.nlm.nih.gov/1702129

DMBO28J	DI	DMBO28J
DMBO28J	DN	CI-976
DMBO28J	MI	TTMF541
DMBO28J	MN	Liver carboxylesterase (CES1)
DMBO28J	MT	DTT
DMBO28J	MA	Inhibitor
DMBO28J	RN	Acyl-coenzyme A:cholesterol-acyltransferase (ACAT) inhibitors modulate monocyte adhesion to aortic endothelial cells. Atherosclerosis. 1995 Jan 6;112(1):7-17.
DMBO28J	RU	https://pubmed.ncbi.nlm.nih.gov/7772069

DMTAKNF	DI	DMTAKNF
DMTAKNF	DN	Cipralisant
DMTAKNF	MI	TT9JNIC
DMTAKNF	MN	Histamine H3 receptor (H3R)
DMTAKNF	MT	DTT
DMTAKNF	MA	Binder
DMTAKNF	RN	G protein-dependent pharmacology of histamine H3 receptor ligands: evidence for heterogeneous active state receptor conformations. J Pharmacol Exp Ther. 2005 Jul;314(1):271-81.
DMTAKNF	RU	https://pubmed.ncbi.nlm.nih.gov/15821027

DM1CDNS	DI	DM1CDNS
DM1CDNS	DN	CJ-13610
DM1CDNS	MI	TT2J34L
DM1CDNS	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM1CDNS	MT	DTT
DM1CDNS	MA	Inhibitor
DM1CDNS	RN	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
DM1CDNS	RU	https://pubmed.ncbi.nlm.nih.gov/16634702

DMQD2LS	DI	DMQD2LS
DMQD2LS	DN	CJC-1131
DMQD2LS	MI	TTVIMDE
DMQD2LS	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMQD2LS	MT	DTT
DMQD2LS	MA	Modulator
DMQD2LS	RN	Pharmacokinetics and tolerability of a novel long-acting glucagon-like peptide-1 analog, CJC-1131, in healthy and diabetic subjects. Int J Clin Pharmacol Ther. 2008 Sep;46(9):443-52.
DMQD2LS	RU	https://pubmed.ncbi.nlm.nih.gov/18793574

DM7LIDT	DI	DM7LIDT
DM7LIDT	DN	CL-283796
DM7LIDT	MI	TTMF541
DM7LIDT	MN	Liver carboxylesterase (CES1)
DM7LIDT	MT	DTT
DM7LIDT	MA	Modulator
DM7LIDT	RN	ACAT inhibitors CL 283,546 and CL 283,796 reduce LDL cholesterol without affecting cholesterol absorption in African green monkeys. J Lipid Res. 1995 Jun;36(6):1199-210.
DM7LIDT	RU	https://pubmed.ncbi.nlm.nih.gov/7665998

DMKFMYR	DI	DMKFMYR
DMKFMYR	DN	CLOTURIN
DMKFMYR	MI	TTUBNVO
DMKFMYR	MN	DNA synthesis (DNA synth)
DMKFMYR	MT	DTT
DMKFMYR	MA	Modulator
DMKFMYR	RN	Inhibition of biosynthetic processes in P388 and Ehrlich ascites cells by cloturin. Drugs Exp Clin Res. 1988;14(9):575-80.
DMKFMYR	RU	https://pubmed.ncbi.nlm.nih.gov/3229320

DMRVJ1A	DI	DMRVJ1A
DMRVJ1A	DN	Corus 1030
DMRVJ1A	MI	TT4G2JS
DMRVJ1A	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DMRVJ1A	MT	DTT
DMRVJ1A	MA	Modulator
DMRVJ1A	RN	Differential modulation of Nav1.7 and Nav1.8 peripheral nerve sodium channels by the local anesthetic lidocaine. Br J Pharmacol. 2004 Jun;142(3):576-84.
DMRVJ1A	RU	https://pubmed.ncbi.nlm.nih.gov/15148257

DMRVJ1A	DI	DMRVJ1A
DMRVJ1A	DN	Corus 1030
DMRVJ1A	MI	TT90XZ8
DMRVJ1A	MN	Voltage-gated sodium channel alpha Nav1.8 (SCN10A)
DMRVJ1A	MT	DTT
DMRVJ1A	MA	Modulator
DMRVJ1A	RN	Differential modulation of Nav1.7 and Nav1.8 peripheral nerve sodium channels by the local anesthetic lidocaine. Br J Pharmacol. 2004 Jun;142(3):576-84.
DMRVJ1A	RU	https://pubmed.ncbi.nlm.nih.gov/15148257

DMNJD9H	DI	DMNJD9H
DMNJD9H	DN	CP-118
DMNJD9H	MI	TT7CXIM
DMNJD9H	MN	Histamine receptor (HR)
DMNJD9H	MT	DTT
DMNJD9H	MA	Antagonist
DMNJD9H	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025139)
DMNJD9H	RU	http://adisinsight.springer.com/drugs/800025139

DM3OJP0	DI	DM3OJP0
DM3OJP0	DN	CP-122288
DM3OJP0	MI	TT6MSOK
DM3OJP0	MN	5-HT 1D receptor (HTR1D)
DM3OJP0	MT	DTT
DM3OJP0	MA	Agonist
DM3OJP0	RN	The 5-HT1D receptor antagonist GR-127,935 prevents inhibitory effects of sumatriptan but not CP-122,288 and 5-CT on neurogenic plasma extravasation within guinea pig dura mater. Neuropharmacology. 1997 Jan;36(1):83-91.
DM3OJP0	RU	https://pubmed.ncbi.nlm.nih.gov/9144644

DM1OSUR	DI	DM1OSUR
DM1OSUR	DN	CP-195543
DM1OSUR	MI	TTN53ZF
DM1OSUR	MN	Leukotriene B4 receptor 1 (LTB4R)
DM1OSUR	MT	DTT
DM1OSUR	MA	Antagonist
DM1OSUR	RN	The synthesis of CP-195543, an LTB4 antagonist for the treatment of inflammatory diseases. Curr Opin Drug Discov Devel. 1999 Nov;2(6):550-6.
DM1OSUR	RU	https://pubmed.ncbi.nlm.nih.gov/19649826

DMZ76EM	DI	DMZ76EM
DMZ76EM	DN	CP-316,311
DMZ76EM	MI	TT7EFHR
DMZ76EM	MN	Corticotropin-releasing factor receptor 1 (CRHR1)
DMZ76EM	MT	DTT
DMZ76EM	MA	Antagonist
DMZ76EM	RN	Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
DMZ76EM	RU	https://pubmed.ncbi.nlm.nih.gov/18172433

DMH5LKS	DI	DMH5LKS
DMH5LKS	DN	CPA-926
DMH5LKS	MI	TTG3K2U
DMH5LKS	MN	Lipoxygenase (ALOX)
DMH5LKS	MT	DTT
DMH5LKS	MA	Modulator
DMH5LKS	RN	Esculetin (dihydroxycoumarin) inhibits the production of matrix metalloproteinases in cartilage explants, and oral administration of its prodrug, CPA-926, suppresses cartilage destruction in rabbit experimental osteoarthritis. J Rheumatol. 1999 Mar;26(3):654-62.
DMH5LKS	RU	https://pubmed.ncbi.nlm.nih.gov/10090178

DMVU4A5	DI	DMVU4A5
DMVU4A5	DN	CRD-5
DMVU4A5	MI	TT7GN3U
DMVU4A5	MN	Apolipoprotein A-I (APOA1)
DMVU4A5	MT	DTT
DMVU4A5	MA	Stimulator
DMVU4A5	RN	Emerging antidyslipidemic drugs. Expert Opin Emerg Drugs. 2008 Jun;13(2):363-81.
DMVU4A5	RU	https://pubmed.ncbi.nlm.nih.gov/18537526

DMZLIUQ	DI	DMZLIUQ
DMZLIUQ	DN	Cromafiban
DMZLIUQ	MI	TT38RM1
DMZLIUQ	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DMZLIUQ	MT	DTT
DMZLIUQ	MA	Modulator
DMZLIUQ	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMZLIUQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMB9QSJ	DI	DMB9QSJ
DMB9QSJ	DN	CRx-191
DMB9QSJ	MI	TT93WF5
DMB9QSJ	MN	Interferon-gamma (IFNG)
DMB9QSJ	MT	DTT
DMB9QSJ	MA	Inhibitor
DMB9QSJ	RN	CombinatoRx Drug Candidate CRx-191 Demonstrates Positive Phase 2 Results In Psoriasis. CombinatoRx. 2008.
DMB9QSJ	RU	http://www.medicalnewstoday.com/articles/100566.php

DMB9QSJ	DI	DMB9QSJ
DMB9QSJ	DN	CRx-191
DMB9QSJ	MI	TTF8CQI
DMB9QSJ	MN	Tumor necrosis factor (TNF)
DMB9QSJ	MT	DTT
DMB9QSJ	MA	Inhibitor
DMB9QSJ	RN	CombinatoRx Drug Candidate CRx-191 Demonstrates Positive Phase 2 Results In Psoriasis. CombinatoRx. 2008.
DMB9QSJ	RU	http://www.medicalnewstoday.com/articles/100566.php

DM39N7W	DI	DM39N7W
DM39N7W	DN	CRx-401
DM39N7W	MI	TT8NGED
DM39N7W	MN	Prostaglandin G/H synthase 1 (COX-1)
DM39N7W	MT	DTT
DM39N7W	MA	Inhibitor
DM39N7W	RN	ClinicalTrials.gov (NCT00506298) Study of CRx-401 on Glucose Levels in Subjects With Type II Diabetes. U.S. National Institutes of Health.
DM39N7W	RU	https://clinicaltrials.gov/ct2/show/NCT00506298

DM39N7W	DI	DM39N7W
DM39N7W	DN	CRx-401
DM39N7W	MI	TTVKILB
DM39N7W	MN	Prostaglandin G/H synthase 2 (COX-2)
DM39N7W	MT	DTT
DM39N7W	MA	Inhibitor
DM39N7W	RN	ClinicalTrials.gov (NCT00506298) Study of CRx-401 on Glucose Levels in Subjects With Type II Diabetes. U.S. National Institutes of Health.
DM39N7W	RU	https://clinicaltrials.gov/ct2/show/NCT00506298

DM73C4K	DI	DM73C4K
DM73C4K	DN	Cryptophycin
DM73C4K	MI	TTML2WA
DM73C4K	MN	Tubulin (TUB)
DM73C4K	MT	DTT
DM73C4K	MA	Inducer
DM73C4K	RN	Single-walled tubulin ring polymers. Biopolymers. 2007 Aug 5-15;86(5-6):424-36.
DM73C4K	RU	https://pubmed.ncbi.nlm.nih.gov/17480000

DM1AEVT	DI	DM1AEVT
DM1AEVT	DN	CS-003
DM1AEVT	MI	TTBPGLU
DM1AEVT	MN	Neuromedin-K receptor (TACR3)
DM1AEVT	MT	DTT
DM1AEVT	MA	Antagonist
DM1AEVT	RN	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
DM1AEVT	RU	https://pubmed.ncbi.nlm.nih.gov/16634702

DM1AEVT	DI	DM1AEVT
DM1AEVT	DN	CS-003
DM1AEVT	MI	TTYO0A3
DM1AEVT	MN	Substance-K receptor (TACR2)
DM1AEVT	MT	DTT
DM1AEVT	MA	Antagonist
DM1AEVT	RN	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
DM1AEVT	RU	https://pubmed.ncbi.nlm.nih.gov/16634702

DM1AEVT	DI	DM1AEVT
DM1AEVT	DN	CS-003
DM1AEVT	MI	TTZPO1L
DM1AEVT	MN	Substance-P receptor (TACR1)
DM1AEVT	MT	DTT
DM1AEVT	MA	Antagonist
DM1AEVT	RN	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
DM1AEVT	RU	https://pubmed.ncbi.nlm.nih.gov/16634702

DMGYXA4	DI	DMGYXA4
DMGYXA4	DN	CS-722
DMGYXA4	MI	TT3WG5C
DMGYXA4	MN	Monoamine oxidase type A (MAO-A)
DMGYXA4	MT	DTT
DMGYXA4	MA	Inhibitor
DMGYXA4	RN	Mechanisms of spinal reflex depressant effects of CS-722, a newly synthesized centrally acting muscle relaxant, in spinal rats. Neuropharmacology. 1992 Sep;31(9):949-54.
DMGYXA4	RU	https://pubmed.ncbi.nlm.nih.gov/1436401

DM17I8O	DI	DM17I8O
DM17I8O	DN	CS-891B
DM17I8O	MI	TT2A0DR
DM17I8O	MN	Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A)
DM17I8O	MT	DTT
DM17I8O	MA	Inhibitor
DM17I8O	RN	The novel drug CS-891 inhibits 5alpha-reductase activity in freshly isolated dermal papilla of human hair follicles. Eur J Dermatol. 2000 Dec;10(8):593-5.
DM17I8O	RU	https://pubmed.ncbi.nlm.nih.gov/11125319

DM09CUO	DI	DM09CUO
DM09CUO	DN	CTL-102-GDEPT
DM09CUO	MI	TTFBNVI
DM09CUO	MN	Aldose reductase (AKR1B1)
DM09CUO	MT	DTT
DM09CUO	MA	Modulator
DM09CUO	RN	Genes in the Service of Therapeutic Index: Progress for Virus-Directed Enzyme Prodrug Therapy. JCO May 1, 2004 vol. 22 no. 9 1535-1537c.
DM09CUO	RU	http://jco.ascopubs.org/content/22/9/1535.full

DMG3HX2	DI	DMG3HX2
DMG3HX2	DN	CV-6504
DMG3HX2	MI	TT2J34L
DMG3HX2	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMG3HX2	MT	DTT
DMG3HX2	MA	Inhibitor
DMG3HX2	RN	A phase II study of the 5-lipoxygenase inhibitor, CV6504, in advanced pancreatic cancer: correlation of clinical data with pharmacokinetic and pharmacodynamic endpoints. Ann Oncol. 2000 Sep;11(9):1165-70.
DMG3HX2	RU	https://pubmed.ncbi.nlm.nih.gov/11061613

DMP8TKA	DI	DMP8TKA
DMP8TKA	DN	CY-208243
DMP8TKA	MI	TTZFYLI
DMP8TKA	MN	Dopamine D1 receptor (D1R)
DMP8TKA	MT	DTT
DMP8TKA	MA	Agonist
DMP8TKA	RN	The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset. Eur J Pharmacol. 1988 Nov 1;156(2):197-206.
DMP8TKA	RU	https://pubmed.ncbi.nlm.nih.gov/2977118

DMP8TKA	DI	DMP8TKA
DMP8TKA	DN	CY-208243
DMP8TKA	MI	TT0R12H
DMP8TKA	MN	Neuron-specific vesicular protein calcyon (CALY)
DMP8TKA	MT	DTT
DMP8TKA	MA	Activator
DMP8TKA	RN	Dopamine D1 receptor agonists induce penile erections in rats. Eur J Pharmacol. 2003 Jan 26;460(1):71-4.
DMP8TKA	RU	https://pubmed.ncbi.nlm.nih.gov/12535862

DMO9HWU	DI	DMO9HWU
DMO9HWU	DN	D-7193
DMO9HWU	MI	TTK0943
DMO9HWU	MN	Prostaglandin G/H synthase (COX)
DMO9HWU	MT	DTT
DMO9HWU	MA	Modulator
DMO9HWU	RN	US patent application no. 6,673,908, Tumor necrosis factor receptor 2.
DMO9HWU	RU	http://www.google.com/patents/US6673908

DM48ECA	DI	DM48ECA
DM48ECA	DN	DA-5018
DM48ECA	MI	TTMI6F5
DM48ECA	MN	Transient receptor potential cation channel V1 (TRPV1)
DM48ECA	MT	DTT
DM48ECA	MA	Modulator
DM48ECA	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM48ECA	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMDQH5E	DI	DMDQH5E
DMDQH5E	DN	Dabuzalgron
DMDQH5E	MI	TT34BHT
DMDQH5E	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMDQH5E	MT	DTT
DMDQH5E	MA	Agonist
DMDQH5E	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3469).
DMDQH5E	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3469

DMF3E51	DI	DMF3E51
DMF3E51	DN	DANOFLOXACIN
DMF3E51	MI	TTN6J5F
DMF3E51	MN	Bacterial DNA gyrase (Bact gyrase)
DMF3E51	MT	DTT
DMF3E51	MA	Modulator
DMF3E51	RN	Pharmacokinetics and penetration of danofloxacin from the blood into the milk of cows. J Vet Pharmacol Ther. 1998 Jun;21(3):209-13.
DMF3E51	RU	https://www.ncbi.nlm.nih.gov/pubmed/9673962

DMJ4WR6	DI	DMJ4WR6
DMJ4WR6	DN	Darotropium
DMJ4WR6	MI	TTZ9SOR
DMJ4WR6	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMJ4WR6	MT	DTT
DMJ4WR6	MA	Agonist
DMJ4WR6	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMJ4WR6	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMOWIGC	DI	DMOWIGC
DMOWIGC	DN	DASANTAFIL
DMOWIGC	MI	TTJ0IQB
DMOWIGC	MN	Phosphodiesterase 5A (PDE5A)
DMOWIGC	MT	DTT
DMOWIGC	MA	Inhibitor
DMOWIGC	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMOWIGC	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMY3M0J	DI	DMY3M0J
DMY3M0J	DN	DAT-582
DMY3M0J	MI	TTNXLKE
DMY3M0J	MN	5-HT 3 receptor (5HT3R)
DMY3M0J	MT	DTT
DMY3M0J	MA	Antagonist
DMY3M0J	RN	5-HT3 receptor antagonist effects of DAT-582, (R) enantiomer of AS-5370. Eur J Pharmacol. 1992 Jun 17;216(3):435-40.
DMY3M0J	RU	https://pubmed.ncbi.nlm.nih.gov/1425931

DM9S3R8	DI	DM9S3R8
DM9S3R8	DN	Davalintide
DM9S3R8	MI	TTAT87F
DM9S3R8	MN	Amylin receptor (IAPPR)
DM9S3R8	MT	DTT
DM9S3R8	MA	Agonist
DM9S3R8	RN	Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight. Int J Obes (Lond). 2010 Feb;34(2):385-95.
DM9S3R8	RU	https://pubmed.ncbi.nlm.nih.gov/19935749

DMXO9BQ	DI	DMXO9BQ
DMXO9BQ	DN	Daxalipram
DMXO9BQ	MI	TTZ97H5
DMXO9BQ	MN	Phosphodiesterase 4A (PDE4A)
DMXO9BQ	MT	DTT
DMXO9BQ	MA	Inhibitor
DMXO9BQ	RN	Inhibition of phosphodiesterase 4 reduces ethanol intake and preference in C57BL/6J mice. Front Neurosci. 2014 May 27;8:129.
DMXO9BQ	RU	https://pubmed.ncbi.nlm.nih.gov/24904269

DMXO9BQ	DI	DMXO9BQ
DMXO9BQ	DN	Daxalipram
DMXO9BQ	MI	TTVIAT9
DMXO9BQ	MN	Phosphodiesterase 4B (PDE4B)
DMXO9BQ	MT	DTT
DMXO9BQ	MA	Inhibitor
DMXO9BQ	RN	Inhibition of phosphodiesterase 4 reduces ethanol intake and preference in C57BL/6J mice. Front Neurosci. 2014 May 27;8:129.
DMXO9BQ	RU	https://pubmed.ncbi.nlm.nih.gov/24904269

DMXO9BQ	DI	DMXO9BQ
DMXO9BQ	DN	Daxalipram
DMXO9BQ	MI	TTSKMI8
DMXO9BQ	MN	Phosphodiesterase 4D (PDE4D)
DMXO9BQ	MT	DTT
DMXO9BQ	MA	Inhibitor
DMXO9BQ	RN	Inhibition of phosphodiesterase 4 reduces ethanol intake and preference in C57BL/6J mice. Front Neurosci. 2014 May 27;8:129.
DMXO9BQ	RU	https://pubmed.ncbi.nlm.nih.gov/24904269

DMGM2HY	DI	DMGM2HY
DMGM2HY	DN	DCDT-2980S
DMGM2HY	MI	TTM6QSK
DMGM2HY	MN	B-cell receptor CD22 (CD22)
DMGM2HY	MT	DTT
DMGM2HY	RN	Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin's lymphoma. Oncoimmunology. 2012 December 1; 1(9): 1469-1475.
DMGM2HY	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525602/

DMMV6RK	DI	DMMV6RK
DMMV6RK	DN	DDP-200
DMMV6RK	MI	TTH18TF
DMMV6RK	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMMV6RK	MT	DTT
DMMV6RK	MA	Modulator
DMMV6RK	RN	CA patent application no. 753057, Sustained release oral dosage forms of an r-baclofen prodrug.
DMMV6RK	RU	http://www.google.com/patents/CA2753057A1?cl=en

DM3AVO1	DI	DM3AVO1
DM3AVO1	DN	DE-081
DM3AVO1	MI	DTUGYRD
DM3AVO1	MN	P-glycoprotein 1 (ABCB1)
DM3AVO1	MT	DTP
DM3AVO1	MA	Substrate
DM3AVO1	RN	Altered drug disposition of the platelet activating factor antagonist apafant in mdr1a knockout mice. Eur J Pharm Sci. 2002 Aug;16(3):119-28.
DM3AVO1	RU	https://doi.org/10.1016/S0928-0987(02)00088-X

DM3AVO1	DI	DM3AVO1
DM3AVO1	DN	DE-081
DM3AVO1	MI	TTQL5VC
DM3AVO1	MN	Platelet-activating factor receptor (PTAFR)
DM3AVO1	MT	DTT
DM3AVO1	MA	Modulator
DM3AVO1	RN	Characterization of [3H]apafant binding to PAF receptor on rabbit platelet membranes: a comparison of a microplate filtration system and a standard... J Pharmacol Toxicol Methods. 1996 Sep;36(1):53-62.
DM3AVO1	RU	https://pubmed.ncbi.nlm.nih.gov/8872920

DM5QFT4	DI	DM5QFT4
DM5QFT4	DN	Declopramide
DM5QFT4	MI	TTEX248
DM5QFT4	MN	Dopamine D2 receptor (D2R)
DM5QFT4	MT	DTT
DM5QFT4	MA	Modulator
DM5QFT4	RN	Pharmacokinetics and central nervous system toxicity of declopramide (3-chloroprocainamide) in rats and mice. Anticancer Drugs. 1999 Jan;10(1):79-88.
DM5QFT4	RU	https://pubmed.ncbi.nlm.nih.gov/10194550

DM5QFT4	DI	DM5QFT4
DM5QFT4	DN	Declopramide
DM5QFT4	MI	TTZ9SOR
DM5QFT4	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DM5QFT4	MT	DTT
DM5QFT4	MA	Modulator
DM5QFT4	RN	Pharmacokinetics and central nervous system toxicity of declopramide (3-chloroprocainamide) in rats and mice. Anticancer Drugs. 1999 Jan;10(1):79-88.
DM5QFT4	RU	https://pubmed.ncbi.nlm.nih.gov/10194550

DMYJ28R	DI	DMYJ28R
DMYJ28R	DN	Deriglidole
DMYJ28R	MI	TT34BHT
DMYJ28R	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMYJ28R	MT	DTT
DMYJ28R	MA	Modulator
DMYJ28R	RN	Mechanisms of the hypoglycemic effects of the alpha2-adrenoceptor antagonists SL84.0418 and deriglidole. Life Sci. 1998;62(9):839-52.
DMYJ28R	RU	https://pubmed.ncbi.nlm.nih.gov/9496702

DMYJ28R	DI	DMYJ28R
DMYJ28R	DN	Deriglidole
DMYJ28R	MI	TT2NUT5
DMYJ28R	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMYJ28R	MT	DTT
DMYJ28R	MA	Modulator
DMYJ28R	RN	Mechanisms of the hypoglycemic effects of the alpha2-adrenoceptor antagonists SL84.0418 and deriglidole. Life Sci. 1998;62(9):839-52.
DMYJ28R	RU	https://pubmed.ncbi.nlm.nih.gov/9496702

DM6WSU2	DI	DM6WSU2
DM6WSU2	DN	Dermolastin
DM6WSU2	MI	TTQAJF1
DM6WSU2	MN	Cathepsin G (CTSG)
DM6WSU2	MT	DTT
DM6WSU2	MA	Inhibitor
DM6WSU2	RN	Arriva-ProMetic recombinant alpha 1-antitrypsin (rAAT) moves into the clinic for dermatology applications. ProMetic Life Sciences. 2009.
DM6WSU2	RU	http://www.prnewswire.co.uk/news-releases/arriva-prometic-recombinant-alpha-1-antitrypsin-raat-moves-into-the-clinic-for-dermatology-applications-154329065.html

DM6WSU2	DI	DM6WSU2
DM6WSU2	DN	Dermolastin
DM6WSU2	MI	TT2WR1T
DM6WSU2	MN	Cationic trypsinogen (PRSS1)
DM6WSU2	MT	DTT
DM6WSU2	MA	Inhibitor
DM6WSU2	RN	Arriva-ProMetic recombinant alpha 1-antitrypsin (rAAT) moves into the clinic for dermatology applications. ProMetic Life Sciences. 2009.
DM6WSU2	RU	http://www.prnewswire.co.uk/news-releases/arriva-prometic-recombinant-alpha-1-antitrypsin-raat-moves-into-the-clinic-for-dermatology-applications-154329065.html

DM6WSU2	DI	DM6WSU2
DM6WSU2	DN	Dermolastin
DM6WSU2	MI	TT6L509
DM6WSU2	MN	Coagulation factor IIa (F2)
DM6WSU2	MT	DTT
DM6WSU2	MA	Inhibitor
DM6WSU2	RN	Arriva-ProMetic recombinant alpha 1-antitrypsin (rAAT) moves into the clinic for dermatology applications. ProMetic Life Sciences. 2009.
DM6WSU2	RU	http://www.prnewswire.co.uk/news-releases/arriva-prometic-recombinant-alpha-1-antitrypsin-raat-moves-into-the-clinic-for-dermatology-applications-154329065.html

DM6WSU2	DI	DM6WSU2
DM6WSU2	DN	Dermolastin
DM6WSU2	MI	TTPLTSQ
DM6WSU2	MN	Neutrophil elastase (NE)
DM6WSU2	MT	DTT
DM6WSU2	MA	Inhibitor
DM6WSU2	RN	Arriva-ProMetic recombinant alpha 1-antitrypsin (rAAT) moves into the clinic for dermatology applications. ProMetic Life Sciences. 2009.
DM6WSU2	RU	http://www.prnewswire.co.uk/news-releases/arriva-prometic-recombinant-alpha-1-antitrypsin-raat-moves-into-the-clinic-for-dermatology-applications-154329065.html

DM6WSU2	DI	DM6WSU2
DM6WSU2	DN	Dermolastin
DM6WSU2	MI	TTJLNAW
DM6WSU2	MN	Tissue kallikrein (KLK2)
DM6WSU2	MT	DTT
DM6WSU2	MA	Inhibitor
DM6WSU2	RN	Arriva-ProMetic recombinant alpha 1-antitrypsin (rAAT) moves into the clinic for dermatology applications. ProMetic Life Sciences. 2009.
DM6WSU2	RU	http://www.prnewswire.co.uk/news-releases/arriva-prometic-recombinant-alpha-1-antitrypsin-raat-moves-into-the-clinic-for-dermatology-applications-154329065.html

DMLZIT2	DI	DMLZIT2
DMLZIT2	DN	Dexniguldipine
DMLZIT2	MI	DE4LYSA
DMLZIT2	MN	Cytochrome P450 3A4 (CYP3A4)
DMLZIT2	MT	DME
DMLZIT2	MA	Metabolism
DMLZIT2	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DMLZIT2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DMLZIT2	DI	DMLZIT2
DMLZIT2	DN	Dexniguldipine
DMLZIT2	MI	TTJUXV6
DMLZIT2	MN	Multidrug resistance protein 3 (ABCB4)
DMLZIT2	MT	DTT
DMLZIT2	MA	Modulator
DMLZIT2	RN	Mechanism of action of dexniguldipine-HCl (B8509-035), a new potent modulator of multidrug resistance. Biochem Pharmacol. 1995 Mar 1;49(5):603-9.
DMLZIT2	RU	https://pubmed.ncbi.nlm.nih.gov/7887974

DMLZIT2	DI	DMLZIT2
DMLZIT2	DN	Dexniguldipine
DMLZIT2	MI	DTUGYRD
DMLZIT2	MN	P-glycoprotein 1 (ABCB1)
DMLZIT2	MT	DTP
DMLZIT2	MA	Substrate
DMLZIT2	RN	Fingerprint-based in silico models for the prediction of P-glycoprotein substrates and inhibitors. Bioorg Med Chem. 2012 Sep 15;20(18):5388-95.
DMLZIT2	RU	https://doi.org/10.1016/j.bmc.2012.03.045

DMLZIT2	DI	DMLZIT2
DMLZIT2	DN	Dexniguldipine
DMLZIT2	MI	DEX2KIA
DMLZIT2	MN	Steroid 17-alpha-monooxygenase (CYP17A1)
DMLZIT2	MT	DME
DMLZIT2	MA	Metabolism
DMLZIT2	RN	In vitro metabolism of dexamethasone (DEX) in human liver and kidney: the involvement of CYP3A4 and CYP17 (17,20 LYASE) and molecular modelling studies. Biochem Pharmacol. 1997 Sep 1;54(5):605-11.
DMLZIT2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9337077

DMJT8Q0	DI	DMJT8Q0
DMJT8Q0	DN	Dezinamide
DMJT8Q0	MI	TTNJYV2
DMJT8Q0	MN	Gamma-aminobutyric acid receptor (GAR)
DMJT8Q0	MT	DTT
DMJT8Q0	MA	Modulator
DMJT8Q0	RN	Clobazam, oxcarbazepine, tiagabine, topiramate, and other new antiepileptic drugs. Epilepsia. 1995;36 Suppl 2:S105-14.
DMJT8Q0	RU	https://pubmed.ncbi.nlm.nih.gov/8784219

DMVO9WM	DI	DMVO9WM
DMVO9WM	DN	DG041
DMVO9WM	MI	TTPNGDE
DMVO9WM	MN	Prostaglandin E2 receptor EP3 (PTGER3)
DMVO9WM	MT	DTT
DMVO9WM	MA	Antagonist
DMVO9WM	RN	BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol. 2007 Sep;58(3):583-8.
DMVO9WM	RU	https://pubmed.ncbi.nlm.nih.gov/17928652

DM3I0GS	DI	DM3I0GS
DM3I0GS	DN	DG051
DM3I0GS	MI	TTXZEAJ
DM3I0GS	MN	Leukotriene A-4 hydrolase (LTA4H)
DM3I0GS	MT	DTT
DM3I0GS	MA	Inhibitor
DM3I0GS	RN	BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol. 2007 Sep;58(3):583-8.
DM3I0GS	RU	https://pubmed.ncbi.nlm.nih.gov/17928652

DM64CAS	DI	DM64CAS
DM64CAS	DN	Didox
DM64CAS	MI	TTX09M4
DM64CAS	MN	Ribonucleotide reductase (RIR)
DM64CAS	MT	DTT
DM64CAS	MA	Inhibitor
DM64CAS	RN	Didox (a novel ribonucleotide reductase inhibitor) overcomes Bcl-2 mediated radiation resistance in prostate cancer cell line PC-3. Cancer Biol Ther. 2002 Sep-Oct;1(5):539-45.
DM64CAS	RU	https://pubmed.ncbi.nlm.nih.gov/12496485

DMIP3EC	DI	DMIP3EC
DMIP3EC	DN	DM-83
DMIP3EC	MI	TTCBFJO
DMIP3EC	MN	Insulin receptor (INSR)
DMIP3EC	MT	DTT
DMIP3EC	MA	Stimulator
DMIP3EC	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800).
DMIP3EC	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800

DMCNEOZ	DI	DMCNEOZ
DMCNEOZ	DN	DMP-543
DMCNEOZ	MI	TTQ29KF
DMCNEOZ	MN	Voltage-gated potassium channel Kv7 (KCNQ)
DMCNEOZ	MT	DTT
DMCNEOZ	MA	Modulator
DMCNEOZ	RN	KV7 channels regulate muscle tone and nonadrenergic noncholinergic relaxation of the rat gastric fundus.Pharmacol Res.2011 Oct;64(4):397-409.
DMCNEOZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/21740972

DMI5XKC	DI	DMI5XKC
DMI5XKC	DN	DMP-961
DMI5XKC	MI	TT84ETX
DMI5XKC	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMI5XKC	MT	DTT
DMI5XKC	MA	Inhibitor
DMI5XKC	RN	Effect of drug substance particle size on the characteristics of granulation manufactured in a high-shear mixer. AAPS PharmSciTech. 2000 December; 1(4): 55-61.
DMI5XKC	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750457/

DM4ZO01	DI	DM4ZO01
DM4ZO01	DN	DNK-333
DM4ZO01	MI	TTYO0A3
DM4ZO01	MN	Substance-K receptor (TACR2)
DM4ZO01	MT	DTT
DM4ZO01	MA	Modulator
DM4ZO01	RN	Dual tachykinin NK1/NK2 antagonist DNK333 inhibits neurokinin A-induced bronchoconstriction in asthma patients. Eur Respir J. 2004 Jan;23(1):76-81.
DM4ZO01	RU	https://www.ncbi.nlm.nih.gov/pubmed/14738235

DM4ZO01	DI	DM4ZO01
DM4ZO01	DN	DNK-333
DM4ZO01	MI	TTZPO1L
DM4ZO01	MN	Substance-P receptor (TACR1)
DM4ZO01	MT	DTT
DM4ZO01	MA	Modulator
DM4ZO01	RN	Dual tachykinin NK1/NK2 antagonist DNK333 inhibits neurokinin A-induced bronchoconstriction in asthma patients. Eur Respir J. 2004 Jan;23(1):76-81.
DM4ZO01	RU	https://www.ncbi.nlm.nih.gov/pubmed/14738235

DMMC6H7	DI	DMMC6H7
DMMC6H7	DN	Dopropidil
DMMC6H7	MI	TT5HONZ
DMMC6H7	MN	Calcium channel unspecific (CaC)
DMMC6H7	MT	DTT
DMMC6H7	MA	Modulator
DMMC6H7	RN	Effects of bepridil and CERM 4205 (ORG 30701) on the relation between cardiac cycle length and QT duration in healthy volunteers. Am J Cardiol. 1990 Sep 1;66(5):636-41.
DMMC6H7	RU	https://pubmed.ncbi.nlm.nih.gov/2203243

DMTE14H	DI	DMTE14H
DMTE14H	DN	DOV-216303
DMTE14H	MI	TTVBI8W
DMTE14H	MN	Dopamine transporter (DAT)
DMTE14H	MT	DTT
DMTE14H	MA	Inhibitor
DMTE14H	RN	Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
DMTE14H	RU	https://pubmed.ncbi.nlm.nih.gov/18172433

DMTE14H	DI	DMTE14H
DMTE14H	DN	DOV-216303
DMTE14H	MI	TTAWNKZ
DMTE14H	MN	Norepinephrine transporter (NET)
DMTE14H	MT	DTT
DMTE14H	MA	Inhibitor
DMTE14H	RN	Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
DMTE14H	RU	https://pubmed.ncbi.nlm.nih.gov/18172433

DMTE14H	DI	DMTE14H
DMTE14H	DN	DOV-216303
DMTE14H	MI	TT3ROYC
DMTE14H	MN	Serotonin transporter (SERT)
DMTE14H	MT	DTT
DMTE14H	MA	Inhibitor
DMTE14H	RN	Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
DMTE14H	RU	https://pubmed.ncbi.nlm.nih.gov/18172433

DMKGXT2	DI	DMKGXT2
DMKGXT2	DN	DPI-3290
DMKGXT2	MI	TT27RFC
DMKGXT2	MN	Opioid receptor delta (OPRD1)
DMKGXT2	MT	DTT
DMKGXT2	MA	Agonist
DMKGXT2	RN	DPI-3290 [(+)-3-((alpha-R)-alpha-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide]. II. A mixed opioid agonist with potent antinociceptive activity and limited effects on respiratory function. J Pharmacol Exp Ther. 2003 Dec;307(3):1227-33.
DMKGXT2	RU	https://pubmed.ncbi.nlm.nih.gov/14534367

DMKGXT2	DI	DMKGXT2
DMKGXT2	DN	DPI-3290
DMKGXT2	MI	TTKWM86
DMKGXT2	MN	Opioid receptor mu (MOP)
DMKGXT2	MT	DTT
DMKGXT2	MA	Agonist
DMKGXT2	RN	DPI-3290 [(+)-3-((alpha-R)-alpha-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide]. II. A mixed opioid agonist with potent antinociceptive activity and limited effects on respiratory function. J Pharmacol Exp Ther. 2003 Dec;307(3):1227-33.
DMKGXT2	RU	https://pubmed.ncbi.nlm.nih.gov/14534367

DMCZ75T	DI	DMCZ75T
DMCZ75T	DN	DRAFLAZINE
DMCZ75T	MI	TT5BN70
DMCZ75T	MN	Nucleoside transporter (SLC)
DMCZ75T	MT	DTT
DMCZ75T	MA	Modulator
DMCZ75T	RN	Studies of the nucleoside transporter inhibitor, draflazine, in the human myocardium. Br J Pharmacol. 1994 May;112(1):137-42.
DMCZ75T	RU	https://pubmed.ncbi.nlm.nih.gov/8032635

DM9JPUD	DI	DM9JPUD
DM9JPUD	DN	Droloxifene
DM9JPUD	MI	TTZAYWL
DM9JPUD	MN	Estrogen receptor (ESR)
DM9JPUD	MT	DTT
DM9JPUD	MA	Modulator
DM9JPUD	RN	Droloxifene, a new antiestrogen: its role in metastatic breast cancer. Breast Cancer Res Treat. 1994;31(1):83-94.
DM9JPUD	RU	https://pubmed.ncbi.nlm.nih.gov/7981460

DM9JPUD	DI	DM9JPUD
DM9JPUD	DN	Droloxifene
DM9JPUD	MI	DTUGYRD
DM9JPUD	MN	P-glycoprotein 1 (ABCB1)
DM9JPUD	MT	DTP
DM9JPUD	MA	Substrate
DM9JPUD	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM9JPUD	RU	https://doi.org/10.1007/s11095-012-0935-x

DM8GZWC	DI	DM8GZWC
DM8GZWC	DN	DS-4574
DM8GZWC	MI	TTGKOY9
DM8GZWC	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DM8GZWC	MT	DTT
DM8GZWC	MA	Modulator
DM8GZWC	RN	Inhibitory effect of DS-4574, a mast cell stabilizer with peptidoleukotriene receptor antagonism, on gastric acid secretion in rats. Eur J Pharmacol. 1994 Apr 1;255(1-3):229-34.
DM8GZWC	RU	https://pubmed.ncbi.nlm.nih.gov/8026547

DM8GZWC	DI	DM8GZWC
DM8GZWC	DN	DS-4574
DM8GZWC	MI	TT0PZR5
DM8GZWC	MN	Leukotriene CysLT2 receptor (CYSLTR2)
DM8GZWC	MT	DTT
DM8GZWC	MA	Modulator
DM8GZWC	RN	Inhibitory effect of DS-4574, a mast cell stabilizer with peptidoleukotriene receptor antagonism, on gastric acid secretion in rats. Eur J Pharmacol. 1994 Apr 1;255(1-3):229-34.
DM8GZWC	RU	https://pubmed.ncbi.nlm.nih.gov/8026547

DM63UA9	DI	DM63UA9
DM63UA9	DN	DU 125530
DM63UA9	MI	TTSQIFT
DM63UA9	MN	5-HT 1A receptor (HTR1A)
DM63UA9	MT	DTT
DM63UA9	MA	Antagonist
DM63UA9	RN	5-Hydroxytryptamine1A receptor occupancy by novel full antagonist 2-[4-[4-(7-chloro-2,3-dihydro-1,4-benzdioxyn-5-yl)-1-piperazinyl]butyl]-1,2-benzisothiazol-3-(2H)-one-1,1-dioxide: a[11C][O-methyl-3H]-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide trihydrochloride (WAY-100635) positron emission tomography study in humans. J Pharmacol Exp Ther. 2002 Jun;301(3):1144-50.
DM63UA9	RU	https://pubmed.ncbi.nlm.nih.gov/12023549

DMQ9IO0	DI	DMQ9IO0
DMQ9IO0	DN	DuP-654
DMQ9IO0	MI	TT2J34L
DMQ9IO0	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMQ9IO0	MT	DTT
DMQ9IO0	MA	Inhibitor
DMQ9IO0	RN	The lipoxygenase inhibitor 2-phenylmethyl-1-naphthol (DuP 654) is a 12(S)-hydroxyeicosatetraenoic acid receptor antagonist in the human epidermal cell line SCL-II. Skin Pharmacol. 1993;6(2):148-51.
DMQ9IO0	RU	https://pubmed.ncbi.nlm.nih.gov/8394724

DMSTA5L	DI	DMSTA5L
DMSTA5L	DN	DX-619
DMSTA5L	MI	TTN6J5F
DMSTA5L	MN	Bacterial DNA gyrase (Bact gyrase)
DMSTA5L	MT	DTT
DMSTA5L	MA	Modulator
DMSTA5L	RN	DX-619, a novel des-fluoro(6) quinolone manifesting low frequency of selection of resistant Staphylococcus aureus mutants: quinolone resistance beyond modification of type II topoisomerases. Antimicrob Agents Chemother. 2005 Dec;49(12):5051-7.
DMSTA5L	RU	https://pubmed.ncbi.nlm.nih.gov/16304172

DMSTA5L	DI	DMSTA5L
DMSTA5L	DN	DX-619
DMSTA5L	MI	TTIXTO3
DMSTA5L	MN	Staphylococcus Topoisomerase IV (Stap-coc parC)
DMSTA5L	MT	DTT
DMSTA5L	MA	Modulator
DMSTA5L	RN	DX-619, a novel des-fluoro(6) quinolone manifesting low frequency of selection of resistant Staphylococcus aureus mutants: quinolone resistance beyond modification of type II topoisomerases. Antimicrob Agents Chemother. 2005 Dec;49(12):5051-7.
DMSTA5L	RU	https://pubmed.ncbi.nlm.nih.gov/16304172

DMEQLC4	DI	DMEQLC4
DMEQLC4	DN	DX-9065
DMEQLC4	MI	TTCIHJA
DMEQLC4	MN	Coagulation factor Xa (F10)
DMEQLC4	MT	DTT
DMEQLC4	MA	Inhibitor
DMEQLC4	RN	Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7.
DMEQLC4	RU	https://pubmed.ncbi.nlm.nih.gov/22844656

DMIXUMZ	DI	DMIXUMZ
DMIXUMZ	DN	DX-9065a
DMIXUMZ	MI	TTCIHJA
DMIXUMZ	MN	Coagulation factor Xa (F10)
DMIXUMZ	MT	DTT
DMIXUMZ	MA	Inhibitor
DMIXUMZ	RN	DX-9065a inhibition of factor Xa and the prothrombinase complex: mechanism of inhibition and comparison with therapeutic heparins. Thromb Haemost. 2003 Jan;89(1):112-21.
DMIXUMZ	RU	https://pubmed.ncbi.nlm.nih.gov/12540961

DMT2WVP	DI	DMT2WVP
DMT2WVP	DN	Dynorphin A
DMT2WVP	MI	DENZF0O
DMT2WVP	MN	Cytosol aminopeptidase (LAP3)
DMT2WVP	MT	DME
DMT2WVP	MA	Metabolism
DMT2WVP	RN	Human brain leucyl aminopeptidase: isolation, characterization and specificity against some neuropeptides. Neuropeptides. 1991 Jul;19(3):163-8.
DMT2WVP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1680222

DMT2WVP	DI	DMT2WVP
DMT2WVP	DN	Dynorphin A
DMT2WVP	MI	TT27RFC
DMT2WVP	MN	Opioid receptor delta (OPRD1)
DMT2WVP	MT	DTT
DMT2WVP	MA	Inhibitor
DMT2WVP	RN	Design and synthesis of highly potent and selective cyclic dynorphin A analogs. 2. New analogs. J Med Chem. 1993 Mar 19;36(6):750-7.
DMT2WVP	RU	https://pubmed.ncbi.nlm.nih.gov/8096246

DMT2WVP	DI	DMT2WVP
DMT2WVP	DN	Dynorphin A
DMT2WVP	MI	TTQW87Y
DMT2WVP	MN	Opioid receptor kappa (OPRK1)
DMT2WVP	MT	DTT
DMT2WVP	MA	Inhibitor
DMT2WVP	RN	Use of receptor chimeras to identify small molecules with high affinity for the dynorphin A binding domain of the kappa opioid receptor. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3667-71.
DMT2WVP	RU	https://pubmed.ncbi.nlm.nih.gov/18487043

DMT2WVP	DI	DMT2WVP
DMT2WVP	DN	Dynorphin A
DMT2WVP	MI	TTKWM86
DMT2WVP	MN	Opioid receptor mu (MOP)
DMT2WVP	MT	DTT
DMT2WVP	MA	Inhibitor
DMT2WVP	RN	Use of receptor chimeras to identify small molecules with high affinity for the dynorphin A binding domain of the kappa opioid receptor. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3667-71.
DMT2WVP	RU	https://pubmed.ncbi.nlm.nih.gov/18487043

DMHEW40	DI	DMHEW40
DMHEW40	DN	E-2078
DMHEW40	MI	TTQW87Y
DMHEW40	MN	Opioid receptor kappa (OPRK1)
DMHEW40	MT	DTT
DMHEW40	MA	Modulator
DMHEW40	RN	Systemic effects of E-2078, a stabilized dynorphin A(1-8) analog, in rhesus monkeys. Psychopharmacology (Berl). 1999 Apr;143(2):190-6.
DMHEW40	RU	https://pubmed.ncbi.nlm.nih.gov/10326782

DM35KZG	DI	DM35KZG
DM35KZG	DN	E-3040
DM35KZG	MI	TT2J34L
DM35KZG	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM35KZG	MT	DTT
DM35KZG	MA	Inhibitor
DM35KZG	RN	In vitro effects of E3040, a dual inhibitor of 5-lipoxygenase and thromboxane A(2) synthetase, on eicosanoid production. Eur J Pharmacol. 2001 Jun 22;422(1-3):209-16.
DM35KZG	RU	https://pubmed.ncbi.nlm.nih.gov/11430933

DM35KZG	DI	DM35KZG
DM35KZG	DN	E-3040
DM35KZG	MI	DTI7UX6
DM35KZG	MN	Breast cancer resistance protein (ABCG2)
DM35KZG	MT	DTP
DM35KZG	MA	Substrate
DM35KZG	RN	Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J. 2005 May 11;7(1):E118-33.
DM35KZG	RU	https://doi.org/10.1208/aapsj070112

DMWF95G	DI	DMWF95G
DMWF95G	DN	E-3620
DMWF95G	MI	TTNXLKE
DMWF95G	MN	5-HT 3 receptor (5HT3R)
DMWF95G	MT	DTT
DMWF95G	MA	Modulator
DMWF95G	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMWF95G	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMWF95G	DI	DMWF95G
DMWF95G	DN	E-3620
DMWF95G	MI	TT07C3Y
DMWF95G	MN	5-HT 4 receptor (HTR4)
DMWF95G	MT	DTT
DMWF95G	MA	Modulator
DMWF95G	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMWF95G	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMWIA56	DI	DMWIA56
DMWIA56	DN	E-4021
DMWIA56	MI	TTJ0IQB
DMWIA56	MN	Phosphodiesterase 5A (PDE5A)
DMWIA56	MT	DTT
DMWIA56	MA	Inhibitor
DMWIA56	RN	Potency and mechanism of action of E4021, a type 5 phosphodiesterase isozyme-selective inhibitor, on the photoreceptor phosphodiesterase depend on the state of activation of the enzyme. Mol Pharmacol. 1999 Mar;55(3):508-14.
DMWIA56	RU	https://pubmed.ncbi.nlm.nih.gov/10051534

DMU872N	DI	DMU872N
DMU872N	DN	E-4031
DMU872N	MI	TT1VOHK
DMU872N	MN	Potassium channel unspecific (KC)
DMU872N	MT	DTT
DMU872N	MA	Modulator
DMU872N	RN	Comparison of the IKr blockers moxifloxacin, dofetilide and E-4031 in five screening models of pro-arrhythmia reveals lack of specificity of isolated cardiomyocytes.Br J Pharmacol.2012 Jan;165(2):467-78.
DMU872N	RU	https://www.ncbi.nlm.nih.gov/pubmed/21718297

DM2G7IP	DI	DM2G7IP
DM2G7IP	DN	E-4177
DM2G7IP	MI	TTGN1ZA
DM2G7IP	MN	Angiotensin II receptor (AGTR)
DM2G7IP	MT	DTT
DM2G7IP	MA	Modulator
DM2G7IP	RN	Prevention of renal damage by angiotensin II blockade, accompanied by increased renal hepatocyte growth factor in experimental hypertensive rats. Hypertension. 1999 Aug;34(2):279-84.
DM2G7IP	RU	https://pubmed.ncbi.nlm.nih.gov/10454454

DM562BM	DI	DM562BM
DM562BM	DN	E-5324
DM562BM	MI	TTMF541
DM562BM	MN	Liver carboxylesterase (CES1)
DM562BM	MT	DTT
DM562BM	MA	Modulator
DM562BM	RN	Effect of the acyl-CoA:cholesterol acyltransferase inhibitor, E5324, on experimental atherosclerosis in rabbits. Atherosclerosis. 1994 Jun;107(2):187-201.
DM562BM	RU	https://pubmed.ncbi.nlm.nih.gov/7980693

DMBFYWU	DI	DMBFYWU
DMBFYWU	DN	E-5531
DMBFYWU	MI	TTVQJLY
DMBFYWU	MN	Lipopolysaccharide-binding protein (LBP)
DMBFYWU	MT	DTT
DMBFYWU	MA	Modulator
DMBFYWU	RN	The cellular Toll-like receptor 4 antagonist E5531 can act as an agonist in horse whole blood. Vet Immunol Immunopathol. 2007 Apr 15;116(3-4):182-9.
DMBFYWU	RU	https://pubmed.ncbi.nlm.nih.gov/17320193

DM296V7	DI	DM296V7
DM296V7	DN	E-6080
DM296V7	MI	TT2J34L
DM296V7	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM296V7	MT	DTT
DM296V7	MA	Inhibitor
DM296V7	RN	Effects of the new 5-lipoxygenase inhibitor E6080 on leukotriene release in vitro. Int Arch Allergy Immunol. 1992;97(4):267-73.
DM296V7	RU	https://pubmed.ncbi.nlm.nih.gov/1375926

DMUW6QX	DI	DMUW6QX
DMUW6QX	DN	E-6123
DMUW6QX	MI	TTQL5VC
DMUW6QX	MN	Platelet-activating factor receptor (PTAFR)
DMUW6QX	MT	DTT
DMUW6QX	MA	Modulator
DMUW6QX	RN	Inhibitory effects of a novel PAF antagonist E6123 on anaphylactic responses in passively and actively sensitized guinea pigs and passively sensiti... Prostaglandins. 1991 Dec;42(6):541-55.
DMUW6QX	RU	https://www.ncbi.nlm.nih.gov/pubmed/1801063

DMC28Y4	DI	DMC28Y4
DMC28Y4	DN	EAA-090
DMC28Y4	MI	TT9IK2Z
DMC28Y4	MN	N-methyl-D-aspartate receptor (NMDAR)
DMC28Y4	MT	DTT
DMC28Y4	MA	Antagonist
DMC28Y4	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DMC28Y4	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DMJ2ZFV	DI	DMJ2ZFV
DMJ2ZFV	DN	EB-1053
DMJ2ZFV	MI	TTKOBY0
DMJ2ZFV	MN	Bone resorption factor (BRF)
DMJ2ZFV	MT	DTT
DMJ2ZFV	MA	Modulator
DMJ2ZFV	RN	Disodium 1-hydroxy-3-(1-pyrrolidinyl)-propylidene-1,1-bisphosphonate (EB-1053) is a potent inhibitor of bone resorption in vitro and in vivo. J Bone Miner Res. 1992 Aug;7(8):981-6.
DMJ2ZFV	RU	https://pubmed.ncbi.nlm.nih.gov/1442212

DMRPUEC	DI	DMRPUEC
DMRPUEC	DN	EDONENTAN HYDRATE
DMRPUEC	MI	TTKRD0G
DMRPUEC	MN	Endothelin A receptor (EDNRA)
DMRPUEC	MT	DTT
DMRPUEC	MA	Antagonist
DMRPUEC	RN	US patent application no. 9,062,094, Dipeptide-based prodrug linkers for aliphatic amine-containing drugs.
DMRPUEC	RU	http://www.google.com/patents/US9062094

DMZXRF2	DI	DMZXRF2
DMZXRF2	DN	Eflucimibe
DMZXRF2	MI	TTMF541
DMZXRF2	MN	Liver carboxylesterase (CES1)
DMZXRF2	MT	DTT
DMZXRF2	MA	Inhibitor
DMZXRF2	RN	Prospects for drug therapy for hyperlipoproteinaemia. Diabete Metab. 1995 Apr;21(2):139-46.
DMZXRF2	RU	https://pubmed.ncbi.nlm.nih.gov/7621974

DM7TM91	DI	DM7TM91
DM7TM91	DN	ELAROFIBAN
DM7TM91	MI	TT38RM1
DM7TM91	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DM7TM91	MT	DTT
DM7TM91	MA	Modulator
DM7TM91	RN	1,2,4-triazolo[3,4-a]pyridine as a novel, constrained template for fibrinogen receptor (GPIIb/IIIa) antagonists. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2619-22.
DM7TM91	RU	https://pubmed.ncbi.nlm.nih.gov/11551763

DM0B23J	DI	DM0B23J
DM0B23J	DN	ELB-139
DM0B23J	MI	TTAN6JD
DM0B23J	MN	Glutamate receptor AMPA (GRIA)
DM0B23J	MT	DTT
DM0B23J	MA	Modulator
DM0B23J	RN	Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
DM0B23J	RU	https://pubmed.ncbi.nlm.nih.gov/16377242

DMBCYRG	DI	DMBCYRG
DMBCYRG	DN	ELINAFIDE MESILATE
DMBCYRG	MI	TT0IHXV
DMBCYRG	MN	DNA topoisomerase II (TOP2)
DMBCYRG	MT	DTT
DMBCYRG	MA	Inhibitor
DMBCYRG	RN	Solution structure and dynamics of a complex between DNA and the antitumor bisnaphthalimide LU-79553: intercalated ring flipping on the millisecond time scale. Biochemistry. 1999 Nov 16;38(46):15104-15.
DMBCYRG	RU	https://pubmed.ncbi.nlm.nih.gov/10563793

DM0XF8J	DI	DM0XF8J
DM0XF8J	DN	Elisartan potassium
DM0XF8J	MI	TTGN1ZA
DM0XF8J	MN	Angiotensin II receptor (AGTR)
DM0XF8J	MT	DTT
DM0XF8J	MA	Modulator
DM0XF8J	RN	Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol. 1995 Apr 15;75(12):793-5.
DM0XF8J	RU	https://pubmed.ncbi.nlm.nih.gov/7717281

DMM5WQL	DI	DMM5WQL
DMM5WQL	DN	Elvucitabine
DMM5WQL	MI	TT84ETX
DMM5WQL	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMM5WQL	MT	DTT
DMM5WQL	MA	Modulator
DMM5WQL	RN	Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.Antimicrob Agents Chemother.2009 Feb;53(2):662-9.
DMM5WQL	RU	https://www.ncbi.nlm.nih.gov/pubmed/19015343

DM1EOC3	DI	DM1EOC3
DM1EOC3	DN	Elzasonan hydrochloride
DM1EOC3	MI	TTK8CXU
DM1EOC3	MN	5-HT 1B receptor (HTR1B)
DM1EOC3	MT	DTT
DM1EOC3	MA	Modulator
DM1EOC3	RN	DOI: 10.1002/9781118541203.xen439
DM1EOC3	RU	http://onlinelibrary.wiley.com/doi/10.1002/9781118541203.xen439/abstract

DM1EOC3	DI	DM1EOC3
DM1EOC3	DN	Elzasonan hydrochloride
DM1EOC3	MI	TT6MSOK
DM1EOC3	MN	5-HT 1D receptor (HTR1D)
DM1EOC3	MT	DTT
DM1EOC3	MA	Modulator
DM1EOC3	RN	DOI: 10.1002/9781118541203.xen439
DM1EOC3	RU	http://onlinelibrary.wiley.com/doi/10.1002/9781118541203.xen439/abstract

DM0RXCK	DI	DM0RXCK
DM0RXCK	DN	Emapunil
DM0RXCK	MI	TTPTXIN
DM0RXCK	MN	Translocator protein (TSPO)
DM0RXCK	MT	DTT
DM0RXCK	MA	Agonist
DM0RXCK	RN	Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
DM0RXCK	RU	https://pubmed.ncbi.nlm.nih.gov/18172433

DMML2PX	DI	DMML2PX
DMML2PX	DN	EML-336
DMML2PX	MI	TTCBFJO
DMML2PX	MN	Insulin receptor (INSR)
DMML2PX	MT	DTT
DMML2PX	MA	Modulator
DMML2PX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800).
DMML2PX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800

DMIQRJW	DI	DMIQRJW
DMIQRJW	DN	EMR-62203
DMIQRJW	MI	TTJ0IQB
DMIQRJW	MN	Phosphodiesterase 5A (PDE5A)
DMIQRJW	MT	DTT
DMIQRJW	MA	Inhibitor
DMIQRJW	RN	WO patent application no. 2006,0180,88, Use of a pde 5 inhibitor for treating and preventing hypopigmentary disorders.
DMIQRJW	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20060223&CC=WO&NR=2006018088A1&KC=A1

DMDAS5B	DI	DMDAS5B
DMDAS5B	DN	Enalkiren
DMDAS5B	MI	TTB2MXP
DMDAS5B	MN	Angiotensinogenase renin (REN)
DMDAS5B	MT	DTT
DMDAS5B	MA	Inhibitor
DMDAS5B	RN	Comparative effects of three different potent renin inhibitors in primates. Hypertension. 1993 Jul;22(1):9-17.
DMDAS5B	RU	https://pubmed.ncbi.nlm.nih.gov/8319997

DME7OCX	DI	DME7OCX
DME7OCX	DN	ENIPORIDE
DME7OCX	MI	TTGSEFH
DME7OCX	MN	Sodium/hydrogen exchanger 1 (SLC9A1)
DME7OCX	MT	DTT
DME7OCX	MA	Inhibitor
DME7OCX	RN	Bicyclic acylguanidine Na+/H+ antiporter inhibitors. J Med Chem. 1998 Sep 10;41(19):3736-47.
DME7OCX	RU	https://pubmed.ncbi.nlm.nih.gov/9733499

DME7OCX	DI	DME7OCX
DME7OCX	DN	ENIPORIDE
DME7OCX	MI	TTFZVPO
DME7OCX	MN	Sodium/hydrogen exchanger 3 (SLC9A3)
DME7OCX	MT	DTT
DME7OCX	MA	Inhibitor
DME7OCX	RN	Bicyclic acylguanidine Na+/H+ antiporter inhibitors. J Med Chem. 1998 Sep 10;41(19):3736-47.
DME7OCX	RU	https://pubmed.ncbi.nlm.nih.gov/9733499

DM05F1Z	DI	DM05F1Z
DM05F1Z	DN	ENRASENTAN
DM05F1Z	MI	TTKRD0G
DM05F1Z	MN	Endothelin A receptor (EDNRA)
DM05F1Z	MT	DTT
DM05F1Z	MA	Modulator
DM05F1Z	RN	Enrasentan, an antagonist of endothelin receptors. Cardiovasc Drug Rev. 2003 Spring;21(1):1-16.
DM05F1Z	RU	https://pubmed.ncbi.nlm.nih.gov/12595914

DM05F1Z	DI	DM05F1Z
DM05F1Z	DN	ENRASENTAN
DM05F1Z	MI	TT3ZTGU
DM05F1Z	MN	Endothelin B receptor (EDNRB)
DM05F1Z	MT	DTT
DM05F1Z	MA	Modulator
DM05F1Z	RN	Enrasentan, an antagonist of endothelin receptors. Cardiovasc Drug Rev. 2003 Spring;21(1):1-16.
DM05F1Z	RU	https://pubmed.ncbi.nlm.nih.gov/12595914

DMG3R14	DI	DMG3R14
DMG3R14	DN	EP-2104R
DMG3R14	MI	TTWODQF
DMG3R14	MN	Fibrin (FG)
DMG3R14	MT	DTT
DMG3R14	MA	Modulator
DMG3R14	RN	EP-2104R: a fibrin-specific gadolinium-Based MRI contrast agent for detection of thrombus. J Am Chem Soc. 2008 May 7;130(18):6025-39.
DMG3R14	RU	https://pubmed.ncbi.nlm.nih.gov/18393503

DMZKBU9	DI	DMZKBU9
DMZKBU9	DN	EPC-K1
DMZKBU9	MI	TT9V5JH
DMZKBU9	MN	Phospholipase A2 (PLA2G1B)
DMZKBU9	MT	DTT
DMZKBU9	MA	Inhibitor
DMZKBU9	RN	Posttreatment with EPC-K1, an inhibitor of lipid peroxidation and of phospholipase A2 activity, reduces functional deficits after global ischemia in rats. Brain Res Bull. 1995;36(3):257-60.
DMZKBU9	RU	https://pubmed.ncbi.nlm.nih.gov/7697379

DMJ52FZ	DI	DMJ52FZ
DMJ52FZ	DN	EPI-2010
DMJ52FZ	MI	TT92EIB
DMJ52FZ	MN	ADORA1 messenger RNA (ADORA1 mRNA)
DMJ52FZ	MT	DTT
DMJ52FZ	RN	RASONs: a novel antisense oligonucleotide therapeutic approach for asthma. Expert Opin Biol Ther. 2001 Nov;1(6):979-83.
DMJ52FZ	RU	https://pubmed.ncbi.nlm.nih.gov/11728229

DM1WGUT	DI	DM1WGUT
DM1WGUT	DN	Epothilone D
DM1WGUT	MI	TTYFKSZ
DM1WGUT	MN	Tubulin beta (TUBB)
DM1WGUT	MT	DTT
DM1WGUT	MA	Inhibitor
DM1WGUT	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM1WGUT	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM6NTAS	DI	DM6NTAS
DM6NTAS	DN	ERA-923
DM6NTAS	MI	TTZAYWL
DM6NTAS	MN	Estrogen receptor (ESR)
DM6NTAS	MT	DTT
DM6NTAS	MA	Inhibitor
DM6NTAS	RN	Combination therapy for treating breast cancer using antiestrogen, ERA-923, and the mammalian target of rapamycin inhibitor, temsirolimus. Endocr Relat Cancer. 2006 Sep;13(3):863-73.
DM6NTAS	RU	https://pubmed.ncbi.nlm.nih.gov/16954435

DM6NTAS	DI	DM6NTAS
DM6NTAS	DN	ERA-923
DM6NTAS	MI	TTOM3J0
DM6NTAS	MN	Estrogen receptor beta (ESR2)
DM6NTAS	MT	DTT
DM6NTAS	MA	Inhibitor
DM6NTAS	RN	Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens. J Med Chem. 2001 May 24;44(11):1654-7.
DM6NTAS	RU	https://pubmed.ncbi.nlm.nih.gov/11356100

DM03I7V	DI	DM03I7V
DM03I7V	DN	ERBULOZOLE
DM03I7V	MI	TTML2WA
DM03I7V	MN	Tubulin (TUB)
DM03I7V	MT	DTT
DM03I7V	MA	Modulator
DM03I7V	RN	Influence of the synthetic microtubule inhibitor erbulozole (P.I.N.N.) (R 55 104), a new tubulozole congener, and gamma irradiation on murine tumors in vivo. Eur J Cancer Clin Oncol. 1989 Oct;25(10):1499-504.
DM03I7V	RU	https://pubmed.ncbi.nlm.nih.gov/2591442

DMYR5OX	DI	DMYR5OX
DMYR5OX	DN	EREMOMYCIN
DMYR5OX	MI	TTXT4D5
DMYR5OX	MN	Bacterial Cell membrane (Bact CM)
DMYR5OX	MT	DTT
DMYR5OX	MA	Modulator
DMYR5OX	RN	Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics. J Med Chem. 2003 Mar 27;46(7):1204-9.
DMYR5OX	RU	https://pubmed.ncbi.nlm.nih.gov/12646030

DMTUHWM	DI	DMTUHWM
DMTUHWM	DN	Esreboxetine
DMTUHWM	MI	TTAWNKZ
DMTUHWM	MN	Norepinephrine transporter (NET)
DMTUHWM	MT	DTT
DMTUHWM	MA	Blocker
DMTUHWM	RN	Pfizer. Product Development Pipeline. March 31 2009.
DMTUHWM	RU	http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf

DM1DHOT	DI	DM1DHOT
DM1DHOT	DN	Esuprone
DM1DHOT	MI	TT3WG5C
DM1DHOT	MN	Monoamine oxidase type A (MAO-A)
DM1DHOT	MT	DTT
DM1DHOT	MA	Inhibitor
DM1DHOT	RN	MAO-A inhibition in brain after dosing with esuprone, moclobemide and placebo in healthy volunteers: in vivo studies with positron emission tomography. Eur J Clin Pharmacol. 1997;52(2):121-8.
DM1DHOT	RU	https://pubmed.ncbi.nlm.nih.gov/9174681

DMEGMA2	DI	DMEGMA2
DMEGMA2	DN	ETH615
DMEGMA2	MI	TT2J34L
DMEGMA2	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMEGMA2	MT	DTT
DMEGMA2	MA	Inhibitor
DMEGMA2	RN	Preview of potential therapeutic applications of leukotriene B4 inhibitors in dermatology. Skin Pharmacol Appl Skin Physiol. 2000 Sep-Oct;13(5):235-45.
DMEGMA2	RU	https://pubmed.ncbi.nlm.nih.gov/10940813

DMRB23N	DI	DMRB23N
DMRB23N	DN	ETRX-101
DMRB23N	MI	TTGN1ZA
DMRB23N	MN	Angiotensin II receptor (AGTR)
DMRB23N	MT	DTT
DMRB23N	MA	Modulator
DMRB23N	RN	WO patent application no. 2010,0332,07, Polymer conjugates of therapeutic peptides.
DMRB23N	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20100325&CC=WO&NR=2010033207A1&KC=A1

DMOYMGV	DI	DMOYMGV
DMOYMGV	DN	EVT-101
DMOYMGV	MI	TTN9D8E
DMOYMGV	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMOYMGV	MT	DTT
DMOYMGV	MA	Antagonist
DMOYMGV	RN	Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
DMOYMGV	RU	https://pubmed.ncbi.nlm.nih.gov/16377242

DMGJMQH	DI	DMGJMQH
DMGJMQH	DN	Examorelin
DMGJMQH	MI	TTG4R8V
DMGJMQH	MN	Growth hormone-releasing hormone receptor (GHRHR)
DMGJMQH	MT	DTT
DMGJMQH	MA	Modulator
DMGJMQH	RN	Hexarelin is a stronger GH-releasing peptide than GHRH in normal cycling women but not in anorexia nervosa. J Endocrinol Invest. 1997 May;20(5):257-63.
DMGJMQH	RU	https://pubmed.ncbi.nlm.nih.gov/9258804

DMTUPZ2	DI	DMTUPZ2
DMTUPZ2	DN	Ezlopitant
DMTUPZ2	MI	DECB0K3
DMTUPZ2	MN	Cytochrome P450 2D6 (CYP2D6)
DMTUPZ2	MT	DME
DMTUPZ2	MA	Metabolism
DMTUPZ2	RN	Metabolism of ezlopitant, a nonpeptidic substance P receptor antagonist, in liver microsomes: enzyme kinetics, cytochrome P450 isoform identity, and in vitro-in vivo correlation. Drug Metab Dispos. 2000 Sep;28(9):1069-76.
DMTUPZ2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10950851

DMTUPZ2	DI	DMTUPZ2
DMTUPZ2	DN	Ezlopitant
DMTUPZ2	MI	DE4LYSA
DMTUPZ2	MN	Cytochrome P450 3A4 (CYP3A4)
DMTUPZ2	MT	DME
DMTUPZ2	MA	Metabolism
DMTUPZ2	RN	Metabolism of ezlopitant, a nonpeptidic substance P receptor antagonist, in liver microsomes: enzyme kinetics, cytochrome P450 isoform identity, and in vitro-in vivo correlation. Drug Metab Dispos. 2000 Sep;28(9):1069-76.
DMTUPZ2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10950851

DMTUPZ2	DI	DMTUPZ2
DMTUPZ2	DN	Ezlopitant
DMTUPZ2	MI	DEIBDNY
DMTUPZ2	MN	Cytochrome P450 3A5 (CYP3A5)
DMTUPZ2	MT	DME
DMTUPZ2	MA	Metabolism
DMTUPZ2	RN	Metabolism of ezlopitant, a nonpeptidic substance P receptor antagonist, in liver microsomes: enzyme kinetics, cytochrome P450 isoform identity, and in vitro-in vivo correlation. Drug Metab Dispos. 2000 Sep;28(9):1069-76.
DMTUPZ2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10950851

DMTUPZ2	DI	DMTUPZ2
DMTUPZ2	DN	Ezlopitant
DMTUPZ2	MI	TTZPO1L
DMTUPZ2	MN	Substance-P receptor (TACR1)
DMTUPZ2	MT	DTT
DMTUPZ2	MA	Antagonist
DMTUPZ2	RN	Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar;11(1):137-51.
DMTUPZ2	RU	https://pubmed.ncbi.nlm.nih.gov/16503832

DMMSFK0	DI	DMMSFK0
DMMSFK0	DN	Fabesetron
DMMSFK0	MI	TTNXLKE
DMMSFK0	MN	5-HT 3 receptor (5HT3R)
DMMSFK0	MT	DTT
DMMSFK0	MA	Modulator
DMMSFK0	RN	Pharmacological characterization of FK1052, a dihydropyridoindole derivative, as a new serotonin 3 and 4 dual receptor antagonist. J Pharmacol Exp Ther. 1993 May;265(2):752-8.
DMMSFK0	RU	https://www.ncbi.nlm.nih.gov/pubmed/8496821

DMMSFK0	DI	DMMSFK0
DMMSFK0	DN	Fabesetron
DMMSFK0	MI	TT07C3Y
DMMSFK0	MN	5-HT 4 receptor (HTR4)
DMMSFK0	MT	DTT
DMMSFK0	MA	Modulator
DMMSFK0	RN	Pharmacological characterization of FK1052, a dihydropyridoindole derivative, as a new serotonin 3 and 4 dual receptor antagonist. J Pharmacol Exp Ther. 1993 May;265(2):752-8.
DMMSFK0	RU	https://www.ncbi.nlm.nih.gov/pubmed/8496821

DM8UC0K	DI	DM8UC0K
DM8UC0K	DN	FANDOFLOXACIN HYDROCHLORIDE
DM8UC0K	MI	TTN6J5F
DM8UC0K	MN	Bacterial DNA gyrase (Bact gyrase)
DM8UC0K	MT	DTT
DM8UC0K	MA	Modulator
DM8UC0K	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM8UC0K	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMRU1KT	DI	DMRU1KT
DMRU1KT	DN	Fasidotril
DMRU1KT	MI	TT5TKPM
DMRU1KT	MN	Neutral endopeptidase (MME)
DMRU1KT	MT	DTT
DMRU1KT	MA	Modulator
DMRU1KT	RN	Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans. Hypertension. 2000 May;35(5):1148-53.
DMRU1KT	RU	https://www.ncbi.nlm.nih.gov/pubmed/10818079

DMT2Z1L	DI	DMT2Z1L
DMT2Z1L	DN	FCE-22716
DMT2Z1L	MI	TTJQOD7
DMT2Z1L	MN	5-HT 2A receptor (HTR2A)
DMT2Z1L	MT	DTT
DMT2Z1L	MA	Antagonist
DMT2Z1L	RN	Mechanism of the antihypertensive effect of FCE 22716, a new ergoline derivative, in the spontaneously hypertensive rat. Pharmacology. 1989;38(2):78-92.
DMT2Z1L	RU	https://pubmed.ncbi.nlm.nih.gov/2727050

DMT2Z1L	DI	DMT2Z1L
DMT2Z1L	DN	FCE-22716
DMT2Z1L	MI	TT34BHT
DMT2Z1L	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMT2Z1L	MT	DTT
DMT2Z1L	MA	Modulator
DMT2Z1L	RN	Mechanism of the antihypertensive effect of FCE 22716, a new ergoline derivative, in the spontaneously hypertensive rat. Pharmacology. 1989;38(2):78-92.
DMT2Z1L	RU	https://pubmed.ncbi.nlm.nih.gov/2727050

DMTQLIJ	DI	DMTQLIJ
DMTQLIJ	DN	FCP-3P1
DMTQLIJ	MI	DEPKLMQ
DMTQLIJ	MN	Cytochrome P450 2B6 (CYP2B6)
DMTQLIJ	MT	DME
DMTQLIJ	MA	Metabolism
DMTQLIJ	RN	Conformational adaptation of human cytochrome P450 2B6 and rabbit cytochrome P450 2B4 revealed upon binding multiple amlodipine molecules. Biochemistry. 2012 Sep 18;51(37):7225-38.
DMTQLIJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22909231

DMTQLIJ	DI	DMTQLIJ
DMTQLIJ	DN	FCP-3P1
DMTQLIJ	MI	DE4LYSA
DMTQLIJ	MN	Cytochrome P450 3A4 (CYP3A4)
DMTQLIJ	MT	DME
DMTQLIJ	MA	Metabolism
DMTQLIJ	RN	Amlodipine metabolism in human liver microsomes and roles of CYP3A4/5 in the dihydropyridine dehydrogenation. Drug Metab Dispos. 2014 Feb;42(2):245-9.
DMTQLIJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24301608

DMTQLIJ	DI	DMTQLIJ
DMTQLIJ	DN	FCP-3P1
DMTQLIJ	MI	DEIBDNY
DMTQLIJ	MN	Cytochrome P450 3A5 (CYP3A5)
DMTQLIJ	MT	DME
DMTQLIJ	MA	Metabolism
DMTQLIJ	RN	Construction and verification of CYP3A5 gene polymorphisms using a Saccharomyces cerevisiae expression system to predict drug metabolism. Mol Med Rep. 2017 Apr;15(4):1593-1600.
DMTQLIJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28259948

DMJRF5G	DI	DMJRF5G
DMJRF5G	DN	FIDUXOSIN HYDROCHLORIDE
DMJRF5G	MI	TT34BHT
DMJRF5G	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMJRF5G	MT	DTT
DMJRF5G	MA	Antagonist
DMJRF5G	RN	Effect of fiduxosin, an antagonist selective for alpha(1A)- and alpha(1D)-adrenoceptors, on intraurethral and arterial pressure responses in conscious dogs. J Pharmacol Exp Ther. 2002 Feb;300(2):487-94.
DMJRF5G	RU	https://pubmed.ncbi.nlm.nih.gov/11805208

DMGD5QN	DI	DMGD5QN
DMGD5QN	DN	Filaminast
DMGD5QN	MI	TTVIAT9
DMGD5QN	MN	Phosphodiesterase 4B (PDE4B)
DMGD5QN	MT	DTT
DMGD5QN	MA	Inhibitor
DMGD5QN	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMGD5QN	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM06SC9	DI	DM06SC9
DM06SC9	DN	FINROZOLE
DM06SC9	MI	TTSZLWK
DM06SC9	MN	Aromatase (CYP19A1)
DM06SC9	MT	DTT
DM06SC9	MA	Inhibitor
DM06SC9	RN	Pharmacokinetics of finrozole (MPV-2213ad), a novel selective aromatase inhibitor, in healthy men. Br J Clin Pharmacol. 2001 Dec;52(6):702-4.
DM06SC9	RU	https://pubmed.ncbi.nlm.nih.gov/11736883

DMCINOE	DI	DMCINOE
DMCINOE	DN	FK-011
DMCINOE	MI	TTGKOY9
DMCINOE	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DMCINOE	MT	DTT
DMCINOE	MA	Modulator
DMCINOE	RN	Evaluation of human peroxisome proliferator-activated receptor (PPAR) subtype selectivity of a variety of anti-inflammatory drugs based on a novel assay for PPAR delta(beta). J Pharmacol Sci. 2003 Nov;93(3):347-55.
DMCINOE	RU	https://pubmed.ncbi.nlm.nih.gov/14646253

DM1JUS0	DI	DM1JUS0
DM1JUS0	DN	FK-224
DM1JUS0	MI	TTYO0A3
DM1JUS0	MN	Substance-K receptor (TACR2)
DM1JUS0	MT	DTT
DM1JUS0	MA	Modulator
DM1JUS0	RN	Effects of FK224, a novel compound NK1 and NK2 receptor antagonist, on airway constriction and airway edema induced by neurokinins and sensory nerv... J Pharmacol Exp Ther. 1992 Jul;262(1):403-8.
DM1JUS0	RU	https://www.ncbi.nlm.nih.gov/pubmed/1378097

DM1JUS0	DI	DM1JUS0
DM1JUS0	DN	FK-224
DM1JUS0	MI	TTZPO1L
DM1JUS0	MN	Substance-P receptor (TACR1)
DM1JUS0	MT	DTT
DM1JUS0	MA	Modulator
DM1JUS0	RN	Effects of FK224, a novel compound NK1 and NK2 receptor antagonist, on airway constriction and airway edema induced by neurokinins and sensory nerv... J Pharmacol Exp Ther. 1992 Jul;262(1):403-8.
DM1JUS0	RU	https://www.ncbi.nlm.nih.gov/pubmed/1378097

DMHIUGT	DI	DMHIUGT
DMHIUGT	DN	FK-352
DMHIUGT	MI	TTK25J1
DMHIUGT	MN	Adenosine A1 receptor (ADORA1)
DMHIUGT	MT	DTT
DMHIUGT	MA	Antagonist
DMHIUGT	RN	Adenosine A1 receptor antagonist improves intradialytic hypotension. Kidney Int. 2006 Mar;69(5):877-83.
DMHIUGT	RU	https://pubmed.ncbi.nlm.nih.gov/16395260

DMH3DXY	DI	DMH3DXY
DMH3DXY	DN	FK-453
DMH3DXY	MI	TTK25J1
DMH3DXY	MN	Adenosine A1 receptor (ADORA1)
DMH3DXY	MT	DTT
DMH3DXY	MA	Modulator
DMH3DXY	RN	Cardiovascular and renal effects of blocking A1 adenosine receptors. J Cardiovasc Pharmacol. 1993 May;21(5):822-8.
DMH3DXY	RU	https://www.ncbi.nlm.nih.gov/pubmed/7685455

DMR2FPO	DI	DMR2FPO
DMR2FPO	DN	FK-584
DMR2FPO	MI	TTH18TF
DMR2FPO	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMR2FPO	MT	DTT
DMR2FPO	MA	Modulator
DMR2FPO	RN	US patent application no. 2005,0261,328, Pharmaceutical composition comprising beta-3-adrenoceptor-agonists and antimuscarinic agents.
DMR2FPO	RU	http://www.google.com/patents/US20050261328

DMQ3O4C	DI	DMQ3O4C
DMQ3O4C	DN	FK-633
DMQ3O4C	MI	TT38RM1
DMQ3O4C	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DMQ3O4C	MT	DTT
DMQ3O4C	MA	Modulator
DMQ3O4C	RN	Efficacy of FK633, an ultra-short acting glycoprotein IIb/IIIa antagonist on platelet preservation during and after cardiopulmonary bypass. Eur J Cardiothorac Surg. 2004 Aug;26(2):289-93.
DMQ3O4C	RU	https://www.ncbi.nlm.nih.gov/pubmed/15296885

DMFGJNW	DI	DMFGJNW
DMFGJNW	DN	FK-664
DMFGJNW	MI	TTTWGIX
DMFGJNW	MN	Leukotriene receptor (LTR)
DMFGJNW	MT	DTT
DMFGJNW	MA	Modulator
DMFGJNW	RN	US patent application no. 7,175,854, Pharmaceutical preparation comprising an active dispersed on a matrix.
DMFGJNW	RU	http://www.google.com/patents/US7175854

DM524J3	DI	DM524J3
DM524J3	DN	FK-706
DM524J3	MI	TTPLTSQ
DM524J3	MN	Neutrophil elastase (NE)
DM524J3	MT	DTT
DM524J3	MA	Inhibitor
DM524J3	RN	Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs. 2002 Jul;11(7):965-80.
DM524J3	RU	https://pubmed.ncbi.nlm.nih.gov/12084007

DM7TLF6	DI	DM7TLF6
DM7TLF6	DN	FK-739
DM7TLF6	MI	TTGN1ZA
DM7TLF6	MN	Angiotensin II receptor (AGTR)
DM7TLF6	MT	DTT
DM7TLF6	MA	Modulator
DM7TLF6	RN	The pharmacological characterization of FK 739, a new angiotensin II-receptor antagonist. Jpn J Pharmacol. 1993 Nov;63(3):335-43.
DM7TLF6	RU	https://pubmed.ncbi.nlm.nih.gov/8107326

DMH6QAI	DI	DMH6QAI
DMH6QAI	DN	FK778
DMH6QAI	MI	TTLVP78
DMH6QAI	MN	Dihydroorotate dehydrogenase (DHODH)
DMH6QAI	MT	DTT
DMH6QAI	MA	Modulator
DMH6QAI	RN	Immunosuppression with FK778 and mycophenolate mofetil in a rat cardiac transplantation model. Transplantation. 2003 Dec 15;76(11):1627-9.
DMH6QAI	RU	https://www.ncbi.nlm.nih.gov/pubmed/14702537

DMS87T9	DI	DMS87T9
DMS87T9	DN	FK-838
DMS87T9	MI	TTK25J1
DMS87T9	MN	Adenosine A1 receptor (ADORA1)
DMS87T9	MT	DTT
DMS87T9	MA	Modulator
DMS87T9	RN	An orally active adenosine A1 receptor antagonist, FK838, increases renal excretion and maintains glomerular filtration rate in furosemide-resistan... Br J Pharmacol. 2003 Aug;139(8):1383-8.
DMS87T9	RU	https://www.ncbi.nlm.nih.gov/pubmed/12922924

DM457B1	DI	DM457B1
DM457B1	DN	FK-888
DM457B1	MI	TTZPO1L
DM457B1	MN	Substance-P receptor (TACR1)
DM457B1	MT	DTT
DM457B1	MA	Antagonist
DM457B1	RN	Pharmacological profile of a high affinity dipeptide NK1 receptor antagonist, FK888. Br J Pharmacol. 1992 Nov;107(3):785-9.
DM457B1	RU	https://pubmed.ncbi.nlm.nih.gov/1282073

DMTEW80	DI	DMTEW80
DMTEW80	DN	FK-906
DMTEW80	MI	TTB2MXP
DMTEW80	MN	Angiotensinogenase renin (REN)
DMTEW80	MT	DTT
DMTEW80	MA	Inhibitor
DMTEW80	RN	Antihypertensive efficacy of FK906, a novel human renin inhibitor. Clin Ther. 1993 May-Jun;15(3):539-48.
DMTEW80	RU	https://pubmed.ncbi.nlm.nih.gov/8364945

DMPD8O2	DI	DMPD8O2
DMPD8O2	DN	FK-960
DMPD8O2	MI	TTOMNR9
DMPD8O2	MN	Somatostatin receptor (SSTR)
DMPD8O2	MT	DTT
DMPD8O2	MA	Modulator
DMPD8O2	RN	FK960, a novel potential anti-dementia drug, enhances high K(+)-evoked release of somatostatin from rat hippocampal slices. Brain Res. 2001 Feb 16;892(1):111-7.
DMPD8O2	RU	https://www.ncbi.nlm.nih.gov/pubmed/11172755

DMUQN83	DI	DMUQN83
DMUQN83	DN	FL-386
DMUQN83	MI	TTZPS91
DMUQN83	MN	Dihydrothymine dehydrogenase (DPYD)
DMUQN83	MT	DTT
DMUQN83	MA	Modulator
DMUQN83	RN	Effects of FL-386 on faecal lipid excretion in humans. J Int Med Res. 1993 Sep-Oct;21(5):225-33.
DMUQN83	RU	https://pubmed.ncbi.nlm.nih.gov/8112480

DMOCMXH	DI	DMOCMXH
DMOCMXH	DN	FLOSATIDIL
DMOCMXH	MI	TT5HONZ
DMOCMXH	MN	Calcium channel unspecific (CaC)
DMOCMXH	MT	DTT
DMOCMXH	MA	Antagonist
DMOCMXH	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMOCMXH	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM3PXLZ	DI	DM3PXLZ
DM3PXLZ	DN	FO-152
DM3PXLZ	MI	TTU6BFZ
DM3PXLZ	MN	Candida Thymidylate synthase (Candi TMP1)
DM3PXLZ	MT	DTT
DM3PXLZ	MA	Modulator
DM3PXLZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2642).
DM3PXLZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2642

DM15LAP	DI	DM15LAP
DM15LAP	DN	Fonsartan
DM15LAP	MI	TTQVOEI
DM15LAP	MN	Angiotensin II receptor type-2 (AGTR2)
DM15LAP	MT	DTT
DM15LAP	MA	Modulator
DM15LAP	RN	Role of the angiotensin II AT2-subtype receptors in the blood pressure-lowering effect of losartan in salt-restricted rats. J Hypertens. 1998 Dec;16(12 Pt 2):2039-43.
DM15LAP	RU	https://pubmed.ncbi.nlm.nih.gov/9886894

DMEH6LV	DI	DMEH6LV
DMEH6LV	DN	Fontolizumab
DMEH6LV	MI	TT93WF5
DMEH6LV	MN	Interferon-gamma (IFNG)
DMEH6LV	MT	DTT
DMEH6LV	RN	Emerging drugs to treat Crohn's disease. Expert Opin Emerg Drugs. 2007 Mar;12(1):49-59.
DMEH6LV	RU	https://pubmed.ncbi.nlm.nih.gov/17355213

DMTYHK4	DI	DMTYHK4
DMTYHK4	DN	FOSOPAMINE
DMTYHK4	MI	TTEX248
DMTYHK4	MN	Dopamine D2 receptor (D2R)
DMTYHK4	MT	DTT
DMTYHK4	MA	Modulator
DMTYHK4	RN	Development of dopaminergic drugs for the chronic treatment of congestive heart failure. J Auton Pharmacol. 1990;10 Suppl 1:s85-93.
DMTYHK4	RU	https://pubmed.ncbi.nlm.nih.gov/1983011

DMUD0IN	DI	DMUD0IN
DMUD0IN	DN	FOZIVUDINE TIDOXIL
DMUD0IN	MI	TT84ETX
DMUD0IN	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMUD0IN	MT	DTT
DMUD0IN	MA	Inhibitor
DMUD0IN	RN	Fozivudine tidoxil as single-agent therapy decreases plasma and cell-associated viremia during acute feline immunodeficiency virus infection. J Vet Intern Med. 2011 May-Jun;25(3):413-8.
DMUD0IN	RU	https://pubmed.ncbi.nlm.nih.gov/21457319

DML6MVP	DI	DML6MVP
DML6MVP	DN	FPL-64170
DML6MVP	MI	TT2J34L
DML6MVP	MN	Arachidonate 5-lipoxygenase (5-LOX)
DML6MVP	MT	DTT
DML6MVP	MA	Inhibitor
DML6MVP	RN	Selective blockade of leukotriene production by a single dose of the FPL 64170XX 0.5% enema in active ulcerative colitis. Pharmacol Toxicol. 1995 Dec;77(6):371-6.
DML6MVP	RU	https://pubmed.ncbi.nlm.nih.gov/8835361

DMTRBU4	DI	DMTRBU4
DMTRBU4	DN	Frakefamide
DMTRBU4	MI	TTKWM86
DMTRBU4	MN	Opioid receptor mu (MOP)
DMTRBU4	MT	DTT
DMTRBU4	MA	Agonist
DMTRBU4	RN	A novel molecule (frakefamide) with peripheral opioid properties: the effects on resting ventilation compared with morphine and placebo. Anesth Analg. 2005 Mar;100(3):713-7, table of contents.
DMTRBU4	RU	https://pubmed.ncbi.nlm.nih.gov/15728057

DMJLEV7	DI	DMJLEV7
DMJLEV7	DN	FS-205-397
DMJLEV7	MI	TTK0943
DMJLEV7	MN	Prostaglandin G/H synthase (COX)
DMJLEV7	MT	DTT
DMJLEV7	MA	Modulator
DMJLEV7	RN	FS 205-397: a new antipyretic analgesic with a paracetamol-like profile of activity but lack of acute hepatotoxicity in mice. Life Sci. 1988;43(11):905-12.
DMJLEV7	RU	https://pubmed.ncbi.nlm.nih.gov/3261827

DMHOMFK	DI	DMHOMFK
DMHOMFK	DN	G-1128
DMHOMFK	MI	TT6B75U
DMHOMFK	MN	ABL messenger RNA (ABL mRNA)
DMHOMFK	MT	DTT
DMHOMFK	RN	Pharmaceutical Design And Development: A Molecular Biology Approach, T V Ramabhadran, 2005. Page(219).
DMHOMFK	RU	https://books.google.com.sg/books?id=wmPsNyVMLVsC&pg=PA219&lpg=PA219&dq=%E2%80%9CG-1128%E2%80%9D+antisense&source=bl&ots=_53NgYwdeA&sig=0CKK88IXybZco5YWV-7pU8EugPs&hl=zh-CN&sa=X&ved=0CCYQ6AEwAWoVChMI8cD98f--yAIVQQSOCh24qgAR

DMTNYSF	DI	DMTNYSF
DMTNYSF	DN	Galarubicin
DMTNYSF	MI	TTLM12X
DMTNYSF	MN	Matrix metalloproteinase-2 (MMP-2)
DMTNYSF	MT	DTT
DMTNYSF	MA	Inhibitor
DMTNYSF	RN	Inhibitory effect of DA-125, a new anthracyclin analog antitumor agent, on the invasion of human fibrosarcoma cells by down-regulating the matrix m... Biochem Pharmacol. 2005 Dec 19;71(1-2):21-31.
DMTNYSF	RU	https://pubmed.ncbi.nlm.nih.gov/16271263

DMTNYSF	DI	DMTNYSF
DMTNYSF	DN	Galarubicin
DMTNYSF	MI	TT6X50U
DMTNYSF	MN	Matrix metalloproteinase-9 (MMP-9)
DMTNYSF	MT	DTT
DMTNYSF	MA	Inhibitor
DMTNYSF	RN	Inhibitory effect of DA-125, a new anthracyclin analog antitumor agent, on the invasion of human fibrosarcoma cells by down-regulating the matrix m... Biochem Pharmacol. 2005 Dec 19;71(1-2):21-31.
DMTNYSF	RU	https://pubmed.ncbi.nlm.nih.gov/16271263

DMX0Z51	DI	DMX0Z51
DMX0Z51	DN	Gallium maltolate
DMX0Z51	MI	TTBWDI0
DMX0Z51	MN	Ribonucleoside-diphosphate reductase M2 (RRM2)
DMX0Z51	MT	DTT
DMX0Z51	MA	Binder
DMX0Z51	RN	Gallium maltolate is a promising chemotherapeutic agent for the treatment of hepatocellular carcinoma. Anticancer Res. 2006 May-Jun;26(3A):1739-43.
DMX0Z51	RU	https://pubmed.ncbi.nlm.nih.gov/16827101

DMHAM2J	DI	DMHAM2J
DMHAM2J	DN	Gantofiban
DMHAM2J	MI	TT38RM1
DMHAM2J	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DMHAM2J	MT	DTT
DMHAM2J	MA	Modulator
DMHAM2J	RN	Enantioseparation of gantofiban precursors on chiral stationary phases of the poly-(N-acryloyl amino acid derivative)-type. J Pharm Biomed Anal. 2002 Jan 15;27(3-4):627-37.
DMHAM2J	RU	https://www.ncbi.nlm.nih.gov/pubmed/11755763

DM8IL1U	DI	DM8IL1U
DM8IL1U	DN	Gavestinel
DM8IL1U	MI	TTZ8EM9
DM8IL1U	MN	Glycine receptor (GlyR)
DM8IL1U	MT	DTT
DM8IL1U	MA	Modulator
DM8IL1U	RN	Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial.GAIN International Investigators.Lancet.2000 Jun 3;355(9219):1949-54.
DM8IL1U	RU	https://www.ncbi.nlm.nih.gov/pubmed/10859040

DM8IL1U	DI	DM8IL1U
DM8IL1U	DN	Gavestinel
DM8IL1U	MI	DEYGVN4
DM8IL1U	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM8IL1U	MT	DME
DM8IL1U	MA	Metabolism
DM8IL1U	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM8IL1U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM8IL1U	DI	DM8IL1U
DM8IL1U	DN	Gavestinel
DM8IL1U	MI	DEF2WXN
DM8IL1U	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DM8IL1U	MT	DME
DM8IL1U	MA	Metabolism
DM8IL1U	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM8IL1U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM8IL1U	DI	DM8IL1U
DM8IL1U	DN	Gavestinel
DM8IL1U	MI	DE85D2P
DM8IL1U	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DM8IL1U	MT	DME
DM8IL1U	MA	Metabolism
DM8IL1U	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM8IL1U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMS7TC5	DI	DMS7TC5
DMS7TC5	DN	Geldanamycin
DMS7TC5	MI	TT78R5H
DMS7TC5	MN	Heat shock protein 90 alpha (HSP90A)
DMS7TC5	MT	DTT
DMS7TC5	MA	Inhibitor
DMS7TC5	RN	Heat shock protein 90 regulates the stability of MEKK3 in HEK293 cells. Cell Immunol. 2009;259(1):49-55.
DMS7TC5	RU	https://pubmed.ncbi.nlm.nih.gov/19560753

DMLMT5O	DI	DMLMT5O
DMLMT5O	DN	Gemopatrilat
DMLMT5O	MI	TT5TKPM
DMLMT5O	MN	Neutral endopeptidase (MME)
DMLMT5O	MT	DTT
DMLMT5O	MA	Modulator
DMLMT5O	RN	Omapatrilat.Bristol-Myers Squibb.Curr Opin Investig Drugs.2001 Oct;2(10):1414-22.
DMLMT5O	RU	https://www.ncbi.nlm.nih.gov/pubmed/11890357

DMIUFS4	DI	DMIUFS4
DMIUFS4	DN	GI 181771
DMIUFS4	MI	TTCG0AL
DMIUFS4	MN	Cholecystokinin receptor type A (CCKAR)
DMIUFS4	MT	DTT
DMIUFS4	MA	Agonist
DMIUFS4	RN	Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Jul-Aug;25(6):483-506.
DMIUFS4	RU	https://pubmed.ncbi.nlm.nih.gov/12949633

DM10CBF	DI	DM10CBF
DM10CBF	DN	GL-331
DM10CBF	MI	TT0IHXV
DM10CBF	MN	DNA topoisomerase II (TOP2)
DM10CBF	MT	DTT
DM10CBF	MA	Modulator
DM10CBF	RN	GL331, a topoisomerase II inhibitor, induces radiosensitization of human glioma cells. Anticancer Res. 2006 May-Jun;26(3A):2149-56.
DM10CBF	RU	https://pubmed.ncbi.nlm.nih.gov/16827158

DMT1LQS	DI	DMT1LQS
DMT1LQS	DN	GLENVASTATIN
DMT1LQS	MI	TTPADOQ
DMT1LQS	MN	HMG-CoA reductase (HMGCR)
DMT1LQS	MT	DTT
DMT1LQS	MA	Inhibitor
DMT1LQS	RN	Bile acid derived HMG-CoA reductase inhibitors. Biochim Biophys Acta. 1994 Nov 29;1227(3):137-54.
DMT1LQS	RU	https://pubmed.ncbi.nlm.nih.gov/7986821

DMC87DR	DI	DMC87DR
DMC87DR	DN	GLPG-0259
DMC87DR	MI	TT3UJ7Z
DMC87DR	MN	MAPK-activated protein kinase 5 (MAPKAPK5)
DMC87DR	MT	DTT
DMC87DR	MA	Inhibitor
DMC87DR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2096).
DMC87DR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2096

DM5JKCL	DI	DM5JKCL
DM5JKCL	DN	GlycoPEGylated erythropoietin
DM5JKCL	MI	TTAUX24
DM5JKCL	MN	Erythropoietin Receptor (EPOR)
DM5JKCL	MT	DTT
DM5JKCL	MA	Modulator
DM5JKCL	RN	Design of Homogeneous, MonoPEGylated Erythropoietin Analogs With Preserved In Vitro Bioactivity. Exp Hematol. 2006 June; 34(6): 697-704.
DM5JKCL	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1634893/

DM07VBW	DI	DM07VBW
DM07VBW	DN	Glypromate
DM07VBW	MI	TTGQUFK
DM07VBW	MN	PI3K/AKT/mTOR pathway (PAm pathway)
DM07VBW	MT	DTT
DM07VBW	MA	Modulator
DM07VBW	RN	Dendritic spine dysgenesis in Rett syndrome. Front Neuroanat. 2014; 8: 97.
DM07VBW	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4159975/

DM7V9CT	DI	DM7V9CT
DM7V9CT	DN	GM6001
DM7V9CT	MI	TTIQSC1
DM7V9CT	MN	Bacterial Lethal factor (Bact lef)
DM7V9CT	MT	DTT
DM7V9CT	MA	Inhibitor
DM7V9CT	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM7V9CT	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM7V9CT	DI	DM7V9CT
DM7V9CT	DN	GM6001
DM7V9CT	MI	TTMX39J
DM7V9CT	MN	Matrix metalloproteinase-1 (MMP-1)
DM7V9CT	MT	DTT
DM7V9CT	MA	Inhibitor
DM7V9CT	RN	Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with i... Bioorg Med Chem. 2008 Sep 15;16(18):8745-59.
DM7V9CT	RU	https://pubmed.ncbi.nlm.nih.gov/18782669

DM7V9CT	DI	DM7V9CT
DM7V9CT	DN	GM6001
DM7V9CT	MI	TTXZ0KQ
DM7V9CT	MN	Matrix metalloproteinase-12 (MMP-12)
DM7V9CT	MT	DTT
DM7V9CT	MA	Inhibitor
DM7V9CT	RN	Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8.
DM7V9CT	RU	https://pubmed.ncbi.nlm.nih.gov/16420030

DM7V9CT	DI	DM7V9CT
DM7V9CT	DN	GM6001
DM7V9CT	MI	TTHY57M
DM7V9CT	MN	Matrix metalloproteinase-13 (MMP-13)
DM7V9CT	MT	DTT
DM7V9CT	MA	Inhibitor
DM7V9CT	RN	Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia si... J Biol Chem. 2007 Sep 21;282(38):27781-91.
DM7V9CT	RU	https://pubmed.ncbi.nlm.nih.gov/17623656

DM7V9CT	DI	DM7V9CT
DM7V9CT	DN	GM6001
DM7V9CT	MI	TTJ4QE7
DM7V9CT	MN	Matrix metalloproteinase-14 (MMP-14)
DM7V9CT	MT	DTT
DM7V9CT	MA	Inhibitor
DM7V9CT	RN	Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with i... Bioorg Med Chem. 2008 Sep 15;16(18):8745-59.
DM7V9CT	RU	https://pubmed.ncbi.nlm.nih.gov/18782669

DM7V9CT	DI	DM7V9CT
DM7V9CT	DN	GM6001
DM7V9CT	MI	TTLM12X
DM7V9CT	MN	Matrix metalloproteinase-2 (MMP-2)
DM7V9CT	MT	DTT
DM7V9CT	MA	Inhibitor
DM7V9CT	RN	Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with i... Bioorg Med Chem. 2008 Sep 15;16(18):8745-59.
DM7V9CT	RU	https://pubmed.ncbi.nlm.nih.gov/18782669

DM7V9CT	DI	DM7V9CT
DM7V9CT	DN	GM6001
DM7V9CT	MI	TTYRF5E
DM7V9CT	MN	Matrix metalloproteinase-21 (MMP-21)
DM7V9CT	MT	DTT
DM7V9CT	MA	Inhibitor
DM7V9CT	RN	Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8.
DM7V9CT	RU	https://pubmed.ncbi.nlm.nih.gov/16420030

DM7V9CT	DI	DM7V9CT
DM7V9CT	DN	GM6001
DM7V9CT	MI	TTUZ2L5
DM7V9CT	MN	Matrix metalloproteinase-3 (MMP-3)
DM7V9CT	MT	DTT
DM7V9CT	MA	Inhibitor
DM7V9CT	RN	Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with i... Bioorg Med Chem. 2008 Sep 15;16(18):8745-59.
DM7V9CT	RU	https://pubmed.ncbi.nlm.nih.gov/18782669

DM7V9CT	DI	DM7V9CT
DM7V9CT	DN	GM6001
DM7V9CT	MI	TTGA1IV
DM7V9CT	MN	Matrix metalloproteinase-8 (MMP-8)
DM7V9CT	MT	DTT
DM7V9CT	MA	Inhibitor
DM7V9CT	RN	Hydroxamate inhibitors of human gelatinase B (92 kDa), Bioorg. Med. Chem. Lett. 5(4):349-352 (1995).
DM7V9CT	RU	http://www.sciencedirect.com/science/article/pii/0960894X9500033P

DM7V9CT	DI	DM7V9CT
DM7V9CT	DN	GM6001
DM7V9CT	MI	TT6X50U
DM7V9CT	MN	Matrix metalloproteinase-9 (MMP-9)
DM7V9CT	MT	DTT
DM7V9CT	MA	Inhibitor
DM7V9CT	RN	Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with i... Bioorg Med Chem. 2008 Sep 15;16(18):8745-59.
DM7V9CT	RU	https://pubmed.ncbi.nlm.nih.gov/18782669

DM9MEAY	DI	DM9MEAY
DM9MEAY	DN	Gonadimmune
DM9MEAY	MI	TT8R70G
DM9MEAY	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DM9MEAY	MT	DTT
DM9MEAY	MA	Modulator
DM9MEAY	RN	A novel retro-inverso gonadotropin-releasing hormone (GnRH) immunogen elicits antibodies that neutralize the activity of native GnRH. Endocrinology. 2003 Jul;144(7):3262-9.
DM9MEAY	RU	https://pubmed.ncbi.nlm.nih.gov/12810583

DMCXLIK	DI	DMCXLIK
DMCXLIK	DN	GR-213487
DMCXLIK	MI	TTCYAXN
DMCXLIK	MN	Chloride channel unspecific (ClC)
DMCXLIK	MT	DTT
DMCXLIK	MA	Modulator
DMCXLIK	RN	EP patent application no. 1336602, Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases.
DMCXLIK	RU	http://www.google.com/patents/EP1336602A1?cl=en

DMSV6KP	DI	DMSV6KP
DMSV6KP	DN	GSK 679769
DMSV6KP	MI	TTZPO1L
DMSV6KP	MN	Substance-P receptor (TACR1)
DMSV6KP	MT	DTT
DMSV6KP	MA	Antagonist
DMSV6KP	RN	Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar;11(1):137-51.
DMSV6KP	RU	https://pubmed.ncbi.nlm.nih.gov/16503832

DMTZBXQ	DI	DMTZBXQ
DMTZBXQ	DN	GSK-159797
DMTZBXQ	MI	TT2CJVK
DMTZBXQ	MN	Adrenergic receptor beta-2 (ADRB2)
DMTZBXQ	MT	DTT
DMTZBXQ	MA	Agonist
DMTZBXQ	RN	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
DMTZBXQ	RU	https://pubmed.ncbi.nlm.nih.gov/16634702

DMTZBXQ	DI	DMTZBXQ
DMTZBXQ	DN	GSK-159797
DMTZBXQ	MI	TTDW3Z2
DMTZBXQ	MN	Telomerase messenger RNA (Telomerase mRNA)
DMTZBXQ	MT	DTT
DMTZBXQ	RN	Combination therapy of 2-5A antisense against telomerase RNA and cisplatin for malignant gliomas. Int J Oncol. 2001 Jun;18(6):1287-92.
DMTZBXQ	RU	https://pubmed.ncbi.nlm.nih.gov/11351264

DM8J2AV	DI	DM8J2AV
DM8J2AV	DN	GSK159802
DM8J2AV	MI	TT2CJVK
DM8J2AV	MN	Adrenergic receptor beta-2 (ADRB2)
DM8J2AV	MT	DTT
DM8J2AV	MA	Agonist
DM8J2AV	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DM8J2AV	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMX7DVH	DI	DMX7DVH
DMX7DVH	DN	GSK163090
DMX7DVH	MI	TTSQIFT
DMX7DVH	MN	5-HT 1A receptor (HTR1A)
DMX7DVH	MT	DTT
DMX7DVH	MA	Antagonist
DMX7DVH	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMX7DVH	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMMIR1K	DI	DMMIR1K
DMMIR1K	DN	GSK184072
DMMIR1K	MI	TTTG60L
DMMIR1K	MN	CAP-dependent endonuclease (CDE)
DMMIR1K	MT	DTT
DMMIR1K	MA	Inhibitor
DMMIR1K	RN	Synthesis of natural flutimide and analogous fully substituted pyrazine-2,6-diones, endonuclease inhibitors of influenza virus. J Org Chem. 2001 Aug 10;66(16):5504-16.
DMMIR1K	RU	https://pubmed.ncbi.nlm.nih.gov/11485475

DMMIR1K	DI	DMMIR1K
DMMIR1K	DN	GSK184072
DMMIR1K	MI	TTUF2HO
DMMIR1K	MN	NAD-dependent deacetylase sirtuin-1 (SIRT1)
DMMIR1K	MT	DTT
DMMIR1K	MA	Activator
DMMIR1K	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMMIR1K	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMHZQ0T	DI	DMHZQ0T
DMHZQ0T	DN	GSK2190914
DMHZQ0T	MI	TTDMBF5
DMHZQ0T	MN	Arachidonate 5-lipoxygenase activating protein (FLAP)
DMHZQ0T	MT	DTT
DMHZQ0T	MA	Inhibitor
DMHZQ0T	RN	FLAP inhibitors for the treatment of inflammatory diseases. Curr Opin Investig Drugs. 2009 Nov;10(11):1163-72.
DMHZQ0T	RU	https://pubmed.ncbi.nlm.nih.gov/19876784

DM89AV2	DI	DM89AV2
DM89AV2	DN	GSK2190915
DM89AV2	MI	TTDMBF5
DM89AV2	MN	Arachidonate 5-lipoxygenase activating protein (FLAP)
DM89AV2	MT	DTT
DM89AV2	MA	Inhibitor
DM89AV2	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DM89AV2	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMBYQJH	DI	DMBYQJH
DMBYQJH	DN	GSK256066
DMBYQJH	MI	TTZ97H5
DMBYQJH	MN	Phosphodiesterase 4A (PDE4A)
DMBYQJH	MT	DTT
DMBYQJH	MA	Inhibitor
DMBYQJH	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMBYQJH	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMUC9OS	DI	DMUC9OS
DMUC9OS	DN	GSK-644784
DMUC9OS	MI	TTVKILB
DMUC9OS	MN	Prostaglandin G/H synthase 2 (COX-2)
DMUC9OS	MT	DTT
DMUC9OS	MA	Inhibitor
DMUC9OS	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DMUC9OS	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DM5WRJX	DI	DM5WRJX
DM5WRJX	DN	GSK-677954
DM5WRJX	MI	TTJ584C
DM5WRJX	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DM5WRJX	MT	DTT
DM5WRJX	MA	Agonist
DM5WRJX	RN	Emerging drugs for non-alcoholic fatty liver disease. Expert Opin Emerg Drugs. 2008 Mar;13(1):145-58.
DM5WRJX	RU	https://pubmed.ncbi.nlm.nih.gov/18321154

DM5WRJX	DI	DM5WRJX
DM5WRJX	DN	GSK-677954
DM5WRJX	MI	TT2JWF6
DM5WRJX	MN	Peroxisome proliferator-activated receptor delta (PPARD)
DM5WRJX	MT	DTT
DM5WRJX	MA	Agonist
DM5WRJX	RN	Emerging drugs for non-alcoholic fatty liver disease. Expert Opin Emerg Drugs. 2008 Mar;13(1):145-58.
DM5WRJX	RU	https://pubmed.ncbi.nlm.nih.gov/18321154

DM5WRJX	DI	DM5WRJX
DM5WRJX	DN	GSK-677954
DM5WRJX	MI	TTZMAO3
DM5WRJX	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DM5WRJX	MT	DTT
DM5WRJX	MA	Agonist
DM5WRJX	RN	Emerging drugs for non-alcoholic fatty liver disease. Expert Opin Emerg Drugs. 2008 Mar;13(1):145-58.
DM5WRJX	RU	https://pubmed.ncbi.nlm.nih.gov/18321154

DMJ0ZB6	DI	DMJ0ZB6
DMJ0ZB6	DN	GSK-732461
DMJ0ZB6	MI	TTFGZB6
DMJ0ZB6	MN	Human immunodeficiency virus GAG protein (HIV gag)
DMJ0ZB6	MT	DTT
DMJ0ZB6	RN	Preventive technologies, research toward a cure, and immune-based and gene therapies. HIV Treatment Bulletin. 30 June 2013.
DMJ0ZB6	RU	http://i-base.info/htb/21502

DMJ0ZB6	DI	DMJ0ZB6
DMJ0ZB6	DN	GSK-732461
DMJ0ZB6	MI	TT4NXYM
DMJ0ZB6	MN	Human immunodeficiency virus Negative factor (HIV nef)
DMJ0ZB6	MT	DTT
DMJ0ZB6	RN	Preventive technologies, research toward a cure, and immune-based and gene therapies. HIV Treatment Bulletin. 30 June 2013.
DMJ0ZB6	RU	http://i-base.info/htb/21502

DMRNJPY	DI	DMRNJPY
DMRNJPY	DN	GSK835726
DMRNJPY	MI	TTTIBOJ
DMRNJPY	MN	Histamine H1 receptor (H1R)
DMRNJPY	MT	DTT
DMRNJPY	MA	Antagonist
DMRNJPY	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMRNJPY	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMRNJPY	DI	DMRNJPY
DMRNJPY	DN	GSK835726
DMRNJPY	MI	TT9JNIC
DMRNJPY	MN	Histamine H3 receptor (H3R)
DMRNJPY	MT	DTT
DMRNJPY	MA	Antagonist
DMRNJPY	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMRNJPY	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DM8J30W	DI	DM8J30W
DM8J30W	DN	GSK870086
DM8J30W	MI	TTYRL6O
DM8J30W	MN	Glucocorticoid receptor (NR3C1)
DM8J30W	MT	DTT
DM8J30W	MA	Modulator
DM8J30W	RN	CN patent application no. 102388025, Pyrimidopyridazine derivatives useful as p38 mapk inhibitors.
DM8J30W	RU	http://www.google.com/patents/CN102388025A?cl=en

DMLFCNY	DI	DMLFCNY
DMLFCNY	DN	GT-389255
DMLFCNY	MI	TT3GKN5
DMLFCNY	MN	Lipase unspecific (LIP)
DMLFCNY	MT	DTT
DMLFCNY	MA	Inhibitor
DMLFCNY	RN	Obesity drugs in clinical development. Curr Opin Investig Drugs. 2006 Apr;7(4):312-8.
DMLFCNY	RU	https://pubmed.ncbi.nlm.nih.gov/16625817

DMZD023	DI	DMZD023
DMZD023	DN	GV-150013
DMZD023	MI	TTVFO0U
DMZD023	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMZD023	MT	DTT
DMZD023	MA	Antagonist
DMZD023	RN	The role of cholecystokinin (CCK), CCK-A or CCK-B receptor antagonists in the spontaneous preference for drugs of abuse (alcohol or cocaine) in naive rats. Methods Find Exp Clin Pharmacol. 1998 Oct;20(8):679-97.
DMZD023	RU	https://pubmed.ncbi.nlm.nih.gov/9922984

DMFN21T	DI	DMFN21T
DMFN21T	DN	GV-196771
DMFN21T	MI	TTZ8EM9
DMFN21T	MN	Glycine receptor (GlyR)
DMFN21T	MT	DTT
DMFN21T	MA	Modulator
DMFN21T	RN	First time in human for GV196771: interspecies scaling applied on dose selection. J Clin Pharmacol. 1999 Jun;39(6):560-6.
DMFN21T	RU	https://pubmed.ncbi.nlm.nih.gov/10354959

DMQ92WF	DI	DMQ92WF
DMQ92WF	DN	GW 468816
DMQ92WF	MI	TTZ8EM9
DMQ92WF	MN	Glycine receptor (GlyR)
DMQ92WF	MT	DTT
DMQ92WF	MA	Modulator
DMQ92WF	RN	A double-blind, placebo-controlled trial of the NMDA glycine site antagonist, GW468816, for prevention of relapse to smoking in females.J Clin Psychopharmacol.2011 Oct;31(5):597-602.
DMQ92WF	RU	https://www.ncbi.nlm.nih.gov/pubmed/21869693

DMOIL29	DI	DMOIL29
DMOIL29	DN	GW-275919
DMOIL29	MI	TTS64P2
DMOIL29	MN	Androgen receptor (AR)
DMOIL29	MT	DTT
DMOIL29	MA	Modulator
DMOIL29	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010426)
DMOIL29	RU	http://adisinsight.springer.com/drugs/800010426

DMZ2OBD	DI	DMZ2OBD
DMZ2OBD	DN	GW-493838
DMZ2OBD	MI	TTK25J1
DMZ2OBD	MN	Adenosine A1 receptor (ADORA1)
DMZ2OBD	MT	DTT
DMZ2OBD	MA	Modulator
DMZ2OBD	RN	A1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Investig Drugs. 2008 Dec;17(12):1901-10.
DMZ2OBD	RU	https://pubmed.ncbi.nlm.nih.gov/19012505

DM1FIN9	DI	DM1FIN9
DM1FIN9	DN	GW-559090
DM1FIN9	MI	TTHIZP9
DM1FIN9	MN	Integrin alpha-5 (ITGA5)
DM1FIN9	MT	DTT
DM1FIN9	MA	Antagonist
DM1FIN9	RN	Roles of integrin activation in eosinophil function and the eosinophilic inflammation of asthma. J Leukoc Biol. 2008 January; 83(1): 1-12.
DM1FIN9	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2859217/

DMKC0J5	DI	DMKC0J5
DMKC0J5	DN	GW-766994
DMKC0J5	MI	TTRQJTC
DMKC0J5	MN	C-X-C chemokine receptor type 7 (ACKR3)
DMKC0J5	MT	DTT
DMKC0J5	MA	Antagonist
DMKC0J5	RN	Safety and efficacy of an oral CCR3 antagonist in patients with asthma and eosinophilic bronchitis: a randomized, placebo-controlled clinical trial. Clin Exp Allergy. 2014 Apr;44(4):508-16.
DMKC0J5	RU	https://pubmed.ncbi.nlm.nih.gov/24286456

DMKC0J5	DI	DMKC0J5
DMKC0J5	DN	GW-766994
DMKC0J5	MI	DE4LYSA
DMKC0J5	MN	Cytochrome P450 3A4 (CYP3A4)
DMKC0J5	MT	DME
DMKC0J5	MA	Metabolism
DMKC0J5	RN	GW766994 CCR3 receptor antagonist.
DMKC0J5	RU	https://mrc.ukri.org/funding/browse/mrc-industry-asset-sharing-initiative-2016/compounds-list-2016/ccr3-receptor-antagonist/

DMLC154	DI	DMLC154
DMLC154	DN	GW842470X
DMLC154	MI	TTV5CGO
DMLC154	MN	Phosphodiesterase 4 (PDE4)
DMLC154	MT	DTT
DMLC154	MA	Inhibitor
DMLC154	RN	Emerging drugs for atopic dermatitis. Expert Opin Emerg Drugs. 2009 Mar;14(1):165-79.
DMLC154	RU	https://pubmed.ncbi.nlm.nih.gov/19216704

DMAXRBI	DI	DMAXRBI
DMAXRBI	DN	GW876008
DMAXRBI	MI	TT7EFHR
DMAXRBI	MN	Corticotropin-releasing factor receptor 1 (CRHR1)
DMAXRBI	MT	DTT
DMAXRBI	MA	Antagonist
DMAXRBI	RN	Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
DMAXRBI	RU	https://pubmed.ncbi.nlm.nih.gov/18172433

DMMZQVS	DI	DMMZQVS
DMMZQVS	DN	GYKI-16084
DMMZQVS	MI	TT34BHT
DMMZQVS	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMMZQVS	MT	DTT
DMMZQVS	MA	Antagonist
DMMZQVS	RN	A novel approach to the treatment of benign prostatic hyperplasia. BJU Int. 2006 Jun;97(6):1252-5.
DMMZQVS	RU	https://pubmed.ncbi.nlm.nih.gov/16686721

DMMZQVS	DI	DMMZQVS
DMMZQVS	DN	GYKI-16084
DMMZQVS	MI	TT2NUT5
DMMZQVS	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMMZQVS	MT	DTT
DMMZQVS	MA	Antagonist
DMMZQVS	RN	A novel approach to the treatment of benign prostatic hyperplasia. BJU Int. 2006 Jun;97(6):1252-5.
DMMZQVS	RU	https://pubmed.ncbi.nlm.nih.gov/16686721

DMYJ9CF	DI	DMYJ9CF
DMYJ9CF	DN	H-409/22
DMYJ9CF	MI	TTRK9JT
DMYJ9CF	MN	Neuropeptide Y receptor type 1 (NPY1R)
DMYJ9CF	MT	DTT
DMYJ9CF	MA	Antagonist
DMYJ9CF	RN	In vivo characterization of the novel neuropeptide Y Y1 receptor antagonist H 409/22. J Cardiovasc Pharmacol. 2000 Oct;36(4):516-25.
DMYJ9CF	RU	https://pubmed.ncbi.nlm.nih.gov/11026655

DMPQSE4	DI	DMPQSE4
DMPQSE4	DN	HCV-796
DMPQSE4	MI	TTMVBWH
DMPQSE4	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMPQSE4	MT	DTT
DMPQSE4	MA	Inhibitor
DMPQSE4	RN	Emerging drugs for hepatitis C. Expert Opin Emerg Drugs. 2008 Mar;13(1):1-19.
DMPQSE4	RU	https://pubmed.ncbi.nlm.nih.gov/18321145

DMWH4CY	DI	DMWH4CY
DMWH4CY	DN	HE-2000
DMWH4CY	MI	TTS64P2
DMWH4CY	MN	Androgen receptor (AR)
DMWH4CY	MT	DTT
DMWH4CY	MA	Inhibitor
DMWH4CY	RN	Dehydroepiandrosterone upregulates neural androgen receptor level and transcriptional activity. J Neurobiol. 2003 Nov;57(2):163-71.
DMWH4CY	RU	https://pubmed.ncbi.nlm.nih.gov/14556282

DM5JZW2	DI	DM5JZW2
DM5JZW2	DN	Her-2-Bi-armed ATC
DM5JZW2	MI	TT6EO5L
DM5JZW2	MN	Erbb2 tyrosine kinase receptor (HER2)
DM5JZW2	MT	DTT
DM5JZW2	RN	Cancer therapy with bispecific antibodies: Clinical experience. Curr Opin Mol Ther. 2010 June; 12(3): 340-349.
DM5JZW2	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3785321/

DMIJSB3	DI	DMIJSB3
DMIJSB3	DN	HMR-1426
DMIJSB3	MI	TT63CB1
DMIJSB3	MN	Food intake (FI)
DMIJSB3	MT	DTT
DMIJSB3	MA	Modulator
DMIJSB3	RN	Analysis of the anorectic efficacy of HMR1426 in rodents and its effects on gastric emptying in rats. Int J Obes Relat Metab Disord. 2004 Feb;28(2):211-21.
DMIJSB3	RU	https://pubmed.ncbi.nlm.nih.gov/14663491

DMYJ1ZB	DI	DMYJ1ZB
DMYJ1ZB	DN	HN-10200
DMYJ1ZB	MI	TTUST1O
DMYJ1ZB	MN	Phosphodiesterase (PDE)
DMYJ1ZB	MT	DTT
DMYJ1ZB	MA	Inhibitor
DMYJ1ZB	RN	HN-10200 causes endothelium-independent relaxations in isolated canine arteries. Cardiovasc Drugs Ther. 1992 Apr;6(2):159-65.
DMYJ1ZB	RU	https://pubmed.ncbi.nlm.nih.gov/1382554

DMUMGCY	DI	DMUMGCY
DMUMGCY	DN	HP-290
DMUMGCY	MI	TT1RS9F
DMUMGCY	MN	Acetylcholinesterase (AChE)
DMUMGCY	MT	DTT
DMUMGCY	MA	Inhibitor
DMUMGCY	RN	NXX-066 in patients with Alzheimer's disease: a bridging study. Life Sci. 1999;64(14):1215-21.
DMUMGCY	RU	https://pubmed.ncbi.nlm.nih.gov/10210264

DM51GZS	DI	DM51GZS
DM51GZS	DN	HR325
DM51GZS	MI	TTLVP78
DM51GZS	MN	Dihydroorotate dehydrogenase (DHODH)
DM51GZS	MT	DTT
DM51GZS	MA	Modulator
DM51GZS	RN	In vitro and in Vivo inhibition of immunoglobulin secretion by the immunosuppressive compound HR325 is reversed by exogenous uridine. Scand J Immunol. 2002 Jul;56(1):35-42.
DM51GZS	RU	https://www.ncbi.nlm.nih.gov/pubmed/12100469

DM1PJ0V	DI	DM1PJ0V
DM1PJ0V	DN	HSR-609
DM1PJ0V	MI	TTTIBOJ
DM1PJ0V	MN	Histamine H1 receptor (H1R)
DM1PJ0V	MT	DTT
DM1PJ0V	MA	Antagonist
DM1PJ0V	RN	Studies on the novel antiallergic agent HSR-609: its penetration into the central nervous system in mice and guinea pigs and its selectivity for the histamine H1-receptor. Jpn J Pharmacol. 1997 Apr;73(4):291-8.
DM1PJ0V	RU	https://pubmed.ncbi.nlm.nih.gov/9165365

DM1LVRP	DI	DM1LVRP
DM1LVRP	DN	IC-747
DM1LVRP	MI	TT48WR6
DM1LVRP	MN	Integrin alpha-L (ITGAL)
DM1LVRP	MT	DTT
DM1LVRP	MA	Antagonist
DM1LVRP	RN	HECA-452&plus; T Cells Migrate Through Superficial Vascular Plexus but Not Through Deep Vascular Plexus Endothelium. Journal of Investigative Dermatology. 04/1997; 108(3):343-8.
DM1LVRP	RU	http://www.nature.com/jid/journal/v121/n5/full/5602003a.html#tbl3

DMKUVZO	DI	DMKUVZO
DMKUVZO	DN	ICI-170809
DMKUVZO	MI	TTYSN63
DMKUVZO	MN	5-HT 2 receptor (5HT2R)
DMKUVZO	MT	DTT
DMKUVZO	MA	Modulator
DMKUVZO	RN	5-HT2 receptor blockade by ICI 170,809 does not affect the inhibitory effect of the 5-HT1A receptor ligand gepirone on neuroleptic-induced catalepsy. Braz J Med Biol Res. 1994 Oct;27(10):2437-41.
DMKUVZO	RU	https://pubmed.ncbi.nlm.nih.gov/7640635

DMY8X6Q	DI	DMY8X6Q
DMY8X6Q	DN	ICI-192605
DMY8X6Q	MI	TT2O84V
DMY8X6Q	MN	Thromboxane A2 receptor (TBXA2R)
DMY8X6Q	MT	DTT
DMY8X6Q	MA	Antagonist
DMY8X6Q	RN	The effects of thromboxane receptor blockade on platelet aggregation and digital skin blood flow in patients with secondary Raynaud's syndrome. Rheumatol Int. 1991;11(4-5):163-8.
DMY8X6Q	RU	https://pubmed.ncbi.nlm.nih.gov/1838424

DM3R8TX	DI	DM3R8TX
DM3R8TX	DN	ICI-D-8731
DM3R8TX	MI	TTGN1ZA
DM3R8TX	MN	Angiotensin II receptor (AGTR)
DM3R8TX	MT	DTT
DM3R8TX	MA	Modulator
DM3R8TX	RN	Vasomotor responses in cyclosporin A-treated rats after chronic angiotensin blockade. Hypertension. 1994 Jun;23(6 Pt 2):832-7.
DM3R8TX	RU	https://pubmed.ncbi.nlm.nih.gov/8206613

DM5WUK9	DI	DM5WUK9
DM5WUK9	DN	Icopezil maleate
DM5WUK9	MI	TT1RS9F
DM5WUK9	MN	Acetylcholinesterase (AChE)
DM5WUK9	MT	DTT
DM5WUK9	MA	Inhibitor
DM5WUK9	RN	A docking score function for estimating ligand-protein interactions: application to acetylcholinesterase inhibition. J Med Chem. 2004 Oct 21;47(22):5492-500.
DM5WUK9	RU	https://pubmed.ncbi.nlm.nih.gov/15481986

DMILUHA	DI	DMILUHA
DMILUHA	DN	IDEC-151
DMILUHA	MI	TTN2JFW
DMILUHA	MN	T-cell surface glycoprotein CD4 (CD4)
DMILUHA	MT	DTT
DMILUHA	RN	Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4. J Pharmacol Exp Ther. 2000 Apr;293(1):33-41.
DMILUHA	RU	https://pubmed.ncbi.nlm.nih.gov/10734150

DM7O0UR	DI	DM7O0UR
DM7O0UR	DN	Idrapril
DM7O0UR	MI	TTL69WB
DM7O0UR	MN	Angiotensin-converting enzyme (ACE)
DM7O0UR	MT	DTT
DM7O0UR	MA	Inhibitor
DM7O0UR	RN	Pharmacology of idrapril: a new class of angiotensin converting enzyme inhibitors. J Cardiovasc Pharmacol. 1992 Jul;20(1):139-46.
DM7O0UR	RU	https://pubmed.ncbi.nlm.nih.gov/1383623

DMRPBJW	DI	DMRPBJW
DMRPBJW	DN	IDX375
DMRPBJW	MI	TTMVBWH
DMRPBJW	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMRPBJW	MT	DTT
DMRPBJW	MA	Inhibitor
DMRPBJW	RN	Therapy with amineptine, a dopamine reuptake inhibitor, in patients with major depression. Indian J Psychiatry. 1997 Apr;39(2):147-53.
DMRPBJW	RU	https://pubmed.ncbi.nlm.nih.gov/21584062

DMOG1LX	DI	DMOG1LX
DMOG1LX	DN	IGN-101
DMOG1LX	MI	TTZ8WH4
DMOG1LX	MN	Tumor-associated calcium signal transducer 1 (EPCAM)
DMOG1LX	MT	DTT
DMOG1LX	RN	Drug evaluation: IGN-101--an anti-EpCAM murine antibody vaccine for cancer. Curr Opin Mol Ther. 2006 Aug;8(4):358-65.
DMOG1LX	RU	https://pubmed.ncbi.nlm.nih.gov/16955700

DMU4N1O	DI	DMU4N1O
DMU4N1O	DN	IGN-2098
DMU4N1O	MI	TTQHJ1K
DMU4N1O	MN	Histamine H2 receptor (H2R)
DMU4N1O	MT	DTT
DMU4N1O	MA	Antagonist
DMU4N1O	RN	Effects of IGN-2098, a new histamine H2-receptor antagonist, on gastric secretion and gastric and duodenal lesions induced in rats. Comparison with roxatidine. Nihon Yakurigaku Zasshi. 1992 Mar;99(3):167-80.
DMU4N1O	RU	https://pubmed.ncbi.nlm.nih.gov/1354631

DMQ2ULV	DI	DMQ2ULV
DMQ2ULV	DN	Imitrodast
DMQ2ULV	MI	TTKNWZ4
DMQ2ULV	MN	Thromboxane-A synthase (TBXAS1)
DMQ2ULV	MT	DTT
DMQ2ULV	MA	Inhibitor
DMQ2ULV	RN	RS-5186, a novel thromboxane synthetase inhibitor with a potent and extended duration of action. Thromb Res. 1988 Sep 1;51(5):507-20.
DMQ2ULV	RU	https://pubmed.ncbi.nlm.nih.gov/3175990

DMRHZBD	DI	DMRHZBD
DMRHZBD	DN	INCB19602
DMRHZBD	MI	TTWNV8U
DMRHZBD	MN	Nicotinic acid receptor (HCAR2)
DMRHZBD	MT	DTT
DMRHZBD	MA	Modulator
DMRHZBD	RN	DOI: 10.1038/scibx.2010.313
DMRHZBD	RU	http://www.nature.com/scibx/journal/v3/n10/full/scibx.2010.313.html

DMNRQA9	DI	DMNRQA9
DMNRQA9	DN	INCB47986
DMNRQA9	MI	TT6DM01
DMNRQA9	MN	Janus kinase 1 (JAK-1)
DMNRQA9	MT	DTT
DMNRQA9	MA	Inhibitor
DMNRQA9	RN	Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.
DMNRQA9	RU	https://pubmed.ncbi.nlm.nih.gov/24818516

DMS56UD	DI	DMS56UD
DMS56UD	DN	Indeglitazar
DMS56UD	MI	TTJ584C
DMS56UD	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMS56UD	MT	DTT
DMS56UD	MA	Agonist
DMS56UD	RN	Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent. Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):262-7.
DMS56UD	RU	https://pubmed.ncbi.nlm.nih.gov/19116277

DMS56UD	DI	DMS56UD
DMS56UD	DN	Indeglitazar
DMS56UD	MI	TT2JWF6
DMS56UD	MN	Peroxisome proliferator-activated receptor delta (PPARD)
DMS56UD	MT	DTT
DMS56UD	MA	Agonist
DMS56UD	RN	Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent. Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):262-7.
DMS56UD	RU	https://pubmed.ncbi.nlm.nih.gov/19116277

DMS56UD	DI	DMS56UD
DMS56UD	DN	Indeglitazar
DMS56UD	MI	TTZMAO3
DMS56UD	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMS56UD	MT	DTT
DMS56UD	MA	Agonist
DMS56UD	RN	Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent. Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):262-7.
DMS56UD	RU	https://pubmed.ncbi.nlm.nih.gov/19116277

DMJM38Q	DI	DMJM38Q
DMJM38Q	DN	INGN-234
DMJM38Q	MI	TT7SBF5
DMJM38Q	MN	Cellular tumor antigen p53 (TP53)
DMJM38Q	MT	DTT
DMJM38Q	MA	Suppressor
DMJM38Q	RN	Prevent Oral Cancer With Mouthwash. Introgen Therapeutics.
DMJM38Q	RU	http://www.medgadget.com/2005/11/prevent_oral_ca.html

DM6HDO3	DI	DM6HDO3
DM6HDO3	DN	INOGATRAN
DM6HDO3	MI	TT6L509
DM6HDO3	MN	Coagulation factor IIa (F2)
DM6HDO3	MT	DTT
DM6HDO3	MA	Modulator
DM6HDO3	RN	Inogatran, a novel direct low molecular weight thrombin inhibitor, given with, but not after, tissue-plasminogen activator, improves thrombolysis. J Pharmacol Exp Ther. 1996 Jun;277(3):1276-83.
DM6HDO3	RU	https://www.ncbi.nlm.nih.gov/pubmed/8667188

DMSATO0	DI	DMSATO0
DMSATO0	DN	IO-21
DMSATO0	MI	TT9GOIR
DMSATO0	MN	Streptococcus Diphtheria protein (Stre DIPP)
DMSATO0	MT	DTT
DMSATO0	MA	Modulator
DMSATO0	RN	Interplay between Longitudinal and Transverse Contrasts in Fe3O4 Nanoplates with (111) Exposed Surfaces. ACS Nano. 2014 August 26; 8(8): 7976-7985.
DMSATO0	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4568839/

DM4WJDK	DI	DM4WJDK
DM4WJDK	DN	IPENOXAZONE
DM4WJDK	MI	TTAN6JD
DM4WJDK	MN	Glutamate receptor AMPA (GRIA)
DM4WJDK	MT	DTT
DM4WJDK	MA	Modulator
DM4WJDK	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DM4WJDK	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMLQWFA	DI	DMLQWFA
DMLQWFA	DN	IS-159
DMLQWFA	MI	TTK8CXU
DMLQWFA	MN	5-HT 1B receptor (HTR1B)
DMLQWFA	MT	DTT
DMLQWFA	MA	Modulator
DMLQWFA	RN	Pronounced effect of caprylocaproyl macrogolglycerides on nasal absorption of IS-159, a peptide serotonin 1B/1D-receptor agonist. Clin Pharmacol Ther. 2000 Aug;68(2):114-21.
DMLQWFA	RU	https://www.ncbi.nlm.nih.gov/pubmed/10976542

DMLQWFA	DI	DMLQWFA
DMLQWFA	DN	IS-159
DMLQWFA	MI	TT6MSOK
DMLQWFA	MN	5-HT 1D receptor (HTR1D)
DMLQWFA	MT	DTT
DMLQWFA	MA	Modulator
DMLQWFA	RN	Pronounced effect of caprylocaproyl macrogolglycerides on nasal absorption of IS-159, a peptide serotonin 1B/1D-receptor agonist. Clin Pharmacol Ther. 2000 Aug;68(2):114-21.
DMLQWFA	RU	https://www.ncbi.nlm.nih.gov/pubmed/10976542

DMURWPH	DI	DMURWPH
DMURWPH	DN	ISIS 104838
DMURWPH	MI	TTC97NF
DMURWPH	MN	TNFA messenger RNA (TNF mRNA)
DMURWPH	MT	DTT
DMURWPH	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DMURWPH	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DMGZV7U	DI	DMGZV7U
DMGZV7U	DN	ISIS 14803
DMGZV7U	MI	TTXWCK2
DMGZV7U	MN	Hepatitis C virus Internal ribosome entry site messenger RNA (HCV IRES mRNA)
DMGZV7U	MT	DTT
DMGZV7U	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DMGZV7U	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DMR2STB	DI	DMR2STB
DMR2STB	DN	ISIS 2105
DMR2STB	MI	TTXQPKC
DMR2STB	MN	Human papillomavirus E2 transactivator messenger RNA (HPV E2 mRNA)
DMR2STB	MT	DTT
DMR2STB	RN	US patent application no. 5,665,580, Antisense oligonucleotide inhibition of papillomavirus transformed cells.
DMR2STB	RU	http://www.patentbuddy.com/Patent/5665580?ft=true&sr=true

DMEMKIS	DI	DMEMKIS
DMEMKIS	DN	ISIS 2503
DMEMKIS	MI	TT28ZON
DMEMKIS	MN	H-ras messenger RNA (HRAS mRNA)
DMEMKIS	MT	DTT
DMEMKIS	RN	A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. Clin Cancer Res. 2003 Jan;9(1):115-23.
DMEMKIS	RU	https://pubmed.ncbi.nlm.nih.gov/12538459

DMZFS69	DI	DMZFS69
DMZFS69	DN	ISIS 3521
DMZFS69	MI	TTFJ8Q1
DMZFS69	MN	Protein kinase C alpha (PRKCA)
DMZFS69	MT	DTT
DMZFS69	MA	Modulator
DMZFS69	RN	Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer.Lung Cancer.2006 May;52(2):173-80.
DMZFS69	RU	https://www.ncbi.nlm.nih.gov/pubmed/16507327

DMKY2UE	DI	DMKY2UE
DMKY2UE	DN	Ispronicline
DMKY2UE	MI	TTL1ATN
DMKY2UE	MN	Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2)
DMKY2UE	MT	DTT
DMKY2UE	MA	Modulator
DMKY2UE	RN	Ispronicline: a novel alpha4beta2 nicotinic acetylcholine receptor-selective agonist with cognition-enhancing and neuroprotective properties. J Mol Neurosci. 2006;30(1-2):19-20.
DMKY2UE	RU	https://www.ncbi.nlm.nih.gov/pubmed/17192610

DMWN09H	DI	DMWN09H
DMWN09H	DN	Istaroxime
DMWN09H	MI	TTQ38E9
DMWN09H	MN	Sodium/potassium-transporting ATPase (SPT ATPase)
DMWN09H	MT	DTT
DMWN09H	MA	Inhibitor
DMWN09H	RN	Novel analogues of istaroxime, a potent inhibitor of Na+,K+-ATPase: synthesis and structure-activity relationship. J Med Chem. 2008 Aug 14;51(15):4601-8.
DMWN09H	RU	https://pubmed.ncbi.nlm.nih.gov/18637667

DM4TE8R	DI	DM4TE8R
DM4TE8R	DN	IX207-887
DM4TE8R	MI	TTPM6HI
DM4TE8R	MN	Interleukin-1 alpha (IL1A)
DM4TE8R	MT	DTT
DM4TE8R	MA	Modulator
DM4TE8R	RN	Inhibition of interleukin-1 release by IX 207-887. Agents Actions. 1990 Jun;30(3-4):350-62.
DM4TE8R	RU	https://pubmed.ncbi.nlm.nih.gov/2386108

DM5E6MK	DI	DM5E6MK
DM5E6MK	DN	J-104132
DM5E6MK	MI	TTKRD0G
DM5E6MK	MN	Endothelin A receptor (EDNRA)
DM5E6MK	MT	DTT
DM5E6MK	MA	Modulator
DM5E6MK	RN	Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ETA/ETB endothelin receptor antagonist. J Pharmacol Exp Ther. 1999 Jun;289(3):1262-70.
DM5E6MK	RU	https://pubmed.ncbi.nlm.nih.gov/10336515

DM5E6MK	DI	DM5E6MK
DM5E6MK	DN	J-104132
DM5E6MK	MI	TT3ZTGU
DM5E6MK	MN	Endothelin B receptor (EDNRB)
DM5E6MK	MT	DTT
DM5E6MK	MA	Modulator
DM5E6MK	RN	Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ETA/ETB endothelin receptor antagonist. J Pharmacol Exp Ther. 1999 Jun;289(3):1262-70.
DM5E6MK	RU	https://pubmed.ncbi.nlm.nih.gov/10336515

DMV3UN4	DI	DMV3UN4
DMV3UN4	DN	JTC-801
DMV3UN4	MI	TTNT7K8
DMV3UN4	MN	Nociceptin receptor (OPRL1)
DMV3UN4	MT	DTT
DMV3UN4	MA	Antagonist
DMV3UN4	RN	Nociceptin receptor antagonist JTC-801 inhibits nitrous oxide-induced analgesia in mice. J Anesth. 2009;23(2):301-3.
DMV3UN4	RU	https://pubmed.ncbi.nlm.nih.gov/19444578

DM1BQFY	DI	DM1BQFY
DM1BQFY	DN	JTE-607
DM1BQFY	MI	TTXM6JN
DM1BQFY	MN	Cytokine receptor unspecific (CRF)
DM1BQFY	MT	DTT
DM1BQFY	MA	Inhibitor
DM1BQFY	RN	JTE-607, a novel inflammatory cytokine synthesis inhibitor without immunosuppression, protects from endotoxin shock in mice. Inflamm Res. 1999 Aug;48(8):461-8.
DM1BQFY	RU	https://pubmed.ncbi.nlm.nih.gov/10493164

DMQRKH4	DI	DMQRKH4
DMQRKH4	DN	JTH-601
DMQRKH4	MI	TT34BHT
DMQRKH4	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMQRKH4	MT	DTT
DMQRKH4	MA	Antagonist
DMQRKH4	RN	Effect of JTH-601, a novel alpha(1)-adrenoceptor antagonist, on prostate function in dogs. Eur J Pharmacol. 2000 Apr 7;394(1):123-30.
DMQRKH4	RU	https://pubmed.ncbi.nlm.nih.gov/10771044

DMQRKH4	DI	DMQRKH4
DMQRKH4	DN	JTH-601
DMQRKH4	MI	TT2NUT5
DMQRKH4	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMQRKH4	MT	DTT
DMQRKH4	MA	Antagonist
DMQRKH4	RN	Effect of JTH-601, a novel alpha(1)-adrenoceptor antagonist, on prostate function in dogs. Eur J Pharmacol. 2000 Apr 7;394(1):123-30.
DMQRKH4	RU	https://pubmed.ncbi.nlm.nih.gov/10771044

DMB0V5Y	DI	DMB0V5Y
DMB0V5Y	DN	JTK-003
DMB0V5Y	MI	TT79JGK
DMB0V5Y	MN	Mycobacterium RNA polymerase (MycB RNAP)
DMB0V5Y	MT	DTT
DMB0V5Y	MA	Inhibitor
DMB0V5Y	RN	Antiviral Therapy for Hepatitis C Virus: Beyond the Standard of Care. Viruses. 2010 April; 2(4): 826-866.
DMB0V5Y	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185663/

DM29C6S	DI	DM29C6S
DM29C6S	DN	JTP-2942
DM29C6S	MI	TT4J8MF
DM29C6S	MN	Thyrotropin-releasing hormone receptor (TRHR)
DM29C6S	MT	DTT
DM29C6S	MA	Modulator
DM29C6S	RN	Effect of JTP-2942, a novel thyrotropin-releasing hormone analogue, on pentobarbital-induced anesthesia in rats. Eur J Pharmacol. 1995 Mar 24;276(1-2):177-82.
DM29C6S	RU	https://pubmed.ncbi.nlm.nih.gov/7781687

DMI0UJS	DI	DMI0UJS
DMI0UJS	DN	JTP-4819
DMI0UJS	MI	TTNGKET
DMI0UJS	MN	Prolyl endopeptidase (PREP)
DMI0UJS	MT	DTT
DMI0UJS	MA	Modulator
DMI0UJS	RN	A novel prolyl endopeptidase inhibitor, JTP-4819, with potential for treating Alzheimer's disease. Behav Brain Res. 1997 Feb;83(1-2):147-51.
DMI0UJS	RU	https://pubmed.ncbi.nlm.nih.gov/9062674

DM35CQ4	DI	DM35CQ4
DM35CQ4	DN	JTS-653
DM35CQ4	MI	TTMI6F5
DM35CQ4	MN	Transient receptor potential cation channel V1 (TRPV1)
DM35CQ4	MT	DTT
DM35CQ4	MA	Antagonist
DM35CQ4	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 507).
DM35CQ4	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=507

DMJ1ZTB	DI	DMJ1ZTB
DMJ1ZTB	DN	JTT-811
DMJ1ZTB	MI	TTFBNVI
DMJ1ZTB	MN	Aldose reductase (AKR1B1)
DMJ1ZTB	MT	DTT
DMJ1ZTB	MA	Inhibitor
DMJ1ZTB	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2768).
DMJ1ZTB	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2768

DMM8UNL	DI	DMM8UNL
DMM8UNL	DN	JTV-506
DMM8UNL	MI	TT1VOHK
DMM8UNL	MN	Potassium channel unspecific (KC)
DMM8UNL	MT	DTT
DMM8UNL	MA	Opener
DMM8UNL	RN	Effects of the new potassium channel opener JTV-506 on coronary vessels in vitro and in vivo. Arzneimittelforschung. 1999 Mar;49(3):199-206.
DMM8UNL	RU	https://pubmed.ncbi.nlm.nih.gov/10219462

DM7IP8U	DI	DM7IP8U
DM7IP8U	DN	KB-5492
DM7IP8U	MI	TT5TPI6
DM7IP8U	MN	Opioid receptor sigma 1 (OPRS1)
DM7IP8U	MT	DTT
DM7IP8U	MA	Antagonist
DM7IP8U	RN	Sigma receptor-mediated effects of a new antiulcer agent, KB-5492, on experimental gastric mucosal lesions and gastric alkaline secretion in rats. J Pharmacol Exp Ther. 1994 May;269(2):799-805.
DM7IP8U	RU	https://pubmed.ncbi.nlm.nih.gov/8182548

DMOITN2	DI	DMOITN2
DMOITN2	DN	KC-11458
DMOITN2	MI	TT953CX
DMOITN2	MN	Motilin receptor (MLNR)
DMOITN2	MT	DTT
DMOITN2	MA	Modulator
DMOITN2	RN	Effect of the motilin agonist KC 11458 on gastric emptying in diabetic gastroparesis. Aliment Pharmacol Ther. 2004 Aug 1;20(3):333-8.
DMOITN2	RU	https://pubmed.ncbi.nlm.nih.gov/15274670

DMBX6C7	DI	DMBX6C7
DMBX6C7	DN	KC706
DMBX6C7	MI	TTYT93M
DMBX6C7	MN	MAP kinase p38 (MAPK12)
DMBX6C7	MT	DTT
DMBX6C7	MA	Inhibitor
DMBX6C7	RN	KC706, an Oral p38 MAP Kinase Inhibitor, Increases HDL-C. Circulation. 2007;116:II_126.
DMBX6C7	RU	http://circ.ahajournals.org/cgi/content/meeting_abstract/116/16_MeetingAbstracts/II_126-c

DMC30N4	DI	DMC30N4
DMC30N4	DN	KCO-912
DMC30N4	MI	TT1VOHK
DMC30N4	MN	Potassium channel unspecific (KC)
DMC30N4	MT	DTT
DMC30N4	MA	Agonist
DMC30N4	RN	KCO912: a potent and selective opener of ATP-dependent potassium (K(ATP)) channels which suppresses airways hyperreactivity at doses devoid of card... Naunyn Schmiedebergs Arch Pharmacol. 2002 Mar;365(3):220-30.
DMC30N4	RU	https://pubmed.ncbi.nlm.nih.gov/11882918

DMX9M53	DI	DMX9M53
DMX9M53	DN	KDS-2000
DMX9M53	MI	TT6OEDT
DMX9M53	MN	Cannabinoid receptor 1 (CB1)
DMX9M53	MT	DTT
DMX9M53	MA	Agonist
DMX9M53	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DMX9M53	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DMN4BIA	DI	DMN4BIA
DMN4BIA	DN	KN-38-7271
DMN4BIA	MI	TT6OEDT
DMN4BIA	MN	Cannabinoid receptor 1 (CB1)
DMN4BIA	MT	DTT
DMN4BIA	MA	Modulator
DMN4BIA	RN	BAY 38-7271: a novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury.CNS Drug Rev.2003 Winter;9(4):343-58.
DMN4BIA	RU	https://www.ncbi.nlm.nih.gov/pubmed/14647528

DMN4BIA	DI	DMN4BIA
DMN4BIA	DN	KN-38-7271
DMN4BIA	MI	TTMSFAW
DMN4BIA	MN	Cannabinoid receptor 2 (CB2)
DMN4BIA	MT	DTT
DMN4BIA	MA	Modulator
DMN4BIA	RN	BAY 38-7271: a novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury.CNS Drug Rev.2003 Winter;9(4):343-58.
DMN4BIA	RU	https://www.ncbi.nlm.nih.gov/pubmed/14647528

DMM1SLF	DI	DMM1SLF
DMM1SLF	DN	KP-736
DMM1SLF	MI	TTJP4SM
DMM1SLF	MN	Bacterial Penicillin binding protein (Bact PBP)
DMM1SLF	MT	DTT
DMM1SLF	MA	Modulator
DMM1SLF	RN	In vitro antibacterial activity of KP-736, a new cephem antibiotic. Antimicrob Agents Chemother. 1991 Jan;35(1):104-10.
DMM1SLF	RU	https://pubmed.ncbi.nlm.nih.gov/2014964

DMIJ6FX	DI	DMIJ6FX
DMIJ6FX	DN	KRH-594
DMIJ6FX	MI	TT8DBY3
DMIJ6FX	MN	Angiotensin II receptor type-1 (AGTR1)
DMIJ6FX	MT	DTT
DMIJ6FX	MA	Antagonist
DMIJ6FX	RN	Binding of KRH-594, an antagonist of the angiotensin II type 1 receptor, to cloned human and rat angiotensin II receptors. Fundam Clin Pharmacol. 2002 Aug;16(4):317-23.
DMIJ6FX	RU	https://pubmed.ncbi.nlm.nih.gov/12570021

DMZ1SEW	DI	DMZ1SEW
DMZ1SEW	DN	KRN-2391
DMZ1SEW	MI	TTEF5MJ
DMZ1SEW	MN	ATP-binding cassette transporter C9 (ABCC9)
DMZ1SEW	MT	DTT
DMZ1SEW	MA	Modulator
DMZ1SEW	RN	Effects of KRN2391 on ionic currents in rabbit femoral arterial myocytes
DMZ1SEW	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1572643

DMBU9O4	DI	DMBU9O4
DMBU9O4	DN	KRP-101
DMBU9O4	MI	TTJ584C
DMBU9O4	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMBU9O4	MT	DTT
DMBU9O4	MA	Agonist
DMBU9O4	RN	Identification of a functional peroxisome proliferator-activated receptor (PPAR) response element (PPRE) in the human apolipoprotein A-IV gene. Biochem Pharmacol. 2009 Sep 1;78(5):523-30.
DMBU9O4	RU	https://pubmed.ncbi.nlm.nih.gov/19433068

DM9VHZC	DI	DM9VHZC
DM9VHZC	DN	KRP-297
DM9VHZC	MI	TTJ584C
DM9VHZC	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DM9VHZC	MT	DTT
DM9VHZC	MA	Modulator
DM9VHZC	RN	KRP-297, MCC-555. Nihon Rinsho. 2001 Nov;59(11):2200-6.
DM9VHZC	RU	https://pubmed.ncbi.nlm.nih.gov/11712408

DM9VHZC	DI	DM9VHZC
DM9VHZC	DN	KRP-297
DM9VHZC	MI	TTZMAO3
DM9VHZC	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DM9VHZC	MT	DTT
DM9VHZC	MA	Modulator
DM9VHZC	RN	KRP-297, MCC-555. Nihon Rinsho. 2001 Nov;59(11):2200-6.
DM9VHZC	RU	https://pubmed.ncbi.nlm.nih.gov/11712408

DM5YHJ2	DI	DM5YHJ2
DM5YHJ2	DN	KW-2170
DM5YHJ2	MI	TT0IHXV
DM5YHJ2	MN	DNA topoisomerase II (TOP2)
DM5YHJ2	MT	DTT
DM5YHJ2	MA	Modulator
DM5YHJ2	RN	KW-2170 (Kyowa Hakko Kogyo). IDrugs. 2002 Oct;5(10):1000-3.
DM5YHJ2	RU	https://pubmed.ncbi.nlm.nih.gov/12800063

DMSWDKX	DI	DMSWDKX
DMSWDKX	DN	KW-4490
DMSWDKX	MI	TTZ97H5
DMSWDKX	MN	Phosphodiesterase 4A (PDE4A)
DMSWDKX	MT	DTT
DMSWDKX	MA	Inhibitor
DMSWDKX	RN	Pharmacokinetics and metabolism of KW-4490, a selective phosphodiesterase 4 inhibitor: difference in excretion of KW-4490 and acylglucuronide metabolites between rats and cynomolgus monkeys. Xenobiotica. 2008 May;38(5):511-26.
DMSWDKX	RU	https://pubmed.ncbi.nlm.nih.gov/18421624

DMSWDKX	DI	DMSWDKX
DMSWDKX	DN	KW-4490
DMSWDKX	MI	TTVIAT9
DMSWDKX	MN	Phosphodiesterase 4B (PDE4B)
DMSWDKX	MT	DTT
DMSWDKX	MA	Inhibitor
DMSWDKX	RN	Pharmacokinetics and metabolism of KW-4490, a selective phosphodiesterase 4 inhibitor: difference in excretion of KW-4490 and acylglucuronide metabolites between rats and cynomolgus monkeys. Xenobiotica. 2008 May;38(5):511-26.
DMSWDKX	RU	https://pubmed.ncbi.nlm.nih.gov/18421624

DMSWDKX	DI	DMSWDKX
DMSWDKX	DN	KW-4490
DMSWDKX	MI	TTSKMI8
DMSWDKX	MN	Phosphodiesterase 4D (PDE4D)
DMSWDKX	MT	DTT
DMSWDKX	MA	Inhibitor
DMSWDKX	RN	Pharmacokinetics and metabolism of KW-4490, a selective phosphodiesterase 4 inhibitor: difference in excretion of KW-4490 and acylglucuronide metabolites between rats and cynomolgus monkeys. Xenobiotica. 2008 May;38(5):511-26.
DMSWDKX	RU	https://pubmed.ncbi.nlm.nih.gov/18421624

DMLOKXI	DI	DMLOKXI
DMLOKXI	DN	KW-5139
DMLOKXI	MI	TT953CX
DMLOKXI	MN	Motilin receptor (MLNR)
DMLOKXI	MT	DTT
DMLOKXI	MA	Modulator
DMLOKXI	RN	Stimulating action of KW-5139 (Leu13-motilin) on gastrointestinal motility in the rabbit. Br J Pharmacol. 1994 Jan;111(1):288-94.
DMLOKXI	RU	https://pubmed.ncbi.nlm.nih.gov/8012708

DMJNSML	DI	DMJNSML
DMJNSML	DN	KW-7158
DMJNSML	MI	TT1VOHK
DMJNSML	MN	Potassium channel unspecific (KC)
DMJNSML	MT	DTT
DMJNSML	MA	Agonist
DMJNSML	RN	KW-7158 [(2S)-(+)-3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide] enhances A-type K+... J Pharmacol Exp Ther. 2004 Jul;310(1):159-68.
DMJNSML	RU	https://pubmed.ncbi.nlm.nih.gov/15010502

DMKSEIY	DI	DMKSEIY
DMKSEIY	DN	L-158282
DMKSEIY	MI	TTQVOEI
DMKSEIY	MN	Angiotensin II receptor type-2 (AGTR2)
DMKSEIY	MT	DTT
DMKSEIY	MA	Inhibitor
DMKSEIY	RN	Subtituted phenylthiophene benzoylsulfonamides with potent binding affinity to angiotensin II AT1 and AT2 receptors, Bioorg. Med. Chem. Lett. 4(1):189-194 (1994).
DMKSEIY	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01811458

DMT13ZR	DI	DMT13ZR
DMT13ZR	DN	L-365260
DMT13ZR	MI	TTVFO0U
DMT13ZR	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMT13ZR	MT	DTT
DMT13ZR	MA	Modulator
DMT13ZR	RN	Pharmacological analysis of CCK(2) receptor ligands using COS-7 and SK-N-MC cells, expressing the human CCK(2) receptor. Regul Pept. 2002 Jan 15;103(1):29-37.
DMT13ZR	RU	https://pubmed.ncbi.nlm.nih.gov/11738246

DM7JZ53	DI	DM7JZ53
DM7JZ53	DN	L-4-OXALYSINE
DM7JZ53	MI	TTNRF4L
DM7JZ53	MN	Histone synthesis (Histone synth)
DM7JZ53	MT	DTT
DM7JZ53	MA	Modulator
DM7JZ53	RN	Immunostimulatory action of L-4-oxalysine counteracts immunosuppression induced by alpha-fetoprotein. Eur J Pharmacol. 1998 Jun 12;351(1):105-11.
DM7JZ53	RU	https://pubmed.ncbi.nlm.nih.gov/9698211

DMG5VJF	DI	DMG5VJF
DMG5VJF	DN	L-660771
DMG5VJF	MI	TTGKOY9
DMG5VJF	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DMG5VJF	MT	DTT
DMG5VJF	MA	Modulator
DMG5VJF	RN	Pharmacology of the leukotriene antagonist verlukast: the (R)-enantiomer of MK-571. Can J Physiol Pharmacol. 1991 Dec;69(12):1847-54.
DMG5VJF	RU	https://www.ncbi.nlm.nih.gov/pubmed/1666333

DM54I8A	DI	DM54I8A
DM54I8A	DN	L-696229
DM54I8A	MI	TT84ETX
DM54I8A	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM54I8A	MT	DTT
DM54I8A	MA	Inhibitor
DM54I8A	RN	L-696,229 specifically inhibits human immunodeficiency virus type 1 reverse transcriptase and possesses antiviral activity in vitro.. Antimicrob Agents Chemother. 1992 May; 36(5): 1019-1023.
DM54I8A	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC188828/

DMW8NOH	DI	DMW8NOH
DMW8NOH	DN	L-771688
DMW8NOH	MI	TTNGILX
DMW8NOH	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMW8NOH	MT	DTT
DMW8NOH	MA	Inhibitor
DMW8NOH	RN	Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
DMW8NOH	RU	https://pubmed.ncbi.nlm.nih.gov/15664832

DMSFL76	DI	DMSFL76
DMSFL76	DN	Labradimil
DMSFL76	MI	TTGY8IW
DMSFL76	MN	B2 bradykinin receptor (BDKRB2)
DMSFL76	MT	DTT
DMSFL76	MA	Agonist
DMSFL76	RN	Metabolically stable bradykinin B2 receptor agonists enhance transvascular drug delivery into malignant brain tumors by increasing drug half-life. J Transl Med. 2009 May 13;7:33.
DMSFL76	RU	https://pubmed.ncbi.nlm.nih.gov/19439100

DM3YABD	DI	DM3YABD
DM3YABD	DN	LANIQUIDAR
DM3YABD	MI	TTJUXV6
DM3YABD	MN	Multidrug resistance protein 3 (ABCB4)
DM3YABD	MT	DTT
DM3YABD	MA	Modulator
DM3YABD	RN	Evaluation of [11C]laniquidar as a tracer of P-glycoprotein: radiosynthesis and biodistribution in rats. Nucl Med Biol. 2009 Aug;36(6):643-9.
DM3YABD	RU	https://pubmed.ncbi.nlm.nih.gov/19647170

DM9J6BX	DI	DM9J6BX
DM9J6BX	DN	LAS-37779
DM9J6BX	MI	TTZ97H5
DM9J6BX	MN	Phosphodiesterase 4A (PDE4A)
DM9J6BX	MT	DTT
DM9J6BX	MA	Inhibitor
DM9J6BX	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022894)
DM9J6BX	RU	http://adisinsight.springer.com/drugs/800022894

DM9J6BX	DI	DM9J6BX
DM9J6BX	DN	LAS-37779
DM9J6BX	MI	TTVIAT9
DM9J6BX	MN	Phosphodiesterase 4B (PDE4B)
DM9J6BX	MT	DTT
DM9J6BX	MA	Inhibitor
DM9J6BX	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022894)
DM9J6BX	RU	http://adisinsight.springer.com/drugs/800022894

DM9J6BX	DI	DM9J6BX
DM9J6BX	DN	LAS-37779
DM9J6BX	MI	TTSKMI8
DM9J6BX	MN	Phosphodiesterase 4D (PDE4D)
DM9J6BX	MT	DTT
DM9J6BX	MA	Inhibitor
DM9J6BX	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022894)
DM9J6BX	RU	http://adisinsight.springer.com/drugs/800022894

DMTY5VE	DI	DMTY5VE
DMTY5VE	DN	Lavoltidine
DMTY5VE	MI	TTQHJ1K
DMTY5VE	MN	Histamine H2 receptor (H2R)
DMTY5VE	MT	DTT
DMTY5VE	MA	Antagonist
DMTY5VE	RN	New and Future Drug Development for Gastroesophageal Reflux Disease. J Neurogastroenterol Motil. 2014 January; 20(1): 6-16.
DMTY5VE	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895610/

DMGQJ2U	DI	DMGQJ2U
DMGQJ2U	DN	LESOPITRON DIHYDROCHLORIDE
DMGQJ2U	MI	TTSQIFT
DMGQJ2U	MN	5-HT 1A receptor (HTR1A)
DMGQJ2U	MT	DTT
DMGQJ2U	MA	Agonist
DMGQJ2U	RN	Effect of acute administration of the 5-HT1A receptor ligand, lesopitron, on rat cortical 5-HT and dopamine turnover. Br J Pharmacol. 1994 Oct;113(2):425-30.
DMGQJ2U	RU	https://pubmed.ncbi.nlm.nih.gov/7530571

DMKSY2R	DI	DMKSY2R
DMKSY2R	DN	Levosemotiadil
DMKSY2R	MI	TT5HONZ
DMKSY2R	MN	Calcium channel unspecific (CaC)
DMKSY2R	MT	DTT
DMKSY2R	MA	Modulator
DMKSY2R	RN	Binding study of semotiadil and levosemotiadil with alpha(1)-acid glycoprotein using high-performance frontal analysis. Anal Biochem. 1999 Oct 1;274(1):27-33.
DMKSY2R	RU	https://pubmed.ncbi.nlm.nih.gov/10527493

DMKSY2R	DI	DMKSY2R
DMKSY2R	DN	Levosemotiadil
DMKSY2R	MI	TTRK8B9
DMKSY2R	MN	Sodium channel unspecific (NaC)
DMKSY2R	MT	DTT
DMKSY2R	MA	Modulator
DMKSY2R	RN	Binding study of semotiadil and levosemotiadil with alpha(1)-acid glycoprotein using high-performance frontal analysis. Anal Biochem. 1999 Oct 1;274(1):27-33.
DMKSY2R	RU	https://pubmed.ncbi.nlm.nih.gov/10527493

DMJ3ZT8	DI	DMJ3ZT8
DMJ3ZT8	DN	Lexacalcitol
DMJ3ZT8	MI	TTK59TV
DMJ3ZT8	MN	Vitamin D3 receptor (VDR)
DMJ3ZT8	MT	DTT
DMJ3ZT8	MA	Agonist
DMJ3ZT8	RN	The vitamin D analog, KH1060, is rapidly degraded both in vivo and in vitro via several pathways: principal metabolites generated retain significant biological activity. Endocrinology. 1997 Dec;138(12):5485-96.
DMJ3ZT8	RU	https://pubmed.ncbi.nlm.nih.gov/9389535

DM8W31H	DI	DM8W31H
DM8W31H	DN	LG-1550
DM8W31H	MI	TTOD7B3
DM8W31H	MN	Retinoic acid receptor (RAR)
DM8W31H	MT	DTT
DM8W31H	MA	Modulator
DM8W31H	RN	US patent application no. 2005,0014,729, Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith.
DM8W31H	RU	http://www.google.com/patents/US20050014729

DM3R8TI	DI	DM3R8TI
DM3R8TI	DN	Lifarizine
DM3R8TI	MI	TT5HONZ
DM3R8TI	MN	Calcium channel unspecific (CaC)
DM3R8TI	MT	DTT
DM3R8TI	MA	Blocker
DM3R8TI	RN	The effect of lifarizine (RS-87476), a novel sodium and calcium channel modulator, on ischaemic dopamine depletion in the corpus striatum of the gerbil. Br J Pharmacol. 1993 May;109(1):175-7.
DM3R8TI	RU	https://pubmed.ncbi.nlm.nih.gov/8388296

DMF8B62	DI	DMF8B62
DMF8B62	DN	Linetastine
DMF8B62	MI	TT2J34L
DMF8B62	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMF8B62	MT	DTT
DMF8B62	MA	Inhibitor
DMF8B62	RN	Preview of potential therapeutic applications of leukotriene B4 inhibitors in dermatology. Skin Pharmacol Appl Skin Physiol. 2000 Sep-Oct;13(5):235-45.
DMF8B62	RU	https://pubmed.ncbi.nlm.nih.gov/10940813

DMF8B62	DI	DMF8B62
DMF8B62	DN	Linetastine
DMF8B62	MI	TTYPXQF
DMF8B62	MN	Protein kinase C beta (PRKCB)
DMF8B62	MT	DTT
DMF8B62	MA	Inhibitor
DMF8B62	RN	Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors. Am J Ophthalmol. 2002 May;133(5):693-8.
DMF8B62	RU	https://pubmed.ncbi.nlm.nih.gov/11992868

DM32JL5	DI	DM32JL5
DM32JL5	DN	Linotroban
DM32JL5	MI	TT2O84V
DM32JL5	MN	Thromboxane A2 receptor (TBXA2R)
DM32JL5	MT	DTT
DM32JL5	MA	Antagonist
DM32JL5	RN	Effects of the novel thromboxane (TXA2) receptor antagonist linotroban on inulin and para-aminohippuric acid clearances in the conscious male and female rat. Arzneimittelforschung. 1997 Sep;47(9):1026-30.
DM32JL5	RU	https://pubmed.ncbi.nlm.nih.gov/9342416

DMS5X94	DI	DMS5X94
DMS5X94	DN	Lintitript
DMS5X94	MI	TTCG0AL
DMS5X94	MN	Cholecystokinin receptor type A (CCKAR)
DMS5X94	MT	DTT
DMS5X94	MA	Antagonist
DMS5X94	RN	A cholecystokinin-1 receptor agonist (CCK-8) mediates increased permeability of brain barriers to leptin. Br J Pharmacol. 2008 Jul;154(5):1009-15.
DMS5X94	RU	https://pubmed.ncbi.nlm.nih.gov/18587446

DMD39G4	DI	DMD39G4
DMD39G4	DN	Lintuzumab
DMD39G4	MI	TTJVYO3
DMD39G4	MN	Myeloid cell surface antigen CD33 (CD33)
DMD39G4	MT	DTT
DMD39G4	RN	Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol. 2005 Jun 20;23(18):4110-6.
DMD39G4	RU	https://pubmed.ncbi.nlm.nih.gov/15961759

DM5ENKG	DI	DM5ENKG
DM5ENKG	DN	Lirequinil
DM5ENKG	MI	TTPTXIN
DM5ENKG	MN	Translocator protein (TSPO)
DM5ENKG	MT	DTT
DM5ENKG	MA	Agonist
DM5ENKG	RN	Pharmacokinetics and pharmacodynamics of Ro 41-3696, a novel nonbenzodiazepine hypnotic. J Clin Pharmacol. 1995 Aug;35(8):821-9.
DM5ENKG	RU	https://pubmed.ncbi.nlm.nih.gov/8522640

DMGZ3BF	DI	DMGZ3BF
DMGZ3BF	DN	Lodenosine
DMGZ3BF	MI	TT84ETX
DMGZ3BF	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMGZ3BF	MT	DTT
DMGZ3BF	MA	Inhibitor
DMGZ3BF	RN	2 ,3 -Dialdehyde of ATP, ADP, and adenosine inhibit HIV-1 reverse transcriptase and HIV-1 replication. Curr HIV Res. 2014;12(5):347-58.
DMGZ3BF	RU	https://pubmed.ncbi.nlm.nih.gov/25174839

DMW9MOK	DI	DMW9MOK
DMW9MOK	DN	Lomeguatrib
DMW9MOK	MI	TTX2N1T
DMW9MOK	MN	Transferase unspecific (TF)
DMW9MOK	MT	DTT
DMW9MOK	MA	Inhibitor
DMW9MOK	RN	O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas. Cell Death Dis. 2013 Oct 24;4:e876.
DMW9MOK	RU	https://pubmed.ncbi.nlm.nih.gov/24157870

DMCZI62	DI	DMCZI62
DMCZI62	DN	LORECLEZOLE
DMCZI62	MI	TTEX6LM
DMCZI62	MN	GABA(A) receptor gamma-3 (GABRG3)
DMCZI62	MT	DTT
DMCZI62	MA	Modulator
DMCZI62	RN	Direct activation of GABAA receptors by loreclezole, an anticonvulsant drug with selectivity for the beta-subunit. Neuropharmacology. 1996;35(12):1753-60.
DMCZI62	RU	https://pubmed.ncbi.nlm.nih.gov/9076754

DMM843E	DI	DMM843E
DMM843E	DN	LOSOXANTRONE
DMM843E	MI	TT0IHXV
DMM843E	MN	DNA topoisomerase II (TOP2)
DMM843E	MT	DTT
DMM843E	MA	Modulator
DMM843E	RN	A structure-based 3D-QSAR study of anthrapyrazole analogues of the anticancer agents losoxantrone and piroxantrone. J Chem Inf Model. 2006 Jul-Aug;46(4):1827-35.
DMM843E	RU	https://www.ncbi.nlm.nih.gov/pubmed/16859314

DMD16VS	DI	DMD16VS
DMD16VS	DN	Loviride
DMD16VS	MI	TT84ETX
DMD16VS	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMD16VS	MT	DTT
DMD16VS	MA	Inhibitor
DMD16VS	RN	Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine. J Infect Dis. 2013 Jun 15;207 Suppl 2:S70-7.
DMD16VS	RU	https://pubmed.ncbi.nlm.nih.gov/23687292

DM6G0PN	DI	DM6G0PN
DM6G0PN	DN	LTB 019
DM6G0PN	MI	TTN53ZF
DM6G0PN	MN	Leukotriene B4 receptor 1 (LTB4R)
DM6G0PN	MT	DTT
DM6G0PN	MA	Antagonist
DM6G0PN	RN	Effect of the oral leukotriene B4 receptor antagonist LTB019 on inflammatory sputum markers in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2008;21(2):409-17.
DM6G0PN	RU	https://pubmed.ncbi.nlm.nih.gov/18063399

DMQ7A35	DI	DMQ7A35
DMQ7A35	DN	Lu-35138
DMQ7A35	MI	TTE0A2F
DMQ7A35	MN	Dopamine D4 receptor (D4R)
DMQ7A35	MT	DTT
DMQ7A35	MA	Antagonist
DMQ7A35	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014237)
DMQ7A35	RU	http://adisinsight.springer.com/drugs/800014237

DMYR2U3	DI	DMYR2U3
DMYR2U3	DN	Lurosetron
DMYR2U3	MI	TTNXLKE
DMYR2U3	MN	5-HT 3 receptor (5HT3R)
DMYR2U3	MT	DTT
DMYR2U3	MA	Modulator
DMYR2U3	RN	US patent application no. 7,932,267, Use of &alpha;-glucosidase inhibitors to treat alphavirus infections.
DMYR2U3	RU	http://www.google.is/Patents/US7932267

DMF1RTW	DI	DMF1RTW
DMF1RTW	DN	Lurtotecan
DMF1RTW	MI	DTI7UX6
DMF1RTW	MN	Breast cancer resistance protein (ABCG2)
DMF1RTW	MT	DTP
DMF1RTW	MA	Substrate
DMF1RTW	RN	A prediction model of substrates and non-substrates of breast cancer resistance protein (BCRP) developed by GA-CG-SVM method. Comput Biol Med. 2011 Nov;41(11):1006-13.
DMF1RTW	RU	https://doi.org/10.1016/j.compbiomed.2011.08.009

DMF1RTW	DI	DMF1RTW
DMF1RTW	DN	Lurtotecan
DMF1RTW	MI	TTGTQHC
DMF1RTW	MN	DNA topoisomerase I (TOP1)
DMF1RTW	MT	DTT
DMF1RTW	MA	Inhibitor
DMF1RTW	RN	Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia. Cancer. 2004 Apr 1;100(7):1449-58.
DMF1RTW	RU	https://pubmed.ncbi.nlm.nih.gov/15042679

DMWB7DO	DI	DMWB7DO
DMWB7DO	DN	LY-223982
DMWB7DO	MI	TTN53ZF
DMWB7DO	MN	Leukotriene B4 receptor 1 (LTB4R)
DMWB7DO	MT	DTT
DMWB7DO	MA	Modulator
DMWB7DO	RN	Specific inhibition of leukotriene B4-induced neutrophil activation by LY223982. J Pharmacol Exp Ther. 1992 Dec;263(3):1009-14.
DMWB7DO	RU	https://pubmed.ncbi.nlm.nih.gov/1335049

DMTS1X5	DI	DMTS1X5
DMTS1X5	DN	LY-2300559
DMTS1X5	MI	TTGKOY9
DMTS1X5	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DMTS1X5	MT	DTT
DMTS1X5	MA	Modulator
DMTS1X5	RN	Annual Reports in Medicinal Chemistry. Elsevier (ISBN: 9780123964922). 2012, p78
DMTS1X5	RU	https://books.google.com.hk/books?id=y7GH165YoOsC&pg=PA78&lpg=PA78&dq=LY-2300559++mGluR2&source=bl&ots=oPRCoyeFUF&sig=mBJoAwlOyt44UDkkH77x_aHKhbE&hl=zh-CN&sa=X&ved=0CBoQ6AEwAGoVChMIup7Nm-HwyAIVgRmmCh2Dpgc7#v=onepage&q=LY-2300559%20%20mGluR2&f=false

DMTS1X5	DI	DMTS1X5
DMTS1X5	DN	LY-2300559
DMTS1X5	MI	TTXJ47W
DMTS1X5	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMTS1X5	MT	DTT
DMTS1X5	MA	Modulator
DMTS1X5	RN	Annual Reports in Medicinal Chemistry. Elsevier (ISBN: 9780123964922). 2012, p78
DMTS1X5	RU	https://books.google.com.hk/books?id=y7GH165YoOsC&pg=PA78&lpg=PA78&dq=LY-2300559++mGluR2&source=bl&ots=oPRCoyeFUF&sig=mBJoAwlOyt44UDkkH77x_aHKhbE&hl=zh-CN&sa=X&ved=0CBoQ6AEwAGoVChMIup7Nm-HwyAIVgRmmCh2Dpgc7#v=onepage&q=LY-2300559%20%20mGluR2&f=false

DMGE9OA	DI	DMGE9OA
DMGE9OA	DN	LY-2523199
DMGE9OA	MI	TTN7BL9
DMGE9OA	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMGE9OA	MT	DTT
DMGE9OA	MA	Inhibitor
DMGE9OA	RN	Repurposing Diabetes Drugs for Brain Insulin Resistance in Alzheimer Disease. before print June 15, 2014.
DMGE9OA	RU	http://diabetes.diabetesjournals.org/content/63/7/2253.full

DM03FHA	DI	DM03FHA
DM03FHA	DN	LY293111
DM03FHA	MI	TTN53ZF
DM03FHA	MN	Leukotriene B4 receptor 1 (LTB4R)
DM03FHA	MT	DTT
DM03FHA	MA	Antagonist
DM03FHA	RN	The Role of PPARgamma Receptors and Leukotriene B(4) Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer. PPAR Res. 2008;2008:827096.
DM03FHA	RU	https://pubmed.ncbi.nlm.nih.gov/19190780

DMIS7DW	DI	DMIS7DW
DMIS7DW	DN	LY-307161
DMIS7DW	MI	TTVIMDE
DMIS7DW	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMIS7DW	MT	DTT
DMIS7DW	MA	Modulator
DMIS7DW	RN	Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Sep;25(7):565-97.
DMIS7DW	RU	https://pubmed.ncbi.nlm.nih.gov/14571286

DM08BIZ	DI	DM08BIZ
DM08BIZ	DN	LY354740
DM08BIZ	MI	TTXJ47W
DM08BIZ	MN	Metabotropic glutamate receptor 2 (mGluR2)
DM08BIZ	MT	DTT
DM08BIZ	MA	Agonist
DM08BIZ	RN	Characterization of [(3)H]-LY354740 binding to rat mGlu2 and mGlu3 receptors expressed in CHO cells using semliki forest virus vectors. Neuropharmacology. 2000 Jul 24;39(10):1700-6.
DM08BIZ	RU	https://pubmed.ncbi.nlm.nih.gov/10884552

DM08BIZ	DI	DM08BIZ
DM08BIZ	DN	LY354740
DM08BIZ	MI	TT8A9EF
DM08BIZ	MN	Metabotropic glutamate receptor 3 (mGluR3)
DM08BIZ	MT	DTT
DM08BIZ	MA	Agonist
DM08BIZ	RN	Mutagenesis and molecular modeling of the orthosteric binding site of the mGlu2 receptor determining interactions of the group II receptor antagonist (3)H-HYDIA. ChemMedChem. 2009 Jul;4(7):1086-94.
DM08BIZ	RU	https://pubmed.ncbi.nlm.nih.gov/19402024

DMQ1LWU	DI	DMQ1LWU
DMQ1LWU	DN	M-100240
DMQ1LWU	MI	TTL69WB
DMQ1LWU	MN	Angiotensin-converting enzyme (ACE)
DMQ1LWU	MT	DTT
DMQ1LWU	MA	Modulator
DMQ1LWU	RN	Effects of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase on the vasopressor response to exogenous angiot... J Cardiovasc Pharmacol. 1998 Mar;31(3):408-17.
DMQ1LWU	RU	https://www.ncbi.nlm.nih.gov/pubmed/9514186

DMQ1LWU	DI	DMQ1LWU
DMQ1LWU	DN	M-100240
DMQ1LWU	MI	TT5TKPM
DMQ1LWU	MN	Neutral endopeptidase (MME)
DMQ1LWU	MT	DTT
DMQ1LWU	MA	Modulator
DMQ1LWU	RN	Effects of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase on the vasopressor response to exogenous angiot... J Cardiovasc Pharmacol. 1998 Mar;31(3):408-17.
DMQ1LWU	RU	https://www.ncbi.nlm.nih.gov/pubmed/9514186

DMRN7GC	DI	DMRN7GC
DMRN7GC	DN	Manifaxine
DMRN7GC	MI	TTVBI8W
DMRN7GC	MN	Dopamine transporter (DAT)
DMRN7GC	MT	DTT
DMRN7GC	MA	Modulator
DMRN7GC	RN	Pharmacogenetics and obesity: common gene variants influence weight loss response of the norepinephrine/dopamine transporter inhibitor GW320659 in obese subjects. Pharmacogenet Genomics. 2005 Dec;15(12):883-9.
DMRN7GC	RU	https://pubmed.ncbi.nlm.nih.gov/16272960

DMRN7GC	DI	DMRN7GC
DMRN7GC	DN	Manifaxine
DMRN7GC	MI	TTAWNKZ
DMRN7GC	MN	Norepinephrine transporter (NET)
DMRN7GC	MT	DTT
DMRN7GC	MA	Modulator
DMRN7GC	RN	Pharmacogenetics and obesity: common gene variants influence weight loss response of the norepinephrine/dopamine transporter inhibitor GW320659 in obese subjects. Pharmacogenet Genomics. 2005 Dec;15(12):883-9.
DMRN7GC	RU	https://pubmed.ncbi.nlm.nih.gov/16272960

DM1LM7D	DI	DM1LM7D
DM1LM7D	DN	Mannose phosphate
DM1LM7D	MI	TTR9XHZ
DM1LM7D	MN	Transforming growth factor beta 1 (TGFB1)
DM1LM7D	MT	DTT
DM1LM7D	MA	Modulator
DM1LM7D	RN	The mannose-6-phosphate analogue, PXS64, inhibits fibrosis via TGF-beta1 pathway in human lung fibroblasts. Immunol Lett. 2015 Jun;165(2):90-101.
DM1LM7D	RU	https://pubmed.ncbi.nlm.nih.gov/25929803

DMRHYAU	DI	DMRHYAU
DMRHYAU	DN	MAZAPERTINE
DMRHYAU	MI	TTSQIFT
DMRHYAU	MN	5-HT 1A receptor (HTR1A)
DMRHYAU	MT	DTT
DMRHYAU	MA	Inhibitor
DMRHYAU	RN	A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2.
DMRHYAU	RU	https://pubmed.ncbi.nlm.nih.gov/7909336

DMRHYAU	DI	DMRHYAU
DMRHYAU	DN	MAZAPERTINE
DMRHYAU	MI	TTJQOD7
DMRHYAU	MN	5-HT 2A receptor (HTR2A)
DMRHYAU	MT	DTT
DMRHYAU	MA	Inhibitor
DMRHYAU	RN	A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2.
DMRHYAU	RU	https://pubmed.ncbi.nlm.nih.gov/7909336

DMRHYAU	DI	DMRHYAU
DMRHYAU	DN	MAZAPERTINE
DMRHYAU	MI	TTNGILX
DMRHYAU	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMRHYAU	MT	DTT
DMRHYAU	MA	Inhibitor
DMRHYAU	RN	A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2.
DMRHYAU	RU	https://pubmed.ncbi.nlm.nih.gov/7909336

DMRHYAU	DI	DMRHYAU
DMRHYAU	DN	MAZAPERTINE
DMRHYAU	MI	TTBRKXS
DMRHYAU	MN	Adrenergic receptor alpha-1B (ADRA1B)
DMRHYAU	MT	DTT
DMRHYAU	MA	Inhibitor
DMRHYAU	RN	A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2.
DMRHYAU	RU	https://pubmed.ncbi.nlm.nih.gov/7909336

DMRHYAU	DI	DMRHYAU
DMRHYAU	DN	MAZAPERTINE
DMRHYAU	MI	TT34BHT
DMRHYAU	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMRHYAU	MT	DTT
DMRHYAU	MA	Inhibitor
DMRHYAU	RN	A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2.
DMRHYAU	RU	https://pubmed.ncbi.nlm.nih.gov/7909336

DMRHYAU	DI	DMRHYAU
DMRHYAU	DN	MAZAPERTINE
DMRHYAU	MI	TTWG9A4
DMRHYAU	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMRHYAU	MT	DTT
DMRHYAU	MA	Inhibitor
DMRHYAU	RN	A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2.
DMRHYAU	RU	https://pubmed.ncbi.nlm.nih.gov/7909336

DMRHYAU	DI	DMRHYAU
DMRHYAU	DN	MAZAPERTINE
DMRHYAU	MI	TTWM4TY
DMRHYAU	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMRHYAU	MT	DTT
DMRHYAU	MA	Inhibitor
DMRHYAU	RN	A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2.
DMRHYAU	RU	https://pubmed.ncbi.nlm.nih.gov/7909336

DMRHYAU	DI	DMRHYAU
DMRHYAU	DN	MAZAPERTINE
DMRHYAU	MI	TT2NUT5
DMRHYAU	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMRHYAU	MT	DTT
DMRHYAU	MA	Inhibitor
DMRHYAU	RN	A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2.
DMRHYAU	RU	https://pubmed.ncbi.nlm.nih.gov/7909336

DMRHYAU	DI	DMRHYAU
DMRHYAU	DN	MAZAPERTINE
DMRHYAU	MI	TTEX248
DMRHYAU	MN	Dopamine D2 receptor (D2R)
DMRHYAU	MT	DTT
DMRHYAU	MA	Inhibitor
DMRHYAU	RN	A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2.
DMRHYAU	RU	https://pubmed.ncbi.nlm.nih.gov/7909336

DMRHYAU	DI	DMRHYAU
DMRHYAU	DN	MAZAPERTINE
DMRHYAU	MI	TT4C8EA
DMRHYAU	MN	Dopamine D3 receptor (D3R)
DMRHYAU	MT	DTT
DMRHYAU	MA	Inhibitor
DMRHYAU	RN	A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2.
DMRHYAU	RU	https://pubmed.ncbi.nlm.nih.gov/7909336

DMIG5W8	DI	DMIG5W8
DMIG5W8	DN	MCPP
DMIG5W8	MI	TTWJBZ5
DMIG5W8	MN	5-HT 2C receptor (HTR2C)
DMIG5W8	MT	DTT
DMIG5W8	MA	Agonist
DMIG5W8	RN	mCPP-induced hyperactivity in 5-HT2C receptor mutant mice is mediated by activation of multiple 5-HT receptor subtypes. Neuropharmacology. 2004 Apr;46(5):663-71.
DMIG5W8	RU	https://pubmed.ncbi.nlm.nih.gov/14996544

DMIG5W8	DI	DMIG5W8
DMIG5W8	DN	MCPP
DMIG5W8	MI	DECB0K3
DMIG5W8	MN	Cytochrome P450 2D6 (CYP2D6)
DMIG5W8	MT	DME
DMIG5W8	MA	Metabolism
DMIG5W8	RN	Proof of a 1-(3-chlorophenyl)piperazine (mCPP) intake: use as adulterant of cocaine resulting in drug-drug interactions? J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Aug 15;855(2):127-33.
DMIG5W8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17574934

DMKEYSX	DI	DMKEYSX
DMKEYSX	DN	MDL 101,731
DMKEYSX	MI	TTBWDI0
DMKEYSX	MN	Ribonucleoside-diphosphate reductase M2 (RRM2)
DMKEYSX	MT	DTT
DMKEYSX	MA	Modulator
DMKEYSX	RN	Tezacitabine Hoechst Marion Roussel.Curr Opin Investig Drugs.2000 Sep;1(1):135-40.
DMKEYSX	RU	https://www.ncbi.nlm.nih.gov/pubmed/11249589

DM9ZEGT	DI	DM9ZEGT
DM9ZEGT	DN	MDX-070
DM9ZEGT	MI	TT9G4N0
DM9ZEGT	MN	Glutamate carboxypeptidase II (GCPII)
DM9ZEGT	MT	DTT
DM9ZEGT	RN	Nanoparticles for Improving Cancer Diagnosis. Mater Sci Eng R Rep. 2013 March; 74(3): 35-69.
DM9ZEGT	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3779646/

DM3HIQY	DI	DM3HIQY
DM3HIQY	DN	Melanoma vaccine (ALVAC)
DM3HIQY	MI	TTE5ITK
DM3HIQY	MN	Cancer/testis antigen 1 (NY-ESO-1)
DM3HIQY	MT	DTT
DM3HIQY	RN	Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma. J Immunother. 2010 Oct;33(8):743-58.
DM3HIQY	RU	https://pubmed.ncbi.nlm.nih.gov/20842062

DM3HIQY	DI	DM3HIQY
DM3HIQY	DN	Melanoma vaccine (ALVAC)
DM3HIQY	MI	TT362RB
DM3HIQY	MN	MART-1 melanoma antigen (MLANA)
DM3HIQY	MT	DTT
DM3HIQY	RN	Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma. J Immunother. 2010 Oct;33(8):743-58.
DM3HIQY	RU	https://pubmed.ncbi.nlm.nih.gov/20842062

DM3HIQY	DI	DM3HIQY
DM3HIQY	DN	Melanoma vaccine (ALVAC)
DM3HIQY	MI	TT8MK59
DM3HIQY	MN	Melanocytes lineage-specific antigen GP100 (PMEL)
DM3HIQY	MT	DTT
DM3HIQY	RN	Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma. J Immunother. 2010 Oct;33(8):743-58.
DM3HIQY	RU	https://pubmed.ncbi.nlm.nih.gov/20842062

DM3HIQY	DI	DM3HIQY
DM3HIQY	DN	Melanoma vaccine (ALVAC)
DM3HIQY	MI	TT63M7Q
DM3HIQY	MN	Melanoma-associated antigen 1 (MAGEA1)
DM3HIQY	MT	DTT
DM3HIQY	RN	Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma. J Immunother. 2010 Oct;33(8):743-58.
DM3HIQY	RU	https://pubmed.ncbi.nlm.nih.gov/20842062

DM3HIQY	DI	DM3HIQY
DM3HIQY	DN	Melanoma vaccine (ALVAC)
DM3HIQY	MI	TTWSKHD
DM3HIQY	MN	Melanoma-associated antigen 3 (MAGEA3)
DM3HIQY	MT	DTT
DM3HIQY	RN	Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma. J Immunother. 2010 Oct;33(8):743-58.
DM3HIQY	RU	https://pubmed.ncbi.nlm.nih.gov/20842062

DM2DK4A	DI	DM2DK4A
DM2DK4A	DN	Mequitamium iodide
DM2DK4A	MI	TTTIBOJ
DM2DK4A	MN	Histamine H1 receptor (H1R)
DM2DK4A	MT	DTT
DM2DK4A	MA	Modulator
DM2DK4A	RN	High-affinity binding of mequitamium iodide (LG 30435) to muscarinic and histamine H1 receptors. Eur J Pharmacol. 1990 Jul 17;182(3):413-20.
DM2DK4A	RU	https://pubmed.ncbi.nlm.nih.gov/2226618

DMMZ4E9	DI	DMMZ4E9
DMMZ4E9	DN	Merbarone
DMMZ4E9	MI	TT0IHXV
DMMZ4E9	MN	DNA topoisomerase II (TOP2)
DMMZ4E9	MT	DTT
DMMZ4E9	MA	Modulator
DMMZ4E9	RN	The DNA topoisomerase II catalytic inhibitor merbarone is genotoxic and induces endoreduplication. Mutat Res. 2012 Oct-Nov;738-739:45-51.
DMMZ4E9	RU	https://pubmed.ncbi.nlm.nih.gov/22921906

DM90SHY	DI	DM90SHY
DM90SHY	DN	METIAPRIL
DM90SHY	MI	TTL69WB
DM90SHY	MN	Angiotensin-converting enzyme (ACE)
DM90SHY	MT	DTT
DM90SHY	MA	Inhibitor
DM90SHY	RN	The clinical efficacy of the first Russian angiotensin-converting enzyme inhibitor methiopril in patients with heart failure. Klin Med (Mosk). 1995;73(3):49-51.
DM90SHY	RU	https://pubmed.ncbi.nlm.nih.gov/8577109

DMJLNUD	DI	DMJLNUD
DMJLNUD	DN	MILACAINIDE TARTRATE
DMJLNUD	MI	TTKNWZ4
DMJLNUD	MN	Thromboxane-A synthase (TBXAS1)
DMJLNUD	MT	DTT
DMJLNUD	MA	Antagonist
DMJLNUD	RN	Effects of the new class I antiarrhythmic agent Ro 22-9194, (2R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate, on ischemia- and reperfusion-induced arrhythmias in dogs: involvement of thromboxane A2 synthase inhibitory activity. J Pharmacol Exp Ther. 1996 Nov;279(2):877-83.
DMJLNUD	RU	https://pubmed.ncbi.nlm.nih.gov/8930195

DMTX97J	DI	DMTX97J
DMTX97J	DN	MILFASARTAN
DMTX97J	MI	TT8DBY3
DMTX97J	MN	Angiotensin II receptor type-1 (AGTR1)
DMTX97J	MT	DTT
DMTX97J	MA	Antagonist
DMTX97J	RN	Dual action molecules: bioassays of combined novel antioxidants and angiotensin II receptor antagonists. Eur J Pharmacol. 2012 Nov 15;695(1-3):96-103.
DMTX97J	RU	https://pubmed.ncbi.nlm.nih.gov/22975712

DMF1IH5	DI	DMF1IH5
DMF1IH5	DN	Milveterol
DMF1IH5	MI	TT2CJVK
DMF1IH5	MN	Adrenergic receptor beta-2 (ADRB2)
DMF1IH5	MT	DTT
DMF1IH5	MA	Agonist
DMF1IH5	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMF1IH5	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMP8CVD	DI	DMP8CVD
DMP8CVD	DN	Milveterol+Fluticasone
DMP8CVD	MI	TT2CJVK
DMP8CVD	MN	Adrenergic receptor beta-2 (ADRB2)
DMP8CVD	MT	DTT
DMP8CVD	MA	Agonist
DMP8CVD	RN	Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94.
DMP8CVD	RU	https://pubmed.ncbi.nlm.nih.gov/19265487

DMVF2R1	DI	DMVF2R1
DMVF2R1	DN	Minopafant
DMVF2R1	MI	TTQL5VC
DMVF2R1	MN	Platelet-activating factor receptor (PTAFR)
DMVF2R1	MT	DTT
DMVF2R1	MA	Antagonist
DMVF2R1	RN	Formation of spherical micelles composed of the novel platelet activating factor receptor antagonist, E5880. Pharm Dev Technol. 2005;10(1):11-6.
DMVF2R1	RU	https://pubmed.ncbi.nlm.nih.gov/15776809

DMT6IUR	DI	DMT6IUR
DMT6IUR	DN	MIRFENTANIL HYDROCHLORIDE
DMT6IUR	MI	TTKWM86
DMT6IUR	MN	Opioid receptor mu (MOP)
DMT6IUR	MT	DTT
DMT6IUR	MA	Agonist
DMT6IUR	RN	Mirfentanil: pharmacological profile of a novel fentanyl derivative with opioid and nonopioid effects. J Pharmacol Exp Ther. 1991 Aug;258(2):502-10.
DMT6IUR	RU	https://pubmed.ncbi.nlm.nih.gov/1650830

DMW59FE	DI	DMW59FE
DMW59FE	DN	Mitonafide
DMW59FE	MI	TT0IHXV
DMW59FE	MN	DNA topoisomerase II (TOP2)
DMW59FE	MT	DTT
DMW59FE	MA	Modulator
DMW59FE	RN	Effect of mitonafide analogs on topoisomerase II of Leishmania chagasi. Antimicrob Agents Chemother. 1996 Mar;40(3):706-9.
DMW59FE	RU	https://pubmed.ncbi.nlm.nih.gov/8851597

DMCAKPG	DI	DMCAKPG
DMCAKPG	DN	MK-287
DMCAKPG	MI	TTQL5VC
DMCAKPG	MN	Platelet-activating factor receptor (PTAFR)
DMCAKPG	MT	DTT
DMCAKPG	MA	Antagonist
DMCAKPG	RN	MK 287: a potent, specific, and orally active receptor antagonist of platelet-activating factor. J Lipid Mediat. 1993 Jun;7(2):115-34.
DMCAKPG	RU	https://pubmed.ncbi.nlm.nih.gov/8400114

DM48ELZ	DI	DM48ELZ
DM48ELZ	DN	MK-386
DM48ELZ	MI	TTTU72V
DM48ELZ	MN	Steroid 5-alpha-reductase 1 (SRD5A1)
DM48ELZ	MT	DTT
DM48ELZ	MA	Inhibitor
DM48ELZ	RN	Synthesis of 8-chloro-benzo[c]quinolizin-3-ones as potent and selective inhibitors of human steroid 5alpha-reductase 1. Bioorg Med Chem Lett. 2000 Feb 21;10(4):353-6.
DM48ELZ	RU	https://pubmed.ncbi.nlm.nih.gov/10714498

DMVEGW6	DI	DMVEGW6
DMVEGW6	DN	MK-499
DMVEGW6	MI	TTQ6VDM
DMVEGW6	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMVEGW6	MT	DTT
DMVEGW6	MA	Inhibitor
DMVEGW6	RN	Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. Bioorg Med Chem Lett. 2003 May 19;13(10):1829-35.
DMVEGW6	RU	https://pubmed.ncbi.nlm.nih.gov/12729675

DMVXTZG	DI	DMVXTZG
DMVXTZG	DN	MK-591
DMVXTZG	MI	TT2J34L
DMVXTZG	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMVXTZG	MT	DTT
DMVXTZG	MA	Inhibitor
DMVXTZG	RN	Antileukotriene therapy for asthma. Am J Health Syst Pharm. 1996 Dec 1;53(23):2821-30; quiz 2877-8.
DMVXTZG	RU	https://pubmed.ncbi.nlm.nih.gov/8957342

DMBJLZG	DI	DMBJLZG
DMBJLZG	DN	MK-852
DMBJLZG	MI	TT38RM1
DMBJLZG	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DMBJLZG	MT	DTT
DMBJLZG	MA	Modulator
DMBJLZG	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMBJLZG	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMT0O7H	DI	DMT0O7H
DMT0O7H	DN	MK-886
DMT0O7H	MI	TT2J34L
DMT0O7H	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMT0O7H	MT	DTT
DMT0O7H	MA	Modulator
DMT0O7H	RN	Inhibitory effects of MK-886 on arachidonic acid metabolism in human phagocytes. Br J Pharmacol. 1990 May;100(1):15-20.
DMT0O7H	RU	https://www.ncbi.nlm.nih.gov/pubmed/2164857

DMMNUZC	DI	DMMNUZC
DMMNUZC	DN	MK-912
DMMNUZC	MI	TT2NUT5
DMMNUZC	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMMNUZC	MT	DTT
DMMNUZC	MA	Antagonist
DMMNUZC	RN	Silent alpha(2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. Am J Physiol Heart Circ Physiol. 2000 Apr;278(4):H1075-83.
DMMNUZC	RU	https://pubmed.ncbi.nlm.nih.gov/10749700

DMOZUPB	DI	DMOZUPB
DMOZUPB	DN	MK-944a
DMOZUPB	MI	TT5FNQT
DMOZUPB	MN	Human immunodeficiency virus Protease (HIV PR)
DMOZUPB	MT	DTT
DMOZUPB	MA	Inhibitor
DMOZUPB	RN	Identification of MK-944a: a second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors. J Med Chem. 2000 Sep 7;43(18):3386-99.
DMOZUPB	RU	https://pubmed.ncbi.nlm.nih.gov/10978186

DMRA3EZ	DI	DMRA3EZ
DMRA3EZ	DN	MLN3897
DMRA3EZ	MI	TTC24WT
DMRA3EZ	MN	C-C chemokine receptor type 1 (CCR1)
DMRA3EZ	MT	DTT
DMRA3EZ	MA	Antagonist
DMRA3EZ	RN	Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
DMRA3EZ	RU	https://pubmed.ncbi.nlm.nih.gov/18321156

DMTWLG8	DI	DMTWLG8
DMTWLG8	DN	MLN-977
DMTWLG8	MI	TT2J34L
DMTWLG8	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMTWLG8	MT	DTT
DMTWLG8	MA	Inhibitor
DMTWLG8	RN	Inflammation, Cancer and Oxidative Lipoxygenase Activity are Intimately Linked. Cancers (Basel) 2014 September; 6(3): 1500-1521.
DMTWLG8	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190552/

DMLG7QB	DI	DMLG7QB
DMLG7QB	DN	Mozenavir
DMLG7QB	MI	TT5FNQT
DMLG7QB	MN	Human immunodeficiency virus Protease (HIV PR)
DMLG7QB	MT	DTT
DMLG7QB	MA	Inhibitor
DMLG7QB	RN	Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450. Chem Biol. 1996 Apr;3(4):301-14.
DMLG7QB	RU	https://pubmed.ncbi.nlm.nih.gov/8807858

DMMKHGN	DI	DMMKHGN
DMMKHGN	DN	MP-435
DMMKHGN	MI	TTKANGO
DMMKHGN	MN	Complement C5 (CO5)
DMMKHGN	MT	DTT
DMMKHGN	MA	Antagonist
DMMKHGN	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027730)
DMMKHGN	RU	http://adisinsight.springer.com/drugs/800027730

DMKF3TD	DI	DMKF3TD
DMKF3TD	DN	Nafagrel
DMKF3TD	MI	TT2GVH5
DMKF3TD	MN	Isomerase unspecific (IsoM)
DMKF3TD	MT	DTT
DMKF3TD	MA	Modulator
DMKF3TD	RN	FMLP actions and its binding sites in isolated human coronary arteries. J Mol Cell Cardiol. 1997 Mar;29(3):881-94.
DMKF3TD	RU	https://pubmed.ncbi.nlm.nih.gov/9152849

DMF9Y57	DI	DMF9Y57
DMF9Y57	DN	Napitane mesilate
DMF9Y57	MI	TTAWNKZ
DMF9Y57	MN	Norepinephrine transporter (NET)
DMF9Y57	MT	DTT
DMF9Y57	MA	Modulator
DMF9Y57	RN	Enhancing central noradrenergic function in depression: is there still a place for a new antidepressant 
DMF9Y57	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2426812

DM8L4Z0	DI	DM8L4Z0
DM8L4Z0	DN	Napsagatran
DM8L4Z0	MI	TT6L509
DM8L4Z0	MN	Coagulation factor IIa (F2)
DM8L4Z0	MT	DTT
DM8L4Z0	MA	Inhibitor
DM8L4Z0	RN	Effects of napsagatran (Ro 46-6240), a new synthetic thrombin inhibitor and of heparin in a canine model of coronary artery thrombosis: comparison with an ex vivo annular perfusion chamber model. J Pharmacol Exp Ther. 1996 Apr;277(1):71-8.
DM8L4Z0	RU	https://pubmed.ncbi.nlm.nih.gov/8613969

DM8BHL6	DI	DM8BHL6
DM8BHL6	DN	Naronapride
DM8BHL6	MI	TT07C3Y
DM8BHL6	MN	5-HT 4 receptor (HTR4)
DM8BHL6	MT	DTT
DM8BHL6	MA	Agonist
DM8BHL6	RN	Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther. 2012 Apr;35(7):745-67.
DM8BHL6	RU	https://pubmed.ncbi.nlm.nih.gov/22356640

DM9K2IO	DI	DM9K2IO
DM9K2IO	DN	Naxagolide
DM9K2IO	MI	TTEX248
DM9K2IO	MN	Dopamine D2 receptor (D2R)
DM9K2IO	MT	DTT
DM9K2IO	MA	Modulator
DM9K2IO	RN	Comparison between the pharmacology of dopamine receptors mediating the inhibition of cell firing in rat brain slices through the substantia nigra pars compacta and ventral tegmental area. Br J Pharmacol. 1994 Jul;112(3):873-80.
DM9K2IO	RU	https://pubmed.ncbi.nlm.nih.gov/7921615

DMGVYXB	DI	DMGVYXB
DMGVYXB	DN	NB-506
DMGVYXB	MI	DTI7UX6
DMGVYXB	MN	Breast cancer resistance protein (ABCG2)
DMGVYXB	MT	DTP
DMGVYXB	MA	Substrate
DMGVYXB	RN	Pharmacogenomic importance of ABCG2. Pharmacogenomics. 2008 Aug;9(8):1005-9.
DMGVYXB	RU	https://doi.org/10.2217/14622416.9.8.1005

DMGVYXB	DI	DMGVYXB
DMGVYXB	DN	NB-506
DMGVYXB	MI	TTUTN1I
DMGVYXB	MN	Human Deoxyribonucleic acid (hDNA)
DMGVYXB	MT	DTT
DMGVYXB	MA	Inhibitor
DMGVYXB	RN	DNA binding properties of the indolocarbazole antitumor drug NB-506. Anticancer Drug Des. 2001 Apr-Jun;16(2-3):99-107.
DMGVYXB	RU	https://pubmed.ncbi.nlm.nih.gov/11962518

DMTRMBL	DI	DMTRMBL
DMTRMBL	DN	NBI-6024
DMTRMBL	MI	TTZOPHG
DMTRMBL	MN	Insulin (INS)
DMTRMBL	MT	DTT
DMTRMBL	MA	Modulator
DMTRMBL	RN	No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes.Diabetes Care.2009 Nov;32(11):2036-40.
DMTRMBL	RU	https://www.ncbi.nlm.nih.gov/pubmed/19690081

DMGEBUQ	DI	DMGEBUQ
DMGEBUQ	DN	NC-190
DMGEBUQ	MI	TT0IHXV
DMGEBUQ	MN	DNA topoisomerase II (TOP2)
DMGEBUQ	MT	DTT
DMGEBUQ	MA	Modulator
DMGEBUQ	RN	The topoisomerase II-inhibitor NC-190 reduces the level of thymidine kinase mRNA in murine tumor cells. Res Commun Mol Pathol Pharmacol. 2002;111(1-4):77-87.
DMGEBUQ	RU	https://pubmed.ncbi.nlm.nih.gov/14632316

DMWROJ5	DI	DMWROJ5
DMWROJ5	DN	NCX-701
DMWROJ5	MI	TTK0943
DMWROJ5	MN	Prostaglandin G/H synthase (COX)
DMWROJ5	MT	DTT
DMWROJ5	MA	Modulator
DMWROJ5	RN	Antinociceptive effects of NCX-701 (nitro-paracetamol) in neuropathic rats: enhancement of antinociception by co-administration with gabapentin. Br J Pharmacol. 2009 September; 158(2): 601-609.
DMWROJ5	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2757700/

DM6VP9U	DI	DM6VP9U
DM6VP9U	DN	Nemifitide
DM6VP9U	MI	DEJGDUW
DM6VP9U	MN	Cytochrome P450 1A2 (CYP1A2)
DM6VP9U	MT	DME
DM6VP9U	MA	Metabolism
DM6VP9U	RN	Antidepressants: Past, Present and Future. Edited by Sheldon H. Preskorn Christina Y. Stanga John P. Feighner Ruth Ross. Page: 574.
DM6VP9U	RU	https://books.google.com/books?id=Ue3uCAAAQBAJ&pg=PA574&lpg=PA574&dq=Nemifitide+metabolism&source=bl&ots=GQLQ8gSF2U&sig=ACfU3U27jlKMS_W2CDicejY8jKnpE1dFaw&hl=zh-CN&sa=X&ved=2ahUKEwiL7fCx8rTnAhXK-GEKHc_aD0UQ6AEwAHoECAkQAQ#v=onepage&q=Nemifitide%20metabolism&f=false

DM6VP9U	DI	DM6VP9U
DM6VP9U	DN	Nemifitide
DM6VP9U	MI	DECB0K3
DM6VP9U	MN	Cytochrome P450 2D6 (CYP2D6)
DM6VP9U	MT	DME
DM6VP9U	MA	Metabolism
DM6VP9U	RN	Antidepressants: Past, Present and Future. Edited by Sheldon H. Preskorn Christina Y. Stanga John P. Feighner Ruth Ross. Page: 574.
DM6VP9U	RU	https://books.google.com/books?id=Ue3uCAAAQBAJ&pg=PA574&lpg=PA574&dq=Nemifitide+metabolism&source=bl&ots=GQLQ8gSF2U&sig=ACfU3U27jlKMS_W2CDicejY8jKnpE1dFaw&hl=zh-CN&sa=X&ved=2ahUKEwiL7fCx8rTnAhXK-GEKHc_aD0UQ6AEwAHoECAkQAQ#v=onepage&q=Nemifitide%20metabolism&f=false

DM6VP9U	DI	DM6VP9U
DM6VP9U	DN	Nemifitide
DM6VP9U	MI	DEGTFWK
DM6VP9U	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM6VP9U	MT	DME
DM6VP9U	MA	Metabolism
DM6VP9U	RN	Antidepressants: Past, Present and Future. Edited by Sheldon H. Preskorn Christina Y. Stanga John P. Feighner Ruth Ross. Page: 574.
DM6VP9U	RU	https://books.google.com/books?id=Ue3uCAAAQBAJ&pg=PA574&lpg=PA574&dq=Nemifitide+metabolism&source=bl&ots=GQLQ8gSF2U&sig=ACfU3U27jlKMS_W2CDicejY8jKnpE1dFaw&hl=zh-CN&sa=X&ved=2ahUKEwiL7fCx8rTnAhXK-GEKHc_aD0UQ6AEwAHoECAkQAQ#v=onepage&q=Nemifitide%20metabolism&f=false

DMDAUCR	DI	DMDAUCR
DMDAUCR	DN	NGD 91-3
DMDAUCR	MI	TTEX6LM
DMDAUCR	MN	GABA(A) receptor gamma-3 (GABRG3)
DMDAUCR	MT	DTT
DMDAUCR	MA	Agonist
DMDAUCR	RN	Anxioselective compounds acting at the GABA(A) receptor benzodiazepine binding site. Curr Drug Targets CNS Neurol Disord. 2003 Aug;2(4):213-32.
DMDAUCR	RU	https://pubmed.ncbi.nlm.nih.gov/12871032

DMOWLVF	DI	DMOWLVF
DMOWLVF	DN	NGD-8243
DMOWLVF	MI	TTMI6F5
DMOWLVF	MN	Transient receptor potential cation channel V1 (TRPV1)
DMOWLVF	MT	DTT
DMOWLVF	MA	Blocker
DMOWLVF	RN	Analgesic potential of TRPV1 antagonists. Biochem Pharmacol. 2009 Aug 1;78(3):211-6.
DMOWLVF	RU	https://pubmed.ncbi.nlm.nih.gov/19481638

DMSJYEX	DI	DMSJYEX
DMSJYEX	DN	Nitecapone
DMSJYEX	MI	TTKWFB8
DMSJYEX	MN	Catechol-O-methyl-transferase (COMT)
DMSJYEX	MT	DTT
DMSJYEX	MA	Modulator
DMSJYEX	RN	Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-dopa in healthy volunteers. Clin Neuropharmacol. 1990 Oct;13(5):436-47.
DMSJYEX	RU	https://pubmed.ncbi.nlm.nih.gov/2272023

DMZMQDN	DI	DMZMQDN
DMZMQDN	DN	NK-1001
DMZMQDN	MI	TTMG98T
DMZMQDN	MN	Heat shock protein 27 (HSP27)
DMZMQDN	MT	DTT
DMZMQDN	MA	Modulator
DMZMQDN	RN	Novel therapeutic targets in the management of atrial fibrillation. Am J Cardiovasc Drugs. 2014 Dec;14(6):403-21.
DMZMQDN	RU	https://pubmed.ncbi.nlm.nih.gov/25090973

DMZMQDN	DI	DMZMQDN
DMZMQDN	DN	NK-1001
DMZMQDN	MI	TTHYBIX
DMZMQDN	MN	Heat shock protein 70 (HSP70)
DMZMQDN	MT	DTT
DMZMQDN	MA	Modulator
DMZMQDN	RN	Novel therapeutic targets in the management of atrial fibrillation. Am J Cardiovasc Drugs. 2014 Dec;14(6):403-21.
DMZMQDN	RU	https://pubmed.ncbi.nlm.nih.gov/25090973

DM5OVGH	DI	DM5OVGH
DM5OVGH	DN	NK-611
DM5OVGH	MI	TTGTQHC
DM5OVGH	MN	DNA topoisomerase I (TOP1)
DM5OVGH	MT	DTT
DM5OVGH	MA	Inhibitor
DM5OVGH	RN	DNA topoisomerase II poisons and inhibitors. Cancer Chemother Biol Response Modif. 1997;17:114-31.
DM5OVGH	RU	https://pubmed.ncbi.nlm.nih.gov/9551211

DMV5FN1	DI	DMV5FN1
DMV5FN1	DN	NKS-01
DMV5FN1	MI	TTSZLWK
DMV5FN1	MN	Aromatase (CYP19A1)
DMV5FN1	MT	DTT
DMV5FN1	MA	Inhibitor
DMV5FN1	RN	Effects of aromatase inhibitors on the pathobiology of the human breast, endometrial and ovarian carcinoma. Endocr Relat Cancer. 1999 Jun;6(2):197-204.
DMV5FN1	RU	https://pubmed.ncbi.nlm.nih.gov/10731109

DM6NPUJ	DI	DM6NPUJ
DM6NPUJ	DN	NLX-P101
DM6NPUJ	MI	TTURQ2G
DM6NPUJ	MN	Glutamate decarboxylase (GLUL)
DM6NPUJ	MT	DTT
DM6NPUJ	MA	Modulator
DM6NPUJ	RN	NLX-P101, an adeno-associated virus gene therapy encoding glutamic acid decarboxylase, for the potential treatment of Parkinson's disease. Curr Opin Investig Drugs. 2010 Jul;11(7):813-22.
DM6NPUJ	RU	https://pubmed.ncbi.nlm.nih.gov/20571977

DMVH3I7	DI	DMVH3I7
DMVH3I7	DN	NM-135
DMVH3I7	MI	TTYRL6O
DMVH3I7	MN	Glucocorticoid receptor (NR3C1)
DMVH3I7	MT	DTT
DMVH3I7	MA	Modulator
DMVH3I7	RN	Local anti-inflammatory activity and systemic side effects of NM-135, a new prodrug glucocorticoid, in an experimental inflammatory rat model. Jpn J Pharmacol. 1998 Dec;78(4):505-9.
DMVH3I7	RU	https://pubmed.ncbi.nlm.nih.gov/9920209

DMU596F	DI	DMU596F
DMU596F	DN	NMI-870
DMU596F	MI	TTWG9A4
DMU596F	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMU596F	MT	DTT
DMU596F	MA	Modulator
DMU596F	RN	Female Sexual Dysfunction: Therapeutic Options and Experimental Challenges. Cardiovasc Hematol Agents Med Chem. 2009 October; 7(4): 260-269.
DMU596F	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3008577/

DMU596F	DI	DMU596F
DMU596F	DN	NMI-870
DMU596F	MI	TT2NUT5
DMU596F	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMU596F	MT	DTT
DMU596F	MA	Modulator
DMU596F	RN	Female Sexual Dysfunction: Therapeutic Options and Experimental Challenges. Cardiovasc Hematol Agents Med Chem. 2009 October; 7(4): 260-269.
DMU596F	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3008577/

DM2TDE7	DI	DM2TDE7
DM2TDE7	DN	NN8209
DM2TDE7	MI	TTHXFA1
DM2TDE7	MN	C5a anaphylatoxin chemotactic receptor (C5AR1)
DM2TDE7	MT	DTT
DM2TDE7	MA	Modulator
DM2TDE7	RN	Complement in immune and inflammatory disorders: therapeutic interventions. J Immunol. 2013 Apr 15;190(8):3839-47.
DM2TDE7	RU	https://pubmed.ncbi.nlm.nih.gov/23564578

DMK5WLZ	DI	DMK5WLZ
DMK5WLZ	DN	Nolpitantium besilate
DMK5WLZ	MI	TTZPO1L
DMK5WLZ	MN	Substance-P receptor (TACR1)
DMK5WLZ	MT	DTT
DMK5WLZ	MA	Antagonist
DMK5WLZ	RN	SR 140333, a novel, selective, and potent nonpeptide antagonist of the NK1 tachykinin receptor: characterization on the U373MG cell line. J Neurochem. 1994 Apr;62(4):1399-407.
DMK5WLZ	RU	https://pubmed.ncbi.nlm.nih.gov/7510780

DMJSKUI	DI	DMJSKUI
DMJSKUI	DN	Norcisapride
DMJSKUI	MI	TTPC4TU
DMJSKUI	MN	5-HT 3A receptor (HTR3A)
DMJSKUI	MT	DTT
DMJSKUI	MA	Inhibitor
DMJSKUI	RN	mu-Opioid/5-HT4 dual pharmacologically active agents-efforts towards an effective opioid analgesic with less GI and respiratory side effects (Part I). Bioorg Med Chem Lett. 2009 Oct 1;19(19):5679-83.
DMJSKUI	RU	https://pubmed.ncbi.nlm.nih.gov/19700325

DMJSKUI	DI	DMJSKUI
DMJSKUI	DN	Norcisapride
DMJSKUI	MI	TT07C3Y
DMJSKUI	MN	5-HT 4 receptor (HTR4)
DMJSKUI	MT	DTT
DMJSKUI	MA	Inhibitor
DMJSKUI	RN	mu-Opioid/5-HT4 dual pharmacologically active agents-efforts towards an effective opioid analgesic with less GI and respiratory side effects (Part I). Bioorg Med Chem Lett. 2009 Oct 1;19(19):5679-83.
DMJSKUI	RU	https://pubmed.ncbi.nlm.nih.gov/19700325

DMJSKUI	DI	DMJSKUI
DMJSKUI	DN	Norcisapride
DMJSKUI	MI	DE4LYSA
DMJSKUI	MN	Cytochrome P450 3A4 (CYP3A4)
DMJSKUI	MT	DME
DMJSKUI	MA	Metabolism
DMJSKUI	RN	Cytochrome P450 Involvement in the biotransformation of cisapride and racemic norcisapride in vitro: differential activity of individual human CYP3A isoforms. Drug Metab Dispos. 2001 Dec;29(12):1548-54.
DMJSKUI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11717173

DMYCLZR	DI	DMYCLZR
DMYCLZR	DN	Norelin
DMYCLZR	MI	TT0ID4A
DMYCLZR	MN	Leutinizing-hormone-releasing hormone (GNRH1)
DMYCLZR	MT	DTT
DMYCLZR	MA	Inhibitor
DMYCLZR	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011623)
DMYCLZR	RU	http://adisinsight.springer.com/drugs/800011623

DM8A64W	DI	DM8A64W
DM8A64W	DN	NP-118809
DM8A64W	MI	TTFK1JQ
DM8A64W	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DM8A64W	MT	DTT
DM8A64W	MA	Inhibitor
DM8A64W	RN	Scaffold-based design and synthesis of potent N-type calcium channel blockers. Bioorg Med Chem Lett. 2009 Nov 15;19(22):6467-72.
DM8A64W	RU	https://pubmed.ncbi.nlm.nih.gov/19815411

DMPMR2I	DI	DMPMR2I
DMPMR2I	DN	NP-50301
DMPMR2I	MI	TTZAYWL
DMPMR2I	MN	Estrogen receptor (ESR)
DMPMR2I	MT	DTT
DMPMR2I	MA	Modulator
DMPMR2I	RN	Therapeutic targets in dry eye syndrome. Drug News Perspect. 2008 Apr;21(3):166-76.
DMPMR2I	RU	https://pubmed.ncbi.nlm.nih.gov/18560615

DM50PZH	DI	DM50PZH
DM50PZH	DN	NP-619
DM50PZH	MI	TTS64P2
DM50PZH	MN	Androgen receptor (AR)
DM50PZH	MT	DTT
DM50PZH	MA	Modulator
DM50PZH	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028305)
DM50PZH	RU	http://adisinsight.springer.com/drugs/800028305

DMAVZ1F	DI	DMAVZ1F
DMAVZ1F	DN	NPC-567
DMAVZ1F	MI	TTGY8IW
DMAVZ1F	MN	B2 bradykinin receptor (BDKRB2)
DMAVZ1F	MT	DTT
DMAVZ1F	MA	Inhibitor
DMAVZ1F	RN	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
DMAVZ1F	RU	https://pubmed.ncbi.nlm.nih.gov/18983139

DM0CF3B	DI	DM0CF3B
DM0CF3B	DN	NPS 1776
DM0CF3B	MI	TTB6UM0
DM0CF3B	MN	Fatty aldehyde dehydrogenase (ALDH3A2)
DM0CF3B	MT	DTT
DM0CF3B	MA	Modulator
DM0CF3B	RN	Diverse Mechanisms of Antiepileptic Drugs in the Development Pipeline. Epilepsy Res. 2006 June; 69(3): 273-294.
DM0CF3B	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1562526/

DMQPXLF	DI	DMQPXLF
DMQPXLF	DN	NPS-2143
DMQPXLF	MI	TTBUYHA
DMQPXLF	MN	Extracellular calcium-sensing receptor (CASR)
DMQPXLF	MT	DTT
DMQPXLF	MA	Antagonist
DMQPXLF	RN	Calcium-sensing receptor antagonist (calcilytic) NPS 2143 specifically blocks the increased secretion of endogenous Abeta42 prompted by exogenous fibrillary or soluble Abeta25-35 in human cortical astrocytes and neurons-therapeutic relevance to Alzheimer's disease. Biochim Biophys Acta. 2013 Oct;1832(10):1634-52.
DMQPXLF	RU	https://pubmed.ncbi.nlm.nih.gov/23628734

DMQ82T5	DI	DMQ82T5
DMQ82T5	DN	NS-220
DMQ82T5	MI	TTJ584C
DMQ82T5	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMQ82T5	MT	DTT
DMQ82T5	MA	Agonist
DMQ82T5	RN	Modulation of PPAR receptor subtype selectivity of the ligands: aliphatic chain vs aromatic ring as a spacer between pharmacophore and the lipophilic moiety. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6471-5.
DMQ82T5	RU	https://pubmed.ncbi.nlm.nih.gov/18976908

DMVRJ8D	DI	DMVRJ8D
DMVRJ8D	DN	NS-2389
DMVRJ8D	MI	TTVBI8W
DMVRJ8D	MN	Dopamine transporter (DAT)
DMVRJ8D	MT	DTT
DMVRJ8D	MA	Modulator
DMVRJ8D	RN	Clinical pipeline report, company report or official report of Neurosearch.
DMVRJ8D	RU	http://neurosearch.com/Default.aspx

DMVRJ8D	DI	DMVRJ8D
DMVRJ8D	DN	NS-2389
DMVRJ8D	MI	TTAWNKZ
DMVRJ8D	MN	Norepinephrine transporter (NET)
DMVRJ8D	MT	DTT
DMVRJ8D	MA	Modulator
DMVRJ8D	RN	Clinical pipeline report, company report or official report of Neurosearch.
DMVRJ8D	RU	http://neurosearch.com/Default.aspx

DMVRJ8D	DI	DMVRJ8D
DMVRJ8D	DN	NS-2389
DMVRJ8D	MI	TT3ROYC
DMVRJ8D	MN	Serotonin transporter (SERT)
DMVRJ8D	MT	DTT
DMVRJ8D	MA	Modulator
DMVRJ8D	RN	Clinical pipeline report, company report or official report of Neurosearch.
DMVRJ8D	RU	http://neurosearch.com/Default.aspx

DMQ8P4U	DI	DMQ8P4U
DMQ8P4U	DN	NS-49
DMQ8P4U	MI	TT34BHT
DMQ8P4U	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMQ8P4U	MT	DTT
DMQ8P4U	MA	Modulator
DMQ8P4U	RN	Pharmacokinetics of NS-49, a phenethylamine class alpha 1A-adrenoceptor agonist. 3rd communication: metabolism in rats, rabbits, dogs and monkeys, and effects on hepatic drug-metabolizing enzyme activities in rats after repeated administration. Arzneimittelforschung. 1999 Jul;49(7):612-7.
DMQ8P4U	RU	https://pubmed.ncbi.nlm.nih.gov/10442210

DMH2QBM	DI	DMH2QBM
DMH2QBM	DN	NSP-805
DMH2QBM	MI	TTZCG4L
DMH2QBM	MN	Phosphodiesterase 3 (PDE3)
DMH2QBM	MT	DTT
DMH2QBM	MA	Modulator
DMH2QBM	RN	[The effect of phosphodiesterase type 3 inhibitor on chorio-retinal blood flow in rabbits eyes].Nippon Ganka Gakkai Zasshi.2002 Oct;106(10):615-20.
DMH2QBM	RU	https://www.ncbi.nlm.nih.gov/pubmed/12420371

DMGZ3DR	DI	DMGZ3DR
DMGZ3DR	DN	NT-3
DMGZ3DR	MI	TTZHKV9
DMGZ3DR	MN	Neurotrophin-3 (NTF3)
DMGZ3DR	MT	DTT
DMGZ3DR	MA	Modulator
DMGZ3DR	RN	NT-3. Takeda/Regeneron/Amgen. IDrugs. 2001 Jul;4(7):820-4.
DMGZ3DR	RU	https://pubmed.ncbi.nlm.nih.gov/15995939

DMX9KYW	DI	DMX9KYW
DMX9KYW	DN	NTx-488
DMX9KYW	MI	TTJ2TSA
DMX9KYW	MN	Prolactin (PRL)
DMX9KYW	MT	DTT
DMX9KYW	MA	Modulator
DMX9KYW	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028330)
DMX9KYW	RU	http://adisinsight.springer.com/drugs/800028330

DMPM58S	DI	DMPM58S
DMPM58S	DN	Nuvanil
DMPM58S	MI	TTMI6F5
DMPM58S	MN	Transient receptor potential cation channel V1 (TRPV1)
DMPM58S	MT	DTT
DMPM58S	MA	Agonist
DMPM58S	RN	TRPV1: ON THE ROAD TO PAIN RELIEF. Curr Mol Pharmacol. 2008 November; 1(3): 255-269.
DMPM58S	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2802457/

DM9HKOM	DI	DM9HKOM
DM9HKOM	DN	NVP-DPP728
DM9HKOM	MI	TTDIGC1
DM9HKOM	MN	Dipeptidyl peptidase 4 (DPP-4)
DM9HKOM	MT	DTT
DM9HKOM	MA	Inhibitor
DM9HKOM	RN	A three-dimensional pharmacophore model for dipeptidyl peptidase IV inhibitors. Eur J Med Chem. 2008 Aug;43(8):1603-11.
DM9HKOM	RU	https://pubmed.ncbi.nlm.nih.gov/18207285

DMO8PN9	DI	DMO8PN9
DMO8PN9	DN	OBERADILOL MONOETHYL MALEATE
DMO8PN9	MI	TTMXGCW
DMO8PN9	MN	Adrenergic receptor beta-3 (ADRB3)
DMO8PN9	MT	DTT
DMO8PN9	MA	Modulator
DMO8PN9	RN	US patent application no. 9,062,094, Dipeptide-based prodrug linkers for aliphatic amine-containing drugs.
DMO8PN9	RU	http://www.google.com/patents/US9062094

DMX6GFR	DI	DMX6GFR
DMX6GFR	DN	Omega interferon
DMX6GFR	MI	TTSYFMA
DMX6GFR	MN	Interferon alpha/beta receptor 1 (IFNAR1)
DMX6GFR	MT	DTT
DMX6GFR	MA	Modulator
DMX6GFR	RN	Human interferon omega--a review. Mult Scler. 1995;1 Suppl 1:S44-7.
DMX6GFR	RU	https://pubmed.ncbi.nlm.nih.gov/9345398

DMIZXFJ	DI	DMIZXFJ
DMIZXFJ	DN	ONO-4007
DMIZXFJ	MI	TTOK0LR
DMIZXFJ	MN	Toll-like receptor (TLR)
DMIZXFJ	MT	DTT
DMIZXFJ	MA	Modulator
DMIZXFJ	RN	Toll-like receptors TLR2 and TLR4 initiate the innate immune response of the renal tubular epithelium to bacterial products. Clin Exp Immunol. 2006 August; 145(2): 346-356.
DMIZXFJ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1809678/

DMNEA78	DI	DMNEA78
DMNEA78	DN	ONO-4057
DMNEA78	MI	TTVJX54
DMNEA78	MN	Leukotriene B4 receptor 2 (LTB4R2)
DMNEA78	MT	DTT
DMNEA78	MA	Modulator
DMNEA78	RN	ONO-4057, a novel, orally active leukotriene B4 antagonist: effects on LTB4-induced neutrophil functions. Prostaglandins. 1992 Oct;44(4):261-75.
DMNEA78	RU	https://pubmed.ncbi.nlm.nih.gov/1332129

DMSVQK2	DI	DMSVQK2
DMSVQK2	DN	ONO-4819
DMSVQK2	MI	TT79WV3
DMSVQK2	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DMSVQK2	MT	DTT
DMSVQK2	MA	Agonist
DMSVQK2	RN	Effect of a prostaglandin EP4 receptor agonist on early fixation of hydroxyapatite/titanium composite- and titanium-coated rough-surfaced implants ... J Biomed Mater Res A. 2010 Mar 1;92(3):1202-9.
DMSVQK2	RU	https://pubmed.ncbi.nlm.nih.gov/19322876

DMWS7C2	DI	DMWS7C2
DMWS7C2	DN	ONO-5334
DMWS7C2	MI	TTDZN01
DMWS7C2	MN	Cathepsin K (CTSK)
DMWS7C2	MT	DTT
DMWS7C2	MA	Inhibitor
DMWS7C2	RN	New approach for osteoporosis treatment: cathepsin K inhibitor, ONO-5334. Clin Calcium. 2011 Jan;21(1):64-9.
DMWS7C2	RU	https://pubmed.ncbi.nlm.nih.gov/21187596

DMQM4OV	DI	DMQM4OV
DMQM4OV	DN	OP-2507
DMQM4OV	MI	TTOFYT1
DMQM4OV	MN	Prostacyclin receptor (PTGIR)
DMQM4OV	MT	DTT
DMQM4OV	MA	Modulator
DMQM4OV	RN	Effect of a prostaglandin I(2) analog on the expression of thrombomodulin in liver and spleen endothelial cells after an extensive hepatectomy. Surg Today. 2011 Feb;41(2):230-6.
DMQM4OV	RU	https://pubmed.ncbi.nlm.nih.gov/21264759

DMP0ARJ	DI	DMP0ARJ
DMP0ARJ	DN	Opaviraline
DMP0ARJ	MI	TT84ETX
DMP0ARJ	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMP0ARJ	MT	DTT
DMP0ARJ	MA	Modulator
DMP0ARJ	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMP0ARJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM7OVMH	DI	DM7OVMH
DM7OVMH	DN	OPC-21268
DM7OVMH	MI	TT2J34L
DM7OVMH	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM7OVMH	MT	DTT
DM7OVMH	MA	Inhibitor
DM7OVMH	RN	Fuscoside: an anti-inflammatory marine natural product which selectively inhibits 5-lipoxygenase. Part II: Biochemical studies in the human neutrophil. J Pharmacol Exp Ther. 1992 Aug;262(2):874-82.
DM7OVMH	RU	https://pubmed.ncbi.nlm.nih.gov/1323665

DM7OVMH	DI	DM7OVMH
DM7OVMH	DN	OPC-21268
DM7OVMH	MI	TTPFZJ1
DM7OVMH	MN	Vasopressin V1 receptor (V1R)
DM7OVMH	MT	DTT
DM7OVMH	MA	Antagonist
DM7OVMH	RN	Vasopressin (ADH). Nippon Rinsho. 1992 Dec;50(12):2893-900.
DM7OVMH	RU	https://pubmed.ncbi.nlm.nih.gov/1337114

DM7OVMH	DI	DM7OVMH
DM7OVMH	DN	OPC-21268
DM7OVMH	MI	TT4TFGN
DM7OVMH	MN	Vasopressin V1a receptor (V1AR)
DM7OVMH	MT	DTT
DM7OVMH	MA	Antagonist
DM7OVMH	RN	Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res. 2002;139:197-210.
DM7OVMH	RU	https://pubmed.ncbi.nlm.nih.gov/12436936

DMYM8OG	DI	DMYM8OG
DMYM8OG	DN	OPC-28326
DMYM8OG	MI	TT34BHT
DMYM8OG	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMYM8OG	MT	DTT
DMYM8OG	MA	Antagonist
DMYM8OG	RN	Mechanisms of action of OPC-28326, a selective hindlimb vasodilator. J Pharmacol Exp Ther. 1999 Nov;291(2):604-11.
DMYM8OG	RU	https://pubmed.ncbi.nlm.nih.gov/10525078

DM9ORUL	DI	DM9ORUL
DM9ORUL	DN	OPC-8490
DM9ORUL	MI	TTZCG4L
DM9ORUL	MN	Phosphodiesterase 3 (PDE3)
DM9ORUL	MT	DTT
DM9ORUL	MA	Modulator
DM9ORUL	RN	Mechanism of action of OPC-8490 in human ventricular myocardium. Circulation. 1996 Feb 15;93(4):817-25.
DM9ORUL	RU	https://www.ncbi.nlm.nih.gov/pubmed/8641012

DMVM4NE	DI	DMVM4NE
DMVM4NE	DN	OPM-3023
DMVM4NE	MI	TTOV74C
DMVM4NE	MN	Bone metabolism (Bone metab)
DMVM4NE	MT	DTT
DMVM4NE	MA	Inhibitor
DMVM4NE	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030958)
DMVM4NE	RU	http://adisinsight.springer.com/drugs/800030958

DMWZXF7	DI	DMWZXF7
DMWZXF7	DN	ORG-33628
DMWZXF7	MI	TTHL6YX
DMWZXF7	MN	Progesterone (PG)
DMWZXF7	MT	DTT
DMWZXF7	MA	Modulator
DMWZXF7	RN	ORG 33628 and ORG 31710 to control vaginal bleeding in progestin-only contraceptive regimens. Semin Reprod Med. 2005 Feb;23(1):101-11.
DMWZXF7	RU	https://pubmed.ncbi.nlm.nih.gov/15714394

DMU5PFD	DI	DMU5PFD
DMU5PFD	DN	Org-7797
DMU5PFD	MI	TTRK8B9
DMU5PFD	MN	Sodium channel unspecific (NaC)
DMU5PFD	MT	DTT
DMU5PFD	MA	Modulator
DMU5PFD	RN	Electrophysiologic effects of Org 7797, a new steroidal antiarrhythmic agent: comparison with class 1a, 1b, and 1c drugs. J Cardiovasc Pharmacol. 1989 Aug;14(2):205-12.
DMU5PFD	RU	https://pubmed.ncbi.nlm.nih.gov/2476592

DMW1FT0	DI	DMW1FT0
DMW1FT0	DN	ORG-9273
DMW1FT0	MI	TTJSZTB
DMW1FT0	MN	Nicotinic acetylcholine receptor (nAChR)
DMW1FT0	MT	DTT
DMW1FT0	MA	Modulator
DMW1FT0	RN	Dose-response relation, neuromuscular blocking action, intubation conditions, and cardiovascular effects of Org 9273, a new neuromuscular blocking agent. Anesth Analg. 1991 Jun;72(6):811-6.
DMW1FT0	RU	https://pubmed.ncbi.nlm.nih.gov/1674648

DMZEV63	DI	DMZEV63
DMZEV63	DN	Org-9731
DMZEV63	MI	TTZCG4L
DMZEV63	MN	Phosphodiesterase 3 (PDE3)
DMZEV63	MT	DTT
DMZEV63	MA	Modulator
DMZEV63	RN	Effects of a novel cardiotonic agent, Org 9731, on force and aequorin light transients in intact ventricular myocardium of the dog: involvement of ... J Card Fail. 1995 Mar;1(2):143-53.
DMZEV63	RU	https://www.ncbi.nlm.nih.gov/pubmed/9420644

DMRXHAC	DI	DMRXHAC
DMRXHAC	DN	Otenzepad
DMRXHAC	MI	TTYEG6Q
DMRXHAC	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMRXHAC	MT	DTT
DMRXHAC	MA	Antagonist
DMRXHAC	RN	Beneficial effect of muscarinic-2 antagonist on dilated cardiomyopathy induced by autoimmune mechanism against muscarinic-2 receptor. J Cardiovasc Pharmacol. 2001 Oct;38 Suppl 1:S43-9.
DMRXHAC	RU	https://pubmed.ncbi.nlm.nih.gov/11811358

DMHFOIX	DI	DMHFOIX
DMHFOIX	DN	OxycoDex
DMHFOIX	MI	TTN4QDT
DMHFOIX	MN	Opioid receptor (OPR)
DMHFOIX	MT	DTT
DMHFOIX	MA	Modulator
DMHFOIX	RN	Differential activation of the -opioid receptor by oxycodone and morphine in pain-related brain regions in a bone cancer pain model. Br J Pharmacol. 2013 Jan;168(2):375-88.
DMHFOIX	RU	https://pubmed.ncbi.nlm.nih.gov/22889192

DMHFOIX	DI	DMHFOIX
DMHFOIX	DN	OxycoDex
DMHFOIX	MI	TT5TPI6
DMHFOIX	MN	Opioid receptor sigma 1 (OPRS1)
DMHFOIX	MT	DTT
DMHFOIX	MA	Modulator
DMHFOIX	RN	Antitussives and substance abuse. Subst Abuse Rehabil. 2013 Nov 6;4:75-82.
DMHFOIX	RU	https://pubmed.ncbi.nlm.nih.gov/24648790

DMHFOIX	DI	DMHFOIX
DMHFOIX	DN	OxycoDex
DMHFOIX	MI	TT3ROYC
DMHFOIX	MN	Serotonin transporter (SERT)
DMHFOIX	MT	DTT
DMHFOIX	MA	Inhibitor
DMHFOIX	RN	Antitussives and substance abuse. Subst Abuse Rehabil. 2013 Nov 6;4:75-82.
DMHFOIX	RU	https://pubmed.ncbi.nlm.nih.gov/24648790

DM02ANM	DI	DM02ANM
DM02ANM	DN	P-1075
DM02ANM	MI	TT1VOHK
DM02ANM	MN	Potassium channel unspecific (KC)
DM02ANM	MT	DTT
DM02ANM	MA	Opener
DM02ANM	RN	The effects of potassium channel opener P1075 on the human saphenous vein and human internal mammary artery. J Cardiovasc Pharmacol. 2011 Jun;57(6):648-55.
DM02ANM	RU	https://pubmed.ncbi.nlm.nih.gov/21346595

DMWCAQD	DI	DMWCAQD
DMWCAQD	DN	P1A
DMWCAQD	MI	TTHI19T
DMWCAQD	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMWCAQD	MT	DTT
DMWCAQD	MA	Modulator
DMWCAQD	RN	IPSAT P1A, a class A beta-lactamase therapy for the prevention of penicillin-induced disruption to the intestinal microflora. Curr Opin Investig Drugs. 2009 Aug;10(8):838-44.
DMWCAQD	RU	https://pubmed.ncbi.nlm.nih.gov/19649928

DM4ZNKX	DI	DM4ZNKX
DM4ZNKX	DN	PA-1806
DM4ZNKX	MI	TTJP4SM
DM4ZNKX	MN	Bacterial Penicillin binding protein (Bact PBP)
DM4ZNKX	MT	DTT
DM4ZNKX	MA	Modulator
DM4ZNKX	RN	Antibacterial activity of BMS-180680, a new catechol-containing monobactam. Antimicrob Agents Chemother. 1997 May;41(5):1010-6.
DM4ZNKX	RU	https://www.ncbi.nlm.nih.gov/pubmed/9145861

DMRSMW8	DI	DMRSMW8
DMRSMW8	DN	PAI-2
DMRSMW8	MI	TTGY7WI
DMRSMW8	MN	Urokinase-type plasminogen activator (PLAU)
DMRSMW8	MT	DTT
DMRSMW8	MA	Inhibitor
DMRSMW8	RN	Topological localization of plasminogen activator inhibitor type 2. Cytometry. 2000 May 1;40(1):32-41.
DMRSMW8	RU	https://pubmed.ncbi.nlm.nih.gov/10754515

DMWCLZ6	DI	DMWCLZ6
DMWCLZ6	DN	PALOSURAN
DMWCLZ6	MI	TTW5UDX
DMWCLZ6	MN	Urotensin II receptor (UTS2R)
DMWCLZ6	MT	DTT
DMWCLZ6	MA	Inhibitor
DMWCLZ6	RN	Urotensin-II receptor modulators as potential drugs. J Med Chem. 2010 Apr 8;53(7):2695-708.
DMWCLZ6	RU	https://pubmed.ncbi.nlm.nih.gov/20043680

DM9SYUT	DI	DM9SYUT
DM9SYUT	DN	PAMAPIMOD
DM9SYUT	MI	TTQBR95
DM9SYUT	MN	Stress-activated protein kinase 2a (p38 alpha)
DM9SYUT	MT	DTT
DM9SYUT	MA	Inhibitor
DM9SYUT	RN	Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. J Med Chem. 2010 Mar 25;53(6):2345-53.
DM9SYUT	RU	https://pubmed.ncbi.nlm.nih.gov/19950901

DM6TPCJ	DI	DM6TPCJ
DM6TPCJ	DN	Panamesine
DM6TPCJ	MI	TT5TPI6
DM6TPCJ	MN	Opioid receptor sigma 1 (OPRS1)
DM6TPCJ	MT	DTT
DM6TPCJ	MA	Binder
DM6TPCJ	RN	Efficacy and safety of the sigma receptor ligand EMD 57445 (panamesine) in patients with schizophrenia: an open clinical trial. Pharmacopsychiatry. 1999 Mar;32(2):68-72.
DM6TPCJ	RU	https://pubmed.ncbi.nlm.nih.gov/10333165

DME4RSI	DI	DME4RSI
DME4RSI	DN	Panomifene
DME4RSI	MI	TTZAYWL
DME4RSI	MN	Estrogen receptor (ESR)
DME4RSI	MT	DTT
DME4RSI	MA	Modulator
DME4RSI	RN	Species differences in metabolism of panomifene, an analogue of tamoxifen. Drug Metab Dispos. 1997 Dec;25(12):1370-8.
DME4RSI	RU	https://pubmed.ncbi.nlm.nih.gov/9394026

DM80UNM	DI	DM80UNM
DM80UNM	DN	PD-134308
DM80UNM	MI	TTVFO0U
DM80UNM	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DM80UNM	MT	DTT
DM80UNM	MA	Modulator
DM80UNM	RN	Comparison of the effects of the cholecystokinin-B receptor antagonist, PD 134308, and the cholecystokinin-A receptor antagonist, L-364,718, on dop... Synapse. 1993 Feb;13(2):117-22.
DM80UNM	RU	https://www.ncbi.nlm.nih.gov/pubmed/8446920

DMMYNKH	DI	DMMYNKH
DMMYNKH	DN	PD-348292
DMMYNKH	MI	TTCIHJA
DMMYNKH	MN	Coagulation factor Xa (F10)
DMMYNKH	MT	DTT
DMMYNKH	MA	Inhibitor
DMMYNKH	RN	Pfizer. Product Development Pipeline. March 31 2009.
DMMYNKH	RU	http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf

DMGD20T	DI	DMGD20T
DMGD20T	DN	PEG-Infergen
DMGD20T	MI	TT95SOA
DMGD20T	MN	Interferon alpha (IFNA)
DMGD20T	MT	DTT
DMGD20T	MA	Modulator
DMGD20T	RN	Patent CN102245599 B.
DMGD20T	RU	http://www.google.com/patents/CN102245599B?cl=en

DMTGBPW	DI	DMTGBPW
DMTGBPW	DN	Pentisomide
DMTGBPW	MI	TTRK8B9
DMTGBPW	MN	Sodium channel unspecific (NaC)
DMTGBPW	MT	DTT
DMTGBPW	MA	Modulator
DMTGBPW	RN	Antiarrhythmic effect related to the plasma concentration of pentisomide in vivo and the antiarrhythmic-concentration relationship in vitro. Drugs Exp Clin Res. 1995;21(4):145-51.
DMTGBPW	RU	https://pubmed.ncbi.nlm.nih.gov/8529527

DMFWC3O	DI	DMFWC3O
DMFWC3O	DN	Perillyl alcohol
DMFWC3O	MI	TTW2R9X
DMFWC3O	MN	GTPase NRas (NRAS)
DMFWC3O	MT	DTT
DMFWC3O	MA	Modulator
DMFWC3O	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2823).
DMFWC3O	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2823

DMBDPN2	DI	DMBDPN2
DMBDPN2	DN	PF-217830
DMBDPN2	MI	TTEX248
DMBDPN2	MN	Dopamine D2 receptor (D2R)
DMBDPN2	MT	DTT
DMBDPN2	MA	Modulator
DMBDPN2	RN	Dual ligands targeting dopamine D2 and serotonin 5-HT1A receptors as new antipsychotical or anti-Parkinsonian agents.Curr Med Chem.2014;21(4):437-57.
DMBDPN2	RU	https://www.ncbi.nlm.nih.gov/pubmed/24164194

DMWYJHC	DI	DMWYJHC
DMWYJHC	DN	PF-4480682
DMWYJHC	MI	TTBMV1G
DMWYJHC	MN	GABA(A) receptor alpha-2 (GABRA2)
DMWYJHC	MT	DTT
DMWYJHC	MA	Modulator
DMWYJHC	RN	WO patent application no. 2014,1515,17, Methods of improving microvascular integrity.
DMWYJHC	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20140925&CC=WO&NR=2014151517A1&KC=A1

DMWYJHC	DI	DMWYJHC
DMWYJHC	DN	PF-4480682
DMWYJHC	MI	TTGXH6N
DMWYJHC	MN	GABA(A) receptor delta (GABRD)
DMWYJHC	MT	DTT
DMWYJHC	MA	Modulator
DMWYJHC	RN	WO patent application no. 2014,1515,17, Methods of improving microvascular integrity.
DMWYJHC	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20140925&CC=WO&NR=2014151517A1&KC=A1

DM6XEQA	DI	DM6XEQA
DM6XEQA	DN	PF-610355
DM6XEQA	MI	TT2CJVK
DM6XEQA	MN	Adrenergic receptor beta-2 (ADRB2)
DM6XEQA	MT	DTT
DM6XEQA	MA	Agonist
DM6XEQA	RN	Inhalation by design: novel ultra-long-acting beta(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup. J Med Chem. 2010 Sep 23;53(18):6640-52.
DM6XEQA	RU	https://pubmed.ncbi.nlm.nih.gov/20804199

DMELXBQ	DI	DMELXBQ
DMELXBQ	DN	PG-530742
DMELXBQ	MI	TTUZ2L5
DMELXBQ	MN	Matrix metalloproteinase-3 (MMP-3)
DMELXBQ	MT	DTT
DMELXBQ	MA	Inhibitor
DMELXBQ	RN	Selective matrix metalloproteinase inhibition attenuates progression of left ventricular dysfunction and remodeling in dogs with chronic heart fail... Am J Physiol Heart Circ Physiol. 2006 Jun;290(6):H2522-7.
DMELXBQ	RU	https://pubmed.ncbi.nlm.nih.gov/16428338

DM2N0TO	DI	DM2N0TO
DM2N0TO	DN	Physostigmine
DM2N0TO	MI	TT1RS9F
DM2N0TO	MN	Acetylcholinesterase (AChE)
DM2N0TO	MT	DTT
DM2N0TO	MA	Inhibitor
DM2N0TO	RN	The effects of physostigmine on acetylcholinesterase activity of CSF plasma and brain. A comparison of intravenous and intraventricular administration in beagle dogs. Neuropharmacology. 1986 Oct;25(10):1167-77.
DM2N0TO	RU	https://pubmed.ncbi.nlm.nih.gov/3785584

DMJKN0B	DI	DMJKN0B
DMJKN0B	DN	PIBROZELESIN HYDROCHLORIDE
DMJKN0B	MI	TTUTN1I
DMJKN0B	MN	Human Deoxyribonucleic acid (hDNA)
DMJKN0B	MT	DTT
DMJKN0B	MA	Binder
DMJKN0B	RN	Use of KW-2189, a DNA minor groove-binding agent, in patients with hepatocellular carcinoma: a north central cancer treatment group (NCCTG) phase II clinical trial. J Gastrointest Cancer. 2007;38(1):10-4.
DMJKN0B	RU	https://pubmed.ncbi.nlm.nih.gov/19065716

DMA13WI	DI	DMA13WI
DMA13WI	DN	Picumeterol
DMA13WI	MI	TT2CJVK
DMA13WI	MN	Adrenergic receptor beta-2 (ADRB2)
DMA13WI	MT	DTT
DMA13WI	MA	Agonist
DMA13WI	RN	Picumeterol: dissociation of improvement in lung function and reduction of airways hyperresponsiveness in asthmatics. Br J Clin Pharmacol. 1997 Feb;43(2):169-76.
DMA13WI	RU	https://pubmed.ncbi.nlm.nih.gov/9131949

DM3ISKB	DI	DM3ISKB
DM3ISKB	DN	PIRODAVIR
DM3ISKB	MI	TT8R3VP
DM3ISKB	MN	Rhinovirus Capsid protein (HRV VP)
DM3ISKB	MT	DTT
DM3ISKB	MA	Modulator
DM3ISKB	RN	In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity. Antimicrob Agents Chemother. 2004 May;48(5):1766-72.
DM3ISKB	RU	https://pubmed.ncbi.nlm.nih.gov/15105133

DMSQ794	DI	DMSQ794
DMSQ794	DN	PKI166
DMSQ794	MI	TTGKNB4
DMSQ794	MN	Epidermal growth factor receptor (EGFR)
DMSQ794	MT	DTT
DMSQ794	MA	Modulator
DMSQ794	RN	Epidermal growth factor receptor inhibitor PKI-166 governs cardiovascular protection without beneficial effects on the kidney in hypertensive 5/6 nephrectomized rats.J Pharmacol Exp Ther.2013 Jun;345(3):393-403.
DMSQ794	RU	https://www.ncbi.nlm.nih.gov/pubmed/23528611

DMLK5IM	DI	DMLK5IM
DMLK5IM	DN	PNU-142633
DMLK5IM	MI	TT6MSOK
DMLK5IM	MN	5-HT 1D receptor (HTR1D)
DMLK5IM	MT	DTT
DMLK5IM	MA	Agonist
DMLK5IM	RN	Further characterization of the 5-HT1 receptors mediating cardiac sympatho-inhibition in pithed rats: pharmacological correlation with the 5-HT1B a... Naunyn Schmiedebergs Arch Pharmacol. 2004 Feb;369(2):220-7.
DMLK5IM	RU	https://pubmed.ncbi.nlm.nih.gov/14673512

DMP43IR	DI	DMP43IR
DMP43IR	DN	Pranazepide
DMP43IR	MI	TTCG0AL
DMP43IR	MN	Cholecystokinin receptor type A (CCKAR)
DMP43IR	MT	DTT
DMP43IR	MA	Inhibitor
DMP43IR	RN	Dual CCK-A and -B receptor antagonists (I) C9-methyl-1,4-benzodiazepines, Bioorg. Med. Chem. Lett. 7(2):169-174 (1997).
DMP43IR	RU	http://www.sciencedirect.com/science/article/pii/S0960894X96006099

DM082ZW	DI	DM082ZW
DM082ZW	DN	Prednisolone sodium metazoate
DM082ZW	MI	DE4LYSA
DM082ZW	MN	Cytochrome P450 3A4 (CYP3A4)
DM082ZW	MT	DME
DM082ZW	MA	Metabolism
DM082ZW	RN	Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor. Biol Pharm Bull. 2003 Apr;26(4):510-7.
DM082ZW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12673034

DM082ZW	DI	DM082ZW
DM082ZW	DN	Prednisolone sodium metazoate
DM082ZW	MI	TTP3UTW
DM082ZW	MN	Steroid hormone receptor ERR (ESRR)
DM082ZW	MT	DTT
DM082ZW	MA	Modulator
DM082ZW	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM082ZW	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMLOGR3	DI	DMLOGR3
DMLOGR3	DN	Pro 542
DMLOGR3	MI	TTBYP1X
DMLOGR3	MN	Human immunodeficiency virus Envelope glycoprotein gp120 (HIV gp120)
DMLOGR3	MT	DTT
DMLOGR3	MA	Modulator
DMLOGR3	RN	Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob Agents Chemother. 2004 Feb;48(2):423-9.
DMLOGR3	RU	https://www.ncbi.nlm.nih.gov/pubmed/14742190

DM8U3R6	DI	DM8U3R6
DM8U3R6	DN	PROXODOLOL
DM8U3R6	MI	TTMXGCW
DM8U3R6	MN	Adrenergic receptor beta-3 (ADRB3)
DM8U3R6	MT	DTT
DM8U3R6	MA	Modulator
DM8U3R6	RN	The efficacy of proxodolol, a new beta-adrenoblockader with alpha-adrenoblockader properties, in its single use in patients with stable stenocardia of effort. Eksp Klin Farmakol. 1994 May-Jun;57(3):47-50.
DM8U3R6	RU	https://pubmed.ncbi.nlm.nih.gov/7914121

DMHDP9R	DI	DMHDP9R
DMHDP9R	DN	PRS-211375 iv
DMHDP9R	MI	TTMSFAW
DMHDP9R	MN	Cannabinoid receptor 2 (CB2)
DMHDP9R	MT	DTT
DMHDP9R	MA	Agonist
DMHDP9R	RN	Brain CB2 Receptors: Implications for Neuropsychiatric Disorders. Pharmaceuticals (Basel) 2010 August; 3(8): 2517-2553.
DMHDP9R	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033937/

DMN4RV0	DI	DMN4RV0
DMN4RV0	DN	PRX-00023
DMN4RV0	MI	TTSQIFT
DMN4RV0	MN	5-HT 1A receptor (HTR1A)
DMN4RV0	MT	DTT
DMN4RV0	MA	Modulator
DMN4RV0	RN	PRX-00023, a selective serotonin 1A receptor agonist, reduces ultrasonic vocalizations in infant rats bred for high infantile anxiety.Pharmacol Biochem Behav.2009 Nov;94(1):8-15.
DMN4RV0	RU	https://www.ncbi.nlm.nih.gov/pubmed/19576924

DMT0KB1	DI	DMT0KB1
DMT0KB1	DN	PSD-506
DMT0KB1	MI	TTYEG6Q
DMT0KB1	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMT0KB1	MT	DTT
DMT0KB1	MA	Modulator
DMT0KB1	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMT0KB1	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMT0KB1	DI	DMT0KB1
DMT0KB1	DN	PSD-506
DMT0KB1	MI	TTQ13Z5
DMT0KB1	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMT0KB1	MT	DTT
DMT0KB1	MA	Modulator
DMT0KB1	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMT0KB1	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMR1OJM	DI	DMR1OJM
DMR1OJM	DN	PSD-508
DMR1OJM	MI	TTK0943
DMR1OJM	MN	Prostaglandin G/H synthase (COX)
DMR1OJM	MT	DTT
DMR1OJM	MA	Inhibitor
DMR1OJM	RN	CN patent application no. 104797935, A method for prognosis and treatment of cancer metastasis.
DMR1OJM	RU	http://www.google.com/patents/CN104797935A?cl=en

DMDOFE7	DI	DMDOFE7
DMDOFE7	DN	PSN357
DMDOFE7	MI	TT31JXP
DMDOFE7	MN	Myophosphorylase (PYGM)
DMDOFE7	MT	DTT
DMDOFE7	MA	Modulator
DMDOFE7	RN	PhRMA
DMDOFE7	RU	http://phrma.org/sites/default/files/pdf/2015-neurological-disorders_drug-list.pdf

DMMF9RS	DI	DMMF9RS
DMMF9RS	DN	PSN-9301
DMMF9RS	MI	TTDIGC1
DMMF9RS	MN	Dipeptidyl peptidase 4 (DPP-4)
DMMF9RS	MT	DTT
DMMF9RS	MA	Inhibitor
DMMF9RS	RN	Navigating the chemical space of dipeptidyl peptidase-4 inhibitors. Drug Des Devel Ther. 2015; 9: 4515-4549.
DMMF9RS	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539085/

DMYM9JL	DI	DMYM9JL
DMYM9JL	DN	PT-14
DMYM9JL	MI	TTD0CIQ
DMYM9JL	MN	Melanocortin receptor 4 (MC4R)
DMYM9JL	MT	DTT
DMYM9JL	MA	Agonist
DMYM9JL	RN	The protective effects of the melanocortin receptor (MCR) agonist, melanotan-II (MTII), against binge-like ethanol drinking are facilitated by deletion of the MC3 receptor in mice. Neuropeptides. 2014 Feb;48(1):47-51.
DMYM9JL	RU	https://pubmed.ncbi.nlm.nih.gov/24290566

DMGO2AV	DI	DMGO2AV
DMGO2AV	DN	PTI-701
DMGO2AV	MI	TTN4QDT
DMGO2AV	MN	Opioid receptor (OPR)
DMGO2AV	MT	DTT
DMGO2AV	MA	Modulator
DMGO2AV	RN	Clinical pipeline report, company report or official report of Pain Therapeutics.
DMGO2AV	RU	http://www.paintrials.com/

DMI8T41	DI	DMI8T41
DMI8T41	DN	Pumafentrine
DMI8T41	MI	TTZCG4L
DMI8T41	MN	Phosphodiesterase 3 (PDE3)
DMI8T41	MT	DTT
DMI8T41	MA	Modulator
DMI8T41	RN	The selective phosphodiesterase 4 inhibitor roflumilast and phosphodiesterase 3/4 inhibitor pumafentrine reduce clinical score and TNF expression in experimental colitis in mice.PLoS One.2013;8(2):e56867.
DMI8T41	RU	https://www.ncbi.nlm.nih.gov/pubmed/23468885

DMWE6V1	DI	DMWE6V1
DMWE6V1	DN	Putrescine
DMWE6V1	MI	DETECWH
DMWE6V1	MN	Amiloride-sensitive amine oxidase (AOC1)
DMWE6V1	MT	DME
DMWE6V1	MA	Metabolism
DMWE6V1	RN	Putrescine metabolism and the study of diamine oxidase activity in vivo. Agents Actions. 1981 Apr;11(1-2):20-7.
DMWE6V1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=6787849

DMWE6V1	DI	DMWE6V1
DMWE6V1	DN	Putrescine
DMWE6V1	MI	TTUMGNO
DMWE6V1	MN	Ornithine decarboxylase (ODC1)
DMWE6V1	MT	DTT
DMWE6V1	MA	Inhibitor
DMWE6V1	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMWE6V1	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMWE6V1	DI	DMWE6V1
DMWE6V1	DN	Putrescine
DMWE6V1	MI	TTBFROQ
DMWE6V1	MN	S-adenosylmethionine decarboxylase proenzyme (AMD1)
DMWE6V1	MT	DTT
DMWE6V1	MA	Inhibitor
DMWE6V1	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMWE6V1	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMRODZS	DI	DMRODZS
DMRODZS	DN	PV-707
DMRODZS	MI	TTDB5IS
DMRODZS	MN	Receptor unspecific (Rec)
DMRODZS	MT	DTT
DMRODZS	MA	Modulator
DMRODZS	RN	EP patent application no. 1904089, Promotion of epithelial regeneration.
DMRODZS	RU	http://www.google.com/patents/EP1904089A2?cl=en

DMD308S	DI	DMD308S
DMD308S	DN	Pyrazinoylguanidine
DMD308S	MI	TTRK8B9
DMD308S	MN	Sodium channel unspecific (NaC)
DMD308S	MT	DTT
DMD308S	MA	Modulator
DMD308S	RN	Design, synthesis, and structure-activity relationships of novel 2-substituted pyrazinoylguanidine epithelial sodium channel blockers: drugs for cystic fibrosis and chronic bronchitis. J Med Chem. 2006 Jul 13;49(14):4098-115.
DMD308S	RU	https://pubmed.ncbi.nlm.nih.gov/16821771

DMTGFV6	DI	DMTGFV6
DMTGFV6	DN	PYY3-36
DMTGFV6	MI	TTJ6WK9
DMTGFV6	MN	Neuropeptide Y receptor type 2 (NPY2R)
DMTGFV6	MT	DTT
DMTGFV6	MA	Agonist
DMTGFV6	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DMTGFV6	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DM2Q5IS	DI	DM2Q5IS
DM2Q5IS	DN	R-1438
DM2Q5IS	MI	TTDIGC1
DM2Q5IS	MN	Dipeptidyl peptidase 4 (DPP-4)
DM2Q5IS	MT	DTT
DM2Q5IS	MA	Inhibitor
DM2Q5IS	RN	Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87.
DM2Q5IS	RU	https://pubmed.ncbi.nlm.nih.gov/19149538

DMAPRGQ	DI	DMAPRGQ
DMAPRGQ	DN	R-1578
DMAPRGQ	MI	TTXJ47W
DMAPRGQ	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMAPRGQ	MT	DTT
DMAPRGQ	MA	Antagonist
DMAPRGQ	RN	Clinical pipeline report, company report or official report of Roche.
DMAPRGQ	RU	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm

DMAPRGQ	DI	DMAPRGQ
DMAPRGQ	DN	R-1578
DMAPRGQ	MI	TT8A9EF
DMAPRGQ	MN	Metabotropic glutamate receptor 3 (mGluR3)
DMAPRGQ	MT	DTT
DMAPRGQ	MA	Antagonist
DMAPRGQ	RN	Clinical pipeline report, company report or official report of Roche.
DMAPRGQ	RU	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm

DMGVRQ2	DI	DMGVRQ2
DMGVRQ2	DN	R-18893
DMGVRQ2	MI	TT84ETX
DMGVRQ2	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMGVRQ2	MT	DTT
DMGVRQ2	MA	Modulator
DMGVRQ2	RN	EP patent application no. 0767664, Combination therapy for hiv infection.
DMGVRQ2	RU	http://www.google.com/patents/EP0767664A2?cl=en

DMEJNM1	DI	DMEJNM1
DMEJNM1	DN	R-343
DMEJNM1	MI	TTOU65C
DMEJNM1	MN	Tyrosine-protein kinase SYK (SYK)
DMEJNM1	MT	DTT
DMEJNM1	MA	Inhibitor
DMEJNM1	RN	A novel Syk kinase inhibitor suitable for inhalation: R-343(. Expert Opin Ther Pat. 2009 Oct;19(10):1469-72.
DMEJNM1	RU	https://pubmed.ncbi.nlm.nih.gov/19552507

DM5NWPD	DI	DM5NWPD
DM5NWPD	DN	R-568
DM5NWPD	MI	TTBUYHA
DM5NWPD	MN	Extracellular calcium-sensing receptor (CASR)
DM5NWPD	MT	DTT
DM5NWPD	MA	Agonist
DM5NWPD	RN	Mixed-effects modeling of the pharmacodynamic response to the calcimimetic agent R-568. Clin Pharmacol Ther. 1999 Jan;65(1):40-9.
DM5NWPD	RU	https://pubmed.ncbi.nlm.nih.gov/9951429

DMJTOP8	DI	DMJTOP8
DMJTOP8	DN	R-61837
DMJTOP8	MI	TT2Y1AN
DMJTOP8	MN	Rhinovirus Protein 1 (HRV P1D)
DMJTOP8	MT	DTT
DMJTOP8	MA	Modulator
DMJTOP8	RN	In vitro activity of R 61837, a new antirhinovirus compound. Arch Virol. 1988;101(3-4):155-67.
DMJTOP8	RU	https://pubmed.ncbi.nlm.nih.gov/2845889

DM2NTJY	DI	DM2NTJY
DM2NTJY	DN	R-68151
DM2NTJY	MI	TT2J34L
DM2NTJY	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM2NTJY	MT	DTT
DM2NTJY	MA	Inhibitor
DM2NTJY	RN	Preview of potential therapeutic applications of leukotriene B4 inhibitors in dermatology. Skin Pharmacol Appl Skin Physiol. 2000 Sep-Oct;13(5):235-45.
DM2NTJY	RU	https://pubmed.ncbi.nlm.nih.gov/10940813

DM2NTJY	DI	DM2NTJY
DM2NTJY	DN	R-68151
DM2NTJY	MI	TTCIHJA
DM2NTJY	MN	Coagulation factor Xa (F10)
DM2NTJY	MT	DTT
DM2NTJY	MA	Inhibitor
DM2NTJY	RN	Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as a factor Xa inhibitor II. Substituent effect on biological activities. Chem Pharm Bull (Tokyo). 2002 Sep;50(9):1187-94.
DM2NTJY	RU	https://pubmed.ncbi.nlm.nih.gov/12237534

DM9BI3Y	DI	DM9BI3Y
DM9BI3Y	DN	R7128
DM9BI3Y	MI	TTMVBWH
DM9BI3Y	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DM9BI3Y	MT	DTT
DM9BI3Y	MA	Inhibitor
DM9BI3Y	RN	Clinical pipeline report, company report or official report of Roche (2009).
DM9BI3Y	RU	http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm

DM4O7KA	DI	DM4O7KA
DM4O7KA	DN	R-84760
DM4O7KA	MI	TTQW87Y
DM4O7KA	MN	Opioid receptor kappa (OPRK1)
DM4O7KA	MT	DTT
DM4O7KA	MA	Agonist
DM4O7KA	RN	Effects of R-84760, a selective kappa-opioid receptor agonist, on nociceptive reflex in isolated neonatal rat spinal cord. Eur J Pharmacol. 1998 Feb 19;343(2-3):171-7.
DM4O7KA	RU	https://pubmed.ncbi.nlm.nih.gov/9570465

DMDOETQ	DI	DMDOETQ
DMDOETQ	DN	R-873
DMDOETQ	MI	TTXEU7H
DMDOETQ	MN	GPCR unspecific (GPCR)
DMDOETQ	MT	DTT
DMDOETQ	MA	Agonist
DMDOETQ	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020830)
DMDOETQ	RU	http://adisinsight.springer.com/drugs/800020830

DMRZI3C	DI	DMRZI3C
DMRZI3C	DN	R-87366
DMRZI3C	MI	TT5FNQT
DMRZI3C	MN	Human immunodeficiency virus Protease (HIV PR)
DMRZI3C	MT	DTT
DMRZI3C	MA	Inhibitor
DMRZI3C	RN	In vitro and ex vivo anti-human immunodeficiency virus (HIV) activities of a new water-soluble HIV protease inhibitor, R-87366, containing (2S,3S)-3-amino-2-hydroxy-4-phenylbutanoic acid. Biol Pharm Bull. 1997 Feb;20(2):175-80.
DMRZI3C	RU	https://pubmed.ncbi.nlm.nih.gov/9057982

DMARQE0	DI	DMARQE0
DMARQE0	DN	Radafaxine
DMARQE0	MI	TTVBI8W
DMARQE0	MN	Dopamine transporter (DAT)
DMARQE0	MT	DTT
DMARQE0	MA	Inhibitor
DMARQE0	RN	Emerging drugs for bipolar disorder. Expert Opin Emerg Drugs. 2006 Nov;11(4):621-34.
DMARQE0	RU	https://pubmed.ncbi.nlm.nih.gov/17064222

DMARQE0	DI	DMARQE0
DMARQE0	DN	Radafaxine
DMARQE0	MI	TTAWNKZ
DMARQE0	MN	Norepinephrine transporter (NET)
DMARQE0	MT	DTT
DMARQE0	MA	Inhibitor
DMARQE0	RN	Emerging drugs for bipolar disorder. Expert Opin Emerg Drugs. 2006 Nov;11(4):621-34.
DMARQE0	RU	https://pubmed.ncbi.nlm.nih.gov/17064222

DMARQE0	DI	DMARQE0
DMARQE0	DN	Radafaxine
DMARQE0	MI	DTUGYRD
DMARQE0	MN	P-glycoprotein 1 (ABCB1)
DMARQE0	MT	DTP
DMARQE0	MA	Substrate
DMARQE0	RN	Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein. Biol Pharm Bull. 2008 Feb;31(2):231-4.
DMARQE0	RU	https://doi.org/10.1248/bpb.31.231

DMI1SXB	DI	DMI1SXB
DMI1SXB	DN	Rafabegron
DMI1SXB	MI	TTMXGCW
DMI1SXB	MN	Adrenergic receptor beta-3 (ADRB3)
DMI1SXB	MT	DTT
DMI1SXB	MA	Modulator
DMI1SXB	RN	Lack of an effect of a novel beta3-adrenoceptor agonist, TAK-677, on energy metabolism in obese individuals: a double-blind, placebo-controlled ran... J Clin Endocrinol Metab. 2007 Feb;92(2):527-31.
DMI1SXB	RU	https://pubmed.ncbi.nlm.nih.gov/17118998

DMYSADI	DI	DMYSADI
DMYSADI	DN	RBx10558
DMYSADI	MI	TTPADOQ
DMYSADI	MN	HMG-CoA reductase (HMGCR)
DMYSADI	MT	DTT
DMYSADI	MA	Inhibitor
DMYSADI	RN	New Frontiers in the Treatment of Diabetic Dyslipidemia. Rev Diabet Stud. 2013 Summer-Fall; 10(2-3): 204-212.
DMYSADI	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063101/

DM7OD3J	DI	DM7OD3J
DM7OD3J	DN	RBx-2258
DM7OD3J	MI	TTNGILX
DM7OD3J	MN	Adrenergic receptor alpha-1A (ADRA1A)
DM7OD3J	MT	DTT
DM7OD3J	MA	Antagonist
DM7OD3J	RN	Drug Metabolism and Pharmacokinetics. Indian J Pharmacol. 2008 October; 40(Suppl 2): S91-S97.
DM7OD3J	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3086155/

DMIEFH0	DI	DMIEFH0
DMIEFH0	DN	REC-15/3079
DMIEFH0	MI	TTSQIFT
DMIEFH0	MN	5-HT 1A receptor (HTR1A)
DMIEFH0	MT	DTT
DMIEFH0	MA	Antagonist
DMIEFH0	RN	N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-nitrophenyl) cyclohexanecarboxamide: a novel pre- and postsynaptic 5-hydroxytryptamine(1A) receptor antagonist active on the lower urinary tract. JPharmacol Exp Ther. 2001 Dec;299(3):1027-37.
DMIEFH0	RU	https://pubmed.ncbi.nlm.nih.gov/11714892

DMX4ZWK	DI	DMX4ZWK
DMX4ZWK	DN	REC-15-2739
DMX4ZWK	MI	TTNGILX
DMX4ZWK	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMX4ZWK	MT	DTT
DMX4ZWK	MA	Inhibitor
DMX4ZWK	RN	Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
DMX4ZWK	RU	https://pubmed.ncbi.nlm.nih.gov/15664832

DMX4ZWK	DI	DMX4ZWK
DMX4ZWK	DN	REC-15-2739
DMX4ZWK	MI	TT34BHT
DMX4ZWK	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMX4ZWK	MT	DTT
DMX4ZWK	MA	Modulator
DMX4ZWK	RN	Functional antagonistic activity of Rec 15/2739, a novel alpha-1 antagonist selective for the lower urinary tract, on noradrenaline-induced contraction of human prostate and mesenteric artery. J Pharmacol Exp Ther. 1996 Jun;277(3):1237-46.
DMX4ZWK	RU	https://pubmed.ncbi.nlm.nih.gov/8667184

DMIN73Y	DI	DMIN73Y
DMIN73Y	DN	Reglixane
DMIN73Y	MI	TTJ584C
DMIN73Y	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMIN73Y	MT	DTT
DMIN73Y	MA	Modulator
DMIN73Y	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMIN73Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMIN73Y	DI	DMIN73Y
DMIN73Y	DN	Reglixane
DMIN73Y	MI	TTZMAO3
DMIN73Y	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMIN73Y	MT	DTT
DMIN73Y	MA	Modulator
DMIN73Y	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMIN73Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMLJEFH	DI	DMLJEFH
DMLJEFH	DN	Relacatib
DMLJEFH	MI	TTDZN01
DMLJEFH	MN	Cathepsin K (CTSK)
DMLJEFH	MT	DTT
DMLJEFH	MA	Inhibitor
DMLJEFH	RN	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett. 2008 Feb 1;18(3):923-8.
DMLJEFH	RU	https://pubmed.ncbi.nlm.nih.gov/18226527

DMHCBQS	DI	DMHCBQS
DMHCBQS	DN	ReN-1869
DMHCBQS	MI	TTTIBOJ
DMHCBQS	MN	Histamine H1 receptor (H1R)
DMHCBQS	MT	DTT
DMHCBQS	MA	Antagonist
DMHCBQS	RN	ReN 1869, a novel tricyclic antihistamine, is active against neurogenic pain and inflammation. Eur J Pharmacol. 2002 Jan 18;435(1):43-57.
DMHCBQS	RU	https://pubmed.ncbi.nlm.nih.gov/11790377

DMSOALX	DI	DMSOALX
DMSOALX	DN	Repifermin
DMSOALX	MI	TTNPEFX
DMSOALX	MN	Fibroblast growth factor-10 (FGF10)
DMSOALX	MT	DTT
DMSOALX	MA	Modulator
DMSOALX	RN	Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Aliment Pharmacol Ther. 2003 Jun 1;17(11):1355-64.
DMSOALX	RU	https://pubmed.ncbi.nlm.nih.gov/12786629

DM3EAYN	DI	DM3EAYN
DM3EAYN	DN	RESEQUINIL
DM3EAYN	MI	TTEX6LM
DM3EAYN	MN	GABA(A) receptor gamma-3 (GABRG3)
DM3EAYN	MT	DTT
DM3EAYN	MA	Agonist
DM3EAYN	RN	WO patent application no. 2010,0024,51, Naphthyridin derivatives.
DM3EAYN	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20100107&CC=WO&NR=2010002451A1&KC=A1

DM3TU7D	DI	DM3TU7D
DM3TU7D	DN	RG1578
DM3TU7D	MI	TTXJ47W
DM3TU7D	MN	Metabotropic glutamate receptor 2 (mGluR2)
DM3TU7D	MT	DTT
DM3TU7D	MA	Modulator
DM3TU7D	RN	Company report (Roche pipeline: 15 April 2014)
DM3TU7D	RU	http://www.roche.com/irp1q14e-a.pdf

DM5KJGB	DI	DM5KJGB
DM5KJGB	DN	RG7160
DM5KJGB	MI	TTGKNB4
DM5KJGB	MN	Epidermal growth factor receptor (EGFR)
DM5KJGB	MT	DTT
DM5KJGB	MA	Modulator
DM5KJGB	RN	GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab. Clin Cancer Res. 2013 Mar 1;19(5):1126-38.
DM5KJGB	RU	https://pubmed.ncbi.nlm.nih.gov/23209031

DMCQRS2	DI	DMCQRS2
DMCQRS2	DN	RG7414
DMCQRS2	MI	TT7WD0H
DMCQRS2	MN	Epidermal growth factor-like protein 7 (EGFL7)
DMCQRS2	MT	DTT
DMCQRS2	MA	Modulator
DMCQRS2	RN	Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy. J Clin Invest. 2013 September 3; 123(9): 3997-4009.
DMCQRS2	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3754254/

DM32IV4	DI	DM32IV4
DM32IV4	DN	RG7593
DM32IV4	MI	TTM6QSK
DM32IV4	MN	B-cell receptor CD22 (CD22)
DM32IV4	MT	DTT
DM32IV4	MA	Modulator
DM32IV4	RN	Clinical pipeline report, company report or official report of Roche.
DM32IV4	RU	http://www.roche.com/irp3q12e-a.pdf

DMPQC18	DI	DMPQC18
DMPQC18	DN	RG7685
DMPQC18	MI	TTYMKBE
DMPQC18	MN	Gastric inhibitory polypeptide receptor (GIPR)
DMPQC18	MT	DTT
DMPQC18	MA	Modulator
DMPQC18	RN	Company report (Roche pipeline: October 16, 2012)
DMPQC18	RU	http://www.roche.com/irp3q12e-a.pdf

DMPQC18	DI	DMPQC18
DMPQC18	DN	RG7685
DMPQC18	MI	TTVIMDE
DMPQC18	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMPQC18	MT	DTT
DMPQC18	MA	Modulator
DMPQC18	RN	Company report (Roche pipeline: October 16, 2012)
DMPQC18	RU	http://www.roche.com/irp3q12e-a.pdf

DMI1XQ9	DI	DMI1XQ9
DMI1XQ9	DN	RG7697
DMI1XQ9	MI	TTYMKBE
DMI1XQ9	MN	Gastric inhibitory polypeptide receptor (GIPR)
DMI1XQ9	MT	DTT
DMI1XQ9	MA	Modulator
DMI1XQ9	RN	Company report (Roche pipeline: 16 October 2014)
DMI1XQ9	RU	http://www.roche.com/dam/jcr:d7744c7f-f7de-46b5-b028-df69d7bc3a05/en/irp3q14e-a.pdf

DMQ4IKZ	DI	DMQ4IKZ
DMQ4IKZ	DN	RHIZOXIN
DMQ4IKZ	MI	TTML2WA
DMQ4IKZ	MN	Tubulin (TUB)
DMQ4IKZ	MT	DTT
DMQ4IKZ	MA	Inhibitor
DMQ4IKZ	RN	Tubulin polymerization inhibitors with a fluorinated phthalimide skeleton derived from thalidomide. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4748-51.
DMQ4IKZ	RU	https://pubmed.ncbi.nlm.nih.gov/16870433

DMQ4IKZ	DI	DMQ4IKZ
DMQ4IKZ	DN	RHIZOXIN
DMQ4IKZ	MI	TTYFKSZ
DMQ4IKZ	MN	Tubulin beta (TUBB)
DMQ4IKZ	MT	DTT
DMQ4IKZ	MA	Inhibitor
DMQ4IKZ	RN	Tubulin polymerization inhibitors with a fluorinated phthalimide skeleton derived from thalidomide. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4748-51.
DMQ4IKZ	RU	https://pubmed.ncbi.nlm.nih.gov/16870433

DMD8ZSW	DI	DMD8ZSW
DMD8ZSW	DN	Rilotumumab
DMD8ZSW	MI	TT4V2JM
DMD8ZSW	MN	Hepatocyte growth factor (HGF)
DMD8ZSW	MT	DTT
DMD8ZSW	RN	Clinical pipeline report, company report or official report of Amgen (2009).
DMD8ZSW	RU	http://www.amgen.com/science/pipe.jsp

DME5MGP	DI	DME5MGP
DME5MGP	DN	RIPISARTAN
DME5MGP	MI	TT8DBY3
DME5MGP	MN	Angiotensin II receptor type-1 (AGTR1)
DME5MGP	MT	DTT
DME5MGP	MA	Antagonist
DME5MGP	RN	In vitro pharmacological characterization of UP 269-6, a novel nonpeptide angiotensin II receptor antagonist. Fundam Clin Pharmacol. 1995;9(2):119-28.
DME5MGP	RU	https://pubmed.ncbi.nlm.nih.gov/7628824

DMNRGB7	DI	DMNRGB7
DMNRGB7	DN	Risotilide
DMNRGB7	MI	TT1VOHK
DMNRGB7	MN	Potassium channel unspecific (KC)
DMNRGB7	MT	DTT
DMNRGB7	MA	Opener
DMNRGB7	RN	Electrophysiological effects of left ventricular hypertrophy. Effect of calcium and potassium channel blockade. Circulation. 1991 Jun;83(6):2067-75.
DMNRGB7	RU	https://pubmed.ncbi.nlm.nih.gov/1645624

DMVHT6F	DI	DMVHT6F
DMVHT6F	DN	Rispenzepine
DMVHT6F	MI	TTZ9SOR
DMVHT6F	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMVHT6F	MT	DTT
DMVHT6F	MA	Antagonist
DMVHT6F	RN	Evidence for prejunctional muscarinic autoreceptors in human and guinea pig trachea. Am J Respir Crit Care Med. 1995 Sep;152(3):872-8.
DMVHT6F	RU	https://pubmed.ncbi.nlm.nih.gov/7663798

DMOZEN6	DI	DMOZEN6
DMOZEN6	DN	RJR-2403
DMOZEN6	MI	TTJSZTB
DMOZEN6	MN	Nicotinic acetylcholine receptor (nAChR)
DMOZEN6	MT	DTT
DMOZEN6	MA	Agonist
DMOZEN6	RN	The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control. Expert Opin Investig Drugs. 2001 Oct;10(10):1819-30.
DMOZEN6	RU	https://pubmed.ncbi.nlm.nih.gov/11772288

DMHSUQ1	DI	DMHSUQ1
DMHSUQ1	DN	R-ketoprofen
DMHSUQ1	MI	TTMWT8Z
DMHSUQ1	MN	C-X-C chemokine receptor type 1 (CXCR1)
DMHSUQ1	MT	DTT
DMHSUQ1	MA	Inhibitor
DMHSUQ1	RN	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
DMHSUQ1	RU	https://pubmed.ncbi.nlm.nih.gov/15974585

DMHSUQ1	DI	DMHSUQ1
DMHSUQ1	DN	R-ketoprofen
DMHSUQ1	MI	TT30C9G
DMHSUQ1	MN	C-X-C chemokine receptor type 2 (CXCR2)
DMHSUQ1	MT	DTT
DMHSUQ1	MA	Inhibitor
DMHSUQ1	RN	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
DMHSUQ1	RU	https://pubmed.ncbi.nlm.nih.gov/15974585

DMHSUQ1	DI	DMHSUQ1
DMHSUQ1	DN	R-ketoprofen
DMHSUQ1	MI	TTCTE1G
DMHSUQ1	MN	Interleukin-8 (IL8)
DMHSUQ1	MT	DTT
DMHSUQ1	MA	Inhibitor
DMHSUQ1	RN	Structure-Activity Relationship of novel phenylacetic CXCR1 inhibitors. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4026-30.
DMHSUQ1	RU	https://pubmed.ncbi.nlm.nih.gov/19560921

DMHSUQ1	DI	DMHSUQ1
DMHSUQ1	DN	R-ketoprofen
DMHSUQ1	MI	TT8NGED
DMHSUQ1	MN	Prostaglandin G/H synthase 1 (COX-1)
DMHSUQ1	MT	DTT
DMHSUQ1	MA	Inhibitor
DMHSUQ1	RN	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
DMHSUQ1	RU	https://pubmed.ncbi.nlm.nih.gov/15974585

DMHSUQ1	DI	DMHSUQ1
DMHSUQ1	DN	R-ketoprofen
DMHSUQ1	MI	TTVKILB
DMHSUQ1	MN	Prostaglandin G/H synthase 2 (COX-2)
DMHSUQ1	MT	DTT
DMHSUQ1	MA	Inhibitor
DMHSUQ1	RN	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
DMHSUQ1	RU	https://pubmed.ncbi.nlm.nih.gov/15974585

DM5P1KQ	DI	DM5P1KQ
DM5P1KQ	DN	RN6G
DM5P1KQ	MI	TTE4KHA
DM5P1KQ	MN	Amyloid beta A4 protein (APP)
DM5P1KQ	MT	DTT
DM5P1KQ	MA	Inhibitor
DM5P1KQ	RN	Advances in the management of macular degeneration. F1000Prime Rep. 2014; 6: 29.
DM5P1KQ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017905/

DME9V0I	DI	DME9V0I
DME9V0I	DN	RNAPc2
DME9V0I	MI	TTF0EGX
DME9V0I	MN	Coagulation factor VII (F7)
DME9V0I	MT	DTT
DME9V0I	MA	Modulator
DME9V0I	RN	rNAPc2 inhibits colorectal cancer in mice through tissue factor. Clin Cancer Res. 2009 Jan 1;15(1):208-16.
DME9V0I	RU	https://pubmed.ncbi.nlm.nih.gov/19118048

DM4YA63	DI	DM4YA63
DM4YA63	DN	Ro-23-9424
DM4YA63	MI	TTN6J5F
DM4YA63	MN	Bacterial DNA gyrase (Bact gyrase)
DM4YA63	MT	DTT
DM4YA63	MA	Modulator
DM4YA63	RN	Mode of action of the dual-action cephalosporin Ro 23-9424. Antimicrob Agents Chemother. 1989 Jul;33(7):1067-71.
DM4YA63	RU	https://www.ncbi.nlm.nih.gov/pubmed/2675755

DM01MRZ	DI	DM01MRZ
DM01MRZ	DN	Ro-24-4736
DM01MRZ	MI	TTQL5VC
DM01MRZ	MN	Platelet-activating factor receptor (PTAFR)
DM01MRZ	MT	DTT
DM01MRZ	MA	Antagonist
DM01MRZ	RN	Pharmacology of a potent platelet-activating factor antagonist: Ro 24-4736. J Pharmacol Exp Ther. 1991 Oct;259(1):78-85.
DM01MRZ	RU	https://pubmed.ncbi.nlm.nih.gov/1656030

DMPB80O	DI	DMPB80O
DMPB80O	DN	RO-26-9228
DMPB80O	MI	TTK59TV
DMPB80O	MN	Vitamin D3 receptor (VDR)
DMPB80O	MT	DTT
DMPB80O	MA	Agonist
DMPB80O	RN	Evidence for tissue- and cell-type selective activation of the vitamin D receptor by Ro-26-9228, a noncalcemic analog of vitamin D3. J Cell Biochem. 2003 Feb 1;88(2):267-73.
DMPB80O	RU	https://pubmed.ncbi.nlm.nih.gov/12520525

DMH912O	DI	DMH912O
DMH912O	DN	RO-48-6791
DMH912O	MI	TTEX6LM
DMH912O	MN	GABA(A) receptor gamma-3 (GABRG3)
DMH912O	MT	DTT
DMH912O	MA	Modulator
DMH912O	RN	Integrated pharmacokinetics and pharmacodynamics of Ro 48-6791, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects. Br J Clin Pharmacol. 1997 Nov;44(5):477-86.
DMH912O	RU	https://pubmed.ncbi.nlm.nih.gov/9384465

DMZAISC	DI	DMZAISC
DMZAISC	DN	Robalzotan
DMZAISC	MI	TTSQIFT
DMZAISC	MN	5-HT 1A receptor (HTR1A)
DMZAISC	MT	DTT
DMZAISC	MA	Antagonist
DMZAISC	RN	Use of PET and the radioligand [carbonyl-(11)C]WAY-100635 in psychotropic drug development. Nucl Med Biol. 2000 Jul;27(5):515-21.
DMZAISC	RU	https://pubmed.ncbi.nlm.nih.gov/10962260

DM6OSPQ	DI	DM6OSPQ
DM6OSPQ	DN	Rofleponide
DM6OSPQ	MI	TTPNQAC
DM6OSPQ	MN	Estrogen-related receptor-alpha (ESRRA)
DM6OSPQ	MT	DTT
DM6OSPQ	MA	Modulator
DM6OSPQ	RN	Direct activation of GABAA receptors by loreclezole, an anticonvulsant drug with selectivity for the beta-subunit. Neuropharmacology. 1996;35(12):1753-60.
DM6OSPQ	RU	https://pubmed.ncbi.nlm.nih.gov/9076754

DM8Q7XV	DI	DM8Q7XV
DM8Q7XV	DN	Rolafagrel
DM8Q7XV	MI	TTKNWZ4
DM8Q7XV	MN	Thromboxane-A synthase (TBXAS1)
DM8Q7XV	MT	DTT
DM8Q7XV	MA	Inhibitor
DM8Q7XV	RN	Inhibition by FCE 22178 of platelet and glomerular thromboxane synthase in animal and human kidney disease. Adv Prostaglandin Thromboxane Leukot Res. 1991;21B:707-10.
DM8Q7XV	RU	https://pubmed.ncbi.nlm.nih.gov/1825400

DMYDWHN	DI	DMYDWHN
DMYDWHN	DN	Romergoline
DMYDWHN	MI	TTEX248
DMYDWHN	MN	Dopamine D2 receptor (D2R)
DMYDWHN	MT	DTT
DMYDWHN	MA	Modulator
DMYDWHN	RN	CA patent application no. 648479, Implants for the treatment of dopamine associated states.
DMYDWHN	RU	https://www.google.com.ar/patents/CA2648479A1?cl=en&hl=zh-CN

DM10ZJP	DI	DM10ZJP
DM10ZJP	DN	Ronacaleret
DM10ZJP	MI	TTBUYHA
DM10ZJP	MN	Extracellular calcium-sensing receptor (CASR)
DM10ZJP	MT	DTT
DM10ZJP	MA	Antagonist
DM10ZJP	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DM10ZJP	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMNBUS7	DI	DMNBUS7
DMNBUS7	DN	Rozrolimupab
DMNBUS7	MI	TTLCKI8
DMNBUS7	MN	Blood group Rh(D) polypeptide (RHD)
DMNBUS7	MT	DTT
DMNBUS7	RN	Rozrolimupab, symphobodies against rhesus D, for the potential prevention of hemolytic disease of the newborn and the treatment of idiopathic thrombocytopenic purpura. Curr Opin Mol Ther. 2010 Dec;12(6):734-40.
DMNBUS7	RU	https://pubmed.ncbi.nlm.nih.gov/21154165

DMTQ3BS	DI	DMTQ3BS
DMTQ3BS	DN	RP-64477
DMTQ3BS	MI	TTMF541
DMTQ3BS	MN	Liver carboxylesterase (CES1)
DMTQ3BS	MT	DTT
DMTQ3BS	MA	Modulator
DMTQ3BS	RN	RP 64477: a potent inhibitor of acyl-coenzyme A:cholesterol O-acyltransferase with low systemic bioavailability. Biochem Pharmacol. 1996 Feb 23;51(4):413-21.
DMTQ3BS	RU	https://pubmed.ncbi.nlm.nih.gov/8619885

DMRGC5B	DI	DMRGC5B
DMRGC5B	DN	RPR-106541
DMRGC5B	MI	TTPNQAC
DMRGC5B	MN	Estrogen-related receptor-alpha (ESRRA)
DMRGC5B	MT	DTT
DMRGC5B	MA	Agonist
DMRGC5B	RN	Use of the steroid derivative RPR 106541 in combination with site-directed mutagenesis for enhanced cytochrome P-450 3A4 structure/function analysis. J Pharmacol Exp Ther. 1999 Aug;290(2):594-602.
DMRGC5B	RU	https://pubmed.ncbi.nlm.nih.gov/10411567

DM4GVZ9	DI	DM4GVZ9
DM4GVZ9	DN	RQ-00317076
DM4GVZ9	MI	TTVKILB
DM4GVZ9	MN	Prostaglandin G/H synthase 2 (COX-2)
DM4GVZ9	MT	DTT
DM4GVZ9	MA	Inhibitor
DM4GVZ9	RN	Clinical pipeline report, company report or official report of raqualia.
DM4GVZ9	RU	http://www.raqualia.com/rq-cms/wp-content/uploads/2012/03/240313_Mid-Term-Business-Plan_final.pdf

DMOTANY	DI	DMOTANY
DMOTANY	DN	RS-130830
DMOTANY	MI	TTMX39J
DMOTANY	MN	Matrix metalloproteinase-1 (MMP-1)
DMOTANY	MT	DTT
DMOTANY	MA	Inhibitor
DMOTANY	RN	Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13). Bioorg Med Chem Lett. 2005 Feb 15;15(4):1101-6.
DMOTANY	RU	https://pubmed.ncbi.nlm.nih.gov/15686921

DMOTANY	DI	DMOTANY
DMOTANY	DN	RS-130830
DMOTANY	MI	TTHY57M
DMOTANY	MN	Matrix metalloproteinase-13 (MMP-13)
DMOTANY	MT	DTT
DMOTANY	MA	Inhibitor
DMOTANY	RN	Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13). Bioorg Med Chem Lett. 2005 Feb 15;15(4):1101-6.
DMOTANY	RU	https://pubmed.ncbi.nlm.nih.gov/15686921

DMOTANY	DI	DMOTANY
DMOTANY	DN	RS-130830
DMOTANY	MI	TTLM12X
DMOTANY	MN	Matrix metalloproteinase-2 (MMP-2)
DMOTANY	MT	DTT
DMOTANY	MA	Inhibitor
DMOTANY	RN	Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13). Bioorg Med Chem Lett. 2005 Feb 15;15(4):1101-6.
DMOTANY	RU	https://pubmed.ncbi.nlm.nih.gov/15686921

DMOTANY	DI	DMOTANY
DMOTANY	DN	RS-130830
DMOTANY	MI	TTUZ2L5
DMOTANY	MN	Matrix metalloproteinase-3 (MMP-3)
DMOTANY	MT	DTT
DMOTANY	MA	Inhibitor
DMOTANY	RN	Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13). Bioorg Med Chem Lett. 2005 Feb 15;15(4):1101-6.
DMOTANY	RU	https://pubmed.ncbi.nlm.nih.gov/15686921

DMOTANY	DI	DMOTANY
DMOTANY	DN	RS-130830
DMOTANY	MI	TT6X50U
DMOTANY	MN	Matrix metalloproteinase-9 (MMP-9)
DMOTANY	MT	DTT
DMOTANY	MA	Inhibitor
DMOTANY	RN	Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13). Bioorg Med Chem Lett. 2005 Feb 15;15(4):1101-6.
DMOTANY	RU	https://pubmed.ncbi.nlm.nih.gov/15686921

DMERM0K	DI	DMERM0K
DMERM0K	DN	RS-8359
DMERM0K	MI	DE4LYSA
DMERM0K	MN	Cytochrome P450 3A4 (CYP3A4)
DMERM0K	MT	DME
DMERM0K	MA	Metabolism
DMERM0K	RN	Stereoselective pharmacokinetics of RS-8359, a selective and reversible MAO-A inhibitor, by species-dependent drug-metabolizing enzymes. Chirality. 2005 Mar;17(3):135-41.
DMERM0K	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15704197

DMERM0K	DI	DMERM0K
DMERM0K	DN	RS-8359
DMERM0K	MI	TT3WG5C
DMERM0K	MN	Monoamine oxidase type A (MAO-A)
DMERM0K	MT	DTT
DMERM0K	MA	Inhibitor
DMERM0K	RN	Stereospecific oxidation of the (S)-enantiomer of RS-8359, a selective and reversible monoamine oxidase A (MAO-A) inhibitor, by aldehyde oxidase. Xenobiotica. 2005 Jun;35(6):561-73.
DMERM0K	RU	https://pubmed.ncbi.nlm.nih.gov/16192108

DMIKUXN	DI	DMIKUXN
DMIKUXN	DN	RSD-921
DMIKUXN	MI	TTRK8B9
DMIKUXN	MN	Sodium channel unspecific (NaC)
DMIKUXN	MT	DTT
DMIKUXN	MA	Modulator
DMIKUXN	RN	Molecular analysis of the Na+ channel blocking actions of the novel class I anti-arrhythmic agent RSD 921. Br J Pharmacol. 1999 May;127(1):9-18.
DMIKUXN	RU	https://pubmed.ncbi.nlm.nih.gov/10369450

DMPAH74	DI	DMPAH74
DMPAH74	DN	R-sibutramine metabolite
DMPAH74	MI	TTAWNKZ
DMPAH74	MN	Norepinephrine transporter (NET)
DMPAH74	MT	DTT
DMPAH74	MA	Modulator
DMPAH74	RN	Monoamine reuptake site occupancy of sibutramine: Relationship to antidepressant-like and thermogenic effects in rats.Eur J Pharmacol.2014 Aug 15;737:47-56.
DMPAH74	RU	https://www.ncbi.nlm.nih.gov/pubmed/24821570

DMPAH74	DI	DMPAH74
DMPAH74	DN	R-sibutramine metabolite
DMPAH74	MI	TT3ROYC
DMPAH74	MN	Serotonin transporter (SERT)
DMPAH74	MT	DTT
DMPAH74	MA	Modulator
DMPAH74	RN	Monoamine reuptake site occupancy of sibutramine: Relationship to antidepressant-like and thermogenic effects in rats.Eur J Pharmacol.2014 Aug 15;737:47-56.
DMPAH74	RU	https://www.ncbi.nlm.nih.gov/pubmed/24821570

DMR0K85	DI	DMR0K85
DMR0K85	DN	RX-77368
DMR0K85	MI	TT2Z39D
DMR0K85	MN	Thyrotropin-releasing hormone (TRH)
DMR0K85	MT	DTT
DMR0K85	MA	Modulator
DMR0K85	RN	Intracisternal urocortin inhibits vagally stimulated gastric motility in rats: role of CRF(2).Br J Pharmacol.2002 May;136(2):237-47.
DMR0K85	RU	https://www.ncbi.nlm.nih.gov/pubmed/12010772

DMS6NAK	DI	DMS6NAK
DMS6NAK	DN	S-12363
DMS6NAK	MI	TTYFKSZ
DMS6NAK	MN	Tubulin beta (TUBB)
DMS6NAK	MT	DTT
DMS6NAK	MA	Modulator
DMS6NAK	RN	Microtubule assembly protects the region 28-38 of the beta- tubulin subunit. Article first published online: 4 FEB 2005.
DMS6NAK	RU	http://onlinelibrary.wiley.com/doi/10.1002/cm.970220104/abstract

DMLCYX8	DI	DMLCYX8
DMLCYX8	DN	S-15261
DMLCYX8	MI	TTZOPHG
DMLCYX8	MN	Insulin (INS)
DMLCYX8	MT	DTT
DMLCYX8	MA	Modulator
DMLCYX8	RN	Beneficial insulin-sensitizing and vascular effects of S15261 in the insulin-resistant JCR:LA-cp rat. J Pharmacol Exp Ther. 2000 Nov;295(2):753-60.
DMLCYX8	RU	https://pubmed.ncbi.nlm.nih.gov/11046115

DM51WJN	DI	DM51WJN
DM51WJN	DN	S-16020-2
DM51WJN	MI	TTGTQHC
DM51WJN	MN	DNA topoisomerase I (TOP1)
DM51WJN	MT	DTT
DM51WJN	MA	Modulator
DM51WJN	RN	Cellular resistance to the antitumor DNA topoisomerase II inhibitor S16020-2: importance of the N-[2(Dimethylamino)ethyl]carbamoyl side chain. Mol Pharmacol. 2000 Oct;58(4):709-18.
DM51WJN	RU	https://www.ncbi.nlm.nih.gov/pubmed/10999940

DMA01BV	DI	DMA01BV
DMA01BV	DN	S-18986
DMA01BV	MI	TTAN6JD
DMA01BV	MN	Glutamate receptor AMPA (GRIA)
DMA01BV	MT	DTT
DMA01BV	MA	Modulator
DMA01BV	RN	Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
DMA01BV	RU	https://pubmed.ncbi.nlm.nih.gov/16377242

DMMSZ1A	DI	DMMSZ1A
DMMSZ1A	DN	S-2474
DMMSZ1A	MI	TTVKILB
DMMSZ1A	MN	Prostaglandin G/H synthase 2 (COX-2)
DMMSZ1A	MT	DTT
DMMSZ1A	MA	Inhibitor
DMMSZ1A	RN	Effects of S-2474, a novel nonsteroidal anti-inflammatory drug, on amyloid beta protein-induced neuronal cell death. Br J Pharmacol. 2001 Oct;134(3):673-81.
DMMSZ1A	RU	https://pubmed.ncbi.nlm.nih.gov/11588123

DMQ2RDZ	DI	DMQ2RDZ
DMQ2RDZ	DN	S-312-d
DMQ2RDZ	MI	TT5HONZ
DMQ2RDZ	MN	Calcium channel unspecific (CaC)
DMQ2RDZ	MT	DTT
DMQ2RDZ	MA	Blocker
DMQ2RDZ	RN	Protective effects of a selective L-type voltage-sensitive calcium channel blocker, S-312-d, on neuronal cell death. Biochem Pharmacol. 2004 Mar 15;67(6):1153-65.
DMQ2RDZ	RU	https://pubmed.ncbi.nlm.nih.gov/15006551

DM2X6ME	DI	DM2X6ME
DM2X6ME	DN	S-5751
DM2X6ME	MI	TTNVEIR
DM2X6ME	MN	Prostaglandin D2 receptor (PTGDR)
DM2X6ME	MT	DTT
DM2X6ME	MA	Antagonist
DM2X6ME	RN	Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36.
DM2X6ME	RU	https://pubmed.ncbi.nlm.nih.gov/21948793

DM9BEDL	DI	DM9BEDL
DM9BEDL	DN	S-8510
DM9BEDL	MI	TTPTXIN
DM9BEDL	MN	Translocator protein (TSPO)
DM9BEDL	MT	DTT
DM9BEDL	MA	Agonist
DM9BEDL	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DM9BEDL	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMER3I9	DI	DMER3I9
DMER3I9	DN	S-9788
DMER3I9	MI	TTO32GK
DMER3I9	MN	P-glycoprotein (P-GP)
DMER3I9	MT	DTT
DMER3I9	MA	Modulator
DMER3I9	RN	In vitro activity of S 9788 on a multidrug-resistant leukemic cell line and on normal hematopoietic cells-reversal of multidrug resistance by sera from phase I-treated patients. Cancer Chemother Pharmacol. 1995;36(3):195-203.
DMER3I9	RU	https://pubmed.ncbi.nlm.nih.gov/7781138

DMER3I9	DI	DMER3I9
DMER3I9	DN	S-9788
DMER3I9	MI	DTUGYRD
DMER3I9	MN	P-glycoprotein 1 (ABCB1)
DMER3I9	MT	DTP
DMER3I9	MA	Substrate
DMER3I9	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMER3I9	RU	https://doi.org/10.1007/s11095-012-0935-x

DMEO6A5	DI	DMEO6A5
DMEO6A5	DN	S-9977
DMEO6A5	MI	TT1RS9F
DMEO6A5	MN	Acetylcholinesterase (AChE)
DMEO6A5	MT	DTT
DMEO6A5	MA	Inhibitor
DMEO6A5	RN	Xanthine derivatives IBMX and S-9977-2 potentiate transmission at an Aplysia central cholinergic synapse. Brain Res. 1992 Jul 17;586(1):78-85.
DMEO6A5	RU	https://pubmed.ncbi.nlm.nih.gov/1380883

DMC57JU	DI	DMC57JU
DMC57JU	DN	Saperconazole
DMC57JU	MI	TT8YUAD
DMC57JU	MN	P450-dependent ergosterol synthesis (PDE synth)
DMC57JU	MT	DTT
DMC57JU	MA	Modulator
DMC57JU	RN	Saperconazole: a selective inhibitor of the cytochrome P-450-dependent ergosterol synthesis in Candida albicans, Aspergillus fumigatus and Trichophyton mentagrophytes. Mycoses. 1990 Jul-Aug;33(7-8):335-52.
DMC57JU	RU	https://pubmed.ncbi.nlm.nih.gov/2090934

DMQMA17	DI	DMQMA17
DMQMA17	DN	SAVOXEPIN MESYLATE
DMQMA17	MI	TTEX248
DMQMA17	MN	Dopamine D2 receptor (D2R)
DMQMA17	MT	DTT
DMQMA17	MA	Agonist
DMQMA17	RN	Savoxepine: striatal dopamine-D2 receptor occupancy in human volunteers measured using positron emission tomography (PET). Eur J Clin Pharmacol. 1993;44(2):135-40.
DMQMA17	RU	https://pubmed.ncbi.nlm.nih.gov/8095895

DMIF4VJ	DI	DMIF4VJ
DMIF4VJ	DN	SB-201993
DMIF4VJ	MI	TTN53ZF
DMIF4VJ	MN	Leukotriene B4 receptor 1 (LTB4R)
DMIF4VJ	MT	DTT
DMIF4VJ	MA	Inhibitor
DMIF4VJ	RN	(E)-3-[6-[[(2,6-dichlorophenyl)thio]methyl]-3-(2-phenylethoxy)-2- pyridinyl]-2-propenoic acid: a high-affinity leukotriene B4 receptor antagonist w... J Med Chem. 1996 Sep 13;39(19):3837-41.
DMIF4VJ	RU	https://pubmed.ncbi.nlm.nih.gov/8809171

DMJYW80	DI	DMJYW80
DMJYW80	DN	SB-209670
DMJYW80	MI	TTKRD0G
DMJYW80	MN	Endothelin A receptor (EDNRA)
DMJYW80	MT	DTT
DMJYW80	MA	Modulator
DMJYW80	RN	Effects of the endothelin receptor antagonist, SB 209670, on circulatory failure and organ injury in endotoxic shock in the anaesthetized rat. Br J Pharmacol. 1996 May;118(1):198-204.
DMJYW80	RU	https://pubmed.ncbi.nlm.nih.gov/8733596

DMJYW80	DI	DMJYW80
DMJYW80	DN	SB-209670
DMJYW80	MI	TT3ZTGU
DMJYW80	MN	Endothelin B receptor (EDNRB)
DMJYW80	MT	DTT
DMJYW80	MA	Modulator
DMJYW80	RN	Effects of the endothelin receptor antagonist, SB 209670, on circulatory failure and organ injury in endotoxic shock in the anaesthetized rat. Br J Pharmacol. 1996 May;118(1):198-204.
DMJYW80	RU	https://pubmed.ncbi.nlm.nih.gov/8733596

DMXFQS1	DI	DMXFQS1
DMXFQS1	DN	SB-756050
DMXFQS1	MI	TTS4UGC
DMXFQS1	MN	Farnesoid X-activated receptor (FXR)
DMXFQS1	MT	DTT
DMXFQS1	MA	Agonist
DMXFQS1	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMXFQS1	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMTZ7E4	DI	DMTZ7E4
DMTZ7E4	DN	SC-106
DMTZ7E4	MI	TT9V5JH
DMTZ7E4	MN	Phospholipase A2 (PLA2G1B)
DMTZ7E4	MT	DTT
DMTZ7E4	MA	Inhibitor
DMTZ7E4	RN	US patent application no. 6,673,908, Tumor necrosis factor receptor 2.
DMTZ7E4	RU	http://www.google.com/patents/US6673908

DMQ0T6L	DI	DMQ0T6L
DMQ0T6L	DN	SC-45662
DMQ0T6L	MI	TT2J34L
DMQ0T6L	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMQ0T6L	MT	DTT
DMQ0T6L	MA	Inhibitor
DMQ0T6L	RN	The immunosuppressive properties of enisoprost and a 5-lipoxygenase inhibitor (SC-45662). Transplantation. 1991 Dec;52(6):1053-7.
DMQ0T6L	RU	https://pubmed.ncbi.nlm.nih.gov/1750068

DMAGBM2	DI	DMAGBM2
DMAGBM2	DN	SCH-32615
DMAGBM2	MI	TT5TKPM
DMAGBM2	MN	Neutral endopeptidase (MME)
DMAGBM2	MT	DTT
DMAGBM2	MA	Inhibitor
DMAGBM2	RN	The antinociceptive effects of SCH-32615, a neutral endopeptidase (enkephalinase) inhibitor, microinjected into the periaqueductal, ventral medulla and amygdala. Brain Res. 1990 Jun 18;520(1-2):123-30.
DMAGBM2	RU	https://pubmed.ncbi.nlm.nih.gov/2207626

DMZR6GI	DI	DMZR6GI
DMZR6GI	DN	Sch-34826
DMZR6GI	MI	TT5TKPM
DMZR6GI	MN	Neutral endopeptidase (MME)
DMZR6GI	MT	DTT
DMZR6GI	MA	Modulator
DMZR6GI	RN	Pharmacology of SCH 34826, an orally active enkephalinase inhibitor analgesic. J Pharmacol Exp Ther. 1988 Jun;245(3):829-38.
DMZR6GI	RU	https://pubmed.ncbi.nlm.nih.gov/3164388

DM2RH51	DI	DM2RH51
DM2RH51	DN	SCH-42495
DM2RH51	MI	TT5TKPM
DM2RH51	MN	Neutral endopeptidase (MME)
DM2RH51	MT	DTT
DM2RH51	MA	Inhibitor
DM2RH51	RN	Endopeptidase 24.11 inhibition by SCH 42495 in essential hypertension. Hypertension. 1993 Jul;22(1):119-26.
DM2RH51	RU	https://pubmed.ncbi.nlm.nih.gov/8391513

DM28AFU	DI	DM28AFU
DM28AFU	DN	SCH-48461
DM28AFU	MI	TTNA5ZS
DM28AFU	MN	Cholesterol absorption (Chole absorp)
DM28AFU	MT	DTT
DM28AFU	MA	Modulator
DM28AFU	RN	Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461. Atherosclerosis. 1995 May;115(1):45-63.
DM28AFU	RU	https://pubmed.ncbi.nlm.nih.gov/7669087

DMX4938	DI	DMX4938
DMX4938	DN	SDZ-LAP-977
DMX4938	MI	TTJSQEF
DMX4938	MN	Tyrosine-protein kinase (PTK)
DMX4938	MT	DTT
DMX4938	MA	Inhibitor
DMX4938	RN	Structure-activity relationship studies on a novel class of antiproliferative agents derived from Lavendustin A. Part I: Ring A modifications. Bioorg Med Chem. 2008 Aug 15;16(16):7552-60.
DMX4938	RU	https://pubmed.ncbi.nlm.nih.gov/18678497

DMXZVPH	DI	DMXZVPH
DMXZVPH	DN	SEGLITIDE
DMXZVPH	MI	TTOMNR9
DMXZVPH	MN	Somatostatin receptor (SSTR)
DMXZVPH	MT	DTT
DMXZVPH	MA	Modulator
DMXZVPH	RN	Antagonist effects of seglitide (MK 678) at somatostatin receptors in guinea-pig isolated right atria.. Br J Pharmacol. 1993 August; 109(4): 898-899.
DMXZVPH	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2175736/

DMLK605	DI	DMLK605
DMLK605	DN	Semparatide
DMLK605	MI	TTEPJL5
DMLK605	MN	Parathyroid hormone receptor (PTH2R)
DMLK605	MT	DTT
DMLK605	MA	Modulator
DMLK605	RN	Quantitative cell membrane-based radioligand binding assays for parathyroid hormone receptors. J Pharmacol Toxicol Methods. 1999 Apr-Jun;41(2-3):83-90.
DMLK605	RU	https://pubmed.ncbi.nlm.nih.gov/10598679

DM75ZO0	DI	DM75ZO0
DM75ZO0	DN	SERAZAPINE HYDROCHLORIDE
DM75ZO0	MI	TTJQOD7
DM75ZO0	MN	5-HT 2A receptor (HTR2A)
DM75ZO0	MT	DTT
DM75ZO0	MA	Antagonist
DM75ZO0	RN	Serotonergic (5-HT2) mediation of anxiety-therapeutic effects of serazepine in generalized anxiety disorder. Biol Psychiatry. 1993 Jul 1-15;34(1-2):41-4.
DM75ZO0	RU	https://pubmed.ncbi.nlm.nih.gov/8104044

DM9KB8A	DI	DM9KB8A
DM9KB8A	DN	SERGOLEXOLE MALEATE
DM9KB8A	MI	TTJQOD7
DM9KB8A	MN	5-HT 2A receptor (HTR2A)
DM9KB8A	MT	DTT
DM9KB8A	MA	Antagonist
DM9KB8A	RN	5-Hydroxytryptamine2 receptor antagonist activity of the acid metabolite (1-isopropyl dihydrolysergic acid) of the ergoline ester, sergolexole (LY281067). J Pharmacol Exp Ther. 1989 Dec;251(3):1006-11.
DM9KB8A	RU	https://pubmed.ncbi.nlm.nih.gov/2600800

DMSLP2O	DI	DMSLP2O
DMSLP2O	DN	SERM-3339
DMSLP2O	MI	TTZAYWL
DMSLP2O	MN	Estrogen receptor (ESR)
DMSLP2O	MT	DTT
DMSLP2O	MA	Modulator
DMSLP2O	RN	CN patent application no. 102406650, Sex steroid precursors alone or in combination with selective estrogen receptor modulator for prevention and treatment of vaginal dryness and sexual dysfunction in postmenop.
DMSLP2O	RU	http://www.google.com/patents/CN102406650A?cl=en

DMBG6LP	DI	DMBG6LP
DMBG6LP	DN	SGB-1534
DMBG6LP	MI	TT2NUT5
DMBG6LP	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMBG6LP	MT	DTT
DMBG6LP	MA	Modulator
DMBG6LP	RN	Potent alpha-adrenoceptor blocking action of SGB-1534, a new quinazoline antihypertensive agent in vitro experiments. Gen Pharmacol. 1986;17(2):143-9.
DMBG6LP	RU	https://pubmed.ncbi.nlm.nih.gov/2870954

DM6XJ9D	DI	DM6XJ9D
DM6XJ9D	DN	SGS-111
DM6XJ9D	MI	TT9IK2Z
DM6XJ9D	MN	N-methyl-D-aspartate receptor (NMDAR)
DM6XJ9D	MT	DTT
DM6XJ9D	MA	Modulator
DM6XJ9D	RN	Molecular basis of pharmacotherapies for cognition in Down syndrome. Trends Pharmacol Sci. 2010 February; 31(2): 66.
DM6XJ9D	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2815198/

DM7XC0U	DI	DM7XC0U
DM7XC0U	DN	SIB-1553A
DM7XC0U	MI	TTTVAFQ
DM7XC0U	MN	Neuronal acetylcholine receptor beta-4 (CHRNB4)
DM7XC0U	MT	DTT
DM7XC0U	MA	Agonist
DM7XC0U	RN	SIB-1553A, (+/-)-4-[[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride, a subtype-selective ligand for nicotinic acetylcholine receptors with putative cognitive-enhancing properties: effectson working and reference memory performances in aged rodents and nonhuman primates. J Pharmacol Exp Ther. 2001 Oct;299(1):297-306.
DM7XC0U	RU	https://pubmed.ncbi.nlm.nih.gov/11561092

DM7XC0U	DI	DM7XC0U
DM7XC0U	DN	SIB-1553A
DM7XC0U	MI	TTJSZTB
DM7XC0U	MN	Nicotinic acetylcholine receptor (nAChR)
DM7XC0U	MT	DTT
DM7XC0U	MA	Agonist
DM7XC0U	RN	The potential of subtype-selective neuronal nicotinic acetylcholine receptor agonists as therapeutic agents. Life Sci. 1998;62(17-18):1601-6.
DM7XC0U	RU	https://pubmed.ncbi.nlm.nih.gov/9585143

DMY30G2	DI	DMY30G2
DMY30G2	DN	SILPERISONE HYDROCHLORIDE
DMY30G2	MI	TTRK8B9
DMY30G2	MN	Sodium channel unspecific (NaC)
DMY30G2	MT	DTT
DMY30G2	MA	Modulator
DMY30G2	RN	Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec;315(3):1237-46.
DMY30G2	RU	https://pubmed.ncbi.nlm.nih.gov/16126840

DMMZ2JT	DI	DMMZ2JT
DMMZ2JT	DN	SINITRODIL
DMMZ2JT	MI	TTJ0IQB
DMMZ2JT	MN	Phosphodiesterase 5A (PDE5A)
DMMZ2JT	MT	DTT
DMMZ2JT	MA	Modulator
DMMZ2JT	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMMZ2JT	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMYP3KI	DI	DMYP3KI
DMYP3KI	DN	SINOMENINE
DMYP3KI	MI	TTFQVUT
DMYP3KI	MN	NADPH oxidase (NOX)
DMYP3KI	MT	DTT
DMYP3KI	MA	Modulator
DMYP3KI	RN	Sinomenine, a natural dextrorotatory morphinan analog, is anti-inflammatory and neuroprotective through inhibition of microglial NADPH oxidase. J Neuroinflammation. 2007 Sep 19;4:23.
DMYP3KI	RU	https://pubmed.ncbi.nlm.nih.gov/17880684

DMMQ4GC	DI	DMMQ4GC
DMMQ4GC	DN	Sipatrigine
DMMQ4GC	MI	TTRK8B9
DMMQ4GC	MN	Sodium channel unspecific (NaC)
DMMQ4GC	MT	DTT
DMMQ4GC	MA	Inhibitor
DMMQ4GC	RN	Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37.
DMMQ4GC	RU	https://pubmed.ncbi.nlm.nih.gov/11170622

DMMQ4GC	DI	DMMQ4GC
DMMQ4GC	DN	Sipatrigine
DMMQ4GC	MI	TT7RGTM
DMMQ4GC	MN	Voltage-gated calcium channel alpha Cav1.3 (CACNA1D)
DMMQ4GC	MT	DTT
DMMQ4GC	MA	Inhibitor
DMMQ4GC	RN	Synthesis and characterization of N-(acenaphth-5-yl)-N'-(4-methoxynaphth-1-yl)guanidine as a glutamate release inhibitor and potential anti-ischemic agent, Bioorg. Med. Chem. Lett. 5(19):2259-2262 (1995).
DMMQ4GC	RU	http://www.sciencedirect.com/science/article/pii/0960894X95003927

DMMQ4GC	DI	DMMQ4GC
DMMQ4GC	DN	Sipatrigine
DMMQ4GC	MI	TTAXZ0K
DMMQ4GC	MN	Voltage-gated sodium channel alpha Nav1.3 (SCN3A)
DMMQ4GC	MT	DTT
DMMQ4GC	MA	Inhibitor
DMMQ4GC	RN	Synthesis and structure-activity relationships of 6,7-benzomorphan derivatives as use-dependent sodium channel blockers for the treatment of stroke. J Med Chem. 2002 Aug 15;45(17):3755-64.
DMMQ4GC	RU	https://pubmed.ncbi.nlm.nih.gov/12166948

DMMQ4GC	DI	DMMQ4GC
DMMQ4GC	DN	Sipatrigine
DMMQ4GC	MI	TT84DRB
DMMQ4GC	MN	Voltage-gated sodium channel alpha Nav1.4 (SCN4A)
DMMQ4GC	MT	DTT
DMMQ4GC	MA	Inhibitor
DMMQ4GC	RN	Oxadiazolylindazole sodium channel modulators are neuroprotective toward hippocampal neurones. J Med Chem. 2009 May 14;52(9):2694-707.
DMMQ4GC	RU	https://pubmed.ncbi.nlm.nih.gov/19341281

DMMQ4GC	DI	DMMQ4GC
DMMQ4GC	DN	Sipatrigine
DMMQ4GC	MI	TTZOVE0
DMMQ4GC	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DMMQ4GC	MT	DTT
DMMQ4GC	MA	Inhibitor
DMMQ4GC	RN	Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37.
DMMQ4GC	RU	https://pubmed.ncbi.nlm.nih.gov/11170622

DMMQ4GC	DI	DMMQ4GC
DMMQ4GC	DN	Sipatrigine
DMMQ4GC	MI	TT4G2JS
DMMQ4GC	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DMMQ4GC	MT	DTT
DMMQ4GC	MA	Inhibitor
DMMQ4GC	RN	Oxadiazolylindazole sodium channel modulators are neuroprotective toward hippocampal neurones. J Med Chem. 2009 May 14;52(9):2694-707.
DMMQ4GC	RU	https://pubmed.ncbi.nlm.nih.gov/19341281

DMMQ4GC	DI	DMMQ4GC
DMMQ4GC	DN	Sipatrigine
DMMQ4GC	MI	TT90XZ8
DMMQ4GC	MN	Voltage-gated sodium channel alpha Nav1.8 (SCN10A)
DMMQ4GC	MT	DTT
DMMQ4GC	MA	Inhibitor
DMMQ4GC	RN	Oxadiazolylindazole sodium channel modulators are neuroprotective toward hippocampal neurones. J Med Chem. 2009 May 14;52(9):2694-707.
DMMQ4GC	RU	https://pubmed.ncbi.nlm.nih.gov/19341281

DM2BDAW	DI	DM2BDAW
DM2BDAW	DN	SK&F-S-106203
DM2BDAW	MI	TTTWGIX
DM2BDAW	MN	Leukotriene receptor (LTR)
DM2BDAW	MT	DTT
DM2BDAW	MA	Modulator
DM2BDAW	RN	Pharmacologic and pharmacokinetic profile of SK&amp;F S-106203, a potent, orally active peptidoleukotriene receptor antagonist, in guinea-pig. Pulm Pharmacol. 1991;4(3):177-89.
DM2BDAW	RU	https://pubmed.ncbi.nlm.nih.gov/1668219

DM40HTZ	DI	DM40HTZ
DM40HTZ	DN	SKF-97426
DM40HTZ	MI	TTS4UGC
DM40HTZ	MN	Farnesoid X-activated receptor (FXR)
DM40HTZ	MT	DTT
DM40HTZ	MA	Modulator
DM40HTZ	RN	SK&amp;F 97426-A a more potent bile acid sequestrant and hypocholesterolaemic agent than cholestyramine in the hamster. Atherosclerosis. 1993 Jun;101(1):51-60.
DM40HTZ	RU	https://pubmed.ncbi.nlm.nih.gov/8216502

DME1JYP	DI	DME1JYP
DME1JYP	DN	SL-25.1039
DME1JYP	MI	TT34BHT
DME1JYP	MN	Adrenergic receptor alpha-1D (ADRA1D)
DME1JYP	MT	DTT
DME1JYP	MA	Agonist
DME1JYP	RN	Pharmaceutical co analysis sanofi aventis, 2006, Page(216).
DME1JYP	RU	http://www.alacrastore.com/storecontent/Thomson-Reuters-Market-Research/PHARMACEUTICAL-CO-ANALYSIS-SANOFI-AVENTIS-ESPICOM-HEALTHCARE-INTELLIGENCE-50201119

DMAM9BD	DI	DMAM9BD
DMAM9BD	DN	SL65.0155
DMAM9BD	MI	TT07C3Y
DMAM9BD	MN	5-HT 4 receptor (HTR4)
DMAM9BD	MT	DTT
DMAM9BD	MA	Agonist
DMAM9BD	RN	SL65.0155, a novel 5-hydroxytryptamine(4) receptor partial agonist with potent cognition-enhancing properties. J Pharmacol Exp Ther. 2002 Aug;302(2):731-41.
DMAM9BD	RU	https://pubmed.ncbi.nlm.nih.gov/12130738

DMU5RKC	DI	DMU5RKC
DMU5RKC	DN	SL65.0472
DMU5RKC	MI	TTJQOD7
DMU5RKC	MN	5-HT 2A receptor (HTR2A)
DMU5RKC	MT	DTT
DMU5RKC	MA	Modulator
DMU5RKC	RN	Antiplatelet and antithrombotic activity of SL65.0472, a mixed 5-HT1B/5-HT2A receptor antagonist.Thromb Haemost.2001 Mar;85(3):521-8.
DMU5RKC	RU	https://www.ncbi.nlm.nih.gov/pubmed/11307825

DMS8AHE	DI	DMS8AHE
DMS8AHE	DN	SL-65.1498
DMS8AHE	MI	TTEX6LM
DMS8AHE	MN	GABA(A) receptor gamma-3 (GABRG3)
DMS8AHE	MT	DTT
DMS8AHE	MA	Agonist
DMS8AHE	RN	WO patent application no. 2005,0749,31, Pharmaceutical combinations comprising (s) -pantoprazole.
DMS8AHE	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20050818&CC=WO&NR=2005074931A1&KC=A1

DMOXUEP	DI	DMOXUEP
DMOXUEP	DN	SL-89.0591
DMOXUEP	MI	TT34BHT
DMOXUEP	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMOXUEP	MT	DTT
DMOXUEP	MA	Modulator
DMOXUEP	RN	Effects of alpha1-adrenoceptor antagonists on agonist and tilt-induced changes in blood pressure: relationships to uroselectivity. Eur J Pharmacol. 1999 May 28;373(1):51-62.
DMOXUEP	RU	https://pubmed.ncbi.nlm.nih.gov/10408251

DMBZM0D	DI	DMBZM0D
DMBZM0D	DN	SLV-305
DMBZM0D	MI	TT953CX
DMBZM0D	MN	Motilin receptor (MLNR)
DMBZM0D	MT	DTT
DMBZM0D	MA	Modulator
DMBZM0D	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 297).
DMBZM0D	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=297

DM71WGZ	DI	DM71WGZ
DM71WGZ	DN	SLV-310
DM71WGZ	MI	TTEX248
DM71WGZ	MN	Dopamine D2 receptor (D2R)
DM71WGZ	MT	DTT
DM71WGZ	MA	Modulator
DM71WGZ	RN	SLV310, a novel, potential antipsychotic, combining potent dopamine D2 receptor antagonism with serotonin reuptake inhibition. Bioorg Med Chem Lett. 2003 Feb 10;13(3):405-8.
DM71WGZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/12565939

DM0GKHX	DI	DM0GKHX
DM0GKHX	DN	SLV319
DM0GKHX	MI	TT6OEDT
DM0GKHX	MN	Cannabinoid receptor 1 (CB1)
DM0GKHX	MT	DTT
DM0GKHX	MA	Antagonist
DM0GKHX	RN	JD-5006 and JD-5037: peripherally restricted (PR) cannabinoid-1 receptor blockers related to SLV-319 (Ibipinabant) as metabolic disorder therapeutics devoid of CNS liabilities. Bioorg Med Chem Lett. 2012 Oct 1;22(19):6173-80.
DM0GKHX	RU	https://pubmed.ncbi.nlm.nih.gov/22959249

DM1J0YB	DI	DM1J0YB
DM1J0YB	DN	SLX-2101
DM1J0YB	MI	TTJ0IQB
DM1J0YB	MN	Phosphodiesterase 5A (PDE5A)
DM1J0YB	MT	DTT
DM1J0YB	MA	Inhibitor
DM1J0YB	RN	Novel phosphodiesterase-5 (PDE5) inhibitors in the alleviation of erectile dysfunction due to diabetes and ageing-induced oxidative stress. Expert Opin Investig Drugs. 2008 Jun;17(6):855-64.
DM1J0YB	RU	https://pubmed.ncbi.nlm.nih.gov/18491987

DMZYGW0	DI	DMZYGW0
DMZYGW0	DN	SM-10661
DMZYGW0	MI	TTQL5VC
DMZYGW0	MN	Platelet-activating factor receptor (PTAFR)
DMZYGW0	MT	DTT
DMZYGW0	MA	Antagonist
DMZYGW0	RN	Effect of the PAF-receptor antagonist SM-12502 on human platelets. Inflammation. 1996 Feb;20(1):71-85.
DMZYGW0	RU	https://pubmed.ncbi.nlm.nih.gov/8926050

DMBUH7E	DI	DMBUH7E
DMBUH7E	DN	SM-10888
DMBUH7E	MI	TT1RS9F
DMBUH7E	MN	Acetylcholinesterase (AChE)
DMBUH7E	MT	DTT
DMBUH7E	MA	Inhibitor
DMBUH7E	RN	Pharmacological and biochemical assessment of SM-10888, a novel cholinesterase inhibitor. Jpn J Pharmacol. 1990 Jun;53(2):145-55.
DMBUH7E	RU	https://pubmed.ncbi.nlm.nih.gov/2385001

DMJ816F	DI	DMJ816F
DMJ816F	DN	Sodelglitazar
DMJ816F	MI	TTJ584C
DMJ816F	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMJ816F	MT	DTT
DMJ816F	MA	Agonist
DMJ816F	RN	Docking and molecular dynamics simulations of peroxisome proliferator activated receptors interacting with pan agonist sodelglitazar. Protein Pept Lett. 2011 Oct;18(10):1021-7.
DMJ816F	RU	https://pubmed.ncbi.nlm.nih.gov/21592078

DMJ816F	DI	DMJ816F
DMJ816F	DN	Sodelglitazar
DMJ816F	MI	TT2JWF6
DMJ816F	MN	Peroxisome proliferator-activated receptor delta (PPARD)
DMJ816F	MT	DTT
DMJ816F	MA	Agonist
DMJ816F	RN	Docking and molecular dynamics simulations of peroxisome proliferator activated receptors interacting with pan agonist sodelglitazar. Protein Pept Lett. 2011 Oct;18(10):1021-7.
DMJ816F	RU	https://pubmed.ncbi.nlm.nih.gov/21592078

DMJ816F	DI	DMJ816F
DMJ816F	DN	Sodelglitazar
DMJ816F	MI	TTZMAO3
DMJ816F	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMJ816F	MT	DTT
DMJ816F	MA	Agonist
DMJ816F	RN	Docking and molecular dynamics simulations of peroxisome proliferator activated receptors interacting with pan agonist sodelglitazar. Protein Pept Lett. 2011 Oct;18(10):1021-7.
DMJ816F	RU	https://pubmed.ncbi.nlm.nih.gov/21592078

DMHITR4	DI	DMHITR4
DMHITR4	DN	SOLPECAINOL HYDROCHLORIDE
DMHITR4	MI	TTRK8B9
DMHITR4	MN	Sodium channel unspecific (NaC)
DMHITR4	MT	DTT
DMHITR4	MA	Modulator
DMHITR4	RN	US patent application no. 2002,0102,217, Diagnostic,therapeutic agents.
DMHITR4	RU	http://www.google.com.na/patents/US20020102217

DMCS8FM	DI	DMCS8FM
DMCS8FM	DN	SORAPRAZAN
DMCS8FM	MI	TTLOKXP
DMCS8FM	MN	Gastric H(+)/K(+) ATPase (Proton pump)
DMCS8FM	MT	DTT
DMCS8FM	MA	Modulator
DMCS8FM	RN	Soraprazan: setting new standards in inhibition of gastric acid secretion.J Pharmacol Exp Ther.2007 Jun;321(3):866-74.
DMCS8FM	RU	https://www.ncbi.nlm.nih.gov/pubmed/17369284

DMPAEK5	DI	DMPAEK5
DMPAEK5	DN	SOU-001
DMPAEK5	MI	TTNGILX
DMPAEK5	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMPAEK5	MT	DTT
DMPAEK5	MA	Modulator
DMPAEK5	RN	Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004 Aug;3(8):673-83.
DMPAEK5	RU	https://pubmed.ncbi.nlm.nih.gov/15286734

DMPAEK5	DI	DMPAEK5
DMPAEK5	DN	SOU-001
DMPAEK5	MI	TTBRKXS
DMPAEK5	MN	Adrenergic receptor alpha-1B (ADRA1B)
DMPAEK5	MT	DTT
DMPAEK5	MA	Modulator
DMPAEK5	RN	Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004 Aug;3(8):673-83.
DMPAEK5	RU	https://pubmed.ncbi.nlm.nih.gov/15286734

DMPAEK5	DI	DMPAEK5
DMPAEK5	DN	SOU-001
DMPAEK5	MI	TT34BHT
DMPAEK5	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMPAEK5	MT	DTT
DMPAEK5	MA	Modulator
DMPAEK5	RN	Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004 Aug;3(8):673-83.
DMPAEK5	RU	https://pubmed.ncbi.nlm.nih.gov/15286734

DMTJNRL	DI	DMTJNRL
DMTJNRL	DN	SPD-473
DMTJNRL	MI	TTVBI8W
DMTJNRL	MN	Dopamine transporter (DAT)
DMTJNRL	MT	DTT
DMTJNRL	MA	Inhibitor
DMTJNRL	RN	Dopamine uptake inhibitor-induced rotation in 6-hydroxydopamine-lesioned rats involves both D1 and D2 receptors but is modulated through 5-hydroxyt... J Pharmacol Exp Ther. 2005 Mar;312(3):1124-31.
DMTJNRL	RU	https://pubmed.ncbi.nlm.nih.gov/15542624

DMTJNRL	DI	DMTJNRL
DMTJNRL	DN	SPD-473
DMTJNRL	MI	TTAWNKZ
DMTJNRL	MN	Norepinephrine transporter (NET)
DMTJNRL	MT	DTT
DMTJNRL	MA	Inhibitor
DMTJNRL	RN	Dopamine uptake inhibitor-induced rotation in 6-hydroxydopamine-lesioned rats involves both D1 and D2 receptors but is modulated through 5-hydroxyt... J Pharmacol Exp Ther. 2005 Mar;312(3):1124-31.
DMTJNRL	RU	https://pubmed.ncbi.nlm.nih.gov/15542624

DMTJNRL	DI	DMTJNRL
DMTJNRL	DN	SPD-473
DMTJNRL	MI	TT3ROYC
DMTJNRL	MN	Serotonin transporter (SERT)
DMTJNRL	MT	DTT
DMTJNRL	MA	Inhibitor
DMTJNRL	RN	Dopamine uptake inhibitor-induced rotation in 6-hydroxydopamine-lesioned rats involves both D1 and D2 receptors but is modulated through 5-hydroxyt... J Pharmacol Exp Ther. 2005 Mar;312(3):1124-31.
DMTJNRL	RU	https://pubmed.ncbi.nlm.nih.gov/15542624

DMTC4VY	DI	DMTC4VY
DMTC4VY	DN	SQ-30741
DMTC4VY	MI	TT2O84V
DMTC4VY	MN	Thromboxane A2 receptor (TBXA2R)
DMTC4VY	MT	DTT
DMTC4VY	MA	Antagonist
DMTC4VY	RN	Influence of SQ 30741 on thromboxane receptor-mediated responses in the feline pulmonary vascular bed. J Appl Physiol (1985). 1991 Nov;71(5):2012-8.
DMTC4VY	RU	https://pubmed.ncbi.nlm.nih.gov/1837015

DMSQRXW	DI	DMSQRXW
DMSQRXW	DN	SQ-32709
DMSQRXW	MI	DEFNVD7
DMSQRXW	MN	Ras proteins prenyltransferase alpha (FNTA)
DMSQRXW	MT	DME
DMSQRXW	MA	Metabolism
DMSQRXW	RN	Site-selective enzymatic labeling of designed ankyrin repeat proteins using protein farnesyltransferase. Methods Mol Biol. 2019;2033:207-219.
DMSQRXW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31332756

DMSQRXW	DI	DMSQRXW
DMSQRXW	DN	SQ-32709
DMSQRXW	MI	DEIDTHQ
DMSQRXW	MN	Squalene synthase (FDFT1)
DMSQRXW	MT	DME
DMSQRXW	MA	Metabolism
DMSQRXW	RN	Increased activity of the sterol branch of the mevalonate pathway elevates glycosylation of secretory proteins and improves antifungal properties of Trichoderma atroviride. Fungal Genet Biol. 2020 Jan 17;137:103334.
DMSQRXW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31958566

DMSQRXW	DI	DMSQRXW
DMSQRXW	DN	SQ-32709
DMSQRXW	MI	TTFQEO5
DMSQRXW	MN	Squalene synthetase (FDFT1)
DMSQRXW	MT	DTT
DMSQRXW	MA	Modulator
DMSQRXW	RN	Clinical pharmacokinetics and pharmacodynamics of a new squalene synthase inhibitor, BMS-188494, in healthy volunteers. J Clin Pharmacol. 1998 Dec;38(12):1116-21.
DMSQRXW	RU	https://pubmed.ncbi.nlm.nih.gov/11301563

DMCEQKG	DI	DMCEQKG
DMCEQKG	DN	SR-121787
DMCEQKG	MI	TT38RM1
DMCEQKG	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DMCEQKG	MT	DTT
DMCEQKG	MA	Modulator
DMCEQKG	RN	Prevention of thrombosis and enhancement of thrombolysis in rabbits by SR 121787, a glycoprotein II/III antagonist. J Pharmacol Exp Ther. 1998 Aug;286(2):670-5.
DMCEQKG	RU	https://www.ncbi.nlm.nih.gov/pubmed/9694919

DMV4FT2	DI	DMV4FT2
DMV4FT2	DN	SR-57227
DMV4FT2	MI	TTNXLKE
DMV4FT2	MN	5-HT 3 receptor (5HT3R)
DMV4FT2	MT	DTT
DMV4FT2	MA	Modulator
DMV4FT2	RN	Antidepressant-like effects of SR 57227A, a 5-HT3 receptor agonist, in rodents. J Neural Transm Gen Sect. 1995;102(2):83-90.
DMV4FT2	RU	https://pubmed.ncbi.nlm.nih.gov/8748673

DMROKDM	DI	DMROKDM
DMROKDM	DN	SR-90067
DMROKDM	MI	TTZAYWL
DMROKDM	MN	Estrogen receptor (ESR)
DMROKDM	MT	DTT
DMROKDM	MA	Agonist
DMROKDM	RN	US patent application no. 2010,0278,784, Methods and compositions for treating skin conditions.
DMROKDM	RU	https://www.google.com.ar/patents/US20100278784

DMRKE9G	DI	DMRKE9G
DMRKE9G	DN	SRI-62-834
DMRKE9G	MI	TT8FYO9
DMRKE9G	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMRKE9G	MT	DTT
DMRKE9G	MA	Inhibitor
DMRKE9G	RN	Antitumor activity of SRI 62-834, a cyclic ether analog of ET-18-OCH3. Lipids. 1987 Nov;22(11):884-90.
DMRKE9G	RU	https://pubmed.ncbi.nlm.nih.gov/2832680

DMRKE9G	DI	DMRKE9G
DMRKE9G	DN	SRI-62-834
DMRKE9G	MI	TTI7421
DMRKE9G	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMRKE9G	MT	DTT
DMRKE9G	MA	Inhibitor
DMRKE9G	RN	Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36.
DMRKE9G	RU	https://pubmed.ncbi.nlm.nih.gov/21948793

DMN7BM3	DI	DMN7BM3
DMN7BM3	DN	SSR-182289
DMN7BM3	MI	TT6L509
DMN7BM3	MN	Coagulation factor IIa (F2)
DMN7BM3	MT	DTT
DMN7BM3	MA	Inhibitor
DMN7BM3	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMN7BM3	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMNRW68	DI	DMNRW68
DMNRW68	DN	SU-14813
DMNRW68	MI	TTUTJGQ
DMNRW68	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMNRW68	MT	DTT
DMNRW68	MA	Inhibitor
DMNRW68	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMNRW68	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMBSLZV	DI	DMBSLZV
DMBSLZV	DN	Sulukast
DMBSLZV	MI	TTGKOY9
DMBSLZV	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DMBSLZV	MT	DTT
DMBSLZV	MA	Modulator
DMBSLZV	RN	The pharmacological evaluation of LY 170680, a novel leukotriene D4 and E4 antagonist in the guinea-pig. Br J Pharmacol. 1989 Sep;98(1):259-67.
DMBSLZV	RU	https://www.ncbi.nlm.nih.gov/pubmed/2553189

DMBSLZV	DI	DMBSLZV
DMBSLZV	DN	Sulukast
DMBSLZV	MI	TT0PZR5
DMBSLZV	MN	Leukotriene CysLT2 receptor (CYSLTR2)
DMBSLZV	MT	DTT
DMBSLZV	MA	Modulator
DMBSLZV	RN	The pharmacological evaluation of LY 170680, a novel leukotriene D4 and E4 antagonist in the guinea-pig. Br J Pharmacol. 1989 Sep;98(1):259-67.
DMBSLZV	RU	https://www.ncbi.nlm.nih.gov/pubmed/2553189

DMWTLQ4	DI	DMWTLQ4
DMWTLQ4	DN	SUN-1334H
DMWTLQ4	MI	TTTIBOJ
DMWTLQ4	MN	Histamine H1 receptor (H1R)
DMWTLQ4	MT	DTT
DMWTLQ4	MA	Antagonist
DMWTLQ4	RN	Preclinical efficacy and safety pharmacology of SUN-1334H, a potent orally active antihistamine agent. Drugs R D. 2008;9(2):93-112.
DMWTLQ4	RU	https://pubmed.ncbi.nlm.nih.gov/18298128

DMZ8VI0	DI	DMZ8VI0
DMZ8VI0	DN	SUN-C5174
DMZ8VI0	MI	TTYSN63
DMZ8VI0	MN	5-HT 2 receptor (5HT2R)
DMZ8VI0	MT	DTT
DMZ8VI0	MA	Antagonist
DMZ8VI0	RN	Synthesis and serotonin 2 (5-HT2) receptor antagonist activity of 5-aminoalkyl-substituted pyrrolo[3,2-c]azepines and related compounds. Chem Pharm Bull (Tokyo). 2000 May;48(5):623-35.
DMZ8VI0	RU	https://pubmed.ncbi.nlm.nih.gov/10823697

DM19Y0T	DI	DM19Y0T
DM19Y0T	DN	SUPER-LEU-DOX
DM19Y0T	MI	TT0IHXV
DM19Y0T	MN	DNA topoisomerase II (TOP2)
DM19Y0T	MT	DTT
DM19Y0T	MA	Modulator
DM19Y0T	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM19Y0T	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMDZ7AY	DI	DMDZ7AY
DMDZ7AY	DN	Suritozole
DMDZ7AY	MI	TTEX6LM
DMDZ7AY	MN	GABA(A) receptor gamma-3 (GABRG3)
DMDZ7AY	MT	DTT
DMDZ7AY	MA	Modulator
DMDZ7AY	RN	Chronic postinjury administration of MDL 26,479 (Suritozole), a negative modulator at the GABAA receptor, and cognitive impairment in rats following traumatic brain injury. J Neurosurg. 1995 Nov;83(5):878-83.
DMDZ7AY	RU	https://pubmed.ncbi.nlm.nih.gov/7472558

DMGFS51	DI	DMGFS51
DMGFS51	DN	T-1095
DMGFS51	MI	TT2UE56
DMGFS51	MN	Sodium/glucose cotransporter 1 (SGLT1)
DMGFS51	MT	DTT
DMGFS51	MA	Modulator
DMGFS51	RN	T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes. 1999 Sep;48(9):1794-800.
DMGFS51	RU	https://pubmed.ncbi.nlm.nih.gov/10480610

DMZTL7H	DI	DMZTL7H
DMZTL7H	DN	T487
DMZTL7H	MI	TT1UCIJ
DMZTL7H	MN	C-X-C chemokine receptor type 3 (CXCR3)
DMZTL7H	MT	DTT
DMZTL7H	MA	Antagonist
DMZTL7H	RN	Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonist. J Pharmacol Exp Ther. 2005 Jun;313(3):1263-71.
DMZTL7H	RU	https://pubmed.ncbi.nlm.nih.gov/15761110

DM7XGJY	DI	DM7XGJY
DM7XGJY	DN	T-506
DM7XGJY	MI	TTFH2RS
DM7XGJY	MN	FK506-binding protein (FKBP)
DM7XGJY	MT	DTT
DM7XGJY	MA	Modulator
DM7XGJY	RN	EP patent application no. 0831812, Methods and compositions for stimulating neurite growth.
DM7XGJY	RU	https://www.google.com/patents/EP0831812A2?cl=en

DMD3CUJ	DI	DMD3CUJ
DMD3CUJ	DN	T-5224
DMD3CUJ	MI	TTN3GBV
DMD3CUJ	MN	Transcription factor AP-1 (JUN)
DMD3CUJ	MT	DTT
DMD3CUJ	MA	Inhibitor
DMD3CUJ	RN	CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
DMD3CUJ	RU	http://www.centerwatch.com/

DM3M5TU	DI	DM3M5TU
DM3M5TU	DN	T-588
DM3M5TU	MI	TTV8KWS
DM3M5TU	MN	Vesicular acetylcholine transporter (SLC18A3)
DM3M5TU	MT	DTT
DM3M5TU	MA	Modulator
DM3M5TU	RN	Involvement of noradrenaline transporters in S-nitrosocysteine-stimulated noradrenaline release from rat brain slices: existence of functional Na(+)-independent transporter activity. Neurochem Int. 2001 Apr;38(4):323-31.
DM3M5TU	RU	https://pubmed.ncbi.nlm.nih.gov/11137627

DMDN3TV	DI	DMDN3TV
DMDN3TV	DN	T611
DMDN3TV	MI	TT01UPE
DMDN3TV	MN	Cytomegalovirus Replication (CMV replication)
DMDN3TV	MT	DTT
DMDN3TV	MA	Inhibitor
DMDN3TV	RN	A Systematic Screen for CDK4/6 Substrates Links FOXM1 Phosphorylation to Senescence Suppression in Cancer Cells. Cancer Cell. 2011 November 15; 20(5): 620-634.
DMDN3TV	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3237683/

DMBZG2Y	DI	DMBZG2Y
DMBZG2Y	DN	TA-5538
DMBZG2Y	MI	TTZPO1L
DMBZG2Y	MN	Substance-P receptor (TACR1)
DMBZG2Y	MT	DTT
DMBZG2Y	MA	Antagonist
DMBZG2Y	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021639)
DMBZG2Y	RU	http://adisinsight.springer.com/drugs/800021639

DMB3W20	DI	DMB3W20
DMB3W20	DN	TA-6666
DMB3W20	MI	TTDIGC1
DMB3W20	MN	Dipeptidyl peptidase 4 (DPP-4)
DMB3W20	MT	DTT
DMB3W20	MA	Inhibitor
DMB3W20	RN	Dipeptidyl Peptidase-4 Inhibitors Clinical data and clinical implications. before print March 2, 2007.
DMB3W20	RU	http://care.diabetesjournals.org/content/30/6/1344.full

DM1Z74X	DI	DM1Z74X
DM1Z74X	DN	Tacedinaline
DM1Z74X	MI	TT6R7JZ
DM1Z74X	MN	Histone deacetylase 1 (HDAC1)
DM1Z74X	MT	DTT
DM1Z74X	MA	Inhibitor
DM1Z74X	RN	Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92.
DM1Z74X	RU	https://pubmed.ncbi.nlm.nih.gov/17896917

DM0TDZI	DI	DM0TDZI
DM0TDZI	DN	TAK-013
DM0TDZI	MI	TT8R70G
DM0TDZI	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DM0TDZI	MT	DTT
DM0TDZI	MA	Inhibitor
DM0TDZI	RN	Non-peptide gonadotropin-releasing hormone receptor antagonists. J Med Chem. 2008 Jun 26;51(12):3331-48.
DM0TDZI	RU	https://pubmed.ncbi.nlm.nih.gov/18419112

DMBQ87R	DI	DMBQ87R
DMBQ87R	DN	TAK-044
DMBQ87R	MI	TTCV6O0
DMBQ87R	MN	Endothelin receptor (EDNR)
DMBQ87R	MT	DTT
DMBQ87R	MA	Modulator
DMBQ87R	RN	Pharmacology of a non-selective ETA and ETB receptor antagonist, TAK-044 and the inhibition of myocardial infarct size in rats. Br J Pharmacol. 1995 Mar;114(5):949-54.
DMBQ87R	RU	https://pubmed.ncbi.nlm.nih.gov/7780649

DM8S173	DI	DM8S173
DM8S173	DN	TAK-201
DM8S173	MI	TTYJQTF
DM8S173	MN	Immunoglobulin E (IgE)
DM8S173	MT	DTT
DM8S173	MA	Modulator
DM8S173	RN	Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside. Expert Opin Biol Ther. 2010 Jun;10(6):951-8.
DM8S173	RU	https://pubmed.ncbi.nlm.nih.gov/20426706

DM7S69Q	DI	DM7S69Q
DM7S69Q	DN	TAK-218
DM7S69Q	MI	TTV0YFR
DM7S69Q	MN	Lipid peroxidation (LPO)
DM7S69Q	MT	DTT
DM7S69Q	MA	Modulator
DM7S69Q	RN	ESR study on the antioxidant activity of TAK-218 in biological model membranes. Chem Pharm Bull (Tokyo). 2000 Jun;48(6):784-92.
DM7S69Q	RU	https://pubmed.ncbi.nlm.nih.gov/10866137

DMG4RFO	DI	DMG4RFO
DMG4RFO	DN	TAK-442
DMG4RFO	MI	TTCIHJA
DMG4RFO	MN	Coagulation factor Xa (F10)
DMG4RFO	MT	DTT
DMG4RFO	MA	Inhibitor
DMG4RFO	RN	Clinical pipeline report, company report or official report of Takeda (2009).
DMG4RFO	RU	http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf

DMN1YHP	DI	DMN1YHP
DMN1YHP	DN	TAK-603
DMN1YHP	MI	TT93WF5
DMN1YHP	MN	Interferon-gamma (IFNG)
DMN1YHP	MT	DTT
DMN1YHP	MA	Modulator
DMN1YHP	RN	T helper 1 inhibitor TAK-603 inhibits IFN-gamma and IL-12 production with no effect on IL-18: an observation in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis. 2004 Oct;21(3):204-11.
DMN1YHP	RU	https://pubmed.ncbi.nlm.nih.gov/15554077

DMDVJKW	DI	DMDVJKW
DMDVJKW	DN	TAK-637
DMDVJKW	MI	TTZPO1L
DMDVJKW	MN	Substance-P receptor (TACR1)
DMDVJKW	MT	DTT
DMDVJKW	MA	Antagonist
DMDVJKW	RN	Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
DMDVJKW	RU	https://pubmed.ncbi.nlm.nih.gov/18172433

DMHNZ31	DI	DMHNZ31
DMHNZ31	DN	TAK-802
DMHNZ31	MI	TT1RS9F
DMHNZ31	MN	Acetylcholinesterase (AChE)
DMHNZ31	MT	DTT
DMHNZ31	MA	Inhibitor
DMHNZ31	RN	Effects of TAK-802, a novel acetylcholinesterase inhibitor, on distension-induced rhythmic bladder contractions in rats and guinea pigs. Eur J Pharmacol. 2004 Feb 6;485(1-3):299-305.
DMHNZ31	RU	https://pubmed.ncbi.nlm.nih.gov/14757154

DMWVPEU	DI	DMWVPEU
DMWVPEU	DN	Tallimustine
DMWVPEU	MI	TTUTN1I
DMWVPEU	MN	Human Deoxyribonucleic acid (hDNA)
DMWVPEU	MT	DTT
DMWVPEU	MA	Modulator
DMWVPEU	RN	Sequence-specific DNA alkylation of novel tallimustine derivatives. Anticancer Drug Des. 1998 Apr;13(3):193-205.
DMWVPEU	RU	https://www.ncbi.nlm.nih.gov/pubmed/9595033

DM2KH9Y	DI	DM2KH9Y
DM2KH9Y	DN	Talsaclidine fumarate
DM2KH9Y	MI	TTZ9SOR
DM2KH9Y	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DM2KH9Y	MT	DTT
DM2KH9Y	MA	Agonist
DM2KH9Y	RN	Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur J Pharmacol. 2009 Mar 1;605(1-3):53-6.
DM2KH9Y	RU	https://pubmed.ncbi.nlm.nih.gov/19168056

DM1L5UX	DI	DM1L5UX
DM1L5UX	DN	TAMOLARIZINE HYDROCHLORIDE
DM1L5UX	MI	TT5HONZ
DM1L5UX	MN	Calcium channel unspecific (CaC)
DM1L5UX	MT	DTT
DM1L5UX	MA	Blocker
DM1L5UX	RN	Reversal of multidrug resistance in human leukemia K562 by tamolarizine, a novel calcium antagonist. Jpn J Pharmacol. 2000 Mar;82(3):265-8.
DM1L5UX	RU	https://pubmed.ncbi.nlm.nih.gov/10887958

DMNU2MH	DI	DMNU2MH
DMNU2MH	DN	Tandutinib
DMNU2MH	MI	TTGJCWZ
DMNU2MH	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMNU2MH	MT	DTT
DMNU2MH	MA	Inhibitor
DMNU2MH	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMNU2MH	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMF1VY4	DI	DMF1VY4
DMF1VY4	DN	Taprizosin
DMF1VY4	MI	TTNGILX
DMF1VY4	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMF1VY4	MT	DTT
DMF1VY4	MA	Antagonist
DMF1VY4	RN	Impact of physicochemical and structural properties on the pharmacokinetics of a series of alpha1L-adrenoceptor antagonists. Drug Metab Dispos. 2007 Aug;35(8):1435-45.
DMF1VY4	RU	https://pubmed.ncbi.nlm.nih.gov/17502340

DMX6ZYE	DI	DMX6ZYE
DMX6ZYE	DN	Tarazepide
DMX6ZYE	MI	TTCG0AL
DMX6ZYE	MN	Cholecystokinin receptor type A (CCKAR)
DMX6ZYE	MT	DTT
DMX6ZYE	MA	Antagonist
DMX6ZYE	RN	Melatonin as modulator of pancreatic enzyme secretion and pancreatoprotector. J Physiol Pharmacol. 2007 Dec;58 Suppl 6:65-80.
DMX6ZYE	RU	https://pubmed.ncbi.nlm.nih.gov/18212401

DMJG7VP	DI	DMJG7VP
DMJG7VP	DN	Tariquidar
DMJG7VP	MI	TT3OT40
DMJG7VP	MN	Multidrug resistance protein 1 (ABCB1)
DMJG7VP	MT	DTT
DMJG7VP	MA	Modulator
DMJG7VP	RN	Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).Biochem Pharmacol.2008 Mar 15;75(6):1302-12.
DMJG7VP	RU	https://www.ncbi.nlm.nih.gov/pubmed/18234154

DMP1A4S	DI	DMP1A4S
DMP1A4S	DN	TC-2696
DMP1A4S	MI	TTL1ATN
DMP1A4S	MN	Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2)
DMP1A4S	MT	DTT
DMP1A4S	MA	Modulator
DMP1A4S	RN	alpha4beta2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats. Neuropharmacology. 2013 Aug;71:191-203.
DMP1A4S	RU	https://pubmed.ncbi.nlm.nih.gov/23583932

DM3VZ87	DI	DM3VZ87
DM3VZ87	DN	TCV-309
DM3VZ87	MI	TTQL5VC
DM3VZ87	MN	Platelet-activating factor receptor (PTAFR)
DM3VZ87	MT	DTT
DM3VZ87	MA	Modulator
DM3VZ87	RN	Inhibitory effect of TCV-309, a novel platelet activating factor (PAF) antagonist, on endotoxin-induced disseminated intravascular coagulation in r... Thromb Res. 1993 May 15;70(4):281-93.
DM3VZ87	RU	https://www.ncbi.nlm.nih.gov/pubmed/8332959

DMMUE8P	DI	DMMUE8P
DMMUE8P	DN	TEBUFELONE
DMMUE8P	MI	TT2J34L
DMMUE8P	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMMUE8P	MT	DTT
DMMUE8P	MA	Inhibitor
DMMUE8P	RN	New cyclooxygenase-2/5-lipoxygenase inhibitors. 2. 7-tert-butyl-2,3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflamm... J Med Chem. 1998 Mar 26;41(7):1124-37.
DMMUE8P	RU	https://pubmed.ncbi.nlm.nih.gov/9544212

DMMUE8P	DI	DMMUE8P
DMMUE8P	DN	TEBUFELONE
DMMUE8P	MI	TTSJ6Q4
DMMUE8P	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DMMUE8P	MT	DTT
DMMUE8P	MA	Inhibitor
DMMUE8P	RN	New cyclooxygenase-2/5-lipoxygenase inhibitors. 3. 7-tert-butyl-2, 3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflam... J Med Chem. 1998 Aug 27;41(18):3515-29.
DMMUE8P	RU	https://pubmed.ncbi.nlm.nih.gov/9719605

DMMUE8P	DI	DMMUE8P
DMMUE8P	DN	TEBUFELONE
DMMUE8P	MI	TT8NGED
DMMUE8P	MN	Prostaglandin G/H synthase 1 (COX-1)
DMMUE8P	MT	DTT
DMMUE8P	MA	Inhibitor
DMMUE8P	RN	New cyclooxygenase-2/5-lipoxygenase inhibitors. 2. 7-tert-butyl-2,3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflamm... J Med Chem. 1998 Mar 26;41(7):1124-37.
DMMUE8P	RU	https://pubmed.ncbi.nlm.nih.gov/9544212

DMMUE8P	DI	DMMUE8P
DMMUE8P	DN	TEBUFELONE
DMMUE8P	MI	TTVKILB
DMMUE8P	MN	Prostaglandin G/H synthase 2 (COX-2)
DMMUE8P	MT	DTT
DMMUE8P	MA	Inhibitor
DMMUE8P	RN	New cyclooxygenase-2/5-lipoxygenase inhibitors. 2. 7-tert-butyl-2,3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflamm... J Med Chem. 1998 Mar 26;41(7):1124-37.
DMMUE8P	RU	https://pubmed.ncbi.nlm.nih.gov/9544212

DMPCRUT	DI	DMPCRUT
DMPCRUT	DN	Teglicar
DMPCRUT	MI	TTC8M31
DMPCRUT	MN	Carnitine acyltransferase (CRAT)
DMPCRUT	MT	DTT
DMPCRUT	MA	Inhibitor
DMPCRUT	RN	Selective Reversible Inhibition of Liver Carnitine Palmitoyl-Transferase 1 by Teglicar Reduces Gluconeogenesis and Improves Glucose Homeostasis. Diabetes. 2011 February; 60(2): 644-651.
DMPCRUT	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3028366/

DM3F5E0	DI	DM3F5E0
DM3F5E0	DN	TEI-6122
DM3F5E0	MI	TT9B4N3
DM3F5E0	MN	Prostaglandin receptor (PTGR)
DM3F5E0	MT	DTT
DM3F5E0	MA	Modulator
DM3F5E0	RN	The effect of a synthetic 7-thiaprostaglandin E1 derivative, TEI-6122, on monocyte chemoattractant protein-1 induced chemotaxis in THP-1 cells.. Br J Pharmacol. 1995 October; 116(4): 2298-2302.
DM3F5E0	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1908987/

DMIDGZU	DI	DMIDGZU
DMIDGZU	DN	Telbermin
DMIDGZU	MI	TT2Q6G1
DMIDGZU	MN	Vascular endothelial growth factor receptor 1 (FLT-1)
DMIDGZU	MT	DTT
DMIDGZU	MA	Activator
DMIDGZU	RN	Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
DMIDGZU	RU	https://pubmed.ncbi.nlm.nih.gov/17064227

DM8OWID	DI	DM8OWID
DM8OWID	DN	Telinavir
DM8OWID	MI	TT5FNQT
DM8OWID	MN	Human immunodeficiency virus Protease (HIV PR)
DM8OWID	MT	DTT
DM8OWID	MA	Inhibitor
DM8OWID	RN	Improvement of bioavailability of the HIV protease inhibitor SC-52151 in the beagle dog by coadministration of the CYP3A4 inhibitor, ketoconazole. Xenobiotica. 1997 May;27(5):489-97.
DM8OWID	RU	https://pubmed.ncbi.nlm.nih.gov/9179989

DM4K3P9	DI	DM4K3P9
DM4K3P9	DN	Terflavoxate
DM4K3P9	MI	TTOXS3C
DM4K3P9	MN	Muscarinic acetylcholine receptor (CHRM)
DM4K3P9	MT	DTT
DM4K3P9	MA	Modulator
DM4K3P9	RN	Effects of terflavoxate on stimulated contractions of urinary bladder in vitro. Arzneimittelforschung. 1993 Feb;43(2):122-8.
DM4K3P9	RU	https://pubmed.ncbi.nlm.nih.gov/8384453

DMPB36I	DI	DMPB36I
DMPB36I	DN	Tesmilifene
DMPB36I	MI	DECB0K3
DMPB36I	MN	Cytochrome P450 2D6 (CYP2D6)
DMPB36I	MT	DME
DMPB36I	MA	Metabolism
DMPB36I	RN	N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine (DPPE) a chemopotentiating and cytoprotective agent in clinical trials: interaction with histamine at cytochrome P450 3A4 and other isozymes that metabolize antineoplastic drugs. Cancer Chemother Pharmacol. 2000;45(4):298-304.
DMPB36I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10755318

DMPB36I	DI	DMPB36I
DMPB36I	DN	Tesmilifene
DMPB36I	MI	DE4LYSA
DMPB36I	MN	Cytochrome P450 3A4 (CYP3A4)
DMPB36I	MT	DME
DMPB36I	MA	Metabolism
DMPB36I	RN	Effects of tesmilifene, a substrate of CYP3A and an inhibitor of P-glycoprotein, on the pharmacokinetics of intravenous and oral docetaxel in rats. J Pharm Pharmacol. 2010 Aug;62(8):1084-8.
DMPB36I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20663044

DMPB36I	DI	DMPB36I
DMPB36I	DN	Tesmilifene
DMPB36I	MI	TT7CXIM
DMPB36I	MN	Histamine receptor (HR)
DMPB36I	MT	DTT
DMPB36I	MA	Modulator
DMPB36I	RN	Effects of tesmilifene, a substrate of CYP3A and an inhibitor of P-glycoprotein, on the pharmacokinetics of intravenous and oral docetaxel in rats. J Pharm Pharmacol. 2010 Aug;62(8):1084-8.
DMPB36I	RU	https://pubmed.ncbi.nlm.nih.gov/20663044

DM5O6HM	DI	DM5O6HM
DM5O6HM	DN	Testosterone glucoside
DM5O6HM	MI	TTS64P2
DM5O6HM	MN	Androgen receptor (AR)
DM5O6HM	MT	DTT
DM5O6HM	MA	Agonist
DM5O6HM	RN	Evidence for a role of testosterone-androgen receptor interactions in mediating masculine sexual behavior in male rats. Endocrinology. 1989 Feb;124(2):618-26.
DM5O6HM	RU	https://pubmed.ncbi.nlm.nih.gov/2912689

DMC0WNB	DI	DMC0WNB
DMC0WNB	DN	Tetramethylpyrazine
DMC0WNB	MI	TTJR60Z
DMC0WNB	MN	Endothelin-1 (EDN1)
DMC0WNB	MT	DTT
DMC0WNB	MA	Modulator
DMC0WNB	RN	Tetramethylpyrazine, a Chinese drug, blocks coronary vasoconstriction by endothelin-1 and decreases plasma endothelin-1 levels in experimental animals. J Cardiovasc Pharmacol. 1998;31 Suppl 1:S313-6.
DMC0WNB	RU	https://pubmed.ncbi.nlm.nih.gov/9595468

DMS4BUK	DI	DMS4BUK
DMS4BUK	DN	TG-1042
DMS4BUK	MI	TT93WF5
DMS4BUK	MN	Interferon-gamma (IFNG)
DMS4BUK	MT	DTT
DMS4BUK	MA	Modulator
DMS4BUK	RN	Drug evaluation: TG-1042, an adenovirus-mediated IFNgamma gene delivery for the intratumoral therapy of primary cutaneous lymphomas. Curr Opin Investig Drugs. 2007 Jun;8(6):493-8.
DMS4BUK	RU	https://pubmed.ncbi.nlm.nih.gov/17621880

DMQSNV8	DI	DMQSNV8
DMQSNV8	DN	TgAAV-CFTR
DMQSNV8	MI	TTCYAXN
DMQSNV8	MN	Chloride channel unspecific (ClC)
DMQSNV8	MT	DTT
DMQSNV8	MA	Modulator
DMQSNV8	RN	Novel molecular approaches to cystic fibrosis gene therapy. Biochem J. 2005 April 1; 387(Pt 1): 1-15.
DMQSNV8	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1134927/

DMYN6G0	DI	DMYN6G0
DMYN6G0	DN	TGP-580
DMYN6G0	MI	TTGKIED
DMYN6G0	MN	Fibroblast growth factor-2 (FGF2)
DMYN6G0	MT	DTT
DMYN6G0	MA	Modulator
DMYN6G0	RN	Expression of fibroblast growth factor-2 transcripts in the healing of acetic acid-induced gastric ulcers. APMIS. 1999 Aug;107(8):767-72.
DMYN6G0	RU	https://pubmed.ncbi.nlm.nih.gov/10515127

DMGR7Y3	DI	DMGR7Y3
DMGR7Y3	DN	Theradigm-HBV
DMGR7Y3	MI	TTZTEFH
DMGR7Y3	MN	Major histocompatibility complex (MHC)
DMGR7Y3	MT	DTT
DMGR7Y3	MA	Modulator
DMGR7Y3	RN	Molecular features of the hepatitis B virus nucleocapsid T-cell epitope 18-27: interaction with HLA and T-cell receptor. Hepatology. 1997 Oct;26(4):1027-34.
DMGR7Y3	RU	https://pubmed.ncbi.nlm.nih.gov/9328331

DMYH2PU	DI	DMYH2PU
DMYH2PU	DN	TIBENELAST
DMYH2PU	MI	TTUST1O
DMYH2PU	MN	Phosphodiesterase (PDE)
DMYH2PU	MT	DTT
DMYH2PU	MA	Inhibitor
DMYH2PU	RN	Effect of tibenelast (a phosphodiesterase inhibitor) and theophylline on isoproterenol-stimulated heart rate, cyclic AMP and norepinephrine levels. Pharmacology. 1993;46(3):142-7.
DMYH2PU	RU	https://pubmed.ncbi.nlm.nih.gov/8382824

DMLWBYO	DI	DMLWBYO
DMLWBYO	DN	Tienoxolol
DMLWBYO	MI	TTMXGCW
DMLWBYO	MN	Adrenergic receptor beta-3 (ADRB3)
DMLWBYO	MT	DTT
DMLWBYO	MA	Modulator
DMLWBYO	RN	Effects of the beta-adrenoceptor antagonists atenolol and propranolol on human parotid and submandibular-sublingual salivary secretion. J Dent Res. 1994 Jan;73(1):5-10.
DMLWBYO	RU	https://pubmed.ncbi.nlm.nih.gov/8294618

DMPWSRA	DI	DMPWSRA
DMPWSRA	DN	Tilmacoxib
DMPWSRA	MI	TTVKILB
DMPWSRA	MN	Prostaglandin G/H synthase 2 (COX-2)
DMPWSRA	MT	DTT
DMPWSRA	MA	Inhibitor
DMPWSRA	RN	4-(4-cycloalkyl/aryl-oxazol-5-yl)benzenesulfonamides as selective cyclooxygenase-2 inhibitors: enhancement of the selectivity by introduction of a ... J Med Chem. 2002 Mar 28;45(7):1511-7.
DMPWSRA	RU	https://pubmed.ncbi.nlm.nih.gov/11906292

DMUJ2X6	DI	DMUJ2X6
DMUJ2X6	DN	Tiqueside
DMUJ2X6	MI	TTNA5ZS
DMUJ2X6	MN	Cholesterol absorption (Chole absorp)
DMUJ2X6	MT	DTT
DMUJ2X6	MA	Modulator
DMUJ2X6	RN	Inhibiting cholesterol absorption with CP-88,818 (beta-tigogenin cellobioside; tiqueside): studies in normal and hyperlipidemic subjects. J Cardiovasc Pharmacol. 1997 Jul;30(1):55-60.
DMUJ2X6	RU	https://pubmed.ncbi.nlm.nih.gov/9268221

DMGF35T	DI	DMGF35T
DMGF35T	DN	Tisocalcitate
DMGF35T	MI	TTK59TV
DMGF35T	MN	Vitamin D3 receptor (VDR)
DMGF35T	MT	DTT
DMGF35T	MA	Inhibitor
DMGF35T	RN	The Rationale Behind Topical Vitamin D Analogs in the Treatment of Psoriasis: Where Does Topical Calcitriol Fit In . J Clin Aesthet Dermatol. 2010 August; 3(8): 46-53.
DMGF35T	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2945865/

DMXNQLU	DI	DMXNQLU
DMXNQLU	DN	TM30338
DMXNQLU	MI	TTJ6WK9
DMXNQLU	MN	Neuropeptide Y receptor type 2 (NPY2R)
DMXNQLU	MT	DTT
DMXNQLU	MA	Modulator
DMXNQLU	RN	Anti-Obesity Drug Discovery and Development, Atta-ur- Rahman, page(108)
DMXNQLU	RU	https://books.google.com.hk/books?id=lc4WdvCmD54C&pg=PA108&lpg=PA108&dq=obinepitide++agonist%27&source=bl&ots=8jUZzCOibY&sig=RbRzNpJyEKp_V0-bNYHEwcTnPL8&hl=zh-CN&sa=X#v=onepage&q=obinepitide%20%20agonist%27&f=false

DMXNQLU	DI	DMXNQLU
DMXNQLU	DN	TM30338
DMXNQLU	MI	TTW4N16
DMXNQLU	MN	Neuropeptide Y receptor type 4 (NPY4R)
DMXNQLU	MT	DTT
DMXNQLU	MA	Modulator
DMXNQLU	RN	Anti-Obesity Drug Discovery and Development, Atta-ur- Rahman, page(108)
DMXNQLU	RU	https://books.google.com.hk/books?id=lc4WdvCmD54C&pg=PA108&lpg=PA108&dq=obinepitide++agonist%27&source=bl&ots=8jUZzCOibY&sig=RbRzNpJyEKp_V0-bNYHEwcTnPL8&hl=zh-CN&sa=X#v=onepage&q=obinepitide%20%20agonist%27&f=false

DMW7LQT	DI	DMW7LQT
DMW7LQT	DN	TM30339
DMW7LQT	MI	TTW4N16
DMW7LQT	MN	Neuropeptide Y receptor type 4 (NPY4R)
DMW7LQT	MT	DTT
DMW7LQT	MA	Agonist
DMW7LQT	RN	Neuropeptide y receptor selective ligands in the treatment of obesity. Endocr Rev. 2007 Oct;28(6):664-84.
DMW7LQT	RU	https://pubmed.ncbi.nlm.nih.gov/17785427

DMW05DS	DI	DMW05DS
DMW05DS	DN	TNP-351
DMW05DS	MI	TTYZVDJ
DMW05DS	MN	Dihydrofolate reductase (DHFR)
DMW05DS	MT	DTT
DMW05DS	MA	Inhibitor
DMW05DS	RN	A Ring-Transformation/Ring-Annulation Strategy for the Synthesis of the DHFR Inhibitor, TNP-351: A Correction. J Org Chem. 1996 Nov 1;61(22):7973-7974.
DMW05DS	RU	https://pubmed.ncbi.nlm.nih.gov/11667765

DMT0QK8	DI	DMT0QK8
DMT0QK8	DN	TNP-470
DMT0QK8	MI	TTZL0OI
DMT0QK8	MN	Methionine aminopeptidase 2 (METAP2)
DMT0QK8	MT	DTT
DMT0QK8	MA	Inhibitor
DMT0QK8	RN	Tumor suppression by a rationally designed reversible inhibitor of methionine aminopeptidase-2. Cancer Res. 2003 Nov 15;63(22):7861-9.
DMT0QK8	RU	https://pubmed.ncbi.nlm.nih.gov/14633714

DMEROU4	DI	DMEROU4
DMEROU4	DN	Tolafentrine
DMEROU4	MI	DTUGYRD
DMEROU4	MN	P-glycoprotein 1 (ABCB1)
DMEROU4	MT	DTP
DMEROU4	MA	Substrate
DMEROU4	RN	A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26.
DMEROU4	RU	https://doi.org/10.1007/s00210-008-0345-0

DMEROU4	DI	DMEROU4
DMEROU4	DN	Tolafentrine
DMEROU4	MI	TTZCG4L
DMEROU4	MN	Phosphodiesterase 3 (PDE3)
DMEROU4	MT	DTT
DMEROU4	MA	Modulator
DMEROU4	RN	Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration
DMEROU4	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1291406

DMY40KZ	DI	DMY40KZ
DMY40KZ	DN	Tomeglovir
DMY40KZ	MI	TTIU7X1
DMY40KZ	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMY40KZ	MT	DTT
DMY40KZ	MA	Inhibitor
DMY40KZ	RN	Focus on new drugs in development against human cytomegalovirus. Drugs. 2002;62(13):1853-8.
DMY40KZ	RU	https://pubmed.ncbi.nlm.nih.gov/12215056

DM1YXPL	DI	DM1YXPL
DM1YXPL	DN	Tomopenem
DM1YXPL	MI	TTJP4SM
DM1YXPL	MN	Bacterial Penicillin binding protein (Bact PBP)
DM1YXPL	MT	DTT
DM1YXPL	MA	Modulator
DM1YXPL	RN	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.Antimicrob Agents Chemother.2009 Mar;53(3):1238-41.
DM1YXPL	RU	https://www.ncbi.nlm.nih.gov/pubmed/19104025

DMZA06U	DI	DMZA06U
DMZA06U	DN	TOPIXANTRONE HYDROCHLORIDE
DMZA06U	MI	TTUTN1I
DMZA06U	MN	Human Deoxyribonucleic acid (hDNA)
DMZA06U	MT	DTT
DMZA06U	MA	Inhibitor
DMZA06U	RN	Clinical pipeline report, company report or official report of CTI BioPharma.
DMZA06U	RU	http://www.ctibiopharma.com/pipeline/pixantrone/

DMDHYM7	DI	DMDHYM7
DMDHYM7	DN	Torcetrapib
DMDHYM7	MI	TTFQAYR
DMDHYM7	MN	Cholesteryl ester transfer protein (CETP)
DMDHYM7	MT	DTT
DMDHYM7	MA	Inhibitor
DMDHYM7	RN	Safety and tolerability of dalcetrapib. Am J Cardiol. 2009 Jul 1;104(1):82-91.
DMDHYM7	RU	https://pubmed.ncbi.nlm.nih.gov/19576325

DMDHYM7	DI	DMDHYM7
DMDHYM7	DN	Torcetrapib
DMDHYM7	MI	DE4LYSA
DMDHYM7	MN	Cytochrome P450 3A4 (CYP3A4)
DMDHYM7	MT	DME
DMDHYM7	MA	Metabolism
DMDHYM7	RN	Pharmacokinetics, metabolism, and excretion of torcetrapib, a cholesteryl ester transfer protein inhibitor, in humans. Drug Metab Dispos. 2008 Nov;36(11):2185-98.
DMDHYM7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18694908

DMX32RC	DI	DMX32RC
DMX32RC	DN	Transdur-sufentanil
DMX32RC	MI	TTKWM86
DMX32RC	MN	Opioid receptor mu (MOP)
DMX32RC	MT	DTT
DMX32RC	MA	Agonist
DMX32RC	RN	[3H]Sufentanil, a superior ligand for mu-opiate receptors: binding properties and regional distribution in rat brain and spinal cord. Eur J Pharmacol. 1983 Feb 18;87(2-3):209-25.
DMX32RC	RU	https://pubmed.ncbi.nlm.nih.gov/6132825

DME85Z9	DI	DME85Z9
DME85Z9	DN	TREFENTANIL HYDROCHLORIDE
DME85Z9	MI	TTKWM86
DME85Z9	MN	Opioid receptor mu (MOP)
DME85Z9	MT	DTT
DME85Z9	MA	Agonist
DME85Z9	RN	Pharmacokinetic-pharmacodynamic modeling in drug development: application to the investigational opioid trefentanil. Clin Pharmacol Ther. 1994 Sep;56(3):261-71.
DME85Z9	RU	https://pubmed.ncbi.nlm.nih.gov/7924121

DMUZNF0	DI	DMUZNF0
DMUZNF0	DN	Tridolgosir
DMUZNF0	MI	TT34DCN
DMUZNF0	MN	Golgi alpha-mannosidase II (MAN2A1)
DMUZNF0	MT	DTT
DMUZNF0	MA	Inhibitor
DMUZNF0	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010383)
DMUZNF0	RU	http://adisinsight.springer.com/drugs/800010383

DMZ98Y4	DI	DMZ98Y4
DMZ98Y4	DN	TRO-40303
DMZ98Y4	MI	TTPTXIN
DMZ98Y4	MN	Translocator protein (TSPO)
DMZ98Y4	MT	DTT
DMZ98Y4	MA	Modulator
DMZ98Y4	RN	Translation of TRO40303 from myocardial infarction models to demonstration of safety and tolerance in a randomized Phase I trial. J Transl Med. 2014; 12: 38.
DMZ98Y4	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3923730/

DM6032E	DI	DM6032E
DM6032E	DN	Trombodipine
DM6032E	MI	TT438XZ
DM6032E	MN	Cyclin D1/E2F pathway (CCND1/E2F pathway)
DM6032E	MT	DTT
DM6032E	MA	Modulator
DM6032E	RN	Inhibition of the cyclin D1/E2F pathway by PCA-4230, a potent repressor of cellular proliferation. Br J Pharmacol. 2001 April; 132(7): 1597-1605.
DM6032E	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1572687/

DMALIFO	DI	DMALIFO
DMALIFO	DN	TS-033
DMALIFO	MI	TTLWPVF
DMALIFO	MN	Sodium/glucose cotransporter 2 (SGLT2)
DMALIFO	MT	DTT
DMALIFO	MA	Modulator
DMALIFO	RN	Company report (Taisho)
DMALIFO	RU	http://www.taisho.co.jp/en/company/release/2008/2008100201-e.pdf

DMWXOJN	DI	DMWXOJN
DMWXOJN	DN	TT-62
DMWXOJN	MI	TTU6BFZ
DMWXOJN	MN	Candida Thymidylate synthase (Candi TMP1)
DMWXOJN	MT	DTT
DMWXOJN	MA	Inhibitor
DMWXOJN	RN	TECHNOLOGY, PRODUCTS, MARKETS AND SERVICE OPPORTUNITIES. Future Oncology. AUGUST 1995. VOLUME 1, NUMBER 4.
DMWXOJN	RU	http://www.oncologyknowledgebase.net/futureoncology/pdfs/Future_Oncology.Vol.1.No.4.pdf

DMCEGN4	DI	DMCEGN4
DMCEGN4	DN	TTP-355
DMCEGN4	MI	TTDLNGZ
DMCEGN4	MN	Glucokinase (GCK)
DMCEGN4	MT	DTT
DMCEGN4	MA	Activator
DMCEGN4	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025266)
DMCEGN4	RU	http://adisinsight.springer.com/drugs/800025266

DM81XLA	DI	DM81XLA
DM81XLA	DN	TV-4710
DM81XLA	MI	TTUTN1I
DM81XLA	MN	Human Deoxyribonucleic acid (hDNA)
DM81XLA	MT	DTT
DM81XLA	MA	Inhibitor
DM81XLA	RN	Emergence of targeted immune therapies for systemic lupus. Expert Opin Emerg Drugs. 2005 Feb;10(1):53-65.
DM81XLA	RU	https://pubmed.ncbi.nlm.nih.gov/15757403

DMQWA2R	DI	DMQWA2R
DMQWA2R	DN	TY-11345
DMQWA2R	MI	TTLOKXP
DMQWA2R	MN	Gastric H(+)/K(+) ATPase (Proton pump)
DMQWA2R	MT	DTT
DMQWA2R	MA	Modulator
DMQWA2R	RN	Biochemical and pharmacological properties of a newly synthesized proton pump (H+/K(+)-ATPase) inhibitor, TY-11345 in experimental animals. Jpn J Pharmacol. 1993 Aug;62(4):363-71.
DMQWA2R	RU	https://pubmed.ncbi.nlm.nih.gov/8230863

DM4FZWP	DI	DM4FZWP
DM4FZWP	DN	UK-279,276
DM4FZWP	MI	TTIJWR7
DM4FZWP	MN	Integrin beta-2 (ITGB2)
DM4FZWP	MT	DTT
DM4FZWP	MA	Antagonist
DM4FZWP	RN	Advances in ischemic stroke treatment: neuroprotective and combination therapies. Expert Opin Emerg Drugs. 2007 Mar;12(1):97-112.
DM4FZWP	RU	https://pubmed.ncbi.nlm.nih.gov/17355216

DMAD1S5	DI	DMAD1S5
DMAD1S5	DN	UK-74505
DMAD1S5	MI	TTQL5VC
DMAD1S5	MN	Platelet-activating factor receptor (PTAFR)
DMAD1S5	MT	DTT
DMAD1S5	MA	Antagonist
DMAD1S5	RN	Differential effects of the PAF receptor antagonist UK-74,505 on neutrophil and eosinophil accumulation in guinea-pig skin. Br J Pharmacol. 1994 Oct;113(2):513-21.
DMAD1S5	RU	https://pubmed.ncbi.nlm.nih.gov/7834203

DMRDXYV	DI	DMRDXYV
DMRDXYV	DN	Ultramorph
DMRDXYV	MI	TTN4QDT
DMRDXYV	MN	Opioid receptor (OPR)
DMRDXYV	MT	DTT
DMRDXYV	MA	Agonist
DMRDXYV	RN	Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability. Pain. 2000 Feb;84(2-3):121-31.
DMRDXYV	RU	https://pubmed.ncbi.nlm.nih.gov/10666516

DMBJ8KG	DI	DMBJ8KG
DMBJ8KG	DN	Urtoxazumab
DMBJ8KG	MI	TTRV7FQ
DMBJ8KG	MN	Enterobacteria Shiga-like toxin 2B (EntBac stxB2)
DMBJ8KG	MT	DTT
DMBJ8KG	RN	Safety and pharmacokinetics of urtoxazumab, a humanized monoclonal antibody, against Shiga-like toxin 2 in healthy adults and in pediatric patients infected with Shiga-like toxin-producing Escherichia coli. Antimicrob Agents Chemother. 2010 Jan;54(1):239-43.
DMBJ8KG	RU	https://pubmed.ncbi.nlm.nih.gov/19822704

DMOB2K5	DI	DMOB2K5
DMOB2K5	DN	UTIBAPRIL
DMOB2K5	MI	TTL69WB
DMOB2K5	MN	Angiotensin-converting enzyme (ACE)
DMOB2K5	MT	DTT
DMOB2K5	MA	Inhibitor
DMOB2K5	RN	Differential inhibition of plasma versus tissue ACE by utibapril: biochemical and functional evidence for inhibition of vascular ACE activity. J Cardiovasc Pharmacol. 1997 May;29(5):684-91.
DMOB2K5	RU	https://pubmed.ncbi.nlm.nih.gov/9213213

DMEV1H5	DI	DMEV1H5
DMEV1H5	DN	V-11294A
DMEV1H5	MI	TTZ97H5
DMEV1H5	MN	Phosphodiesterase 4A (PDE4A)
DMEV1H5	MT	DTT
DMEV1H5	MA	Inhibitor
DMEV1H5	RN	Pharmacokinetic and pharmacodynamic profile following oral administration of the phosphodiesterase (PDE)4 inhibitor V11294A in healthy volunteers. Br J Clin Pharmacol. 2002 Nov;54(5):478-84.
DMEV1H5	RU	https://pubmed.ncbi.nlm.nih.gov/12445026

DMEV1H5	DI	DMEV1H5
DMEV1H5	DN	V-11294A
DMEV1H5	MI	TTVIAT9
DMEV1H5	MN	Phosphodiesterase 4B (PDE4B)
DMEV1H5	MT	DTT
DMEV1H5	MA	Inhibitor
DMEV1H5	RN	Pharmacokinetic and pharmacodynamic profile following oral administration of the phosphodiesterase (PDE)4 inhibitor V11294A in healthy volunteers. Br J Clin Pharmacol. 2002 Nov;54(5):478-84.
DMEV1H5	RU	https://pubmed.ncbi.nlm.nih.gov/12445026

DMEV1H5	DI	DMEV1H5
DMEV1H5	DN	V-11294A
DMEV1H5	MI	TTSKMI8
DMEV1H5	MN	Phosphodiesterase 4D (PDE4D)
DMEV1H5	MT	DTT
DMEV1H5	MA	Inhibitor
DMEV1H5	RN	Pharmacokinetic and pharmacodynamic profile following oral administration of the phosphodiesterase (PDE)4 inhibitor V11294A in healthy volunteers. Br J Clin Pharmacol. 2002 Nov;54(5):478-84.
DMEV1H5	RU	https://pubmed.ncbi.nlm.nih.gov/12445026

DMXQCBU	DI	DMXQCBU
DMXQCBU	DN	Valtorcitabine
DMXQCBU	MI	TTT4SY6
DMXQCBU	MN	Hepatitis B virus Polymerase (HBV P)
DMXQCBU	MT	DTT
DMXQCBU	MA	Inhibitor
DMXQCBU	RN	Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting. J Pharm Sci. 2008 Mar;97(3):1109-34.
DMXQCBU	RU	https://pubmed.ncbi.nlm.nih.gov/17696166

DMHCOFM	DI	DMHCOFM
DMHCOFM	DN	Vasoflux
DMHCOFM	MI	TT6L509
DMHCOFM	MN	Coagulation factor IIa (F2)
DMHCOFM	MT	DTT
DMHCOFM	MA	Inhibitor
DMHCOFM	RN	Vasoflux, a new anticoagulant with a novel mechanism of action. Circulation. 1999 Feb 9;99(5):682-9.
DMHCOFM	RU	https://pubmed.ncbi.nlm.nih.gov/9950667

DMROSHN	DI	DMROSHN
DMROSHN	DN	Velneperit
DMROSHN	MI	TTY6EWA
DMROSHN	MN	Neuropeptide Y receptor type 5 (NPY5R)
DMROSHN	MT	DTT
DMROSHN	MA	Antagonist
DMROSHN	RN	Clinical pipeline report, company report or official report of Shionogi (2011).
DMROSHN	RU	http://www.shionogi.co.jp/index_e.html

DMHCLVQ	DI	DMHCLVQ
DMHCLVQ	DN	Vitaxin
DMHCLVQ	MI	TT69TQN
DMHCLVQ	MN	Integrin alpha-V/beta-3 (ITGAV/B3)
DMHCLVQ	MT	DTT
DMHCLVQ	MA	Modulator
DMHCLVQ	RN	Monoclonal antibodies to alphaVbeta3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor. Blood. 2000 Jan 15;95(2):368-74.
DMHCLVQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/10627437

DMOS6CM	DI	DMOS6CM
DMOS6CM	DN	VLTS-587
DMOS6CM	MI	TTF89GD
DMOS6CM	MN	Interleukin-2 (IL2)
DMOS6CM	MT	DTT
DMOS6CM	MA	Modulator
DMOS6CM	RN	CN patent application no. 101039956, Cell surface glycoprotein.
DMOS6CM	RU	http://www.google.com/patents/CN101039956A?cl=en

DM32N5G	DI	DM32N5G
DM32N5G	DN	VOROZOLE
DM32N5G	MI	TTSZLWK
DM32N5G	MN	Aromatase (CYP19A1)
DM32N5G	MT	DTT
DM32N5G	MA	Inhibitor
DM32N5G	RN	Chiral aromatase and dual aromatase-steroid sulfatase inhibitors from the letrozole template: synthesis, absolute configuration, and in vitro activ... J Med Chem. 2008 Jul 24;51(14):4226-38.
DM32N5G	RU	https://pubmed.ncbi.nlm.nih.gov/18590272

DMFYM61	DI	DMFYM61
DMFYM61	DN	VTP-201227
DMFYM61	MI	TTOQ9GZ
DMFYM61	MN	Cytochrome P450 reductase (P450)
DMFYM61	MT	DTT
DMFYM61	MA	Inhibitor
DMFYM61	RN	VTP-201227. VietMedix.
DMFYM61	RU	http://vietmedix.com/Drug/drug-vtp-201227.5277.html

DMLCTBP	DI	DMLCTBP
DMLCTBP	DN	VTX-2337
DMLCTBP	MI	TT8CWFK
DMLCTBP	MN	Toll-like receptor 8 (TLR8)
DMLCTBP	MT	DTT
DMLCTBP	MA	Modulator
DMLCTBP	RN	Clinical pipeline report, company report or official report of Array BioPharma (Drug: Motolimod / VTX2337).
DMLCTBP	RU	http://www.arraybiopharma.com/product-pipeline/other-compounds/vtx-2337/

DMH4U87	DI	DMH4U87
DMH4U87	DN	VX-366
DMH4U87	MI	TTQO71U
DMH4U87	MN	Hemoglobin (HB)
DMH4U87	MT	DTT
DMH4U87	MA	Inhibitor
DMH4U87	RN	A combination of hydroxyurea and isobutyramide to induce fetal hemoglobin in transgenic mice is more hematotoxic than the individual agents. Blood Cells Mol Dis. 1999 Jun-Aug;25(3-4):255-69.
DMH4U87	RU	https://pubmed.ncbi.nlm.nih.gov/10575551

DMPE5XM	DI	DMPE5XM
DMPE5XM	DN	WAY-123641
DMPE5XM	MI	TT9V5JH
DMPE5XM	MN	Phospholipase A2 (PLA2G1B)
DMPE5XM	MT	DTT
DMPE5XM	MA	Inhibitor
DMPE5XM	RN	Phosphodiesterase-IV inhibition, respiratory muscle relaxation and bronchodilation by WAY-PDA-641. J Pharmacol Exp Ther. 1994 Feb;268(2):888-96.
DMPE5XM	RU	https://pubmed.ncbi.nlm.nih.gov/8114002

DMLA4DU	DI	DMLA4DU
DMLA4DU	DN	WC-3027
DMLA4DU	MI	TTYRL6O
DMLA4DU	MN	Glucocorticoid receptor (NR3C1)
DMLA4DU	MT	DTT
DMLA4DU	MA	Agonist
DMLA4DU	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021444)
DMLA4DU	RU	http://adisinsight.springer.com/drugs/800021444

DM7VCDZ	DI	DM7VCDZ
DM7VCDZ	DN	WY-47766
DM7VCDZ	MI	TTTK3BH
DM7VCDZ	MN	Vacuolar-type proton ATPase (v-ATPase)
DM7VCDZ	MT	DTT
DM7VCDZ	MA	Modulator
DM7VCDZ	RN	A pharmacological assessment of the mammalian osteoclast vacuolar H(+)-ATPase. Bone Miner. 1994 Nov;27(2):159-66.
DM7VCDZ	RU	https://pubmed.ncbi.nlm.nih.gov/7711523

DMICR39	DI	DMICR39
DMICR39	DN	XL784
DMICR39	MI	TTMX39J
DMICR39	MN	Matrix metalloproteinase-1 (MMP-1)
DMICR39	MT	DTT
DMICR39	MA	Inhibitor
DMICR39	RN	Agents in development for the treatment of diabetic nephropathy. Expert Opin Emerg Drugs. 2008 Sep;13(3):447-63.
DMICR39	RU	https://pubmed.ncbi.nlm.nih.gov/18764722

DMO90RN	DI	DMO90RN
DMO90RN	DN	Y-27152
DMO90RN	MI	TT1VOHK
DMO90RN	MN	Potassium channel unspecific (KC)
DMO90RN	MT	DTT
DMO90RN	MA	Opener
DMO90RN	RN	Pharmacokinetics and safety of a novel, long-acting, prodrug-type potassium channel opener, Y-27152, in healthy volunteers. J Clin Pharmacol. 1996 May;36(5):439-51.
DMO90RN	RU	https://pubmed.ncbi.nlm.nih.gov/8739023

DMHFTD0	DI	DMHFTD0
DMHFTD0	DN	Y-700
DMHFTD0	MI	TT7RJY8
DMHFTD0	MN	Xanthine dehydrogenase/oxidase (XDH)
DMHFTD0	MT	DTT
DMHFTD0	MA	Inhibitor
DMHFTD0	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMHFTD0	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DML2IXO	DI	DML2IXO
DML2IXO	DN	YM-114
DML2IXO	MI	TTPC4TU
DML2IXO	MN	5-HT 3A receptor (HTR3A)
DML2IXO	MT	DTT
DML2IXO	MA	Antagonist
DML2IXO	RN	Effect of serotonin (5-HT)3-receptor antagonists YM060, YM114 (KAE-393), ondansetron and granisetron on 5-HT4 receptors and gastric emptying in rodents. Jpn J Pharmacol. 1995 Nov;69(3):205-14.
DML2IXO	RU	https://pubmed.ncbi.nlm.nih.gov/8699628

DMIRSLV	DI	DMIRSLV
DMIRSLV	DN	YM-17K
DMIRSLV	MI	TTR8XOH
DMIRSLV	MN	GPCR secretin protein unspecific (GPCRB)
DMIRSLV	MT	DTT
DMIRSLV	MA	Modulator
DMIRSLV	RN	Antibiotics, Macrolides. Published Online: 18 OCT 2001.
DMIRSLV	RU	http://onlinelibrary.wiley.com/doi/10.1002/0471238961.1301031811091819.a01.pub2/abstract

DMCZIGQ	DI	DMCZIGQ
DMCZIGQ	DN	YM-337
DMCZIGQ	MI	TT38RM1
DMCZIGQ	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DMCZIGQ	MT	DTT
DMCZIGQ	MA	Modulator
DMCZIGQ	RN	Pharmacodynamic characterization of the interaction between the glycoprotein IIb/IIIa inhibitor YM337 and unfractionated heparin and aspirin in hum... Br J Clin Pharmacol. 2003 Sep;56(3):321-6.
DMCZIGQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/12919181

DM7OHR6	DI	DM7OHR6
DM7OHR6	DN	YM-440
DM7OHR6	MI	TTZMAO3
DM7OHR6	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DM7OHR6	MT	DTT
DM7OHR6	MA	Inhibitor
DM7OHR6	RN	The novel hypoglycemic agent YM440 improves hepatic insulin resistance in obese Zucker fatty rats. J Pharmacol Sci. 2006 Aug;101(4):311-7.
DM7OHR6	RU	https://pubmed.ncbi.nlm.nih.gov/16891767

DM7WDAG	DI	DM7WDAG
DM7WDAG	DN	YM-511
DM7WDAG	MI	TTSZLWK
DM7WDAG	MN	Aromatase (CYP19A1)
DM7WDAG	MT	DTT
DM7WDAG	MA	Inhibitor
DM7WDAG	RN	First dual aromatase-steroid sulfatase inhibitors. J Med Chem. 2003 Jul 17;46(15):3193-6.
DM7WDAG	RU	https://pubmed.ncbi.nlm.nih.gov/12852749

DMDXP3C	DI	DMDXP3C
DMDXP3C	DN	YM-796
DMDXP3C	MI	TTZ9SOR
DMDXP3C	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMDXP3C	MT	DTT
DMDXP3C	MA	Modulator
DMDXP3C	RN	YM796, a novel muscarinic agonist, improves the impairment of learning behavior in a rat model of chronic focal cerebral ischemia. Brain Res. 1995 Jan 9;669(1):107-14.
DMDXP3C	RU	https://www.ncbi.nlm.nih.gov/pubmed/7712153

DMWRT4L	DI	DMWRT4L
DMWRT4L	DN	YM-90K
DMWRT4L	MI	TTAN6JD
DMWRT4L	MN	Glutamate receptor AMPA (GRIA)
DMWRT4L	MT	DTT
DMWRT4L	MA	Inhibitor
DMWRT4L	RN	Synthesis and AMPA receptor antagonistic activity of a novel 7-imidazolyl-6-trifluoromethyl quinoxalinecarboxylic acid with a substituted phenyl gr... Bioorg Med Chem Lett. 2004 Oct 18;14(20):5107-11.
DMWRT4L	RU	https://pubmed.ncbi.nlm.nih.gov/15380209

DMWRT4L	DI	DMWRT4L
DMWRT4L	DN	YM-90K
DMWRT4L	MI	TTVPQTF
DMWRT4L	MN	Glutamate receptor AMPA 1 (GRIA1)
DMWRT4L	MT	DTT
DMWRT4L	MA	Inhibitor
DMWRT4L	RN	Synthesis and AMPA receptor antagonistic activity of a novel 7-imidazolyl-6-trifluoromethyl quinoxalinecarboxylic acid with a substituted phenyl gr... Bioorg Med Chem Lett. 2004 Oct 18;14(20):5107-11.
DMWRT4L	RU	https://pubmed.ncbi.nlm.nih.gov/15380209

DMWRT4L	DI	DMWRT4L
DMWRT4L	DN	YM-90K
DMWRT4L	MI	TT0MYE2
DMWRT4L	MN	Glutamate receptor ionotropic kainate 1 (GRIK1)
DMWRT4L	MT	DTT
DMWRT4L	MA	Inhibitor
DMWRT4L	RN	4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with... Bioorg Med Chem Lett. 2000 May 15;10(10):1133-7.
DMWRT4L	RU	https://pubmed.ncbi.nlm.nih.gov/10843235

DMWRT4L	DI	DMWRT4L
DMWRT4L	DN	YM-90K
DMWRT4L	MI	TTLD29N
DMWRT4L	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMWRT4L	MT	DTT
DMWRT4L	MA	Inhibitor
DMWRT4L	RN	4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with... Bioorg Med Chem Lett. 2000 May 15;10(10):1133-7.
DMWRT4L	RU	https://pubmed.ncbi.nlm.nih.gov/10843235

DMWRT4L	DI	DMWRT4L
DMWRT4L	DN	YM-90K
DMWRT4L	MI	TTKJEMQ
DMWRT4L	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMWRT4L	MT	DTT
DMWRT4L	MA	Inhibitor
DMWRT4L	RN	4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with... Bioorg Med Chem Lett. 2000 May 15;10(10):1133-7.
DMWRT4L	RU	https://pubmed.ncbi.nlm.nih.gov/10843235

DMWRT4L	DI	DMWRT4L
DMWRT4L	DN	YM-90K
DMWRT4L	MI	TTN9D8E
DMWRT4L	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMWRT4L	MT	DTT
DMWRT4L	MA	Inhibitor
DMWRT4L	RN	4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with... Bioorg Med Chem Lett. 2000 May 15;10(10):1133-7.
DMWRT4L	RU	https://pubmed.ncbi.nlm.nih.gov/10843235

DM845NM	DI	DM845NM
DM845NM	DN	YM-992
DM845NM	MI	TTJQOD7
DM845NM	MN	5-HT 2A receptor (HTR2A)
DM845NM	MT	DTT
DM845NM	MA	Inhibitor
DM845NM	RN	Serotonin reuptake inhibitors: the corner stone in treatment of depression for half a century--a medicinal chemistry survey. Curr Top Med Chem. 2006;6(17):1801-23.
DM845NM	RU	https://pubmed.ncbi.nlm.nih.gov/17017959

DM845NM	DI	DM845NM
DM845NM	DN	YM-992
DM845NM	MI	TT3ROYC
DM845NM	MN	Serotonin transporter (SERT)
DM845NM	MT	DTT
DM845NM	MA	Inhibitor
DM845NM	RN	Serotonin reuptake inhibitors: the corner stone in treatment of depression for half a century--a medicinal chemistry survey. Curr Top Med Chem. 2006;6(17):1801-23.
DM845NM	RU	https://pubmed.ncbi.nlm.nih.gov/17017959

DM2438J	DI	DM2438J
DM2438J	DN	Z-335
DM2438J	MI	TT2O84V
DM2438J	MN	Thromboxane A2 receptor (TBXA2R)
DM2438J	MT	DTT
DM2438J	MA	Antagonist
DM2438J	RN	Pharmacokinetic and pharmacodynamic properties of a new thromboxane receptor antagonist (Z-335) after single and multiple oral administrations to healthy volunteers. J Clin Pharmacol. 2002 Jul;42(7):782-90.
DM2438J	RU	https://pubmed.ncbi.nlm.nih.gov/12092745

DMBSHJ6	DI	DMBSHJ6
DMBSHJ6	DN	Zabiciprilat
DMBSHJ6	MI	TTL69WB
DMBSHJ6	MN	Angiotensin-converting enzyme (ACE)
DMBSHJ6	MT	DTT
DMBSHJ6	MA	Inhibitor
DMBSHJ6	RN	Enzyme immunoassays for a new angiotensin-converting enzyme inhibitor, zabicipril, and its active metabolite in human plasma: application to pharmacokinetic studies. Ther Drug Monit. 1993 Oct;15(5):448-54.
DMBSHJ6	RU	https://pubmed.ncbi.nlm.nih.gov/8249053

DM9F650	DI	DM9F650
DM9F650	DN	ZANKIREN
DM9F650	MI	TTB2MXP
DM9F650	MN	Angiotensinogenase renin (REN)
DM9F650	MT	DTT
DM9F650	MA	Inhibitor
DM9F650	RN	Design and preparation of potent, nonpeptidic, bioavailable renin inhibitors. J Med Chem. 2009 Jun 25;52(12):3689-702.
DM9F650	RU	https://pubmed.ncbi.nlm.nih.gov/19358611

DMS95DX	DI	DMS95DX
DMS95DX	DN	ZD-0947
DMS95DX	MI	TT1VOHK
DMS95DX	MN	Potassium channel unspecific (KC)
DMS95DX	MT	DTT
DMS95DX	MA	Opener
DMS95DX	RN	Effects of ZD6169 and ZD0947, 2 potassium adenosine triphosphate channel openers, on bladder function of spinalized rats. J Urol. 2002 Aug;168(2):837-42.
DMS95DX	RU	https://pubmed.ncbi.nlm.nih.gov/12131377

DMVFCX7	DI	DMVFCX7
DMVFCX7	DN	ZD-2138
DMVFCX7	MI	TTSJ6Q4
DMVFCX7	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DMVFCX7	MT	DTT
DMVFCX7	MA	Inhibitor
DMVFCX7	RN	Synthesis and biological activity of N-aroyl-tetrahydro-gamma-carbolines. Bioorg Med Chem. 2010 Jun 1;18(11):3910-24.
DMVFCX7	RU	https://pubmed.ncbi.nlm.nih.gov/20451397

DMLFNMB	DI	DMLFNMB
DMLFNMB	DN	ZD-2486
DMLFNMB	MI	TT38RM1
DMLFNMB	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DMLFNMB	MT	DTT
DMLFNMB	MA	Modulator
DMLFNMB	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMLFNMB	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM5UCHW	DI	DM5UCHW
DM5UCHW	DN	ZD-4953
DM5UCHW	MI	TT9B4N3
DM5UCHW	MN	Prostaglandin receptor (PTGR)
DM5UCHW	MT	DTT
DM5UCHW	MA	Modulator
DM5UCHW	RN	WO patent application no. 2013,1675,82, Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease.
DM5UCHW	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20131114&CC=WO&NR=2013167582A1&KC=A1

DMVBL25	DI	DMVBL25
DMVBL25	DN	ZD-6169
DMVBL25	MI	TT1VOHK
DMVBL25	MN	Potassium channel unspecific (KC)
DMVBL25	MT	DTT
DMVBL25	MA	Opener
DMVBL25	RN	Effects of ZD6169 and ZD0947, 2 potassium adenosine triphosphate channel openers, on bladder function of spinalized rats. J Urol. 2002 Aug;168(2):837-42.
DMVBL25	RU	https://pubmed.ncbi.nlm.nih.gov/12131377

DM46JIR	DI	DM46JIR
DM46JIR	DN	ZD6416
DM46JIR	MI	TTG1QMU
DM46JIR	MN	Prostaglandin E2 receptor EP1 (PTGER1)
DM46JIR	MT	DTT
DM46JIR	MA	Antagonist
DM46JIR	RN	The prostaglandin E2 receptor-1 (EP-1) mediates acid-induced visceral pain hypersensitivity in humans. Gastroenterology. 2003 Jan;124(1):18-25.
DM46JIR	RU	https://pubmed.ncbi.nlm.nih.gov/12512025

DMBSXPJ	DI	DMBSXPJ
DMBSXPJ	DN	ZD-8321
DMBSXPJ	MI	TTPLTSQ
DMBSXPJ	MN	Neutrophil elastase (NE)
DMBSXPJ	MT	DTT
DMBSXPJ	MA	Inhibitor
DMBSXPJ	RN	Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs. 2002 Jul;11(7):965-80.
DMBSXPJ	RU	https://pubmed.ncbi.nlm.nih.gov/12084007

DM1QXPE	DI	DM1QXPE
DM1QXPE	DN	ZELANDOPAM HYDROCHLORIDE
DM1QXPE	MI	TTZFYLI
DM1QXPE	MN	Dopamine D1 receptor (D1R)
DM1QXPE	MT	DTT
DM1QXPE	MA	Antagonist
DM1QXPE	RN	Effect of zelandopam, a dopamine D1-like receptor agonist, in puromycin aminonucleoside nephrosis rats. Eur J Pharmacol. 2005 Mar 7;510(1-2):121-6.
DM1QXPE	RU	https://pubmed.ncbi.nlm.nih.gov/15740732

DMC6H4Y	DI	DMC6H4Y
DMC6H4Y	DN	ZIFROSILONE
DMC6H4Y	MI	TT1RS9F
DMC6H4Y	MN	Acetylcholinesterase (AChE)
DMC6H4Y	MT	DTT
DMC6H4Y	MA	Inhibitor
DMC6H4Y	RN	Acetylcholinesterase inhibition by zifrosilone: pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 1995 Jul;58(1):54-61.
DMC6H4Y	RU	https://pubmed.ncbi.nlm.nih.gov/7628183

DM3IRES	DI	DM3IRES
DM3IRES	DN	Zilascorb (2H)
DM3IRES	MI	TTLIZBJ
DM3IRES	MN	Protein synthesis (hPRO synth)
DM3IRES	MT	DTT
DM3IRES	MA	Modulator
DM3IRES	RN	Zilascorb(2H), a new reversible protein synthesis inhibitor: clinical study of an oral preparation. Anticancer Drugs. 1997 Mar;8(3):296-303.
DM3IRES	RU	https://pubmed.ncbi.nlm.nih.gov/9095337

DM9FQI0	DI	DM9FQI0
DM9FQI0	DN	Zolasartan
DM9FQI0	MI	TT8DBY3
DM9FQI0	MN	Angiotensin II receptor type-1 (AGTR1)
DM9FQI0	MT	DTT
DM9FQI0	MA	Agonist
DM9FQI0	RN	Azilsartan: a newly approved angiotensin II receptor blocker. Cardiol Rev. 2011 Nov-Dec;19(6):300-4.
DM9FQI0	RU	https://pubmed.ncbi.nlm.nih.gov/21983318

DMWOT92	DI	DMWOT92
DMWOT92	DN	ZOPOLRESTAT
DMWOT92	MI	TTFBNVI
DMWOT92	MN	Aldose reductase (AKR1B1)
DMWOT92	MT	DTT
DMWOT92	MA	Modulator
DMWOT92	RN	Comparison of the effects of Zopolrestat and Sorbinil on lens myo-inositol influx. Pharmacology. 1997 Feb;54(2):76-83.
DMWOT92	RU	https://www.ncbi.nlm.nih.gov/pubmed/9088040

DMB8XJM	DI	DMB8XJM
DMB8XJM	DN	AD-121
DMB8XJM	MI	TTPNQAC
DMB8XJM	MN	Estrogen-related receptor-alpha (ESRRA)
DMB8XJM	MT	DTT
DMB8XJM	MA	Modulator
DMB8XJM	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 622).
DMB8XJM	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=622

DMR8XEN	DI	DMR8XEN
DMR8XEN	DN	AME-527
DMR8XEN	MI	TTF8CQI
DMR8XEN	MN	Tumor necrosis factor (TNF)
DMR8XEN	MT	DTT
DMR8XEN	RN	IND Filed for AME-527, Monoclonal Antibody That Is a Potential Treatment for Rheumatoid Arthritis. P&T Community. 2015.
DMR8XEN	RU	http://ww.ptjournal.com/news/2003-11-26-000000/ind-filed-ame-527-monoclonal-antibody-potential-treatment-rheumatoid

DM3P84V	DI	DM3P84V
DM3P84V	DN	AVE-5883
DM3P84V	MI	TTYO0A3
DM3P84V	MN	Substance-K receptor (TACR2)
DM3P84V	MT	DTT
DM3P84V	MA	Modulator
DM3P84V	RN	Effect of an NK1/NK2 receptor antagonist on airway responses and inflammation to allergen in asthma. Am J Respir Crit Care Med. 2007 Mar 1;175(5):450-7.
DM3P84V	RU	https://pubmed.ncbi.nlm.nih.gov/17170385

DM3P84V	DI	DM3P84V
DM3P84V	DN	AVE-5883
DM3P84V	MI	TTZPO1L
DM3P84V	MN	Substance-P receptor (TACR1)
DM3P84V	MT	DTT
DM3P84V	MA	Modulator
DM3P84V	RN	Effect of an NK1/NK2 receptor antagonist on airway responses and inflammation to allergen in asthma. Am J Respir Crit Care Med. 2007 Mar 1;175(5):450-7.
DM3P84V	RU	https://pubmed.ncbi.nlm.nih.gov/17170385

DMGEDAY	DI	DMGEDAY
DMGEDAY	DN	AVI-4065
DMGEDAY	MI	TT20AHC
DMGEDAY	MN	Hepatitis C virus NS3 helicase messenger RNA (HCV NS3 mRNA)
DMGEDAY	MT	DTT
DMGEDAY	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DMGEDAY	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DM7L8SG	DI	DM7L8SG
DM7L8SG	DN	AZD8055
DM7L8SG	MI	TTCJG29
DM7L8SG	MN	Serine/threonine-protein kinase mTOR (mTOR)
DM7L8SG	MT	DTT
DM7L8SG	MA	Inhibitor
DM7L8SG	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DM7L8SG	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DMJTB4E	DI	DMJTB4E
DMJTB4E	DN	CDP-484
DMJTB4E	MI	TTRYK0X
DMJTB4E	MN	Interleukin-1 beta (IL1B)
DMJTB4E	MT	DTT
DMJTB4E	MA	Inhibitor
DMJTB4E	RN	Biological targets for therapeutic interventions in COPD: clinical potential. Int J Chron Obstruct Pulmon Dis. 2006 September; 1(3): 321-334.
DMJTB4E	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2707155/

DMMZ79C	DI	DMMZ79C
DMMZ79C	DN	CER-227185
DMMZ79C	MI	TT3PTB6
DMMZ79C	MN	Translationally-controlled tumor protein (TPT1)
DMMZ79C	MT	DTT
DMMZ79C	MA	Inhibitor
DMMZ79C	RN	Clinical pipeline report, company report or official report of Cerep.
DMMZ79C	RU	http://www.cerep.fr/Cerep/Users/pages/News/PressReleases/2006/215.pdf

DMH40I3	DI	DMH40I3
DMH40I3	DN	CM-GLP-1
DMH40I3	MI	TTVIMDE
DMH40I3	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMH40I3	MT	DTT
DMH40I3	MA	Modulator
DMH40I3	RN	Reversal of diabetes in rats using GLP-1-expressing adult pancreatic duct-like precursor cells transformed from acinar to ductal cells. Stem Cells Dev. 2009 Sep;18(7):991-1002.
DMH40I3	RU	https://pubmed.ncbi.nlm.nih.gov/19125629

DMKFIBH	DI	DMKFIBH
DMKFIBH	DN	CYT-007-TNFQb
DMKFIBH	MI	TTF8CQI
DMKFIBH	MN	Tumor necrosis factor (TNF)
DMKFIBH	MT	DTT
DMKFIBH	MA	Inhibitor
DMKFIBH	RN	Therapeutic Vaccination with TNF-Kinoid in TNF Antagonist-Resistant Rheumatoid Arthritis: A Phase II Randomized, Controlled Clinical Trial. PLoS One. 2014; 9(12): e113465.
DMKFIBH	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269456/

DMCWRYS	DI	DMCWRYS
DMCWRYS	DN	CYT-009-GhrQb
DMCWRYS	MI	TTWDC17
DMCWRYS	MN	Growth hormone secretagogue receptor 1 (GHSR)
DMCWRYS	MT	DTT
DMCWRYS	MA	Antagonist
DMCWRYS	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DMCWRYS	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DM17GMN	DI	DM17GMN
DM17GMN	DN	EG-011
DM17GMN	MI	TTOM5H4
DM17GMN	MN	Vascular endothelial growth factor D (VEGFD)
DM17GMN	MT	DTT
DM17GMN	MA	Modulator
DM17GMN	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030807)
DM17GMN	RU	http://adisinsight.springer.com/drugs/800030807

DM7JMVR	DI	DM7JMVR
DM7JMVR	DN	EG-016
DM7JMVR	MI	TTOM5H4
DM7JMVR	MN	Vascular endothelial growth factor D (VEGFD)
DM7JMVR	MT	DTT
DM7JMVR	MA	Modulator
DM7JMVR	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030807)
DM7JMVR	RU	http://adisinsight.springer.com/drugs/800030807

DMB35UN	DI	DMB35UN
DMB35UN	DN	FGF-21
DMB35UN	MI	TTQ916P
DMB35UN	MN	Fibroblast growth factor-21 (FGF21)
DMB35UN	MT	DTT
DMB35UN	MA	Agonist
DMB35UN	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028644)
DMB35UN	RU	http://adisinsight.springer.com/drugs/800028644

DMYR7LO	DI	DMYR7LO
DMYR7LO	DN	GPG
DMYR7LO	MI	TTEC2T3
DMYR7LO	MN	Human immunodeficiency virus Envelope glycoprotein gp160 (HIV env)
DMYR7LO	MT	DTT
DMYR7LO	MA	Inhibitor
DMYR7LO	RN	GPG-NH2 acts via the metabolite alphaHGA to target HIV-1 Env to the ER-associated protein degradation pathway. Retrovirology 2010, 7:20.
DMYR7LO	RU	http://www.retrovirology.com/content/7/1/20

DM7R126	DI	DM7R126
DM7R126	DN	GS-9005
DM7R126	MI	TT5FNQT
DM7R126	MN	Human immunodeficiency virus Protease (HIV PR)
DM7R126	MT	DTT
DM7R126	MA	Inhibitor
DM7R126	RN	WO patent application no. 2003,0906,90, Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds and the compounds as such.
DM7R126	RU	http://www.google.com/patents/WO2003090690A2?cl=pt

DMXB4T9	DI	DMXB4T9
DMXB4T9	DN	GS-9132
DMXB4T9	MI	TTRHUKY
DMXB4T9	MN	Hepatitis C virus Serine protease NS4A (HCV NS4A)
DMXB4T9	MT	DTT
DMXB4T9	MA	Modulator
DMXB4T9	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMXB4T9	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM9AOJT	DI	DM9AOJT
DM9AOJT	DN	HuM-195-Bi-213
DM9AOJT	MI	TTJVYO3
DM9AOJT	MN	Myeloid cell surface antigen CD33 (CD33)
DM9AOJT	MT	DTT
DM9AOJT	MA	Inhibitor
DM9AOJT	RN	Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res. 2010 Nov 1;16(21):5303-11.
DM9AOJT	RU	https://pubmed.ncbi.nlm.nih.gov/20858843

DMAYLS3	DI	DMAYLS3
DMAYLS3	DN	IDX-320
DMAYLS3	MI	TTRHUKY
DMAYLS3	MN	Hepatitis C virus Serine protease NS4A (HCV NS4A)
DMAYLS3	MT	DTT
DMAYLS3	MA	Modulator
DMAYLS3	RN	Rapid decline of viral RNA in chronic hepatitis C patients treated once daily with IDX320: a novel macrocyclic HCV protease inhibitor.Antivir Ther.2012;17(4):633-42.
DMAYLS3	RU	https://www.ncbi.nlm.nih.gov/pubmed/22427481

DMEF9JW	DI	DMEF9JW
DMEF9JW	DN	IM0-8400
DMEF9JW	MI	TTRJ1K4
DMEF9JW	MN	Toll-like receptor 7 (TLR7)
DMEF9JW	MT	DTT
DMEF9JW	MA	Antagonist
DMEF9JW	RN	Clinical pipeline report, company report or official report of Idera Pharmaceuticals.
DMEF9JW	RU	http://www.iderapharma.com/pipeline

DMEF9JW	DI	DMEF9JW
DMEF9JW	DN	IM0-8400
DMEF9JW	MI	TT8CWFK
DMEF9JW	MN	Toll-like receptor 8 (TLR8)
DMEF9JW	MT	DTT
DMEF9JW	MA	Antagonist
DMEF9JW	RN	Clinical pipeline report, company report or official report of Idera Pharmaceuticals.
DMEF9JW	RU	http://www.iderapharma.com/pipeline

DMEF9JW	DI	DMEF9JW
DMEF9JW	DN	IM0-8400
DMEF9JW	MI	TTSHG0T
DMEF9JW	MN	Toll-like receptor 9 (TLR9)
DMEF9JW	MT	DTT
DMEF9JW	MA	Antagonist
DMEF9JW	RN	Clinical pipeline report, company report or official report of Idera Pharmaceuticals.
DMEF9JW	RU	http://www.iderapharma.com/pipeline

DMMJC4Q	DI	DMMJC4Q
DMMJC4Q	DN	KSB-303
DMMJC4Q	MI	TTY6DTE
DMMJC4Q	MN	Carcinoembryonic antigen CEA (CD66e)
DMMJC4Q	MT	DTT
DMMJC4Q	RN	Anticancer Antibodies. (2003) American Journal of Clinical Pathology, 119, 472-485.
DMMJC4Q	RU	http://ajcp.ascpjournals.org/content/119/4/472.full.pdf

DM7QGSX	DI	DM7QGSX
DM7QGSX	DN	KW-2450
DM7QGSX	MI	TTCBFJO
DM7QGSX	MN	Insulin receptor (INSR)
DM7QGSX	MT	DTT
DM7QGSX	MA	Modulator
DM7QGSX	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM7QGSX	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM7QGSX	DI	DM7QGSX
DM7QGSX	DN	KW-2450
DM7QGSX	MI	TTHRID2
DM7QGSX	MN	Insulin-like growth factor I receptor (IGF1R)
DM7QGSX	MT	DTT
DM7QGSX	MA	Modulator
DM7QGSX	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM7QGSX	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMXB20Y	DI	DMXB20Y
DMXB20Y	DN	MDX-214
DMXB20Y	MI	TTGUJAO
DMXB20Y	MN	Immunoglobulin alpha Fc receptor (FCAR)
DMXB20Y	MT	DTT
DMXB20Y	RN	A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of MDX-214, a novel immune-mediated mechanism agent targeting the epithelial growth factor receptor (EGFR), in patients with advanced solid tumors. Journal of Clinical Oncology, Vol 24, No 18S (June 20 Supplement), 2006: 2523.
DMXB20Y	RU	http://meeting.ascopubs.org/cgi/content/short/24/18_suppl/2523

DMNXCFZ	DI	DMNXCFZ
DMNXCFZ	DN	NCX 950
DMNXCFZ	MI	TTMXGCW
DMNXCFZ	MN	Adrenergic receptor beta-3 (ADRB3)
DMNXCFZ	MT	DTT
DMNXCFZ	MA	Agonist
DMNXCFZ	RN	A Nitric Oxide-Releasing Salbutamol Elicits Potent Relaxant and Anti-Inflammatory Activities. JPET July 2004 vol. 310 no. 1 367-375.
DMNXCFZ	RU	http://jpet.aspetjournals.org/content/310/1/367.abstract

DMO34NQ	DI	DMO34NQ
DMO34NQ	DN	PD-151832
DMO34NQ	MI	TTZ9SOR
DMO34NQ	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMO34NQ	MT	DTT
DMO34NQ	MA	Agonist
DMO34NQ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMO34NQ	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMRQPOD	DI	DMRQPOD
DMRQPOD	DN	R-803
DMRQPOD	MI	TTMVBWH
DMRQPOD	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMRQPOD	MT	DTT
DMRQPOD	MA	Modulator
DMRQPOD	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMRQPOD	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMIAZJ9	DI	DMIAZJ9
DMIAZJ9	DN	RhApo2L/TRAIL
DMIAZJ9	MI	TT5WLRX
DMIAZJ9	MN	TRAIL receptor 1 (TRAIL-R1)
DMIAZJ9	MT	DTT
DMIAZJ9	MA	Agonist
DMIAZJ9	RN	Clinical pipeline report, company report or official report of Amgen (2009).
DMIAZJ9	RU	http://www.amgen.com/science/pipe.jsp

DMIAZJ9	DI	DMIAZJ9
DMIAZJ9	DN	RhApo2L/TRAIL
DMIAZJ9	MI	TTW20TU
DMIAZJ9	MN	TRAIL receptor 2 (TRAIL-R2)
DMIAZJ9	MT	DTT
DMIAZJ9	MA	Agonist
DMIAZJ9	RN	Clinical pipeline report, company report or official report of Amgen (2009).
DMIAZJ9	RU	http://www.amgen.com/science/pipe.jsp

DMHXRZF	DI	DMHXRZF
DMHXRZF	DN	UK-369003
DMHXRZF	MI	TTJ0IQB
DMHXRZF	MN	Phosphodiesterase 5A (PDE5A)
DMHXRZF	MT	DTT
DMHXRZF	MA	Inhibitor
DMHXRZF	RN	Pfizer. Product Development Pipeline. March 31 2009.
DMHXRZF	RU	http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf

DM8Q2ZR	DI	DM8Q2ZR
DM8Q2ZR	DN	WX-UK1
DM8Q2ZR	MI	TTGY7WI
DM8Q2ZR	MN	Urokinase-type plasminogen activator (PLAU)
DM8Q2ZR	MT	DTT
DM8Q2ZR	MA	Inhibitor
DM8Q2ZR	RN	Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system. Int J Cancer. 2004 Jul 20;110(6):815-24.
DM8Q2ZR	RU	https://pubmed.ncbi.nlm.nih.gov/15170662

DMC7M3K	DI	DMC7M3K
DMC7M3K	DN	447C88
DMC7M3K	MI	TTMF541
DMC7M3K	MN	Liver carboxylesterase (CES1)
DMC7M3K	MT	DTT
DMC7M3K	MA	Modulator
DMC7M3K	RN	The tolerability, pharmacokinetics and lack of effect on plasma cholesterol of 447C88, an AcylCoA: Cholesterol Acyl Transferase (ACAT) inhibitor with low bioavailability, in healthy volunteers. Eur JClin Pharmacol. 1995;49(3):243-9.
DMC7M3K	RU	https://pubmed.ncbi.nlm.nih.gov/8666002

DMHT84I	DI	DMHT84I
DMHT84I	DN	A-216546
DMHT84I	MI	TTKRD0G
DMHT84I	MN	Endothelin A receptor (EDNRA)
DMHT84I	MT	DTT
DMHT84I	MA	Antagonist
DMHT84I	RN	Pharmacology of A-216546: a highly selective antagonist for endothelin ET(A) receptor. Eur J Pharmacol. 1999 Feb 5;366(2-3):189-201.
DMHT84I	RU	https://pubmed.ncbi.nlm.nih.gov/10082200

DM0DLC1	DI	DM0DLC1
DM0DLC1	DN	A-75998
DM0DLC1	MI	TT8R70G
DM0DLC1	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DM0DLC1	MT	DTT
DM0DLC1	MA	Antagonist
DM0DLC1	RN	Physicochemical properties of A-75998, an antagonist of luteinizing hormone releasing hormone. J Pharm Sci. 1995 Aug;84(8):953-8.
DM0DLC1	RU	https://pubmed.ncbi.nlm.nih.gov/7500280

DMGEWQ7	DI	DMGEWQ7
DMGEWQ7	DN	A-80987
DMGEWQ7	MI	TT5FNQT
DMGEWQ7	MN	Human immunodeficiency virus Protease (HIV PR)
DMGEWQ7	MT	DTT
DMGEWQ7	MA	Inhibitor
DMGEWQ7	RN	Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother. 1996 Jun;40(6):1491-7.
DMGEWQ7	RU	https://pubmed.ncbi.nlm.nih.gov/8726025

DMJTIUP	DI	DMJTIUP
DMJTIUP	DN	ABJ-879
DMJTIUP	MI	TTML2WA
DMJTIUP	MN	Tubulin (TUB)
DMJTIUP	MT	DTT
DMJTIUP	MA	Modulator
DMJTIUP	RN	Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol. 2007 Jul;18 Suppl 5:v9-15.
DMJTIUP	RU	https://pubmed.ncbi.nlm.nih.gov/17656562

DMADKHB	DI	DMADKHB
DMADKHB	DN	ABN-912
DMADKHB	MI	TTNAY0P
DMADKHB	MN	Monocyte chemotactic and activating factor (CCL2)
DMADKHB	MT	DTT
DMADKHB	RN	A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum. 2006 Aug;54(8):2387-92.
DMADKHB	RU	https://pubmed.ncbi.nlm.nih.gov/16869001

DMTYWE9	DI	DMTYWE9
DMTYWE9	DN	ABT-080
DMTYWE9	MI	TTTWGIX
DMTYWE9	MN	Leukotriene receptor (LTR)
DMTYWE9	MT	DTT
DMTYWE9	MA	Modulator
DMTYWE9	RN	An update on the role of leukotrienes in asthma. Curr Opin Allergy Clin Immunol. 2010 February; 10(1): 60-66.
DMTYWE9	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2838730/

DMPCYV6	DI	DMPCYV6
DMPCYV6	DN	ABT-107
DMPCYV6	MI	TTLA931
DMPCYV6	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMPCYV6	MT	DTT
DMPCYV6	MA	Modulator
DMPCYV6	RN	In vitro pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107. J Pharmacol Exp Ther. 2010 Sep 1;334(3):863-74.
DMPCYV6	RU	https://pubmed.ncbi.nlm.nih.gov/20504915

DMG9Y80	DI	DMG9Y80
DMG9Y80	DN	ABT-202
DMG9Y80	MI	TTJSZTB
DMG9Y80	MN	Nicotinic acetylcholine receptor (nAChR)
DMG9Y80	MT	DTT
DMG9Y80	MA	Modulator
DMG9Y80	RN	Modulators of nicotinic acetylcholine receptors as analgesics. Curr Opin Investig Drugs. 2004 Jan;5(1):76-81.
DMG9Y80	RU	https://pubmed.ncbi.nlm.nih.gov/14983978

DMWVFDH	DI	DMWVFDH
DMWVFDH	DN	ABT-279
DMWVFDH	MI	TTDIGC1
DMWVFDH	MN	Dipeptidyl peptidase 4 (DPP-4)
DMWVFDH	MT	DTT
DMWVFDH	MA	Inhibitor
DMWVFDH	RN	Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87.
DMWVFDH	RU	https://pubmed.ncbi.nlm.nih.gov/19149538

DM8GZAS	DI	DM8GZAS
DM8GZAS	DN	ABT-299
DM8GZAS	MI	TTQL5VC
DM8GZAS	MN	Platelet-activating factor receptor (PTAFR)
DM8GZAS	MT	DTT
DM8GZAS	MA	Antagonist
DM8GZAS	RN	ABT-299, a novel PAF antagonist, attenuates multiple effects of endotoxemia in conscious rats. Shock. 1996 Aug;6(2):112-7.
DM8GZAS	RU	https://pubmed.ncbi.nlm.nih.gov/8856845

DMA2RM3	DI	DMA2RM3
DMA2RM3	DN	ABT-518
DMA2RM3	MI	TT1GHVO
DMA2RM3	MN	Matrix metalloproteinase (MMP)
DMA2RM3	MT	DTT
DMA2RM3	MA	Inhibitor
DMA2RM3	RN	Quantitative analysis of the novel anticancer drug ABT-518, a matrix metalloproteinase inhibitor, plus the screening of six metabolites in human plasma using high-performance liquid chromatography coupled with electrospray tandem mass spectrometry. J Mass Spectrom. 2004 Mar;39(3):277-88.
DMA2RM3	RU	https://pubmed.ncbi.nlm.nih.gov/15039935

DMZYVPB	DI	DMZYVPB
DMZYVPB	DN	ABX-MA1
DMZYVPB	MI	TTD26RC
DMZYVPB	MN	Cell adhesion molecule (CADM)
DMZYVPB	MT	DTT
DMZYVPB	RN	Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Res. 2002 Sep 1;62(17):5106-14.
DMZYVPB	RU	https://pubmed.ncbi.nlm.nih.gov/12208768

DME98LV	DI	DME98LV
DME98LV	DN	AC-162352
DME98LV	MI	TTJ6WK9
DME98LV	MN	Neuropeptide Y receptor type 2 (NPY2R)
DME98LV	MT	DTT
DME98LV	MA	Agonist
DME98LV	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DME98LV	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DM704HO	DI	DM704HO
DM704HO	DN	AC-253
DM704HO	MI	TTAT87F
DM704HO	MN	Amylin receptor (IAPPR)
DM704HO	MT	DTT
DM704HO	MA	Antagonist
DM704HO	RN	Biotechnology and Its Application in Pharmacy. Kulkarn. 2002. Page157.
DM704HO	RU	https://books.google.com.hk/books?id=cw7bgQnWz9YC&pg=PA157&lpg=PA157&dq=AC-625+++Amylin+receptor&source=bl&ots=sLtM1OBea8&sig=MvdugRHN-VfgpBV2ac2K8BTY7d8&hl=zh-CN&sa=X&ved=0CCQQ6AEwAWoVChMIv7Wi4vS2yAIVDhuOCh3wKgMe#v=onepage&q=AC-625%20%20%20Amylin%20receptor&f=false

DM54W9A	DI	DM54W9A
DM54W9A	DN	AC3056
DM54W9A	MI	TTC0BEN
DM54W9A	MN	Oxidative stress (OS)
DM54W9A	MT	DTT
DM54W9A	MA	Inhibitor
DM54W9A	RN	The novel antioxidant, AC3056 (2,6-di-t-butyl-4-((dimethyl-4-methoxyphenylsilyl)methyloxy)phenol), reverses erectile dysfunction in diabetic rats and improves NO-mediated responses in penile tissue from diabetic men. J Sex Med. 2009 Feb;6(2):373-87.
DM54W9A	RU	https://pubmed.ncbi.nlm.nih.gov/19040617

DMIJB68	DI	DMIJB68
DMIJB68	DN	AC-625
DMIJB68	MI	TTAT87F
DMIJB68	MN	Amylin receptor (IAPPR)
DMIJB68	MT	DTT
DMIJB68	MA	Modulator
DMIJB68	RN	Biotechnology and Its Application in Pharmacy. Kulkarn. 2002. Page157.
DMIJB68	RU	https://books.google.com.hk/books?id=cw7bgQnWz9YC&pg=PA157&lpg=PA157&dq=AC-625+++Amylin+receptor&source=bl&ots=sLtM1OBea8&sig=MvdugRHN-VfgpBV2ac2K8BTY7d8&hl=zh-CN&sa=X&ved=0CCQQ6AEwAWoVChMIv7Wi4vS2yAIVDhuOCh3wKgMe#v=onepage&q=AC-625%20%20%20Amylin%20receptor&f=false

DMSPW3N	DI	DMSPW3N
DMSPW3N	DN	ACH-2928
DMSPW3N	MI	TTCJ2X8
DMSPW3N	MN	Hepatitis C virus Non-structural 5A (HCV NS5A)
DMSPW3N	MT	DTT
DMSPW3N	MA	Modulator
DMSPW3N	RN	Company report (Achillion)
DMSPW3N	RU	http://ir.achillion.com/releasedetail.cfm?releaseid=629849

DML1AUZ	DI	DML1AUZ
DML1AUZ	DN	ADL-7445
DML1AUZ	MI	TTKWM86
DML1AUZ	MN	Opioid receptor mu (MOP)
DML1AUZ	MT	DTT
DML1AUZ	MA	Antagonist
DML1AUZ	RN	Novel opioid antagonists for opioid-induced bowel dysfunction. Expert Opin Investig Drugs. 2011 Aug;20(8):1047-56.
DML1AUZ	RU	https://pubmed.ncbi.nlm.nih.gov/21663526

DMRSEZD	DI	DMRSEZD
DMRSEZD	DN	AE-3763
DMRSEZD	MI	TTPLTSQ
DMRSEZD	MN	Neutrophil elastase (NE)
DMRSEZD	MT	DTT
DMRSEZD	MA	Inhibitor
DMRSEZD	RN	Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs. 2002 Jul;11(7):965-80.
DMRSEZD	RU	https://pubmed.ncbi.nlm.nih.gov/12084007

DM1TYM4	DI	DM1TYM4
DM1TYM4	DN	AG-021541
DM1TYM4	MI	TTMVBWH
DM1TYM4	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DM1TYM4	MT	DTT
DM1TYM4	MA	Inhibitor
DM1TYM4	RN	Emerging drugs for hepatitis C. Expert Opin Emerg Drugs. 2008 Mar;13(1):1-19.
DM1TYM4	RU	https://pubmed.ncbi.nlm.nih.gov/18321145

DMCEM0L	DI	DMCEM0L
DMCEM0L	DN	AG-331
DMCEM0L	MI	TTU6BFZ
DMCEM0L	MN	Candida Thymidylate synthase (Candi TMP1)
DMCEM0L	MT	DTT
DMCEM0L	MA	Inhibitor
DMCEM0L	RN	Phase I trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion. Clin Cancer Res. 1996 Oct;2(10):1685-92.
DMCEM0L	RU	https://pubmed.ncbi.nlm.nih.gov/9816117

DM8XODL	DI	DM8XODL
DM8XODL	DN	AGN-191743
DM8XODL	MI	TTQL5VC
DM8XODL	MN	Platelet-activating factor receptor (PTAFR)
DM8XODL	MT	DTT
DM8XODL	MA	Modulator
DM8XODL	RN	US patent application no. 6,274,627, Conjugates of dithiocarbamate disulfides with pharmacologically active agents and uses therefor.
DM8XODL	RU	http://www.google.com/patents/US6274627

DMGAERX	DI	DMGAERX
DMGAERX	DN	AIR-Epinephrine
DMGAERX	MI	TTVIREA
DMGAERX	MN	Adrenergic receptor (ADR)
DMGAERX	MT	DTT
DMGAERX	MA	Agonist
DMGAERX	RN	Prostaglandin synthesis inhibitors reverse alpha-adrenergic inhibition of acute insulin response to glucose. Am J Physiol. 1980 Dec;239(6):E490-500.
DMGAERX	RU	https://pubmed.ncbi.nlm.nih.gov/6255805

DMVBKLO	DI	DMVBKLO
DMVBKLO	DN	ALBIFYLLINE
DMVBKLO	MI	TTUST1O
DMVBKLO	MN	Phosphodiesterase (PDE)
DMVBKLO	MT	DTT
DMVBKLO	MA	Inhibitor
DMVBKLO	RN	Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids. Eur J Immunol. 1995 Jan;25(1):147-53.
DMVBKLO	RU	https://pubmed.ncbi.nlm.nih.gov/7843225

DM2QMKJ	DI	DM2QMKJ
DM2QMKJ	DN	ALS-00T2-0501
DM2QMKJ	MI	TTF8CQI
DM2QMKJ	MN	Tumor necrosis factor (TNF)
DM2QMKJ	MT	DTT
DM2QMKJ	MA	Modulator
DM2QMKJ	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM2QMKJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMS5C06	DI	DMS5C06
DMS5C06	DN	ALTU-237
DMS5C06	MI	TTMDQIJ
DMS5C06	MN	Oxalate absorption (Oxalate absor)
DMS5C06	MT	DTT
DMS5C06	MA	Modulator
DMS5C06	RN	Hyperoxaluria: a gut-kidney axis. Kidney Int. 2011 Dec;80(11):1146-58.
DMS5C06	RU	https://pubmed.ncbi.nlm.nih.gov/21866092

DMNOZAI	DI	DMNOZAI
DMNOZAI	DN	ALX-0646
DMNOZAI	MI	TT6MSOK
DMNOZAI	MN	5-HT 1D receptor (HTR1D)
DMNOZAI	MT	DTT
DMNOZAI	MA	Agonist
DMNOZAI	RN	Sustained pain relief with dihydroergotamine in migraine is potentially due to persistent binding to 5-HT1B and 5-HT1D receptors. . The Journal of Headache and Pain 201314(Suppl 1):P75.
DMNOZAI	RU	http://www.thejournalofheadacheandpain.com/content/pdf/1129-2377-14-S1-P75.pdf

DMO7920	DI	DMO7920
DMO7920	DN	AM-831
DMO7920	MI	TTJQOD7
DMO7920	MN	5-HT 2A receptor (HTR2A)
DMO7920	MT	DTT
DMO7920	MA	Agonist
DMO7920	RN	Clinical pipeline report, company report or official report of Avarx.
DMO7920	RU	http://www.avarx.com/AvaRx/SubDomains/Company44/Listings/bucket496701808487035926/Public.Listing.display.html

DMO7920	DI	DMO7920
DMO7920	DN	AM-831
DMO7920	MI	TTEX248
DMO7920	MN	Dopamine D2 receptor (D2R)
DMO7920	MT	DTT
DMO7920	MA	Agonist
DMO7920	RN	Clinical pipeline report, company report or official report of Avarx.
DMO7920	RU	http://www.avarx.com/AvaRx/SubDomains/Company44/Listings/bucket496701808487035926/Public.Listing.display.html

DMO7920	DI	DMO7920
DMO7920	DN	AM-831
DMO7920	MI	TTH18TF
DMO7920	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMO7920	MT	DTT
DMO7920	MA	Agonist
DMO7920	RN	Clinical pipeline report, company report or official report of Avarx.
DMO7920	RU	http://www.avarx.com/AvaRx/SubDomains/Company44/Listings/bucket496701808487035926/Public.Listing.display.html

DMALVX2	DI	DMALVX2
DMALVX2	DN	AMELTOLIDE
DMALVX2	MI	TTRK8B9
DMALVX2	MN	Sodium channel unspecific (NaC)
DMALVX2	MT	DTT
DMALVX2	MA	Modulator
DMALVX2	RN	Synthesis and pharmacological evaluation of a major metabolite of ameltolide, a potent anticonvulsant. J Med Chem. 1991 Apr;34(4):1253-7.
DMALVX2	RU	https://pubmed.ncbi.nlm.nih.gov/2016702

DMIKQ40	DI	DMIKQ40
DMIKQ40	DN	AMG 076
DMIKQ40	MI	TTX4RTB
DMIKQ40	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMIKQ40	MT	DTT
DMIKQ40	MA	Antagonist
DMIKQ40	RN	Stereoselective synthesis of a MCHr1 antagonist. J Org Chem. 2007 Dec 7;72(25):9648-55.
DMIKQ40	RU	https://pubmed.ncbi.nlm.nih.gov/17997573

DMUO3T2	DI	DMUO3T2
DMUO3T2	DN	AMG 317
DMUO3T2	MI	TTDWHC3
DMUO3T2	MN	Interleukin 4 receptor alpha (IL4R)
DMUO3T2	MT	DTT
DMUO3T2	MA	Antagonist
DMUO3T2	RN	Clinical pipeline report, company report or official report of Amgen (2009).
DMUO3T2	RU	http://www.amgen.com/science/pipe.jsp

DMFCKJ1	DI	DMFCKJ1
DMFCKJ1	DN	AMG-221
DMFCKJ1	MI	TTN7BL9
DMFCKJ1	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMFCKJ1	MT	DTT
DMFCKJ1	MA	Inhibitor
DMFCKJ1	RN	Discovery of a potent, orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor for clinical study: identification of (S)-2-((1S,2S,4R)-b... J Med Chem. 2010 Jun 10;53(11):4481-7.
DMFCKJ1	RU	https://pubmed.ncbi.nlm.nih.gov/20465278

DM3HB06	DI	DM3HB06
DM3HB06	DN	AMG-517
DM3HB06	MI	TTMI6F5
DM3HB06	MN	Transient receptor potential cation channel V1 (TRPV1)
DM3HB06	MT	DTT
DM3HB06	MA	Blocker
DM3HB06	RN	Analgesic potential of TRPV1 antagonists. Biochem Pharmacol. 2009 Aug 1;78(3):211-6.
DM3HB06	RU	https://pubmed.ncbi.nlm.nih.gov/19481638

DMFR3PD	DI	DMFR3PD
DMFR3PD	DN	ANA-975
DMFR3PD	MI	TTRJ1K4
DMFR3PD	MN	Toll-like receptor 7 (TLR7)
DMFR3PD	MT	DTT
DMFR3PD	MA	Agonist
DMFR3PD	RN	Discovery of ANA975: an oral prodrug of the TLR-7 agonist isatoribine. Nucleosides Nucleotides Nucleic Acids. 2007;26(6-7):635-40.
DMFR3PD	RU	https://pubmed.ncbi.nlm.nih.gov/18066870

DMRQFIE	DI	DMRQFIE
DMRQFIE	DN	ANQ-9040
DMRQFIE	MI	TTJSZTB
DMRQFIE	MN	Nicotinic acetylcholine receptor (nAChR)
DMRQFIE	MT	DTT
DMRQFIE	MA	Modulator
DMRQFIE	RN	Patent US20030087306 A1.
DMRQFIE	RU	http://www.google.com/patents/US20030087306

DM9GSWY	DI	DM9GSWY
DM9GSWY	DN	Anthrax vaccine
DM9GSWY	MI	TT3YGCD
DM9GSWY	MN	Bacterial Protective antigen (Bact pagA)
DM9GSWY	MT	DTT
DM9GSWY	RN	Annual Reports in Medicinal Chemistry. Annette M. Doherty. 2005. Page(214).
DM9GSWY	RU	https://books.google.com.hk/books?id=TRA7aZ90tGsC&pg=PA214&lpg=PA214&dq=anthrax+vaccine,+DynPort/AVANT&source=bl&ots=WIkYd7mdbg&sig=8JNU9x-vtT17RRlxsG9FJ0_QZ2c&hl=zh-CN&sa=X&ved=0CBoQ6AEwAGoVChMI2b_539DEyAIVSBiOCh1eBAQb#v=onepage&q=anthrax%20vaccine%2C%20DynPort%2FAVANT&f=false

DMN8R2U	DI	DMN8R2U
DMN8R2U	DN	APD668
DMN8R2U	MI	TT7QNVC
DMN8R2U	MN	Glucose-dependent insulinotropic receptor (GPR119)
DMN8R2U	MT	DTT
DMN8R2U	MA	Agonist
DMN8R2U	RN	Announces Initiation of Phase 1 Clinical Trial of Arena Type 2 Diabetes Drug Candidate in Collaboration With Ortho-McNeil. Arena Pharmaceuticals, Inc. FEBRUARY 07, 2006.
DMN8R2U	RU	http://www.prnewswire.com/news-releases/arena-pharmaceuticals-inc-announces-initiation-of-phase-1-clinical-trial-of-arena-type-2-diabetes-drug-candidate-in-collaboration-with-ortho-mcneil-55232422.html

DM71C6D	DI	DM71C6D
DM71C6D	DN	Aphidicolin
DM71C6D	MI	TTIU7X1
DM71C6D	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DM71C6D	MT	DTT
DM71C6D	MA	Inhibitor
DM71C6D	RN	Proteasome regulation of ULBP1 transcription. J Immunol. 2009 May 15;182(10):6600-9.
DM71C6D	RU	https://pubmed.ncbi.nlm.nih.gov/19414815

DM5L9I2	DI	DM5L9I2
DM5L9I2	DN	APP-018
DM5L9I2	MI	TT7GN3U
DM5L9I2	MN	Apolipoprotein A-I (APOA1)
DM5L9I2	MT	DTT
DM5L9I2	MA	Modulator
DM5L9I2	RN	Apolipoprotein A-I and its mimetics for the treatment of atherosclerosis. Curr Opin Investig Drugs. 2010 September; 11(9): 989-996.
DM5L9I2	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3074469/

DMRLHNW	DI	DMRLHNW
DMRLHNW	DN	Aprosulate sodium
DMRLHNW	MI	TTZBFA0
DMRLHNW	MN	Protease unspecific (PRO)
DMRLHNW	MT	DTT
DMRLHNW	MA	Modulator
DMRLHNW	RN	Interaction between the sulfated lactobionic acid (LW 10082) and other antithrombotic agents in animal thrombosis model. Pol J Pharmacol. 1996 May-Jun;48(3):317-22.
DMRLHNW	RU	https://pubmed.ncbi.nlm.nih.gov/9112669

DMKLCRI	DI	DMKLCRI
DMKLCRI	DN	ARC-183
DMKLCRI	MI	TT6L509
DMKLCRI	MN	Coagulation factor IIa (F2)
DMKLCRI	MT	DTT
DMKLCRI	RN	A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity. J Thromb Haemost. 2012 May;10(5):870-80.
DMKLCRI	RU	https://pubmed.ncbi.nlm.nih.gov/22385910

DMHZN42	DI	DMHZN42
DMHZN42	DN	AR-H049020
DMHZN42	MI	TTJ584C
DMHZN42	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMHZN42	MT	DTT
DMHZN42	MA	Agonist
DMHZN42	RN	CN patent application no. 100577175, Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators.
DMHZN42	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20050119&CC=CN&NR=1568190A&KC=A

DMXD93K	DI	DMXD93K
DMXD93K	DN	ARRY-614
DMXD93K	MI	TT9VGXW
DMXD93K	MN	Angiopoietin 1 receptor (TEK)
DMXD93K	MT	DTT
DMXD93K	MA	Modulator
DMXD93K	RN	Cmpany report (Arraybiopharma)
DMXD93K	RU	http://www.arraybiopharma.com/product-pipeline/other-compounds/arry-614/

DMXD93K	DI	DMXD93K
DMXD93K	DN	ARRY-614
DMXD93K	MI	TTWELHI
DMXD93K	MN	Stress-activated protein kinase (p38)
DMXD93K	MT	DTT
DMXD93K	MA	Modulator
DMXD93K	RN	Cmpany report (Arraybiopharma)
DMXD93K	RU	http://www.arraybiopharma.com/product-pipeline/other-compounds/arry-614/

DMJDYBX	DI	DMJDYBX
DMJDYBX	DN	Artilide
DMJDYBX	MI	TTRK8B9
DMJDYBX	MN	Sodium channel unspecific (NaC)
DMJDYBX	MT	DTT
DMJDYBX	MA	Modulator
DMJDYBX	RN	Potassium channel blockers as antiarrhythmic drugs. Drug Development Research Volume 33, Issue 3, pages 235-249, November 1994.
DMJDYBX	RU	http://onlinelibrary.wiley.com/doi/10.1002/ddr.430330307/abstract

DMINF80	DI	DMINF80
DMINF80	DN	AS-601811
DMINF80	MI	TTTU72V
DMINF80	MN	Steroid 5-alpha-reductase 1 (SRD5A1)
DMINF80	MT	DTT
DMINF80	MA	Inhibitor
DMINF80	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013228)
DMINF80	RU	http://adisinsight.springer.com/drugs/800013228

DMKXDOI	DI	DMKXDOI
DMKXDOI	DN	AS602868
DMKXDOI	MI	TT3WG5C
DMKXDOI	MN	Monoamine oxidase type A (MAO-A)
DMKXDOI	MT	DTT
DMKXDOI	MA	Inhibitor
DMKXDOI	RN	Inhibition of rat brain monoamine oxidase activities by psoralen and isopsoralen: implications for the treatment of affective disorders. Pharmacol Toxicol. 2001 Feb;88(2):75-80.
DMKXDOI	RU	https://pubmed.ncbi.nlm.nih.gov/11169165

DMKXDOI	DI	DMKXDOI
DMKXDOI	DN	AS602868
DMKXDOI	MI	TTGP7BY
DMKXDOI	MN	Monoamine oxidase type B (MAO-B)
DMKXDOI	MT	DTT
DMKXDOI	MA	Inhibitor
DMKXDOI	RN	Inhibition of rat brain monoamine oxidase activities by psoralen and isopsoralen: implications for the treatment of affective disorders. Pharmacol Toxicol. 2001 Feb;88(2):75-80.
DMKXDOI	RU	https://pubmed.ncbi.nlm.nih.gov/11169165

DMKXDOI	DI	DMKXDOI
DMKXDOI	DN	AS602868
DMKXDOI	MI	TTSXVID
DMKXDOI	MN	Nuclear factor NF-kappa-B (NFKB)
DMKXDOI	MT	DTT
DMKXDOI	MA	Inhibitor
DMKXDOI	RN	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
DMKXDOI	RU	https://pubmed.ncbi.nlm.nih.gov/19249983

DMMPBZF	DI	DMMPBZF
DMMPBZF	DN	AVE-3247
DMMPBZF	MI	TTCIHJA
DMMPBZF	MN	Coagulation factor Xa (F10)
DMMPBZF	MT	DTT
DMMPBZF	MA	Inhibitor
DMMPBZF	RN	Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7.
DMMPBZF	RU	https://pubmed.ncbi.nlm.nih.gov/22844656

DM5FDX2	DI	DM5FDX2
DM5FDX2	DN	AVE-5997EF
DM5FDX2	MI	TT4C8EA
DM5FDX2	MN	Dopamine D3 receptor (D3R)
DM5FDX2	MT	DTT
DM5FDX2	MA	Antagonist
DM5FDX2	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DM5FDX2	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMIB3AT	DI	DMIB3AT
DMIB3AT	DN	AVE-9940
DMIB3AT	MI	TTWELHI
DMIB3AT	MN	Stress-activated protein kinase (p38)
DMIB3AT	MT	DTT
DMIB3AT	MA	Inhibitor
DMIB3AT	RN	US patent application no. 2008,0119,498, Therapeutic agent for pruritus comprising p38 map kinase inhibitor as the active ingredient.
DMIB3AT	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=1&ND=3&adjacent=true&locale=en_EP&FT=D&date=20080522&CC=US&NR=2008119498A1&KC=A1

DMTG9EZ	DI	DMTG9EZ
DMTG9EZ	DN	AWD-140-190
DMTG9EZ	MI	TTRK8B9
DMTG9EZ	MN	Sodium channel unspecific (NaC)
DMTG9EZ	MT	DTT
DMTG9EZ	MA	Modulator
DMTG9EZ	RN	Effects of AWD 140-190 on stimulus-induced field potentials and on different patterns of epileptiform activity induced by low calcium or low magnesium in rat entorhinal cortex hippocampal slices. Epilepsy Res. 1997 Dec;29(1):59-69.
DMTG9EZ	RU	https://pubmed.ncbi.nlm.nih.gov/9416460

DM1JN6A	DI	DM1JN6A
DM1JN6A	DN	Axovan-3
DM1JN6A	MI	TTY6EWA
DM1JN6A	MN	Neuropeptide Y receptor type 5 (NPY5R)
DM1JN6A	MT	DTT
DM1JN6A	MA	Antagonist
DM1JN6A	RN	Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36.
DM1JN6A	RU	https://pubmed.ncbi.nlm.nih.gov/16634704

DMIM9N1	DI	DMIM9N1
DMIM9N1	DN	AZD-1080
DMIM9N1	MI	TTRSMW9
DMIM9N1	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMIM9N1	MT	DTT
DMIM9N1	MA	Modulator
DMIM9N1	RN	AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans.J Neurochem.2013 May;125(3):446-56.
DMIM9N1	RU	https://www.ncbi.nlm.nih.gov/pubmed/23410232

DM65MUI	DI	DM65MUI
DM65MUI	DN	AZD1175
DM65MUI	MI	TT6OEDT
DM65MUI	MN	Cannabinoid receptor 1 (CB1)
DM65MUI	MT	DTT
DM65MUI	MA	Antagonist
DM65MUI	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DM65MUI	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DMVE4P3	DI	DMVE4P3
DMVE4P3	DN	AZD1704
DMVE4P3	MI	TT6OEDT
DMVE4P3	MN	Cannabinoid receptor 1 (CB1)
DMVE4P3	MT	DTT
DMVE4P3	MA	Antagonist
DMVE4P3	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DMVE4P3	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DMCOMG5	DI	DMCOMG5
DMCOMG5	DN	AZD-1744
DMCOMG5	MI	TTD3XFU
DMCOMG5	MN	C-C chemokine receptor type 3 (CCR3)
DMCOMG5	MT	DTT
DMCOMG5	MA	Modulator
DMCOMG5	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMCOMG5	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMCOMG5	DI	DMCOMG5
DMCOMG5	DN	AZD-1744
DMCOMG5	MI	TTTIBOJ
DMCOMG5	MN	Histamine H1 receptor (H1R)
DMCOMG5	MT	DTT
DMCOMG5	MA	Modulator
DMCOMG5	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMCOMG5	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMUCQPB	DI	DMUCQPB
DMUCQPB	DN	AZD-3342
DMUCQPB	MI	TTZBFA0
DMUCQPB	MN	Protease unspecific (PRO)
DMUCQPB	MT	DTT
DMUCQPB	MA	Modulator
DMUCQPB	RN	New Drugs and Targets for Asthma and COPD. Trevor T. Hansel, Peter J. Barnes. 2010. Page(227).
DMUCQPB	RU	https://books.google.com.hk/books?id=aHipG471tVgC&pg=PT241&lpg=PT241&dq=%22AZD-3342%22++Protease&source=bl&ots=y_RqGK1AQK&sig=_sZUylCbhLctfTNcybYmrZ3Mbvo&hl=zh-CN&sa=X&ved=0CBoQ6AEwAGoVChMIuJj-gOPAyAIVChmOCh0K3Amt#v=onepage&q=%22AZD-3342%22%20%20Protease&f=false

DM7XQTM	DI	DM7XQTM
DM7XQTM	DN	AZD-4407
DM7XQTM	MI	TT2J34L
DM7XQTM	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM7XQTM	MT	DTT
DM7XQTM	MA	Inhibitor
DM7XQTM	RN	Palladium catalyzed aryl(alkyl)thiolation of unactivated arenes. Org Lett. 2014 Feb 7;16(3):848-51.
DM7XQTM	RU	https://pubmed.ncbi.nlm.nih.gov/24437617

DMQ2VYT	DI	DMQ2VYT
DMQ2VYT	DN	AZD-4750
DMQ2VYT	MI	TTQR8Z6
DMQ2VYT	MN	Chemokine receptor (CHR)
DMQ2VYT	MT	DTT
DMQ2VYT	MA	Modulator
DMQ2VYT	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018778)
DMQ2VYT	RU	http://adisinsight.springer.com/drugs/800018778

DMA3OWI	DI	DMA3OWI
DMA3OWI	DN	AZD4769
DMA3OWI	MI	TTDMBF5
DMA3OWI	MN	Arachidonate 5-lipoxygenase activating protein (FLAP)
DMA3OWI	MT	DTT
DMA3OWI	MA	Inhibitor
DMA3OWI	RN	5-Lipoxygenase-activating protein is the target of a novel hybrid of two classes of leukotriene biosynthesis inhibitors. Mol Pharmacol. 1992 Feb;41(2):267-72.
DMA3OWI	RU	https://pubmed.ncbi.nlm.nih.gov/1538707

DMA3OWI	DI	DMA3OWI
DMA3OWI	DN	AZD4769
DMA3OWI	MI	TTGKNB4
DMA3OWI	MN	Epidermal growth factor receptor (EGFR)
DMA3OWI	MT	DTT
DMA3OWI	MA	Inhibitor
DMA3OWI	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DMA3OWI	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DMWKYV7	DI	DMWKYV7
DMWKYV7	DN	AZD-5099
DMWKYV7	MI	TTN6J5F
DMWKYV7	MN	Bacterial DNA gyrase (Bact gyrase)
DMWKYV7	MT	DTT
DMWKYV7	MA	Modulator
DMWKYV7	RN	Optimization of pyrrolamide topoisomerase II inhibitors toward identification of an antibacterial clinical candidate (AZD5099). J Med Chem. 2014 Jul 24;57(14):6060-82.
DMWKYV7	RU	https://pubmed.ncbi.nlm.nih.gov/24959892

DM8SCON	DI	DM8SCON
DM8SCON	DN	AZD5904
DM8SCON	MI	TTVCZPI
DM8SCON	MN	Myeloperoxidase (MPO)
DM8SCON	MT	DTT
DM8SCON	MA	Inhibitor
DM8SCON	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DM8SCON	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DMCAKMV	DI	DMCAKMV
DMCAKMV	DN	AZD5985
DMCAKMV	MI	TTQDMX5
DMCAKMV	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMCAKMV	MT	DTT
DMCAKMV	MA	Antagonist
DMCAKMV	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DMCAKMV	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DMFAZLU	DI	DMFAZLU
DMFAZLU	DN	AZD6280
DMFAZLU	MI	TT37EDJ
DMFAZLU	MN	GABA(A) receptor alpha-3 (GABRA3)
DMFAZLU	MT	DTT
DMFAZLU	MA	Modulator
DMFAZLU	RN	AZD6280, a novel partial -aminobutyric acid A receptor modulator, demonstrates a pharmacodynamically selective effect profile in healthy male volunteers.J Clin Psychopharmacol.2015 Feb;35(1):22-33.
DMFAZLU	RU	https://www.ncbi.nlm.nih.gov/pubmed/25493397

DMQZCET	DI	DMQZCET
DMQZCET	DN	AZD-6553
DMQZCET	MI	TTPLTSQ
DMQZCET	MN	Neutrophil elastase (NE)
DMQZCET	MT	DTT
DMQZCET	MA	Inhibitor
DMQZCET	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032703)
DMQZCET	RU	http://adisinsight.springer.com/drugs/800032703

DM9KLD3	DI	DM9KLD3
DM9KLD3	DN	AZD-6703
DM9KLD3	MI	TTWELHI
DM9KLD3	MN	Stress-activated protein kinase (p38)
DM9KLD3	MT	DTT
DM9KLD3	MA	Inhibitor
DM9KLD3	RN	The discovery of N-cyclopropyl-4-methyl-3-[6-(4-methylpiperazin-1-yl)-4-oxoquinazolin-3(4H)-yl]benzamide (AZD6703), a clinical p38alpha MAP kinase inhibitor for the treatment of inflammatory diseases. Bioorg Med Chem Lett. 2012 Jun 15;22(12):3879-83.
DM9KLD3	RU	https://pubmed.ncbi.nlm.nih.gov/22608965

DMHV3IW	DI	DMHV3IW
DMHV3IW	DN	AZD-6714
DMHV3IW	MI	TTDLNGZ
DMHV3IW	MN	Glucokinase (GCK)
DMHV3IW	MT	DTT
DMHV3IW	MA	Stimulator
DMHV3IW	RN	Glucokinase (GCK). SciBX 2(37); doi:10.1038/scibx.2009.1408. Sep. 24 2009
DMHV3IW	RU	http://www.nature.com/scibx/journal/v2/n37/full/scibx.2009.1408.html

DM2QHVW	DI	DM2QHVW
DM2QHVW	DN	AZD6918
DM2QHVW	MI	TTTDVOJ
DM2QHVW	MN	Tropomyosin-related kinase A (TrkA)
DM2QHVW	MT	DTT
DM2QHVW	MA	Inhibitor
DM2QHVW	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DM2QHVW	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DMX63W1	DI	DMX63W1
DMX63W1	DN	AZD-7140
DMX63W1	MI	TTQR8Z6
DMX63W1	MN	Chemokine receptor (CHR)
DMX63W1	MT	DTT
DMX63W1	MA	Antagonist
DMX63W1	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017126)
DMX63W1	RU	http://adisinsight.springer.com/drugs/800017126

DMKF9U3	DI	DMKF9U3
DMKF9U3	DN	AZD8075
DMKF9U3	MI	TTQDMX5
DMKF9U3	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMKF9U3	MT	DTT
DMKF9U3	MA	Antagonist
DMKF9U3	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DMKF9U3	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DMW6IUB	DI	DMW6IUB
DMW6IUB	DN	AZD-8309
DMW6IUB	MI	TTQR8Z6
DMW6IUB	MN	Chemokine receptor (CHR)
DMW6IUB	MT	DTT
DMW6IUB	MA	Modulator
DMW6IUB	RN	CXCR2: From Bench to Bedside. Front Immunol. 2012; 3: 263.
DMW6IUB	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3426767/

DMUKNQ5	DI	DMUKNQ5
DMUKNQ5	DN	AZD8330
DMUKNQ5	MI	TTROQ37
DMUKNQ5	MN	MAPK/ERK kinase kinase (MAP3K)
DMUKNQ5	MT	DTT
DMUKNQ5	MA	Modulator
DMUKNQ5	RN	MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013; 6: 27.
DMUKNQ5	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626705/

DMIYEZG	DI	DMIYEZG
DMIYEZG	DN	AZD8566
DMIYEZG	MI	TT2CEJG
DMIYEZG	MN	C-C chemokine receptor type 5 (CCR5)
DMIYEZG	MT	DTT
DMIYEZG	MA	Antagonist
DMIYEZG	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DMIYEZG	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DMYSBN3	DI	DMYSBN3
DMYSBN3	DN	AZD-9272
DMYSBN3	MI	TTVBPDM
DMYSBN3	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMYSBN3	MT	DTT
DMYSBN3	MA	Modulator
DMYSBN3	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DMYSBN3	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DM1ZVO3	DI	DM1ZVO3
DM1ZVO3	DN	AZD-9343
DM1ZVO3	MI	TTDCVZW
DM1ZVO3	MN	Gamma-aminobutyric acid B receptor (GABBR)
DM1ZVO3	MT	DTT
DM1ZVO3	MA	Modulator
DM1ZVO3	RN	The GABA(B) receptor agonist AZD9343 inhibits transient lower oesophageal sphincter relaxations and acid reflux in healthy volunteers: a phase I study. Aliment Pharmacol Ther. 2009 Nov 1;30(9):937-46.
DM1ZVO3	RU	https://pubmed.ncbi.nlm.nih.gov/19650825

DMK5I07	DI	DMK5I07
DMK5I07	DN	Banoxantrone
DMK5I07	MI	DEPKLMQ
DMK5I07	MN	Cytochrome P450 2B6 (CYP2B6)
DMK5I07	MT	DME
DMK5I07	MA	Metabolism
DMK5I07	RN	Tumor-selective drug activation: a GDEPT approach utilizing cytochrome P450 1A1 and AQ4N. Cancer Gene Ther. 2006 Jun;13(6):598-605.
DMK5I07	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16410820

DMK5I07	DI	DMK5I07
DMK5I07	DN	Banoxantrone
DMK5I07	MI	DE4LYSA
DMK5I07	MN	Cytochrome P450 3A4 (CYP3A4)
DMK5I07	MT	DME
DMK5I07	MA	Metabolism
DMK5I07	RN	Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N. Cancer Gene Ther. 2003 Jan;10(1):40-8.
DMK5I07	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12489027

DMK5I07	DI	DMK5I07
DMK5I07	DN	Banoxantrone
DMK5I07	MI	TT0IHXV
DMK5I07	MN	DNA topoisomerase II (TOP2)
DMK5I07	MT	DTT
DMK5I07	MA	Modulator
DMK5I07	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMK5I07	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMGDSCK	DI	DMGDSCK
DMGDSCK	DN	BAY-27-9955
DMGDSCK	MI	TT9O6WS
DMGDSCK	MN	Glucagon receptor (GCGR)
DMGDSCK	MT	DTT
DMGDSCK	MA	Antagonist
DMGDSCK	RN	Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia. 2001 Nov;44(11):2018-24.
DMGDSCK	RU	https://pubmed.ncbi.nlm.nih.gov/11719833

DMKJ3IA	DI	DMKJ3IA
DMKJ3IA	DN	BAY-73-7977
DMKJ3IA	MI	TT9O6WS
DMKJ3IA	MN	Glucagon receptor (GCGR)
DMKJ3IA	MT	DTT
DMKJ3IA	MA	Antagonist
DMKJ3IA	RN	WO patent application no. 2012,0351,39, Prodrugs comprising an exendin linker conjugate.
DMKJ3IA	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20120322&CC=WO&NR=2012035139A1&KC=A1

DM0UEKF	DI	DM0UEKF
DM0UEKF	DN	BAY-Y-1015
DM0UEKF	MI	TTTWGIX
DM0UEKF	MN	Leukotriene receptor (LTR)
DM0UEKF	MT	DTT
DM0UEKF	MA	Modulator
DM0UEKF	RN	The effect of leukotriene synthesis inhibitors in models of acute and chronic inflammation. Arthritis Rheum. 1996 Mar;39(3):515-21.
DM0UEKF	RU	https://pubmed.ncbi.nlm.nih.gov/8607901

DMYK8OG	DI	DMYK8OG
DMYK8OG	DN	BB-2983
DMYK8OG	MI	TT1GHVO
DMYK8OG	MN	Matrix metalloproteinase (MMP)
DMYK8OG	MT	DTT
DMYK8OG	MA	Modulator
DMYK8OG	RN	Matrix metalloproteinase inhibition reduces intimal hyperplasia in a porcine arteriovenous-graft model. J Vasc Surg. 2004 Feb;39(2):432-9.
DMYK8OG	RU	https://pubmed.ncbi.nlm.nih.gov/14743149

DMN2XR7	DI	DMN2XR7
DMN2XR7	DN	BCX-1470
DMN2XR7	MI	TT6L509
DMN2XR7	MN	Coagulation factor IIa (F2)
DMN2XR7	MT	DTT
DMN2XR7	MA	Inhibitor
DMN2XR7	RN	Recent Developments in Low Molecular Weight Complement Inhibitors. Mol Immunol. 2009 December; 47(2-3): 185-195.
DMN2XR7	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2788007/

DMCOKFY	DI	DMCOKFY
DMCOKFY	DN	Beloxepin
DMCOKFY	MI	TTYSN63
DMCOKFY	MN	5-HT 2 receptor (5HT2R)
DMCOKFY	MT	DTT
DMCOKFY	MA	Modulator
DMCOKFY	RN	WO patent application no. 2009,1055,07, Beloxepin, its enantiomers, and analogs thereof for the treatment of pain.
DMCOKFY	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20090827&CC=WO&NR=2009105507A2&KC=A2

DMQI2F4	DI	DMQI2F4
DMQI2F4	DN	BEPH
DMQI2F4	MI	TT0DBAO
DMQI2F4	MN	Polyamine unspecific (PLA)
DMQI2F4	MT	DTT
DMQI2F4	MA	Modulator
DMQI2F4	RN	Antitumor activity of a novel synthetic polyamine analogue, N,N'-bis-[3-(ethylamino)-propyl]-1-7-heptane diamine: potentiation by polyamine oxidase inhibitors. Anticancer Res. 1990 Sep-Oct;10(5A):1281-7.
DMQI2F4	RU	https://pubmed.ncbi.nlm.nih.gov/2241104

DMU1YON	DI	DMU1YON
DMU1YON	DN	Berupipam
DMU1YON	MI	TTZFYLI
DMU1YON	MN	Dopamine D1 receptor (D1R)
DMU1YON	MT	DTT
DMU1YON	MA	Antagonist
DMU1YON	RN	Characterization of benzazepine UDP-glucuronosyl-transferases in laboratory animals and man. Xenobiotica. 1995 Jun;25(6):611-22.
DMU1YON	RU	https://pubmed.ncbi.nlm.nih.gov/7483661

DMMAFQP	DI	DMMAFQP
DMMAFQP	DN	Besonprodil
DMMAFQP	MI	TTN9D8E
DMMAFQP	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMMAFQP	MT	DTT
DMMAFQP	MA	Antagonist
DMMAFQP	RN	Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
DMMAFQP	RU	https://pubmed.ncbi.nlm.nih.gov/16377242

DM9F4LP	DI	DM9F4LP
DM9F4LP	DN	BIM-26226
DM9F4LP	MI	TTC1MVT
DM9F4LP	MN	Gastrin-releasing peptide receptor (GRPR)
DM9F4LP	MT	DTT
DM9F4LP	MA	Modulator
DM9F4LP	RN	Effect of the gastrin-releasing peptide antagonist BIM 26226 and lanreotide on an acinar pancreatic carcinoma. Eur J Pharmacol. 1998 Apr 17;347(1):77-86.
DM9F4LP	RU	https://pubmed.ncbi.nlm.nih.gov/9650851

DM3HRQI	DI	DM3HRQI
DM3HRQI	DN	BINOSPIRONE MESYLATE
DM3HRQI	MI	TTSQIFT
DM3HRQI	MN	5-HT 1A receptor (HTR1A)
DM3HRQI	MT	DTT
DM3HRQI	MA	Antagonist
DM3HRQI	RN	Quantifying the 5-HT1A agonist action of buspirone in man. Psychopharmacology (Berl). 2001 Nov;158(3):224-9.
DM3HRQI	RU	https://pubmed.ncbi.nlm.nih.gov/11713611

DMJWLBU	DI	DMJWLBU
DMJWLBU	DN	BL-1827
DMJWLBU	MI	TTN4QDT
DMJWLBU	MN	Opioid receptor (OPR)
DMJWLBU	MT	DTT
DMJWLBU	MA	Agonist
DMJWLBU	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013581)
DMJWLBU	RU	http://adisinsight.springer.com/drugs/800013581

DMR7WYX	DI	DMR7WYX
DMR7WYX	DN	BLX-883
DMR7WYX	MI	TTSYFMA
DMR7WYX	MN	Interferon alpha/beta receptor 1 (IFNAR1)
DMR7WYX	MT	DTT
DMR7WYX	MA	Modulator
DMR7WYX	RN	Patent CN103536906 A.
DMR7WYX	RU	http://www.google.com/patents/CN103536906A?cl=en

DMKFXTD	DI	DMKFXTD
DMKFXTD	DN	BMS-191095
DMKFXTD	MI	TTEF5MJ
DMKFXTD	MN	ATP-binding cassette transporter C9 (ABCC9)
DMKFXTD	MT	DTT
DMKFXTD	MA	Modulator
DMKFXTD	RN	The mitochondrial K(ATP) channel opener BMS-191095 reduces neuronal damage after transient focal cerebral ischemia in rats.J Cereb Blood Flow Metab.2007 Feb;27(2):348-55.
DMKFXTD	RU	https://www.ncbi.nlm.nih.gov/pubmed/16736040

DMIX9O0	DI	DMIX9O0
DMIX9O0	DN	BRL-44154
DMIX9O0	MI	TTJP4SM
DMIX9O0	MN	Bacterial Penicillin binding protein (Bact PBP)
DMIX9O0	MT	DTT
DMIX9O0	MA	Modulator
DMIX9O0	RN	Can beta-lactams be re-engineered to beat MRSA . Clinical Microbiology and Infection Volume 12, Issue Supplement s2, pages 11-16, April 2006.
DMIX9O0	RU	http://onlinelibrary.wiley.com/doi/10.1111/j.1469-0691.2006.01403.x/full

DMGVEJ6	DI	DMGVEJ6
DMGVEJ6	DN	BTS-73947
DMGVEJ6	MI	TTZFYLI
DMGVEJ6	MN	Dopamine D1 receptor (D1R)
DMGVEJ6	MT	DTT
DMGVEJ6	MA	Antagonist
DMGVEJ6	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008043)
DMGVEJ6	RU	http://adisinsight.springer.com/drugs/800008043

DM296HE	DI	DM296HE
DM296HE	DN	BW-1370U87
DM296HE	MI	TT3WG5C
DM296HE	MN	Monoamine oxidase type A (MAO-A)
DM296HE	MT	DTT
DM296HE	MA	Inhibitor
DM296HE	RN	Preclinical and early clinical studies with BW 1370U87, a reversible competitive monoamine oxidase-A inhibitor. Clin Neuropharmacol. 1993;16 Suppl 2:S25-33.
DM296HE	RU	https://pubmed.ncbi.nlm.nih.gov/8313394

DMUD6IK	DI	DMUD6IK
DMUD6IK	DN	BXL-746
DMUD6IK	MI	TTK59TV
DMUD6IK	MN	Vitamin D3 receptor (VDR)
DMUD6IK	MT	DTT
DMUD6IK	MA	Stimulator
DMUD6IK	RN	Inter-species differences in sensitivity to the calcemic activity of the novel 1,25-dihydroxyvitamin D3 analog BXL746. Regul Toxicol Pharmacol. 2008 Dec;52(3):332-41.
DMUD6IK	RU	https://pubmed.ncbi.nlm.nih.gov/18854204

DMSTN6W	DI	DMSTN6W
DMSTN6W	DN	CA9-ADC
DMSTN6W	MI	TT2LVK8
DMSTN6W	MN	Carbonic anhydrase IX (CA-IX)
DMSTN6W	MT	DTT
DMSTN6W	RN	Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9. Mol Cancer Ther. 2012 Feb;11(2):340-9.
DMSTN6W	RU	https://pubmed.ncbi.nlm.nih.gov/22147747

DMQ4HUA	DI	DMQ4HUA
DMQ4HUA	DN	CAB-2
DMQ4HUA	MI	TTA0P7K
DMQ4HUA	MN	Complement factor B (CFB)
DMQ4HUA	MT	DTT
DMQ4HUA	MA	Inhibitor
DMQ4HUA	RN	A soluble chimeric inhibitor of C3 and C5 convertases, complement activation blocker-2, prolongs graft survival in pig-to-rhesus monkey heart transplantation. Xenotransplantation. 2002 Mar;9(2):125-34.
DMQ4HUA	RU	https://pubmed.ncbi.nlm.nih.gov/11897005

DMQIWZL	DI	DMQIWZL
DMQIWZL	DN	Candoxatrilat
DMQIWZL	MI	TT5TKPM
DMQIWZL	MN	Neutral endopeptidase (MME)
DMQIWZL	MT	DTT
DMQIWZL	MA	Inhibitor
DMQIWZL	RN	Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension. J Hypertens. 1992 Mar;10(3):271-7.
DMQIWZL	RU	https://pubmed.ncbi.nlm.nih.gov/1315825

DMYCPF9	DI	DMYCPF9
DMYCPF9	DN	CB-182804
DMYCPF9	MI	TTXT4D5
DMYCPF9	MN	Bacterial Cell membrane (Bact CM)
DMYCPF9	MT	DTT
DMYCPF9	MA	Inhibitor
DMYCPF9	RN	Activity of polymyxin B and the novel polymyxin analogue CB-182,804 against contemporary Gram-negative pathogens in New York City. Microb Drug Resist. 2012 Apr;18(2):132-6.
DMYCPF9	RU	https://pubmed.ncbi.nlm.nih.gov/22196342

DM3G4JD	DI	DM3G4JD
DM3G4JD	DN	CBD cannabis derivative
DM3G4JD	MI	TT6OEDT
DM3G4JD	MN	Cannabinoid receptor 1 (CB1)
DM3G4JD	MT	DTT
DM3G4JD	MA	Antagonist
DM3G4JD	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DM3G4JD	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMMEC1W	DI	DMMEC1W
DMMEC1W	DN	CCD-3693
DMMEC1W	MI	TTEX6LM
DMMEC1W	MN	GABA(A) receptor gamma-3 (GABRG3)
DMMEC1W	MT	DTT
DMMEC1W	MA	Modulator
DMMEC1W	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMMEC1W	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMD8QHV	DI	DMD8QHV
DMD8QHV	DN	CCX-832
DMD8QHV	MI	TTE836A
DMD8QHV	MN	C-C chemokine receptor type 8 (CCR8)
DMD8QHV	MT	DTT
DMD8QHV	MA	Antagonist
DMD8QHV	RN	Increased Expression of Chemerin in Squamous Esophageal Cancer Myofibroblasts and Role in Recruitment of Mesenchymal Stromal Cells. PLoS One. 2014; 9(8): e104877.
DMD8QHV	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134237/

DMHMST3	DI	DMHMST3
DMHMST3	DN	CCX915
DMHMST3	MI	TTEF5MJ
DMHMST3	MN	ATP-binding cassette transporter C9 (ABCC9)
DMHMST3	MT	DTT
DMHMST3	MA	Blocker
DMHMST3	RN	Analysis of the differential modulation of sulphonylurea block of beta-cell and cardiac ATP-sensitive K+ (K(ATP)) channels by Mg-nucleotides. J Physiol. 2003 Feb 15;547(Pt 1):159-68.
DMHMST3	RU	https://pubmed.ncbi.nlm.nih.gov/12562963

DMHMST3	DI	DMHMST3
DMHMST3	DN	CCX915
DMHMST3	MI	TTFZYTO
DMHMST3	MN	C-C chemokine receptor type 2 (CCR2)
DMHMST3	MT	DTT
DMHMST3	MA	Antagonist
DMHMST3	RN	Marketed and experimental medicines for the treatment of multiple sclerosis. The Association of the British Pharmaceutical Industry. 2009.
DMHMST3	RU	http://www.abpi.org.uk/publications/publication_details/targetMS/table.asp

DMOCBQW	DI	DMOCBQW
DMOCBQW	DN	CD-581
DMOCBQW	MI	TT2J34L
DMOCBQW	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMOCBQW	MT	DTT
DMOCBQW	MA	Inhibitor
DMOCBQW	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMOCBQW	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM5BG4P	DI	DM5BG4P
DM5BG4P	DN	CDP-1050
DM5BG4P	MI	TTU5CIX
DM5BG4P	MN	Ryanodine receptor 1 (RYR1)
DM5BG4P	MT	DTT
DM5BG4P	MA	Modulator
DM5BG4P	RN	The Ryanodine Receptor Stabilizer S44121 / Arm036 Improves Peripheral and Respiratory Muscle Function in a Mouse Model of Heart Failure. Circulation. 2014; 130: A13726.
DM5BG4P	RU	http://circ.ahajournals.org/content/130/Suppl_2/A13726.abstract

DMJVZ9O	DI	DMJVZ9O
DMJVZ9O	DN	Cefdaloxime pentexil tosilate
DMJVZ9O	MI	TTJP4SM
DMJVZ9O	MN	Bacterial Penicillin binding protein (Bact PBP)
DMJVZ9O	MT	DTT
DMJVZ9O	MA	Modulator
DMJVZ9O	RN	Activity of cefpodoxime and other oral beta-lactams against Haemophilus influenzae and Streptococcus pneumoniae with different susceptibilities to penicillin. Rev Esp Quimioter. 2006 Mar;19(1):39-44.
DMJVZ9O	RU	https://pubmed.ncbi.nlm.nih.gov/16688290

DMO075K	DI	DMO075K
DMO075K	DN	CEFTRAZONAL BOPENTIL
DMO075K	MI	TTJP4SM
DMO075K	MN	Bacterial Penicillin binding protein (Bact PBP)
DMO075K	MT	DTT
DMO075K	MA	Inhibitor
DMO075K	RN	Comparative in vitro activity of Ro 40-6890, Ro 41-3399, and other antimicrobial agents against anaerobic bacteria. Eur J Clin Microbiol Infect Dis. 1992 Oct;11(10):946-9.
DMO075K	RU	https://pubmed.ncbi.nlm.nih.gov/1486894

DMH1PQ0	DI	DMH1PQ0
DMH1PQ0	DN	CEP-2563
DMH1PQ0	MI	TTXABCW
DMH1PQ0	MN	NT-3 growth factor receptor (TrkC)
DMH1PQ0	MT	DTT
DMH1PQ0	MA	Modulator
DMH1PQ0	RN	Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors. Invest New Drugs. 2004 Nov;22(4):449-58.
DMH1PQ0	RU	https://pubmed.ncbi.nlm.nih.gov/15292715

DMH1PQ0	DI	DMH1PQ0
DMH1PQ0	DN	CEP-2563
DMH1PQ0	MI	TT8FYO9
DMH1PQ0	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMH1PQ0	MT	DTT
DMH1PQ0	MA	Inhibitor
DMH1PQ0	RN	Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors. Invest New Drugs. 2004 Nov;22(4):449-58.
DMH1PQ0	RU	https://pubmed.ncbi.nlm.nih.gov/15292715

DMH1PQ0	DI	DMH1PQ0
DMH1PQ0	DN	CEP-2563
DMH1PQ0	MI	TTI7421
DMH1PQ0	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMH1PQ0	MT	DTT
DMH1PQ0	MA	Inhibitor
DMH1PQ0	RN	Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36.
DMH1PQ0	RU	https://pubmed.ncbi.nlm.nih.gov/21948793

DMK93VQ	DI	DMK93VQ
DMK93VQ	DN	CEREBROCRAST
DMK93VQ	MI	TT5HONZ
DMK93VQ	MN	Calcium channel unspecific (CaC)
DMK93VQ	MT	DTT
DMK93VQ	MA	Inhibitor
DMK93VQ	RN	The dihydropyridine analogue cerebrocrast blocks both T-type and L-type calcium currents. Can J Physiol Pharmacol. 2009 Nov;87(11):923-32.
DMK93VQ	RU	https://pubmed.ncbi.nlm.nih.gov/19935900

DMQKRWO	DI	DMQKRWO
DMQKRWO	DN	CERM-11956
DMQKRWO	MI	TT5HONZ
DMQKRWO	MN	Calcium channel unspecific (CaC)
DMQKRWO	MT	DTT
DMQKRWO	MA	Antagonist
DMQKRWO	RN	The anti-ischaemic activity of the novel compound, CERM 11956, compared with that of bepridil and nifedipine in isolated guinea-pig hearts. Eur J Pharmacol. 1988 May 10;149(3):195-203.
DMQKRWO	RU	https://pubmed.ncbi.nlm.nih.gov/3261692

DM85SYL	DI	DM85SYL
DM85SYL	DN	Cetefloxacin
DM85SYL	MI	TTN6J5F
DM85SYL	MN	Bacterial DNA gyrase (Bact gyrase)
DM85SYL	MT	DTT
DM85SYL	MA	Modulator
DM85SYL	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM85SYL	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMOULQ4	DI	DMOULQ4
DMOULQ4	DN	CGP-37849
DMOULQ4	MI	TT9IK2Z
DMOULQ4	MN	N-methyl-D-aspartate receptor (NMDAR)
DMOULQ4	MT	DTT
DMOULQ4	MA	Modulator
DMOULQ4	RN	The competitive NMDA receptor antagonists CGP 37849 and CGP 39551 are potent, orally-active anticonvulsants in rodents. Naunyn Schmiedebergs Arch Pharmacol. 1990 Jul;342(1):61-6.
DMOULQ4	RU	https://pubmed.ncbi.nlm.nih.gov/1976233

DMY8KO4	DI	DMY8KO4
DMY8KO4	DN	CGP-48369
DMY8KO4	MI	TTGN1ZA
DMY8KO4	MN	Angiotensin II receptor (AGTR)
DMY8KO4	MT	DTT
DMY8KO4	MA	Modulator
DMY8KO4	RN	Antihypertensive therapy augments endothelium-dependent relaxations in coronary arteries of spontaneously hypertensive rats. Circulation. 1994 May;89(5):2212-8.
DMY8KO4	RU	https://pubmed.ncbi.nlm.nih.gov/8181147

DMF0O2H	DI	DMF0O2H
DMF0O2H	DN	CGP-53437
DMF0O2H	MI	TT5FNQT
DMF0O2H	MN	Human immunodeficiency virus Protease (HIV PR)
DMF0O2H	MT	DTT
DMF0O2H	MA	Inhibitor
DMF0O2H	RN	CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity. Antimicrob Agents Chemother. 1993 Oct;37(10):2087-92.
DMF0O2H	RU	https://pubmed.ncbi.nlm.nih.gov/8257128

DMF05DL	DI	DMF05DL
DMF05DL	DN	CGS-22652
DMF05DL	MI	TT2O84V
DMF05DL	MN	Thromboxane A2 receptor (TBXA2R)
DMF05DL	MT	DTT
DMF05DL	MA	Modulator
DMF05DL	RN	Blood pressure effects of thromboxane A2 blockade in spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 1993 Nov;20(11):679-87.
DMF05DL	RU	https://www.ncbi.nlm.nih.gov/pubmed/8306513

DM0JUAL	DI	DM0JUAL
DM0JUAL	DN	ChelASE
DM0JUAL	MI	TTLG1PD
DM0JUAL	MN	Proliferating cell nuclear antigen (PCNA)
DM0JUAL	MT	DTT
DM0JUAL	MA	Inhibitor
DM0JUAL	RN	Safety and efficacy assessment of chimeric ribozyme to proliferating cell nuclear antigen to prevent recurrence of proliferative vitreoretinopathy. Arch Ophthalmol. 2007 Sep;125(9):1161-7.
DM0JUAL	RU	https://pubmed.ncbi.nlm.nih.gov/17846353

DMJ5UYL	DI	DMJ5UYL
DMJ5UYL	DN	Chpmpc
DMJ5UYL	MI	TTIU7X1
DMJ5UYL	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMJ5UYL	MT	DTT
DMJ5UYL	MA	Modulator
DMJ5UYL	RN	Conversion of 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine to cidofovir by an intracellular cyclic CMP phosphodiesterase.. Antimicrob Agents Chemother. 1997 March; 41(3): 641-646.
DMJ5UYL	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC163765/

DM9ZBO0	DI	DM9ZBO0
DM9ZBO0	DN	CI-972
DM9ZBO0	MI	TTMCF1Y
DM9ZBO0	MN	Purine nucleoside phosphorylase (PNP)
DM9ZBO0	MT	DTT
DM9ZBO0	MA	Inhibitor
DM9ZBO0	RN	Inhibitors of human purine nucleoside phosphorylase. Synthesis of pyrrolo[3,2-d]pyrimidines, a new class of purine nucleoside phosphorylase inhibitors as potentially T-cell selective immunosuppressive agents. Description of 2,6-diamino-3,5-dihydro-7-(3-thienylmethyl)-4H-pyrrolo[3,2-d] pyrimidin-4-one. J Med Chem. 1992 May 1;35(9):1605-9.
DM9ZBO0	RU	https://pubmed.ncbi.nlm.nih.gov/1578487

DM3Q8UW	DI	DM3Q8UW
DM3Q8UW	DN	CJC-1004
DM3Q8UW	MI	TT6L509
DM3Q8UW	MN	Coagulation factor IIa (F2)
DM3Q8UW	MT	DTT
DM3Q8UW	MA	Inhibitor
DM3Q8UW	RN	Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Jun;25(5):387-408.
DM3Q8UW	RU	https://pubmed.ncbi.nlm.nih.gov/12851663

DMSB7WV	DI	DMSB7WV
DMSB7WV	DN	CL-277082
DMSB7WV	MI	TTMF541
DMSB7WV	MN	Liver carboxylesterase (CES1)
DMSB7WV	MT	DTT
DMSB7WV	MA	Modulator
DMSB7WV	RN	CL 277,082: a novel inhibitor of ACAT-catalyzed cholesterol esterification and cholesterol absorption. J Lipid Res. 1989 May;30(5):681-90.
DMSB7WV	RU	https://pubmed.ncbi.nlm.nih.gov/2760542

DMYPFLR	DI	DMYPFLR
DMYPFLR	DN	Clomet
DMYPFLR	MI	TTUTN1I
DMYPFLR	MN	Human Deoxyribonucleic acid (hDNA)
DMYPFLR	MT	DTT
DMYPFLR	MA	Inhibitor
DMYPFLR	RN	The comet assay: a sensitive genotoxicity test for the detection of DNA damage and repair. Methods Mol Biol. 2006;314:275-86.
DMYPFLR	RU	https://pubmed.ncbi.nlm.nih.gov/16673888

DM1C4IN	DI	DM1C4IN
DM1C4IN	DN	CP-105696
DM1C4IN	MI	TTN53ZF
DM1C4IN	MN	Leukotriene B4 receptor 1 (LTB4R)
DM1C4IN	MT	DTT
DM1C4IN	MA	Inhibitor
DM1C4IN	RN	3-Substituted-4-hydroxy-7-chromanylacetic acid derivatives as antagonists of the leukotriene B4 (LTB4) receptor, Bioorg. Med. Chem. Lett. 7(17):2307-2312 (1997).
DM1C4IN	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97004149

DM1C4IN	DI	DM1C4IN
DM1C4IN	DN	CP-105696
DM1C4IN	MI	TTVJX54
DM1C4IN	MN	Leukotriene B4 receptor 2 (LTB4R2)
DM1C4IN	MT	DTT
DM1C4IN	MA	Inhibitor
DM1C4IN	RN	3-Substituted-4-hydroxy-7-chromanylacetic acid derivatives as antagonists of the leukotriene B4 (LTB4) receptor, Bioorg. Med. Chem. Lett. 7(17):2307-2312 (1997).
DM1C4IN	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97004149

DMTM0UI	DI	DMTM0UI
DMTM0UI	DN	CP-66948
DMTM0UI	MI	TTQHJ1K
DMTM0UI	MN	Histamine H2 receptor (H2R)
DMTM0UI	MT	DTT
DMTM0UI	MA	Antagonist
DMTM0UI	RN	CP-66,948: an antisecretory histamine H2-receptor antagonist with mucosal protective properties. Dig Dis Sci. 1991 Dec;36(12):1721-8.
DMTM0UI	RU	https://pubmed.ncbi.nlm.nih.gov/1748041

DMZ0YU7	DI	DMZ0YU7
DMZ0YU7	DN	CP-800569
DMZ0YU7	MI	TTFQAYR
DMZ0YU7	MN	Cholesteryl ester transfer protein (CETP)
DMZ0YU7	MT	DTT
DMZ0YU7	MA	Inhibitor
DMZ0YU7	RN	Pfizer. Product Development Pipeline. March 31 2009.
DMZ0YU7	RU	http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf

DMWVBGD	DI	DMWVBGD
DMWVBGD	DN	CR-2093
DMWVBGD	MI	TTVFO0U
DMWVBGD	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMWVBGD	MT	DTT
DMWVBGD	MA	Modulator
DMWVBGD	RN	Inhibitory effects of the gastrin receptor antagonist CR2093 on basal, gastrin-stimulated and growth factor-stimulated growth of the rat pancreatic cell line AR42J. Anticancer Drugs. 1994 Oct;5(5):591-7.
DMWVBGD	RU	https://pubmed.ncbi.nlm.nih.gov/7858292

DMVDLT4	DI	DMVDLT4
DMVDLT4	DN	CS-4771
DMVDLT4	MI	TTISGCA
DMVDLT4	MN	Toll-like receptor 4 (TLR4)
DMVDLT4	MT	DTT
DMVDLT4	MA	Modulator
DMVDLT4	RN	Eritoran insight for influenza treatment. SciBX 6(19); doi:10.1038/scibx.2013.453. May 16 2013
DMVDLT4	RU	http://www.nature.com/scibx/journal/v6/n19/full/scibx.2013.453.html

DMXKB8V	DI	DMXKB8V
DMXKB8V	DN	CS-526
DMXKB8V	MI	TTLOKXP
DMXKB8V	MN	Gastric H(+)/K(+) ATPase (Proton pump)
DMXKB8V	MT	DTT
DMXKB8V	MA	Modulator
DMXKB8V	RN	Pharmacological profile of novel acid pump antagonist 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methyl cyclopropyl]methyl}-1H-pyrrolo[2,3-d]... J Pharmacol Exp Ther. 2007 Oct;323(1):308-17.
DMXKB8V	RU	https://pubmed.ncbi.nlm.nih.gov/17630360

DMXY43L	DI	DMXY43L
DMXY43L	DN	CTP-354
DMXY43L	MI	TTEX6LM
DMXY43L	MN	GABA(A) receptor gamma-3 (GABRG3)
DMXY43L	MT	DTT
DMXY43L	MA	Modulator
DMXY43L	RN	Clinical pipeline report, company report or official report of Concert Pharmaceuticals.
DMXY43L	RU	http://www.concertpharma.com/news/documents/CTP-354_ACNP_Liu_final.pdf

DMDRFZV	DI	DMDRFZV
DMDRFZV	DN	CVS-1123
DMDRFZV	MI	TT6L509
DMDRFZV	MN	Coagulation factor IIa (F2)
DMDRFZV	MT	DTT
DMDRFZV	MA	Inhibitor
DMDRFZV	RN	CVS-1123, a direct thrombin inhibitor, prevents occlusive arterial and venous thrombosis in a canine model of vascular injury. J Cardiovasc Pharmacol. 1997 Feb;29(2):240-9.
DMDRFZV	RU	https://pubmed.ncbi.nlm.nih.gov/9057074

DMWY2NT	DI	DMWY2NT
DMWY2NT	DN	CY-1787
DMWY2NT	MI	TTE5VG0
DMWY2NT	MN	P-selectin (SELP)
DMWY2NT	MT	DTT
DMWY2NT	MA	Modulator
DMWY2NT	RN	Administration of an antibody to E-selectin in patients with septic shock. Crit Care Med. 1996 Feb;24(2):229-33.
DMWY2NT	RU	https://pubmed.ncbi.nlm.nih.gov/8605793

DM1I7UO	DI	DM1I7UO
DM1I7UO	DN	Cyclocreatine
DM1I7UO	MI	TTU8W4S
DM1I7UO	MN	Protein kinase (PK)
DM1I7UO	MT	DTT
DM1I7UO	MA	Inhibitor
DM1I7UO	RN	Direct determination of creatine kinase equilibrium constants with creatine or cyclocreatine substrate. Biochim Biophys Acta. 1989 Oct 19;998(3):317-20.
DM1I7UO	RU	https://pubmed.ncbi.nlm.nih.gov/2804134

DMB24V7	DI	DMB24V7
DMB24V7	DN	D-1367
DMB24V7	MI	TTK0943
DMB24V7	MN	Prostaglandin G/H synthase (COX)
DMB24V7	MT	DTT
DMB24V7	MA	Modulator
DMB24V7	RN	US patent application no. 2007,0072,861, Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders.
DMB24V7	RU	http://www.google.com.ar/patents/US20070072861

DM5D8JW	DI	DM5D8JW
DM5D8JW	DN	D-1927
DM5D8JW	MI	TT1GHVO
DM5D8JW	MN	Matrix metalloproteinase (MMP)
DM5D8JW	MT	DTT
DM5D8JW	MA	Modulator
DM5D8JW	RN	Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor. Cancer Res. 1999 Mar15;59(6):1231-5.
DM5D8JW	RU	https://pubmed.ncbi.nlm.nih.gov/10096553

DMUPEJK	DI	DMUPEJK
DMUPEJK	DN	D-4418
DMUPEJK	MI	TTZ97H5
DMUPEJK	MN	Phosphodiesterase 4A (PDE4A)
DMUPEJK	MT	DTT
DMUPEJK	MA	Inhibitor
DMUPEJK	RN	Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking. Br J Pharmacol. 2008 Oct;155(3):288-90.
DMUPEJK	RU	https://pubmed.ncbi.nlm.nih.gov/18660832

DMUPEJK	DI	DMUPEJK
DMUPEJK	DN	D-4418
DMUPEJK	MI	TTVIAT9
DMUPEJK	MN	Phosphodiesterase 4B (PDE4B)
DMUPEJK	MT	DTT
DMUPEJK	MA	Inhibitor
DMUPEJK	RN	Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking. Br J Pharmacol. 2008 Oct;155(3):288-90.
DMUPEJK	RU	https://pubmed.ncbi.nlm.nih.gov/18660832

DMUPEJK	DI	DMUPEJK
DMUPEJK	DN	D-4418
DMUPEJK	MI	TTSKMI8
DMUPEJK	MN	Phosphodiesterase 4D (PDE4D)
DMUPEJK	MT	DTT
DMUPEJK	MA	Inhibitor
DMUPEJK	RN	Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking. Br J Pharmacol. 2008 Oct;155(3):288-90.
DMUPEJK	RU	https://pubmed.ncbi.nlm.nih.gov/18660832

DMDUZ5W	DI	DMDUZ5W
DMDUZ5W	DN	DACOPAFANT
DMDUZ5W	MI	TTQL5VC
DMDUZ5W	MN	Platelet-activating factor receptor (PTAFR)
DMDUZ5W	MT	DTT
DMDUZ5W	MA	Antagonist
DMDUZ5W	RN	RP 55778, a PAF receptor antagonist, prevents and reverses LPS-induced hemoconcentration and TNF release. J Lipid Mediat. 1989 Nov-Dec;1(6):349-60.
DMDUZ5W	RU	https://pubmed.ncbi.nlm.nih.gov/2519903

DMAOZH3	DI	DMAOZH3
DMAOZH3	DN	DE-310
DMAOZH3	MI	TTGTQHC
DMAOZH3	MN	DNA topoisomerase I (TOP1)
DMAOZH3	MT	DTT
DMAOZH3	MA	Inhibitor
DMAOZH3	RN	DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors. Invest New Drugs. 2005 Aug;23(4):339-47.
DMAOZH3	RU	https://pubmed.ncbi.nlm.nih.gov/16012793

DMFUCZQ	DI	DMFUCZQ
DMFUCZQ	DN	Delucemine
DMFUCZQ	MI	TT9IK2Z
DMFUCZQ	MN	N-methyl-D-aspartate receptor (NMDAR)
DMFUCZQ	MT	DTT
DMFUCZQ	MA	Modulator
DMFUCZQ	RN	NPS 1506, a novel NMDA receptor antagonist and neuroprotectant. Review of preclinical and clinical studies. Ann N Y Acad Sci. 1999;890:450-7.
DMFUCZQ	RU	https://pubmed.ncbi.nlm.nih.gov/10668449

DM5G43H	DI	DM5G43H
DM5G43H	DN	Denibulin
DM5G43H	MI	TTYFKSZ
DM5G43H	MN	Tubulin beta (TUBB)
DM5G43H	MT	DTT
DM5G43H	MA	Inhibitor
DM5G43H	RN	An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site. Pharm Res. 2012 November; 29(11): 2943-2971.
DM5G43H	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667160/

DMZYVFH	DI	DMZYVFH
DMZYVFH	DN	DF-1111301
DMZYVFH	MI	TTQL5VC
DMZYVFH	MN	Platelet-activating factor receptor (PTAFR)
DMZYVFH	MT	DTT
DMZYVFH	MA	Antagonist
DMZYVFH	RN	US patent application no. 2007,0196,421, Soft tissue implants and drug combination compositions, and use thereof.
DMZYVFH	RU	http://www.google.is/patents/US20070196421

DMAR068	DI	DMAR068
DMAR068	DN	Discodermolide
DMAR068	MI	TTML2WA
DMAR068	MN	Tubulin (TUB)
DMAR068	MT	DTT
DMAR068	MA	Modulator
DMAR068	RN	The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, andinhibits the growth of paclitaxel-resistant cells. Mol Pharmacol. 1997 Oct;52(4):613-22.
DMAR068	RU	https://pubmed.ncbi.nlm.nih.gov/9380024

DME5PXL	DI	DME5PXL
DME5PXL	DN	DK-507k
DME5PXL	MI	TTIXTO3
DME5PXL	MN	Staphylococcus Topoisomerase IV (Stap-coc parC)
DME5PXL	MT	DTT
DME5PXL	MA	Modulator
DME5PXL	RN	In Vitro and In Vivo Antibacterial Activities of DK-507k, a Novel Fluoroquinolone
DME5PXL	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC296186

DMCK7LM	DI	DMCK7LM
DMCK7LM	DN	DMP-728
DMCK7LM	MI	TT38RM1
DMCK7LM	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DMCK7LM	MT	DTT
DMCK7LM	MA	Modulator
DMCK7LM	RN	Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist. Circulation. 1994 Jan;89(1):3-12.
DMCK7LM	RU	https://www.ncbi.nlm.nih.gov/pubmed/8281661

DMDK6HP	DI	DMDK6HP
DMDK6HP	DN	DMP-802
DMDK6HP	MI	TTJA1ZO
DMDK6HP	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMDK6HP	MT	DTT
DMDK6HP	MA	Inhibitor
DMDK6HP	RN	Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J Med Chem. 2000 Sep 21;43(19):3453-73.
DMDK6HP	RU	https://pubmed.ncbi.nlm.nih.gov/10999999

DM412S9	DI	DM412S9
DM412S9	DN	DMP-851
DM412S9	MI	TT5FNQT
DM412S9	MN	Human immunodeficiency virus Protease (HIV PR)
DM412S9	MT	DTT
DM412S9	MA	Inhibitor
DM412S9	RN	Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors. Chem Biol. 1998 Oct;5(10):597-608.
DM412S9	RU	https://pubmed.ncbi.nlm.nih.gov/9818151

DMR6INY	DI	DMR6INY
DMR6INY	DN	DPC 423
DMR6INY	MI	TTCIHJA
DMR6INY	MN	Coagulation factor Xa (F10)
DMR6INY	MT	DTT
DMR6INY	MA	Inhibitor
DMR6INY	RN	The design and synthesis of noncovalent factor Xa inhibitors. Curr Top Med Chem. 2001 Jun;1(2):137-49.
DMR6INY	RU	https://pubmed.ncbi.nlm.nih.gov/11899249

DMSOHR6	DI	DMSOHR6
DMSOHR6	DN	DPC-082
DMSOHR6	MI	TT84ETX
DMSOHR6	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMSOHR6	MT	DTT
DMSOHR6	MA	Inhibitor
DMSOHR6	RN	Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1999 Dec;43(12):2893-7.
DMSOHR6	RU	https://pubmed.ncbi.nlm.nih.gov/10582878

DMA7DH0	DI	DMA7DH0
DMA7DH0	DN	DPC-168
DMA7DH0	MI	TTD3XFU
DMA7DH0	MN	C-C chemokine receptor type 3 (CCR3)
DMA7DH0	MT	DTT
DMA7DH0	MA	Antagonist
DMA7DH0	RN	CC chemokine receptor-3 (CCR3) antagonists: improving the selectivity of DPC168 by reducing central ring lipophilicity. Bioorg Med Chem Lett. 2007 Jun 1;17(11):2992-7.
DMA7DH0	RU	https://pubmed.ncbi.nlm.nih.gov/17418570

DM5HAG0	DI	DM5HAG0
DM5HAG0	DN	DPC-681
DM5HAG0	MI	TT5FNQT
DM5HAG0	MN	Human immunodeficiency virus Protease (HIV PR)
DM5HAG0	MT	DTT
DM5HAG0	MA	Inhibitor
DM5HAG0	RN	DPC 681 and DPC 684: potent, selective inhibitors of human immunodeficiency virus protease active against clinically relevant mutant variants. Antimicrob Agents Chemother. 2001 Nov;45(11):3021-8.
DM5HAG0	RU	https://pubmed.ncbi.nlm.nih.gov/11600351

DMS19VG	DI	DMS19VG
DMS19VG	DN	DPC-684
DMS19VG	MI	TT5FNQT
DMS19VG	MN	Human immunodeficiency virus Protease (HIV PR)
DMS19VG	MT	DTT
DMS19VG	MA	Inhibitor
DMS19VG	RN	DPC 681 and DPC 684: potent, selective inhibitors of human immunodeficiency virus protease active against clinically relevant mutant variants. Antimicrob Agents Chemother. 2001 Nov;45(11):3021-8.
DMS19VG	RU	https://pubmed.ncbi.nlm.nih.gov/11600351

DMOPM7L	DI	DMOPM7L
DMOPM7L	DN	DRF 10945
DMOPM7L	MI	TTJ584C
DMOPM7L	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMOPM7L	MT	DTT
DMOPM7L	MA	Agonist
DMOPM7L	RN	Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease. Future Cardiol. 2010 September; 6(5): 657-691.
DMOPM7L	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3246744/

DMS4IBW	DI	DMS4IBW
DMS4IBW	DN	DS-1442
DMS4IBW	MI	TTFQAYR
DMS4IBW	MN	Cholesteryl ester transfer protein (CETP)
DMS4IBW	MT	DTT
DMS4IBW	MA	Modulator
DMS4IBW	RN	Ds-1442b is a Novel, Potent Cetp Inhibitor That Reduces Atherosclerosis by Hdl Elevation and Non-hdl Reduction. Circulation. 2012; 126: A11806.
DMS4IBW	RU	http://circ.ahajournals.org/cgi/content/meeting_abstract/126/21_MeetingAbstracts/A11806

DMDAO8E	DI	DMDAO8E
DMDAO8E	DN	DS-6930
DMDAO8E	MI	TTZMAO3
DMDAO8E	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMDAO8E	MT	DTT
DMDAO8E	MA	Modulator
DMDAO8E	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036558)
DMDAO8E	RU	http://adisinsight.springer.com/drugs/800036558

DMQK53O	DI	DMQK53O
DMQK53O	DN	DS-7250
DMQK53O	MI	TTF8P9I
DMQK53O	MN	Diacylglycerol acyltransferase 1 (DGAT1)
DMQK53O	MT	DTT
DMQK53O	MA	Modulator
DMQK53O	RN	Clinical pipeline report, company report or official report of Daiichi Sankyo.
DMQK53O	RU	http://www.daiichisankyo.com/rd/pipeline/pdf/20130513_Pipeline_EN1.pdf

DMN9KXU	DI	DMN9KXU
DMN9KXU	DN	DU-29894
DMN9KXU	MI	TTSQIFT
DMN9KXU	MN	5-HT 1A receptor (HTR1A)
DMN9KXU	MT	DTT
DMN9KXU	MA	Modulator
DMN9KXU	RN	A comparison of the neuro-endocrinological and temperature effects of DU 29894, flesinoxan, sulpiride and haloperidol in normal volunteers. Br J Clin Pharmacol. 1995 Jan;39(1):7-14.
DMN9KXU	RU	https://pubmed.ncbi.nlm.nih.gov/7756102

DMN9KXU	DI	DMN9KXU
DMN9KXU	DN	DU-29894
DMN9KXU	MI	TTEX248
DMN9KXU	MN	Dopamine D2 receptor (D2R)
DMN9KXU	MT	DTT
DMN9KXU	MA	Modulator
DMN9KXU	RN	A comparison of the neuro-endocrinological and temperature effects of DU 29894, flesinoxan, sulpiride and haloperidol in normal volunteers. Br J Clin Pharmacol. 1995 Jan;39(1):7-14.
DMN9KXU	RU	https://pubmed.ncbi.nlm.nih.gov/7756102

DM9S51Q	DI	DM9S51Q
DM9S51Q	DN	DU-6681
DM9S51Q	MI	TTJP4SM
DM9S51Q	MN	Bacterial Penicillin binding protein (Bact PBP)
DM9S51Q	MT	DTT
DM9S51Q	MA	Modulator
DM9S51Q	RN	Pharmacokinetics and Safety of Ascending Single Doses of DZ-2640, a New Oral Carbapenem Antibiotic, Administered to Healthy Japanese Subjects. Antimicrob Agents Chemother. 2000 March; 44(3): 578-582.
DM9S51Q	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC89729/

DMUMAHC	DI	DMUMAHC
DMUMAHC	DN	DUP 697
DMUMAHC	MI	TTVKILB
DMUMAHC	MN	Prostaglandin G/H synthase 2 (COX-2)
DMUMAHC	MT	DTT
DMUMAHC	MA	Inhibitor
DMUMAHC	RN	Current status of COX-2 inhibitors. Mini Rev Med Chem. 2008 Jan;8(1):73-90.
DMUMAHC	RU	https://pubmed.ncbi.nlm.nih.gov/18220987

DM59WQ7	DI	DM59WQ7
DM59WQ7	DN	DuP-532
DM59WQ7	MI	TTGN1ZA
DM59WQ7	MN	Angiotensin II receptor (AGTR)
DM59WQ7	MT	DTT
DM59WQ7	MA	Modulator
DM59WQ7	RN	DuP 532, an angiotensin II receptor antagonist: first administration and comparison with losartan. Clin Pharmacol Ther. 1997 Jan;61(1):59-69.
DM59WQ7	RU	https://pubmed.ncbi.nlm.nih.gov/9024174

DMI5EPB	DI	DMI5EPB
DMI5EPB	DN	DUP-734
DMI5EPB	MI	TTJQOD7
DMI5EPB	MN	5-HT 2A receptor (HTR2A)
DMI5EPB	MT	DTT
DMI5EPB	MA	Modulator
DMI5EPB	RN	Piperidinyltetralin sigma ligands. J Med Chem. 1994 Feb 4;37(3):364-70.
DMI5EPB	RU	https://www.ncbi.nlm.nih.gov/pubmed/7905926

DMI5EPB	DI	DMI5EPB
DMI5EPB	DN	DUP-734
DMI5EPB	MI	TT5TPI6
DMI5EPB	MN	Opioid receptor sigma 1 (OPRS1)
DMI5EPB	MT	DTT
DMI5EPB	MA	Modulator
DMI5EPB	RN	Piperidinyltetralin sigma ligands. J Med Chem. 1994 Feb 4;37(3):364-70.
DMI5EPB	RU	https://www.ncbi.nlm.nih.gov/pubmed/7905926

DMDC4BA	DI	DMDC4BA
DMDC4BA	DN	DV-7751A
DMDC4BA	MI	TTN6J5F
DMDC4BA	MN	Bacterial DNA gyrase (Bact gyrase)
DMDC4BA	MT	DTT
DMDC4BA	MA	Modulator
DMDC4BA	RN	Antimicrobial activity of DV-7751a, a new fluoroquinolone.
DMDC4BA	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC192237

DMXJ54Z	DI	DMXJ54Z
DMXJ54Z	DN	DW-908e
DMXJ54Z	MI	TTHIZP9
DMXJ54Z	MN	Integrin alpha-5 (ITGA5)
DMXJ54Z	MT	DTT
DMXJ54Z	MA	Antagonist
DMXJ54Z	RN	WO patent application no. 2008,1439,28, Methods and compositions for treating skin conditions.
DMXJ54Z	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20081127&CC=WO&NR=2008143928A1&KC=A1

DMI9NZ3	DI	DMI9NZ3
DMI9NZ3	DN	E2101
DMI9NZ3	MI	TTSQIFT
DMI9NZ3	MN	5-HT 1A receptor (HTR1A)
DMI9NZ3	MT	DTT
DMI9NZ3	MA	Modulator
DMI9NZ3	RN	In vitro interactions between a potential muscle relaxant E2101 and human cytochromes P450. Drug Metab Dispos. 2002 Jul;30(7):805-13.
DMI9NZ3	RU	https://pubmed.ncbi.nlm.nih.gov/12065439

DMJWR1I	DI	DMJWR1I
DMJWR1I	DN	E-3030
DMJWR1I	MI	TTJ584C
DMJWR1I	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMJWR1I	MT	DTT
DMJWR1I	MA	Modulator
DMJWR1I	RN	Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs.J Pharmacol Sci.2008 Sep;108(1):40-8.
DMJWR1I	RU	https://www.ncbi.nlm.nih.gov/pubmed/18776709

DMJWR1I	DI	DMJWR1I
DMJWR1I	DN	E-3030
DMJWR1I	MI	TTZMAO3
DMJWR1I	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMJWR1I	MT	DTT
DMJWR1I	MA	Modulator
DMJWR1I	RN	Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs.J Pharmacol Sci.2008 Sep;108(1):40-8.
DMJWR1I	RU	https://www.ncbi.nlm.nih.gov/pubmed/18776709

DM79MI4	DI	DM79MI4
DM79MI4	DN	E-6087
DM79MI4	MI	TTVKILB
DM79MI4	MN	Prostaglandin G/H synthase 2 (COX-2)
DM79MI4	MT	DTT
DM79MI4	MA	Inhibitor
DM79MI4	RN	Enantioselective HPLC determination of E-6087, a new COX-2 inhibitor, in human plasma: Validation and pharmacokinetic application. Chirality. 2004 May 15;16(5):302-8.
DM79MI4	RU	https://pubmed.ncbi.nlm.nih.gov/15069660

DMSOH09	DI	DMSOH09
DMSOH09	DN	Ebalzotan
DMSOH09	MI	TTSQIFT
DMSOH09	MN	5-HT 1A receptor (HTR1A)
DMSOH09	MT	DTT
DMSOH09	MA	Agonist
DMSOH09	RN	The pharmacological profile of (R)-3,4-dihydro-N-isopropyl-3-(N-isopropyl-N-propylamino)-2H-1-benzopyran-5-carboxamide, a selective 5-hydroxytryptamine(1A) receptor agonist. J Pharmacol Exp Ther. 2001 Dec;299(3):883-93.
DMSOH09	RU	https://pubmed.ncbi.nlm.nih.gov/11714872

DMURVE8	DI	DMURVE8
DMURVE8	DN	Elacridar
DMURVE8	MI	TT3OT40
DMURVE8	MN	Multidrug resistance protein 1 (ABCB1)
DMURVE8	MT	DTT
DMURVE8	MA	Inhibitor
DMURVE8	RN	2-[(3-Methoxyphenylethyl)phenoxy]-based ABCB1 inhibitors: effect of different basic side-chains on their biological properties. J Med Chem. 2008 Dec 11;51(23):7602-13.
DMURVE8	RU	https://pubmed.ncbi.nlm.nih.gov/19053888

DMWRQG7	DI	DMWRQG7
DMWRQG7	DN	Eltenac
DMWRQG7	MI	TTK0943
DMWRQG7	MN	Prostaglandin G/H synthase (COX)
DMWRQG7	MT	DTT
DMWRQG7	MA	Modulator
DMWRQG7	RN	Effect of eltenac in horses with induced endotoxaemia. Equine Vet J Suppl. 2000 Jun;(32):26-31.
DMWRQG7	RU	https://pubmed.ncbi.nlm.nih.gov/11202378

DM2V5XP	DI	DM2V5XP
DM2V5XP	DN	Emakalim
DM2V5XP	MI	TT1VOHK
DM2V5XP	MN	Potassium channel unspecific (KC)
DM2V5XP	MT	DTT
DM2V5XP	MA	Opener
DM2V5XP	RN	Therapeutic potential of potassium channel activators in coronary heart disease. Eur Heart J. 1994 Aug;15 Suppl C:82-8.
DM2V5XP	RU	https://pubmed.ncbi.nlm.nih.gov/7995277

DMQH8L2	DI	DMQH8L2
DMQH8L2	DN	EMD-503982
DMQH8L2	MI	TTCIHJA
DMQH8L2	MN	Coagulation factor Xa (F10)
DMQH8L2	MT	DTT
DMQH8L2	MA	Inhibitor
DMQH8L2	RN	Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7.
DMQH8L2	RU	https://pubmed.ncbi.nlm.nih.gov/22844656

DMVS8IE	DI	DMVS8IE
DMVS8IE	DN	EMD-53998
DMVS8IE	MI	TT06AWU
DMVS8IE	MN	Phosphodiesterase 3A (PDE3A)
DMVS8IE	MT	DTT
DMVS8IE	MA	Inhibitor
DMVS8IE	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMVS8IE	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMFGTMR	DI	DMFGTMR
DMFGTMR	DN	Eptapirone
DMFGTMR	MI	TTSQIFT
DMFGTMR	MN	5-HT 1A receptor (HTR1A)
DMFGTMR	MT	DTT
DMFGTMR	MA	Agonist
DMFGTMR	RN	The use of sleep measures to compare a new 5HT1A agonist with buspirone in humans. J Psychopharmacol. 2005 Nov;19(6):609-13.
DMFGTMR	RU	https://pubmed.ncbi.nlm.nih.gov/16272182

DM3LKAR	DI	DM3LKAR
DM3LKAR	DN	ER-35786
DM3LKAR	MI	TTJP4SM
DM3LKAR	MN	Bacterial Penicillin binding protein (Bact PBP)
DM3LKAR	MT	DTT
DM3LKAR	MA	Inhibitor
DM3LKAR	RN	In vitro and in vivo antibacterial activities of ER-35786, a new antipseudomonal carbapenem. Antimicrob Agents Chemother. 1997 Feb;41(2):298-307.
DM3LKAR	RU	https://pubmed.ncbi.nlm.nih.gov/9021183

DMGX08C	DI	DMGX08C
DMGX08C	DN	ERB-196
DMGX08C	MI	TTOM3J0
DMGX08C	MN	Estrogen receptor beta (ESR2)
DMGX08C	MT	DTT
DMGX08C	MA	Agonist
DMGX08C	RN	WAY-202196, a selective estrogen receptor-beta agonist, protects against death in experimental septic shock. Crit Care Med. 2006 Aug;34(8):2188-93.
DMGX08C	RU	https://pubmed.ncbi.nlm.nih.gov/16755255

DMW9LHG	DI	DMW9LHG
DMW9LHG	DN	ES-285
DMW9LHG	MI	TTFNDGV
DMW9LHG	MN	Transforming protein RhoA (RHOA)
DMW9LHG	MT	DTT
DMW9LHG	MA	Inhibitor
DMW9LHG	RN	Spisulosine (ES-285) induces prostate tumor PC-3 and LNCaP cell death by de novo synthesis of ceramide and PKCzeta activation. Eur J Pharmacol. 2008 Apr 28;584(2-3):237-45.
DMW9LHG	RU	https://pubmed.ncbi.nlm.nih.gov/18343365

DM9450Z	DI	DM9450Z
DM9450Z	DN	EVT-103
DM9450Z	MI	TTN9D8E
DM9450Z	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DM9450Z	MT	DTT
DM9450Z	MA	Antagonist
DM9450Z	RN	Clinical pipeline report, company report or official report of Evotec.
DM9450Z	RU	https://www.evotec.com/archive/en/Press-releases/2009/Evotec-starts-Phase-I-with-EVT-103-an-NR2B-selective-NMDA-receptor-antagonist/1956/1

DMCZ8SF	DI	DMCZ8SF
DMCZ8SF	DN	EVT-301
DMCZ8SF	MI	TTGP7BY
DMCZ8SF	MN	Monoamine oxidase type B (MAO-B)
DMCZ8SF	MT	DTT
DMCZ8SF	MA	Inhibitor
DMCZ8SF	RN	Assessment of MAO-B occupancy in the brain with PET and [11C]-L-deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301. Clin Pharmacol Ther. 2009 May;85(5):506-12.
DMCZ8SF	RU	https://pubmed.ncbi.nlm.nih.gov/19129751

DMLRF7U	DI	DMLRF7U
DMLRF7U	DN	F-11105
DMLRF7U	MI	TTK0943
DMLRF7U	MN	Prostaglandin G/H synthase (COX)
DMLRF7U	MT	DTT
DMLRF7U	MA	Inhibitor
DMLRF7U	RN	US patent application no. 6,673,908, Tumor necrosis factor receptor 2.
DMLRF7U	RU	http://www.google.com/patents/US6673908

DMPC9K3	DI	DMPC9K3
DMPC9K3	DN	F-1394
DMPC9K3	MI	TTMF541
DMPC9K3	MN	Liver carboxylesterase (CES1)
DMPC9K3	MT	DTT
DMPC9K3	MA	Modulator
DMPC9K3	RN	ACAT inhibitor F-1394 prevents intimal hyperplasia induced by balloon injury in rabbits. J Lipid Res. 2001 Apr;42(4):480-8.
DMPC9K3	RU	https://pubmed.ncbi.nlm.nih.gov/11290819

DMMG6W5	DI	DMMG6W5
DMMG6W5	DN	F-50040
DMMG6W5	MI	TT362RB
DMMG6W5	MN	MART-1 melanoma antigen (MLANA)
DMMG6W5	MT	DTT
DMMG6W5	MA	Modulator
DMMG6W5	RN	Stability and CTL-activity of P40/ELA melanoma vaccine candidate. Biologicals. 2001 Sep-Dec;29(3-4):293-8.
DMMG6W5	RU	https://pubmed.ncbi.nlm.nih.gov/11851331

DMMG6W5	DI	DMMG6W5
DMMG6W5	DN	F-50040
DMMG6W5	MI	TTY7ZHS
DMMG6W5	MN	Toll-like receptor 2 (TLR2)
DMMG6W5	MT	DTT
DMMG6W5	MA	Modulator
DMMG6W5	RN	Stability and CTL-activity of P40/ELA melanoma vaccine candidate. Biologicals. 2001 Sep-Dec;29(3-4):293-8.
DMMG6W5	RU	https://pubmed.ncbi.nlm.nih.gov/11851331

DM76GRQ	DI	DM76GRQ
DM76GRQ	DN	Farampator
DM76GRQ	MI	TTVPQTF
DM76GRQ	MN	Glutamate receptor AMPA 1 (GRIA1)
DM76GRQ	MT	DTT
DM76GRQ	MA	Binder
DM76GRQ	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DM76GRQ	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMEX12T	DI	DMEX12T
DMEX12T	DN	FC EPO
DMEX12T	MI	TTQG4NR
DMEX12T	MN	Erythropoietin (EPO)
DMEX12T	MT	DTT
DMEX12T	MA	Agonist
DMEX12T	RN	Detection of EPO-Fc fusion protein in human blood: screening and confirmation protocols for sports drug testing. Drug Test Anal. 2012 Nov;4(11):818-29.
DMEX12T	RU	https://pubmed.ncbi.nlm.nih.gov/22764129

DMSFA7L	DI	DMSFA7L
DMSFA7L	DN	FCE-28161
DMSFA7L	MI	TTML2WA
DMSFA7L	MN	Tubulin (TUB)
DMSFA7L	MT	DTT
DMSFA7L	MA	Modulator
DMSFA7L	RN	CN patent application no. 101065129, A combination of n-(3-metoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an anti-mitotic agent for the treatment of cancer.
DMSFA7L	RU	http://www.google.com/patents/CN101065129B?cl=en

DMC3DVB	DI	DMC3DVB
DMC3DVB	DN	Figitumumab
DMC3DVB	MI	TTHRID2
DMC3DVB	MN	Insulin-like growth factor I receptor (IGF1R)
DMC3DVB	MT	DTT
DMC3DVB	MA	Inhibitor
DMC3DVB	RN	Pfizer. Product Development Pipeline. March 31 2009.
DMC3DVB	RU	http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf

DMVL5RC	DI	DMVL5RC
DMVL5RC	DN	FK-041
DMVL5RC	MI	TTJP4SM
DMVL5RC	MN	Bacterial Penicillin binding protein (Bact PBP)
DMVL5RC	MT	DTT
DMVL5RC	MA	Inhibitor
DMVL5RC	RN	In vitro antibacterial activity of FK041, a new orally active cephalosporin. J Antibiot (Tokyo). 1999 Jul;52(7):649-59.
DMVL5RC	RU	https://pubmed.ncbi.nlm.nih.gov/10513845

DMB5HMS	DI	DMB5HMS
DMB5HMS	DN	FK-973
DMB5HMS	MI	TTUTN1I
DMB5HMS	MN	Human Deoxyribonucleic acid (hDNA)
DMB5HMS	MT	DTT
DMB5HMS	MA	Binder
DMB5HMS	RN	Specific metabolic activation of FK973, a new antitumor antibiotic, in L1210 leukemia cells. Jpn J Pharmacol. 1990 Aug;53(4):463-72.
DMB5HMS	RU	https://pubmed.ncbi.nlm.nih.gov/2214370

DMKWTPX	DI	DMKWTPX
DMKWTPX	DN	FLM-5011
DMKWTPX	MI	TTG3K2U
DMKWTPX	MN	Lipoxygenase (ALOX)
DMKWTPX	MT	DTT
DMKWTPX	MA	Modulator
DMKWTPX	RN	Lipoxygenase inhibitor FLM 5011, an effective protectant of myocardial microvessels against ischemia-reperfusion injury. Exp Toxicol Pathol. 2000 Mar;52(1):27-36.
DMKWTPX	RU	https://pubmed.ncbi.nlm.nih.gov/10779150

DM5FW8Y	DI	DM5FW8Y
DM5FW8Y	DN	FR-158999
DM5FW8Y	MI	TT38RM1
DM5FW8Y	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DM5FW8Y	MT	DTT
DM5FW8Y	MA	Antagonist
DM5FW8Y	RN	QSAR study of the peptidic fibrinogen inhibitors FK633, FR158999 and related derivatives, using a novel and useful hydrophobic descriptor (logPmw). Bioorganic & Medicinal Chemistry Letters Volume 8, Issue 18, 22 September 1998, Pages 2483-2488.
DM5FW8Y	RU	http://www.sciencedirect.com/science/article/pii/S0960894X98004053

DM69OR8	DI	DM69OR8
DM69OR8	DN	FR167653
DM69OR8	MI	TTPLTSQ
DM69OR8	MN	Neutrophil elastase (NE)
DM69OR8	MT	DTT
DM69OR8	MA	Inhibitor
DM69OR8	RN	Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs. 2002 Jul;11(7):965-80.
DM69OR8	RU	https://pubmed.ncbi.nlm.nih.gov/12084007

DM69OR8	DI	DM69OR8
DM69OR8	DN	FR167653
DM69OR8	MI	TTQBR95
DM69OR8	MN	Stress-activated protein kinase 2a (p38 alpha)
DM69OR8	MT	DTT
DM69OR8	MA	Inhibitor
DM69OR8	RN	Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653. Arthritis Rheum. 2003 Sep;48(9):2670-81.
DM69OR8	RU	https://pubmed.ncbi.nlm.nih.gov/13130488

DMDW64X	DI	DMDW64X
DMDW64X	DN	FT-105
DMDW64X	MI	TTZOPHG
DMDW64X	MN	Insulin (INS)
DMDW64X	MT	DTT
DMDW64X	MA	Modulator
DMDW64X	RN	Degludec insulin: A novel basal insulin. Indian J Endocrinol Metab. 2011 July; 15(Suppl1): S12-S16.
DMDW64X	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152187/

DMCZAJW	DI	DMCZAJW
DMCZAJW	DN	Garnocestim
DMCZAJW	MI	TTBID49
DMCZAJW	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMCZAJW	MT	DTT
DMCZAJW	MA	Modulator
DMCZAJW	RN	CN patent application no. 101094684, With the combination of chemokine activation progenitor cells/stem cells.
DMCZAJW	RU	https://www.google.com.ar/patents/CN101094684A

DM041IZ	DI	DM041IZ
DM041IZ	DN	GED-aPC
DM041IZ	MI	TTZUXYS
DM041IZ	MN	Vitamin K-dependent protein C (PROC)
DM041IZ	MT	DTT
DM041IZ	MA	Modulator
DM041IZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2396).
DM041IZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2396

DMNFWR1	DI	DMNFWR1
DMNFWR1	DN	Gedocarnil
DMNFWR1	MI	TTNJYV2
DMNFWR1	MN	Gamma-aminobutyric acid receptor (GAR)
DMNFWR1	MT	DTT
DMNFWR1	MA	Modulator
DMNFWR1	RN	US patent application no. US20040102438 A1.
DMNFWR1	RU	https://www.google.com.ar/patents/US20040102438

DM4ZDVY	DI	DM4ZDVY
DM4ZDVY	DN	Gem 92
DM4ZDVY	MI	TTFGZB6
DM4ZDVY	MN	Human immunodeficiency virus GAG protein (HIV gag)
DM4ZDVY	MT	DTT
DM4ZDVY	MA	Modulator
DM4ZDVY	RN	Technology evaluation: GEM-92, Hybridon Inc. Curr Opin Mol Ther. 1999 Aug;1(4):521-3.
DM4ZDVY	RU	https://www.ncbi.nlm.nih.gov/pubmed/11713769

DM520D8	DI	DM520D8
DM520D8	DN	Gevotroline
DM520D8	MI	TT5TPI6
DM520D8	MN	Opioid receptor sigma 1 (OPRS1)
DM520D8	MT	DTT
DM520D8	MA	Modulator
DM520D8	RN	Sigma receptor ligands alter concentrations of corticosterone in plasma in the rat. Neuropharmacology. 1991 Jan;30(1):79-87.
DM520D8	RU	https://www.ncbi.nlm.nih.gov/pubmed/1675451

DMSGUY9	DI	DMSGUY9
DMSGUY9	DN	Goxalapladib
DMSGUY9	MI	TTDNFMT
DMSGUY9	MN	Platelet-activating factor acetylhydrolase (PLA2G7)
DMSGUY9	MT	DTT
DMSGUY9	MA	Modulator
DMSGUY9	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020582)
DMSGUY9	RU	http://adisinsight.springer.com/drugs/800020582

DMRNI6K	DI	DMRNI6K
DMRNI6K	DN	GR-127607
DMRNI6K	MI	TTSQIFT
DMRNI6K	MN	5-HT 1A receptor (HTR1A)
DMRNI6K	MT	DTT
DMRNI6K	MA	Agonist
DMRNI6K	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003531)
DMRNI6K	RU	http://adisinsight.springer.com/drugs/800003531

DMWY2F6	DI	DMWY2F6
DMWY2F6	DN	GR-253035
DMWY2F6	MI	TTVKILB
DMWY2F6	MN	Prostaglandin G/H synthase 2 (COX-2)
DMWY2F6	MT	DTT
DMWY2F6	MA	Modulator
DMWY2F6	RN	Role of cyclooxygenases 1 and 2 in the modulation of neuromuscular functions in the distal colon of humans and mice. Gut. 2005 May; 54(5): 608-616.
DMWY2F6	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1774510/

DMUANK9	DI	DMUANK9
DMUANK9	DN	GR-328713
DMUANK9	MI	TTUS1RD
DMUANK9	MN	Microsomal triglyceride transfer protein (MTTP)
DMUANK9	MT	DTT
DMUANK9	MA	Modulator
DMUANK9	RN	Patent CN101237870 B.
DMUANK9	RU	http://www.google.com/patents/CN101237870B?cl=en

DM13GK8	DI	DM13GK8
DM13GK8	DN	GR-63799X
DM13GK8	MI	TTPNGDE
DM13GK8	MN	Prostaglandin E2 receptor EP3 (PTGER3)
DM13GK8	MT	DTT
DM13GK8	MA	Modulator
DM13GK8	RN	Effects of the prostanoid EP3-receptor agonists M&amp;B 28767 and GR 63799X on infarct size caused by regional myocardial ischaemia in the anaesthetized rat. Br J Pharmacol. 1999 Feb;126(4):849-58.
DM13GK8	RU	https://pubmed.ncbi.nlm.nih.gov/10193764

DM9C1LQ	DI	DM9C1LQ
DM9C1LQ	DN	GR-79236
DM9C1LQ	MI	TTK25J1
DM9C1LQ	MN	Adenosine A1 receptor (ADORA1)
DM9C1LQ	MT	DTT
DM9C1LQ	MA	Agonist
DM9C1LQ	RN	Effect of the adenosine A1 receptor agonist GR79236 on trigeminal nociception with blink reflex recordings in healthy human subjects. Cephalalgia. 2003 May;23(4):287-92.
DM9C1LQ	RU	https://pubmed.ncbi.nlm.nih.gov/12716347

DMEC6RD	DI	DMEC6RD
DMEC6RD	DN	GSK1004723
DMEC6RD	MI	TTTIBOJ
DMEC6RD	MN	Histamine H1 receptor (H1R)
DMEC6RD	MT	DTT
DMEC6RD	MA	Antagonist
DMEC6RD	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMEC6RD	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMEC6RD	DI	DMEC6RD
DMEC6RD	DN	GSK1004723
DMEC6RD	MI	TT9JNIC
DMEC6RD	MN	Histamine H3 receptor (H3R)
DMEC6RD	MT	DTT
DMEC6RD	MA	Antagonist
DMEC6RD	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMEC6RD	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DM7ACJ4	DI	DM7ACJ4
DM7ACJ4	DN	GSK1018921
DM7ACJ4	MI	TTHJTF7
DM7ACJ4	MN	Glycine transporter GlyT-1 (SLC6A9)
DM7ACJ4	MT	DTT
DM7ACJ4	MA	Blocker
DM7ACJ4	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DM7ACJ4	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMI6KQM	DI	DMI6KQM
DMI6KQM	DN	GSK1059615
DMI6KQM	MI	TTHBTOP
DMI6KQM	MN	PI3-kinase gamma (PIK3CG)
DMI6KQM	MT	DTT
DMI6KQM	MA	Inhibitor
DMI6KQM	RN	Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44.
DMI6KQM	RU	https://pubmed.ncbi.nlm.nih.gov/19644473

DMBXYKG	DI	DMBXYKG
DMBXYKG	DN	GSK-1362885
DMBXYKG	MI	TT31JXP
DMBXYKG	MN	Myophosphorylase (PYGM)
DMBXYKG	MT	DTT
DMBXYKG	MA	Modulator
DMBXYKG	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMBXYKG	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMM7Q3L	DI	DMM7Q3L
DMM7Q3L	DN	GSK2849466
DMM7Q3L	MI	TTS64P2
DMM7Q3L	MN	Androgen receptor (AR)
DMM7Q3L	MT	DTT
DMM7Q3L	MA	Modulator
DMM7Q3L	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036899)
DMM7Q3L	RU	http://adisinsight.springer.com/drugs/800036899

DM6E84O	DI	DM6E84O
DM6E84O	DN	GSK568859
DM6E84O	MI	TTDNFMT
DM6E84O	MN	Platelet-activating factor acetylhydrolase (PLA2G7)
DM6E84O	MT	DTT
DM6E84O	MA	Modulator
DM6E84O	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1432).
DM6E84O	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1432

DMRTPY6	DI	DMRTPY6
DMRTPY6	DN	GSK729327
DMRTPY6	MI	TTAN6JD
DMRTPY6	MN	Glutamate receptor AMPA (GRIA)
DMRTPY6	MT	DTT
DMRTPY6	MA	Modulator
DMRTPY6	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMRTPY6	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DM2AP64	DI	DM2AP64
DM2AP64	DN	GSK945237
DM2AP64	MI	TTN6J5F
DM2AP64	MN	Bacterial DNA gyrase (Bact gyrase)
DM2AP64	MT	DTT
DM2AP64	MA	Modulator
DM2AP64	RN	Company report (gsk)
DM2AP64	RU	http://www.gsk-clinicalstudyregister.com/study/107895#ps

DMWJZAP	DI	DMWJZAP
DMWJZAP	DN	GW-250495
DMWJZAP	MI	TTPNQAC
DMWJZAP	MN	Estrogen-related receptor-alpha (ESRRA)
DMWJZAP	MT	DTT
DMWJZAP	MA	Agonist
DMWJZAP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 622).
DMWJZAP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=622

DM62T1C	DI	DM62T1C
DM62T1C	DN	GW-311616
DM62T1C	MI	TTPLTSQ
DM62T1C	MN	Neutrophil elastase (NE)
DM62T1C	MT	DTT
DM62T1C	MA	Inhibitor
DM62T1C	RN	Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs. 2002 Jul;11(7):965-80.
DM62T1C	RU	https://pubmed.ncbi.nlm.nih.gov/12084007

DMRQVI9	DI	DMRQVI9
DMRQVI9	DN	GW-473178
DMRQVI9	MI	TT6L509
DMRQVI9	MN	Coagulation factor IIa (F2)
DMRQVI9	MT	DTT
DMRQVI9	MA	Inhibitor
DMRQVI9	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015039)
DMRQVI9	RU	http://adisinsight.springer.com/drugs/800015039

DMQNX02	DI	DMQNX02
DMQNX02	DN	GYKI-12743
DMQNX02	MI	TT2NUT5
DMQNX02	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMQNX02	MT	DTT
DMQNX02	MA	Modulator
DMQNX02	RN	GYKI-12743 a new postsynaptic vascular alpha-adrenoceptor antagonist. Acta Physiol Hung. 1991;77(3-4):257-67.
DMQNX02	RU	https://pubmed.ncbi.nlm.nih.gov/1684485

DM2RF06	DI	DM2RF06
DM2RF06	DN	HCV-086
DM2RF06	MI	TTMVBWH
DM2RF06	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DM2RF06	MT	DTT
DM2RF06	MA	Inhibitor
DM2RF06	RN	Challenges and successes in developing new therapies for hepatitis C. Nature. 2005 Aug 18;436(7053):953-60.
DM2RF06	RU	https://pubmed.ncbi.nlm.nih.gov/16107835

DMCP2KH	DI	DMCP2KH
DMCP2KH	DN	HE2100
DMCP2KH	MI	DERDQWN
DMCP2KH	MN	Dihydrotestosterone oxidoreductase (HSD3B1)
DMCP2KH	MT	DME
DMCP2KH	MA	Metabolism
DMCP2KH	RN	Steroid signalling in the ovarian surface epithelium. Trends Endocrinol Metab. 2005 Sep;16(7):327-33.
DMCP2KH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16054388

DMCP2KH	DI	DMCP2KH
DMCP2KH	DN	HE2100
DMCP2KH	MI	TTZAYWL
DMCP2KH	MN	Estrogen receptor (ESR)
DMCP2KH	MT	DTT
DMCP2KH	MA	Inhibitor
DMCP2KH	RN	Androstene-3,5-dienes as ER-beta selective SERMs. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6295-8.
DMCP2KH	RU	https://pubmed.ncbi.nlm.nih.gov/17890084

DMCP2KH	DI	DMCP2KH
DMCP2KH	DN	HE2100
DMCP2KH	MI	TTOM3J0
DMCP2KH	MN	Estrogen receptor beta (ESR2)
DMCP2KH	MT	DTT
DMCP2KH	MA	Inhibitor
DMCP2KH	RN	Androstene-3,5-dienes as ER-beta selective SERMs. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6295-8.
DMCP2KH	RU	https://pubmed.ncbi.nlm.nih.gov/17890084

DM0W2TA	DI	DM0W2TA
DM0W2TA	DN	HGS-TR2J
DM0W2TA	MI	TTW20TU
DM0W2TA	MN	TRAIL receptor 2 (TRAIL-R2)
DM0W2TA	MT	DTT
DM0W2TA	RN	Enhancement of Glioma Radiation Therapy and Chemotherapy Response with Targeted Antibody Therapy Against Death Receptor 5. Int J Radiat Oncol Biol Phys. 2008 June 1; 71(2): 507-516.
DM0W2TA	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750837/

DMH4ANG	DI	DMH4ANG
DMH4ANG	DN	HMN-214
DMH4ANG	MI	TTIYVQP
DMH4ANG	MN	Polo-like kinase 1 (PLK1)
DMH4ANG	MT	DTT
DMH4ANG	MA	Inhibitor
DMH4ANG	RN	Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009 Jun;14(6):559-70.
DMH4ANG	RU	https://pubmed.ncbi.nlm.nih.gov/19474163

DMKA612	DI	DMKA612
DMKA612	DN	HMR-3562
DMKA612	MI	TTUWYEA
DMKA612	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DMKA612	MT	DTT
DMKA612	MA	Modulator
DMKA612	RN	Structure-activity relationships for six ketolide antibiotics. Curr Microbiol. 2001 Mar;42(3):203-10.
DMKA612	RU	https://pubmed.ncbi.nlm.nih.gov/11270656

DMQOW8H	DI	DMQOW8H
DMQOW8H	DN	HO-221
DMQOW8H	MI	TTGPJ0U
DMQOW8H	MN	DNA polymerase alpha catalytic p180 (POLA1)
DMQOW8H	MT	DTT
DMQOW8H	MA	Modulator
DMQOW8H	RN	Effect of novel benzoylphenylurea derivatives on DNA polymerase alpha activity using the synthesome-based in vitro model system. Invest New Drugs. 2003 Nov;21(4):421-8.
DMQOW8H	RU	https://www.ncbi.nlm.nih.gov/pubmed/14586209

DMNC1A3	DI	DMNC1A3
DMNC1A3	DN	HOE-065
DMNC1A3	MI	TTZJD1B
DMNC1A3	MN	Acetylcholine release (Ach rele)
DMNC1A3	MT	DTT
DMNC1A3	MA	Modulator
DMNC1A3	RN	Effects of the novel compound, Hoe 065, upon impaired learning and memory in rodents. Eur J Pharmacol. 1989 Nov 14;171(1):79-85.
DMNC1A3	RU	https://pubmed.ncbi.nlm.nih.gov/2612569

DMH32LM	DI	DMH32LM
DMH32LM	DN	HRC-302
DMH32LM	MI	TTQO71U
DMH32LM	MN	Hemoglobin (HB)
DMH32LM	MT	DTT
DMH32LM	MA	Modulator
DMH32LM	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014790)
DMH32LM	RU	http://adisinsight.springer.com/drugs/800014790

DMQYWAH	DI	DMQYWAH
DMQYWAH	DN	HRT
DMQYWAH	MI	TTZAYWL
DMQYWAH	MN	Estrogen receptor (ESR)
DMQYWAH	MT	DTT
DMQYWAH	MA	Agonist
DMQYWAH	RN	US patent application no. 2010,0278,784, Methods and compositions for treating skin conditions.
DMQYWAH	RU	https://www.google.com.ar/patents/US20100278784

DMCS06R	DI	DMCS06R
DMCS06R	DN	HSR-6071
DMCS06R	MI	TT4IN7L
DMCS06R	MN	Histamine release (His rele)
DMCS06R	MT	DTT
DMCS06R	MA	Modulator
DMCS06R	RN	Inhibitory effect of HSR-6071, a new anti-allergic agent, on experimental asthma in rats and guinea-pigs. J Pharm Pharmacol. 1990 Apr;42(4):236-41.
DMCS06R	RU	https://pubmed.ncbi.nlm.nih.gov/1974289

DMUPOIG	DI	DMUPOIG
DMUPOIG	DN	HT-1067
DMUPOIG	MI	TTGP7BY
DMUPOIG	MN	Monoamine oxidase type B (MAO-B)
DMUPOIG	MT	DTT
DMUPOIG	MA	Inhibitor
DMUPOIG	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034020)
DMUPOIG	RU	http://adisinsight.springer.com/drugs/800034020

DM9LY4Q	DI	DM9LY4Q
DM9LY4Q	DN	HuMV833
DM9LY4Q	MI	TTVJ1D8
DM9LY4Q	MN	Vascular endothelial growth factor receptor (VEGFR)
DM9LY4Q	MT	DTT
DM9LY4Q	RN	Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst. 2002 Oct 2;94(19):1484-93.
DM9LY4Q	RU	https://pubmed.ncbi.nlm.nih.gov/12359857

DMZYA9E	DI	DMZYA9E
DMZYA9E	DN	ICI-D-6888
DMZYA9E	MI	TTGN1ZA
DMZYA9E	MN	Angiotensin II receptor (AGTR)
DMZYA9E	MT	DTT
DMZYA9E	MA	Modulator
DMZYA9E	RN	WO patent application no. 1995,0216,09, Treatment of normotensive glaucoma with angiotensin ii antagonists.
DMZYA9E	RU	http://www.google.com.au/patents/WO1995021609A1

DMAU79Q	DI	DMAU79Q
DMAU79Q	DN	IDEC-131
DMAU79Q	MI	TTIJP3Q
DMAU79Q	MN	TNF related activation protein (CD40LG)
DMAU79Q	MT	DTT
DMAU79Q	RN	Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol. 2001 Jan;28(1):95-101.
DMAU79Q	RU	https://pubmed.ncbi.nlm.nih.gov/11196549

DMP8MBW	DI	DMP8MBW
DMP8MBW	DN	IGANIDIPINE HYDROCHLORIDE
DMP8MBW	MI	TT5HONZ
DMP8MBW	MN	Calcium channel unspecific (CaC)
DMP8MBW	MT	DTT
DMP8MBW	MA	Blocker
DMP8MBW	RN	Improving effects of topical administration of iganidipine, a new calcium channel blocker, on the impaired visual evoked potential after endothelin-1 injection into the vitreous body of rabbits. CurrEye Res. 2000 Feb;20(2):101-8.
DMP8MBW	RU	https://pubmed.ncbi.nlm.nih.gov/10617910

DMRSJ49	DI	DMRSJ49
DMRSJ49	DN	IL-18BP
DMRSJ49	MI	TTRICUF
DMRSJ49	MN	Interleukin-18 (IL18)
DMRSJ49	MT	DTT
DMRSJ49	MA	Binder
DMRSJ49	RN	Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
DMRSJ49	RU	https://pubmed.ncbi.nlm.nih.gov/18321156

DMQIXD2	DI	DMQIXD2
DMQIXD2	DN	IMC-1C11
DMQIXD2	MI	TTUTJGQ
DMQIXD2	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMQIXD2	MT	DTT
DMQIXD2	RN	Technology evaluation: IMC-1C11, ImClone Systems. Curr Opin Mol Ther. 2001 Aug;3(4):418-24.
DMQIXD2	RU	https://pubmed.ncbi.nlm.nih.gov/11525567

DM8OYZB	DI	DM8OYZB
DM8OYZB	DN	Imepitoin
DM8OYZB	MI	TTPTXIN
DM8OYZB	MN	Translocator protein (TSPO)
DM8OYZB	MT	DTT
DM8OYZB	MA	Agonist
DM8OYZB	RN	The pharmacology of imepitoin: the first partial benzodiazepine receptor agonist developed for the treatment of epilepsy. CNS Drugs. 2014 Jan;28(1):29-43.
DM8OYZB	RU	https://pubmed.ncbi.nlm.nih.gov/24357084

DMFACQU	DI	DMFACQU
DMFACQU	DN	IMS
DMFACQU	MI	TTCAQMW
DMFACQU	MN	Inosine-5'-monophosphate dehydrogenase (IMPDH)
DMFACQU	MT	DTT
DMFACQU	MA	Modulator
DMFACQU	RN	The novel inosine analogue INO-2002 exerts an anti-inflammatory effect in a murine model of acute lung injury. Shock. 2009 Sep;32(3):258-62.
DMFACQU	RU	https://pubmed.ncbi.nlm.nih.gov/19174745

DM8PTUC	DI	DM8PTUC
DM8PTUC	DN	INCB8696
DM8PTUC	MI	TTFZYTO
DM8PTUC	MN	C-C chemokine receptor type 2 (CCR2)
DM8PTUC	MT	DTT
DM8PTUC	MA	Antagonist
DM8PTUC	RN	Incyte. Product Development Pipeline.
DM8PTUC	RU	http://www.incyte.com/drugs_product_pipeline.html

DMGCUTI	DI	DMGCUTI
DMGCUTI	DN	INOC-002
DMGCUTI	MI	TTW1KTD
DMGCUTI	MN	Phosphoric monoester hydrolase (PMH)
DMGCUTI	MT	DTT
DMGCUTI	MA	Inhibitor
DMGCUTI	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022435)
DMGCUTI	RU	http://adisinsight.springer.com/drugs/800022435

DMCF0XK	DI	DMCF0XK
DMCF0XK	DN	IPI-493
DMCF0XK	MI	TT78R5H
DMCF0XK	MN	Heat shock protein 90 alpha (HSP90A)
DMCF0XK	MT	DTT
DMCF0XK	MA	Inhibitor
DMCF0XK	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DMCF0XK	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DM8139E	DI	DM8139E
DM8139E	DN	ITAMELINE
DM8139E	MI	TTZ9SOR
DM8139E	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DM8139E	MT	DTT
DM8139E	MA	Agonist
DM8139E	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DM8139E	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMUNYR7	DI	DMUNYR7
DMUNYR7	DN	JTK-109
DMUNYR7	MI	TTMVBWH
DMUNYR7	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMUNYR7	MT	DTT
DMUNYR7	MA	Inhibitor
DMUNYR7	RN	Benzimidazole derivatives bearing substituted biphenyls as hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors: structure-activity relationship studies and identification of a potent and highly selective inhibitor JTK-109. J Med Chem. 2006 Jul 27;49(15):4721-36.
DMUNYR7	RU	https://pubmed.ncbi.nlm.nih.gov/16854079

DMZFEY1	DI	DMZFEY1
DMZFEY1	DN	JTK-652
DMZFEY1	MI	TTMVBWH
DMZFEY1	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMZFEY1	MT	DTT
DMZFEY1	MA	Inhibitor
DMZFEY1	RN	Safety and antiviral activity of JTK-652: a novel HCV infection inhibitor. Antivir Ther. 2010;15(5):765-73.
DMZFEY1	RU	https://pubmed.ncbi.nlm.nih.gov/20710058

DMEADBG	DI	DMEADBG
DMEADBG	DN	JTK-656
DMEADBG	MI	TT5FH9Y
DMEADBG	MN	Human immunodeficiency virus Integrase (HIV IN)
DMEADBG	MT	DTT
DMEADBG	MA	Inhibitor
DMEADBG	RN	US patent application no. 8,497,270, Macrocyclic integrase inhibitors.
DMEADBG	RU	http://www.google.com/patents/US8497270

DM64FX9	DI	DM64FX9
DM64FX9	DN	JTK-853
DM64FX9	MI	TTMVBWH
DM64FX9	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DM64FX9	MT	DTT
DM64FX9	MA	Inhibitor
DM64FX9	RN	Preclinical Characterization of JTK-853, a Novel Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase. Antimicrob Agents Chemother. 2012 August; 56(8): 4250-4256.
DM64FX9	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3421577/

DMI7Z1Y	DI	DMI7Z1Y
DMI7Z1Y	DN	JTT-553
DMI7Z1Y	MI	TTF8P9I
DMI7Z1Y	MN	Diacylglycerol acyltransferase 1 (DGAT1)
DMI7Z1Y	MT	DTT
DMI7Z1Y	MA	Inhibitor
DMI7Z1Y	RN	JTT-553, a novel Acyl CoA:diacylglycerol acyltransferase (DGAT) 1 inhibitor, improves glucose metabolism in diet-induced obesity and genetic T2DM mice. J Pharmacol Sci. 2015 Sep;129(1):51-8.
DMI7Z1Y	RU	https://pubmed.ncbi.nlm.nih.gov/26354408

DMGP42Q	DI	DMGP42Q
DMGP42Q	DN	JTT-651
DMGP42Q	MI	TTZHY6R
DMGP42Q	MN	Glycogen phosphorylase muscle form (GP)
DMGP42Q	MT	DTT
DMGP42Q	MA	Inhibitor
DMGP42Q	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026877)
DMGP42Q	RU	http://adisinsight.springer.com/drugs/800026877

DMXUH6W	DI	DMXUH6W
DMXUH6W	DN	JTV-803
DMXUH6W	MI	TTCIHJA
DMXUH6W	MN	Coagulation factor Xa (F10)
DMXUH6W	MT	DTT
DMXUH6W	MA	Inhibitor
DMXUH6W	RN	Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7.
DMXUH6W	RU	https://pubmed.ncbi.nlm.nih.gov/22844656

DM37IH5	DI	DM37IH5
DM37IH5	DN	KN-203
DM37IH5	MI	TTKWM86
DM37IH5	MN	Opioid receptor mu (MOP)
DM37IH5	MT	DTT
DM37IH5	MA	Agonist
DM37IH5	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026307)
DM37IH5	RU	http://adisinsight.springer.com/drugs/800026307

DM6LTRC	DI	DM6LTRC
DM6LTRC	DN	KNI-764
DM6LTRC	MI	TT5FNQT
DM6LTRC	MN	Human immunodeficiency virus Protease (HIV PR)
DM6LTRC	MT	DTT
DM6LTRC	MA	Modulator
DM6LTRC	RN	JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1. Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8675-80.
DM6LTRC	RU	https://www.ncbi.nlm.nih.gov/pubmed/10411934

DMICLMR	DI	DMICLMR
DMICLMR	DN	KP106
DMICLMR	MI	TTVBI8W
DMICLMR	MN	Dopamine transporter (DAT)
DMICLMR	MT	DTT
DMICLMR	MA	Agonist
DMICLMR	RN	Treating Attention-Deficit/Hyperactivity Disorder in Adults: Focus on Once-Daily Medications. Prim Care Companion CNS Disord 2011.
DMICLMR	RU	http://www.psychiatrist.com/PCC/article/Pages/2011/v13n06/11r01168.aspx

DMMD6LR	DI	DMMD6LR
DMMD6LR	DN	KR-30450
DMMD6LR	MI	TT1VOHK
DMMD6LR	MN	Potassium channel unspecific (KC)
DMMD6LR	MT	DTT
DMMD6LR	MA	Opener
DMMD6LR	RN	Cardioprotective effects of KR-30450, a novel K+(ATP) opener, and its major metabolite KR-30818 on isolated rat hearts. Jpn J Pharmacol. 1998 Jan;76(1):65-73.
DMMD6LR	RU	https://pubmed.ncbi.nlm.nih.gov/9517406

DMBH5G3	DI	DMBH5G3
DMBH5G3	DN	KT2-962
DMBH5G3	MI	TT2O84V
DMBH5G3	MN	Thromboxane A2 receptor (TBXA2R)
DMBH5G3	MT	DTT
DMBH5G3	MA	Antagonist
DMBH5G3	RN	Azulene derivatives as TXA2/PGH2 receptor antagonists--II. Synthesis and biological activity of 6-mono- and 6-dihydroxylated-isopropylazulenes. Bioorg Med Chem. 1996 Apr;4(4):575-91.
DMBH5G3	RU	https://pubmed.ncbi.nlm.nih.gov/8735846

DM74BK8	DI	DM74BK8
DM74BK8	DN	KT-362
DM74BK8	MI	TT5HONZ
DM74BK8	MN	Calcium channel unspecific (CaC)
DM74BK8	MT	DTT
DM74BK8	MA	Modulator
DM74BK8	RN	Comparative cardiac effects of KT-362 and verapamil in isolated heart--correlation to calcium channel current depression. J Cardiovasc Pharmacol. 1991 Oct;18(4):594-604.
DM74BK8	RU	https://pubmed.ncbi.nlm.nih.gov/1724538

DMG068H	DI	DMG068H
DMG068H	DN	KW-3635
DMG068H	MI	TT2O84V
DMG068H	MN	Thromboxane A2 receptor (TBXA2R)
DMG068H	MT	DTT
DMG068H	MA	Antagonist
DMG068H	RN	Antithrombotic effects of KW-3635, a thromboxane A2-receptor antagonist, in guinea pigs. Jpn J Pharmacol. 1994 Jun;65(2):93-8.
DMG068H	RU	https://pubmed.ncbi.nlm.nih.gov/7967232

DM76O23	DI	DM76O23
DM76O23	DN	KW-6055
DM76O23	MI	TTZJD1B
DM76O23	MN	Acetylcholine release (Ach rele)
DM76O23	MT	DTT
DM76O23	MA	Modulator
DM76O23	RN	Effects of KW-6055, a novel benzylpyridine derivative, on central cholinergic systems. Nihon Yakurigaku Zasshi. 1992 Jun;99(6):435-43.
DM76O23	RU	https://pubmed.ncbi.nlm.nih.gov/1398340

DM5LRKC	DI	DM5LRKC
DM5LRKC	DN	L-368899
DM5LRKC	MI	TTSCIUP
DM5LRKC	MN	Oxytocin receptor (OTR)
DM5LRKC	MT	DTT
DM5LRKC	MA	Antagonist
DM5LRKC	RN	Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs. Drug Metab Dispos. 1997 Oct;25(10):1113-8.
DM5LRKC	RU	https://pubmed.ncbi.nlm.nih.gov/9321512

DMLHE5A	DI	DMLHE5A
DMLHE5A	DN	L-692429
DMLHE5A	MI	TTG4R8V
DMLHE5A	MN	Growth hormone-releasing hormone receptor (GHRHR)
DMLHE5A	MT	DTT
DMLHE5A	MA	Modulator
DMLHE5A	RN	Nonpeptide and peptide growth hormone secretagogues act both as ghrelin receptor agonist and as positive or negative allosteric modulators of ghrel... Mol Endocrinol. 2005 Sep;19(9):2400-11.
DMLHE5A	RU	https://pubmed.ncbi.nlm.nih.gov/15905359

DMBIR5P	DI	DMBIR5P
DMBIR5P	DN	L-697639
DMBIR5P	MI	TT84ETX
DMBIR5P	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMBIR5P	MT	DTT
DMBIR5P	MA	Inhibitor
DMBIR5P	RN	Human pharmacokinetics and tolerability of L-697,639, a non-nucleoside HIV-1 reverse transcriptase inhibitor. Int J Clin Pharmacol Res. 1994;14(2):45-50.
DMBIR5P	RU	https://pubmed.ncbi.nlm.nih.gov/7530697

DMSB0J8	DI	DMSB0J8
DMSB0J8	DN	L-734217
DMSB0J8	MI	TT38RM1
DMSB0J8	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DMSB0J8	MT	DTT
DMSB0J8	MA	Modulator
DMSB0J8	RN	Nonpeptide glycoprotein IIb/IIIa inhibitors. 8. Antiplatelet activity and oral antithrombotic efficacy of L-734,217. J Pharmacol Exp Ther. 1996 Jul;278(1):62-73.
DMSB0J8	RU	https://www.ncbi.nlm.nih.gov/pubmed/8764336

DMHEKIN	DI	DMHEKIN
DMHEKIN	DN	LASINAVIR
DMHEKIN	MI	TT5FNQT
DMHEKIN	MN	Human immunodeficiency virus Protease (HIV PR)
DMHEKIN	MT	DTT
DMHEKIN	MA	Inhibitor
DMHEKIN	RN	Quantitative determination of CGP 61755, a protease inhibitor, in plasma and urine by high-performance liquid chromatography and fluorescence detection. J Chromatogr B Biomed Sci Appl. 1997 Aug 15;696(1):123-30.
DMHEKIN	RU	https://pubmed.ncbi.nlm.nih.gov/9300916

DMSRD5U	DI	DMSRD5U
DMSRD5U	DN	LBY-135
DMSRD5U	MI	TTW20TU
DMSRD5U	MN	TRAIL receptor 2 (TRAIL-R2)
DMSRD5U	MT	DTT
DMSRD5U	RN	Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors. Invest New Drugs. 2014 Feb;32(1):135-44.
DMSRD5U	RU	https://pubmed.ncbi.nlm.nih.gov/23589214

DM41RK2	DI	DM41RK2
DM41RK2	DN	LG100268
DM41RK2	MI	TTW38KT
DM41RK2	MN	Retinoic acid receptor alpha (RARA)
DM41RK2	MT	DTT
DM41RK2	MA	Agonist
DM41RK2	RN	Placental steroidogenesis in rats is independent of signaling pathways induced by retinoic acids. Gen Comp Endocrinol. 2009 Sep 15;163(3):285-91.
DM41RK2	RU	https://pubmed.ncbi.nlm.nih.gov/19409899

DM0PXGU	DI	DM0PXGU
DM0PXGU	DN	LG-101280
DM0PXGU	MI	TTJ584C
DM0PXGU	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DM0PXGU	MT	DTT
DM0PXGU	MA	Modulator
DM0PXGU	RN	A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent... Mol Endocrinol. 2005 Jun;19(6):1593-605.
DM0PXGU	RU	https://pubmed.ncbi.nlm.nih.gov/15831517

DM9LEGU	DI	DM9LEGU
DM9LEGU	DN	LGD2941
DM9LEGU	MI	TTS64P2
DM9LEGU	MN	Androgen receptor (AR)
DM9LEGU	MT	DTT
DM9LEGU	MA	Modulator
DM9LEGU	RN	Influence of testosterone and a novel SARM on gene expression in whole blood of Macaca fascicularis. J Steroid Biochem Mol Biol. 2009 Apr;114(3-5):167-73.
DM9LEGU	RU	https://pubmed.ncbi.nlm.nih.gov/19429447

DM7HLFD	DI	DM7HLFD
DM7HLFD	DN	Licofelone
DM7HLFD	MI	TT2J34L
DM7HLFD	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM7HLFD	MT	DTT
DM7HLFD	MA	Inhibitor
DM7HLFD	RN	Cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) selectivity of COX inhibitors. Prostaglandins Leukot Essent Fatty Acids. 2008 Feb;78(2):99-108.
DM7HLFD	RU	https://pubmed.ncbi.nlm.nih.gov/18280718

DM7HLFD	DI	DM7HLFD
DM7HLFD	DN	Licofelone
DM7HLFD	MI	DES5XRU
DM7HLFD	MN	Cytochrome P450 2C8 (CYP2C8)
DM7HLFD	MT	DME
DM7HLFD	MA	Metabolism
DM7HLFD	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM7HLFD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM7HLFD	DI	DM7HLFD
DM7HLFD	DN	Licofelone
DM7HLFD	MI	DE5IED8
DM7HLFD	MN	Cytochrome P450 2C9 (CYP2C9)
DM7HLFD	MT	DME
DM7HLFD	MA	Metabolism
DM7HLFD	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM7HLFD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM7HLFD	DI	DM7HLFD
DM7HLFD	DN	Licofelone
DM7HLFD	MI	DEF2WXN
DM7HLFD	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DM7HLFD	MT	DME
DM7HLFD	MA	Metabolism
DM7HLFD	RN	In vitro metabolism of 2-[6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl] acetic acid (licofelone, ML3000), an inhibitor of cyclooxygenase-1 and -2 and 5-lipoxygenase. Drug Metab Dispos. 2008 May;36(5):894-903.
DM7HLFD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18268076

DMMWCU3	DI	DMMWCU3
DMMWCU3	DN	Licostinel
DMMWCU3	MI	TT6L509
DMMWCU3	MN	Coagulation factor IIa (F2)
DMMWCU3	MT	DTT
DMMWCU3	MA	Inhibitor
DMMWCU3	RN	Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2003 Jan;3(1):9-20.
DMMWCU3	RU	https://pubmed.ncbi.nlm.nih.gov/12507405

DM9WEP5	DI	DM9WEP5
DM9WEP5	DN	LJP-1082
DM9WEP5	MI	TT2OUI9
DM9WEP5	MN	Beta-2-glycoprotein 1 (APOH)
DM9WEP5	MT	DTT
DM9WEP5	MA	Inhibitor
DM9WEP5	RN	Emergence of targeted immune therapies for systemic lupus. Expert Opin Emerg Drugs. 2005 Feb;10(1):53-65.
DM9WEP5	RU	https://pubmed.ncbi.nlm.nih.gov/15757403

DMSL0Y5	DI	DMSL0Y5
DMSL0Y5	DN	LOR-2501
DMSL0Y5	MI	TTWP0NS
DMSL0Y5	MN	RRM1 messenger RNA (RRM1 mRNA)
DMSL0Y5	MT	DTT
DMSL0Y5	RN	Non-covalent complexes of folic acid and oleic acid conjugated polyethylenimine: An efficient vehicle for antisense oligonucleotide delivery. Colloids Surf B Biointerfaces. 2015 Jul 26;135:274-282.
DMSL0Y5	RU	https://pubmed.ncbi.nlm.nih.gov/26263216

DMGUX5Y	DI	DMGUX5Y
DMGUX5Y	DN	Lu-AA38466
DMGUX5Y	MI	TTM7WCE
DMGUX5Y	MN	Ion channel unspecific (IC)
DMGUX5Y	MT	DTT
DMGUX5Y	MA	Modulator
DMGUX5Y	RN	Lundbeck is developing new and promising pharmaceuticals for the treatment of depression, anxiety and psychotic disorders and for new disease areas such as stroke and alcohol dependence. Pipeline report of Lundbeck in 2008.
DMGUX5Y	RU	http://www.e-pages.dk/lundbeck/157/swf/20.swf

DMH0AMG	DI	DMH0AMG
DMH0AMG	DN	Lu-AA44608
DMH0AMG	MI	TTKG67B
DMH0AMG	MN	Neuropeptide Y receptor (NPYR)
DMH0AMG	MT	DTT
DMH0AMG	MA	Antagonist
DMH0AMG	RN	CA patent application no. 690841, Synthetic bile acid composition, method, and preparation.
DMH0AMG	RU	http://www.google.com/patents/CA2690841A1?cl=en

DML86MJ	DI	DML86MJ
DML86MJ	DN	Lu-AA47070
DML86MJ	MI	TTM2AOE
DML86MJ	MN	Adenosine A2a receptor (ADORA2A)
DML86MJ	MT	DTT
DML86MJ	MA	Antagonist
DML86MJ	RN	The novel adenosine A2A antagonist Lu AA47070 reverses the motor and motivational effects produced by dopamine D2 receptor blockade. Pharmacol Biochem Behav. 2012 Jan;100(3):498-505.
DML86MJ	RU	https://pubmed.ncbi.nlm.nih.gov/22037410

DMKMIQ6	DI	DMKMIQ6
DMKMIQ6	DN	LY-315902
DMKMIQ6	MI	TTVIMDE
DMKMIQ6	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMKMIQ6	MT	DTT
DMKMIQ6	MA	Modulator
DMKMIQ6	RN	Glucagon-like peptide-1 analogue LY315902: effect on intestinal motility and release of insulin and somatostatin. Regul Pept. 2002 Jun 15;106(1-3):89-95.
DMKMIQ6	RU	https://pubmed.ncbi.nlm.nih.gov/12047915

DMNPJL3	DI	DMNPJL3
DMNPJL3	DN	LY-444711
DMNPJL3	MI	TTWDC17
DMNPJL3	MN	Growth hormone secretagogue receptor 1 (GHSR)
DMNPJL3	MT	DTT
DMNPJL3	MA	Agonist
DMNPJL3	RN	Synthesis and biological evaluation of an orally active ghrelin agonist that stimulates food consumption and adiposity in rats. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5873-6.
DMNPJL3	RU	https://pubmed.ncbi.nlm.nih.gov/15501059

DMB1OAR	DI	DMB1OAR
DMB1OAR	DN	LY-73497
DMB1OAR	MI	TT84ETX
DMB1OAR	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMB1OAR	MT	DTT
DMB1OAR	MA	Inhibitor
DMB1OAR	RN	Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36.
DMB1OAR	RU	https://pubmed.ncbi.nlm.nih.gov/8523406

DMVYG5X	DI	DMVYG5X
DMVYG5X	DN	LY-929
DMVYG5X	MI	TTJ584C
DMVYG5X	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMVYG5X	MT	DTT
DMVYG5X	MA	Agonist
DMVYG5X	RN	CN patent application no. 1882326, Ppar agonists for the treatment of hcv infection.
DMVYG5X	RU	http://www.google.com.ar/patents/CN1882326A?cl=en

DMVYG5X	DI	DMVYG5X
DMVYG5X	DN	LY-929
DMVYG5X	MI	TTZMAO3
DMVYG5X	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMVYG5X	MT	DTT
DMVYG5X	MA	Agonist
DMVYG5X	RN	CN patent application no. 1882326, Ppar agonists for the treatment of hcv infection.
DMVYG5X	RU	http://www.google.com.ar/patents/CN1882326A?cl=en

DMDUM0Z	DI	DMDUM0Z
DMDUM0Z	DN	LymphoRad-131
DMDUM0Z	MI	TTWMIDN
DMDUM0Z	MN	B-cell-activating factor (TNFSF13B)
DMDUM0Z	MT	DTT
DMDUM0Z	MA	Modulator
DMDUM0Z	RN	Fusion Toxin BLyS-Gelonin Inhibits Growth of Malignant Human B Cell Lines In Vitro and In Vivo. PLoS One. 2012; 7(10): e47361.
DMDUM0Z	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3467252/

DMP19KT	DI	DMP19KT
DMP19KT	DN	MBI 1121
DMP19KT	MI	TTK025N
DMP19KT	MN	Human papillomavirus E1 region messenger RNA (HPV E1 mRNA)
DMP19KT	MT	DTT
DMP19KT	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DMP19KT	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DMRIK2Y	DI	DMRIK2Y
DMRIK2Y	DN	MC-02,479
DMRIK2Y	MI	TTJP4SM
DMRIK2Y	MN	Bacterial Penicillin binding protein (Bact PBP)
DMRIK2Y	MT	DTT
DMRIK2Y	MA	Inhibitor
DMRIK2Y	RN	RWJ-54428 (MC-02,479), a new cephalosporin with high affinity for penicillin-binding proteins, including PBP 2a, and stability to staphylococcal be... Antimicrob Agents Chemother. 2003 Feb;47(2):658-64.
DMRIK2Y	RU	https://pubmed.ncbi.nlm.nih.gov/12543674

DMUMSFR	DI	DMUMSFR
DMUMSFR	DN	ME-3277
DMUMSFR	MI	TT38RM1
DMUMSFR	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DMUMSFR	MT	DTT
DMUMSFR	MA	Modulator
DMUMSFR	RN	ME3277, a GPIIb/IIIa antagonist reduces cerebral infarction without enhancing intracranial hemorrhage in photothrombotic occlusion of rabbit middle cerebral artery. J Cereb Blood Flow Metab. 2000 Jun;20(6):988-97.
DMUMSFR	RU	https://pubmed.ncbi.nlm.nih.gov/10894182

DMC2V5J	DI	DMC2V5J
DMC2V5J	DN	Mirisetron maleate
DMC2V5J	MI	TTNXLKE
DMC2V5J	MN	5-HT 3 receptor (5HT3R)
DMC2V5J	MT	DTT
DMC2V5J	MA	Modulator
DMC2V5J	RN	The effects of 5-HT3 receptor antagonists on cognitive performance in aged monkeys. Neurobiol Aging. 1997 Jan-Feb;18(1):21-8.
DMC2V5J	RU	https://pubmed.ncbi.nlm.nih.gov/8983029

DM23KBM	DI	DM23KBM
DM23KBM	DN	MIV-701
DM23KBM	MI	TTDZN01
DM23KBM	MN	Cathepsin K (CTSK)
DM23KBM	MT	DTT
DM23KBM	MA	Inhibitor
DM23KBM	RN	Medivir designates MIV-710 a Candidate Drug (CD) for Osteoporosis and Osteoarthritis, 2009
DM23KBM	RU	http://www.medivir.se/v5/en/uptodate/pressrelease.cfm?releaseid=D575F7294C8454BE&year=2009

DMNAJGK	DI	DMNAJGK
DMNAJGK	DN	MK-0963
DMNAJGK	MI	TT2A0DR
DMNAJGK	MN	Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A)
DMNAJGK	MT	DTT
DMNAJGK	MA	Inhibitor
DMNAJGK	RN	Pharmacodynamics of MK-0963, a new 5 alpha-reductase inhibitor: effects on serum androgen concentrations. Clin Pharmacol Ther. 1994 Jan;55(1):50-4.
DMNAJGK	RU	https://pubmed.ncbi.nlm.nih.gov/8299317

DMERKWM	DI	DMERKWM
DMERKWM	DN	MK-434
DMERKWM	MI	TT2A0DR
DMERKWM	MN	Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A)
DMERKWM	MT	DTT
DMERKWM	MA	Inhibitor
DMERKWM	RN	The effects of progesterone, 4,16-androstadien-3-one and MK-434 on the kinetics of pig testis microsomal testosterone-4-ene-5alpha-reductase activity. J Steroid Biochem Mol Biol. 1997 Mar;60(5-6):353-9.
DMERKWM	RU	https://pubmed.ncbi.nlm.nih.gov/9219928

DMB5NOI	DI	DMB5NOI
DMB5NOI	DN	MK-6592
DMB5NOI	MI	TTLYXIT
DMB5NOI	MN	Aurora kinase C (AURKC)
DMB5NOI	MT	DTT
DMB5NOI	MA	Inhibitor
DMB5NOI	RN	Clinical experience with aurora kinase inhibitors: a review. Oncologist. 2009 Aug;14(8):780-93.
DMB5NOI	RU	https://pubmed.ncbi.nlm.nih.gov/19684075

DMG72VK	DI	DMG72VK
DMG72VK	DN	MLN0415
DMG72VK	MI	TTJ3E9X
DMG72VK	MN	Inhibitor of nuclear factor kappa-B kinase beta (IKKB)
DMG72VK	MT	DTT
DMG72VK	MA	Modulator
DMG72VK	RN	Company report (Millennium)
DMG72VK	RU	http://investor.millennium.com/phoenix.zhtml?c=80159&p=irol-newsArticle_Print&ID=900341

DMQA5JW	DI	DMQA5JW
DMQA5JW	DN	MLN-2201
DMQA5JW	MI	TTIJWR7
DMQA5JW	MN	Integrin beta-2 (ITGB2)
DMQA5JW	MT	DTT
DMQA5JW	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010178)
DMQA5JW	RU	http://adisinsight.springer.com/drugs/800010178

DM2PUYI	DI	DM2PUYI
DM2PUYI	DN	MN-246
DM2PUYI	MI	TTMXGCW
DM2PUYI	MN	Adrenergic receptor beta-3 (ADRB3)
DM2PUYI	MT	DTT
DM2PUYI	MA	Agonist
DM2PUYI	RN	CA patent application no. 630818, Pharmaceutical composition for prevention or treatment of neurogenic pain.
DM2PUYI	RU	http://www.google.com/patents/CA2630818A1?cl=en

DMKHEQL	DI	DMKHEQL
DMKHEQL	DN	Mofarotene
DMKHEQL	MI	DEJGDUW
DMKHEQL	MN	Cytochrome P450 1A2 (CYP1A2)
DMKHEQL	MT	DME
DMKHEQL	MA	Metabolism
DMKHEQL	RN	Metabolism of mofarotene in hepatocytes and liver microsomes from different species. Comparison with in vivo data and evaluation of the cytochrome P450 isoenzymes involved in human biotransformation. Drug Metab Dispos. 1995 Oct;23(10):1051-7.
DMKHEQL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8654192

DMKHEQL	DI	DMKHEQL
DMKHEQL	DN	Mofarotene
DMKHEQL	MI	DE4LYSA
DMKHEQL	MN	Cytochrome P450 3A4 (CYP3A4)
DMKHEQL	MT	DME
DMKHEQL	MA	Metabolism
DMKHEQL	RN	Metabolism of mofarotene in hepatocytes and liver microsomes from different species. Comparison with in vivo data and evaluation of the cytochrome P450 isoenzymes involved in human biotransformation. Drug Metab Dispos. 1995 Oct;23(10):1051-7.
DMKHEQL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8654192

DMKHEQL	DI	DMKHEQL
DMKHEQL	DN	Mofarotene
DMKHEQL	MI	TT8WZ3Q
DMKHEQL	MN	Mitochondrial gene transcription (MGT)
DMKHEQL	MT	DTT
DMKHEQL	MA	Modulator
DMKHEQL	RN	Down-regulation of mitochondrial gene expression by the anti-tumor arotinoid mofarotene (Ro 40-8757). Int J Cancer. 1994 Sep 15;58(6):891-7.
DMKHEQL	RU	https://pubmed.ncbi.nlm.nih.gov/7927884

DMK91WR	DI	DMK91WR
DMK91WR	DN	MP-136
DMK91WR	MI	TTJ584C
DMK91WR	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMK91WR	MT	DTT
DMK91WR	MA	Agonist
DMK91WR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 593).
DMK91WR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=593

DMMVG34	DI	DMMVG34
DMMVG34	DN	MPC-0920
DMMVG34	MI	TT6L509
DMMVG34	MN	Coagulation factor IIa (F2)
DMMVG34	MT	DTT
DMMVG34	MA	Inhibitor
DMMVG34	RN	Clinical pipeline report, company report or official report of MYRIAD GENETICS, INC.
DMMVG34	RU	http://investor.myriad.com/secfiling.cfm?filingid=1193125-08-186392&cik=

DMCMNKV	DI	DMCMNKV
DMCMNKV	DN	MPC-9055
DMCMNKV	MI	TTFGZB6
DMCMNKV	MN	Human immunodeficiency virus GAG protein (HIV gag)
DMCMNKV	MT	DTT
DMCMNKV	MA	Inhibitor
DMCMNKV	RN	New Small-Molecule Inhibitor Class Targeting Human Immunodeficiency Virus Type 1 Virion Maturation . Antimicrob Agents Chemother. 2009 December; 53(12): 5080-5087.
DMCMNKV	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2786326/

DMCJ1B2	DI	DMCJ1B2
DMCJ1B2	DN	MT-500
DMCJ1B2	MI	TT0K1SC
DMCJ1B2	MN	5-HT 2B receptor (HTR2B)
DMCJ1B2	MT	DTT
DMCJ1B2	MA	Antagonist
DMCJ1B2	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMCJ1B2	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMC4RK7	DI	DMC4RK7
DMC4RK7	DN	MX-4509
DMC4RK7	MI	TTS64P2
DMC4RK7	MN	Androgen receptor (AR)
DMC4RK7	MT	DTT
DMC4RK7	MA	Antagonist
DMC4RK7	RN	Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor. Biochem Pharmacol. 1998 May 1;55(9):1427-33.
DMC4RK7	RU	https://pubmed.ncbi.nlm.nih.gov/10076535

DMC4RK7	DI	DMC4RK7
DMC4RK7	DN	MX-4509
DMC4RK7	MI	TTZAYWL
DMC4RK7	MN	Estrogen receptor (ESR)
DMC4RK7	MT	DTT
DMC4RK7	MA	Inhibitor
DMC4RK7	RN	Review of the effects of 17alpha-estradiol in humans: a less feminizing estrogen with neuroprotective potential. Article first published online: 9 FEB 2009.
DMC4RK7	RU	http://onlinelibrary.wiley.com/doi/10.1002/ddr.20284/pdf

DM4MTPU	DI	DM4MTPU
DM4MTPU	DN	NBI-42902
DM4MTPU	MI	TT8R70G
DM4MTPU	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DM4MTPU	MT	DTT
DM4MTPU	MA	Inhibitor
DM4MTPU	RN	Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor. J Med Chem. 2008 Dec 11;51(23):7478-85.
DM4MTPU	RU	https://pubmed.ncbi.nlm.nih.gov/19006286

DMMLESX	DI	DMMLESX
DMMLESX	DN	ND1251
DMMLESX	MI	TTNT7K8
DMMLESX	MN	Nociceptin receptor (OPRL1)
DMMLESX	MT	DTT
DMMLESX	MA	Agonist
DMMLESX	RN	The nociceptin receptor as a potential target in drug design. Drug News Perspect. 2001 Aug;14(6):335-45.
DMMLESX	RU	https://pubmed.ncbi.nlm.nih.gov/12813596

DMMLESX	DI	DMMLESX
DMMLESX	DN	ND1251
DMMLESX	MI	TTZSJIV
DMMLESX	MN	Sphingomyelin phosphodiesterase 4 (SMPD4)
DMMLESX	MT	DTT
DMMLESX	MA	Inhibitor
DMMLESX	RN	CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
DMMLESX	RU	http://www.centerwatch.com/

DMK5VB2	DI	DMK5VB2
DMK5VB2	DN	Nerisopam
DMK5VB2	MI	TTSQIFT
DMK5VB2	MN	5-HT 1A receptor (HTR1A)
DMK5VB2	MT	DTT
DMK5VB2	MA	Agonist
DMK5VB2	RN	Simultaneous determination of nerisopam, a novel anxiolytic agent showing polymorphic metabolism, and its N-acetyl metabolite from human plasma by a validated high performance liquid chromatographic method. J Chromatogr B Biomed Appl. 1996 Mar 29;678(1):63-72.
DMK5VB2	RU	https://pubmed.ncbi.nlm.nih.gov/8861657

DMXDLUH	DI	DMXDLUH
DMXDLUH	DN	NGD-4715
DMXDLUH	MI	TTX4RTB
DMXDLUH	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMXDLUH	MT	DTT
DMXDLUH	MA	Antagonist
DMXDLUH	RN	CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
DMXDLUH	RU	http://www.centerwatch.com/

DMZ9WLO	DI	DMZ9WLO
DMZ9WLO	DN	NGD-94-4
DMZ9WLO	MI	TTE0A2F
DMZ9WLO	MN	Dopamine D4 receptor (D4R)
DMZ9WLO	MT	DTT
DMZ9WLO	MA	Modulator
DMZ9WLO	RN	I. NGD 94-1: identification of a novel, high-affinity antagonist at the human dopamine D4 receptor. J Pharmacol Exp Ther. 1997 Aug;282(2):1011-9.
DMZ9WLO	RU	https://pubmed.ncbi.nlm.nih.gov/9262370

DMMT7BC	DI	DMMT7BC
DMMT7BC	DN	NIP-520
DMMT7BC	MI	TTZCG4L
DMMT7BC	MN	Phosphodiesterase 3 (PDE3)
DMMT7BC	MT	DTT
DMMT7BC	MA	Modulator
DMMT7BC	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMMT7BC	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM95NDT	DI	DM95NDT
DM95NDT	DN	NN-2501
DM95NDT	MI	TT9O6WS
DM95NDT	MN	Glucagon receptor (GCGR)
DM95NDT	MT	DTT
DM95NDT	MA	Antagonist
DM95NDT	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018428)
DM95NDT	RU	http://adisinsight.springer.com/drugs/800018428

DM8Z5VH	DI	DM8Z5VH
DM8Z5VH	DN	NN8210
DM8Z5VH	MI	TTHXFA1
DM8Z5VH	MN	C5a anaphylatoxin chemotactic receptor (C5AR1)
DM8Z5VH	MT	DTT
DM8Z5VH	MA	Modulator
DM8Z5VH	RN	Complement in immune and inflammatory disorders: therapeutic interventions. J Immunol. 2013 Apr 15;190(8):3839-47.
DM8Z5VH	RU	https://pubmed.ncbi.nlm.nih.gov/23564578

DMWDE8K	DI	DMWDE8K
DMWDE8K	DN	NOStentin
DMWDE8K	MI	TTF10I9
DMWDE8K	MN	Nitric-oxide synthase inducible (NOS2)
DMWDE8K	MT	DTT
DMWDE8K	MA	Modulator
DMWDE8K	RN	Gene therapy with iNOS provides long-term protection against myocardial infarction without adverse functional consequences. Am J Physiol Heart Circ Physiol. 2006 Feb;290(2):H584-9.
DMWDE8K	RU	https://pubmed.ncbi.nlm.nih.gov/16172153

DMT8IGE	DI	DMT8IGE
DMT8IGE	DN	NP-252
DMT8IGE	MI	TT5HONZ
DMT8IGE	MN	Calcium channel unspecific (CaC)
DMT8IGE	MT	DTT
DMT8IGE	MA	Blocker
DMT8IGE	RN	Pharmacological characteristics of NP-252, a new dihydropyridine slow Ca2+ channel blocker, in isolated rabbit vascular smooth muscle and guinea pig myocardium: vascular selectivity. Eur J Pharmacol.1991 Oct 22;203(3):337-44.
DMT8IGE	RU	https://pubmed.ncbi.nlm.nih.gov/1773820

DMXI5YW	DI	DMXI5YW
DMXI5YW	DN	NP-61
DMXI5YW	MI	TT1RS9F
DMXI5YW	MN	Acetylcholinesterase (AChE)
DMXI5YW	MT	DTT
DMXI5YW	MA	Inhibitor
DMXI5YW	RN	Potent beta-amyloid modulators. Neurodegener Dis. 2008;5(3-4):153-6.
DMXI5YW	RU	https://pubmed.ncbi.nlm.nih.gov/18322376

DMOMVW9	DI	DMOMVW9
DMOMVW9	DN	NPC-15669
DMOMVW9	MI	TTJAY96
DMOMVW9	MN	Polymorphonuclear neutrophil adhesion (PMNA)
DMOMVW9	MT	DTT
DMOMVW9	MA	Modulator
DMOMVW9	RN	NPC 15669-modulated human polymorphonuclear neutrophil functional responsiveness: effects on receptor-coupled signal transduction. Br J Pharmacol. 1995 Apr;114(8):1694-702.
DMOMVW9	RU	https://pubmed.ncbi.nlm.nih.gov/7599938

DMNL9DS	DI	DMNL9DS
DMNL9DS	DN	NSD-644
DMNL9DS	MI	TTVBI8W
DMNL9DS	MN	Dopamine transporter (DAT)
DMNL9DS	MT	DTT
DMNL9DS	MA	Activator
DMNL9DS	RN	NSD-644: Phase I started.NeuroSearch A/S (CSE:NEUR), Ballerup, Denmark, GlaxoSmithKline plc (LSE:GSK; GSK), London, U.K.
DMNL9DS	RU	http://www.biocentury.com/weekinreview/clinicalstatus/2007-12-10/nsd-644-phase-i-started-199006

DMNL9DS	DI	DMNL9DS
DMNL9DS	DN	NSD-644
DMNL9DS	MI	TTAWNKZ
DMNL9DS	MN	Norepinephrine transporter (NET)
DMNL9DS	MT	DTT
DMNL9DS	MA	Activator
DMNL9DS	RN	Clinical pipeline report, company report or official report of Neurosearch.
DMNL9DS	RU	http://www.neurosearch.dk/Admin/Public/Download.aspx?file=Files%2FFiler%2FPdf%2FFonds.08-08_-_selskabsmeddelelser_i_2007_-_uk.pdf

DMNL9DS	DI	DMNL9DS
DMNL9DS	DN	NSD-644
DMNL9DS	MI	TT3ROYC
DMNL9DS	MN	Serotonin transporter (SERT)
DMNL9DS	MT	DTT
DMNL9DS	MA	Activator
DMNL9DS	RN	NSD-644: Phase I started.NeuroSearch A/S (CSE:NEUR), Ballerup, Denmark, GlaxoSmithKline plc (LSE:GSK; GSK), London, U.K.
DMNL9DS	RU	http://www.biocentury.com/weekinreview/clinicalstatus/2007-12-10/nsd-644-phase-i-started-199006

DM1QZKS	DI	DM1QZKS
DM1QZKS	DN	NTC-801
DM1QZKS	MI	TT1VOHK
DM1QZKS	MN	Potassium channel unspecific (KC)
DM1QZKS	MT	DTT
DM1QZKS	MA	Inhibitor
DM1QZKS	RN	Effects of the selective KACh channel blocker NTC-801 on atrial fibrillation in a canine model of atrial tachypacing: comparison with class Ic and III drugs. J Cardiovasc Pharmacol. 2014 May;63(5):421-7.
DM1QZKS	RU	https://pubmed.ncbi.nlm.nih.gov/24805146

DMXJO5F	DI	DMXJO5F
DMXJO5F	DN	NZ-107
DMXJO5F	MI	TTTWGIX
DMXJO5F	MN	Leukotriene receptor (LTR)
DMXJO5F	MT	DTT
DMXJO5F	MA	Modulator
DMXJO5F	RN	Effects of NZ-107 on tracheal responses to adenosine in the guinea pig. Jpn J Pharmacol. 1991 May;56(1):79-84.
DMXJO5F	RU	https://pubmed.ncbi.nlm.nih.gov/1880989

DMZN6F3	DI	DMZN6F3
DMZN6F3	DN	Odapipam
DMZN6F3	MI	TTZFYLI
DMZN6F3	MN	Dopamine D1 receptor (D1R)
DMZN6F3	MT	DTT
DMZN6F3	MA	Antagonist
DMZN6F3	RN	PET studies of binding competition between endogenous dopamine and the D1 radiotracer [11C]NNC 756. Synapse. 1999 May;32(2):93-109.
DMZN6F3	RU	https://pubmed.ncbi.nlm.nih.gov/10231129

DM47ELH	DI	DM47ELH
DM47ELH	DN	Oncolysin M
DM47ELH	MI	TTJVYO3
DM47ELH	MN	Myeloid cell surface antigen CD33 (CD33)
DM47ELH	MT	DTT
DM47ELH	MA	Modulator
DM47ELH	RN	US patent application no. 6,926,898, Albumin fusion proteins.
DM47ELH	RU	http://www.google.com/patents/US6926898

DML7Q56	DI	DML7Q56
DML7Q56	DN	ONO-1714
DML7Q56	MI	TTF10I9
DML7Q56	MN	Nitric-oxide synthase inducible (NOS2)
DML7Q56	MT	DTT
DML7Q56	MA	Modulator
DML7Q56	RN	ONO-1714, a new inducible nitric oxide synthase inhibitor, attenuates diaphragmatic dysfunction associated with cerulein-induced pancreatitis in rats. Crit Care Med. 2001 Jun;29(6):1215-21.
DML7Q56	RU	https://www.ncbi.nlm.nih.gov/pubmed/11395607

DM8KN2M	DI	DM8KN2M
DM8KN2M	DN	ONO-2231
DM8KN2M	MI	TTEBCY8
DM8KN2M	MN	Poly [ADP-ribose] polymerase (PARP)
DM8KN2M	MT	DTT
DM8KN2M	MA	Modulator
DM8KN2M	RN	Company report (ONO PHARMACEUTICAL)
DM8KN2M	RU	https://www.ono.co.jp/eng/investor/pdf/fr/2006/fi0618.pdf

DMUSKY0	DI	DMUSKY0
DMUSKY0	DN	ONO-4127
DMUSKY0	MI	TTNVEIR
DMUSKY0	MN	Prostaglandin D2 receptor (PTGDR)
DMUSKY0	MT	DTT
DMUSKY0	MA	Antagonist
DMUSKY0	RN	Sleep-wake regulation by prostaglandin D2 and adenosine. Brain Nerve. 2012 Jun;64(6):621-8.
DMUSKY0	RU	https://pubmed.ncbi.nlm.nih.gov/22647469

DMKRVUN	DI	DMKRVUN
DMKRVUN	DN	ONO-4817
DMKRVUN	MI	TT1GHVO
DMKRVUN	MN	Matrix metalloproteinase (MMP)
DMKRVUN	MT	DTT
DMKRVUN	MA	Inhibitor
DMKRVUN	RN	ONO-4817, an orally active matrix metalloproteinase inhibitor, prevents lipopolysaccharide-induced proteoglycan release from the joint cartilage in guinea pigs. Inflamm Res. 2000 Apr;49(4):144-6.
DMKRVUN	RU	https://pubmed.ncbi.nlm.nih.gov/10858013

DMB8T5U	DI	DMB8T5U
DMB8T5U	DN	ONT-093
DMB8T5U	MI	TT3OT40
DMB8T5U	MN	Multidrug resistance protein 1 (ABCB1)
DMB8T5U	MT	DTT
DMB8T5U	MA	Inhibitor
DMB8T5U	RN	A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer. Invest New Drugs. 2005 Aug;23(4):311-5.
DMB8T5U	RU	https://pubmed.ncbi.nlm.nih.gov/16012790

DMDCOSP	DI	DMDCOSP
DMDCOSP	DN	OPC-51803
DMDCOSP	MI	TTK8R02
DMDCOSP	MN	Vasopressin V2 receptor (V2R)
DMDCOSP	MT	DTT
DMDCOSP	MA	Agonist
DMDCOSP	RN	Effects of OPC-51803, a novel, nonpeptide vasopressin V2-receptor agonist, on micturition frequency in Brattleboro and aged rats. J Pharmacol Sci. 2003 Dec;93(4):484-8.
DMDCOSP	RU	https://pubmed.ncbi.nlm.nih.gov/14737021

DMPDJC8	DI	DMPDJC8
DMPDJC8	DN	Opterone
DMPDJC8	MI	TTS64P2
DMPDJC8	MN	Androgen receptor (AR)
DMPDJC8	MT	DTT
DMPDJC8	MA	Inhibitor
DMPDJC8	RN	Evidence for a role of testosterone-androgen receptor interactions in mediating masculine sexual behavior in male rats. Endocrinology. 1989 Feb;124(2):618-26.
DMPDJC8	RU	https://pubmed.ncbi.nlm.nih.gov/2912689

DMB5TL9	DI	DMB5TL9
DMB5TL9	DN	Orazipone
DMB5TL9	MI	TTNSUK0
DMB5TL9	MN	Protein thiol group (PTG)
DMB5TL9	MT	DTT
DMB5TL9	MA	Modulator
DMB5TL9	RN	Antieosinophilic activity of orazipone. Mol Pharmacol. 2006 Jun;69(6):1861-70.
DMB5TL9	RU	https://pubmed.ncbi.nlm.nih.gov/16540599

DMQBURK	DI	DMQBURK
DMQBURK	DN	Ordopidine
DMQBURK	MI	TTEX248
DMQBURK	MN	Dopamine D2 receptor (D2R)
DMQBURK	MT	DTT
DMQBURK	MA	Modulator
DMQBURK	RN	The dopaminergic stabilizers pridopidine and ordopidine enhance cortico-striatal Arc gene expression. J Neural Transm. 2014 Nov;121(11):1337-47.
DMQBURK	RU	https://pubmed.ncbi.nlm.nih.gov/24817271

DMMYI9U	DI	DMMYI9U
DMMYI9U	DN	Org-21465
DMMYI9U	MI	TTEX6LM
DMMYI9U	MN	GABA(A) receptor gamma-3 (GABRG3)
DMMYI9U	MT	DTT
DMMYI9U	MA	Modulator
DMMYI9U	RN	Computer-controlled infusion of ORG 21465, a water soluble steroid i.v. anaesthetic agent, into human volunteers. Br J Anaesth. 1997 Oct;79(4):433-9.
DMMYI9U	RU	https://pubmed.ncbi.nlm.nih.gov/9389258

DMZKTU5	DI	DMZKTU5
DMZKTU5	DN	Org-31710
DMZKTU5	MI	TTUV8G9
DMZKTU5	MN	Progesterone receptor (PGR)
DMZKTU5	MT	DTT
DMZKTU5	MA	Modulator
DMZKTU5	RN	Progesterone receptor antagonists Org 31710 and RU 486 increase apoptosis in human periovulatory granulosa cells. Fertil Steril. 2001 Dec;76(6):1225-31.
DMZKTU5	RU	https://pubmed.ncbi.nlm.nih.gov/11730755

DM5UYI7	DI	DM5UYI7
DM5UYI7	DN	OX 19
DM5UYI7	MI	TTK8R02
DM5UYI7	MN	Vasopressin V2 receptor (V2R)
DM5UYI7	MT	DTT
DM5UYI7	MA	Agonist
DM5UYI7	RN	Investigation of mechanism of desmopressin binding in vasopressin V2 receptor versus vasopressin V1a and oxytocin receptors: molecular dynamics simulation of the agonist-bound state in the membrane-aqueous system. Biopolymers. 2006 Apr 5;81(5):321-38.
DM5UYI7	RU	https://pubmed.ncbi.nlm.nih.gov/16333859

DMF4KPM	DI	DMF4KPM
DMF4KPM	DN	PA-1050040
DMF4KPM	MI	TTFGZB6
DMF4KPM	MN	Human immunodeficiency virus GAG protein (HIV gag)
DMF4KPM	MT	DTT
DMF4KPM	MA	Inhibitor
DMF4KPM	RN	US patent application no. 2015,0105,350, Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections.
DMF4KPM	RU	http://www.google.com.ar/patents/US20150105350

DM6LQGO	DI	DM6LQGO
DM6LQGO	DN	Pafenolol
DM6LQGO	MI	TTMXGCW
DM6LQGO	MN	Adrenergic receptor beta-3 (ADRB3)
DM6LQGO	MT	DTT
DM6LQGO	MA	Modulator
DM6LQGO	RN	Presystemic elimination of the beta-blocker pafenolol in the rat after oral and intraperitoneal administration and identification of a main metabolite in both rats and humans. Drug Metab Dispos. 1993May-Jun;21(3):435-40.
DM6LQGO	RU	https://pubmed.ncbi.nlm.nih.gov/8100498

DM6LQGO	DI	DM6LQGO
DM6LQGO	DN	Pafenolol
DM6LQGO	MI	DTUGYRD
DM6LQGO	MN	P-glycoprotein 1 (ABCB1)
DM6LQGO	MT	DTP
DM6LQGO	MA	Substrate
DM6LQGO	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM6LQGO	RU	https://doi.org/10.1007/s11095-012-0935-x

DMVFGWM	DI	DMVFGWM
DMVFGWM	DN	PD-131112
DMVFGWM	MI	TTN6J5F
DMVFGWM	MN	Bacterial DNA gyrase (Bact gyrase)
DMVFGWM	MT	DTT
DMVFGWM	MA	Modulator
DMVFGWM	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMVFGWM	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM7KJTI	DI	DM7KJTI
DM7KJTI	DN	PD-153035
DM7KJTI	MI	TTGKNB4
DM7KJTI	MN	Epidermal growth factor receptor (EGFR)
DM7KJTI	MT	DTT
DM7KJTI	MA	Modulator
DM7KJTI	RN	EGFR tyrosine kinase inhibitor (PD153035) improves glucose tolerance and insulin action in high-fat diet-fed mice.Diabetes.2009 Dec;58(12):2910-9.
DM7KJTI	RU	https://www.ncbi.nlm.nih.gov/pubmed/19696185

DMO4S6T	DI	DMO4S6T
DMO4S6T	DN	PF-03814735
DMO4S6T	MI	TTPS3C0
DMO4S6T	MN	Aurora kinase A (AURKA)
DMO4S6T	MT	DTT
DMO4S6T	MA	Inhibitor
DMO4S6T	RN	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
DMO4S6T	RU	https://pubmed.ncbi.nlm.nih.gov/19568282

DMO4S6T	DI	DMO4S6T
DMO4S6T	DN	PF-03814735
DMO4S6T	MI	TT5LS6T
DMO4S6T	MN	Aurora kinase B (AURKB)
DMO4S6T	MT	DTT
DMO4S6T	MA	Inhibitor
DMO4S6T	RN	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
DMO4S6T	RU	https://pubmed.ncbi.nlm.nih.gov/19568282

DMD83VY	DI	DMD83VY
DMD83VY	DN	PF-05212372
DMD83VY	MI	TT9V5JH
DMD83VY	MN	Phospholipase A2 (PLA2G1B)
DMD83VY	MT	DTT
DMD83VY	MA	Inhibitor
DMD83VY	RN	Phagedena due to leishmaniasis. Immunologic and experimental studies. Ann Dermatol Syphiligr (Paris). 1976;103(1):23-30.
DMD83VY	RU	https://pubmed.ncbi.nlm.nih.gov/793505

DM68PYA	DI	DM68PYA
DM68PYA	DN	PF-05236812
DM68PYA	MI	TTE4KHA
DM68PYA	MN	Amyloid beta A4 protein (APP)
DM68PYA	MT	DTT
DM68PYA	MA	Inhibitor
DM68PYA	RN	Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets . Immun Ageing. 2013; 10: 18.
DM68PYA	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681567/

DMSE3WP	DI	DMSE3WP
DMSE3WP	DN	PF-06260414
DMSE3WP	MI	TTS64P2
DMSE3WP	MN	Androgen receptor (AR)
DMSE3WP	MT	DTT
DMSE3WP	MA	Modulator
DMSE3WP	RN	Phase I clinical trail of PF-06260414 for treating cachexia. Pfizer Inc.
DMSE3WP	RU	http://www.biocentury.com/products/pf-06260414

DM5R2MG	DI	DM5R2MG
DM5R2MG	DN	PF-2393296
DM5R2MG	MI	TTGXH6N
DM5R2MG	MN	GABA(A) receptor delta (GABRD)
DM5R2MG	MT	DTT
DM5R2MG	MA	Agonist
DM5R2MG	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 416).
DM5R2MG	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=416

DM2V7WH	DI	DM2V7WH
DM2V7WH	DN	PF-251802
DM2V7WH	MI	TTYRL6O
DM2V7WH	MN	Glucocorticoid receptor (NR3C1)
DM2V7WH	MT	DTT
DM2V7WH	MA	Agonist
DM2V7WH	RN	Glucocorticoids Pharmacology: Past, Present and Future. Current Pharmaceutical Design. VOLUME 16, ISSUE 32, Page(3540-3553), DOI: 10.2174/138161210793797915.
DM2V7WH	RU	http://www.eurekaselect.com/72976/article

DMOQZIW	DI	DMOQZIW
DMOQZIW	DN	PF-3052334
DMOQZIW	MI	TTPADOQ
DMOQZIW	MN	HMG-CoA reductase (HMGCR)
DMOQZIW	MT	DTT
DMOQZIW	MA	Inhibitor
DMOQZIW	RN	Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylca... J Med Chem. 2008 Jan 10;51(1):31-45.
DMOQZIW	RU	https://pubmed.ncbi.nlm.nih.gov/18072721

DMCFYZM	DI	DMCFYZM
DMCFYZM	DN	PF-3185043
DMCFYZM	MI	TTFQAYR
DMCFYZM	MN	Cholesteryl ester transfer protein (CETP)
DMCFYZM	MT	DTT
DMCFYZM	MA	Inhibitor
DMCFYZM	RN	Pfizer. Product Development Pipeline. March 31 2009.
DMCFYZM	RU	http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf

DMD42MN	DI	DMD42MN
DMD42MN	DN	PF-3274167
DMD42MN	MI	TTSCIUP
DMD42MN	MN	Oxytocin receptor (OTR)
DMD42MN	MT	DTT
DMD42MN	MA	Inhibitor
DMD42MN	RN	Oral oxytocin antagonists. J Med Chem. 2010 Sep 23;53(18):6525-38.
DMD42MN	RU	https://pubmed.ncbi.nlm.nih.gov/20550119

DMD42MN	DI	DMD42MN
DMD42MN	DN	PF-3274167
DMD42MN	MI	TT4TFGN
DMD42MN	MN	Vasopressin V1a receptor (V1AR)
DMD42MN	MT	DTT
DMD42MN	MA	Inhibitor
DMD42MN	RN	Oral oxytocin antagonists. J Med Chem. 2010 Sep 23;53(18):6525-38.
DMD42MN	RU	https://pubmed.ncbi.nlm.nih.gov/20550119

DMMU1W3	DI	DMMU1W3
DMMU1W3	DN	PF-3526299
DMMU1W3	MI	TTOU65C
DMMU1W3	MN	Tyrosine-protein kinase SYK (SYK)
DMMU1W3	MT	DTT
DMMU1W3	MA	Inhibitor
DMMU1W3	RN	Pipeline report of RIGEL Pharmaceuticals.
DMMU1W3	RU	http://www.rigel.com/index.php/pipeline/

DMITYCN	DI	DMITYCN
DMITYCN	DN	PF-3557156
DMITYCN	MI	TT1BC3A
DMITYCN	MN	Phosphodiesterase 7A (PDE7A)
DMITYCN	MT	DTT
DMITYCN	MA	Modulator
DMITYCN	RN	Company report (Pfizer pipeline: October 28, 2008)
DMITYCN	RU	https://www.pfizer.com/files/investors/presentations/acr_102808_v2.pdf

DMITYCN	DI	DMITYCN
DMITYCN	DN	PF-3557156
DMITYCN	MI	TTWIEY9
DMITYCN	MN	Phosphodiesterase 7B (PDE7B)
DMITYCN	MT	DTT
DMITYCN	MA	Modulator
DMITYCN	RN	Company report (Pfizer pipeline: October 28, 2008)
DMITYCN	RU	https://www.pfizer.com/files/investors/presentations/acr_102808_v2.pdf

DMNLAU7	DI	DMNLAU7
DMNLAU7	DN	PF-4629991
DMNLAU7	MI	TT9JZCK
DMNLAU7	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMNLAU7	MT	DTT
DMNLAU7	MA	Agonist
DMNLAU7	RN	US patent application no. 2010,0158,905, Combination therapy of arthritis with tranilast.
DMNLAU7	RU	https://www.google.com/patents/US20100158905

DMDOTW0	DI	DMDOTW0
DMDOTW0	DN	PF-477736
DMDOTW0	MI	TTTU902
DMDOTW0	MN	Checkpoint kinase-1 (CHK1)
DMDOTW0	MT	DTT
DMDOTW0	MA	Inhibitor
DMDOTW0	RN	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
DMDOTW0	RU	https://pubmed.ncbi.nlm.nih.gov/19568282

DMS7M0U	DI	DMS7M0U
DMS7M0U	DN	PF-514273
DMS7M0U	MI	TT6OEDT
DMS7M0U	MN	Cannabinoid receptor 1 (CB1)
DMS7M0U	MT	DTT
DMS7M0U	MA	Modulator
DMS7M0U	RN	Effects of the novel cannabinoid CB1 receptor antagonist PF 514273 on the acquisition and expression of ethanol conditioned place preference. Alcohol. 2014 Aug;48(5):427-31.
DMS7M0U	RU	https://pubmed.ncbi.nlm.nih.gov/24954022

DMB7EIN	DI	DMB7EIN
DMB7EIN	DN	PF-915275
DMB7EIN	MI	TTN7BL9
DMB7EIN	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMB7EIN	MT	DTT
DMB7EIN	MA	Inhibitor
DMB7EIN	RN	N-(Pyridin-2-yl) arylsulfonamide inhibitors of 11beta-hydroxysteroid dehydrogenase type 1: Discovery of PF-915275. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3493-7.
DMB7EIN	RU	https://pubmed.ncbi.nlm.nih.gov/19473839

DMAPD6M	DI	DMAPD6M
DMAPD6M	DN	PLD-147
DMAPD6M	MI	TTUTN1I
DMAPD6M	MN	Human Deoxyribonucleic acid (hDNA)
DMAPD6M	MT	DTT
DMAPD6M	MA	Binder
DMAPD6M	RN	The new platinum(IV) derivative LA-12 shows stronger inhibitory effect on Hsp90 function compared to cisplatin. Mol Cancer. 2010 Jun 15;9:147.
DMAPD6M	RU	https://pubmed.ncbi.nlm.nih.gov/20550649

DMFKC7L	DI	DMFKC7L
DMFKC7L	DN	PN-355
DMFKC7L	MI	TTJSQEF
DMFKC7L	MN	Tyrosine-protein kinase (PTK)
DMFKC7L	MT	DTT
DMFKC7L	MA	Inhibitor
DMFKC7L	RN	WO patent application no. 2005,0502,03, Biological materials and uses thereof.
DMFKC7L	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20050602&CC=WO&NR=2005050203A2&KC=A2

DMPWG2K	DI	DMPWG2K
DMPWG2K	DN	PNU-142721
DMPWG2K	MI	TT84ETX
DMPWG2K	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMPWG2K	MT	DTT
DMPWG2K	MA	Inhibitor
DMPWG2K	RN	Activation of the human nuclear xenobiotic receptor PXR by the reverse transcriptase-targeted anti-HIV drug PNU-142721. Protein Sci. 2011 Oct;20(10):1713-9.
DMPWG2K	RU	https://pubmed.ncbi.nlm.nih.gov/21805522

DMG2WAX	DI	DMG2WAX
DMG2WAX	DN	Prostate cancer vaccine
DMG2WAX	MI	TT8R70G
DMG2WAX	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMG2WAX	MT	DTT
DMG2WAX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 256).
DMG2WAX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=256

DM4LNBQ	DI	DM4LNBQ
DM4LNBQ	DN	Pyroxamide
DM4LNBQ	MI	TT6R7JZ
DM4LNBQ	MN	Histone deacetylase 1 (HDAC1)
DM4LNBQ	MT	DTT
DM4LNBQ	MA	Inhibitor
DM4LNBQ	RN	Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92.
DM4LNBQ	RU	https://pubmed.ncbi.nlm.nih.gov/17896917

DMU93JL	DI	DMU93JL
DMU93JL	DN	R 80122
DMU93JL	MI	TTZCG4L
DMU93JL	MN	Phosphodiesterase 3 (PDE3)
DMU93JL	MT	DTT
DMU93JL	MA	Modulator
DMU93JL	RN	Inhibition of human cardiac cyclic AMP-phosphodiesterases by R 80122, a new selective cyclic AMP-phosphodiesterase III inhibitor: a comparison with other cardiotonic compounds. J Pharmacol Exp Ther. 1992 Oct;263(1):6-14.
DMU93JL	RU	https://pubmed.ncbi.nlm.nih.gov/1328613

DMHPV1D	DI	DMHPV1D
DMHPV1D	DN	R-1065
DMHPV1D	MI	TTWJBZ5
DMHPV1D	MN	5-HT 2C receptor (HTR2C)
DMHPV1D	MT	DTT
DMHPV1D	MA	Agonist
DMHPV1D	RN	Antiaversive effects of 5HT2C receptor agonists and fluoxetine in a model of panic-like anxiety in rats. Eur Neuropsychopharmacol. 1998 Aug;8(3):161-8.
DMHPV1D	RU	https://pubmed.ncbi.nlm.nih.gov/9716307

DML7M3S	DI	DML7M3S
DML7M3S	DN	R-1068
DML7M3S	MI	TTXEU7H
DML7M3S	MN	GPCR unspecific (GPCR)
DML7M3S	MT	DTT
DML7M3S	MA	Modulator
DML7M3S	RN	R 1068 Roche discontinued, Europe (emesis). R & D Focus Drug New. February 16, 2004
DML7M3S	RU	http://business.highbeam.com/436989/article-1G1-113216640/r-1068-roche-discontinued-europe

DMRHF97	DI	DMRHF97
DMRHF97	DN	R1204
DMRHF97	MI	TTXEU7H
DMRHF97	MN	GPCR unspecific (GPCR)
DMRHF97	MT	DTT
DMRHF97	MA	Modulator
DMRHF97	RN	Clinical pipeline report, company report or official report of Roche.
DMRHF97	RU	http://www.roche.com/pages/downloads/investor/pdf/praesentations/irp2702ch.pdf

DMT8V9G	DI	DMT8V9G
DMT8V9G	DN	R1295
DMT8V9G	MI	TT7ZMI1
DMT8V9G	MN	Integrin alpha-4/beta-7 (ITGA4/B7)
DMT8V9G	MT	DTT
DMT8V9G	MA	Modulator
DMT8V9G	RN	Vedolizumab: an 47 integrin inhibitor for inflammatory bowel diseases.Ann Pharmacother.2014 Dec;48(12):1629-35.
DMT8V9G	RU	https://www.ncbi.nlm.nih.gov/pubmed/25186623

DM9C6LN	DI	DM9C6LN
DM9C6LN	DN	R-1479
DM9C6LN	MI	TT79JGK
DM9C6LN	MN	Mycobacterium RNA polymerase (MycB RNAP)
DM9C6LN	MT	DTT
DM9C6LN	MA	Inhibitor
DM9C6LN	RN	The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cel... J Biol Chem. 2006 Feb 17;281(7):3793-9.
DM9C6LN	RU	https://pubmed.ncbi.nlm.nih.gov/16316989

DM7WPI0	DI	DM7WPI0
DM7WPI0	DN	R-1487
DM7WPI0	MI	TTQBR95
DM7WPI0	MN	Stress-activated protein kinase 2a (p38 alpha)
DM7WPI0	MT	DTT
DM7WPI0	MA	Inhibitor
DM7WPI0	RN	Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors of p38alpha mitogen-activated protein kinase. J Med Chem. 2011 Apr 14;54(7):2255-65.
DM7WPI0	RU	https://pubmed.ncbi.nlm.nih.gov/21375264

DM2J5AO	DI	DM2J5AO
DM2J5AO	DN	R-1518
DM2J5AO	MI	TTCAQMW
DM2J5AO	MN	Inosine-5'-monophosphate dehydrogenase (IMPDH)
DM2J5AO	MT	DTT
DM2J5AO	MA	Modulator
DM2J5AO	RN	US patent application no. 2010,0092,479, Compositions and methods for treatment of viral diseases.
DM2J5AO	RU	http://www.google.com/patents/US20100092479

DMK25FU	DI	DMK25FU
DMK25FU	DN	R547
DMK25FU	MI	TTH6V3D
DMK25FU	MN	Cyclin-dependent kinase 1 (CDK1)
DMK25FU	MT	DTT
DMK25FU	MA	Inhibitor
DMK25FU	RN	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
DMK25FU	RU	https://pubmed.ncbi.nlm.nih.gov/19568282

DMK25FU	DI	DMK25FU
DMK25FU	DN	R547
DMK25FU	MI	TT7HF4W
DMK25FU	MN	Cyclin-dependent kinase 2 (CDK2)
DMK25FU	MT	DTT
DMK25FU	MA	Inhibitor
DMK25FU	RN	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
DMK25FU	RU	https://pubmed.ncbi.nlm.nih.gov/19568282

DMK25FU	DI	DMK25FU
DMK25FU	DN	R547
DMK25FU	MI	TT0PG8F
DMK25FU	MN	Cyclin-dependent kinase 4 (CDK4)
DMK25FU	MT	DTT
DMK25FU	MA	Inhibitor
DMK25FU	RN	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
DMK25FU	RU	https://pubmed.ncbi.nlm.nih.gov/19568282

DMK25FU	DI	DMK25FU
DMK25FU	DN	R547
DMK25FU	MI	TTQYF7G
DMK25FU	MN	Cyclin-dependent kinase 7 (CDK7)
DMK25FU	MT	DTT
DMK25FU	MA	Inhibitor
DMK25FU	RN	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
DMK25FU	RU	https://pubmed.ncbi.nlm.nih.gov/19568282

DMF3A6H	DI	DMF3A6H
DMF3A6H	DN	R-701
DMF3A6H	MI	TTXEU7H
DMF3A6H	MN	GPCR unspecific (GPCR)
DMF3A6H	MT	DTT
DMF3A6H	MA	Antagonist
DMF3A6H	RN	R 701 Roche discontinued, USA (overactive bladder), R & D Focus Drug News. February 23, 2004
DMF3A6H	RU	http://business.highbeam.com/436989/article-1G1-113440920/r-701-roche-discontinued-usa

DMETAP8	DI	DMETAP8
DMETAP8	DN	R7232
DMETAP8	MI	TTFQAYR
DMETAP8	MN	Cholesteryl ester transfer protein (CETP)
DMETAP8	MT	DTT
DMETAP8	MA	Inhibitor
DMETAP8	RN	Clinical pipeline report, company report or official report of Roche (2009).
DMETAP8	RU	http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm

DMTK3DR	DI	DMTK3DR
DMTK3DR	DN	R-82150
DMTK3DR	MI	TT84ETX
DMTK3DR	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMTK3DR	MT	DTT
DMTK3DR	MA	Modulator
DMTK3DR	RN	Kinetic interaction of human immunodeficiency virus type 1 reverse transcriptase with the antiviral tetrahydroimidazo[4,5,1-jk]-[1,4]-benzodiazepin... J Biol Chem. 1991 Aug 5;266(22):14232-6.
DMTK3DR	RU	https://www.ncbi.nlm.nih.gov/pubmed/1713579

DM4WJHY	DI	DM4WJHY
DM4WJHY	DN	R-82913
DM4WJHY	MI	TT84ETX
DM4WJHY	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM4WJHY	MT	DTT
DM4WJHY	MA	Modulator
DM4WJHY	RN	A TIBO derivative, R82913, is a potent inhibitor of HIV-1 reverse transcriptase with heteropolymer templates. Antiviral Res. 1991 Oct;16(3):257-66.
DM4WJHY	RU	https://www.ncbi.nlm.nih.gov/pubmed/1725247

DMJ2ZVW	DI	DMJ2ZVW
DMJ2ZVW	DN	R-944
DMJ2ZVW	MI	TT5FNQT
DMJ2ZVW	MN	Human immunodeficiency virus Protease (HIV PR)
DMJ2ZVW	MT	DTT
DMJ2ZVW	MA	Inhibitor
DMJ2ZVW	RN	CN patent application no. 101115713, Hiv protease inhibitors.
DMJ2ZVW	RU	http://www.google.com/patents/CN101115713A?cl=en

DMVID8E	DI	DMVID8E
DMVID8E	DN	Ramorelix
DMVID8E	MI	TT8R70G
DMVID8E	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMVID8E	MT	DTT
DMVID8E	MA	Antagonist
DMVID8E	RN	Effects of the luteinizing-hormone-releasing hormone (LHRH) antagonist ramorelix (hoe013) and the LHRH agonist buserelin on dimethylbenz[]anthracene-induced mammary carcinoma: studies with slow-release formulations. J Cancer Res Clin Oncol. 1993;119(8):457-62.
DMVID8E	RU	https://pubmed.ncbi.nlm.nih.gov/8509436

DM3V5O2	DI	DM3V5O2
DM3V5O2	DN	RB-6145
DM3V5O2	MI	TTUTN1I
DM3V5O2	MN	Human Deoxyribonucleic acid (hDNA)
DM3V5O2	MT	DTT
DM3V5O2	MA	Binder
DM3V5O2	RN	Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. II. RSU 1069.. Br J Cancer. 1995 March; 71(3): 537-542.
DM3V5O2	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033631/

DMR6QMJ	DI	DMR6QMJ
DMR6QMJ	DN	RC-8800
DMR6QMJ	MI	TTTHCPF
DMR6QMJ	MN	Cholesterol 24-monooxygenase (CYP46A1)
DMR6QMJ	MT	DTT
DMR6QMJ	MA	Inhibitor
DMR6QMJ	RN	Clinical pipeline report, company report or official report of Boston Millennia Partners.
DMR6QMJ	RU	http://www.bostonmillenniapartners.com/OurPortfolio/Default.asp?PortfolioCompanyID=68

DM0ILRU	DI	DM0ILRU
DM0ILRU	DN	RDEA-436
DM0ILRU	MI	TTIDAPM
DM0ILRU	MN	ERK activator kinase 1 (MEK1)
DM0ILRU	MT	DTT
DM0ILRU	MA	Inhibitor
DM0ILRU	RN	Clinical pipeline report, company report or official report of MedKoo Biosciences.
DM0ILRU	RU	http://www.medkoo.com/Anticancer-trials/RDEA-436.htm

DM0ILRU	DI	DM0ILRU
DM0ILRU	DN	RDEA-436
DM0ILRU	MI	TTTW2NY
DM0ILRU	MN	ERK activator kinase 2 (MEK2)
DM0ILRU	MT	DTT
DM0ILRU	MA	Inhibitor
DM0ILRU	RN	Clinical pipeline report, company report or official report of MedKoo Biosciences.
DM0ILRU	RU	http://www.medkoo.com/Anticancer-trials/RDEA-436.htm

DMW08TD	DI	DMW08TD
DMW08TD	DN	REGN 3048
DMW08TD	MI	TT85VHW
DMW08TD	MN	MERS-CoV spike glycoprotein (S)
DMW08TD	MT	DTT
DMW08TD	MA	Inhibitor
DMW08TD	RN	Pre- And Postexposure Efficacy of Fully Human Antibodies Against Spike Protein in a Novel Humanized Mouse Model of MERS-CoV Infection. Proc Natl Acad Sci U S A. 2015 Jul 14;112(28):8738-43. doi: 10.1073/pnas.1510830112.
DMW08TD	RU	https://pubmed.ncbi.nlm.nih.gov/26124093

DMLH28J	DI	DMLH28J
DMLH28J	DN	REGN 3051
DMLH28J	MI	TT85VHW
DMLH28J	MN	MERS-CoV spike glycoprotein (S)
DMLH28J	MT	DTT
DMLH28J	MA	Inhibitor
DMLH28J	RN	Pre- And Postexposure Efficacy of Fully Human Antibodies Against Spike Protein in a Novel Humanized Mouse Model of MERS-CoV Infection. Proc Natl Acad Sci U S A. 2015 Jul 14;112(28):8738-43. doi: 10.1073/pnas.1510830112.
DMLH28J	RU	https://pubmed.ncbi.nlm.nih.gov/26124093

DMT5VXF	DI	DMT5VXF
DMT5VXF	DN	Revatropate
DMT5VXF	MI	TTQ13Z5
DMT5VXF	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMT5VXF	MT	DTT
DMT5VXF	MA	Modulator
DMT5VXF	RN	Discovery &amp; development of selective M3 antagonists for clinical use.Life Sci.1997;60(13-14):1053-60.
DMT5VXF	RU	https://www.ncbi.nlm.nih.gov/pubmed/9121347

DMW4G68	DI	DMW4G68
DMW4G68	DN	RG-201
DMW4G68	MI	TT1D5X3
DMW4G68	MN	Pneumocystis jirovecii DNA topoisomerase 2 (PJ top2)
DMW4G68	MT	DTT
DMW4G68	MA	Modulator
DMW4G68	RN	US patent application no. 2004,0023,290, Novel therapeutic agents that modulate enzymatic processes.
DMW4G68	RU	http://www.google.com/patents/US20040023290

DMOI037	DI	DMOI037
DMOI037	DN	RG-4934
DMOI037	MI	TTG0MT6
DMOI037	MN	Interleukin-17 (IL17)
DMOI037	MT	DTT
DMOI037	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032677)
DMOI037	RU	http://adisinsight.springer.com/drugs/800032677

DMG9U8D	DI	DMG9U8D
DMG9U8D	DN	RG-7152
DMG9U8D	MI	TTGKOY9
DMG9U8D	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DMG9U8D	MT	DTT
DMG9U8D	MA	Antagonist
DMG9U8D	RN	Induction of peroxisomal enzymes by a tetrazole-substituted 2-quinolinylmethoxy leukotriene D4 antagonist. Fundam Appl Toxicol. 1994 Aug;23(2):298-303.
DMG9U8D	RU	https://pubmed.ncbi.nlm.nih.gov/7982537

DMKLPMW	DI	DMKLPMW
DMKLPMW	DN	RG-7166
DMKLPMW	MI	TTVBI8W
DMKLPMW	MN	Dopamine transporter (DAT)
DMKLPMW	MT	DTT
DMKLPMW	MA	Inhibitor
DMKLPMW	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031598)
DMKLPMW	RU	http://adisinsight.springer.com/drugs/800031598

DMKLPMW	DI	DMKLPMW
DMKLPMW	DN	RG-7166
DMKLPMW	MI	TTAWNKZ
DMKLPMW	MN	Norepinephrine transporter (NET)
DMKLPMW	MT	DTT
DMKLPMW	MA	Inhibitor
DMKLPMW	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031598)
DMKLPMW	RU	http://adisinsight.springer.com/drugs/800031598

DMKLPMW	DI	DMKLPMW
DMKLPMW	DN	RG-7166
DMKLPMW	MI	TT3ROYC
DMKLPMW	MN	Serotonin transporter (SERT)
DMKLPMW	MT	DTT
DMKLPMW	MA	Inhibitor
DMKLPMW	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031598)
DMKLPMW	RU	http://adisinsight.springer.com/drugs/800031598

DMGLRK0	DI	DMGLRK0
DMGLRK0	DN	RG-7167
DMGLRK0	MI	TTROQ37
DMGLRK0	MN	MAPK/ERK kinase kinase (MAP3K)
DMGLRK0	MT	DTT
DMGLRK0	MA	Inhibitor
DMGLRK0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2063).
DMGLRK0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2063

DM12VHC	DI	DM12VHC
DM12VHC	DN	RG-7185
DM12VHC	MI	TTQDMX5
DM12VHC	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DM12VHC	MT	DTT
DM12VHC	MA	Antagonist
DM12VHC	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033115)
DM12VHC	RU	http://adisinsight.springer.com/drugs/800033115

DMDPWCM	DI	DMDPWCM
DMDPWCM	DN	RG-7236
DMDPWCM	MI	TTUMQVO
DMDPWCM	MN	Cathepsin S (CTSS)
DMDPWCM	MT	DTT
DMDPWCM	MA	Inhibitor
DMDPWCM	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2353).
DMDPWCM	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2353

DM0LXBW	DI	DM0LXBW
DM0LXBW	DN	RG-7256
DM0LXBW	MI	TTWCGQT
DM0LXBW	MN	Serine/threonine-protein kinase B-raf (BRAF)
DM0LXBW	MT	DTT
DM0LXBW	MA	Inhibitor
DM0LXBW	RN	First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors. Target Oncol. 2016 Apr;11(2):149-56.
DM0LXBW	RU	https://pubmed.ncbi.nlm.nih.gov/26310975

DMXMQAT	DI	DMXMQAT
DMXMQAT	DN	RG-7273
DMXMQAT	MI	TTJW1GN
DMXMQAT	MN	ATP-binding cassette transporter A1 (ABCA1)
DMXMQAT	MT	DTT
DMXMQAT	MA	Inducer
DMXMQAT	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 756).
DMXMQAT	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=756

DMUR6OV	DI	DMUR6OV
DMUR6OV	DN	RG-7356
DMUR6OV	MI	TTG8DNU
DMUR6OV	MN	Hyaluronic acid receptor (LYVE1)
DMUR6OV	MT	DTT
DMUR6OV	RN	Preclinical evaluation of 89Zr-labeled anti-CD44 monoclonal antibody RG7356 in mice and cynomolgus monkeys: Prelude to Phase 1 clinical studies. MAbs. 2014 Mar-Apr;6(2):567-75.
DMUR6OV	RU	https://pubmed.ncbi.nlm.nih.gov/24492295

DMXRHDL	DI	DMXRHDL
DMXRHDL	DN	RG7418
DMXRHDL	MI	TTKSND3
DMXRHDL	MN	Lectin-like oxidized LDL receptor (OLR1)
DMXRHDL	MT	DTT
DMXRHDL	MA	Modulator
DMXRHDL	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMXRHDL	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMSUV3B	DI	DMSUV3B
DMSUV3B	DN	RG-7432
DMSUV3B	MI	TTMVBWH
DMSUV3B	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMSUV3B	MT	DTT
DMSUV3B	MA	Inhibitor
DMSUV3B	RN	Chutes and Ladders in Hepatitis C Nucleoside Drug Development. Antiviral Res. 2014 February; 102: 119-147.
DMSUV3B	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910353/

DMW87YE	DI	DMW87YE
DMW87YE	DN	RG7458
DMW87YE	MI	TTC1PS3
DMW87YE	MN	Ovarian carcinoma antigen CA125 (MUC16)
DMW87YE	MT	DTT
DMW87YE	RN	Phase I clinical trail of RG7458 for treating Ovarian cancer. Genentech Inc.
DMW87YE	RU	http://www.biocentury.com/products/rg7458

DMXJAFC	DI	DMXJAFC
DMXJAFC	DN	RG7602
DMXJAFC	MI	TTTU902
DMXJAFC	MN	Checkpoint kinase-1 (CHK1)
DMXJAFC	MT	DTT
DMXJAFC	MA	Modulator
DMXJAFC	RN	National Cancer Institute Drug Dictionary (drug id 701310).
DMXJAFC	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=701310

DMQAK6T	DI	DMQAK6T
DMQAK6T	DN	Rhodamine-123
DMQAK6T	MI	DTI7UX6
DMQAK6T	MN	Breast cancer resistance protein (ABCG2)
DMQAK6T	MT	DTP
DMQAK6T	MA	Substrate
DMQAK6T	RN	Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo. Exp Mol Med. 2017 Mar 17;49(3):e303.
DMQAK6T	RU	http://www.ncbi.nlm.nih.gov/pubmed/28303028

DMQAK6T	DI	DMQAK6T
DMQAK6T	DN	Rhodamine-123
DMQAK6T	MI	DTFI42L
DMQAK6T	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMQAK6T	MT	DTP
DMQAK6T	MA	Substrate
DMQAK6T	RN	Characterization of rhodamine-123, calcein and 5(6)-carboxy-2',7'-dichlorofluorescein (CDCF) export via MRP2 (ABCC2) in MES-SA and A549 cells. Eur J Pharm Sci. 2011 Aug 17;43(5):359-69.
DMQAK6T	RU	https://doi.org/10.1016/j.ejps.2011.05.003

DMQAK6T	DI	DMQAK6T
DMQAK6T	DN	Rhodamine-123
DMQAK6T	MI	DTE2B1D
DMQAK6T	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMQAK6T	MT	DTP
DMQAK6T	MA	Substrate
DMQAK6T	RN	Characterization of rhodamine-123 as a tracer dye for use in in vitro drug transport assays. PLoS One. 2012;7(3):e33253.
DMQAK6T	RU	https://doi.org/10.1371/journal.pone.0033253

DMQAK6T	DI	DMQAK6T
DMQAK6T	DN	Rhodamine-123
DMQAK6T	MI	DTUGYRD
DMQAK6T	MN	P-glycoprotein 1 (ABCB1)
DMQAK6T	MT	DTP
DMQAK6T	MA	Substrate
DMQAK6T	RN	Modulation of drug-stimulated ATPase activity of human MDR1/P-glycoprotein by cholesterol. Biochem J. 2007 Jan 15;401(2):597-605.
DMQAK6T	RU	http://www.ncbi.nlm.nih.gov/pubmed/17029589

DMLQD6F	DI	DMLQD6F
DMLQD6F	DN	RIG-200
DMLQD6F	MI	TTLBYH1
DMLQD6F	MN	Guanylate cyclase soluble beta-1 (GUCY1B1)
DMLQD6F	MT	DTT
DMLQD6F	MA	Modulator
DMLQD6F	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMLQD6F	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMBQZTO	DI	DMBQZTO
DMBQZTO	DN	Rilmakalim
DMBQZTO	MI	TT1VOHK
DMBQZTO	MN	Potassium channel unspecific (KC)
DMBQZTO	MT	DTT
DMBQZTO	MA	Opener
DMBQZTO	RN	Hypotonic stress increases efficacy of rilmakalim, but not pinacidil, to activate ATP-sensitive K(+) current in guinea pig ventricular myocytes. J Pharmacol Sci. 2004 Jun;95(2):189-95.
DMBQZTO	RU	https://pubmed.ncbi.nlm.nih.gov/15215643

DMOVZDY	DI	DMOVZDY
DMOVZDY	DN	RO-16-8714
DMOVZDY	MI	TTMXGCW
DMOVZDY	MN	Adrenergic receptor beta-3 (ADRB3)
DMOVZDY	MT	DTT
DMOVZDY	MA	Modulator
DMOVZDY	RN	The novel thermogenic beta-adrenergic agonist Ro 16-8714 increases the interscapular brown-fat beta-receptor-adenylate cyclase and the uncoupling-protein mRNA level in obese (fa/fa) Zucker rats. Biochem J. 1989 Aug 1;261(3):721-4.
DMOVZDY	RU	https://pubmed.ncbi.nlm.nih.gov/2572217

DMAJDPN	DI	DMAJDPN
DMAJDPN	DN	Ro-31-6930
DMAJDPN	MI	TT1VOHK
DMAJDPN	MN	Potassium channel unspecific (KC)
DMAJDPN	MT	DTT
DMAJDPN	MA	Opener
DMAJDPN	RN	Evaluation of the bronchodilator properties of Ro 31-6930, a novel potassium channel opener, in the guinea-pig. Br J Pharmacol. 1990 Jun;100(2):289-94.
DMAJDPN	RU	https://pubmed.ncbi.nlm.nih.gov/2379034

DMOX8AD	DI	DMOX8AD
DMOX8AD	DN	RO-48-8684
DMOX8AD	MI	TTEX6LM
DMOX8AD	MN	GABA(A) receptor gamma-3 (GABRG3)
DMOX8AD	MT	DTT
DMOX8AD	MA	Modulator
DMOX8AD	RN	Integrated pharmacokinetics and pharmacodynamics of Ro 48-8684, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects. Br J Clin Pharmacol. 1997 Nov;44(5):487-93.
DMOX8AD	RU	https://pubmed.ncbi.nlm.nih.gov/9384466

DMMF0OP	DI	DMMF0OP
DMMF0OP	DN	RO-4987655
DMMF0OP	MI	TTROQ37
DMMF0OP	MN	MAPK/ERK kinase kinase (MAP3K)
DMMF0OP	MT	DTT
DMMF0OP	MA	Modulator
DMMF0OP	RN	MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013; 6: 27.
DMMF0OP	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626705/

DMP0YNU	DI	DMP0YNU
DMP0YNU	DN	RO7040547
DMP0YNU	MI	TT0GVCH
DMP0YNU	MN	Interleukin-13 (IL13)
DMP0YNU	MT	DTT
DMP0YNU	MA	Inhibitor
DMP0YNU	RN	Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.
DMP0YNU	RU	https://pubmed.ncbi.nlm.nih.gov/31175342

DMP0YNU	DI	DMP0YNU
DMP0YNU	DN	RO7040547
DMP0YNU	MI	TTG0MT6
DMP0YNU	MN	Interleukin-17 (IL17)
DMP0YNU	MT	DTT
DMP0YNU	MA	Inhibitor
DMP0YNU	RN	Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.
DMP0YNU	RU	https://pubmed.ncbi.nlm.nih.gov/31175342

DMMK42O	DI	DMMK42O
DMMK42O	DN	Roquinimex
DMMK42O	MI	DE4LYSA
DMMK42O	MN	Cytochrome P450 3A4 (CYP3A4)
DMMK42O	MT	DME
DMMK42O	MA	Metabolism
DMMK42O	RN	Identification of cytochrome P4503A as the major subfamily responsible for the metabolism of roquinimex in man. Xenobiotica. 2000 Sep;30(9):905-14.
DMMK42O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11055268

DMMK42O	DI	DMMK42O
DMMK42O	DN	Roquinimex
DMMK42O	MI	TTF89GD
DMMK42O	MN	Interleukin-2 (IL2)
DMMK42O	MT	DTT
DMMK42O	MA	Modulator
DMMK42O	RN	The novel immunomodulator, Linomide, stimulates interleukin-2-induced human natural killer (NK) cell and PHA-stimulated T cell proliferation from normal donors. Leuk Res. 1996 Jan;20(1):57-63.
DMMK42O	RU	https://pubmed.ncbi.nlm.nih.gov/8632678

DM94R8B	DI	DM94R8B
DM94R8B	DN	RS-100975
DM94R8B	MI	TTNGILX
DM94R8B	MN	Adrenergic receptor alpha-1A (ADRA1A)
DM94R8B	MT	DTT
DM94R8B	MA	Antagonist
DM94R8B	RN	In vitro alpha1-adrenoceptor pharmacology of Ro 70-0004 and RS-100329, novel alpha1A-adrenoceptor selective antagonists. Br J Pharmacol. 1999 May;127(1):252-8.
DM94R8B	RU	https://pubmed.ncbi.nlm.nih.gov/10369480

DM4P5WO	DI	DM4P5WO
DM4P5WO	DN	RS-8891
DM4P5WO	MI	TTB2MXP
DM4P5WO	MN	Angiotensinogenase renin (REN)
DM4P5WO	MT	DTT
DM4P5WO	MA	Inhibitor
DM4P5WO	RN	Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertension Research (2006) 29, 997-1005. doi:10.1291/hypres.29.997
DM4P5WO	RU	http://www.nature.com/hr/journal/v29/n12/full/hr2006137a.html

DMMEAZ2	DI	DMMEAZ2
DMMEAZ2	DN	RU-58841
DMMEAZ2	MI	TTKPW01
DMMEAZ2	MN	Androgen receptor messenger RNA (AR mRNA)
DMMEAZ2	MT	DTT
DMMEAZ2	MA	Inhibitor
DMMEAZ2	RN	Rational design and synthesis of 4-((1R,2R)-2-hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a novel, nonsteroidal androgen recepto... J Med Chem. 2008 Nov 13;51(21):7010-4.
DMMEAZ2	RU	https://pubmed.ncbi.nlm.nih.gov/18921992

DMSHYAP	DI	DMSHYAP
DMSHYAP	DN	RUS 3108
DMSHYAP	MI	TT5UM29
DMSHYAP	MN	Perlecan (HSPG)
DMSHYAP	MT	DTT
DMSHYAP	MA	Modulator
DMSHYAP	RN	A perlecan-inducing compound significantly inhibits smooth muscle cell function and in-stent intimal hyperplasia: novel insights into the diverse biological effects of perlecan. EuroIntervention. 2010 May;6(1):134-40.
DMSHYAP	RU	https://pubmed.ncbi.nlm.nih.gov/20542809

DM6BIHE	DI	DM6BIHE
DM6BIHE	DN	RWJ-56423
DM6BIHE	MI	TT2WR1T
DM6BIHE	MN	Cationic trypsinogen (PRSS1)
DM6BIHE	MT	DTT
DM6BIHE	MA	Inhibitor
DM6BIHE	RN	Inhibitors of serine proteases as potential therapeutic agents: the road from thrombin to tryptase to cathepsin G. J Med Chem. 2004 Feb 12;47(4):769-87.
DM6BIHE	RU	https://pubmed.ncbi.nlm.nih.gov/14761180

DMRXB8F	DI	DMRXB8F
DMRXB8F	DN	S-1746
DMRXB8F	MI	TTAN6JD
DMRXB8F	MN	Glutamate receptor AMPA (GRIA)
DMRXB8F	MT	DTT
DMRXB8F	MA	Antagonist
DMRXB8F	RN	1,026 experimental treatments in acute stroke. Ann Neurol. 2006 Mar;59(3):467-77.
DMRXB8F	RU	https://pubmed.ncbi.nlm.nih.gov/16453316

DMRXB8F	DI	DMRXB8F
DMRXB8F	DN	S-1746
DMRXB8F	MI	TT9IK2Z
DMRXB8F	MN	N-methyl-D-aspartate receptor (NMDAR)
DMRXB8F	MT	DTT
DMRXB8F	MA	Antagonist
DMRXB8F	RN	1,026 experimental treatments in acute stroke. Ann Neurol. 2006 Mar;59(3):467-77.
DMRXB8F	RU	https://pubmed.ncbi.nlm.nih.gov/16453316

DMX59E8	DI	DMX59E8
DMX59E8	DN	S-18326
DMX59E8	MI	TT6L509
DMX59E8	MN	Coagulation factor IIa (F2)
DMX59E8	MT	DTT
DMX59E8	MA	Inhibitor
DMX59E8	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMX59E8	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DML6A8X	DI	DML6A8X
DML6A8X	DN	S-18327
DML6A8X	MI	TTEX248
DML6A8X	MN	Dopamine D2 receptor (D2R)
DML6A8X	MT	DTT
DML6A8X	MA	Modulator
DML6A8X	RN	S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile. J Pharmacol Exp Ther. 2000 Jan;292(1):38-53.
DML6A8X	RU	https://pubmed.ncbi.nlm.nih.gov/10604930

DM80P4U	DI	DM80P4U
DM80P4U	DN	S-234462
DM80P4U	MI	TTY6EWA
DM80P4U	MN	Neuropeptide Y receptor type 5 (NPY5R)
DM80P4U	MT	DTT
DM80P4U	MA	Antagonist
DM80P4U	RN	Clinical pipeline report, company report or official report of Shionogi (2011).
DM80P4U	RU	http://www.shionogi.co.jp/index_e.html

DM6SON1	DI	DM6SON1
DM6SON1	DN	S-23906-1
DM6SON1	MI	TTUTN1I
DM6SON1	MN	Human Deoxyribonucleic acid (hDNA)
DM6SON1	MT	DTT
DM6SON1	MA	Binder
DM6SON1	RN	Induction of cyclin E and inhibition of DNA synthesis by the novel acronycine derivative S23906-1 precede the irreversible arrest of tumor cells in S phase leading to apoptosis. Mol Pharmacol. 2001 Dec;60(6):1383-91.
DM6SON1	RU	https://pubmed.ncbi.nlm.nih.gov/11723246

DM1R8Z7	DI	DM1R8Z7
DM1R8Z7	DN	S-33138
DM1R8Z7	MI	TT4C8EA
DM1R8Z7	MN	Dopamine D3 receptor (D3R)
DM1R8Z7	MT	DTT
DM1R8Z7	MA	Antagonist
DM1R8Z7	RN	The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures. Int J Neuropsychopharmacol. 2010 Sep;13(8):1035-51.
DM1R8Z7	RU	https://pubmed.ncbi.nlm.nih.gov/20663270

DMZYRI3	DI	DMZYRI3
DMZYRI3	DN	S-3536
DMZYRI3	MI	TT1GHVO
DMZYRI3	MN	Matrix metalloproteinase (MMP)
DMZYRI3	MT	DTT
DMZYRI3	MA	Inhibitor
DMZYRI3	RN	CIINE Reflects Collagenase-Specific CII Breakdown in Cartilage Explant and Whole Body of Canine. Biomark Insights. 2013; 8: 77-83.
DMZYRI3	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3694827/

DMCEOAJ	DI	DMCEOAJ
DMCEOAJ	DN	Sabcomeline
DMCEOAJ	MI	TTZ9SOR
DMCEOAJ	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMCEOAJ	MT	DTT
DMCEOAJ	MA	Agonist
DMCEOAJ	RN	Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur J Pharmacol. 2009 Mar 1;605(1-3):53-6.
DMCEOAJ	RU	https://pubmed.ncbi.nlm.nih.gov/19168056

DMIZ7Q4	DI	DMIZ7Q4
DMIZ7Q4	DN	SAR101099
DMIZ7Q4	MI	TTW5UDX
DMIZ7Q4	MN	Urotensin II receptor (UTS2R)
DMIZ7Q4	MT	DTT
DMIZ7Q4	MA	Antagonist
DMIZ7Q4	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 365).
DMIZ7Q4	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=365

DM7OR48	DI	DM7OR48
DM7OR48	DN	SAR-152954
DM7OR48	MI	TT9JNIC
DM7OR48	MN	Histamine H3 receptor (H3R)
DM7OR48	MT	DTT
DM7OR48	MA	Antagonist
DM7OR48	RN	Clinical pipeline report, company report or official report of Sanofi.
DM7OR48	RU	https://ncats.nih.gov/files/SAR152954.pdf

DMNH8XU	DI	DMNH8XU
DMNH8XU	DN	SB 235699
DMNH8XU	MI	TTYT93M
DMNH8XU	MN	MAP kinase p38 (MAPK12)
DMNH8XU	MT	DTT
DMNH8XU	MA	Inhibitor
DMNH8XU	RN	Synthesis and structure-activity relationship of aminobenzophenones. A novel class of p38 MAP kinase inhibitors with high antiinflammatory activity. J Med Chem. 2003 Dec 18;46(26):5651-62.
DMNH8XU	RU	https://pubmed.ncbi.nlm.nih.gov/14667219

DMNH8XU	DI	DMNH8XU
DMNH8XU	DN	SB 235699
DMNH8XU	MI	TTQBR95
DMNH8XU	MN	Stress-activated protein kinase 2a (p38 alpha)
DMNH8XU	MT	DTT
DMNH8XU	MA	Inhibitor
DMNH8XU	RN	Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
DMNH8XU	RU	https://pubmed.ncbi.nlm.nih.gov/11804650

DMNH8XU	DI	DMNH8XU
DMNH8XU	DN	SB 235699
DMNH8XU	MI	TT73U6C
DMNH8XU	MN	Stress-activated protein kinase 2b (p38 beta)
DMNH8XU	MT	DTT
DMNH8XU	MA	Inhibitor
DMNH8XU	RN	Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
DMNH8XU	RU	https://pubmed.ncbi.nlm.nih.gov/11804650

DM2C0LN	DI	DM2C0LN
DM2C0LN	DN	SB 249417
DM2C0LN	MI	TTFEZ5Q
DM2C0LN	MN	Coagulation factor IX (F9)
DM2C0LN	MT	DTT
DM2C0LN	RN	Pharmacokinetic and pharmacodynamic modeling of humanized anti-factor IX antibody (SB 249417) in humans. Clin Pharmacol Ther. 2002 Apr;71(4):235-45.
DM2C0LN	RU	https://pubmed.ncbi.nlm.nih.gov/11956506

DMGHDTB	DI	DMGHDTB
DMGHDTB	DN	SB 418790
DMGHDTB	MI	TTMXGCW
DMGHDTB	MN	Adrenergic receptor beta-3 (ADRB3)
DMGHDTB	MT	DTT
DMGHDTB	MA	Agonist
DMGHDTB	RN	News and Analysis. Nature Reviews Drug Discovery 1, 257-258 (April 2002).
DMGHDTB	RU	http://www.nature.com/nrd/journal/v1/n4/fig_tab/nrd781_T1.html

DMX7PNY	DI	DMX7PNY
DMX7PNY	DN	SB-234551
DMX7PNY	MI	TTKRD0G
DMX7PNY	MN	Endothelin A receptor (EDNRA)
DMX7PNY	MT	DTT
DMX7PNY	MA	Antagonist
DMX7PNY	RN	Effects of the novel selective endothelin ET(A) receptor antagonist, SB 234551, on the cardiovascular responses to endotoxaemia in conscious rats. Br J Pharmacol. 2001 Aug;133(8):1371-7.
DMX7PNY	RU	https://pubmed.ncbi.nlm.nih.gov/11498524

DMKSFL0	DI	DMKSFL0
DMKSFL0	DN	SB-242235
DMKSFL0	MI	TT9AZWY
DMKSFL0	MN	HSPB1 messenger RNA (HSPB1 mRNA)
DMKSFL0	MT	DTT
DMKSFL0	MA	Inhibitor
DMKSFL0	RN	Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes. Bioorg Med Chem Lett. 2008 Aug 1;18(15):4433-7.
DMKSFL0	RU	https://pubmed.ncbi.nlm.nih.gov/18602262

DMKSFL0	DI	DMKSFL0
DMKSFL0	DN	SB-242235
DMKSFL0	MI	TTQBR95
DMKSFL0	MN	Stress-activated protein kinase 2a (p38 alpha)
DMKSFL0	MT	DTT
DMKSFL0	MA	Inhibitor
DMKSFL0	RN	Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes. Bioorg Med Chem Lett. 2008 Aug 1;18(15):4433-7.
DMKSFL0	RU	https://pubmed.ncbi.nlm.nih.gov/18602262

DMOVLDT	DI	DMOVLDT
DMOVLDT	DN	SB-247853
DMOVLDT	MI	TTWJBZ5
DMOVLDT	MN	5-HT 2C receptor (HTR2C)
DMOVLDT	MT	DTT
DMOVLDT	MA	Agonist
DMOVLDT	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016366)
DMOVLDT	RU	http://adisinsight.springer.com/drugs/800016366

DMIBFAV	DI	DMIBFAV
DMIBFAV	DN	SB-267268
DMIBFAV	MI	TT69TQN
DMIBFAV	MN	Integrin alpha-V/beta-3 (ITGAV/B3)
DMIBFAV	MT	DTT
DMIBFAV	MA	Modulator
DMIBFAV	RN	SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1600-5.
DMIBFAV	RU	https://pubmed.ncbi.nlm.nih.gov/16565398

DMIBFAV	DI	DMIBFAV
DMIBFAV	DN	SB-267268
DMIBFAV	MI	TTPRDH7
DMIBFAV	MN	Integrin alpha-V/beta-5 (ITGAV/B5)
DMIBFAV	MT	DTT
DMIBFAV	MA	Modulator
DMIBFAV	RN	SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1600-5.
DMIBFAV	RU	https://pubmed.ncbi.nlm.nih.gov/16565398

DMV7M1H	DI	DMV7M1H
DMV7M1H	DN	SB-273005
DMV7M1H	MI	TT69TQN
DMV7M1H	MN	Integrin alpha-V/beta-3 (ITGAV/B3)
DMV7M1H	MT	DTT
DMV7M1H	MA	Modulator
DMV7M1H	RN	Disease-modifying activity of SB 273005, an orally active, nonpeptide alphavbeta3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthri... Arthritis Rheum. 2001 Jan;44(1):128-37.
DMV7M1H	RU	https://www.ncbi.nlm.nih.gov/pubmed/11212150

DMYTAJW	DI	DMYTAJW
DMYTAJW	DN	SB-281832
DMYTAJW	MI	TTWELHI
DMYTAJW	MN	Stress-activated protein kinase (p38)
DMYTAJW	MT	DTT
DMYTAJW	MA	Inhibitor
DMYTAJW	RN	p38 MAPK inhibitors ameliorate target organ damage in hypertension: Part 1. p38 MAPK-dependent endothelial dysfunction and hypertension. J Pharmacol Exp Ther. 2003 Dec;307(3):932-8.
DMYTAJW	RU	https://pubmed.ncbi.nlm.nih.gov/14561851

DM57HZW	DI	DM57HZW
DM57HZW	DN	SB-332235
DM57HZW	MI	TT30C9G
DM57HZW	MN	C-X-C chemokine receptor type 2 (CXCR2)
DM57HZW	MT	DTT
DM57HZW	MA	Antagonist
DM57HZW	RN	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
DM57HZW	RU	https://pubmed.ncbi.nlm.nih.gov/16634702

DM92BXN	DI	DM92BXN
DM92BXN	DN	SB-435495
DM92BXN	MI	TT9V5JH
DM92BXN	MN	Phospholipase A2 (PLA2G1B)
DM92BXN	MT	DTT
DM92BXN	MA	Inhibitor
DM92BXN	RN	The effect of lipoprotein-associated phospholipase A2 deficiency on pulmonary allergic responses in Aspergillus fumigatus sensitized mice. Respir Res. 2012 Nov 12;13:100.
DM92BXN	RU	https://pubmed.ncbi.nlm.nih.gov/23140447

DMFC19E	DI	DMFC19E
DMFC19E	DN	SC-52012
DMFC19E	MI	TT38RM1
DMFC19E	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DMFC19E	MT	DTT
DMFC19E	MA	Modulator
DMFC19E	RN	Characterization of Binding of an RGD Mimetic, [(3)H]-SC-52012, to Platelet GPIIb/IIIa. Platelets. 1995;6(5):288-95.
DMFC19E	RU	https://pubmed.ncbi.nlm.nih.gov/21043715

DMIVRWS	DI	DMIVRWS
DMIVRWS	DN	SC-57666
DMIVRWS	MI	TTVKILB
DMIVRWS	MN	Prostaglandin G/H synthase 2 (COX-2)
DMIVRWS	MT	DTT
DMIVRWS	MA	Inhibitor
DMIVRWS	RN	New cyclooxygenase-2/5-lipoxygenase inhibitors. 2. 7-tert-butyl-2,3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflamm... J Med Chem. 1998 Mar 26;41(7):1124-37.
DMIVRWS	RU	https://pubmed.ncbi.nlm.nih.gov/9544212

DM92E0W	DI	DM92E0W
DM92E0W	DN	SCH-211803
DM92E0W	MI	TTYEG6Q
DM92E0W	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DM92E0W	MT	DTT
DM92E0W	MA	Inhibitor
DM92E0W	RN	Improving the oral efficacy of CNS drug candidates: discovery of highly orally efficacious piperidinyl piperidine M2 muscarinic receptor antagonists. J Med Chem. 2002 Dec 5;45(25):5415-8.
DM92E0W	RU	https://pubmed.ncbi.nlm.nih.gov/12459007

DMK40VO	DI	DMK40VO
DMK40VO	DN	SCH-351591
DMK40VO	MI	TTZ97H5
DMK40VO	MN	Phosphodiesterase 4A (PDE4A)
DMK40VO	MT	DTT
DMK40VO	MA	Inhibitor
DMK40VO	RN	Synthesis and profile of SCH351591, a novel PDE4 inhibitor. Bioorg Med Chem Lett. 2002 Jun 17;12(12):1621-3.
DMK40VO	RU	https://pubmed.ncbi.nlm.nih.gov/12039576

DMK40VO	DI	DMK40VO
DMK40VO	DN	SCH-351591
DMK40VO	MI	TTVIAT9
DMK40VO	MN	Phosphodiesterase 4B (PDE4B)
DMK40VO	MT	DTT
DMK40VO	MA	Inhibitor
DMK40VO	RN	Synthesis and profile of SCH351591, a novel PDE4 inhibitor. Bioorg Med Chem Lett. 2002 Jun 17;12(12):1621-3.
DMK40VO	RU	https://pubmed.ncbi.nlm.nih.gov/12039576

DMK40VO	DI	DMK40VO
DMK40VO	DN	SCH-351591
DMK40VO	MI	TTSKMI8
DMK40VO	MN	Phosphodiesterase 4D (PDE4D)
DMK40VO	MT	DTT
DMK40VO	MA	Inhibitor
DMK40VO	RN	Synthesis and profile of SCH351591, a novel PDE4 inhibitor. Bioorg Med Chem Lett. 2002 Jun 17;12(12):1621-3.
DMK40VO	RU	https://pubmed.ncbi.nlm.nih.gov/12039576

DM8J9SF	DI	DM8J9SF
DM8J9SF	DN	SCH-C
DM8J9SF	MI	TT2CEJG
DM8J9SF	MN	C-C chemokine receptor type 5 (CCR5)
DM8J9SF	MT	DTT
DM8J9SF	MA	Binder
DM8J9SF	RN	Progress in targeting HIV-1 entry. Drug Discov Today. 2005 Aug 15;10(16):1085-94.
DM8J9SF	RU	https://pubmed.ncbi.nlm.nih.gov/16182193

DM8J9SF	DI	DM8J9SF
DM8J9SF	DN	SCH-C
DM8J9SF	MI	TTJIH8Q
DM8J9SF	MN	CCR5 messenger RNA (CCR5 mRNA)
DM8J9SF	MT	DTT
DM8J9SF	MA	Antagonist
DM8J9SF	RN	Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2005 Dec;49(12):4911-9.
DM8J9SF	RU	https://pubmed.ncbi.nlm.nih.gov/16304152

DM8BIV4	DI	DM8BIV4
DM8BIV4	DN	SDZ-210-086
DM8BIV4	MI	TTZ9SOR
DM8BIV4	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DM8BIV4	MT	DTT
DM8BIV4	MA	Agonist
DM8BIV4	RN	Influence of the cholinergic agonist SDZ 210-086 on sleep in healthy subjects. Neuropsychopharmacology. 1993 Nov;9(3):225-32.
DM8BIV4	RU	https://pubmed.ncbi.nlm.nih.gov/8280346

DMU3TQJ	DI	DMU3TQJ
DMU3TQJ	DN	SDZ-62-434
DMU3TQJ	MI	TTQL5VC
DMU3TQJ	MN	Platelet-activating factor receptor (PTAFR)
DMU3TQJ	MT	DTT
DMU3TQJ	MA	Antagonist
DMU3TQJ	RN	In vitro antitumour activity of the novel imidazoisoquinoline SDZ 62-434. Br J Cancer. 1993 May;67(5):989-95.
DMU3TQJ	RU	https://pubmed.ncbi.nlm.nih.gov/8388233

DM70MJQ	DI	DM70MJQ
DM70MJQ	DN	SDZ-CPI-975
DM70MJQ	MI	TTDL0NY
DM70MJQ	MN	Carnitine O-palmitoyltransferase I (CPT1B)
DM70MJQ	MT	DTT
DM70MJQ	MA	Inhibitor
DM70MJQ	RN	Hypoglycemic effects of a novel fatty acid oxidation inhibitor in rats and monkeys. Am J Physiol. 1998 Feb;274(2 Pt 2):R524-8.
DM70MJQ	RU	https://pubmed.ncbi.nlm.nih.gov/9486313

DM1C0K4	DI	DM1C0K4
DM1C0K4	DN	SDZ-GLC-756
DM1C0K4	MI	TTZFYLI
DM1C0K4	MN	Dopamine D1 receptor (D1R)
DM1C0K4	MT	DTT
DM1C0K4	MA	Modulator
DM1C0K4	RN	SDZ GLC 756, a novel octahydrobenzo[g]quinoline derivative exerts opposing effects on dopamine D1 and D2 receptors. J Neural Transm. 1996;103(1-2):17-30.
DM1C0K4	RU	https://pubmed.ncbi.nlm.nih.gov/9026371

DM1C0K4	DI	DM1C0K4
DM1C0K4	DN	SDZ-GLC-756
DM1C0K4	MI	TTEX248
DM1C0K4	MN	Dopamine D2 receptor (D2R)
DM1C0K4	MT	DTT
DM1C0K4	MA	Modulator
DM1C0K4	RN	SDZ GLC 756, a novel octahydrobenzo[g]quinoline derivative exerts opposing effects on dopamine D1 and D2 receptors. J Neural Transm. 1996;103(1-2):17-30.
DM1C0K4	RU	https://pubmed.ncbi.nlm.nih.gov/9026371

DM8C3G5	DI	DM8C3G5
DM8C3G5	DN	SDZ-NKT-343
DM8C3G5	MI	TTZPO1L
DM8C3G5	MN	Substance-P receptor (TACR1)
DM8C3G5	MT	DTT
DM8C3G5	MA	Antagonist
DM8C3G5	RN	The effects of SDZ NKT 343, a potent NK1 receptor antagonist, on cutaneous responses of primate spinothalamic tract neurones sensitized by intradermal capsaicin injection. Exp Brain Res. 1998 Aug;121(3):355-8.
DM8C3G5	RU	https://pubmed.ncbi.nlm.nih.gov/9746141

DMTOH03	DI	DMTOH03
DMTOH03	DN	SDZ-NVI-085
DMTOH03	MI	TTNGILX
DMTOH03	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMTOH03	MT	DTT
DMTOH03	MA	Antagonist
DMTOH03	RN	SDZ NVI 085, an alpha 1A-adrenoceptor agonist with 5-HT2A receptor antagonist properties. Eur J Pharmacol. 1996 Feb 15;297(1-2):83-6.
DMTOH03	RU	https://pubmed.ncbi.nlm.nih.gov/8851170

DMZHOYM	DI	DMZHOYM
DMZHOYM	DN	SDZ-PCO-400
DMZHOYM	MI	TT1VOHK
DMZHOYM	MN	Potassium channel unspecific (KC)
DMZHOYM	MT	DTT
DMZHOYM	MA	Opener
DMZHOYM	RN	Effects of a potassium channel opener (SDZ PCO 400) on guinea-pig and human pulmonary airways. Br J Pharmacol. 1992 Jun;106(2):423-9.
DMZHOYM	RU	https://pubmed.ncbi.nlm.nih.gov/1382782

DMFLOT4	DI	DMFLOT4
DMFLOT4	DN	SDZ-WAG-994
DMFLOT4	MI	TTK25J1
DMFLOT4	MN	Adenosine A1 receptor (ADORA1)
DMFLOT4	MT	DTT
DMFLOT4	MA	Agonist
DMFLOT4	RN	The cardiac effects of a novel A1-adenosine receptor agonist in guinea pig isolated heart. J Pharmacol Exp Ther. 1994 Dec;271(3):1371-82.
DMFLOT4	RU	https://pubmed.ncbi.nlm.nih.gov/7996449

DMCQI25	DI	DMCQI25
DMCQI25	DN	SEP-226332
DMCQI25	MI	TTNXLKE
DMCQI25	MN	5-HT 3 receptor (5HT3R)
DMCQI25	MT	DTT
DMCQI25	MA	Antagonist
DMCQI25	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020129)
DMCQI25	RU	http://adisinsight.springer.com/drugs/800020129

DMTGCSX	DI	DMTGCSX
DMTGCSX	DN	SIM-916
DMTGCSX	MI	TTSXVID
DMTGCSX	MN	Nuclear factor NF-kappa-B (NFKB)
DMTGCSX	MT	DTT
DMTGCSX	MA	Modulator
DMTGCSX	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMTGCSX	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM1XEUV	DI	DM1XEUV
DM1XEUV	DN	SKF-97574
DM1XEUV	MI	TTLOKXP
DM1XEUV	MN	Gastric H(+)/K(+) ATPase (Proton pump)
DM1XEUV	MT	DTT
DM1XEUV	MA	Modulator
DM1XEUV	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM1XEUV	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMP0DLW	DI	DMP0DLW
DMP0DLW	DN	SL-25.1188
DMP0DLW	MI	TTGP7BY
DMP0DLW	MN	Monoamine oxidase type B (MAO-B)
DMP0DLW	MT	DTT
DMP0DLW	MA	Inhibitor
DMP0DLW	RN	[(11)C]SL25.1188, a new reversible radioligand to study the monoamine oxidase type B with PET: preclinical characterisation in nonhuman primate. Synapse. 2010 Jan;64(1):61-9.
DMP0DLW	RU	https://pubmed.ncbi.nlm.nih.gov/19728365

DMFUTHB	DI	DMFUTHB
DMFUTHB	DN	SL-90.0571
DMFUTHB	MI	TTRK8B9
DMFUTHB	MN	Sodium channel unspecific (NaC)
DMFUTHB	MT	DTT
DMFUTHB	MA	Modulator
DMFUTHB	RN	WO patent application no. 19990639849, Novel sodium channel drugs and uses.
DMFUTHB	RU	http://www.google.com/patents/WO1999063984A9?cl=en

DM5TJIY	DI	DM5TJIY
DM5TJIY	DN	SLV-311
DM5TJIY	MI	TT953CX
DM5TJIY	MN	Motilin receptor (MLNR)
DM5TJIY	MT	DTT
DM5TJIY	MA	Modulator
DM5TJIY	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017412)
DM5TJIY	RU	http://adisinsight.springer.com/drugs/800017412

DMJFWB7	DI	DMJFWB7
DMJFWB7	DN	SLV-313
DMJFWB7	MI	TTSQIFT
DMJFWB7	MN	5-HT 1A receptor (HTR1A)
DMJFWB7	MT	DTT
DMJFWB7	MA	Modulator
DMJFWB7	RN	Synthesis and dual D2 and 5-HT1A receptor binding affinities of 7-piperazinyl and 7-piperidinyl-3,4-dihydroquinazolin-2(1H)-ones. Med Chem. 2014;10(5):484-96.
DMJFWB7	RU	https://www.ncbi.nlm.nih.gov/pubmed/24024527

DMJFWB7	DI	DMJFWB7
DMJFWB7	DN	SLV-313
DMJFWB7	MI	TTEX248
DMJFWB7	MN	Dopamine D2 receptor (D2R)
DMJFWB7	MT	DTT
DMJFWB7	MA	Modulator
DMJFWB7	RN	Synthesis and dual D2 and 5-HT1A receptor binding affinities of 7-piperazinyl and 7-piperidinyl-3,4-dihydroquinazolin-2(1H)-ones. Med Chem. 2014;10(5):484-96.
DMJFWB7	RU	https://www.ncbi.nlm.nih.gov/pubmed/24024527

DMHRYX6	DI	DMHRYX6
DMHRYX6	DN	SLV-323
DMHRYX6	MI	TTZPO1L
DMHRYX6	MN	Substance-P receptor (TACR1)
DMHRYX6	MT	DTT
DMHRYX6	MA	Modulator
DMHRYX6	RN	Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar;11(1):137-51.
DMHRYX6	RU	https://pubmed.ncbi.nlm.nih.gov/16503832

DM6CLX9	DI	DM6CLX9
DM6CLX9	DN	SM-6586
DM6CLX9	MI	TT5HONZ
DM6CLX9	MN	Calcium channel unspecific (CaC)
DM6CLX9	MT	DTT
DM6CLX9	MA	Antagonist
DM6CLX9	RN	Calcium channel blocking properties of SM-6586 in rat heart and brain as assessed by radioligand binding assay. Jpn J Pharmacol. 1993 Oct;63(2):165-9.
DM6CLX9	RU	https://pubmed.ncbi.nlm.nih.gov/8283826

DMC49KO	DI	DMC49KO
DMC49KO	DN	SMART anti-E/P selectin
DMC49KO	MI	TTAU4D6
DMC49KO	MN	E-selectin (SELE)
DMC49KO	MT	DTT
DMC49KO	MA	Modulator
DMC49KO	RN	HuEP5C7 as a humanized monoclonal anti-E/P-selectin neurovascular protective strategy in a blinded placebo-controlled trial of nonhuman primate stroke. Circ Res. 2002 Nov 15;91(10):907-14.
DMC49KO	RU	https://pubmed.ncbi.nlm.nih.gov/12433835

DMC49KO	DI	DMC49KO
DMC49KO	DN	SMART anti-E/P selectin
DMC49KO	MI	TTE5VG0
DMC49KO	MN	P-selectin (SELP)
DMC49KO	MT	DTT
DMC49KO	MA	Modulator
DMC49KO	RN	HuEP5C7 as a humanized monoclonal anti-E/P-selectin neurovascular protective strategy in a blinded placebo-controlled trial of nonhuman primate stroke. Circ Res. 2002 Nov 15;91(10):907-14.
DMC49KO	RU	https://pubmed.ncbi.nlm.nih.gov/12433835

DMQSGOD	DI	DMQSGOD
DMQSGOD	DN	SMP-028
DMQSGOD	MI	TTTWGIX
DMQSGOD	MN	Leukotriene receptor (LTR)
DMQSGOD	MT	DTT
DMQSGOD	MA	Modulator
DMQSGOD	RN	Effect of SMP-028 on steroidogenesis in rats; mechanism of toxicological events on endocrine organs of rats. Toxicol In Vitro. 2014 Apr;28(3):397-402.
DMQSGOD	RU	https://pubmed.ncbi.nlm.nih.gov/24362046

DMKGL2I	DI	DMKGL2I
DMKGL2I	DN	SPI-256
DMKGL2I	MI	TT5FNQT
DMKGL2I	MN	Human immunodeficiency virus Protease (HIV PR)
DMKGL2I	MT	DTT
DMKGL2I	MA	Inhibitor
DMKGL2I	RN	Current and Novel Inhibitors of HIV Protease. Viruses. 2009 December; 1(3): 1209-1239.
DMKGL2I	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185513/

DMWQKEN	DI	DMWQKEN
DMWQKEN	DN	SPP-1148
DMWQKEN	MI	TTB2MXP
DMWQKEN	MN	Angiotensinogenase renin (REN)
DMWQKEN	MT	DTT
DMWQKEN	MA	Inhibitor
DMWQKEN	RN	New Developments in the Pharmacological Treatment of Hypertension: Dead-End or a Glimmer at the Horizon . Curr Hypertens Rep. 2015; 17(6): 42.
DMWQKEN	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412646/

DMKEHGT	DI	DMKEHGT
DMKEHGT	DN	SPP-676
DMKEHGT	MI	TTB2MXP
DMKEHGT	MN	Angiotensinogenase renin (REN)
DMKEHGT	MT	DTT
DMKEHGT	MA	Inhibitor
DMKEHGT	RN	New Developments in the Pharmacological Treatment of Hypertension: Dead-End or a Glimmer at the Horizon . Curr Hypertens Rep. 2015; 17(6): 42.
DMKEHGT	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412646/

DMK4XT8	DI	DMK4XT8
DMK4XT8	DN	SR 144190
DMK4XT8	MI	TTYO0A3
DMK4XT8	MN	Substance-K receptor (TACR2)
DMK4XT8	MT	DTT
DMK4XT8	MA	Antagonist
DMK4XT8	RN	Pharmacologic evaluation of neurokinin-2 receptor antagonists in the guinea pig respiratory tract. Am J Vet Res. 2004 Jul;65(7):984-91.
DMK4XT8	RU	https://pubmed.ncbi.nlm.nih.gov/15281659

DML7KCO	DI	DML7KCO
DML7KCO	DN	SR-146131
DML7KCO	MI	TTCG0AL
DML7KCO	MN	Cholecystokinin receptor type A (CCKAR)
DML7KCO	MT	DTT
DML7KCO	MA	Agonist
DML7KCO	RN	SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. I. In vitro studies. J Pharmacol Exp Ther. 1999 May;289(2):742-51.
DML7KCO	RU	https://pubmed.ncbi.nlm.nih.gov/10215648

DM6X9M8	DI	DM6X9M8
DM6X9M8	DN	SR-271425
DM6X9M8	MI	TTUTN1I
DM6X9M8	MN	Human Deoxyribonucleic acid (hDNA)
DM6X9M8	MT	DTT
DM6X9M8	MA	Binder
DM6X9M8	RN	A phase I dose-escalation study of SR271425, an intravenously dosed thioxanthone analog, administered weekly in patients with refractory solid tumors. Am J Clin Oncol. 2009 Feb;32(1):9-14.
DM6X9M8	RU	https://pubmed.ncbi.nlm.nih.gov/19194116

DM471IG	DI	DM471IG
DM471IG	DN	SR-33805
DM471IG	MI	TT5HONZ
DM471IG	MN	Calcium channel unspecific (CaC)
DM471IG	MT	DTT
DM471IG	MA	Modulator
DM471IG	RN	Effects of a new class of calcium antagonists, SR33557 (fantofarone) and SR33805, on neuronal voltage-activated Ca++ channels. J Pharmacol Exp Ther. 1994 Dec;271(3):1348-52.
DM471IG	RU	https://pubmed.ncbi.nlm.nih.gov/7996445

DMAICVN	DI	DMAICVN
DMAICVN	DN	SR-47063
DMAICVN	MI	TT1VOHK
DMAICVN	MN	Potassium channel unspecific (KC)
DMAICVN	MT	DTT
DMAICVN	MA	Opener
DMAICVN	RN	Vasorelaxant effects of the potassium channel opener SR 47063 on the isolated human saphenous vein and rat aorta. Braz J Med Biol Res. 2000 Aug;33(8):961-6.
DMAICVN	RU	https://pubmed.ncbi.nlm.nih.gov/10920439

DM3O4ST	DI	DM3O4ST
DM3O4ST	DN	SS1(dsFv)-PE38
DM3O4ST	MI	TT4RXME
DM3O4ST	MN	Mesothelin (MSLN)
DM3O4ST	MT	DTT
DM3O4ST	RN	Mesothelin targeted cancer immunotherapy. Eur J Cancer. 2008 Jan;44(1):46-53.
DM3O4ST	RU	https://pubmed.ncbi.nlm.nih.gov/17945478

DMSOBW2	DI	DMSOBW2
DMSOBW2	DN	SSR-125180
DMSOBW2	MI	TTCG0AL
DMSOBW2	MN	Cholecystokinin receptor type A (CCKAR)
DMSOBW2	MT	DTT
DMSOBW2	MA	Agonist
DMSOBW2	RN	US patent application no. 8,748,419, Antagonists.
DMSOBW2	RU	http://www.google.com.ar/Patents/US8748419

DMR9JA8	DI	DMR9JA8
DMR9JA8	DN	SSR-146977
DMR9JA8	MI	TTBPGLU
DMR9JA8	MN	Neuromedin-K receptor (TACR3)
DMR9JA8	MT	DTT
DMR9JA8	MA	Antagonist
DMR9JA8	RN	Biochemical and pharmacological activities of SSR 146977, a new potent nonpeptide tachykinin NK3 receptor antagonist. Can J Physiol Pharmacol. 2002 May;80(5):482-8.
DMR9JA8	RU	https://pubmed.ncbi.nlm.nih.gov/12056557

DMI3K2D	DI	DMI3K2D
DMI3K2D	DN	SSR-162369
DMI3K2D	MI	TTDIGC1
DMI3K2D	MN	Dipeptidyl peptidase 4 (DPP-4)
DMI3K2D	MT	DTT
DMI3K2D	MA	Inhibitor
DMI3K2D	RN	Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87.
DMI3K2D	RU	https://pubmed.ncbi.nlm.nih.gov/19149538

DMBCQFH	DI	DMBCQFH
DMBCQFH	DN	SUN-8399
DMBCQFH	MI	TTSQIFT
DMBCQFH	MN	5-HT 1A receptor (HTR1A)
DMBCQFH	MT	DTT
DMBCQFH	MA	Agonist
DMBCQFH	RN	Effects of SUN 8399, a potent and selective 5-HT1A agonist, on conflict behavior and ambulatory activity in mice: comparison with those of buspirone, tandospirone and diazepam. Jpn J Pharmacol. 1994 Apr;64(4):273-80.
DMBCQFH	RU	https://pubmed.ncbi.nlm.nih.gov/8057528

DM6BO7R	DI	DM6BO7R
DM6BO7R	DN	SUN-9221
DM6BO7R	MI	TTYSN63
DM6BO7R	MN	5-HT 2 receptor (5HT2R)
DM6BO7R	MT	DTT
DM6BO7R	MA	Modulator
DM6BO7R	RN	Synthesis and pharmacological evaluation of pyrroloazepine derivatives as potent antihypertensive agents with antiplatelet aggregation activity. Chem Pharm Bull (Tokyo). 1999 Feb;47(2):246-56.
DM6BO7R	RU	https://pubmed.ncbi.nlm.nih.gov/10071857

DM6BO7R	DI	DM6BO7R
DM6BO7R	DN	SUN-9221
DM6BO7R	MI	TT34BHT
DM6BO7R	MN	Adrenergic receptor alpha-1D (ADRA1D)
DM6BO7R	MT	DTT
DM6BO7R	MA	Modulator
DM6BO7R	RN	Synthesis and pharmacological evaluation of pyrroloazepine derivatives as potent antihypertensive agents with antiplatelet aggregation activity. Chem Pharm Bull (Tokyo). 1999 Feb;47(2):246-56.
DM6BO7R	RU	https://pubmed.ncbi.nlm.nih.gov/10071857

DM1Z42H	DI	DM1Z42H
DM1Z42H	DN	SURADISTA
DM1Z42H	MI	TTBID49
DM1Z42H	MN	C-X-C chemokine receptor type 4 (CXCR4)
DM1Z42H	MT	DTT
DM1Z42H	MA	Modulator
DM1Z42H	RN	Suradista NSC 651016 inhibits the angiogenic activity of CXCL12-stromal cell-derived factor 1alpha. Clin Cancer Res. 2002 Dec;8(12):3955-60.
DM1Z42H	RU	https://pubmed.ncbi.nlm.nih.gov/12473612

DMY3FES	DI	DMY3FES
DMY3FES	DN	SW-33377
DMY3FES	MI	TTUTN1I
DMY3FES	MN	Human Deoxyribonucleic acid (hDNA)
DMY3FES	MT	DTT
DMY3FES	MA	Binder
DMY3FES	RN	Effects of SW 33377, SW 68210 and SW 71425 thioxanthones on in vitro colony formation of freshly explanted human tumor cells. Invest New Drugs. 1998-1999;16(3):221-5.
DMY3FES	RU	https://pubmed.ncbi.nlm.nih.gov/10360601

DMSPBJ9	DI	DMSPBJ9
DMSPBJ9	DN	Symakalim
DMSPBJ9	MI	TT1VOHK
DMSPBJ9	MN	Potassium channel unspecific (KC)
DMSPBJ9	MT	DTT
DMSPBJ9	MA	Agonist
DMSPBJ9	RN	Synthesis and antihypertensive activity of 4-(diazabicyclo[4.1.0]-heptenyloxy)benzopyran derivatives and their analogues. Chem Pharm Bull (Tokyo). 1998 Apr;46(4):602-9.
DMSPBJ9	RU	https://pubmed.ncbi.nlm.nih.gov/9579035

DM4JPLM	DI	DM4JPLM
DM4JPLM	DN	SYN-114
DM4JPLM	MI	TTJS8PY
DM4JPLM	MN	5-HT 6 receptor (HTR6)
DM4JPLM	MT	DTT
DM4JPLM	MA	Antagonist
DM4JPLM	RN	Lewy bodies. Proc Natl Acad Sci U S A. 2006 February 7; 103(6): 1661-1668.
DM4JPLM	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1413649/

DML4M5K	DI	DML4M5K
DML4M5K	DN	T-0632
DML4M5K	MI	TTCG0AL
DML4M5K	MN	Cholecystokinin receptor type A (CCKAR)
DML4M5K	MT	DTT
DML4M5K	MA	Antagonist
DML4M5K	RN	Effect of T-0632, a cholecystokininA receptor antagonist, on experimental acute pancreatitis. Jpn J Pharmacol. 1997 Feb;73(2):105-12.
DML4M5K	RU	https://pubmed.ncbi.nlm.nih.gov/9074944

DMQVLZH	DI	DMQVLZH
DMQVLZH	DN	T-62
DMQVLZH	MI	TTM2AOE
DMQVLZH	MN	Adenosine A2a receptor (ADORA2A)
DMQVLZH	MT	DTT
DMQVLZH	MA	Antagonist
DMQVLZH	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DMQVLZH	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DMFES2K	DI	DMFES2K
DMFES2K	DN	TA-5493
DMFES2K	MI	TTWELHI
DMFES2K	MN	Stress-activated protein kinase (p38)
DMFES2K	MT	DTT
DMFES2K	MA	Inhibitor
DMFES2K	RN	US patent application no. 2008,0269,123, Methods for treating polycystic kidney disease (pkd) or other cyst forming diseases.
DMFES2K	RU	http://www.google.com/patents/US20080269123

DMI52NT	DI	DMI52NT
DMI52NT	DN	TAFA-93
DMI52NT	MI	TTCJG29
DMI52NT	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMI52NT	MT	DTT
DMI52NT	MA	Inhibitor
DMI52NT	RN	EP patent application no. 2275103, Mtor inhibitors in the treatment of endocrine tumors.
DMI52NT	RU	http://www.google.com/patents/EP2275103A2?cl=en

DMN02XD	DI	DMN02XD
DMN02XD	DN	TAK-029
DMN02XD	MI	TT38RM1
DMN02XD	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DMN02XD	MT	DTT
DMN02XD	MA	Modulator
DMN02XD	RN	Platelet protective effect of TAK-029, a novel glycoprotein IIb/IIIa antagonist: an in vitro study. Artif Organs. 1998 Apr;22(4):348-52.
DMN02XD	RU	https://www.ncbi.nlm.nih.gov/pubmed/9555968

DMH16ND	DI	DMH16ND
DMH16ND	DN	TAK-100
DMH16ND	MI	TTDIGC1
DMH16ND	MN	Dipeptidyl peptidase 4 (DPP-4)
DMH16ND	MT	DTT
DMH16ND	MA	Inhibitor
DMH16ND	RN	Clinical pipeline report, company report or official report of Takeda (2009).
DMH16ND	RU	http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf

DMBE5OF	DI	DMBE5OF
DMBE5OF	DN	TAK165
DMBE5OF	MI	TTGKNB4
DMBE5OF	MN	Epidermal growth factor receptor (EGFR)
DMBE5OF	MT	DTT
DMBE5OF	MA	Inhibitor
DMBE5OF	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMBE5OF	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMBE5OF	DI	DMBE5OF
DMBE5OF	DN	TAK165
DMBE5OF	MI	TT6EO5L
DMBE5OF	MN	Erbb2 tyrosine kinase receptor (HER2)
DMBE5OF	MT	DTT
DMBE5OF	MA	Inhibitor
DMBE5OF	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMBE5OF	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DM25DB4	DI	DM25DB4
DM25DB4	DN	TAK-591
DM25DB4	MI	TT8DBY3
DM25DB4	MN	Angiotensin II receptor type-1 (AGTR1)
DM25DB4	MT	DTT
DM25DB4	MA	Antagonist
DM25DB4	RN	Clinical pipeline report, company report or official report of Takeda (2009).
DM25DB4	RU	http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf

DM25DB4	DI	DM25DB4
DM25DB4	DN	TAK-591
DM25DB4	MI	TTQVOEI
DM25DB4	MN	Angiotensin II receptor type-2 (AGTR2)
DM25DB4	MT	DTT
DM25DB4	MA	Antagonist
DM25DB4	RN	Clinical pipeline report, company report or official report of Takeda (2009).
DM25DB4	RU	http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf

DMRD8HK	DI	DMRD8HK
DMRD8HK	DN	TAK-683
DMRD8HK	MI	TT3KBZY
DMRD8HK	MN	G-protein coupled receptor 54 (KISS1R)
DMRD8HK	MT	DTT
DMRD8HK	MA	Agonist
DMRD8HK	RN	Clinical pipeline report, company report or official report of Takeda (2009).
DMRD8HK	RU	http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf

DMRD8HK	DI	DMRD8HK
DMRD8HK	DN	TAK-683
DMRD8HK	MI	TTN53ZF
DMRD8HK	MN	Leukotriene B4 receptor 1 (LTB4R)
DMRD8HK	MT	DTT
DMRD8HK	MA	Antagonist
DMRD8HK	RN	A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J Exp Med. 2000 Aug 7;192(3):421-32.
DMRD8HK	RU	https://pubmed.ncbi.nlm.nih.gov/10934230

DMCFOSG	DI	DMCFOSG
DMCFOSG	DN	TAK-810
DMCFOSG	MI	TT0ID4A
DMCFOSG	MN	Leutinizing-hormone-releasing hormone (GNRH1)
DMCFOSG	MT	DTT
DMCFOSG	MA	Inhibitor
DMCFOSG	RN	EP patent application no. 2018865, Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an lhrh analogue and/or a bisphosphonate.
DMCFOSG	RU	http://www.google.es/patents/EP2018865A2?hl=es&cl=en

DM13YN0	DI	DM13YN0
DM13YN0	DN	TAK-937
DM13YN0	MI	TT6OEDT
DM13YN0	MN	Cannabinoid receptor 1 (CB1)
DM13YN0	MT	DTT
DM13YN0	MA	Modulator
DM13YN0	RN	Cerebroprotective effects of TAK-937, a cannabinoid receptor agonist, on ischemic brain damage in middle cerebral artery occluded rats and non-human primates. Brain Res. 2012 Jan 9;1430:93-100.
DM13YN0	RU	https://pubmed.ncbi.nlm.nih.gov/22119394

DM13YN0	DI	DM13YN0
DM13YN0	DN	TAK-937
DM13YN0	MI	TTMSFAW
DM13YN0	MN	Cannabinoid receptor 2 (CB2)
DM13YN0	MT	DTT
DM13YN0	MA	Modulator
DM13YN0	RN	Cerebroprotective effects of TAK-937, a cannabinoid receptor agonist, on ischemic brain damage in middle cerebral artery occluded rats and non-human primates. Brain Res. 2012 Jan 9;1430:93-100.
DM13YN0	RU	https://pubmed.ncbi.nlm.nih.gov/22119394

DM1ZYCA	DI	DM1ZYCA
DM1ZYCA	DN	TALTOBULIN
DM1ZYCA	MI	TTML2WA
DM1ZYCA	MN	Tubulin (TUB)
DM1ZYCA	MT	DTT
DM1ZYCA	MA	Inhibitor
DM1ZYCA	RN	Absolute configurations of tubulin inhibitors taltobulin (HTI-286) and HTI-042 characterized by X-ray diffraction analysis and NMR studies. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1535-8.
DM1ZYCA	RU	https://pubmed.ncbi.nlm.nih.gov/20137930

DM5PZ60	DI	DM5PZ60
DM5PZ60	DN	TAZOMELINE
DM5PZ60	MI	TTZ9SOR
DM5PZ60	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DM5PZ60	MT	DTT
DM5PZ60	MA	Agonist
DM5PZ60	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DM5PZ60	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMCA97F	DI	DMCA97F
DMCA97F	DN	TD-2749
DMCA97F	MI	TT07C3Y
DMCA97F	MN	5-HT 4 receptor (HTR4)
DMCA97F	MT	DTT
DMCA97F	MA	Agonist
DMCA97F	RN	A Hybrid Structural Approach to Analyze Ligand Binding by the Serotonin Type 4 Receptor (5-HT4). Mol Cell Proteomics. 2013 May; 12(5): 1259-1271.
DMCA97F	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3650337/

DMDT5HZ	DI	DMDT5HZ
DMDT5HZ	DN	Teloxantrone
DMDT5HZ	MI	TT0IHXV
DMDT5HZ	MN	DNA topoisomerase II (TOP2)
DMDT5HZ	MT	DTT
DMDT5HZ	MA	Modulator
DMDT5HZ	RN	Topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles DuP 937 and DuP 941 (Losoxantrone) in the National Cancer Institute preclinical... J Natl Cancer Inst. 1994 Aug 17;86(16):1239-44.
DMDT5HZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/8040892

DM9KYVQ	DI	DM9KYVQ
DM9KYVQ	DN	TG-1024
DM9KYVQ	MI	TTF89GD
DM9KYVQ	MN	Interleukin-2 (IL2)
DM9KYVQ	MT	DTT
DM9KYVQ	MA	Modulator
DM9KYVQ	RN	Melanoma and Immunotherapy. Hematology/Oncology Clinics of North America Volume 23, Issue 3, June 2009, Pages 547-564.
DM9KYVQ	RU	http://www.sciencedirect.com/science/article/pii/S0889858809000458

DMELNA8	DI	DMELNA8
DMELNA8	DN	TGN-1412
DMELNA8	MI	TTQ13FT
DMELNA8	MN	T-cell-specific surface glycoprotein CD28 (CD28)
DMELNA8	MT	DTT
DMELNA8	RN	TGN1412: From Discovery to Disaster. J Young Pharm. 2010 Jul-Sep; 2(3): 332-336.
DMELNA8	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2964774/

DMTC4LP	DI	DMTC4LP
DMTC4LP	DN	Tidembersat
DMTC4LP	MI	TT6MSOK
DMTC4LP	MN	5-HT 1D receptor (HTR1D)
DMTC4LP	MT	DTT
DMTC4LP	MA	Antagonist
DMTC4LP	RN	Sustained pain relief with dihydroergotamine in migraine is potentially due to persistent binding to 5-HT1B and 5-HT1D receptors. . The Journal of Headache and Pain 201314(Suppl 1):P75.
DMTC4LP	RU	http://www.thejournalofheadacheandpain.com/content/pdf/1129-2377-14-S1-P75.pdf

DMI0Q8Y	DI	DMI0Q8Y
DMI0Q8Y	DN	TOP-53
DMI0Q8Y	MI	TT0IHXV
DMI0Q8Y	MN	DNA topoisomerase II (TOP2)
DMI0Q8Y	MT	DTT
DMI0Q8Y	MA	Modulator
DMI0Q8Y	RN	DNA topoisomerase II as the target for the anticancer drug TOP-53: mechanistic basis for drug action. Biochemistry. 2001 Jan 23;40(3):712-8.
DMI0Q8Y	RU	https://pubmed.ncbi.nlm.nih.gov/11170388

DM6SUDC	DI	DM6SUDC
DM6SUDC	DN	Totrombopag
DM6SUDC	MI	TTIHYA4
DM6SUDC	MN	Thrombopoietin receptor (MPL)
DM6SUDC	MT	DTT
DM6SUDC	MA	Agonist
DM6SUDC	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DM6SUDC	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMCV2KQ	DI	DMCV2KQ
DMCV2KQ	DN	TP-9201
DMCV2KQ	MI	TT38RM1
DMCV2KQ	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DMCV2KQ	MT	DTT
DMCV2KQ	MA	Modulator
DMCV2KQ	RN	TP-9201, a glycoprotein IIb/IIIa platelet receptor antagonist, prevents rethrombosis after successful arterial thrombolysis in the dog. Stroke. 1997 Sep;28(9):1789-96.
DMCV2KQ	RU	https://pubmed.ncbi.nlm.nih.gov/9303027

DMWD39E	DI	DMWD39E
DMWD39E	DN	Tr-14035
DMWD39E	MI	TT6S84X
DMWD39E	MN	Integrin alpha-4/beta-1 (ITGA4/B1)
DMWD39E	MT	DTT
DMWD39E	MA	Modulator
DMWD39E	RN	Pharmacokinetics and metabolism of TR-14035, a novel antagonist of a4ss1/a4ss7 integrin mediated cell adhesion, in rat and dog. Xenobiotica. 2005 Apr;35(4):373-89.
DMWD39E	RU	https://www.ncbi.nlm.nih.gov/pubmed/16019958

DMWD39E	DI	DMWD39E
DMWD39E	DN	Tr-14035
DMWD39E	MI	TT7ZMI1
DMWD39E	MN	Integrin alpha-4/beta-7 (ITGA4/B7)
DMWD39E	MT	DTT
DMWD39E	MA	Modulator
DMWD39E	RN	Pharmacokinetics and metabolism of TR-14035, a novel antagonist of a4ss1/a4ss7 integrin mediated cell adhesion, in rat and dog. Xenobiotica. 2005 Apr;35(4):373-89.
DMWD39E	RU	https://www.ncbi.nlm.nih.gov/pubmed/16019958

DMWD39E	DI	DMWD39E
DMWD39E	DN	Tr-14035
DMWD39E	MI	DTE2B1D
DMWD39E	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMWD39E	MT	DTP
DMWD39E	MA	Substrate
DMWD39E	RN	Characterization of hepatobiliary transport systems of a novel alpha4beta1/alpha4beta7 dual antagonist, TR-14035. Pharm Res. 2006 Nov;23(11):2646-56.
DMWD39E	RU	https://doi.org/10.1007/s11095-006-9102-6

DMWD39E	DI	DMWD39E
DMWD39E	DN	Tr-14035
DMWD39E	MI	DT3D8F0
DMWD39E	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMWD39E	MT	DTP
DMWD39E	MA	Substrate
DMWD39E	RN	Cellular entry of thyroid hormones by organic anion transporting polypeptides. Best Pract Res Clin Endocrinol Metab. 2007 Jun;21(2):209-21.
DMWD39E	RU	https://doi.org/10.1016/j.beem.2007.03.004

DMH5SA6	DI	DMH5SA6
DMH5SA6	DN	TR-14531
DMH5SA6	MI	TTHIZP9
DMH5SA6	MN	Integrin alpha-5 (ITGA5)
DMH5SA6	MT	DTT
DMH5SA6	MA	Antagonist
DMH5SA6	RN	US patent application no. US2010278784 (A1), Methods and compositions for treating skin conditions.
DMH5SA6	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20101104&CC=US&NR=2010278784A1&KC=A1

DMZ5RA7	DI	DMZ5RA7
DMZ5RA7	DN	TRK-851
DMZ5RA7	MI	TT27RFC
DMZ5RA7	MN	Opioid receptor delta (OPRD1)
DMZ5RA7	MT	DTT
DMZ5RA7	MA	Antagonist
DMZ5RA7	RN	Design and synthesis of a metabolically stable and potent antitussive agent, a novel delta opioid receptor antagonist, TRK-851. Bioorg Med Chem. 2008 Sep 1;16(17):7956-67.
DMZ5RA7	RU	https://pubmed.ncbi.nlm.nih.gov/18701308

DMSFV9T	DI	DMSFV9T
DMSFV9T	DN	TRM-115
DMSFV9T	MI	TTQHJ1K
DMSFV9T	MN	Histamine H2 receptor (H2R)
DMSFV9T	MT	DTT
DMSFV9T	MA	Antagonist
DMSFV9T	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002138)
DMSFV9T	RU	http://adisinsight.springer.com/drugs/800002138

DMOHEYU	DI	DMOHEYU
DMOHEYU	DN	TS-032
DMOHEYU	MI	TTXJ47W
DMOHEYU	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMOHEYU	MT	DTT
DMOHEYU	MA	Agonist
DMOHEYU	RN	Metabotropic glutamate receptor subtype 2/3 (mGluR2/3); serotonin receptor (5-HT2A receptor). SciBX 1(6); doi:10.1038/scibx.2008.145. March 6 2008
DMOHEYU	RU	http://www.nature.com/scibx/journal/v1/n6/full/scibx.2008.145.html

DMHJXL6	DI	DMHJXL6
DMHJXL6	DN	TT-235
DMHJXL6	MI	TTSCIUP
DMHJXL6	MN	Oxytocin receptor (OTR)
DMHJXL6	MT	DTT
DMHJXL6	MA	Antagonist
DMHJXL6	RN	In vivo activity of the potent oxytocin antagonist on uterine activity in the rat. In Vivo. 2004 Nov-Dec;18(6):763-6.
DMHJXL6	RU	https://pubmed.ncbi.nlm.nih.gov/15646817

DMTVC3W	DI	DMTVC3W
DMTVC3W	DN	U-103017
DMTVC3W	MI	TT5FNQT
DMTVC3W	MN	Human immunodeficiency virus Protease (HIV PR)
DMTVC3W	MT	DTT
DMTVC3W	MA	Inhibitor
DMTVC3W	RN	Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors. J Med Chem. 1995 Dec 22;38(26):4968-71.
DMTVC3W	RU	https://pubmed.ncbi.nlm.nih.gov/8544171

DMC94D2	DI	DMC94D2
DMC94D2	DN	U-104067F
DMC94D2	MI	TTV0YFR
DMC94D2	MN	Lipid peroxidation (LPO)
DMC94D2	MT	DTT
DMC94D2	MA	Modulator
DMC94D2	RN	Two novel pyrrolopyrimidine lipid peroxidation inhibitors U-101033E and U-104067F protect facial motor neurons following neonatal axotomy. Exp Neurol. 1996 Oct;141(2):304-9.
DMC94D2	RU	https://pubmed.ncbi.nlm.nih.gov/8812165

DM2WOPX	DI	DM2WOPX
DM2WOPX	DN	U-78875
DM2WOPX	MI	TT1MPAY
DM2WOPX	MN	GABA(A) receptor alpha-1 (GABRA1)
DM2WOPX	MT	DTT
DM2WOPX	MA	Inhibitor
DM2WOPX	RN	Piperazine imidazo[1,5-a]quinoxaline ureas as high-affinity GABAA ligands of dual functionality. J Med Chem. 1999 Apr 8;42(7):1123-44.
DM2WOPX	RU	https://pubmed.ncbi.nlm.nih.gov/10197957

DM2WOPX	DI	DM2WOPX
DM2WOPX	DN	U-78875
DM2WOPX	MI	TTZA1NY
DM2WOPX	MN	GABA(A) receptor beta-2 (GABRB2)
DM2WOPX	MT	DTT
DM2WOPX	MA	Inhibitor
DM2WOPX	RN	High-affinity alpha-aminobutyric acid A/benzodiazepine ligands: synthesis and structure-activity relationship studies of a new series of tetracycli... J Med Chem. 1996 Nov 8;39(23):4654-66.
DM2WOPX	RU	https://pubmed.ncbi.nlm.nih.gov/8917654

DM2WOPX	DI	DM2WOPX
DM2WOPX	DN	U-78875
DM2WOPX	MI	TT06RH5
DM2WOPX	MN	GABA(A) receptor gamma-2 (GABRG2)
DM2WOPX	MT	DTT
DM2WOPX	MA	Inhibitor
DM2WOPX	RN	3-Phenyl-substituted imidazo[1,5-alpha]quinoxalin-4-ones and imidazo[1,5-alpha]quinoxaline ureas that have high affinity at the GABAA/benzodiazepin... J Med Chem. 1996 Sep 13;39(19):3820-36.
DM2WOPX	RU	https://pubmed.ncbi.nlm.nih.gov/8809170

DM2WOPX	DI	DM2WOPX
DM2WOPX	DN	U-78875
DM2WOPX	MI	TTNJYV2
DM2WOPX	MN	Gamma-aminobutyric acid receptor (GAR)
DM2WOPX	MT	DTT
DM2WOPX	MA	Inhibitor
DM2WOPX	RN	Piperazine imidazo[1,5-a]quinoxaline ureas as high-affinity GABAA ligands of dual functionality. J Med Chem. 1999 Apr 8;42(7):1123-44.
DM2WOPX	RU	https://pubmed.ncbi.nlm.nih.gov/10197957

DMMSWJ3	DI	DMMSWJ3
DMMSWJ3	DN	U-93385
DMMSWJ3	MI	TTSQIFT
DMMSWJ3	MN	5-HT 1A receptor (HTR1A)
DMMSWJ3	MT	DTT
DMMSWJ3	MA	Agonist
DMMSWJ3	RN	Tolerance development to the vagal-mediated bradycardia produced by 5-HT1A receptor agonists. J Pharmacol Exp Ther. 1994 Nov;271(2):776-81.
DMMSWJ3	RU	https://pubmed.ncbi.nlm.nih.gov/7965796

DML73BR	DI	DML73BR
DML73BR	DN	U-96988
DML73BR	MI	TT5FNQT
DML73BR	MN	Human immunodeficiency virus Protease (HIV PR)
DML73BR	MT	DTT
DML73BR	MA	Inhibitor
DML73BR	RN	Structure-based design of HIV protease inhibitors: 4-hydroxycoumarins and 4-hydroxy-2-pyrones as non-peptidic inhibitors. J Med Chem. 1994 Sep 30;37(20):3200-4.
DML73BR	RU	https://pubmed.ncbi.nlm.nih.gov/7932546

DML51D0	DI	DML51D0
DML51D0	DN	UCL-2000; butabindide
DML51D0	MI	TTCG0AL
DML51D0	MN	Cholecystokinin receptor type A (CCKAR)
DML51D0	MT	DTT
DML51D0	MA	Agonist
DML51D0	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DML51D0	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DML51D0	DI	DML51D0
DML51D0	DN	UCL-2000; butabindide
DML51D0	MI	TTQ7R2V
DML51D0	MN	Tripeptidyl-peptidase II (TPP2)
DML51D0	MT	DTT
DML51D0	MA	Inhibitor
DML51D0	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DML51D0	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMGFPIY	DI	DMGFPIY
DMGFPIY	DN	UK-156406
DMGFPIY	MI	TT6L509
DMGFPIY	MN	Coagulation factor IIa (F2)
DMGFPIY	MT	DTT
DMGFPIY	MA	Inhibitor
DMGFPIY	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMGFPIY	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMDTRJB	DI	DMDTRJB
DMDTRJB	DN	UK-224671
DMDTRJB	MI	TTYO0A3
DMDTRJB	MN	Substance-K receptor (TACR2)
DMDTRJB	MT	DTT
DMDTRJB	MA	Antagonist
DMDTRJB	RN	Pharmacokinetics and metabolism of a sulphamide NK2 antagonist in rat, dog and human. Xenobiotica. 2000 Jun;30(6):627-42.
DMDTRJB	RU	https://pubmed.ncbi.nlm.nih.gov/10923864

DMXN9Z5	DI	DMXN9Z5
DMXN9Z5	DN	UR-7198
DMXN9Z5	MI	TT8DBY3
DMXN9Z5	MN	Angiotensin II receptor type-1 (AGTR1)
DMXN9Z5	MT	DTT
DMXN9Z5	MA	Antagonist
DMXN9Z5	RN	Pharmacologic profile of UR-7247, an orally active angiotensin II AT1 receptor antagonist, in healthy volunteers. p6. J Cardiovasc Pharmacol. 2000 Mar;35(3):383-9.
DMXN9Z5	RU	https://pubmed.ncbi.nlm.nih.gov/10710122

DMR2EUV	DI	DMR2EUV
DMR2EUV	DN	V-102862
DMR2EUV	MI	TT84DRB
DMR2EUV	MN	Voltage-gated sodium channel alpha Nav1.4 (SCN4A)
DMR2EUV	MT	DTT
DMR2EUV	MA	Inhibitor
DMR2EUV	RN	3-(4-phenoxyphenyl)pyrazoles: a novel class of sodium channel blockers. J Med Chem. 2004 Mar 11;47(6):1547-52.
DMR2EUV	RU	https://pubmed.ncbi.nlm.nih.gov/14998340

DMR2EUV	DI	DMR2EUV
DMR2EUV	DN	V-102862
DMR2EUV	MI	TT4G2JS
DMR2EUV	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DMR2EUV	MT	DTT
DMR2EUV	MA	Inhibitor
DMR2EUV	RN	Substituted biaryl oxazoles, imidazoles, and thiazoles as sodium channel blockers. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5536-40.
DMR2EUV	RU	https://pubmed.ncbi.nlm.nih.gov/20709552

DMLFMSY	DI	DMLFMSY
DMLFMSY	DN	V85546
DMLFMSY	MI	TTXZ0KQ
DMLFMSY	MN	Matrix metalloproteinase-12 (MMP-12)
DMLFMSY	MT	DTT
DMLFMSY	MA	Inhibitor
DMLFMSY	RN	Clinical pipeline report, company report or official report of Vernalis.
DMLFMSY	RU	http://www.vernalis.com/partnering/out-licensing/v158866-1

DMBQPA5	DI	DMBQPA5
DMBQPA5	DN	Vanoxerine
DMBQPA5	MI	DE4LYSA
DMBQPA5	MN	Cytochrome P450 3A4 (CYP3A4)
DMBQPA5	MT	DME
DMBQPA5	MA	Metabolism
DMBQPA5	RN	Metabolism of vanoxerine, 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine, by human cytochrome P450 enzymes. Drug Metab Dispos. 2001 Sep;29(9):1216-20.
DMBQPA5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11502731

DMBQPA5	DI	DMBQPA5
DMBQPA5	DN	Vanoxerine
DMBQPA5	MI	TTVBI8W
DMBQPA5	MN	Dopamine transporter (DAT)
DMBQPA5	MT	DTT
DMBQPA5	MA	Blocker
DMBQPA5	RN	Emerging pharmacological strategies in the fight against cocaine addiction. Expert Opin Emerg Drugs. 2006 Mar;11(1):91-8.
DMBQPA5	RU	https://pubmed.ncbi.nlm.nih.gov/16503828

DMKRG0I	DI	DMKRG0I
DMKRG0I	DN	VNA-932
DMKRG0I	MI	TTK8R02
DMKRG0I	MN	Vasopressin V2 receptor (V2R)
DMKRG0I	MT	DTT
DMKRG0I	MA	Agonist
DMKRG0I	RN	Biased Agonist Pharmacochaperones of the AVP V2 Receptor May Treat Congenital Nephrogenic Diabetes Insipidus. J Am Soc Nephrol. 2009 October; 20(10): 2190-2203.
DMKRG0I	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2754097/

DMATEL0	DI	DMATEL0
DMATEL0	DN	Vorsetuzumab mafodotin
DMATEL0	MI	TTNCIE0
DMATEL0	MN	CD70 antigen (CD27-L)
DMATEL0	MT	DTT
DMATEL0	RN	National Cancer Institute Drug Dictionary (drug id 660730).
DMATEL0	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=660730

DMXK8FQ	DI	DMXK8FQ
DMXK8FQ	DN	VP004
DMXK8FQ	MI	TT27RFC
DMXK8FQ	MN	Opioid receptor delta (OPRD1)
DMXK8FQ	MT	DTT
DMXK8FQ	RN	WO patent application no. 2007,0677,14, Treatment of sequelae of psychiatric disorders.
DMXK8FQ	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20070614&CC=WO&NR=2007067714A2&KC=A2

DMXK8FQ	DI	DMXK8FQ
DMXK8FQ	DN	VP004
DMXK8FQ	MI	TTQW87Y
DMXK8FQ	MN	Opioid receptor kappa (OPRK1)
DMXK8FQ	MT	DTT
DMXK8FQ	RN	WO patent application no. 2007,0677,14, Treatment of sequelae of psychiatric disorders.
DMXK8FQ	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20070614&CC=WO&NR=2007067714A2&KC=A2

DMXK8FQ	DI	DMXK8FQ
DMXK8FQ	DN	VP004
DMXK8FQ	MI	TTKWM86
DMXK8FQ	MN	Opioid receptor mu (MOP)
DMXK8FQ	MT	DTT
DMXK8FQ	RN	WO patent application no. 2007,0677,14, Treatment of sequelae of psychiatric disorders.
DMXK8FQ	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20070614&CC=WO&NR=2007067714A2&KC=A2

DM0HZBU	DI	DM0HZBU
DM0HZBU	DN	VP-025
DM0HZBU	MI	TTXM6JN
DM0HZBU	MN	Cytokine receptor unspecific (CRF)
DM0HZBU	MT	DTT
DM0HZBU	MA	Modulator
DM0HZBU	RN	List of Drugs in Development for Neurodegenerative Diseases. Neurodegenerative Dis 2007;4:443-486.
DM0HZBU	RU	http://www.karger.com/Article/PDF/107705

DMFQWNI	DI	DMFQWNI
DMFQWNI	DN	VR-776
DMFQWNI	MI	DEJGDUW
DMFQWNI	MN	Cytochrome P450 1A2 (CYP1A2)
DMFQWNI	MT	DME
DMFQWNI	MA	Metabolism
DMFQWNI	RN	Erythromycin interaction with risperidone or clomipramine in an adolescent. J Child Adolesc Psychopharmacol. 1996 Summer;6(2):133-8.
DMFQWNI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9231305

DMFQWNI	DI	DMFQWNI
DMFQWNI	DN	VR-776
DMFQWNI	MI	DECB0K3
DMFQWNI	MN	Cytochrome P450 2D6 (CYP2D6)
DMFQWNI	MT	DME
DMFQWNI	MA	Metabolism
DMFQWNI	RN	The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. J Pharmacol Exp Ther. 1996 Jun;277(3):1659-64.
DMFQWNI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8667235

DMFQWNI	DI	DMFQWNI
DMFQWNI	DN	VR-776
DMFQWNI	MI	DE4LYSA
DMFQWNI	MN	Cytochrome P450 3A4 (CYP3A4)
DMFQWNI	MT	DME
DMFQWNI	MA	Metabolism
DMFQWNI	RN	Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007 Jul;151(6):737-48.
DMFQWNI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17471183

DMFQWNI	DI	DMFQWNI
DMFQWNI	DN	VR-776
DMFQWNI	MI	DEGTFWK
DMFQWNI	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMFQWNI	MT	DME
DMFQWNI	MA	Metabolism
DMFQWNI	RN	Serum clomipramine and desmethylclomipramine levels in a CYP2C19 and CYP2D6 intermediate metabolizer. Pharmacogenomics. 2017 May;18(7):601-605.
DMFQWNI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28470111

DMFQWNI	DI	DMFQWNI
DMFQWNI	DN	VR-776
DMFQWNI	MI	DEYGVN4
DMFQWNI	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMFQWNI	MT	DME
DMFQWNI	MA	Metabolism
DMFQWNI	RN	Role of human UGT2B10 in N-glucuronidation of tricyclic antidepressants, amitriptyline, imipramine, clomipramine, and trimipramine. Drug Metab Dispos. 2010 May;38(5):863-70.
DMFQWNI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20133892

DM3GD7V	DI	DM3GD7V
DM3GD7V	DN	WAY-100289
DM3GD7V	MI	TTNXLKE
DM3GD7V	MN	5-HT 3 receptor (5HT3R)
DM3GD7V	MT	DTT
DM3GD7V	MA	Modulator
DM3GD7V	RN	The selective 5-HT3 receptor antagonist, WAY100289, enhances spatial memory in rats with ibotenate lesions of the forebrain cholinergic projection system. Psychopharmacology (Berl). 1995 Feb;117(3):318-32.
DM3GD7V	RU	https://pubmed.ncbi.nlm.nih.gov/7770608

DM8SVHI	DI	DM8SVHI
DM8SVHI	DN	WAY-181187
DM8SVHI	MI	TTJS8PY
DM8SVHI	MN	5-HT 6 receptor (HTR6)
DM8SVHI	MT	DTT
DM8SVHI	MA	Modulator
DM8SVHI	RN	Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466.Neuropsychopharmacology.2008 May;33(6):1323-35.
DM8SVHI	RU	https://www.ncbi.nlm.nih.gov/pubmed/17625499

DMSZJ5H	DI	DMSZJ5H
DMSZJ5H	DN	Wetimicin
DMSZJ5H	MI	TTOVFH2
DMSZJ5H	MN	Bacterial 30S ribosomal RNA (Bact 30S rRNA)
DMSZJ5H	MT	DTT
DMSZJ5H	MA	Inhibitor
DMSZJ5H	RN	Cross susceptibility of ototoxicity about aminoglycoside antibiotics. Lin Chuang Er Bi Yan Hou Ke Za Zhi. 1997 Jan;11(1):9-10.
DMSZJ5H	RU	https://pubmed.ncbi.nlm.nih.gov/9644172

DMHTG38	DI	DMHTG38
DMHTG38	DN	XL844
DMHTG38	MI	TTTU902
DMHTG38	MN	Checkpoint kinase-1 (CHK1)
DMHTG38	MT	DTT
DMHTG38	MA	Modulator
DMHTG38	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMHTG38	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMHTG38	DI	DMHTG38
DMHTG38	DN	XL844
DMHTG38	MI	TT9ABMF
DMHTG38	MN	Serine/threonine-protein kinase Chk2 (RAD53)
DMHTG38	MT	DTT
DMHTG38	MA	Modulator
DMHTG38	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMHTG38	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMQKH07	DI	DMQKH07
DMQKH07	DN	XM-323
DMQKH07	MI	TT5FNQT
DMQKH07	MN	Human immunodeficiency virus Protease (HIV PR)
DMQKH07	MT	DTT
DMQKH07	MA	Inhibitor
DMQKH07	RN	In vitro anti-human immunodeficiency virus (HIV) activity of XM323, a novel HIV protease inhibitor. Antimicrob Agents Chemother. 1993 Dec;37(12):2606-11.
DMQKH07	RU	https://pubmed.ncbi.nlm.nih.gov/8109924

DMCK210	DI	DMCK210
DMCK210	DN	XR-9051
DMCK210	MI	TTO32GK
DMCK210	MN	P-glycoprotein (P-GP)
DMCK210	MT	DTT
DMCK210	MA	Inhibitor
DMCK210	RN	Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol. 2000 Sep;58(3):624-32.
DMCK210	RU	https://pubmed.ncbi.nlm.nih.gov/10953057

DM3Y6M7	DI	DM3Y6M7
DM3Y6M7	DN	XTL-2125
DM3Y6M7	MI	TT79JGK
DM3Y6M7	MN	Mycobacterium RNA polymerase (MycB RNAP)
DM3Y6M7	MT	DTT
DM3Y6M7	MA	Modulator
DM3Y6M7	RN	DOI: 10.1111/j.1365-2036.2009.03927.x
DM3Y6M7	RU	http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2036.2009.03927.x/full

DM0FSA9	DI	DM0FSA9
DM0FSA9	DN	YM-17E
DM0FSA9	MI	TTMF541
DM0FSA9	MN	Liver carboxylesterase (CES1)
DM0FSA9	MT	DTT
DM0FSA9	MA	Modulator
DM0FSA9	RN	Pharmacological properties of YM17E, an acyl-CoA:cholesterol acyltransferase inhibitor, and diarrheal effect in beagle dogs. Jpn J Pharmacol. 1997 Jan;73(1):41-50.
DM0FSA9	RU	https://pubmed.ncbi.nlm.nih.gov/9032133

DMLD2R0	DI	DMLD2R0
DMLD2R0	DN	YM-750
DMLD2R0	MI	TTMF541
DMLD2R0	MN	Liver carboxylesterase (CES1)
DMLD2R0	MT	DTT
DMLD2R0	MA	Inhibitor
DMLD2R0	RN	Effects of an anti-oxidative ACAT inhibitor on apoptosis/necrosis and cholesterol accumulation under oxidative stress in THP-1 cell-derived foam ce... Life Sci. 2008 Jan 2;82(1-2):79-84.
DMLD2R0	RU	https://pubmed.ncbi.nlm.nih.gov/18037448

DMDJ2O5	DI	DMDJ2O5
DMDJ2O5	DN	YM-75466
DMDJ2O5	MI	TTCIHJA
DMDJ2O5	MN	Coagulation factor Xa (F10)
DMDJ2O5	MT	DTT
DMDJ2O5	MA	Inhibitor
DMDJ2O5	RN	Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7.
DMDJ2O5	RU	https://pubmed.ncbi.nlm.nih.gov/22844656

DMCDK6S	DI	DMCDK6S
DMCDK6S	DN	YM-976
DMCDK6S	MI	TTZ97H5
DMCDK6S	MN	Phosphodiesterase 4A (PDE4A)
DMCDK6S	MT	DTT
DMCDK6S	MA	Inhibitor
DMCDK6S	RN	Antiasthmatic effect of YM976, a novel PDE4 inhibitor, in guinea pigs. J Pharmacol Exp Ther. 2001 Apr;297(1):165-73.
DMCDK6S	RU	https://pubmed.ncbi.nlm.nih.gov/11259541

DMCDK6S	DI	DMCDK6S
DMCDK6S	DN	YM-976
DMCDK6S	MI	TTVIAT9
DMCDK6S	MN	Phosphodiesterase 4B (PDE4B)
DMCDK6S	MT	DTT
DMCDK6S	MA	Inhibitor
DMCDK6S	RN	Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36.
DMCDK6S	RU	https://pubmed.ncbi.nlm.nih.gov/21948793

DMCDK6S	DI	DMCDK6S
DMCDK6S	DN	YM-976
DMCDK6S	MI	TTSKMI8
DMCDK6S	MN	Phosphodiesterase 4D (PDE4D)
DMCDK6S	MT	DTT
DMCDK6S	MA	Inhibitor
DMCDK6S	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMCDK6S	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMA412G	DI	DMA412G
DMA412G	DN	Z-300
DMA412G	MI	TTQHJ1K
DMA412G	MN	Histamine H2 receptor (H2R)
DMA412G	MT	DTT
DMA412G	MA	Antagonist
DMA412G	RN	Effects of a new histamine H2-receptor antagonist, Z-300, on gastric secretion and gastro-duodenal lesions in rats: comparison with roxatidine. Jpn J Pharmacol. 1992 Jul;59(3):275-89.
DMA412G	RU	https://pubmed.ncbi.nlm.nih.gov/1359178

DMLO2QY	DI	DMLO2QY
DMLO2QY	DN	Z-321
DMLO2QY	MI	TTNGKET
DMLO2QY	MN	Prolyl endopeptidase (PREP)
DMLO2QY	MT	DTT
DMLO2QY	MA	Modulator
DMLO2QY	RN	Z-321, a prolyl endopeptidase inhibitor, augments the potentiation of synaptic transmission in rat hippocampal slices. Behav Brain Res. 1997 Feb;83(1-2):213-6.
DMLO2QY	RU	https://pubmed.ncbi.nlm.nih.gov/9062687

DM82V1D	DI	DM82V1D
DM82V1D	DN	ZD-0892
DM82V1D	MI	TTPLTSQ
DM82V1D	MN	Neutrophil elastase (NE)
DM82V1D	MT	DTT
DM82V1D	MA	Inhibitor
DM82V1D	RN	Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs. 2002 Jul;11(7):965-80.
DM82V1D	RU	https://pubmed.ncbi.nlm.nih.gov/12084007

DMUDLFM	DI	DMUDLFM
DMUDLFM	DN	ZD-1611
DMUDLFM	MI	TTKRD0G
DMUDLFM	MN	Endothelin A receptor (EDNRA)
DMUDLFM	MT	DTT
DMUDLFM	MA	Antagonist
DMUDLFM	RN	Pharmacological profile of ZD1611, a novel, orally active endothelin ETA receptor antagonist. J Pharmacol Exp Ther. 1999 Sep;290(3):1085-91.
DMUDLFM	RU	https://pubmed.ncbi.nlm.nih.gov/10454481

DM7JUCI	DI	DM7JUCI
DM7JUCI	DN	ZD-2767
DM7JUCI	MI	TTUTN1I
DM7JUCI	MN	Human Deoxyribonucleic acid (hDNA)
DM7JUCI	MT	DTT
DM7JUCI	MA	Binder
DM7JUCI	RN	Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue. Br J Cancer. 2001 September; 85(5): 764-771.
DM7JUCI	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364118/

DMQDNU1	DI	DMQDNU1
DMQDNU1	DN	ZD-4927
DMQDNU1	MI	TTCIHJA
DMQDNU1	MN	Coagulation factor Xa (F10)
DMQDNU1	MT	DTT
DMQDNU1	MA	Inhibitor
DMQDNU1	RN	Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7.
DMQDNU1	RU	https://pubmed.ncbi.nlm.nih.gov/22844656

DM1EB6H	DI	DM1EB6H
DM1EB6H	DN	ZD-7349
DM1EB6H	MI	TTHIZP9
DM1EB6H	MN	Integrin alpha-5 (ITGA5)
DM1EB6H	MT	DTT
DM1EB6H	MA	Antagonist
DM1EB6H	RN	Eosinophil adhesion to cholinergic nerves via ICAM-1 and VCAM-1 and associated eosinophil degranulation. Am J Physiol Lung Cell Mol Physiol. 2002 Jun;282(6):L1279-88.
DM1EB6H	RU	https://pubmed.ncbi.nlm.nih.gov/12003784

DMJ9R4A	DI	DMJ9R4A
DMJ9R4A	DN	ZK 304709
DMJ9R4A	MI	TTH6V3D
DMJ9R4A	MN	Cyclin-dependent kinase 1 (CDK1)
DMJ9R4A	MT	DTT
DMJ9R4A	MA	Inhibitor
DMJ9R4A	RN	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
DMJ9R4A	RU	https://pubmed.ncbi.nlm.nih.gov/19568282

DMJ9R4A	DI	DMJ9R4A
DMJ9R4A	DN	ZK 304709
DMJ9R4A	MI	TT7HF4W
DMJ9R4A	MN	Cyclin-dependent kinase 2 (CDK2)
DMJ9R4A	MT	DTT
DMJ9R4A	MA	Inhibitor
DMJ9R4A	RN	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
DMJ9R4A	RU	https://pubmed.ncbi.nlm.nih.gov/19568282

DMJ9R4A	DI	DMJ9R4A
DMJ9R4A	DN	ZK 304709
DMJ9R4A	MI	TT0PG8F
DMJ9R4A	MN	Cyclin-dependent kinase 4 (CDK4)
DMJ9R4A	MT	DTT
DMJ9R4A	MA	Inhibitor
DMJ9R4A	RN	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
DMJ9R4A	RU	https://pubmed.ncbi.nlm.nih.gov/19568282

DMJ9R4A	DI	DMJ9R4A
DMJ9R4A	DN	ZK 304709
DMJ9R4A	MI	TTQYF7G
DMJ9R4A	MN	Cyclin-dependent kinase 7 (CDK7)
DMJ9R4A	MT	DTT
DMJ9R4A	MA	Inhibitor
DMJ9R4A	RN	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
DMJ9R4A	RU	https://pubmed.ncbi.nlm.nih.gov/19568282

DMJ9R4A	DI	DMJ9R4A
DMJ9R4A	DN	ZK 304709
DMJ9R4A	MI	TT1LVF2
DMJ9R4A	MN	Cyclin-dependent kinase 9 (CDK9)
DMJ9R4A	MT	DTT
DMJ9R4A	MA	Inhibitor
DMJ9R4A	RN	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
DMJ9R4A	RU	https://pubmed.ncbi.nlm.nih.gov/19568282

DMHXVN1	DI	DMHXVN1
DMHXVN1	DN	DFD-11
DMHXVN1	MI	TT1GHVO
DMHXVN1	MN	Matrix metalloproteinase (MMP)
DMHXVN1	MT	DTT
DMHXVN1	MA	Inhibitor
DMHXVN1	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMHXVN1	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMCA7LN	DI	DMCA7LN
DMCA7LN	DN	Oxycodone hydrochloride
DMCA7LN	MI	DECB0K3
DMCA7LN	MN	Cytochrome P450 2D6 (CYP2D6)
DMCA7LN	MT	DME
DMCA7LN	MA	Metabolism
DMCA7LN	RN	Metabolism and disposition of prescription opioids: a review. Forensic Sci Rev. 2015 Jul;27(2):115-45.
DMCA7LN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26227254

DMCA7LN	DI	DMCA7LN
DMCA7LN	DN	Oxycodone hydrochloride
DMCA7LN	MI	DE4LYSA
DMCA7LN	MN	Cytochrome P450 3A4 (CYP3A4)
DMCA7LN	MT	DME
DMCA7LN	MA	Metabolism
DMCA7LN	RN	Metabolism and disposition of prescription opioids: a review. Forensic Sci Rev. 2015 Jul;27(2):115-45.
DMCA7LN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26227254

DMCA7LN	DI	DMCA7LN
DMCA7LN	DN	Oxycodone hydrochloride
DMCA7LN	MI	DEIBDNY
DMCA7LN	MN	Cytochrome P450 3A5 (CYP3A5)
DMCA7LN	MT	DME
DMCA7LN	MA	Metabolism
DMCA7LN	RN	Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004 Apr;32(4):447-54.
DMCA7LN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15039299

DMCA7LN	DI	DMCA7LN
DMCA7LN	DN	Oxycodone hydrochloride
DMCA7LN	MI	DERD86B
DMCA7LN	MN	Cytochrome P450 3A7 (CYP3A7)
DMCA7LN	MT	DME
DMCA7LN	MA	Metabolism
DMCA7LN	RN	Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004 Apr;32(4):447-54.
DMCA7LN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15039299

DMC7EQT	DI	DMC7EQT
DMC7EQT	DN	AAB-002
DMC7EQT	MI	TTE4KHA
DMC7EQT	MN	Amyloid beta A4 protein (APP)
DMC7EQT	MT	DTT
DMC7EQT	MA	Modulator
DMC7EQT	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
DMC7EQT	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402

DM3V8JN	DI	DM3V8JN
DM3V8JN	DN	Anti-CD19 CAR T cells
DM3V8JN	MI	TTW640A
DM3V8JN	MN	B-lymphocyte surface antigen B4 (CD19)
DM3V8JN	MT	DTT
DM3V8JN	MA	CAR-T-Cell-Therapy
DM3V8JN	RN	ClinicalTrials.gov (NCT02277522) CD19 Redirected Autologous T Cells for Hodgkin Lymphoma
DM3V8JN	RU	https://clinicaltrials.gov/ct2/show/NCT02277522

DMYZ3O9	DI	DMYZ3O9
DMYZ3O9	DN	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes
DMYZ3O9	MI	TTENHJ0
DMYZ3O9	MN	Interleukin 3 receptor alpha (IL3RA)
DMYZ3O9	MT	DTT
DMYZ3O9	MA	CAR-T-Cell-Therapy
DMYZ3O9	RN	ClinicalTrials.gov (NCT02623582) CD123 Redirected Autologous T Cells for AML
DMYZ3O9	RU	https://clinicaltrials.gov/ct2/show/NCT02623582

DMFRA38	DI	DMFRA38
DMFRA38	DN	CART19 cells
DMFRA38	MI	TTW640A
DMFRA38	MN	B-lymphocyte surface antigen B4 (CD19)
DMFRA38	MT	DTT
DMFRA38	MA	CAR-T-Cell-Therapy
DMFRA38	RN	ClinicalTrials.gov (NCT02624258) Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma
DMFRA38	RU	https://clinicaltrials.gov/ct2/show/NCT02624258

DMA85ND	DI	DMA85ND
DMA85ND	DN	ET-1
DMA85ND	MI	DEXKD7J
DMA85ND	MN	Carboxypeptidase A4 (CPA4)
DMA85ND	MT	DME
DMA85ND	MA	Metabolism
DMA85ND	RN	Rapid degradation of endothelin-1 by an enzyme released by the rat isolated perfused mesentery. Br J Pharmacol. 1995 Feb;114(4):867-71.
DMA85ND	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7773548

DMA85ND	DI	DMA85ND
DMA85ND	DN	ET-1
DMA85ND	MI	TTKRD0G
DMA85ND	MN	Endothelin A receptor (EDNRA)
DMA85ND	MT	DTT
DMA85ND	MA	Inhibitor
DMA85ND	RN	5-OHKF and NorKA, depsipeptides from a Hawaiian collection of Bryopsis pennata: binding properties for NorKA to the human neuropeptide Y Y1 receptor. J Nat Prod. 2009 Dec;72(12):2172-6.
DMA85ND	RU	https://pubmed.ncbi.nlm.nih.gov/19916528

DMA85ND	DI	DMA85ND
DMA85ND	DN	ET-1
DMA85ND	MI	TT3ZTGU
DMA85ND	MN	Endothelin B receptor (EDNRB)
DMA85ND	MT	DTT
DMA85ND	MA	Inhibitor
DMA85ND	RN	IRL 2500: A potent ETB selective endothelin antagonist, Bioorg. Med. Chem. Lett. 6(19):2323-2328 (1996).
DMA85ND	RU	http://www.sciencedirect.com/science/article/pii/0960894X96004210

DMIUZEX	DI	DMIUZEX
DMIUZEX	DN	(R)-PFI-2
DMIUZEX	MI	TTJ0FSU
DMIUZEX	MN	Histone-lysine N-methyltransferase SETD7 (SETD7)
DMIUZEX	MT	DTT
DMIUZEX	MA	Inhibitor
DMIUZEX	RN	(R)-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells. Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):12853-8.
DMIUZEX	RU	https://pubmed.ncbi.nlm.nih.gov/25136132

DMXWD08	DI	DMXWD08
DMXWD08	DN	(R)-Xamoterol
DMXWD08	MI	DTT79CX
DMXWD08	MN	Organic cation transporter 1 (SLC22A1)
DMXWD08	MT	DTP
DMXWD08	MA	Substrate
DMXWD08	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMXWD08	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DMEJYV4	DI	DMEJYV4
DMEJYV4	DN	(S)-4-(Ethylsulfonyl)benzoylalanine
DMEJYV4	MI	TTT3IXG
DMEJYV4	MN	Kynurenine oxoglutarate transaminase II (AADAT)
DMEJYV4	MT	DTT
DMEJYV4	MA	Inhibitor
DMEJYV4	RN	Specific inhibition of kynurenate synthesis enhances extracellular dopamine levels in the rodent striatum. Neuroscience. 2009 Mar 3;159(1):196-203.
DMEJYV4	RU	https://pubmed.ncbi.nlm.nih.gov/19138730

DM1ZQ5G	DI	DM1ZQ5G
DM1ZQ5G	DN	(S)-Xamoterol
DM1ZQ5G	MI	DTT79CX
DM1ZQ5G	MN	Organic cation transporter 1 (SLC22A1)
DM1ZQ5G	MT	DTP
DM1ZQ5G	MA	Substrate
DM1ZQ5G	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DM1ZQ5G	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DM9TQDE	DI	DM9TQDE
DM9TQDE	DN	111In-hEGF
DM9TQDE	MI	TTGKNB4
DM9TQDE	MN	Epidermal growth factor receptor (EGFR)
DM9TQDE	MT	DTT
DM9TQDE	MA	Modulator
DM9TQDE	RN	A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer. J Nucl Med. 2000 May;41(5):903-11.
DM9TQDE	RU	https://pubmed.ncbi.nlm.nih.gov/10809207

DM5IUN8	DI	DM5IUN8
DM5IUN8	DN	12B9m
DM5IUN8	MI	TTPCG5T
DM5IUN8	MN	Hepcidin (HAMP)
DM5IUN8	MT	DTT
DM5IUN8	MA	Inhibitor
DM5IUN8	RN	Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys. AAPS J. 2010 Dec;12(4):646-57.
DM5IUN8	RU	https://pubmed.ncbi.nlm.nih.gov/20737261

DM503DN	DI	DM503DN
DM503DN	DN	1954U89
DM503DN	MI	TTYZVDJ
DM503DN	MN	Dihydrofolate reductase (DHFR)
DM503DN	MT	DTT
DM503DN	MA	Modulator
DM503DN	RN	The pharmacokinetics of 1954U89, 1,3-diamino-7-(1-ethylpropyl)-8-methyl-7H-pyrrolo-(3,2-f)quinazoline, in dogs and rats after intravenous and oral administration. Biopharm Drug Dispos. 1997 Jul;18(5):433-42.
DM503DN	RU	https://pubmed.ncbi.nlm.nih.gov/9210981

DMT8SFV	DI	DMT8SFV
DMT8SFV	DN	1-methyl-L-tryptophan
DMT8SFV	MI	TTZJYKH
DMT8SFV	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMT8SFV	MT	DTT
DMT8SFV	MA	Inhibitor
DMT8SFV	RN	Discovery of tryptanthrin derivatives as potent inhibitors of indoleamine 2,3-dioxygenase with therapeutic activity in Lewis lung cancer (LLC) tumor-bearing mice. J Med Chem. 2013 Nov 14;56(21):8321-31.
DMT8SFV	RU	https://pubmed.ncbi.nlm.nih.gov/24099220

DMIS1G7	DI	DMIS1G7
DMIS1G7	DN	2-(1H-indole-3,-carbonyl)-thiazole-4-carboxylic acid methyl ester
DMIS1G7	MI	TT037IE
DMIS1G7	MN	Aryl hydrocarbon receptor (AHR)
DMIS1G7	MT	DTT
DMIS1G7	MA	Agonist
DMIS1G7	RN	1'H-Indole-3'-Carbonyl-Thiazole-4-Carboxylic Acid Methyl Ester Blocked Human Glioma Cell Invasion via Aryl Hydrocarbon Receptor's Regulation of Cytoskeletal Contraction. Biomed Res Int. 2020 Oct 3;2020:2616930.
DMIS1G7	RU	https://pubmed.ncbi.nlm.nih.gov/33083460

DMLVADH	DI	DMLVADH
DMLVADH	DN	212Pb-labelled aCD37
DMLVADH	MI	TTFCW29
DMLVADH	MN	Leukocyte antigen CD37 (CD37)
DMLVADH	MT	DTT
DMLVADH	RN	Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608.
DMLVADH	RU	https://pubmed.ncbi.nlm.nih.gov/32728208

DM1O2C3	DI	DM1O2C3
DM1O2C3	DN	227Th-labelled HER2-TTC
DM1O2C3	MI	TT6EO5L
DM1O2C3	MN	Erbb2 tyrosine kinase receptor (HER2)
DM1O2C3	MT	DTT
DM1O2C3	RN	Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608.
DM1O2C3	RU	https://pubmed.ncbi.nlm.nih.gov/32728208

DM1R3VC	DI	DM1R3VC
DM1R3VC	DN	2-Amino-4-[3-hydroxyphenyl]-4-hydroxybutanoic acid
DM1R3VC	MI	TTWQM3J
DM1R3VC	MN	Kynureninase (KYNU)
DM1R3VC	MT	DTT
DM1R3VC	MA	Inhibitor
DM1R3VC	RN	2-Amino-4-[3'-hydroxyphenyl]-4-hydroxybutanoic acid; a potent inhibitor of rat and recombinant human kynureninase. Bioorg Med Chem Lett. 2002 Feb 11;12(3):361-3.
DM1R3VC	RU	https://pubmed.ncbi.nlm.nih.gov/11814797

DMRDQPT	DI	DMRDQPT
DMRDQPT	DN	2-D08
DMRDQPT	MI	TTW30FR
DMRDQPT	MN	Small ubiquitin-related modifier (SUMO)
DMRDQPT	MT	DTT
DMRDQPT	MA	Inhibitor
DMRDQPT	RN	Inhibiting SUMO1-mediated SUMOylation induces autophagy-mediated cancer cell death and reduces tumour cell invasion via RAC1. J Cell Sci. 2019 Oct 22;132(20):jcs234120.
DMRDQPT	RU	https://pubmed.ncbi.nlm.nih.gov/31578236

DM4NURZ	DI	DM4NURZ
DM4NURZ	DN	2E9IgA1
DM4NURZ	MI	TTTB3L1
DM4NURZ	MN	Alpha-crystallin (CRYA)
DM4NURZ	MT	DTT
DM4NURZ	MA	Inhibitor
DM4NURZ	RN	A novel human IgA monoclonal antibody protects against tuberculosis. J Immunol. 2011 Mar 1;186(5):3113-9.
DM4NURZ	RU	https://pubmed.ncbi.nlm.nih.gov/21257971

DMAM4FE	DI	DMAM4FE
DMAM4FE	DN	2-Ethoxypropanoic acid
DMAM4FE	MI	TT5MLZR
DMAM4FE	MN	Cryptochrome circadian clock 1 (CRY1)
DMAM4FE	MT	DTT
DMAM4FE	MA	Inhibitor
DMAM4FE	RN	The cryptochrome inhibitor KS15 enhances E-box-mediated transcription by disrupting the feedback action of a circadian transcription-repressor complex. Life Sci. 2018 May 1;200:49-55.
DMAM4FE	RU	https://pubmed.ncbi.nlm.nih.gov/29534992

DMAM4FE	DI	DMAM4FE
DMAM4FE	DN	2-Ethoxypropanoic acid
DMAM4FE	MI	TTAO58M
DMAM4FE	MN	Cryptochrome-2 (CRY2)
DMAM4FE	MT	DTT
DMAM4FE	MA	Inhibitor
DMAM4FE	RN	The cryptochrome inhibitor KS15 enhances E-box-mediated transcription by disrupting the feedback action of a circadian transcription-repressor complex. Life Sci. 2018 May 1;200:49-55.
DMAM4FE	RU	https://pubmed.ncbi.nlm.nih.gov/29534992

DM5CVBM	DI	DM5CVBM
DM5CVBM	DN	3-Oxo-C12-(2-amino-cyclohexanone)
DM5CVBM	MI	TTOMVUW
DM5CVBM	MN	Pseudomonas Transcriptional activator protein LasR (Pseudo LasR)
DM5CVBM	MT	DTT
DM5CVBM	MA	Agonist
DM5CVBM	RN	Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance. Nat Rev Drug Discov. 2017 Jul;16(7):457-471.
DM5CVBM	RU	https://pubmed.ncbi.nlm.nih.gov/28337021

DM57GL1	DI	DM57GL1
DM57GL1	DN	4-(4-fluoropyrazol-1-yl)-1,2-oxazol-5-amine
DM57GL1	MI	TTXNCBV
DM57GL1	MN	Tryptophan 2,3-dioxygenase (TDO)
DM57GL1	MT	DTT
DM57GL1	MA	Inhibitor
DM57GL1	RN	Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019 May;18(5):379-401.
DM57GL1	RU	https://pubmed.ncbi.nlm.nih.gov/30760888

DMXFC3W	DI	DMXFC3W
DMXFC3W	DN	4SC-202
DMXFC3W	MI	TT6R7JZ
DMXFC3W	MN	Histone deacetylase 1 (HDAC1)
DMXFC3W	MT	DTT
DMXFC3W	MA	Inhibitor
DMXFC3W	RN	2011 Pipeline of 4SC AG.
DMXFC3W	RU	http://www.pharmaceutical-market-research.com/publications/pharmaceutical_companies/4sc_ag_product_pipeline_review.html

DMAJWLD	DI	DMAJWLD
DMAJWLD	DN	5-(4-(4-Acetylphenyl)piperazin-1-ylsulfonyl)-6-chloroindolin-2-one
DMAJWLD	MI	TTLPC70
DMAJWLD	MN	Lysosomal alpha-glucosidase (GAA)
DMAJWLD	MT	DTT
DMAJWLD	MA	Inhibitor
DMAJWLD	RN	5-(4-(4-Acetylphenyl)piperazin-1-ylsulfonyl)indolin-2-one Analogs as Inhibitors of Acid alpha-Glucosidase for Potential Chaperone Treatment of Pompe Disease or Intervention for Diabetes Mellitus Type 2. N.A.. N.A.
DMAJWLD	RU	https://pubmed.ncbi.nlm.nih.gov/23905200

DMC4IUQ	DI	DMC4IUQ
DMC4IUQ	DN	5-(N,N-hexamethylene)-amiloride
DMC4IUQ	MI	TT2NUT5
DMC4IUQ	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMC4IUQ	MT	DTT
DMC4IUQ	MA	Modulator (allosteric modulator)
DMC4IUQ	RN	Characterization of the allosteric interactions between antagonists and amiloride analogues at the human alpha2A-adrenergic receptor. Mol Pharmacol. 1998 May;53(5):916-25.
DMC4IUQ	RU	https://pubmed.ncbi.nlm.nih.gov/9584219

DMC4IUQ	DI	DMC4IUQ
DMC4IUQ	DN	5-(N,N-hexamethylene)-amiloride
DMC4IUQ	MI	TT8R70G
DMC4IUQ	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMC4IUQ	MT	DTT
DMC4IUQ	MA	Modulator (allosteric modulator)
DMC4IUQ	RN	Amiloride derivatives and a nonpeptidic antagonist bind at two distinct allosteric sites in the human gonadotropin-releasing hormone receptor. Mol Pharmacol. 2008 Jun;73(6):1808-15.
DMC4IUQ	RU	https://pubmed.ncbi.nlm.nih.gov/18344315

DM7RHOC	DI	DM7RHOC
DM7RHOC	DN	5N,6S-(N'-butyliminomethylidene)-6-thio-1-deoxygalactonojirimycin
DM7RHOC	MI	TTNGJPH
DM7RHOC	MN	Beta-galactosidase (GLB1)
DM7RHOC	MT	DTT
DM7RHOC	MA	Inhibitor
DM7RHOC	RN	A bicyclic 1-deoxygalactonojirimycin derivative as a novel pharmacological chaperone for GM1 gangliosidosis. Mol Ther. 2013 Mar;21(3):526-32.
DM7RHOC	RU	https://pubmed.ncbi.nlm.nih.gov/23337983

DMCDTIG	DI	DMCDTIG
DMCDTIG	DN	680C91
DMCDTIG	MI	TTXNCBV
DMCDTIG	MN	Tryptophan 2,3-dioxygenase (TDO)
DMCDTIG	MT	DTT
DMCDTIG	MA	Inhibitor
DMCDTIG	RN	Effects of IDO1 and TDO2 inhibition on cognitive deficits and anxiety following LPS-induced neuroinflammation. Acta Neuropsychiatr. 2020 Feb;32(1):43-53.
DMCDTIG	RU	https://pubmed.ncbi.nlm.nih.gov/31753057

DMEKMV0	DI	DMEKMV0
DMEKMV0	DN	9-(Ethoxyimino)-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile
DMEKMV0	MI	TT1J07C
DMEKMV0	MN	Ubiquitin isopeptidase Y (USP8)
DMEKMV0	MT	DTT
DMEKMV0	MA	Inhibitor
DMEKMV0	RN	Synthesis and biological evaluation of 9-oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile analogues as potential inhibitors of deubiquitinating enzymes. ChemMedChem. 2010 Apr 6;5(4):552-8.
DMEKMV0	RU	https://pubmed.ncbi.nlm.nih.gov/20186914

DMFP316	DI	DMFP316
DMFP316	DN	A-196
DMFP316	MI	TTJGV7F
DMFP316	MN	Histone-lysine N-methyltransferase KMT5B (KMT5B)
DMFP316	MT	DTT
DMFP316	MA	Inhibitor
DMFP316	RN	The SUV4-20 inhibitor A-196 verifies a role for epigenetics in genomic integrity. Nat Chem Biol. 2017 Mar;13(3):317-324.
DMFP316	RU	https://pubmed.ncbi.nlm.nih.gov/28114273

DMFP316	DI	DMFP316
DMFP316	DN	A-196
DMFP316	MI	TT7H3YM
DMFP316	MN	Histone-lysine N-methyltransferase KMT5C (KMT5C)
DMFP316	MT	DTT
DMFP316	MA	Inhibitor
DMFP316	RN	The SUV4-20 inhibitor A-196 verifies a role for epigenetics in genomic integrity. Nat Chem Biol. 2017 Mar;13(3):317-324.
DMFP316	RU	https://pubmed.ncbi.nlm.nih.gov/28114273

DM1H45U	DI	DM1H45U
DM1H45U	DN	A-366
DM1H45U	MI	TTOFXD7
DM1H45U	MN	Euchromatic histone-lysine N-methyltransferase 1 (EHMT1)
DM1H45U	MT	DTT
DM1H45U	MA	Inhibitor
DM1H45U	RN	Discovery and development of potent and selective inhibitors of histone methyltransferase g9a. ACS Med Chem Lett. 2014 Jan 2;5(2):205-9.
DM1H45U	RU	https://pubmed.ncbi.nlm.nih.gov/24900801

DM1H45U	DI	DM1H45U
DM1H45U	DN	A-366
DM1H45U	MI	TTS6RZT
DM1H45U	MN	Histone-lysine N-methyltransferase EHMT2 (EHMT2)
DM1H45U	MT	DTT
DM1H45U	MA	Inhibitor
DM1H45U	RN	Discovery and development of potent and selective inhibitors of histone methyltransferase g9a. ACS Med Chem Lett. 2014 Jan 2;5(2):205-9.
DM1H45U	RU	https://pubmed.ncbi.nlm.nih.gov/24900801

DML5SO1	DI	DML5SO1
DML5SO1	DN	A-366833
DML5SO1	MI	TTL1ATN
DML5SO1	MN	Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2)
DML5SO1	MT	DTT
DML5SO1	MA	Modulator
DML5SO1	RN	Antinociceptive activity of alpha4beta2* neuronal nicotinic receptor agonist A-366833 in experimental models of neuropathic and inflammatory pain. Eur J Pharmacol. 2011 Oct 1;668(1-2):155-62.
DML5SO1	RU	https://pubmed.ncbi.nlm.nih.gov/21756895

DMECV6L	DI	DMECV6L
DMECV6L	DN	A-425619
DMECV6L	MI	TTMI6F5
DMECV6L	MN	Transient receptor potential cation channel V1 (TRPV1)
DMECV6L	MT	DTT
DMECV6L	MA	Blocker
DMECV6L	RN	Analgesic potential of TRPV1 antagonists. Biochem Pharmacol. 2009 Aug 1;78(3):211-6.
DMECV6L	RU	https://pubmed.ncbi.nlm.nih.gov/19481638

DMZ4HMP	DI	DMZ4HMP
DMZ4HMP	DN	A-71378
DMZ4HMP	MI	TTCG0AL
DMZ4HMP	MN	Cholecystokinin receptor type A (CCKAR)
DMZ4HMP	MT	DTT
DMZ4HMP	MA	Agonist
DMZ4HMP	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DMZ4HMP	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMAK6H3	DI	DMAK6H3
DMAK6H3	DN	A-74498
DMAK6H3	MI	TTCG0AL
DMAK6H3	MN	Cholecystokinin receptor type A (CCKAR)
DMAK6H3	MT	DTT
DMAK6H3	MA	Agonist
DMAK6H3	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DMAK6H3	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMSO8IE	DI	DMSO8IE
DMSO8IE	DN	A-841720
DMSO8IE	MI	TTVBPDM
DMSO8IE	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMSO8IE	MT	DTT
DMSO8IE	MA	Antagonist
DMSO8IE	RN	Comparison of the mGluR1 antagonist A-841720 in rat models of pain and cognition. Behav Pharmacol. 2007 Jul;18(4):273-81.
DMSO8IE	RU	https://pubmed.ncbi.nlm.nih.gov/17551319

DM8XHJG	DI	DM8XHJG
DM8XHJG	DN	A-893
DM8XHJG	MI	TT7YJFO
DM8XHJG	MN	SET and MYND domain-containing protein 2 (SMYD2)
DM8XHJG	MT	DTT
DM8XHJG	MA	Inhibitor
DM8XHJG	RN	Discovery of A-893, A New Cell-Active Benzoxazinone Inhibitor of Lysine Methyltransferase SMYD2. ACS Med Chem Lett. 2015 Apr 29;6(6):695-700.
DM8XHJG	RU	https://pubmed.ncbi.nlm.nih.gov/26101576

DMRSATG	DI	DMRSATG
DMRSATG	DN	Abamectin B1A
DMRSATG	MI	DTUGYRD
DMRSATG	MN	P-glycoprotein 1 (ABCB1)
DMRSATG	MT	DTP
DMRSATG	MA	Substrate
DMRSATG	RN	Interaction of macrocyclic lactones with P-glycoprotein: structure-affinity relationship. Eur J Pharm Sci. 2007 Jan;30(1):84-94.
DMRSATG	RU	https://doi.org/10.1016/j.ejps.2006.10.004

DMQ0NU1	DI	DMQ0NU1
DMQ0NU1	DN	ABI-013
DMQ0NU1	MI	TTML2WA
DMQ0NU1	MN	Tubulin (TUB)
DMQ0NU1	MT	DTT
DMQ0NU1	RN	Cardiovascular and CNS safety profile of ABI-013, a novel nanoparticle albumin-bound (nab) analog of docetaxel. Cancer Research. 01/2011; 70(8 Supplement):2617-2617.
DMQ0NU1	RU	http://cancerres.aacrjournals.org/content/70/8_Supplement/2617.short

DMKUPW0	DI	DMKUPW0
DMKUPW0	DN	ABX-0401
DMKUPW0	MI	TTF8CQI
DMKUPW0	MN	Tumor necrosis factor (TNF)
DMKUPW0	MT	DTT
DMKUPW0	MA	Inhibitor
DMKUPW0	RN	US patent application no. 8007,790, Methods for treating polycystic kidney disease (pkd) or other cyst forming diseases.
DMKUPW0	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20081030&CC=US&NR=2008269123A1&KC=A1

DMBI1H2	DI	DMBI1H2
DMBI1H2	DN	AD-529
DMBI1H2	MI	TT9IK2Z
DMBI1H2	MN	N-methyl-D-aspartate receptor (NMDAR)
DMBI1H2	MT	DTT
DMBI1H2	MA	Antagonist
DMBI1H2	RN	WO patent application no. 2009,0164,86, Use of nmda receptor antagonists for treatment of urologic tumors.
DMBI1H2	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20090205&CC=WO&NR=2009016486A2&KC=A2

DM19R28	DI	DM19R28
DM19R28	DN	ADC-01
DM19R28	MI	TTXU3EQ
DM19R28	MN	Herpesvirus ubiquitin-specific protease (HAUSP)
DM19R28	MT	DTT
DM19R28	MA	Inhibitor
DM19R28	RN	Advances in Deubiquitinating Enzyme Inhibition and Applications in Cancer Therapeutics. Cancers (Basel). 2020 Jun 15;12(6):1579.
DM19R28	RU	https://pubmed.ncbi.nlm.nih.gov/32549302

DM21I35	DI	DM21I35
DM21I35	DN	ADC-03
DM21I35	MI	TTXU3EQ
DM21I35	MN	Herpesvirus ubiquitin-specific protease (HAUSP)
DM21I35	MT	DTT
DM21I35	MA	Inhibitor
DM21I35	RN	Advances in Deubiquitinating Enzyme Inhibition and Applications in Cancer Therapeutics. Cancers (Basel). 2020 Jun 15;12(6):1579.
DM21I35	RU	https://pubmed.ncbi.nlm.nih.gov/32549302

DM2WKDN	DI	DM2WKDN
DM2WKDN	DN	ADX-2 series
DM2WKDN	MI	TT9IK2Z
DM2WKDN	MN	N-methyl-D-aspartate receptor (NMDAR)
DM2WKDN	MT	DTT
DM2WKDN	MA	Antagonist
DM2WKDN	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DM2WKDN	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMEWFOL	DI	DMEWFOL
DMEWFOL	DN	ADX-71943
DMEWFOL	MI	TTDCVZW
DMEWFOL	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMEWFOL	MT	DTT
DMEWFOL	MA	Modulator
DMEWFOL	RN	Evaluation of peripheral versus central effects of GABA(B) receptor activation using a novel, positive allosteric modulator of the GABA(B) receptor ADX71943, a pharmacological tool compound with a fully peripheral activity profile. Br J Pharmacol. 2014 Nov;171(21):4941-54.
DMEWFOL	RU	https://pubmed.ncbi.nlm.nih.gov/24923436

DM13YRT	DI	DM13YRT
DM13YRT	DN	AEOL-10150
DM13YRT	MI	TT6RVLG
DM13YRT	MN	Superoxide dismutase Cu-Zn (SOD Cu-Zn)
DM13YRT	MT	DTT
DM13YRT	MA	Modulator
DM13YRT	RN	AEOL-10150 (Aeolus). Curr Opin Investig Drugs. 2006 Jan;7(1):70-80.
DM13YRT	RU	https://pubmed.ncbi.nlm.nih.gov/16425674

DMYIK5D	DI	DMYIK5D
DMYIK5D	DN	AEZS-123
DMYIK5D	MI	TTWDC17
DMYIK5D	MN	Growth hormone secretagogue receptor 1 (GHSR)
DMYIK5D	MT	DTT
DMYIK5D	MA	Antagonist
DMYIK5D	RN	2011 Pipeline of Aeterna Zentaris.
DMYIK5D	RU	http://www.aezsinc.com/en/index.php

DM648KQ	DI	DM648KQ
DM648KQ	DN	ALN-FLU01
DM648KQ	MI	TTM27B5
DM648KQ	MN	Influenza NA messenger RNA (Influenza NA mRNA)
DM648KQ	MT	DTT
DM648KQ	RN	Respiratory viral diseases: access to RNA interference therapy. Drug Discov Today Ther Strateg. 2007; 4(4): 273-276.
DM648KQ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2597863/

DM8T6H7	DI	DM8T6H7
DM8T6H7	DN	ALN-HTT
DM8T6H7	MI	TTIWZ0O
DM8T6H7	MN	Huntingtin messenger RNA (HTT mRNA)
DM8T6H7	MT	DTT
DM8T6H7	RN	Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc (2011).
DM8T6H7	RU	http://www.alnylam.com/Programs-and-Pipeline/index.php

DMCJMOS	DI	DMCJMOS
DMCJMOS	DN	ALN-PCS
DMCJMOS	MI	TTNIZ2B
DMCJMOS	MN	PCSK9 messenger RNA (PCSK9 mRNA)
DMCJMOS	MT	DTT
DMCJMOS	RN	Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc (2011).
DMCJMOS	RU	http://www.alnylam.com/Programs-and-Pipeline/index.php

DMW7XEU	DI	DMW7XEU
DMW7XEU	DN	ALN-TMP
DMW7XEU	MI	TTNIUKC
DMW7XEU	MN	TMPRSS6 messenger RNA (TMPRSS6 mRNA)
DMW7XEU	MT	DTT
DMW7XEU	MA	Inhibitor
DMW7XEU	RN	Targeting iron metabolism in drug discovery and delivery. Nat Rev Drug Discov. 2017 Jun;16(6):400-423.
DMW7XEU	RU	https://pubmed.ncbi.nlm.nih.gov/28154410

DMATQB7	DI	DMATQB7
DMATQB7	DN	Alpha-Helical lipopeptides FFS
DMATQB7	MI	TT85VHW
DMATQB7	MN	MERS-CoV spike glycoprotein (S)
DMATQB7	MT	DTT
DMATQB7	MA	Inhibitor
DMATQB7	RN	De Novo Design of -Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. J Med Chem. 2018 Oct 11;61(19):8734-8745.
DMATQB7	RU	https://pubmed.ncbi.nlm.nih.gov/30192544

DMVSKQF	DI	DMVSKQF
DMVSKQF	DN	Alpha-Helical lipopeptides IIK
DMVSKQF	MI	TT85VHW
DMVSKQF	MN	MERS-CoV spike glycoprotein (S)
DMVSKQF	MT	DTT
DMVSKQF	MA	Inhibitor
DMVSKQF	RN	De Novo Design of -Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. J Med Chem. 2018 Oct 11;61(19):8734-8745.
DMVSKQF	RU	https://pubmed.ncbi.nlm.nih.gov/30192544

DM1MGBX	DI	DM1MGBX
DM1MGBX	DN	Alpha-Helical lipopeptides IIS
DM1MGBX	MI	TT85VHW
DM1MGBX	MN	MERS-CoV spike glycoprotein (S)
DM1MGBX	MT	DTT
DM1MGBX	MA	Inhibitor
DM1MGBX	RN	De Novo Design of -Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. J Med Chem. 2018 Oct 11;61(19):8734-8745.
DM1MGBX	RU	https://pubmed.ncbi.nlm.nih.gov/30192544

DM3WVM4	DI	DM3WVM4
DM3WVM4	DN	Alpha-Helical lipopeptides LLS
DM3WVM4	MI	TT85VHW
DM3WVM4	MN	MERS-CoV spike glycoprotein (S)
DM3WVM4	MT	DTT
DM3WVM4	MA	Inhibitor
DM3WVM4	RN	De Novo Design of -Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. J Med Chem. 2018 Oct 11;61(19):8734-8745.
DM3WVM4	RU	https://pubmed.ncbi.nlm.nih.gov/30192544

DMQMAWK	DI	DMQMAWK
DMQMAWK	DN	Alpha-Zearalenol
DMQMAWK	MI	DTFI42L
DMQMAWK	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMQMAWK	MT	DTP
DMQMAWK	MA	Substrate
DMQMAWK	RN	ABCC1, ABCC2 and ABCC3 are implicated in the transepithelial transport of the myco-estrogen zearalenone and its major metabolites. Toxicol Lett. 2009 Oct 28;190(2):215-23.
DMQMAWK	RU	https://doi.org/10.1016/j.toxlet.2009.07.021

DM2U16Z	DI	DM2U16Z
DM2U16Z	DN	ANAVEX 1007
DM2U16Z	MI	TT5TPI6
DM2U16Z	MN	Opioid receptor sigma 1 (OPRS1)
DM2U16Z	MT	DTT
DM2U16Z	MA	Agonist
DM2U16Z	RN	2011 Pipeline of Anavex.
DM2U16Z	RU	http://anavex.com/pipeline.html

DM2U16Z	DI	DM2U16Z
DM2U16Z	DN	ANAVEX 1007
DM2U16Z	MI	TT9NXW4
DM2U16Z	MN	Sigma intracellular receptor 2 (TMEM97)
DM2U16Z	MT	DTT
DM2U16Z	MA	Agonist
DM2U16Z	RN	2011 Pipeline of Anavex.
DM2U16Z	RU	http://anavex.com/pipeline.html

DM1MQON	DI	DM1MQON
DM1MQON	DN	ANAVEX 1-41
DM1MQON	MI	TT5TPI6
DM1MQON	MN	Opioid receptor sigma 1 (OPRS1)
DM1MQON	MT	DTT
DM1MQON	MA	Agonist
DM1MQON	RN	2011 Pipeline of Anavex.
DM1MQON	RU	http://anavex.com/pipeline.html

DM61TDB	DI	DM61TDB
DM61TDB	DN	ARI-809
DM61TDB	MI	TTFBNVI
DM61TDB	MN	Aldose reductase (AKR1B1)
DM61TDB	MT	DTT
DM61TDB	MA	Inhibitor
DM61TDB	RN	A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy. Diabetes. 2006 Oct;55(10):2757-62.
DM61TDB	RU	https://pubmed.ncbi.nlm.nih.gov/17003340

DMMD8VY	DI	DMMD8VY
DMMD8VY	DN	AR-R-1589
DMMD8VY	MI	TTCG0AL
DMMD8VY	MN	Cholecystokinin receptor type A (CCKAR)
DMMD8VY	MT	DTT
DMMD8VY	MA	Agonist
DMMD8VY	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DMMD8VY	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMRPX4W	DI	DMRPX4W
DMRPX4W	DN	ASP8497
DMRPX4W	MI	TTDIGC1
DMRPX4W	MN	Dipeptidyl peptidase 4 (DPP-4)
DMRPX4W	MT	DTT
DMRPX4W	MA	Inhibitor
DMRPX4W	RN	Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87.
DMRPX4W	RU	https://pubmed.ncbi.nlm.nih.gov/19149538

DM34FEA	DI	DM34FEA
DM34FEA	DN	ATA2431
DM34FEA	MI	TTM6QSK
DM34FEA	MN	B-cell receptor CD22 (CD22)
DM34FEA	MT	DTT
DM34FEA	RN	Clinical pipeline report, company report or official report of Atara Biotherapeutics.
DM34FEA	RU	https://www.atarabio.com/pipeline/

DM34FEA	DI	DM34FEA
DM34FEA	DN	ATA2431
DM34FEA	MI	TTW640A
DM34FEA	MN	B-lymphocyte surface antigen B4 (CD19)
DM34FEA	MT	DTT
DM34FEA	RN	Clinical pipeline report, company report or official report of Atara Biotherapeutics.
DM34FEA	RU	https://www.atarabio.com/pipeline/

DM34FEA	DI	DM34FEA
DM34FEA	DN	ATA2431
DM34FEA	MI	TTUE541
DM34FEA	MN	Leukocyte surface antigen Leu-16 (CD20)
DM34FEA	MT	DTT
DM34FEA	RN	Clinical pipeline report, company report or official report of Atara Biotherapeutics.
DM34FEA	RU	https://www.atarabio.com/pipeline/

DMJTYH3	DI	DMJTYH3
DMJTYH3	DN	ATA3219
DMJTYH3	MI	TTW640A
DMJTYH3	MN	B-lymphocyte surface antigen B4 (CD19)
DMJTYH3	MT	DTT
DMJTYH3	RN	Clinical pipeline report, company report or official report of Atara Biotherapeutics.
DMJTYH3	RU	https://www.atarabio.com/pipeline/

DMXQVBT	DI	DMXQVBT
DMXQVBT	DN	ATA3271
DMXQVBT	MI	TT4RXME
DMXQVBT	MN	Mesothelin (MSLN)
DMXQVBT	MT	DTT
DMXQVBT	RN	Clinical pipeline report, company report or official report of Atara Biotherapeutics.
DMXQVBT	RU	https://www.atarabio.com/pipeline/

DMZJVR5	DI	DMZJVR5
DMZJVR5	DN	ATI-17000
DMZJVR5	MI	TTPC4TU
DMZJVR5	MN	5-HT 3A receptor (HTR3A)
DMZJVR5	MT	DTT
DMZJVR5	MA	Antagonist
DMZJVR5	RN	Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
DMZJVR5	RU	https://pubmed.ncbi.nlm.nih.gov/16634703

DMZJVR5	DI	DMZJVR5
DMZJVR5	DN	ATI-17000
DMZJVR5	MI	TTNT7K8
DMZJVR5	MN	Nociceptin receptor (OPRL1)
DMZJVR5	MT	DTT
DMZJVR5	MA	Antagonist
DMZJVR5	RN	Nocistatin and nociceptin given centrally induce opioid-mediated gastric mucosal protection. Peptides. 2008 Dec;29(12):2257-65.
DMZJVR5	RU	https://pubmed.ncbi.nlm.nih.gov/18930088

DM4XZU2	DI	DM4XZU2
DM4XZU2	DN	ATL-1101
DM4XZU2	MI	TTQFBMY
DM4XZU2	MN	IGF1R messenger RNA (IGF1R mRNA)
DM4XZU2	MT	DTT
DM4XZU2	RN	Clinical pipeline report, company report or official report of Antisense Therapeutics.
DM4XZU2	RU	http://www.antisense.com.au/product-pipeline/atl1101-for-prostate-cancer/

DM0KM6F	DI	DM0KM6F
DM0KM6F	DN	AUNP-12
DM0KM6F	MI	TTNBFWK
DM0KM6F	MN	Programmed cell death protein 1 (PD-1)
DM0KM6F	MT	DTT
DM0KM6F	MA	Inhibitor
DM0KM6F	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DM0KM6F	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMKQ20J	DI	DMKQ20J
DMKQ20J	DN	AZ505
DMKQ20J	MI	TT7YJFO
DMKQ20J	MN	SET and MYND domain-containing protein 2 (SMYD2)
DMKQ20J	MT	DTT
DMKQ20J	MA	Inhibitor
DMKQ20J	RN	Structural basis of substrate methylation and inhibition of SMYD2. Structure. 2011 Sep 7;19(9):1262-73.
DMKQ20J	RU	https://pubmed.ncbi.nlm.nih.gov/21782458

DMY7R3X	DI	DMY7R3X
DMY7R3X	DN	AZD-1678
DMY7R3X	MI	TT7HQD0
DMY7R3X	MN	C-C chemokine receptor type 4 (CCR4)
DMY7R3X	MT	DTT
DMY7R3X	MA	Antagonist
DMY7R3X	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030818)
DMY7R3X	RU	http://adisinsight.springer.com/drugs/800030818

DM3FLMR	DI	DM3FLMR
DM3FLMR	DN	Azidothymidine monophosphate
DM3FLMR	MI	DTI7UX6
DM3FLMR	MN	Breast cancer resistance protein (ABCG2)
DM3FLMR	MT	DTP
DM3FLMR	MA	Substrate
DM3FLMR	RN	Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J. 2005 May 11;7(1):E118-33.
DM3FLMR	RU	https://doi.org/10.1208/aapsj070112

DM3FLMR	DI	DM3FLMR
DM3FLMR	DN	Azidothymidine monophosphate
DM3FLMR	MI	DTCSGPB
DM3FLMR	MN	Multidrug resistance-associated protein 4 (ABCC4)
DM3FLMR	MT	DTP
DM3FLMR	MA	Substrate
DM3FLMR	RN	MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med. 1999 Sep;5(9):1048-51.
DM3FLMR	RU	https://doi.org/10.1038/12487

DMOW07D	DI	DMOW07D
DMOW07D	DN	BAP-15
DMOW07D	MI	TTGYTMA
DMOW07D	MN	Isopeptidase T (USP5)
DMOW07D	MT	DTT
DMOW07D	MA	Inhibitor
DMOW07D	RN	The proteasome deubiquitinase inhibitor bAP15 downregulates TGF-/Smad signaling and induces apoptosis via UCHL5 inhibition in ovarian cancer. Oncotarget. 2019 Oct 15;10(57):5932-5948.
DMOW07D	RU	https://pubmed.ncbi.nlm.nih.gov/31666925

DMOW07D	DI	DMOW07D
DMOW07D	DN	BAP-15
DMOW07D	MI	TTVSYP9
DMOW07D	MN	Ubiquitin carboxyl-terminal hydrolase 14 (USP14)
DMOW07D	MT	DTT
DMOW07D	MA	Inhibitor
DMOW07D	RN	The proteasome deubiquitinase inhibitor bAP15 downregulates TGF-/Smad signaling and induces apoptosis via UCHL5 inhibition in ovarian cancer. Oncotarget. 2019 Oct 15;10(57):5932-5948.
DMOW07D	RU	https://pubmed.ncbi.nlm.nih.gov/31666925

DMTJZIL	DI	DMTJZIL
DMTJZIL	DN	Barasertib-hQPA
DMTJZIL	MI	DTI7UX6
DMTJZIL	MN	Breast cancer resistance protein (ABCG2)
DMTJZIL	MT	DTP
DMTJZIL	MA	Substrate
DMTJZIL	RN	P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA. BMC Cancer. 2011 Jun 16;11:254.
DMTJZIL	RU	https://doi.org/10.1186/1471-2407-11-254

DM92VRP	DI	DM92VRP
DM92VRP	DN	Batimastat
DM92VRP	MI	TTUZ2L5
DM92VRP	MN	Matrix metalloproteinase-3 (MMP-3)
DM92VRP	MT	DTT
DM92VRP	MA	Modulator
DM92VRP	RN	Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res. 1994 Sep 1;54(17):4726-8.
DM92VRP	RU	https://www.ncbi.nlm.nih.gov/pubmed/8062271

DMWH19X	DI	DMWH19X
DMWH19X	DN	BAY 598
DMWH19X	MI	TT7YJFO
DMWH19X	MN	SET and MYND domain-containing protein 2 (SMYD2)
DMWH19X	MT	DTT
DMWH19X	MA	Inhibitor
DMWH19X	RN	Discovery and Characterization of a Highly Potent and Selective Aminopyrazoline-Based in Vivo Probe (BAY-598) for the Protein Lysine Methyltransferase SMYD2. J Med Chem. 2016 May 26;59(10):4578-600.
DMWH19X	RU	https://pubmed.ncbi.nlm.nih.gov/27075367

DMTEJV1	DI	DMTEJV1
DMTEJV1	DN	BAY 60-6583
DMTEJV1	MI	TTK25J1
DMTEJV1	MN	Adenosine A1 receptor (ADORA1)
DMTEJV1	MT	DTT
DMTEJV1	MA	Agonist
DMTEJV1	RN	Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion. J Mol Cell Cardiol. 2007 Sep;43(3):262-71.
DMTEJV1	RU	https://pubmed.ncbi.nlm.nih.gov/17632123

DMTEJV1	DI	DMTEJV1
DMTEJV1	DN	BAY 60-6583
DMTEJV1	MI	TTNE7KG
DMTEJV1	MN	Adenosine A2b receptor (ADORA2B)
DMTEJV1	MT	DTT
DMTEJV1	MA	Agonist
DMTEJV1	RN	Cardioprotection by ecto-5'-nucleotidase (CD73) and A2B adenosine receptors. Circulation. 2007 Mar 27;115(12):1581-90.
DMTEJV1	RU	https://pubmed.ncbi.nlm.nih.gov/17353435

DMTEJV1	DI	DMTEJV1
DMTEJV1	DN	BAY 60-6583
DMTEJV1	MI	TTJFY5U
DMTEJV1	MN	Adenosine A3 receptor (ADORA3)
DMTEJV1	MT	DTT
DMTEJV1	MA	Agonist
DMTEJV1	RN	Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion. J Mol Cell Cardiol. 2007 Sep;43(3):262-71.
DMTEJV1	RU	https://pubmed.ncbi.nlm.nih.gov/17632123

DMVESTF	DI	DMVESTF
DMVESTF	DN	BAY-38-1315
DMVESTF	MI	TTFQAYR
DMVESTF	MN	Cholesteryl ester transfer protein (CETP)
DMVESTF	MT	DTT
DMVESTF	MA	Inhibitor
DMVESTF	RN	Chromanol derivatives--a novel class of CETP inhibitors. Bioorg Med Chem Lett. 2011 Jan 1;21(1):488-91.
DMVESTF	RU	https://pubmed.ncbi.nlm.nih.gov/21084191

DM3EUBA	DI	DM3EUBA
DM3EUBA	DN	BC-1215
DM3EUBA	MI	TTUX14L
DM3EUBA	MN	F-box only protein 3 (FBXO3)
DM3EUBA	MT	DTT
DM3EUBA	MA	Antagonist
DM3EUBA	RN	Targeting F box protein Fbxo3 to control cytokine-driven inflammation. J Immunol. 2013 Nov 15;191(10):5247-55.
DM3EUBA	RU	https://pubmed.ncbi.nlm.nih.gov/24123678

DMSJ2I6	DI	DMSJ2I6
DMSJ2I6	DN	Beta-aminopropionitrile
DMSJ2I6	MI	TTFSUHX
DMSJ2I6	MN	Lysyl oxidase homolog 2 (LOXL2)
DMSJ2I6	MT	DTT
DMSJ2I6	MA	Inhibitor
DMSJ2I6	RN	Wnt signaling and Loxl2 promote aggressive osteosarcoma. Cell Res. 2020 Oct;30(10):885-901.
DMSJ2I6	RU	https://pubmed.ncbi.nlm.nih.gov/32686768

DM6BGJ9	DI	DM6BGJ9
DM6BGJ9	DN	BFF-122
DM6BGJ9	MI	TTT3IXG
DM6BGJ9	MN	Kynurenine oxoglutarate transaminase II (AADAT)
DM6BGJ9	MT	DTT
DM6BGJ9	MA	Inhibitor
DM6BGJ9	RN	Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019 May;18(5):379-401.
DM6BGJ9	RU	https://pubmed.ncbi.nlm.nih.gov/30760888

DMK3SAF	DI	DMK3SAF
DMK3SAF	DN	BI-D1870
DMK3SAF	MI	TTIXKA4
DMK3SAF	MN	Ribosomal protein S6 kinase alpha-1 (RSK1)
DMK3SAF	MT	DTT
DMK3SAF	MA	Inhibitor
DMK3SAF	RN	BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. Biochem J. 2007 Jan 1;401(1):29-38.
DMK3SAF	RU	https://pubmed.ncbi.nlm.nih.gov/17040210

DMK3SAF	DI	DMK3SAF
DMK3SAF	DN	BI-D1870
DMK3SAF	MI	TT0ZW9O
DMK3SAF	MN	Ribosomal protein S6 kinase alpha-2 (RSK2)
DMK3SAF	MT	DTT
DMK3SAF	MA	Inhibitor
DMK3SAF	RN	BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. Biochem J. 2007 Jan 1;401(1):29-38.
DMK3SAF	RU	https://pubmed.ncbi.nlm.nih.gov/17040210

DMK3SAF	DI	DMK3SAF
DMK3SAF	DN	BI-D1870
DMK3SAF	MI	TTUM2ZR
DMK3SAF	MN	Ribosomal protein S6 kinase alpha-3 (RSK3)
DMK3SAF	MT	DTT
DMK3SAF	MA	Inhibitor
DMK3SAF	RN	BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. Biochem J. 2007 Jan 1;401(1):29-38.
DMK3SAF	RU	https://pubmed.ncbi.nlm.nih.gov/17040210

DMK3SAF	DI	DMK3SAF
DMK3SAF	DN	BI-D1870
DMK3SAF	MI	TT3KYWB
DMK3SAF	MN	Ribosomal protein S6 kinase alpha-6 (RSK6)
DMK3SAF	MT	DTT
DMK3SAF	MA	Inhibitor
DMK3SAF	RN	BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. Biochem J. 2007 Jan 1;401(1):29-38.
DMK3SAF	RU	https://pubmed.ncbi.nlm.nih.gov/17040210

DM2JOXF	DI	DM2JOXF
DM2JOXF	DN	BIIR-777
DM2JOXF	MI	TTAN6JD
DM2JOXF	MN	Glutamate receptor AMPA (GRIA)
DM2JOXF	MT	DTT
DM2JOXF	MA	Modulator
DM2JOXF	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM2JOXF	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMPUBK8	DI	DMPUBK8
DMPUBK8	DN	BIO-306
DMPUBK8	MI	TT27RFC
DMPUBK8	MN	Opioid receptor delta (OPRD1)
DMPUBK8	MT	DTT
DMPUBK8	MA	Agonist
DMPUBK8	RN	Pharmacologic therapeutics for cardiac reperfusion injury. Expert Opin Emerg Drugs. 2007 Sep;12(3):367-88.
DMPUBK8	RU	https://pubmed.ncbi.nlm.nih.gov/17874967

DM5CBNY	DI	DM5CBNY
DM5CBNY	DN	BIX-01294
DM5CBNY	MI	TTOFXD7
DM5CBNY	MN	Euchromatic histone-lysine N-methyltransferase 1 (EHMT1)
DM5CBNY	MT	DTT
DM5CBNY	MA	Inhibitor
DM5CBNY	RN	Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell. 2007 Feb 9;25(3):473-81.
DM5CBNY	RU	https://pubmed.ncbi.nlm.nih.gov/17289593

DM5CBNY	DI	DM5CBNY
DM5CBNY	DN	BIX-01294
DM5CBNY	MI	TTS6RZT
DM5CBNY	MN	Histone-lysine N-methyltransferase EHMT2 (EHMT2)
DM5CBNY	MT	DTT
DM5CBNY	MA	Inhibitor
DM5CBNY	RN	Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell. 2007 Feb 9;25(3):473-81.
DM5CBNY	RU	https://pubmed.ncbi.nlm.nih.gov/17289593

DMDJH2L	DI	DMDJH2L
DMDJH2L	DN	BMS 536924
DMDJH2L	MI	DTI7UX6
DMDJH2L	MN	Breast cancer resistance protein (ABCG2)
DMDJH2L	MT	DTP
DMDJH2L	MA	Substrate
DMDJH2L	RN	Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924. Mol Cancer Ther. 2011 Jan;10(1):117-25.
DMDJH2L	RU	https://doi.org/10.1158/1535-7163.MCT-10-0438

DMHAWBR	DI	DMHAWBR
DMHAWBR	DN	BMS-192548
DMHAWBR	MI	TTJ6WK9
DMHAWBR	MN	Neuropeptide Y receptor type 2 (NPY2R)
DMHAWBR	MT	DTT
DMHAWBR	MA	Antagonist
DMHAWBR	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DMHAWBR	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMCWIBU	DI	DMCWIBU
DMCWIBU	DN	BMS-3870032
DMCWIBU	MI	DTUGYRD
DMCWIBU	MN	P-glycoprotein 1 (ABCB1)
DMCWIBU	MT	DTP
DMCWIBU	MA	Substrate
DMCWIBU	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMCWIBU	RU	https://doi.org/10.1007/s11095-012-0935-x

DMQG39T	DI	DMQG39T
DMQG39T	DN	BMS-695735
DMQG39T	MI	TTRLW2X
DMQG39T	MN	Fibroblast growth factor receptor 1 (FGFR1)
DMQG39T	MT	DTT
DMQG39T	MA	Inhibitor
DMQG39T	RN	Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)py... J Med Chem. 2008 Oct 9;51(19):5897-900.
DMQG39T	RU	https://pubmed.ncbi.nlm.nih.gov/18763755

DMQG39T	DI	DMQG39T
DMQG39T	DN	BMS-695735
DMQG39T	MI	TTHRID2
DMQG39T	MN	Insulin-like growth factor I receptor (IGF1R)
DMQG39T	MT	DTT
DMQG39T	MA	Inhibitor
DMQG39T	RN	Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)py... J Med Chem. 2008 Oct 9;51(19):5897-900.
DMQG39T	RU	https://pubmed.ncbi.nlm.nih.gov/18763755

DM4BZEJ	DI	DM4BZEJ
DM4BZEJ	DN	BMS-986118
DM4BZEJ	MI	TTB8FUC
DM4BZEJ	MN	Free fatty acid receptor 1 (GPR40)
DM4BZEJ	MT	DTT
DM4BZEJ	MA	Agonist
DM4BZEJ	RN	Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists. J Med Chem. 2018 Feb 8;61(3):681-694.
DM4BZEJ	RU	https://pubmed.ncbi.nlm.nih.gov/29316397

DM8TAI9	DI	DM8TAI9
DM8TAI9	DN	BMS-986202
DM8TAI9	MI	TTQ6S1K
DM8TAI9	MN	Lysophosphatidic acid receptor 1 (LPAR1)
DM8TAI9	MT	DTT
DM8TAI9	MA	Antagonist
DM8TAI9	RN	Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist. J Pharmacol Exp Ther. 2011 Mar;336(3):693-700.
DM8TAI9	RU	https://pubmed.ncbi.nlm.nih.gov/21159750

DMRCMEK	DI	DMRCMEK
DMRCMEK	DN	BMS-PCSK9
DMRCMEK	MI	TTNIZ2B
DMRCMEK	MN	PCSK9 messenger RNA (PCSK9 mRNA)
DMRCMEK	MT	DTT
DMRCMEK	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
DMRCMEK	RU	http://www.isispharm.com/index.htm

DMCPQJ9	DI	DMCPQJ9
DMCPQJ9	DN	BN-AA-003-NY
DMCPQJ9	MI	TTZAYWL
DMCPQJ9	MN	Estrogen receptor (ESR)
DMCPQJ9	MT	DTT
DMCPQJ9	MA	Modulator
DMCPQJ9	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023897)
DMCPQJ9	RU	http://adisinsight.springer.com/drugs/800023897

DMVMY4X	DI	DMVMY4X
DMVMY4X	DN	BN-AO-014
DMVMY4X	MI	TTZAYWL
DMVMY4X	MN	Estrogen receptor (ESR)
DMVMY4X	MT	DTT
DMVMY4X	MA	Modulator
DMVMY4X	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023897)
DMVMY4X	RU	http://adisinsight.springer.com/drugs/800023897

DMM1O0P	DI	DMM1O0P
DMM1O0P	DN	BNC-102
DMM1O0P	MI	TTY6C71
DMM1O0P	MN	G-protein coupled receptor 48 (LGR4)
DMM1O0P	MT	DTT
DMM1O0P	MA	Inhibitor
DMM1O0P	RN	Opportunities for therapeutic antibodies directed at G-protein-coupled receptors. Nat Rev Drug Discov. 2017 Sep 1;16(9):661.
DMM1O0P	RU	https://pubmed.ncbi.nlm.nih.gov/28860586

DMM1O0P	DI	DMM1O0P
DMM1O0P	DN	BNC-102
DMM1O0P	MI	TTTSGRH
DMM1O0P	MN	Leucine-rich repeat-containing GPCR 5 (LGR5)
DMM1O0P	MT	DTT
DMM1O0P	MA	Inhibitor
DMM1O0P	RN	Opportunities for therapeutic antibodies directed at G-protein-coupled receptors. Nat Rev Drug Discov. 2017 Sep 1;16(9):661.
DMM1O0P	RU	https://pubmed.ncbi.nlm.nih.gov/28860586

DMBPTDC	DI	DMBPTDC
DMBPTDC	DN	BN-CB-045
DMBPTDC	MI	TTZAYWL
DMBPTDC	MN	Estrogen receptor (ESR)
DMBPTDC	MT	DTT
DMBPTDC	MA	Modulator
DMBPTDC	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023897)
DMBPTDC	RU	http://adisinsight.springer.com/drugs/800023897

DMFNLE6	DI	DMFNLE6
DMFNLE6	DN	BN-DF-037
DMFNLE6	MI	TTZAYWL
DMFNLE6	MN	Estrogen receptor (ESR)
DMFNLE6	MT	DTT
DMFNLE6	MA	Modulator
DMFNLE6	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023897)
DMFNLE6	RU	http://adisinsight.springer.com/drugs/800023897

DM0PJU9	DI	DM0PJU9
DM0PJU9	DN	BN-GU-005-DHP
DM0PJU9	MI	TTZAYWL
DM0PJU9	MN	Estrogen receptor (ESR)
DM0PJU9	MT	DTT
DM0PJU9	MA	Modulator
DM0PJU9	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023897)
DM0PJU9	RU	http://adisinsight.springer.com/drugs/800023897

DM8WDAL	DI	DM8WDAL
DM8WDAL	DN	BN-OD-026
DM8WDAL	MI	TTZAYWL
DM8WDAL	MN	Estrogen receptor (ESR)
DM8WDAL	MT	DTT
DM8WDAL	MA	Modulator
DM8WDAL	RN	Clinical pipeline report, company report or official report of Bionovo.
DM8WDAL	RU	http://bionovo.com/investors/pr/MjAxMTEyMDgwODAw

DM5O3HC	DI	DM5O3HC
DM5O3HC	DN	Bouvardin
DM5O3HC	MI	DTUGYRD
DM5O3HC	MN	P-glycoprotein 1 (ABCB1)
DM5O3HC	MT	DTP
DM5O3HC	MA	Substrate
DM5O3HC	RN	Fingerprint-based in silico models for the prediction of P-glycoprotein substrates and inhibitors. Bioorg Med Chem. 2012 Sep 15;20(18):5388-95.
DM5O3HC	RU	https://doi.org/10.1016/j.bmc.2012.03.045

DMT2C78	DI	DMT2C78
DMT2C78	DN	Brensocatib
DMT2C78	MI	TTQ9J6R
DMT2C78	MN	HUMAN dipeptidyl peptidase 1 (CTSC)
DMT2C78	MT	DTT
DMT2C78	MA	Inhibitor
DMT2C78	RN	Brensocatib (Formerly INS1007) to be Studied in Patients with Severe COVID-19 in Investigator-Initiated Trial. Apr 23, 2020.
DMT2C78	RU	https://www.biospace.com/article/releases/brensocatib-formerly-ins1007-to-be-studied-in-patients-with-severe-covid-19-in-investigator-initiated-trial/

DMO15TX	DI	DMO15TX
DMO15TX	DN	BSF-78438
DMO15TX	MI	TTZFYLI
DMO15TX	MN	Dopamine D1 receptor (D1R)
DMO15TX	MT	DTT
DMO15TX	MA	Binder
DMO15TX	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMO15TX	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DM3WHB2	DI	DM3WHB2
DM3WHB2	DN	BST-1005
DM3WHB2	MI	TTNS7H3
DM3WHB2	MN	Laminin gamma-2 subunit (LAMC2)
DM3WHB2	MT	DTT
DM3WHB2	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019225)
DM3WHB2	RU	http://adisinsight.springer.com/drugs/800019225

DMT4532	DI	DMT4532
DMT4532	DN	Bunitrolol
DMT4532	MI	DTUGYRD
DMT4532	MN	P-glycoprotein 1 (ABCB1)
DMT4532	MT	DTP
DMT4532	MA	Substrate
DMT4532	RN	Contribution of P-glycoprotein to bunitrolol efflux across blood-brain barrier. Biopharm Drug Dispos. 1999 Mar;20(2):85-90.
DMT4532	RU	https://doi.org/10.1002/(SICI)1099-081X(199903)20:2<85::AID-BDD159>3.0.CO;2-3

DMDSX58	DI	DMDSX58
DMDSX58	DN	BVT-A
DMDSX58	MI	TTKMAZ6
DMDSX58	MN	Growth hormone receptor (GHR)
DMDSX58	MT	DTT
DMDSX58	MA	Antagonist
DMDSX58	RN	Emerging drugs for acromegaly. Expert Opin Emerg Drugs. 2008 Jun;13(2):273-93.
DMDSX58	RU	https://pubmed.ncbi.nlm.nih.gov/18537521

DMY9F1M	DI	DMY9F1M
DMY9F1M	DN	C30
DMY9F1M	MI	TTOMVUW
DMY9F1M	MN	Pseudomonas Transcriptional activator protein LasR (Pseudo LasR)
DMY9F1M	MT	DTT
DMY9F1M	MA	Inhibitor
DMY9F1M	RN	Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance. Nat Rev Drug Discov. 2017 Jul;16(7):457-471.
DMY9F1M	RU	https://pubmed.ncbi.nlm.nih.gov/28337021

DMVN3FU	DI	DMVN3FU
DMVN3FU	DN	CA-074Me
DMVN3FU	MI	TTF2LRI
DMVN3FU	MN	Cathepsin B (CTSB)
DMVN3FU	MT	DTT
DMVN3FU	MA	Inhibitor
DMVN3FU	RN	CA-074Me inhibits Cathepsin-B and alleviates fibrosis after myocardial infarction. Panminerva Med. 2019 Sep 24.
DMVN3FU	RU	https://pubmed.ncbi.nlm.nih.gov/31577087

DM9HG6S	DI	DM9HG6S
DM9HG6S	DN	CAR-T cells targeting CD117
DM9HG6S	MI	TTX41N9
DM9HG6S	MN	Tyrosine-protein kinase Kit (KIT)
DM9HG6S	MT	DTT
DM9HG6S	MA	CAR-T-Cell-Therapy
DM9HG6S	RN	ClinicalTrials.gov (NCT03473457) CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia
DM9HG6S	RU	https://clinicaltrials.gov/ct2/show/NCT03473457

DMSZNQE	DI	DMSZNQE
DMSZNQE	DN	CAR-T cells targeting CD123
DMSZNQE	MI	TTENHJ0
DMSZNQE	MN	Interleukin 3 receptor alpha (IL3RA)
DMSZNQE	MT	DTT
DMSZNQE	MA	CAR-T-Cell-Therapy
DMSZNQE	RN	ClinicalTrials.gov (NCT03473457) CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia
DMSZNQE	RU	https://clinicaltrials.gov/ct2/show/NCT03473457

DMYOR5T	DI	DMYOR5T
DMYOR5T	DN	CAR-T cells targeting CD133
DMYOR5T	MI	TTXMZ81
DMYOR5T	MN	Prominin-1 (PROM1)
DMYOR5T	MT	DTT
DMYOR5T	MA	CAR-T-Cell-Therapy
DMYOR5T	RN	ClinicalTrials.gov (NCT03473457) CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia
DMYOR5T	RU	https://clinicaltrials.gov/ct2/show/NCT03473457

DMH7BT9	DI	DMH7BT9
DMH7BT9	DN	CAR-T cells targeting CD33
DMH7BT9	MI	TTJVYO3
DMH7BT9	MN	Myeloid cell surface antigen CD33 (CD33)
DMH7BT9	MT	DTT
DMH7BT9	MA	CAR-T-Cell-Therapy
DMH7BT9	RN	ClinicalTrials.gov (NCT03473457) CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia
DMH7BT9	RU	https://clinicaltrials.gov/ct2/show/NCT03473457

DM3G0OP	DI	DM3G0OP
DM3G0OP	DN	CAR-T cells targeting CD34
DM3G0OP	MI	TTZAVYN
DM3G0OP	MN	Hematopoietic progenitor cell antigen CD34 (CD34)
DM3G0OP	MT	DTT
DM3G0OP	MA	CAR-T-Cell-Therapy
DM3G0OP	RN	ClinicalTrials.gov (NCT03473457) CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia
DM3G0OP	RU	https://clinicaltrials.gov/ct2/show/NCT03473457

DMA1BLC	DI	DMA1BLC
DMA1BLC	DN	CAR-T cells targeting Mucl
DMA1BLC	MI	TTBHFYQ
DMA1BLC	MN	Mucin-1 (MUC1)
DMA1BLC	MT	DTT
DMA1BLC	MA	CAR-T-Cell-Therapy
DMA1BLC	RN	ClinicalTrials.gov (NCT03473457) CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia
DMA1BLC	RU	https://clinicaltrials.gov/ct2/show/NCT03473457

DMDUKMR	DI	DMDUKMR
DMDUKMR	DN	CAT4001
DMDUKMR	MI	TTA6ZN2
DMDUKMR	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMDUKMR	MT	DTT
DMDUKMR	MA	Activator
DMDUKMR	RN	Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat Rev Drug Discov. 2019 Apr;18(4):295-317.
DMDUKMR	RU	https://pubmed.ncbi.nlm.nih.gov/30610225

DMKFAG3	DI	DMKFAG3
DMKFAG3	DN	CB-01-16
DMKFAG3	MI	TTN4QDT
DMKFAG3	MN	Opioid receptor (OPR)
DMKFAG3	MT	DTT
DMKFAG3	MA	Antagonist
DMKFAG3	RN	Clinical pipeline report, company report or official report of Cosmo.
DMKFAG3	RU	http://www.cosmopharmaceuticals.com/activities/pipeline/cb-01-16.aspx

DM53JW0	DI	DM53JW0
DM53JW0	DN	CB1 antagonist, Bayer
DM53JW0	MI	TT6OEDT
DM53JW0	MN	Cannabinoid receptor 1 (CB1)
DM53JW0	MT	DTT
DM53JW0	MA	Antagonist
DM53JW0	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DM53JW0	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMJUQ6E	DI	DMJUQ6E
DMJUQ6E	DN	CB7993113
DMJUQ6E	MI	TT037IE
DMJUQ6E	MN	Aryl hydrocarbon receptor (AHR)
DMJUQ6E	MT	DTT
DMJUQ6E	MA	Antagonist
DMJUQ6E	RN	In silico identification of an aryl hydrocarbon receptor antagonist with biological activity in vitro and in vivo. Mol Pharmacol. 2014 Nov;86(5):593-608.
DMJUQ6E	RU	https://pubmed.ncbi.nlm.nih.gov/25159092

DMCFEUG	DI	DMCFEUG
DMCFEUG	DN	CCG-208408
DMCFEUG	MI	DEUQTKA
DMCFEUG	MN	Beta-glucosidase (bglA)
DMCFEUG	MT	DME
DMCFEUG	MA	Metabolism
DMCFEUG	RN	Catabolism of citrus flavanones by the probiotics Bifidobacterium longum and Lactobacillus rhamnosus. Eur J Nutr. 2018 Feb;57(1):231-242.
DMCFEUG	RU	https://pubmed.ncbi.nlm.nih.gov/27722779

DM065ZH	DI	DM065ZH
DM065ZH	DN	CCT-018159
DM065ZH	MI	TT78R5H
DM065ZH	MN	Heat shock protein 90 alpha (HSP90A)
DM065ZH	MT	DTT
DM065ZH	MA	Inhibitor
DM065ZH	RN	Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008 Oct;8(7):761-82.
DM065ZH	RU	https://pubmed.ncbi.nlm.nih.gov/18855578

DMNA9KW	DI	DMNA9KW
DMNA9KW	DN	CCT251545
DMNA9KW	MI	TTBJR4L
DMNA9KW	MN	Cyclin-dependent kinase 8 (CDK8)
DMNA9KW	MT	DTT
DMNA9KW	MA	Inhibitor
DMNA9KW	RN	Kinase inhibitors: the road ahead. Nat Rev Drug Discov. 2018 May;17(5):353-377.
DMNA9KW	RU	https://pubmed.ncbi.nlm.nih.gov/29545548

DMWQIJX	DI	DMWQIJX
DMWQIJX	DN	Celastrol
DMWQIJX	MI	TTRYK0X
DMWQIJX	MN	Interleukin-1 beta (IL1B)
DMWQIJX	MT	DTT
DMWQIJX	MA	Suppressor
DMWQIJX	RN	Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
DMWQIJX	RU	https://pubmed.ncbi.nlm.nih.gov/17604499

DMWQIJX	DI	DMWQIJX
DMWQIJX	DN	Celastrol
DMWQIJX	MI	TTF8CQI
DMWQIJX	MN	Tumor necrosis factor (TNF)
DMWQIJX	MT	DTT
DMWQIJX	MA	Suppressor
DMWQIJX	RN	Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
DMWQIJX	RU	https://pubmed.ncbi.nlm.nih.gov/17604499

DM1ZFCS	DI	DM1ZFCS
DM1ZFCS	DN	Cephaeline
DM1ZFCS	MI	DTUGYRD
DM1ZFCS	MN	P-glycoprotein 1 (ABCB1)
DM1ZFCS	MT	DTP
DM1ZFCS	MA	Substrate
DM1ZFCS	RN	Fingerprint-based in silico models for the prediction of P-glycoprotein substrates and inhibitors. Bioorg Med Chem. 2012 Sep 15;20(18):5388-95.
DM1ZFCS	RU	https://doi.org/10.1016/j.bmc.2012.03.045

DMQSJ20	DI	DMQSJ20
DMQSJ20	DN	CF502
DMQSJ20	MI	TTJFY5U
DMQSJ20	MN	Adenosine A3 receptor (ADORA3)
DMQSJ20	MT	DTT
DMQSJ20	MA	Agonist
DMQSJ20	RN	2011 Pipeline of Can-Fite BioPharm.
DMQSJ20	RU	http://www.canfite.com/pipeline.html

DM0ULO2	DI	DM0ULO2
DM0ULO2	DN	CF602
DM0ULO2	MI	TTJFY5U
DM0ULO2	MN	Adenosine A3 receptor (ADORA3)
DM0ULO2	MT	DTT
DM0ULO2	MA	Agonist
DM0ULO2	RN	2011 Pipeline of Can-Fite BioPharm.
DM0ULO2	RU	http://www.canfite.com/pipeline.html

DMYGITU	DI	DMYGITU
DMYGITU	DN	CHDI-340246
DMYGITU	MI	TTIY56R
DMYGITU	MN	Kynurenine 3-hydroxylase (KMO)
DMYGITU	MT	DTT
DMYGITU	MA	Inhibitor
DMYGITU	RN	The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease. Exp Neurol. 2016 Aug;282:99-118.
DMYGITU	RU	https://pubmed.ncbi.nlm.nih.gov/27163548

DM89DQP	DI	DM89DQP
DM89DQP	DN	Chlamydocin
DM89DQP	MI	TT6R7JZ
DM89DQP	MN	Histone deacetylase 1 (HDAC1)
DM89DQP	MT	DTT
DM89DQP	MA	Inhibitor
DM89DQP	RN	Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92.
DM89DQP	RU	https://pubmed.ncbi.nlm.nih.gov/17896917

DMAPO0T	DI	DMAPO0T
DMAPO0T	DN	Ciglitazone
DMAPO0T	MI	DES5XRU
DMAPO0T	MN	Cytochrome P450 2C8 (CYP2C8)
DMAPO0T	MT	DME
DMAPO0T	MA	Metabolism
DMAPO0T	RN	Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther. 2005 May;77(5):404-14.
DMAPO0T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15900286

DMAPO0T	DI	DMAPO0T
DMAPO0T	DN	Ciglitazone
DMAPO0T	MI	DE4LYSA
DMAPO0T	MN	Cytochrome P450 3A4 (CYP3A4)
DMAPO0T	MT	DME
DMAPO0T	MA	Metabolism
DMAPO0T	RN	Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther. 2005 May;77(5):404-14.
DMAPO0T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15900286

DMAPO0T	DI	DMAPO0T
DMAPO0T	DN	Ciglitazone
DMAPO0T	MI	TTZMAO3
DMAPO0T	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMAPO0T	MT	DTT
DMAPO0T	MA	Agonist
DMAPO0T	RN	New drugs in development for the treatment of endometriosis. Expert Opin Investig Drugs. 2008 Aug;17(8):1187-202.
DMAPO0T	RU	https://pubmed.ncbi.nlm.nih.gov/18616415

DM37NYK	DI	DM37NYK
DM37NYK	DN	Citrate
DM37NYK	MI	DTFPWJ9
DM37NYK	MN	Sodium-coupled citrate transporter (SLC13A5)
DM37NYK	MT	DTP
DM37NYK	MA	Substrate
DM37NYK	RN	SLC13 family of Na+ coupled di- and tri-carboxylate/sulfate transporters. Mol Aspects Med. 2013 Apr-Jun;34(2-3):299-312.
DM37NYK	RU	http://www.ncbi.nlm.nih.gov/pubmed/23506872

DMV0RFU	DI	DMV0RFU
DMV0RFU	DN	CKI-7
DMV0RFU	MI	TT7OGZP
DMV0RFU	MN	Casein kinase 1 (CK1)
DMV0RFU	MT	DTT
DMV0RFU	MA	Inhibitor
DMV0RFU	RN	Crystal structures of two aminoglycoside kinases bound with a eukaryotic protein kinase inhibitor. PLoS One. 2011 May 9;6(5):e19589.
DMV0RFU	RU	https://pubmed.ncbi.nlm.nih.gov/21573013

DM6HADZ	DI	DM6HADZ
DM6HADZ	DN	CL-314698
DM6HADZ	MI	TTMXGCW
DM6HADZ	MN	Adrenergic receptor beta-3 (ADRB3)
DM6HADZ	MT	DTT
DM6HADZ	MA	Agonist
DM6HADZ	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DM6HADZ	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DM0BHL8	DI	DM0BHL8
DM0BHL8	DN	CLIK-148
DM0BHL8	MI	TT36ETB
DM0BHL8	MN	Cathepsin L (CTSL)
DM0BHL8	MT	DTT
DM0BHL8	MA	Inhibitor
DM0BHL8	RN	Structure-based development of specific inhibitors for individual cathepsins and their medical applications. Proc Jpn Acad Ser B Phys Biol Sci. 2011;87(2):29-39.
DM0BHL8	RU	https://pubmed.ncbi.nlm.nih.gov/21321479

DMXKN6R	DI	DMXKN6R
DMXKN6R	DN	CLIK-181
DMXKN6R	MI	TT36ETB
DMXKN6R	MN	Cathepsin L (CTSL)
DMXKN6R	MT	DTT
DMXKN6R	MA	Inhibitor
DMXKN6R	RN	Lysosomes as a therapeutic target. Nat Rev Drug Discov. 2019 Dec;18(12):923-948.
DMXKN6R	RU	https://pubmed.ncbi.nlm.nih.gov/31477883

DMP9EJ7	DI	DMP9EJ7
DMP9EJ7	DN	CM-2236
DMP9EJ7	MI	TTSQIFT
DMP9EJ7	MN	5-HT 1A receptor (HTR1A)
DMP9EJ7	MT	DTT
DMP9EJ7	MA	Agonist
DMP9EJ7	RN	CN patent application no. 104151292, Indole derivative or a pharmaceutically acceptable salt thereof.
DMP9EJ7	RU	http://www.google.com/patents/CN104151292A?cl=en

DMP9EJ7	DI	DMP9EJ7
DMP9EJ7	DN	CM-2236
DMP9EJ7	MI	TTNGILX
DMP9EJ7	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMP9EJ7	MT	DTT
DMP9EJ7	MA	Agonist
DMP9EJ7	RN	CN patent application no. 104151292, Indole derivative or a pharmaceutically acceptable salt thereof.
DMP9EJ7	RU	http://www.google.com/patents/CN104151292A?cl=en

DMHAI0M	DI	DMHAI0M
DMHAI0M	DN	CNSB-004
DMHAI0M	MI	TT4FDG6
DMHAI0M	MN	Voltage-gated calcium channel alpha Cav2.2 (CACNA1B)
DMHAI0M	MT	DTT
DMHAI0M	MA	Modulator
DMHAI0M	RN	CNSB004 (Leconotide) causes antihyperalgesia without side effects when given intravenously: a comparison with ziconotide in a rat model of diabetic neuropathic pain. Pain Med. 2010 Feb;11(2):262-73.
DMHAI0M	RU	https://pubmed.ncbi.nlm.nih.gov/20002322

DM1H8D6	DI	DM1H8D6
DM1H8D6	DN	CNX-011-67
DM1H8D6	MI	TTB8FUC
DM1H8D6	MN	Free fatty acid receptor 1 (GPR40)
DM1H8D6	MT	DTT
DM1H8D6	MA	Inhibitor
DM1H8D6	RN	CNX-011-67, a novel GPR40 agonist, enhances glucose responsiveness, insulin secretion and islet insulin content in n-STZ rats and in islets from type 2 diabetic patients. BMC Pharmacol Toxicol. 2014 Mar 25;15:19.
DM1H8D6	RU	https://pubmed.ncbi.nlm.nih.gov/24666736

DMG3BE1	DI	DMG3BE1
DMG3BE1	DN	Coelenterazine
DMG3BE1	MI	DTUGYRD
DMG3BE1	MN	P-glycoprotein 1 (ABCB1)
DMG3BE1	MT	DTP
DMG3BE1	MA	Substrate
DMG3BE1	RN	Imaging reversal of multidrug resistance in living mice with bioluminescence: MDR1 P-glycoprotein transports coelenterazine. Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1702-7.
DMG3BE1	RU	https://doi.org/10.1073/pnas.0304326101

DMN0GTR	DI	DMN0GTR
DMN0GTR	DN	COR100140
DMN0GTR	MI	TT2AST1
DMN0GTR	MN	Macrophage migration inhibitory factor (MIF)
DMN0GTR	MT	DTT
DMN0GTR	MA	Inhibitor
DMN0GTR	RN	Cortical Pty Ltd Presents MIF Antagonist Data at World Congress on Inflammation. Cortical Pty Ltd. 2005.
DMN0GTR	RU	http://www.cortical.com.au/downloads/20050901_mediarelease_MIF_Antagonist_Data.pdf

DMLXMCB	DI	DMLXMCB
DMLXMCB	DN	COR-D
DMLXMCB	MI	TT1MG9E
DMLXMCB	MN	Extracellular signal-regulated kinase 1 (ERK1)
DMLXMCB	MT	DTT
DMLXMCB	MA	Activator
DMLXMCB	RN	Corchorusin-D directed apoptosis of K562 cells occurs through activation of mitochondrial and death receptor pathways and suppression of AKT/PKB pathway. Cell Physiol Biochem. 2012;30(4):915-26.
DMLXMCB	RU	https://pubmed.ncbi.nlm.nih.gov/22965801

DMLXMCB	DI	DMLXMCB
DMLXMCB	DN	COR-D
DMLXMCB	MI	TT4TQBX
DMLXMCB	MN	Extracellular signal-regulated kinase 2 (ERK2)
DMLXMCB	MT	DTT
DMLXMCB	MA	Activator
DMLXMCB	RN	Corchorusin-D directed apoptosis of K562 cells occurs through activation of mitochondrial and death receptor pathways and suppression of AKT/PKB pathway. Cell Physiol Biochem. 2012;30(4):915-26.
DMLXMCB	RU	https://pubmed.ncbi.nlm.nih.gov/22965801

DMLXMCB	DI	DMLXMCB
DMLXMCB	DN	COR-D
DMLXMCB	MI	TT0K6EO
DMLXMCB	MN	Stress-activated protein kinase JNK1 (JNK1)
DMLXMCB	MT	DTT
DMLXMCB	MA	Activator
DMLXMCB	RN	Corchorusin-D directed apoptosis of K562 cells occurs through activation of mitochondrial and death receptor pathways and suppression of AKT/PKB pathway. Cell Physiol Biochem. 2012;30(4):915-26.
DMLXMCB	RU	https://pubmed.ncbi.nlm.nih.gov/22965801

DMLXMCB	DI	DMLXMCB
DMLXMCB	DN	COR-D
DMLXMCB	MI	TTHS0U8
DMLXMCB	MN	Stress-activated protein kinase JNK2 (JNK2)
DMLXMCB	MT	DTT
DMLXMCB	MA	Activator
DMLXMCB	RN	Corchorusin-D directed apoptosis of K562 cells occurs through activation of mitochondrial and death receptor pathways and suppression of AKT/PKB pathway. Cell Physiol Biochem. 2012;30(4):915-26.
DMLXMCB	RU	https://pubmed.ncbi.nlm.nih.gov/22965801

DMATUKO	DI	DMATUKO
DMATUKO	DN	CP-114271
DMATUKO	MI	TTMXGCW
DMATUKO	MN	Adrenergic receptor beta-3 (ADRB3)
DMATUKO	MT	DTT
DMATUKO	MA	Agonist
DMATUKO	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DMATUKO	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMQGRC8	DI	DMQGRC8
DMQGRC8	DN	CPH-102
DMQGRC8	MI	TTVDSZ0
DMQGRC8	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMQGRC8	MT	DTT
DMQGRC8	MA	Inhibitor
DMQGRC8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2771).
DMQGRC8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2771

DMWMBIV	DI	DMWMBIV
DMWMBIV	DN	CRA1000
DMWMBIV	MI	TT7EFHR
DMWMBIV	MN	Corticotropin-releasing factor receptor 1 (CRHR1)
DMWMBIV	MT	DTT
DMWMBIV	MA	Antagonist
DMWMBIV	RN	A review of drug options in age-related macular degeneration therapy and potential new agents. Expert Opin Pharmacother. 2006 Dec;7(17):2355-68.
DMWMBIV	RU	https://pubmed.ncbi.nlm.nih.gov/17109611

DM8AR0E	DI	DM8AR0E
DM8AR0E	DN	Cruentaren
DM8AR0E	MI	TTL2PXZ
DM8AR0E	MN	Vacuolar-type proton ATPase catalytic A (v-ATPase-A)
DM8AR0E	MT	DTT
DM8AR0E	MA	Inhibitor
DM8AR0E	RN	Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22.
DM8AR0E	RU	https://pubmed.ncbi.nlm.nih.gov/19463273

DMB4FWX	DI	DMB4FWX
DMB4FWX	DN	CS-00028
DMB4FWX	MI	TTBH0VX
DMB4FWX	MN	Histone deacetylase (HDAC)
DMB4FWX	MT	DTT
DMB4FWX	MA	Antagonist
DMB4FWX	RN	US patent application no. 2009,0162,329, Compositions comprising hdac inhibitors and methods of their use in restoring stem cell function and preventing heart failure.
DMB4FWX	RU	https://www.google.com/patents/US20090162329

DMK230A	DI	DMK230A
DMK230A	DN	CS-3030
DMK230A	MI	TTCIHJA
DMK230A	MN	Coagulation factor Xa (F10)
DMK230A	MT	DTT
DMK230A	MA	Inhibitor
DMK230A	RN	Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7.
DMK230A	RU	https://pubmed.ncbi.nlm.nih.gov/22844656

DMKVW25	DI	DMKVW25
DMKVW25	DN	Cu-anti-hAXL
DMKVW25	MI	TTZPY6J
DMKVW25	MN	Tyrosine-protein kinase UFO (AXL)
DMKVW25	MT	DTT
DMKVW25	RN	MicroPET/CT Imaging of AXL Downregulation by HSP90 Inhibition in Triple-Negative Breast Cancer. Contrast Media Mol Imaging. 2017 May 14;2017:1686525.
DMKVW25	RU	https://pubmed.ncbi.nlm.nih.gov/29097911

DMB1ET0	DI	DMB1ET0
DMB1ET0	DN	Cutamesine
DMB1ET0	MI	TT5TPI6
DMB1ET0	MN	Opioid receptor sigma 1 (OPRS1)
DMB1ET0	MT	DTT
DMB1ET0	MA	Agonist
DMB1ET0	RN	Effect of SA4503, a novel sigma1 receptor agonist, against glutamate neurotoxicity in cultured rat retinal neurons. Eur J Pharmacol. 1998 Jan 19;342(1):105-11.
DMB1ET0	RU	https://pubmed.ncbi.nlm.nih.gov/9544798

DM8YUJT	DI	DM8YUJT
DM8YUJT	DN	CWHM-12
DM8YUJT	MI	TTIQSVM
DM8YUJT	MN	Integrin alpha-V/beta-6 (ITGAV/B6)
DM8YUJT	MT	DTT
DM8YUJT	MA	Inhibitor
DM8YUJT	RN	Targeting of alphav integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med. 2013 Dec;19(12):1617-24.
DM8YUJT	RU	https://pubmed.ncbi.nlm.nih.gov/24216753

DMKZCBE	DI	DMKZCBE
DMKZCBE	DN	CX-1501
DMKZCBE	MI	TTAN6JD
DMKZCBE	MN	Glutamate receptor AMPA (GRIA)
DMKZCBE	MT	DTT
DMKZCBE	MA	Modulator
DMKZCBE	RN	Pharmacology of ampakine modulators: from AMPA receptors to synapses and behavior. Curr Drug Targets. 2007 May;8(5):583-602.
DMKZCBE	RU	https://pubmed.ncbi.nlm.nih.gov/17504103

DMA1MK5	DI	DMA1MK5
DMA1MK5	DN	CYC-800
DMA1MK5	MI	TTIYVQP
DMA1MK5	MN	Polo-like kinase 1 (PLK1)
DMA1MK5	MT	DTT
DMA1MK5	MA	Inhibitor
DMA1MK5	RN	Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009 Jun;14(6):559-70.
DMA1MK5	RU	https://pubmed.ncbi.nlm.nih.gov/19474163

DMV8APG	DI	DMV8APG
DMV8APG	DN	Cytolin
DMV8APG	MI	TT48WR6
DMV8APG	MN	Integrin alpha-L (ITGAL)
DMV8APG	MT	DTT
DMV8APG	RN	Cytokine-induced phagocyte adhesion to human mesangial cells: role of CD11/CD18 integrins and ICAM-1. Am J Physiol. 1991 Dec;261(6 Pt 2):F1071-9.
DMV8APG	RU	https://pubmed.ncbi.nlm.nih.gov/1721495

DMHD3R8	DI	DMHD3R8
DMHD3R8	DN	D-4476
DMHD3R8	MI	TTFQEMX
DMHD3R8	MN	Casein kinase I alpha (CSNK1A1)
DMHD3R8	MT	DTT
DMHD3R8	MA	Inhibitor
DMHD3R8	RN	Discovery of N6-phenyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine derivatives as novel CK1 inhibitors using common-feature pharmacophore model based virtual screening and hit-to-lead optimization. Eur J Med Chem. 2012 Oct;56:30-8.
DMHD3R8	RU	https://pubmed.ncbi.nlm.nih.gov/22944772

DMHD3R8	DI	DMHD3R8
DMHD3R8	DN	D-4476
DMHD3R8	MI	TTH30UI
DMHD3R8	MN	Casein kinase I delta (CSNK1D)
DMHD3R8	MT	DTT
DMHD3R8	MA	Inhibitor
DMHD3R8	RN	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
DMHD3R8	RU	https://pubmed.ncbi.nlm.nih.gov/17850214

DMUWRIF	DI	DMUWRIF
DMUWRIF	DN	DAP-81
DMUWRIF	MI	TTIYVQP
DMUWRIF	MN	Polo-like kinase 1 (PLK1)
DMUWRIF	MT	DTT
DMUWRIF	MA	Inhibitor
DMUWRIF	RN	Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009 Jun;14(6):559-70.
DMUWRIF	RU	https://pubmed.ncbi.nlm.nih.gov/19474163

DM8WTAZ	DI	DM8WTAZ
DM8WTAZ	DN	Debio1453
DM8WTAZ	MI	TT9142J
DM8WTAZ	MN	Neisseria gonorrhoeae Enoyl-[acyl-carrier-protein] reductase (Neisseria fabI)
DM8WTAZ	MT	DTT
DM8WTAZ	MA	Inhibitor
DM8WTAZ	RN	Clinical pipeline report, company report or official report of Debiopharm.
DM8WTAZ	RU	https://www.debiopharm.com/drug-development/pipeline/debio-1453/

DMAUILH	DI	DMAUILH
DMAUILH	DN	DecRVKRCMK
DMAUILH	MI	TTH9WF6
DMAUILH	MN	Dibasic-processing enzyme (Furin)
DMAUILH	MT	DTT
DMAUILH	MA	Inhibitor
DMAUILH	RN	Decanoyl-Arg-Val-Lys-Arg-Chloromethylketone: An Antiviral Compound That Acts against Flaviviruses through the Inhibition of Furin-Mediated prM Cleavage. Viruses. 2019 Oct 31;11(11):1011.
DMAUILH	RU	https://pubmed.ncbi.nlm.nih.gov/31683742

DMJKQFT	DI	DMJKQFT
DMJKQFT	DN	Dec-RVKR-CMK
DMJKQFT	MI	TTUD6MS
DMJKQFT	MN	HUMAN dibasic-processing enzyme (Furin)
DMJKQFT	MT	DTT
DMJKQFT	MA	Blocker
DMJKQFT	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DMJKQFT	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DMD0T1U	DI	DMD0T1U
DMD0T1U	DN	Depudecin
DMD0T1U	MI	TT6R7JZ
DMD0T1U	MN	Histone deacetylase 1 (HDAC1)
DMD0T1U	MT	DTT
DMD0T1U	MA	Inhibitor
DMD0T1U	RN	Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92.
DMD0T1U	RU	https://pubmed.ncbi.nlm.nih.gov/17896917

DM2I76R	DI	DM2I76R
DM2I76R	DN	Desmethylsertraline
DM2I76R	MI	DTUGYRD
DM2I76R	MN	P-glycoprotein 1 (ABCB1)
DM2I76R	MT	DTP
DM2I76R	MA	Substrate
DM2I76R	RN	Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein. Biol Pharm Bull. 2008 Feb;31(2):231-4.
DM2I76R	RU	https://doi.org/10.1248/bpb.31.231

DM5H2W9	DI	DM5H2W9
DM5H2W9	DN	Dioscin
DM5H2W9	MI	TT1UCIJ
DM5H2W9	MN	C-X-C chemokine receptor type 3 (CXCR3)
DM5H2W9	MT	DTT
DM5H2W9	MA	Antagonist
DM5H2W9	RN	Discovery of structurally diverse natural product antagonists of chemokine receptor CXCR3. Mol Divers. 2005;9(1-3):123-9.
DM5H2W9	RU	https://pubmed.ncbi.nlm.nih.gov/15789559

DMA2K7C	DI	DMA2K7C
DMA2K7C	DN	Donitriptan
DMA2K7C	MI	TTK8CXU
DMA2K7C	MN	5-HT 1B receptor (HTR1B)
DMA2K7C	MT	DTT
DMA2K7C	MA	Modulator
DMA2K7C	RN	Donitriptan, but not sumatriptan, inhibits capsaicin-induced canine external carotid vasodilatation via 5-HT1B rather than 5-HT1D receptors.Br J Pharmacol.2006 Sep;149(1):82-91.
DMA2K7C	RU	https://www.ncbi.nlm.nih.gov/pubmed/16880765

DMA2K7C	DI	DMA2K7C
DMA2K7C	DN	Donitriptan
DMA2K7C	MI	TT6MSOK
DMA2K7C	MN	5-HT 1D receptor (HTR1D)
DMA2K7C	MT	DTT
DMA2K7C	MA	Modulator
DMA2K7C	RN	Donitriptan, but not sumatriptan, inhibits capsaicin-induced canine external carotid vasodilatation via 5-HT1B rather than 5-HT1D receptors.Br J Pharmacol.2006 Sep;149(1):82-91.
DMA2K7C	RU	https://www.ncbi.nlm.nih.gov/pubmed/16880765

DMYH3VR	DI	DMYH3VR
DMYH3VR	DN	DP-3975
DMYH3VR	MI	TTZPY6J
DMYH3VR	MN	Tyrosine-protein kinase UFO (AXL)
DMYH3VR	MT	DTT
DMYH3VR	MA	Inhibitor
DMYH3VR	RN	AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer. 2019 Nov 4;18(1):153.
DMYH3VR	RU	https://pubmed.ncbi.nlm.nih.gov/31684958

DMMI2EY	DI	DMMI2EY
DMMI2EY	DN	DS-1558
DMMI2EY	MI	TTB8FUC
DMMI2EY	MN	Free fatty acid receptor 1 (GPR40)
DMMI2EY	MT	DTT
DMMI2EY	MA	Agonist
DMMI2EY	RN	Discovery of DS-1558: A Potent and Orally Bioavailable GPR40 Agonist. ACS Med Chem Lett. 2015 Jan 13;6(3):266-70.
DMMI2EY	RU	https://pubmed.ncbi.nlm.nih.gov/25815144

DM8YSW7	DI	DM8YSW7
DM8YSW7	DN	DX-2802
DM8YSW7	MI	TT6X50U
DM8YSW7	MN	Matrix metalloproteinase-9 (MMP-9)
DM8YSW7	MT	DTT
DM8YSW7	RN	Clinical pipeline report, company report or official report of DeepDyve.
DM8YSW7	RU	https://www.deepdyve.com/lp/elsevier/490-mmp-9-as-a-stromal-target-in-cancer-pzh95qPjis

DMCVXBE	DI	DMCVXBE
DMCVXBE	DN	E-64D
DMCVXBE	MI	TTS586L
DMCVXBE	MN	HUMAN cathepsin L (CTSL)
DMCVXBE	MT	DTT
DMCVXBE	MA	Blocker
DMCVXBE	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DMCVXBE	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DMG4DHX	DI	DMG4DHX
DMG4DHX	DN	ED-1812
DMG4DHX	MI	TT9IK2Z
DMG4DHX	MN	N-methyl-D-aspartate receptor (NMDAR)
DMG4DHX	MT	DTT
DMG4DHX	MA	Antagonist
DMG4DHX	RN	WO patent application no. 2009,0164,86, Use of nmda receptor antagonists for treatment of urologic tumors.
DMG4DHX	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20090205&CC=WO&NR=2009016486A2&KC=A2

DMELPJM	DI	DMELPJM
DMELPJM	DN	EDD7H9
DMELPJM	MI	TTDYP7I
DMELPJM	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DMELPJM	MT	DTT
DMELPJM	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 277).
DMELPJM	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=277

DMZ3YP6	DI	DMZ3YP6
DMZ3YP6	DN	EGFR/IGFR tandem adnectin
DMZ3YP6	MI	TTGKNB4
DMZ3YP6	MN	Epidermal growth factor receptor (EGFR)
DMZ3YP6	MT	DTT
DMZ3YP6	MA	Inhibitor
DMZ3YP6	RN	Clinical pipeline report, company report or official report of Bristol-Myers Squibb.
DMZ3YP6	RU	http://news.bms.com/press-release/rd-news/bristol-myers-squibb-announces-collaboration-evaluate-opdivo-nivolumab-combina

DMZ3YP6	DI	DMZ3YP6
DMZ3YP6	DN	EGFR/IGFR tandem adnectin
DMZ3YP6	MI	TTHRID2
DMZ3YP6	MN	Insulin-like growth factor I receptor (IGF1R)
DMZ3YP6	MT	DTT
DMZ3YP6	MA	Inhibitor
DMZ3YP6	RN	Clinical pipeline report, company report or official report of Bristol-Myers Squibb.
DMZ3YP6	RU	http://news.bms.com/press-release/rd-news/bristol-myers-squibb-announces-collaboration-evaluate-opdivo-nivolumab-combina

DMK6WIO	DI	DMK6WIO
DMK6WIO	DN	Enrofloxacin
DMK6WIO	MI	DTI7UX6
DMK6WIO	MN	Breast cancer resistance protein (ABCG2)
DMK6WIO	MT	DTP
DMK6WIO	MA	Substrate
DMK6WIO	RN	Interaction of enrofloxacin with breast cancer resistance protein (BCRP/ABCG2): influence of flavonoids and role in milk secretion in sheep. J Vet Pharmacol Ther. 2006 Aug;29(4):279-87.
DMK6WIO	RU	https://doi.org/10.1111/j.1365-2885.2006.00744.x

DM2K51E	DI	DM2K51E
DM2K51E	DN	EP-01492
DM2K51E	MI	TTWDC17
DM2K51E	MN	Growth hormone secretagogue receptor 1 (GHSR)
DM2K51E	MT	DTT
DM2K51E	MA	Antagonist
DM2K51E	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DM2K51E	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMJEKQM	DI	DMJEKQM
DMJEKQM	DN	EP-128504
DMJEKQM	MI	TTPNE41
DMJEKQM	MN	CI Man-6-P receptor (IGF2R)
DMJEKQM	MT	DTT
DMJEKQM	MA	Modulator
DMJEKQM	RN	The discovery and mechanism of action of novel tumor-selective and apoptosis-inducing 3,5-diaryl-1,2,4-oxadiazole series using a chemical genetics approach. Mol Cancer Ther. 2005 May;4(5):761-71.
DMJEKQM	RU	https://pubmed.ncbi.nlm.nih.gov/15897240

DMERKYO	DI	DMERKYO
DMERKYO	DN	EP-2167
DMERKYO	MI	TTV5YEH
DMERKYO	MN	Transferrin (TF)
DMERKYO	MT	DTT
DMERKYO	MA	Inducer
DMERKYO	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017941)
DMERKYO	RU	http://adisinsight.springer.com/drugs/800017941

DMVNR20	DI	DMVNR20
DMVNR20	DN	Epipodophyllotoxins
DMVNR20	MI	DTQ3ZHF
DMVNR20	MN	Multidrug resistance-associated protein 3 (ABCC3)
DMVNR20	MT	DTP
DMVNR20	MA	Substrate
DMVNR20	RN	Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem. 2001 Dec 7;276(49):46400-7.
DMVNR20	RU	http://www.ncbi.nlm.nih.gov/pubmed/11581266

DMVNR20	DI	DMVNR20
DMVNR20	DN	Epipodophyllotoxins
DMVNR20	MI	DT582KR
DMVNR20	MN	Multidrug resistance-associated protein 6 (ABCC6)
DMVNR20	MT	DTP
DMVNR20	MA	Substrate
DMVNR20	RN	Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res. 2002 Nov 1;62(21):6172-7.
DMVNR20	RU	http://www.ncbi.nlm.nih.gov/pubmed/12414644

DM5K17C	DI	DM5K17C
DM5K17C	DN	EPL-1410
DM5K17C	MI	TTZJYKH
DM5K17C	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DM5K17C	MT	DTT
DM5K17C	MA	Inhibitor
DM5K17C	RN	Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019 May;18(5):379-401.
DM5K17C	RU	https://pubmed.ncbi.nlm.nih.gov/30760888

DM5K17C	DI	DM5K17C
DM5K17C	DN	EPL-1410
DM5K17C	MI	TTXNCBV
DM5K17C	MN	Tryptophan 2,3-dioxygenase (TDO)
DM5K17C	MT	DTT
DM5K17C	MA	Inhibitor
DM5K17C	RN	Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019 May;18(5):379-401.
DM5K17C	RU	https://pubmed.ncbi.nlm.nih.gov/30760888

DMX2FZS	DI	DMX2FZS
DMX2FZS	DN	Epothilone A
DMX2FZS	MI	DTUGYRD
DMX2FZS	MN	P-glycoprotein 1 (ABCB1)
DMX2FZS	MT	DTP
DMX2FZS	MA	Substrate
DMX2FZS	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMX2FZS	RU	https://doi.org/10.1007/s11095-012-0935-x

DM2TESM	DI	DM2TESM
DM2TESM	DN	EPZ028862
DM2TESM	MI	TTKLJYX
DM2TESM	MN	Histone-lysine N-methyltransferase SMYD3 (SMYD3)
DM2TESM	MT	DTT
DM2TESM	MA	Inhibitor
DM2TESM	RN	Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021 Apr;20(4):265-286.
DM2TESM	RU	https://pubmed.ncbi.nlm.nih.gov/33469207

DM8UKL0	DI	DM8UKL0
DM8UKL0	DN	EPZ031686
DM8UKL0	MI	TTKLJYX
DM8UKL0	MN	Histone-lysine N-methyltransferase SMYD3 (SMYD3)
DM8UKL0	MT	DTT
DM8UKL0	MA	Inhibitor
DM8UKL0	RN	Therapeutical potential of deregulated lysine methyltransferase SMYD3 as a safe target for novel anticancer agents. Expert Opin Ther Targets. 2017 Feb;21(2):145-157.
DM8UKL0	RU	https://pubmed.ncbi.nlm.nih.gov/28019723

DMHU742	DI	DMHU742
DMHU742	DN	EPZ032597
DMHU742	MI	TT7YJFO
DMHU742	MN	SET and MYND domain-containing protein 2 (SMYD2)
DMHU742	MT	DTT
DMHU742	MA	Inhibitor
DMHU742	RN	Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021 Apr;20(4):265-286.
DMHU742	RU	https://pubmed.ncbi.nlm.nih.gov/33469207

DMUKVYL	DI	DMUKVYL
DMUKVYL	DN	EPZ0330456
DMUKVYL	MI	TTKLJYX
DMUKVYL	MN	Histone-lysine N-methyltransferase SMYD3 (SMYD3)
DMUKVYL	MT	DTT
DMUKVYL	MA	Inhibitor
DMUKVYL	RN	Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021 Apr;20(4):265-286.
DMUKVYL	RU	https://pubmed.ncbi.nlm.nih.gov/33469207

DMDO6NZ	DI	DMDO6NZ
DMDO6NZ	DN	EPZ033294
DMDO6NZ	MI	TT7YJFO
DMDO6NZ	MN	SET and MYND domain-containing protein 2 (SMYD2)
DMDO6NZ	MT	DTT
DMDO6NZ	MA	Inhibitor
DMDO6NZ	RN	Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021 Apr;20(4):265-286.
DMDO6NZ	RU	https://pubmed.ncbi.nlm.nih.gov/33469207

DMBINP0	DI	DMBINP0
DMBINP0	DN	ER-319711-15
DMBINP0	MI	TTDIGC1
DMBINP0	MN	Dipeptidyl peptidase 4 (DPP-4)
DMBINP0	MT	DTT
DMBINP0	MA	Inhibitor
DMBINP0	RN	Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87.
DMBINP0	RU	https://pubmed.ncbi.nlm.nih.gov/19149538

DMUFP05	DI	DMUFP05
DMUFP05	DN	F-15063
DMUFP05	MI	TTEX248
DMUFP05	MN	Dopamine D2 receptor (D2R)
DMUFP05	MT	DTT
DMUFP05	MA	Modulator
DMUFP05	RN	F15063, a potential antipsychotic with dopamine D(2)/D(3) antagonist, 5-HT(1A) agonist and D(4) partial agonist properties: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice.Naunyn Schmiedebergs Arch Pharmacol.2007 Jun;375(4):241-50.
DMUFP05	RU	https://www.ncbi.nlm.nih.gov/pubmed/17453175

DMUFP05	DI	DMUFP05
DMUFP05	DN	F-15063
DMUFP05	MI	TT4C8EA
DMUFP05	MN	Dopamine D3 receptor (D3R)
DMUFP05	MT	DTT
DMUFP05	MA	Modulator
DMUFP05	RN	F15063, a potential antipsychotic with dopamine D(2)/D(3) antagonist, 5-HT(1A) agonist and D(4) partial agonist properties: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice.Naunyn Schmiedebergs Arch Pharmacol.2007 Jun;375(4):241-50.
DMUFP05	RU	https://www.ncbi.nlm.nih.gov/pubmed/17453175

DM29M4R	DI	DM29M4R
DM29M4R	DN	F24F2
DM29M4R	MI	TTM0O8B
DM29M4R	MN	Bacillus poly-gamma-d-glutamic acid (Bacillus PGA)
DM29M4R	MT	DTT
DM29M4R	RN	Protective and immunochemical activities of monoclonal antibodies reactive with the Bacillus anthracis polypeptide capsule. Infect Immun. 2007 Jan;75(1):152-63.
DM29M4R	RU	https://pubmed.ncbi.nlm.nih.gov/17060470

DM2GEHA	DI	DM2GEHA
DM2GEHA	DN	F26G3
DM2GEHA	MI	TTM0O8B
DM2GEHA	MN	Bacillus poly-gamma-d-glutamic acid (Bacillus PGA)
DM2GEHA	MT	DTT
DM2GEHA	RN	Protective and immunochemical activities of monoclonal antibodies reactive with the Bacillus anthracis polypeptide capsule. Infect Immun. 2007 Jan;75(1):152-63.
DM2GEHA	RU	https://pubmed.ncbi.nlm.nih.gov/17060470

DMAVQ2X	DI	DMAVQ2X
DMAVQ2X	DN	F26G4
DMAVQ2X	MI	TTM0O8B
DMAVQ2X	MN	Bacillus poly-gamma-d-glutamic acid (Bacillus PGA)
DMAVQ2X	MT	DTT
DMAVQ2X	RN	Protective and immunochemical activities of monoclonal antibodies reactive with the Bacillus anthracis polypeptide capsule. Infect Immun. 2007 Jan;75(1):152-63.
DMAVQ2X	RU	https://pubmed.ncbi.nlm.nih.gov/17060470

DMTHLB8	DI	DMTHLB8
DMTHLB8	DN	FA-613
DMTHLB8	MI	TT3UY29
DMTHLB8	MN	HUMAN dihydroorotate dehydrogenase (DHODH)
DMTHLB8	MT	DTT
DMTHLB8	MA	Inhibitor
DMTHLB8	RN	Broad-spectrum inhibition of common respiratory RNA viruses by a pyrimidine synthesis inhibitor with involvement of the host antiviral response. J Gen Virol. 2017 May;98(5):946-954.
DMTHLB8	RU	https://pubmed.ncbi.nlm.nih.gov/28555543

DMYFVZ3	DI	DMYFVZ3
DMYFVZ3	DN	FAP5-DM1
DMYFVZ3	MI	TTGPQ0F
DMYFVZ3	MN	Prolyl endopeptidase FAP (FAP)
DMYFVZ3	MT	DTT
DMYFVZ3	RN	Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. Clin Cancer Res. 2008 Jul 15;14(14):4584-92.
DMYFVZ3	RU	https://pubmed.ncbi.nlm.nih.gov/18628473

DMAX2EW	DI	DMAX2EW
DMAX2EW	DN	FAS1
DMAX2EW	MI	TT7AOUD
DMAX2EW	MN	Fatty acid synthase (FASN)
DMAX2EW	MT	DTT
DMAX2EW	MA	Inhibitor
DMAX2EW	RN	Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22.
DMAX2EW	RU	https://pubmed.ncbi.nlm.nih.gov/19463273

DMBZVYG	DI	DMBZVYG
DMBZVYG	DN	FOXO4-DRI
DMBZVYG	MI	TTKW9CI
DMBZVYG	MN	FOXO4-P53 interaction (FOXO4-P53 PPI)
DMBZVYG	MT	DTT
DMBZVYG	MA	Antagonist
DMBZVYG	RN	FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice. Aging (Albany NY). 2020 Jan 20;12(2):1272-1284.
DMBZVYG	RU	https://pubmed.ncbi.nlm.nih.gov/31959736

DMUHVEA	DI	DMUHVEA
DMUHVEA	DN	FPL-14294
DMUHVEA	MI	TTCG0AL
DMUHVEA	MN	Cholecystokinin receptor type A (CCKAR)
DMUHVEA	MT	DTT
DMUHVEA	MA	Agonist
DMUHVEA	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DMUHVEA	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMF53Z7	DI	DMF53Z7
DMF53Z7	DN	FR167356
DMF53Z7	MI	TTTK3BH
DMF53Z7	MN	Vacuolar-type proton ATPase (v-ATPase)
DMF53Z7	MT	DTT
DMF53Z7	MA	Inhibitor
DMF53Z7	RN	Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36.
DMF53Z7	RU	https://pubmed.ncbi.nlm.nih.gov/21948793

DMXR287	DI	DMXR287
DMXR287	DN	FR-79620
DMXR287	MI	TTY6EWA
DMXR287	MN	Neuropeptide Y receptor type 5 (NPY5R)
DMXR287	MT	DTT
DMXR287	MA	Antagonist
DMXR287	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DMXR287	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMLNRCI	DI	DMLNRCI
DMLNRCI	DN	FSA2
DMLNRCI	MI	TT7AOUD
DMLNRCI	MN	Fatty acid synthase (FASN)
DMLNRCI	MT	DTT
DMLNRCI	MA	Inhibitor
DMLNRCI	RN	Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22.
DMLNRCI	RU	https://pubmed.ncbi.nlm.nih.gov/19463273

DMXE6ML	DI	DMXE6ML
DMXE6ML	DN	FX-007
DMXE6ML	MI	TTTDVOJ
DMXE6ML	MN	Tropomyosin-related kinase A (TrkA)
DMXE6ML	MT	DTT
DMXE6ML	MA	Inhibitor
DMXE6ML	RN	Preclinical trail of FX007 for treating osteoarthritis. Flexion Therapeutics Inc.
DMXE6ML	RU	http://www.biocentury.com/products/fx007

DM7UJ1I	DI	DM7UJ1I
DM7UJ1I	DN	FX-107
DM7UJ1I	MI	TTWODQF
DM7UJ1I	MN	Fibrin (FG)
DM7UJ1I	MT	DTT
DM7UJ1I	MA	Inhibitor
DM7UJ1I	RN	FX-06, a fibrin-derived Bbeta15-42 peptide for the potential treatment of reperfusion injury following myocardial infarction. Curr Opin Investig Drugs. 2009 Sep;10(9):997-1003.
DM7UJ1I	RU	https://pubmed.ncbi.nlm.nih.gov/19705343

DMR1CLY	DI	DMR1CLY
DMR1CLY	DN	GC376
DMR1CLY	MI	TT1D53B
DMR1CLY	MN	COVID-19 3C-like protease (3CLpro)
DMR1CLY	MT	DTT
DMR1CLY	MA	Inhibitor
DMR1CLY	RN	Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. 2020. April 20. doi: https://doi.org/10.1101/2020.04.20.051581
DMR1CLY	RU	https://www.biorxiv.org/content/10.1101/2020.04.20.051581v1

DMR1CLY	DI	DMR1CLY
DMR1CLY	DN	GC376
DMR1CLY	MI	TTWOH4Q
DMR1CLY	MN	MERS-CoV 3C-like proteinase (3CLpro)
DMR1CLY	MT	DTT
DMR1CLY	MA	Inhibitor
DMR1CLY	RN	Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor. PLoS Pathog. 2016 Mar 30;12(3):e1005531.
DMR1CLY	RU	https://pubmed.ncbi.nlm.nih.gov/27027316

DMR1CLY	DI	DMR1CLY
DMR1CLY	DN	GC376
DMR1CLY	MI	TTPZG3C
DMR1CLY	MN	SARS-CoV 3C-like protease (3CLpro)
DMR1CLY	MT	DTT
DMR1CLY	MA	Inhibitor
DMR1CLY	RN	Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor. PLoS Pathog. 2016 Mar 30;12(3):e1005531.
DMR1CLY	RU	https://pubmed.ncbi.nlm.nih.gov/27027316

DM7PBJC	DI	DM7PBJC
DM7PBJC	DN	GC813
DM7PBJC	MI	TTWOH4Q
DM7PBJC	MN	MERS-CoV 3C-like proteinase (3CLpro)
DM7PBJC	MT	DTT
DM7PBJC	MA	Inhibitor
DM7PBJC	RN	Structure-guided Design of Potent and Permeable Inhibitors of MERS Coronavirus 3CL Protease That Utilize a Piperidine Moiety as a Novel Design Element Eur J Med Chem. 2018 Apr 25;150:334-346.
DM7PBJC	RU	https://pubmed.ncbi.nlm.nih.gov/29544147

DMFW0H9	DI	DMFW0H9
DMFW0H9	DN	GCR-1087
DMFW0H9	MI	TTMXGCW
DMFW0H9	MN	Adrenergic receptor beta-3 (ADRB3)
DMFW0H9	MT	DTT
DMFW0H9	MA	Agonist
DMFW0H9	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DMFW0H9	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMFQI38	DI	DMFQI38
DMFQI38	DN	GG-8573
DMFQI38	MI	TTCG0AL
DMFQI38	MN	Cholecystokinin receptor type A (CCKAR)
DMFQI38	MT	DTT
DMFQI38	MA	Agonist
DMFQI38	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DMFQI38	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMFQI38	DI	DMFQI38
DMFQI38	DN	GG-8573
DMFQI38	MI	TTVFO0U
DMFQI38	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMFQI38	MT	DTT
DMFQI38	MA	Antagonist
DMFQI38	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DMFQI38	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DM25N8B	DI	DM25N8B
DM25N8B	DN	GI-264879A
DM25N8B	MI	TTRK9JT
DM25N8B	MN	Neuropeptide Y receptor type 1 (NPY1R)
DM25N8B	MT	DTT
DM25N8B	MA	Antagonist
DM25N8B	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DM25N8B	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMZC91G	DI	DMZC91G
DMZC91G	DN	GL21.T
DMZC91G	MI	TTZPY6J
DMZC91G	MN	Tyrosine-protein kinase UFO (AXL)
DMZC91G	MT	DTT
DMZC91G	RN	AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer. 2019 Nov 4;18(1):153.
DMZC91G	RU	https://pubmed.ncbi.nlm.nih.gov/31684958

DMSW07R	DI	DMSW07R
DMSW07R	DN	GLPG-0492
DMSW07R	MI	TTS64P2
DMSW07R	MN	Androgen receptor (AR)
DMSW07R	MT	DTT
DMSW07R	MA	Modulator
DMSW07R	RN	GLPG0492, a novel selective androgen receptor modulator, improves muscle performance in the exercised-mdx mouse model of muscular dystrophy. Pharmacol Res. 2013 Jun;72:9-24.
DMSW07R	RU	https://pubmed.ncbi.nlm.nih.gov/23523664

DMXVHOQ	DI	DMXVHOQ
DMXVHOQ	DN	GNE684
DMXVHOQ	MI	TTAIQSN
DMXVHOQ	MN	Receptor-interacting protein 1 (RIPK1)
DMXVHOQ	MT	DTT
DMXVHOQ	MA	Inhibitor
DMXVHOQ	RN	Impaired RIPK1 ubiquitination sensitizes mice to TNF toxicity and inflammatory cell death. Cell Death Differ. 2021 Mar;28(3):985-1000.
DMXVHOQ	RU	https://pubmed.ncbi.nlm.nih.gov/32999468

DMTJRLU	DI	DMTJRLU
DMTJRLU	DN	GNTI
DMTJRLU	MI	TTQW87Y
DMTJRLU	MN	Opioid receptor kappa (OPRK1)
DMTJRLU	MT	DTT
DMTJRLU	MA	Antagonist
DMTJRLU	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DMTJRLU	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMTJRLU	DI	DMTJRLU
DMTJRLU	DN	GNTI
DMTJRLU	MI	TTKWM86
DMTJRLU	MN	Opioid receptor mu (MOP)
DMTJRLU	MT	DTT
DMTJRLU	MA	Antagonist
DMTJRLU	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DMTJRLU	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMNZA4L	DI	DMNZA4L
DMNZA4L	DN	Griffithsin
DMNZA4L	MI	TTTL19V
DMNZA4L	MN	SARS-CoV spike glycoprotein (S)
DMNZA4L	MT	DTT
DMNZA4L	MA	Blocker
DMNZA4L	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DMNZA4L	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DM19T2V	DI	DM19T2V
DM19T2V	DN	GRL001
DM19T2V	MI	TT1D53B
DM19T2V	MN	COVID-19 3C-like protease (3CLpro)
DM19T2V	MT	DTT
DM19T2V	MA	Inhibitor
DM19T2V	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DM19T2V	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DMVB1PD	DI	DMVB1PD
DMVB1PD	DN	GRL-001
DMVB1PD	MI	TTWOH4Q
DMVB1PD	MN	MERS-CoV 3C-like proteinase (3CLpro)
DMVB1PD	MT	DTT
DMVB1PD	MA	Inhibitor
DMVB1PD	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DMVB1PD	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DMVB1PD	DI	DMVB1PD
DMVB1PD	DN	GRL-001
DMVB1PD	MI	TTPZG3C
DMVB1PD	MN	SARS-CoV 3C-like protease (3CLpro)
DMVB1PD	MT	DTT
DMVB1PD	MA	Inhibitor
DMVB1PD	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DMVB1PD	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DMX9AGF	DI	DMX9AGF
DMX9AGF	DN	GRL0617
DMX9AGF	MI	TTNHMO8
DMX9AGF	MN	COVID-19 papain-like proteinase (PL-PRO)
DMX9AGF	MT	DTT
DMX9AGF	MA	Inhibitor
DMX9AGF	RN	Crystal structure of SARS-CoV-2 papain-like protease. Acta Pharm Sin B. 2021 Jan;11(1):237-245.
DMX9AGF	RU	https://pubmed.ncbi.nlm.nih.gov/32895623

DMNU3SI	DI	DMNU3SI
DMNU3SI	DN	GSK180
DMNU3SI	MI	TTIY56R
DMNU3SI	MN	Kynurenine 3-hydroxylase (KMO)
DMNU3SI	MT	DTT
DMNU3SI	MA	Inhibitor
DMNU3SI	RN	Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019 May;18(5):379-401.
DMNU3SI	RU	https://pubmed.ncbi.nlm.nih.gov/30760888

DM5AOI3	DI	DM5AOI3
DM5AOI3	DN	GSK2643943A
DM5AOI3	MI	TT07QDI
DM5AOI3	MN	Ubiquitin carboxyl-terminal hydrolase 20 (USP20)
DM5AOI3	MT	DTT
DM5AOI3	MA	Inhibitor
DM5AOI3	RN	Deubiquitylating enzymes and drug discovery: emerging opportunities. Nat Rev Drug Discov. 2018 Jan;17(1):57-78.
DM5AOI3	RU	https://pubmed.ncbi.nlm.nih.gov/28959952

DMAZROV	DI	DMAZROV
DMAZROV	DN	GSK2807
DMAZROV	MI	TTKLJYX
DMAZROV	MN	Histone-lysine N-methyltransferase SMYD3 (SMYD3)
DMAZROV	MT	DTT
DMAZROV	MA	Inhibitor
DMAZROV	RN	Structure-Based Design of a Novel SMYD3 Inhibitor that Bridges the SAM-and MEKK2-Binding Pockets. Structure. 2016 May 3;24(5):774-781.
DMAZROV	RU	https://pubmed.ncbi.nlm.nih.gov/27066749

DMFJ0ZA	DI	DMFJ0ZA
DMFJ0ZA	DN	GSK-326416
DMFJ0ZA	MI	TT953CX
DMFJ0ZA	MN	Motilin receptor (MLNR)
DMFJ0ZA	MT	DTT
DMFJ0ZA	MA	Agonist
DMFJ0ZA	RN	Emerging drugs for postoperative ileus. Expert Opin Emerg Drugs. 2007 Nov;12(4):619-26.
DMFJ0ZA	RU	https://pubmed.ncbi.nlm.nih.gov/17979603

DM04UGQ	DI	DM04UGQ
DM04UGQ	DN	GSK366
DM04UGQ	MI	TTIY56R
DM04UGQ	MN	Kynurenine 3-hydroxylase (KMO)
DM04UGQ	MT	DTT
DM04UGQ	MA	Inhibitor
DM04UGQ	RN	Structural and mechanistic basis of differentiated inhibitors of the acute pancreatitis target kynurenine-3-monooxygenase. Nat Commun. 2017 Jun 12;8:15827.
DM04UGQ	RU	https://pubmed.ncbi.nlm.nih.gov/28604669

DM1S5UO	DI	DM1S5UO
DM1S5UO	DN	GSK4112
DM1S5UO	MI	TTAD1O8
DM1S5UO	MN	V-erbA-related protein 1 (NR1D1)
DM1S5UO	MT	DTT
DM1S5UO	MA	Agonist
DM1S5UO	RN	Identification of SR8278, a synthetic antagonist of the nuclear heme receptor REV-ERB. ACS Chem Biol. 2011 Feb 18;6(2):131-4.
DM1S5UO	RU	https://pubmed.ncbi.nlm.nih.gov/21043485

DMNAT5V	DI	DMNAT5V
DMNAT5V	DN	GW-2592X
DMNAT5V	MI	TTDZN01
DMNAT5V	MN	Cathepsin K (CTSK)
DMNAT5V	MT	DTT
DMNAT5V	MA	Inhibitor
DMNAT5V	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2350).
DMNAT5V	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2350

DM3PMAZ	DI	DM3PMAZ
DM3PMAZ	DN	GW-3333
DM3PMAZ	MI	TTDU0HP
DM3PMAZ	MN	Bacterial Cystathionine gamma-synthase (Bact metB)
DM3PMAZ	MT	DTT
DM3PMAZ	MA	Inhibitor
DM3PMAZ	RN	Crystal structures of cystathionine gamma-synthase inhibitor complexes rationalize the increased affinity of a novel inhibitor. J Mol Biol. 2001 Aug 24;311(4):789-801.
DM3PMAZ	RU	https://pubmed.ncbi.nlm.nih.gov/11518531

DM3PMAZ	DI	DM3PMAZ
DM3PMAZ	DN	GW-3333
DM3PMAZ	MI	TT6AZXG
DM3PMAZ	MN	TNF alpha converting enzyme (ADAM17)
DM3PMAZ	MT	DTT
DM3PMAZ	MA	Inhibitor
DM3PMAZ	RN	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
DM3PMAZ	RU	https://pubmed.ncbi.nlm.nih.gov/16634702

DMHUD27	DI	DMHUD27
DMHUD27	DN	GW-594884A
DMHUD27	MI	TTY6EWA
DMHUD27	MN	Neuropeptide Y receptor type 5 (NPY5R)
DMHUD27	MT	DTT
DMHUD27	MA	Antagonist
DMHUD27	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DMHUD27	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DM97RV4	DI	DM97RV4
DM97RV4	DN	GYKI-47261
DM97RV4	MI	TTAN6JD
DM97RV4	MN	Glutamate receptor AMPA (GRIA)
DM97RV4	MT	DTT
DM97RV4	MA	Antagonist
DM97RV4	RN	Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42.
DM97RV4	RU	https://pubmed.ncbi.nlm.nih.gov/18991661

DM6GSI1	DI	DM6GSI1
DM6GSI1	DN	HBX19818
DM6GSI1	MI	TTXU3EQ
DM6GSI1	MN	Herpesvirus ubiquitin-specific protease (HAUSP)
DM6GSI1	MT	DTT
DM6GSI1	MA	Inhibitor
DM6GSI1	RN	Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Mol Cancer Ther. 2009 Aug;8(8):2286-95.
DM6GSI1	RU	https://pubmed.ncbi.nlm.nih.gov/19671755

DMPLZ7E	DI	DMPLZ7E
DMPLZ7E	DN	HC-Toxin
DMPLZ7E	MI	TT6R7JZ
DMPLZ7E	MN	Histone deacetylase 1 (HDAC1)
DMPLZ7E	MT	DTT
DMPLZ7E	MA	Inhibitor
DMPLZ7E	RN	Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92.
DMPLZ7E	RU	https://pubmed.ncbi.nlm.nih.gov/17896917

DMLZ5TQ	DI	DMLZ5TQ
DMLZ5TQ	DN	Hexamethylene amiloride
DMLZ5TQ	MI	TTL3H2W
DMLZ5TQ	MN	SARS-CoV envelope small membrane protein (E)
DMLZ5TQ	MT	DTT
DMLZ5TQ	MA	Inhibitor
DMLZ5TQ	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DMLZ5TQ	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DMRE52S	DI	DMRE52S
DMRE52S	DN	HL-004
DMRE52S	MI	TTMF541
DMRE52S	MN	Liver carboxylesterase (CES1)
DMRE52S	MT	DTT
DMRE52S	MA	Modulator
DMRE52S	RN	ACAT inhibitor HL-004 accelerates the regression of hypercholesterolemia in stroke-prone spontaneously hypertensive rats (SHRSP): stimulation of bile acid production by HL-004. Atherosclerosis. 1997 Aug;133(1):97-104.
DMRE52S	RU	https://pubmed.ncbi.nlm.nih.gov/9258412

DMBQDA3	DI	DMBQDA3
DMBQDA3	DN	Homocamptothecin
DMBQDA3	MI	DTI7UX6
DMBQDA3	MN	Breast cancer resistance protein (ABCG2)
DMBQDA3	MT	DTP
DMBQDA3	MA	Substrate
DMBQDA3	RN	ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev. 2007 Mar;26(1):39-57.
DMBQDA3	RU	http://www.ncbi.nlm.nih.gov/pubmed/17323127

DM69UZG	DI	DM69UZG
DM69UZG	DN	HPP-851
DM69UZG	MI	TTN7BL9
DM69UZG	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DM69UZG	MT	DTT
DM69UZG	MA	Inhibitor
DM69UZG	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027759)
DM69UZG	RU	http://adisinsight.springer.com/drugs/800027759

DMNF9P5	DI	DMNF9P5
DMNF9P5	DN	HR1P peptide
DMNF9P5	MI	TTJ4EIV
DMNF9P5	MN	MERS-CoV spike glycoprotein S2 subunit (S S2)
DMNF9P5	MT	DTT
DMNF9P5	MA	Inhibitor
DMNF9P5	RN	Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun. 2014;5:3067.
DMNF9P5	RU	https://pubmed.ncbi.nlm.nih.gov/24473083

DM6WC1Q	DI	DM6WC1Q
DM6WC1Q	DN	HR2P peptide
DM6WC1Q	MI	TTJ4EIV
DM6WC1Q	MN	MERS-CoV spike glycoprotein S2 subunit (S S2)
DM6WC1Q	MT	DTT
DM6WC1Q	MA	Inhibitor
DM6WC1Q	RN	Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun. 2014;5:3067.
DM6WC1Q	RU	https://pubmed.ncbi.nlm.nih.gov/24473083

DMSR96X	DI	DMSR96X
DMSR96X	DN	HR2P-M1 peptide
DMSR96X	MI	TTJ4EIV
DMSR96X	MN	MERS-CoV spike glycoprotein S2 subunit (S S2)
DMSR96X	MT	DTT
DMSR96X	MA	Inhibitor
DMSR96X	RN	Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun. 2014;5:3067.
DMSR96X	RU	https://pubmed.ncbi.nlm.nih.gov/24473083

DM7X4SV	DI	DM7X4SV
DM7X4SV	DN	HR2P-M2 peptide
DM7X4SV	MI	TTJ4EIV
DM7X4SV	MN	MERS-CoV spike glycoprotein S2 subunit (S S2)
DM7X4SV	MT	DTT
DM7X4SV	MA	Inhibitor
DM7X4SV	RN	Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun. 2014;5:3067.
DM7X4SV	RU	https://pubmed.ncbi.nlm.nih.gov/24473083

DMR8VJA	DI	DMR8VJA
DMR8VJA	DN	HSDB-41
DMR8VJA	MI	DE3YZC9
DMR8VJA	MN	Acetone carboxylase (ACX)
DMR8VJA	MT	DME
DMR8VJA	MA	Metabolism
DMR8VJA	RN	The human gastric pathogen Helicobacter pylori has a potential acetone carboxylase that enhances its ability to colonize mice. BMC Microbiol. 2008 Jan 23;8:14.
DMR8VJA	RU	https://pubmed.ncbi.nlm.nih.gov/18215283

DMR8VJA	DI	DMR8VJA
DMR8VJA	DN	HSDB-41
DMR8VJA	MI	DEFUSL7
DMR8VJA	MN	Acetone carboxylase (ACX)
DMR8VJA	MT	DME
DMR8VJA	MA	Metabolism
DMR8VJA	RN	The human gastric pathogen Helicobacter pylori has a potential acetone carboxylase that enhances its ability to colonize mice. BMC Microbiol. 2008 Jan 23;8:14.
DMR8VJA	RU	https://pubmed.ncbi.nlm.nih.gov/18215283

DMUAPNF	DI	DMUAPNF
DMUAPNF	DN	humanin
DMUAPNF	MI	TTOJ1NF
DMUAPNF	MN	FMLP-related receptor I (FPR2)
DMUAPNF	MT	DTT
DMUAPNF	MA	Agonist
DMUAPNF	RN	N-Formylated humanin activates both formyl peptide receptor-like 1 and 2. Biochem Biophys Res Commun. 2004 Nov 5;324(1):255-61.
DMUAPNF	RU	https://pubmed.ncbi.nlm.nih.gov/15465011

DMUAPNF	DI	DMUAPNF
DMUAPNF	DN	humanin
DMUAPNF	MI	TT16TM5
DMUAPNF	MN	N-formyl peptide receptor 3 (FPR3)
DMUAPNF	MT	DTT
DMUAPNF	MA	Agonist
DMUAPNF	RN	N-Formylated humanin activates both formyl peptide receptor-like 1 and 2. Biochem Biophys Res Commun. 2004 Nov 5;324(1):255-61.
DMUAPNF	RU	https://pubmed.ncbi.nlm.nih.gov/15465011

DM3NP4I	DI	DM3NP4I
DM3NP4I	DN	Huntingtin gene antisense
DM3NP4I	MI	TTIWZ0O
DM3NP4I	MN	Huntingtin messenger RNA (HTT mRNA)
DM3NP4I	MT	DTT
DM3NP4I	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DM3NP4I	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DM349AM	DI	DM349AM
DM349AM	DN	HY-N0040
DM349AM	MI	DEUO7V8
DM349AM	MN	Beta-glucosidase (bglA)
DM349AM	MT	DME
DM349AM	MA	Metabolism
DM349AM	RN	Constitutive beta-glucosidases hydrolyzing ginsenoside Rb1 and Rb2 from human intestinal bacteria. Biol Pharm Bull. 2000 Dec;23(12):1481-5.
DM349AM	RU	https://pubmed.ncbi.nlm.nih.gov/11145182

DM349AM	DI	DM349AM
DM349AM	DN	HY-N0040
DM349AM	MI	DE4LKZ9
DM349AM	MN	Beta-glucosidase (bglA)
DM349AM	MT	DME
DM349AM	MA	Metabolism
DM349AM	RN	Constitutive beta-glucosidases hydrolyzing ginsenoside Rb1 and Rb2 from human intestinal bacteria. Biol Pharm Bull. 2000 Dec;23(12):1481-5.
DM349AM	RU	https://pubmed.ncbi.nlm.nih.gov/11145182

DM349AM	DI	DM349AM
DM349AM	DN	HY-N0040
DM349AM	MI	DEM6GYO
DM349AM	MN	Beta-glucosidase (bglA)
DM349AM	MT	DME
DM349AM	MA	Metabolism
DM349AM	RN	Constitutive beta-glucosidases hydrolyzing ginsenoside Rb1 and Rb2 from human intestinal bacteria. Biol Pharm Bull. 2000 Dec;23(12):1481-5.
DM349AM	RU	https://pubmed.ncbi.nlm.nih.gov/11145182

DM349AM	DI	DM349AM
DM349AM	DN	HY-N0040
DM349AM	MI	DERPJZ6
DM349AM	MN	Beta-glucosidase (bglA)
DM349AM	MT	DME
DM349AM	MA	Metabolism
DM349AM	RN	Fermentation of protopanaxadiol type ginsenosides (PD) with probiotic Bifidobacterium lactis and Lactobacillus rhamnosus. Appl Microbiol Biotechnol. 2017 Jul;101(13):5427-5437.
DM349AM	RU	https://pubmed.ncbi.nlm.nih.gov/28478490

DM349AM	DI	DM349AM
DM349AM	DN	HY-N0040
DM349AM	MI	DEUQTKA
DM349AM	MN	Beta-glucosidase (bglA)
DM349AM	MT	DME
DM349AM	MA	Metabolism
DM349AM	RN	Fermentation of protopanaxadiol type ginsenosides (PD) with probiotic Bifidobacterium lactis and Lactobacillus rhamnosus. Appl Microbiol Biotechnol. 2017 Jul;101(13):5427-5437.
DM349AM	RU	https://pubmed.ncbi.nlm.nih.gov/28478490

DML4IAX	DI	DML4IAX
DML4IAX	DN	HY-N2258
DML4IAX	MI	DEBI82Z
DML4IAX	MN	Alpha-L-rhamnosidase (lrA)
DML4IAX	MT	DME
DML4IAX	MA	Metabolism
DML4IAX	RN	Metabolism of rutin and poncirin by human intestinal microbiota and cloning of their metabolizing alpha-L-rhamnosidase from Bifidobacterium dentium. J Microbiol Biotechnol. 2015 Jan;25(1):18-25.
DML4IAX	RU	https://pubmed.ncbi.nlm.nih.gov/25179902

DMXB95R	DI	DMXB95R
DMXB95R	DN	IC261
DMXB95R	MI	TTFQEMX
DMXB95R	MN	Casein kinase I alpha (CSNK1A1)
DMXB95R	MT	DTT
DMXB95R	MA	Inhibitor
DMXB95R	RN	Crystal structure of a conformation-selective casein kinase-1 inhibitor. J Biol Chem. 2000 Jun 30;275(26):20052-60.
DMXB95R	RU	https://pubmed.ncbi.nlm.nih.gov/10749871

DMXB95R	DI	DMXB95R
DMXB95R	DN	IC261
DMXB95R	MI	TTH30UI
DMXB95R	MN	Casein kinase I delta (CSNK1D)
DMXB95R	MT	DTT
DMXB95R	MA	Inhibitor
DMXB95R	RN	Crystal structure of a conformation-selective casein kinase-1 inhibitor. J Biol Chem. 2000 Jun 30;275(26):20052-60.
DMXB95R	RU	https://pubmed.ncbi.nlm.nih.gov/10749871

DMXB95R	DI	DMXB95R
DMXB95R	DN	IC261
DMXB95R	MI	TTA8PLI
DMXB95R	MN	Casein kinase I epsilon (CSNK1E)
DMXB95R	MT	DTT
DMXB95R	MA	Inhibitor
DMXB95R	RN	Crystal structure of a conformation-selective casein kinase-1 inhibitor. J Biol Chem. 2000 Jun 30;275(26):20052-60.
DMXB95R	RU	https://pubmed.ncbi.nlm.nih.gov/10749871

DM1RZVI	DI	DM1RZVI
DM1RZVI	DN	ICA-69673
DM1RZVI	MI	TTPXI3S
DM1RZVI	MN	Voltage-gated potassium channel Kv7.2 (KCNQ2)
DM1RZVI	MT	DTT
DM1RZVI	MA	Modulator
DM1RZVI	RN	Voltage-gated Potassium Channels as Therapeutic Drug Targets
DM1RZVI	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2790170

DM1RZVI	DI	DM1RZVI
DM1RZVI	DN	ICA-69673
DM1RZVI	MI	TTIVDM3
DM1RZVI	MN	Voltage-gated potassium channel Kv7.3 (KCNQ3)
DM1RZVI	MT	DTT
DM1RZVI	MA	Modulator
DM1RZVI	RN	Voltage-gated Potassium Channels as Therapeutic Drug Targets
DM1RZVI	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2790170

DMIYSD4	DI	DMIYSD4
DMIYSD4	DN	IDDB-41331
DMIYSD4	MI	TTTM6W8
DMIYSD4	MN	Melanin-concentrating hormone receptor (MCHR)
DMIYSD4	MT	DTT
DMIYSD4	MA	Antagonist
DMIYSD4	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DMIYSD4	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMQ3BXV	DI	DMQ3BXV
DMQ3BXV	DN	IDDBCP-150101
DMQ3BXV	MI	TTD0CIQ
DMQ3BXV	MN	Melanocortin receptor 4 (MC4R)
DMQ3BXV	MT	DTT
DMQ3BXV	MA	Agonist
DMQ3BXV	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DMQ3BXV	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMRIMZL	DI	DMRIMZL
DMRIMZL	DN	IDX136
DMRIMZL	MI	TTIU7X1
DMRIMZL	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMRIMZL	MT	DTT
DMRIMZL	MA	Inhibitor
DMRIMZL	RN	Therapy with amineptine, a dopamine reuptake inhibitor, in patients with major depression. Indian J Psychiatry. 1997 Apr;39(2):147-53.
DMRIMZL	RU	https://pubmed.ncbi.nlm.nih.gov/21584062

DMXN2ZQ	DI	DMXN2ZQ
DMXN2ZQ	DN	IMO-2134
DMXN2ZQ	MI	TTSHG0T
DMXN2ZQ	MN	Toll-like receptor 9 (TLR9)
DMXN2ZQ	MT	DTT
DMXN2ZQ	MA	Agonist
DMXN2ZQ	RN	Clinical pipeline report, company report or official report of Idera Pharmaceuticals (2011).
DMXN2ZQ	RU	http://www.iderapharma.com/

DMV5KSA	DI	DMV5KSA
DMV5KSA	DN	IMX-942
DMV5KSA	MI	TTOT2RY
DMV5KSA	MN	Sequestosome-1 p62 (SQSTM1)
DMV5KSA	MT	DTT
DMV5KSA	MA	Regulator (upregulator)
DMV5KSA	RN	Clinical pipeline report, company report or official report of SARomics Biostructures.
DMV5KSA	RU	http://www.saromics.com/news/news/News2010.html

DMXJO20	DI	DMXJO20
DMXJO20	DN	Indol-3-carbinol
DMXJO20	MI	TTUTN1I
DMXJO20	MN	Human Deoxyribonucleic acid (hDNA)
DMXJO20	MT	DTT
DMXJO20	MA	Binder
DMXJO20	RN	Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22.
DMXJO20	RU	https://pubmed.ncbi.nlm.nih.gov/19463273

DMXJO20	DI	DMXJO20
DMXJO20	DN	Indol-3-carbinol
DMXJO20	MI	TT27K59
DMXJO20	MN	Platelet activating factor (PAF)
DMXJO20	MT	DTT
DMXJO20	MA	Inhibitor
DMXJO20	RN	Pinusolide from the leaves of Biota orientalis as potent platelet activating factor antagonist. Planta Med. 1999 Feb;65(1):39-42.
DMXJO20	RU	https://pubmed.ncbi.nlm.nih.gov/10083843

DMBQGZ9	DI	DMBQGZ9
DMBQGZ9	DN	INOC-005
DMBQGZ9	MI	TT7HF4W
DMBQGZ9	MN	Cyclin-dependent kinase 2 (CDK2)
DMBQGZ9	MT	DTT
DMBQGZ9	MA	Inhibitor
DMBQGZ9	RN	What are next generation innovative therapeutic targets. J Pharmacol Exp Ther. 2009 Jul;330(1):304-15.
DMBQGZ9	RU	https://pubmed.ncbi.nlm.nih.gov/19357322

DMBQGZ9	DI	DMBQGZ9
DMBQGZ9	DN	INOC-005
DMBQGZ9	MI	TT0PG8F
DMBQGZ9	MN	Cyclin-dependent kinase 4 (CDK4)
DMBQGZ9	MT	DTT
DMBQGZ9	MA	Inhibitor
DMBQGZ9	RN	Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154.
DMBQGZ9	RU	https://pubmed.ncbi.nlm.nih.gov/21253554

DMBQGZ9	DI	DMBQGZ9
DMBQGZ9	DN	INOC-005
DMBQGZ9	MI	TTO0FDJ
DMBQGZ9	MN	Cyclin-dependent kinase 6 (CDK6)
DMBQGZ9	MT	DTT
DMBQGZ9	MA	Inhibitor
DMBQGZ9	RN	What are next generation innovative therapeutic targets. J Pharmacol Exp Ther. 2009 Jul;330(1):304-15.
DMBQGZ9	RU	https://pubmed.ncbi.nlm.nih.gov/19357322

DMRJ9P4	DI	DMRJ9P4
DMRJ9P4	DN	INT-767
DMRJ9P4	MI	TTS4UGC
DMRJ9P4	MN	Farnesoid X-activated receptor (FXR)
DMRJ9P4	MT	DTT
DMRJ9P4	MA	Agonist
DMRJ9P4	RN	FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity. J Am Soc Nephrol. 2018 Jan;29(1):118-137.
DMRJ9P4	RU	https://pubmed.ncbi.nlm.nih.gov/29089371

DMRJ9P4	DI	DMRJ9P4
DMRJ9P4	DN	INT-767
DMRJ9P4	MI	TTSDVTR
DMRJ9P4	MN	G-protein coupled bile acid receptor 1 (GPBAR1)
DMRJ9P4	MT	DTT
DMRJ9P4	MA	Agonist
DMRJ9P4	RN	FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity. J Am Soc Nephrol. 2018 Jan;29(1):118-137.
DMRJ9P4	RU	https://pubmed.ncbi.nlm.nih.gov/29089371

DMMUVAF	DI	DMMUVAF
DMMUVAF	DN	IRX-4
DMMUVAF	MI	TT9G4N0
DMMUVAF	MN	Glutamate carboxypeptidase II (GCPII)
DMMUVAF	MT	DTT
DMMUVAF	MA	Immunomodulator (Immunostimulant)
DMMUVAF	RN	Irx4 identifies a chamber-specific cell population that contributes to ventricular myocardium development. Dev Dyn. 2014 Mar;243(3):381-92.
DMMUVAF	RU	https://pubmed.ncbi.nlm.nih.gov/24123507

DMJ0A2R	DI	DMJ0A2R
DMJ0A2R	DN	IU1
DMJ0A2R	MI	TTVSYP9
DMJ0A2R	MN	Ubiquitin carboxyl-terminal hydrolase 14 (USP14)
DMJ0A2R	MT	DTT
DMJ0A2R	MA	Inhibitor
DMJ0A2R	RN	Neurotoxic mechanisms by which the USP14 inhibitor IU1 depletes ubiquitinated proteins and Tau in rat cerebral cortical neurons: Relevance to Alzheimer's disease. Biochim Biophys Acta Mol Basis Dis. 2017 Jun;1863(6):1157-1170.
DMJ0A2R	RU	https://pubmed.ncbi.nlm.nih.gov/28372990

DMTGI64	DI	DMTGI64
DMTGI64	DN	JD-5037
DMTGI64	MI	TT6OEDT
DMTGI64	MN	Cannabinoid receptor 1 (CB1)
DMTGI64	MT	DTT
DMTGI64	MA	Agonist
DMTGI64	RN	2011 Pipeline of Jenrin Discovery.
DMTGI64	RU	http://www.jenrindiscovery.com/pipeline.html

DMSXOPE	DI	DMSXOPE
DMSXOPE	DN	JNJ-26070109
DMSXOPE	MI	TTVFO0U
DMSXOPE	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMSXOPE	MT	DTT
DMSXOPE	MA	Antagonist
DMSXOPE	RN	The cholecystokinin CCK2 receptor antagonist, JNJ-26070109, inhibits gastric acid secretion and prevents omeprazole-induced acid rebound in the rat. Br J Pharmacol. 2012 Jul;166(5):1684-93.
DMSXOPE	RU	https://pubmed.ncbi.nlm.nih.gov/22300007

DMCNBHY	DI	DMCNBHY
DMCNBHY	DN	JNJ-42905343
DMCNBHY	MI	TTJQFBG
DMCNBHY	MN	HIF-prolyl hydroxylase (HPH)
DMCNBHY	MT	DTT
DMCNBHY	MA	Inhibitor
DMCNBHY	RN	Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation-induced anaemia in rats. Br J Pharmacol. 2015 Aug;172(16):4078-88.
DMCNBHY	RU	https://pubmed.ncbi.nlm.nih.gov/25988595

DMHBWOP	DI	DMHBWOP
DMHBWOP	DN	JT07
DMHBWOP	MI	TT1UCIJ
DMHBWOP	MN	C-X-C chemokine receptor type 3 (CXCR3)
DMHBWOP	MT	DTT
DMHBWOP	MA	Inhibitor
DMHBWOP	RN	Clinical pipeline report, company report or official report of Jyant Technologies.
DMHBWOP	RU	http://jyanttech.com/index.php?/pipeline

DMHBWOP	DI	DMHBWOP
DMHBWOP	DN	JT07
DMHBWOP	MI	TTRQJTC
DMHBWOP	MN	C-X-C chemokine receptor type 7 (ACKR3)
DMHBWOP	MT	DTT
DMHBWOP	MA	Inhibitor
DMHBWOP	RN	Clinical pipeline report, company report or official report of Jyant Technologies.
DMHBWOP	RU	http://jyanttech.com/index.php?/pipeline

DM8OAZ6	DI	DM8OAZ6
DM8OAZ6	DN	JT08
DM8OAZ6	MI	TTIW59R
DM8OAZ6	MN	C-X-C chemokine receptor type 5 (CXCR5)
DM8OAZ6	MT	DTT
DM8OAZ6	MA	Inhibitor
DM8OAZ6	RN	Clinical pipeline report, company report or official report of Jyant Technologies.
DM8OAZ6	RU	http://jyanttech.com/index.php?/pipeline

DM86YBK	DI	DM86YBK
DM86YBK	DN	K11777
DM86YBK	MI	TTS586L
DM86YBK	MN	HUMAN cathepsin L (CTSL)
DM86YBK	MT	DTT
DM86YBK	MA	Blocker
DM86YBK	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DM86YBK	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DMIQXEP	DI	DMIQXEP
DMIQXEP	DN	KD-3020
DMIQXEP	MI	TT2JWF6
DMIQXEP	MN	Peroxisome proliferator-activated receptor delta (PPARD)
DMIQXEP	MT	DTT
DMIQXEP	MA	Agonist
DMIQXEP	RN	Emerging drugs for non-alcoholic fatty liver disease. Expert Opin Emerg Drugs. 2008 Mar;13(1):145-58.
DMIQXEP	RU	https://pubmed.ncbi.nlm.nih.gov/18321154

DML93TN	DI	DML93TN
DML93TN	DN	Kestose
DML93TN	MI	DECWNTP
DML93TN	MN	Beta-fructofuranosidase (BFRU)
DML93TN	MT	DME
DML93TN	MA	Metabolism
DML93TN	RN	Characterization of fructooligosaccharide-degrading enzymes in human commensal Bifidobacterium longum and Anaerostipes caccae. Biochem Biophys Res Commun. 2019 Oct 15;518(2):294-298.
DML93TN	RU	https://pubmed.ncbi.nlm.nih.gov/31420164

DML93TN	DI	DML93TN
DML93TN	DN	Kestose
DML93TN	MI	DEJ4FO2
DML93TN	MN	Sucrose phosphorylase (Spase)
DML93TN	MT	DME
DML93TN	MA	Metabolism
DML93TN	RN	Characterization of fructooligosaccharide-degrading enzymes in human commensal Bifidobacterium longum and Anaerostipes caccae. Biochem Biophys Res Commun. 2019 Oct 15;518(2):294-298.
DML93TN	RU	https://pubmed.ncbi.nlm.nih.gov/31420164

DML93TN	DI	DML93TN
DML93TN	DN	Kestose
DML93TN	MI	DEICTXP
DML93TN	MN	Sucrose-6-phosphate hydrolase scrB (ScrB)
DML93TN	MT	DME
DML93TN	MA	Metabolism
DML93TN	RN	Characterization of fructooligosaccharide-degrading enzymes in human commensal Bifidobacterium longum and Anaerostipes caccae. Biochem Biophys Res Commun. 2019 Oct 15;518(2):294-298.
DML93TN	RU	https://pubmed.ncbi.nlm.nih.gov/31420164

DMHX1LA	DI	DMHX1LA
DMHX1LA	DN	KL001
DMHX1LA	MI	TT5MLZR
DMHX1LA	MN	Cryptochrome circadian clock 1 (CRY1)
DMHX1LA	MT	DTT
DMHX1LA	MA	Activator
DMHX1LA	RN	Identification of small molecule activators of cryptochrome. Science. 2012 Aug 31;337(6098):1094-7.
DMHX1LA	RU	https://pubmed.ncbi.nlm.nih.gov/22798407

DMHX1LA	DI	DMHX1LA
DMHX1LA	DN	KL001
DMHX1LA	MI	TTAO58M
DMHX1LA	MN	Cryptochrome-2 (CRY2)
DMHX1LA	MT	DTT
DMHX1LA	MA	Activator
DMHX1LA	RN	Identification of small molecule activators of cryptochrome. Science. 2012 Aug 31;337(6098):1094-7.
DMHX1LA	RU	https://pubmed.ncbi.nlm.nih.gov/22798407

DMFLIC0	DI	DMFLIC0
DMFLIC0	DN	KOS-1803
DMFLIC0	MI	TTYFKSZ
DMFLIC0	MN	Tubulin beta (TUBB)
DMFLIC0	MT	DTT
DMFLIC0	MA	Inhibitor
DMFLIC0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2640).
DMFLIC0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2640

DMCGFY6	DI	DMCGFY6
DMCGFY6	DN	KOS-1815
DMCGFY6	MI	TTCJUR4
DMCGFY6	MN	Exportin-1 (XPO1)
DMCGFY6	MT	DTT
DMCGFY6	MA	Inhibitor
DMCGFY6	RN	Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents. Semin Cancer Biol. 2014 August; 0: 62-73.
DMCGFY6	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108511/

DMXY81K	DI	DMXY81K
DMXY81K	DN	KOS-2484
DMXY81K	MI	TT78R5H
DMXY81K	MN	Heat shock protein 90 alpha (HSP90A)
DMXY81K	MT	DTT
DMXY81K	MA	Inhibitor
DMXY81K	RN	US patent application no. 2014,0079,636, Targeted therapeutics.
DMXY81K	RU	http://www.google.com.na/patents/US20140079636

DMZCW3J	DI	DMZCW3J
DMZCW3J	DN	KP3
DMZCW3J	MI	TTHDS05
DMZCW3J	MN	Klebsiella Fimbrial subunit type 3 (Klebsiella mrkA)
DMZCW3J	MT	DTT
DMZCW3J	MA	Inhibitor
DMZCW3J	RN	Anti-MrkA Monoclonal Antibodies Reveal Distinct Structural and Antigenic Features of MrkA. PLoS One. 2017 Jan 20;12(1):e0170529.
DMZCW3J	RU	https://pubmed.ncbi.nlm.nih.gov/28107434

DMMEH12	DI	DMMEH12
DMMEH12	DN	L-006235-1
DMMEH12	MI	TTF2LRI
DMMEH12	MN	Cathepsin B (CTSB)
DMMEH12	MT	DTT
DMMEH12	MA	Inhibitor
DMMEH12	RN	Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional se... J Med Chem. 2005 Dec 1;48(24):7535-43.
DMMEH12	RU	https://pubmed.ncbi.nlm.nih.gov/16302795

DMMEH12	DI	DMMEH12
DMMEH12	DN	L-006235-1
DMMEH12	MI	TTDZN01
DMMEH12	MN	Cathepsin K (CTSK)
DMMEH12	MT	DTT
DMMEH12	MA	Inhibitor
DMMEH12	RN	Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional se... J Med Chem. 2005 Dec 1;48(24):7535-43.
DMMEH12	RU	https://pubmed.ncbi.nlm.nih.gov/16302795

DMMEH12	DI	DMMEH12
DMMEH12	DN	L-006235-1
DMMEH12	MI	TT36ETB
DMMEH12	MN	Cathepsin L (CTSL)
DMMEH12	MT	DTT
DMMEH12	MA	Inhibitor
DMMEH12	RN	Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional se... J Med Chem. 2005 Dec 1;48(24):7535-43.
DMMEH12	RU	https://pubmed.ncbi.nlm.nih.gov/16302795

DMMEH12	DI	DMMEH12
DMMEH12	DN	L-006235-1
DMMEH12	MI	TTUMQVO
DMMEH12	MN	Cathepsin S (CTSS)
DMMEH12	MT	DTT
DMMEH12	MA	Inhibitor
DMMEH12	RN	Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional se... J Med Chem. 2005 Dec 1;48(24):7535-43.
DMMEH12	RU	https://pubmed.ncbi.nlm.nih.gov/16302795

DMK3TXY	DI	DMK3TXY
DMK3TXY	DN	L-742791
DMK3TXY	MI	TTMXGCW
DMK3TXY	MN	Adrenergic receptor beta-3 (ADRB3)
DMK3TXY	MT	DTT
DMK3TXY	MA	Agonist
DMK3TXY	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DMK3TXY	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMOERXK	DI	DMOERXK
DMOERXK	DN	L-751250
DMOERXK	MI	TTMXGCW
DMOERXK	MN	Adrenergic receptor beta-3 (ADRB3)
DMOERXK	MT	DTT
DMOERXK	MA	Agonist
DMOERXK	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DMOERXK	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMOERXK	DI	DMOERXK
DMOERXK	DN	L-751250
DMOERXK	MI	TTH6V3D
DMOERXK	MN	Cyclin-dependent kinase 1 (CDK1)
DMOERXK	MT	DTT
DMOERXK	MA	Binder
DMOERXK	RN	Down-regulation of survivin in nitric oxide-induced cell growth inhibition and apoptosis of the human lung carcinoma cells. J Biol Chem. 2004 May 7;279(19):20267-76.
DMOERXK	RU	https://pubmed.ncbi.nlm.nih.gov/14988404

DMOERXK	DI	DMOERXK
DMOERXK	DN	L-751250
DMOERXK	MI	TT7HF4W
DMOERXK	MN	Cyclin-dependent kinase 2 (CDK2)
DMOERXK	MT	DTT
DMOERXK	MA	Inhibitor
DMOERXK	RN	Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
DMOERXK	RU	https://pubmed.ncbi.nlm.nih.gov/12237154

DMOERXK	DI	DMOERXK
DMOERXK	DN	L-751250
DMOERXK	MI	TTL4Q97
DMOERXK	MN	Cyclin-dependent kinase 5 (CDK5)
DMOERXK	MT	DTT
DMOERXK	MA	Inhibitor
DMOERXK	RN	Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
DMOERXK	RU	https://pubmed.ncbi.nlm.nih.gov/12237154

DMFBMXD	DI	DMFBMXD
DMFBMXD	DN	LAS-101057
DMFBMXD	MI	TTNE7KG
DMFBMXD	MN	Adenosine A2b receptor (ADORA2B)
DMFBMXD	MT	DTT
DMFBMXD	MA	Antagonist
DMFBMXD	RN	Discovery of LAS101057: A Potent, Selective, and Orally Efficacious A2B Adenosine Receptor Antagonist. ACS Med Chem Lett. 2010 Dec 20;2(3):213-8.
DMFBMXD	RU	https://pubmed.ncbi.nlm.nih.gov/24900298

DM1982I	DI	DM1982I
DM1982I	DN	LDN-57444
DM1982I	MI	TTX9IFP
DM1982I	MN	Ubiquitin thioesterase L1 (UCHL1)
DM1982I	MT	DTT
DM1982I	MA	Inhibitor
DM1982I	RN	Inhibition of UCH-L1 Deubiquitinating Activity with Two Forms of LDN-57444 Has Anti-Invasive Effects in Metastatic Carcinoma Cells. Int J Mol Sci. 2019 Jul 31;20(15):3733.
DM1982I	RU	https://pubmed.ncbi.nlm.nih.gov/31370144

DMGJL16	DI	DMGJL16
DMGJL16	DN	LE-300
DMGJL16	MI	TTS2PH3
DMGJL16	MN	Dopamine D5 receptor (D5R)
DMGJL16	MT	DTT
DMGJL16	MA	Antagonist
DMGJL16	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMGJL16	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMJXZIS	DI	DMJXZIS
DMJXZIS	DN	LH846
DMJXZIS	MI	TT7OGZP
DMJXZIS	MN	Casein kinase 1 (CK1)
DMJXZIS	MT	DTT
DMJXZIS	MA	Inhibitor
DMJXZIS	RN	A small molecule modulates circadian rhythms through phosphorylation of the period protein. Angew Chem Int Ed Engl. 2011 Nov 4;50(45):10608-11.
DMJXZIS	RU	https://pubmed.ncbi.nlm.nih.gov/21954091

DMNOE1M	DI	DMNOE1M
DMNOE1M	DN	LLY-507
DMNOE1M	MI	TT7YJFO
DMNOE1M	MN	SET and MYND domain-containing protein 2 (SMYD2)
DMNOE1M	MT	DTT
DMNOE1M	MA	Inhibitor
DMNOE1M	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2714).
DMNOE1M	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2714

DMXYDMP	DI	DMXYDMP
DMXYDMP	DN	LM10
DMXYDMP	MI	TTXNCBV
DMXYDMP	MN	Tryptophan 2,3-dioxygenase (TDO)
DMXYDMP	MT	DTT
DMXYDMP	MA	Inhibitor
DMXYDMP	RN	The autoimmune response elicited by mouse hepatitis virus (MHV-A59) infection is modulated by liver tryptophan-2,3-dioxygenase (TDO). Immunol Lett. 2020 Jan;217:25-30.
DMXYDMP	RU	https://pubmed.ncbi.nlm.nih.gov/31726186

DMNIWF5	DI	DMNIWF5
DMNIWF5	DN	Lopinavir
DMNIWF5	MI	TTWOH4Q
DMNIWF5	MN	MERS-CoV 3C-like proteinase (3CLpro)
DMNIWF5	MT	DTT
DMNIWF5	MA	Inhibitor
DMNIWF5	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DMNIWF5	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DMNIWF5	DI	DMNIWF5
DMNIWF5	DN	Lopinavir
DMNIWF5	MI	TTPZG3C
DMNIWF5	MN	SARS-CoV 3C-like protease (3CLpro)
DMNIWF5	MT	DTT
DMNIWF5	MA	Inhibitor
DMNIWF5	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DMNIWF5	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DM0URLP	DI	DM0URLP
DM0URLP	DN	Lopinavir + ritonavir + interferon alpha
DM0URLP	MI	TT1D53B
DM0URLP	MN	COVID-19 3C-like protease (3CLpro)
DM0URLP	MT	DTT
DM0URLP	MA	Inhibitor
DM0URLP	RN	Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381.
DM0URLP	RU	https://pubmed.ncbi.nlm.nih.gov/32205870

DMV1A25	DI	DMV1A25
DMV1A25	DN	LpxC-1
DMV1A25	MI	TT0OFWN
DMV1A25	MN	Pseudomonas UDP-3-O-acyl-GlcNAc deacetylase (Pseudo lpxC)
DMV1A25	MT	DTT
DMV1A25	MA	Inhibitor
DMV1A25	RN	Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance. Nat Rev Drug Discov. 2017 Jul;16(7):457-471.
DMV1A25	RU	https://pubmed.ncbi.nlm.nih.gov/28337021

DM7XPDB	DI	DM7XPDB
DM7XPDB	DN	LY-2463665
DM7XPDB	MI	TTDIGC1
DM7XPDB	MN	Dipeptidyl peptidase 4 (DPP-4)
DM7XPDB	MT	DTT
DM7XPDB	MA	Inhibitor
DM7XPDB	RN	Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87.
DM7XPDB	RU	https://pubmed.ncbi.nlm.nih.gov/19149538

DM2N637	DI	DM2N637
DM2N637	DN	LY-25582
DM2N637	MI	TT27RFC
DM2N637	MN	Opioid receptor delta (OPRD1)
DM2N637	MT	DTT
DM2N637	MA	Inhibitor
DM2N637	RN	Investigation of the N-substituent conformation governing potency and mu receptor subtype-selectivity in (+)-(3R, 4R)-dimethyl-4-(3-hydroxyphenyl)p... J Med Chem. 1998 May 21;41(11):1980-90.
DM2N637	RU	https://pubmed.ncbi.nlm.nih.gov/9599247

DM2N637	DI	DM2N637
DM2N637	DN	LY-25582
DM2N637	MI	TTQW87Y
DM2N637	MN	Opioid receptor kappa (OPRK1)
DM2N637	MT	DTT
DM2N637	MA	Inhibitor
DM2N637	RN	Investigation of the N-substituent conformation governing potency and mu receptor subtype-selectivity in (+)-(3R, 4R)-dimethyl-4-(3-hydroxyphenyl)p... J Med Chem. 1998 May 21;41(11):1980-90.
DM2N637	RU	https://pubmed.ncbi.nlm.nih.gov/9599247

DM2N637	DI	DM2N637
DM2N637	DN	LY-25582
DM2N637	MI	TTKWM86
DM2N637	MN	Opioid receptor mu (MOP)
DM2N637	MT	DTT
DM2N637	MA	Antagonist
DM2N637	RN	Structure activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 2. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6841-6.
DM2N637	RU	https://pubmed.ncbi.nlm.nih.gov/17980586

DMUFIO9	DI	DMUFIO9
DMUFIO9	DN	M102
DMUFIO9	MI	TTA6ZN2
DMUFIO9	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMUFIO9	MT	DTT
DMUFIO9	MA	Activator
DMUFIO9	RN	Clinical pipeline report, company report or official report of Aclipse Therapeutics.
DMUFIO9	RU	https://aclipsetherapeutics.com/therapeutics/m102/

DM7HUVB	DI	DM7HUVB
DM7HUVB	DN	m337
DM7HUVB	MI	TTZ3COY
DM7HUVB	MN	COVID-19 spike glycoprotein (S)
DM7HUVB	MT	DTT
DM7HUVB	MA	Inhibitor
DM7HUVB	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DM7HUVB	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DM32XJS	DI	DM32XJS
DM32XJS	DN	M64
DM32XJS	MI	TT7L1ZX
DM32XJS	MN	Pseudomonas Multiple virulence factor regulator MvfR (Pseudo MvfR)
DM32XJS	MT	DTT
DM32XJS	MA	Inhibitor
DM32XJS	RN	Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance. Nat Rev Drug Discov. 2017 Jul;16(7):457-471.
DM32XJS	RU	https://pubmed.ncbi.nlm.nih.gov/28337021

DM5IMAU	DI	DM5IMAU
DM5IMAU	DN	MAb173
DM5IMAU	MI	TTBID49
DM5IMAU	MN	C-X-C chemokine receptor type 4 (CXCR4)
DM5IMAU	MT	DTT
DM5IMAU	MA	Antagonist
DM5IMAU	RN	Caspase-dependent apoptosis of cells expressing the chemokine receptor CXCR4 is induced by cell membrane-associated human immunodeficiency virus type 1 envelope glycoprotein (gp120). Virology. 2000 Mar 15;268(2):329-44.
DM5IMAU	RU	https://pubmed.ncbi.nlm.nih.gov/10704341

DMNO20J	DI	DMNO20J
DMNO20J	DN	mAb926
DMNO20J	MI	TTTCRU2
DMNO20J	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DMNO20J	MT	DTT
DMNO20J	MA	Inhibitor
DMNO20J	RN	FimH as a scaffold for regulated molecular recognition. J Biol Eng. 2021 Jan 12;15(1):3.
DMNO20J	RU	https://pubmed.ncbi.nlm.nih.gov/33436006

DMZHT39	DI	DMZHT39
DMZHT39	DN	Macrolactin A
DMZHT39	MI	DEHD2Q8
DMZHT39	MN	Glycosyltransferase (Gtf)
DMZHT39	MT	DME
DMZHT39	MA	Metabolism
DMZHT39	RN	A bacterial glycosyltransferase gene toolbox: generation and applications. Phytochemistry. 2009 Oct-Nov;70(15-16):1812-21.
DMZHT39	RU	https://pubmed.ncbi.nlm.nih.gov/19559449

DM1XYGF	DI	DM1XYGF
DM1XYGF	DN	MAX-10129
DM1XYGF	MI	TT23XQV
DM1XYGF	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DM1XYGF	MT	DTT
DM1XYGF	MA	Inhibitor
DM1XYGF	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DM1XYGF	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMBT2RJ	DI	DMBT2RJ
DMBT2RJ	DN	MC-2001
DMBT2RJ	MI	TTGJCWZ
DMBT2RJ	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMBT2RJ	MT	DTT
DMBT2RJ	MA	Inhibitor
DMBT2RJ	RN	Vascular endothelial growth factor and its receptors in multiple myeloma. Leukemia. 2003 Oct;17(10):1961-6.
DMBT2RJ	RU	https://pubmed.ncbi.nlm.nih.gov/14513045

DMBT2RJ	DI	DMBT2RJ
DMBT2RJ	DN	MC-2001
DMBT2RJ	MI	TT3PJMV
DMBT2RJ	MN	Tyrosine-protein kinase ABL1 (ABL)
DMBT2RJ	MT	DTT
DMBT2RJ	MA	Inhibitor
DMBT2RJ	RN	Vascular endothelial growth factor and its receptors in multiple myeloma. Leukemia. 2003 Oct;17(10):1961-6.
DMBT2RJ	RU	https://pubmed.ncbi.nlm.nih.gov/14513045

DMLK2D0	DI	DMLK2D0
DMLK2D0	DN	MC-3001
DMLK2D0	MI	TTJ584C
DMLK2D0	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMLK2D0	MT	DTT
DMLK2D0	MA	Agonist
DMLK2D0	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021175)
DMLK2D0	RU	http://adisinsight.springer.com/drugs/800021175

DM7UGY9	DI	DM7UGY9
DM7UGY9	DN	MC-3002
DM7UGY9	MI	TTJ584C
DM7UGY9	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DM7UGY9	MT	DTT
DM7UGY9	MA	Modulator
DM7UGY9	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM7UGY9	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM7UGY9	DI	DM7UGY9
DM7UGY9	DN	MC-3002
DM7UGY9	MI	TTZMAO3
DM7UGY9	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DM7UGY9	MT	DTT
DM7UGY9	MA	Modulator
DM7UGY9	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM7UGY9	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMHJLPS	DI	DMHJLPS
DMHJLPS	DN	M-carboxycinnamic acid bishydroxamide
DMHJLPS	MI	TT6R7JZ
DMHJLPS	MN	Histone deacetylase 1 (HDAC1)
DMHJLPS	MT	DTT
DMHJLPS	MA	Inhibitor
DMHJLPS	RN	Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92.
DMHJLPS	RU	https://pubmed.ncbi.nlm.nih.gov/17896917

DMYEFKH	DI	DMYEFKH
DMYEFKH	DN	MCP-1
DMYEFKH	MI	TTFZYTO
DMYEFKH	MN	C-C chemokine receptor type 2 (CCR2)
DMYEFKH	MT	DTT
DMYEFKH	MA	Antagonist
DMYEFKH	RN	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
DMYEFKH	RU	https://pubmed.ncbi.nlm.nih.gov/16634702

DMYEFKH	DI	DMYEFKH
DMYEFKH	DN	MCP-1
DMYEFKH	MI	TTNAY0P
DMYEFKH	MN	Monocyte chemotactic and activating factor (CCL2)
DMYEFKH	MT	DTT
DMYEFKH	MA	Inhibitor
DMYEFKH	RN	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
DMYEFKH	RU	https://pubmed.ncbi.nlm.nih.gov/16634702

DM7Q1PF	DI	DM7Q1PF
DM7Q1PF	DN	MEDI-543
DM7Q1PF	MI	TTRJB2G
DM7Q1PF	MN	Ephrin type-A receptor 2 (EPHA2)
DM7Q1PF	MT	DTT
DM7Q1PF	RN	Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer. Cancer Biol Ther. 2010 Dec 15;10(12):1306-14.
DM7Q1PF	RU	https://pubmed.ncbi.nlm.nih.gov/20948320

DMYK8MV	DI	DMYK8MV
DMYK8MV	DN	Melanotetan II
DMYK8MV	MI	TTNI91K
DMYK8MV	MN	Melanocortin receptor 3 (MC3R)
DMYK8MV	MT	DTT
DMYK8MV	MA	Agonist
DMYK8MV	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DMYK8MV	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMYK8MV	DI	DMYK8MV
DMYK8MV	DN	Melanotetan II
DMYK8MV	MI	TTD0CIQ
DMYK8MV	MN	Melanocortin receptor 4 (MC4R)
DMYK8MV	MT	DTT
DMYK8MV	MA	Agonist
DMYK8MV	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DMYK8MV	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMX4IS3	DI	DMX4IS3
DMX4IS3	DN	Mephenoxalone
DMX4IS3	MI	DTZGT0P
DMX4IS3	MN	Multidrug and toxin extrusion protein 1 (SLC47A1)
DMX4IS3	MT	DTP
DMX4IS3	MA	Substrate
DMX4IS3	RN	Preclinical and clinical evidence for the collaborative transport and renal secretion of an oxazolidinone antibiotic by organic anion transporter 3 (OAT3/SLC22A8) and multidrug and toxin extrusion protein 1 (MATE1/SLC47A1). J Pharmacol Exp Ther. 2010 Sep 1;334(3):936-44.
DMX4IS3	RU	http://www.ncbi.nlm.nih.gov/pubmed/20519552

DMTQXS7	DI	DMTQXS7
DMTQXS7	DN	Mercaptopurine
DMTQXS7	MI	TTYJOLE
DMTQXS7	MN	MERS-CoV papain-like proteinase (PL-PRO)
DMTQXS7	MT	DTT
DMTQXS7	MA	Inhibitor
DMTQXS7	RN	Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus. Antiviral Res. 2015 Mar;115:9-16.
DMTQXS7	RU	https://pubmed.ncbi.nlm.nih.gov/25542975

DMTQXS7	DI	DMTQXS7
DMTQXS7	DN	Mercaptopurine
DMTQXS7	MI	TTRGHB2
DMTQXS7	MN	SARS-CoV papain-like proteinase (PL-PRO)
DMTQXS7	MT	DTT
DMTQXS7	MA	Inhibitor
DMTQXS7	RN	Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus. Antiviral Res. 2015 Mar;115:9-16.
DMTQXS7	RU	https://pubmed.ncbi.nlm.nih.gov/25542975

DMVGIB4	DI	DMVGIB4
DMVGIB4	DN	MERS-27
DMVGIB4	MI	TTZ3COY
DMVGIB4	MN	COVID-19 spike glycoprotein (S)
DMVGIB4	MT	DTT
DMVGIB4	MA	Inhibitor
DMVGIB4	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DMVGIB4	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DMS6KT8	DI	DMS6KT8
DMS6KT8	DN	MERS-4
DMS6KT8	MI	TTZ3COY
DMS6KT8	MN	COVID-19 spike glycoprotein (S)
DMS6KT8	MT	DTT
DMS6KT8	MA	Inhibitor
DMS6KT8	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DMS6KT8	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DMG5YRP	DI	DMG5YRP
DMG5YRP	DN	MERS-five-helix bundle
DMG5YRP	MI	TT85VHW
DMG5YRP	MN	MERS-CoV spike glycoprotein (S)
DMG5YRP	MT	DTT
DMG5YRP	MA	Inhibitor
DMG5YRP	RN	Identification of a Novel Inhibitor against Middle East Respiratory Syndrome Coronavirus. Viruses. 2017 Sep 14;9(9). pii: E255.
DMG5YRP	RU	https://pubmed.ncbi.nlm.nih.gov/28906430

DMQW5MH	DI	DMQW5MH
DMQW5MH	DN	Metampicillin
DMQW5MH	MI	DT9G7XN
DMQW5MH	MN	Peptide transporter 1 (SLC15A1)
DMQW5MH	MT	DTP
DMQW5MH	MA	Substrate
DMQW5MH	RN	Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60.
DMQW5MH	RU	http://www.ncbi.nlm.nih.gov/pubmed/16597710

DMQW5MH	DI	DMQW5MH
DMQW5MH	DN	Metampicillin
DMQW5MH	MI	DT8QKNP
DMQW5MH	MN	Peptide transporter 2 (SLC15A2)
DMQW5MH	MT	DTP
DMQW5MH	MA	Substrate
DMQW5MH	RN	Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60.
DMQW5MH	RU	http://www.ncbi.nlm.nih.gov/pubmed/16597710

DMDPV82	DI	DMDPV82
DMDPV82	DN	Metildigoxin
DMDPV82	MI	DTUGYRD
DMDPV82	MN	P-glycoprotein 1 (ABCB1)
DMDPV82	MT	DTP
DMDPV82	MA	Substrate
DMDPV82	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
DMDPV82	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01665

DMDU8KC	DI	DMDU8KC
DMDU8KC	DN	Metkephamid
DMDU8KC	MI	DTUGYRD
DMDU8KC	MN	P-glycoprotein 1 (ABCB1)
DMDU8KC	MT	DTP
DMDU8KC	MA	Substrate
DMDU8KC	RN	Fingerprint-based in silico models for the prediction of P-glycoprotein substrates and inhibitors. Bioorg Med Chem. 2012 Sep 15;20(18):5388-95.
DMDU8KC	RU	https://doi.org/10.1016/j.bmc.2012.03.045

DMKA2YS	DI	DMKA2YS
DMKA2YS	DN	MG-132
DMKA2YS	MI	DTUGYRD
DMKA2YS	MN	P-glycoprotein 1 (ABCB1)
DMKA2YS	MT	DTP
DMKA2YS	MA	Substrate
DMKA2YS	RN	Increased ABCB1 expression in TP-110-resistant RPMI-8226 cells. Biosci Biotechnol Biochem. 2010;74(9):1913-9.
DMKA2YS	RU	https://doi.org/10.1271/bbb.100325

DMI3E0Y	DI	DMI3E0Y
DMI3E0Y	DN	MK6-83
DMI3E0Y	MI	TT9XBVO
DMI3E0Y	MN	Mucolipin-1 (TRPML1)
DMI3E0Y	MT	DTT
DMI3E0Y	MA	Agonist
DMI3E0Y	RN	ML-SA1, a selective TRPML agonist, inhibits DENV2 and ZIKV by promoting lysosomal acidification and protease activity. Antiviral Res. 2020 Oct;182:104922.
DMI3E0Y	RU	https://pubmed.ncbi.nlm.nih.gov/32858116

DMV2F84	DI	DMV2F84
DMV2F84	DN	ML209
DMV2F84	MI	TTGV6LY
DMV2F84	MN	Nuclear receptor ROR-gamma (RORG)
DMV2F84	MT	DTT
DMV2F84	MA	Agonist
DMV2F84	RN	ROR nuclear receptors: structures, related diseases, and drug discovery. Acta Pharmacol Sin. 2015 Jan;36(1):71-87.
DMV2F84	RU	https://pubmed.ncbi.nlm.nih.gov/25500868

DMY91A3	DI	DMY91A3
DMY91A3	DN	ML323
DMY91A3	MI	TTG9MT5
DMY91A3	MN	Deubiquitinating enzyme 1 (USP1)
DMY91A3	MT	DTT
DMY91A3	MA	Inhibitor
DMY91A3	RN	Synthesis and structure-activity relationship studies of N-benzyl-2-phenylpyrimidin-4-amine derivatives as potent USP1/UAF1 deubiquitinase inhibitors with anticancer activity against nonsmall cell lung cancer. J Med Chem. 2014 Oct 9;57(19):8099-110.
DMY91A3	RU	https://pubmed.ncbi.nlm.nih.gov/25229643

DM6RFLE	DI	DM6RFLE
DM6RFLE	DN	ML364
DM6RFLE	MI	TTUEQ1W
DM6RFLE	MN	Ubiquitin carboxyl-terminal hydrolase 2 (USP2)
DM6RFLE	MT	DTT
DM6RFLE	MA	Inhibitor
DM6RFLE	RN	The deubiquitylase USP2 maintains ErbB2 abundance via counteracting endocytic degradation and represents a therapeutic target in ErbB2-positive breast cancer. Cell Death Differ. 2020 Sep;27(9):2710-2725.
DM6RFLE	RU	https://pubmed.ncbi.nlm.nih.gov/32327714

DMEK78T	DI	DMEK78T
DMEK78T	DN	MNLP-18
DMEK78T	MI	TTZ7HX8
DMEK78T	MN	Glycoside hydrolase (GlyH)
DMEK78T	MT	DTT
DMEK78T	MA	Inhibitor
DMEK78T	RN	viral infection therapy, MNLpharma MNLpharma partnering opportunity, Worldwide, R & D Focus Drug News, May 29, 2006
DMEK78T	RU	http://business.highbeam.com/436989/article-1G1-146237368/viral-infection-therapy-mnlpharma-mnlpharma-partnering

DMG2UJS	DI	DMG2UJS
DMG2UJS	DN	Monomethyl-auristatin-E
DMG2UJS	MI	DTQ3ZHF
DMG2UJS	MN	Multidrug resistance-associated protein 3 (ABCC3)
DMG2UJS	MT	DTP
DMG2UJS	MA	Substrate
DMG2UJS	RN	Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer. Cancer Res. 2008 Jul 1;68(13):5380-9.
DMG2UJS	RU	https://doi.org/10.1158/0008-5472.CAN-08-0234

DM5AMFV	DI	DM5AMFV
DM5AMFV	DN	MS012
DM5AMFV	MI	TTS6RZT
DM5AMFV	MN	Histone-lysine N-methyltransferase EHMT2 (EHMT2)
DM5AMFV	MT	DTT
DM5AMFV	MA	Inhibitor
DM5AMFV	RN	Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021 Apr;20(4):265-286.
DM5AMFV	RU	https://pubmed.ncbi.nlm.nih.gov/33469207

DMDEJBQ	DI	DMDEJBQ
DMDEJBQ	DN	MS2177
DMDEJBQ	MI	TTGC95K
DMDEJBQ	MN	SET domain containing 8 (KMT5A)
DMDEJBQ	MT	DTT
DMDEJBQ	MA	Inhibitor
DMDEJBQ	RN	Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021 Apr;20(4):265-286.
DMDEJBQ	RU	https://pubmed.ncbi.nlm.nih.gov/33469207

DMCZW4Q	DI	DMCZW4Q
DMCZW4Q	DN	Mteron-F1
DMCZW4Q	MI	TTNDSF4
DMCZW4Q	MN	Proto-oncogene c-Met (MET)
DMCZW4Q	MT	DTT
DMCZW4Q	MA	Stimulator
DMCZW4Q	RN	Emerging drugs for chemotherapy-induced mucositis. Expert Opin Emerg Drugs. 2008 Sep;13(3):511-22.
DMCZW4Q	RU	https://pubmed.ncbi.nlm.nih.gov/18764726

DMC3NSK	DI	DMC3NSK
DMC3NSK	DN	MUT-056399
DMC3NSK	MI	TTFKXOM
DMC3NSK	MN	Bacterial NADH-dependent enoyl-ACP reductase (Bact fabI)
DMC3NSK	MT	DTT
DMC3NSK	MA	Modulator
DMC3NSK	RN	The MUT056399 inhibitor of FabI is a new antistaphylococcal compound. Antimicrob Agents Chemother. 2011 Oct;55(10):4692-7.
DMC3NSK	RU	https://pubmed.ncbi.nlm.nih.gov/21825292

DMC3NSK	DI	DMC3NSK
DMC3NSK	DN	MUT-056399
DMC3NSK	MI	TTZBRVL
DMC3NSK	MN	Staphylococcus Enoyl ACP reductase (Stap-coc fabI)
DMC3NSK	MT	DTT
DMC3NSK	MA	Modulator
DMC3NSK	RN	The MUT056399 inhibitor of FabI is a new antistaphylococcal compound. Antimicrob Agents Chemother. 2011 Oct;55(10):4692-7.
DMC3NSK	RU	https://pubmed.ncbi.nlm.nih.gov/21825292

DMDE7OR	DI	DMDE7OR
DMDE7OR	DN	NA-808
DMDE7OR	MI	TTZVMA7
DMDE7OR	MN	Serine palmitoyltransferase (SPTC)
DMDE7OR	MT	DTT
DMDE7OR	MA	Modulator
DMDE7OR	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMDE7OR	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMEHO9G	DI	DMEHO9G
DMEHO9G	DN	NC043
DMEHO9G	MI	TTQ9EDI
DMEHO9G	MN	Ubiquitin carboxyl-terminal hydrolase 30 (USP30)
DMEHO9G	MT	DTT
DMEHO9G	MA	Inhibitor
DMEHO9G	RN	A small natural molecule promotes mitochondrial fusion through inhibition of the deubiquitinase USP30. Cell Res. 2014 Apr;24(4):482-96.
DMEHO9G	RU	https://pubmed.ncbi.nlm.nih.gov/24513856

DMXG0O1	DI	DMXG0O1
DMXG0O1	DN	NCGC607
DMXG0O1	MI	TT1B5PU
DMXG0O1	MN	Glucosylceramidase (GBA)
DMXG0O1	MT	DTT
DMXG0O1	MA	Inhibitor
DMXG0O1	RN	A New Glucocerebrosidase Chaperone Reduces alpha-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism. J Neurosci. 2016 Jul 13;36(28):7441-52.
DMXG0O1	RU	https://pubmed.ncbi.nlm.nih.gov/27413154

DM5ATJ0	DI	DM5ATJ0
DM5ATJ0	DN	N-desethyl sunitinib
DM5ATJ0	MI	DTI7UX6
DM5ATJ0	MN	Breast cancer resistance protein (ABCG2)
DM5ATJ0	MT	DTP
DM5ATJ0	MA	Substrate
DM5ATJ0	RN	P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib. J Pharmacol Exp Ther. 2012 Apr;341(1):164-73.
DM5ATJ0	RU	https://doi.org/10.1124/jpet.111.186908

DM5ATJ0	DI	DM5ATJ0
DM5ATJ0	DN	N-desethyl sunitinib
DM5ATJ0	MI	DTUGYRD
DM5ATJ0	MN	P-glycoprotein 1 (ABCB1)
DM5ATJ0	MT	DTP
DM5ATJ0	MA	Substrate
DM5ATJ0	RN	P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib. J Pharmacol Exp Ther. 2012 Apr;341(1):164-73.
DM5ATJ0	RU	https://doi.org/10.1124/jpet.111.186908

DMX7Q3H	DI	DMX7Q3H
DMX7Q3H	DN	Nemorubicin
DMX7Q3H	MI	TT0IHXV
DMX7Q3H	MN	DNA topoisomerase II (TOP2)
DMX7Q3H	MT	DTT
DMX7Q3H	MA	Modulator
DMX7Q3H	RN	The interaction of nemorubicin metabolite PNU-159682 with DNA fragments d(CGTACG)(2), d(CGATCG)(2) and d(CGCGCG)(2) shows a strong but reversible binding to G:C base pairs. Bioorg Med Chem. 2012 Dec 15;20(24):6979-88.
DMX7Q3H	RU	https://pubmed.ncbi.nlm.nih.gov/23154079

DMW1LKP	DI	DMW1LKP
DMW1LKP	DN	Nicotinamide mononucleotide
DMW1LKP	MI	DT0OA2B
DMW1LKP	MN	Cation-chloride cotransporter 9 (SLC12A8)
DMW1LKP	MT	DTP
DMW1LKP	MA	Substrate
DMW1LKP	RN	Slc12a8 is a nicotinamide mononucleotide transporter. Nature Metabolismvolume 1, pages4757 (2019).
DMW1LKP	RU	https://www.nature.com/articles/s42255-018-0009-4

DMK8UD0	DI	DMK8UD0
DMK8UD0	DN	NKP-46
DMK8UD0	MI	TTBWDI0
DMK8UD0	MN	Ribonucleoside-diphosphate reductase M2 (RRM2)
DMK8UD0	MT	DTT
DMK8UD0	RN	Phase I and pharmacokinetic study of the oral tris-(8-quinolinolato)gallium(III) complex (FFC11, KP46) in patients with solid tumors - a study of the CESAR Central European Society for Anticancer Drug Research - EWIV. J Clin Oncol (Meeting Abstracts) June 2005 vol. 23 no. 16_suppl 3205.
DMK8UD0	RU	http://meeting.ascopubs.org/cgi/content/short/23/16_suppl/3205

DMVUKEW	DI	DMVUKEW
DMVUKEW	DN	N-methylpyridinium
DMVUKEW	MI	DTZGT0P
DMVUKEW	MN	Multidrug and toxin extrusion protein 1 (SLC47A1)
DMVUKEW	MT	DTP
DMVUKEW	MA	Substrate
DMVUKEW	RN	Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
DMVUKEW	RU	http://www.ncbi.nlm.nih.gov/pubmed/17509534

DMVUKEW	DI	DMVUKEW
DMVUKEW	DN	N-methylpyridinium
DMVUKEW	MI	DT3TX4H
DMVUKEW	MN	Multidrug and toxin extrusion protein 2 (SLC47A2)
DMVUKEW	MT	DTP
DMVUKEW	MA	Substrate
DMVUKEW	RN	Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
DMVUKEW	RU	http://www.ncbi.nlm.nih.gov/pubmed/17509534

DMVUKEW	DI	DMVUKEW
DMVUKEW	DN	N-methylpyridinium
DMVUKEW	MI	DTT79CX
DMVUKEW	MN	Organic cation transporter 1 (SLC22A1)
DMVUKEW	MT	DTP
DMVUKEW	MA	Substrate
DMVUKEW	RN	Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on organic anion transporting polypeptides and organic cation transporter 1. Diabetes. 2008 Jun;57(6):1463-9.
DMVUKEW	RU	http://www.ncbi.nlm.nih.gov/pubmed/18314419

DMVUKEW	DI	DMVUKEW
DMVUKEW	DN	N-methylpyridinium
DMVUKEW	MI	DT9IDPW
DMVUKEW	MN	Organic cation transporter 2 (SLC22A2)
DMVUKEW	MT	DTP
DMVUKEW	MA	Substrate
DMVUKEW	RN	Functional characterization of the human organic cation transporter 2 variant p.270Ala>Ser. Drug Metab Dispos. 2009 Jun;37(6):1312-8.
DMVUKEW	RU	http://www.ncbi.nlm.nih.gov/pubmed/19251820

DMVUKEW	DI	DMVUKEW
DMVUKEW	DN	N-methylpyridinium
DMVUKEW	MI	DT6201N
DMVUKEW	MN	Organic cation transporter 3 (SLC22A3)
DMVUKEW	MT	DTP
DMVUKEW	MA	Substrate
DMVUKEW	RN	Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. Am J Physiol Renal Physiol. 2000 Sep;279(3):F449-58.
DMVUKEW	RU	http://www.ncbi.nlm.nih.gov/pubmed/10966924

DMLNYGX	DI	DMLNYGX
DMLNYGX	DN	NN-818
DMLNYGX	MI	TTE4KHA
DMLNYGX	MN	Amyloid beta A4 protein (APP)
DMLNYGX	MT	DTT
DMLNYGX	MA	Modulator
DMLNYGX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
DMLNYGX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402

DM7R3B6	DI	DM7R3B6
DM7R3B6	DN	Nobiletin
DM7R3B6	MI	TTGV6LY
DM7R3B6	MN	Nuclear receptor ROR-gamma (RORG)
DM7R3B6	MT	DTT
DM7R3B6	MA	Agonist
DM7R3B6	RN	The Small Molecule Nobiletin Targets the Molecular Oscillator to Enhance Circadian Rhythms and Protect against Metabolic Syndrome. Cell Metab. 2016 Apr 12;23(4):610-21.
DM7R3B6	RU	https://pubmed.ncbi.nlm.nih.gov/27076076

DMTQ2UD	DI	DMTQ2UD
DMTQ2UD	DN	N-Octyl-4-epi-beta-valienamine
DMTQ2UD	MI	TTNGJPH
DMTQ2UD	MN	Beta-galactosidase (GLB1)
DMTQ2UD	MT	DTT
DMTQ2UD	MA	Inhibitor
DMTQ2UD	RN	Chemical modification of the beta-glucocerebrosidase inhibitor N-octyl-beta-valienamine: synthesis and biological evaluation of 4-epimeric and 4-O-(beta-D-galactopyranosyl) derivatives. Bioorg Med Chem. 2002 Jun;10(6):1967-72.
DMTQ2UD	RU	https://pubmed.ncbi.nlm.nih.gov/11937356

DM39C47	DI	DM39C47
DM39C47	DN	N-Octyl-beta-valienamine
DM39C47	MI	TT1B5PU
DM39C47	MN	Glucosylceramidase (GBA)
DM39C47	MT	DTT
DM39C47	MA	Inhibitor
DM39C47	RN	Chemical modification of the beta-glucocerebrosidase inhibitor N-octyl-beta-valienamine: synthesis and biological evaluation of 4-epimeric and 4-O-(beta-D-galactopyranosyl) derivatives. Bioorg Med Chem. 2002 Jun;10(6):1967-72.
DM39C47	RU	https://pubmed.ncbi.nlm.nih.gov/11937356

DMKF2H0	DI	DMKF2H0
DMKF2H0	DN	Nonactin
DMKF2H0	MI	DTUGYRD
DMKF2H0	MN	P-glycoprotein 1 (ABCB1)
DMKF2H0	MT	DTP
DMKF2H0	MA	Substrate
DMKF2H0	RN	Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia. 2005 Feb;46(2):224-35.
DMKF2H0	RU	https://doi.org/10.1111/j.0013-9580.2005.31904.x

DM83DSA	DI	DM83DSA
DM83DSA	DN	NOX-F37
DM83DSA	MI	TT4TFGN
DM83DSA	MN	Vasopressin V1a receptor (V1AR)
DM83DSA	MT	DTT
DM83DSA	MA	Antagonist
DM83DSA	RN	Emerging drugs for acute and chronic heart failure: current and future developments. Expert Opin Emerg Drugs. 2007 Mar;12(1):75-95.
DM83DSA	RU	https://pubmed.ncbi.nlm.nih.gov/17355215

DMOGRWB	DI	DMOGRWB
DMOGRWB	DN	NPS-1034
DMOGRWB	MI	TTNDSF4
DMOGRWB	MN	Proto-oncogene c-Met (MET)
DMOGRWB	MT	DTT
DMOGRWB	MA	Inhibitor
DMOGRWB	RN	NPS-1034, a novel MET inhibitor, inhibits the activated MET receptor and its constitutively active mutants. Invest New Drugs. 2014 Jun;32(3):389-99.
DMOGRWB	RU	https://pubmed.ncbi.nlm.nih.gov/24173966

DMMRY0Z	DI	DMMRY0Z
DMMRY0Z	DN	NPS-2390
DMMRY0Z	MI	TTBUYHA
DMMRY0Z	MN	Extracellular calcium-sensing receptor (CASR)
DMMRY0Z	MT	DTT
DMMRY0Z	MA	Modulator
DMMRY0Z	RN	The Extracellular Calcium-Sensing Receptor (CASR) Regulates Gonadotropins-Induced Meiotic Maturation of Porcine Oocytes.Biol Reprod.2015 Dec;93(6):131.
DMMRY0Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/26490840

DMMRY0Z	DI	DMMRY0Z
DMMRY0Z	DN	NPS-2390
DMMRY0Z	MI	TTVBPDM
DMMRY0Z	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMMRY0Z	MT	DTT
DMMRY0Z	MA	Inhibitor
DMMRY0Z	RN	Positive and negative modulation of group I metabotropic glutamate receptors. J Med Chem. 2008 Feb 14;51(3):634-47.
DMMRY0Z	RU	https://pubmed.ncbi.nlm.nih.gov/18173231

DMXUCSN	DI	DMXUCSN
DMXUCSN	DN	NPY5RA-972
DMXUCSN	MI	TTY6EWA
DMXUCSN	MN	Neuropeptide Y receptor type 5 (NPY5R)
DMXUCSN	MT	DTT
DMXUCSN	MA	Antagonist
DMXUCSN	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DMXUCSN	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMO5MUY	DI	DMO5MUY
DMO5MUY	DN	NSC-207895
DMO5MUY	MI	TT9OUDQ
DMO5MUY	MN	p53-binding protein Mdm4 (MDM4)
DMO5MUY	MT	DTT
DMO5MUY	MA	Inhibitor
DMO5MUY	RN	Emerging therapies targeting the ubiquitin proteasome system in cancer. J Clin Invest. 2014 Jan;124(1):6-12.
DMO5MUY	RU	https://pubmed.ncbi.nlm.nih.gov/24382383

DMQRZ4T	DI	DMQRZ4T
DMQRZ4T	DN	NSC632839
DMQRZ4T	MI	TTX9IFP
DMQRZ4T	MN	Ubiquitin thioesterase L1 (UCHL1)
DMQRZ4T	MT	DTT
DMQRZ4T	MA	Inhibitor
DMQRZ4T	RN	Ubiquitin C-Terminal Hydrolase L1 regulates autophagy by inhibiting autophagosome formation through its deubiquitinating enzyme activity. Biochem Biophys Res Commun. 2018 Mar 4;497(2):726-733.
DMQRZ4T	RU	https://pubmed.ncbi.nlm.nih.gov/29462615

DM65UZ2	DI	DM65UZ2
DM65UZ2	DN	NTU281
DM65UZ2	MI	TT2F4OL
DM65UZ2	MN	Tissue transglutaminase (TG2)
DM65UZ2	MT	DTT
DM65UZ2	MA	Inhibitor
DM65UZ2	RN	Drugs and Targets in Fibrosis. Front Pharmacol. 2017 Nov 23;8:855.
DM65UZ2	RU	https://pubmed.ncbi.nlm.nih.gov/29218009

DMO5EXL	DI	DMO5EXL
DMO5EXL	DN	NVP-2
DMO5EXL	MI	TT1LVF2
DMO5EXL	MN	Cyclin-dependent kinase 9 (CDK9)
DMO5EXL	MT	DTT
DMO5EXL	MA	Inhibitor
DMO5EXL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1981).
DMO5EXL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1981

DMEXLU5	DI	DMEXLU5
DMEXLU5	DN	ON-01135
DMEXLU5	MI	TTH6V3D
DMEXLU5	MN	Cyclin-dependent kinase 1 (CDK1)
DMEXLU5	MT	DTT
DMEXLU5	MA	Inhibitor
DMEXLU5	RN	Phase 1 study of intravenous rigosertib (ON 01910.Na), a novel benzyl styryl sulfone structure producing G2/M arrest and apoptosis, in adult patients with advanced cancer. Am J Cancer Res. 2013; 3(3): 323-338.
DMEXLU5	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3696538/

DMMBIHO	DI	DMMBIHO
DMMBIHO	DN	ONO-1301
DMMBIHO	MI	TTKNWZ4
DMMBIHO	MN	Thromboxane-A synthase (TBXAS1)
DMMBIHO	MT	DTT
DMMBIHO	MA	Agonist
DMMBIHO	RN	A synthetic prostacyclin agonist with thromboxane synthase inhibitory activity, ONO-1301, protects myocardium from ischemia/reperfusion injury. Eur J Pharmacol. 2012 Jan 15;674(2-3):352-8.
DMMBIHO	RU	https://pubmed.ncbi.nlm.nih.gov/22094066

DMHQUM2	DI	DMHQUM2
DMHQUM2	DN	Org-23366
DMHQUM2	MI	TTJQOD7
DMHQUM2	MN	5-HT 2A receptor (HTR2A)
DMHQUM2	MT	DTT
DMHQUM2	MA	Antagonist
DMHQUM2	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMHQUM2	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMHQUM2	DI	DMHQUM2
DMHQUM2	DN	Org-23366
DMHQUM2	MI	TTEX248
DMHQUM2	MN	Dopamine D2 receptor (D2R)
DMHQUM2	MT	DTT
DMHQUM2	MA	Antagonist
DMHQUM2	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMHQUM2	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMHQUM2	DI	DMHQUM2
DMHQUM2	DN	Org-23366
DMHQUM2	MI	TTH18TF
DMHQUM2	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMHQUM2	MT	DTT
DMHQUM2	MA	Antagonist
DMHQUM2	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMHQUM2	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMCMS7V	DI	DMCMS7V
DMCMS7V	DN	Org-24461
DMCMS7V	MI	TTHJTF7
DMCMS7V	MN	Glycine transporter GlyT-1 (SLC6A9)
DMCMS7V	MT	DTT
DMCMS7V	MA	Blocker
DMCMS7V	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMCMS7V	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMERWUC	DI	DMERWUC
DMERWUC	DN	Organon
DMERWUC	MI	DE4LYSA
DMERWUC	MN	Cytochrome P450 3A4 (CYP3A4)
DMERWUC	MT	DME
DMERWUC	MA	Metabolism
DMERWUC	RN	Identification of the human P450 enzymes involved in the in vitro metabolism of the synthetic steroidal hormones Org 4060 and Org 30659. Xenobiotica. 2002 Feb;32(2):109-18.
DMERWUC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11871398

DMERWUC	DI	DMERWUC
DMERWUC	DN	Organon
DMERWUC	MI	TTHJTF7
DMERWUC	MN	Glycine transporter GlyT-1 (SLC6A9)
DMERWUC	MT	DTT
DMERWUC	MA	Blocker
DMERWUC	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMERWUC	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DM46QXZ	DI	DM46QXZ
DM46QXZ	DN	Organon-2
DM46QXZ	MI	TTHJTF7
DM46QXZ	MN	Glycine transporter GlyT-1 (SLC6A9)
DM46QXZ	MT	DTT
DM46QXZ	MA	Blocker
DM46QXZ	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DM46QXZ	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DM07EU4	DI	DM07EU4
DM07EU4	DN	Organon-3
DM07EU4	MI	TTHJTF7
DM07EU4	MN	Glycine transporter GlyT-1 (SLC6A9)
DM07EU4	MT	DTT
DM07EU4	MA	Blocker
DM07EU4	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DM07EU4	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMPUSM5	DI	DMPUSM5
DMPUSM5	DN	Otamixaban
DMPUSM5	MI	TTK9LUQ
DMPUSM5	MN	HUAMN serine protease factor Xa (SERPINA5)
DMPUSM5	MT	DTT
DMPUSM5	MA	Inhibitor
DMPUSM5	RN	A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29. Br J Pharmacol. 2020 May 1;10.1111/bph.15094.
DMPUSM5	RU	https://pubmed.ncbi.nlm.nih.gov/32358833

DMYKG8R	DI	DMYKG8R
DMYKG8R	DN	Oxypertine
DMYKG8R	MI	DTAV4SY
DMYKG8R	MN	Sodium-dependent serotonin transporter (SLC6A4)
DMYKG8R	MT	DTP
DMYKG8R	MA	Substrate
DMYKG8R	RN	Serotonin transporter gene and treatment of alcoholism.
DMYKG8R	RU	https://patents.google.com/patent/CA2760675A1

DMD8JIC	DI	DMD8JIC
DMD8JIC	DN	P22077
DMD8JIC	MI	TTXU3EQ
DMD8JIC	MN	Herpesvirus ubiquitin-specific protease (HAUSP)
DMD8JIC	MT	DTT
DMD8JIC	MA	Inhibitor
DMD8JIC	RN	P22077 inhibits LPS-induced inflammatory response by promoting K48-linked ubiquitination and degradation of TRAF6. Aging (Albany NY). 2020 Jun 9;12(11):10969-10982.
DMD8JIC	RU	https://pubmed.ncbi.nlm.nih.gov/32516131

DMGIR3F	DI	DMGIR3F
DMGIR3F	DN	P5091
DMGIR3F	MI	TTXU3EQ
DMGIR3F	MN	Herpesvirus ubiquitin-specific protease (HAUSP)
DMGIR3F	MT	DTT
DMGIR3F	MA	Inhibitor
DMGIR3F	RN	USP7 inhibitor P5091 inhibits Wnt signaling and colorectal tumor growth. Biochem Pharmacol. 2017 May 1;131:29-39.
DMGIR3F	RU	https://pubmed.ncbi.nlm.nih.gov/28216017

DM3YUGA	DI	DM3YUGA
DM3YUGA	DN	Pancratistatin
DM3YUGA	MI	DTI7UX6
DM3YUGA	MN	Breast cancer resistance protein (ABCG2)
DM3YUGA	MT	DTP
DM3YUGA	MA	Substrate
DM3YUGA	RN	Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug Screen. Mol Pharmacol. 2009 Nov;76(5):946-56.
DM3YUGA	RU	https://doi.org/10.1124/mol.109.056192

DMNIM96	DI	DMNIM96
DMNIM96	DN	P-BCMA-ALL01
DMNIM96	MI	TTZ3P4W
DMNIM96	MN	B-cell maturation protein (TNFRSF17)
DMNIM96	MT	DTT
DMNIM96	RN	Clinical pipeline report, company report or official report of Poseida Therapeutics.
DMNIM96	RU	https://poseida.com/science/pipeline/

DMW3TGI	DI	DMW3TGI
DMW3TGI	DN	PCI-45292
DMW3TGI	MI	TTGM6VW
DMW3TGI	MN	Tyrosine-protein kinase BTK (ATK)
DMW3TGI	MT	DTT
DMW3TGI	MA	Inhibitor
DMW3TGI	RN	Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013 October 10; 122(15): 2539-2549.
DMW3TGI	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3795457/

DMTG730	DI	DMTG730
DMTG730	DN	PD-157533
DMTG730	MI	TT4C8EA
DMTG730	MN	Dopamine D3 receptor (D3R)
DMTG730	MT	DTT
DMTG730	MA	Antagonist
DMTG730	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMTG730	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMDSR1X	DI	DMDSR1X
DMDSR1X	DN	PD-157695
DMDSR1X	MI	TT38ECI
DMDSR1X	MN	Bacterial Hydroxymethyl-dihydropterin pyrophosphokinase (Bact folK)
DMDSR1X	MT	DTT
DMDSR1X	MA	Inhibitor
DMDSR1X	RN	Bisubstrate analogue inhibitors of 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase: synthesis and biochemical and crystallographic studies. J Med Chem. 2001 Apr 26;44(9):1364-71.
DMDSR1X	RU	https://pubmed.ncbi.nlm.nih.gov/11311059

DMDSR1X	DI	DMDSR1X
DMDSR1X	DN	PD-157695
DMDSR1X	MI	TT30C9G
DMDSR1X	MN	C-X-C chemokine receptor type 2 (CXCR2)
DMDSR1X	MT	DTT
DMDSR1X	MA	Antagonist
DMDSR1X	RN	Interleukin-8 receptor antagonists in pulmonary diseases. Curr Opin Pharmacol. 2001 Jun;1(3):242-7.
DMDSR1X	RU	https://pubmed.ncbi.nlm.nih.gov/11712746

DMDSR1X	DI	DMDSR1X
DMDSR1X	DN	PD-157695
DMDSR1X	MI	TTEX248
DMDSR1X	MN	Dopamine D2 receptor (D2R)
DMDSR1X	MT	DTT
DMDSR1X	MA	Antagonist
DMDSR1X	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMDSR1X	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMDSR1X	DI	DMDSR1X
DMDSR1X	DN	PD-157695
DMDSR1X	MI	TT4C8EA
DMDSR1X	MN	Dopamine D3 receptor (D3R)
DMDSR1X	MT	DTT
DMDSR1X	MA	Antagonist
DMDSR1X	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMDSR1X	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DM682UV	DI	DM682UV
DM682UV	DN	PD-158771
DM682UV	MI	TTSQIFT
DM682UV	MN	5-HT 1A receptor (HTR1A)
DM682UV	MT	DTT
DM682UV	MA	Antagonist
DM682UV	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DM682UV	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DM682UV	DI	DM682UV
DM682UV	DN	PD-158771
DM682UV	MI	TTEX248
DM682UV	MN	Dopamine D2 receptor (D2R)
DM682UV	MT	DTT
DM682UV	MA	Antagonist
DM682UV	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DM682UV	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DM682UV	DI	DM682UV
DM682UV	DN	PD-158771
DM682UV	MI	TT4C8EA
DM682UV	MN	Dopamine D3 receptor (D3R)
DM682UV	MT	DTT
DM682UV	MA	Antagonist
DM682UV	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DM682UV	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMB9Z4C	DI	DMB9Z4C
DMB9Z4C	DN	PD-160170
DMB9Z4C	MI	TTRK9JT
DMB9Z4C	MN	Neuropeptide Y receptor type 1 (NPY1R)
DMB9Z4C	MT	DTT
DMB9Z4C	MA	Antagonist
DMB9Z4C	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DMB9Z4C	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMD0GB4	DI	DMD0GB4
DMD0GB4	DN	PD-165167
DMD0GB4	MI	TTE0A2F
DMD0GB4	MN	Dopamine D4 receptor (D4R)
DMD0GB4	MT	DTT
DMD0GB4	MA	Antagonist
DMD0GB4	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMD0GB4	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMEOVDQ	DI	DMEOVDQ
DMEOVDQ	DN	PD-170292
DMEOVDQ	MI	TTCG0AL
DMEOVDQ	MN	Cholecystokinin receptor type A (CCKAR)
DMEOVDQ	MT	DTT
DMEOVDQ	MA	Agonist
DMEOVDQ	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DMEOVDQ	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMEOVDQ	DI	DMEOVDQ
DMEOVDQ	DN	PD-170292
DMEOVDQ	MI	TTVFO0U
DMEOVDQ	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMEOVDQ	MT	DTT
DMEOVDQ	MA	Agonist
DMEOVDQ	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DMEOVDQ	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMA5T3J	DI	DMA5T3J
DMA5T3J	DN	Pepticlere
DMA5T3J	MI	TTE4KHA
DMA5T3J	MN	Amyloid beta A4 protein (APP)
DMA5T3J	MT	DTT
DMA5T3J	MA	Inhibitor
DMA5T3J	RN	Preclinical trail of Pepticlere (DP-74) for treating Alzheimer's disease. ProteoTech Inc.
DMA5T3J	RU	http://www.biocentury.com/products/pepticlere

DMMWQTI	DI	DMMWQTI
DMMWQTI	DN	Peptide P21S10
DMMWQTI	MI	TT85VHW
DMMWQTI	MN	MERS-CoV spike glycoprotein (S)
DMMWQTI	MT	DTT
DMMWQTI	MA	Inhibitor
DMMWQTI	RN	Discovery of Hydrocarbon-Stapled Short -Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. J Med Chem. 2018 Mar 8;61(5):2018-2026.
DMMWQTI	RU	https://pubmed.ncbi.nlm.nih.gov/29442512

DM3U2S5	DI	DM3U2S5
DM3U2S5	DN	PF-04859989
DM3U2S5	MI	TTT3IXG
DM3U2S5	MN	Kynurenine oxoglutarate transaminase II (AADAT)
DM3U2S5	MT	DTT
DM3U2S5	MA	Inhibitor
DM3U2S5	RN	Investigating KYNA production and kynurenergic manipulation on acute mouse brain slice preparations. Brain Res Bull. 2019 Mar;146:185-191.
DM3U2S5	RU	https://pubmed.ncbi.nlm.nih.gov/30639278

DM8P9ST	DI	DM8P9ST
DM8P9ST	DN	PF-4800567
DM8P9ST	MI	TTH30UI
DM8P9ST	MN	Casein kinase I delta (CSNK1D)
DM8P9ST	MT	DTT
DM8P9ST	MA	Inhibitor
DM8P9ST	RN	Selective inhibition of casein kinase 1 epsilon minimally alters circadian clock period. J Pharmacol Exp Ther. 2009 Aug;330(2):430-9.
DM8P9ST	RU	https://pubmed.ncbi.nlm.nih.gov/19458106

DM8P9ST	DI	DM8P9ST
DM8P9ST	DN	PF-4800567
DM8P9ST	MI	TTA8PLI
DM8P9ST	MN	Casein kinase I epsilon (CSNK1E)
DM8P9ST	MT	DTT
DM8P9ST	MA	Inhibitor
DM8P9ST	RN	Selective inhibition of casein kinase 1 epsilon minimally alters circadian clock period. J Pharmacol Exp Ther. 2009 Aug;330(2):430-9.
DM8P9ST	RU	https://pubmed.ncbi.nlm.nih.gov/19458106

DMTJBP9	DI	DMTJBP9
DMTJBP9	DN	PF-670462
DMTJBP9	MI	TTH30UI
DMTJBP9	MN	Casein kinase I delta (CSNK1D)
DMTJBP9	MT	DTT
DMTJBP9	MA	Inhibitor
DMTJBP9	RN	Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia. Blood. 2018 Mar 15;131(11):1206-1218.
DMTJBP9	RU	https://pubmed.ncbi.nlm.nih.gov/29317454

DMTJBP9	DI	DMTJBP9
DMTJBP9	DN	PF-670462
DMTJBP9	MI	TTA8PLI
DMTJBP9	MN	Casein kinase I epsilon (CSNK1E)
DMTJBP9	MT	DTT
DMTJBP9	MA	Inhibitor
DMTJBP9	RN	Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia. Blood. 2018 Mar 15;131(11):1206-1218.
DMTJBP9	RU	https://pubmed.ncbi.nlm.nih.gov/29317454

DMNZG8T	DI	DMNZG8T
DMNZG8T	DN	PF-821385
DMNZG8T	MI	TTBYP1X
DMNZG8T	MN	Human immunodeficiency virus Envelope glycoprotein gp120 (HIV gp120)
DMNZG8T	MT	DTT
DMNZG8T	MA	Inhibitor
DMNZG8T	RN	Increased Functional Stability and Homogeneity of Viral Envelope Spikes through Directed Evolution. PLoS Pathog. 2013 February; 9(2): e1003184.
DMNZG8T	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585149/

DM1A2UI	DI	DM1A2UI
DM1A2UI	DN	PGX-200097
DM1A2UI	MI	TTKWFB8
DM1A2UI	MN	Catechol-O-methyl-transferase (COMT)
DM1A2UI	MT	DTT
DM1A2UI	MA	Inhibitor
DM1A2UI	RN	Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future. Schizophr Res. 2010 Sep;122(1-3):1-23.
DM1A2UI	RU	https://pubmed.ncbi.nlm.nih.gov/20655178

DM1A2UI	DI	DM1A2UI
DM1A2UI	DN	PGX-200097
DM1A2UI	MI	TTEX248
DM1A2UI	MN	Dopamine D2 receptor (D2R)
DM1A2UI	MT	DTT
DM1A2UI	MA	Inhibitor
DM1A2UI	RN	Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future. Schizophr Res. 2010 Sep;122(1-3):1-23.
DM1A2UI	RU	https://pubmed.ncbi.nlm.nih.gov/20655178

DMM149N	DI	DMM149N
DMM149N	DN	PHA-568487
DMM149N	MI	TTLA931
DMM149N	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMM149N	MT	DTT
DMM149N	MA	Agonist
DMM149N	RN	Multiple species metabolism of PHA-568487, a selective alpha 7 nicotinic acetylcholine receptor agonist. Drug Metab Lett. 2010 Aug;4(3):162-72.
DMM149N	RU	https://pubmed.ncbi.nlm.nih.gov/20642449

DMIGH6W	DI	DMIGH6W
DMIGH6W	DN	PHENSERINE TARTRATE
DMIGH6W	MI	TT1RS9F
DMIGH6W	MN	Acetylcholinesterase (AChE)
DMIGH6W	MT	DTT
DMIGH6W	MA	Inhibitor
DMIGH6W	RN	An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Curr Alzheimer Res. 2005 Jul;2(3):281-90.
DMIGH6W	RU	https://pubmed.ncbi.nlm.nih.gov/15974893

DM16W8F	DI	DM16W8F
DM16W8F	DN	Phenylisoserine derivatives SK80
DM16W8F	MI	TTPZG3C
DM16W8F	MN	SARS-CoV 3C-like protease (3CLpro)
DM16W8F	MT	DTT
DM16W8F	MA	Inhibitor
DM16W8F	RN	Synthesis and Evaluation of Phenylisoserine Derivatives for the SARS-CoV 3CL Protease Inhibitor. Bioorg Med Chem Lett. 2017 Jun 15;27(12):2746-2751.
DM16W8F	RU	https://pubmed.ncbi.nlm.nih.gov/28454669

DMIZCOE	DI	DMIZCOE
DMIZCOE	DN	Piperlongumine
DMIZCOE	MI	TTWO3SH
DMIZCOE	MN	Glutathione S-transferase omega-1 (GSTO-1)
DMIZCOE	MT	DTT
DMIZCOE	MA	Inhibitor
DMIZCOE	RN	Activity-based protein profiling reveals GSTO1 as the covalent target of piperlongumine and a promising target for combination therapy for cancer. Chem Commun (Camb). 2019 Apr 9;55(30):4407-4410.
DMIZCOE	RU	https://pubmed.ncbi.nlm.nih.gov/30916079

DM82Y75	DI	DM82Y75
DM82Y75	DN	PIRINIXIC ACID
DM82Y75	MI	TTJ584C
DM82Y75	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DM82Y75	MT	DTT
DM82Y75	MA	Inhibitor
DM82Y75	RN	O-arylmandelic acids as highly selective human PPAR alpha/gamma agonists. Bioorg Med Chem Lett. 2003 Oct 6;13(19):3185-90.
DM82Y75	RU	https://pubmed.ncbi.nlm.nih.gov/12951090

DMXO6YH	DI	DMXO6YH
DMXO6YH	DN	PJ34
DMXO6YH	MI	TTVDSZ0
DMXO6YH	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMXO6YH	MT	DTT
DMXO6YH	MA	Inhibitor
DMXO6YH	RN	Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med. 2001 Jan;7(1):108-13.
DMXO6YH	RU	https://pubmed.ncbi.nlm.nih.gov/11135624

DM94ZOI	DI	DM94ZOI
DM94ZOI	DN	PMID21925774-compound-5e
DM94ZOI	MI	TTQKWR5
DM94ZOI	MN	SARS-CoV helicase (Hel)
DM94ZOI	MT	DTT
DM94ZOI	MA	Inhibitor
DM94ZOI	RN	2,6-Bis-arylmethyloxy-5-hydroxychromones With Antiviral Activity Against Both Hepatitis C Virus (HCV) and SARS-associated Coronavirus (SCV) Eur J Med Chem. 2011 Nov;46(11):5698-704.
DM94ZOI	RU	https://pubmed.ncbi.nlm.nih.gov/21925774

DMOHPX4	DI	DMOHPX4
DMOHPX4	DN	PMID25197057-Compound6e
DMOHPX4	MI	TTEN986
DMOHPX4	MN	Staphylococcus Sortase A (Stap-coc srtA)
DMOHPX4	MT	DTT
DMOHPX4	MA	Inhibitor
DMOHPX4	RN	Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance. Nat Rev Drug Discov. 2017 Jul;16(7):457-471.
DMOHPX4	RU	https://pubmed.ncbi.nlm.nih.gov/28337021

DMFNS7U	DI	DMFNS7U
DMFNS7U	DN	PMID26048809-compound2
DMFNS7U	MI	TTOA6YT
DMFNS7U	MN	MERS-CoV RNA-directed RNA polymerase (RdRp)
DMFNS7U	MT	DTT
DMFNS7U	MA	Inhibitor
DMFNS7U	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DMFNS7U	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DMZMYU5	DI	DMZMYU5
DMZMYU5	DN	PMID26868298-compound-5705213
DMZMYU5	MI	TTS586L
DMZMYU5	MN	HUMAN cathepsin L (CTSL)
DMZMYU5	MT	DTT
DMZMYU5	MA	Blocker
DMZMYU5	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DMZMYU5	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DMQFUCD	DI	DMQFUCD
DMQFUCD	DN	PMID26868298-compound-N3
DMQFUCD	MI	TTNHMO8
DMQFUCD	MN	COVID-19 papain-like proteinase (PL-PRO)
DMQFUCD	MT	DTT
DMQFUCD	MA	Inhibitor
DMQFUCD	RN	Structure of Mpro from COVID-19 virus and discovery of its inhibitors. Nature. 2020 Apr 9.
DMQFUCD	RU	https://pubmed.ncbi.nlm.nih.gov/32272481

DMQFUCD	DI	DMQFUCD
DMQFUCD	DN	PMID26868298-compound-N3
DMQFUCD	MI	TTWOH4Q
DMQFUCD	MN	MERS-CoV 3C-like proteinase (3CLpro)
DMQFUCD	MT	DTT
DMQFUCD	MA	Inhibitor
DMQFUCD	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DMQFUCD	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DMQFUCD	DI	DMQFUCD
DMQFUCD	DN	PMID26868298-compound-N3
DMQFUCD	MI	TTPZG3C
DMQFUCD	MN	SARS-CoV 3C-like protease (3CLpro)
DMQFUCD	MT	DTT
DMQFUCD	MA	Inhibitor
DMQFUCD	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DMQFUCD	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DMUH012	DI	DMUH012
DMUH012	DN	PMID26911565-peptide-P9
DMUH012	MI	TT85VHW
DMUH012	MN	MERS-CoV spike glycoprotein (S)
DMUH012	MT	DTT
DMUH012	MA	Inhibitor
DMUH012	RN	A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses. Sci Rep. 2016 Feb 25;6:22008.
DMUH012	RU	https://pubmed.ncbi.nlm.nih.gov/26911565

DMUH012	DI	DMUH012
DMUH012	DN	PMID26911565-peptide-P9
DMUH012	MI	TTTL19V
DMUH012	MN	SARS-CoV spike glycoprotein (S)
DMUH012	MT	DTT
DMUH012	MA	Inhibitor
DMUH012	RN	A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses. Sci Rep. 2016 Feb 25;6:22008.
DMUH012	RU	https://pubmed.ncbi.nlm.nih.gov/26911565

DMPC29W	DI	DMPC29W
DMPC29W	DN	PMID27240464-compound-3f
DMPC29W	MI	TTWOH4Q
DMPC29W	MN	MERS-CoV 3C-like proteinase (3CLpro)
DMPC29W	MT	DTT
DMPC29W	MA	Inhibitor
DMPC29W	RN	Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors. Bioorg Med Chem. 2016 Jul 1;24(13):3035-3042.
DMPC29W	RU	https://pubmed.ncbi.nlm.nih.gov/27240464

DMPC29W	DI	DMPC29W
DMPC29W	DN	PMID27240464-compound-3f
DMPC29W	MI	TTPZG3C
DMPC29W	MN	SARS-CoV 3C-like protease (3CLpro)
DMPC29W	MT	DTT
DMPC29W	MA	Inhibitor
DMPC29W	RN	Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors. Bioorg Med Chem. 2016 Jul 1;24(13):3035-3042.
DMPC29W	RU	https://pubmed.ncbi.nlm.nih.gov/27240464

DMPWUFT	DI	DMPWUFT
DMPWUFT	DN	PMID28216367-compound-6d
DMPWUFT	MI	TTWOH4Q
DMPWUFT	MN	MERS-CoV 3C-like proteinase (3CLpro)
DMPWUFT	MT	DTT
DMPWUFT	MA	Inhibitor
DMPWUFT	RN	Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CLPro inhibitors. Antiviral Res. 2017 May;141:101-106.
DMPWUFT	RU	https://pubmed.ncbi.nlm.nih.gov/28216367

DMPWUFT	DI	DMPWUFT
DMPWUFT	DN	PMID28216367-compound-6d
DMPWUFT	MI	TTPZG3C
DMPWUFT	MN	SARS-CoV 3C-like protease (3CLpro)
DMPWUFT	MT	DTT
DMPWUFT	MA	Inhibitor
DMPWUFT	RN	Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CLPro inhibitors. Antiviral Res. 2017 May;141:101-106.
DMPWUFT	RU	https://pubmed.ncbi.nlm.nih.gov/28216367

DMYNCWK	DI	DMYNCWK
DMYNCWK	DN	PMID28624700-compound-3-31
DMYNCWK	MI	TTPZG3C
DMYNCWK	MN	SARS-CoV 3C-like protease (3CLpro)
DMYNCWK	MT	DTT
DMYNCWK	MA	Inhibitor
DMYNCWK	RN	Discovery of Unsymmetrical Aromatic Disulfides as Novel Inhibitors of SARS-CoV Main Protease: Chemical Synthesis, Biological Evaluation, Molecular Docking and 3D-QSAR Study Eur J Med Chem. 2017 Sep 8;137:450-461.
DMYNCWK	RU	https://pubmed.ncbi.nlm.nih.gov/28624700

DMVB0P3	DI	DMVB0P3
DMVB0P3	DN	PMID30784880-compound-6-5
DMVB0P3	MI	TTPZG3C
DMVB0P3	MN	SARS-CoV 3C-like protease (3CLpro)
DMVB0P3	MT	DTT
DMVB0P3	MA	Inhibitor
DMVB0P3	RN	Chemical synthesis, crystal structure, versatile evaluation of their biological activities and molecular simulations of novel pyrithiobac derivatives. Eur J Med Chem. 2019 Apr 1;167:472-484.
DMVB0P3	RU	https://pubmed.ncbi.nlm.nih.gov/30784880

DMXCKL9	DI	DMXCKL9
DMXCKL9	DN	PMID30940566-compound-6
DMXCKL9	MI	TTYJOLE
DMXCKL9	MN	MERS-CoV papain-like proteinase (PL-PRO)
DMXCKL9	MT	DTT
DMXCKL9	MA	Inhibitor
DMXCKL9	RN	Identification and Design of Novel Small Molecule Inhibitors Against MERS-CoV Papain-Like Protease via High-Throughput Screening and Molecular Modeling Bioorg Med Chem. 2019 May 15;27(10):1981-1989.
DMXCKL9	RU	https://pubmed.ncbi.nlm.nih.gov/30940566

DMZJWON	DI	DMZJWON
DMZJWON	DN	PMID31244113-compound-2c
DMZJWON	MI	TTOA6YT
DMZJWON	MN	MERS-CoV RNA-directed RNA polymerase (RdRp)
DMZJWON	MT	DTT
DMZJWON	MA	Inhibitor
DMZJWON	RN	Design, Synthesis, and Anti-RNA Virus Activity of 6'-Fluorinated-Aristeromycin Analogues. J Med Chem. 2019 Jul 11;62(13):6346-6362.
DMZJWON	RU	https://pubmed.ncbi.nlm.nih.gov/31244113

DMZJWON	DI	DMZJWON
DMZJWON	DN	PMID31244113-compound-2c
DMZJWON	MI	TTKXI53
DMZJWON	MN	SARS-CoV RNA-directed RNA polymerase (RdRp)
DMZJWON	MT	DTT
DMZJWON	MA	Inhibitor
DMZJWON	RN	Design, Synthesis, and Anti-RNA Virus Activity of 6'-Fluorinated-Aristeromycin Analogues. J Med Chem. 2019 Jul 11;62(13):6346-6362.
DMZJWON	RU	https://pubmed.ncbi.nlm.nih.gov/31244113

DM9LS0R	DI	DM9LS0R
DM9LS0R	DN	PMID31955138-compound-16
DM9LS0R	MI	TTY732E
DM9LS0R	MN	MERS-CoV helicase (Hel)
DM9LS0R	MT	DTT
DM9LS0R	MA	Inhibitor
DM9LS0R	RN	Design, synthesis and molecular docking of novel triazole derivatives as potential CoV helicase inhibitors. Acta Pharm. 2020 Jun 1;70(2):145-159.
DM9LS0R	RU	https://pubmed.ncbi.nlm.nih.gov/31955138

DMMXR3L	DI	DMMXR3L
DMMXR3L	DN	PMX205
DMMXR3L	MI	TTHXFA1
DMMXR3L	MN	C5a anaphylatoxin chemotactic receptor (C5AR1)
DMMXR3L	MT	DTT
DMMXR3L	MA	Antagonist
DMMXR3L	RN	Development and validation of a LC-MS/MS assay for pharmacokinetic studies of complement C5a receptor antagonists PMX53 and PMX205 in mice. Sci Rep. 2018 May 25;8(1):8101.
DMMXR3L	RU	https://pubmed.ncbi.nlm.nih.gov/29802264

DM9SY8E	DI	DM9SY8E
DM9SY8E	DN	PT630
DM9SY8E	MI	TTDIGC1
DM9SY8E	MN	Dipeptidyl peptidase 4 (DPP-4)
DM9SY8E	MT	DTT
DM9SY8E	MA	Inhibitor
DM9SY8E	RN	Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest. 2009 Dec;119(12):3613-25.
DM9SY8E	RU	https://pubmed.ncbi.nlm.nih.gov/19920354

DM9SY8E	DI	DM9SY8E
DM9SY8E	DN	PT630
DM9SY8E	MI	TTGPQ0F
DM9SY8E	MN	Prolyl endopeptidase FAP (FAP)
DM9SY8E	MT	DTT
DM9SY8E	MA	Inhibitor
DM9SY8E	RN	Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest. 2009 Dec;119(12):3613-25.
DM9SY8E	RU	https://pubmed.ncbi.nlm.nih.gov/19920354

DMDKLB5	DI	DMDKLB5
DMDKLB5	DN	Puromycin
DMDKLB5	MI	DTI7UX6
DMDKLB5	MN	Breast cancer resistance protein (ABCG2)
DMDKLB5	MT	DTP
DMDKLB5	MA	Substrate
DMDKLB5	RN	A prediction model of substrates and non-substrates of breast cancer resistance protein (BCRP) developed by GA-CG-SVM method. Comput Biol Med. 2011 Nov;41(11):1006-13.
DMDKLB5	RU	https://doi.org/10.1016/j.compbiomed.2011.08.009

DMDKLB5	DI	DMDKLB5
DMDKLB5	DN	Puromycin
DMDKLB5	MI	DTUGYRD
DMDKLB5	MN	P-glycoprotein 1 (ABCB1)
DMDKLB5	MT	DTP
DMDKLB5	MA	Substrate
DMDKLB5	RN	ATP-binding cassette transporters as pitfalls in selection of transgenic cells. Anal Biochem. 2010 Apr 15;399(2):246-50.
DMDKLB5	RU	https://doi.org/10.1016/j.ab.2009.12.014

DMLBFC0	DI	DMLBFC0
DMLBFC0	DN	Q-44287045
DMLBFC0	MI	DEHD2Q8
DMLBFC0	MN	Glycosyltransferase (Gtf)
DMLBFC0	MT	DME
DMLBFC0	MA	Metabolism
DMLBFC0	RN	A bacterial glycosyltransferase gene toolbox: generation and applications. Phytochemistry. 2009 Oct-Nov;70(15-16):1812-21.
DMLBFC0	RU	https://pubmed.ncbi.nlm.nih.gov/19559449

DMASVOD	DI	DMASVOD
DMASVOD	DN	QSP
DMASVOD	MI	DT9G7XN
DMASVOD	MN	Peptide transporter 1 (SLC15A1)
DMASVOD	MT	DTP
DMASVOD	MA	Substrate
DMASVOD	RN	Tripeptides of RS1 (RSC1A1) inhibit a monosaccharide-dependent exocytotic pathway of Na+-D-glucose cotransporter SGLT1 with high affinity. J Biol Chem. 2007 Sep 28;282(39):28501-13.
DMASVOD	RU	http://www.ncbi.nlm.nih.gov/pubmed/17686765

DMRZBM7	DI	DMRZBM7
DMRZBM7	DN	RANBEZOLID HYDROCHLORIDE
DMRZBM7	MI	TTUWYEA
DMRZBM7	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DMRZBM7	MT	DTT
DMRZBM7	MA	Modulator
DMRZBM7	RN	Mode of Action of Ranbezolid against Staphylococci and Structural Modeling Studies of Its Interaction with Ribosomes . Antimicrob Agents Chemother. 2009 April; 53(4): 1427-1433.
DMRZBM7	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663096/

DM7JH0K	DI	DM7JH0K
DM7JH0K	DN	RG70099
DM7JH0K	MI	TTZJYKH
DM7JH0K	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DM7JH0K	MT	DTT
DM7JH0K	MA	Inhibitor
DM7JH0K	RN	Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019 May;18(5):379-401.
DM7JH0K	RU	https://pubmed.ncbi.nlm.nih.gov/30760888

DM7JH0K	DI	DM7JH0K
DM7JH0K	DN	RG70099
DM7JH0K	MI	TTXNCBV
DM7JH0K	MN	Tryptophan 2,3-dioxygenase (TDO)
DM7JH0K	MT	DTT
DM7JH0K	MA	Inhibitor
DM7JH0K	RN	Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019 May;18(5):379-401.
DM7JH0K	RU	https://pubmed.ncbi.nlm.nih.gov/30760888

DMJGQD2	DI	DMJGQD2
DMJGQD2	DN	RMG-40083
DMJGQD2	MI	TTLA931
DMJGQD2	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMJGQD2	MT	DTT
DMJGQD2	MA	Antagonist
DMJGQD2	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMJGQD2	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMWAR1T	DI	DMWAR1T
DMWAR1T	DN	Ro 61-8048
DMWAR1T	MI	TTIY56R
DMWAR1T	MN	Kynurenine 3-hydroxylase (KMO)
DMWAR1T	MT	DTT
DMWAR1T	MA	Inhibitor
DMWAR1T	RN	Modification of kynurenine pathway via inhibition of kynurenine hydroxylase attenuates surgical brain injury complications in a male rat model. J Neurosci Res. 2020 Jan;98(1):155-167.
DMWAR1T	RU	https://pubmed.ncbi.nlm.nih.gov/31257634

DM3ZE5A	DI	DM3ZE5A
DM3ZE5A	DN	RO-26-2853
DM3ZE5A	MI	TTLM12X
DM3ZE5A	MN	Matrix metalloproteinase-2 (MMP-2)
DM3ZE5A	MT	DTT
DM3ZE5A	MA	Inhibitor
DM3ZE5A	RN	Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
DM3ZE5A	RU	https://pubmed.ncbi.nlm.nih.gov/17604499

DMF3YQZ	DI	DMF3YQZ
DMF3YQZ	DN	Ro-27-3225
DMF3YQZ	MI	TTD0CIQ
DMF3YQZ	MN	Melanocortin receptor 4 (MC4R)
DMF3YQZ	MT	DTT
DMF3YQZ	MA	Agonist
DMF3YQZ	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DMF3YQZ	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMRT3FK	DI	DMRT3FK
DMRT3FK	DN	RO5461111
DMRT3FK	MI	TTUMQVO
DMRT3FK	MN	Cathepsin S (CTSS)
DMRT3FK	MT	DTT
DMRT3FK	MA	Inhibitor
DMRT3FK	RN	Cathepsin S inhibition suppresses systemic lupus erythematosus and lupus nephritis because cathepsin S is essential for MHC class II-mediated CD4 T cell and B cell priming. Ann Rheum Dis. 2015 Feb;74(2):452-63.
DMRT3FK	RU	https://pubmed.ncbi.nlm.nih.gov/24300027

DMZOUX4	DI	DMZOUX4
DMZOUX4	DN	Romazarit
DMZOUX4	MI	TTJ584C
DMZOUX4	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMZOUX4	MT	DTT
DMZOUX4	MA	Modulator
DMZOUX4	RN	Fibrates as therapy for osteoarthritis and rheumatoid arthritis A systematic review. Ther Adv Musculoskelet Dis. 2013 February; 5(1): 33-44.
DMZOUX4	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3582306/

DMOQ63E	DI	DMOQ63E
DMOQ63E	DN	Rottlerin
DMOQ63E	MI	TTYVX59
DMOQ63E	MN	Protein kinase C (PRKC)
DMOQ63E	MT	DTT
DMOQ63E	MA	Inhibitor
DMOQ63E	RN	Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42.
DMOQ63E	RU	https://pubmed.ncbi.nlm.nih.gov/18991661

DM89VIO	DI	DM89VIO
DM89VIO	DN	RS2-1G9
DM89VIO	MI	TTM2AGN
DM89VIO	MN	3-oxo-dodecanoyl-homoserine lactone (C12)
DM89VIO	MT	DTT
DM89VIO	MA	Inhibitor
DM89VIO	RN	Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance. Nat Rev Drug Discov. 2017 Jul;16(7):457-471.
DM89VIO	RU	https://pubmed.ncbi.nlm.nih.gov/28337021

DMB9IPR	DI	DMB9IPR
DMB9IPR	DN	RS-504393
DMB9IPR	MI	TTFZYTO
DMB9IPR	MN	C-C chemokine receptor type 2 (CCR2)
DMB9IPR	MT	DTT
DMB9IPR	MA	Antagonist
DMB9IPR	RN	Beneficial or detrimental effects of carotenoids contained in food: cell culture models. Mini Rev Med Chem. 2007 Nov;7(11):1120-8.
DMB9IPR	RU	https://pubmed.ncbi.nlm.nih.gov/18045215

DMB9IPR	DI	DMB9IPR
DMB9IPR	DN	RS-504393
DMB9IPR	MI	TTNAY0P
DMB9IPR	MN	Monocyte chemotactic and activating factor (CCL2)
DMB9IPR	MT	DTT
DMB9IPR	MA	Inhibitor
DMB9IPR	RN	Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
DMB9IPR	RU	https://pubmed.ncbi.nlm.nih.gov/18045214

DMH1FRY	DI	DMH1FRY
DMH1FRY	DN	RWJ-416457
DMH1FRY	MI	TTGP7BY
DMH1FRY	MN	Monoamine oxidase type B (MAO-B)
DMH1FRY	MT	DTT
DMH1FRY	MA	Inhibitor
DMH1FRY	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2490).
DMH1FRY	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2490

DMMVS07	DI	DMMVS07
DMMVS07	DN	RWJ-51204
DMMVS07	MI	TTEX6LM
DMMVS07	MN	GABA(A) receptor gamma-3 (GABRG3)
DMMVS07	MT	DTT
DMMVS07	MA	Modulator
DMMVS07	RN	5-ethoxymethyl-7-fluoro-3-oxo-1,2,3,5-tetrahydrobenzo[4,5]imidazo[1,2a]pyridine-4-N-(2-fluorophenyl)carboxamide (RWJ-51204), a new nonbenzodiazepine anxiolytic. J Pharmacol Exp Ther. 2002 Nov;303(2):777-90.
DMMVS07	RU	https://pubmed.ncbi.nlm.nih.gov/12388665

DM3AIQO	DI	DM3AIQO
DM3AIQO	DN	RX-01-423
DM3AIQO	MI	TTUWYEA
DM3AIQO	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DM3AIQO	MT	DTT
DM3AIQO	MA	Modulator
DM3AIQO	RN	DOI: 10.1038/nrd2202
DM3AIQO	RU	http://www.nature.com/nrd/journal/v6/n1/full/nrd2202.html

DMXM2BZ	DI	DMXM2BZ
DMXM2BZ	DN	Rycals
DMXM2BZ	MI	TT5HONZ
DMXM2BZ	MN	Calcium channel unspecific (CaC)
DMXM2BZ	MT	DTT
DMXM2BZ	MA	Modulator
DMXM2BZ	RN	Fixing ryanodine receptor Ca2+ leak - a novel therapeutic strategy for contractile failure in heart and skeletal muscle. Drug Discov Today Dis Mech. 2010 SUMMER; 7(2): e151-e157.
DMXM2BZ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2989530/

DM9Y05C	DI	DM9Y05C
DM9Y05C	DN	S-(2-Aminophenyl)-L-cysteine S,S-dioxide
DM9Y05C	MI	TTWQM3J
DM9Y05C	MN	Kynureninase (KYNU)
DM9Y05C	MT	DTT
DM9Y05C	MA	Inhibitor
DM9Y05C	RN	Structure, mechanism, and substrate specificity of kynureninase. Biochim Biophys Acta. 2011 Nov;1814(11):1481-8.
DM9Y05C	RU	https://pubmed.ncbi.nlm.nih.gov/21167323

DM4V8ZD	DI	DM4V8ZD
DM4V8ZD	DN	S32504
DM4V8ZD	MI	TTEX248
DM4V8ZD	MN	Dopamine D2 receptor (D2R)
DM4V8ZD	MT	DTT
DM4V8ZD	MA	Modulator
DM4V8ZD	RN	S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity ... J Pharmacol Exp Ther. 2004 Jun;309(3):921-35.
DM4V8ZD	RU	https://pubmed.ncbi.nlm.nih.gov/14978195

DM4V8ZD	DI	DM4V8ZD
DM4V8ZD	DN	S32504
DM4V8ZD	MI	TT4C8EA
DM4V8ZD	MN	Dopamine D3 receptor (D3R)
DM4V8ZD	MT	DTT
DM4V8ZD	MA	Modulator
DM4V8ZD	RN	S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity ... J Pharmacol Exp Ther. 2004 Jun;309(3):921-35.
DM4V8ZD	RU	https://pubmed.ncbi.nlm.nih.gov/14978195

DMWQ3TH	DI	DMWQ3TH
DMWQ3TH	DN	S-33084
DMWQ3TH	MI	TT4C8EA
DMWQ3TH	MN	Dopamine D3 receptor (D3R)
DMWQ3TH	MT	DTT
DMWQ3TH	MA	Modulator
DMWQ3TH	RN	S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther. 2000 Jun;293(3):1063-73.
DMWQ3TH	RU	https://pubmed.ncbi.nlm.nih.gov/10869411

DMGXVRZ	DI	DMGXVRZ
DMGXVRZ	DN	Salicylihalamide A
DMGXVRZ	MI	TTTK3BH
DMGXVRZ	MN	Vacuolar-type proton ATPase (v-ATPase)
DMGXVRZ	MT	DTT
DMGXVRZ	MA	Inhibitor
DMGXVRZ	RN	Discovery of a novel antitumor benzolactone enamide class that selectively inhibits mammalian vacuolar-type (H+)-atpases. J Pharmacol Exp Ther. 2001 Apr;297(1):114-20.
DMGXVRZ	RU	https://pubmed.ncbi.nlm.nih.gov/11259534

DMLMRGH	DI	DMLMRGH
DMLMRGH	DN	Saliphenylhalamide
DMLMRGH	MI	TTF1QVM
DMLMRGH	MN	Gastric H(+)/K(+) ATPase alpha (ATP4A)
DMLMRGH	MT	DTT
DMLMRGH	MA	Inhibitor
DMLMRGH	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 849).
DMLMRGH	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=849

DM7E324	DI	DM7E324
DM7E324	DN	SAND-5
DM7E324	MI	TTKANGO
DM7E324	MN	Complement C5 (CO5)
DM7E324	MT	DTT
DM7E324	MA	Inhibitor
DM7E324	RN	Progress and Trends in Complement Therapeutics. Adv Exp Med Biol. 2013; 734: 1-22.
DM7E324	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526805/

DM7NS1L	DI	DM7NS1L
DM7NS1L	DN	Savirin
DM7NS1L	MI	TTWPX3M
DM7NS1L	MN	Staphylococcus Accessory gene regulator protein A (Stap-coc agrA)
DM7NS1L	MT	DTT
DM7NS1L	MA	Inhibitor
DM7NS1L	RN	Selective chemical inhibition of agr quorum sensing in Staphylococcus aureus promotes host defense with minimal impact on resistance. PLoS Pathog. 2014 Jun 12;10(6):e1004174.
DM7NS1L	RU	https://pubmed.ncbi.nlm.nih.gov/24945495

DMFXJDL	DI	DMFXJDL
DMFXJDL	DN	SB 242784
DMFXJDL	MI	TTTK3BH
DMFXJDL	MN	Vacuolar-type proton ATPase (v-ATPase)
DMFXJDL	MT	DTT
DMFXJDL	MA	Inhibitor
DMFXJDL	RN	SB 242784, a selective inhibitor of the osteoclastic V-H+ATPase, inhibits arterial calcification in the rat. Circ Res. 2002 Sep 20;91(6):547-52.
DMFXJDL	RU	https://pubmed.ncbi.nlm.nih.gov/12242274

DM6X0PZ	DI	DM6X0PZ
DM6X0PZ	DN	SB222200
DM6X0PZ	MI	TTBPGLU
DM6X0PZ	MN	Neuromedin-K receptor (TACR3)
DM6X0PZ	MT	DTT
DM6X0PZ	MA	Antagonist
DM6X0PZ	RN	Evidence for mediation of nociception by injection of the NK-3 receptor agonist, senktide, into the dorsal periaqueductal gray of rats. Psychopharmacology (Berl). 2009 May;204(1):13-24.
DM6X0PZ	RU	https://pubmed.ncbi.nlm.nih.gov/19093101

DM0YOXQ	DI	DM0YOXQ
DM0YOXQ	DN	SB-431542
DM0YOXQ	MI	TTP4520
DM0YOXQ	MN	TGF-beta receptor type I (TGFBR1)
DM0YOXQ	MT	DTT
DM0YOXQ	MA	Inhibitor
DM0YOXQ	RN	Pyrazolone based TGFbetaR1 kinase inhibitors. Bioorg Med Chem Lett. 2010 Jan 1;20(1):326-9.
DM0YOXQ	RU	https://pubmed.ncbi.nlm.nih.gov/19914068

DMXN4UC	DI	DMXN4UC
DMXN4UC	DN	SBX-101
DMXN4UC	MI	TTQALFH
DMXN4UC	MN	Bacterial Beta-glucuronidase (Bact uidA)
DMXN4UC	MT	DTT
DMXN4UC	MA	Inhibitor
DMXN4UC	RN	Microbiome therapeutics go small molecule. Nat Rev Drug Discov. 2019 Jul;18(8):569-572.
DMXN4UC	RU	https://pubmed.ncbi.nlm.nih.gov/31367062

DMLG682	DI	DMLG682
DMLG682	DN	SCH-1359113
DMLG682	MI	TT8JRS7
DMLG682	MN	Beta-secretase (BACE)
DMLG682	MT	DTT
DMLG682	MA	Inhibitor
DMLG682	RN	ACS Meeting News: Using chemistry tools to refine an Alzheimer's drug candidate. C&EN. April 5, 2010. Volume 88, Number 14 p.14.
DMLG682	RU	https://pubs.acs.org/cen/coverstory/88/8814cover1.html

DM9JZ21	DI	DM9JZ21
DM9JZ21	DN	Scriptaid
DM9JZ21	MI	TT6R7JZ
DM9JZ21	MN	Histone deacetylase 1 (HDAC1)
DM9JZ21	MT	DTT
DM9JZ21	MA	Inhibitor
DM9JZ21	RN	Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92.
DM9JZ21	RU	https://pubmed.ncbi.nlm.nih.gov/17896917

DMJT1E5	DI	DMJT1E5
DMJT1E5	DN	Scutellarin
DMJT1E5	MI	DTI7UX6
DMJT1E5	MN	Breast cancer resistance protein (ABCG2)
DMJT1E5	MT	DTP
DMJT1E5	MA	Substrate
DMJT1E5	RN	Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics. Drug Metab Dispos. 2012 Oct;40(10):2009-20.
DMJT1E5	RU	https://doi.org/10.1124/dmd.112.047183

DMJT1E5	DI	DMJT1E5
DMJT1E5	DN	Scutellarin
DMJT1E5	MI	DTFI42L
DMJT1E5	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMJT1E5	MT	DTP
DMJT1E5	MA	Substrate
DMJT1E5	RN	Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics. Drug Metab Dispos. 2012 Oct;40(10):2009-20.
DMJT1E5	RU	https://doi.org/10.1124/dmd.112.047183

DMJT1E5	DI	DMJT1E5
DMJT1E5	DN	Scutellarin
DMJT1E5	MI	DTQ3ZHF
DMJT1E5	MN	Multidrug resistance-associated protein 3 (ABCC3)
DMJT1E5	MT	DTP
DMJT1E5	MA	Substrate
DMJT1E5	RN	Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics. Drug Metab Dispos. 2012 Oct;40(10):2009-20.
DMJT1E5	RU	https://doi.org/10.1124/dmd.112.047183

DMJT1E5	DI	DMJT1E5
DMJT1E5	DN	Scutellarin
DMJT1E5	MI	DTPFTEQ
DMJT1E5	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DMJT1E5	MT	DTP
DMJT1E5	MA	Substrate
DMJT1E5	RN	Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics. Drug Metab Dispos. 2012 Oct;40(10):2009-20.
DMJT1E5	RU	https://doi.org/10.1124/dmd.112.047183

DMELFBU	DI	DMELFBU
DMELFBU	DN	SCY-641
DMELFBU	MI	TTATDGJ
DMELFBU	MN	Calcium signal-modulating cyclophilin ligand (CAML)
DMELFBU	MT	DTT
DMELFBU	MA	Inhibitor
DMELFBU	RN	2011 Pipeline of SCYNEXIS.
DMELFBU	RU	http://www.scynexis.com/pipeline/

DMLAF6C	DI	DMLAF6C
DMLAF6C	DN	SD1002
DMLAF6C	MI	TTF2LRI
DMLAF6C	MN	Cathepsin B (CTSB)
DMLAF6C	MT	DTT
DMLAF6C	MA	Inhibitor
DMLAF6C	RN	Lysosomes as a therapeutic target. Nat Rev Drug Discov. 2019 Dec;18(12):923-948.
DMLAF6C	RU	https://pubmed.ncbi.nlm.nih.gov/31477883

DMLAF6C	DI	DMLAF6C
DMLAF6C	DN	SD1002
DMLAF6C	MI	TT36ETB
DMLAF6C	MN	Cathepsin L (CTSL)
DMLAF6C	MT	DTT
DMLAF6C	MA	Inhibitor
DMLAF6C	RN	Lysosomes as a therapeutic target. Nat Rev Drug Discov. 2019 Dec;18(12):923-948.
DMLAF6C	RU	https://pubmed.ncbi.nlm.nih.gov/31477883

DM29BW1	DI	DM29BW1
DM29BW1	DN	SD1003
DM29BW1	MI	TTF2LRI
DM29BW1	MN	Cathepsin B (CTSB)
DM29BW1	MT	DTT
DM29BW1	MA	Inhibitor
DM29BW1	RN	Lysosomes as a therapeutic target. Nat Rev Drug Discov. 2019 Dec;18(12):923-948.
DM29BW1	RU	https://pubmed.ncbi.nlm.nih.gov/31477883

DM29BW1	DI	DM29BW1
DM29BW1	DN	SD1003
DM29BW1	MI	TT36ETB
DM29BW1	MN	Cathepsin L (CTSL)
DM29BW1	MT	DTT
DM29BW1	MA	Inhibitor
DM29BW1	RN	Lysosomes as a therapeutic target. Nat Rev Drug Discov. 2019 Dec;18(12):923-948.
DM29BW1	RU	https://pubmed.ncbi.nlm.nih.gov/31477883

DM5LU3N	DI	DM5LU3N
DM5LU3N	DN	Selamectin
DM5LU3N	MI	DTUGYRD
DM5LU3N	MN	P-glycoprotein 1 (ABCB1)
DM5LU3N	MT	DTP
DM5LU3N	MA	Substrate
DM5LU3N	RN	Interaction of macrocyclic lactones with P-glycoprotein: structure-affinity relationship. Eur J Pharm Sci. 2007 Jan;30(1):84-94.
DM5LU3N	RU	https://doi.org/10.1016/j.ejps.2006.10.004

DMH1WNI	DI	DMH1WNI
DMH1WNI	DN	SGN-19A
DMH1WNI	MI	TTW640A
DMH1WNI	MN	B-lymphocyte surface antigen B4 (CD19)
DMH1WNI	MT	DTT
DMH1WNI	RN	2011 Pipeline of Seattle Genetics.
DMH1WNI	RU	http://www.seagen.com/product_pipeline.php

DMHAONP	DI	DMHAONP
DMHAONP	DN	SHP-627
DMHAONP	MI	TTO3HT7
DMHAONP	MN	Transforming growth factor beta (TGFB)
DMHAONP	MT	DTT
DMHAONP	MA	Inhibitor
DMHAONP	RN	Drugs and Targets in Fibrosis. Front Pharmacol. 2017 Nov 23;8:855.
DMHAONP	RU	https://pubmed.ncbi.nlm.nih.gov/29218009

DM8DYJQ	DI	DM8DYJQ
DM8DYJQ	DN	SHP656
DM8DYJQ	MI	TT5MLZR
DM8DYJQ	MN	Cryptochrome circadian clock 1 (CRY1)
DM8DYJQ	MT	DTT
DM8DYJQ	MA	Modulator
DM8DYJQ	RN	Circadian rhythm as a therapeutic target. Nat Rev Drug Discov. 2021 Apr;20(4):287-307.
DM8DYJQ	RU	https://pubmed.ncbi.nlm.nih.gov/33589815

DM8DYJQ	DI	DM8DYJQ
DM8DYJQ	DN	SHP656
DM8DYJQ	MI	TTAO58M
DM8DYJQ	MN	Cryptochrome-2 (CRY2)
DM8DYJQ	MT	DTT
DM8DYJQ	MA	Modulator
DM8DYJQ	RN	Circadian rhythm as a therapeutic target. Nat Rev Drug Discov. 2021 Apr;20(4):287-307.
DM8DYJQ	RU	https://pubmed.ncbi.nlm.nih.gov/33589815

DMWBCTA	DI	DMWBCTA
DMWBCTA	DN	SIS-3
DMWBCTA	MI	TTHQZV7
DMWBCTA	MN	Mothers against decapentaplegic homolog 3 (SMAD3)
DMWBCTA	MT	DTT
DMWBCTA	MA	Inhibitor
DMWBCTA	RN	Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-beta1-induced extracellular matrix expression. Mol Pharmacol. 2006 Feb;69(2):597-607.
DMWBCTA	RU	https://pubmed.ncbi.nlm.nih.gov/16288083

DM7DNOG	DI	DM7DNOG
DM7DNOG	DN	SK-7041
DM7DNOG	MI	TT6R7JZ
DM7DNOG	MN	Histone deacetylase 1 (HDAC1)
DM7DNOG	MT	DTT
DM7DNOG	MA	Inhibitor
DM7DNOG	RN	Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92.
DM7DNOG	RU	https://pubmed.ncbi.nlm.nih.gov/17896917

DMCI371	DI	DMCI371
DMCI371	DN	SK-7068
DMCI371	MI	TT6R7JZ
DMCI371	MN	Histone deacetylase 1 (HDAC1)
DMCI371	MT	DTT
DMCI371	MA	Inhibitor
DMCI371	RN	Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92.
DMCI371	RU	https://pubmed.ncbi.nlm.nih.gov/17896917

DMY9DA3	DI	DMY9DA3
DMY9DA3	DN	SLV-332
DMY9DA3	MI	TTYO0A3
DMY9DA3	MN	Substance-K receptor (TACR2)
DMY9DA3	MT	DTT
DMY9DA3	MA	Antagonist
DMY9DA3	RN	Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
DMY9DA3	RU	https://pubmed.ncbi.nlm.nih.gov/16634703

DM3X4JL	DI	DM3X4JL
DM3X4JL	DN	SMITB14
DM3X4JL	MI	TT3V4L8
DM3X4JL	MN	Mycobacterial lipoarabinomannan (MycB LAM)
DM3X4JL	MT	DTT
DM3X4JL	MA	Inhibitor
DM3X4JL	RN	Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance. Nat Rev Drug Discov. 2017 Jul;16(7):457-471.
DM3X4JL	RU	https://pubmed.ncbi.nlm.nih.gov/28337021

DM5KE4R	DI	DM5KE4R
DM5KE4R	DN	SNAP-7941
DM5KE4R	MI	TTX4RTB
DM5KE4R	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DM5KE4R	MT	DTT
DM5KE4R	MA	Antagonist
DM5KE4R	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DM5KE4R	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMSNX4O	DI	DMSNX4O
DMSNX4O	DN	SoRI-9409
DMSNX4O	MI	TT27RFC
DMSNX4O	MN	Opioid receptor delta (OPRD1)
DMSNX4O	MT	DTT
DMSNX4O	MA	Antagonist
DMSNX4O	RN	In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence. J Pharmacol Exp Ther. 2001 May;297(2):597-605.
DMSNX4O	RU	https://pubmed.ncbi.nlm.nih.gov/11303048

DMJHWYP	DI	DMJHWYP
DMJHWYP	DN	Spautin 1
DMJHWYP	MI	TT5IH09
DMJHWYP	MN	Ubiquitin carboxyl-terminal hydrolase 10 (USP10)
DMJHWYP	MT	DTT
DMJHWYP	MA	Inhibitor
DMJHWYP	RN	Potent USP10/13 antagonist spautin-1 suppresses melanoma growth via ROS-mediated DNA damage and exhibits synergy with cisplatin. J Cell Mol Med. 2020 Apr;24(7):4324-4340.
DMJHWYP	RU	https://pubmed.ncbi.nlm.nih.gov/32129945

DMJHWYP	DI	DMJHWYP
DMJHWYP	DN	Spautin 1
DMJHWYP	MI	TTVJIO2
DMJHWYP	MN	Ubiquitin carboxyl-terminal hydrolase 13 (USP13)
DMJHWYP	MT	DTT
DMJHWYP	MA	Inhibitor
DMJHWYP	RN	Potent USP10/13 antagonist spautin-1 suppresses melanoma growth via ROS-mediated DNA damage and exhibits synergy with cisplatin. J Cell Mol Med. 2020 Apr;24(7):4324-4340.
DMJHWYP	RU	https://pubmed.ncbi.nlm.nih.gov/32129945

DMMA2ZW	DI	DMMA2ZW
DMMA2ZW	DN	SPH-1285
DMMA2ZW	MI	TT1RS9F
DMMA2ZW	MN	Acetylcholinesterase (AChE)
DMMA2ZW	MT	DTT
DMMA2ZW	MA	Inhibitor
DMMA2ZW	RN	Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease. Biol Psychiatry. 2001 Feb 1;49(3):289-99.
DMMA2ZW	RU	https://pubmed.ncbi.nlm.nih.gov/11230880

DM32NMB	DI	DM32NMB
DM32NMB	DN	S-Phenyl-L-cysteine sulfoxide
DM32NMB	MI	TTLQ3OP
DM32NMB	MN	Pseudomonas Kynureninase (Pseudo kynU)
DM32NMB	MT	DTT
DM32NMB	MA	Inhibitor
DM32NMB	RN	Chemical Inhibition of Kynureninase Reduces Pseudomonas aeruginosa Quorum Sensing and Virulence Factor Expression. ACS Chem Biol. 2016 Apr 15;11(4):1106-17.
DM32NMB	RU	https://pubmed.ncbi.nlm.nih.gov/26785289

DMYZQKC	DI	DMYZQKC
DMYZQKC	DN	SPHINX31
DMYZQKC	MI	TTU3WV6
DMYZQKC	MN	SRSF protein kinase 1 (SRPK1)
DMYZQKC	MT	DTT
DMYZQKC	MA	Inhibitor
DMYZQKC	RN	Kinase inhibitors: the road ahead. Nat Rev Drug Discov. 2018 May;17(5):353-377.
DMYZQKC	RU	https://pubmed.ncbi.nlm.nih.gov/29545548

DMC1WAJ	DI	DMC1WAJ
DMC1WAJ	DN	SPI-376
DMC1WAJ	MI	TTE0A2F
DMC1WAJ	MN	Dopamine D4 receptor (D4R)
DMC1WAJ	MT	DTT
DMC1WAJ	MA	Binder
DMC1WAJ	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMC1WAJ	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMO2UKI	DI	DMO2UKI
DMO2UKI	DN	SP-MET-1
DMO2UKI	MI	TTPR5SX
DMO2UKI	MN	S100 calcium-binding protein A4 (S100A4)
DMO2UKI	MT	DTT
DMO2UKI	MA	Antagonist
DMO2UKI	RN	Lost in migration. Nat Biotechnol. 2010 Mar;28(3):214-29.
DMO2UKI	RU	https://pubmed.ncbi.nlm.nih.gov/20212481

DM7MDZE	DI	DM7MDZE
DM7MDZE	DN	SR1078
DM7MDZE	MI	TT1TYN7
DM7MDZE	MN	Nuclear receptor ROR-alpha (RORA)
DM7MDZE	MT	DTT
DM7MDZE	MA	Agonist
DM7MDZE	RN	Identification of SR1078, a synthetic agonist for the orphan nuclear receptors RORalpha and ROR. ACS Chem Biol. 2010 Nov 19;5(11):1029-34.
DM7MDZE	RU	https://pubmed.ncbi.nlm.nih.gov/20735016

DM7MDZE	DI	DM7MDZE
DM7MDZE	DN	SR1078
DM7MDZE	MI	TTGV6LY
DM7MDZE	MN	Nuclear receptor ROR-gamma (RORG)
DM7MDZE	MT	DTT
DM7MDZE	MA	Agonist
DM7MDZE	RN	Identification of SR1078, a synthetic agonist for the orphan nuclear receptors RORalpha and ROR. ACS Chem Biol. 2010 Nov 19;5(11):1029-34.
DM7MDZE	RU	https://pubmed.ncbi.nlm.nih.gov/20735016

DMZV9JX	DI	DMZV9JX
DMZV9JX	DN	SR1555
DMZV9JX	MI	TTGV6LY
DMZV9JX	MN	Nuclear receptor ROR-gamma (RORG)
DMZV9JX	MT	DTT
DMZV9JX	MA	Agonist
DMZV9JX	RN	Circadian rhythm as a therapeutic target. Nat Rev Drug Discov. 2021 Apr;20(4):287-307.
DMZV9JX	RU	https://pubmed.ncbi.nlm.nih.gov/33589815

DMWCBG8	DI	DMWCBG8
DMWCBG8	DN	SR2211
DMWCBG8	MI	TTGV6LY
DMWCBG8	MN	Nuclear receptor ROR-gamma (RORG)
DMWCBG8	MT	DTT
DMWCBG8	MA	Agonist
DMWCBG8	RN	Circadian rhythm as a therapeutic target. Nat Rev Drug Discov. 2021 Apr;20(4):287-307.
DMWCBG8	RU	https://pubmed.ncbi.nlm.nih.gov/33589815

DM96IUW	DI	DM96IUW
DM96IUW	DN	SR3335
DM96IUW	MI	TT1TYN7
DM96IUW	MN	Nuclear receptor ROR-alpha (RORA)
DM96IUW	MT	DTT
DM96IUW	MA	Agonist
DM96IUW	RN	Identification of SR3335 (ML-176): a synthetic RORalpha selective inverse agonist. ACS Chem Biol. 2011 Mar 18;6(3):218-22.
DM96IUW	RU	https://pubmed.ncbi.nlm.nih.gov/21090593

DMSK5N3	DI	DMSK5N3
DMSK5N3	DN	SR8278
DMSK5N3	MI	TTAD1O8
DMSK5N3	MN	V-erbA-related protein 1 (NR1D1)
DMSK5N3	MT	DTT
DMSK5N3	MA	Antagonist
DMSK5N3	RN	Identification of SR8278, a synthetic antagonist of the nuclear heme receptor REV-ERB. ACS Chem Biol. 2011 Feb 18;6(2):131-4.
DMSK5N3	RU	https://pubmed.ncbi.nlm.nih.gov/21043485

DM8SKU1	DI	DM8SKU1
DM8SKU1	DN	SR9009
DM8SKU1	MI	TTAD1O8
DM8SKU1	MN	V-erbA-related protein 1 (NR1D1)
DM8SKU1	MT	DTT
DM8SKU1	MA	Agonist
DM8SKU1	RN	Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence. Nature. 2018 Jan 18;553(7688):351-355.
DM8SKU1	RU	https://pubmed.ncbi.nlm.nih.gov/29320480

DMZ9BO8	DI	DMZ9BO8
DMZ9BO8	DN	SR9011
DMZ9BO8	MI	TTAD1O8
DMZ9BO8	MN	V-erbA-related protein 1 (NR1D1)
DMZ9BO8	MT	DTT
DMZ9BO8	MA	Agonist
DMZ9BO8	RN	Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence. Nature. 2018 Jan 18;553(7688):351-355.
DMZ9BO8	RU	https://pubmed.ncbi.nlm.nih.gov/29320480

DM84EOW	DI	DM84EOW
DM84EOW	DN	SSR-103800
DM84EOW	MI	TTHJTF7
DM84EOW	MN	Glycine transporter GlyT-1 (SLC6A9)
DM84EOW	MT	DTT
DM84EOW	MA	Blocker
DM84EOW	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DM84EOW	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMQTR4I	DI	DMQTR4I
DMQTR4I	DN	SSR-504734
DMQTR4I	MI	TTHJTF7
DMQTR4I	MN	Glycine transporter GlyT-1 (SLC6A9)
DMQTR4I	MT	DTT
DMQTR4I	MA	Blocker
DMQTR4I	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMQTR4I	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DM0NPIO	DI	DM0NPIO
DM0NPIO	DN	SSYA10-001
DM0NPIO	MI	TTY732E
DM0NPIO	MN	MERS-CoV helicase (Hel)
DM0NPIO	MT	DTT
DM0NPIO	MA	Inhibitor
DM0NPIO	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DM0NPIO	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DM0NPIO	DI	DM0NPIO
DM0NPIO	DN	SSYA10-001
DM0NPIO	MI	TTQKWR5
DM0NPIO	MN	SARS-CoV helicase (Hel)
DM0NPIO	MT	DTT
DM0NPIO	MA	Inhibitor
DM0NPIO	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DM0NPIO	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DMXZ08K	DI	DMXZ08K
DMXZ08K	DN	SSYA10-001
DMXZ08K	MI	TTQKWR5
DMXZ08K	MN	SARS-CoV helicase (Hel)
DMXZ08K	MT	DTT
DMXZ08K	MA	Inhibitor
DMXZ08K	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DMXZ08K	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DM7Y4GT	DI	DM7Y4GT
DM7Y4GT	DN	T-226293
DM7Y4GT	MI	TTTK0NH
DM7Y4GT	MN	Delta(24)-sterol reductase (DHCR24)
DM7Y4GT	MT	DTT
DM7Y4GT	MA	Inhibitor
DM7Y4GT	RN	Antilipemic drug-induced skin manifestations. Hautarzt. 1995 Feb;46(2):76-80.
DM7Y4GT	RU	https://pubmed.ncbi.nlm.nih.gov/7706076

DM7Y4GT	DI	DM7Y4GT
DM7Y4GT	DN	T-226293
DM7Y4GT	MI	TTX4RTB
DM7Y4GT	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DM7Y4GT	MT	DTT
DM7Y4GT	MA	Antagonist
DM7Y4GT	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DM7Y4GT	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMJ6P9U	DI	DMJ6P9U
DMJ6P9U	DN	T-226296
DMJ6P9U	MI	TTX4RTB
DMJ6P9U	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMJ6P9U	MT	DTT
DMJ6P9U	MA	Antagonist
DMJ6P9U	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DMJ6P9U	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMJ6P9U	DI	DMJ6P9U
DMJ6P9U	DN	T-226296
DMJ6P9U	MI	TTW0CMT
DMJ6P9U	MN	Voltage-gated potassium channel Kv1.5 (KCNA5)
DMJ6P9U	MT	DTT
DMJ6P9U	MA	Blocker
DMJ6P9U	RN	New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22.
DMJ6P9U	RU	https://pubmed.ncbi.nlm.nih.gov/15934869

DMQJSF9	DI	DMQJSF9
DMQJSF9	DN	Taxifolin
DMQJSF9	MI	DTFI42L
DMQJSF9	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMQJSF9	MT	DTP
DMQJSF9	MA	Substrate
DMQJSF9	RN	Permeation of astilbin and taxifolin in Caco-2 cell and their effects on the P-gp. Int J Pharm. 2009 Aug 13;378(1-2):1-8.
DMQJSF9	RU	https://doi.org/10.1016/j.ijpharm.2009.05.022

DMY8QP5	DI	DMY8QP5
DMY8QP5	DN	TFM735
DMY8QP5	MI	TTA6ZN2
DMY8QP5	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMY8QP5	MT	DTT
DMY8QP5	MA	Activator
DMY8QP5	RN	The novel Nrf2 inducer TFM-735 ameliorates experimental autoimmune encephalomyelitis in mice. Eur J Pharmacol. 2017 May 5;802:76-84.
DMY8QP5	RU	https://pubmed.ncbi.nlm.nih.gov/28246026

DM1KTOC	DI	DM1KTOC
DM1KTOC	DN	TGX-6B4
DM1KTOC	MI	TTVB0Q9
DM1KTOC	MN	Platelet glycoprotein Ib alpha (CD42b)
DM1KTOC	MT	DTT
DM1KTOC	RN	Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates. Arterioscler Thromb Vasc Biol. 2000 May;20(5):1347-53.
DM1KTOC	RU	https://pubmed.ncbi.nlm.nih.gov/10807753

DM4BDGW	DI	DM4BDGW
DM4BDGW	DN	TH301
DM4BDGW	MI	TT5MLZR
DM4BDGW	MN	Cryptochrome circadian clock 1 (CRY1)
DM4BDGW	MT	DTT
DM4BDGW	MA	Modulator
DM4BDGW	RN	Circadian rhythm as a therapeutic target. Nat Rev Drug Discov. 2021 Apr;20(4):287-307.
DM4BDGW	RU	https://pubmed.ncbi.nlm.nih.gov/33589815

DM4BDGW	DI	DM4BDGW
DM4BDGW	DN	TH301
DM4BDGW	MI	TTAO58M
DM4BDGW	MN	Cryptochrome-2 (CRY2)
DM4BDGW	MT	DTT
DM4BDGW	MA	Modulator
DM4BDGW	RN	Circadian rhythm as a therapeutic target. Nat Rev Drug Discov. 2021 Apr;20(4):287-307.
DM4BDGW	RU	https://pubmed.ncbi.nlm.nih.gov/33589815

DMDMQIE	DI	DMDMQIE
DMDMQIE	DN	THAPSIGARGIN
DMDMQIE	MI	TTZVSJ2
DMDMQIE	MN	Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A)
DMDMQIE	MT	DTT
DMDMQIE	MA	Inhibitor
DMDMQIE	RN	Elucidation of the topography of the thapsigargin binding site in the sarco-endoplasmic calcium ATPase. Bioorg Med Chem. 2010 Aug 1;18(15):5634-46.
DMDMQIE	RU	https://pubmed.ncbi.nlm.nih.gov/20615710

DM7RMG9	DI	DM7RMG9
DM7RMG9	DN	Thioguanine
DM7RMG9	MI	TTYJOLE
DM7RMG9	MN	MERS-CoV papain-like proteinase (PL-PRO)
DM7RMG9	MT	DTT
DM7RMG9	MA	Inhibitor
DM7RMG9	RN	Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus. Antiviral Res. 2015 Mar;115:9-16.
DM7RMG9	RU	https://pubmed.ncbi.nlm.nih.gov/25542975

DM7RMG9	DI	DM7RMG9
DM7RMG9	DN	Thioguanine
DM7RMG9	MI	TTRGHB2
DM7RMG9	MN	SARS-CoV papain-like proteinase (PL-PRO)
DM7RMG9	MT	DTT
DM7RMG9	MA	Inhibitor
DM7RMG9	RN	Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus. Antiviral Res. 2015 Mar;115:9-16.
DM7RMG9	RU	https://pubmed.ncbi.nlm.nih.gov/25542975

DMDSJO8	DI	DMDSJO8
DMDSJO8	DN	TMC-353121
DMDSJO8	MI	TT57ID8
DMDSJO8	MN	Respiratory syncytial virus protein F (RSV F)
DMDSJO8	MT	DTT
DMDSJO8	MA	Inhibitor
DMDSJO8	RN	Prospects for the development of fusion inhibitors to treat human respiratory syncytial virus infection. Curr Opin Drug Discov Devel. 2009 Jul;12(4):479-87.
DMDSJO8	RU	https://pubmed.ncbi.nlm.nih.gov/19562644

DMONGIR	DI	DMONGIR
DMONGIR	DN	Tosyl-l-arginine methyl ester
DMONGIR	MI	TTBKFDV
DMONGIR	MN	Cell division cycle protein 20 homolog (CDC20)
DMONGIR	MT	DTT
DMONGIR	MA	Inhibitor
DMONGIR	RN	Targeting Cdc20 as a novel cancer therapeutic strategy. Pharmacol Ther. 2015 Jul;151:141-51.
DMONGIR	RU	https://pubmed.ncbi.nlm.nih.gov/25850036

DM6W9YM	DI	DM6W9YM
DM6W9YM	DN	TP-023
DM6W9YM	MI	TTAN6JD
DM6W9YM	MN	Glutamate receptor AMPA (GRIA)
DM6W9YM	MT	DTT
DM6W9YM	MA	Modulator
DM6W9YM	RN	Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
DM6W9YM	RU	https://pubmed.ncbi.nlm.nih.gov/16377242

DM06BUL	DI	DM06BUL
DM06BUL	DN	TPT-43
DM06BUL	MI	TTAN6JD
DM06BUL	MN	Glutamate receptor AMPA (GRIA)
DM06BUL	MT	DTT
DM06BUL	MA	Modulator
DM06BUL	RN	Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
DM06BUL	RU	https://pubmed.ncbi.nlm.nih.gov/16377242

DMY8GDA	DI	DMY8GDA
DMY8GDA	DN	Trimidox
DMY8GDA	MI	TTCIHJA
DMY8GDA	MN	Coagulation factor Xa (F10)
DMY8GDA	MT	DTT
DMY8GDA	MA	Inhibitor
DMY8GDA	RN	Computer-aided design of a factor Xa inhibitor by using MCSS functionality maps and a CAVEAT linker search. J Mol Graph Model. 2003 Nov;22(2):105-14.
DMY8GDA	RU	https://pubmed.ncbi.nlm.nih.gov/12932781

DMY8GDA	DI	DMY8GDA
DMY8GDA	DN	Trimidox
DMY8GDA	MI	TTX09M4
DMY8GDA	MN	Ribonucleotide reductase (RIR)
DMY8GDA	MT	DTT
DMY8GDA	MA	Inhibitor
DMY8GDA	RN	Suppression of retrovirus-induced immunodeficiency disease (murine AIDS) by trimidox and didox: novel ribonucleotide reductase inhibitors with less bone marrow toxicity than hydroxyurea. Antiviral Res. 2002 Nov;56(2):167-81.
DMY8GDA	RU	https://pubmed.ncbi.nlm.nih.gov/12367722

DMWZCIF	DI	DMWZCIF
DMWZCIF	DN	TTA-A8
DMWZCIF	MI	TTZPWGN
DMWZCIF	MN	Voltage-gated calcium channel alpha Cav3.2 (CACNA1H)
DMWZCIF	MT	DTT
DMWZCIF	MA	Antagonist
DMWZCIF	RN	Short-acting T-type calcium channel antagonists significantly modify sleep architecture in rodents. ACS Med Chem Lett. 2010 Aug 24;1(9):504-9.
DMWZCIF	RU	https://pubmed.ncbi.nlm.nih.gov/24900239

DMB7WEY	DI	DMB7WEY
DMB7WEY	DN	TV-1390
DMB7WEY	MI	TT4TZ8J
DMB7WEY	MN	Interferon-beta (IFNB1)
DMB7WEY	MT	DTT
DMB7WEY	MA	Modulator
DMB7WEY	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032947)
DMB7WEY	RU	http://adisinsight.springer.com/drugs/800032947

DMRGZQA	DI	DMRGZQA
DMRGZQA	DN	TZP-202
DMRGZQA	MI	TT953CX
DMRGZQA	MN	Motilin receptor (MLNR)
DMRGZQA	MT	DTT
DMRGZQA	MA	Antagonist
DMRGZQA	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023009)
DMRGZQA	RU	http://adisinsight.springer.com/drugs/800023009

DME8AL0	DI	DME8AL0
DME8AL0	DN	TZP-301
DME8AL0	MI	TTWDC17
DME8AL0	MN	Growth hormone secretagogue receptor 1 (GHSR)
DME8AL0	MT	DTT
DME8AL0	MA	Antagonist
DME8AL0	RN	Clinical pipeline report, company report or official report of Tranzyme Pharma (2011).
DME8AL0	RU	http://www.tranzyme.com/products

DMW87JR	DI	DMW87JR
DMW87JR	DN	U-99194A
DMW87JR	MI	TT4C8EA
DMW87JR	MN	Dopamine D3 receptor (D3R)
DMW87JR	MT	DTT
DMW87JR	MA	Binder
DMW87JR	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMW87JR	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMOIWVC	DI	DMOIWVC
DMOIWVC	DN	U-99363E
DMOIWVC	MI	TTE0A2F
DMOIWVC	MN	Dopamine D4 receptor (D4R)
DMOIWVC	MT	DTT
DMOIWVC	MA	Binder
DMOIWVC	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMOIWVC	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMT06MI	DI	DMT06MI
DMT06MI	DN	UCART-CLL1
DMT06MI	MI	TT70N8V
DMT06MI	MN	Myeloid inhibitory C-type lectin-like receptor (CD371)
DMT06MI	MT	DTT
DMT06MI	RN	Off-the-shelf' allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020 Mar;19(3):185-199.
DMT06MI	RU	https://pubmed.ncbi.nlm.nih.gov/31900462

DMD1E4J	DI	DMD1E4J
DMD1E4J	DN	UNC0379
DMD1E4J	MI	TTGC95K
DMD1E4J	MN	SET domain containing 8 (KMT5A)
DMD1E4J	MT	DTT
DMD1E4J	MA	Inhibitor
DMD1E4J	RN	Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021 Apr;20(4):265-286.
DMD1E4J	RU	https://pubmed.ncbi.nlm.nih.gov/33469207

DMDVZQ8	DI	DMDVZQ8
DMDVZQ8	DN	UPF-648
DMDVZQ8	MI	TTIY56R
DMDVZQ8	MN	Kynurenine 3-hydroxylase (KMO)
DMDVZQ8	MT	DTT
DMDVZQ8	MA	Inhibitor
DMDVZQ8	RN	Structural basis of kynurenine 3-monooxygenase inhibition. Nature. 2013 Apr 18;496(7445):382-5.
DMDVZQ8	RU	https://pubmed.ncbi.nlm.nih.gov/23575632

DMUO6XC	DI	DMUO6XC
DMUO6XC	DN	VCB101
DMUO6XC	MI	TT3Z6Y9
DMUO6XC	MN	Cysteines of Keap1 (KEAP1 Cysteines)
DMUO6XC	MT	DTT
DMUO6XC	MA	Inactivator
DMUO6XC	RN	NRF2 Regulation Processes as a Source of Potential Drug Targets against Neurodegenerative Diseases. Biomolecules. 2020 Jun 14;10(6):904.
DMUO6XC	RU	https://pubmed.ncbi.nlm.nih.gov/32545924

DMR3XDH	DI	DMR3XDH
DMR3XDH	DN	VCB102
DMR3XDH	MI	TT3Z6Y9
DMR3XDH	MN	Cysteines of Keap1 (KEAP1 Cysteines)
DMR3XDH	MT	DTT
DMR3XDH	MA	Inactivator
DMR3XDH	RN	NRF2 Regulation Processes as a Source of Potential Drug Targets against Neurodegenerative Diseases. Biomolecules. 2020 Jun 14;10(6):904.
DMR3XDH	RU	https://pubmed.ncbi.nlm.nih.gov/32545924

DM95VQ6	DI	DM95VQ6
DM95VQ6	DN	vialinin A
DM95VQ6	MI	TTGYTMA
DM95VQ6	MN	Isopeptidase T (USP5)
DM95VQ6	MT	DTT
DM95VQ6	MA	Inhibitor
DM95VQ6	RN	Vialinin A is a ubiquitin-specific peptidase inhibitor. Bioorg Med Chem Lett. 2013 Aug 1;23(15):4328-31.
DM95VQ6	RU	https://pubmed.ncbi.nlm.nih.gov/23791076

DMS5LPF	DI	DMS5LPF
DMS5LPF	DN	Viquidacin
DMS5LPF	MI	TTN6J5F
DMS5LPF	MN	Bacterial DNA gyrase (Bact gyrase)
DMS5LPF	MT	DTT
DMS5LPF	MA	Modulator
DMS5LPF	RN	Selenophene-containing inhibitors of type IIA bacterial topoisomerases.J Med Chem.2011 May 12;54(9):3418-25.
DMS5LPF	RU	https://www.ncbi.nlm.nih.gov/pubmed/21443219

DMQG2EY	DI	DMQG2EY
DMQG2EY	DN	Virstatin
DMQG2EY	MI	TTVFR2S
DMQG2EY	MN	Vibrio TCP pilus virulence regulatory protein (Vibrio tcpN)
DMQG2EY	MT	DTT
DMQG2EY	MA	Inhibitor
DMQG2EY	RN	Virstatin inhibits dimerization of the transcriptional activator ToxT. Proc Natl Acad Sci U S A. 2007 Feb 13;104(7):2372-7.
DMQG2EY	RU	https://pubmed.ncbi.nlm.nih.gov/17283330

DMJDT5O	DI	DMJDT5O
DMJDT5O	DN	VIS513
DMJDT5O	MI	TTMYZNX
DMJDT5O	MN	Dengue virus Envelope (DENV E)
DMJDT5O	MT	DTT
DMJDT5O	MA	Inhibitor
DMJDT5O	RN	Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein. PLoS Negl Trop Dis. 2018 Feb 9;12(2):e0006209.
DMJDT5O	RU	https://pubmed.ncbi.nlm.nih.gov/29425203

DMZHAVG	DI	DMZHAVG
DMZHAVG	DN	VPM-4-001
DMZHAVG	MI	TT93WF5
DMZHAVG	MN	Interferon-gamma (IFNG)
DMZHAVG	MT	DTT
DMZHAVG	RN	BioPartnering North America--Programs from Pharma in Europe and the Middle East. IDrugs. 2010 Mar;13(3):162-5.
DMZHAVG	RU	https://pubmed.ncbi.nlm.nih.gov/20191431

DMZHAVG	DI	DMZHAVG
DMZHAVG	DN	VPM-4-001
DMZHAVG	MI	TTF89GD
DMZHAVG	MN	Interleukin-2 (IL2)
DMZHAVG	MT	DTT
DMZHAVG	RN	BioPartnering North America--Programs from Pharma in Europe and the Middle East. IDrugs. 2010 Mar;13(3):162-5.
DMZHAVG	RU	https://pubmed.ncbi.nlm.nih.gov/20191431

DMOY15R	DI	DMOY15R
DMOY15R	DN	VT-111
DMOY15R	MI	TTEMV5X
DMOY15R	MN	Serine protease unspecific (SP)
DMOY15R	MT	DTT
DMOY15R	MA	Inhibitor
DMOY15R	RN	New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
DMOY15R	RU	https://pubmed.ncbi.nlm.nih.gov/19265486

DM7WFR0	DI	DM7WFR0
DM7WFR0	DN	VUFB-11502
DM7WFR0	MI	DEAWHS8
DM7WFR0	MN	Aldehyde oxidase (AOX1)
DM7WFR0	MT	DME
DM7WFR0	MA	Metabolism
DM7WFR0	RN	The critical role of oxidative stress in the toxicity and metabolism of quinoxaline 1,4-di-N-oxides in vitro and in vivo. Drug Metab Rev. 2016 May;48(2):159-82.
DM7WFR0	RU	https://pubmed.ncbi.nlm.nih.gov/27285897

DM7WFR0	DI	DM7WFR0
DM7WFR0	DN	VUFB-11502
DM7WFR0	MI	DE4LYSA
DM7WFR0	MN	Cytochrome P450 3A4 (CYP3A4)
DM7WFR0	MT	DME
DM7WFR0	MA	Metabolism
DM7WFR0	RN	The critical role of oxidative stress in the toxicity and metabolism of quinoxaline 1,4-di-N-oxides in vitro and in vivo. Drug Metab Rev. 2016 May;48(2):159-82.
DM7WFR0	RU	https://pubmed.ncbi.nlm.nih.gov/27285897

DM7WFR0	DI	DM7WFR0
DM7WFR0	DN	VUFB-11502
DM7WFR0	MI	DE9JFMC
DM7WFR0	MN	NADPH-dependent carbonyl reductase 1 (CBR1)
DM7WFR0	MT	DME
DM7WFR0	MA	Metabolism
DM7WFR0	RN	The critical role of oxidative stress in the toxicity and metabolism of quinoxaline 1,4-di-N-oxides in vitro and in vivo. Drug Metab Rev. 2016 May;48(2):159-82.
DM7WFR0	RU	https://pubmed.ncbi.nlm.nih.gov/27285897

DMZKY56	DI	DMZKY56
DMZKY56	DN	VX-166
DMZKY56	MI	TTZY5KP
DMZKY56	MN	Caspase (CASP)
DMZKY56	MT	DTT
DMZKY56	MA	Inhibitor
DMZKY56	RN	VX-166: a novel potent small molecule caspase inhibitor as a potential therapy for sepsis. Crit Care. 2009;13(5):R146.
DMZKY56	RU	https://pubmed.ncbi.nlm.nih.gov/19740426

DM68HNR	DI	DM68HNR
DM68HNR	DN	W-201259
DM68HNR	MI	DE12T80
DM68HNR	MN	Beta-mannosidase (manB)
DM68HNR	MT	DME
DM68HNR	MA	Metabolism
DM68HNR	RN	Structure and function of Bs164 beta-mannosidase from Bacteroides salyersiae the founding member of glycoside hydrolase family GH164. J Biol Chem. 2020 Mar 27;295(13):4316-4326.
DM68HNR	RU	https://pubmed.ncbi.nlm.nih.gov/31871050

DMKE5QH	DI	DMKE5QH
DMKE5QH	DN	WZB-117
DMKE5QH	MI	TT79TKF
DMKE5QH	MN	HepG2 glucose transporter (SLC2A1)
DMKE5QH	MT	DTT
DMKE5QH	MA	Inhibitor
DMKE5QH	RN	Quercetin inhibits glucose transport by binding to an exofacial site on GLUT1. Biochimie. 2018 Aug;151:107-114.
DMKE5QH	RU	https://pubmed.ncbi.nlm.nih.gov/29857184

DMD8TNK	DI	DMD8TNK
DMD8TNK	DN	XL475
DMD8TNK	MI	TTSDVTR
DMD8TNK	MN	G-protein coupled bile acid receptor 1 (GPBAR1)
DMD8TNK	MT	DTT
DMD8TNK	MA	Agonist
DMD8TNK	RN	Clinical pipeline report, company report or official report of Exelixis (2011).
DMD8TNK	RU	http://www.exelixis.com/pipeline

DMINSA5	DI	DMINSA5
DMINSA5	DN	XL-499
DMINSA5	MI	TTGBPJE
DMINSA5	MN	PI3-kinase delta (PIK3CD)
DMINSA5	MT	DTT
DMINSA5	MA	Inhibitor
DMINSA5	RN	Clinical pipeline report, company report or official report of Exelixis.
DMINSA5	RU	http://www.exelixis.com/pipeline/xl499

DMU86XT	DI	DMU86XT
DMU86XT	DN	YM-201636
DMU86XT	MI	TTA4M1N
DMU86XT	MN	Phosphatidylinositol-3-phosphate 5-kinase (PIP5K3)
DMU86XT	MT	DTT
DMU86XT	MA	Inhibitor
DMU86XT	RN	PIKfyve negatively regulates exocytosis in neurosecretory cells. J Biol Chem. 2008 Feb 1;283(5):2804-13.
DMU86XT	RU	https://pubmed.ncbi.nlm.nih.gov/18039667

DMMUYC2	DI	DMMUYC2
DMMUYC2	DN	YM-344031
DMMUYC2	MI	TTD3XFU
DMMUYC2	MN	C-C chemokine receptor type 3 (CCR3)
DMMUYC2	MT	DTT
DMMUYC2	MA	Antagonist
DMMUYC2	RN	Emerging drugs for asthma. Expert Opin Emerg Drugs. 2008 Dec;13(4):643-53.
DMMUYC2	RU	https://pubmed.ncbi.nlm.nih.gov/19046132

DMTM1LK	DI	DMTM1LK
DMTM1LK	DN	YM-355179
DMTM1LK	MI	TTD3XFU
DMTM1LK	MN	C-C chemokine receptor type 3 (CCR3)
DMTM1LK	MT	DTT
DMTM1LK	MA	Antagonist
DMTM1LK	RN	Emerging drugs for asthma. Expert Opin Emerg Drugs. 2008 Dec;13(4):643-53.
DMTM1LK	RU	https://pubmed.ncbi.nlm.nih.gov/19046132

DMH0I9N	DI	DMH0I9N
DMH0I9N	DN	YW327.6S2
DMH0I9N	MI	TTZPY6J
DMH0I9N	MN	Tyrosine-protein kinase UFO (AXL)
DMH0I9N	MT	DTT
DMH0I9N	RN	AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer. 2019 Nov 4;18(1):153.
DMH0I9N	RU	https://pubmed.ncbi.nlm.nih.gov/31684958

DMDRQIA	DI	DMDRQIA
DMDRQIA	DN	ZBzl-YAA5911
DMDRQIA	MI	TTZXI0P
DMDRQIA	MN	Enterococcus fsrC (Ente-cocc fsrC)
DMDRQIA	MT	DTT
DMDRQIA	MA	Antagonist
DMDRQIA	RN	Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance. Nat Rev Drug Discov. 2017 Jul;16(7):457-471.
DMDRQIA	RU	https://pubmed.ncbi.nlm.nih.gov/28337021

DMNG84V	DI	DMNG84V
DMNG84V	DN	ZK-thiazolidinone
DMNG84V	MI	TTIYVQP
DMNG84V	MN	Polo-like kinase 1 (PLK1)
DMNG84V	MT	DTT
DMNG84V	MA	Inhibitor
DMNG84V	RN	Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009 Jun;14(6):559-70.
DMNG84V	RU	https://pubmed.ncbi.nlm.nih.gov/19474163

DMX23CZ	DI	DMX23CZ
DMX23CZ	DN	Z-Phe-Ala-diazomethylketone
DMX23CZ	MI	TTF2LRI
DMX23CZ	MN	Cathepsin B (CTSB)
DMX23CZ	MT	DTT
DMX23CZ	MA	Inhibitor
DMX23CZ	RN	Lysosomes as a therapeutic target. Nat Rev Drug Discov. 2019 Dec;18(12):923-948.
DMX23CZ	RU	https://pubmed.ncbi.nlm.nih.gov/31477883

DMX23CZ	DI	DMX23CZ
DMX23CZ	DN	Z-Phe-Ala-diazomethylketone
DMX23CZ	MI	TT36ETB
DMX23CZ	MN	Cathepsin L (CTSL)
DMX23CZ	MT	DTT
DMX23CZ	MA	Inhibitor
DMX23CZ	RN	Lysosomes as a therapeutic target. Nat Rev Drug Discov. 2019 Dec;18(12):923-948.
DMX23CZ	RU	https://pubmed.ncbi.nlm.nih.gov/31477883

DMTDG7L	DI	DMTDG7L
DMTDG7L	DN	Z-VAD-fmk
DMTDG7L	MI	TTZY5KP
DMTDG7L	MN	Caspase (CASP)
DMTDG7L	MT	DTT
DMTDG7L	MA	Inhibitor
DMTDG7L	RN	Clinical pipeline report, company report or official report of InvivoGen.
DMTDG7L	RU	https://www.invivogen.com/z-vad-fmk

DMVO0LU	DI	DMVO0LU
DMVO0LU	DN	131I-81C6
DMVO0LU	MI	TTUCPMY
DMVO0LU	MN	Tenascin (TNC)
DMVO0LU	MT	DTT
DMVO0LU	RN	Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent. Clin Cancer Res. 1998 Oct;4(10):2495-502.
DMVO0LU	RU	https://pubmed.ncbi.nlm.nih.gov/9796983

DMTH52F	DI	DMTH52F
DMTH52F	DN	21-AMINOEPOTHILONE B
DMTH52F	MI	TTML2WA
DMTH52F	MN	Tubulin (TUB)
DMTH52F	MT	DTT
DMTH52F	MA	Inhibitor
DMTH52F	RN	Tubulin-Interactive Natural Products as Anticancer Agents. Correction in: J Nat Prod. 2011 May 27; 74(5): 1352.
DMTH52F	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2765517/

DMO6BA0	DI	DMO6BA0
DMO6BA0	DN	3-DEAZAADENOSINE
DMO6BA0	MI	TTANY71
DMO6BA0	MN	AdoHcy hydrolase (SAHase)
DMO6BA0	MT	DTT
DMO6BA0	MA	Modulator
DMO6BA0	RN	Anti-HIV-1 activity of 3-deaza-adenosine analogs. Inhibition of S-adenosylhomocysteine hydrolase and nucleotide congeners. Eur J Biochem. 2003 Sep;270(17):3507-17.
DMO6BA0	RU	https://pubmed.ncbi.nlm.nih.gov/12919315

DMQ4X7Y	DI	DMQ4X7Y
DMQ4X7Y	DN	443C81
DMQ4X7Y	MI	TTKWM86
DMQ4X7Y	MN	Opioid receptor mu (MOP)
DMQ4X7Y	MT	DTT
DMQ4X7Y	MA	Modulator
DMQ4X7Y	RN	Inhibition of cholinergic neurotransmission in human airways by opioids. J Appl Physiol (1985). 1992 Mar;72(3):1096-100.
DMQ4X7Y	RU	https://pubmed.ncbi.nlm.nih.gov/1314798

DMM3UK5	DI	DMM3UK5
DMM3UK5	DN	50-235
DMM3UK5	MI	TTKRD0G
DMM3UK5	MN	Endothelin A receptor (EDNRA)
DMM3UK5	MT	DTT
DMM3UK5	MA	Modulator
DMM3UK5	RN	Structure-activity relationships of an endothelin ETA receptor antagonist, 50-235, and its derivatives. Eur J Pharmacol. 1993 Oct 15;247(2):219-21.
DMM3UK5	RU	https://pubmed.ncbi.nlm.nih.gov/8282010

DM5MVF9	DI	DM5MVF9
DM5MVF9	DN	6-nitroquipazine
DM5MVF9	MI	TT3ROYC
DM5MVF9	MN	Serotonin transporter (SERT)
DM5MVF9	MT	DTT
DM5MVF9	MA	Inhibitor
DM5MVF9	RN	Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 5: 2'-Substituted 6-nitroquipazines. Bioorg Med Chem. 2007 May 15;15(10):3499-504.
DM5MVF9	RU	https://pubmed.ncbi.nlm.nih.gov/17376695

DMX5K4C	DI	DMX5K4C
DMX5K4C	DN	7-methoxytacrine
DMX5K4C	MI	TT1RS9F
DMX5K4C	MN	Acetylcholinesterase (AChE)
DMX5K4C	MT	DTT
DMX5K4C	MA	Inhibitor
DMX5K4C	RN	Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease. Bioorg Med Chem Lett. 2010 Oct 15;20(20):6093-5.
DMX5K4C	RU	https://pubmed.ncbi.nlm.nih.gov/20817518

DM0NY6K	DI	DM0NY6K
DM0NY6K	DN	A 77636
DM0NY6K	MI	TTZFYLI
DM0NY6K	MN	Dopamine D1 receptor (D1R)
DM0NY6K	MT	DTT
DM0NY6K	MA	Modulator
DM0NY6K	RN	Actions of the D1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosets. Psychopharmacology (Berl). 1999 Feb;142(1):51-60.
DM0NY6K	RU	https://www.ncbi.nlm.nih.gov/pubmed/10102782

DMZ5NQP	DI	DMZ5NQP
DMZ5NQP	DN	A-11259
DMZ5NQP	MI	TT3C1VN
DMZ5NQP	MN	Enzyme unspecific (Enz)
DMZ5NQP	MT	DTT
DMZ5NQP	MA	Inhibitor
DMZ5NQP	RN	The Identification of Nanomolar 1,4-benzoquinone Inhibitors of Shikimate Kinase. Aspergillus & Aspergillosis Website. 2002.
DMZ5NQP	RU	http://www.aspergillus.org.uk/content/identification-nanomolar-14-benzoquinone-inhibitors-shikimate-kinase

DM6CSRU	DI	DM6CSRU
DM6CSRU	DN	A-131701
DM6CSRU	MI	TTNGILX
DM6CSRU	MN	Adrenergic receptor alpha-1A (ADRA1A)
DM6CSRU	MT	DTT
DM6CSRU	MA	Inhibitor
DM6CSRU	RN	Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
DM6CSRU	RU	https://pubmed.ncbi.nlm.nih.gov/15664832

DMRWDX5	DI	DMRWDX5
DMRWDX5	DN	A-134974
DMRWDX5	MI	TTL732K
DMRWDX5	MN	Adenosine kinase (ADK)
DMRWDX5	MT	DTT
DMRWDX5	MA	Inhibitor
DMRWDX5	RN	Effects of A-134974, a novel adenosine kinase inhibitor, on carrageenan-induced inflammatory hyperalgesia and locomotor activity in rats: evaluation of the sites of action. J Pharmacol Exp Ther. 2001Feb;296(2):501-9.
DMRWDX5	RU	https://pubmed.ncbi.nlm.nih.gov/11160637

DMPEJ4O	DI	DMPEJ4O
DMPEJ4O	DN	A-204176
DMPEJ4O	MI	TTNGILX
DMPEJ4O	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMPEJ4O	MT	DTT
DMPEJ4O	MA	Agonist
DMPEJ4O	RN	Pharmacological properties of A-204176, a novel and selective alpha1A adrenergic agonist, in in vitro and in vivo models of urethral function. Life Sci. 2001 Nov 30;70(2):181-97.
DMPEJ4O	RU	https://pubmed.ncbi.nlm.nih.gov/11787943

DMDTA36	DI	DMDTA36
DMDTA36	DN	A-252444.0
DMDTA36	MI	TTCT6F7
DMDTA36	MN	Intercellular adhesion molecule ICAM-1 (ICAM1)
DMDTA36	MT	DTT
DMDTA36	MA	Antagonist
DMDTA36	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012566)
DMDTA36	RU	http://adisinsight.springer.com/drugs/800012566

DMKL482	DI	DMKL482
DMKL482	DN	A-364
DMKL482	MI	TT3C1VN
DMKL482	MN	Enzyme unspecific (Enz)
DMKL482	MT	DTT
DMKL482	MA	Inhibitor
DMKL482	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015550)
DMKL482	RU	http://adisinsight.springer.com/drugs/800015550

DM4WT7Z	DI	DM4WT7Z
DM4WT7Z	DN	A-62176
DM4WT7Z	MI	TT0IHXV
DM4WT7Z	MN	DNA topoisomerase II (TOP2)
DM4WT7Z	MT	DTT
DM4WT7Z	MA	Inhibitor
DM4WT7Z	RN	Design of new topoisomerase II inhibitors based upon a quinobenzoxazine self-assembly model. J Med Chem. 1998 Oct 22;41(22):4273-8.
DM4WT7Z	RU	https://pubmed.ncbi.nlm.nih.gov/9784102

DM4WT7Z	DI	DM4WT7Z
DM4WT7Z	DN	A-62176
DM4WT7Z	MI	TT4NVEM
DM4WT7Z	MN	DNA topoisomerase II beta (TOP2B)
DM4WT7Z	MT	DTT
DM4WT7Z	MA	Inhibitor
DM4WT7Z	RN	Design of new topoisomerase II inhibitors based upon a quinobenzoxazine self-assembly model. J Med Chem. 1998 Oct 22;41(22):4273-8.
DM4WT7Z	RU	https://pubmed.ncbi.nlm.nih.gov/9784102

DM1BDHY	DI	DM1BDHY
DM1BDHY	DN	A-68552
DM1BDHY	MI	TTKAPQ1
DM1BDHY	MN	Cholecystokinin receptor (CCKR)
DM1BDHY	MT	DTT
DM1BDHY	MA	Modulator
DM1BDHY	RN	CN patent application no. 102481276, Chemosensory receptor ligand-based therapies.
DM1BDHY	RU	http://www.google.com/patents/CN102481276A?cl=en

DMUJ94B	DI	DMUJ94B
DMUJ94B	DN	A-68930
DMUJ94B	MI	TTZFYLI
DMUJ94B	MN	Dopamine D1 receptor (D1R)
DMUJ94B	MT	DTT
DMUJ94B	MA	Modulator
DMUJ94B	RN	Comparison of the D1-dopamine agonists SKF-38393 and A-68930 in neonatal 6-hydroxydopamine-lesioned rats: behavioral effects and induction of c-fos-like immunoreactivity. J Pharmacol Exp Ther. 1992 Aug;262(2):855-65.
DMUJ94B	RU	https://pubmed.ncbi.nlm.nih.gov/1354257

DMUJ94B	DI	DMUJ94B
DMUJ94B	DN	A-68930
DMUJ94B	MI	TTEX248
DMUJ94B	MN	Dopamine D2 receptor (D2R)
DMUJ94B	MT	DTT
DMUJ94B	MA	Inhibitor
DMUJ94B	RN	(1R,3S)-1-(aminomethyl)-3,4-dihydro-5,6-dihydroxy-3-phenyl-1H-2-benzopyran: a potent and selective D1 agonist. J Med Chem. 1990 Nov;33(11):2948-50.
DMUJ94B	RU	https://pubmed.ncbi.nlm.nih.gov/1977907

DMPL1OV	DI	DMPL1OV
DMPL1OV	DN	A-69024
DMPL1OV	MI	TTZFYLI
DMPL1OV	MN	Dopamine D1 receptor (D1R)
DMPL1OV	MT	DTT
DMPL1OV	MA	Modulator
DMPL1OV	RN	(+)-[76Br]A-69024: a non-benzazepine radioligand for studies of dopamine D1 receptors using PET. Nucl Med Biol. 2002 Apr;29(3):295-302.
DMPL1OV	RU	https://pubmed.ncbi.nlm.nih.gov/11929698

DM9KNFZ	DI	DM9KNFZ
DM9KNFZ	DN	A-70276
DM9KNFZ	MI	TTCG0AL
DM9KNFZ	MN	Cholecystokinin receptor type A (CCKAR)
DM9KNFZ	MT	DTT
DM9KNFZ	MA	Modulator
DM9KNFZ	RN	Cholecystokinin antagonists: (R)-tryptophan-based hybrid antagonists of high affinity and selectivity for CCK-A receptors. J Med Chem. 1991 Dec;34(12):3350-9.
DM9KNFZ	RU	https://pubmed.ncbi.nlm.nih.gov/1766000

DM9X24J	DI	DM9X24J
DM9X24J	DN	A-70826
DM9X24J	MI	TTN6J5F
DM9X24J	MN	Bacterial DNA gyrase (Bact gyrase)
DM9X24J	MT	DTT
DM9X24J	MA	Modulator
DM9X24J	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001978)
DM9X24J	RU	http://adisinsight.springer.com/drugs/800001978

DMKZNTY	DI	DMKZNTY
DMKZNTY	DN	A-71623
DMKZNTY	MI	TTCG0AL
DMKZNTY	MN	Cholecystokinin receptor type A (CCKAR)
DMKZNTY	MT	DTT
DMKZNTY	MA	Modulator
DMKZNTY	RN	Characterization of two novel cholecystokinin tetrapeptide (30-33) analogues, A-71623 and A-70874, that exhibit high potency and selectivity for cholecystokinin-A receptors. Mol Pharmacol. 1991 Mar;39(3):346-51.
DMKZNTY	RU	https://pubmed.ncbi.nlm.nih.gov/1706470

DM7FI3S	DI	DM7FI3S
DM7FI3S	DN	A-72055
DM7FI3S	MI	TTOXS3C
DM7FI3S	MN	Muscarinic acetylcholine receptor (CHRM)
DM7FI3S	MT	DTT
DM7FI3S	MA	Modulator
DM7FI3S	RN	US patent application no. 2011,0020,423, Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation.
DM7FI3S	RU	http://www.google.com.ar/patents/US20110020423

DMBEIFL	DI	DMBEIFL
DMBEIFL	DN	A-74273
DMBEIFL	MI	TTB2MXP
DMBEIFL	MN	Angiotensinogenase renin (REN)
DMBEIFL	MT	DTT
DMBEIFL	MA	Inhibitor
DMBEIFL	RN	The orally active renin inhibitor A-74273. In vivo and in vitro morpholine ring metabolism in rats, dogs, and humans. Drug Metab Dispos. 1994 Nov-Dec;22(6):880-8.
DMBEIFL	RU	https://pubmed.ncbi.nlm.nih.gov/7895605

DMS3R15	DI	DMS3R15
DMS3R15	DN	A-74283
DMS3R15	MI	TTSQIFT
DMS3R15	MN	5-HT 1A receptor (HTR1A)
DMS3R15	MT	DTT
DMS3R15	MA	Agonist
DMS3R15	RN	Cardiovascular activity of A-74283, a 5-hydroxytryptamine 1A agent, in the spontaneously hypertensive rat. Pharmacology. 1998 Jan;56(1):17-29.
DMS3R15	RU	https://pubmed.ncbi.nlm.nih.gov/9467184

DMNCGOP	DI	DMNCGOP
DMNCGOP	DN	A-74932
DMNCGOP	MI	TT0IHXV
DMNCGOP	MN	DNA topoisomerase II (TOP2)
DMNCGOP	MT	DTT
DMNCGOP	MA	Modulator
DMNCGOP	RN	Use of catalytic topoisomerase II inhibitors to probe mechanisms of chemical-induced clastogenicity in Chinese hamster V79 cells. Environ Mol Mutagen. 2000;35(1):13-21.
DMNCGOP	RU	https://www.ncbi.nlm.nih.gov/pubmed/10692223

DMPX37E	DI	DMPX37E
DMPX37E	DN	A-75169
DMPX37E	MI	TT2NUT5
DMPX37E	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMPX37E	MT	DTT
DMPX37E	MA	Modulator
DMPX37E	RN	A-75169 HCI: Pharmacological profile and ocular pharmacology studies of a new alpha-2 antagonist. Drug Development Research Volume 28, Issue 1, pages 56-64, January 1993.
DMPX37E	RU	http://onlinelibrary.wiley.com/doi/10.1002/ddr.430280107/abstract

DMC3MH5	DI	DMC3MH5
DMC3MH5	DN	A-75729
DMC3MH5	MI	TTR8XOH
DMC3MH5	MN	GPCR secretin protein unspecific (GPCRB)
DMC3MH5	MT	DTT
DMC3MH5	MA	Modulator
DMC3MH5	RN	Olfaction. Leffingwell Reports, Vol. 2 (No. 1). May, 2002.
DMC3MH5	RU	http://www.leffingwell.com/download/Olfaction5.pdf

DMRHEWX	DI	DMRHEWX
DMRHEWX	DN	A-76202M
DMRHEWX	MI	TTXWASR
DMRHEWX	MN	Intestinal maltase-glucoamylase (MGAM)
DMRHEWX	MT	DTT
DMRHEWX	MA	Modulator
DMRHEWX	RN	Synthesis and biological activity of 4',8-dihydroxyisoflavon-7-yl D-hexopyranosides. Carbohydr Res. 2001 Oct 15;335(4):283-9.
DMRHEWX	RU	https://pubmed.ncbi.nlm.nih.gov/11595222

DMTF6D9	DI	DMTF6D9
DMTF6D9	DN	A-76895
DMTF6D9	MI	TTRK8B9
DMTF6D9	MN	Sodium channel unspecific (NaC)
DMTF6D9	MT	DTT
DMTF6D9	MA	Modulator
DMTF6D9	RN	CA patent application no. 849505, Sodium channel blockers reduce glucagon secretion.
DMTF6D9	RU	http://www.google.com/patents/CA2849505A1?cl=en

DM4HRXI	DI	DM4HRXI
DM4HRXI	DN	A-78773
DM4HRXI	MI	TT2J34L
DM4HRXI	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM4HRXI	MT	DTT
DM4HRXI	MA	Inhibitor
DM4HRXI	RN	(+/-)-trans-2-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-(N-methyl-N- hydroxyureidyl)methylphenyl]-5-(3,4, 5-trimethoxyphenyl)tetrahydrofuran (CMI-3... J Med Chem. 1998 May 21;41(11):1970-9.
DM4HRXI	RU	https://pubmed.ncbi.nlm.nih.gov/9599246

DMT5ZFG	DI	DMT5ZFG
DMT5ZFG	DN	A-79175
DMT5ZFG	MI	TT2J34L
DMT5ZFG	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMT5ZFG	MT	DTT
DMT5ZFG	MA	Inhibitor
DMT5ZFG	RN	The role of platelet-activating factor (PAF) and the efficacy of ABT-491, a highly potent and selective PAF antagonist, in experimental allergic rhinitis. J Pharmacol Exp Ther. 1998 Jan;284(1):83-8.
DMT5ZFG	RU	https://pubmed.ncbi.nlm.nih.gov/9435164

DM3IYMF	DI	DM3IYMF
DM3IYMF	DN	A-79296
DM3IYMF	MI	TT84ETX
DM3IYMF	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM3IYMF	MT	DTT
DM3IYMF	MA	Modulator
DM3IYMF	RN	US patent application no. 5,830,759, Unique associated kaposi's sarcoma virus sequences and uses thereof.
DM3IYMF	RU	http://www.google.com/patents/US5830759

DMXWG6Z	DI	DMXWG6Z
DMXWG6Z	DN	A-798
DMXWG6Z	MI	TTX4RTB
DMXWG6Z	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMXWG6Z	MT	DTT
DMXWG6Z	MA	Antagonist
DMXWG6Z	RN	Disruption of the melanin-concentrating hormone receptor 1 (MCH1R) affects thyroid function. Endocrinology. 2012 Dec;153(12):6145-54.
DMXWG6Z	RU	https://pubmed.ncbi.nlm.nih.gov/23024261

DM89BGE	DI	DM89BGE
DM89BGE	DN	A-80263
DM89BGE	MI	TT2J34L
DM89BGE	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM89BGE	MT	DTT
DM89BGE	MA	Inhibitor
DM89BGE	RN	CA patent application no. 445634, Acne treatment comprising lipoxygenase inhibitors.
DM89BGE	RU	http://www.google.com/patents/CA2445634A1?cl=en

DMBC3DG	DI	DMBC3DG
DMBC3DG	DN	A-80426
DMBC3DG	MI	TTSQIFT
DMBC3DG	MN	5-HT 1A receptor (HTR1A)
DMBC3DG	MT	DTT
DMBC3DG	MA	Inhibitor
DMBC3DG	RN	Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.
DMBC3DG	RU	https://pubmed.ncbi.nlm.nih.gov/16220969

DMBC3DG	DI	DMBC3DG
DMBC3DG	DN	A-80426
DMBC3DG	MI	TTJQOD7
DMBC3DG	MN	5-HT 2A receptor (HTR2A)
DMBC3DG	MT	DTT
DMBC3DG	MA	Inhibitor
DMBC3DG	RN	Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.
DMBC3DG	RU	https://pubmed.ncbi.nlm.nih.gov/16220969

DMBC3DG	DI	DMBC3DG
DMBC3DG	DN	A-80426
DMBC3DG	MI	TTWG9A4
DMBC3DG	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMBC3DG	MT	DTT
DMBC3DG	MA	Inhibitor
DMBC3DG	RN	Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking... J Med Chem. 2005 Mar 24;48(6):2054-71.
DMBC3DG	RU	https://pubmed.ncbi.nlm.nih.gov/15771448

DMBC3DG	DI	DMBC3DG
DMBC3DG	DN	A-80426
DMBC3DG	MI	TTWM4TY
DMBC3DG	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMBC3DG	MT	DTT
DMBC3DG	MA	Inhibitor
DMBC3DG	RN	Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking... J Med Chem. 2005 Mar 24;48(6):2054-71.
DMBC3DG	RU	https://pubmed.ncbi.nlm.nih.gov/15771448

DMBC3DG	DI	DMBC3DG
DMBC3DG	DN	A-80426
DMBC3DG	MI	TT2NUT5
DMBC3DG	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMBC3DG	MT	DTT
DMBC3DG	MA	Inhibitor
DMBC3DG	RN	Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking... J Med Chem. 2005 Mar 24;48(6):2054-71.
DMBC3DG	RU	https://pubmed.ncbi.nlm.nih.gov/15771448

DMBC3DG	DI	DMBC3DG
DMBC3DG	DN	A-80426
DMBC3DG	MI	TTEX248
DMBC3DG	MN	Dopamine D2 receptor (D2R)
DMBC3DG	MT	DTT
DMBC3DG	MA	Inhibitor
DMBC3DG	RN	Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.
DMBC3DG	RU	https://pubmed.ncbi.nlm.nih.gov/16220969

DMBC3DG	DI	DMBC3DG
DMBC3DG	DN	A-80426
DMBC3DG	MI	TTE0A2F
DMBC3DG	MN	Dopamine D4 receptor (D4R)
DMBC3DG	MT	DTT
DMBC3DG	MA	Inhibitor
DMBC3DG	RN	Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking... J Med Chem. 2005 Mar 24;48(6):2054-71.
DMBC3DG	RU	https://pubmed.ncbi.nlm.nih.gov/15771448

DMBC3DG	DI	DMBC3DG
DMBC3DG	DN	A-80426
DMBC3DG	MI	TT3ROYC
DMBC3DG	MN	Serotonin transporter (SERT)
DMBC3DG	MT	DTT
DMBC3DG	MA	Inhibitor
DMBC3DG	RN	Structure-activity studies for a novel series of N-(arylethyl)-N-(1,2,3,4-tetrahydronaphthalen-1-ylmethyl)-N-methylamine s possessing dual 5-HT upt... J Med Chem. 1997 Mar 28;40(7):1049-62.
DMBC3DG	RU	https://pubmed.ncbi.nlm.nih.gov/9089327

DMH6LCD	DI	DMH6LCD
DMH6LCD	DN	A-81282
DMH6LCD	MI	TTGN1ZA
DMH6LCD	MN	Angiotensin II receptor (AGTR)
DMH6LCD	MT	DTT
DMH6LCD	MA	Modulator
DMH6LCD	RN	Pharmacological characterization of Abbott-81282, a novel, non-peptide angiotensin-II antagonist selective for type-1 receptors. Life Sci. 1993;53(11):929-37.
DMH6LCD	RU	https://pubmed.ncbi.nlm.nih.gov/8366760

DM1GLIN	DI	DM1GLIN
DM1GLIN	DN	A-81988
DM1GLIN	MI	TTGN1ZA
DM1GLIN	MN	Angiotensin II receptor (AGTR)
DM1GLIN	MT	DTT
DM1GLIN	MA	Modulator
DM1GLIN	RN	[3H]A-81988, a potent, selective, competitive antagonist radioligand for angiotensin AT1 receptors. Eur J Pharmacol. 1994 Mar 15;267(1):49-54.
DM1GLIN	RU	https://pubmed.ncbi.nlm.nih.gov/8206129

DM1GLIN	DI	DM1GLIN
DM1GLIN	DN	A-81988
DM1GLIN	MI	TT8DBY3
DM1GLIN	MN	Angiotensin II receptor type-1 (AGTR1)
DM1GLIN	MT	DTT
DM1GLIN	MA	Antagonist
DM1GLIN	RN	[3H]A-81988, a potent, selective, competitive antagonist radioligand for angiotensin AT1 receptors. Eur J Pharmacol. 1994 Mar 15;267(1):49-54.
DM1GLIN	RU	https://pubmed.ncbi.nlm.nih.gov/8206129

DMUID46	DI	DMUID46
DMUID46	DN	A-87049
DMUID46	MI	TTFQEO5
DMUID46	MN	Squalene synthetase (FDFT1)
DMUID46	MT	DTT
DMUID46	MA	Inhibitor
DMUID46	RN	(1 alpha, 2 beta, 3 beta, 4 alpha)-1,2-bis[N-propyl-N-(4-phenoxybenzyl) amino]carbonyl]cyclobutane-3,4-dicarboxylic acid (A-87049): a novel potent ... J Med Chem. 1997 Jul 4;40(14):2123-5.
DMUID46	RU	https://pubmed.ncbi.nlm.nih.gov/9216829

DM1KBAY	DI	DM1KBAY
DM1KBAY	DN	A-93178
DM1KBAY	MI	TTDMBF5
DM1KBAY	MN	Arachidonate 5-lipoxygenase activating protein (FLAP)
DM1KBAY	MT	DTT
DM1KBAY	MA	Modulator
DM1KBAY	RN	Characterization of A-93178, an iminoxy-quinoline inhibitor of leukotriene biosynthesis. Adv Exp Med Biol. 1997;433:91-4.
DM1KBAY	RU	https://pubmed.ncbi.nlm.nih.gov/9561111

DMPEB0Z	DI	DMPEB0Z
DMPEB0Z	DN	AA-861
DMPEB0Z	MI	TT2J34L
DMPEB0Z	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMPEB0Z	MT	DTT
DMPEB0Z	MA	Inhibitor
DMPEB0Z	RN	Platelets stimulate airway smooth muscle cell proliferation through mechanisms involving 5-lipoxygenase and reactive oxygen species. Platelets. 2008 Nov;19(7):528-36.
DMPEB0Z	RU	https://pubmed.ncbi.nlm.nih.gov/18979365

DMDOQCV	DI	DMDOQCV
DMDOQCV	DN	ABANOQUIL
DMDOQCV	MI	TTNGILX
DMDOQCV	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMDOQCV	MT	DTT
DMDOQCV	MA	Inhibitor
DMDOQCV	RN	Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem. 1995 Sep 1;38(18):3415-44.
DMDOQCV	RU	https://pubmed.ncbi.nlm.nih.gov/7658428

DMDOQCV	DI	DMDOQCV
DMDOQCV	DN	ABANOQUIL
DMDOQCV	MI	TTBRKXS
DMDOQCV	MN	Adrenergic receptor alpha-1B (ADRA1B)
DMDOQCV	MT	DTT
DMDOQCV	MA	Inhibitor
DMDOQCV	RN	Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem. 1995 Sep 1;38(18):3415-44.
DMDOQCV	RU	https://pubmed.ncbi.nlm.nih.gov/7658428

DMDOQCV	DI	DMDOQCV
DMDOQCV	DN	ABANOQUIL
DMDOQCV	MI	TT34BHT
DMDOQCV	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMDOQCV	MT	DTT
DMDOQCV	MA	Inhibitor
DMDOQCV	RN	Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem. 1995 Sep 1;38(18):3415-44.
DMDOQCV	RU	https://pubmed.ncbi.nlm.nih.gov/7658428

DMALPDW	DI	DMALPDW
DMALPDW	DN	ABS-205
DMALPDW	MI	TTD26RC
DMALPDW	MN	Cell adhesion molecule (CADM)
DMALPDW	MT	DTT
DMALPDW	MA	Modulator
DMALPDW	RN	Drug Discovery and Development for Alzheimer's Disease, 2000. Page(21).
DMALPDW	RU	https://books.google.com.hk/books?id=mB0SXrpofmwC&pg=PA184&lpg=PA184&dq=%22ABS-205%22++Cell+adhesion&source=bl&ots=UtcoGEnNKZ&sig=1dVQ1oxHOCcy90TN5liCl__WXno&hl=zh-CN&sa=X&ved=0CCsQ6AEwAmoVChMIhIOO3Me_yAIVAsKOCh2rAgWU#v=onepage&q=%22ABS-205%22%20%20Cell%20adhesion&f=false

DMZ52P6	DI	DMZ52P6
DMZ52P6	DN	ABS-212
DMZ52P6	MI	TTTUMEP
DMZ52P6	MN	Neurotensin receptor type 1 (NTSR1)
DMZ52P6	MT	DTT
DMZ52P6	MA	Agonist
DMZ52P6	RN	Identification and functional characterization of a stable, centrally active derivative of the neurotensin (8-13) fragment as a potential first-in-class analgesic. J Med Chem. 2010 Jun 24;53(12):4623-32.
DMZ52P6	RU	https://pubmed.ncbi.nlm.nih.gov/20481538

DMCW5DJ	DI	DMCW5DJ
DMCW5DJ	DN	ABS-301
DMCW5DJ	MI	TT1RS9F
DMCW5DJ	MN	Acetylcholinesterase (AChE)
DMCW5DJ	MT	DTT
DMCW5DJ	MA	Modulator
DMCW5DJ	RN	Novel tacrine analogues for potential use against Alzheimer's disease: potent and selective acetylcholinesterase inhibitors and 5-HT uptake inhibitors. J Med Chem. 1997 Oct 24;40(22):3516-23.
DMCW5DJ	RU	https://pubmed.ncbi.nlm.nih.gov/9357518

DMPFLS5	DI	DMPFLS5
DMPFLS5	DN	ABT-100
DMPFLS5	MI	TT7WZIJ
DMPFLS5	MN	CAAX farnesyltransferase beta (FNTB)
DMPFLS5	MT	DTT
DMPFLS5	MA	Inhibitor
DMPFLS5	RN	Potent farnesyltransferase inhibitor ABT-100 abrogates acute allograft rejection. J Heart Lung Transplant. 2005 Sep;24(9):1403-9.
DMPFLS5	RU	https://pubmed.ncbi.nlm.nih.gov/16143263

DMYJMV9	DI	DMYJMV9
DMYJMV9	DN	ABT-702
DMYJMV9	MI	TTL732K
DMYJMV9	MN	Adenosine kinase (ADK)
DMYJMV9	MT	DTT
DMYJMV9	MA	Inhibitor
DMYJMV9	RN	ABT-702, an adenosine kinase inhibitor, attenuates inflammation in diabetic retinopathy. Life Sci. 2013 Jul 30;93(2-3):78-88.
DMYJMV9	RU	https://pubmed.ncbi.nlm.nih.gov/23770229

DML0DBV	DI	DML0DBV
DML0DBV	DN	ABT-737
DML0DBV	MI	TTJGNVC
DML0DBV	MN	Apoptosis regulator Bcl-2 (BCL-2)
DML0DBV	MT	DTT
DML0DBV	MA	Inhibitor
DML0DBV	RN	Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. J Med Chem. 2007 Feb 22;50(4):641-62.
DML0DBV	RU	https://pubmed.ncbi.nlm.nih.gov/17256834

DML0DBV	DI	DML0DBV
DML0DBV	DN	ABT-737
DML0DBV	MI	DTUGYRD
DML0DBV	MN	P-glycoprotein 1 (ABCB1)
DML0DBV	MT	DTP
DML0DBV	MA	Substrate
DML0DBV	RN	The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein. Biochem Biophys Res Commun. 2011 May 6;408(2):344-9.
DML0DBV	RU	https://doi.org/10.1016/j.bbrc.2011.04.043

DM4UN9A	DI	DM4UN9A
DM4UN9A	DN	ABT-839
DM4UN9A	MI	TT7WZIJ
DM4UN9A	MN	CAAX farnesyltransferase beta (FNTB)
DM4UN9A	MT	DTT
DM4UN9A	MA	Inhibitor
DM4UN9A	RN	Design and synthesis of o-trifluoromethylbiphenyl substituted 2-amino-nicotinonitriles as inhibitors of farnesyltransferase. Bioorg Med Chem Lett. 2005 Jan 3;15(1):153-8.
DM4UN9A	RU	https://pubmed.ncbi.nlm.nih.gov/15582430

DM4UN9A	DI	DM4UN9A
DM4UN9A	DN	ABT-839
DM4UN9A	MI	TTXQKM3
DM4UN9A	MN	Farnesyl protein transferase (Ftase)
DM4UN9A	MT	DTT
DM4UN9A	MA	Inhibitor
DM4UN9A	RN	Aryl tetrahydropyridine inhibitors of farnesyltransferase: glycine, phenylalanine and histidine derivatives. Bioorg Med Chem Lett. 2003 Apr 7;13(7):1359-62.
DM4UN9A	RU	https://pubmed.ncbi.nlm.nih.gov/12657282

DMDPUK6	DI	DMDPUK6
DMDPUK6	DN	ABX-PTH
DMDPUK6	MI	TT6F7GZ
DMDPUK6	MN	Parathyroid hormone (PTH)
DMDPUK6	MT	DTT
DMDPUK6	RN	Focus on parathyroid carcinoma. International Journal of Surgery Volume 9, Issue 1, 2011, Pages 13-19.
DMDPUK6	RU	http://www.sciencedirect.com/science/article/pii/S1743919110004437

DM5IDAQ	DI	DM5IDAQ
DM5IDAQ	DN	AC-187
DM5IDAQ	MI	TTAT87F
DM5IDAQ	MN	Amylin receptor (IAPPR)
DM5IDAQ	MT	DTT
DM5IDAQ	MA	Modulator
DM5IDAQ	RN	Antagonist of the amylin receptor blocks beta-amyloid toxicity in rat cholinergic basal forebrain neurons. J Neurosci. 2004 Jun 16;24(24):5579-84.
DM5IDAQ	RU	https://pubmed.ncbi.nlm.nih.gov/15201330

DMA93D8	DI	DMA93D8
DMA93D8	DN	AC-260584
DMA93D8	MI	TTZ9SOR
DMA93D8	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMA93D8	MT	DTT
DMA93D8	MA	Agonist
DMA93D8	RN	Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur J Pharmacol. 2009 Mar 1;605(1-3):53-6.
DMA93D8	RU	https://pubmed.ncbi.nlm.nih.gov/19168056

DMBY7AZ	DI	DMBY7AZ
DMBY7AZ	DN	ACEA-1011
DMBY7AZ	MI	TT9IK2Z
DMBY7AZ	MN	N-methyl-D-aspartate receptor (NMDAR)
DMBY7AZ	MT	DTT
DMBY7AZ	MA	Modulator
DMBY7AZ	RN	NMDA receptor antagonists, MK-801 and ACEA-1011, prevent the development of tonic pain following subcutaneous formalin. Brain Res. 1993 Jul 2;615(2):331-4.
DMBY7AZ	RU	https://pubmed.ncbi.nlm.nih.gov/8364741

DMCWNVB	DI	DMCWNVB
DMCWNVB	DN	ACEA-1031
DMCWNVB	MI	TT9IK2Z
DMCWNVB	MN	N-methyl-D-aspartate receptor (NMDAR)
DMCWNVB	MT	DTT
DMCWNVB	MA	Modulator
DMCWNVB	RN	In vitro pharmacology of ACEA-1021 and ACEA-1031: systemically active quinoxalinediones with high affinity and selectivity for N-methyl-D-aspartate receptor glycine sites. Mol Pharmacol. 1995 Mar;47(3):568-81.
DMCWNVB	RU	https://pubmed.ncbi.nlm.nih.gov/7700254

DMEH9OY	DI	DMEH9OY
DMEH9OY	DN	ACEA-1328
DMEH9OY	MI	TT9IK2Z
DMEH9OY	MN	N-methyl-D-aspartate receptor (NMDAR)
DMEH9OY	MT	DTT
DMEH9OY	MA	Antagonist
DMEH9OY	RN	Emerging analgesics in cancer pain management. Expert Opin Emerg Drugs. 2005 Feb;10(1):151-71.
DMEH9OY	RU	https://pubmed.ncbi.nlm.nih.gov/15757410

DMRHSG4	DI	DMRHSG4
DMRHSG4	DN	ACEA-1416
DMRHSG4	MI	TT9IK2Z
DMRHSG4	MN	N-methyl-D-aspartate receptor (NMDAR)
DMRHSG4	MT	DTT
DMRHSG4	MA	Modulator
DMRHSG4	RN	Tolerance develops to the antinociceptive and motor impairing effects of ACEA-1416, a NMDA receptor antagonist, in the formalin and rotarod test in mice. Pharmacol Res. 1998 Apr;37(4):295-302.
DMRHSG4	RU	https://pubmed.ncbi.nlm.nih.gov/9634646

DMXLB02	DI	DMXLB02
DMXLB02	DN	ACEA-2085
DMXLB02	MI	TTAN6JD
DMXLB02	MN	Glutamate receptor AMPA (GRIA)
DMXLB02	MT	DTT
DMXLB02	MA	Antagonist
DMXLB02	RN	Interaction among NMDA receptor-, NMDA glycine site- and AMPA receptor antagonists in spinally mediated analgesia. Can J Anaesth. 2000 Jul;47(7):693-8.
DMXLB02	RU	https://pubmed.ncbi.nlm.nih.gov/10930211

DM0YHKB	DI	DM0YHKB
DM0YHKB	DN	Acteoside
DM0YHKB	MI	TTFJ8Q1
DM0YHKB	MN	Protein kinase C alpha (PRKCA)
DM0YHKB	MT	DTT
DM0YHKB	MA	Inhibitor
DM0YHKB	RN	Phenylethanoid glycosides from Digitalis purpurea and Penstemon linarioides with PKCalpha-inhibitory activity. J Nat Prod. 1998 Nov;61(11):1410-2.
DM0YHKB	RU	https://pubmed.ncbi.nlm.nih.gov/9834166

DMT4P89	DI	DMT4P89
DMT4P89	DN	Actinonin
DMT4P89	MI	TTICO5G
DMT4P89	MN	Staphylococcus Peptide deformylase (Stap-coc def)
DMT4P89	MT	DTT
DMT4P89	MA	Inhibitor
DMT4P89	RN	Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor. Biochemistry. 2000 Feb 15;39(6):1256-62.
DMT4P89	RU	https://pubmed.ncbi.nlm.nih.gov/10684604

DMJFY2I	DI	DMJFY2I
DMJFY2I	DN	AD 198
DMJFY2I	MI	TT9WJ8U
DMJFY2I	MN	Protein kinase C delta (PRKCD)
DMJFY2I	MT	DTT
DMJFY2I	MA	Activator
DMJFY2I	RN	Novel extranuclear-targeted anthracyclines override the antiapoptotic functions of Bcl-2 and target protein kinase C pathways to induce apoptosis. Mol Cancer Ther. 2002 May;1(7):469-81.
DMJFY2I	RU	https://pubmed.ncbi.nlm.nih.gov/12479265

DM1SLJ9	DI	DM1SLJ9
DM1SLJ9	DN	AD-5075
DM1SLJ9	MI	TTZMAO3
DM1SLJ9	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DM1SLJ9	MT	DTT
DM1SLJ9	MA	Modulator
DM1SLJ9	RN	Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology. 1996 Oct;137(10):4189-95.
DM1SLJ9	RU	https://pubmed.ncbi.nlm.nih.gov/8828476

DM1SLJ9	DI	DM1SLJ9
DM1SLJ9	DN	AD-5075
DM1SLJ9	MI	TTT2SVW
DM1SLJ9	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DM1SLJ9	MT	DTT
DM1SLJ9	MA	Agonist
DM1SLJ9	RN	Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology. 1996 Oct;137(10):4189-95.
DM1SLJ9	RU	https://pubmed.ncbi.nlm.nih.gov/8828476

DMQNFZE	DI	DMQNFZE
DMQNFZE	DN	Ad5-AC6
DMQNFZE	MI	TT2QM9D
DMQNFZE	MN	Adenylate cyclase (ADCY)
DMQNFZE	MT	DTT
DMQNFZE	MA	Modulator
DMQNFZE	RN	Unanticipated Signaling Events Associated with Cardiac Adenylyl Cyclase Gene Transfer. J Mol Cell Cardiol. 2011 May; 50(5): 751-758.
DMQNFZE	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3095111/

DM61AV4	DI	DM61AV4
DM61AV4	DN	ADX415
DM61AV4	MI	TTQ8AFT
DM61AV4	MN	Adrenergic receptor Alpha-2 (ADRA2)
DM61AV4	MT	DTT
DM61AV4	MA	Antagonist
DM61AV4	RN	Clinical pipeline report, company report or official report of Shionogi (2011).
DM61AV4	RU	http://www.shionogi.co.jp/index_e.html

DM625LN	DI	DM625LN
DM625LN	DN	AG-041R
DM625LN	MI	TTVFO0U
DM625LN	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DM625LN	MT	DTT
DM625LN	MA	Modulator
DM625LN	RN	AG-041R, a gastrin/CCK-B antagonist, stimulates chondrocyte proliferation and metabolism in vitro. Biochem Biophys Res Commun. 2001 May 25;283(5):1118-23.
DM625LN	RU	https://pubmed.ncbi.nlm.nih.gov/11355888

DMRI7YB	DI	DMRI7YB
DMRI7YB	DN	AG-1284
DMRI7YB	MI	TT5FNQT
DMRI7YB	MN	Human immunodeficiency virus Protease (HIV PR)
DMRI7YB	MT	DTT
DMRI7YB	MA	Modulator
DMRI7YB	RN	Exploring the energy landscapes of molecular recognition by a genetic algorithm: analysis of the requirements for robust docking of HIV-1 protease and FKBP-12 complexes. Proteins. 1996 Jul;25(3):342-53.
DMRI7YB	RU	https://pubmed.ncbi.nlm.nih.gov/8844869

DMT10C2	DI	DMT10C2
DMT10C2	DN	AG1295
DMT10C2	MI	TTGJCWZ
DMT10C2	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMT10C2	MT	DTT
DMT10C2	MA	Inhibitor
DMT10C2	RN	Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorg Med Chem. 2007 Mar 1;15(5):2187-97.
DMT10C2	RU	https://pubmed.ncbi.nlm.nih.gov/17210255

DMT10C2	DI	DMT10C2
DMT10C2	DN	AG1295
DMT10C2	MI	TT8FYO9
DMT10C2	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMT10C2	MT	DTT
DMT10C2	MA	Inhibitor
DMT10C2	RN	Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15.
DMT10C2	RU	https://pubmed.ncbi.nlm.nih.gov/16722630

DMT10C2	DI	DMT10C2
DMT10C2	DN	AG1295
DMT10C2	MI	TTI7421
DMT10C2	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMT10C2	MT	DTT
DMT10C2	MA	Inhibitor
DMT10C2	RN	Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorg Med Chem. 2007 Mar 1;15(5):2187-97.
DMT10C2	RU	https://pubmed.ncbi.nlm.nih.gov/17210255

DMT10C2	DI	DMT10C2
DMT10C2	DN	AG1295
DMT10C2	MI	TTUTJGQ
DMT10C2	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMT10C2	MT	DTT
DMT10C2	MA	Inhibitor
DMT10C2	RN	Design, synthesis, and X-ray crystal structures of 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase i... Bioorg Med Chem. 2009 Oct 15;17(20):7324-36.
DMT10C2	RU	https://pubmed.ncbi.nlm.nih.gov/19748785

DMALV1W	DI	DMALV1W
DMALV1W	DN	AG-1350
DMALV1W	MI	TT5FNQT
DMALV1W	MN	Human immunodeficiency virus Protease (HIV PR)
DMALV1W	MT	DTT
DMALV1W	MA	Inhibitor
DMALV1W	RN	Ly316340: A potent HIV-1 protease inhibitor containing a high affinity octahydrothienopyridine hydroxyethylamine isostere. Bioorganic & Medicinal Chemistry Letters Volume 5, Issue 23, 7 December 1995, Pages 2885-2890.
DMALV1W	RU	http://www.sciencedirect.com/science/article/pii/0960894X9500506O

DMS7UPZ	DI	DMS7UPZ
DMS7UPZ	DN	AG-2024
DMS7UPZ	MI	TT1GHVO
DMS7UPZ	MN	Matrix metalloproteinase (MMP)
DMS7UPZ	MT	DTT
DMS7UPZ	MA	Modulator
DMS7UPZ	RN	US patent application no. 6,858,598, Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia.
DMS7UPZ	RU	https://www.google.com.ar/patents/US6858598

DMF2ME4	DI	DMF2ME4
DMF2ME4	DN	AG-3296
DMF2ME4	MI	TT1GHVO
DMF2ME4	MN	Matrix metalloproteinase (MMP)
DMF2ME4	MT	DTT
DMF2ME4	MA	Modulator
DMF2ME4	RN	US patent application no. 6,858,598, Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia.
DMF2ME4	RU	https://www.google.com.ar/patents/US6858598

DM3WKO5	DI	DM3WKO5
DM3WKO5	DN	AG490
DM3WKO5	MI	TTRMX3V
DM3WKO5	MN	Janus kinase 2 (JAK-2)
DM3WKO5	MT	DTT
DM3WKO5	MA	Inhibitor
DM3WKO5	RN	Jak2 tyrosine kinase mediates oxidative stress-induced apoptosis in vascular smooth muscle cells. J Biol Chem. 2004 Aug 13;279(33):34547-52.
DM3WKO5	RU	https://pubmed.ncbi.nlm.nih.gov/15159394

DM3WKO5	DI	DM3WKO5
DM3WKO5	DN	AG490
DM3WKO5	MI	TTT7PJU
DM3WKO5	MN	Janus kinase 3 (JAK-3)
DM3WKO5	MT	DTT
DM3WKO5	MA	Inhibitor
DM3WKO5	RN	Immunotherapy for De Novo renal transplantation: what's in the pipeline Drugs. 2006;66(13):1665-84.
DM3WKO5	RU	https://pubmed.ncbi.nlm.nih.gov/16978033

DMVS6BN	DI	DMVS6BN
DMVS6BN	DN	AGN-193080
DMVS6BN	MI	TTNGILX
DMVS6BN	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMVS6BN	MT	DTT
DMVS6BN	MA	Inhibitor
DMVS6BN	RN	Analogs of UK 14,304: Structural features responsible for alpha2 adrenoceptor activity, Bioorg. Med. Chem. Lett. 5(15):1745-1750 (1995).
DMVS6BN	RU	http://www.sciencedirect.com/science/article/pii/0960894X95002955

DMVS6BN	DI	DMVS6BN
DMVS6BN	DN	AGN-193080
DMVS6BN	MI	TTBRKXS
DMVS6BN	MN	Adrenergic receptor alpha-1B (ADRA1B)
DMVS6BN	MT	DTT
DMVS6BN	MA	Inhibitor
DMVS6BN	RN	Analogs of UK 14,304: Structural features responsible for alpha2 adrenoceptor activity, Bioorg. Med. Chem. Lett. 5(15):1745-1750 (1995).
DMVS6BN	RU	http://www.sciencedirect.com/science/article/pii/0960894X95002955

DMVS6BN	DI	DMVS6BN
DMVS6BN	DN	AGN-193080
DMVS6BN	MI	TT34BHT
DMVS6BN	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMVS6BN	MT	DTT
DMVS6BN	MA	Inhibitor
DMVS6BN	RN	Analogs of UK 14,304: Structural features responsible for alpha2 adrenoceptor activity, Bioorg. Med. Chem. Lett. 5(15):1745-1750 (1995).
DMVS6BN	RU	http://www.sciencedirect.com/science/article/pii/0960894X95002955

DMXY5AV	DI	DMXY5AV
DMXY5AV	DN	AH-9700
DMXY5AV	MI	TT5TPI6
DMXY5AV	MN	Opioid receptor sigma 1 (OPRS1)
DMXY5AV	MT	DTT
DMXY5AV	MA	Modulator
DMXY5AV	RN	Pharmacological actions of AH-9700 on micturition reflex in anesthetized rats. Eur J Pharmacol. 2001 Jan 26;412(2):171-9.
DMXY5AV	RU	https://pubmed.ncbi.nlm.nih.gov/11165228

DMJZ48W	DI	DMJZ48W
DMJZ48W	DN	AHR-16303B
DMJZ48W	MI	TTYSN63
DMJZ48W	MN	5-HT 2 receptor (5HT2R)
DMJZ48W	MT	DTT
DMJZ48W	MA	Modulator
DMJZ48W	RN	AHR-16303B, a novel antagonist of 5-HT2 receptors and voltage-sensitive calcium channels. J Cardiovasc Pharmacol. 1991 Jan;17(1):41-53.
DMJZ48W	RU	https://pubmed.ncbi.nlm.nih.gov/1708055

DMJZ48W	DI	DMJZ48W
DMJZ48W	DN	AHR-16303B
DMJZ48W	MI	TT5HONZ
DMJZ48W	MN	Calcium channel unspecific (CaC)
DMJZ48W	MT	DTT
DMJZ48W	MA	Modulator
DMJZ48W	RN	AHR-16303B, a novel antagonist of 5-HT2 receptors and voltage-sensitive calcium channels. J Cardiovasc Pharmacol. 1991 Jan;17(1):41-53.
DMJZ48W	RU	https://pubmed.ncbi.nlm.nih.gov/1708055

DMJ6BEO	DI	DMJ6BEO
DMJ6BEO	DN	AHR-16462B
DMJ6BEO	MI	TT5HONZ
DMJ6BEO	MN	Calcium channel unspecific (CaC)
DMJ6BEO	MT	DTT
DMJ6BEO	MA	Modulator
DMJ6BEO	RN	A pharmacological and biochemical examination of AHR-16462B, a novel calcium antagonist coronary vasodilator/antihypertensive. Drug Development Research. 01/1991; 22(3):259-271.
DMJ6BEO	RU	http://www.researchgate.net/publication/240125183_A_pharmacological_and_biochemical_examination_of_AHR-16462B_a_novel_calcium_antagonist_coronary_vasodilatorantihypertensive

DMOJTZV	DI	DMOJTZV
DMOJTZV	DN	AJ-3941
DMOJTZV	MI	TT5HONZ
DMOJTZV	MN	Calcium channel unspecific (CaC)
DMOJTZV	MT	DTT
DMOJTZV	MA	Modulator
DMOJTZV	RN	Prevention by the new Ca2+ channel antagonist, AJ-3941, of loss of endothelium-dependent relaxation after subarachnoid hemorrhage in rats. Eur J Pharmacol. 1996 Nov 21;315(3):297-303.
DMOJTZV	RU	https://pubmed.ncbi.nlm.nih.gov/8982668

DM51NI0	DI	DM51NI0
DM51NI0	DN	AK-295
DM51NI0	MI	TTG5QB7
DM51NI0	MN	Calpain-2 (CAPN2)
DM51NI0	MT	DTT
DM51NI0	MA	Inhibitor
DM51NI0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2336).
DM51NI0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2336

DMMTZXV	DI	DMMTZXV
DMMTZXV	DN	AKP-320
DMMTZXV	MI	TTZMAO3
DMMTZXV	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMMTZXV	MT	DTT
DMMTZXV	MA	Modulator
DMMTZXV	RN	Chronic glucose-lowering effects of rosiglitazone and bis(ethylmaltolato) oxovanadium(IV) in ZDF rats. Canadian Journal of Physiology and Pharmacology. 12/2003; 81(11):1049-55.
DMMTZXV	RU	http://www.researchgate.net/publication/8922382_Chronic_glucose-lowering_effects_of_rosiglitazone_and_bis(ethylmaltolato)_oxovanadium(IV)_in_ZDF_rats

DMRYJ40	DI	DMRYJ40
DMRYJ40	DN	AL-0671
DMRYJ40	MI	TT1VOHK
DMRYJ40	MN	Potassium channel unspecific (KC)
DMRYJ40	MT	DTT
DMRYJ40	MA	Opener
DMRYJ40	RN	A possible mechanism of action of a new potassium channel opener, AL0671, on lipid metabolism in obese Zucker rats. J Pharmacol Exp Ther. 1994 Dec;271(3):1666-71.
DMRYJ40	RU	https://pubmed.ncbi.nlm.nih.gov/7996482

DMWNMYS	DI	DMWNMYS
DMWNMYS	DN	ALB-127158(a)
DMWNMYS	MI	TTX4RTB
DMWNMYS	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMWNMYS	MT	DTT
DMWNMYS	MA	Antagonist
DMWNMYS	RN	Clinical pipeline report, company report or official report of Albany Molecular Research (2011).
DMWNMYS	RU	http://www.amriglobal.com/

DMXK4CI	DI	DMXK4CI
DMXK4CI	DN	Albupoietin
DMXK4CI	MI	TTAUX24
DMXK4CI	MN	Erythropoietin Receptor (EPOR)
DMXK4CI	MT	DTT
DMXK4CI	MA	Modulator
DMXK4CI	RN	Clinical pipeline report, company report or official report of cogenesys.
DMXK4CI	RU	http://cogenesys.com/Collaboration.asp

DMQALR5	DI	DMQALR5
DMQALR5	DN	Almorexant
DMQALR5	MI	TT60Q8D
DMQALR5	MN	Orexin receptor type 1 (HCRTR1)
DMQALR5	MT	DTT
DMQALR5	MA	Antagonist
DMQALR5	RN	Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison ... Mol Pharmacol. 2009 Sep;76(3):618-31.
DMQALR5	RU	https://pubmed.ncbi.nlm.nih.gov/19542319

DMT584A	DI	DMT584A
DMT584A	DN	ALN-VEG01
DMT584A	MI	TT3LJ9K
DMT584A	MN	VEGF messenger RNA (VEGF mRNA)
DMT584A	MT	DTT
DMT584A	RN	Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals.
DMT584A	RU	http://investors.alnylam.com/releasedetail.cfm?ReleaseID=446269

DM592WE	DI	DM592WE
DM592WE	DN	ALP-242
DM592WE	MI	TTZBFA0
DM592WE	MN	Protease unspecific (PRO)
DM592WE	MT	DTT
DM592WE	MA	Modulator
DM592WE	RN	Oxidation resistant muteins of antileukoproteinase as potential therapeutic agents. Agents Actions Suppl. 1993;42:111-21.
DM592WE	RU	https://pubmed.ncbi.nlm.nih.gov/8356918

DMGBT9Z	DI	DMGBT9Z
DMGBT9Z	DN	ALS-769
DMGBT9Z	MI	TTZY5KP
DMGBT9Z	MN	Caspase (CASP)
DMGBT9Z	MT	DTT
DMGBT9Z	MA	Inducer
DMGBT9Z	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025089)
DMGBT9Z	RU	http://adisinsight.springer.com/drugs/800025089

DMLN0Y5	DI	DMLN0Y5
DMLN0Y5	DN	Alvameline
DMLN0Y5	MI	TTZ9SOR
DMLN0Y5	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMLN0Y5	MT	DTT
DMLN0Y5	MA	Modulator
DMLN0Y5	RN	In vivo muscarinic cholinergic mediated effects of Lu 25-109, a M1 agonist and M2/M3 antagonist in vitro. Psychopharmacology (Berl). 1998 Jun;137(3):233-40.
DMLN0Y5	RU	https://pubmed.ncbi.nlm.nih.gov/9683000

DMLN0Y5	DI	DMLN0Y5
DMLN0Y5	DN	Alvameline
DMLN0Y5	MI	TTYEG6Q
DMLN0Y5	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMLN0Y5	MT	DTT
DMLN0Y5	MA	Modulator
DMLN0Y5	RN	In vivo muscarinic cholinergic mediated effects of Lu 25-109, a M1 agonist and M2/M3 antagonist in vitro. Psychopharmacology (Berl). 1998 Jun;137(3):233-40.
DMLN0Y5	RU	https://pubmed.ncbi.nlm.nih.gov/9683000

DMLN0Y5	DI	DMLN0Y5
DMLN0Y5	DN	Alvameline
DMLN0Y5	MI	TTQ13Z5
DMLN0Y5	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMLN0Y5	MT	DTT
DMLN0Y5	MA	Modulator
DMLN0Y5	RN	In vivo muscarinic cholinergic mediated effects of Lu 25-109, a M1 agonist and M2/M3 antagonist in vitro. Psychopharmacology (Berl). 1998 Jun;137(3):233-40.
DMLN0Y5	RU	https://pubmed.ncbi.nlm.nih.gov/9683000

DMOIWFM	DI	DMOIWFM
DMOIWFM	DN	AM-577
DMOIWFM	MI	TTMSFAW
DMOIWFM	MN	Cannabinoid receptor 2 (CB2)
DMOIWFM	MT	DTT
DMOIWFM	MA	Agonist
DMOIWFM	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018288)
DMOIWFM	RU	http://adisinsight.springer.com/drugs/800018288

DMGBT63	DI	DMGBT63
DMGBT63	DN	AM-66
DMGBT63	MI	TTRK8B9
DMGBT63	MN	Sodium channel unspecific (NaC)
DMGBT63	MT	DTT
DMGBT63	MA	Blocker
DMGBT63	RN	CA patent application no. 849505, Sodium channel blockers reduce glucagon secretion.
DMGBT63	RU	http://www.google.com/patents/CA2849505A1?cl=en

DMMZNSC	DI	DMMZNSC
DMMZNSC	DN	AM-92016
DMMZNSC	MI	TTLD29N
DMMZNSC	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMMZNSC	MT	DTT
DMMZNSC	MA	Inhibitor
DMMZNSC	RN	Enantiomeric propanolamines as selective N-methyl-D-aspartate 2B receptor antagonists. J Med Chem. 2008 Sep 25;51(18):5506-21.
DMMZNSC	RU	https://pubmed.ncbi.nlm.nih.gov/18800760

DMYIPLH	DI	DMYIPLH
DMYIPLH	DN	AMG-548
DMYIPLH	MI	TTWELHI
DMYIPLH	MN	Stress-activated protein kinase (p38)
DMYIPLH	MT	DTT
DMYIPLH	MA	Inhibitor
DMYIPLH	RN	p38 MAP kinase inhibitors: many are made, but few are chosen. Curr Opin Drug Discov Devel. 2005 Jul;8(4):421-30.
DMYIPLH	RU	https://pubmed.ncbi.nlm.nih.gov/16022178

DMXRQS6	DI	DMXRQS6
DMXRQS6	DN	AMG-8562
DMXRQS6	MI	TTMI6F5
DMXRQS6	MN	Transient receptor potential cation channel V1 (TRPV1)
DMXRQS6	MT	DTT
DMXRQS6	MA	Blocker
DMXRQS6	RN	Analgesic potential of TRPV1 antagonists. Biochem Pharmacol. 2009 Aug 1;78(3):211-6.
DMXRQS6	RU	https://pubmed.ncbi.nlm.nih.gov/19481638

DM3D0WA	DI	DM3D0WA
DM3D0WA	DN	Amidox
DM3D0WA	MI	TTX09M4
DM3D0WA	MN	Ribonucleotide reductase (RIR)
DM3D0WA	MT	DTT
DM3D0WA	MA	Inhibitor
DM3D0WA	RN	Metabolism of the new ribonucleotide reductase inhibitor amidox in the isolated perfused rat liver. Anticancer Res. 2000 Sep- Oct;20(5B):3521-6.
DM3D0WA	RU	https://pubmed.ncbi.nlm.nih.gov/11131656

DM64YJW	DI	DM64YJW
DM64YJW	DN	Amitivir
DM64YJW	MI	TTIU7X1
DM64YJW	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DM64YJW	MT	DTT
DM64YJW	MA	Modulator
DM64YJW	RN	Approaches and strategies for the treatment of influenza virus infections. Antivir Chem Chemother. 1999 Jul;10(4):155-85.
DM64YJW	RU	https://pubmed.ncbi.nlm.nih.gov/10480736

DMDAMBW	DI	DMDAMBW
DMDAMBW	DN	AMPEROZIDE
DMDAMBW	MI	TTJQOD7
DMDAMBW	MN	5-HT 2A receptor (HTR2A)
DMDAMBW	MT	DTT
DMDAMBW	MA	Modulator
DMDAMBW	RN	Action of the 5-HT2A antagonist amperozide on alcohol-induced poikilothermia in rats. Pharmacol Biochem Behav. 1998 Jan;59(1):91-5.
DMDAMBW	RU	https://www.ncbi.nlm.nih.gov/pubmed/9443541

DMW5RNZ	DI	DMW5RNZ
DMW5RNZ	DN	AMR-103
DMW5RNZ	MI	TTEX248
DMW5RNZ	MN	Dopamine D2 receptor (D2R)
DMW5RNZ	MT	DTT
DMW5RNZ	MA	Agonist
DMW5RNZ	RN	ACP-103, a 5-HT2A/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Psychopharmacology (Berl). 2005 Dec;183(2):144-53.
DMW5RNZ	RU	https://pubmed.ncbi.nlm.nih.gov/16220333

DMD82LM	DI	DMD82LM
DMD82LM	DN	AMT-030
DMD82LM	MI	TTF5NVW
DMD82LM	MN	Alanine glyoxylate aminotransferase (AGXT)
DMD82LM	MT	DTT
DMD82LM	MA	Modulator
DMD82LM	RN	Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011 Dec 22;365(25):2357-65.
DMD82LM	RU	https://pubmed.ncbi.nlm.nih.gov/22149959

DMMKOCL	DI	DMMKOCL
DMMKOCL	DN	AMT-050
DMMKOCL	MI	TT7GN3U
DMMKOCL	MN	Apolipoprotein A-I (APOA1)
DMMKOCL	MT	DTT
DMMKOCL	MA	Modulator
DMMKOCL	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026835)
DMMKOCL	RU	http://adisinsight.springer.com/drugs/800026835

DM50HB8	DI	DM50HB8
DM50HB8	DN	AN-10
DM50HB8	MI	TTQO71U
DM50HB8	MN	Hemoglobin (HB)
DM50HB8	MT	DTT
DM50HB8	MA	Modulator
DM50HB8	RN	Genes for Development, Cell Growth and Infectious Diseases, Gabriel Gachelin, 1995. Page(215).
DM50HB8	RU	https://books.google.com.hk/books?id=pFFFUsab0P4C&pg=PA215&lpg=PA215&dq=%22AN-10%22+Hemoglobin&source=bl&ots=qL5psDKJAZ&sig=fpeRIeD9GtukNkelArzs80kTSAo&hl=zh-CN&sa=X&ved=0CBoQ6AEwAGoVChMI-cbDu7DDyAIVzQmOCh3V2QwO#v=onepage&q=%22AN-10%22%20Hemoglobin&f=false

DMMLDG8	DI	DMMLDG8
DMMLDG8	DN	Anatumomab mafenatox
DMMLDG8	MI	TT70MLA
DMMLDG8	MN	Oncotrophoblast glycoprotein 5T4 (TPBG)
DMMLDG8	MT	DTT
DMMLDG8	RN	A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma. Br J Cancer. 2007 Feb 26;96(4):567-74.
DMMLDG8	RU	https://pubmed.ncbi.nlm.nih.gov/17285137

DM35LJC	DI	DM35LJC
DM35LJC	DN	Anpirtoline
DM35LJC	MI	TTSQIFT
DM35LJC	MN	5-HT 1A receptor (HTR1A)
DM35LJC	MT	DTT
DM35LJC	MA	Modulator
DM35LJC	RN	Effects of anpirtoline on regional serotonin synthesis in the rat brain: an autoradiographic study. Nucl Med Biol. 2006 Apr;33(3):325-32.
DM35LJC	RU	https://pubmed.ncbi.nlm.nih.gov/16631081

DM35LJC	DI	DM35LJC
DM35LJC	DN	Anpirtoline
DM35LJC	MI	TTK8CXU
DM35LJC	MN	5-HT 1B receptor (HTR1B)
DM35LJC	MT	DTT
DM35LJC	MA	Modulator
DM35LJC	RN	Effects of anpirtoline on regional serotonin synthesis in the rat brain: an autoradiographic study. Nucl Med Biol. 2006 Apr;33(3):325-32.
DM35LJC	RU	https://pubmed.ncbi.nlm.nih.gov/16631081

DM2EKX5	DI	DM2EKX5
DM2EKX5	DN	Antalarmin
DM2EKX5	MI	TT7EFHR
DM2EKX5	MN	Corticotropin-releasing factor receptor 1 (CRHR1)
DM2EKX5	MT	DTT
DM2EKX5	MA	Antagonist
DM2EKX5	RN	Chronic administration of the non-peptide CRH type 1 receptor antagonist antalarmin does not blunt hypothalamic-pituitary-adrenal axis responses to acute immobilization stress. Life Sci. 1999;65(4):PL53-8.
DM2EKX5	RU	https://pubmed.ncbi.nlm.nih.gov/10421433

DMXI185	DI	DMXI185
DMXI185	DN	Anti-IFN gamma
DMXI185	MI	TTG043C
DMXI185	MN	Tumor necrosis factor receptor type I (TNF-R1)
DMXI185	MT	DTT
DMXI185	RN	Secretion of a TNFR:Fc fusion protein following pulmonary administration of pseudotyped adeno-associated virus vectors. J Virol. 2004 Nov;78(22):12355-65.
DMXI185	RU	https://pubmed.ncbi.nlm.nih.gov/15507622

DMXKZDU	DI	DMXKZDU
DMXKZDU	DN	Antova
DMXKZDU	MI	TTIJP3Q
DMXKZDU	MN	TNF related activation protein (CD40LG)
DMXKZDU	MT	DTT
DMXKZDU	MA	Modulator
DMXKZDU	RN	CD40 and Autoimmunity: The Dark Side of a Great Activator
DMXKZDU	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2753170

DMOJP9E	DI	DMOJP9E
DMOJP9E	DN	ANX-201
DMOJP9E	MI	TT84ETX
DMOJP9E	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMOJP9E	MT	DTT
DMOJP9E	MA	Modulator
DMOJP9E	RN	DOI: 10.1038/scibx.2008.591
DMOJP9E	RU	http://www.nature.com/scibx/journal/v1/n25/full/scibx.2008.591.html

DM5B72D	DI	DM5B72D
DM5B72D	DN	AP22408
DM5B72D	MI	TT6PKBN
DM5B72D	MN	Proto-oncogene c-Src (SRC)
DM5B72D	MT	DTT
DM5B72D	MA	Inhibitor
DM5B72D	RN	Structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activity. Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9373-8.
DM5B72D	RU	https://pubmed.ncbi.nlm.nih.gov/10944210

DM7LAXF	DI	DM7LAXF
DM7LAXF	DN	AP-227
DM7LAXF	MI	TTOFYT1
DM7LAXF	MN	Prostacyclin receptor (PTGIR)
DM7LAXF	MT	DTT
DM7LAXF	MA	Inhibitor
DM7LAXF	RN	Molecular design of novel PGI2 agonists without PG skeleton, Bioorg. Med. Chem. Lett. 5(10):1071-1076 (1995).
DM7LAXF	RU	http://www.sciencedirect.com/science/article/pii/0960894X9500168S

DMXLJBA	DI	DMXLJBA
DMXLJBA	DN	AP-23588
DMXLJBA	MI	TTJSQEF
DMXLJBA	MN	Tyrosine-protein kinase (PTK)
DMXLJBA	MT	DTT
DMXLJBA	MA	Inhibitor
DMXLJBA	RN	Foye's Principles of Medicinal Chemistry, Thomas L. Lemke, David A. Williams. 2008. Page(950).
DMXLJBA	RU	https://books.google.com.hk/books?id=R0W1ErpsQpkC&pg=PA950&lpg=PA950&dq=%22AP-23588%22++Protein+tyrosine+kinase&source=bl&ots=oCPoj5ZYqs&sig=4H-SJKuzkNOCopt3dSUJP3i2EEA&hl=zh-CN&sa=X&ved=0CCEQ6AEwAWoVChMIv4zt6NC_yAIVEHCOCh3qywXw#v=onepage&q=%22AP-23588%22%20%20Protein%20tyrosine%20kinase&f=false

DMBA4DK	DI	DMBA4DK
DMBA4DK	DN	APC-6336
DMBA4DK	MI	TT3C1VN
DMBA4DK	MN	Enzyme unspecific (Enz)
DMBA4DK	MT	DTT
DMBA4DK	MA	Inhibitor
DMBA4DK	RN	CN patent application no. 103263414, Application of 2,2'-(1,4-phenylene)di(benzimidazole-5-carboxylic acid) in preparation of antitumor drug.
DMBA4DK	RU	http://www.google.com/patents/CN103263414A?cl=en

DMYD04O	DI	DMYD04O
DMYD04O	DN	APF-580
DMYD04O	MI	TTN4QDT
DMYD04O	MN	Opioid receptor (OPR)
DMYD04O	MT	DTT
DMYD04O	MA	Modulator
DMYD04O	RN	WO patent application no. 2010,0094,51, Long-acting injectable analgesic formulations for animals.
DMYD04O	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20100121&CC=WO&NR=2010009451A2&KC=A2

DMIYTPE	DI	DMIYTPE
DMIYTPE	DN	Apolipoprotein E
DMIYTPE	MI	TTKS9CB
DMIYTPE	MN	Apolipoprotein E (APOE)
DMIYTPE	MT	DTT
DMIYTPE	MA	Modulator
DMIYTPE	RN	Apolipoprotein E: a potent inhibitor of endothelial and tumor cell proliferation. J Cell Biochem. 1994 Mar;54(3):299-308.
DMIYTPE	RU	https://pubmed.ncbi.nlm.nih.gov/8200910

DMPMW03	DI	DMPMW03
DMPMW03	DN	AQ-RA-741
DMPMW03	MI	TTYEG6Q
DMPMW03	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMPMW03	MT	DTT
DMPMW03	MA	Modulator
DMPMW03	RN	Pharmacological profile of selective muscarinic receptor antagonists on guinea-pig ileal smooth muscle. Eur J Pharmacol. 1994 Mar 3;253(3):275-81.
DMPMW03	RU	https://pubmed.ncbi.nlm.nih.gov/8200421

DMHU1E8	DI	DMHU1E8
DMHU1E8	DN	AR177
DMHU1E8	MI	TT5FH9Y
DMHU1E8	MN	Human immunodeficiency virus Integrase (HIV IN)
DMHU1E8	MT	DTT
DMHU1E8	MA	Inhibitor
DMHU1E8	RN	Specific inhibition of human immunodeficiency virus type 1 (HIV-1) integration in cell culture: putative inhibitors of HIV-1 integrase. Antimicrob Agents Chemother. 2001 Sep;45(9):2510-6.
DMHU1E8	RU	https://pubmed.ncbi.nlm.nih.gov/11502522

DMUI81C	DI	DMUI81C
DMUI81C	DN	AR-709
DMUI81C	MI	TTV8DM2
DMUI81C	MN	Bacterial Dihydrofolate reductase (Bact DHFR)
DMUI81C	MT	DTT
DMUI81C	MA	Modulator
DMUI81C	RN	Activity of the Diaminopyrimidine AR-709 against Recently Collected Multidrug-Resistant Isolates of Invasive Streptococcus pneumoniae from North America
DMUI81C	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2258536

DMQ52JR	DI	DMQ52JR
DMQ52JR	DN	ARC239
DMQ52JR	MI	TT2NUT5
DMQ52JR	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMQ52JR	MT	DTT
DMQ52JR	MA	Antagonist
DMQ52JR	RN	Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries. Invest Ophthalmol Vis Sci. 2001 Aug;42(9):2049-55.
DMQ52JR	RU	https://pubmed.ncbi.nlm.nih.gov/11481271

DM9HZ8D	DI	DM9HZ8D
DM9HZ8D	DN	AR-C-89855
DM9HZ8D	MI	TT2CJVK
DM9HZ8D	MN	Adrenergic receptor beta-2 (ADRB2)
DM9HZ8D	MT	DTT
DM9HZ8D	MA	Agonist
DM9HZ8D	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013263)
DM9HZ8D	RU	http://adisinsight.springer.com/drugs/800013263

DMRXB74	DI	DMRXB74
DMRXB74	DN	ARISTEROMYCIN
DMRXB74	MI	TTK25J1
DMRXB74	MN	Adenosine A1 receptor (ADORA1)
DMRXB74	MT	DTT
DMRXB74	MA	Inhibitor
DMRXB74	RN	Methanocarba analogues of purine nucleosides as potent and selective adenosine receptor agonists. J Med Chem. 2000 Jun 1;43(11):2196-203.
DMRXB74	RU	https://pubmed.ncbi.nlm.nih.gov/10841798

DMRXB74	DI	DMRXB74
DMRXB74	DN	ARISTEROMYCIN
DMRXB74	MI	TTM2AOE
DMRXB74	MN	Adenosine A2a receptor (ADORA2A)
DMRXB74	MT	DTT
DMRXB74	MA	Inhibitor
DMRXB74	RN	Methanocarba analogues of purine nucleosides as potent and selective adenosine receptor agonists. J Med Chem. 2000 Jun 1;43(11):2196-203.
DMRXB74	RU	https://pubmed.ncbi.nlm.nih.gov/10841798

DMRXB74	DI	DMRXB74
DMRXB74	DN	ARISTEROMYCIN
DMRXB74	MI	TTE2KUJ
DMRXB74	MN	Adenosylhomocysteinase (AHCY)
DMRXB74	MT	DTT
DMRXB74	MA	Inhibitor
DMRXB74	RN	Synthesis of 2-modified aristeromycins and their analogs as potent inhibitors against Plasmodium falciparum S-adenosyl-L-homocysteine hydrolase. Bioorg Med Chem. 2008 Apr 1;16(7):3809-15.
DMRXB74	RU	https://pubmed.ncbi.nlm.nih.gov/18295495

DMRYQBE	DI	DMRYQBE
DMRYQBE	DN	AS-1406
DMRYQBE	MI	TTRBUYN
DMRYQBE	MN	Ribonuclease (RNase)
DMRYQBE	MT	DTT
DMRYQBE	MA	Modulator
DMRYQBE	RN	WO patent application no. 2005,0657,17, Liquid formulations of antibody conjugates.
DMRYQBE	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20050721&CC=WO&NR=2005065717A2&KC=A2

DMH78J6	DI	DMH78J6
DMH78J6	DN	AS-602305
DMH78J6	MI	TTSCIUP
DMH78J6	MN	Oxytocin receptor (OTR)
DMH78J6	MT	DTT
DMH78J6	MA	Antagonist
DMH78J6	RN	Clinical pipeline report, company report or official report of darkpharma.
DMH78J6	RU	http://www.darkpharma.nl/uploads/7/3/2/8/7328594/journal.pmed.0050022.pdf

DMIFDPL	DI	DMIFDPL
DMIFDPL	DN	AS-8112
DMIFDPL	MI	TTPC4TU
DMIFDPL	MN	5-HT 3A receptor (HTR3A)
DMIFDPL	MT	DTT
DMIFDPL	MA	Antagonist
DMIFDPL	RN	Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar;11(1):137-51.
DMIFDPL	RU	https://pubmed.ncbi.nlm.nih.gov/16503832

DMIFDPL	DI	DMIFDPL
DMIFDPL	DN	AS-8112
DMIFDPL	MI	TT4C8EA
DMIFDPL	MN	Dopamine D3 receptor (D3R)
DMIFDPL	MT	DTT
DMIFDPL	MA	Antagonist
DMIFDPL	RN	Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar;11(1):137-51.
DMIFDPL	RU	https://pubmed.ncbi.nlm.nih.gov/16503832

DMS2FB3	DI	DMS2FB3
DMS2FB3	DN	ATLIPROFEN METHYL ESTER
DMS2FB3	MI	TT8NGED
DMS2FB3	MN	Prostaglandin G/H synthase 1 (COX-1)
DMS2FB3	MT	DTT
DMS2FB3	MA	Modulator
DMS2FB3	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMS2FB3	RU	https://www.fda.gov/

DMS2FB3	DI	DMS2FB3
DMS2FB3	DN	ATLIPROFEN METHYL ESTER
DMS2FB3	MI	TTVKILB
DMS2FB3	MN	Prostaglandin G/H synthase 2 (COX-2)
DMS2FB3	MT	DTT
DMS2FB3	MA	Modulator
DMS2FB3	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMS2FB3	RU	https://www.fda.gov/

DM4UTXV	DI	DM4UTXV
DM4UTXV	DN	AVE0675
DM4UTXV	MI	TTSHG0T
DM4UTXV	MN	Toll-like receptor 9 (TLR9)
DM4UTXV	MT	DTT
DM4UTXV	MA	Agonist
DM4UTXV	RN	Pharma & Vaccines. Product Development Pipeline. April 29 2009.
DM4UTXV	RU	http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf

DMD8ZM1	DI	DMD8ZM1
DMD8ZM1	DN	AWD-23-111
DMD8ZM1	MI	TT1VOHK
DMD8ZM1	MN	Potassium channel unspecific (KC)
DMD8ZM1	MT	DTT
DMD8ZM1	MA	Opener
DMD8ZM1	RN	The new antiarrhythmic substance AWD 23-111 inhibits the delayed rectifier potassium current (IK) in guinea pig ventricular myocytes. Pharmazie. 1999 Jan;54(1):61-8.
DMD8ZM1	RU	https://pubmed.ncbi.nlm.nih.gov/9987799

DMJH7IX	DI	DMJH7IX
DMJH7IX	DN	AZD-0275
DMJH7IX	MI	TTQR8Z6
DMJH7IX	MN	Chemokine receptor (CHR)
DMJH7IX	MT	DTT
DMJH7IX	MA	Antagonist
DMJH7IX	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019127)
DMJH7IX	RU	http://adisinsight.springer.com/drugs/800019127

DMS7INR	DI	DMS7INR
DMS7INR	DN	AZD-0902
DMS7INR	MI	TTM7WCE
DMS7INR	MN	Ion channel unspecific (IC)
DMS7INR	MT	DTT
DMS7INR	MA	Antagonist
DMS7INR	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019129)
DMS7INR	RU	http://adisinsight.springer.com/drugs/800019129

DMPCFRN	DI	DMPCFRN
DMPCFRN	DN	AZD-1134
DMPCFRN	MI	TTK8CXU
DMPCFRN	MN	5-HT 1B receptor (HTR1B)
DMPCFRN	MT	DTT
DMPCFRN	MA	Antagonist
DMPCFRN	RN	N-methyl-3H3AZ10419369 binding to the 5-HT1B receptor: in vitro characterization and in vivo receptor occupancy. J Pharmacol Exp Ther. 2009 Jul;330(1):342-51.
DMPCFRN	RU	https://pubmed.ncbi.nlm.nih.gov/19401496

DM3WFB5	DI	DM3WFB5
DM3WFB5	DN	AZD3409
DM3WFB5	MI	TTXQKM3
DM3WFB5	MN	Farnesyl protein transferase (Ftase)
DM3WFB5	MT	DTT
DM3WFB5	MA	Inhibitor
DM3WFB5	RN	AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib. Breast Cancer Res Treat. 2007 May;102(3):275-82.
DM3WFB5	RU	https://pubmed.ncbi.nlm.nih.gov/17004112

DMABY43	DI	DMABY43
DMABY43	DN	AZD-5106
DMABY43	MI	TTYO0A3
DMABY43	MN	Substance-K receptor (TACR2)
DMABY43	MT	DTT
DMABY43	MA	Antagonist
DMABY43	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015341)
DMABY43	RU	http://adisinsight.springer.com/drugs/800015341

DMQUX28	DI	DMQUX28
DMQUX28	DN	AZD5672
DMQUX28	MI	TT2CEJG
DMQUX28	MN	C-C chemokine receptor type 5 (CCR5)
DMQUX28	MT	DTT
DMQUX28	MA	Antagonist
DMQUX28	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DMQUX28	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DMVP4E5	DI	DMVP4E5
DMVP4E5	DN	AZD6482
DMVP4E5	MI	TTTHBCA
DMVP4E5	MN	PI3-kinase beta (PIK3CB)
DMVP4E5	MT	DTT
DMVP4E5	MA	Modulator
DMVP4E5	RN	Human target validation of phosphoinositide 3-kinase (PI3K)beta: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kbeta inhibitor. J Thromb Haemost. 2012 Oct;10(10):2127-36.
DMVP4E5	RU	https://pubmed.ncbi.nlm.nih.gov/22906130

DMZ90OV	DI	DMZ90OV
DMZ90OV	DN	AZD-6942
DMZ90OV	MI	TTFZYTO
DMZ90OV	MN	C-C chemokine receptor type 2 (CCR2)
DMZ90OV	MT	DTT
DMZ90OV	MA	Antagonist
DMZ90OV	RN	Patent EP2727944 A1.
DMZ90OV	RU	http://www.google.com/patents/EP2727944A1?cl=en

DMU6L4I	DI	DMU6L4I
DMU6L4I	DN	AZD-7545
DMU6L4I	MI	TTJGCKM
DMU6L4I	MN	Pyruvate dehydrogenase kinase 2 (PDHK2)
DMU6L4I	MT	DTT
DMU6L4I	MA	Inhibitor
DMU6L4I	RN	Recognition of the inner lipoyl-bearing domain of dihydrolipoyl transacetylase and of the blood glucose-lowering compound AZD7545 by pyruvate dehyd... Biochemistry. 2007 Jul 24;46(29):8592-602.
DMU6L4I	RU	https://pubmed.ncbi.nlm.nih.gov/17602666

DMFE3CD	DI	DMFE3CD
DMFE3CD	DN	AZD-9935
DMFE3CD	MI	TTGKNB4
DMFE3CD	MN	Epidermal growth factor receptor (EGFR)
DMFE3CD	MT	DTT
DMFE3CD	MA	Antagonist
DMFE3CD	RN	WO patent application no. 2009,0582,67, Benzomorpholine derivatives and methods of use.
DMFE3CD	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20090507&CC=WO&NR=2009058267A2&KC=A2

DMFE3CD	DI	DMFE3CD
DMFE3CD	DN	AZD-9935
DMFE3CD	MI	TTVJ1D8
DMFE3CD	MN	Vascular endothelial growth factor receptor (VEGFR)
DMFE3CD	MT	DTT
DMFE3CD	MA	Antagonist
DMFE3CD	RN	WO patent application no. 2009,0582,67, Benzomorpholine derivatives and methods of use.
DMFE3CD	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20090507&CC=WO&NR=2009058267A2&KC=A2

DMLCSRF	DI	DMLCSRF
DMLCSRF	DN	AZM-131
DMLCSRF	MI	TTXMY0J
DMLCSRF	MN	Pancreatic triacylglycerol lipase (PNLIP)
DMLCSRF	MT	DTT
DMLCSRF	MA	Modulator
DMLCSRF	RN	US patent application no. 7217,697, Glucopyranosyloxypyrazole derivative medicinal composition containing the same medicinal use thereof and intermediate therefor.
DMLCSRF	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20040909&CC=US&NR=2004176308A1&KC=A1

DMIWC64	DI	DMIWC64
DMIWC64	DN	AZM-134
DMIWC64	MI	TTVIMDE
DMIWC64	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMIWC64	MT	DTT
DMIWC64	MA	Modulator
DMIWC64	RN	US patent application no. 2011,0171,312, Modified therapeutic peptides, methods of their preparation and use.
DMIWC64	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20110714&CC=US&NR=2011171312A1&KC=A1

DME6OFU	DI	DME6OFU
DME6OFU	DN	B-428
DME6OFU	MI	TTGY7WI
DME6OFU	MN	Urokinase-type plasminogen activator (PLAU)
DME6OFU	MT	DTT
DME6OFU	MA	Inhibitor
DME6OFU	RN	Natural and synthetic inhibitors of the tumor-associated serine protease urokinase-type plasminogen activator. Adv Exp Med Biol. 2000;477:331-41.
DME6OFU	RU	https://pubmed.ncbi.nlm.nih.gov/10849761

DM8I5UF	DI	DM8I5UF
DM8I5UF	DN	B-5354a
DM8I5UF	MI	TTOHFIY
DM8I5UF	MN	Sphingosine kinase 1 (SPHK1)
DM8I5UF	MT	DTT
DM8I5UF	MA	Inhibitor
DM8I5UF	RN	Characterization of B-5354c, a new sphingosine kinase inhibitor, produced by a marine bacterium. J Antibiot (Tokyo). 2000 Aug;53(8):759-64.
DM8I5UF	RU	https://pubmed.ncbi.nlm.nih.gov/11079797

DM5EKPM	DI	DM5EKPM
DM5EKPM	DN	B-581
DM5EKPM	MI	TTV8ETH
DM5EKPM	MN	Protein prenyl transferase (PPTF)
DM5EKPM	MT	DTT
DM5EKPM	MA	Inhibitor
DM5EKPM	RN	Spectroscopic study of fluorescent peptides for prenyl transferase assays. J Pharm Biomed Anal. 2005 Mar 9;37(3):417-22.
DM5EKPM	RU	https://pubmed.ncbi.nlm.nih.gov/15740898

DM1IO9X	DI	DM1IO9X
DM1IO9X	DN	B-956
DM1IO9X	MI	TT7WZIJ
DM1IO9X	MN	CAAX farnesyltransferase beta (FNTB)
DM1IO9X	MT	DTT
DM1IO9X	MA	Modulator
DM1IO9X	RN	Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res. 1995 Nov 15;55(22):5310-4.
DM1IO9X	RU	https://pubmed.ncbi.nlm.nih.gov/7585593

DM8AGOE	DI	DM8AGOE
DM8AGOE	DN	BABIM
DM8AGOE	MI	TTM1TDX
DM8AGOE	MN	Tryptase alpha/beta-1 (Tryptase)
DM8AGOE	MT	DTT
DM8AGOE	MA	Inhibitor
DM8AGOE	RN	Inhibitors of tryptase for the treatment of mast cell-mediated diseases. Curr Pharm Des. 1998 Oct;4(5):381-96.
DM8AGOE	RU	https://pubmed.ncbi.nlm.nih.gov/10197050

DMY1TLZ	DI	DMY1TLZ
DMY1TLZ	DN	Baicalin
DMY1TLZ	MI	TTNGKET
DMY1TLZ	MN	Prolyl endopeptidase (PREP)
DMY1TLZ	MT	DTT
DMY1TLZ	MA	Inhibitor
DMY1TLZ	RN	Inhibitors of prolyl oligopeptidases for the therapy of human diseases: defining diseases and inhibitors. J Med Chem. 2010 May 13;53(9):3423-38.
DMY1TLZ	RU	https://pubmed.ncbi.nlm.nih.gov/20058865

DMDLN9E	DI	DMDLN9E
DMDLN9E	DN	BALANOL
DMDLN9E	MI	TTW4Y2M
DMDLN9E	MN	cAMP protein kinase type II-beta (PRKAR2B)
DMDLN9E	MT	DTT
DMDLN9E	MA	Inhibitor
DMDLN9E	RN	Joys of molecules. 2. Endeavors in chemical biology and medicinal chemistry. J Med Chem. 2005 Sep 8;48(18):5613-38. Address;
DMDLN9E	RU	https://pubmed.ncbi.nlm.nih.gov/16134928

DMDLN9E	DI	DMDLN9E
DMDLN9E	DN	BALANOL
DMDLN9E	MI	TTER6YH
DMDLN9E	MN	Casein kinase II alpha (CSNK2A1)
DMDLN9E	MT	DTT
DMDLN9E	MA	Inhibitor
DMDLN9E	RN	Synthesis and protein kinase C inhibitory activities of acyclic balanol analogs that are highly selective for protein kinase C over protein kinase A. J Med Chem. 1996 Dec 20;39(26):5215-27.
DMDLN9E	RU	https://pubmed.ncbi.nlm.nih.gov/8978850

DMDLN9E	DI	DMDLN9E
DMDLN9E	DN	BALANOL
DMDLN9E	MI	TTYVI76
DMDLN9E	MN	Fungal Protein kinase A (Fung ypkA)
DMDLN9E	MT	DTT
DMDLN9E	MA	Inhibitor
DMDLN9E	RN	Joys of molecules. 2. Endeavors in chemical biology and medicinal chemistry. J Med Chem. 2005 Sep 8;48(18):5613-38. Address;
DMDLN9E	RU	https://pubmed.ncbi.nlm.nih.gov/16134928

DMDLN9E	DI	DMDLN9E
DMDLN9E	DN	BALANOL
DMDLN9E	MI	TT7A1BO
DMDLN9E	MN	PKC-delta messenger RNA (PRKCD mRNA)
DMDLN9E	MT	DTT
DMDLN9E	MA	Inhibitor
DMDLN9E	RN	Evaluation of differential hypoxic cytotoxicity and electrochemical studies of nitro 5-deazaflavins, Bioorg. Med. Chem. Lett. 5(18):2155-2160 (1995).
DMDLN9E	RU	http://www.sciencedirect.com/science/article/pii/0960894X9500352T

DMDLN9E	DI	DMDLN9E
DMDLN9E	DN	BALANOL
DMDLN9E	MI	TT57MT2
DMDLN9E	MN	PKC-epsilon messenger RNA (PRKCE mRNA)
DMDLN9E	MT	DTT
DMDLN9E	MA	Inhibitor
DMDLN9E	RN	Evaluation of differential hypoxic cytotoxicity and electrochemical studies of nitro 5-deazaflavins, Bioorg. Med. Chem. Lett. 5(18):2155-2160 (1995).
DMDLN9E	RU	http://www.sciencedirect.com/science/article/pii/0960894X9500352T

DMDLN9E	DI	DMDLN9E
DMDLN9E	DN	BALANOL
DMDLN9E	MI	TTONI0R
DMDLN9E	MN	PKC-eta messenger RNA (PRKCH mRNA)
DMDLN9E	MT	DTT
DMDLN9E	MA	Inhibitor
DMDLN9E	RN	Evaluation of differential hypoxic cytotoxicity and electrochemical studies of nitro 5-deazaflavins, Bioorg. Med. Chem. Lett. 5(18):2155-2160 (1995).
DMDLN9E	RU	http://www.sciencedirect.com/science/article/pii/0960894X9500352T

DMDLN9E	DI	DMDLN9E
DMDLN9E	DN	BALANOL
DMDLN9E	MI	TTBSN0L
DMDLN9E	MN	PKC-zeta messenger RNA (PRKCZ mRNA)
DMDLN9E	MT	DTT
DMDLN9E	MA	Inhibitor
DMDLN9E	RN	Evaluation of differential hypoxic cytotoxicity and electrochemical studies of nitro 5-deazaflavins, Bioorg. Med. Chem. Lett. 5(18):2155-2160 (1995).
DMDLN9E	RU	http://www.sciencedirect.com/science/article/pii/0960894X9500352T

DMDLN9E	DI	DMDLN9E
DMDLN9E	DN	BALANOL
DMDLN9E	MI	TT5U49F
DMDLN9E	MN	PRKACA messenger RNA (PRKACA mRNA)
DMDLN9E	MT	DTT
DMDLN9E	MA	Inhibitor
DMDLN9E	RN	Joys of molecules. 2. Endeavors in chemical biology and medicinal chemistry. J Med Chem. 2005 Sep 8;48(18):5613-38. Address;
DMDLN9E	RU	https://pubmed.ncbi.nlm.nih.gov/16134928

DMDLN9E	DI	DMDLN9E
DMDLN9E	DN	BALANOL
DMDLN9E	MI	TTFJ8Q1
DMDLN9E	MN	Protein kinase C alpha (PRKCA)
DMDLN9E	MT	DTT
DMDLN9E	MA	Inhibitor
DMDLN9E	RN	Evaluation of differential hypoxic cytotoxicity and electrochemical studies of nitro 5-deazaflavins, Bioorg. Med. Chem. Lett. 5(18):2155-2160 (1995).
DMDLN9E	RU	http://www.sciencedirect.com/science/article/pii/0960894X9500352T

DMDLN9E	DI	DMDLN9E
DMDLN9E	DN	BALANOL
DMDLN9E	MI	TTYPXQF
DMDLN9E	MN	Protein kinase C beta (PRKCB)
DMDLN9E	MT	DTT
DMDLN9E	MA	Inhibitor
DMDLN9E	RN	Evaluation of differential hypoxic cytotoxicity and electrochemical studies of nitro 5-deazaflavins, Bioorg. Med. Chem. Lett. 5(18):2155-2160 (1995).
DMDLN9E	RU	http://www.sciencedirect.com/science/article/pii/0960894X9500352T

DMDLN9E	DI	DMDLN9E
DMDLN9E	DN	BALANOL
DMDLN9E	MI	TTRFOXJ
DMDLN9E	MN	Protein kinase C gamma (PRKCG)
DMDLN9E	MT	DTT
DMDLN9E	MA	Inhibitor
DMDLN9E	RN	Evaluation of differential hypoxic cytotoxicity and electrochemical studies of nitro 5-deazaflavins, Bioorg. Med. Chem. Lett. 5(18):2155-2160 (1995).
DMDLN9E	RU	http://www.sciencedirect.com/science/article/pii/0960894X9500352T

DMTMS3L	DI	DMTMS3L
DMTMS3L	DN	Barucainide
DMTMS3L	MI	TT05DLS
DMTMS3L	MN	E3 ubiquitin-protein ligase COP1 (RFWD2)
DMTMS3L	MT	DTT
DMTMS3L	MA	Modulator
DMTMS3L	RN	Barucainide, a novel class Ib antiarrhythmic agent with a slow kinetic property: electrophysiologic observations in isolated canine and rabbit cardiac muscle. Am Heart J. 1990 May;119(5):1050-60.
DMTMS3L	RU	https://pubmed.ncbi.nlm.nih.gov/2330863

DM7LZFQ	DI	DM7LZFQ
DM7LZFQ	DN	BAY-17-1998
DM7LZFQ	MI	TTM1TDX
DM7LZFQ	MN	Tryptase alpha/beta-1 (Tryptase)
DM7LZFQ	MT	DTT
DM7LZFQ	MA	Modulator
DM7LZFQ	RN	Bayer AG to Develop Arris Asthma Compound; Arris to Receive Milestone Payment. 1996 Business Wire
DM7LZFQ	RU	http://www.thefreelibrary.com/Axys+Pharmaceuticals+Announces+Bayer+AG's+Decision+to+Discontinue...-a062275428

DMPUG18	DI	DMPUG18
DMPUG18	DN	BAY-39-9624
DMPUG18	MI	TTUV8G9
DMPUG18	MN	Progesterone receptor (PGR)
DMPUG18	MT	DTT
DMPUG18	MA	Agonist
DMPUG18	RN	Bayer is seeking an exclusive licensee for its end-of-Phase I progestinagonist Bay 39-9624. Thepharmaletter. 29-04-2002.
DMPUG18	RU	http://www.thepharmaletter.com/article/bayer-offers-license-opportunity

DM40ORU	DI	DM40ORU
DM40ORU	DN	BAY-44-3428
DM40ORU	MI	TTM1TDX
DM40ORU	MN	Tryptase alpha/beta-1 (Tryptase)
DM40ORU	MT	DTT
DM40ORU	MA	Inhibitor
DM40ORU	RN	Bayer AG to Develop Arris Asthma Compound; Arris to Receive Milestone Payment. 1996 Business Wire
DM40ORU	RU	http://www.thefreelibrary.com/Axys+Pharmaceuticals+Announces+Bayer+AG's+Decision+to+Discontinue...-a062275428

DMAKXN3	DI	DMAKXN3
DMAKXN3	DN	BAY-50-9062
DMAKXN3	MI	TTVC5K6
DMAKXN3	MN	Estradiol 17 beta-dehydrogenase (17-beta-HSD)
DMAKXN3	MT	DTT
DMAKXN3	MA	Inhibitor
DMAKXN3	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015540)
DMAKXN3	RU	http://adisinsight.springer.com/drugs/800015540

DM69EHF	DI	DM69EHF
DM69EHF	DN	BAY-793
DM69EHF	MI	TT5FNQT
DM69EHF	MN	Human immunodeficiency virus Protease (HIV PR)
DM69EHF	MT	DTT
DM69EHF	MA	Modulator
DM69EHF	RN	HIV protease inhibitor HOE/BAY 793, structure-activity relationships in a series of C2-symmetric diols. Bioorg Med Chem. 1995 May;3(5):559-71.
DM69EHF	RU	https://pubmed.ncbi.nlm.nih.gov/7648204

DMZGFM6	DI	DMZGFM6
DMZGFM6	DN	BAY-Z-4305
DMZGFM6	MI	TT84ETX
DMZGFM6	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMZGFM6	MT	DTT
DMZGFM6	MA	Inhibitor
DMZGFM6	RN	US patent application no. 2008,0161,324, Compositions and methods for treatment of viral diseases.
DMZGFM6	RU	http://www.google.com/patents/US20080161324

DM7GH5Z	DI	DM7GH5Z
DM7GH5Z	DN	BB-1101
DM7GH5Z	MI	TTMX39J
DM7GH5Z	MN	Matrix metalloproteinase-1 (MMP-1)
DM7GH5Z	MT	DTT
DM7GH5Z	MA	Inhibitor
DM7GH5Z	RN	Broad spectrum matrix metalloproteinase inhibitors: an examination of succinamide hydroxamate inhibitors with P1 C alpha gem-disubstitution. Bioorg Med Chem Lett. 1998 Jun 16;8(12):1443-8.
DM7GH5Z	RU	https://pubmed.ncbi.nlm.nih.gov/9873367

DM7GH5Z	DI	DM7GH5Z
DM7GH5Z	DN	BB-1101
DM7GH5Z	MI	TTLM12X
DM7GH5Z	MN	Matrix metalloproteinase-2 (MMP-2)
DM7GH5Z	MT	DTT
DM7GH5Z	MA	Inhibitor
DM7GH5Z	RN	Broad spectrum matrix metalloproteinase inhibitors: an examination of succinamide hydroxamate inhibitors with P1 C alpha gem-disubstitution. Bioorg Med Chem Lett. 1998 Jun 16;8(12):1443-8.
DM7GH5Z	RU	https://pubmed.ncbi.nlm.nih.gov/9873367

DM7GH5Z	DI	DM7GH5Z
DM7GH5Z	DN	BB-1101
DM7GH5Z	MI	TTUZ2L5
DM7GH5Z	MN	Matrix metalloproteinase-3 (MMP-3)
DM7GH5Z	MT	DTT
DM7GH5Z	MA	Inhibitor
DM7GH5Z	RN	Broad spectrum matrix metalloproteinase inhibitors: an examination of succinamide hydroxamate inhibitors with P1 C alpha gem-disubstitution. Bioorg Med Chem Lett. 1998 Jun 16;8(12):1443-8.
DM7GH5Z	RU	https://pubmed.ncbi.nlm.nih.gov/9873367

DM7GH5Z	DI	DM7GH5Z
DM7GH5Z	DN	BB-1101
DM7GH5Z	MI	TTGA1IV
DM7GH5Z	MN	Matrix metalloproteinase-8 (MMP-8)
DM7GH5Z	MT	DTT
DM7GH5Z	MA	Inhibitor
DM7GH5Z	RN	New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors. J Med Chem. 1999 Nov 18;42(23):4890-908.
DM7GH5Z	RU	https://pubmed.ncbi.nlm.nih.gov/10579851

DMWAKC8	DI	DMWAKC8
DMWAKC8	DN	BB-1433
DMWAKC8	MI	TT1GHVO
DMWAKC8	MN	Matrix metalloproteinase (MMP)
DMWAKC8	MT	DTT
DMWAKC8	MA	Inhibitor
DMWAKC8	RN	Anti-arthritic activity of hydroxamic acid-based pseudopeptide inhibitors of matrix metalloproteinases and TNF alpha processing. Inflamm Res. 1997 Jun;46(6):211-5.
DMWAKC8	RU	https://pubmed.ncbi.nlm.nih.gov/9243304

DM6ETM8	DI	DM6ETM8
DM6ETM8	DN	BB-2275
DM6ETM8	MI	TTZXH48
DM6ETM8	MN	TNF receptor (TNFR)
DM6ETM8	MT	DTT
DM6ETM8	MA	Modulator
DM6ETM8	RN	Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF alpha processing in RA sy... J Clin Invest. 1996 Jun 15;97(12):2833-41.
DM6ETM8	RU	https://www.ncbi.nlm.nih.gov/pubmed/8675695

DM7YRFE	DI	DM7YRFE
DM7YRFE	DN	BB-3644
DM7YRFE	MI	TTMX39J
DM7YRFE	MN	Matrix metalloproteinase-1 (MMP-1)
DM7YRFE	MT	DTT
DM7YRFE	MA	Inhibitor
DM7YRFE	RN	Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006 Mar;6(3):227-39.
DM7YRFE	RU	https://pubmed.ncbi.nlm.nih.gov/16498445

DM7YRFE	DI	DM7YRFE
DM7YRFE	DN	BB-3644
DM7YRFE	MI	TTLM12X
DM7YRFE	MN	Matrix metalloproteinase-2 (MMP-2)
DM7YRFE	MT	DTT
DM7YRFE	MA	Inhibitor
DM7YRFE	RN	Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006 Mar;6(3):227-39.
DM7YRFE	RU	https://pubmed.ncbi.nlm.nih.gov/16498445

DM7YRFE	DI	DM7YRFE
DM7YRFE	DN	BB-3644
DM7YRFE	MI	TTMTWOS
DM7YRFE	MN	Matrix metalloproteinase-7 (MMP-7)
DM7YRFE	MT	DTT
DM7YRFE	MA	Inhibitor
DM7YRFE	RN	Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006 Mar;6(3):227-39.
DM7YRFE	RU	https://pubmed.ncbi.nlm.nih.gov/16498445

DMITV4F	DI	DMITV4F
DMITV4F	DN	BBB-022
DMITV4F	MI	TTUST1O
DMITV4F	MN	Phosphodiesterase (PDE)
DMITV4F	MT	DTT
DMITV4F	MA	Inhibitor
DMITV4F	RN	Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia. J Cereb Blood Flow Metab. 2001 Dec;21(12):1393-400.
DMITV4F	RU	https://pubmed.ncbi.nlm.nih.gov/11740200

DMNH9A6	DI	DMNH9A6
DMNH9A6	DN	BCH-150
DMNH9A6	MI	TTKWM86
DMNH9A6	MN	Opioid receptor mu (MOP)
DMNH9A6	MT	DTT
DMNH9A6	MA	Modulator
DMNH9A6	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003724)
DMNH9A6	RU	http://adisinsight.springer.com/drugs/800003724

DM3TP8X	DI	DM3TP8X
DM3TP8X	DN	BCH-2763
DM3TP8X	MI	TT6L509
DM3TP8X	MN	Coagulation factor IIa (F2)
DM3TP8X	MT	DTT
DM3TP8X	MA	Inhibitor
DM3TP8X	RN	BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban. Thromb Haemost. 1998 Feb;79(2):431-8.
DM3TP8X	RU	https://pubmed.ncbi.nlm.nih.gov/9493603

DMBJERO	DI	DMBJERO
DMBJERO	DN	BCX-140
DMBJERO	MI	TT50QJ3
DMBJERO	MN	Influenza Neuraminidase (Influ NA)
DMBJERO	MT	DTT
DMBJERO	MA	Inhibitor
DMBJERO	RN	CN patent application no. 104447481, Benzoic acid thiourea anti-influenza virus compounds as well as preparation method and use thereof.
DMBJERO	RU	http://www.google.com/patents/CN104447481A?cl=en

DM4GEUF	DI	DM4GEUF
DM4GEUF	DN	BCX-25
DM4GEUF	MI	TTX2N1T
DM4GEUF	MN	Transferase unspecific (TF)
DM4GEUF	MT	DTT
DM4GEUF	MA	Modulator
DM4GEUF	RN	CN patent application no. 1096855, Composition produced by treatment and induction of nitrogen mono oxide synthase expressed matter, and use thereof.
DM4GEUF	RU	http://www.google.com/patents/CN1096855C?cl=en

DMV5K0I	DI	DMV5K0I
DMV5K0I	DN	BDF-9148
DMV5K0I	MI	TTRK8B9
DMV5K0I	MN	Sodium channel unspecific (NaC)
DMV5K0I	MT	DTT
DMV5K0I	MA	Modulator
DMV5K0I	RN	The relaxing effect of BDF 9148 on the KCl-contracted aorta isolated from normo- and hyper-tensive rats. Naunyn Schmiedebergs Arch Pharmacol. 1998 Feb;357(2):126-32.
DMV5K0I	RU	https://pubmed.ncbi.nlm.nih.gov/9521485

DM6WQ8F	DI	DM6WQ8F
DM6WQ8F	DN	BE-13793C
DM6WQ8F	MI	TTGTQHC
DM6WQ8F	MN	DNA topoisomerase I (TOP1)
DM6WQ8F	MT	DTT
DM6WQ8F	MA	Modulator
DM6WQ8F	RN	DOI: 10.1002/3527601783.ch20
DM6WQ8F	RU	http://onlinelibrary.wiley.com/doi/10.1002/3527601783.ch20/pdf

DM1SVQX	DI	DM1SVQX
DM1SVQX	DN	BE-16627B
DM1SVQX	MI	TT1GHVO
DM1SVQX	MN	Matrix metalloproteinase (MMP)
DM1SVQX	MT	DTT
DM1SVQX	MA	Modulator
DM1SVQX	RN	Gelatinase B (MMP-9), but not its inhibitor (TIMP-1), dictates the growth rate of experimental thymic lymphoma. Int J Cancer. 1999 Aug 27;82(5):743-7.
DM1SVQX	RU	https://pubmed.ncbi.nlm.nih.gov/10417774

DM39SEK	DI	DM39SEK
DM39SEK	DN	BE-22179
DM39SEK	MI	TT0IHXV
DM39SEK	MN	DNA topoisomerase II (TOP2)
DM39SEK	MT	DTT
DM39SEK	MA	Modulator
DM39SEK	RN	A new topoisomerase II inhibitor, BE-22179, produced by a streptomycete. I. Producing strain, fermentation, isolation and biological activity. J Antibiot (Tokyo). 1994 Feb;47(2):129-35.
DM39SEK	RU	https://pubmed.ncbi.nlm.nih.gov/8150706

DM6KRJW	DI	DM6KRJW
DM6KRJW	DN	BEA-005
DM6KRJW	MI	TT84ETX
DM6KRJW	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM6KRJW	MT	DTT
DM6KRJW	MA	Modulator
DM6KRJW	RN	Efficacy of Postexposure Prophylaxis after Intravaginal Exposure of Pig-Tailed Macaques to a Human-Derived Retrovirus (Human Immunodeficiency Virus Type 2). J Virol. 2000 October; 74(20): 9771-9775.
DM6KRJW	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC112413/

DMGAPH1	DI	DMGAPH1
DMGAPH1	DN	Befiperide
DMGAPH1	MI	TTWT5K7
DMGAPH1	MN	5-HT 1 receptor (5HT1R)
DMGAPH1	MT	DTT
DMGAPH1	MA	Modulator
DMGAPH1	RN	Behavioral Pharmacology of 5-ht. Paul Bevan, Paul Bevan Duphar, Alexander R. Cools. 2013. Figure(15.2).
DMGAPH1	RU	https://books.google.com.hk/books?id=oJIFi5E-YI0C&pg=PT294&lpg=PT294&dq=befiperide+++5HT&source=bl&ots=MsOmWqq_Lp&sig=XqN92Fe4GBpDtwToXK7DG-tUXVk&hl=zh-CN&sa=X&ved=0CBwQ6AEwAGoVChMIq4aV3uy8yAIVDsWOCh0H6AMC#v=onepage&q=befiperide%20%20%205HT&f=false

DMM0ZIJ	DI	DMM0ZIJ
DMM0ZIJ	DN	Belaperidone
DMM0ZIJ	MI	TTE0A2F
DMM0ZIJ	MN	Dopamine D4 receptor (D4R)
DMM0ZIJ	MT	DTT
DMM0ZIJ	MA	Antagonist
DMM0ZIJ	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMM0ZIJ	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMXH3A2	DI	DMXH3A2
DMXH3A2	DN	Benafentrine dimaleate
DMXH3A2	MI	TTZCG4L
DMXH3A2	MN	Phosphodiesterase 3 (PDE3)
DMXH3A2	MT	DTT
DMXH3A2	MA	Modulator
DMXH3A2	RN	Studies on anti-allergic action of AH 21-132, a novel isozyme-selective phosphodiesterase inhibitor in airways. Jpn J Pharmacol. 1995 Feb;67(2):149-56.
DMXH3A2	RU	https://pubmed.ncbi.nlm.nih.gov/7542355

DMVK78Q	DI	DMVK78Q
DMVK78Q	DN	Bepafant
DMVK78Q	MI	TTQL5VC
DMVK78Q	MN	Platelet-activating factor receptor (PTAFR)
DMVK78Q	MT	DTT
DMVK78Q	MA	Antagonist
DMVK78Q	RN	Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor. J Pharmacol Exp Ther. 1990 Dec;255(3):962-8.
DMVK78Q	RU	https://pubmed.ncbi.nlm.nih.gov/2262914

DMXRTFM	DI	DMXRTFM
DMXRTFM	DN	Ber-H2/saporin
DMXRTFM	MI	TT2GM5R
DMXRTFM	MN	Lymphocyte activation antigen CD30 (TNFRSF8)
DMXRTFM	MT	DTT
DMXRTFM	RN	Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma. Blood. 1995 Apr15;85(8):2139-46.
DMXRTFM	RU	https://pubmed.ncbi.nlm.nih.gov/7718885

DMQA4JU	DI	DMQA4JU
DMQA4JU	DN	Berlafenone
DMQA4JU	MI	TTRK8B9
DMQA4JU	MN	Sodium channel unspecific (NaC)
DMQA4JU	MT	DTT
DMQA4JU	MA	Modulator
DMQA4JU	RN	WO patent application no. 19990639849, Novel sodium channel drugs and uses.
DMQA4JU	RU	http://www.google.com/patents/WO1999063984A9?cl=en

DM56WD3	DI	DM56WD3
DM56WD3	DN	Bertosamil
DM56WD3	MI	TTQ6VDM
DM56WD3	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DM56WD3	MT	DTT
DM56WD3	MA	Modulator
DM56WD3	RN	Bertosamil blocks HERG potassium channels in their open and inactivated states. Br J Pharmacol. 2002 Sep;137(2):221-8.
DM56WD3	RU	https://pubmed.ncbi.nlm.nih.gov/12208779

DMH7YD4	DI	DMH7YD4
DMH7YD4	DN	Bexlosteride
DMH7YD4	MI	TTTU72V
DMH7YD4	MN	Steroid 5-alpha-reductase 1 (SRD5A1)
DMH7YD4	MT	DTT
DMH7YD4	MA	Inhibitor
DMH7YD4	RN	Synthesis of 8-chloro-benzo[c]quinolizin-3-ones as potent and selective inhibitors of human steroid 5alpha-reductase 1. Bioorg Med Chem Lett. 2000 Feb 21;10(4):353-6.
DMH7YD4	RU	https://pubmed.ncbi.nlm.nih.gov/10714498

DM6QT9P	DI	DM6QT9P
DM6QT9P	DN	BIBB-515
DM6QT9P	MI	TT7O8ZA
DM6QT9P	MN	Lanosterol synthase (LSS)
DM6QT9P	MT	DTT
DM6QT9P	MA	Modulator
DM6QT9P	RN	Effects of a novel 2,3-oxidosqualene cyclase inhibitor on cholesterol biosynthesis and lipid metabolism in vivo. J Lipid Res. 1997 Mar;38(3):564-75.
DM6QT9P	RU	https://pubmed.ncbi.nlm.nih.gov/9101437

DM019Y7	DI	DM019Y7
DM019Y7	DN	BIBN-140
DM019Y7	MI	TTYEG6Q
DM019Y7	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DM019Y7	MT	DTT
DM019Y7	MA	Modulator
DM019Y7	RN	Therapeutic potential of CNS-active M2 antagonists: novel structures and pharmacology. Life Sci. 1993;52(5-6):497-503.
DM019Y7	RU	https://pubmed.ncbi.nlm.nih.gov/8441330

DMZTPCX	DI	DMZTPCX
DMZTPCX	DN	BIBN-99
DMZTPCX	MI	TTYEG6Q
DMZTPCX	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMZTPCX	MT	DTT
DMZTPCX	MA	Modulator
DMZTPCX	RN	Characterization of BIBN 99: a lipophilic and selective muscarinic M2 receptor antagonist. Eur J Pharmacol. 1993 Sep 21;242(1):23-30.
DMZTPCX	RU	https://pubmed.ncbi.nlm.nih.gov/8223934

DMYBR9D	DI	DMYBR9D
DMYBR9D	DN	BIBP 3226
DMYBR9D	MI	TTRK9JT
DMYBR9D	MN	Neuropeptide Y receptor type 1 (NPY1R)
DMYBR9D	MT	DTT
DMYBR9D	MA	Antagonist
DMYBR9D	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 305).
DMYBR9D	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=305

DM5107E	DI	DM5107E
DM5107E	DN	BIBS-222
DM5107E	MI	TTGN1ZA
DM5107E	MN	Angiotensin II receptor (AGTR)
DM5107E	MT	DTT
DM5107E	MA	Modulator
DM5107E	RN	Characterization of BIBS 39 and BIBS 222: two new nonpeptide angiotensin II receptor antagonists. Eur J Pharmacol. 1992 Jul 21;218(1):35-41.
DM5107E	RU	https://pubmed.ncbi.nlm.nih.gov/1397034

DM098BL	DI	DM098BL
DM098BL	DN	BIBS-39
DM098BL	MI	TTGN1ZA
DM098BL	MN	Angiotensin II receptor (AGTR)
DM098BL	MT	DTT
DM098BL	MA	Modulator
DM098BL	RN	Characterization of BIBS 39 and BIBS 222: two new nonpeptide angiotensin II receptor antagonists. Eur J Pharmacol. 1992 Jul 21;218(1):35-41.
DM098BL	RU	https://pubmed.ncbi.nlm.nih.gov/1397034

DMMNI5K	DI	DMMNI5K
DMMNI5K	DN	BIBU-251
DMMNI5K	MI	TT38RM1
DMMNI5K	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DMMNI5K	MT	DTT
DMMNI5K	MA	Modulator
DMMNI5K	RN	CN patent application no. 101312747, Anticoagulant antithrombotic dual inhibitors comprising a biotin label.
DMMNI5K	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20081126&CC=CN&NR=101312747A&KC=A

DMXIH3Q	DI	DMXIH3Q
DMXIH3Q	DN	BIBW-22
DMXIH3Q	MI	TTHQENC
DMXIH3Q	MN	Phosphodiesterase 1 (PDE1)
DMXIH3Q	MT	DTT
DMXIH3Q	MA	Inhibitor
DMXIH3Q	RN	BIBW22 BS, potent multidrug resistance-reversing agent, binds directly to P-glycoprotein and accumulates in drug-resistant cells. Mol Pharmacol. 1996 Sep;50(3):482-92.
DMXIH3Q	RU	https://pubmed.ncbi.nlm.nih.gov/8794885

DMRXWCO	DI	DMRXWCO
DMRXWCO	DN	BIBX-79
DMRXWCO	MI	TT7O8ZA
DMRXWCO	MN	Lanosterol synthase (LSS)
DMRXWCO	MT	DTT
DMRXWCO	MA	Modulator
DMRXWCO	RN	Effects of a novel 2,3-oxidosqualene cyclase inhibitor on the regulation of cholesterol biosynthesis in HepG2 cells. J Lipid Res. 1996 Jan;37(1):148-58.
DMRXWCO	RU	https://pubmed.ncbi.nlm.nih.gov/8820110

DMU73F0	DI	DMU73F0
DMU73F0	DN	Bifemelane
DMU73F0	MI	TT3WG5C
DMU73F0	MN	Monoamine oxidase type A (MAO-A)
DMU73F0	MT	DTT
DMU73F0	MA	Modulator
DMU73F0	RN	4-(O-benzylphenoxy)-N-methylbutylamine (bifemelane) and other 4-(O-benzylphenoxy)-N-methylalkylamines as new inhibitors of type A and B monoamine oxidase. J Neurochem. 1988 Jan;50(1):243-7.
DMU73F0	RU	https://pubmed.ncbi.nlm.nih.gov/3335842

DMBR48G	DI	DMBR48G
DMBR48G	DN	BI-L-357
DMBR48G	MI	TT2J34L
DMBR48G	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMBR48G	MT	DTT
DMBR48G	MA	Inhibitor
DMBR48G	RN	A prodrug of a 2,6-disubstituted 4-(2-arylethenyl)phenol is a selective and orally active 5-lipoxygenase inhibitor. J Pharmacol Exp Ther. 1993 May;265(2):483-9.
DMBR48G	RU	https://pubmed.ncbi.nlm.nih.gov/8388452

DMRV4UL	DI	DMRV4UL
DMRV4UL	DN	BILA-2157BS
DMRV4UL	MI	TTB2MXP
DMRV4UL	MN	Angiotensinogenase renin (REN)
DMRV4UL	MT	DTT
DMRV4UL	MA	Inhibitor
DMRV4UL	RN	Comparative studies on differential inhibition of the renin - angiotensin system in the anesthetized guinea pig. Can J Physiol Pharmacol. 1995 Oct;73(10):1512-8.
DMRV4UL	RU	https://pubmed.ncbi.nlm.nih.gov/8748944

DMUOPBF	DI	DMUOPBF
DMUOPBF	DN	BILD-1263
DMUOPBF	MI	TTMJX4U
DMUOPBF	MN	Herpes simplex virus Ribonucleoside-diphosphate reductase (HSV RIR1)
DMUOPBF	MT	DTT
DMUOPBF	MA	Inhibitor
DMUOPBF	RN	Evaluation of a peptidomimetic ribonucleotide reductase inhibitor with a murine model of herpes simplex virus type 1 ocular disease. Antimicrob Agents Chemother. 1996 May;40(5):1078-84.
DMUOPBF	RU	https://pubmed.ncbi.nlm.nih.gov/8723444

DMR01WE	DI	DMR01WE
DMR01WE	DN	BILD-1351
DMR01WE	MI	TTMJX4U
DMR01WE	MN	Herpes simplex virus Ribonucleoside-diphosphate reductase (HSV RIR1)
DMR01WE	MT	DTT
DMR01WE	MA	Inhibitor
DMR01WE	RN	The antiviral activity of the ribonucleotide reductase inhibitor BILD 1351 SE in combination with acyclovir against HSV type-1 in cell culture. Antiviral Res. 1998 Jul;39(1):35-46.
DMR01WE	RU	https://pubmed.ncbi.nlm.nih.gov/9754948

DMZMUG2	DI	DMZMUG2
DMZMUG2	DN	BILD-1357
DMZMUG2	MI	TTMJX4U
DMZMUG2	MN	Herpes simplex virus Ribonucleoside-diphosphate reductase (HSV RIR1)
DMZMUG2	MT	DTT
DMZMUG2	MA	Inhibitor
DMZMUG2	RN	Peptidomimetic inhibitors of herpes simplex virus ribonucleotide reductase with improved in vivo antiviral activity. J Med Chem. 1996 Oct 11;39(21):4173-80.
DMZMUG2	RU	https://pubmed.ncbi.nlm.nih.gov/8863795

DMAU5WL	DI	DMAU5WL
DMAU5WL	DN	BILD-733
DMAU5WL	MI	TTMJX4U
DMAU5WL	MN	Herpes simplex virus Ribonucleoside-diphosphate reductase (HSV RIR1)
DMAU5WL	MT	DTT
DMAU5WL	MA	Inhibitor
DMAU5WL	RN	Resistance of herpes simplex virus type 1 to peptidomimetic ribonucleotide reductase inhibitors: selection and characterization of mutant isolates. J Virol. 1996 Feb;70(2):787-93.
DMAU5WL	RU	https://pubmed.ncbi.nlm.nih.gov/8551616

DM9X1DZ	DI	DM9X1DZ
DM9X1DZ	DN	BIMG80
DM9X1DZ	MI	TTZFYLI
DM9X1DZ	MN	Dopamine D1 receptor (D1R)
DM9X1DZ	MT	DTT
DM9X1DZ	MA	Modulator
DM9X1DZ	RN	BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex. J Neurochem. 1997 Jul;69(1):182-90.
DM9X1DZ	RU	https://pubmed.ncbi.nlm.nih.gov/9202309

DM9X1DZ	DI	DM9X1DZ
DM9X1DZ	DN	BIMG80
DM9X1DZ	MI	TTEX248
DM9X1DZ	MN	Dopamine D2 receptor (D2R)
DM9X1DZ	MT	DTT
DM9X1DZ	MA	Modulator
DM9X1DZ	RN	BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex. J Neurochem. 1997 Jul;69(1):182-90.
DM9X1DZ	RU	https://pubmed.ncbi.nlm.nih.gov/9202309

DM9X1DZ	DI	DM9X1DZ
DM9X1DZ	DN	BIMG80
DM9X1DZ	MI	TTE0A2F
DM9X1DZ	MN	Dopamine D4 receptor (D4R)
DM9X1DZ	MT	DTT
DM9X1DZ	MA	Modulator
DM9X1DZ	RN	BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex. J Neurochem. 1997 Jul;69(1):182-90.
DM9X1DZ	RU	https://pubmed.ncbi.nlm.nih.gov/9202309

DMKNS10	DI	DMKNS10
DMKNS10	DN	BIPHALIN
DMKNS10	MI	TT27RFC
DMKNS10	MN	Opioid receptor delta (OPRD1)
DMKNS10	MT	DTT
DMKNS10	MA	Inhibitor
DMKNS10	RN	The biological activity and metabolic stability of peptidic bifunctional compounds that are opioid receptor agonists and neurokinin-1 receptor anta... Bioorg Med Chem. 2009 Oct 15;17(20):7337-43.
DMKNS10	RU	https://pubmed.ncbi.nlm.nih.gov/19762245

DMKNS10	DI	DMKNS10
DMKNS10	DN	BIPHALIN
DMKNS10	MI	TTKWM86
DMKNS10	MN	Opioid receptor mu (MOP)
DMKNS10	MT	DTT
DMKNS10	MA	Inhibitor
DMKNS10	RN	Biological and conformational evaluation of bifunctional compounds for opioid receptor agonists and neurokinin 1 receptor antagonists possessing tw... J Med Chem. 2010 Aug 12;53(15):5491-501.
DMKNS10	RU	https://pubmed.ncbi.nlm.nih.gov/20617791

DMKRBL2	DI	DMKRBL2
DMKRBL2	DN	Bisbenzimide
DMKRBL2	MI	TTUTN1I
DMKRBL2	MN	Human Deoxyribonucleic acid (hDNA)
DMKRBL2	MT	DTT
DMKRBL2	MA	Binder (minor groove binder)
DMKRBL2	RN	Sequence-dependent effects in drug-DNA interaction: the crystal structure of Hoechst 33258 bound to the d(CGCAAATTTGCG)2 duplex. Nucleic Acids Res. 1994 May 11;22(9):1607-12.
DMKRBL2	RU	https://pubmed.ncbi.nlm.nih.gov/7515488

DMKRBL2	DI	DMKRBL2
DMKRBL2	DN	Bisbenzimide
DMKRBL2	MI	DTUGYRD
DMKRBL2	MN	P-glycoprotein 1 (ABCB1)
DMKRBL2	MT	DTP
DMKRBL2	MA	Substrate
DMKRBL2	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMKRBL2	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DM0DO4S	DI	DM0DO4S
DM0DO4S	DN	Bivatuzumab mertansine
DM0DO4S	MI	TTWFBT7
DM0DO4S	MN	Extracellular matrix receptor III (CD44)
DM0DO4S	MT	DTT
DM0DO4S	RN	A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6064-72.
DM0DO4S	RU	https://pubmed.ncbi.nlm.nih.gov/17062682

DM9IQR6	DI	DM9IQR6
DM9IQR6	DN	BK-218
DM9IQR6	MI	TTJP4SM
DM9IQR6	MN	Bacterial Penicillin binding protein (Bact PBP)
DM9IQR6	MT	DTT
DM9IQR6	MA	Inhibitor
DM9IQR6	RN	In vitro investigation of BK-218, a new oral and parenteral cephalosporin. Antimicrob Agents Chemother. 1990 Feb;34(2):349-54.
DM9IQR6	RU	https://pubmed.ncbi.nlm.nih.gov/2109582

DMGDTLX	DI	DMGDTLX
DMGDTLX	DN	BL-1872
DMGDTLX	MI	TTMI6F5
DMGDTLX	MN	Transient receptor potential cation channel V1 (TRPV1)
DMGDTLX	MT	DTT
DMGDTLX	MA	Modulator
DMGDTLX	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMGDTLX	RU	https://www.fda.gov/

DMKITQN	DI	DMKITQN
DMKITQN	DN	BM-13677
DMKITQN	MI	TT3C1VN
DMKITQN	MN	Enzyme unspecific (Enz)
DMKITQN	MT	DTT
DMKITQN	MA	Modulator
DMKITQN	RN	Progress in medicinal chemistry, 1994. Page(448).
DMKITQN	RU	https://books.google.com.hk/books?id=5_7mxy2G9a0C&pg=PA448&lpg=PA448&dq=%22BM-13677%22+enzyme&source=bl&ots=UzcIa2xi2D&sig=dx8ohd8OK-bXYWQUJ32VCTQc48A&hl=zh-CN&sa=X&ved=0CBoQ6AEwAGoVChMIn6Gx-cG_yAIVTyOOCh1w6Qe_#v=onepage&q=%22BM-13677%22%20enzyme&f=false

DMWDRI0	DI	DMWDRI0
DMWDRI0	DN	BMS-180560
DMWDRI0	MI	TTGN1ZA
DMWDRI0	MN	Angiotensin II receptor (AGTR)
DMWDRI0	MT	DTT
DMWDRI0	MA	Modulator
DMWDRI0	RN	BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: comparison with losartan and EXP3174. Br J Pharmacol. 1994 Sep;113(1):179-89.
DMWDRI0	RU	https://pubmed.ncbi.nlm.nih.gov/7812609

DM1Y75C	DI	DM1Y75C
DM1Y75C	DN	BMS-181184
DM1Y75C	MI	TTXT4D5
DM1Y75C	MN	Bacterial Cell membrane (Bact CM)
DM1Y75C	MT	DTT
DM1Y75C	MA	Modulator
DM1Y75C	RN	Antifungal Activity of the Pradimicin Derivative BMS 181184 in the Treatment of Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits. Antimicrob Agents Chemother. 1998 September; 42(9): 2399-2404.
DM1Y75C	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC105840/

DMYWI04	DI	DMYWI04
DMYWI04	DN	BMS-181885
DMYWI04	MI	TT6MSOK
DMYWI04	MN	5-HT 1D receptor (HTR1D)
DMYWI04	MT	DTT
DMYWI04	MA	Agonist
DMYWI04	RN	Sensitive triple-quadrupole mass spectrometric assay for the determination of BMS-181885, a 5-HT1 agonist, in human plasma following solid phase extraction. Biomed Chromatogr. 1999 Oct;13(6):425-30.
DMYWI04	RU	https://pubmed.ncbi.nlm.nih.gov/10477901

DMEDLHG	DI	DMEDLHG
DMEDLHG	DN	BMS-182193
DMEDLHG	MI	TT5FNQT
DMEDLHG	MN	Human immunodeficiency virus Protease (HIV PR)
DMEDLHG	MT	DTT
DMEDLHG	MA	Modulator
DMEDLHG	RN	Antiviral properties of aminodiol inhibitors against human immunodeficiency virus and protease. Antimicrob Agents Chemother. 1995 Feb;39(2):374-9.
DMEDLHG	RU	https://pubmed.ncbi.nlm.nih.gov/7726501

DMO7C09	DI	DMO7C09
DMO7C09	DN	BMS-182566
DMO7C09	MI	TT7WZIJ
DMO7C09	MN	CAAX farnesyltransferase beta (FNTB)
DMO7C09	MT	DTT
DMO7C09	MA	Modulator
DMO7C09	RN	US patent application no. 2005,0227,929, Combination therapy comprising a cox-2 inhibitor and an antineoplastic agent.
DMO7C09	RU	http://www.google.com/patents/US20050227929

DM0K4DZ	DI	DM0K4DZ
DM0K4DZ	DN	BMS-182657
DM0K4DZ	MI	TTL69WB
DM0K4DZ	MN	Angiotensin-converting enzyme (ACE)
DM0K4DZ	MT	DTT
DM0K4DZ	MA	Modulator
DM0K4DZ	RN	Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure. J Pharmacol Exp Ther. 1995 Nov;275(2):745-52.
DM0K4DZ	RU	https://pubmed.ncbi.nlm.nih.gov/7473162

DM0K4DZ	DI	DM0K4DZ
DM0K4DZ	DN	BMS-182657
DM0K4DZ	MI	TT5TKPM
DM0K4DZ	MN	Neutral endopeptidase (MME)
DM0K4DZ	MT	DTT
DM0K4DZ	MA	Modulator
DM0K4DZ	RN	Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure. J Pharmacol Exp Ther. 1995 Nov;275(2):745-52.
DM0K4DZ	RU	https://pubmed.ncbi.nlm.nih.gov/7473162

DM5PG6C	DI	DM5PG6C
DM5PG6C	DN	BMS-182874
DM5PG6C	MI	TTKRD0G
DM5PG6C	MN	Endothelin A receptor (EDNRA)
DM5PG6C	MT	DTT
DM5PG6C	MA	Inhibitor
DM5PG6C	RN	Biphenylsulfonamide endothelin receptor antagonists. 2. Discovery of 4'-oxazolyl biphenylsulfonamides as a new class of potent, highly selective ET... J Med Chem. 2000 Aug 10;43(16):3111-7.
DM5PG6C	RU	https://pubmed.ncbi.nlm.nih.gov/10956219

DMTA7O8	DI	DMTA7O8
DMTA7O8	DN	BMS-185857
DMTA7O8	MI	TT7WZIJ
DMTA7O8	MN	CAAX farnesyltransferase beta (FNTB)
DMTA7O8	MT	DTT
DMTA7O8	MA	Modulator
DMTA7O8	RN	US patent application no. 2005,0227,929, Combination therapy comprising a cox-2 inhibitor and an antineoplastic agent.
DMTA7O8	RU	http://www.google.com/patents/US20050227929

DMKZ3PW	DI	DMKZ3PW
DMKZ3PW	DN	BMS-186318
DMKZ3PW	MI	TT5FNQT
DMKZ3PW	MN	Human immunodeficiency virus Protease (HIV PR)
DMKZ3PW	MT	DTT
DMKZ3PW	MA	Modulator
DMKZ3PW	RN	Determination of BMS-186318 in dog, rat and monkey plasma by liquid chromatography-ionspray mass spectrometry. J Pharm Biomed Anal. 1995 Dec;14(1-2):43-8.
DMKZ3PW	RU	https://pubmed.ncbi.nlm.nih.gov/8833965

DMV3B5Y	DI	DMV3B5Y
DMV3B5Y	DN	BMS-189664
DMV3B5Y	MI	TT6L509
DMV3B5Y	MN	Coagulation factor IIa (F2)
DMV3B5Y	MT	DTT
DMV3B5Y	MA	Inhibitor
DMV3B5Y	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMV3B5Y	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMMBTU6	DI	DMMBTU6
DMMBTU6	DN	BMS-210285
DMMBTU6	MI	TTMXGCW
DMMBTU6	MN	Adrenergic receptor beta-3 (ADRB3)
DMMBTU6	MT	DTT
DMMBTU6	MA	Agonist
DMMBTU6	RN	CA patent application no. 509835, Nitrogen-containing heterocyclic derivatives, medicinal compositions containing the same and medicinal use thereof.
DMMBTU6	RU	https://www.google.com.ar/patents/CA2509835A1?cl=en

DME20VP	DI	DME20VP
DME20VP	DN	BMS-433771
DME20VP	MI	TT8DSFC
DME20VP	MN	Hydroxyphenylpyruvate dioxygenase (HPD)
DME20VP	MT	DTT
DME20VP	MA	Inhibitor
DME20VP	RN	Emerging drugs for respiratory syncytial virus infection. Expert Opin Emerg Drugs. 2009 Jun;14(2):207-17.
DME20VP	RU	https://pubmed.ncbi.nlm.nih.gov/19453286

DMY7ZRA	DI	DMY7ZRA
DMY7ZRA	DN	BMS-605339
DMY7ZRA	MI	TTWXB3E
DMY7ZRA	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DMY7ZRA	MT	DTT
DMY7ZRA	MA	Inhibitor
DMY7ZRA	RN	Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection. J Med Chem.2014 Mar 13;57(5):1708-29.
DMY7ZRA	RU	https://pubmed.ncbi.nlm.nih.gov/24555570

DMDPJ8M	DI	DMDPJ8M
DMDPJ8M	DN	BMY-20844
DMDPJ8M	MI	TT06AWU
DMDPJ8M	MN	Phosphodiesterase 3A (PDE3A)
DMDPJ8M	MT	DTT
DMDPJ8M	MA	Inhibitor
DMDPJ8M	RN	Inhibitors of blood platelet cAMP phosphodiesterase. 3. 1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-one derivatives with enhanced aqueous solubility. J Med Chem. 1992 Jul 10;35(14):2688-96.
DMDPJ8M	RU	https://pubmed.ncbi.nlm.nih.gov/1321911

DMZFTLK	DI	DMZFTLK
DMZFTLK	DN	BMY-22089
DMZFTLK	MI	TTPADOQ
DMZFTLK	MN	HMG-CoA reductase (HMGCR)
DMZFTLK	MT	DTT
DMZFTLK	MA	Inhibitor
DMZFTLK	RN	Selective inhibition of cholesterol synthesis in liver versus extrahepatic tissues by HMG-CoA reductase inhibitors. J Lipid Res. 1990 Jul;31(7):1271-82.
DMZFTLK	RU	https://pubmed.ncbi.nlm.nih.gov/2401858

DM2TF9P	DI	DM2TF9P
DM2TF9P	DN	BMY-40062
DM2TF9P	MI	TTN6J5F
DM2TF9P	MN	Bacterial DNA gyrase (Bact gyrase)
DM2TF9P	MT	DTT
DM2TF9P	MA	Modulator
DM2TF9P	RN	Relationships among antibacterial activity, inhibition of DNA gyrase, and intracellular accumulation of 11 fluoroquinolones. Antimicrob Agents Chemother. 1992 Dec;36(12):2622-7.
DM2TF9P	RU	https://www.ncbi.nlm.nih.gov/pubmed/1336340

DM8R3N0	DI	DM8R3N0
DM8R3N0	DN	BMY-44621
DM8R3N0	MI	TT2WR1T
DM8R3N0	MN	Cationic trypsinogen (PRSS1)
DM8R3N0	MT	DTT
DM8R3N0	MA	Inhibitor
DM8R3N0	RN	Design and synthesis of conformationally constrained arginal thrombin inhibitors, Bioorg. Med. Chem. Lett. 7(17):2205-2210 (1997).
DM8R3N0	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97004034

DMRHCEG	DI	DMRHCEG
DMRHCEG	DN	BMY-7378
DMRHCEG	MI	TTSQIFT
DMRHCEG	MN	5-HT 1A receptor (HTR1A)
DMRHCEG	MT	DTT
DMRHCEG	MA	Inhibitor
DMRHCEG	RN	8-[4-[2-(1,2,3,4-Tetrahydroisoquinolinyl]butyl-8-azaspiro[4.5]decane-7,9-dione: a new 5-HT1A receptor ligand with the same activity profile as busp... J Med Chem. 1996 Mar 1;39(5):1125-9.
DMRHCEG	RU	https://pubmed.ncbi.nlm.nih.gov/8676348

DMRHCEG	DI	DMRHCEG
DMRHCEG	DN	BMY-7378
DMRHCEG	MI	TTNGILX
DMRHCEG	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMRHCEG	MT	DTT
DMRHCEG	MA	Inhibitor
DMRHCEG	RN	Synthesis and structure-activity relationship of fluoro analogues of 8-{2-[4-(4-methoxyphenyl)piperazin-1yl]ethyl}-8-azaspiro[4.5]decane-7,9-dione ... J Med Chem. 2005 Apr 21;48(8):3076-9.
DMRHCEG	RU	https://pubmed.ncbi.nlm.nih.gov/15828846

DMRHCEG	DI	DMRHCEG
DMRHCEG	DN	BMY-7378
DMRHCEG	MI	TTBRKXS
DMRHCEG	MN	Adrenergic receptor alpha-1B (ADRA1B)
DMRHCEG	MT	DTT
DMRHCEG	MA	Inhibitor
DMRHCEG	RN	Synthesis and structure-activity relationship of fluoro analogues of 8-{2-[4-(4-methoxyphenyl)piperazin-1yl]ethyl}-8-azaspiro[4.5]decane-7,9-dione ... J Med Chem. 2005 Apr 21;48(8):3076-9.
DMRHCEG	RU	https://pubmed.ncbi.nlm.nih.gov/15828846

DMRHCEG	DI	DMRHCEG
DMRHCEG	DN	BMY-7378
DMRHCEG	MI	TT34BHT
DMRHCEG	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMRHCEG	MT	DTT
DMRHCEG	MA	Inhibitor
DMRHCEG	RN	Synthesis and structure-activity relationship of fluoro analogues of 8-{2-[4-(4-methoxyphenyl)piperazin-1yl]ethyl}-8-azaspiro[4.5]decane-7,9-dione ... J Med Chem. 2005 Apr 21;48(8):3076-9.
DMRHCEG	RU	https://pubmed.ncbi.nlm.nih.gov/15828846

DMTKJDS	DI	DMTKJDS
DMTKJDS	DN	BN-50726
DMTKJDS	MI	TTQL5VC
DMTKJDS	MN	Platelet-activating factor receptor (PTAFR)
DMTKJDS	MT	DTT
DMTKJDS	MA	Antagonist
DMTKJDS	RN	Effects of the PAF antagonists BN50726 and BN50739 on arrhythmogenesis and extent of necrosis during myocardial ischaemia/reperfusion in rabbits. Br J Pharmacol. 1992 Nov;107(3):705-9.
DMTKJDS	RU	https://pubmed.ncbi.nlm.nih.gov/1472967

DMU1TRQ	DI	DMU1TRQ
DMU1TRQ	DN	BN50739
DMU1TRQ	MI	TTQL5VC
DMU1TRQ	MN	Platelet-activating factor receptor (PTAFR)
DMU1TRQ	MT	DTT
DMU1TRQ	MA	Modulator
DMU1TRQ	RN	Effect of the platelet-activating factor antagonist BN 50739 and its diluents on mitochondrial respiration and membrane lipids during and following... J Neurochem. 1994 May;62(5):1929-38.
DMU1TRQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/8158141

DMMZ9DY	DI	DMMZ9DY
DMMZ9DY	DN	BN-80245
DMMZ9DY	MI	TTGTQHC
DMMZ9DY	MN	DNA topoisomerase I (TOP1)
DMMZ9DY	MT	DTT
DMMZ9DY	MA	Inhibitor
DMMZ9DY	RN	BN 80245: An E-ring modified camptothecin with potent antiproliferative and topoisomerase I inhibitory activities. Bioorganic & Medicinal Chemistry Letters Volume 7, Issue 17, 9 September 1997, Pages2235-2238.
DMMZ9DY	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97003983

DMN8FAG	DI	DMN8FAG
DMN8FAG	DN	BP4.879a
DMN8FAG	MI	TTNXLKE
DMN8FAG	MN	5-HT 3 receptor (5HT3R)
DMN8FAG	MT	DTT
DMN8FAG	MA	Antagonist
DMN8FAG	RN	5-HT(3A) receptor subunit is required for 5-HT3 antagonist-induced reductions in alcohol drinking. Neuropsychopharmacology. 2004 Oct;29(10):1807-13.
DMN8FAG	RU	https://pubmed.ncbi.nlm.nih.gov/15162158

DMN8FAG	DI	DMN8FAG
DMN8FAG	DN	BP4.879a
DMN8FAG	MI	TTPC4TU
DMN8FAG	MN	5-HT 3A receptor (HTR3A)
DMN8FAG	MT	DTT
DMN8FAG	MA	Antagonist
DMN8FAG	RN	Pharmacological and regional characterization of [3H]LY278584 binding sites in human brain. J Neurochem. 1993 Feb;60(2):730-7.
DMN8FAG	RU	https://pubmed.ncbi.nlm.nih.gov/8419547

DMN8FAG	DI	DMN8FAG
DMN8FAG	DN	BP4.879a
DMN8FAG	MI	TT4C8EA
DMN8FAG	MN	Dopamine D3 receptor (D3R)
DMN8FAG	MT	DTT
DMN8FAG	MA	Antagonist
DMN8FAG	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMN8FAG	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DM3O4BG	DI	DM3O4BG
DM3O4BG	DN	BQ-518
DM3O4BG	MI	TTKRD0G
DM3O4BG	MN	Endothelin A receptor (EDNRA)
DM3O4BG	MT	DTT
DM3O4BG	MA	Modulator
DM3O4BG	RN	Structure-activity relationships of cyclic pentapeptide endothelin A receptor antagonists. J Med Chem. 1995 Oct 13;38(21):4309-24.
DM3O4BG	RU	https://pubmed.ncbi.nlm.nih.gov/7473559

DMPRNQL	DI	DMPRNQL
DMPRNQL	DN	BQ610
DMPRNQL	MI	TTKRD0G
DMPRNQL	MN	Endothelin A receptor (EDNRA)
DMPRNQL	MT	DTT
DMPRNQL	MA	Antagonist
DMPRNQL	RN	Human optic nerve head astrocytes as a target for endothelin-1. Invest Ophthalmol Vis Sci. 2002 Aug;43(8):2704-13.
DMPRNQL	RU	https://pubmed.ncbi.nlm.nih.gov/12147606

DMGX0E1	DI	DMGX0E1
DMGX0E1	DN	BRL 26830A
DMGX0E1	MI	TTMXGCW
DMGX0E1	MN	Adrenergic receptor beta-3 (ADRB3)
DMGX0E1	MT	DTT
DMGX0E1	MA	Agonist
DMGX0E1	RN	Anti-obesity and anti-diabetic actions of a beta 3-adrenoceptor agonist, BRL 26830A, in yellow KK mice. Endocrinol Jpn. 1991 Aug;38(4):397-403.
DMGX0E1	RU	https://pubmed.ncbi.nlm.nih.gov/1687027

DMS4320	DI	DMS4320
DMS4320	DN	BRL 37344
DMS4320	MI	TTMXGCW
DMS4320	MN	Adrenergic receptor beta-3 (ADRB3)
DMS4320	MT	DTT
DMS4320	MA	Agonist
DMS4320	RN	Effects of several putative beta 3-adrenoceptor agonists on lipolysis in human omental adipocytes. Int J Obes Relat Metab Disord. 1996 May;20(5):428-34.
DMS4320	RU	https://pubmed.ncbi.nlm.nih.gov/8696421

DMBC12X	DI	DMBC12X
DMBC12X	DN	BRL-42715
DMBC12X	MI	TTHI19T
DMBC12X	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMBC12X	MT	DTT
DMBC12X	MA	Inhibitor
DMBC12X	RN	In vitro evaluation of BRL 42715, a novel beta-lactamase inhibitor. Antimicrob Agents Chemother. 1989 Sep;33(9):1580-7.
DMBC12X	RU	https://pubmed.ncbi.nlm.nih.gov/2817854

DMAH3Z9	DI	DMAH3Z9
DMAH3Z9	DN	BTS-79018
DMAH3Z9	MI	TTSQIFT
DMAH3Z9	MN	5-HT 1A receptor (HTR1A)
DMAH3Z9	MT	DTT
DMAH3Z9	MA	Binder
DMAH3Z9	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMAH3Z9	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMAH3Z9	DI	DMAH3Z9
DMAH3Z9	DN	BTS-79018
DMAH3Z9	MI	TT4C8EA
DMAH3Z9	MN	Dopamine D3 receptor (D3R)
DMAH3Z9	MT	DTT
DMAH3Z9	MA	Binder
DMAH3Z9	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMAH3Z9	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMJDMTK	DI	DMJDMTK
DMJDMTK	DN	BU-4514N
DMJDMTK	MI	TTEDJN4
DMJDMTK	MN	Low-affinity nerve growth factor receptor (NGFR)
DMJDMTK	MT	DTT
DMJDMTK	MA	Modulator
DMJDMTK	RN	A new neuritogenetic compound BU-4514N produced by Microtetraspora sp. J Antibiot (Tokyo). 1993 Jun;46(6):875-83.
DMJDMTK	RU	https://pubmed.ncbi.nlm.nih.gov/8344867

DM4OT0S	DI	DM4OT0S
DM4OT0S	DN	BU-4601A
DM4OT0S	MI	TT2J34L
DM4OT0S	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM4OT0S	MT	DTT
DM4OT0S	MA	Inhibitor
DM4OT0S	RN	5-Hydroxyanthranilic acid derivatives as potent 5-lipoxygenase inhibitors. J Antibiot (Tokyo). 1993 May;46(5):705-11.
DM4OT0S	RU	https://pubmed.ncbi.nlm.nih.gov/8514624

DMIYPLU	DI	DMIYPLU
DMIYPLU	DN	BVT-142
DMIYPLU	MI	TTJ584C
DMIYPLU	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMIYPLU	MT	DTT
DMIYPLU	MA	Agonist
DMIYPLU	RN	A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects. J Biol Chem. 2004 Sep 24;279(39):41124-30.
DMIYPLU	RU	https://pubmed.ncbi.nlm.nih.gov/15258145

DMIYPLU	DI	DMIYPLU
DMIYPLU	DN	BVT-142
DMIYPLU	MI	TTZMAO3
DMIYPLU	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMIYPLU	MT	DTT
DMIYPLU	MA	Agonist
DMIYPLU	RN	A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects. J Biol Chem. 2004 Sep 24;279(39):41124-30.
DMIYPLU	RU	https://pubmed.ncbi.nlm.nih.gov/15258145

DMHLUFN	DI	DMHLUFN
DMHLUFN	DN	BVT-24834
DMHLUFN	MI	TTMY6L1
DMHLUFN	MN	Fatty acid-binding protein (FABP)
DMHLUFN	MT	DTT
DMHLUFN	MA	Inhibitor
DMHLUFN	RN	Fragment-Based Drug Discovery: A Practical Approach. Edward Zartler, Michael Shapiro, 2008. Page(84).
DMHLUFN	RU	https://books.google.com.hk/books?id=9F9lZr6efAYC&pg=PA84&lpg=PA84&dq=%22BVT-1960%22++Fatty+acid&source=bl&ots=7Gqa3Stpb2&sig=jhrU7gjl54K0_vD7DwfrRUCfLpQ&hl=zh-CN&sa=X&ved=0CBoQ6AEwAGoVChMI0MaW3PzFyAIVFZCOCh1D2QNI#v=onepage&q=%22BVT-1960%22%20%20Fatty%20acid&f=false

DMOZQHX	DI	DMOZQHX
DMOZQHX	DN	BVT-3498
DMOZQHX	MI	TTN7BL9
DMOZQHX	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMOZQHX	MT	DTT
DMOZQHX	MA	Inhibitor
DMOZQHX	RN	Current and future drug targets in weight management. Pharm Res. 2011 Aug;28(8):1792-818.
DMOZQHX	RU	https://pubmed.ncbi.nlm.nih.gov/21181547

DMXFZWJ	DI	DMXFZWJ
DMXFZWJ	DN	BW 373U86
DMXFZWJ	MI	TT27RFC
DMXFZWJ	MN	Opioid receptor delta (OPRD1)
DMXFZWJ	MT	DTT
DMXFZWJ	MA	Agonist
DMXFZWJ	RN	BW373U86, a delta opioid agonist, partially mediates delayed cardioprotection via a free radical mechanism that is independent of opioid receptor stimulation. J Mol Cell Cardiol. 2001 Aug;33(8):1455-65.
DMXFZWJ	RU	https://pubmed.ncbi.nlm.nih.gov/11448134

DMNUMDG	DI	DMNUMDG
DMNUMDG	DN	BW A4C
DMNUMDG	MI	TT2J34L
DMNUMDG	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMNUMDG	MT	DTT
DMNUMDG	MA	Inhibitor
DMNUMDG	RN	Reactive oxygen species and lipoxygenases regulate the oncogenicity of NPM-ALK-positive anaplastic large cell lymphomas. Oncogene. 2009 Jul 23;28(29):2690-6.
DMNUMDG	RU	https://pubmed.ncbi.nlm.nih.gov/19503098

DMNUMDG	DI	DMNUMDG
DMNUMDG	DN	BW A4C
DMNUMDG	MI	TTSJ6Q4
DMNUMDG	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DMNUMDG	MT	DTT
DMNUMDG	MA	Inhibitor
DMNUMDG	RN	Novel and potent inhibitors of 5-lipoxygenase product synthesis based on the structure of pirinixic acid. J Med Chem. 2008 Sep 11;51(17):5449-53.
DMNUMDG	RU	https://pubmed.ncbi.nlm.nih.gov/18710209

DMTYCJ6	DI	DMTYCJ6
DMTYCJ6	DN	BW B70C
DMTYCJ6	MI	TT2J34L
DMTYCJ6	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMTYCJ6	MT	DTT
DMTYCJ6	MA	Inhibitor
DMTYCJ6	RN	Hydroxamic acids and hydroxyureas as novel, selective 5-lipoxygenase inhibitors for possible use in asthma. Agents Actions Suppl. 1991;34:189-99.
DMTYCJ6	RU	https://pubmed.ncbi.nlm.nih.gov/1793063

DMEP9B6	DI	DMEP9B6
DMEP9B6	DN	BW-1003C87
DMEP9B6	MI	TTRK8B9
DMEP9B6	MN	Sodium channel unspecific (NaC)
DMEP9B6	MT	DTT
DMEP9B6	MA	Modulator
DMEP9B6	RN	The pyrimidine-derivative, BW1003C87, protects CA1 and striatal neurons following transient severe forebrain ischaemia in rats. A microdialysis and histological study. Neuroscience. 1993 Sep;56(1):93-9.
DMEP9B6	RU	https://pubmed.ncbi.nlm.nih.gov/7901808

DMQM3P4	DI	DMQM3P4
DMQM3P4	DN	BW755C
DMQM3P4	MI	TT2J34L
DMQM3P4	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMQM3P4	MT	DTT
DMQM3P4	MA	Inhibitor
DMQM3P4	RN	Anti-inflammatory activity of Acanthus ilicifolius. J Ethnopharmacol. 2008 Oct 30;120(1):7-12.
DMQM3P4	RU	https://pubmed.ncbi.nlm.nih.gov/18703126

DMF6OY8	DI	DMF6OY8
DMF6OY8	DN	BW-A502U
DMF6OY8	MI	TTUTN1I
DMF6OY8	MN	Human Deoxyribonucleic acid (hDNA)
DMF6OY8	MT	DTT
DMF6OY8	MA	Binder
DMF6OY8	RN	Pharmacokinetics and disposition in the rat of a DNA intercalator 502U83. Drug Metab Dispos. 1993 Jan-Feb;21(1):62-70.
DMF6OY8	RU	https://pubmed.ncbi.nlm.nih.gov/8095228

DM0P8CE	DI	DM0P8CE
DM0P8CE	DN	BX-044
DM0P8CE	MI	TT5QA2I
DM0P8CE	MN	Plasminogen activator inhibitor (PAI)
DM0P8CE	MT	DTT
DM0P8CE	MA	Inhibitor
DM0P8CE	RN	Characterization of a small molecule PAI-1 inhibitor, ZK4044. Thromb Res. 2005;115(4):341-50.
DM0P8CE	RU	https://pubmed.ncbi.nlm.nih.gov/15668194

DMPL0C9	DI	DMPL0C9
DMPL0C9	DN	C-202
DMPL0C9	MI	TTNJYV2
DMPL0C9	MN	Gamma-aminobutyric acid receptor (GAR)
DMPL0C9	MT	DTT
DMPL0C9	MA	Modulator
DMPL0C9	RN	Capreomycin Binds across the Ribosomal Subunit Interface Using tlyA-Encoded 2 O-Methylations in 16S and 23S rRNAs. Molecular Cell Volume 23, Issue 2, 21 July 2006, Pages 173-182.
DMPL0C9	RU	http://www.sciencedirect.com/science/article/pii/S1097276506004333

DMJQ3WR	DI	DMJQ3WR
DMJQ3WR	DN	C-AFG
DMJQ3WR	MI	TT84ETX
DMJQ3WR	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMJQ3WR	MT	DTT
DMJQ3WR	MA	Modulator
DMJQ3WR	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003394)
DMJQ3WR	RU	http://adisinsight.springer.com/drugs/800003394

DM9X2D0	DI	DM9X2D0
DM9X2D0	DN	Calphostin C
DM9X2D0	MI	DTUGYRD
DM9X2D0	MN	P-glycoprotein 1 (ABCB1)
DM9X2D0	MT	DTP
DM9X2D0	MA	Substrate
DM9X2D0	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM9X2D0	RU	https://doi.org/10.1007/s11095-012-0935-x

DM9X2D0	DI	DM9X2D0
DM9X2D0	DN	Calphostin C
DM9X2D0	MI	TTYVX59
DM9X2D0	MN	Protein kinase C (PRKC)
DM9X2D0	MT	DTT
DM9X2D0	MA	Inhibitor
DM9X2D0	RN	Protein kinase C zeta isoform is critical for proliferation in human glioblastoma cell lines. J Neurooncol. 2000 Apr;47(2):109-15.
DM9X2D0	RU	https://pubmed.ncbi.nlm.nih.gov/10982151

DMZ3QHF	DI	DMZ3QHF
DMZ3QHF	DN	CB-102930
DMZ3QHF	MI	TTBZHDM
DMZ3QHF	MN	Fungal Isoleucyl t-RNA synthetase (Fung ILS1)
DMZ3QHF	MT	DTT
DMZ3QHF	MA	Inhibitor
DMZ3QHF	RN	Prospects for Aminoacyl-tRNA Synthetase Inhibitors as New Antimicrobial Agents. Antimicrob Agents Chemother. 2005 December; 49(12): 4821-4833.
DMZ3QHF	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315952/

DM75KBM	DI	DM75KBM
DM75KBM	DN	CB-1267
DM75KBM	MI	TTK59TV
DM75KBM	MN	Vitamin D3 receptor (VDR)
DM75KBM	MT	DTT
DM75KBM	MA	Modulator
DM75KBM	RN	Novel 20-epi-vitamin D3 analog combined with 9-cis-retinoic acid markedly inhibits colony growth of prostate cancer cells. Prostate. 1999 Aug 1;40(3):141-9.
DM75KBM	RU	https://pubmed.ncbi.nlm.nih.gov/10398275

DMJAGKY	DI	DMJAGKY
DMJAGKY	DN	CBR-2092
DMJAGKY	MI	TTN6J5F
DMJAGKY	MN	Bacterial DNA gyrase (Bact gyrase)
DMJAGKY	MT	DTT
DMJAGKY	MA	Modulator
DMJAGKY	RN	In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus.Antimicrob Agents Chemother.2008 Jul;52(7):2313-23.
DMJAGKY	RU	https://www.ncbi.nlm.nih.gov/pubmed/18443108

DMJAGKY	DI	DMJAGKY
DMJAGKY	DN	CBR-2092
DMJAGKY	MI	TTIXTO3
DMJAGKY	MN	Staphylococcus Topoisomerase IV (Stap-coc parC)
DMJAGKY	MT	DTT
DMJAGKY	MA	Modulator
DMJAGKY	RN	In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus.Antimicrob Agents Chemother.2008 Jul;52(7):2313-23.
DMJAGKY	RU	https://www.ncbi.nlm.nih.gov/pubmed/18443108

DMAZB1R	DI	DMAZB1R
DMAZB1R	DN	CCR5Qb
DMAZB1R	MI	TT2CEJG
DMAZB1R	MN	C-C chemokine receptor type 5 (CCR5)
DMAZB1R	MT	DTT
DMAZB1R	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021743)
DMAZB1R	RU	http://adisinsight.springer.com/drugs/800021743

DM5FEBQ	DI	DM5FEBQ
DM5FEBQ	DN	CD-832
DM5FEBQ	MI	TT5HONZ
DM5FEBQ	MN	Calcium channel unspecific (CaC)
DM5FEBQ	MT	DTT
DM5FEBQ	MA	Modulator
DM5FEBQ	RN	Effects of CD-832, a new calcium antagonist, on intracranial pressure in anesthetized dogs. Life Sci. 1998;62(19):PL283-8.
DM5FEBQ	RU	https://pubmed.ncbi.nlm.nih.gov/9585114

DMGQ9WP	DI	DMGQ9WP
DMGQ9WP	DN	CDE-5110
DMGQ9WP	MI	TTZN7RP
DMGQ9WP	MN	Rho-associated protein kinase 1 (ROCK1)
DMGQ9WP	MT	DTT
DMGQ9WP	MA	Inhibitor
DMGQ9WP	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025959)
DMGQ9WP	RU	http://adisinsight.springer.com/drugs/800025959

DMGQ9WP	DI	DMGQ9WP
DMGQ9WP	DN	CDE-5110
DMGQ9WP	MI	TTGWKQJ
DMGQ9WP	MN	Rho-associated protein kinase 2 (ROCK2)
DMGQ9WP	MT	DTT
DMGQ9WP	MA	Inhibitor
DMGQ9WP	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025959)
DMGQ9WP	RU	http://adisinsight.springer.com/drugs/800025959

DMVHTQI	DI	DMVHTQI
DMVHTQI	DN	CDE-5498
DMVHTQI	MI	TTPLQO0
DMVHTQI	MN	Voltage-gated potassium channel Kv4.3 (KCND3)
DMVHTQI	MT	DTT
DMVHTQI	MA	Antagonist
DMVHTQI	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020444)
DMVHTQI	RU	http://adisinsight.springer.com/drugs/800020444

DMA0DKI	DI	DMA0DKI
DMA0DKI	DN	CDE-6960
DMA0DKI	MI	TTBZ7OD
DMA0DKI	MN	Protein kinase C epsilon (PRKCE)
DMA0DKI	MT	DTT
DMA0DKI	MA	Inhibitor
DMA0DKI	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025002)
DMA0DKI	RU	http://adisinsight.springer.com/drugs/800025002

DMA0DKI	DI	DMA0DKI
DMA0DKI	DN	CDE-6960
DMA0DKI	MI	TT8QL1J
DMA0DKI	MN	Protein kinase C theta (PRKCQ)
DMA0DKI	MT	DTT
DMA0DKI	MA	Inhibitor
DMA0DKI	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025002)
DMA0DKI	RU	http://adisinsight.springer.com/drugs/800025002

DMGMS2D	DI	DMGMS2D
DMGMS2D	DN	CDP-845
DMGMS2D	MI	TTLM12X
DMGMS2D	MN	Matrix metalloproteinase-2 (MMP-2)
DMGMS2D	MT	DTT
DMGMS2D	MA	Modulator
DMGMS2D	RN	Clinical potential of matrix metalloprotease inhibitors. Drugs R D. 1999 Feb;1(2):117-29.
DMGMS2D	RU	https://pubmed.ncbi.nlm.nih.gov/10566004

DMGMS2D	DI	DMGMS2D
DMGMS2D	DN	CDP-845
DMGMS2D	MI	TT6X50U
DMGMS2D	MN	Matrix metalloproteinase-9 (MMP-9)
DMGMS2D	MT	DTT
DMGMS2D	MA	Modulator
DMGMS2D	RN	Clinical potential of matrix metalloprotease inhibitors. Drugs R D. 1999 Feb;1(2):117-29.
DMGMS2D	RU	https://pubmed.ncbi.nlm.nih.gov/10566004

DMNJXRG	DI	DMNJXRG
DMNJXRG	DN	CEB-925
DMNJXRG	MI	TTMF541
DMNJXRG	MN	Liver carboxylesterase (CES1)
DMNJXRG	MT	DTT
DMNJXRG	MA	Inhibitor
DMNJXRG	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010079)
DMNJXRG	RU	http://adisinsight.springer.com/drugs/800010079

DMGEFX7	DI	DMGEFX7
DMGEFX7	DN	CEE-03-320
DMGEFX7	MI	TTZFYLI
DMGEFX7	MN	Dopamine D1 receptor (D1R)
DMGEFX7	MT	DTT
DMGEFX7	MA	Modulator
DMGEFX7	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007189)
DMGEFX7	RU	http://adisinsight.springer.com/drugs/800007189

DMZE0SJ	DI	DMZE0SJ
DMZE0SJ	DN	CEP-4186
DMZE0SJ	MI	TTK59TV
DMZE0SJ	MN	Vitamin D3 receptor (VDR)
DMZE0SJ	MT	DTT
DMZE0SJ	MA	Modulator
DMZE0SJ	RN	Novel vitamin D3 analog (CB1093) when combined with paclitaxel and cisplatin inhibit growth of MCF-7 human breast cancer cells in vivo. Int J Oncol. 1998 Sep;13(3):421-8.
DMZE0SJ	RU	https://pubmed.ncbi.nlm.nih.gov/9683773

DMTI10C	DI	DMTI10C
DMTI10C	DN	CEP-427
DMTI10C	MI	TTEDJN4
DMTI10C	MN	Low-affinity nerve growth factor receptor (NGFR)
DMTI10C	MT	DTT
DMTI10C	MA	Modulator
DMTI10C	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1888).
DMTI10C	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1888

DMDH0AM	DI	DMDH0AM
DMDH0AM	DN	CEP-431
DMDH0AM	MI	TTZBFA0
DMDH0AM	MN	Protease unspecific (PRO)
DMDH0AM	MT	DTT
DMDH0AM	MA	Inhibitor
DMDH0AM	RN	US patent application no. 7,935,815, Imidazoyl pyridine compounds and salts thereof.
DMDH0AM	RU	http://www.google.com/patents/US7935815

DMFRW0G	DI	DMFRW0G
DMFRW0G	DN	CEP-5214
DMFRW0G	MI	TTUTJGQ
DMFRW0G	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMFRW0G	MT	DTT
DMFRW0G	MA	Antagonist
DMFRW0G	RN	Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration. Blood. 2006 Aug 15;108(4):1243-50.
DMFRW0G	RU	https://pubmed.ncbi.nlm.nih.gov/16621967

DM956N7	DI	DM956N7
DM956N7	DN	CEP-751
DM956N7	MI	TT4DXQT
DM956N7	MN	Proto-oncogene c-Ret (RET)
DM956N7	MT	DTT
DM956N7	MA	Inhibitor
DM956N7	RN	CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth. Cancer Res. 2003 Sep 1;63(17):5559-63.
DM956N7	RU	https://pubmed.ncbi.nlm.nih.gov/14500395

DMIDFLV	DI	DMIDFLV
DMIDFLV	DN	Cetamolol
DMIDFLV	MI	TTR6W5O
DMIDFLV	MN	Adrenergic receptor beta-1 (ADRB1)
DMIDFLV	MT	DTT
DMIDFLV	MA	Modulator
DMIDFLV	RN	Comparison of the beta-adrenoceptor affinity and selectivity of cetamolol, atenolol, betaxolol, and ICI-118,551. J Cardiovasc Pharmacol. 1988 Aug;12(2):208-17.
DMIDFLV	RU	https://pubmed.ncbi.nlm.nih.gov/2459552

DM5ESZU	DI	DM5ESZU
DM5ESZU	DN	CGP-25454A
DM5ESZU	MI	TTEX248
DM5ESZU	MN	Dopamine D2 receptor (D2R)
DM5ESZU	MT	DTT
DM5ESZU	MA	Modulator
DM5ESZU	RN	CGP 25454A, a novel and selective presynaptic dopamine autoreceptor antagonist. Naunyn Schmiedebergs Arch Pharmacol. 1994 Sep;350(3):230-8.
DM5ESZU	RU	https://pubmed.ncbi.nlm.nih.gov/7824038

DMZM70X	DI	DMZM70X
DMZM70X	DN	CGP-35348
DMZM70X	MI	TTDCVZW
DMZM70X	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMZM70X	MT	DTT
DMZM70X	MA	Modulator
DMZM70X	RN	The selective GABAB antagonist CGP-35348 blocks spike-wave bursts in the cholesterol synthesis rat absence epilepsy model. Brain Res. 1996 Aug 12;729(2):147-50.
DMZM70X	RU	https://www.ncbi.nlm.nih.gov/pubmed/8876982

DM69YWS	DI	DM69YWS
DM69YWS	DN	CGP-40215A
DM69YWS	MI	TTBFROQ
DM69YWS	MN	S-adenosylmethionine decarboxylase proenzyme (AMD1)
DM69YWS	MT	DTT
DM69YWS	MA	Modulator
DM69YWS	RN	Antileishmanial effect of a potent S-adenosylmethionine decarboxylase inhibitor: CGP 40215A. Pharmacol Res. 1996 Jan;33(1):67-70.
DM69YWS	RU	https://pubmed.ncbi.nlm.nih.gov/8817649

DMIWUFC	DI	DMIWUFC
DMIWUFC	DN	CGP-52411
DMIWUFC	MI	TTGKNB4
DMIWUFC	MN	Epidermal growth factor receptor (EGFR)
DMIWUFC	MT	DTT
DMIWUFC	MA	Inhibitor
DMIWUFC	RN	Retinoic acid-induced RB (retinoblastoma) hypophosphorylation enhanced by CGP 52411 (4,5-dianilinophthalimide), an EGF family tyrosine kinase receptor inhibitor. Eur J Cell Biol. 1996 Apr;69(4):327-34.
DMIWUFC	RU	https://pubmed.ncbi.nlm.nih.gov/8741214

DM9VDZP	DI	DM9VDZP
DM9VDZP	DN	CGP-53353
DM9VDZP	MI	TTGKNB4
DM9VDZP	MN	Epidermal growth factor receptor (EGFR)
DM9VDZP	MT	DTT
DM9VDZP	MA	Inhibitor
DM9VDZP	RN	Dianilinophthalimides: potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase. J Med Chem. 1994 Apr 1;37(7):1015-27.
DM9VDZP	RU	https://pubmed.ncbi.nlm.nih.gov/8151612

DMJ325M	DI	DMJ325M
DMJ325M	DN	CGP-53716
DMJ325M	MI	TTI2WET
DMJ325M	MN	Platelet-derived growth factor receptor (PDGFR)
DMJ325M	MT	DTT
DMJ325M	MA	Modulator
DMJ325M	RN	Inhibition of cell growth: effects of the tyrosine kinase inhibitor CGP 53716. J Pharmacol Exp Ther. 1997 Oct;283(1):402-10.
DMJ325M	RU	https://pubmed.ncbi.nlm.nih.gov/9336349

DM4TGY0	DI	DM4TGY0
DM4TGY0	DN	CGP-60474
DM4TGY0	MI	TTH6V3D
DM4TGY0	MN	Cyclin-dependent kinase 1 (CDK1)
DM4TGY0	MT	DTT
DM4TGY0	MA	Inhibitor
DM4TGY0	RN	Synthesis and discovery of pyrazine-pyridine biheteroaryl as a novel series of potent vascular endothelial growth factor receptor-2 inhibitors. J Med Chem. 2005 Mar 24;48(6):1886-900.
DM4TGY0	RU	https://pubmed.ncbi.nlm.nih.gov/15771433

DMRLXC3	DI	DMRLXC3
DMRLXC3	DN	CGP-70726
DMRLXC3	MI	TT5FNQT
DMRLXC3	MN	Human immunodeficiency virus Protease (HIV PR)
DMRLXC3	MT	DTT
DMRLXC3	MA	Modulator
DMRLXC3	RN	Oral bioavailability of a poorly water soluble HIV-1 protease inhibitor incorporated into pH-sensitive particles: effect of the particle size and nutritional state. J Control Release. 2000 Aug 10;68(2):291-8.
DMRLXC3	RU	https://pubmed.ncbi.nlm.nih.gov/10925137

DMKUETX	DI	DMKUETX
DMKUETX	DN	CGS 8515
DMKUETX	MI	TT2J34L
DMKUETX	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMKUETX	MT	DTT
DMKUETX	MA	Inhibitor
DMKUETX	RN	Characterization of CGS 8515 as a selective 5-lipoxygenase inhibitor using in vitro and in vivo models. Biochim Biophys Acta. 1988 Apr 15;959(3):332-42.
DMKUETX	RU	https://pubmed.ncbi.nlm.nih.gov/2833314

DM6MEX4	DI	DM6MEX4
DM6MEX4	DN	CGS-12066B
DM6MEX4	MI	TTK8CXU
DM6MEX4	MN	5-HT 1B receptor (HTR1B)
DM6MEX4	MT	DTT
DM6MEX4	MA	Modulator
DM6MEX4	RN	Biochemical and pharmacological characterization of CGS 12066B, a selective serotonin-1B agonist. Eur J Pharmacol. 1987 Apr 7;136(1):1-9.
DM6MEX4	RU	https://www.ncbi.nlm.nih.gov/pubmed/3496228

DMUPKYO	DI	DMUPKYO
DMUPKYO	DN	CGS-13080
DMUPKYO	MI	TTKNWZ4
DMUPKYO	MN	Thromboxane-A synthase (TBXAS1)
DMUPKYO	MT	DTT
DMUPKYO	MA	Inhibitor
DMUPKYO	RN	Imidazo[1,5-a]pyridines: a new class of thromboxane A2 synthetase inhibitors. J Med Chem. 1985 Feb;28(2):164-70.
DMUPKYO	RU	https://pubmed.ncbi.nlm.nih.gov/3918169

DMMZJY3	DI	DMMZJY3
DMMZJY3	DN	CGS-17867A
DMMZJY3	MI	TTBMV1G
DMMZJY3	MN	GABA(A) receptor alpha-2 (GABRA2)
DMMZJY3	MT	DTT
DMMZJY3	MA	Inhibitor
DMMZJY3	RN	2,5-Dihydropyrazolo[4,3-c]pyridin-3-ones: functionally selective benzodiazepine binding site ligands on the GABAA receptor. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3441-4.
DMMZJY3	RU	https://pubmed.ncbi.nlm.nih.gov/15177449

DMMZJY3	DI	DMMZJY3
DMMZJY3	DN	CGS-17867A
DMMZJY3	MI	TT06RH5
DMMZJY3	MN	GABA(A) receptor gamma-2 (GABRG2)
DMMZJY3	MT	DTT
DMMZJY3	MA	Inhibitor
DMMZJY3	RN	2,5-Dihydropyrazolo[4,3-c]pyridin-3-ones: functionally selective benzodiazepine binding site ligands on the GABAA receptor. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3441-4.
DMMZJY3	RU	https://pubmed.ncbi.nlm.nih.gov/15177449

DMMZJY3	DI	DMMZJY3
DMMZJY3	DN	CGS-17867A
DMMZJY3	MI	TTNJYV2
DMMZJY3	MN	Gamma-aminobutyric acid receptor (GAR)
DMMZJY3	MT	DTT
DMMZJY3	MA	Inhibitor
DMMZJY3	RN	2,5-Dihydropyrazolo[4,3-c]pyridin-3-ones: functionally selective benzodiazepine binding site ligands on the GABAA receptor. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3441-4.
DMMZJY3	RU	https://pubmed.ncbi.nlm.nih.gov/15177449

DM4W3MU	DI	DM4W3MU
DM4W3MU	DN	CGS-18102A
DM4W3MU	MI	TTSQIFT
DM4W3MU	MN	5-HT 1A receptor (HTR1A)
DM4W3MU	MT	DTT
DM4W3MU	MA	Modulator
DM4W3MU	RN	Quantitative determination of CGS 18102A, a new anxiolytic, in human plasma using capillary gas chromatography/mass spectrometry. Biomed Chromatogr. 1992 Sep-Oct;6(5):244-7.
DM4W3MU	RU	https://pubmed.ncbi.nlm.nih.gov/1361157

DMFZM09	DI	DMFZM09
DMFZM09	DN	CGS-26303
DMFZM09	MI	TT5TKPM
DMFZM09	MN	Neutral endopeptidase (MME)
DMFZM09	MT	DTT
DMFZM09	MA	Inhibitor
DMFZM09	RN	Potent non-peptidic dual inhibitors of endothelin-converting enzyme and neutral endopeptidase 24.11, Bioorg. Med. Chem. Lett. 7(8):1059-1064 (1997).
DMFZM09	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97001595

DM4U72A	DI	DM4U72A
DM4U72A	DN	CGS-26393
DM4U72A	MI	TT5TKPM
DM4U72A	MN	Neutral endopeptidase (MME)
DM4U72A	MT	DTT
DM4U72A	MA	Modulator
DM4U72A	RN	Oral administration of an inhibitor of endothelin-converting enzyme attenuates cerebral vasospasm following experimental subarachnoid haemorrhage in rabbits. Clin Sci (Lond). 2002 Aug;103 Suppl 48:414S-417S.
DM4U72A	RU	https://pubmed.ncbi.nlm.nih.gov/12193135

DMJ4FGZ	DI	DMJ4FGZ
DMJ4FGZ	DN	CGS-26529
DMJ4FGZ	MI	TT2J34L
DMJ4FGZ	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMJ4FGZ	MT	DTT
DMJ4FGZ	MA	Inhibitor
DMJ4FGZ	RN	CGS 26529: the biological profile of a novel, orally active 5-lipoxygenase inhibitor with an extended duration of action. Inflamm Res. 1995 Aug;44 Suppl 2:S147-8.
DMJ4FGZ	RU	https://pubmed.ncbi.nlm.nih.gov/8548371

DM8TLY3	DI	DM8TLY3
DM8TLY3	DN	CGS-27830
DM8TLY3	MI	TTZIFHC
DM8TLY3	MN	Voltage-gated calcium channel alpha Cav1.2 (CACNA1C)
DM8TLY3	MT	DTT
DM8TLY3	MA	Inhibitor
DM8TLY3	RN	CGS 27830, a potent nonpeptide endothelin receptor antagonist, Bioorg. Med. Chem. Lett. 3(10):2099-2104 (1993).
DM8TLY3	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01810258

DM8TLY3	DI	DM8TLY3
DM8TLY3	DN	CGS-27830
DM8TLY3	MI	TT7RGTM
DM8TLY3	MN	Voltage-gated calcium channel alpha Cav1.3 (CACNA1D)
DM8TLY3	MT	DTT
DM8TLY3	MA	Inhibitor
DM8TLY3	RN	CGS 27830, a potent nonpeptide endothelin receptor antagonist, Bioorg. Med. Chem. Lett. 3(10):2099-2104 (1993).
DM8TLY3	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01810258

DM94WIO	DI	DM94WIO
DM94WIO	DN	CGS-30440
DM94WIO	MI	TTL69WB
DM94WIO	MN	Angiotensin-converting enzyme (ACE)
DM94WIO	MT	DTT
DM94WIO	MA	Modulator
DM94WIO	RN	Antihypertensive and natriuretic effects of CGS 30440, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase 24.11. J Pharmacol Exp Ther. 1998 Mar;284(3):974-82.
DM94WIO	RU	https://pubmed.ncbi.nlm.nih.gov/9495857

DM94WIO	DI	DM94WIO
DM94WIO	DN	CGS-30440
DM94WIO	MI	TT5TKPM
DM94WIO	MN	Neutral endopeptidase (MME)
DM94WIO	MT	DTT
DM94WIO	MA	Modulator
DM94WIO	RN	Antihypertensive and natriuretic effects of CGS 30440, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase 24.11. J Pharmacol Exp Ther. 1998 Mar;284(3):974-82.
DM94WIO	RU	https://pubmed.ncbi.nlm.nih.gov/9495857

DM1VZ2I	DI	DM1VZ2I
DM1VZ2I	DN	CGS-32359
DM1VZ2I	MI	TTKANGO
DM1VZ2I	MN	Complement C5 (CO5)
DM1VZ2I	MT	DTT
DM1VZ2I	MA	Inhibitor
DM1VZ2I	RN	Anticomplement therapy. Biologics. 2008 December; 2(4): 671-685.
DM1VZ2I	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727911/

DM39PQI	DI	DM39PQI
DM39PQI	DN	CGS-9896
DM39PQI	MI	TT1MPAY
DM39PQI	MN	GABA(A) receptor alpha-1 (GABRA1)
DM39PQI	MT	DTT
DM39PQI	MA	Inhibitor
DM39PQI	RN	Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors. J Med Chem. 2006 Mar 23;49(6):1855-66.
DM39PQI	RU	https://pubmed.ncbi.nlm.nih.gov/16539371

DM39PQI	DI	DM39PQI
DM39PQI	DN	CGS-9896
DM39PQI	MI	TTZA1NY
DM39PQI	MN	GABA(A) receptor beta-2 (GABRB2)
DM39PQI	MT	DTT
DM39PQI	MA	Inhibitor
DM39PQI	RN	Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors. J Med Chem. 2006 Mar 23;49(6):1855-66.
DM39PQI	RU	https://pubmed.ncbi.nlm.nih.gov/16539371

DM39PQI	DI	DM39PQI
DM39PQI	DN	CGS-9896
DM39PQI	MI	TT06RH5
DM39PQI	MN	GABA(A) receptor gamma-2 (GABRG2)
DM39PQI	MT	DTT
DM39PQI	MA	Inhibitor
DM39PQI	RN	Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors. J Med Chem. 2006 Mar 23;49(6):1855-66.
DM39PQI	RU	https://pubmed.ncbi.nlm.nih.gov/16539371

DM39PQI	DI	DM39PQI
DM39PQI	DN	CGS-9896
DM39PQI	MI	TTNJYV2
DM39PQI	MN	Gamma-aminobutyric acid receptor (GAR)
DM39PQI	MT	DTT
DM39PQI	MA	Inhibitor
DM39PQI	RN	Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors. J Med Chem. 2006 Mar 23;49(6):1855-66.
DM39PQI	RU	https://pubmed.ncbi.nlm.nih.gov/16539371

DMADYF7	DI	DMADYF7
DMADYF7	DN	CGX-1160
DMADYF7	MI	TTTUMEP
DMADYF7	MN	Neurotensin receptor type 1 (NTSR1)
DMADYF7	MT	DTT
DMADYF7	MA	Agonist
DMADYF7	RN	Clinical status of anti-cancer agents derived from marine sources. Anticancer Agents Med Chem. 2008 Aug;8(6):603-17.
DMADYF7	RU	https://pubmed.ncbi.nlm.nih.gov/18690825

DMJ2P1Q	DI	DMJ2P1Q
DMJ2P1Q	DN	CI-1002
DMJ2P1Q	MI	TT1RS9F
DMJ2P1Q	MN	Acetylcholinesterase (AChE)
DMJ2P1Q	MT	DTT
DMJ2P1Q	MA	Modulator
DMJ2P1Q	RN	PD 142676 (CI 1002), a novel anticholinesterase and muscarinic antagonist. Mol Neurobiol. 1994 Aug-Dec;9(1-3):93-106.
DMJ2P1Q	RU	https://pubmed.ncbi.nlm.nih.gov/7888109

DMUK9L4	DI	DMUK9L4
DMUK9L4	DN	CI-1021
DMUK9L4	MI	TTZPO1L
DMUK9L4	MN	Substance-P receptor (TACR1)
DMUK9L4	MT	DTT
DMUK9L4	MA	Antagonist
DMUK9L4	RN	Gabapentin and the neurokinin(1) receptor antagonist CI-1021 act synergistically in two rat models of neuropathic pain. J Pharmacol Exp Ther. 2002 Nov;303(2):730-5.
DMUK9L4	RU	https://pubmed.ncbi.nlm.nih.gov/12388658

DMI0TD8	DI	DMI0TD8
DMI0TD8	DN	CI-986
DMI0TD8	MI	TT2J34L
DMI0TD8	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMI0TD8	MT	DTT
DMI0TD8	MA	Modulator
DMI0TD8	RN	Role of leukotrienes on coronary vasoconstriction in isolated hearts of arthritic rats: effect of in vivo treatment with CI-986, a dual inhibitor of cyclooxygenase and lipoxygenase. Pharmacology. 2000 Jan;60(1):41-6.
DMI0TD8	RU	https://pubmed.ncbi.nlm.nih.gov/10629442

DMBHYIJ	DI	DMBHYIJ
DMBHYIJ	DN	CI-992
DMBHYIJ	MI	TTPT2QI
DMBHYIJ	MN	Cathepsin D (CTSD)
DMBHYIJ	MT	DTT
DMBHYIJ	MA	Inhibitor
DMBHYIJ	RN	Structure-activity relationships of a series of 2-amino-4-thiazole-containing renin inhibitors. J Med Chem. 1992 Jul 10;35(14):2562-72.
DMBHYIJ	RU	https://pubmed.ncbi.nlm.nih.gov/1635057

DMCJ7N1	DI	DMCJ7N1
DMCJ7N1	DN	CI-996
DMCJ7N1	MI	TTGN1ZA
DMCJ7N1	MN	Angiotensin II receptor (AGTR)
DMCJ7N1	MT	DTT
DMCJ7N1	MA	Modulator
DMCJ7N1	RN	Pharmacologic characterization of CI-996, a new angiotensin receptor antagonist. J Pharmacol Exp Ther. 1995 Mar;272(3):963-9.
DMCJ7N1	RU	https://pubmed.ncbi.nlm.nih.gov/7891350

DMV1J0P	DI	DMV1J0P
DMV1J0P	DN	CI-999
DMV1J0P	MI	TTMF541
DMV1J0P	MN	Liver carboxylesterase (CES1)
DMV1J0P	MT	DTT
DMV1J0P	MA	Inhibitor
DMV1J0P	RN	Inhibitors of acyl-CoA:cholesterol O-acyltransferase (ACAT) as hypocholesterolemic agents: synthesis and structure-activity relationships of novel series of sulfonamides, acylphosphonamides and acylphosphoramidates. Bioorg Med Chem Lett. 1998 Feb 3;8(3):289-94.
DMV1J0P	RU	https://pubmed.ncbi.nlm.nih.gov/9871672

DMBNWM1	DI	DMBNWM1
DMBNWM1	DN	Cilofungin
DMBNWM1	MI	TTZMS1L
DMBNWM1	MN	Fungal Papulacandin B resistance protein 1 (Fung FKS1)
DMBNWM1	MT	DTT
DMBNWM1	MA	Inhibitor
DMBNWM1	RN	Cryptococcus neoformans resistance to echinocandins: (1,3)beta-glucan synthase activity is sensitive to echinocandins. Antimicrob Agents Chemother. 2005 Jul;49(7):2851-6.
DMBNWM1	RU	https://pubmed.ncbi.nlm.nih.gov/15980360

DM0NJMG	DI	DM0NJMG
DM0NJMG	DN	Ciprokiren
DM0NJMG	MI	TTB2MXP
DM0NJMG	MN	Angiotensinogenase renin (REN)
DM0NJMG	MT	DTT
DM0NJMG	MA	Inhibitor
DM0NJMG	RN	Ciprokiren (Ro 44-9375). A renin inhibitor with increasing effects on chronic treatment. Hypertension. 1994 Aug;24(2):163-9.
DM0NJMG	RU	https://pubmed.ncbi.nlm.nih.gov/8039839

DMJBGI1	DI	DMJBGI1
DMJBGI1	DN	CL-184005
DMJBGI1	MI	TTQL5VC
DMJBGI1	MN	Platelet-activating factor receptor (PTAFR)
DMJBGI1	MT	DTT
DMJBGI1	MA	Modulator
DMJBGI1	RN	Studies of the effect of a platelet-activating factor antagonist, CL 184,005, in animal models of gram-negative bacterial sepsis. Antimicrob Agents Chemother. 1992 Sep;36(9):1971-7.
DMJBGI1	RU	https://www.ncbi.nlm.nih.gov/pubmed/1416889

DMYML2N	DI	DMYML2N
DMYML2N	DN	CL-186659
DMYML2N	MI	TTHI19T
DMYML2N	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMYML2N	MT	DTT
DMYML2N	MA	Modulator
DMYML2N	RN	US patent application no. 2004,0023,290, Novel therapeutic agents that modulate enzymatic processes.
DMYML2N	RU	http://www.google.com/patents/US20040023290

DMA4DNX	DI	DMA4DNX
DMA4DNX	DN	CL-387626
DMA4DNX	MI	TT57ID8
DMA4DNX	MN	Respiratory syncytial virus protein F (RSV F)
DMA4DNX	MT	DTT
DMA4DNX	MA	Inhibitor
DMA4DNX	RN	Respiratory Syncytial Virus Entry Inhibitors Targeting the F Protein. Viruses. 2013 January; 5(1): 211-225.
DMA4DNX	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564118/

DM8TQC9	DI	DM8TQC9
DM8TQC9	DN	Clentiazem
DM8TQC9	MI	TT5HONZ
DM8TQC9	MN	Calcium channel unspecific (CaC)
DM8TQC9	MT	DTT
DM8TQC9	MA	Modulator
DM8TQC9	RN	Coronary and cardiac sensitivity to the vasoselective benzothiazepine-like calcium antagonist, clentiazem, in experimental heart failure. Cardiovasc Drugs Ther. 1997 Mar;11(1):71-9.
DM8TQC9	RU	https://www.ncbi.nlm.nih.gov/pubmed/9140681

DM6F8L5	DI	DM6F8L5
DM6F8L5	DN	Clinafloxacin
DM6F8L5	MI	TTN6J5F
DM6F8L5	MN	Bacterial DNA gyrase (Bact gyrase)
DM6F8L5	MT	DTT
DM6F8L5	MA	Modulator
DM6F8L5	RN	DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae. Antimicrob Agents Chemother. 1998 Nov;42(11):2810-6.
DM6F8L5	RU	https://pubmed.ncbi.nlm.nih.gov/9797208

DMVUL4P	DI	DMVUL4P
DMVUL4P	DN	CLX-0301
DMVUL4P	MI	TTJSQEF
DMVUL4P	MN	Tyrosine-protein kinase (PTK)
DMVUL4P	MT	DTT
DMVUL4P	MA	Inhibitor
DMVUL4P	RN	CLX-0901 (Calyx Therapeutics). Curr Opin Investig Drugs. 2001 May;2(5):650-3.
DMVUL4P	RU	https://pubmed.ncbi.nlm.nih.gov/11569941

DMYPRS9	DI	DMYPRS9
DMYPRS9	DN	CLX-0900
DMYPRS9	MI	TTCBFJO
DMYPRS9	MN	Insulin receptor (INSR)
DMYPRS9	MT	DTT
DMYPRS9	MA	Modulator
DMYPRS9	RN	CLX-0901 (Calyx Therapeutics). Curr Opin Investig Drugs. 2001 May;2(5):650-3.
DMYPRS9	RU	https://pubmed.ncbi.nlm.nih.gov/11569941

DMEIW7K	DI	DMEIW7K
DMEIW7K	DN	CMI-206
DMEIW7K	MI	TT2J34L
DMEIW7K	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMEIW7K	MT	DTT
DMEIW7K	MA	Modulator
DMEIW7K	RN	DOI: 10.1016/0960-894X(95)00088-B
DMEIW7K	RU	http://www.sciencedirect.com/science/article/pii/0960894X9500088B

DMEIW7K	DI	DMEIW7K
DMEIW7K	DN	CMI-206
DMEIW7K	MI	TTQL5VC
DMEIW7K	MN	Platelet-activating factor receptor (PTAFR)
DMEIW7K	MT	DTT
DMEIW7K	MA	Modulator
DMEIW7K	RN	DOI: 10.1016/0960-894X(95)00088-B
DMEIW7K	RU	http://www.sciencedirect.com/science/article/pii/0960894X9500088B

DMP3QAZ	DI	DMP3QAZ
DMP3QAZ	DN	CNS-1237
DMP3QAZ	MI	TT1AQ50
DMP3QAZ	MN	Charybdotoxin receptor beta-4 (BKbeta4)
DMP3QAZ	MT	DTT
DMP3QAZ	MA	Modulator
DMP3QAZ	RN	Effects of Ca2+ and Na+ channel inhibitors in vitro and in global cerebral ischaemia in vivo. Eur J Pharmacol. 1997 Aug 6;332(2):121-31.
DMP3QAZ	RU	https://pubmed.ncbi.nlm.nih.gov/9286613

DM03LZB	DI	DM03LZB
DM03LZB	DN	CNS-1307
DM03LZB	MI	TT5TPI6
DM03LZB	MN	Opioid receptor sigma 1 (OPRS1)
DM03LZB	MT	DTT
DM03LZB	MA	Modulator
DM03LZB	RN	Antitussives and substance abuse. Subst Abuse Rehabil. 2013 Nov 6;4:75-82.
DM03LZB	RU	https://pubmed.ncbi.nlm.nih.gov/24648790

DMZ5N2I	DI	DMZ5N2I
DMZ5N2I	DN	CNS-1531
DMZ5N2I	MI	TT9IK2Z
DMZ5N2I	MN	N-methyl-D-aspartate receptor (NMDAR)
DMZ5N2I	MT	DTT
DMZ5N2I	MA	Modulator
DMZ5N2I	RN	WO patent application no. 2009,0164,86, Use of nmda receptor antagonists for treatment of urologic tumors.
DMZ5N2I	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20090205&CC=WO&NR=2009016486A2&KC=A2

DMZY0SF	DI	DMZY0SF
DMZY0SF	DN	CNS-5788
DMZY0SF	MI	TT9IK2Z
DMZY0SF	MN	N-methyl-D-aspartate receptor (NMDAR)
DMZY0SF	MT	DTT
DMZY0SF	MA	Antagonist
DMZY0SF	RN	Identification and characterization of a potential ischemia-selective N-methyl-D-aspartate (NMDA) receptor ion-channel blocker, CNS 5788. Bioorg Med Chem Lett. 2001 Feb 26;11(4):501-4.
DMZY0SF	RU	https://pubmed.ncbi.nlm.nih.gov/11229757

DMU5TZD	DI	DMU5TZD
DMU5TZD	DN	Co-152791
DMU5TZD	MI	TTEX6LM
DMU5TZD	MN	GABA(A) receptor gamma-3 (GABRG3)
DMU5TZD	MT	DTT
DMU5TZD	MA	Modulator
DMU5TZD	RN	Substituted 3beta-phenylethynyl derivatives of 3alpha-hydroxy-5alpha-pregnan-20-one: remarkably potent neuroactive steroid modulators of gamma-aminobutyric acidA receptors. J Pharmacol Exp Ther. 1998Oct;287(1):198-207.
DMU5TZD	RU	https://pubmed.ncbi.nlm.nih.gov/9765338

DMGIZHX	DI	DMGIZHX
DMGIZHX	DN	Co-60549
DMGIZHX	MI	TTGXH6N
DMGIZHX	MN	GABA(A) receptor delta (GABRD)
DMGIZHX	MT	DTT
DMGIZHX	MA	Modulator
DMGIZHX	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007012)
DMGIZHX	RU	http://adisinsight.springer.com/drugs/800007012

DMQESM7	DI	DMQESM7
DMQESM7	DN	Cordil
DMQESM7	MI	TTQ38E9
DMQESM7	MN	Sodium/potassium-transporting ATPase (SPT ATPase)
DMQESM7	MT	DTT
DMQESM7	MA	Modulator
DMQESM7	RN	WO patent application no. 1995,0085,58, Novel deoxy and oxygen-substituted sugar-containing 14-aminosteroid compounds.
DMQESM7	RU	http://www.google.com/patents/WO1995008558A1?cl=en

DMO3486	DI	DMO3486
DMO3486	DN	COSALANE
DMO3486	MI	TTC24WT
DMO3486	MN	C-C chemokine receptor type 1 (CCR1)
DMO3486	MT	DTT
DMO3486	MA	Inhibitor
DMO3486	RN	Inhibition of RANTES/CCR1-mediated chemotaxis by cosalane and related compounds. Bioorg Med Chem Lett. 2001 Jan 8;11(1):59-62.
DMO3486	RU	https://pubmed.ncbi.nlm.nih.gov/11140734

DMS23JX	DI	DMS23JX
DMS23JX	DN	CP-0597
DMS23JX	MI	TTGY8IW
DMS23JX	MN	B2 bradykinin receptor (BDKRB2)
DMS23JX	MT	DTT
DMS23JX	MA	Antagonist
DMS23JX	RN	CP-0597, a selective bradykinin B2 receptor antagonist, inhibits brain injury in a rat model of reversible middle cerebral artery occlusion. Stroke. 1997 Jul;28(7):1430-6.
DMS23JX	RU	https://pubmed.ncbi.nlm.nih.gov/9227696

DMDQBAL	DI	DMDQBAL
DMDQBAL	DN	CP-293019
DMDQBAL	MI	TTSQIFT
DMDQBAL	MN	5-HT 1A receptor (HTR1A)
DMDQBAL	MT	DTT
DMDQBAL	MA	Inhibitor
DMDQBAL	RN	Synthesis, SAR and pharmacology of CP-293,019: a potent, selective dopamine D4 receptor antagonist. Bioorg Med Chem Lett. 1998 Apr 7;8(7):725-30.
DMDQBAL	RU	https://pubmed.ncbi.nlm.nih.gov/9871530

DMCIXYR	DI	DMCIXYR
DMCIXYR	DN	CP-331
DMCIXYR	MI	TTQHJ1K
DMCIXYR	MN	Histamine H2 receptor (H2R)
DMCIXYR	MT	DTT
DMCIXYR	MA	Modulator
DMCIXYR	RN	Conjugation of chlorin p(6) to histamine enhances its cellular uptake and phototoxicity in oral cancer cells. Cancer Chemother Pharmacol. 2011 Aug;68(2):359-69.
DMCIXYR	RU	https://pubmed.ncbi.nlm.nih.gov/20978762

DMDEPKM	DI	DMDEPKM
DMDEPKM	DN	CP-471358
DMDEPKM	MI	TT1GHVO
DMDEPKM	MN	Matrix metalloproteinase (MMP)
DMDEPKM	MT	DTT
DMDEPKM	MA	Inhibitor
DMDEPKM	RN	A phase I and pharmacologic study of the matrix metalloproteinase inhibitor CP-471,358 in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2005 Feb;55(2):136-42.
DMDEPKM	RU	https://pubmed.ncbi.nlm.nih.gov/15592721

DMIZMJD	DI	DMIZMJD
DMIZMJD	DN	CP-663427
DMIZMJD	MI	TT7WZIJ
DMIZMJD	MN	CAAX farnesyltransferase beta (FNTB)
DMIZMJD	MT	DTT
DMIZMJD	MA	Inhibitor
DMIZMJD	RN	WO patent application no. 2011,0881,26, Treatment of viral infection with prenyltransferase inhibitors.
DMIZMJD	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20110721&CC=WO&NR=2011088126A2&KC=A2

DMWFI4A	DI	DMWFI4A
DMWFI4A	DN	CP-67015
DMWFI4A	MI	TTN6J5F
DMWFI4A	MN	Bacterial DNA gyrase (Bact gyrase)
DMWFI4A	MT	DTT
DMWFI4A	MA	Modulator
DMWFI4A	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMWFI4A	RU	https://www.fda.gov/

DMSOT07	DI	DMSOT07
DMSOT07	DN	CP-83101
DMSOT07	MI	TTPADOQ
DMSOT07	MN	HMG-CoA reductase (HMGCR)
DMSOT07	MT	DTT
DMSOT07	MA	Inhibitor
DMSOT07	RN	Efficacy, tissue distribution and biliary excretion of methyl (3R*,5S*)-(E)-3,5-dihydroxy-9,9-diphenyl-6,8-nonadienoate (CP-83101), a hepatoselective inhibitor of HMG-CoA reductase activity in the rat. Biochem Pharmacol. 1990 Sep 15;40(6):1281-93.
DMSOT07	RU	https://pubmed.ncbi.nlm.nih.gov/2403382

DMEJBQY	DI	DMEJBQY
DMEJBQY	DN	CP-903397
DMEJBQY	MI	TTEX248
DMEJBQY	MN	Dopamine D2 receptor (D2R)
DMEJBQY	MT	DTT
DMEJBQY	MA	Modulator
DMEJBQY	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025558)
DMEJBQY	RU	http://adisinsight.springer.com/drugs/800025558

DM4HYWR	DI	DM4HYWR
DM4HYWR	DN	CP-96345
DM4HYWR	MI	TTZPO1L
DM4HYWR	MN	Substance-P receptor (TACR1)
DM4HYWR	MT	DTT
DM4HYWR	MA	Inhibitor
DM4HYWR	RN	2-Aryl-1-azabicyclo[2.2.2]octanes as novel nonpeptide substance P antagonists, Bioorg. Med. Chem. Lett. 4(6):839-842 (1994).
DM4HYWR	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01808593

DM8NVZQ	DI	DM8NVZQ
DM8NVZQ	DN	CR-1795
DM8NVZQ	MI	TTCG0AL
DM8NVZQ	MN	Cholecystokinin receptor type A (CCKAR)
DM8NVZQ	MT	DTT
DM8NVZQ	MA	Inhibitor
DM8NVZQ	RN	Biological properties of (R)-4-benzamido-5-oxopentanoic basic derivatives as CCK-antagonists, Bioorg. Med. Chem. Lett. 3(5):861-866 (1993).
DM8NVZQ	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00806812

DM51XDU	DI	DM51XDU
DM51XDU	DN	CR-2991
DM51XDU	MI	TT34BHT
DM51XDU	MN	Adrenergic receptor alpha-1D (ADRA1D)
DM51XDU	MT	DTT
DM51XDU	MA	Antagonist
DM51XDU	RN	WO patent application no. 2006,1244,90, Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia.
DM51XDU	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20061123&CC=WO&NR=2006124490A2&KC=A2

DM1MBG9	DI	DM1MBG9
DM1MBG9	DN	CR-3124
DM1MBG9	MI	TTNXLKE
DM1MBG9	MN	5-HT 3 receptor (5HT3R)
DM1MBG9	MT	DTT
DM1MBG9	MA	Modulator
DM1MBG9	RN	Physicochemical and biopharmaceutical characterization of endo-2-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-2,3-dihydro-1H-benz[e]isoindol-1-one (CR312... J Pharm Sci. 2006 Dec;95(12):2706-21.
DM1MBG9	RU	https://www.ncbi.nlm.nih.gov/pubmed/16924684

DMTPDX7	DI	DMTPDX7
DMTPDX7	DN	CR-3834
DMTPDX7	MI	TT8DBY3
DMTPDX7	MN	Angiotensin II receptor type-1 (AGTR1)
DMTPDX7	MT	DTT
DMTPDX7	MA	Antagonist
DMTPDX7	RN	Pharmacokinetic study of a new angiotensin-AT1 antagonist by HPLC. J Pharm Biomed Anal. 2008 Sep 29;48(2):422-7.
DMTPDX7	RU	https://pubmed.ncbi.nlm.nih.gov/18514458

DMRNB7V	DI	DMRNB7V
DMRNB7V	DN	CRA-028129
DMRNB7V	MI	TTUMQVO
DMRNB7V	MN	Cathepsin S (CTSS)
DMRNB7V	MT	DTT
DMRNB7V	MA	Inhibitor
DMRNB7V	RN	Phase I clinical trial for cathepsin S inhibitor for psoriasis begins. Celera Genomics. 2005.
DMRNB7V	RU	http://www.newsrx.com/newsletters/FDA-Law-Weekly/2005-10-20/10172005333500FL.html

DM1E7H3	DI	DM1E7H3
DM1E7H3	DN	CS-204
DM1E7H3	MI	TTJ584C
DM1E7H3	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DM1E7H3	MT	DTT
DM1E7H3	MA	Agonist
DM1E7H3	RN	Peroxisome Proliferators-Activated Receptor (PPAR) Modulators and Metabolic Disorders. PPAR Res. 2008; 2008: 679137.
DM1E7H3	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2430035/

DM1E7H3	DI	DM1E7H3
DM1E7H3	DN	CS-204
DM1E7H3	MI	TT2JWF6
DM1E7H3	MN	Peroxisome proliferator-activated receptor delta (PPARD)
DM1E7H3	MT	DTT
DM1E7H3	MA	Agonist
DM1E7H3	RN	Peroxisome Proliferators-Activated Receptor (PPAR) Modulators and Metabolic Disorders. PPAR Res. 2008; 2008: 679137.
DM1E7H3	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2430035/

DM1E7H3	DI	DM1E7H3
DM1E7H3	DN	CS-204
DM1E7H3	MI	TTZMAO3
DM1E7H3	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DM1E7H3	MT	DTT
DM1E7H3	MA	Agonist
DM1E7H3	RN	Peroxisome Proliferators-Activated Receptor (PPAR) Modulators and Metabolic Disorders. PPAR Res. 2008; 2008: 679137.
DM1E7H3	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2430035/

DMFJ4VT	DI	DMFJ4VT
DMFJ4VT	DN	CS-207
DMFJ4VT	MI	TTJ584C
DMFJ4VT	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMFJ4VT	MT	DTT
DMFJ4VT	MA	Agonist
DMFJ4VT	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026848)
DMFJ4VT	RU	http://adisinsight.springer.com/drugs/800026848

DM84KOY	DI	DM84KOY
DM84KOY	DN	CT-1746
DM84KOY	MI	TT6X50U
DM84KOY	MN	Matrix metalloproteinase-9 (MMP-9)
DM84KOY	MT	DTT
DM84KOY	MA	Modulator
DM84KOY	RN	Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor. Clin Exp Metastasis. 1997 Mar;15(2):184-95.
DM84KOY	RU	https://pubmed.ncbi.nlm.nih.gov/9062395

DMQBULC	DI	DMQBULC
DMQBULC	DN	CV 6209
DMQBULC	MI	TTQL5VC
DMQBULC	MN	Platelet-activating factor receptor (PTAFR)
DMQBULC	MT	DTT
DMQBULC	MA	Modulator
DMQBULC	RN	CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo. J Pharmacol Exp Ther. 1987 Jul;242(1):263-8.
DMQBULC	RU	https://www.ncbi.nlm.nih.gov/pubmed/3612533

DMMDO3X	DI	DMMDO3X
DMMDO3X	DN	CVS-995
DMMDO3X	MI	TT6L509
DMMDO3X	MN	Coagulation factor IIa (F2)
DMMDO3X	MT	DTT
DMMDO3X	MA	Inhibitor
DMMDO3X	RN	Synthesis, structure, and structure-activity relationships of divalent thrombin inhibitors containing an alpha-keto-amide transition-state mimetic. Protein Sci. 1996 Mar;5(3):422-33.
DMMDO3X	RU	https://pubmed.ncbi.nlm.nih.gov/8868478

DMPWZCI	DI	DMPWZCI
DMPWZCI	DN	CVT-1
DMPWZCI	MI	TTTRNQW
DMPWZCI	MN	Bile-salt-activated lipase (CEL)
DMPWZCI	MT	DTT
DMPWZCI	MA	Modulator
DMPWZCI	RN	Lack of effect of cholesterol esterase inhibitor CVT-1 on cholesterol absorption and LDL cholesterol in humans. Cardiovasc Drugs Ther. 1999 Sep;13(5):449-54.
DMPWZCI	RU	https://pubmed.ncbi.nlm.nih.gov/10547226

DM0X147	DI	DM0X147
DM0X147	DN	CY-1748
DM0X147	MI	TTD26RC
DM0X147	MN	Cell adhesion molecule (CADM)
DM0X147	MT	DTT
DM0X147	MA	Modulator
DM0X147	RN	US patent application no. 6,492,332, Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation.
DM0X147	RU	https://www.google.com/patents/US6492332

DMPBCLA	DI	DMPBCLA
DMPBCLA	DN	CY-9652
DMPBCLA	MI	TT6S84X
DMPBCLA	MN	Integrin alpha-4/beta-1 (ITGA4/B1)
DMPBCLA	MT	DTT
DMPBCLA	MA	Antagonist
DMPBCLA	RN	US patent application no. 2010,0278,784, Methods and compositions for treating skin conditions.
DMPBCLA	RU	https://www.google.com.ar/patents/US20100278784

DM17NYA	DI	DM17NYA
DM17NYA	DN	CYC-103
DM17NYA	MI	TT0PG8F
DM17NYA	MN	Cyclin-dependent kinase 4 (CDK4)
DM17NYA	MT	DTT
DM17NYA	MA	Inhibitor
DM17NYA	RN	Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154.
DM17NYA	RU	https://pubmed.ncbi.nlm.nih.gov/21253554

DM17NYA	DI	DM17NYA
DM17NYA	DN	CYC-103
DM17NYA	MI	TTO0FDJ
DM17NYA	MN	Cyclin-dependent kinase 6 (CDK6)
DM17NYA	MT	DTT
DM17NYA	MA	Inhibitor
DM17NYA	RN	WO patent application no. 2007,0898,78, Sutures and anti-scarring agents.
DM17NYA	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20070809&CC=WO&NR=2007089878A2&KC=A2

DMF8TCI	DI	DMF8TCI
DMF8TCI	DN	CZ-112
DMF8TCI	MI	TTGTQHC
DMF8TCI	MN	DNA topoisomerase I (TOP1)
DMF8TCI	MT	DTT
DMF8TCI	MA	Inhibitor
DMF8TCI	RN	Pharmacology of camptothecin esters. Ann N Y Acad Sci. 2000;922:216-23.
DMF8TCI	RU	https://pubmed.ncbi.nlm.nih.gov/11193897

DME07ML	DI	DME07ML
DME07ML	DN	D-21775
DME07ML	MI	TT8R70G
DME07ML	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DME07ML	MT	DTT
DME07ML	MA	Modulator
DME07ML	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 256).
DME07ML	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=256

DM7FTCV	DI	DM7FTCV
DM7FTCV	DN	D-22888
DM7FTCV	MI	TTZ97H5
DM7FTCV	MN	Phosphodiesterase 4A (PDE4A)
DM7FTCV	MT	DTT
DM7FTCV	MA	Inhibitor
DM7FTCV	RN	Effects of a selective PDE4 inhibitor, D-22888, on human airways and eosinophils in vitro and late phase allergic pulmonary eosinophilia in guinea pigs. Pulm Pharmacol Ther. 1998 Feb;11(1):13-21.
DM7FTCV	RU	https://pubmed.ncbi.nlm.nih.gov/9802959

DM7FTCV	DI	DM7FTCV
DM7FTCV	DN	D-22888
DM7FTCV	MI	TTVIAT9
DM7FTCV	MN	Phosphodiesterase 4B (PDE4B)
DM7FTCV	MT	DTT
DM7FTCV	MA	Modulator
DM7FTCV	RN	Effects of a selective PDE4 inhibitor, D-22888, on human airways and eosinophils in vitro and late phase allergic pulmonary eosinophilia in guinea pigs. Pulm Pharmacol Ther. 1998 Feb;11(1):13-21.
DM7FTCV	RU	https://pubmed.ncbi.nlm.nih.gov/9802959

DM7FTCV	DI	DM7FTCV
DM7FTCV	DN	D-22888
DM7FTCV	MI	TTSKMI8
DM7FTCV	MN	Phosphodiesterase 4D (PDE4D)
DM7FTCV	MT	DTT
DM7FTCV	MA	Modulator
DM7FTCV	RN	Effects of a selective PDE4 inhibitor, D-22888, on human airways and eosinophils in vitro and late phase allergic pulmonary eosinophilia in guinea pigs. Pulm Pharmacol Ther. 1998 Feb;11(1):13-21.
DM7FTCV	RU	https://pubmed.ncbi.nlm.nih.gov/9802959

DMBJAUC	DI	DMBJAUC
DMBJAUC	DN	D-26344
DMBJAUC	MI	TT8R70G
DMBJAUC	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMBJAUC	MT	DTT
DMBJAUC	MA	Inhibitor
DMBJAUC	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003256)
DMBJAUC	RU	http://adisinsight.springer.com/drugs/800003256

DM0YFZ6	DI	DM0YFZ6
DM0YFZ6	DN	D-43787
DM0YFZ6	MI	TTATDGJ
DM0YFZ6	MN	Calcium signal-modulating cyclophilin ligand (CAML)
DM0YFZ6	MT	DTT
DM0YFZ6	MA	Binder
DM0YFZ6	RN	Anti-inflammatory effects of a cyclosporine receptor-binding compound, D-43787. J Pharmacol Exp Ther. 2002 May;301(2):738-46.
DM0YFZ6	RU	https://pubmed.ncbi.nlm.nih.gov/11961080

DMXHN6U	DI	DMXHN6U
DMXHN6U	DN	D-5410
DMXHN6U	MI	TT1GHVO
DMXHN6U	MN	Matrix metalloproteinase (MMP)
DMXHN6U	MT	DTT
DMXHN6U	MA	Modulator
DMXHN6U	RN	US patent application no. US20080187572 A1.
DMXHN6U	RU	https://www.google.com.ar/patents/US20080187572

DMHNZ1P	DI	DMHNZ1P
DMHNZ1P	DN	D-9120
DMHNZ1P	MI	TT1GHVO
DMHNZ1P	MN	Matrix metalloproteinase (MMP)
DMHNZ1P	MT	DTT
DMHNZ1P	MA	Inhibitor
DMHNZ1P	RN	WO patent application no. 2006,1139,93, Matrix metalloproteinase inhibitors of tgfss -induced subcapsular cataract formation.
DMHNZ1P	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20061102&CC=WO&NR=2006113993A1&KC=A1

DM3LJK5	DI	DM3LJK5
DM3LJK5	DN	DAA-1097
DM3LJK5	MI	TTPTXIN
DM3LJK5	MN	Translocator protein (TSPO)
DM3LJK5	MT	DTT
DM3LJK5	MA	Agonist
DM3LJK5	RN	Neuropharmacological profile of peripheral benzodiazepine receptor agonists, DAA1097 and DAA1106. Life Sci. 1999;64(16):1455-64.
DM3LJK5	RU	https://pubmed.ncbi.nlm.nih.gov/10321725

DMP3X6Q	DI	DMP3X6Q
DMP3X6Q	DN	Dacetuzumab
DMP3X6Q	MI	TTIJP3Q
DMP3X6Q	MN	TNF related activation protein (CD40LG)
DMP3X6Q	MT	DTT
DMP3X6Q	MA	Modulator
DMP3X6Q	RN	A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia.Leuk Lymphoma.2010 Feb;51(2):228-35.
DMP3X6Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/20038235

DMZ8OMT	DI	DMZ8OMT
DMZ8OMT	DN	DACTIMICIN
DMZ8OMT	MI	TTOVFH2
DMZ8OMT	MN	Bacterial 30S ribosomal RNA (Bact 30S rRNA)
DMZ8OMT	MT	DTT
DMZ8OMT	MA	Inhibitor
DMZ8OMT	RN	Aminoglycosides: Activity and Resistance. Antimicrob Agents Chemother. 1999 April; 43(4): 727-737.
DMZ8OMT	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC89199/

DMFCMPS	DI	DMFCMPS
DMFCMPS	DN	Daidzin
DMFCMPS	MI	TTFLN4T
DMFCMPS	MN	Mitochondrial aldehyde dehydrogenase (ALDH2)
DMFCMPS	MT	DTT
DMFCMPS	MA	Inhibitor
DMFCMPS	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMFCMPS	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMHJAD4	DI	DMHJAD4
DMHJAD4	DN	Daniplestim
DMHJAD4	MI	TTENHJ0
DMHJAD4	MN	Interleukin 3 receptor alpha (IL3RA)
DMHJAD4	MT	DTT
DMHJAD4	MA	Agonist
DMHJAD4	RN	The combined administration of daniplestim and Mpl ligand augments the hematopoietic reconstitution observed with single cytokine administration in a nonhuman primate model of myelosuppression. Stem Cells. 1998;16 Suppl 2:143-54.
DMHJAD4	RU	https://pubmed.ncbi.nlm.nih.gov/11012186

DM6IGRL	DI	DM6IGRL
DM6IGRL	DN	DARGLITAZONE
DM6IGRL	MI	TTZMAO3
DM6IGRL	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DM6IGRL	MT	DTT
DM6IGRL	MA	Agonist
DM6IGRL	RN	The PPAR-gamma agonist, darglitazone, restores acute inflammatory responses to cerebral hypoxia-ischemia in the diabetic ob/ob mouse. J Cereb Blood Flow Metab. 2010 February; 30(2): 352-360.
DM6IGRL	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2949120/

DM160FM	DI	DM160FM
DM160FM	DN	Darodipine
DM160FM	MI	TT5HONZ
DM160FM	MN	Calcium channel unspecific (CaC)
DM160FM	MT	DTT
DM160FM	MA	Modulator
DM160FM	RN	Effect of cromakalim on contractions in rabbit isolated renal artery in the presence and absence of extracellular Ca2+. Br J Pharmacol. 1989 Dec;98(4):1303-11.
DM160FM	RU	https://pubmed.ncbi.nlm.nih.gov/2575415

DM160FM	DI	DM160FM
DM160FM	DN	Darodipine
DM160FM	MI	DE4LYSA
DM160FM	MN	Cytochrome P450 3A4 (CYP3A4)
DM160FM	MT	DME
DM160FM	MA	Metabolism
DM160FM	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DM160FM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DMR80AL	DI	DMR80AL
DMR80AL	DN	Datelliptium chloride
DMR80AL	MI	TTGTQHC
DMR80AL	MN	DNA topoisomerase I (TOP1)
DMR80AL	MT	DTT
DMR80AL	MA	Modulator
DMR80AL	RN	Toxicity of the antitumoral drug datelliptium in hepatic cells: Use of models in vitro for the prediction of toxicity in vivo. Toxicol In Vitro. 1992 Jul;6(4):295-302.
DMR80AL	RU	https://pubmed.ncbi.nlm.nih.gov/20732126

DMR80AL	DI	DMR80AL
DMR80AL	DN	Datelliptium chloride
DMR80AL	MI	TT0IHXV
DMR80AL	MN	DNA topoisomerase II (TOP2)
DMR80AL	MT	DTT
DMR80AL	MA	Modulator
DMR80AL	RN	Toxicity of the antitumoral drug datelliptium in hepatic cells: Use of models in vitro for the prediction of toxicity in vivo. Toxicol In Vitro. 1992 Jul;6(4):295-302.
DMR80AL	RU	https://pubmed.ncbi.nlm.nih.gov/20732126

DMP9GFZ	DI	DMP9GFZ
DMP9GFZ	DN	DAU-6285
DMP9GFZ	MI	TT07C3Y
DMP9GFZ	MN	5-HT 4 receptor (HTR4)
DMP9GFZ	MT	DTT
DMP9GFZ	MA	Modulator
DMP9GFZ	RN	The novel 5-HT4 receptor antagonist DAU 6285 antagonizes 5-hydroxytryptamine-induced tachycardia in pigs. Eur J Pharmacol. 1993 Mar 23;233(2-3):295-7.
DMP9GFZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/8467876

DMJUW8H	DI	DMJUW8H
DMJUW8H	DN	Dazoxiben
DMJUW8H	MI	TTKNWZ4
DMJUW8H	MN	Thromboxane-A synthase (TBXAS1)
DMJUW8H	MT	DTT
DMJUW8H	MA	Inhibitor
DMJUW8H	RN	Metabolic protection of the reperfused canine endocardium by the thromboxane synthetase inhibitor, dazoxiben. Prostaglandins Leukot Essent Fatty Acids. 1988 Jul;33(1):13-22.
DMJUW8H	RU	https://pubmed.ncbi.nlm.nih.gov/3054935

DMTXPSB	DI	DMTXPSB
DMTXPSB	DN	DB-200
DMTXPSB	MI	TTDL0NY
DMTXPSB	MN	Carnitine O-palmitoyltransferase I (CPT1B)
DMTXPSB	MT	DTT
DMTXPSB	MA	Inhibitor
DMTXPSB	RN	Comparison of the effects of carnitine palmitoyltransferase-1 and -2 inhibitors on rat heart hypertrophy. Cardioscience. 1994 Sep;5(3):193-7.
DMTXPSB	RU	https://pubmed.ncbi.nlm.nih.gov/7827256

DM8GHT2	DI	DM8GHT2
DM8GHT2	DN	DBO-11
DM8GHT2	MI	TTKWM86
DM8GHT2	MN	Opioid receptor mu (MOP)
DM8GHT2	MT	DTT
DM8GHT2	MA	Agonist
DM8GHT2	RN	Emerging analgesics in cancer pain management. Expert Opin Emerg Drugs. 2005 Feb;10(1):151-71.
DM8GHT2	RU	https://pubmed.ncbi.nlm.nih.gov/15757410

DMFJ3UW	DI	DMFJ3UW
DMFJ3UW	DN	DBO-17
DMFJ3UW	MI	TTKWM86
DMFJ3UW	MN	Opioid receptor mu (MOP)
DMFJ3UW	MT	DTT
DMFJ3UW	MA	Agonist
DMFJ3UW	RN	Emerging analgesics in cancer pain management. Expert Opin Emerg Drugs. 2005 Feb;10(1):151-71.
DMFJ3UW	RU	https://pubmed.ncbi.nlm.nih.gov/15757410

DM0JDCS	DI	DM0JDCS
DM0JDCS	DN	DBO-83
DM0JDCS	MI	TTJSZTB
DM0JDCS	MN	Nicotinic acetylcholine receptor (nAChR)
DM0JDCS	MT	DTT
DM0JDCS	MA	Agonist
DM0JDCS	RN	The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control. Expert Opin Investig Drugs. 2001 Oct;10(10):1819-30.
DM0JDCS	RU	https://pubmed.ncbi.nlm.nih.gov/11772288

DMCDMWJ	DI	DMCDMWJ
DMCDMWJ	DN	DC-015
DMCDMWJ	MI	TTG28O6
DMCDMWJ	MN	Adrenergic receptor Alpha-1 (ADRA1)
DMCDMWJ	MT	DTT
DMCDMWJ	MA	Antagonist
DMCDMWJ	RN	Antihypertensive and Hypolipidemic Effects of DC-015, a Novel, Potent and Specific alpha(1)-Adrenoceptor Antagonist: Comparison with Prazosin in Spontaneously Hypertensive Rats. J Biomed Sci. 1996 Apr;3(2):108-116.
DMCDMWJ	RU	https://pubmed.ncbi.nlm.nih.gov/11725091

DM5VFR0	DI	DM5VFR0
DM5VFR0	DN	DHP-218
DM5VFR0	MI	TT5HONZ
DM5VFR0	MN	Calcium channel unspecific (CaC)
DM5VFR0	MT	DTT
DM5VFR0	MA	Modulator
DM5VFR0	RN	Effect of DHP-218, a novel dihydropyridine phosphonate, on atrioventricular nodal conductivity compared with its vascular effect in dogs. J Cardiovasc Pharmacol. 1987 Sep;10(3):274-9.
DM5VFR0	RU	https://pubmed.ncbi.nlm.nih.gov/2444774

DM6LP0R	DI	DM6LP0R
DM6LP0R	DN	Dianicline+rimonabant
DM6LP0R	MI	TT6OEDT
DM6LP0R	MN	Cannabinoid receptor 1 (CB1)
DM6LP0R	MT	DTT
DM6LP0R	MA	Agonist
DM6LP0R	RN	Emerging drugs for the treatment of tobacco dependence. Expert Opin Emerg Drugs. 2009 Mar;14(1):23-32.
DM6LP0R	RU	https://pubmed.ncbi.nlm.nih.gov/19278367

DM6LP0R	DI	DM6LP0R
DM6LP0R	DN	Dianicline+rimonabant
DM6LP0R	MI	TTEX248
DM6LP0R	MN	Dopamine D2 receptor (D2R)
DM6LP0R	MT	DTT
DM6LP0R	MA	Antagonist
DM6LP0R	RN	Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole. J Neurochem. 2003 Nov;87(3):631-41.
DM6LP0R	RU	https://pubmed.ncbi.nlm.nih.gov/14535946

DM6LP0R	DI	DM6LP0R
DM6LP0R	DN	Dianicline+rimonabant
DM6LP0R	MI	TT4C8EA
DM6LP0R	MN	Dopamine D3 receptor (D3R)
DM6LP0R	MT	DTT
DM6LP0R	MA	Antagonist
DM6LP0R	RN	Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole. J Neurochem. 2003 Nov;87(3):631-41.
DM6LP0R	RU	https://pubmed.ncbi.nlm.nih.gov/14535946

DM6LP0R	DI	DM6LP0R
DM6LP0R	DN	Dianicline+rimonabant
DM6LP0R	MI	TTJSZTB
DM6LP0R	MN	Nicotinic acetylcholine receptor (nAChR)
DM6LP0R	MT	DTT
DM6LP0R	MA	Agonist
DM6LP0R	RN	Emerging drugs for the treatment of tobacco dependence. Expert Opin Emerg Drugs. 2009 Mar;14(1):23-32.
DM6LP0R	RU	https://pubmed.ncbi.nlm.nih.gov/19278367

DM61BWZ	DI	DM61BWZ
DM61BWZ	DN	Diaspirin crosslinked hemoglobin
DM61BWZ	MI	TTQO71U
DM61BWZ	MN	Hemoglobin (HB)
DM61BWZ	MT	DTT
DM61BWZ	MA	Modulator
DM61BWZ	RN	Diaspirin cross-linked hemoglobin infusion did not influence base deficit and lactic acid levels in two clinical trials of traumatic hemorrhagic shock patient resuscitation. J Trauma. 2010 May;68(5):1158-71.
DM61BWZ	RU	https://pubmed.ncbi.nlm.nih.gov/20145575

DMB74CM	DI	DMB74CM
DMB74CM	DN	DIAVERIDINE
DMB74CM	MI	TTV8DM2
DMB74CM	MN	Bacterial Dihydrofolate reductase (Bact DHFR)
DMB74CM	MT	DTT
DMB74CM	MA	Modulator
DMB74CM	RN	Acute and sub-chronic toxicity study of diaveridine in Wistar rats.Regul Toxicol Pharmacol.2015 Oct;73(1):232-40.
DMB74CM	RU	https://www.ncbi.nlm.nih.gov/pubmed/26209270

DMAK3V7	DI	DMAK3V7
DMAK3V7	DN	DIO-901
DMAK3V7	MI	TT9O6WS
DMAK3V7	MN	Glucagon receptor (GCGR)
DMAK3V7	MT	DTT
DMAK3V7	MA	Agonist
DMAK3V7	RN	Effects of low-dose and high-dose glucagon on glucose production and gluconeogenesis in humans. Metabolism. 2000 Jan;49(1):39-46.
DMAK3V7	RU	https://pubmed.ncbi.nlm.nih.gov/10647062

DMO3XBP	DI	DMO3XBP
DMO3XBP	DN	Divaplon
DMO3XBP	MI	TT1MPAY
DMO3XBP	MN	GABA(A) receptor alpha-1 (GABRA1)
DMO3XBP	MT	DTT
DMO3XBP	MA	Inhibitor
DMO3XBP	RN	(Imidazo[1,2-a]pyrimidin-2-yl)phenylmethanones and related compounds as potential nonsedative anxiolytics. J Med Chem. 1988 Jun;31(6):1220-6.
DMO3XBP	RU	https://pubmed.ncbi.nlm.nih.gov/2897468

DMO3XBP	DI	DMO3XBP
DMO3XBP	DN	Divaplon
DMO3XBP	MI	TTNJYV2
DMO3XBP	MN	Gamma-aminobutyric acid receptor (GAR)
DMO3XBP	MT	DTT
DMO3XBP	MA	Inhibitor
DMO3XBP	RN	(Imidazo[1,2-a]pyrimidin-2-yl)phenylmethanones and related compounds as potential nonsedative anxiolytics. J Med Chem. 1988 Jun;31(6):1220-6.
DMO3XBP	RU	https://pubmed.ncbi.nlm.nih.gov/2897468

DMMGYXR	DI	DMMGYXR
DMMGYXR	DN	Dizocilpine
DMMGYXR	MI	TTJFY5U
DMMGYXR	MN	Adenosine A3 receptor (ADORA3)
DMMGYXR	MT	DTT
DMMGYXR	MA	Inhibitor
DMMGYXR	RN	2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96.
DMMGYXR	RU	https://pubmed.ncbi.nlm.nih.gov/16250647

DMMGYXR	DI	DMMGYXR
DMMGYXR	DN	Dizocilpine
DMMGYXR	MI	TTLD29N
DMMGYXR	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMMGYXR	MT	DTT
DMMGYXR	MA	Inhibitor
DMMGYXR	RN	Synthesis and evaluation of 6,11-ethanohexahydrobenzo[b]quinolizidines: a new class of noncompetitive N-methyl-D-aspartate antagonists. J Med Chem. 1995 Jun 23;38(13):2483-9.
DMMGYXR	RU	https://pubmed.ncbi.nlm.nih.gov/7608913

DMMGYXR	DI	DMMGYXR
DMMGYXR	DN	Dizocilpine
DMMGYXR	MI	TTKJEMQ
DMMGYXR	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMMGYXR	MT	DTT
DMMGYXR	MA	Inhibitor
DMMGYXR	RN	Synthesis and evaluation of 6,11-ethanohexahydrobenzo[b]quinolizidines: a new class of noncompetitive N-methyl-D-aspartate antagonists. J Med Chem. 1995 Jun 23;38(13):2483-9.
DMMGYXR	RU	https://pubmed.ncbi.nlm.nih.gov/7608913

DMMGYXR	DI	DMMGYXR
DMMGYXR	DN	Dizocilpine
DMMGYXR	MI	TTN9D8E
DMMGYXR	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMMGYXR	MT	DTT
DMMGYXR	MA	Inhibitor
DMMGYXR	RN	Synthesis and evaluation of 6,11-ethanohexahydrobenzo[b]quinolizidines: a new class of noncompetitive N-methyl-D-aspartate antagonists. J Med Chem. 1995 Jun 23;38(13):2483-9.
DMMGYXR	RU	https://pubmed.ncbi.nlm.nih.gov/7608913

DMNSDM1	DI	DMNSDM1
DMNSDM1	DN	DMP-696
DMNSDM1	MI	TT7EFHR
DMNSDM1	MN	Corticotropin-releasing factor receptor 1 (CRHR1)
DMNSDM1	MT	DTT
DMNSDM1	MA	Inhibitor
DMNSDM1	RN	In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists. J Med Chem. 2009 Jul 23;52(14):4161-72.
DMNSDM1	RU	https://pubmed.ncbi.nlm.nih.gov/19552436

DMGNUXC	DI	DMGNUXC
DMGNUXC	DN	DMP-757
DMGNUXC	MI	TTJA1ZO
DMGNUXC	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMGNUXC	MT	DTT
DMGNUXC	MA	Inhibitor
DMGNUXC	RN	Synthesis and antiplatelet activity of DMP 757 analogs, Bioorg. Med. Chem. Lett. 5(18):2097-2100 (1995).
DMGNUXC	RU	http://www.sciencedirect.com/science/article/pii/0960894X9500351S

DMO26E7	DI	DMO26E7
DMO26E7	DN	DMP-811
DMO26E7	MI	TTGN1ZA
DMO26E7	MN	Angiotensin II receptor (AGTR)
DMO26E7	MT	DTT
DMO26E7	MA	Modulator
DMO26E7	RN	Disposition of DMP 811 (L-708,404), a potent angiotensin II receptor antagonist, in the rat, monkey, and chimpanzee. Drug Metab Dispos. 1995 Oct;23(10):1104-9.
DMO26E7	RU	https://pubmed.ncbi.nlm.nih.gov/8654199

DMKU469	DI	DMKU469
DMKU469	DN	DMP-963
DMKU469	MI	TT84ETX
DMKU469	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMKU469	MT	DTT
DMKU469	MA	Inhibitor
DMKU469	RN	Effect of drug substance particle size on the characteristics of granulation manufactured in a high-shear mixer. AAPS PharmSciTech. 2000 December; 1(4): 55-61.
DMKU469	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750457/

DMLBS83	DI	DMLBS83
DMLBS83	DN	DMPDDF
DMLBS83	MI	TTU6BFZ
DMLBS83	MN	Candida Thymidylate synthase (Candi TMP1)
DMLBS83	MT	DTT
DMLBS83	MA	Inhibitor
DMLBS83	RN	Folate analogues. 32. Synthesis and biological evaluation of 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid and related compounds. J Med Chem. 1989 Jun;32(6):1284-9.
DMLBS83	RU	https://pubmed.ncbi.nlm.nih.gov/2542557

DMXR3V1	DI	DMXR3V1
DMXR3V1	DN	DNP-004089
DMXR3V1	MI	TT8JRS7
DMXR3V1	MN	Beta-secretase (BACE)
DMXR3V1	MT	DTT
DMXR3V1	MA	Inhibitor
DMXR3V1	RN	US patent application no. 8,269,019, Inhibitors.
DMXR3V1	RU	http://www.google.co.in/patents/US8269019?cl=pt-PT

DM6Q05K	DI	DM6Q05K
DM6Q05K	DN	Dotarizine
DM6Q05K	MI	TTYSN63
DM6Q05K	MN	5-HT 2 receptor (5HT2R)
DM6Q05K	MT	DTT
DM6Q05K	MA	Modulator
DM6Q05K	RN	Vasostabilizing effect of Dotarizine (Ca(2+)-channel blocker) on cerebrovascular reactivity in rabbits. Neurol Res. 2000 Mar;22(2):229-32.
DM6Q05K	RU	https://pubmed.ncbi.nlm.nih.gov/10763515

DM6Q05K	DI	DM6Q05K
DM6Q05K	DN	Dotarizine
DM6Q05K	MI	DE4LYSA
DM6Q05K	MN	Cytochrome P450 3A4 (CYP3A4)
DM6Q05K	MT	DME
DM6Q05K	MA	Metabolism
DM6Q05K	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DM6Q05K	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DM4BPFV	DI	DM4BPFV
DM4BPFV	DN	Doxorubicin-CEA conjugate
DM4BPFV	MI	TT0IHXV
DM4BPFV	MN	DNA topoisomerase II (TOP2)
DM4BPFV	MT	DTT
DM4BPFV	MA	Modulator
DM4BPFV	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM4BPFV	RU	https://www.fda.gov/

DM4BPFV	DI	DM4BPFV
DM4BPFV	DN	Doxorubicin-CEA conjugate
DM4BPFV	MI	TTUTN1I
DM4BPFV	MN	Human Deoxyribonucleic acid (hDNA)
DM4BPFV	MT	DTT
DM4BPFV	MA	Modulator
DM4BPFV	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM4BPFV	RU	https://www.fda.gov/

DM4JBQD	DI	DM4JBQD
DM4JBQD	DN	DPC-333
DM4JBQD	MI	TT6AZXG
DM4JBQD	MN	TNF alpha converting enzyme (ADAM17)
DM4JBQD	MT	DTT
DM4JBQD	MA	Inhibitor
DM4JBQD	RN	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
DM4JBQD	RU	https://pubmed.ncbi.nlm.nih.gov/16634702

DM67VDK	DI	DM67VDK
DM67VDK	DN	DPC-A78277
DM67VDK	MI	TT84ETX
DM67VDK	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM67VDK	MT	DTT
DM67VDK	MA	Inhibitor
DM67VDK	RN	The chimpanzee (Pan troglodytes) as a pharmacokinetic model for selection of drug candidates: model characterization and application. Drug Metab Dispos. 2004 Dec;32(12):1359-69.
DM67VDK	RU	https://pubmed.ncbi.nlm.nih.gov/15333515

DM1AQVE	DI	DM1AQVE
DM1AQVE	DN	DPI-201-106
DM1AQVE	MI	TT2CJVK
DM1AQVE	MN	Adrenergic receptor beta-2 (ADRB2)
DM1AQVE	MT	DTT
DM1AQVE	MA	Inhibitor
DM1AQVE	RN	Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds. Bioorg Med Chem Lett. 2008 Oct 15;18(20):5391-5.
DM1AQVE	RU	https://pubmed.ncbi.nlm.nih.gov/18829308

DM1AQVE	DI	DM1AQVE
DM1AQVE	DN	DPI-201-106
DM1AQVE	MI	TTRK8B9
DM1AQVE	MN	Sodium channel unspecific (NaC)
DM1AQVE	MT	DTT
DM1AQVE	MA	Modulator
DM1AQVE	RN	Interaction between DPI 201-106 enantiomers at the cardiac sodium channel. Mol Pharmacol. 1990 Jan;37(1):17-24.
DM1AQVE	RU	https://pubmed.ncbi.nlm.nih.gov/2153906

DMX4KIT	DI	DMX4KIT
DMX4KIT	DN	Draculin
DMX4KIT	MI	TTFEZ5Q
DMX4KIT	MN	Coagulation factor IX (F9)
DMX4KIT	MT	DTT
DMX4KIT	MA	Modulator
DMX4KIT	RN	Expression of biological activity of draculin, the anticoagulant factor from vampire bat saliva, is strictly dependent on the appropriate glycosylation of the native molecule. Biochim Biophys Acta. 1998 Oct 23;1425(2):291-9.
DMX4KIT	RU	https://pubmed.ncbi.nlm.nih.gov/9795244

DMX4KIT	DI	DMX4KIT
DMX4KIT	DN	Draculin
DMX4KIT	MI	TTCIHJA
DMX4KIT	MN	Coagulation factor Xa (F10)
DMX4KIT	MT	DTT
DMX4KIT	MA	Modulator
DMX4KIT	RN	Expression of biological activity of draculin, the anticoagulant factor from vampire bat saliva, is strictly dependent on the appropriate glycosylation of the native molecule. Biochim Biophys Acta. 1998 Oct 23;1425(2):291-9.
DMX4KIT	RU	https://pubmed.ncbi.nlm.nih.gov/9795244

DM6EJVF	DI	DM6EJVF
DM6EJVF	DN	Droxinavir hydrochloride
DM6EJVF	MI	TT5FNQT
DM6EJVF	MN	Human immunodeficiency virus Protease (HIV PR)
DM6EJVF	MT	DTT
DM6EJVF	MA	Modulator
DM6EJVF	RN	A mutation in human immunodeficiency virus type 1 protease at position 88, located outside the active site, confers resistance to the hydroxyethylurea inhibitor SC-55389A. Antimicrob Agents Chemother. 1997 Mar;41(3):515-22.
DM6EJVF	RU	https://pubmed.ncbi.nlm.nih.gov/9055985

DMAE43P	DI	DMAE43P
DMAE43P	DN	DSP-7238
DMAE43P	MI	TTDIGC1
DMAE43P	MN	Dipeptidyl peptidase 4 (DPP-4)
DMAE43P	MT	DTT
DMAE43P	MA	Inhibitor
DMAE43P	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1612).
DMAE43P	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1612

DMX5SN8	DI	DMX5SN8
DMX5SN8	DN	Du-123015
DMX5SN8	MI	TTSQIFT
DMX5SN8	MN	5-HT 1A receptor (HTR1A)
DMX5SN8	MT	DTT
DMX5SN8	MA	Modulator
DMX5SN8	RN	Neither in vivo MRI nor behavioural assessment indicate therapeutic efficacy for a novel 5HT1A agonist in rat models of ischaemic stroke. BMC Neuroscience 2009, 10:82.
DMX5SN8	RU	http://www.biomedcentral.com/1471-2202/10/82

DM87ZWP	DI	DM87ZWP
DM87ZWP	DN	DU-1777
DM87ZWP	MI	TTL69WB
DM87ZWP	MN	Angiotensin-converting enzyme (ACE)
DM87ZWP	MT	DTT
DM87ZWP	MA	Inhibitor
DM87ZWP	RN	Antihypertensive properties of a new long-acting angiotensin converting enzyme inhibitor in renin-dependent and independent hypertensive models. Arzneimittelforschung. 1995 Aug;45(8):853-8.
DM87ZWP	RU	https://pubmed.ncbi.nlm.nih.gov/7575746

DMZOCHT	DI	DMZOCHT
DMZOCHT	DN	DuP 714
DMZOCHT	MI	TT6L509
DMZOCHT	MN	Coagulation factor IIa (F2)
DMZOCHT	MT	DTT
DMZOCHT	MA	Inhibitor
DMZOCHT	RN	Anticoagulation: the present and future. Clin Appl Thromb Hemost. 2001 Jul;7(3):195-204.
DMZOCHT	RU	https://pubmed.ncbi.nlm.nih.gov/11441979

DMJGCYO	DI	DMJGCYO
DMJGCYO	DN	DuP-129
DMJGCYO	MI	TTMF541
DMJGCYO	MN	Liver carboxylesterase (CES1)
DMJGCYO	MT	DTT
DMJGCYO	MA	Inhibitor
DMJGCYO	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2592).
DMJGCYO	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2592

DM7YORJ	DI	DM7YORJ
DM7YORJ	DN	DuP-630
DM7YORJ	MI	TTOQ9GZ
DM7YORJ	MN	Cytochrome P450 reductase (P450)
DM7YORJ	MT	DTT
DM7YORJ	MA	Modulator
DM7YORJ	RN	CN patent application no. 1096855, Composition produced by treatment and induction of nitrogen mono oxide synthase expressed matter, and use thereof.
DM7YORJ	RU	http://www.google.com/patents/CN1096855C?cl=en

DM872CU	DI	DM872CU
DM872CU	DN	DuP-983
DM872CU	MI	TTOQ9GZ
DM872CU	MN	Cytochrome P450 reductase (P450)
DM872CU	MT	DTT
DM872CU	MA	Modulator
DM872CU	RN	CN patent application no. 1096855, Composition produced by treatment and induction of nitrogen mono oxide synthase expressed matter, and use thereof.
DM872CU	RU	http://www.google.com/patents/CN1096855C?cl=en

DMKNJM7	DI	DMKNJM7
DMKNJM7	DN	DV-7028
DMKNJM7	MI	TTJQOD7
DMKNJM7	MN	5-HT 2A receptor (HTR2A)
DMKNJM7	MT	DTT
DMKNJM7	MA	Agonist
DMKNJM7	RN	Vascular and cardiac effects of DV-7028, a selective, 5-HT2-receptor antagonist in rats. J Cardiovasc Pharmacol. 1998 Aug;32(2):266-73.
DMKNJM7	RU	https://pubmed.ncbi.nlm.nih.gov/9700989

DM3L0T1	DI	DM3L0T1
DM3L0T1	DN	DW-1350
DM3L0T1	MI	TTN53ZF
DM3L0T1	MN	Leukotriene B4 receptor 1 (LTB4R)
DM3L0T1	MT	DTT
DM3L0T1	MA	Modulator
DM3L0T1	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026850)
DM3L0T1	RU	http://adisinsight.springer.com/drugs/800026850

DM2PVMZ	DI	DM2PVMZ
DM2PVMZ	DN	E-0722
DM2PVMZ	MI	TTFBNVI
DM2PVMZ	MN	Aldose reductase (AKR1B1)
DM2PVMZ	MT	DTT
DM2PVMZ	MA	Modulator
DM2PVMZ	RN	Aldose reductase inhibitors and prevention of galactose cataracts in rats. Invest Ophthalmol Vis Sci. 1989 Jul;30(7):1623-32.
DM2PVMZ	RU	https://pubmed.ncbi.nlm.nih.gov/2545646

DMD4GQ8	DI	DMD4GQ8
DMD4GQ8	DN	E-2011
DMD4GQ8	MI	TT3WG5C
DMD4GQ8	MN	Monoamine oxidase type A (MAO-A)
DMD4GQ8	MT	DTT
DMD4GQ8	MA	Modulator
DMD4GQ8	RN	Species differences and mechanism of the epimerization of a new MAO-A inhibitor. Xenobiotica. 1998 Mar;28(3):269-80.
DMD4GQ8	RU	https://pubmed.ncbi.nlm.nih.gov/9574815

DMZWU8V	DI	DMZWU8V
DMZWU8V	DN	E-2040
DMZWU8V	MI	TTYSN63
DMZWU8V	MN	5-HT 2 receptor (5HT2R)
DMZWU8V	MT	DTT
DMZWU8V	MA	Modulator
DMZWU8V	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009126)
DMZWU8V	RU	http://adisinsight.springer.com/drugs/800009126

DMZWU8V	DI	DMZWU8V
DMZWU8V	DN	E-2040
DMZWU8V	MI	TTEX248
DMZWU8V	MN	Dopamine D2 receptor (D2R)
DMZWU8V	MT	DTT
DMZWU8V	MA	Modulator
DMZWU8V	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009126)
DMZWU8V	RU	http://adisinsight.springer.com/drugs/800009126

DMZWU8V	DI	DMZWU8V
DMZWU8V	DN	E-2040
DMZWU8V	MI	TT4C8EA
DMZWU8V	MN	Dopamine D3 receptor (D3R)
DMZWU8V	MT	DTT
DMZWU8V	MA	Modulator
DMZWU8V	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009126)
DMZWU8V	RU	http://adisinsight.springer.com/drugs/800009126

DMQKEHA	DI	DMQKEHA
DMQKEHA	DN	E-2050
DMQKEHA	MI	TT5HONZ
DMQKEHA	MN	Calcium channel unspecific (CaC)
DMQKEHA	MT	DTT
DMQKEHA	MA	Modulator
DMQKEHA	RN	Solubility of E2050 at various pH: a case in which apparent solubility is affected by the amount of excess solid. J Pharm Sci. 2002 Jun;91(6):1445-55.
DMQKEHA	RU	https://www.ncbi.nlm.nih.gov/pubmed/12115844

DMAU0FP	DI	DMAU0FP
DMAU0FP	DN	E-2070
DMAU0FP	MI	TTRK8B9
DMAU0FP	MN	Sodium channel unspecific (NaC)
DMAU0FP	MT	DTT
DMAU0FP	MA	Blocker
DMAU0FP	RN	Emerging therapies for neuropathic pain. Expert Opin Emerg Drugs. 2005 Feb;10(1):95-108.
DMAU0FP	RU	https://pubmed.ncbi.nlm.nih.gov/15757406

DMZ1JKX	DI	DMZ1JKX
DMZ1JKX	DN	E-4080
DMZ1JKX	MI	TT1VOHK
DMZ1JKX	MN	Potassium channel unspecific (KC)
DMZ1JKX	MT	DTT
DMZ1JKX	MA	Opener
DMZ1JKX	RN	Ionic currents involved in vasodilating actions of E4080, a newly synthesized bradycardia-inducing agent, in dispersed smooth muscle cells of the rabbit portal vein. J Pharmacol Exp Ther. 1991 Dec;259(3):1396-403.
DMZ1JKX	RU	https://pubmed.ncbi.nlm.nih.gov/1762086

DMR861Q	DI	DMR861Q
DMR861Q	DN	E-5110
DMR861Q	MI	TTK0943
DMR861Q	MN	Prostaglandin G/H synthase (COX)
DMR861Q	MT	DTT
DMR861Q	MA	Modulator
DMR861Q	RN	Effect of E-5110, a novel non-steroidal anti-inflammatory drug, on trimethadione metabolism as an indicator of hepatic drug-oxidizing capacity in beagle dog. Xenobiotica. 1994 Mar;24(3):215-20.
DMR861Q	RU	https://pubmed.ncbi.nlm.nih.gov/8009884

DMV0QI1	DI	DMV0QI1
DMV0QI1	DN	E-5842
DMV0QI1	MI	TT5TPI6
DMV0QI1	MN	Opioid receptor sigma 1 (OPRS1)
DMV0QI1	MT	DTT
DMV0QI1	MA	Binder
DMV0QI1	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMV0QI1	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMTEY8W	DI	DMTEY8W
DMTEY8W	DN	E-6276
DMTEY8W	MI	TT5TPI6
DMTEY8W	MN	Opioid receptor sigma 1 (OPRS1)
DMTEY8W	MT	DTT
DMTEY8W	MA	Binder
DMTEY8W	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMTEY8W	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DM5ITJF	DI	DM5ITJF
DM5ITJF	DN	EC-154
DM5ITJF	MI	TT78R5H
DM5ITJF	MN	Heat shock protein 90 alpha (HSP90A)
DM5ITJF	MT	DTT
DM5ITJF	MA	Inhibitor
DM5ITJF	RN	WO patent application no. 2013,1734,36, Pre-selection of subjects for therapeutic treatment with an hsp90 inhibitor based on hypoxic status.
DM5ITJF	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20131121&CC=WO&NR=2013173436A1&KC=A1

DMUR1FK	DI	DMUR1FK
DMUR1FK	DN	Ecalcidene
DMUR1FK	MI	TTK59TV
DMUR1FK	MN	Vitamin D3 receptor (VDR)
DMUR1FK	MT	DTT
DMUR1FK	MA	Modulator
DMUR1FK	RN	Degradation chemistry of a Vitamin D analogue (ecalcidene) investigated by HPLC-MS, HPLC-NMR and chemical derivatization. J Pharm Biomed Anal. 2006 Mar 3;40(4):850-63.
DMUR1FK	RU	https://pubmed.ncbi.nlm.nih.gov/16242878

DMJN7MY	DI	DMJN7MY
DMJN7MY	DN	ED-110
DMJN7MY	MI	TTGTQHC
DMJN7MY	MN	DNA topoisomerase I (TOP1)
DMJN7MY	MT	DTT
DMJN7MY	MA	Modulator
DMJN7MY	RN	ED-110, a novel indolocarbazole, prevents the growth of experimental tumors in mice. Jpn J Cancer Res. 1993 May;84(5):574-81.
DMJN7MY	RU	https://www.ncbi.nlm.nih.gov/pubmed/8320174

DMIC460	DI	DMIC460
DMIC460	DN	Edaglitazone
DMIC460	MI	TTZMAO3
DMIC460	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMIC460	MT	DTT
DMIC460	MA	Modulator
DMIC460	RN	A specific peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligand, pioglitazone, ameliorates gastric mucosal damage induced by ischemia and reperfusion in rats. Redox Rep. 2002;7(5):343-6.
DMIC460	RU	https://pubmed.ncbi.nlm.nih.gov/12688526

DM7ROS1	DI	DM7ROS1
DM7ROS1	DN	Efegatran
DM7ROS1	MI	TT6L509
DM7ROS1	MN	Coagulation factor IIa (F2)
DM7ROS1	MT	DTT
DM7ROS1	MA	Inhibitor
DM7ROS1	RN	Anticoagulation: the present and future. Clin Appl Thromb Hemost. 2001 Jul;7(3):195-204.
DM7ROS1	RU	https://pubmed.ncbi.nlm.nih.gov/11441979

DMJ0A5U	DI	DMJ0A5U
DMJ0A5U	DN	EFIPLADIB
DMJ0A5U	MI	TTT1JVS
DMJ0A5U	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DMJ0A5U	MT	DTT
DMJ0A5U	MA	Inhibitor
DMJ0A5U	RN	Reactions of functionalized sulfonamides: application to lowering the lipophilicity of cytosolic phospholipase A2alpha inhibitors. J Med Chem. 2009 Feb 26;52(4):1156-71.
DMJ0A5U	RU	https://pubmed.ncbi.nlm.nih.gov/19178292

DMYAMP5	DI	DMYAMP5
DMYAMP5	DN	EHT-1864
DMYAMP5	MI	TT2M9CG
DMYAMP5	MN	Ras-related C3 botulinum toxin substrate 1 (RAC1)
DMYAMP5	MT	DTT
DMYAMP5	MA	Inhibitor
DMYAMP5	RN	Specificity and mechanism of action of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases. J Biol Chem. 2007 Dec 7;282(49):35666-78.
DMYAMP5	RU	https://pubmed.ncbi.nlm.nih.gov/17932039

DMIP8NB	DI	DMIP8NB
DMIP8NB	DN	EK-399
DMIP8NB	MI	TTN4QDT
DMIP8NB	MN	Opioid receptor (OPR)
DMIP8NB	MT	DTT
DMIP8NB	MA	Modulator
DMIP8NB	RN	Evaluation of the discriminative stimulus effect of an enkephalin analog, EK-399, in the rat. Nihon Yakurigaku Zasshi. 1991 Jun;97(6):361-9.
DMIP8NB	RU	https://pubmed.ncbi.nlm.nih.gov/1651892

DMG9R8E	DI	DMG9R8E
DMG9R8E	DN	EM-2487
DMG9R8E	MI	TTT3ZC9
DMG9R8E	MN	Human immunodeficiency virus Tat protein (HIV tat)
DMG9R8E	MT	DTT
DMG9R8E	MA	Inhibitor
DMG9R8E	RN	EM2487, a novel anti-HIV-1 antibiotic, produced by Streptomyces sp. Mer-2487: taxonomy, fermentation, biological properties, isolation and structure elucidation. J Antibiot (Tokyo). 1999 Nov;52(11):971-82.
DMG9R8E	RU	https://pubmed.ncbi.nlm.nih.gov/10656569

DMFZO4Y	DI	DMFZO4Y
DMFZO4Y	DN	EMBELIN
DMFZO4Y	MI	TTK3WBU
DMFZO4Y	MN	XIAP messenger RNA (XIAP mRNA)
DMFZO4Y	MT	DTT
DMFZO4Y	MA	Inhibitor
DMFZO4Y	RN	Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional... J Med Chem. 2004 May 6;47(10):2430-40.
DMFZO4Y	RU	https://pubmed.ncbi.nlm.nih.gov/15115387

DMAEDQG	DI	DMAEDQG
DMAEDQG	DN	EMODIN
DMAEDQG	MI	TTER6YH
DMAEDQG	MN	Casein kinase II alpha (CSNK2A1)
DMAEDQG	MT	DTT
DMAEDQG	MA	Inhibitor
DMAEDQG	RN	Structural insight into human CK2alpha in complex with the potent inhibitor ellagic acid. Bioorg Med Chem Lett. 2009 Jun 1;19(11):2920-3.
DMAEDQG	RU	https://pubmed.ncbi.nlm.nih.gov/19414254

DMW210B	DI	DMW210B
DMW210B	DN	Emopamil
DMW210B	MI	TTYSN63
DMW210B	MN	5-HT 2 receptor (5HT2R)
DMW210B	MT	DTT
DMW210B	MA	Modulator
DMW210B	RN	Calcium entry and 5-HT2 receptor blockade in oliguric ischaemic acute renal failure: effects of levemopamil in conscious rats. Br J Pharmacol. 1996 Mar;117(6):1348-54.
DMW210B	RU	https://pubmed.ncbi.nlm.nih.gov/8882635

DMW210B	DI	DMW210B
DMW210B	DN	Emopamil
DMW210B	MI	TT5HONZ
DMW210B	MN	Calcium channel unspecific (CaC)
DMW210B	MT	DTT
DMW210B	MA	Modulator
DMW210B	RN	Calcium entry and 5-HT2 receptor blockade in oliguric ischaemic acute renal failure: effects of levemopamil in conscious rats. Br J Pharmacol. 1996 Mar;117(6):1348-54.
DMW210B	RU	https://pubmed.ncbi.nlm.nih.gov/8882635

DMW210B	DI	DMW210B
DMW210B	DN	Emopamil
DMW210B	MI	DE4LYSA
DMW210B	MN	Cytochrome P450 3A4 (CYP3A4)
DMW210B	MT	DME
DMW210B	MA	Metabolism
DMW210B	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DMW210B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DMJU39N	DI	DMJU39N
DMJU39N	DN	Endovion
DMJU39N	MI	TTCYAXN
DMJU39N	MN	Chloride channel unspecific (ClC)
DMJU39N	MT	DTT
DMJU39N	MA	Antagonist
DMJU39N	RN	Inhibition of the endogenous volume-regulated anion channel (VRAC) in HEK293 cells by acidic di-aryl-ureas. J Membr Biol. 2003 Nov 15;196(2):83-94.
DMJU39N	RU	https://pubmed.ncbi.nlm.nih.gov/14724745

DMZA5Q4	DI	DMZA5Q4
DMZA5Q4	DN	EP-2060
DMZA5Q4	MI	TTZBFA0
DMZA5Q4	MN	Protease unspecific (PRO)
DMZA5Q4	MT	DTT
DMZA5Q4	MA	Inducer
DMZA5Q4	RN	Discovery of 4-aryl-4H-chromenes as potent apoptosis inducers using a cell- and caspase-based Anti-cancer Screening Apoptosis Program (ASAP): SAR studies and the identification of novel vascular disrupting agents. Anticancer Agents Med Chem. 2009 May;9(4):437-56.
DMZA5Q4	RU	https://pubmed.ncbi.nlm.nih.gov/19442043

DM149HL	DI	DM149HL
DM149HL	DN	EPD-clofarabine
DM149HL	MI	TTUBNVO
DM149HL	MN	DNA synthesis (DNA synth)
DM149HL	MT	DTT
DM149HL	MA	Inhibitor
DM149HL	RN	2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4.
DM149HL	RU	https://pubmed.ncbi.nlm.nih.gov/15756752

DM6IY4M	DI	DM6IY4M
DM6IY4M	DN	Epiroprim
DM6IY4M	MI	TTV8DM2
DM6IY4M	MN	Bacterial Dihydrofolate reductase (Bact DHFR)
DM6IY4M	MT	DTT
DM6IY4M	MA	Modulator
DM6IY4M	RN	In vitro activity of epiroprim, a dihydrofolate reductase inhibitor, singly and in combination with brodimoprim and dapsone, against Mycobacterium ... Int J Antimicrob Agents. 1999 Aug;12(4):319-23.
DM6IY4M	RU	https://www.ncbi.nlm.nih.gov/pubmed/10493608

DMWRSXK	DI	DMWRSXK
DMWRSXK	DN	Epocarbazolin-A
DMWRSXK	MI	TT2J34L
DMWRSXK	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMWRSXK	MT	DTT
DMWRSXK	MA	Inhibitor
DMWRSXK	RN	Epocarbazolins A and B, novel 5-lipoxygenase inhibitors. Taxonomy, fermentation, isolation, structures and biological activities. J Antibiot (Tokyo). 1993 Jan;46(1):25-33.
DMWRSXK	RU	https://pubmed.ncbi.nlm.nih.gov/8436556

DM2NHLW	DI	DM2NHLW
DM2NHLW	DN	EPTALOPROST
DM2NHLW	MI	TTOFYT1
DM2NHLW	MN	Prostacyclin receptor (PTGIR)
DM2NHLW	MT	DTT
DM2NHLW	MA	Modulator
DM2NHLW	RN	Bioactivation of eptaloprost in animals and man. Prostaglandins. 1993 Aug;46(2):177-89.
DM2NHLW	RU	https://pubmed.ncbi.nlm.nih.gov/7692471

DMAZVUB	DI	DMAZVUB
DMAZVUB	DN	ER-34122
DMAZVUB	MI	TT2J34L
DMAZVUB	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMAZVUB	MT	DTT
DMAZVUB	MA	Modulator
DMAZVUB	RN	Improvement of dissolution and oral absorption of ER-34122, a poorly water-soluble dual 5-lipoxygenase/cyclooxygenase inhibitor with anti-inflammatory activity by preparing solid dispersion. J Pharm Sci. 2002 Jan;91(1):258-66.
DMAZVUB	RU	https://pubmed.ncbi.nlm.nih.gov/11782915

DMYSTAD	DI	DMYSTAD
DMYSTAD	DN	ER-37328
DMYSTAD	MI	TT0IHXV
DMYSTAD	MN	DNA topoisomerase II (TOP2)
DMYSTAD	MT	DTT
DMYSTAD	MA	Inhibitor
DMYSTAD	RN	Antitumor activity of ER-37328, a novel carbazole topoisomerase II inhibitor. Mol Cancer Ther. 2002 Jan;1(3):169-75.
DMYSTAD	RU	https://pubmed.ncbi.nlm.nih.gov/12467211

DM08XS2	DI	DM08XS2
DM08XS2	DN	ERIC-1
DM08XS2	MI	TTUBJQ3
DM08XS2	MN	Neural cell adhesion molecule (NCAM)
DM08XS2	MT	DTT
DM08XS2	MA	Antagonist
DM08XS2	RN	Monoclonal antibody UJ13A recognizes the neural cell adhesion molecule (NCAM). Int J Cancer. 1989 Dec 15;44(6):1062-8.
DM08XS2	RU	https://pubmed.ncbi.nlm.nih.gov/2558078

DMJXEV7	DI	DMJXEV7
DMJXEV7	DN	ERTIPROTAFIB
DMJXEV7	MI	TTELIN2
DMJXEV7	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMJXEV7	MT	DTT
DMJXEV7	MA	Inhibitor
DMJXEV7	RN	2-O-carboxymethylpyrogallol derivatives as PTP1B inhibitors with antihyperglycemic activity. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5357-60.
DMJXEV7	RU	https://pubmed.ncbi.nlm.nih.gov/17728130

DMRP7BX	DI	DMRP7BX
DMRP7BX	DN	ES-1005
DMRP7BX	MI	TTB2MXP
DMRP7BX	MN	Angiotensinogenase renin (REN)
DMRP7BX	MT	DTT
DMRP7BX	MA	Inhibitor
DMRP7BX	RN	The effect of the renin inhibitor ES-1005 on the expression of the kidney renin gene in sodium-depleted marmosets. J Hypertens. 1990 Dec;8(12):1143-6.
DMRP7BX	RU	https://pubmed.ncbi.nlm.nih.gov/1962804

DM3BHN1	DI	DM3BHN1
DM3BHN1	DN	Etomoxir
DM3BHN1	MI	TTDL0NY
DM3BHN1	MN	Carnitine O-palmitoyltransferase I (CPT1B)
DM3BHN1	MT	DTT
DM3BHN1	MA	Modulator
DM3BHN1	RN	Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine. Circ Res. 1988 Dec;63(6):1036-43.
DM3BHN1	RU	https://pubmed.ncbi.nlm.nih.gov/3197271

DMRQOXG	DI	DMRQOXG
DMRQOXG	DN	Etrabamine
DMRQOXG	MI	TTEX248
DMRQOXG	MN	Dopamine D2 receptor (D2R)
DMRQOXG	MT	DTT
DMRQOXG	MA	Modulator
DMRQOXG	RN	WO patent application no. 2009,0568,11, Medicaments.
DMRQOXG	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20090507&CC=WO&NR=2009056811A2&KC=A2

DMLA3P1	DI	DMLA3P1
DMLA3P1	DN	EUK-207
DMLA3P1	MI	TT6RVLG
DMLA3P1	MN	Superoxide dismutase Cu-Zn (SOD Cu-Zn)
DMLA3P1	MT	DTT
DMLA3P1	MA	Modulator
DMLA3P1	RN	A synthetic superoxide dismutase/catalase mimetic EUK-207 mitigates radiation dermatitis and promotes wound healing in irradiated rat skin. J Invest Dermatol. 2013 Apr;133(4):1088-96.
DMLA3P1	RU	https://pubmed.ncbi.nlm.nih.gov/23190879

DM9P4ZN	DI	DM9P4ZN
DM9P4ZN	DN	EXP-6803
DM9P4ZN	MI	TTGN1ZA
DM9P4ZN	MN	Angiotensin II receptor (AGTR)
DM9P4ZN	MT	DTT
DM9P4ZN	MA	Modulator
DM9P4ZN	RN	Nonpeptide angiotensin II receptor antagonists. IV. EXP6155 and EXP6803. Hypertension. 1989 May;13(5):489-97.
DM9P4ZN	RU	https://pubmed.ncbi.nlm.nih.gov/2656519

DMR1X2U	DI	DMR1X2U
DMR1X2U	DN	F-0401
DMR1X2U	MI	TT27K59
DMR1X2U	MN	Platelet activating factor (PAF)
DMR1X2U	MT	DTT
DMR1X2U	MA	Inhibitor
DMR1X2U	RN	Protective effects of a novel calcium antagonist with platelet-activating factor-antagonistic action, F-0401, against ischemic brain damage. Arch Int Pharmacodyn Ther. 1994 May-Jun;327(3):266-78.
DMR1X2U	RU	https://pubmed.ncbi.nlm.nih.gov/7848011

DM3786U	DI	DM3786U
DM3786U	DN	F-12509A
DM3786U	MI	TTOHFIY
DM3786U	MN	Sphingosine kinase 1 (SPHK1)
DM3786U	MT	DTT
DM3786U	MA	Inhibitor
DM3786U	RN	F-12509A, a new sphingosine kinase inhibitor, produced by a discomycete. J Antibiot (Tokyo). 2000 May;53(5):459-66.
DM3786U	RU	https://pubmed.ncbi.nlm.nih.gov/10908108

DM23OHW	DI	DM23OHW
DM23OHW	DN	F-12682
DM23OHW	MI	TTK8CXU
DM23OHW	MN	5-HT 1B receptor (HTR1B)
DM23OHW	MT	DTT
DM23OHW	MA	Antagonist
DM23OHW	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010898)
DM23OHW	RU	http://adisinsight.springer.com/drugs/800010898

DMGH3QD	DI	DMGH3QD
DMGH3QD	DN	F-14413
DMGH3QD	MI	TT2NUT5
DMGH3QD	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMGH3QD	MT	DTT
DMGH3QD	MA	Antagonist
DMGH3QD	RN	Activation of noradrenergic transmission by alpha2-adrenoceptor antagonists counteracts deafferentation-induced neuronal death and cell proliferation in the adult mouse olfactory bulb. Exp Neurol. 2005 Aug;194(2):444-56.
DMGH3QD	RU	https://pubmed.ncbi.nlm.nih.gov/16022870

DMVWZN1	DI	DMVWZN1
DMVWZN1	DN	F-200
DMVWZN1	MI	TTH4QIS
DMVWZN1	MN	Integrin alpha-5/beta-1 (ITGA5/B1)
DMVWZN1	MT	DTT
DMVWZN1	MA	Inhibitor
DMVWZN1	RN	US patent application no. 8,541,413, Sustained release eye drop formulations.
DMVWZN1	RU	http://www.google.com/patents/US8541413

DMXB8SE	DI	DMXB8SE
DMXB8SE	DN	F-3796
DMXB8SE	MI	TT1RS9F
DMXB8SE	MN	Acetylcholinesterase (AChE)
DMXB8SE	MT	DTT
DMXB8SE	MA	Inhibitor
DMXB8SE	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004498)
DMXB8SE	RU	http://adisinsight.springer.com/drugs/800004498

DMJ3MAZ	DI	DMJ3MAZ
DMJ3MAZ	DN	F-992
DMJ3MAZ	MI	TTYCILE
DMJ3MAZ	MN	Vasopressin receptor (VR)
DMJ3MAZ	MT	DTT
DMJ3MAZ	MA	Agonist
DMJ3MAZ	RN	A site of tyrosine phosphorylation in the C terminus of the epidermal growth factor receptor is required to activate phospholipase C.. Mol Cell Biol. 1992 January; 12(1): 128-135.
DMJ3MAZ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC364076/

DME694O	DI	DME694O
DME694O	DN	Fananserin
DME694O	MI	TTJQOD7
DME694O	MN	5-HT 2A receptor (HTR2A)
DME694O	MT	DTT
DME694O	MA	Antagonist
DME694O	RN	Autoradiographic studies of RP 62203, a potent 5-HT2 receptor antagonist. Pharmacological characterization of [3H]RP 62203 binding in the rat brain. Eur J Pharmacol. 1993 Mar 16;233(1):37-45.
DME694O	RU	https://pubmed.ncbi.nlm.nih.gov/8472747

DMR3ZWA	DI	DMR3ZWA
DMR3ZWA	DN	FCE-25876
DMR3ZWA	MI	TTWT5K7
DMR3ZWA	MN	5-HT 1 receptor (5HT1R)
DMR3ZWA	MT	DTT
DMR3ZWA	MA	Modulator
DMR3ZWA	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001389)
DMR3ZWA	RU	http://adisinsight.springer.com/drugs/800001389

DMJX1IB	DI	DMJX1IB
DMJX1IB	DN	Fedotozine
DMJX1IB	MI	TTQW87Y
DMJX1IB	MN	Opioid receptor kappa (OPRK1)
DMJX1IB	MT	DTT
DMJX1IB	MA	Agonist
DMJX1IB	RN	Irritable bowel syndrome neuropharmacology. A review of approved and investigational compounds. J Clin Gastroenterol. 2002 Jul;35(1 Suppl):S58-67.
DMJX1IB	RU	https://pubmed.ncbi.nlm.nih.gov/12184141

DMJ35RC	DI	DMJ35RC
DMJ35RC	DN	FH-510
DMJ35RC	MI	TT5TPI6
DMJ35RC	MN	Opioid receptor sigma 1 (OPRS1)
DMJ35RC	MT	DTT
DMJ35RC	MA	Modulator
DMJ35RC	RN	FH-510, a potent and selective ligand for rat brain sigma recognition sites. Eur J Pharmacol. 1993 Jul 6;238(1):89-92.
DMJ35RC	RU	https://pubmed.ncbi.nlm.nih.gov/8104803

DMIGXQF	DI	DMIGXQF
DMIGXQF	DN	FK-355
DMIGXQF	MI	TTZPO1L
DMIGXQF	MN	Substance-P receptor (TACR1)
DMIGXQF	MT	DTT
DMIGXQF	MA	Antagonist
DMIGXQF	RN	FK 224, a novel cyclopeptide substance P antagonist with NK1 and NK2 receptor selectivity. J Pharmacol Exp Ther. 1992 Jul;262(1):398-402.
DMIGXQF	RU	https://pubmed.ncbi.nlm.nih.gov/1378096

DMDVAI5	DI	DMDVAI5
DMDVAI5	DN	Florifenine
DMDVAI5	MI	TTK0943
DMDVAI5	MN	Prostaglandin G/H synthase (COX)
DMDVAI5	MT	DTT
DMDVAI5	MA	Modulator
DMDVAI5	RN	A study of the novel anti-inflammatory agent florifenine topical anti-inflammatory activity and influence on arachidonic acid metabolism and neutrophil functions. Naunyn Schmiedebergs Arch Pharmacol.1995 Mar;351(3):298-304.
DMDVAI5	RU	https://pubmed.ncbi.nlm.nih.gov/7609784

DMY89KQ	DI	DMY89KQ
DMY89KQ	DN	Flosequinan
DMY89KQ	MI	DE4LYSA
DMY89KQ	MN	Cytochrome P450 3A4 (CYP3A4)
DMY89KQ	MT	DME
DMY89KQ	MA	Metabolism
DMY89KQ	RN	Cytochrome P450 responsible for the stereoselective S-oxidation of flosequinan in hepatic microsomes from rats and humans. Drug Metab Dispos. 1997 Jun;25(6):716-24.
DMY89KQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9193873

DM6OIJ1	DI	DM6OIJ1
DM6OIJ1	DN	Flosulide
DM6OIJ1	MI	TTVKILB
DM6OIJ1	MN	Prostaglandin G/H synthase 2 (COX-2)
DM6OIJ1	MT	DTT
DM6OIJ1	MA	Modulator
DM6OIJ1	RN	Effect of flosulide, a selective cyclooxygenase 2 inhibitor, on passive heymann nephritis in the rat. Kidney Int. 1999 Nov;56(5):1770-8.
DM6OIJ1	RU	https://pubmed.ncbi.nlm.nih.gov/10571785

DM7JT3D	DI	DM7JT3D
DM7JT3D	DN	Fluoratec
DM7JT3D	MI	TTVBI8W
DM7JT3D	MN	Dopamine transporter (DAT)
DM7JT3D	MT	DTT
DM7JT3D	MA	Modulator
DM7JT3D	RN	Technepine: a high-affinity 99m-technetium probe to label the dopamine transporter in brain by SPECT imaging. Synapse. 1996 Mar;22(3):239-46.
DM7JT3D	RU	https://pubmed.ncbi.nlm.nih.gov/9132992

DMSYLIF	DI	DMSYLIF
DMSYLIF	DN	Fosfluridine tidoxil
DMSYLIF	MI	TTU6BFZ
DMSYLIF	MN	Candida Thymidylate synthase (Candi TMP1)
DMSYLIF	MT	DTT
DMSYLIF	MA	Inhibitor
DMSYLIF	RN	Selective protection by uridine of growth inhibition by 5-fluorouracil (5FU) mediated by 5FU incorporation into RNA, but not the thymidylate synthase mediated growth inhibition by 5FU-leucovorin. Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):733-9.
DMSYLIF	RU	https://pubmed.ncbi.nlm.nih.gov/18600533

DMF1CDK	DI	DMF1CDK
DMF1CDK	DN	FPL-55712
DMF1CDK	MI	TTGKOY9
DMF1CDK	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DMF1CDK	MT	DTT
DMF1CDK	MA	Modulator
DMF1CDK	RN	Effect of the leukotriene receptor antagonists FPL 55712, LY 163443, and MK-571 on the elimination of cysteinyl leukotrienes in the rat. Br J Pharmacol. 1991 Apr;102(4):865-70.
DMF1CDK	RU	https://pubmed.ncbi.nlm.nih.gov/1855116

DMF1CDK	DI	DMF1CDK
DMF1CDK	DN	FPL-55712
DMF1CDK	MI	TT0PZR5
DMF1CDK	MN	Leukotriene CysLT2 receptor (CYSLTR2)
DMF1CDK	MT	DTT
DMF1CDK	MA	Modulator
DMF1CDK	RN	Effect of the leukotriene receptor antagonists FPL 55712, LY 163443, and MK-571 on the elimination of cysteinyl leukotrienes in the rat. Br J Pharmacol. 1991 Apr;102(4):865-70.
DMF1CDK	RU	https://pubmed.ncbi.nlm.nih.gov/1855116

DMCAZPR	DI	DMCAZPR
DMCAZPR	DN	FR-113680
DMCAZPR	MI	TTZPO1L
DMCAZPR	MN	Substance-P receptor (TACR1)
DMCAZPR	MT	DTT
DMCAZPR	MA	Inhibitor
DMCAZPR	RN	FR 113680: a novel tripeptide substance P antagonist with NK1 receptor selectivity. Br J Pharmacol. 1992 May;106(1):123-6.
DMCAZPR	RU	https://pubmed.ncbi.nlm.nih.gov/1380378

DMY2IB8	DI	DMY2IB8
DMY2IB8	DN	FR-115427
DMY2IB8	MI	TT9IK2Z
DMY2IB8	MN	N-methyl-D-aspartate receptor (NMDAR)
DMY2IB8	MT	DTT
DMY2IB8	MA	Modulator
DMY2IB8	RN	Non-competitive NMDA antagonists, FR115427 and MK801, enhance neuronal survival in primary culture. Neurosci Lett. 1995 Feb 9;185(2):107-10.
DMY2IB8	RU	https://pubmed.ncbi.nlm.nih.gov/7746498

DMNRUGA	DI	DMNRUGA
DMNRUGA	DN	FR-121196
DMNRUGA	MI	TTIND6G
DMNRUGA	MN	Somatostatin receptor type 1 (SSTR1)
DMNRUGA	MT	DTT
DMNRUGA	MA	Modulator
DMNRUGA	RN	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
DMNRUGA	RU	https://pubmed.ncbi.nlm.nih.gov/23370234

DMNRUGA	DI	DMNRUGA
DMNRUGA	DN	FR-121196
DMNRUGA	MI	TTZ6T9E
DMNRUGA	MN	Somatostatin receptor type 2 (SSTR2)
DMNRUGA	MT	DTT
DMNRUGA	MA	Modulator
DMNRUGA	RN	Role of somatostatin in the augmentation of hippocampal long-term potentiation by FR121196, a putative cognitive enhancer. Eur J Pharmacol. 1993 Sep 7;241(1):27-34.
DMNRUGA	RU	https://pubmed.ncbi.nlm.nih.gov/7901036

DMNRUGA	DI	DMNRUGA
DMNRUGA	DN	FR-121196
DMNRUGA	MI	TTJX3UE
DMNRUGA	MN	Somatostatin receptor type 3 (SSTR3)
DMNRUGA	MT	DTT
DMNRUGA	MA	Modulator
DMNRUGA	RN	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
DMNRUGA	RU	https://pubmed.ncbi.nlm.nih.gov/23370234

DMNRUGA	DI	DMNRUGA
DMNRUGA	DN	FR-121196
DMNRUGA	MI	TTAE1BR
DMNRUGA	MN	Somatostatin receptor type 4 (SSTR4)
DMNRUGA	MT	DTT
DMNRUGA	MA	Modulator
DMNRUGA	RN	Role of somatostatin in the augmentation of hippocampal long-term potentiation by FR121196, a putative cognitive enhancer. Eur J Pharmacol. 1993 Sep 7;241(1):27-34.
DMNRUGA	RU	https://pubmed.ncbi.nlm.nih.gov/7901036

DMNRUGA	DI	DMNRUGA
DMNRUGA	DN	FR-121196
DMNRUGA	MI	TT2BC4G
DMNRUGA	MN	Somatostatin receptor type 5 (SSTR5)
DMNRUGA	MT	DTT
DMNRUGA	MA	Modulator
DMNRUGA	RN	Role of somatostatin in the augmentation of hippocampal long-term potentiation by FR121196, a putative cognitive enhancer. Eur J Pharmacol. 1993 Sep 7;241(1):27-34.
DMNRUGA	RU	https://pubmed.ncbi.nlm.nih.gov/7901036

DM0582D	DI	DM0582D
DM0582D	DN	FR-123826
DM0582D	MI	TTVKILB
DM0582D	MN	Prostaglandin G/H synthase 2 (COX-2)
DM0582D	MT	DTT
DM0582D	MA	Inhibitor
DM0582D	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007983)
DM0582D	RU	http://adisinsight.springer.com/drugs/800007983

DMMOBHW	DI	DMMOBHW
DMMOBHW	DN	FR-128998
DMMOBHW	MI	TTQL5VC
DMMOBHW	MN	Platelet-activating factor receptor (PTAFR)
DMMOBHW	MT	DTT
DMMOBHW	MA	Modulator
DMMOBHW	RN	Effect of FR128998, a novel PAF receptor antagonist, on endotoxin-induced disseminated intravascular coagulation. Eur J Pharmacol. 1994 Jun 13;258(3):239-46.
DMMOBHW	RU	https://pubmed.ncbi.nlm.nih.gov/8088357

DM9V6AU	DI	DM9V6AU
DM9V6AU	DN	FR-129169
DM9V6AU	MI	TTMF541
DM9V6AU	MN	Liver carboxylesterase (CES1)
DM9V6AU	MT	DTT
DM9V6AU	MA	Modulator
DM9V6AU	RN	Plasma cholesterol reducing effect of FR129169, a novel acyl-CoA:cholesterol acyltransferase inhibitor, in the rat. Jpn J Pharmacol. 1996 Jan;70(1):35-41.
DM9V6AU	RU	https://pubmed.ncbi.nlm.nih.gov/8822087

DMXWL0N	DI	DMXWL0N
DMXWL0N	DN	FR-133605
DMXWL0N	MI	TT51DEV
DMXWL0N	MN	Interleukin 1 receptor type 2 (IL1R2)
DMXWL0N	MT	DTT
DMXWL0N	MA	Modulator
DMXWL0N	RN	Effect of FR133605, a novel cytokine suppressive agent, on bone and cartilage destruction in adjuvant arthritic rats. J Rheumatol. 1996 Oct;23(10):1778-83.
DMXWL0N	RU	https://pubmed.ncbi.nlm.nih.gov/8895158

DMXWL0N	DI	DMXWL0N
DMXWL0N	DN	FR-133605
DMXWL0N	MI	TTF8CQI
DMXWL0N	MN	Tumor necrosis factor (TNF)
DMXWL0N	MT	DTT
DMXWL0N	MA	Modulator
DMXWL0N	RN	Effect of FR133605, a novel cytokine suppressive agent, on bone and cartilage destruction in adjuvant arthritic rats. J Rheumatol. 1996 Oct;23(10):1778-83.
DMXWL0N	RU	https://pubmed.ncbi.nlm.nih.gov/8895158

DMHV43M	DI	DMHV43M
DMHV43M	DN	FR-145237
DMHV43M	MI	TTMF541
DMHV43M	MN	Liver carboxylesterase (CES1)
DMHV43M	MT	DTT
DMHV43M	MA	Modulator
DMHV43M	RN	Effect of FR145237, a novel ACAT inhibitor, on atherogenesis in cholesterol-fed and WHHL rabbits. Evidence for a direct effect on the arterial wall. Biochim Biophys Acta. 1995 Dec 7;1259(3):254-60.
DMHV43M	RU	https://pubmed.ncbi.nlm.nih.gov/8541332

DMBOFSQ	DI	DMBOFSQ
DMBOFSQ	DN	FR-149581
DMBOFSQ	MI	TTGN1ZA
DMBOFSQ	MN	Angiotensin II receptor (AGTR)
DMBOFSQ	MT	DTT
DMBOFSQ	MA	Antagonist
DMBOFSQ	RN	US patent application no. 2003,0087,306, Methods for identifying novel multimeric agents that modulate receptors.
DMBOFSQ	RU	http://www.google.com/patents/US20030087306

DMOEYX2	DI	DMOEYX2
DMOEYX2	DN	FR-152558
DMOEYX2	MI	TT1RS9F
DMOEYX2	MN	Acetylcholinesterase (AChE)
DMOEYX2	MT	DTT
DMOEYX2	MA	Inhibitor
DMOEYX2	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006757)
DMOEYX2	RU	http://adisinsight.springer.com/drugs/800006757

DMIQB9E	DI	DMIQB9E
DMIQB9E	DN	FR-171113
DMIQB9E	MI	TTL935N
DMIQB9E	MN	Proteinase activated receptor 1 (F2R)
DMIQB9E	MT	DTT
DMIQB9E	MA	Modulator
DMIQB9E	RN	In vitro antiplatelet profile of FR171113, a novel non-peptide thrombin receptor antagonist. Eur J Pharmacol. 1999 Nov 19;384(2-3):197-202.
DMIQB9E	RU	https://pubmed.ncbi.nlm.nih.gov/10611442

DMY1LRI	DI	DMY1LRI
DMY1LRI	DN	FR-172357
DMY1LRI	MI	TTGY8IW
DMY1LRI	MN	B2 bradykinin receptor (BDKRB2)
DMY1LRI	MT	DTT
DMY1LRI	MA	Antagonist
DMY1LRI	RN	Characterization of FR 172357, a new non-peptide bradykinin B(2) receptor antagonist, in human, pig and rabbit preparations. Eur J Pharmacol. 1999 Dec 10;386(1):25-31.
DMY1LRI	RU	https://pubmed.ncbi.nlm.nih.gov/10611460

DM37OS4	DI	DM37OS4
DM37OS4	DN	FR-173657
DM37OS4	MI	TTGY8IW
DM37OS4	MN	B2 bradykinin receptor (BDKRB2)
DM37OS4	MT	DTT
DM37OS4	MA	Inhibitor
DM37OS4	RN	Novel small molecule bradykinin B2 receptor antagonists. J Med Chem. 2009 Jul 23;52(14):4370-9.
DM37OS4	RU	https://pubmed.ncbi.nlm.nih.gov/19552431

DMCQHG4	DI	DMCQHG4
DMCQHG4	DN	FR-183998
DMCQHG4	MI	TT70SZ3
DMCQHG4	MN	Sodium/hydrogen exchanger (SLC)
DMCQHG4	MT	DTT
DMCQHG4	MA	Modulator
DMCQHG4	RN	Protective effect of FR183998, a Na+/H+ exchanger inhibitor, and its inhibition of iNOS induction in hepatic ischemia-reperfusion injury in rats. Shock. 2008 Sep;30(3):311-7.
DMCQHG4	RU	https://pubmed.ncbi.nlm.nih.gov/18277953

DMNACIV	DI	DMNACIV
DMNACIV	DN	FR-194738
DMNACIV	MI	TTE14XG
DMNACIV	MN	Squalene monooxygenase (SQLE)
DMNACIV	MT	DTT
DMNACIV	MA	Modulator
DMNACIV	RN	Synthesis and biological activity of a novel squalene epoxidase inhibitor, FR194738. Bioorg Med Chem Lett. 2004 Feb 9;14(3):633-7.
DMNACIV	RU	https://pubmed.ncbi.nlm.nih.gov/14741258

DMLG426	DI	DMLG426
DMLG426	DN	FR-208419
DMLG426	MI	TTCG0AL
DMLG426	MN	Cholecystokinin receptor type A (CCKAR)
DMLG426	MT	DTT
DMLG426	MA	Modulator
DMLG426	RN	Dual CCK-A and CCK-B receptor antagonists (II). Preparation and structure activity relationships of 5-alkyl-9-methyl-1,4-benzodiazepines and discovery of FR208419. Chem Pharm Bull (Tokyo). 2000 Jan;48(1):1-15.
DMLG426	RU	https://pubmed.ncbi.nlm.nih.gov/10705468

DMLG426	DI	DMLG426
DMLG426	DN	FR-208419
DMLG426	MI	TTVFO0U
DMLG426	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMLG426	MT	DTT
DMLG426	MA	Modulator
DMLG426	RN	Dual CCK-A and CCK-B receptor antagonists (II). Preparation and structure activity relationships of 5-alkyl-9-methyl-1,4-benzodiazepines and discovery of FR208419. Chem Pharm Bull (Tokyo). 2000 Jan;48(1):1-15.
DMLG426	RU	https://pubmed.ncbi.nlm.nih.gov/10705468

DMT6R8I	DI	DMT6R8I
DMT6R8I	DN	FR-229934
DMT6R8I	MI	TTJ0IQB
DMT6R8I	MN	Phosphodiesterase 5A (PDE5A)
DMT6R8I	MT	DTT
DMT6R8I	MA	Inhibitor
DMT6R8I	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014897)
DMT6R8I	RU	http://adisinsight.springer.com/drugs/800014897

DMJS9YB	DI	DMJS9YB
DMJS9YB	DN	FR-62765
DMJS9YB	MI	TTFBNVI
DMJS9YB	MN	Aldose reductase (AKR1B1)
DMJS9YB	MT	DTT
DMJS9YB	MA	Modulator
DMJS9YB	RN	Studies on WF-3681, a novel aldose reductase inhibitor. IV. Effect of FR-62765, a derivative of WF-3681, on the diabetic neuropathy in rats. J Antibiot (Tokyo). 1991 Apr;44(4):441-4.
DMJS9YB	RU	https://pubmed.ncbi.nlm.nih.gov/1903376

DM7WGXS	DI	DM7WGXS
DM7WGXS	DN	FR-76830
DM7WGXS	MI	TT5WKM8
DM7WGXS	MN	ATP phosphatase (ATPase)
DM7WGXS	MT	DTT
DM7WGXS	MA	Modulator
DM7WGXS	RN	On the mode of cardioprotection produced by a new bradycardic agent, FR 76830, during ischaemia and after reperfusion in the isolated perfused rat heart: a 31P-NMR study. Cardiovasc Res. 1990 Dec;24(12):1008-12.
DM7WGXS	RU	https://pubmed.ncbi.nlm.nih.gov/2151429

DM6PFVD	DI	DM6PFVD
DM6PFVD	DN	FR-901277
DM6PFVD	MI	TTPLTSQ
DM6PFVD	MN	Neutrophil elastase (NE)
DM6PFVD	MT	DTT
DM6PFVD	MA	Inhibitor
DM6PFVD	RN	Resisting degradation by human elastase: commonality of design features shared by 'canonical' plant and bacterial macrocyclic protease inhibitor sc... Bioorg Med Chem. 2007 Jul 1;15(13):4618-28.
DM6PFVD	RU	https://pubmed.ncbi.nlm.nih.gov/17470393

DM2FNPO	DI	DM2FNPO
DM2FNPO	DN	FR-901451
DM2FNPO	MI	TTPLTSQ
DM2FNPO	MN	Neutrophil elastase (NE)
DM2FNPO	MT	DTT
DM2FNPO	MA	Inhibitor
DM2FNPO	RN	Resisting degradation by human elastase: commonality of design features shared by 'canonical' plant and bacterial macrocyclic protease inhibitor sc... Bioorg Med Chem. 2007 Jul 1;15(13):4618-28.
DM2FNPO	RU	https://pubmed.ncbi.nlm.nih.gov/17470393

DMN4E5H	DI	DMN4E5H
DMN4E5H	DN	Fradafiban
DMN4E5H	MI	TT38RM1
DMN4E5H	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DMN4E5H	MT	DTT
DMN4E5H	MA	Modulator
DMN4E5H	RN	Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men. Circulation. 1997Aug 19;96(4):1130-8.
DMN4E5H	RU	https://pubmed.ncbi.nlm.nih.gov/9286940

DMC5O3X	DI	DMC5O3X
DMC5O3X	DN	FRG-8701
DMC5O3X	MI	TTQHJ1K
DMC5O3X	MN	Histamine H2 receptor (H2R)
DMC5O3X	MT	DTT
DMC5O3X	MA	Modulator
DMC5O3X	RN	Effects of FRG-8701 on gastric acid secretion, gastric mucosal lesions by necrotizing agents and experimental gastric or duodenal ulcer in rats. Jpn J Pharmacol. 1990 Nov;54(3):277-85.
DMC5O3X	RU	https://pubmed.ncbi.nlm.nih.gov/1982548

DMI1Y92	DI	DMI1Y92
DMI1Y92	DN	FUSIDIENOL
DMI1Y92	MI	TT7WZIJ
DMI1Y92	MN	CAAX farnesyltransferase beta (FNTB)
DMI1Y92	MT	DTT
DMI1Y92	MA	Inhibitor
DMI1Y92	RN	Modeling of binding modes and inhibition mechanism of some natural ligands of farnesyl transferase using molecular docking. J Med Chem. 2002 Mar 28;45(7):1460-5.
DMI1Y92	RU	https://pubmed.ncbi.nlm.nih.gov/11906287

DMZXA0W	DI	DMZXA0W
DMZXA0W	DN	Garenoxacin
DMZXA0W	MI	TT0IHXV
DMZXA0W	MN	DNA topoisomerase II (TOP2)
DMZXA0W	MT	DTT
DMZXA0W	MA	Inhibitor
DMZXA0W	RN	The inhibition and selectivity of bacterial topoisomerases by BMS-284756 and its analogues. J Antimicrob Chemother. 2001 Aug;48(2):195-201.
DMZXA0W	RU	https://pubmed.ncbi.nlm.nih.gov/11481288

DMOAURL	DI	DMOAURL
DMOAURL	DN	GDC-0834
DMOAURL	MI	TTGM6VW
DMOAURL	MN	Tyrosine-protein kinase BTK (ATK)
DMOAURL	MT	DTT
DMOAURL	MA	Inhibitor
DMOAURL	RN	Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy. J Pharmacol Exp Ther. 2011 Jul;338(1):154-63.
DMOAURL	RU	https://pubmed.ncbi.nlm.nih.gov/21521773

DMGM3VP	DI	DMGM3VP
DMGM3VP	DN	GE-20372A
DMGM3VP	MI	TT5FNQT
DMGM3VP	MN	Human immunodeficiency virus Protease (HIV PR)
DMGM3VP	MT	DTT
DMGM3VP	MA	Inhibitor
DMGM3VP	RN	US patent application no. 2008,0161,324, Compositions and methods for treatment of viral diseases.
DMGM3VP	RU	http://www.google.com/patents/US20080161324

DMZF9CY	DI	DMZF9CY
DMZF9CY	DN	GE-68
DMZF9CY	MI	TTRK8B9
DMZF9CY	MN	Sodium channel unspecific (NaC)
DMZF9CY	MT	DTT
DMZF9CY	MA	Modulator
DMZF9CY	RN	Electrophysiological properties of the propafenone-analogue GE 68 (1-[3-(phenylethyl)-2-benzofuryl]-2-(propylamino)-ethanol) in isolated preparations and ventricular myocytes of guinea-pig hearts. Naunyn Schmiedebergs Arch Pharmacol. 1997 Feb;355(2):230-8.
DMZF9CY	RU	https://pubmed.ncbi.nlm.nih.gov/9050017

DMVAM18	DI	DMVAM18
DMVAM18	DN	Gene therapy, IFN-alpha
DMVAM18	MI	TT95SOA
DMVAM18	MN	Interferon alpha (IFNA)
DMVAM18	MT	DTT
DMVAM18	MA	Modulator
DMVAM18	RN	2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
DMVAM18	RU	https://pubmed.ncbi.nlm.nih.gov/18246607

DM6JNV3	DI	DM6JNV3
DM6JNV3	DN	Genevx
DM6JNV3	MI	TTVJ1D8
DM6JNV3	MN	Vascular endothelial growth factor receptor (VEGFR)
DM6JNV3	MT	DTT
DM6JNV3	MA	Modulator
DM6JNV3	RN	Vascular Endothelial Growth Factor Gene Therapy Increases Survival, Promotes Lung Angiogenesis, and Prevents Alveolar Damage in Hyperoxia-Induced Lung Injury. Circulation. 2005; 112: 2477-2486.
DM6JNV3	RU	http://circ.ahajournals.org/content/112/16/2477.figures-only?sid=d5a20876-08aa-4d32-9f57-765c26558bd6

DMGX5Q0	DI	DMGX5Q0
DMGX5Q0	DN	Gepirone
DMGX5Q0	MI	TTSQIFT
DMGX5Q0	MN	5-HT 1A receptor (HTR1A)
DMGX5Q0	MT	DTT
DMGX5Q0	MA	Agonist
DMGX5Q0	RN	Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
DMGX5Q0	RU	https://pubmed.ncbi.nlm.nih.gov/18172433

DMGX5Q0	DI	DMGX5Q0
DMGX5Q0	DN	Gepirone
DMGX5Q0	MI	DECB0K3
DMGX5Q0	MN	Cytochrome P450 2D6 (CYP2D6)
DMGX5Q0	MT	DME
DMGX5Q0	MA	Metabolism
DMGX5Q0	RN	Metabolism of the newest antidepressants: comparisons with related predecessors. IDrugs. 2004 Feb;7(2):143-50.
DMGX5Q0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15057659

DMGX5Q0	DI	DMGX5Q0
DMGX5Q0	DN	Gepirone
DMGX5Q0	MI	DE4LYSA
DMGX5Q0	MN	Cytochrome P450 3A4 (CYP3A4)
DMGX5Q0	MT	DME
DMGX5Q0	MA	Metabolism
DMGX5Q0	RN	Metabolism of the newest antidepressants: comparisons with related predecessors. IDrugs. 2004 Feb;7(2):143-50.
DMGX5Q0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15057659

DM1CG0J	DI	DM1CG0J
DM1CG0J	DN	GGTI-298
DM1CG0J	MI	TTX20QP
DM1CG0J	MN	Geranylgeranyl transferase I (GGTase-I)
DM1CG0J	MT	DTT
DM1CG0J	MA	Inhibitor
DM1CG0J	RN	The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner. J Biol Chem. 1997 Oct 24;272(43):27224-9.
DM1CG0J	RU	https://pubmed.ncbi.nlm.nih.gov/9341167

DMXVP13	DI	DMXVP13
DMXVP13	DN	GI-129471
DMXVP13	MI	TT1GHVO
DMXVP13	MN	Matrix metalloproteinase (MMP)
DMXVP13	MT	DTT
DMXVP13	MA	Modulator
DMXVP13	RN	Stimulation of matrix metalloproteinase-9 expression in human fibrosarcoma cells by synthetic matrix metalloproteinase inhibitors. Exp Cell Res. 2002 Apr 15;275(1):110-21.
DMXVP13	RU	https://pubmed.ncbi.nlm.nih.gov/11925109

DM6HZU1	DI	DM6HZU1
DM6HZU1	DN	GI-197111
DM6HZU1	MI	TT2A0DR
DM6HZU1	MN	Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A)
DM6HZU1	MT	DTT
DM6HZU1	MA	Modulator
DM6HZU1	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008867)
DM6HZU1	RU	http://adisinsight.springer.com/drugs/800008867

DMT6J1E	DI	DMT6J1E
DMT6J1E	DN	GI-248573
DMT6J1E	MI	TTCG0AL
DMT6J1E	MN	Cholecystokinin receptor type A (CCKAR)
DMT6J1E	MT	DTT
DMT6J1E	MA	Modulator
DMT6J1E	RN	US patent application no. 8,748,419, Antagonists.
DMT6J1E	RU	http://www.google.com.ar/Patents/US8748419

DM3KN2Q	DI	DM3KN2Q
DM3KN2Q	DN	GI-270384X
DM3KN2Q	MI	TTAU4D6
DM3KN2Q	MN	E-selectin (SELE)
DM3KN2Q	MT	DTT
DM3KN2Q	MA	Modulator
DM3KN2Q	RN	Inhibition of endothelial cell adhesion molecule expression improves colonic hyperalgaesia. Neurogastroenterol Motil. 2009 Feb;21(2):189-96.
DM3KN2Q	RU	https://pubmed.ncbi.nlm.nih.gov/19126181

DM3KN2Q	DI	DM3KN2Q
DM3KN2Q	DN	GI-270384X
DM3KN2Q	MI	TTCT6F7
DM3KN2Q	MN	Intercellular adhesion molecule ICAM-1 (ICAM1)
DM3KN2Q	MT	DTT
DM3KN2Q	MA	Modulator
DM3KN2Q	RN	Inhibition of endothelial cell adhesion molecule expression improves colonic hyperalgaesia. Neurogastroenterol Motil. 2009 Feb;21(2):189-96.
DM3KN2Q	RU	https://pubmed.ncbi.nlm.nih.gov/19126181

DMX0N9P	DI	DMX0N9P
DMX0N9P	DN	Ginkgolide B (GKB)
DMX0N9P	MI	TTPTXIN
DMX0N9P	MN	Translocator protein (TSPO)
DMX0N9P	MT	DTT
DMX0N9P	MA	Suppressor
DMX0N9P	RN	Drug-induced inhibition of the peripheral-type benzodiazepine receptor expression and cell proliferation in human breast cancer cells. Anticancer Res. 2000 Sep-Oct;20(5A):2835-47.
DMX0N9P	RU	https://pubmed.ncbi.nlm.nih.gov/11062691

DMLIM7B	DI	DMLIM7B
DMLIM7B	DN	GINKOLIDE B
DMLIM7B	MI	TTZ8EM9
DMLIM7B	MN	Glycine receptor (GlyR)
DMLIM7B	MT	DTT
DMLIM7B	MA	Inhibitor
DMLIM7B	RN	Probing the pharmacophore of ginkgolides as glycine receptor antagonists. J Med Chem. 2007 Apr 5;50(7):1610-7.
DMLIM7B	RU	https://pubmed.ncbi.nlm.nih.gov/17352465

DMLIM7B	DI	DMLIM7B
DMLIM7B	DN	GINKOLIDE B
DMLIM7B	MI	TTF45NW
DMLIM7B	MN	Strychnine-binding glycine receptor (GLRA1)
DMLIM7B	MT	DTT
DMLIM7B	MA	Inhibitor
DMLIM7B	RN	Probing the pharmacophore of ginkgolides as glycine receptor antagonists. J Med Chem. 2007 Apr 5;50(7):1610-7.
DMLIM7B	RU	https://pubmed.ncbi.nlm.nih.gov/17352465

DMSVMF2	DI	DMSVMF2
DMSVMF2	DN	Girisopam
DMSVMF2	MI	TTEX6LM
DMSVMF2	MN	GABA(A) receptor gamma-3 (GABRG3)
DMSVMF2	MT	DTT
DMSVMF2	MA	Modulator
DMSVMF2	RN	[(3)H]-girisopam, a novel selective benzodiazepine for the 2, 3-benzodiazepine binding site. Brain Res Brain Res Protoc. 1999 Jul;4(2):230-5.
DMSVMF2	RU	https://www.ncbi.nlm.nih.gov/pubmed/10446419

DM4RKDU	DI	DM4RKDU
DM4RKDU	DN	GK-128
DM4RKDU	MI	TTNXLKE
DM4RKDU	MN	5-HT 3 receptor (5HT3R)
DM4RKDU	MT	DTT
DM4RKDU	MA	Modulator
DM4RKDU	RN	Effect of a novel 5-hydroxytryptamine3 (5-HT3) receptor antagonist, GK-128, on 5-HT3 receptors mediating contractions and relaxations in guinea-pig distal colon. Gen Pharmacol. 1997 Sep;29(3):353-9.
DM4RKDU	RU	https://pubmed.ncbi.nlm.nih.gov/9378239

DMONQYZ	DI	DMONQYZ
DMONQYZ	DN	Gliotoxin
DMONQYZ	MI	TTSXVID
DMONQYZ	MN	Nuclear factor NF-kappa-B (NFKB)
DMONQYZ	MT	DTT
DMONQYZ	MA	Inhibitor
DMONQYZ	RN	Gliotoxin inhibits neointimal hyperplasia after vascular injury in rats. J Vasc Res. 2009;46(4):278-89.
DMONQYZ	RU	https://pubmed.ncbi.nlm.nih.gov/19033690

DM0IKB4	DI	DM0IKB4
DM0IKB4	DN	GLY-515n
DM0IKB4	MI	TTQG4NR
DM0IKB4	MN	Erythropoietin (EPO)
DM0IKB4	MT	DTT
DM0IKB4	MA	Modulator
DM0IKB4	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027536)
DM0IKB4	RU	http://adisinsight.springer.com/drugs/800027536

DMEVIP9	DI	DMEVIP9
DMEVIP9	DN	GM-7050
DMEVIP9	MI	TTD26RC
DMEVIP9	MN	Cell adhesion molecule (CADM)
DMEVIP9	MT	DTT
DMEVIP9	MA	Modulator
DMEVIP9	RN	US patent application no. 6,673,908, Tumor necrosis factor receptor 2.
DMEVIP9	RU	http://www.google.com/patents/US6673908

DMT1RH6	DI	DMT1RH6
DMT1RH6	DN	GMC-283
DMT1RH6	MI	TTJQOD7
DMT1RH6	MN	5-HT 2A receptor (HTR2A)
DMT1RH6	MT	DTT
DMT1RH6	MA	Antagonist
DMT1RH6	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMT1RH6	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMT1RH6	DI	DMT1RH6
DMT1RH6	DN	GMC-283
DMT1RH6	MI	TTEX248
DMT1RH6	MN	Dopamine D2 receptor (D2R)
DMT1RH6	MT	DTT
DMT1RH6	MA	Antagonist
DMT1RH6	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMT1RH6	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMT1RH6	DI	DMT1RH6
DMT1RH6	DN	GMC-283
DMT1RH6	MI	TTS2PH3
DMT1RH6	MN	Dopamine D5 receptor (D5R)
DMT1RH6	MT	DTT
DMT1RH6	MA	Antagonist
DMT1RH6	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMT1RH6	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMHXRN8	DI	DMHXRN8
DMHXRN8	DN	GNI-104
DMHXRN8	MI	TTXAKVF
DMHXRN8	MN	Hepatitis C virus Envelope glycoprotein (HCV Env)
DMHXRN8	MT	DTT
DMHXRN8	RN	WO patent application no. 2009,1433,45, Nucleic acid silencing agent-protein conjugates and use thereof for treating hcv-related disorders.
DMHXRN8	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20091126&CC=WO&NR=2009143345A2&KC=A2

DMPODL9	DI	DMPODL9
DMPODL9	DN	GP-683
DMPODL9	MI	TTL732K
DMPODL9	MN	Adenosine kinase (ADK)
DMPODL9	MT	DTT
DMPODL9	MA	Inhibitor
DMPODL9	RN	The effect of GP683, an adenosine kinase inhibitor, on the desflurane anesthetic requirement in dogs. Anesth Analg. 1997 Sep;85(3):675-80.
DMPODL9	RU	https://pubmed.ncbi.nlm.nih.gov/9296430

DMD5WK4	DI	DMD5WK4
DMD5WK4	DN	Gpi-1046
DMD5WK4	MI	TTMW94E
DMD5WK4	MN	FK506-binding protein 1A (FKBP1A)
DMD5WK4	MT	DTT
DMD5WK4	MA	Inhibitor
DMD5WK4	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMD5WK4	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMBMAPH	DI	DMBMAPH
DMBMAPH	DN	GPI-3000
DMBMAPH	MI	TT9IK2Z
DMBMAPH	MN	N-methyl-D-aspartate receptor (NMDAR)
DMBMAPH	MT	DTT
DMBMAPH	MA	Modulator
DMBMAPH	RN	Treatment with the competitive NMDA antagonist GPI 3000 does not improve outcome after cardiac arrest in dogs. Stroke. 1998 Apr;29(4):824-9.
DMBMAPH	RU	https://pubmed.ncbi.nlm.nih.gov/9550518

DM01HLX	DI	DM01HLX
DM01HLX	DN	GR-127935
DM01HLX	MI	TTK8CXU
DM01HLX	MN	5-HT 1B receptor (HTR1B)
DM01HLX	MT	DTT
DM01HLX	MA	Modulator
DM01HLX	RN	GR127935: a potent and selective 5-HT1D receptor antagonist.Behav Brain Res.1996;73(1-2):157-61.
DM01HLX	RU	https://www.ncbi.nlm.nih.gov/pubmed/8788495

DM01HLX	DI	DM01HLX
DM01HLX	DN	GR-127935
DM01HLX	MI	TT6MSOK
DM01HLX	MN	5-HT 1D receptor (HTR1D)
DM01HLX	MT	DTT
DM01HLX	MA	Modulator
DM01HLX	RN	GR127935: a potent and selective 5-HT1D receptor antagonist.Behav Brain Res.1996;73(1-2):157-61.
DM01HLX	RU	https://www.ncbi.nlm.nih.gov/pubmed/8788495

DMKAGLV	DI	DMKAGLV
DMKAGLV	DN	GR-131663
DMKAGLV	MI	TT0WAIE
DMKAGLV	MN	Melatonin receptor type 1A (MTNR1A)
DMKAGLV	MT	DTT
DMKAGLV	MA	Modulator
DMKAGLV	RN	Novel non-indolic melatonin receptor agonists differentially entrain endogenous melatonin rhythm and increase its amplitude. Eur J Pharmacol. 1999 Oct 15;382(3):157-66.
DMKAGLV	RU	https://pubmed.ncbi.nlm.nih.gov/10556666

DMNRJA0	DI	DMNRJA0
DMNRJA0	DN	GR-133347
DMNRJA0	MI	TT0WAIE
DMNRJA0	MN	Melatonin receptor type 1A (MTNR1A)
DMNRJA0	MT	DTT
DMNRJA0	MA	Modulator
DMNRJA0	RN	US patent application no. 5,151,446, Substituted 2-amidotetralins as melatonin agonists and antagonists.
DMNRJA0	RU	http://www.google.com/patents/US5151446

DMN8TH1	DI	DMN8TH1
DMN8TH1	DN	GR-144053
DMN8TH1	MI	TT38RM1
DMN8TH1	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DMN8TH1	MT	DTT
DMN8TH1	MA	Modulator
DMN8TH1	RN	GR144053, a fibrinogen receptor antagonist, enhances the suppression of neointima formation by losartan, an angiotensin II receptor antagonist, in ... Br J Pharmacol. 1997 Nov;122(6):1099-104.
DMN8TH1	RU	https://www.ncbi.nlm.nih.gov/pubmed/9480031

DMLQ71Y	DI	DMLQ71Y
DMLQ71Y	DN	GR-159897
DMLQ71Y	MI	TTYO0A3
DMLQ71Y	MN	Substance-K receptor (TACR2)
DMLQ71Y	MT	DTT
DMLQ71Y	MA	Modulator
DMLQ71Y	RN	GR159897, a potent non-peptide antagonist at tachykinin NK2 receptors. Eur J Pharmacol. 1995 Jan 16;272(2-3):241-8.
DMLQ71Y	RU	https://pubmed.ncbi.nlm.nih.gov/7713168

DMOY8UA	DI	DMOY8UA
DMOY8UA	DN	GR-175737
DMOY8UA	MI	TT9JNIC
DMOY8UA	MN	Histamine H3 receptor (H3R)
DMOY8UA	MT	DTT
DMOY8UA	MA	Inhibitor
DMOY8UA	RN	New acetylene based histamine H3 receptor antagonists derived from the marine natural product verongamine. Bioorg Med Chem Lett. 1998 May 19;8(10):1133-8.
DMOY8UA	RU	https://pubmed.ncbi.nlm.nih.gov/9871722

DMA7FX1	DI	DMA7FX1
DMA7FX1	DN	GR-199114X
DMA7FX1	MI	TTVFO0U
DMA7FX1	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMA7FX1	MT	DTT
DMA7FX1	MA	Modulator
DMA7FX1	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009210)
DMA7FX1	RU	http://adisinsight.springer.com/drugs/800009210

DMIJCH1	DI	DMIJCH1
DMIJCH1	DN	GR-218231
DMIJCH1	MI	TT4C8EA
DMIJCH1	MN	Dopamine D3 receptor (D3R)
DMIJCH1	MT	DTT
DMIJCH1	MA	Inhibitor
DMIJCH1	RN	Design, synthesis, and binding affinities of potential positron emission tomography (PET) ligands with optimal lipophilicity for brain imaging of t... Bioorg Med Chem. 2009 Jan 15;17(2):758-66.
DMIJCH1	RU	https://pubmed.ncbi.nlm.nih.gov/19081257

DMHM0EU	DI	DMHM0EU
DMHM0EU	DN	GR-233548
DMHM0EU	MI	TT38RM1
DMHM0EU	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DMHM0EU	MT	DTT
DMHM0EU	MA	Modulator
DMHM0EU	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMHM0EU	RU	https://www.fda.gov/

DMRPE3D	DI	DMRPE3D
DMRPE3D	DN	GR-65630
DMRPE3D	MI	TTNXLKE
DMRPE3D	MN	5-HT 3 receptor (5HT3R)
DMRPE3D	MT	DTT
DMRPE3D	MA	Modulator
DMRPE3D	RN	Binding of the 5-HT3 ligand, [3H]GR65630, to rat area postrema, vagus nerve and the brains of several species. Eur J Pharmacol. 1989 Jan 10;159(2):157-64.
DMRPE3D	RU	https://pubmed.ncbi.nlm.nih.gov/2707305

DMR2TZK	DI	DMR2TZK
DMR2TZK	DN	GR-82334
DMR2TZK	MI	TTZPO1L
DMR2TZK	MN	Substance-P receptor (TACR1)
DMR2TZK	MT	DTT
DMR2TZK	MA	Antagonist
DMR2TZK	RN	Effect of the NK-1 receptor antagonist GR 82,334 on reflexly-induced bladder contractions. Life Sci. 1992;51(26):PL277-80.
DMR2TZK	RU	https://pubmed.ncbi.nlm.nih.gov/1335533

DMTGH8N	DI	DMTGH8N
DMTGH8N	DN	GR-89696
DMTGH8N	MI	TTQW87Y
DMTGH8N	MN	Opioid receptor kappa (OPRK1)
DMTGH8N	MT	DTT
DMTGH8N	MA	Modulator
DMTGH8N	RN	[(11)C]-GR89696, a potent kappa opiate receptor radioligand; in vivo binding of the R and S enantiomers. Nucl Med Biol. 2002 Jan;29(1):47-53.
DMTGH8N	RU	https://pubmed.ncbi.nlm.nih.gov/11786275

DM96KF7	DI	DM96KF7
DM96KF7	DN	GR-94839
DM96KF7	MI	TTQW87Y
DM96KF7	MN	Opioid receptor kappa (OPRK1)
DM96KF7	MT	DTT
DM96KF7	MA	Modulator
DM96KF7	RN	GR94839, a kappa-opioid agonist with limited access to the central nervous system, has antinociceptive activity. Br J Pharmacol. 1992 Aug;106(4):783-9.
DM96KF7	RU	https://pubmed.ncbi.nlm.nih.gov/1327387

DMAHNF6	DI	DMAHNF6
DMAHNF6	DN	GR-95168
DMAHNF6	MI	TTIU7X1
DMAHNF6	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMAHNF6	MT	DTT
DMAHNF6	MA	Modulator
DMAHNF6	RN	US patent application no. 2004,0023,290, Novel therapeutic agents that modulate enzymatic processes.
DMAHNF6	RU	http://www.google.com/patents/US20040023290

DMPSZR0	DI	DMPSZR0
DMPSZR0	DN	GS-2992
DMPSZR0	MI	TT5FNQT
DMPSZR0	MN	Human immunodeficiency virus Protease (HIV PR)
DMPSZR0	MT	DTT
DMPSZR0	MA	Modulator
DMPSZR0	RN	US patent application no. 2008,0161,324, Compositions and methods for treatment of viral diseases.
DMPSZR0	RU	http://www.google.com/patents/US20080161324

DMV7JC6	DI	DMV7JC6
DMV7JC6	DN	GS-3435
DMV7JC6	MI	TT50QJ3
DMV7JC6	MN	Influenza Neuraminidase (Influ NA)
DMV7JC6	MT	DTT
DMV7JC6	MA	Modulator
DMV7JC6	RN	US patent application no. 2010,0081,713, Compositions and methods for treating viral infections.
DMV7JC6	RU	http://www.google.com/patents/US20100081713

DMT6S9B	DI	DMT6S9B
DMT6S9B	DN	GS-522
DMT6S9B	MI	TT6L509
DMT6S9B	MN	Coagulation factor IIa (F2)
DMT6S9B	MT	DTT
DMT6S9B	MA	Inhibitor
DMT6S9B	RN	A novel oligodeoxynucleotide inhibitor of thrombin. I. In vitro metabolic stability in plasma and serum. Pharm Res. 1995 Dec;12(12):1937-42.
DMT6S9B	RU	https://pubmed.ncbi.nlm.nih.gov/8786969

DMCYZL3	DI	DMCYZL3
DMCYZL3	DN	GS-9148
DMCYZL3	MI	TT84ETX
DMCYZL3	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMCYZL3	MT	DTT
DMCYZL3	MA	Inhibitor
DMCYZL3	RN	Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation. Antimicrob Agents Chemother. 2009 Jan;53(1):150-6.
DMCYZL3	RU	https://pubmed.ncbi.nlm.nih.gov/19001108

DMQSMB1	DI	DMQSMB1
DMQSMB1	DN	GS-9160
DMQSMB1	MI	TT5FH9Y
DMQSMB1	MN	Human immunodeficiency virus Integrase (HIV IN)
DMQSMB1	MT	DTT
DMQSMB1	MA	Inhibitor
DMQSMB1	RN	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase. Antimicrob Agents Chemother. 2009 Mar;53(3):1194-203.
DMQSMB1	RU	https://pubmed.ncbi.nlm.nih.gov/19104010

DMOALVR	DI	DMOALVR
DMOALVR	DN	GSK-2485852
DMOALVR	MI	TTMVBWH
DMOALVR	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMOALVR	MT	DTT
DMOALVR	MA	Inhibitor
DMOALVR	RN	In vitro characterization of GSK2485852, a novel hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother. 2013 Nov;57(11):5216-24.
DMOALVR	RU	https://pubmed.ncbi.nlm.nih.gov/23939896

DMMYUWT	DI	DMMYUWT
DMMYUWT	DN	GSK-923295
DMMYUWT	MI	TTZD5QR
DMMYUWT	MN	Centromeric protein E (CENPE)
DMMYUWT	MT	DTT
DMMYUWT	MA	Inhibitor
DMMYUWT	RN	Cytokinetics Announces Non-Clinical Trial Data Presented at 2007 AACR Annual Meeting. Cytokinetics, Incorporated. 2007.
DMMYUWT	RU	http://www.newsrx.com/newsletters/Blood-Weekly/2007-05-10/80510200710BW.html

DMA6RL2	DI	DMA6RL2
DMA6RL2	DN	GT-16-239
DMA6RL2	MI	TTPADOQ
DMA6RL2	MN	HMG-CoA reductase (HMGCR)
DMA6RL2	MT	DTT
DMA6RL2	MA	Modulator
DMA6RL2	RN	Studies of cholesterol and bile acid metabolism, and early atherogenesis in hamsters fed GT16-239, a novel bile acid sequestrant (BAS). Atherosclerosis. 1998 Oct;140(2):315-24.
DMA6RL2	RU	https://pubmed.ncbi.nlm.nih.gov/9862274

DM42XHS	DI	DM42XHS
DM42XHS	DN	GT-2016
DM42XHS	MI	TT9JNIC
DM42XHS	MN	Histamine H3 receptor (H3R)
DM42XHS	MT	DTT
DM42XHS	MA	Inhibitor
DM42XHS	RN	New acetylene based histamine H3 receptor antagonists derived from the marine natural product verongamine. Bioorg Med Chem Lett. 1998 May 19;8(10):1133-8.
DM42XHS	RU	https://pubmed.ncbi.nlm.nih.gov/9871722

DMJ4PNR	DI	DMJ4PNR
DMJ4PNR	DN	GT-2203
DMJ4PNR	MI	TT9JNIC
DMJ4PNR	MN	Histamine H3 receptor (H3R)
DMJ4PNR	MT	DTT
DMJ4PNR	MA	Agonist
DMJ4PNR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 264).
DMJ4PNR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=264

DMGSN1V	DI	DMGSN1V
DMGSN1V	DN	GW-275175
DMGSN1V	MI	TTZHSBO
DMGSN1V	MN	Cytomegalovirus Terminase (CMV TRM)
DMGSN1V	MT	DTT
DMGSN1V	MA	Inhibitor
DMGSN1V	RN	Progress in Drug Research, 2012. Page(106).
DMGSN1V	RU	https://books.google.com.hk/books?id=MoEECAAAQBAJ&pg=PA106&lpg=PA106&dq=%22GW-275175%22++terminase&source=bl&ots=f4vjuv3udg&sig=PDAZfA0gFYZn-7A4DEHDiG2ffEY&hl=zh-CN&sa=X&ved=0CBwQ6AEwAGoVChMIg9Tgov_AyAIVFAmOCh1lPgeT#v=onepage&q=%22GW-275175%22%20%20terminase&f=false

DMUG82P	DI	DMUG82P
DMUG82P	DN	GW-278884
DMUG82P	MI	TT3C1VN
DMUG82P	MN	Enzyme unspecific (Enz)
DMUG82P	MT	DTT
DMUG82P	MA	Modulator
DMUG82P	RN	WO patent application no. 2010,1112,71, Orally bioavailable lipid-based constructs.
DMUG82P	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20100930&CC=WO&NR=2010111271A1&KC=A1

DMSZH0I	DI	DMSZH0I
DMSZH0I	DN	GW-3600
DMSZH0I	MI	TTZ97H5
DMSZH0I	MN	Phosphodiesterase 4A (PDE4A)
DMSZH0I	MT	DTT
DMSZH0I	MA	Inhibitor
DMSZH0I	RN	Dual inhibition of human type 4 phosphodiesterase isostates by (R, R)-(+/-)-methyl 3-acetyl-4-[3-(cyclopentyloxy)-4-methoxyphenyl]-3- methyl-1-pyrrolidinecarboxylate. Biochemistry. 1998 May 12;37(19):6894-904.
DMSZH0I	RU	https://pubmed.ncbi.nlm.nih.gov/9578576

DMSZH0I	DI	DMSZH0I
DMSZH0I	DN	GW-3600
DMSZH0I	MI	TTVIAT9
DMSZH0I	MN	Phosphodiesterase 4B (PDE4B)
DMSZH0I	MT	DTT
DMSZH0I	MA	Inhibitor
DMSZH0I	RN	Dual inhibition of human type 4 phosphodiesterase isostates by (R, R)-(+/-)-methyl 3-acetyl-4-[3-(cyclopentyloxy)-4-methoxyphenyl]-3- methyl-1-pyrrolidinecarboxylate. Biochemistry. 1998 May 12;37(19):6894-904.
DMSZH0I	RU	https://pubmed.ncbi.nlm.nih.gov/9578576

DMSZH0I	DI	DMSZH0I
DMSZH0I	DN	GW-3600
DMSZH0I	MI	TTSKMI8
DMSZH0I	MN	Phosphodiesterase 4D (PDE4D)
DMSZH0I	MT	DTT
DMSZH0I	MA	Inhibitor
DMSZH0I	RN	Dual inhibition of human type 4 phosphodiesterase isostates by (R, R)-(+/-)-methyl 3-acetyl-4-[3-(cyclopentyloxy)-4-methoxyphenyl]-3- methyl-1-pyrrolidinecarboxylate. Biochemistry. 1998 May 12;37(19):6894-904.
DMSZH0I	RU	https://pubmed.ncbi.nlm.nih.gov/9578576

DMG5A1Z	DI	DMG5A1Z
DMG5A1Z	DN	GW-660511
DMG5A1Z	MI	TTL69WB
DMG5A1Z	MN	Angiotensin-converting enzyme (ACE)
DMG5A1Z	MT	DTT
DMG5A1Z	MA	Modulator
DMG5A1Z	RN	The effects of Z13752A, a combined ACE/NEP inhibitor, on responses to coronary artery occlusion; a primary protective role for bradykinin. Br J Pharmacol. 2000 Feb;129(4):671-80.
DMG5A1Z	RU	https://pubmed.ncbi.nlm.nih.gov/10683191

DMG5A1Z	DI	DMG5A1Z
DMG5A1Z	DN	GW-660511
DMG5A1Z	MI	TT5TKPM
DMG5A1Z	MN	Neutral endopeptidase (MME)
DMG5A1Z	MT	DTT
DMG5A1Z	MA	Modulator
DMG5A1Z	RN	The effects of Z13752A, a combined ACE/NEP inhibitor, on responses to coronary artery occlusion; a primary protective role for bradykinin. Br J Pharmacol. 2000 Feb;129(4):671-80.
DMG5A1Z	RU	https://pubmed.ncbi.nlm.nih.gov/10683191

DMPLYHU	DI	DMPLYHU
DMPLYHU	DN	GW-974
DMPLYHU	MI	TT6EO5L
DMPLYHU	MN	Erbb2 tyrosine kinase receptor (HER2)
DMPLYHU	MT	DTT
DMPLYHU	MA	Inhibitor
DMPLYHU	RN	WO patent application no. 2005,0443,02, Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer.
DMPLYHU	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20050519&CC=WO&NR=2005044302A1&KC=A1

DM3YG5P	DI	DM3YG5P
DM3YG5P	DN	GYKI-52466
DM3YG5P	MI	TTAN6JD
DM3YG5P	MN	Glutamate receptor AMPA (GRIA)
DM3YG5P	MT	DTT
DM3YG5P	MA	Inhibitor
DM3YG5P	RN	New 7,8-ethylenedioxy-2,3-benzodiazepines as noncompetitive AMPA receptor antagonists. Bioorg Med Chem Lett. 2006 Jan 1;16(1):167-70.
DM3YG5P	RU	https://pubmed.ncbi.nlm.nih.gov/16216501

DM3YG5P	DI	DM3YG5P
DM3YG5P	DN	GYKI-52466
DM3YG5P	MI	TTVPQTF
DM3YG5P	MN	Glutamate receptor AMPA 1 (GRIA1)
DM3YG5P	MT	DTT
DM3YG5P	MA	Inhibitor
DM3YG5P	RN	New 7,8-ethylenedioxy-2,3-benzodiazepines as noncompetitive AMPA receptor antagonists. Bioorg Med Chem Lett. 2006 Jan 1;16(1):167-70.
DM3YG5P	RU	https://pubmed.ncbi.nlm.nih.gov/16216501

DMC0JN8	DI	DMC0JN8
DMC0JN8	DN	GYKI-53655
DMC0JN8	MI	TTAN6JD
DMC0JN8	MN	Glutamate receptor AMPA (GRIA)
DMC0JN8	MT	DTT
DMC0JN8	MA	Inhibitor
DMC0JN8	RN	Substituted 1,2-dihydrophthalazines: potent, selective, and noncompetitive inhibitors of the AMPA receptor. J Med Chem. 1996 Jan 19;39(2):343-6.
DMC0JN8	RU	https://pubmed.ncbi.nlm.nih.gov/8558499

DMC0JN8	DI	DMC0JN8
DMC0JN8	DN	GYKI-53655
DMC0JN8	MI	TTVPQTF
DMC0JN8	MN	Glutamate receptor AMPA 1 (GRIA1)
DMC0JN8	MT	DTT
DMC0JN8	MA	Inhibitor
DMC0JN8	RN	Substituted 1,2-dihydrophthalazines: potent, selective, and noncompetitive inhibitors of the AMPA receptor. J Med Chem. 1996 Jan 19;39(2):343-6.
DMC0JN8	RU	https://pubmed.ncbi.nlm.nih.gov/8558499

DM904UQ	DI	DM904UQ
DM904UQ	DN	H-216/44
DM904UQ	MI	TTMXGCW
DM904UQ	MN	Adrenergic receptor beta-3 (ADRB3)
DM904UQ	MT	DTT
DM904UQ	MA	Modulator
DM904UQ	RN	Binding of the beta-blockers timolol and H 216/44 to ocular melanin. Exp Eye Res. 1988 Oct;47(4):565-77.
DM904UQ	RU	https://pubmed.ncbi.nlm.nih.gov/2903066

DMMCI4H	DI	DMMCI4H
DMMCI4H	DN	HELENALIN
DMMCI4H	MI	TT8DBY3
DMMCI4H	MN	Angiotensin II receptor type-1 (AGTR1)
DMMCI4H	MT	DTT
DMMCI4H	MA	Inhibitor
DMMCI4H	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMMCI4H	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMMCI4H	DI	DMMCI4H
DMMCI4H	DN	HELENALIN
DMMCI4H	MI	TTSXVID
DMMCI4H	MN	Nuclear factor NF-kappa-B (NFKB)
DMMCI4H	MT	DTT
DMMCI4H	MA	Inhibitor
DMMCI4H	RN	Quantitative structure-activity relationship of sesquiterpene lactones as inhibitors of the transcription factor NF-kappaB. J Med Chem. 2004 Nov 18;47(24):6042-54.
DMMCI4H	RU	https://pubmed.ncbi.nlm.nih.gov/15537359

DM5HMZW	DI	DM5HMZW
DM5HMZW	DN	Hementin
DM5HMZW	MI	TT6L509
DM5HMZW	MN	Coagulation factor IIa (F2)
DM5HMZW	MT	DTT
DM5HMZW	MA	Inhibitor
DM5HMZW	RN	Hementin: anticoagulant protease from the salivary gland of the leech Haementeria ghilianii. J Lab Clin Med. 1984 Jan;103(1):44-58.
DM5HMZW	RU	https://pubmed.ncbi.nlm.nih.gov/6361187

DMMXG2I	DI	DMMXG2I
DMMXG2I	DN	Heparin-EGF-like factor
DMMXG2I	MI	TTGKNB4
DMMXG2I	MN	Epidermal growth factor receptor (EGFR)
DMMXG2I	MT	DTT
DMMXG2I	MA	Modulator
DMMXG2I	RN	The heparin-binding domain of heparin-binding EGF-like growth factor can target Pseudomonas exotoxin to kill cells exclusively through heparan sulfate proteoglycans. J Cell Sci. 1994 Sep;107 ( Pt 9):2599-608.
DMMXG2I	RU	https://pubmed.ncbi.nlm.nih.gov/7844173

DMGAKD8	DI	DMGAKD8
DMGAKD8	DN	HIMBACINE
DMGAKD8	MI	TTZ9SOR
DMGAKD8	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMGAKD8	MT	DTT
DMGAKD8	MA	Inhibitor
DMGAKD8	RN	Himbacine analogs as muscarinic receptor antagonists--effects of tether and heterocyclic variations. Bioorg Med Chem Lett. 2004 Aug 2;14(15):3967-70.
DMGAKD8	RU	https://pubmed.ncbi.nlm.nih.gov/15225708

DMGAKD8	DI	DMGAKD8
DMGAKD8	DN	HIMBACINE
DMGAKD8	MI	TTYEG6Q
DMGAKD8	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMGAKD8	MT	DTT
DMGAKD8	MA	Inhibitor
DMGAKD8	RN	Himbacine analogs as muscarinic receptor antagonists--effects of tether and heterocyclic variations. Bioorg Med Chem Lett. 2004 Aug 2;14(15):3967-70.
DMGAKD8	RU	https://pubmed.ncbi.nlm.nih.gov/15225708

DM784QJ	DI	DM784QJ
DM784QJ	DN	Hirufaxin
DM784QJ	MI	TTCIHJA
DM784QJ	MN	Coagulation factor Xa (F10)
DM784QJ	MT	DTT
DM784QJ	MA	Inhibitor
DM784QJ	RN	Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7.
DM784QJ	RU	https://pubmed.ncbi.nlm.nih.gov/22844656

DMCHFIT	DI	DMCHFIT
DMCHFIT	DN	HMR-3787
DMCHFIT	MI	TTUWYEA
DMCHFIT	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DMCHFIT	MT	DTT
DMCHFIT	MA	Modulator
DMCHFIT	RN	Structure-activity relationships for six ketolide antibiotics. Curr Microbiol. 2001 Mar;42(3):203-10.
DMCHFIT	RU	https://pubmed.ncbi.nlm.nih.gov/11270656

DML0B97	DI	DML0B97
DML0B97	DN	HOE-694
DML0B97	MI	TTGSEFH
DML0B97	MN	Sodium/hydrogen exchanger 1 (SLC9A1)
DML0B97	MT	DTT
DML0B97	MA	Inhibitor
DML0B97	RN	(2-Methyl-5-(methylsulfonyl)benzoyl)guanidine Na+/H+ antiporter inhibitors. J Med Chem. 1997 Jun 20;40(13):2017-34.
DML0B97	RU	https://pubmed.ncbi.nlm.nih.gov/9207943

DML0B97	DI	DML0B97
DML0B97	DN	HOE-694
DML0B97	MI	TTFZVPO
DML0B97	MN	Sodium/hydrogen exchanger 3 (SLC9A3)
DML0B97	MT	DTT
DML0B97	MA	Inhibitor
DML0B97	RN	(2-Methyl-5-(methylsulfonyl)benzoyl)guanidine Na+/H+ antiporter inhibitors. J Med Chem. 1997 Jun 20;40(13):2017-34.
DML0B97	RU	https://pubmed.ncbi.nlm.nih.gov/9207943

DMHP9WV	DI	DMHP9WV
DMHP9WV	DN	HOMOEPIBATIDINE
DMHP9WV	MI	TT4H1MQ
DMHP9WV	MN	Neuronal acetylcholine receptor alpha-4 (CHRNA4)
DMHP9WV	MT	DTT
DMHP9WV	MA	Inhibitor
DMHP9WV	RN	Epibatidine isomers and analogues: structure-activity relationships. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5493-7.
DMHP9WV	RU	https://pubmed.ncbi.nlm.nih.gov/16934977

DMHP9WV	DI	DMHP9WV
DMHP9WV	DN	HOMOEPIBATIDINE
DMHP9WV	MI	TT5KPZR
DMHP9WV	MN	Neuronal acetylcholine receptor beta-2 (CHRNB2)
DMHP9WV	MT	DTT
DMHP9WV	MA	Inhibitor
DMHP9WV	RN	Epibatidine isomers and analogues: structure-activity relationships. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5493-7.
DMHP9WV	RU	https://pubmed.ncbi.nlm.nih.gov/16934977

DMHP9WV	DI	DMHP9WV
DMHP9WV	DN	HOMOEPIBATIDINE
DMHP9WV	MI	TTTVAFQ
DMHP9WV	MN	Neuronal acetylcholine receptor beta-4 (CHRNB4)
DMHP9WV	MT	DTT
DMHP9WV	MA	Inhibitor
DMHP9WV	RN	Epibatidine isomers and analogues: structure-activity relationships. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5493-7.
DMHP9WV	RU	https://pubmed.ncbi.nlm.nih.gov/16934977

DMEZ5P2	DI	DMEZ5P2
DMEZ5P2	DN	HRC-101
DMEZ5P2	MI	TTQO71U
DMEZ5P2	MN	Hemoglobin (HB)
DMEZ5P2	MT	DTT
DMEZ5P2	MA	Modulator
DMEZ5P2	RN	The novel hemoglobin-based oxygen carrier HRC 101 improves survival in murine sickle cell disease. Anesthesiology. 2007 Aug;107(2):281-7.
DMEZ5P2	RU	https://pubmed.ncbi.nlm.nih.gov/17667573

DMJACXN	DI	DMJACXN
DMJACXN	DN	HRC-102
DMJACXN	MI	TTQO71U
DMJACXN	MN	Hemoglobin (HB)
DMJACXN	MT	DTT
DMJACXN	MA	Modulator
DMJACXN	RN	WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.
DMJACXN	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20131212&CC=WO&NR=2013185032A1&KC=A1

DM5A3GX	DI	DM5A3GX
DM5A3GX	DN	HRC-201
DM5A3GX	MI	TTQO71U
DM5A3GX	MN	Hemoglobin (HB)
DM5A3GX	MT	DTT
DM5A3GX	MA	Enhancer
DM5A3GX	RN	WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.
DM5A3GX	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20131212&CC=WO&NR=2013185032A1&KC=A1

DMQINWF	DI	DMQINWF
DMQINWF	DN	HT-90B
DMQINWF	MI	TTSQIFT
DMQINWF	MN	5-HT 1A receptor (HTR1A)
DMQINWF	MT	DTT
DMQINWF	MA	Modulator
DMQINWF	RN	Pharmacological profile of (-)HT-90B, a novel 5-HT1A receptor agonist/5-HT2 receptor antagonist. Prog Neuropsychopharmacol Biol Psychiatry. 1995 Nov;19(7):1201-16.
DMQINWF	RU	https://pubmed.ncbi.nlm.nih.gov/8787043

DMK1VHF	DI	DMK1VHF
DMK1VHF	DN	Hu Dreg 55
DMK1VHF	MI	TT2IYXF
DMK1VHF	MN	L-selectin (SELL)
DMK1VHF	MT	DTT
DMK1VHF	RN	Clinical pipeline report, company report or official report of glycomimetics.
DMK1VHF	RU	http://www.glycomimetics.com/programs-pipeline/gmi-1271/

DMTGCA6	DI	DMTGCA6
DMTGCA6	DN	HuCD40L
DMTGCA6	MI	TTN6Y9A
DMTGCA6	MN	CD40L receptor (CD40)
DMTGCA6	MT	DTT
DMTGCA6	MA	Binder
DMTGCA6	RN	Recombinant human CD40 ligand inhibits simian immunodeficiency virus replication: a role for interleukin- 16. J Med Primatol. 1999 Aug-Oct;28(4-5):190-4.
DMTGCA6	RU	https://pubmed.ncbi.nlm.nih.gov/10593485

DMA7EFM	DI	DMA7EFM
DMA7EFM	DN	Human chorionic gonadotropin
DMA7EFM	MI	TT2O4W9
DMA7EFM	MN	Luteinizing hormone receptor (LHCGR)
DMA7EFM	MT	DTT
DMA7EFM	MA	Inhibitor
DMA7EFM	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 254).
DMA7EFM	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=254

DMFVB7Z	DI	DMFVB7Z
DMFVB7Z	DN	HuMax-HepC
DMFVB7Z	MI	TTDBG95
DMFVB7Z	MN	Hepatitis C virus Envelope glycoprotein E2 (HCV NS1)
DMFVB7Z	MT	DTT
DMFVB7Z	RN	Clinical pipeline report, company report or official report of Genmab.
DMFVB7Z	RU	http://www.genmab.com/docs/products/humax-hepc-fact-sheet.pdf

DM8BSF3	DI	DM8BSF3
DM8BSF3	DN	HuMax-TAC
DM8BSF3	MI	TT10Y9E
DM8BSF3	MN	Interleukin 2 receptor alpha (IL2RA)
DM8BSF3	MT	DTT
DM8BSF3	RN	Biosynthesis, synthesis, and biological activities of pyrrolobenzodiazepines. Med Res Rev. 2012 Mar;32(2):254-93. 
DM8BSF3	RU	https://pubmed.ncbi.nlm.nih.gov/20544978

DM37KVY	DI	DM37KVY
DM37KVY	DN	HY-12638
DM37KVY	MI	DEMQRS9
DM37KVY	MN	Cytochrome P450 BM3 (cypBM3)
DM37KVY	MT	DME
DM37KVY	MA	Metabolism
DM37KVY	RN	PEGylation of cytochrome P450 enhances its biocatalytic performance for pesticide transformation. Int J Biol Macromol. 2017 Dec;105(Pt 1):163-170.
DM37KVY	RU	https://pubmed.ncbi.nlm.nih.gov/28690168

DM4HA9C	DI	DM4HA9C
DM4HA9C	DN	HydrocoDex
DM4HA9C	MI	TT5TPI6
DM4HA9C	MN	Opioid receptor sigma 1 (OPRS1)
DM4HA9C	MT	DTT
DM4HA9C	MA	Modulator
DM4HA9C	RN	Antitussives and substance abuse. Subst Abuse Rehabil. 2013 Nov 6;4:75-82.
DM4HA9C	RU	https://pubmed.ncbi.nlm.nih.gov/24648790

DM4HA9C	DI	DM4HA9C
DM4HA9C	DN	HydrocoDex
DM4HA9C	MI	TT3ROYC
DM4HA9C	MN	Serotonin transporter (SERT)
DM4HA9C	MT	DTT
DM4HA9C	MA	Modulator
DM4HA9C	RN	Antitussives and substance abuse. Subst Abuse Rehabil. 2013 Nov 6;4:75-82.
DM4HA9C	RU	https://pubmed.ncbi.nlm.nih.gov/24648790

DM1C4IG	DI	DM1C4IG
DM1C4IG	DN	ICA-1
DM1C4IG	MI	TTWJTHX
DM1C4IG	MN	Protein kinase C iota (PRKCI)
DM1C4IG	MT	DTT
DM1C4IG	MA	Inhibitor
DM1C4IG	RN	A novel PKC- inhibitor abrogates cell proliferation and induces apoptosis in neuroblastoma. Int J Biochem Cell Biol. 2011 May;43(5):784-94.
DM1C4IG	RU	https://pubmed.ncbi.nlm.nih.gov/21315177

DMYN3WG	DI	DMYN3WG
DMYN3WG	DN	ICI-164384
DMYN3WG	MI	TTZAYWL
DMYN3WG	MN	Estrogen receptor (ESR)
DMYN3WG	MT	DTT
DMYN3WG	MA	Inhibitor
DMYN3WG	RN	Synthesis and biological activity of new halo-steroidal antiestrogens. J Med Chem. 1991 May;34(5):1624-30.
DMYN3WG	RU	https://pubmed.ncbi.nlm.nih.gov/2033587

DMYN3WG	DI	DMYN3WG
DMYN3WG	DN	ICI-164384
DMYN3WG	MI	TTOM3J0
DMYN3WG	MN	Estrogen receptor beta (ESR2)
DMYN3WG	MT	DTT
DMYN3WG	MA	Inhibitor
DMYN3WG	RN	Synthesis and biological activity of new halo-steroidal antiestrogens. J Med Chem. 1991 May;34(5):1624-30.
DMYN3WG	RU	https://pubmed.ncbi.nlm.nih.gov/2033587

DMQ0IOF	DI	DMQ0IOF
DMQ0IOF	DN	ICI-169369
DMQ0IOF	MI	TTJQOD7
DMQ0IOF	MN	5-HT 2A receptor (HTR2A)
DMQ0IOF	MT	DTT
DMQ0IOF	MA	Modulator
DMQ0IOF	RN	Serotonin 5-HT(2A) receptor antagonists in the treatment of insomnia: present status and future prospects.Drugs Today (Barc).2010 Mar;46(3):183-93.
DMQ0IOF	RU	https://www.ncbi.nlm.nih.gov/pubmed/20467592

DMQ0IOF	DI	DMQ0IOF
DMQ0IOF	DN	ICI-169369
DMQ0IOF	MI	TTWJBZ5
DMQ0IOF	MN	5-HT 2C receptor (HTR2C)
DMQ0IOF	MT	DTT
DMQ0IOF	MA	Modulator
DMQ0IOF	RN	Serotonin 5-HT(2A) receptor antagonists in the treatment of insomnia: present status and future prospects.Drugs Today (Barc).2010 Mar;46(3):183-93.
DMQ0IOF	RU	https://www.ncbi.nlm.nih.gov/pubmed/20467592

DM0XU4P	DI	DM0XU4P
DM0XU4P	DN	ICI-181037
DM0XU4P	MI	TT1VOHK
DM0XU4P	MN	Potassium channel unspecific (KC)
DM0XU4P	MT	DTT
DM0XU4P	MA	Opener
DM0XU4P	RN	ICI 181,037: a novel eukalemic diuretic with antiarrhythmic activity. Jpn J Pharmacol. 1991 Nov;57(3):263-77.
DM0XU4P	RU	https://pubmed.ncbi.nlm.nih.gov/1813657

DM0195G	DI	DM0195G
DM0195G	DN	ICI-198615
DM0195G	MI	TTGKOY9
DM0195G	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DM0195G	MT	DTT
DM0195G	MA	Antagonist
DM0195G	RN	Heterogeneity of binding sites for ICI 198,615 in human lung parenchyma. Biochem Pharmacol. 1992 Oct 6;44(7):1411-5.
DM0195G	RU	https://pubmed.ncbi.nlm.nih.gov/1329767

DM0195G	DI	DM0195G
DM0195G	DN	ICI-198615
DM0195G	MI	TT0PZR5
DM0195G	MN	Leukotriene CysLT2 receptor (CYSLTR2)
DM0195G	MT	DTT
DM0195G	MA	Antagonist
DM0195G	RN	Heterogeneity of binding sites for ICI 198,615 in human lung parenchyma. Biochem Pharmacol. 1992 Oct 6;44(7):1411-5.
DM0195G	RU	https://pubmed.ncbi.nlm.nih.gov/1329767

DM0195G	DI	DM0195G
DM0195G	DN	ICI-198615
DM0195G	MI	TTTWGIX
DM0195G	MN	Leukotriene receptor (LTR)
DM0195G	MT	DTT
DM0195G	MA	Modulator
DM0195G	RN	In vitro pharmacology of ICI 198,615: a novel, potent and selective peptide leukotriene antagonist. J Pharmacol Exp Ther. 1987 Nov;243(2):548-56.
DM0195G	RU	https://pubmed.ncbi.nlm.nih.gov/2824751

DMDBICR	DI	DMDBICR
DMDBICR	DN	ICM-3
DMDBICR	MI	TTD26RC
DMDBICR	MN	Cell adhesion molecule (CADM)
DMDBICR	MT	DTT
DMDBICR	RN	Anti-tumor activity of an ICAM-3 antibody (ICM3) Against human leukemic xenograft tumors in nude mice. Volume 28, Issue 7, Supplement 1, 1 July 2000, Pages 59-60.
DMDBICR	RU	http://www.sciencedirect.com/science/article/pii/S0301472X00002745

DMG1FQW	DI	DMG1FQW
DMG1FQW	DN	IDRA-21
DMG1FQW	MI	TTAN6JD
DMG1FQW	MN	Glutamate receptor AMPA (GRIA)
DMG1FQW	MT	DTT
DMG1FQW	MA	Modulator
DMG1FQW	RN	IDRA-21, a positive AMPA receptor modulator, inhibits synaptic and extrasynaptic NMDA receptor mediated events in cultured cerebellar granule cells. Neuropharmacology. 2004 Jun;46(8):1105-13.
DMG1FQW	RU	https://pubmed.ncbi.nlm.nih.gov/15111017

DMG1FQW	DI	DMG1FQW
DMG1FQW	DN	IDRA-21
DMG1FQW	MI	TT9IK2Z
DMG1FQW	MN	N-methyl-D-aspartate receptor (NMDAR)
DMG1FQW	MT	DTT
DMG1FQW	MA	Modulator
DMG1FQW	RN	IDRA-21, a positive AMPA receptor modulator, inhibits synaptic and extrasynaptic NMDA receptor mediated events in cultured cerebellar granule cells. Neuropharmacology. 2004 Jun;46(8):1105-13.
DMG1FQW	RU	https://pubmed.ncbi.nlm.nih.gov/15111017

DM16S98	DI	DM16S98
DM16S98	DN	IGE-026
DM16S98	MI	TTYJQTF
DM16S98	MN	Immunoglobulin E (IgE)
DM16S98	MT	DTT
DM16S98	MA	Inhibitor
DM16S98	RN	IgE inhibition as a therapy for allergic disease. Int Arch Allergy Immunol. 1999 Feb-Apr;118(2-4):112-5.
DM16S98	RU	https://pubmed.ncbi.nlm.nih.gov/10224354

DMBKZ4R	DI	DMBKZ4R
DMBKZ4R	DN	IGN-311
DMBKZ4R	MI	TTV75BJ
DMBKZ4R	MN	Carbohydrate antigen Lewis-Y (Lewis-Y)
DMBKZ4R	MT	DTT
DMBKZ4R	RN	IGN-311. Igeneon. Curr Opin Investig Drugs. 2005 Dec;6(12):1272-9.
DMBKZ4R	RU	https://pubmed.ncbi.nlm.nih.gov/16370394

DMKS4Z9	DI	DMKS4Z9
DMKS4Z9	DN	IL1aQb
DMKS4Z9	MI	TTPM6HI
DMKS4Z9	MN	Interleukin-1 alpha (IL1A)
DMKS4Z9	MT	DTT
DMKS4Z9	RN	Cytos Biotechnology AG - Product Pipeline Review - 2013. Global Markets Direct. Dec 2013.
DMKS4Z9	RU	http://www.researchmoz.us/cytos-biotechnology-ag-product-pipeline-review-2013-report.html

DMWTFO3	DI	DMWTFO3
DMWTFO3	DN	IMAZODAN
DMWTFO3	MI	TTJGW1Z
DMWTFO3	MN	Phosphodiesterase 2A (PDE2A)
DMWTFO3	MT	DTT
DMWTFO3	MA	Inhibitor
DMWTFO3	RN	Cardiotonic agents. 1. 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3 (2H)-pyridazinones: novel positive inotropic agents for the treatment of conges... J Med Chem. 1984 Sep;27(9):1099-101.
DMWTFO3	RU	https://pubmed.ncbi.nlm.nih.gov/6471063

DMWTFO3	DI	DMWTFO3
DMWTFO3	DN	IMAZODAN
DMWTFO3	MI	TT06AWU
DMWTFO3	MN	Phosphodiesterase 3A (PDE3A)
DMWTFO3	MT	DTT
DMWTFO3	MA	Inhibitor
DMWTFO3	RN	3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase. J Med Chem. 1992 Feb 21;35(4):620-8.
DMWTFO3	RU	https://pubmed.ncbi.nlm.nih.gov/1311763

DMWTFO3	DI	DMWTFO3
DMWTFO3	DN	IMAZODAN
DMWTFO3	MI	TTJ0IQB
DMWTFO3	MN	Phosphodiesterase 5A (PDE5A)
DMWTFO3	MT	DTT
DMWTFO3	MA	Inhibitor
DMWTFO3	RN	Cardiotonic agents. 1. 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3 (2H)-pyridazinones: novel positive inotropic agents for the treatment of conges... J Med Chem. 1984 Sep;27(9):1099-101.
DMWTFO3	RU	https://pubmed.ncbi.nlm.nih.gov/6471063

DMW39DV	DI	DMW39DV
DMW39DV	DN	INCB3344
DMW39DV	MI	TTFZYTO
DMW39DV	MN	C-C chemokine receptor type 2 (CCR2)
DMW39DV	MT	DTT
DMW39DV	MA	Antagonist
DMW39DV	RN	Discovery of ((1S,3R)-1-isopropyl-3-((3S,4S)-3-methoxy-tetrahydro-2H-pyran-4-ylamino)cyclopentyl)(4-(5-(trifluoromethyl)pyridazin-3-yl)piperazin-1-yl)methanone, PF-4254196, a CCR2 antagonist with an improved cardiovascular profile. Bioorg Med Chem Lett. 2011 May 1;21(9):2626-30.
DMW39DV	RU	https://pubmed.ncbi.nlm.nih.gov/21315584

DMODQW0	DI	DMODQW0
DMODQW0	DN	INXC-ICAM1
DMODQW0	MI	TTA1L39
DMODQW0	MN	ICAM1 messenger RNA (ICAM1 mRNA)
DMODQW0	MT	DTT
DMODQW0	RN	ISIS 2302. INXC ICAM1, Oligo-TCS. Drugs R D. 1999 Jan;1(1):85-6.
DMODQW0	RU	https://pubmed.ncbi.nlm.nih.gov/10565996

DMY3BMC	DI	DMY3BMC
DMY3BMC	DN	IPH-3102
DMY3BMC	MI	TTD24Y0
DMY3BMC	MN	Toll-like receptor 3 (TLR3)
DMY3BMC	MT	DTT
DMY3BMC	MA	Agonist
DMY3BMC	RN	Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012 August 1; 1(5): 699-716.
DMY3BMC	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3429574/

DM7J8IO	DI	DM7J8IO
DM7J8IO	DN	IPH-3201
DM7J8IO	MI	TTRJ1K4
DM7J8IO	MN	Toll-like receptor 7 (TLR7)
DM7J8IO	MT	DTT
DM7J8IO	MA	Modulator
DM7J8IO	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1757).
DM7J8IO	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1757

DMRVZMX	DI	DMRVZMX
DMRVZMX	DN	IPH-4201
DMRVZMX	MI	TTBFHXC
DMRVZMX	MN	Feto-acinar pancreatic protein (FAPP)
DMRVZMX	MT	DTT
DMRVZMX	RN	Clinical pipeline report, company report or official report of Gimv.
DMRVZMX	RU	http://www.gimv.com/nl/media-en-nieuws/persberichten/innate-pharma-announces-the-entry-into-pre-clinical-validation-of-iph-4201-a-new-monoclonal-antibody-targeting-pancreatic-cancer-745404

DMEJU1L	DI	DMEJU1L
DMEJU1L	DN	Ipsapirone
DMEJU1L	MI	TTSQIFT
DMEJU1L	MN	5-HT 1A receptor (HTR1A)
DMEJU1L	MT	DTT
DMEJU1L	MA	Agonist
DMEJU1L	RN	Chronic voluntary ethanol intake hypersensitizes 5-HT(1A) autoreceptors in C57BL/6J mice. J Neurochem. 2008 Dec;107(6):1660-70.
DMEJU1L	RU	https://pubmed.ncbi.nlm.nih.gov/19094059

DMYCPFU	DI	DMYCPFU
DMYCPFU	DN	IQM-95333
DMYCPFU	MI	TTCG0AL
DMYCPFU	MN	Cholecystokinin receptor type A (CCKAR)
DMYCPFU	MT	DTT
DMYCPFU	MA	Inhibitor
DMYCPFU	RN	Synthesis and stereochemical structure-activity relationships of 1,3-dioxoperhydropyrido[1,2-c]pyrimidine derivatives: potent and selective cholecy... J Med Chem. 1997 Oct 10;40(21):3402-7.
DMYCPFU	RU	https://pubmed.ncbi.nlm.nih.gov/9341915

DMYCPFU	DI	DMYCPFU
DMYCPFU	DN	IQM-95333
DMYCPFU	MI	TTVFO0U
DMYCPFU	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMYCPFU	MT	DTT
DMYCPFU	MA	Inhibitor
DMYCPFU	RN	Synthesis and stereochemical structure-activity relationships of 1,3-dioxoperhydropyrido[1,2-c]pyrimidine derivatives: potent and selective cholecy... J Med Chem. 1997 Oct 10;40(21):3402-7.
DMYCPFU	RU	https://pubmed.ncbi.nlm.nih.gov/9341915

DMJ3ZUN	DI	DMJ3ZUN
DMJ3ZUN	DN	Irindalone
DMJ3ZUN	MI	TT3ROYC
DMJ3ZUN	MN	Serotonin transporter (SERT)
DMJ3ZUN	MT	DTT
DMJ3ZUN	MA	Inhibitor
DMJ3ZUN	RN	Antihypertensive activity in a series of 1-piperazino-3-phenylindans with potent 5-HT2-antagonistic activity. J Med Chem. 1988 Dec;31(12):2247-56.
DMJ3ZUN	RU	https://pubmed.ncbi.nlm.nih.gov/2903929

DMH6K7N	DI	DMH6K7N
DMH6K7N	DN	IRL-2500
DMH6K7N	MI	TT3ZTGU
DMH6K7N	MN	Endothelin B receptor (EDNRB)
DMH6K7N	MT	DTT
DMH6K7N	MA	Inhibitor
DMH6K7N	RN	IRL 2500: A potent ETB selective endothelin antagonist, Bioorg. Med. Chem. Lett. 6(19):2323-2328 (1996).
DMH6K7N	RU	http://www.sciencedirect.com/science/article/pii/0960894X96004210

DMD6SXO	DI	DMD6SXO
DMD6SXO	DN	ISIS-1082
DMD6SXO	MI	TT84ETX
DMD6SXO	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMD6SXO	MT	DTT
DMD6SXO	MA	Modulator
DMD6SXO	RN	Comparison of the toxicity profiles of ISIS 1082 and ISIS 2105, phosphorothioate oligonucleotides, following subacute intradermal administration in Sprague-Dawley rats. Toxicology. 1997 Jan 15;116(1-3):77-88.
DMD6SXO	RU	https://pubmed.ncbi.nlm.nih.gov/9020509

DM4YJ2W	DI	DM4YJ2W
DM4YJ2W	DN	Isomazole
DM4YJ2W	MI	TTUST1O
DM4YJ2W	MN	Phosphodiesterase (PDE)
DM4YJ2W	MT	DTT
DM4YJ2W	MA	Inhibitor
DM4YJ2W	RN	Effects of isomazole on force of contraction and phosphodiesterase isoenzymes I-IV in nonfailing and failing human hearts. J Cardiovasc Pharmacol. 1991 Sep;18(3):386-97.
DM4YJ2W	RU	https://pubmed.ncbi.nlm.nih.gov/1720839

DMU5TGC	DI	DMU5TGC
DMU5TGC	DN	JSM-10292
DMU5TGC	MI	TTGY8IW
DMU5TGC	MN	B2 bradykinin receptor (BDKRB2)
DMU5TGC	MT	DTT
DMU5TGC	MA	Antagonist
DMU5TGC	RN	Binding characteristics of [3H]-JSM10292: a new cell membrane-permeant non-peptide bradykinin B2 receptor antagonist. Br J Pharmacol. 2012 Oct;167(4):839-53.
DMU5TGC	RU	https://pubmed.ncbi.nlm.nih.gov/22646218

DMG7B61	DI	DMG7B61
DMG7B61	DN	JTP-2724
DMG7B61	MI	TTB2MXP
DMG7B61	MN	Angiotensinogenase renin (REN)
DMG7B61	MT	DTT
DMG7B61	MA	Inhibitor
DMG7B61	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010026)
DMG7B61	RU	http://adisinsight.springer.com/drugs/800010026

DM6TXKR	DI	DM6TXKR
DM6TXKR	DN	JTP-4761
DM6TXKR	MI	TTB2MXP
DM6TXKR	MN	Angiotensinogenase renin (REN)
DM6TXKR	MT	DTT
DM6TXKR	MA	Inhibitor
DM6TXKR	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005981)
DM6TXKR	RU	http://adisinsight.springer.com/drugs/800005981

DM48HVI	DI	DM48HVI
DM48HVI	DN	JTT-551
DM48HVI	MI	TTMS7KP
DM48HVI	MN	Protein-tyrosine phosphatase 1B (PTP1B)
DM48HVI	MT	DTT
DM48HVI	MA	Inhibitor
DM48HVI	RN	Pharmacological effects of JTT-551, a novel protein tyrosine phosphatase 1B inhibitor, in diet-induced obesity mice. J Diabetes Res. 2014;2014:680348.
DM48HVI	RU	https://pubmed.ncbi.nlm.nih.gov/24987707

DMZBNHC	DI	DMZBNHC
DMZBNHC	DN	JTT-608
DMZBNHC	MI	TTUST1O
DMZBNHC	MN	Phosphodiesterase (PDE)
DMZBNHC	MT	DTT
DMZBNHC	MA	Inhibitor
DMZBNHC	RN	JTT-608 controls blood glucose by enhancement of glucose-stimulated insulin secretion in normal and diabetes mellitus rats. Eur J Pharmacol. 1999 Feb 12;367(1):91-9.
DMZBNHC	RU	https://pubmed.ncbi.nlm.nih.gov/10082270

DM89TXB	DI	DM89TXB
DM89TXB	DN	JTV-605
DM89TXB	MI	TT4TFGN
DM89TXB	MN	Vasopressin V1a receptor (V1AR)
DM89TXB	MT	DTT
DM89TXB	MA	Antagonist
DM89TXB	RN	Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res. 2002;139:197-210.
DM89TXB	RU	https://pubmed.ncbi.nlm.nih.gov/12436936

DM89TXB	DI	DM89TXB
DM89TXB	DN	JTV-605
DM89TXB	MI	TTK8R02
DM89TXB	MN	Vasopressin V2 receptor (V2R)
DM89TXB	MT	DTT
DM89TXB	MA	Antagonist
DM89TXB	RN	Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res. 2002;139:197-210.
DM89TXB	RU	https://pubmed.ncbi.nlm.nih.gov/12436936

DM0MXWC	DI	DM0MXWC
DM0MXWC	DN	KA-398
DM0MXWC	MI	TTTIBOJ
DM0MXWC	MN	Histamine H1 receptor (H1R)
DM0MXWC	MT	DTT
DM0MXWC	MA	Modulator
DM0MXWC	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 262).
DM0MXWC	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=262

DM2LFYD	DI	DM2LFYD
DM2LFYD	DN	KB-5246
DM2LFYD	MI	TTN6J5F
DM2LFYD	MN	Bacterial DNA gyrase (Bact gyrase)
DM2LFYD	MT	DTT
DM2LFYD	MA	Modulator
DM2LFYD	RN	Activity of KB-5246 against outer membrane mutants of Escherichia coli and Salmonella typhimurium.. Antimicrob Agents Chemother. 1990 July; 34(7): 1323-1325.
DM2LFYD	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC175974/

DMM7S3V	DI	DMM7S3V
DMM7S3V	DN	KB-5359
DMM7S3V	MI	TTQWUPT
DMM7S3V	MN	Thyroid hormone receptor (THR)
DMM7S3V	MT	DTT
DMM7S3V	MA	Modulator
DMM7S3V	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMM7S3V	RU	https://www.fda.gov/

DM3H90W	DI	DM3H90W
DM3H90W	DN	KC-11404
DM3H90W	MI	TT2J34L
DM3H90W	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM3H90W	MT	DTT
DM3H90W	MA	Modulator
DM3H90W	RN	Synthesis, structure-activity relationships, and pharmacological evaluation of pyrrolo[3,2,1-ij]quinoline derivatives: potent histamine and platelet activating factor antagonism and 5-lipoxygenase inhibitory properties. Potential therapeutic application in asthma. J Med Chem. 1995 Feb 17;38(4):669-85.
DM3H90W	RU	https://pubmed.ncbi.nlm.nih.gov/7861415

DM3H90W	DI	DM3H90W
DM3H90W	DN	KC-11404
DM3H90W	MI	TTQL5VC
DM3H90W	MN	Platelet-activating factor receptor (PTAFR)
DM3H90W	MT	DTT
DM3H90W	MA	Modulator
DM3H90W	RN	Synthesis, structure-activity relationships, and pharmacological evaluation of pyrrolo[3,2,1-ij]quinoline derivatives: potent histamine and platelet activating factor antagonism and 5-lipoxygenase inhibitory properties. Potential therapeutic application in asthma. J Med Chem. 1995 Feb 17;38(4):669-85.
DM3H90W	RU	https://pubmed.ncbi.nlm.nih.gov/7861415

DMC295V	DI	DMC295V
DMC295V	DN	KC-11425
DMC295V	MI	TT2J34L
DMC295V	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMC295V	MT	DTT
DMC295V	MA	Antagonist
DMC295V	RN	WO patent application no. 2002,01223,5, 1,4-dihydropyridines as bradykinin antagonists.
DMC295V	RU	https://www.google.com/patents/WO2002012235A1?cl=en&hl=zh-CN

DMC295V	DI	DMC295V
DMC295V	DN	KC-11425
DMC295V	MI	TTQL5VC
DMC295V	MN	Platelet-activating factor receptor (PTAFR)
DMC295V	MT	DTT
DMC295V	MA	Antagonist
DMC295V	RN	WO patent application no. 2002,01223,5, 1,4-dihydropyridines as bradykinin antagonists.
DMC295V	RU	https://www.google.com/patents/WO2002012235A1?cl=en&hl=zh-CN

DMD0FNH	DI	DMD0FNH
DMD0FNH	DN	KC-399
DMD0FNH	MI	TT1VOHK
DMD0FNH	MN	Potassium channel unspecific (KC)
DMD0FNH	MT	DTT
DMD0FNH	MA	Opener
DMD0FNH	RN	Action of KC-399, a newly synthesized potassium channel opener, on mechanical activity and 86Rb efflux in rat aorta. J Cardiovasc Pharmacol. 1994 Feb;23(2):220-6.
DMD0FNH	RU	https://pubmed.ncbi.nlm.nih.gov/7511750

DMNZ1LR	DI	DMNZ1LR
DMNZ1LR	DN	KF-15766
DMNZ1LR	MI	TT7CXIM
DMNZ1LR	MN	Histamine receptor (HR)
DMNZ1LR	MT	DTT
DMNZ1LR	MA	Modulator
DMNZ1LR	RN	Mutational analysis of the antagonist-binding site of the histamine H(1) receptor. J Biol Chem. 1999 Oct 15;274(42):29994-30000.
DMNZ1LR	RU	https://pubmed.ncbi.nlm.nih.gov/10514483

DMQXPJB	DI	DMQXPJB
DMQXPJB	DN	Ki-1769
DMQXPJB	MI	TT1VOHK
DMQXPJB	MN	Potassium channel unspecific (KC)
DMQXPJB	MT	DTT
DMQXPJB	MA	Opener
DMQXPJB	RN	Vasorelaxant action of Ki1769, a new pyridinecarboximidamide, in isolated porcine coronary artery. Eur J Pharmacol. 1993 Sep 14;241(2-3):177-81.
DMQXPJB	RU	https://pubmed.ncbi.nlm.nih.gov/8243553

DMXZNB2	DI	DMXZNB2
DMXZNB2	DN	KNI-102
DMXZNB2	MI	TT5FNQT
DMXZNB2	MN	Human immunodeficiency virus Protease (HIV PR)
DMXZNB2	MT	DTT
DMXZNB2	MA	Modulator
DMXZNB2	RN	KNI-102, a novel tripeptide HIV protease inhibitor containing allophenylnorstatine as a transition-state mimic. Chem Pharm Bull (Tokyo). 1991 Nov;39(11):3088-90.
DMXZNB2	RU	https://pubmed.ncbi.nlm.nih.gov/1799953

DMXT2SL	DI	DMXT2SL
DMXT2SL	DN	KRG-3332
DMXT2SL	MI	TTNGILX
DMXT2SL	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMXT2SL	MT	DTT
DMXT2SL	MA	Antagonist
DMXT2SL	RN	The beta-adrenoceptor. Am J Respir Crit Care Med. 1998 Nov;158(5 Pt 3):S146-53.
DMXT2SL	RU	https://pubmed.ncbi.nlm.nih.gov/9817738

DM2L0VF	DI	DM2L0VF
DM2L0VF	DN	KRH-2731
DM2L0VF	MI	TTBID49
DM2L0VF	MN	C-X-C chemokine receptor type 4 (CXCR4)
DM2L0VF	MT	DTT
DM2L0VF	MA	Binder
DM2L0VF	RN	Progress in targeting HIV-1 entry. Drug Discov Today. 2005 Aug 15;10(16):1085-94.
DM2L0VF	RU	https://pubmed.ncbi.nlm.nih.gov/16182193

DM4QHNG	DI	DM4QHNG
DM4QHNG	DN	KRI-1314
DM4QHNG	MI	TTB2MXP
DM4QHNG	MN	Angiotensinogenase renin (REN)
DM4QHNG	MT	DTT
DM4QHNG	MA	Inhibitor
DM4QHNG	RN	KRI-1314: an orally effective inhibitor of human renin. Jpn J Pharmacol. 1993 Sep;63(1):109-19.
DM4QHNG	RU	https://pubmed.ncbi.nlm.nih.gov/8271523

DMVZSAM	DI	DMVZSAM
DMVZSAM	DN	KRP-105
DMVZSAM	MI	TTJ584C
DMVZSAM	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMVZSAM	MT	DTT
DMVZSAM	MA	Agonist
DMVZSAM	RN	Discovery of cyclic amine-substituted benzoic acids as PPARalpha agonists. Bioorg Med Chem Lett. 2012 Jan 1;22(1):334-8.
DMVZSAM	RU	https://pubmed.ncbi.nlm.nih.gov/22133631

DM8VMJ3	DI	DM8VMJ3
DM8VMJ3	DN	KT-95
DM8VMJ3	MI	TTQW87Y
DM8VMJ3	MN	Opioid receptor kappa (OPRK1)
DM8VMJ3	MT	DTT
DM8VMJ3	MA	Modulator
DM8VMJ3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 318).
DM8VMJ3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=318

DMS2KEG	DI	DMS2KEG
DMS2KEG	DN	KW-3433
DMS2KEG	MI	TTGN1ZA
DMS2KEG	MN	Angiotensin II receptor (AGTR)
DMS2KEG	MT	DTT
DMS2KEG	MA	Modulator
DMS2KEG	RN	Effects of various antihypertensive drugs on the function of osteoblast. Biol Pharm Bull. 2001 Jun;24(6):628-33.
DMS2KEG	RU	https://pubmed.ncbi.nlm.nih.gov/11411549

DMQ4LDB	DI	DMQ4LDB
DMQ4LDB	DN	L-158809
DMQ4LDB	MI	TT8DBY3
DMQ4LDB	MN	Angiotensin II receptor type-1 (AGTR1)
DMQ4LDB	MT	DTT
DMQ4LDB	MA	Antagonist
DMQ4LDB	RN	Characterization of the binding of [3H]L-158,809: a new potent and selective nonpeptide angiotensin II receptor (AT1) antagonist radioligand. Mol Pharmacol. 1992 Dec;42(6):1077-82.
DMQ4LDB	RU	https://pubmed.ncbi.nlm.nih.gov/1480133

DMQ4LDB	DI	DMQ4LDB
DMQ4LDB	DN	L-158809
DMQ4LDB	MI	TTQVOEI
DMQ4LDB	MN	Angiotensin II receptor type-2 (AGTR2)
DMQ4LDB	MT	DTT
DMQ4LDB	MA	Inhibitor
DMQ4LDB	RN	Subtituted phenylthiophene benzoylsulfonamides with potent binding affinity to angiotensin II AT1 and AT2 receptors, Bioorg. Med. Chem. Lett. 4(1):189-194 (1994).
DMQ4LDB	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01811458

DM9JE7Y	DI	DM9JE7Y
DM9JE7Y	DN	L-159689
DM9JE7Y	MI	TT8DBY3
DM9JE7Y	MN	Angiotensin II receptor type-1 (AGTR1)
DM9JE7Y	MT	DTT
DM9JE7Y	MA	Inhibitor
DM9JE7Y	RN	Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.
DM9JE7Y	RU	https://pubmed.ncbi.nlm.nih.gov/16220969

DM9JE7Y	DI	DM9JE7Y
DM9JE7Y	DN	L-159689
DM9JE7Y	MI	TTQVOEI
DM9JE7Y	MN	Angiotensin II receptor type-2 (AGTR2)
DM9JE7Y	MT	DTT
DM9JE7Y	MA	Inhibitor
DM9JE7Y	RN	The design, binding affinity prediction and synthesis of macrocyclic angiotensin II AT1 and AT2 receptor antagonists, Bioorg. Med. Chem. Lett. 6(8):923-928 (1996).
DM9JE7Y	RU	http://www.sciencedirect.com/science/article/pii/0960894X96001163

DMYSEBK	DI	DMYSEBK
DMYSEBK	DN	L-162234
DMYSEBK	MI	TTQVOEI
DMYSEBK	MN	Angiotensin II receptor type-2 (AGTR2)
DMYSEBK	MT	DTT
DMYSEBK	MA	Inhibitor
DMYSEBK	RN	Quantized surface complementarity diversity (QSCD): a model based on small molecule-target complementarity. J Med Chem. 2000 May 18;43(10):1993-2006.
DMYSEBK	RU	https://pubmed.ncbi.nlm.nih.gov/10821712

DMYB5RV	DI	DMYB5RV
DMYB5RV	DN	L-163017
DMYB5RV	MI	TTGN1ZA
DMYB5RV	MN	Angiotensin II receptor (AGTR)
DMYB5RV	MT	DTT
DMYB5RV	MA	Modulator
DMYB5RV	RN	In vivo pharmacology of an angiotensin AT1 receptor antagonist with balanced affinity for AT2 receptors. Eur J Pharmacol. 1995 Dec 29;294(2-3):439-50.
DMYB5RV	RU	https://pubmed.ncbi.nlm.nih.gov/8750704

DMCRQTH	DI	DMCRQTH
DMCRQTH	DN	L-371257
DMCRQTH	MI	TTSCIUP
DMCRQTH	MN	Oxytocin receptor (OTR)
DMCRQTH	MT	DTT
DMCRQTH	MA	Inhibitor
DMCRQTH	RN	Oral oxytocin antagonists. J Med Chem. 2010 Sep 23;53(18):6525-38.
DMCRQTH	RU	https://pubmed.ncbi.nlm.nih.gov/20550119

DMCRQTH	DI	DMCRQTH
DMCRQTH	DN	L-371257
DMCRQTH	MI	TT4TFGN
DMCRQTH	MN	Vasopressin V1a receptor (V1AR)
DMCRQTH	MT	DTT
DMCRQTH	MA	Inhibitor
DMCRQTH	RN	Oral oxytocin antagonists. J Med Chem. 2010 Sep 23;53(18):6525-38.
DMCRQTH	RU	https://pubmed.ncbi.nlm.nih.gov/20550119

DMOKZ2V	DI	DMOKZ2V
DMOKZ2V	DN	L-373890
DMOKZ2V	MI	TT6L509
DMOKZ2V	MN	Coagulation factor IIa (F2)
DMOKZ2V	MT	DTT
DMOKZ2V	MA	Inhibitor
DMOKZ2V	RN	L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitor. Bioorg Med Chem Lett. 1998 Apr 7;8(7):817-22.
DMOKZ2V	RU	https://pubmed.ncbi.nlm.nih.gov/9871547

DMK2QW0	DI	DMK2QW0
DMK2QW0	DN	L-374,087
DMK2QW0	MI	TT6L509
DMK2QW0	MN	Coagulation factor IIa (F2)
DMK2QW0	MT	DTT
DMK2QW0	MA	Inhibitor
DMK2QW0	RN	Pharmacological intervention at disparate sites in the coagulation cascade: comparison of anti-thrombotic efficacy vs bleeding propensity in a rat model of acute arterial thrombosis. J Thromb Thrombolysis. 2002 Oct;14(2):113-21.
DMK2QW0	RU	https://pubmed.ncbi.nlm.nih.gov/12714830

DMTKCNJ	DI	DMTKCNJ
DMTKCNJ	DN	L-648051
DMTKCNJ	MI	TTGKOY9
DMTKCNJ	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DMTKCNJ	MT	DTT
DMTKCNJ	MA	Modulator
DMTKCNJ	RN	Effects of a leukotriene D4 receptor antagonist, L-648,051, and a dual inhibitor lypoxygenase and cyclooxygenase, BW-755C, on digoxin-induced arrhy... Arch Int Pharmacodyn Ther. 1993 Jan-Feb;321:72-80.
DMTKCNJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/8391788

DMGX3MK	DI	DMGX3MK
DMGX3MK	DN	L-655240
DMGX3MK	MI	TTYLQ8V
DMGX3MK	MN	Prostaglandin E synthase (PTGES)
DMGX3MK	MT	DTT
DMGX3MK	MA	Inhibitor
DMGX3MK	RN	Inhibitors of the inducible microsomal prostaglandin E2 synthase (mPGES-1) derived from MK-886. Bioorg Med Chem Lett. 2005 Jul 15;15(14):3352-5.
DMGX3MK	RU	https://pubmed.ncbi.nlm.nih.gov/15953724

DMOTY3G	DI	DMOTY3G
DMOTY3G	DN	L-657925
DMOTY3G	MI	TT2O84V
DMOTY3G	MN	Thromboxane A2 receptor (TBXA2R)
DMOTY3G	MT	DTT
DMOTY3G	MA	Inhibitor
DMOTY3G	RN	Novel synthesis and biochemical properties of an [125I]-labeled photoaffinity probe for thromboxane A2/prostaglandin H2 receptors. J Med Chem. 1991 Apr;34(4):1511-4.
DMOTY3G	RU	https://pubmed.ncbi.nlm.nih.gov/1826745

DMLENQ7	DI	DMLENQ7
DMLENQ7	DN	L-659989
DMLENQ7	MI	TTQL5VC
DMLENQ7	MN	Platelet-activating factor receptor (PTAFR)
DMLENQ7	MT	DTT
DMLENQ7	MA	Inhibitor
DMLENQ7	RN	Development, synthesis, and biological evaluation of (-)-trans-(2S,5S)-2-[3-[(2-oxopropyl)sulfonyl]-4-n-propoxy-5-(3- hydroxypropoxy)-phenyl]-5-(3,... J Med Chem. 1992 Sep 18;35(19):3474-82.
DMLENQ7	RU	https://pubmed.ncbi.nlm.nih.gov/1404229

DM56VPY	DI	DM56VPY
DM56VPY	DN	L-687414
DM56VPY	MI	TTLD29N
DM56VPY	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DM56VPY	MT	DTT
DM56VPY	MA	Inhibitor
DM56VPY	RN	Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993).
DM56VPY	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01808970

DM56VPY	DI	DM56VPY
DM56VPY	DN	L-687414
DM56VPY	MI	TTKJEMQ
DM56VPY	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DM56VPY	MT	DTT
DM56VPY	MA	Inhibitor
DM56VPY	RN	Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993).
DM56VPY	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01808970

DM56VPY	DI	DM56VPY
DM56VPY	DN	L-687414
DM56VPY	MI	TTN9D8E
DM56VPY	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DM56VPY	MT	DTT
DM56VPY	MA	Inhibitor
DM56VPY	RN	Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993).
DM56VPY	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01808970

DMCVY4U	DI	DMCVY4U
DMCVY4U	DN	L-689560
DMCVY4U	MI	TTLD29N
DMCVY4U	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMCVY4U	MT	DTT
DMCVY4U	MA	Antagonist
DMCVY4U	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455).
DMCVY4U	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=455

DMCVY4U	DI	DMCVY4U
DMCVY4U	DN	L-689560
DMCVY4U	MI	TTKJEMQ
DMCVY4U	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMCVY4U	MT	DTT
DMCVY4U	MA	Antagonist
DMCVY4U	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456).
DMCVY4U	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=456

DMCVY4U	DI	DMCVY4U
DMCVY4U	DN	L-689560
DMCVY4U	MI	TTN9D8E
DMCVY4U	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMCVY4U	MT	DTT
DMCVY4U	MA	Antagonist
DMCVY4U	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457).
DMCVY4U	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=457

DMCVY4U	DI	DMCVY4U
DMCVY4U	DN	L-689560
DMCVY4U	MI	TT1M8OW
DMCVY4U	MN	Glutamate receptor ionotropic NMDA 2C (GluN2C)
DMCVY4U	MT	DTT
DMCVY4U	MA	Antagonist
DMCVY4U	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 458).
DMCVY4U	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=458

DMCVY4U	DI	DMCVY4U
DMCVY4U	DN	L-689560
DMCVY4U	MI	TT5POTG
DMCVY4U	MN	Glutamate receptor ionotropic NMDA 2D (GluN2D)
DMCVY4U	MT	DTT
DMCVY4U	MA	Antagonist
DMCVY4U	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 459).
DMCVY4U	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=459

DMCVY4U	DI	DMCVY4U
DMCVY4U	DN	L-689560
DMCVY4U	MI	TT9IK2Z
DMCVY4U	MN	N-methyl-D-aspartate receptor (NMDAR)
DMCVY4U	MT	DTT
DMCVY4U	MA	Modulator
DMCVY4U	RN	Characterization of the binding of [3H]L-689,560, an antagonist for the glycine site on the N-methyl-D-aspartate receptor, to rat brain membranes. Mol Pharmacol. 1992 May;41(5):923-30.
DMCVY4U	RU	https://pubmed.ncbi.nlm.nih.gov/1375318

DM2F4GT	DI	DM2F4GT
DM2F4GT	DN	L-694247
DM2F4GT	MI	TT6MSOK
DM2F4GT	MN	5-HT 1D receptor (HTR1D)
DM2F4GT	MT	DTT
DM2F4GT	MA	Agonist
DM2F4GT	RN	L-694,247: a potent 5-HT1D receptor agonist. Br J Pharmacol. 1993 Nov;110(3):1196-200.
DM2F4GT	RU	https://pubmed.ncbi.nlm.nih.gov/8298808

DMT1DNS	DI	DMT1DNS
DMT1DNS	DN	L-695902
DMT1DNS	MI	TTLD29N
DMT1DNS	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMT1DNS	MT	DTT
DMT1DNS	MA	Inhibitor
DMT1DNS	RN	Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993).
DMT1DNS	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01808970

DMT1DNS	DI	DMT1DNS
DMT1DNS	DN	L-695902
DMT1DNS	MI	TTKJEMQ
DMT1DNS	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMT1DNS	MT	DTT
DMT1DNS	MA	Inhibitor
DMT1DNS	RN	Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993).
DMT1DNS	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01808970

DMT1DNS	DI	DMT1DNS
DMT1DNS	DN	L-695902
DMT1DNS	MI	TTN9D8E
DMT1DNS	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMT1DNS	MT	DTT
DMT1DNS	MA	Inhibitor
DMT1DNS	RN	Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993).
DMT1DNS	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01808970

DMV785R	DI	DMV785R
DMV785R	DN	L-696418
DMV785R	MI	TTMX39J
DMV785R	MN	Matrix metalloproteinase-1 (MMP-1)
DMV785R	MT	DTT
DMV785R	MA	Inhibitor
DMV785R	RN	Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides containing extended alkyl residues At P1', Bioorg. Med. Chem. Lett. 5(6):539-542 (1995).
DMV785R	RU	http://www.sciencedirect.com/science/article/pii/0960894X95000799

DMV785R	DI	DMV785R
DMV785R	DN	L-696418
DMV785R	MI	TTLM12X
DMV785R	MN	Matrix metalloproteinase-2 (MMP-2)
DMV785R	MT	DTT
DMV785R	MA	Inhibitor
DMV785R	RN	Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides containing extended alkyl residues At P1', Bioorg. Med. Chem. Lett. 5(6):539-542 (1995).
DMV785R	RU	http://www.sciencedirect.com/science/article/pii/0960894X95000799

DMV785R	DI	DMV785R
DMV785R	DN	L-696418
DMV785R	MI	TTUZ2L5
DMV785R	MN	Matrix metalloproteinase-3 (MMP-3)
DMV785R	MT	DTT
DMV785R	MA	Inhibitor
DMV785R	RN	Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides containing extended alkyl residues At P1', Bioorg. Med. Chem. Lett. 5(6):539-542 (1995).
DMV785R	RU	http://www.sciencedirect.com/science/article/pii/0960894X95000799

DMO9HM7	DI	DMO9HM7
DMO9HM7	DN	L-698532
DMO9HM7	MI	TTLD29N
DMO9HM7	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMO9HM7	MT	DTT
DMO9HM7	MA	Inhibitor
DMO9HM7	RN	Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor. J Med Chem. 2006 Feb 9;49(3):864-71.
DMO9HM7	RU	https://pubmed.ncbi.nlm.nih.gov/16451052

DMO9HM7	DI	DMO9HM7
DMO9HM7	DN	L-698532
DMO9HM7	MI	TTKJEMQ
DMO9HM7	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMO9HM7	MT	DTT
DMO9HM7	MA	Inhibitor
DMO9HM7	RN	Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor. J Med Chem. 2006 Feb 9;49(3):864-71.
DMO9HM7	RU	https://pubmed.ncbi.nlm.nih.gov/16451052

DMO9HM7	DI	DMO9HM7
DMO9HM7	DN	L-698532
DMO9HM7	MI	TTN9D8E
DMO9HM7	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMO9HM7	MT	DTT
DMO9HM7	MA	Inhibitor
DMO9HM7	RN	Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor. J Med Chem. 2006 Feb 9;49(3):864-71.
DMO9HM7	RU	https://pubmed.ncbi.nlm.nih.gov/16451052

DMLRBN1	DI	DMLRBN1
DMLRBN1	DN	L-698544
DMLRBN1	MI	TTAN6JD
DMLRBN1	MN	Glutamate receptor AMPA (GRIA)
DMLRBN1	MT	DTT
DMLRBN1	MA	Antagonist
DMLRBN1	RN	3-Nitro-3,4-dihydro-2(1H)-quinolones. Excitatory amino acid antagonists acting at glycine-site NMDA and (RS)-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. J Med Chem. 1993 Oct 29;36(22):3397-408.
DMLRBN1	RU	https://pubmed.ncbi.nlm.nih.gov/8230130

DMLRBN1	DI	DMLRBN1
DMLRBN1	DN	L-698544
DMLRBN1	MI	TTLD29N
DMLRBN1	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMLRBN1	MT	DTT
DMLRBN1	MA	Inhibitor
DMLRBN1	RN	Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993).
DMLRBN1	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01808970

DMLRBN1	DI	DMLRBN1
DMLRBN1	DN	L-698544
DMLRBN1	MI	TTKJEMQ
DMLRBN1	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMLRBN1	MT	DTT
DMLRBN1	MA	Inhibitor
DMLRBN1	RN	Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993).
DMLRBN1	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01808970

DMLRBN1	DI	DMLRBN1
DMLRBN1	DN	L-698544
DMLRBN1	MI	TTN9D8E
DMLRBN1	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMLRBN1	MT	DTT
DMLRBN1	MA	Inhibitor
DMLRBN1	RN	Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993).
DMLRBN1	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01808970

DMLRBN1	DI	DMLRBN1
DMLRBN1	DN	L-698544
DMLRBN1	MI	TT9IK2Z
DMLRBN1	MN	N-methyl-D-aspartate receptor (NMDAR)
DMLRBN1	MT	DTT
DMLRBN1	MA	Modulator
DMLRBN1	RN	3-Nitro-3,4-dihydro-2(1H)-quinolones. Excitatory amino acid antagonists acting at glycine-site NMDA and (RS)-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. J Med Chem. 1993 Oct 29;36(22):3397-408.
DMLRBN1	RU	https://pubmed.ncbi.nlm.nih.gov/8230130

DMAIJSX	DI	DMAIJSX
DMAIJSX	DN	L-701324
DMAIJSX	MI	TTLD29N
DMAIJSX	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMAIJSX	MT	DTT
DMAIJSX	MA	Inhibitor
DMAIJSX	RN	Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor. J Med Chem. 2006 Feb 9;49(3):864-71.
DMAIJSX	RU	https://pubmed.ncbi.nlm.nih.gov/16451052

DMAIJSX	DI	DMAIJSX
DMAIJSX	DN	L-701324
DMAIJSX	MI	TTKJEMQ
DMAIJSX	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMAIJSX	MT	DTT
DMAIJSX	MA	Inhibitor
DMAIJSX	RN	Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor. J Med Chem. 2006 Feb 9;49(3):864-71.
DMAIJSX	RU	https://pubmed.ncbi.nlm.nih.gov/16451052

DMAIJSX	DI	DMAIJSX
DMAIJSX	DN	L-701324
DMAIJSX	MI	TTN9D8E
DMAIJSX	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMAIJSX	MT	DTT
DMAIJSX	MA	Inhibitor
DMAIJSX	RN	Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor. J Med Chem. 2006 Feb 9;49(3):864-71.
DMAIJSX	RU	https://pubmed.ncbi.nlm.nih.gov/16451052

DMO7GWC	DI	DMO7GWC
DMO7GWC	DN	L-702958
DMO7GWC	MI	TTQ6VDM
DMO7GWC	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMO7GWC	MT	DTT
DMO7GWC	MA	Modulator
DMO7GWC	RN	Analogs of MK-499 are differentially affected by a mutation in the S6 domain of the hERG K+ channel.Biochem Pharmacol.2009 May 15;77(10):1602-11.
DMO7GWC	RU	https://www.ncbi.nlm.nih.gov/pubmed/19426697

DM47MKE	DI	DM47MKE
DM47MKE	DN	L-703014
DM47MKE	MI	TT38RM1
DM47MKE	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DM47MKE	MT	DTT
DM47MKE	MA	Modulator
DM47MKE	RN	Pharmacokinetics and pharmacodynamics of L-703,014, a potent fibrinogen receptor antagonist, after intravenous and oral administration in the dog. Pharm Res. 1994 Mar;11(3):426-31.
DM47MKE	RU	https://www.ncbi.nlm.nih.gov/pubmed/8008711

DMQZW6D	DI	DMQZW6D
DMQZW6D	DN	L-709049
DMQZW6D	MI	TTCQIBE
DMQZW6D	MN	Caspase-1 (CASP1)
DMQZW6D	MT	DTT
DMQZW6D	MA	Inhibitor
DMQZW6D	RN	Succinic acid amides as P2-P3 replacements for inhibitors of interleukin-1beta converting enzyme (ICE or caspase 1). Bioorg Med Chem Lett. 2010 Sep 1;20(17):5184-90.
DMQZW6D	RU	https://pubmed.ncbi.nlm.nih.gov/20656488

DMB3ZTI	DI	DMB3ZTI
DMB3ZTI	DN	L-709780
DMB3ZTI	MI	TTJA1ZO
DMB3ZTI	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMB3ZTI	MT	DTT
DMB3ZTI	MA	Inhibitor
DMB3ZTI	RN	Non-peptide fibrinogen receptor antagonists. 3. design and discovery of a centrally constrained inhibitorc, Bioorg. Med. Chem. Lett. 4(15):1835-1840 (1994).
DMB3ZTI	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01803802

DM1XBKC	DI	DM1XBKC
DM1XBKC	DN	L-731735
DM1XBKC	MI	TT7WZIJ
DM1XBKC	MN	CAAX farnesyltransferase beta (FNTB)
DM1XBKC	MT	DTT
DM1XBKC	MA	Inhibitor
DM1XBKC	RN	Ras farnesyltransferase: a new therapeutic target. J Med Chem. 1997 Sep 12;40(19):2971-90.
DM1XBKC	RU	https://pubmed.ncbi.nlm.nih.gov/9301658

DM1XBKC	DI	DM1XBKC
DM1XBKC	DN	L-731735
DM1XBKC	MI	TTXQKM3
DM1XBKC	MN	Farnesyl protein transferase (Ftase)
DM1XBKC	MT	DTT
DM1XBKC	MA	Inhibitor
DM1XBKC	RN	N-Arylalkyl pseudopeptide inhibitors of farnesyltransferase. J Med Chem. 1998 Jul 2;41(14):2651-6.
DM1XBKC	RU	https://pubmed.ncbi.nlm.nih.gov/9651171

DMVXKMF	DI	DMVXKMF
DMVXKMF	DN	L-732138
DMVXKMF	MI	TTYO0A3
DMVXKMF	MN	Substance-K receptor (TACR2)
DMVXKMF	MT	DTT
DMVXKMF	MA	Inhibitor
DMVXKMF	RN	Biological and conformational evaluation of bifunctional compounds for opioid receptor agonists and neurokinin 1 receptor antagonists possessing tw... J Med Chem. 2010 Aug 12;53(15):5491-501.
DMVXKMF	RU	https://pubmed.ncbi.nlm.nih.gov/20617791

DMVXKMF	DI	DMVXKMF
DMVXKMF	DN	L-732138
DMVXKMF	MI	TTZPO1L
DMVXKMF	MN	Substance-P receptor (TACR1)
DMVXKMF	MT	DTT
DMVXKMF	MA	Inhibitor
DMVXKMF	RN	The biological activity and metabolic stability of peptidic bifunctional compounds that are opioid receptor agonists and neurokinin-1 receptor anta... Bioorg Med Chem. 2009 Oct 15;17(20):7337-43.
DMVXKMF	RU	https://pubmed.ncbi.nlm.nih.gov/19762245

DMA1NJW	DI	DMA1NJW
DMA1NJW	DN	L-733060
DMA1NJW	MI	TTZPO1L
DMA1NJW	MN	Substance-P receptor (TACR1)
DMA1NJW	MT	DTT
DMA1NJW	MA	Inhibitor
DMA1NJW	RN	3-Benzyloxy-2-phenylpiperidine NK1 antagonists: the influence of alpha methyl substitution, Bioorg. Med. Chem. Lett. 7(23):2959-2962 (1997).
DMA1NJW	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97101184

DMYZPJU	DI	DMYZPJU
DMYZPJU	DN	L-733560
DMYZPJU	MI	TT0SFXH
DMYZPJU	MN	Fungal 1,3-beta-glucan synthase (Fung GSC2)
DMYZPJU	MT	DTT
DMYZPJU	MA	Modulator
DMYZPJU	RN	Discovery of Novel Antifungal (1,3)--d-Glucan Synthase Inhibitors
DMYZPJU	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC89685

DMO69X8	DI	DMO69X8
DMO69X8	DN	L-738167
DMO69X8	MI	TTJA1ZO
DMO69X8	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMO69X8	MT	DTT
DMO69X8	MA	Inhibitor
DMO69X8	RN	Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J Med Chem. 2000 Sep 21;43(19):3453-73.
DMO69X8	RU	https://pubmed.ncbi.nlm.nih.gov/10999999

DMAUG0L	DI	DMAUG0L
DMAUG0L	DN	L-739749
DMAUG0L	MI	TT7WZIJ
DMAUG0L	MN	CAAX farnesyltransferase beta (FNTB)
DMAUG0L	MT	DTT
DMAUG0L	MA	Inhibitor
DMAUG0L	RN	Ras farnesyltransferase: a new therapeutic target. J Med Chem. 1997 Sep 12;40(19):2971-90.
DMAUG0L	RU	https://pubmed.ncbi.nlm.nih.gov/9301658

DMNSH0V	DI	DMNSH0V
DMNSH0V	DN	L-741604
DMNSH0V	MI	TT6MSOK
DMNSH0V	MN	5-HT 1D receptor (HTR1D)
DMNSH0V	MT	DTT
DMNSH0V	MA	Inhibitor
DMNSH0V	RN	3-(Piperazinylpropyl)indoles: selective, orally bioavailable h5-HT1D receptor agonists as potential antimigraine agents. J Med Chem. 1999 Feb 25;42(4):691-705.
DMNSH0V	RU	https://pubmed.ncbi.nlm.nih.gov/10052976

DMRVXEQ	DI	DMRVXEQ
DMRVXEQ	DN	L-741671
DMRVXEQ	MI	TTZPO1L
DMRVXEQ	MN	Substance-P receptor (TACR1)
DMRVXEQ	MT	DTT
DMRVXEQ	MA	Inhibitor
DMRVXEQ	RN	N-heteroaryl-2-phenyl-3-(benzyloxy)piperidines: a novel class of potent orally active human NK1 antagonists. J Med Chem. 1996 Jul 19;39(15):2907-14.
DMRVXEQ	RU	https://pubmed.ncbi.nlm.nih.gov/8709125

DMOQIWH	DI	DMOQIWH
DMOQIWH	DN	L-745337
DMOQIWH	MI	TTVKILB
DMOQIWH	MN	Prostaglandin G/H synthase 2 (COX-2)
DMOQIWH	MT	DTT
DMOQIWH	MA	Modulator
DMOQIWH	RN	Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect ... J Pharmacol Exp Ther. 1995 Sep;274(3):1531-7.
DMOQIWH	RU	https://www.ncbi.nlm.nih.gov/pubmed/7562530

DM4UP7R	DI	DM4UP7R
DM4UP7R	DN	L-745631
DM4UP7R	MI	TT7WZIJ
DM4UP7R	MN	CAAX farnesyltransferase beta (FNTB)
DM4UP7R	MT	DTT
DM4UP7R	MA	Inhibitor
DM4UP7R	RN	Ras farnesyltransferase: a new therapeutic target. J Med Chem. 1997 Sep 12;40(19):2971-90.
DM4UP7R	RU	https://pubmed.ncbi.nlm.nih.gov/9301658

DM4UP7R	DI	DM4UP7R
DM4UP7R	DN	L-745631
DM4UP7R	MI	TTXQKM3
DM4UP7R	MN	Farnesyl protein transferase (Ftase)
DM4UP7R	MT	DTT
DM4UP7R	MA	Inhibitor
DM4UP7R	RN	Ras farnesyltransferase: a new therapeutic target. J Med Chem. 1997 Sep 12;40(19):2971-90.
DM4UP7R	RU	https://pubmed.ncbi.nlm.nih.gov/9301658

DM4UP7R	DI	DM4UP7R
DM4UP7R	DN	L-745631
DM4UP7R	MI	TTX20QP
DM4UP7R	MN	Geranylgeranyl transferase I (GGTase-I)
DM4UP7R	MT	DTT
DM4UP7R	MA	Inhibitor
DM4UP7R	RN	Ras farnesyltransferase: a new therapeutic target. J Med Chem. 1997 Sep 12;40(19):2971-90.
DM4UP7R	RU	https://pubmed.ncbi.nlm.nih.gov/9301658

DMPWBNU	DI	DMPWBNU
DMPWBNU	DN	L-755507
DMPWBNU	MI	TTR6W5O
DMPWBNU	MN	Adrenergic receptor beta-1 (ADRB1)
DMPWBNU	MT	DTT
DMPWBNU	MA	Inhibitor
DMPWBNU	RN	(4-Piperidin-1-yl)phenyl amides: potent and selective human beta(3) agonists. J Med Chem. 2001 Apr 26;44(9):1456-66.
DMPWBNU	RU	https://pubmed.ncbi.nlm.nih.gov/11311069

DMPWBNU	DI	DMPWBNU
DMPWBNU	DN	L-755507
DMPWBNU	MI	TT2CJVK
DMPWBNU	MN	Adrenergic receptor beta-2 (ADRB2)
DMPWBNU	MT	DTT
DMPWBNU	MA	Inhibitor
DMPWBNU	RN	(4-Piperidin-1-yl)phenyl amides: potent and selective human beta(3) agonists. J Med Chem. 2001 Apr 26;44(9):1456-66.
DMPWBNU	RU	https://pubmed.ncbi.nlm.nih.gov/11311069

DMPWBNU	DI	DMPWBNU
DMPWBNU	DN	L-755507
DMPWBNU	MI	TTEAID7
DMPWBNU	MN	Trypanosoma Cruzipain (Trypano CYSP)
DMPWBNU	MT	DTT
DMPWBNU	MA	Inhibitor
DMPWBNU	RN	Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease. J Med Chem. 2010 Jan 14;53(1):37-51.
DMPWBNU	RU	https://pubmed.ncbi.nlm.nih.gov/19908840

DM17S85	DI	DM17S85
DM17S85	DN	L-757464
DM17S85	MI	TTNGILX
DM17S85	MN	Adrenergic receptor alpha-1A (ADRA1A)
DM17S85	MT	DTT
DM17S85	MA	Antagonist
DM17S85	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010051)
DM17S85	RU	http://adisinsight.springer.com/drugs/800010051

DM7J6QH	DI	DM7J6QH
DM7J6QH	DN	L-768277
DM7J6QH	MI	TTVKILB
DM7J6QH	MN	Prostaglandin G/H synthase 2 (COX-2)
DM7J6QH	MT	DTT
DM7J6QH	MA	Modulator
DM7J6QH	RN	Characterization of the in vitro oxidative metabolites of the COX-2 selective inhibitor L-766,112. Bioorganic & Medicinal Chemistry Letters Volume 7, Issue 1, 7 January 1997, Pages 53-56.
DM7J6QH	RU	http://www.sciencedirect.com/science/article/pii/S0960894X96005811

DMZ402C	DI	DMZ402C
DMZ402C	DN	L-768673
DMZ402C	MI	TT846HF
DMZ402C	MN	Voltage-gated potassium channel Kv7.1 (KCNQ1)
DMZ402C	MT	DTT
DMZ402C	MA	Inhibitor
DMZ402C	RN	Class III antiarrhythmic activity in vivo by selective blockade of the slowly activating cardiac delayed rectifier potassium current IKs by (R)-2-(... J Med Chem. 1997 Nov 21;40(24):3865-8.
DMZ402C	RU	https://pubmed.ncbi.nlm.nih.gov/9397166

DMJ37IX	DI	DMJ37IX
DMJ37IX	DN	L-775606
DMJ37IX	MI	TTK8CXU
DMJ37IX	MN	5-HT 1B receptor (HTR1B)
DMJ37IX	MT	DTT
DMJ37IX	MA	Inhibitor
DMJ37IX	RN	Selective, orally active 5-HT1D receptor agonists as potential antimigraine agents. J Med Chem. 1997 Oct 24;40(22):3501-3.
DMJ37IX	RU	https://pubmed.ncbi.nlm.nih.gov/9357515

DMJ37IX	DI	DMJ37IX
DMJ37IX	DN	L-775606
DMJ37IX	MI	TT6MSOK
DMJ37IX	MN	5-HT 1D receptor (HTR1D)
DMJ37IX	MT	DTT
DMJ37IX	MA	Inhibitor
DMJ37IX	RN	Designing selective, high affinity ligands of 5-HT1D receptor by covalent dimerization of 5-HT1F ligands derived from 4-fluoro-N-[3-(1-methyl-4-pip... J Med Chem. 2008 Jun 26;51(12):3609-16.
DMJ37IX	RU	https://pubmed.ncbi.nlm.nih.gov/18507369

DM07S4N	DI	DM07S4N
DM07S4N	DN	LAS-30538
DM07S4N	MI	TT5HONZ
DM07S4N	MN	Calcium channel unspecific (CaC)
DM07S4N	MT	DTT
DM07S4N	MA	Modulator
DM07S4N	RN	The calcium channel blocker LAS 30538, unlike nifedipine, verapamil, diltiazem or flunarizine, potently inhibits insulin secretion in-vivo in rats and dogs. J Pharm Pharmacol. 1992 Oct;44(10):851-5.
DM07S4N	RU	https://pubmed.ncbi.nlm.nih.gov/1360513

DMW2K1L	DI	DMW2K1L
DMW2K1L	DN	LAS-31180
DMW2K1L	MI	TT06AWU
DMW2K1L	MN	Phosphodiesterase 3A (PDE3A)
DMW2K1L	MT	DTT
DMW2K1L	MA	Modulator
DMW2K1L	RN	Pharmacological profile of LAS 31180, a new inotropic/vasodilator quinolone derivative. Arzneimittelforschung. 2000 Nov;50(11):980-6.
DMW2K1L	RU	https://pubmed.ncbi.nlm.nih.gov/11148864

DMYGJCL	DI	DMYGJCL
DMYGJCL	DN	LB30057
DMYGJCL	MI	TT6L509
DMYGJCL	MN	Coagulation factor IIa (F2)
DMYGJCL	MT	DTT
DMYGJCL	MA	Inhibitor
DMYGJCL	RN	Antithrombotic activity of LB30057, a newly synthesized direct thrombin inhibitor. Thromb Haemost. 2003 Jan;89(1):104-11.
DMYGJCL	RU	https://pubmed.ncbi.nlm.nih.gov/12540960

DMFEMTG	DI	DMFEMTG
DMFEMTG	DN	Lecimibide
DMFEMTG	MI	TTMF541
DMFEMTG	MN	Liver carboxylesterase (CES1)
DMFEMTG	MT	DTT
DMFEMTG	MA	Modulator
DMFEMTG	RN	Effect of the acyl-CoA:cholesterol acyltransferase inhibitor DuP 128 on cholesterol absorption and serum cholesterol in humans. Clin Pharmacol Ther. 1994 Jul;56(1):65-74.
DMFEMTG	RU	https://pubmed.ncbi.nlm.nih.gov/8033496

DMIYMS2	DI	DMIYMS2
DMIYMS2	DN	LF-984
DMIYMS2	MI	TTP4520
DMIYMS2	MN	TGF-beta receptor type I (TGFBR1)
DMIYMS2	MT	DTT
DMIYMS2	MA	Inhibitor
DMIYMS2	RN	US patent application no. 2013,0028,978, Compositions and methods for wound treatment.
DMIYMS2	RU	https://www.google.com.ar/patents/US20130028978

DMNXKR2	DI	DMNXKR2
DMNXKR2	DN	LG-2293
DMNXKR2	MI	TTS64P2
DMNXKR2	MN	Androgen receptor (AR)
DMNXKR2	MT	DTT
DMNXKR2	MA	Modulator
DMNXKR2	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006840)
DMNXKR2	RU	http://adisinsight.springer.com/drugs/800006840

DMF9XU4	DI	DMF9XU4
DMF9XU4	DN	LM-1376
DMF9XU4	MI	TTGKOY9
DMF9XU4	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DMF9XU4	MT	DTT
DMF9XU4	MA	Modulator
DMF9XU4	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMF9XU4	RU	https://www.fda.gov/

DM6Y49D	DI	DM6Y49D
DM6Y49D	DN	L-NIL
DM6Y49D	MI	TTZUFI5
DM6Y49D	MN	Nitric-oxide synthase brain (NOS1)
DM6Y49D	MT	DTT
DM6Y49D	MA	Inhibitor
DM6Y49D	RN	Discovery of a series of aminopiperidines as novel iNOS inhibitors. Bioorg Med Chem Lett. 2008 Jan 1;18(1):336-43.
DM6Y49D	RU	https://pubmed.ncbi.nlm.nih.gov/18024030

DM6Y49D	DI	DM6Y49D
DM6Y49D	DN	L-NIL
DM6Y49D	MI	TTCM4B3
DM6Y49D	MN	Nitric-oxide synthase endothelial (NOS3)
DM6Y49D	MT	DTT
DM6Y49D	MA	Inhibitor
DM6Y49D	RN	Discovery of a series of aminopiperidines as novel iNOS inhibitors. Bioorg Med Chem Lett. 2008 Jan 1;18(1):336-43.
DM6Y49D	RU	https://pubmed.ncbi.nlm.nih.gov/18024030

DM6Y49D	DI	DM6Y49D
DM6Y49D	DN	L-NIL
DM6Y49D	MI	TTF10I9
DM6Y49D	MN	Nitric-oxide synthase inducible (NOS2)
DM6Y49D	MT	DTT
DM6Y49D	MA	Inhibitor
DM6Y49D	RN	Discovery of a series of aminopiperidines as novel iNOS inhibitors. Bioorg Med Chem Lett. 2008 Jan 1;18(1):336-43.
DM6Y49D	RU	https://pubmed.ncbi.nlm.nih.gov/18024030

DM904B6	DI	DM904B6
DM904B6	DN	Lorglumide
DM904B6	MI	TTCG0AL
DM904B6	MN	Cholecystokinin receptor type A (CCKAR)
DM904B6	MT	DTT
DM904B6	MA	Antagonist
DM904B6	RN	Behavioral and neurochemical study on the role of the brain cholecystokinin system in anxiety. Hokkaido Igaku Zasshi. 1998 Sep;73(5):463-73.
DM904B6	RU	https://pubmed.ncbi.nlm.nih.gov/9846276

DMFJPYV	DI	DMFJPYV
DMFJPYV	DN	LSI-518P
DMFJPYV	MI	TT7GN3U
DMFJPYV	MN	Apolipoprotein A-I (APOA1)
DMFJPYV	MT	DTT
DMFJPYV	MA	Modulator
DMFJPYV	RN	Clinical review: The evolving role of HDL in the treatment of high-risk patients with cardiovascular disease. J Clin Endocrinol Metab. 2011 May;96(5):1246-57.
DMFJPYV	RU	https://pubmed.ncbi.nlm.nih.gov/21389140

DMDHLUC	DI	DMDHLUC
DMDHLUC	DN	LU-29252
DMDHLUC	MI	TT5TPI6
DMDHLUC	MN	Opioid receptor sigma 1 (OPRS1)
DMDHLUC	MT	DTT
DMDHLUC	MA	Modulator
DMDHLUC	RN	Involvement of sigma receptors in the modulation of the glutamatergic/NMDA neurotransmission in the dopaminergic systems. Eur J Pharmacol. 1999 Mar 5;368(2-3):183-96.
DMDHLUC	RU	https://pubmed.ncbi.nlm.nih.gov/10193654

DMXRJQV	DI	DMXRJQV
DMXRJQV	DN	Luzindole
DMXRJQV	MI	TT0WAIE
DMXRJQV	MN	Melatonin receptor type 1A (MTNR1A)
DMXRJQV	MT	DTT
DMXRJQV	MA	Modulator
DMXRJQV	RN	Luzindole (N-0774): a novel melatonin receptor antagonist. J Pharmacol Exp Ther. 1988 Sep;246(3):902-10.
DMXRJQV	RU	https://pubmed.ncbi.nlm.nih.gov/2843633

DMMRLPF	DI	DMMRLPF
DMMRLPF	DN	LX-2932
DMMRLPF	MI	TT618Q2
DMMRLPF	MN	Sphingosine-1-phosphate lyase 1 (SGPL1)
DMMRLPF	MT	DTT
DMMRLPF	MA	Inhibitor
DMMRLPF	RN	Inhibition of sphingosine 1-phosphate lyase for the treatment of rheumatoid arthritis: discovery of (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime (LX2931) and (1R,2S,3R)-1-(2-(isoxazol-3-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol (LX2932). J Med Chem. 2010 Dec 23;53(24):8650-62.
DMMRLPF	RU	https://pubmed.ncbi.nlm.nih.gov/21090716

DMXYDJR	DI	DMXYDJR
DMXYDJR	DN	LXR-015-2
DMXYDJR	MI	TTC8M31
DMXYDJR	MN	Carnitine acyltransferase (CRAT)
DMXYDJR	MT	DTT
DMXYDJR	MA	Inhibitor
DMXYDJR	RN	EDG receptors as a potential therapeutic target in retinal ischemia-reperfusion injury. Brain Res. 2006 Nov 6;1118(1):168-75.
DMXYDJR	RU	https://pubmed.ncbi.nlm.nih.gov/17026968

DMUHG0F	DI	DMUHG0F
DMUHG0F	DN	LY-117018
DMUHG0F	MI	TTZAYWL
DMUHG0F	MN	Estrogen receptor (ESR)
DMUHG0F	MT	DTT
DMUHG0F	MA	Inhibitor
DMUHG0F	RN	Structure-activity relationship of antiestrogens. Phenolic analogues of 2,3-diaryl-2H-1-benzopyrans. J Med Chem. 1990 Dec;33(12):3222-9.
DMUHG0F	RU	https://pubmed.ncbi.nlm.nih.gov/2258908

DMUHG0F	DI	DMUHG0F
DMUHG0F	DN	LY-117018
DMUHG0F	MI	TTOM3J0
DMUHG0F	MN	Estrogen receptor beta (ESR2)
DMUHG0F	MT	DTT
DMUHG0F	MA	Inhibitor
DMUHG0F	RN	Structure-activity relationship of antiestrogens. Phenolic analogues of 2,3-diaryl-2H-1-benzopyrans. J Med Chem. 1990 Dec;33(12):3222-9.
DMUHG0F	RU	https://pubmed.ncbi.nlm.nih.gov/2258908

DMUEB4P	DI	DMUEB4P
DMUEB4P	DN	LY-210073
DMUEB4P	MI	TTN53ZF
DMUEB4P	MN	Leukotriene B4 receptor 1 (LTB4R)
DMUEB4P	MT	DTT
DMUEB4P	MA	Modulator
DMUEB4P	RN	Design, synthesis, and pharmacological evaluation of potent xanthone dicarboxylic acid leukotriene B4 receptor antagonists. J Med Chem. 1993 Jun 11;36(12):1726-34.
DMUEB4P	RU	https://pubmed.ncbi.nlm.nih.gov/8389876

DMJ54E9	DI	DMJ54E9
DMJ54E9	DN	LY-221068
DMJ54E9	MI	TT2J34L
DMJ54E9	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMJ54E9	MT	DTT
DMJ54E9	MA	Inhibitor
DMJ54E9	RN	Anti-inflammatory effects of LY221068 and LY269415. Agents Actions. 1991 Sep;34(1-2):100-2.
DMJ54E9	RU	https://pubmed.ncbi.nlm.nih.gov/1793009

DMIDK36	DI	DMIDK36
DMIDK36	DN	LY-243062
DMIDK36	MI	TTEX248
DMIDK36	MN	Dopamine D2 receptor (D2R)
DMIDK36	MT	DTT
DMIDK36	MA	Modulator
DMIDK36	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005079)
DMIDK36	RU	http://adisinsight.springer.com/drugs/800005079

DMFIR0S	DI	DMFIR0S
DMFIR0S	DN	LY-255283
DMFIR0S	MI	TTN53ZF
DMFIR0S	MN	Leukotriene B4 receptor 1 (LTB4R)
DMFIR0S	MT	DTT
DMFIR0S	MA	Inhibitor
DMFIR0S	RN	o-phenylphenols: potent and orally active leukotriene B4 receptor antagonists. J Med Chem. 1993 Nov 26;36(24):3978-81.
DMFIR0S	RU	https://pubmed.ncbi.nlm.nih.gov/7902871

DMFIR0S	DI	DMFIR0S
DMFIR0S	DN	LY-255283
DMFIR0S	MI	TTVJX54
DMFIR0S	MN	Leukotriene B4 receptor 2 (LTB4R2)
DMFIR0S	MT	DTT
DMFIR0S	MA	Inhibitor
DMFIR0S	RN	o-phenylphenols: potent and orally active leukotriene B4 receptor antagonists. J Med Chem. 1993 Nov 26;36(24):3978-81.
DMFIR0S	RU	https://pubmed.ncbi.nlm.nih.gov/7902871

DMG79NT	DI	DMG79NT
DMG79NT	DN	LY-274614
DMG79NT	MI	TT9IK2Z
DMG79NT	MN	N-methyl-D-aspartate receptor (NMDAR)
DMG79NT	MT	DTT
DMG79NT	MA	Modulator
DMG79NT	RN	The NMDA receptor antagonists, LY274614 and MK-801, and the nitric oxide synthase inhibitor, NG-nitro-L-arginine, attenuate analgesic tolerance to the mu-opioid morphine but not to kappa opioids. Pain. 1994 Jan;56(1):69-75.
DMG79NT	RU	https://pubmed.ncbi.nlm.nih.gov/7512709

DMG8YE9	DI	DMG8YE9
DMG8YE9	DN	LY288513
DMG8YE9	MI	TTVFO0U
DMG8YE9	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMG8YE9	MT	DTT
DMG8YE9	MA	Antagonist
DMG8YE9	RN	Behavioral and neurochemical study on the role of the brain cholecystokinin system in anxiety. Hokkaido Igaku Zasshi. 1998 Sep;73(5):463-73.
DMG8YE9	RU	https://pubmed.ncbi.nlm.nih.gov/9846276

DMPZ7AO	DI	DMPZ7AO
DMPZ7AO	DN	LY-290154
DMPZ7AO	MI	TTGKOY9
DMPZ7AO	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DMPZ7AO	MT	DTT
DMPZ7AO	MA	Modulator
DMPZ7AO	RN	DOI: 10.1021/op060036x
DMPZ7AO	RU	http://pubs.acs.org/doi/abs/10.1021/op060036x

DMPZ7AO	DI	DMPZ7AO
DMPZ7AO	DN	LY-290154
DMPZ7AO	MI	TT0PZR5
DMPZ7AO	MN	Leukotriene CysLT2 receptor (CYSLTR2)
DMPZ7AO	MT	DTT
DMPZ7AO	MA	Modulator
DMPZ7AO	RN	DOI: 10.1021/op060036x
DMPZ7AO	RU	http://pubs.acs.org/doi/abs/10.1021/op060036x

DMU24HR	DI	DMU24HR
DMU24HR	DN	LY-292728
DMU24HR	MI	TTN53ZF
DMU24HR	MN	Leukotriene B4 receptor 1 (LTB4R)
DMU24HR	MT	DTT
DMU24HR	MA	Inhibitor
DMU24HR	RN	Biphenylyl-substituted xanthones: highly potent leukotriene B4 receptor antagonists. J Med Chem. 1993 Nov 26;36(24):3982-4.
DMU24HR	RU	https://pubmed.ncbi.nlm.nih.gov/8254628

DMU24HR	DI	DMU24HR
DMU24HR	DN	LY-292728
DMU24HR	MI	TTVJX54
DMU24HR	MN	Leukotriene B4 receptor 2 (LTB4R2)
DMU24HR	MT	DTT
DMU24HR	MA	Inhibitor
DMU24HR	RN	Biphenylyl-substituted xanthones: highly potent leukotriene B4 receptor antagonists. J Med Chem. 1993 Nov 26;36(24):3982-4.
DMU24HR	RU	https://pubmed.ncbi.nlm.nih.gov/8254628

DMH21JG	DI	DMH21JG
DMH21JG	DN	LY-293284
DMH21JG	MI	TTSQIFT
DMH21JG	MN	5-HT 1A receptor (HTR1A)
DMH21JG	MT	DTT
DMH21JG	MA	Agonist
DMH21JG	RN	Pharmacological characterization of LY293284: A 5-HT1A receptor agonist with high potency and selectivity. J Pharmacol Exp Ther. 1994 Sep;270(3):1270-81.
DMH21JG	RU	https://pubmed.ncbi.nlm.nih.gov/7523657

DMM20PI	DI	DMM20PI
DMM20PI	DN	LY-317644
DMM20PI	MI	TTFJ8Q1
DMM20PI	MN	Protein kinase C alpha (PRKCA)
DMM20PI	MT	DTT
DMM20PI	MA	Inhibitor
DMM20PI	RN	Synthesis of bisindolylmaleimide macrocycles, Bioorg. Med. Chem. Lett. 5(18):2093-2096 (1995).
DMM20PI	RU	http://www.sciencedirect.com/science/article/pii/0960894X95003503

DMM20PI	DI	DMM20PI
DMM20PI	DN	LY-317644
DMM20PI	MI	TTYPXQF
DMM20PI	MN	Protein kinase C beta (PRKCB)
DMM20PI	MT	DTT
DMM20PI	MA	Inhibitor
DMM20PI	RN	Synthesis of bisindolylmaleimide macrocycles, Bioorg. Med. Chem. Lett. 5(18):2093-2096 (1995).
DMM20PI	RU	http://www.sciencedirect.com/science/article/pii/0960894X95003503

DMM20PI	DI	DMM20PI
DMM20PI	DN	LY-317644
DMM20PI	MI	TT9WJ8U
DMM20PI	MN	Protein kinase C delta (PRKCD)
DMM20PI	MT	DTT
DMM20PI	MA	Inhibitor
DMM20PI	RN	Synthesis of bisindolylmaleimide macrocycles, Bioorg. Med. Chem. Lett. 5(18):2093-2096 (1995).
DMM20PI	RU	http://www.sciencedirect.com/science/article/pii/0960894X95003503

DMM20PI	DI	DMM20PI
DMM20PI	DN	LY-317644
DMM20PI	MI	TTBZ7OD
DMM20PI	MN	Protein kinase C epsilon (PRKCE)
DMM20PI	MT	DTT
DMM20PI	MA	Inhibitor
DMM20PI	RN	Synthesis of bisindolylmaleimide macrocycles, Bioorg. Med. Chem. Lett. 5(18):2093-2096 (1995).
DMM20PI	RU	http://www.sciencedirect.com/science/article/pii/0960894X95003503

DMM20PI	DI	DMM20PI
DMM20PI	DN	LY-317644
DMM20PI	MI	TTRFOXJ
DMM20PI	MN	Protein kinase C gamma (PRKCG)
DMM20PI	MT	DTT
DMM20PI	MA	Inhibitor
DMM20PI	RN	Synthesis of bisindolylmaleimide macrocycles, Bioorg. Med. Chem. Lett. 5(18):2093-2096 (1995).
DMM20PI	RU	http://www.sciencedirect.com/science/article/pii/0960894X95003503

DMM20PI	DI	DMM20PI
DMM20PI	DN	LY-317644
DMM20PI	MI	TT8QL1J
DMM20PI	MN	Protein kinase C theta (PRKCQ)
DMM20PI	MT	DTT
DMM20PI	MA	Inhibitor
DMM20PI	RN	Synthesis of bisindolylmaleimide macrocycles, Bioorg. Med. Chem. Lett. 5(18):2093-2096 (1995).
DMM20PI	RU	http://www.sciencedirect.com/science/article/pii/0960894X95003503

DMM20PI	DI	DMM20PI
DMM20PI	DN	LY-317644
DMM20PI	MI	TTUWGRA
DMM20PI	MN	Protein kinase C zeta (PRKCZ)
DMM20PI	MT	DTT
DMM20PI	MA	Inhibitor
DMM20PI	RN	Synthesis of bisindolylmaleimide macrocycles, Bioorg. Med. Chem. Lett. 5(18):2093-2096 (1995).
DMM20PI	RU	http://www.sciencedirect.com/science/article/pii/0960894X95003503

DMFVYID	DI	DMFVYID
DMFVYID	DN	LY-353433
DMFVYID	MI	TT07C3Y
DMFVYID	MN	5-HT 4 receptor (HTR4)
DMFVYID	MT	DTT
DMFVYID	MA	Antagonist
DMFVYID	RN	LY353433, a potent, orally effective, long-acting 5-HT(4) receptor antagonist: comparison to cisapride and RS23597-190. J Pharmacol Exp Ther. 1996 Apr;277(1):97-104.
DMFVYID	RU	https://pubmed.ncbi.nlm.nih.gov/8613972

DM98POQ	DI	DM98POQ
DM98POQ	DN	LY-367385
DM98POQ	MI	TTVBPDM
DM98POQ	MN	Metabotropic glutamate receptor 1 (mGluR1)
DM98POQ	MT	DTT
DM98POQ	MA	Agonist
DM98POQ	RN	Anticonvulsant actions of LY 367385 ((+)-2-methyl-4-carboxyphenylglycine) and AIDA ((RS)-1-aminoindan-1,5-dicarboxylic acid). Eur J Pharmacol. 1999 Feb 26;368(1):17-24.
DM98POQ	RU	https://pubmed.ncbi.nlm.nih.gov/10096765

DM0TV9L	DI	DM0TV9L
DM0TV9L	DN	LY467711
DM0TV9L	MI	TTHS256
DM0TV9L	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM0TV9L	MT	DTT
DM0TV9L	MA	Antagonist
DM0TV9L	RN	Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
DM0TV9L	RU	https://pubmed.ncbi.nlm.nih.gov/16377242

DMPNMAR	DI	DMPNMAR
DMPNMAR	DN	LY525327
DMPNMAR	MI	TTHS256
DMPNMAR	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMPNMAR	MT	DTT
DMPNMAR	MA	Antagonist
DMPNMAR	RN	Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
DMPNMAR	RU	https://pubmed.ncbi.nlm.nih.gov/16377242

DMY71LJ	DI	DMY71LJ
DMY71LJ	DN	LY53857
DMY71LJ	MI	TTJQOD7
DMY71LJ	MN	5-HT 2A receptor (HTR2A)
DMY71LJ	MT	DTT
DMY71LJ	MA	Antagonist
DMY71LJ	RN	The 5-hydroxytryptamine2A receptor is involved in (+)-norfenfluramine-induced arterial contraction and blood pressure increase in deoxycorticostero... J Pharmacol Exp Ther. 2007 May;321(2):485-91.
DMY71LJ	RU	https://pubmed.ncbi.nlm.nih.gov/17289838

DMY71LJ	DI	DMY71LJ
DMY71LJ	DN	LY53857
DMY71LJ	MI	TT0K1SC
DMY71LJ	MN	5-HT 2B receptor (HTR2B)
DMY71LJ	MT	DTT
DMY71LJ	MA	Antagonist
DMY71LJ	RN	p-Chloroamphetamine, a serotonin-releasing drug, elicited in rats a hyperglycemia mediated by the 5-HT1A and 5-HT2B/2C receptors. Eur J Pharmacol. 1998 Oct 23;359(2-3):185-90.
DMY71LJ	RU	https://pubmed.ncbi.nlm.nih.gov/9832390

DMY71LJ	DI	DMY71LJ
DMY71LJ	DN	LY53857
DMY71LJ	MI	TTWJBZ5
DMY71LJ	MN	5-HT 2C receptor (HTR2C)
DMY71LJ	MT	DTT
DMY71LJ	MA	Antagonist
DMY71LJ	RN	The 5-hydroxytryptamine2A receptor is involved in (+)-norfenfluramine-induced arterial contraction and blood pressure increase in deoxycorticostero... J Pharmacol Exp Ther. 2007 May;321(2):485-91.
DMY71LJ	RU	https://pubmed.ncbi.nlm.nih.gov/17289838

DM679IY	DI	DM679IY
DM679IY	DN	LZ-8
DM679IY	MI	TTISGCA
DM679IY	MN	Toll-like receptor 4 (TLR4)
DM679IY	MT	DTT
DM679IY	MA	Modulator
DM679IY	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1754).
DM679IY	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1754

DMUIGM3	DI	DMUIGM3
DMUIGM3	DN	M-216765
DMUIGM3	MI	TTSLI08
DMUIGM3	MN	Adenosine receptor (ADOR)
DMUIGM3	MT	DTT
DMUIGM3	MA	Modulator
DMUIGM3	RN	US patent application no. 2010,0009,934, Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders.
DMUIGM3	RU	http://www.google.com/patents/US20100009934

DMIY51U	DI	DMIY51U
DMIY51U	DN	M-241247
DMIY51U	MI	TTZ8EM9
DMIY51U	MN	Glycine receptor (GlyR)
DMIY51U	MT	DTT
DMIY51U	MA	Antagonist
DMIY51U	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003415)
DMIY51U	RU	http://adisinsight.springer.com/drugs/800003415

DMIY51U	DI	DMIY51U
DMIY51U	DN	M-241247
DMIY51U	MI	TT9IK2Z
DMIY51U	MN	N-methyl-D-aspartate receptor (NMDAR)
DMIY51U	MT	DTT
DMIY51U	MA	Antagonist
DMIY51U	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003415)
DMIY51U	RU	http://adisinsight.springer.com/drugs/800003415

DMBFCHW	DI	DMBFCHW
DMBFCHW	DN	M-40401
DMBFCHW	MI	TT6RVLG
DMBFCHW	MN	Superoxide dismutase Cu-Zn (SOD Cu-Zn)
DMBFCHW	MT	DTT
DMBFCHW	MA	Modulator
DMBFCHW	RN	Protective effects of a new stable, highly active SOD mimetic, M40401 in splanchnic artery occlusion and reperfusion. Br J Pharmacol. 2001 Jan;132(1):19-29.
DMBFCHW	RU	https://pubmed.ncbi.nlm.nih.gov/11156557

DM1SWOY	DI	DM1SWOY
DM1SWOY	DN	MANUMYCIN A
DM1SWOY	MI	TT7WZIJ
DM1SWOY	MN	CAAX farnesyltransferase beta (FNTB)
DM1SWOY	MT	DTT
DM1SWOY	MA	Inhibitor
DM1SWOY	RN	A novel metal-chelating inhibitor of protein farnesyltransferase. Bioorg Med Chem Lett. 2003 May 5;13(9):1523-6.
DM1SWOY	RU	https://pubmed.ncbi.nlm.nih.gov/12699746

DM1SWOY	DI	DM1SWOY
DM1SWOY	DN	MANUMYCIN A
DM1SWOY	MI	TTXQKM3
DM1SWOY	MN	Farnesyl protein transferase (Ftase)
DM1SWOY	MT	DTT
DM1SWOY	MA	Inhibitor
DM1SWOY	RN	A novel metal-chelating inhibitor of protein farnesyltransferase. Bioorg Med Chem Lett. 2003 May 5;13(9):1523-6.
DM1SWOY	RU	https://pubmed.ncbi.nlm.nih.gov/12699746

DM31WQC	DI	DM31WQC
DM31WQC	DN	Maxy-10
DM31WQC	MI	TT4TZ8J
DM31WQC	MN	Interferon-beta (IFNB1)
DM31WQC	MT	DTT
DM31WQC	MA	Modulator
DM31WQC	RN	US patent application no. 8,669,257, Phenazine derivatives and uses thereof as potassium channel modulators.
DM31WQC	RU	https://www.google.com/patents/US8669257

DMXLCB6	DI	DMXLCB6
DMXLCB6	DN	MCI-826
DMXLCB6	MI	TTGKOY9
DMXLCB6	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DMXLCB6	MT	DTT
DMXLCB6	MA	Antagonist
DMXLCB6	RN	Leukotriene receptors in the skin of rats differ from those of mouse skin or rat stomach strip. Eur J Pharmacol. 1992 Oct 20;221(2-3):333-42.
DMXLCB6	RU	https://pubmed.ncbi.nlm.nih.gov/1330627

DMRSOBG	DI	DMRSOBG
DMRSOBG	DN	Mdl 101,146
DMRSOBG	MI	TTPLTSQ
DMRSOBG	MN	Neutrophil elastase (NE)
DMRSOBG	MT	DTT
DMRSOBG	MA	Inhibitor
DMRSOBG	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMRSOBG	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMRSOBG	DI	DMRSOBG
DMRSOBG	DN	Mdl 101,146
DMRSOBG	MI	TT3NKIB
DMRSOBG	MN	Pancreatic elastase 1 (CELA1)
DMRSOBG	MT	DTT
DMRSOBG	MA	Inhibitor
DMRSOBG	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMRSOBG	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMHUJCI	DI	DMHUJCI
DMHUJCI	DN	MDL-105519
DMHUJCI	MI	TTLD29N
DMHUJCI	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMHUJCI	MT	DTT
DMHUJCI	MA	Inhibitor
DMHUJCI	RN	CoMFA, synthesis, and pharmacological evaluation of (E)-3-(2-carboxy-2-arylvinyl)-4,6-dichloro-1H-indole-2-carboxylic acids: 3-[2-(3-aminophenyl)-2... J Med Chem. 2005 Feb 24;48(4):995-1018.
DMHUJCI	RU	https://pubmed.ncbi.nlm.nih.gov/15715469

DMHUJCI	DI	DMHUJCI
DMHUJCI	DN	MDL-105519
DMHUJCI	MI	TTKJEMQ
DMHUJCI	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMHUJCI	MT	DTT
DMHUJCI	MA	Inhibitor
DMHUJCI	RN	CoMFA, synthesis, and pharmacological evaluation of (E)-3-(2-carboxy-2-arylvinyl)-4,6-dichloro-1H-indole-2-carboxylic acids: 3-[2-(3-aminophenyl)-2... J Med Chem. 2005 Feb 24;48(4):995-1018.
DMHUJCI	RU	https://pubmed.ncbi.nlm.nih.gov/15715469

DMHUJCI	DI	DMHUJCI
DMHUJCI	DN	MDL-105519
DMHUJCI	MI	TTN9D8E
DMHUJCI	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMHUJCI	MT	DTT
DMHUJCI	MA	Inhibitor
DMHUJCI	RN	CoMFA, synthesis, and pharmacological evaluation of (E)-3-(2-carboxy-2-arylvinyl)-4,6-dichloro-1H-indole-2-carboxylic acids: 3-[2-(3-aminophenyl)-2... J Med Chem. 2005 Feb 24;48(4):995-1018.
DMHUJCI	RU	https://pubmed.ncbi.nlm.nih.gov/15715469

DMMG1K3	DI	DMMG1K3
DMMG1K3	DN	MDL-201112
DMMG1K3	MI	TTF8CQI
DMMG1K3	MN	Tumor necrosis factor (TNF)
DMMG1K3	MT	DTT
DMMG1K3	MA	Inhibitor
DMMG1K3	RN	Effect of the carbocyclic nucleoside analogue MDL 201,112 on inhibition of interferon-gamma-induced priming of Lewis (LEW/N) rat macrophages for enhanced respiratory burst and MHC class II Ia+ antigen expression. J Leukoc Biol. 1994 Aug;56(2):133-44.
DMMG1K3	RU	https://pubmed.ncbi.nlm.nih.gov/8071590

DM6X4IT	DI	DM6X4IT
DM6X4IT	DN	MDL-28133A
DM6X4IT	MI	TTYSN63
DM6X4IT	MN	5-HT 2 receptor (5HT2R)
DM6X4IT	MT	DTT
DM6X4IT	MA	Modulator
DM6X4IT	RN	Effects of MDL 28,133A, a 5-HT2 receptor antagonist, on platelet aggregation and coronary thrombosis in dogs. J Cardiovasc Pharmacol. 1994 Nov;24(5):761-72.
DM6X4IT	RU	https://pubmed.ncbi.nlm.nih.gov/7532754

DM8ZDU2	DI	DM8ZDU2
DM8ZDU2	DN	MDL-28161
DM8ZDU2	MI	TTJQOD7
DM8ZDU2	MN	5-HT 2A receptor (HTR2A)
DM8ZDU2	MT	DTT
DM8ZDU2	MA	Inhibitor
DM8ZDU2	RN	Ketanserin analogues: structure-affinity relationships for 5-HT2 and 5-HT1C serotonin receptor binding. J Med Chem. 1992 Dec 25;35(26):4903-10.
DM8ZDU2	RU	https://pubmed.ncbi.nlm.nih.gov/1479590

DMYK31O	DI	DMYK31O
DMYK31O	DN	MDL-28170
DMYK31O	MI	TTG5QB7
DMYK31O	MN	Calpain-2 (CAPN2)
DMYK31O	MT	DTT
DMYK31O	MA	Inhibitor
DMYK31O	RN	Synthesis of a small library of diketopiperazines as potential inhibitors of calpain. Bioorg Med Chem Lett. 2005 Jun 15;15(12):3034-8.
DMYK31O	RU	https://pubmed.ncbi.nlm.nih.gov/15896956

DMBIDQX	DI	DMBIDQX
DMBIDQX	DN	MDL-43291
DMBIDQX	MI	TTGKOY9
DMBIDQX	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DMBIDQX	MT	DTT
DMBIDQX	MA	Modulator
DMBIDQX	RN	Conformationally restricted leukotriene receptor antagonists: [(octahydro-2-oxo-7-tetradecylidene-2H-1-benzopyran-8-yl)thio]ace tic acids. Pharmacology. 1990;40(5):271-6.
DMBIDQX	RU	https://www.ncbi.nlm.nih.gov/pubmed/2177202

DMBIDQX	DI	DMBIDQX
DMBIDQX	DN	MDL-43291
DMBIDQX	MI	TT0PZR5
DMBIDQX	MN	Leukotriene CysLT2 receptor (CYSLTR2)
DMBIDQX	MT	DTT
DMBIDQX	MA	Modulator
DMBIDQX	RN	Conformationally restricted leukotriene receptor antagonists: [(octahydro-2-oxo-7-tetradecylidene-2H-1-benzopyran-8-yl)thio]ace tic acids. Pharmacology. 1990;40(5):271-6.
DMBIDQX	RU	https://www.ncbi.nlm.nih.gov/pubmed/2177202

DMHX6IC	DI	DMHX6IC
DMHX6IC	DN	ME-3221
DMHX6IC	MI	TTGN1ZA
DMHX6IC	MN	Angiotensin II receptor (AGTR)
DMHX6IC	MT	DTT
DMHX6IC	MA	Modulator
DMHX6IC	RN	Protective effects of ME3221 on hypertensive complications and lifespan in salt-loaded stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 1996 Mar;23(3):229-35.
DMHX6IC	RU	https://pubmed.ncbi.nlm.nih.gov/8934613

DMT3B4G	DI	DMT3B4G
DMT3B4G	DN	MEDI-500
DMT3B4G	MI	TTBMAOZ
DMT3B4G	MN	Regulatory protein unspecific (RGP)
DMT3B4G	MT	DTT
DMT3B4G	MA	Modulator
DMT3B4G	RN	T10B9 (MEDI-500) mediated immunosuppression: studies on the mechanism of action. Clin Transplant. 1996 Dec;10(6 Pt 2):607-13.
DMT3B4G	RU	https://pubmed.ncbi.nlm.nih.gov/8996751

DM4G0D5	DI	DM4G0D5
DM4G0D5	DN	MEDI-542
DM4G0D5	MI	TTG84D3
DM4G0D5	MN	Ephrin type-A receptor 4 (EPHA4)
DM4G0D5	MT	DTT
DM4G0D5	RN	Product Pipeline Review of MedImmune, LLC in 2012.
DM4G0D5	RU	http://www.researchandmarkets.com/reports/2245301/medimmune_llc_product_pipeline_review_2012.pdf

DM185DR	DI	DM185DR
DM185DR	DN	MEN-10207
DM185DR	MI	TTYO0A3
DM185DR	MN	Substance-K receptor (TACR2)
DM185DR	MT	DTT
DM185DR	MA	Modulator
DM185DR	RN	Role of D-tryptophan for affinity of MEN 10207 tachykinin antagonist at NK2 receptors. Peptides. 1991 Sep-Oct;12(5):1015-8.
DM185DR	RU	https://pubmed.ncbi.nlm.nih.gov/1666180

DM35ABD	DI	DM35ABD
DM35ABD	DN	MEN-10627
DM35ABD	MI	TTYO0A3
DM35ABD	MN	Substance-K receptor (TACR2)
DM35ABD	MT	DTT
DM35ABD	MA	Modulator
DM35ABD	RN	MEN 10,627, a novel polycyclic peptide antagonist of tachykinin NK2 receptors. J Pharmacol Exp Ther. 1994 Dec;271(3):1489-500.
DM35ABD	RU	https://pubmed.ncbi.nlm.nih.gov/7996462

DM57S3D	DI	DM57S3D
DM57S3D	DN	MEN-10690
DM57S3D	MI	TT84ETX
DM57S3D	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM57S3D	MT	DTT
DM57S3D	MA	Modulator
DM57S3D	RN	US patent application no. 2004,0023,290, Novel therapeutic agents that modulate enzymatic processes.
DM57S3D	RU	http://www.google.com/patents/US20040023290

DMKS1W0	DI	DMKS1W0
DMKS1W0	DN	MEN-10880
DMKS1W0	MI	TT84ETX
DMKS1W0	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMKS1W0	MT	DTT
DMKS1W0	MA	Modulator
DMKS1W0	RN	US patent application no. 2004,0023,290, Novel therapeutic agents that modulate enzymatic processes.
DMKS1W0	RU	http://www.google.com/patents/US20040023290

DM6UYN1	DI	DM6UYN1
DM6UYN1	DN	MEN-10979
DM6UYN1	MI	TT84ETX
DM6UYN1	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM6UYN1	MT	DTT
DM6UYN1	MA	Modulator
DM6UYN1	RN	New arylpyrido-diazepine and -thiodiazepine derivatives are potent and highly selective HIV-1 inhibitors targeted at the reverse transcriptase. Antiviral Res. 1996 May;30(2-3):109-24.
DM6UYN1	RU	https://pubmed.ncbi.nlm.nih.gov/8783803

DMEYNB0	DI	DMEYNB0
DMEYNB0	DN	MEN-11149
DMEYNB0	MI	TTZPO1L
DMEYNB0	MN	Substance-P receptor (TACR1)
DMEYNB0	MT	DTT
DMEYNB0	MA	Antagonist
DMEYNB0	RN	Pharmacology of the peptidomimetic, MEN 11149, a new potent, selective and orally effective tachykinin NK1 receptor antagonist. Eur J Pharmacol. 1998 Jan 12;341(2-3):201-9.
DMEYNB0	RU	https://pubmed.ncbi.nlm.nih.gov/9543241

DMNTIWC	DI	DMNTIWC
DMNTIWC	DN	MEN-11467
DMNTIWC	MI	TTZPO1L
DMNTIWC	MN	Substance-P receptor (TACR1)
DMNTIWC	MT	DTT
DMNTIWC	MA	Antagonist
DMNTIWC	RN	Effect of the long-acting tachykinin NK(1) receptor antagonist MEN 11467 on tracheal mucus secretion in allergic ferrets. Br J Pharmacol. 2001 Jan;132(1):189-96.
DMNTIWC	RU	https://pubmed.ncbi.nlm.nih.gov/11156577

DMC8J6F	DI	DMC8J6F
DMC8J6F	DN	Methylthioadenosine
DMC8J6F	MI	TTK25J1
DMC8J6F	MN	Adenosine A1 receptor (ADORA1)
DMC8J6F	MT	DTT
DMC8J6F	MA	Inhibitor
DMC8J6F	RN	Novel amino acid derived natural products from the ascidian Atriolum robustum: identification and pharmacological characterization of a unique aden... J Med Chem. 2004 Apr 22;47(9):2243-55.
DMC8J6F	RU	https://pubmed.ncbi.nlm.nih.gov/15084123

DMC8J6F	DI	DMC8J6F
DMC8J6F	DN	Methylthioadenosine
DMC8J6F	MI	TTM2AOE
DMC8J6F	MN	Adenosine A2a receptor (ADORA2A)
DMC8J6F	MT	DTT
DMC8J6F	MA	Inhibitor
DMC8J6F	RN	Novel amino acid derived natural products from the ascidian Atriolum robustum: identification and pharmacological characterization of a unique aden... J Med Chem. 2004 Apr 22;47(9):2243-55.
DMC8J6F	RU	https://pubmed.ncbi.nlm.nih.gov/15084123

DMC8J6F	DI	DMC8J6F
DMC8J6F	DN	Methylthioadenosine
DMC8J6F	MI	TTNE7KG
DMC8J6F	MN	Adenosine A2b receptor (ADORA2B)
DMC8J6F	MT	DTT
DMC8J6F	MA	Inhibitor
DMC8J6F	RN	Novel amino acid derived natural products from the ascidian Atriolum robustum: identification and pharmacological characterization of a unique aden... J Med Chem. 2004 Apr 22;47(9):2243-55.
DMC8J6F	RU	https://pubmed.ncbi.nlm.nih.gov/15084123

DMC8J6F	DI	DMC8J6F
DMC8J6F	DN	Methylthioadenosine
DMC8J6F	MI	TTJFY5U
DMC8J6F	MN	Adenosine A3 receptor (ADORA3)
DMC8J6F	MT	DTT
DMC8J6F	MA	Inhibitor
DMC8J6F	RN	Novel amino acid derived natural products from the ascidian Atriolum robustum: identification and pharmacological characterization of a unique aden... J Med Chem. 2004 Apr 22;47(9):2243-55.
DMC8J6F	RU	https://pubmed.ncbi.nlm.nih.gov/15084123

DMC8J6F	DI	DMC8J6F
DMC8J6F	DN	Methylthioadenosine
DMC8J6F	MI	DE1DR6Y
DMC8J6F	MN	S-adenosylhomocysteine nucleosidase (mtnN)
DMC8J6F	MT	DME
DMC8J6F	MA	Metabolism
DMC8J6F	RN	Selective killing of Klebsiella pneumoniae by 5-trifluoromethylthioribose. Chemotherapeutic exploitation of the enzyme 5-methylthioribose kinase. J Biol Chem. 1990 Jan 15;265(2):831-7.
DMC8J6F	RU	https://pubmed.ncbi.nlm.nih.gov/2153115

DMC8J6F	DI	DMC8J6F
DMC8J6F	DN	Methylthioadenosine
DMC8J6F	MI	TTDBX7N
DMC8J6F	MN	S-methyl-5'-thioadenosine phosphorylase (MTAP)
DMC8J6F	MT	DTT
DMC8J6F	MA	Inhibitor
DMC8J6F	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMC8J6F	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMC8J6F	DI	DMC8J6F
DMC8J6F	DN	Methylthioadenosine
DMC8J6F	MI	DEXHBCR
DMC8J6F	MN	S-methyl-5'-thioadenosine phosphorylase (MTAP)
DMC8J6F	MT	DME
DMC8J6F	MA	Metabolism
DMC8J6F	RN	Picomolar transition state analogue inhibitors of human 5'-methylthioadenosine phosphorylase and X-ray structure with MT-immucillin-A. Biochemistry. 2004 Jan 13;43(1):9-18.
DMC8J6F	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14705926

DMS5CZ4	DI	DMS5CZ4
DMS5CZ4	DN	METRIFUDIL
DMS5CZ4	MI	TTK25J1
DMS5CZ4	MN	Adenosine A1 receptor (ADORA1)
DMS5CZ4	MT	DTT
DMS5CZ4	MA	Inhibitor
DMS5CZ4	RN	N-substituted adenosines as novel neuroprotective A(1) agonists with diminished hypotensive effects. J Med Chem. 1999 Sep 9;42(18):3463-77.
DMS5CZ4	RU	https://pubmed.ncbi.nlm.nih.gov/10479279

DMS5CZ4	DI	DMS5CZ4
DMS5CZ4	DN	METRIFUDIL
DMS5CZ4	MI	TTM2AOE
DMS5CZ4	MN	Adenosine A2a receptor (ADORA2A)
DMS5CZ4	MT	DTT
DMS5CZ4	MA	Inhibitor
DMS5CZ4	RN	N-substituted adenosines as novel neuroprotective A(1) agonists with diminished hypotensive effects. J Med Chem. 1999 Sep 9;42(18):3463-77.
DMS5CZ4	RU	https://pubmed.ncbi.nlm.nih.gov/10479279

DMS5CZ4	DI	DMS5CZ4
DMS5CZ4	DN	METRIFUDIL
DMS5CZ4	MI	TTJFY5U
DMS5CZ4	MN	Adenosine A3 receptor (ADORA3)
DMS5CZ4	MT	DTT
DMS5CZ4	MA	Inhibitor
DMS5CZ4	RN	(N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists. J Med Chem. 2005 Mar 24;48(6):1745-58.
DMS5CZ4	RU	https://pubmed.ncbi.nlm.nih.gov/15771421

DM1LGKP	DI	DM1LGKP
DM1LGKP	DN	Mevastatin
DM1LGKP	MI	DECV2ME
DM1LGKP	MN	Cytochrome P450 105D7 (cyp105)
DM1LGKP	MT	DME
DM1LGKP	MA	Metabolism
DM1LGKP	RN	The metagenome of Caracolus marginella gut microbiome using culture independent approaches and shotgun sequencing. Data Brief. 2017 Nov 22;16:501-505.
DM1LGKP	RU	https://pubmed.ncbi.nlm.nih.gov/29270447

DM1LGKP	DI	DM1LGKP
DM1LGKP	DN	Mevastatin
DM1LGKP	MI	TTPADOQ
DM1LGKP	MN	HMG-CoA reductase (HMGCR)
DM1LGKP	MT	DTT
DM1LGKP	MA	Antagonist
DM1LGKP	RN	Regulation of CYP2B6 and CYP3A expression by hydroxymethylglutaryl coenzyme A inhibitors in primary cultured human hepatocytes. Drug Metab Dispos. 2002 Dec;30(12):1400-5.
DM1LGKP	RU	https://pubmed.ncbi.nlm.nih.gov/12433810

DMHV5OD	DI	DMHV5OD
DMHV5OD	DN	MF268
DMHV5OD	MI	TT1RS9F
DMHV5OD	MN	Acetylcholinesterase (AChE)
DMHV5OD	MT	DTT
DMHV5OD	MA	Inhibitor
DMHV5OD	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMHV5OD	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM72MQP	DI	DM72MQP
DM72MQP	DN	MF-5137
DM72MQP	MI	TTN6J5F
DM72MQP	MN	Bacterial DNA gyrase (Bact gyrase)
DM72MQP	MT	DTT
DM72MQP	MA	Modulator
DM72MQP	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM72MQP	RU	https://www.fda.gov/

DM47WS2	DI	DM47WS2
DM47WS2	DN	MF-8615
DM47WS2	MI	TT1RS9F
DM47WS2	MN	Acetylcholinesterase (AChE)
DM47WS2	MT	DTT
DM47WS2	MA	Inhibitor
DM47WS2	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006922)
DM47WS2	RU	http://adisinsight.springer.com/drugs/800006922

DM9GOT6	DI	DM9GOT6
DM9GOT6	DN	MGBG
DM9GOT6	MI	TTBFROQ
DM9GOT6	MN	S-adenosylmethionine decarboxylase proenzyme (AMD1)
DM9GOT6	MT	DTT
DM9GOT6	MA	Inhibitor
DM9GOT6	RN	A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumours. Br J Cancer. 2000 Sep;83(5):594-601.
DM9GOT6	RU	https://pubmed.ncbi.nlm.nih.gov/10944598

DM96WKA	DI	DM96WKA
DM96WKA	DN	Midaglizole
DM96WKA	MI	TT2NUT5
DM96WKA	MN	Adrenergic receptor alpha-2C (ADRA2C)
DM96WKA	MT	DTT
DM96WKA	MA	Modulator
DM96WKA	RN	Studies of midaglizole (DG-5128). A new type of oral hypoglycemic drug in healthy subjects. Diabetes. 1987 Feb;36(2):216-20.
DM96WKA	RU	https://pubmed.ncbi.nlm.nih.gov/3542646

DMJTR0U	DI	DMJTR0U
DMJTR0U	DN	Milacemide
DMJTR0U	MI	TTGP7BY
DMJTR0U	MN	Monoamine oxidase type B (MAO-B)
DMJTR0U	MT	DTT
DMJTR0U	MA	Modulator
DMJTR0U	RN	Milacemide, the selective substrate and enzyme-activated specific inhibitor of monoamine oxidase B, increases dopamine but not serotonin in caudate nucleus of rhesus monkey. Neurochem Int. 1990;17(2):325-9.
DMJTR0U	RU	https://pubmed.ncbi.nlm.nih.gov/20504633

DMZNWAV	DI	DMZNWAV
DMZNWAV	DN	Miltirone
DMZNWAV	MI	TTPTXIN
DMZNWAV	MN	Translocator protein (TSPO)
DMZNWAV	MT	DTT
DMZNWAV	MA	Modulator
DMZNWAV	RN	Miltirone, a central benzodiazepine receptor partial agonist from a Chinese medicinal herb Salvia miltiorrhiza. Neurosci Lett. 1991 Jun 24;127(2):237-41.
DMZNWAV	RU	https://pubmed.ncbi.nlm.nih.gov/1652718

DMQB8TW	DI	DMQB8TW
DMQB8TW	DN	Mimosine
DMQB8TW	MI	TTO8YH2
DMQB8TW	MN	Plasmodium Serine hydroxymethyltransferase (Malaria SHMT)
DMQB8TW	MT	DTT
DMQB8TW	MA	Inhibitor
DMQB8TW	RN	Mimosine targets serine hydroxymethyltransferase. J Biol Chem. 1996 Feb 2;271(5):2548-56.
DMQB8TW	RU	https://pubmed.ncbi.nlm.nih.gov/8576220

DM7IXH3	DI	DM7IXH3
DM7IXH3	DN	MINAMESTANE
DM7IXH3	MI	TTSZLWK
DM7IXH3	MN	Aromatase (CYP19A1)
DM7IXH3	MT	DTT
DM7IXH3	MA	Inhibitor
DM7IXH3	RN	High-performance liquid chromatographic determination of FCE 24928, a new aromatase inhibitor, in human plasma. J Chromatogr A. 1994 Feb 4;660(1-2):293-8.
DM7IXH3	RU	https://pubmed.ncbi.nlm.nih.gov/8148992

DMO06JV	DI	DMO06JV
DMO06JV	DN	Mitoflaxone
DMO06JV	MI	TT3SZBT
DMO06JV	MN	von Willebrand factor (VWF)
DMO06JV	MT	DTT
DMO06JV	MA	Inhibitor
DMO06JV	RN	Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci. 2002 Jan;23(1):25-32.
DMO06JV	RU	https://pubmed.ncbi.nlm.nih.gov/11804648

DMT9QB5	DI	DMT9QB5
DMT9QB5	DN	MIV-170
DMT9QB5	MI	TT84ETX
DMT9QB5	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMT9QB5	MT	DTT
DMT9QB5	MA	Inhibitor
DMT9QB5	RN	Inhibition of HIV-1 by non-nucleoside reverse transcriptase inhibitors via an induced fit mechanism-Importance of slow dissociation and relaxation rates for antiviral efficacy. Biochem Pharmacol. 2010 Oct 15;80(8):1133-40.
DMT9QB5	RU	https://pubmed.ncbi.nlm.nih.gov/20599774

DMAITRL	DI	DMAITRL
DMAITRL	DN	MKC-1313
DMAITRL	MI	TTBH0VX
DMAITRL	MN	Histone deacetylase (HDAC)
DMAITRL	MT	DTT
DMAITRL	MA	Inhibitor
DMAITRL	RN	ENTREMED TO ACQUIRE MIIKANA THERAPEUTICS. U.S. Securities and Exchange Commission. December 22, 2005.
DMAITRL	RU	http://www.sec.gov/Archives/edgar/data/895051/000095013305005669/w15948exv99w1.htm

DMF27BS	DI	DMF27BS
DMF27BS	DN	MMV00/0053
DMF27BS	MI	TTVTX4N
DMF27BS	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DMF27BS	MT	DTT
DMF27BS	MA	Inhibitor
DMF27BS	RN	SAR and pharmacophore models for the rhodanine inhibitors of Plasmodium falciparum enoyl-acyl carrier protein reductase. IUBMB Life. 2010 Mar;62(3):204-13.
DMF27BS	RU	https://pubmed.ncbi.nlm.nih.gov/20131353

DM543VY	DI	DM543VY
DM543VY	DN	MOL-218
DM543VY	MI	TTSXVID
DM543VY	MN	Nuclear factor NF-kappa-B (NFKB)
DM543VY	MT	DTT
DM543VY	MA	Inhibitor
DM543VY	RN	NF-kappaB plays a major role during the systemic and local acute inflammatory response following intestinal reperfusion injury. Br J Pharmacol. 2005 May;145(2):246-54.
DM543VY	RU	https://pubmed.ncbi.nlm.nih.gov/15765103

DMRCH1M	DI	DMRCH1M
DMRCH1M	DN	MOR-102
DMRCH1M	MI	TTCT6F7
DMRCH1M	MN	Intercellular adhesion molecule ICAM-1 (ICAM1)
DMRCH1M	MT	DTT
DMRCH1M	RN	Efficacy of the fully human monoclonal antibody MOR102 (#5) against intercellular adhesion molecule 1 in the psoriasis-severe combined immunodeficient mouse model. Br J Dermatol. 2005 Oct;153(4):758-66.
DMRCH1M	RU	https://pubmed.ncbi.nlm.nih.gov/16181457

DMO2S6T	DI	DMO2S6T
DMO2S6T	DN	MOXIFETIN HYDROGEN MALEATE
DMO2S6T	MI	TT3ROYC
DMO2S6T	MN	Serotonin transporter (SERT)
DMO2S6T	MT	DTT
DMO2S6T	RN	Moxidectin causes adult worm mortality of human lymphatic filarial parasite Brugia malayi in rodent models. Folia Parasitol (Praha). 2014 Dec;61(6):561-70.
DMO2S6T	RU	https://pubmed.ncbi.nlm.nih.gov/25651699

DMAVD4Q	DI	DMAVD4Q
DMAVD4Q	DN	MPI-461359
DMAVD4Q	MI	TTFGZB6
DMAVD4Q	MN	Human immunodeficiency virus GAG protein (HIV gag)
DMAVD4Q	MT	DTT
DMAVD4Q	MA	Inhibitor
DMAVD4Q	RN	Human Immunodeficiency Virus Gag and protease: partners in resistance. Retrovirology. 2012 Aug 6;9:63.
DMAVD4Q	RU	https://pubmed.ncbi.nlm.nih.gov/22867298

DM4A92X	DI	DM4A92X
DM4A92X	DN	MRL-953
DM4A92X	MI	TT51DEV
DM4A92X	MN	Interleukin 1 receptor type 2 (IL1R2)
DM4A92X	MT	DTT
DM4A92X	MA	Agonist
DM4A92X	RN	SDZ MRL 953, a lipid A analog as selective cytokine inducer. Prog Clin Biol Res. 1995;392:549-65.
DM4A92X	RU	https://pubmed.ncbi.nlm.nih.gov/8524963

DMXERCA	DI	DMXERCA
DMXERCA	DN	MS-377
DMXERCA	MI	TT5TPI6
DMXERCA	MN	Opioid receptor sigma 1 (OPRS1)
DMXERCA	MT	DTT
DMXERCA	MA	Antagonist
DMXERCA	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMXERCA	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMNYLEU	DI	DMNYLEU
DMNYLEU	DN	MSC-204
DMNYLEU	MI	TT84ETX
DMNYLEU	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMNYLEU	MT	DTT
DMNYLEU	MA	Modulator
DMNYLEU	RN	WO patent application no. 2004,0290,42, Pyrazole derivatives as reverse transcriptase inhibitors.
DMNYLEU	RU	http://www.google.com/patents/WO2004029042A1?cl=en

DMXW67H	DI	DMXW67H
DMXW67H	DN	MX-6120
DMXW67H	MI	TTKRD0G
DMXW67H	MN	Endothelin A receptor (EDNRA)
DMXW67H	MT	DTT
DMXW67H	MA	Antagonist
DMXW67H	RN	Endothelin receptor antagonists in heart failure: current status and future directions. Drugs. 2004;64(10):1029-40.
DMXW67H	RU	https://pubmed.ncbi.nlm.nih.gov/15139784

DMP26BW	DI	DMP26BW
DMP26BW	DN	MX-7065
DMP26BW	MI	TTLZS4Q
DMP26BW	MN	M-phase inducer phosphatase 1 (MPIP1)
DMP26BW	MT	DTT
DMP26BW	MA	Inhibitor
DMP26BW	RN	Handbook of Assay Development in Drug Discovery, Lisa K. Minor, 2013. Page(11).
DMP26BW	RU	https://books.google.com.hk/books?id=RmrLBQAAQBAJ&pg=PA11&lpg=PA11&dq=%22MX-7214%22+++Cdc25&source=bl&ots=un9o85IdEu&sig=UeS1s5P6-6iLhA8n-4L8xMrnpuo&hl=zh-CN&sa=X&ved=0CBoQ6AEwAGoVChMIxIXHkOHFyAIVRASOCh2thghY#v=onepage&q=%22MX-7214%22%20%20%20Cdc25&f=false

DMP26BW	DI	DMP26BW
DMP26BW	DN	MX-7065
DMP26BW	MI	TTR0SWN
DMP26BW	MN	M-phase inducer phosphatase 2 (MPIP2)
DMP26BW	MT	DTT
DMP26BW	MA	Inhibitor
DMP26BW	RN	Handbook of Assay Development in Drug Discovery, Lisa K. Minor, 2013. Page(11).
DMP26BW	RU	https://books.google.com.hk/books?id=RmrLBQAAQBAJ&pg=PA11&lpg=PA11&dq=%22MX-7214%22+++Cdc25&source=bl&ots=un9o85IdEu&sig=UeS1s5P6-6iLhA8n-4L8xMrnpuo&hl=zh-CN&sa=X&ved=0CBoQ6AEwAGoVChMIxIXHkOHFyAIVRASOCh2thghY#v=onepage&q=%22MX-7214%22%20%20%20Cdc25&f=false

DMP26BW	DI	DMP26BW
DMP26BW	DN	MX-7065
DMP26BW	MI	TTESBNC
DMP26BW	MN	M-phase inducer phosphatase 3 (MPIP3)
DMP26BW	MT	DTT
DMP26BW	MA	Inhibitor
DMP26BW	RN	Handbook of Assay Development in Drug Discovery, Lisa K. Minor, 2013. Page(11).
DMP26BW	RU	https://books.google.com.hk/books?id=RmrLBQAAQBAJ&pg=PA11&lpg=PA11&dq=%22MX-7214%22+++Cdc25&source=bl&ots=un9o85IdEu&sig=UeS1s5P6-6iLhA8n-4L8xMrnpuo&hl=zh-CN&sa=X&ved=0CBoQ6AEwAGoVChMIxIXHkOHFyAIVRASOCh2thghY#v=onepage&q=%22MX-7214%22%20%20%20Cdc25&f=false

DMNZ356	DI	DMNZ356
DMNZ356	DN	MX-781
DMNZ356	MI	TTOD7B3
DMNZ356	MN	Retinoic acid receptor (RAR)
DMNZ356	MT	DTT
DMNZ356	MA	Modulator
DMNZ356	RN	The retinoid antagonist MX781 induces clusterin expression in prostate cancer cells via heat shock factor-1 and activator protein-1 transcription factors. Cancer Res. 2004 Aug 15;64(16):5905-12.
DMNZ356	RU	https://pubmed.ncbi.nlm.nih.gov/15313936

DM31CV2	DI	DM31CV2
DM31CV2	DN	NAFAZATROM
DM31CV2	MI	TT2J34L
DM31CV2	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM31CV2	MT	DTT
DM31CV2	MA	Inhibitor
DM31CV2	RN	Design, synthesis, and 5-lipoxygenase-inhibiting properties of 1-thio-substituted butadienes. J Med Chem. 1990 Apr;33(4):1163-70.
DM31CV2	RU	https://pubmed.ncbi.nlm.nih.gov/2319562

DM7T2FO	DI	DM7T2FO
DM7T2FO	DN	Naltiazem hydrochloride
DM7T2FO	MI	TT5HONZ
DM7T2FO	MN	Calcium channel unspecific (CaC)
DM7T2FO	MT	DTT
DM7T2FO	MA	Blocker
DM7T2FO	RN	Assessment of hyperglycemia after calcium channel blocker overdoses involving diltiazem or verapamil. Crit Care Med. 2007 Sep;35(9):2071-5.
DM7T2FO	RU	https://pubmed.ncbi.nlm.nih.gov/17855820

DMML3J4	DI	DMML3J4
DMML3J4	DN	NAN-190
DMML3J4	MI	TTSQIFT
DMML3J4	MN	5-HT 1A receptor (HTR1A)
DMML3J4	MT	DTT
DMML3J4	MA	Antagonist
DMML3J4	RN	Influence of 5-HT1A receptor antagonism on plus-maze behaviour in mice. II. WAY 100635, SDZ 216-525 and NAN-190. Pharmacol Biochem Behav. 1997 Oct;58(2):593-603.
DMML3J4	RU	https://pubmed.ncbi.nlm.nih.gov/9300624

DM8FB6E	DI	DM8FB6E
DM8FB6E	DN	Navuridine
DM8FB6E	MI	TT84ETX
DM8FB6E	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM8FB6E	MT	DTT
DM8FB6E	MA	Inhibitor
DM8FB6E	RN	Synthesis and anti-human immunodeficiency virus (HIV-1) activity of 3'-deoxy-3'-(triazol-1-yl)thymidines and 2',3'-dideoxy-3'-(triazol-1-yl)uridines and inhibition of reverse transcriptase by their 5'-triphosphates. Chem Pharm Bull (Tokyo). 1990 Sep;38(9):2597-601.
DM8FB6E	RU	https://pubmed.ncbi.nlm.nih.gov/1704819

DMJVTQN	DI	DMJVTQN
DMJVTQN	DN	NB-598
DMJVTQN	MI	TTE14XG
DMJVTQN	MN	Squalene monooxygenase (SQLE)
DMJVTQN	MT	DTT
DMJVTQN	MA	Inhibitor
DMJVTQN	RN	Squalene epoxidase as hypocholesterolemic drug target revisited. Prog Lipid Res. 2003 Jan;42(1):37-50.
DMJVTQN	RU	https://pubmed.ncbi.nlm.nih.gov/12467639

DM3JY2N	DI	DM3JY2N
DM3JY2N	DN	NBI-37582
DM3JY2N	MI	TT7EFHR
DM3JY2N	MN	Corticotropin-releasing factor receptor 1 (CRHR1)
DM3JY2N	MT	DTT
DM3JY2N	MA	Antagonist
DM3JY2N	RN	CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
DM3JY2N	RU	http://www.centerwatch.com/

DMEH50J	DI	DMEH50J
DMEH50J	DN	NE-033
DMEH50J	MI	TT5TPI6
DMEH50J	MN	Opioid receptor sigma 1 (OPRS1)
DMEH50J	MT	DTT
DMEH50J	MA	Modulator
DMEH50J	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004064)
DMEH50J	RU	http://adisinsight.springer.com/drugs/800004064

DMP4J7T	DI	DMP4J7T
DMP4J7T	DN	NE-100
DMP4J7T	MI	TT5TPI6
DMP4J7T	MN	Opioid receptor sigma 1 (OPRS1)
DMP4J7T	MT	DTT
DMP4J7T	MA	Antagonist
DMP4J7T	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMP4J7T	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMHYQ8K	DI	DMHYQ8K
DMHYQ8K	DN	Nerve growth factor
DMHYQ8K	MI	TTDN3LF
DMHYQ8K	MN	Nerve growth factor (NGF)
DMHYQ8K	MT	DTT
DMHYQ8K	MA	Modulator
DMHYQ8K	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMHYQ8K	RU	https://www.fda.gov/

DMFA26E	DI	DMFA26E
DMFA26E	DN	NGD-93-1
DMFA26E	MI	TTEX248
DMFA26E	MN	Dopamine D2 receptor (D2R)
DMFA26E	MT	DTT
DMFA26E	MA	Modulator
DMFA26E	RN	Dopamine D4 receptors in human postmortem brain tissue of normal and schizophrenic subjects. An [3]NGD-94-1 study. Schizophrenia Research Volume 29, Issues 1-2, January 1998, Pages 93.
DMFA26E	RU	http://www.sciencedirect.com/science/article/pii/S0920996497885337

DMSPWMF	DI	DMSPWMF
DMSPWMF	DN	Niguldipine
DMSPWMF	MI	TTNGILX
DMSPWMF	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMSPWMF	MT	DTT
DMSPWMF	MA	Inhibitor
DMSPWMF	RN	Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
DMSPWMF	RU	https://pubmed.ncbi.nlm.nih.gov/7562902

DMSPWMF	DI	DMSPWMF
DMSPWMF	DN	Niguldipine
DMSPWMF	MI	TTBRKXS
DMSPWMF	MN	Adrenergic receptor alpha-1B (ADRA1B)
DMSPWMF	MT	DTT
DMSPWMF	MA	Inhibitor
DMSPWMF	RN	Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
DMSPWMF	RU	https://pubmed.ncbi.nlm.nih.gov/7562902

DMSPWMF	DI	DMSPWMF
DMSPWMF	DN	Niguldipine
DMSPWMF	MI	TT34BHT
DMSPWMF	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMSPWMF	MT	DTT
DMSPWMF	MA	Inhibitor
DMSPWMF	RN	Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
DMSPWMF	RU	https://pubmed.ncbi.nlm.nih.gov/7562902

DMSPWMF	DI	DMSPWMF
DMSPWMF	DN	Niguldipine
DMSPWMF	MI	DE4LYSA
DMSPWMF	MN	Cytochrome P450 3A4 (CYP3A4)
DMSPWMF	MT	DME
DMSPWMF	MA	Metabolism
DMSPWMF	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DMSPWMF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DMSPWMF	DI	DMSPWMF
DMSPWMF	DN	Niguldipine
DMSPWMF	MI	DTUGYRD
DMSPWMF	MN	P-glycoprotein 1 (ABCB1)
DMSPWMF	MT	DTP
DMSPWMF	MA	Substrate
DMSPWMF	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMSPWMF	RU	https://doi.org/10.1007/s11095-012-0935-x

DMSPWMF	DI	DMSPWMF
DMSPWMF	DN	Niguldipine
DMSPWMF	MI	TTZIFHC
DMSPWMF	MN	Voltage-gated calcium channel alpha Cav1.2 (CACNA1C)
DMSPWMF	MT	DTT
DMSPWMF	MA	Inhibitor
DMSPWMF	RN	Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
DMSPWMF	RU	https://pubmed.ncbi.nlm.nih.gov/7562902

DM4U7XB	DI	DM4U7XB
DM4U7XB	DN	NIK-616
DM4U7XB	MI	TTZ97H5
DM4U7XB	MN	Phosphodiesterase 4A (PDE4A)
DM4U7XB	MT	DTT
DM4U7XB	MA	Inhibitor
DM4U7XB	RN	Preclinical trials in Chronic obstructive pulmonary disease in Japan (PO). 2004
DM4U7XB	RU	http://adisinsight.springer.com/drugs/800020194

DM4U7XB	DI	DM4U7XB
DM4U7XB	DN	NIK-616
DM4U7XB	MI	TTVIAT9
DM4U7XB	MN	Phosphodiesterase 4B (PDE4B)
DM4U7XB	MT	DTT
DM4U7XB	MA	Inhibitor
DM4U7XB	RN	Preclinical trials in Chronic obstructive pulmonary disease in Japan (PO). 2004
DM4U7XB	RU	http://adisinsight.springer.com/drugs/800020194

DM4U7XB	DI	DM4U7XB
DM4U7XB	DN	NIK-616
DM4U7XB	MI	TTSKMI8
DM4U7XB	MN	Phosphodiesterase 4D (PDE4D)
DM4U7XB	MT	DTT
DM4U7XB	MA	Inhibitor
DM4U7XB	RN	Preclinical trials in Chronic obstructive pulmonary disease in Japan (PO). 2004
DM4U7XB	RU	http://adisinsight.springer.com/drugs/800020194

DMR1NMD	DI	DMR1NMD
DMR1NMD	DN	Nimesulide
DMR1NMD	MI	DE4LYSA
DMR1NMD	MN	Cytochrome P450 3A4 (CYP3A4)
DMR1NMD	MT	DME
DMR1NMD	MA	Metabolism
DMR1NMD	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DMR1NMD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DMR1NMD	DI	DMR1NMD
DMR1NMD	DN	Nimesulide
DMR1NMD	MI	TTSZDQU
DMR1NMD	MN	Lactotransferrin (LTF)
DMR1NMD	MT	DTT
DMR1NMD	MA	Inhibitor
DMR1NMD	RN	Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
DMR1NMD	RU	https://pubmed.ncbi.nlm.nih.gov/11752352

DMR1NMD	DI	DMR1NMD
DMR1NMD	DN	Nimesulide
DMR1NMD	MI	TTVKILB
DMR1NMD	MN	Prostaglandin G/H synthase 2 (COX-2)
DMR1NMD	MT	DTT
DMR1NMD	MA	Inhibitor
DMR1NMD	RN	Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
DMR1NMD	RU	https://pubmed.ncbi.nlm.nih.gov/11752352

DMR1NMD	DI	DMR1NMD
DMR1NMD	DN	Nimesulide
DMR1NMD	MI	TTA5MS9
DMR1NMD	MN	TNF related apoptosis inducing ligand (TNFSF10)
DMR1NMD	MT	DTT
DMR1NMD	MA	Modulator
DMR1NMD	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMR1NMD	RU	https://www.fda.gov/

DM5IFU9	DI	DM5IFU9
DM5IFU9	DN	NMI-1182
DM5IFU9	MI	TTK0943
DM5IFU9	MN	Prostaglandin G/H synthase (COX)
DM5IFU9	MT	DTT
DM5IFU9	MA	Inhibitor
DM5IFU9	RN	NMI-1182, a gastro-protective cyclo-oxygenase-inhibiting nitric oxide donor. Inflammopharmacology. 2005;12(5-6):521-34.
DM5IFU9	RU	https://pubmed.ncbi.nlm.nih.gov/16259719

DMX6DNZ	DI	DMX6DNZ
DMX6DNZ	DN	NMI-150
DMX6DNZ	MI	TTVKILB
DMX6DNZ	MN	Prostaglandin G/H synthase 2 (COX-2)
DMX6DNZ	MT	DTT
DMX6DNZ	MA	Inhibitor
DMX6DNZ	RN	Selective COX-2 Inhibitors: A Review of Their Structure-Activity Relationships. Iran J Pharm Res. 2011 Autumn; 10(4): 655-683.
DMX6DNZ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3813081/

DMPZ1EC	DI	DMPZ1EC
DMPZ1EC	DN	NNC 05-2045
DMPZ1EC	MI	TTV9MQG
DMPZ1EC	MN	Gamma-aminobutyric acid uptake (GABAU)
DMPZ1EC	MT	DTT
DMPZ1EC	MA	Inhibitor
DMPZ1EC	RN	GABA-level increasing and anticonvulsant effects of three different GABA uptake inhibitors. Neuropharmacology. 2000 Sep;39(12):2399-407.
DMPZ1EC	RU	https://pubmed.ncbi.nlm.nih.gov/10974324

DMGEHZ9	DI	DMGEHZ9
DMGEHZ9	DN	NNC-09-0026
DMGEHZ9	MI	TT5HONZ
DMGEHZ9	MN	Calcium channel unspecific (CaC)
DMGEHZ9	MT	DTT
DMGEHZ9	MA	Modulator
DMGEHZ9	RN	Pharmacological profile of a novel neuronal calcium channel blocker includes reduced cerebral damage and neurological deficits in rat focal ischemia. Pharmacol Biochem Behav. 1994 May;48(1):77-85.
DMGEHZ9	RU	https://pubmed.ncbi.nlm.nih.gov/8029306

DMMOAN0	DI	DMMOAN0
DMMOAN0	DN	NNC-13-8119
DMMOAN0	MI	TTPTXIN
DMMOAN0	MN	Translocator protein (TSPO)
DMMOAN0	MT	DTT
DMMOAN0	MA	Modulator
DMMOAN0	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004060)
DMMOAN0	RU	http://adisinsight.springer.com/drugs/800004060

DMK7BV9	DI	DMK7BV9
DMK7BV9	DN	NNC-22-0031
DMK7BV9	MI	TTZFYLI
DMK7BV9	MN	Dopamine D1 receptor (D1R)
DMK7BV9	MT	DTT
DMK7BV9	MA	Modulator
DMK7BV9	RN	NNC-19-1228 and NNC 22-0031, novel neuroleptics with a "mesolimbic-selective" behavioral profile. Psychopharmacology (Berl). 1997 Jan;129(2):168-78.
DMK7BV9	RU	https://pubmed.ncbi.nlm.nih.gov/9040123

DMK7BV9	DI	DMK7BV9
DMK7BV9	DN	NNC-22-0031
DMK7BV9	MI	TTEX248
DMK7BV9	MN	Dopamine D2 receptor (D2R)
DMK7BV9	MT	DTT
DMK7BV9	MA	Modulator
DMK7BV9	RN	NNC-19-1228 and NNC 22-0031, novel neuroleptics with a "mesolimbic-selective" behavioral profile. Psychopharmacology (Berl). 1997 Jan;129(2):168-78.
DMK7BV9	RU	https://pubmed.ncbi.nlm.nih.gov/9040123

DM0BYU2	DI	DM0BYU2
DM0BYU2	DN	NNC-252504
DM0BYU2	MI	TT9O6WS
DM0BYU2	MN	Glucagon receptor (GCGR)
DM0BYU2	MT	DTT
DM0BYU2	MA	Antagonist
DM0BYU2	RN	A novel glucagon receptor antagonist, NNC 25-0926, blunts hepatic glucose production in the conscious dog. J Pharmacol Exp Ther. 2007 May;321(2):743-52.
DM0BYU2	RU	https://pubmed.ncbi.nlm.nih.gov/17308040

DMLTYFI	DI	DMLTYFI
DMLTYFI	DN	NNC-26-0762
DMLTYFI	MI	TTG4R8V
DMLTYFI	MN	Growth hormone-releasing hormone receptor (GHRHR)
DMLTYFI	MT	DTT
DMLTYFI	MA	Agonist
DMLTYFI	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010046)
DMLTYFI	RU	http://adisinsight.springer.com/drugs/800010046

DM1SXG9	DI	DM1SXG9
DM1SXG9	DN	NNC-90-0270
DM1SXG9	MI	TTJSZTB
DM1SXG9	MN	Nicotinic acetylcholine receptor (nAChR)
DM1SXG9	MT	DTT
DM1SXG9	MA	Agonist
DM1SXG9	RN	Nicotinic agonists, antagonists, and modulators from natural sources. Cell Mol Neurobiol. 2005 Jun;25(3-4):513-52.
DM1SXG9	RU	https://pubmed.ncbi.nlm.nih.gov/16075378

DMX24FM	DI	DMX24FM
DMX24FM	DN	Nomifensine
DMX24FM	MI	DEBMX7C
DMX24FM	MN	Dimethylaniline oxidase 5 (FMO5)
DMX24FM	MT	DME
DMX24FM	MA	Metabolism
DMX24FM	RN	Drug metabolism by flavin-containing monooxygenases of human and mouse. Expert Opin Drug Metab Toxicol. 2017 Feb;13(2):167-181.
DMX24FM	RU	https://pubmed.ncbi.nlm.nih.gov/27678284

DM78P4X	DI	DM78P4X
DM78P4X	DN	NOX-200
DM78P4X	MI	TTB6H2S
DM78P4X	MN	Amino acid transporter ATB0+ (SLC6A14)
DM78P4X	MT	DTT
DM78P4X	MA	Inhibitor
DM78P4X	RN	Interaction of tryptophan derivatives with SLC6A14 (ATB0,+) reveals the potential of the transporter as a drug target for cancer chemotherapy. Biochem J. 2008 Sep 15;414(3):343-55.
DM78P4X	RU	https://pubmed.ncbi.nlm.nih.gov/18522536

DM78P4X	DI	DM78P4X
DM78P4X	DN	NOX-200
DM78P4X	MI	TT5U0XA
DM78P4X	MN	Solute carrier family 36 member 2 (SLC36A2)
DM78P4X	MT	DTT
DM78P4X	MA	Inhibitor
DM78P4X	RN	Amino acid derivatives are substrates or non-transported inhibitors of the amino acid transporter PAT2 (slc36a2). Biochim Biophys Acta. 2011 Jan;1808(1):260-70.
DM78P4X	RU	https://pubmed.ncbi.nlm.nih.gov/20691150

DM4B1VF	DI	DM4B1VF
DM4B1VF	DN	NP-7557
DM4B1VF	MI	TT1RS9F
DM4B1VF	MN	Acetylcholinesterase (AChE)
DM4B1VF	MT	DTT
DM4B1VF	MA	Inhibitor
DM4B1VF	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017551)
DM4B1VF	RU	http://adisinsight.springer.com/drugs/800017551

DM35RTJ	DI	DM35RTJ
DM35RTJ	DN	NPC-16377
DM35RTJ	MI	TT5TPI6
DM35RTJ	MN	Opioid receptor sigma 1 (OPRS1)
DM35RTJ	MT	DTT
DM35RTJ	MA	Modulator
DM35RTJ	RN	Effects of the selective sigma receptor ligand, 6-[6-(4-hydroxypiperidinyl)hexyloxy]-3-methylflavone (NPC 16377), on behavioral and toxic effects of cocaine. J Pharmacol Exp Ther. 1993 Aug;266(2):473-82.
DM35RTJ	RU	https://pubmed.ncbi.nlm.nih.gov/8355185

DMGVIZY	DI	DMGVIZY
DMGVIZY	DN	NPC-17731
DMGVIZY	MI	TTGY8IW
DMGVIZY	MN	B2 bradykinin receptor (BDKRB2)
DMGVIZY	MT	DTT
DMGVIZY	MA	Antagonist
DMGVIZY	RN	Antinociceptive profile of the pseudopeptide B2 bradykinin receptor antagonist NPC 18688 in mice. Br J Pharmacol. 1996 Feb;117(3):552-558.
DMGVIZY	RU	https://pubmed.ncbi.nlm.nih.gov/8821548

DMD01GK	DI	DMD01GK
DMD01GK	DN	NPC-17923
DMD01GK	MI	TTD26RC
DMD01GK	MN	Cell adhesion molecule (CADM)
DMD01GK	MT	DTT
DMD01GK	MA	Modulator
DMD01GK	RN	Inhibition of platelet-activating factor-induced leukocyte adhesion in vivo by a leumedin. Eur J Pharmacol. 1993 Mar 2;232(2-3):169-72.
DMD01GK	RU	https://pubmed.ncbi.nlm.nih.gov/8467855

DMAIH90	DI	DMAIH90
DMAIH90	DN	NPC-18166
DMAIH90	MI	TTYSN63
DMAIH90	MN	5-HT 2 receptor (5HT2R)
DMAIH90	MT	DTT
DMAIH90	MA	Modulator
DMAIH90	RN	WO patent application no. 2004,0825,84, 5ht2c receptor antagonists in the treatment of schizophrenia.
DMAIH90	RU	http://www.google.nl/patents/WO2004082584A2?cl=en

DMH1YL8	DI	DMH1YL8
DMH1YL8	DN	NPI-1999
DMH1YL8	MI	TTEMV5X
DMH1YL8	MN	Serine protease unspecific (SP)
DMH1YL8	MT	DTT
DMH1YL8	MA	Inhibitor
DMH1YL8	RN	US patent application no. 2005,0096,323, Diketopiperazine derivatives to inhibit thrombin.
DMH1YL8	RU	http://www.google.com/patents/US20050096323

DMTWXE3	DI	DMTWXE3
DMTWXE3	DN	NPS-1392
DMTWXE3	MI	TT9IK2Z
DMTWXE3	MN	N-methyl-D-aspartate receptor (NMDAR)
DMTWXE3	MT	DTT
DMTWXE3	MA	Antagonist
DMTWXE3	RN	Synthesis, biological activity, and absolute stereochemical assignment of NPS 1392: a potent and stereoselective NMDA receptor antagonist. Bioorg Med Chem Lett. 1999 Jul 19;9(14):1915-20.
DMTWXE3	RU	https://pubmed.ncbi.nlm.nih.gov/10450953

DMNL1VM	DI	DMNL1VM
DMNL1VM	DN	NPS-846
DMNL1VM	MI	TTDXZ24
DMNL1VM	MN	Glutamate receptor ionotropic (GRI)
DMNL1VM	MT	DTT
DMNL1VM	MA	Modulator
DMNL1VM	RN	Neuroprotective effects of NPS 846, a novel N-methyl-D-aspartate receptor antagonist, after closed head trauma in rats. J Neurosurg. 1998 Jun;88(6):1066-74.
DMNL1VM	RU	https://pubmed.ncbi.nlm.nih.gov/9609302

DMCHLJ4	DI	DMCHLJ4
DMCHLJ4	DN	NS-004
DMCHLJ4	MI	TT1VOHK
DMCHLJ4	MN	Potassium channel unspecific (KC)
DMCHLJ4	MT	DTT
DMCHLJ4	MA	Opener
DMCHLJ4	RN	Effects of K+ channel inhibitors and antagonists on NS-004 evoked relaxations in guinea-pig isolated trachea. Fundam Clin Pharmacol. 1997;11(1):78-82.
DMCHLJ4	RU	https://pubmed.ncbi.nlm.nih.gov/9182080

DM75DZ1	DI	DM75DZ1
DM75DZ1	DN	NS-1546
DM75DZ1	MI	TT1VOHK
DM75DZ1	MN	Potassium channel unspecific (KC)
DM75DZ1	MT	DTT
DM75DZ1	MA	Opener
DM75DZ1	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006187)
DM75DZ1	RU	http://adisinsight.springer.com/drugs/800006187

DMYV9M1	DI	DMYV9M1
DMYV9M1	DN	NS-1608
DMYV9M1	MI	TT1VOHK
DMYV9M1	MN	Potassium channel unspecific (KC)
DMYV9M1	MT	DTT
DMYV9M1	MA	Opener
DMYV9M1	RN	Modulation of the Ca(2+)-dependent K+ channel, hslo, by the substituted diphenylurea NS 1608, paxilline and internal Ca2+. Neuropharmacology. 1996;35(7):903-14.
DMYV9M1	RU	https://pubmed.ncbi.nlm.nih.gov/8938721

DMES0OT	DI	DMES0OT
DMES0OT	DN	NS-1619
DMES0OT	MI	TT1AQ50
DMES0OT	MN	Charybdotoxin receptor beta-4 (BKbeta4)
DMES0OT	MT	DTT
DMES0OT	MA	Modulator
DMES0OT	RN	BK channel activation by NS-1619 is partially mediated by intracellular Ca2+ release in smooth muscle cells of porcine coronary artery
DMES0OT	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1572625

DM9F81Z	DI	DM9F81Z
DM9F81Z	DN	NS-257
DM9F81Z	MI	TTAN6JD
DM9F81Z	MN	Glutamate receptor AMPA (GRIA)
DM9F81Z	MT	DTT
DM9F81Z	MA	Antagonist
DM9F81Z	RN	Characterization of the binding of [3H]NS 257, a novel competitive AMPA receptor antagonist, to rat brain membranes and brain sections. J Neurochem. 1995 Sep;65(3):1264-73.
DM9F81Z	RU	https://pubmed.ncbi.nlm.nih.gov/7543932

DM19OGY	DI	DM19OGY
DM19OGY	DN	NS-2979
DM19OGY	MI	TTPTXIN
DM19OGY	MN	Translocator protein (TSPO)
DM19OGY	MT	DTT
DM19OGY	MA	Modulator
DM19OGY	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013494)
DM19OGY	RU	http://adisinsight.springer.com/drugs/800013494

DM2MU98	DI	DM2MU98
DM2MU98	DN	NS-377
DM2MU98	MI	TTAN6JD
DM2MU98	MN	Glutamate receptor AMPA (GRIA)
DM2MU98	MT	DTT
DM2MU98	MA	Antagonist
DM2MU98	RN	In vivo and in vitro evaluation of AMPA receptor antagonists in rat hippocampal neurones and cultured mouse cortical neurones. Eur J Pharmacol. 1998 Jul 24;353(2-3):159-67.
DM2MU98	RU	https://pubmed.ncbi.nlm.nih.gov/9726646

DMINUWH	DI	DMINUWH
DMINUWH	DN	NS398
DMINUWH	MI	TTVKILB
DMINUWH	MN	Prostaglandin G/H synthase 2 (COX-2)
DMINUWH	MT	DTT
DMINUWH	MA	Inhibitor
DMINUWH	RN	New drugs in development for the treatment of endometriosis. Expert Opin Investig Drugs. 2008 Aug;17(8):1187-202.
DMINUWH	RU	https://pubmed.ncbi.nlm.nih.gov/18616415

DMPT74G	DI	DMPT74G
DMPT74G	DN	NS-638
DMPT74G	MI	TT5HONZ
DMPT74G	MN	Calcium channel unspecific (CaC)
DMPT74G	MT	DTT
DMPT74G	MA	Modulator
DMPT74G	RN	Pharmacological profile and anti-ischemic properties of the Ca(2+)-channel blocker NS-638. Neurol Res. 1995 Oct;17(5):353-60.
DMPT74G	RU	https://pubmed.ncbi.nlm.nih.gov/8584126

DMXKMRV	DI	DMXKMRV
DMXKMRV	DN	NS-649
DMXKMRV	MI	TT5HONZ
DMXKMRV	MN	Calcium channel unspecific (CaC)
DMXKMRV	MT	DTT
DMXKMRV	MA	Modulator
DMXKMRV	RN	Effects of Ca2+ and Na+ channel inhibitors in vitro and in global cerebral ischaemia in vivo. Eur J Pharmacol. 1997 Aug 6;332(2):121-31.
DMXKMRV	RU	https://pubmed.ncbi.nlm.nih.gov/9286613

DMI46T3	DI	DMI46T3
DMI46T3	DN	NS-696
DMI46T3	MI	TT5HONZ
DMI46T3	MN	Calcium channel unspecific (CaC)
DMI46T3	MT	DTT
DMI46T3	MA	Modulator
DMI46T3	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005355)
DMI46T3	RU	http://adisinsight.springer.com/drugs/800005355

DMEYMHB	DI	DMEYMHB
DMEYMHB	DN	NSC-303812
DMEYMHB	MI	DE4LYSA
DMEYMHB	MN	Cytochrome P450 3A4 (CYP3A4)
DMEYMHB	MT	DME
DMEYMHB	MA	Metabolism
DMEYMHB	RN	The mechanism of aphidicolin bioinactivation by rat liver in vitro systems. Xenobiotica. 1990 Mar;20(3):273-87.
DMEYMHB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=2110702

DMDJT7U	DI	DMDJT7U
DMDJT7U	DN	NSC-661755
DMDJT7U	MI	TT12ABZ
DMDJT7U	MN	Arachidonate 12-lipoxygenase (12-LOX)
DMDJT7U	MT	DTT
DMDJT7U	MA	Inhibitor
DMDJT7U	RN	Discovery of platelet-type 12-human lipoxygenase selective inhibitors by high-throughput screening of structurally diverse libraries. Bioorg Med Chem. 2007 Nov 15;15(22):6900-8.
DMDJT7U	RU	https://pubmed.ncbi.nlm.nih.gov/17826100

DMDJT7U	DI	DMDJT7U
DMDJT7U	DN	NSC-661755
DMDJT7U	MI	TTN9T81
DMDJT7U	MN	Arachidonate 15-lipoxygenase (15-LOX)
DMDJT7U	MT	DTT
DMDJT7U	MA	Inhibitor
DMDJT7U	RN	Discovery of platelet-type 12-human lipoxygenase selective inhibitors by high-throughput screening of structurally diverse libraries. Bioorg Med Chem. 2007 Nov 15;15(22):6900-8.
DMDJT7U	RU	https://pubmed.ncbi.nlm.nih.gov/17826100

DMF2XMA	DI	DMF2XMA
DMF2XMA	DN	NSD-721
DMF2XMA	MI	TTEX6LM
DMF2XMA	MN	GABA(A) receptor gamma-3 (GABRG3)
DMF2XMA	MT	DTT
DMF2XMA	MA	Modulator
DMF2XMA	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415).
DMF2XMA	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415

DMPG703	DI	DMPG703
DMPG703	DN	NSL-036
DMPG703	MI	TTU593I
DMPG703	MN	Neurokinin receptor (NKR)
DMPG703	MT	DTT
DMPG703	MA	Antagonist
DMPG703	RN	US patent application no. 2008,0039,404, Bifunctional analgesic compounds for opioid receptor agonists and neurokinin-1 receptor antagonists.
DMPG703	RU	http://www.google.com/patents/US20080039404

DMU3D1K	DI	DMU3D1K
DMU3D1K	DN	NTE-122
DMU3D1K	MI	TTMF541
DMU3D1K	MN	Liver carboxylesterase (CES1)
DMU3D1K	MT	DTT
DMU3D1K	MA	Inhibitor
DMU3D1K	RN	Cholesterol-lowering effects of NTE-122, a novel acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor, on cholesterol diet-fed rats and rabbits. Jpn J Pharmacol. 1998 Nov;78(3):355-64.
DMU3D1K	RU	https://pubmed.ncbi.nlm.nih.gov/9869270

DMPA8WO	DI	DMPA8WO
DMPA8WO	DN	NU1025
DMPA8WO	MI	TTVDSZ0
DMPA8WO	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMPA8WO	MT	DTT
DMPA8WO	MA	Inhibitor
DMPA8WO	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMPA8WO	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMINSRW	DI	DMINSRW
DMINSRW	DN	NZ-1002
DMINSRW	MI	TT3C1VN
DMINSRW	MN	Enzyme unspecific (Enz)
DMINSRW	MT	DTT
DMINSRW	MA	Modulator
DMINSRW	RN	Expression of a cytokinin synthesis gene from Agrobacterium tumefaciens T-DNA in basket willow (Salix viminalis). Physiologia Plantarum Volume 88, Issue 3, pages 439-445, July 1993.
DMINSRW	RU	http://onlinelibrary.wiley.com/doi/10.1111/j.1399-3054.1993.tb01357.x/abstract?userIsAuthenticated=false&deniedAccessCustomisedMessage=

DMNAFG1	DI	DMNAFG1
DMNAFG1	DN	Olomoucine
DMNAFG1	MI	TTH6V3D
DMNAFG1	MN	Cyclin-dependent kinase 1 (CDK1)
DMNAFG1	MT	DTT
DMNAFG1	MA	Binder
DMNAFG1	RN	Antiproliferative activity of olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor. Cell Mol Life Sci. 2005 Aug;62(15):1763-71.
DMNAFG1	RU	https://pubmed.ncbi.nlm.nih.gov/16003486

DMNAFG1	DI	DMNAFG1
DMNAFG1	DN	Olomoucine
DMNAFG1	MI	TT7HF4W
DMNAFG1	MN	Cyclin-dependent kinase 2 (CDK2)
DMNAFG1	MT	DTT
DMNAFG1	MA	Inhibitor
DMNAFG1	RN	Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
DMNAFG1	RU	https://pubmed.ncbi.nlm.nih.gov/12237154

DMNAFG1	DI	DMNAFG1
DMNAFG1	DN	Olomoucine
DMNAFG1	MI	TTL4Q97
DMNAFG1	MN	Cyclin-dependent kinase 5 (CDK5)
DMNAFG1	MT	DTT
DMNAFG1	MA	Inhibitor
DMNAFG1	RN	Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
DMNAFG1	RU	https://pubmed.ncbi.nlm.nih.gov/12237154

DMAGUY0	DI	DMAGUY0
DMAGUY0	DN	Omapatrilat
DMAGUY0	MI	TTL69WB
DMAGUY0	MN	Angiotensin-converting enzyme (ACE)
DMAGUY0	MT	DTT
DMAGUY0	MA	Modulator
DMAGUY0	RN	Omapatrilat, a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, prevents fatty streak deposit in apolipoprotein E-deficient mice. Atherosclerosis. 2001 Apr;155(2):291-5.
DMAGUY0	RU	https://pubmed.ncbi.nlm.nih.gov/11254898

DMAGUY0	DI	DMAGUY0
DMAGUY0	DN	Omapatrilat
DMAGUY0	MI	TT5TKPM
DMAGUY0	MN	Neutral endopeptidase (MME)
DMAGUY0	MT	DTT
DMAGUY0	MA	Modulator
DMAGUY0	RN	Omapatrilat, a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, prevents fatty streak deposit in apolipoprotein E-deficient mice. Atherosclerosis. 2001 Apr;155(2):291-5.
DMAGUY0	RU	https://pubmed.ncbi.nlm.nih.gov/11254898

DMSKAGP	DI	DMSKAGP
DMSKAGP	DN	Omniferon
DMSKAGP	MI	TTV2CN0
DMSKAGP	MN	Interferon receptor (IFNR)
DMSKAGP	MT	DTT
DMSKAGP	MA	Modulator
DMSKAGP	RN	US patent application no. 2004,0229,936, Treatment of hepatitis c virus infection with sesquiterpene lactones.
DMSKAGP	RU	http://www.google.co.ve/patents/US20040229936

DMMLXRG	DI	DMMLXRG
DMMLXRG	DN	ON-09300
DMMLXRG	MI	TTVKILB
DMMLXRG	MN	Prostaglandin G/H synthase 2 (COX-2)
DMMLXRG	MT	DTT
DMMLXRG	MA	Modulator
DMMLXRG	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMMLXRG	RU	https://www.fda.gov/

DMTS6HB	DI	DMTS6HB
DMTS6HB	DN	ON-579
DMTS6HB	MI	TT2O84V
DMTS6HB	MN	Thromboxane A2 receptor (TBXA2R)
DMTS6HB	MT	DTT
DMTS6HB	MA	Modulator
DMTS6HB	RN	The effect of a TXA2 receptor antagonist ON-579 on experimental allergic reactions. Prostaglandins Leukot Essent Fatty Acids. 1995 Aug;53(2):123-33.
DMTS6HB	RU	https://pubmed.ncbi.nlm.nih.gov/7480074

DMBDCL4	DI	DMBDCL4
DMBDCL4	DN	ONO-8130
DMBDCL4	MI	TTG1QMU
DMBDCL4	MN	Prostaglandin E2 receptor EP1 (PTGER1)
DMBDCL4	MT	DTT
DMBDCL4	MA	Modulator
DMBDCL4	RN	ONO-8130, a selective prostanoid EP1 receptor antagonist, relieves bladder pain in mice with cyclophosphamide-induced cystitis. Pain. 2011 Jun;152(6):1373-81.
DMBDCL4	RU	https://pubmed.ncbi.nlm.nih.gov/21396778

DM2VRK7	DI	DM2VRK7
DM2VRK7	DN	ONO-8711
DM2VRK7	MI	TTG1QMU
DM2VRK7	MN	Prostaglandin E2 receptor EP1 (PTGER1)
DM2VRK7	MT	DTT
DM2VRK7	MA	Antagonist
DM2VRK7	RN	Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development. Carcinogenesis. 2001 Dec;22(12):2001-4.
DM2VRK7	RU	https://pubmed.ncbi.nlm.nih.gov/11751431

DM4CVEG	DI	DM4CVEG
DM4CVEG	DN	ONO-8815Ly
DM4CVEG	MI	TT1ZAVI
DM4CVEG	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DM4CVEG	MT	DTT
DM4CVEG	MA	Agonist
DM4CVEG	RN	Prostaglandin E2 receptor type 2-selective agonist prevents the degeneration of articular cartilage in rabbit knees with traumatic instability. Arthritis Res Ther. 2011;13(5):R146.
DM4CVEG	RU	https://pubmed.ncbi.nlm.nih.gov/21914215

DMW68CE	DI	DMW68CE
DMW68CE	DN	Oral insulin
DMW68CE	MI	TTZOPHG
DMW68CE	MN	Insulin (INS)
DMW68CE	MT	DTT
DMW68CE	MA	Modulator
DMW68CE	RN	ClinicalTrials.gov (NCT01120912) Safety and Efficacy of Single Administration of Oshadi Oral Insulin in Type I Diabetes Patients. U.S. National Institutes of Health.
DMW68CE	RU	https://clinicaltrials.gov/ct2/show/NCT01120912

DMUGC2X	DI	DMUGC2X
DMUGC2X	DN	Org-10490
DMUGC2X	MI	TTZFYLI
DMUGC2X	MN	Dopamine D1 receptor (D1R)
DMUGC2X	MT	DTT
DMUGC2X	MA	Modulator
DMUGC2X	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMUGC2X	RU	https://www.fda.gov/

DMUGC2X	DI	DMUGC2X
DMUGC2X	DN	Org-10490
DMUGC2X	MI	TTEX248
DMUGC2X	MN	Dopamine D2 receptor (D2R)
DMUGC2X	MT	DTT
DMUGC2X	MA	Modulator
DMUGC2X	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMUGC2X	RU	https://www.fda.gov/

DMQU8AR	DI	DMQU8AR
DMQU8AR	DN	Org-20599
DMQU8AR	MI	TTGXH6N
DMQU8AR	MN	GABA(A) receptor delta (GABRD)
DMQU8AR	MT	DTT
DMQU8AR	MA	Modulator
DMQU8AR	RN	The anaesthetic action and modulation of GABAA receptor activity by the novel water-soluble aminosteroid Org 20599. Neuropharmacology. 1996;35(9-10):1209-22.
DMQU8AR	RU	https://pubmed.ncbi.nlm.nih.gov/9014136

DM95QG2	DI	DM95QG2
DM95QG2	DN	Org-20781
DM95QG2	MI	TT1VOHK
DM95QG2	MN	Potassium channel unspecific (KC)
DM95QG2	MT	DTT
DM95QG2	MA	Opener
DM95QG2	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003350)
DM95QG2	RU	http://adisinsight.springer.com/drugs/800003350

DMMA92L	DI	DMMA92L
DMMA92L	DN	Org-30035
DMMA92L	MI	TTN4QDT
DMMA92L	MN	Opioid receptor (OPR)
DMMA92L	MT	DTT
DMMA92L	MA	Modulator
DMMA92L	RN	WO patent application no. 2010,0332,07, Polymer conjugates of therapeutic peptides.
DMMA92L	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20100325&CC=WO&NR=2010033207A1&KC=A1

DM3VWZF	DI	DM3VWZF
DM3VWZF	DN	Org-34092
DM3VWZF	MI	TT6L509
DM3VWZF	MN	Coagulation factor IIa (F2)
DM3VWZF	MT	DTT
DM3VWZF	MA	Inhibitor
DM3VWZF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362).
DM3VWZF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2362

DMB0IQT	DI	DMB0IQT
DMB0IQT	DN	Org-34116
DMB0IQT	MI	TTYRL6O
DMB0IQT	MN	Glucocorticoid receptor (NR3C1)
DMB0IQT	MT	DTT
DMB0IQT	MA	Antagonist
DMB0IQT	RN	Blockade of glucocorticoid receptors with ORG 34116 does not normalize stress-induced symptoms in male tree shrews. Eur J Pharmacol. 2002 Dec 20;457(2-3):207-16.
DMB0IQT	RU	https://pubmed.ncbi.nlm.nih.gov/12464368

DMY3LXH	DI	DMY3LXH
DMY3LXH	DN	Org-37684
DMY3LXH	MI	TTWJBZ5
DMY3LXH	MN	5-HT 2C receptor (HTR2C)
DMY3LXH	MT	DTT
DMY3LXH	MA	Agonist
DMY3LXH	RN	Role of 5-hT2C receptors in the hypophagic effect of m-CPP, ORG 37684 and CP-94,253 in the rat. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Apr;26(3):441-9.
DMY3LXH	RU	https://pubmed.ncbi.nlm.nih.gov/11999893

DMRZCH4	DI	DMRZCH4
DMRZCH4	DN	Org-9935
DMRZCH4	MI	TTZCG4L
DMRZCH4	MN	Phosphodiesterase 3 (PDE3)
DMRZCH4	MT	DTT
DMRZCH4	MA	Modulator
DMRZCH4	RN	The phosphodiesterase 3 inhibitor ORG 9935 inhibits oocyte maturation in the naturally selected dominant follicle in rhesus macaques.Contraception.2008 Apr;77(4):303-7.
DMRZCH4	RU	https://www.ncbi.nlm.nih.gov/pubmed/18342656

DM9YOMX	DI	DM9YOMX
DM9YOMX	DN	OT-4003
DM9YOMX	MI	TTGKOY9
DM9YOMX	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DM9YOMX	MT	DTT
DM9YOMX	MA	Modulator
DM9YOMX	RN	Discovery of OT4003, a novel, potent, and orally active cys-LT1 receptor antagonist. Bioorg Med Chem. 1997 Feb;5(2):415-27.
DM9YOMX	RU	https://pubmed.ncbi.nlm.nih.gov/9061206

DMESWV1	DI	DMESWV1
DMESWV1	DN	OX-23
DMESWV1	MI	TTN4QDT
DMESWV1	MN	Opioid receptor (OPR)
DMESWV1	MT	DTT
DMESWV1	RN	CA patent application no. 212323, Method for improving gastrointestinal motility.
DMESWV1	RU	http://www.google.com/patents/CA1212323A1?cl=en

DMVPG1N	DI	DMVPG1N
DMVPG1N	DN	OX-30
DMVPG1N	MI	TTUS45N
DMVPG1N	MN	Leukocyte common antigen (PTPRC)
DMVPG1N	MT	DTT
DMVPG1N	RN	CD45 / PTPRC Antibody, Biotin conjugate (OX-30).
DMVPG1N	RU	http://www.thermofisher.com/order/genome-database/details/antibody/MA5-17376.html

DM1TG3C	DI	DM1TG3C
DM1TG3C	DN	Oxamflatin
DM1TG3C	MI	TT6R7JZ
DM1TG3C	MN	Histone deacetylase 1 (HDAC1)
DM1TG3C	MT	DTT
DM1TG3C	MA	Inhibitor
DM1TG3C	RN	Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92.
DM1TG3C	RU	https://pubmed.ncbi.nlm.nih.gov/17896917

DMLKQUR	DI	DMLKQUR
DMLKQUR	DN	Palinavir
DMLKQUR	MI	TT5FNQT
DMLKQUR	MN	Human immunodeficiency virus Protease (HIV PR)
DMLKQUR	MT	DTT
DMLKQUR	MA	Modulator
DMLKQUR	RN	Antiviral properties of palinavir, a potent inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother. 1997 May;41(5):965-71.
DMLKQUR	RU	https://pubmed.ncbi.nlm.nih.gov/9145853

DM6HBQJ	DI	DM6HBQJ
DM6HBQJ	DN	Patamostat
DM6HBQJ	MI	TT2WR1T
DM6HBQJ	MN	Cationic trypsinogen (PRSS1)
DM6HBQJ	MT	DTT
DM6HBQJ	MA	Modulator
DM6HBQJ	RN	US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT.
DM6HBQJ	RU	http://www.patentbuddy.com/Patent/20120251516?ft=true&sr=true

DMWD1RC	DI	DMWD1RC
DMWD1RC	DN	PBI-1101
DMWD1RC	MI	TT3NKIB
DMWD1RC	MN	Pancreatic elastase 1 (CELA1)
DMWD1RC	MT	DTT
DMWD1RC	MA	Inhibitor
DMWD1RC	RN	CN patent application no. 1813706, Use of elastic protease inhibitor for preparing medicine for protecting cerebral hemorrhage.
DMWD1RC	RU	http://www.google.com/patents/CN1813706A?cl=en

DMWYP86	DI	DMWYP86
DMWYP86	DN	PD-0183812
DMWYP86	MI	TTAMQ62
DMWYP86	MN	Cyclin A2 (CCNA2)
DMWYP86	MT	DTT
DMWYP86	MA	Inhibitor
DMWYP86	RN	Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J Med Chem. 2000 Nov 30;43(24):4606-16.
DMWYP86	RU	https://pubmed.ncbi.nlm.nih.gov/11101352

DMWYP86	DI	DMWYP86
DMWYP86	DN	PD-0183812
DMWYP86	MI	TT7HF4W
DMWYP86	MN	Cyclin-dependent kinase 2 (CDK2)
DMWYP86	MT	DTT
DMWYP86	MA	Inhibitor
DMWYP86	RN	Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J Med Chem. 2000 Nov 30;43(24):4606-16.
DMWYP86	RU	https://pubmed.ncbi.nlm.nih.gov/11101352

DMWYP86	DI	DMWYP86
DMWYP86	DN	PD-0183812
DMWYP86	MI	TT0PG8F
DMWYP86	MN	Cyclin-dependent kinase 4 (CDK4)
DMWYP86	MT	DTT
DMWYP86	MA	Inhibitor
DMWYP86	RN	Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
DMWYP86	RU	https://pubmed.ncbi.nlm.nih.gov/12237154

DMWYP86	DI	DMWYP86
DMWYP86	DN	PD-0183812
DMWYP86	MI	TTO0FDJ
DMWYP86	MN	Cyclin-dependent kinase 6 (CDK6)
DMWYP86	MT	DTT
DMWYP86	MA	Inhibitor
DMWYP86	RN	Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
DMWYP86	RU	https://pubmed.ncbi.nlm.nih.gov/12237154

DMWYP86	DI	DMWYP86
DMWYP86	DN	PD-0183812
DMWYP86	MI	TT1KX2S
DMWYP86	MN	FGFR4 messenger RNA (FGFR4 mRNA)
DMWYP86	MT	DTT
DMWYP86	MA	Inhibitor
DMWYP86	RN	Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J Med Chem. 2000 Nov 30;43(24):4606-16.
DMWYP86	RU	https://pubmed.ncbi.nlm.nih.gov/11101352

DMWYP86	DI	DMWYP86
DMWYP86	DN	PD-0183812
DMWYP86	MI	TTRLW2X
DMWYP86	MN	Fibroblast growth factor receptor 1 (FGFR1)
DMWYP86	MT	DTT
DMWYP86	MA	Inhibitor
DMWYP86	RN	Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J Med Chem. 2000 Nov 30;43(24):4606-16.
DMWYP86	RU	https://pubmed.ncbi.nlm.nih.gov/11101352

DMWYP86	DI	DMWYP86
DMWYP86	DN	PD-0183812
DMWYP86	MI	TTGJVQM
DMWYP86	MN	Fibroblast growth factor receptor 2 (FGFR2)
DMWYP86	MT	DTT
DMWYP86	MA	Inhibitor
DMWYP86	RN	Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J Med Chem. 2000 Nov 30;43(24):4606-16.
DMWYP86	RU	https://pubmed.ncbi.nlm.nih.gov/11101352

DMWYP86	DI	DMWYP86
DMWYP86	DN	PD-0183812
DMWYP86	MI	TTST7KB
DMWYP86	MN	Fibroblast growth factor receptor 3 (FGFR3)
DMWYP86	MT	DTT
DMWYP86	MA	Inhibitor
DMWYP86	RN	Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J Med Chem. 2000 Nov 30;43(24):4606-16.
DMWYP86	RU	https://pubmed.ncbi.nlm.nih.gov/11101352

DMWYP86	DI	DMWYP86
DMWYP86	DN	PD-0183812
DMWYP86	MI	TTCEJ4F
DMWYP86	MN	G1/S-specific cyclin-E1 (CCNE1)
DMWYP86	MT	DTT
DMWYP86	MA	Inhibitor
DMWYP86	RN	Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J Med Chem. 2000 Nov 30;43(24):4606-16.
DMWYP86	RU	https://pubmed.ncbi.nlm.nih.gov/11101352

DMGKVPH	DI	DMGKVPH
DMGKVPH	DN	PD-0204318
DMGKVPH	MI	TT4FDG6
DMGKVPH	MN	Voltage-gated calcium channel alpha Cav2.2 (CACNA1B)
DMGKVPH	MT	DTT
DMGKVPH	MA	Antagonist
DMGKVPH	RN	US patent application no. 2012,0172,429, Permanently charged sodium and calcium channel blockers as anti- inflammatory agents.
DMGKVPH	RU	http://www.google.com/Patents/US20120172429

DMN1A70	DI	DMN1A70
DMN1A70	DN	PD-117596
DMN1A70	MI	TTN6J5F
DMN1A70	MN	Bacterial DNA gyrase (Bact gyrase)
DMN1A70	MT	DTT
DMN1A70	MA	Modulator
DMN1A70	RN	In vitro antibacterial activities of the fluoroquinolones PD 117596, PD 124816, and PD 127391. Diagn Microbiol Infect Dis. 1991 May-Jun;14(3):245-58.
DMN1A70	RU	https://www.ncbi.nlm.nih.gov/pubmed/1889177

DM92VUF	DI	DM92VUF
DM92VUF	DN	PD-123319
DM92VUF	MI	TTQVOEI
DM92VUF	MN	Angiotensin II receptor type-2 (AGTR2)
DM92VUF	MT	DTT
DM92VUF	MA	Inhibitor
DM92VUF	RN	Synthesis and structure-activity relationships of a novel series of non-peptide angiotensin II receptor binding inhibitors specific for the AT2 sub... J Med Chem. 1991 Nov;34(11):3248-60.
DM92VUF	RU	https://pubmed.ncbi.nlm.nih.gov/1956044

DM0YXRQ	DI	DM0YXRQ
DM0YXRQ	DN	PD-128483
DM0YXRQ	MI	TTEX248
DM0YXRQ	MN	Dopamine D2 receptor (D2R)
DM0YXRQ	MT	DTT
DM0YXRQ	MA	Inhibitor
DM0YXRQ	RN	Synthesis and pharmacological evaluation of the enantiomers of the dopamine autoreceptor agonist PD 135385, Bioorg. Med. Chem. Lett. 3(4):639-644 (1993).
DM0YXRQ	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01812452

DMLEVNC	DI	DMLEVNC
DMLEVNC	DN	PD-135666
DMLEVNC	MI	TTCG0AL
DMLEVNC	MN	Cholecystokinin receptor type A (CCKAR)
DMLEVNC	MT	DTT
DMLEVNC	MA	Inhibitor
DMLEVNC	RN	Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class, Bioorg. Med. Chem. Lett. 3(5):881-884 (1993).
DMLEVNC	RU	http://www.sciencedirect.com/science/article/pii/S0960894X0080685X

DMLEVNC	DI	DMLEVNC
DMLEVNC	DN	PD-135666
DMLEVNC	MI	TTVFO0U
DMLEVNC	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMLEVNC	MT	DTT
DMLEVNC	MA	Inhibitor
DMLEVNC	RN	Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class, Bioorg. Med. Chem. Lett. 3(5):881-884 (1993).
DMLEVNC	RU	http://www.sciencedirect.com/science/article/pii/S0960894X0080685X

DMD6L82	DI	DMD6L82
DMD6L82	DN	PD136450
DMD6L82	MI	TTVFO0U
DMD6L82	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMD6L82	MT	DTT
DMD6L82	MA	Antagonist
DMD6L82	RN	Cholecystokinin type B receptor antagonist PD-136,450 is a partial secretory agonist in the stomach and a full agonist in the pancreas of the rat. Gut. 1994 Feb;35(2):270-4.
DMD6L82	RU	https://pubmed.ncbi.nlm.nih.gov/8307482

DMFA27N	DI	DMFA27N
DMFA27N	DN	PD142893
DMFA27N	MI	TTKRD0G
DMFA27N	MN	Endothelin A receptor (EDNRA)
DMFA27N	MT	DTT
DMFA27N	MA	Antagonist
DMFA27N	RN	Human optic nerve head astrocytes as a target for endothelin-1. Invest Ophthalmol Vis Sci. 2002 Aug;43(8):2704-13.
DMFA27N	RU	https://pubmed.ncbi.nlm.nih.gov/12147606

DMFA27N	DI	DMFA27N
DMFA27N	DN	PD142893
DMFA27N	MI	TT3ZTGU
DMFA27N	MN	Endothelin B receptor (EDNRB)
DMFA27N	MT	DTT
DMFA27N	MA	Antagonist
DMFA27N	RN	Human optic nerve head astrocytes as a target for endothelin-1. Invest Ophthalmol Vis Sci. 2002 Aug;43(8):2704-13.
DMFA27N	RU	https://pubmed.ncbi.nlm.nih.gov/12147606

DMHQSF8	DI	DMHQSF8
DMHQSF8	DN	PD-146176
DMHQSF8	MI	TT2J34L
DMHQSF8	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMHQSF8	MT	DTT
DMHQSF8	MA	Modulator
DMHQSF8	RN	A specific 15-lipoxygenase inhibitor limits the progression and monocyte-macrophage enrichment of hypercholesterolemia-induced atherosclerosis in the rabbit.Atherosclerosis.1998 Feb;136(2):203-16.
DMHQSF8	RU	https://www.ncbi.nlm.nih.gov/pubmed/9543090

DMVEXID	DI	DMVEXID
DMVEXID	DN	PD-153103
DMVEXID	MI	TT5FNQT
DMVEXID	MN	Human immunodeficiency virus Protease (HIV PR)
DMVEXID	MT	DTT
DMVEXID	MA	Modulator
DMVEXID	RN	US patent application no. 2008,0161,324, Compositions and methods for treatment of viral diseases.
DMVEXID	RU	http://www.google.com/patents/US20080161324

DMQCNWD	DI	DMQCNWD
DMQCNWD	DN	PD-155080
DMQCNWD	MI	TTKRD0G
DMQCNWD	MN	Endothelin A receptor (EDNRA)
DMQCNWD	MT	DTT
DMQCNWD	MA	Modulator
DMQCNWD	RN	Potency of PD155080, an orally active ETA receptor antagonist, determined for human endothelin receptors. J Cardiovasc Pharmacol. 1995;26 Suppl 3:S362-4.
DMQCNWD	RU	https://www.ncbi.nlm.nih.gov/pubmed/8587415

DMAVZEJ	DI	DMAVZEJ
DMAVZEJ	DN	PD156707
DMAVZEJ	MI	TTKRD0G
DMAVZEJ	MN	Endothelin A receptor (EDNRA)
DMAVZEJ	MT	DTT
DMAVZEJ	MA	Antagonist
DMAVZEJ	RN	Discovery and development of an endothelin A receptor-selective antagonist PD 156707. Pharm Biotechnol. 1998;11:81-112.
DMAVZEJ	RU	https://pubmed.ncbi.nlm.nih.gov/9760677

DM61NFD	DI	DM61NFD
DM61NFD	DN	PD-157667
DM61NFD	MI	TT4FDG6
DM61NFD	MN	Voltage-gated calcium channel alpha Cav2.2 (CACNA1B)
DM61NFD	MT	DTT
DM61NFD	MA	Inhibitor
DM61NFD	RN	Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52.
DM61NFD	RU	https://pubmed.ncbi.nlm.nih.gov/10476885

DMS1XK5	DI	DMS1XK5
DMS1XK5	DN	PD-158473
DMS1XK5	MI	TT9IK2Z
DMS1XK5	MN	N-methyl-D-aspartate receptor (NMDAR)
DMS1XK5	MT	DTT
DMS1XK5	MA	Modulator
DMS1XK5	RN	Improved intestinal transport of PD 158473, an N-methyl-D-aspartate (NMDA) antagonist, by involvement of multiple transporters. J Pharm Sci. 2002 Dec;91(12):2579-87.
DMS1XK5	RU	https://pubmed.ncbi.nlm.nih.gov/12434401

DMJ5STO	DI	DMJ5STO
DMJ5STO	DN	PD-159913
DMJ5STO	MI	TT9IK2Z
DMJ5STO	MN	N-methyl-D-aspartate receptor (NMDAR)
DMJ5STO	MT	DTT
DMJ5STO	MA	Modulator
DMJ5STO	RN	WO patent application no. 2009,0164,86, Use of nmda receptor antagonists for treatment of urologic tumors.
DMJ5STO	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20090205&CC=WO&NR=2009016486A2&KC=A2

DMAOHXY	DI	DMAOHXY
DMAOHXY	DN	PD166285
DMAOHXY	MI	TT6PKBN
DMAOHXY	MN	Proto-oncogene c-Src (SRC)
DMAOHXY	MT	DTT
DMAOHXY	MA	Inhibitor
DMAOHXY	RN	Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy. Invest New Drugs. 1999;17(2):121-35.
DMAOHXY	RU	https://pubmed.ncbi.nlm.nih.gov/10638483

DMQRHMT	DI	DMQRHMT
DMQRHMT	DN	PD-29361
DMQRHMT	MI	TT4FDG6
DMQRHMT	MN	Voltage-gated calcium channel alpha Cav2.2 (CACNA1B)
DMQRHMT	MT	DTT
DMQRHMT	MA	Inhibitor
DMQRHMT	RN	Synthesis and structure-activity relationship of substituted 1,2,3,4-tetrahydroisoquinolines as N-type calcium channel blockers. Bioorg Med Chem Lett. 1998 Sep 22;8(18):2415-8.
DMQRHMT	RU	https://pubmed.ncbi.nlm.nih.gov/9873552

DMNUKB4	DI	DMNUKB4
DMNUKB4	DN	PD-85639
DMNUKB4	MI	TTRK8B9
DMNUKB4	MN	Sodium channel unspecific (NaC)
DMNUKB4	MT	DTT
DMNUKB4	MA	Inhibitor
DMNUKB4	RN	Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37.
DMNUKB4	RU	https://pubmed.ncbi.nlm.nih.gov/11170622

DMNUKB4	DI	DMNUKB4
DMNUKB4	DN	PD-85639
DMNUKB4	MI	TTAXZ0K
DMNUKB4	MN	Voltage-gated sodium channel alpha Nav1.3 (SCN3A)
DMNUKB4	MT	DTT
DMNUKB4	MA	Inhibitor
DMNUKB4	RN	Synthesis and pharmacological evaluation of phenylacetamides as sodium-channel blockers. J Med Chem. 1994 Jan 21;37(2):268-74.
DMNUKB4	RU	https://pubmed.ncbi.nlm.nih.gov/8295214

DMNUKB4	DI	DMNUKB4
DMNUKB4	DN	PD-85639
DMNUKB4	MI	TTZOVE0
DMNUKB4	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DMNUKB4	MT	DTT
DMNUKB4	MA	Inhibitor
DMNUKB4	RN	Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37.
DMNUKB4	RU	https://pubmed.ncbi.nlm.nih.gov/11170622

DMT819N	DI	DMT819N
DMT819N	DN	Pegorgotein
DMT819N	MI	TT6RVLG
DMT819N	MN	Superoxide dismutase Cu-Zn (SOD Cu-Zn)
DMT819N	MT	DTT
DMT819N	MA	Modulator
DMT819N	RN	Clinical trials with Dismutec (pegorgotein; polyethylene glycol-conjugated superoxide dismutase; PEG-SOD) in the treatment of severe closed head injury. Adv Exp Med Biol. 1994;366:389-400.
DMT819N	RU	https://pubmed.ncbi.nlm.nih.gov/7771267

DM9S1EA	DI	DM9S1EA
DM9S1EA	DN	Pepstatin
DM9S1EA	MI	TTJNPTK
DM9S1EA	MN	Plasmodium Cysteine protease falcipain (Malaria CPF)
DM9S1EA	MT	DTT
DM9S1EA	MA	Inhibitor
DM9S1EA	RN	Novel molecular targets for antimalarial chemotherapy. Int J Antimicrob Agents. 2007 Jul;30(1):4-10.
DM9S1EA	RU	https://pubmed.ncbi.nlm.nih.gov/17339102

DM9S1EA	DI	DM9S1EA
DM9S1EA	DN	Pepstatin
DM9S1EA	MI	TT7EASG
DM9S1EA	MN	Plasmodium Cysteine protease falcipain-2 (Malaria CPF2)
DM9S1EA	MT	DTT
DM9S1EA	MA	Inhibitor
DM9S1EA	RN	Novel molecular targets for antimalarial drug development. Chem Biol Drug Des. 2008 Apr;71(4):287-97.
DM9S1EA	RU	https://pubmed.ncbi.nlm.nih.gov/18298458

DM9S1EA	DI	DM9S1EA
DM9S1EA	DN	Pepstatin
DM9S1EA	MI	TTH9VL3
DM9S1EA	MN	Plasmodium Plasmepsin 1 (Malaria PLA1)
DM9S1EA	MT	DTT
DM9S1EA	MA	Inhibitor
DM9S1EA	RN	Novel molecular targets for antimalarial chemotherapy. Int J Antimicrob Agents. 2007 Jul;30(1):4-10.
DM9S1EA	RU	https://pubmed.ncbi.nlm.nih.gov/17339102

DM9S1EA	DI	DM9S1EA
DM9S1EA	DN	Pepstatin
DM9S1EA	MI	TTXMNHO
DM9S1EA	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DM9S1EA	MT	DTT
DM9S1EA	MA	Inhibitor
DM9S1EA	RN	Novel molecular targets for antimalarial chemotherapy. Int J Antimicrob Agents. 2007 Jul;30(1):4-10.
DM9S1EA	RU	https://pubmed.ncbi.nlm.nih.gov/17339102

DMOS9NZ	DI	DMOS9NZ
DMOS9NZ	DN	PF-03882845
DMOS9NZ	MI	TT26PHO
DMOS9NZ	MN	Mineralocorticoid receptor  (MR)
DMOS9NZ	MT	DTT
DMOS9NZ	MA	Modulator
DMOS9NZ	RN	Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g] indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy.J Med Chem.2010 Aug 26;53(16):5979-6002.
DMOS9NZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/20672822

DMSNOH3	DI	DMSNOH3
DMSNOH3	DN	PF-04620110
DMSNOH3	MI	TTF8P9I
DMSNOH3	MN	Diacylglycerol acyltransferase 1 (DGAT1)
DMSNOH3	MT	DTT
DMSNOH3	MA	Inhibitor
DMSNOH3	RN	Clinical pipeline report, company report or official report of Pfizer (2011).
DMSNOH3	RU	http://www.pfizer.com/home/

DMZ8HW7	DI	DMZ8HW7
DMZ8HW7	DN	PF-572778
DMZ8HW7	MI	TTIY658
DMZ8HW7	MN	Corticotropin-releasing factor receptor 2 (CRHR2)
DMZ8HW7	MT	DTT
DMZ8HW7	MA	Modulator
DMZ8HW7	RN	WO patent application no. 2013,1603,15, Genetic predictors of response to treatment with crhr1 antagonists.
DMZ8HW7	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20131031&CC=WO&NR=2013160315A2&KC=A2

DMAJ9ZD	DI	DMAJ9ZD
DMAJ9ZD	DN	Phosphonate
DMAJ9ZD	MI	TT1UZQH
DMAJ9ZD	MN	Phospholipase C (PLC)
DMAJ9ZD	MT	DTT
DMAJ9ZD	MA	Inhibitor
DMAJ9ZD	RN	Inhibition of phosphatidylinositol-specific phospholipase C by phosphonate substrate analogues. Biochim Biophys Acta. 1990 Feb 23;1042(3):410-2.
DMAJ9ZD	RU	https://pubmed.ncbi.nlm.nih.gov/2106349

DM63OD7	DI	DM63OD7
DM63OD7	DN	Pifithrin-alpha
DM63OD7	MI	TT7SBF5
DM63OD7	MN	Cellular tumor antigen p53 (TP53)
DM63OD7	MT	DTT
DM63OD7	MA	Inhibitor
DM63OD7	RN	An evaluation of the ability of pifithrin-alpha and -beta to inhibit p53 function in two wild-type p53 human tumor cell lines. Mol Cancer Ther. 2005 Sep;4(9):1369-77.
DM63OD7	RU	https://pubmed.ncbi.nlm.nih.gov/16170029

DMR87MO	DI	DMR87MO
DMR87MO	DN	PIROXANTRONE
DMR87MO	MI	TTGTQHC
DMR87MO	MN	DNA topoisomerase I (TOP1)
DMR87MO	MT	DTT
DMR87MO	MA	Modulator
DMR87MO	RN	The displacement of iron(III) from its complexes with the anticancer drugs piroxantrone and losoxantrone by the hydrolyzed form of the cardioprotec... J Inorg Biochem. 1999 Nov-Dec;77(3-4):257-9.
DMR87MO	RU	https://www.ncbi.nlm.nih.gov/pubmed/10643663

DMPHUBO	DI	DMPHUBO
DMPHUBO	DN	PLD-177
DMPHUBO	MI	TTPNQAC
DMPHUBO	MN	Estrogen-related receptor-alpha (ESRRA)
DMPHUBO	MT	DTT
DMPHUBO	MA	Modulator
DMPHUBO	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 622).
DMPHUBO	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=622

DMT83V6	DI	DMT83V6
DMT83V6	DN	PNQX
DMT83V6	MI	TTAN6JD
DMT83V6	MN	Glutamate receptor AMPA (GRIA)
DMT83V6	MT	DTT
DMT83V6	MA	Antagonist
DMT83V6	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005697)
DMT83V6	RU	http://adisinsight.springer.com/drugs/800005697

DMZNM2K	DI	DMZNM2K
DMZNM2K	DN	PNU-109291
DMZNM2K	MI	TT6MSOK
DMZNM2K	MN	5-HT 1D receptor (HTR1D)
DMZNM2K	MT	DTT
DMZNM2K	MA	Agonist
DMZNM2K	RN	Role of 5-HT(1) receptor subtypes in the modulation of pain and synaptic transmission in rat spinal superficial dorsal horn. Br J Pharmacol. 2012 Mar;165(6):1956-65.
DMZNM2K	RU	https://pubmed.ncbi.nlm.nih.gov/21950560

DM23ZHN	DI	DM23ZHN
DM23ZHN	DN	PNU156804
DM23ZHN	MI	TTT7PJU
DM23ZHN	MN	Janus kinase 3 (JAK-3)
DM23ZHN	MT	DTT
DM23ZHN	MA	Inhibitor
DM23ZHN	RN	Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. Blood. 2002 Jan 15;99(2):680-9.
DM23ZHN	RU	https://pubmed.ncbi.nlm.nih.gov/11781254

DMRT69H	DI	DMRT69H
DMRT69H	DN	PNU-177864
DMRT69H	MI	TT4C8EA
DMRT69H	MN	Dopamine D3 receptor (D3R)
DMRT69H	MT	DTT
DMRT69H	MA	Antagonist
DMRT69H	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMRT69H	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMGDC36	DI	DMGDC36
DMGDC36	DN	PNU-282987
DMGDC36	MI	TTLA931
DMGDC36	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMGDC36	MT	DTT
DMGDC36	MA	Antagonist
DMGDC36	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMGDC36	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMGDC36	DI	DMGDC36
DMGDC36	DN	PNU-282987
DMGDC36	MI	TTC97NF
DMGDC36	MN	TNFA messenger RNA (TNF mRNA)
DMGDC36	MT	DTT
DMGDC36	RN	Antisense oligonucleotide blockade of tumor necrosis factor-alpha in two murine models of colitis. J Pharmacol Exp Ther. 2003 Jan;304(1):411-24.
DMGDC36	RU	https://pubmed.ncbi.nlm.nih.gov/12490618

DMLMISK	DI	DMLMISK
DMLMISK	DN	PNU-96391A
DMLMISK	MI	TTEX248
DMLMISK	MN	Dopamine D2 receptor (D2R)
DMLMISK	MT	DTT
DMLMISK	MA	Modulator
DMLMISK	RN	The dopamine stabilizer (-)-OSU6162 occupies a subpopulation of striatal dopamine D2/D3 receptors: an [(11)C]raclopride PET study in healthy human subjects. Neuropsychopharmacology. 2015 Jan;40(2):472-9.
DMLMISK	RU	https://pubmed.ncbi.nlm.nih.gov/25248987

DMLMISK	DI	DMLMISK
DMLMISK	DN	PNU-96391A
DMLMISK	MI	TT4C8EA
DMLMISK	MN	Dopamine D3 receptor (D3R)
DMLMISK	MT	DTT
DMLMISK	MA	Modulator
DMLMISK	RN	The dopamine stabilizer (-)-OSU6162 occupies a subpopulation of striatal dopamine D2/D3 receptors: an [(11)C]raclopride PET study in healthy human subjects. Neuropsychopharmacology. 2015 Jan;40(2):472-9.
DMLMISK	RU	https://pubmed.ncbi.nlm.nih.gov/25248987

DMLY2TN	DI	DMLY2TN
DMLY2TN	DN	PPACK
DMLY2TN	MI	TT6L509
DMLY2TN	MN	Coagulation factor IIa (F2)
DMLY2TN	MT	DTT
DMLY2TN	MA	Inhibitor
DMLY2TN	RN	Anticoagulation: the present and future. Clin Appl Thromb Hemost. 2001 Jul;7(3):195-204.
DMLY2TN	RU	https://pubmed.ncbi.nlm.nih.gov/11441979

DMI2N9H	DI	DMI2N9H
DMI2N9H	DN	Pranidipine
DMI2N9H	MI	TT5HONZ
DMI2N9H	MN	Calcium channel unspecific (CaC)
DMI2N9H	MT	DTT
DMI2N9H	MA	Modulator
DMI2N9H	RN	Pranidipine, a new 1,4-dihydropyridine calcium channel blocker, enhances cyclic GMP-independent nitric oxide-induced relaxation of the rat aorta. Mol Cell Biochem. 1998 Jan;178(1-2):335-43.
DMI2N9H	RU	https://pubmed.ncbi.nlm.nih.gov/9546618

DMDIYFH	DI	DMDIYFH
DMDIYFH	DN	PRE-084
DMDIYFH	MI	TT5TPI6
DMDIYFH	MN	Opioid receptor sigma 1 (OPRS1)
DMDIYFH	MT	DTT
DMDIYFH	MA	Modulator
DMDIYFH	RN	Antidepressant-like effect of PRE-084, a selective sigma1 receptor agonist, in Albino Swiss and C57BL/6J mice. Pharmacol Rep. 2009 Nov-Dec;61(6):1179-83.
DMDIYFH	RU	https://pubmed.ncbi.nlm.nih.gov/20081254

DMS4FG0	DI	DMS4FG0
DMS4FG0	DN	Promegapoietin
DMS4FG0	MI	TTIHYA4
DMS4FG0	MN	Thrombopoietin receptor (MPL)
DMS4FG0	MT	DTT
DMS4FG0	MA	Modulator
DMS4FG0	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMS4FG0	RU	https://www.fda.gov/

DM57YO8	DI	DM57YO8
DM57YO8	DN	Protosufloxacin
DM57YO8	MI	TTN6J5F
DM57YO8	MN	Bacterial DNA gyrase (Bact gyrase)
DM57YO8	MT	DTT
DM57YO8	MA	Modulator
DM57YO8	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM57YO8	RU	https://www.fda.gov/

DMNK2I0	DI	DMNK2I0
DMNK2I0	DN	PRS-639058
DMNK2I0	MI	TTMSFAW
DMNK2I0	MN	Cannabinoid receptor 2 (CB2)
DMNK2I0	MT	DTT
DMNK2I0	MA	Agonist
DMNK2I0	RN	Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Res Rev. 2009 April; 60(1): 255-266.
DMNK2I0	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4549801/

DM8P05S	DI	DM8P05S
DM8P05S	DN	PS-388023
DM8P05S	MI	TT69TQN
DM8P05S	MN	Integrin alpha-V/beta-3 (ITGAV/B3)
DM8P05S	MT	DTT
DM8P05S	MA	Modulator
DM8P05S	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM8P05S	RU	https://www.fda.gov/

DM8P05S	DI	DM8P05S
DM8P05S	DN	PS-388023
DM8P05S	MI	TTPRDH7
DM8P05S	MN	Integrin alpha-V/beta-5 (ITGAV/B5)
DM8P05S	MT	DTT
DM8P05S	MA	Modulator
DM8P05S	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM8P05S	RU	https://www.fda.gov/

DMI0WHC	DI	DMI0WHC
DMI0WHC	DN	PS-519
DMI0WHC	MI	TTU7ZMG
DMI0WHC	MN	Proteasome (PS)
DMI0WHC	MT	DTT
DMI0WHC	MA	Modulator
DMI0WHC	RN	Effect of the proteasome inhibitor MLN519 on the expression of inflammatory molecules following middle cerebral artery occlusion and reperfusion in... Neurotox Res. 2003;5(7):505-14.
DMI0WHC	RU	https://www.ncbi.nlm.nih.gov/pubmed/14715434

DMWUOA8	DI	DMWUOA8
DMWUOA8	DN	PSI-6130
DMWUOA8	MI	TTMVBWH
DMWUOA8	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMWUOA8	MT	DTT
DMWUOA8	MA	Inhibitor
DMWUOA8	RN	An efficient and diastereoselective synthesis of PSI-6130: a clinically efficacious inhibitor of HCV NS5B polymerase. J Org Chem. 2009 Sep 4;74(17):6819-24.
DMWUOA8	RU	https://pubmed.ncbi.nlm.nih.gov/19642660

DM579WS	DI	DM579WS
DM579WS	DN	PSI-661
DM579WS	MI	TTMVBWH
DM579WS	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DM579WS	MT	DTT
DM579WS	MA	Modulator
DM579WS	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM579WS	RU	https://www.fda.gov/

DMGEWUS	DI	DMGEWUS
DMGEWUS	DN	PSN821
DMGEWUS	MI	TT7QNVC
DMGEWUS	MN	Glucose-dependent insulinotropic receptor (GPR119)
DMGEWUS	MT	DTT
DMGEWUS	MA	Agonist
DMGEWUS	RN	Clinical pipeline report, company report or official report of Astellas Pharma (2011).
DMGEWUS	RU	http://www.astellas.com/en/

DMH3RPO	DI	DMH3RPO
DMH3RPO	DN	PT-630
DMH3RPO	MI	TTDIGC1
DMH3RPO	MN	Dipeptidyl peptidase 4 (DPP-4)
DMH3RPO	MT	DTT
DMH3RPO	MA	Modulator
DMH3RPO	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMH3RPO	RU	https://www.fda.gov/

DM89RT7	DI	DM89RT7
DM89RT7	DN	PTX-007011
DM89RT7	MI	TT4YO0Z
DM89RT7	MN	Phosphopantetheine adenylyltransferase (PPAT)
DM89RT7	MT	DTT
DM89RT7	MA	Inhibitor
DM89RT7	RN	NME DIGEST. Drug News & Perspect 2002, 15(8):519, ISSN 0214-0934.
DM89RT7	RU	https://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=3&p_RefId=695454&p_IsPs=N

DM84RHP	DI	DM84RHP
DM84RHP	DN	PTX-008313
DM84RHP	MI	TTQAOZR
DM84RHP	MN	Bacterial Chorismate synthase (Bact aroC)
DM84RHP	MT	DTT
DM84RHP	MA	Inhibitor
DM84RHP	RN	US patent application no. 2009,0048,155, Methods for preventing and treating tissue injury and sepsis associated with yersinia pestis infection.
DM84RHP	RU	http://www.google.com/patents/US20090048155

DM63O4F	DI	DM63O4F
DM63O4F	DN	PURPUROGALLIN
DM63O4F	MI	TTRE6AX
DM63O4F	MN	Bcl-x messenger RNA (BCL2L1 mRNA)
DM63O4F	MT	DTT
DM63O4F	MA	Inhibitor
DM63O4F	RN	Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem. 2003 Sep 25;46(20):4259-64.
DM63O4F	RU	https://pubmed.ncbi.nlm.nih.gov/13678404

DM63O4F	DI	DM63O4F
DM63O4F	DN	PURPUROGALLIN
DM63O4F	MI	TT2IYXF
DM63O4F	MN	L-selectin (SELL)
DM63O4F	MT	DTT
DM63O4F	MA	Inhibitor
DM63O4F	RN	Rational design of novel, potent small molecule pan-selectin antagonists. J Med Chem. 2007 Mar 22;50(6):1101-15.
DM63O4F	RU	https://pubmed.ncbi.nlm.nih.gov/17302397

DM63O4F	DI	DM63O4F
DM63O4F	DN	PURPUROGALLIN
DM63O4F	MI	TTE5VG0
DM63O4F	MN	P-selectin (SELP)
DM63O4F	MT	DTT
DM63O4F	MA	Inhibitor
DM63O4F	RN	Rational design of novel, potent small molecule pan-selectin antagonists. J Med Chem. 2007 Mar 22;50(6):1101-15.
DM63O4F	RU	https://pubmed.ncbi.nlm.nih.gov/17302397

DMCNE2G	DI	DMCNE2G
DMCNE2G	DN	PX-867
DMCNE2G	MI	TTHBTOP
DMCNE2G	MN	PI3-kinase gamma (PIK3CG)
DMCNE2G	MT	DTT
DMCNE2G	MA	Modulator
DMCNE2G	RN	Pharmacologic profiling of phosphoinositide 3-kinase inhibitors as mitigators of ionizing radiation-induced cell death. J Pharmacol Exp Ther. 2013 Dec;347(3):669-80.
DMCNE2G	RU	https://pubmed.ncbi.nlm.nih.gov/24068833

DM1AXZ6	DI	DM1AXZ6
DM1AXZ6	DN	PXS-2076
DM1AXZ6	MI	TTMSFAW
DM1AXZ6	MN	Cannabinoid receptor 2 (CB2)
DM1AXZ6	MT	DTT
DM1AXZ6	MA	Agonist
DM1AXZ6	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 57).
DM1AXZ6	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=57

DM8RHST	DI	DM8RHST
DM8RHST	DN	QAP-642
DM8RHST	MI	TTD3XFU
DM8RHST	MN	C-C chemokine receptor type 3 (CCR3)
DM8RHST	MT	DTT
DM8RHST	MA	Antagonist
DM8RHST	RN	New Drugs and Targets for Asthma and COPD. T.T. Hansel, P.J. Barnes. 2010. Page 158.
DM8RHST	RU	https://books.google.com.hk/books?id=-Zg7AQAAQBAJ&pg=PT172&lpg=PT172&dq=QAP-642++CCR3&source=bl&ots=mTJNnzpSCz&sig=TbtUMK5VhyKIqvrzRk-gWt9mjqk&hl=zh-CN&sa=X&ved=0CCEQ6AEwAWoVChMIjYeezrbGyAIVChuOCh1s3QSC#v=onepage&q=QAP-642%20%20CCR3&f=false

DMAV2FM	DI	DMAV2FM
DMAV2FM	DN	QX-314
DMAV2FM	MI	TTN9VTF
DMAV2FM	MN	Voltage-gated sodium channel alpha Nav1.9 (SCN11A)
DMAV2FM	MT	DTT
DMAV2FM	MA	Blocker
DMAV2FM	RN	Voltage-gated sodium channel blockers for the treatment of chronic pain. Curr Top Med Chem. 2009;9(4):362-76.
DMAV2FM	RU	https://pubmed.ncbi.nlm.nih.gov/19442207

DMA187T	DI	DMA187T
DMA187T	DN	R zileuton
DMA187T	MI	TT2J34L
DMA187T	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMA187T	MT	DTT
DMA187T	MA	Inhibitor
DMA187T	RN	Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos. 2003 Nov;31(11):1352-60.
DMA187T	RU	https://pubmed.ncbi.nlm.nih.gov/14570767

DM46YHG	DI	DM46YHG
DM46YHG	DN	R-102444
DM46YHG	MI	TTJQOD7
DM46YHG	MN	5-HT 2A receptor (HTR2A)
DM46YHG	MT	DTT
DM46YHG	MA	Modulator
DM46YHG	RN	Effects of R-102444 and its active metabolite R-96544, selective 5-HT2A receptor antagonists, on experimental acute and chronic pancreatitis: Additional evidence for possible involvement of 5-HT2A receptors in the development of experimental pancreatitis.Eur J Pharmacol.2005 Oct 3;521(1-3):156-63.
DM46YHG	RU	https://www.ncbi.nlm.nih.gov/pubmed/16183055

DMIBCZ5	DI	DMIBCZ5
DMIBCZ5	DN	R-1315
DMIBCZ5	MI	TTXEU7H
DMIBCZ5	MN	GPCR unspecific (GPCR)
DMIBCZ5	MT	DTT
DMIBCZ5	MA	Modulator
DMIBCZ5	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017252)
DMIBCZ5	RU	http://adisinsight.springer.com/drugs/800017252

DMBU24I	DI	DMBU24I
DMBU24I	DN	R-1437
DMBU24I	MI	TTXEU7H
DMBU24I	MN	GPCR unspecific (GPCR)
DMBU24I	MT	DTT
DMBU24I	MA	Antagonist
DMBU24I	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017122)
DMBU24I	RU	http://adisinsight.springer.com/drugs/800017122

DM8XBKG	DI	DM8XBKG
DM8XBKG	DN	R-1554
DM8XBKG	MI	TTXEU7H
DM8XBKG	MN	GPCR unspecific (GPCR)
DM8XBKG	MT	DTT
DM8XBKG	MA	Antagonist
DM8XBKG	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018539)
DM8XBKG	RU	http://adisinsight.springer.com/drugs/800018539

DM12EYR	DI	DM12EYR
DM12EYR	DN	R348
DM12EYR	MI	TTT7PJU
DM12EYR	MN	Janus kinase 3 (JAK-3)
DM12EYR	MT	DTT
DM12EYR	MA	Inhibitor
DM12EYR	RN	Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
DM12EYR	RU	https://pubmed.ncbi.nlm.nih.gov/19249988

DMYTI3J	DI	DMYTI3J
DMYTI3J	DN	R-56865
DMYTI3J	MI	TTZIFHC
DMYTI3J	MN	Voltage-gated calcium channel alpha Cav1.2 (CACNA1C)
DMYTI3J	MT	DTT
DMYTI3J	MA	Inhibitor
DMYTI3J	RN	Novel calcium antagonists with both calcium overload inhibition and antioxidant activity. 1. 2-(3, 5-di-tert-butyl-4-hydroxyphenyl)-3-(aminopropyl)... J Med Chem. 1998 Oct 22;41(22):4309-16.
DMYTI3J	RU	https://pubmed.ncbi.nlm.nih.gov/9784106

DM36JFP	DI	DM36JFP
DM36JFP	DN	R-59494
DM36JFP	MI	TTRK8B9
DM36JFP	MN	Sodium channel unspecific (NaC)
DM36JFP	MT	DTT
DM36JFP	MA	Modulator
DM36JFP	RN	Veratridine activates a silent sodium channel in rat isolated aorta. Eur J Pharmacol. 1992 Aug 25;219(2):253-9.
DM36JFP	RU	https://pubmed.ncbi.nlm.nih.gov/1330608

DMLAIZG	DI	DMLAIZG
DMLAIZG	DN	R-7025
DMLAIZG	MI	TT95SOA
DMLAIZG	MN	Interferon alpha (IFNA)
DMLAIZG	MT	DTT
DMLAIZG	MA	Modulator
DMLAIZG	RN	WO patent application no. 2013,0667,53, Compositions useful for the treatment of viral diseases.
DMLAIZG	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20130510&CC=WO&NR=2013066753A1&KC=A1

DMZQJVN	DI	DMZQJVN
DMZQJVN	DN	R-85355
DMZQJVN	MI	TT2J34L
DMZQJVN	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMZQJVN	MT	DTT
DMZQJVN	MA	Inhibitor
DMZQJVN	RN	Topical R-85355, a potent and selective 5-lipoxygenase inhibitor, fails to improve psoriasis. Skin Pharmacol. 1996;9(5):307-11.
DMZQJVN	RU	https://pubmed.ncbi.nlm.nih.gov/8990505

DM7HAE9	DI	DM7HAE9
DM7HAE9	DN	Ralitoline
DM7HAE9	MI	TTRK8B9
DM7HAE9	MN	Sodium channel unspecific (NaC)
DM7HAE9	MT	DTT
DM7HAE9	MA	Modulator
DM7HAE9	RN	Anticonvulsant and sodium channel blocking effects of ralitoline in different screening models. Naunyn Schmiedebergs Arch Pharmacol. 1992 Oct;346(4):442-52.
DM7HAE9	RU	https://pubmed.ncbi.nlm.nih.gov/1331817

DM4FNWO	DI	DM4FNWO
DM4FNWO	DN	RC-01
DM4FNWO	MI	TT0OFWN
DM4FNWO	MN	Pseudomonas UDP-3-O-acyl-GlcNAc deacetylase (Pseudo lpxC)
DM4FNWO	MT	DTT
DM4FNWO	MA	Inhibitor
DM4FNWO	RN	The global preclinical antibacterial pipeline. Nat Rev Microbiol. 2020 May;18(5):275-285.
DM4FNWO	RU	https://pubmed.ncbi.nlm.nih.gov/31745331

DM08BUV	DI	DM08BUV
DM08BUV	DN	RDEA-427
DM08BUV	MI	TT84ETX
DM08BUV	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM08BUV	MT	DTT
DM08BUV	MA	Inhibitor
DM08BUV	RN	CN patent application no. 103360398, Triazolopyrimidine hiv-1 retrovirus inhibitor and its preparation method and application thereof.
DM08BUV	RU	http://www.google.com/patents/CN103360398A?cl=en

DM61RGQ	DI	DM61RGQ
DM61RGQ	DN	RDEA-640
DM61RGQ	MI	TT84ETX
DM61RGQ	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM61RGQ	MT	DTT
DM61RGQ	MA	Inhibitor
DM61RGQ	RN	WO patent application no. 2008,0165,22, Novel hiv reverse transcriptase inhibitors.
DM61RGQ	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20080207&CC=WO&NR=2008016522A2&KC=A2

DMDC2E8	DI	DMDC2E8
DMDC2E8	DN	Recainam
DMDC2E8	MI	TTRK8B9
DMDC2E8	MN	Sodium channel unspecific (NaC)
DMDC2E8	MT	DTT
DMDC2E8	MA	Modulator
DMDC2E8	RN	Effects of renal function on recainam pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 1995 May;57(5):492-8.
DMDC2E8	RU	https://pubmed.ncbi.nlm.nih.gov/7768071

DMWIAUK	DI	DMWIAUK
DMWIAUK	DN	ReN-1820
DMWIAUK	MI	TTEDJN4
DMWIAUK	MN	Low-affinity nerve growth factor receptor (NGFR)
DMWIAUK	MT	DTT
DMWIAUK	MA	Inhibitor
DMWIAUK	RN	Phosphorylation of Extracellular Signal-Regulated Kinases (pERK1/2) in Bladder Afferent Pathways with Cyclophosphamide (CYP)-Induced Cystitis. Neuroscience. 2009 November 10; 163(4): 1353-1362.
DMWIAUK	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2760658/

DMGY51F	DI	DMGY51F
DMGY51F	DN	ReN-1826
DMGY51F	MI	TTZHKV9
DMGY51F	MN	Neurotrophin-3 (NTF3)
DMGY51F	MT	DTT
DMGY51F	MA	Inhibitor
DMGY51F	RN	Pulmonary distribution, regulation, and functional role of Trk receptors in a murine model of asthma. J Allergy Clin Immunol. 2006 Sep;118(3):597-605.
DMGY51F	RU	https://pubmed.ncbi.nlm.nih.gov/16950277

DMGY51F	DI	DMGY51F
DMGY51F	DN	ReN-1826
DMGY51F	MI	TTIM2WO
DMGY51F	MN	Neurotrophin-4 (NTF4)
DMGY51F	MT	DTT
DMGY51F	MA	Inhibitor
DMGY51F	RN	Pulmonary distribution, regulation, and functional role of Trk receptors in a murine model of asthma. J Allergy Clin Immunol. 2006 Sep;118(3):597-605.
DMGY51F	RU	https://pubmed.ncbi.nlm.nih.gov/16950277

DM1XYJU	DI	DM1XYJU
DM1XYJU	DN	RES-701-1
DM1XYJU	MI	TT3ZTGU
DM1XYJU	MN	Endothelin B receptor (EDNRB)
DM1XYJU	MT	DTT
DM1XYJU	MA	Inhibitor
DM1XYJU	RN	RES-701-1/endothelin-1 hybrid peptide having a potent binding activity for type B receptor, Bioorg. Med. Chem. Lett. 7(13):1715-1720 (1997).
DM1XYJU	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97002965

DMI94L1	DI	DMI94L1
DMI94L1	DN	REV-5901
DMI94L1	MI	TT2J34L
DMI94L1	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMI94L1	MT	DTT
DMI94L1	MA	Inhibitor
DMI94L1	RN	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
DMI94L1	RU	https://pubmed.ncbi.nlm.nih.gov/1848292

DM314CZ	DI	DM314CZ
DM314CZ	DN	REV-598
DM314CZ	MI	TT85JO3
DM314CZ	MN	5-HT receptor (5HTR)
DM314CZ	MT	DTT
DM314CZ	MA	Inhibitor
DM314CZ	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016819)
DM314CZ	RU	http://adisinsight.springer.com/drugs/800016819

DM314CZ	DI	DM314CZ
DM314CZ	DN	REV-598
DM314CZ	MI	TT7CXIM
DM314CZ	MN	Histamine receptor (HR)
DM314CZ	MT	DTT
DM314CZ	MA	Inhibitor
DM314CZ	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016819)
DM314CZ	RU	http://adisinsight.springer.com/drugs/800016819

DMA971L	DI	DMA971L
DMA971L	DN	Reveromycin A
DMA971L	MI	TT6KYJ5
DMA971L	MN	Bacterial Isoleucyl-tRNA synthetase (Bact ileS)
DMA971L	MT	DTT
DMA971L	MA	Inhibitor
DMA971L	RN	Chemical modification of reveromycin A and its biological activities. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3363-6.
DMA971L	RU	https://pubmed.ncbi.nlm.nih.gov/12419362

DMA971L	DI	DMA971L
DMA971L	DN	Reveromycin A
DMA971L	MI	TTYD3AN
DMA971L	MN	Isoleucyl-tRNA synthetase (IARS)
DMA971L	MT	DTT
DMA971L	MA	Inhibitor
DMA971L	RN	Synthesis and biological activities of reveromycin A and spirofungin A derivatives. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3756-60.
DMA971L	RU	https://pubmed.ncbi.nlm.nih.gov/18519164

DMRFYOS	DI	DMRFYOS
DMRFYOS	DN	RG-13022
DMRFYOS	MI	TT8FYO9
DMRFYOS	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMRFYOS	MT	DTT
DMRFYOS	MA	Inhibitor
DMRFYOS	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMRFYOS	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMRFYOS	DI	DMRFYOS
DMRFYOS	DN	RG-13022
DMRFYOS	MI	TTI7421
DMRFYOS	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMRFYOS	MT	DTT
DMRFYOS	MA	Inhibitor
DMRFYOS	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMRFYOS	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMKFQC7	DI	DMKFQC7
DMKFQC7	DN	RG-14893
DMKFQC7	MI	TTN53ZF
DMKFQC7	MN	Leukotriene B4 receptor 1 (LTB4R)
DMKFQC7	MT	DTT
DMKFQC7	MA	Modulator
DMKFQC7	RN	Structure-activity relationships study of two series of leukotriene B4 antagonists: novel indolyl and naphthyl compounds substituted with a 2-[methyl(2-phenethyl)amino]-2-oxoethyl side chain. J Med Chem. 1996 Sep 13;39(19):3756-68.
DMKFQC7	RU	https://pubmed.ncbi.nlm.nih.gov/8809164

DMI0CYV	DI	DMI0CYV
DMI0CYV	DN	RG-8803
DMI0CYV	MI	TTGKIED
DMI0CYV	MN	Fibroblast growth factor-2 (FGF2)
DMI0CYV	MT	DTT
DMI0CYV	MA	Inhibitor
DMI0CYV	RN	US patent application no. 2010,0278,784, Methods and compositions for treating skin conditions.
DMI0CYV	RU	https://www.google.com.ar/patents/US20100278784

DMI0CYV	DI	DMI0CYV
DMI0CYV	DN	RG-8803
DMI0CYV	MI	TTVJ1D8
DMI0CYV	MN	Vascular endothelial growth factor receptor (VEGFR)
DMI0CYV	MT	DTT
DMI0CYV	MA	Inhibitor
DMI0CYV	RN	US patent application no. 2010,0278,784, Methods and compositions for treating skin conditions.
DMI0CYV	RU	https://www.google.com.ar/patents/US20100278784

DM8RIA6	DI	DM8RIA6
DM8RIA6	DN	RGH-1756
DM8RIA6	MI	TT4C8EA
DM8RIA6	MN	Dopamine D3 receptor (D3R)
DM8RIA6	MT	DTT
DM8RIA6	MA	Antagonist
DM8RIA6	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DM8RIA6	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMBCIPO	DI	DMBCIPO
DMBCIPO	DN	RGH-2721
DMBCIPO	MI	TT85JO3
DMBCIPO	MN	5-HT receptor (5HTR)
DMBCIPO	MT	DTT
DMBCIPO	MA	Modulator
DMBCIPO	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004008)
DMBCIPO	RU	http://adisinsight.springer.com/drugs/800004008

DM7CY0T	DI	DM7CY0T
DM7CY0T	DN	RHb1.1
DM7CY0T	MI	TTQO71U
DM7CY0T	MN	Hemoglobin (HB)
DM7CY0T	MT	DTT
DM7CY0T	MA	Modulator
DM7CY0T	RN	Effects of recombinant-hemoglobin solutions rHb2.0 and rHb1.1 on blood pressure, intestinal blood flow, and gut oxygenation in a rat model of hemorrhagic shock. J Lab Clin Med. 2005 Jan;145(1):21-32.
DM7CY0T	RU	https://pubmed.ncbi.nlm.nih.gov/15668658

DMW4UTB	DI	DMW4UTB
DMW4UTB	DN	RhuCD40L
DMW4UTB	MI	TTN6Y9A
DMW4UTB	MN	CD40L receptor (CD40)
DMW4UTB	MT	DTT
DMW4UTB	MA	Binder
DMW4UTB	RN	Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin. Cancer Res. 2001 Oct 15;61(20):7556-62.
DMW4UTB	RU	https://pubmed.ncbi.nlm.nih.gov/11606394

DMKDS1C	DI	DMKDS1C
DMKDS1C	DN	Rimcazole
DMKDS1C	MI	TT5TPI6
DMKDS1C	MN	Opioid receptor sigma 1 (OPRS1)
DMKDS1C	MT	DTT
DMKDS1C	MA	Antagonist
DMKDS1C	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMKDS1C	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMHQ5ZE	DI	DMHQ5ZE
DMHQ5ZE	DN	RN-1005
DMHQ5ZE	MI	TTVZ87F
DMHQ5ZE	MN	Wnt protein (WNT)
DMHQ5ZE	MT	DTT
DMHQ5ZE	MA	Modulator
DMHQ5ZE	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033803)
DMHQ5ZE	RU	http://adisinsight.springer.com/drugs/800033803

DM0PSCF	DI	DM0PSCF
DM0PSCF	DN	Ro 20-1724
DM0PSCF	MI	TTLZS4Q
DM0PSCF	MN	M-phase inducer phosphatase 1 (MPIP1)
DM0PSCF	MT	DTT
DM0PSCF	MA	Inhibitor
DM0PSCF	RN	Role of the Cdc25A phosphatase in human breast cancer. J Clin Invest. 2000 Sep;106(6):753-61.
DM0PSCF	RU	https://pubmed.ncbi.nlm.nih.gov/10995786

DM0PSCF	DI	DM0PSCF
DM0PSCF	DN	Ro 20-1724
DM0PSCF	MI	TTV5CGO
DM0PSCF	MN	Phosphodiesterase 4 (PDE4)
DM0PSCF	MT	DTT
DM0PSCF	MA	Inhibitor
DM0PSCF	RN	Increased interleukin-4 production by atopic mononuclear leukocytes correlates with increased cyclic adenosine monophosphate-phosphodiesterase activity and is reversible by phosphodiesterase inhibition. J Invest Dermatol. 1993 May;100(5):681-4.
DM0PSCF	RU	https://pubmed.ncbi.nlm.nih.gov/8388009

DMFRCM2	DI	DMFRCM2
DMFRCM2	DN	Ro-19-8022
DMFRCM2	MI	TTEX6LM
DMFRCM2	MN	GABA(A) receptor gamma-3 (GABRG3)
DMFRCM2	MT	DTT
DMFRCM2	MA	Modulator
DMFRCM2	RN	Partial agonist of benzodiazepine receptors Ro 19-8022 elicits withdrawal symptoms after short-term administration in immature rats. Physiol Res. 2012;61(3):319-23.
DMFRCM2	RU	https://www.ncbi.nlm.nih.gov/pubmed/22816377

DM7B2WH	DI	DM7B2WH
DM7B2WH	DN	Ro-23-7777
DM7B2WH	MI	TTN6J5F
DM7B2WH	MN	Bacterial DNA gyrase (Bact gyrase)
DM7B2WH	MT	DTT
DM7B2WH	MA	Modulator
DM7B2WH	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM7B2WH	RU	https://www.fda.gov/

DMJQA0D	DI	DMJQA0D
DMJQA0D	DN	Ro-24-0238
DMJQA0D	MI	TTQL5VC
DMJQA0D	MN	Platelet-activating factor receptor (PTAFR)
DMJQA0D	MT	DTT
DMJQA0D	MA	Inhibitor
DMJQA0D	RN	Pentadienyl carboxamide derivatives as antagonists of platelet-activating factor. J Med Chem. 1989 Aug;32(8):1820-35.
DMJQA0D	RU	https://pubmed.ncbi.nlm.nih.gov/2754709

DMVB0C3	DI	DMVB0C3
DMVB0C3	DN	Ro-25-4094
DMVB0C3	MI	TTN53ZF
DMVB0C3	MN	Leukotriene B4 receptor 1 (LTB4R)
DMVB0C3	MT	DTT
DMVB0C3	MA	Modulator
DMVB0C3	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005401)
DMVB0C3	RU	http://adisinsight.springer.com/drugs/800005401

DM07ZSC	DI	DM07ZSC
DM07ZSC	DN	Ro-25-6833
DM07ZSC	MI	TTXT4D5
DM07ZSC	MN	Bacterial Cell membrane (Bact CM)
DM07ZSC	MT	DTT
DM07ZSC	MA	Modulator
DM07ZSC	RN	Animal pharmacokinetics and interspecies scaling of Ro 25-6833 and related (lactamylvinyl)cephalosporins. J Pharm Sci. 1998 Apr;87(4):496-500.
DM07ZSC	RU	https://pubmed.ncbi.nlm.nih.gov/9548904

DM3H921	DI	DM3H921
DM3H921	DN	RO-25-6981
DM3H921	MI	TTN9D8E
DM3H921	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DM3H921	MT	DTT
DM3H921	MA	Antagonist
DM3H921	RN	Emerging analgesics in cancer pain management. Expert Opin Emerg Drugs. 2005 Feb;10(1):151-71.
DM3H921	RU	https://pubmed.ncbi.nlm.nih.gov/15757410

DM8B9YT	DI	DM8B9YT
DM8B9YT	DN	Ro-31-4724
DM8B9YT	MI	TTMX39J
DM8B9YT	MN	Matrix metalloproteinase-1 (MMP-1)
DM8B9YT	MT	DTT
DM8B9YT	MA	Inhibitor
DM8B9YT	RN	Receptor flexibility in the in silico screening of reagents in the S1' pocket of human collagenase. J Med Chem. 2004 May 20;47(11):2761-7.
DM8B9YT	RU	https://pubmed.ncbi.nlm.nih.gov/15139754

DMTIW6K	DI	DMTIW6K
DMTIW6K	DN	Ro-31-8830
DMTIW6K	MI	TTYVX59
DMTIW6K	MN	Protein kinase C (PRKC)
DMTIW6K	MT	DTT
DMTIW6K	MA	Inhibitor
DMTIW6K	RN	Oral, anti-inflammatory activity of a potent, selective, protein kinase C inhibitor. Agents Actions. 1992 Sep;37(1-2):85-9.
DMTIW6K	RU	https://pubmed.ncbi.nlm.nih.gov/1456183

DML3NEU	DI	DML3NEU
DML3NEU	DN	RO-319790
DML3NEU	MI	TTMX39J
DML3NEU	MN	Matrix metalloproteinase-1 (MMP-1)
DML3NEU	MT	DTT
DML3NEU	MA	Inhibitor
DML3NEU	RN	The asymmetric synthesis and in vitro characterization of succinyl mercaptoalcohol and mercaptoketone inhibitors of matrix metalloproteinases. Bioorg Med Chem Lett. 1998 May 19;8(10):1163-8.
DML3NEU	RU	https://pubmed.ncbi.nlm.nih.gov/9871728

DML3NEU	DI	DML3NEU
DML3NEU	DN	RO-319790
DML3NEU	MI	TTUZ2L5
DML3NEU	MN	Matrix metalloproteinase-3 (MMP-3)
DML3NEU	MT	DTT
DML3NEU	MA	Inhibitor
DML3NEU	RN	The asymmetric synthesis and in vitro characterization of succinyl mercaptoalcohol and mercaptoketone inhibitors of matrix metalloproteinases. Bioorg Med Chem Lett. 1998 May 19;8(10):1163-8.
DML3NEU	RU	https://pubmed.ncbi.nlm.nih.gov/9871728

DML3NEU	DI	DML3NEU
DML3NEU	DN	RO-319790
DML3NEU	MI	TT6X50U
DML3NEU	MN	Matrix metalloproteinase-9 (MMP-9)
DML3NEU	MT	DTT
DML3NEU	MA	Inhibitor
DML3NEU	RN	The asymmetric synthesis and in vitro characterization of succinyl mercaptoalcohol and mercaptoketone inhibitors of matrix metalloproteinases. Bioorg Med Chem Lett. 1998 May 19;8(10):1163-8.
DML3NEU	RU	https://pubmed.ncbi.nlm.nih.gov/9871728

DMFZ1YW	DI	DMFZ1YW
DMFZ1YW	DN	RO-320432
DMFZ1YW	MI	TTRSMW9
DMFZ1YW	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMFZ1YW	MT	DTT
DMFZ1YW	MA	Inhibitor
DMFZ1YW	RN	Discovery of potent and bioavailable GSK-3beta inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1693-6.
DMFZ1YW	RU	https://pubmed.ncbi.nlm.nih.gov/20138512

DMFZ1YW	DI	DMFZ1YW
DMFZ1YW	DN	RO-320432
DMFZ1YW	MI	TTFJ8Q1
DMFZ1YW	MN	Protein kinase C alpha (PRKCA)
DMFZ1YW	MT	DTT
DMFZ1YW	MA	Inhibitor
DMFZ1YW	RN	Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994).
DMFZ1YW	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01803498

DMFZ1YW	DI	DMFZ1YW
DMFZ1YW	DN	RO-320432
DMFZ1YW	MI	TTYPXQF
DMFZ1YW	MN	Protein kinase C beta (PRKCB)
DMFZ1YW	MT	DTT
DMFZ1YW	MA	Inhibitor
DMFZ1YW	RN	Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994).
DMFZ1YW	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01803498

DMFZ1YW	DI	DMFZ1YW
DMFZ1YW	DN	RO-320432
DMFZ1YW	MI	TT9WJ8U
DMFZ1YW	MN	Protein kinase C delta (PRKCD)
DMFZ1YW	MT	DTT
DMFZ1YW	MA	Inhibitor
DMFZ1YW	RN	Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994).
DMFZ1YW	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01803498

DMFZ1YW	DI	DMFZ1YW
DMFZ1YW	DN	RO-320432
DMFZ1YW	MI	TTBZ7OD
DMFZ1YW	MN	Protein kinase C epsilon (PRKCE)
DMFZ1YW	MT	DTT
DMFZ1YW	MA	Inhibitor
DMFZ1YW	RN	Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994).
DMFZ1YW	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01803498

DMFZ1YW	DI	DMFZ1YW
DMFZ1YW	DN	RO-320432
DMFZ1YW	MI	TTRFOXJ
DMFZ1YW	MN	Protein kinase C gamma (PRKCG)
DMFZ1YW	MT	DTT
DMFZ1YW	MA	Inhibitor
DMFZ1YW	RN	Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994).
DMFZ1YW	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01803498

DMFZ1YW	DI	DMFZ1YW
DMFZ1YW	DN	RO-320432
DMFZ1YW	MI	TT8QL1J
DMFZ1YW	MN	Protein kinase C theta (PRKCQ)
DMFZ1YW	MT	DTT
DMFZ1YW	MA	Inhibitor
DMFZ1YW	RN	Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994).
DMFZ1YW	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01803498

DMFZ1YW	DI	DMFZ1YW
DMFZ1YW	DN	RO-320432
DMFZ1YW	MI	TTUWGRA
DMFZ1YW	MN	Protein kinase C zeta (PRKCZ)
DMFZ1YW	MT	DTT
DMFZ1YW	MA	Inhibitor
DMFZ1YW	RN	Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994).
DMFZ1YW	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01803498

DMPNHF0	DI	DMPNHF0
DMPNHF0	DN	Ro-43-5054
DMPNHF0	MI	TTJA1ZO
DMPNHF0	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMPNHF0	MT	DTT
DMPNHF0	MA	Inhibitor
DMPNHF0	RN	Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J Med Chem. 2000 Sep 21;43(19):3453-73.
DMPNHF0	RU	https://pubmed.ncbi.nlm.nih.gov/10999999

DM4VY8S	DI	DM4VY8S
DM4VY8S	DN	Ro-43-8857
DM4VY8S	MI	TTJA1ZO
DM4VY8S	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DM4VY8S	MT	DTT
DM4VY8S	MA	Inhibitor
DM4VY8S	RN	Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J Med Chem. 2000 Sep 21;43(19):3453-73.
DM4VY8S	RU	https://pubmed.ncbi.nlm.nih.gov/10999999

DMRT6FV	DI	DMRT6FV
DMRT6FV	DN	Ro-46-2005
DMRT6FV	MI	TTCV6O0
DMRT6FV	MN	Endothelin receptor (EDNR)
DMRT6FV	MT	DTT
DMRT6FV	MA	Modulator
DMRT6FV	RN	In vitro characterization of Ro 46-2005, a novel synthetic non-peptide endothelin antagonist of ETA and ETB receptors. FEBS Lett. 1993 Nov 15;334(2):210-4.
DMRT6FV	RU	https://pubmed.ncbi.nlm.nih.gov/8224248

DMU9JAH	DI	DMU9JAH
DMU9JAH	DN	Ro-46-5934
DMU9JAH	MI	TT1RS9F
DMU9JAH	MN	Acetylcholinesterase (AChE)
DMU9JAH	MT	DTT
DMU9JAH	MA	Inhibitor
DMU9JAH	RN	A novel acetylcholinesterase inhibitor, Ro 46-5934, which interacts with muscarinic M2 receptors. Biochem Soc Trans. 1994 Aug;22(3):755-8.
DMU9JAH	RU	https://pubmed.ncbi.nlm.nih.gov/7821679

DMXMP3D	DI	DMXMP3D
DMXMP3D	DN	Ro-48-1220
DMXMP3D	MI	TTHI19T
DMXMP3D	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMXMP3D	MT	DTT
DMXMP3D	MA	Modulator
DMXMP3D	RN	Comparative in vitro activity of apalcillin alone and combined with Ro 48-1220, a novel penam beta-lactamase inhibitor. Clin Microbiol Infect. 1995 Feb;1(2):86-100.
DMXMP3D	RU	https://pubmed.ncbi.nlm.nih.gov/11866735

DM7AUF2	DI	DM7AUF2
DM7AUF2	DN	Ro-48-5545
DM7AUF2	MI	TTHI19T
DM7AUF2	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DM7AUF2	MT	DTT
DM7AUF2	MA	Inhibitor
DM7AUF2	RN	Potentiation of beta-lactams against Pseudomonas aeruginosa strains by Ro 48-1256, a bridged monobactam inhibitor of AmpC beta-lactamases. J Antimicrob Chemother. 1997 Sep;40(3):335-43.
DM7AUF2	RU	https://pubmed.ncbi.nlm.nih.gov/9338484

DM0RZEO	DI	DM0RZEO
DM0RZEO	DN	Ro-48-8724
DM0RZEO	MI	TTHI19T
DM0RZEO	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DM0RZEO	MT	DTT
DM0RZEO	MA	Modulator
DM0RZEO	RN	Activity of a broad-spectrum cephalosporin (Ro 48-8391) alone and in combination with two novel beta-lactamase inhibitors (Ro 48-5545 and Ro 48-8724). Diagn Microbiol Infect Dis. 1998 Oct;32(2):85-94.
DM0RZEO	RU	https://pubmed.ncbi.nlm.nih.gov/9823530

DMZSQU8	DI	DMZSQU8
DMZSQU8	DN	Ro-60-0175
DMZSQU8	MI	TTJQOD7
DMZSQU8	MN	5-HT 2A receptor (HTR2A)
DMZSQU8	MT	DTT
DMZSQU8	MA	Inhibitor
DMZSQU8	RN	Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor a... Bioorg Med Chem. 2008 Feb 15;16(4):1966-82.
DMZSQU8	RU	https://pubmed.ncbi.nlm.nih.gov/18035544

DMZSQU8	DI	DMZSQU8
DMZSQU8	DN	Ro-60-0175
DMZSQU8	MI	TT0K1SC
DMZSQU8	MN	5-HT 2B receptor (HTR2B)
DMZSQU8	MT	DTT
DMZSQU8	MA	Inhibitor
DMZSQU8	RN	Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists. Bioorg Med Chem Lett. 2006 Feb;16(3):677-80.
DMZSQU8	RU	https://pubmed.ncbi.nlm.nih.gov/16257207

DMZSQU8	DI	DMZSQU8
DMZSQU8	DN	Ro-60-0175
DMZSQU8	MI	TTWJBZ5
DMZSQU8	MN	5-HT 2C receptor (HTR2C)
DMZSQU8	MT	DTT
DMZSQU8	MA	Inhibitor
DMZSQU8	RN	Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor a... Bioorg Med Chem. 2008 Feb 15;16(4):1966-82.
DMZSQU8	RU	https://pubmed.ncbi.nlm.nih.gov/18035544

DM6JO30	DI	DM6JO30
DM6JO30	DN	Rogletimide
DM6JO30	MI	TTSZLWK
DM6JO30	MN	Aromatase (CYP19A1)
DM6JO30	MT	DTT
DM6JO30	MA	Inhibitor
DM6JO30	RN	Analogues of 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione as selective inhibitors of aromatase: derivatives with variable 1-alkyl and 3-alkyl substitu... J Med Chem. 1987 Sep;30(9):1550-4.
DM6JO30	RU	https://pubmed.ncbi.nlm.nih.gov/3625703

DM4VCJI	DI	DM4VCJI
DM4VCJI	DN	Rovelizumab
DM4VCJI	MI	TTD26RC
DM4VCJI	MN	Cell adhesion molecule (CADM)
DM4VCJI	MT	DTT
DM4VCJI	RN	Rovelizumab (ICOS Corp). IDrugs. 2000 Apr;3(4):442-6.
DM4VCJI	RU	https://pubmed.ncbi.nlm.nih.gov/16100700

DMQZ2JA	DI	DMQZ2JA
DMQZ2JA	DN	RP-58802B
DMQZ2JA	MI	TT2CJVK
DMQZ2JA	MN	Adrenergic receptor beta-2 (ADRB2)
DMQZ2JA	MT	DTT
DMQZ2JA	MA	Modulator
DMQZ2JA	RN	RP 58802B, a long-acting beta 2-adrenoceptor agonist: assessment of antiasthma activity in the guinea-pig in vivo. Pulm Pharmacol. 1992 Sep;5(3):203-12.
DMQZ2JA	RU	https://pubmed.ncbi.nlm.nih.gov/1280178

DM09QLY	DI	DM09QLY
DM09QLY	DN	RP-66055
DM09QLY	MI	TTRK8B9
DM09QLY	MN	Sodium channel unspecific (NaC)
DM09QLY	MT	DTT
DM09QLY	MA	Modulator
DM09QLY	RN	Synthesis, anticonvulsant and neuroprotective activities of RP 66055, a riluzole derivative. Bioorg Med Chem. 1994 Aug;2(8):793-8.
DM09QLY	RU	https://pubmed.ncbi.nlm.nih.gov/7894973

DMX4E75	DI	DMX4E75
DMX4E75	DN	RP-66153
DMX4E75	MI	TTN53ZF
DMX4E75	MN	Leukotriene B4 receptor 1 (LTB4R)
DMX4E75	MT	DTT
DMX4E75	MA	Modulator
DMX4E75	RN	Omega-[(omega-arylalkyl)thienyl]alkanoic acids: from specific LTA4 hydrolase inhibitors to LTB4 receptor antagonists. J Med Chem. 1992 Aug 21;35(17):3170-9.
DMX4E75	RU	https://pubmed.ncbi.nlm.nih.gov/1324316

DM6HJX7	DI	DM6HJX7
DM6HJX7	DN	RP-66364
DM6HJX7	MI	TTN53ZF
DM6HJX7	MN	Leukotriene B4 receptor 1 (LTB4R)
DM6HJX7	MT	DTT
DM6HJX7	MA	Modulator
DM6HJX7	RN	WO patent application no. 1997,0297,75, Compositions comprising a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist.
DM6HJX7	RU	http://www.google.com/patents/WO1997029775A1?cl=en

DM6HJX7	DI	DM6HJX7
DM6HJX7	DN	RP-66364
DM6HJX7	MI	TTK0943
DM6HJX7	MN	Prostaglandin G/H synthase (COX)
DM6HJX7	MT	DTT
DM6HJX7	MA	Modulator
DM6HJX7	RN	WO patent application no. 1997,0297,75, Compositions comprising a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist.
DM6HJX7	RU	http://www.google.com/patents/WO1997029775A1?cl=en

DM2GV78	DI	DM2GV78
DM2GV78	DN	RP-66784
DM2GV78	MI	TT1VOHK
DM2GV78	MN	Potassium channel unspecific (KC)
DM2GV78	MT	DTT
DM2GV78	MA	Opener
DM2GV78	RN	Syntheses and biological activities of potent potassium channel openers derived from (+/-)-2-oxo-1-pyridin-3-yl-cyclohexanecarbothioic acid methylamide: new potassium channel openers. J Med Chem. 1993 May 28;36(11):1604-12.
DM2GV78	RU	https://pubmed.ncbi.nlm.nih.gov/8496928

DMDLW64	DI	DMDLW64
DMDLW64	DN	RP-67580
DMDLW64	MI	TTZPO1L
DMDLW64	MN	Substance-P receptor (TACR1)
DMDLW64	MT	DTT
DMDLW64	MA	Antagonist
DMDLW64	RN	Effects of RP 67580, a tachykinin NK1 receptor antagonist, on a primary afferent-evoked response of ventral roots in the neonatal rat spinal cord. Br J Pharmacol. 1994 Dec;113(4):1141-6.
DMDLW64	RU	https://pubmed.ncbi.nlm.nih.gov/7534180

DM0BEM3	DI	DM0BEM3
DM0BEM3	DN	RP-68303
DM0BEM3	MI	TTJQOD7
DM0BEM3	MN	5-HT 2A receptor (HTR2A)
DM0BEM3	MT	DTT
DM0BEM3	MA	Inhibitor
DM0BEM3	RN	New indole derivatives as potent and selective serotonin uptake inhibitors. J Med Chem. 1993 Apr 30;36(9):1194-202.
DM0BEM3	RU	https://pubmed.ncbi.nlm.nih.gov/8487257

DMUY4FD	DI	DMUY4FD
DMUY4FD	DN	RP-69698
DMUY4FD	MI	TTN53ZF
DMUY4FD	MN	Leukotriene B4 receptor 1 (LTB4R)
DMUY4FD	MT	DTT
DMUY4FD	MA	Modulator
DMUY4FD	RN	omega-[(4,6-Diphenyl-2-pyridyl)oxy]alkanoic acid derivatives: a new family of potent and orally active LTB4 antagonists. J Med Chem. 1992 Nov 13;35(23):4315-24.
DMUY4FD	RU	https://pubmed.ncbi.nlm.nih.gov/1333012

DMHO5AG	DI	DMHO5AG
DMHO5AG	DN	RP-70676
DMHO5AG	MI	TTMF541
DMHO5AG	MN	Liver carboxylesterase (CES1)
DMHO5AG	MT	DTT
DMHO5AG	MA	Modulator
DMHO5AG	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002876)
DMHO5AG	RU	http://adisinsight.springer.com/drugs/800002876

DMO3FYI	DI	DMO3FYI
DMO3FYI	DN	RP-73163
DMO3FYI	MI	TTMF541
DMO3FYI	MN	Liver carboxylesterase (CES1)
DMO3FYI	MT	DTT
DMO3FYI	MA	Modulator
DMO3FYI	RN	Hypolipidaemic properties of a potent and bioavailable alkylsulphinyl-diphenylimidazole ACAT inhibitor (RP 73163) in animals fed diets low in cholesterol. Biochem Pharmacol. 1996 Oct 25;52(8):1177-86.
DMO3FYI	RU	https://pubmed.ncbi.nlm.nih.gov/8937424

DMUCP8K	DI	DMUCP8K
DMUCP8K	DN	RPK-739
DMUCP8K	MI	TTNYZG2
DMUCP8K	MN	Granulocyte-macrophage colony-stimulating factor (CSF2)
DMUCP8K	MT	DTT
DMUCP8K	MA	Modulator
DMUCP8K	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMUCP8K	RU	https://www.fda.gov/

DM1U0TB	DI	DM1U0TB
DM1U0TB	DN	RPR 200765A
DM1U0TB	MI	TTVKILB
DM1U0TB	MN	Prostaglandin G/H synthase 2 (COX-2)
DM1U0TB	MT	DTT
DM1U0TB	MA	Inhibitor
DM1U0TB	RN	The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy. Bioorg Med Chem. 2001 Feb;9(2):537-54.
DM1U0TB	RU	https://pubmed.ncbi.nlm.nih.gov/11249145

DM21Y75	DI	DM21Y75
DM21Y75	DN	RPR-101821
DM21Y75	MI	TTFQEO5
DM21Y75	MN	Squalene synthetase (FDFT1)
DM21Y75	MT	DTT
DM21Y75	MA	Modulator
DM21Y75	RN	RPR 101821, a new potent cholesterol-lowering agent: inhibition of squalene synthase and 7-dehydrocholesterol reductase. Naunyn Schmiedebergs Arch Pharmacol. 1996 Jan;353(2):233-40.
DM21Y75	RU	https://pubmed.ncbi.nlm.nih.gov/8717165

DM9L50N	DI	DM9L50N
DM9L50N	DN	RPR-104632
DM9L50N	MI	TTLD29N
DM9L50N	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DM9L50N	MT	DTT
DM9L50N	MA	Inhibitor
DM9L50N	RN	Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity. J Med Chem. 2000 Jun 15;43(12):2371-81.
DM9L50N	RU	https://pubmed.ncbi.nlm.nih.gov/10882363

DM9L50N	DI	DM9L50N
DM9L50N	DN	RPR-104632
DM9L50N	MI	TTKJEMQ
DM9L50N	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DM9L50N	MT	DTT
DM9L50N	MA	Inhibitor
DM9L50N	RN	Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity. J Med Chem. 2000 Jun 15;43(12):2371-81.
DM9L50N	RU	https://pubmed.ncbi.nlm.nih.gov/10882363

DM9L50N	DI	DM9L50N
DM9L50N	DN	RPR-104632
DM9L50N	MI	TTN9D8E
DM9L50N	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DM9L50N	MT	DTT
DM9L50N	MA	Inhibitor
DM9L50N	RN	Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity. J Med Chem. 2000 Jun 15;43(12):2371-81.
DM9L50N	RU	https://pubmed.ncbi.nlm.nih.gov/10882363

DMJ63GW	DI	DMJ63GW
DMJ63GW	DN	RPR-113829
DMJ63GW	MI	TT7WZIJ
DMJ63GW	MN	CAAX farnesyltransferase beta (FNTB)
DMJ63GW	MT	DTT
DMJ63GW	MA	Inhibitor
DMJ63GW	RN	Novel conformationally extended naphthalene-based inhibitors of farnesyltransferase. J Med Chem. 1997 Jun 6;40(12):1763-7.
DMJ63GW	RU	https://pubmed.ncbi.nlm.nih.gov/9191950

DMJ63GW	DI	DMJ63GW
DMJ63GW	DN	RPR-113829
DMJ63GW	MI	TTXQKM3
DMJ63GW	MN	Farnesyl protein transferase (Ftase)
DMJ63GW	MT	DTT
DMJ63GW	MA	Inhibitor
DMJ63GW	RN	Novel conformationally extended naphthalene-based inhibitors of farnesyltransferase. J Med Chem. 1997 Jun 6;40(12):1763-7.
DMJ63GW	RU	https://pubmed.ncbi.nlm.nih.gov/9191950

DMAIJT6	DI	DMAIJT6
DMAIJT6	DN	RPR-114334
DMAIJT6	MI	TT7WZIJ
DMAIJT6	MN	CAAX farnesyltransferase beta (FNTB)
DMAIJT6	MT	DTT
DMAIJT6	MA	Inhibitor
DMAIJT6	RN	Novel conformationally extended naphthalene-based inhibitors of farnesyltransferase. J Med Chem. 1997 Jun 6;40(12):1763-7.
DMAIJT6	RU	https://pubmed.ncbi.nlm.nih.gov/9191950

DMAIJT6	DI	DMAIJT6
DMAIJT6	DN	RPR-114334
DMAIJT6	MI	TTXQKM3
DMAIJT6	MN	Farnesyl protein transferase (Ftase)
DMAIJT6	MT	DTT
DMAIJT6	MA	Inhibitor
DMAIJT6	RN	Novel conformationally extended naphthalene-based inhibitors of farnesyltransferase. J Med Chem. 1997 Jun 6;40(12):1763-7.
DMAIJT6	RU	https://pubmed.ncbi.nlm.nih.gov/9191950

DMKQV9A	DI	DMKQV9A
DMKQV9A	DN	RS 86
DMKQV9A	MI	TTH18TF
DMKQV9A	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMKQV9A	MT	DTT
DMKQV9A	MA	Agonist
DMKQV9A	RN	The pharmacological assessment of RS 86 (2-ethyl-8-methyl-2,8-diazaspiro-[4,5]-decan-1,3-dion hydrobromide). A potent, specific muscarinic acetylcholine receptor agonist. Eur J Pharmacol. 1986 Jun 5;125(1):45-62.
DMKQV9A	RU	https://pubmed.ncbi.nlm.nih.gov/3732391

DMFJ0KC	DI	DMFJ0KC
DMFJ0KC	DN	RS-2135
DMFJ0KC	MI	TTRK8B9
DMFJ0KC	MN	Sodium channel unspecific (NaC)
DMFJ0KC	MT	DTT
DMFJ0KC	MA	Modulator
DMFJ0KC	RN	Electrophysiologic effects of RS-2135, a new antiarrhythmic compound, on canine Purkinje fibers. J Cardiovasc Pharmacol. 1992 Dec;20(6):955-60.
DMFJ0KC	RU	https://pubmed.ncbi.nlm.nih.gov/1282599

DMT5DH0	DI	DMT5DH0
DMT5DH0	DN	RS-66252
DMT5DH0	MI	TT8DBY3
DMT5DH0	MN	Angiotensin II receptor type-1 (AGTR1)
DMT5DH0	MT	DTT
DMT5DH0	MA	Modulator
DMT5DH0	RN	Virtual Screening in Drug Discovery, Juan Alvarez Brian Shoichet. Page(218).
DMT5DH0	RU	https://books.google.com.hk/books?id=Yj9HgUgq_uwC&pg=PA218&lpg=PA218&dq=RS-66252++++angiotensin+II&source=bl&ots=ohMTzwCVx9&sig=wzHmoRk4h2AhEdyLvkPdYcfjhPk&hl=zh-CN&sa=X&ved=0CB8Q6AEwAGoVChMIzrnc9469yAIVEAmOCh0byQrL

DMZHS9U	DI	DMZHS9U
DMZHS9U	DN	RS-93522
DMZHS9U	MI	TT5HONZ
DMZHS9U	MN	Calcium channel unspecific (CaC)
DMZHS9U	MT	DTT
DMZHS9U	MA	Blocker
DMZHS9U	RN	Intranasal delivery of RS-93522, a dihydropyridine-type calcium-channel antagonist. Pharm Res. 1991 Jan;8(1):134-5.
DMZHS9U	RU	https://pubmed.ncbi.nlm.nih.gov/2014202

DMVW3I9	DI	DMVW3I9
DMVW3I9	DN	RU 24969
DMVW3I9	MI	TTWT5K7
DMVW3I9	MN	5-HT 1 receptor (5HT1R)
DMVW3I9	MT	DTT
DMVW3I9	MA	Agonist
DMVW3I9	RN	Effect of chronic treatment with 5-HT1 agonist (8-OH-DPAT and RU 24969) and antagonist (isapirone) drugs on the behavioural responses of mice to 5-HT1 and 5-HT2 agonists. Br J Pharmacol. 1986 Oct;89(2):377-84.
DMVW3I9	RU	https://pubmed.ncbi.nlm.nih.gov/2946344

DMSWFMQ	DI	DMSWFMQ
DMSWFMQ	DN	RU-33965
DMSWFMQ	MI	TTEX6LM
DMSWFMQ	MN	GABA(A) receptor gamma-3 (GABRG3)
DMSWFMQ	MT	DTT
DMSWFMQ	MA	Modulator
DMSWFMQ	RN	Discriminative stimulus properties of RU 33965, a benzodiazepine receptor weak partial inverse agonist. Pharmacol Biochem Behav. 1992 Oct;43(2):583-8.
DMSWFMQ	RU	https://pubmed.ncbi.nlm.nih.gov/1359581

DM8B1DH	DI	DM8B1DH
DM8B1DH	DN	RU-46556
DM8B1DH	MI	TTUV8G9
DM8B1DH	MN	Progesterone receptor (PGR)
DM8B1DH	MT	DTT
DM8B1DH	MA	Modulator
DM8B1DH	RN	New analogues of mifepristone with more dissociated antiprogesterone activities. J Steroid Biochem. 1989;34(1-6):413-7.
DM8B1DH	RU	https://pubmed.ncbi.nlm.nih.gov/2560520

DMBXDQG	DI	DMBXDQG
DMBXDQG	DN	RWJ-22108
DMBXDQG	MI	TT5HONZ
DMBXDQG	MN	Calcium channel unspecific (CaC)
DMBXDQG	MT	DTT
DMBXDQG	MA	Modulator
DMBXDQG	RN	Design and discovery of RWJ 22108--a novel bronchoselective calcium channel blocker. Drug Des Discov. 1998 May;15(3):135-48.
DMBXDQG	RU	https://pubmed.ncbi.nlm.nih.gov/9689497

DMRQZWN	DI	DMRQZWN
DMRQZWN	DN	RWJ-25730
DMRQZWN	MI	TTSQIFT
DMRQZWN	MN	5-HT 1A receptor (HTR1A)
DMRQZWN	MT	DTT
DMRQZWN	MA	Modulator
DMRQZWN	RN	Piperazinylalkyl heterocycles as potential antipsychotic agents. J Med Chem. 1995 Oct 13;38(21):4198-210.
DMRQZWN	RU	https://www.ncbi.nlm.nih.gov/pubmed/7473547

DMRQZWN	DI	DMRQZWN
DMRQZWN	DN	RWJ-25730
DMRQZWN	MI	TTEX248
DMRQZWN	MN	Dopamine D2 receptor (D2R)
DMRQZWN	MT	DTT
DMRQZWN	MA	Modulator
DMRQZWN	RN	Piperazinylalkyl heterocycles as potential antipsychotic agents. J Med Chem. 1995 Oct 13;38(21):4198-210.
DMRQZWN	RU	https://www.ncbi.nlm.nih.gov/pubmed/7473547

DM17WNG	DI	DM17WNG
DM17WNG	DN	RWJ-37868
DM17WNG	MI	TT5HONZ
DM17WNG	MN	Calcium channel unspecific (CaC)
DM17WNG	MT	DTT
DM17WNG	MA	Modulator
DM17WNG	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008896)
DM17WNG	RU	http://adisinsight.springer.com/drugs/800008896

DMEO7YD	DI	DMEO7YD
DMEO7YD	DN	RWJ-46458
DMEO7YD	MI	TTGN1ZA
DMEO7YD	MN	Angiotensin II receptor (AGTR)
DMEO7YD	MT	DTT
DMEO7YD	MA	Modulator
DMEO7YD	RN	WO patent application no. 1996,0402,58, Spironolactone and angiotensin ii antagonist combination therapy for treatment of congestive heart failure.
DMEO7YD	RU	http://www.google.com/patents/WO1996040258A2?cl=en

DMUGZMO	DI	DMUGZMO
DMUGZMO	DN	RWJ-49815
DMUGZMO	MI	TTJVCG0
DMUGZMO	MN	Bacterial Sporulation kinase A (Bact kinA)
DMUGZMO	MT	DTT
DMUGZMO	MA	Inhibitor
DMUGZMO	RN	Histidine kinases as targets for new antimicrobial agents. Bioorg Med Chem. 2002 Apr;10(4):855-67.
DMUGZMO	RU	https://pubmed.ncbi.nlm.nih.gov/11836091

DMUGZMO	DI	DMUGZMO
DMUGZMO	DN	RWJ-49815
DMUGZMO	MI	TTY6EWA
DMUGZMO	MN	Neuropeptide Y receptor type 5 (NPY5R)
DMUGZMO	MT	DTT
DMUGZMO	MA	Antagonist
DMUGZMO	RN	Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36.
DMUGZMO	RU	https://pubmed.ncbi.nlm.nih.gov/16634704

DMYXD6A	DI	DMYXD6A
DMYXD6A	DN	RWJ-58259
DMYXD6A	MI	TTL935N
DMYXD6A	MN	Proteinase activated receptor 1 (F2R)
DMYXD6A	MT	DTT
DMYXD6A	MA	Modulator
DMYXD6A	RN	RWJ-58259: a selective antagonist of protease activated receptor-1. Cardiovasc Drug Rev. 2003 Winter;21(4):313-26.
DMYXD6A	RU	https://pubmed.ncbi.nlm.nih.gov/14647534

DMUDE1T	DI	DMUDE1T
DMUDE1T	DN	RWJ-63556
DMUDE1T	MI	TT2J34L
DMUDE1T	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMUDE1T	MT	DTT
DMUDE1T	MA	Modulator
DMUDE1T	RN	Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation. J Pharmacol Exp Ther. 1997 Aug;282(2):1094-101.
DMUDE1T	RU	https://pubmed.ncbi.nlm.nih.gov/9262379

DMUDE1T	DI	DMUDE1T
DMUDE1T	DN	RWJ-63556
DMUDE1T	MI	TTVKILB
DMUDE1T	MN	Prostaglandin G/H synthase 2 (COX-2)
DMUDE1T	MT	DTT
DMUDE1T	MA	Modulator
DMUDE1T	RN	Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation. J Pharmacol Exp Ther. 1997 Aug;282(2):1094-101.
DMUDE1T	RU	https://pubmed.ncbi.nlm.nih.gov/9262379

DMDQGFR	DI	DMDQGFR
DMDQGFR	DN	S-1389
DMDQGFR	MI	TT1VOHK
DMDQGFR	MN	Potassium channel unspecific (KC)
DMDQGFR	MT	DTT
DMDQGFR	MA	Opener
DMDQGFR	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000214)
DMDQGFR	RU	http://adisinsight.springer.com/drugs/800000214

DM759KX	DI	DM759KX
DM759KX	DN	S-14080
DM759KX	MI	TTK0943
DM759KX	MN	Prostaglandin G/H synthase (COX)
DM759KX	MT	DTT
DM759KX	MA	Modulator
DM759KX	RN	US patent application no. 7,022,689, 5-amidino-n-(2-aminophenethyl)-n-hydroxy-benzenesulffonamide derivative, medical composition containing the same, pharmaceutical use thereof and intermediate therefor.
DM759KX	RU	http://www.google.com/patents/US7022689

DM05IQU	DI	DM05IQU
DM05IQU	DN	S-14506
DM05IQU	MI	TTSQIFT
DM05IQU	MN	5-HT 1A receptor (HTR1A)
DM05IQU	MT	DTT
DM05IQU	MA	Modulator
DM05IQU	RN	S 14506: novel receptor coupling at 5-HT(1A) receptors. Neuropharmacology. 2001 Mar;40(3):334-44.
DM05IQU	RU	https://www.ncbi.nlm.nih.gov/pubmed/11166326

DMQ8S4L	DI	DMQ8S4L
DMQ8S4L	DN	S-18616
DMQ8S4L	MI	TTWG9A4
DMQ8S4L	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMQ8S4L	MT	DTT
DMQ8S4L	MA	Modulator
DMQ8S4L	RN	S18616, a highly potent spiroimidazoline agonist at alpha(2)-adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidine. J Pharmacol Exp Ther. 2000 Dec;295(3):1206-22.
DMQ8S4L	RU	https://pubmed.ncbi.nlm.nih.gov/11082458

DMQDWMJ	DI	DMQDWMJ
DMQDWMJ	DN	S-20928
DMQDWMJ	MI	TT0WAIE
DMQDWMJ	MN	Melatonin receptor type 1A (MTNR1A)
DMQDWMJ	MT	DTT
DMQDWMJ	MA	Modulator
DMQDWMJ	RN	Effects of two melatonin analogues, S-20098 and S-20928, on melatonin receptors in the pars tuberalis of the rat. J Pineal Res. 1998 Oct;25(3):172-6.
DMQDWMJ	RU	https://pubmed.ncbi.nlm.nih.gov/9745986

DMF710M	DI	DMF710M
DMF710M	DN	S-33516
DMF710M	MI	TTVKILB
DMF710M	MN	Prostaglandin G/H synthase 2 (COX-2)
DMF710M	MT	DTT
DMF710M	MA	Inhibitor
DMF710M	RN	S 33516 Servier preclinical data. R & D Focus Drug News. July 12, 1999.
DMF710M	RU	http://business.highbeam.com/436989/article-1G1-56540224/s-33516-servier-preclinical-data

DMPQIUH	DI	DMPQIUH
DMPQIUH	DN	S-34109
DMPQIUH	MI	TTN6J5F
DMPQIUH	MN	Bacterial DNA gyrase (Bact gyrase)
DMPQIUH	MT	DTT
DMPQIUH	MA	Modulator
DMPQIUH	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007670)
DMPQIUH	RU	http://adisinsight.springer.com/drugs/800007670

DMEN6YO	DI	DMEN6YO
DMEN6YO	DN	Sameridine
DMEN6YO	MI	TTKWM86
DMEN6YO	MN	Opioid receptor mu (MOP)
DMEN6YO	MT	DTT
DMEN6YO	MA	Modulator
DMEN6YO	RN	The effects on resting ventilation of intravenous infusions of morphine or sameridine, a novel molecule with both local anesthetic and opioid properties. Anesth Analg. 1999 Jan;88(1):160-5.
DMEN6YO	RU	https://pubmed.ncbi.nlm.nih.gov/9895085

DMGUA9Y	DI	DMGUA9Y
DMGUA9Y	DN	SAN-61
DMGUA9Y	MI	TTRSMW9
DMGUA9Y	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMGUA9Y	MT	DTT
DMGUA9Y	MA	Inhibitor
DMGUA9Y	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029796)
DMGUA9Y	RU	http://adisinsight.springer.com/drugs/800029796

DM79E6W	DI	DM79E6W
DM79E6W	DN	Saviprazole
DM79E6W	MI	TTLOKXP
DM79E6W	MN	Gastric H(+)/K(+) ATPase (Proton pump)
DM79E6W	MT	DTT
DM79E6W	MA	Modulator
DM79E6W	RN	Gastric acid inhibitory profile of saviprazole (HOE 731) compared to omeprazole. Pharmacology. 1991;43(6):293-303.
DM79E6W	RU	https://pubmed.ncbi.nlm.nih.gov/1664524

DMNJ7LY	DI	DMNJ7LY
DMNJ7LY	DN	SB 203186
DMNJ7LY	MI	TT07C3Y
DMNJ7LY	MN	5-HT 4 receptor (HTR4)
DMNJ7LY	MT	DTT
DMNJ7LY	MA	Antagonist
DMNJ7LY	RN	5-Hydroxytryptamine mediated contractions in isolated preparations of equine ileum and pelvic flexure: pharmacological characterization of a new 5-HT(4) agonist. J Vet Pharmacol Ther. 2002 Feb;25(1):49-58.
DMNJ7LY	RU	https://pubmed.ncbi.nlm.nih.gov/11874527

DMAET6F	DI	DMAET6F
DMAET6F	DN	SB 203580
DMAET6F	MI	TTWOTEA
DMAET6F	MN	Interleukin 1 receptor type 1 (IL1R1)
DMAET6F	MT	DTT
DMAET6F	MA	Antagonist
DMAET6F	RN	IL-1- and TNF-induced bone resorption is mediated by p38 mitogen activated protein kinase. J Cell Physiol. 2001 Jun;187(3):294-303.
DMAET6F	RU	https://pubmed.ncbi.nlm.nih.gov/11319753

DMAET6F	DI	DMAET6F
DMAET6F	DN	SB 203580
DMAET6F	MI	TTVKILB
DMAET6F	MN	Prostaglandin G/H synthase 2 (COX-2)
DMAET6F	MT	DTT
DMAET6F	MA	Inhibitor
DMAET6F	RN	Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology. 2000 May;47(2-3):185-201.
DMAET6F	RU	https://pubmed.ncbi.nlm.nih.gov/10878289

DMAET6F	DI	DMAET6F
DMAET6F	DN	SB 203580
DMAET6F	MI	TTQBR95
DMAET6F	MN	Stress-activated protein kinase 2a (p38 alpha)
DMAET6F	MT	DTT
DMAET6F	MA	Inhibitor
DMAET6F	RN	The p38 mitogen-activated protein kinase pathway plays a critical role in thrombin-induced endothelial chemokine production and leukocyte recruitment. Blood. 2001 Aug 1;98(3):667-73.
DMAET6F	RU	https://pubmed.ncbi.nlm.nih.gov/11468165

DMS0QEP	DI	DMS0QEP
DMS0QEP	DN	SB 206553
DMS0QEP	MI	TT0K1SC
DMS0QEP	MN	5-HT 2B receptor (HTR2B)
DMS0QEP	MT	DTT
DMS0QEP	MA	Antagonist
DMS0QEP	RN	Strain-dependent effects of diazepam and the 5-HT2B/2C receptor antagonist SB 206553 in spontaneously hypertensive and Lewis rats tested in the elevated plus-maze. Braz J Med Biol Res. 2001 May;34(5):675-82.
DMS0QEP	RU	https://pubmed.ncbi.nlm.nih.gov/11323756

DMGNZUX	DI	DMGNZUX
DMGNZUX	DN	SB-201146
DMGNZUX	MI	TTN53ZF
DMGNZUX	MN	Leukotriene B4 receptor 1 (LTB4R)
DMGNZUX	MT	DTT
DMGNZUX	MA	Inhibitor
DMGNZUX	RN	(E)-3-[6-[[(2,6-dichlorophenyl)thio]methyl]-3-(2-phenylethoxy)-2- pyridinyl]-2-propenoic acid: a high-affinity leukotriene B4 receptor antagonist w... J Med Chem. 1996 Sep 13;39(19):3837-41.
DMGNZUX	RU	https://pubmed.ncbi.nlm.nih.gov/8809171

DM5ZPQJ	DI	DM5ZPQJ
DM5ZPQJ	DN	SB-206284A
DM5ZPQJ	MI	TT5HONZ
DM5ZPQJ	MN	Calcium channel unspecific (CaC)
DM5ZPQJ	MT	DTT
DM5ZPQJ	MA	Modulator
DM5ZPQJ	RN	The effects of SB 206284A, a novel neuronal calcium-channel antagonist, in models of cerebral ischemia. J Cereb Blood Flow Metab. 1997 Apr;17(4):421-9.
DM5ZPQJ	RU	https://pubmed.ncbi.nlm.nih.gov/9143224

DMYFE23	DI	DMYFE23
DMYFE23	DN	SB-206343
DMYFE23	MI	TT5FNQT
DMYFE23	MN	Human immunodeficiency virus Protease (HIV PR)
DMYFE23	MT	DTT
DMYFE23	MA	Modulator
DMYFE23	RN	Rational design, synthesis, and crystallographic analysis of a hydroxyethylene-based HIV-1 protease inhibitor containing a heterocyclic P1'--P2' amide bond isostere. J Med Chem. 1994 Sep 16;37(19):3100-7.
DMYFE23	RU	https://pubmed.ncbi.nlm.nih.gov/7932533

DMJD15H	DI	DMJD15H
DMJD15H	DN	SB-208651
DMJD15H	MI	TT38RM1
DMJD15H	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DMJD15H	MT	DTT
DMJD15H	MA	Modulator
DMJD15H	RN	Design of a potent and orally active nonpeptide platelet fibrinogen receptor (GPIIb/IIIa) antagonist. Bioorg Med Chem. 1994 Sep;2(9):897-908.
DMJD15H	RU	https://www.ncbi.nlm.nih.gov/pubmed/7712125

DMVBNTP	DI	DMVBNTP
DMVBNTP	DN	SB-209247
DMVBNTP	MI	TTN53ZF
DMVBNTP	MN	Leukotriene B4 receptor 1 (LTB4R)
DMVBNTP	MT	DTT
DMVBNTP	MA	Antagonist
DMVBNTP	RN	Formation and protein binding of the acyl glucuronide of a leukotriene B4 antagonist (SB-209247): relation to species differences in hepatotoxicity. Drug Metab Dispos. 2005 Feb;33(2):271-81.
DMVBNTP	RU	https://pubmed.ncbi.nlm.nih.gov/15523047

DM58PKG	DI	DM58PKG
DM58PKG	DN	SB-213698
DM58PKG	MI	TT27RFC
DM58PKG	MN	Opioid receptor delta (OPRD1)
DM58PKG	MT	DTT
DM58PKG	MA	Inhibitor
DM58PKG	RN	Design and synthesis of novel delta opioid receptor agonists and their pharmacologies. Bioorg Med Chem Lett. 2009 May 15;19(10):2792-5.
DM58PKG	RU	https://pubmed.ncbi.nlm.nih.gov/19362480

DM58PKG	DI	DM58PKG
DM58PKG	DN	SB-213698
DM58PKG	MI	TTQW87Y
DM58PKG	MN	Opioid receptor kappa (OPRK1)
DM58PKG	MT	DTT
DM58PKG	MA	Inhibitor
DM58PKG	RN	Design and synthesis of novel delta opioid receptor agonists and their pharmacologies. Bioorg Med Chem Lett. 2009 May 15;19(10):2792-5.
DM58PKG	RU	https://pubmed.ncbi.nlm.nih.gov/19362480

DM58PKG	DI	DM58PKG
DM58PKG	DN	SB-213698
DM58PKG	MI	TTKWM86
DM58PKG	MN	Opioid receptor mu (MOP)
DM58PKG	MT	DTT
DM58PKG	MA	Inhibitor
DM58PKG	RN	Design and synthesis of novel delta opioid receptor agonists and their pharmacologies. Bioorg Med Chem Lett. 2009 May 15;19(10):2792-5.
DM58PKG	RU	https://pubmed.ncbi.nlm.nih.gov/19362480

DMQW6B0	DI	DMQW6B0
DMQW6B0	DN	SB-219825
DMQW6B0	MI	TT27RFC
DMQW6B0	MN	Opioid receptor delta (OPRD1)
DMQW6B0	MT	DTT
DMQW6B0	MA	Modulator
DMQW6B0	RN	Mutation W284L of the human delta opioid receptor reveals agonist specific receptor conformations for G protein activation. Life Sci. 2001 Apr 6;68(19-20):2233-42.
DMQW6B0	RU	https://pubmed.ncbi.nlm.nih.gov/11358332

DMCZDE9	DI	DMCZDE9
DMCZDE9	DN	SB-219994
DMCZDE9	MI	TTZMAO3
DMCZDE9	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMCZDE9	MT	DTT
DMCZDE9	MA	Agonist
DMCZDE9	RN	PPAR-gamma agonists as therapy for diseases involving airway neutrophilia. Eur Respir J. 2004 Jul;24(1):18-23.
DMCZDE9	RU	https://pubmed.ncbi.nlm.nih.gov/15293600

DMSBUET	DI	DMSBUET
DMSBUET	DN	SB220025
DMSBUET	MI	TT4TQBX
DMSBUET	MN	Extracellular signal-regulated kinase 2 (ERK2)
DMSBUET	MT	DTT
DMSBUET	MA	Inhibitor
DMSBUET	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMSBUET	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMSBUET	DI	DMSBUET
DMSBUET	DN	SB220025
DMSBUET	MI	TTQBR95
DMSBUET	MN	Stress-activated protein kinase 2a (p38 alpha)
DMSBUET	MT	DTT
DMSBUET	MA	Inhibitor
DMSBUET	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMSBUET	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM3JQCF	DI	DM3JQCF
DM3JQCF	DN	SB-223245
DM3JQCF	MI	TTT1R2L
DM3JQCF	MN	Integrin alpha-V (ITGAV)
DM3JQCF	MT	DTT
DM3JQCF	MA	Inhibitor
DM3JQCF	RN	Discovery of an imidazopyridine-containing 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonist with efficacy in a resten... Bioorg Med Chem Lett. 1998 Nov 17;8(22):3171-6.
DM3JQCF	RU	https://pubmed.ncbi.nlm.nih.gov/9873697

DM3JQCF	DI	DM3JQCF
DM3JQCF	DN	SB-223245
DM3JQCF	MI	TTJA1ZO
DM3JQCF	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DM3JQCF	MT	DTT
DM3JQCF	MA	Inhibitor
DM3JQCF	RN	Discovery of an imidazopyridine-containing 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonist with efficacy in a resten... Bioorg Med Chem Lett. 1998 Nov 17;8(22):3171-6.
DM3JQCF	RU	https://pubmed.ncbi.nlm.nih.gov/9873697

DM5JDH1	DI	DM5JDH1
DM5JDH1	DN	SB-236049
DM5JDH1	MI	TTHI19T
DM5JDH1	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DM5JDH1	MT	DTT
DM5JDH1	MA	Inhibitor
DM5JDH1	RN	Identification of a series of tricyclic natural products as potent broad-spectrum inhibitors of metallo-beta-lactamases. Antimicrob Agents Chemother. 2002 Jun;46(6):1880-6.
DM5JDH1	RU	https://pubmed.ncbi.nlm.nih.gov/12019104

DMBCANZ	DI	DMBCANZ
DMBCANZ	DN	SB-237376
DMBCANZ	MI	TT5HONZ
DMBCANZ	MN	Calcium channel unspecific (CaC)
DMBCANZ	MT	DTT
DMBCANZ	MA	Modulator
DMBCANZ	RN	Electrophysiologic effects of SB-237376: a new antiarrhythmic compound with dual potassium and calcium channel blocking action. J Cardiovasc Pharmacol. 2003 Mar;41(3):414-21.
DMBCANZ	RU	https://pubmed.ncbi.nlm.nih.gov/12605020

DMBCANZ	DI	DMBCANZ
DMBCANZ	DN	SB-237376
DMBCANZ	MI	TT1VOHK
DMBCANZ	MN	Potassium channel unspecific (KC)
DMBCANZ	MT	DTT
DMBCANZ	MA	Modulator
DMBCANZ	RN	Electrophysiologic effects of SB-237376: a new antiarrhythmic compound with dual potassium and calcium channel blocking action. J Cardiovasc Pharmacol. 2003 Mar;41(3):414-21.
DMBCANZ	RU	https://pubmed.ncbi.nlm.nih.gov/12605020

DM8WTGA	DI	DM8WTGA
DM8WTGA	DN	SB-269970
DM8WTGA	MI	TTO9X1H
DM8WTGA	MN	5-HT 7 receptor (HTR7)
DM8WTGA	MT	DTT
DM8WTGA	MA	Modulator
DM8WTGA	RN	[(3)H]-SB-269970--A selective antagonist radioligand for 5-HT(7) receptors. Br J Pharmacol. 2000 May;130(2):409-17.
DM8WTGA	RU	https://pubmed.ncbi.nlm.nih.gov/10807680

DM3M16Q	DI	DM3M16Q
DM3M16Q	DN	SB-277011
DM3M16Q	MI	TT4C8EA
DM3M16Q	MN	Dopamine D3 receptor (D3R)
DM3M16Q	MT	DTT
DM3M16Q	MA	Antagonist
DM3M16Q	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DM3M16Q	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMZLKCF	DI	DMZLKCF
DMZLKCF	DN	SB-282241
DMZLKCF	MI	TTFZYTO
DMZLKCF	MN	C-C chemokine receptor type 2 (CCR2)
DMZLKCF	MT	DTT
DMZLKCF	MA	Antagonist
DMZLKCF	RN	Patent EP2727944 A1.
DMZLKCF	RU	http://www.google.com/patents/EP2727944A1?cl=en

DM9F7R0	DI	DM9F7R0
DM9F7R0	DN	SBP-002
DM9F7R0	MI	TT0E5SK
DM9F7R0	MN	Interleukin 6 receptor (IL6R)
DM9F7R0	MT	DTT
DM9F7R0	MA	Modulator
DM9F7R0	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM9F7R0	RU	https://www.fda.gov/

DM1MQ6Z	DI	DM1MQ6Z
DM1MQ6Z	DN	SC-102
DM1MQ6Z	MI	TTQBR95
DM1MQ6Z	MN	Stress-activated protein kinase 2a (p38 alpha)
DM1MQ6Z	MT	DTT
DM1MQ6Z	MA	Inhibitor
DM1MQ6Z	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM1MQ6Z	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMO1URE	DI	DMO1URE
DMO1URE	DN	SC-236
DMO1URE	MI	TTVKILB
DMO1URE	MN	Prostaglandin G/H synthase 2 (COX-2)
DMO1URE	MT	DTT
DMO1URE	MA	Inhibitor
DMO1URE	RN	Cyclooxygenase (COX)-2-dependent effects of the inhibitor SC236 when combined with ionizing radiation in mammary tumor cells derived from HER-2/neu mice. Mol Cancer Ther. 2004 Apr;3(4):417-24.
DMO1URE	RU	https://pubmed.ncbi.nlm.nih.gov/15078985

DM7I6VO	DI	DM7I6VO
DM7I6VO	DN	SC-241
DM7I6VO	MI	TTIY658
DM7I6VO	MN	Corticotropin-releasing factor receptor 2 (CRHR2)
DM7I6VO	MT	DTT
DM7I6VO	MA	Modulator
DM7I6VO	RN	US patent application no. 2015,0094,310, Crhr1 antagonists for use in the treatment of patients having crh overactivity.
DM7I6VO	RU	http://www.google.com.ar/patents/US20150094310

DMBPNKT	DI	DMBPNKT
DMBPNKT	DN	SC-44463
DMBPNKT	MI	TTXSU2Y
DMBPNKT	MN	Aggrecanase (ADAMTS5)
DMBPNKT	MT	DTT
DMBPNKT	MA	Inhibitor
DMBPNKT	RN	Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivati... J Med Chem. 2001 Oct 11;44(21):3347-50.
DMBPNKT	RU	https://pubmed.ncbi.nlm.nih.gov/11585439

DMBPNKT	DI	DMBPNKT
DMBPNKT	DN	SC-44463
DMBPNKT	MI	TTYG6BU
DMBPNKT	MN	Aggrecanase-1 (ADAMTS4)
DMBPNKT	MT	DTT
DMBPNKT	MA	Inhibitor
DMBPNKT	RN	Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivati... J Med Chem. 2001 Oct 11;44(21):3347-50.
DMBPNKT	RU	https://pubmed.ncbi.nlm.nih.gov/11585439

DMBPNKT	DI	DMBPNKT
DMBPNKT	DN	SC-44463
DMBPNKT	MI	TTMX39J
DMBPNKT	MN	Matrix metalloproteinase-1 (MMP-1)
DMBPNKT	MT	DTT
DMBPNKT	MA	Inhibitor
DMBPNKT	RN	A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. J Med Chem. 2003 Jul 31;46(16):3514-25.
DMBPNKT	RU	https://pubmed.ncbi.nlm.nih.gov/12877590

DMBPNKT	DI	DMBPNKT
DMBPNKT	DN	SC-44463
DMBPNKT	MI	TTLM12X
DMBPNKT	MN	Matrix metalloproteinase-2 (MMP-2)
DMBPNKT	MT	DTT
DMBPNKT	MA	Inhibitor
DMBPNKT	RN	A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. J Med Chem. 2003 Jul 31;46(16):3514-25.
DMBPNKT	RU	https://pubmed.ncbi.nlm.nih.gov/12877590

DMBPNKT	DI	DMBPNKT
DMBPNKT	DN	SC-44463
DMBPNKT	MI	TTUZ2L5
DMBPNKT	MN	Matrix metalloproteinase-3 (MMP-3)
DMBPNKT	MT	DTT
DMBPNKT	MA	Inhibitor
DMBPNKT	RN	Amide surrogates of matrix metalloproteinase inhibitors: Urea and sulfonamide mimics, Bioorg. Med. Chem. Lett. 7(18):2331-2336 (1997).
DMBPNKT	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97001820

DMBPNKT	DI	DMBPNKT
DMBPNKT	DN	SC-44463
DMBPNKT	MI	TTMTWOS
DMBPNKT	MN	Matrix metalloproteinase-7 (MMP-7)
DMBPNKT	MT	DTT
DMBPNKT	MA	Inhibitor
DMBPNKT	RN	A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. J Med Chem. 2003 Jul 31;46(16):3514-25.
DMBPNKT	RU	https://pubmed.ncbi.nlm.nih.gov/12877590

DMBPNKT	DI	DMBPNKT
DMBPNKT	DN	SC-44463
DMBPNKT	MI	TTGA1IV
DMBPNKT	MN	Matrix metalloproteinase-8 (MMP-8)
DMBPNKT	MT	DTT
DMBPNKT	MA	Inhibitor
DMBPNKT	RN	Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivati... J Med Chem. 2001 Oct 11;44(21):3347-50.
DMBPNKT	RU	https://pubmed.ncbi.nlm.nih.gov/11585439

DMBPNKT	DI	DMBPNKT
DMBPNKT	DN	SC-44463
DMBPNKT	MI	TT6X50U
DMBPNKT	MN	Matrix metalloproteinase-9 (MMP-9)
DMBPNKT	MT	DTT
DMBPNKT	MA	Inhibitor
DMBPNKT	RN	Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivati... J Med Chem. 2001 Oct 11;44(21):3347-50.
DMBPNKT	RU	https://pubmed.ncbi.nlm.nih.gov/11585439

DMIE039	DI	DMIE039
DMIE039	DN	SC-47643
DMIE039	MI	TTJA1ZO
DMIE039	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMIE039	MT	DTT
DMIE039	MA	Inhibitor
DMIE039	RN	Novel thiazole-based heterocycles as selective inhibitors of fibrinogen-mediated platelet aggregation. J Med Chem. 1995 Jan 6;38(1):34-41.
DMIE039	RU	https://pubmed.ncbi.nlm.nih.gov/7837237

DMIE039	DI	DMIE039
DMIE039	DN	SC-47643
DMIE039	MI	TTD0652
DMIE039	MN	Proteinase activated receptor 4 (F2RL3)
DMIE039	MT	DTT
DMIE039	MA	Inhibitor
DMIE039	RN	Novel thiazole-based heterocycles as selective inhibitors of fibrinogen-mediated platelet aggregation. J Med Chem. 1995 Jan 6;38(1):34-41.
DMIE039	RU	https://pubmed.ncbi.nlm.nih.gov/7837237

DMY7KHW	DI	DMY7KHW
DMY7KHW	DN	SC-49992
DMY7KHW	MI	TT38RM1
DMY7KHW	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DMY7KHW	MT	DTT
DMY7KHW	MA	Modulator
DMY7KHW	RN	SC-49992--a potent and specific inhibitor of platelet aggregation. Thromb Res. 1994 Jun 1;74(5):523-35.
DMY7KHW	RU	https://www.ncbi.nlm.nih.gov/pubmed/8085253

DM8UDSF	DI	DM8UDSF
DM8UDSF	DN	SC-50560
DM8UDSF	MI	TTQVOEI
DM8UDSF	MN	Angiotensin II receptor type-2 (AGTR2)
DM8UDSF	MT	DTT
DM8UDSF	MA	Inhibitor
DM8UDSF	RN	N1-sterically hindered 2H-imidazol-2-one angiotensin II receptor antagonists: The conversion of surmountable antagonists to insurmountable antagonists, Bioorg. Med. Chem. Lett. 3(6):1055-1060 (1993).
DM8UDSF	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00802863

DMI0QZ3	DI	DMI0QZ3
DMI0QZ3	DN	SC-51146
DMI0QZ3	MI	TTN53ZF
DMI0QZ3	MN	Leukotriene B4 receptor 1 (LTB4R)
DMI0QZ3	MT	DTT
DMI0QZ3	MA	Inhibitor
DMI0QZ3	RN	Synthesis and pharmacological activity of SC-53228, a leukotriene B4 receptor antagonist with high intrinsic potency and selectivity, Bioorg. Med. Chem. Lett. 4(6):811-816 (1994).
DMI0QZ3	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01808532

DMB26LO	DI	DMB26LO
DMB26LO	DN	SC-51316
DMB26LO	MI	TTGN1ZA
DMB26LO	MN	Angiotensin II receptor (AGTR)
DMB26LO	MT	DTT
DMB26LO	MA	Modulator
DMB26LO	RN	In vitro pharmacology of a nonpeptidic angiotensin II receptor antagonist, SC-51316. J Pharmacol Exp Ther. 1992 Jun;261(3):1037-43.
DMB26LO	RU	https://pubmed.ncbi.nlm.nih.gov/1602371

DMWO107	DI	DMWO107
DMWO107	DN	SC-51895
DMWO107	MI	TTQVOEI
DMWO107	MN	Angiotensin II receptor type-2 (AGTR2)
DMWO107	MT	DTT
DMWO107	MA	Inhibitor
DMWO107	RN	N1-sterically hindered 2H-imidazol-2-one angiotensin II receptor antagonists: The conversion of surmountable antagonists to insurmountable antagonists, Bioorg. Med. Chem. Lett. 3(6):1055-1060 (1993).
DMWO107	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00802863

DMKWJ59	DI	DMKWJ59
DMKWJ59	DN	SC-52150
DMKWJ59	MI	TTNXLKE
DMKWJ59	MN	5-HT 3 receptor (5HT3R)
DMKWJ59	MT	DTT
DMKWJ59	MA	Modulator
DMKWJ59	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001830)
DMKWJ59	RU	http://adisinsight.springer.com/drugs/800001830

DM2O8SF	DI	DM2O8SF
DM2O8SF	DN	SC-53116
DM2O8SF	MI	TT07C3Y
DM2O8SF	MN	5-HT 4 receptor (HTR4)
DM2O8SF	MT	DTT
DM2O8SF	MA	Modulator
DM2O8SF	RN	Bridgehead-methyl analog of SC-53116 as a 5-HT4 agonist. Bioorg Med Chem Lett. 2004 Jun 21;14(12):3073-5.
DM2O8SF	RU	https://www.ncbi.nlm.nih.gov/pubmed/15149647

DMSKHGQ	DI	DMSKHGQ
DMSKHGQ	DN	SC-53228
DMSKHGQ	MI	TTN53ZF
DMSKHGQ	MN	Leukotriene B4 receptor 1 (LTB4R)
DMSKHGQ	MT	DTT
DMSKHGQ	MA	Inhibitor
DMSKHGQ	RN	Synthesis and pharmacological activity of SC-53228, a leukotriene B4 receptor antagonist with high intrinsic potency and selectivity, Bioorg. Med. Chem. Lett. 4(6):811-816 (1994).
DMSKHGQ	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01808532

DM25MUA	DI	DM25MUA
DM25MUA	DN	SC-56525
DM25MUA	MI	TTB2MXP
DM25MUA	MN	Angiotensinogenase renin (REN)
DM25MUA	MT	DTT
DM25MUA	MA	Inhibitor
DM25MUA	RN	Effects of SC-56525, a potent, orally active renin inhibitor, in salt-depleted and renal hypertensive dogs. Hypertension. 1995 Jul;26(1):95-100.
DM25MUA	RU	https://pubmed.ncbi.nlm.nih.gov/7607739

DM874YU	DI	DM874YU
DM874YU	DN	SC-58125
DM874YU	MI	TTVKILB
DM874YU	MN	Prostaglandin G/H synthase 2 (COX-2)
DM874YU	MT	DTT
DM874YU	MA	Inhibitor
DM874YU	RN	Identification and optimisation of a novel series of pyrimidine based cyclooxygenase-2 (COX-2) inhibitors. Utilisation of a biotransformation appro... Bioorg Med Chem Lett. 2009 Aug 1;19(15):4509-14.
DM874YU	RU	https://pubmed.ncbi.nlm.nih.gov/19523822

DMVGK24	DI	DMVGK24
DMVGK24	DN	SC-58451
DMVGK24	MI	TT8NGED
DMVGK24	MN	Prostaglandin G/H synthase 1 (COX-1)
DMVGK24	MT	DTT
DMVGK24	MA	Inhibitor
DMVGK24	RN	Novel 1,2-diarylcyclobutenes: Selective and orally active cox-2 inhibitors, Bioorg. Med. Chem. Lett. 6(22):2677-2682 (1996).
DMVGK24	RU	http://www.sciencedirect.com/science/article/pii/S0960894X9600501X

DMVGK24	DI	DMVGK24
DMVGK24	DN	SC-58451
DMVGK24	MI	TTVKILB
DMVGK24	MN	Prostaglandin G/H synthase 2 (COX-2)
DMVGK24	MT	DTT
DMVGK24	MA	Inhibitor
DMVGK24	RN	Novel 1,2-diarylcyclobutenes: Selective and orally active cox-2 inhibitors, Bioorg. Med. Chem. Lett. 6(22):2677-2682 (1996).
DMVGK24	RU	http://www.sciencedirect.com/science/article/pii/S0960894X9600501X

DMW9H4A	DI	DMW9H4A
DMW9H4A	DN	SCH 50911
DMW9H4A	MI	TTDCVZW
DMW9H4A	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMW9H4A	MT	DTT
DMW9H4A	MA	Antagonist
DMW9H4A	RN	Activation of nigral dopamine neurons by the selective GABA(B)-receptor antagonist SCH 50911. J Neural Transm. 1999;106(5-6):383-94.
DMW9H4A	RU	https://pubmed.ncbi.nlm.nih.gov/10443545

DM037SB	DI	DM037SB
DM037SB	DN	Sch-207758
DM037SB	MI	TT7WZIJ
DM037SB	MN	CAAX farnesyltransferase beta (FNTB)
DM037SB	MT	DTT
DM037SB	MA	Inhibitor
DM037SB	RN	Exploring the role of bromine at C(10) of (+)-4-[2-[4-(8-chloro-3,10-dibromo- 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11(R)-yl)-1-piperidinyl]-2- oxoethyl]-1-piperidinecarboxamide (Sch-66336): the discovery of indolocycloheptapyridine inhibitors of farnesyl protein transferase. J Med Chem. 2002 Aug 29;45(18):3854-64.
DM037SB	RU	https://pubmed.ncbi.nlm.nih.gov/12190309

DMXBJCY	DI	DMXBJCY
DMXBJCY	DN	Sch-40120
DMXBJCY	MI	TT2J34L
DMXBJCY	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMXBJCY	MT	DTT
DMXBJCY	MA	Modulator
DMXBJCY	RN	Actions of a 5-lipoxygenase inhibitor, Sch 40120, on acute inflammatory responses. J Pharmacol Exp Ther. 1992 Aug;262(2):721-8.
DMXBJCY	RU	https://pubmed.ncbi.nlm.nih.gov/1386887

DM3G5IB	DI	DM3G5IB
DM3G5IB	DN	Sch-40338
DM3G5IB	MI	TTQL5VC
DM3G5IB	MN	Platelet-activating factor receptor (PTAFR)
DM3G5IB	MT	DTT
DM3G5IB	MA	Modulator
DM3G5IB	RN	Conformational considerations in the design of dual antagonists of platelet-activating factor (PAF) and histamine. Bioorg Med Chem. 1999 Jul;7(7):1413-23.
DM3G5IB	RU	https://www.ncbi.nlm.nih.gov/pubmed/10465415

DMUL4VX	DI	DMUL4VX
DMUL4VX	DN	SCH-44342
DMUL4VX	MI	TT7WZIJ
DMUL4VX	MN	CAAX farnesyltransferase beta (FNTB)
DMUL4VX	MT	DTT
DMUL4VX	MA	Inhibitor
DMUL4VX	RN	Ras farnesyltransferase: a new therapeutic target. J Med Chem. 1997 Sep 12;40(19):2971-90.
DMUL4VX	RU	https://pubmed.ncbi.nlm.nih.gov/9301658

DMUL4VX	DI	DMUL4VX
DMUL4VX	DN	SCH-44342
DMUL4VX	MI	TTXQKM3
DMUL4VX	MN	Farnesyl protein transferase (Ftase)
DMUL4VX	MT	DTT
DMUL4VX	MA	Inhibitor
DMUL4VX	RN	Tricyclic farnesyl protein transferase inhibitors: crystallographic and calorimetric studies of structure-activity relationships. J Med Chem. 1999 Jun 17;42(12):2125-35.
DMUL4VX	RU	https://pubmed.ncbi.nlm.nih.gov/10377218

DME9Q3V	DI	DME9Q3V
DME9Q3V	DN	Sch-45752
DME9Q3V	MI	TTL53M6
DME9Q3V	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DME9Q3V	MT	DTT
DME9Q3V	MA	Inhibitor
DME9Q3V	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DME9Q3V	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DME9Q3V	DI	DME9Q3V
DME9Q3V	DN	Sch-45752
DME9Q3V	MI	TTUST1O
DME9Q3V	MN	Phosphodiesterase (PDE)
DME9Q3V	MT	DTT
DME9Q3V	MA	Inhibitor
DME9Q3V	RN	SCH 45752--an inhibitor of calmodulin-sensitive cyclic nucleotide phosphodiesterase activity. J Antibiot (Tokyo). 1993 Feb;46(2):207-13.
DME9Q3V	RU	https://pubmed.ncbi.nlm.nih.gov/8385657

DMEWLZ7	DI	DMEWLZ7
DMEWLZ7	DN	SCH-54470
DMEWLZ7	MI	TTL69WB
DMEWLZ7	MN	Angiotensin-converting enzyme (ACE)
DMEWLZ7	MT	DTT
DMEWLZ7	MA	Inhibitor
DMEWLZ7	RN	Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors. J Med Chem. 2010 Jan 14;53(1):208-20.
DMEWLZ7	RU	https://pubmed.ncbi.nlm.nih.gov/19899765

DMEWLZ7	DI	DMEWLZ7
DMEWLZ7	DN	SCH-54470
DMEWLZ7	MI	TTQ9RYT
DMEWLZ7	MN	Endothelin-converting enzyme 1 (ECE1)
DMEWLZ7	MT	DTT
DMEWLZ7	MA	Inhibitor
DMEWLZ7	RN	Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors. J Med Chem. 2010 Jan 14;53(1):208-20.
DMEWLZ7	RU	https://pubmed.ncbi.nlm.nih.gov/19899765

DMEWLZ7	DI	DMEWLZ7
DMEWLZ7	DN	SCH-54470
DMEWLZ7	MI	TT5TKPM
DMEWLZ7	MN	Neutral endopeptidase (MME)
DMEWLZ7	MT	DTT
DMEWLZ7	MA	Inhibitor
DMEWLZ7	RN	Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors. J Med Chem. 2010 Jan 14;53(1):208-20.
DMEWLZ7	RU	https://pubmed.ncbi.nlm.nih.gov/19899765

DMGCYPE	DI	DMGCYPE
DMGCYPE	DN	Sch-57790
DMGCYPE	MI	TTYEG6Q
DMGCYPE	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMGCYPE	MT	DTT
DMGCYPE	MA	Antagonist
DMGCYPE	RN	SCH 57790: a novel M2 receptor selective antagonist. Life Sci. 1999;64(6-7):535-9.
DMGCYPE	RU	https://pubmed.ncbi.nlm.nih.gov/10069520

DMFZNUA	DI	DMFZNUA
DMFZNUA	DN	SCR-44001
DMFZNUA	MI	TTHBTOP
DMFZNUA	MN	PI3-kinase gamma (PIK3CG)
DMFZNUA	MT	DTT
DMFZNUA	MA	Inhibitor
DMFZNUA	RN	Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice. PLoS One. 2010 Sep 24;5(9):e12965.
DMFZNUA	RU	https://pubmed.ncbi.nlm.nih.gov/20885974

DMFZNUA	DI	DMFZNUA
DMFZNUA	DN	SCR-44001
DMFZNUA	MI	TTCJG29
DMFZNUA	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMFZNUA	MT	DTT
DMFZNUA	MA	Inhibitor
DMFZNUA	RN	Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice. PLoS One. 2010 Sep 24;5(9):e12965.
DMFZNUA	RU	https://pubmed.ncbi.nlm.nih.gov/20885974

DMPUVFH	DI	DMPUVFH
DMPUVFH	DN	SDZ 216-525
DMPUVFH	MI	TTSQIFT
DMPUVFH	MN	5-HT 1A receptor (HTR1A)
DMPUVFH	MT	DTT
DMPUVFH	MA	Antagonist
DMPUVFH	RN	Influence of 5-HT1A receptor antagonism on plus-maze behaviour in mice. II. WAY 100635, SDZ 216-525 and NAN-190. Pharmacol Biochem Behav. 1997 Oct;58(2):593-603.
DMPUVFH	RU	https://pubmed.ncbi.nlm.nih.gov/9300624

DMY1KE8	DI	DMY1KE8
DMY1KE8	DN	SDZ-224-015
DMY1KE8	MI	TTCQIBE
DMY1KE8	MN	Caspase-1 (CASP1)
DMY1KE8	MT	DTT
DMY1KE8	MA	Modulator
DMY1KE8	RN	Reduction of inflammation and pyrexia in the rat by oral administration of SDZ 224-015, an inhibitor of the interleukin-1 beta converting enzyme. Br J Pharmacol. 1995 Jun;115(4):601-6.
DMY1KE8	RU	https://pubmed.ncbi.nlm.nih.gov/7582478

DMPZLKC	DI	DMPZLKC
DMPZLKC	DN	SDZ-249482
DMPZLKC	MI	TT5HONZ
DMPZLKC	MN	Calcium channel unspecific (CaC)
DMPZLKC	MT	DTT
DMPZLKC	MA	Modulator
DMPZLKC	RN	Physiology and Pharmacology of the Vanilloid Receptor. Curr Neuropharmacol. 2006 January; 4(1): 1-15.
DMPZLKC	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2430674/

DMAT657	DI	DMAT657
DMAT657	DN	SDZ-62-826
DMAT657	MI	TT6MP2Z
DMAT657	MN	GMCSFR-alpha (CSF2RA)
DMAT657	MT	DTT
DMAT657	MA	Modulator
DMAT657	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1707).
DMAT657	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1707

DM2CBTU	DI	DM2CBTU
DM2CBTU	DN	SDZ-64-412
DM2CBTU	MI	TTQL5VC
DM2CBTU	MN	Platelet-activating factor receptor (PTAFR)
DM2CBTU	MT	DTT
DM2CBTU	MA	Inhibitor
DM2CBTU	RN	Structural modification of 5-aryl-2,3-dihydroimidazo[2,1-a]isoquinoline platelet activating factor receptor antagonists. J Med Chem. 1993 Oct 15;36(21):3098-102.
DM2CBTU	RU	https://pubmed.ncbi.nlm.nih.gov/8230095

DMBY6CQ	DI	DMBY6CQ
DMBY6CQ	DN	SDZ-87-469
DMBY6CQ	MI	TTE14XG
DMBY6CQ	MN	Squalene monooxygenase (SQLE)
DMBY6CQ	MT	DTT
DMBY6CQ	MA	Modulator
DMBY6CQ	RN	Effects of squalene epoxidase inhibitors on Candida albicans. Antimicrob Agents Chemother. 1992 Aug;36(8):1779-81.
DMBY6CQ	RU	https://pubmed.ncbi.nlm.nih.gov/1416865

DMN5IY7	DI	DMN5IY7
DMN5IY7	DN	SDZ-ICM-567
DMN5IY7	MI	TTNXLKE
DMN5IY7	MN	5-HT 3 receptor (5HT3R)
DMN5IY7	MT	DTT
DMN5IY7	MA	Antagonist
DMN5IY7	RN	Microdialysis sampling to determine the pharmacokinetics of unbound SDZ ICM 567 in blood and brain in awake, freely-moving rats. Pharm Res. 1995 Feb;12(2):291-4.
DMN5IY7	RU	https://pubmed.ncbi.nlm.nih.gov/7784347

DMSZJUM	DI	DMSZJUM
DMSZJUM	DN	SDZ-ISQ-844
DMSZJUM	MI	TTZCG4L
DMSZJUM	MN	Phosphodiesterase 3 (PDE3)
DMSZJUM	MT	DTT
DMSZJUM	MA	Modulator
DMSZJUM	RN	[Effects of SDZ ISQ 844, a cyclic nucleotide phosphodiesterase isozyme type III/IV inhibitor, on the release of histamine from human peripheral leukocytes].Arerugi.1997 May;46(5):426-32.
DMSZJUM	RU	https://www.ncbi.nlm.nih.gov/pubmed/9232912

DMKCXBJ	DI	DMKCXBJ
DMKCXBJ	DN	SDZ-MTH-958
DMKCXBJ	MI	TTEMV5X
DMKCXBJ	MN	Serine protease unspecific (SP)
DMKCXBJ	MT	DTT
DMKCXBJ	MA	Modulator
DMKCXBJ	RN	Thrombin inhibition in an ex vivo model of porcine heart xenograft hyperacute rejection. Transplantation. 1996 Mar 27;61(6):862-8.
DMKCXBJ	RU	https://pubmed.ncbi.nlm.nih.gov/8623150

DM48MCL	DI	DM48MCL
DM48MCL	DN	SDZ-PSD-958
DM48MCL	MI	TTZFYLI
DM48MCL	MN	Dopamine D1 receptor (D1R)
DM48MCL	MT	DTT
DM48MCL	MA	Modulator
DM48MCL	RN	SDZ PSD 958, a novel D1 receptor antagonist with potential limbic selectivity. J Neural Transm. 1996;103(3):261-76.
DM48MCL	RU	https://pubmed.ncbi.nlm.nih.gov/8739838

DMXHW91	DI	DMXHW91
DMXHW91	DN	SDZ-SER-082
DMXHW91	MI	TTWJBZ5
DMXHW91	MN	5-HT 2C receptor (HTR2C)
DMXHW91	MT	DTT
DMXHW91	MA	Modulator
DMXHW91	RN	Effect of the activation of central 5-HT2C receptors by the 5-HT2C agonist mCPP on blood pressure and heart rate in rats. Brain Res. 2005 Apr 8;1040(1-2):64-72.
DMXHW91	RU	https://www.ncbi.nlm.nih.gov/pubmed/15804427

DM4ESAP	DI	DM4ESAP
DM4ESAP	DN	Selenotifen
DM4ESAP	MI	TTTIBOJ
DM4ESAP	MN	Histamine H1 receptor (H1R)
DM4ESAP	MT	DTT
DM4ESAP	MA	Modulator
DM4ESAP	RN	Effect of BN 52256 and other mediator antagonists on ouabain-induced cardiac arrhythmia in a model of anaphylaxis in guinea-pigs. Pharmacol Res. 1992 Feb-Mar;25(2):173-80.
DM4ESAP	RU	https://pubmed.ncbi.nlm.nih.gov/1635894

DMXRU72	DI	DMXRU72
DMXRU72	DN	SEP-227900
DMXRU72	MI	TT7Y3EJ
DMXRU72	MN	D-amino acid oxidase (DAO)
DMXRU72	MT	DTT
DMXRU72	MA	Inhibitor
DMXRU72	RN	The Therapeutic Potential of D-Amino Acid Oxidase (DAAO) Inhibitors. Open Med Chem J. 2010; 4: 3-9.
DMXRU72	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2905773/

DMTBWU1	DI	DMTBWU1
DMTBWU1	DN	Seridopidine
DMTBWU1	MI	TTVBI8W
DMTBWU1	MN	Dopamine transporter (DAT)
DMTBWU1	MT	DTT
DMTBWU1	MA	Modulator
DMTBWU1	RN	Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses. Psychopharmacology (Berl). 2015 Sep;232(18):3443-53.
DMTBWU1	RU	https://pubmed.ncbi.nlm.nih.gov/26159455

DMT43AI	DI	DMT43AI
DMT43AI	DN	SIB-1508Y
DMT43AI	MI	TTL1ATN
DMT43AI	MN	Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2)
DMT43AI	MT	DTT
DMT43AI	MA	Modulator
DMT43AI	RN	Nicotinic Receptors in Neurodegeneration
DMT43AI	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3648781

DMO4WB8	DI	DMO4WB8
DMO4WB8	DN	SIB-1663
DMO4WB8	MI	TTJSZTB
DMO4WB8	MN	Nicotinic acetylcholine receptor (nAChR)
DMO4WB8	MT	DTT
DMO4WB8	MA	Agonist
DMO4WB8	RN	The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control. Expert Opin Investig Drugs. 2001 Oct;10(10):1819-30.
DMO4WB8	RU	https://pubmed.ncbi.nlm.nih.gov/11772288

DM6MSKT	DI	DM6MSKT
DM6MSKT	DN	SIB-1765F
DM6MSKT	MI	TTJSZTB
DM6MSKT	MN	Nicotinic acetylcholine receptor (nAChR)
DM6MSKT	MT	DTT
DM6MSKT	MA	Agonist
DM6MSKT	RN	Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats. J Pharmacol Exp Ther. 1997 Jan;280(1):393-401.
DM6MSKT	RU	https://pubmed.ncbi.nlm.nih.gov/8996220

DM98K76	DI	DM98K76
DM98K76	DN	Siguazodan
DM98K76	MI	TTZCG4L
DM98K76	MN	Phosphodiesterase 3 (PDE3)
DM98K76	MT	DTT
DM98K76	MA	Modulator
DM98K76	RN	Cyclic-AMP-dependent proliferation of a human osteoblast cell line (HOS cells) induced by hydroxyapatite: effect of exogenous nitric oxide. Acta Biomed. 2008 Aug;79(2):110-6.
DM98K76	RU	https://www.ncbi.nlm.nih.gov/pubmed/18788505

DMBZ7SF	DI	DMBZ7SF
DMBZ7SF	DN	SIM-6080
DMBZ7SF	MI	TT5HONZ
DMBZ7SF	MN	Calcium channel unspecific (CaC)
DMBZ7SF	MT	DTT
DMBZ7SF	MA	Blocker
DMBZ7SF	RN	Determination of the calcium antagonist SIM6080 and its N- and O-demethylated metabolites in plasma, urine and tissues by high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1996 Feb 9;676(1):77-85.
DMBZ7SF	RU	https://pubmed.ncbi.nlm.nih.gov/8852047

DM5SBUJ	DI	DM5SBUJ
DM5SBUJ	DN	Sipoglitazar
DM5SBUJ	MI	TTJ584C
DM5SBUJ	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DM5SBUJ	MT	DTT
DM5SBUJ	MA	Modulator
DM5SBUJ	RN	Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARalpha agonist with moderate PPARgamma agonist activity in healthy human subjects. Clin Drug Investig. 2013 Nov;33(11):809-16.
DM5SBUJ	RU	https://pubmed.ncbi.nlm.nih.gov/24062180

DM5SBUJ	DI	DM5SBUJ
DM5SBUJ	DN	Sipoglitazar
DM5SBUJ	MI	TTZMAO3
DM5SBUJ	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DM5SBUJ	MT	DTT
DM5SBUJ	MA	Modulator
DM5SBUJ	RN	Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARalpha agonist with moderate PPARgamma agonist activity in healthy human subjects. Clin Drug Investig. 2013 Nov;33(11):809-16.
DM5SBUJ	RU	https://pubmed.ncbi.nlm.nih.gov/24062180

DMB6T7K	DI	DMB6T7K
DMB6T7K	DN	Siramesine
DMB6T7K	MI	TTNGILX
DMB6T7K	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMB6T7K	MT	DTT
DMB6T7K	MA	Inhibitor
DMB6T7K	RN	Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 1. 3-(omega-aminoalkyl)-1H-indoles. J Med Chem. 1995 May 26;38(11):1998-2008.
DMB6T7K	RU	https://pubmed.ncbi.nlm.nih.gov/7783131

DMB6T7K	DI	DMB6T7K
DMB6T7K	DN	Siramesine
DMB6T7K	MI	TTBRKXS
DMB6T7K	MN	Adrenergic receptor alpha-1B (ADRA1B)
DMB6T7K	MT	DTT
DMB6T7K	MA	Inhibitor
DMB6T7K	RN	Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 1. 3-(omega-aminoalkyl)-1H-indoles. J Med Chem. 1995 May 26;38(11):1998-2008.
DMB6T7K	RU	https://pubmed.ncbi.nlm.nih.gov/7783131

DMB6T7K	DI	DMB6T7K
DMB6T7K	DN	Siramesine
DMB6T7K	MI	TT34BHT
DMB6T7K	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMB6T7K	MT	DTT
DMB6T7K	MA	Inhibitor
DMB6T7K	RN	Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 1. 3-(omega-aminoalkyl)-1H-indoles. J Med Chem. 1995 May 26;38(11):1998-2008.
DMB6T7K	RU	https://pubmed.ncbi.nlm.nih.gov/7783131

DMG90YW	DI	DMG90YW
DMG90YW	DN	Siratiazem
DMG90YW	MI	TT5HONZ
DMG90YW	MN	Calcium channel unspecific (CaC)
DMG90YW	MT	DTT
DMG90YW	MA	Modulator
DMG90YW	RN	Comparison of the effects of diltiazem and its analogue siratiazem on contractility in arteries, ileum and cardiac muscle. J Auton Pharmacol. 1995 Apr;15(2):107-13.
DMG90YW	RU	https://pubmed.ncbi.nlm.nih.gov/7615573

DM6X430	DI	DM6X430
DM6X430	DN	SJA-6017
DM6X430	MI	TTG5QB7
DM6X430	MN	Calpain-2 (CAPN2)
DM6X430	MT	DTT
DM6X430	MA	Inhibitor
DM6X430	RN	Synthesis, biological evaluation and molecular modelling of N-heterocyclic dipeptide aldehydes as selective calpain inhibitors. Bioorg Med Chem. 2008 Jul 15;16(14):6911-23.
DM6X430	RU	https://pubmed.ncbi.nlm.nih.gov/18571418

DMRADBU	DI	DMRADBU
DMRADBU	DN	SK&F-104078
DMRADBU	MI	TTNGILX
DMRADBU	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMRADBU	MT	DTT
DMRADBU	MA	Inhibitor
DMRADBU	RN	Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
DMRADBU	RU	https://pubmed.ncbi.nlm.nih.gov/7562902

DMRADBU	DI	DMRADBU
DMRADBU	DN	SK&F-104078
DMRADBU	MI	TTBRKXS
DMRADBU	MN	Adrenergic receptor alpha-1B (ADRA1B)
DMRADBU	MT	DTT
DMRADBU	MA	Inhibitor
DMRADBU	RN	Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
DMRADBU	RU	https://pubmed.ncbi.nlm.nih.gov/7562902

DMRADBU	DI	DMRADBU
DMRADBU	DN	SK&F-104078
DMRADBU	MI	TT34BHT
DMRADBU	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMRADBU	MT	DTT
DMRADBU	MA	Inhibitor
DMRADBU	RN	Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
DMRADBU	RU	https://pubmed.ncbi.nlm.nih.gov/7562902

DMRADBU	DI	DMRADBU
DMRADBU	DN	SK&F-104078
DMRADBU	MI	TTWG9A4
DMRADBU	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMRADBU	MT	DTT
DMRADBU	MA	Inhibitor
DMRADBU	RN	Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem. 1995 Sep 1;38(18):3415-44.
DMRADBU	RU	https://pubmed.ncbi.nlm.nih.gov/7658428

DMRADBU	DI	DMRADBU
DMRADBU	DN	SK&F-104078
DMRADBU	MI	TTWM4TY
DMRADBU	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMRADBU	MT	DTT
DMRADBU	MA	Inhibitor
DMRADBU	RN	Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem. 1995 Sep 1;38(18):3415-44.
DMRADBU	RU	https://pubmed.ncbi.nlm.nih.gov/7658428

DMRADBU	DI	DMRADBU
DMRADBU	DN	SK&F-104078
DMRADBU	MI	TT2NUT5
DMRADBU	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMRADBU	MT	DTT
DMRADBU	MA	Inhibitor
DMRADBU	RN	Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem. 1995 Sep 1;38(18):3415-44.
DMRADBU	RU	https://pubmed.ncbi.nlm.nih.gov/7658428

DMN91EK	DI	DMN91EK
DMN91EK	DN	SK&F-104856
DMN91EK	MI	TTNGILX
DMN91EK	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMN91EK	MT	DTT
DMN91EK	MA	Inhibitor
DMN91EK	RN	Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
DMN91EK	RU	https://pubmed.ncbi.nlm.nih.gov/7562902

DMN91EK	DI	DMN91EK
DMN91EK	DN	SK&F-104856
DMN91EK	MI	TTBRKXS
DMN91EK	MN	Adrenergic receptor alpha-1B (ADRA1B)
DMN91EK	MT	DTT
DMN91EK	MA	Inhibitor
DMN91EK	RN	Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
DMN91EK	RU	https://pubmed.ncbi.nlm.nih.gov/7562902

DMN91EK	DI	DMN91EK
DMN91EK	DN	SK&F-104856
DMN91EK	MI	TT34BHT
DMN91EK	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMN91EK	MT	DTT
DMN91EK	MA	Inhibitor
DMN91EK	RN	Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
DMN91EK	RU	https://pubmed.ncbi.nlm.nih.gov/7562902

DMRM7H0	DI	DMRM7H0
DMRM7H0	DN	SK&F-95601
DMRM7H0	MI	TTLOKXP
DMRM7H0	MN	Gastric H(+)/K(+) ATPase (Proton pump)
DMRM7H0	MT	DTT
DMRM7H0	MA	Modulator
DMRM7H0	RN	2-[[(4-Amino-2-pyridyl)methyl]sulfinyl]benzimidazole H+/K+-ATPase inhibitors.The relationship between pyridine basicity, stability, and activity.J Med Chem.1989 Aug;32(8):1970-7.
DMRM7H0	RU	https://www.ncbi.nlm.nih.gov/pubmed/2547073

DM6RVXU	DI	DM6RVXU
DM6RVXU	DN	SK-951
DM6RVXU	MI	TT07C3Y
DM6RVXU	MN	5-HT 4 receptor (HTR4)
DM6RVXU	MT	DTT
DM6RVXU	MA	Agonist
DM6RVXU	RN	Identification of SK-951, a novel benzofuran derivative, as an agonist to 5-HT4 receptors. Jpn J Pharmacol. 1999 Feb;79(2):203-12.
DM6RVXU	RU	https://pubmed.ncbi.nlm.nih.gov/10202856

DMIMJ8Z	DI	DMIMJ8Z
DMIMJ8Z	DN	SKF 38393
DMIMJ8Z	MI	TTZFYLI
DMIMJ8Z	MN	Dopamine D1 receptor (D1R)
DMIMJ8Z	MT	DTT
DMIMJ8Z	MA	Modulator
DMIMJ8Z	RN	The D1 dopamine receptor agonist SKF-38393 stimulates the release of glutamate in the hippocampus. Neuroscience. 1999;94(4):1063-70.
DMIMJ8Z	RU	https://pubmed.ncbi.nlm.nih.gov/10625048

DM8MWFZ	DI	DM8MWFZ
DM8MWFZ	DN	SKF-104351
DM8MWFZ	MI	TT2J34L
DM8MWFZ	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM8MWFZ	MT	DTT
DM8MWFZ	MA	Modulator
DM8MWFZ	RN	WO patent application no. 2006,1317,37, Method and composition for treating inflammatory disorders.
DM8MWFZ	RU	http://www.google.com/patents/WO2006131737A2?cl=en

DM7QPYK	DI	DM7QPYK
DM7QPYK	DN	SKF-106760
DM7QPYK	MI	TT38RM1
DM7QPYK	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DM7QPYK	MT	DTT
DM7QPYK	MA	Modulator
DM7QPYK	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM7QPYK	RU	https://www.fda.gov/

DMM8F0V	DI	DMM8F0V
DMM8F0V	DN	SKF-107260
DMM8F0V	MI	TTJA1ZO
DMM8F0V	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMM8F0V	MT	DTT
DMM8F0V	MA	Inhibitor
DMM8F0V	RN	Preparation and Properties of a fibrinogen receptor antagonist containing the Arg-Gly-Asp sequence and nitroxide radicals, Bioorg. Med. Chem. Lett. 3(6):1179-1184 (1993).
DMM8F0V	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00803108

DM4LGPT	DI	DM4LGPT
DM4LGPT	DN	SKF-81297
DM4LGPT	MI	TTZFYLI
DM4LGPT	MN	Dopamine D1 receptor (D1R)
DM4LGPT	MT	DTT
DM4LGPT	MA	Modulator
DM4LGPT	RN	Dopamine D1 receptor involvement in the discriminative-stimulus effects of SKF 81297 in squirrel monkeys. J Pharmacol Exp Ther. 1993 Nov;267(2):765-75.
DM4LGPT	RU	https://pubmed.ncbi.nlm.nih.gov/7902432

DMS2M58	DI	DMS2M58
DMS2M58	DN	SKF-96231
DMS2M58	MI	TTJ0IQB
DMS2M58	MN	Phosphodiesterase 5A (PDE5A)
DMS2M58	MT	DTT
DMS2M58	MA	Inhibitor
DMS2M58	RN	Analogue-based Drug Discovery II. Janos Fischer,C. Robin Ganellin. Page(150).
DMS2M58	RU	https://books.google.com.hk/books?id=h2Kd8ci4Ln8C&pg=PA150&lpg=PA150&dq=SKF-96231++++++++++++++PDE+5&source=bl&ots=yRj1Q8yHYq&sig=60AYTs3Vk3T_KDV-F7MHenbl4T4&hl=zh-CN&sa=X&ved=0CB8Q6AEwAGoVChMIhvKspOq5yAIVCXKOCh3MhAmi#v=onepage&q=SKF-96231%20%20%20%20%20%20%20%20%20%20%20%20%20%20PDE%205&f=false

DMI79JN	DI	DMI79JN
DMI79JN	DN	SKF-96365
DMI79JN	MI	TT5HONZ
DMI79JN	MN	Calcium channel unspecific (CaC)
DMI79JN	MT	DTT
DMI79JN	MA	Modulator
DMI79JN	RN	The transient receptor potential channel antagonist SKF96365 is a potent blocker of low-voltage-activated T-type calcium channels. Br J Pharmacol. 2010 Jul;160(6):1464-75.
DMI79JN	RU	https://pubmed.ncbi.nlm.nih.gov/20590636

DMI1WNF	DI	DMI1WNF
DMI1WNF	DN	SL-18.1616
DMI1WNF	MI	TT0WAIE
DMI1WNF	MN	Melatonin receptor type 1A (MTNR1A)
DMI1WNF	MT	DTT
DMI1WNF	MA	Agonist
DMI1WNF	RN	US patent application no. 2005,016,4987, Melatonin combination therapy for improving sleep quality.
DMI1WNF	RU	http://www.google.com/patents/US20050164987

DMJ9RLX	DI	DMJ9RLX
DMJ9RLX	DN	SL-91.0893
DMJ9RLX	MI	TT34BHT
DMJ9RLX	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMJ9RLX	MT	DTT
DMJ9RLX	MA	Modulator
DMJ9RLX	RN	Tissue Selectivity of in vivo alpha1-Adrenoceptor Biding of KMD-3213 in Rats. Eur Urol 1999;36(suppl 1):113-117.
DMJ9RLX	RU	https://www.karger.com/Article/Pdf/52331

DMNTGXQ	DI	DMNTGXQ
DMNTGXQ	DN	SL-910102
DMNTGXQ	MI	TTGN1ZA
DMNTGXQ	MN	Angiotensin II receptor (AGTR)
DMNTGXQ	MT	DTT
DMNTGXQ	MA	Modulator
DMNTGXQ	RN	A radioreceptor assay for the analysis of AT1-receptor antagonists. Correlation with complementary LC data reveals a potential contribution of active metabolites. J Pharm Biomed Anal. 1998 May;17(1):111-24.
DMNTGXQ	RU	https://pubmed.ncbi.nlm.nih.gov/9608433

DMCPDBS	DI	DMCPDBS
DMCPDBS	DN	SLV-307
DMCPDBS	MI	TTSQIFT
DMCPDBS	MN	5-HT 1A receptor (HTR1A)
DMCPDBS	MT	DTT
DMCPDBS	MA	Antagonist
DMCPDBS	RN	Development and validation of a capillary electrophoresis method for the enantiomeric purity determination of SLV307, a basic potential antipsychotic compound. Electrophoresis. 2004 Aug;25(16):2854-9.
DMCPDBS	RU	https://pubmed.ncbi.nlm.nih.gov/15352019

DMCPDBS	DI	DMCPDBS
DMCPDBS	DN	SLV-307
DMCPDBS	MI	TTEX248
DMCPDBS	MN	Dopamine D2 receptor (D2R)
DMCPDBS	MT	DTT
DMCPDBS	MA	Antagonist
DMCPDBS	RN	Development and validation of a capillary electrophoresis method for the enantiomeric purity determination of SLV307, a basic potential antipsychotic compound. Electrophoresis. 2004 Aug;25(16):2854-9.
DMCPDBS	RU	https://pubmed.ncbi.nlm.nih.gov/15352019

DMF0QMD	DI	DMF0QMD
DMF0QMD	DN	SM 11044
DMF0QMD	MI	TTMXGCW
DMF0QMD	MN	Adrenergic receptor beta-3 (ADRB3)
DMF0QMD	MT	DTT
DMF0QMD	MA	Agonist
DMF0QMD	RN	Effects of several putative beta 3-adrenoceptor agonists on lipolysis in human omental adipocytes. Int J Obes Relat Metab Disord. 1996 May;20(5):428-34.
DMF0QMD	RU	https://pubmed.ncbi.nlm.nih.gov/8696421

DMHXJV2	DI	DMHXJV2
DMHXJV2	DN	SM-16
DMHXJV2	MI	TTP4520
DMHXJV2	MN	TGF-beta receptor type I (TGFBR1)
DMHXJV2	MT	DTT
DMHXJV2	MA	Inhibitor
DMHXJV2	RN	TGF-beta type I receptor kinase inhibitor down-regulates rheumatoid synoviocytes and prevents the arthritis induced by type II collagen antibody. Int Immunol. 2007 Feb;19(2):117-26.
DMHXJV2	RU	https://pubmed.ncbi.nlm.nih.gov/17135447

DMNX93E	DI	DMNX93E
DMNX93E	DN	SM-19712
DMNX93E	MI	TT1BGDH
DMNX93E	MN	Endothelin-converting enzyme (ECE)
DMNX93E	MT	DTT
DMNX93E	MA	Inhibitor
DMNX93E	RN	Protective effect of SM-19712, a novel and potent endothelin converting enzyme inhibitor, on ischemic acute renal failure in rats. Jpn J Pharmacol. 2000 Sep;84(1):16-24.
DMNX93E	RU	https://pubmed.ncbi.nlm.nih.gov/11043448

DMROJEN	DI	DMROJEN
DMROJEN	DN	SNAP-5089
DMROJEN	MI	TTNGILX
DMROJEN	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMROJEN	MT	DTT
DMROJEN	MA	Inhibitor
DMROJEN	RN	Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
DMROJEN	RU	https://pubmed.ncbi.nlm.nih.gov/7562902

DMROJEN	DI	DMROJEN
DMROJEN	DN	SNAP-5089
DMROJEN	MI	TTBRKXS
DMROJEN	MN	Adrenergic receptor alpha-1B (ADRA1B)
DMROJEN	MT	DTT
DMROJEN	MA	Inhibitor
DMROJEN	RN	Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
DMROJEN	RU	https://pubmed.ncbi.nlm.nih.gov/7562902

DMROJEN	DI	DMROJEN
DMROJEN	DN	SNAP-5089
DMROJEN	MI	TT34BHT
DMROJEN	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMROJEN	MT	DTT
DMROJEN	MA	Inhibitor
DMROJEN	RN	Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
DMROJEN	RU	https://pubmed.ncbi.nlm.nih.gov/7562902

DMROJEN	DI	DMROJEN
DMROJEN	DN	SNAP-5089
DMROJEN	MI	TTWG9A4
DMROJEN	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMROJEN	MT	DTT
DMROJEN	MA	Inhibitor
DMROJEN	RN	Design and synthesis of novel dihydropyridine alpha-1a antagonists. Bioorg Med Chem Lett. 1999 Oct 4;9(19):2843-8.
DMROJEN	RU	https://pubmed.ncbi.nlm.nih.gov/10522703

DMROJEN	DI	DMROJEN
DMROJEN	DN	SNAP-5089
DMROJEN	MI	TTWM4TY
DMROJEN	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMROJEN	MT	DTT
DMROJEN	MA	Inhibitor
DMROJEN	RN	Design and synthesis of novel dihydropyridine alpha-1a antagonists. Bioorg Med Chem Lett. 1999 Oct 4;9(19):2843-8.
DMROJEN	RU	https://pubmed.ncbi.nlm.nih.gov/10522703

DMROJEN	DI	DMROJEN
DMROJEN	DN	SNAP-5089
DMROJEN	MI	TT2NUT5
DMROJEN	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMROJEN	MT	DTT
DMROJEN	MA	Inhibitor
DMROJEN	RN	Design and synthesis of novel dihydropyridine alpha-1a antagonists. Bioorg Med Chem Lett. 1999 Oct 4;9(19):2843-8.
DMROJEN	RU	https://pubmed.ncbi.nlm.nih.gov/10522703

DMROJEN	DI	DMROJEN
DMROJEN	DN	SNAP-5089
DMROJEN	MI	TTZIFHC
DMROJEN	MN	Voltage-gated calcium channel alpha Cav1.2 (CACNA1C)
DMROJEN	MT	DTT
DMROJEN	MA	Inhibitor
DMROJEN	RN	Design and synthesis of novel dihydropyridine alpha-1a antagonists. Bioorg Med Chem Lett. 1999 Oct 4;9(19):2843-8.
DMROJEN	RU	https://pubmed.ncbi.nlm.nih.gov/10522703

DMROJEN	DI	DMROJEN
DMROJEN	DN	SNAP-5089
DMROJEN	MI	TT7RGTM
DMROJEN	MN	Voltage-gated calcium channel alpha Cav1.3 (CACNA1D)
DMROJEN	MT	DTT
DMROJEN	MA	Inhibitor
DMROJEN	RN	Discovery of alpha 1a-adrenergic receptor antagonists based on the L-type Ca2+ channel antagonist niguldipine. J Med Chem. 1995 May 12;38(10):1579-81.
DMROJEN	RU	https://pubmed.ncbi.nlm.nih.gov/7752182

DMNE4TS	DI	DMNE4TS
DMNE4TS	DN	SNAP-6201
DMNE4TS	MI	TTNGILX
DMNE4TS	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMNE4TS	MT	DTT
DMNE4TS	MA	Inhibitor
DMNE4TS	RN	Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
DMNE4TS	RU	https://pubmed.ncbi.nlm.nih.gov/15664832

DM4CNM9	DI	DM4CNM9
DM4CNM9	DN	SNF-9007
DM4CNM9	MI	TTCG0AL
DM4CNM9	MN	Cholecystokinin receptor type A (CCKAR)
DM4CNM9	MT	DTT
DM4CNM9	MA	Inhibitor
DM4CNM9	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DM4CNM9	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DM4CNM9	DI	DM4CNM9
DM4CNM9	DN	SNF-9007
DM4CNM9	MI	TTVFO0U
DM4CNM9	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DM4CNM9	MT	DTT
DM4CNM9	MA	Inhibitor
DM4CNM9	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DM4CNM9	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DM4CNM9	DI	DM4CNM9
DM4CNM9	DN	SNF-9007
DM4CNM9	MI	TT27RFC
DM4CNM9	MN	Opioid receptor delta (OPRD1)
DM4CNM9	MT	DTT
DM4CNM9	MA	Inhibitor
DM4CNM9	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DM4CNM9	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DM4CNM9	DI	DM4CNM9
DM4CNM9	DN	SNF-9007
DM4CNM9	MI	TTKWM86
DM4CNM9	MN	Opioid receptor mu (MOP)
DM4CNM9	MT	DTT
DM4CNM9	MA	Inhibitor
DM4CNM9	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DM4CNM9	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMFI0GW	DI	DMFI0GW
DMFI0GW	DN	Sonepiprazole
DMFI0GW	MI	TTE0A2F
DMFI0GW	MN	Dopamine D4 receptor (D4R)
DMFI0GW	MT	DTT
DMFI0GW	MA	Binder
DMFI0GW	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMFI0GW	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DM31VE4	DI	DM31VE4
DM31VE4	DN	Sorbinil
DM31VE4	MI	TTFBNVI
DM31VE4	MN	Aldose reductase (AKR1B1)
DM31VE4	MT	DTT
DM31VE4	MA	Inhibitor
DM31VE4	RN	A controlled trial of sorbinil, an aldose reductase inhibitor, in chronic painful diabetic neuropathy. Diabetes. 1983 Oct;32(10):938-42.
DM31VE4	RU	https://pubmed.ncbi.nlm.nih.gov/6225686

DMTDLHG	DI	DMTDLHG
DMTDLHG	DN	SORETOLIDE
DMTDLHG	MI	TTVPQTF
DMTDLHG	MN	Glutamate receptor AMPA 1 (GRIA1)
DMTDLHG	MT	DTT
DMTDLHG	MA	Modulator
DMTDLHG	RN	Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist. Acta Neurol Scand Suppl. 2013;(197):19-24.
DMTDLHG	RU	https://pubmed.ncbi.nlm.nih.gov/23480152

DM9HFV7	DI	DM9HFV7
DM9HFV7	DN	SPD-756
DM9HFV7	MI	TT84ETX
DM9HFV7	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM9HFV7	MT	DTT
DM9HFV7	MA	Inhibitor
DM9HFV7	RN	Single dose pharmacokinetics of SPD-756 in healthy adult volunteers, P F Smith, Poster Exhibition: The XIV International AIDS Conference: Abstract no. WePeB6050.
DM9HFV7	RU	https://www.aids2014.org/Abstracts/A1704.aspx

DMD4BFY	DI	DMD4BFY
DMD4BFY	DN	Spermine
DMD4BFY	MI	TTUNARX
DMD4BFY	MN	Carbonic anhydrase (CA)
DMD4BFY	MT	DTT
DMD4BFY	MA	Inhibitor
DMD4BFY	RN	Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22.
DMD4BFY	RU	https://pubmed.ncbi.nlm.nih.gov/20590092

DMD4BFY	DI	DMD4BFY
DMD4BFY	DN	Spermine
DMD4BFY	MI	TTZHA0O
DMD4BFY	MN	Carbonic anhydrase IV (CA-IV)
DMD4BFY	MT	DTT
DMD4BFY	MA	Inhibitor
DMD4BFY	RN	Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22.
DMD4BFY	RU	https://pubmed.ncbi.nlm.nih.gov/20590092

DMD4BFY	DI	DMD4BFY
DMD4BFY	DN	Spermine
DMD4BFY	MI	TT2LVK8
DMD4BFY	MN	Carbonic anhydrase IX (CA-IX)
DMD4BFY	MT	DTT
DMD4BFY	MA	Inhibitor
DMD4BFY	RN	Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22.
DMD4BFY	RU	https://pubmed.ncbi.nlm.nih.gov/20590092

DMD4BFY	DI	DMD4BFY
DMD4BFY	DN	Spermine
DMD4BFY	MI	TTCFSPE
DMD4BFY	MN	Carbonic anhydrase VI (CA-VI)
DMD4BFY	MT	DTT
DMD4BFY	MA	Inhibitor
DMD4BFY	RN	Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22.
DMD4BFY	RU	https://pubmed.ncbi.nlm.nih.gov/20590092

DMD4BFY	DI	DMD4BFY
DMD4BFY	DN	Spermine
DMD4BFY	MI	TTEYTKG
DMD4BFY	MN	Carbonic anhydrase XIV (CA-XIV)
DMD4BFY	MT	DTT
DMD4BFY	MA	Inhibitor
DMD4BFY	RN	Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22.
DMD4BFY	RU	https://pubmed.ncbi.nlm.nih.gov/20590092

DMD4BFY	DI	DMD4BFY
DMD4BFY	DN	Spermine
DMD4BFY	MI	TTLD29N
DMD4BFY	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMD4BFY	MT	DTT
DMD4BFY	MA	Inhibitor
DMD4BFY	RN	Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents. J Med Chem. 2010 May 13;53(9):3611-7.
DMD4BFY	RU	https://pubmed.ncbi.nlm.nih.gov/20361801

DMD4BFY	DI	DMD4BFY
DMD4BFY	DN	Spermine
DMD4BFY	MI	TTKJEMQ
DMD4BFY	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMD4BFY	MT	DTT
DMD4BFY	MA	Inhibitor
DMD4BFY	RN	Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents. J Med Chem. 2010 May 13;53(9):3611-7.
DMD4BFY	RU	https://pubmed.ncbi.nlm.nih.gov/20361801

DMD4BFY	DI	DMD4BFY
DMD4BFY	DN	Spermine
DMD4BFY	MI	DTOFXP5
DMD4BFY	MN	MFS-type transporter SLC18B1 (SLC18B1)
DMD4BFY	MT	DTP
DMD4BFY	MA	Substrate
DMD4BFY	RN	Identification of a mammalian vesicular polyamine transporter. Sci Rep. 2014 Oct 30;4:6836.
DMD4BFY	RU	http://www.ncbi.nlm.nih.gov/pubmed/25355561

DMD4BFY	DI	DMD4BFY
DMD4BFY	DN	Spermine
DMD4BFY	MI	DEW7V0G
DMD4BFY	MN	Polyamine oxidase (PAOX)
DMD4BFY	MT	DME
DMD4BFY	MA	Metabolism
DMD4BFY	RN	Polyamine catabolism and disease. Biochem J. 2009 Jul 15;421(3):323-38.
DMD4BFY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19589128

DMD4BFY	DI	DMD4BFY
DMD4BFY	DN	Spermine
DMD4BFY	MI	DEMWO83
DMD4BFY	MN	Putrescine acetyltransferase (SSAT1)
DMD4BFY	MT	DME
DMD4BFY	MA	Metabolism
DMD4BFY	RN	Mechanistic and structural analysis of human spermidine/spermine N1-acetyltransferase. Biochemistry. 2007 Jun 19;46(24):7187-95.
DMD4BFY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17516632

DMD4BFY	DI	DMD4BFY
DMD4BFY	DN	Spermine
DMD4BFY	MI	DEOH5V3
DMD4BFY	MN	Spermine oxidase (SMOX)
DMD4BFY	MT	DME
DMD4BFY	MA	Metabolism
DMD4BFY	RN	Distinct immunomodulatory effects of spermine oxidase in colitis induced by epithelial injury or infection. Front Immunol. 2018 Jun 5;9:1242.
DMD4BFY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29922289

DMTGIUV	DI	DMTGIUV
DMTGIUV	DN	SPR-210
DMTGIUV	MI	TTFBNVI
DMTGIUV	MN	Aldose reductase (AKR1B1)
DMTGIUV	MT	DTT
DMTGIUV	MA	Inhibitor
DMTGIUV	RN	Pharmacological profiles of a novel aldose reductase inhibitor, SPR-210, and its effects on streptozotocin-induced diabetic rats. Jpn J Pharmacol. 1994 Feb;64(2):115-24.
DMTGIUV	RU	https://pubmed.ncbi.nlm.nih.gov/8028228

DM6SW2R	DI	DM6SW2R
DM6SW2R	DN	SQ-26332
DM6SW2R	MI	TTL69WB
DM6SW2R	MN	Angiotensin-converting enzyme (ACE)
DM6SW2R	MT	DTT
DM6SW2R	MA	Inhibitor
DM6SW2R	RN	Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.
DM6SW2R	RU	https://pubmed.ncbi.nlm.nih.gov/16220969

DM6SW2R	DI	DM6SW2R
DM6SW2R	DN	SQ-26332
DM6SW2R	MI	TT5TKPM
DM6SW2R	MN	Neutral endopeptidase (MME)
DM6SW2R	MT	DTT
DM6SW2R	MA	Inhibitor
DM6SW2R	RN	Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.
DM6SW2R	RU	https://pubmed.ncbi.nlm.nih.gov/16220969

DM9DJFS	DI	DM9DJFS
DM9DJFS	DN	SQ-28603
DM9DJFS	MI	TT5TKPM
DM9DJFS	MN	Neutral endopeptidase (MME)
DM9DJFS	MT	DTT
DM9DJFS	MA	Modulator
DM9DJFS	RN	Evaluation of SQ 28,603, an inhibitor of neutral endopeptidase, in conscious monkeys. Can J Physiol Pharmacol. 1991 Oct;69(10):1609-17.
DM9DJFS	RU	https://pubmed.ncbi.nlm.nih.gov/1663819

DM083JB	DI	DM083JB
DM083JB	DN	SQ-33351
DM083JB	MI	TT5HONZ
DM083JB	MN	Calcium channel unspecific (CaC)
DM083JB	MT	DTT
DM083JB	MA	Modulator
DM083JB	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002577)
DM083JB	RU	http://adisinsight.springer.com/drugs/800002577

DMT5LX0	DI	DMT5LX0
DMT5LX0	DN	SQ-33600
DMT5LX0	MI	TTPADOQ
DMT5LX0	MN	HMG-CoA reductase (HMGCR)
DMT5LX0	MT	DTT
DMT5LX0	MA	Inhibitor
DMT5LX0	RN	Determination of SQ 33,600, a phosphinic acid containing HMG CoA reductase inhibitor, in human serum by high-performance liquid chromatography combined with ionspray mass spectrometry. Biol Mass Spectrom. 1992 Apr;21(4):189-94.
DMT5LX0	RU	https://pubmed.ncbi.nlm.nih.gov/1567915

DMMRWKP	DI	DMMRWKP
DMMRWKP	DN	SQ-33800
DMMRWKP	MI	TTB2MXP
DMMRWKP	MN	Angiotensinogenase renin (REN)
DMMRWKP	MT	DTT
DMMRWKP	MA	Inhibitor
DMMRWKP	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002406)
DMMRWKP	RU	http://adisinsight.springer.com/drugs/800002406

DMZBQ4I	DI	DMZBQ4I
DMZBQ4I	DN	SQ-33961
DMZBQ4I	MI	TT2O84V
DMZBQ4I	MN	Thromboxane A2 receptor (TBXA2R)
DMZBQ4I	MT	DTT
DMZBQ4I	MA	Modulator
DMZBQ4I	RN	Conformationally-restricted analogs of TXA2 antagonist SQ 33,961: Receptor binding conformation of the carboxyl sidechain. Bioorganic & Medicinal Chemistry Letters Volume 1, Issue 9, 1991, Pages 465-470.
DMZBQ4I	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01811070

DMT7O9V	DI	DMT7O9V
DMT7O9V	DN	SQ-34919
DMT7O9V	MI	TTFQEO5
DMT7O9V	MN	Squalene synthetase (FDFT1)
DMT7O9V	MT	DTT
DMT7O9V	MA	Inhibitor
DMT7O9V	RN	Inhibition of farnesyl protein transferase by new farnesyl phosphonate derivatives of phenylalanine, Bioorg. Med. Chem. Lett. 6(12):1291-1296 (1996).
DMT7O9V	RU	http://www.sciencedirect.com/science/article/pii/0960894X96002387

DM4JZPT	DI	DM4JZPT
DM4JZPT	DN	Squalestatin 1
DM4JZPT	MI	TTWTSCV
DM4JZPT	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DM4JZPT	MT	DTT
DM4JZPT	MA	Inhibitor
DM4JZPT	RN	Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activation. Nat Chem Biol. 2008 Sep;4(9):538-47.
DM4JZPT	RU	https://pubmed.ncbi.nlm.nih.gov/18641634

DM4JZPT	DI	DM4JZPT
DM4JZPT	DN	Squalestatin 1
DM4JZPT	MI	TTFQEO5
DM4JZPT	MN	Squalene synthetase (FDFT1)
DM4JZPT	MT	DTT
DM4JZPT	MA	Modulator
DM4JZPT	RN	Squalestatin 1, a potent inhibitor of squalene synthase, which lowers serum cholesterol in vivo. J Biol Chem. 1992 Jun 15;267(17):11705-8.
DM4JZPT	RU	https://pubmed.ncbi.nlm.nih.gov/1601846

DMETDFM	DI	DMETDFM
DMETDFM	DN	SR 120819A
DMETDFM	MI	TTRK9JT
DMETDFM	MN	Neuropeptide Y receptor type 1 (NPY1R)
DMETDFM	MT	DTT
DMETDFM	MA	Antagonist
DMETDFM	RN	SR 120819A, an orally-active and selective neuropeptide Y Y1 receptor antagonist. FEBS Lett. 1995 Apr 3;362(2):192-6.
DMETDFM	RU	https://pubmed.ncbi.nlm.nih.gov/7720871

DMQG3CK	DI	DMQG3CK
DMQG3CK	DN	SR-11237
DMQG3CK	MI	TTH029C
DMQG3CK	MN	Retinoic acid receptor RXR-gamma (RXRG)
DMQG3CK	MT	DTT
DMQG3CK	MA	Modulator
DMQG3CK	RN	Silicon analogues of the RXR-selective retinoid agonist SR11237 (BMS649): chemistry and biology. ChemMedChem. 2009 Jul;4(7):1143-52.
DMQG3CK	RU	https://pubmed.ncbi.nlm.nih.gov/19496083

DMU2ZVY	DI	DMU2ZVY
DMU2ZVY	DN	SR12813
DMU2ZVY	MI	TTPADOQ
DMU2ZVY	MN	HMG-CoA reductase (HMGCR)
DMU2ZVY	MT	DTT
DMU2ZVY	MA	Modulator
DMU2ZVY	RN	The novel cholesterol-lowering drug SR-12813 inhibits cholesterol synthesis via an increased degradation of 3-hydroxy-3-methylglutaryl-coenzyme A r... J Biol Chem. 1996 Jun 14;271(24):14376-82.
DMU2ZVY	RU	https://www.ncbi.nlm.nih.gov/pubmed/8662919

DM1GKTS	DI	DM1GKTS
DM1GKTS	DN	SR-26831
DM1GKTS	MI	TTPLTSQ
DM1GKTS	MN	Neutrophil elastase (NE)
DM1GKTS	MT	DTT
DM1GKTS	MA	Modulator
DM1GKTS	RN	Biochemical and pharmacological activities of SR 26831, a potent and selective elastase inhibitor. J Pharmacol Exp Ther. 1992 Feb;260(2):809-16.
DM1GKTS	RU	https://pubmed.ncbi.nlm.nih.gov/1738126

DMZ8SXP	DI	DMZ8SXP
DMZ8SXP	DN	SR-27950
DMZ8SXP	MI	TTCG0AL
DMZ8SXP	MN	Cholecystokinin receptor type A (CCKAR)
DMZ8SXP	MT	DTT
DMZ8SXP	MA	Modulator
DMZ8SXP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 76).
DMZ8SXP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=76

DM7ZOLE	DI	DM7ZOLE
DM7ZOLE	DN	SR-31742A
DM7ZOLE	MI	TT5TPI6
DM7ZOLE	MN	Opioid receptor sigma 1 (OPRS1)
DM7ZOLE	MT	DTT
DM7ZOLE	MA	Binder
DM7ZOLE	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DM7ZOLE	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMS9EJ5	DI	DMS9EJ5
DMS9EJ5	DN	SR-58878
DMS9EJ5	MI	TTMXGCW
DMS9EJ5	MN	Adrenergic receptor beta-3 (ADRB3)
DMS9EJ5	MT	DTT
DMS9EJ5	MA	Modulator
DMS9EJ5	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 30).
DMS9EJ5	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=30

DMQUF9I	DI	DMQUF9I
DMQUF9I	DN	SR-58894A
DMQUF9I	MI	TTMXGCW
DMQUF9I	MN	Adrenergic receptor beta-3 (ADRB3)
DMQUF9I	MT	DTT
DMQUF9I	MA	Modulator
DMQUF9I	RN	Pharmacological characterization of beta-adrenoceptor subtypes mediating relaxation in porcine isolated ureteral smooth muscle. J Urol. 2004 Sep;172(3):1155-9.
DMQUF9I	RU	https://pubmed.ncbi.nlm.nih.gov/15311061

DM6ASLF	DI	DM6ASLF
DM6ASLF	DN	SR-80027A
DM6ASLF	MI	TT6L509
DM6ASLF	MN	Coagulation factor IIa (F2)
DM6ASLF	MT	DTT
DM6ASLF	MA	Inhibitor
DM6ASLF	RN	Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216. Blood. 1994 Oct 15;84(8):2571-7.
DM6ASLF	RU	https://pubmed.ncbi.nlm.nih.gov/7919374

DMMPSY2	DI	DMMPSY2
DMMPSY2	DN	SRI 63-441
DMMPSY2	MI	TT27K59
DMMPSY2	MN	Platelet activating factor (PAF)
DMMPSY2	MT	DTT
DMMPSY2	MA	Inhibitor
DMMPSY2	RN	Pharmacologic modulation of experimental postischemic hepatic function. Ann Surg. 1989 Feb;209(2):200-10.
DMMPSY2	RU	https://pubmed.ncbi.nlm.nih.gov/2916864

DMBEUN6	DI	DMBEUN6
DMBEUN6	DN	SRI-3072
DMBEUN6	MI	TT3C1VN
DMBEUN6	MN	Enzyme unspecific (Enz)
DMBEUN6	MT	DTT
DMBEUN6	MA	Inhibitor
DMBEUN6	RN	2-Alkoxycarbonylaminopyridines: inhibitors of Mycobacterium tuberculosis FtsZ. J Antimicrob Chemother. 2002 Jul;50(1):111-4.
DMBEUN6	RU	https://pubmed.ncbi.nlm.nih.gov/12096015

DMFLPU5	DI	DMFLPU5
DMFLPU5	DN	SRSC-355
DMFLPU5	MI	TTRK8B9
DMFLPU5	MN	Sodium channel unspecific (NaC)
DMFLPU5	MT	DTT
DMFLPU5	MA	Modulator
DMFLPU5	RN	WO patent application no. 2013,0439,25, Sodium channel blockers reduce glucagon secretion.
DMFLPU5	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20130328&CC=WO&NR=2013043925A1&KC=A1

DM8MZWR	DI	DM8MZWR
DM8MZWR	DN	SRSS-021
DM8MZWR	MI	TTNXLKE
DM8MZWR	MN	5-HT 3 receptor (5HT3R)
DM8MZWR	MT	DTT
DM8MZWR	MA	Antagonist
DM8MZWR	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019090)
DM8MZWR	RU	http://adisinsight.springer.com/drugs/800019090

DMUGPDB	DI	DMUGPDB
DMUGPDB	DN	SRSS-023
DMUGPDB	MI	TTWT5K7
DMUGPDB	MN	5-HT 1 receptor (5HT1R)
DMUGPDB	MT	DTT
DMUGPDB	MA	Agonist
DMUGPDB	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019089)
DMUGPDB	RU	http://adisinsight.springer.com/drugs/800019089

DMWL4MI	DI	DMWL4MI
DMWL4MI	DN	SSR-69071
DMWL4MI	MI	TT3NKIB
DMWL4MI	MN	Pancreatic elastase 1 (CELA1)
DMWL4MI	MT	DTT
DMWL4MI	MA	Inhibitor
DMWL4MI	RN	Pivotal role for alpha1-antichymotrypsin in skin repair. J Biol Chem. 2011 Aug 19;286(33):28889-901.
DMWL4MI	RU	https://pubmed.ncbi.nlm.nih.gov/21693707

DMOJM08	DI	DMOJM08
DMOJM08	DN	Steroid hormone conjugates
DMOJM08	MI	TTPNQAC
DMOJM08	MN	Estrogen-related receptor-alpha (ESRRA)
DMOJM08	MT	DTT
DMOJM08	MA	Modulator
DMOJM08	RN	The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol (Oxf). 1998 Oct;49(4):421-32.
DMOJM08	RU	https://pubmed.ncbi.nlm.nih.gov/9876338

DMO9UCK	DI	DMO9UCK
DMO9UCK	DN	SU5614
DMO9UCK	MI	TTGJCWZ
DMO9UCK	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMO9UCK	MT	DTT
DMO9UCK	MA	Inhibitor
DMO9UCK	RN	FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro. Cancer Res. 2009 Apr 1;69(7):3032-41.
DMO9UCK	RU	https://pubmed.ncbi.nlm.nih.gov/19318574

DMWCR1Z	DI	DMWCR1Z
DMWCR1Z	DN	SU-740
DMWCR1Z	MI	TTH18TF
DMWCR1Z	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMWCR1Z	MT	DTT
DMWCR1Z	MA	Modulator
DMWCR1Z	RN	SU-840, a novel synthetic flavonoid derivative of sophoradin, with potent gastroprotective and ulcer healing activity. Journal of physiology and pharmacology. 49:1 1998 Mar pg 83-98
DMWCR1Z	RU	http://www.unboundmedicine.com/medline/citation/9594413/SU_840_a_novel_synthetic_flavonoid_derivative_of_sophoradin_with_potent_gastroprotective_and_ulcer_healing_activity_

DM4SVIR	DI	DM4SVIR
DM4SVIR	DN	Sulotroban
DM4SVIR	MI	TT2O84V
DM4SVIR	MN	Thromboxane A2 receptor (TBXA2R)
DM4SVIR	MT	DTT
DM4SVIR	MA	Modulator
DM4SVIR	RN	The PGI2-analogue iloprost and the TXA2-receptor antagonist sulotroban synergistically inhibit TXA2-dependent platelet activation. Prostaglandins. 1988 Dec;36(6):751-60.
DM4SVIR	RU	https://pubmed.ncbi.nlm.nih.gov/2469101

DMC1A42	DI	DMC1A42
DMC1A42	DN	SUN-11031
DMC1A42	MI	TTWDC17
DMC1A42	MN	Growth hormone secretagogue receptor 1 (GHSR)
DMC1A42	MT	DTT
DMC1A42	MA	Agonist
DMC1A42	RN	Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36.
DMC1A42	RU	https://pubmed.ncbi.nlm.nih.gov/16634704

DMAM3OH	DI	DMAM3OH
DMAM3OH	DN	SUN-E3001
DMAM3OH	MI	TT6F7GZ
DMAM3OH	MN	Parathyroid hormone (PTH)
DMAM3OH	MT	DTT
DMAM3OH	MA	Modulator
DMAM3OH	RN	Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res. 2003 Mar;18(3):539-43.
DMAM3OH	RU	https://www.ncbi.nlm.nih.gov/pubmed/12619939

DMG2SQM	DI	DMG2SQM
DMG2SQM	DN	SYN-1134
DMG2SQM	MI	TT3NKIB
DMG2SQM	MN	Pancreatic elastase 1 (CELA1)
DMG2SQM	MT	DTT
DMG2SQM	MA	Inhibitor
DMG2SQM	RN	EP patent application no. 1292314, Method for treating respiratory disorders associated with pulmonary elastic fiber injury comprising the use of glycosaminoglycans.
DMG2SQM	RU	http://www.google.com/patents/EP1292314A2?cl=en

DMOGQ2L	DI	DMOGQ2L
DMOGQ2L	DN	T-686
DMOGQ2L	MI	TT5QA2I
DMOGQ2L	MN	Plasminogen activator inhibitor (PAI)
DMOGQ2L	MT	DTT
DMOGQ2L	MA	Inhibitor
DMOGQ2L	RN	T-686, a novel inhibitor of plasminogen activator inhibitor-1, inhibits thrombosis without impairment of hemostasis in rats. Eur J Pharmacol. 1997 Jul 9;330(2-3):151-6.
DMOGQ2L	RU	https://pubmed.ncbi.nlm.nih.gov/9253948

DM0TELR	DI	DM0TELR
DM0TELR	DN	TAK-779
DM0TELR	MI	TT2CEJG
DM0TELR	MN	C-C chemokine receptor type 5 (CCR5)
DM0TELR	MT	DTT
DM0TELR	MA	Antagonist
DM0TELR	RN	Species selectivity of small-molecular antagonists for the CCR5 chemokine receptor. Int Immunopharmacol. 2007 Dec 5;7(12):1528-34.
DM0TELR	RU	https://pubmed.ncbi.nlm.nih.gov/17920529

DM2OFBT	DI	DM2OFBT
DM2OFBT	DN	Talisomycin
DM2OFBT	MI	TTUTN1I
DM2OFBT	MN	Human Deoxyribonucleic acid (hDNA)
DM2OFBT	MT	DTT
DM2OFBT	MA	Breaker
DM2OFBT	RN	Bleomycin and talisomycin sequence-specific strand scission of DNA: a mechanism of double-strand cleavage. Cancer Res. 1982 Jul;42(7):2779-85.
DM2OFBT	RU	https://pubmed.ncbi.nlm.nih.gov/6177398

DM54V0X	DI	DM54V0X
DM54V0X	DN	Tamoxifen methyl iodide
DM54V0X	MI	TTZAYWL
DM54V0X	MN	Estrogen receptor (ESR)
DM54V0X	MT	DTT
DM54V0X	MA	Inhibitor
DM54V0X	RN	Genomic action of permanently charged tamoxifen derivatives via estrogen receptor-alpha. Bioorg Med Chem. 2010 Aug 1;18(15):5593-601.
DM54V0X	RU	https://pubmed.ncbi.nlm.nih.gov/20621492

DMU3BDY	DI	DMU3BDY
DMU3BDY	DN	TAN-1496
DMU3BDY	MI	TTGTQHC
DMU3BDY	MN	DNA topoisomerase I (TOP1)
DMU3BDY	MT	DTT
DMU3BDY	MA	Modulator
DMU3BDY	RN	TAN-1496 A, C and E, diketopiperazine antibiotics with inhibitory activity against mammalian DNA topoisomerase I. J Antibiot (Tokyo). 1994 Nov;47(11):1202-18.
DMU3BDY	RU	https://pubmed.ncbi.nlm.nih.gov/8002382

DM197D0	DI	DM197D0
DM197D0	DN	TAR-1
DM197D0	MI	TT7SBF5
DM197D0	MN	Cellular tumor antigen p53 (TP53)
DM197D0	MT	DTT
DM197D0	RN	Regulation of host gene expression by HIV-1 TAR microRNAs. Retrovirology. 2013; 10: 86.
DM197D0	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751525/

DMCFGS6	DI	DMCFGS6
DMCFGS6	DN	TCV-295
DMCFGS6	MI	TT1VOHK
DMCFGS6	MN	Potassium channel unspecific (KC)
DMCFGS6	MT	DTT
DMCFGS6	MA	Opener
DMCFGS6	RN	Antihypertensive and cardiovascular effects of a new potassium channel opener, TCV-295, in rats and dogs. J Cardiovasc Pharmacol. 1994 Dec;24(6):929-36.
DMCFGS6	RU	https://pubmed.ncbi.nlm.nih.gov/7898076

DMHS5DX	DI	DMHS5DX
DMHS5DX	DN	TEI-6522
DMHS5DX	MI	TTMF541
DMHS5DX	MN	Liver carboxylesterase (CES1)
DMHS5DX	MT	DTT
DMHS5DX	MA	Modulator
DMHS5DX	RN	Potent inhibitors of acyl-CoA:cholesterol acyltransferase. Structure-activity relationships of novel N-(4-oxochroman-8-yl)amides. J Med Chem. 1995 Aug 4;38(16):3174-86.
DMHS5DX	RU	https://pubmed.ncbi.nlm.nih.gov/7636880

DMXM3B4	DI	DMXM3B4
DMXM3B4	DN	TEI-9874
DMXM3B4	MI	TTYJQTF
DMXM3B4	MN	Immunoglobulin E (IgE)
DMXM3B4	MT	DTT
DMXM3B4	MA	Modulator
DMXM3B4	RN	Effect of TEI-9874, an inhibitor of immunoglobulin E production, on allergen-induced asthmatic model in rats. Eur J Pharmacol. 2000 Aug 25;402(3):287-95.
DMXM3B4	RU	https://pubmed.ncbi.nlm.nih.gov/10958896

DMQIYZR	DI	DMQIYZR
DMQIYZR	DN	TER-16998
DMQIYZR	MI	TTCBFJO
DMQIYZR	MN	Insulin receptor (INSR)
DMQIYZR	MT	DTT
DMQIYZR	MA	Activator
DMQIYZR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800).
DMQIYZR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800

DM2X5R6	DI	DM2X5R6
DM2X5R6	DN	TERIKALANT
DM2X5R6	MI	TT1VOHK
DM2X5R6	MN	Potassium channel unspecific (KC)
DM2X5R6	MT	DTT
DM2X5R6	MA	Modulator
DM2X5R6	RN	Terikalant, an inward-rectifier potassium channel blocker, does not abolish the cardioprotection induced by ischemic preconditioning in the rat. J Mol Cell Cardiol. 1998 Sep;30(9):1817-25.
DM2X5R6	RU	https://www.ncbi.nlm.nih.gov/pubmed/9769237

DMSRDGE	DI	DMSRDGE
DMSRDGE	DN	TH-0318
DMSRDGE	MI	TTVIMDE
DMSRDGE	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMSRDGE	MT	DTT
DMSRDGE	MA	Modulator
DMSRDGE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249).
DMSRDGE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=249

DMG1MPD	DI	DMG1MPD
DMG1MPD	DN	TH-9229
DMG1MPD	MI	TTZIFHC
DMG1MPD	MN	Voltage-gated calcium channel alpha Cav1.2 (CACNA1C)
DMG1MPD	MT	DTT
DMG1MPD	MA	Modulator
DMG1MPD	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008159)
DMG1MPD	RU	http://adisinsight.springer.com/drugs/800008159

DMG1MPD	DI	DMG1MPD
DMG1MPD	DN	TH-9229
DMG1MPD	MI	TT7RGTM
DMG1MPD	MN	Voltage-gated calcium channel alpha Cav1.3 (CACNA1D)
DMG1MPD	MT	DTT
DMG1MPD	MA	Modulator
DMG1MPD	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008159)
DMG1MPD	RU	http://adisinsight.springer.com/drugs/800008159

DMG1MPD	DI	DMG1MPD
DMG1MPD	DN	TH-9229
DMG1MPD	MI	TTX4QDJ
DMG1MPD	MN	Voltage-gated calcium channel alpha Cav2.1 (CACNA1A)
DMG1MPD	MT	DTT
DMG1MPD	MA	Modulator
DMG1MPD	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008159)
DMG1MPD	RU	http://adisinsight.springer.com/drugs/800008159

DMG1MPD	DI	DMG1MPD
DMG1MPD	DN	TH-9229
DMG1MPD	MI	TT4FDG6
DMG1MPD	MN	Voltage-gated calcium channel alpha Cav2.2 (CACNA1B)
DMG1MPD	MT	DTT
DMG1MPD	MA	Modulator
DMG1MPD	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008159)
DMG1MPD	RU	http://adisinsight.springer.com/drugs/800008159

DMG1MPD	DI	DMG1MPD
DMG1MPD	DN	TH-9229
DMG1MPD	MI	TTYRP0M
DMG1MPD	MN	Voltage-gated calcium channel alpha Cav2.3 (CACNA1E)
DMG1MPD	MT	DTT
DMG1MPD	MA	Modulator
DMG1MPD	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008159)
DMG1MPD	RU	http://adisinsight.springer.com/drugs/800008159

DM8S593	DI	DM8S593
DM8S593	DN	Thioperamide
DM8S593	MI	TT9JNIC
DM8S593	MN	Histamine H3 receptor (H3R)
DM8S593	MT	DTT
DM8S593	MA	Antagonist
DM8S593	RN	The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20.
DM8S593	RU	https://pubmed.ncbi.nlm.nih.gov/15665857

DM8S593	DI	DM8S593
DM8S593	DN	Thioperamide
DM8S593	MI	TTXJ178
DM8S593	MN	Histamine H4 receptor (H4R)
DM8S593	MT	DTT
DM8S593	MA	Antagonist
DM8S593	RN	Role of histamine in short- and long-term effects of methamphetamine on the developing mouse brain. J Neurochem. 2008 Nov;107(4):976-86.
DM8S593	RU	https://pubmed.ncbi.nlm.nih.gov/18786166

DM0SCDB	DI	DM0SCDB
DM0SCDB	DN	TIAPAFANT
DM0SCDB	MI	TTQL5VC
DM0SCDB	MN	Platelet-activating factor receptor (PTAFR)
DM0SCDB	MT	DTT
DM0SCDB	MA	Antagonist
DM0SCDB	RN	PCA-4248, a PAF receptor antagonist, inhibits PAF-induced phosphoinositide turnover. Eur J Pharmacol. 1995 Aug 15;290(3):183-8.
DM0SCDB	RU	https://pubmed.ncbi.nlm.nih.gov/7589212

DMGCI6E	DI	DMGCI6E
DMGCI6E	DN	Tipredane
DMGCI6E	MI	TTTWGIX
DMGCI6E	MN	Leukotriene receptor (LTR)
DMGCI6E	MT	DTT
DMGCI6E	MA	Modulator
DMGCI6E	RN	New drugs for asthma. Nat Rev Drug Discov. 2004 Oct;3(10):831-44.
DMGCI6E	RU	https://pubmed.ncbi.nlm.nih.gov/15459674

DM4YQDX	DI	DM4YQDX
DM4YQDX	DN	TJN-220
DM4YQDX	MI	TTLWS2O
DM4YQDX	MN	Calcitonin receptor (CALCR)
DM4YQDX	MT	DTT
DM4YQDX	MA	Modulator
DM4YQDX	RN	Evaluation of the long-lasting antihypertensive action of 7-O-ethylfangchinoline. Jpn J Pharmacol. 1994 Sep;66(1):35-46.
DM4YQDX	RU	https://pubmed.ncbi.nlm.nih.gov/7861666

DMKSPYI	DI	DMKSPYI
DMKSPYI	DN	TJN-598
DMKSPYI	MI	TTZ97H5
DMKSPYI	MN	Phosphodiesterase 4A (PDE4A)
DMKSPYI	MT	DTT
DMKSPYI	MA	Inhibitor
DMKSPYI	RN	Effects of TJN-598, a new selective phosphodiesterase type IV inhibitor on anti-Thy1 nephritis in rats. Clin Exp Nephrol. 2011 Feb;15(1):14-24.
DMKSPYI	RU	https://pubmed.ncbi.nlm.nih.gov/20820840

DMKSPYI	DI	DMKSPYI
DMKSPYI	DN	TJN-598
DMKSPYI	MI	TTVIAT9
DMKSPYI	MN	Phosphodiesterase 4B (PDE4B)
DMKSPYI	MT	DTT
DMKSPYI	MA	Inhibitor
DMKSPYI	RN	Effects of TJN-598, a new selective phosphodiesterase type IV inhibitor on anti-Thy1 nephritis in rats. Clin Exp Nephrol. 2011 Feb;15(1):14-24.
DMKSPYI	RU	https://pubmed.ncbi.nlm.nih.gov/20820840

DMKSPYI	DI	DMKSPYI
DMKSPYI	DN	TJN-598
DMKSPYI	MI	TTSKMI8
DMKSPYI	MN	Phosphodiesterase 4D (PDE4D)
DMKSPYI	MT	DTT
DMKSPYI	MA	Inhibitor
DMKSPYI	RN	Effects of TJN-598, a new selective phosphodiesterase type IV inhibitor on anti-Thy1 nephritis in rats. Clin Exp Nephrol. 2011 Feb;15(1):14-24.
DMKSPYI	RU	https://pubmed.ncbi.nlm.nih.gov/20820840

DMTNB6G	DI	DMTNB6G
DMTNB6G	DN	TNFQb therapeutic vaccines
DMTNB6G	MI	TTF8CQI
DMTNB6G	MN	Tumor necrosis factor (TNF)
DMTNB6G	MT	DTT
DMTNB6G	RN	Therapeutic Vaccination with TNF-Kinoid in TNF Antagonist-Resistant Rheumatoid Arthritis: A Phase II Randomized, Controlled Clinical Trial. PLoS One. 2014; 9(12): e113465.
DMTNB6G	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269456/

DMZKIE0	DI	DMZKIE0
DMZKIE0	DN	Tolerimab
DMZKIE0	MI	TTFZDNP
DMZKIE0	MN	Activation B7-1 antigen (CD80)
DMZKIE0	MT	DTT
DMZKIE0	RN	US patent application no. 2004,0171,123, Albumin fusion proteins.
DMZKIE0	RU	https://www.google.com/patents/US20040171123

DMZKIE0	DI	DMZKIE0
DMZKIE0	DN	Tolerimab
DMZKIE0	MI	TTHGXBU
DMZKIE0	MN	T-lymphocyte activation antigen CD86 (FUN1)
DMZKIE0	MT	DTT
DMZKIE0	RN	US patent application no. 2004,0171,123, Albumin fusion proteins.
DMZKIE0	RU	https://www.google.com/patents/US20040171123

DM385D9	DI	DM385D9
DM385D9	DN	Tomelukast
DM385D9	MI	TTGKOY9
DM385D9	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DM385D9	MT	DTT
DM385D9	MA	Modulator
DM385D9	RN	Effects of chronic treatment with the leukotriene D4 antagonist compound LY171883 on Fischer 344 rats and rhesus monkeys. Fundam Appl Toxicol. 1990 Jan;14(1):123-30.
DM385D9	RU	https://www.ncbi.nlm.nih.gov/pubmed/2307311

DMRBGI6	DI	DMRBGI6
DMRBGI6	DN	Torbafylline
DMRBGI6	MI	TTZ97H5
DMRBGI6	MN	Phosphodiesterase 4A (PDE4A)
DMRBGI6	MT	DTT
DMRBGI6	MA	Inhibitor
DMRBGI6	RN	Phosphodiesterase (PDE) inhibitor torbafylline (HWA 448) attenuates burn-induced rat skeletal muscle proteolysis through the PDE4/cAMP/EPAC/PI3K/Akt pathway. Mol Cell Endocrinol. 2014 Aug 5;393(1-2):152-63.
DMRBGI6	RU	https://pubmed.ncbi.nlm.nih.gov/24973766

DMRBGI6	DI	DMRBGI6
DMRBGI6	DN	Torbafylline
DMRBGI6	MI	TTVIAT9
DMRBGI6	MN	Phosphodiesterase 4B (PDE4B)
DMRBGI6	MT	DTT
DMRBGI6	MA	Modulator
DMRBGI6	RN	Phosphodiesterase (PDE) inhibitor torbafylline (HWA 448) attenuates burn-induced rat skeletal muscle proteolysis through the PDE4/cAMP/EPAC/PI3K/Akt pathway. Mol Cell Endocrinol. 2014 Aug 5;393(1-2):152-63.
DMRBGI6	RU	https://pubmed.ncbi.nlm.nih.gov/24973766

DMRBGI6	DI	DMRBGI6
DMRBGI6	DN	Torbafylline
DMRBGI6	MI	TTSKMI8
DMRBGI6	MN	Phosphodiesterase 4D (PDE4D)
DMRBGI6	MT	DTT
DMRBGI6	MA	Modulator
DMRBGI6	RN	Phosphodiesterase (PDE) inhibitor torbafylline (HWA 448) attenuates burn-induced rat skeletal muscle proteolysis through the PDE4/cAMP/EPAC/PI3K/Akt pathway. Mol Cell Endocrinol. 2014 Aug 5;393(1-2):152-63.
DMRBGI6	RU	https://pubmed.ncbi.nlm.nih.gov/24973766

DM5ZNSQ	DI	DM5ZNSQ
DM5ZNSQ	DN	TP-20
DM5ZNSQ	MI	TT6ATLX
DM5ZNSQ	MN	Complement factor I (CFI)
DM5ZNSQ	MT	DTT
DM5ZNSQ	MA	Inhibitor
DM5ZNSQ	RN	Endothelial targeting and enhanced antiinflammatory effects of complement inhibitors possessing sialyl Lewisx moieties. J Immunol. 1999 Apr 15;162(8):4952-9.
DM5ZNSQ	RU	https://pubmed.ncbi.nlm.nih.gov/10202042

DMQRSMD	DI	DMQRSMD
DMQRSMD	DN	Trequinsin
DMQRSMD	MI	TTJ0IQB
DMQRSMD	MN	Phosphodiesterase 5A (PDE5A)
DMQRSMD	MT	DTT
DMQRSMD	MA	Inhibitor
DMQRSMD	RN	Inhibition of cyclic adenosine-3',5'-monophosphate phosphodiesterase from vascular smooth muscle by rolipram analogues. J Med Chem. 1989 Jul;32(7):1450-7.
DMQRSMD	RU	https://pubmed.ncbi.nlm.nih.gov/2544722

DMUHBSI	DI	DMUHBSI
DMUHBSI	DN	Tridegin
DMUHBSI	MI	TTAXGIP
DMUHBSI	MN	Coagulation factor XIII (F13B)
DMUHBSI	MT	DTT
DMUHBSI	MA	Modulator
DMUHBSI	RN	Tridegin, a new peptidic inhibitor of factor XIIIa, from the blood-sucking leech Haementeria ghilianii. Biochem J. 1997 Jun 15;324 ( Pt 3):797-805.
DMUHBSI	RU	https://www.ncbi.nlm.nih.gov/pubmed/9210403

DMASENP	DI	DMASENP
DMASENP	DN	TULOPAFANT
DMASENP	MI	TTQL5VC
DMASENP	MN	Platelet-activating factor receptor (PTAFR)
DMASENP	MT	DTT
DMASENP	MA	Antagonist
DMASENP	RN	Tulopafant, a PAF receptor antagonist, increases capillary patency and prolongs survival in discordant cardiac xenotransplants. J Lipid Mediat. 1993 May;7(1):79-84.
DMASENP	RU	https://pubmed.ncbi.nlm.nih.gov/8395256

DMR3S9B	DI	DMR3S9B
DMR3S9B	DN	Tyloxapol
DMR3S9B	MI	TTSXVID
DMR3S9B	MN	Nuclear factor NF-kappa-B (NFKB)
DMR3S9B	MT	DTT
DMR3S9B	MA	Inhibitor
DMR3S9B	RN	Study of influence of additives of tyloxapol on the chromatographic characteristics of the model compounds: the comparative characterization of micellar mobile phases of tyloxapol and Triton X-100. Biomed Chromatogr. 2009 Jul;23(7):700-6.
DMR3S9B	RU	https://pubmed.ncbi.nlm.nih.gov/19309752

DM4WUEP	DI	DM4WUEP
DM4WUEP	DN	U-54494A
DM4WUEP	MI	TTRK8B9
DM4WUEP	MN	Sodium channel unspecific (NaC)
DM4WUEP	MT	DTT
DM4WUEP	MA	Modulator
DM4WUEP	RN	U-54494A: a unique anticonvulsant related to kappa opioid agonists. J Pharmacol Exp Ther. 1987 Nov;243(2):542-7.
DM4WUEP	RU	https://pubmed.ncbi.nlm.nih.gov/2824750

DMRBXEA	DI	DMRBXEA
DMRBXEA	DN	U-75875
DMRBXEA	MI	TT5FNQT
DMRBXEA	MN	Human immunodeficiency virus Protease (HIV PR)
DMRBXEA	MT	DTT
DMRBXEA	MA	Modulator
DMRBXEA	RN	Effects of U-75875, a peptidomimetic inhibitor of retroviral proteases, on simian immunodeficiency virus infection in rhesus monkeys. Antimicrob Agents Chemother. 1994 Jun;38(6):1277-83.
DMRBXEA	RU	https://pubmed.ncbi.nlm.nih.gov/7522427

DMGUMWP	DI	DMGUMWP
DMGUMWP	DN	U-80816
DMGUMWP	MI	TTOXS3C
DMGUMWP	MN	Muscarinic acetylcholine receptor (CHRM)
DMGUMWP	MT	DTT
DMGUMWP	MA	Modulator
DMGUMWP	RN	U-80816: A novel partial muscarinic agonist. Drug Development Research Volume 24, Issue 1, pages 53-66, 1991.
DMGUMWP	RU	http://onlinelibrary.wiley.com/doi/10.1002/ddr.430240105/abstract

DMTMZJ4	DI	DMTMZJ4
DMTMZJ4	DN	U-90042
DMTMZJ4	MI	TTNJYV2
DMTMZJ4	MN	Gamma-aminobutyric acid receptor (GAR)
DMTMZJ4	MT	DTT
DMTMZJ4	MA	Modulator
DMTMZJ4	RN	U-90042, a sedative/hypnotic compound that interacts differentially with the GABAA receptor subtypes. J Pharmacol Exp Ther. 1995 Nov;275(2):761-7.
DMTMZJ4	RU	https://pubmed.ncbi.nlm.nih.gov/7473164

DMTYO3P	DI	DMTYO3P
DMTYO3P	DN	U-92032
DMTYO3P	MI	TTRK8B9
DMTYO3P	MN	Sodium channel unspecific (NaC)
DMTYO3P	MT	DTT
DMTYO3P	MA	Inhibitor
DMTYO3P	RN	Discovery of (2S)-1-(4-amino-2,3,5- trimethylphenoxy)-3-[4-[4-(4- fluorobenzyl)phenyl]-1-piperazinyl]-2-propanol dimethanesulfonate (SUN N8075): a ... J Med Chem. 2000 Sep 7;43(18):3372-6.
DMTYO3P	RU	https://pubmed.ncbi.nlm.nih.gov/10978184

DMTYO3P	DI	DMTYO3P
DMTYO3P	DN	U-92032
DMTYO3P	MI	TTZPWGN
DMTYO3P	MN	Voltage-gated calcium channel alpha Cav3.2 (CACNA1H)
DMTYO3P	MT	DTT
DMTYO3P	MA	Inhibitor
DMTYO3P	RN	Discovery of (2S)-1-(4-amino-2,3,5- trimethylphenoxy)-3-[4-[4-(4- fluorobenzyl)phenyl]-1-piperazinyl]-2-propanol dimethanesulfonate (SUN N8075): a ... J Med Chem. 2000 Sep 7;43(18):3372-6.
DMTYO3P	RU	https://pubmed.ncbi.nlm.nih.gov/10978184

DMTYO3P	DI	DMTYO3P
DMTYO3P	DN	U-92032
DMTYO3P	MI	TTQZFTH
DMTYO3P	MN	Voltage-gated calcium channel alpha Cav3.3 (CACNA1I)
DMTYO3P	MT	DTT
DMTYO3P	MA	Inhibitor
DMTYO3P	RN	Discovery of (2S)-1-(4-amino-2,3,5- trimethylphenoxy)-3-[4-[4-(4- fluorobenzyl)phenyl]-1-piperazinyl]-2-propanol dimethanesulfonate (SUN N8075): a ... J Med Chem. 2000 Sep 7;43(18):3372-6.
DMTYO3P	RU	https://pubmed.ncbi.nlm.nih.gov/10978184

DMTYO3P	DI	DMTYO3P
DMTYO3P	DN	U-92032
DMTYO3P	MI	TTAXZ0K
DMTYO3P	MN	Voltage-gated sodium channel alpha Nav1.3 (SCN3A)
DMTYO3P	MT	DTT
DMTYO3P	MA	Inhibitor
DMTYO3P	RN	Discovery of (2S)-1-(4-amino-2,3,5- trimethylphenoxy)-3-[4-[4-(4- fluorobenzyl)phenyl]-1-piperazinyl]-2-propanol dimethanesulfonate (SUN N8075): a ... J Med Chem. 2000 Sep 7;43(18):3372-6.
DMTYO3P	RU	https://pubmed.ncbi.nlm.nih.gov/10978184

DM0Z7PK	DI	DM0Z7PK
DM0Z7PK	DN	UC-38
DM0Z7PK	MI	TT84ETX
DM0Z7PK	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM0Z7PK	MT	DTT
DM0Z7PK	MA	Modulator
DM0Z7PK	RN	Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor. J Pharmacol Exp Ther. 1996 Jan;276(1):298-305.
DM0Z7PK	RU	https://pubmed.ncbi.nlm.nih.gov/8558446

DMY9UEZ	DI	DMY9UEZ
DMY9UEZ	DN	UC-84
DMY9UEZ	MI	TT84ETX
DMY9UEZ	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMY9UEZ	MT	DTT
DMY9UEZ	MA	Modulator
DMY9UEZ	RN	Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives. Biochemistry. 1998 Oct 13;37(41):14394-403.
DMY9UEZ	RU	https://pubmed.ncbi.nlm.nih.gov/9772165

DMD3CA5	DI	DMD3CA5
DMD3CA5	DN	UCL-1390
DMD3CA5	MI	TT9JNIC
DMD3CA5	MN	Histamine H3 receptor (H3R)
DMD3CA5	MT	DTT
DMD3CA5	MA	Antagonist
DMD3CA5	RN	Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36.
DMD3CA5	RU	https://pubmed.ncbi.nlm.nih.gov/16634704

DM9FT5E	DI	DM9FT5E
DM9FT5E	DN	UD-CG-212
DM9FT5E	MI	TTZCG4L
DM9FT5E	MN	Phosphodiesterase 3 (PDE3)
DM9FT5E	MT	DTT
DM9FT5E	MA	Modulator
DM9FT5E	RN	Phosphodiesterase inhibition in ventricular cardiomyocytes from guinea-pig hearts. Br J Pharmacol. 1992 Sep;107(1):127-33.
DM9FT5E	RU	https://www.ncbi.nlm.nih.gov/pubmed/1384905

DMQFSAB	DI	DMQFSAB
DMQFSAB	DN	UK-290795
DMQFSAB	MI	TTYO0A3
DMQFSAB	MN	Substance-K receptor (TACR2)
DMQFSAB	MT	DTT
DMQFSAB	MA	Antagonist
DMQFSAB	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017162)
DMQFSAB	RU	http://adisinsight.springer.com/drugs/800017162

DM23YPS	DI	DM23YPS
DM23YPS	DN	UK-51656
DM23YPS	MI	TT5HONZ
DM23YPS	MN	Calcium channel unspecific (CaC)
DM23YPS	MT	DTT
DM23YPS	MA	Modulator
DM23YPS	RN	Long-acting dihydropyridine calcium antagonists. 4. Synthesis and structure-activity relationships for a series of basic and nonbasic derivatives of 2-[(2-aminoethoxy)methyl]-1,4-dihydropyridine calcium antagonists. J Med Chem. 1990 Feb;33(2):585-91.
DM23YPS	RU	https://pubmed.ncbi.nlm.nih.gov/2153819

DMKBILF	DI	DMKBILF
DMKBILF	DN	UK-78282
DMKBILF	MI	TTY3UE6
DMKBILF	MN	Voltage-gated potassium channel Kv1.3 (KCNA3)
DMKBILF	MT	DTT
DMKBILF	MA	Inhibitor
DMKBILF	RN	Angular methoxy-substituted furo- and pyranoquinolinones as blockers of the voltage-gated potassium channel Kv1.3. J Med Chem. 2001 Apr 12;44(8):1249-56.
DMKBILF	RU	https://pubmed.ncbi.nlm.nih.gov/11312924

DMEIR7F	DI	DMEIR7F
DMEIR7F	DN	UP-116-77
DMEIR7F	MI	TT2O84V
DMEIR7F	MN	Thromboxane A2 receptor (TBXA2R)
DMEIR7F	MT	DTT
DMEIR7F	MA	Modulator
DMEIR7F	RN	Synthesis and structure-activity relationships of novel benzimidazole and imidazo[4,5-b]pyridine acid derivatives as thromboxane A2 receptor antagonists. J Med Chem. 1993 Apr 30;36(9):1175-87.
DMEIR7F	RU	https://pubmed.ncbi.nlm.nih.gov/8487256

DM37DOC	DI	DM37DOC
DM37DOC	DN	UP-275-22
DM37DOC	MI	TT8DBY3
DM37DOC	MN	Angiotensin II receptor type-1 (AGTR1)
DM37DOC	MT	DTT
DM37DOC	MA	Modulator
DM37DOC	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 34).
DM37DOC	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=34

DMV8GUE	DI	DMV8GUE
DMV8GUE	DN	UR-12460
DMV8GUE	MI	TTQL5VC
DMV8GUE	MN	Platelet-activating factor receptor (PTAFR)
DMV8GUE	MT	DTT
DMV8GUE	MA	Modulator
DMV8GUE	RN	Platelet-activating factor: the effector of protein-rich plasma extravasation and nitric oxide synthase induction in rat immune complex peritonitis. Br J Pharmacol. 1995 Feb;114(4):895-901.
DMV8GUE	RU	https://pubmed.ncbi.nlm.nih.gov/7539698

DM7F94W	DI	DM7F94W
DM7F94W	DN	UR-12670
DM7F94W	MI	TT27K59
DM7F94W	MN	Platelet activating factor (PAF)
DM7F94W	MT	DTT
DM7F94W	MA	Inhibitor
DM7F94W	RN	Long-term protective effect of UR-12670 after warm renal ischemia in uninephrectomized rats. Kidney Int. 1999 Nov;56(5):1798-808.
DM7F94W	RU	https://pubmed.ncbi.nlm.nih.gov/10571788

DMJC82N	DI	DMJC82N
DMJC82N	DN	UR-8225
DMJC82N	MI	TT1VOHK
DMJC82N	MN	Potassium channel unspecific (KC)
DMJC82N	MT	DTT
DMJC82N	MA	Opener
DMJC82N	RN	Effects of the novel potassium channel opener, UR-8225, on contractile responses in rat isolated smooth muscle. Br J Pharmacol. 1993 Nov;110(3):1165-71.
DMJC82N	RU	https://pubmed.ncbi.nlm.nih.gov/8298804

DM6C7WJ	DI	DM6C7WJ
DM6C7WJ	DN	UR-8308
DM6C7WJ	MI	TT1VOHK
DM6C7WJ	MN	Potassium channel unspecific (KC)
DM6C7WJ	MT	DTT
DM6C7WJ	MA	Opener
DM6C7WJ	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005294)
DM6C7WJ	RU	http://adisinsight.springer.com/drugs/800005294

DM4KOTA	DI	DM4KOTA
DM4KOTA	DN	UR-8328
DM4KOTA	MI	TT1VOHK
DM4KOTA	MN	Potassium channel unspecific (KC)
DM4KOTA	MT	DTT
DM4KOTA	MA	Opener
DM4KOTA	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005293)
DM4KOTA	RU	http://adisinsight.springer.com/drugs/800005293

DM73EPK	DI	DM73EPK
DM73EPK	DN	Vapaliximab
DM73EPK	MI	TT7HC21
DM73EPK	MN	Membrane copper amine oxidase (AOC3)
DM73EPK	MT	DTT
DM73EPK	RN	Clinical pipeline report, company report or official report of Huginonline.
DM73EPK	RU	http://reports.huginonline.com/845929/98523.pdf

DMJLV03	DI	DMJLV03
DMJLV03	DN	Vapiprost
DMJLV03	MI	TT2O84V
DMJLV03	MN	Thromboxane A2 receptor (TBXA2R)
DMJLV03	MT	DTT
DMJLV03	MA	Modulator
DMJLV03	RN	Effects of vapiprost, a novel thromboxane receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tissue-type plasminogen activator.. Br J Pharmacol. 1992 July; 106(3): 533-538.
DMJLV03	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1907568/

DMHG70W	DI	DMHG70W
DMHG70W	DN	VE-16084
DMHG70W	MI	TTCQIBE
DMHG70W	MN	Caspase-1 (CASP1)
DMHG70W	MT	DTT
DMHG70W	MA	Inhibitor
DMHG70W	RN	Interleukin-1 beta converting enzyme inhibition blocks progression of type II collagen-induced arthritis in mice. Cytokine. 1996 May;8(5):377-86.
DMHG70W	RU	https://pubmed.ncbi.nlm.nih.gov/8726666

DMY0V6J	DI	DMY0V6J
DMY0V6J	DN	VG-106
DMY0V6J	MI	TTXM6JN
DMY0V6J	MN	Cytokine receptor unspecific (CRF)
DMY0V6J	MT	DTT
DMY0V6J	MA	Modulator
DMY0V6J	RN	WO patent application no. 2011,0955,45, Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same.
DMY0V6J	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20110811&CC=WO&NR=2011095545A1&KC=A1

DMLWQOP	DI	DMLWQOP
DMLWQOP	DN	VR-147
DMLWQOP	MI	TTK8CXU
DMLWQOP	MN	5-HT 1B receptor (HTR1B)
DMLWQOP	MT	DTT
DMLWQOP	MA	Modulator
DMLWQOP	RN	US patent application no. 2010,0112,050, Dosage form for insertion into the mouth.
DMLWQOP	RU	http://www.google.com/patents/US20100112050

DMLWQOP	DI	DMLWQOP
DMLWQOP	DN	VR-147
DMLWQOP	MI	TT6MSOK
DMLWQOP	MN	5-HT 1D receptor (HTR1D)
DMLWQOP	MT	DTT
DMLWQOP	MA	Modulator
DMLWQOP	RN	US patent application no. 2010,0112,050, Dosage form for insertion into the mouth.
DMLWQOP	RU	http://www.google.com/patents/US20100112050

DM0CWJZ	DI	DM0CWJZ
DM0CWJZ	DN	VUF-8929
DM0CWJZ	MI	TT5HONZ
DM0CWJZ	MN	Calcium channel unspecific (CaC)
DM0CWJZ	MT	DTT
DM0CWJZ	MA	Modulator
DM0CWJZ	RN	In vitro and in vivo characterization of a calcium modulator of the diphenylalkylamine type with selective coronary dilatory properties. Arzneimittelforschung. 1997 Nov;47(11):1211-8.
DM0CWJZ	RU	https://pubmed.ncbi.nlm.nih.gov/9428976

DMG58FX	DI	DMG58FX
DMG58FX	DN	WAY-100635
DMG58FX	MI	TTSQIFT
DMG58FX	MN	5-HT 1A receptor (HTR1A)
DMG58FX	MT	DTT
DMG58FX	MA	Antagonist
DMG58FX	RN	Pharmacological characterization of recombinant human 5-hydroxytryptamine1A receptors using a novel antagonist radioligand, [3H]WAY-100635. Life Sci. 1997;60(9):653-65.
DMG58FX	RU	https://pubmed.ncbi.nlm.nih.gov/9048968

DMMOS8G	DI	DMMOS8G
DMMOS8G	DN	WAY-123223
DMMOS8G	MI	TT1VOHK
DMMOS8G	MN	Potassium channel unspecific (KC)
DMMOS8G	MT	DTT
DMMOS8G	MA	Opener
DMMOS8G	RN	Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives. J Med Chem. 1991 Nov;34(11):3212-28.
DMMOS8G	RU	https://pubmed.ncbi.nlm.nih.gov/1956040

DMTY7PE	DI	DMTY7PE
DMTY7PE	DN	WAY-126227
DMTY7PE	MI	TTGN1ZA
DMTY7PE	MN	Angiotensin II receptor (AGTR)
DMTY7PE	MT	DTT
DMTY7PE	MA	Modulator
DMTY7PE	RN	WO patent application no. 1996,0402,58, Spironolactone and angiotensin ii antagonist combination therapy for treatment of congestive heart failure.
DMTY7PE	RU	http://www.google.com/patents/WO1996040258A2?cl=en

DM2XTB9	DI	DM2XTB9
DM2XTB9	DN	WAY-132983
DM2XTB9	MI	TTZ9SOR
DM2XTB9	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DM2XTB9	MT	DTT
DM2XTB9	MA	Agonist
DM2XTB9	RN	Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur J Pharmacol. 2009 Mar 1;605(1-3):53-6.
DM2XTB9	RU	https://pubmed.ncbi.nlm.nih.gov/19168056

DMQU8B1	DI	DMQU8B1
DMQU8B1	DN	WB-4101
DMQU8B1	MI	TTSQIFT
DMQU8B1	MN	5-HT 1A receptor (HTR1A)
DMQU8B1	MT	DTT
DMQU8B1	MA	Inhibitor
DMQU8B1	RN	Synthesis of (R,S)-trans-8-hydroxy-2-[N-n-propyl-N-(3'-iodo-2'-propenyl)amino]tetral in (trans-8-OH-PIPAT): a new 5-HT1A receptor ligand. J Med Chem. 1993 Oct 15;36(21):3161-5.
DMQU8B1	RU	https://pubmed.ncbi.nlm.nih.gov/8230102

DMQU8B1	DI	DMQU8B1
DMQU8B1	DN	WB-4101
DMQU8B1	MI	TTNGILX
DMQU8B1	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMQU8B1	MT	DTT
DMQU8B1	MA	Inhibitor
DMQU8B1	RN	Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem. 1995 Sep 1;38(18):3415-44.
DMQU8B1	RU	https://pubmed.ncbi.nlm.nih.gov/7658428

DMQU8B1	DI	DMQU8B1
DMQU8B1	DN	WB-4101
DMQU8B1	MI	TTBRKXS
DMQU8B1	MN	Adrenergic receptor alpha-1B (ADRA1B)
DMQU8B1	MT	DTT
DMQU8B1	MA	Inhibitor
DMQU8B1	RN	Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem. 1995 Sep 1;38(18):3415-44.
DMQU8B1	RU	https://pubmed.ncbi.nlm.nih.gov/7658428

DMQU8B1	DI	DMQU8B1
DMQU8B1	DN	WB-4101
DMQU8B1	MI	TT34BHT
DMQU8B1	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMQU8B1	MT	DTT
DMQU8B1	MA	Inhibitor
DMQU8B1	RN	Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem. 1995 Sep 1;38(18):3415-44.
DMQU8B1	RU	https://pubmed.ncbi.nlm.nih.gov/7658428

DMQU8B1	DI	DMQU8B1
DMQU8B1	DN	WB-4101
DMQU8B1	MI	TTWG9A4
DMQU8B1	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMQU8B1	MT	DTT
DMQU8B1	MA	Inhibitor
DMQU8B1	RN	alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs. J Med Chem. 1982 Dec;25(12):1389-401.
DMQU8B1	RU	https://pubmed.ncbi.nlm.nih.gov/6296387

DMQU8B1	DI	DMQU8B1
DMQU8B1	DN	WB-4101
DMQU8B1	MI	TTWM4TY
DMQU8B1	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMQU8B1	MT	DTT
DMQU8B1	MA	Inhibitor
DMQU8B1	RN	alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs. J Med Chem. 1982 Dec;25(12):1389-401.
DMQU8B1	RU	https://pubmed.ncbi.nlm.nih.gov/6296387

DMQU8B1	DI	DMQU8B1
DMQU8B1	DN	WB-4101
DMQU8B1	MI	TT2NUT5
DMQU8B1	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMQU8B1	MT	DTT
DMQU8B1	MA	Inhibitor
DMQU8B1	RN	alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs. J Med Chem. 1982 Dec;25(12):1389-401.
DMQU8B1	RU	https://pubmed.ncbi.nlm.nih.gov/6296387

DMY9NG1	DI	DMY9NG1
DMY9NG1	DN	WEB-2347
DMY9NG1	MI	TTQL5VC
DMY9NG1	MN	Platelet-activating factor receptor (PTAFR)
DMY9NG1	MT	DTT
DMY9NG1	MA	Modulator
DMY9NG1	RN	WEB 2347: pharmacology of a new very potent and long acting hetrazepinoic PAF-antagonist and its action in repeatedly sensitized guinea-pigs. J Lipid Mediat. 1991 Jul-Aug;4(1):39-44.
DMY9NG1	RU	https://pubmed.ncbi.nlm.nih.gov/1893086

DMBMOI6	DI	DMBMOI6
DMBMOI6	DN	WF-2421
DMBMOI6	MI	TTFBNVI
DMBMOI6	MN	Aldose reductase (AKR1B1)
DMBMOI6	MT	DTT
DMBMOI6	MA	Modulator
DMBMOI6	RN	WF-2421, a new aldose reductase inhibitor produced from a fungus, Humicola grisea. J Antibiot (Tokyo). 1991 Feb;44(2):130-5.
DMBMOI6	RU	https://pubmed.ncbi.nlm.nih.gov/1901310

DMACBIW	DI	DMACBIW
DMACBIW	DN	WIN-55212-2
DMACBIW	MI	TT6OEDT
DMACBIW	MN	Cannabinoid receptor 1 (CB1)
DMACBIW	MT	DTT
DMACBIW	MA	Inhibitor
DMACBIW	RN	Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists. Bioorg Med Chem. 2009 Apr 1;17(7):2842-51.
DMACBIW	RU	https://pubmed.ncbi.nlm.nih.gov/19278853

DMACBIW	DI	DMACBIW
DMACBIW	DN	WIN-55212-2
DMACBIW	MI	TTMSFAW
DMACBIW	MN	Cannabinoid receptor 2 (CB2)
DMACBIW	MT	DTT
DMACBIW	MA	Inhibitor
DMACBIW	RN	Synthesis and cannabinoid activity of 1-substituted-indole-3-oxadiazole derivatives: novel agonists for the CB1 receptor. Eur J Med Chem. 2008 Mar;43(3):513-39.
DMACBIW	RU	https://pubmed.ncbi.nlm.nih.gov/17582659

DMACBIW	DI	DMACBIW
DMACBIW	DN	WIN-55212-2
DMACBIW	MI	DE4LYSA
DMACBIW	MN	Cytochrome P450 3A4 (CYP3A4)
DMACBIW	MT	DME
DMACBIW	MA	Metabolism
DMACBIW	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DMACBIW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DMRV48P	DI	DMRV48P
DMRV48P	DN	WIN-63759
DMRV48P	MI	TT3NKIB
DMRV48P	MN	Pancreatic elastase 1 (CELA1)
DMRV48P	MT	DTT
DMRV48P	MA	Modulator
DMRV48P	RN	Biological activity of WIN 63759, an orally bioavailable inhibitor of human neutrophil elastase. Drug Development Research Volume 34, Issue 3, pages 306-316, March 1995.
DMRV48P	RU	http://onlinelibrary.wiley.com/doi/10.1002/ddr.430340308/abstract

DM960I8	DI	DM960I8
DM960I8	DN	WIN-64821
DM960I8	MI	TTZPO1L
DM960I8	MN	Substance-P receptor (TACR1)
DM960I8	MT	DTT
DM960I8	MA	Antagonist
DM960I8	RN	WIN 64821, a novel neurokinin antagonist produced by an Aspergillus sp. II. Biological activity. J Antibiot (Tokyo). 1994 Apr;47(4):399-410.
DM960I8	RU	https://pubmed.ncbi.nlm.nih.gov/7515038

DM8EVK5	DI	DM8EVK5
DM8EVK5	DN	Wortmannin
DM8EVK5	MI	TTGBPJE
DM8EVK5	MN	PI3-kinase delta (PIK3CD)
DM8EVK5	MT	DTT
DM8EVK5	MA	Inhibitor
DM8EVK5	RN	Selective role of PI3K delta in neutrophil inflammatory responses. Biochem Biophys Res Commun. 2003 Sep 5;308(4):764-9.
DM8EVK5	RU	https://pubmed.ncbi.nlm.nih.gov/12927784

DM8EVK5	DI	DM8EVK5
DM8EVK5	DN	Wortmannin
DM8EVK5	MI	TTHBTOP
DM8EVK5	MN	PI3-kinase gamma (PIK3CG)
DM8EVK5	MT	DTT
DM8EVK5	MA	Inhibitor
DM8EVK5	RN	Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation. Cancer Res. 2002 Aug 15;62(16):4671-7.
DM8EVK5	RU	https://pubmed.ncbi.nlm.nih.gov/12183424

DM89BA1	DI	DM89BA1
DM89BA1	DN	WS-75624B
DM89BA1	MI	TT1BGDH
DM89BA1	MN	Endothelin-converting enzyme (ECE)
DM89BA1	MT	DTT
DM89BA1	MA	Modulator
DM89BA1	RN	WS75624 A and B, new endothelin converting enzyme inhibitors isolated from Saccharothrix sp. No. 75624. II. Structure elucidation of WS75624 A and B. J Antibiot (Tokyo). 1995 Oct;48(10):1073-5.
DM89BA1	RU	https://pubmed.ncbi.nlm.nih.gov/7490209

DMAG86C	DI	DMAG86C
DMAG86C	DN	WY-28342
DMAG86C	MI	TT2J34L
DMAG86C	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMAG86C	MT	DTT
DMAG86C	MA	Modulator
DMAG86C	RN	Synthesis and antiinflammatory activity of certain 5,6,7,8-tetrahydroquinolines and related compounds. J Med Chem. 1995 Apr 28;38(9):1473-81.
DMAG86C	RU	https://pubmed.ncbi.nlm.nih.gov/7739006

DMAG86C	DI	DMAG86C
DMAG86C	DN	WY-28342
DMAG86C	MI	TTK0943
DMAG86C	MN	Prostaglandin G/H synthase (COX)
DMAG86C	MT	DTT
DMAG86C	MA	Modulator
DMAG86C	RN	Synthesis and antiinflammatory activity of certain 5,6,7,8-tetrahydroquinolines and related compounds. J Med Chem. 1995 Apr 28;38(9):1473-81.
DMAG86C	RU	https://pubmed.ncbi.nlm.nih.gov/7739006

DMGJNQW	DI	DMGJNQW
DMGJNQW	DN	WY-48989
DMGJNQW	MI	TTZBFA0
DMGJNQW	MN	Protease unspecific (PRO)
DMGJNQW	MT	DTT
DMGJNQW	MA	Modulator
DMGJNQW	RN	Inhibition of interleukin-1 (IL-1) induced neutral proteases from rabbit articular chondrocytes by WY-46,135 and WY-48,989. Agents Actions. 1991 Sep;34(1-2):223-5.
DMGJNQW	RU	https://pubmed.ncbi.nlm.nih.gov/1665295

DM965P4	DI	DM965P4
DM965P4	DN	XL-541
DM965P4	MI	TT9JZCK
DM965P4	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DM965P4	MT	DTT
DM965P4	MA	Antagonist
DM965P4	RN	Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists. J Med Chem. 2012 Feb 9;55(3):1368-81.
DM965P4	RU	https://pubmed.ncbi.nlm.nih.gov/22214363

DMFHR2O	DI	DMFHR2O
DMFHR2O	DN	XR-1853
DMFHR2O	MI	TT5QA2I
DMFHR2O	MN	Plasminogen activator inhibitor (PAI)
DMFHR2O	MT	DTT
DMFHR2O	MA	Modulator
DMFHR2O	RN	Characterization and comparative evaluation of a novel PAI-1 inhibitor. Thromb Haemost. 2002 Jul;88(1):137-43.
DMFHR2O	RU	https://pubmed.ncbi.nlm.nih.gov/12152654

DMJLRC7	DI	DMJLRC7
DMJLRC7	DN	XR-3005
DMJLRC7	MI	TT7WZIJ
DMJLRC7	MN	CAAX farnesyltransferase beta (FNTB)
DMJLRC7	MT	DTT
DMJLRC7	MA	Modulator
DMJLRC7	RN	US patent application no. 2005,0227,929, Combination therapy comprising a cox-2 inhibitor and an antineoplastic agent.
DMJLRC7	RU	http://www.google.com/patents/US20050227929

DMXI39O	DI	DMXI39O
DMXI39O	DN	XR-3054
DMXI39O	MI	TT7WZIJ
DMXI39O	MN	CAAX farnesyltransferase beta (FNTB)
DMXI39O	MT	DTT
DMXI39O	MA	Inhibitor
DMXI39O	RN	XR3054, structurally related to limonene, is a novel inhibitor of farnesyl protein transferase. Eur J Cancer. 1999 Jun;35(6):1014-9.
DMXI39O	RU	https://pubmed.ncbi.nlm.nih.gov/10533487

DMX0PTO	DI	DMX0PTO
DMX0PTO	DN	XR-368
DMX0PTO	MI	TTNJYV2
DMX0PTO	MN	Gamma-aminobutyric acid receptor (GAR)
DMX0PTO	MT	DTT
DMX0PTO	MA	Modulator
DMX0PTO	RN	Regulation of neuronal and recombinant GABA(A) receptor ion channels by xenovulene A, a natural product isolated from Acremonium strictum. J Pharmacol Exp Ther. 1997 Aug;282(2):513-20.
DMX0PTO	RU	https://pubmed.ncbi.nlm.nih.gov/9262310

DMEVSZO	DI	DMEVSZO
DMEVSZO	DN	XR-5082
DMEVSZO	MI	TT5QA2I
DMEVSZO	MN	Plasminogen activator inhibitor (PAI)
DMEVSZO	MT	DTT
DMEVSZO	MA	Inhibitor
DMEVSZO	RN	Evaluation of a low molecular weight modulator of human plasminogen activator inhibitor-1 activity. Thromb Haemost. 1996 May;75(5):808-15.
DMEVSZO	RU	https://pubmed.ncbi.nlm.nih.gov/8725728

DMA13OD	DI	DMA13OD
DMA13OD	DN	XR-510
DMA13OD	MI	TT8DBY3
DMA13OD	MN	Angiotensin II receptor type-1 (AGTR1)
DMA13OD	MT	DTT
DMA13OD	MA	Modulator
DMA13OD	RN	Pharmacology of XR510, a potent orally active nonpeptide angiotensin II AT1 receptor antagonist with high affinity for the AT2 receptor subtype. J Cardiovasc Pharmacol. 1995 Sep;26(3):354-62.
DMA13OD	RU	https://pubmed.ncbi.nlm.nih.gov/8583775

DMIK72F	DI	DMIK72F
DMIK72F	DN	XR-5118
DMIK72F	MI	TTTO43N
DMIK72F	MN	Endothelial plasminogen activator inhibitor (SERPINE1)
DMIK72F	MT	DTT
DMIK72F	MA	Inhibitor
DMIK72F	RN	Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization. J Med Chem. 2004 Jul 1;47(14):3491-4.
DMIK72F	RU	https://pubmed.ncbi.nlm.nih.gov/15214776

DM7TQYF	DI	DM7TQYF
DM7TQYF	DN	Y-20024
DM7TQYF	MI	TTEX248
DM7TQYF	MN	Dopamine D2 receptor (D2R)
DM7TQYF	MT	DTT
DM7TQYF	MA	Agonist
DM7TQYF	RN	Neuroleptic properties of Y-20024, a new benzofurancarboxamide derivative. Nihon Yakurigaku Zasshi. 1989 Nov;94(5):269-80.
DM7TQYF	RU	https://pubmed.ncbi.nlm.nih.gov/2575566

DMLAVES	DI	DMLAVES
DMLAVES	DN	Y-29794
DMLAVES	MI	TTNGKET
DMLAVES	MN	Prolyl endopeptidase (PREP)
DMLAVES	MT	DTT
DMLAVES	MA	Inhibitor
DMLAVES	RN	Inhibitors of prolyl oligopeptidases for the therapy of human diseases: defining diseases and inhibitors. J Med Chem. 2010 May 13;53(9):3423-38.
DMLAVES	RU	https://pubmed.ncbi.nlm.nih.gov/20058865

DMG024B	DI	DMG024B
DMG024B	DN	Y-931
DMG024B	MI	TTEX248
DMG024B	MN	Dopamine D2 receptor (D2R)
DMG024B	MT	DTT
DMG024B	MA	Binder
DMG024B	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMG024B	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DM97ULM	DI	DM97ULM
DM97ULM	DN	YM-022
DM97ULM	MI	TTVFO0U
DM97ULM	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DM97ULM	MT	DTT
DM97ULM	MA	Antagonist
DM97ULM	RN	YM022, a potent and selective gastrin/CCK-B receptor antagonist, inhibits peptone meal-induced gastric acid secretion in Heidenhain pouch dogs. Dig Dis Sci. 1997 Apr;42(4):707-14.
DM97ULM	RU	https://pubmed.ncbi.nlm.nih.gov/9125636

DMDXLG2	DI	DMDXLG2
DMDXLG2	DN	YM-099
DMDXLG2	MI	TT1VOHK
DMDXLG2	MN	Potassium channel unspecific (KC)
DMDXLG2	MT	DTT
DMDXLG2	MA	Opener
DMDXLG2	RN	Potassium channel-opening and vasorelaxant profiles of a novel compound YM099 in rat isolated portal vein and rabbit isolated aorta. Arch Int Pharmacodyn Ther. 1994 May-Jun;327(3):330-43.
DMDXLG2	RU	https://pubmed.ncbi.nlm.nih.gov/7848015

DMEHAI2	DI	DMEHAI2
DMEHAI2	DN	YM-26734
DMEHAI2	MI	TT9V5JH
DMEHAI2	MN	Phospholipase A2 (PLA2G1B)
DMEHAI2	MT	DTT
DMEHAI2	MA	Modulator
DMEHAI2	RN	Simplified YM-26734 Inhibitors of Secreted Phospholipase A2 Group IIA
DMEHAI2	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2578825

DMWI094	DI	DMWI094
DMWI094	DN	YM-43611
DMWI094	MI	TT4C8EA
DMWI094	MN	Dopamine D3 receptor (D3R)
DMWI094	MT	DTT
DMWI094	MA	Modulator
DMWI094	RN	Effects of YM-43611, a novel dopamine D2-like receptor antagonist, on immediate early gene expression in the rat forebrain. Neuropsychopharmacology. 1997 Jul;17(1):27-33.
DMWI094	RU	https://www.ncbi.nlm.nih.gov/pubmed/9194047

DMWI094	DI	DMWI094
DMWI094	DN	YM-43611
DMWI094	MI	TTE0A2F
DMWI094	MN	Dopamine D4 receptor (D4R)
DMWI094	MT	DTT
DMWI094	MA	Modulator
DMWI094	RN	Effects of YM-43611, a novel dopamine D2-like receptor antagonist, on immediate early gene expression in the rat forebrain. Neuropsychopharmacology. 1997 Jul;17(1):27-33.
DMWI094	RU	https://www.ncbi.nlm.nih.gov/pubmed/9194047

DM7VGOC	DI	DM7VGOC
DM7VGOC	DN	Ym60828
DM7VGOC	MI	TTCIHJA
DM7VGOC	MN	Coagulation factor Xa (F10)
DM7VGOC	MT	DTT
DM7VGOC	MA	Inhibitor
DM7VGOC	RN	Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci. 2002 Jan;23(1):25-32.
DM7VGOC	RU	https://pubmed.ncbi.nlm.nih.gov/11804648

DMK1UJM	DI	DMK1UJM
DMK1UJM	DN	YP-004
DMK1UJM	MI	TTDB5IS
DMK1UJM	MN	Receptor unspecific (Rec)
DMK1UJM	MT	DTT
DMK1UJM	MA	Inhibitor
DMK1UJM	RN	CA patent application no. 815512, Method for increasing the efficiency of double-strand break-induced mutagenesis.
DMK1UJM	RU	http://www.google.com/patents/CA2815512A1?cl=en

DM2N76V	DI	DM2N76V
DM2N76V	DN	YP-008
DM2N76V	MI	TT9B4N3
DM2N76V	MN	Prostaglandin receptor (PTGR)
DM2N76V	MT	DTT
DM2N76V	MA	Inhibitor
DM2N76V	RN	CA patent application no. 841416, Method of selecting therapeutic indications.
DM2N76V	RU	http://www.google.com/patents/CA2841416A1?cl=en

DMPXLG2	DI	DMPXLG2
DMPXLG2	DN	YP-009
DMPXLG2	MI	TT9B4N3
DMPXLG2	MN	Prostaglandin receptor (PTGR)
DMPXLG2	MT	DTT
DMPXLG2	MA	Agonist
DMPXLG2	RN	YP 009 York Pharma pc preclinical, UK(cancer), R & D Focus Drug News, November 12, 2007
DMPXLG2	RU	http://business.highbeam.com/436989/article-1G1-171156623/yp-009-york-pharma-pc-preclinical-uk

DMQ6K8J	DI	DMQ6K8J
DMQ6K8J	DN	Z-6568
DMQ6K8J	MI	TT5HONZ
DMQ6K8J	MN	Calcium channel unspecific (CaC)
DMQ6K8J	MT	DTT
DMQ6K8J	MA	Modulator
DMQ6K8J	RN	Determination of the dihydropyridine aryloxypropanolamine Z6568 and its acidic metabolites in plasma, urine and tissues by solid phase extraction and liquid chromatography/negative-ion mass spectrometry. J Mass Spectrom. 1996 Sep;31(9):994-1002.
DMQ6K8J	RU	https://pubmed.ncbi.nlm.nih.gov/8831152

DMGH3T5	DI	DMGH3T5
DMGH3T5	DN	Zaprinast
DMGH3T5	MI	TTHQENC
DMGH3T5	MN	Phosphodiesterase 1 (PDE1)
DMGH3T5	MT	DTT
DMGH3T5	MA	Inhibitor
DMGH3T5	RN	The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases. J Med Chem. 2005 May 19;48(10):3449-62.
DMGH3T5	RU	https://pubmed.ncbi.nlm.nih.gov/15887951

DMGH3T5	DI	DMGH3T5
DMGH3T5	DN	Zaprinast
DMGH3T5	MI	TTSKMI8
DMGH3T5	MN	Phosphodiesterase 4D (PDE4D)
DMGH3T5	MT	DTT
DMGH3T5	MA	Inhibitor
DMGH3T5	RN	8-Substituted analogues of 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-isopropyl-adenine: highly potent and selective PDE4 inhibitors. J Med Chem. 2005 Feb 24;48(4):1237-43.
DMGH3T5	RU	https://pubmed.ncbi.nlm.nih.gov/15715490

DMGH3T5	DI	DMGH3T5
DMGH3T5	DN	Zaprinast
DMGH3T5	MI	TTJ0IQB
DMGH3T5	MN	Phosphodiesterase 5A (PDE5A)
DMGH3T5	MT	DTT
DMGH3T5	MA	Inhibitor
DMGH3T5	RN	4-(3-Chloro-4-methoxybenzyl)aminophthalazines: synthesis and inhibitory activity toward phosphodiesterase 5. J Med Chem. 2000 Jun 29;43(13):2523-9.
DMGH3T5	RU	https://pubmed.ncbi.nlm.nih.gov/10891111

DMC38FO	DI	DMC38FO
DMC38FO	DN	ZARDAVERINE
DMC38FO	MI	TTZCG4L
DMC38FO	MN	Phosphodiesterase 3 (PDE3)
DMC38FO	MT	DTT
DMC38FO	MA	Modulator
DMC38FO	RN	Zardaverine: a cyclic AMP specific PDE III/IV inhibitor.Agents Actions Suppl.1991;34:379-402.
DMC38FO	RU	https://www.ncbi.nlm.nih.gov/pubmed/1665311

DMNYKOT	DI	DMNYKOT
DMNYKOT	DN	Zatebradine
DMNYKOT	MI	TTW0CMT
DMNYKOT	MN	Voltage-gated potassium channel Kv1.5 (KCNA5)
DMNYKOT	MT	DTT
DMNYKOT	MA	Modulator
DMNYKOT	RN	DOI: 10.1161/01.CIR.94.3.562
DMNYKOT	RU	http://circ.ahajournals.org/content/94/3/562.abstract

DM6M9GC	DI	DM6M9GC
DM6M9GC	DN	ZD-3638
DM6M9GC	MI	TTJQOD7
DM6M9GC	MN	5-HT 2A receptor (HTR2A)
DM6M9GC	MT	DTT
DM6M9GC	MA	Binder
DM6M9GC	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DM6M9GC	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DM6M9GC	DI	DM6M9GC
DM6M9GC	DN	ZD-3638
DM6M9GC	MI	TTEX248
DM6M9GC	MN	Dopamine D2 receptor (D2R)
DM6M9GC	MT	DTT
DM6M9GC	MA	Binder
DM6M9GC	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DM6M9GC	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DM6M9GC	DI	DM6M9GC
DM6M9GC	DN	ZD-3638
DM6M9GC	MI	TTS2PH3
DM6M9GC	MN	Dopamine D5 receptor (D5R)
DM6M9GC	MT	DTT
DM6M9GC	MA	Binder
DM6M9GC	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DM6M9GC	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DM91IPH	DI	DM91IPH
DM91IPH	DN	ZD-3980
DM91IPH	MI	TTS64P2
DM91IPH	MN	Androgen receptor (AR)
DM91IPH	MT	DTT
DM91IPH	MA	Modulator
DM91IPH	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009538)
DM91IPH	RU	http://adisinsight.springer.com/drugs/800009538

DMVWRU9	DI	DMVWRU9
DMVWRU9	DN	ZD-4190
DMVWRU9	MI	TTVJ1D8
DMVWRU9	MN	Vascular endothelial growth factor receptor (VEGFR)
DMVWRU9	MT	DTT
DMVWRU9	MA	Modulator
DMVWRU9	RN	ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res. 2000 Feb 15;60(4):970-5.
DMVWRU9	RU	https://pubmed.ncbi.nlm.nih.gov/10706112

DMU2F6Q	DI	DMU2F6Q
DMU2F6Q	DN	ZD-6003
DMU2F6Q	MI	TTC70AJ
DMU2F6Q	MN	Granulocyte colony-stimulating factor receptor (G-CSF-R)
DMU2F6Q	MT	DTT
DMU2F6Q	MA	Modulator
DMU2F6Q	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1719).
DMU2F6Q	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1719

DM5KSCI	DI	DM5KSCI
DM5KSCI	DN	ZD-7155
DM5KSCI	MI	TTGN1ZA
DM5KSCI	MN	Angiotensin II receptor (AGTR)
DM5KSCI	MT	DTT
DM5KSCI	MA	Modulator
DM5KSCI	RN	Comparative cardiovascular effects of the angiotensin II type 1 receptor antagonists ZD 7155 and losartan in the rat. J Pharm Pharmacol. 1996 Aug;48(8):829-33.
DM5KSCI	RU	https://pubmed.ncbi.nlm.nih.gov/8887734

DMJEZOP	DI	DMJEZOP
DMJEZOP	DN	ZD-7717
DMJEZOP	MI	TT2J34L
DMJEZOP	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMJEZOP	MT	DTT
DMJEZOP	MA	Modulator
DMJEZOP	RN	CA patent application no. 445634, Acne treatment comprising lipoxygenase inhibitors.
DMJEZOP	RU	http://www.google.hr/patents/CA2445634A1?cl=en&hl=hr

DMCT1IX	DI	DMCT1IX
DMCT1IX	DN	ZD-7944
DMCT1IX	MI	TTYO0A3
DMCT1IX	MN	Substance-K receptor (TACR2)
DMCT1IX	MT	DTT
DMCT1IX	MA	Modulator
DMCT1IX	RN	Discovery of novel, orally active dual NK1/NK2 antagonists. Bioorg Med Chem Lett. 2001 Oct 22;11(20):2769-73.
DMCT1IX	RU	https://pubmed.ncbi.nlm.nih.gov/11591520

DMFV47R	DI	DMFV47R
DMFV47R	DN	ZD-9720
DMFV47R	MI	TT7O8ZA
DMFV47R	MN	Lanosterol synthase (LSS)
DMFV47R	MT	DTT
DMFV47R	MA	Modulator
DMFV47R	RN	Toxicologic lesions associated with two related inhibitors of oxidosqualene cyclase in the dog and mouse. Toxicol Pathol. 2001 Mar-Apr;29(2):174-9.
DMFV47R	RU	https://pubmed.ncbi.nlm.nih.gov/11421484

DMQUSG9	DI	DMQUSG9
DMQUSG9	DN	Zenarestat
DMQUSG9	MI	TTFBNVI
DMQUSG9	MN	Aldose reductase (AKR1B1)
DMQUSG9	MT	DTT
DMQUSG9	MA	Inhibitor
DMQUSG9	RN	The effects of zenarestat, an aldose reductase inhibitor, on minimal F-wave latency and nerve blood flow in streptozotocin-induced diabetic rats. Life Sci. 2001 Feb 9;68(12):1439-48.
DMQUSG9	RU	https://pubmed.ncbi.nlm.nih.gov/11388695

DM81DJV	DI	DM81DJV
DM81DJV	DN	Zindoxifene
DM81DJV	MI	TTZAYWL
DM81DJV	MN	Estrogen receptor (ESR)
DM81DJV	MT	DTT
DM81DJV	MA	Modulator
DM81DJV	RN	Phase I/II study of the anti-oestrogen zindoxifene (D16726) in the treatment of advanced breast cancer. A Cancer Research Campaign Phase I/II Clinical Trials Committee study.. Br J Cancer. 1990 March; 61(3): 451-453.
DM81DJV	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971274/

DMJZH7N	DI	DMJZH7N
DMJZH7N	DN	ZK-118182
DMJZH7N	MI	TTNVEIR
DMJZH7N	MN	Prostaglandin D2 receptor (PTGDR)
DMJZH7N	MT	DTT
DMJZH7N	MA	Modulator
DMJZH7N	RN	Characterization of prostanoid receptors mediating inhibition of histamine release from anti-IgE-activated rat peritoneal mast cells. Br J Pharmacol. 2000 Feb;129(3):589-97.
DMJZH7N	RU	https://pubmed.ncbi.nlm.nih.gov/10711359

DMKFYDE	DI	DMKFYDE
DMKFYDE	DN	ZK-119010
DMKFYDE	MI	TTZAYWL
DMKFYDE	MN	Estrogen receptor (ESR)
DMKFYDE	MT	DTT
DMKFYDE	MA	Inhibitor
DMKFYDE	RN	2-Phenylindole-linked [2-(aminoalkyl)pyridine]dichloroplatinum(II): complexes with a selective action on estrogen receptor positive mammary tumors. J Med Chem. 1991 Jul;34(7):2145-52.
DMKFYDE	RU	https://pubmed.ncbi.nlm.nih.gov/2066987

DMKFYDE	DI	DMKFYDE
DMKFYDE	DN	ZK-119010
DMKFYDE	MI	TTOM3J0
DMKFYDE	MN	Estrogen receptor beta (ESR2)
DMKFYDE	MT	DTT
DMKFYDE	MA	Inhibitor
DMKFYDE	RN	2-Phenylindole-linked [2-(aminoalkyl)pyridine]dichloroplatinum(II): complexes with a selective action on estrogen receptor positive mammary tumors. J Med Chem. 1991 Jul;34(7):2145-52.
DMKFYDE	RU	https://pubmed.ncbi.nlm.nih.gov/2066987

DMJYIVA	DI	DMJYIVA
DMJYIVA	DN	ZK-91296
DMJYIVA	MI	TTEX6LM
DMJYIVA	MN	GABA(A) receptor gamma-3 (GABRG3)
DMJYIVA	MT	DTT
DMJYIVA	MA	Modulator
DMJYIVA	RN	Enhancement of gamma-aminobutyric acid binding by the anxiolytic beta-carbolines ZK 93423 and ZK 91296. J Neurochem. 1987 May;48(5):1355-8.
DMJYIVA	RU	https://www.ncbi.nlm.nih.gov/pubmed/2881979

DMMDQ5T	DI	DMMDQ5T
DMMDQ5T	DN	ZK-93426
DMMDQ5T	MI	TTEX6LM
DMMDQ5T	MN	GABA(A) receptor gamma-3 (GABRG3)
DMMDQ5T	MT	DTT
DMMDQ5T	MA	Modulator
DMMDQ5T	RN	Actions of the beta-carboline ZK 93426 in an animal test of anxiety and the holeboard: interactions with Ro 15-1788. J Neural Transm. 1986;65(2):103-14.
DMMDQ5T	RU	https://www.ncbi.nlm.nih.gov/pubmed/3009709

DM8V0YA	DI	DM8V0YA
DM8V0YA	DN	ZM-224832
DM8V0YA	MI	TT5HONZ
DM8V0YA	MN	Calcium channel unspecific (CaC)
DM8V0YA	MT	DTT
DM8V0YA	MA	Modulator
DM8V0YA	RN	Diuretic and antihypertensive activity of ZENECA ZM224,832: a novel eukalemic diuretic with calcium channel blocking activity. Pharmacology. 1994 Mar;48(3):167-75.
DM8V0YA	RU	https://pubmed.ncbi.nlm.nih.gov/8153144

DM0TBQK	DI	DM0TBQK
DM0TBQK	DN	ZM-230487
DM0TBQK	MI	TT2J34L
DM0TBQK	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM0TBQK	MT	DTT
DM0TBQK	MA	Inhibitor
DM0TBQK	RN	Pharmacological nature of nicotine-induced contraction in the rat basilar artery: involvement of arachidonic acid metabolites. Eur J Pharmacol. 2007 Dec 22;577(1-3):109-14.
DM0TBQK	RU	https://pubmed.ncbi.nlm.nih.gov/17765890

DMWQ38G	DI	DMWQ38G
DMWQ38G	DN	ZM-241385
DMWQ38G	MI	TTK25J1
DMWQ38G	MN	Adenosine A1 receptor (ADORA1)
DMWQ38G	MT	DTT
DMWQ38G	MA	Inhibitor
DMWQ38G	RN	2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into ... J Med Chem. 2009 Dec 10;52(23):7640-52.
DMWQ38G	RU	https://pubmed.ncbi.nlm.nih.gov/19743865

DMWQ38G	DI	DMWQ38G
DMWQ38G	DN	ZM-241385
DMWQ38G	MI	TTM2AOE
DMWQ38G	MN	Adenosine A2a receptor (ADORA2A)
DMWQ38G	MT	DTT
DMWQ38G	MA	Inhibitor
DMWQ38G	RN	2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into ... J Med Chem. 2009 Dec 10;52(23):7640-52.
DMWQ38G	RU	https://pubmed.ncbi.nlm.nih.gov/19743865

DMWQ38G	DI	DMWQ38G
DMWQ38G	DN	ZM-241385
DMWQ38G	MI	TTNE7KG
DMWQ38G	MN	Adenosine A2b receptor (ADORA2B)
DMWQ38G	MT	DTT
DMWQ38G	MA	Inhibitor
DMWQ38G	RN	Synthesis of theophylline derivatives and study of their activity as antagonists at adenosine receptors. Bioorg Med Chem. 2010 Mar 15;18(6):2081-2088.
DMWQ38G	RU	https://pubmed.ncbi.nlm.nih.gov/20202853

DM70HZD	DI	DM70HZD
DM70HZD	DN	Zonampanel
DM70HZD	MI	TTAN6JD
DM70HZD	MN	Glutamate receptor AMPA (GRIA)
DM70HZD	MT	DTT
DM70HZD	MA	Inhibitor
DM70HZD	RN	Synthesis and AMPA receptor antagonistic activity of a novel 7-imidazolyl-6-trifluoromethyl quinoxalinecarboxylic acid with a substituted phenyl gr... Bioorg Med Chem Lett. 2004 Oct 18;14(20):5107-11.
DM70HZD	RU	https://pubmed.ncbi.nlm.nih.gov/15380209

DM70HZD	DI	DM70HZD
DM70HZD	DN	Zonampanel
DM70HZD	MI	TTVPQTF
DM70HZD	MN	Glutamate receptor AMPA 1 (GRIA1)
DM70HZD	MT	DTT
DM70HZD	MA	Inhibitor
DM70HZD	RN	Synthesis and AMPA receptor antagonistic activity of a novel 7-imidazolyl-6-trifluoromethyl quinoxalinecarboxylic acid with a substituted phenyl gr... Bioorg Med Chem Lett. 2004 Oct 18;14(20):5107-11.
DM70HZD	RU	https://pubmed.ncbi.nlm.nih.gov/15380209

DM70TKB	DI	DM70TKB
DM70TKB	DN	zoxazolamine
DM70TKB	MI	TT2T5M0
DM70TKB	MN	Calcium-activated potassium channel KCa2.2 (KCNN2)
DM70TKB	MT	DTT
DM70TKB	MA	Activator
DM70TKB	RN	Modulation of recombinant small-conductance Ca(2+)-activated K(+) channels by the muscle relaxant chlorzoxazone and structurally related compounds. J Pharmacol Exp Ther. 2001 Mar;296(3):683-9.
DM70TKB	RU	https://pubmed.ncbi.nlm.nih.gov/11181893

DM193WR	DI	DM193WR
DM193WR	DN	ZT-386
DM193WR	MI	TT2O84V
DM193WR	MN	Thromboxane A2 receptor (TBXA2R)
DM193WR	MT	DTT
DM193WR	MA	Modulator
DM193WR	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004057)
DM193WR	RU	http://adisinsight.springer.com/drugs/800004057

DM2TIU3	DI	DM2TIU3
DM2TIU3	DN	((3R,4R)-4-(o-tolyloxy)chroman-3-yl)methanamine
DM2TIU3	MI	TTAWNKZ
DM2TIU3	MN	Norepinephrine transporter (NET)
DM2TIU3	MT	DTT
DM2TIU3	MA	Inhibitor
DM2TIU3	RN	Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4495-8.
DM2TIU3	RU	https://pubmed.ncbi.nlm.nih.gov/18667309

DM2TIU3	DI	DM2TIU3
DM2TIU3	DN	((3R,4R)-4-(o-tolyloxy)chroman-3-yl)methanamine
DM2TIU3	MI	TT3ROYC
DM2TIU3	MN	Serotonin transporter (SERT)
DM2TIU3	MT	DTT
DM2TIU3	MA	Inhibitor
DM2TIU3	RN	Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4495-8.
DM2TIU3	RU	https://pubmed.ncbi.nlm.nih.gov/18667309

DMEJRVW	DI	DMEJRVW
DMEJRVW	DN	((E)-3-Amino-propenyl)-methyl-phosphinic acid
DMEJRVW	MI	TTDCVZW
DMEJRVW	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMEJRVW	MT	DTT
DMEJRVW	MA	Inhibitor
DMEJRVW	RN	Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists. J Med Chem. 1995 Aug 18;38(17):3297-312.
DMEJRVW	RU	https://pubmed.ncbi.nlm.nih.gov/7650684

DMEJRVW	DI	DMEJRVW
DMEJRVW	DN	((E)-3-Amino-propenyl)-methyl-phosphinic acid
DMEJRVW	MI	TTNJYV2
DMEJRVW	MN	Gamma-aminobutyric acid receptor (GAR)
DMEJRVW	MT	DTT
DMEJRVW	MA	Inhibitor
DMEJRVW	RN	Novel gamma-aminobutyric acid rho1 receptor antagonists; synthesis, pharmacological activity and structure-activity relationships. J Med Chem. 2008 Jul 10;51(13):3825-40.
DMEJRVW	RU	https://pubmed.ncbi.nlm.nih.gov/18528996

DMCW65Q	DI	DMCW65Q
DMCW65Q	DN	((E)-7-But-2-enyl)-azepan-(2Z)-ylideneamine
DMCW65Q	MI	TTZUFI5
DMCW65Q	MN	Nitric-oxide synthase brain (NOS1)
DMCW65Q	MT	DTT
DMCW65Q	MA	Inhibitor
DMCW65Q	RN	Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3.
DMCW65Q	RU	https://pubmed.ncbi.nlm.nih.gov/11551770

DMCW65Q	DI	DMCW65Q
DMCW65Q	DN	((E)-7-But-2-enyl)-azepan-(2Z)-ylideneamine
DMCW65Q	MI	TTF10I9
DMCW65Q	MN	Nitric-oxide synthase inducible (NOS2)
DMCW65Q	MT	DTT
DMCW65Q	MA	Inhibitor
DMCW65Q	RN	Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3.
DMCW65Q	RU	https://pubmed.ncbi.nlm.nih.gov/11551770

DM6H0FW	DI	DM6H0FW
DM6H0FW	DN	((Z)-3-Amino-propenyl)-methyl-phosphinic acid
DM6H0FW	MI	TTDCVZW
DM6H0FW	MN	Gamma-aminobutyric acid B receptor (GABBR)
DM6H0FW	MT	DTT
DM6H0FW	MA	Inhibitor
DM6H0FW	RN	Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists. J Med Chem. 1995 Aug 18;38(17):3297-312.
DM6H0FW	RU	https://pubmed.ncbi.nlm.nih.gov/7650684

DM974LP	DI	DM974LP
DM974LP	DN	(-)-(1S,1'R)-O,O-dimethylgrisbine hydrochloride
DM974LP	MI	TTZFYLI
DM974LP	MN	Dopamine D1 receptor (D1R)
DM974LP	MT	DTT
DM974LP	MA	Inhibitor
DM974LP	RN	Displacement activity of bisbenzylisoquinoline alkaloids at striatal 3H-SCH 23390 and 3H-raclopride binding sites. J Nat Prod. 1992 Sep;55(9):1281-6.
DM974LP	RU	https://pubmed.ncbi.nlm.nih.gov/1431946

DM974LP	DI	DM974LP
DM974LP	DN	(-)-(1S,1'R)-O,O-dimethylgrisbine hydrochloride
DM974LP	MI	TTEX248
DM974LP	MN	Dopamine D2 receptor (D2R)
DM974LP	MT	DTT
DM974LP	MA	Inhibitor
DM974LP	RN	Displacement activity of bisbenzylisoquinoline alkaloids at striatal 3H-SCH 23390 and 3H-raclopride binding sites. J Nat Prod. 1992 Sep;55(9):1281-6.
DM974LP	RU	https://pubmed.ncbi.nlm.nih.gov/1431946

DMV6EMN	DI	DMV6EMN
DMV6EMN	DN	(-)-(R)-efonidipine
DMV6EMN	MI	TTZIFHC
DMV6EMN	MN	Voltage-gated calcium channel alpha Cav1.2 (CACNA1C)
DMV6EMN	MT	DTT
DMV6EMN	MA	Blocker (channel blocker)
DMV6EMN	RN	Identification of R(-)-isomer of efonidipine as a selective blocker of T-type Ca2+ channels. Br J Pharmacol. 2004 Dec;143(8):1050-7.
DMV6EMN	RU	https://pubmed.ncbi.nlm.nih.gov/15545287

DMV6EMN	DI	DMV6EMN
DMV6EMN	DN	(-)-(R)-efonidipine
DMV6EMN	MI	TT729IR
DMV6EMN	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DMV6EMN	MT	DTT
DMV6EMN	MA	Blocker (channel blocker)
DMV6EMN	RN	Identification of R(-)-isomer of efonidipine as a selective blocker of T-type Ca2+ channels. Br J Pharmacol. 2004 Dec;143(8):1050-7.
DMV6EMN	RU	https://pubmed.ncbi.nlm.nih.gov/15545287

DMEA9KH	DI	DMEA9KH
DMEA9KH	DN	(-)-(S)-BayK8644
DMEA9KH	MI	TT94HRF
DMEA9KH	MN	Voltage-gated calcium channel alpha Cav1.1 (CACNA1S)
DMEA9KH	MT	DTT
DMEA9KH	MA	Activator
DMEA9KH	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 528).
DMEA9KH	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=528

DMEA9KH	DI	DMEA9KH
DMEA9KH	DN	(-)-(S)-BayK8644
DMEA9KH	MI	TTZIFHC
DMEA9KH	MN	Voltage-gated calcium channel alpha Cav1.2 (CACNA1C)
DMEA9KH	MT	DTT
DMEA9KH	MA	Activator
DMEA9KH	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 529).
DMEA9KH	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=529

DMEA9KH	DI	DMEA9KH
DMEA9KH	DN	(-)-(S)-BayK8644
DMEA9KH	MI	TT7RGTM
DMEA9KH	MN	Voltage-gated calcium channel alpha Cav1.3 (CACNA1D)
DMEA9KH	MT	DTT
DMEA9KH	MA	Activator
DMEA9KH	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 530).
DMEA9KH	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=530

DMEA9KH	DI	DMEA9KH
DMEA9KH	DN	(-)-(S)-BayK8644
DMEA9KH	MI	TTJ0SO4
DMEA9KH	MN	Voltage-gated calcium channel alpha Cav1.4 (CACNA1F)
DMEA9KH	MT	DTT
DMEA9KH	MA	Activator
DMEA9KH	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 531).
DMEA9KH	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=531

DME5TIR	DI	DME5TIR
DME5TIR	DN	(-)-3-(1-Propyl-piperidin-3-yl)-benzonitrile
DME5TIR	MI	TTEX248
DME5TIR	MN	Dopamine D2 receptor (D2R)
DME5TIR	MT	DTT
DME5TIR	MA	Inhibitor
DME5TIR	RN	Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists. J Med Chem. 1993 Oct 15;36(21):3188-96.
DME5TIR	RU	https://pubmed.ncbi.nlm.nih.gov/8230107

DME5TIR	DI	DME5TIR
DME5TIR	DN	(-)-3-(1-Propyl-piperidin-3-yl)-benzonitrile
DME5TIR	MI	TT4C8EA
DME5TIR	MN	Dopamine D3 receptor (D3R)
DME5TIR	MT	DTT
DME5TIR	MA	Inhibitor
DME5TIR	RN	Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists. J Med Chem. 1993 Oct 15;36(21):3188-96.
DME5TIR	RU	https://pubmed.ncbi.nlm.nih.gov/8230107

DMGC7F5	DI	DMGC7F5
DMGC7F5	DN	(-)-3,3'-bisdemethylpinoresinol
DMGC7F5	MI	TTN9T81
DMGC7F5	MN	Arachidonate 15-lipoxygenase (15-LOX)
DMGC7F5	MT	DTT
DMGC7F5	MA	Inhibitor
DMGC7F5	RN	Lipoxygenase inhibitory constituents of the fruits of noni (Morinda citrifolia) collected in Tahiti. J Nat Prod. 2007 May;70(5):859-62.
DMGC7F5	RU	https://pubmed.ncbi.nlm.nih.gov/17378609

DMGC7F5	DI	DMGC7F5
DMGC7F5	DN	(-)-3,3'-bisdemethylpinoresinol
DMGC7F5	MI	TTSJ6Q4
DMGC7F5	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DMGC7F5	MT	DTT
DMGC7F5	MA	Inhibitor
DMGC7F5	RN	Lipoxygenase inhibitory constituents of the fruits of noni (Morinda citrifolia) collected in Tahiti. J Nat Prod. 2007 May;70(5):859-62.
DMGC7F5	RU	https://pubmed.ncbi.nlm.nih.gov/17378609

DMKRTBM	DI	DMKRTBM
DMKRTBM	DN	(-)-3-O-acetylspectaline
DMKRTBM	MI	TT8NGED
DMKRTBM	MN	Prostaglandin G/H synthase 1 (COX-1)
DMKRTBM	MT	DTT
DMKRTBM	MA	Inhibitor
DMKRTBM	RN	Lipoperoxidation and cyclooxygenase enzyme inhibitory piperidine alkaloids from Cassia spectabilis green fruits. J Nat Prod. 2007 Dec;70(12):2026-8.
DMKRTBM	RU	https://pubmed.ncbi.nlm.nih.gov/18047293

DM396OK	DI	DM396OK
DM396OK	DN	(-)-7-N-methyldibromophakellin
DM396OK	MI	TT12ABZ
DM396OK	MN	Arachidonate 12-lipoxygenase (12-LOX)
DM396OK	MT	DTT
DM396OK	MA	Inhibitor
DM396OK	RN	An analysis of phakellin and oroidin structures stimulated by further study of an Agelas sponge. J Nat Prod. 2004 Aug;67(8):1256-61.
DM396OK	RU	https://pubmed.ncbi.nlm.nih.gov/15332838

DMZOGSK	DI	DMZOGSK
DMZOGSK	DN	(-)-CATECHINGALLATE
DMZOGSK	MI	TT8JRS7
DMZOGSK	MN	Beta-secretase (BACE)
DMZOGSK	MT	DTT
DMZOGSK	MA	Inhibitor
DMZOGSK	RN	Green tea catechins as a BACE1 (beta-secretase) inhibitor. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3905-8.
DMZOGSK	RU	https://pubmed.ncbi.nlm.nih.gov/14592472

DMZOGSK	DI	DMZOGSK
DMZOGSK	DN	(-)-CATECHINGALLATE
DMZOGSK	MI	TT7AOUD
DMZOGSK	MN	Fatty acid synthase (FASN)
DMZOGSK	MT	DTT
DMZOGSK	MA	Inhibitor
DMZOGSK	RN	Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
DMZOGSK	RU	https://pubmed.ncbi.nlm.nih.gov/16722653

DMZOGSK	DI	DMZOGSK
DMZOGSK	DN	(-)-CATECHINGALLATE
DMZOGSK	MI	TTHPFTS
DMZOGSK	MN	Plasmodium Beta-hydroxyacyl-ACP dehydratase (Malaria FabZ)
DMZOGSK	MT	DTT
DMZOGSK	MA	Inhibitor
DMZOGSK	RN	Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
DMZOGSK	RU	https://pubmed.ncbi.nlm.nih.gov/16722653

DMZOGSK	DI	DMZOGSK
DMZOGSK	DN	(-)-CATECHINGALLATE
DMZOGSK	MI	TTNX2CS
DMZOGSK	MN	Plasmodium Enoyl-ACP reductase (Malaria fabI)
DMZOGSK	MT	DTT
DMZOGSK	MA	Inhibitor
DMZOGSK	RN	Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
DMZOGSK	RU	https://pubmed.ncbi.nlm.nih.gov/16722653

DMZOGSK	DI	DMZOGSK
DMZOGSK	DN	(-)-CATECHINGALLATE
DMZOGSK	MI	TTBE4IR
DMZOGSK	MN	Plasmodium Oxoacyl-[acyl-carrier protein] reductase (Malaria fabG)
DMZOGSK	MT	DTT
DMZOGSK	MA	Inhibitor
DMZOGSK	RN	Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
DMZOGSK	RU	https://pubmed.ncbi.nlm.nih.gov/16722653

DMJ249P	DI	DMJ249P
DMJ249P	DN	(-)-Cercosporamide
DMJ249P	MI	TTFJ8Q1
DMJ249P	MN	Protein kinase C alpha (PRKCA)
DMJ249P	MT	DTT
DMJ249P	MA	Inhibitor
DMJ249P	RN	(-)-Cercosporamide derivatives as novel antihyperglycemic agents. Bioorg Med Chem Lett. 2009 Feb 1;19(3):724-6.
DMJ249P	RU	https://pubmed.ncbi.nlm.nih.gov/19109017

DMJ249P	DI	DMJ249P
DMJ249P	DN	(-)-Cercosporamide
DMJ249P	MI	TTYPXQF
DMJ249P	MN	Protein kinase C beta (PRKCB)
DMJ249P	MT	DTT
DMJ249P	MA	Inhibitor
DMJ249P	RN	(-)-Cercosporamide derivatives as novel antihyperglycemic agents. Bioorg Med Chem Lett. 2009 Feb 1;19(3):724-6.
DMJ249P	RU	https://pubmed.ncbi.nlm.nih.gov/19109017

DMJ249P	DI	DMJ249P
DMJ249P	DN	(-)-Cercosporamide
DMJ249P	MI	TTRFOXJ
DMJ249P	MN	Protein kinase C gamma (PRKCG)
DMJ249P	MT	DTT
DMJ249P	MA	Inhibitor
DMJ249P	RN	(-)-Cercosporamide derivatives as novel antihyperglycemic agents. Bioorg Med Chem Lett. 2009 Feb 1;19(3):724-6.
DMJ249P	RU	https://pubmed.ncbi.nlm.nih.gov/19109017

DMPGJE6	DI	DMPGJE6
DMPGJE6	DN	(-)-clusin
DMPGJE6	MI	TTXV4FI
DMPGJE6	MN	Albendazole monooxygenase (CYP3A4)
DMPGJE6	MT	DTT
DMPGJE6	MA	Inhibitor
DMPGJE6	RN	Potent CYP3A4 inhibitory constituents of Piper cubeba. J Nat Prod. 2005 Jan;68(1):64-8.
DMPGJE6	RU	https://pubmed.ncbi.nlm.nih.gov/15679319

DM57LVW	DI	DM57LVW
DM57LVW	DN	(-)-cubebin
DM57LVW	MI	TTXV4FI
DM57LVW	MN	Albendazole monooxygenase (CYP3A4)
DM57LVW	MT	DTT
DM57LVW	MA	Inhibitor
DM57LVW	RN	Potent CYP3A4 inhibitory constituents of Piper cubeba. J Nat Prod. 2005 Jan;68(1):64-8.
DM57LVW	RU	https://pubmed.ncbi.nlm.nih.gov/15679319

DMSTZF9	DI	DMSTZF9
DMSTZF9	DN	(-)-cubebinin
DMSTZF9	MI	TTXV4FI
DMSTZF9	MN	Albendazole monooxygenase (CYP3A4)
DMSTZF9	MT	DTT
DMSTZF9	MA	Inhibitor
DMSTZF9	RN	Potent CYP3A4 inhibitory constituents of Piper cubeba. J Nat Prod. 2005 Jan;68(1):64-8.
DMSTZF9	RU	https://pubmed.ncbi.nlm.nih.gov/15679319

DM8Q6I0	DI	DM8Q6I0
DM8Q6I0	DN	(-)-cubebininolide
DM8Q6I0	MI	TTXV4FI
DM8Q6I0	MN	Albendazole monooxygenase (CYP3A4)
DM8Q6I0	MT	DTT
DM8Q6I0	MA	Inhibitor
DM8Q6I0	RN	Potent CYP3A4 inhibitory constituents of Piper cubeba. J Nat Prod. 2005 Jan;68(1):64-8.
DM8Q6I0	RU	https://pubmed.ncbi.nlm.nih.gov/15679319

DMC8WS4	DI	DMC8WS4
DMC8WS4	DN	(-)-cyclorphan
DMC8WS4	MI	TT27RFC
DMC8WS4	MN	Opioid receptor delta (OPRD1)
DMC8WS4	MT	DTT
DMC8WS4	MA	Inhibitor
DMC8WS4	RN	Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opio... J Med Chem. 2006 Jan 12;49(1):256-62.
DMC8WS4	RU	https://pubmed.ncbi.nlm.nih.gov/16392810

DMC8WS4	DI	DMC8WS4
DMC8WS4	DN	(-)-cyclorphan
DMC8WS4	MI	TTQW87Y
DMC8WS4	MN	Opioid receptor kappa (OPRK1)
DMC8WS4	MT	DTT
DMC8WS4	MA	Inhibitor
DMC8WS4	RN	Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opio... J Med Chem. 2006 Jan 12;49(1):256-62.
DMC8WS4	RU	https://pubmed.ncbi.nlm.nih.gov/16392810

DMC8WS4	DI	DMC8WS4
DMC8WS4	DN	(-)-cyclorphan
DMC8WS4	MI	TTKWM86
DMC8WS4	MN	Opioid receptor mu (MOP)
DMC8WS4	MT	DTT
DMC8WS4	MA	Inhibitor
DMC8WS4	RN	Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opio... J Med Chem. 2006 Jan 12;49(1):256-62.
DMC8WS4	RU	https://pubmed.ncbi.nlm.nih.gov/16392810

DM6LGHU	DI	DM6LGHU
DM6LGHU	DN	(-)-DEBROMOFLUSTRAMINE B
DM6LGHU	MI	TTEB0GD
DM6LGHU	MN	Cholinesterase (BCHE)
DM6LGHU	MT	DTT
DM6LGHU	MA	Inhibitor
DM6LGHU	RN	Synthesis and biological evaluation of (-)- and (+)-debromoflustramine B and its analogues as selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Sep 11;51(17):5271-84.
DM6LGHU	RU	https://pubmed.ncbi.nlm.nih.gov/18686941

DMNYH3X	DI	DMNYH3X
DMNYH3X	DN	(-)-dihydroclusin
DMNYH3X	MI	TTXV4FI
DMNYH3X	MN	Albendazole monooxygenase (CYP3A4)
DMNYH3X	MT	DTT
DMNYH3X	MA	Inhibitor
DMNYH3X	RN	Potent CYP3A4 inhibitory constituents of Piper cubeba. J Nat Prod. 2005 Jan;68(1):64-8.
DMNYH3X	RU	https://pubmed.ncbi.nlm.nih.gov/15679319

DMPQBWY	DI	DMPQBWY
DMPQBWY	DN	(-)-englerin A
DMPQBWY	MI	TTX0H5W
DMPQBWY	MN	Short transient receptor potential channel 4 (TRPC4)
DMPQBWY	MT	DTT
DMPQBWY	MA	Agonist
DMPQBWY	RN	(-)-Englerin is a potent and selective activator of TRPC4 and TRPC5 calcium channels. Angew Chem Int Ed Engl. 2015 Mar 16;54(12):3787-91.
DMPQBWY	RU	https://pubmed.ncbi.nlm.nih.gov/25707820

DMPQBWY	DI	DMPQBWY
DMPQBWY	DN	(-)-englerin A
DMPQBWY	MI	TT32NQ1
DMPQBWY	MN	Short transient receptor potential channel 5 (TRPC5)
DMPQBWY	MT	DTT
DMPQBWY	MA	Agonist
DMPQBWY	RN	(-)-Englerin is a potent and selective activator of TRPC4 and TRPC5 calcium channels. Angew Chem Int Ed Engl. 2015 Mar 16;54(12):3787-91.
DMPQBWY	RU	https://pubmed.ncbi.nlm.nih.gov/25707820

DMJD34Q	DI	DMJD34Q
DMJD34Q	DN	(-)-eseroline
DMJD34Q	MI	TT27RFC
DMJD34Q	MN	Opioid receptor delta (OPRD1)
DMJD34Q	MT	DTT
DMJD34Q	MA	Inhibitor
DMJD34Q	RN	Akuammine and dihydroakuammine, two indolomonoterpene alkaloids displaying affinity for opioid receptors. J Nat Prod. 1992 Mar;55(3):380-4.
DMJD34Q	RU	https://pubmed.ncbi.nlm.nih.gov/1317407

DMJD34Q	DI	DMJD34Q
DMJD34Q	DN	(-)-eseroline
DMJD34Q	MI	TTKWM86
DMJD34Q	MN	Opioid receptor mu (MOP)
DMJD34Q	MT	DTT
DMJD34Q	MA	Inhibitor
DMJD34Q	RN	Akuammine and dihydroakuammine, two indolomonoterpene alkaloids displaying affinity for opioid receptors. J Nat Prod. 1992 Mar;55(3):380-4.
DMJD34Q	RU	https://pubmed.ncbi.nlm.nih.gov/1317407

DMBO9J3	DI	DMBO9J3
DMBO9J3	DN	(-)-huperzine B
DMBO9J3	MI	TT1RS9F
DMBO9J3	MN	Acetylcholinesterase (AChE)
DMBO9J3	MT	DTT
DMBO9J3	MA	Inhibitor
DMBO9J3	RN	Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely... J Med Chem. 2008 Jun 12;51(11):3154-70.
DMBO9J3	RU	https://pubmed.ncbi.nlm.nih.gov/18479118

DMJVNQB	DI	DMJVNQB
DMJVNQB	DN	(-)-hydroxycitrate
DMJVNQB	MI	TT0Z6Y2
DMJVNQB	MN	ATP-citrate synthase (ACLY)
DMJVNQB	MT	DTT
DMJVNQB	MA	Inhibitor
DMJVNQB	RN	2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3208-11.
DMJVNQB	RU	https://pubmed.ncbi.nlm.nih.gov/17383874

DMJS6IZ	DI	DMJS6IZ
DMJS6IZ	DN	(-)-isoelaeocarpiline
DMJS6IZ	MI	TT27RFC
DMJS6IZ	MN	Opioid receptor delta (OPRD1)
DMJS6IZ	MT	DTT
DMJS6IZ	MA	Inhibitor
DMJS6IZ	RN	Grandisines C-G, indolizidine alkaloids from the Australian rainforest tree Elaeocarpus grandis. J Nat Prod. 2006 Sep;69(9):1295-9.
DMJS6IZ	RU	https://pubmed.ncbi.nlm.nih.gov/16989522

DMOY9J8	DI	DMOY9J8
DMOY9J8	DN	(-)-norfenfluramine
DMOY9J8	MI	TT0K1SC
DMOY9J8	MN	5-HT 2B receptor (HTR2B)
DMOY9J8	MT	DTT
DMOY9J8	MA	Agonist
DMOY9J8	RN	Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 2000 Dec 5;102(23):2836-41.
DMOY9J8	RU	https://pubmed.ncbi.nlm.nih.gov/11104741

DMVUEW5	DI	DMVUEW5
DMVUEW5	DN	(-)-Phenethylcymserine
DMVUEW5	MI	TTEB0GD
DMVUEW5	MN	Cholinesterase (BCHE)
DMVUEW5	MT	DTT
DMVUEW5	MA	Inhibitor
DMVUEW5	RN	Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. Bioorg Med Chem. 2010 Jul 1;18(13):4687-93. 
DMVUEW5	RU	https://pubmed.ncbi.nlm.nih.gov/20627738

DM4INSG	DI	DM4INSG
DM4INSG	DN	(-)-pinoresinol
DM4INSG	MI	TTN9T81
DM4INSG	MN	Arachidonate 15-lipoxygenase (15-LOX)
DM4INSG	MT	DTT
DM4INSG	MA	Inhibitor
DM4INSG	RN	Lipoxygenase inhibitory constituents of the fruits of noni (Morinda citrifolia) collected in Tahiti. J Nat Prod. 2007 May;70(5):859-62.
DM4INSG	RU	https://pubmed.ncbi.nlm.nih.gov/17378609

DM4INSG	DI	DM4INSG
DM4INSG	DN	(-)-pinoresinol
DM4INSG	MI	TTSJ6Q4
DM4INSG	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DM4INSG	MT	DTT
DM4INSG	MA	Inhibitor
DM4INSG	RN	Lipoxygenase inhibitory constituents of the fruits of noni (Morinda citrifolia) collected in Tahiti. J Nat Prod. 2007 May;70(5):859-62.
DM4INSG	RU	https://pubmed.ncbi.nlm.nih.gov/17378609

DMH6EVM	DI	DMH6EVM
DMH6EVM	DN	(-)-Ro 363
DMH6EVM	MI	TTMXGCW
DMH6EVM	MN	Adrenergic receptor beta-3 (ADRB3)
DMH6EVM	MT	DTT
DMH6EVM	MA	Agonist
DMH6EVM	RN	Effects of (-)-RO363 at human atrial beta-adrenoceptor subtypes, the human cloned beta 3-adrenoceptor and rodent intestinal beta 3-adrenoceptors. Br J Pharmacol. 1997 Jan;120(2):165-76.
DMH6EVM	RU	https://pubmed.ncbi.nlm.nih.gov/9117106

DMFE3YK	DI	DMFE3YK
DMFE3YK	DN	(-)-SNAP-5399
DMFE3YK	MI	TTNGILX
DMFE3YK	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMFE3YK	MT	DTT
DMFE3YK	MA	Inhibitor
DMFE3YK	RN	Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
DMFE3YK	RU	https://pubmed.ncbi.nlm.nih.gov/15664832

DMKWIYP	DI	DMKWIYP
DMKWIYP	DN	(-)-thujaplicatintrimethyl ether
DMKWIYP	MI	TTXV4FI
DMKWIYP	MN	Albendazole monooxygenase (CYP3A4)
DMKWIYP	MT	DTT
DMKWIYP	MA	Inhibitor
DMKWIYP	RN	Potent CYP3A4 inhibitory constituents of Piper cubeba. J Nat Prod. 2005 Jan;68(1):64-8.
DMKWIYP	RU	https://pubmed.ncbi.nlm.nih.gov/15679319

DMAT58Z	DI	DMAT58Z
DMAT58Z	DN	(-)-Tolserine
DMAT58Z	MI	TT1RS9F
DMAT58Z	MN	Acetylcholinesterase (AChE)
DMAT58Z	MT	DTT
DMAT58Z	MA	Inhibitor
DMAT58Z	RN	Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. Bioorg Med Chem. 2010 Jul 1;18(13):4687-93. 
DMAT58Z	RU	https://pubmed.ncbi.nlm.nih.gov/20627738

DMAT58Z	DI	DMAT58Z
DMAT58Z	DN	(-)-Tolserine
DMAT58Z	MI	TTEB0GD
DMAT58Z	MN	Cholinesterase (BCHE)
DMAT58Z	MT	DTT
DMAT58Z	MA	Inhibitor
DMAT58Z	RN	Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. Bioorg Med Chem. 2010 Jul 1;18(13):4687-93. 
DMAT58Z	RU	https://pubmed.ncbi.nlm.nih.gov/20627738

DMITWZ7	DI	DMITWZ7
DMITWZ7	DN	(-)-trans-H2-PAT
DMITWZ7	MI	TTTIBOJ
DMITWZ7	MN	Histamine H1 receptor (H1R)
DMITWZ7	MT	DTT
DMITWZ7	MA	Antagonist
DMITWZ7	RN	A novel phenylaminotetralin radioligand reveals a subpopulation of histamine H(1) receptors. J Pharmacol Exp Ther. 2002 Jul;302(1):328-36.
DMITWZ7	RU	https://pubmed.ncbi.nlm.nih.gov/12065734

DMRGVNJ	DI	DMRGVNJ
DMRGVNJ	DN	(-)-uniflorine A
DMRGVNJ	MI	TTLPC70
DMRGVNJ	MN	Lysosomal alpha-glucosidase (GAA)
DMRGVNJ	MT	DTT
DMRGVNJ	MA	Inhibitor
DMRGVNJ	RN	Total synthesis of (-)-uniflorine A. J Nat Prod. 2009 Nov;72(11):2058-60.
DMRGVNJ	RU	https://pubmed.ncbi.nlm.nih.gov/19835391

DMDHGIR	DI	DMDHGIR
DMDHGIR	DN	(-)-yatein
DMDHGIR	MI	TTXV4FI
DMDHGIR	MN	Albendazole monooxygenase (CYP3A4)
DMDHGIR	MT	DTT
DMDHGIR	MA	Inhibitor
DMDHGIR	RN	Potent CYP3A4 inhibitory constituents of Piper cubeba. J Nat Prod. 2005 Jan;68(1):64-8.
DMDHGIR	RU	https://pubmed.ncbi.nlm.nih.gov/15679319

DMF62GN	DI	DMF62GN
DMF62GN	DN	(+)-(1R,1'S)-berbamunine hydrochloride
DMF62GN	MI	TTZFYLI
DMF62GN	MN	Dopamine D1 receptor (D1R)
DMF62GN	MT	DTT
DMF62GN	MA	Inhibitor
DMF62GN	RN	Displacement activity of bisbenzylisoquinoline alkaloids at striatal 3H-SCH 23390 and 3H-raclopride binding sites. J Nat Prod. 1992 Sep;55(9):1281-6.
DMF62GN	RU	https://pubmed.ncbi.nlm.nih.gov/1431946

DMF62GN	DI	DMF62GN
DMF62GN	DN	(+)-(1R,1'S)-berbamunine hydrochloride
DMF62GN	MI	TTEX248
DMF62GN	MN	Dopamine D2 receptor (D2R)
DMF62GN	MT	DTT
DMF62GN	MA	Inhibitor
DMF62GN	RN	Displacement activity of bisbenzylisoquinoline alkaloids at striatal 3H-SCH 23390 and 3H-raclopride binding sites. J Nat Prod. 1992 Sep;55(9):1281-6.
DMF62GN	RU	https://pubmed.ncbi.nlm.nih.gov/1431946

DM521S4	DI	DM521S4
DM521S4	DN	(+)-(1R,1'S)-thaligrisine hydrochloride
DM521S4	MI	TTZFYLI
DM521S4	MN	Dopamine D1 receptor (D1R)
DM521S4	MT	DTT
DM521S4	MA	Inhibitor
DM521S4	RN	Displacement activity of bisbenzylisoquinoline alkaloids at striatal 3H-SCH 23390 and 3H-raclopride binding sites. J Nat Prod. 1992 Sep;55(9):1281-6.
DM521S4	RU	https://pubmed.ncbi.nlm.nih.gov/1431946

DM521S4	DI	DM521S4
DM521S4	DN	(+)-(1R,1'S)-thaligrisine hydrochloride
DM521S4	MI	TTEX248
DM521S4	MN	Dopamine D2 receptor (D2R)
DM521S4	MT	DTT
DM521S4	MA	Inhibitor
DM521S4	RN	Displacement activity of bisbenzylisoquinoline alkaloids at striatal 3H-SCH 23390 and 3H-raclopride binding sites. J Nat Prod. 1992 Sep;55(9):1281-6.
DM521S4	RU	https://pubmed.ncbi.nlm.nih.gov/1431946

DMLDQWT	DI	DMLDQWT
DMLDQWT	DN	(+)-(5S,8S,10S)-20-methoxy-9,15-ene-puupehenol
DMLDQWT	MI	TT12ABZ
DMLDQWT	MN	Arachidonate 12-lipoxygenase (12-LOX)
DMLDQWT	MT	DTT
DMLDQWT	MA	Inhibitor
DMLDQWT	RN	Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases. J Nat Prod. 2003 Feb;66(2):230-5.
DMLDQWT	RU	https://pubmed.ncbi.nlm.nih.gov/12608855

DMLDQWT	DI	DMLDQWT
DMLDQWT	DN	(+)-(5S,8S,10S)-20-methoxy-9,15-ene-puupehenol
DMLDQWT	MI	TTN9T81
DMLDQWT	MN	Arachidonate 15-lipoxygenase (15-LOX)
DMLDQWT	MT	DTT
DMLDQWT	MA	Inhibitor
DMLDQWT	RN	Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases. J Nat Prod. 2003 Feb;66(2):230-5.
DMLDQWT	RU	https://pubmed.ncbi.nlm.nih.gov/12608855

DMU7BJA	DI	DMU7BJA
DMU7BJA	DN	(+)-(5S,8S,10S)-20-methoxypuupehenol
DMU7BJA	MI	TT12ABZ
DMU7BJA	MN	Arachidonate 12-lipoxygenase (12-LOX)
DMU7BJA	MT	DTT
DMU7BJA	MA	Inhibitor
DMU7BJA	RN	Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases. J Nat Prod. 2003 Feb;66(2):230-5.
DMU7BJA	RU	https://pubmed.ncbi.nlm.nih.gov/12608855

DMU7BJA	DI	DMU7BJA
DMU7BJA	DN	(+)-(5S,8S,10S)-20-methoxypuupehenol
DMU7BJA	MI	TTN9T81
DMU7BJA	MN	Arachidonate 15-lipoxygenase (15-LOX)
DMU7BJA	MT	DTT
DMU7BJA	MA	Inhibitor
DMU7BJA	RN	Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases. J Nat Prod. 2003 Feb;66(2):230-5.
DMU7BJA	RU	https://pubmed.ncbi.nlm.nih.gov/12608855

DMD4YPO	DI	DMD4YPO
DMD4YPO	DN	(+)-(5S,8S,9R,10S)-20-methoxypuupehenone
DMD4YPO	MI	TT12ABZ
DMD4YPO	MN	Arachidonate 12-lipoxygenase (12-LOX)
DMD4YPO	MT	DTT
DMD4YPO	MA	Inhibitor
DMD4YPO	RN	Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases. J Nat Prod. 2003 Feb;66(2):230-5.
DMD4YPO	RU	https://pubmed.ncbi.nlm.nih.gov/12608855

DMD4YPO	DI	DMD4YPO
DMD4YPO	DN	(+)-(5S,8S,9R,10S)-20-methoxypuupehenone
DMD4YPO	MI	TTN9T81
DMD4YPO	MN	Arachidonate 15-lipoxygenase (15-LOX)
DMD4YPO	MT	DTT
DMD4YPO	MA	Inhibitor
DMD4YPO	RN	Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases. J Nat Prod. 2003 Feb;66(2):230-5.
DMD4YPO	RU	https://pubmed.ncbi.nlm.nih.gov/12608855

DMNUWVB	DI	DMNUWVB
DMNUWVB	DN	(+)-3,3'-bisdemethyltanegool
DMNUWVB	MI	TTN9T81
DMNUWVB	MN	Arachidonate 15-lipoxygenase (15-LOX)
DMNUWVB	MT	DTT
DMNUWVB	MA	Inhibitor
DMNUWVB	RN	Lipoxygenase inhibitory constituents of the fruits of noni (Morinda citrifolia) collected in Tahiti. J Nat Prod. 2007 May;70(5):859-62.
DMNUWVB	RU	https://pubmed.ncbi.nlm.nih.gov/17378609

DMNUWVB	DI	DMNUWVB
DMNUWVB	DN	(+)-3,3'-bisdemethyltanegool
DMNUWVB	MI	TTSJ6Q4
DMNUWVB	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DMNUWVB	MT	DTT
DMNUWVB	MA	Inhibitor
DMNUWVB	RN	Lipoxygenase inhibitory constituents of the fruits of noni (Morinda citrifolia) collected in Tahiti. J Nat Prod. 2007 May;70(5):859-62.
DMNUWVB	RU	https://pubmed.ncbi.nlm.nih.gov/17378609

DM2CHX8	DI	DM2CHX8
DM2CHX8	DN	(+)-5-(5-bromothiophen-3-yl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid
DM2CHX8	MI	TTWNV8U
DM2CHX8	MN	Nicotinic acid receptor (HCAR2)
DM2CHX8	MT	DTT
DM2CHX8	MA	Agonist
DM2CHX8	RN	(D)-beta-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. J Biol Chem. 2005 Jul 22;280(29):26649-52.
DM2CHX8	RU	https://pubmed.ncbi.nlm.nih.gov/15929991

DMF8C50	DI	DMF8C50
DMF8C50	DN	(+)-5-deoxyadeenophorine
DMF8C50	MI	TTIS03D
DMF8C50	MN	Alpha-galactosidase A (GLA)
DMF8C50	MT	DTT
DMF8C50	MA	Inhibitor
DMF8C50	RN	Flexible synthesis and biological evaluation of novel 5-deoxyadenophorine analogues. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3262-7.
DMF8C50	RU	https://pubmed.ncbi.nlm.nih.gov/16603357

DMXWCVY	DI	DMXWCVY
DMXWCVY	DN	(+)-ADTN
DMXWCVY	MI	TTZFYLI
DMXWCVY	MN	Dopamine D1 receptor (D1R)
DMXWCVY	MT	DTT
DMXWCVY	MA	Agonist
DMXWCVY	RN	Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature. 1991 Apr 18;350(6319):614-9.
DMXWCVY	RU	https://pubmed.ncbi.nlm.nih.gov/1826762

DMXWCVY	DI	DMXWCVY
DMXWCVY	DN	(+)-ADTN
DMXWCVY	MI	TTS2PH3
DMXWCVY	MN	Dopamine D5 receptor (D5R)
DMXWCVY	MT	DTT
DMXWCVY	MA	Agonist
DMXWCVY	RN	Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature. 1991 Apr 18;350(6319):614-9.
DMXWCVY	RU	https://pubmed.ncbi.nlm.nih.gov/1826762

DMEDMC0	DI	DMEDMC0
DMEDMC0	DN	(+)-AJ76
DMEDMC0	MI	TT4C8EA
DMEDMC0	MN	Dopamine D3 receptor (D3R)
DMEDMC0	MT	DTT
DMEDMC0	MA	Antagonist
DMEDMC0	RN	Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature. 1990 Sep 13;347(6289):146-51.
DMEDMC0	RU	https://pubmed.ncbi.nlm.nih.gov/1975644

DMX6UYN	DI	DMX6UYN
DMX6UYN	DN	(+)-BUTACLAMOL
DMX6UYN	MI	TTJFY5U
DMX6UYN	MN	Adenosine A3 receptor (ADORA3)
DMX6UYN	MT	DTT
DMX6UYN	MA	Inhibitor
DMX6UYN	RN	2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96.
DMX6UYN	RU	https://pubmed.ncbi.nlm.nih.gov/16250647

DMX6UYN	DI	DMX6UYN
DMX6UYN	DN	(+)-BUTACLAMOL
DMX6UYN	MI	TTZFYLI
DMX6UYN	MN	Dopamine D1 receptor (D1R)
DMX6UYN	MT	DTT
DMX6UYN	MA	Inhibitor
DMX6UYN	RN	7-Methyl-6,7,8,9,14,15-hexahydro-5H-benz[d]indolo[2,3-g]azecine: a new heterocyclic system and a new lead compound for dopamine receptor antagonists. J Med Chem. 2000 May 18;43(10):2079-81.
DMX6UYN	RU	https://pubmed.ncbi.nlm.nih.gov/10821720

DMX6UYN	DI	DMX6UYN
DMX6UYN	DN	(+)-BUTACLAMOL
DMX6UYN	MI	TTEX248
DMX6UYN	MN	Dopamine D2 receptor (D2R)
DMX6UYN	MT	DTT
DMX6UYN	MA	Inhibitor
DMX6UYN	RN	Synthesis and structure-activity relationships of 1-aralkyl-4-benzylpiperidine and 1-aralkyl-4-benzylpiperazine derivatives as potent sigma ligands. J Med Chem. 2005 Jan 13;48(1):266-73.
DMX6UYN	RU	https://pubmed.ncbi.nlm.nih.gov/15634021

DMX6UYN	DI	DMX6UYN
DMX6UYN	DN	(+)-BUTACLAMOL
DMX6UYN	MI	TT4C8EA
DMX6UYN	MN	Dopamine D3 receptor (D3R)
DMX6UYN	MT	DTT
DMX6UYN	MA	Inhibitor
DMX6UYN	RN	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
DMX6UYN	RU	https://pubmed.ncbi.nlm.nih.gov/18983139

DMDFR59	DI	DMDFR59
DMDFR59	DN	(+)-cis-H2-PAT
DMDFR59	MI	TTTIBOJ
DMDFR59	MN	Histamine H1 receptor (H1R)
DMDFR59	MT	DTT
DMDFR59	MA	Antagonist
DMDFR59	RN	A novel phenylaminotetralin radioligand reveals a subpopulation of histamine H(1) receptors. J Pharmacol Exp Ther. 2002 Jul;302(1):328-36.
DMDFR59	RU	https://pubmed.ncbi.nlm.nih.gov/12065734

DMKWEAJ	DI	DMKWEAJ
DMKWEAJ	DN	(+)-HA966
DMKWEAJ	MI	TTLD29N
DMKWEAJ	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMKWEAJ	MT	DTT
DMKWEAJ	MA	Agonist
DMKWEAJ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455).
DMKWEAJ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=455

DMKWEAJ	DI	DMKWEAJ
DMKWEAJ	DN	(+)-HA966
DMKWEAJ	MI	TTKJEMQ
DMKWEAJ	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMKWEAJ	MT	DTT
DMKWEAJ	MA	Agonist
DMKWEAJ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456).
DMKWEAJ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=456

DMKWEAJ	DI	DMKWEAJ
DMKWEAJ	DN	(+)-HA966
DMKWEAJ	MI	TTN9D8E
DMKWEAJ	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMKWEAJ	MT	DTT
DMKWEAJ	MA	Agonist
DMKWEAJ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457).
DMKWEAJ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=457

DMG5QJB	DI	DMG5QJB
DMG5QJB	DN	(+)-MCPG
DMG5QJB	MI	TTVBPDM
DMG5QJB	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMG5QJB	MT	DTT
DMG5QJB	MA	Antagonist
DMG5QJB	RN	[3H]R214127: a novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists. Mol Pharmacol. 2003 May;63(5):1082-93.
DMG5QJB	RU	https://pubmed.ncbi.nlm.nih.gov/12695537

DMG5QJB	DI	DMG5QJB
DMG5QJB	DN	(+)-MCPG
DMG5QJB	MI	TTXJ47W
DMG5QJB	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMG5QJB	MT	DTT
DMG5QJB	MA	Antagonist
DMG5QJB	RN	Characterization of [3H]-(2S,2'R,3'R)-2-(2',3'-dicarboxy-cyclopropyl)glycine ([3H]-DCG IV) binding to metabotropic mGlu2 receptor-transfected cell membranes. Br J Pharmacol. 1998 Feb;123(3):497-504.
DMG5QJB	RU	https://pubmed.ncbi.nlm.nih.gov/9504391

DMG5QJB	DI	DMG5QJB
DMG5QJB	DN	(+)-MCPG
DMG5QJB	MI	TT8A9EF
DMG5QJB	MN	Metabotropic glutamate receptor 3 (mGluR3)
DMG5QJB	MT	DTT
DMG5QJB	MA	Antagonist
DMG5QJB	RN	[3H]-LY341495 as a novel antagonist radioligand for group II metabotropic glutamate (mGlu) receptors: characterization of binding to membranes of mGlu receptor subtype expressing cells. Neuropharmacology. 1999 Oct;38(10):1519-29.
DMG5QJB	RU	https://pubmed.ncbi.nlm.nih.gov/10530814

DMG5QJB	DI	DMG5QJB
DMG5QJB	DN	(+)-MCPG
DMG5QJB	MI	TTHS256
DMG5QJB	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMG5QJB	MT	DTT
DMG5QJB	MA	Antagonist
DMG5QJB	RN	Characterization of [(3)H]Quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections. J Neurochem. 2000 Dec;75(6):2590-601.
DMG5QJB	RU	https://pubmed.ncbi.nlm.nih.gov/11080213

DMG5QJB	DI	DMG5QJB
DMG5QJB	DN	(+)-MCPG
DMG5QJB	MI	TT0I76D
DMG5QJB	MN	Metabotropic glutamate receptor 7 (mGluR7)
DMG5QJB	MT	DTT
DMG5QJB	MA	Antagonist
DMG5QJB	RN	Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 2000 Dec;362(6):546-54.
DMG5QJB	RU	https://pubmed.ncbi.nlm.nih.gov/11138847

DM7FZHI	DI	DM7FZHI
DM7FZHI	DN	(+)-Myristinin A
DM7FZHI	MI	TTIU7X1
DM7FZHI	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DM7FZHI	MT	DTT
DM7FZHI	MA	Inhibitor
DM7FZHI	RN	(+)-Myristinins A and D from Knema elegans, which inhibit DNA polymerase beta and cleave DNA. J Nat Prod. 2005 Nov;68(11):1625-8.
DM7FZHI	RU	https://pubmed.ncbi.nlm.nih.gov/16309311

DMEK07T	DI	DMEK07T
DMEK07T	DN	(+)-Myristinin D
DMEK07T	MI	TTIU7X1
DMEK07T	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMEK07T	MT	DTT
DMEK07T	MA	Inhibitor
DMEK07T	RN	(+)-Myristinins A and D from Knema elegans, which inhibit DNA polymerase beta and cleave DNA. J Nat Prod. 2005 Nov;68(11):1625-8.
DMEK07T	RU	https://pubmed.ncbi.nlm.nih.gov/16309311

DMOZJA5	DI	DMOZJA5
DMOZJA5	DN	(+)-norfenfluramine
DMOZJA5	MI	TT0K1SC
DMOZJA5	MN	5-HT 2B receptor (HTR2B)
DMOZJA5	MT	DTT
DMOZJA5	MA	Agonist
DMOZJA5	RN	Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 2000 Dec 5;102(23):2836-41.
DMOZJA5	RU	https://pubmed.ncbi.nlm.nih.gov/11104741

DMX7ECD	DI	DMX7ECD
DMX7ECD	DN	(+)-S-14297
DMX7ECD	MI	TTEX248
DMX7ECD	MN	Dopamine D2 receptor (D2R)
DMX7ECD	MT	DTT
DMX7ECD	MA	Antagonist
DMX7ECD	RN	Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy. J Pharmacol Exp Ther. 1995 Nov;275(2):885-98.
DMX7ECD	RU	https://pubmed.ncbi.nlm.nih.gov/7473180

DMX7ECD	DI	DMX7ECD
DMX7ECD	DN	(+)-S-14297
DMX7ECD	MI	TT4C8EA
DMX7ECD	MN	Dopamine D3 receptor (D3R)
DMX7ECD	MT	DTT
DMX7ECD	MA	Antagonist
DMX7ECD	RN	S 14297, a novel selective ligand at cloned human dopamine D3 receptors, blocks 7-OH-DPAT-induced hypothermia in rats. Eur J Pharmacol. 1994 Aug 1;260(2-3):R3-5.
DMX7ECD	RU	https://pubmed.ncbi.nlm.nih.gov/7988633

DM1QPA4	DI	DM1QPA4
DM1QPA4	DN	(+)-SK&F10047
DM1QPA4	MI	TT5TPI6
DM1QPA4	MN	Opioid receptor sigma 1 (OPRS1)
DM1QPA4	MT	DTT
DM1QPA4	MA	Agonist
DM1QPA4	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2552).
DM1QPA4	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2552

DMAN63P	DI	DMAN63P
DMAN63P	DN	(+)-trans-H2-PAT
DMAN63P	MI	TTTIBOJ
DMAN63P	MN	Histamine H1 receptor (H1R)
DMAN63P	MT	DTT
DMAN63P	MA	Antagonist
DMAN63P	RN	A novel phenylaminotetralin radioligand reveals a subpopulation of histamine H(1) receptors. J Pharmacol Exp Ther. 2002 Jul;302(1):328-36.
DMAN63P	RU	https://pubmed.ncbi.nlm.nih.gov/12065734

DMDXKQ6	DI	DMDXKQ6
DMDXKQ6	DN	(+/-)-2-(4'-Benzyloxyphenyl)thiomorpholin-5-one
DMDXKQ6	MI	TTGP7BY
DMDXKQ6	MN	Monoamine oxidase type B (MAO-B)
DMDXKQ6	MT	DTT
DMDXKQ6	MA	Inhibitor
DMDXKQ6	RN	2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95.
DMDXKQ6	RU	https://pubmed.ncbi.nlm.nih.gov/20123154

DMCB74T	DI	DMCB74T
DMCB74T	DN	(+/-)-2-(4'-Benzyloxyphenyl)thiomorpholine
DMCB74T	MI	TT3WG5C
DMCB74T	MN	Monoamine oxidase type A (MAO-A)
DMCB74T	MT	DTT
DMCB74T	MA	Inhibitor
DMCB74T	RN	2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95.
DMCB74T	RU	https://pubmed.ncbi.nlm.nih.gov/20123154

DMCB74T	DI	DMCB74T
DMCB74T	DN	(+/-)-2-(4'-Benzyloxyphenyl)thiomorpholine
DMCB74T	MI	TTGP7BY
DMCB74T	MN	Monoamine oxidase type B (MAO-B)
DMCB74T	MT	DTT
DMCB74T	MA	Inhibitor
DMCB74T	RN	2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95.
DMCB74T	RU	https://pubmed.ncbi.nlm.nih.gov/20123154

DM1WCJV	DI	DM1WCJV
DM1WCJV	DN	(+/-)-2-(4'-Butoxyphenyl)thiomorpholin-5-one
DM1WCJV	MI	TT3WG5C
DM1WCJV	MN	Monoamine oxidase type A (MAO-A)
DM1WCJV	MT	DTT
DM1WCJV	MA	Inhibitor
DM1WCJV	RN	2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95.
DM1WCJV	RU	https://pubmed.ncbi.nlm.nih.gov/20123154

DM1WCJV	DI	DM1WCJV
DM1WCJV	DN	(+/-)-2-(4'-Butoxyphenyl)thiomorpholin-5-one
DM1WCJV	MI	TTGP7BY
DM1WCJV	MN	Monoamine oxidase type B (MAO-B)
DM1WCJV	MT	DTT
DM1WCJV	MA	Inhibitor
DM1WCJV	RN	2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95.
DM1WCJV	RU	https://pubmed.ncbi.nlm.nih.gov/20123154

DMG3MF2	DI	DMG3MF2
DMG3MF2	DN	(+/-)-2-(4'-Butoxyphenyl)thiomorpholine
DMG3MF2	MI	TT3WG5C
DMG3MF2	MN	Monoamine oxidase type A (MAO-A)
DMG3MF2	MT	DTT
DMG3MF2	MA	Inhibitor
DMG3MF2	RN	2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95.
DMG3MF2	RU	https://pubmed.ncbi.nlm.nih.gov/20123154

DMG3MF2	DI	DMG3MF2
DMG3MF2	DN	(+/-)-2-(4'-Butoxyphenyl)thiomorpholine
DMG3MF2	MI	TTGP7BY
DMG3MF2	MN	Monoamine oxidase type B (MAO-B)
DMG3MF2	MT	DTT
DMG3MF2	MA	Inhibitor
DMG3MF2	RN	2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95.
DMG3MF2	RU	https://pubmed.ncbi.nlm.nih.gov/20123154

DM1YBJ2	DI	DM1YBJ2
DM1YBJ2	DN	(+/-)-2-(4'-Ethoxyphenyl)thiomorpholin-5-one
DM1YBJ2	MI	TT3WG5C
DM1YBJ2	MN	Monoamine oxidase type A (MAO-A)
DM1YBJ2	MT	DTT
DM1YBJ2	MA	Inhibitor
DM1YBJ2	RN	2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95.
DM1YBJ2	RU	https://pubmed.ncbi.nlm.nih.gov/20123154

DM1YBJ2	DI	DM1YBJ2
DM1YBJ2	DN	(+/-)-2-(4'-Ethoxyphenyl)thiomorpholin-5-one
DM1YBJ2	MI	TTGP7BY
DM1YBJ2	MN	Monoamine oxidase type B (MAO-B)
DM1YBJ2	MT	DTT
DM1YBJ2	MA	Inhibitor
DM1YBJ2	RN	2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95.
DM1YBJ2	RU	https://pubmed.ncbi.nlm.nih.gov/20123154

DMKPX7W	DI	DMKPX7W
DMKPX7W	DN	(+/-)-2-(4'-Ethoxyphenyl)thiomorpholine
DMKPX7W	MI	TT3WG5C
DMKPX7W	MN	Monoamine oxidase type A (MAO-A)
DMKPX7W	MT	DTT
DMKPX7W	MA	Inhibitor
DMKPX7W	RN	2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95.
DMKPX7W	RU	https://pubmed.ncbi.nlm.nih.gov/20123154

DMKPX7W	DI	DMKPX7W
DMKPX7W	DN	(+/-)-2-(4'-Ethoxyphenyl)thiomorpholine
DMKPX7W	MI	TTGP7BY
DMKPX7W	MN	Monoamine oxidase type B (MAO-B)
DMKPX7W	MT	DTT
DMKPX7W	MA	Inhibitor
DMKPX7W	RN	2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95.
DMKPX7W	RU	https://pubmed.ncbi.nlm.nih.gov/20123154

DMGY5WB	DI	DMGY5WB
DMGY5WB	DN	(+/-)-2-(4-fluorophenyl)-7-methoxychroman-4-one
DMGY5WB	MI	TTGP7BY
DMGY5WB	MN	Monoamine oxidase type B (MAO-B)
DMGY5WB	MT	DTT
DMGY5WB	MA	Inhibitor
DMGY5WB	RN	A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9.
DMGY5WB	RU	https://pubmed.ncbi.nlm.nih.gov/20045650

DMHL7BC	DI	DMHL7BC
DMHL7BC	DN	(+/-)-2-(4-fluorophenyl)-7-methylchroman-4-one
DMHL7BC	MI	TTGP7BY
DMHL7BC	MN	Monoamine oxidase type B (MAO-B)
DMHL7BC	MT	DTT
DMHL7BC	MA	Inhibitor
DMHL7BC	RN	A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9.
DMHL7BC	RU	https://pubmed.ncbi.nlm.nih.gov/20045650

DMXK4HR	DI	DMXK4HR
DMXK4HR	DN	(+/-)-2-(4-fluorophenyl)chroman-4-one
DMXK4HR	MI	TTGP7BY
DMXK4HR	MN	Monoamine oxidase type B (MAO-B)
DMXK4HR	MT	DTT
DMXK4HR	MA	Inhibitor
DMXK4HR	RN	A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9.
DMXK4HR	RU	https://pubmed.ncbi.nlm.nih.gov/20045650

DMTUFOE	DI	DMTUFOE
DMTUFOE	DN	(+/-)-2-(4-methoxyphenyl)-7-methylchroman-4-one
DMTUFOE	MI	TTGP7BY
DMTUFOE	MN	Monoamine oxidase type B (MAO-B)
DMTUFOE	MT	DTT
DMTUFOE	MA	Inhibitor
DMTUFOE	RN	A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9.
DMTUFOE	RU	https://pubmed.ncbi.nlm.nih.gov/20045650

DM7BY4T	DI	DM7BY4T
DM7BY4T	DN	(+/-)-2-(4'-Methoxyphenyl)thiomorpholin-5-one
DM7BY4T	MI	TT3WG5C
DM7BY4T	MN	Monoamine oxidase type A (MAO-A)
DM7BY4T	MT	DTT
DM7BY4T	MA	Inhibitor
DM7BY4T	RN	2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95.
DM7BY4T	RU	https://pubmed.ncbi.nlm.nih.gov/20123154

DM7BY4T	DI	DM7BY4T
DM7BY4T	DN	(+/-)-2-(4'-Methoxyphenyl)thiomorpholin-5-one
DM7BY4T	MI	TTGP7BY
DM7BY4T	MN	Monoamine oxidase type B (MAO-B)
DM7BY4T	MT	DTT
DM7BY4T	MA	Inhibitor
DM7BY4T	RN	2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95.
DM7BY4T	RU	https://pubmed.ncbi.nlm.nih.gov/20123154

DMKFSQ8	DI	DMKFSQ8
DMKFSQ8	DN	(+/-)-2-(4'-Methoxyphenyl)thiomorpholine
DMKFSQ8	MI	TT3WG5C
DMKFSQ8	MN	Monoamine oxidase type A (MAO-A)
DMKFSQ8	MT	DTT
DMKFSQ8	MA	Inhibitor
DMKFSQ8	RN	2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95.
DMKFSQ8	RU	https://pubmed.ncbi.nlm.nih.gov/20123154

DMKFSQ8	DI	DMKFSQ8
DMKFSQ8	DN	(+/-)-2-(4'-Methoxyphenyl)thiomorpholine
DMKFSQ8	MI	TTGP7BY
DMKFSQ8	MN	Monoamine oxidase type B (MAO-B)
DMKFSQ8	MT	DTT
DMKFSQ8	MA	Inhibitor
DMKFSQ8	RN	2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95.
DMKFSQ8	RU	https://pubmed.ncbi.nlm.nih.gov/20123154

DMY1W20	DI	DMY1W20
DMY1W20	DN	(+/-)-2-(4'-Propoxyphenyl)thiomorpholin-5-one
DMY1W20	MI	TT3WG5C
DMY1W20	MN	Monoamine oxidase type A (MAO-A)
DMY1W20	MT	DTT
DMY1W20	MA	Inhibitor
DMY1W20	RN	2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95.
DMY1W20	RU	https://pubmed.ncbi.nlm.nih.gov/20123154

DMY1W20	DI	DMY1W20
DMY1W20	DN	(+/-)-2-(4'-Propoxyphenyl)thiomorpholin-5-one
DMY1W20	MI	TTGP7BY
DMY1W20	MN	Monoamine oxidase type B (MAO-B)
DMY1W20	MT	DTT
DMY1W20	MA	Inhibitor
DMY1W20	RN	2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95.
DMY1W20	RU	https://pubmed.ncbi.nlm.nih.gov/20123154

DMUPYN1	DI	DMUPYN1
DMUPYN1	DN	(+/-)-2-(4'-Propoxyphenyl)thiomorpholine
DMUPYN1	MI	TT3WG5C
DMUPYN1	MN	Monoamine oxidase type A (MAO-A)
DMUPYN1	MT	DTT
DMUPYN1	MA	Inhibitor
DMUPYN1	RN	2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95.
DMUPYN1	RU	https://pubmed.ncbi.nlm.nih.gov/20123154

DMUPYN1	DI	DMUPYN1
DMUPYN1	DN	(+/-)-2-(4'-Propoxyphenyl)thiomorpholine
DMUPYN1	MI	TTGP7BY
DMUPYN1	MN	Monoamine oxidase type B (MAO-B)
DMUPYN1	MT	DTT
DMUPYN1	MA	Inhibitor
DMUPYN1	RN	2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95.
DMUPYN1	RU	https://pubmed.ncbi.nlm.nih.gov/20123154

DMX768L	DI	DMX768L
DMX768L	DN	(+/-)-2-Amino-1,2,3,4-tetrahydro-2-naphthoic acid
DMX768L	MI	TTPH2JB
DMX768L	MN	Large neutral amino acids transporter 1 (SLC7A5)
DMX768L	MT	DTT
DMX768L	MA	Inhibitor
DMX768L	RN	Regiospecific and conformationally restrained analogs of melphalan and DL-2-NAM-7 and their affinities for the large neutral amino acid transporter... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3688-91.
DMX768L	RU	https://pubmed.ncbi.nlm.nih.gov/20466543

DML5URN	DI	DML5URN
DML5URN	DN	(+/-)-2-Aminoindane-2-carboxylic acid
DML5URN	MI	TTPH2JB
DML5URN	MN	Large neutral amino acids transporter 1 (SLC7A5)
DML5URN	MT	DTT
DML5URN	MA	Inhibitor
DML5URN	RN	Regiospecific and conformationally restrained analogs of melphalan and DL-2-NAM-7 and their affinities for the large neutral amino acid transporter... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3688-91.
DML5URN	RU	https://pubmed.ncbi.nlm.nih.gov/20466543

DMJ6MPO	DI	DMJ6MPO
DMJ6MPO	DN	(+/-)-2-Methyl-1-(1-phenylethyl)-1H-imidazole
DMJ6MPO	MI	TTZUFI5
DMJ6MPO	MN	Nitric-oxide synthase brain (NOS1)
DMJ6MPO	MT	DTT
DMJ6MPO	MA	Inhibitor
DMJ6MPO	RN	N-Substituted acetamidines and 2-methylimidazole derivatives as selective inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6495-9.
DMJ6MPO	RU	https://pubmed.ncbi.nlm.nih.gov/20933416

DMSHDNO	DI	DMSHDNO
DMSHDNO	DN	(+/-)-2-Phenylthiomorpholin-5-one
DMSHDNO	MI	TT3WG5C
DMSHDNO	MN	Monoamine oxidase type A (MAO-A)
DMSHDNO	MT	DTT
DMSHDNO	MA	Inhibitor
DMSHDNO	RN	2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95.
DMSHDNO	RU	https://pubmed.ncbi.nlm.nih.gov/20123154

DMSHDNO	DI	DMSHDNO
DMSHDNO	DN	(+/-)-2-Phenylthiomorpholin-5-one
DMSHDNO	MI	TTGP7BY
DMSHDNO	MN	Monoamine oxidase type B (MAO-B)
DMSHDNO	MT	DTT
DMSHDNO	MA	Inhibitor
DMSHDNO	RN	2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95.
DMSHDNO	RU	https://pubmed.ncbi.nlm.nih.gov/20123154

DMNR3YL	DI	DMNR3YL
DMNR3YL	DN	(+/-)-2-Phenylthiomorpholine
DMNR3YL	MI	TT3WG5C
DMNR3YL	MN	Monoamine oxidase type A (MAO-A)
DMNR3YL	MT	DTT
DMNR3YL	MA	Inhibitor
DMNR3YL	RN	2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95.
DMNR3YL	RU	https://pubmed.ncbi.nlm.nih.gov/20123154

DMNR3YL	DI	DMNR3YL
DMNR3YL	DN	(+/-)-2-Phenylthiomorpholine
DMNR3YL	MI	TTGP7BY
DMNR3YL	MN	Monoamine oxidase type B (MAO-B)
DMNR3YL	MT	DTT
DMNR3YL	MA	Inhibitor
DMNR3YL	RN	2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95.
DMNR3YL	RU	https://pubmed.ncbi.nlm.nih.gov/20123154

DMYJGZ4	DI	DMYJGZ4
DMYJGZ4	DN	(+/-)-2-p-tolylchroman-4-one
DMYJGZ4	MI	TTGP7BY
DMYJGZ4	MN	Monoamine oxidase type B (MAO-B)
DMYJGZ4	MT	DTT
DMYJGZ4	MA	Inhibitor
DMYJGZ4	RN	A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9.
DMYJGZ4	RU	https://pubmed.ncbi.nlm.nih.gov/20045650

DML68KX	DI	DML68KX
DML68KX	DN	(+/-)-3-((naphthalen-2-yloxy)methyl)pyrrolidine
DML68KX	MI	TTVBI8W
DML68KX	MN	Dopamine transporter (DAT)
DML68KX	MT	DTT
DML68KX	MA	Inhibitor
DML68KX	RN	Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32.
DML68KX	RU	https://pubmed.ncbi.nlm.nih.gov/19282174

DML68KX	DI	DML68KX
DML68KX	DN	(+/-)-3-((naphthalen-2-yloxy)methyl)pyrrolidine
DML68KX	MI	TTAWNKZ
DML68KX	MN	Norepinephrine transporter (NET)
DML68KX	MT	DTT
DML68KX	MA	Inhibitor
DML68KX	RN	Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32.
DML68KX	RU	https://pubmed.ncbi.nlm.nih.gov/19282174

DML68KX	DI	DML68KX
DML68KX	DN	(+/-)-3-((naphthalen-2-yloxy)methyl)pyrrolidine
DML68KX	MI	TT3ROYC
DML68KX	MN	Serotonin transporter (SERT)
DML68KX	MT	DTT
DML68KX	MA	Inhibitor
DML68KX	RN	Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32.
DML68KX	RU	https://pubmed.ncbi.nlm.nih.gov/19282174

DM9AJSU	DI	DM9AJSU
DM9AJSU	DN	(+/-)-3-(but-3-enyl)-1-pent-4-enoylazetidin-2-one
DM9AJSU	MI	TTDP1UC
DM9AJSU	MN	Fatty acid amide hydrolase (FAAH)
DM9AJSU	MT	DTT
DM9AJSU	MA	Inhibitor
DM9AJSU	RN	3-Alkenyl-2-azetidinones as fatty acid amide hydrolase inhibitors. Bioorg Med Chem Lett. 2008 Jul 15;18(14):4163-7.
DM9AJSU	RU	https://pubmed.ncbi.nlm.nih.gov/18547805

DMWIABE	DI	DMWIABE
DMWIABE	DN	(+/-)-3-(pent-4-enyl)azetidin-2-one
DMWIABE	MI	TTDP1UC
DMWIABE	MN	Fatty acid amide hydrolase (FAAH)
DMWIABE	MT	DTT
DMWIABE	MA	Inhibitor
DMWIABE	RN	3-Alkenyl-2-azetidinones as fatty acid amide hydrolase inhibitors. Bioorg Med Chem Lett. 2008 Jul 15;18(14):4163-7.
DMWIABE	RU	https://pubmed.ncbi.nlm.nih.gov/18547805

DMS5AWP	DI	DMS5AWP
DMS5AWP	DN	(+/-)-3-allyl-1-pent-4-enoylazetidin-2-one
DMS5AWP	MI	TTDP1UC
DMS5AWP	MN	Fatty acid amide hydrolase (FAAH)
DMS5AWP	MT	DTT
DMS5AWP	MA	Inhibitor
DMS5AWP	RN	3-Alkenyl-2-azetidinones as fatty acid amide hydrolase inhibitors. Bioorg Med Chem Lett. 2008 Jul 15;18(14):4163-7.
DMS5AWP	RU	https://pubmed.ncbi.nlm.nih.gov/18547805

DMK42RU	DI	DMK42RU
DMK42RU	DN	(+/-)-3-allylazetidin-2-one
DMK42RU	MI	TTDP1UC
DMK42RU	MN	Fatty acid amide hydrolase (FAAH)
DMK42RU	MT	DTT
DMK42RU	MA	Inhibitor
DMK42RU	RN	3-Alkenyl-2-azetidinones as fatty acid amide hydrolase inhibitors. Bioorg Med Chem Lett. 2008 Jul 15;18(14):4163-7.
DMK42RU	RU	https://pubmed.ncbi.nlm.nih.gov/18547805

DMSN7GJ	DI	DMSN7GJ
DMSN7GJ	DN	(+/-)5-(biphenyl-4-yl)-3-hydroxypentanoic acid
DMSN7GJ	MI	TTXZ0KQ
DMSN7GJ	MN	Matrix metalloproteinase-12 (MMP-12)
DMSN7GJ	MT	DTT
DMSN7GJ	MA	Inhibitor
DMSN7GJ	RN	The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3.
DMSN7GJ	RU	https://pubmed.ncbi.nlm.nih.gov/19703773

DMSN7GJ	DI	DMSN7GJ
DMSN7GJ	DN	(+/-)5-(biphenyl-4-yl)-3-hydroxypentanoic acid
DMSN7GJ	MI	TTHY57M
DMSN7GJ	MN	Matrix metalloproteinase-13 (MMP-13)
DMSN7GJ	MT	DTT
DMSN7GJ	MA	Inhibitor
DMSN7GJ	RN	The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3.
DMSN7GJ	RU	https://pubmed.ncbi.nlm.nih.gov/19703773

DMSN7GJ	DI	DMSN7GJ
DMSN7GJ	DN	(+/-)5-(biphenyl-4-yl)-3-hydroxypentanoic acid
DMSN7GJ	MI	TTLM12X
DMSN7GJ	MN	Matrix metalloproteinase-2 (MMP-2)
DMSN7GJ	MT	DTT
DMSN7GJ	MA	Inhibitor
DMSN7GJ	RN	The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3.
DMSN7GJ	RU	https://pubmed.ncbi.nlm.nih.gov/19703773

DMSN7GJ	DI	DMSN7GJ
DMSN7GJ	DN	(+/-)5-(biphenyl-4-yl)-3-hydroxypentanoic acid
DMSN7GJ	MI	TT6X50U
DMSN7GJ	MN	Matrix metalloproteinase-9 (MMP-9)
DMSN7GJ	MT	DTT
DMSN7GJ	MA	Inhibitor
DMSN7GJ	RN	The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3.
DMSN7GJ	RU	https://pubmed.ncbi.nlm.nih.gov/19703773

DMSNWA6	DI	DMSNWA6
DMSNWA6	DN	(+/-)-5-amino-2-(mercaptomethyl)pentanoic acid
DMSNWA6	MI	TTP18AY
DMSNWA6	MN	Carboxypeptidase B2 (CPB2)
DMSNWA6	MT	DTT
DMSNWA6	MA	Inhibitor
DMSNWA6	RN	Discovery of potent &amp; selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis. J Med Chem. 2007 Nov 29;50(24):6095-103.
DMSNWA6	RU	https://pubmed.ncbi.nlm.nih.gov/17990866

DMQP5U9	DI	DMQP5U9
DMQP5U9	DN	(+/-)-5'-deoxy-4'-fluoro-5'-methylthio-DADMe-ImmH
DMQP5U9	MI	TTMCF1Y
DMQP5U9	MN	Purine nucleoside phosphorylase (PNP)
DMQP5U9	MT	DTT
DMQP5U9	MA	Inhibitor
DMQP5U9	RN	Immucillins in custom catalytic-site cavities. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5900-3.
DMQP5U9	RU	https://pubmed.ncbi.nlm.nih.gov/18778937

DM23W58	DI	DM23W58
DM23W58	DN	(+/-)-6-(2-chlorophenyl)cyclohex-3-enamine
DM23W58	MI	TTDIGC1
DM23W58	MN	Dipeptidyl peptidase 4 (DPP-4)
DM23W58	MT	DTT
DM23W58	MA	Inhibitor
DM23W58	RN	Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)... J Med Chem. 2006 Nov 2;49(22):6439-42.
DM23W58	RU	https://pubmed.ncbi.nlm.nih.gov/17064063

DMKWBY8	DI	DMKWBY8
DMKWBY8	DN	(+/-)-7-fluoro-2-(4-fluorophenyl)chroman-4-one
DMKWBY8	MI	TTGP7BY
DMKWBY8	MN	Monoamine oxidase type B (MAO-B)
DMKWBY8	MT	DTT
DMKWBY8	MA	Inhibitor
DMKWBY8	RN	A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9.
DMKWBY8	RU	https://pubmed.ncbi.nlm.nih.gov/20045650

DMYHV9P	DI	DMYHV9P
DMYHV9P	DN	(+/-)-7-fluoro-2-(4-methoxyphenyl)chroman-4-one
DMYHV9P	MI	TTGP7BY
DMYHV9P	MN	Monoamine oxidase type B (MAO-B)
DMYHV9P	MT	DTT
DMYHV9P	MA	Inhibitor
DMYHV9P	RN	A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9.
DMYHV9P	RU	https://pubmed.ncbi.nlm.nih.gov/20045650

DMJEBXA	DI	DMJEBXA
DMJEBXA	DN	(+/-)-7-fluoro-2-phenylchroman-4-one
DMJEBXA	MI	TTGP7BY
DMJEBXA	MN	Monoamine oxidase type B (MAO-B)
DMJEBXA	MT	DTT
DMJEBXA	MA	Inhibitor
DMJEBXA	RN	A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9.
DMJEBXA	RU	https://pubmed.ncbi.nlm.nih.gov/20045650

DM4H1JO	DI	DM4H1JO
DM4H1JO	DN	(+/-)-7-fluoro-2-p-tolylchroman-4-one
DM4H1JO	MI	TTGP7BY
DM4H1JO	MN	Monoamine oxidase type B (MAO-B)
DM4H1JO	MT	DTT
DM4H1JO	MA	Inhibitor
DM4H1JO	RN	A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9.
DM4H1JO	RU	https://pubmed.ncbi.nlm.nih.gov/20045650

DMYJGDK	DI	DMYJGDK
DMYJGDK	DN	(+/-)-7-methoxy-2-(4-methoxyphenyl)chroman-4-one
DMYJGDK	MI	TTSZLWK
DMYJGDK	MN	Aromatase (CYP19A1)
DMYJGDK	MT	DTT
DMYJGDK	MA	Inhibitor
DMYJGDK	RN	Synthesis and biological evaluation of (+/-)-abyssinone II and its analogues as aromatase inhibitors for chemoprevention of breast cancer. J Med Chem. 2007 Jun 14;50(12):2799-806.
DMYJGDK	RU	https://pubmed.ncbi.nlm.nih.gov/17511439

DMYJGDK	DI	DMYJGDK
DMYJGDK	DN	(+/-)-7-methoxy-2-(4-methoxyphenyl)chroman-4-one
DMYJGDK	MI	TTGP7BY
DMYJGDK	MN	Monoamine oxidase type B (MAO-B)
DMYJGDK	MT	DTT
DMYJGDK	MA	Inhibitor
DMYJGDK	RN	A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9.
DMYJGDK	RU	https://pubmed.ncbi.nlm.nih.gov/20045650

DMC0OKA	DI	DMC0OKA
DMC0OKA	DN	(+/-)-7-methoxy-2-phenylchroman-4-one
DMC0OKA	MI	TTSZLWK
DMC0OKA	MN	Aromatase (CYP19A1)
DMC0OKA	MT	DTT
DMC0OKA	MA	Inhibitor
DMC0OKA	RN	New 7,8-benzoflavanones as potent aromatase inhibitors: synthesis and biological evaluation. Bioorg Med Chem. 2008 Feb 1;16(3):1474-80.
DMC0OKA	RU	https://pubmed.ncbi.nlm.nih.gov/18042388

DMC0OKA	DI	DMC0OKA
DMC0OKA	DN	(+/-)-7-methoxy-2-phenylchroman-4-one
DMC0OKA	MI	TTGP7BY
DMC0OKA	MN	Monoamine oxidase type B (MAO-B)
DMC0OKA	MT	DTT
DMC0OKA	MA	Inhibitor
DMC0OKA	RN	A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9.
DMC0OKA	RU	https://pubmed.ncbi.nlm.nih.gov/20045650

DMJMTVQ	DI	DMJMTVQ
DMJMTVQ	DN	(+/-)-7-methoxy-2-p-tolylchroman-4-one
DMJMTVQ	MI	TTGP7BY
DMJMTVQ	MN	Monoamine oxidase type B (MAO-B)
DMJMTVQ	MT	DTT
DMJMTVQ	MA	Inhibitor
DMJMTVQ	RN	A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9.
DMJMTVQ	RU	https://pubmed.ncbi.nlm.nih.gov/20045650

DMI3URD	DI	DMI3URD
DMI3URD	DN	(+/-)-7-methyl-2-phenylchroman-4-one
DMI3URD	MI	TTGP7BY
DMI3URD	MN	Monoamine oxidase type B (MAO-B)
DMI3URD	MT	DTT
DMI3URD	MA	Inhibitor
DMI3URD	RN	A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9.
DMI3URD	RU	https://pubmed.ncbi.nlm.nih.gov/20045650

DMBN3WE	DI	DMBN3WE
DMBN3WE	DN	(+/-)-7-methyl-2-p-tolylchroman-4-one
DMBN3WE	MI	TTGP7BY
DMBN3WE	MN	Monoamine oxidase type B (MAO-B)
DMBN3WE	MT	DTT
DMBN3WE	MA	Inhibitor
DMBN3WE	RN	A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9.
DMBN3WE	RU	https://pubmed.ncbi.nlm.nih.gov/20045650

DMY3J0B	DI	DMY3J0B
DMY3J0B	DN	(+/-)-cis-2-CAMP
DMY3J0B	MI	TT6XFEU
DMY3J0B	MN	GABA(A) receptor rho1 (GABRR1)
DMY3J0B	MT	DTT
DMY3J0B	MA	Agonist
DMY3J0B	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 420).
DMY3J0B	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=420

DMY3J0B	DI	DMY3J0B
DMY3J0B	DN	(+/-)-cis-2-CAMP
DMY3J0B	MI	TTQMXLS
DMY3J0B	MN	GABA(A) receptor rho2 (GABRR2)
DMY3J0B	MT	DTT
DMY3J0B	MA	Agonist
DMY3J0B	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 421).
DMY3J0B	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=421

DMY3J0B	DI	DMY3J0B
DMY3J0B	DN	(+/-)-cis-2-CAMP
DMY3J0B	MI	TT4N6D8
DMY3J0B	MN	GABA(A) receptor rho3 (GABRR3)
DMY3J0B	MT	DTT
DMY3J0B	MA	Agonist
DMY3J0B	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 422).
DMY3J0B	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=422

DMAHO9M	DI	DMAHO9M
DMAHO9M	DN	(+/-)-cis-H2-PAT
DMAHO9M	MI	TTTIBOJ
DMAHO9M	MN	Histamine H1 receptor (H1R)
DMAHO9M	MT	DTT
DMAHO9M	MA	Antagonist
DMAHO9M	RN	A novel phenylaminotetralin radioligand reveals a subpopulation of histamine H(1) receptors. J Pharmacol Exp Ther. 2002 Jul;302(1):328-36.
DMAHO9M	RU	https://pubmed.ncbi.nlm.nih.gov/12065734

DMBSH5L	DI	DMBSH5L
DMBSH5L	DN	(+/-)-Daedalin A
DMBSH5L	MI	TTULVH8
DMBSH5L	MN	Tyrosinase (TYR)
DMBSH5L	MT	DTT
DMBSH5L	MA	Inhibitor
DMBSH5L	RN	Asymmetric syntheses of daedalin A and quercinol and their tyrosinase inhibitory activity. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1063-4.
DMBSH5L	RU	https://pubmed.ncbi.nlm.nih.gov/20036119

DM0L3GE	DI	DM0L3GE
DM0L3GE	DN	(+/-)-nantenine
DM0L3GE	MI	TTK8CXU
DM0L3GE	MN	5-HT 1B receptor (HTR1B)
DM0L3GE	MT	DTT
DM0L3GE	MA	Inhibitor
DM0L3GE	RN	Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
DM0L3GE	RU	https://pubmed.ncbi.nlm.nih.gov/19963380

DM0L3GE	DI	DM0L3GE
DM0L3GE	DN	(+/-)-nantenine
DM0L3GE	MI	TT6MSOK
DM0L3GE	MN	5-HT 1D receptor (HTR1D)
DM0L3GE	MT	DTT
DM0L3GE	MA	Inhibitor
DM0L3GE	RN	Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
DM0L3GE	RU	https://pubmed.ncbi.nlm.nih.gov/19963380

DM0L3GE	DI	DM0L3GE
DM0L3GE	DN	(+/-)-nantenine
DM0L3GE	MI	TTJQOD7
DM0L3GE	MN	5-HT 2A receptor (HTR2A)
DM0L3GE	MT	DTT
DM0L3GE	MA	Inhibitor
DM0L3GE	RN	Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
DM0L3GE	RU	https://pubmed.ncbi.nlm.nih.gov/19963380

DM0L3GE	DI	DM0L3GE
DM0L3GE	DN	(+/-)-nantenine
DM0L3GE	MI	TT0K1SC
DM0L3GE	MN	5-HT 2B receptor (HTR2B)
DM0L3GE	MT	DTT
DM0L3GE	MA	Inhibitor
DM0L3GE	RN	Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
DM0L3GE	RU	https://pubmed.ncbi.nlm.nih.gov/19963380

DM0L3GE	DI	DM0L3GE
DM0L3GE	DN	(+/-)-nantenine
DM0L3GE	MI	TTWJBZ5
DM0L3GE	MN	5-HT 2C receptor (HTR2C)
DM0L3GE	MT	DTT
DM0L3GE	MA	Inhibitor
DM0L3GE	RN	Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
DM0L3GE	RU	https://pubmed.ncbi.nlm.nih.gov/19963380

DM0L3GE	DI	DM0L3GE
DM0L3GE	DN	(+/-)-nantenine
DM0L3GE	MI	TTRUFDT
DM0L3GE	MN	5-HT 5A receptor (HTR5A)
DM0L3GE	MT	DTT
DM0L3GE	MA	Inhibitor
DM0L3GE	RN	Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
DM0L3GE	RU	https://pubmed.ncbi.nlm.nih.gov/19963380

DM0L3GE	DI	DM0L3GE
DM0L3GE	DN	(+/-)-nantenine
DM0L3GE	MI	TTJS8PY
DM0L3GE	MN	5-HT 6 receptor (HTR6)
DM0L3GE	MT	DTT
DM0L3GE	MA	Inhibitor
DM0L3GE	RN	Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
DM0L3GE	RU	https://pubmed.ncbi.nlm.nih.gov/19963380

DM0L3GE	DI	DM0L3GE
DM0L3GE	DN	(+/-)-nantenine
DM0L3GE	MI	TTO9X1H
DM0L3GE	MN	5-HT 7 receptor (HTR7)
DM0L3GE	MT	DTT
DM0L3GE	MA	Inhibitor
DM0L3GE	RN	Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
DM0L3GE	RU	https://pubmed.ncbi.nlm.nih.gov/19963380

DM0L3GE	DI	DM0L3GE
DM0L3GE	DN	(+/-)-nantenine
DM0L3GE	MI	TTNGILX
DM0L3GE	MN	Adrenergic receptor alpha-1A (ADRA1A)
DM0L3GE	MT	DTT
DM0L3GE	MA	Inhibitor
DM0L3GE	RN	Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
DM0L3GE	RU	https://pubmed.ncbi.nlm.nih.gov/19963380

DM0L3GE	DI	DM0L3GE
DM0L3GE	DN	(+/-)-nantenine
DM0L3GE	MI	TTBRKXS
DM0L3GE	MN	Adrenergic receptor alpha-1B (ADRA1B)
DM0L3GE	MT	DTT
DM0L3GE	MA	Inhibitor
DM0L3GE	RN	Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
DM0L3GE	RU	https://pubmed.ncbi.nlm.nih.gov/19963380

DM0L3GE	DI	DM0L3GE
DM0L3GE	DN	(+/-)-nantenine
DM0L3GE	MI	TT34BHT
DM0L3GE	MN	Adrenergic receptor alpha-1D (ADRA1D)
DM0L3GE	MT	DTT
DM0L3GE	MA	Inhibitor
DM0L3GE	RN	Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
DM0L3GE	RU	https://pubmed.ncbi.nlm.nih.gov/19963380

DM0L3GE	DI	DM0L3GE
DM0L3GE	DN	(+/-)-nantenine
DM0L3GE	MI	TTWG9A4
DM0L3GE	MN	Adrenergic receptor alpha-2A (ADRA2A)
DM0L3GE	MT	DTT
DM0L3GE	MA	Inhibitor
DM0L3GE	RN	Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
DM0L3GE	RU	https://pubmed.ncbi.nlm.nih.gov/19963380

DM0L3GE	DI	DM0L3GE
DM0L3GE	DN	(+/-)-nantenine
DM0L3GE	MI	TTWM4TY
DM0L3GE	MN	Adrenergic receptor alpha-2B (ADRA2B)
DM0L3GE	MT	DTT
DM0L3GE	MA	Inhibitor
DM0L3GE	RN	Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
DM0L3GE	RU	https://pubmed.ncbi.nlm.nih.gov/19963380

DM0L3GE	DI	DM0L3GE
DM0L3GE	DN	(+/-)-nantenine
DM0L3GE	MI	TT2NUT5
DM0L3GE	MN	Adrenergic receptor alpha-2C (ADRA2C)
DM0L3GE	MT	DTT
DM0L3GE	MA	Inhibitor
DM0L3GE	RN	Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
DM0L3GE	RU	https://pubmed.ncbi.nlm.nih.gov/19963380

DM0L3GE	DI	DM0L3GE
DM0L3GE	DN	(+/-)-nantenine
DM0L3GE	MI	TTR6W5O
DM0L3GE	MN	Adrenergic receptor beta-1 (ADRB1)
DM0L3GE	MT	DTT
DM0L3GE	MA	Inhibitor
DM0L3GE	RN	Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
DM0L3GE	RU	https://pubmed.ncbi.nlm.nih.gov/19963380

DM0L3GE	DI	DM0L3GE
DM0L3GE	DN	(+/-)-nantenine
DM0L3GE	MI	TTZFYLI
DM0L3GE	MN	Dopamine D1 receptor (D1R)
DM0L3GE	MT	DTT
DM0L3GE	MA	Inhibitor
DM0L3GE	RN	Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
DM0L3GE	RU	https://pubmed.ncbi.nlm.nih.gov/19963380

DM0L3GE	DI	DM0L3GE
DM0L3GE	DN	(+/-)-nantenine
DM0L3GE	MI	TTEX248
DM0L3GE	MN	Dopamine D2 receptor (D2R)
DM0L3GE	MT	DTT
DM0L3GE	MA	Inhibitor
DM0L3GE	RN	Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
DM0L3GE	RU	https://pubmed.ncbi.nlm.nih.gov/19963380

DM0L3GE	DI	DM0L3GE
DM0L3GE	DN	(+/-)-nantenine
DM0L3GE	MI	TT4C8EA
DM0L3GE	MN	Dopamine D3 receptor (D3R)
DM0L3GE	MT	DTT
DM0L3GE	MA	Inhibitor
DM0L3GE	RN	Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
DM0L3GE	RU	https://pubmed.ncbi.nlm.nih.gov/19963380

DM0L3GE	DI	DM0L3GE
DM0L3GE	DN	(+/-)-nantenine
DM0L3GE	MI	TTE0A2F
DM0L3GE	MN	Dopamine D4 receptor (D4R)
DM0L3GE	MT	DTT
DM0L3GE	MA	Inhibitor
DM0L3GE	RN	Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
DM0L3GE	RU	https://pubmed.ncbi.nlm.nih.gov/19963380

DM0L3GE	DI	DM0L3GE
DM0L3GE	DN	(+/-)-nantenine
DM0L3GE	MI	TTS2PH3
DM0L3GE	MN	Dopamine D5 receptor (D5R)
DM0L3GE	MT	DTT
DM0L3GE	MA	Inhibitor
DM0L3GE	RN	Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
DM0L3GE	RU	https://pubmed.ncbi.nlm.nih.gov/19963380

DM0L3GE	DI	DM0L3GE
DM0L3GE	DN	(+/-)-nantenine
DM0L3GE	MI	TTQHJ1K
DM0L3GE	MN	Histamine H2 receptor (H2R)
DM0L3GE	MT	DTT
DM0L3GE	MA	Inhibitor
DM0L3GE	RN	Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
DM0L3GE	RU	https://pubmed.ncbi.nlm.nih.gov/19963380

DM0L3GE	DI	DM0L3GE
DM0L3GE	DN	(+/-)-nantenine
DM0L3GE	MI	TTKWM86
DM0L3GE	MN	Opioid receptor mu (MOP)
DM0L3GE	MT	DTT
DM0L3GE	MA	Inhibitor
DM0L3GE	RN	Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
DM0L3GE	RU	https://pubmed.ncbi.nlm.nih.gov/19963380

DM0L3GE	DI	DM0L3GE
DM0L3GE	DN	(+/-)-nantenine
DM0L3GE	MI	TT3ROYC
DM0L3GE	MN	Serotonin transporter (SERT)
DM0L3GE	MT	DTT
DM0L3GE	MA	Inhibitor
DM0L3GE	RN	Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
DM0L3GE	RU	https://pubmed.ncbi.nlm.nih.gov/19963380

DM8023E	DI	DM8023E
DM8023E	DN	(+/-)-oxiran-2-ylmethyl (9Z)-hexadec-9-enoate
DM8023E	MI	TTDP1UC
DM8023E	MN	Fatty acid amide hydrolase (FAAH)
DM8023E	MT	DTT
DM8023E	MA	Inhibitor
DM8023E	RN	Structure-activity relationship of a series of inhibitors of monoacylglycerol hydrolysis--comparison with effects upon fatty acid amide hydrolase. J Med Chem. 2007 Oct 4;50(20):5012-23.
DM8023E	RU	https://pubmed.ncbi.nlm.nih.gov/17764163

DMI5R3E	DI	DMI5R3E
DMI5R3E	DN	(+/-)-oxiran-2-ylmethyl (9Z)-octadec-9-enoate
DMI5R3E	MI	TTDP1UC
DMI5R3E	MN	Fatty acid amide hydrolase (FAAH)
DMI5R3E	MT	DTT
DMI5R3E	MA	Inhibitor
DMI5R3E	RN	Structure-activity relationship of a series of inhibitors of monoacylglycerol hydrolysis--comparison with effects upon fatty acid amide hydrolase. J Med Chem. 2007 Oct 4;50(20):5012-23.
DMI5R3E	RU	https://pubmed.ncbi.nlm.nih.gov/17764163

DMFSZ8H	DI	DMFSZ8H
DMFSZ8H	DN	(+/-)-threo-3',4'-Dichloromethylphenidate amide
DMFSZ8H	MI	TTVBI8W
DMFSZ8H	MN	Dopamine transporter (DAT)
DMFSZ8H	MT	DTT
DMFSZ8H	MA	Inhibitor
DMFSZ8H	RN	Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38.
DMFSZ8H	RU	https://pubmed.ncbi.nlm.nih.gov/20846865

DM5MLZ0	DI	DM5MLZ0
DM5MLZ0	DN	(+/-)-threo-3',4'-Dichlororitalinol methyl ether
DM5MLZ0	MI	TTVBI8W
DM5MLZ0	MN	Dopamine transporter (DAT)
DM5MLZ0	MT	DTT
DM5MLZ0	MA	Inhibitor
DM5MLZ0	RN	Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38.
DM5MLZ0	RU	https://pubmed.ncbi.nlm.nih.gov/20846865

DM4UQBI	DI	DM4UQBI
DM4UQBI	DN	(+/-)-threo-3',5'-Dichloromethylphenidate
DM4UQBI	MI	TTVBI8W
DM4UQBI	MN	Dopamine transporter (DAT)
DM4UQBI	MT	DTT
DM4UQBI	MA	Inhibitor
DM4UQBI	RN	Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38.
DM4UQBI	RU	https://pubmed.ncbi.nlm.nih.gov/20846865

DMUWKNX	DI	DMUWKNX
DMUWKNX	DN	(+/-)-threo-3',5'-Dimethylmethylphenidate
DMUWKNX	MI	TTVBI8W
DMUWKNX	MN	Dopamine transporter (DAT)
DMUWKNX	MT	DTT
DMUWKNX	MA	Inhibitor
DMUWKNX	RN	Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38.
DMUWKNX	RU	https://pubmed.ncbi.nlm.nih.gov/20846865

DM3O4FI	DI	DM3O4FI
DM3O4FI	DN	(+/-)-threo-3-Fluororitalinol
DM3O4FI	MI	TTVBI8W
DM3O4FI	MN	Dopamine transporter (DAT)
DM3O4FI	MT	DTT
DM3O4FI	MA	Inhibitor
DM3O4FI	RN	Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38.
DM3O4FI	RU	https://pubmed.ncbi.nlm.nih.gov/20846865

DMU5T28	DI	DMU5T28
DMU5T28	DN	(+/-)-threo-4'-Ethylmethylphenidate
DMU5T28	MI	TTVBI8W
DMU5T28	MN	Dopamine transporter (DAT)
DMU5T28	MT	DTT
DMU5T28	MA	Inhibitor
DMU5T28	RN	Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38.
DMU5T28	RU	https://pubmed.ncbi.nlm.nih.gov/20846865

DM9TSW0	DI	DM9TSW0
DM9TSW0	DN	(+/-)-threo-Benzylphenidate
DM9TSW0	MI	TTVBI8W
DM9TSW0	MN	Dopamine transporter (DAT)
DM9TSW0	MT	DTT
DM9TSW0	MA	Inhibitor
DM9TSW0	RN	Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38.
DM9TSW0	RU	https://pubmed.ncbi.nlm.nih.gov/20846865

DMRZOVP	DI	DMRZOVP
DMRZOVP	DN	(+/-)-threo-Methylphenidate amide
DMRZOVP	MI	TTVBI8W
DMRZOVP	MN	Dopamine transporter (DAT)
DMRZOVP	MT	DTT
DMRZOVP	MA	Inhibitor
DMRZOVP	RN	Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38.
DMRZOVP	RU	https://pubmed.ncbi.nlm.nih.gov/20846865

DM80JOH	DI	DM80JOH
DM80JOH	DN	(+/-)-threo-N-(2-Chlorobenzyl)methylphenidate
DM80JOH	MI	TTVBI8W
DM80JOH	MN	Dopamine transporter (DAT)
DM80JOH	MT	DTT
DM80JOH	MA	Inhibitor
DM80JOH	RN	Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38.
DM80JOH	RU	https://pubmed.ncbi.nlm.nih.gov/20846865

DM6CWBO	DI	DM6CWBO
DM6CWBO	DN	(+/-)-threo-N-(2-Methylfuran)methylphenidate
DM6CWBO	MI	TTVBI8W
DM6CWBO	MN	Dopamine transporter (DAT)
DM6CWBO	MT	DTT
DM6CWBO	MA	Inhibitor
DM6CWBO	RN	Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38.
DM6CWBO	RU	https://pubmed.ncbi.nlm.nih.gov/20846865

DMN6ZX9	DI	DMN6ZX9
DMN6ZX9	DN	(+/-)-threo-N-(2-Methylpyridine)methylphenidate
DMN6ZX9	MI	TTVBI8W
DMN6ZX9	MN	Dopamine transporter (DAT)
DMN6ZX9	MT	DTT
DMN6ZX9	MA	Inhibitor
DMN6ZX9	RN	Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38.
DMN6ZX9	RU	https://pubmed.ncbi.nlm.nih.gov/20846865

DMWUGSV	DI	DMWUGSV
DMWUGSV	DN	(+/-)-threo-N-(2-Methylthiopene)methylphenidate
DMWUGSV	MI	TTVBI8W
DMWUGSV	MN	Dopamine transporter (DAT)
DMWUGSV	MT	DTT
DMWUGSV	MA	Inhibitor
DMWUGSV	RN	Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38.
DMWUGSV	RU	https://pubmed.ncbi.nlm.nih.gov/20846865

DM2WRED	DI	DM2WRED
DM2WRED	DN	(+/-)-threo-N-(2-Phenylethyl)methylphenidate
DM2WRED	MI	TTVBI8W
DM2WRED	MN	Dopamine transporter (DAT)
DM2WRED	MT	DTT
DM2WRED	MA	Inhibitor
DM2WRED	RN	Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38.
DM2WRED	RU	https://pubmed.ncbi.nlm.nih.gov/20846865

DM9Y3MT	DI	DM9Y3MT
DM9Y3MT	DN	(+/-)-threo-N-(2-Phenylethyl)ritalinol
DM9Y3MT	MI	TTVBI8W
DM9Y3MT	MN	Dopamine transporter (DAT)
DM9Y3MT	MT	DTT
DM9Y3MT	MA	Inhibitor
DM9Y3MT	RN	Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38.
DM9Y3MT	RU	https://pubmed.ncbi.nlm.nih.gov/20846865

DMU08WO	DI	DMU08WO
DMU08WO	DN	(+/-)-threo-N-(3-Chlorobenzyl)methylphenidate
DMU08WO	MI	TTVBI8W
DMU08WO	MN	Dopamine transporter (DAT)
DMU08WO	MT	DTT
DMU08WO	MA	Inhibitor
DMU08WO	RN	Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38.
DMU08WO	RU	https://pubmed.ncbi.nlm.nih.gov/20846865

DMHPE4L	DI	DMHPE4L
DMHPE4L	DN	(+/-)-threo-N-(3-Methylfuran)methylphenidate
DMHPE4L	MI	TTVBI8W
DMHPE4L	MN	Dopamine transporter (DAT)
DMHPE4L	MT	DTT
DMHPE4L	MA	Inhibitor
DMHPE4L	RN	Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38.
DMHPE4L	RU	https://pubmed.ncbi.nlm.nih.gov/20846865

DMDMTZK	DI	DMDMTZK
DMDMTZK	DN	(+/-)-threo-N-(3-Methylpyridine)methylphenidate
DMDMTZK	MI	TTVBI8W
DMDMTZK	MN	Dopamine transporter (DAT)
DMDMTZK	MT	DTT
DMDMTZK	MA	Inhibitor
DMDMTZK	RN	Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38.
DMDMTZK	RU	https://pubmed.ncbi.nlm.nih.gov/20846865

DMIJ7PC	DI	DMIJ7PC
DMIJ7PC	DN	(+/-)-threo-N-(3-Methylthiopene)methylphenidate
DMIJ7PC	MI	TTVBI8W
DMIJ7PC	MN	Dopamine transporter (DAT)
DMIJ7PC	MT	DTT
DMIJ7PC	MA	Inhibitor
DMIJ7PC	RN	Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38.
DMIJ7PC	RU	https://pubmed.ncbi.nlm.nih.gov/20846865

DMD926H	DI	DMD926H
DMD926H	DN	(+/-)-threo-N-(3-Phenylpropyl)methylphenidate
DMD926H	MI	TTVBI8W
DMD926H	MN	Dopamine transporter (DAT)
DMD926H	MT	DTT
DMD926H	MA	Inhibitor
DMD926H	RN	Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38.
DMD926H	RU	https://pubmed.ncbi.nlm.nih.gov/20846865

DMVP183	DI	DMVP183
DMVP183	DN	(+/-)-threo-N-(3-Phenylpropyl)ritalinol
DMVP183	MI	TTVBI8W
DMVP183	MN	Dopamine transporter (DAT)
DMVP183	MT	DTT
DMVP183	MA	Inhibitor
DMVP183	RN	Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38.
DMVP183	RU	https://pubmed.ncbi.nlm.nih.gov/20846865

DM3HWQY	DI	DM3HWQY
DM3HWQY	DN	(+/-)-threo-N-(4-Chlorobenzyl)methylphenidate
DM3HWQY	MI	TTVBI8W
DM3HWQY	MN	Dopamine transporter (DAT)
DM3HWQY	MT	DTT
DM3HWQY	MA	Inhibitor
DM3HWQY	RN	Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38.
DM3HWQY	RU	https://pubmed.ncbi.nlm.nih.gov/20846865

DMHIKD2	DI	DMHIKD2
DMHIKD2	DN	(+/-)-threo-N-(4-Methoxybenzyl)methylphenidate
DMHIKD2	MI	TTVBI8W
DMHIKD2	MN	Dopamine transporter (DAT)
DMHIKD2	MT	DTT
DMHIKD2	MA	Inhibitor
DMHIKD2	RN	Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38.
DMHIKD2	RU	https://pubmed.ncbi.nlm.nih.gov/20846865

DM9QIAL	DI	DM9QIAL
DM9QIAL	DN	(+/-)-threo-N-(4-Methylpyridine)methylphenidate
DM9QIAL	MI	TTVBI8W
DM9QIAL	MN	Dopamine transporter (DAT)
DM9QIAL	MT	DTT
DM9QIAL	MA	Inhibitor
DM9QIAL	RN	Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38.
DM9QIAL	RU	https://pubmed.ncbi.nlm.nih.gov/20846865

DMB3JY8	DI	DMB3JY8
DMB3JY8	DN	(+/-)-threo-N-(4-Nitrobenzyl)methylphenidate
DMB3JY8	MI	TTVBI8W
DMB3JY8	MN	Dopamine transporter (DAT)
DMB3JY8	MT	DTT
DMB3JY8	MA	Inhibitor
DMB3JY8	RN	Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38.
DMB3JY8	RU	https://pubmed.ncbi.nlm.nih.gov/20846865

DMK6IJW	DI	DMK6IJW
DMK6IJW	DN	(+/-)-threo-N-(4-Phenylbutyl)methylphenidate
DMK6IJW	MI	TTVBI8W
DMK6IJW	MN	Dopamine transporter (DAT)
DMK6IJW	MT	DTT
DMK6IJW	MA	Inhibitor
DMK6IJW	RN	Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38.
DMK6IJW	RU	https://pubmed.ncbi.nlm.nih.gov/20846865

DMG3FA1	DI	DMG3FA1
DMG3FA1	DN	(+/-)-threo-N-(4-Phenylbutyl)ritalinol
DMG3FA1	MI	TTVBI8W
DMG3FA1	MN	Dopamine transporter (DAT)
DMG3FA1	MT	DTT
DMG3FA1	MA	Inhibitor
DMG3FA1	RN	Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38.
DMG3FA1	RU	https://pubmed.ncbi.nlm.nih.gov/20846865

DMHNQO9	DI	DMHNQO9
DMHNQO9	DN	(+/-)-threo-N-(5-Phenylpentyl)methylphenidate
DMHNQO9	MI	TTVBI8W
DMHNQO9	MN	Dopamine transporter (DAT)
DMHNQO9	MT	DTT
DMHNQO9	MA	Inhibitor
DMHNQO9	RN	Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38.
DMHNQO9	RU	https://pubmed.ncbi.nlm.nih.gov/20846865

DMG1K5H	DI	DMG1K5H
DMG1K5H	DN	(+/-)-threo-N-(6-Phenylhexyl)methylphenidate
DMG1K5H	MI	TTVBI8W
DMG1K5H	MN	Dopamine transporter (DAT)
DMG1K5H	MT	DTT
DMG1K5H	MA	Inhibitor
DMG1K5H	RN	Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38.
DMG1K5H	RU	https://pubmed.ncbi.nlm.nih.gov/20846865

DMYNO71	DI	DMYNO71
DMYNO71	DN	(+/-)-threo-N-Allylmethylphenidate
DMYNO71	MI	TTVBI8W
DMYNO71	MN	Dopamine transporter (DAT)
DMYNO71	MT	DTT
DMYNO71	MA	Inhibitor
DMYNO71	RN	Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38.
DMYNO71	RU	https://pubmed.ncbi.nlm.nih.gov/20846865

DMOJXCK	DI	DMOJXCK
DMOJXCK	DN	(+/-)-threo-N-Benzyl-3',4'-dichlororitalinol
DMOJXCK	MI	TTVBI8W
DMOJXCK	MN	Dopamine transporter (DAT)
DMOJXCK	MT	DTT
DMOJXCK	MA	Inhibitor
DMOJXCK	RN	Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38.
DMOJXCK	RU	https://pubmed.ncbi.nlm.nih.gov/20846865

DM15LE0	DI	DM15LE0
DM15LE0	DN	(+/-)-threo-N-Benzyl-3'-chloromethylphenidate
DM15LE0	MI	TTVBI8W
DM15LE0	MN	Dopamine transporter (DAT)
DM15LE0	MT	DTT
DM15LE0	MA	Inhibitor
DM15LE0	RN	Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38.
DM15LE0	RU	https://pubmed.ncbi.nlm.nih.gov/20846865

DMUACDH	DI	DMUACDH
DMUACDH	DN	(+/-)-threo-N-Benzylmethylphenidate amide
DMUACDH	MI	TTVBI8W
DMUACDH	MN	Dopamine transporter (DAT)
DMUACDH	MT	DTT
DMUACDH	MA	Inhibitor
DMUACDH	RN	Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38.
DMUACDH	RU	https://pubmed.ncbi.nlm.nih.gov/20846865

DM6D18M	DI	DM6D18M
DM6D18M	DN	(+/-)-threo-N-Methyl-30-methylmethylphenidate
DM6D18M	MI	TTVBI8W
DM6D18M	MN	Dopamine transporter (DAT)
DM6D18M	MT	DTT
DM6D18M	MA	Inhibitor
DM6D18M	RN	Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38.
DM6D18M	RU	https://pubmed.ncbi.nlm.nih.gov/20846865

DMYE0MZ	DI	DMYE0MZ
DMYE0MZ	DN	(+/-)-threo-N-Propargylmethylphenidate
DMYE0MZ	MI	TTVBI8W
DMYE0MZ	MN	Dopamine transporter (DAT)
DMYE0MZ	MT	DTT
DMYE0MZ	MA	Inhibitor
DMYE0MZ	RN	Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38.
DMYE0MZ	RU	https://pubmed.ncbi.nlm.nih.gov/20846865

DMM2QOX	DI	DMM2QOX
DMM2QOX	DN	(+/-)-TRANS-U-50488 METHANESULFONATE
DMM2QOX	MI	TTKWM86
DMM2QOX	MN	Opioid receptor mu (MOP)
DMM2QOX	MT	DTT
DMM2QOX	MA	Inhibitor
DMM2QOX	RN	Akuammine and dihydroakuammine, two indolomonoterpene alkaloids displaying affinity for opioid receptors. J Nat Prod. 1992 Mar;55(3):380-4.
DMM2QOX	RU	https://pubmed.ncbi.nlm.nih.gov/1317407

DMDK59X	DI	DMDK59X
DMDK59X	DN	(1,1-Difluoro-pentadecyl)-phosphonic acid
DMDK59X	MI	TTQ6S1K
DMDK59X	MN	Lysophosphatidic acid receptor 1 (LPAR1)
DMDK59X	MT	DTT
DMDK59X	MA	Inhibitor
DMDK59X	RN	Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30.
DMDK59X	RU	https://pubmed.ncbi.nlm.nih.gov/16033271

DMF6WHC	DI	DMF6WHC
DMF6WHC	DN	(1,2,3,4-Tetrahydro-isoquinolin-3-yl)-methanol
DMF6WHC	MI	TTWG9A4
DMF6WHC	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMF6WHC	MT	DTT
DMF6WHC	MA	Inhibitor
DMF6WHC	RN	3,7-Disubstituted-1,2,3,4-tetrahydroisoquinolines display remarkable potency and selectivity as inhibitors of phenylethanolamine N-methyltransferas... J Med Chem. 1999 Jun 3;42(11):1982-90.
DMF6WHC	RU	https://pubmed.ncbi.nlm.nih.gov/10354406

DMF6WHC	DI	DMF6WHC
DMF6WHC	DN	(1,2,3,4-Tetrahydro-isoquinolin-3-yl)-methanol
DMF6WHC	MI	TTWM4TY
DMF6WHC	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMF6WHC	MT	DTT
DMF6WHC	MA	Inhibitor
DMF6WHC	RN	3,7-Disubstituted-1,2,3,4-tetrahydroisoquinolines display remarkable potency and selectivity as inhibitors of phenylethanolamine N-methyltransferas... J Med Chem. 1999 Jun 3;42(11):1982-90.
DMF6WHC	RU	https://pubmed.ncbi.nlm.nih.gov/10354406

DMF6WHC	DI	DMF6WHC
DMF6WHC	DN	(1,2,3,4-Tetrahydro-isoquinolin-3-yl)-methanol
DMF6WHC	MI	TT2NUT5
DMF6WHC	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMF6WHC	MT	DTT
DMF6WHC	MA	Inhibitor
DMF6WHC	RN	3,7-Disubstituted-1,2,3,4-tetrahydroisoquinolines display remarkable potency and selectivity as inhibitors of phenylethanolamine N-methyltransferas... J Med Chem. 1999 Jun 3;42(11):1982-90.
DMF6WHC	RU	https://pubmed.ncbi.nlm.nih.gov/10354406

DM2J9RI	DI	DM2J9RI
DM2J9RI	DN	(10H-phenothiazin-10-yl)(m-tolyl)methanone
DM2J9RI	MI	TTEB0GD
DM2J9RI	MN	Cholinesterase (BCHE)
DM2J9RI	MT	DTT
DM2J9RI	MA	Inhibitor
DM2J9RI	RN	Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. Bioorg Med Chem. 2007 Oct 1;15(19):6367-78.
DM2J9RI	RU	https://pubmed.ncbi.nlm.nih.gov/17681768

DM8BKTV	DI	DM8BKTV
DM8BKTV	DN	(10H-phenothiazin-10-yl)(o-tolyl)methanone
DM8BKTV	MI	TTEB0GD
DM8BKTV	MN	Cholinesterase (BCHE)
DM8BKTV	MT	DTT
DM8BKTV	MA	Inhibitor
DM8BKTV	RN	Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. Bioorg Med Chem. 2007 Oct 1;15(19):6367-78.
DM8BKTV	RU	https://pubmed.ncbi.nlm.nih.gov/17681768

DMT3GAD	DI	DMT3GAD
DMT3GAD	DN	(10H-phenothiazin-10-yl)(phenyl)methanone
DMT3GAD	MI	TTEB0GD
DMT3GAD	MN	Cholinesterase (BCHE)
DMT3GAD	MT	DTT
DMT3GAD	MA	Inhibitor
DMT3GAD	RN	Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. Bioorg Med Chem. 2007 Oct 1;15(19):6367-78.
DMT3GAD	RU	https://pubmed.ncbi.nlm.nih.gov/17681768

DMRQ0ZF	DI	DMRQ0ZF
DMRQ0ZF	DN	(10H-phenothiazin-10-yl)(p-tolyl)methanone
DMRQ0ZF	MI	TTEB0GD
DMRQ0ZF	MN	Cholinesterase (BCHE)
DMRQ0ZF	MT	DTT
DMRQ0ZF	MA	Inhibitor
DMRQ0ZF	RN	Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. Bioorg Med Chem. 2007 Oct 1;15(19):6367-78.
DMRQ0ZF	RU	https://pubmed.ncbi.nlm.nih.gov/17681768

DMVTLF9	DI	DMVTLF9
DMVTLF9	DN	(10r)-10-Formyl-5,8,10-Trideazafolic Acid
DMVTLF9	MI	TTEXB9Z
DMVTLF9	MN	Glycinamide ribonucleotide formyltransferase (GART)
DMVTLF9	MT	DTT
DMVTLF9	MA	Inhibitor
DMVTLF9	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMVTLF9	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMTPQ84	DI	DMTPQ84
DMTPQ84	DN	(11-BETA)-11,21-DIHYDROXY-PREGN-4-ENE-3,20-DIONE
DMTPQ84	MI	TTN7BL9
DMTPQ84	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMTPQ84	MT	DTT
DMTPQ84	MA	Inhibitor
DMTPQ84	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMTPQ84	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMTPQ84	DI	DMTPQ84
DMTPQ84	DN	(11-BETA)-11,21-DIHYDROXY-PREGN-4-ENE-3,20-DIONE
DMTPQ84	MI	DE4LYSA
DMTPQ84	MN	Cytochrome P450 3A4 (CYP3A4)
DMTPQ84	MT	DME
DMTPQ84	MA	Metabolism
DMTPQ84	RN	Studies on pharmacokinetic drug interaction potential of vinpocetine. Medicines (Basel). 2015 Jun 5;2(2):93-105.
DMTPQ84	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28930203

DMTPQ84	DI	DMTPQ84
DMTPQ84	DN	(11-BETA)-11,21-DIHYDROXY-PREGN-4-ENE-3,20-DIONE
DMTPQ84	MI	TTOZRK6
DMTPQ84	MN	Glucocorticoid receptor messenger RNA (GCR mRNA)
DMTPQ84	MT	DTT
DMTPQ84	MA	Agonist
DMTPQ84	RN	Functional probing of the human glucocorticoid receptor steroid-interacting surface by site-directed mutagenesis. Gln-642 plays an important role in steroid recognition and binding. J Biol Chem. 2000Jun 23;275(25):19041-9.
DMTPQ84	RU	https://pubmed.ncbi.nlm.nih.gov/10747884

DMTPQ84	DI	DMTPQ84
DMTPQ84	DN	(11-BETA)-11,21-DIHYDROXY-PREGN-4-ENE-3,20-DIONE
DMTPQ84	MI	TT26PHO
DMTPQ84	MN	Mineralocorticoid receptor  (MR)
DMTPQ84	MT	DTT
DMTPQ84	MA	Inhibitor
DMTPQ84	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMTPQ84	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMTPQ84	DI	DMTPQ84
DMTPQ84	DN	(11-BETA)-11,21-DIHYDROXY-PREGN-4-ENE-3,20-DIONE
DMTPQ84	MI	DTUGYRD
DMTPQ84	MN	P-glycoprotein 1 (ABCB1)
DMTPQ84	MT	DTP
DMTPQ84	MA	Substrate
DMTPQ84	RN	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
DMTPQ84	RU	http://www.ncbi.nlm.nih.gov/pubmed/7914405

DMZ5YMH	DI	DMZ5YMH
DMZ5YMH	DN	(11E)-OCTADEC-11-ENOIC ACID
DMZ5YMH	MI	TT2JWF6
DMZ5YMH	MN	Peroxisome proliferator-activated receptor delta (PPARD)
DMZ5YMH	MT	DTT
DMZ5YMH	MA	Inhibitor
DMZ5YMH	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMZ5YMH	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMSUPVE	DI	DMSUPVE
DMSUPVE	DN	(11H-Dibenzo[b,e][1,4]dioxepin-2-yl)-acetic acid
DMSUPVE	MI	TT8NGED
DMSUPVE	MN	Prostaglandin G/H synthase 1 (COX-1)
DMSUPVE	MT	DTT
DMSUPVE	MA	Inhibitor
DMSUPVE	RN	Synthesis and antiinflammatory/analgesic activities of 11H-dibenzo[b, e,][1,4]dioxepinacetic acids. J Med Chem. 1986 Aug;29(8):1436-41.
DMSUPVE	RU	https://pubmed.ncbi.nlm.nih.gov/3488405

DMSUPVE	DI	DMSUPVE
DMSUPVE	DN	(11H-Dibenzo[b,e][1,4]dioxepin-2-yl)-acetic acid
DMSUPVE	MI	TTVKILB
DMSUPVE	MN	Prostaglandin G/H synthase 2 (COX-2)
DMSUPVE	MT	DTT
DMSUPVE	MA	Inhibitor
DMSUPVE	RN	Synthesis and antiinflammatory/analgesic activities of 11H-dibenzo[b, e,][1,4]dioxepinacetic acids. J Med Chem. 1986 Aug;29(8):1436-41.
DMSUPVE	RU	https://pubmed.ncbi.nlm.nih.gov/3488405

DM5ZTXL	DI	DM5ZTXL
DM5ZTXL	DN	(11H-Dibenzo[b,e][1,4]dioxepin-7-yl)-acetic acid
DM5ZTXL	MI	TT8NGED
DM5ZTXL	MN	Prostaglandin G/H synthase 1 (COX-1)
DM5ZTXL	MT	DTT
DM5ZTXL	MA	Inhibitor
DM5ZTXL	RN	Synthesis and antiinflammatory/analgesic activities of 11H-dibenzo[b, e,][1,4]dioxepinacetic acids. J Med Chem. 1986 Aug;29(8):1436-41.
DM5ZTXL	RU	https://pubmed.ncbi.nlm.nih.gov/3488405

DM5ZTXL	DI	DM5ZTXL
DM5ZTXL	DN	(11H-Dibenzo[b,e][1,4]dioxepin-7-yl)-acetic acid
DM5ZTXL	MI	TTVKILB
DM5ZTXL	MN	Prostaglandin G/H synthase 2 (COX-2)
DM5ZTXL	MT	DTT
DM5ZTXL	MA	Inhibitor
DM5ZTXL	RN	Synthesis and antiinflammatory/analgesic activities of 11H-dibenzo[b, e,][1,4]dioxepinacetic acids. J Med Chem. 1986 Aug;29(8):1436-41.
DM5ZTXL	RU	https://pubmed.ncbi.nlm.nih.gov/3488405

DMBY623	DI	DMBY623
DMBY623	DN	(11H-Dibenzo[b,e][1,4]dioxepin-8-yl)-acetic acid
DMBY623	MI	TT8NGED
DMBY623	MN	Prostaglandin G/H synthase 1 (COX-1)
DMBY623	MT	DTT
DMBY623	MA	Inhibitor
DMBY623	RN	Synthesis and antiinflammatory/analgesic activities of 11H-dibenzo[b, e,][1,4]dioxepinacetic acids. J Med Chem. 1986 Aug;29(8):1436-41.
DMBY623	RU	https://pubmed.ncbi.nlm.nih.gov/3488405

DMBY623	DI	DMBY623
DMBY623	DN	(11H-Dibenzo[b,e][1,4]dioxepin-8-yl)-acetic acid
DMBY623	MI	TTVKILB
DMBY623	MN	Prostaglandin G/H synthase 2 (COX-2)
DMBY623	MT	DTT
DMBY623	MA	Inhibitor
DMBY623	RN	Synthesis and antiinflammatory/analgesic activities of 11H-dibenzo[b, e,][1,4]dioxepinacetic acids. J Med Chem. 1986 Aug;29(8):1436-41.
DMBY623	RU	https://pubmed.ncbi.nlm.nih.gov/3488405

DMJNLQ5	DI	DMJNLQ5
DMJNLQ5	DN	(12E,20Z,18S)-8-hydroxyvariabilin
DMJNLQ5	MI	TTZ8EM9
DMJNLQ5	MN	Glycine receptor (GlyR)
DMJNLQ5	MT	DTT
DMJNLQ5	MA	Inhibitor
DMJNLQ5	RN	Ircinialactams: subunit-selective glycine receptor modulators from Australian sponges of the family Irciniidae. Bioorg Med Chem. 2010 Apr 15;18(8):2912-9.
DMJNLQ5	RU	https://pubmed.ncbi.nlm.nih.gov/20346682

DMXD8H1	DI	DMXD8H1
DMXD8H1	DN	(1-Amino-2-phenyl-ethyl)-phosphinic acid
DMXD8H1	MI	TTPHMWB
DMXD8H1	MN	Aminopeptidase N (ANPEP)
DMXD8H1	MT	DTT
DMXD8H1	MA	Inhibitor
DMXD8H1	RN	Design of the first highly potent and selective aminopeptidase N (EC 3.4.11.2) inhibitor. Bioorg Med Chem Lett. 1999 Jun 7;9(11):1511-6.
DMXD8H1	RU	https://pubmed.ncbi.nlm.nih.gov/10386926

DMNUO79	DI	DMNUO79
DMNUO79	DN	(1-Amino-3-methyl-butyl)-phosphinic acid
DMNUO79	MI	TTPHMWB
DMNUO79	MN	Aminopeptidase N (ANPEP)
DMNUO79	MT	DTT
DMNUO79	MA	Inhibitor
DMNUO79	RN	Design of the first highly potent and selective aminopeptidase N (EC 3.4.11.2) inhibitor. Bioorg Med Chem Lett. 1999 Jun 7;9(11):1511-6.
DMNUO79	RU	https://pubmed.ncbi.nlm.nih.gov/10386926

DMJL8QZ	DI	DMJL8QZ
DMJL8QZ	DN	(1-Amino-3-methylsulfanyl-propyl)-phosphinic acid
DMJL8QZ	MI	TTPHMWB
DMJL8QZ	MN	Aminopeptidase N (ANPEP)
DMJL8QZ	MT	DTT
DMJL8QZ	MA	Inhibitor
DMJL8QZ	RN	Design of the first highly potent and selective aminopeptidase N (EC 3.4.11.2) inhibitor. Bioorg Med Chem Lett. 1999 Jun 7;9(11):1511-6.
DMJL8QZ	RU	https://pubmed.ncbi.nlm.nih.gov/10386926

DMXD697	DI	DMXD697
DMXD697	DN	(1-Amino-3-phenyl-propyl)-phosphinic acid
DMXD697	MI	TTPHMWB
DMXD697	MN	Aminopeptidase N (ANPEP)
DMXD697	MT	DTT
DMXD697	MA	Inhibitor
DMXD697	RN	Design of the first highly potent and selective aminopeptidase N (EC 3.4.11.2) inhibitor. Bioorg Med Chem Lett. 1999 Jun 7;9(11):1511-6.
DMXD697	RU	https://pubmed.ncbi.nlm.nih.gov/10386926

DMUACZF	DI	DMUACZF
DMUACZF	DN	(1-Amino-ethyl)-phosphinic acid
DMUACZF	MI	TTPHMWB
DMUACZF	MN	Aminopeptidase N (ANPEP)
DMUACZF	MT	DTT
DMUACZF	MA	Inhibitor
DMUACZF	RN	Design of the first highly potent and selective aminopeptidase N (EC 3.4.11.2) inhibitor. Bioorg Med Chem Lett. 1999 Jun 7;9(11):1511-6.
DMUACZF	RU	https://pubmed.ncbi.nlm.nih.gov/10386926

DMNIP7J	DI	DMNIP7J
DMNIP7J	DN	(1-Benzyl-1H-indazol-5-yl)-quinazolin-4-yl-amine
DMNIP7J	MI	TT6EO5L
DMNIP7J	MN	Erbb2 tyrosine kinase receptor (HER2)
DMNIP7J	MT	DTT
DMNIP7J	MA	Inhibitor
DMNIP7J	RN	Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2. Bioorg Med Chem Lett. 2001 Jun 4;11(11):1401-5.
DMNIP7J	RU	https://pubmed.ncbi.nlm.nih.gov/11378364

DM0SCW9	DI	DM0SCW9
DM0SCW9	DN	(1-Benzyl-1H-indol-5-yl)-quinazolin-4-yl-amine
DM0SCW9	MI	TTR5TV4
DM0SCW9	MN	ERBB2 messenger RNA (HER2 mRNA)
DM0SCW9	MT	DTT
DM0SCW9	MA	Inhibitor
DM0SCW9	RN	Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2. Bioorg Med Chem Lett. 2001 Jun 4;11(11):1401-5.
DM0SCW9	RU	https://pubmed.ncbi.nlm.nih.gov/11378364

DM0SCW9	DI	DM0SCW9
DM0SCW9	DN	(1-Benzyl-1H-indol-5-yl)-quinazolin-4-yl-amine
DM0SCW9	MI	TT6EO5L
DM0SCW9	MN	Erbb2 tyrosine kinase receptor (HER2)
DM0SCW9	MT	DTT
DM0SCW9	MA	Inhibitor
DM0SCW9	RN	Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2. Bioorg Med Chem Lett. 2001 Jun 4;11(11):1401-5.
DM0SCW9	RU	https://pubmed.ncbi.nlm.nih.gov/11378364

DMWK3RO	DI	DMWK3RO
DMWK3RO	DN	(1-Benzyl-2-oxo-ethyl)-carbamic acid benzyl ester
DMWK3RO	MI	TTG5QB7
DMWK3RO	MN	Calpain-2 (CAPN2)
DMWK3RO	MT	DTT
DMWK3RO	MA	Inhibitor
DMWK3RO	RN	Alpha-diketone and alpha-keto ester derivatives of N-protected amino acids and peptides as novel inhibitors of cysteine and serine proteinases. J Med Chem. 1990 Jan;33(1):11-3.
DMWK3RO	RU	https://pubmed.ncbi.nlm.nih.gov/2296008

DMPKM9B	DI	DMPKM9B
DMPKM9B	DN	(1H-Benzoimidazol-5-yl)-(1H-imidazol-2-yl)-amine
DMPKM9B	MI	TTWG9A4
DMPKM9B	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMPKM9B	MT	DTT
DMPKM9B	MA	Inhibitor
DMPKM9B	RN	Synthesis and evaluation of 2-(arylamino)imidazoles as alpha 2-adrenergic agonists. J Med Chem. 1997 Jan 3;40(1):18-23.
DMPKM9B	RU	https://pubmed.ncbi.nlm.nih.gov/9016324

DMPKM9B	DI	DMPKM9B
DMPKM9B	DN	(1H-Benzoimidazol-5-yl)-(1H-imidazol-2-yl)-amine
DMPKM9B	MI	TT2NUT5
DMPKM9B	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMPKM9B	MT	DTT
DMPKM9B	MA	Inhibitor
DMPKM9B	RN	Synthesis and evaluation of 2-(arylamino)imidazoles as alpha 2-adrenergic agonists. J Med Chem. 1997 Jan 3;40(1):18-23.
DMPKM9B	RU	https://pubmed.ncbi.nlm.nih.gov/9016324

DM4FSTL	DI	DM4FSTL
DM4FSTL	DN	(1H-Imidazo[4,5-c]quinolin-4-yl)-phenyl-amine HCl
DM4FSTL	MI	TTK25J1
DM4FSTL	MN	Adenosine A1 receptor (ADORA1)
DM4FSTL	MT	DTT
DM4FSTL	MA	Inhibitor
DM4FSTL	RN	1H-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists. J Med Chem. 1991 Mar;34(3):1202-6.
DM4FSTL	RU	https://pubmed.ncbi.nlm.nih.gov/2002461

DM4FSTL	DI	DM4FSTL
DM4FSTL	DN	(1H-Imidazo[4,5-c]quinolin-4-yl)-phenyl-amine HCl
DM4FSTL	MI	TTM2AOE
DM4FSTL	MN	Adenosine A2a receptor (ADORA2A)
DM4FSTL	MT	DTT
DM4FSTL	MA	Inhibitor
DM4FSTL	RN	1H-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists. J Med Chem. 1991 Mar;34(3):1202-6.
DM4FSTL	RU	https://pubmed.ncbi.nlm.nih.gov/2002461

DM4FSTL	DI	DM4FSTL
DM4FSTL	DN	(1H-Imidazo[4,5-c]quinolin-4-yl)-phenyl-amine HCl
DM4FSTL	MI	TTNE7KG
DM4FSTL	MN	Adenosine A2b receptor (ADORA2B)
DM4FSTL	MT	DTT
DM4FSTL	MA	Inhibitor
DM4FSTL	RN	1H-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists. J Med Chem. 1991 Mar;34(3):1202-6.
DM4FSTL	RU	https://pubmed.ncbi.nlm.nih.gov/2002461

DMRDHL2	DI	DMRDHL2
DMRDHL2	DN	(1H-Imidazol-2-yl)-quinoxalin-6-yl-amine
DMRDHL2	MI	TTWG9A4
DMRDHL2	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMRDHL2	MT	DTT
DMRDHL2	MA	Inhibitor
DMRDHL2	RN	Synthesis and evaluation of 2-(arylamino)imidazoles as alpha 2-adrenergic agonists. J Med Chem. 1997 Jan 3;40(1):18-23.
DMRDHL2	RU	https://pubmed.ncbi.nlm.nih.gov/9016324

DMRDHL2	DI	DMRDHL2
DMRDHL2	DN	(1H-Imidazol-2-yl)-quinoxalin-6-yl-amine
DMRDHL2	MI	TT2NUT5
DMRDHL2	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMRDHL2	MT	DTT
DMRDHL2	MA	Inhibitor
DMRDHL2	RN	Synthesis and evaluation of 2-(arylamino)imidazoles as alpha 2-adrenergic agonists. J Med Chem. 1997 Jan 3;40(1):18-23.
DMRDHL2	RU	https://pubmed.ncbi.nlm.nih.gov/9016324

DM21CXZ	DI	DM21CXZ
DM21CXZ	DN	(1H-indol-2-yl)(5-methoxy-1H-indol-2-yl)methanone
DM21CXZ	MI	TTGJCWZ
DM21CXZ	MN	Fms-like tyrosine kinase 3 (FLT-3)
DM21CXZ	MT	DTT
DM21CXZ	MA	Inhibitor
DM21CXZ	RN	Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15.
DM21CXZ	RU	https://pubmed.ncbi.nlm.nih.gov/16722630

DM21CXZ	DI	DM21CXZ
DM21CXZ	DN	(1H-indol-2-yl)(5-methoxy-1H-indol-2-yl)methanone
DM21CXZ	MI	TT8FYO9
DM21CXZ	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DM21CXZ	MT	DTT
DM21CXZ	MA	Inhibitor
DM21CXZ	RN	Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15.
DM21CXZ	RU	https://pubmed.ncbi.nlm.nih.gov/16722630

DM21CXZ	DI	DM21CXZ
DM21CXZ	DN	(1H-indol-2-yl)(5-methoxy-1H-indol-2-yl)methanone
DM21CXZ	MI	TTI7421
DM21CXZ	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM21CXZ	MT	DTT
DM21CXZ	MA	Inhibitor
DM21CXZ	RN	Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15.
DM21CXZ	RU	https://pubmed.ncbi.nlm.nih.gov/16722630

DM94XJ2	DI	DM94XJ2
DM94XJ2	DN	(1H-indol-2-yl)(5-phenoxy-1H-indol-2-yl)methanone
DM94XJ2	MI	TTGJCWZ
DM94XJ2	MN	Fms-like tyrosine kinase 3 (FLT-3)
DM94XJ2	MT	DTT
DM94XJ2	MA	Inhibitor
DM94XJ2	RN	Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15.
DM94XJ2	RU	https://pubmed.ncbi.nlm.nih.gov/16722630

DM94XJ2	DI	DM94XJ2
DM94XJ2	DN	(1H-indol-2-yl)(5-phenoxy-1H-indol-2-yl)methanone
DM94XJ2	MI	TT8FYO9
DM94XJ2	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DM94XJ2	MT	DTT
DM94XJ2	MA	Inhibitor
DM94XJ2	RN	Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15.
DM94XJ2	RU	https://pubmed.ncbi.nlm.nih.gov/16722630

DM94XJ2	DI	DM94XJ2
DM94XJ2	DN	(1H-indol-2-yl)(5-phenoxy-1H-indol-2-yl)methanone
DM94XJ2	MI	TTI7421
DM94XJ2	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM94XJ2	MT	DTT
DM94XJ2	MA	Inhibitor
DM94XJ2	RN	Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15.
DM94XJ2	RU	https://pubmed.ncbi.nlm.nih.gov/16722630

DM7KDNM	DI	DM7KDNM
DM7KDNM	DN	(1H-indol-2-yl)(6-methoxy-1H-indol-2-yl)methanone
DM7KDNM	MI	TTGJCWZ
DM7KDNM	MN	Fms-like tyrosine kinase 3 (FLT-3)
DM7KDNM	MT	DTT
DM7KDNM	MA	Inhibitor
DM7KDNM	RN	Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15.
DM7KDNM	RU	https://pubmed.ncbi.nlm.nih.gov/16722630

DM7KDNM	DI	DM7KDNM
DM7KDNM	DN	(1H-indol-2-yl)(6-methoxy-1H-indol-2-yl)methanone
DM7KDNM	MI	TT8FYO9
DM7KDNM	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DM7KDNM	MT	DTT
DM7KDNM	MA	Inhibitor
DM7KDNM	RN	Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15.
DM7KDNM	RU	https://pubmed.ncbi.nlm.nih.gov/16722630

DM7KDNM	DI	DM7KDNM
DM7KDNM	DN	(1H-indol-2-yl)(6-methoxy-1H-indol-2-yl)methanone
DM7KDNM	MI	TTI7421
DM7KDNM	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM7KDNM	MT	DTT
DM7KDNM	MA	Inhibitor
DM7KDNM	RN	Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15.
DM7KDNM	RU	https://pubmed.ncbi.nlm.nih.gov/16722630

DMW15DS	DI	DMW15DS
DMW15DS	DN	(1H-indol-2-yl)(piperazin-1-yl)methanone
DMW15DS	MI	TT9JNIC
DMW15DS	MN	Histamine H3 receptor (H3R)
DMW15DS	MT	DTT
DMW15DS	MA	Inhibitor
DMW15DS	RN	Preparation and biological evaluation of indole, benzimidazole, and thienopyrrole piperazine carboxamides: potent human histamine h(4) antagonists. J Med Chem. 2005 Dec 29;48(26):8289-98.
DMW15DS	RU	https://pubmed.ncbi.nlm.nih.gov/16366610

DMW15DS	DI	DMW15DS
DMW15DS	DN	(1H-indol-2-yl)(piperazin-1-yl)methanone
DMW15DS	MI	TTXJ178
DMW15DS	MN	Histamine H4 receptor (H4R)
DMW15DS	MT	DTT
DMW15DS	MA	Inhibitor
DMW15DS	RN	Preparation and biological evaluation of indole, benzimidazole, and thienopyrrole piperazine carboxamides: potent human histamine h(4) antagonists. J Med Chem. 2005 Dec 29;48(26):8289-98.
DMW15DS	RU	https://pubmed.ncbi.nlm.nih.gov/16366610

DMHEYOK	DI	DMHEYOK
DMHEYOK	DN	(1'H-Phenothiazin-1'-yl)(piperidin-1-yl)methanone
DMHEYOK	MI	TTEB0GD
DMHEYOK	MN	Cholinesterase (BCHE)
DMHEYOK	MT	DTT
DMHEYOK	MA	Inhibitor
DMHEYOK	RN	Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorg Med Chem. 2010 Mar 15;18(6):2232-2244.
DMHEYOK	RU	https://pubmed.ncbi.nlm.nih.gov/20181484

DMACN68	DI	DMACN68
DMACN68	DN	(1H-pyrazol-1-yl)(o-tolyl)methanone
DMACN68	MI	TTPLTSQ
DMACN68	MN	Neutrophil elastase (NE)
DMACN68	MT	DTT
DMACN68	MA	Inhibitor
DMACN68	RN	N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
DMACN68	RU	https://pubmed.ncbi.nlm.nih.gov/17850059

DM5L8WX	DI	DM5L8WX
DM5L8WX	DN	(1-hydroxy-1-phosphono-heptyl)-phosphonic acid
DM5L8WX	MI	TTIKWV4
DM5L8WX	MN	Geranyltranstransferase (FDPS)
DM5L8WX	MT	DTT
DM5L8WX	MA	Inhibitor
DM5L8WX	RN	Synthesis and biological evaluation of 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl... Bioorg Med Chem. 2008 Mar 15;16(6):3283-90.
DM5L8WX	RU	https://pubmed.ncbi.nlm.nih.gov/18096393

DMXY9R5	DI	DMXY9R5
DMXY9R5	DN	(1-Phenethyl-piperidin-4-yl)-phenyl-methanone
DMXY9R5	MI	TTJQOD7
DMXY9R5	MN	5-HT 2A receptor (HTR2A)
DMXY9R5	MT	DTT
DMXY9R5	MA	Inhibitor
DMXY9R5	RN	Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501.
DMXY9R5	RU	https://pubmed.ncbi.nlm.nih.gov/11170639

DM0TUKZ	DI	DM0TUKZ
DM0TUKZ	DN	(1-phenylcyclopentyl)methanamine
DM0TUKZ	MI	TTDIGC1
DM0TUKZ	MN	Dipeptidyl peptidase 4 (DPP-4)
DM0TUKZ	MT	DTT
DM0TUKZ	MA	Inhibitor
DM0TUKZ	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM0TUKZ	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMECH9W	DI	DMECH9W
DMECH9W	DN	(1-Phenyl-ethyl)-(2-phenyl-quinazolin-4-yl)-amine
DMECH9W	MI	TTVBI8W
DMECH9W	MN	Dopamine transporter (DAT)
DMECH9W	MT	DTT
DMECH9W	MA	Inhibitor
DMECH9W	RN	Identification of a novel partial inhibitor of dopamine transporter among 4-substituted 2-phenylquinazolines. Bioorg Med Chem Lett. 2002 Aug 19;12(16):2225-8.
DMECH9W	RU	https://pubmed.ncbi.nlm.nih.gov/12127543

DMZU2VG	DI	DMZU2VG
DMZU2VG	DN	(1-Phenyl-propyl)-(9-phenyl-9H-purin-6-yl)-amine
DMZU2VG	MI	TTK25J1
DMZU2VG	MN	Adenosine A1 receptor (ADORA1)
DMZU2VG	MT	DTT
DMZU2VG	MA	Inhibitor
DMZU2VG	RN	N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor. J Med Chem. 1991 Sep;34(9):2877-82.
DMZU2VG	RU	https://pubmed.ncbi.nlm.nih.gov/1895305

DMVE34H	DI	DMVE34H
DMVE34H	DN	(1r)-1,2,2-trimethylpropyl (r)-methylphosphinate
DMVE34H	MI	TTMF541
DMVE34H	MN	Liver carboxylesterase (CES1)
DMVE34H	MT	DTT
DMVE34H	MA	Inhibitor
DMVE34H	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMVE34H	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMVE34H	DI	DMVE34H
DMVE34H	DN	(1r)-1,2,2-trimethylpropyl (r)-methylphosphinate
DMVE34H	MI	TTDNFMT
DMVE34H	MN	Platelet-activating factor acetylhydrolase (PLA2G7)
DMVE34H	MT	DTT
DMVE34H	MA	Inhibitor
DMVE34H	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMVE34H	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMCVKTB	DI	DMCVKTB
DMCVKTB	DN	(1R)-1,2,2-TRIMETHYLPROPYL (S)-METHYLPHOSPHINATE
DMCVKTB	MI	TT1RS9F
DMCVKTB	MN	Acetylcholinesterase (AChE)
DMCVKTB	MT	DTT
DMCVKTB	MA	Inhibitor
DMCVKTB	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMCVKTB	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMGAJYW	DI	DMGAJYW
DMGAJYW	DN	(1R)-MENTHYL HEXYL PHOSPHONATE GROUP
DMGAJYW	MI	TTEB0GD
DMGAJYW	MN	Cholinesterase (BCHE)
DMGAJYW	MT	DTT
DMGAJYW	MA	Inhibitor
DMGAJYW	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMGAJYW	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM18E9D	DI	DM18E9D
DM18E9D	DN	(1R,2R)-1,2-diphenylethane-1,2-diamine
DM18E9D	MI	TTDIGC1
DM18E9D	MN	Dipeptidyl peptidase 4 (DPP-4)
DM18E9D	MT	DTT
DM18E9D	MA	Inhibitor
DM18E9D	RN	In silico fragment-based discovery of DPP-IV S1 pocket binders. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1405-9.
DM18E9D	RU	https://pubmed.ncbi.nlm.nih.gov/16321524

DM5ROS1	DI	DM5ROS1
DM5ROS1	DN	(1R,2R)-2-(1H-Imidazol-4-yl)-1-methyl-propylamine
DM5ROS1	MI	TT9JNIC
DM5ROS1	MN	Histamine H3 receptor (H3R)
DM5ROS1	MT	DTT
DM5ROS1	MA	Inhibitor
DM5ROS1	RN	A novel pyrrolidine analog of histamine as a potent, highly selective histamine H3 receptor agonist. J Med Chem. 1995 May 12;38(10):1593-9.
DM5ROS1	RU	https://pubmed.ncbi.nlm.nih.gov/7752184

DMYLPV1	DI	DMYLPV1
DMYLPV1	DN	(1R,2R)-N-Arachidonoylcyclopropanolamide
DMYLPV1	MI	TT6OEDT
DMYLPV1	MN	Cannabinoid receptor 1 (CB1)
DMYLPV1	MT	DTT
DMYLPV1	MA	Inhibitor
DMYLPV1	RN	Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. J Med Chem. 2009 May 14;52(9):3001-9.
DMYLPV1	RU	https://pubmed.ncbi.nlm.nih.gov/19361197

DMYLPV1	DI	DMYLPV1
DMYLPV1	DN	(1R,2R)-N-Arachidonoylcyclopropanolamide
DMYLPV1	MI	TTMSFAW
DMYLPV1	MN	Cannabinoid receptor 2 (CB2)
DMYLPV1	MT	DTT
DMYLPV1	MA	Inhibitor
DMYLPV1	RN	Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. J Med Chem. 2009 May 14;52(9):3001-9.
DMYLPV1	RU	https://pubmed.ncbi.nlm.nih.gov/19361197

DM28D9E	DI	DM28D9E
DM28D9E	DN	(1R,2S)-1,2-diphenylethane-1,2-diamine
DM28D9E	MI	TTDIGC1
DM28D9E	MN	Dipeptidyl peptidase 4 (DPP-4)
DM28D9E	MT	DTT
DM28D9E	MA	Inhibitor
DM28D9E	RN	In silico fragment-based discovery of DPP-IV S1 pocket binders. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1405-9.
DM28D9E	RU	https://pubmed.ncbi.nlm.nih.gov/16321524

DMZ3DMX	DI	DMZ3DMX
DMZ3DMX	DN	(1R,2S)-2-(1H-Imidazol-4-yl)-1-methyl-propylamine
DMZ3DMX	MI	TT9JNIC
DMZ3DMX	MN	Histamine H3 receptor (H3R)
DMZ3DMX	MT	DTT
DMZ3DMX	MA	Inhibitor
DMZ3DMX	RN	A novel pyrrolidine analog of histamine as a potent, highly selective histamine H3 receptor agonist. J Med Chem. 1995 May 12;38(10):1593-9.
DMZ3DMX	RU	https://pubmed.ncbi.nlm.nih.gov/7752184

DM39AFU	DI	DM39AFU
DM39AFU	DN	(1R,2S)-N-Arachidonoylcyclopropanolamide
DM39AFU	MI	TT6OEDT
DM39AFU	MN	Cannabinoid receptor 1 (CB1)
DM39AFU	MT	DTT
DM39AFU	MA	Inhibitor
DM39AFU	RN	Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. J Med Chem. 2009 May 14;52(9):3001-9.
DM39AFU	RU	https://pubmed.ncbi.nlm.nih.gov/19361197

DM39AFU	DI	DM39AFU
DM39AFU	DN	(1R,2S)-N-Arachidonoylcyclopropanolamide
DM39AFU	MI	TTMSFAW
DM39AFU	MN	Cannabinoid receptor 2 (CB2)
DM39AFU	MT	DTT
DM39AFU	MA	Inhibitor
DM39AFU	RN	Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. J Med Chem. 2009 May 14;52(9):3001-9.
DM39AFU	RU	https://pubmed.ncbi.nlm.nih.gov/19361197

DMITW5P	DI	DMITW5P
DMITW5P	DN	(1R,2S)-N-Oleoylcyclopropanolamide
DMITW5P	MI	TT6OEDT
DMITW5P	MN	Cannabinoid receptor 1 (CB1)
DMITW5P	MT	DTT
DMITW5P	MA	Inhibitor
DMITW5P	RN	Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. J Med Chem. 2009 May 14;52(9):3001-9.
DMITW5P	RU	https://pubmed.ncbi.nlm.nih.gov/19361197

DMITW5P	DI	DMITW5P
DMITW5P	DN	(1R,2S)-N-Oleoylcyclopropanolamide
DMITW5P	MI	TTMSFAW
DMITW5P	MN	Cannabinoid receptor 2 (CB2)
DMITW5P	MT	DTT
DMITW5P	MA	Inhibitor
DMITW5P	RN	Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. J Med Chem. 2009 May 14;52(9):3001-9.
DMITW5P	RU	https://pubmed.ncbi.nlm.nih.gov/19361197

DMUJ7ZE	DI	DMUJ7ZE
DMUJ7ZE	DN	(1R,5R)-30-OXO-19-OXA-2,6,10,12-TETRAAZAHEXACYCLO[18.6.2.1^{2,5}.1^{14,18}.0^{8,12}.0^{23,27}]TRIACONTA-8,10,14(29),15,17,20(28),21,23(27)-OCTAENE-17-CARBONITRILE (STRUCTURAL MIX)
DMUJ7ZE	MI	TTQ6VDM
DMUJ7ZE	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMUJ7ZE	MT	DTT
DMUJ7ZE	MA	Inhibitor
DMUJ7ZE	RN	Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new ... J Med Chem. 2009 Jul 23;52(14):4266-76.
DMUJ7ZE	RU	https://pubmed.ncbi.nlm.nih.gov/19534531

DMJ2WD5	DI	DMJ2WD5
DMJ2WD5	DN	(1S)-MENTHYL HEXYL PHOSPHONATE GROUP
DMJ2WD5	MI	TTEB0GD
DMJ2WD5	MN	Cholinesterase (BCHE)
DMJ2WD5	MT	DTT
DMJ2WD5	MA	Inhibitor
DMJ2WD5	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMJ2WD5	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMZCS2K	DI	DMZCS2K
DMZCS2K	DN	(1S,2S)-2-(1H-Imidazol-4-yl)-cyclopentylamine
DMZCS2K	MI	TT9JNIC
DMZCS2K	MN	Histamine H3 receptor (H3R)
DMZCS2K	MT	DTT
DMZCS2K	MA	Inhibitor
DMZCS2K	RN	A novel pyrrolidine analog of histamine as a potent, highly selective histamine H3 receptor agonist. J Med Chem. 1995 May 12;38(10):1593-9.
DMZCS2K	RU	https://pubmed.ncbi.nlm.nih.gov/7752184

DMKA0ON	DI	DMKA0ON
DMKA0ON	DN	(1S,2S)-N-Arachidonoylcyclopropanolamide
DMKA0ON	MI	TT6OEDT
DMKA0ON	MN	Cannabinoid receptor 1 (CB1)
DMKA0ON	MT	DTT
DMKA0ON	MA	Inhibitor
DMKA0ON	RN	Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. J Med Chem. 2009 May 14;52(9):3001-9.
DMKA0ON	RU	https://pubmed.ncbi.nlm.nih.gov/19361197

DMKA0ON	DI	DMKA0ON
DMKA0ON	DN	(1S,2S)-N-Arachidonoylcyclopropanolamide
DMKA0ON	MI	TTMSFAW
DMKA0ON	MN	Cannabinoid receptor 2 (CB2)
DMKA0ON	MT	DTT
DMKA0ON	MA	Inhibitor
DMKA0ON	RN	Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. J Med Chem. 2009 May 14;52(9):3001-9.
DMKA0ON	RU	https://pubmed.ncbi.nlm.nih.gov/19361197

DMIV2OY	DI	DMIV2OY
DMIV2OY	DN	(1S,2S)-N-Oleoylcyclopropanolamide
DMIV2OY	MI	TT6OEDT
DMIV2OY	MN	Cannabinoid receptor 1 (CB1)
DMIV2OY	MT	DTT
DMIV2OY	MA	Inhibitor
DMIV2OY	RN	Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. J Med Chem. 2009 May 14;52(9):3001-9.
DMIV2OY	RU	https://pubmed.ncbi.nlm.nih.gov/19361197

DMIV2OY	DI	DMIV2OY
DMIV2OY	DN	(1S,2S)-N-Oleoylcyclopropanolamide
DMIV2OY	MI	TTMSFAW
DMIV2OY	MN	Cannabinoid receptor 2 (CB2)
DMIV2OY	MT	DTT
DMIV2OY	MA	Inhibitor
DMIV2OY	RN	Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. J Med Chem. 2009 May 14;52(9):3001-9.
DMIV2OY	RU	https://pubmed.ncbi.nlm.nih.gov/19361197

DM5DOAF	DI	DM5DOAF
DM5DOAF	DN	(1S,3R)-ACPD
DM5DOAF	MI	TTVBPDM
DM5DOAF	MN	Metabotropic glutamate receptor 1 (mGluR1)
DM5DOAF	MT	DTT
DM5DOAF	MA	Agonist
DM5DOAF	RN	Characterization of [(3)H]Quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections. J Neurochem. 2000 Dec;75(6):2590-601.
DM5DOAF	RU	https://pubmed.ncbi.nlm.nih.gov/11080213

DM5DOAF	DI	DM5DOAF
DM5DOAF	DN	(1S,3R)-ACPD
DM5DOAF	MI	TTXJ47W
DM5DOAF	MN	Metabotropic glutamate receptor 2 (mGluR2)
DM5DOAF	MT	DTT
DM5DOAF	MA	Agonist
DM5DOAF	RN	[3H]-LY341495 as a novel antagonist radioligand for group II metabotropic glutamate (mGlu) receptors: characterization of binding to membranes of mGlu receptor subtype expressing cells. Neuropharmacology. 1999 Oct;38(10):1519-29.
DM5DOAF	RU	https://pubmed.ncbi.nlm.nih.gov/10530814

DM5DOAF	DI	DM5DOAF
DM5DOAF	DN	(1S,3R)-ACPD
DM5DOAF	MI	TT8A9EF
DM5DOAF	MN	Metabotropic glutamate receptor 3 (mGluR3)
DM5DOAF	MT	DTT
DM5DOAF	MA	Agonist
DM5DOAF	RN	[3H]-LY341495 as a novel antagonist radioligand for group II metabotropic glutamate (mGlu) receptors: characterization of binding to membranes of mGlu receptor subtype expressing cells. Neuropharmacology. 1999 Oct;38(10):1519-29.
DM5DOAF	RU	https://pubmed.ncbi.nlm.nih.gov/10530814

DM5DOAF	DI	DM5DOAF
DM5DOAF	DN	(1S,3R)-ACPD
DM5DOAF	MI	TTHS256
DM5DOAF	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM5DOAF	MT	DTT
DM5DOAF	MA	Agonist
DM5DOAF	RN	Characterization of [(3)H]Quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections. J Neurochem. 2000 Dec;75(6):2590-601.
DM5DOAF	RU	https://pubmed.ncbi.nlm.nih.gov/11080213

DM5DOAF	DI	DM5DOAF
DM5DOAF	DN	(1S,3R)-ACPD
DM5DOAF	MI	TTWRP2F
DM5DOAF	MN	Metabotropic glutamate receptor 6 (mGluR6)
DM5DOAF	MT	DTT
DM5DOAF	MA	Agonist
DM5DOAF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 294).
DM5DOAF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=294

DM5DOAF	DI	DM5DOAF
DM5DOAF	DN	(1S,3R)-ACPD
DM5DOAF	MI	TT0I76D
DM5DOAF	MN	Metabotropic glutamate receptor 7 (mGluR7)
DM5DOAF	MT	DTT
DM5DOAF	MA	Agonist
DM5DOAF	RN	Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 2000 Dec;362(6):546-54.
DM5DOAF	RU	https://pubmed.ncbi.nlm.nih.gov/11138847

DM5DOAF	DI	DM5DOAF
DM5DOAF	DN	(1S,3R)-ACPD
DM5DOAF	MI	TT0IFKL
DM5DOAF	MN	Metabotropic glutamate receptor 8 (mGluR8)
DM5DOAF	MT	DTT
DM5DOAF	MA	Agonist
DM5DOAF	RN	Group III human metabotropic glutamate receptors 4, 7 and 8: molecular cloning, functional expression, and comparison of pharmacological properties in RGT cells. Brain Res Mol Brain Res. 1998 Jan;53(1-2):88-97.
DM5DOAF	RU	https://pubmed.ncbi.nlm.nih.gov/9473604

DMYOTMP	DI	DMYOTMP
DMYOTMP	DN	(2-(2-chlorophenyl)pyridin-3-yl)methanamine
DMYOTMP	MI	TTDIGC1
DMYOTMP	MN	Dipeptidyl peptidase 4 (DPP-4)
DMYOTMP	MT	DTT
DMYOTMP	MA	Inhibitor
DMYOTMP	RN	In silico fragment-based discovery of DPP-IV S1 pocket binders. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1405-9.
DMYOTMP	RU	https://pubmed.ncbi.nlm.nih.gov/16321524

DMA15WU	DI	DMA15WU
DMA15WU	DN	(2-(4-chlorobenzyloxy)-5-bromophenyl)methanamine
DMA15WU	MI	TT2CEJG
DMA15WU	MN	C-C chemokine receptor type 5 (CCR5)
DMA15WU	MT	DTT
DMA15WU	MA	Inhibitor
DMA15WU	RN	CCR5 receptor antagonists: discovery and SAR of novel 4-hydroxypiperidine derivatives. Bioorg Med Chem Lett. 2007 Apr 1;17(7):1883-7.
DMA15WU	RU	https://pubmed.ncbi.nlm.nih.gov/17314043

DM2ATRC	DI	DM2ATRC
DM2ATRC	DN	(2,2-dimethyl-1,3-dioxolan-4-yl)methyl sulfamate
DM2ATRC	MI	TTANPDJ
DM2ATRC	MN	Carbonic anhydrase II (CA-II)
DM2ATRC	MT	DTT
DM2ATRC	MA	Inhibitor
DM2ATRC	RN	Inhibition of carbonic anhydrase-II by sulfamate and sulfamide groups: an investigation involving direct thermodynamic binding measurements. J Med Chem. 2006 Jun 15;49(12):3496-500.
DM2ATRC	RU	https://pubmed.ncbi.nlm.nih.gov/16759092

DMNGEFS	DI	DMNGEFS
DMNGEFS	DN	(2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamine
DMNGEFS	MI	TTI7421
DMNGEFS	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMNGEFS	MT	DTT
DMNGEFS	MA	Inhibitor
DMNGEFS	RN	(6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad ant... J Med Chem. 2005 Dec 29;48(26):8163-73.
DMNGEFS	RU	https://pubmed.ncbi.nlm.nih.gov/16366598

DM97GFB	DI	DM97GFB
DM97GFB	DN	(2,5-Diphenyl-furan-3-yl)-phenyl-methanone
DM97GFB	MI	TTZ97H5
DM97GFB	MN	Phosphodiesterase 4A (PDE4A)
DM97GFB	MT	DTT
DM97GFB	MA	Inhibitor
DM97GFB	RN	Substituted furans as inhibitors of the PDE4 enzyme. Bioorg Med Chem Lett. 1999 Feb 8;9(3):323-6.
DM97GFB	RU	https://pubmed.ncbi.nlm.nih.gov/10091677

DMWRCM1	DI	DMWRCM1
DMWRCM1	DN	(2,6-Diamino-pyridin-3-yl)-phenyl-methanone
DMWRCM1	MI	TTH6V3D
DMWRCM1	MN	Cyclin-dependent kinase 1 (CDK1)
DMWRCM1	MT	DTT
DMWRCM1	MA	Inhibitor
DMWRCM1	RN	3-Acyl-2,6-diaminopyridines as cyclin-dependent kinase inhibitors: synthesis and biological evaluation. Bioorg Med Chem Lett. 2005 May 2;15(9):2221-4.
DMWRCM1	RU	https://pubmed.ncbi.nlm.nih.gov/15837297

DM27TH9	DI	DM27TH9
DM27TH9	DN	(2,6-Dichloro-phenyl)-(1H-imidazol-2-yl)-amine
DM27TH9	MI	TTNGILX
DM27TH9	MN	Adrenergic receptor alpha-1A (ADRA1A)
DM27TH9	MT	DTT
DM27TH9	MA	Inhibitor
DM27TH9	RN	Synthesis and evaluation of 2-(arylamino)imidazoles as alpha 2-adrenergic agonists. J Med Chem. 1997 Jan 3;40(1):18-23.
DM27TH9	RU	https://pubmed.ncbi.nlm.nih.gov/9016324

DM27TH9	DI	DM27TH9
DM27TH9	DN	(2,6-Dichloro-phenyl)-(1H-imidazol-2-yl)-amine
DM27TH9	MI	TTBRKXS
DM27TH9	MN	Adrenergic receptor alpha-1B (ADRA1B)
DM27TH9	MT	DTT
DM27TH9	MA	Inhibitor
DM27TH9	RN	Synthesis and evaluation of 2-(arylamino)imidazoles as alpha 2-adrenergic agonists. J Med Chem. 1997 Jan 3;40(1):18-23.
DM27TH9	RU	https://pubmed.ncbi.nlm.nih.gov/9016324

DM27TH9	DI	DM27TH9
DM27TH9	DN	(2,6-Dichloro-phenyl)-(1H-imidazol-2-yl)-amine
DM27TH9	MI	TT34BHT
DM27TH9	MN	Adrenergic receptor alpha-1D (ADRA1D)
DM27TH9	MT	DTT
DM27TH9	MA	Inhibitor
DM27TH9	RN	Synthesis and evaluation of 2-(arylamino)imidazoles as alpha 2-adrenergic agonists. J Med Chem. 1997 Jan 3;40(1):18-23.
DM27TH9	RU	https://pubmed.ncbi.nlm.nih.gov/9016324

DM27TH9	DI	DM27TH9
DM27TH9	DN	(2,6-Dichloro-phenyl)-(1H-imidazol-2-yl)-amine
DM27TH9	MI	TTWG9A4
DM27TH9	MN	Adrenergic receptor alpha-2A (ADRA2A)
DM27TH9	MT	DTT
DM27TH9	MA	Inhibitor
DM27TH9	RN	Synthesis and evaluation of 2-(arylamino)imidazoles as alpha 2-adrenergic agonists. J Med Chem. 1997 Jan 3;40(1):18-23.
DM27TH9	RU	https://pubmed.ncbi.nlm.nih.gov/9016324

DM27TH9	DI	DM27TH9
DM27TH9	DN	(2,6-Dichloro-phenyl)-(1H-imidazol-2-yl)-amine
DM27TH9	MI	TT2NUT5
DM27TH9	MN	Adrenergic receptor alpha-2C (ADRA2C)
DM27TH9	MT	DTT
DM27TH9	MA	Inhibitor
DM27TH9	RN	Synthesis and evaluation of 2-(arylamino)imidazoles as alpha 2-adrenergic agonists. J Med Chem. 1997 Jan 3;40(1):18-23.
DM27TH9	RU	https://pubmed.ncbi.nlm.nih.gov/9016324

DM1RYH9	DI	DM1RYH9
DM1RYH9	DN	(24E)-3beta-hydroxy-7,24-euphadien-26-oic acid
DM1RYH9	MI	TTIU7X1
DM1RYH9	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DM1RYH9	MT	DTT
DM1RYH9	MA	Inhibitor
DM1RYH9	RN	A new 7,8-euphadien-type triterpenoid from Brackenridgea nitida and Bleasdalea bleasdalei that inhibits DNA polymerase beta. J Nat Prod. 2000 Oct;63(10):1356-60.
DM1RYH9	RU	https://pubmed.ncbi.nlm.nih.gov/11076551

DMPL80G	DI	DMPL80G
DMPL80G	DN	(24S)-ethylcholesta-7,9(11),22(E)-triene-3b-ol
DMPL80G	MI	TT1RS9F
DMPL80G	MN	Acetylcholinesterase (AChE)
DMPL80G	MT	DTT
DMPL80G	MA	Inhibitor
DMPL80G	RN	Isolation and cholinesterase-inhibition studies of sterols from Haloxylon recurvum. Bioorg Med Chem Lett. 2006 Feb;16(3):573-80.
DMPL80G	RU	https://pubmed.ncbi.nlm.nih.gov/16274989

DMPL80G	DI	DMPL80G
DMPL80G	DN	(24S)-ethylcholesta-7,9(11),22(E)-triene-3b-ol
DMPL80G	MI	TTEB0GD
DMPL80G	MN	Cholinesterase (BCHE)
DMPL80G	MT	DTT
DMPL80G	MA	Inhibitor
DMPL80G	RN	Isolation and cholinesterase-inhibition studies of sterols from Haloxylon recurvum. Bioorg Med Chem Lett. 2006 Feb;16(3):573-80.
DMPL80G	RU	https://pubmed.ncbi.nlm.nih.gov/16274989

DMLEZKJ	DI	DMLEZKJ
DMLEZKJ	DN	(2-Amino-4,5-dihydro-thiazol-4-yl)-acetic acid
DMLEZKJ	MI	TT1MPAY
DMLEZKJ	MN	GABA(A) receptor alpha-1 (GABRA1)
DMLEZKJ	MT	DTT
DMLEZKJ	MA	Inhibitor
DMLEZKJ	RN	( )-2-amino-2-thiazoline-4-ethanoic acid; a novel, specific GABAA receptor agonist. Bioorg. Med. Chem. Lett. 1(5):247-248 (1991).
DMLEZKJ	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01810350

DMLEZKJ	DI	DMLEZKJ
DMLEZKJ	DN	(2-Amino-4,5-dihydro-thiazol-4-yl)-acetic acid
DMLEZKJ	MI	TTNJYV2
DMLEZKJ	MN	Gamma-aminobutyric acid receptor (GAR)
DMLEZKJ	MT	DTT
DMLEZKJ	MA	Inhibitor
DMLEZKJ	RN	( )-2-amino-2-thiazoline-4-ethanoic acid; a novel, specific GABAA receptor agonist. Bioorg. Med. Chem. Lett. 1(5):247-248 (1991).
DMLEZKJ	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01810350

DMFRPGX	DI	DMFRPGX
DMFRPGX	DN	(2-Benzyl-phenyl)-(2-pyrrolidin-1-yl-ethyl)-amine
DMFRPGX	MI	TT4C8EA
DMFRPGX	MN	Dopamine D3 receptor (D3R)
DMFRPGX	MT	DTT
DMFRPGX	MA	Inhibitor
DMFRPGX	RN	Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
DMFRPGX	RU	https://pubmed.ncbi.nlm.nih.gov/15293986

DMTW0GD	DI	DMTW0GD
DMTW0GD	DN	(2-biphenyl-3-yl-ethyl)-dimethyl-amine
DMTW0GD	MI	TTO9X1H
DMTW0GD	MN	5-HT 7 receptor (HTR7)
DMTW0GD	MT	DTT
DMTW0GD	MA	Inhibitor
DMTW0GD	RN	Novel aminoethylbiphenyls as 5-HT7 receptor ligands. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3018-22.
DMTW0GD	RU	https://pubmed.ncbi.nlm.nih.gov/17419056

DMZSP7F	DI	DMZSP7F
DMZSP7F	DN	(2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE
DMZSP7F	MI	TT3NKIB
DMZSP7F	MN	Pancreatic elastase 1 (CELA1)
DMZSP7F	MT	DTT
DMZSP7F	MA	Inhibitor
DMZSP7F	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMZSP7F	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM8N79M	DI	DM8N79M
DM8N79M	DN	(2-Bromo-phenyl)-(1H-imidazol-2-yl)-amine
DM8N79M	MI	TTNGILX
DM8N79M	MN	Adrenergic receptor alpha-1A (ADRA1A)
DM8N79M	MT	DTT
DM8N79M	MA	Inhibitor
DM8N79M	RN	Synthesis and evaluation of 2-(arylamino)imidazoles as alpha 2-adrenergic agonists. J Med Chem. 1997 Jan 3;40(1):18-23.
DM8N79M	RU	https://pubmed.ncbi.nlm.nih.gov/9016324

DM8N79M	DI	DM8N79M
DM8N79M	DN	(2-Bromo-phenyl)-(1H-imidazol-2-yl)-amine
DM8N79M	MI	TTBRKXS
DM8N79M	MN	Adrenergic receptor alpha-1B (ADRA1B)
DM8N79M	MT	DTT
DM8N79M	MA	Inhibitor
DM8N79M	RN	Synthesis and evaluation of 2-(arylamino)imidazoles as alpha 2-adrenergic agonists. J Med Chem. 1997 Jan 3;40(1):18-23.
DM8N79M	RU	https://pubmed.ncbi.nlm.nih.gov/9016324

DM8N79M	DI	DM8N79M
DM8N79M	DN	(2-Bromo-phenyl)-(1H-imidazol-2-yl)-amine
DM8N79M	MI	TT34BHT
DM8N79M	MN	Adrenergic receptor alpha-1D (ADRA1D)
DM8N79M	MT	DTT
DM8N79M	MA	Inhibitor
DM8N79M	RN	Synthesis and evaluation of 2-(arylamino)imidazoles as alpha 2-adrenergic agonists. J Med Chem. 1997 Jan 3;40(1):18-23.
DM8N79M	RU	https://pubmed.ncbi.nlm.nih.gov/9016324

DM8N79M	DI	DM8N79M
DM8N79M	DN	(2-Bromo-phenyl)-(1H-imidazol-2-yl)-amine
DM8N79M	MI	TTWG9A4
DM8N79M	MN	Adrenergic receptor alpha-2A (ADRA2A)
DM8N79M	MT	DTT
DM8N79M	MA	Inhibitor
DM8N79M	RN	Synthesis and evaluation of 2-(arylamino)imidazoles as alpha 2-adrenergic agonists. J Med Chem. 1997 Jan 3;40(1):18-23.
DM8N79M	RU	https://pubmed.ncbi.nlm.nih.gov/9016324

DM8N79M	DI	DM8N79M
DM8N79M	DN	(2-Bromo-phenyl)-(1H-imidazol-2-yl)-amine
DM8N79M	MI	TT2NUT5
DM8N79M	MN	Adrenergic receptor alpha-2C (ADRA2C)
DM8N79M	MT	DTT
DM8N79M	MA	Inhibitor
DM8N79M	RN	Synthesis and evaluation of 2-(arylamino)imidazoles as alpha 2-adrenergic agonists. J Med Chem. 1997 Jan 3;40(1):18-23.
DM8N79M	RU	https://pubmed.ncbi.nlm.nih.gov/9016324

DMFX9H8	DI	DMFX9H8
DMFX9H8	DN	(2-bromophenyl)difluoromethanesulfonamide
DMFX9H8	MI	TTUNARX
DMFX9H8	MN	Carbonic anhydrase (CA)
DMFX9H8	MT	DTT
DMFX9H8	MA	Inhibitor
DMFX9H8	RN	Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6.
DMFX9H8	RU	https://pubmed.ncbi.nlm.nih.gov/16203142

DMFX9H8	DI	DMFX9H8
DMFX9H8	DN	(2-bromophenyl)difluoromethanesulfonamide
DMFX9H8	MI	TTHQPL7
DMFX9H8	MN	Carbonic anhydrase I (CA-I)
DMFX9H8	MT	DTT
DMFX9H8	MA	Inhibitor
DMFX9H8	RN	Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6.
DMFX9H8	RU	https://pubmed.ncbi.nlm.nih.gov/16203142

DMFX9H8	DI	DMFX9H8
DMFX9H8	DN	(2-bromophenyl)difluoromethanesulfonamide
DMFX9H8	MI	TTANPDJ
DMFX9H8	MN	Carbonic anhydrase II (CA-II)
DMFX9H8	MT	DTT
DMFX9H8	MA	Inhibitor
DMFX9H8	RN	Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6.
DMFX9H8	RU	https://pubmed.ncbi.nlm.nih.gov/16203142

DMFX9H8	DI	DMFX9H8
DMFX9H8	DN	(2-bromophenyl)difluoromethanesulfonamide
DMFX9H8	MI	TT2LVK8
DMFX9H8	MN	Carbonic anhydrase IX (CA-IX)
DMFX9H8	MT	DTT
DMFX9H8	MA	Inhibitor
DMFX9H8	RN	Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6.
DMFX9H8	RU	https://pubmed.ncbi.nlm.nih.gov/16203142

DMLTMPC	DI	DMLTMPC
DMLTMPC	DN	(2-Butyryloxy-ethyl)-trimethyl-ammonium iodide
DMLTMPC	MI	TT1RS9F
DMLTMPC	MN	Acetylcholinesterase (AChE)
DMLTMPC	MT	DTT
DMLTMPC	MA	Inhibitor
DMLTMPC	RN	Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors. J Med Chem. 1996 Dec 20;39(26):5064-71.
DMLTMPC	RU	https://pubmed.ncbi.nlm.nih.gov/8978837

DMOS864	DI	DMOS864
DMOS864	DN	(2-chloro-6-phenoxyphenyl)methanamine
DMOS864	MI	TTDIGC1
DMOS864	MN	Dipeptidyl peptidase 4 (DPP-4)
DMOS864	MT	DTT
DMOS864	MA	Inhibitor
DMOS864	RN	In silico fragment-based discovery of DPP-IV S1 pocket binders. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1405-9.
DMOS864	RU	https://pubmed.ncbi.nlm.nih.gov/16321524

DMCE1SU	DI	DMCE1SU
DMCE1SU	DN	(2-Chloro-9-methyl-9H-purin-6-yl)-phenyl-amine
DMCE1SU	MI	TTK25J1
DMCE1SU	MN	Adenosine A1 receptor (ADORA1)
DMCE1SU	MT	DTT
DMCE1SU	MA	Inhibitor
DMCE1SU	RN	N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor. J Med Chem. 1991 Sep;34(9):2877-82.
DMCE1SU	RU	https://pubmed.ncbi.nlm.nih.gov/1895305

DM6DH15	DI	DM6DH15
DM6DH15	DN	(2-Chloro-ethyl)-trimethyl-ammonium chloride
DM6DH15	MI	TT1RS9F
DM6DH15	MN	Acetylcholinesterase (AChE)
DM6DH15	MT	DTT
DM6DH15	MA	Inhibitor
DM6DH15	RN	Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors. J Med Chem. 1996 Dec 20;39(26):5064-71.
DM6DH15	RU	https://pubmed.ncbi.nlm.nih.gov/8978837

DMKWRFA	DI	DMKWRFA
DMKWRFA	DN	(2E)-3-(2-OCT-1-YN-1-YLPHENYL)ACRYLIC ACID
DMKWRFA	MI	TTN9T81
DMKWRFA	MN	Arachidonate 15-lipoxygenase (15-LOX)
DMKWRFA	MT	DTT
DMKWRFA	MA	Inhibitor
DMKWRFA	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMKWRFA	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM3ST2Y	DI	DM3ST2Y
DM3ST2Y	DN	(2E, 6E)-farnesylbisphosphonate
DM3ST2Y	MI	TTIKWV4
DM3ST2Y	MN	Geranyltranstransferase (FDPS)
DM3ST2Y	MT	DTT
DM3ST2Y	MA	Inhibitor
DM3ST2Y	RN	Mono- and dialkyl isoprenoid bisphosphonates as geranylgeranyl diphosphate synthase inhibitors. Bioorg Med Chem. 2008 Jan 1;16(1):390-9.
DM3ST2Y	RU	https://pubmed.ncbi.nlm.nih.gov/17905588

DMA9RIS	DI	DMA9RIS
DMA9RIS	DN	(2E,4S)-4-ammoniopent-2-enoate
DMA9RIS	MI	TT1MPAY
DMA9RIS	MN	GABA(A) receptor alpha-1 (GABRA1)
DMA9RIS	MT	DTT
DMA9RIS	MA	Inhibitor
DMA9RIS	RN	gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83.
DMA9RIS	RU	https://pubmed.ncbi.nlm.nih.gov/6118436

DMA9RIS	DI	DMA9RIS
DMA9RIS	DN	(2E,4S)-4-ammoniopent-2-enoate
DMA9RIS	MI	TTBMV1G
DMA9RIS	MN	GABA(A) receptor alpha-2 (GABRA2)
DMA9RIS	MT	DTT
DMA9RIS	MA	Inhibitor
DMA9RIS	RN	gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83.
DMA9RIS	RU	https://pubmed.ncbi.nlm.nih.gov/6118436

DMA9RIS	DI	DMA9RIS
DMA9RIS	DN	(2E,4S)-4-ammoniopent-2-enoate
DMA9RIS	MI	TT37EDJ
DMA9RIS	MN	GABA(A) receptor alpha-3 (GABRA3)
DMA9RIS	MT	DTT
DMA9RIS	MA	Inhibitor
DMA9RIS	RN	gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83.
DMA9RIS	RU	https://pubmed.ncbi.nlm.nih.gov/6118436

DMA9RIS	DI	DMA9RIS
DMA9RIS	DN	(2E,4S)-4-ammoniopent-2-enoate
DMA9RIS	MI	TTNZPQ1
DMA9RIS	MN	GABA(A) receptor alpha-5 (GABRA5)
DMA9RIS	MT	DTT
DMA9RIS	MA	Inhibitor
DMA9RIS	RN	gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83.
DMA9RIS	RU	https://pubmed.ncbi.nlm.nih.gov/6118436

DMA9RIS	DI	DMA9RIS
DMA9RIS	DN	(2E,4S)-4-ammoniopent-2-enoate
DMA9RIS	MI	TTZA1NY
DMA9RIS	MN	GABA(A) receptor beta-2 (GABRB2)
DMA9RIS	MT	DTT
DMA9RIS	MA	Inhibitor
DMA9RIS	RN	gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83.
DMA9RIS	RU	https://pubmed.ncbi.nlm.nih.gov/6118436

DMA9RIS	DI	DMA9RIS
DMA9RIS	DN	(2E,4S)-4-ammoniopent-2-enoate
DMA9RIS	MI	TT06RH5
DMA9RIS	MN	GABA(A) receptor gamma-2 (GABRG2)
DMA9RIS	MT	DTT
DMA9RIS	MA	Inhibitor
DMA9RIS	RN	gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83.
DMA9RIS	RU	https://pubmed.ncbi.nlm.nih.gov/6118436

DMA9RIS	DI	DMA9RIS
DMA9RIS	DN	(2E,4S)-4-ammoniopent-2-enoate
DMA9RIS	MI	TTNJYV2
DMA9RIS	MN	Gamma-aminobutyric acid receptor (GAR)
DMA9RIS	MT	DTT
DMA9RIS	MA	Inhibitor
DMA9RIS	RN	gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83.
DMA9RIS	RU	https://pubmed.ncbi.nlm.nih.gov/6118436

DMN7XT9	DI	DMN7XT9
DMN7XT9	DN	(2-Ethoxy-ethyl)-trimethyl-ammonium iodide
DMN7XT9	MI	TT1RS9F
DMN7XT9	MN	Acetylcholinesterase (AChE)
DMN7XT9	MT	DTT
DMN7XT9	MA	Inhibitor
DMN7XT9	RN	Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors. J Med Chem. 1996 Dec 20;39(26):5064-71.
DMN7XT9	RU	https://pubmed.ncbi.nlm.nih.gov/8978837

DMFV76H	DI	DMFV76H
DMFV76H	DN	(2-fluorophenyl)-(4-fluorophenyl)phenylacetamide
DMFV76H	MI	TTMNI76
DMFV76H	MN	Calcium-activated potassium channel (KCN)
DMFV76H	MT	DTT
DMFV76H	MA	Inhibitor
DMFV76H	RN	Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82.
DMFV76H	RU	https://pubmed.ncbi.nlm.nih.gov/18232633

DMCHJL1	DI	DMCHJL1
DMCHJL1	DN	(2-hydroxy-3-phenoxypropyl)(propan-2-yl)amine
DMCHJL1	MI	TTVG215
DMCHJL1	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DMCHJL1	MT	DTT
DMCHJL1	MA	Inhibitor
DMCHJL1	RN	A 3D-QSAR model for CYP2D6 inhibition in the aryloxypropanolamine series. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3816-20.
DMCHJL1	RU	https://pubmed.ncbi.nlm.nih.gov/15993593

DMEZNXS	DI	DMEZNXS
DMEZNXS	DN	(2-hydroxyphenyl)(4-hydroxyphenyl)methanone
DMEZNXS	MI	TTGX0HR
DMEZNXS	MN	Bacterial DNA ligase (Bact ligA)
DMEZNXS	MT	DTT
DMEZNXS	MA	Inhibitor
DMEZNXS	RN	Identification and validation of human DNA ligase inhibitors using computer-aided drug design. J Med Chem. 2008 Aug 14;51(15):4553-62.
DMEZNXS	RU	https://pubmed.ncbi.nlm.nih.gov/18630893

DM24E08	DI	DM24E08
DM24E08	DN	(2-Indol-1-yl-ethyl)-dimethyl-amine
DM24E08	MI	TTJQOD7
DM24E08	MN	5-HT 2A receptor (HTR2A)
DM24E08	MT	DTT
DM24E08	MA	Inhibitor
DM24E08	RN	Evaluation of isotryptamine derivatives at 5-HT(2) serotonin receptors. Bioorg Med Chem Lett. 2002 Jan 21;12(2):155-8.
DM24E08	RU	https://pubmed.ncbi.nlm.nih.gov/11755343

DMCJKOQ	DI	DMCJKOQ
DMCJKOQ	DN	(2-Mercapto-ethyl)-trimethyl-ammonium iodide
DMCJKOQ	MI	TT1RS9F
DMCJKOQ	MN	Acetylcholinesterase (AChE)
DMCJKOQ	MT	DTT
DMCJKOQ	MA	Inhibitor
DMCJKOQ	RN	Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors. J Med Chem. 1996 Dec 20;39(26):5064-71.
DMCJKOQ	RU	https://pubmed.ncbi.nlm.nih.gov/8978837

DMQWD75	DI	DMQWD75
DMQWD75	DN	(2-Methoxy-phenyl)-(5-phenyl-oxazol-2-yl)-amine
DMQWD75	MI	TTUTJGQ
DMQWD75	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMQWD75	MT	DTT
DMQWD75	MA	Inhibitor
DMQWD75	RN	Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9.
DMQWD75	RU	https://pubmed.ncbi.nlm.nih.gov/15743202

DMQWD75	DI	DMQWD75
DMQWD75	DN	(2-Methoxy-phenyl)-(5-phenyl-oxazol-2-yl)-amine
DMQWD75	MI	TTDCBX5
DMQWD75	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DMQWD75	MT	DTT
DMQWD75	MA	Inhibitor
DMQWD75	RN	Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9.
DMQWD75	RU	https://pubmed.ncbi.nlm.nih.gov/15743202

DMQWD75	DI	DMQWD75
DMQWD75	DN	(2-Methoxy-phenyl)-(5-phenyl-oxazol-2-yl)-amine
DMQWD75	MI	TT1VAUK
DMQWD75	MN	VEGFR1 messenger RNA (VEGFR1 mRNA)
DMQWD75	MT	DTT
DMQWD75	MA	Inhibitor
DMQWD75	RN	Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9.
DMQWD75	RU	https://pubmed.ncbi.nlm.nih.gov/15743202

DME6MYZ	DI	DME6MYZ
DME6MYZ	DN	(2-Methyl-indol-1-yl)-propyl-pyridin-4-yl-amine
DME6MYZ	MI	TTWG9A4
DME6MYZ	MN	Adrenergic receptor alpha-2A (ADRA2A)
DME6MYZ	MT	DTT
DME6MYZ	MA	Inhibitor
DME6MYZ	RN	Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81.
DME6MYZ	RU	https://pubmed.ncbi.nlm.nih.gov/8558529

DME6MYZ	DI	DME6MYZ
DME6MYZ	DN	(2-Methyl-indol-1-yl)-propyl-pyridin-4-yl-amine
DME6MYZ	MI	TTWM4TY
DME6MYZ	MN	Adrenergic receptor alpha-2B (ADRA2B)
DME6MYZ	MT	DTT
DME6MYZ	MA	Inhibitor
DME6MYZ	RN	Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81.
DME6MYZ	RU	https://pubmed.ncbi.nlm.nih.gov/8558529

DME6MYZ	DI	DME6MYZ
DME6MYZ	DN	(2-Methyl-indol-1-yl)-propyl-pyridin-4-yl-amine
DME6MYZ	MI	TT2NUT5
DME6MYZ	MN	Adrenergic receptor alpha-2C (ADRA2C)
DME6MYZ	MT	DTT
DME6MYZ	MA	Inhibitor
DME6MYZ	RN	Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81.
DME6MYZ	RU	https://pubmed.ncbi.nlm.nih.gov/8558529

DMQ2XUE	DI	DMQ2XUE
DMQ2XUE	DN	(2R)-1-(2,6-dimethylphenoxy)propan-2-amine
DMQ2XUE	MI	TTGY7WI
DMQ2XUE	MN	Urokinase-type plasminogen activator (PLAU)
DMQ2XUE	MT	DTT
DMQ2XUE	MA	Inhibitor
DMQ2XUE	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMQ2XUE	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM3K2TI	DI	DM3K2TI
DM3K2TI	DN	(2R)-2-Methyl-4,5-dideoxy
DM3K2TI	MI	TTZ3IFB
DM3K2TI	MN	Phosphogluconate dehydrogenase (PGD)
DM3K2TI	MT	DTT
DM3K2TI	MA	Inhibitor
DM3K2TI	RN	Synthesis and biological evaluation of substrate-based inhibitors of 6-phosphogluconate dehydrogenase as potential drugs against African trypanosomiasis. Bioorg Med Chem. 2003 Jul 17;11(14):3205-14.
DM3K2TI	RU	https://pubmed.ncbi.nlm.nih.gov/12818683

DMXPQU6	DI	DMXPQU6
DMXPQU6	DN	(2R)-N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX)
DMXPQU6	MI	TT6OEDT
DMXPQU6	MN	Cannabinoid receptor 1 (CB1)
DMXPQU6	MT	DTT
DMXPQU6	MA	Inhibitor
DMXPQU6	RN	Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4.
DMXPQU6	RU	https://pubmed.ncbi.nlm.nih.gov/20483606

DMXPQU6	DI	DMXPQU6
DMXPQU6	DN	(2R)-N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX)
DMXPQU6	MI	TTMSFAW
DMXPQU6	MN	Cannabinoid receptor 2 (CB2)
DMXPQU6	MT	DTT
DMXPQU6	MA	Inhibitor
DMXPQU6	RN	Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4.
DMXPQU6	RU	https://pubmed.ncbi.nlm.nih.gov/20483606

DMXPQU6	DI	DMXPQU6
DMXPQU6	DN	(2R)-N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX)
DMXPQU6	MI	TTQ6VDM
DMXPQU6	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMXPQU6	MT	DTT
DMXPQU6	MA	Inhibitor
DMXPQU6	RN	Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4.
DMXPQU6	RU	https://pubmed.ncbi.nlm.nih.gov/20483606

DMX0YIV	DI	DMX0YIV
DMX0YIV	DN	(2R)-N-(7'-(2-CHLOROPHENYL)-6'-(4-CHLOROPHENYL)-3',4'-DIHYDROSPIRO[CYCLOHEXANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX)
DMX0YIV	MI	TT6OEDT
DMX0YIV	MN	Cannabinoid receptor 1 (CB1)
DMX0YIV	MT	DTT
DMX0YIV	MA	Inhibitor
DMX0YIV	RN	Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4.
DMX0YIV	RU	https://pubmed.ncbi.nlm.nih.gov/20483606

DMX0YIV	DI	DMX0YIV
DMX0YIV	DN	(2R)-N-(7'-(2-CHLOROPHENYL)-6'-(4-CHLOROPHENYL)-3',4'-DIHYDROSPIRO[CYCLOHEXANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX)
DMX0YIV	MI	TTMSFAW
DMX0YIV	MN	Cannabinoid receptor 2 (CB2)
DMX0YIV	MT	DTT
DMX0YIV	MA	Inhibitor
DMX0YIV	RN	Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4.
DMX0YIV	RU	https://pubmed.ncbi.nlm.nih.gov/20483606

DMYRHFI	DI	DMYRHFI
DMYRHFI	DN	(2R,3R)-iodoreboxetine
DMYRHFI	MI	TTVBI8W
DMYRHFI	MN	Dopamine transporter (DAT)
DMYRHFI	MT	DTT
DMYRHFI	MA	Inhibitor
DMYRHFI	RN	New iodoreboxetine analogues for SPECT imaging of the noradrenaline transporter. Bioorg Med Chem Lett. 2008 Sep 15;18(18):4940-3.
DMYRHFI	RU	https://pubmed.ncbi.nlm.nih.gov/18762424

DMYRHFI	DI	DMYRHFI
DMYRHFI	DN	(2R,3R)-iodoreboxetine
DMYRHFI	MI	TT3ROYC
DMYRHFI	MN	Serotonin transporter (SERT)
DMYRHFI	MT	DTT
DMYRHFI	MA	Inhibitor
DMYRHFI	RN	New iodoreboxetine analogues for SPECT imaging of the noradrenaline transporter. Bioorg Med Chem Lett. 2008 Sep 15;18(18):4940-3.
DMYRHFI	RU	https://pubmed.ncbi.nlm.nih.gov/18762424

DMY2FX8	DI	DMY2FX8
DMY2FX8	DN	(2R,3S)-2-[(2-Iodophenoxy)phenylmethyl]morpholine
DMY2FX8	MI	TTVBI8W
DMY2FX8	MN	Dopamine transporter (DAT)
DMY2FX8	MT	DTT
DMY2FX8	MA	Inhibitor
DMY2FX8	RN	Design and synthesis of (2R,3S)-iodoreboxetine analogues for SPECT imaging of the noradrenaline transporter. Bioorg Med Chem Lett. 2009 Sep 1;19(17):4996-8.
DMY2FX8	RU	https://pubmed.ncbi.nlm.nih.gov/19640707

DMY2FX8	DI	DMY2FX8
DMY2FX8	DN	(2R,3S)-2-[(2-Iodophenoxy)phenylmethyl]morpholine
DMY2FX8	MI	TT3ROYC
DMY2FX8	MN	Serotonin transporter (SERT)
DMY2FX8	MT	DTT
DMY2FX8	MA	Inhibitor
DMY2FX8	RN	Design and synthesis of (2R,3S)-iodoreboxetine analogues for SPECT imaging of the noradrenaline transporter. Bioorg Med Chem Lett. 2009 Sep 1;19(17):4996-8.
DMY2FX8	RU	https://pubmed.ncbi.nlm.nih.gov/19640707

DM260TI	DI	DM260TI
DM260TI	DN	(2R,3S)-2-[(3-Iodophenoxy)phenylmethyl]morpholine
DM260TI	MI	TTVBI8W
DM260TI	MN	Dopamine transporter (DAT)
DM260TI	MT	DTT
DM260TI	MA	Inhibitor
DM260TI	RN	Design and synthesis of (2R,3S)-iodoreboxetine analogues for SPECT imaging of the noradrenaline transporter. Bioorg Med Chem Lett. 2009 Sep 1;19(17):4996-8.
DM260TI	RU	https://pubmed.ncbi.nlm.nih.gov/19640707

DM260TI	DI	DM260TI
DM260TI	DN	(2R,3S)-2-[(3-Iodophenoxy)phenylmethyl]morpholine
DM260TI	MI	TT3ROYC
DM260TI	MN	Serotonin transporter (SERT)
DM260TI	MT	DTT
DM260TI	MA	Inhibitor
DM260TI	RN	Design and synthesis of (2R,3S)-iodoreboxetine analogues for SPECT imaging of the noradrenaline transporter. Bioorg Med Chem Lett. 2009 Sep 1;19(17):4996-8.
DM260TI	RU	https://pubmed.ncbi.nlm.nih.gov/19640707

DMKM8E2	DI	DMKM8E2
DMKM8E2	DN	(2R,3S)-2-[(4-Iodophenoxy)phenylmethyl]morpholine
DMKM8E2	MI	TTVBI8W
DMKM8E2	MN	Dopamine transporter (DAT)
DMKM8E2	MT	DTT
DMKM8E2	MA	Inhibitor
DMKM8E2	RN	Design and synthesis of (2R,3S)-iodoreboxetine analogues for SPECT imaging of the noradrenaline transporter. Bioorg Med Chem Lett. 2009 Sep 1;19(17):4996-8.
DMKM8E2	RU	https://pubmed.ncbi.nlm.nih.gov/19640707

DMKM8E2	DI	DMKM8E2
DMKM8E2	DN	(2R,3S)-2-[(4-Iodophenoxy)phenylmethyl]morpholine
DMKM8E2	MI	TT3ROYC
DMKM8E2	MN	Serotonin transporter (SERT)
DMKM8E2	MT	DTT
DMKM8E2	MA	Inhibitor
DMKM8E2	RN	Design and synthesis of (2R,3S)-iodoreboxetine analogues for SPECT imaging of the noradrenaline transporter. Bioorg Med Chem Lett. 2009 Sep 1;19(17):4996-8.
DMKM8E2	RU	https://pubmed.ncbi.nlm.nih.gov/19640707

DM852Z6	DI	DM852Z6
DM852Z6	DN	(2R,3S)-3-(6-Amino-purin-9-yl)-nonan-2-ol
DM852Z6	MI	TTM2AOE
DM852Z6	MN	Adenosine A2a receptor (ADORA2A)
DM852Z6	MT	DTT
DM852Z6	MA	Inhibitor
DM852Z6	RN	Structure-activity relationships of 9-alkyladenine and ribose-modified adenosine derivatives at rat A3 adenosine receptors. J Med Chem. 1995 May 12;38(10):1720-35.
DM852Z6	RU	https://pubmed.ncbi.nlm.nih.gov/7752196

DM852Z6	DI	DM852Z6
DM852Z6	DN	(2R,3S)-3-(6-Amino-purin-9-yl)-nonan-2-ol
DM852Z6	MI	TTJFY5U
DM852Z6	MN	Adenosine A3 receptor (ADORA3)
DM852Z6	MT	DTT
DM852Z6	MA	Inhibitor
DM852Z6	RN	Structure-activity relationships of 9-alkyladenine and ribose-modified adenosine derivatives at rat A3 adenosine receptors. J Med Chem. 1995 May 12;38(10):1720-35.
DM852Z6	RU	https://pubmed.ncbi.nlm.nih.gov/7752196

DM852Z6	DI	DM852Z6
DM852Z6	DN	(2R,3S)-3-(6-Amino-purin-9-yl)-nonan-2-ol
DM852Z6	MI	TTJGW1Z
DM852Z6	MN	Phosphodiesterase 2A (PDE2A)
DM852Z6	MT	DTT
DM852Z6	MA	Inhibitor
DM852Z6	RN	The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases. J Med Chem. 2005 May 19;48(10):3449-62.
DM852Z6	RU	https://pubmed.ncbi.nlm.nih.gov/15887951

DMDS8AN	DI	DMDS8AN
DMDS8AN	DN	(2R,3S,4S,5R)-2-hexylpiperidine-3,4,5-triol
DMDS8AN	MI	TT1B5PU
DMDS8AN	MN	Glucosylceramidase (GBA)
DMDS8AN	MT	DTT
DMDS8AN	MA	Inhibitor
DMDS8AN	RN	Synthesis of new beta-1-C-alkylated imino-L-iditols: A comparative study of their activity as beta-glucocerebrosidase inhibitors. Bioorg Med Chem. 2010 Apr 1;18(7):2645-50.
DMDS8AN	RU	https://pubmed.ncbi.nlm.nih.gov/20231099

DMIQNX9	DI	DMIQNX9
DMIQNX9	DN	(2R,3S,4S,5R)-2-nonylpiperidine-3,4,5-triol
DMIQNX9	MI	TT1B5PU
DMIQNX9	MN	Glucosylceramidase (GBA)
DMIQNX9	MT	DTT
DMIQNX9	MA	Inhibitor
DMIQNX9	RN	Synthesis of new beta-1-C-alkylated imino-L-iditols: A comparative study of their activity as beta-glucocerebrosidase inhibitors. Bioorg Med Chem. 2010 Apr 1;18(7):2645-50.
DMIQNX9	RU	https://pubmed.ncbi.nlm.nih.gov/20231099

DM7GI94	DI	DM7GI94
DM7GI94	DN	(2R,3S,4S,5R)-2-propylpiperidine-3,4,5-triol
DM7GI94	MI	TT1B5PU
DM7GI94	MN	Glucosylceramidase (GBA)
DM7GI94	MT	DTT
DM7GI94	MA	Inhibitor
DM7GI94	RN	Synthesis of new beta-1-C-alkylated imino-L-iditols: A comparative study of their activity as beta-glucocerebrosidase inhibitors. Bioorg Med Chem. 2010 Apr 1;18(7):2645-50.
DM7GI94	RU	https://pubmed.ncbi.nlm.nih.gov/20231099

DMYW40T	DI	DMYW40T
DMYW40T	DN	(2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate
DMYW40T	MI	TTXJ47W
DMYW40T	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMYW40T	MT	DTT
DMYW40T	MA	Agonist
DMYW40T	RN	Group II metabotropic glutamate receptors within the amygdala regulate fear as assessed with potentiated startle in rats. Behav Neurosci. 2002 Dec;116(6):1075-83.
DMYW40T	RU	https://pubmed.ncbi.nlm.nih.gov/12492306

DMSFXEO	DI	DMSFXEO
DMSFXEO	DN	(2R,5R)-delta-methyl-alpha-acetylenic putrescine
DMSFXEO	MI	TTUMGNO
DMSFXEO	MN	Ornithine decarboxylase (ODC1)
DMSFXEO	MT	DTT
DMSFXEO	MA	Inhibitor
DMSFXEO	RN	Plasmodium falciparum and Plasmodium berghei: effects of ornithine decarboxylase inhibitors on erythrocytic schizogony. Exp Parasitol. 1987 Oct;64(2):237-43.
DMSFXEO	RU	https://pubmed.ncbi.nlm.nih.gov/3115816

DMIS39C	DI	DMIS39C
DMIS39C	DN	(2S)-1-(1H-furo[2,3-g]indazol-1-yl)propan-2-amine
DMIS39C	MI	TTJQOD7
DMIS39C	MN	5-HT 2A receptor (HTR2A)
DMIS39C	MT	DTT
DMIS39C	MA	Inhibitor
DMIS39C	RN	Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor a... Bioorg Med Chem. 2008 Feb 15;16(4):1966-82.
DMIS39C	RU	https://pubmed.ncbi.nlm.nih.gov/18035544

DMIS39C	DI	DMIS39C
DMIS39C	DN	(2S)-1-(1H-furo[2,3-g]indazol-1-yl)propan-2-amine
DMIS39C	MI	TTWJBZ5
DMIS39C	MN	5-HT 2C receptor (HTR2C)
DMIS39C	MT	DTT
DMIS39C	MA	Inhibitor
DMIS39C	RN	Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor a... Bioorg Med Chem. 2008 Feb 15;16(4):1966-82.
DMIS39C	RU	https://pubmed.ncbi.nlm.nih.gov/18035544

DMW4ARM	DI	DMW4ARM
DMW4ARM	DN	(2S)-1-(5-fluoro-1H-indazol-1-yl)propan-2-amine
DMW4ARM	MI	TTJQOD7
DMW4ARM	MN	5-HT 2A receptor (HTR2A)
DMW4ARM	MT	DTT
DMW4ARM	MA	Inhibitor
DMW4ARM	RN	Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor a... Bioorg Med Chem. 2008 Feb 15;16(4):1966-82.
DMW4ARM	RU	https://pubmed.ncbi.nlm.nih.gov/18035544

DMW4ARM	DI	DMW4ARM
DMW4ARM	DN	(2S)-1-(5-fluoro-1H-indazol-1-yl)propan-2-amine
DMW4ARM	MI	TTWJBZ5
DMW4ARM	MN	5-HT 2C receptor (HTR2C)
DMW4ARM	MT	DTT
DMW4ARM	MA	Inhibitor
DMW4ARM	RN	Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor a... Bioorg Med Chem. 2008 Feb 15;16(4):1966-82.
DMW4ARM	RU	https://pubmed.ncbi.nlm.nih.gov/18035544

DM31SNW	DI	DM31SNW
DM31SNW	DN	(2S)-1-(6-fluoro-1H-indazol-1-yl)propan-2-amine
DM31SNW	MI	TTJQOD7
DM31SNW	MN	5-HT 2A receptor (HTR2A)
DM31SNW	MT	DTT
DM31SNW	MA	Inhibitor
DM31SNW	RN	Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor a... Bioorg Med Chem. 2008 Feb 15;16(4):1966-82.
DM31SNW	RU	https://pubmed.ncbi.nlm.nih.gov/18035544

DM31SNW	DI	DM31SNW
DM31SNW	DN	(2S)-1-(6-fluoro-1H-indazol-1-yl)propan-2-amine
DM31SNW	MI	TTWJBZ5
DM31SNW	MN	5-HT 2C receptor (HTR2C)
DM31SNW	MT	DTT
DM31SNW	MA	Inhibitor
DM31SNW	RN	Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor a... Bioorg Med Chem. 2008 Feb 15;16(4):1966-82.
DM31SNW	RU	https://pubmed.ncbi.nlm.nih.gov/18035544

DMYALON	DI	DMYALON
DMYALON	DN	(2S)-1-(6-methoxy-1H-indazol-1-yl)propan-2-amine
DMYALON	MI	TTJQOD7
DMYALON	MN	5-HT 2A receptor (HTR2A)
DMYALON	MT	DTT
DMYALON	MA	Inhibitor
DMYALON	RN	1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28.
DMYALON	RU	https://pubmed.ncbi.nlm.nih.gov/16392816

DMYALON	DI	DMYALON
DMYALON	DN	(2S)-1-(6-methoxy-1H-indazol-1-yl)propan-2-amine
DMYALON	MI	TT0K1SC
DMYALON	MN	5-HT 2B receptor (HTR2B)
DMYALON	MT	DTT
DMYALON	MA	Inhibitor
DMYALON	RN	1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28.
DMYALON	RU	https://pubmed.ncbi.nlm.nih.gov/16392816

DMYALON	DI	DMYALON
DMYALON	DN	(2S)-1-(6-methoxy-1H-indazol-1-yl)propan-2-amine
DMYALON	MI	TTWJBZ5
DMYALON	MN	5-HT 2C receptor (HTR2C)
DMYALON	MT	DTT
DMYALON	MA	Inhibitor
DMYALON	RN	Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor a... Bioorg Med Chem. 2008 Feb 15;16(4):1966-82.
DMYALON	RU	https://pubmed.ncbi.nlm.nih.gov/18035544

DMNKEUG	DI	DMNKEUG
DMNKEUG	DN	(2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
DMNKEUG	MI	TTZMAO3
DMNKEUG	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMNKEUG	MT	DTT
DMNKEUG	MA	Inhibitor
DMNKEUG	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMNKEUG	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMYBXHF	DI	DMYBXHF
DMYBXHF	DN	(2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
DMYBXHF	MI	TTZMAO3
DMYBXHF	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMYBXHF	MT	DTT
DMYBXHF	MA	Inhibitor
DMYBXHF	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMYBXHF	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM73TPQ	DI	DM73TPQ
DM73TPQ	DN	(2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
DM73TPQ	MI	TTZMAO3
DM73TPQ	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DM73TPQ	MT	DTT
DM73TPQ	MA	Inhibitor
DM73TPQ	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM73TPQ	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMMP8TR	DI	DMMP8TR
DMMP8TR	DN	(2S)-2-(BUTYRYLOXY)-3-HYDROXYPROPYL NONANOATE
DMMP8TR	MI	TTYOMFZ
DMMP8TR	MN	Voltage-gated potassium channel (VGKC)
DMMP8TR	MT	DTT
DMMP8TR	MA	Inhibitor
DMMP8TR	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMMP8TR	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMZOX43	DI	DMZOX43
DMZOX43	DN	(2S)-2'-methoxy kurarinone
DMZOX43	MI	TT8JRS7
DMZOX43	MN	Beta-secretase (BACE)
DMZOX43	MT	DTT
DMZOX43	MA	Inhibitor
DMZOX43	RN	BACE1 inhibitory effects of lavandulyl flavanones from Sophora flavescens. Bioorg Med Chem. 2008 Jul 15;16(14):6669-74.
DMZOX43	RU	https://pubmed.ncbi.nlm.nih.gov/18565755

DMYVBHT	DI	DMYVBHT
DMYVBHT	DN	(2S)-5,7,2',4'-tetrahydroxyflavanone
DMYVBHT	MI	TTSZLWK
DMYVBHT	MN	Aromatase (CYP19A1)
DMYVBHT	MT	DTT
DMYVBHT	MA	Inhibitor
DMYVBHT	RN	Aromatase inhibitors from Broussonetia papyrifera. J Nat Prod. 2001 Oct;64(10):1286-93.
DMYVBHT	RU	https://pubmed.ncbi.nlm.nih.gov/11678652

DM5V3M1	DI	DM5V3M1
DM5V3M1	DN	(2S)-abyssinone II
DM5V3M1	MI	TTSZLWK
DM5V3M1	MN	Aromatase (CYP19A1)
DM5V3M1	MT	DTT
DM5V3M1	MA	Inhibitor
DM5V3M1	RN	Aromatase inhibitors from Broussonetia papyrifera. J Nat Prod. 2001 Oct;64(10):1286-93.
DM5V3M1	RU	https://pubmed.ncbi.nlm.nih.gov/11678652

DMWQK86	DI	DMWQK86
DMWQK86	DN	(2S)-aminobutyryl-(R)-pipecolinic acid amide
DMWQK86	MI	TTQ7R2V
DMWQK86	MN	Tripeptidyl-peptidase II (TPP2)
DMWQK86	MT	DTT
DMWQK86	MA	Inhibitor
DMWQK86	RN	Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach ... J Med Chem. 2005 Nov 17;48(23):7333-42.
DMWQK86	RU	https://pubmed.ncbi.nlm.nih.gov/16279793

DMG0QKL	DI	DMG0QKL
DMG0QKL	DN	(2S)-aminobutyryl-L-prolinamide
DMG0QKL	MI	TTQ7R2V
DMG0QKL	MN	Tripeptidyl-peptidase II (TPP2)
DMG0QKL	MT	DTT
DMG0QKL	MA	Inhibitor
DMG0QKL	RN	Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach ... J Med Chem. 2005 Nov 17;48(23):7333-42.
DMG0QKL	RU	https://pubmed.ncbi.nlm.nih.gov/16279793

DMTFP0Z	DI	DMTFP0Z
DMTFP0Z	DN	(2S)-aminobutyryl-L-proline (R)-sec-butylamide
DMTFP0Z	MI	TTQ7R2V
DMTFP0Z	MN	Tripeptidyl-peptidase II (TPP2)
DMTFP0Z	MT	DTT
DMTFP0Z	MA	Inhibitor
DMTFP0Z	RN	Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach ... J Med Chem. 2005 Nov 17;48(23):7333-42.
DMTFP0Z	RU	https://pubmed.ncbi.nlm.nih.gov/16279793

DMO5ZEK	DI	DMO5ZEK
DMO5ZEK	DN	(2S)-aminobutyryl-L-proline isobutylamide
DMO5ZEK	MI	TTQ7R2V
DMO5ZEK	MN	Tripeptidyl-peptidase II (TPP2)
DMO5ZEK	MT	DTT
DMO5ZEK	MA	Inhibitor
DMO5ZEK	RN	Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach ... J Med Chem. 2005 Nov 17;48(23):7333-42.
DMO5ZEK	RU	https://pubmed.ncbi.nlm.nih.gov/16279793

DM12Q9O	DI	DM12Q9O
DM12Q9O	DN	(2S)-aminobutyryl-L-proline n-butylamide
DM12Q9O	MI	TTQ7R2V
DM12Q9O	MN	Tripeptidyl-peptidase II (TPP2)
DM12Q9O	MT	DTT
DM12Q9O	MA	Inhibitor
DM12Q9O	RN	Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach ... J Med Chem. 2005 Nov 17;48(23):7333-42.
DM12Q9O	RU	https://pubmed.ncbi.nlm.nih.gov/16279793

DM1DJX2	DI	DM1DJX2
DM1DJX2	DN	(2S)-aminobutyryl-L-proline n-pentylamide
DM1DJX2	MI	TTQ7R2V
DM1DJX2	MN	Tripeptidyl-peptidase II (TPP2)
DM1DJX2	MT	DTT
DM1DJX2	MA	Inhibitor
DM1DJX2	RN	Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach ... J Med Chem. 2005 Nov 17;48(23):7333-42.
DM1DJX2	RU	https://pubmed.ncbi.nlm.nih.gov/16279793

DM6WXJO	DI	DM6WXJO
DM6WXJO	DN	(2S)-aminobutyryl-L-proline n-propylamide
DM6WXJO	MI	TTQ7R2V
DM6WXJO	MN	Tripeptidyl-peptidase II (TPP2)
DM6WXJO	MT	DTT
DM6WXJO	MA	Inhibitor
DM6WXJO	RN	Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach ... J Med Chem. 2005 Nov 17;48(23):7333-42.
DM6WXJO	RU	https://pubmed.ncbi.nlm.nih.gov/16279793

DMEWU6Z	DI	DMEWU6Z
DMEWU6Z	DN	(2S)-aminobutyryl-L-proline-(2S)-methylbutylamide
DMEWU6Z	MI	TTQ7R2V
DMEWU6Z	MN	Tripeptidyl-peptidase II (TPP2)
DMEWU6Z	MT	DTT
DMEWU6Z	MA	Inhibitor
DMEWU6Z	RN	Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach ... J Med Chem. 2005 Nov 17;48(23):7333-42.
DMEWU6Z	RU	https://pubmed.ncbi.nlm.nih.gov/16279793

DM6L0KZ	DI	DM6L0KZ
DM6L0KZ	DN	(2S)-euchrenone a7
DM6L0KZ	MI	TTSZLWK
DM6L0KZ	MN	Aromatase (CYP19A1)
DM6L0KZ	MT	DTT
DM6L0KZ	MA	Inhibitor
DM6L0KZ	RN	Aromatase inhibitors from Broussonetia papyrifera. J Nat Prod. 2001 Oct;64(10):1286-93.
DM6L0KZ	RU	https://pubmed.ncbi.nlm.nih.gov/11678652

DMRCMIT	DI	DMRCMIT
DMRCMIT	DN	(2S)-N-(7'-(2-CHLOROPHENYL)-6'-(4-CHLOROPHENYL)-3',4'-DIHYDROSPIRO[CYCLOHEXANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX)
DMRCMIT	MI	TT6OEDT
DMRCMIT	MN	Cannabinoid receptor 1 (CB1)
DMRCMIT	MT	DTT
DMRCMIT	MA	Inhibitor
DMRCMIT	RN	Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4.
DMRCMIT	RU	https://pubmed.ncbi.nlm.nih.gov/20483606

DMRCMIT	DI	DMRCMIT
DMRCMIT	DN	(2S)-N-(7'-(2-CHLOROPHENYL)-6'-(4-CHLOROPHENYL)-3',4'-DIHYDROSPIRO[CYCLOHEXANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX)
DMRCMIT	MI	TTMSFAW
DMRCMIT	MN	Cannabinoid receptor 2 (CB2)
DMRCMIT	MT	DTT
DMRCMIT	MA	Inhibitor
DMRCMIT	RN	Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4.
DMRCMIT	RU	https://pubmed.ncbi.nlm.nih.gov/20483606

DMZON3T	DI	DMZON3T
DMZON3T	DN	(2s)-Pyrrolidin-2-Ylmethylamine
DMZON3T	MI	TTDIGC1
DMZON3T	MN	Dipeptidyl peptidase 4 (DPP-4)
DMZON3T	MT	DTT
DMZON3T	MA	Inhibitor
DMZON3T	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMZON3T	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMLS29E	DI	DMLS29E
DMLS29E	DN	(2S,1'R,2'S)-2-(2'-phosphonocyclopropyl)glycine
DMLS29E	MI	TTICZ1O
DMLS29E	MN	Metabotropic glutamate receptor 4 (mGluR4)
DMLS29E	MT	DTT
DMLS29E	MA	Inhibitor
DMLS29E	RN	Synthesis and preliminary pharmacological evaluation of the four stereoisomers of (2S)-2-(2'-phosphono-3'-phenylcyclopropyl)glycine, the first clas... Bioorg Med Chem. 2007 May 1;15(9):3161-70.
DMLS29E	RU	https://pubmed.ncbi.nlm.nih.gov/17350267

DMJE83O	DI	DMJE83O
DMJE83O	DN	(2S,3R)-2-(benzyloxy)-3-methoxycyclohexanone
DMJE83O	MI	TT9W8GU
DMJE83O	MN	Gamma-secretase (GS)
DMJE83O	MT	DTT
DMJE83O	MA	Inhibitor
DMJE83O	RN	Novel gamma-secretase inhibitors discovered by library screening of in-house synthetic natural product intermediates. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3813-6.
DMJE83O	RU	https://pubmed.ncbi.nlm.nih.gov/16682195

DMJE83O	DI	DMJE83O
DMJE83O	DN	(2S,3R)-2-(benzyloxy)-3-methoxycyclohexanone
DMJE83O	MI	TTZ3S8C
DMJE83O	MN	Presenilin 1 (PSEN1)
DMJE83O	MT	DTT
DMJE83O	MA	Inhibitor
DMJE83O	RN	Novel gamma-secretase inhibitors discovered by library screening of in-house synthetic natural product intermediates. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3813-6.
DMJE83O	RU	https://pubmed.ncbi.nlm.nih.gov/16682195

DMJE83O	DI	DMJE83O
DMJE83O	DN	(2S,3R)-2-(benzyloxy)-3-methoxycyclohexanone
DMJE83O	MI	TTWN3F4
DMJE83O	MN	Presenilin 2 (PSEN2)
DMJE83O	MT	DTT
DMJE83O	MA	Inhibitor
DMJE83O	RN	Novel gamma-secretase inhibitors discovered by library screening of in-house synthetic natural product intermediates. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3813-6.
DMJE83O	RU	https://pubmed.ncbi.nlm.nih.gov/16682195

DM4JQCR	DI	DM4JQCR
DM4JQCR	DN	(2S,3R)-3-(6-amino-9H-purin-9-yl)nonan-2-ol
DM4JQCR	MI	TTLP57V
DM4JQCR	MN	Adenosine deaminase (ADA)
DM4JQCR	MT	DTT
DM4JQCR	MA	Inhibitor
DM4JQCR	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM4JQCR	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMDUI8R	DI	DMDUI8R
DMDUI8R	DN	(2S,3S)-2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol
DMDUI8R	MI	TTVBI8W
DMDUI8R	MN	Dopamine transporter (DAT)
DMDUI8R	MT	DTT
DMDUI8R	MA	Inhibitor
DMDUI8R	RN	Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation. J Med Chem. 2010 Jun 24;53(12):4731-48.
DMDUI8R	RU	https://pubmed.ncbi.nlm.nih.gov/20509659

DMDUI8R	DI	DMDUI8R
DMDUI8R	DN	(2S,3S)-2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol
DMDUI8R	MI	TT4H1MQ
DMDUI8R	MN	Neuronal acetylcholine receptor alpha-4 (CHRNA4)
DMDUI8R	MT	DTT
DMDUI8R	MA	Inhibitor
DMDUI8R	RN	Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation. J Med Chem. 2010 Jun 24;53(12):4731-48.
DMDUI8R	RU	https://pubmed.ncbi.nlm.nih.gov/20509659

DMDUI8R	DI	DMDUI8R
DMDUI8R	DN	(2S,3S)-2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol
DMDUI8R	MI	TT5KPZR
DMDUI8R	MN	Neuronal acetylcholine receptor beta-2 (CHRNB2)
DMDUI8R	MT	DTT
DMDUI8R	MA	Inhibitor
DMDUI8R	RN	Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation. J Med Chem. 2010 Jun 24;53(12):4731-48.
DMDUI8R	RU	https://pubmed.ncbi.nlm.nih.gov/20509659

DMDUI8R	DI	DMDUI8R
DMDUI8R	DN	(2S,3S)-2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol
DMDUI8R	MI	TTTVAFQ
DMDUI8R	MN	Neuronal acetylcholine receptor beta-4 (CHRNB4)
DMDUI8R	MT	DTT
DMDUI8R	MA	Inhibitor
DMDUI8R	RN	Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation. J Med Chem. 2010 Jun 24;53(12):4731-48.
DMDUI8R	RU	https://pubmed.ncbi.nlm.nih.gov/20509659

DMDUI8R	DI	DMDUI8R
DMDUI8R	DN	(2S,3S)-2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol
DMDUI8R	MI	TTAWNKZ
DMDUI8R	MN	Norepinephrine transporter (NET)
DMDUI8R	MT	DTT
DMDUI8R	MA	Inhibitor
DMDUI8R	RN	Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation. J Med Chem. 2010 Jun 24;53(12):4731-48.
DMDUI8R	RU	https://pubmed.ncbi.nlm.nih.gov/20509659

DMDUGZS	DI	DMDUGZS
DMDUGZS	DN	(2S,3S)-2-Phenyl-3,5,5-trimethylmorpholin-2-ol
DMDUGZS	MI	TTVBI8W
DMDUGZS	MN	Dopamine transporter (DAT)
DMDUGZS	MT	DTT
DMDUGZS	MA	Inhibitor
DMDUGZS	RN	Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation. J Med Chem. 2010 Jun 24;53(12):4731-48.
DMDUGZS	RU	https://pubmed.ncbi.nlm.nih.gov/20509659

DMDUGZS	DI	DMDUGZS
DMDUGZS	DN	(2S,3S)-2-Phenyl-3,5,5-trimethylmorpholin-2-ol
DMDUGZS	MI	TT4H1MQ
DMDUGZS	MN	Neuronal acetylcholine receptor alpha-4 (CHRNA4)
DMDUGZS	MT	DTT
DMDUGZS	MA	Inhibitor
DMDUGZS	RN	Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation. J Med Chem. 2010 Jun 24;53(12):4731-48.
DMDUGZS	RU	https://pubmed.ncbi.nlm.nih.gov/20509659

DMDUGZS	DI	DMDUGZS
DMDUGZS	DN	(2S,3S)-2-Phenyl-3,5,5-trimethylmorpholin-2-ol
DMDUGZS	MI	TT5KPZR
DMDUGZS	MN	Neuronal acetylcholine receptor beta-2 (CHRNB2)
DMDUGZS	MT	DTT
DMDUGZS	MA	Inhibitor
DMDUGZS	RN	Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation. J Med Chem. 2010 Jun 24;53(12):4731-48.
DMDUGZS	RU	https://pubmed.ncbi.nlm.nih.gov/20509659

DMDUGZS	DI	DMDUGZS
DMDUGZS	DN	(2S,3S)-2-Phenyl-3,5,5-trimethylmorpholin-2-ol
DMDUGZS	MI	TTTVAFQ
DMDUGZS	MN	Neuronal acetylcholine receptor beta-4 (CHRNB4)
DMDUGZS	MT	DTT
DMDUGZS	MA	Inhibitor
DMDUGZS	RN	Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation. J Med Chem. 2010 Jun 24;53(12):4731-48.
DMDUGZS	RU	https://pubmed.ncbi.nlm.nih.gov/20509659

DMDUGZS	DI	DMDUGZS
DMDUGZS	DN	(2S,3S)-2-Phenyl-3,5,5-trimethylmorpholin-2-ol
DMDUGZS	MI	TTAWNKZ
DMDUGZS	MN	Norepinephrine transporter (NET)
DMDUGZS	MT	DTT
DMDUGZS	MA	Inhibitor
DMDUGZS	RN	Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation. J Med Chem. 2010 Jun 24;53(12):4731-48.
DMDUGZS	RU	https://pubmed.ncbi.nlm.nih.gov/20509659

DMBEOIQ	DI	DMBEOIQ
DMBEOIQ	DN	(2S,3S)-iodoreboxetine
DMBEOIQ	MI	TTVBI8W
DMBEOIQ	MN	Dopamine transporter (DAT)
DMBEOIQ	MT	DTT
DMBEOIQ	MA	Inhibitor
DMBEOIQ	RN	New iodoreboxetine analogues for SPECT imaging of the noradrenaline transporter. Bioorg Med Chem Lett. 2008 Sep 15;18(18):4940-3.
DMBEOIQ	RU	https://pubmed.ncbi.nlm.nih.gov/18762424

DMBEOIQ	DI	DMBEOIQ
DMBEOIQ	DN	(2S,3S)-iodoreboxetine
DMBEOIQ	MI	TT3ROYC
DMBEOIQ	MN	Serotonin transporter (SERT)
DMBEOIQ	MT	DTT
DMBEOIQ	MA	Inhibitor
DMBEOIQ	RN	New iodoreboxetine analogues for SPECT imaging of the noradrenaline transporter. Bioorg Med Chem Lett. 2008 Sep 15;18(18):4940-3.
DMBEOIQ	RU	https://pubmed.ncbi.nlm.nih.gov/18762424

DMTQF2G	DI	DMTQF2G
DMTQF2G	DN	(2S,4R)-4-(3-Methoxy-3-oxopropyl)glutamic Acid
DMTQF2G	MI	TT0MYE2
DMTQF2G	MN	Glutamate receptor ionotropic kainate 1 (GRIK1)
DMTQF2G	MT	DTT
DMTQF2G	MA	Inhibitor
DMTQF2G	RN	Chemo-enzymatic synthesis of a series of 2,4-syn-functionalized (S)-glutamate analogues: new insight into the structure-activity relation of ionotr... J Med Chem. 2008 Jul 24;51(14):4093-103.
DMTQF2G	RU	https://pubmed.ncbi.nlm.nih.gov/18578478

DMGXRSZ	DI	DMGXRSZ
DMGXRSZ	DN	(2'Z,3'E)-5-Chloro-5'-chloro-indirubin-3'-oxime
DMGXRSZ	MI	TT7HF4W
DMGXRSZ	MN	Cyclin-dependent kinase 2 (CDK2)
DMGXRSZ	MT	DTT
DMGXRSZ	MA	Inhibitor
DMGXRSZ	RN	5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706.
DMGXRSZ	RU	https://pubmed.ncbi.nlm.nih.gov/20361800

DMGXRSZ	DI	DMGXRSZ
DMGXRSZ	DN	(2'Z,3'E)-5-Chloro-5'-chloro-indirubin-3'-oxime
DMGXRSZ	MI	TTCEJ4F
DMGXRSZ	MN	G1/S-specific cyclin-E1 (CCNE1)
DMGXRSZ	MT	DTT
DMGXRSZ	MA	Inhibitor
DMGXRSZ	RN	5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706.
DMGXRSZ	RU	https://pubmed.ncbi.nlm.nih.gov/20361800

DM6AUHR	DI	DM6AUHR
DM6AUHR	DN	(2'Z,3'E)-5-Chloro-5'-fluoro-indirubin-3'-oxime
DM6AUHR	MI	TT7HF4W
DM6AUHR	MN	Cyclin-dependent kinase 2 (CDK2)
DM6AUHR	MT	DTT
DM6AUHR	MA	Inhibitor
DM6AUHR	RN	5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706.
DM6AUHR	RU	https://pubmed.ncbi.nlm.nih.gov/20361800

DM6AUHR	DI	DM6AUHR
DM6AUHR	DN	(2'Z,3'E)-5-Chloro-5'-fluoro-indirubin-3'-oxime
DM6AUHR	MI	TTCEJ4F
DM6AUHR	MN	G1/S-specific cyclin-E1 (CCNE1)
DM6AUHR	MT	DTT
DM6AUHR	MA	Inhibitor
DM6AUHR	RN	5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706.
DM6AUHR	RU	https://pubmed.ncbi.nlm.nih.gov/20361800

DMD7WGM	DI	DMD7WGM
DMD7WGM	DN	(2'Z,3'E)-5-Chloro-5'-hydroxy-indirubin-3'-oxime
DMD7WGM	MI	TT7HF4W
DMD7WGM	MN	Cyclin-dependent kinase 2 (CDK2)
DMD7WGM	MT	DTT
DMD7WGM	MA	Inhibitor
DMD7WGM	RN	5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706.
DMD7WGM	RU	https://pubmed.ncbi.nlm.nih.gov/20361800

DMD7WGM	DI	DMD7WGM
DMD7WGM	DN	(2'Z,3'E)-5-Chloro-5'-hydroxy-indirubin-3'-oxime
DMD7WGM	MI	TTCEJ4F
DMD7WGM	MN	G1/S-specific cyclin-E1 (CCNE1)
DMD7WGM	MT	DTT
DMD7WGM	MA	Inhibitor
DMD7WGM	RN	5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706.
DMD7WGM	RU	https://pubmed.ncbi.nlm.nih.gov/20361800

DMZ0V6G	DI	DMZ0V6G
DMZ0V6G	DN	(2'Z,3'E)-5-Chloro-5'-methyl-indirubin-3'-oxime
DMZ0V6G	MI	TT7HF4W
DMZ0V6G	MN	Cyclin-dependent kinase 2 (CDK2)
DMZ0V6G	MT	DTT
DMZ0V6G	MA	Inhibitor
DMZ0V6G	RN	5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706.
DMZ0V6G	RU	https://pubmed.ncbi.nlm.nih.gov/20361800

DMZ0V6G	DI	DMZ0V6G
DMZ0V6G	DN	(2'Z,3'E)-5-Chloro-5'-methyl-indirubin-3'-oxime
DMZ0V6G	MI	TTCEJ4F
DMZ0V6G	MN	G1/S-specific cyclin-E1 (CCNE1)
DMZ0V6G	MT	DTT
DMZ0V6G	MA	Inhibitor
DMZ0V6G	RN	5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706.
DMZ0V6G	RU	https://pubmed.ncbi.nlm.nih.gov/20361800

DMO7RFL	DI	DMO7RFL
DMO7RFL	DN	(2'Z,3'E)-5-Fluoro-5'-chloro-indirubin-3'-oxime
DMO7RFL	MI	TT7HF4W
DMO7RFL	MN	Cyclin-dependent kinase 2 (CDK2)
DMO7RFL	MT	DTT
DMO7RFL	MA	Inhibitor
DMO7RFL	RN	5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706.
DMO7RFL	RU	https://pubmed.ncbi.nlm.nih.gov/20361800

DMO7RFL	DI	DMO7RFL
DMO7RFL	DN	(2'Z,3'E)-5-Fluoro-5'-chloro-indirubin-3'-oxime
DMO7RFL	MI	TTCEJ4F
DMO7RFL	MN	G1/S-specific cyclin-E1 (CCNE1)
DMO7RFL	MT	DTT
DMO7RFL	MA	Inhibitor
DMO7RFL	RN	5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706.
DMO7RFL	RU	https://pubmed.ncbi.nlm.nih.gov/20361800

DMJ4ABD	DI	DMJ4ABD
DMJ4ABD	DN	(2'Z,3'E)-5-Fluoro-5'-fluoro-indirubin-3'-oxime
DMJ4ABD	MI	TT7HF4W
DMJ4ABD	MN	Cyclin-dependent kinase 2 (CDK2)
DMJ4ABD	MT	DTT
DMJ4ABD	MA	Inhibitor
DMJ4ABD	RN	5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706.
DMJ4ABD	RU	https://pubmed.ncbi.nlm.nih.gov/20361800

DMJ4ABD	DI	DMJ4ABD
DMJ4ABD	DN	(2'Z,3'E)-5-Fluoro-5'-fluoro-indirubin-3'-oxime
DMJ4ABD	MI	TTCEJ4F
DMJ4ABD	MN	G1/S-specific cyclin-E1 (CCNE1)
DMJ4ABD	MT	DTT
DMJ4ABD	MA	Inhibitor
DMJ4ABD	RN	5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706.
DMJ4ABD	RU	https://pubmed.ncbi.nlm.nih.gov/20361800

DM9LQH1	DI	DM9LQH1
DM9LQH1	DN	(2'Z,3'E)-5-Fluoro-5'-hydroxy-indirubin-3'-oxime
DM9LQH1	MI	TT7HF4W
DM9LQH1	MN	Cyclin-dependent kinase 2 (CDK2)
DM9LQH1	MT	DTT
DM9LQH1	MA	Inhibitor
DM9LQH1	RN	5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706.
DM9LQH1	RU	https://pubmed.ncbi.nlm.nih.gov/20361800

DM9LQH1	DI	DM9LQH1
DM9LQH1	DN	(2'Z,3'E)-5-Fluoro-5'-hydroxy-indirubin-3'-oxime
DM9LQH1	MI	TTCEJ4F
DM9LQH1	MN	G1/S-specific cyclin-E1 (CCNE1)
DM9LQH1	MT	DTT
DM9LQH1	MA	Inhibitor
DM9LQH1	RN	5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706.
DM9LQH1	RU	https://pubmed.ncbi.nlm.nih.gov/20361800

DMQDH3N	DI	DMQDH3N
DMQDH3N	DN	(2'Z,3'E)-5-Fluoro-5'-methoxy-indirubin-3'-oxime
DMQDH3N	MI	TT7HF4W
DMQDH3N	MN	Cyclin-dependent kinase 2 (CDK2)
DMQDH3N	MT	DTT
DMQDH3N	MA	Inhibitor
DMQDH3N	RN	5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706.
DMQDH3N	RU	https://pubmed.ncbi.nlm.nih.gov/20361800

DMQDH3N	DI	DMQDH3N
DMQDH3N	DN	(2'Z,3'E)-5-Fluoro-5'-methoxy-indirubin-3'-oxime
DMQDH3N	MI	TTCEJ4F
DMQDH3N	MN	G1/S-specific cyclin-E1 (CCNE1)
DMQDH3N	MT	DTT
DMQDH3N	MA	Inhibitor
DMQDH3N	RN	5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706.
DMQDH3N	RU	https://pubmed.ncbi.nlm.nih.gov/20361800

DMAS3JC	DI	DMAS3JC
DMAS3JC	DN	(2'Z,3'E)-5-Fluoro-5'-methyl-indirubin-3'-oxime
DMAS3JC	MI	TT7HF4W
DMAS3JC	MN	Cyclin-dependent kinase 2 (CDK2)
DMAS3JC	MT	DTT
DMAS3JC	MA	Inhibitor
DMAS3JC	RN	5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706.
DMAS3JC	RU	https://pubmed.ncbi.nlm.nih.gov/20361800

DMAS3JC	DI	DMAS3JC
DMAS3JC	DN	(2'Z,3'E)-5-Fluoro-5'-methyl-indirubin-3'-oxime
DMAS3JC	MI	TTCEJ4F
DMAS3JC	MN	G1/S-specific cyclin-E1 (CCNE1)
DMAS3JC	MT	DTT
DMAS3JC	MA	Inhibitor
DMAS3JC	RN	5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706.
DMAS3JC	RU	https://pubmed.ncbi.nlm.nih.gov/20361800

DMYLX0U	DI	DMYLX0U
DMYLX0U	DN	(2'Z,3'E)-5-Nitro-5'-chloro-indirubin-3'-oxime
DMYLX0U	MI	TT7HF4W
DMYLX0U	MN	Cyclin-dependent kinase 2 (CDK2)
DMYLX0U	MT	DTT
DMYLX0U	MA	Inhibitor
DMYLX0U	RN	5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706.
DMYLX0U	RU	https://pubmed.ncbi.nlm.nih.gov/20361800

DMYLX0U	DI	DMYLX0U
DMYLX0U	DN	(2'Z,3'E)-5-Nitro-5'-chloro-indirubin-3'-oxime
DMYLX0U	MI	TTCEJ4F
DMYLX0U	MN	G1/S-specific cyclin-E1 (CCNE1)
DMYLX0U	MT	DTT
DMYLX0U	MA	Inhibitor
DMYLX0U	RN	5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706.
DMYLX0U	RU	https://pubmed.ncbi.nlm.nih.gov/20361800

DMXZ2UC	DI	DMXZ2UC
DMXZ2UC	DN	(2'Z,3'E)-5-Nitro-5'-fluoro-indirubin-3'-oxime
DMXZ2UC	MI	TT7HF4W
DMXZ2UC	MN	Cyclin-dependent kinase 2 (CDK2)
DMXZ2UC	MT	DTT
DMXZ2UC	MA	Inhibitor
DMXZ2UC	RN	5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706.
DMXZ2UC	RU	https://pubmed.ncbi.nlm.nih.gov/20361800

DMXZ2UC	DI	DMXZ2UC
DMXZ2UC	DN	(2'Z,3'E)-5-Nitro-5'-fluoro-indirubin-3'-oxime
DMXZ2UC	MI	TTCEJ4F
DMXZ2UC	MN	G1/S-specific cyclin-E1 (CCNE1)
DMXZ2UC	MT	DTT
DMXZ2UC	MA	Inhibitor
DMXZ2UC	RN	5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706.
DMXZ2UC	RU	https://pubmed.ncbi.nlm.nih.gov/20361800

DM0S82C	DI	DM0S82C
DM0S82C	DN	(2'Z,3'E)-5-Nitro-5'-hydroxy-indirubin-3'-oxime
DM0S82C	MI	TT7HF4W
DM0S82C	MN	Cyclin-dependent kinase 2 (CDK2)
DM0S82C	MT	DTT
DM0S82C	MA	Inhibitor
DM0S82C	RN	5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706.
DM0S82C	RU	https://pubmed.ncbi.nlm.nih.gov/20361800

DM0S82C	DI	DM0S82C
DM0S82C	DN	(2'Z,3'E)-5-Nitro-5'-hydroxy-indirubin-3'-oxime
DM0S82C	MI	TTCEJ4F
DM0S82C	MN	G1/S-specific cyclin-E1 (CCNE1)
DM0S82C	MT	DTT
DM0S82C	MA	Inhibitor
DM0S82C	RN	5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706.
DM0S82C	RU	https://pubmed.ncbi.nlm.nih.gov/20361800

DMLOIUK	DI	DMLOIUK
DMLOIUK	DN	(2'Z,3'E)-5-Nitro-5'-methoxy-indirubin-3'-oxime
DMLOIUK	MI	TT7HF4W
DMLOIUK	MN	Cyclin-dependent kinase 2 (CDK2)
DMLOIUK	MT	DTT
DMLOIUK	MA	Inhibitor
DMLOIUK	RN	5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706.
DMLOIUK	RU	https://pubmed.ncbi.nlm.nih.gov/20361800

DMLOIUK	DI	DMLOIUK
DMLOIUK	DN	(2'Z,3'E)-5-Nitro-5'-methoxy-indirubin-3'-oxime
DMLOIUK	MI	TTCEJ4F
DMLOIUK	MN	G1/S-specific cyclin-E1 (CCNE1)
DMLOIUK	MT	DTT
DMLOIUK	MA	Inhibitor
DMLOIUK	RN	5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706.
DMLOIUK	RU	https://pubmed.ncbi.nlm.nih.gov/20361800

DM6BA5L	DI	DM6BA5L
DM6BA5L	DN	(2'Z,3'E)-5-Nitro-5'-methyl-indirubin-3'-oxime
DM6BA5L	MI	TT7HF4W
DM6BA5L	MN	Cyclin-dependent kinase 2 (CDK2)
DM6BA5L	MT	DTT
DM6BA5L	MA	Inhibitor
DM6BA5L	RN	5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706.
DM6BA5L	RU	https://pubmed.ncbi.nlm.nih.gov/20361800

DM6BA5L	DI	DM6BA5L
DM6BA5L	DN	(2'Z,3'E)-5-Nitro-5'-methyl-indirubin-3'-oxime
DM6BA5L	MI	TTCEJ4F
DM6BA5L	MN	G1/S-specific cyclin-E1 (CCNE1)
DM6BA5L	MT	DTT
DM6BA5L	MA	Inhibitor
DM6BA5L	RN	5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706.
DM6BA5L	RU	https://pubmed.ncbi.nlm.nih.gov/20361800

DMUIOAP	DI	DMUIOAP
DMUIOAP	DN	(2'Z,3'E)-7-Azaindirubin-3'-oxime
DMUIOAP	MI	TTRSMW9
DMUIOAP	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMUIOAP	MT	DTT
DMUIOAP	MA	Inhibitor
DMUIOAP	RN	Synthesis and antiproliferative activity of 7-azaindirubin-3'-oxime, a 7-aza isostere of the natural indirubin pharmacophore. J Nat Prod. 2009 Dec;72(12):2199-202.
DMUIOAP	RU	https://pubmed.ncbi.nlm.nih.gov/19994845

DMBZJT5	DI	DMBZJT5
DMBZJT5	DN	(3-((1H-imidazol-1-yl)methyl)phenyl)methanol
DMBZJT5	MI	TTIQUX7
DMBZJT5	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMBZJT5	MT	DTT
DMBZJT5	MA	Inhibitor
DMBZJT5	RN	Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25.
DMBZJT5	RU	https://pubmed.ncbi.nlm.nih.gov/20121113

DMR6JTQ	DI	DMR6JTQ
DMR6JTQ	DN	(3-(2-methylquinolin-7-yl)phenyl)methanol
DMR6JTQ	MI	TTHS256
DMR6JTQ	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMR6JTQ	MT	DTT
DMR6JTQ	MA	Inhibitor
DMR6JTQ	RN	Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8.
DMR6JTQ	RU	https://pubmed.ncbi.nlm.nih.gov/17590335

DMNVDLI	DI	DMNVDLI
DMNVDLI	DN	(3,4-dichlorophenyl)(1H-pyrazol-1-yl)methanone
DMNVDLI	MI	TT6L509
DMNVDLI	MN	Coagulation factor IIa (F2)
DMNVDLI	MT	DTT
DMNVDLI	MA	Inhibitor
DMNVDLI	RN	N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
DMNVDLI	RU	https://pubmed.ncbi.nlm.nih.gov/17850059

DMNVDLI	DI	DMNVDLI
DMNVDLI	DN	(3,4-dichlorophenyl)(1H-pyrazol-1-yl)methanone
DMNVDLI	MI	TTPLTSQ
DMNVDLI	MN	Neutrophil elastase (NE)
DMNVDLI	MT	DTT
DMNVDLI	MA	Inhibitor
DMNVDLI	RN	N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
DMNVDLI	RU	https://pubmed.ncbi.nlm.nih.gov/17850059

DMNVDLI	DI	DMNVDLI
DMNVDLI	DN	(3,4-dichlorophenyl)(1H-pyrazol-1-yl)methanone
DMNVDLI	MI	TTMF8H9
DMNVDLI	MN	Plasma kallikrein (KLKB1)
DMNVDLI	MT	DTT
DMNVDLI	MA	Inhibitor
DMNVDLI	RN	N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
DMNVDLI	RU	https://pubmed.ncbi.nlm.nih.gov/17850059

DMNVDLI	DI	DMNVDLI
DMNVDLI	DN	(3,4-dichlorophenyl)(1H-pyrazol-1-yl)methanone
DMNVDLI	MI	TTGY7WI
DMNVDLI	MN	Urokinase-type plasminogen activator (PLAU)
DMNVDLI	MT	DTT
DMNVDLI	MA	Inhibitor
DMNVDLI	RN	N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
DMNVDLI	RU	https://pubmed.ncbi.nlm.nih.gov/17850059

DMTB41W	DI	DMTB41W
DMTB41W	DN	(3,4-DIHYDROXY-2-NITROPHENYL)(PHENYL)METHANONE
DMTB41W	MI	TTKWFB8
DMTB41W	MN	Catechol-O-methyl-transferase (COMT)
DMTB41W	MT	DTT
DMTB41W	MA	Inhibitor
DMTB41W	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMTB41W	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMAF43E	DI	DMAF43E
DMAF43E	DN	(3,4-dimethylphenyl)(4-phenoxyphenyl)methanone
DMAF43E	MI	TTVBPDM
DMAF43E	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMAF43E	MT	DTT
DMAF43E	MA	Inhibitor
DMAF43E	RN	Synergism of virtual screening and medicinal chemistry: identification and optimization of allosteric antagonists of metabotropic glutamate recepto... Bioorg Med Chem. 2009 Aug 1;17(15):5708-15.
DMAF43E	RU	https://pubmed.ncbi.nlm.nih.gov/19574055

DM9PDCA	DI	DM9PDCA
DM9PDCA	DN	(3,5-Dibromo-4-butoxy-phenyl)-acetic acid
DM9PDCA	MI	TTGER3L
DM9PDCA	MN	Thyroid hormone receptor beta (THRB)
DM9PDCA	MT	DTT
DM9PDCA	MA	Inhibitor
DM9PDCA	RN	Thyroid receptor ligands. 3. Design and synthesis of 3,5-dihalo-4-alkoxyphenylalkanoic acids as indirect antagonists of the thyroid hormone receptor. J Med Chem. 2005 May 5;48(9):3114-7.
DM9PDCA	RU	https://pubmed.ncbi.nlm.nih.gov/15857115

DM5GN46	DI	DM5GN46
DM5GN46	DN	(3,5-Dibromo-4-hexyloxy-phenyl)-acetic acid
DM5GN46	MI	TTTSEPU
DM5GN46	MN	Thyroid hormone receptor alpha (THRA)
DM5GN46	MT	DTT
DM5GN46	MA	Inhibitor
DM5GN46	RN	Thyroid receptor ligands. 3. Design and synthesis of 3,5-dihalo-4-alkoxyphenylalkanoic acids as indirect antagonists of the thyroid hormone receptor. J Med Chem. 2005 May 5;48(9):3114-7.
DM5GN46	RU	https://pubmed.ncbi.nlm.nih.gov/15857115

DM5GN46	DI	DM5GN46
DM5GN46	DN	(3,5-Dibromo-4-hexyloxy-phenyl)-acetic acid
DM5GN46	MI	TTGER3L
DM5GN46	MN	Thyroid hormone receptor beta (THRB)
DM5GN46	MT	DTT
DM5GN46	MA	Inhibitor
DM5GN46	RN	Thyroid receptor ligands. 3. Design and synthesis of 3,5-dihalo-4-alkoxyphenylalkanoic acids as indirect antagonists of the thyroid hormone receptor. J Med Chem. 2005 May 5;48(9):3114-7.
DM5GN46	RU	https://pubmed.ncbi.nlm.nih.gov/15857115

DMB5KVZ	DI	DMB5KVZ
DMB5KVZ	DN	(3,5-Dibromo-4-pentyloxy-phenyl)-acetic acid
DMB5KVZ	MI	TTGER3L
DMB5KVZ	MN	Thyroid hormone receptor beta (THRB)
DMB5KVZ	MT	DTT
DMB5KVZ	MA	Inhibitor
DMB5KVZ	RN	Thyroid receptor ligands. 3. Design and synthesis of 3,5-dihalo-4-alkoxyphenylalkanoic acids as indirect antagonists of the thyroid hormone receptor. J Med Chem. 2005 May 5;48(9):3114-7.
DMB5KVZ	RU	https://pubmed.ncbi.nlm.nih.gov/15857115

DM3OPNE	DI	DM3OPNE
DM3OPNE	DN	(35)S-labeled oligonucleotide
DM3OPNE	MI	TTSXP1G
DM3OPNE	MN	Protein kinase A alpha messenger RNA (PKA-alpha mRNA)
DM3OPNE	MT	DTT
DM3OPNE	RN	Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration. Proc Natl Acad Sci U S A. 1999 Nov23;96(24):13989-94.
DM3OPNE	RU	https://pubmed.ncbi.nlm.nih.gov/10570186

DM3OPNE	DI	DM3OPNE
DM3OPNE	DN	(35)S-labeled oligonucleotide
DM3OPNE	MI	TTXQFV2
DM3OPNE	MN	Protein kinase A Ri alpha messenger RNA (PKA-Ri-alpha mRNA)
DM3OPNE	MT	DTT
DM3OPNE	RN	Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration. Proc Natl Acad Sci U S A. 1999 Nov23;96(24):13989-94.
DM3OPNE	RU	https://pubmed.ncbi.nlm.nih.gov/10570186

DMPHCX7	DI	DMPHCX7
DMPHCX7	DN	(3-Amino-1-ethyl-propyl)-methyl-phosphinic acid
DMPHCX7	MI	TTDCVZW
DMPHCX7	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMPHCX7	MT	DTT
DMPHCX7	MA	Inhibitor
DMPHCX7	RN	Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists. J Med Chem. 1995 Aug 18;38(17):3297-312.
DMPHCX7	RU	https://pubmed.ncbi.nlm.nih.gov/7650684

DM7HF4I	DI	DM7HF4I
DM7HF4I	DN	(3-Amino-1-hydroxy-propyl)-methyl-phosphinic acid
DM7HF4I	MI	TTDCVZW
DM7HF4I	MN	Gamma-aminobutyric acid B receptor (GABBR)
DM7HF4I	MT	DTT
DM7HF4I	MA	Inhibitor
DM7HF4I	RN	Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists. J Med Chem. 1995 Aug 18;38(17):3297-312.
DM7HF4I	RU	https://pubmed.ncbi.nlm.nih.gov/7650684

DMP2G5W	DI	DMP2G5W
DMP2G5W	DN	(3-amino-5-bromobenzofuran-2-yl)(phenyl)methanone
DMP2G5W	MI	TTM2AOE
DMP2G5W	MN	Adenosine A2a receptor (ADORA2A)
DMP2G5W	MT	DTT
DMP2G5W	MA	Inhibitor
DMP2G5W	RN	Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. J Med Chem. 2010 Feb 25;53(4):1799-809.
DMP2G5W	RU	https://pubmed.ncbi.nlm.nih.gov/20095623

DMDGFS0	DI	DMDGFS0
DMDGFS0	DN	(3-Amino-phenyl)-phosphonic acid diphenyl ester
DMDGFS0	MI	TTDCVZW
DMDGFS0	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMDGFS0	MT	DTT
DMDGFS0	MA	Inhibitor
DMDGFS0	RN	Phosphorus analogues of gamma-aminobutyric acid, a new class of anticonvulsants. J Med Chem. 1984 May;27(5):654-9.
DMDGFS0	RU	https://pubmed.ncbi.nlm.nih.gov/6325692

DMBJYTD	DI	DMBJYTD
DMBJYTD	DN	(3-Amino-propyl)-hexyl-phosphinic acid
DMBJYTD	MI	TTDCVZW
DMBJYTD	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMBJYTD	MT	DTT
DMBJYTD	MA	Inhibitor
DMBJYTD	RN	Biological activity of 3-aminopropyl (methyl) phosphinic acid, a potent and selective GABAB agonist with CNS activity, Bioorg. Med. Chem. Lett. 3(4):515-518 (1993).
DMBJYTD	RU	http://www.sciencedirect.com/science/article/pii/S0960894X0181218X

DMGFIJV	DI	DMGFIJV
DMGFIJV	DN	(3-Amino-propyl)-hydroxymethyl-phosphinic acid
DMGFIJV	MI	TTDCVZW
DMGFIJV	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMGFIJV	MT	DTT
DMGFIJV	MA	Inhibitor
DMGFIJV	RN	Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists. J Med Chem. 1995 Aug 18;38(17):3297-312.
DMGFIJV	RU	https://pubmed.ncbi.nlm.nih.gov/7650684

DMK3JZS	DI	DMK3JZS
DMK3JZS	DN	(3-Amino-propyl)-phosphonic acid
DMK3JZS	MI	TTDCVZW
DMK3JZS	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMK3JZS	MT	DTT
DMK3JZS	MA	Inhibitor
DMK3JZS	RN	Phosphorus analogues of gamma-aminobutyric acid, a new class of anticonvulsants. J Med Chem. 1984 May;27(5):654-9.
DMK3JZS	RU	https://pubmed.ncbi.nlm.nih.gov/6325692

DMHF01G	DI	DMHF01G
DMHF01G	DN	(3-Bromobenzoylpyridine)thiosemicarbazone
DMHF01G	MI	TT36ETB
DMHF01G	MN	Cathepsin L (CTSL)
DMHF01G	MT	DTT
DMHF01G	MA	Inhibitor
DMHF01G	RN	Functionalized benzophenone, thiophene, pyridine, and fluorene thiosemicarbazone derivatives as inhibitors of cathepsin L. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6610-5.
DMHF01G	RU	https://pubmed.ncbi.nlm.nih.gov/20933415

DMIJH7W	DI	DMIJH7W
DMIJH7W	DN	(3-bromophenyl)(10H-phenothiazin-10-yl)methanone
DMIJH7W	MI	TTEB0GD
DMIJH7W	MN	Cholinesterase (BCHE)
DMIJH7W	MT	DTT
DMIJH7W	MA	Inhibitor
DMIJH7W	RN	Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. Bioorg Med Chem. 2007 Oct 1;15(19):6367-78.
DMIJH7W	RU	https://pubmed.ncbi.nlm.nih.gov/17681768

DMHLF2S	DI	DMHLF2S
DMHLF2S	DN	(3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine
DMHLF2S	MI	TTGKNB4
DMHLF2S	MN	Epidermal growth factor receptor (EGFR)
DMHLF2S	MT	DTT
DMHLF2S	MA	Inhibitor
DMHLF2S	RN	Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as poten... J Med Chem. 1995 Sep 1;38(18):3482-7.
DMHLF2S	RU	https://pubmed.ncbi.nlm.nih.gov/7658435

DMMIPZ8	DI	DMMIPZ8
DMMIPZ8	DN	(3-Bromo-phenyl)-quinazolin-4-yl-amine
DMMIPZ8	MI	TTGKNB4
DMMIPZ8	MN	Epidermal growth factor receptor (EGFR)
DMMIPZ8	MT	DTT
DMMIPZ8	MA	Inhibitor
DMMIPZ8	RN	Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase acti... J Med Chem. 1996 Feb 16;39(4):918-28.
DMMIPZ8	RU	https://pubmed.ncbi.nlm.nih.gov/8632415

DMUJ18K	DI	DMUJ18K
DMUJ18K	DN	(3-Bromo-propyl)-trimethyl-ammonium
DMUJ18K	MI	TT1RS9F
DMUJ18K	MN	Acetylcholinesterase (AChE)
DMUJ18K	MT	DTT
DMUJ18K	MA	Inhibitor
DMUJ18K	RN	Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors. J Med Chem. 1996 Dec 20;39(26):5064-71.
DMUJ18K	RU	https://pubmed.ncbi.nlm.nih.gov/8978837

DMHODXG	DI	DMHODXG
DMHODXG	DN	(3-Chloro-4-Propoxy-Phenyl)-Acetic Acid
DMHODXG	MI	TT8NGED
DMHODXG	MN	Prostaglandin G/H synthase 1 (COX-1)
DMHODXG	MT	DTT
DMHODXG	MA	Inhibitor
DMHODXG	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMHODXG	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM7U02R	DI	DM7U02R
DM7U02R	DN	(3-Chloro-phenyl)-piperazin-1-yl-methanone
DM7U02R	MI	TTSQIFT
DM7U02R	MN	5-HT 1A receptor (HTR1A)
DM7U02R	MT	DTT
DM7U02R	MA	Inhibitor
DM7U02R	RN	Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents. J Med Chem. 1986 May;29(5):630-4.
DM7U02R	RU	https://pubmed.ncbi.nlm.nih.gov/3701781

DM7U02R	DI	DM7U02R
DM7U02R	DN	(3-Chloro-phenyl)-piperazin-1-yl-methanone
DM7U02R	MI	TT6MSOK
DM7U02R	MN	5-HT 1D receptor (HTR1D)
DM7U02R	MT	DTT
DM7U02R	MA	Inhibitor
DM7U02R	RN	Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents. J Med Chem. 1986 May;29(5):630-4.
DM7U02R	RU	https://pubmed.ncbi.nlm.nih.gov/3701781

DMG1KIJ	DI	DMG1KIJ
DMG1KIJ	DN	(3-Ethoxy-pyridin-2-yl)-pyridin-2-yl-amine
DMG1KIJ	MI	TTHS256
DMG1KIJ	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMG1KIJ	MT	DTT
DMG1KIJ	MA	Inhibitor
DMG1KIJ	RN	Dipyridyl amines: potent metabotropic glutamate subtype 5 receptor antagonists. Bioorg Med Chem Lett. 2005 Oct 1;15(19):4350-3.
DMG1KIJ	RU	https://pubmed.ncbi.nlm.nih.gov/16039855

DM5WJBH	DI	DM5WJBH
DM5WJBH	DN	(3-Ethyl-indol-1-yl)-propyl-pyridin-4-yl-amine
DM5WJBH	MI	TTWG9A4
DM5WJBH	MN	Adrenergic receptor alpha-2A (ADRA2A)
DM5WJBH	MT	DTT
DM5WJBH	MA	Inhibitor
DM5WJBH	RN	Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81.
DM5WJBH	RU	https://pubmed.ncbi.nlm.nih.gov/8558529

DM5WJBH	DI	DM5WJBH
DM5WJBH	DN	(3-Ethyl-indol-1-yl)-propyl-pyridin-4-yl-amine
DM5WJBH	MI	TTWM4TY
DM5WJBH	MN	Adrenergic receptor alpha-2B (ADRA2B)
DM5WJBH	MT	DTT
DM5WJBH	MA	Inhibitor
DM5WJBH	RN	Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81.
DM5WJBH	RU	https://pubmed.ncbi.nlm.nih.gov/8558529

DM5WJBH	DI	DM5WJBH
DM5WJBH	DN	(3-Ethyl-indol-1-yl)-propyl-pyridin-4-yl-amine
DM5WJBH	MI	TT2NUT5
DM5WJBH	MN	Adrenergic receptor alpha-2C (ADRA2C)
DM5WJBH	MT	DTT
DM5WJBH	MA	Inhibitor
DM5WJBH	RN	Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81.
DM5WJBH	RU	https://pubmed.ncbi.nlm.nih.gov/8558529

DMPHM23	DI	DMPHM23
DMPHM23	DN	(3-fluoro-4-(4-phenoxybenzoyl)phenyl)acetic acid
DMPHM23	MI	TTTU72V
DMPHM23	MN	Steroid 5-alpha-reductase 1 (SRD5A1)
DMPHM23	MT	DTT
DMPHM23	MA	Inhibitor
DMPHM23	RN	Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J Med Chem. 2006 Jan 26;49(2):748-59.
DMPHM23	RU	https://pubmed.ncbi.nlm.nih.gov/16420060

DMPHM23	DI	DMPHM23
DMPHM23	DN	(3-fluoro-4-(4-phenoxybenzoyl)phenyl)acetic acid
DMPHM23	MI	TTT02K8
DMPHM23	MN	Steroid 5-alpha-reductase 2 (SRD5A2)
DMPHM23	MT	DTT
DMPHM23	MA	Inhibitor
DMPHM23	RN	Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J Med Chem. 2006 Jan 26;49(2):748-59.
DMPHM23	RU	https://pubmed.ncbi.nlm.nih.gov/16420060

DM08UQF	DI	DM08UQF
DM08UQF	DN	(3-Hydroxy-2-methyl-phenyl)-trimethyl-ammonium
DM08UQF	MI	TT1RS9F
DM08UQF	MN	Acetylcholinesterase (AChE)
DM08UQF	MT	DTT
DM08UQF	MA	Inhibitor
DM08UQF	RN	Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors. J Med Chem. 1996 Dec 20;39(26):5064-71.
DM08UQF	RU	https://pubmed.ncbi.nlm.nih.gov/8978837

DMX5CY3	DI	DMX5CY3
DMX5CY3	DN	(3-methyl-4-(4-phenoxybenzoyl)phenyl)acetic acid
DMX5CY3	MI	TTTU72V
DMX5CY3	MN	Steroid 5-alpha-reductase 1 (SRD5A1)
DMX5CY3	MT	DTT
DMX5CY3	MA	Inhibitor
DMX5CY3	RN	Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J Med Chem. 2006 Jan 26;49(2):748-59.
DMX5CY3	RU	https://pubmed.ncbi.nlm.nih.gov/16420060

DMX5CY3	DI	DMX5CY3
DMX5CY3	DN	(3-methyl-4-(4-phenoxybenzoyl)phenyl)acetic acid
DMX5CY3	MI	TTT02K8
DMX5CY3	MN	Steroid 5-alpha-reductase 2 (SRD5A2)
DMX5CY3	MT	DTT
DMX5CY3	MA	Inhibitor
DMX5CY3	RN	Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J Med Chem. 2006 Jan 26;49(2):748-59.
DMX5CY3	RU	https://pubmed.ncbi.nlm.nih.gov/16420060

DMHED9G	DI	DMHED9G
DMHED9G	DN	(3-Methyl-indol-1-yl)-propyl-pyridin-4-yl-amine
DMHED9G	MI	TTWG9A4
DMHED9G	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMHED9G	MT	DTT
DMHED9G	MA	Inhibitor
DMHED9G	RN	Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81.
DMHED9G	RU	https://pubmed.ncbi.nlm.nih.gov/8558529

DMHED9G	DI	DMHED9G
DMHED9G	DN	(3-Methyl-indol-1-yl)-propyl-pyridin-4-yl-amine
DMHED9G	MI	TTWM4TY
DMHED9G	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMHED9G	MT	DTT
DMHED9G	MA	Inhibitor
DMHED9G	RN	Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81.
DMHED9G	RU	https://pubmed.ncbi.nlm.nih.gov/8558529

DMHED9G	DI	DMHED9G
DMHED9G	DN	(3-Methyl-indol-1-yl)-propyl-pyridin-4-yl-amine
DMHED9G	MI	TT2NUT5
DMHED9G	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMHED9G	MT	DTT
DMHED9G	MA	Inhibitor
DMHED9G	RN	Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81.
DMHED9G	RU	https://pubmed.ncbi.nlm.nih.gov/8558529

DMD4Z6H	DI	DMD4Z6H
DMD4Z6H	DN	(3-nitro-1H-pyrazol-1-yl)(phenyl)methanone
DMD4Z6H	MI	TT6L509
DMD4Z6H	MN	Coagulation factor IIa (F2)
DMD4Z6H	MT	DTT
DMD4Z6H	MA	Inhibitor
DMD4Z6H	RN	N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
DMD4Z6H	RU	https://pubmed.ncbi.nlm.nih.gov/17850059

DMD4Z6H	DI	DMD4Z6H
DMD4Z6H	DN	(3-nitro-1H-pyrazol-1-yl)(phenyl)methanone
DMD4Z6H	MI	TTPLTSQ
DMD4Z6H	MN	Neutrophil elastase (NE)
DMD4Z6H	MT	DTT
DMD4Z6H	MA	Inhibitor
DMD4Z6H	RN	N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
DMD4Z6H	RU	https://pubmed.ncbi.nlm.nih.gov/17850059

DMD4Z6H	DI	DMD4Z6H
DMD4Z6H	DN	(3-nitro-1H-pyrazol-1-yl)(phenyl)methanone
DMD4Z6H	MI	TTMF8H9
DMD4Z6H	MN	Plasma kallikrein (KLKB1)
DMD4Z6H	MT	DTT
DMD4Z6H	MA	Inhibitor
DMD4Z6H	RN	N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
DMD4Z6H	RU	https://pubmed.ncbi.nlm.nih.gov/17850059

DMT9FZD	DI	DMT9FZD
DMT9FZD	DN	(3-nitro-1H-pyrazol-1-yl)(p-tolyl)methanone
DMT9FZD	MI	TT6L509
DMT9FZD	MN	Coagulation factor IIa (F2)
DMT9FZD	MT	DTT
DMT9FZD	MA	Inhibitor
DMT9FZD	RN	N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
DMT9FZD	RU	https://pubmed.ncbi.nlm.nih.gov/17850059

DMT9FZD	DI	DMT9FZD
DMT9FZD	DN	(3-nitro-1H-pyrazol-1-yl)(p-tolyl)methanone
DMT9FZD	MI	TTPLTSQ
DMT9FZD	MN	Neutrophil elastase (NE)
DMT9FZD	MT	DTT
DMT9FZD	MA	Inhibitor
DMT9FZD	RN	N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
DMT9FZD	RU	https://pubmed.ncbi.nlm.nih.gov/17850059

DMT9FZD	DI	DMT9FZD
DMT9FZD	DN	(3-nitro-1H-pyrazol-1-yl)(p-tolyl)methanone
DMT9FZD	MI	TTMF8H9
DMT9FZD	MN	Plasma kallikrein (KLKB1)
DMT9FZD	MT	DTT
DMT9FZD	MA	Inhibitor
DMT9FZD	RN	N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
DMT9FZD	RU	https://pubmed.ncbi.nlm.nih.gov/17850059

DMT9FZD	DI	DMT9FZD
DMT9FZD	DN	(3-nitro-1H-pyrazol-1-yl)(p-tolyl)methanone
DMT9FZD	MI	TTGY7WI
DMT9FZD	MN	Urokinase-type plasminogen activator (PLAU)
DMT9FZD	MT	DTT
DMT9FZD	MA	Inhibitor
DMT9FZD	RN	N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
DMT9FZD	RU	https://pubmed.ncbi.nlm.nih.gov/17850059

DMGYAP7	DI	DMGYAP7
DMGYAP7	DN	(3-Phenoxy-phenyl)-(5-phenyl-oxazol-2-yl)-amine
DMGYAP7	MI	TTUTJGQ
DMGYAP7	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMGYAP7	MT	DTT
DMGYAP7	MA	Inhibitor
DMGYAP7	RN	Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9.
DMGYAP7	RU	https://pubmed.ncbi.nlm.nih.gov/15743202

DM1C90Y	DI	DM1C90Y
DM1C90Y	DN	(3-Phenyl-propyl)-quinazolin-4-yl-amine
DM1C90Y	MI	TT64EPS
DM1C90Y	MN	Fungal Scytalone dehydratase (Fung SDH1)
DM1C90Y	MT	DTT
DM1C90Y	MA	Inhibitor
DM1C90Y	RN	A diazine heterocycle replaces a six-membered hydrogen-bonded array in the active site of scytalone dehydratase, Bioorg. Med. Chem. Lett. 3(8):1605-1608 (1993).
DM1C90Y	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00800268

DM49YTN	DI	DM49YTN
DM49YTN	DN	(3r)-1-Acetyl-3-Methylpiperidine
DM49YTN	MI	TTL2ADK
DM49YTN	MN	Rotamase A (PPIA)
DM49YTN	MT	DTT
DM49YTN	MA	Inhibitor
DM49YTN	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM49YTN	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMEUBGY	DI	DMEUBGY
DMEUBGY	DN	(3R)-9-amino-3-methyl-1,2,3,4-tetrahydroacridine
DMEUBGY	MI	TT1RS9F
DMEUBGY	MN	Acetylcholinesterase (AChE)
DMEUBGY	MT	DTT
DMEUBGY	MA	Inhibitor
DMEUBGY	RN	Synthesis and AChE inhibitory activity of new chiral tetrahydroacridine analogues from terpenic cyclanones. Eur J Med Chem. 2010 Feb;45(2):526-35.
DMEUBGY	RU	https://pubmed.ncbi.nlm.nih.gov/19954865

DM47BEG	DI	DM47BEG
DM47BEG	DN	(3R,4S)-293B
DM47BEG	MI	TT846HF
DM47BEG	MN	Voltage-gated potassium channel Kv7.1 (KCNQ1)
DM47BEG	MT	DTT
DM47BEG	MA	Blocker (channel blocker)
DM47BEG	RN	A kinetic study on the stereospecific inhibition of KCNQ1 and I(Ks) by the chromanol 293B. Br J Pharmacol. 2001 Dec;134(8):1647-54.
DM47BEG	RU	https://pubmed.ncbi.nlm.nih.gov/11739240

DMET6IS	DI	DMET6IS
DMET6IS	DN	(3S,4R)-3-Benzyl-7-isopropyl-chroman-4-ol
DMET6IS	MI	TTN53ZF
DMET6IS	MN	Leukotriene B4 receptor 1 (LTB4R)
DMET6IS	MT	DTT
DMET6IS	MA	Inhibitor
DMET6IS	RN	3-Substituted-4-hydroxy-7-chromanylacetic acid derivatives as antagonists of the leukotriene B4 (LTB4) receptor, Bioorg. Med. Chem. Lett. 7(17):2307-2312 (1997).
DMET6IS	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97004149

DMET6IS	DI	DMET6IS
DMET6IS	DN	(3S,4R)-3-Benzyl-7-isopropyl-chroman-4-ol
DMET6IS	MI	TTVJX54
DMET6IS	MN	Leukotriene B4 receptor 2 (LTB4R2)
DMET6IS	MT	DTT
DMET6IS	MA	Inhibitor
DMET6IS	RN	3-Substituted-4-hydroxy-7-chromanylacetic acid derivatives as antagonists of the leukotriene B4 (LTB4) receptor, Bioorg. Med. Chem. Lett. 7(17):2307-2312 (1997).
DMET6IS	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97004149

DMAEXO3	DI	DMAEXO3
DMAEXO3	DN	(3S,4R)-3-butyl-1-phenylpiperidin-4-amine
DMAEXO3	MI	TTDIGC1
DMAEXO3	MN	Dipeptidyl peptidase 4 (DPP-4)
DMAEXO3	MT	DTT
DMAEXO3	MA	Inhibitor
DMAEXO3	RN	1,3-disubstituted 4-aminopiperidines as useful tools in the optimization of the 2-aminobenzo[a]quinolizine dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett. 2007 Jun 1;17(11):2966-70.
DMAEXO3	RU	https://pubmed.ncbi.nlm.nih.gov/17418568

DM6P35D	DI	DM6P35D
DM6P35D	DN	(3-Tetradecylamino-cyclohexyl)-phosphonic acid
DM6P35D	MI	TT9JZCK
DM6P35D	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DM6P35D	MT	DTT
DM6P35D	MA	Inhibitor
DM6P35D	RN	Design and synthesis of conformationally constrained 3-(N-alkylamino)propylphosphonic acids as potent agonists of sphingosine-1-phosphate (S1P) rec... Bioorg Med Chem Lett. 2004 Oct 4;14(19):4861-6.
DM6P35D	RU	https://pubmed.ncbi.nlm.nih.gov/15341940

DMFMBPT	DI	DMFMBPT
DMFMBPT	DN	(3-Tetradecylamino-cyclopentyl)-phosphonic acid
DMFMBPT	MI	TT9JZCK
DMFMBPT	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMFMBPT	MT	DTT
DMFMBPT	MA	Inhibitor
DMFMBPT	RN	Design and synthesis of conformationally constrained 3-(N-alkylamino)propylphosphonic acids as potent agonists of sphingosine-1-phosphate (S1P) rec... Bioorg Med Chem Lett. 2004 Oct 4;14(19):4861-6.
DMFMBPT	RU	https://pubmed.ncbi.nlm.nih.gov/15341940

DMI9N8G	DI	DMI9N8G
DMI9N8G	DN	(3Z)-1H-indole-2,3-dione 3-thiosemicarbazone
DMI9N8G	MI	TTEAID7
DMI9N8G	MN	Trypanosoma Cruzipain (Trypano CYSP)
DMI9N8G	MT	DTT
DMI9N8G	MA	Inhibitor
DMI9N8G	RN	Synthesis and evaluation of isatins and thiosemicarbazone derivatives against cruzain, falcipain-2 and rhodesain. Bioorg Med Chem Lett. 2003 Oct 20;13(20):3527-30.
DMI9N8G	RU	https://pubmed.ncbi.nlm.nih.gov/14505663

DMWS35F	DI	DMWS35F
DMWS35F	DN	(4-((1H-imidazol-1-yl)methyl)phenyl)methanol
DMWS35F	MI	TTIQUX7
DMWS35F	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMWS35F	MT	DTT
DMWS35F	MA	Inhibitor
DMWS35F	RN	Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25.
DMWS35F	RU	https://pubmed.ncbi.nlm.nih.gov/20121113

DMUOFW8	DI	DMUOFW8
DMUOFW8	DN	(4-(6-morpholino-9H-purin-2-yl)phenyl)methanol
DMUOFW8	MI	TTCJG29
DMUOFW8	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMUOFW8	MT	DTT
DMUOFW8	MA	Inhibitor
DMUOFW8	RN	Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-alpha: Hit to lead studies. Bioorg Med Chem Lett. 2010 Jan 15;20(2):636-9.
DMUOFW8	RU	https://pubmed.ncbi.nlm.nih.gov/19969455

DMV2CKN	DI	DMV2CKN
DMV2CKN	DN	(4-(thiophen-2-yl)phenyl)methanamine
DMV2CKN	MI	TTXZEAJ
DMV2CKN	MN	Leukotriene A-4 hydrolase (LTA4H)
DMV2CKN	MT	DTT
DMV2CKN	MA	Inhibitor
DMV2CKN	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMV2CKN	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM1XY7C	DI	DM1XY7C
DM1XY7C	DN	(4-benzhydrylpiperazin-1-yl)(cyclohexyl)methanone
DM1XY7C	MI	TT6OEDT
DM1XY7C	MN	Cannabinoid receptor 1 (CB1)
DM1XY7C	MT	DTT
DM1XY7C	MA	Inhibitor
DM1XY7C	RN	Discovery of benzhydrylpiperazine derivatives as CB1 receptor inverse agonists via privileged structure-based approach. Eur J Med Chem. 2010 Mar;45(3):1133-9.
DM1XY7C	RU	https://pubmed.ncbi.nlm.nih.gov/20047779

DM1XY7C	DI	DM1XY7C
DM1XY7C	DN	(4-benzhydrylpiperazin-1-yl)(cyclohexyl)methanone
DM1XY7C	MI	TTMSFAW
DM1XY7C	MN	Cannabinoid receptor 2 (CB2)
DM1XY7C	MT	DTT
DM1XY7C	MA	Inhibitor
DM1XY7C	RN	Discovery of benzhydrylpiperazine derivatives as CB1 receptor inverse agonists via privileged structure-based approach. Eur J Med Chem. 2010 Mar;45(3):1133-9.
DM1XY7C	RU	https://pubmed.ncbi.nlm.nih.gov/20047779

DMGVDEL	DI	DMGVDEL
DMGVDEL	DN	(4-benzylpiperidin-1-yl)(2-fluorophenyl)methanone
DMGVDEL	MI	TTVTX4N
DMGVDEL	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DMGVDEL	MT	DTT
DMGVDEL	MA	Inhibitor
DMGVDEL	RN	Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides. Bioorg Med Chem. 2007 Nov 1;15(21):6649-58.
DMGVDEL	RU	https://pubmed.ncbi.nlm.nih.gov/17723305

DMEQZ5M	DI	DMEQZ5M
DMEQZ5M	DN	(4-benzylpiperidin-1-yl)(3-chlorophenyl)methanone
DMEQZ5M	MI	TTVTX4N
DMEQZ5M	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DMEQZ5M	MT	DTT
DMEQZ5M	MA	Inhibitor
DMEQZ5M	RN	Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides. Bioorg Med Chem. 2007 Nov 1;15(21):6649-58.
DMEQZ5M	RU	https://pubmed.ncbi.nlm.nih.gov/17723305

DMS16CO	DI	DMS16CO
DMS16CO	DN	(4-benzylpiperidin-1-yl)(m-tolyl)methanone
DMS16CO	MI	TTVTX4N
DMS16CO	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DMS16CO	MT	DTT
DMS16CO	MA	Inhibitor
DMS16CO	RN	Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides. Bioorg Med Chem. 2007 Nov 1;15(21):6649-58.
DMS16CO	RU	https://pubmed.ncbi.nlm.nih.gov/17723305

DMJ81M3	DI	DMJ81M3
DMJ81M3	DN	(4-benzylpiperidin-1-yl)(p-tolyl)methanone
DMJ81M3	MI	TTVTX4N
DMJ81M3	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DMJ81M3	MT	DTT
DMJ81M3	MA	Inhibitor
DMJ81M3	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMJ81M3	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMS9125	DI	DMS9125
DMS9125	DN	(4-bromo-1H-pyrazol-1-yl)(m-tolyl)methanone
DMS9125	MI	TTPLTSQ
DMS9125	MN	Neutrophil elastase (NE)
DMS9125	MT	DTT
DMS9125	MA	Inhibitor
DMS9125	RN	N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
DMS9125	RU	https://pubmed.ncbi.nlm.nih.gov/17850059

DM5QDK9	DI	DM5QDK9
DM5QDK9	DN	(4-bromo-1H-pyrazol-1-yl)(o-tolyl)methanone
DM5QDK9	MI	TTPLTSQ
DM5QDK9	MN	Neutrophil elastase (NE)
DM5QDK9	MT	DTT
DM5QDK9	MA	Inhibitor
DM5QDK9	RN	N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
DM5QDK9	RU	https://pubmed.ncbi.nlm.nih.gov/17850059

DM31OSD	DI	DM31OSD
DM31OSD	DN	(4-bromo-1H-pyrazol-1-yl)(p-tolyl)methanone
DM31OSD	MI	TT6L509
DM31OSD	MN	Coagulation factor IIa (F2)
DM31OSD	MT	DTT
DM31OSD	MA	Inhibitor
DM31OSD	RN	N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
DM31OSD	RU	https://pubmed.ncbi.nlm.nih.gov/17850059

DM31OSD	DI	DM31OSD
DM31OSD	DN	(4-bromo-1H-pyrazol-1-yl)(p-tolyl)methanone
DM31OSD	MI	TTPLTSQ
DM31OSD	MN	Neutrophil elastase (NE)
DM31OSD	MT	DTT
DM31OSD	MA	Inhibitor
DM31OSD	RN	N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
DM31OSD	RU	https://pubmed.ncbi.nlm.nih.gov/17850059

DM31OSD	DI	DM31OSD
DM31OSD	DN	(4-bromo-1H-pyrazol-1-yl)(p-tolyl)methanone
DM31OSD	MI	TTMF8H9
DM31OSD	MN	Plasma kallikrein (KLKB1)
DM31OSD	MT	DTT
DM31OSD	MA	Inhibitor
DM31OSD	RN	N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
DM31OSD	RU	https://pubmed.ncbi.nlm.nih.gov/17850059

DM31OSD	DI	DM31OSD
DM31OSD	DN	(4-bromo-1H-pyrazol-1-yl)(p-tolyl)methanone
DM31OSD	MI	TTGY7WI
DM31OSD	MN	Urokinase-type plasminogen activator (PLAU)
DM31OSD	MT	DTT
DM31OSD	MA	Inhibitor
DM31OSD	RN	N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
DM31OSD	RU	https://pubmed.ncbi.nlm.nih.gov/17850059

DMU1HFM	DI	DMU1HFM
DMU1HFM	DN	(4-Bromo-butyl)-trimethyl-ammonium
DMU1HFM	MI	TT1RS9F
DMU1HFM	MN	Acetylcholinesterase (AChE)
DMU1HFM	MT	DTT
DMU1HFM	MA	Inhibitor
DMU1HFM	RN	Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors. J Med Chem. 1996 Dec 20;39(26):5064-71.
DMU1HFM	RU	https://pubmed.ncbi.nlm.nih.gov/8978837

DMLAEPF	DI	DMLAEPF
DMLAEPF	DN	(4-bromophenyl)(10H-phenothiazin-10-yl)methanone
DMLAEPF	MI	TTEB0GD
DMLAEPF	MN	Cholinesterase (BCHE)
DMLAEPF	MT	DTT
DMLAEPF	MA	Inhibitor
DMLAEPF	RN	Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. Bioorg Med Chem. 2007 Oct 1;15(19):6367-78.
DMLAEPF	RU	https://pubmed.ncbi.nlm.nih.gov/17681768

DMOCYZJ	DI	DMOCYZJ
DMOCYZJ	DN	(4-bromophenyl)difluoromethanesulfonamide
DMOCYZJ	MI	TTUNARX
DMOCYZJ	MN	Carbonic anhydrase (CA)
DMOCYZJ	MT	DTT
DMOCYZJ	MA	Inhibitor
DMOCYZJ	RN	Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6.
DMOCYZJ	RU	https://pubmed.ncbi.nlm.nih.gov/16203142

DMOCYZJ	DI	DMOCYZJ
DMOCYZJ	DN	(4-bromophenyl)difluoromethanesulfonamide
DMOCYZJ	MI	TTHQPL7
DMOCYZJ	MN	Carbonic anhydrase I (CA-I)
DMOCYZJ	MT	DTT
DMOCYZJ	MA	Inhibitor
DMOCYZJ	RN	Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6.
DMOCYZJ	RU	https://pubmed.ncbi.nlm.nih.gov/16203142

DMOCYZJ	DI	DMOCYZJ
DMOCYZJ	DN	(4-bromophenyl)difluoromethanesulfonamide
DMOCYZJ	MI	TTANPDJ
DMOCYZJ	MN	Carbonic anhydrase II (CA-II)
DMOCYZJ	MT	DTT
DMOCYZJ	MA	Inhibitor
DMOCYZJ	RN	Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6.
DMOCYZJ	RU	https://pubmed.ncbi.nlm.nih.gov/16203142

DMOCYZJ	DI	DMOCYZJ
DMOCYZJ	DN	(4-bromophenyl)difluoromethanesulfonamide
DMOCYZJ	MI	TT2LVK8
DMOCYZJ	MN	Carbonic anhydrase IX (CA-IX)
DMOCYZJ	MT	DTT
DMOCYZJ	MA	Inhibitor
DMOCYZJ	RN	Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6.
DMOCYZJ	RU	https://pubmed.ncbi.nlm.nih.gov/16203142

DM4MAZ1	DI	DM4MAZ1
DM4MAZ1	DN	(4-chloro-1H-pyrazol-1-yl)(o-tolyl)methanone
DM4MAZ1	MI	TTPLTSQ
DM4MAZ1	MN	Neutrophil elastase (NE)
DM4MAZ1	MT	DTT
DM4MAZ1	MA	Inhibitor
DM4MAZ1	RN	N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
DM4MAZ1	RU	https://pubmed.ncbi.nlm.nih.gov/17850059

DMRIWH2	DI	DMRIWH2
DMRIWH2	DN	(4-Dipropylamino-cyclohexylidene)-acetonitrile
DMRIWH2	MI	TT4C8EA
DMRIWH2	MN	Dopamine D3 receptor (D3R)
DMRIWH2	MT	DTT
DMRIWH2	MA	Inhibitor
DMRIWH2	RN	Conjugated enynes as nonaromatic catechol bioisosteres: synthesis, binding experiments, and computational studies of novel dopamine receptor agonis... J Med Chem. 2000 Feb 24;43(4):756-62.
DMRIWH2	RU	https://pubmed.ncbi.nlm.nih.gov/10691700

DMG27K1	DI	DMG27K1
DMG27K1	DN	(4e)-4-Aminohex-4-Enoic Acid
DMG27K1	MI	TTT2LD9
DMG27K1	MN	GABA transaminase (ABAT)
DMG27K1	MT	DTT
DMG27K1	MA	Inhibitor
DMG27K1	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMG27K1	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMHQCRU	DI	DMHQCRU
DMHQCRU	DN	(4-Ethynyl-cyclohex-3-enyl)-dipropyl-amine
DMHQCRU	MI	TTEX248
DMHQCRU	MN	Dopamine D2 receptor (D2R)
DMHQCRU	MT	DTT
DMHQCRU	MA	Inhibitor
DMHQCRU	RN	Conjugated enynes as nonaromatic catechol bioisosteres: synthesis, binding experiments, and computational studies of novel dopamine receptor agonis... J Med Chem. 2000 Feb 24;43(4):756-62.
DMHQCRU	RU	https://pubmed.ncbi.nlm.nih.gov/10691700

DMHQCRU	DI	DMHQCRU
DMHQCRU	DN	(4-Ethynyl-cyclohex-3-enyl)-dipropyl-amine
DMHQCRU	MI	TT4C8EA
DMHQCRU	MN	Dopamine D3 receptor (D3R)
DMHQCRU	MT	DTT
DMHQCRU	MA	Inhibitor
DMHQCRU	RN	Novel D3 selective dopaminergics incorporating enyne units as nonaromatic catechol bioisosteres: synthesis, bioactivity, and mutagenesis studies. J Med Chem. 2008 Nov 13;51(21):6829-38.
DMHQCRU	RU	https://pubmed.ncbi.nlm.nih.gov/18834111

DMHQCRU	DI	DMHQCRU
DMHQCRU	DN	(4-Ethynyl-cyclohex-3-enyl)-dipropyl-amine
DMHQCRU	MI	TTE0A2F
DMHQCRU	MN	Dopamine D4 receptor (D4R)
DMHQCRU	MT	DTT
DMHQCRU	MA	Inhibitor
DMHQCRU	RN	Conjugated enynes as nonaromatic catechol bioisosteres: synthesis, binding experiments, and computational studies of novel dopamine receptor agonis... J Med Chem. 2000 Feb 24;43(4):756-62.
DMHQCRU	RU	https://pubmed.ncbi.nlm.nih.gov/10691700

DM75EAT	DI	DM75EAT
DM75EAT	DN	(4-Fluoro-phenyl)-(9H-purin-6-yl)-amine
DM75EAT	MI	TTZN7RP
DM75EAT	MN	Rho-associated protein kinase 1 (ROCK1)
DM75EAT	MT	DTT
DM75EAT	MA	Inhibitor
DM75EAT	RN	Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22.
DM75EAT	RU	https://pubmed.ncbi.nlm.nih.gov/15689155

DMYAJQU	DI	DMYAJQU
DMYAJQU	DN	(4-Fluoro-phenyl)-(9-methyl-9H-purin-6-yl)-amine
DMYAJQU	MI	TT4TQBX
DMYAJQU	MN	Extracellular signal-regulated kinase 2 (ERK2)
DMYAJQU	MT	DTT
DMYAJQU	MA	Inhibitor
DMYAJQU	RN	Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22.
DMYAJQU	RU	https://pubmed.ncbi.nlm.nih.gov/15689155

DMOS68D	DI	DMOS68D
DMOS68D	DN	(4-fluorophenyl)(pyridin-4-yl)methanone
DMOS68D	MI	TTXZEAJ
DMOS68D	MN	Leukotriene A-4 hydrolase (LTA4H)
DMOS68D	MT	DTT
DMOS68D	MA	Inhibitor
DMOS68D	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMOS68D	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM0KXP1	DI	DM0KXP1
DM0KXP1	DN	(4-guanidino-benzyl)-carbamic acid benzyl ester
DM0KXP1	MI	TTGY7WI
DM0KXP1	MN	Urokinase-type plasminogen activator (PLAU)
DM0KXP1	MT	DTT
DM0KXP1	MA	Inhibitor
DM0KXP1	RN	Small, potent, and selective diaryl phosphonate inhibitors for urokinase-type plasminogen activator with in vivo antimetastatic properties. J Med Chem. 2007 Dec 27;50(26):6638-46.
DM0KXP1	RU	https://pubmed.ncbi.nlm.nih.gov/18052026

DM1WZXL	DI	DM1WZXL
DM1WZXL	DN	(4-hexylphenyl)(oxiran-2-yl)methanone
DM1WZXL	MI	TTGER3L
DM1WZXL	MN	Thyroid hormone receptor beta (THRB)
DM1WZXL	MT	DTT
DM1WZXL	MA	Inhibitor
DM1WZXL	RN	Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80.
DM1WZXL	RU	https://pubmed.ncbi.nlm.nih.gov/17918822

DMRCM5O	DI	DMRCM5O
DMRCM5O	DN	(4-Hydroxy-phenoxy)-acetic acid
DMRCM5O	MI	TT8DSFC
DMRCM5O	MN	Hydroxyphenylpyruvate dioxygenase (HPD)
DMRCM5O	MT	DTT
DMRCM5O	MA	Inhibitor
DMRCM5O	RN	Design, synthesis, and evaluation of postulated transient intermediate and substrate analogues as inhibitors of 4-hydroxyphenylpyruvate dioxygenase. Bioorg Med Chem Lett. 2002 Jul 8;12(13):1709-13.
DMRCM5O	RU	https://pubmed.ncbi.nlm.nih.gov/12067543

DMOWFE5	DI	DMOWFE5
DMOWFE5	DN	(4-Iodo-butyl)-trimethyl-ammonium iodide
DMOWFE5	MI	TT1RS9F
DMOWFE5	MN	Acetylcholinesterase (AChE)
DMOWFE5	MT	DTT
DMOWFE5	MA	Inhibitor
DMOWFE5	RN	Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors. J Med Chem. 1996 Dec 20;39(26):5064-71.
DMOWFE5	RU	https://pubmed.ncbi.nlm.nih.gov/8978837

DMZD0KG	DI	DMZD0KG
DMZD0KG	DN	(4-methoxyphenyl)(4-phenylazepan-1-yl)methanone
DMZD0KG	MI	TTN7BL9
DMZD0KG	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMZD0KG	MT	DTT
DMZD0KG	MA	Inhibitor
DMZD0KG	RN	The discovery of azepane sulfonamides as potent 11beta-HSD1 inhibitors. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4563-5.
DMZD0KG	RU	https://pubmed.ncbi.nlm.nih.gov/19625185

DMPU7KE	DI	DMPU7KE
DMPU7KE	DN	(4-Methyl-2-oxo-2H-quinolin-1-yl)-acetic acid
DMPU7KE	MI	TTFBNVI
DMPU7KE	MN	Aldose reductase (AKR1B1)
DMPU7KE	MT	DTT
DMPU7KE	MA	Inhibitor
DMPU7KE	RN	Synthesis and aldose reductase inhibitory activity of substituted 2-oxoquinoline-1-acetic acid derivatives. J Med Chem. 1986 Oct;29(10):2024-8.
DMPU7KE	RU	https://pubmed.ncbi.nlm.nih.gov/3093680

DMBPL3J	DI	DMBPL3J
DMBPL3J	DN	(4-nitro-1H-pyrazol-1-yl)(o-tolyl)methanone
DMBPL3J	MI	TT6L509
DMBPL3J	MN	Coagulation factor IIa (F2)
DMBPL3J	MT	DTT
DMBPL3J	MA	Inhibitor
DMBPL3J	RN	N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
DMBPL3J	RU	https://pubmed.ncbi.nlm.nih.gov/17850059

DMBPL3J	DI	DMBPL3J
DMBPL3J	DN	(4-nitro-1H-pyrazol-1-yl)(o-tolyl)methanone
DMBPL3J	MI	TTPLTSQ
DMBPL3J	MN	Neutrophil elastase (NE)
DMBPL3J	MT	DTT
DMBPL3J	MA	Inhibitor
DMBPL3J	RN	N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
DMBPL3J	RU	https://pubmed.ncbi.nlm.nih.gov/17850059

DMBPL3J	DI	DMBPL3J
DMBPL3J	DN	(4-nitro-1H-pyrazol-1-yl)(o-tolyl)methanone
DMBPL3J	MI	TTGY7WI
DMBPL3J	MN	Urokinase-type plasminogen activator (PLAU)
DMBPL3J	MT	DTT
DMBPL3J	MA	Inhibitor
DMBPL3J	RN	N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
DMBPL3J	RU	https://pubmed.ncbi.nlm.nih.gov/17850059

DMIDUO9	DI	DMIDUO9
DMIDUO9	DN	(4-nitro-1H-pyrazol-1-yl)(phenyl)methanone
DMIDUO9	MI	TT6L509
DMIDUO9	MN	Coagulation factor IIa (F2)
DMIDUO9	MT	DTT
DMIDUO9	MA	Inhibitor
DMIDUO9	RN	N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
DMIDUO9	RU	https://pubmed.ncbi.nlm.nih.gov/17850059

DMIDUO9	DI	DMIDUO9
DMIDUO9	DN	(4-nitro-1H-pyrazol-1-yl)(phenyl)methanone
DMIDUO9	MI	TTPLTSQ
DMIDUO9	MN	Neutrophil elastase (NE)
DMIDUO9	MT	DTT
DMIDUO9	MA	Inhibitor
DMIDUO9	RN	N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
DMIDUO9	RU	https://pubmed.ncbi.nlm.nih.gov/17850059

DMIDUO9	DI	DMIDUO9
DMIDUO9	DN	(4-nitro-1H-pyrazol-1-yl)(phenyl)methanone
DMIDUO9	MI	TTGY7WI
DMIDUO9	MN	Urokinase-type plasminogen activator (PLAU)
DMIDUO9	MT	DTT
DMIDUO9	MA	Inhibitor
DMIDUO9	RN	N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
DMIDUO9	RU	https://pubmed.ncbi.nlm.nih.gov/17850059

DM1YC0B	DI	DM1YC0B
DM1YC0B	DN	(4-nitrophenyl)(10H-phenothiazin-10-yl)methanone
DM1YC0B	MI	TTEB0GD
DM1YC0B	MN	Cholinesterase (BCHE)
DM1YC0B	MT	DTT
DM1YC0B	MA	Inhibitor
DM1YC0B	RN	Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. Bioorg Med Chem. 2007 Oct 1;15(19):6367-78.
DM1YC0B	RU	https://pubmed.ncbi.nlm.nih.gov/17681768

DMFO8DR	DI	DMFO8DR
DMFO8DR	DN	(4-Phenoxy-phenyl)-quinazolin-4-yl-amine
DMFO8DR	MI	TT9VGXW
DMFO8DR	MN	Angiopoietin 1 receptor (TEK)
DMFO8DR	MT	DTT
DMFO8DR	MA	Inhibitor
DMFO8DR	RN	Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I. Bioorg Med Chem Lett. 2000 Oct 2;10(19):2167-70.
DMFO8DR	RU	https://pubmed.ncbi.nlm.nih.gov/11012021

DMFO8DR	DI	DMFO8DR
DMFO8DR	DN	(4-Phenoxy-phenyl)-quinazolin-4-yl-amine
DMFO8DR	MI	TT860QF
DMFO8DR	MN	LCK tyrosine protein kinase (LCK)
DMFO8DR	MT	DTT
DMFO8DR	MA	Inhibitor
DMFO8DR	RN	Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I. Bioorg Med Chem Lett. 2000 Oct 2;10(19):2167-70.
DMFO8DR	RU	https://pubmed.ncbi.nlm.nih.gov/11012021

DMFO8DR	DI	DMFO8DR
DMFO8DR	DN	(4-Phenoxy-phenyl)-quinazolin-4-yl-amine
DMFO8DR	MI	TTUTJGQ
DMFO8DR	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMFO8DR	MT	DTT
DMFO8DR	MA	Inhibitor
DMFO8DR	RN	Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I. Bioorg Med Chem Lett. 2000 Oct 2;10(19):2167-70.
DMFO8DR	RU	https://pubmed.ncbi.nlm.nih.gov/11012021

DMQM8O5	DI	DMQM8O5
DMQM8O5	DN	(4-Phenylethynyl-cyclohex-3-enyl)-dipropyl-amine
DMQM8O5	MI	TT4C8EA
DMQM8O5	MN	Dopamine D3 receptor (D3R)
DMQM8O5	MT	DTT
DMQM8O5	MA	Inhibitor
DMQM8O5	RN	Conjugated enynes as nonaromatic catechol bioisosteres: synthesis, binding experiments, and computational studies of novel dopamine receptor agonis... J Med Chem. 2000 Feb 24;43(4):756-62.
DMQM8O5	RU	https://pubmed.ncbi.nlm.nih.gov/10691700

DMQM8O5	DI	DMQM8O5
DMQM8O5	DN	(4-Phenylethynyl-cyclohex-3-enyl)-dipropyl-amine
DMQM8O5	MI	TTE0A2F
DMQM8O5	MN	Dopamine D4 receptor (D4R)
DMQM8O5	MT	DTT
DMQM8O5	MA	Inhibitor
DMQM8O5	RN	Conjugated enynes as nonaromatic catechol bioisosteres: synthesis, binding experiments, and computational studies of novel dopamine receptor agonis... J Med Chem. 2000 Feb 24;43(4):756-62.
DMQM8O5	RU	https://pubmed.ncbi.nlm.nih.gov/10691700

DM0NTA3	DI	DM0NTA3
DM0NTA3	DN	(4-phenylpiperazin-1-yl)(p-tolyl)methanone
DM0NTA3	MI	TTVTX4N
DM0NTA3	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DM0NTA3	MT	DTT
DM0NTA3	MA	Inhibitor
DM0NTA3	RN	Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides. Bioorg Med Chem. 2007 Nov 1;15(21):6649-58.
DM0NTA3	RU	https://pubmed.ncbi.nlm.nih.gov/17723305

DMKF3U6	DI	DMKF3U6
DMKF3U6	DN	(4-Quinolin-2-ylpiperazin-1-yl)acetic Acid
DMKF3U6	MI	TTPC4TU
DMKF3U6	MN	5-HT 3A receptor (HTR3A)
DMKF3U6	MT	DTT
DMKF3U6	MA	Inhibitor
DMKF3U6	RN	Specific targeting of peripheral serotonin 5-HT(3) receptors. Synthesis, biological investigation, and structure-activity relationships. J Med Chem. 2009 Jun 11;52(11):3548-62.
DMKF3U6	RU	https://pubmed.ncbi.nlm.nih.gov/19425598

DMKF3U6	DI	DMKF3U6
DMKF3U6	DN	(4-Quinolin-2-ylpiperazin-1-yl)acetic Acid
DMKF3U6	MI	TTEX248
DMKF3U6	MN	Dopamine D2 receptor (D2R)
DMKF3U6	MT	DTT
DMKF3U6	MA	Inhibitor
DMKF3U6	RN	Specific targeting of peripheral serotonin 5-HT(3) receptors. Synthesis, biological investigation, and structure-activity relationships. J Med Chem. 2009 Jun 11;52(11):3548-62.
DMKF3U6	RU	https://pubmed.ncbi.nlm.nih.gov/19425598

DMZFTI4	DI	DMZFTI4
DMZFTI4	DN	(4R)-4-ammoniopentanoate
DMZFTI4	MI	TT1MPAY
DMZFTI4	MN	GABA(A) receptor alpha-1 (GABRA1)
DMZFTI4	MT	DTT
DMZFTI4	MA	Inhibitor
DMZFTI4	RN	gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83.
DMZFTI4	RU	https://pubmed.ncbi.nlm.nih.gov/6118436

DMZFTI4	DI	DMZFTI4
DMZFTI4	DN	(4R)-4-ammoniopentanoate
DMZFTI4	MI	TTBMV1G
DMZFTI4	MN	GABA(A) receptor alpha-2 (GABRA2)
DMZFTI4	MT	DTT
DMZFTI4	MA	Inhibitor
DMZFTI4	RN	gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83.
DMZFTI4	RU	https://pubmed.ncbi.nlm.nih.gov/6118436

DMZFTI4	DI	DMZFTI4
DMZFTI4	DN	(4R)-4-ammoniopentanoate
DMZFTI4	MI	TT37EDJ
DMZFTI4	MN	GABA(A) receptor alpha-3 (GABRA3)
DMZFTI4	MT	DTT
DMZFTI4	MA	Inhibitor
DMZFTI4	RN	gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83.
DMZFTI4	RU	https://pubmed.ncbi.nlm.nih.gov/6118436

DMZFTI4	DI	DMZFTI4
DMZFTI4	DN	(4R)-4-ammoniopentanoate
DMZFTI4	MI	TTNZPQ1
DMZFTI4	MN	GABA(A) receptor alpha-5 (GABRA5)
DMZFTI4	MT	DTT
DMZFTI4	MA	Inhibitor
DMZFTI4	RN	gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83.
DMZFTI4	RU	https://pubmed.ncbi.nlm.nih.gov/6118436

DMZFTI4	DI	DMZFTI4
DMZFTI4	DN	(4R)-4-ammoniopentanoate
DMZFTI4	MI	TTZA1NY
DMZFTI4	MN	GABA(A) receptor beta-2 (GABRB2)
DMZFTI4	MT	DTT
DMZFTI4	MA	Inhibitor
DMZFTI4	RN	gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83.
DMZFTI4	RU	https://pubmed.ncbi.nlm.nih.gov/6118436

DMZFTI4	DI	DMZFTI4
DMZFTI4	DN	(4R)-4-ammoniopentanoate
DMZFTI4	MI	TT06RH5
DMZFTI4	MN	GABA(A) receptor gamma-2 (GABRG2)
DMZFTI4	MT	DTT
DMZFTI4	MA	Inhibitor
DMZFTI4	RN	gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83.
DMZFTI4	RU	https://pubmed.ncbi.nlm.nih.gov/6118436

DMZFTI4	DI	DMZFTI4
DMZFTI4	DN	(4R)-4-ammoniopentanoate
DMZFTI4	MI	TTNJYV2
DMZFTI4	MN	Gamma-aminobutyric acid receptor (GAR)
DMZFTI4	MT	DTT
DMZFTI4	MA	Inhibitor
DMZFTI4	RN	gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83.
DMZFTI4	RU	https://pubmed.ncbi.nlm.nih.gov/6118436

DMBLAY1	DI	DMBLAY1
DMBLAY1	DN	(4S)-4-ammoniopentanoate
DMBLAY1	MI	TT1MPAY
DMBLAY1	MN	GABA(A) receptor alpha-1 (GABRA1)
DMBLAY1	MT	DTT
DMBLAY1	MA	Inhibitor
DMBLAY1	RN	gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83.
DMBLAY1	RU	https://pubmed.ncbi.nlm.nih.gov/6118436

DMBLAY1	DI	DMBLAY1
DMBLAY1	DN	(4S)-4-ammoniopentanoate
DMBLAY1	MI	TTBMV1G
DMBLAY1	MN	GABA(A) receptor alpha-2 (GABRA2)
DMBLAY1	MT	DTT
DMBLAY1	MA	Inhibitor
DMBLAY1	RN	gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83.
DMBLAY1	RU	https://pubmed.ncbi.nlm.nih.gov/6118436

DMBLAY1	DI	DMBLAY1
DMBLAY1	DN	(4S)-4-ammoniopentanoate
DMBLAY1	MI	TT37EDJ
DMBLAY1	MN	GABA(A) receptor alpha-3 (GABRA3)
DMBLAY1	MT	DTT
DMBLAY1	MA	Inhibitor
DMBLAY1	RN	gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83.
DMBLAY1	RU	https://pubmed.ncbi.nlm.nih.gov/6118436

DMBLAY1	DI	DMBLAY1
DMBLAY1	DN	(4S)-4-ammoniopentanoate
DMBLAY1	MI	TTNZPQ1
DMBLAY1	MN	GABA(A) receptor alpha-5 (GABRA5)
DMBLAY1	MT	DTT
DMBLAY1	MA	Inhibitor
DMBLAY1	RN	gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83.
DMBLAY1	RU	https://pubmed.ncbi.nlm.nih.gov/6118436

DMBLAY1	DI	DMBLAY1
DMBLAY1	DN	(4S)-4-ammoniopentanoate
DMBLAY1	MI	TTZA1NY
DMBLAY1	MN	GABA(A) receptor beta-2 (GABRB2)
DMBLAY1	MT	DTT
DMBLAY1	MA	Inhibitor
DMBLAY1	RN	gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83.
DMBLAY1	RU	https://pubmed.ncbi.nlm.nih.gov/6118436

DMBLAY1	DI	DMBLAY1
DMBLAY1	DN	(4S)-4-ammoniopentanoate
DMBLAY1	MI	TT06RH5
DMBLAY1	MN	GABA(A) receptor gamma-2 (GABRG2)
DMBLAY1	MT	DTT
DMBLAY1	MA	Inhibitor
DMBLAY1	RN	gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83.
DMBLAY1	RU	https://pubmed.ncbi.nlm.nih.gov/6118436

DMBLAY1	DI	DMBLAY1
DMBLAY1	DN	(4S)-4-ammoniopentanoate
DMBLAY1	MI	TTNJYV2
DMBLAY1	MN	Gamma-aminobutyric acid receptor (GAR)
DMBLAY1	MT	DTT
DMBLAY1	MA	Inhibitor
DMBLAY1	RN	gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83.
DMBLAY1	RU	https://pubmed.ncbi.nlm.nih.gov/6118436

DMM6QV5	DI	DMM6QV5
DMM6QV5	DN	(4S,5R)-4,5-Diethyl-oxazolidin-(2Z)-ylideneamine
DMM6QV5	MI	TTZUFI5
DMM6QV5	MN	Nitric-oxide synthase brain (NOS1)
DMM6QV5	MT	DTT
DMM6QV5	MA	Inhibitor
DMM6QV5	RN	4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor. Bioorg Med Chem Lett. 2004 Jan 19;14(2):313-6.
DMM6QV5	RU	https://pubmed.ncbi.nlm.nih.gov/14698148

DMM6QV5	DI	DMM6QV5
DMM6QV5	DN	(4S,5R)-4,5-Diethyl-oxazolidin-(2Z)-ylideneamine
DMM6QV5	MI	TTF10I9
DMM6QV5	MN	Nitric-oxide synthase inducible (NOS2)
DMM6QV5	MT	DTT
DMM6QV5	MA	Inhibitor
DMM6QV5	RN	4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor. Bioorg Med Chem Lett. 2004 Jan 19;14(2):313-6.
DMM6QV5	RU	https://pubmed.ncbi.nlm.nih.gov/14698148

DM0V9HB	DI	DM0V9HB
DM0V9HB	DN	(4S,5R)-4,5-Dimethyl-oxazolidin-(2Z)-ylideneamine
DM0V9HB	MI	TTZUFI5
DM0V9HB	MN	Nitric-oxide synthase brain (NOS1)
DM0V9HB	MT	DTT
DM0V9HB	MA	Inhibitor
DM0V9HB	RN	4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor. Bioorg Med Chem Lett. 2004 Jan 19;14(2):313-6.
DM0V9HB	RU	https://pubmed.ncbi.nlm.nih.gov/14698148

DM0V9HB	DI	DM0V9HB
DM0V9HB	DN	(4S,5R)-4,5-Dimethyl-oxazolidin-(2Z)-ylideneamine
DM0V9HB	MI	TTF10I9
DM0V9HB	MN	Nitric-oxide synthase inducible (NOS2)
DM0V9HB	MT	DTT
DM0V9HB	MA	Inhibitor
DM0V9HB	RN	4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor. Bioorg Med Chem Lett. 2004 Jan 19;14(2):313-6.
DM0V9HB	RU	https://pubmed.ncbi.nlm.nih.gov/14698148

DMDC84U	DI	DMDC84U
DMDC84U	DN	(4S,5R)-4,5-Dipropyl-oxazolidin-(2Z)-ylideneamine
DMDC84U	MI	TTF10I9
DMDC84U	MN	Nitric-oxide synthase inducible (NOS2)
DMDC84U	MT	DTT
DMDC84U	MA	Inhibitor
DMDC84U	RN	4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor. Bioorg Med Chem Lett. 2004 Jan 19;14(2):313-6.
DMDC84U	RU	https://pubmed.ncbi.nlm.nih.gov/14698148

DM1VJUZ	DI	DM1VJUZ
DM1VJUZ	DN	(4S,5S)-4,5-Diethyl-oxazolidin-(2Z)-ylideneamine
DM1VJUZ	MI	TTZUFI5
DM1VJUZ	MN	Nitric-oxide synthase brain (NOS1)
DM1VJUZ	MT	DTT
DM1VJUZ	MA	Inhibitor
DM1VJUZ	RN	4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor. Bioorg Med Chem Lett. 2004 Jan 19;14(2):313-6.
DM1VJUZ	RU	https://pubmed.ncbi.nlm.nih.gov/14698148

DM1VJUZ	DI	DM1VJUZ
DM1VJUZ	DN	(4S,5S)-4,5-Diethyl-oxazolidin-(2Z)-ylideneamine
DM1VJUZ	MI	TTF10I9
DM1VJUZ	MN	Nitric-oxide synthase inducible (NOS2)
DM1VJUZ	MT	DTT
DM1VJUZ	MA	Inhibitor
DM1VJUZ	RN	4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor. Bioorg Med Chem Lett. 2004 Jan 19;14(2):313-6.
DM1VJUZ	RU	https://pubmed.ncbi.nlm.nih.gov/14698148

DM5EKF4	DI	DM5EKF4
DM5EKF4	DN	(4S,5S)-4,5-Dipropyl-oxazolidin-(2Z)-ylideneamine
DM5EKF4	MI	TTF10I9
DM5EKF4	MN	Nitric-oxide synthase inducible (NOS2)
DM5EKF4	MT	DTT
DM5EKF4	MA	Inhibitor
DM5EKF4	RN	4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor. Bioorg Med Chem Lett. 2004 Jan 19;14(2):313-6.
DM5EKF4	RU	https://pubmed.ncbi.nlm.nih.gov/14698148

DMGCZOI	DI	DMGCZOI
DMGCZOI	DN	(4-sulfamoylphenylethylthioureido)fluorescein
DMGCZOI	MI	TT2LVK8
DMGCZOI	MN	Carbonic anhydrase IX (CA-IX)
DMGCZOI	MT	DTT
DMGCZOI	MA	Inhibitor
DMGCZOI	RN	Recent developments of carbonic anhydrase inhibitors as potential anticancer drugs. J Med Chem. 2008 Jun 12;51(11):3051-6.
DMGCZOI	RU	https://pubmed.ncbi.nlm.nih.gov/18348513

DM15P2G	DI	DM15P2G
DM15P2G	DN	(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol
DM15P2G	MI	TTSN6QU
DM15P2G	MN	HIF1-alpha messenger RNA (HIF1A mRNA)
DM15P2G	MT	DTT
DM15P2G	MA	Inhibitor
DM15P2G	RN	Synthesis of (aryloxyacetylamino)-isonicotinic/nicotinic acid analogues as potent hypoxia-inducible factor (HIF)-1alpha inhibitors. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6305-10.
DM15P2G	RU	https://pubmed.ncbi.nlm.nih.gov/17884495

DM15P2G	DI	DM15P2G
DM15P2G	DN	(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol
DM15P2G	MI	TT23PYC
DM15P2G	MN	Soluble guanylate cyclase (GCS)
DM15P2G	MT	DTT
DM15P2G	MA	Activator
DM15P2G	RN	Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction. Int J Impot Res. 2002 Feb;14(1):8-14.
DM15P2G	RU	https://pubmed.ncbi.nlm.nih.gov/11896472

DMTC5VF	DI	DMTC5VF
DMTC5VF	DN	(5-(pyridin-3-yl)furan-2-yl)methanamine
DMTC5VF	MI	TTVG215
DMTC5VF	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DMTC5VF	MT	DTT
DMTC5VF	MA	Inhibitor
DMTC5VF	RN	Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallization. J Med Chem. 2006 Nov 30;49(24):6987-7001.
DMTC5VF	RU	https://pubmed.ncbi.nlm.nih.gov/17125252

DMF0YJ3	DI	DMF0YJ3
DMF0YJ3	DN	(5-amino-1-phenyl-1H-pyrazol-4-yl)phenylmethanone
DMF0YJ3	MI	TTQBR95
DMF0YJ3	MN	Stress-activated protein kinase 2a (p38 alpha)
DMF0YJ3	MT	DTT
DMF0YJ3	MA	Inhibitor
DMF0YJ3	RN	Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highl... J Med Chem. 2006 Mar 9;49(5):1562-75.
DMF0YJ3	RU	https://pubmed.ncbi.nlm.nih.gov/16509574

DMVQ6RN	DI	DMVQ6RN
DMVQ6RN	DN	(5BETA)-PREGNANE-3,20-DIONE
DMVQ6RN	MI	TTRANFM
DMVQ6RN	MN	Orphan nuclear receptor NR1I3 (NR1I3)
DMVQ6RN	MT	DTT
DMVQ6RN	MA	Inhibitor
DMVQ6RN	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMVQ6RN	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMVQ6RN	DI	DMVQ6RN
DMVQ6RN	DN	(5BETA)-PREGNANE-3,20-DIONE
DMVQ6RN	MI	TT6PEUO
DMVQ6RN	MN	Retinoic acid receptor RXR-alpha (RXRA)
DMVQ6RN	MT	DTT
DMVQ6RN	MA	Inhibitor
DMVQ6RN	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMVQ6RN	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM4EH2J	DI	DM4EH2J
DM4EH2J	DN	(5-Bromo-pentyl)-trimethyl-ammonium
DM4EH2J	MI	TT1RS9F
DM4EH2J	MN	Acetylcholinesterase (AChE)
DM4EH2J	MT	DTT
DM4EH2J	MA	Inhibitor
DM4EH2J	RN	Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors. J Med Chem. 1996 Dec 20;39(26):5064-71.
DM4EH2J	RU	https://pubmed.ncbi.nlm.nih.gov/8978837

DM8JHWS	DI	DM8JHWS
DM8JHWS	DN	(5E,8E,11E,14E)-Icosa-5,8,11,14-tetraenal
DM8JHWS	MI	TTMI6F5
DM8JHWS	MN	Transient receptor potential cation channel V1 (TRPV1)
DM8JHWS	MT	DTT
DM8JHWS	MA	Inhibitor
DM8JHWS	RN	The taming of capsaicin. Reversal of the vanilloid activity of N-acylvanillamines by aromatic iodination. J Med Chem. 2005 Jul 14;48(14):4663-9.
DM8JHWS	RU	https://pubmed.ncbi.nlm.nih.gov/16000002

DMIV4BU	DI	DMIV4BU
DMIV4BU	DN	(5-fluoro-1H-indol-2-yl)-(1H-indol-2-yl)methanone
DMIV4BU	MI	TTGJCWZ
DMIV4BU	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMIV4BU	MT	DTT
DMIV4BU	MA	Inhibitor
DMIV4BU	RN	Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15.
DMIV4BU	RU	https://pubmed.ncbi.nlm.nih.gov/16722630

DMIV4BU	DI	DMIV4BU
DMIV4BU	DN	(5-fluoro-1H-indol-2-yl)-(1H-indol-2-yl)methanone
DMIV4BU	MI	TT8FYO9
DMIV4BU	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMIV4BU	MT	DTT
DMIV4BU	MA	Inhibitor
DMIV4BU	RN	Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15.
DMIV4BU	RU	https://pubmed.ncbi.nlm.nih.gov/16722630

DMIV4BU	DI	DMIV4BU
DMIV4BU	DN	(5-fluoro-1H-indol-2-yl)-(1H-indol-2-yl)methanone
DMIV4BU	MI	TTI7421
DMIV4BU	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMIV4BU	MT	DTT
DMIV4BU	MA	Inhibitor
DMIV4BU	RN	Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15.
DMIV4BU	RU	https://pubmed.ncbi.nlm.nih.gov/16722630

DMPBNYM	DI	DMPBNYM
DMPBNYM	DN	(5-hydroxy-1H-indol-2-yl)(1H-indol-2-yl)methanone
DMPBNYM	MI	TTGJCWZ
DMPBNYM	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMPBNYM	MT	DTT
DMPBNYM	MA	Inhibitor
DMPBNYM	RN	Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15.
DMPBNYM	RU	https://pubmed.ncbi.nlm.nih.gov/16722630

DMPBNYM	DI	DMPBNYM
DMPBNYM	DN	(5-hydroxy-1H-indol-2-yl)(1H-indol-2-yl)methanone
DMPBNYM	MI	TT8FYO9
DMPBNYM	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMPBNYM	MT	DTT
DMPBNYM	MA	Inhibitor
DMPBNYM	RN	Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15.
DMPBNYM	RU	https://pubmed.ncbi.nlm.nih.gov/16722630

DMPBNYM	DI	DMPBNYM
DMPBNYM	DN	(5-hydroxy-1H-indol-2-yl)(1H-indol-2-yl)methanone
DMPBNYM	MI	TTI7421
DMPBNYM	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMPBNYM	MT	DTT
DMPBNYM	MA	Inhibitor
DMPBNYM	RN	Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15.
DMPBNYM	RU	https://pubmed.ncbi.nlm.nih.gov/16722630

DMBKZDJ	DI	DMBKZDJ
DMBKZDJ	DN	(5-Imino-[1,4]thiazepan-3-yl)-methanol
DMBKZDJ	MI	TTZUFI5
DMBKZDJ	MN	Nitric-oxide synthase brain (NOS1)
DMBKZDJ	MT	DTT
DMBKZDJ	MA	Inhibitor
DMBKZDJ	RN	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
DMBKZDJ	RU	https://pubmed.ncbi.nlm.nih.gov/15501067

DMBKZDJ	DI	DMBKZDJ
DMBKZDJ	DN	(5-Imino-[1,4]thiazepan-3-yl)-methanol
DMBKZDJ	MI	TTCM4B3
DMBKZDJ	MN	Nitric-oxide synthase endothelial (NOS3)
DMBKZDJ	MT	DTT
DMBKZDJ	MA	Inhibitor
DMBKZDJ	RN	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
DMBKZDJ	RU	https://pubmed.ncbi.nlm.nih.gov/15501067

DMBKZDJ	DI	DMBKZDJ
DMBKZDJ	DN	(5-Imino-[1,4]thiazepan-3-yl)-methanol
DMBKZDJ	MI	TTF10I9
DMBKZDJ	MN	Nitric-oxide synthase inducible (NOS2)
DMBKZDJ	MT	DTT
DMBKZDJ	MA	Inhibitor
DMBKZDJ	RN	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
DMBKZDJ	RU	https://pubmed.ncbi.nlm.nih.gov/15501067

DMOPMNC	DI	DMOPMNC
DMOPMNC	DN	(5-methoxy-1H-indol-3-yl)methanamine
DMOPMNC	MI	TT0K1SC
DMOPMNC	MN	5-HT 2B receptor (HTR2B)
DMOPMNC	MT	DTT
DMOPMNC	MA	Inhibitor
DMOPMNC	RN	Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify no... J Med Chem. 2010 Nov 11;53(21):7573-86.
DMOPMNC	RU	https://pubmed.ncbi.nlm.nih.gov/20958049

DM4FJHO	DI	DM4FJHO
DM4FJHO	DN	(5-Methoxy-chroman-3-yl)-dipropyl-amine
DM4FJHO	MI	TTEX248
DM4FJHO	MN	Dopamine D2 receptor (D2R)
DM4FJHO	MT	DTT
DM4FJHO	MA	Inhibitor
DM4FJHO	RN	3-amino-3,4-dihydro-2H-1-benzopyran derivatives as 5-HT1A receptor ligands and potential anxiolytic agents. 2. Synthesis and quantitative structure... J Med Chem. 1996 Oct 11;39(21):4285-98.
DM4FJHO	RU	https://pubmed.ncbi.nlm.nih.gov/8863806

DM2HCUK	DI	DM2HCUK
DM2HCUK	DN	(5-phenyl-3H-benzo[d]imidazol-4-yl)methanamine
DM2HCUK	MI	TTDIGC1
DM2HCUK	MN	Dipeptidyl peptidase 4 (DPP-4)
DM2HCUK	MT	DTT
DM2HCUK	MA	Inhibitor
DM2HCUK	RN	Structure-based design and synthesis of benzimidazole derivatives as dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett. 2008 Apr 1;18(7):2362-7.
DM2HCUK	RU	https://pubmed.ncbi.nlm.nih.gov/18346892

DMORD8S	DI	DMORD8S
DMORD8S	DN	(5-phenylfuran-2-yl)methanamine
DMORD8S	MI	TTVG215
DMORD8S	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DMORD8S	MT	DTT
DMORD8S	MA	Inhibitor
DMORD8S	RN	Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallization. J Med Chem. 2006 Nov 30;49(24):6987-7001.
DMORD8S	RU	https://pubmed.ncbi.nlm.nih.gov/17125252

DM1R5SF	DI	DM1R5SF
DM1R5SF	DN	(5-Phenyl-oxazol-2-yl)-m-tolyl-amine
DM1R5SF	MI	TTUTJGQ
DM1R5SF	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM1R5SF	MT	DTT
DM1R5SF	MA	Inhibitor
DM1R5SF	RN	Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9.
DM1R5SF	RU	https://pubmed.ncbi.nlm.nih.gov/15743202

DM1R5SF	DI	DM1R5SF
DM1R5SF	DN	(5-Phenyl-oxazol-2-yl)-m-tolyl-amine
DM1R5SF	MI	TTDCBX5
DM1R5SF	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DM1R5SF	MT	DTT
DM1R5SF	MA	Inhibitor
DM1R5SF	RN	Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9.
DM1R5SF	RU	https://pubmed.ncbi.nlm.nih.gov/15743202

DM1R5SF	DI	DM1R5SF
DM1R5SF	DN	(5-Phenyl-oxazol-2-yl)-m-tolyl-amine
DM1R5SF	MI	TT1VAUK
DM1R5SF	MN	VEGFR1 messenger RNA (VEGFR1 mRNA)
DM1R5SF	MT	DTT
DM1R5SF	MA	Inhibitor
DM1R5SF	RN	Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9.
DM1R5SF	RU	https://pubmed.ncbi.nlm.nih.gov/15743202

DMKC2BE	DI	DMKC2BE
DMKC2BE	DN	(5-pyridin-3-yl-furan-2-yl)methanethiol
DMKC2BE	MI	TTXV4FI
DMKC2BE	MN	Albendazole monooxygenase (CYP3A4)
DMKC2BE	MT	DTT
DMKC2BE	MA	Inhibitor
DMKC2BE	RN	Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallization. J Med Chem. 2006 Nov 30;49(24):6987-7001.
DMKC2BE	RU	https://pubmed.ncbi.nlm.nih.gov/17125252

DMKC2BE	DI	DMKC2BE
DMKC2BE	DN	(5-pyridin-3-yl-furan-2-yl)methanethiol
DMKC2BE	MI	TTVG215
DMKC2BE	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DMKC2BE	MT	DTT
DMKC2BE	MA	Inhibitor
DMKC2BE	RN	Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallization. J Med Chem. 2006 Nov 30;49(24):6987-7001.
DMKC2BE	RU	https://pubmed.ncbi.nlm.nih.gov/17125252

DMREVX9	DI	DMREVX9
DMREVX9	DN	(5R,6S)-5,6-bis(benzyloxy)cyclohex-2-enone
DMREVX9	MI	TT9W8GU
DMREVX9	MN	Gamma-secretase (GS)
DMREVX9	MT	DTT
DMREVX9	MA	Inhibitor
DMREVX9	RN	Novel gamma-secretase inhibitors discovered by library screening of in-house synthetic natural product intermediates. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3813-6.
DMREVX9	RU	https://pubmed.ncbi.nlm.nih.gov/16682195

DMREVX9	DI	DMREVX9
DMREVX9	DN	(5R,6S)-5,6-bis(benzyloxy)cyclohex-2-enone
DMREVX9	MI	TTZ3S8C
DMREVX9	MN	Presenilin 1 (PSEN1)
DMREVX9	MT	DTT
DMREVX9	MA	Inhibitor
DMREVX9	RN	Novel gamma-secretase inhibitors discovered by library screening of in-house synthetic natural product intermediates. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3813-6.
DMREVX9	RU	https://pubmed.ncbi.nlm.nih.gov/16682195

DMREVX9	DI	DMREVX9
DMREVX9	DN	(5R,6S)-5,6-bis(benzyloxy)cyclohex-2-enone
DMREVX9	MI	TTWN3F4
DMREVX9	MN	Presenilin 2 (PSEN2)
DMREVX9	MT	DTT
DMREVX9	MA	Inhibitor
DMREVX9	RN	Novel gamma-secretase inhibitors discovered by library screening of in-house synthetic natural product intermediates. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3813-6.
DMREVX9	RU	https://pubmed.ncbi.nlm.nih.gov/16682195

DMHG7MU	DI	DMHG7MU
DMHG7MU	DN	(5R,6S)-6-(benzyloxy)-5-methoxycyclohex-2-enone
DMHG7MU	MI	TT9W8GU
DMHG7MU	MN	Gamma-secretase (GS)
DMHG7MU	MT	DTT
DMHG7MU	MA	Inhibitor
DMHG7MU	RN	Novel gamma-secretase inhibitors discovered by library screening of in-house synthetic natural product intermediates. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3813-6.
DMHG7MU	RU	https://pubmed.ncbi.nlm.nih.gov/16682195

DMHG7MU	DI	DMHG7MU
DMHG7MU	DN	(5R,6S)-6-(benzyloxy)-5-methoxycyclohex-2-enone
DMHG7MU	MI	TTZ3S8C
DMHG7MU	MN	Presenilin 1 (PSEN1)
DMHG7MU	MT	DTT
DMHG7MU	MA	Inhibitor
DMHG7MU	RN	Novel gamma-secretase inhibitors discovered by library screening of in-house synthetic natural product intermediates. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3813-6.
DMHG7MU	RU	https://pubmed.ncbi.nlm.nih.gov/16682195

DMHG7MU	DI	DMHG7MU
DMHG7MU	DN	(5R,6S)-6-(benzyloxy)-5-methoxycyclohex-2-enone
DMHG7MU	MI	TTWN3F4
DMHG7MU	MN	Presenilin 2 (PSEN2)
DMHG7MU	MT	DTT
DMHG7MU	MA	Inhibitor
DMHG7MU	RN	Novel gamma-secretase inhibitors discovered by library screening of in-house synthetic natural product intermediates. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3813-6.
DMHG7MU	RU	https://pubmed.ncbi.nlm.nih.gov/16682195

DMA5DO2	DI	DMA5DO2
DMA5DO2	DN	(5s)-5-Iododihydro-2,4(1h,3h)-Pyrimidinedione
DMA5DO2	MI	TTZPS91
DMA5DO2	MN	Dihydrothymine dehydrogenase (DPYD)
DMA5DO2	MT	DTT
DMA5DO2	MA	Inhibitor
DMA5DO2	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMA5DO2	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMT9CXD	DI	DMT9CXD
DMT9CXD	DN	(5S,6R)-[Octahydro-quinolin-(2E)-ylidene]amine
DMT9CXD	MI	TTZUFI5
DMT9CXD	MN	Nitric-oxide synthase brain (NOS1)
DMT9CXD	MT	DTT
DMT9CXD	MA	Inhibitor
DMT9CXD	RN	Bicyclic amidine inhibitors of nitric oxide synthase: discovery of perhydro-iminopyrindine and perhydro-iminoquinoline as potent, orally active inh... Bioorg Med Chem Lett. 2005 Apr 15;15(8):1997-2001.
DMT9CXD	RU	https://pubmed.ncbi.nlm.nih.gov/15808455

DMT9CXD	DI	DMT9CXD
DMT9CXD	DN	(5S,6R)-[Octahydro-quinolin-(2E)-ylidene]amine
DMT9CXD	MI	TTCM4B3
DMT9CXD	MN	Nitric-oxide synthase endothelial (NOS3)
DMT9CXD	MT	DTT
DMT9CXD	MA	Inhibitor
DMT9CXD	RN	Bicyclic amidine inhibitors of nitric oxide synthase: discovery of perhydro-iminopyrindine and perhydro-iminoquinoline as potent, orally active inh... Bioorg Med Chem Lett. 2005 Apr 15;15(8):1997-2001.
DMT9CXD	RU	https://pubmed.ncbi.nlm.nih.gov/15808455

DMT9CXD	DI	DMT9CXD
DMT9CXD	DN	(5S,6R)-[Octahydro-quinolin-(2E)-ylidene]amine
DMT9CXD	MI	TTF10I9
DMT9CXD	MN	Nitric-oxide synthase inducible (NOS2)
DMT9CXD	MT	DTT
DMT9CXD	MA	Inhibitor
DMT9CXD	RN	Bicyclic amidine inhibitors of nitric oxide synthase: discovery of perhydro-iminopyrindine and perhydro-iminoquinoline as potent, orally active inh... Bioorg Med Chem Lett. 2005 Apr 15;15(8):1997-2001.
DMT9CXD	RU	https://pubmed.ncbi.nlm.nih.gov/15808455

DMP4UC1	DI	DMP4UC1
DMP4UC1	DN	(5S,6S)-[Octahydro-quinolin-(2E)-ylidene]amine
DMP4UC1	MI	TTZUFI5
DMP4UC1	MN	Nitric-oxide synthase brain (NOS1)
DMP4UC1	MT	DTT
DMP4UC1	MA	Inhibitor
DMP4UC1	RN	Bicyclic amidine inhibitors of nitric oxide synthase: discovery of perhydro-iminopyrindine and perhydro-iminoquinoline as potent, orally active inh... Bioorg Med Chem Lett. 2005 Apr 15;15(8):1997-2001.
DMP4UC1	RU	https://pubmed.ncbi.nlm.nih.gov/15808455

DMP4UC1	DI	DMP4UC1
DMP4UC1	DN	(5S,6S)-[Octahydro-quinolin-(2E)-ylidene]amine
DMP4UC1	MI	TTCM4B3
DMP4UC1	MN	Nitric-oxide synthase endothelial (NOS3)
DMP4UC1	MT	DTT
DMP4UC1	MA	Inhibitor
DMP4UC1	RN	Bicyclic amidine inhibitors of nitric oxide synthase: discovery of perhydro-iminopyrindine and perhydro-iminoquinoline as potent, orally active inh... Bioorg Med Chem Lett. 2005 Apr 15;15(8):1997-2001.
DMP4UC1	RU	https://pubmed.ncbi.nlm.nih.gov/15808455

DMP4UC1	DI	DMP4UC1
DMP4UC1	DN	(5S,6S)-[Octahydro-quinolin-(2E)-ylidene]amine
DMP4UC1	MI	TTF10I9
DMP4UC1	MN	Nitric-oxide synthase inducible (NOS2)
DMP4UC1	MT	DTT
DMP4UC1	MA	Inhibitor
DMP4UC1	RN	Bicyclic amidine inhibitors of nitric oxide synthase: discovery of perhydro-iminopyrindine and perhydro-iminoquinoline as potent, orally active inh... Bioorg Med Chem Lett. 2005 Apr 15;15(8):1997-2001.
DMP4UC1	RU	https://pubmed.ncbi.nlm.nih.gov/15808455

DMA97CS	DI	DMA97CS
DMA97CS	DN	(5Z,9Z)-5,9-heptacosadienoic acid
DMA97CS	MI	TTGTQHC
DMA97CS	MN	DNA topoisomerase I (TOP1)
DMA97CS	MT	DTT
DMA97CS	MA	Inhibitor
DMA97CS	RN	Total synthesis and biological evaluation of (5Z,9Z)-5,9-hexadecadienoic acid, an inhibitor of human topoisomerase I. J Nat Prod. 2002 Nov;65(11):1715-8.
DMA97CS	RU	https://pubmed.ncbi.nlm.nih.gov/12444712

DMAXS9H	DI	DMAXS9H
DMAXS9H	DN	(6-Benzylamino-9H-beta-carbolin-3-yl)-methanol
DMAXS9H	MI	TT1MPAY
DMAXS9H	MN	GABA(A) receptor alpha-1 (GABRA1)
DMAXS9H	MT	DTT
DMAXS9H	MA	Inhibitor
DMAXS9H	RN	Synthesis of 6-substituted beta-carbolines that behave as benzodiazepine receptor antagonists or inverse agonists. J Med Chem. 1987 Apr;30(4):750-3.
DMAXS9H	RU	https://pubmed.ncbi.nlm.nih.gov/3031296

DMAXS9H	DI	DMAXS9H
DMAXS9H	DN	(6-Benzylamino-9H-beta-carbolin-3-yl)-methanol
DMAXS9H	MI	TTNJYV2
DMAXS9H	MN	Gamma-aminobutyric acid receptor (GAR)
DMAXS9H	MT	DTT
DMAXS9H	MA	Inhibitor
DMAXS9H	RN	Synthesis of 6-substituted beta-carbolines that behave as benzodiazepine receptor antagonists or inverse agonists. J Med Chem. 1987 Apr;30(4):750-3.
DMAXS9H	RU	https://pubmed.ncbi.nlm.nih.gov/3031296

DMF7LST	DI	DMF7LST
DMF7LST	DN	(6-Benzyloxy-2-naphthyl)-2-aminopropane
DMF7LST	MI	TT3WG5C
DMF7LST	MN	Monoamine oxidase type A (MAO-A)
DMF7LST	MT	DTT
DMF7LST	MA	Inhibitor
DMF7LST	RN	Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg Med Chem. 2009 Mar 15;17(6):2452-60.
DMF7LST	RU	https://pubmed.ncbi.nlm.nih.gov/19243954

DMF7LST	DI	DMF7LST
DMF7LST	DN	(6-Benzyloxy-2-naphthyl)-2-aminopropane
DMF7LST	MI	TTGP7BY
DMF7LST	MN	Monoamine oxidase type B (MAO-B)
DMF7LST	MT	DTT
DMF7LST	MA	Inhibitor
DMF7LST	RN	Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg Med Chem. 2009 Mar 15;17(6):2452-60.
DMF7LST	RU	https://pubmed.ncbi.nlm.nih.gov/19243954

DM7BK9A	DI	DM7BK9A
DM7BK9A	DN	(6-Butoxy-2-naphthyl)-2-aminopropane
DM7BK9A	MI	TT3WG5C
DM7BK9A	MN	Monoamine oxidase type A (MAO-A)
DM7BK9A	MT	DTT
DM7BK9A	MA	Inhibitor
DM7BK9A	RN	Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg Med Chem. 2009 Mar 15;17(6):2452-60.
DM7BK9A	RU	https://pubmed.ncbi.nlm.nih.gov/19243954

DMM2EX6	DI	DMM2EX6
DMM2EX6	DN	(6-Ethoxy-2-naphthyl)-2-aminopropane
DMM2EX6	MI	TT3WG5C
DMM2EX6	MN	Monoamine oxidase type A (MAO-A)
DMM2EX6	MT	DTT
DMM2EX6	MA	Inhibitor
DMM2EX6	RN	Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg Med Chem. 2009 Mar 15;17(6):2452-60.
DMM2EX6	RU	https://pubmed.ncbi.nlm.nih.gov/19243954

DMM2EX6	DI	DMM2EX6
DMM2EX6	DN	(6-Ethoxy-2-naphthyl)-2-aminopropane
DMM2EX6	MI	TTGP7BY
DMM2EX6	MN	Monoamine oxidase type B (MAO-B)
DMM2EX6	MT	DTT
DMM2EX6	MA	Inhibitor
DMM2EX6	RN	Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg Med Chem. 2009 Mar 15;17(6):2452-60.
DMM2EX6	RU	https://pubmed.ncbi.nlm.nih.gov/19243954

DMQJ5RU	DI	DMQJ5RU
DMQJ5RU	DN	(6-Hydroxy-2-oxo-2H-quinolin-1-yl)-acetic acid
DMQJ5RU	MI	TTFBNVI
DMQJ5RU	MN	Aldose reductase (AKR1B1)
DMQJ5RU	MT	DTT
DMQJ5RU	MA	Inhibitor
DMQJ5RU	RN	Synthesis and aldose reductase inhibitory activity of substituted 2-oxoquinoline-1-acetic acid derivatives. J Med Chem. 1986 Oct;29(10):2024-8.
DMQJ5RU	RU	https://pubmed.ncbi.nlm.nih.gov/3093680

DM6YGQ3	DI	DM6YGQ3
DM6YGQ3	DN	(6-Methoxy-2-naphthyl)-2-aminopropane
DM6YGQ3	MI	TT3WG5C
DM6YGQ3	MN	Monoamine oxidase type A (MAO-A)
DM6YGQ3	MT	DTT
DM6YGQ3	MA	Inhibitor
DM6YGQ3	RN	Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg Med Chem. 2009 Mar 15;17(6):2452-60.
DM6YGQ3	RU	https://pubmed.ncbi.nlm.nih.gov/19243954

DM6YGQ3	DI	DM6YGQ3
DM6YGQ3	DN	(6-Methoxy-2-naphthyl)-2-aminopropane
DM6YGQ3	MI	TTGP7BY
DM6YGQ3	MN	Monoamine oxidase type B (MAO-B)
DM6YGQ3	MT	DTT
DM6YGQ3	MA	Inhibitor
DM6YGQ3	RN	Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg Med Chem. 2009 Mar 15;17(6):2452-60.
DM6YGQ3	RU	https://pubmed.ncbi.nlm.nih.gov/19243954

DMTYXFU	DI	DMTYXFU
DMTYXFU	DN	(6-Methoxy-2-oxo-2H-quinolin-1-yl)-acetic acid
DMTYXFU	MI	TTFBNVI
DMTYXFU	MN	Aldose reductase (AKR1B1)
DMTYXFU	MT	DTT
DMTYXFU	MA	Inhibitor
DMTYXFU	RN	Synthesis and aldose reductase inhibitory activity of substituted 2-oxoquinoline-1-acetic acid derivatives. J Med Chem. 1986 Oct;29(10):2024-8.
DMTYXFU	RU	https://pubmed.ncbi.nlm.nih.gov/3093680

DM39W5K	DI	DM39W5K
DM39W5K	DN	(6-methylthio-2-naphthyl)isopropylamine
DM39W5K	MI	TT3WG5C
DM39W5K	MN	Monoamine oxidase type A (MAO-A)
DM39W5K	MT	DTT
DM39W5K	MA	Inhibitor
DM39W5K	RN	Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg Med Chem. 2009 Mar 15;17(6):2452-60.
DM39W5K	RU	https://pubmed.ncbi.nlm.nih.gov/19243954

DMIFL3V	DI	DMIFL3V
DMIFL3V	DN	(6-Propoxy-2-naphthyl)-2-aminopropane
DMIFL3V	MI	TT3WG5C
DMIFL3V	MN	Monoamine oxidase type A (MAO-A)
DMIFL3V	MT	DTT
DMIFL3V	MA	Inhibitor
DMIFL3V	RN	Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg Med Chem. 2009 Mar 15;17(6):2452-60.
DMIFL3V	RU	https://pubmed.ncbi.nlm.nih.gov/19243954

DMIFL3V	DI	DMIFL3V
DMIFL3V	DN	(6-Propoxy-2-naphthyl)-2-aminopropane
DMIFL3V	MI	TTGP7BY
DMIFL3V	MN	Monoamine oxidase type B (MAO-B)
DMIFL3V	MT	DTT
DMIFL3V	MA	Inhibitor
DMIFL3V	RN	Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg Med Chem. 2009 Mar 15;17(6):2452-60.
DMIFL3V	RU	https://pubmed.ncbi.nlm.nih.gov/19243954

DMOD9R7	DI	DMOD9R7
DMOD9R7	DN	(6r,1'r,2's)-5,6,7,8 Tetrahydrobiopterin
DMOD9R7	MI	TTZUFI5
DMOD9R7	MN	Nitric-oxide synthase brain (NOS1)
DMOD9R7	MT	DTT
DMOD9R7	MA	Inhibitor
DMOD9R7	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMOD9R7	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMOD9R7	DI	DMOD9R7
DMOD9R7	DN	(6r,1'r,2's)-5,6,7,8 Tetrahydrobiopterin
DMOD9R7	MI	TTCM4B3
DMOD9R7	MN	Nitric-oxide synthase endothelial (NOS3)
DMOD9R7	MT	DTT
DMOD9R7	MA	Inhibitor
DMOD9R7	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMOD9R7	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMOD9R7	DI	DMOD9R7
DMOD9R7	DN	(6r,1'r,2's)-5,6,7,8 Tetrahydrobiopterin
DMOD9R7	MI	TTF10I9
DMOD9R7	MN	Nitric-oxide synthase inducible (NOS2)
DMOD9R7	MT	DTT
DMOD9R7	MA	Inhibitor
DMOD9R7	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMOD9R7	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMRAC6T	DI	DMRAC6T
DMRAC6T	DN	(6s)-5,6,7,8-Tetrahydrofolate
DMRAC6T	MI	TTU6BFZ
DMRAC6T	MN	Candida Thymidylate synthase (Candi TMP1)
DMRAC6T	MT	DTT
DMRAC6T	MA	Inhibitor
DMRAC6T	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMRAC6T	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMB9YAO	DI	DMB9YAO
DMB9YAO	DN	(7-Benzyloxy-2-oxo-2H-chromen-4-yl)acetonitrile
DMB9YAO	MI	TT3WG5C
DMB9YAO	MN	Monoamine oxidase type A (MAO-A)
DMB9YAO	MT	DTT
DMB9YAO	MA	Inhibitor
DMB9YAO	RN	Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: development and biopharmacological profiling of 7-[(3-chlorobenzyl)ox... J Med Chem. 2009 Nov 12;52(21):6685-706.
DMB9YAO	RU	https://pubmed.ncbi.nlm.nih.gov/19810674

DMB9YAO	DI	DMB9YAO
DMB9YAO	DN	(7-Benzyloxy-2-oxo-2H-chromen-4-yl)acetonitrile
DMB9YAO	MI	TTGP7BY
DMB9YAO	MN	Monoamine oxidase type B (MAO-B)
DMB9YAO	MT	DTT
DMB9YAO	MA	Inhibitor
DMB9YAO	RN	Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: development and biopharmacological profiling of 7-[(3-chlorobenzyl)ox... J Med Chem. 2009 Nov 12;52(21):6685-706.
DMB9YAO	RU	https://pubmed.ncbi.nlm.nih.gov/19810674

DMRU0IB	DI	DMRU0IB
DMRU0IB	DN	(8-Hydroxy-2-oxo-2H-quinolin-1-yl)-acetic acid
DMRU0IB	MI	TTFBNVI
DMRU0IB	MN	Aldose reductase (AKR1B1)
DMRU0IB	MT	DTT
DMRU0IB	MA	Inhibitor
DMRU0IB	RN	Synthesis and aldose reductase inhibitory activity of substituted 2-oxoquinoline-1-acetic acid derivatives. J Med Chem. 1986 Oct;29(10):2024-8.
DMRU0IB	RU	https://pubmed.ncbi.nlm.nih.gov/3093680

DM1UGQN	DI	DM1UGQN
DM1UGQN	DN	(8R,8'R)-4-hydroxycubebinone
DM1UGQN	MI	TTXV4FI
DM1UGQN	MN	Albendazole monooxygenase (CYP3A4)
DM1UGQN	MT	DTT
DM1UGQN	MA	Inhibitor
DM1UGQN	RN	Potent CYP3A4 inhibitory constituents of Piper cubeba. J Nat Prod. 2005 Jan;68(1):64-8.
DM1UGQN	RU	https://pubmed.ncbi.nlm.nih.gov/15679319

DMVIHTF	DI	DMVIHTF
DMVIHTF	DN	(8R,8'R,9'S)-5-methoxyclusin
DMVIHTF	MI	TTXV4FI
DMVIHTF	MN	Albendazole monooxygenase (CYP3A4)
DMVIHTF	MT	DTT
DMVIHTF	MA	Inhibitor
DMVIHTF	RN	Potent CYP3A4 inhibitory constituents of Piper cubeba. J Nat Prod. 2005 Jan;68(1):64-8.
DMVIHTF	RU	https://pubmed.ncbi.nlm.nih.gov/15679319

DMHJG5N	DI	DMHJG5N
DMHJG5N	DN	(9-Benzyl-9H-purin-6-yl)-cyclopropyl-amine
DMHJG5N	MI	TT1MPAY
DMHJG5N	MN	GABA(A) receptor alpha-1 (GABRA1)
DMHJG5N	MT	DTT
DMHJG5N	MA	Inhibitor
DMHJG5N	RN	Benzodiazepine receptor binding activity of 6,9-disubstituted purines. J Med Chem. 1989 May;32(5):1020-4.
DMHJG5N	RU	https://pubmed.ncbi.nlm.nih.gov/2540330

DMHJG5N	DI	DMHJG5N
DMHJG5N	DN	(9-Benzyl-9H-purin-6-yl)-cyclopropyl-amine
DMHJG5N	MI	TTZA1NY
DMHJG5N	MN	GABA(A) receptor beta-2 (GABRB2)
DMHJG5N	MT	DTT
DMHJG5N	MA	Inhibitor
DMHJG5N	RN	Benzodiazepine receptor binding activity of 6,9-disubstituted purines. J Med Chem. 1989 May;32(5):1020-4.
DMHJG5N	RU	https://pubmed.ncbi.nlm.nih.gov/2540330

DMHJG5N	DI	DMHJG5N
DMHJG5N	DN	(9-Benzyl-9H-purin-6-yl)-cyclopropyl-amine
DMHJG5N	MI	TT06RH5
DMHJG5N	MN	GABA(A) receptor gamma-2 (GABRG2)
DMHJG5N	MT	DTT
DMHJG5N	MA	Inhibitor
DMHJG5N	RN	Benzodiazepine receptor binding activity of 6,9-disubstituted purines. J Med Chem. 1989 May;32(5):1020-4.
DMHJG5N	RU	https://pubmed.ncbi.nlm.nih.gov/2540330

DMHJG5N	DI	DMHJG5N
DMHJG5N	DN	(9-Benzyl-9H-purin-6-yl)-cyclopropyl-amine
DMHJG5N	MI	TTNJYV2
DMHJG5N	MN	Gamma-aminobutyric acid receptor (GAR)
DMHJG5N	MT	DTT
DMHJG5N	MA	Inhibitor
DMHJG5N	RN	Benzodiazepine receptor binding activity of 6,9-disubstituted purines. J Med Chem. 1989 May;32(5):1020-4.
DMHJG5N	RU	https://pubmed.ncbi.nlm.nih.gov/2540330

DMKI2Y9	DI	DMKI2Y9
DMKI2Y9	DN	(9H-beta-Carbolin-3-yl)-carbamic acid ethyl ester
DMKI2Y9	MI	TT1MPAY
DMKI2Y9	MN	GABA(A) receptor alpha-1 (GABRA1)
DMKI2Y9	MT	DTT
DMKI2Y9	MA	Inhibitor
DMKI2Y9	RN	3-Amino-beta-carboline derivatives and the benzodiazepine receptor. Synthesis of a selective antagonist of the sedative action of diazepam. J Med Chem. 1985 Jun;28(6):824-8.
DMKI2Y9	RU	https://pubmed.ncbi.nlm.nih.gov/2989520

DMKI2Y9	DI	DMKI2Y9
DMKI2Y9	DN	(9H-beta-Carbolin-3-yl)-carbamic acid ethyl ester
DMKI2Y9	MI	TTNJYV2
DMKI2Y9	MN	Gamma-aminobutyric acid receptor (GAR)
DMKI2Y9	MT	DTT
DMKI2Y9	MA	Inhibitor
DMKI2Y9	RN	3-Amino-beta-carboline derivatives and the benzodiazepine receptor. Synthesis of a selective antagonist of the sedative action of diazepam. J Med Chem. 1985 Jun;28(6):824-8.
DMKI2Y9	RU	https://pubmed.ncbi.nlm.nih.gov/2989520

DMVHMPC	DI	DMVHMPC
DMVHMPC	DN	(9H-beta-Carbolin-3-yl)-ethyl-amine
DMVHMPC	MI	TT1MPAY
DMVHMPC	MN	GABA(A) receptor alpha-1 (GABRA1)
DMVHMPC	MT	DTT
DMVHMPC	MA	Inhibitor
DMVHMPC	RN	3-Amino-beta-carboline derivatives and the benzodiazepine receptor. Synthesis of a selective antagonist of the sedative action of diazepam. J Med Chem. 1985 Jun;28(6):824-8.
DMVHMPC	RU	https://pubmed.ncbi.nlm.nih.gov/2989520

DMVHMPC	DI	DMVHMPC
DMVHMPC	DN	(9H-beta-Carbolin-3-yl)-ethyl-amine
DMVHMPC	MI	TTNJYV2
DMVHMPC	MN	Gamma-aminobutyric acid receptor (GAR)
DMVHMPC	MT	DTT
DMVHMPC	MA	Inhibitor
DMVHMPC	RN	3-Amino-beta-carboline derivatives and the benzodiazepine receptor. Synthesis of a selective antagonist of the sedative action of diazepam. J Med Chem. 1985 Jun;28(6):824-8.
DMVHMPC	RU	https://pubmed.ncbi.nlm.nih.gov/2989520

DMUF16A	DI	DMUF16A
DMUF16A	DN	(9H-beta-Carbolin-3-yl)-methanol
DMUF16A	MI	TT1MPAY
DMUF16A	MN	GABA(A) receptor alpha-1 (GABRA1)
DMUF16A	MT	DTT
DMUF16A	MA	Inhibitor
DMUF16A	RN	Synthesis of 6-substituted beta-carbolines that behave as benzodiazepine receptor antagonists or inverse agonists. J Med Chem. 1987 Apr;30(4):750-3.
DMUF16A	RU	https://pubmed.ncbi.nlm.nih.gov/3031296

DMUF16A	DI	DMUF16A
DMUF16A	DN	(9H-beta-Carbolin-3-yl)-methanol
DMUF16A	MI	TTNJYV2
DMUF16A	MN	Gamma-aminobutyric acid receptor (GAR)
DMUF16A	MT	DTT
DMUF16A	MA	Inhibitor
DMUF16A	RN	Synthesis of 6-substituted beta-carbolines that behave as benzodiazepine receptor antagonists or inverse agonists. J Med Chem. 1987 Apr;30(4):750-3.
DMUF16A	RU	https://pubmed.ncbi.nlm.nih.gov/3031296

DMWJNFC	DI	DMWJNFC
DMWJNFC	DN	(9-Methyl-9H-purin-6-yl)-phenyl-amine
DMWJNFC	MI	TTK25J1
DMWJNFC	MN	Adenosine A1 receptor (ADORA1)
DMWJNFC	MT	DTT
DMWJNFC	MA	Inhibitor
DMWJNFC	RN	N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor. J Med Chem. 1991 Sep;34(9):2877-82.
DMWJNFC	RU	https://pubmed.ncbi.nlm.nih.gov/1895305

DM12GHQ	DI	DM12GHQ
DM12GHQ	DN	(9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
DM12GHQ	MI	TTZMAO3
DM12GHQ	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DM12GHQ	MT	DTT
DM12GHQ	MA	Inhibitor
DM12GHQ	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM12GHQ	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM2REIN	DI	DM2REIN
DM2REIN	DN	(9Z,12E)-12-nitrooctadeca-9,12-dienoic acid
DM2REIN	MI	TTJ584C
DM2REIN	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DM2REIN	MT	DTT
DM2REIN	MA	Inhibitor
DM2REIN	RN	Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree ... J Med Chem. 2009 Aug 13;52(15):4631-9.
DM2REIN	RU	https://pubmed.ncbi.nlm.nih.gov/19719236

DM2REIN	DI	DM2REIN
DM2REIN	DN	(9Z,12E)-12-nitrooctadeca-9,12-dienoic acid
DM2REIN	MI	TTT2SVW
DM2REIN	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DM2REIN	MT	DTT
DM2REIN	MA	Inhibitor
DM2REIN	RN	Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree ... J Med Chem. 2009 Aug 13;52(15):4631-9.
DM2REIN	RU	https://pubmed.ncbi.nlm.nih.gov/19719236

DMS4ZVK	DI	DMS4ZVK
DMS4ZVK	DN	(Amino-phenyl-methyl)-phosphinic acid
DMS4ZVK	MI	TTPHMWB
DMS4ZVK	MN	Aminopeptidase N (ANPEP)
DMS4ZVK	MT	DTT
DMS4ZVK	MA	Inhibitor
DMS4ZVK	RN	Design of the first highly potent and selective aminopeptidase N (EC 3.4.11.2) inhibitor. Bioorg Med Chem Lett. 1999 Jun 7;9(11):1511-6.
DMS4ZVK	RU	https://pubmed.ncbi.nlm.nih.gov/10386926

DME80RK	DI	DME80RK
DME80RK	DN	(benzo[b]furan-2-yl)-(1H-indol-2-yl)methanone
DME80RK	MI	TTGJCWZ
DME80RK	MN	Fms-like tyrosine kinase 3 (FLT-3)
DME80RK	MT	DTT
DME80RK	MA	Inhibitor
DME80RK	RN	Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorg Med Chem. 2007 Mar 1;15(5):2187-97.
DME80RK	RU	https://pubmed.ncbi.nlm.nih.gov/17210255

DME80RK	DI	DME80RK
DME80RK	DN	(benzo[b]furan-2-yl)-(1H-indol-2-yl)methanone
DME80RK	MI	TTI7421
DME80RK	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DME80RK	MT	DTT
DME80RK	MA	Inhibitor
DME80RK	RN	Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorg Med Chem. 2007 Mar 1;15(5):2187-97.
DME80RK	RU	https://pubmed.ncbi.nlm.nih.gov/17210255

DMVWQ26	DI	DMVWQ26
DMVWQ26	DN	(beta-CCE)9H-beta-Carboline-3-carboxylic acid
DMVWQ26	MI	TT1MPAY
DMVWQ26	MN	GABA(A) receptor alpha-1 (GABRA1)
DMVWQ26	MT	DTT
DMVWQ26	MA	Inhibitor
DMVWQ26	RN	Benzodiazepine receptor affinity and interaction of some N-(indol-3-ylglyoxylyl)amine derivatives. J Med Chem. 1992 Jun 12;35(12):2214-20.
DMVWQ26	RU	https://pubmed.ncbi.nlm.nih.gov/1319492

DMVWQ26	DI	DMVWQ26
DMVWQ26	DN	(beta-CCE)9H-beta-Carboline-3-carboxylic acid
DMVWQ26	MI	TT06RH5
DMVWQ26	MN	GABA(A) receptor gamma-2 (GABRG2)
DMVWQ26	MT	DTT
DMVWQ26	MA	Inhibitor
DMVWQ26	RN	Benzodiazepine receptor affinity and interaction of some N-(indol-3-ylglyoxylyl)amine derivatives. J Med Chem. 1992 Jun 12;35(12):2214-20.
DMVWQ26	RU	https://pubmed.ncbi.nlm.nih.gov/1319492

DMVWQ26	DI	DMVWQ26
DMVWQ26	DN	(beta-CCE)9H-beta-Carboline-3-carboxylic acid
DMVWQ26	MI	TTNJYV2
DMVWQ26	MN	Gamma-aminobutyric acid receptor (GAR)
DMVWQ26	MT	DTT
DMVWQ26	MA	Inhibitor
DMVWQ26	RN	Benzodiazepine receptor affinity and interaction of some N-(indol-3-ylglyoxylyl)amine derivatives. J Med Chem. 1992 Jun 12;35(12):2214-20.
DMVWQ26	RU	https://pubmed.ncbi.nlm.nih.gov/1319492

DMGB97I	DI	DMGB97I
DMGB97I	DN	(biphenyl-3-ylamino)methylenediphosphonic acid
DMGB97I	MI	TTIKWV4
DMGB97I	MN	Geranyltranstransferase (FDPS)
DMGB97I	MT	DTT
DMGB97I	MA	Inhibitor
DMGB97I	RN	Bisphosphonate inhibitors of ATP-mediated HIV-1 reverse transcriptase catalyzed excision of chain-terminating 3'-azido, 3'-deoxythymidine: a QSAR i... Bioorg Med Chem. 2008 Oct 1;16(19):8959-67.
DMGB97I	RU	https://pubmed.ncbi.nlm.nih.gov/18789701

DM5WH6R	DI	DM5WH6R
DM5WH6R	DN	(C8-R)-Hydantocidin 5'-Phosphate
DM5WH6R	MI	TTYQ4AE
DM5WH6R	MN	Plasmodium Adenylosuccinate synthetase (Malaria Adss)
DM5WH6R	MT	DTT
DM5WH6R	MA	Inhibitor
DM5WH6R	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM5WH6R	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMMH179	DI	DMMH179
DMMH179	DN	(C8-S)-Hydantocidin 5'-Phosphate
DMMH179	MI	TTYQ4AE
DMMH179	MN	Plasmodium Adenylosuccinate synthetase (Malaria Adss)
DMMH179	MT	DTT
DMMH179	MA	Inhibitor
DMMH179	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMMH179	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMZB0C3	DI	DMZB0C3
DMZB0C3	DN	(Carboxyhydroxyamino)Ethanoic Acid
DMZB0C3	MI	TTYQ4AE
DMZB0C3	MN	Plasmodium Adenylosuccinate synthetase (Malaria Adss)
DMZB0C3	MT	DTT
DMZB0C3	MA	Inhibitor
DMZB0C3	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMZB0C3	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD0P4G	DI	DMD0P4G
DMD0P4G	DN	(CH3)CCO-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2
DMD0P4G	MI	TTC1MVT
DMD0P4G	MN	Gastrin-releasing peptide receptor (GRPR)
DMD0P4G	MT	DTT
DMD0P4G	MA	Inhibitor
DMD0P4G	RN	Gastrin releasing peptide antagonists with improved potency and stability. J Med Chem. 1991 Jul;34(7):2102-7.
DMD0P4G	RU	https://pubmed.ncbi.nlm.nih.gov/2066982

DMMC139	DI	DMMC139
DMMC139	DN	(cis)-1,6-diphenyl-3-aza-bicyclo[3.1.0]hexane
DMMC139	MI	TTVBI8W
DMMC139	MN	Dopamine transporter (DAT)
DMMC139	MT	DTT
DMMC139	MA	Inhibitor
DMMC139	RN	Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3682-6.
DMMC139	RU	https://pubmed.ncbi.nlm.nih.gov/18539031

DMMC139	DI	DMMC139
DMMC139	DN	(cis)-1,6-diphenyl-3-aza-bicyclo[3.1.0]hexane
DMMC139	MI	TT3ROYC
DMMC139	MN	Serotonin transporter (SERT)
DMMC139	MT	DTT
DMMC139	MA	Inhibitor
DMMC139	RN	Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3682-6.
DMMC139	RU	https://pubmed.ncbi.nlm.nih.gov/18539031

DMGXTSB	DI	DMGXTSB
DMGXTSB	DN	(D)-Ala-Pro-Glu
DMGXTSB	MI	TTLD29N
DMGXTSB	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMGXTSB	MT	DTT
DMGXTSB	MA	Inhibitor
DMGXTSB	RN	New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6.
DMGXTSB	RU	https://pubmed.ncbi.nlm.nih.gov/16321525

DMGXTSB	DI	DMGXTSB
DMGXTSB	DN	(D)-Ala-Pro-Glu
DMGXTSB	MI	TTKJEMQ
DMGXTSB	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMGXTSB	MT	DTT
DMGXTSB	MA	Inhibitor
DMGXTSB	RN	New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6.
DMGXTSB	RU	https://pubmed.ncbi.nlm.nih.gov/16321525

DMGXTSB	DI	DMGXTSB
DMGXTSB	DN	(D)-Ala-Pro-Glu
DMGXTSB	MI	TTN9D8E
DMGXTSB	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMGXTSB	MT	DTT
DMGXTSB	MA	Inhibitor
DMGXTSB	RN	New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6.
DMGXTSB	RU	https://pubmed.ncbi.nlm.nih.gov/16321525

DMWE42T	DI	DMWE42T
DMWE42T	DN	(D)Arg-Arg-Pro-Hyp-Gly-Phe-Ser-(d)Phe-Phe-Arg
DMWE42T	MI	TTGY8IW
DMWE42T	MN	B2 bradykinin receptor (BDKRB2)
DMWE42T	MT	DTT
DMWE42T	MA	Inhibitor
DMWE42T	RN	Design and conformational analysis of several highly potent bradykinin receptor antagonists. J Med Chem. 1991 Mar;34(3):1230-3.
DMWE42T	RU	https://pubmed.ncbi.nlm.nih.gov/1848297

DMYSE3O	DI	DMYSE3O
DMYSE3O	DN	(D)Arg-Arg-Pro-Hyp-Gly-Thi-Cys-(D)Phe-Phe-Cys-Arg
DMYSE3O	MI	TTGY8IW
DMYSE3O	MN	B2 bradykinin receptor (BDKRB2)
DMYSE3O	MT	DTT
DMYSE3O	MA	Inhibitor
DMYSE3O	RN	Design and conformational analysis of several highly potent bradykinin receptor antagonists. J Med Chem. 1991 Mar;34(3):1230-3.
DMYSE3O	RU	https://pubmed.ncbi.nlm.nih.gov/1848297

DMLSJKM	DI	DMLSJKM
DMLSJKM	DN	(D)Arg-Arg-Pro-Hyp-Gly-Thi-Ser-(D)Tic-Aoc-Arg
DMLSJKM	MI	TTGY8IW
DMLSJKM	MN	B2 bradykinin receptor (BDKRB2)
DMLSJKM	MT	DTT
DMLSJKM	MA	Inhibitor
DMLSJKM	RN	Design and conformational analysis of several highly potent bradykinin receptor antagonists. J Med Chem. 1991 Mar;34(3):1230-3.
DMLSJKM	RU	https://pubmed.ncbi.nlm.nih.gov/1848297

DMP0627	DI	DMP0627
DMP0627	DN	(D)Arg-Arg-Pro-Hyp-Gly-Thi-Ser-(D)Tic-Tic-Arg
DMP0627	MI	TTGY8IW
DMP0627	MN	B2 bradykinin receptor (BDKRB2)
DMP0627	MT	DTT
DMP0627	MA	Inhibitor
DMP0627	RN	Design and conformational analysis of several highly potent bradykinin receptor antagonists. J Med Chem. 1991 Mar;34(3):1230-3.
DMP0627	RU	https://pubmed.ncbi.nlm.nih.gov/1848297

DM5ZIUW	DI	DM5ZIUW
DM5ZIUW	DN	(D)-Phe-(D)-Phe-NH2
DM5ZIUW	MI	TTZPO1L
DM5ZIUW	MN	Substance-P receptor (TACR1)
DM5ZIUW	MT	DTT
DM5ZIUW	MA	Inhibitor
DM5ZIUW	RN	Discovery of dipeptides with high affinity to the specific binding site for substance P1-7. J Med Chem. 2010 Mar 25;53(6):2383-9.
DM5ZIUW	RU	https://pubmed.ncbi.nlm.nih.gov/20178322

DMS32YA	DI	DMS32YA
DMS32YA	DN	(D)-Phe-(L)-Phe-NH2
DMS32YA	MI	TTZPO1L
DMS32YA	MN	Substance-P receptor (TACR1)
DMS32YA	MT	DTT
DMS32YA	MA	Inhibitor
DMS32YA	RN	Discovery of dipeptides with high affinity to the specific binding site for substance P1-7. J Med Chem. 2010 Mar 25;53(6):2383-9.
DMS32YA	RU	https://pubmed.ncbi.nlm.nih.gov/20178322

DMQN14X	DI	DMQN14X
DMQN14X	DN	(D)Phe-Gln-Trp-Ala-Val-Gly-His-Leu-Leu-NH2
DMQN14X	MI	TTC1MVT
DMQN14X	MN	Gastrin-releasing peptide receptor (GRPR)
DMQN14X	MT	DTT
DMQN14X	MA	Inhibitor
DMQN14X	RN	Synthesis and biological evaluation of bombesin constrained analogues. J Med Chem. 2000 Jun 15;43(12):2356-61.
DMQN14X	RU	https://pubmed.ncbi.nlm.nih.gov/10882361

DMI39LV	DI	DMI39LV
DMI39LV	DN	(D-Arg)(9)-p19(ARF) 26-44 peptide
DMI39LV	MI	TTD3KOX
DMI39LV	MN	Forkhead box protein M1 (FOXM1)
DMI39LV	MT	DTT
DMI39LV	MA	Inhibitor
DMI39LV	RN	Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. Genes Dev. 2004 Apr 1;18(7):830-50.
DMI39LV	RU	https://pubmed.ncbi.nlm.nih.gov/15082532

DMHSJAT	DI	DMHSJAT
DMHSJAT	DN	(E)-(thiophen-2-ylmethylidene)amino benzoate
DMHSJAT	MI	TTDNFMT
DMHSJAT	MN	Platelet-activating factor acetylhydrolase (PLA2G7)
DMHSJAT	MT	DTT
DMHSJAT	MA	Inhibitor
DMHSJAT	RN	(E)-Phenyl- and -heteroaryl-substituted O-benzoyl-(or acyl)oximes as lipoprotein-associated phospholipase A2 inhibitors. Bioorg Med Chem Lett. 2005 Mar 1;15(5):1525-7.
DMHSJAT	RU	https://pubmed.ncbi.nlm.nih.gov/15713421

DMBXK5L	DI	DMBXK5L
DMBXK5L	DN	(E)-1-(4-heptylphenyl)but-2-en-1-one
DMBXK5L	MI	TTTSEPU
DMBXK5L	MN	Thyroid hormone receptor alpha (THRA)
DMBXK5L	MT	DTT
DMBXK5L	MA	Inhibitor
DMBXK5L	RN	Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80.
DMBXK5L	RU	https://pubmed.ncbi.nlm.nih.gov/17918822

DMBXK5L	DI	DMBXK5L
DMBXK5L	DN	(E)-1-(4-heptylphenyl)but-2-en-1-one
DMBXK5L	MI	TTGER3L
DMBXK5L	MN	Thyroid hormone receptor beta (THRB)
DMBXK5L	MT	DTT
DMBXK5L	MA	Inhibitor
DMBXK5L	RN	Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80.
DMBXK5L	RU	https://pubmed.ncbi.nlm.nih.gov/17918822

DMEP903	DI	DMEP903
DMEP903	DN	(E)-1-(4-Nitro-phenyl)-3-pyridin-2-yl-propenone
DMEP903	MI	TTSFWA7
DMEP903	MN	Plasmodium CDK Pfmrk (Malaria Pfmrk)
DMEP903	MT	DTT
DMEP903	MA	Inhibitor
DMEP903	RN	A three-dimensional in silico pharmacophore model for inhibition of Plasmodium falciparum cyclin-dependent kinases and discovery of different class... J Med Chem. 2004 Oct 21;47(22):5418-26.
DMEP903	RU	https://pubmed.ncbi.nlm.nih.gov/15481979

DMO38CP	DI	DMO38CP
DMO38CP	DN	(E)-10-Nitrohexadec-9-enoic Acid
DMO38CP	MI	TTT2SVW
DMO38CP	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DMO38CP	MT	DTT
DMO38CP	MA	Inhibitor
DMO38CP	RN	Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree ... J Med Chem. 2009 Aug 13;52(15):4631-9.
DMO38CP	RU	https://pubmed.ncbi.nlm.nih.gov/19719236

DMTF7JA	DI	DMTF7JA
DMTF7JA	DN	(E)-10-nitrooctadec-9-enoic acid
DMTF7JA	MI	TTT2SVW
DMTF7JA	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DMTF7JA	MT	DTT
DMTF7JA	MA	Inhibitor
DMTF7JA	RN	Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree ... J Med Chem. 2009 Aug 13;52(15):4631-9.
DMTF7JA	RU	https://pubmed.ncbi.nlm.nih.gov/19719236

DMBQTZL	DI	DMBQTZL
DMBQTZL	DN	(E)-12-Nitrooctadec-12-enoic Acid
DMBQTZL	MI	TTJ584C
DMBQTZL	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMBQTZL	MT	DTT
DMBQTZL	MA	Inhibitor
DMBQTZL	RN	Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree ... J Med Chem. 2009 Aug 13;52(15):4631-9.
DMBQTZL	RU	https://pubmed.ncbi.nlm.nih.gov/19719236

DMBQTZL	DI	DMBQTZL
DMBQTZL	DN	(E)-12-Nitrooctadec-12-enoic Acid
DMBQTZL	MI	TTT2SVW
DMBQTZL	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DMBQTZL	MT	DTT
DMBQTZL	MA	Inhibitor
DMBQTZL	RN	Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree ... J Med Chem. 2009 Aug 13;52(15):4631-9.
DMBQTZL	RU	https://pubmed.ncbi.nlm.nih.gov/19719236

DMF74GJ	DI	DMF74GJ
DMF74GJ	DN	(E)-13-Nitrooctadec-12-enoic Acid
DMF74GJ	MI	TTJ584C
DMF74GJ	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMF74GJ	MT	DTT
DMF74GJ	MA	Inhibitor
DMF74GJ	RN	Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree ... J Med Chem. 2009 Aug 13;52(15):4631-9.
DMF74GJ	RU	https://pubmed.ncbi.nlm.nih.gov/19719236

DMF74GJ	DI	DMF74GJ
DMF74GJ	DN	(E)-13-Nitrooctadec-12-enoic Acid
DMF74GJ	MI	TTT2SVW
DMF74GJ	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DMF74GJ	MT	DTT
DMF74GJ	MA	Inhibitor
DMF74GJ	RN	Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree ... J Med Chem. 2009 Aug 13;52(15):4631-9.
DMF74GJ	RU	https://pubmed.ncbi.nlm.nih.gov/19719236

DMQ9TWD	DI	DMQ9TWD
DMQ9TWD	DN	(E)-1-Adamantan-1-yl-3-quinolin-3-yl-propenone
DMQ9TWD	MI	TTVBPDM
DMQ9TWD	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMQ9TWD	MT	DTT
DMQ9TWD	MA	Inhibitor
DMQ9TWD	RN	Synergism of virtual screening and medicinal chemistry: identification and optimization of allosteric antagonists of metabotropic glutamate recepto... Bioorg Med Chem. 2009 Aug 1;17(15):5708-15.
DMQ9TWD	RU	https://pubmed.ncbi.nlm.nih.gov/19574055

DMQ9TWD	DI	DMQ9TWD
DMQ9TWD	DN	(E)-1-Adamantan-1-yl-3-quinolin-3-yl-propenone
DMQ9TWD	MI	TTHS256
DMQ9TWD	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMQ9TWD	MT	DTT
DMQ9TWD	MA	Inhibitor
DMQ9TWD	RN	Synergism of virtual screening and medicinal chemistry: identification and optimization of allosteric antagonists of metabotropic glutamate recepto... Bioorg Med Chem. 2009 Aug 1;17(15):5708-15.
DMQ9TWD	RU	https://pubmed.ncbi.nlm.nih.gov/19574055

DMI146O	DI	DMI146O
DMI146O	DN	(E)-2-(1-decyl-2-oxoindolin-3-ylidene)acetic acid
DMI146O	MI	TTLZS4Q
DMI146O	MN	M-phase inducer phosphatase 1 (MPIP1)
DMI146O	MT	DTT
DMI146O	MA	Inhibitor
DMI146O	RN	Design and synthesis of N-alkyl oxindolylidene acetic acids as a new class of potent Cdc25A inhibitors. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3350-3.
DMI146O	RU	https://pubmed.ncbi.nlm.nih.gov/18442908

DMH2U4Z	DI	DMH2U4Z
DMH2U4Z	DN	(E)-2-(4-(methylsulfonyl)styryl)furan
DMH2U4Z	MI	TTVKILB
DMH2U4Z	MN	Prostaglandin G/H synthase 2 (COX-2)
DMH2U4Z	MT	DTT
DMH2U4Z	MA	Inhibitor
DMH2U4Z	RN	Sulfonamide derivatives of styrylheterocycles as a potent inhibitor of COX-2-mediated prostaglandin E2 production. Bioorg Med Chem Lett. 2010 Dec 1;20(23):6938-41.
DMH2U4Z	RU	https://pubmed.ncbi.nlm.nih.gov/20970329

DMDFE1R	DI	DMDFE1R
DMDFE1R	DN	(E)-2-(4-(methylsulfonyl)styryl)thiophene
DMDFE1R	MI	TTVKILB
DMDFE1R	MN	Prostaglandin G/H synthase 2 (COX-2)
DMDFE1R	MT	DTT
DMDFE1R	MA	Inhibitor
DMDFE1R	RN	Sulfonamide derivatives of styrylheterocycles as a potent inhibitor of COX-2-mediated prostaglandin E2 production. Bioorg Med Chem Lett. 2010 Dec 1;20(23):6938-41.
DMDFE1R	RU	https://pubmed.ncbi.nlm.nih.gov/20970329

DMTJI4F	DI	DMTJI4F
DMTJI4F	DN	(E)-2-(4-fluorostyryl)-5-(phenylsulfinyl)pyridine
DMTJI4F	MI	TTJQOD7
DMTJI4F	MN	5-HT 2A receptor (HTR2A)
DMTJI4F	MT	DTT
DMTJI4F	MA	Inhibitor
DMTJI4F	RN	2,5-Disubstituted pyridines: the discovery of a novel series of 5-HT2A ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2643-8.
DMTJI4F	RU	https://pubmed.ncbi.nlm.nih.gov/17314044

DMTJI4F	DI	DMTJI4F
DMTJI4F	DN	(E)-2-(4-fluorostyryl)-5-(phenylsulfinyl)pyridine
DMTJI4F	MI	TTWJBZ5
DMTJI4F	MN	5-HT 2C receptor (HTR2C)
DMTJI4F	MT	DTT
DMTJI4F	MA	Inhibitor
DMTJI4F	RN	2,5-Disubstituted pyridines: the discovery of a novel series of 5-HT2A ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2643-8.
DMTJI4F	RU	https://pubmed.ncbi.nlm.nih.gov/17314044

DMTJI4F	DI	DMTJI4F
DMTJI4F	DN	(E)-2-(4-fluorostyryl)-5-(phenylsulfinyl)pyridine
DMTJI4F	MI	TTQ6VDM
DMTJI4F	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMTJI4F	MT	DTT
DMTJI4F	MA	Inhibitor
DMTJI4F	RN	2,5-Disubstituted pyridines: the discovery of a novel series of 5-HT2A ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2643-8.
DMTJI4F	RU	https://pubmed.ncbi.nlm.nih.gov/17314044

DM7P5VM	DI	DM7P5VM
DM7P5VM	DN	(E)-2-(4-fluorostyryl)-5-(phenylsulfonyl)pyridine
DM7P5VM	MI	TTJQOD7
DM7P5VM	MN	5-HT 2A receptor (HTR2A)
DM7P5VM	MT	DTT
DM7P5VM	MA	Inhibitor
DM7P5VM	RN	2,5-Disubstituted pyridines: the discovery of a novel series of 5-HT2A ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2643-8.
DM7P5VM	RU	https://pubmed.ncbi.nlm.nih.gov/17314044

DM1LG27	DI	DM1LG27
DM1LG27	DN	(E)-3-(2,3-dichlorophenylimino)indolin-2-one
DM1LG27	MI	TTOPAY7
DM1LG27	MN	Galanin receptor (GAL-R)
DM1LG27	MT	DTT
DM1LG27	MA	Inhibitor
DM1LG27	RN	3-arylimino-2-indolones are potent and selective galanin GAL3 receptor antagonists. J Med Chem. 2006 Jun 29;49(13):3757-8.
DM1LG27	RU	https://pubmed.ncbi.nlm.nih.gov/16789730

DMOWGT3	DI	DMOWGT3
DMOWGT3	DN	(E)-3-(4-(4-phenoxybenzoyl)phenyl)acrylic acid
DMOWGT3	MI	TTTU72V
DMOWGT3	MN	Steroid 5-alpha-reductase 1 (SRD5A1)
DMOWGT3	MT	DTT
DMOWGT3	MA	Inhibitor
DMOWGT3	RN	Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J Med Chem. 2006 Jan 26;49(2):748-59.
DMOWGT3	RU	https://pubmed.ncbi.nlm.nih.gov/16420060

DMOWGT3	DI	DMOWGT3
DMOWGT3	DN	(E)-3-(4-(4-phenoxybenzoyl)phenyl)acrylic acid
DMOWGT3	MI	TTT02K8
DMOWGT3	MN	Steroid 5-alpha-reductase 2 (SRD5A2)
DMOWGT3	MT	DTT
DMOWGT3	MA	Inhibitor
DMOWGT3	RN	Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J Med Chem. 2006 Jan 26;49(2):748-59.
DMOWGT3	RU	https://pubmed.ncbi.nlm.nih.gov/16420060

DMUS0D8	DI	DMUS0D8
DMUS0D8	DN	(E)-3-(4-(methylsulfonyl)styryl)thiophene
DMUS0D8	MI	TTVKILB
DMUS0D8	MN	Prostaglandin G/H synthase 2 (COX-2)
DMUS0D8	MT	DTT
DMUS0D8	MA	Inhibitor
DMUS0D8	RN	Sulfonamide derivatives of styrylheterocycles as a potent inhibitor of COX-2-mediated prostaglandin E2 production. Bioorg Med Chem Lett. 2010 Dec 1;20(23):6938-41.
DMUS0D8	RU	https://pubmed.ncbi.nlm.nih.gov/20970329

DMPOYK2	DI	DMPOYK2
DMPOYK2	DN	(E)-3-(4-chlorophenylimino)indolin-2-one
DMPOYK2	MI	TTOPAY7
DMPOYK2	MN	Galanin receptor (GAL-R)
DMPOYK2	MT	DTT
DMPOYK2	MA	Inhibitor
DMPOYK2	RN	3-arylimino-2-indolones are potent and selective galanin GAL3 receptor antagonists. J Med Chem. 2006 Jun 29;49(13):3757-8.
DMPOYK2	RU	https://pubmed.ncbi.nlm.nih.gov/16789730

DMX4U9L	DI	DMX4U9L
DMX4U9L	DN	(E)-3-(4-hydroxybenzylidene)indolin-2-one
DMX4U9L	MI	TT4DXQT
DMX4U9L	MN	Proto-oncogene c-Ret (RET)
DMX4U9L	MT	DTT
DMX4U9L	MA	Inhibitor
DMX4U9L	RN	Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1482-96.
DMX4U9L	RU	https://pubmed.ncbi.nlm.nih.gov/20117004

DMTKCAL	DI	DMTKCAL
DMTKCAL	DN	(E)-3-(4-tert-Butyl-phenyl)-N-phenyl-acrylamide
DMTKCAL	MI	TTMI6F5
DMTKCAL	MN	Transient receptor potential cation channel V1 (TRPV1)
DMTKCAL	MT	DTT
DMTKCAL	MA	Inhibitor
DMTKCAL	RN	Discovery of potent, orally available vanilloid receptor-1 antagonists. Structure-activity relationship of N-aryl cinnamides. J Med Chem. 2005 Jan 13;48(1):71-90.
DMTKCAL	RU	https://pubmed.ncbi.nlm.nih.gov/15634002

DMITXKJ	DI	DMITXKJ
DMITXKJ	DN	(E)-3-[2-(2-methyl-4-thiazolyl)vinyl]pyridine
DMITXKJ	MI	TTHS256
DMITXKJ	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMITXKJ	MT	DTT
DMITXKJ	MA	Inhibitor
DMITXKJ	RN	Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100.
DMITXKJ	RU	https://pubmed.ncbi.nlm.nih.gov/16451073

DMDF7M4	DI	DMDF7M4
DMDF7M4	DN	(E)-4-(2-(furan-2-yl)vinyl)benzenesulfonamide
DMDF7M4	MI	TTVKILB
DMDF7M4	MN	Prostaglandin G/H synthase 2 (COX-2)
DMDF7M4	MT	DTT
DMDF7M4	MA	Inhibitor
DMDF7M4	RN	Sulfonamide derivatives of styrylheterocycles as a potent inhibitor of COX-2-mediated prostaglandin E2 production. Bioorg Med Chem Lett. 2010 Dec 1;20(23):6938-41.
DMDF7M4	RU	https://pubmed.ncbi.nlm.nih.gov/20970329

DM7204O	DI	DM7204O
DM7204O	DN	(E)-4-(2-(thiophen-2-yl)vinyl)benzenesulfonamide
DM7204O	MI	TTVKILB
DM7204O	MN	Prostaglandin G/H synthase 2 (COX-2)
DM7204O	MT	DTT
DM7204O	MA	Inhibitor
DM7204O	RN	Sulfonamide derivatives of styrylheterocycles as a potent inhibitor of COX-2-mediated prostaglandin E2 production. Bioorg Med Chem Lett. 2010 Dec 1;20(23):6938-41.
DM7204O	RU	https://pubmed.ncbi.nlm.nih.gov/20970329

DMTAB8W	DI	DMTAB8W
DMTAB8W	DN	(E)-4-(2-(thiophen-3-yl)vinyl)benzenesulfonamide
DMTAB8W	MI	TTVKILB
DMTAB8W	MN	Prostaglandin G/H synthase 2 (COX-2)
DMTAB8W	MT	DTT
DMTAB8W	MA	Inhibitor
DMTAB8W	RN	Sulfonamide derivatives of styrylheterocycles as a potent inhibitor of COX-2-mediated prostaglandin E2 production. Bioorg Med Chem Lett. 2010 Dec 1;20(23):6938-41.
DMTAB8W	RU	https://pubmed.ncbi.nlm.nih.gov/20970329

DMYXI2V	DI	DMYXI2V
DMYXI2V	DN	(E)-4-(3,5-dimethoxystyryl)phenol
DMYXI2V	MI	TTS7G69
DMYXI2V	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMYXI2V	MT	DTT
DMYXI2V	MA	Inhibitor
DMYXI2V	RN	Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells. J Med Chem. 2006 May 18;49(10):3012-8.
DMYXI2V	RU	https://pubmed.ncbi.nlm.nih.gov/16686543

DMYXI2V	DI	DMYXI2V
DMYXI2V	DN	(E)-4-(3,5-dimethoxystyryl)phenol
DMYXI2V	MI	TTJ584C
DMYXI2V	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMYXI2V	MT	DTT
DMYXI2V	MA	Agonist
DMYXI2V	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 593).
DMYXI2V	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=593

DMJGAFV	DI	DMJGAFV
DMJGAFV	DN	(E)-4,4-Dimethyl-1-quinolin-3-yl-pent-1-en-3-one
DMJGAFV	MI	TTVBPDM
DMJGAFV	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMJGAFV	MT	DTT
DMJGAFV	MA	Inhibitor
DMJGAFV	RN	Synergism of virtual screening and medicinal chemistry: identification and optimization of allosteric antagonists of metabotropic glutamate recepto... Bioorg Med Chem. 2009 Aug 1;17(15):5708-15.
DMJGAFV	RU	https://pubmed.ncbi.nlm.nih.gov/19574055

DM75OHG	DI	DM75OHG
DM75OHG	DN	(E)-4-Methyl-6-(prop-1-enyl)pyridin-2-amine
DM75OHG	MI	TTF10I9
DM75OHG	MN	Nitric-oxide synthase inducible (NOS2)
DM75OHG	MT	DTT
DM75OHG	MA	Inhibitor
DM75OHG	RN	Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [18F]6-(2-fl... J Med Chem. 2009 Apr 23;52(8):2443-53.
DM75OHG	RU	https://pubmed.ncbi.nlm.nih.gov/19323559

DMLIQUA	DI	DMLIQUA
DMLIQUA	DN	(E)-5-(3-Chlorostyryl)isatin
DMLIQUA	MI	TT3WG5C
DMLIQUA	MN	Monoamine oxidase type A (MAO-A)
DMLIQUA	MT	DTT
DMLIQUA	MA	Inhibitor
DMLIQUA	RN	Inhibition of monoamine oxidase by (E)-styrylisatin analogues. Bioorg Med Chem Lett. 2009 May 1;19(9):2509-13.
DMLIQUA	RU	https://pubmed.ncbi.nlm.nih.gov/19342233

DMLIQUA	DI	DMLIQUA
DMLIQUA	DN	(E)-5-(3-Chlorostyryl)isatin
DMLIQUA	MI	TTGP7BY
DMLIQUA	MN	Monoamine oxidase type B (MAO-B)
DMLIQUA	MT	DTT
DMLIQUA	MA	Inhibitor
DMLIQUA	RN	Inhibition of monoamine oxidase by (E)-styrylisatin analogues. Bioorg Med Chem Lett. 2009 May 1;19(9):2509-13.
DMLIQUA	RU	https://pubmed.ncbi.nlm.nih.gov/19342233

DMP4T9Z	DI	DMP4T9Z
DMP4T9Z	DN	(E)-5-(3-Fluorostyryl)isatin
DMP4T9Z	MI	TT3WG5C
DMP4T9Z	MN	Monoamine oxidase type A (MAO-A)
DMP4T9Z	MT	DTT
DMP4T9Z	MA	Inhibitor
DMP4T9Z	RN	Inhibition of monoamine oxidase by (E)-styrylisatin analogues. Bioorg Med Chem Lett. 2009 May 1;19(9):2509-13.
DMP4T9Z	RU	https://pubmed.ncbi.nlm.nih.gov/19342233

DMP4T9Z	DI	DMP4T9Z
DMP4T9Z	DN	(E)-5-(3-Fluorostyryl)isatin
DMP4T9Z	MI	TTGP7BY
DMP4T9Z	MN	Monoamine oxidase type B (MAO-B)
DMP4T9Z	MT	DTT
DMP4T9Z	MA	Inhibitor
DMP4T9Z	RN	Inhibition of monoamine oxidase by (E)-styrylisatin analogues. Bioorg Med Chem Lett. 2009 May 1;19(9):2509-13.
DMP4T9Z	RU	https://pubmed.ncbi.nlm.nih.gov/19342233

DM81JRF	DI	DM81JRF
DM81JRF	DN	(E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin
DM81JRF	MI	TTGKNB4
DM81JRF	MN	Epidermal growth factor receptor (EGFR)
DM81JRF	MT	DTT
DM81JRF	MA	Inhibitor
DM81JRF	RN	5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line. Eur J Med Chem. 2009 Sep;44(9):3471-9.
DM81JRF	RU	https://pubmed.ncbi.nlm.nih.gov/19268405

DMJKOFW	DI	DMJKOFW
DMJKOFW	DN	(E)-5-Nitrooctadec-5-enoic Acid
DMJKOFW	MI	TTT2SVW
DMJKOFW	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DMJKOFW	MT	DTT
DMJKOFW	MA	Inhibitor
DMJKOFW	RN	Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree ... J Med Chem. 2009 Aug 13;52(15):4631-9.
DMJKOFW	RU	https://pubmed.ncbi.nlm.nih.gov/19719236

DMIPY3W	DI	DMIPY3W
DMIPY3W	DN	(E)-5-octadecen-7,9-diynoic acid
DMIPY3W	MI	TTPADOQ
DMIPY3W	MN	HMG-CoA reductase (HMGCR)
DMIPY3W	MT	DTT
DMIPY3W	MA	Inhibitor
DMIPY3W	RN	Novel Acetylenic Acids from the Root Bark of Paramacrolobium caeruleum: Inhibitors of 3-Hydroxy-3-methyl-glutaryl Coenzyme A Reductase J. Nat. Prod. 52(1):153-161 (1989).
DMIPY3W	RU	http://pubs.acs.org/doi/abs/10.1021/np50061a020

DM1PCIX	DI	DM1PCIX
DM1PCIX	DN	(E)-5-Styrylisatin
DM1PCIX	MI	TT3WG5C
DM1PCIX	MN	Monoamine oxidase type A (MAO-A)
DM1PCIX	MT	DTT
DM1PCIX	MA	Inhibitor
DM1PCIX	RN	Inhibition of monoamine oxidase by (E)-styrylisatin analogues. Bioorg Med Chem Lett. 2009 May 1;19(9):2509-13.
DM1PCIX	RU	https://pubmed.ncbi.nlm.nih.gov/19342233

DM1PCIX	DI	DM1PCIX
DM1PCIX	DN	(E)-5-Styrylisatin
DM1PCIX	MI	TTGP7BY
DM1PCIX	MN	Monoamine oxidase type B (MAO-B)
DM1PCIX	MT	DTT
DM1PCIX	MA	Inhibitor
DM1PCIX	RN	Inhibition of monoamine oxidase by (E)-styrylisatin analogues. Bioorg Med Chem Lett. 2009 May 1;19(9):2509-13.
DM1PCIX	RU	https://pubmed.ncbi.nlm.nih.gov/19342233

DMACVNM	DI	DMACVNM
DMACVNM	DN	(E)-6-Nitrooctadec-5-enoic Acid
DMACVNM	MI	TTT2SVW
DMACVNM	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DMACVNM	MT	DTT
DMACVNM	MA	Inhibitor
DMACVNM	RN	Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree ... J Med Chem. 2009 Aug 13;52(15):4631-9.
DMACVNM	RU	https://pubmed.ncbi.nlm.nih.gov/19719236

DMG47QU	DI	DMG47QU
DMG47QU	DN	(E)-6-Styrylisatin
DMG47QU	MI	TTGP7BY
DMG47QU	MN	Monoamine oxidase type B (MAO-B)
DMG47QU	MT	DTT
DMG47QU	MA	Inhibitor
DMG47QU	RN	Inhibition of monoamine oxidase by (E)-styrylisatin analogues. Bioorg Med Chem Lett. 2009 May 1;19(9):2509-13.
DMG47QU	RU	https://pubmed.ncbi.nlm.nih.gov/19342233

DMQT15Z	DI	DMQT15Z
DMQT15Z	DN	(E)-8-(3-chlorostyryl)-caffeine
DMQT15Z	MI	TTK25J1
DMQT15Z	MN	Adenosine A1 receptor (ADORA1)
DMQT15Z	MT	DTT
DMQT15Z	MA	Antagonist
DMQT15Z	RN	Structure-activity relationships of 8-styrylxanthines as A2-selective adenosine antagonists. J Med Chem. 1993 May 14;36(10):1333-42.
DMQT15Z	RU	https://pubmed.ncbi.nlm.nih.gov/8496902

DMQT15Z	DI	DMQT15Z
DMQT15Z	DN	(E)-8-(3-chlorostyryl)-caffeine
DMQT15Z	MI	TTNE7KG
DMQT15Z	MN	Adenosine A2b receptor (ADORA2B)
DMQT15Z	MT	DTT
DMQT15Z	MA	Antagonist
DMQT15Z	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 20).
DMQT15Z	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=20

DMQT15Z	DI	DMQT15Z
DMQT15Z	DN	(E)-8-(3-chlorostyryl)-caffeine
DMQT15Z	MI	TTJFY5U
DMQT15Z	MN	Adenosine A3 receptor (ADORA3)
DMQT15Z	MT	DTT
DMQT15Z	MA	Antagonist
DMQT15Z	RN	A binding site model and structure-activity relationships for the rat A3 adenosine receptor. Mol Pharmacol. 1994 Jun;45(6):1101-11.
DMQT15Z	RU	https://pubmed.ncbi.nlm.nih.gov/8022403

DMQT15Z	DI	DMQT15Z
DMQT15Z	DN	(E)-8-(3-chlorostyryl)-caffeine
DMQT15Z	MI	TTGP7BY
DMQT15Z	MN	Monoamine oxidase type B (MAO-B)
DMQT15Z	MT	DTT
DMQT15Z	MA	Inhibitor
DMQT15Z	RN	Synthesis and in vitro evaluation of pteridine analogues as monoamine oxidase B and nitric oxide synthase inhibitors. Bioorg Med Chem. 2009 Nov 1;17(21):7523-30.
DMQT15Z	RU	https://pubmed.ncbi.nlm.nih.gov/19804982

DM5LSY9	DI	DM5LSY9
DM5LSY9	DN	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one
DM5LSY9	MI	TTBH0VX
DM5LSY9	MN	Histone deacetylase (HDAC)
DM5LSY9	MT	DTT
DM5LSY9	MA	Inhibitor
DM5LSY9	RN	Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.
DM5LSY9	RU	https://pubmed.ncbi.nlm.nih.gov/14592473

DM5LSY9	DI	DM5LSY9
DM5LSY9	DN	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one
DM5LSY9	MI	TT6R7JZ
DM5LSY9	MN	Histone deacetylase 1 (HDAC1)
DM5LSY9	MT	DTT
DM5LSY9	MA	Inhibitor
DM5LSY9	RN	Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.
DM5LSY9	RU	https://pubmed.ncbi.nlm.nih.gov/14592473

DM5LSY9	DI	DM5LSY9
DM5LSY9	DN	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one
DM5LSY9	MI	TTYHPU6
DM5LSY9	MN	Histone deacetylase 10 (HDAC10)
DM5LSY9	MT	DTT
DM5LSY9	MA	Inhibitor
DM5LSY9	RN	Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.
DM5LSY9	RU	https://pubmed.ncbi.nlm.nih.gov/14592473

DM5LSY9	DI	DM5LSY9
DM5LSY9	DN	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one
DM5LSY9	MI	TTSHTOI
DM5LSY9	MN	Histone deacetylase 2 (HDAC2)
DM5LSY9	MT	DTT
DM5LSY9	MA	Inhibitor
DM5LSY9	RN	Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.
DM5LSY9	RU	https://pubmed.ncbi.nlm.nih.gov/14592473

DM5LSY9	DI	DM5LSY9
DM5LSY9	DN	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one
DM5LSY9	MI	TTTQGH8
DM5LSY9	MN	Histone deacetylase 4 (HDAC4)
DM5LSY9	MT	DTT
DM5LSY9	MA	Inhibitor
DM5LSY9	RN	Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.
DM5LSY9	RU	https://pubmed.ncbi.nlm.nih.gov/14592473

DM5LSY9	DI	DM5LSY9
DM5LSY9	DN	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one
DM5LSY9	MI	TT5ZKDI
DM5LSY9	MN	Histone deacetylase 6 (HDAC6)
DM5LSY9	MT	DTT
DM5LSY9	MA	Inhibitor
DM5LSY9	RN	Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.
DM5LSY9	RU	https://pubmed.ncbi.nlm.nih.gov/14592473

DM5LSY9	DI	DM5LSY9
DM5LSY9	DN	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one
DM5LSY9	MI	TTT6LFV
DM5LSY9	MN	Histone deacetylase 8 (HDAC8)
DM5LSY9	MT	DTT
DM5LSY9	MA	Inhibitor
DM5LSY9	RN	Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.
DM5LSY9	RU	https://pubmed.ncbi.nlm.nih.gov/14592473

DMULW35	DI	DMULW35
DMULW35	DN	(E)-9-Nitrohexadec-9-enoicAcid
DMULW35	MI	TTT2SVW
DMULW35	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DMULW35	MT	DTT
DMULW35	MA	Inhibitor
DMULW35	RN	Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree ... J Med Chem. 2009 Aug 13;52(15):4631-9.
DMULW35	RU	https://pubmed.ncbi.nlm.nih.gov/19719236

DMWC2F9	DI	DMWC2F9
DMWC2F9	DN	(E)-9-nitrooctadec-9-enoic acid
DMWC2F9	MI	TTT2SVW
DMWC2F9	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DMWC2F9	MT	DTT
DMWC2F9	MA	Inhibitor
DMWC2F9	RN	Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree ... J Med Chem. 2009 Aug 13;52(15):4631-9.
DMWC2F9	RU	https://pubmed.ncbi.nlm.nih.gov/19719236

DM9WHD2	DI	DM9WHD2
DM9WHD2	DN	(E)-N-(3,5-dimethoxyphenethyl)undec-2-enamide
DM9WHD2	MI	TT6OEDT
DM9WHD2	MN	Cannabinoid receptor 1 (CB1)
DM9WHD2	MT	DTT
DM9WHD2	MA	Inhibitor
DM9WHD2	RN	New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies. Bioorg Med Chem Lett. 2006 Jan 1;16(1):138-41.
DM9WHD2	RU	https://pubmed.ncbi.nlm.nih.gov/16213718

DM9WHD2	DI	DM9WHD2
DM9WHD2	DN	(E)-N-(3,5-dimethoxyphenethyl)undec-2-enamide
DM9WHD2	MI	TTMSFAW
DM9WHD2	MN	Cannabinoid receptor 2 (CB2)
DM9WHD2	MT	DTT
DM9WHD2	MA	Inhibitor
DM9WHD2	RN	New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies. Bioorg Med Chem Lett. 2006 Jan 1;16(1):138-41.
DM9WHD2	RU	https://pubmed.ncbi.nlm.nih.gov/16213718

DMW3RJL	DI	DMW3RJL
DMW3RJL	DN	(E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-methylphenyl)n
DMW3RJL	MI	TT8DBY3
DMW3RJL	MN	Angiotensin II receptor type-1 (AGTR1)
DMW3RJL	MT	DTT
DMW3RJL	MA	Antagonist
DMW3RJL	RN	Pharmacological characterization of (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-methylphenyl)n ortropane as a selective and potent inhibitor of the neuronal dopamine transporter. J Pharmacol Exp Ther. 1999 Nov;291(2):648-54.
DMW3RJL	RU	https://pubmed.ncbi.nlm.nih.gov/10525084

DML6PJD	DI	DML6PJD
DML6PJD	DN	(E)-N-(4-methoxyphenethyl)undec-2-enamide
DML6PJD	MI	TT6OEDT
DML6PJD	MN	Cannabinoid receptor 1 (CB1)
DML6PJD	MT	DTT
DML6PJD	MA	Inhibitor
DML6PJD	RN	New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies. Bioorg Med Chem Lett. 2006 Jan 1;16(1):138-41.
DML6PJD	RU	https://pubmed.ncbi.nlm.nih.gov/16213718

DML6PJD	DI	DML6PJD
DML6PJD	DN	(E)-N-(4-methoxyphenethyl)undec-2-enamide
DML6PJD	MI	TTMSFAW
DML6PJD	MN	Cannabinoid receptor 2 (CB2)
DML6PJD	MT	DTT
DML6PJD	MA	Inhibitor
DML6PJD	RN	New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies. Bioorg Med Chem Lett. 2006 Jan 1;16(1):138-41.
DML6PJD	RU	https://pubmed.ncbi.nlm.nih.gov/16213718

DM1PCEM	DI	DM1PCEM
DM1PCEM	DN	(E)-N-(4-methoxyphenyl)undec-2-enamide
DM1PCEM	MI	TT6OEDT
DM1PCEM	MN	Cannabinoid receptor 1 (CB1)
DM1PCEM	MT	DTT
DM1PCEM	MA	Inhibitor
DM1PCEM	RN	New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies. Bioorg Med Chem Lett. 2006 Jan 1;16(1):138-41.
DM1PCEM	RU	https://pubmed.ncbi.nlm.nih.gov/16213718

DM1PCEM	DI	DM1PCEM
DM1PCEM	DN	(E)-N-(4-methoxyphenyl)undec-2-enamide
DM1PCEM	MI	TTMSFAW
DM1PCEM	MN	Cannabinoid receptor 2 (CB2)
DM1PCEM	MT	DTT
DM1PCEM	MA	Inhibitor
DM1PCEM	RN	New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies. Bioorg Med Chem Lett. 2006 Jan 1;16(1):138-41.
DM1PCEM	RU	https://pubmed.ncbi.nlm.nih.gov/16213718

DM7XIH3	DI	DM7XIH3
DM7XIH3	DN	(E)-N-(4-Phenylthiazol-2-yl) cinnamamide
DM7XIH3	MI	TTVDSZ0
DM7XIH3	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DM7XIH3	MT	DTT
DM7XIH3	MA	Inhibitor
DM7XIH3	RN	Design, synthesis, and cytoprotective effect of 2-aminothiazole analogues as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2009 Feb 12;52(3):718-25.
DM7XIH3	RU	https://pubmed.ncbi.nlm.nih.gov/19125579

DMHKXPM	DI	DMHKXPM
DMHKXPM	DN	(E)-N-(6-(prop-1-enyl)-1H-indazol-3-yl)butyramide
DMHKXPM	MI	TTRSMW9
DMHKXPM	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMHKXPM	MT	DTT
DMHKXPM	MA	Inhibitor
DMHKXPM	RN	Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9.
DMHKXPM	RU	https://pubmed.ncbi.nlm.nih.gov/20167481

DMXYAIQ	DI	DMXYAIQ
DMXYAIQ	DN	(E)-Octadec-9-enal
DMXYAIQ	MI	TTMI6F5
DMXYAIQ	MN	Transient receptor potential cation channel V1 (TRPV1)
DMXYAIQ	MT	DTT
DMXYAIQ	MA	Inhibitor
DMXYAIQ	RN	The taming of capsaicin. Reversal of the vanilloid activity of N-acylvanillamines by aromatic iodination. J Med Chem. 2005 Jul 14;48(14):4663-9.
DMXYAIQ	RU	https://pubmed.ncbi.nlm.nih.gov/16000002

DMP7TK0	DI	DMP7TK0
DMP7TK0	DN	(E)-Octadec-9-enoic acid phenylamide
DMP7TK0	MI	TTMF541
DMP7TK0	MN	Liver carboxylesterase (CES1)
DMP7TK0	MT	DTT
DMP7TK0	MA	Inhibitor
DMP7TK0	RN	Acyl-CoA: cholesterol acyltransferase inhibitory activities of fatty acid amides isolated from Mylabris phalerate Pallas. Bioorg Med Chem Lett. 2004 Aug 16;14(16):4277-80.
DMP7TK0	RU	https://pubmed.ncbi.nlm.nih.gov/15261286

DMBLGF6	DI	DMBLGF6
DMBLGF6	DN	(E)-octadecan-9-ynoic acid
DMBLGF6	MI	TTPADOQ
DMBLGF6	MN	HMG-CoA reductase (HMGCR)
DMBLGF6	MT	DTT
DMBLGF6	MA	Inhibitor
DMBLGF6	RN	Novel Acetylenic Acids from the Root Bark of Paramacrolobium caeruleum: Inhibitors of 3-Hydroxy-3-methyl-glutaryl Coenzyme A Reductase J. Nat. Prod. 52(1):153-161 (1989).
DMBLGF6	RU	http://pubs.acs.org/doi/abs/10.1021/np50061a020

DMWU17O	DI	DMWU17O
DMWU17O	DN	(E,E)-1,7-Diphenyl-4,6-heptadien-3-one
DMWU17O	MI	TT50QJ3
DMWU17O	MN	Influenza Neuraminidase (Influ NA)
DMWU17O	MT	DTT
DMWU17O	MA	Inhibitor
DMWU17O	RN	Antiviral potential and molecular insight into neuraminidase inhibiting diarylheptanoids from Alpinia katsumadai. J Med Chem. 2010 Jan 28;53(2):778-86.
DMWU17O	RU	https://pubmed.ncbi.nlm.nih.gov/20014777

DMBIV6M	DI	DMBIV6M
DMBIV6M	DN	(E,E)-5-Hydroxy-1,7-diphenyl-4,6-heptadien-3-one
DMBIV6M	MI	TT50QJ3
DMBIV6M	MN	Influenza Neuraminidase (Influ NA)
DMBIV6M	MT	DTT
DMBIV6M	MA	Inhibitor
DMBIV6M	RN	Antiviral potential and molecular insight into neuraminidase inhibiting diarylheptanoids from Alpinia katsumadai. J Med Chem. 2010 Jan 28;53(2):778-86.
DMBIV6M	RU	https://pubmed.ncbi.nlm.nih.gov/20014777

DMPIUKZ	DI	DMPIUKZ
DMPIUKZ	DN	(E,E)-8-(4-Phenylbutadien-1-yl)caffeine
DMPIUKZ	MI	TTM2AOE
DMPIUKZ	MN	Adenosine A2a receptor (ADORA2A)
DMPIUKZ	MT	DTT
DMPIUKZ	MA	Inhibitor
DMPIUKZ	RN	Dual inhibition of monoamine oxidase B and antagonism of the adenosine A(2A) receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues. Bioorg Med Chem. 2008 Sep 15;16(18):8676-84.
DMPIUKZ	RU	https://pubmed.ncbi.nlm.nih.gov/18723354

DMPEV7S	DI	DMPEV7S
DMPEV7S	DN	(E,E)-8-[4-(3-Bromophenyl)butadien-1-yl]caffeine
DMPEV7S	MI	TTM2AOE
DMPEV7S	MN	Adenosine A2a receptor (ADORA2A)
DMPEV7S	MT	DTT
DMPEV7S	MA	Inhibitor
DMPEV7S	RN	Dual inhibition of monoamine oxidase B and antagonism of the adenosine A(2A) receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues. Bioorg Med Chem. 2008 Sep 15;16(18):8676-84.
DMPEV7S	RU	https://pubmed.ncbi.nlm.nih.gov/18723354

DMY4W25	DI	DMY4W25
DMY4W25	DN	(E,E)-8-[4-(3-Chlorophenyl)butadien-1-yl]caffeine
DMY4W25	MI	TTM2AOE
DMY4W25	MN	Adenosine A2a receptor (ADORA2A)
DMY4W25	MT	DTT
DMY4W25	MA	Inhibitor
DMY4W25	RN	Dual inhibition of monoamine oxidase B and antagonism of the adenosine A(2A) receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues. Bioorg Med Chem. 2008 Sep 15;16(18):8676-84.
DMY4W25	RU	https://pubmed.ncbi.nlm.nih.gov/18723354

DMPHJO2	DI	DMPHJO2
DMPHJO2	DN	(E,E)-8-[4-(3-Fluorophenyl)butadien-1-yl]caffeine
DMPHJO2	MI	TTM2AOE
DMPHJO2	MN	Adenosine A2a receptor (ADORA2A)
DMPHJO2	MT	DTT
DMPHJO2	MA	Inhibitor
DMPHJO2	RN	Dual inhibition of monoamine oxidase B and antagonism of the adenosine A(2A) receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues. Bioorg Med Chem. 2008 Sep 15;16(18):8676-84.
DMPHJO2	RU	https://pubmed.ncbi.nlm.nih.gov/18723354

DMVKJ0H	DI	DMVKJ0H
DMVKJ0H	DN	(H-261)Boc-His-Pro-Phe-His-Leu(OH)-Val-Ile-His-OH
DMVKJ0H	MI	TTB2MXP
DMVKJ0H	MN	Angiotensinogenase renin (REN)
DMVKJ0H	MT	DTT
DMVKJ0H	MA	Inhibitor
DMVKJ0H	RN	Renin inhibitors. Dipeptide analogues of angiotensinogen incorporating transition-state, nonpeptidic replacements at the scissile bond. J Med Chem. 1987 Oct;30(10):1729-37.
DMVKJ0H	RU	https://pubmed.ncbi.nlm.nih.gov/3309313

DMSCQ64	DI	DMSCQ64
DMSCQ64	DN	(H-Dmt-Tic-Glu-NH-(CH(2))(5)-CO-Dap(6DMN)-NH(2)
DMSCQ64	MI	TT27RFC
DMSCQ64	MN	Opioid receptor delta (OPRD1)
DMSCQ64	MT	DTT
DMSCQ64	MA	Inhibitor
DMSCQ64	RN	6-N,N-dimethylamino-2,3-naphthalimide: a new environment-sensitive fluorescent probe in delta- and mu-selective opioid peptides. J Med Chem. 2006 Jun 15;49(12):3653-8.
DMSCQ64	RU	https://pubmed.ncbi.nlm.nih.gov/16759107

DMSCQ64	DI	DMSCQ64
DMSCQ64	DN	(H-Dmt-Tic-Glu-NH-(CH(2))(5)-CO-Dap(6DMN)-NH(2)
DMSCQ64	MI	TTKWM86
DMSCQ64	MN	Opioid receptor mu (MOP)
DMSCQ64	MT	DTT
DMSCQ64	MA	Inhibitor
DMSCQ64	RN	6-N,N-dimethylamino-2,3-naphthalimide: a new environment-sensitive fluorescent probe in delta- and mu-selective opioid peptides. J Med Chem. 2006 Jun 15;49(12):3653-8.
DMSCQ64	RU	https://pubmed.ncbi.nlm.nih.gov/16759107

DMY6FUD	DI	DMY6FUD
DMY6FUD	DN	(Hydroxyethyloxy)Tri(Ethyloxy)Octane
DMY6FUD	MI	TTXMY0J
DMY6FUD	MN	Pancreatic triacylglycerol lipase (PNLIP)
DMY6FUD	MT	DTT
DMY6FUD	MA	Inhibitor
DMY6FUD	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMY6FUD	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMY6FUD	DI	DMY6FUD
DMY6FUD	DN	(Hydroxyethyloxy)Tri(Ethyloxy)Octane
DMY6FUD	MI	TTH0KSX
DMY6FUD	MN	Rhodopsin (RHO)
DMY6FUD	MT	DTT
DMY6FUD	MA	Inhibitor
DMY6FUD	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMY6FUD	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMOJUEC	DI	DMOJUEC
DMOJUEC	DN	(hydroxymethylphenyl)agomelatine
DMOJUEC	MI	TT0WAIE
DMOJUEC	MN	Melatonin receptor type 1A (MTNR1A)
DMOJUEC	MT	DTT
DMOJUEC	MA	Antagonist
DMOJUEC	RN	Synthesis of 3-phenylnaphthalenic derivatives as new selective MT(2) melatoninergic ligands. Bioorg Med Chem. 2008 Sep 15;16(18):8339-48.
DMOJUEC	RU	https://pubmed.ncbi.nlm.nih.gov/18778943

DMP9ZVQ	DI	DMP9ZVQ
DMP9ZVQ	DN	(L)-Phe-(D)-Phe-NH2
DMP9ZVQ	MI	TTZPO1L
DMP9ZVQ	MN	Substance-P receptor (TACR1)
DMP9ZVQ	MT	DTT
DMP9ZVQ	MA	Inhibitor
DMP9ZVQ	RN	Discovery of dipeptides with high affinity to the specific binding site for substance P1-7. J Med Chem. 2010 Mar 25;53(6):2383-9.
DMP9ZVQ	RU	https://pubmed.ncbi.nlm.nih.gov/20178322

DMDUN83	DI	DMDUN83
DMDUN83	DN	(L-)-S-adenosyl-L-homocysteine
DMDUN83	MI	TTHVCUP
DMDUN83	MN	DNA [cytosine-5]-methyltransferase (DNMT)
DMDUN83	MT	DTT
DMDUN83	MA	Inhibitor
DMDUN83	RN	Constrained (l-)-S-adenosyl-l-homocysteine (SAH) analogues as DNA methyltransferase inhibitors. Bioorg Med Chem Lett. 2009 May 15;19(10):2742-6.
DMDUN83	RU	https://pubmed.ncbi.nlm.nih.gov/19364644

DMDUN83	DI	DMDUN83
DMDUN83	DN	(L-)-S-adenosyl-L-homocysteine
DMDUN83	MI	TT6VZ78
DMDUN83	MN	DNA [cytosine-5]-methyltransferase 3B (DNMT3B)
DMDUN83	MT	DTT
DMDUN83	MA	Inhibitor
DMDUN83	RN	Constrained (l-)-S-adenosyl-l-homocysteine (SAH) analogues as DNA methyltransferase inhibitors. Bioorg Med Chem Lett. 2009 May 15;19(10):2742-6.
DMDUN83	RU	https://pubmed.ncbi.nlm.nih.gov/19364644

DMDUN83	DI	DMDUN83
DMDUN83	DN	(L-)-S-adenosyl-L-homocysteine
DMDUN83	MI	TT2B6EV
DMDUN83	MN	Histamine N-methyltransferase (HNMT)
DMDUN83	MT	DTT
DMDUN83	MA	Inhibitor
DMDUN83	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMDUN83	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMRGIF3	DI	DMRGIF3
DMRGIF3	DN	(LTB4-(Csa)4)2-Glu-H Conjugate
DMRGIF3	MI	TTN53ZF
DMRGIF3	MN	Leukotriene B4 receptor 1 (LTB4R)
DMRGIF3	MT	DTT
DMRGIF3	MA	Inhibitor
DMRGIF3	RN	Synthesis of leukotriene B4 antagonists labeled with In-111 or Tc-99m to image infectious and inflammatory foci. J Med Chem. 2005 Oct 6;48(20):6442-53.
DMRGIF3	RU	https://pubmed.ncbi.nlm.nih.gov/16190770

DM9ATZ8	DI	DM9ATZ8
DM9ATZ8	DN	(N-(3-phenoxycinnamyl)-acetohydroxamic acid
DM9ATZ8	MI	TTSJ6Q4
DM9ATZ8	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DM9ATZ8	MT	DTT
DM9ATZ8	MA	Inhibitor
DM9ATZ8	RN	Structural optimization and biological evaluation of 2-substituted 5-hydroxyindole-3-carboxylates as potent inhibitors of human 5-lipoxygenase. J Med Chem. 2009 Jun 11;52(11):3474-83.
DM9ATZ8	RU	https://pubmed.ncbi.nlm.nih.gov/19492852

DM6SV7I	DI	DM6SV7I
DM6SV7I	DN	(N)methanocarba-UTP
DM6SV7I	MI	TT24DGP
DM6SV7I	MN	P2Y purinoceptor 4 (P2RY4)
DM6SV7I	MT	DTT
DM6SV7I	MA	Agonist
DM6SV7I	RN	Methanocarba modification of uracil and adenine nucleotides: high potency of Northern ring conformation at P2Y1, P2Y2, P2Y4, and P2Y11 but not P2Y6 receptors. J Med Chem. 2002 Jan 3;45(1):208-18.
DM6SV7I	RU	https://pubmed.ncbi.nlm.nih.gov/11754592

DMPYK1T	DI	DMPYK1T
DMPYK1T	DN	(O10eq)-Benzyloxycarbonyl-beta-alanylryanodine
DMPYK1T	MI	TTU5CIX
DMPYK1T	MN	Ryanodine receptor 1 (RYR1)
DMPYK1T	MT	DTT
DMPYK1T	MA	Inhibitor
DMPYK1T	RN	Amino- and guanidinoacylryanodines: basic ryanodine esters with enhanced affinity for the sarcoplasmic reticulum Ca(2+)-release channel. J Med Chem. 1993 May 14;36(10):1319-23.
DMPYK1T	RU	https://pubmed.ncbi.nlm.nih.gov/8388466

DMRSZGB	DI	DMRSZGB
DMRSZGB	DN	(O10eq)-beta-alanyl-anhydro-ryanodine
DMRSZGB	MI	TTU5CIX
DMRSZGB	MN	Ryanodine receptor 1 (RYR1)
DMRSZGB	MT	DTT
DMRSZGB	MA	Inhibitor
DMRSZGB	RN	Amino- and guanidinoacylryanodines: basic ryanodine esters with enhanced affinity for the sarcoplasmic reticulum Ca(2+)-release channel. J Med Chem. 1993 May 14;36(10):1319-23.
DMRSZGB	RU	https://pubmed.ncbi.nlm.nih.gov/8388466

DMVGARN	DI	DMVGARN
DMVGARN	DN	(O10eq)-beta-alanylryanodine
DMVGARN	MI	TTU5CIX
DMVGARN	MN	Ryanodine receptor 1 (RYR1)
DMVGARN	MT	DTT
DMVGARN	MA	Inhibitor
DMVGARN	RN	Amino- and guanidinoacylryanodines: basic ryanodine esters with enhanced affinity for the sarcoplasmic reticulum Ca(2+)-release channel. J Med Chem. 1993 May 14;36(10):1319-23.
DMVGARN	RU	https://pubmed.ncbi.nlm.nih.gov/8388466

DMSV8XM	DI	DMSV8XM
DMSV8XM	DN	(O10eq)-beta-guanidinopropionylryanodine
DMSV8XM	MI	TTU5CIX
DMSV8XM	MN	Ryanodine receptor 1 (RYR1)
DMSV8XM	MT	DTT
DMSV8XM	MA	Inhibitor
DMSV8XM	RN	Amino- and guanidinoacylryanodines: basic ryanodine esters with enhanced affinity for the sarcoplasmic reticulum Ca(2+)-release channel. J Med Chem. 1993 May 14;36(10):1319-23.
DMSV8XM	RU	https://pubmed.ncbi.nlm.nih.gov/8388466

DM97W5T	DI	DM97W5T
DM97W5T	DN	(O10eq)-guanidino acetylryanodine
DM97W5T	MI	TTU5CIX
DM97W5T	MN	Ryanodine receptor 1 (RYR1)
DM97W5T	MT	DTT
DM97W5T	MA	Inhibitor
DM97W5T	RN	Amino- and guanidinoacylryanodines: basic ryanodine esters with enhanced affinity for the sarcoplasmic reticulum Ca(2+)-release channel. J Med Chem. 1993 May 14;36(10):1319-23.
DM97W5T	RU	https://pubmed.ncbi.nlm.nih.gov/8388466

DMB8NWI	DI	DMB8NWI
DMB8NWI	DN	(P-Iodophenylacetylamino)Methylphosphinic Acid
DMB8NWI	MI	TTHI19T
DMB8NWI	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMB8NWI	MT	DTT
DMB8NWI	MA	Inhibitor
DMB8NWI	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMB8NWI	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMYJAM5	DI	DMYJAM5
DMYJAM5	DN	(R)-(-)-10-methyl-11-hydroxyaporphine
DMYJAM5	MI	TTSQIFT
DMYJAM5	MN	5-HT 1A receptor (HTR1A)
DMYJAM5	MT	DTT
DMYJAM5	MA	Inhibitor
DMYJAM5	RN	R-(-)-N-alkyl-11-hydroxy-10-hydroxymethyl- and 10-methyl-aporphines as 5-HT1A receptor ligands. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4128-30.
DMYJAM5	RU	https://pubmed.ncbi.nlm.nih.gov/17543523

DMYJAM5	DI	DMYJAM5
DMYJAM5	DN	(R)-(-)-10-methyl-11-hydroxyaporphine
DMYJAM5	MI	TTZFYLI
DMYJAM5	MN	Dopamine D1 receptor (D1R)
DMYJAM5	MT	DTT
DMYJAM5	MA	Inhibitor
DMYJAM5	RN	R-(-)-N-alkyl-11-hydroxy-10-hydroxymethyl- and 10-methyl-aporphines as 5-HT1A receptor ligands. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4128-30.
DMYJAM5	RU	https://pubmed.ncbi.nlm.nih.gov/17543523

DMYJAM5	DI	DMYJAM5
DMYJAM5	DN	(R)-(-)-10-methyl-11-hydroxyaporphine
DMYJAM5	MI	TTEX248
DMYJAM5	MN	Dopamine D2 receptor (D2R)
DMYJAM5	MT	DTT
DMYJAM5	MA	Inhibitor
DMYJAM5	RN	R-(-)-N-alkyl-11-hydroxy-10-hydroxymethyl- and 10-methyl-aporphines as 5-HT1A receptor ligands. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4128-30.
DMYJAM5	RU	https://pubmed.ncbi.nlm.nih.gov/17543523

DMKB621	DI	DMKB621
DMKB621	DN	(R)-(-)-11-hydroxy-N-n-propylnoraporphine
DMKB621	MI	TTJQOD7
DMKB621	MN	5-HT 2A receptor (HTR2A)
DMKB621	MT	DTT
DMKB621	MA	Inhibitor
DMKB621	RN	N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D(2) and serotonin 5-HT(1A) receptor dual ligands. Bioorg Med Chem. 2008 Sep 15;16(18):8335-8.
DMKB621	RU	https://pubmed.ncbi.nlm.nih.gov/18783955

DMKB621	DI	DMKB621
DMKB621	DN	(R)-(-)-11-hydroxy-N-n-propylnoraporphine
DMKB621	MI	TTZFYLI
DMKB621	MN	Dopamine D1 receptor (D1R)
DMKB621	MT	DTT
DMKB621	MA	Inhibitor
DMKB621	RN	Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selec... J Med Chem. 2008 Feb 28;51(4):983-7.
DMKB621	RU	https://pubmed.ncbi.nlm.nih.gov/18251489

DMKB621	DI	DMKB621
DMKB621	DN	(R)-(-)-11-hydroxy-N-n-propylnoraporphine
DMKB621	MI	TTEX248
DMKB621	MN	Dopamine D2 receptor (D2R)
DMKB621	MT	DTT
DMKB621	MA	Inhibitor
DMKB621	RN	Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selec... J Med Chem. 2008 Feb 28;51(4):983-7.
DMKB621	RU	https://pubmed.ncbi.nlm.nih.gov/18251489

DMQ2INJ	DI	DMQ2INJ
DMQ2INJ	DN	(R)-(-)-2-methoxy-11-hydroxyaporphine
DMQ2INJ	MI	TTZFYLI
DMQ2INJ	MN	Dopamine D1 receptor (D1R)
DMQ2INJ	MT	DTT
DMQ2INJ	MA	Inhibitor
DMQ2INJ	RN	Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selec... J Med Chem. 2008 Feb 28;51(4):983-7.
DMQ2INJ	RU	https://pubmed.ncbi.nlm.nih.gov/18251489

DMQ2INJ	DI	DMQ2INJ
DMQ2INJ	DN	(R)-(-)-2-methoxy-11-hydroxyaporphine
DMQ2INJ	MI	TTEX248
DMQ2INJ	MN	Dopamine D2 receptor (D2R)
DMQ2INJ	MT	DTT
DMQ2INJ	MA	Inhibitor
DMQ2INJ	RN	Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selec... J Med Chem. 2008 Feb 28;51(4):983-7.
DMQ2INJ	RU	https://pubmed.ncbi.nlm.nih.gov/18251489

DMLXB62	DI	DMLXB62
DMLXB62	DN	(R)-(-)-2-methoxy-N-npropylnorapomorphine
DMLXB62	MI	TTZFYLI
DMLXB62	MN	Dopamine D1 receptor (D1R)
DMLXB62	MT	DTT
DMLXB62	MA	Inhibitor
DMLXB62	RN	Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selec... J Med Chem. 2008 Feb 28;51(4):983-7.
DMLXB62	RU	https://pubmed.ncbi.nlm.nih.gov/18251489

DMLXB62	DI	DMLXB62
DMLXB62	DN	(R)-(-)-2-methoxy-N-npropylnorapomorphine
DMLXB62	MI	TTEX248
DMLXB62	MN	Dopamine D2 receptor (D2R)
DMLXB62	MT	DTT
DMLXB62	MA	Inhibitor
DMLXB62	RN	Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selec... J Med Chem. 2008 Feb 28;51(4):983-7.
DMLXB62	RU	https://pubmed.ncbi.nlm.nih.gov/18251489

DMAYEJL	DI	DMAYEJL
DMAYEJL	DN	(R)-(-)-2-Methyl-apomorphine hydrochloride
DMAYEJL	MI	TTEX248
DMAYEJL	MN	Dopamine D2 receptor (D2R)
DMAYEJL	MT	DTT
DMAYEJL	MA	Inhibitor
DMAYEJL	RN	Synthesis and neuropharmacological evaluation of 2-aryl- and alkylapomorphines. Bioorg Med Chem. 2008 Apr 1;16(7):3773-9.
DMAYEJL	RU	https://pubmed.ncbi.nlm.nih.gov/18289859

DMAYEJL	DI	DMAYEJL
DMAYEJL	DN	(R)-(-)-2-Methyl-apomorphine hydrochloride
DMAYEJL	MI	TT4C8EA
DMAYEJL	MN	Dopamine D3 receptor (D3R)
DMAYEJL	MT	DTT
DMAYEJL	MA	Inhibitor
DMAYEJL	RN	Synthesis and neuropharmacological evaluation of 2-aryl- and alkylapomorphines. Bioorg Med Chem. 2008 Apr 1;16(7):3773-9.
DMAYEJL	RU	https://pubmed.ncbi.nlm.nih.gov/18289859

DME62U0	DI	DME62U0
DME62U0	DN	(R)-(-)-2-Phenyl-apomorphine hydrochloride
DME62U0	MI	TTEX248
DME62U0	MN	Dopamine D2 receptor (D2R)
DME62U0	MT	DTT
DME62U0	MA	Inhibitor
DME62U0	RN	Synthesis and neuropharmacological evaluation of 2-aryl- and alkylapomorphines. Bioorg Med Chem. 2008 Apr 1;16(7):3773-9.
DME62U0	RU	https://pubmed.ncbi.nlm.nih.gov/18289859

DME62U0	DI	DME62U0
DME62U0	DN	(R)-(-)-2-Phenyl-apomorphine hydrochloride
DME62U0	MI	TT4C8EA
DME62U0	MN	Dopamine D3 receptor (D3R)
DME62U0	MT	DTT
DME62U0	MA	Inhibitor
DME62U0	RN	Synthesis and neuropharmacological evaluation of 2-aryl- and alkylapomorphines. Bioorg Med Chem. 2008 Apr 1;16(7):3773-9.
DME62U0	RU	https://pubmed.ncbi.nlm.nih.gov/18289859

DMPSEZV	DI	DMPSEZV
DMPSEZV	DN	(R)-(-)-N-ethyl-2-methoxy-11-hydroxynoraporphine
DMPSEZV	MI	TTZFYLI
DMPSEZV	MN	Dopamine D1 receptor (D1R)
DMPSEZV	MT	DTT
DMPSEZV	MA	Inhibitor
DMPSEZV	RN	Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selec... J Med Chem. 2008 Feb 28;51(4):983-7.
DMPSEZV	RU	https://pubmed.ncbi.nlm.nih.gov/18251489

DMPSEZV	DI	DMPSEZV
DMPSEZV	DN	(R)-(-)-N-ethyl-2-methoxy-11-hydroxynoraporphine
DMPSEZV	MI	TTEX248
DMPSEZV	MN	Dopamine D2 receptor (D2R)
DMPSEZV	MT	DTT
DMPSEZV	MA	Inhibitor
DMPSEZV	RN	Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selec... J Med Chem. 2008 Feb 28;51(4):983-7.
DMPSEZV	RU	https://pubmed.ncbi.nlm.nih.gov/18251489

DM48SML	DI	DM48SML
DM48SML	DN	(R)-(-)-N-propyl-2-methoxy-11-hydroxynoraporphine
DM48SML	MI	TTZFYLI
DM48SML	MN	Dopamine D1 receptor (D1R)
DM48SML	MT	DTT
DM48SML	MA	Inhibitor
DM48SML	RN	Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selec... J Med Chem. 2008 Feb 28;51(4):983-7.
DM48SML	RU	https://pubmed.ncbi.nlm.nih.gov/18251489

DM48SML	DI	DM48SML
DM48SML	DN	(R)-(-)-N-propyl-2-methoxy-11-hydroxynoraporphine
DM48SML	MI	TTEX248
DM48SML	MN	Dopamine D2 receptor (D2R)
DM48SML	MT	DTT
DM48SML	MA	Inhibitor
DM48SML	RN	Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selec... J Med Chem. 2008 Feb 28;51(4):983-7.
DM48SML	RU	https://pubmed.ncbi.nlm.nih.gov/18251489

DM9DBHU	DI	DM9DBHU
DM9DBHU	DN	(R)-(+)-(4,5,6-trimethoxyindan-1-yl)methanamine
DM9DBHU	MI	TTJQOD7
DM9DBHU	MN	5-HT 2A receptor (HTR2A)
DM9DBHU	MT	DTT
DM9DBHU	MA	Inhibitor
DM9DBHU	RN	C-(4,5,6-trimethoxyindan-1-yl)methanamine: a mescaline analogue designed using a homology model of the 5-HT2A receptor. J Med Chem. 2006 Jul 13;49(14):4269-74.
DM9DBHU	RU	https://pubmed.ncbi.nlm.nih.gov/16821786

DM5UOFY	DI	DM5UOFY
DM5UOFY	DN	(R)(+)-2-(4-fluorophenyl)-7-methoxychroman-4-one
DM5UOFY	MI	TTGP7BY
DM5UOFY	MN	Monoamine oxidase type B (MAO-B)
DM5UOFY	MT	DTT
DM5UOFY	MA	Inhibitor
DM5UOFY	RN	A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9.
DM5UOFY	RU	https://pubmed.ncbi.nlm.nih.gov/20045650

DM6WTLZ	DI	DM6WTLZ
DM6WTLZ	DN	(R)(+)-7-fluoro-2-(4-fluorophenyl)chroman-4-one
DM6WTLZ	MI	TTGP7BY
DM6WTLZ	MN	Monoamine oxidase type B (MAO-B)
DM6WTLZ	MT	DTT
DM6WTLZ	MA	Inhibitor
DM6WTLZ	RN	A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9.
DM6WTLZ	RU	https://pubmed.ncbi.nlm.nih.gov/20045650

DMJCN0Y	DI	DMJCN0Y
DMJCN0Y	DN	(R)(+)-7-fluoro-2-phenylchroman-4-one
DMJCN0Y	MI	TTGP7BY
DMJCN0Y	MN	Monoamine oxidase type B (MAO-B)
DMJCN0Y	MT	DTT
DMJCN0Y	MA	Inhibitor
DMJCN0Y	RN	A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9.
DMJCN0Y	RU	https://pubmed.ncbi.nlm.nih.gov/20045650

DMHNKWR	DI	DMHNKWR
DMHNKWR	DN	(R)(+)-7-fluoro-2-p-tolylchroman-4-one
DMHNKWR	MI	TTGP7BY
DMHNKWR	MN	Monoamine oxidase type B (MAO-B)
DMHNKWR	MT	DTT
DMHNKWR	MA	Inhibitor
DMHNKWR	RN	A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9.
DMHNKWR	RU	https://pubmed.ncbi.nlm.nih.gov/20045650

DM8ZHYR	DI	DM8ZHYR
DM8ZHYR	DN	(R)(+)-7-methyl-2-phenylchroman-4-one
DM8ZHYR	MI	TTGP7BY
DM8ZHYR	MN	Monoamine oxidase type B (MAO-B)
DM8ZHYR	MT	DTT
DM8ZHYR	MA	Inhibitor
DM8ZHYR	RN	A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9.
DM8ZHYR	RU	https://pubmed.ncbi.nlm.nih.gov/20045650

DMVN50D	DI	DMVN50D
DMVN50D	DN	(R)(+)-7-methyl-2-p-tolylchroman-4-one
DMVN50D	MI	TTGP7BY
DMVN50D	MN	Monoamine oxidase type B (MAO-B)
DMVN50D	MT	DTT
DMVN50D	MA	Inhibitor
DMVN50D	RN	A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9.
DMVN50D	RU	https://pubmed.ncbi.nlm.nih.gov/20045650

DM7C148	DI	DM7C148
DM7C148	DN	(R)-(+)-coclaurine
DM7C148	MI	TTZFYLI
DM7C148	MN	Dopamine D1 receptor (D1R)
DM7C148	MT	DTT
DM7C148	MA	Inhibitor
DM7C148	RN	Synthesis and dopamine receptor selectivity of the benzyltetrahydroisoquinoline, (R)-(+)-nor-roefractine. J Nat Prod. 1998 Jun 26;61(6):709-12.
DM7C148	RU	https://pubmed.ncbi.nlm.nih.gov/9644051

DM7C148	DI	DM7C148
DM7C148	DN	(R)-(+)-coclaurine
DM7C148	MI	TTEX248
DM7C148	MN	Dopamine D2 receptor (D2R)
DM7C148	MT	DTT
DM7C148	MA	Inhibitor
DM7C148	RN	Synthesis and dopamine receptor selectivity of the benzyltetrahydroisoquinoline, (R)-(+)-nor-roefractine. J Nat Prod. 1998 Jun 26;61(6):709-12.
DM7C148	RU	https://pubmed.ncbi.nlm.nih.gov/9644051

DMBXRKS	DI	DMBXRKS
DMBXRKS	DN	(R)-1-((S)-morpholin-2-yl)-1,2-diphenylethanol
DMBXRKS	MI	TTAWNKZ
DMBXRKS	MN	Norepinephrine transporter (NET)
DMBXRKS	MT	DTT
DMBXRKS	MA	Inhibitor
DMBXRKS	RN	Discovery of novel and selective tertiary alcohol containing inhibitors of the norepinephrine transporter. Bioorg Med Chem Lett. 2006 Apr 1;16(7):2022-5.
DMBXRKS	RU	https://pubmed.ncbi.nlm.nih.gov/16413778

DMYBC24	DI	DMYBC24
DMYBC24	DN	(R)-1-(1H-indazol-4-yl)-3-(1-p-tolylethyl)urea
DMYBC24	MI	TTMI6F5
DMYBC24	MN	Transient receptor potential cation channel V1 (TRPV1)
DMYBC24	MT	DTT
DMYBC24	MA	Inhibitor
DMYBC24	RN	Alpha-methylation at benzylic fragment of N-aryl-N'-benzyl ureas provides TRPV1 antagonists with better pharmacokinetic properties and higher effic... Bioorg Med Chem Lett. 2007 Jul 15;17(14):3894-9.
DMYBC24	RU	https://pubmed.ncbi.nlm.nih.gov/17507218

DMGD026	DI	DMGD026
DMGD026	DN	(R)-1-(2-aminoacetyl)pyrrolidin-2-ylboronic acid
DMGD026	MI	TTDIGC1
DMGD026	MN	Dipeptidyl peptidase 4 (DPP-4)
DMGD026	MT	DTT
DMGD026	MA	Inhibitor
DMGD026	RN	Dipeptide boronic acid inhibitors of dipeptidyl peptidase IV: determinants of potency and in vivo efficacy and safety. J Med Chem. 2008 Oct 9;51(19):6005-13.
DMGD026	RU	https://pubmed.ncbi.nlm.nih.gov/18783201

DMMY0NF	DI	DMMY0NF
DMMY0NF	DN	(R)-1-(2-methoxyphenethyl)-2-methylpyrrolidine
DMMY0NF	MI	TT9JNIC
DMMY0NF	MN	Histamine H3 receptor (H3R)
DMMY0NF	MT	DTT
DMMY0NF	MA	Inhibitor
DMMY0NF	RN	In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9.
DMMY0NF	RU	https://pubmed.ncbi.nlm.nih.gov/18077160

DM76SZK	DI	DM76SZK
DM76SZK	DN	(R)-1-(3-methoxyphenethyl)-2-methylpyrrolidine
DM76SZK	MI	TT9JNIC
DM76SZK	MN	Histamine H3 receptor (H3R)
DM76SZK	MT	DTT
DM76SZK	MA	Inhibitor
DM76SZK	RN	In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9.
DM76SZK	RU	https://pubmed.ncbi.nlm.nih.gov/18077160

DMDC297	DI	DMDC297
DMDC297	DN	(R)-1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine
DMDC297	MI	TTJQOD7
DMDC297	MN	5-HT 2A receptor (HTR2A)
DMDC297	MT	DTT
DMDC297	MA	Inhibitor
DMDC297	RN	Novel benzodifuran analogs as potent 5-HT2A receptor agonists with ocular hypotensive activity. Bioorg Med Chem Lett. 2007 Jun 1;17(11):2998-3002.
DMDC297	RU	https://pubmed.ncbi.nlm.nih.gov/17419053

DMR3DSG	DI	DMR3DSG
DMR3DSG	DN	(R)-1-(4-methoxyphenethyl)-2-methylpyrrolidine
DMR3DSG	MI	TT9JNIC
DMR3DSG	MN	Histamine H3 receptor (H3R)
DMR3DSG	MT	DTT
DMR3DSG	MA	Inhibitor
DMR3DSG	RN	In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9.
DMR3DSG	RU	https://pubmed.ncbi.nlm.nih.gov/18077160

DMNROUV	DI	DMNROUV
DMNROUV	DN	(R)-1-(4-nitrophenethyl)-2-methylpyrrolidine
DMNROUV	MI	TT9JNIC
DMNROUV	MN	Histamine H3 receptor (H3R)
DMNROUV	MT	DTT
DMNROUV	MA	Inhibitor
DMNROUV	RN	In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9.
DMNROUV	RU	https://pubmed.ncbi.nlm.nih.gov/18077160

DMKJWMC	DI	DMKJWMC
DMKJWMC	DN	(R)-11-Amino-2-methoxyaporphine
DMKJWMC	MI	TTSQIFT
DMKJWMC	MN	5-HT 1A receptor (HTR1A)
DMKJWMC	MT	DTT
DMKJWMC	MA	Inhibitor
DMKJWMC	RN	Synthesis and pharmacological investigation of novel 2-aminothiazole-privileged aporphines. Bioorg Med Chem. 2008 Jul 15;16(14):6675-81.
DMKJWMC	RU	https://pubmed.ncbi.nlm.nih.gov/18562201

DMKJWMC	DI	DMKJWMC
DMKJWMC	DN	(R)-11-Amino-2-methoxyaporphine
DMKJWMC	MI	TTZFYLI
DMKJWMC	MN	Dopamine D1 receptor (D1R)
DMKJWMC	MT	DTT
DMKJWMC	MA	Inhibitor
DMKJWMC	RN	Synthesis and pharmacological investigation of novel 2-aminothiazole-privileged aporphines. Bioorg Med Chem. 2008 Jul 15;16(14):6675-81.
DMKJWMC	RU	https://pubmed.ncbi.nlm.nih.gov/18562201

DMXUHV3	DI	DMXUHV3
DMXUHV3	DN	(R)-2-((4-benzylphenoxy)methyl)piperidine
DMXUHV3	MI	TTXZEAJ
DMXUHV3	MN	Leukotriene A-4 hydrolase (LTA4H)
DMXUHV3	MT	DTT
DMXUHV3	MA	Inhibitor
DMXUHV3	RN	Discovery of novel leukotriene A4 hydrolase inhibitors based on piperidine and piperazine scaffolds. Bioorg Med Chem Lett. 2010 May 1;20(9):2851-4.
DMXUHV3	RU	https://pubmed.ncbi.nlm.nih.gov/20371179

DM6KJ3D	DI	DM6KJ3D
DM6KJ3D	DN	(R)-2-((4-phenoxyphenoxy)methyl)piperidine
DM6KJ3D	MI	TTXZEAJ
DM6KJ3D	MN	Leukotriene A-4 hydrolase (LTA4H)
DM6KJ3D	MT	DTT
DM6KJ3D	MA	Inhibitor
DM6KJ3D	RN	Discovery of novel leukotriene A4 hydrolase inhibitors based on piperidine and piperazine scaffolds. Bioorg Med Chem Lett. 2010 May 1;20(9):2851-4.
DM6KJ3D	RU	https://pubmed.ncbi.nlm.nih.gov/20371179

DMFDW4C	DI	DMFDW4C
DMFDW4C	DN	(R)-2-(2-(2-methylpyrrolidin-1-yl)ethyl)phenol
DMFDW4C	MI	TT9JNIC
DMFDW4C	MN	Histamine H3 receptor (H3R)
DMFDW4C	MT	DTT
DMFDW4C	MA	Inhibitor
DMFDW4C	RN	In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9.
DMFDW4C	RU	https://pubmed.ncbi.nlm.nih.gov/18077160

DM0L6ES	DI	DM0L6ES
DM0L6ES	DN	(R)-2-(2-(2-methylpyrrolidin-1-yl)ethyl)pyridine
DM0L6ES	MI	TT9JNIC
DM0L6ES	MN	Histamine H3 receptor (H3R)
DM0L6ES	MT	DTT
DM0L6ES	MA	Inhibitor
DM0L6ES	RN	In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9.
DM0L6ES	RU	https://pubmed.ncbi.nlm.nih.gov/18077160

DMVEMNA	DI	DMVEMNA
DMVEMNA	DN	(R)-2-(2-naphthamido)-3-m-tolylpropanoic acid
DMVEMNA	MI	TTJNTSI
DMVEMNA	MN	Rotamase Pin1 (PIN1)
DMVEMNA	MT	DTT
DMVEMNA	MA	Inhibitor
DMVEMNA	RN	Structure-based design of novel human Pin1 inhibitors (II). Bioorg Med Chem Lett. 2010 Apr 1;20(7):2210-4.
DMVEMNA	RU	https://pubmed.ncbi.nlm.nih.gov/20207139

DMXGCYZ	DI	DMXGCYZ
DMXGCYZ	DN	(R)-2-(2-naphthamido)-3-p-tolylpropanoic acid
DMXGCYZ	MI	TTJNTSI
DMXGCYZ	MN	Rotamase Pin1 (PIN1)
DMXGCYZ	MT	DTT
DMXGCYZ	MA	Inhibitor
DMXGCYZ	RN	Structure-based design of novel human Pin1 inhibitors (II). Bioorg Med Chem Lett. 2010 Apr 1;20(7):2210-4.
DMXGCYZ	RU	https://pubmed.ncbi.nlm.nih.gov/20207139

DM9WL6O	DI	DM9WL6O
DM9WL6O	DN	(R)-2-(2-naphthamido)-5-phenylpent-4-ynoic acid
DM9WL6O	MI	TTJNTSI
DM9WL6O	MN	Rotamase Pin1 (PIN1)
DM9WL6O	MT	DTT
DM9WL6O	MA	Inhibitor
DM9WL6O	RN	Structure-based design of novel human Pin1 inhibitors (II). Bioorg Med Chem Lett. 2010 Apr 1;20(7):2210-4.
DM9WL6O	RU	https://pubmed.ncbi.nlm.nih.gov/20207139

DM74IWX	DI	DM74IWX
DM74IWX	DN	(R)-2-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol
DM74IWX	MI	TTVBI8W
DM74IWX	MN	Dopamine transporter (DAT)
DM74IWX	MT	DTT
DM74IWX	MA	Inhibitor
DM74IWX	RN	Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92.
DM74IWX	RU	https://pubmed.ncbi.nlm.nih.gov/20471260

DM74IWX	DI	DM74IWX
DM74IWX	DN	(R)-2-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol
DM74IWX	MI	TTAWNKZ
DM74IWX	MN	Norepinephrine transporter (NET)
DM74IWX	MT	DTT
DM74IWX	MA	Inhibitor
DM74IWX	RN	Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92.
DM74IWX	RU	https://pubmed.ncbi.nlm.nih.gov/20471260

DM74IWX	DI	DM74IWX
DM74IWX	DN	(R)-2-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol
DM74IWX	MI	TT3ROYC
DM74IWX	MN	Serotonin transporter (SERT)
DM74IWX	MT	DTT
DM74IWX	MA	Inhibitor
DM74IWX	RN	Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92.
DM74IWX	RU	https://pubmed.ncbi.nlm.nih.gov/20471260

DM1GCV3	DI	DM1GCV3
DM1GCV3	DN	(R)-2-(4-Benzylphenoxymethyl)pyrrolidine
DM1GCV3	MI	TTXZEAJ
DM1GCV3	MN	Leukotriene A-4 hydrolase (LTA4H)
DM1GCV3	MT	DTT
DM1GCV3	MA	Inhibitor
DM1GCV3	RN	Discovery of 4-[(2S)-2-{[4-(4-chlorophenoxy)phenoxy]methyl}-1-pyrrolidinyl]butanoic acid (DG-051) as a novel leukotriene A4 hydrolase inhibitor of ... J Med Chem. 2010 Jan 28;53(2):573-85.
DM1GCV3	RU	https://pubmed.ncbi.nlm.nih.gov/19950900

DMR8E0G	DI	DMR8E0G
DMR8E0G	DN	(R)-2-(4-Isobutyl-phenyl)-N-methoxy-propionamide
DMR8E0G	MI	TTMWT8Z
DMR8E0G	MN	C-X-C chemokine receptor type 1 (CXCR1)
DMR8E0G	MT	DTT
DMR8E0G	MA	Inhibitor
DMR8E0G	RN	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
DMR8E0G	RU	https://pubmed.ncbi.nlm.nih.gov/15974585

DMR8E0G	DI	DMR8E0G
DMR8E0G	DN	(R)-2-(4-Isobutyl-phenyl)-N-methoxy-propionamide
DMR8E0G	MI	TT30C9G
DMR8E0G	MN	C-X-C chemokine receptor type 2 (CXCR2)
DMR8E0G	MT	DTT
DMR8E0G	MA	Inhibitor
DMR8E0G	RN	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
DMR8E0G	RU	https://pubmed.ncbi.nlm.nih.gov/15974585

DMAD4JY	DI	DMAD4JY
DMAD4JY	DN	(R)-2-(4-Isobutyl-phenyl)-N-phenyl-propionamide
DMAD4JY	MI	TT8NGED
DMAD4JY	MN	Prostaglandin G/H synthase 1 (COX-1)
DMAD4JY	MT	DTT
DMAD4JY	MA	Inhibitor
DMAD4JY	RN	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
DMAD4JY	RU	https://pubmed.ncbi.nlm.nih.gov/15974585

DMAD4JY	DI	DMAD4JY
DMAD4JY	DN	(R)-2-(4-Isobutyl-phenyl)-N-phenyl-propionamide
DMAD4JY	MI	TTVKILB
DMAD4JY	MN	Prostaglandin G/H synthase 2 (COX-2)
DMAD4JY	MT	DTT
DMAD4JY	MA	Inhibitor
DMAD4JY	RN	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
DMAD4JY	RU	https://pubmed.ncbi.nlm.nih.gov/15974585

DMBQ0PR	DI	DMBQ0PR
DMBQ0PR	DN	(R)-2-(4-Isobutyl-phenyl)-propionamide
DMBQ0PR	MI	TTMWT8Z
DMBQ0PR	MN	C-X-C chemokine receptor type 1 (CXCR1)
DMBQ0PR	MT	DTT
DMBQ0PR	MA	Inhibitor
DMBQ0PR	RN	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
DMBQ0PR	RU	https://pubmed.ncbi.nlm.nih.gov/15974585

DMBQ0PR	DI	DMBQ0PR
DMBQ0PR	DN	(R)-2-(4-Isobutyl-phenyl)-propionamide
DMBQ0PR	MI	TT30C9G
DMBQ0PR	MN	C-X-C chemokine receptor type 2 (CXCR2)
DMBQ0PR	MT	DTT
DMBQ0PR	MA	Inhibitor
DMBQ0PR	RN	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
DMBQ0PR	RU	https://pubmed.ncbi.nlm.nih.gov/15974585

DMJVQN8	DI	DMJVQN8
DMJVQN8	DN	(R)-2-(Benzylamino-methyl)-chroman-7-ol
DMJVQN8	MI	TT4C8EA
DMJVQN8	MN	Dopamine D3 receptor (D3R)
DMJVQN8	MT	DTT
DMJVQN8	MA	Inhibitor
DMJVQN8	RN	Molecular modeling of the three-dimensional structure of dopamine 3 (D3) subtype receptor: discovery of novel and potent D3 ligands through a hybri... J Med Chem. 2003 Oct 9;46(21):4377-92.
DMJVQN8	RU	https://pubmed.ncbi.nlm.nih.gov/14521403

DM16JFS	DI	DM16JFS
DM16JFS	DN	(R)-2-(biphenyl-4-sulfonylamino)-propionic acid
DM16JFS	MI	TTYG6BU
DM16JFS	MN	Aggrecanase-1 (ADAMTS4)
DM16JFS	MT	DTT
DM16JFS	MA	Inhibitor
DM16JFS	RN	Synthesis and biological evaluation of biphenylsulfonamide carboxylate aggrecanase-1 inhibitors. Bioorg Med Chem Lett. 2006 Jan 15;16(2):311-6.
DM16JFS	RU	https://pubmed.ncbi.nlm.nih.gov/16275085

DM70ZIF	DI	DM70ZIF
DM70ZIF	DN	(R)-2,11-Diaminoaporphine
DM70ZIF	MI	TTSQIFT
DM70ZIF	MN	5-HT 1A receptor (HTR1A)
DM70ZIF	MT	DTT
DM70ZIF	MA	Inhibitor
DM70ZIF	RN	Synthesis and pharmacological investigation of novel 2-aminothiazole-privileged aporphines. Bioorg Med Chem. 2008 Jul 15;16(14):6675-81.
DM70ZIF	RU	https://pubmed.ncbi.nlm.nih.gov/18562201

DM70ZIF	DI	DM70ZIF
DM70ZIF	DN	(R)-2,11-Diaminoaporphine
DM70ZIF	MI	TTZFYLI
DM70ZIF	MN	Dopamine D1 receptor (D1R)
DM70ZIF	MT	DTT
DM70ZIF	MA	Inhibitor
DM70ZIF	RN	Synthesis and pharmacological investigation of novel 2-aminothiazole-privileged aporphines. Bioorg Med Chem. 2008 Jul 15;16(14):6675-81.
DM70ZIF	RU	https://pubmed.ncbi.nlm.nih.gov/18562201

DMRO9C7	DI	DMRO9C7
DMRO9C7	DN	(R)-2,6-Bis-hydroxymethyl-piperidine-3,4,5-triol
DMRO9C7	MI	TTLPC70
DMRO9C7	MN	Lysosomal alpha-glucosidase (GAA)
DMRO9C7	MT	DTT
DMRO9C7	MA	Inhibitor
DMRO9C7	RN	Homonojirimycin isomers and N-alkylated homonojirimycins: structural and conformational basis of inhibition of glycosidases. J Med Chem. 1998 Jul 2;41(14):2565-71.
DMRO9C7	RU	https://pubmed.ncbi.nlm.nih.gov/9651160

DMZXT34	DI	DMZXT34
DMZXT34	DN	(R)-2-amino-3-(4-octylphenylamino)propan-1-ol
DMZXT34	MI	TTCN0M9
DMZXT34	MN	Sphingosine kinase 2 (SPHK2)
DMZXT34	MT	DTT
DMZXT34	MA	Inhibitor
DMZXT34	RN	Discovery of novel sphingosine kinase 1 inhibitors. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6119-21.
DMZXT34	RU	https://pubmed.ncbi.nlm.nih.gov/19800228

DMA1EFL	DI	DMA1EFL
DMA1EFL	DN	(R)-2-amino-4-hydroxy-N-(4-octylphenyl)butanamide
DMA1EFL	MI	TTCN0M9
DMA1EFL	MN	Sphingosine kinase 2 (SPHK2)
DMA1EFL	MT	DTT
DMA1EFL	MA	Inhibitor
DMA1EFL	RN	Discovery of novel sphingosine kinase 1 inhibitors. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6119-21.
DMA1EFL	RU	https://pubmed.ncbi.nlm.nih.gov/19800228

DMSY4CK	DI	DMSY4CK
DMSY4CK	DN	(R)-2-Amino-5-phosphono-pentanoic acid
DMSY4CK	MI	TTLD29N
DMSY4CK	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMSY4CK	MT	DTT
DMSY4CK	MA	Inhibitor
DMSY4CK	RN	Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists. J Med Chem. 2005 Apr 7;48(7):2627-37.
DMSY4CK	RU	https://pubmed.ncbi.nlm.nih.gov/15801853

DMSY4CK	DI	DMSY4CK
DMSY4CK	DN	(R)-2-Amino-5-phosphono-pentanoic acid
DMSY4CK	MI	TTKJEMQ
DMSY4CK	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMSY4CK	MT	DTT
DMSY4CK	MA	Inhibitor
DMSY4CK	RN	Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists. J Med Chem. 2005 Apr 7;48(7):2627-37.
DMSY4CK	RU	https://pubmed.ncbi.nlm.nih.gov/15801853

DMSY4CK	DI	DMSY4CK
DMSY4CK	DN	(R)-2-Amino-5-phosphono-pentanoic acid
DMSY4CK	MI	TTN9D8E
DMSY4CK	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMSY4CK	MT	DTT
DMSY4CK	MA	Inhibitor
DMSY4CK	RN	Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists. J Med Chem. 2005 Apr 7;48(7):2627-37.
DMSY4CK	RU	https://pubmed.ncbi.nlm.nih.gov/15801853

DM4XEHR	DI	DM4XEHR
DM4XEHR	DN	(R)-2-Amino-7-phosphono-heptanoic acid
DM4XEHR	MI	TTLD29N
DM4XEHR	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DM4XEHR	MT	DTT
DM4XEHR	MA	Inhibitor
DM4XEHR	RN	Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists. J Med Chem. 2005 Apr 7;48(7):2627-37.
DM4XEHR	RU	https://pubmed.ncbi.nlm.nih.gov/15801853

DM4XEHR	DI	DM4XEHR
DM4XEHR	DN	(R)-2-Amino-7-phosphono-heptanoic acid
DM4XEHR	MI	TTKJEMQ
DM4XEHR	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DM4XEHR	MT	DTT
DM4XEHR	MA	Inhibitor
DM4XEHR	RN	Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists. J Med Chem. 2005 Apr 7;48(7):2627-37.
DM4XEHR	RU	https://pubmed.ncbi.nlm.nih.gov/15801853

DM4XEHR	DI	DM4XEHR
DM4XEHR	DN	(R)-2-Amino-7-phosphono-heptanoic acid
DM4XEHR	MI	TTN9D8E
DM4XEHR	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DM4XEHR	MT	DTT
DM4XEHR	MA	Inhibitor
DM4XEHR	RN	Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists. J Med Chem. 2005 Apr 7;48(7):2627-37.
DM4XEHR	RU	https://pubmed.ncbi.nlm.nih.gov/15801853

DMT8HP1	DI	DMT8HP1
DMT8HP1	DN	(R)-2-methyl-1-(2-m-tolyl-ethyl)-pyrrolidine
DMT8HP1	MI	TT9JNIC
DMT8HP1	MN	Histamine H3 receptor (H3R)
DMT8HP1	MT	DTT
DMT8HP1	MA	Inhibitor
DMT8HP1	RN	In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9.
DMT8HP1	RU	https://pubmed.ncbi.nlm.nih.gov/18077160

DMA1FUH	DI	DMA1FUH
DMA1FUH	DN	(R)-2-methyl-1-(2-p-tolyl-ethyl)-pyrrolidine
DMA1FUH	MI	TT9JNIC
DMA1FUH	MN	Histamine H3 receptor (H3R)
DMA1FUH	MT	DTT
DMA1FUH	MA	Inhibitor
DMA1FUH	RN	In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9.
DMA1FUH	RU	https://pubmed.ncbi.nlm.nih.gov/18077160

DMRZDM0	DI	DMRZDM0
DMRZDM0	DN	(R)-3-(1'-Adamantanecarbonyl)amino-caprolactam
DMRZDM0	MI	TTFZYTO
DMRZDM0	MN	C-C chemokine receptor type 2 (CCR2)
DMRZDM0	MT	DTT
DMRZDM0	MA	Inhibitor
DMRZDM0	RN	Highly potent, orally available anti-inflammatory broad-spectrum chemokine inhibitors. J Med Chem. 2009 Jun 11;52(11):3591-5.
DMRZDM0	RU	https://pubmed.ncbi.nlm.nih.gov/19425597

DMCSHI3	DI	DMCSHI3
DMCSHI3	DN	(R)-3-(1H-imidazol-4-yl)propyl sec-butylcarbamate
DMCSHI3	MI	TT9JNIC
DMCSHI3	MN	Histamine H3 receptor (H3R)
DMCSHI3	MT	DTT
DMCSHI3	MA	Inhibitor
DMCSHI3	RN	Histamine H3 and H4 receptor affinity of branched 3-(1H-imidazol-4-yl)propyl N-alkylcarbamates. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6682-5.
DMCSHI3	RU	https://pubmed.ncbi.nlm.nih.gov/19846299

DMCSHI3	DI	DMCSHI3
DMCSHI3	DN	(R)-3-(1H-imidazol-4-yl)propyl sec-butylcarbamate
DMCSHI3	MI	TTXJ178
DMCSHI3	MN	Histamine H4 receptor (H4R)
DMCSHI3	MT	DTT
DMCSHI3	MA	Inhibitor
DMCSHI3	RN	Histamine H3 and H4 receptor affinity of branched 3-(1H-imidazol-4-yl)propyl N-alkylcarbamates. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6682-5.
DMCSHI3	RU	https://pubmed.ncbi.nlm.nih.gov/19846299

DMUFP7W	DI	DMUFP7W
DMUFP7W	DN	(R)-3-(2-(2-methylpyrrolidin-1-yl)ethyl)pyridine
DMUFP7W	MI	TT9JNIC
DMUFP7W	MN	Histamine H3 receptor (H3R)
DMUFP7W	MT	DTT
DMUFP7W	MA	Inhibitor
DMUFP7W	RN	In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9.
DMUFP7W	RU	https://pubmed.ncbi.nlm.nih.gov/18077160

DM5TH2W	DI	DM5TH2W
DM5TH2W	DN	(R)-3-(2-naphthamido)-4-m-tolylbutanoic acid
DM5TH2W	MI	TTJNTSI
DM5TH2W	MN	Rotamase Pin1 (PIN1)
DM5TH2W	MT	DTT
DM5TH2W	MA	Inhibitor
DM5TH2W	RN	Structure-based design of novel human Pin1 inhibitors (II). Bioorg Med Chem Lett. 2010 Apr 1;20(7):2210-4.
DM5TH2W	RU	https://pubmed.ncbi.nlm.nih.gov/20207139

DMQ2KF8	DI	DMQ2KF8
DMQ2KF8	DN	(R)-3-(4-Isobutyl-phenyl)-butan-2-one
DMQ2KF8	MI	TTMWT8Z
DMQ2KF8	MN	C-X-C chemokine receptor type 1 (CXCR1)
DMQ2KF8	MT	DTT
DMQ2KF8	MA	Inhibitor
DMQ2KF8	RN	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
DMQ2KF8	RU	https://pubmed.ncbi.nlm.nih.gov/15974585

DMQ2KF8	DI	DMQ2KF8
DMQ2KF8	DN	(R)-3-(4-Isobutyl-phenyl)-butan-2-one
DMQ2KF8	MI	TT30C9G
DMQ2KF8	MN	C-X-C chemokine receptor type 2 (CXCR2)
DMQ2KF8	MT	DTT
DMQ2KF8	MA	Inhibitor
DMQ2KF8	RN	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
DMQ2KF8	RU	https://pubmed.ncbi.nlm.nih.gov/15974585

DMC73DY	DI	DMC73DY
DMC73DY	DN	(R)-3-(4-propylmorpholin-2-yl)phenol
DMC73DY	MI	TTJQOD7
DMC73DY	MN	5-HT 2A receptor (HTR2A)
DMC73DY	MT	DTT
DMC73DY	MA	Inhibitor
DMC73DY	RN	Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6691-6.
DMC73DY	RU	https://pubmed.ncbi.nlm.nih.gov/17976986

DM2DVNT	DI	DM2DVNT
DM2DVNT	DN	(R)-3-(aminomethyl)-4-(furan-2-yl)butanoic acid
DM2DVNT	MI	TTFK1JQ
DM2DVNT	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DM2DVNT	MT	DTT
DM2DVNT	MA	Inhibitor
DM2DVNT	RN	Heteroaromatic side-chain analogs of pregabalin. Bioorg Med Chem Lett. 2006 May 1;16(9):2329-32.
DM2DVNT	RU	https://pubmed.ncbi.nlm.nih.gov/16099652

DM94B12	DI	DM94B12
DM94B12	DN	(R)-3-(naphthalen-2-ylmethoxy)pyrrolidine
DM94B12	MI	TTVBI8W
DM94B12	MN	Dopamine transporter (DAT)
DM94B12	MT	DTT
DM94B12	MA	Inhibitor
DM94B12	RN	Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32.
DM94B12	RU	https://pubmed.ncbi.nlm.nih.gov/19282174

DM94B12	DI	DM94B12
DM94B12	DN	(R)-3-(naphthalen-2-ylmethoxy)pyrrolidine
DM94B12	MI	TTAWNKZ
DM94B12	MN	Norepinephrine transporter (NET)
DM94B12	MT	DTT
DM94B12	MA	Inhibitor
DM94B12	RN	Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32.
DM94B12	RU	https://pubmed.ncbi.nlm.nih.gov/19282174

DM94B12	DI	DM94B12
DM94B12	DN	(R)-3-(naphthalen-2-ylmethoxy)pyrrolidine
DM94B12	MI	TT3ROYC
DM94B12	MN	Serotonin transporter (SERT)
DM94B12	MT	DTT
DM94B12	MA	Inhibitor
DM94B12	RN	Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32.
DM94B12	RU	https://pubmed.ncbi.nlm.nih.gov/19282174

DM94B12	DI	DM94B12
DM94B12	DN	(R)-3-(naphthalen-2-ylmethoxy)pyrrolidine
DM94B12	MI	TTQ6VDM
DM94B12	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DM94B12	MT	DTT
DM94B12	MA	Inhibitor
DM94B12	RN	Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32.
DM94B12	RU	https://pubmed.ncbi.nlm.nih.gov/19282174

DM98L2X	DI	DM98L2X
DM98L2X	DN	(R)-3-Methyl-1,2,3,4-tetrahydro-isoquinoline
DM98L2X	MI	TTWG9A4
DM98L2X	MN	Adrenergic receptor alpha-2A (ADRA2A)
DM98L2X	MT	DTT
DM98L2X	MA	Inhibitor
DM98L2X	RN	Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46.
DM98L2X	RU	https://pubmed.ncbi.nlm.nih.gov/8784452

DM98L2X	DI	DM98L2X
DM98L2X	DN	(R)-3-Methyl-1,2,3,4-tetrahydro-isoquinoline
DM98L2X	MI	TTWM4TY
DM98L2X	MN	Adrenergic receptor alpha-2B (ADRA2B)
DM98L2X	MT	DTT
DM98L2X	MA	Inhibitor
DM98L2X	RN	Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46.
DM98L2X	RU	https://pubmed.ncbi.nlm.nih.gov/8784452

DM98L2X	DI	DM98L2X
DM98L2X	DN	(R)-3-Methyl-1,2,3,4-tetrahydro-isoquinoline
DM98L2X	MI	TT2NUT5
DM98L2X	MN	Adrenergic receptor alpha-2C (ADRA2C)
DM98L2X	MT	DTT
DM98L2X	MA	Inhibitor
DM98L2X	RN	Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46.
DM98L2X	RU	https://pubmed.ncbi.nlm.nih.gov/8784452

DMPEV2W	DI	DMPEV2W
DMPEV2W	DN	(R)-3-Prop-2-ynylamino-indan-5-ol
DMPEV2W	MI	TTGP7BY
DMPEV2W	MN	Monoamine oxidase type B (MAO-B)
DMPEV2W	MT	DTT
DMPEV2W	MA	Inhibitor
DMPEV2W	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMPEV2W	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM1Y9MZ	DI	DM1Y9MZ
DM1Y9MZ	DN	(R)-3-Propyl-[1,4]thiazepan-(5E)-ylideneamine
DM1Y9MZ	MI	TTZUFI5
DM1Y9MZ	MN	Nitric-oxide synthase brain (NOS1)
DM1Y9MZ	MT	DTT
DM1Y9MZ	MA	Inhibitor
DM1Y9MZ	RN	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
DM1Y9MZ	RU	https://pubmed.ncbi.nlm.nih.gov/15501067

DM1Y9MZ	DI	DM1Y9MZ
DM1Y9MZ	DN	(R)-3-Propyl-[1,4]thiazepan-(5E)-ylideneamine
DM1Y9MZ	MI	TTF10I9
DM1Y9MZ	MN	Nitric-oxide synthase inducible (NOS2)
DM1Y9MZ	MT	DTT
DM1Y9MZ	MA	Inhibitor
DM1Y9MZ	RN	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
DM1Y9MZ	RU	https://pubmed.ncbi.nlm.nih.gov/15501067

DM5CL8B	DI	DM5CL8B
DM5CL8B	DN	(R)-4-(2-(2-methylpyrrolidin-1-yl)ethyl)pyridine
DM5CL8B	MI	TT9JNIC
DM5CL8B	MN	Histamine H3 receptor (H3R)
DM5CL8B	MT	DTT
DM5CL8B	MA	Inhibitor
DM5CL8B	RN	In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9.
DM5CL8B	RU	https://pubmed.ncbi.nlm.nih.gov/18077160

DMRVOLN	DI	DMRVOLN
DMRVOLN	DN	(R)-4-[2-[3-(4-methoxy-benzoylamino)-benzyl]-piperidin-1-ylmethyl]piperidine-1-carboxylic acid amide (Ro-320-6206)
DMRVOLN	MI	TTYEG6Q
DMRVOLN	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMRVOLN	MT	DTT
DMRVOLN	MA	Antagonist
DMRVOLN	RN	Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther. 2004 Jun;309(3):1148-53.
DMRVOLN	RU	https://pubmed.ncbi.nlm.nih.gov/14769832

DM3F56O	DI	DM3F56O
DM3F56O	DN	(R)-4-amino-2-methylbutanoic acid
DM3F56O	MI	TTNJYV2
DM3F56O	MN	Gamma-aminobutyric acid receptor (GAR)
DM3F56O	MT	DTT
DM3F56O	MA	Inhibitor
DM3F56O	RN	Enantioselective actions of 4-amino-3-hydroxybutanoic acid and (3-amino-2-hydroxypropyl)methylphosphinic acid at recombinant GABA(C) receptors. Bioorg Med Chem Lett. 2008 Jan 1;18(1):402-4.
DM3F56O	RU	https://pubmed.ncbi.nlm.nih.gov/17981464

DMW87OE	DI	DMW87OE
DMW87OE	DN	(R)-5-Amino-3-(4-chloro-phenyl)-pentanoic acid
DMW87OE	MI	TTDCVZW
DMW87OE	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMW87OE	MT	DTT
DMW87OE	MA	Inhibitor
DMW87OE	RN	Synthesis and pharmacology of the baclofen homologues 5-amino-4-(4-chlorophenyl)pentanoic acid and the R- and S-enantiomers of 5-amino-3-(4-chlorop... J Med Chem. 1999 Jun 3;42(11):2053-9.
DMW87OE	RU	https://pubmed.ncbi.nlm.nih.gov/10354414

DMOESL1	DI	DMOESL1
DMOESL1	DN	(R)-5-diphosphomevalonate
DMOESL1	MI	DE7G63U
DMOESL1	MN	Mevalonate pyrophosphate decarboxylase (MPD)
DMOESL1	MT	DME
DMOESL1	MA	Metabolism
DMOESL1	RN	The Putative mevalonate diphosphate decarboxylase from Picrophilus torridus is in reality a mevalonate-3-kinase with high potential for bioproduction of isobutene. Appl Environ Microbiol. 2015 Apr;81(7):2625-34.
DMOESL1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25636853

DMOESL1	DI	DMOESL1
DMOESL1	DN	(R)-5-diphosphomevalonate
DMOESL1	MI	TTXMI0C
DMOESL1	MN	Phosphomevalonate kinase (PMVK)
DMOESL1	MT	DTT
DMOESL1	MA	Inhibitor
DMOESL1	RN	Functional evaluation of conserved basic residues in human phosphomevalonate kinase. Biochemistry. 2007 Oct 23;46(42):11780-8.
DMOESL1	RU	https://pubmed.ncbi.nlm.nih.gov/17902708

DM3LQFK	DI	DM3LQFK
DM3LQFK	DN	(R)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinoline
DM3LQFK	MI	TT9JNIC
DM3LQFK	MN	Histamine H3 receptor (H3R)
DM3LQFK	MT	DTT
DM3LQFK	MA	Inhibitor
DM3LQFK	RN	In vitro studies on a class of quinoline containing histamine H3 antagonists. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3295-300.
DM3LQFK	RU	https://pubmed.ncbi.nlm.nih.gov/20457525

DM3LQFK	DI	DM3LQFK
DM3LQFK	DN	(R)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinoline
DM3LQFK	MI	TTQ6VDM
DM3LQFK	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DM3LQFK	MT	DTT
DM3LQFK	MA	Inhibitor
DM3LQFK	RN	In vitro studies on a class of quinoline containing histamine H3 antagonists. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3295-300.
DM3LQFK	RU	https://pubmed.ncbi.nlm.nih.gov/20457525

DM134UV	DI	DM134UV
DM134UV	DN	(R)-6-(pyrrolidin-3-ylmethoxy)-2-naphthonitrile
DM134UV	MI	TTAWNKZ
DM134UV	MN	Norepinephrine transporter (NET)
DM134UV	MT	DTT
DM134UV	MA	Inhibitor
DM134UV	RN	Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32.
DM134UV	RU	https://pubmed.ncbi.nlm.nih.gov/19282174

DM134UV	DI	DM134UV
DM134UV	DN	(R)-6-(pyrrolidin-3-ylmethoxy)-2-naphthonitrile
DM134UV	MI	TT3ROYC
DM134UV	MN	Serotonin transporter (SERT)
DM134UV	MT	DTT
DM134UV	MA	Inhibitor
DM134UV	RN	Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32.
DM134UV	RU	https://pubmed.ncbi.nlm.nih.gov/19282174

DMCY76E	DI	DMCY76E
DMCY76E	DN	(R)-8-phenyl-N,N-dipropylchroman-3-amine
DMCY76E	MI	TTO9X1H
DMCY76E	MN	5-HT 7 receptor (HTR7)
DMCY76E	MT	DTT
DMCY76E	MA	Inhibitor
DMCY76E	RN	SAR studies on new bis-aryls 5-HT7 ligands: Synthesis and molecular modeling. Bioorg Med Chem. 2010 Mar 1;18(5):1958-67.
DMCY76E	RU	https://pubmed.ncbi.nlm.nih.gov/20138771

DMKAW4P	DI	DMKAW4P
DMKAW4P	DN	(R)-alpha-methylhistamine
DMKAW4P	MI	TT9JNIC
DMKAW4P	MN	Histamine H3 receptor (H3R)
DMKAW4P	MT	DTT
DMKAW4P	MA	Agonist
DMKAW4P	RN	The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20.
DMKAW4P	RU	https://pubmed.ncbi.nlm.nih.gov/15665857

DMKAW4P	DI	DMKAW4P
DMKAW4P	DN	(R)-alpha-methylhistamine
DMKAW4P	MI	TTXJ178
DMKAW4P	MN	Histamine H4 receptor (H4R)
DMKAW4P	MT	DTT
DMKAW4P	MA	Agonist
DMKAW4P	RN	Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol. 2001 Mar;59(3):420-6.
DMKAW4P	RU	https://pubmed.ncbi.nlm.nih.gov/11179434

DMECK7H	DI	DMECK7H
DMECK7H	DN	(R)-DULOXETINE
DMECK7H	MI	TTVBI8W
DMECK7H	MN	Dopamine transporter (DAT)
DMECK7H	MT	DTT
DMECK7H	MA	Inhibitor
DMECK7H	RN	1-Naphthyl and 4-indolyl arylalkylamines as selective monoamine reuptake inhibitors. Bioorg Med Chem Lett. 2009 Jan 1;19(1):58-61.
DMECK7H	RU	https://pubmed.ncbi.nlm.nih.gov/19038547

DMECK7H	DI	DMECK7H
DMECK7H	DN	(R)-DULOXETINE
DMECK7H	MI	TTAWNKZ
DMECK7H	MN	Norepinephrine transporter (NET)
DMECK7H	MT	DTT
DMECK7H	MA	Inhibitor
DMECK7H	RN	Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression. Bioorg Med Chem. 2009 Oct 1;17(19):6890-7.
DMECK7H	RU	https://pubmed.ncbi.nlm.nih.gov/19740668

DMECK7H	DI	DMECK7H
DMECK7H	DN	(R)-DULOXETINE
DMECK7H	MI	TT3ROYC
DMECK7H	MN	Serotonin transporter (SERT)
DMECK7H	MT	DTT
DMECK7H	MA	Inhibitor
DMECK7H	RN	1-Naphthyl and 4-indolyl arylalkylamines as selective monoamine reuptake inhibitors. Bioorg Med Chem Lett. 2009 Jan 1;19(1):58-61.
DMECK7H	RU	https://pubmed.ncbi.nlm.nih.gov/19038547

DM297MU	DI	DM297MU
DM297MU	DN	(R)-EF-1520
DM297MU	MI	TTPRKM0
DM297MU	MN	GABA transporter GAT-1 (SLC6A1)
DM297MU	MT	DTT
DM297MU	MA	Inhibitor
DM297MU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 929).
DM297MU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=929

DM297MU	DI	DM297MU
DM297MU	DN	(R)-EF-1520
DM297MU	MI	TTQBMPI
DM297MU	MN	Na(+)/Cl(-) betaine/GABA transporter (SLC6A12)
DM297MU	MT	DTT
DM297MU	MA	Inhibitor
DM297MU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 932).
DM297MU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=932

DM2KBOU	DI	DM2KBOU
DM2KBOU	DN	(R)-flurocarazolol
DM2KBOU	MI	TTSQIFT
DM2KBOU	MN	5-HT 1A receptor (HTR1A)
DM2KBOU	MT	DTT
DM2KBOU	MA	Antagonist
DM2KBOU	RN	The in vitro pharmacology of the beta-adrenergic receptor pet ligand (s)-fluorocarazolol reveals high affinity for cloned beta-adrenergic receptors and moderate affinity for the human 5-HT1A receptor. Psychopharmacology (Berl). 2001 Aug;157(1):111-4.
DM2KBOU	RU	https://pubmed.ncbi.nlm.nih.gov/11512051

DM2KBOU	DI	DM2KBOU
DM2KBOU	DN	(R)-flurocarazolol
DM2KBOU	MI	TTK8CXU
DM2KBOU	MN	5-HT 1B receptor (HTR1B)
DM2KBOU	MT	DTT
DM2KBOU	MA	Antagonist
DM2KBOU	RN	The in vitro pharmacology of the beta-adrenergic receptor pet ligand (s)-fluorocarazolol reveals high affinity for cloned beta-adrenergic receptors and moderate affinity for the human 5-HT1A receptor. Psychopharmacology (Berl). 2001 Aug;157(1):111-4.
DM2KBOU	RU	https://pubmed.ncbi.nlm.nih.gov/11512051

DMKFPMC	DI	DMKFPMC
DMKFPMC	DN	(R)-Indan-1-yl-methyl-prop-2-ynyl-amine
DMKFPMC	MI	TT3WG5C
DMKFPMC	MN	Monoamine oxidase type A (MAO-A)
DMKFPMC	MT	DTT
DMKFPMC	MA	Inhibitor
DMKFPMC	RN	Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. J Med Chem. 2002 Nov 21;45(24):5260-79.
DMKFPMC	RU	https://pubmed.ncbi.nlm.nih.gov/12431053

DMKFPMC	DI	DMKFPMC
DMKFPMC	DN	(R)-Indan-1-yl-methyl-prop-2-ynyl-amine
DMKFPMC	MI	TTGP7BY
DMKFPMC	MN	Monoamine oxidase type B (MAO-B)
DMKFPMC	MT	DTT
DMKFPMC	MA	Inhibitor
DMKFPMC	RN	Docking studies on monoamine oxidase-B inhibitors: estimation of inhibition constants (K(i)) of a series of experimentally tested compounds. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4438-46.
DMKFPMC	RU	https://pubmed.ncbi.nlm.nih.gov/16137882

DMEXLUR	DI	DMEXLUR
DMEXLUR	DN	(R)-Mevalonate
DMEXLUR	MI	TTPADOQ
DMEXLUR	MN	HMG-CoA reductase (HMGCR)
DMEXLUR	MT	DTT
DMEXLUR	MA	Inhibitor
DMEXLUR	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMEXLUR	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMEXLUR	DI	DMEXLUR
DMEXLUR	DN	(R)-Mevalonate
DMEXLUR	MI	DEAO92K
DMEXLUR	MN	Mevalonate kinase (MVK)
DMEXLUR	MT	DME
DMEXLUR	MA	Metabolism
DMEXLUR	RN	Biochemical and structural basis for feedback inhibition of mevalonate kinase and isoprenoid metabolism. Biochemistry. 2008 Mar 25;47(12):3715-24.
DMEXLUR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18302342

DMPKWIN	DI	DMPKWIN
DMPKWIN	DN	(R)-N2-{4-[(3-chlorobenzyl)oxy]benzyl}alaninamide
DMPKWIN	MI	TTGP7BY
DMPKWIN	MN	Monoamine oxidase type B (MAO-B)
DMPKWIN	MT	DTT
DMPKWIN	MA	Inhibitor
DMPKWIN	RN	Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoa... J Med Chem. 2007 Oct 4;50(20):4909-16.
DMPKWIN	RU	https://pubmed.ncbi.nlm.nih.gov/17824599

DMEVM6G	DI	DMEVM6G
DMEVM6G	DN	(R)-N2-{4-[(3-chlorobenzyl)oxy]benzyl}serinamide
DMEVM6G	MI	TTGP7BY
DMEVM6G	MN	Monoamine oxidase type B (MAO-B)
DMEVM6G	MT	DTT
DMEVM6G	MA	Inhibitor
DMEVM6G	RN	Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoa... J Med Chem. 2007 Oct 4;50(20):4909-16.
DMEVM6G	RU	https://pubmed.ncbi.nlm.nih.gov/17824599

DMU49JN	DI	DMU49JN
DMU49JN	DN	(R)-N2-{4-[(3-fluorobenzyl)oxy]benzyl}alaninamide
DMU49JN	MI	TTGP7BY
DMU49JN	MN	Monoamine oxidase type B (MAO-B)
DMU49JN	MT	DTT
DMU49JN	MA	Inhibitor
DMU49JN	RN	Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoa... J Med Chem. 2007 Oct 4;50(20):4909-16.
DMU49JN	RU	https://pubmed.ncbi.nlm.nih.gov/17824599

DMM8TE0	DI	DMM8TE0
DMM8TE0	DN	(R)-N-benzyl-4-(pyrrolidin-2-ylmethoxy)aniline
DMM8TE0	MI	TTXZEAJ
DMM8TE0	MN	Leukotriene A-4 hydrolase (LTA4H)
DMM8TE0	MT	DTT
DMM8TE0	MA	Inhibitor
DMM8TE0	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMM8TE0	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMWRIQG	DI	DMWRIQG
DMWRIQG	DN	(R)-N-Hydroxy-2-(4-isobutyl-phenyl)-propionamide
DMWRIQG	MI	TTMWT8Z
DMWRIQG	MN	C-X-C chemokine receptor type 1 (CXCR1)
DMWRIQG	MT	DTT
DMWRIQG	MA	Inhibitor
DMWRIQG	RN	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
DMWRIQG	RU	https://pubmed.ncbi.nlm.nih.gov/15974585

DMWRIQG	DI	DMWRIQG
DMWRIQG	DN	(R)-N-Hydroxy-2-(4-isobutyl-phenyl)-propionamide
DMWRIQG	MI	TT30C9G
DMWRIQG	MN	C-X-C chemokine receptor type 2 (CXCR2)
DMWRIQG	MT	DTT
DMWRIQG	MA	Inhibitor
DMWRIQG	RN	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
DMWRIQG	RU	https://pubmed.ncbi.nlm.nih.gov/15974585

DMWGB40	DI	DMWGB40
DMWGB40	DN	(R)-nipecotic acid
DMWGB40	MI	TTPRKM0
DMWGB40	MN	GABA transporter GAT-1 (SLC6A1)
DMWGB40	MT	DTT
DMWGB40	MA	Inhibitor
DMWGB40	RN	Novel secoergoline derivatives inhibit both GABA and glutamate uptake in rat brain homogenates: synthesis, in vitro pharmacology, and modeling. J Med Chem. 2004 Nov 4;47(23):5620-9.
DMWGB40	RU	https://pubmed.ncbi.nlm.nih.gov/15509161

DMWGB40	DI	DMWGB40
DMWGB40	DN	(R)-nipecotic acid
DMWGB40	MI	TTV9MQG
DMWGB40	MN	Gamma-aminobutyric acid uptake (GABAU)
DMWGB40	MT	DTT
DMWGB40	MA	Inhibitor
DMWGB40	RN	GABA uptake inhibitors. Design, molecular pharmacology and therapeutic aspects. Curr Pharm Des. 2000 Aug;6(12):1193-209.
DMWGB40	RU	https://pubmed.ncbi.nlm.nih.gov/10903390

DMJFH97	DI	DMJFH97
DMJFH97	DN	(R)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide
DMJFH97	MI	TTVBI8W
DMJFH97	MN	Dopamine transporter (DAT)
DMJFH97	MT	DTT
DMJFH97	MA	Inhibitor
DMJFH97	RN	Bioorg Med Chem Lett. 2009 Oct 15;19(20):5893-7. Epub 2009 Aug 21.Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.
DMJFH97	RU	https://pubmed.ncbi.nlm.nih.gov/19740658

DMJFH97	DI	DMJFH97
DMJFH97	DN	(R)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide
DMJFH97	MI	TTAWNKZ
DMJFH97	MN	Norepinephrine transporter (NET)
DMJFH97	MT	DTT
DMJFH97	MA	Inhibitor
DMJFH97	RN	Bioorg Med Chem Lett. 2009 Oct 15;19(20):5893-7. Epub 2009 Aug 21.Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.
DMJFH97	RU	https://pubmed.ncbi.nlm.nih.gov/19740658

DMJFH97	DI	DMJFH97
DMJFH97	DN	(R)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide
DMJFH97	MI	TT3ROYC
DMJFH97	MN	Serotonin transporter (SERT)
DMJFH97	MT	DTT
DMJFH97	MA	Inhibitor
DMJFH97	RN	Bioorg Med Chem Lett. 2009 Oct 15;19(20):5893-7. Epub 2009 Aug 21.Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.
DMJFH97	RU	https://pubmed.ncbi.nlm.nih.gov/19740658

DMJFH97	DI	DMJFH97
DMJFH97	DN	(R)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide
DMJFH97	MI	TTQ6VDM
DMJFH97	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMJFH97	MT	DTT
DMJFH97	MA	Inhibitor
DMJFH97	RN	Bioorg Med Chem Lett. 2009 Oct 15;19(20):5893-7. Epub 2009 Aug 21.Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.
DMJFH97	RU	https://pubmed.ncbi.nlm.nih.gov/19740658

DMQIUOB	DI	DMQIUOB
DMQIUOB	DN	(R)-N-isopropyl-N-(pyrrolidin-3-yl)-2-naphthamide
DMQIUOB	MI	TTAWNKZ
DMQIUOB	MN	Norepinephrine transporter (NET)
DMQIUOB	MT	DTT
DMQIUOB	MA	Inhibitor
DMQIUOB	RN	Bioorg Med Chem Lett. 2009 Oct 15;19(20):5893-7. Epub 2009 Aug 21.Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.
DMQIUOB	RU	https://pubmed.ncbi.nlm.nih.gov/19740658

DMQIUOB	DI	DMQIUOB
DMQIUOB	DN	(R)-N-isopropyl-N-(pyrrolidin-3-yl)-2-naphthamide
DMQIUOB	MI	TT3ROYC
DMQIUOB	MN	Serotonin transporter (SERT)
DMQIUOB	MT	DTT
DMQIUOB	MA	Inhibitor
DMQIUOB	RN	Bioorg Med Chem Lett. 2009 Oct 15;19(20):5893-7. Epub 2009 Aug 21.Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.
DMQIUOB	RU	https://pubmed.ncbi.nlm.nih.gov/19740658

DMIHR14	DI	DMIHR14
DMIHR14	DN	(R)-N-oleoyltyrosinol
DMIHR14	MI	TT7QNVC
DMIHR14	MN	Glucose-dependent insulinotropic receptor (GPR119)
DMIHR14	MT	DTT
DMIHR14	MA	Agonist
DMIHR14	RN	N-oleoyldopamine enhances glucose homeostasis through the activation of GPR119. Mol Endocrinol. 2010 Jan;24(1):161-70.
DMIHR14	RU	https://pubmed.ncbi.nlm.nih.gov/19901198

DMS30KU	DI	DMS30KU
DMS30KU	DN	(R)-Norfluoxetine
DMS30KU	MI	TTVBI8W
DMS30KU	MN	Dopamine transporter (DAT)
DMS30KU	MT	DTT
DMS30KU	MA	Inhibitor
DMS30KU	RN	Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression. Bioorg Med Chem. 2009 Jan 1;17(1):337-43.
DMS30KU	RU	https://pubmed.ncbi.nlm.nih.gov/19014888

DMS30KU	DI	DMS30KU
DMS30KU	DN	(R)-Norfluoxetine
DMS30KU	MI	TTAWNKZ
DMS30KU	MN	Norepinephrine transporter (NET)
DMS30KU	MT	DTT
DMS30KU	MA	Inhibitor
DMS30KU	RN	Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression. Bioorg Med Chem. 2009 Jan 1;17(1):337-43.
DMS30KU	RU	https://pubmed.ncbi.nlm.nih.gov/19014888

DMS30KU	DI	DMS30KU
DMS30KU	DN	(R)-Norfluoxetine
DMS30KU	MI	TT3ROYC
DMS30KU	MN	Serotonin transporter (SERT)
DMS30KU	MT	DTT
DMS30KU	MA	Inhibitor
DMS30KU	RN	Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression. Bioorg Med Chem. 2009 Jan 1;17(1):337-43.
DMS30KU	RU	https://pubmed.ncbi.nlm.nih.gov/19014888

DMCYD8Q	DI	DMCYD8Q
DMCYD8Q	DN	(R)-ONDANSETRON
DMCYD8Q	MI	TTQ6VDM
DMCYD8Q	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMCYD8Q	MT	DTT
DMCYD8Q	MA	Inhibitor
DMCYD8Q	RN	A binary QSAR model for classification of hERG potassium channel blockers. Bioorg Med Chem. 2008 Apr 1;16(7):4107-19.
DMCYD8Q	RU	https://pubmed.ncbi.nlm.nih.gov/18243713

DM03N5V	DI	DM03N5V
DM03N5V	DN	(R)PK-11195
DM03N5V	MI	TTPTXIN
DM03N5V	MN	Translocator protein (TSPO)
DM03N5V	MT	DTT
DM03N5V	MA	Inhibitor
DM03N5V	RN	[18F]FMDAA1106 and [18F]FEDAA1106: two positron-emitter labeled ligands for peripheral benzodiazepine receptor (PBR). Bioorg Med Chem Lett. 2003 Jan 20;13(2):201-4.
DM03N5V	RU	https://pubmed.ncbi.nlm.nih.gov/12482423

DM95Z4Q	DI	DM95Z4Q
DM95Z4Q	DN	(R)-Rolipram
DM95Z4Q	MI	TTV5CGO
DM95Z4Q	MN	Phosphodiesterase 4 (PDE4)
DM95Z4Q	MT	DTT
DM95Z4Q	MA	Inhibitor
DM95Z4Q	RN	PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated fibroblasts. Am J Physiol Lung Cell Mol Physiol. 2009 Jun;296(6):L959-69.
DM95Z4Q	RU	https://pubmed.ncbi.nlm.nih.gov/19304913

DM95Z4Q	DI	DM95Z4Q
DM95Z4Q	DN	(R)-Rolipram
DM95Z4Q	MI	TTZ97H5
DM95Z4Q	MN	Phosphodiesterase 4A (PDE4A)
DM95Z4Q	MT	DTT
DM95Z4Q	MA	Inhibitor
DM95Z4Q	RN	PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated fibroblasts. Am J Physiol Lung Cell Mol Physiol. 2009 Jun;296(6):L959-69.
DM95Z4Q	RU	https://pubmed.ncbi.nlm.nih.gov/19304913

DM95Z4Q	DI	DM95Z4Q
DM95Z4Q	DN	(R)-Rolipram
DM95Z4Q	MI	TTVIAT9
DM95Z4Q	MN	Phosphodiesterase 4B (PDE4B)
DM95Z4Q	MT	DTT
DM95Z4Q	MA	Inhibitor
DM95Z4Q	RN	PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated fibroblasts. Am J Physiol Lung Cell Mol Physiol. 2009 Jun;296(6):L959-69.
DM95Z4Q	RU	https://pubmed.ncbi.nlm.nih.gov/19304913

DMV1IS8	DI	DMV1IS8
DMV1IS8	DN	(R)-sirtinol
DMV1IS8	MI	TTUF2HO
DMV1IS8	MN	NAD-dependent deacetylase sirtuin-1 (SIRT1)
DMV1IS8	MT	DTT
DMV1IS8	MA	Inhibitor
DMV1IS8	RN	Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (Sirtuin) inhibitors. J Med Chem. 2005 Dec 1;48(24):7789-95.
DMV1IS8	RU	https://pubmed.ncbi.nlm.nih.gov/16302818

DMSFA2D	DI	DMSFA2D
DMSFA2D	DN	(R)-tacrine(10)-hupyridone
DMSFA2D	MI	TT1RS9F
DMSFA2D	MN	Acetylcholinesterase (AChE)
DMSFA2D	MT	DTT
DMSFA2D	MA	Inhibitor
DMSFA2D	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMSFA2D	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMT6J51	DI	DMT6J51
DMT6J51	DN	(R)-zacopride
DMT6J51	MI	TTNXLKE
DMT6J51	MN	5-HT 3 receptor (5HT3R)
DMT6J51	MT	DTT
DMT6J51	MA	Modulator
DMT6J51	RN	R-zacopride, a 5-HT3 antagonist/5-HT4 agonist, reduces sleep apneas in rats. Pharmacol Biochem Behav. 2001 May-Jun;69(1-2):283-9.
DMT6J51	RU	https://www.ncbi.nlm.nih.gov/pubmed/11420096

DMT6J51	DI	DMT6J51
DMT6J51	DN	(R)-zacopride
DMT6J51	MI	TT07C3Y
DMT6J51	MN	5-HT 4 receptor (HTR4)
DMT6J51	MT	DTT
DMT6J51	MA	Modulator
DMT6J51	RN	R-zacopride, a 5-HT3 antagonist/5-HT4 agonist, reduces sleep apneas in rats. Pharmacol Biochem Behav. 2001 May-Jun;69(1-2):283-9.
DMT6J51	RU	https://www.ncbi.nlm.nih.gov/pubmed/11420096

DMCW5A9	DI	DMCW5A9
DMCW5A9	DN	(R,)-2-(2-naphthamido)-5-phenylpent-4-enoic acid
DMCW5A9	MI	TTJNTSI
DMCW5A9	MN	Rotamase Pin1 (PIN1)
DMCW5A9	MT	DTT
DMCW5A9	MA	Inhibitor
DMCW5A9	RN	Structure-based design of novel human Pin1 inhibitors (II). Bioorg Med Chem Lett. 2010 Apr 1;20(7):2210-4.
DMCW5A9	RU	https://pubmed.ncbi.nlm.nih.gov/20207139

DM3FQYS	DI	DM3FQYS
DM3FQYS	DN	(R,R)-(-)-fenoterol
DM3FQYS	MI	TTR6W5O
DM3FQYS	MN	Adrenergic receptor beta-1 (ADRB1)
DM3FQYS	MT	DTT
DM3FQYS	MA	Inhibitor
DM3FQYS	RN	Comparative molecular field analysis of the binding of the stereoisomers of fenoterol and fenoterol derivatives to the beta2 adrenergic receptor. J Med Chem. 2007 Jun 14;50(12):2903-15.
DM3FQYS	RU	https://pubmed.ncbi.nlm.nih.gov/17506540

DM3FQYS	DI	DM3FQYS
DM3FQYS	DN	(R,R)-(-)-fenoterol
DM3FQYS	MI	TT2CJVK
DM3FQYS	MN	Adrenergic receptor beta-2 (ADRB2)
DM3FQYS	MT	DTT
DM3FQYS	MA	Inhibitor
DM3FQYS	RN	Comparative molecular field analysis of the binding of the stereoisomers of fenoterol and fenoterol derivatives to the beta2 adrenergic receptor. J Med Chem. 2007 Jun 14;50(12):2903-15.
DM3FQYS	RU	https://pubmed.ncbi.nlm.nih.gov/17506540

DMETQBI	DI	DMETQBI
DMETQBI	DN	(R,S)-(-)-fenoterol
DMETQBI	MI	TTR6W5O
DMETQBI	MN	Adrenergic receptor beta-1 (ADRB1)
DMETQBI	MT	DTT
DMETQBI	MA	Inhibitor
DMETQBI	RN	Comparative molecular field analysis of the binding of the stereoisomers of fenoterol and fenoterol derivatives to the beta2 adrenergic receptor. J Med Chem. 2007 Jun 14;50(12):2903-15.
DMETQBI	RU	https://pubmed.ncbi.nlm.nih.gov/17506540

DMETQBI	DI	DMETQBI
DMETQBI	DN	(R,S)-(-)-fenoterol
DMETQBI	MI	TT2CJVK
DMETQBI	MN	Adrenergic receptor beta-2 (ADRB2)
DMETQBI	MT	DTT
DMETQBI	MA	Inhibitor
DMETQBI	RN	Comparative molecular field analysis of the binding of the stereoisomers of fenoterol and fenoterol derivatives to the beta2 adrenergic receptor. J Med Chem. 2007 Jun 14;50(12):2903-15.
DMETQBI	RU	https://pubmed.ncbi.nlm.nih.gov/17506540

DMKZ4C6	DI	DMKZ4C6
DMKZ4C6	DN	(R,S)-1-(5-bromo-1H-indol-1-yl)propan-2-amine
DMKZ4C6	MI	TTJQOD7
DMKZ4C6	MN	5-HT 2A receptor (HTR2A)
DMKZ4C6	MT	DTT
DMKZ4C6	MA	Inhibitor
DMKZ4C6	RN	Synthesis and structure-affinity relationships of novel small molecule natural product derivatives capable of discriminating between serotonin 5-HT1A, 5-HT2A, 5-HT2C receptor subtypes. Bioorg Med Chem. 2010 Jul 1;18(13):4783-92. 
DMKZ4C6	RU	https://pubmed.ncbi.nlm.nih.gov/20570529

DMKZ4C6	DI	DMKZ4C6
DMKZ4C6	DN	(R,S)-1-(5-bromo-1H-indol-1-yl)propan-2-amine
DMKZ4C6	MI	TTWJBZ5
DMKZ4C6	MN	5-HT 2C receptor (HTR2C)
DMKZ4C6	MT	DTT
DMKZ4C6	MA	Inhibitor
DMKZ4C6	RN	Synthesis and structure-affinity relationships of novel small molecule natural product derivatives capable of discriminating between serotonin 5-HT1A, 5-HT2A, 5-HT2C receptor subtypes. Bioorg Med Chem. 2010 Jul 1;18(13):4783-92. 
DMKZ4C6	RU	https://pubmed.ncbi.nlm.nih.gov/20570529

DMTZDAJ	DI	DMTZDAJ
DMTZDAJ	DN	(R,S)-1-(5-chloro-1H-indol-1-yl)propan-2-amine
DMTZDAJ	MI	TTJQOD7
DMTZDAJ	MN	5-HT 2A receptor (HTR2A)
DMTZDAJ	MT	DTT
DMTZDAJ	MA	Inhibitor
DMTZDAJ	RN	Synthesis and structure-affinity relationships of novel small molecule natural product derivatives capable of discriminating between serotonin 5-HT1A, 5-HT2A, 5-HT2C receptor subtypes. Bioorg Med Chem. 2010 Jul 1;18(13):4783-92. 
DMTZDAJ	RU	https://pubmed.ncbi.nlm.nih.gov/20570529

DMTZDAJ	DI	DMTZDAJ
DMTZDAJ	DN	(R,S)-1-(5-chloro-1H-indol-1-yl)propan-2-amine
DMTZDAJ	MI	TTWJBZ5
DMTZDAJ	MN	5-HT 2C receptor (HTR2C)
DMTZDAJ	MT	DTT
DMTZDAJ	MA	Inhibitor
DMTZDAJ	RN	Synthesis and structure-affinity relationships of novel small molecule natural product derivatives capable of discriminating between serotonin 5-HT1A, 5-HT2A, 5-HT2C receptor subtypes. Bioorg Med Chem. 2010 Jul 1;18(13):4783-92. 
DMTZDAJ	RU	https://pubmed.ncbi.nlm.nih.gov/20570529

DMAU1M5	DI	DMAU1M5
DMAU1M5	DN	(R,S)-1-(5-fluoro-1H-indol-1-yl)propan-2-amine
DMAU1M5	MI	TTJQOD7
DMAU1M5	MN	5-HT 2A receptor (HTR2A)
DMAU1M5	MT	DTT
DMAU1M5	MA	Inhibitor
DMAU1M5	RN	Synthesis and structure-affinity relationships of novel small molecule natural product derivatives capable of discriminating between serotonin 5-HT1A, 5-HT2A, 5-HT2C receptor subtypes. Bioorg Med Chem. 2010 Jul 1;18(13):4783-92. 
DMAU1M5	RU	https://pubmed.ncbi.nlm.nih.gov/20570529

DMAU1M5	DI	DMAU1M5
DMAU1M5	DN	(R,S)-1-(5-fluoro-1H-indol-1-yl)propan-2-amine
DMAU1M5	MI	TTWJBZ5
DMAU1M5	MN	5-HT 2C receptor (HTR2C)
DMAU1M5	MT	DTT
DMAU1M5	MA	Inhibitor
DMAU1M5	RN	Synthesis and structure-affinity relationships of novel small molecule natural product derivatives capable of discriminating between serotonin 5-HT1A, 5-HT2A, 5-HT2C receptor subtypes. Bioorg Med Chem. 2010 Jul 1;18(13):4783-92. 
DMAU1M5	RU	https://pubmed.ncbi.nlm.nih.gov/20570529

DMS2DI9	DI	DMS2DI9
DMS2DI9	DN	(R,S)-1-(5-methyl-1H-indol-1-yl)propan-2-amine
DMS2DI9	MI	TTJQOD7
DMS2DI9	MN	5-HT 2A receptor (HTR2A)
DMS2DI9	MT	DTT
DMS2DI9	MA	Inhibitor
DMS2DI9	RN	Synthesis and structure-affinity relationships of novel small molecule natural product derivatives capable of discriminating between serotonin 5-HT1A, 5-HT2A, 5-HT2C receptor subtypes. Bioorg Med Chem. 2010 Jul 1;18(13):4783-92. 
DMS2DI9	RU	https://pubmed.ncbi.nlm.nih.gov/20570529

DMS2DI9	DI	DMS2DI9
DMS2DI9	DN	(R,S)-1-(5-methyl-1H-indol-1-yl)propan-2-amine
DMS2DI9	MI	TTWJBZ5
DMS2DI9	MN	5-HT 2C receptor (HTR2C)
DMS2DI9	MT	DTT
DMS2DI9	MA	Inhibitor
DMS2DI9	RN	Synthesis and structure-affinity relationships of novel small molecule natural product derivatives capable of discriminating between serotonin 5-HT1A, 5-HT2A, 5-HT2C receptor subtypes. Bioorg Med Chem. 2010 Jul 1;18(13):4783-92. 
DMS2DI9	RU	https://pubmed.ncbi.nlm.nih.gov/20570529

DM0YELX	DI	DM0YELX
DM0YELX	DN	(R,S)-1-(6-fluoro-1H-indol-1-yl)propan-2-amine
DM0YELX	MI	TTJQOD7
DM0YELX	MN	5-HT 2A receptor (HTR2A)
DM0YELX	MT	DTT
DM0YELX	MA	Inhibitor
DM0YELX	RN	Synthesis and structure-affinity relationships of novel small molecule natural product derivatives capable of discriminating between serotonin 5-HT1A, 5-HT2A, 5-HT2C receptor subtypes. Bioorg Med Chem. 2010 Jul 1;18(13):4783-92. 
DM0YELX	RU	https://pubmed.ncbi.nlm.nih.gov/20570529

DM0YELX	DI	DM0YELX
DM0YELX	DN	(R,S)-1-(6-fluoro-1H-indol-1-yl)propan-2-amine
DM0YELX	MI	TTWJBZ5
DM0YELX	MN	5-HT 2C receptor (HTR2C)
DM0YELX	MT	DTT
DM0YELX	MA	Inhibitor
DM0YELX	RN	Synthesis and structure-affinity relationships of novel small molecule natural product derivatives capable of discriminating between serotonin 5-HT1A, 5-HT2A, 5-HT2C receptor subtypes. Bioorg Med Chem. 2010 Jul 1;18(13):4783-92. 
DM0YELX	RU	https://pubmed.ncbi.nlm.nih.gov/20570529

DM7COSH	DI	DM7COSH
DM7COSH	DN	(R,S)-4-phosphonophenylglycine
DM7COSH	MI	TT0IFKL
DM7COSH	MN	Metabotropic glutamate receptor 8 (mGluR8)
DM7COSH	MT	DTT
DM7COSH	MA	Agonist
DM7COSH	RN	Anticonvulsant activity of a metabotropic glutamate receptor 8 preferential agonist, (R,S)-4-phosphonophenylglycine. Eur J Pharmacol. 1999 Oct 21;383(1):23-7.
DM7COSH	RU	https://pubmed.ncbi.nlm.nih.gov/10556677

DMUG451	DI	DMUG451
DMUG451	DN	(R,S)-homoaromaline hydrochloride
DMUG451	MI	TTZFYLI
DMUG451	MN	Dopamine D1 receptor (D1R)
DMUG451	MT	DTT
DMUG451	MA	Inhibitor
DMUG451	RN	Displacement activity of bisbenzylisoquinoline alkaloids at striatal 3H-SCH 23390 and 3H-raclopride binding sites. J Nat Prod. 1992 Sep;55(9):1281-6.
DMUG451	RU	https://pubmed.ncbi.nlm.nih.gov/1431946

DMPDO43	DI	DMPDO43
DMPDO43	DN	(R,S)-N-(R-phenylethyl)-1H-pyrrole-2-carboxamide
DMPDO43	MI	TT3WG5C
DMPDO43	MN	Monoamine oxidase type A (MAO-A)
DMPDO43	MT	DTT
DMPDO43	MA	Inhibitor
DMPDO43	RN	New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J Med Chem. 2007 Mar 8;50(5):922-31.
DMPDO43	RU	https://pubmed.ncbi.nlm.nih.gov/17256833

DMQO71C	DI	DMQO71C
DMQO71C	DN	(R,S)-PHPNECA
DMQO71C	MI	TTK25J1
DMQO71C	MN	Adenosine A1 receptor (ADORA1)
DMQO71C	MT	DTT
DMQO71C	MA	Agonist
DMQO71C	RN	N(6)-alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A(3) receptor and a starting point for searching A(2B) ligands. J Med Chem. 2002 Jul 18;45(15):3271-9.
DMQO71C	RU	https://pubmed.ncbi.nlm.nih.gov/12109910

DMQO71C	DI	DMQO71C
DMQO71C	DN	(R,S)-PHPNECA
DMQO71C	MI	TTNE7KG
DMQO71C	MN	Adenosine A2b receptor (ADORA2B)
DMQO71C	MT	DTT
DMQO71C	MA	Agonist
DMQO71C	RN	N(6)-alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A(3) receptor and a starting point for searching A(2B) ligands. J Med Chem. 2002 Jul 18;45(15):3271-9.
DMQO71C	RU	https://pubmed.ncbi.nlm.nih.gov/12109910

DMQO71C	DI	DMQO71C
DMQO71C	DN	(R,S)-PHPNECA
DMQO71C	MI	TTJFY5U
DMQO71C	MN	Adenosine A3 receptor (ADORA3)
DMQO71C	MT	DTT
DMQO71C	MA	Agonist
DMQO71C	RN	N(6)-alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A(3) receptor and a starting point for searching A(2B) ligands. J Med Chem. 2002 Jul 18;45(15):3271-9.
DMQO71C	RU	https://pubmed.ncbi.nlm.nih.gov/12109910

DM8I6MG	DI	DM8I6MG
DM8I6MG	DN	(R/R)BEFLOXATONE
DM8I6MG	MI	TT3WG5C
DM8I6MG	MN	Monoamine oxidase type A (MAO-A)
DM8I6MG	MT	DTT
DM8I6MG	MA	Inhibitor
DM8I6MG	RN	3-(1H-Pyrrol-1-yl)-2-oxazolidinones as reversible, highly potent, and selective inhibitors of monoamine oxidase type A. J Med Chem. 2002 Mar 14;45(6):1180-3.
DM8I6MG	RU	https://pubmed.ncbi.nlm.nih.gov/11881986

DM8I6MG	DI	DM8I6MG
DM8I6MG	DN	(R/R)BEFLOXATONE
DM8I6MG	MI	TTGP7BY
DM8I6MG	MN	Monoamine oxidase type B (MAO-B)
DM8I6MG	MT	DTT
DM8I6MG	MA	Inhibitor
DM8I6MG	RN	3-(1H-Pyrrol-1-yl)-2-oxazolidinones as reversible, highly potent, and selective inhibitors of monoamine oxidase type A. J Med Chem. 2002 Mar 14;45(6):1180-3.
DM8I6MG	RU	https://pubmed.ncbi.nlm.nih.gov/11881986

DMYDG27	DI	DMYDG27
DMYDG27	DN	(R/S) EF-1500
DMYDG27	MI	TTPRKM0
DMYDG27	MN	GABA transporter GAT-1 (SLC6A1)
DMYDG27	MT	DTT
DMYDG27	MA	Inhibitor
DMYDG27	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 929).
DMYDG27	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=929

DMYDG27	DI	DMYDG27
DMYDG27	DN	(R/S) EF-1500
DMYDG27	MI	TTQBMPI
DMYDG27	MN	Na(+)/Cl(-) betaine/GABA transporter (SLC6A12)
DMYDG27	MT	DTT
DMYDG27	MA	Inhibitor
DMYDG27	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 932).
DMYDG27	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=932

DM3MEQB	DI	DM3MEQB
DM3MEQB	DN	(R/S)-2-((4-benzylphenoxy)methyl)piperazine
DM3MEQB	MI	TTXZEAJ
DM3MEQB	MN	Leukotriene A-4 hydrolase (LTA4H)
DM3MEQB	MT	DTT
DM3MEQB	MA	Inhibitor
DM3MEQB	RN	Discovery of novel leukotriene A4 hydrolase inhibitors based on piperidine and piperazine scaffolds. Bioorg Med Chem Lett. 2010 May 1;20(9):2851-4.
DM3MEQB	RU	https://pubmed.ncbi.nlm.nih.gov/20371179

DMRXD82	DI	DMRXD82
DMRXD82	DN	(R/S)-2-((4-benzylphenoxy)methyl)piperidine
DMRXD82	MI	TTXZEAJ
DMRXD82	MN	Leukotriene A-4 hydrolase (LTA4H)
DMRXD82	MT	DTT
DMRXD82	MA	Inhibitor
DMRXD82	RN	Discovery of novel leukotriene A4 hydrolase inhibitors based on piperidine and piperazine scaffolds. Bioorg Med Chem Lett. 2010 May 1;20(9):2851-4.
DMRXD82	RU	https://pubmed.ncbi.nlm.nih.gov/20371179

DMDA285	DI	DMDA285
DMDA285	DN	(R/S)-2-((4-phenoxyphenoxy)methyl)piperidine
DMDA285	MI	TTXZEAJ
DMDA285	MN	Leukotriene A-4 hydrolase (LTA4H)
DMDA285	MT	DTT
DMDA285	MA	Inhibitor
DMDA285	RN	Discovery of novel leukotriene A4 hydrolase inhibitors based on piperidine and piperazine scaffolds. Bioorg Med Chem Lett. 2010 May 1;20(9):2851-4.
DMDA285	RU	https://pubmed.ncbi.nlm.nih.gov/20371179

DMYZCRF	DI	DMYZCRF
DMYZCRF	DN	(RS)-(tetrazol-5-yl)glycine
DMYZCRF	MI	TTLD29N
DMYZCRF	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMYZCRF	MT	DTT
DMYZCRF	MA	Agonist
DMYZCRF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455).
DMYZCRF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=455

DMYZCRF	DI	DMYZCRF
DMYZCRF	DN	(RS)-(tetrazol-5-yl)glycine
DMYZCRF	MI	TTKJEMQ
DMYZCRF	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMYZCRF	MT	DTT
DMYZCRF	MA	Agonist
DMYZCRF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456).
DMYZCRF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=456

DMYZCRF	DI	DMYZCRF
DMYZCRF	DN	(RS)-(tetrazol-5-yl)glycine
DMYZCRF	MI	TTN9D8E
DMYZCRF	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMYZCRF	MT	DTT
DMYZCRF	MA	Agonist
DMYZCRF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457).
DMYZCRF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=457

DMYZCRF	DI	DMYZCRF
DMYZCRF	DN	(RS)-(tetrazol-5-yl)glycine
DMYZCRF	MI	TT1M8OW
DMYZCRF	MN	Glutamate receptor ionotropic NMDA 2C (GluN2C)
DMYZCRF	MT	DTT
DMYZCRF	MA	Agonist
DMYZCRF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 458).
DMYZCRF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=458

DMYZCRF	DI	DMYZCRF
DMYZCRF	DN	(RS)-(tetrazol-5-yl)glycine
DMYZCRF	MI	TT5POTG
DMYZCRF	MN	Glutamate receptor ionotropic NMDA 2D (GluN2D)
DMYZCRF	MT	DTT
DMYZCRF	MA	Agonist
DMYZCRF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 459).
DMYZCRF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=459

DMCPEBF	DI	DMCPEBF
DMCPEBF	DN	(RS)-5-diphosphomevalonate
DMCPEBF	MI	TT5DFHW
DMCPEBF	MN	Mevalonate kinase (MVK)
DMCPEBF	MT	DTT
DMCPEBF	MA	Inhibitor
DMCPEBF	RN	Bifunctional inhibitors of mevalonate kinase and mevalonate 5-diphosphate decarboxylase. Org Lett. 2006 Mar 16;8(6):1013-6.
DMCPEBF	RU	https://pubmed.ncbi.nlm.nih.gov/16524256

DMA8DEG	DI	DMA8DEG
DMA8DEG	DN	(RS)-PPCC
DMA8DEG	MI	TT5TPI6
DMA8DEG	MN	Opioid receptor sigma 1 (OPRS1)
DMA8DEG	MT	DTT
DMA8DEG	MA	Agonist
DMA8DEG	RN	Novel sigma receptor ligands: synthesis and biological profile. J Med Chem. 2007 Mar 8;50(5):951-61.
DMA8DEG	RU	https://pubmed.ncbi.nlm.nih.gov/17328523

DMCN6WR	DI	DMCN6WR
DMCN6WR	DN	(RS)-tacrine(10)-hupyridone
DMCN6WR	MI	TT1RS9F
DMCN6WR	MN	Acetylcholinesterase (AChE)
DMCN6WR	MT	DTT
DMCN6WR	MA	Inhibitor
DMCN6WR	RN	Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely... J Med Chem. 2008 Jun 12;51(11):3154-70.
DMCN6WR	RU	https://pubmed.ncbi.nlm.nih.gov/18479118

DMCN6WR	DI	DMCN6WR
DMCN6WR	DN	(RS)-tacrine(10)-hupyridone
DMCN6WR	MI	TTEB0GD
DMCN6WR	MN	Cholinesterase (BCHE)
DMCN6WR	MT	DTT
DMCN6WR	MA	Inhibitor
DMCN6WR	RN	Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely... J Med Chem. 2008 Jun 12;51(11):3154-70.
DMCN6WR	RU	https://pubmed.ncbi.nlm.nih.gov/18479118

DM6EYQ2	DI	DM6EYQ2
DM6EYQ2	DN	(RS/SR)-2-[1-(3,4-dichlorophenyl)butyl]piperidine
DM6EYQ2	MI	TTVBI8W
DM6EYQ2	MN	Dopamine transporter (DAT)
DM6EYQ2	MT	DTT
DM6EYQ2	MA	Inhibitor
DM6EYQ2	RN	Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter. J Med Chem. 2007 Jan 25;50(2):219-32.
DM6EYQ2	RU	https://pubmed.ncbi.nlm.nih.gov/17228864

DMGHWJ5	DI	DMGHWJ5
DMGHWJ5	DN	(RS/SR)-2-[1-(4-chlorophenyl)butyl]piperidine
DMGHWJ5	MI	TTVBI8W
DMGHWJ5	MN	Dopamine transporter (DAT)
DMGHWJ5	MT	DTT
DMGHWJ5	MA	Inhibitor
DMGHWJ5	RN	Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter. J Med Chem. 2007 Jan 25;50(2):219-32.
DMGHWJ5	RU	https://pubmed.ncbi.nlm.nih.gov/17228864

DMAIGM2	DI	DMAIGM2
DMAIGM2	DN	(RS/SR)-2-[1-(4-chlorophenyl)ethyl]piperidine
DMAIGM2	MI	TTVBI8W
DMAIGM2	MN	Dopamine transporter (DAT)
DMAIGM2	MT	DTT
DMAIGM2	MA	Inhibitor
DMAIGM2	RN	Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter. J Med Chem. 2007 Jan 25;50(2):219-32.
DMAIGM2	RU	https://pubmed.ncbi.nlm.nih.gov/17228864

DMDVMSP	DI	DMDVMSP
DMDVMSP	DN	(RS/SR)-2-[1-(4-chlorophenyl)hexyl]piperidine
DMDVMSP	MI	TTVBI8W
DMDVMSP	MN	Dopamine transporter (DAT)
DMDVMSP	MT	DTT
DMDVMSP	MA	Inhibitor
DMDVMSP	RN	Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter. J Med Chem. 2007 Jan 25;50(2):219-32.
DMDVMSP	RU	https://pubmed.ncbi.nlm.nih.gov/17228864

DMMUV7R	DI	DMMUV7R
DMMUV7R	DN	(RS/SR)-2-[1-(4-chlorophenyl)pentyl]piperidine
DMMUV7R	MI	TTVBI8W
DMMUV7R	MN	Dopamine transporter (DAT)
DMMUV7R	MT	DTT
DMMUV7R	MA	Inhibitor
DMMUV7R	RN	Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter. J Med Chem. 2007 Jan 25;50(2):219-32.
DMMUV7R	RU	https://pubmed.ncbi.nlm.nih.gov/17228864

DMPQAGL	DI	DMPQAGL
DMPQAGL	DN	(RS/SR)-2-[1-(4-chlorophenyl)propyl]piperidine
DMPQAGL	MI	TTVBI8W
DMPQAGL	MN	Dopamine transporter (DAT)
DMPQAGL	MT	DTT
DMPQAGL	MA	Inhibitor
DMPQAGL	RN	Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter. J Med Chem. 2007 Jan 25;50(2):219-32.
DMPQAGL	RU	https://pubmed.ncbi.nlm.nih.gov/17228864

DML1GP5	DI	DML1GP5
DML1GP5	DN	(S-(2-oxo)pentadecyl-CoA)
DML1GP5	MI	TTBAF05
DML1GP5	MN	Candida Peptide N-myristoyltransferase (Candi NMT1)
DML1GP5	MT	DTT
DML1GP5	MA	Inhibitor
DML1GP5	RN	Crystal structures of Saccharomyces cerevisiae N-myristoyltransferase with bound myristoyl-CoA and inhibitors reveal the functional roles of the N-... J Biol Chem. 2007 Jul 27;282(30):22185-94.
DML1GP5	RU	https://pubmed.ncbi.nlm.nih.gov/17513302

DMUNQY7	DI	DMUNQY7
DMUNQY7	DN	(S)-(-)-(4,5,6-trimethoxyindan-1-yl)methanamine
DMUNQY7	MI	TTJQOD7
DMUNQY7	MN	5-HT 2A receptor (HTR2A)
DMUNQY7	MT	DTT
DMUNQY7	MA	Inhibitor
DMUNQY7	RN	C-(4,5,6-trimethoxyindan-1-yl)methanamine: a mescaline analogue designed using a homology model of the 5-HT2A receptor. J Med Chem. 2006 Jul 13;49(14):4269-74.
DMUNQY7	RU	https://pubmed.ncbi.nlm.nih.gov/16821786

DMC5Z2I	DI	DMC5Z2I
DMC5Z2I	DN	(S)(+)-2-(4-fluorophenyl)-7-methoxychroman-4-one
DMC5Z2I	MI	TTGP7BY
DMC5Z2I	MN	Monoamine oxidase type B (MAO-B)
DMC5Z2I	MT	DTT
DMC5Z2I	MA	Inhibitor
DMC5Z2I	RN	A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9.
DMC5Z2I	RU	https://pubmed.ncbi.nlm.nih.gov/20045650

DMILWE7	DI	DMILWE7
DMILWE7	DN	(S)(+)-7-fluoro-2-(4-fluorophenyl)chroman-4-one
DMILWE7	MI	TTGP7BY
DMILWE7	MN	Monoamine oxidase type B (MAO-B)
DMILWE7	MT	DTT
DMILWE7	MA	Inhibitor
DMILWE7	RN	A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9.
DMILWE7	RU	https://pubmed.ncbi.nlm.nih.gov/20045650

DMHR1IB	DI	DMHR1IB
DMHR1IB	DN	(S)(+)-7-fluoro-2-phenylchroman-4-one
DMHR1IB	MI	TTGP7BY
DMHR1IB	MN	Monoamine oxidase type B (MAO-B)
DMHR1IB	MT	DTT
DMHR1IB	MA	Inhibitor
DMHR1IB	RN	A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9.
DMHR1IB	RU	https://pubmed.ncbi.nlm.nih.gov/20045650

DMTFZBQ	DI	DMTFZBQ
DMTFZBQ	DN	(S)(+)-7-fluoro-2-p-tolylchroman-4-one
DMTFZBQ	MI	TTGP7BY
DMTFZBQ	MN	Monoamine oxidase type B (MAO-B)
DMTFZBQ	MT	DTT
DMTFZBQ	MA	Inhibitor
DMTFZBQ	RN	A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9.
DMTFZBQ	RU	https://pubmed.ncbi.nlm.nih.gov/20045650

DMBG4KN	DI	DMBG4KN
DMBG4KN	DN	(S)(+)-7-methyl-2-phenylchroman-4-one
DMBG4KN	MI	TTGP7BY
DMBG4KN	MN	Monoamine oxidase type B (MAO-B)
DMBG4KN	MT	DTT
DMBG4KN	MA	Inhibitor
DMBG4KN	RN	A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9.
DMBG4KN	RU	https://pubmed.ncbi.nlm.nih.gov/20045650

DMVBD6H	DI	DMVBD6H
DMVBD6H	DN	(S)(+)-7-methyl-2-p-tolylchroman-4-one
DMVBD6H	MI	TTGP7BY
DMVBD6H	MN	Monoamine oxidase type B (MAO-B)
DMVBD6H	MT	DTT
DMVBD6H	MA	Inhibitor
DMVBD6H	RN	A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9.
DMVBD6H	RU	https://pubmed.ncbi.nlm.nih.gov/20045650

DMPDOY8	DI	DMPDOY8
DMPDOY8	DN	(S)-(+)-CBPG
DMPDOY8	MI	TTVBPDM
DMPDOY8	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMPDOY8	MT	DTT
DMPDOY8	MA	Antagonist
DMPDOY8	RN	Biochemical and electrophysiological studies on (S)-(+)-2-(3'-carboxybicyclo(1.1.1)pentyl)-glycine (CBPG), a novel mGlu5 receptor agonist endowed with mGlu1 receptor antagonist activity. Neuropharmacology. 1999 Jul;38(7):917-26.
DMPDOY8	RU	https://pubmed.ncbi.nlm.nih.gov/10428410

DMPDOY8	DI	DMPDOY8
DMPDOY8	DN	(S)-(+)-CBPG
DMPDOY8	MI	TTHS256
DMPDOY8	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMPDOY8	MT	DTT
DMPDOY8	MA	Agonist
DMPDOY8	RN	Biochemical and electrophysiological studies on (S)-(+)-2-(3'-carboxybicyclo(1.1.1)pentyl)-glycine (CBPG), a novel mGlu5 receptor agonist endowed with mGlu1 receptor antagonist activity. Neuropharmacology. 1999 Jul;38(7):917-26.
DMPDOY8	RU	https://pubmed.ncbi.nlm.nih.gov/10428410

DMF2IY8	DI	DMF2IY8
DMF2IY8	DN	(S)-1-(1H-indazol-4-yl)-3-(1-p-tolylethyl)urea
DMF2IY8	MI	TTMI6F5
DMF2IY8	MN	Transient receptor potential cation channel V1 (TRPV1)
DMF2IY8	MT	DTT
DMF2IY8	MA	Inhibitor
DMF2IY8	RN	Alpha-methylation at benzylic fragment of N-aryl-N'-benzyl ureas provides TRPV1 antagonists with better pharmacokinetic properties and higher effic... Bioorg Med Chem Lett. 2007 Jul 15;17(14):3894-9.
DMF2IY8	RU	https://pubmed.ncbi.nlm.nih.gov/17507218

DMF9YLR	DI	DMF9YLR
DMF9YLR	DN	(S)-1-(2-methoxyphenethyl)-2-methylpyrrolidine
DMF9YLR	MI	TT9JNIC
DMF9YLR	MN	Histamine H3 receptor (H3R)
DMF9YLR	MT	DTT
DMF9YLR	MA	Inhibitor
DMF9YLR	RN	In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9.
DMF9YLR	RU	https://pubmed.ncbi.nlm.nih.gov/18077160

DM8UWT9	DI	DM8UWT9
DM8UWT9	DN	(S)-1-(3-methoxyphenethyl)-2-methylpyrrolidine
DM8UWT9	MI	TT9JNIC
DM8UWT9	MN	Histamine H3 receptor (H3R)
DM8UWT9	MT	DTT
DM8UWT9	MA	Inhibitor
DM8UWT9	RN	In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9.
DM8UWT9	RU	https://pubmed.ncbi.nlm.nih.gov/18077160

DMDBHY1	DI	DMDBHY1
DMDBHY1	DN	(S)-1-(4-methoxyphenethyl)-2-methylpyrrolidine
DMDBHY1	MI	TT9JNIC
DMDBHY1	MN	Histamine H3 receptor (H3R)
DMDBHY1	MT	DTT
DMDBHY1	MA	Inhibitor
DMDBHY1	RN	In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9.
DMDBHY1	RU	https://pubmed.ncbi.nlm.nih.gov/18077160

DMG7XL5	DI	DMG7XL5
DMG7XL5	DN	(S)-1-(4-nitrophenethyl)-2-methylpyrrolidine
DMG7XL5	MI	TT9JNIC
DMG7XL5	MN	Histamine H3 receptor (H3R)
DMG7XL5	MT	DTT
DMG7XL5	MA	Inhibitor
DMG7XL5	RN	In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9.
DMG7XL5	RU	https://pubmed.ncbi.nlm.nih.gov/18077160

DMEIB8F	DI	DMEIB8F
DMEIB8F	DN	(S)-1-(5,6-difluoro-1H-indol-1-yl)propan-2-amine
DMEIB8F	MI	TTJQOD7
DMEIB8F	MN	5-HT 2A receptor (HTR2A)
DMEIB8F	MT	DTT
DMEIB8F	MA	Inhibitor
DMEIB8F	RN	Synthesis and structure-affinity relationships of novel small molecule natural product derivatives capable of discriminating between serotonin 5-HT1A, 5-HT2A, 5-HT2C receptor subtypes. Bioorg Med Chem. 2010 Jul 1;18(13):4783-92. 
DMEIB8F	RU	https://pubmed.ncbi.nlm.nih.gov/20570529

DMEIB8F	DI	DMEIB8F
DMEIB8F	DN	(S)-1-(5,6-difluoro-1H-indol-1-yl)propan-2-amine
DMEIB8F	MI	TTWJBZ5
DMEIB8F	MN	5-HT 2C receptor (HTR2C)
DMEIB8F	MT	DTT
DMEIB8F	MA	Inhibitor
DMEIB8F	RN	Synthesis and structure-affinity relationships of novel small molecule natural product derivatives capable of discriminating between serotonin 5-HT1A, 5-HT2A, 5-HT2C receptor subtypes. Bioorg Med Chem. 2010 Jul 1;18(13):4783-92. 
DMEIB8F	RU	https://pubmed.ncbi.nlm.nih.gov/20570529

DM1U7MC	DI	DM1U7MC
DM1U7MC	DN	(S)-1,7-Diphenyl-6(E)-hepten-3-ol
DM1U7MC	MI	TT50QJ3
DM1U7MC	MN	Influenza Neuraminidase (Influ NA)
DM1U7MC	MT	DTT
DM1U7MC	MA	Inhibitor
DM1U7MC	RN	Antiviral potential and molecular insight into neuraminidase inhibiting diarylheptanoids from Alpinia katsumadai. J Med Chem. 2010 Jan 28;53(2):778-86.
DM1U7MC	RU	https://pubmed.ncbi.nlm.nih.gov/20014777

DMICUQK	DI	DMICUQK
DMICUQK	DN	(S)-1-benzylcyclopentyl 1-oxohexan-2-ylcarbamate
DMICUQK	MI	TTF2LRI
DMICUQK	MN	Cathepsin B (CTSB)
DMICUQK	MT	DTT
DMICUQK	MA	Inhibitor
DMICUQK	RN	Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors Bioorg Med Chem Lett. 2006 Feb 15;16(4):978-83.
DMICUQK	RU	https://pubmed.ncbi.nlm.nih.gov/16290936

DMICUQK	DI	DMICUQK
DMICUQK	DN	(S)-1-benzylcyclopentyl 1-oxohexan-2-ylcarbamate
DMICUQK	MI	TTDZN01
DMICUQK	MN	Cathepsin K (CTSK)
DMICUQK	MT	DTT
DMICUQK	MA	Inhibitor
DMICUQK	RN	Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors Bioorg Med Chem Lett. 2006 Feb 15;16(4):978-83.
DMICUQK	RU	https://pubmed.ncbi.nlm.nih.gov/16290936

DMICUQK	DI	DMICUQK
DMICUQK	DN	(S)-1-benzylcyclopentyl 1-oxohexan-2-ylcarbamate
DMICUQK	MI	TT36ETB
DMICUQK	MN	Cathepsin L (CTSL)
DMICUQK	MT	DTT
DMICUQK	MA	Inhibitor
DMICUQK	RN	Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors Bioorg Med Chem Lett. 2006 Feb 15;16(4):978-83.
DMICUQK	RU	https://pubmed.ncbi.nlm.nih.gov/16290936

DM2VOAS	DI	DM2VOAS
DM2VOAS	DN	(S)-2-((4-phenoxyphenoxy)methyl)piperidine
DM2VOAS	MI	TTXZEAJ
DM2VOAS	MN	Leukotriene A-4 hydrolase (LTA4H)
DM2VOAS	MT	DTT
DM2VOAS	MA	Inhibitor
DM2VOAS	RN	Discovery of novel leukotriene A4 hydrolase inhibitors based on piperidine and piperazine scaffolds. Bioorg Med Chem Lett. 2010 May 1;20(9):2851-4.
DM2VOAS	RU	https://pubmed.ncbi.nlm.nih.gov/20371179

DMQGCKX	DI	DMQGCKX
DMQGCKX	DN	(S)-2-(2-(2-methylpyrrolidin-1-yl)ethyl)phenol
DMQGCKX	MI	TT9JNIC
DMQGCKX	MN	Histamine H3 receptor (H3R)
DMQGCKX	MT	DTT
DMQGCKX	MA	Inhibitor
DMQGCKX	RN	In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9.
DMQGCKX	RU	https://pubmed.ncbi.nlm.nih.gov/18077160

DMVKL84	DI	DMVKL84
DMVKL84	DN	(S)-2-(2-(2-methylpyrrolidin-1-yl)ethyl)pyridine
DMVKL84	MI	TT9JNIC
DMVKL84	MN	Histamine H3 receptor (H3R)
DMVKL84	MT	DTT
DMVKL84	MA	Inhibitor
DMVKL84	RN	In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9.
DMVKL84	RU	https://pubmed.ncbi.nlm.nih.gov/18077160

DMPQ53V	DI	DMPQ53V
DMPQ53V	DN	(S)-2-amino-1-(4-butylthiophenyl)-propane
DMPQ53V	MI	TT3WG5C
DMPQ53V	MN	Monoamine oxidase type A (MAO-A)
DMPQ53V	MT	DTT
DMPQ53V	MA	Inhibitor
DMPQ53V	RN	Human and rat monoamine oxidase-A are differentially inhibited by (S)-4-alkylthioamphetamine derivatives: insights from molecular modeling studies. Bioorg Med Chem. 2007 Aug 1;15(15):5198-206.
DMPQ53V	RU	https://pubmed.ncbi.nlm.nih.gov/17521909

DMPQ53V	DI	DMPQ53V
DMPQ53V	DN	(S)-2-amino-1-(4-butylthiophenyl)-propane
DMPQ53V	MI	TTGP7BY
DMPQ53V	MN	Monoamine oxidase type B (MAO-B)
DMPQ53V	MT	DTT
DMPQ53V	MA	Inhibitor
DMPQ53V	RN	Human and rat monoamine oxidase-A are differentially inhibited by (S)-4-alkylthioamphetamine derivatives: insights from molecular modeling studies. Bioorg Med Chem. 2007 Aug 1;15(15):5198-206.
DMPQ53V	RU	https://pubmed.ncbi.nlm.nih.gov/17521909

DMFK7O1	DI	DMFK7O1
DMFK7O1	DN	(S)-2-amino-1-(4-ethylthiophenyl)-propane
DMFK7O1	MI	TT3WG5C
DMFK7O1	MN	Monoamine oxidase type A (MAO-A)
DMFK7O1	MT	DTT
DMFK7O1	MA	Inhibitor
DMFK7O1	RN	Human and rat monoamine oxidase-A are differentially inhibited by (S)-4-alkylthioamphetamine derivatives: insights from molecular modeling studies. Bioorg Med Chem. 2007 Aug 1;15(15):5198-206.
DMFK7O1	RU	https://pubmed.ncbi.nlm.nih.gov/17521909

DM06NUM	DI	DM06NUM
DM06NUM	DN	(S)-2-amino-1-(4-methylthiophenyl)-propane
DM06NUM	MI	TT3WG5C
DM06NUM	MN	Monoamine oxidase type A (MAO-A)
DM06NUM	MT	DTT
DM06NUM	MA	Inhibitor
DM06NUM	RN	Human and rat monoamine oxidase-A are differentially inhibited by (S)-4-alkylthioamphetamine derivatives: insights from molecular modeling studies. Bioorg Med Chem. 2007 Aug 1;15(15):5198-206.
DM06NUM	RU	https://pubmed.ncbi.nlm.nih.gov/17521909

DMAN7YJ	DI	DMAN7YJ
DMAN7YJ	DN	(S)-2-amino-1-(4-propylthiophenyl)-propane
DMAN7YJ	MI	TT3WG5C
DMAN7YJ	MN	Monoamine oxidase type A (MAO-A)
DMAN7YJ	MT	DTT
DMAN7YJ	MA	Inhibitor
DMAN7YJ	RN	Human and rat monoamine oxidase-A are differentially inhibited by (S)-4-alkylthioamphetamine derivatives: insights from molecular modeling studies. Bioorg Med Chem. 2007 Aug 1;15(15):5198-206.
DMAN7YJ	RU	https://pubmed.ncbi.nlm.nih.gov/17521909

DMAN7YJ	DI	DMAN7YJ
DMAN7YJ	DN	(S)-2-amino-1-(4-propylthiophenyl)-propane
DMAN7YJ	MI	TTGP7BY
DMAN7YJ	MN	Monoamine oxidase type B (MAO-B)
DMAN7YJ	MT	DTT
DMAN7YJ	MA	Inhibitor
DMAN7YJ	RN	Human and rat monoamine oxidase-A are differentially inhibited by (S)-4-alkylthioamphetamine derivatives: insights from molecular modeling studies. Bioorg Med Chem. 2007 Aug 1;15(15):5198-206.
DMAN7YJ	RU	https://pubmed.ncbi.nlm.nih.gov/17521909

DMWBH9N	DI	DMWBH9N
DMWBH9N	DN	(S)-2-Amino-1-azetidin-1-yl-2-cyclohexyl-ethanone
DMWBH9N	MI	TTDIGC1
DMWBH9N	MN	Dipeptidyl peptidase 4 (DPP-4)
DMWBH9N	MT	DTT
DMWBH9N	MA	Inhibitor
DMWBH9N	RN	New fluorinated pyrrolidine and azetidine amides as dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4770-3.
DMWBH9N	RU	https://pubmed.ncbi.nlm.nih.gov/16115768

DMORFZE	DI	DMORFZE
DMORFZE	DN	(S)-2-Amino-1-thiazolidin-3-yl-propane-1-thione
DMORFZE	MI	TTDIGC1
DMORFZE	MN	Dipeptidyl peptidase 4 (DPP-4)
DMORFZE	MT	DTT
DMORFZE	MA	Inhibitor
DMORFZE	RN	Development of potent and selective dipeptidyl peptidase II inhibitors. Bioorg Med Chem Lett. 2002 Oct 21;12(20):2825-8.
DMORFZE	RU	https://pubmed.ncbi.nlm.nih.gov/12270155

DMVD05E	DI	DMVD05E
DMVD05E	DN	(S)-2-amino-2-cyclohexylacetic acid
DMVD05E	MI	TTFK1JQ
DMVD05E	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMVD05E	MT	DTT
DMVD05E	MA	Inhibitor
DMVD05E	RN	Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41.
DMVD05E	RU	https://pubmed.ncbi.nlm.nih.gov/16380257

DMG9KMN	DI	DMG9KMN
DMG9KMN	DN	(S)-2-amino-2-o-tolylacetic acid
DMG9KMN	MI	TTFK1JQ
DMG9KMN	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMG9KMN	MT	DTT
DMG9KMN	MA	Inhibitor
DMG9KMN	RN	Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41.
DMG9KMN	RU	https://pubmed.ncbi.nlm.nih.gov/16380257

DMFEGPX	DI	DMFEGPX
DMFEGPX	DN	(S)-2-Amino-2-phenyl-ethanethiol
DMFEGPX	MI	TTPHMWB
DMFEGPX	MN	Aminopeptidase N (ANPEP)
DMFEGPX	MT	DTT
DMFEGPX	MA	Inhibitor
DMFEGPX	RN	Design of the first highly potent and selective aminopeptidase N (EC 3.4.11.2) inhibitor. Bioorg Med Chem Lett. 1999 Jun 7;9(11):1511-6.
DMFEGPX	RU	https://pubmed.ncbi.nlm.nih.gov/10386926

DM2104G	DI	DM2104G
DM2104G	DN	(S)-2-amino-2-phenylpropanoic acid
DM2104G	MI	TTFK1JQ
DM2104G	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DM2104G	MT	DTT
DM2104G	MA	Inhibitor
DM2104G	RN	Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41.
DM2104G	RU	https://pubmed.ncbi.nlm.nih.gov/16380257

DMCDZ8A	DI	DMCDZ8A
DMCDZ8A	DN	(S)-2-amino-2-p-tolylacetic acid
DMCDZ8A	MI	TTFK1JQ
DMCDZ8A	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMCDZ8A	MT	DTT
DMCDZ8A	MA	Inhibitor
DMCDZ8A	RN	Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41.
DMCDZ8A	RU	https://pubmed.ncbi.nlm.nih.gov/16380257

DM6OUW0	DI	DM6OUW0
DM6OUW0	DN	(S)-2-amino-3-(benzylthio)propanoic acid
DM6OUW0	MI	TTFK1JQ
DM6OUW0	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DM6OUW0	MT	DTT
DM6OUW0	MA	Inhibitor
DM6OUW0	RN	Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41.
DM6OUW0	RU	https://pubmed.ncbi.nlm.nih.gov/16380257

DM1GBX8	DI	DM1GBX8
DM1GBX8	DN	(S)-2-amino-3-cyclohexylpropanoic acid
DM1GBX8	MI	TTFK1JQ
DM1GBX8	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DM1GBX8	MT	DTT
DM1GBX8	MA	Inhibitor
DM1GBX8	RN	Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41.
DM1GBX8	RU	https://pubmed.ncbi.nlm.nih.gov/16380257

DMMAUKO	DI	DMMAUKO
DMMAUKO	DN	(S)-2-Amino-3-phenyl-propane-1-thiol
DMMAUKO	MI	TTPHMWB
DMMAUKO	MN	Aminopeptidase N (ANPEP)
DMMAUKO	MT	DTT
DMMAUKO	MA	Inhibitor
DMMAUKO	RN	Design of the first highly potent and selective aminopeptidase N (EC 3.4.11.2) inhibitor. Bioorg Med Chem Lett. 1999 Jun 7;9(11):1511-6.
DMMAUKO	RU	https://pubmed.ncbi.nlm.nih.gov/10386926

DMF8I2W	DI	DMF8I2W
DMF8I2W	DN	(S)-2-amino-4-(benzylthio)butanoic acid
DMF8I2W	MI	TTFK1JQ
DMF8I2W	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMF8I2W	MT	DTT
DMF8I2W	MA	Inhibitor
DMF8I2W	RN	Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41.
DMF8I2W	RU	https://pubmed.ncbi.nlm.nih.gov/16380257

DM8A1HG	DI	DM8A1HG
DM8A1HG	DN	(S)-2-amino-4-hydroxy-N-(4-octylphenyl)butanamide
DM8A1HG	MI	TTCN0M9
DM8A1HG	MN	Sphingosine kinase 2 (SPHK2)
DM8A1HG	MT	DTT
DM8A1HG	MA	Inhibitor
DM8A1HG	RN	Discovery of novel sphingosine kinase 1 inhibitors. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6119-21.
DM8A1HG	RU	https://pubmed.ncbi.nlm.nih.gov/19800228

DM96XYI	DI	DM96XYI
DM96XYI	DN	(S)-2-Amino-4-methyl-pentane-1-thiol
DM96XYI	MI	TTPHMWB
DM96XYI	MN	Aminopeptidase N (ANPEP)
DM96XYI	MT	DTT
DM96XYI	MA	Inhibitor
DM96XYI	RN	Design of the first highly potent and selective aminopeptidase N (EC 3.4.11.2) inhibitor. Bioorg Med Chem Lett. 1999 Jun 7;9(11):1511-6.
DM96XYI	RU	https://pubmed.ncbi.nlm.nih.gov/10386926

DMOVQ1T	DI	DMOVQ1T
DMOVQ1T	DN	(S)-2-Amino-4-methylsulfanyl-butane-1-thiol
DMOVQ1T	MI	TTPHMWB
DMOVQ1T	MN	Aminopeptidase N (ANPEP)
DMOVQ1T	MT	DTT
DMOVQ1T	MA	Inhibitor
DMOVQ1T	RN	Design of the first highly potent and selective aminopeptidase N (EC 3.4.11.2) inhibitor. Bioorg Med Chem Lett. 1999 Jun 7;9(11):1511-6.
DMOVQ1T	RU	https://pubmed.ncbi.nlm.nih.gov/10386926

DMJEGMI	DI	DMJEGMI
DMJEGMI	DN	(S)-2-Amino-4-phenyl-butane-1-thiol
DMJEGMI	MI	TTPHMWB
DMJEGMI	MN	Aminopeptidase N (ANPEP)
DMJEGMI	MT	DTT
DMJEGMI	MA	Inhibitor
DMJEGMI	RN	Design of the first highly potent and selective aminopeptidase N (EC 3.4.11.2) inhibitor. Bioorg Med Chem Lett. 1999 Jun 7;9(11):1511-6.
DMJEGMI	RU	https://pubmed.ncbi.nlm.nih.gov/10386926

DMZSWDM	DI	DMZSWDM
DMZSWDM	DN	(S)-2-Amino-5-(N-methyl-guanidino)-pentanoic acid
DMZSWDM	MI	TTZUFI5
DMZSWDM	MN	Nitric-oxide synthase brain (NOS1)
DMZSWDM	MT	DTT
DMZSWDM	MA	Inhibitor
DMZSWDM	RN	2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. J Med Chem. 1996 Feb 2;39(3):669-72.
DMZSWDM	RU	https://pubmed.ncbi.nlm.nih.gov/8576908

DMZSWDM	DI	DMZSWDM
DMZSWDM	DN	(S)-2-Amino-5-(N-methyl-guanidino)-pentanoic acid
DMZSWDM	MI	TTCM4B3
DMZSWDM	MN	Nitric-oxide synthase endothelial (NOS3)
DMZSWDM	MT	DTT
DMZSWDM	MA	Inhibitor
DMZSWDM	RN	2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. J Med Chem. 1996 Feb 2;39(3):669-72.
DMZSWDM	RU	https://pubmed.ncbi.nlm.nih.gov/8576908

DMZSWDM	DI	DMZSWDM
DMZSWDM	DN	(S)-2-Amino-5-(N-methyl-guanidino)-pentanoic acid
DMZSWDM	MI	TTF10I9
DMZSWDM	MN	Nitric-oxide synthase inducible (NOS2)
DMZSWDM	MT	DTT
DMZSWDM	MA	Inhibitor
DMZSWDM	RN	2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. J Med Chem. 1996 Feb 2;39(3):669-72.
DMZSWDM	RU	https://pubmed.ncbi.nlm.nih.gov/8576908

DMRG80O	DI	DMRG80O
DMRG80O	DN	(S)-2-Amino-6-[(E)-ethylimino]-hexanoic acid
DMRG80O	MI	TTF10I9
DMRG80O	MN	Nitric-oxide synthase inducible (NOS2)
DMRG80O	MT	DTT
DMRG80O	MA	Inhibitor
DMRG80O	RN	2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. J Med Chem. 1996 Feb 2;39(3):669-72.
DMRG80O	RU	https://pubmed.ncbi.nlm.nih.gov/8576908

DMG0CSZ	DI	DMG0CSZ
DMG0CSZ	DN	(S)-2-amino-6-hydroxy-N-(4-octylphenyl)hexanamide
DMG0CSZ	MI	TTCN0M9
DMG0CSZ	MN	Sphingosine kinase 2 (SPHK2)
DMG0CSZ	MT	DTT
DMG0CSZ	MA	Inhibitor
DMG0CSZ	RN	Discovery of novel sphingosine kinase 1 inhibitors. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6119-21.
DMG0CSZ	RU	https://pubmed.ncbi.nlm.nih.gov/19800228

DMN1G8L	DI	DMN1G8L
DMN1G8L	DN	(S)-2-amino-N-(1-cyano-2-phenylethyl)acetamide
DMN1G8L	MI	TT4H0V2
DMN1G8L	MN	Dipeptidyl peptidase I (CTSC)
DMN1G8L	MT	DTT
DMN1G8L	MA	Inhibitor
DMN1G8L	RN	Dipeptidyl nitriles as human dipeptidyl peptidase I inhibitors. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3614-7.
DMN1G8L	RU	https://pubmed.ncbi.nlm.nih.gov/16647256

DMDWFHV	DI	DMDWFHV
DMDWFHV	DN	(S)-2-Amino-N-cyclopentyl-7-mercaptoheptanamide
DMDWFHV	MI	TT5ZKDI
DMDWFHV	MN	Histone deacetylase 6 (HDAC6)
DMDWFHV	MT	DTT
DMDWFHV	MA	Inhibitor
DMDWFHV	RN	Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhib... J Med Chem. 2007 Nov 1;50(22):5425-38.
DMDWFHV	RU	https://pubmed.ncbi.nlm.nih.gov/17929798

DMYG8EV	DI	DMYG8EV
DMYG8EV	DN	(S)-2-Amino-propane-1-thiol
DMYG8EV	MI	TTPHMWB
DMYG8EV	MN	Aminopeptidase N (ANPEP)
DMYG8EV	MT	DTT
DMYG8EV	MA	Inhibitor
DMYG8EV	RN	Design of the first highly potent and selective aminopeptidase N (EC 3.4.11.2) inhibitor. Bioorg Med Chem Lett. 1999 Jun 7;9(11):1511-6.
DMYG8EV	RU	https://pubmed.ncbi.nlm.nih.gov/10386926

DMQGCM3	DI	DMQGCM3
DMQGCM3	DN	(S)-2-methyl-1-(2-m-tolyl-ethyl)-pyrrolidine
DMQGCM3	MI	TT9JNIC
DMQGCM3	MN	Histamine H3 receptor (H3R)
DMQGCM3	MT	DTT
DMQGCM3	MA	Inhibitor
DMQGCM3	RN	In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9.
DMQGCM3	RU	https://pubmed.ncbi.nlm.nih.gov/18077160

DMJFI75	DI	DMJFI75
DMJFI75	DN	(S)-2-methyl-1-(2-p-tolyl-ethyl)-pyrrolidine
DMJFI75	MI	TT9JNIC
DMJFI75	MN	Histamine H3 receptor (H3R)
DMJFI75	MT	DTT
DMJFI75	MA	Inhibitor
DMJFI75	RN	In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9.
DMJFI75	RU	https://pubmed.ncbi.nlm.nih.gov/18077160

DMS5IHX	DI	DMS5IHX
DMS5IHX	DN	(S)-3-(1'-Adamantanecarbonyl)amino-caprolactam
DMS5IHX	MI	TTFZYTO
DMS5IHX	MN	C-C chemokine receptor type 2 (CCR2)
DMS5IHX	MT	DTT
DMS5IHX	MA	Inhibitor
DMS5IHX	RN	Highly potent, orally available anti-inflammatory broad-spectrum chemokine inhibitors. J Med Chem. 2009 Jun 11;52(11):3591-5.
DMS5IHX	RU	https://pubmed.ncbi.nlm.nih.gov/19425597

DM435QN	DI	DM435QN
DM435QN	DN	(S)-3-(1H-imidazol-4-yl)propyl sec-butylcarbamate
DM435QN	MI	TT9JNIC
DM435QN	MN	Histamine H3 receptor (H3R)
DM435QN	MT	DTT
DM435QN	MA	Inhibitor
DM435QN	RN	Histamine H3 and H4 receptor affinity of branched 3-(1H-imidazol-4-yl)propyl N-alkylcarbamates. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6682-5.
DM435QN	RU	https://pubmed.ncbi.nlm.nih.gov/19846299

DMANICH	DI	DMANICH
DMANICH	DN	(S)-3-(2',2'-Dimethyl-propionyl)amino-caprolactam
DMANICH	MI	TTFZYTO
DMANICH	MN	C-C chemokine receptor type 2 (CCR2)
DMANICH	MT	DTT
DMANICH	MA	Inhibitor
DMANICH	RN	Highly potent, orally available anti-inflammatory broad-spectrum chemokine inhibitors. J Med Chem. 2009 Jun 11;52(11):3591-5.
DMANICH	RU	https://pubmed.ncbi.nlm.nih.gov/19425597

DMTBG57	DI	DMTBG57
DMTBG57	DN	(S)-3-(aminomethyl)-4-(furan-2-yl)butanoic acid
DMTBG57	MI	TTFK1JQ
DMTBG57	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMTBG57	MT	DTT
DMTBG57	MA	Inhibitor
DMTBG57	RN	Heteroaromatic side-chain analogs of pregabalin. Bioorg Med Chem Lett. 2006 May 1;16(9):2329-32.
DMTBG57	RU	https://pubmed.ncbi.nlm.nih.gov/16099652

DMB9CQL	DI	DMB9CQL
DMB9CQL	DN	(S)-3-(azetidin-2-ylmethoxy)-2-fluoropyridine
DMB9CQL	MI	TTF4E0J
DMB9CQL	MN	Neuronal acetylcholine receptor alpha-2 (CHRNA2)
DMB9CQL	MT	DTT
DMB9CQL	MA	Inhibitor
DMB9CQL	RN	Synthesis and biological evaluation of novel carbon-11 labeled pyridyl ethers: candidate ligands for in vivo imaging of alpha4beta2 nicotinic acety... Bioorg Med Chem. 2009 Jul 1;17(13):4367-77.
DMB9CQL	RU	https://pubmed.ncbi.nlm.nih.gov/19481945

DM5ILK1	DI	DM5ILK1
DM5ILK1	DN	(S)-3-(naphthalen-2-ylmethoxy)pyrrolidine
DM5ILK1	MI	TTVBI8W
DM5ILK1	MN	Dopamine transporter (DAT)
DM5ILK1	MT	DTT
DM5ILK1	MA	Inhibitor
DM5ILK1	RN	Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32.
DM5ILK1	RU	https://pubmed.ncbi.nlm.nih.gov/19282174

DM5ILK1	DI	DM5ILK1
DM5ILK1	DN	(S)-3-(naphthalen-2-ylmethoxy)pyrrolidine
DM5ILK1	MI	TTAWNKZ
DM5ILK1	MN	Norepinephrine transporter (NET)
DM5ILK1	MT	DTT
DM5ILK1	MA	Inhibitor
DM5ILK1	RN	Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32.
DM5ILK1	RU	https://pubmed.ncbi.nlm.nih.gov/19282174

DM5ILK1	DI	DM5ILK1
DM5ILK1	DN	(S)-3-(naphthalen-2-ylmethoxy)pyrrolidine
DM5ILK1	MI	TT3ROYC
DM5ILK1	MN	Serotonin transporter (SERT)
DM5ILK1	MT	DTT
DM5ILK1	MA	Inhibitor
DM5ILK1	RN	Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32.
DM5ILK1	RU	https://pubmed.ncbi.nlm.nih.gov/19282174

DM5ILK1	DI	DM5ILK1
DM5ILK1	DN	(S)-3-(naphthalen-2-ylmethoxy)pyrrolidine
DM5ILK1	MI	TTQ6VDM
DM5ILK1	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DM5ILK1	MT	DTT
DM5ILK1	MA	Inhibitor
DM5ILK1	RN	Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32.
DM5ILK1	RU	https://pubmed.ncbi.nlm.nih.gov/19282174

DMG5BUA	DI	DMG5BUA
DMG5BUA	DN	(S)-3,4-DCPG
DMG5BUA	MI	TTICZ1O
DMG5BUA	MN	Metabotropic glutamate receptor 4 (mGluR4)
DMG5BUA	MT	DTT
DMG5BUA	MA	Agonist
DMG5BUA	RN	(S)-3,4-DCPG, a potent and selective mGlu8a receptor agonist, activates metabotropic glutamate receptors on primary afferent terminals in the neonatal rat spinal cord. Neuropharmacology. 2001 Mar;40(3):311-8.
DMG5BUA	RU	https://pubmed.ncbi.nlm.nih.gov/11166323

DMG5BUA	DI	DMG5BUA
DMG5BUA	DN	(S)-3,4-DCPG
DMG5BUA	MI	TTWRP2F
DMG5BUA	MN	Metabotropic glutamate receptor 6 (mGluR6)
DMG5BUA	MT	DTT
DMG5BUA	MA	Agonist
DMG5BUA	RN	(S)-3,4-DCPG, a potent and selective mGlu8a receptor agonist, activates metabotropic glutamate receptors on primary afferent terminals in the neonatal rat spinal cord. Neuropharmacology. 2001 Mar;40(3):311-8.
DMG5BUA	RU	https://pubmed.ncbi.nlm.nih.gov/11166323

DMG5BUA	DI	DMG5BUA
DMG5BUA	DN	(S)-3,4-DCPG
DMG5BUA	MI	TT0IFKL
DMG5BUA	MN	Metabotropic glutamate receptor 8 (mGluR8)
DMG5BUA	MT	DTT
DMG5BUA	MA	Agonist
DMG5BUA	RN	(S)-3,4-DCPG, a potent and selective mGlu8a receptor agonist, activates metabotropic glutamate receptors on primary afferent terminals in the neonatal rat spinal cord. Neuropharmacology. 2001 Mar;40(3):311-8.
DMG5BUA	RU	https://pubmed.ncbi.nlm.nih.gov/11166323

DMQ0FVJ	DI	DMQ0FVJ
DMQ0FVJ	DN	(S)-3HPG
DMQ0FVJ	MI	TTVBPDM
DMQ0FVJ	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMQ0FVJ	MT	DTT
DMQ0FVJ	MA	Agonist
DMQ0FVJ	RN	Characterization of [(3)H]Quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections. J Neurochem. 2000 Dec;75(6):2590-601.
DMQ0FVJ	RU	https://pubmed.ncbi.nlm.nih.gov/11080213

DMQ0FVJ	DI	DMQ0FVJ
DMQ0FVJ	DN	(S)-3HPG
DMQ0FVJ	MI	TTHS256
DMQ0FVJ	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMQ0FVJ	MT	DTT
DMQ0FVJ	MA	Agonist
DMQ0FVJ	RN	Characterization of [(3)H]Quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections. J Neurochem. 2000 Dec;75(6):2590-601.
DMQ0FVJ	RU	https://pubmed.ncbi.nlm.nih.gov/11080213

DM3TW9V	DI	DM3TW9V
DM3TW9V	DN	(S)-3-hydroxy-3-methylglutaryl-CoA
DM3TW9V	MI	TTQF4TK
DM3TW9V	MN	Hydroxymethylglutaryl-CoA synthase 1 (HMGCS1)
DM3TW9V	MT	DTT
DM3TW9V	MA	Inhibitor
DM3TW9V	RN	A visible wavelength spectrophotometric assay suitable for high-throughput screening of 3-hydroxy-3-methylglutaryl-CoA synthase. Anal Biochem. 2010 Jan 1;396(1):96-102.
DM3TW9V	RU	https://pubmed.ncbi.nlm.nih.gov/19706283

DMS4JAG	DI	DMS4JAG
DMS4JAG	DN	(S)-3-Methyl-1,2,3,4-tetrahydro-isoquinoline
DMS4JAG	MI	TTWG9A4
DMS4JAG	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMS4JAG	MT	DTT
DMS4JAG	MA	Inhibitor
DMS4JAG	RN	Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46.
DMS4JAG	RU	https://pubmed.ncbi.nlm.nih.gov/8784452

DMS4JAG	DI	DMS4JAG
DMS4JAG	DN	(S)-3-Methyl-1,2,3,4-tetrahydro-isoquinoline
DMS4JAG	MI	TTWM4TY
DMS4JAG	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMS4JAG	MT	DTT
DMS4JAG	MA	Inhibitor
DMS4JAG	RN	Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46.
DMS4JAG	RU	https://pubmed.ncbi.nlm.nih.gov/8784452

DMS4JAG	DI	DMS4JAG
DMS4JAG	DN	(S)-3-Methyl-1,2,3,4-tetrahydro-isoquinoline
DMS4JAG	MI	TT2NUT5
DMS4JAG	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMS4JAG	MT	DTT
DMS4JAG	MA	Inhibitor
DMS4JAG	RN	Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46.
DMS4JAG	RU	https://pubmed.ncbi.nlm.nih.gov/8784452

DMIG9H3	DI	DMIG9H3
DMIG9H3	DN	(S)-3-Propyl-[1,4]thiazepan-(5E)-ylideneamine
DMIG9H3	MI	TTZUFI5
DMIG9H3	MN	Nitric-oxide synthase brain (NOS1)
DMIG9H3	MT	DTT
DMIG9H3	MA	Inhibitor
DMIG9H3	RN	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
DMIG9H3	RU	https://pubmed.ncbi.nlm.nih.gov/15501067

DMIG9H3	DI	DMIG9H3
DMIG9H3	DN	(S)-3-Propyl-[1,4]thiazepan-(5E)-ylideneamine
DMIG9H3	MI	TTCM4B3
DMIG9H3	MN	Nitric-oxide synthase endothelial (NOS3)
DMIG9H3	MT	DTT
DMIG9H3	MA	Inhibitor
DMIG9H3	RN	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
DMIG9H3	RU	https://pubmed.ncbi.nlm.nih.gov/15501067

DMIG9H3	DI	DMIG9H3
DMIG9H3	DN	(S)-3-Propyl-[1,4]thiazepan-(5E)-ylideneamine
DMIG9H3	MI	TTF10I9
DMIG9H3	MN	Nitric-oxide synthase inducible (NOS2)
DMIG9H3	MT	DTT
DMIG9H3	MA	Inhibitor
DMIG9H3	RN	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
DMIG9H3	RU	https://pubmed.ncbi.nlm.nih.gov/15501067

DMLZBJT	DI	DMLZBJT
DMLZBJT	DN	(S)-4-(2-(2-methylpyrrolidin-1-yl)ethyl)pyridine
DMLZBJT	MI	TT9JNIC
DMLZBJT	MN	Histamine H3 receptor (H3R)
DMLZBJT	MT	DTT
DMLZBJT	MA	Inhibitor
DMLZBJT	RN	In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9.
DMLZBJT	RU	https://pubmed.ncbi.nlm.nih.gov/18077160

DMN9YXL	DI	DMN9YXL
DMN9YXL	DN	(S)-4-AHCP
DMN9YXL	MI	TT0MYE2
DMN9YXL	MN	Glutamate receptor ionotropic kainate 1 (GRIK1)
DMN9YXL	MT	DTT
DMN9YXL	MA	Agonist
DMN9YXL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 450).
DMN9YXL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=450

DMQK4I2	DI	DMQK4I2
DMQK4I2	DN	(S)-4C3HPG
DMQK4I2	MI	TTVBPDM
DMQK4I2	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMQK4I2	MT	DTT
DMQK4I2	MA	Antagonist
DMQK4I2	RN	Characterization of [(3)H]Quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections. J Neurochem. 2000 Dec;75(6):2590-601.
DMQK4I2	RU	https://pubmed.ncbi.nlm.nih.gov/11080213

DMQK4I2	DI	DMQK4I2
DMQK4I2	DN	(S)-4C3HPG
DMQK4I2	MI	TTXJ47W
DMQK4I2	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMQK4I2	MT	DTT
DMQK4I2	MA	Agonist
DMQK4I2	RN	Characterization of [3H]-(2S,2'R,3'R)-2-(2',3'-dicarboxy-cyclopropyl)glycine ([3H]-DCG IV) binding to metabotropic mGlu2 receptor-transfected cell membranes. Br J Pharmacol. 1998 Feb;123(3):497-504.
DMQK4I2	RU	https://pubmed.ncbi.nlm.nih.gov/9504391

DMQK4I2	DI	DMQK4I2
DMQK4I2	DN	(S)-4C3HPG
DMQK4I2	MI	TTHS256
DMQK4I2	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMQK4I2	MT	DTT
DMQK4I2	MA	Antagonist
DMQK4I2	RN	Characterization of [(3)H]Quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections. J Neurochem. 2000 Dec;75(6):2590-601.
DMQK4I2	RU	https://pubmed.ncbi.nlm.nih.gov/11080213

DMI12X9	DI	DMI12X9
DMI12X9	DN	(S)-4-CMTB
DMI12X9	MI	TT0FYAN
DMI12X9	MN	Free fatty acid receptor 2 (FFAR2)
DMI12X9	MT	DTT
DMI12X9	MA	Agonist
DMI12X9	RN	Extracellular ionic locks determine variation in constitutive activity and ligand potency between species orthologs of the free fatty acid receptors FFA2 and FFA3. J Biol Chem. 2012 Nov 30;287(49):41195-209.
DMI12X9	RU	https://pubmed.ncbi.nlm.nih.gov/23066016

DMI12X9	DI	DMI12X9
DMI12X9	DN	(S)-4-CMTB
DMI12X9	MI	TTXDOHN
DMI12X9	MN	Free fatty acid receptor 3 (FFAR3)
DMI12X9	MT	DTT
DMI12X9	MA	Agonist
DMI12X9	RN	Identification and functional characterization of allosteric agonists for the G protein-coupled receptor FFA2. Mol Pharmacol. 2008 Dec;74(6):1599-609.
DMI12X9	RU	https://pubmed.ncbi.nlm.nih.gov/18818303

DMZ9UIL	DI	DMZ9UIL
DMZ9UIL	DN	(S)-4CPG
DMZ9UIL	MI	TTVBPDM
DMZ9UIL	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMZ9UIL	MT	DTT
DMZ9UIL	MA	Antagonist
DMZ9UIL	RN	[3H]R214127: a novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists. Mol Pharmacol. 2003 May;63(5):1082-93.
DMZ9UIL	RU	https://pubmed.ncbi.nlm.nih.gov/12695537

DMZ9UIL	DI	DMZ9UIL
DMZ9UIL	DN	(S)-4CPG
DMZ9UIL	MI	TTHS256
DMZ9UIL	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMZ9UIL	MT	DTT
DMZ9UIL	MA	Antagonist
DMZ9UIL	RN	Characterization of [(3)H]Quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections. J Neurochem. 2000 Dec;75(6):2590-601.
DMZ9UIL	RU	https://pubmed.ncbi.nlm.nih.gov/11080213

DMCIZ7P	DI	DMCIZ7P
DMCIZ7P	DN	(S)-5-fluorowillardiine
DMCIZ7P	MI	TTVPQTF
DMCIZ7P	MN	Glutamate receptor AMPA 1 (GRIA1)
DMCIZ7P	MT	DTT
DMCIZ7P	MA	Agonist
DMCIZ7P	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 444).
DMCIZ7P	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=444

DMCIZ7P	DI	DMCIZ7P
DMCIZ7P	DN	(S)-5-fluorowillardiine
DMCIZ7P	MI	TT9HLZ0
DMCIZ7P	MN	Glutamate receptor AMPA 2 (GRIA2)
DMCIZ7P	MT	DTT
DMCIZ7P	MA	Agonist
DMCIZ7P	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 445).
DMCIZ7P	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=445

DMCIZ7P	DI	DMCIZ7P
DMCIZ7P	DN	(S)-5-fluorowillardiine
DMCIZ7P	MI	TT82EZV
DMCIZ7P	MN	Glutamate receptor AMPA 3 (GRIA3)
DMCIZ7P	MT	DTT
DMCIZ7P	MA	Agonist
DMCIZ7P	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 446).
DMCIZ7P	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=446

DMCIZ7P	DI	DMCIZ7P
DMCIZ7P	DN	(S)-5-fluorowillardiine
DMCIZ7P	MI	TTPJR0G
DMCIZ7P	MN	Glutamate receptor AMPA 4 (GRIA4)
DMCIZ7P	MT	DTT
DMCIZ7P	MA	Agonist
DMCIZ7P	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 447).
DMCIZ7P	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=447

DM1DNRP	DI	DM1DNRP
DM1DNRP	DN	(S)-5-iodowillardiine
DM1DNRP	MI	TT0MYE2
DM1DNRP	MN	Glutamate receptor ionotropic kainate 1 (GRIK1)
DM1DNRP	MT	DTT
DM1DNRP	MA	Agonist
DM1DNRP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 450).
DM1DNRP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=450

DM32PJ5	DI	DM32PJ5
DM32PJ5	DN	(S)-6-(pyrrolidin-3-ylmethoxy)-2-naphthonitrile
DM32PJ5	MI	TTAWNKZ
DM32PJ5	MN	Norepinephrine transporter (NET)
DM32PJ5	MT	DTT
DM32PJ5	MA	Inhibitor
DM32PJ5	RN	Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32.
DM32PJ5	RU	https://pubmed.ncbi.nlm.nih.gov/19282174

DM32PJ5	DI	DM32PJ5
DM32PJ5	DN	(S)-6-(pyrrolidin-3-ylmethoxy)-2-naphthonitrile
DM32PJ5	MI	TT3ROYC
DM32PJ5	MN	Serotonin transporter (SERT)
DM32PJ5	MT	DTT
DM32PJ5	MA	Inhibitor
DM32PJ5	RN	Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32.
DM32PJ5	RU	https://pubmed.ncbi.nlm.nih.gov/19282174

DMG58HM	DI	DMG58HM
DMG58HM	DN	(S)-6-Amino-2-(2-imino-ethylamino)-hexanoic acid
DMG58HM	MI	TTZUFI5
DMG58HM	MN	Nitric-oxide synthase brain (NOS1)
DMG58HM	MT	DTT
DMG58HM	MA	Inhibitor
DMG58HM	RN	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
DMG58HM	RU	https://pubmed.ncbi.nlm.nih.gov/15501067

DMG58HM	DI	DMG58HM
DMG58HM	DN	(S)-6-Amino-2-(2-imino-ethylamino)-hexanoic acid
DMG58HM	MI	TTCM4B3
DMG58HM	MN	Nitric-oxide synthase endothelial (NOS3)
DMG58HM	MT	DTT
DMG58HM	MA	Inhibitor
DMG58HM	RN	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
DMG58HM	RU	https://pubmed.ncbi.nlm.nih.gov/15501067

DMG58HM	DI	DMG58HM
DMG58HM	DN	(S)-6-Amino-2-(2-imino-ethylamino)-hexanoic acid
DMG58HM	MI	TTF10I9
DMG58HM	MN	Nitric-oxide synthase inducible (NOS2)
DMG58HM	MT	DTT
DMG58HM	MA	Inhibitor
DMG58HM	RN	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
DMG58HM	RU	https://pubmed.ncbi.nlm.nih.gov/15501067

DMTUZIN	DI	DMTUZIN
DMTUZIN	DN	(S)-alpha-methylhistamine
DMTUZIN	MI	TT9JNIC
DMTUZIN	MN	Histamine H3 receptor (H3R)
DMTUZIN	MT	DTT
DMTUZIN	MA	Agonist
DMTUZIN	RN	Characteristics of recombinantly expressed rat and human histamine H3 receptors. Eur J Pharmacol. 2002 Oct 18;453(1):33-41.
DMTUZIN	RU	https://pubmed.ncbi.nlm.nih.gov/12393057

DMTUZIN	DI	DMTUZIN
DMTUZIN	DN	(S)-alpha-methylhistamine
DMTUZIN	MI	TTXJ178
DMTUZIN	MN	Histamine H4 receptor (H4R)
DMTUZIN	MT	DTT
DMTUZIN	MA	Agonist
DMTUZIN	RN	Cloning and characterization of a novel human histamine receptor. J Pharmacol Exp Ther. 2001 Mar;296(3):1058-66.
DMTUZIN	RU	https://pubmed.ncbi.nlm.nih.gov/11181941

DMNJSTM	DI	DMNJSTM
DMNJSTM	DN	(S)-AMPA
DMNJSTM	MI	TTAN6JD
DMNJSTM	MN	Glutamate receptor AMPA (GRIA)
DMNJSTM	MT	DTT
DMNJSTM	MA	Inhibitor
DMNJSTM	RN	Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors. J Med Chem. 2005 Dec 1;48(24):7867-81.
DMNJSTM	RU	https://pubmed.ncbi.nlm.nih.gov/16302825

DMNJSTM	DI	DMNJSTM
DMNJSTM	DN	(S)-AMPA
DMNJSTM	MI	TTVPQTF
DMNJSTM	MN	Glutamate receptor AMPA 1 (GRIA1)
DMNJSTM	MT	DTT
DMNJSTM	MA	Inhibitor
DMNJSTM	RN	Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors. J Med Chem. 2005 Dec 1;48(24):7867-81.
DMNJSTM	RU	https://pubmed.ncbi.nlm.nih.gov/16302825

DMEKGIX	DI	DMEKGIX
DMEKGIX	DN	(S)APOMORPHINE
DMEKGIX	MI	TTZFYLI
DMEKGIX	MN	Dopamine D1 receptor (D1R)
DMEKGIX	MT	DTT
DMEKGIX	MA	Inhibitor
DMEKGIX	RN	Synthesis and dopamine receptor affinities of enantiomers of 2-substituted apomorphines and their N-n-propyl analogues. J Med Chem. 1990 Jun;33(6):1800-5.
DMEKGIX	RU	https://pubmed.ncbi.nlm.nih.gov/1971309

DMEKGIX	DI	DMEKGIX
DMEKGIX	DN	(S)APOMORPHINE
DMEKGIX	MI	TTEX248
DMEKGIX	MN	Dopamine D2 receptor (D2R)
DMEKGIX	MT	DTT
DMEKGIX	MA	Inhibitor
DMEKGIX	RN	Synthesis and dopamine receptor affinities of enantiomers of 2-substituted apomorphines and their N-n-propyl analogues. J Med Chem. 1990 Jun;33(6):1800-5.
DMEKGIX	RU	https://pubmed.ncbi.nlm.nih.gov/1971309

DMA43NY	DI	DMA43NY
DMA43NY	DN	(S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate
DMA43NY	MI	TTGKNB4
DMA43NY	MN	Epidermal growth factor receptor (EGFR)
DMA43NY	MT	DTT
DMA43NY	MA	Inhibitor
DMA43NY	RN	Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J Nat Prod. 1992 Nov;55(11):1529-60.
DMA43NY	RU	https://pubmed.ncbi.nlm.nih.gov/1479375

DMPI0AX	DI	DMPI0AX
DMPI0AX	DN	(S)-BULBOCAPNINE
DMPI0AX	MI	TTZFYLI
DMPI0AX	MN	Dopamine D1 receptor (D1R)
DMPI0AX	MT	DTT
DMPI0AX	MA	Inhibitor
DMPI0AX	RN	Advances in development of dopaminergic aporphinoids. J Med Chem. 2007 Jan 25;50(2):171-81.
DMPI0AX	RU	https://pubmed.ncbi.nlm.nih.gov/17228858

DMPI0AX	DI	DMPI0AX
DMPI0AX	DN	(S)-BULBOCAPNINE
DMPI0AX	MI	TTEX248
DMPI0AX	MN	Dopamine D2 receptor (D2R)
DMPI0AX	MT	DTT
DMPI0AX	MA	Inhibitor
DMPI0AX	RN	Advances in development of dopaminergic aporphinoids. J Med Chem. 2007 Jan 25;50(2):171-81.
DMPI0AX	RU	https://pubmed.ncbi.nlm.nih.gov/17228858

DMJN659	DI	DMJN659
DMJN659	DN	(S)-cetirizine
DMJN659	MI	TTTIBOJ
DMJN659	MN	Histamine H1 receptor (H1R)
DMJN659	MT	DTT
DMJN659	MA	Antagonist
DMJN659	RN	Large-scale overproduction, functional purification and ligand affinities of the His-tagged human histamine H1 receptor. Eur J Biochem. 2004 Jul;271(13):2636-46.
DMJN659	RU	https://pubmed.ncbi.nlm.nih.gov/15206929

DMQSC21	DI	DMQSC21
DMQSC21	DN	(S)-DHPA
DMQSC21	MI	TTM2AOE
DMQSC21	MN	Adenosine A2a receptor (ADORA2A)
DMQSC21	MT	DTT
DMQSC21	MA	Inhibitor
DMQSC21	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMQSC21	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DM0SEYN	DI	DM0SEYN
DM0SEYN	DN	(S)-dimethylenastron
DM0SEYN	MI	TTBGTCW
DM0SEYN	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DM0SEYN	MT	DTT
DM0SEYN	MA	Inhibitor
DM0SEYN	RN	Structural basis for inhibition of Eg5 by dihydropyrimidines: stereoselectivity of antimitotic inhibitors enastron, dimethylenastron and fluorastrol. J Med Chem. 2010 Aug 12;53(15):5676-83.
DM0SEYN	RU	https://pubmed.ncbi.nlm.nih.gov/20597485

DM0EQTM	DI	DM0EQTM
DM0EQTM	DN	(S)-EF-1520
DM0EQTM	MI	TTPRKM0
DM0EQTM	MN	GABA transporter GAT-1 (SLC6A1)
DM0EQTM	MT	DTT
DM0EQTM	MA	Inhibitor
DM0EQTM	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 929).
DM0EQTM	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=929

DM0EQTM	DI	DM0EQTM
DM0EQTM	DN	(S)-EF-1520
DM0EQTM	MI	TTQBMPI
DM0EQTM	MN	Na(+)/Cl(-) betaine/GABA transporter (SLC6A12)
DM0EQTM	MT	DTT
DM0EQTM	MA	Inhibitor
DM0EQTM	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 932).
DM0EQTM	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=932

DMWNEA1	DI	DMWNEA1
DMWNEA1	DN	(S)-enastron
DMWNEA1	MI	TTBGTCW
DMWNEA1	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DMWNEA1	MT	DTT
DMWNEA1	MA	Inhibitor
DMWNEA1	RN	Structural basis for inhibition of Eg5 by dihydropyrimidines: stereoselectivity of antimitotic inhibitors enastron, dimethylenastron and fluorastrol. J Med Chem. 2010 Aug 12;53(15):5676-83.
DMWNEA1	RU	https://pubmed.ncbi.nlm.nih.gov/20597485

DMFSXTJ	DI	DMFSXTJ
DMFSXTJ	DN	(S)-Ethyl 6-(2-oxohexadecanamido)decanoate
DMFSXTJ	MI	TTT1JVS
DMFSXTJ	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DMFSXTJ	MT	DTT
DMFSXTJ	MA	Inhibitor
DMFSXTJ	RN	Structure-activity relationships of natural and non-natural amino acid-based amide and 2-oxoamide inhibitors of human phospholipase A(2) enzymes. Bioorg Med Chem. 2008 Dec 15;16(24):10257-69.
DMFSXTJ	RU	https://pubmed.ncbi.nlm.nih.gov/18993078

DM715AS	DI	DM715AS
DM715AS	DN	(S)-flurocarazolol
DM715AS	MI	TTSQIFT
DM715AS	MN	5-HT 1A receptor (HTR1A)
DM715AS	MT	DTT
DM715AS	MA	Antagonist
DM715AS	RN	The in vitro pharmacology of the beta-adrenergic receptor pet ligand (s)-fluorocarazolol reveals high affinity for cloned beta-adrenergic receptors and moderate affinity for the human 5-HT1A receptor. Psychopharmacology (Berl). 2001 Aug;157(1):111-4.
DM715AS	RU	https://pubmed.ncbi.nlm.nih.gov/11512051

DM715AS	DI	DM715AS
DM715AS	DN	(S)-flurocarazolol
DM715AS	MI	TTK8CXU
DM715AS	MN	5-HT 1B receptor (HTR1B)
DM715AS	MT	DTT
DM715AS	MA	Antagonist
DM715AS	RN	The in vitro pharmacology of the beta-adrenergic receptor pet ligand (s)-fluorocarazolol reveals high affinity for cloned beta-adrenergic receptors and moderate affinity for the human 5-HT1A receptor. Psychopharmacology (Berl). 2001 Aug;157(1):111-4.
DM715AS	RU	https://pubmed.ncbi.nlm.nih.gov/11512051

DM5WETL	DI	DM5WETL
DM5WETL	DN	(S)-FTY720P
DM5WETL	MI	TT9JZCK
DM5WETL	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DM5WETL	MT	DTT
DM5WETL	MA	Inhibitor
DM5WETL	RN	Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors. Nat Chem Biol. 2009 Jun;5(6):428-34.
DM5WETL	RU	https://pubmed.ncbi.nlm.nih.gov/19430484

DM8H0ND	DI	DM8H0ND
DM8H0ND	DN	(S)-Methyl 4-(2-oxohexadecanamido)octanoate
DM8H0ND	MI	TTT1JVS
DM8H0ND	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DM8H0ND	MT	DTT
DM8H0ND	MA	Inhibitor
DM8H0ND	RN	Structure-activity relationships of natural and non-natural amino acid-based amide and 2-oxoamide inhibitors of human phospholipase A(2) enzymes. Bioorg Med Chem. 2008 Dec 15;16(24):10257-69.
DM8H0ND	RU	https://pubmed.ncbi.nlm.nih.gov/18993078

DMLR0N3	DI	DMLR0N3
DMLR0N3	DN	(S)-N-(1-phenylethyl)acetimidamide hydrobromide
DMLR0N3	MI	TTF10I9
DMLR0N3	MN	Nitric-oxide synthase inducible (NOS2)
DMLR0N3	MT	DTT
DMLR0N3	MA	Inhibitor
DMLR0N3	RN	N-Substituted acetamidines and 2-methylimidazole derivatives as selective inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6495-9.
DMLR0N3	RU	https://pubmed.ncbi.nlm.nih.gov/20933416

DMGFOQJ	DI	DMGFOQJ
DMGFOQJ	DN	(S)-N-[1-(3-morpholin-4-yl-phenyl)-ethyl]-3-phenyl-acrylamide
DMGFOQJ	MI	TTPXI3S
DMGFOQJ	MN	Voltage-gated potassium channel Kv7.2 (KCNQ2)
DMGFOQJ	MT	DTT
DMGFOQJ	MA	Activator
DMGFOQJ	RN	The acrylamide (S)-1 differentially affects Kv7 (KCNQ) potassium channels. Neuropharmacology. 2006 Nov;51(6):1068-77.
DMGFOQJ	RU	https://pubmed.ncbi.nlm.nih.gov/16904708

DMGFOQJ	DI	DMGFOQJ
DMGFOQJ	DN	(S)-N-[1-(3-morpholin-4-yl-phenyl)-ethyl]-3-phenyl-acrylamide
DMGFOQJ	MI	TT8HGRW
DMGFOQJ	MN	Voltage-gated potassium channel Kv7.4 (KCNQ4)
DMGFOQJ	MT	DTT
DMGFOQJ	MA	Activator
DMGFOQJ	RN	The acrylamide (S)-1 differentially affects Kv7 (KCNQ) potassium channels. Neuropharmacology. 2006 Nov;51(6):1068-77.
DMGFOQJ	RU	https://pubmed.ncbi.nlm.nih.gov/16904708

DMGFOQJ	DI	DMGFOQJ
DMGFOQJ	DN	(S)-N-[1-(3-morpholin-4-yl-phenyl)-ethyl]-3-phenyl-acrylamide
DMGFOQJ	MI	TTWVL5Q
DMGFOQJ	MN	Voltage-gated potassium channel Kv7.5 (KCNQ5)
DMGFOQJ	MT	DTT
DMGFOQJ	MA	Activator
DMGFOQJ	RN	The acrylamide (S)-1 differentially affects Kv7 (KCNQ) potassium channels. Neuropharmacology. 2006 Nov;51(6):1068-77.
DMGFOQJ	RU	https://pubmed.ncbi.nlm.nih.gov/16904708

DMGMAPB	DI	DMGMAPB
DMGMAPB	DN	(S)-N2-[4-(benzyloxy)benzyl]alaninamide
DMGMAPB	MI	TTGP7BY
DMGMAPB	MN	Monoamine oxidase type B (MAO-B)
DMGMAPB	MT	DTT
DMGMAPB	MA	Inhibitor
DMGMAPB	RN	Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoa... J Med Chem. 2007 Oct 4;50(20):4909-16.
DMGMAPB	RU	https://pubmed.ncbi.nlm.nih.gov/17824599

DMW5ZK7	DI	DMW5ZK7
DMW5ZK7	DN	(S)-N2-[4-(benzyloxy)benzyl]serinamide
DMW5ZK7	MI	TTGP7BY
DMW5ZK7	MN	Monoamine oxidase type B (MAO-B)
DMW5ZK7	MT	DTT
DMW5ZK7	MA	Inhibitor
DMW5ZK7	RN	Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoa... J Med Chem. 2007 Oct 4;50(20):4909-16.
DMW5ZK7	RU	https://pubmed.ncbi.nlm.nih.gov/17824599

DMKMJBL	DI	DMKMJBL
DMKMJBL	DN	(S)-N2-{4-[(3-chlorobenzyl)oxy]benzyl}alaninamide
DMKMJBL	MI	TTGP7BY
DMKMJBL	MN	Monoamine oxidase type B (MAO-B)
DMKMJBL	MT	DTT
DMKMJBL	MA	Inhibitor
DMKMJBL	RN	Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoa... J Med Chem. 2007 Oct 4;50(20):4909-16.
DMKMJBL	RU	https://pubmed.ncbi.nlm.nih.gov/17824599

DMINLCJ	DI	DMINLCJ
DMINLCJ	DN	(S)-N2-{4-[(3-chlorobenzyl)oxy]benzyl}serinamide
DMINLCJ	MI	TTGP7BY
DMINLCJ	MN	Monoamine oxidase type B (MAO-B)
DMINLCJ	MT	DTT
DMINLCJ	MA	Inhibitor
DMINLCJ	RN	Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoa... J Med Chem. 2007 Oct 4;50(20):4909-16.
DMINLCJ	RU	https://pubmed.ncbi.nlm.nih.gov/17824599

DMSC8ZW	DI	DMSC8ZW
DMSC8ZW	DN	(S)-N2-{4-[(3-fluorobenzyl)oxy]benzyl}serinamide
DMSC8ZW	MI	TTGP7BY
DMSC8ZW	MN	Monoamine oxidase type B (MAO-B)
DMSC8ZW	MT	DTT
DMSC8ZW	MA	Inhibitor
DMSC8ZW	RN	Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoa... J Med Chem. 2007 Oct 4;50(20):4909-16.
DMSC8ZW	RU	https://pubmed.ncbi.nlm.nih.gov/17824599

DMU3F7H	DI	DMU3F7H
DMU3F7H	DN	(S)-N2-{4-[(4-chlorobenzyl)oxy]benzyl}alaninamide
DMU3F7H	MI	TTGP7BY
DMU3F7H	MN	Monoamine oxidase type B (MAO-B)
DMU3F7H	MT	DTT
DMU3F7H	MA	Inhibitor
DMU3F7H	RN	Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoa... J Med Chem. 2007 Oct 4;50(20):4909-16.
DMU3F7H	RU	https://pubmed.ncbi.nlm.nih.gov/17824599

DMLFOPV	DI	DMLFOPV
DMLFOPV	DN	(S)-N2-{4-[(4-chlorobenzyl)oxy]benzyl}serinamide
DMLFOPV	MI	TTGP7BY
DMLFOPV	MN	Monoamine oxidase type B (MAO-B)
DMLFOPV	MT	DTT
DMLFOPV	MA	Inhibitor
DMLFOPV	RN	Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoa... J Med Chem. 2007 Oct 4;50(20):4909-16.
DMLFOPV	RU	https://pubmed.ncbi.nlm.nih.gov/17824599

DMLP63J	DI	DMLP63J
DMLP63J	DN	(S)-N2-{4-[(4-nitrobenzyl)oxy]benzyl}serinamide
DMLP63J	MI	TTGP7BY
DMLP63J	MN	Monoamine oxidase type B (MAO-B)
DMLP63J	MT	DTT
DMLP63J	MA	Inhibitor
DMLP63J	RN	Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoa... J Med Chem. 2007 Oct 4;50(20):4909-16.
DMLP63J	RU	https://pubmed.ncbi.nlm.nih.gov/17824599

DMUAYZJ	DI	DMUAYZJ
DMUAYZJ	DN	(S)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide
DMUAYZJ	MI	TTAWNKZ
DMUAYZJ	MN	Norepinephrine transporter (NET)
DMUAYZJ	MT	DTT
DMUAYZJ	MA	Inhibitor
DMUAYZJ	RN	Bioorg Med Chem Lett. 2009 Oct 15;19(20):5893-7. Epub 2009 Aug 21.Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.
DMUAYZJ	RU	https://pubmed.ncbi.nlm.nih.gov/19740658

DMUAYZJ	DI	DMUAYZJ
DMUAYZJ	DN	(S)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide
DMUAYZJ	MI	TT3ROYC
DMUAYZJ	MN	Serotonin transporter (SERT)
DMUAYZJ	MT	DTT
DMUAYZJ	MA	Inhibitor
DMUAYZJ	RN	Bioorg Med Chem Lett. 2009 Oct 15;19(20):5893-7. Epub 2009 Aug 21.Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.
DMUAYZJ	RU	https://pubmed.ncbi.nlm.nih.gov/19740658

DMNOWZ2	DI	DMNOWZ2
DMNOWZ2	DN	(S)-N-oleoyltyrosinol
DMNOWZ2	MI	TT7QNVC
DMNOWZ2	MN	Glucose-dependent insulinotropic receptor (GPR119)
DMNOWZ2	MT	DTT
DMNOWZ2	MA	Agonist
DMNOWZ2	RN	N-oleoyldopamine enhances glucose homeostasis through the activation of GPR119. Mol Endocrinol. 2010 Jan;24(1):161-70.
DMNOWZ2	RU	https://pubmed.ncbi.nlm.nih.gov/19901198

DMULFYA	DI	DMULFYA
DMULFYA	DN	(S)-NORDULOXETINE
DMULFYA	MI	TTAWNKZ
DMULFYA	MN	Norepinephrine transporter (NET)
DMULFYA	MT	DTT
DMULFYA	MA	Inhibitor
DMULFYA	RN	Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression. Bioorg Med Chem. 2009 Oct 1;17(19):6890-7.
DMULFYA	RU	https://pubmed.ncbi.nlm.nih.gov/19740668

DMULFYA	DI	DMULFYA
DMULFYA	DN	(S)-NORDULOXETINE
DMULFYA	MI	TT3ROYC
DMULFYA	MN	Serotonin transporter (SERT)
DMULFYA	MT	DTT
DMULFYA	MA	Inhibitor
DMULFYA	RN	Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression. Bioorg Med Chem. 2009 Oct 1;17(19):6890-7.
DMULFYA	RU	https://pubmed.ncbi.nlm.nih.gov/19740668

DM8ZTPF	DI	DM8ZTPF
DM8ZTPF	DN	(S)-Norfluoxetine
DM8ZTPF	MI	TTVBI8W
DM8ZTPF	MN	Dopamine transporter (DAT)
DM8ZTPF	MT	DTT
DM8ZTPF	MA	Inhibitor
DM8ZTPF	RN	Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression. Bioorg Med Chem. 2009 Jan 1;17(1):337-43.
DM8ZTPF	RU	https://pubmed.ncbi.nlm.nih.gov/19014888

DM8ZTPF	DI	DM8ZTPF
DM8ZTPF	DN	(S)-Norfluoxetine
DM8ZTPF	MI	TTAWNKZ
DM8ZTPF	MN	Norepinephrine transporter (NET)
DM8ZTPF	MT	DTT
DM8ZTPF	MA	Inhibitor
DM8ZTPF	RN	Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression. Bioorg Med Chem. 2009 Jan 1;17(1):337-43.
DM8ZTPF	RU	https://pubmed.ncbi.nlm.nih.gov/19014888

DM8ZTPF	DI	DM8ZTPF
DM8ZTPF	DN	(S)-Norfluoxetine
DM8ZTPF	MI	TT3ROYC
DM8ZTPF	MN	Serotonin transporter (SERT)
DM8ZTPF	MT	DTT
DM8ZTPF	MA	Inhibitor
DM8ZTPF	RN	Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression. Bioorg Med Chem. 2009 Jan 1;17(1):337-43.
DM8ZTPF	RU	https://pubmed.ncbi.nlm.nih.gov/19014888

DMAI1HU	DI	DMAI1HU
DMAI1HU	DN	(S)-phenylglycine
DMAI1HU	MI	TTFK1JQ
DMAI1HU	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMAI1HU	MT	DTT
DMAI1HU	MA	Inhibitor
DMAI1HU	RN	Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41.
DMAI1HU	RU	https://pubmed.ncbi.nlm.nih.gov/16380257

DM04BHI	DI	DM04BHI
DM04BHI	DN	(S)-PIA
DM04BHI	MI	TTK25J1
DM04BHI	MN	Adenosine A1 receptor (ADORA1)
DM04BHI	MT	DTT
DM04BHI	MA	Agonist
DM04BHI	RN	A threonine residue in the seventh transmembrane domain of the human A1 adenosine receptor mediates specific agonist binding. J Biol Chem. 1994 Jan 28;269(4):2373-6.
DM04BHI	RU	https://pubmed.ncbi.nlm.nih.gov/8300561

DM04BHI	DI	DM04BHI
DM04BHI	DN	(S)-PIA
DM04BHI	MI	TTNE7KG
DM04BHI	MN	Adenosine A2b receptor (ADORA2B)
DM04BHI	MT	DTT
DM04BHI	MA	Agonist
DM04BHI	RN	Characterization of human A(2B) adenosine receptors: radioligand binding, western blotting, and coupling to G(q) in human embryonic kidney 293 cells and HMC-1 mast cells. Mol Pharmacol. 1999 Oct;56(4):705-13.
DM04BHI	RU	https://pubmed.ncbi.nlm.nih.gov/10496952

DM04BHI	DI	DM04BHI
DM04BHI	DN	(S)-PIA
DM04BHI	MI	TTJFY5U
DM04BHI	MN	Adenosine A3 receptor (ADORA3)
DM04BHI	MT	DTT
DM04BHI	MA	Agonist
DM04BHI	RN	[(3)H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors. Mol Pharmacol. 2000 May;57(5):968-75.
DM04BHI	RU	https://pubmed.ncbi.nlm.nih.gov/10779381

DMST89H	DI	DMST89H
DMST89H	DN	(S)-Piperidine-3-carboxylic acid
DMST89H	MI	TTPRKM0
DMST89H	MN	GABA transporter GAT-1 (SLC6A1)
DMST89H	MT	DTT
DMST89H	MA	Inhibitor
DMST89H	RN	Novel secoergoline derivatives inhibit both GABA and glutamate uptake in rat brain homogenates: synthesis, in vitro pharmacology, and modeling. J Med Chem. 2004 Nov 4;47(23):5620-9.
DMST89H	RU	https://pubmed.ncbi.nlm.nih.gov/15509161

DMXVQJI	DI	DMXVQJI
DMXVQJI	DN	(S)-pyrrolidin-1-yl(pyrrolidin-2-yl)methanone
DMXVQJI	MI	TTDIGC1
DMXVQJI	MN	Dipeptidyl peptidase 4 (DPP-4)
DMXVQJI	MT	DTT
DMXVQJI	MA	Inhibitor
DMXVQJI	RN	Design and synthesis of DPP-IV inhibitors lacking the electrophilic nitrile group. Bioorg Med Chem. 2008 Feb 15;16(4):1613-31.
DMXVQJI	RU	https://pubmed.ncbi.nlm.nih.gov/18039579

DM16N7Z	DI	DM16N7Z
DM16N7Z	DN	(S)-pyrrolidin-2-yl(thiazolidin-3-yl)methanone
DM16N7Z	MI	TTDIGC1
DM16N7Z	MN	Dipeptidyl peptidase 4 (DPP-4)
DM16N7Z	MT	DTT
DM16N7Z	MA	Inhibitor
DM16N7Z	RN	[(S)-gamma-(4-Aryl-1-piperazinyl)-l-prolyl]thiazolidines as a novel series of highly potent and long-lasting DPP-IV inhibitors. Bioorg Med Chem Lett. 2007 May 1;17(9):2618-21.
DM16N7Z	RU	https://pubmed.ncbi.nlm.nih.gov/17317162

DM1SJZ3	DI	DM1SJZ3
DM1SJZ3	DN	(S)-Rolipram
DM1SJZ3	MI	TTV5CGO
DM1SJZ3	MN	Phosphodiesterase 4 (PDE4)
DM1SJZ3	MT	DTT
DM1SJZ3	MA	Inhibitor
DM1SJZ3	RN	PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated fibroblasts. Am J Physiol Lung Cell Mol Physiol. 2009 Jun;296(6):L959-69.
DM1SJZ3	RU	https://pubmed.ncbi.nlm.nih.gov/19304913

DM1SJZ3	DI	DM1SJZ3
DM1SJZ3	DN	(S)-Rolipram
DM1SJZ3	MI	TTZ97H5
DM1SJZ3	MN	Phosphodiesterase 4A (PDE4A)
DM1SJZ3	MT	DTT
DM1SJZ3	MA	Inhibitor
DM1SJZ3	RN	PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated fibroblasts. Am J Physiol Lung Cell Mol Physiol. 2009 Jun;296(6):L959-69.
DM1SJZ3	RU	https://pubmed.ncbi.nlm.nih.gov/19304913

DM1SJZ3	DI	DM1SJZ3
DM1SJZ3	DN	(S)-Rolipram
DM1SJZ3	MI	TTVIAT9
DM1SJZ3	MN	Phosphodiesterase 4B (PDE4B)
DM1SJZ3	MT	DTT
DM1SJZ3	MA	Inhibitor
DM1SJZ3	RN	PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated fibroblasts. Am J Physiol Lung Cell Mol Physiol. 2009 Jun;296(6):L959-69.
DM1SJZ3	RU	https://pubmed.ncbi.nlm.nih.gov/19304913

DMG4KIU	DI	DMG4KIU
DMG4KIU	DN	(S)-secoantioquine hydrochloride
DMG4KIU	MI	TTEX248
DMG4KIU	MN	Dopamine D2 receptor (D2R)
DMG4KIU	MT	DTT
DMG4KIU	MA	Inhibitor
DMG4KIU	RN	Displacement activity of bisbenzylisoquinoline alkaloids at striatal 3H-SCH 23390 and 3H-raclopride binding sites. J Nat Prod. 1992 Sep;55(9):1281-6.
DMG4KIU	RU	https://pubmed.ncbi.nlm.nih.gov/1431946

DMS8WG3	DI	DMS8WG3
DMS8WG3	DN	(S)-sirtinol
DMS8WG3	MI	TTUF2HO
DMS8WG3	MN	NAD-dependent deacetylase sirtuin-1 (SIRT1)
DMS8WG3	MT	DTT
DMS8WG3	MA	Inhibitor
DMS8WG3	RN	Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (Sirtuin) inhibitors. J Med Chem. 2005 Dec 1;48(24):7789-95.
DMS8WG3	RU	https://pubmed.ncbi.nlm.nih.gov/16302818

DMH7QZ2	DI	DMH7QZ2
DMH7QZ2	DN	(S)-tacrine(10)-hupyridone
DMH7QZ2	MI	TT1RS9F
DMH7QZ2	MN	Acetylcholinesterase (AChE)
DMH7QZ2	MT	DTT
DMH7QZ2	MA	Inhibitor
DMH7QZ2	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMH7QZ2	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM68XFZ	DI	DM68XFZ
DM68XFZ	DN	(S)-TBPG
DM68XFZ	MI	TTVBPDM
DM68XFZ	MN	Metabotropic glutamate receptor 1 (mGluR1)
DM68XFZ	MT	DTT
DM68XFZ	MA	Antagonist
DM68XFZ	RN	Synthesis and biological evaluation of 2-(3'-(1H-tetrazol-5-yl) bicyclo[1.1.1]pent-1-yl)glycine (S-TBPG), a novel mGlu1 receptor antagonist. Bioorg Med Chem. 2001 Feb;9(2):221-7.
DM68XFZ	RU	https://pubmed.ncbi.nlm.nih.gov/11249114

DMAQX4K	DI	DMAQX4K
DMAQX4K	DN	(S)-tert-butyl 1-oxohexan-2-ylcarbamate
DMAQX4K	MI	TTDZN01
DMAQX4K	MN	Cathepsin K (CTSK)
DMAQX4K	MT	DTT
DMAQX4K	MA	Inhibitor
DMAQX4K	RN	Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors Bioorg Med Chem Lett. 2006 Feb 15;16(4):978-83.
DMAQX4K	RU	https://pubmed.ncbi.nlm.nih.gov/16290936

DMAQX4K	DI	DMAQX4K
DMAQX4K	DN	(S)-tert-butyl 1-oxohexan-2-ylcarbamate
DMAQX4K	MI	TT36ETB
DMAQX4K	MN	Cathepsin L (CTSL)
DMAQX4K	MT	DTT
DMAQX4K	MA	Inhibitor
DMAQX4K	RN	Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors Bioorg Med Chem Lett. 2006 Feb 15;16(4):978-83.
DMAQX4K	RU	https://pubmed.ncbi.nlm.nih.gov/16290936

DMLG8Q2	DI	DMLG8Q2
DMLG8Q2	DN	(S)-tert-Butyl 4-(2-oxohexadecanamido)pentanoate
DMLG8Q2	MI	TTT1JVS
DMLG8Q2	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DMLG8Q2	MT	DTT
DMLG8Q2	MA	Inhibitor
DMLG8Q2	RN	Structure-activity relationships of natural and non-natural amino acid-based amide and 2-oxoamide inhibitors of human phospholipase A(2) enzymes. Bioorg Med Chem. 2008 Dec 15;16(24):10257-69.
DMLG8Q2	RU	https://pubmed.ncbi.nlm.nih.gov/18993078

DMR1HQ3	DI	DMR1HQ3
DMR1HQ3	DN	(S)-tert-butyl 4-methyl-1-oxopentan-2-ylcarbamate
DMR1HQ3	MI	TTDZN01
DMR1HQ3	MN	Cathepsin K (CTSK)
DMR1HQ3	MT	DTT
DMR1HQ3	MA	Inhibitor
DMR1HQ3	RN	Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors Bioorg Med Chem Lett. 2006 Feb 15;16(4):978-83.
DMR1HQ3	RU	https://pubmed.ncbi.nlm.nih.gov/16290936

DMXQ47M	DI	DMXQ47M
DMXQ47M	DN	(S)-WILLARDIINE
DMXQ47M	MI	TTAN6JD
DMXQ47M	MN	Glutamate receptor AMPA (GRIA)
DMXQ47M	MT	DTT
DMXQ47M	MA	Inhibitor
DMXQ47M	RN	Synthesis of willardiine and 6-azawillardiine analogs: pharmacological characterization on cloned homomeric human AMPA and kainate receptor subtypes. J Med Chem. 1997 Oct 24;40(22):3645-50.
DMXQ47M	RU	https://pubmed.ncbi.nlm.nih.gov/9357531

DMXQ47M	DI	DMXQ47M
DMXQ47M	DN	(S)-WILLARDIINE
DMXQ47M	MI	TTVPQTF
DMXQ47M	MN	Glutamate receptor AMPA 1 (GRIA1)
DMXQ47M	MT	DTT
DMXQ47M	MA	Inhibitor
DMXQ47M	RN	Synthesis of willardiine and 6-azawillardiine analogs: pharmacological characterization on cloned homomeric human AMPA and kainate receptor subtypes. J Med Chem. 1997 Oct 24;40(22):3645-50.
DMXQ47M	RU	https://pubmed.ncbi.nlm.nih.gov/9357531

DM6BON2	DI	DM6BON2
DM6BON2	DN	(S)-zacopride
DM6BON2	MI	TTPC4TU
DM6BON2	MN	5-HT 3A receptor (HTR3A)
DM6BON2	MT	DTT
DM6BON2	MA	Antagonist
DM6BON2	RN	Pharmacological comparison of human homomeric 5-HT3A receptors versus heteromeric 5-HT3A/3B receptors. Neuropharmacology. 2001 Aug;41(2):282-4.
DM6BON2	RU	https://pubmed.ncbi.nlm.nih.gov/11489465

DM6BON2	DI	DM6BON2
DM6BON2	DN	(S)-zacopride
DM6BON2	MI	TTR6K75
DM6BON2	MN	5-HT 3B receptor (HTR3B)
DM6BON2	MT	DTT
DM6BON2	MA	Antagonist
DM6BON2	RN	Pharmacological comparison of human homomeric 5-HT3A receptors versus heteromeric 5-HT3A/3B receptors. Neuropharmacology. 2001 Aug;41(2):282-4.
DM6BON2	RU	https://pubmed.ncbi.nlm.nih.gov/11489465

DMA30RW	DI	DMA30RW
DMA30RW	DN	(S,R)-(+)-fenoterol
DMA30RW	MI	TT2CJVK
DMA30RW	MN	Adrenergic receptor beta-2 (ADRB2)
DMA30RW	MT	DTT
DMA30RW	MA	Inhibitor
DMA30RW	RN	Comparative molecular field analysis of the binding of the stereoisomers of fenoterol and fenoterol derivatives to the beta2 adrenergic receptor. J Med Chem. 2007 Jun 14;50(12):2903-15.
DMA30RW	RU	https://pubmed.ncbi.nlm.nih.gov/17506540

DMIV0MT	DI	DMIV0MT
DMIV0MT	DN	(S,R)-antioquine hydrochloride
DMIV0MT	MI	TTEX248
DMIV0MT	MN	Dopamine D2 receptor (D2R)
DMIV0MT	MT	DTT
DMIV0MT	MA	Inhibitor
DMIV0MT	RN	Displacement activity of bisbenzylisoquinoline alkaloids at striatal 3H-SCH 23390 and 3H-raclopride binding sites. J Nat Prod. 1992 Sep;55(9):1281-6.
DMIV0MT	RU	https://pubmed.ncbi.nlm.nih.gov/1431946

DMZV52W	DI	DMZV52W
DMZV52W	DN	(S,R)-isotetrandrine hydrochloride
DMZV52W	MI	TTEX248
DMZV52W	MN	Dopamine D2 receptor (D2R)
DMZV52W	MT	DTT
DMZV52W	MA	Inhibitor
DMZV52W	RN	Displacement activity of bisbenzylisoquinoline alkaloids at striatal 3H-SCH 23390 and 3H-raclopride binding sites. J Nat Prod. 1992 Sep;55(9):1281-6.
DMZV52W	RU	https://pubmed.ncbi.nlm.nih.gov/1431946

DMMRUVF	DI	DMMRUVF
DMMRUVF	DN	(S,R)-pseudoxandrine hydrochloride
DMMRUVF	MI	TTEX248
DMMRUVF	MN	Dopamine D2 receptor (D2R)
DMMRUVF	MT	DTT
DMMRUVF	MA	Inhibitor
DMMRUVF	RN	Displacement activity of bisbenzylisoquinoline alkaloids at striatal 3H-SCH 23390 and 3H-raclopride binding sites. J Nat Prod. 1992 Sep;55(9):1281-6.
DMMRUVF	RU	https://pubmed.ncbi.nlm.nih.gov/1431946

DMBR1JS	DI	DMBR1JS
DMBR1JS	DN	(S,S)-(-)-bis(10)-hupyridone
DMBR1JS	MI	TT1RS9F
DMBR1JS	MN	Acetylcholinesterase (AChE)
DMBR1JS	MT	DTT
DMBR1JS	MA	Inhibitor
DMBR1JS	RN	Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely... J Med Chem. 2008 Jun 12;51(11):3154-70.
DMBR1JS	RU	https://pubmed.ncbi.nlm.nih.gov/18479118

DM6PQ8D	DI	DM6PQ8D
DM6PQ8D	DN	(S,S)-(-)-bis(12)-hupyridone
DM6PQ8D	MI	TT1RS9F
DM6PQ8D	MN	Acetylcholinesterase (AChE)
DM6PQ8D	MT	DTT
DM6PQ8D	MA	Inhibitor
DM6PQ8D	RN	Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely... J Med Chem. 2008 Jun 12;51(11):3154-70.
DM6PQ8D	RU	https://pubmed.ncbi.nlm.nih.gov/18479118

DMYDS6F	DI	DMYDS6F
DMYDS6F	DN	(S,S)-oxandrine hydrochloride
DMYDS6F	MI	TTZFYLI
DMYDS6F	MN	Dopamine D1 receptor (D1R)
DMYDS6F	MT	DTT
DMYDS6F	MA	Inhibitor
DMYDS6F	RN	Displacement activity of bisbenzylisoquinoline alkaloids at striatal 3H-SCH 23390 and 3H-raclopride binding sites. J Nat Prod. 1992 Sep;55(9):1281-6.
DMYDS6F	RU	https://pubmed.ncbi.nlm.nih.gov/1431946

DMYDS6F	DI	DMYDS6F
DMYDS6F	DN	(S,S)-oxandrine hydrochloride
DMYDS6F	MI	TTEX248
DMYDS6F	MN	Dopamine D2 receptor (D2R)
DMYDS6F	MT	DTT
DMYDS6F	MA	Inhibitor
DMYDS6F	RN	Displacement activity of bisbenzylisoquinoline alkaloids at striatal 3H-SCH 23390 and 3H-raclopride binding sites. J Nat Prod. 1992 Sep;55(9):1281-6.
DMYDS6F	RU	https://pubmed.ncbi.nlm.nih.gov/1431946

DMJL8SE	DI	DMJL8SE
DMJL8SE	DN	(Sar)WTLNSAGYLLGPKK(Lys-decanoyl)K
DMJL8SE	MI	TTX3HNZ
DMJL8SE	MN	Galanin receptor type 1 (GAL1-R)
DMJL8SE	MT	DTT
DMJL8SE	MA	Inhibitor
DMJL8SE	RN	Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues. J Med Chem. 2009 Mar 12;52(5):1310-6.
DMJL8SE	RU	https://pubmed.ncbi.nlm.nih.gov/19199479

DMJL8SE	DI	DMJL8SE
DMJL8SE	DN	(Sar)WTLNSAGYLLGPKK(Lys-decanoyl)K
DMJL8SE	MI	TTBPW3J
DMJL8SE	MN	Galanin receptor type 2 (GAL2-R)
DMJL8SE	MT	DTT
DMJL8SE	MA	Inhibitor
DMJL8SE	RN	Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues. J Med Chem. 2009 Mar 12;52(5):1310-6.
DMJL8SE	RU	https://pubmed.ncbi.nlm.nih.gov/19199479

DMPZHIE	DI	DMPZHIE
DMPZHIE	DN	(Sar)WTLNSAGYLLGPKK(Lys-lauroyl)K
DMPZHIE	MI	TTX3HNZ
DMPZHIE	MN	Galanin receptor type 1 (GAL1-R)
DMPZHIE	MT	DTT
DMPZHIE	MA	Inhibitor
DMPZHIE	RN	Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues. J Med Chem. 2009 Mar 12;52(5):1310-6.
DMPZHIE	RU	https://pubmed.ncbi.nlm.nih.gov/19199479

DMPZHIE	DI	DMPZHIE
DMPZHIE	DN	(Sar)WTLNSAGYLLGPKK(Lys-lauroyl)K
DMPZHIE	MI	TTBPW3J
DMPZHIE	MN	Galanin receptor type 2 (GAL2-R)
DMPZHIE	MT	DTT
DMPZHIE	MA	Inhibitor
DMPZHIE	RN	Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues. J Med Chem. 2009 Mar 12;52(5):1310-6.
DMPZHIE	RU	https://pubmed.ncbi.nlm.nih.gov/19199479

DMQIHZU	DI	DMQIHZU
DMQIHZU	DN	(Sar)WTLNSAGYLLGPKK(Lys-MPEG4)K
DMQIHZU	MI	TTX3HNZ
DMQIHZU	MN	Galanin receptor type 1 (GAL1-R)
DMQIHZU	MT	DTT
DMQIHZU	MA	Inhibitor
DMQIHZU	RN	Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues. J Med Chem. 2009 Mar 12;52(5):1310-6.
DMQIHZU	RU	https://pubmed.ncbi.nlm.nih.gov/19199479

DMQIHZU	DI	DMQIHZU
DMQIHZU	DN	(Sar)WTLNSAGYLLGPKK(Lys-MPEG4)K
DMQIHZU	MI	TTBPW3J
DMQIHZU	MN	Galanin receptor type 2 (GAL2-R)
DMQIHZU	MT	DTT
DMQIHZU	MA	Inhibitor
DMQIHZU	RN	Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues. J Med Chem. 2009 Mar 12;52(5):1310-6.
DMQIHZU	RU	https://pubmed.ncbi.nlm.nih.gov/19199479

DMVHDF4	DI	DMVHDF4
DMVHDF4	DN	(Sar)WTLNSAGYLLGPKK(Lys-myristoyl)K
DMVHDF4	MI	TTX3HNZ
DMVHDF4	MN	Galanin receptor type 1 (GAL1-R)
DMVHDF4	MT	DTT
DMVHDF4	MA	Inhibitor
DMVHDF4	RN	Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues. J Med Chem. 2009 Mar 12;52(5):1310-6.
DMVHDF4	RU	https://pubmed.ncbi.nlm.nih.gov/19199479

DMVHDF4	DI	DMVHDF4
DMVHDF4	DN	(Sar)WTLNSAGYLLGPKK(Lys-myristoyl)K
DMVHDF4	MI	TTBPW3J
DMVHDF4	MN	Galanin receptor type 2 (GAL2-R)
DMVHDF4	MT	DTT
DMVHDF4	MA	Inhibitor
DMVHDF4	RN	Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues. J Med Chem. 2009 Mar 12;52(5):1310-6.
DMVHDF4	RU	https://pubmed.ncbi.nlm.nih.gov/19199479

DMX3K4E	DI	DMX3K4E
DMX3K4E	DN	(Sar)WTLNSAGYLLGPKK(Lys-octanoyl)K
DMX3K4E	MI	TTX3HNZ
DMX3K4E	MN	Galanin receptor type 1 (GAL1-R)
DMX3K4E	MT	DTT
DMX3K4E	MA	Inhibitor
DMX3K4E	RN	Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues. J Med Chem. 2009 Mar 12;52(5):1310-6.
DMX3K4E	RU	https://pubmed.ncbi.nlm.nih.gov/19199479

DMX3K4E	DI	DMX3K4E
DMX3K4E	DN	(Sar)WTLNSAGYLLGPKK(Lys-octanoyl)K
DMX3K4E	MI	TTBPW3J
DMX3K4E	MN	Galanin receptor type 2 (GAL2-R)
DMX3K4E	MT	DTT
DMX3K4E	MA	Inhibitor
DMX3K4E	RN	Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues. J Med Chem. 2009 Mar 12;52(5):1310-6.
DMX3K4E	RU	https://pubmed.ncbi.nlm.nih.gov/19199479

DMSVMI8	DI	DMSVMI8
DMSVMI8	DN	(Sar)WTLNSAGYLLGPKK(Lys-palmitoyl)K
DMSVMI8	MI	TTX3HNZ
DMSVMI8	MN	Galanin receptor type 1 (GAL1-R)
DMSVMI8	MT	DTT
DMSVMI8	MA	Inhibitor
DMSVMI8	RN	Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues. J Med Chem. 2009 Mar 12;52(5):1310-6.
DMSVMI8	RU	https://pubmed.ncbi.nlm.nih.gov/19199479

DMSVMI8	DI	DMSVMI8
DMSVMI8	DN	(Sar)WTLNSAGYLLGPKK(Lys-palmitoyl)K
DMSVMI8	MI	TTBPW3J
DMSVMI8	MN	Galanin receptor type 2 (GAL2-R)
DMSVMI8	MT	DTT
DMSVMI8	MA	Inhibitor
DMSVMI8	RN	Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues. J Med Chem. 2009 Mar 12;52(5):1310-6.
DMSVMI8	RU	https://pubmed.ncbi.nlm.nih.gov/19199479

DMO6N7C	DI	DMO6N7C
DMO6N7C	DN	(Sar)WTLNSAGYLLGPKK(Lys-stearoyl)K
DMO6N7C	MI	TTX3HNZ
DMO6N7C	MN	Galanin receptor type 1 (GAL1-R)
DMO6N7C	MT	DTT
DMO6N7C	MA	Inhibitor
DMO6N7C	RN	Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues. J Med Chem. 2009 Mar 12;52(5):1310-6.
DMO6N7C	RU	https://pubmed.ncbi.nlm.nih.gov/19199479

DMO6N7C	DI	DMO6N7C
DMO6N7C	DN	(Sar)WTLNSAGYLLGPKK(Lys-stearoyl)K
DMO6N7C	MI	TTBPW3J
DMO6N7C	MN	Galanin receptor type 2 (GAL2-R)
DMO6N7C	MT	DTT
DMO6N7C	MA	Inhibitor
DMO6N7C	RN	Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues. J Med Chem. 2009 Mar 12;52(5):1310-6.
DMO6N7C	RU	https://pubmed.ncbi.nlm.nih.gov/19199479

DMT2NVG	DI	DMT2NVG
DMT2NVG	DN	(Sar)WTLNSAGYLLGPKKKK
DMT2NVG	MI	TTX3HNZ
DMT2NVG	MN	Galanin receptor type 1 (GAL1-R)
DMT2NVG	MT	DTT
DMT2NVG	MA	Inhibitor
DMT2NVG	RN	Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues. J Med Chem. 2009 Mar 12;52(5):1310-6.
DMT2NVG	RU	https://pubmed.ncbi.nlm.nih.gov/19199479

DMT2NVG	DI	DMT2NVG
DMT2NVG	DN	(Sar)WTLNSAGYLLGPKKKK
DMT2NVG	MI	TTBPW3J
DMT2NVG	MN	Galanin receptor type 2 (GAL2-R)
DMT2NVG	MT	DTT
DMT2NVG	MA	Inhibitor
DMT2NVG	RN	Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues. J Med Chem. 2009 Mar 12;52(5):1310-6.
DMT2NVG	RU	https://pubmed.ncbi.nlm.nih.gov/19199479

DMT3S72	DI	DMT3S72
DMT3S72	DN	(South)-Methanocarba-Thymidine
DMT3S72	MI	TTP3QRF
DMT3S72	MN	Thymidine kinase 1 (TK1)
DMT3S72	MT	DTT
DMT3S72	MA	Inhibitor
DMT3S72	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMT3S72	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMLW7TV	DI	DMLW7TV
DMLW7TV	DN	(Tert-Butyloxycarbonyl)-Alanyl-Alanyl-Amine
DMLW7TV	MI	TT3NKIB
DMLW7TV	MN	Pancreatic elastase 1 (CELA1)
DMLW7TV	MT	DTT
DMLW7TV	MA	Inhibitor
DMLW7TV	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMLW7TV	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMVZYNH	DI	DMVZYNH
DMVZYNH	DN	(Z)-1-(4-phenyloxazol-2-yl)octadec-9-en-1-one
DMVZYNH	MI	TTDP1UC
DMVZYNH	MN	Fatty acid amide hydrolase (FAAH)
DMVZYNH	MT	DTT
DMVZYNH	MA	Inhibitor
DMVZYNH	RN	Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. Bioorg Med Chem. 2008 Feb 15;16(4):1562-95.
DMVZYNH	RU	https://pubmed.ncbi.nlm.nih.gov/18053726

DMNBDGH	DI	DMNBDGH
DMNBDGH	DN	(Z)-1-(benzo[d]oxazol-2-yl)octadec-9-en-1-one
DMNBDGH	MI	TTDP1UC
DMNBDGH	MN	Fatty acid amide hydrolase (FAAH)
DMNBDGH	MT	DTT
DMNBDGH	MA	Inhibitor
DMNBDGH	RN	Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. Bioorg Med Chem. 2008 Feb 15;16(4):1562-95.
DMNBDGH	RU	https://pubmed.ncbi.nlm.nih.gov/18053726

DMMTXKO	DI	DMMTXKO
DMMTXKO	DN	(Z)-1-(pyridazin-3-yl)octadec-9-en-1-one
DMMTXKO	MI	TTDP1UC
DMMTXKO	MN	Fatty acid amide hydrolase (FAAH)
DMMTXKO	MT	DTT
DMMTXKO	MA	Inhibitor
DMMTXKO	RN	Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. Bioorg Med Chem. 2008 Feb 15;16(4):1562-95.
DMMTXKO	RU	https://pubmed.ncbi.nlm.nih.gov/18053726

DMSVBZO	DI	DMSVBZO
DMSVBZO	DN	(Z)-1,1,1,2,2,3,3-heptafluorohenicos-12-en-4-one
DMSVBZO	MI	TTT1JVS
DMSVBZO	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DMSVBZO	MT	DTT
DMSVBZO	MA	Inhibitor
DMSVBZO	RN	Potent and selective fluoroketone inhibitors of group VIA calcium-independent phospholipase A2. J Med Chem. 2010 May 13;53(9):3602-10.
DMSVBZO	RU	https://pubmed.ncbi.nlm.nih.gov/20369880

DMBTMDG	DI	DMBTMDG
DMBTMDG	DN	(Z)-1,1,1-Trifluoro-nonadec-10-en-2-one
DMBTMDG	MI	TTDP1UC
DMBTMDG	MN	Fatty acid amide hydrolase (FAAH)
DMBTMDG	MT	DTT
DMBTMDG	MA	Inhibitor
DMBTMDG	RN	Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as a... J Med Chem. 2005 Mar 24;48(6):1849-56.
DMBTMDG	RU	https://pubmed.ncbi.nlm.nih.gov/15771430

DMKQ679	DI	DMKQ679
DMKQ679	DN	(Z)-2-(1-decyl-2-oxoindolin-3-ylidene)acetic acid
DMKQ679	MI	TTLZS4Q
DMKQ679	MN	M-phase inducer phosphatase 1 (MPIP1)
DMKQ679	MT	DTT
DMKQ679	MA	Inhibitor
DMKQ679	RN	Design and synthesis of N-alkyl oxindolylidene acetic acids as a new class of potent Cdc25A inhibitors. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3350-3.
DMKQ679	RU	https://pubmed.ncbi.nlm.nih.gov/18442908

DM2HZX8	DI	DM2HZX8
DM2HZX8	DN	(Z)-2,2-Dimethyl-1-oxazol-2-yl-octadec-9-en-1-one
DM2HZX8	MI	TTDP1UC
DM2HZX8	MN	Fatty acid amide hydrolase (FAAH)
DM2HZX8	MT	DTT
DM2HZX8	MA	Inhibitor
DM2HZX8	RN	alpha-Keto heterocycle inhibitors of fatty acid amide hydrolase: carbonyl group modification and alpha-substitution. Bioorg Med Chem Lett. 2001 Jun 18;11(12):1517-20.
DM2HZX8	RU	https://pubmed.ncbi.nlm.nih.gov/11412972

DMFLDPU	DI	DMFLDPU
DMFLDPU	DN	(Z)-2,6-diisopropyl-N-phenyloctadec-9-enamide
DMFLDPU	MI	TTK3C21
DMFLDPU	MN	Acetoacetyl-CoA thiolase (ACAT1)
DMFLDPU	MT	DTT
DMFLDPU	MA	Inhibitor
DMFLDPU	RN	Biphenyl versus phenylpyridazine derivatives: the role of the heterocycle in a series of acyl-CoA:cholesterol acyl transferase inhibitors. J Med Chem. 2008 Mar 13;51(5):1474-7.
DMFLDPU	RU	https://pubmed.ncbi.nlm.nih.gov/18284184

DM0OEQJ	DI	DM0OEQJ
DM0OEQJ	DN	(Z)-2'-des-methyl sulindac sulfide
DM0OEQJ	MI	TT8NGED
DM0OEQJ	MN	Prostaglandin G/H synthase 1 (COX-1)
DM0OEQJ	MT	DTT
DM0OEQJ	MA	Inhibitor
DM0OEQJ	RN	The influence of double bond geometry in the inhibition of cyclooxygenases by sulindac derivatives. Bioorg Med Chem Lett. 2009 Jun 15;19(12):3271-4.
DM0OEQJ	RU	https://pubmed.ncbi.nlm.nih.gov/19427206

DM0OEQJ	DI	DM0OEQJ
DM0OEQJ	DN	(Z)-2'-des-methyl sulindac sulfide
DM0OEQJ	MI	TTVKILB
DM0OEQJ	MN	Prostaglandin G/H synthase 2 (COX-2)
DM0OEQJ	MT	DTT
DM0OEQJ	MA	Inhibitor
DM0OEQJ	RN	The influence of double bond geometry in the inhibition of cyclooxygenases by sulindac derivatives. Bioorg Med Chem Lett. 2009 Jun 15;19(12):3271-4.
DM0OEQJ	RU	https://pubmed.ncbi.nlm.nih.gov/19427206

DMYH9BC	DI	DMYH9BC
DMYH9BC	DN	(Z)-2-Methyl-1-oxazol-2-yl-octadec-9-en-1-one
DMYH9BC	MI	TTDP1UC
DMYH9BC	MN	Fatty acid amide hydrolase (FAAH)
DMYH9BC	MT	DTT
DMYH9BC	MA	Inhibitor
DMYH9BC	RN	alpha-Keto heterocycle inhibitors of fatty acid amide hydrolase: carbonyl group modification and alpha-substitution. Bioorg Med Chem Lett. 2001 Jun 18;11(12):1517-20.
DMYH9BC	RU	https://pubmed.ncbi.nlm.nih.gov/11412972

DM18R6J	DI	DM18R6J
DM18R6J	DN	(Z)-2-Methyl-3-tetradecyl-but-2-enedioic acid
DM18R6J	MI	TT7WZIJ
DM18R6J	MN	CAAX farnesyltransferase beta (FNTB)
DM18R6J	MT	DTT
DM18R6J	MA	Inhibitor
DM18R6J	RN	Ras farnesyltransferase: a new therapeutic target. J Med Chem. 1997 Sep 12;40(19):2971-90.
DM18R6J	RU	https://pubmed.ncbi.nlm.nih.gov/9301658

DM18R6J	DI	DM18R6J
DM18R6J	DN	(Z)-2-Methyl-3-tetradecyl-but-2-enedioic acid
DM18R6J	MI	TTXQKM3
DM18R6J	MN	Farnesyl protein transferase (Ftase)
DM18R6J	MT	DTT
DM18R6J	MA	Inhibitor
DM18R6J	RN	Ras farnesyltransferase: a new therapeutic target. J Med Chem. 1997 Sep 12;40(19):2971-90.
DM18R6J	RU	https://pubmed.ncbi.nlm.nih.gov/9301658

DM27WDP	DI	DM27WDP
DM27WDP	DN	(Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one
DM27WDP	MI	TTYMGWX
DM27WDP	MN	PDK-1 messenger RNA (PDK-1 mRNA)
DM27WDP	MT	DTT
DM27WDP	MA	Inhibitor
DM27WDP	RN	Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity. Bioorg Med Chem Lett. 2007 Jul 15;17(14):3814-8.
DM27WDP	RU	https://pubmed.ncbi.nlm.nih.gov/17531483

DM27WDP	DI	DM27WDP
DM27WDP	DN	(Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one
DM27WDP	MI	TT4DXQT
DM27WDP	MN	Proto-oncogene c-Ret (RET)
DM27WDP	MT	DTT
DM27WDP	MA	Inhibitor
DM27WDP	RN	Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1482-96.
DM27WDP	RU	https://pubmed.ncbi.nlm.nih.gov/20117004

DM27WDP	DI	DM27WDP
DM27WDP	DN	(Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one
DM27WDP	MI	TTWTSCV
DM27WDP	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DM27WDP	MT	DTT
DM27WDP	MA	Inhibitor
DM27WDP	RN	Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity. Bioorg Med Chem Lett. 2007 Jul 15;17(14):3814-8.
DM27WDP	RU	https://pubmed.ncbi.nlm.nih.gov/17531483

DMIQ14F	DI	DMIQ14F
DMIQ14F	DN	(Z)-3-[2-(9H-fluoren-2-yloxy)ethylidene]-quinuclidine hydrochloride 31
DMIQ14F	MI	TTFQEO5
DMIQ14F	MN	Squalene synthetase (FDFT1)
DMIQ14F	MT	DTT
DMIQ14F	MA	Inhibitor
DMIQ14F	RN	Syntheses and biological evaluation of novel quinuclidine derivatives as squalene synthase inhibitors. Bioorg Med Chem. 2003 May 29;11(11):2403-14.
DMIQ14F	RU	https://pubmed.ncbi.nlm.nih.gov/12735986

DM30YQF	DI	DM30YQF
DM30YQF	DN	(Z)-4-(4-hexylphenylamino)-4-oxobut-2-enoic acid
DM30YQF	MI	TTTSEPU
DM30YQF	MN	Thyroid hormone receptor alpha (THRA)
DM30YQF	MT	DTT
DM30YQF	MA	Inhibitor
DM30YQF	RN	Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80.
DM30YQF	RU	https://pubmed.ncbi.nlm.nih.gov/17918822

DM30YQF	DI	DM30YQF
DM30YQF	DN	(Z)-4-(4-hexylphenylamino)-4-oxobut-2-enoic acid
DM30YQF	MI	TTGER3L
DM30YQF	MN	Thyroid hormone receptor beta (THRB)
DM30YQF	MT	DTT
DM30YQF	MA	Inhibitor
DM30YQF	RN	Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80.
DM30YQF	RU	https://pubmed.ncbi.nlm.nih.gov/17918822

DMPJAKL	DI	DMPJAKL
DMPJAKL	DN	(Z)-5-Amino-3-(4-methoxybenzylidene)indolin-2-one
DMPJAKL	MI	TT4DXQT
DMPJAKL	MN	Proto-oncogene c-Ret (RET)
DMPJAKL	MT	DTT
DMPJAKL	MA	Inhibitor
DMPJAKL	RN	Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1482-96.
DMPJAKL	RU	https://pubmed.ncbi.nlm.nih.gov/20117004

DM3ALJD	DI	DM3ALJD
DM3ALJD	DN	(Z)-5-Benzylidene-2-thioxothiazolidin-4-one
DM3ALJD	MI	TT1K6Q4
DM3ALJD	MN	Arylamine N-acetyltransferase (NAT)
DM3ALJD	MT	DTT
DM3ALJD	MA	Inhibitor
DM3ALJD	RN	Selective small molecule inhibitors of the potential breast cancer marker, human arylamine N-acetyltransferase 1, and its murine homologue, mouse a... Bioorg Med Chem. 2009 Jan 15;17(2):905-18.
DM3ALJD	RU	https://pubmed.ncbi.nlm.nih.gov/19059786

DMLRWAF	DI	DMLRWAF
DMLRWAF	DN	(Z)-5-Butylidene-2-thioxothiazolidin-4-one
DMLRWAF	MI	TT1K6Q4
DMLRWAF	MN	Arylamine N-acetyltransferase (NAT)
DMLRWAF	MT	DTT
DMLRWAF	MA	Inhibitor
DMLRWAF	RN	Selective small molecule inhibitors of the potential breast cancer marker, human arylamine N-acetyltransferase 1, and its murine homologue, mouse a... Bioorg Med Chem. 2009 Jan 15;17(2):905-18.
DMLRWAF	RU	https://pubmed.ncbi.nlm.nih.gov/19059786

DM5U1M8	DI	DM5U1M8
DM5U1M8	DN	(Z)-5-Decylidene-2-thioxothiazolidin-4-one
DM5U1M8	MI	TT1K6Q4
DM5U1M8	MN	Arylamine N-acetyltransferase (NAT)
DM5U1M8	MT	DTT
DM5U1M8	MA	Inhibitor
DM5U1M8	RN	Selective small molecule inhibitors of the potential breast cancer marker, human arylamine N-acetyltransferase 1, and its murine homologue, mouse a... Bioorg Med Chem. 2009 Jan 15;17(2):905-18.
DM5U1M8	RU	https://pubmed.ncbi.nlm.nih.gov/19059786

DMV70YA	DI	DMV70YA
DMV70YA	DN	(Z)-5-Hexylidene-2-thioxothiazolidin-4-one
DMV70YA	MI	TT1K6Q4
DMV70YA	MN	Arylamine N-acetyltransferase (NAT)
DMV70YA	MT	DTT
DMV70YA	MA	Inhibitor
DMV70YA	RN	Selective small molecule inhibitors of the potential breast cancer marker, human arylamine N-acetyltransferase 1, and its murine homologue, mouse a... Bioorg Med Chem. 2009 Jan 15;17(2):905-18.
DMV70YA	RU	https://pubmed.ncbi.nlm.nih.gov/19059786

DM4X9GW	DI	DM4X9GW
DM4X9GW	DN	(Z)-5-octadecen-7,9-diynoic acid
DM4X9GW	MI	TTPADOQ
DM4X9GW	MN	HMG-CoA reductase (HMGCR)
DM4X9GW	MT	DTT
DM4X9GW	MA	Inhibitor
DM4X9GW	RN	Novel Acetylenic Acids from the Root Bark of Paramacrolobium caeruleum: Inhibitors of 3-Hydroxy-3-methyl-glutaryl Coenzyme A Reductase J. Nat. Prod. 52(1):153-161 (1989).
DM4X9GW	RU	http://pubs.acs.org/doi/abs/10.1021/np50061a020

DMEJNFS	DI	DMEJNFS
DMEJNFS	DN	(Z)-5-Octylidene-2-thioxothiazolidin-4-one
DMEJNFS	MI	TT1K6Q4
DMEJNFS	MN	Arylamine N-acetyltransferase (NAT)
DMEJNFS	MT	DTT
DMEJNFS	MA	Inhibitor
DMEJNFS	RN	Selective small molecule inhibitors of the potential breast cancer marker, human arylamine N-acetyltransferase 1, and its murine homologue, mouse a... Bioorg Med Chem. 2009 Jan 15;17(2):905-18.
DMEJNFS	RU	https://pubmed.ncbi.nlm.nih.gov/19059786

DMKWLSB	DI	DMKWLSB
DMKWLSB	DN	(Z)-7-octedecan-9-ynoic acid
DMKWLSB	MI	TTPADOQ
DMKWLSB	MN	HMG-CoA reductase (HMGCR)
DMKWLSB	MT	DTT
DMKWLSB	MA	Inhibitor
DMKWLSB	RN	Novel Acetylenic Acids from the Root Bark of Paramacrolobium caeruleum: Inhibitors of 3-Hydroxy-3-methyl-glutaryl Coenzyme A Reductase J. Nat. Prod. 52(1):153-161 (1989).
DMKWLSB	RU	http://pubs.acs.org/doi/abs/10.1021/np50061a020

DMOB9E4	DI	DMOB9E4
DMOB9E4	DN	(Z)-8-(3-chlorostyryl)caffeine
DMOB9E4	MI	TTM2AOE
DMOB9E4	MN	Adenosine A2a receptor (ADORA2A)
DMOB9E4	MT	DTT
DMOB9E4	MA	Inhibitor
DMOB9E4	RN	Dual inhibition of monoamine oxidase B and antagonism of the adenosine A(2A) receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues. Bioorg Med Chem. 2008 Sep 15;16(18):8676-84.
DMOB9E4	RU	https://pubmed.ncbi.nlm.nih.gov/18723354

DMX0G7E	DI	DMX0G7E
DMX0G7E	DN	[(125)I] RB129
DMX0G7E	MI	TTPHMWB
DMX0G7E	MN	Aminopeptidase N (ANPEP)
DMX0G7E	MT	DTT
DMX0G7E	MA	Inhibitor
DMX0G7E	RN	Ontogenic and adult whole body distribution of aminopeptidase N in rat investigated by in vitro autoradiography. Biochimie. 2004 Feb;86(2):105-13.
DMX0G7E	RU	https://pubmed.ncbi.nlm.nih.gov/15016448

DMX0G7E	DI	DMX0G7E
DMX0G7E	DN	[(125)I] RB129
DMX0G7E	MI	TTN7BL9
DMX0G7E	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMX0G7E	MT	DTT
DMX0G7E	MA	Inhibitor
DMX0G7E	RN	Rapid hepatic metabolism of 7-ketocholesterol by 11beta-hydroxysteroid dehydrogenase type 1: species-specific differences between the rat, human, a... J Biol Chem. 2004 Apr 30;279(18):18415-24.
DMX0G7E	RU	https://pubmed.ncbi.nlm.nih.gov/14973125

DMX0G7E	DI	DMX0G7E
DMX0G7E	DN	[(125)I] RB129
DMX0G7E	MI	TT9H85R
DMX0G7E	MN	Corticosteroid 11-beta-dehydrogenase 2 (HSD11B2)
DMX0G7E	MT	DTT
DMX0G7E	MA	Inhibitor
DMX0G7E	RN	Abnormal expression of 11 beta-hydroxysteroid dehydrogenase type 2 in human pituitary adenomas: a prereceptor determinant of pituitary cell proliferation. Oncogene. 2003 Mar 20;22(11):1663-7.
DMX0G7E	RU	https://pubmed.ncbi.nlm.nih.gov/12642869

DMG1ATX	DI	DMG1ATX
DMG1ATX	DN	[(1e)-4-Phenylbut-1-Enyl]Benzene
DMG1ATX	MI	TTGP7BY
DMG1ATX	MN	Monoamine oxidase type B (MAO-B)
DMG1ATX	MT	DTT
DMG1ATX	MA	Inhibitor
DMG1ATX	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMG1ATX	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM3WDOY	DI	DM3WDOY
DM3WDOY	DN	[(2-aminooxyethyl)methylamino]-5'-deoxyadenosine
DM3WDOY	MI	TTBFROQ
DM3WDOY	MN	S-adenosylmethionine decarboxylase proenzyme (AMD1)
DM3WDOY	MT	DTT
DM3WDOY	MA	Inhibitor
DM3WDOY	RN	New insights into the design of inhibitors of human S-adenosylmethionine decarboxylase: studies of adenine C8 substitution in structural analogues ... J Med Chem. 2009 Mar 12;52(5):1388-407.
DM3WDOY	RU	https://pubmed.ncbi.nlm.nih.gov/19209891

DMTK9V7	DI	DMTK9V7
DMTK9V7	DN	[(3-Bromophenyl)-m-tolyl-ketone]thiosemicarbazone
DMTK9V7	MI	TT36ETB
DMTK9V7	MN	Cathepsin L (CTSL)
DMTK9V7	MT	DTT
DMTK9V7	MA	Inhibitor
DMTK9V7	RN	Design, synthesis, and biological evaluation of potent thiosemicarbazone based cathepsin L inhibitors. Bioorg Med Chem Lett. 2010 Feb 15;20(4):1415-9.
DMTK9V7	RU	https://pubmed.ncbi.nlm.nih.gov/20089402

DMZG7TH	DI	DMZG7TH
DMZG7TH	DN	[(3-Bromophenyl)-p-tolyl-ketone]thiosemicarbazone
DMZG7TH	MI	TTF2LRI
DMZG7TH	MN	Cathepsin B (CTSB)
DMZG7TH	MT	DTT
DMZG7TH	MA	Inhibitor
DMZG7TH	RN	Design, synthesis, and biological evaluation of potent thiosemicarbazone based cathepsin L inhibitors. Bioorg Med Chem Lett. 2010 Feb 15;20(4):1415-9.
DMZG7TH	RU	https://pubmed.ncbi.nlm.nih.gov/20089402

DMZG7TH	DI	DMZG7TH
DMZG7TH	DN	[(3-Bromophenyl)-p-tolyl-ketone]thiosemicarbazone
DMZG7TH	MI	TT36ETB
DMZG7TH	MN	Cathepsin L (CTSL)
DMZG7TH	MT	DTT
DMZG7TH	MA	Inhibitor
DMZG7TH	RN	Design, synthesis, and biological evaluation of potent thiosemicarbazone based cathepsin L inhibitors. Bioorg Med Chem Lett. 2010 Feb 15;20(4):1415-9.
DMZG7TH	RU	https://pubmed.ncbi.nlm.nih.gov/20089402

DM9YHA7	DI	DM9YHA7
DM9YHA7	DN	[(40-OH) MeLeu]4-CsA derivatives
DM9YHA7	MI	TT84ETX
DM9YHA7	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM9YHA7	MT	DTT
DM9YHA7	MA	Inhibitor
DM9YHA7	RN	Synthesis of non-immunosuppressive cyclophilin-Binding cyclosporin A derivatives as potential anti-HIV-1 drugs. Bioorg Med Chem Lett. 2003 Dec 15;13(24):4415-9.
DM9YHA7	RU	https://pubmed.ncbi.nlm.nih.gov/14643337

DM1ZM5R	DI	DM1ZM5R
DM1ZM5R	DN	[(40-OH)MeLeu]4-Cyclosporin A
DM1ZM5R	MI	TT84ETX
DM1ZM5R	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM1ZM5R	MT	DTT
DM1ZM5R	MA	Inhibitor
DM1ZM5R	RN	Synthesis of non-immunosuppressive cyclophilin-Binding cyclosporin A derivatives as potential anti-HIV-1 drugs. Bioorg Med Chem Lett. 2003 Dec 15;13(24):4415-9.
DM1ZM5R	RU	https://pubmed.ncbi.nlm.nih.gov/14643337

DMV30N2	DI	DMV30N2
DMV30N2	DN	[(D)MeSer]3-[(40-OH) MeLeu]4-Cyclosporin A
DMV30N2	MI	TT84ETX
DMV30N2	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMV30N2	MT	DTT
DMV30N2	MA	Inhibitor
DMV30N2	RN	Synthesis of non-immunosuppressive cyclophilin-Binding cyclosporin A derivatives as potential anti-HIV-1 drugs. Bioorg Med Chem Lett. 2003 Dec 15;13(24):4415-9.
DMV30N2	RU	https://pubmed.ncbi.nlm.nih.gov/14643337

DMVWCTL	DI	DMVWCTL
DMVWCTL	DN	[(N4-Bzdig)0,Nle14]BB(7-14)
DMVWCTL	MI	TTC1MVT
DMVWCTL	MN	Gastrin-releasing peptide receptor (GRPR)
DMVWCTL	MT	DTT
DMVWCTL	MA	Inhibitor
DMVWCTL	RN	Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study. J Med Chem. 2005 Jan 13;48(1):100-10.
DMVWCTL	RU	https://pubmed.ncbi.nlm.nih.gov/15634004

DMD4BSJ	DI	DMD4BSJ
DMD4BSJ	DN	[(N4-Bzdig)0]BB(7-14)
DMD4BSJ	MI	TTHYDUM
DMD4BSJ	MN	Bombesin receptor (BS)
DMD4BSJ	MT	DTT
DMD4BSJ	MA	Inhibitor
DMD4BSJ	RN	Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study. J Med Chem. 2005 Jan 13;48(1):100-10.
DMD4BSJ	RU	https://pubmed.ncbi.nlm.nih.gov/15634004

DMD4BSJ	DI	DMD4BSJ
DMD4BSJ	DN	[(N4-Bzdig)0]BB(7-14)
DMD4BSJ	MI	TTC1MVT
DMD4BSJ	MN	Gastrin-releasing peptide receptor (GRPR)
DMD4BSJ	MT	DTT
DMD4BSJ	MA	Inhibitor
DMD4BSJ	RN	Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study. J Med Chem. 2005 Jan 13;48(1):100-10.
DMD4BSJ	RU	https://pubmed.ncbi.nlm.nih.gov/15634004

DMPFUBE	DI	DMPFUBE
DMPFUBE	DN	[(R)-(+)-deoxytylophorinidine
DMPFUBE	MI	TTS7IR5
DMPFUBE	MN	c-Jun messenger RNA (c-Jun mRNA)
DMPFUBE	MT	DTT
DMPFUBE	MA	Inhibitor
DMPFUBE	RN	Structure-activity studies of phenanthroindolizidine alkaloids as potential antitumor agents. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4338-42.
DMPFUBE	RU	https://pubmed.ncbi.nlm.nih.gov/17531481

DMU9F2P	DI	DMU9F2P
DMU9F2P	DN	[[4-(Aminomethyl)Phenyl]Amino]Oxo-Acetic Acid,
DMU9F2P	MI	TTELIN2
DMU9F2P	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMU9F2P	MT	DTT
DMU9F2P	MA	Inhibitor
DMU9F2P	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMU9F2P	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM86305	DI	DM86305
DM86305	DN	[[N-(Benzyloxycarbonyl)Amino]Methyl]Phosphate
DM86305	MI	TTHI19T
DM86305	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DM86305	MT	DTT
DM86305	MA	Inhibitor
DM86305	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM86305	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMAGW3R	DI	DMAGW3R
DMAGW3R	DN	[1-(4-p-Tolyl-butyl)-piperidin-4-yl]-methanol
DMAGW3R	MI	TTQ6VDM
DMAGW3R	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMAGW3R	MT	DTT
DMAGW3R	MA	Inhibitor
DMAGW3R	RN	Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs. Bioorg Med Chem Lett. 2009 Sep 1;19(17):5043-7.
DMAGW3R	RU	https://pubmed.ncbi.nlm.nih.gov/19660947

DMVOY4D	DI	DMVOY4D
DMVOY4D	DN	[1,1':2',1'']-terphenyl-4,3'',5''-triol
DMVOY4D	MI	TT3OT40
DMVOY4D	MN	Multidrug resistance protein 1 (ABCB1)
DMVOY4D	MT	DTT
DMVOY4D	MA	Inhibitor
DMVOY4D	RN	Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells. J Med Chem. 2006 May 18;49(10):3012-8.
DMVOY4D	RU	https://pubmed.ncbi.nlm.nih.gov/16686543

DMVOY4D	DI	DMVOY4D
DMVOY4D	DN	[1,1':2',1'']-terphenyl-4,3'',5''-triol
DMVOY4D	MI	TT3PJMV
DMVOY4D	MN	Tyrosine-protein kinase ABL1 (ABL)
DMVOY4D	MT	DTT
DMVOY4D	MA	Inhibitor
DMVOY4D	RN	Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells. J Med Chem. 2006 May 18;49(10):3012-8.
DMVOY4D	RU	https://pubmed.ncbi.nlm.nih.gov/16686543

DMFXA8P	DI	DMFXA8P
DMFXA8P	DN	[1,1':2',1'']Terphenyl-4'-carbaldehyde oxime
DMFXA8P	MI	TTZAYWL
DMFXA8P	MN	Estrogen receptor (ESR)
DMFXA8P	MT	DTT
DMFXA8P	MA	Inhibitor
DMFXA8P	RN	Novel estrogen receptor ligands based on an anthranylaldoxime structure: role of the phenol-type pseudocycle in the binding process. J Med Chem. 2003 Sep 11;46(19):4032-42.
DMFXA8P	RU	https://pubmed.ncbi.nlm.nih.gov/12954056

DMFXA8P	DI	DMFXA8P
DMFXA8P	DN	[1,1':2',1'']Terphenyl-4'-carbaldehyde oxime
DMFXA8P	MI	TTOM3J0
DMFXA8P	MN	Estrogen receptor beta (ESR2)
DMFXA8P	MT	DTT
DMFXA8P	MA	Inhibitor
DMFXA8P	RN	Novel estrogen receptor ligands based on an anthranylaldoxime structure: role of the phenol-type pseudocycle in the binding process. J Med Chem. 2003 Sep 11;46(19):4032-42.
DMFXA8P	RU	https://pubmed.ncbi.nlm.nih.gov/12954056

DMPV0QN	DI	DMPV0QN
DMPV0QN	DN	[1,2,4]triazolo[1,5-a]quinoxalin-4(5H)-one
DMPV0QN	MI	TTJFY5U
DMPV0QN	MN	Adenosine A3 receptor (ADORA3)
DMPV0QN	MT	DTT
DMPV0QN	MA	Inhibitor
DMPV0QN	RN	1,2,4-Triazolo[1,5-a]quinoxaline as a versatile tool for the design of selective human A3 adenosine receptor antagonists: synthesis, biological eva... J Med Chem. 2005 Dec 15;48(25):7932-45.
DMPV0QN	RU	https://pubmed.ncbi.nlm.nih.gov/16335918

DMDX6W4	DI	DMDX6W4
DMDX6W4	DN	[1,3]Oxazinan-(2E)-ylideneamine
DMDX6W4	MI	TTZUFI5
DMDX6W4	MN	Nitric-oxide synthase brain (NOS1)
DMDX6W4	MT	DTT
DMDX6W4	MA	Inhibitor
DMDX6W4	RN	2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. J Med Chem. 1996 Feb 2;39(3):669-72.
DMDX6W4	RU	https://pubmed.ncbi.nlm.nih.gov/8576908

DMDX6W4	DI	DMDX6W4
DMDX6W4	DN	[1,3]Oxazinan-(2E)-ylideneamine
DMDX6W4	MI	TTCM4B3
DMDX6W4	MN	Nitric-oxide synthase endothelial (NOS3)
DMDX6W4	MT	DTT
DMDX6W4	MA	Inhibitor
DMDX6W4	RN	2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. J Med Chem. 1996 Feb 2;39(3):669-72.
DMDX6W4	RU	https://pubmed.ncbi.nlm.nih.gov/8576908

DMDX6W4	DI	DMDX6W4
DMDX6W4	DN	[1,3]Oxazinan-(2E)-ylideneamine
DMDX6W4	MI	TTF10I9
DMDX6W4	MN	Nitric-oxide synthase inducible (NOS2)
DMDX6W4	MT	DTT
DMDX6W4	MA	Inhibitor
DMDX6W4	RN	2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. J Med Chem. 1996 Feb 2;39(3):669-72.
DMDX6W4	RU	https://pubmed.ncbi.nlm.nih.gov/8576908

DMOEIHC	DI	DMOEIHC
DMOEIHC	DN	[1,3]Thiazinan-(2E)-ylideneamine
DMOEIHC	MI	TTZUFI5
DMOEIHC	MN	Nitric-oxide synthase brain (NOS1)
DMOEIHC	MT	DTT
DMOEIHC	MA	Inhibitor
DMOEIHC	RN	2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. J Med Chem. 1996 Feb 2;39(3):669-72.
DMOEIHC	RU	https://pubmed.ncbi.nlm.nih.gov/8576908

DMOEIHC	DI	DMOEIHC
DMOEIHC	DN	[1,3]Thiazinan-(2E)-ylideneamine
DMOEIHC	MI	TTCM4B3
DMOEIHC	MN	Nitric-oxide synthase endothelial (NOS3)
DMOEIHC	MT	DTT
DMOEIHC	MA	Inhibitor
DMOEIHC	RN	2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. J Med Chem. 1996 Feb 2;39(3):669-72.
DMOEIHC	RU	https://pubmed.ncbi.nlm.nih.gov/8576908

DMOEIHC	DI	DMOEIHC
DMOEIHC	DN	[1,3]Thiazinan-(2E)-ylideneamine
DMOEIHC	MI	TTF10I9
DMOEIHC	MN	Nitric-oxide synthase inducible (NOS2)
DMOEIHC	MT	DTT
DMOEIHC	MA	Inhibitor
DMOEIHC	RN	2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. J Med Chem. 1996 Feb 2;39(3):669-72.
DMOEIHC	RU	https://pubmed.ncbi.nlm.nih.gov/8576908

DMX58NK	DI	DMX58NK
DMX58NK	DN	[1,4]Oxazepan-(3E)-ylideneamine
DMX58NK	MI	TTZUFI5
DMX58NK	MN	Nitric-oxide synthase brain (NOS1)
DMX58NK	MT	DTT
DMX58NK	MA	Inhibitor
DMX58NK	RN	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
DMX58NK	RU	https://pubmed.ncbi.nlm.nih.gov/15501067

DMX58NK	DI	DMX58NK
DMX58NK	DN	[1,4]Oxazepan-(3E)-ylideneamine
DMX58NK	MI	TTCM4B3
DMX58NK	MN	Nitric-oxide synthase endothelial (NOS3)
DMX58NK	MT	DTT
DMX58NK	MA	Inhibitor
DMX58NK	RN	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
DMX58NK	RU	https://pubmed.ncbi.nlm.nih.gov/15501067

DMX58NK	DI	DMX58NK
DMX58NK	DN	[1,4]Oxazepan-(3E)-ylideneamine
DMX58NK	MI	TTF10I9
DMX58NK	MN	Nitric-oxide synthase inducible (NOS2)
DMX58NK	MT	DTT
DMX58NK	MA	Inhibitor
DMX58NK	RN	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
DMX58NK	RU	https://pubmed.ncbi.nlm.nih.gov/15501067

DMMUZVS	DI	DMMUZVS
DMMUZVS	DN	[1,4]Oxazepan-(5E)-ylideneamine
DMMUZVS	MI	TTZUFI5
DMMUZVS	MN	Nitric-oxide synthase brain (NOS1)
DMMUZVS	MT	DTT
DMMUZVS	MA	Inhibitor
DMMUZVS	RN	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
DMMUZVS	RU	https://pubmed.ncbi.nlm.nih.gov/15501067

DMMUZVS	DI	DMMUZVS
DMMUZVS	DN	[1,4]Oxazepan-(5E)-ylideneamine
DMMUZVS	MI	TTF10I9
DMMUZVS	MN	Nitric-oxide synthase inducible (NOS2)
DMMUZVS	MT	DTT
DMMUZVS	MA	Inhibitor
DMMUZVS	RN	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
DMMUZVS	RU	https://pubmed.ncbi.nlm.nih.gov/15501067

DMCBFJQ	DI	DMCBFJQ
DMCBFJQ	DN	[1,4]Thiazepan-(3E)-ylideneamine
DMCBFJQ	MI	TTZUFI5
DMCBFJQ	MN	Nitric-oxide synthase brain (NOS1)
DMCBFJQ	MT	DTT
DMCBFJQ	MA	Inhibitor
DMCBFJQ	RN	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
DMCBFJQ	RU	https://pubmed.ncbi.nlm.nih.gov/15501067

DMCBFJQ	DI	DMCBFJQ
DMCBFJQ	DN	[1,4]Thiazepan-(3E)-ylideneamine
DMCBFJQ	MI	TTCM4B3
DMCBFJQ	MN	Nitric-oxide synthase endothelial (NOS3)
DMCBFJQ	MT	DTT
DMCBFJQ	MA	Inhibitor
DMCBFJQ	RN	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
DMCBFJQ	RU	https://pubmed.ncbi.nlm.nih.gov/15501067

DMCBFJQ	DI	DMCBFJQ
DMCBFJQ	DN	[1,4]Thiazepan-(3E)-ylideneamine
DMCBFJQ	MI	TTF10I9
DMCBFJQ	MN	Nitric-oxide synthase inducible (NOS2)
DMCBFJQ	MT	DTT
DMCBFJQ	MA	Inhibitor
DMCBFJQ	RN	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
DMCBFJQ	RU	https://pubmed.ncbi.nlm.nih.gov/15501067

DMFQ0Z4	DI	DMFQ0Z4
DMFQ0Z4	DN	[1,4]Thiazepan-(5E)-ylideneamine
DMFQ0Z4	MI	TTZUFI5
DMFQ0Z4	MN	Nitric-oxide synthase brain (NOS1)
DMFQ0Z4	MT	DTT
DMFQ0Z4	MA	Inhibitor
DMFQ0Z4	RN	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
DMFQ0Z4	RU	https://pubmed.ncbi.nlm.nih.gov/15501067

DMFQ0Z4	DI	DMFQ0Z4
DMFQ0Z4	DN	[1,4]Thiazepan-(5E)-ylideneamine
DMFQ0Z4	MI	TTCM4B3
DMFQ0Z4	MN	Nitric-oxide synthase endothelial (NOS3)
DMFQ0Z4	MT	DTT
DMFQ0Z4	MA	Inhibitor
DMFQ0Z4	RN	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
DMFQ0Z4	RU	https://pubmed.ncbi.nlm.nih.gov/15501067

DMFQ0Z4	DI	DMFQ0Z4
DMFQ0Z4	DN	[1,4]Thiazepan-(5E)-ylideneamine
DMFQ0Z4	MI	TTF10I9
DMFQ0Z4	MN	Nitric-oxide synthase inducible (NOS2)
DMFQ0Z4	MT	DTT
DMFQ0Z4	MA	Inhibitor
DMFQ0Z4	RN	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
DMFQ0Z4	RU	https://pubmed.ncbi.nlm.nih.gov/15501067

DMF62JR	DI	DMF62JR
DMF62JR	DN	[1,5]Thiazocan-(4E)-ylideneamine
DMF62JR	MI	TTF10I9
DMF62JR	MN	Nitric-oxide synthase inducible (NOS2)
DMF62JR	MT	DTT
DMF62JR	MA	Inhibitor
DMF62JR	RN	Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3.
DMF62JR	RU	https://pubmed.ncbi.nlm.nih.gov/11551770

DMMZUPX	DI	DMMZUPX
DMMZUPX	DN	[11C]AZ10419369
DMMZUPX	MI	TTK8CXU
DMMZUPX	MN	5-HT 1B receptor (HTR1B)
DMMZUPX	MT	DTT
DMMZUPX	MA	Agonist
DMMZUPX	RN	Quantitative analysis of [11C]AZ10419369 binding to 5-HT1B receptors in human brain. J Cereb Blood Flow Metab. 2011 Jan;31(1):113-23.
DMMZUPX	RU	https://pubmed.ncbi.nlm.nih.gov/20424633

DMQP03A	DI	DMQP03A
DMQP03A	DN	[11C]butylthio-TZTP
DMQP03A	MI	TTOXS3C
DMQP03A	MN	Muscarinic acetylcholine receptor (CHRM)
DMQP03A	MT	DTT
DMQP03A	MA	Agonist
DMQP03A	RN	PET study of the M1-agonists [11C]xanomeline and [11C]butylthio-TZTP in monkey and man. Dementia. 1996 Jul-Aug;7(4):187-95.
DMQP03A	RU	https://pubmed.ncbi.nlm.nih.gov/8835881

DM4ZANH	DI	DM4ZANH
DM4ZANH	DN	[11C]DTBZ
DM4ZANH	MI	TTNZRI3
DM4ZANH	MN	Synaptic vesicle amine transporter (SLC18A2)
DM4ZANH	MT	DTT
DM4ZANH	MA	Inhibitor
DM4ZANH	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1012).
DM4ZANH	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1012

DM5Q08F	DI	DM5Q08F
DM5Q08F	DN	[11C]GlySar
DM5Q08F	MI	TT5LF3C
DM5Q08F	MN	Solute carrier family 15 member 1 (SLC15A1)
DM5Q08F	MT	DTT
DM5Q08F	MA	Modulator
DM5Q08F	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 984).
DM5Q08F	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=984

DM5Q08F	DI	DM5Q08F
DM5Q08F	DN	[11C]GlySar
DM5Q08F	MI	TT27Q3A
DM5Q08F	MN	Solute carrier family 15 member 2 (SLC15A2)
DM5Q08F	MT	DTT
DM5Q08F	MA	Modulator
DM5Q08F	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 985).
DM5Q08F	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=985

DMQRSP7	DI	DMQRSP7
DMQRSP7	DN	[11C]MMTP
DMQRSP7	MI	TTVBPDM
DMQRSP7	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMQRSP7	MT	DTT
DMQRSP7	MA	Modulator (allosteric modulator)
DMQRSP7	RN	Synthesis, in vitro and in vivo evaluation of [11C]MMTP: a potential PET ligand for mGluR1 receptors. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3499-501.
DMQRSP7	RU	https://pubmed.ncbi.nlm.nih.gov/20494576

DMOZ8E3	DI	DMOZ8E3
DMOZ8E3	DN	[11C]SB207145
DMOZ8E3	MI	TT07C3Y
DMOZ8E3	MN	5-HT 4 receptor (HTR4)
DMOZ8E3	MT	DTT
DMOZ8E3	MA	Antagonist
DMOZ8E3	RN	Mass dose effects and in vivo affinity in brain PET receptor studies--a study of cerebral 5-HT4 receptor binding with [11C]SB207145. Nucl Med Biol. 2011 Nov;38(8):1085-91.
DMOZ8E3	RU	https://pubmed.ncbi.nlm.nih.gov/21831646

DMCQTYW	DI	DMCQTYW
DMCQTYW	DN	[11C]volinanserin
DMCQTYW	MI	TTJQOD7
DMCQTYW	MN	5-HT 2A receptor (HTR2A)
DMCQTYW	MT	DTT
DMCQTYW	MA	Antagonist
DMCQTYW	RN	Autoradiographic localization of 5-HT(2A) receptors in the human brain using [(3)H]M100907 and [(11)C]M100907. Synapse. 2000 Dec 15;38(4):421-31.
DMCQTYW	RU	https://pubmed.ncbi.nlm.nih.gov/11044889

DMXIEA1	DI	DMXIEA1
DMXIEA1	DN	[11C]WAY100635
DMXIEA1	MI	TTSQIFT
DMXIEA1	MN	5-HT 1A receptor (HTR1A)
DMXIEA1	MT	DTT
DMXIEA1	MA	Antagonist
DMXIEA1	RN	[11C]-WAY100635 PET demonstrates marked 5-HT1A receptor changes in sporadic ALS. Brain. 2005 Apr;128(Pt 4):896-905.
DMXIEA1	RU	https://pubmed.ncbi.nlm.nih.gov/15689356

DM742L9	DI	DM742L9
DM742L9	DN	[11C]xanomeline
DM742L9	MI	TTOXS3C
DM742L9	MN	Muscarinic acetylcholine receptor (CHRM)
DM742L9	MT	DTT
DM742L9	MA	Agonist
DM742L9	RN	PET study of the M1-agonists [11C]xanomeline and [11C]butylthio-TZTP in monkey and man. Dementia. 1996 Jul-Aug;7(4):187-95.
DM742L9	RU	https://pubmed.ncbi.nlm.nih.gov/8835881

DMHWNOS	DI	DMHWNOS
DMHWNOS	DN	[123I] iodobenzoyl 12-Ex4
DMHWNOS	MI	TTVIMDE
DMHWNOS	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMHWNOS	MT	DTT
DMHWNOS	MA	Modulator
DMHWNOS	RN	2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006).
DMHWNOS	RU	http://www.nature.com/nrd/journal/v11/n1/full/nrd3645.html

DMCJQ0P	DI	DMCJQ0P
DMCJQ0P	DN	[123I]AM251
DMCJQ0P	MI	TT6OEDT
DMCJQ0P	MN	Cannabinoid receptor 1 (CB1)
DMCJQ0P	MT	DTT
DMCJQ0P	MA	Antagonist
DMCJQ0P	RN	Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors. Life Sci. 1997;61(14):PL 191-7.
DMCJQ0P	RU	https://pubmed.ncbi.nlm.nih.gov/9335234

DMOZGLM	DI	DMOZGLM
DMOZGLM	DN	[123I]iodobenzovesamicol
DMOZGLM	MI	TTV8KWS
DMOZGLM	MN	Vesicular acetylcholine transporter (SLC18A3)
DMOZGLM	MT	DTT
DMOZGLM	MA	Modulator
DMOZGLM	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1013).
DMOZGLM	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1013

DM5SRT1	DI	DM5SRT1
DM5SRT1	DN	[123I]iodoproxyfan
DM5SRT1	MI	TT9JNIC
DM5SRT1	MN	Histamine H3 receptor (H3R)
DM5SRT1	MT	DTT
DM5SRT1	MA	Antagonist
DM5SRT1	RN	Distinct pharmacology of rat and human histamine H(3) receptors: role of two amino acids in the third transmembrane domain. Br J Pharmacol. 2000 Dec;131(7):1247-50.
DM5SRT1	RU	https://pubmed.ncbi.nlm.nih.gov/11090094

DMMG1TA	DI	DMMG1TA
DMMG1TA	DN	[123I]SB 207710
DMMG1TA	MI	TT07C3Y
DMMG1TA	MN	5-HT 4 receptor (HTR4)
DMMG1TA	MT	DTT
DMMG1TA	MA	Antagonist
DMMG1TA	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 9).
DMMG1TA	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=9

DMFT5N9	DI	DMFT5N9
DMFT5N9	DN	[125I]7-azido-8-iodoketanserine
DMFT5N9	MI	TTNZRI3
DMFT5N9	MN	Synaptic vesicle amine transporter (SLC18A2)
DMFT5N9	MT	DTT
DMFT5N9	MA	Inhibitor
DMFT5N9	RN	Peptide mapping of the [125I]Iodoazidoketanserin and [125I]2-N-[(3'-iodo-4'-azidophenyl)propionyl]tetrabenazine binding sites for the synaptic vesicle monoamine transporter. J Biol Chem. 1997 Oct 10;272(41):26049-55.
DMFT5N9	RU	https://pubmed.ncbi.nlm.nih.gov/9325342

DM8EQFL	DI	DM8EQFL
DM8EQFL	DN	[125I]AB-MECA
DM8EQFL	MI	TTJFY5U
DM8EQFL	MN	Adenosine A3 receptor (ADORA3)
DM8EQFL	MT	DTT
DM8EQFL	MA	Agonist
DM8EQFL	RN	[(3)H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors. Mol Pharmacol. 2000 May;57(5):968-75.
DM8EQFL	RU	https://pubmed.ncbi.nlm.nih.gov/10779381

DMZBNK9	DI	DMZBNK9
DMZBNK9	DN	[125I]ABOPX
DMZBNK9	MI	TTNE7KG
DMZBNK9	MN	Adenosine A2b receptor (ADORA2B)
DMZBNK9	MT	DTT
DMZBNK9	MA	Antagonist
DMZBNK9	RN	Characterization of human A(2B) adenosine receptors: radioligand binding, western blotting, and coupling to G(q) in human embryonic kidney 293 cells and HMC-1 mast cells. Mol Pharmacol. 1999 Oct;56(4):705-13.
DMZBNK9	RU	https://pubmed.ncbi.nlm.nih.gov/10496952

DM95A4Z	DI	DM95A4Z
DM95A4Z	DN	[125I]APNEA
DM95A4Z	MI	TTJFY5U
DM95A4Z	MN	Adenosine A3 receptor (ADORA3)
DM95A4Z	MT	DTT
DM95A4Z	MA	Agonist
DM95A4Z	RN	Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor. Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7432-6.
DM95A4Z	RU	https://pubmed.ncbi.nlm.nih.gov/1323836

DMYBQOG	DI	DMYBQOG
DMYBQOG	DN	[125I]-BDZ2
DMYBQOG	MI	TTVFO0U
DMYBQOG	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMYBQOG	MT	DTT
DMYBQOG	MA	Antagonist
DMYBQOG	RN	Synthesis and in vitro characterization of radioiodinatable benzodiazepines selective for type 1 and type 2 cholecystokinin receptors. J Med Chem. 2009 Apr 9;52(7):2138-47.
DMYBQOG	RU	https://pubmed.ncbi.nlm.nih.gov/19271701

DM7GVYF	DI	DM7GVYF
DM7GVYF	DN	[125I]BE-2254
DM7GVYF	MI	TTBRKXS
DM7GVYF	MN	Adrenergic receptor alpha-1B (ADRA1B)
DM7GVYF	MT	DTT
DM7GVYF	MA	Antagonist
DM7GVYF	RN	Cloning and pharmacological characterization of human alpha-1 adrenergic receptors: sequence corrections and direct comparison with other species homologues. J Pharmacol Exp Ther. 1995 Jan;272(1):134-42.
DM7GVYF	RU	https://pubmed.ncbi.nlm.nih.gov/7815325

DM7GVYF	DI	DM7GVYF
DM7GVYF	DN	[125I]BE-2254
DM7GVYF	MI	TT2NUT5
DM7GVYF	MN	Adrenergic receptor alpha-2C (ADRA2C)
DM7GVYF	MT	DTT
DM7GVYF	MA	Antagonist
DM7GVYF	RN	Cloning and pharmacological characterization of human alpha-1 adrenergic receptors: sequence corrections and direct comparison with other species homologues. J Pharmacol Exp Ther. 1995 Jan;272(1):134-42.
DM7GVYF	RU	https://pubmed.ncbi.nlm.nih.gov/7815325

DMV6I7H	DI	DMV6I7H
DMV6I7H	DN	[125I]BOP
DMV6I7H	MI	TT2O84V
DMV6I7H	MN	Thromboxane A2 receptor (TBXA2R)
DMV6I7H	MT	DTT
DMV6I7H	MA	Agonist
DMV6I7H	RN	Characterization of an 125I-labeled thromboxane A2/prostaglandin H2 receptor agonist. J Pharmacol Exp Ther. 1989 Nov;251(2):557-62.
DMV6I7H	RU	https://pubmed.ncbi.nlm.nih.gov/2530338

DM0X824	DI	DM0X824
DM0X824	DN	[125I]cetrorelix
DM0X824	MI	TT8R70G
DM0X824	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DM0X824	MT	DTT
DM0X824	MA	Antagonist
DM0X824	RN	Residues within transmembrane helices 2 and 5 of the human gonadotropin-releasing hormone receptor contribute to agonist and antagonist binding. Mol Endocrinol. 2000 Jul;14(7):1099-115.
DM0X824	RU	https://pubmed.ncbi.nlm.nih.gov/10894158

DMIAO4V	DI	DMIAO4V
DMIAO4V	DN	[125I]CGP 64213
DMIAO4V	MI	TTDCVZW
DMIAO4V	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMIAO4V	MT	DTT
DMIAO4V	MA	Antagonist
DMIAO4V	RN	Ca(2+) requirement for high-affinity gamma-aminobutyric acid (GABA) binding at GABA(B) receptors: involvement of serine 269 of the GABA(B)R1 subunit. Mol Pharmacol. 2000 Mar;57(3):419-26.
DMIAO4V	RU	https://pubmed.ncbi.nlm.nih.gov/10692480

DMQVW4E	DI	DMQVW4E
DMQVW4E	DN	[125I]CGP 71872
DMQVW4E	MI	TTDCVZW
DMQVW4E	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMQVW4E	MT	DTT
DMQVW4E	MA	Antagonist
DMQVW4E	RN	Expression cloning of GABA(B) receptors uncovers similarity to metabotropic glutamate receptors. Nature. 1997 Mar 20;386(6622):239-46.
DMQVW4E	RU	https://pubmed.ncbi.nlm.nih.gov/9069281

DM1NXDA	DI	DM1NXDA
DM1NXDA	DN	[125I]CGP42112
DM1NXDA	MI	TTQVOEI
DM1NXDA	MN	Angiotensin II receptor type-2 (AGTR2)
DM1NXDA	MT	DTT
DM1NXDA	MA	Agonist
DM1NXDA	RN	Radioiodinated CGP 42112A: a novel high affinity and highly selective ligand for the characterization of angiotensin AT2 receptors. Biochem Biophys Res Commun. 1991 Dec 31;181(3):1365-71.
DM1NXDA	RU	https://pubmed.ncbi.nlm.nih.gov/1764088

DMEPT8H	DI	DMEPT8H
DMEPT8H	DN	[125I]DIV880
DMEPT8H	MI	TT0WAIE
DMEPT8H	MN	Melatonin receptor type 1A (MTNR1A)
DMEPT8H	MT	DTT
DMEPT8H	MA	Agonist
DMEPT8H	RN	New radioligands for describing the molecular pharmacology of MT1 and MT2 melatonin receptors. Int J Mol Sci. 2013 Apr 25;14(5):8948-62.
DMEPT8H	RU	https://pubmed.ncbi.nlm.nih.gov/23698757

DMQUY08	DI	DMQUY08
DMQUY08	DN	[125I]DOI
DMQUY08	MI	TTJQOD7
DMQUY08	MN	5-HT 2A receptor (HTR2A)
DMQUY08	MT	DTT
DMQUY08	MA	Agonist
DMQUY08	RN	Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. J Med Chem. 2000 Nov 30;43(24):4701-10.
DMQUY08	RU	https://pubmed.ncbi.nlm.nih.gov/11101361

DMQUY08	DI	DMQUY08
DMQUY08	DN	[125I]DOI
DMQUY08	MI	TT0K1SC
DMQUY08	MN	5-HT 2B receptor (HTR2B)
DMQUY08	MT	DTT
DMQUY08	MA	Agonist
DMQUY08	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 7).
DMQUY08	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=7

DMQUY08	DI	DMQUY08
DMQUY08	DN	[125I]DOI
DMQUY08	MI	TTWJBZ5
DMQUY08	MN	5-HT 2C receptor (HTR2C)
DMQUY08	MT	DTT
DMQUY08	MA	Agonist
DMQUY08	RN	High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action. J Neurochem. 1999 May;72(5):2127-34.
DMQUY08	RU	https://pubmed.ncbi.nlm.nih.gov/10217294

DMZWQH3	DI	DMZWQH3
DMZWQH3	DN	[125I]epibatidine
DMZWQH3	MI	TTH18TF
DMZWQH3	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMZWQH3	MT	DTT
DMZWQH3	MA	Agonist
DMZWQH3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 467).
DMZWQH3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=467

DMZWQH3	DI	DMZWQH3
DMZWQH3	DN	[125I]epibatidine
DMZWQH3	MI	TTF4E0J
DMZWQH3	MN	Neuronal acetylcholine receptor alpha-2 (CHRNA2)
DMZWQH3	MT	DTT
DMZWQH3	MA	Agonist
DMZWQH3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 463).
DMZWQH3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=463

DMZWQH3	DI	DMZWQH3
DMZWQH3	DN	[125I]epibatidine
DMZWQH3	MI	TTLA931
DMZWQH3	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMZWQH3	MT	DTT
DMZWQH3	MA	Agonist
DMZWQH3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 468).
DMZWQH3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=468

DMZWQH3	DI	DMZWQH3
DMZWQH3	DN	[125I]epibatidine
DMZWQH3	MI	TT5KPZR
DMZWQH3	MN	Neuronal acetylcholine receptor beta-2 (CHRNB2)
DMZWQH3	MT	DTT
DMZWQH3	MA	Agonist
DMZWQH3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 465).
DMZWQH3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=465

DMEKGZS	DI	DMEKGZS
DMEKGZS	DN	[125I]EXP985
DMEKGZS	MI	TT8DBY3
DMEKGZS	MN	Angiotensin II receptor type-1 (AGTR1)
DMEKGZS	MT	DTT
DMEKGZS	MA	Antagonist
DMEKGZS	RN	[125I]EXP985: a highly potent and specific nonpeptide radioligand antagonist for the AT1 angiotensin receptor. Biochem Biophys Res Commun. 1992 Nov 16;188(3):1030-9.
DMEKGZS	RU	https://pubmed.ncbi.nlm.nih.gov/1445340

DMFWE4H	DI	DMFWE4H
DMFWE4H	DN	[125I]GR231118
DMFWE4H	MI	TTRK9JT
DMFWE4H	MN	Neuropeptide Y receptor type 1 (NPY1R)
DMFWE4H	MT	DTT
DMFWE4H	MA	Antagonist
DMFWE4H	RN	[(125)I]-GR231118: a high affinity radioligand to investigate neuropeptide Y Y(1) and Y(4) receptors. Br J Pharmacol. 2000 Jan;129(1):37-46.
DMFWE4H	RU	https://pubmed.ncbi.nlm.nih.gov/10694200

DMFWE4H	DI	DMFWE4H
DMFWE4H	DN	[125I]GR231118
DMFWE4H	MI	TTW4N16
DMFWE4H	MN	Neuropeptide Y receptor type 4 (NPY4R)
DMFWE4H	MT	DTT
DMFWE4H	MA	Agonist
DMFWE4H	RN	[(125)I]-GR231118: a high affinity radioligand to investigate neuropeptide Y Y(1) and Y(4) receptors. Br J Pharmacol. 2000 Jan;129(1):37-46.
DMFWE4H	RU	https://pubmed.ncbi.nlm.nih.gov/10694200

DMSYT5P	DI	DMSYT5P
DMSYT5P	DN	[125I]GTI
DMSYT5P	MI	TTK8CXU
DMSYT5P	MN	5-HT 1B receptor (HTR1B)
DMSYT5P	MT	DTT
DMSYT5P	MA	Agonist
DMSYT5P	RN	Autoradiographic characterisation and localisation of 5-HT1D compared to 5-HT1B binding sites in rat brain. Naunyn Schmiedebergs Arch Pharmacol. 1993 Jun;347(6):569-82.
DMSYT5P	RU	https://pubmed.ncbi.nlm.nih.gov/8361548

DMSYT5P	DI	DMSYT5P
DMSYT5P	DN	[125I]GTI
DMSYT5P	MI	TT6MSOK
DMSYT5P	MN	5-HT 1D receptor (HTR1D)
DMSYT5P	MT	DTT
DMSYT5P	MA	Agonist
DMSYT5P	RN	Autoradiographic characterisation and localisation of 5-HT1D compared to 5-HT1B binding sites in rat brain. Naunyn Schmiedebergs Arch Pharmacol. 1993 Jun;347(6):569-82.
DMSYT5P	RU	https://pubmed.ncbi.nlm.nih.gov/8361548

DMTFP5Q	DI	DMTFP5Q
DMTFP5Q	DN	[125I]HEAT
DMTFP5Q	MI	TTBRKXS
DMTFP5Q	MN	Adrenergic receptor alpha-1B (ADRA1B)
DMTFP5Q	MT	DTT
DMTFP5Q	MA	Agonist
DMTFP5Q	RN	KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues. Mol Pharmacol. 1995 Aug;48(2):250-8.
DMTFP5Q	RU	https://pubmed.ncbi.nlm.nih.gov/7651358

DMTFP5Q	DI	DMTFP5Q
DMTFP5Q	DN	[125I]HEAT
DMTFP5Q	MI	TT2NUT5
DMTFP5Q	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMTFP5Q	MT	DTT
DMTFP5Q	MA	Agonist
DMTFP5Q	RN	KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues. Mol Pharmacol. 1995 Aug;48(2):250-8.
DMTFP5Q	RU	https://pubmed.ncbi.nlm.nih.gov/7651358

DM3BQHO	DI	DM3BQHO
DM3BQHO	DN	[125I]ICYP
DM3BQHO	MI	TTMXGCW
DM3BQHO	MN	Adrenergic receptor beta-3 (ADRB3)
DM3BQHO	MT	DTT
DM3BQHO	MA	Agonist
DM3BQHO	RN	Stereoselectivity for interactions of agonists and antagonists at mouse, rat and human beta3-adrenoceptors. Eur J Pharmacol. 2004 Jan 26;484(2-3):323-31.
DM3BQHO	RU	https://pubmed.ncbi.nlm.nih.gov/14744619

DMHJL58	DI	DMHJL58
DMHJL58	DN	[125I]iodoaminopotentidine
DMHJL58	MI	TTQHJ1K
DMHJL58	MN	Histamine H2 receptor (H2R)
DMHJL58	MT	DTT
DMHJL58	MA	Antagonist
DMHJL58	RN	G proteins of the Gq family couple the H2 histamine receptor to phospholipase C. Mol Endocrinol. 1996 Dec;10(12):1697-707.
DMHJL58	RU	https://pubmed.ncbi.nlm.nih.gov/8961278

DMN4ABU	DI	DMN4ABU
DMN4ABU	DN	[125I]iodophenpropit
DMN4ABU	MI	TT9JNIC
DMN4ABU	MN	Histamine H3 receptor (H3R)
DMN4ABU	MT	DTT
DMN4ABU	MA	Antagonist
DMN4ABU	RN	Characterization of the binding of the first selective radiolabelled histamine H3-receptor antagonist, [125I]-iodophenpropit, to rat brain. Br J Pharmacol. 1994 Oct;113(2):355-62.
DMN4ABU	RU	https://pubmed.ncbi.nlm.nih.gov/7834183

DMN4ABU	DI	DMN4ABU
DMN4ABU	DN	[125I]iodophenpropit
DMN4ABU	MI	TTXJ178
DMN4ABU	MN	Histamine H4 receptor (H4R)
DMN4ABU	MT	DTT
DMN4ABU	MA	Inhibitor
DMN4ABU	RN	Discovery of novel human histamine H4 receptor ligands by large-scale structure-based virtual screening. J Med Chem. 2008 Jun 12;51(11):3145-53.
DMN4ABU	RU	https://pubmed.ncbi.nlm.nih.gov/18459760

DMVEHI7	DI	DMVEHI7
DMVEHI7	DN	[125I]IRL1620
DMVEHI7	MI	TT3ZTGU
DMVEHI7	MN	Endothelin B receptor (EDNRB)
DMVEHI7	MT	DTT
DMVEHI7	MA	Agonist
DMVEHI7	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 220).
DMVEHI7	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=220

DMKSI80	DI	DMKSI80
DMKSI80	DN	[125I]L703,606
DMKSI80	MI	TTZPO1L
DMKSI80	MN	Substance-P receptor (TACR1)
DMKSI80	MT	DTT
DMKSI80	MA	Antagonist
DMKSI80	RN	Radioiodinated L-703,606: a potent, selective antagonist to the human NK1 receptor. Appl Radiat Isot. 1994 Jan;45(1):97-103.
DMKSI80	RU	https://pubmed.ncbi.nlm.nih.gov/8287060

DMO7VRJ	DI	DMO7VRJ
DMO7VRJ	DN	[125I]L750667
DMO7VRJ	MI	TTE0A2F
DMO7VRJ	MN	Dopamine D4 receptor (D4R)
DMO7VRJ	MT	DTT
DMO7VRJ	MA	Antagonist
DMO7VRJ	RN	Identification and pharmacological characterization of [125I]L-750,667, a novel radioligand for the dopamine D4 receptor. Mol Pharmacol. 1996 Dec;50(6):1658-64.
DMO7VRJ	RU	https://pubmed.ncbi.nlm.nih.gov/8967990

DMP69QG	DI	DMP69QG
DMP69QG	DN	[125I]LSD
DMP69QG	MI	TT0MI3F
DMP69QG	MN	5-HT 1F receptor (HTR1F)
DMP69QG	MT	DTT
DMP69QG	MA	Agonist
DMP69QG	RN	Isolation of a mouse "5HT1E-like" serotonin receptor expressed predominantly in hippocampus. J Biol Chem. 1992 Oct 5;267(28):19761-4.
DMP69QG	RU	https://pubmed.ncbi.nlm.nih.gov/1328180

DMP69QG	DI	DMP69QG
DMP69QG	DN	[125I]LSD
DMP69QG	MI	TTRUFDT
DMP69QG	MN	5-HT 5A receptor (HTR5A)
DMP69QG	MT	DTT
DMP69QG	MA	Agonist
DMP69QG	RN	Human 5-HT(5) receptors: the 5-HT(5A) receptor is functional but the 5-HT(5B) receptor was lost during mammalian evolution. Eur J Pharmacol. 2001 Apr 27;418(3):157-67.
DMP69QG	RU	https://pubmed.ncbi.nlm.nih.gov/11343685

DMP69QG	DI	DMP69QG
DMP69QG	DN	[125I]LSD
DMP69QG	MI	TT9KJ1X
DMP69QG	MN	5-HT 5B receptor (HTR5B)
DMP69QG	MT	DTT
DMP69QG	MA	Agonist
DMP69QG	RN	Mouse 5-hydroxytryptamine5A and 5-hydroxytryptamine5B receptors define a new family of serotonin receptors: cloning, functional expression, and chromosomal localization. Mol Pharmacol. 1993 Mar;43(3):313-9.
DMP69QG	RU	https://pubmed.ncbi.nlm.nih.gov/8450829

DMP69QG	DI	DMP69QG
DMP69QG	DN	[125I]LSD
DMP69QG	MI	TTO9X1H
DMP69QG	MN	5-HT 7 receptor (HTR7)
DMP69QG	MT	DTT
DMP69QG	MA	Agonist
DMP69QG	RN	A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms. Neuron. 1993 Sep;11(3):449-58.
DMP69QG	RU	https://pubmed.ncbi.nlm.nih.gov/8398139

DMEHK9M	DI	DMEHK9M
DMEHK9M	DN	[125I]PD142308
DMEHK9M	MI	TTVFO0U
DMEHK9M	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMEHK9M	MT	DTT
DMEHK9M	MA	Antagonist
DMEHK9M	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 77).
DMEHK9M	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=77

DM4HLO5	DI	DM4HLO5
DM4HLO5	DN	[125I]PD151242
DM4HLO5	MI	TTKRD0G
DM4HLO5	MN	Endothelin A receptor (EDNRA)
DM4HLO5	MT	DTT
DM4HLO5	MA	Antagonist
DM4HLO5	RN	[125I]-PD151242: a selective radioligand for human ETA receptors. Br J Pharmacol. 1994 Jan;111(1):4-6.
DM4HLO5	RU	https://pubmed.ncbi.nlm.nih.gov/8012722

DMROKJP	DI	DMROKJP
DMROKJP	DN	[125I]PTA-OH
DMROKJP	MI	TT2O84V
DMROKJP	MN	Thromboxane A2 receptor (TBXA2R)
DMROKJP	MT	DTT
DMROKJP	MA	Antagonist
DMROKJP	RN	Binding of thromboxane A2/prostaglandin H2 agonists to human platelets. Br J Pharmacol. 1987 May;91(1):223-7.
DMROKJP	RU	https://pubmed.ncbi.nlm.nih.gov/3594077

DMUD3A8	DI	DMUD3A8
DMUD3A8	DN	[125I]resiniferatoxin
DMUD3A8	MI	TTMI6F5
DMUD3A8	MN	Transient receptor potential cation channel V1 (TRPV1)
DMUD3A8	MT	DTT
DMUD3A8	MA	Blocker (channel blocker)
DMUD3A8	RN	Iodo-resiniferatoxin, a new potent vanilloid receptor antagonist. Mol Pharmacol. 2001 Jan;59(1):9-15.
DMUD3A8	RU	https://pubmed.ncbi.nlm.nih.gov/11125018

DMHC6KX	DI	DMHC6KX
DMHC6KX	DN	[125I]S70254
DMHC6KX	MI	TT0WAIE
DMHC6KX	MN	Melatonin receptor type 1A (MTNR1A)
DMHC6KX	MT	DTT
DMHC6KX	MA	Agonist
DMHC6KX	RN	New radioligands for describing the molecular pharmacology of MT1 and MT2 melatonin receptors. Int J Mol Sci. 2013 Apr 25;14(5):8948-62.
DMHC6KX	RU	https://pubmed.ncbi.nlm.nih.gov/23698757

DM1DXHG	DI	DM1DXHG
DM1DXHG	DN	[125I]SAP
DM1DXHG	MI	TT2O84V
DM1DXHG	MN	Thromboxane A2 receptor (TBXA2R)
DM1DXHG	MT	DTT
DM1DXHG	MA	Antagonist
DM1DXHG	RN	7-[(1R,2S,3S,5R)-6,6-dimethyl-3-(4- iodobenzenesulfonylamino)bicyclo[3.1.1]hept-2-yl]-5(Z)-heptenoic acid: a novel high-affinity radiolabeled antagonist for platelet thromboxane A2/prostaglandin H2 receptors. J Pharmacol Exp Ther. 1992 Aug;262(2):632-7.
DM1DXHG	RU	https://pubmed.ncbi.nlm.nih.gov/1386885

DM0XUPK	DI	DM0XUPK
DM0XUPK	DN	[125I]SB-236636
DM0XUPK	MI	TTT2SVW
DM0XUPK	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DM0XUPK	MT	DTT
DM0XUPK	MA	Agonist
DM0XUPK	RN	Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. J Pharmacol Exp Ther. 1998 Feb;284(2):751-9.
DM0XUPK	RU	https://pubmed.ncbi.nlm.nih.gov/9454824

DMXWZCB	DI	DMXWZCB
DMXWZCB	DN	[125I]SB-258585
DMXWZCB	MI	TTJS8PY
DMXWZCB	MN	5-HT 6 receptor (HTR6)
DMXWZCB	MT	DTT
DMXWZCB	MA	Antagonist
DMXWZCB	RN	5-HT6 receptor binding sites in schizophrenia and following antipsychotic drug administration: autoradiographic studies with [125I]SB-258585. Synapse. 2002 Sep 1;45(3):191-9.
DMXWZCB	RU	https://pubmed.ncbi.nlm.nih.gov/12112397

DM06S9X	DI	DM06S9X
DM06S9X	DN	[125I]SCH23982
DM06S9X	MI	TTZFYLI
DM06S9X	MN	Dopamine D1 receptor (D1R)
DM06S9X	MT	DTT
DM06S9X	MA	Antagonist
DM06S9X	RN	Molecular cloning and expression of the gene for a human D1 dopamine receptor. Nature. 1990 Sep 6;347(6288):72-6.
DM06S9X	RU	https://pubmed.ncbi.nlm.nih.gov/2144334

DM06S9X	DI	DM06S9X
DM06S9X	DN	[125I]SCH23982
DM06S9X	MI	TTS2PH3
DM06S9X	MN	Dopamine D5 receptor (D5R)
DM06S9X	MT	DTT
DM06S9X	MA	Antagonist
DM06S9X	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 218).
DM06S9X	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=218

DM285MQ	DI	DM285MQ
DM285MQ	DN	[125I]SD6
DM285MQ	MI	TT0WAIE
DM285MQ	MN	Melatonin receptor type 1A (MTNR1A)
DM285MQ	MT	DTT
DM285MQ	MA	Agonist
DM285MQ	RN	New radioligands for describing the molecular pharmacology of MT1 and MT2 melatonin receptors. Int J Mol Sci. 2013 Apr 25;14(5):8948-62.
DM285MQ	RU	https://pubmed.ncbi.nlm.nih.gov/23698757

DM0GKMA	DI	DM0GKMA
DM0GKMA	DN	[125I]SQ-29548
DM0GKMA	MI	TT2O84V
DM0GKMA	MN	Thromboxane A2 receptor (TBXA2R)
DM0GKMA	MT	DTT
DM0GKMA	MA	Antagonist
DM0GKMA	RN	Characterization of [5,6-3H]SQ 29,548 as a high affinity radioligand, binding to thromboxane A2/prostaglandin H2-receptors in human platelets. J Pharmacol Exp Ther. 1988 Jun;245(3):786-92.
DM0GKMA	RU	https://pubmed.ncbi.nlm.nih.gov/2968449

DME53D6	DI	DME53D6
DME53D6	DN	[125I]ZM-241385
DME53D6	MI	TTNE7KG
DME53D6	MN	Adenosine A2b receptor (ADORA2B)
DME53D6	MT	DTT
DME53D6	MA	Antagonist
DME53D6	RN	125I-4-(2-[7-amino-2-[2-furyl][1,2,4]triazolo[2,3-a][1,3,5] triazin-5-yl-amino]ethyl)phenol, a high affinity antagonist radioligand selective for the A2a adenosine receptor. Mol Pharmacol. 1995 Dec;48(6):970-4.
DME53D6	RU	https://pubmed.ncbi.nlm.nih.gov/8848012

DM42B5D	DI	DM42B5D
DM42B5D	DN	[14C]acetylCoA
DM42B5D	MI	TTLJKZ0
DM42B5D	MN	Acetyl-CoA transporter (SLC33A1)
DM42B5D	MT	DTT
DM42B5D	MA	Modulator
DM42B5D	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1134).
DM42B5D	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1134

DMGLQ72	DI	DMGLQ72
DMGLQ72	DN	[14C]GlySar
DMGLQ72	MI	TT5LF3C
DMGLQ72	MN	Solute carrier family 15 member 1 (SLC15A1)
DMGLQ72	MT	DTT
DMGLQ72	MA	Modulator
DMGLQ72	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 984).
DMGLQ72	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=984

DMGLQ72	DI	DMGLQ72
DMGLQ72	DN	[14C]GlySar
DMGLQ72	MI	TT27Q3A
DMGLQ72	MN	Solute carrier family 15 member 2 (SLC15A2)
DMGLQ72	MT	DTT
DMGLQ72	MA	Modulator
DMGLQ72	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 985).
DMGLQ72	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=985

DMVUF71	DI	DMVUF71
DMVUF71	DN	[14C]histidine
DMVUF71	MI	TTAYPWS
DMVUF71	MN	Solute carrier family 15 member 3 (SLC15A3)
DMVUF71	MT	DTT
DMVUF71	MA	Modulator
DMVUF71	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 986).
DMVUF71	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=986

DMVUF71	DI	DMVUF71
DMVUF71	DN	[14C]histidine
DMVUF71	MI	TTG2XRE
DMVUF71	MN	Solute carrier family 15 member 4 (SLC15A4)
DMVUF71	MT	DTT
DMVUF71	MA	Modulator
DMVUF71	RN	Cloning and functional expression of a brain peptide/histidine transporter. J Biol Chem. 1997 Apr 11;272(15):10205-11.
DMVUF71	RU	https://pubmed.ncbi.nlm.nih.gov/9092568

DMVUF71	DI	DMVUF71
DMVUF71	DN	[14C]histidine
DMVUF71	MI	TTC8YPT
DMVUF71	MN	Solute carrier family 38 member 5 (SLC38A5)
DMVUF71	MT	DTT
DMVUF71	MA	Modulator
DMVUF71	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1173).
DMVUF71	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1173

DMRBZ3X	DI	DMRBZ3X
DMRBZ3X	DN	[14C]methylamine
DMRBZ3X	MI	TTVHFE8
DMRBZ3X	MN	Ammonium transporter Rh type A (RHAG)
DMRBZ3X	MT	DTT
DMRBZ3X	MA	Modulator
DMRBZ3X	RN	The Rh complex exports ammonium from human red blood cells. Br J Haematol. 2003 Jul;122(2):333-40.
DMRBZ3X	RU	https://pubmed.ncbi.nlm.nih.gov/12846905

DMRBZ3X	DI	DMRBZ3X
DMRBZ3X	DN	[14C]methylamine
DMRBZ3X	MI	TTN5MZ3
DMRBZ3X	MN	Ammonium transporter Rh type C (RHCG)
DMRBZ3X	MT	DTT
DMRBZ3X	MA	Modulator
DMRBZ3X	RN	Characterization of ammonia transport by the kidney Rh glycoproteins RhBG and RhCG. Am J Physiol Renal Physiol. 2006 Feb;290(2):F297-305.
DMRBZ3X	RU	https://pubmed.ncbi.nlm.nih.gov/16131648

DMG17IU	DI	DMG17IU
DMG17IU	DN	[14C]MTEP
DMG17IU	MI	TTHS256
DMG17IU	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMG17IU	MT	DTT
DMG17IU	MA	Modulator (allosteric modulator)
DMG17IU	RN	[3H]Methoxymethyl-3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine binding to metabotropic glutamate receptor subtype 5 in rodent brain: in vitro and in vivo characterization. J Pharmacol Exp Ther. 2002 Dec;303(3):1044-51.
DMG17IU	RU	https://pubmed.ncbi.nlm.nih.gov/12438526

DM6SFYH	DI	DM6SFYH
DM6SFYH	DN	[14C]TEA
DM6SFYH	MI	TTSF1KH
DM6SFYH	MN	Aquaporin-1 (AQP1)
DM6SFYH	MT	DTT
DM6SFYH	MA	Inhibitor
DM6SFYH	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 688).
DM6SFYH	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=688

DM6SFYH	DI	DM6SFYH
DM6SFYH	DN	[14C]TEA
DM6SFYH	MI	TT9R6BE
DM6SFYH	MN	Calcium-activated potassium channel KCa2.1 (KCNN1)
DM6SFYH	MT	DTT
DM6SFYH	MA	Blocker (channel blocker)
DM6SFYH	RN	Small conductance calcium-activated potassium channels: from structure to function. Prog Neurobiol. 2010 Jul;91(3):242-55.
DM6SFYH	RU	https://pubmed.ncbi.nlm.nih.gov/20359520

DM6SFYH	DI	DM6SFYH
DM6SFYH	DN	[14C]TEA
DM6SFYH	MI	TT2T5M0
DM6SFYH	MN	Calcium-activated potassium channel KCa2.2 (KCNN2)
DM6SFYH	MT	DTT
DM6SFYH	MA	Blocker (channel blocker)
DM6SFYH	RN	Small conductance calcium-activated potassium channels: from structure to function. Prog Neurobiol. 2010 Jul;91(3):242-55.
DM6SFYH	RU	https://pubmed.ncbi.nlm.nih.gov/20359520

DM6SFYH	DI	DM6SFYH
DM6SFYH	DN	[14C]TEA
DM6SFYH	MI	TT9JH25
DM6SFYH	MN	Calcium-activated potassium channel KCa2.3 (KCNN3)
DM6SFYH	MT	DTT
DM6SFYH	MA	Blocker (channel blocker)
DM6SFYH	RN	Small conductance calcium-activated potassium channels: from structure to function. Prog Neurobiol. 2010 Jul;91(3):242-55.
DM6SFYH	RU	https://pubmed.ncbi.nlm.nih.gov/20359520

DM6SFYH	DI	DM6SFYH
DM6SFYH	DN	[14C]TEA
DM6SFYH	MI	TTGJFK1
DM6SFYH	MN	Calcium-activated potassium channel KCa4.1 (KCNT1)
DM6SFYH	MT	DTT
DM6SFYH	MA	Blocker (channel blocker)
DM6SFYH	RN	For K+ channels, Na+ is the new Ca2+. Trends Neurosci. 2005 Aug;28(8):422-8.
DM6SFYH	RU	https://pubmed.ncbi.nlm.nih.gov/15979166

DM6SFYH	DI	DM6SFYH
DM6SFYH	DN	[14C]TEA
DM6SFYH	MI	TTLU5FO
DM6SFYH	MN	Calcium-activated potassium channel KCa4.2 (KCNT2)
DM6SFYH	MT	DTT
DM6SFYH	MA	Blocker (channel blocker)
DM6SFYH	RN	Opposite regulation of Slick and Slack K+ channels by neuromodulators. J Neurosci. 2006 May 10;26(19):5059-68.
DM6SFYH	RU	https://pubmed.ncbi.nlm.nih.gov/16687497

DM6SFYH	DI	DM6SFYH
DM6SFYH	DN	[14C]TEA
DM6SFYH	MI	TTI9XK6
DM6SFYH	MN	Calcium-activated potassium channel KCa5.1 (KCNU1)
DM6SFYH	MT	DTT
DM6SFYH	MA	Blocker (channel blocker)
DM6SFYH	RN	Block of mouse Slo1 and Slo3 K+ channels by CTX, IbTX, TEA, 4-AP and quinidine. Channels (Austin). 2010 Jan-Feb;4(1):22-41.
DM6SFYH	RU	https://pubmed.ncbi.nlm.nih.gov/19934650

DM6SFYH	DI	DM6SFYH
DM6SFYH	DN	[14C]TEA
DM6SFYH	MI	TT1AQ50
DM6SFYH	MN	Charybdotoxin receptor beta-4 (BKbeta4)
DM6SFYH	MT	DTT
DM6SFYH	MA	Inhibitor
DM6SFYH	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 380).
DM6SFYH	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=380

DM6SFYH	DI	DM6SFYH
DM6SFYH	DN	[14C]TEA
DM6SFYH	MI	TTXF0ZW
DM6SFYH	MN	Inward rectifier potassium channel Kir2.3 (KCNJ4)
DM6SFYH	MT	DTT
DM6SFYH	MA	Blocker (channel blocker)
DM6SFYH	RN	Cloning and expression of a novel human brain inward rectifier potassium channel. J Biol Chem. 1994 Aug 12;269(32):20468-74.
DM6SFYH	RU	https://pubmed.ncbi.nlm.nih.gov/8051145

DM6SFYH	DI	DM6SFYH
DM6SFYH	DN	[14C]TEA
DM6SFYH	MI	DTZGT0P
DM6SFYH	MN	Multidrug and toxin extrusion protein 1 (SLC47A1)
DM6SFYH	MT	DTP
DM6SFYH	MA	Substrate
DM6SFYH	RN	A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):17923-8.
DM6SFYH	RU	http://www.ncbi.nlm.nih.gov/pubmed/16330770

DM6SFYH	DI	DM6SFYH
DM6SFYH	DN	[14C]TEA
DM6SFYH	MI	TT7HXSL
DM6SFYH	MN	Multidrug and toxin extrusion protein 2 (MATE2)
DM6SFYH	MT	DTT
DM6SFYH	MA	Modulator
DM6SFYH	RN	Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
DM6SFYH	RU	https://pubmed.ncbi.nlm.nih.gov/17509534

DM6SFYH	DI	DM6SFYH
DM6SFYH	DN	[14C]TEA
DM6SFYH	MI	DT3TX4H
DM6SFYH	MN	Multidrug and toxin extrusion protein 2 (SLC47A2)
DM6SFYH	MT	DTP
DM6SFYH	MA	Substrate
DM6SFYH	RN	Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
DM6SFYH	RU	http://www.ncbi.nlm.nih.gov/pubmed/17509534

DM6SFYH	DI	DM6SFYH
DM6SFYH	DN	[14C]TEA
DM6SFYH	MI	DTT79CX
DM6SFYH	MN	Organic cation transporter 1 (SLC22A1)
DM6SFYH	MT	DTP
DM6SFYH	MA	Substrate
DM6SFYH	RN	Involvement of human organic cation transporter 1 in the hepatic uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel, small molecule survivin suppressant. Drug Metab Dispos. 2009 Sep;37(9):1856-63.
DM6SFYH	RU	http://www.ncbi.nlm.nih.gov/pubmed/19520775

DM6SFYH	DI	DM6SFYH
DM6SFYH	DN	[14C]TEA
DM6SFYH	MI	DT9IDPW
DM6SFYH	MN	Organic cation transporter 2 (SLC22A2)
DM6SFYH	MT	DTP
DM6SFYH	MA	Substrate
DM6SFYH	RN	Molecular mechanisms of organic cation transport in OCT2-expressing Xenopus oocytes. Biochim Biophys Acta. 1999 Mar 4;1417(2):224-31.
DM6SFYH	RU	http://www.ncbi.nlm.nih.gov/pubmed/10082798

DM6SFYH	DI	DM6SFYH
DM6SFYH	DN	[14C]TEA
DM6SFYH	MI	DT2EG60
DM6SFYH	MN	Organic cation/carnitine transporter 1 (SLC22A4)
DM6SFYH	MT	DTP
DM6SFYH	MA	Substrate
DM6SFYH	RN	Functional effects of protein sequence polymorphisms in the organic cation/ergothioneine transporter OCTN1 (SLC22A4). Pharmacogenet Genomics. 2007 Sep;17(9):773-82.
DM6SFYH	RU	http://www.ncbi.nlm.nih.gov/pubmed/17700366

DM6SFYH	DI	DM6SFYH
DM6SFYH	DN	[14C]TEA
DM6SFYH	MI	TTMHCGA
DM6SFYH	MN	Solute carrier family 47 member 1 (SLC47A1)
DM6SFYH	MT	DTT
DM6SFYH	MA	Modulator
DM6SFYH	RN	Molecular cloning, functional characterization and tissue distribution of rat H+/organic cation antiporter MATE1. Pharm Res. 2006 Aug;23(8):1696-701.
DM6SFYH	RU	https://pubmed.ncbi.nlm.nih.gov/16850272

DM6SFYH	DI	DM6SFYH
DM6SFYH	DN	[14C]TEA
DM6SFYH	MI	TTBECWA
DM6SFYH	MN	Transient receptor potential cation channel V2 (TRPV2)
DM6SFYH	MT	DTT
DM6SFYH	MA	Blocker (channel blocker)
DM6SFYH	RN	Pharmacological characterization and molecular determinants of the activation of transient receptor potential V2 channel orthologs by 2-aminoethoxy... Mol Pharmacol. 2007 Nov;72(5):1258-68.
DM6SFYH	RU	https://pubmed.ncbi.nlm.nih.gov/17673572

DM6SFYH	DI	DM6SFYH
DM6SFYH	DN	[14C]TEA
DM6SFYH	MI	TTS3DIK
DM6SFYH	MN	Voltage-gated potassium channel Kv1.1 (KCNA1)
DM6SFYH	MT	DTT
DM6SFYH	MA	Blocker (channel blocker)
DM6SFYH	RN	Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol. 1994 Jun;45(6):1227-34.
DM6SFYH	RU	https://pubmed.ncbi.nlm.nih.gov/7517498

DM6SFYH	DI	DM6SFYH
DM6SFYH	DN	[14C]TEA
DM6SFYH	MI	TTVFB0O
DM6SFYH	MN	Voltage-gated potassium channel Kv1.2 (KCNA2)
DM6SFYH	MT	DTT
DM6SFYH	MA	Blocker (channel blocker)
DM6SFYH	RN	Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol. 1994 Jun;45(6):1227-34.
DM6SFYH	RU	https://pubmed.ncbi.nlm.nih.gov/7517498

DM6SFYH	DI	DM6SFYH
DM6SFYH	DN	[14C]TEA
DM6SFYH	MI	TTY3UE6
DM6SFYH	MN	Voltage-gated potassium channel Kv1.3 (KCNA3)
DM6SFYH	MT	DTT
DM6SFYH	MA	Blocker (channel blocker)
DM6SFYH	RN	Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol. 1994 Jun;45(6):1227-34.
DM6SFYH	RU	https://pubmed.ncbi.nlm.nih.gov/7517498

DM6SFYH	DI	DM6SFYH
DM6SFYH	DN	[14C]TEA
DM6SFYH	MI	TTW0CMT
DM6SFYH	MN	Voltage-gated potassium channel Kv1.5 (KCNA5)
DM6SFYH	MT	DTT
DM6SFYH	MA	Blocker (channel blocker)
DM6SFYH	RN	Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol. 1994 Jun;45(6):1227-34.
DM6SFYH	RU	https://pubmed.ncbi.nlm.nih.gov/7517498

DM6SFYH	DI	DM6SFYH
DM6SFYH	DN	[14C]TEA
DM6SFYH	MI	TTJ2W69
DM6SFYH	MN	Voltage-gated potassium channel Kv1.6 (KCNA6)
DM6SFYH	MT	DTT
DM6SFYH	MA	Blocker (channel blocker)
DM6SFYH	RN	Cloning and expression of a human voltage-gated potassium channel. A novel member of the RCK potassium channel family. EMBO J. 1990 Jun;9(6):1749-56.
DM6SFYH	RU	https://pubmed.ncbi.nlm.nih.gov/2347305

DM6SFYH	DI	DM6SFYH
DM6SFYH	DN	[14C]TEA
DM6SFYH	MI	TTCVBT7
DM6SFYH	MN	Voltage-gated potassium channel Kv1.7 (KCNA7)
DM6SFYH	MT	DTT
DM6SFYH	MA	Blocker (channel blocker)
DM6SFYH	RN	Characterisation of the human voltage-gated potassium channel gene, KCNA7, a candidate gene for inherited cardiac disorders, and its exclusion as cause of progressive familial heart block I (PFHBI). Eur J Hum Genet. 2002 Jan;10(1):36-43.
DM6SFYH	RU	https://pubmed.ncbi.nlm.nih.gov/11896454

DM6SFYH	DI	DM6SFYH
DM6SFYH	DN	[14C]TEA
DM6SFYH	MI	TTT4Y0X
DM6SFYH	MN	Voltage-gated potassium channel Kv1.8 (KCNA10)
DM6SFYH	MT	DTT
DM6SFYH	MA	Blocker (channel blocker)
DM6SFYH	RN	KCNA10: a novel ion channel functionally related to both voltage-gated potassium and CNG cation channels. Am J Physiol Renal Physiol. 2000 Jun;278(6):F1013-21.
DM6SFYH	RU	https://pubmed.ncbi.nlm.nih.gov/10836990

DM6SFYH	DI	DM6SFYH
DM6SFYH	DN	[14C]TEA
DM6SFYH	MI	TT5OEKU
DM6SFYH	MN	Voltage-gated potassium channel Kv2.1 (KCNB1)
DM6SFYH	MT	DTT
DM6SFYH	MA	Blocker (channel blocker)
DM6SFYH	RN	Modulation of Kv2.1 channel gating and TEA sensitivity by distinct domains of SNAP-25. Biochem J. 2006 Jun 1;396(2):363-9.
DM6SFYH	RU	https://pubmed.ncbi.nlm.nih.gov/16478442

DM6SFYH	DI	DM6SFYH
DM6SFYH	DN	[14C]TEA
DM6SFYH	MI	TT5PFNG
DM6SFYH	MN	Voltage-gated potassium channel Kv2.2 (KCNB2)
DM6SFYH	MT	DTT
DM6SFYH	MA	Blocker (channel blocker)
DM6SFYH	RN	Molecular identification of a component of delayed rectifier current in gastrointestinal smooth muscles. Am J Physiol. 1998 May;274(5 Pt 1):G901-11.
DM6SFYH	RU	https://pubmed.ncbi.nlm.nih.gov/9612272

DM6SFYH	DI	DM6SFYH
DM6SFYH	DN	[14C]TEA
DM6SFYH	MI	TTVUWHQ
DM6SFYH	MN	Voltage-gated potassium channel Kv3.1 (KCNC1)
DM6SFYH	MT	DTT
DM6SFYH	MA	Blocker (channel blocker)
DM6SFYH	RN	Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol. 1994 Jun;45(6):1227-34.
DM6SFYH	RU	https://pubmed.ncbi.nlm.nih.gov/7517498

DM6SFYH	DI	DM6SFYH
DM6SFYH	DN	[14C]TEA
DM6SFYH	MI	TTGK3ZO
DM6SFYH	MN	Voltage-gated potassium channel Kv3.2 (KCNC2)
DM6SFYH	MT	DTT
DM6SFYH	MA	Blocker (channel blocker)
DM6SFYH	RN	Gating, modulation and subunit composition of voltage-gated K(+) channels in dendritic inhibitory interneurones of rat hippocampus. J Physiol. 2002 Jan 15;538(Pt 2):405-19.
DM6SFYH	RU	https://pubmed.ncbi.nlm.nih.gov/11790809

DM6SFYH	DI	DM6SFYH
DM6SFYH	DN	[14C]TEA
DM6SFYH	MI	TTALSY9
DM6SFYH	MN	Voltage-gated potassium channel Kv3.3 (KCNC3)
DM6SFYH	MT	DTT
DM6SFYH	MA	Blocker (channel blocker)
DM6SFYH	RN	Cloning of ShIII (Shaw-like) cDNAs encoding a novel high-voltage-activating, TEA-sensitive, type-A K+ channel. Proc Biol Sci. 1992 Apr 22;248(1321):9-18.
DM6SFYH	RU	https://pubmed.ncbi.nlm.nih.gov/1381835

DM6SFYH	DI	DM6SFYH
DM6SFYH	DN	[14C]TEA
DM6SFYH	MI	TTODZF1
DM6SFYH	MN	Voltage-gated potassium channel Kv3.4 (KCNC4)
DM6SFYH	MT	DTT
DM6SFYH	MA	Blocker (channel blocker)
DM6SFYH	RN	Characterization of a Shaw-related potassium channel family in rat brain. EMBO J. 1992 Jul;11(7):2473-86.
DM6SFYH	RU	https://pubmed.ncbi.nlm.nih.gov/1378392

DM6SFYH	DI	DM6SFYH
DM6SFYH	DN	[14C]TEA
DM6SFYH	MI	TT4DI0J
DM6SFYH	MN	Voltage-gated potassium channel Kv4.1 (KCND1)
DM6SFYH	MT	DTT
DM6SFYH	MA	Blocker (channel blocker)
DM6SFYH	RN	Endogenous Kv channels in human embryonic kidney (HEK-293) cells. Mol Cell Biochem. 2002 Sep;238(1-2):69-79.
DM6SFYH	RU	https://pubmed.ncbi.nlm.nih.gov/12349911

DM6SFYH	DI	DM6SFYH
DM6SFYH	DN	[14C]TEA
DM6SFYH	MI	TTPXI3S
DM6SFYH	MN	Voltage-gated potassium channel Kv7.2 (KCNQ2)
DM6SFYH	MT	DTT
DM6SFYH	MA	Blocker (channel blocker)
DM6SFYH	RN	Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol Pharmacol. 2000 Sep;58(3):591-600.
DM6SFYH	RU	https://pubmed.ncbi.nlm.nih.gov/10953053

DM6SFYH	DI	DM6SFYH
DM6SFYH	DN	[14C]TEA
DM6SFYH	MI	TTIVDM3
DM6SFYH	MN	Voltage-gated potassium channel Kv7.3 (KCNQ3)
DM6SFYH	MT	DTT
DM6SFYH	MA	Blocker (channel blocker)
DM6SFYH	RN	Differential tetraethylammonium sensitivity of KCNQ1-4 potassium channels. Br J Pharmacol. 2000 Feb;129(3):413-5.
DM6SFYH	RU	https://pubmed.ncbi.nlm.nih.gov/10711337

DM6SFYH	DI	DM6SFYH
DM6SFYH	DN	[14C]TEA
DM6SFYH	MI	TT8HGRW
DM6SFYH	MN	Voltage-gated potassium channel Kv7.4 (KCNQ4)
DM6SFYH	MT	DTT
DM6SFYH	MA	Blocker (channel blocker)
DM6SFYH	RN	Homomeric and heteromeric assembly of KCNQ (Kv7) K+ channels assayed by total internal reflection fluorescence/fluorescence resonance energy transfer and patch clamp analysis. J Biol Chem. 2008 Nov 7;283(45):30668-76.
DM6SFYH	RU	https://pubmed.ncbi.nlm.nih.gov/18786918

DM6SFYH	DI	DM6SFYH
DM6SFYH	DN	[14C]TEA
DM6SFYH	MI	TTWVL5Q
DM6SFYH	MN	Voltage-gated potassium channel Kv7.5 (KCNQ5)
DM6SFYH	MT	DTT
DM6SFYH	MA	Blocker (channel blocker)
DM6SFYH	RN	KCNQ5, a novel potassium channel broadly expressed in brain, mediates M-type currents. J Biol Chem. 2000 Aug 4;275(31):24089-95.
DM6SFYH	RU	https://pubmed.ncbi.nlm.nih.gov/10816588

DMZJQC0	DI	DMZJQC0
DMZJQC0	DN	[18F](R,R)-quinuclidinyl-4-fluoromethyl-benzilate
DMZJQC0	MI	TTOXS3C
DMZJQC0	MN	Muscarinic acetylcholine receptor (CHRM)
DMZJQC0	MT	DTT
DMZJQC0	MA	Antagonist
DMZJQC0	RN	In vivo muscarinic binding selectivity of (R,S)- and (R,R)-[18F]-fluoromethyl QNB. Bioorg Med Chem. 1997 Aug;5(8):1555-67.
DMZJQC0	RU	https://pubmed.ncbi.nlm.nih.gov/9313861

DM65BDN	DI	DM65BDN
DM65BDN	DN	[18F]altanserin
DM65BDN	MI	TTJQOD7
DM65BDN	MN	5-HT 2A receptor (HTR2A)
DM65BDN	MT	DTT
DM65BDN	MA	Antagonist
DM65BDN	RN	Visualisation of loss of 5-HT2A receptors with age in healthy volunteers using [18F]altanserin and positron emission tomographic imaging. Psychiatry Res. 1996 Nov 25;68(1):11-22.
DM65BDN	RU	https://pubmed.ncbi.nlm.nih.gov/9027929

DM4VQNE	DI	DM4VQNE
DM4VQNE	DN	[18F]FITM
DM4VQNE	MI	TTVBPDM
DM4VQNE	MN	Metabotropic glutamate receptor 1 (mGluR1)
DM4VQNE	MT	DTT
DM4VQNE	MA	Modulator (allosteric modulator)
DM4VQNE	RN	Radiosynthesis and preliminary evaluation of 4-[18F]fluoro-N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methylbenzamide as a new positron emission tomography ligand for metabotropic glutamate receptor subtype 1. Bioorg Med Chem Lett. 2011 May 15;21(10):2998-3001.
DM4VQNE	RU	https://pubmed.ncbi.nlm.nih.gov/21470858

DMPWART	DI	DMPWART
DMPWART	DN	[18F]fluoroethylflumazenil
DMPWART	MI	TTBMV1G
DMPWART	MN	GABA(A) receptor alpha-2 (GABRA2)
DMPWART	MT	DTT
DMPWART	MA	Modulator (allosteric modulator)
DMPWART	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 405).
DMPWART	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=405

DMPWART	DI	DMPWART
DMPWART	DN	[18F]fluoroethylflumazenil
DMPWART	MI	TT37EDJ
DMPWART	MN	GABA(A) receptor alpha-3 (GABRA3)
DMPWART	MT	DTT
DMPWART	MA	Modulator (allosteric modulator)
DMPWART	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 406).
DMPWART	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=406

DMPWART	DI	DMPWART
DMPWART	DN	[18F]fluoroethylflumazenil
DMPWART	MI	TTNZPQ1
DMPWART	MN	GABA(A) receptor alpha-5 (GABRA5)
DMPWART	MT	DTT
DMPWART	MA	Modulator (allosteric modulator)
DMPWART	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 408).
DMPWART	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=408

DMPWART	DI	DMPWART
DMPWART	DN	[18F]fluoroethylflumazenil
DMPWART	MI	TTEX6LM
DMPWART	MN	GABA(A) receptor gamma-3 (GABRG3)
DMPWART	MT	DTT
DMPWART	MA	Modulator (allosteric modulator)
DMPWART	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415).
DMPWART	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415

DMRQ6XD	DI	DMRQ6XD
DMRQ6XD	DN	[18F]FPIT
DMRQ6XD	MI	TTVBPDM
DMRQ6XD	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMRQ6XD	MT	DTT
DMRQ6XD	MA	Modulator (allosteric modulator)
DMRQ6XD	RN	Characterization of 1-(2-[18F] fluoro-3-pyridyl)-4-(2-isopropyl-1-oxo- isoindoline-5-yl)-5-methyl-1H-1,2,3-triazole, a PET ligand for imaging the metabotropic glutamate receptor type 1 in rat and monkey brains. J Neurochem. 2012 Apr;121(1):115-24.
DMRQ6XD	RU	https://pubmed.ncbi.nlm.nih.gov/21668889

DMM2YU9	DI	DMM2YU9
DMM2YU9	DN	[18F]FP-TZTP
DMM2YU9	MI	TTOXS3C
DMM2YU9	MN	Muscarinic acetylcholine receptor (CHRM)
DMM2YU9	MT	DTT
DMM2YU9	MA	Agonist
DMM2YU9	RN	Regional brain uptake of the muscarinic ligand, [18F]FP-TZTP, is greatly decreased in M2 receptor knockout mice but not in M1, M3 and M4 receptor knockout mice. Neuropharmacology. 2003 Apr;44(5):653-61.
DMM2YU9	RU	https://pubmed.ncbi.nlm.nih.gov/12668051

DMQ6AR5	DI	DMQ6AR5
DMQ6AR5	DN	[18F]MK-1312
DMQ6AR5	MI	TTVBPDM
DMQ6AR5	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMQ6AR5	MT	DTT
DMQ6AR5	MA	Modulator (allosteric modulator)
DMQ6AR5	RN	Synthesis, characterization, and monkey PET studies of [ ]MK-1312, a PET tracer for quantification of mGluR1 receptor occupancy by MK-5435. Synapse. 2011 Feb;65(2):125-35.
DMQ6AR5	RU	https://pubmed.ncbi.nlm.nih.gov/20524178

DMXIO84	DI	DMXIO84
DMXIO84	DN	[18F]SPA-RQ
DMXIO84	MI	TTZPO1L
DMXIO84	MN	Substance-P receptor (TACR1)
DMXIO84	MT	DTT
DMXIO84	MA	Antagonist
DMXIO84	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 360).
DMXIO84	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=360

DMH3BG5	DI	DMH3BG5
DMH3BG5	DN	[1-Benzyl-1H-quinolin-(4E)-ylidene]-hexyl-amine
DMH3BG5	MI	TTY3UE6
DMH3BG5	MN	Voltage-gated potassium channel Kv1.3 (KCNA3)
DMH3BG5	MT	DTT
DMH3BG5	MA	Inhibitor
DMH3BG5	RN	Novel inhibitors of potassium ion channels on human T lymphocytes. J Med Chem. 1995 May 26;38(11):1877-83.
DMH3BG5	RU	https://pubmed.ncbi.nlm.nih.gov/7540207

DMS1YN3	DI	DMS1YN3
DMS1YN3	DN	[1-bromo-(3S)-hydrox-4-(palmitoyloxy)butyl]phosphate
DMS1YN3	MI	TT7ZMY4
DMS1YN3	MN	Lysophosphatidic acid receptor 4 (LPAR4)
DMS1YN3	MT	DTT
DMS1YN3	MA	Antagonist
DMS1YN3	RN	LPA and its analogs-attractive tools for elucidation of LPA biology and drug development. Curr Med Chem. 2008;15(21):2122-31.
DMS1YN3	RU	https://pubmed.ncbi.nlm.nih.gov/18781939

DMSPMHE	DI	DMSPMHE
DMSPMHE	DN	[2-(1H-Benzoimidazol-4-yloxy)-ethyl]-benzyl-amine
DMSPMHE	MI	TTEX248
DMSPMHE	MN	Dopamine D2 receptor (D2R)
DMSPMHE	MT	DTT
DMSPMHE	MA	Inhibitor
DMSPMHE	RN	New generation dopaminergic agents. 7. Heterocyclic bioisosteres that exploit the 3-OH-phenoxyethylamine D2 template. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2593-8.
DMSPMHE	RU	https://pubmed.ncbi.nlm.nih.gov/10498215

DMSPMHE	DI	DMSPMHE
DMSPMHE	DN	[2-(1H-Benzoimidazol-4-yloxy)-ethyl]-benzyl-amine
DMSPMHE	MI	TT4C8EA
DMSPMHE	MN	Dopamine D3 receptor (D3R)
DMSPMHE	MT	DTT
DMSPMHE	MA	Inhibitor
DMSPMHE	RN	New generation dopaminergic agents. 7. Heterocyclic bioisosteres that exploit the 3-OH-phenoxyethylamine D2 template. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2593-8.
DMSPMHE	RU	https://pubmed.ncbi.nlm.nih.gov/10498215

DMSPMHE	DI	DMSPMHE
DMSPMHE	DN	[2-(1H-Benzoimidazol-4-yloxy)-ethyl]-benzyl-amine
DMSPMHE	MI	TTE0A2F
DMSPMHE	MN	Dopamine D4 receptor (D4R)
DMSPMHE	MT	DTT
DMSPMHE	MA	Inhibitor
DMSPMHE	RN	New generation dopaminergic agents. 7. Heterocyclic bioisosteres that exploit the 3-OH-phenoxyethylamine D2 template. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2593-8.
DMSPMHE	RU	https://pubmed.ncbi.nlm.nih.gov/10498215

DMAJCVL	DI	DMAJCVL
DMAJCVL	DN	[2-(3-Benzyl-3H-inden-1-yl)-ethyl]-methyl-amine
DMAJCVL	MI	TTJS8PY
DMAJCVL	MN	5-HT 6 receptor (HTR6)
DMAJCVL	MT	DTT
DMAJCVL	MA	Inhibitor
DMAJCVL	RN	Binding of isotryptamines and indenes at h5-HT6 serotonin receptors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1987-91.
DMAJCVL	RU	https://pubmed.ncbi.nlm.nih.gov/15808453

DMU5P8O	DI	DMU5P8O
DMU5P8O	DN	[2-(3-Benzyl-3H-indol-1-yl)-ethyl]-dimethyl-amine
DMU5P8O	MI	TTJS8PY
DMU5P8O	MN	5-HT 6 receptor (HTR6)
DMU5P8O	MT	DTT
DMU5P8O	MA	Inhibitor
DMU5P8O	RN	Possible differences in modes of agonist and antagonist binding at human 5-HT6 receptors. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4569-73.
DMU5P8O	RU	https://pubmed.ncbi.nlm.nih.gov/15357994

DMBTRN6	DI	DMBTRN6
DMBTRN6	DN	[2-(3-Benzyl-indol-1-yl)-ethyl]-dimethyl-amine
DMBTRN6	MI	TTJS8PY
DMBTRN6	MN	5-HT 6 receptor (HTR6)
DMBTRN6	MT	DTT
DMBTRN6	MA	Inhibitor
DMBTRN6	RN	Binding of isotryptamines and indenes at h5-HT6 serotonin receptors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1987-91.
DMBTRN6	RU	https://pubmed.ncbi.nlm.nih.gov/15808453

DM1RW4U	DI	DM1RW4U
DM1RW4U	DN	[2-(3H-Indol-1-yl)-ethyl]-dimethyl-amine
DM1RW4U	MI	TTJS8PY
DM1RW4U	MN	5-HT 6 receptor (HTR6)
DM1RW4U	MT	DTT
DM1RW4U	MA	Inhibitor
DM1RW4U	RN	Possible differences in modes of agonist and antagonist binding at human 5-HT6 receptors. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4569-73.
DM1RW4U	RU	https://pubmed.ncbi.nlm.nih.gov/15357994

DMDIH96	DI	DMDIH96
DMDIH96	DN	[2-(4-Fluoro-1H-indol-3-yl)-ethyl]-dimethyl-amine
DMDIH96	MI	TTJQOD7
DMDIH96	MN	5-HT 2A receptor (HTR2A)
DMDIH96	MT	DTT
DMDIH96	MA	Inhibitor
DMDIH96	RN	SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.
DMDIH96	RU	https://pubmed.ncbi.nlm.nih.gov/16061378

DMDIH96	DI	DMDIH96
DMDIH96	DN	[2-(4-Fluoro-1H-indol-3-yl)-ethyl]-dimethyl-amine
DMDIH96	MI	TT0K1SC
DMDIH96	MN	5-HT 2B receptor (HTR2B)
DMDIH96	MT	DTT
DMDIH96	MA	Inhibitor
DMDIH96	RN	SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.
DMDIH96	RU	https://pubmed.ncbi.nlm.nih.gov/16061378

DMDIH96	DI	DMDIH96
DMDIH96	DN	[2-(4-Fluoro-1H-indol-3-yl)-ethyl]-dimethyl-amine
DMDIH96	MI	TTWJBZ5
DMDIH96	MN	5-HT 2C receptor (HTR2C)
DMDIH96	MT	DTT
DMDIH96	MA	Inhibitor
DMDIH96	RN	SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.
DMDIH96	RU	https://pubmed.ncbi.nlm.nih.gov/16061378

DMOZ73L	DI	DMOZ73L
DMOZ73L	DN	[2-(5-Ethyl-1H-indol-3-yl)-ethyl]-dimethyl-amine
DMOZ73L	MI	TTK8CXU
DMOZ73L	MN	5-HT 1B receptor (HTR1B)
DMOZ73L	MT	DTT
DMOZ73L	MA	Inhibitor
DMOZ73L	RN	5-Alkyltryptamine derivatives as highly selective and potent 5-HT1D receptor agonists. Bioorg Med Chem Lett. 2000 Aug 7;10(15):1707-9.
DMOZ73L	RU	https://pubmed.ncbi.nlm.nih.gov/10937729

DMOZ73L	DI	DMOZ73L
DMOZ73L	DN	[2-(5-Ethyl-1H-indol-3-yl)-ethyl]-dimethyl-amine
DMOZ73L	MI	TT6MSOK
DMOZ73L	MN	5-HT 1D receptor (HTR1D)
DMOZ73L	MT	DTT
DMOZ73L	MA	Inhibitor
DMOZ73L	RN	5-Alkyltryptamine derivatives as highly selective and potent 5-HT1D receptor agonists. Bioorg Med Chem Lett. 2000 Aug 7;10(15):1707-9.
DMOZ73L	RU	https://pubmed.ncbi.nlm.nih.gov/10937729

DM5LVIR	DI	DM5LVIR
DM5LVIR	DN	[2-(6-Chloro-purin-9-yl)ethyl]-bisphosphonic acid
DM5LVIR	MI	TTIKWV4
DM5LVIR	MN	Geranyltranstransferase (FDPS)
DM5LVIR	MT	DTT
DM5LVIR	MA	Inhibitor
DM5LVIR	RN	Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a gammadelta-T lymphocy... J Med Chem. 2008 Nov 13;51(21):6800-7.
DM5LVIR	RU	https://pubmed.ncbi.nlm.nih.gov/18937434

DMHPBQC	DI	DMHPBQC
DMHPBQC	DN	[2-(6-Methoxy-indol-1-yl)-ethyl]-dimethyl-amine
DMHPBQC	MI	TTJQOD7
DMHPBQC	MN	5-HT 2A receptor (HTR2A)
DMHPBQC	MT	DTT
DMHPBQC	MA	Inhibitor
DMHPBQC	RN	Evaluation of isotryptamine derivatives at 5-HT(2) serotonin receptors. Bioorg Med Chem Lett. 2002 Jan 21;12(2):155-8.
DMHPBQC	RU	https://pubmed.ncbi.nlm.nih.gov/11755343

DM98MXT	DI	DM98MXT
DM98MXT	DN	[2-(Benzoimidazol-1-yl)ethyl]-bisphosphonic acid
DM98MXT	MI	TTIKWV4
DM98MXT	MN	Geranyltranstransferase (FDPS)
DM98MXT	MT	DTT
DM98MXT	MA	Inhibitor
DM98MXT	RN	Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a gammadelta-T lymphocy... J Med Chem. 2008 Nov 13;51(21):6800-7.
DM98MXT	RU	https://pubmed.ncbi.nlm.nih.gov/18937434

DM37C25	DI	DM37C25
DM37C25	DN	[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid
DM37C25	MI	TTXZ0KQ
DM37C25	MN	Matrix metalloproteinase-12 (MMP-12)
DM37C25	MT	DTT
DM37C25	MA	Inhibitor
DM37C25	RN	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
DM37C25	RU	https://pubmed.ncbi.nlm.nih.gov/19775099

DM37C25	DI	DM37C25
DM37C25	DN	[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid
DM37C25	MI	TTHY57M
DM37C25	MN	Matrix metalloproteinase-13 (MMP-13)
DM37C25	MT	DTT
DM37C25	MA	Inhibitor
DM37C25	RN	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
DM37C25	RU	https://pubmed.ncbi.nlm.nih.gov/19775099

DM37C25	DI	DM37C25
DM37C25	DN	[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid
DM37C25	MI	TTJ4QE7
DM37C25	MN	Matrix metalloproteinase-14 (MMP-14)
DM37C25	MT	DTT
DM37C25	MA	Inhibitor
DM37C25	RN	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
DM37C25	RU	https://pubmed.ncbi.nlm.nih.gov/19775099

DM37C25	DI	DM37C25
DM37C25	DN	[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid
DM37C25	MI	TTLM12X
DM37C25	MN	Matrix metalloproteinase-2 (MMP-2)
DM37C25	MT	DTT
DM37C25	MA	Inhibitor
DM37C25	RN	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
DM37C25	RU	https://pubmed.ncbi.nlm.nih.gov/19775099

DM37C25	DI	DM37C25
DM37C25	DN	[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid
DM37C25	MI	TTYRF5E
DM37C25	MN	Matrix metalloproteinase-21 (MMP-21)
DM37C25	MT	DTT
DM37C25	MA	Inhibitor
DM37C25	RN	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
DM37C25	RU	https://pubmed.ncbi.nlm.nih.gov/19775099

DM37C25	DI	DM37C25
DM37C25	DN	[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid
DM37C25	MI	TTGA1IV
DM37C25	MN	Matrix metalloproteinase-8 (MMP-8)
DM37C25	MT	DTT
DM37C25	MA	Inhibitor
DM37C25	RN	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
DM37C25	RU	https://pubmed.ncbi.nlm.nih.gov/19775099

DM37C25	DI	DM37C25
DM37C25	DN	[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid
DM37C25	MI	TT6X50U
DM37C25	MN	Matrix metalloproteinase-9 (MMP-9)
DM37C25	MT	DTT
DM37C25	MA	Inhibitor
DM37C25	RN	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
DM37C25	RU	https://pubmed.ncbi.nlm.nih.gov/19775099

DMQZUD9	DI	DMQZUD9
DMQZUD9	DN	[2-(Imidazol-1-yl)ethyl]-bisphosphonic acid
DMQZUD9	MI	TTIKWV4
DMQZUD9	MN	Geranyltranstransferase (FDPS)
DMQZUD9	MT	DTT
DMQZUD9	MA	Inhibitor
DMQZUD9	RN	Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a gammadelta-T lymphocy... J Med Chem. 2008 Nov 13;51(21):6800-7.
DMQZUD9	RU	https://pubmed.ncbi.nlm.nih.gov/18937434

DMBVDY5	DI	DMBVDY5
DMBVDY5	DN	[2-(Imidazol-2-yl-thio)ethyl]-bisphosphonic acid
DMBVDY5	MI	TTIKWV4
DMBVDY5	MN	Geranyltranstransferase (FDPS)
DMBVDY5	MT	DTT
DMBVDY5	MA	Inhibitor
DMBVDY5	RN	Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a gammadelta-T lymphocy... J Med Chem. 2008 Nov 13;51(21):6800-7.
DMBVDY5	RU	https://pubmed.ncbi.nlm.nih.gov/18937434

DM3VT8M	DI	DM3VT8M
DM3VT8M	DN	[2-(Purin-9-yl)ethyl]-bisphosphonic acid
DM3VT8M	MI	TTIKWV4
DM3VT8M	MN	Geranyltranstransferase (FDPS)
DM3VT8M	MT	DTT
DM3VT8M	MA	Inhibitor
DM3VT8M	RN	Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a gammadelta-T lymphocy... J Med Chem. 2008 Nov 13;51(21):6800-7.
DM3VT8M	RU	https://pubmed.ncbi.nlm.nih.gov/18937434

DMJN8XK	DI	DMJN8XK
DMJN8XK	DN	[2-(Pyrazol-1-yl)ethyl]-bisphosphonic acid
DMJN8XK	MI	TTIKWV4
DMJN8XK	MN	Geranyltranstransferase (FDPS)
DMJN8XK	MT	DTT
DMJN8XK	MA	Inhibitor
DMJN8XK	RN	Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a gammadelta-T lymphocy... J Med Chem. 2008 Nov 13;51(21):6800-7.
DMJN8XK	RU	https://pubmed.ncbi.nlm.nih.gov/18937434

DMI9RLZ	DI	DMI9RLZ
DMI9RLZ	DN	[2(R,S)-2-Sulfanylheptanoyl]-Phe-Ala
DMI9RLZ	MI	TT5TKPM
DMI9RLZ	MN	Neutral endopeptidase (MME)
DMI9RLZ	MT	DTT
DMI9RLZ	MA	Inhibitor
DMI9RLZ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMI9RLZ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMI9RLZ	DI	DMI9RLZ
DMI9RLZ	DN	[2(R,S)-2-Sulfanylheptanoyl]-Phe-Ala
DMI9RLZ	MI	TTVDSZ0
DMI9RLZ	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMI9RLZ	MT	DTT
DMI9RLZ	MA	Inhibitor
DMI9RLZ	RN	Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clin Cancer Res. 2003 Jul;9(7):2711-8.
DMI9RLZ	RU	https://pubmed.ncbi.nlm.nih.gov/12855651

DMRQC1F	DI	DMRQC1F
DMRQC1F	DN	[2,2':5',2'']Terthiophen-4-yl-methanol
DMRQC1F	MI	TTFJ8Q1
DMRQC1F	MN	Protein kinase C alpha (PRKCA)
DMRQC1F	MT	DTT
DMRQC1F	MA	Inhibitor
DMRQC1F	RN	Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82.
DMRQC1F	RU	https://pubmed.ncbi.nlm.nih.gov/10465561

DMRQC1F	DI	DMRQC1F
DMRQC1F	DN	[2,2':5',2'']Terthiophen-4-yl-methanol
DMRQC1F	MI	TTYPXQF
DMRQC1F	MN	Protein kinase C beta (PRKCB)
DMRQC1F	MT	DTT
DMRQC1F	MA	Inhibitor
DMRQC1F	RN	Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82.
DMRQC1F	RU	https://pubmed.ncbi.nlm.nih.gov/10465561

DMRQC1F	DI	DMRQC1F
DMRQC1F	DN	[2,2':5',2'']Terthiophen-4-yl-methanol
DMRQC1F	MI	TT9WJ8U
DMRQC1F	MN	Protein kinase C delta (PRKCD)
DMRQC1F	MT	DTT
DMRQC1F	MA	Inhibitor
DMRQC1F	RN	Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82.
DMRQC1F	RU	https://pubmed.ncbi.nlm.nih.gov/10465561

DMRQC1F	DI	DMRQC1F
DMRQC1F	DN	[2,2':5',2'']Terthiophen-4-yl-methanol
DMRQC1F	MI	TTBZ7OD
DMRQC1F	MN	Protein kinase C epsilon (PRKCE)
DMRQC1F	MT	DTT
DMRQC1F	MA	Inhibitor
DMRQC1F	RN	Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82.
DMRQC1F	RU	https://pubmed.ncbi.nlm.nih.gov/10465561

DMRQC1F	DI	DMRQC1F
DMRQC1F	DN	[2,2':5',2'']Terthiophen-4-yl-methanol
DMRQC1F	MI	TTRFOXJ
DMRQC1F	MN	Protein kinase C gamma (PRKCG)
DMRQC1F	MT	DTT
DMRQC1F	MA	Inhibitor
DMRQC1F	RN	Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82.
DMRQC1F	RU	https://pubmed.ncbi.nlm.nih.gov/10465561

DMRQC1F	DI	DMRQC1F
DMRQC1F	DN	[2,2':5',2'']Terthiophen-4-yl-methanol
DMRQC1F	MI	TT8QL1J
DMRQC1F	MN	Protein kinase C theta (PRKCQ)
DMRQC1F	MT	DTT
DMRQC1F	MA	Inhibitor
DMRQC1F	RN	Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82.
DMRQC1F	RU	https://pubmed.ncbi.nlm.nih.gov/10465561

DMRQC1F	DI	DMRQC1F
DMRQC1F	DN	[2,2':5',2'']Terthiophen-4-yl-methanol
DMRQC1F	MI	TTUWGRA
DMRQC1F	MN	Protein kinase C zeta (PRKCZ)
DMRQC1F	MT	DTT
DMRQC1F	MA	Inhibitor
DMRQC1F	RN	Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82.
DMRQC1F	RU	https://pubmed.ncbi.nlm.nih.gov/10465561

DMWDNLI	DI	DMWDNLI
DMWDNLI	DN	[2,2':5',2'']Terthiophene-4,5''-dicarbaldehyde
DMWDNLI	MI	TTFJ8Q1
DMWDNLI	MN	Protein kinase C alpha (PRKCA)
DMWDNLI	MT	DTT
DMWDNLI	MA	Inhibitor
DMWDNLI	RN	Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82.
DMWDNLI	RU	https://pubmed.ncbi.nlm.nih.gov/10465561

DMWDNLI	DI	DMWDNLI
DMWDNLI	DN	[2,2':5',2'']Terthiophene-4,5''-dicarbaldehyde
DMWDNLI	MI	TTYPXQF
DMWDNLI	MN	Protein kinase C beta (PRKCB)
DMWDNLI	MT	DTT
DMWDNLI	MA	Inhibitor
DMWDNLI	RN	Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82.
DMWDNLI	RU	https://pubmed.ncbi.nlm.nih.gov/10465561

DMWDNLI	DI	DMWDNLI
DMWDNLI	DN	[2,2':5',2'']Terthiophene-4,5''-dicarbaldehyde
DMWDNLI	MI	TT9WJ8U
DMWDNLI	MN	Protein kinase C delta (PRKCD)
DMWDNLI	MT	DTT
DMWDNLI	MA	Inhibitor
DMWDNLI	RN	Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82.
DMWDNLI	RU	https://pubmed.ncbi.nlm.nih.gov/10465561

DMWDNLI	DI	DMWDNLI
DMWDNLI	DN	[2,2':5',2'']Terthiophene-4,5''-dicarbaldehyde
DMWDNLI	MI	TTBZ7OD
DMWDNLI	MN	Protein kinase C epsilon (PRKCE)
DMWDNLI	MT	DTT
DMWDNLI	MA	Inhibitor
DMWDNLI	RN	Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82.
DMWDNLI	RU	https://pubmed.ncbi.nlm.nih.gov/10465561

DMWDNLI	DI	DMWDNLI
DMWDNLI	DN	[2,2':5',2'']Terthiophene-4,5''-dicarbaldehyde
DMWDNLI	MI	TTRFOXJ
DMWDNLI	MN	Protein kinase C gamma (PRKCG)
DMWDNLI	MT	DTT
DMWDNLI	MA	Inhibitor
DMWDNLI	RN	Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82.
DMWDNLI	RU	https://pubmed.ncbi.nlm.nih.gov/10465561

DMWDNLI	DI	DMWDNLI
DMWDNLI	DN	[2,2':5',2'']Terthiophene-4,5''-dicarbaldehyde
DMWDNLI	MI	TT8QL1J
DMWDNLI	MN	Protein kinase C theta (PRKCQ)
DMWDNLI	MT	DTT
DMWDNLI	MA	Inhibitor
DMWDNLI	RN	Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82.
DMWDNLI	RU	https://pubmed.ncbi.nlm.nih.gov/10465561

DMWDNLI	DI	DMWDNLI
DMWDNLI	DN	[2,2':5',2'']Terthiophene-4,5''-dicarbaldehyde
DMWDNLI	MI	TTUWGRA
DMWDNLI	MN	Protein kinase C zeta (PRKCZ)
DMWDNLI	MT	DTT
DMWDNLI	MA	Inhibitor
DMWDNLI	RN	Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82.
DMWDNLI	RU	https://pubmed.ncbi.nlm.nih.gov/10465561

DM2S5EJ	DI	DM2S5EJ
DM2S5EJ	DN	[2,2':5',2'']Terthiophene-4-carbaldehyde
DM2S5EJ	MI	TTFJ8Q1
DM2S5EJ	MN	Protein kinase C alpha (PRKCA)
DM2S5EJ	MT	DTT
DM2S5EJ	MA	Inhibitor
DM2S5EJ	RN	Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82.
DM2S5EJ	RU	https://pubmed.ncbi.nlm.nih.gov/10465561

DM2S5EJ	DI	DM2S5EJ
DM2S5EJ	DN	[2,2':5',2'']Terthiophene-4-carbaldehyde
DM2S5EJ	MI	TTYPXQF
DM2S5EJ	MN	Protein kinase C beta (PRKCB)
DM2S5EJ	MT	DTT
DM2S5EJ	MA	Inhibitor
DM2S5EJ	RN	Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82.
DM2S5EJ	RU	https://pubmed.ncbi.nlm.nih.gov/10465561

DM2S5EJ	DI	DM2S5EJ
DM2S5EJ	DN	[2,2':5',2'']Terthiophene-4-carbaldehyde
DM2S5EJ	MI	TT9WJ8U
DM2S5EJ	MN	Protein kinase C delta (PRKCD)
DM2S5EJ	MT	DTT
DM2S5EJ	MA	Inhibitor
DM2S5EJ	RN	Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82.
DM2S5EJ	RU	https://pubmed.ncbi.nlm.nih.gov/10465561

DM2S5EJ	DI	DM2S5EJ
DM2S5EJ	DN	[2,2':5',2'']Terthiophene-4-carbaldehyde
DM2S5EJ	MI	TTBZ7OD
DM2S5EJ	MN	Protein kinase C epsilon (PRKCE)
DM2S5EJ	MT	DTT
DM2S5EJ	MA	Inhibitor
DM2S5EJ	RN	Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82.
DM2S5EJ	RU	https://pubmed.ncbi.nlm.nih.gov/10465561

DM2S5EJ	DI	DM2S5EJ
DM2S5EJ	DN	[2,2':5',2'']Terthiophene-4-carbaldehyde
DM2S5EJ	MI	TTRFOXJ
DM2S5EJ	MN	Protein kinase C gamma (PRKCG)
DM2S5EJ	MT	DTT
DM2S5EJ	MA	Inhibitor
DM2S5EJ	RN	Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82.
DM2S5EJ	RU	https://pubmed.ncbi.nlm.nih.gov/10465561

DM2S5EJ	DI	DM2S5EJ
DM2S5EJ	DN	[2,2':5',2'']Terthiophene-4-carbaldehyde
DM2S5EJ	MI	TT8QL1J
DM2S5EJ	MN	Protein kinase C theta (PRKCQ)
DM2S5EJ	MT	DTT
DM2S5EJ	MA	Inhibitor
DM2S5EJ	RN	Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82.
DM2S5EJ	RU	https://pubmed.ncbi.nlm.nih.gov/10465561

DM2S5EJ	DI	DM2S5EJ
DM2S5EJ	DN	[2,2':5',2'']Terthiophene-4-carbaldehyde
DM2S5EJ	MI	TTUWGRA
DM2S5EJ	MN	Protein kinase C zeta (PRKCZ)
DM2S5EJ	MT	DTT
DM2S5EJ	MA	Inhibitor
DM2S5EJ	RN	Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82.
DM2S5EJ	RU	https://pubmed.ncbi.nlm.nih.gov/10465561

DM4WXD2	DI	DM4WXD2
DM4WXD2	DN	[2-Phenylacetophenone]thiosemicarbazone
DM4WXD2	MI	TT36ETB
DM4WXD2	MN	Cathepsin L (CTSL)
DM4WXD2	MT	DTT
DM4WXD2	MA	Inhibitor
DM4WXD2	RN	Functionalized benzophenone, thiophene, pyridine, and fluorene thiosemicarbazone derivatives as inhibitors of cathepsin L. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6610-5.
DM4WXD2	RU	https://pubmed.ncbi.nlm.nih.gov/20933415

DM4BYEQ	DI	DM4BYEQ
DM4BYEQ	DN	[3-(3,4-Dichloro-phenyl)-indan-1-yl]-methyl-amine
DM4BYEQ	MI	TTVBI8W
DM4BYEQ	MN	Dopamine transporter (DAT)
DM4BYEQ	MT	DTT
DM4BYEQ	MA	Inhibitor
DM4BYEQ	RN	Synthesis and pharmacological evaluation of 3-(3,4-dichlorophenyl)-1-indanamine derivatives as nonselective ligands for biogenic amine transporters. J Med Chem. 2004 May 6;47(10):2624-34.
DM4BYEQ	RU	https://pubmed.ncbi.nlm.nih.gov/15115403

DM4BYEQ	DI	DM4BYEQ
DM4BYEQ	DN	[3-(3,4-Dichloro-phenyl)-indan-1-yl]-methyl-amine
DM4BYEQ	MI	TTAWNKZ
DM4BYEQ	MN	Norepinephrine transporter (NET)
DM4BYEQ	MT	DTT
DM4BYEQ	MA	Inhibitor
DM4BYEQ	RN	Synthesis and pharmacological evaluation of 3-(3,4-dichlorophenyl)-1-indanamine derivatives as nonselective ligands for biogenic amine transporters. J Med Chem. 2004 May 6;47(10):2624-34.
DM4BYEQ	RU	https://pubmed.ncbi.nlm.nih.gov/15115403

DM4BYEQ	DI	DM4BYEQ
DM4BYEQ	DN	[3-(3,4-Dichloro-phenyl)-indan-1-yl]-methyl-amine
DM4BYEQ	MI	TT3ROYC
DM4BYEQ	MN	Serotonin transporter (SERT)
DM4BYEQ	MT	DTT
DM4BYEQ	MA	Inhibitor
DM4BYEQ	RN	Synthesis and pharmacological evaluation of 3-(3,4-dichlorophenyl)-1-indanamine derivatives as nonselective ligands for biogenic amine transporters. J Med Chem. 2004 May 6;47(10):2624-34.
DM4BYEQ	RU	https://pubmed.ncbi.nlm.nih.gov/15115403

DMGD487	DI	DMGD487
DMGD487	DN	[3-(4-Nonyl-benzylamino)-propyl]-phosphonic acid
DMGD487	MI	TT9JZCK
DMGD487	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMGD487	MT	DTT
DMGD487	MA	Inhibitor
DMGD487	RN	Design and synthesis of conformationally constrained 3-(N-alkylamino)propylphosphonic acids as potent agonists of sphingosine-1-phosphate (S1P) rec... Bioorg Med Chem Lett. 2004 Oct 4;14(19):4861-6.
DMGD487	RU	https://pubmed.ncbi.nlm.nih.gov/15341940

DMD0LCU	DI	DMD0LCU
DMD0LCU	DN	[3-(5-Phenyl-oxazol-2-ylamino)-phenyl]-methanol
DMD0LCU	MI	TTUTJGQ
DMD0LCU	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMD0LCU	MT	DTT
DMD0LCU	MA	Inhibitor
DMD0LCU	RN	Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9.
DMD0LCU	RU	https://pubmed.ncbi.nlm.nih.gov/15743202

DMD0LCU	DI	DMD0LCU
DMD0LCU	DN	[3-(5-Phenyl-oxazol-2-ylamino)-phenyl]-methanol
DMD0LCU	MI	TTDCBX5
DMD0LCU	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DMD0LCU	MT	DTT
DMD0LCU	MA	Inhibitor
DMD0LCU	RN	Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9.
DMD0LCU	RU	https://pubmed.ncbi.nlm.nih.gov/15743202

DMD0LCU	DI	DMD0LCU
DMD0LCU	DN	[3-(5-Phenyl-oxazol-2-ylamino)-phenyl]-methanol
DMD0LCU	MI	TT1VAUK
DMD0LCU	MN	VEGFR1 messenger RNA (VEGFR1 mRNA)
DMD0LCU	MT	DTT
DMD0LCU	MA	Inhibitor
DMD0LCU	RN	Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9.
DMD0LCU	RU	https://pubmed.ncbi.nlm.nih.gov/15743202

DMRBJ4V	DI	DMRBJ4V
DMRBJ4V	DN	[3-(Biphenyl-4-yloxy)-propyl]-dimethyl-amine
DMRBJ4V	MI	TT7O8ZA
DMRBJ4V	MN	Lanosterol synthase (LSS)
DMRBJ4V	MT	DTT
DMRBJ4V	MA	Inhibitor
DMRBJ4V	RN	Oxidosqualene cyclase inhibitors as antimicrobial agents. J Med Chem. 2003 Sep 25;46(20):4240-3.
DMRBJ4V	RU	https://pubmed.ncbi.nlm.nih.gov/13678402

DMHU4NS	DI	DMHU4NS
DMHU4NS	DN	[3,4''']biflavone
DMHU4NS	MI	TTT1JVS
DMHU4NS	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DMHU4NS	MT	DTT
DMHU4NS	MA	Inhibitor
DMHU4NS	RN	Inhibitory effect of synthetic C-C biflavones on various phospholipase A(2)s activity. Bioorg Med Chem. 2007 Nov 15;15(22):7138-43.
DMHU4NS	RU	https://pubmed.ncbi.nlm.nih.gov/17826099

DMEMVY5	DI	DMEMVY5
DMEMVY5	DN	[32P]MRS2500
DMEMVY5	MI	TTA93TL
DMEMVY5	MN	P2Y purinoceptor 1 (P2RY1)
DMEMVY5	MT	DTT
DMEMVY5	MA	Antagonist
DMEMVY5	RN	[32P]2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate ([32P]MRS2500), a novel radioligand for quantification of native P2Y1 receptors. Br J Pharmacol. 2006 Mar;147(5):459-67.
DMEMVY5	RU	https://pubmed.ncbi.nlm.nih.gov/16299552

DM218VZ	DI	DM218VZ
DM218VZ	DN	[33P]2MeSADP
DM218VZ	MI	TT1FE3L
DM218VZ	MN	P2Y purinoceptor 13 (P2RY13)
DM218VZ	MT	DTT
DM218VZ	MA	Agonist
DM218VZ	RN	Pharmacological characterization of the human P2Y13 receptor. Mol Pharmacol. 2003 Jul;64(1):104-12.
DM218VZ	RU	https://pubmed.ncbi.nlm.nih.gov/12815166

DMVUEYM	DI	DMVUEYM
DMVUEYM	DN	[35S]ACPPB
DMVUEYM	MI	TTHJTF7
DMVUEYM	MN	Glycine transporter GlyT-1 (SLC6A9)
DMVUEYM	MT	DTT
DMVUEYM	MA	Modulator
DMVUEYM	RN	A novel radioligand for glycine transporter 1: characterization and use in autoradiographic and in vivo brain occupancy studies. Nucl Med Biol. 2008 Apr;35(3):315-25.
DMVUEYM	RU	https://pubmed.ncbi.nlm.nih.gov/18355687

DMAYPTO	DI	DMAYPTO
DMAYPTO	DN	[35S]ADPbetaS
DMAYPTO	MI	TTA93TL
DMAYPTO	MN	P2Y purinoceptor 1 (P2RY1)
DMAYPTO	MT	DTT
DMAYPTO	MA	Agonist
DMAYPTO	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 323).
DMAYPTO	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=323

DMQ0NK8	DI	DMQ0NK8
DMQ0NK8	DN	[35S]ibutamoren
DMQ0NK8	MI	TTWDC17
DMQ0NK8	MN	Growth hormone secretagogue receptor 1 (GHSR)
DMQ0NK8	MT	DTT
DMQ0NK8	MA	Agonist
DMQ0NK8	RN	Molecular analysis of rat pituitary and hypothalamic growth hormone secretagogue receptors. Mol Endocrinol. 1997 Apr;11(4):415-23.
DMQ0NK8	RU	https://pubmed.ncbi.nlm.nih.gov/9092793

DMSHOQ8	DI	DMSHOQ8
DMSHOQ8	DN	[35S]-non-peptide OT antagonist
DMSHOQ8	MI	TTSCIUP
DMSHOQ8	MN	Oxytocin receptor (OTR)
DMSHOQ8	MT	DTT
DMSHOQ8	MA	Antagonist
DMSHOQ8	RN	A nonpeptide oxytocin receptor antagonist radioligand highly selective for human receptors. Eur J Pharmacol. 2002 Aug 16;450(1):19-28.
DMSHOQ8	RU	https://pubmed.ncbi.nlm.nih.gov/12176104

DMSD51L	DI	DMSD51L
DMSD51L	DN	[35S]TBPS
DMSD51L	MI	TTBMV1G
DMSD51L	MN	GABA(A) receptor alpha-2 (GABRA2)
DMSD51L	MT	DTT
DMSD51L	MA	Blocker (channel blocker)
DMSD51L	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 405).
DMSD51L	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=405

DMSD51L	DI	DMSD51L
DMSD51L	DN	[35S]TBPS
DMSD51L	MI	TT37EDJ
DMSD51L	MN	GABA(A) receptor alpha-3 (GABRA3)
DMSD51L	MT	DTT
DMSD51L	MA	Blocker (channel blocker)
DMSD51L	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 406).
DMSD51L	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=406

DMSD51L	DI	DMSD51L
DMSD51L	DN	[35S]TBPS
DMSD51L	MI	TTNZPQ1
DMSD51L	MN	GABA(A) receptor alpha-5 (GABRA5)
DMSD51L	MT	DTT
DMSD51L	MA	Blocker (channel blocker)
DMSD51L	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 408).
DMSD51L	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=408

DMSD51L	DI	DMSD51L
DMSD51L	DN	[35S]TBPS
DMSD51L	MI	TTEX6LM
DMSD51L	MN	GABA(A) receptor gamma-3 (GABRG3)
DMSD51L	MT	DTT
DMSD51L	MA	Blocker (channel blocker)
DMSD51L	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415).
DMSD51L	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415

DMN35BY	DI	DMN35BY
DMN35BY	DN	[3H](-)CGP 12177
DMN35BY	MI	TTMXGCW
DMN35BY	MN	Adrenergic receptor beta-3 (ADRB3)
DMN35BY	MT	DTT
DMN35BY	MA	Agonist
DMN35BY	RN	Binding of (-)-[3H]-CGP12177 at two sites in recombinant human beta 1-adrenoceptors and interaction with beta-blockers. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):525-32.
DMN35BY	RU	https://pubmed.ncbi.nlm.nih.gov/15060759

DM0KGHP	DI	DM0KGHP
DM0KGHP	DN	[3H](-)devapamil
DM0KGHP	MI	TT94HRF
DM0KGHP	MN	Voltage-gated calcium channel alpha Cav1.1 (CACNA1S)
DM0KGHP	MT	DTT
DM0KGHP	MA	Inhibitor (gating inhibitor)
DM0KGHP	RN	(-)-[3H]Desmethoxyverapamil, a novel Ca2+ channel probe. Binding characteristics and target size analysis of its receptor in skeletal muscle. FEBS Lett. 1984 Oct 29;176(2):371-7.
DM0KGHP	RU	https://pubmed.ncbi.nlm.nih.gov/6092142

DM0KGHP	DI	DM0KGHP
DM0KGHP	DN	[3H](-)devapamil
DM0KGHP	MI	TTZIFHC
DM0KGHP	MN	Voltage-gated calcium channel alpha Cav1.2 (CACNA1C)
DM0KGHP	MT	DTT
DM0KGHP	MA	Inhibitor (gating inhibitor)
DM0KGHP	RN	Pharmacological, radioligand binding, and electrophysiological characteristics of FPL 64176, a novel nondihydropyridine Ca2+ channel activator, in cardiac and vascular preparations. Mol Pharmacol. 1991 Nov;40(5):734-41.
DM0KGHP	RU	https://pubmed.ncbi.nlm.nih.gov/1719369

DM0KGHP	DI	DM0KGHP
DM0KGHP	DN	[3H](-)devapamil
DM0KGHP	MI	TTXHYV6
DM0KGHP	MN	Voltage-gated L-type calcium channel (L-CaC)
DM0KGHP	MT	DTT
DM0KGHP	MA	Blocker
DM0KGHP	RN	Role of apoptosis in the kidney after reperfusion. Orv Hetil. 2008 Feb 17;149(7):305-15.
DM0KGHP	RU	https://pubmed.ncbi.nlm.nih.gov/18258561

DMP6XL9	DI	DMP6XL9
DMP6XL9	DN	[3H](+)-cis-diltiazem
DMP6XL9	MI	TT94HRF
DMP6XL9	MN	Voltage-gated calcium channel alpha Cav1.1 (CACNA1S)
DMP6XL9	MT	DTT
DMP6XL9	MA	Inhibitor (gating inhibitor)
DMP6XL9	RN	High-affinity binding of DTZ323, a novel derivative of diltiazem, to rabbit skeletal muscle L-type Ca++ channels. J Pharmacol Exp Ther. 1997 Apr;281(1):173-9.
DMP6XL9	RU	https://pubmed.ncbi.nlm.nih.gov/9103495

DMP6XL9	DI	DMP6XL9
DMP6XL9	DN	[3H](+)-cis-diltiazem
DMP6XL9	MI	TTZIFHC
DMP6XL9	MN	Voltage-gated calcium channel alpha Cav1.2 (CACNA1C)
DMP6XL9	MT	DTT
DMP6XL9	MA	Inhibitor (gating inhibitor)
DMP6XL9	RN	SR 33557, a novel calcium entry blocker. II. Interactions with 1,4-dihydropyridine, phenylalkylamine and benzothiazepine binding sites in rat heart sarcolemmal membranes. J Pharmacol Exp Ther. 1990 Nov;255(2):600-7.
DMP6XL9	RU	https://pubmed.ncbi.nlm.nih.gov/2147036

DM7QE1J	DI	DM7QE1J
DM7QE1J	DN	[3H](+)-isradipine
DM7QE1J	MI	TT94HRF
DM7QE1J	MN	Voltage-gated calcium channel alpha Cav1.1 (CACNA1S)
DM7QE1J	MT	DTT
DM7QE1J	MA	Inhibitor (gating inhibitor)
DM7QE1J	RN	Biochemical characterization of plasma membrane isolated from human skeletal muscle. FEBS Lett. 1985 Sep 2;188(2):222-6.
DM7QE1J	RU	https://pubmed.ncbi.nlm.nih.gov/2411596

DM7QE1J	DI	DM7QE1J
DM7QE1J	DN	[3H](+)-isradipine
DM7QE1J	MI	TTZIFHC
DM7QE1J	MN	Voltage-gated calcium channel alpha Cav1.2 (CACNA1C)
DM7QE1J	MT	DTT
DM7QE1J	MA	Inhibitor (gating inhibitor)
DM7QE1J	RN	Isoform-specific regulation of mood behavior and pancreatic beta cell and cardiovascular function by L-type Ca 2+ channels. J Clin Invest. 2004 May;113(10):1430-9.
DM7QE1J	RU	https://pubmed.ncbi.nlm.nih.gov/15146240

DM7QE1J	DI	DM7QE1J
DM7QE1J	DN	[3H](+)-isradipine
DM7QE1J	MI	TT7RGTM
DM7QE1J	MN	Voltage-gated calcium channel alpha Cav1.3 (CACNA1D)
DM7QE1J	MT	DTT
DM7QE1J	MA	Inhibitor (gating inhibitor)
DM7QE1J	RN	alpha 1D (Cav1.3) subunits can form l-type Ca2+ channels activating at negative voltages. J Biol Chem. 2001 Jun 22;276(25):22100-6.
DM7QE1J	RU	https://pubmed.ncbi.nlm.nih.gov/11285265

DMRPS2X	DI	DMRPS2X
DMRPS2X	DN	[3H](R)-NPTS
DMRPS2X	MI	TTHJTF7
DMRPS2X	MN	Glycine transporter GlyT-1 (SLC6A9)
DMRPS2X	MT	DTT
DMRPS2X	MA	Modulator
DMRPS2X	RN	[3H]-(R)-NPTS, a radioligand for the type 1 glycine transporter. Bioorg Med Chem Lett. 2003 Apr 7;13(7):1291-2.
DMRPS2X	RU	https://pubmed.ncbi.nlm.nih.gov/12657266

DM0B54M	DI	DM0B54M
DM0B54M	DN	[3H](S)-zacopride
DM0B54M	MI	TTPC4TU
DM0B54M	MN	5-HT 3A receptor (HTR3A)
DM0B54M	MT	DTT
DM0B54M	MA	Antagonist
DM0B54M	RN	Autoradiographic distribution of [3H]-(S)-zacopride-labelled 5-HT3 receptors in human brain. J Neurol Sci. 1996 Dec;144(1-2):119-27.
DM0B54M	RU	https://pubmed.ncbi.nlm.nih.gov/8994113

DMQO8AF	DI	DMQO8AF
DMQO8AF	DN	[3H]2,2,2-TEMPS
DMQO8AF	MI	TTXJ47W
DMQO8AF	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMQO8AF	MT	DTT
DMQO8AF	MA	Modulator (allosteric modulator)
DMQO8AF	RN	Structural determinants of allosteric antagonism at metabotropic glutamate receptor 2: mechanistic studies with new potent negative allosteric modulators. Br J Pharmacol. 2011 Sep;164(2b):521-37.
DMQO8AF	RU	https://pubmed.ncbi.nlm.nih.gov/21470207

DM5SWI1	DI	DM5SWI1
DM5SWI1	DN	[3H]4NMPB
DM5SWI1	MI	TTOXS3C
DM5SWI1	MN	Muscarinic acetylcholine receptor (CHRM)
DM5SWI1	MT	DTT
DM5SWI1	MA	Antagonist
DM5SWI1	RN	Cloned M1 muscarinic receptors mediate both adenylate cyclase inhibition and phosphoinositide turnover. EMBO J. 1988 Oct;7(10):3031-5.
DM5SWI1	RU	https://pubmed.ncbi.nlm.nih.gov/2846274

DMEAHFZ	DI	DMEAHFZ
DMEAHFZ	DN	[3H]5-CT
DMEAHFZ	MI	TT6MSOK
DMEAHFZ	MN	5-HT 1D receptor (HTR1D)
DMEAHFZ	MT	DTT
DMEAHFZ	MA	Agonist
DMEAHFZ	RN	Serotonin 5-HT1B and 5-HT1D receptors form homodimers when expressed alone and heterodimers when co-expressed. FEBS Lett. 1999 Jul 30;456(1):63-7.
DMEAHFZ	RU	https://pubmed.ncbi.nlm.nih.gov/10452531

DMEAHFZ	DI	DMEAHFZ
DMEAHFZ	DN	[3H]5-CT
DMEAHFZ	MI	TTRUFDT
DMEAHFZ	MN	5-HT 5A receptor (HTR5A)
DMEAHFZ	MT	DTT
DMEAHFZ	MA	Agonist
DMEAHFZ	RN	Human 5-HT(5) receptors: the 5-HT(5A) receptor is functional but the 5-HT(5B) receptor was lost during mammalian evolution. Eur J Pharmacol. 2001 Apr 27;418(3):157-67.
DMEAHFZ	RU	https://pubmed.ncbi.nlm.nih.gov/11343685

DMEAHFZ	DI	DMEAHFZ
DMEAHFZ	DN	[3H]5-CT
DMEAHFZ	MI	TT9KJ1X
DMEAHFZ	MN	5-HT 5B receptor (HTR5B)
DMEAHFZ	MT	DTT
DMEAHFZ	MA	Agonist
DMEAHFZ	RN	Putative 5-ht5 receptors: localization in the mouse CNS and lack of effect in the inhibition of dural protein extravasation. Ann N Y Acad Sci. 1998 Dec 15;861:85-90.
DMEAHFZ	RU	https://pubmed.ncbi.nlm.nih.gov/9928243

DMEAHFZ	DI	DMEAHFZ
DMEAHFZ	DN	[3H]5-CT
DMEAHFZ	MI	TTJS8PY
DMEAHFZ	MN	5-HT 6 receptor (HTR6)
DMEAHFZ	MT	DTT
DMEAHFZ	MA	Agonist
DMEAHFZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 11).
DMEAHFZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=11

DMEAHFZ	DI	DMEAHFZ
DMEAHFZ	DN	[3H]5-CT
DMEAHFZ	MI	TTO9X1H
DMEAHFZ	MN	5-HT 7 receptor (HTR7)
DMEAHFZ	MT	DTT
DMEAHFZ	MA	Agonist
DMEAHFZ	RN	[(3)H]-SB-269970--A selective antagonist radioligand for 5-HT(7) receptors. Br J Pharmacol. 2000 May;130(2):409-17.
DMEAHFZ	RU	https://pubmed.ncbi.nlm.nih.gov/10807680

DMYJXV7	DI	DMYJXV7
DMYJXV7	DN	[3H]5-HT
DMYJXV7	MI	TT6MSOK
DMYJXV7	MN	5-HT 1D receptor (HTR1D)
DMYJXV7	MT	DTT
DMYJXV7	MA	Agonist
DMYJXV7	RN	Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines. Br J Pharmacol. 1998 Apr;123(8):1655-65.
DMYJXV7	RU	https://pubmed.ncbi.nlm.nih.gov/9605573

DMYJXV7	DI	DMYJXV7
DMYJXV7	DN	[3H]5-HT
DMYJXV7	MI	TTCPG9S
DMYJXV7	MN	5-HT 1E receptor (HTR1E)
DMYJXV7	MT	DTT
DMYJXV7	MA	Agonist
DMYJXV7	RN	Molecular cloning of a serotonin receptor from human brain (5HT1E): a fifth 5HT1-like subtype. Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5517-21.
DMYJXV7	RU	https://pubmed.ncbi.nlm.nih.gov/1608964

DMYJXV7	DI	DMYJXV7
DMYJXV7	DN	[3H]5-HT
DMYJXV7	MI	TT0K1SC
DMYJXV7	MN	5-HT 2B receptor (HTR2B)
DMYJXV7	MT	DTT
DMYJXV7	MA	Agonist
DMYJXV7	RN	Pharmacological characteristics of the newly cloned rat 5-hydroxytryptamine2F receptor. Mol Pharmacol. 1993 Mar;43(3):419-26.
DMYJXV7	RU	https://pubmed.ncbi.nlm.nih.gov/8450835

DMYJXV7	DI	DMYJXV7
DMYJXV7	DN	[3H]5-HT
DMYJXV7	MI	TTO9X1H
DMYJXV7	MN	5-HT 7 receptor (HTR7)
DMYJXV7	MT	DTT
DMYJXV7	MA	Agonist
DMYJXV7	RN	Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase. J Biol Chem. 1993 Nov 5;268(31):23422-6.
DMYJXV7	RU	https://pubmed.ncbi.nlm.nih.gov/8226867

DM50WFM	DI	DM50WFM
DM50WFM	DN	[3H]5-oxo-ETE
DM50WFM	MI	TT7WBSV
DM50WFM	MN	Oxoeicosanoid receptor 1 (OXER1)
DM50WFM	MT	DTT
DM50WFM	MA	Agonist
DM50WFM	RN	Receptors for the 5-oxo class of eicosanoids in neutrophils. J Biol Chem. 1998 Dec 4;273(49):32535-41.
DM50WFM	RU	https://pubmed.ncbi.nlm.nih.gov/9829988

DM2PW8T	DI	DM2PW8T
DM2PW8T	DN	[3H]7-OH-DPAT
DM2PW8T	MI	TTEX248
DM2PW8T	MN	Dopamine D2 receptor (D2R)
DM2PW8T	MT	DTT
DM2PW8T	MA	Inhibitor
DM2PW8T	RN	Structurally constrained hybrid derivatives containing octahydrobenzo[g or f]quinoline moieties for dopamine D2 and D3 receptors: binding character... J Med Chem. 2008 Dec 25;51(24):7806-19.
DM2PW8T	RU	https://pubmed.ncbi.nlm.nih.gov/19053758

DM2PW8T	DI	DM2PW8T
DM2PW8T	DN	[3H]7-OH-DPAT
DM2PW8T	MI	TT4C8EA
DM2PW8T	MN	Dopamine D3 receptor (D3R)
DM2PW8T	MT	DTT
DM2PW8T	MA	Agonist
DM2PW8T	RN	Radioligand binding characterization of putative dopamine D3 receptor in human peripheral blood lymphocytes with [3H]7-OH-DPAT. J Neuroimmunol. 1995 May;58(2):139-44.
DM2PW8T	RU	https://pubmed.ncbi.nlm.nih.gov/7759603

DM4KCYU	DI	DM4KCYU
DM4KCYU	DN	[3H]8-OH-DPAT
DM4KCYU	MI	TTSQIFT
DM4KCYU	MN	5-HT 1A receptor (HTR1A)
DM4KCYU	MT	DTT
DM4KCYU	MA	Agonist
DM4KCYU	RN	Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. J Med Chem. 2000 Nov 30;43(24):4701-10.
DM4KCYU	RU	https://pubmed.ncbi.nlm.nih.gov/11101361

DM4KCYU	DI	DM4KCYU
DM4KCYU	DN	[3H]8-OH-DPAT
DM4KCYU	MI	TTK8CXU
DM4KCYU	MN	5-HT 1B receptor (HTR1B)
DM4KCYU	MT	DTT
DM4KCYU	MA	Agonist
DM4KCYU	RN	Actions of roxindole at recombinant human dopamine D2, D3 and D4 and serotonin 5-HT1A, 5-HT1B and 5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1999 Jun;359(6):447-53.
DM4KCYU	RU	https://pubmed.ncbi.nlm.nih.gov/10431754

DM4KCYU	DI	DM4KCYU
DM4KCYU	DN	[3H]8-OH-DPAT
DM4KCYU	MI	TT6MSOK
DM4KCYU	MN	5-HT 1D receptor (HTR1D)
DM4KCYU	MT	DTT
DM4KCYU	MA	Agonist
DM4KCYU	RN	Actions of roxindole at recombinant human dopamine D2, D3 and D4 and serotonin 5-HT1A, 5-HT1B and 5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1999 Jun;359(6):447-53.
DM4KCYU	RU	https://pubmed.ncbi.nlm.nih.gov/10431754

DMTBAXD	DI	DMTBAXD
DMTBAXD	DN	[3H]A317491
DMTBAXD	MI	TT2THBD
DMTBAXD	MN	P2X purinoceptor 3 (P2RX3)
DMTBAXD	MT	DTT
DMTBAXD	MA	Antagonist
DMTBAXD	RN	Crossing the pain barrier: P2 receptors as targets for novel analgesics. J Physiol. 2003 Dec 15;553(Pt 3):683-94.
DMTBAXD	RU	https://pubmed.ncbi.nlm.nih.gov/14514872

DMSDY2Z	DI	DMSDY2Z
DMSDY2Z	DN	[3H]A-585539
DMSDY2Z	MI	TTLA931
DMSDY2Z	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMSDY2Z	MT	DTT
DMSDY2Z	MA	Agonist
DMSDY2Z	RN	[3H]A-585539 [(1S,4S)-2,2-dimethyl-5-(6-phenylpyridazin-3-yl)-5-aza-2-azoniabicyclo[2.2.1]heptane], a novel high-affinity alpha7 neuronal nicotinic... J Pharmacol Exp Ther. 2008 Jan;324(1):179-87.
DMSDY2Z	RU	https://pubmed.ncbi.nlm.nih.gov/17959745

DMVJKCH	DI	DMVJKCH
DMVJKCH	DN	[3H]A778317
DMVJKCH	MI	TTMI6F5
DMVJKCH	MN	Transient receptor potential cation channel V1 (TRPV1)
DMVJKCH	MT	DTT
DMVJKCH	MA	Blocker (channel blocker)
DMVJKCH	RN	[3H]A-778317 [1-((R)-5-tert-butyl-indan-1-yl)-3-isoquinolin-5-yl-urea]: a novel, stereoselective, high-affinity antagonist is a useful radioligand ... J Pharmacol Exp Ther. 2007 Oct;323(1):285-93.
DMVJKCH	RU	https://pubmed.ncbi.nlm.nih.gov/17660385

DMWV5C3	DI	DMWV5C3
DMWV5C3	DN	[3H]alphabeta-meATP
DMWV5C3	MI	TT2QM9D
DMWV5C3	MN	Adenylate cyclase (ADCY)
DMWV5C3	MT	DTT
DMWV5C3	MA	Inhibitor
DMWV5C3	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMWV5C3	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMWV5C3	DI	DMWV5C3
DMWV5C3	DN	[3H]alphabeta-meATP
DMWV5C3	MI	TT38ECI
DMWV5C3	MN	Bacterial Hydroxymethyl-dihydropterin pyrophosphokinase (Bact folK)
DMWV5C3	MT	DTT
DMWV5C3	MA	Inhibitor
DMWV5C3	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMWV5C3	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMWV5C3	DI	DMWV5C3
DMWV5C3	DN	[3H]alphabeta-meATP
DMWV5C3	MI	TT8WCXO
DMWV5C3	MN	Bacterial NH(3)-dependent NAD(+) synthetase (Bact nadE)
DMWV5C3	MT	DTT
DMWV5C3	MA	Inhibitor
DMWV5C3	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMWV5C3	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMLF7SG	DI	DMLF7SG
DMLF7SG	DN	[3H]AMPA
DMLF7SG	MI	TTVPQTF
DMLF7SG	MN	Glutamate receptor AMPA 1 (GRIA1)
DMLF7SG	MT	DTT
DMLF7SG	MA	Agonist
DMLF7SG	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 444).
DMLF7SG	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=444

DMLF7SG	DI	DMLF7SG
DMLF7SG	DN	[3H]AMPA
DMLF7SG	MI	TT9HLZ0
DMLF7SG	MN	Glutamate receptor AMPA 2 (GRIA2)
DMLF7SG	MT	DTT
DMLF7SG	MA	Agonist
DMLF7SG	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 445).
DMLF7SG	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=445

DMLF7SG	DI	DMLF7SG
DMLF7SG	DN	[3H]AMPA
DMLF7SG	MI	TT82EZV
DMLF7SG	MN	Glutamate receptor AMPA 3 (GRIA3)
DMLF7SG	MT	DTT
DMLF7SG	MA	Modulator
DMLF7SG	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 446).
DMLF7SG	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=446

DMLF7SG	DI	DMLF7SG
DMLF7SG	DN	[3H]AMPA
DMLF7SG	MI	TTPJR0G
DMLF7SG	MN	Glutamate receptor AMPA 4 (GRIA4)
DMLF7SG	MT	DTT
DMLF7SG	MA	Agonist
DMLF7SG	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 447).
DMLF7SG	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=447

DMPVG5Y	DI	DMPVG5Y
DMPVG5Y	DN	[3H]AZ11637326
DMPVG5Y	MI	TTLA931
DMPVG5Y	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMPVG5Y	MT	DTT
DMPVG5Y	MA	Agonist
DMPVG5Y	RN	In vitro binding characteristics of [3H]AZ11637326, a novel alpha7-selective neuronal nicotinic receptor agonist radioligand. Eur J Pharmacol. 2010 Oct 25;645(1-3):63-9.
DMPVG5Y	RU	https://pubmed.ncbi.nlm.nih.gov/20674564

DMKL9X7	DI	DMKL9X7
DMKL9X7	DN	[3H]bag-2
DMKL9X7	MI	TTHYDUM
DMKL9X7	MN	Bombesin receptor (BS)
DMKL9X7	MT	DTT
DMKL9X7	MA	Agonist
DMKL9X7	RN	Regulation of energy homeostasis by bombesin receptor subtype-3: selective receptor agonists for the treatment of obesity. Cell Metab. 2010 Feb 3;11(2):101-12.
DMKL9X7	RU	https://pubmed.ncbi.nlm.nih.gov/20096642

DMG8T3W	DI	DMG8T3W
DMG8T3W	DN	[3H]BQ123
DMG8T3W	MI	TTKRD0G
DMG8T3W	MN	Endothelin A receptor (EDNRA)
DMG8T3W	MT	DTT
DMG8T3W	MA	Antagonist
DMG8T3W	RN	[3H]BQ-123, a highly specific and reversible radioligand for the endothelin ETA receptor subtype. Eur J Pharmacol. 1995 Feb 14;274(1-3):1-6.
DMG8T3W	RU	https://pubmed.ncbi.nlm.nih.gov/7768260

DMZRQU7	DI	DMZRQU7
DMZRQU7	DN	[3H]cAMP
DMZRQU7	MI	TT2QM9D
DMZRQU7	MN	Adenylate cyclase (ADCY)
DMZRQU7	MT	DTT
DMZRQU7	MA	Inhibitor
DMZRQU7	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMZRQU7	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMZRQU7	DI	DMZRQU7
DMZRQU7	DN	[3H]cAMP
DMZRQU7	MI	TTW4Y2M
DMZRQU7	MN	cAMP protein kinase type II-beta (PRKAR2B)
DMZRQU7	MT	DTT
DMZRQU7	MA	Inhibitor
DMZRQU7	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMZRQU7	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMZRQU7	DI	DMZRQU7
DMZRQU7	DN	[3H]cAMP
DMZRQU7	MI	TTNAHEX
DMZRQU7	MN	cAMP-dependent protein kinase A type I (PRKAR1A)
DMZRQU7	MT	DTT
DMZRQU7	MA	Inhibitor
DMZRQU7	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMZRQU7	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMZRQU7	DI	DMZRQU7
DMZRQU7	DN	[3H]cAMP
DMZRQU7	MI	TTYVI76
DMZRQU7	MN	Fungal Protein kinase A (Fung ypkA)
DMZRQU7	MT	DTT
DMZRQU7	MA	Activator
DMZRQU7	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1694).
DMZRQU7	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1694

DMZRQU7	DI	DMZRQU7
DMZRQU7	DN	[3H]cAMP
DMZRQU7	MI	DTCSGPB
DMZRQU7	MN	Multidrug resistance-associated protein 4 (ABCC4)
DMZRQU7	MT	DTP
DMZRQU7	MA	Substrate
DMZRQU7	RN	cAMP regulates expression of the cyclic nucleotide transporter MRP4 (ABCC4) through the EPAC pathway. Pharmacogenet Genomics. 2014 Oct;24(10):522-6.
DMZRQU7	RU	http://www.ncbi.nlm.nih.gov/pubmed/25121519

DMZRQU7	DI	DMZRQU7
DMZRQU7	DN	[3H]cAMP
DMZRQU7	MI	DTYVM24
DMZRQU7	MN	Multidrug resistance-associated protein 5 (ABCC5)
DMZRQU7	MT	DTP
DMZRQU7	MA	Substrate
DMZRQU7	RN	The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J Biol Chem. 2000 Sep 29;275(39):30069-74.
DMZRQU7	RU	http://www.ncbi.nlm.nih.gov/pubmed/10893247

DMZRQU7	DI	DMZRQU7
DMZRQU7	DN	[3H]cAMP
DMZRQU7	MI	DEON3ED
DMZRQU7	MN	Phosphodiesterase 7B (PDE7B)
DMZRQU7	MT	DME
DMZRQU7	MA	Metabolism
DMZRQU7	RN	Cloning and characterization of the human and mouse PDE7B, a novel cAMP-specific cyclic nucleotide phosphodiesterase. Biochem Biophys Res Commun. 2000 May 27;272(1):186-92.
DMZRQU7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10872825

DMHDGB3	DI	DMHDGB3
DMHDGB3	DN	[3H]CCPA
DMHDGB3	MI	TTK25J1
DMHDGB3	MN	Adenosine A1 receptor (ADORA1)
DMHDGB3	MT	DTT
DMHDGB3	MA	Agonist
DMHDGB3	RN	Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 1998 Jan;357(1):1-9.
DMHDGB3	RU	https://pubmed.ncbi.nlm.nih.gov/9459566

DMHDGB3	DI	DMHDGB3
DMHDGB3	DN	[3H]CCPA
DMHDGB3	MI	TTM2AOE
DMHDGB3	MN	Adenosine A2a receptor (ADORA2A)
DMHDGB3	MT	DTT
DMHDGB3	MA	Inhibitor
DMHDGB3	RN	5'-Carbamoyl derivatives of 2'-C-methyl-purine nucleosides as selective A1 adenosine receptor agonists: affinity, efficacy, and selectivity for A1 ... Bioorg Med Chem. 2008 Jan 1;16(1):336-53.
DMHDGB3	RU	https://pubmed.ncbi.nlm.nih.gov/17933541

DMHDGB3	DI	DMHDGB3
DMHDGB3	DN	[3H]CCPA
DMHDGB3	MI	TTNE7KG
DMHDGB3	MN	Adenosine A2b receptor (ADORA2B)
DMHDGB3	MT	DTT
DMHDGB3	MA	Inhibitor
DMHDGB3	RN	5'-Carbamoyl derivatives of 2'-C-methyl-purine nucleosides as selective A1 adenosine receptor agonists: affinity, efficacy, and selectivity for A1 ... Bioorg Med Chem. 2008 Jan 1;16(1):336-53.
DMHDGB3	RU	https://pubmed.ncbi.nlm.nih.gov/17933541

DMHDGB3	DI	DMHDGB3
DMHDGB3	DN	[3H]CCPA
DMHDGB3	MI	TTJFY5U
DMHDGB3	MN	Adenosine A3 receptor (ADORA3)
DMHDGB3	MT	DTT
DMHDGB3	MA	Inhibitor
DMHDGB3	RN	5'-Carbamoyl derivatives of 2'-C-methyl-purine nucleosides as selective A1 adenosine receptor agonists: affinity, efficacy, and selectivity for A1 ... Bioorg Med Chem. 2008 Jan 1;16(1):336-53.
DMHDGB3	RU	https://pubmed.ncbi.nlm.nih.gov/17933541

DMZN1A3	DI	DMZN1A3
DMZN1A3	DN	[3H]CGP12177
DMZN1A3	MI	TTR6W5O
DMZN1A3	MN	Adrenergic receptor beta-1 (ADRB1)
DMZN1A3	MT	DTT
DMZN1A3	MA	Inhibitor
DMZN1A3	RN	(4-Piperidin-1-yl)phenyl amides: potent and selective human beta(3) agonists. J Med Chem. 2001 Apr 26;44(9):1456-66.
DMZN1A3	RU	https://pubmed.ncbi.nlm.nih.gov/11311069

DMZN1A3	DI	DMZN1A3
DMZN1A3	DN	[3H]CGP12177
DMZN1A3	MI	TT2CJVK
DMZN1A3	MN	Adrenergic receptor beta-2 (ADRB2)
DMZN1A3	MT	DTT
DMZN1A3	MA	Inhibitor
DMZN1A3	RN	(4-Piperidin-1-yl)phenyl amides: potent and selective human beta(3) agonists. J Med Chem. 2001 Apr 26;44(9):1456-66.
DMZN1A3	RU	https://pubmed.ncbi.nlm.nih.gov/11311069

DMZN1A3	DI	DMZN1A3
DMZN1A3	DN	[3H]CGP12177
DMZN1A3	MI	TTMXGCW
DMZN1A3	MN	Adrenergic receptor beta-3 (ADRB3)
DMZN1A3	MT	DTT
DMZN1A3	MA	Agonist
DMZN1A3	RN	Effects of several putative beta 3-adrenoceptor agonists on lipolysis in human omental adipocytes. Int J Obes Relat Metab Disord. 1996 May;20(5):428-34.
DMZN1A3	RU	https://pubmed.ncbi.nlm.nih.gov/8696421

DMQTBRM	DI	DMQTBRM
DMQTBRM	DN	[3H]CGP27492
DMQTBRM	MI	TT1MPAY
DMQTBRM	MN	GABA(A) receptor alpha-1 (GABRA1)
DMQTBRM	MT	DTT
DMQTBRM	MA	Inhibitor
DMQTBRM	RN	Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists. J Med Chem. 1995 Aug 18;38(17):3297-312.
DMQTBRM	RU	https://pubmed.ncbi.nlm.nih.gov/7650684

DMQTBRM	DI	DMQTBRM
DMQTBRM	DN	[3H]CGP27492
DMQTBRM	MI	TTDCVZW
DMQTBRM	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMQTBRM	MT	DTT
DMQTBRM	MA	Inhibitor
DMQTBRM	RN	Biological activity of 3-aminopropyl (methyl) phosphinic acid, a potent and selective GABAB agonist with CNS activity, Bioorg. Med. Chem. Lett. 3(4):515-518 (1993).
DMQTBRM	RU	http://www.sciencedirect.com/science/article/pii/S0960894X0181218X

DMQTBRM	DI	DMQTBRM
DMQTBRM	DN	[3H]CGP27492
DMQTBRM	MI	TTNJYV2
DMQTBRM	MN	Gamma-aminobutyric acid receptor (GAR)
DMQTBRM	MT	DTT
DMQTBRM	MA	Inhibitor
DMQTBRM	RN	Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists. J Med Chem. 1995 Aug 18;38(17):3297-312.
DMQTBRM	RU	https://pubmed.ncbi.nlm.nih.gov/7650684

DMITR7A	DI	DMITR7A
DMITR7A	DN	[3H]CGP39653
DMITR7A	MI	TTLD29N
DMITR7A	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMITR7A	MT	DTT
DMITR7A	MA	Antagonist
DMITR7A	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455).
DMITR7A	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=455

DMITR7A	DI	DMITR7A
DMITR7A	DN	[3H]CGP39653
DMITR7A	MI	TTKJEMQ
DMITR7A	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMITR7A	MT	DTT
DMITR7A	MA	Antagonist
DMITR7A	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456).
DMITR7A	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=456

DMITR7A	DI	DMITR7A
DMITR7A	DN	[3H]CGP39653
DMITR7A	MI	TTN9D8E
DMITR7A	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMITR7A	MT	DTT
DMITR7A	MA	Antagonist
DMITR7A	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457).
DMITR7A	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=457

DMITR7A	DI	DMITR7A
DMITR7A	DN	[3H]CGP39653
DMITR7A	MI	TT1M8OW
DMITR7A	MN	Glutamate receptor ionotropic NMDA 2C (GluN2C)
DMITR7A	MT	DTT
DMITR7A	MA	Antagonist
DMITR7A	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 458).
DMITR7A	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=458

DMITR7A	DI	DMITR7A
DMITR7A	DN	[3H]CGP39653
DMITR7A	MI	TT5POTG
DMITR7A	MN	Glutamate receptor ionotropic NMDA 2D (GluN2D)
DMITR7A	MT	DTT
DMITR7A	MA	Antagonist
DMITR7A	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 459).
DMITR7A	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=459

DM7H3JN	DI	DM7H3JN
DM7H3JN	DN	[3H]CGS19755
DM7H3JN	MI	TTLD29N
DM7H3JN	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DM7H3JN	MT	DTT
DM7H3JN	MA	Antagonist
DM7H3JN	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455).
DM7H3JN	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=455

DM7H3JN	DI	DM7H3JN
DM7H3JN	DN	[3H]CGS19755
DM7H3JN	MI	TTKJEMQ
DM7H3JN	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DM7H3JN	MT	DTT
DM7H3JN	MA	Antagonist
DM7H3JN	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456).
DM7H3JN	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=456

DM7H3JN	DI	DM7H3JN
DM7H3JN	DN	[3H]CGS19755
DM7H3JN	MI	TTN9D8E
DM7H3JN	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DM7H3JN	MT	DTT
DM7H3JN	MA	Antagonist
DM7H3JN	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457).
DM7H3JN	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=457

DM7H3JN	DI	DM7H3JN
DM7H3JN	DN	[3H]CGS19755
DM7H3JN	MI	TT1M8OW
DM7H3JN	MN	Glutamate receptor ionotropic NMDA 2C (GluN2C)
DM7H3JN	MT	DTT
DM7H3JN	MA	Antagonist
DM7H3JN	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 458).
DM7H3JN	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=458

DM7H3JN	DI	DM7H3JN
DM7H3JN	DN	[3H]CGS19755
DM7H3JN	MI	TT5POTG
DM7H3JN	MN	Glutamate receptor ionotropic NMDA 2D (GluN2D)
DM7H3JN	MT	DTT
DM7H3JN	MA	Antagonist
DM7H3JN	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 459).
DM7H3JN	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=459

DMLP68J	DI	DMLP68J
DMLP68J	DN	[3H]CGS8216
DMLP68J	MI	TT1MPAY
DMLP68J	MN	GABA(A) receptor alpha-1 (GABRA1)
DMLP68J	MT	DTT
DMLP68J	MA	Inhibitor
DMLP68J	RN	Synthesis and benzodiazepine binding activity of a series of novel [1,2,4]triazolo[1,5-c]quinazolin-5(6H)-ones. J Med Chem. 1991 Jan;34(1):281-90.
DMLP68J	RU	https://pubmed.ncbi.nlm.nih.gov/1846920

DMLP68J	DI	DMLP68J
DMLP68J	DN	[3H]CGS8216
DMLP68J	MI	TTBMV1G
DMLP68J	MN	GABA(A) receptor alpha-2 (GABRA2)
DMLP68J	MT	DTT
DMLP68J	MA	Modulator (allosteric modulator)
DMLP68J	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 405).
DMLP68J	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=405

DMLP68J	DI	DMLP68J
DMLP68J	DN	[3H]CGS8216
DMLP68J	MI	TT37EDJ
DMLP68J	MN	GABA(A) receptor alpha-3 (GABRA3)
DMLP68J	MT	DTT
DMLP68J	MA	Modulator (allosteric modulator)
DMLP68J	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 406).
DMLP68J	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=406

DMLP68J	DI	DMLP68J
DMLP68J	DN	[3H]CGS8216
DMLP68J	MI	TTNZPQ1
DMLP68J	MN	GABA(A) receptor alpha-5 (GABRA5)
DMLP68J	MT	DTT
DMLP68J	MA	Modulator (allosteric modulator)
DMLP68J	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 408).
DMLP68J	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=408

DMLP68J	DI	DMLP68J
DMLP68J	DN	[3H]CGS8216
DMLP68J	MI	TTZA1NY
DMLP68J	MN	GABA(A) receptor beta-2 (GABRB2)
DMLP68J	MT	DTT
DMLP68J	MA	Inhibitor
DMLP68J	RN	Substituted 3-(2-benzoxazyl)-benzimidazol-2-(1H)-ones: a new class of GABA(A) brain receptor ligands. Bioorg Med Chem Lett. 2000 Dec 18;10(24):2723-6.
DMLP68J	RU	https://pubmed.ncbi.nlm.nih.gov/11133077

DMLP68J	DI	DMLP68J
DMLP68J	DN	[3H]CGS8216
DMLP68J	MI	TT06RH5
DMLP68J	MN	GABA(A) receptor gamma-2 (GABRG2)
DMLP68J	MT	DTT
DMLP68J	MA	Inhibitor
DMLP68J	RN	Synthesis and benzodiazepine binding activity of a series of novel [1,2,4]triazolo[1,5-c]quinazolin-5(6H)-ones. J Med Chem. 1991 Jan;34(1):281-90.
DMLP68J	RU	https://pubmed.ncbi.nlm.nih.gov/1846920

DMLP68J	DI	DMLP68J
DMLP68J	DN	[3H]CGS8216
DMLP68J	MI	TTEX6LM
DMLP68J	MN	GABA(A) receptor gamma-3 (GABRG3)
DMLP68J	MT	DTT
DMLP68J	MA	Modulator (allosteric modulator)
DMLP68J	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415).
DMLP68J	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415

DMLP68J	DI	DMLP68J
DMLP68J	DN	[3H]CGS8216
DMLP68J	MI	TTNJYV2
DMLP68J	MN	Gamma-aminobutyric acid receptor (GAR)
DMLP68J	MT	DTT
DMLP68J	MA	Inhibitor
DMLP68J	RN	Synthesis and benzodiazepine binding activity of a series of novel [1,2,4]triazolo[1,5-c]quinazolin-5(6H)-ones. J Med Chem. 1991 Jan;34(1):281-90.
DMLP68J	RU	https://pubmed.ncbi.nlm.nih.gov/1846920

DMIFKUX	DI	DMIFKUX
DMIFKUX	DN	[3H]CNQX
DMIFKUX	MI	TTAN6JD
DMIFKUX	MN	Glutamate receptor AMPA (GRIA)
DMIFKUX	MT	DTT
DMIFKUX	MA	Inhibitor
DMIFKUX	RN	Structure-activity relationship studies on N3-substituted willardiine derivatives acting as AMPA or kainate receptor antagonists. J Med Chem. 2006 Apr 20;49(8):2579-92.
DMIFKUX	RU	https://pubmed.ncbi.nlm.nih.gov/16610801

DMIFKUX	DI	DMIFKUX
DMIFKUX	DN	[3H]CNQX
DMIFKUX	MI	TTVPQTF
DMIFKUX	MN	Glutamate receptor AMPA 1 (GRIA1)
DMIFKUX	MT	DTT
DMIFKUX	MA	Antagonist
DMIFKUX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 444).
DMIFKUX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=444

DMIFKUX	DI	DMIFKUX
DMIFKUX	DN	[3H]CNQX
DMIFKUX	MI	TT9HLZ0
DMIFKUX	MN	Glutamate receptor AMPA 2 (GRIA2)
DMIFKUX	MT	DTT
DMIFKUX	MA	Antagonist
DMIFKUX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 445).
DMIFKUX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=445

DMIFKUX	DI	DMIFKUX
DMIFKUX	DN	[3H]CNQX
DMIFKUX	MI	TT82EZV
DMIFKUX	MN	Glutamate receptor AMPA 3 (GRIA3)
DMIFKUX	MT	DTT
DMIFKUX	MA	Modulator
DMIFKUX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 446).
DMIFKUX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=446

DMIFKUX	DI	DMIFKUX
DMIFKUX	DN	[3H]CNQX
DMIFKUX	MI	TTPJR0G
DMIFKUX	MN	Glutamate receptor AMPA 4 (GRIA4)
DMIFKUX	MT	DTT
DMIFKUX	MA	Modulator
DMIFKUX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 447).
DMIFKUX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=447

DMU7FC5	DI	DMU7FC5
DMU7FC5	DN	[3H]CP55940
DMU7FC5	MI	TT6OEDT
DMU7FC5	MN	Cannabinoid receptor 1 (CB1)
DMU7FC5	MT	DTT
DMU7FC5	MA	Agonist
DMU7FC5	RN	Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A. J Biol Chem. 1996 Mar 22;271(12):6941-6.
DMU7FC5	RU	https://pubmed.ncbi.nlm.nih.gov/8636122

DMU7FC5	DI	DMU7FC5
DMU7FC5	DN	[3H]CP55940
DMU7FC5	MI	TTMSFAW
DMU7FC5	MN	Cannabinoid receptor 2 (CB2)
DMU7FC5	MT	DTT
DMU7FC5	MA	Agonist
DMU7FC5	RN	Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur J Biochem. 1996 May1;237(3):704-11.
DMU7FC5	RU	https://pubmed.ncbi.nlm.nih.gov/8647116

DMU7FC5	DI	DMU7FC5
DMU7FC5	DN	[3H]CP55940
DMU7FC5	MI	TTNET8J
DMU7FC5	MN	G-protein coupled receptor 55 (GPR55)
DMU7FC5	MT	DTT
DMU7FC5	MA	Agonist
DMU7FC5	RN	The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007 Dec;152(7):1092-101.
DMU7FC5	RU	https://pubmed.ncbi.nlm.nih.gov/17876302

DMR5UBF	DI	DMR5UBF
DMR5UBF	DN	[3H]CPP
DMR5UBF	MI	TTLD29N
DMR5UBF	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMR5UBF	MT	DTT
DMR5UBF	MA	Antagonist
DMR5UBF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455).
DMR5UBF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=455

DMR5UBF	DI	DMR5UBF
DMR5UBF	DN	[3H]CPP
DMR5UBF	MI	TTKJEMQ
DMR5UBF	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMR5UBF	MT	DTT
DMR5UBF	MA	Antagonist
DMR5UBF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456).
DMR5UBF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=456

DMR5UBF	DI	DMR5UBF
DMR5UBF	DN	[3H]CPP
DMR5UBF	MI	TTN9D8E
DMR5UBF	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMR5UBF	MT	DTT
DMR5UBF	MA	Antagonist
DMR5UBF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457).
DMR5UBF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=457

DMR5UBF	DI	DMR5UBF
DMR5UBF	DN	[3H]CPP
DMR5UBF	MI	TT1M8OW
DMR5UBF	MN	Glutamate receptor ionotropic NMDA 2C (GluN2C)
DMR5UBF	MT	DTT
DMR5UBF	MA	Antagonist
DMR5UBF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 458).
DMR5UBF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=458

DMR5UBF	DI	DMR5UBF
DMR5UBF	DN	[3H]CPP
DMR5UBF	MI	TT5POTG
DMR5UBF	MN	Glutamate receptor ionotropic NMDA 2D (GluN2D)
DMR5UBF	MT	DTT
DMR5UBF	MA	Antagonist
DMR5UBF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 459).
DMR5UBF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=459

DMVLRHW	DI	DMVLRHW
DMVLRHW	DN	[3H]cytisine
DMVLRHW	MI	TTH18TF
DMVLRHW	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMVLRHW	MT	DTT
DMVLRHW	MA	Agonist
DMVLRHW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 467).
DMVLRHW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=467

DMVLRHW	DI	DMVLRHW
DMVLRHW	DN	[3H]cytisine
DMVLRHW	MI	TTF4E0J
DMVLRHW	MN	Neuronal acetylcholine receptor alpha-2 (CHRNA2)
DMVLRHW	MT	DTT
DMVLRHW	MA	Agonist
DMVLRHW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 463).
DMVLRHW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=463

DMVLRHW	DI	DMVLRHW
DMVLRHW	DN	[3H]cytisine
DMVLRHW	MI	TT5KPZR
DMVLRHW	MN	Neuronal acetylcholine receptor beta-2 (CHRNB2)
DMVLRHW	MT	DTT
DMVLRHW	MA	Agonist
DMVLRHW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 465).
DMVLRHW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=465

DM4NXRO	DI	DM4NXRO
DM4NXRO	DN	[3H]devazepide
DM4NXRO	MI	TTCG0AL
DM4NXRO	MN	Cholecystokinin receptor type A (CCKAR)
DM4NXRO	MT	DTT
DM4NXRO	MA	Antagonist
DM4NXRO	RN	Characterization of the binding of [3H]-(+/-)-L-364,718: a new potent, nonpeptide cholecystokinin antagonist radioligand selective for peripheral receptors. Mol Pharmacol. 1986 Sep;30(3):212-7.
DM4NXRO	RU	https://pubmed.ncbi.nlm.nih.gov/3018478

DMBWAIE	DI	DMBWAIE
DMBWAIE	DN	[3H]dimethyl-W84
DMBWAIE	MI	TTOXS3C
DMBWAIE	MN	Muscarinic acetylcholine receptor (CHRM)
DMBWAIE	MT	DTT
DMBWAIE	MA	Modulator (allosteric modulator)
DMBWAIE	RN	Interactions of orthosteric and allosteric ligands with [3H]dimethyl-W84 at the common allosteric site of muscarinic M2 receptors. Mol Pharmacol. 2003 Jul;64(1):180-90.
DMBWAIE	RU	https://pubmed.ncbi.nlm.nih.gov/12815174

DMBMS1U	DI	DMBMS1U
DMBMS1U	DN	[3H]diprenorphine
DMBMS1U	MI	TT27RFC
DMBMS1U	MN	Opioid receptor delta (OPRD1)
DMBMS1U	MT	DTT
DMBMS1U	MA	Agonist
DMBMS1U	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317).
DMBMS1U	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=317

DMBMS1U	DI	DMBMS1U
DMBMS1U	DN	[3H]diprenorphine
DMBMS1U	MI	TTQW87Y
DMBMS1U	MN	Opioid receptor kappa (OPRK1)
DMBMS1U	MT	DTT
DMBMS1U	MA	Antagonist
DMBMS1U	RN	kappa-Opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system. Proc Natl Acad Sci U S A.1995 Jul 18;92(15):7006-10.
DMBMS1U	RU	https://pubmed.ncbi.nlm.nih.gov/7624359

DMBMS1U	DI	DMBMS1U
DMBMS1U	DN	[3H]diprenorphine
DMBMS1U	MI	TTKWM86
DMBMS1U	MN	Opioid receptor mu (MOP)
DMBMS1U	MT	DTT
DMBMS1U	MA	Antagonist
DMBMS1U	RN	Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol Pharmacol. 1994 Feb;45(2):330-4.
DMBMS1U	RU	https://pubmed.ncbi.nlm.nih.gov/8114680

DMEC2PF	DI	DMEC2PF
DMEC2PF	DN	[3H]dizocilpine
DMEC2PF	MI	TTLD29N
DMEC2PF	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMEC2PF	MT	DTT
DMEC2PF	MA	Antagonist
DMEC2PF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455).
DMEC2PF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=455

DMEC2PF	DI	DMEC2PF
DMEC2PF	DN	[3H]dizocilpine
DMEC2PF	MI	TTKJEMQ
DMEC2PF	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMEC2PF	MT	DTT
DMEC2PF	MA	Blocker (channel blocker)
DMEC2PF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456).
DMEC2PF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=456

DMEC2PF	DI	DMEC2PF
DMEC2PF	DN	[3H]dizocilpine
DMEC2PF	MI	TTN9D8E
DMEC2PF	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMEC2PF	MT	DTT
DMEC2PF	MA	Blocker (channel blocker)
DMEC2PF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457).
DMEC2PF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=457

DMEC2PF	DI	DMEC2PF
DMEC2PF	DN	[3H]dizocilpine
DMEC2PF	MI	TT1M8OW
DMEC2PF	MN	Glutamate receptor ionotropic NMDA 2C (GluN2C)
DMEC2PF	MT	DTT
DMEC2PF	MA	Blocker (channel blocker)
DMEC2PF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 458).
DMEC2PF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=458

DMEC2PF	DI	DMEC2PF
DMEC2PF	DN	[3H]dizocilpine
DMEC2PF	MI	TT5POTG
DMEC2PF	MN	Glutamate receptor ionotropic NMDA 2D (GluN2D)
DMEC2PF	MT	DTT
DMEC2PF	MA	Blocker (channel blocker)
DMEC2PF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 459).
DMEC2PF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=459

DM9GY7O	DI	DM9GY7O
DM9GY7O	DN	[3H]DPCPX
DM9GY7O	MI	TTK25J1
DM9GY7O	MN	Adenosine A1 receptor (ADORA1)
DM9GY7O	MT	DTT
DM9GY7O	MA	Antagonist
DM9GY7O	RN	Inhibition of human mast cell activation with the novel selective adenosine A(2B) receptor antagonist 3-isobutyl-8-pyrrolidinoxanthine (IPDX)(2). Biochem Pharmacol. 2001 Nov 1;62(9):1163-73.
DM9GY7O	RU	https://pubmed.ncbi.nlm.nih.gov/11705449

DM9GY7O	DI	DM9GY7O
DM9GY7O	DN	[3H]DPCPX
DM9GY7O	MI	TTNE7KG
DM9GY7O	MN	Adenosine A2b receptor (ADORA2B)
DM9GY7O	MT	DTT
DM9GY7O	MA	Antagonist
DM9GY7O	RN	[3H]OSIP339391, a selective, novel, and high affinity antagonist radioligand for adenosine A2B receptors. Biochem Pharmacol. 2004 Jul 15;68(2):305-12.
DM9GY7O	RU	https://pubmed.ncbi.nlm.nih.gov/15194002

DMDTYRV	DI	DMDTYRV
DMDTYRV	DN	[3H]eletriptan
DMDTYRV	MI	TTK8CXU
DMDTYRV	MN	5-HT 1B receptor (HTR1B)
DMDTYRV	MT	DTT
DMDTYRV	MA	Agonist
DMDTYRV	RN	Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur J Pharmacol. 1999 Mar 5;368(2-3):259-68.
DMDTYRV	RU	https://pubmed.ncbi.nlm.nih.gov/10193663

DMDTYRV	DI	DMDTYRV
DMDTYRV	DN	[3H]eletriptan
DMDTYRV	MI	TT6MSOK
DMDTYRV	MN	5-HT 1D receptor (HTR1D)
DMDTYRV	MT	DTT
DMDTYRV	MA	Agonist
DMDTYRV	RN	Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur J Pharmacol. 1999 Mar 5;368(2-3):259-68.
DMDTYRV	RU	https://pubmed.ncbi.nlm.nih.gov/10193663

DMM1KBW	DI	DMM1KBW
DMM1KBW	DN	[3H]EM-TBPC
DMM1KBW	MI	TTVBPDM
DMM1KBW	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMM1KBW	MT	DTT
DMM1KBW	MA	Modulator (allosteric modulator)
DMM1KBW	RN	Mutational analysis and molecular modeling of the allosteric binding site of a novel, selective, noncompetitive antagonist of the metabotropic glut... J Biol Chem. 2003 Mar 7;278(10):8340-7.
DMM1KBW	RU	https://pubmed.ncbi.nlm.nih.gov/12509432

DM3KJ45	DI	DM3KJ45
DM3KJ45	DN	[3H]estradiol-17beta-glucuronide
DM3KJ45	MI	DTI7UX6
DM3KJ45	MN	Breast cancer resistance protein (ABCG2)
DM3KJ45	MT	DTP
DM3KJ45	MA	Substrate
DM3KJ45	RN	Regulation of the function of the human ABCG2 multidrug transporter by cholesterol and bile acids: effects of mutations in potential substrate and steroid binding sites. Drug Metab Dispos. 2014 Apr;42(4):575-85.
DM3KJ45	RU	http://www.ncbi.nlm.nih.gov/pubmed/24384916

DM3KJ45	DI	DM3KJ45
DM3KJ45	DN	[3H]estradiol-17beta-glucuronide
DM3KJ45	MI	TTFGXEB
DM3KJ45	MN	Liver organic anion transporter 1 (SLCO1B1)
DM3KJ45	MT	DTT
DM3KJ45	MA	Modulator
DM3KJ45	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1220).
DM3KJ45	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1220

DM3KJ45	DI	DM3KJ45
DM3KJ45	DN	[3H]estradiol-17beta-glucuronide
DM3KJ45	MI	TTU86P0
DM3KJ45	MN	Liver organic anion transporter 2 (SLCO1B3)
DM3KJ45	MT	DTT
DM3KJ45	MA	Modulator
DM3KJ45	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1221).
DM3KJ45	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1221

DM3KJ45	DI	DM3KJ45
DM3KJ45	DN	[3H]estradiol-17beta-glucuronide
DM3KJ45	MI	DTSYQGK
DM3KJ45	MN	Multidrug resistance-associated protein 1 (ABCC1)
DM3KJ45	MT	DTP
DM3KJ45	MA	Substrate
DM3KJ45	RN	Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol. 1999 May;55(5):929-37.
DM3KJ45	RU	http://www.ncbi.nlm.nih.gov/pubmed/10220572

DM3KJ45	DI	DM3KJ45
DM3KJ45	DN	[3H]estradiol-17beta-glucuronide
DM3KJ45	MI	DTFI42L
DM3KJ45	MN	Multidrug resistance-associated protein 2 (ABCC2)
DM3KJ45	MT	DTP
DM3KJ45	MA	Substrate
DM3KJ45	RN	Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol. 1999 May;55(5):929-37.
DM3KJ45	RU	http://www.ncbi.nlm.nih.gov/pubmed/10220572

DM3KJ45	DI	DM3KJ45
DM3KJ45	DN	[3H]estradiol-17beta-glucuronide
DM3KJ45	MI	DTQ3ZHF
DM3KJ45	MN	Multidrug resistance-associated protein 3 (ABCC3)
DM3KJ45	MT	DTP
DM3KJ45	MA	Substrate
DM3KJ45	RN	Characterization of the role of polar amino acid residues within predicted transmembrane helix 17 in determining the substrate specificity of multidrug resistance protein 3. Biochemistry. 2003 Aug 26;42(33):9989-10000.
DM3KJ45	RU	http://www.ncbi.nlm.nih.gov/pubmed/12924948

DM3KJ45	DI	DM3KJ45
DM3KJ45	DN	[3H]estradiol-17beta-glucuronide
DM3KJ45	MI	DTCSGPB
DM3KJ45	MN	Multidrug resistance-associated protein 4 (ABCC4)
DM3KJ45	MT	DTP
DM3KJ45	MA	Substrate
DM3KJ45	RN	Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch. 2007 Feb;453(5):661-73.
DM3KJ45	RU	http://www.ncbi.nlm.nih.gov/pubmed/16586096

DM3KJ45	DI	DM3KJ45
DM3KJ45	DN	[3H]estradiol-17beta-glucuronide
DM3KJ45	MI	DTE2B1D
DM3KJ45	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DM3KJ45	MT	DTP
DM3KJ45	MA	Substrate
DM3KJ45	RN	Regulation of renal oatp mRNA expression by testosterone. Am J Physiol. 1996 Feb;270(2 Pt 2):F332-7.
DM3KJ45	RU	http://www.ncbi.nlm.nih.gov/pubmed/8779895

DM3KJ45	DI	DM3KJ45
DM3KJ45	DN	[3H]estradiol-17beta-glucuronide
DM3KJ45	MI	DT3D8F0
DM3KJ45	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM3KJ45	MT	DTP
DM3KJ45	MA	Substrate
DM3KJ45	RN	Identification, Ki determination and CoMFA analysis of nuclear receptor ligands as competitive inhibitors of OATP1B1-mediated estradiol-17beta-glucuronide transport. Pharmacol Res. 2009 Jul;60(1):50-6.
DM3KJ45	RU	http://www.ncbi.nlm.nih.gov/pubmed/19427586

DM3KJ45	DI	DM3KJ45
DM3KJ45	DN	[3H]estradiol-17beta-glucuronide
DM3KJ45	MI	DT9C1TS
DM3KJ45	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM3KJ45	MT	DTP
DM3KJ45	MA	Substrate
DM3KJ45	RN	Interactions of green tea catechins with organic anion-transporting polypeptides. Drug Metab Dispos. 2011 May;39(5):920-6.
DM3KJ45	RU	http://www.ncbi.nlm.nih.gov/pubmed/21278283

DM3KJ45	DI	DM3KJ45
DM3KJ45	DN	[3H]estradiol-17beta-glucuronide
DM3KJ45	MI	DTPYCQ4
DM3KJ45	MN	Organic anion transporting polypeptide 1C1 (SLCO1C1)
DM3KJ45	MT	DTP
DM3KJ45	MA	Substrate
DM3KJ45	RN	The blood-brain barrier thyroxine transporter organic anion-transporting polypeptide 1c1 displays atypical transport kinetics. Endocrinology. 2009 Nov;150(11):5153-62.
DM3KJ45	RU	http://www.ncbi.nlm.nih.gov/pubmed/19819953

DMGPF0N	DI	DMGPF0N
DMGPF0N	DN	[3H]estrone-3-sulphate
DMGPF0N	MI	DEJGDUW
DMGPF0N	MN	Cytochrome P450 1A2 (CYP1A2)
DMGPF0N	MT	DME
DMGPF0N	MA	Metabolism
DMGPF0N	RN	Role of polymorphic human cytochrome P450 enzymes in estrone oxidation. Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):551-8.
DMGPF0N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16537715

DMGPF0N	DI	DMGPF0N
DMGPF0N	DN	[3H]estrone-3-sulphate
DMGPF0N	MI	DE5IED8
DMGPF0N	MN	Cytochrome P450 2C9 (CYP2C9)
DMGPF0N	MT	DME
DMGPF0N	MA	Metabolism
DMGPF0N	RN	Pharmacogenomics of CYP2C9: functional and clinical considerations. J Pers Med. 2017 Dec 28;8(1).
DMGPF0N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29283396

DMGPF0N	DI	DMGPF0N
DMGPF0N	DN	[3H]estrone-3-sulphate
DMGPF0N	MI	DE4LYSA
DMGPF0N	MN	Cytochrome P450 3A4 (CYP3A4)
DMGPF0N	MT	DME
DMGPF0N	MA	Metabolism
DMGPF0N	RN	Estrogen regulation of the cytochrome P450 3A subfamily in humans. J Pharmacol Exp Ther. 2004 Nov;311(2):728-35.
DMGPF0N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15282264

DMGPF0N	DI	DMGPF0N
DMGPF0N	DN	[3H]estrone-3-sulphate
DMGPF0N	MI	TTFGXEB
DMGPF0N	MN	Liver organic anion transporter 1 (SLCO1B1)
DMGPF0N	MT	DTT
DMGPF0N	MA	Modulator
DMGPF0N	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1220).
DMGPF0N	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1220

DMGPF0N	DI	DMGPF0N
DMGPF0N	DN	[3H]estrone-3-sulphate
DMGPF0N	MI	TTDL3UZ
DMGPF0N	MN	Organic anion transporter B (SLCO2B1)
DMGPF0N	MT	DTT
DMGPF0N	MA	Modulator
DMGPF0N	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1224).
DMGPF0N	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1224

DMGPF0N	DI	DMGPF0N
DMGPF0N	DN	[3H]estrone-3-sulphate
DMGPF0N	MI	TT5CE6L
DMGPF0N	MN	Organic anion transporter D (SLCO3A1)
DMGPF0N	MT	DTT
DMGPF0N	MA	Modulator
DMGPF0N	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1225).
DMGPF0N	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1225

DMGPF0N	DI	DMGPF0N
DMGPF0N	DN	[3H]estrone-3-sulphate
DMGPF0N	MI	TTV1YIE
DMGPF0N	MN	Organic anion transporter E (SLCO4A1)
DMGPF0N	MT	DTT
DMGPF0N	MA	Modulator
DMGPF0N	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1226).
DMGPF0N	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1226

DMGPF0N	DI	DMGPF0N
DMGPF0N	DN	[3H]estrone-3-sulphate
DMGPF0N	MI	TT340CE
DMGPF0N	MN	Organic anion transporter F (SLCO1C1)
DMGPF0N	MT	DTT
DMGPF0N	MA	Modulator
DMGPF0N	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1222).
DMGPF0N	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1222

DMGPF0N	DI	DMGPF0N
DMGPF0N	DN	[3H]estrone-3-sulphate
DMGPF0N	MI	TTUGD21
DMGPF0N	MN	Sodium-independent organic anion transporter (SLCO1A2)
DMGPF0N	MT	DTT
DMGPF0N	MA	Modulator
DMGPF0N	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1219).
DMGPF0N	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1219

DMGPF0N	DI	DMGPF0N
DMGPF0N	DN	[3H]estrone-3-sulphate
DMGPF0N	MI	DE7WRSB
DMGPF0N	MN	Sulfatase (sulF)
DMGPF0N	MT	DME
DMGPF0N	MA	Metabolism
DMGPF0N	RN	Parabacteroides pacaensis sp. nov. and Parabacteroides provencensis sp. nov., two new species identified from human gut microbiota. New Microbes New Infect. 2020 Jan 7;34:100642.
DMGPF0N	RU	https://pubmed.ncbi.nlm.nih.gov/32071723

DMGPF0N	DI	DMGPF0N
DMGPF0N	DN	[3H]estrone-3-sulphate
DMGPF0N	MI	DE9THM7
DMGPF0N	MN	Sulfatase (sulF)
DMGPF0N	MT	DME
DMGPF0N	MA	Metabolism
DMGPF0N	RN	Two rheumatoid arthritis-specific autoantigens correlate microbial immunity with autoimmune responses in joints. J Clin Invest. 2017 Aug 1;127(8):2946-2956.
DMGPF0N	RU	https://pubmed.ncbi.nlm.nih.gov/28650341

DMGPF0N	DI	DMGPF0N
DMGPF0N	DN	[3H]estrone-3-sulphate
DMGPF0N	MI	DE10BJ5
DMGPF0N	MN	Tyrosine-protein phosphatase STS1/TULA2 (UBASH3B)
DMGPF0N	MT	DME
DMGPF0N	MA	Metabolism
DMGPF0N	RN	Steroid sulfatase: a pivotal player in estrogen synthesis and metabolism. Mol Cell Endocrinol. 2011 Jul 4;340(2):154-60.
DMGPF0N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21693170

DMWGY61	DI	DMWGY61
DMWGY61	DN	[3H]ETB-TBOA
DMWGY61	MI	TT8WRDA
DMWGY61	MN	Excitatory amino acid transporter 1 (SLC1A3)
DMWGY61	MT	DTT
DMWGY61	MA	Modulator
DMWGY61	RN	Characterization of the tritium-labeled analog of L-threo-beta-benzyloxyaspartate binding to glutamate transporters. Mol Pharmacol. 2007 Jan;71(1):294-302.
DMWGY61	RU	https://pubmed.ncbi.nlm.nih.gov/17047096

DMWGY61	DI	DMWGY61
DMWGY61	DN	[3H]ETB-TBOA
DMWGY61	MI	TT2F078
DMWGY61	MN	Excitatory amino acid transporter 2 (SLC1A2)
DMWGY61	MT	DTT
DMWGY61	MA	Modulator
DMWGY61	RN	Characterization of the tritium-labeled analog of L-threo-beta-benzyloxyaspartate binding to glutamate transporters. Mol Pharmacol. 2007 Jan;71(1):294-302.
DMWGY61	RU	https://pubmed.ncbi.nlm.nih.gov/17047096

DMWGY61	DI	DMWGY61
DMWGY61	DN	[3H]ETB-TBOA
DMWGY61	MI	TTG2A6F
DMWGY61	MN	Excitatory amino acid transporter 3 (SLC1A1)
DMWGY61	MT	DTT
DMWGY61	MA	Modulator
DMWGY61	RN	Characterization of the tritium-labeled analog of L-threo-beta-benzyloxyaspartate binding to glutamate transporters. Mol Pharmacol. 2007 Jan;71(1):294-302.
DMWGY61	RU	https://pubmed.ncbi.nlm.nih.gov/17047096

DMWGY61	DI	DMWGY61
DMWGY61	DN	[3H]ETB-TBOA
DMWGY61	MI	TT6KMPN
DMWGY61	MN	Excitatory amino acid transporter 4 (SLC1A6)
DMWGY61	MT	DTT
DMWGY61	MA	Modulator
DMWGY61	RN	Characterization of the tritium-labeled analog of L-threo-beta-benzyloxyaspartate binding to glutamate transporters. Mol Pharmacol. 2007 Jan;71(1):294-302.
DMWGY61	RU	https://pubmed.ncbi.nlm.nih.gov/17047096

DMWGY61	DI	DMWGY61
DMWGY61	DN	[3H]ETB-TBOA
DMWGY61	MI	TTK41DM
DMWGY61	MN	Excitatory amino acid transporter 5 (SLC1A7)
DMWGY61	MT	DTT
DMWGY61	MA	Modulator
DMWGY61	RN	Characterization of the tritium-labeled analog of L-threo-beta-benzyloxyaspartate binding to glutamate transporters. Mol Pharmacol. 2007 Jan;71(1):294-302.
DMWGY61	RU	https://pubmed.ncbi.nlm.nih.gov/17047096

DME0XHN	DI	DME0XHN
DME0XHN	DN	[3H]folinic acid
DME0XHN	MI	TTY8Z2E
DME0XHN	MN	Proton-coupled folate transporter (SLC46A1)
DME0XHN	MT	DTT
DME0XHN	MA	Modulator
DME0XHN	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1213).
DME0XHN	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1213

DMGQDLU	DI	DMGQDLU
DMGQDLU	DN	[3H]GBR12935
DMGQDLU	MI	TT8DBY3
DMGQDLU	MN	Angiotensin II receptor type-1 (AGTR1)
DMGQDLU	MT	DTT
DMGQDLU	MA	Antagonist
DMGQDLU	RN	Specific binding of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenyl propyl) piperazine (GBR-12935), an inhibitor of the dopamine transporter, to human CYP2D6. Biochem Pharmacol. 1997 Jun 15;53(12):1937-9.
DMGQDLU	RU	https://pubmed.ncbi.nlm.nih.gov/9256169

DMGQDLU	DI	DMGQDLU
DMGQDLU	DN	[3H]GBR12935
DMGQDLU	MI	TTVBI8W
DMGQDLU	MN	Dopamine transporter (DAT)
DMGQDLU	MT	DTT
DMGQDLU	MA	Inhibitor
DMGQDLU	RN	Pharmacological heterogeneity of the cloned and native human dopamine transporter: disassociation of [3H]WIN 35,428 and [3H]GBR 12,935 binding. Mol Pharmacol. 1994 Jan;45(1):125-35.
DMGQDLU	RU	https://pubmed.ncbi.nlm.nih.gov/8302271

DMFEYLS	DI	DMFEYLS
DMFEYLS	DN	[3H]GlySar
DMFEYLS	MI	TT5LF3C
DMFEYLS	MN	Solute carrier family 15 member 1 (SLC15A1)
DMFEYLS	MT	DTT
DMFEYLS	MA	Modulator
DMFEYLS	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 984).
DMFEYLS	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=984

DMFEYLS	DI	DMFEYLS
DMFEYLS	DN	[3H]GlySar
DMFEYLS	MI	TT27Q3A
DMFEYLS	MN	Solute carrier family 15 member 2 (SLC15A2)
DMFEYLS	MT	DTT
DMFEYLS	MA	Modulator
DMFEYLS	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 985).
DMFEYLS	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=985

DM4URBO	DI	DM4URBO
DM4URBO	DN	[3H]GR 125,743
DM4URBO	MI	TTK8CXU
DM4URBO	MN	5-HT 1B receptor (HTR1B)
DM4URBO	MT	DTT
DM4URBO	MA	Antagonist
DM4URBO	RN	Serotonin 5-HT1B and 5-HT1D receptors form homodimers when expressed alone and heterodimers when co-expressed. FEBS Lett. 1999 Jul 30;456(1):63-7.
DM4URBO	RU	https://pubmed.ncbi.nlm.nih.gov/10452531

DM4URBO	DI	DM4URBO
DM4URBO	DN	[3H]GR 125,743
DM4URBO	MI	TT6MSOK
DM4URBO	MN	5-HT 1D receptor (HTR1D)
DM4URBO	MT	DTT
DM4URBO	MA	Antagonist
DM4URBO	RN	Serotonin 5-HT1B and 5-HT1D receptors form homodimers when expressed alone and heterodimers when co-expressed. FEBS Lett. 1999 Jul 30;456(1):63-7.
DM4URBO	RU	https://pubmed.ncbi.nlm.nih.gov/10452531

DMMHSYA	DI	DMMHSYA
DMMHSYA	DN	[3H]GR65630
DMMHSYA	MI	TTPC4TU
DMMHSYA	MN	5-HT 3A receptor (HTR3A)
DMMHSYA	MT	DTT
DMMHSYA	MA	Antagonist
DMMHSYA	RN	Evaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndrome. J Pharmacol Sci. 2007 Jul;104(3):263-73.
DMMHSYA	RU	https://pubmed.ncbi.nlm.nih.gov/17652911

DMB9VGW	DI	DMB9VGW
DMB9VGW	DN	[3H]granisetron
DMB9VGW	MI	TTPC4TU
DMB9VGW	MN	5-HT 3A receptor (HTR3A)
DMB9VGW	MT	DTT
DMB9VGW	MA	Antagonist
DMB9VGW	RN	Characterization of a human 5-hydroxytryptamine3 receptor type A (h5-HT3R-AS) subunit stably expressed in HEK 293 cells. Br J Pharmacol. 1996 Jul;118(5):1237-45.
DMB9VGW	RU	https://pubmed.ncbi.nlm.nih.gov/8818349

DMB9VGW	DI	DMB9VGW
DMB9VGW	DN	[3H]granisetron
DMB9VGW	MI	TTR6K75
DMB9VGW	MN	5-HT 3B receptor (HTR3B)
DMB9VGW	MT	DTT
DMB9VGW	MA	Antagonist
DMB9VGW	RN	Pharmacological comparison of human homomeric 5-HT3A receptors versus heteromeric 5-HT3A/3B receptors. Neuropharmacology. 2001 Aug;41(2):282-4.
DMB9VGW	RU	https://pubmed.ncbi.nlm.nih.gov/11489465

DMU6A3W	DI	DMU6A3W
DMU6A3W	DN	[3H]GSK931145
DMU6A3W	MI	TTHJTF7
DMU6A3W	MN	Glycine transporter GlyT-1 (SLC6A9)
DMU6A3W	MT	DTT
DMU6A3W	MA	Modulator
DMU6A3W	RN	Pharmacological characterisation of the GlyT-1 glycine transporter using two novel radioligands. Neuropharmacology. 2010 Nov;59(6):558-65.
DMU6A3W	RU	https://pubmed.ncbi.nlm.nih.gov/20691713

DMJT6D3	DI	DMJT6D3
DMJT6D3	DN	[3H]GW2331
DMJT6D3	MI	TTT2SVW
DMJT6D3	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DMJT6D3	MT	DTT
DMJT6D3	MA	Agonist
DMJT6D3	RN	Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4318-23.
DMJT6D3	RU	https://pubmed.ncbi.nlm.nih.gov/9113987

DMEO6AH	DI	DMEO6AH
DMEO6AH	DN	[3H]HEMADO
DMEO6AH	MI	TTK25J1
DMEO6AH	MN	Adenosine A1 receptor (ADORA1)
DMEO6AH	MT	DTT
DMEO6AH	MA	Agonist
DMEO6AH	RN	[3H]HEMADO--a novel tritiated agonist selective for the human adenosine A3 receptor. Eur J Pharmacol. 2007 Feb 5;556(1-3):14-8.
DMEO6AH	RU	https://pubmed.ncbi.nlm.nih.gov/17126322

DMEO6AH	DI	DMEO6AH
DMEO6AH	DN	[3H]HEMADO
DMEO6AH	MI	TTNE7KG
DMEO6AH	MN	Adenosine A2b receptor (ADORA2B)
DMEO6AH	MT	DTT
DMEO6AH	MA	Agonist
DMEO6AH	RN	[3H]HEMADO--a novel tritiated agonist selective for the human adenosine A3 receptor. Eur J Pharmacol. 2007 Feb 5;556(1-3):14-8.
DMEO6AH	RU	https://pubmed.ncbi.nlm.nih.gov/17126322

DMEO6AH	DI	DMEO6AH
DMEO6AH	DN	[3H]HEMADO
DMEO6AH	MI	TTJFY5U
DMEO6AH	MN	Adenosine A3 receptor (ADORA3)
DMEO6AH	MT	DTT
DMEO6AH	MA	Agonist
DMEO6AH	RN	[3H]HEMADO--a novel tritiated agonist selective for the human adenosine A3 receptor. Eur J Pharmacol. 2007 Feb 5;556(1-3):14-8.
DMEO6AH	RU	https://pubmed.ncbi.nlm.nih.gov/17126322

DM190QW	DI	DM190QW
DM190QW	DN	[3H]hemicholinium-3
DM190QW	MI	TTRV7W3
DM190QW	MN	High affinity choline transporter 1 (CHT)
DM190QW	MT	DTT
DM190QW	MA	Modulator
DM190QW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 914).
DM190QW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=914

DMJ5BDQ	DI	DMJ5BDQ
DMJ5BDQ	DN	[3H]histidine
DMJ5BDQ	MI	TTAYPWS
DMJ5BDQ	MN	Solute carrier family 15 member 3 (SLC15A3)
DMJ5BDQ	MT	DTT
DMJ5BDQ	MA	Modulator
DMJ5BDQ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 986).
DMJ5BDQ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=986

DMJ5BDQ	DI	DMJ5BDQ
DMJ5BDQ	DN	[3H]histidine
DMJ5BDQ	MI	TTG2XRE
DMJ5BDQ	MN	Solute carrier family 15 member 4 (SLC15A4)
DMJ5BDQ	MT	DTT
DMJ5BDQ	MA	Modulator
DMJ5BDQ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 987).
DMJ5BDQ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=987

DMJ5BDQ	DI	DMJ5BDQ
DMJ5BDQ	DN	[3H]histidine
DMJ5BDQ	MI	TTC8YPT
DMJ5BDQ	MN	Solute carrier family 38 member 5 (SLC38A5)
DMJ5BDQ	MT	DTT
DMJ5BDQ	MA	Modulator
DMJ5BDQ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1173).
DMJ5BDQ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1173

DM8YUW6	DI	DM8YUW6
DM8YUW6	DN	[3H]HU-243
DM8YUW6	MI	TT6OEDT
DM8YUW6	MN	Cannabinoid receptor 1 (CB1)
DM8YUW6	MT	DTT
DM8YUW6	MA	Agonist
DM8YUW6	RN	A novel probe for the cannabinoid receptor. J Med Chem. 1992 May 29;35(11):2065-9.
DM8YUW6	RU	https://pubmed.ncbi.nlm.nih.gov/1317925

DM8YUW6	DI	DM8YUW6
DM8YUW6	DN	[3H]HU-243
DM8YUW6	MI	TTMSFAW
DM8YUW6	MN	Cannabinoid receptor 2 (CB2)
DM8YUW6	MT	DTT
DM8YUW6	MA	Agonist
DM8YUW6	RN	The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Lett. 1995 Nov 13;375(1-2):143-7.
DM8YUW6	RU	https://pubmed.ncbi.nlm.nih.gov/7498464

DMJCI2A	DI	DMJCI2A
DMJCI2A	DN	[3H]JB-93182
DMJCI2A	MI	TTVFO0U
DMJCI2A	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMJCI2A	MT	DTT
DMJCI2A	MA	Antagonist
DMJCI2A	RN	Characterization of the binding of a novel radioligand to CCKB/gastrin receptors in membranes from rat cerebral cortex. Br J Pharmacol. 1999 Mar;126(6):1504-12.
DMJCI2A	RU	https://pubmed.ncbi.nlm.nih.gov/10217546

DMZT8UD	DI	DMZT8UD
DMZT8UD	DN	[3H]JNJ 7777120
DMZT8UD	MI	TTXJ178
DMZT8UD	MN	Histamine H4 receptor (H4R)
DMZT8UD	MT	DTT
DMZT8UD	MA	Antagonist
DMZT8UD	RN	A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties. J Pharmacol Exp Ther. 2004 Apr;309(1):404-13.
DMZT8UD	RU	https://pubmed.ncbi.nlm.nih.gov/14722321

DMSE56B	DI	DMSE56B
DMSE56B	DN	[3H]JNJ-40068782
DMSE56B	MI	TTXJ47W
DMSE56B	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMSE56B	MT	DTT
DMSE56B	MA	Modulator (allosteric modulator)
DMSE56B	RN	Pharmacological characterization of JNJ-40068782, a new potent, selective, and systemically active positive allosteric modulator of the mGlu2 receptor and its radioligand [3H]JNJ-40068782. J Pharmacol Exp Ther. 2013 Sep;346(3):514-27.
DMSE56B	RU	https://pubmed.ncbi.nlm.nih.gov/23766542

DMMK7XU	DI	DMMK7XU
DMMK7XU	DN	[3H]kainate
DMMK7XU	MI	TTJFY5U
DMMK7XU	MN	Adenosine A3 receptor (ADORA3)
DMMK7XU	MT	DTT
DMMK7XU	MA	Inhibitor
DMMK7XU	RN	2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96.
DMMK7XU	RU	https://pubmed.ncbi.nlm.nih.gov/16250647

DMMK7XU	DI	DMMK7XU
DMMK7XU	DN	[3H]kainate
DMMK7XU	MI	TTAN6JD
DMMK7XU	MN	Glutamate receptor AMPA (GRIA)
DMMK7XU	MT	DTT
DMMK7XU	MA	Inhibitor
DMMK7XU	RN	1H-cyclopentapyrimidine-2,4(1H,3H)-dione-related ionotropic glutamate receptors ligands. structure-activity relationships and identification of pot... J Med Chem. 2008 Oct 23;51(20):6614-8.
DMMK7XU	RU	https://pubmed.ncbi.nlm.nih.gov/18811139

DMMK7XU	DI	DMMK7XU
DMMK7XU	DN	[3H]kainate
DMMK7XU	MI	TTVPQTF
DMMK7XU	MN	Glutamate receptor AMPA 1 (GRIA1)
DMMK7XU	MT	DTT
DMMK7XU	MA	Inhibitor
DMMK7XU	RN	1H-cyclopentapyrimidine-2,4(1H,3H)-dione-related ionotropic glutamate receptors ligands. structure-activity relationships and identification of pot... J Med Chem. 2008 Oct 23;51(20):6614-8.
DMMK7XU	RU	https://pubmed.ncbi.nlm.nih.gov/18811139

DMMK7XU	DI	DMMK7XU
DMMK7XU	DN	[3H]kainate
DMMK7XU	MI	TT0MYE2
DMMK7XU	MN	Glutamate receptor ionotropic kainate 1 (GRIK1)
DMMK7XU	MT	DTT
DMMK7XU	MA	Agonist
DMMK7XU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 450).
DMMK7XU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=450

DMMK7XU	DI	DMMK7XU
DMMK7XU	DN	[3H]kainate
DMMK7XU	MI	TT0K5RG
DMMK7XU	MN	Glutamate receptor ionotropic kainate 2 (GRIK2)
DMMK7XU	MT	DTT
DMMK7XU	MA	Agonist
DMMK7XU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 451).
DMMK7XU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=451

DMMK7XU	DI	DMMK7XU
DMMK7XU	DN	[3H]kainate
DMMK7XU	MI	TTNP6O2
DMMK7XU	MN	Glutamate receptor ionotropic kainate 3 (GluK3)
DMMK7XU	MT	DTT
DMMK7XU	MA	Agonist
DMMK7XU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 452).
DMMK7XU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=452

DMMK7XU	DI	DMMK7XU
DMMK7XU	DN	[3H]kainate
DMMK7XU	MI	TTQV6BO
DMMK7XU	MN	Glutamate receptor ionotropic kainate 4 (GluK4)
DMMK7XU	MT	DTT
DMMK7XU	MA	Agonist
DMMK7XU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 453).
DMMK7XU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=453

DMMK7XU	DI	DMMK7XU
DMMK7XU	DN	[3H]kainate
DMMK7XU	MI	TTO6LI7
DMMK7XU	MN	Glutamate receptor ionotropic kainate 5 (GRIK5)
DMMK7XU	MT	DTT
DMMK7XU	MA	Agonist
DMMK7XU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 454).
DMMK7XU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=454

DMUZ9LX	DI	DMUZ9LX
DMUZ9LX	DN	[3H]L655708
DMUZ9LX	MI	TTNZPQ1
DMUZ9LX	MN	GABA(A) receptor alpha-5 (GABRA5)
DMUZ9LX	MT	DTT
DMUZ9LX	MA	Modulator (allosteric modulator)
DMUZ9LX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 408).
DMUZ9LX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=408

DM0YJHS	DI	DM0YJHS
DM0YJHS	DN	[3H]LSD
DM0YJHS	MI	TT0K1SC
DM0YJHS	MN	5-HT 2B receptor (HTR2B)
DM0YJHS	MT	DTT
DM0YJHS	MA	Agonist
DM0YJHS	RN	Identification of the binding sites and selectivity of sarpogrelate, a novel 5-HT2 antagonist, to human 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes by molecular modeling. Life Sci. 2003 May 30;73(2):193-207.
DM0YJHS	RU	https://pubmed.ncbi.nlm.nih.gov/12738034

DM0YJHS	DI	DM0YJHS
DM0YJHS	DN	[3H]LSD
DM0YJHS	MI	TTWJBZ5
DM0YJHS	MN	5-HT 2C receptor (HTR2C)
DM0YJHS	MT	DTT
DM0YJHS	MA	Agonist
DM0YJHS	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 8).
DM0YJHS	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=8

DM0YJHS	DI	DM0YJHS
DM0YJHS	DN	[3H]LSD
DM0YJHS	MI	TTJS8PY
DM0YJHS	MN	5-HT 6 receptor (HTR6)
DM0YJHS	MT	DTT
DM0YJHS	MA	Agonist
DM0YJHS	RN	Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology. 1999 Jun;20(6):612-27.
DM0YJHS	RU	https://pubmed.ncbi.nlm.nih.gov/10327430

DM0YJHS	DI	DM0YJHS
DM0YJHS	DN	[3H]LSD
DM0YJHS	MI	TTO9X1H
DM0YJHS	MN	5-HT 7 receptor (HTR7)
DM0YJHS	MT	DTT
DM0YJHS	MA	Agonist
DM0YJHS	RN	Human serotonin 5-HT7 receptor: cloning and pharmacological characterisation of two receptor variants. FEBS Lett. 1997 Aug 25;413(3):489-94.
DM0YJHS	RU	https://pubmed.ncbi.nlm.nih.gov/9303561

DMDOJVX	DI	DMDOJVX
DMDOJVX	DN	[3H]LTB4
DMDOJVX	MI	TTVJX54
DMDOJVX	MN	Leukotriene B4 receptor 2 (LTB4R2)
DMDOJVX	MT	DTT
DMDOJVX	MA	Modulator
DMDOJVX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 268).
DMDOJVX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=268

DMD09BO	DI	DMD09BO
DMD09BO	DN	[3H]LTC4
DMD09BO	MI	TT0PZR5
DMD09BO	MN	Leukotriene CysLT2 receptor (CYSLTR2)
DMD09BO	MT	DTT
DMD09BO	MA	Agonist
DMD09BO	RN	The molecular characterization and tissue distribution of the human cysteinyl leukotriene CysLT(2) receptor. Biochem Biophys Res Commun. 2000 Aug 2;274(2):316-22.
DMD09BO	RU	https://pubmed.ncbi.nlm.nih.gov/10913337

DMGX0Y8	DI	DMGX0Y8
DMGX0Y8	DN	[3H]LY341495
DMGX0Y8	MI	TTXJ47W
DMGX0Y8	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMGX0Y8	MT	DTT
DMGX0Y8	MA	Antagonist
DMGX0Y8	RN	[3H]-LY341495 as a novel antagonist radioligand for group II metabotropic glutamate (mGlu) receptors: characterization of binding to membranes of mGlu receptor subtype expressing cells. Neuropharmacology. 1999 Oct;38(10):1519-29.
DMGX0Y8	RU	https://pubmed.ncbi.nlm.nih.gov/10530814

DMGX0Y8	DI	DMGX0Y8
DMGX0Y8	DN	[3H]LY341495
DMGX0Y8	MI	TT8A9EF
DMGX0Y8	MN	Metabotropic glutamate receptor 3 (mGluR3)
DMGX0Y8	MT	DTT
DMGX0Y8	MA	Agonist
DMGX0Y8	RN	Characterization of [(3)H]-LY354740 binding to rat mGlu2 and mGlu3 receptors expressed in CHO cells using semliki forest virus vectors. Neuropharmacology. 2000 Jul 24;39(10):1700-6.
DMGX0Y8	RU	https://pubmed.ncbi.nlm.nih.gov/10884552

DMGX0Y8	DI	DMGX0Y8
DMGX0Y8	DN	[3H]LY341495
DMGX0Y8	MI	TTWRP2F
DMGX0Y8	MN	Metabotropic glutamate receptor 6 (mGluR6)
DMGX0Y8	MT	DTT
DMGX0Y8	MA	Antagonist
DMGX0Y8	RN	Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 2000 Dec;362(6):546-54.
DMGX0Y8	RU	https://pubmed.ncbi.nlm.nih.gov/11138847

DMGX0Y8	DI	DMGX0Y8
DMGX0Y8	DN	[3H]LY341495
DMGX0Y8	MI	TT0I76D
DMGX0Y8	MN	Metabotropic glutamate receptor 7 (mGluR7)
DMGX0Y8	MT	DTT
DMGX0Y8	MA	Antagonist
DMGX0Y8	RN	Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 2000 Dec;362(6):546-54.
DMGX0Y8	RU	https://pubmed.ncbi.nlm.nih.gov/11138847

DMPKGHB	DI	DMPKGHB
DMPKGHB	DN	[3H]MDL105519
DMPKGHB	MI	TTLD29N
DMPKGHB	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMPKGHB	MT	DTT
DMPKGHB	MA	Antagonist
DMPKGHB	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455).
DMPKGHB	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=455

DMPKGHB	DI	DMPKGHB
DMPKGHB	DN	[3H]MDL105519
DMPKGHB	MI	TTKJEMQ
DMPKGHB	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMPKGHB	MT	DTT
DMPKGHB	MA	Antagonist
DMPKGHB	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456).
DMPKGHB	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=456

DMPKGHB	DI	DMPKGHB
DMPKGHB	DN	[3H]MDL105519
DMPKGHB	MI	TTN9D8E
DMPKGHB	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMPKGHB	MT	DTT
DMPKGHB	MA	Antagonist
DMPKGHB	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457).
DMPKGHB	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=457

DMPKGHB	DI	DMPKGHB
DMPKGHB	DN	[3H]MDL105519
DMPKGHB	MI	TT1M8OW
DMPKGHB	MN	Glutamate receptor ionotropic NMDA 2C (GluN2C)
DMPKGHB	MT	DTT
DMPKGHB	MA	Antagonist
DMPKGHB	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 458).
DMPKGHB	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=458

DMPKGHB	DI	DMPKGHB
DMPKGHB	DN	[3H]MDL105519
DMPKGHB	MI	TT5POTG
DMPKGHB	MN	Glutamate receptor ionotropic NMDA 2D (GluN2D)
DMPKGHB	MT	DTT
DMPKGHB	MA	Antagonist
DMPKGHB	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 459).
DMPKGHB	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=459

DMEX6GT	DI	DMEX6GT
DMEX6GT	DN	[3H]meclinertant
DMEX6GT	MI	TTTUMEP
DMEX6GT	MN	Neurotensin receptor type 1 (NTSR1)
DMEX6GT	MT	DTT
DMEX6GT	MA	Antagonist
DMEX6GT	RN	[3H]SR 48692, the first nonpeptide neurotensin antagonist radioligand: characterization of binding properties and evidence for distinct agonist and antagonist binding domains on the rat neurotensin receptor. Mol Pharmacol. 1995 May;47(5):1050-6.
DMEX6GT	RU	https://pubmed.ncbi.nlm.nih.gov/7746272

DM8K6VF	DI	DM8K6VF
DM8K6VF	DN	[3H]mesulergine
DM8K6VF	MI	TT0K1SC
DM8K6VF	MN	5-HT 2B receptor (HTR2B)
DM8K6VF	MT	DTT
DM8K6VF	MA	Antagonist
DM8K6VF	RN	Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
DM8K6VF	RU	https://pubmed.ncbi.nlm.nih.gov/15322733

DM8K6VF	DI	DM8K6VF
DM8K6VF	DN	[3H]mesulergine
DM8K6VF	MI	TTWJBZ5
DM8K6VF	MN	5-HT 2C receptor (HTR2C)
DM8K6VF	MT	DTT
DM8K6VF	MA	Antagonist
DM8K6VF	RN	High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action. J Neurochem. 1999 May;72(5):2127-34.
DM8K6VF	RU	https://pubmed.ncbi.nlm.nih.gov/10217294

DMONI13	DI	DMONI13
DMONI13	DN	[3H]methoxymethyl-MTEP
DMONI13	MI	TTHS256
DMONI13	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMONI13	MT	DTT
DMONI13	MA	Modulator (allosteric modulator)
DMONI13	RN	[3H]Methoxymethyl-3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine binding to metabotropic glutamate receptor subtype 5 in rodent brain: in vitro and in vivo characterization. J Pharmacol Exp Ther. 2002 Dec;303(3):1044-51.
DMONI13	RU	https://pubmed.ncbi.nlm.nih.gov/12438526

DMZ2R1O	DI	DMZ2R1O
DMZ2R1O	DN	[3H]methoxy-PEPy
DMZ2R1O	MI	TTHS256
DMZ2R1O	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMZ2R1O	MT	DTT
DMZ2R1O	MA	Modulator (allosteric modulator)
DMZ2R1O	RN	[3H]-methoxymethyl-MTEP and [3H]-methoxy-PEPy: potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor. Bioorg Med Chem Lett. 2003 Feb 10;13(3):351-4.
DMZ2R1O	RU	https://pubmed.ncbi.nlm.nih.gov/12565928

DMYWGCS	DI	DMYWGCS
DMYWGCS	DN	[3H]methyllycaconitine
DMYWGCS	MI	TTJ49OM
DMYWGCS	MN	Neuronal acetylcholine receptor alpha-10 (CHRNA10)
DMYWGCS	MT	DTT
DMYWGCS	MA	Antagonist
DMYWGCS	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 470).
DMYWGCS	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=470

DMYWGCS	DI	DMYWGCS
DMYWGCS	DN	[3H]methyllycaconitine
DMYWGCS	MI	TTLA931
DMYWGCS	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMYWGCS	MT	DTT
DMYWGCS	MA	Antagonist
DMYWGCS	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 468).
DMYWGCS	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=468

DMYWGCS	DI	DMYWGCS
DMYWGCS	DN	[3H]methyllycaconitine
DMYWGCS	MI	TTQACP9
DMYWGCS	MN	Neuronal acetylcholine receptor alpha-9 (CHRNA9)
DMYWGCS	MT	DTT
DMYWGCS	MA	Antagonist
DMYWGCS	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 469).
DMYWGCS	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=469

DMTSGOW	DI	DMTSGOW
DMTSGOW	DN	[3H]methyltrienolone
DMTSGOW	MI	TTS64P2
DMTSGOW	MN	Androgen receptor (AR)
DMTSGOW	MT	DTT
DMTSGOW	MA	Inhibitor
DMTSGOW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMTSGOW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMTSGOW	DI	DMTSGOW
DMTSGOW	DN	[3H]methyltrienolone
DMTSGOW	MI	TTKPW01
DMTSGOW	MN	Androgen receptor messenger RNA (AR mRNA)
DMTSGOW	MT	DTT
DMTSGOW	MA	Agonist
DMTSGOW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 628).
DMTSGOW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=628

DMTSGOW	DI	DMTSGOW
DMTSGOW	DN	[3H]methyltrienolone
DMTSGOW	MI	TTUV8G9
DMTSGOW	MN	Progesterone receptor (PGR)
DMTSGOW	MT	DTT
DMTSGOW	MA	Inhibitor
DMTSGOW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMTSGOW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM6HDKQ	DI	DM6HDKQ
DM6HDKQ	DN	[3H]mibolerone
DM6HDKQ	MI	TTS64P2
DM6HDKQ	MN	Androgen receptor (AR)
DM6HDKQ	MT	DTT
DM6HDKQ	MA	Inhibitor
DM6HDKQ	RN	Design, synthesis, and pharmacological characterization of 4-[4, 4-dimethyl-3-(4-hydroxybutyl)-5-oxo-2-thioxo-1-imidazolidinyl]- 2-iodobenzonitrile... J Med Chem. 2000 Aug 24;43(17):3344-7.
DM6HDKQ	RU	https://pubmed.ncbi.nlm.nih.gov/10966753

DM6HDKQ	DI	DM6HDKQ
DM6HDKQ	DN	[3H]mibolerone
DM6HDKQ	MI	TTKPW01
DM6HDKQ	MN	Androgen receptor messenger RNA (AR mRNA)
DM6HDKQ	MT	DTT
DM6HDKQ	MA	Agonist
DM6HDKQ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 628).
DM6HDKQ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=628

DMO89N0	DI	DMO89N0
DMO89N0	DN	[3H]MK-912
DMO89N0	MI	TTWM4TY
DMO89N0	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMO89N0	MT	DTT
DMO89N0	MA	Antagonist
DMO89N0	RN	The novel alpha-2 adrenergic radioligand [3H]-MK912 is alpha-2C selective among human alpha-2A, alpha-2B and alpha-2C adrenoceptors. J Pharmacol Exp Ther. 1994 Dec;271(3):1558-65.
DMO89N0	RU	https://pubmed.ncbi.nlm.nih.gov/7996470

DMO89N0	DI	DMO89N0
DMO89N0	DN	[3H]MK-912
DMO89N0	MI	TT2NUT5
DMO89N0	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMO89N0	MT	DTT
DMO89N0	MA	Antagonist
DMO89N0	RN	The novel alpha-2 adrenergic radioligand [3H]-MK912 is alpha-2C selective among human alpha-2A, alpha-2B and alpha-2C adrenoceptors. J Pharmacol Exp Ther. 1994 Dec;271(3):1558-65.
DMO89N0	RU	https://pubmed.ncbi.nlm.nih.gov/7996470

DM0THB9	DI	DM0THB9
DM0THB9	DN	[3H]N5-methylfolate
DM0THB9	MI	TTY8Z2E
DM0THB9	MN	Proton-coupled folate transporter (SLC46A1)
DM0THB9	MT	DTT
DM0THB9	MA	Modulator
DM0THB9	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1213).
DM0THB9	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1213

DMQW3A9	DI	DMQW3A9
DMQW3A9	DN	[3H]naltrindole
DMQW3A9	MI	TT27RFC
DMQW3A9	MN	Opioid receptor delta (OPRD1)
DMQW3A9	MT	DTT
DMQW3A9	MA	Antagonist
DMQW3A9	RN	Characterization of [3H]naltrindole binding to delta opioid receptors in rat brain. Life Sci. 1992;50(16):PL119-24.
DMQW3A9	RU	https://pubmed.ncbi.nlm.nih.gov/1313133

DMAO9SH	DI	DMAO9SH
DMAO9SH	DN	[3H]NECA
DMAO9SH	MI	TTK25J1
DMAO9SH	MN	Adenosine A1 receptor (ADORA1)
DMAO9SH	MT	DTT
DMAO9SH	MA	Inhibitor
DMAO9SH	RN	Adenosine receptor agonists: synthesis and biological evaluation of 1-deaza analogues of adenosine derivatives. J Med Chem. 1988 Jun;31(6):1179-83.
DMAO9SH	RU	https://pubmed.ncbi.nlm.nih.gov/3373486

DMAO9SH	DI	DMAO9SH
DMAO9SH	DN	[3H]NECA
DMAO9SH	MI	TTM2AOE
DMAO9SH	MN	Adenosine A2a receptor (ADORA2A)
DMAO9SH	MT	DTT
DMAO9SH	MA	Inhibitor
DMAO9SH	RN	Adenosine receptor agonists: synthesis and biological evaluation of 1-deaza analogues of adenosine derivatives. J Med Chem. 1988 Jun;31(6):1179-83.
DMAO9SH	RU	https://pubmed.ncbi.nlm.nih.gov/3373486

DMAO9SH	DI	DMAO9SH
DMAO9SH	DN	[3H]NECA
DMAO9SH	MI	TTNE7KG
DMAO9SH	MN	Adenosine A2b receptor (ADORA2B)
DMAO9SH	MT	DTT
DMAO9SH	MA	Agonist
DMAO9SH	RN	Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 1998 Jan;357(1):1-9.
DMAO9SH	RU	https://pubmed.ncbi.nlm.nih.gov/9459566

DMAO9SH	DI	DMAO9SH
DMAO9SH	DN	[3H]NECA
DMAO9SH	MI	TTJFY5U
DMAO9SH	MN	Adenosine A3 receptor (ADORA3)
DMAO9SH	MT	DTT
DMAO9SH	MA	Agonist
DMAO9SH	RN	Inhibition of human mast cell activation with the novel selective adenosine A(2B) receptor antagonist 3-isobutyl-8-pyrrolidinoxanthine (IPDX)(2). Biochem Pharmacol. 2001 Nov 1;62(9):1163-73.
DMAO9SH	RU	https://pubmed.ncbi.nlm.nih.gov/11705449

DM0163O	DI	DM0163O
DM0163O	DN	[3H]nelivaptan
DM0163O	MI	TTL9MHW
DM0163O	MN	Vasopressin V1b receptor (V1BR)
DM0163O	MT	DTT
DM0163O	MA	Antagonist
DM0163O	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 367).
DM0163O	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=367

DM6PO49	DI	DM6PO49
DM6PO49	DN	[3H]NFPS
DM6PO49	MI	TTHJTF7
DM6PO49	MN	Glycine transporter GlyT-1 (SLC6A9)
DM6PO49	MT	DTT
DM6PO49	MA	Modulator
DM6PO49	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 935).
DM6PO49	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=935

DM9E2YI	DI	DM9E2YI
DM9E2YI	DN	[3H]nicotine
DM9E2YI	MI	TT5KPZR
DM9E2YI	MN	Neuronal acetylcholine receptor beta-2 (CHRNB2)
DM9E2YI	MT	DTT
DM9E2YI	MA	Agonist
DM9E2YI	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 465).
DM9E2YI	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=465

DMS3WNG	DI	DMS3WNG
DMS3WNG	DN	[3H]nisoxetine
DMS3WNG	MI	TTAWNKZ
DMS3WNG	MN	Norepinephrine transporter (NET)
DMS3WNG	MT	DTT
DMS3WNG	MA	Inhibitor
DMS3WNG	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 926).
DMS3WNG	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=926

DM5TDFQ	DI	DM5TDFQ
DM5TDFQ	DN	[3H]nitrobenzylmercaptopurine ribonucleoside
DM5TDFQ	MI	TTLXAKE
DM5TDFQ	MN	Solute carrier family 29 member 1 (SLC29A1)
DM5TDFQ	MT	DTT
DM5TDFQ	MA	Modulator
DM5TDFQ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1117).
DM5TDFQ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1117

DMG1TIV	DI	DMG1TIV
DMG1TIV	DN	[3H]NLX-112
DMG1TIV	MI	TTSQIFT
DMG1TIV	MN	5-HT 1A receptor (HTR1A)
DMG1TIV	MT	DTT
DMG1TIV	MA	Agonist
DMG1TIV	RN	[(3)H]-F13640, a novel, selective and high-efficacy serotonin 5-HT(1A) receptor agonist radioligand. Naunyn Schmiedebergs Arch Pharmacol. 2010 Oct;382(4):321-30.
DMG1TIV	RU	https://pubmed.ncbi.nlm.nih.gov/20799027

DM5176Y	DI	DM5176Y
DM5176Y	DN	[3H]N-methylspiperone
DM5176Y	MI	TTJQOD7
DM5176Y	MN	5-HT 2A receptor (HTR2A)
DM5176Y	MT	DTT
DM5176Y	MA	Antagonist
DM5176Y	RN	Differential modes of agonist binding to 5-hydroxytryptamine(2A) serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5. Mol Pharmacol. 2000 Nov;58(5):877-86.
DM5176Y	RU	https://pubmed.ncbi.nlm.nih.gov/11040033

DM5176Y	DI	DM5176Y
DM5176Y	DN	[3H]N-methylspiperone
DM5176Y	MI	TTEX248
DM5176Y	MN	Dopamine D2 receptor (D2R)
DM5176Y	MT	DTT
DM5176Y	MA	Antagonist
DM5176Y	RN	Nonconserved residues in the second transmembrane-spanning domain of the D(4) dopamine receptor are molecular determinants of D(4)-selective pharmacology. Mol Pharmacol. 2000 Jan;57(1):144-52.
DM5176Y	RU	https://pubmed.ncbi.nlm.nih.gov/10617689

DM5176Y	DI	DM5176Y
DM5176Y	DN	[3H]N-methylspiperone
DM5176Y	MI	TTE0A2F
DM5176Y	MN	Dopamine D4 receptor (D4R)
DM5176Y	MT	DTT
DM5176Y	MA	Antagonist
DM5176Y	RN	Nonconserved residues in the second transmembrane-spanning domain of the D(4) dopamine receptor are molecular determinants of D(4)-selective pharmacology. Mol Pharmacol. 2000 Jan;57(1):144-52.
DM5176Y	RU	https://pubmed.ncbi.nlm.nih.gov/10617689

DMX4RJ8	DI	DMX4RJ8
DMX4RJ8	DN	[3H]N-methyl-SSR504734
DMX4RJ8	MI	TTHJTF7
DMX4RJ8	MN	Glycine transporter GlyT-1 (SLC6A9)
DMX4RJ8	MT	DTT
DMX4RJ8	MA	Modulator
DMX4RJ8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 935).
DMX4RJ8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=935

DM4BY5J	DI	DM4BY5J
DM4BY5J	DN	[3H]OSIP339391
DM4BY5J	MI	TTK25J1
DM4BY5J	MN	Adenosine A1 receptor (ADORA1)
DM4BY5J	MT	DTT
DM4BY5J	MA	Inhibitor
DM4BY5J	RN	Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods. Eur J Med Chem. 2010 Aug;45(8):3459-71.
DM4BY5J	RU	https://pubmed.ncbi.nlm.nih.gov/20537438

DM4BY5J	DI	DM4BY5J
DM4BY5J	DN	[3H]OSIP339391
DM4BY5J	MI	TTM2AOE
DM4BY5J	MN	Adenosine A2a receptor (ADORA2A)
DM4BY5J	MT	DTT
DM4BY5J	MA	Inhibitor
DM4BY5J	RN	Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods. Eur J Med Chem. 2010 Aug;45(8):3459-71.
DM4BY5J	RU	https://pubmed.ncbi.nlm.nih.gov/20537438

DM4BY5J	DI	DM4BY5J
DM4BY5J	DN	[3H]OSIP339391
DM4BY5J	MI	TTNE7KG
DM4BY5J	MN	Adenosine A2b receptor (ADORA2B)
DM4BY5J	MT	DTT
DM4BY5J	MA	Antagonist
DM4BY5J	RN	[3H]OSIP339391, a selective, novel, and high affinity antagonist radioligand for adenosine A2B receptors. Biochem Pharmacol. 2004 Jul 15;68(2):305-12.
DM4BY5J	RU	https://pubmed.ncbi.nlm.nih.gov/15194002

DM4BY5J	DI	DM4BY5J
DM4BY5J	DN	[3H]OSIP339391
DM4BY5J	MI	TTJFY5U
DM4BY5J	MN	Adenosine A3 receptor (ADORA3)
DM4BY5J	MT	DTT
DM4BY5J	MA	Inhibitor
DM4BY5J	RN	Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods. Eur J Med Chem. 2010 Aug;45(8):3459-71.
DM4BY5J	RU	https://pubmed.ncbi.nlm.nih.gov/20537438

DM5L7D3	DI	DM5L7D3
DM5L7D3	DN	[3H]oxotremorine-M
DM5L7D3	MI	TTOXS3C
DM5L7D3	MN	Muscarinic acetylcholine receptor (CHRM)
DM5L7D3	MT	DTT
DM5L7D3	MA	Agonist
DM5L7D3	RN	Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol. 1997 Jul;52(1):172-9.
DM5L7D3	RU	https://pubmed.ncbi.nlm.nih.gov/9224827

DM5L7D3	DI	DM5L7D3
DM5L7D3	DN	[3H]oxotremorine-M
DM5L7D3	MI	TTQ13Z5
DM5L7D3	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DM5L7D3	MT	DTT
DM5L7D3	MA	Agonist
DM5L7D3	RN	Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol. 1997 Jul;52(1):172-9.
DM5L7D3	RU	https://pubmed.ncbi.nlm.nih.gov/9224827

DMK46C7	DI	DMK46C7
DMK46C7	DN	[3H]PBC-264
DMK46C7	MI	TTVFO0U
DMK46C7	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMK46C7	MT	DTT
DMK46C7	MA	Agonist
DMK46C7	RN	[3H]pBC 264, a suitable probe for studying cholecystokinin-B receptors: binding characteristics in rodent brains and comparison with [3H]SNF 8702. Mol Pharmacol. 1992 Jun;41(6):1089-95.
DMK46C7	RU	https://pubmed.ncbi.nlm.nih.gov/1614411

DMWAT5S	DI	DMWAT5S
DMWAT5S	DN	[3H]PD140376
DMWAT5S	MI	TTVFO0U
DMWAT5S	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMWAT5S	MT	DTT
DMWAT5S	MA	Antagonist
DMWAT5S	RN	[3H]PD 140376: a novel and highly selective antagonist radioligand for the cholecystokininB/gastrin receptor in guinea pig cerebral cortex and gastric mucosa. Mol Pharmacol. 1993 Apr;43(4):595-602.
DMWAT5S	RU	https://pubmed.ncbi.nlm.nih.gov/8474432

DMF4TWE	DI	DMF4TWE
DMF4TWE	DN	[3H]pentazocine
DMF4TWE	MI	TT5TPI6
DMF4TWE	MN	Opioid receptor sigma 1 (OPRS1)
DMF4TWE	MT	DTT
DMF4TWE	MA	Agonist
DMF4TWE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2552).
DMF4TWE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2552

DMPE1B2	DI	DMPE1B2
DMPE1B2	DN	[3H]PGF2alpha
DMPE1B2	MI	TTT2ZAR
DMPE1B2	MN	Prostaglandin F2-alpha receptor (PTGFR)
DMPE1B2	MT	DTT
DMPE1B2	MA	Agonist
DMPE1B2	RN	Cloning and expression of a cDNA for the human prostanoid FP receptor. J Biol Chem. 1994 Jan 28;269(4):2632-6.
DMPE1B2	RU	https://pubmed.ncbi.nlm.nih.gov/8300593

DMAMD5H	DI	DMAMD5H
DMAMD5H	DN	[3H]pirenzepine
DMAMD5H	MI	TTOXS3C
DMAMD5H	MN	Muscarinic acetylcholine receptor (CHRM)
DMAMD5H	MT	DTT
DMAMD5H	MA	Antagonist
DMAMD5H	RN	[3H]Pirenzepine identifies putative M1 muscarinic receptors in human stellate ganglia. Brain Res. 1984 Jan 2;290(1):179-82.
DMAMD5H	RU	https://pubmed.ncbi.nlm.nih.gov/6546354

DM2LA9X	DI	DM2LA9X
DM2LA9X	DN	[3H]p-MPPF
DM2LA9X	MI	TTSQIFT
DM2LA9X	MN	5-HT 1A receptor (HTR1A)
DM2LA9X	MT	DTT
DM2LA9X	MA	Antagonist
DM2LA9X	RN	Ligand binding characteristics of the human serotonin1A receptor heterologously expressed in CHO cells. Biosci Rep. 2004 Apr;24(2):101-15.
DM2LA9X	RU	https://pubmed.ncbi.nlm.nih.gov/15628665

DMP98AQ	DI	DMP98AQ
DMP98AQ	DN	[3H]PSB-0413
DMP98AQ	MI	TTZ1DT0
DMP98AQ	MN	P2Y purinoceptor 12 (P2RY12)
DMP98AQ	MT	DTT
DMP98AQ	MA	Antagonist
DMP98AQ	RN	Synthesis and preliminary evaluation of [3H]PSB-0413, a selective antagonist radioligand for platelet P2Y12 receptors. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5450-2.
DMP98AQ	RU	https://pubmed.ncbi.nlm.nih.gov/16213725

DMFDCJK	DI	DMFDCJK
DMFDCJK	DN	[3H]PSB-11
DMFDCJK	MI	TTJFY5U
DMFDCJK	MN	Adenosine A3 receptor (ADORA3)
DMFDCJK	MT	DTT
DMFDCJK	MA	Antagonist
DMFDCJK	RN	[(3)H]8-Ethyl-4-methyl-2-phenyl-(8R)-4,5,7,8-tetrahydro-1H-imidazo[2,1-i]-purin-5-one ([(3)H]PSB-11), a novel high-affinity antagonist radioligand for human A(3) adenosine receptors. Bioorg Med Chem Lett. 2002 Feb 11;12(3):501-3.
DMFDCJK	RU	https://pubmed.ncbi.nlm.nih.gov/11814828

DMC1WHR	DI	DMC1WHR
DMC1WHR	DN	[3H]QNB
DMC1WHR	MI	TTOXS3C
DMC1WHR	MN	Muscarinic acetylcholine receptor (CHRM)
DMC1WHR	MT	DTT
DMC1WHR	MA	Antagonist
DMC1WHR	RN	Interaction of anandamide with the M(1) and M(4) muscarinic acetylcholine receptors. Brain Res. 2001 Oct 5;915(1):70-8.
DMC1WHR	RU	https://pubmed.ncbi.nlm.nih.gov/11578621

DMC1WHR	DI	DMC1WHR
DMC1WHR	DN	[3H]QNB
DMC1WHR	MI	TTQ13Z5
DMC1WHR	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMC1WHR	MT	DTT
DMC1WHR	MA	Antagonist
DMC1WHR	RN	Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. EMBO J. 1987 Dec 20;6(13):3923-9.
DMC1WHR	RU	https://pubmed.ncbi.nlm.nih.gov/3443095

DMDQBTX	DI	DMDQBTX
DMDQBTX	DN	[3H]quisqualate
DMDQBTX	MI	TT9G4N0
DMDQBTX	MN	Glutamate carboxypeptidase II (GCPII)
DMDQBTX	MT	DTT
DMDQBTX	MA	Inhibitor
DMDQBTX	RN	Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II. J Med Chem. 2007 Jul 12;50(14):3267-73.
DMDQBTX	RU	https://pubmed.ncbi.nlm.nih.gov/17567119

DMDQBTX	DI	DMDQBTX
DMDQBTX	DN	[3H]quisqualate
DMDQBTX	MI	TT0MYE2
DMDQBTX	MN	Glutamate receptor ionotropic kainate 1 (GRIK1)
DMDQBTX	MT	DTT
DMDQBTX	MA	Inhibitor
DMDQBTX	RN	Chemo-enzymatic synthesis of a series of 2,4-syn-functionalized (S)-glutamate analogues: new insight into the structure-activity relation of ionotr... J Med Chem. 2008 Jul 24;51(14):4093-103.
DMDQBTX	RU	https://pubmed.ncbi.nlm.nih.gov/18578478

DMDQBTX	DI	DMDQBTX
DMDQBTX	DN	[3H]quisqualate
DMDQBTX	MI	TTVBPDM
DMDQBTX	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMDQBTX	MT	DTT
DMDQBTX	MA	Agonist
DMDQBTX	RN	Mutational analysis and molecular modeling of the allosteric binding site of a novel, selective, noncompetitive antagonist of the metabotropic glut... J Biol Chem. 2003 Mar 7;278(10):8340-7.
DMDQBTX	RU	https://pubmed.ncbi.nlm.nih.gov/12509432

DMDQBTX	DI	DMDQBTX
DMDQBTX	DN	[3H]quisqualate
DMDQBTX	MI	TTXJ47W
DMDQBTX	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMDQBTX	MT	DTT
DMDQBTX	MA	Inhibitor
DMDQBTX	RN	Excitatory amino acid receptor ligands: resolution, absolute stereochemistry, and enantiopharmacology of 2-amino-3-(4-butyl-3-hydroxyisoxazol-5-yl)... J Med Chem. 1998 Mar 12;41(6):930-9.
DMDQBTX	RU	https://pubmed.ncbi.nlm.nih.gov/9526567

DMDQBTX	DI	DMDQBTX
DMDQBTX	DN	[3H]quisqualate
DMDQBTX	MI	TT8A9EF
DMDQBTX	MN	Metabotropic glutamate receptor 3 (mGluR3)
DMDQBTX	MT	DTT
DMDQBTX	MA	Inhibitor
DMDQBTX	RN	Excitatory amino acid receptor ligands: resolution, absolute stereochemistry, and enantiopharmacology of 2-amino-3-(4-butyl-3-hydroxyisoxazol-5-yl)... J Med Chem. 1998 Mar 12;41(6):930-9.
DMDQBTX	RU	https://pubmed.ncbi.nlm.nih.gov/9526567

DMDQBTX	DI	DMDQBTX
DMDQBTX	DN	[3H]quisqualate
DMDQBTX	MI	TTHS256
DMDQBTX	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMDQBTX	MT	DTT
DMDQBTX	MA	Inhibitor
DMDQBTX	RN	Excitatory amino acid receptor ligands: resolution, absolute stereochemistry, and enantiopharmacology of 2-amino-3-(4-butyl-3-hydroxyisoxazol-5-yl)... J Med Chem. 1998 Mar 12;41(6):930-9.
DMDQBTX	RU	https://pubmed.ncbi.nlm.nih.gov/9526567

DMDQBTX	DI	DMDQBTX
DMDQBTX	DN	[3H]quisqualate
DMDQBTX	MI	TT0I76D
DMDQBTX	MN	Metabotropic glutamate receptor 7 (mGluR7)
DMDQBTX	MT	DTT
DMDQBTX	MA	Inhibitor
DMDQBTX	RN	Excitatory amino acid receptor ligands: resolution, absolute stereochemistry, and enantiopharmacology of 2-amino-3-(4-butyl-3-hydroxyisoxazol-5-yl)... J Med Chem. 1998 Mar 12;41(6):930-9.
DMDQBTX	RU	https://pubmed.ncbi.nlm.nih.gov/9526567

DMDQBTX	DI	DMDQBTX
DMDQBTX	DN	[3H]quisqualate
DMDQBTX	MI	TT0IFKL
DMDQBTX	MN	Metabotropic glutamate receptor 8 (mGluR8)
DMDQBTX	MT	DTT
DMDQBTX	MA	Inhibitor
DMDQBTX	RN	Excitatory amino acid receptor ligands: resolution, absolute stereochemistry, and enantiopharmacology of 2-amino-3-(4-butyl-3-hydroxyisoxazol-5-yl)... J Med Chem. 1998 Mar 12;41(6):930-9.
DMDQBTX	RU	https://pubmed.ncbi.nlm.nih.gov/9526567

DM21B46	DI	DM21B46
DM21B46	DN	[3H]ramosetron
DM21B46	MI	TTPC4TU
DM21B46	MN	5-HT 3A receptor (HTR3A)
DM21B46	MT	DTT
DM21B46	MA	Antagonist
DM21B46	RN	Molecular cloning of human 5-hydroxytryptamine3 receptor: heterogeneity in distribution and function among species. Mol Pharmacol. 1995 Sep;48(3):407-16.
DM21B46	RU	https://pubmed.ncbi.nlm.nih.gov/7565620

DMBQZ2H	DI	DMBQZ2H
DMBQZ2H	DN	[3H]rauwolscine
DMBQZ2H	MI	TT0K1SC
DMBQZ2H	MN	5-HT 2B receptor (HTR2B)
DMBQZ2H	MT	DTT
DMBQZ2H	MA	Antagonist
DMBQZ2H	RN	[3H]Rauwolscine: an antagonist radioligand for the cloned human 5-hydroxytryptamine2b (5-HT2B) receptor. Naunyn Schmiedebergs Arch Pharmacol. 1998 Jan;357(1):17-24.
DMBQZ2H	RU	https://pubmed.ncbi.nlm.nih.gov/9459568

DMBQZ2H	DI	DMBQZ2H
DMBQZ2H	DN	[3H]rauwolscine
DMBQZ2H	MI	TTQ8AFT
DMBQZ2H	MN	Adrenergic receptor Alpha-2 (ADRA2)
DMBQZ2H	MT	DTT
DMBQZ2H	MA	Antagonist
DMBQZ2H	RN	Characterization of alpha-adrenoceptor subtypes in smooth muscle of equine ileum. Am J Vet Res. 2001 Sep;62(9):1370-4.
DMBQZ2H	RU	https://pubmed.ncbi.nlm.nih.gov/11560262

DMBQZ2H	DI	DMBQZ2H
DMBQZ2H	DN	[3H]rauwolscine
DMBQZ2H	MI	TTWM4TY
DMBQZ2H	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMBQZ2H	MT	DTT
DMBQZ2H	MA	Antagonist
DMBQZ2H	RN	Pharmacological characteristics of alpha 2-adrenergic receptors: comparison of pharmacologically defined subtypes with subtypes identified by molecular cloning. Mol Pharmacol. 1992 Jul;42(1):1-5.
DMBQZ2H	RU	https://pubmed.ncbi.nlm.nih.gov/1353247

DMBQZ2H	DI	DMBQZ2H
DMBQZ2H	DN	[3H]rauwolscine
DMBQZ2H	MI	TT2NUT5
DMBQZ2H	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMBQZ2H	MT	DTT
DMBQZ2H	MA	Antagonist
DMBQZ2H	RN	Pharmacological characteristics of alpha 2-adrenergic receptors: comparison of pharmacologically defined subtypes with subtypes identified by molecular cloning. Mol Pharmacol. 1992 Jul;42(1):1-5.
DMBQZ2H	RU	https://pubmed.ncbi.nlm.nih.gov/1353247

DMFT0HU	DI	DMFT0HU
DMFT0HU	DN	[3H]resolvin D1
DMFT0HU	MI	TTOJ1NF
DMFT0HU	MN	FMLP-related receptor I (FPR2)
DMFT0HU	MT	DTT
DMFT0HU	MA	Agonist
DMFT0HU	RN	Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1660-5.
DMFT0HU	RU	https://pubmed.ncbi.nlm.nih.gov/20080636

DMFT0HU	DI	DMFT0HU
DMFT0HU	DN	[3H]resolvin D1
DMFT0HU	MI	TT7OCUB
DMFT0HU	MN	G-protein coupled receptor 32 (GPR32)
DMFT0HU	MT	DTT
DMFT0HU	MA	Agonist
DMFT0HU	RN	Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1660-5.
DMFT0HU	RU	https://pubmed.ncbi.nlm.nih.gov/20080636

DMFT0HU	DI	DMFT0HU
DMFT0HU	DN	[3H]resolvin D1
DMFT0HU	MI	TTELV3W
DMFT0HU	MN	Transformation-sensitive protein p120 (TRPA1)
DMFT0HU	MT	DTT
DMFT0HU	MA	Inhibitor (gating inhibitor)
DMFT0HU	RN	Resolvin D1 attenuates activation of sensory transient receptor potential channels leading to multiple anti-nociception. Br J Pharmacol. 2010 Oct;161(3):707-20.
DMFT0HU	RU	https://pubmed.ncbi.nlm.nih.gov/20880407

DMAMK3P	DI	DMAMK3P
DMAMK3P	DN	[3H]resolvin E1
DMAMK3P	MI	TT4UGZL
DMAMK3P	MN	Chemerin receptor (CMKLR1)
DMAMK3P	MT	DTT
DMAMK3P	MA	Agonist
DMAMK3P	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 79).
DMAMK3P	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=79

DMAMK3P	DI	DMAMK3P
DMAMK3P	DN	[3H]resolvin E1
DMAMK3P	MI	TTHS256
DMAMK3P	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMAMK3P	MT	DTT
DMAMK3P	MA	Modulator (allosteric modulator)
DMAMK3P	RN	Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8.
DMAMK3P	RU	https://pubmed.ncbi.nlm.nih.gov/17590335

DM5XSMN	DI	DM5XSMN
DM5XSMN	DN	[3H]Ro 63-0563
DM5XSMN	MI	TTJS8PY
DM5XSMN	MN	5-HT 6 receptor (HTR6)
DM5XSMN	MT	DTT
DM5XSMN	MA	Antagonist
DM5XSMN	RN	The 5-hydroxytryptamine6 receptor-selective radioligand [3H]Ro 63-0563 labels 5-hydroxytryptamine receptor binding sites in rat and porcine striatum. Mol Pharmacol. 1998 Sep;54(3):577-83.
DM5XSMN	RU	https://pubmed.ncbi.nlm.nih.gov/9730917

DMMBWKL	DI	DMMBWKL
DMMBWKL	DN	[3H]Ro154513
DMMBWKL	MI	TT1MPAY
DMMBWKL	MN	GABA(A) receptor alpha-1 (GABRA1)
DMMBWKL	MT	DTT
DMMBWKL	MA	Inhibitor
DMMBWKL	RN	Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6.
DMMBWKL	RU	https://pubmed.ncbi.nlm.nih.gov/8386769

DMMBWKL	DI	DMMBWKL
DMMBWKL	DN	[3H]Ro154513
DMMBWKL	MI	TTBMV1G
DMMBWKL	MN	GABA(A) receptor alpha-2 (GABRA2)
DMMBWKL	MT	DTT
DMMBWKL	MA	Inhibitor
DMMBWKL	RN	Synthesis and pharmacological properties of novel 8-substituted imidazobenzodiazepines: high-affinity, selective probes for alpha 5-containing GABA... J Med Chem. 1996 Apr 26;39(9):1928-34.
DMMBWKL	RU	https://pubmed.ncbi.nlm.nih.gov/8627617

DMMBWKL	DI	DMMBWKL
DMMBWKL	DN	[3H]Ro154513
DMMBWKL	MI	TT37EDJ
DMMBWKL	MN	GABA(A) receptor alpha-3 (GABRA3)
DMMBWKL	MT	DTT
DMMBWKL	MA	Inhibitor
DMMBWKL	RN	Synthesis and pharmacological properties of novel 8-substituted imidazobenzodiazepines: high-affinity, selective probes for alpha 5-containing GABA... J Med Chem. 1996 Apr 26;39(9):1928-34.
DMMBWKL	RU	https://pubmed.ncbi.nlm.nih.gov/8627617

DMMBWKL	DI	DMMBWKL
DMMBWKL	DN	[3H]Ro154513
DMMBWKL	MI	TTNZPQ1
DMMBWKL	MN	GABA(A) receptor alpha-5 (GABRA5)
DMMBWKL	MT	DTT
DMMBWKL	MA	Inhibitor
DMMBWKL	RN	Synthesis and pharmacological properties of novel 8-substituted imidazobenzodiazepines: high-affinity, selective probes for alpha 5-containing GABA... J Med Chem. 1996 Apr 26;39(9):1928-34.
DMMBWKL	RU	https://pubmed.ncbi.nlm.nih.gov/8627617

DMMBWKL	DI	DMMBWKL
DMMBWKL	DN	[3H]Ro154513
DMMBWKL	MI	TTZA1NY
DMMBWKL	MN	GABA(A) receptor beta-2 (GABRB2)
DMMBWKL	MT	DTT
DMMBWKL	MA	Inhibitor
DMMBWKL	RN	Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6.
DMMBWKL	RU	https://pubmed.ncbi.nlm.nih.gov/8386769

DMMBWKL	DI	DMMBWKL
DMMBWKL	DN	[3H]Ro154513
DMMBWKL	MI	TT06RH5
DMMBWKL	MN	GABA(A) receptor gamma-2 (GABRG2)
DMMBWKL	MT	DTT
DMMBWKL	MA	Inhibitor
DMMBWKL	RN	Antagonist, partial agonist, and full agonist imidazo[1,5-a]quinoxaline amides and carbamates acting through the GABAA/benzodiazepine receptor. J Med Chem. 1994 Mar 18;37(6):758-68.
DMMBWKL	RU	https://pubmed.ncbi.nlm.nih.gov/8145225

DMMBWKL	DI	DMMBWKL
DMMBWKL	DN	[3H]Ro154513
DMMBWKL	MI	TTEX6LM
DMMBWKL	MN	GABA(A) receptor gamma-3 (GABRG3)
DMMBWKL	MT	DTT
DMMBWKL	MA	Modulator (allosteric modulator)
DMMBWKL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415).
DMMBWKL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415

DMMBWKL	DI	DMMBWKL
DMMBWKL	DN	[3H]Ro154513
DMMBWKL	MI	TTNJYV2
DMMBWKL	MN	Gamma-aminobutyric acid receptor (GAR)
DMMBWKL	MT	DTT
DMMBWKL	MA	Inhibitor
DMMBWKL	RN	Synthesis and pharmacological properties of novel 8-substituted imidazobenzodiazepines: high-affinity, selective probes for alpha 5-containing GABA... J Med Chem. 1996 Apr 26;39(9):1928-34.
DMMBWKL	RU	https://pubmed.ncbi.nlm.nih.gov/8627617

DMK1TRG	DI	DMK1TRG
DMK1TRG	DN	[3H]robalzotan
DMK1TRG	MI	TTSQIFT
DMK1TRG	MN	5-HT 1A receptor (HTR1A)
DMK1TRG	MT	DTT
DMK1TRG	MA	Antagonist
DMK1TRG	RN	Receptor binding characteristics of [3H]NAD-299, a new selective 5-HT1A receptor antagonist. Eur J Pharmacol. 1998 Nov 6;360(2-3):219-25.
DMK1TRG	RU	https://pubmed.ncbi.nlm.nih.gov/9851589

DM6IRN4	DI	DM6IRN4
DM6IRN4	DN	[3H]RX821002
DM6IRN4	MI	TTNGILX
DM6IRN4	MN	Adrenergic receptor alpha-1A (ADRA1A)
DM6IRN4	MT	DTT
DM6IRN4	MA	Inhibitor
DM6IRN4	RN	Alpha-adrenoreceptor reagents. 4. Resolution of some potent selective prejunctional alpha 2-adrenoreceptor antagonists. J Med Chem. 1986 Oct;29(10):2000-3.
DM6IRN4	RU	https://pubmed.ncbi.nlm.nih.gov/2876101

DM6IRN4	DI	DM6IRN4
DM6IRN4	DN	[3H]RX821002
DM6IRN4	MI	TTBRKXS
DM6IRN4	MN	Adrenergic receptor alpha-1B (ADRA1B)
DM6IRN4	MT	DTT
DM6IRN4	MA	Inhibitor
DM6IRN4	RN	Alpha-adrenoreceptor reagents. 4. Resolution of some potent selective prejunctional alpha 2-adrenoreceptor antagonists. J Med Chem. 1986 Oct;29(10):2000-3.
DM6IRN4	RU	https://pubmed.ncbi.nlm.nih.gov/2876101

DM6IRN4	DI	DM6IRN4
DM6IRN4	DN	[3H]RX821002
DM6IRN4	MI	TT34BHT
DM6IRN4	MN	Adrenergic receptor alpha-1D (ADRA1D)
DM6IRN4	MT	DTT
DM6IRN4	MA	Inhibitor
DM6IRN4	RN	Alpha-adrenoreceptor reagents. 4. Resolution of some potent selective prejunctional alpha 2-adrenoreceptor antagonists. J Med Chem. 1986 Oct;29(10):2000-3.
DM6IRN4	RU	https://pubmed.ncbi.nlm.nih.gov/2876101

DM6IRN4	DI	DM6IRN4
DM6IRN4	DN	[3H]RX821002
DM6IRN4	MI	TTWG9A4
DM6IRN4	MN	Adrenergic receptor alpha-2A (ADRA2A)
DM6IRN4	MT	DTT
DM6IRN4	MA	Inhibitor
DM6IRN4	RN	Alpha-adrenoreceptor reagents. 4. Resolution of some potent selective prejunctional alpha 2-adrenoreceptor antagonists. J Med Chem. 1986 Oct;29(10):2000-3.
DM6IRN4	RU	https://pubmed.ncbi.nlm.nih.gov/2876101

DM6IRN4	DI	DM6IRN4
DM6IRN4	DN	[3H]RX821002
DM6IRN4	MI	TTWM4TY
DM6IRN4	MN	Adrenergic receptor alpha-2B (ADRA2B)
DM6IRN4	MT	DTT
DM6IRN4	MA	Antagonist
DM6IRN4	RN	Further characterization of human alpha 2-adrenoceptor subtypes: [3H]RX821002 binding and definition of additional selective drugs. Eur J Pharmacol. 1994 Jan 24;252(1):43-9.
DM6IRN4	RU	https://pubmed.ncbi.nlm.nih.gov/7908642

DM6IRN4	DI	DM6IRN4
DM6IRN4	DN	[3H]RX821002
DM6IRN4	MI	TT2NUT5
DM6IRN4	MN	Adrenergic receptor alpha-2C (ADRA2C)
DM6IRN4	MT	DTT
DM6IRN4	MA	Antagonist
DM6IRN4	RN	Further characterization of human alpha 2-adrenoceptor subtypes: [3H]RX821002 binding and definition of additional selective drugs. Eur J Pharmacol. 1994 Jan 24;252(1):43-9.
DM6IRN4	RU	https://pubmed.ncbi.nlm.nih.gov/7908642

DMJKWNY	DI	DMJKWNY
DMJKWNY	DN	[3H]RY80
DMJKWNY	MI	TTNZPQ1
DMJKWNY	MN	GABA(A) receptor alpha-5 (GABRA5)
DMJKWNY	MT	DTT
DMJKWNY	MA	Modulator
DMJKWNY	RN	[3H]RY 80: A high-affinity, selective ligand for gamma-aminobutyric acidA receptors containing alpha-5 subunits. J Pharmacol Exp Ther. 1997 Nov;283(2):488-93.
DMJKWNY	RU	https://pubmed.ncbi.nlm.nih.gov/9353361

DM32IAB	DI	DM32IAB
DM32IAB	DN	[3H]S0139
DM32IAB	MI	TTKRD0G
DM32IAB	MN	Endothelin A receptor (EDNRA)
DM32IAB	MT	DTT
DM32IAB	MA	Antagonist
DM32IAB	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 219).
DM32IAB	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=219

DMO9L38	DI	DMO9L38
DMO9L38	DN	[3H]SB-674042
DMO9L38	MI	TT60Q8D
DMO9L38	MN	Orexin receptor type 1 (HCRTR1)
DMO9L38	MT	DTT
DMO9L38	MA	Antagonist
DMO9L38	RN	Mapping the binding pocket of dual antagonist almorexant to human orexin 1 and orexin 2 receptors: comparison with the selective OX1 antagonist SB-674042 and the selective OX2 antagonist N-ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-N-pyridin-3-ylmethyl-acetamide (EMPA). Mol Pharmacol. 2010 Jul;78(1):81-93.
DMO9L38	RU	https://pubmed.ncbi.nlm.nih.gov/20404073

DMO9L38	DI	DMO9L38
DMO9L38	DN	[3H]SB-674042
DMO9L38	MI	TT9N02I
DMO9L38	MN	Orexin receptor type 2 (HCRTR2)
DMO9L38	MT	DTT
DMO9L38	MA	Antagonist
DMO9L38	RN	Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison ... Mol Pharmacol. 2009 Sep;76(3):618-31.
DMO9L38	RU	https://pubmed.ncbi.nlm.nih.gov/19542319

DMUS7EH	DI	DMUS7EH
DMUS7EH	DN	[3H]SB-733993
DMUS7EH	MI	TTHJTF7
DMUS7EH	MN	Glycine transporter GlyT-1 (SLC6A9)
DMUS7EH	MT	DTT
DMUS7EH	MA	Modulator
DMUS7EH	RN	Pharmacological characterisation of the GlyT-1 glycine transporter using two novel radioligands. Neuropharmacology. 2010 Nov;59(6):558-65.
DMUS7EH	RU	https://pubmed.ncbi.nlm.nih.gov/20691713

DM0MLU9	DI	DM0MLU9
DM0MLU9	DN	[3H]SNAP-7941
DM0MLU9	MI	TTX4RTB
DM0MLU9	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DM0MLU9	MT	DTT
DM0MLU9	MA	Antagonist
DM0MLU9	RN	Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist. Nat Med. 2002 Aug;8(8):825-30.
DM0MLU9	RU	https://pubmed.ncbi.nlm.nih.gov/12118247

DMWHEV8	DI	DMWHEV8
DMWHEV8	DN	[3H]spiperone
DMWHEV8	MI	TTSQIFT
DMWHEV8	MN	5-HT 1A receptor (HTR1A)
DMWHEV8	MT	DTT
DMWHEV8	MA	Inhibitor
DMWHEV8	RN	Synthesis of (R,S)-trans-8-hydroxy-2-[N-n-propyl-N-(3'-iodo-2'-propenyl)amino]tetral in (trans-8-OH-PIPAT): a new 5-HT1A receptor ligand. J Med Chem. 1993 Oct 15;36(21):3161-5.
DMWHEV8	RU	https://pubmed.ncbi.nlm.nih.gov/8230102

DMWHEV8	DI	DMWHEV8
DMWHEV8	DN	[3H]spiperone
DMWHEV8	MI	TTJQOD7
DMWHEV8	MN	5-HT 2A receptor (HTR2A)
DMWHEV8	MT	DTT
DMWHEV8	MA	Inhibitor
DMWHEV8	RN	Activity of Parthenolide at 5HT2A receptors. J Nat Prod. 1997 Jun;60(6):651-3.
DMWHEV8	RU	https://pubmed.ncbi.nlm.nih.gov/9214741

DMWHEV8	DI	DMWHEV8
DMWHEV8	DN	[3H]spiperone
DMWHEV8	MI	TTJS8PY
DMWHEV8	MN	5-HT 6 receptor (HTR6)
DMWHEV8	MT	DTT
DMWHEV8	MA	Inhibitor
DMWHEV8	RN	Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). J Med Chem. 2003 Jul 3;46(14):2795-812.
DMWHEV8	RU	https://pubmed.ncbi.nlm.nih.gov/12825922

DMWHEV8	DI	DMWHEV8
DMWHEV8	DN	[3H]spiperone
DMWHEV8	MI	TTO9X1H
DMWHEV8	MN	5-HT 7 receptor (HTR7)
DMWHEV8	MT	DTT
DMWHEV8	MA	Inhibitor
DMWHEV8	RN	Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). J Med Chem. 2003 Jul 3;46(14):2795-812.
DMWHEV8	RU	https://pubmed.ncbi.nlm.nih.gov/12825922

DMWHEV8	DI	DMWHEV8
DMWHEV8	DN	[3H]spiperone
DMWHEV8	MI	TTNGILX
DMWHEV8	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMWHEV8	MT	DTT
DMWHEV8	MA	Inhibitor
DMWHEV8	RN	Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
DMWHEV8	RU	https://pubmed.ncbi.nlm.nih.gov/15664832

DMWHEV8	DI	DMWHEV8
DMWHEV8	DN	[3H]spiperone
DMWHEV8	MI	TTEX248
DMWHEV8	MN	Dopamine D2 receptor (D2R)
DMWHEV8	MT	DTT
DMWHEV8	MA	Antagonist
DMWHEV8	RN	Regulation of human D(1), d(2(long)), d(2(short)), D(3) and D(4) dopamine receptors by amiloride and amiloride analogues. Br J Pharmacol. 2000 Jul;130(5):1045-59.
DMWHEV8	RU	https://pubmed.ncbi.nlm.nih.gov/10882389

DMWHEV8	DI	DMWHEV8
DMWHEV8	DN	[3H]spiperone
DMWHEV8	MI	TT4C8EA
DMWHEV8	MN	Dopamine D3 receptor (D3R)
DMWHEV8	MT	DTT
DMWHEV8	MA	Antagonist
DMWHEV8	RN	Regulation of human D(1), d(2(long)), d(2(short)), D(3) and D(4) dopamine receptors by amiloride and amiloride analogues. Br J Pharmacol. 2000 Jul;130(5):1045-59.
DMWHEV8	RU	https://pubmed.ncbi.nlm.nih.gov/10882389

DMWHEV8	DI	DMWHEV8
DMWHEV8	DN	[3H]spiperone
DMWHEV8	MI	TTE0A2F
DMWHEV8	MN	Dopamine D4 receptor (D4R)
DMWHEV8	MT	DTT
DMWHEV8	MA	Antagonist
DMWHEV8	RN	Differential effects of [3H]nemonapride and [3H]spiperone binding on human dopamine D4 receptors. Neurosci Lett. 1995 Feb 17;186(2-3):145-8.
DMWHEV8	RU	https://pubmed.ncbi.nlm.nih.gov/7777184

DMWHEV8	DI	DMWHEV8
DMWHEV8	DN	[3H]spiperone
DMWHEV8	MI	DTUGYRD
DMWHEV8	MN	P-glycoprotein 1 (ABCB1)
DMWHEV8	MT	DTP
DMWHEV8	MA	Substrate
DMWHEV8	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMWHEV8	RU	https://doi.org/10.1007/s11095-012-0935-x

DM0Y2SC	DI	DM0Y2SC
DM0Y2SC	DN	[3H]strychnine
DM0Y2SC	MI	TTZ8EM9
DM0Y2SC	MN	Glycine receptor (GlyR)
DM0Y2SC	MT	DTT
DM0Y2SC	MA	Antagonist
DM0Y2SC	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 425).
DM0Y2SC	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=425

DM0Y2SC	DI	DM0Y2SC
DM0Y2SC	DN	[3H]strychnine
DM0Y2SC	MI	TTF45NW
DM0Y2SC	MN	Strychnine-binding glycine receptor (GLRA1)
DM0Y2SC	MT	DTT
DM0Y2SC	MA	Inhibitor
DM0Y2SC	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DM0Y2SC	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DM3MBGV	DI	DM3MBGV
DM3MBGV	DN	[3H]sumatriptan
DM3MBGV	MI	TTK8CXU
DM3MBGV	MN	5-HT 1B receptor (HTR1B)
DM3MBGV	MT	DTT
DM3MBGV	MA	Agonist
DM3MBGV	RN	Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur J Pharmacol. 1999 Mar 5;368(2-3):259-68.
DM3MBGV	RU	https://pubmed.ncbi.nlm.nih.gov/10193663

DM3MBGV	DI	DM3MBGV
DM3MBGV	DN	[3H]sumatriptan
DM3MBGV	MI	TT6MSOK
DM3MBGV	MN	5-HT 1D receptor (HTR1D)
DM3MBGV	MT	DTT
DM3MBGV	MA	Agonist
DM3MBGV	RN	Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur J Pharmacol. 1999 Mar 5;368(2-3):259-68.
DM3MBGV	RU	https://pubmed.ncbi.nlm.nih.gov/10193663

DMSHW2E	DI	DMSHW2E
DMSHW2E	DN	[3H]thiamine
DMSHW2E	MI	TT2A1DZ
DMSHW2E	MN	Solute carrier family 19 member 2 (SLC19A2)
DMSHW2E	MT	DTT
DMSHW2E	MA	Modulator
DMSHW2E	RN	Cloning of the human thiamine transporter, a member of the folate transporter family. J Biol Chem. 1999 Nov 5;274(45):31925-9.
DMSHW2E	RU	https://pubmed.ncbi.nlm.nih.gov/10542220

DMSHW2E	DI	DMSHW2E
DMSHW2E	DN	[3H]thiamine
DMSHW2E	MI	TT9BTWM
DMSHW2E	MN	Solute carrier family 19 member 3 (SLC19A3)
DMSHW2E	MT	DTT
DMSHW2E	MA	Modulator
DMSHW2E	RN	SLC19A3 encodes a second thiamine transporter ThTr2. Biochim Biophys Acta. 2001 Nov 29;1537(3):175-8.
DMSHW2E	RU	https://pubmed.ncbi.nlm.nih.gov/11731220

DM6RSZ9	DI	DM6RSZ9
DM6RSZ9	DN	[3H]U69593
DM6RSZ9	MI	TTQW87Y
DM6RSZ9	MN	Opioid receptor kappa (OPRK1)
DM6RSZ9	MT	DTT
DM6RSZ9	MA	Agonist
DM6RSZ9	RN	[3H]U-69593 a highly selective ligand for the opioid kappa receptor. Eur J Pharmacol. 1985 Feb 26;109(2):281-4.
DM6RSZ9	RU	https://pubmed.ncbi.nlm.nih.gov/2986999

DM6RSZ9	DI	DM6RSZ9
DM6RSZ9	DN	[3H]U69593
DM6RSZ9	MI	TTKWM86
DM6RSZ9	MN	Opioid receptor mu (MOP)
DM6RSZ9	MT	DTT
DM6RSZ9	MA	Inhibitor
DM6RSZ9	RN	Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5.
DM6RSZ9	RU	https://pubmed.ncbi.nlm.nih.gov/16777416

DM3MK8S	DI	DM3MK8S
DM3MK8S	DN	[3H]vesamicol
DM3MK8S	MI	TTV8KWS
DM3MK8S	MN	Vesicular acetylcholine transporter (SLC18A3)
DM3MK8S	MT	DTT
DM3MK8S	MA	Modulator
DM3MK8S	RN	Active transport of acetylcholine by the human vesicular acetylcholine transporter. J Biol Chem. 1996 Nov 1;271(44):27229-32.
DM3MK8S	RU	https://pubmed.ncbi.nlm.nih.gov/8910293

DMI8RU0	DI	DMI8RU0
DMI8RU0	DN	[3H]WIN35428
DMI8RU0	MI	TTVBI8W
DMI8RU0	MN	Dopamine transporter (DAT)
DMI8RU0	MT	DTT
DMI8RU0	MA	Inhibitor
DMI8RU0	RN	Pharmacological heterogeneity of the cloned and native human dopamine transporter: disassociation of [3H]WIN 35,428 and [3H]GBR 12,935 binding. Mol Pharmacol. 1994 Jan;45(1):125-35.
DMI8RU0	RU	https://pubmed.ncbi.nlm.nih.gov/8302271

DMI8RU0	DI	DMI8RU0
DMI8RU0	DN	[3H]WIN35428
DMI8RU0	MI	TTAWNKZ
DMI8RU0	MN	Norepinephrine transporter (NET)
DMI8RU0	MT	DTT
DMI8RU0	MA	Inhibitor
DMI8RU0	RN	3 alpha-(4'-substituted phenyl)tropane-2 beta-carboxylic acid methyl esters: novel ligands with high affinity and selectivity at the dopamine trans... J Med Chem. 1996 Oct 11;39(21):4139-41.
DMI8RU0	RU	https://pubmed.ncbi.nlm.nih.gov/8863789

DMI8RU0	DI	DMI8RU0
DMI8RU0	DN	[3H]WIN35428
DMI8RU0	MI	TT3ROYC
DMI8RU0	MN	Serotonin transporter (SERT)
DMI8RU0	MT	DTT
DMI8RU0	MA	Inhibitor
DMI8RU0	RN	3 alpha-(4'-substituted phenyl)tropane-2 beta-carboxylic acid methyl esters: novel ligands with high affinity and selectivity at the dopamine trans... J Med Chem. 1996 Oct 11;39(21):4139-41.
DMI8RU0	RU	https://pubmed.ncbi.nlm.nih.gov/8863789

DM0TRAZ	DI	DM0TRAZ
DM0TRAZ	DN	[3H]WIN55212-2
DM0TRAZ	MI	TT6OEDT
DM0TRAZ	MN	Cannabinoid receptor 1 (CB1)
DM0TRAZ	MT	DTT
DM0TRAZ	MA	Agonist
DM0TRAZ	RN	Ligand binding and modulation of cyclic AMP levels depend on the chemical nature of residue 192 of the human cannabinoid receptor 1. J Neurochem. 1998 Jan;70(1):366-73.
DM0TRAZ	RU	https://pubmed.ncbi.nlm.nih.gov/9422383

DM0TRAZ	DI	DM0TRAZ
DM0TRAZ	DN	[3H]WIN55212-2
DM0TRAZ	MI	TTMSFAW
DM0TRAZ	MN	Cannabinoid receptor 2 (CB2)
DM0TRAZ	MT	DTT
DM0TRAZ	MA	Agonist
DM0TRAZ	RN	Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase. Mol Pharmacol. 1995 Aug;48(2):352-61.
DM0TRAZ	RU	https://pubmed.ncbi.nlm.nih.gov/7651369

DMKU4YQ	DI	DMKU4YQ
DMKU4YQ	DN	[3H]ZM 241385
DMKU4YQ	MI	TTNE7KG
DMKU4YQ	MN	Adenosine A2b receptor (ADORA2B)
DMKU4YQ	MT	DTT
DMKU4YQ	MA	Antagonist
DMKU4YQ	RN	Use of the triazolotriazine [3H]ZM 241385 as a radioligand at recombinant human A2B adenosine receptors. Drug Des Discov. 1999 Nov;16(3):217-26.
DMKU4YQ	RU	https://pubmed.ncbi.nlm.nih.gov/10624567

DMNCAE9	DI	DMNCAE9
DMNCAE9	DN	[4-(3-Adamantan-1-yl-ureido)-phenyl]-acetic acid
DMNCAE9	MI	TT7WVHI
DMNCAE9	MN	Soluble epoxide hydrolase (EPHX2)
DMNCAE9	MT	DTT
DMNCAE9	MA	Inhibitor
DMNCAE9	RN	Salicylate-urea-based soluble epoxide hydrolase inhibitors with high metabolic and chemical stabilities. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1784-9.
DMNCAE9	RU	https://pubmed.ncbi.nlm.nih.gov/19216074

DM7JSQL	DI	DM7JSQL
DM7JSQL	DN	[4',4''']-biflavone
DM7JSQL	MI	TTT1JVS
DM7JSQL	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DM7JSQL	MT	DTT
DM7JSQL	MA	Inhibitor
DM7JSQL	RN	Inhibitory effect of synthetic C-C biflavones on various phospholipase A(2)s activity. Bioorg Med Chem. 2007 Nov 15;15(22):7138-43.
DM7JSQL	RU	https://pubmed.ncbi.nlm.nih.gov/17826099

DM86Z4H	DI	DM86Z4H
DM86Z4H	DN	[4Aph(CO-(C2H4O)3-C2H4-NH-CO-NH-OCH3)5]degarelix
DM86Z4H	MI	TT8R70G
DM86Z4H	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DM86Z4H	MT	DTT
DM86Z4H	MA	Inhibitor
DM86Z4H	RN	Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III. J Med Chem. 2006 Jun 15;49(12):3536-43.
DM86Z4H	RU	https://pubmed.ncbi.nlm.nih.gov/16759096

DM4IXJA	DI	DM4IXJA
DM4IXJA	DN	[4Aph(CO-NH-(C2H4O)2-C2H5)5]degarelix
DM4IXJA	MI	TT8R70G
DM4IXJA	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DM4IXJA	MT	DTT
DM4IXJA	MA	Inhibitor
DM4IXJA	RN	Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III. J Med Chem. 2006 Jun 15;49(12):3536-43.
DM4IXJA	RU	https://pubmed.ncbi.nlm.nih.gov/16759096

DM57TIU	DI	DM57TIU
DM57TIU	DN	[4Aph(CO-NH-OCH3)5,D-4Aph(CO-NH-OCH3)6]degarelix
DM57TIU	MI	TT8R70G
DM57TIU	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DM57TIU	MT	DTT
DM57TIU	MA	Inhibitor
DM57TIU	RN	Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III. J Med Chem. 2006 Jun 15;49(12):3536-43.
DM57TIU	RU	https://pubmed.ncbi.nlm.nih.gov/16759096

DM6C8K1	DI	DM6C8K1
DM6C8K1	DN	[4Aph(CO-NH-OCH3)5]degarelix
DM6C8K1	MI	TT8R70G
DM6C8K1	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DM6C8K1	MT	DTT
DM6C8K1	MA	Inhibitor
DM6C8K1	RN	Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III. J Med Chem. 2006 Jun 15;49(12):3536-43.
DM6C8K1	RU	https://pubmed.ncbi.nlm.nih.gov/16759096

DMFMB31	DI	DMFMB31
DMFMB31	DN	[4Aph(CO-NH-OH)5]degarelix
DMFMB31	MI	TT8R70G
DMFMB31	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMFMB31	MT	DTT
DMFMB31	MA	Inhibitor
DMFMB31	RN	Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III. J Med Chem. 2006 Jun 15;49(12):3536-43.
DMFMB31	RU	https://pubmed.ncbi.nlm.nih.gov/16759096

DMA9PW7	DI	DMA9PW7
DMA9PW7	DN	[6,3''']biflavone
DMA9PW7	MI	TTT1JVS
DMA9PW7	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DMA9PW7	MT	DTT
DMA9PW7	MA	Inhibitor
DMA9PW7	RN	Inhibitory effect of synthetic C-C biflavones on various phospholipase A(2)s activity. Bioorg Med Chem. 2007 Nov 15;15(22):7138-43.
DMA9PW7	RU	https://pubmed.ncbi.nlm.nih.gov/17826099

DMVOX4L	DI	DMVOX4L
DMVOX4L	DN	[6,4''']biflavone
DMVOX4L	MI	TTT1JVS
DMVOX4L	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DMVOX4L	MT	DTT
DMVOX4L	MA	Inhibitor
DMVOX4L	RN	Inhibitory effect of synthetic C-C biflavones on various phospholipase A(2)s activity. Bioorg Med Chem. 2007 Nov 15;15(22):7138-43.
DMVOX4L	RU	https://pubmed.ncbi.nlm.nih.gov/17826099

DMUCAXT	DI	DMUCAXT
DMUCAXT	DN	[Aib7]OT
DMUCAXT	MI	TTSCIUP
DMUCAXT	MN	Oxytocin receptor (OTR)
DMUCAXT	MT	DTT
DMUCAXT	MA	Inhibitor
DMUCAXT	RN	Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7. Eur J Med Chem. 2007 Jun;42(6):799-806.
DMUCAXT	RU	https://pubmed.ncbi.nlm.nih.gov/17316912

DMHJEQL	DI	DMHJEQL
DMHJEQL	DN	[Asp6,Lys10]N/OFQ(1-13)NH2
DMHJEQL	MI	TTNT7K8
DMHJEQL	MN	Nociceptin receptor (OPRL1)
DMHJEQL	MT	DTT
DMHJEQL	MA	Inhibitor
DMHJEQL	RN	High affinity conformationally constrained nociceptin/orphanin FQ(1-13) amide analogues. J Med Chem. 2008 Aug 14;51(15):4385-7.
DMHJEQL	RU	https://pubmed.ncbi.nlm.nih.gov/18624395

DMN70VT	DI	DMN70VT
DMN70VT	DN	[Au(CN)2]-
DMN70VT	MI	TTHQPL7
DMN70VT	MN	Carbonic anhydrase I (CA-I)
DMN70VT	MT	DTT
DMN70VT	MA	Inhibitor
DMN70VT	RN	Carbonic anhydrase inhibitors. Inhibition of isozymes I, II, IV, V and IX with complex fluorides, chlorides and cyanides. Bioorg Med Chem Lett. 2005 Apr 1;15(7):1909-13.
DMN70VT	RU	https://pubmed.ncbi.nlm.nih.gov/15780631

DMB78GP	DI	DMB78GP
DMB78GP	DN	[Bpa1]AngII
DMB78GP	MI	TT8DBY3
DMB78GP	MN	Angiotensin II receptor type-1 (AGTR1)
DMB78GP	MT	DTT
DMB78GP	MA	Inhibitor
DMB78GP	RN	The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1. J Med Chem. 2010 Mar 11;53(5):2063-75.
DMB78GP	RU	https://pubmed.ncbi.nlm.nih.gov/20146480

DMV6NP1	DI	DMV6NP1
DMV6NP1	DN	[Cu(CN)2]-
DMV6NP1	MI	TTHQPL7
DMV6NP1	MN	Carbonic anhydrase I (CA-I)
DMV6NP1	MT	DTT
DMV6NP1	MA	Inhibitor
DMV6NP1	RN	Carbonic anhydrase inhibitors. Inhibition of isozymes I, II, IV, V and IX with complex fluorides, chlorides and cyanides. Bioorg Med Chem Lett. 2005 Apr 1;15(7):1909-13.
DMV6NP1	RU	https://pubmed.ncbi.nlm.nih.gov/15780631

DMV6NP1	DI	DMV6NP1
DMV6NP1	DN	[Cu(CN)2]-
DMV6NP1	MI	TTZHA0O
DMV6NP1	MN	Carbonic anhydrase IV (CA-IV)
DMV6NP1	MT	DTT
DMV6NP1	MA	Inhibitor
DMV6NP1	RN	Carbonic anhydrase inhibitors. Inhibition of isozymes I, II, IV, V and IX with complex fluorides, chlorides and cyanides. Bioorg Med Chem Lett. 2005 Apr 1;15(7):1909-13.
DMV6NP1	RU	https://pubmed.ncbi.nlm.nih.gov/15780631

DMQ8CD3	DI	DMQ8CD3
DMQ8CD3	DN	[Cyclopentyl-(2-nitro-benzoyl)-amino]-acetic acid
DMQ8CD3	MI	TTL69WB
DMQ8CD3	MN	Angiotensin-converting enzyme (ACE)
DMQ8CD3	MT	DTT
DMQ8CD3	MA	Inhibitor
DMQ8CD3	RN	Angiotensin converting enzyme inhibitors. (Mercaptoaroyl)amino acids. J Med Chem. 1985 Mar;28(3):328-32.
DMQ8CD3	RU	https://pubmed.ncbi.nlm.nih.gov/2983075

DMWFGBC	DI	DMWFGBC
DMWFGBC	DN	[Cys-Trp-Arg-Nva-Arg-Tyr-NH2]2
DMWFGBC	MI	TTRK9JT
DMWFGBC	MN	Neuropeptide Y receptor type 1 (NPY1R)
DMWFGBC	MT	DTT
DMWFGBC	MA	Inhibitor
DMWFGBC	RN	Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5.
DMWFGBC	RU	https://pubmed.ncbi.nlm.nih.gov/16610810

DMWFGBC	DI	DMWFGBC
DMWFGBC	DN	[Cys-Trp-Arg-Nva-Arg-Tyr-NH2]2
DMWFGBC	MI	TTW4N16
DMWFGBC	MN	Neuropeptide Y receptor type 4 (NPY4R)
DMWFGBC	MT	DTT
DMWFGBC	MA	Inhibitor
DMWFGBC	RN	Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5.
DMWFGBC	RU	https://pubmed.ncbi.nlm.nih.gov/16610810

DMFKTJ8	DI	DMFKTJ8
DMFKTJ8	DN	[D-4Aph(CO-NH-(C2H4O)2-C2H5)6]degarelix
DMFKTJ8	MI	TT8R70G
DMFKTJ8	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMFKTJ8	MT	DTT
DMFKTJ8	MA	Inhibitor
DMFKTJ8	RN	Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III. J Med Chem. 2006 Jun 15;49(12):3536-43.
DMFKTJ8	RU	https://pubmed.ncbi.nlm.nih.gov/16759096

DMR7TEQ	DI	DMR7TEQ
DMR7TEQ	DN	[D-4Aph(CO-NH-OCH3)6]degarelix
DMR7TEQ	MI	TT8R70G
DMR7TEQ	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMR7TEQ	MT	DTT
DMR7TEQ	MA	Inhibitor
DMR7TEQ	RN	Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III. J Med Chem. 2006 Jun 15;49(12):3536-43.
DMR7TEQ	RU	https://pubmed.ncbi.nlm.nih.gov/16759096

DMMVIX7	DI	DMMVIX7
DMMVIX7	DN	[D-4Aph(CO-NH-OH)6]degarelix
DMMVIX7	MI	TT8R70G
DMMVIX7	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMMVIX7	MT	DTT
DMMVIX7	MA	Inhibitor
DMMVIX7	RN	Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III. J Med Chem. 2006 Jun 15;49(12):3536-43.
DMMVIX7	RU	https://pubmed.ncbi.nlm.nih.gov/16759096

DM18ZNJ	DI	DM18ZNJ
DM18ZNJ	DN	[D-Ala2]Met-enkephalinamide
DM18ZNJ	MI	TTKWM86
DM18ZNJ	MN	Opioid receptor mu (MOP)
DM18ZNJ	MT	DTT
DM18ZNJ	MA	Inhibitor
DM18ZNJ	RN	Synthesis and biological evaluation of a metazocine-containing enkephalinamide. Evidence for nonidentical roles of the tyramine moiety in opiates a... J Med Chem. 1982 Dec;25(12):1423-7.
DM18ZNJ	RU	https://pubmed.ncbi.nlm.nih.gov/7154002

DMSGW51	DI	DMSGW51
DMSGW51	DN	[D-Asp7,Lys10]N/OFQ(1-13)NH2
DMSGW51	MI	TTNT7K8
DMSGW51	MN	Nociceptin receptor (OPRL1)
DMSGW51	MT	DTT
DMSGW51	MA	Inhibitor
DMSGW51	RN	High affinity conformationally constrained nociceptin/orphanin FQ(1-13) amide analogues. J Med Chem. 2008 Aug 14;51(15):4385-7.
DMSGW51	RU	https://pubmed.ncbi.nlm.nih.gov/18624395

DM23GCK	DI	DM23GCK
DM23GCK	DN	[Dcp1]Dyn A(1-11)-NH2
DM23GCK	MI	TT27RFC
DM23GCK	MN	Opioid receptor delta (OPRD1)
DM23GCK	MT	DTT
DM23GCK	MA	Inhibitor
DM23GCK	RN	Replacement of the N-terminal tyrosine residue in opioid peptides with 3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid (Dcp) results in novel opio... J Med Chem. 2006 Aug 24;49(17):5382-5.
DM23GCK	RU	https://pubmed.ncbi.nlm.nih.gov/16913729

DM23GCK	DI	DM23GCK
DM23GCK	DN	[Dcp1]Dyn A(1-11)-NH2
DM23GCK	MI	TTQW87Y
DM23GCK	MN	Opioid receptor kappa (OPRK1)
DM23GCK	MT	DTT
DM23GCK	MA	Inhibitor
DM23GCK	RN	Replacement of the N-terminal tyrosine residue in opioid peptides with 3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid (Dcp) results in novel opio... J Med Chem. 2006 Aug 24;49(17):5382-5.
DM23GCK	RU	https://pubmed.ncbi.nlm.nih.gov/16913729

DM23GCK	DI	DM23GCK
DM23GCK	DN	[Dcp1]Dyn A(1-11)-NH2
DM23GCK	MI	TTKWM86
DM23GCK	MN	Opioid receptor mu (MOP)
DM23GCK	MT	DTT
DM23GCK	MA	Inhibitor
DM23GCK	RN	Replacement of the N-terminal tyrosine residue in opioid peptides with 3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid (Dcp) results in novel opio... J Med Chem. 2006 Aug 24;49(17):5382-5.
DM23GCK	RU	https://pubmed.ncbi.nlm.nih.gov/16913729

DMEZKX0	DI	DMEZKX0
DMEZKX0	DN	[D-Dab(CO-NH-OCH3)3]degarelix
DMEZKX0	MI	TT8R70G
DMEZKX0	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMEZKX0	MT	DTT
DMEZKX0	MA	Inhibitor
DMEZKX0	RN	Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III. J Med Chem. 2006 Jun 15;49(12):3536-43.
DMEZKX0	RU	https://pubmed.ncbi.nlm.nih.gov/16759096

DMRVPN1	DI	DMRVPN1
DMRVPN1	DN	[D-Dab(CO-NH-OH)3]degarelix
DMRVPN1	MI	TT8R70G
DMRVPN1	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMRVPN1	MT	DTT
DMRVPN1	MA	Inhibitor
DMRVPN1	RN	Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III. J Med Chem. 2006 Jun 15;49(12):3536-43.
DMRVPN1	RU	https://pubmed.ncbi.nlm.nih.gov/16759096

DM5ZR4S	DI	DM5ZR4S
DM5ZR4S	DN	[D-Dap(CO-NH-OCH3)3]degarelix
DM5ZR4S	MI	TT8R70G
DM5ZR4S	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DM5ZR4S	MT	DTT
DM5ZR4S	MA	Inhibitor
DM5ZR4S	RN	Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III. J Med Chem. 2006 Jun 15;49(12):3536-43.
DM5ZR4S	RU	https://pubmed.ncbi.nlm.nih.gov/16759096

DMS0LFT	DI	DMS0LFT
DMS0LFT	DN	[D-Dap(CO-NH-OH)3]degarelix
DMS0LFT	MI	TT8R70G
DMS0LFT	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMS0LFT	MT	DTT
DMS0LFT	MA	Inhibitor
DMS0LFT	RN	Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III. J Med Chem. 2006 Jun 15;49(12):3536-43.
DMS0LFT	RU	https://pubmed.ncbi.nlm.nih.gov/16759096

DMEL0SZ	DI	DMEL0SZ
DMEL0SZ	DN	[des-Arg9]bradykinin
DMEL0SZ	MI	TTGY8IW
DMEL0SZ	MN	B2 bradykinin receptor (BDKRB2)
DMEL0SZ	MT	DTT
DMEL0SZ	MA	Agonist
DMEL0SZ	RN	Stable expression of human kinin B1 receptor in 293 cells: pharmacological and functional characterization. Br J Pharmacol. 1997 Sep;122(2):393-9.
DMEL0SZ	RU	https://pubmed.ncbi.nlm.nih.gov/9313952

DM1EPZB	DI	DM1EPZB
DM1EPZB	DN	[des-His1,Tyr5,Glu9,D-Ala10]glucagon-NH2
DM1EPZB	MI	TT9O6WS
DM1EPZB	MN	Glucagon receptor (GCGR)
DM1EPZB	MT	DTT
DM1EPZB	MA	Inhibitor
DM1EPZB	RN	Topographical amino acid substitution in position 10 of glucagon leads to antagonists/partial agonists with greater binding differences. J Med Chem. 1996 Jun 21;39(13):2449-55.
DM1EPZB	RU	https://pubmed.ncbi.nlm.nih.gov/8691441

DM06Q2V	DI	DM06Q2V
DM06Q2V	DN	[des-His1,Tyr5,Glu9,D-Phe10]glucagon-NH2
DM06Q2V	MI	TT9O6WS
DM06Q2V	MN	Glucagon receptor (GCGR)
DM06Q2V	MT	DTT
DM06Q2V	MA	Inhibitor
DM06Q2V	RN	Topographical amino acid substitution in position 10 of glucagon leads to antagonists/partial agonists with greater binding differences. J Med Chem. 1996 Jun 21;39(13):2449-55.
DM06Q2V	RU	https://pubmed.ncbi.nlm.nih.gov/8691441

DMFLVED	DI	DMFLVED
DMFLVED	DN	[des-His1,Tyr5,Glu9,D-Tyr10]glucagon-NH2
DMFLVED	MI	TT9O6WS
DMFLVED	MN	Glucagon receptor (GCGR)
DMFLVED	MT	DTT
DMFLVED	MA	Inhibitor
DMFLVED	RN	Topographical amino acid substitution in position 10 of glucagon leads to antagonists/partial agonists with greater binding differences. J Med Chem. 1996 Jun 21;39(13):2449-55.
DMFLVED	RU	https://pubmed.ncbi.nlm.nih.gov/8691441

DM93I0B	DI	DM93I0B
DM93I0B	DN	[des-His1,Tyr5,Glu9]glucagon-NH2
DM93I0B	MI	TT9O6WS
DM93I0B	MN	Glucagon receptor (GCGR)
DM93I0B	MT	DTT
DM93I0B	MA	Inhibitor
DM93I0B	RN	Topographical amino acid substitution in position 10 of glucagon leads to antagonists/partial agonists with greater binding differences. J Med Chem. 1996 Jun 21;39(13):2449-55.
DM93I0B	RU	https://pubmed.ncbi.nlm.nih.gov/8691441

DMP1D7Q	DI	DMP1D7Q
DMP1D7Q	DN	[D-Gln3,D-Ncy(isopropyl)7]acyline
DMP1D7Q	MI	TT8R70G
DMP1D7Q	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMP1D7Q	MT	DTT
DMP1D7Q	MA	Inhibitor
DMP1D7Q	RN	Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77.
DMP1D7Q	RU	https://pubmed.ncbi.nlm.nih.gov/17402723

DMFAX1Q	DI	DMFAX1Q
DMFAX1Q	DN	[D-Gln3,D-Ncy(SO,isopropyl)7]acyline
DMFAX1Q	MI	TT8R70G
DMFAX1Q	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMFAX1Q	MT	DTT
DMFAX1Q	MA	Inhibitor
DMFAX1Q	RN	Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77.
DMFAX1Q	RU	https://pubmed.ncbi.nlm.nih.gov/17402723

DM3H0CX	DI	DM3H0CX
DM3H0CX	DN	[D-Gln3,D-Ncy(SO2,isopropyl)7]acyline
DM3H0CX	MI	TT8R70G
DM3H0CX	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DM3H0CX	MT	DTT
DM3H0CX	MA	Inhibitor
DM3H0CX	RN	Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77.
DM3H0CX	RU	https://pubmed.ncbi.nlm.nih.gov/17402723

DMMEQ3R	DI	DMMEQ3R
DMMEQ3R	DN	[D-Gln3,Ncy(isopropyl)7]acyline
DMMEQ3R	MI	TT8R70G
DMMEQ3R	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMMEQ3R	MT	DTT
DMMEQ3R	MA	Inhibitor
DMMEQ3R	RN	Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77.
DMMEQ3R	RU	https://pubmed.ncbi.nlm.nih.gov/17402723

DM2QDXW	DI	DM2QDXW
DM2QDXW	DN	[D-Gln3,Ncy(SO,isopropyl)7]acyline
DM2QDXW	MI	TT8R70G
DM2QDXW	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DM2QDXW	MT	DTT
DM2QDXW	MA	Inhibitor
DM2QDXW	RN	Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77.
DM2QDXW	RU	https://pubmed.ncbi.nlm.nih.gov/17402723

DMJSCO7	DI	DMJSCO7
DMJSCO7	DN	[D-Gln3,Ncy(SO2,isopropyl)7]acyline
DMJSCO7	MI	TT8R70G
DMJSCO7	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMJSCO7	MT	DTT
DMJSCO7	MA	Inhibitor
DMJSCO7	RN	Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77.
DMJSCO7	RU	https://pubmed.ncbi.nlm.nih.gov/17402723

DMAFNTL	DI	DMAFNTL
DMAFNTL	DN	[D-Ncy(2-naphthyl)1]acyline
DMAFNTL	MI	TT8R70G
DMAFNTL	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMAFNTL	MT	DTT
DMAFNTL	MA	Inhibitor
DMAFNTL	RN	Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77.
DMAFNTL	RU	https://pubmed.ncbi.nlm.nih.gov/17402723

DMVBTAM	DI	DMVBTAM
DMVBTAM	DN	[D-Ncy(isopropyl)7]acyline
DMVBTAM	MI	TT8R70G
DMVBTAM	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMVBTAM	MT	DTT
DMVBTAM	MA	Inhibitor
DMVBTAM	RN	Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77.
DMVBTAM	RU	https://pubmed.ncbi.nlm.nih.gov/17402723

DM9TORW	DI	DM9TORW
DM9TORW	DN	[D-Ncy(methyl)10] acyline
DM9TORW	MI	TT8R70G
DM9TORW	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DM9TORW	MT	DTT
DM9TORW	MA	Inhibitor
DM9TORW	RN	Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77.
DM9TORW	RU	https://pubmed.ncbi.nlm.nih.gov/17402723

DM63FN5	DI	DM63FN5
DM63FN5	DN	[D-Ncy(methyl)4]acyline
DM63FN5	MI	TT8R70G
DM63FN5	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DM63FN5	MT	DTT
DM63FN5	MA	Inhibitor
DM63FN5	RN	Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77.
DM63FN5	RU	https://pubmed.ncbi.nlm.nih.gov/17402723

DME9AN4	DI	DME9AN4
DME9AN4	DN	[D-Ncy(SO,isopropyl)7]acyline
DME9AN4	MI	TT8R70G
DME9AN4	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DME9AN4	MT	DTT
DME9AN4	MA	Inhibitor
DME9AN4	RN	Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77.
DME9AN4	RU	https://pubmed.ncbi.nlm.nih.gov/17402723

DMT2X98	DI	DMT2X98
DMT2X98	DN	[D-Ncy(SO,methyl)10]acyline
DMT2X98	MI	TT8R70G
DMT2X98	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMT2X98	MT	DTT
DMT2X98	MA	Inhibitor
DMT2X98	RN	Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77.
DMT2X98	RU	https://pubmed.ncbi.nlm.nih.gov/17402723

DM6HEXG	DI	DM6HEXG
DM6HEXG	DN	[D-Ncy(SO,methyl)4]acyline
DM6HEXG	MI	TT8R70G
DM6HEXG	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DM6HEXG	MT	DTT
DM6HEXG	MA	Inhibitor
DM6HEXG	RN	Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77.
DM6HEXG	RU	https://pubmed.ncbi.nlm.nih.gov/17402723

DME8W3R	DI	DME8W3R
DME8W3R	DN	[D-Tic7]OT
DME8W3R	MI	TTSCIUP
DME8W3R	MN	Oxytocin receptor (OTR)
DME8W3R	MT	DTT
DME8W3R	MA	Inhibitor
DME8W3R	RN	Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7. Eur J Med Chem. 2007 Jun;42(6):799-806.
DME8W3R	RU	https://pubmed.ncbi.nlm.nih.gov/17316912

DMWGADP	DI	DMWGADP
DMWGADP	DN	[Fe(CN)6]4-
DMWGADP	MI	TTZHA0O
DMWGADP	MN	Carbonic anhydrase IV (CA-IV)
DMWGADP	MT	DTT
DMWGADP	MA	Inhibitor
DMWGADP	RN	Carbonic anhydrase inhibitors. Inhibition of isozymes I, II, IV, V and IX with complex fluorides, chlorides and cyanides. Bioorg Med Chem Lett. 2005 Apr 1;15(7):1909-13.
DMWGADP	RU	https://pubmed.ncbi.nlm.nih.gov/15780631

DMZM3GB	DI	DMZM3GB
DMZM3GB	DN	[Gly(But)7]OT
DMZM3GB	MI	TTSCIUP
DMZM3GB	MN	Oxytocin receptor (OTR)
DMZM3GB	MT	DTT
DMZM3GB	MA	Inhibitor
DMZM3GB	RN	Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7. Eur J Med Chem. 2007 Jun;42(6):799-806.
DMZM3GB	RU	https://pubmed.ncbi.nlm.nih.gov/17316912

DM9SP2U	DI	DM9SP2U
DM9SP2U	DN	[Gly8, aib22]GLP-1(7-37)-NH2
DM9SP2U	MI	TTVIMDE
DM9SP2U	MN	Glucagon-like peptide 1 receptor (GLP1R)
DM9SP2U	MT	DTT
DM9SP2U	MA	Inhibitor
DM9SP2U	RN	Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo acti... J Med Chem. 2008 May 8;51(9):2758-65.
DM9SP2U	RU	https://pubmed.ncbi.nlm.nih.gov/18412318

DMO8U3S	DI	DMO8U3S
DMO8U3S	DN	[Gly8,Glu22]GLP-1(7,37)-NH2
DMO8U3S	MI	TTVIMDE
DMO8U3S	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMO8U3S	MT	DTT
DMO8U3S	MA	Inhibitor
DMO8U3S	RN	Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo acti... J Med Chem. 2008 May 8;51(9):2758-65.
DMO8U3S	RU	https://pubmed.ncbi.nlm.nih.gov/18412318

DM1SOT4	DI	DM1SOT4
DM1SOT4	DN	[Gly8]GLP-1(7-37)-NH2
DM1SOT4	MI	TTVIMDE
DM1SOT4	MN	Glucagon-like peptide 1 receptor (GLP1R)
DM1SOT4	MT	DTT
DM1SOT4	MA	Inhibitor
DM1SOT4	RN	Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo acti... J Med Chem. 2008 May 8;51(9):2758-65.
DM1SOT4	RU	https://pubmed.ncbi.nlm.nih.gov/18412318

DMLZNK6	DI	DMLZNK6
DMLZNK6	DN	[HO1][Lys8(5/6C-Flu)]VT
DMLZNK6	MI	TTSCIUP
DMLZNK6	MN	Oxytocin receptor (OTR)
DMLZNK6	MT	DTT
DMLZNK6	MA	Inhibitor
DMLZNK6	RN	Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88.
DMLZNK6	RU	https://pubmed.ncbi.nlm.nih.gov/12036367

DMLZNK6	DI	DMLZNK6
DMLZNK6	DN	[HO1][Lys8(5/6C-Flu)]VT
DMLZNK6	MI	TT4TFGN
DMLZNK6	MN	Vasopressin V1a receptor (V1AR)
DMLZNK6	MT	DTT
DMLZNK6	MA	Inhibitor
DMLZNK6	RN	Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88.
DMLZNK6	RU	https://pubmed.ncbi.nlm.nih.gov/12036367

DMLZNK6	DI	DMLZNK6
DMLZNK6	DN	[HO1][Lys8(5/6C-Flu)]VT
DMLZNK6	MI	TTL9MHW
DMLZNK6	MN	Vasopressin V1b receptor (V1BR)
DMLZNK6	MT	DTT
DMLZNK6	MA	Inhibitor
DMLZNK6	RN	Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88.
DMLZNK6	RU	https://pubmed.ncbi.nlm.nih.gov/12036367

DMFK9V5	DI	DMFK9V5
DMFK9V5	DN	[HO1][Orn8(5/6C-Flu)]VT
DMFK9V5	MI	TTSCIUP
DMFK9V5	MN	Oxytocin receptor (OTR)
DMFK9V5	MT	DTT
DMFK9V5	MA	Inhibitor
DMFK9V5	RN	Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88.
DMFK9V5	RU	https://pubmed.ncbi.nlm.nih.gov/12036367

DMFK9V5	DI	DMFK9V5
DMFK9V5	DN	[HO1][Orn8(5/6C-Flu)]VT
DMFK9V5	MI	TT4TFGN
DMFK9V5	MN	Vasopressin V1a receptor (V1AR)
DMFK9V5	MT	DTT
DMFK9V5	MA	Inhibitor
DMFK9V5	RN	Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88.
DMFK9V5	RU	https://pubmed.ncbi.nlm.nih.gov/12036367

DMFK9V5	DI	DMFK9V5
DMFK9V5	DN	[HO1][Orn8(5/6C-Flu)]VT
DMFK9V5	MI	TTL9MHW
DMFK9V5	MN	Vasopressin V1b receptor (V1BR)
DMFK9V5	MT	DTT
DMFK9V5	MA	Inhibitor
DMFK9V5	RN	Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88.
DMFK9V5	RU	https://pubmed.ncbi.nlm.nih.gov/12036367

DM7COAM	DI	DM7COAM
DM7COAM	DN	[HO1][Orn8(5/6C-Rhm)]VT
DM7COAM	MI	TTSCIUP
DM7COAM	MN	Oxytocin receptor (OTR)
DM7COAM	MT	DTT
DM7COAM	MA	Inhibitor
DM7COAM	RN	Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88.
DM7COAM	RU	https://pubmed.ncbi.nlm.nih.gov/12036367

DM7COAM	DI	DM7COAM
DM7COAM	DN	[HO1][Orn8(5/6C-Rhm)]VT
DM7COAM	MI	TT4TFGN
DM7COAM	MN	Vasopressin V1a receptor (V1AR)
DM7COAM	MT	DTT
DM7COAM	MA	Inhibitor
DM7COAM	RN	Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88.
DM7COAM	RU	https://pubmed.ncbi.nlm.nih.gov/12036367

DMT2UYR	DI	DMT2UYR
DMT2UYR	DN	[HO1][Thr4,Lys8(5/6C-Flu)]VT
DMT2UYR	MI	TTSCIUP
DMT2UYR	MN	Oxytocin receptor (OTR)
DMT2UYR	MT	DTT
DMT2UYR	MA	Inhibitor
DMT2UYR	RN	Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88.
DMT2UYR	RU	https://pubmed.ncbi.nlm.nih.gov/12036367

DMT2UYR	DI	DMT2UYR
DMT2UYR	DN	[HO1][Thr4,Lys8(5/6C-Flu)]VT
DMT2UYR	MI	TT4TFGN
DMT2UYR	MN	Vasopressin V1a receptor (V1AR)
DMT2UYR	MT	DTT
DMT2UYR	MA	Inhibitor
DMT2UYR	RN	Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88.
DMT2UYR	RU	https://pubmed.ncbi.nlm.nih.gov/12036367

DMT2UYR	DI	DMT2UYR
DMT2UYR	DN	[HO1][Thr4,Lys8(5/6C-Flu)]VT
DMT2UYR	MI	TTL9MHW
DMT2UYR	MN	Vasopressin V1b receptor (V1BR)
DMT2UYR	MT	DTT
DMT2UYR	MA	Inhibitor
DMT2UYR	RN	Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88.
DMT2UYR	RU	https://pubmed.ncbi.nlm.nih.gov/12036367

DM81B4W	DI	DM81B4W
DM81B4W	DN	[HO1][Thr4,Orn8(5/6C-Flu)]VT
DM81B4W	MI	TTSCIUP
DM81B4W	MN	Oxytocin receptor (OTR)
DM81B4W	MT	DTT
DM81B4W	MA	Inhibitor
DM81B4W	RN	Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88.
DM81B4W	RU	https://pubmed.ncbi.nlm.nih.gov/12036367

DM81B4W	DI	DM81B4W
DM81B4W	DN	[HO1][Thr4,Orn8(5/6C-Flu)]VT
DM81B4W	MI	TT4TFGN
DM81B4W	MN	Vasopressin V1a receptor (V1AR)
DM81B4W	MT	DTT
DM81B4W	MA	Inhibitor
DM81B4W	RN	Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88.
DM81B4W	RU	https://pubmed.ncbi.nlm.nih.gov/12036367

DM81B4W	DI	DM81B4W
DM81B4W	DN	[HO1][Thr4,Orn8(5/6C-Flu)]VT
DM81B4W	MI	TTL9MHW
DM81B4W	MN	Vasopressin V1b receptor (V1BR)
DM81B4W	MT	DTT
DM81B4W	MA	Inhibitor
DM81B4W	RN	Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88.
DM81B4W	RU	https://pubmed.ncbi.nlm.nih.gov/12036367

DM7NXMB	DI	DM7NXMB
DM7NXMB	DN	[HYDROXY(3-PHENYLPROPYL)AMINO]METHANOL
DM7NXMB	MI	TTICO5G
DM7NXMB	MN	Staphylococcus Peptide deformylase (Stap-coc def)
DM7NXMB	MT	DTT
DM7NXMB	MA	Inhibitor
DM7NXMB	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM7NXMB	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMXTY6L	DI	DMXTY6L
DMXTY6L	DN	[Leu13]motilin (human)
DMXTY6L	MI	TT953CX
DMXTY6L	MN	Motilin receptor (MLNR)
DMXTY6L	MT	DTT
DMXTY6L	MA	Agonist
DMXTY6L	RN	Receptor for motilin identified in the human gastrointestinal system. Science. 1999 Jun 25;284(5423):2184-8.
DMXTY6L	RU	https://pubmed.ncbi.nlm.nih.gov/10381885

DMA0N32	DI	DMA0N32
DMA0N32	DN	[Leu5]enkephalin
DMA0N32	MI	TT27RFC
DMA0N32	MN	Opioid receptor delta (OPRD1)
DMA0N32	MT	DTT
DMA0N32	MA	Inhibitor
DMA0N32	RN	Carba-analogues of fentanyl are opioid receptor agonists. J Med Chem. 2010 Apr 8;53(7):2875-81.
DMA0N32	RU	https://pubmed.ncbi.nlm.nih.gov/20218625

DMA0N32	DI	DMA0N32
DMA0N32	DN	[Leu5]enkephalin
DMA0N32	MI	TTQW87Y
DMA0N32	MN	Opioid receptor kappa (OPRK1)
DMA0N32	MT	DTT
DMA0N32	MA	Inhibitor
DMA0N32	RN	Carba-analogues of fentanyl are opioid receptor agonists. J Med Chem. 2010 Apr 8;53(7):2875-81.
DMA0N32	RU	https://pubmed.ncbi.nlm.nih.gov/20218625

DMA0N32	DI	DMA0N32
DMA0N32	DN	[Leu5]enkephalin
DMA0N32	MI	TTKWM86
DMA0N32	MN	Opioid receptor mu (MOP)
DMA0N32	MT	DTT
DMA0N32	MA	Inhibitor
DMA0N32	RN	Carba-analogues of fentanyl are opioid receptor agonists. J Med Chem. 2010 Apr 8;53(7):2875-81.
DMA0N32	RU	https://pubmed.ncbi.nlm.nih.gov/20218625

DM3JHRC	DI	DM3JHRC
DM3JHRC	DN	[Leu8,des-Arg9]bradykinin
DM3JHRC	MI	TTGY8IW
DM3JHRC	MN	B2 bradykinin receptor (BDKRB2)
DM3JHRC	MT	DTT
DM3JHRC	MA	Agonist
DM3JHRC	RN	Partial agonists and full antagonists at the human and murine bradykinin B1 receptors. Can J Physiol Pharmacol. 1997 Jun;75(6):735-40.
DM3JHRC	RU	https://pubmed.ncbi.nlm.nih.gov/9276157

DMHUMDR	DI	DMHUMDR
DMHUMDR	DN	[L-Tic7]OT
DMHUMDR	MI	TTSCIUP
DMHUMDR	MN	Oxytocin receptor (OTR)
DMHUMDR	MT	DTT
DMHUMDR	MA	Inhibitor
DMHUMDR	RN	Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7. Eur J Med Chem. 2007 Jun;42(6):799-806.
DMHUMDR	RU	https://pubmed.ncbi.nlm.nih.gov/17316912

DM7STF6	DI	DM7STF6
DM7STF6	DN	[Lys8(Alexa 488) ]PVA
DM7STF6	MI	TTSCIUP
DM7STF6	MN	Oxytocin receptor (OTR)
DM7STF6	MT	DTT
DM7STF6	MA	Inhibitor
DM7STF6	RN	Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands. J Med Chem. 2007 Oct 4;50(20):4976-85.
DM7STF6	RU	https://pubmed.ncbi.nlm.nih.gov/17850055

DM7STF6	DI	DM7STF6
DM7STF6	DN	[Lys8(Alexa 488) ]PVA
DM7STF6	MI	TT4TFGN
DM7STF6	MN	Vasopressin V1a receptor (V1AR)
DM7STF6	MT	DTT
DM7STF6	MA	Inhibitor
DM7STF6	RN	Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands. J Med Chem. 2007 Oct 4;50(20):4976-85.
DM7STF6	RU	https://pubmed.ncbi.nlm.nih.gov/17850055

DM7STF6	DI	DM7STF6
DM7STF6	DN	[Lys8(Alexa 488) ]PVA
DM7STF6	MI	TTL9MHW
DM7STF6	MN	Vasopressin V1b receptor (V1BR)
DM7STF6	MT	DTT
DM7STF6	MA	Inhibitor
DM7STF6	RN	Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands. J Med Chem. 2007 Oct 4;50(20):4976-85.
DM7STF6	RU	https://pubmed.ncbi.nlm.nih.gov/17850055

DM38L6U	DI	DM38L6U
DM38L6U	DN	[Lys8(Alexa 546) ]PVA
DM38L6U	MI	TTSCIUP
DM38L6U	MN	Oxytocin receptor (OTR)
DM38L6U	MT	DTT
DM38L6U	MA	Inhibitor
DM38L6U	RN	Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands. J Med Chem. 2007 Oct 4;50(20):4976-85.
DM38L6U	RU	https://pubmed.ncbi.nlm.nih.gov/17850055

DM38L6U	DI	DM38L6U
DM38L6U	DN	[Lys8(Alexa 546) ]PVA
DM38L6U	MI	TT4TFGN
DM38L6U	MN	Vasopressin V1a receptor (V1AR)
DM38L6U	MT	DTT
DM38L6U	MA	Inhibitor
DM38L6U	RN	Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands. J Med Chem. 2007 Oct 4;50(20):4976-85.
DM38L6U	RU	https://pubmed.ncbi.nlm.nih.gov/17850055

DM27LNU	DI	DM27LNU
DM27LNU	DN	[Mpa1, D-Tic2, Aib7]OT
DM27LNU	MI	TTSCIUP
DM27LNU	MN	Oxytocin receptor (OTR)
DM27LNU	MT	DTT
DM27LNU	MA	Inhibitor
DM27LNU	RN	Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7. Eur J Med Chem. 2007 Jun;42(6):799-806.
DM27LNU	RU	https://pubmed.ncbi.nlm.nih.gov/17316912

DMPT1ME	DI	DMPT1ME
DMPT1ME	DN	[Mpa1, D-Tic7]OT
DMPT1ME	MI	TTSCIUP
DMPT1ME	MN	Oxytocin receptor (OTR)
DMPT1ME	MT	DTT
DMPT1ME	MA	Inhibitor
DMPT1ME	RN	Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7. Eur J Med Chem. 2007 Jun;42(6):799-806.
DMPT1ME	RU	https://pubmed.ncbi.nlm.nih.gov/17316912

DMBPVSD	DI	DMBPVSD
DMBPVSD	DN	[Mpa1, D-Tyr(Et)2, Aib7, D-Tic9]OT
DMBPVSD	MI	TTSCIUP
DMBPVSD	MN	Oxytocin receptor (OTR)
DMBPVSD	MT	DTT
DMBPVSD	MA	Inhibitor
DMBPVSD	RN	Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7. Eur J Med Chem. 2007 Jun;42(6):799-806.
DMBPVSD	RU	https://pubmed.ncbi.nlm.nih.gov/17316912

DMQSG6Y	DI	DMQSG6Y
DMQSG6Y	DN	[Mpa1, D-Tyr(Et)2, Aib7]OT
DMQSG6Y	MI	TTSCIUP
DMQSG6Y	MN	Oxytocin receptor (OTR)
DMQSG6Y	MT	DTT
DMQSG6Y	MA	Inhibitor
DMQSG6Y	RN	Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7. Eur J Med Chem. 2007 Jun;42(6):799-806.
DMQSG6Y	RU	https://pubmed.ncbi.nlm.nih.gov/17316912

DM5GSXC	DI	DM5GSXC
DM5GSXC	DN	[Mpa1, D-Tyr(Et)2, D-Tic7, Aib9]OT
DM5GSXC	MI	TTSCIUP
DM5GSXC	MN	Oxytocin receptor (OTR)
DM5GSXC	MT	DTT
DM5GSXC	MA	Inhibitor
DM5GSXC	RN	Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7. Eur J Med Chem. 2007 Jun;42(6):799-806.
DM5GSXC	RU	https://pubmed.ncbi.nlm.nih.gov/17316912

DMI9MBO	DI	DMI9MBO
DMI9MBO	DN	[Mpa1, D-Tyr(Et)2, D-Tic7, D-Tic9]OT
DMI9MBO	MI	TTSCIUP
DMI9MBO	MN	Oxytocin receptor (OTR)
DMI9MBO	MT	DTT
DMI9MBO	MA	Inhibitor
DMI9MBO	RN	Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7. Eur J Med Chem. 2007 Jun;42(6):799-806.
DMI9MBO	RU	https://pubmed.ncbi.nlm.nih.gov/17316912

DM3T4JF	DI	DM3T4JF
DM3T4JF	DN	[Mpa1, D-Tyr(Et)2, D-Tic7]OT
DM3T4JF	MI	TTSCIUP
DM3T4JF	MN	Oxytocin receptor (OTR)
DM3T4JF	MT	DTT
DM3T4JF	MA	Inhibitor
DM3T4JF	RN	Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7. Eur J Med Chem. 2007 Jun;42(6):799-806.
DM3T4JF	RU	https://pubmed.ncbi.nlm.nih.gov/17316912

DML8V4F	DI	DML8V4F
DML8V4F	DN	[Mpa1, D-Tyr(Et)2, Gly(But)3, Gly(But)7]OT
DML8V4F	MI	TTSCIUP
DML8V4F	MN	Oxytocin receptor (OTR)
DML8V4F	MT	DTT
DML8V4F	MA	Inhibitor
DML8V4F	RN	Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7. Eur J Med Chem. 2007 Jun;42(6):799-806.
DML8V4F	RU	https://pubmed.ncbi.nlm.nih.gov/17316912

DMX2SU9	DI	DMX2SU9
DMX2SU9	DN	[Mpa1, D-Tyr(Et)2, Gly(But)7]OT
DMX2SU9	MI	TTSCIUP
DMX2SU9	MN	Oxytocin receptor (OTR)
DMX2SU9	MT	DTT
DMX2SU9	MA	Inhibitor
DMX2SU9	RN	Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7. Eur J Med Chem. 2007 Jun;42(6):799-806.
DMX2SU9	RU	https://pubmed.ncbi.nlm.nih.gov/17316912

DM0H3NV	DI	DM0H3NV
DM0H3NV	DN	[Mpa1, D-Tyr(Et)2, L-Tic7]OT
DM0H3NV	MI	TTSCIUP
DM0H3NV	MN	Oxytocin receptor (OTR)
DM0H3NV	MT	DTT
DM0H3NV	MA	Inhibitor
DM0H3NV	RN	Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7. Eur J Med Chem. 2007 Jun;42(6):799-806.
DM0H3NV	RU	https://pubmed.ncbi.nlm.nih.gov/17316912

DM6W4LR	DI	DM6W4LR
DM6W4LR	DN	[Mpa1, D-Tyr(Et)2, Pip7]OT
DM6W4LR	MI	TTSCIUP
DM6W4LR	MN	Oxytocin receptor (OTR)
DM6W4LR	MT	DTT
DM6W4LR	MA	Inhibitor
DM6W4LR	RN	Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7. Eur J Med Chem. 2007 Jun;42(6):799-806.
DM6W4LR	RU	https://pubmed.ncbi.nlm.nih.gov/17316912

DMB4J3N	DI	DMB4J3N
DMB4J3N	DN	[Mpa1, L-Tic7]OT
DMB4J3N	MI	TTSCIUP
DMB4J3N	MN	Oxytocin receptor (OTR)
DMB4J3N	MT	DTT
DMB4J3N	MA	Inhibitor
DMB4J3N	RN	Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7. Eur J Med Chem. 2007 Jun;42(6):799-806.
DMB4J3N	RU	https://pubmed.ncbi.nlm.nih.gov/17316912

DMW9AST	DI	DMW9AST
DMW9AST	DN	[N-[2-[(3'-N'-PROPYL-3''ALPHA-(BIS(4-FLUORORPHENYL)METHOXY)TROPANE-2''BETA-CARBOXYLIC ACID METHYL ESTER)(2-MERCAPTOETHYL)AMINO]ACETYL]-2-AMINOETHANETHIOLATO]RHENIUM(V) OXIDE (DIASTEREOMERIC MIX)
DMW9AST	MI	TTVBI8W
DMW9AST	MN	Dopamine transporter (DAT)
DMW9AST	MT	DTT
DMW9AST	MA	Inhibitor
DMW9AST	RN	A technetium-99m SPECT imaging agent which targets the dopamine transporter in primate brain. J Med Chem. 1997 Jun 6;40(12):1835-44.
DMW9AST	RU	https://pubmed.ncbi.nlm.nih.gov/9191960

DM6EAHF	DI	DM6EAHF
DM6EAHF	DN	[N40,Pro1,Tyr4,Nle 14]BB
DM6EAHF	MI	TTC1MVT
DM6EAHF	MN	Gastrin-releasing peptide receptor (GRPR)
DM6EAHF	MT	DTT
DM6EAHF	MA	Inhibitor
DM6EAHF	RN	Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study. J Med Chem. 2005 Jan 13;48(1):100-10.
DM6EAHF	RU	https://pubmed.ncbi.nlm.nih.gov/15634004

DMVFHNM	DI	DMVFHNM
DMVFHNM	DN	[N40,Pro1,Tyr4]BB
DMVFHNM	MI	TTC1MVT
DMVFHNM	MN	Gastrin-releasing peptide receptor (GRPR)
DMVFHNM	MT	DTT
DMVFHNM	MA	Inhibitor
DMVFHNM	RN	Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study. J Med Chem. 2005 Jan 13;48(1):100-10.
DMVFHNM	RU	https://pubmed.ncbi.nlm.nih.gov/15634004

DMW6LIJ	DI	DMW6LIJ
DMW6LIJ	DN	[N-Ac,des-Sar]Gal-B2
DMW6LIJ	MI	TTX3HNZ
DMW6LIJ	MN	Galanin receptor type 1 (GAL1-R)
DMW6LIJ	MT	DTT
DMW6LIJ	MA	Inhibitor
DMW6LIJ	RN	Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5.
DMW6LIJ	RU	https://pubmed.ncbi.nlm.nih.gov/20121116

DMW6LIJ	DI	DMW6LIJ
DMW6LIJ	DN	[N-Ac,des-Sar]Gal-B2
DMW6LIJ	MI	TTBPW3J
DMW6LIJ	MN	Galanin receptor type 2 (GAL2-R)
DMW6LIJ	MT	DTT
DMW6LIJ	MA	Inhibitor
DMW6LIJ	RN	Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5.
DMW6LIJ	RU	https://pubmed.ncbi.nlm.nih.gov/20121116

DME6LKY	DI	DME6LKY
DME6LKY	DN	[Ncy(2-naphthyl)1]acyline
DME6LKY	MI	TT8R70G
DME6LKY	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DME6LKY	MT	DTT
DME6LKY	MA	Inhibitor
DME6LKY	RN	Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77.
DME6LKY	RU	https://pubmed.ncbi.nlm.nih.gov/17402723

DM5CS8U	DI	DM5CS8U
DM5CS8U	DN	[Ncy(isopropyl)7]acyline
DM5CS8U	MI	TT8R70G
DM5CS8U	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DM5CS8U	MT	DTT
DM5CS8U	MA	Inhibitor
DM5CS8U	RN	Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77.
DM5CS8U	RU	https://pubmed.ncbi.nlm.nih.gov/17402723

DM9RC3O	DI	DM9RC3O
DM9RC3O	DN	[Ncy(methyl)10]acyline
DM9RC3O	MI	TT8R70G
DM9RC3O	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DM9RC3O	MT	DTT
DM9RC3O	MA	Inhibitor
DM9RC3O	RN	Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77.
DM9RC3O	RU	https://pubmed.ncbi.nlm.nih.gov/17402723

DMLK8YQ	DI	DMLK8YQ
DMLK8YQ	DN	[Ncy(methyl)4]acyline
DMLK8YQ	MI	TT8R70G
DMLK8YQ	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMLK8YQ	MT	DTT
DMLK8YQ	MA	Inhibitor
DMLK8YQ	RN	Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77.
DMLK8YQ	RU	https://pubmed.ncbi.nlm.nih.gov/17402723

DMEFIQ9	DI	DMEFIQ9
DMEFIQ9	DN	[Ncy(SO,isopropyl)7]acyline
DMEFIQ9	MI	TT8R70G
DMEFIQ9	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMEFIQ9	MT	DTT
DMEFIQ9	MA	Inhibitor
DMEFIQ9	RN	Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77.
DMEFIQ9	RU	https://pubmed.ncbi.nlm.nih.gov/17402723

DMT8X45	DI	DMT8X45
DMT8X45	DN	[Ncy(SO,methyl)10]acyline
DMT8X45	MI	TT8R70G
DMT8X45	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMT8X45	MT	DTT
DMT8X45	MA	Inhibitor
DMT8X45	RN	Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77.
DMT8X45	RU	https://pubmed.ncbi.nlm.nih.gov/17402723

DM057MP	DI	DM057MP
DM057MP	DN	[Ncy(SO,methyl)4]acyline
DM057MP	MI	TT8R70G
DM057MP	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DM057MP	MT	DTT
DM057MP	MA	Inhibitor
DM057MP	RN	Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77.
DM057MP	RU	https://pubmed.ncbi.nlm.nih.gov/17402723

DM4XFOH	DI	DM4XFOH
DM4XFOH	DN	[N-Me,des-Sar]Gal-B2
DM4XFOH	MI	TTX3HNZ
DM4XFOH	MN	Galanin receptor type 1 (GAL1-R)
DM4XFOH	MT	DTT
DM4XFOH	MA	Inhibitor
DM4XFOH	RN	Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5.
DM4XFOH	RU	https://pubmed.ncbi.nlm.nih.gov/20121116

DM4XFOH	DI	DM4XFOH
DM4XFOH	DN	[N-Me,des-Sar]Gal-B2
DM4XFOH	MI	TTBPW3J
DM4XFOH	MN	Galanin receptor type 2 (GAL2-R)
DM4XFOH	MT	DTT
DM4XFOH	MA	Inhibitor
DM4XFOH	RN	Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5.
DM4XFOH	RU	https://pubmed.ncbi.nlm.nih.gov/20121116

DMTG17Q	DI	DMTG17Q
DMTG17Q	DN	[Nphe(1)]-nociceptin (1-13)-NH(2)
DMTG17Q	MI	TTNT7K8
DMTG17Q	MN	Nociceptin receptor (OPRL1)
DMTG17Q	MT	DTT
DMTG17Q	MA	Antagonist
DMTG17Q	RN	Nociceptin receptor antagonists display antidepressant-like properties in the mouse forced swimming test. Naunyn Schmiedebergs Arch Pharmacol. 2002 Feb;365(2):164-7.
DMTG17Q	RU	https://pubmed.ncbi.nlm.nih.gov/11819035

DMK18CS	DI	DMK18CS
DMK18CS	DN	[Phe3]OT
DMK18CS	MI	TTSCIUP
DMK18CS	MN	Oxytocin receptor (OTR)
DMK18CS	MT	DTT
DMK18CS	MA	Agonist
DMK18CS	RN	Two aromatic residues regulate the response of the human oxytocin receptor to the partial agonist arginine vasopressin. FEBS Lett. 1996 Nov 18;397(2-3):201-6.
DMK18CS	RU	https://pubmed.ncbi.nlm.nih.gov/8955347

DMK18CS	DI	DMK18CS
DMK18CS	DN	[Phe3]OT
DMK18CS	MI	TT4TFGN
DMK18CS	MN	Vasopressin V1a receptor (V1AR)
DMK18CS	MT	DTT
DMK18CS	MA	Agonist
DMK18CS	RN	Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptor. EMBO J. 1995 May 15;14(10):2176-82.
DMK18CS	RU	https://pubmed.ncbi.nlm.nih.gov/7774575

DMK18CS	DI	DMK18CS
DMK18CS	DN	[Phe3]OT
DMK18CS	MI	TTK8R02
DMK18CS	MN	Vasopressin V2 receptor (V2R)
DMK18CS	MT	DTT
DMK18CS	MA	Agonist
DMK18CS	RN	Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptor. EMBO J. 1995 May 15;14(10):2176-82.
DMK18CS	RU	https://pubmed.ncbi.nlm.nih.gov/7774575

DMXJDEA	DI	DMXJDEA
DMXJDEA	DN	[Pip7]OT
DMXJDEA	MI	TTSCIUP
DMXJDEA	MN	Oxytocin receptor (OTR)
DMXJDEA	MT	DTT
DMXJDEA	MA	Inhibitor
DMXJDEA	RN	Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7. Eur J Med Chem. 2007 Jun;42(6):799-806.
DMXJDEA	RU	https://pubmed.ncbi.nlm.nih.gov/17316912

DM4ZY79	DI	DM4ZY79
DM4ZY79	DN	[Pterin-6-Yl Methanyl]-Phosphonophosphate
DM4ZY79	MI	TT4ILYC
DM4ZY79	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DM4ZY79	MT	DTT
DM4ZY79	MA	Inhibitor
DM4ZY79	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM4ZY79	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM4ZY79	DI	DM4ZY79
DM4ZY79	DN	[Pterin-6-Yl Methanyl]-Phosphonophosphate
DM4ZY79	MI	TT38ECI
DM4ZY79	MN	Bacterial Hydroxymethyl-dihydropterin pyrophosphokinase (Bact folK)
DM4ZY79	MT	DTT
DM4ZY79	MA	Inhibitor
DM4ZY79	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM4ZY79	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM8YF3V	DI	DM8YF3V
DM8YF3V	DN	[R-(-)-Apomorphine-2-yl]-(2'-hydroxy-ethyl)ether
DM8YF3V	MI	TTZFYLI
DM8YF3V	MN	Dopamine D1 receptor (D1R)
DM8YF3V	MT	DTT
DM8YF3V	MA	Inhibitor
DM8YF3V	RN	Synthesis and neuropharmacological characterization of 2-O-substituted apomorphines. Bioorg Med Chem. 2008 Apr 15;16(8):4563-8.
DM8YF3V	RU	https://pubmed.ncbi.nlm.nih.gov/18313931

DM8YF3V	DI	DM8YF3V
DM8YF3V	DN	[R-(-)-Apomorphine-2-yl]-(2'-hydroxy-ethyl)ether
DM8YF3V	MI	TTEX248
DM8YF3V	MN	Dopamine D2 receptor (D2R)
DM8YF3V	MT	DTT
DM8YF3V	MA	Inhibitor
DM8YF3V	RN	Synthesis and neuropharmacological characterization of 2-O-substituted apomorphines. Bioorg Med Chem. 2008 Apr 15;16(8):4563-8.
DM8YF3V	RU	https://pubmed.ncbi.nlm.nih.gov/18313931

DMUF7DP	DI	DMUF7DP
DMUF7DP	DN	[Sar,D-Phe8,des-Arg9]bradykinin
DMUF7DP	MI	TTGY8IW
DMUF7DP	MN	B2 bradykinin receptor (BDKRB2)
DMUF7DP	MT	DTT
DMUF7DP	MA	Agonist
DMUF7DP	RN	Molecular characterisation of cloned bradykinin B1 receptors from rat and human. Eur J Pharmacol. 1999 Jun 25;374(3):423-33.
DMUF7DP	RU	https://pubmed.ncbi.nlm.nih.gov/10422787

DM1HQ3D	DI	DM1HQ3D
DM1HQ3D	DN	[Sar1,Bpa2]AngII
DM1HQ3D	MI	TT8DBY3
DM1HQ3D	MN	Angiotensin II receptor type-1 (AGTR1)
DM1HQ3D	MT	DTT
DM1HQ3D	MA	Inhibitor
DM1HQ3D	RN	The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1. J Med Chem. 2010 Mar 11;53(5):2063-75.
DM1HQ3D	RU	https://pubmed.ncbi.nlm.nih.gov/20146480

DMP64XH	DI	DMP64XH
DMP64XH	DN	[Sar1,Bpa3]AngII
DMP64XH	MI	TT8DBY3
DMP64XH	MN	Angiotensin II receptor type-1 (AGTR1)
DMP64XH	MT	DTT
DMP64XH	MA	Inhibitor
DMP64XH	RN	The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1. J Med Chem. 2010 Mar 11;53(5):2063-75.
DMP64XH	RU	https://pubmed.ncbi.nlm.nih.gov/20146480

DMWC10R	DI	DMWC10R
DMWC10R	DN	[Sar1,Bpa8]AngII
DMWC10R	MI	TT8DBY3
DMWC10R	MN	Angiotensin II receptor type-1 (AGTR1)
DMWC10R	MT	DTT
DMWC10R	MA	Inhibitor
DMWC10R	RN	The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1. J Med Chem. 2010 Mar 11;53(5):2063-75.
DMWC10R	RU	https://pubmed.ncbi.nlm.nih.gov/20146480

DM4AUFR	DI	DM4AUFR
DM4AUFR	DN	[Sar1,Tdf2]AngII
DM4AUFR	MI	TT8DBY3
DM4AUFR	MN	Angiotensin II receptor type-1 (AGTR1)
DM4AUFR	MT	DTT
DM4AUFR	MA	Inhibitor
DM4AUFR	RN	The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1. J Med Chem. 2010 Mar 11;53(5):2063-75.
DM4AUFR	RU	https://pubmed.ncbi.nlm.nih.gov/20146480

DMWCS4Y	DI	DMWCS4Y
DMWCS4Y	DN	[Sar1,Tdf3]AngII
DMWCS4Y	MI	TT8DBY3
DMWCS4Y	MN	Angiotensin II receptor type-1 (AGTR1)
DMWCS4Y	MT	DTT
DMWCS4Y	MA	Inhibitor
DMWCS4Y	RN	The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1. J Med Chem. 2010 Mar 11;53(5):2063-75.
DMWCS4Y	RU	https://pubmed.ncbi.nlm.nih.gov/20146480

DMTNGCW	DI	DMTNGCW
DMTNGCW	DN	[Sar1,Tdf8]AngII
DMTNGCW	MI	TT8DBY3
DMTNGCW	MN	Angiotensin II receptor type-1 (AGTR1)
DMTNGCW	MT	DTT
DMTNGCW	MA	Inhibitor
DMTNGCW	RN	The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1. J Med Chem. 2010 Mar 11;53(5):2063-75.
DMTNGCW	RU	https://pubmed.ncbi.nlm.nih.gov/20146480

DMUD0LA	DI	DMUD0LA
DMUD0LA	DN	[Sar1Ala]GAL-B2
DMUD0LA	MI	TTX3HNZ
DMUD0LA	MN	Galanin receptor type 1 (GAL1-R)
DMUD0LA	MT	DTT
DMUD0LA	MA	Inhibitor
DMUD0LA	RN	Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5.
DMUD0LA	RU	https://pubmed.ncbi.nlm.nih.gov/20121116

DMUD0LA	DI	DMUD0LA
DMUD0LA	DN	[Sar1Ala]GAL-B2
DMUD0LA	MI	TTBPW3J
DMUD0LA	MN	Galanin receptor type 2 (GAL2-R)
DMUD0LA	MT	DTT
DMUD0LA	MA	Inhibitor
DMUD0LA	RN	Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5.
DMUD0LA	RU	https://pubmed.ncbi.nlm.nih.gov/20121116

DMUI0XV	DI	DMUI0XV
DMUI0XV	DN	[Sar1Gly]GAL-B2
DMUI0XV	MI	TTX3HNZ
DMUI0XV	MN	Galanin receptor type 1 (GAL1-R)
DMUI0XV	MT	DTT
DMUI0XV	MA	Inhibitor
DMUI0XV	RN	Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5.
DMUI0XV	RU	https://pubmed.ncbi.nlm.nih.gov/20121116

DMUI0XV	DI	DMUI0XV
DMUI0XV	DN	[Sar1Gly]GAL-B2
DMUI0XV	MI	TTBPW3J
DMUI0XV	MN	Galanin receptor type 2 (GAL2-R)
DMUI0XV	MT	DTT
DMUI0XV	MA	Inhibitor
DMUI0XV	RN	Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5.
DMUI0XV	RU	https://pubmed.ncbi.nlm.nih.gov/20121116

DMYF85Q	DI	DMYF85Q
DMYF85Q	DN	[Sar9,Met(O2)11]-SP
DMYF85Q	MI	TTZPO1L
DMYF85Q	MN	Substance-P receptor (TACR1)
DMYF85Q	MT	DTT
DMYF85Q	MA	Inhibitor
DMYF85Q	RN	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
DMYF85Q	RU	https://pubmed.ncbi.nlm.nih.gov/18983139

DMN0BT3	DI	DMN0BT3
DMN0BT3	DN	[Tdf1]AngII
DMN0BT3	MI	TT8DBY3
DMN0BT3	MN	Angiotensin II receptor type-1 (AGTR1)
DMN0BT3	MT	DTT
DMN0BT3	MA	Inhibitor
DMN0BT3	RN	The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1. J Med Chem. 2010 Mar 11;53(5):2063-75.
DMN0BT3	RU	https://pubmed.ncbi.nlm.nih.gov/20146480

DM7QAKB	DI	DM7QAKB
DM7QAKB	DN	[Thr4,Gly7]OT
DM7QAKB	MI	TTSCIUP
DM7QAKB	MN	Oxytocin receptor (OTR)
DM7QAKB	MT	DTT
DM7QAKB	MA	Agonist
DM7QAKB	RN	[3H]-[Thr4,Gly7]OT: a highly selective ligand for central and peripheral OT receptors. Am J Physiol. 1988 Jan;254(1 Pt 1):E31-8.
DM7QAKB	RU	https://pubmed.ncbi.nlm.nih.gov/2827511

DM7QAKB	DI	DM7QAKB
DM7QAKB	DN	[Thr4,Gly7]OT
DM7QAKB	MI	TT4TFGN
DM7QAKB	MN	Vasopressin V1a receptor (V1AR)
DM7QAKB	MT	DTT
DM7QAKB	MA	Agonist
DM7QAKB	RN	Mapping peptide-binding domains of the human V1a vasopressin receptor with a photoactivatable linear peptide antagonist. J Biol Chem. 1997 Oct 17;272(42):26536-44.
DM7QAKB	RU	https://pubmed.ncbi.nlm.nih.gov/9334232

DMA6VNI	DI	DMA6VNI
DMA6VNI	DN	[Tyr4]Bombesin
DMA6VNI	MI	TTC1MVT
DMA6VNI	MN	Gastrin-releasing peptide receptor (GRPR)
DMA6VNI	MT	DTT
DMA6VNI	MA	Inhibitor
DMA6VNI	RN	Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study. J Med Chem. 2005 Jan 13;48(1):100-10.
DMA6VNI	RU	https://pubmed.ncbi.nlm.nih.gov/15634004

DM61RG2	DI	DM61RG2
DM61RG2	DN	[Tyr-Pro-Phe-NH-]2
DM61RG2	MI	TTKWM86
DM61RG2	MN	Opioid receptor mu (MOP)
DM61RG2	MT	DTT
DM61RG2	MA	Inhibitor
DM61RG2	RN	Structure-activity relationship of the novel bivalent and C-terminal modified analogues of endomorphin-2. Bioorg Med Chem Lett. 2005 Apr 1;15(7):1847-50.
DM61RG2	RU	https://pubmed.ncbi.nlm.nih.gov/15780619

DMZTRQ0	DI	DMZTRQ0
DMZTRQ0	DN	[Tyr-Pro-Phe-NH-CH2-]2
DMZTRQ0	MI	TTKWM86
DMZTRQ0	MN	Opioid receptor mu (MOP)
DMZTRQ0	MT	DTT
DMZTRQ0	MA	Inhibitor
DMZTRQ0	RN	Structure-activity relationship of the novel bivalent and C-terminal modified analogues of endomorphin-2. Bioorg Med Chem Lett. 2005 Apr 1;15(7):1847-50.
DMZTRQ0	RU	https://pubmed.ncbi.nlm.nih.gov/15780619

DME6TNL	DI	DME6TNL
DME6TNL	DN	[Tyr-Pro-Phe-Phe-NH-]2
DME6TNL	MI	TTKWM86
DME6TNL	MN	Opioid receptor mu (MOP)
DME6TNL	MT	DTT
DME6TNL	MA	Inhibitor
DME6TNL	RN	Structure-activity relationship of the novel bivalent and C-terminal modified analogues of endomorphin-2. Bioorg Med Chem Lett. 2005 Apr 1;15(7):1847-50.
DME6TNL	RU	https://pubmed.ncbi.nlm.nih.gov/15780619

DMFGO4W	DI	DMFGO4W
DMFGO4W	DN	[Tyr-Pro-Phe-Phe-NH-CH2-]2
DMFGO4W	MI	TTKWM86
DMFGO4W	MN	Opioid receptor mu (MOP)
DMFGO4W	MT	DTT
DMFGO4W	MA	Inhibitor
DMFGO4W	RN	Structure-activity relationship of the novel bivalent and C-terminal modified analogues of endomorphin-2. Bioorg Med Chem Lett. 2005 Apr 1;15(7):1847-50.
DMFGO4W	RU	https://pubmed.ncbi.nlm.nih.gov/15780619

DMP3I6E	DI	DMP3I6E
DMP3I6E	DN	[U-13C]ascomycin
DMP3I6E	MI	TTQW87Y
DMP3I6E	MN	Opioid receptor kappa (OPRK1)
DMP3I6E	MT	DTT
DMP3I6E	MA	Antagonist
DMP3I6E	RN	NMR studies of an FK-506 analog, [U-13C]ascomycin, bound to FK-506-binding protein. J Med Chem. 1992 Jun 26;35(13):2467-73.
DMP3I6E	RU	https://pubmed.ncbi.nlm.nih.gov/1377749

DMW82ZT	DI	DMW82ZT
DMW82ZT	DN	[Val4]AVP
DMW82ZT	MI	TT4TFGN
DMW82ZT	MN	Vasopressin V1a receptor (V1AR)
DMW82ZT	MT	DTT
DMW82ZT	MA	Agonist
DMW82ZT	RN	[1-deamino-4-cyclohexylalanine] arginine vasopressin: a potent and specific agonist for vasopressin V1b receptors. Endocrinology. 2002 Dec;143(12):4655-64.
DMW82ZT	RU	https://pubmed.ncbi.nlm.nih.gov/12446593

DMW82ZT	DI	DMW82ZT
DMW82ZT	DN	[Val4]AVP
DMW82ZT	MI	TTL9MHW
DMW82ZT	MN	Vasopressin V1b receptor (V1BR)
DMW82ZT	MT	DTT
DMW82ZT	MA	Agonist
DMW82ZT	RN	[1-deamino-4-cyclohexylalanine] arginine vasopressin: a potent and specific agonist for vasopressin V1b receptors. Endocrinology. 2002 Dec;143(12):4655-64.
DMW82ZT	RU	https://pubmed.ncbi.nlm.nih.gov/12446593

DMW82ZT	DI	DMW82ZT
DMW82ZT	DN	[Val4]AVP
DMW82ZT	MI	TTK8R02
DMW82ZT	MN	Vasopressin V2 receptor (V2R)
DMW82ZT	MT	DTT
DMW82ZT	MA	Agonist
DMW82ZT	RN	[1-deamino-4-cyclohexylalanine] arginine vasopressin: a potent and specific agonist for vasopressin V1b receptors. Endocrinology. 2002 Dec;143(12):4655-64.
DMW82ZT	RU	https://pubmed.ncbi.nlm.nih.gov/12446593

DMMB4US	DI	DMMB4US
DMMB4US	DN	{[(9Z)-octadec-9-en-1-yl]sulfamoyl}amine
DMMB4US	MI	TT6OEDT
DMMB4US	MN	Cannabinoid receptor 1 (CB1)
DMMB4US	MT	DTT
DMMB4US	MA	Inhibitor
DMMB4US	RN	Synthesis and pharmacological evaluation of sulfamide-based analogues of anandamide. Eur J Med Chem. 2009 Dec;44(12):4889-95.
DMMB4US	RU	https://pubmed.ncbi.nlm.nih.gov/19762126

DM3FBAZ	DI	DM3FBAZ
DM3FBAZ	DN	{2-[3-(Phenylsulfonyl)-1H-indol-4-yl]ethyl}amine
DM3FBAZ	MI	TTAWNKZ
DM3FBAZ	MN	Norepinephrine transporter (NET)
DM3FBAZ	MT	DTT
DM3FBAZ	MA	Inhibitor
DM3FBAZ	RN	Dual acting norepinephrine reuptake inhibitors and 5-HT(2A) receptor antagonists: Identification, synthesis and activity of novel 4-aminoethyl-3-(p... Bioorg Med Chem. 2009 Nov 15;17(22):7802-15.
DM3FBAZ	RU	https://pubmed.ncbi.nlm.nih.gov/19836247

DMX53OY	DI	DMX53OY
DMX53OY	DN	{4-[4-(4-bromophenoxy)benzoyl]phenyl}acetic acid
DMX53OY	MI	TTTU72V
DMX53OY	MN	Steroid 5-alpha-reductase 1 (SRD5A1)
DMX53OY	MT	DTT
DMX53OY	MA	Inhibitor
DMX53OY	RN	Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J Med Chem. 2006 Jan 26;49(2):748-59.
DMX53OY	RU	https://pubmed.ncbi.nlm.nih.gov/16420060

DMX53OY	DI	DMX53OY
DMX53OY	DN	{4-[4-(4-bromophenoxy)benzoyl]phenyl}acetic acid
DMX53OY	MI	TTT02K8
DMX53OY	MN	Steroid 5-alpha-reductase 2 (SRD5A2)
DMX53OY	MT	DTT
DMX53OY	MA	Inhibitor
DMX53OY	RN	Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J Med Chem. 2006 Jan 26;49(2):748-59.
DMX53OY	RU	https://pubmed.ncbi.nlm.nih.gov/16420060

DMQEJVU	DI	DMQEJVU
DMQEJVU	DN	1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole
DMQEJVU	MI	TTMNI76
DMQEJVU	MN	Calcium-activated potassium channel (KCN)
DMQEJVU	MT	DTT
DMQEJVU	MA	Inhibitor
DMQEJVU	RN	Inhibitors of potassium channels KV1.3 and IK-1 as immunosuppressants. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2299-304.
DMQEJVU	RU	https://pubmed.ncbi.nlm.nih.gov/19282171

DMQEJVU	DI	DMQEJVU
DMQEJVU	DN	1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole
DMQEJVU	MI	TT7M9I6
DMQEJVU	MN	Calcium-activated potassium channel KCa3.1 (KCNN4)
DMQEJVU	MT	DTT
DMQEJVU	MA	Blocker (channel blocker)
DMQEJVU	RN	Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis. Circulation. 2003 Sep 2;108(9):1119-25.
DMQEJVU	RU	https://pubmed.ncbi.nlm.nih.gov/12939222

DMGRV8U	DI	DMGRV8U
DMGRV8U	DN	1-((9H-Fluoren-2-yl)ethyl)-1H-imidazole
DMGRV8U	MI	TTRA5BZ
DMGRV8U	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMGRV8U	MT	DTT
DMGRV8U	MA	Inhibitor
DMGRV8U	RN	Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxyl... Bioorg Med Chem. 2008 Aug 15;16(16):7715-27.
DMGRV8U	RU	https://pubmed.ncbi.nlm.nih.gov/18674917

DMPBJ9L	DI	DMPBJ9L
DMPBJ9L	DN	1-((9H-Fluoren-2-yl)methyl)-1H-imidazole
DMPBJ9L	MI	TTRA5BZ
DMPBJ9L	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMPBJ9L	MT	DTT
DMPBJ9L	MA	Inhibitor
DMPBJ9L	RN	Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxyl... Bioorg Med Chem. 2008 Aug 15;16(16):7715-27.
DMPBJ9L	RU	https://pubmed.ncbi.nlm.nih.gov/18674917

DM74R0E	DI	DM74R0E
DM74R0E	DN	1-((R)-2-aminopropyl)-1H-indazol-6-ol
DM74R0E	MI	TTJQOD7
DM74R0E	MN	5-HT 2A receptor (HTR2A)
DM74R0E	MT	DTT
DM74R0E	MA	Inhibitor
DM74R0E	RN	1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28.
DM74R0E	RU	https://pubmed.ncbi.nlm.nih.gov/16392816

DM74R0E	DI	DM74R0E
DM74R0E	DN	1-((R)-2-aminopropyl)-1H-indazol-6-ol
DM74R0E	MI	TT0K1SC
DM74R0E	MN	5-HT 2B receptor (HTR2B)
DM74R0E	MT	DTT
DM74R0E	MA	Inhibitor
DM74R0E	RN	1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28.
DM74R0E	RU	https://pubmed.ncbi.nlm.nih.gov/16392816

DM74R0E	DI	DM74R0E
DM74R0E	DN	1-((R)-2-aminopropyl)-1H-indazol-6-ol
DM74R0E	MI	TTWJBZ5
DM74R0E	MN	5-HT 2C receptor (HTR2C)
DM74R0E	MT	DTT
DM74R0E	MA	Inhibitor
DM74R0E	RN	1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28.
DM74R0E	RU	https://pubmed.ncbi.nlm.nih.gov/16392816

DMU83KP	DI	DMU83KP
DMU83KP	DN	1-((S)-2-aminopropyl)-1H-indazol-6-ol
DMU83KP	MI	TTSQIFT
DMU83KP	MN	5-HT 1A receptor (HTR1A)
DMU83KP	MT	DTT
DMU83KP	MA	Inhibitor
DMU83KP	RN	1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28.
DMU83KP	RU	https://pubmed.ncbi.nlm.nih.gov/16392816

DMU83KP	DI	DMU83KP
DMU83KP	DN	1-((S)-2-aminopropyl)-1H-indazol-6-ol
DMU83KP	MI	TT6MSOK
DMU83KP	MN	5-HT 1D receptor (HTR1D)
DMU83KP	MT	DTT
DMU83KP	MA	Inhibitor
DMU83KP	RN	1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28.
DMU83KP	RU	https://pubmed.ncbi.nlm.nih.gov/16392816

DMU83KP	DI	DMU83KP
DMU83KP	DN	1-((S)-2-aminopropyl)-1H-indazol-6-ol
DMU83KP	MI	TTJQOD7
DMU83KP	MN	5-HT 2A receptor (HTR2A)
DMU83KP	MT	DTT
DMU83KP	MA	Inhibitor
DMU83KP	RN	1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28.
DMU83KP	RU	https://pubmed.ncbi.nlm.nih.gov/16392816

DMU83KP	DI	DMU83KP
DMU83KP	DN	1-((S)-2-aminopropyl)-1H-indazol-6-ol
DMU83KP	MI	TT0K1SC
DMU83KP	MN	5-HT 2B receptor (HTR2B)
DMU83KP	MT	DTT
DMU83KP	MA	Inhibitor
DMU83KP	RN	1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28.
DMU83KP	RU	https://pubmed.ncbi.nlm.nih.gov/16392816

DMU83KP	DI	DMU83KP
DMU83KP	DN	1-((S)-2-aminopropyl)-1H-indazol-6-ol
DMU83KP	MI	TTWJBZ5
DMU83KP	MN	5-HT 2C receptor (HTR2C)
DMU83KP	MT	DTT
DMU83KP	MA	Inhibitor
DMU83KP	RN	1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28.
DMU83KP	RU	https://pubmed.ncbi.nlm.nih.gov/16392816

DMU83KP	DI	DMU83KP
DMU83KP	DN	1-((S)-2-aminopropyl)-1H-indazol-6-ol
DMU83KP	MI	TT07C3Y
DMU83KP	MN	5-HT 4 receptor (HTR4)
DMU83KP	MT	DTT
DMU83KP	MA	Inhibitor
DMU83KP	RN	1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28.
DMU83KP	RU	https://pubmed.ncbi.nlm.nih.gov/16392816

DMU83KP	DI	DMU83KP
DMU83KP	DN	1-((S)-2-aminopropyl)-1H-indazol-6-ol
DMU83KP	MI	TTWG9A4
DMU83KP	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMU83KP	MT	DTT
DMU83KP	MA	Inhibitor
DMU83KP	RN	1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28.
DMU83KP	RU	https://pubmed.ncbi.nlm.nih.gov/16392816

DMU83KP	DI	DMU83KP
DMU83KP	DN	1-((S)-2-aminopropyl)-1H-indazol-6-ol
DMU83KP	MI	TT2NUT5
DMU83KP	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMU83KP	MT	DTT
DMU83KP	MA	Inhibitor
DMU83KP	RN	1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28.
DMU83KP	RU	https://pubmed.ncbi.nlm.nih.gov/16392816

DMRFJNC	DI	DMRFJNC
DMRFJNC	DN	1-((S)-2-aminopropyl)-7-chloro-1H-indazol-6-ol
DMRFJNC	MI	TTJQOD7
DMRFJNC	MN	5-HT 2A receptor (HTR2A)
DMRFJNC	MT	DTT
DMRFJNC	MA	Inhibitor
DMRFJNC	RN	1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28.
DMRFJNC	RU	https://pubmed.ncbi.nlm.nih.gov/16392816

DMRFJNC	DI	DMRFJNC
DMRFJNC	DN	1-((S)-2-aminopropyl)-7-chloro-1H-indazol-6-ol
DMRFJNC	MI	TT0K1SC
DMRFJNC	MN	5-HT 2B receptor (HTR2B)
DMRFJNC	MT	DTT
DMRFJNC	MA	Inhibitor
DMRFJNC	RN	1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28.
DMRFJNC	RU	https://pubmed.ncbi.nlm.nih.gov/16392816

DMRFJNC	DI	DMRFJNC
DMRFJNC	DN	1-((S)-2-aminopropyl)-7-chloro-1H-indazol-6-ol
DMRFJNC	MI	TTWJBZ5
DMRFJNC	MN	5-HT 2C receptor (HTR2C)
DMRFJNC	MT	DTT
DMRFJNC	MA	Inhibitor
DMRFJNC	RN	1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28.
DMRFJNC	RU	https://pubmed.ncbi.nlm.nih.gov/16392816

DM76JVB	DI	DM76JVB
DM76JVB	DN	1-((S)-2-aminopropyl)-7-fluoro-1H-indazol-6-ol
DM76JVB	MI	TTJQOD7
DM76JVB	MN	5-HT 2A receptor (HTR2A)
DM76JVB	MT	DTT
DM76JVB	MA	Inhibitor
DM76JVB	RN	1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28.
DM76JVB	RU	https://pubmed.ncbi.nlm.nih.gov/16392816

DM76JVB	DI	DM76JVB
DM76JVB	DN	1-((S)-2-aminopropyl)-7-fluoro-1H-indazol-6-ol
DM76JVB	MI	TT0K1SC
DM76JVB	MN	5-HT 2B receptor (HTR2B)
DM76JVB	MT	DTT
DM76JVB	MA	Inhibitor
DM76JVB	RN	1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28.
DM76JVB	RU	https://pubmed.ncbi.nlm.nih.gov/16392816

DM76JVB	DI	DM76JVB
DM76JVB	DN	1-((S)-2-aminopropyl)-7-fluoro-1H-indazol-6-ol
DM76JVB	MI	TTWJBZ5
DM76JVB	MN	5-HT 2C receptor (HTR2C)
DM76JVB	MT	DTT
DM76JVB	MA	Inhibitor
DM76JVB	RN	1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28.
DM76JVB	RU	https://pubmed.ncbi.nlm.nih.gov/16392816

DMR2SXL	DI	DMR2SXL
DMR2SXL	DN	1-((S)-2-aminopropyl)-7-iodo-1H-indazol-6-ol
DMR2SXL	MI	TTJQOD7
DMR2SXL	MN	5-HT 2A receptor (HTR2A)
DMR2SXL	MT	DTT
DMR2SXL	MA	Inhibitor
DMR2SXL	RN	1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28.
DMR2SXL	RU	https://pubmed.ncbi.nlm.nih.gov/16392816

DMR2SXL	DI	DMR2SXL
DMR2SXL	DN	1-((S)-2-aminopropyl)-7-iodo-1H-indazol-6-ol
DMR2SXL	MI	TT0K1SC
DMR2SXL	MN	5-HT 2B receptor (HTR2B)
DMR2SXL	MT	DTT
DMR2SXL	MA	Inhibitor
DMR2SXL	RN	1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28.
DMR2SXL	RU	https://pubmed.ncbi.nlm.nih.gov/16392816

DMR2SXL	DI	DMR2SXL
DMR2SXL	DN	1-((S)-2-aminopropyl)-7-iodo-1H-indazol-6-ol
DMR2SXL	MI	TTWJBZ5
DMR2SXL	MN	5-HT 2C receptor (HTR2C)
DMR2SXL	MT	DTT
DMR2SXL	MA	Inhibitor
DMR2SXL	RN	1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28.
DMR2SXL	RU	https://pubmed.ncbi.nlm.nih.gov/16392816

DM8MNZG	DI	DM8MNZG
DM8MNZG	DN	1-((S)-2-aminopropyl)-7-methyl-1H-indazol-6-ol
DM8MNZG	MI	TTJQOD7
DM8MNZG	MN	5-HT 2A receptor (HTR2A)
DM8MNZG	MT	DTT
DM8MNZG	MA	Inhibitor
DM8MNZG	RN	1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28.
DM8MNZG	RU	https://pubmed.ncbi.nlm.nih.gov/16392816

DM8MNZG	DI	DM8MNZG
DM8MNZG	DN	1-((S)-2-aminopropyl)-7-methyl-1H-indazol-6-ol
DM8MNZG	MI	TT0K1SC
DM8MNZG	MN	5-HT 2B receptor (HTR2B)
DM8MNZG	MT	DTT
DM8MNZG	MA	Inhibitor
DM8MNZG	RN	1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28.
DM8MNZG	RU	https://pubmed.ncbi.nlm.nih.gov/16392816

DM8MNZG	DI	DM8MNZG
DM8MNZG	DN	1-((S)-2-aminopropyl)-7-methyl-1H-indazol-6-ol
DM8MNZG	MI	TTWJBZ5
DM8MNZG	MN	5-HT 2C receptor (HTR2C)
DM8MNZG	MT	DTT
DM8MNZG	MA	Inhibitor
DM8MNZG	RN	1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28.
DM8MNZG	RU	https://pubmed.ncbi.nlm.nih.gov/16392816

DMCSOAV	DI	DMCSOAV
DMCSOAV	DN	1-(1-(2-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX)
DMCSOAV	MI	TTAWNKZ
DMCSOAV	MN	Norepinephrine transporter (NET)
DMCSOAV	MT	DTT
DMCSOAV	MA	Inhibitor
DMCSOAV	RN	Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92.
DMCSOAV	RU	https://pubmed.ncbi.nlm.nih.gov/20471260

DMCSOAV	DI	DMCSOAV
DMCSOAV	DN	1-(1-(2-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX)
DMCSOAV	MI	TT3ROYC
DMCSOAV	MN	Serotonin transporter (SERT)
DMCSOAV	MT	DTT
DMCSOAV	MA	Inhibitor
DMCSOAV	RN	Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92.
DMCSOAV	RU	https://pubmed.ncbi.nlm.nih.gov/20471260

DMCSOAV	DI	DMCSOAV
DMCSOAV	DN	1-(1-(2-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX)
DMCSOAV	MI	TTQ6VDM
DMCSOAV	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMCSOAV	MT	DTT
DMCSOAV	MA	Inhibitor
DMCSOAV	RN	Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92.
DMCSOAV	RU	https://pubmed.ncbi.nlm.nih.gov/20471260

DM0XNMP	DI	DM0XNMP
DM0XNMP	DN	1-(1-(3-nitrophenyl)propylidene)thiosemicarbazide
DM0XNMP	MI	TTEAID7
DM0XNMP	MN	Trypanosoma Cruzipain (Trypano CYSP)
DM0XNMP	MT	DTT
DM0XNMP	MA	Inhibitor
DM0XNMP	RN	Design, synthesis, and biochemical evaluation of novel cruzain inhibitors with potential application in the treatment of Chagas' disease. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4405-9.
DM0XNMP	RU	https://pubmed.ncbi.nlm.nih.gov/16781147

DMXJ58Z	DI	DMXJ58Z
DMXJ58Z	DN	1-(1-(4-bromophenyl)ethylidene)thiosemicarbazide
DMXJ58Z	MI	TTULVH8
DMXJ58Z	MN	Tyrosinase (TYR)
DMXJ58Z	MT	DTT
DMXJ58Z	MA	Inhibitor
DMXJ58Z	RN	1-(1-Arylethylidene)thiosemicarbazide derivatives: a new class of tyrosinase inhibitors. Bioorg Med Chem. 2008 Feb 1;16(3):1096-102.
DMXJ58Z	RU	https://pubmed.ncbi.nlm.nih.gov/18326070

DMOQPKT	DI	DMOQPKT
DMOQPKT	DN	1-(1-(4'-Ethylbiphenyl-4-yl)propyl)-1H-imidazole
DMOQPKT	MI	TTRA5BZ
DMOQPKT	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMOQPKT	MT	DTT
DMOQPKT	MA	Inhibitor
DMOQPKT	RN	Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxyl... Bioorg Med Chem. 2008 Aug 15;16(16):7715-27.
DMOQPKT	RU	https://pubmed.ncbi.nlm.nih.gov/18674917

DMS9PZ7	DI	DMS9PZ7
DMS9PZ7	DN	1-(1-(4-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX)
DMS9PZ7	MI	TTVBI8W
DMS9PZ7	MN	Dopamine transporter (DAT)
DMS9PZ7	MT	DTT
DMS9PZ7	MA	Inhibitor
DMS9PZ7	RN	Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92.
DMS9PZ7	RU	https://pubmed.ncbi.nlm.nih.gov/20471260

DMS9PZ7	DI	DMS9PZ7
DMS9PZ7	DN	1-(1-(4-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX)
DMS9PZ7	MI	TTAWNKZ
DMS9PZ7	MN	Norepinephrine transporter (NET)
DMS9PZ7	MT	DTT
DMS9PZ7	MA	Inhibitor
DMS9PZ7	RN	Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92.
DMS9PZ7	RU	https://pubmed.ncbi.nlm.nih.gov/20471260

DMS9PZ7	DI	DMS9PZ7
DMS9PZ7	DN	1-(1-(4-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX)
DMS9PZ7	MI	TT3ROYC
DMS9PZ7	MN	Serotonin transporter (SERT)
DMS9PZ7	MT	DTT
DMS9PZ7	MA	Inhibitor
DMS9PZ7	RN	Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92.
DMS9PZ7	RU	https://pubmed.ncbi.nlm.nih.gov/20471260

DMS9PZ7	DI	DMS9PZ7
DMS9PZ7	DN	1-(1-(4-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX)
DMS9PZ7	MI	TTQ6VDM
DMS9PZ7	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMS9PZ7	MT	DTT
DMS9PZ7	MA	Inhibitor
DMS9PZ7	RN	Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92.
DMS9PZ7	RU	https://pubmed.ncbi.nlm.nih.gov/20471260

DMQBHGK	DI	DMQBHGK
DMQBHGK	DN	1-(1-(4-fluorophenyl)ethylidene)thiosemicarbazide
DMQBHGK	MI	TTULVH8
DMQBHGK	MN	Tyrosinase (TYR)
DMQBHGK	MT	DTT
DMQBHGK	MA	Inhibitor
DMQBHGK	RN	1-(1-Arylethylidene)thiosemicarbazide derivatives: a new class of tyrosinase inhibitors. Bioorg Med Chem. 2008 Feb 1;16(3):1096-102.
DMQBHGK	RU	https://pubmed.ncbi.nlm.nih.gov/18326070

DMEIH5N	DI	DMEIH5N
DMEIH5N	DN	1-(1-(4-thiophen-3-ylphenyl)ethyl)-1H-imidazole
DMEIH5N	MI	TTRA5BZ
DMEIH5N	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMEIH5N	MT	DTT
DMEIH5N	MA	Inhibitor
DMEIH5N	RN	Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxyla... Bioorg Med Chem. 2008 Feb 15;16(4):1992-2010.
DMEIH5N	RU	https://pubmed.ncbi.nlm.nih.gov/18061460

DMQF2N5	DI	DMQF2N5
DMQF2N5	DN	1-(1-(4-thiophen-3-yl-phenyl)propyl)-1Himidazole
DMQF2N5	MI	TTRA5BZ
DMQF2N5	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMQF2N5	MT	DTT
DMQF2N5	MA	Inhibitor
DMQF2N5	RN	Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxyla... Bioorg Med Chem. 2008 Feb 15;16(4):1992-2010.
DMQF2N5	RU	https://pubmed.ncbi.nlm.nih.gov/18061460

DMPGM0V	DI	DMPGM0V
DMPGM0V	DN	1-(1-(benzo[b]thiophen-2-yl)cyclohexyl)piperidine
DMPGM0V	MI	TTVBI8W
DMPGM0V	MN	Dopamine transporter (DAT)
DMPGM0V	MT	DTT
DMPGM0V	MA	Inhibitor
DMPGM0V	RN	Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69.
DMPGM0V	RU	https://pubmed.ncbi.nlm.nih.gov/18588282

DMLJ7WA	DI	DMLJ7WA
DMLJ7WA	DN	1-(1-(Biphenyl-4-yl)allyl)-1H-imidazole
DMLJ7WA	MI	TTRA5BZ
DMLJ7WA	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMLJ7WA	MT	DTT
DMLJ7WA	MA	Inhibitor
DMLJ7WA	RN	Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxyl... Bioorg Med Chem. 2008 Aug 15;16(16):7715-27.
DMLJ7WA	RU	https://pubmed.ncbi.nlm.nih.gov/18674917

DM7WJOY	DI	DM7WJOY
DM7WJOY	DN	1-(1-(pyrazin-2-yl)ethylidene)thiosemicarbazide
DM7WJOY	MI	TTULVH8
DM7WJOY	MN	Tyrosinase (TYR)
DM7WJOY	MT	DTT
DM7WJOY	MA	Inhibitor
DM7WJOY	RN	1-(1-Arylethylidene)thiosemicarbazide derivatives: a new class of tyrosinase inhibitors. Bioorg Med Chem. 2008 Feb 1;16(3):1096-102.
DM7WJOY	RU	https://pubmed.ncbi.nlm.nih.gov/18326070

DMJ21XT	DI	DMJ21XT
DMJ21XT	DN	1-(1-(pyridin-3-yl)ethylidene)thiosemicarbazide
DMJ21XT	MI	TTULVH8
DMJ21XT	MN	Tyrosinase (TYR)
DMJ21XT	MT	DTT
DMJ21XT	MA	Inhibitor
DMJ21XT	RN	1-(1-Arylethylidene)thiosemicarbazide derivatives: a new class of tyrosinase inhibitors. Bioorg Med Chem. 2008 Feb 1;16(3):1096-102.
DMJ21XT	RU	https://pubmed.ncbi.nlm.nih.gov/18326070

DMQSEF6	DI	DMQSEF6
DMQSEF6	DN	1-(1-(thiophen-2-yl)ethylidene)thiosemicarbazide
DMQSEF6	MI	TTULVH8
DMQSEF6	MN	Tyrosinase (TYR)
DMQSEF6	MT	DTT
DMQSEF6	MA	Inhibitor
DMQSEF6	RN	1-(1-Arylethylidene)thiosemicarbazide derivatives: a new class of tyrosinase inhibitors. Bioorg Med Chem. 2008 Feb 1;16(3):1096-102.
DMQSEF6	RU	https://pubmed.ncbi.nlm.nih.gov/18326070

DMPMLZF	DI	DMPMLZF
DMPMLZF	DN	1-(1,2,4-Oxadiazol-3-yl)-7-phenylheptan-1-one
DMPMLZF	MI	TTDP1UC
DMPMLZF	MN	Fatty acid amide hydrolase (FAAH)
DMPMLZF	MT	DTT
DMPMLZF	MA	Inhibitor
DMPMLZF	RN	Optimization of the central heterocycle of alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Aug 14;51(15):4392-403.
DMPMLZF	RU	https://pubmed.ncbi.nlm.nih.gov/18630870

DMBS90M	DI	DMBS90M
DMBS90M	DN	1-(1,2,4-Oxadiazol-5-yl)-7-phenylheptan-1-one
DMBS90M	MI	TTDP1UC
DMBS90M	MN	Fatty acid amide hydrolase (FAAH)
DMBS90M	MT	DTT
DMBS90M	MA	Inhibitor
DMBS90M	RN	Optimization of the central heterocycle of alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Aug 14;51(15):4392-403.
DMBS90M	RU	https://pubmed.ncbi.nlm.nih.gov/18630870

DMOR9EK	DI	DMOR9EK
DMOR9EK	DN	1-(1,2-diphenylethyl)-4-phenylpiperidin-4-ol
DMOR9EK	MI	TTNT7K8
DMOR9EK	MN	Nociceptin receptor (OPRL1)
DMOR9EK	MT	DTT
DMOR9EK	MA	Inhibitor
DMOR9EK	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMOR9EK	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMOR9EK	DI	DMOR9EK
DMOR9EK	DN	1-(1,2-diphenylethyl)-4-phenylpiperidin-4-ol
DMOR9EK	MI	TT27RFC
DMOR9EK	MN	Opioid receptor delta (OPRD1)
DMOR9EK	MT	DTT
DMOR9EK	MA	Inhibitor
DMOR9EK	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMOR9EK	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMOR9EK	DI	DMOR9EK
DMOR9EK	DN	1-(1,2-diphenylethyl)-4-phenylpiperidin-4-ol
DMOR9EK	MI	TTQW87Y
DMOR9EK	MN	Opioid receptor kappa (OPRK1)
DMOR9EK	MT	DTT
DMOR9EK	MA	Inhibitor
DMOR9EK	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMOR9EK	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMOR9EK	DI	DMOR9EK
DMOR9EK	DN	1-(1,2-diphenylethyl)-4-phenylpiperidin-4-ol
DMOR9EK	MI	TTKWM86
DMOR9EK	MN	Opioid receptor mu (MOP)
DMOR9EK	MT	DTT
DMOR9EK	MA	Inhibitor
DMOR9EK	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMOR9EK	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DM0ARKB	DI	DM0ARKB
DM0ARKB	DN	1-(1,2-diphenylethyl)piperazine
DM0ARKB	MI	TTAWNKZ
DM0ARKB	MN	Norepinephrine transporter (NET)
DM0ARKB	MT	DTT
DM0ARKB	MA	Inhibitor
DM0ARKB	RN	N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8.
DM0ARKB	RU	https://pubmed.ncbi.nlm.nih.gov/16750359

DM0ARKB	DI	DM0ARKB
DM0ARKB	DN	1-(1,2-diphenylethyl)piperazine
DM0ARKB	MI	TT3ROYC
DM0ARKB	MN	Serotonin transporter (SERT)
DM0ARKB	MT	DTT
DM0ARKB	MA	Inhibitor
DM0ARKB	RN	N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8.
DM0ARKB	RU	https://pubmed.ncbi.nlm.nih.gov/16750359

DMHIYB3	DI	DMHIYB3
DMHIYB3	DN	1-(1,3,4-Oxadiazol-2-yl)-7-phenylheptan-1-one
DMHIYB3	MI	TTDP1UC
DMHIYB3	MN	Fatty acid amide hydrolase (FAAH)
DMHIYB3	MT	DTT
DMHIYB3	MA	Inhibitor
DMHIYB3	RN	Optimization of the central heterocycle of alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Aug 14;51(15):4392-403.
DMHIYB3	RU	https://pubmed.ncbi.nlm.nih.gov/18630870

DMZ1GH0	DI	DMZ1GH0
DMZ1GH0	DN	1-(1,3,4-oxadiazol-2-yl)octadec-9-en-1-one
DMZ1GH0	MI	TTDP1UC
DMZ1GH0	MN	Fatty acid amide hydrolase (FAAH)
DMZ1GH0	MT	DTT
DMZ1GH0	MA	Inhibitor
DMZ1GH0	RN	Optimization of the central heterocycle of alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Aug 14;51(15):4392-403.
DMZ1GH0	RU	https://pubmed.ncbi.nlm.nih.gov/18630870

DM6B14Q	DI	DM6B14Q
DM6B14Q	DN	1-(1,3,4-thiadiazol-2-yl)octadec-9-en-1-one
DM6B14Q	MI	TTDP1UC
DM6B14Q	MN	Fatty acid amide hydrolase (FAAH)
DM6B14Q	MT	DTT
DM6B14Q	MA	Inhibitor
DM6B14Q	RN	Optimization of the central heterocycle of alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Aug 14;51(15):4392-403.
DM6B14Q	RU	https://pubmed.ncbi.nlm.nih.gov/18630870

DMTC98X	DI	DMTC98X
DMTC98X	DN	1-(1,3-diphenylpropyl)piperazine
DMTC98X	MI	TT3ROYC
DMTC98X	MN	Serotonin transporter (SERT)
DMTC98X	MT	DTT
DMTC98X	MA	Inhibitor
DMTC98X	RN	Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4349-53.
DMTC98X	RU	https://pubmed.ncbi.nlm.nih.gov/16750363

DMYI3F5	DI	DMYI3F5
DMYI3F5	DN	1-(1,3-diphenylpropylidene)thiosemicarbazide
DMYI3F5	MI	TT36ETB
DMYI3F5	MN	Cathepsin L (CTSL)
DMYI3F5	MT	DTT
DMYI3F5	MA	Inhibitor
DMYI3F5	RN	Discovery of trypanocidal thiosemicarbazone inhibitors of rhodesain and TbcatB. Bioorg Med Chem Lett. 2008 May 1;18(9):2883-5.
DMYI3F5	RU	https://pubmed.ncbi.nlm.nih.gov/18420405

DMHNOLA	DI	DMHNOLA
DMHNOLA	DN	1-(1,4-diacetylphenyl)dithiosemicarbazide
DMHNOLA	MI	TTULVH8
DMHNOLA	MN	Tyrosinase (TYR)
DMHNOLA	MT	DTT
DMHNOLA	MA	Inhibitor
DMHNOLA	RN	1-(1-Arylethylidene)thiosemicarbazide derivatives: a new class of tyrosinase inhibitors. Bioorg Med Chem. 2008 Feb 1;16(3):1096-102.
DMHNOLA	RU	https://pubmed.ncbi.nlm.nih.gov/18326070

DM8Z1QU	DI	DM8Z1QU
DM8Z1QU	DN	1-(1,4-diphenylbutan-2-yl)piperazine
DM8Z1QU	MI	TTVBI8W
DM8Z1QU	MN	Dopamine transporter (DAT)
DM8Z1QU	MT	DTT
DM8Z1QU	MA	Inhibitor
DM8Z1QU	RN	Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4349-53.
DM8Z1QU	RU	https://pubmed.ncbi.nlm.nih.gov/16750363

DM8Z1QU	DI	DM8Z1QU
DM8Z1QU	DN	1-(1,4-diphenylbutan-2-yl)piperazine
DM8Z1QU	MI	TTAWNKZ
DM8Z1QU	MN	Norepinephrine transporter (NET)
DM8Z1QU	MT	DTT
DM8Z1QU	MA	Inhibitor
DM8Z1QU	RN	Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4349-53.
DM8Z1QU	RU	https://pubmed.ncbi.nlm.nih.gov/16750363

DM8Z1QU	DI	DM8Z1QU
DM8Z1QU	DN	1-(1,4-diphenylbutan-2-yl)piperazine
DM8Z1QU	MI	TT3ROYC
DM8Z1QU	MN	Serotonin transporter (SERT)
DM8Z1QU	MT	DTT
DM8Z1QU	MA	Inhibitor
DM8Z1QU	RN	Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4349-53.
DM8Z1QU	RU	https://pubmed.ncbi.nlm.nih.gov/16750363

DM2AEO0	DI	DM2AEO0
DM2AEO0	DN	1-(10-Bromoanthracen-9-yl)-2-aminopropane
DM2AEO0	MI	TTJQOD7
DM2AEO0	MN	5-HT 2A receptor (HTR2A)
DM2AEO0	MT	DTT
DM2AEO0	MA	Inhibitor
DM2AEO0	RN	The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands. Bioorg Med Chem. 2008 Apr 15;16(8):4661-9.
DM2AEO0	RU	https://pubmed.ncbi.nlm.nih.gov/18296055

DMKIWBT	DI	DMKIWBT
DMKIWBT	DN	1-(10H-phenothiazin-10-yl)-2-phenylbutan-1-one
DMKIWBT	MI	TTEB0GD
DMKIWBT	MN	Cholinesterase (BCHE)
DMKIWBT	MT	DTT
DMKIWBT	MA	Inhibitor
DMKIWBT	RN	Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. Bioorg Med Chem. 2007 Oct 1;15(19):6367-78.
DMKIWBT	RU	https://pubmed.ncbi.nlm.nih.gov/17681768

DM5WBMY	DI	DM5WBMY
DM5WBMY	DN	1-(10H-phenothiazin-10-yl)-2-phenylethanone
DM5WBMY	MI	TTEB0GD
DM5WBMY	MN	Cholinesterase (BCHE)
DM5WBMY	MT	DTT
DM5WBMY	MA	Inhibitor
DM5WBMY	RN	Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. Bioorg Med Chem. 2007 Oct 1;15(19):6367-78.
DM5WBMY	RU	https://pubmed.ncbi.nlm.nih.gov/17681768

DMYWG7D	DI	DMYWG7D
DMYWG7D	DN	1-(10H-phenothiazin-10-yl)-2-phenylpropan-1-one
DMYWG7D	MI	TTEB0GD
DMYWG7D	MN	Cholinesterase (BCHE)
DMYWG7D	MT	DTT
DMYWG7D	MA	Inhibitor
DMYWG7D	RN	Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. Bioorg Med Chem. 2007 Oct 1;15(19):6367-78.
DMYWG7D	RU	https://pubmed.ncbi.nlm.nih.gov/17681768

DMZCPAQ	DI	DMZCPAQ
DMZCPAQ	DN	1-(10H-phenothiazin-10-yl)-3-phenylbutan-1-one
DMZCPAQ	MI	TTEB0GD
DMZCPAQ	MN	Cholinesterase (BCHE)
DMZCPAQ	MT	DTT
DMZCPAQ	MA	Inhibitor
DMZCPAQ	RN	Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. Bioorg Med Chem. 2007 Oct 1;15(19):6367-78.
DMZCPAQ	RU	https://pubmed.ncbi.nlm.nih.gov/17681768

DMJQNLR	DI	DMJQNLR
DMJQNLR	DN	1-(10H-phenothiazin-10-yl)-3-phenylpropan-1-one
DMJQNLR	MI	TTEB0GD
DMJQNLR	MN	Cholinesterase (BCHE)
DMJQNLR	MT	DTT
DMJQNLR	MA	Inhibitor
DMJQNLR	RN	Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. Bioorg Med Chem. 2007 Oct 1;15(19):6367-78.
DMJQNLR	RU	https://pubmed.ncbi.nlm.nih.gov/17681768

DMGY32O	DI	DMGY32O
DMGY32O	DN	1-(10H-phenothiazin-10-yl)-4-phenylbutan-1-one
DMGY32O	MI	TTEB0GD
DMGY32O	MN	Cholinesterase (BCHE)
DMGY32O	MT	DTT
DMGY32O	MA	Inhibitor
DMGY32O	RN	Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. Bioorg Med Chem. 2007 Oct 1;15(19):6367-78.
DMGY32O	RU	https://pubmed.ncbi.nlm.nih.gov/17681768

DM7G2AB	DI	DM7G2AB
DM7G2AB	DN	1-(1-Adamantyl)-3-(1-propionylpiperidin-4-yl)urea
DM7G2AB	MI	TT7WVHI
DM7G2AB	MN	Soluble epoxide hydrolase (EPHX2)
DM7G2AB	MT	DTT
DM7G2AB	MA	Inhibitor
DM7G2AB	RN	1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, a... J Med Chem. 2010 Oct 14;53(19):7067-75.
DM7G2AB	RU	https://pubmed.ncbi.nlm.nih.gov/20812725

DM2T1CD	DI	DM2T1CD
DM2T1CD	DN	1-(1-Benzo[b]thiophen-2-yl-cycloheptyl)-azepane
DM2T1CD	MI	TTVBI8W
DM2T1CD	MN	Dopamine transporter (DAT)
DM2T1CD	MT	DTT
DM2T1CD	MA	Inhibitor
DM2T1CD	RN	Synthesis and biological evaluation of 1-[1-(2-benzo[b]thienyl)cyclohexyl]piperidine homologues at dopamine-uptake and phencyclidine- and sigma-bin... J Med Chem. 1993 Apr 30;36(9):1188-93.
DM2T1CD	RU	https://pubmed.ncbi.nlm.nih.gov/8098066

DMEFP15	DI	DMEFP15
DMEFP15	DN	1-(1-Benzo[b]thiophen-2-yl-cyclohexyl)-azepane
DMEFP15	MI	TTVBI8W
DMEFP15	MN	Dopamine transporter (DAT)
DMEFP15	MT	DTT
DMEFP15	MA	Inhibitor
DMEFP15	RN	Synthesis and biological evaluation of 1-[1-(2-benzo[b]thienyl)cyclohexyl]piperidine homologues at dopamine-uptake and phencyclidine- and sigma-bin... J Med Chem. 1993 Apr 30;36(9):1188-93.
DMEFP15	RU	https://pubmed.ncbi.nlm.nih.gov/8098066

DM1Q36W	DI	DM1Q36W
DM1Q36W	DN	1-(1-Benzo[b]thiophen-2-yl-cyclopentyl)-azepane
DM1Q36W	MI	TTVBI8W
DM1Q36W	MN	Dopamine transporter (DAT)
DM1Q36W	MT	DTT
DM1Q36W	MA	Inhibitor
DM1Q36W	RN	Synthesis and biological evaluation of 1-[1-(2-benzo[b]thienyl)cyclohexyl]piperidine homologues at dopamine-uptake and phencyclidine- and sigma-bin... J Med Chem. 1993 Apr 30;36(9):1188-93.
DM1Q36W	RU	https://pubmed.ncbi.nlm.nih.gov/8098066

DMLBCE5	DI	DMLBCE5
DMLBCE5	DN	1-(1-Benzyl-2-biphenyl-4-yl-ethyl)-1H-imidazole
DMLBCE5	MI	TTSZLWK
DMLBCE5	MN	Aromatase (CYP19A1)
DMLBCE5	MT	DTT
DMLBCE5	MA	Inhibitor
DMLBCE5	RN	CYP19 (aromatase): exploring the scaffold flexibility for novel selective inhibitors. Bioorg Med Chem. 2008 Sep 15;16(18):8349-58.
DMLBCE5	RU	https://pubmed.ncbi.nlm.nih.gov/18782670

DMPEIQT	DI	DMPEIQT
DMPEIQT	DN	1-(1-Biphenyl-4-yl-2-methyl-propyl)-1H-imidazole
DMPEIQT	MI	TTRA5BZ
DMPEIQT	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMPEIQT	MT	DTT
DMPEIQT	MA	Inhibitor
DMPEIQT	RN	Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxyl... Bioorg Med Chem. 2008 Aug 15;16(16):7715-27.
DMPEIQT	RU	https://pubmed.ncbi.nlm.nih.gov/18674917

DMCTF8X	DI	DMCTF8X
DMCTF8X	DN	1-(1-Biphenyl-4-yl-2-phenyl-ethyl)-1H-imidazole
DMCTF8X	MI	TTRA5BZ
DMCTF8X	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMCTF8X	MT	DTT
DMCTF8X	MA	Inhibitor
DMCTF8X	RN	Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxyl... Bioorg Med Chem. 2008 Aug 15;16(16):7715-27.
DMCTF8X	RU	https://pubmed.ncbi.nlm.nih.gov/18674917

DMWME7I	DI	DMWME7I
DMWME7I	DN	1-(1-Biphenyl-4-yl-3-methyl-butyl)-1H-imidazole
DMWME7I	MI	TTRA5BZ
DMWME7I	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMWME7I	MT	DTT
DMWME7I	MA	Inhibitor
DMWME7I	RN	Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxyl... Bioorg Med Chem. 2008 Aug 15;16(16):7715-27.
DMWME7I	RU	https://pubmed.ncbi.nlm.nih.gov/18674917

DM4XILF	DI	DM4XILF
DM4XILF	DN	1-(1-Biphenyl-4-yl-butyl)-1H-imidazole
DM4XILF	MI	TTRA5BZ
DM4XILF	MN	Steroid 17-alpha-monooxygenase (S17AH)
DM4XILF	MT	DTT
DM4XILF	MA	Inhibitor
DM4XILF	RN	Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxyl... Bioorg Med Chem. 2008 Aug 15;16(16):7715-27.
DM4XILF	RU	https://pubmed.ncbi.nlm.nih.gov/18674917

DMW85CH	DI	DMW85CH
DMW85CH	DN	1-(1-Biphenyl-4-yl-ethyl)-1H-imidazole
DMW85CH	MI	TTRA5BZ
DMW85CH	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMW85CH	MT	DTT
DMW85CH	MA	Inhibitor
DMW85CH	RN	Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxyl... Bioorg Med Chem. 2008 Aug 15;16(16):7715-27.
DMW85CH	RU	https://pubmed.ncbi.nlm.nih.gov/18674917

DM3AD7E	DI	DM3AD7E
DM3AD7E	DN	1-(1-Biphenyl-4-yl-pentyl)-1H-imidazole
DM3AD7E	MI	TTRA5BZ
DM3AD7E	MN	Steroid 17-alpha-monooxygenase (S17AH)
DM3AD7E	MT	DTT
DM3AD7E	MA	Inhibitor
DM3AD7E	RN	Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxyl... Bioorg Med Chem. 2008 Aug 15;16(16):7715-27.
DM3AD7E	RU	https://pubmed.ncbi.nlm.nih.gov/18674917

DMGVE3F	DI	DMGVE3F
DMGVE3F	DN	1-(1-Biphenyl-4-yl-propyl)-1H-imidazole
DMGVE3F	MI	TTRA5BZ
DMGVE3F	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMGVE3F	MT	DTT
DMGVE3F	MA	Inhibitor
DMGVE3F	RN	Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxyl... Bioorg Med Chem. 2008 Aug 15;16(16):7715-27.
DMGVE3F	RU	https://pubmed.ncbi.nlm.nih.gov/18674917

DM9MCAU	DI	DM9MCAU
DM9MCAU	DN	1-(1H-Indazol-6-yl)-3-pyridin-2-yl-urea
DM9MCAU	MI	TT0PG8F
DM9MCAU	MN	Cyclin-dependent kinase 4 (CDK4)
DM9MCAU	MT	DTT
DM9MCAU	MA	Inhibitor
DM9MCAU	RN	Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. J Med Chem. 2001 Dec 20;44(26):4615-27.
DM9MCAU	RU	https://pubmed.ncbi.nlm.nih.gov/11741479

DMSUPCD	DI	DMSUPCD
DMSUPCD	DN	1-(1H-Indol-4-yloxy)-3-phenethylamino-propan-2-ol
DMSUPCD	MI	TTR6W5O
DMSUPCD	MN	Adrenergic receptor beta-1 (ADRB1)
DMSUPCD	MT	DTT
DMSUPCD	MA	Inhibitor
DMSUPCD	RN	Synthesis and beta-adrenergic receptor blocking potency of 1-(substituted amino)-3-(4-indolyloxy)propan-2-ols. J Med Chem. 1986 Aug;29(8):1524-7.
DMSUPCD	RU	https://pubmed.ncbi.nlm.nih.gov/2874227

DMSUPCD	DI	DMSUPCD
DMSUPCD	DN	1-(1H-Indol-4-yloxy)-3-phenethylamino-propan-2-ol
DMSUPCD	MI	TTMXGCW
DMSUPCD	MN	Adrenergic receptor beta-3 (ADRB3)
DMSUPCD	MT	DTT
DMSUPCD	MA	Inhibitor
DMSUPCD	RN	Synthesis and beta-adrenergic receptor blocking potency of 1-(substituted amino)-3-(4-indolyloxy)propan-2-ols. J Med Chem. 1986 Aug;29(8):1524-7.
DMSUPCD	RU	https://pubmed.ncbi.nlm.nih.gov/2874227

DM6X9J3	DI	DM6X9J3
DM6X9J3	DN	1-(1-Naphthyl)-2-aminopropane
DM6X9J3	MI	TT3WG5C
DM6X9J3	MN	Monoamine oxidase type A (MAO-A)
DM6X9J3	MT	DTT
DM6X9J3	MA	Inhibitor
DM6X9J3	RN	Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg Med Chem. 2009 Mar 15;17(6):2452-60.
DM6X9J3	RU	https://pubmed.ncbi.nlm.nih.gov/19243954

DMSUC85	DI	DMSUC85
DMSUC85	DN	1-(1-phenyl-1H-tetrazol-5-ylthio)propan-2-one
DMSUC85	MI	TTN7BL9
DMSUC85	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMSUC85	MT	DTT
DMSUC85	MA	Inhibitor
DMSUC85	RN	Modulation of 11beta-hydroxysteroid dehydrogenase type 1 activity by 1,5-substituted 1H-tetrazoles. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3265-71.
DMSUC85	RU	https://pubmed.ncbi.nlm.nih.gov/20452767

DM54ZKU	DI	DM54ZKU
DM54ZKU	DN	1-(1-phenyl-2-(2-propoxyphenyl)ethyl)piperazine
DM54ZKU	MI	TTVBI8W
DM54ZKU	MN	Dopamine transporter (DAT)
DM54ZKU	MT	DTT
DM54ZKU	MA	Inhibitor
DM54ZKU	RN	Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92.
DM54ZKU	RU	https://pubmed.ncbi.nlm.nih.gov/20471260

DM54ZKU	DI	DM54ZKU
DM54ZKU	DN	1-(1-phenyl-2-(2-propoxyphenyl)ethyl)piperazine
DM54ZKU	MI	TTAWNKZ
DM54ZKU	MN	Norepinephrine transporter (NET)
DM54ZKU	MT	DTT
DM54ZKU	MA	Inhibitor
DM54ZKU	RN	Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92.
DM54ZKU	RU	https://pubmed.ncbi.nlm.nih.gov/20471260

DM54ZKU	DI	DM54ZKU
DM54ZKU	DN	1-(1-phenyl-2-(2-propoxyphenyl)ethyl)piperazine
DM54ZKU	MI	TT3ROYC
DM54ZKU	MN	Serotonin transporter (SERT)
DM54ZKU	MT	DTT
DM54ZKU	MA	Inhibitor
DM54ZKU	RN	Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92.
DM54ZKU	RU	https://pubmed.ncbi.nlm.nih.gov/20471260

DM54ZKU	DI	DM54ZKU
DM54ZKU	DN	1-(1-phenyl-2-(2-propoxyphenyl)ethyl)piperazine
DM54ZKU	MI	TTQ6VDM
DM54ZKU	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DM54ZKU	MT	DTT
DM54ZKU	MA	Inhibitor
DM54ZKU	RN	Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92.
DM54ZKU	RU	https://pubmed.ncbi.nlm.nih.gov/20471260

DMIZBP6	DI	DMIZBP6
DMIZBP6	DN	1-(1-phenyl-2-(pyridin-2-yl)ethyl)piperazine
DMIZBP6	MI	TT3ROYC
DMIZBP6	MN	Serotonin transporter (SERT)
DMIZBP6	MT	DTT
DMIZBP6	MA	Inhibitor
DMIZBP6	RN	Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4349-53.
DMIZBP6	RU	https://pubmed.ncbi.nlm.nih.gov/16750363

DMTVPZC	DI	DMTVPZC
DMTVPZC	DN	1-(1-phenyl-2-(pyridin-4-yl)ethyl)piperazine
DMTVPZC	MI	TT3ROYC
DMTVPZC	MN	Serotonin transporter (SERT)
DMTVPZC	MT	DTT
DMTVPZC	MA	Inhibitor
DMTVPZC	RN	Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4349-53.
DMTVPZC	RU	https://pubmed.ncbi.nlm.nih.gov/16750363

DMZ6QX0	DI	DMZ6QX0
DMZ6QX0	DN	1-(1-phenyl-2-o-tolylethyl)piperazine
DMZ6QX0	MI	TTAWNKZ
DMZ6QX0	MN	Norepinephrine transporter (NET)
DMZ6QX0	MT	DTT
DMZ6QX0	MA	Inhibitor
DMZ6QX0	RN	N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8.
DMZ6QX0	RU	https://pubmed.ncbi.nlm.nih.gov/16750359

DMZ6QX0	DI	DMZ6QX0
DMZ6QX0	DN	1-(1-phenyl-2-o-tolylethyl)piperazine
DMZ6QX0	MI	TT3ROYC
DMZ6QX0	MN	Serotonin transporter (SERT)
DMZ6QX0	MT	DTT
DMZ6QX0	MA	Inhibitor
DMZ6QX0	RN	N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8.
DMZ6QX0	RU	https://pubmed.ncbi.nlm.nih.gov/16750359

DMN5SL6	DI	DMN5SL6
DMN5SL6	DN	1-(1-phenylethylidene)thiosemicarbazide
DMN5SL6	MI	TTULVH8
DMN5SL6	MN	Tyrosinase (TYR)
DMN5SL6	MT	DTT
DMN5SL6	MA	Inhibitor
DMN5SL6	RN	1-(1-Arylethylidene)thiosemicarbazide derivatives: a new class of tyrosinase inhibitors. Bioorg Med Chem. 2008 Feb 1;16(3):1096-102.
DMN5SL6	RU	https://pubmed.ncbi.nlm.nih.gov/18326070

DMER0IY	DI	DMER0IY
DMER0IY	DN	1-(1-Phenyl-propyl)-3-thiazol-2-yl-thiourea
DMER0IY	MI	TT84ETX
DMER0IY	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMER0IY	MT	DTT
DMER0IY	MA	Inhibitor
DMER0IY	RN	Anti-HIV activity of aromatic and heterocyclic thiazolyl thiourea compounds. Bioorg Med Chem Lett. 2001 Feb 26;11(4):523-8.
DMER0IY	RU	https://pubmed.ncbi.nlm.nih.gov/11229762

DMAZR9C	DI	DMAZR9C
DMAZR9C	DN	1-(1-Propionylpiperidin-4-yl)-3-m-tolylurea
DMAZR9C	MI	TT7WVHI
DMAZR9C	MN	Soluble epoxide hydrolase (EPHX2)
DMAZR9C	MT	DTT
DMAZR9C	MA	Inhibitor
DMAZR9C	RN	1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, a... J Med Chem. 2010 Oct 14;53(19):7067-75.
DMAZR9C	RU	https://pubmed.ncbi.nlm.nih.gov/20812725

DMUH59X	DI	DMUH59X
DMUH59X	DN	1-(1-Propionylpiperidin-4-yl)-3-o-tolylurea
DMUH59X	MI	TT7WVHI
DMUH59X	MN	Soluble epoxide hydrolase (EPHX2)
DMUH59X	MT	DTT
DMUH59X	MA	Inhibitor
DMUH59X	RN	1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, a... J Med Chem. 2010 Oct 14;53(19):7067-75.
DMUH59X	RU	https://pubmed.ncbi.nlm.nih.gov/20812725

DMWUBI4	DI	DMWUBI4
DMWUBI4	DN	1-(1-Propionylpiperidin-4-yl)-3-p-tolylurea
DMWUBI4	MI	TT7WVHI
DMWUBI4	MN	Soluble epoxide hydrolase (EPHX2)
DMWUBI4	MT	DTT
DMWUBI4	MA	Inhibitor
DMWUBI4	RN	1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, a... J Med Chem. 2010 Oct 14;53(19):7067-75.
DMWUBI4	RU	https://pubmed.ncbi.nlm.nih.gov/20812725

DM2PQFE	DI	DM2PQFE
DM2PQFE	DN	1-(1-p-tolylethylidene)thiosemicarbazide
DM2PQFE	MI	TTULVH8
DM2PQFE	MN	Tyrosinase (TYR)
DM2PQFE	MT	DTT
DM2PQFE	MA	Inhibitor
DM2PQFE	RN	1-(1-Arylethylidene)thiosemicarbazide derivatives: a new class of tyrosinase inhibitors. Bioorg Med Chem. 2008 Feb 1;16(3):1096-102.
DM2PQFE	RU	https://pubmed.ncbi.nlm.nih.gov/18326070

DMJXKOF	DI	DMJXKOF
DMJXKOF	DN	1-(2-((3-fluorophenoxy)methyl)phenyl)piperazine
DMJXKOF	MI	TTSQIFT
DMJXKOF	MN	5-HT 1A receptor (HTR1A)
DMJXKOF	MT	DTT
DMJXKOF	MA	Inhibitor
DMJXKOF	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMJXKOF	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMJXKOF	DI	DMJXKOF
DMJXKOF	DN	1-(2-((3-fluorophenoxy)methyl)phenyl)piperazine
DMJXKOF	MI	TTAWNKZ
DMJXKOF	MN	Norepinephrine transporter (NET)
DMJXKOF	MT	DTT
DMJXKOF	MA	Inhibitor
DMJXKOF	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMJXKOF	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMJXKOF	DI	DMJXKOF
DMJXKOF	DN	1-(2-((3-fluorophenoxy)methyl)phenyl)piperazine
DMJXKOF	MI	TT3ROYC
DMJXKOF	MN	Serotonin transporter (SERT)
DMJXKOF	MT	DTT
DMJXKOF	MA	Inhibitor
DMJXKOF	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMJXKOF	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMUJ2WB	DI	DMUJ2WB
DMUJ2WB	DN	1-(2-(2-(DIFLUOROMETHOXY)PHENYL)-1-PHENYLETHYL)PIPERAZINE (ENANTIOMERIC MIX)
DMUJ2WB	MI	TTVBI8W
DMUJ2WB	MN	Dopamine transporter (DAT)
DMUJ2WB	MT	DTT
DMUJ2WB	MA	Inhibitor
DMUJ2WB	RN	Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92.
DMUJ2WB	RU	https://pubmed.ncbi.nlm.nih.gov/20471260

DMUJ2WB	DI	DMUJ2WB
DMUJ2WB	DN	1-(2-(2-(DIFLUOROMETHOXY)PHENYL)-1-PHENYLETHYL)PIPERAZINE (ENANTIOMERIC MIX)
DMUJ2WB	MI	TTAWNKZ
DMUJ2WB	MN	Norepinephrine transporter (NET)
DMUJ2WB	MT	DTT
DMUJ2WB	MA	Inhibitor
DMUJ2WB	RN	Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92.
DMUJ2WB	RU	https://pubmed.ncbi.nlm.nih.gov/20471260

DMUJ2WB	DI	DMUJ2WB
DMUJ2WB	DN	1-(2-(2-(DIFLUOROMETHOXY)PHENYL)-1-PHENYLETHYL)PIPERAZINE (ENANTIOMERIC MIX)
DMUJ2WB	MI	TT3ROYC
DMUJ2WB	MN	Serotonin transporter (SERT)
DMUJ2WB	MT	DTT
DMUJ2WB	MA	Inhibitor
DMUJ2WB	RN	Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92.
DMUJ2WB	RU	https://pubmed.ncbi.nlm.nih.gov/20471260

DMUJ2WB	DI	DMUJ2WB
DMUJ2WB	DN	1-(2-(2-(DIFLUOROMETHOXY)PHENYL)-1-PHENYLETHYL)PIPERAZINE (ENANTIOMERIC MIX)
DMUJ2WB	MI	TTQ6VDM
DMUJ2WB	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMUJ2WB	MT	DTT
DMUJ2WB	MA	Inhibitor
DMUJ2WB	RN	Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92.
DMUJ2WB	RU	https://pubmed.ncbi.nlm.nih.gov/20471260

DMPRALC	DI	DMPRALC
DMPRALC	DN	1-(2-(2-bromophenyl)-1-phenylethyl)piperazine
DMPRALC	MI	TTAWNKZ
DMPRALC	MN	Norepinephrine transporter (NET)
DMPRALC	MT	DTT
DMPRALC	MA	Inhibitor
DMPRALC	RN	N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8.
DMPRALC	RU	https://pubmed.ncbi.nlm.nih.gov/16750359

DMPRALC	DI	DMPRALC
DMPRALC	DN	1-(2-(2-bromophenyl)-1-phenylethyl)piperazine
DMPRALC	MI	TT3ROYC
DMPRALC	MN	Serotonin transporter (SERT)
DMPRALC	MT	DTT
DMPRALC	MA	Inhibitor
DMPRALC	RN	N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8.
DMPRALC	RU	https://pubmed.ncbi.nlm.nih.gov/16750359

DM9CVX5	DI	DM9CVX5
DM9CVX5	DN	1-(2-(2-chlorophenoxy)pyridin-3-yl)piperazine
DM9CVX5	MI	TTSQIFT
DM9CVX5	MN	5-HT 1A receptor (HTR1A)
DM9CVX5	MT	DTT
DM9CVX5	MA	Inhibitor
DM9CVX5	RN	Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7.
DM9CVX5	RU	https://pubmed.ncbi.nlm.nih.gov/20031410

DM9CVX5	DI	DM9CVX5
DM9CVX5	DN	1-(2-(2-chlorophenoxy)pyridin-3-yl)piperazine
DM9CVX5	MI	TTAWNKZ
DM9CVX5	MN	Norepinephrine transporter (NET)
DM9CVX5	MT	DTT
DM9CVX5	MA	Inhibitor
DM9CVX5	RN	Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7.
DM9CVX5	RU	https://pubmed.ncbi.nlm.nih.gov/20031410

DMUM4YQ	DI	DMUM4YQ
DMUM4YQ	DN	1-(2-(2-chlorophenyl)-1-phenylethyl)piperazine
DMUM4YQ	MI	TTVBI8W
DMUM4YQ	MN	Dopamine transporter (DAT)
DMUM4YQ	MT	DTT
DMUM4YQ	MA	Inhibitor
DMUM4YQ	RN	N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8.
DMUM4YQ	RU	https://pubmed.ncbi.nlm.nih.gov/16750359

DMUM4YQ	DI	DMUM4YQ
DMUM4YQ	DN	1-(2-(2-chlorophenyl)-1-phenylethyl)piperazine
DMUM4YQ	MI	TTAWNKZ
DMUM4YQ	MN	Norepinephrine transporter (NET)
DMUM4YQ	MT	DTT
DMUM4YQ	MA	Inhibitor
DMUM4YQ	RN	N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8.
DMUM4YQ	RU	https://pubmed.ncbi.nlm.nih.gov/16750359

DMUM4YQ	DI	DMUM4YQ
DMUM4YQ	DN	1-(2-(2-chlorophenyl)-1-phenylethyl)piperazine
DMUM4YQ	MI	TT3ROYC
DMUM4YQ	MN	Serotonin transporter (SERT)
DMUM4YQ	MT	DTT
DMUM4YQ	MA	Inhibitor
DMUM4YQ	RN	N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8.
DMUM4YQ	RU	https://pubmed.ncbi.nlm.nih.gov/16750359

DMBRS3D	DI	DMBRS3D
DMBRS3D	DN	1-(2-(2-ethoxyphenyl)-1-phenylethyl)piperazine
DMBRS3D	MI	TTAWNKZ
DMBRS3D	MN	Norepinephrine transporter (NET)
DMBRS3D	MT	DTT
DMBRS3D	MA	Inhibitor
DMBRS3D	RN	N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8.
DMBRS3D	RU	https://pubmed.ncbi.nlm.nih.gov/16750359

DMBRS3D	DI	DMBRS3D
DMBRS3D	DN	1-(2-(2-ethoxyphenyl)-1-phenylethyl)piperazine
DMBRS3D	MI	TT3ROYC
DMBRS3D	MN	Serotonin transporter (SERT)
DMBRS3D	MT	DTT
DMBRS3D	MA	Inhibitor
DMBRS3D	RN	N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8.
DMBRS3D	RU	https://pubmed.ncbi.nlm.nih.gov/16750359

DMKWRCD	DI	DMKWRCD
DMKWRCD	DN	1-(2-(2-ethylphenyl)-1-phenylethyl)piperazine
DMKWRCD	MI	TTAWNKZ
DMKWRCD	MN	Norepinephrine transporter (NET)
DMKWRCD	MT	DTT
DMKWRCD	MA	Inhibitor
DMKWRCD	RN	N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8.
DMKWRCD	RU	https://pubmed.ncbi.nlm.nih.gov/16750359

DMKWRCD	DI	DMKWRCD
DMKWRCD	DN	1-(2-(2-ethylphenyl)-1-phenylethyl)piperazine
DMKWRCD	MI	TT3ROYC
DMKWRCD	MN	Serotonin transporter (SERT)
DMKWRCD	MT	DTT
DMKWRCD	MA	Inhibitor
DMKWRCD	RN	N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8.
DMKWRCD	RU	https://pubmed.ncbi.nlm.nih.gov/16750359

DM6XCPV	DI	DM6XCPV
DM6XCPV	DN	1-(2-(2-fluorobenzyloxy)phenyl)piperazine
DM6XCPV	MI	TTSQIFT
DM6XCPV	MN	5-HT 1A receptor (HTR1A)
DM6XCPV	MT	DTT
DM6XCPV	MA	Inhibitor
DM6XCPV	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DM6XCPV	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DM6XCPV	DI	DM6XCPV
DM6XCPV	DN	1-(2-(2-fluorobenzyloxy)phenyl)piperazine
DM6XCPV	MI	TTAWNKZ
DM6XCPV	MN	Norepinephrine transporter (NET)
DM6XCPV	MT	DTT
DM6XCPV	MA	Inhibitor
DM6XCPV	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DM6XCPV	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DM6XCPV	DI	DM6XCPV
DM6XCPV	DN	1-(2-(2-fluorobenzyloxy)phenyl)piperazine
DM6XCPV	MI	TT3ROYC
DM6XCPV	MN	Serotonin transporter (SERT)
DM6XCPV	MT	DTT
DM6XCPV	MA	Inhibitor
DM6XCPV	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DM6XCPV	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DM2H38V	DI	DM2H38V
DM2H38V	DN	1-(2-(2-methoxyphenyl)-1-phenylethyl)piperazine
DM2H38V	MI	TTVBI8W
DM2H38V	MN	Dopamine transporter (DAT)
DM2H38V	MT	DTT
DM2H38V	MA	Inhibitor
DM2H38V	RN	N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8.
DM2H38V	RU	https://pubmed.ncbi.nlm.nih.gov/16750359

DM2H38V	DI	DM2H38V
DM2H38V	DN	1-(2-(2-methoxyphenyl)-1-phenylethyl)piperazine
DM2H38V	MI	TTAWNKZ
DM2H38V	MN	Norepinephrine transporter (NET)
DM2H38V	MT	DTT
DM2H38V	MA	Inhibitor
DM2H38V	RN	Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92.
DM2H38V	RU	https://pubmed.ncbi.nlm.nih.gov/20471260

DM2H38V	DI	DM2H38V
DM2H38V	DN	1-(2-(2-methoxyphenyl)-1-phenylethyl)piperazine
DM2H38V	MI	TT3ROYC
DM2H38V	MN	Serotonin transporter (SERT)
DM2H38V	MT	DTT
DM2H38V	MA	Inhibitor
DM2H38V	RN	Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92.
DM2H38V	RU	https://pubmed.ncbi.nlm.nih.gov/20471260

DM4WEGM	DI	DM4WEGM
DM4WEGM	DN	1-(2-(3-chlorophenyl)-1-phenylethyl)piperazine
DM4WEGM	MI	TTAWNKZ
DM4WEGM	MN	Norepinephrine transporter (NET)
DM4WEGM	MT	DTT
DM4WEGM	MA	Inhibitor
DM4WEGM	RN	N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8.
DM4WEGM	RU	https://pubmed.ncbi.nlm.nih.gov/16750359

DM4WEGM	DI	DM4WEGM
DM4WEGM	DN	1-(2-(3-chlorophenyl)-1-phenylethyl)piperazine
DM4WEGM	MI	TT3ROYC
DM4WEGM	MN	Serotonin transporter (SERT)
DM4WEGM	MT	DTT
DM4WEGM	MA	Inhibitor
DM4WEGM	RN	N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8.
DM4WEGM	RU	https://pubmed.ncbi.nlm.nih.gov/16750359

DMXV2KQ	DI	DMXV2KQ
DMXV2KQ	DN	1-(2-(3-fluorophenoxy)phenyl)piperazine
DMXV2KQ	MI	TTSQIFT
DMXV2KQ	MN	5-HT 1A receptor (HTR1A)
DMXV2KQ	MT	DTT
DMXV2KQ	MA	Inhibitor
DMXV2KQ	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMXV2KQ	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMXV2KQ	DI	DMXV2KQ
DMXV2KQ	DN	1-(2-(3-fluorophenoxy)phenyl)piperazine
DMXV2KQ	MI	TTAWNKZ
DMXV2KQ	MN	Norepinephrine transporter (NET)
DMXV2KQ	MT	DTT
DMXV2KQ	MA	Inhibitor
DMXV2KQ	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMXV2KQ	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMXV2KQ	DI	DMXV2KQ
DMXV2KQ	DN	1-(2-(3-fluorophenoxy)phenyl)piperazine
DMXV2KQ	MI	TT3ROYC
DMXV2KQ	MN	Serotonin transporter (SERT)
DMXV2KQ	MT	DTT
DMXV2KQ	MA	Inhibitor
DMXV2KQ	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMXV2KQ	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DM8V5IH	DI	DM8V5IH
DM8V5IH	DN	1-(2-(3-methoxyphenyl)-1-phenylethyl)piperazine
DM8V5IH	MI	TTAWNKZ
DM8V5IH	MN	Norepinephrine transporter (NET)
DM8V5IH	MT	DTT
DM8V5IH	MA	Inhibitor
DM8V5IH	RN	N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8.
DM8V5IH	RU	https://pubmed.ncbi.nlm.nih.gov/16750359

DM8V5IH	DI	DM8V5IH
DM8V5IH	DN	1-(2-(3-methoxyphenyl)-1-phenylethyl)piperazine
DM8V5IH	MI	TT3ROYC
DM8V5IH	MN	Serotonin transporter (SERT)
DM8V5IH	MT	DTT
DM8V5IH	MA	Inhibitor
DM8V5IH	RN	N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8.
DM8V5IH	RU	https://pubmed.ncbi.nlm.nih.gov/16750359

DMU082P	DI	DMU082P
DMU082P	DN	1-(2-(4-fluorophenoxy)phenyl)piperazine
DMU082P	MI	TTSQIFT
DMU082P	MN	5-HT 1A receptor (HTR1A)
DMU082P	MT	DTT
DMU082P	MA	Inhibitor
DMU082P	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMU082P	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMU082P	DI	DMU082P
DMU082P	DN	1-(2-(4-fluorophenoxy)phenyl)piperazine
DMU082P	MI	TTVBI8W
DMU082P	MN	Dopamine transporter (DAT)
DMU082P	MT	DTT
DMU082P	MA	Inhibitor
DMU082P	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMU082P	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMU082P	DI	DMU082P
DMU082P	DN	1-(2-(4-fluorophenoxy)phenyl)piperazine
DMU082P	MI	TTAWNKZ
DMU082P	MN	Norepinephrine transporter (NET)
DMU082P	MT	DTT
DMU082P	MA	Inhibitor
DMU082P	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMU082P	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMU082P	DI	DMU082P
DMU082P	DN	1-(2-(4-fluorophenoxy)phenyl)piperazine
DMU082P	MI	TT3ROYC
DMU082P	MN	Serotonin transporter (SERT)
DMU082P	MT	DTT
DMU082P	MA	Inhibitor
DMU082P	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMU082P	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMR4DJ1	DI	DMR4DJ1
DMR4DJ1	DN	1-(2-(6-fluoronaphthalen-2-yl)ethyl)piperazine
DMR4DJ1	MI	TTAWNKZ
DMR4DJ1	MN	Norepinephrine transporter (NET)
DMR4DJ1	MT	DTT
DMR4DJ1	MA	Inhibitor
DMR4DJ1	RN	Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32.
DMR4DJ1	RU	https://pubmed.ncbi.nlm.nih.gov/19282174

DMR4DJ1	DI	DMR4DJ1
DMR4DJ1	DN	1-(2-(6-fluoronaphthalen-2-yl)ethyl)piperazine
DMR4DJ1	MI	TT3ROYC
DMR4DJ1	MN	Serotonin transporter (SERT)
DMR4DJ1	MT	DTT
DMR4DJ1	MA	Inhibitor
DMR4DJ1	RN	Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32.
DMR4DJ1	RU	https://pubmed.ncbi.nlm.nih.gov/19282174

DMR4DJ1	DI	DMR4DJ1
DMR4DJ1	DN	1-(2-(6-fluoronaphthalen-2-yl)ethyl)piperazine
DMR4DJ1	MI	TTQ6VDM
DMR4DJ1	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMR4DJ1	MT	DTT
DMR4DJ1	MA	Inhibitor
DMR4DJ1	RN	Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32.
DMR4DJ1	RU	https://pubmed.ncbi.nlm.nih.gov/19282174

DMB3HI4	DI	DMB3HI4
DMB3HI4	DN	1-(2-(benzo[b]thiophen-4-yl)ethyl)-1H-imidazole
DMB3HI4	MI	TTSZLWK
DMB3HI4	MN	Aromatase (CYP19A1)
DMB3HI4	MT	DTT
DMB3HI4	MA	Inhibitor
DMB3HI4	RN	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
DMB3HI4	RU	https://pubmed.ncbi.nlm.nih.gov/19072235

DM0UZHL	DI	DM0UZHL
DM0UZHL	DN	1-(2-(benzyloxy)phenyl)piperazine
DM0UZHL	MI	TTSQIFT
DM0UZHL	MN	5-HT 1A receptor (HTR1A)
DM0UZHL	MT	DTT
DM0UZHL	MA	Inhibitor
DM0UZHL	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DM0UZHL	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DM0UZHL	DI	DM0UZHL
DM0UZHL	DN	1-(2-(benzyloxy)phenyl)piperazine
DM0UZHL	MI	TTAWNKZ
DM0UZHL	MN	Norepinephrine transporter (NET)
DM0UZHL	MT	DTT
DM0UZHL	MA	Inhibitor
DM0UZHL	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DM0UZHL	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DM0UZHL	DI	DM0UZHL
DM0UZHL	DN	1-(2-(benzyloxy)phenyl)piperazine
DM0UZHL	MI	TT3ROYC
DM0UZHL	MN	Serotonin transporter (SERT)
DM0UZHL	MT	DTT
DM0UZHL	MA	Inhibitor
DM0UZHL	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DM0UZHL	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMU5BOW	DI	DMU5BOW
DMU5BOW	DN	1-(2-(diethylamino)quinazolin-4-yl)-3-phenylurea
DMU5BOW	MI	TTJFY5U
DMU5BOW	MN	Adenosine A3 receptor (ADORA3)
DMU5BOW	MT	DTT
DMU5BOW	MA	Inhibitor
DMU5BOW	RN	Pharmacophore based receptor modeling: the case of adenosine A3 receptor antagonists. An approach to the optimization of protein models. J Med Chem. 2006 Jul 13;49(14):4085-97.
DMU5BOW	RU	https://pubmed.ncbi.nlm.nih.gov/16821770

DMXL7Z5	DI	DMXL7Z5
DMXL7Z5	DN	1-(2-(naphthalen-1-yl)-1-phenylethyl)piperazine
DMXL7Z5	MI	TT3ROYC
DMXL7Z5	MN	Serotonin transporter (SERT)
DMXL7Z5	MT	DTT
DMXL7Z5	MA	Inhibitor
DMXL7Z5	RN	Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4349-53.
DMXL7Z5	RU	https://pubmed.ncbi.nlm.nih.gov/16750363

DMTEBP0	DI	DMTEBP0
DMTEBP0	DN	1-(2-(naphthalen-2-yl)-1-phenylethyl)piperazine
DMTEBP0	MI	TT3ROYC
DMTEBP0	MN	Serotonin transporter (SERT)
DMTEBP0	MT	DTT
DMTEBP0	MA	Inhibitor
DMTEBP0	RN	Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4349-53.
DMTEBP0	RU	https://pubmed.ncbi.nlm.nih.gov/16750363

DMS7YF6	DI	DMS7YF6
DMS7YF6	DN	1-(2-(naphthalen-2-yl)ethyl)piperazine
DMS7YF6	MI	TT3ROYC
DMS7YF6	MN	Serotonin transporter (SERT)
DMS7YF6	MT	DTT
DMS7YF6	MA	Inhibitor
DMS7YF6	RN	Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32.
DMS7YF6	RU	https://pubmed.ncbi.nlm.nih.gov/19282174

DMYFKID	DI	DMYFKID
DMYFKID	DN	1-(2-(naphthalen-2-yl)ethyl)pyrrolidine
DMYFKID	MI	TT9JNIC
DMYFKID	MN	Histamine H3 receptor (H3R)
DMYFKID	MT	DTT
DMYFKID	MA	Inhibitor
DMYFKID	RN	In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9.
DMYFKID	RU	https://pubmed.ncbi.nlm.nih.gov/18077160

DM7Z19T	DI	DM7Z19T
DM7Z19T	DN	1-(2-(phenoxymethyl)phenyl)piperazine
DM7Z19T	MI	TTSQIFT
DM7Z19T	MN	5-HT 1A receptor (HTR1A)
DM7Z19T	MT	DTT
DM7Z19T	MA	Inhibitor
DM7Z19T	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DM7Z19T	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DM7Z19T	DI	DM7Z19T
DM7Z19T	DN	1-(2-(phenoxymethyl)phenyl)piperazine
DM7Z19T	MI	TTVBI8W
DM7Z19T	MN	Dopamine transporter (DAT)
DM7Z19T	MT	DTT
DM7Z19T	MA	Inhibitor
DM7Z19T	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DM7Z19T	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DM7Z19T	DI	DM7Z19T
DM7Z19T	DN	1-(2-(phenoxymethyl)phenyl)piperazine
DM7Z19T	MI	TTAWNKZ
DM7Z19T	MN	Norepinephrine transporter (NET)
DM7Z19T	MT	DTT
DM7Z19T	MA	Inhibitor
DM7Z19T	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DM7Z19T	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DM7Z19T	DI	DM7Z19T
DM7Z19T	DN	1-(2-(phenoxymethyl)phenyl)piperazine
DM7Z19T	MI	TT3ROYC
DM7Z19T	MN	Serotonin transporter (SERT)
DM7Z19T	MT	DTT
DM7Z19T	MA	Inhibitor
DM7Z19T	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DM7Z19T	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMNX6CE	DI	DMNX6CE
DMNX6CE	DN	1-(2,2'-bithiophen-5-yl)methanamine
DMNX6CE	MI	TTXZEAJ
DMNX6CE	MN	Leukotriene A-4 hydrolase (LTA4H)
DMNX6CE	MT	DTT
DMNX6CE	MA	Inhibitor
DMNX6CE	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMNX6CE	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM1Q0TM	DI	DM1Q0TM
DM1Q0TM	DN	1-(2,3-DICHLOROPHENYL)-2,2,2-TRIFLUORO-1-(1-(4-FLUOROPHENYL)-1H-INDAZOL-5-YL)ETHANOL (ENANTIOMERIC MIX)
DM1Q0TM	MI	TTOZRK6
DM1Q0TM	MN	Glucocorticoid receptor messenger RNA (GCR mRNA)
DM1Q0TM	MT	DTT
DM1Q0TM	MA	Inhibitor
DM1Q0TM	RN	5-Functionalized indazoles as glucocorticoid receptor agonists. Bioorg Med Chem Lett. 2010 May 15;20(10):3017-20.
DM1Q0TM	RU	https://pubmed.ncbi.nlm.nih.gov/20427184

DM0URSE	DI	DM0URSE
DM0URSE	DN	1-(2,3-Dihydro-1H-indol-5-ylmethyl)-propylamine
DM0URSE	MI	TTVBI8W
DM0URSE	MN	Dopamine transporter (DAT)
DM0URSE	MT	DTT
DM0URSE	MA	Inhibitor
DM0URSE	RN	Selective monoamine oxidase inhibitors. 3. Cyclic compounds related to 4-aminophenethylamine. Preparation and neuron-selective action of some 5-(2-... J Med Chem. 1986 Aug;29(8):1406-12.
DM0URSE	RU	https://pubmed.ncbi.nlm.nih.gov/3735309

DM0URSE	DI	DM0URSE
DM0URSE	DN	1-(2,3-Dihydro-1H-indol-5-ylmethyl)-propylamine
DM0URSE	MI	TTAWNKZ
DM0URSE	MN	Norepinephrine transporter (NET)
DM0URSE	MT	DTT
DM0URSE	MA	Inhibitor
DM0URSE	RN	Selective monoamine oxidase inhibitors. 3. Cyclic compounds related to 4-aminophenethylamine. Preparation and neuron-selective action of some 5-(2-... J Med Chem. 1986 Aug;29(8):1406-12.
DM0URSE	RU	https://pubmed.ncbi.nlm.nih.gov/3735309

DM31CVR	DI	DM31CVR
DM31CVR	DN	1-(2,5-Dimethoxy-4-methyl-phenyl)-piperazine
DM31CVR	MI	TTSQIFT
DM31CVR	MN	5-HT 1A receptor (HTR1A)
DM31CVR	MT	DTT
DM31CVR	MA	Inhibitor
DM31CVR	RN	Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents. J Med Chem. 1986 May;29(5):630-4.
DM31CVR	RU	https://pubmed.ncbi.nlm.nih.gov/3701781

DM31CVR	DI	DM31CVR
DM31CVR	DN	1-(2,5-Dimethoxy-4-methyl-phenyl)-piperazine
DM31CVR	MI	TT6MSOK
DM31CVR	MN	5-HT 1D receptor (HTR1D)
DM31CVR	MT	DTT
DM31CVR	MA	Inhibitor
DM31CVR	RN	Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents. J Med Chem. 1986 May;29(5):630-4.
DM31CVR	RU	https://pubmed.ncbi.nlm.nih.gov/3701781

DM31CVR	DI	DM31CVR
DM31CVR	DN	1-(2,5-Dimethoxy-4-methyl-phenyl)-piperazine
DM31CVR	MI	TTJQOD7
DM31CVR	MN	5-HT 2A receptor (HTR2A)
DM31CVR	MT	DTT
DM31CVR	MA	Inhibitor
DM31CVR	RN	Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents. J Med Chem. 1986 May;29(5):630-4.
DM31CVR	RU	https://pubmed.ncbi.nlm.nih.gov/3701781

DMNETHQ	DI	DMNETHQ
DMNETHQ	DN	1-(2,5-Dimethoxy-phenyl)-piperazine
DMNETHQ	MI	TTSQIFT
DMNETHQ	MN	5-HT 1A receptor (HTR1A)
DMNETHQ	MT	DTT
DMNETHQ	MA	Inhibitor
DMNETHQ	RN	Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents. J Med Chem. 1986 May;29(5):630-4.
DMNETHQ	RU	https://pubmed.ncbi.nlm.nih.gov/3701781

DMNETHQ	DI	DMNETHQ
DMNETHQ	DN	1-(2,5-Dimethoxy-phenyl)-piperazine
DMNETHQ	MI	TT6MSOK
DMNETHQ	MN	5-HT 1D receptor (HTR1D)
DMNETHQ	MT	DTT
DMNETHQ	MA	Inhibitor
DMNETHQ	RN	Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents. J Med Chem. 1986 May;29(5):630-4.
DMNETHQ	RU	https://pubmed.ncbi.nlm.nih.gov/3701781

DMNETHQ	DI	DMNETHQ
DMNETHQ	DN	1-(2,5-Dimethoxy-phenyl)-piperazine
DMNETHQ	MI	TTJQOD7
DMNETHQ	MN	5-HT 2A receptor (HTR2A)
DMNETHQ	MT	DTT
DMNETHQ	MA	Inhibitor
DMNETHQ	RN	Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents. J Med Chem. 1986 May;29(5):630-4.
DMNETHQ	RU	https://pubmed.ncbi.nlm.nih.gov/3701781

DM043N8	DI	DM043N8
DM043N8	DN	1-(2,5-dimethoxyphenyl)propan-2-amine
DM043N8	MI	TTSQIFT
DM043N8	MN	5-HT 1A receptor (HTR1A)
DM043N8	MT	DTT
DM043N8	MA	Inhibitor
DM043N8	RN	5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. J Med Chem. 1986 Feb;29(2):194-9.
DM043N8	RU	https://pubmed.ncbi.nlm.nih.gov/3950904

DM043N8	DI	DM043N8
DM043N8	DN	1-(2,5-dimethoxyphenyl)propan-2-amine
DM043N8	MI	TT6MSOK
DM043N8	MN	5-HT 1D receptor (HTR1D)
DM043N8	MT	DTT
DM043N8	MA	Inhibitor
DM043N8	RN	5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. J Med Chem. 1986 Feb;29(2):194-9.
DM043N8	RU	https://pubmed.ncbi.nlm.nih.gov/3950904

DM043N8	DI	DM043N8
DM043N8	DN	1-(2,5-dimethoxyphenyl)propan-2-amine
DM043N8	MI	TTJQOD7
DM043N8	MN	5-HT 2A receptor (HTR2A)
DM043N8	MT	DTT
DM043N8	MA	Inhibitor
DM043N8	RN	The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands. Bioorg Med Chem. 2008 Apr 15;16(8):4661-9.
DM043N8	RU	https://pubmed.ncbi.nlm.nih.gov/18296055

DM3FHJK	DI	DM3FHJK
DM3FHJK	DN	1-(2,5-Dimethyl-1H-pyrrol-1-yl)thiourea
DM3FHJK	MI	TTULVH8
DM3FHJK	MN	Tyrosinase (TYR)
DM3FHJK	MT	DTT
DM3FHJK	MA	Inhibitor
DM3FHJK	RN	A class of potent tyrosinase inhibitors: alkylidenethiosemicarbazide compounds. Eur J Med Chem. 2009 Apr;44(4):1773-8.
DM3FHJK	RU	https://pubmed.ncbi.nlm.nih.gov/18524420

DMV0C6F	DI	DMV0C6F
DMV0C6F	DN	1-(2,6-dimethoxy-4-methylphenyl)propan-2-amine
DMV0C6F	MI	TTJQOD7
DMV0C6F	MN	5-HT 2A receptor (HTR2A)
DMV0C6F	MT	DTT
DMV0C6F	MA	Inhibitor
DMV0C6F	RN	The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands. Bioorg Med Chem. 2008 Apr 15;16(8):4661-9.
DMV0C6F	RU	https://pubmed.ncbi.nlm.nih.gov/18296055

DMRHY2M	DI	DMRHY2M
DMRHY2M	DN	1-(2-adamantyl)-3-benzylpyrrolidin-2-one
DMRHY2M	MI	TTN7BL9
DMRHY2M	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMRHY2M	MT	DTT
DMRHY2M	MA	Inhibitor
DMRHY2M	RN	Discovery of orally active butyrolactam 11beta-HSD1 inhibitors. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5555-60.
DMRHY2M	RU	https://pubmed.ncbi.nlm.nih.gov/16931002

DMLV0PQ	DI	DMLV0PQ
DMLV0PQ	DN	1-(2-allylphenoxy)-3-morpholinopropan-2-ol
DMLV0PQ	MI	TTR6W5O
DMLV0PQ	MN	Adrenergic receptor beta-1 (ADRB1)
DMLV0PQ	MT	DTT
DMLV0PQ	MA	Inhibitor
DMLV0PQ	RN	A vHTS approach for the identification of beta-adrenoceptor ligands. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3399-404.
DMLV0PQ	RU	https://pubmed.ncbi.nlm.nih.gov/20434333

DMLV0PQ	DI	DMLV0PQ
DMLV0PQ	DN	1-(2-allylphenoxy)-3-morpholinopropan-2-ol
DMLV0PQ	MI	TT2CJVK
DMLV0PQ	MN	Adrenergic receptor beta-2 (ADRB2)
DMLV0PQ	MT	DTT
DMLV0PQ	MA	Inhibitor
DMLV0PQ	RN	A vHTS approach for the identification of beta-adrenoceptor ligands. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3399-404.
DMLV0PQ	RU	https://pubmed.ncbi.nlm.nih.gov/20434333

DMLV0PQ	DI	DMLV0PQ
DMLV0PQ	DN	1-(2-allylphenoxy)-3-morpholinopropan-2-ol
DMLV0PQ	MI	TTMXGCW
DMLV0PQ	MN	Adrenergic receptor beta-3 (ADRB3)
DMLV0PQ	MT	DTT
DMLV0PQ	MA	Inhibitor
DMLV0PQ	RN	A vHTS approach for the identification of beta-adrenoceptor ligands. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3399-404.
DMLV0PQ	RU	https://pubmed.ncbi.nlm.nih.gov/20434333

DMAE8BF	DI	DMAE8BF
DMAE8BF	DN	1-(2-amino-benzothiazol-5-yl)-2-ethyl-isothiourea
DMAE8BF	MI	TTZUFI5
DMAE8BF	MN	Nitric-oxide synthase brain (NOS1)
DMAE8BF	MT	DTT
DMAE8BF	MA	Inhibitor
DMAE8BF	RN	Novel 2-aminobenzothiazoles as selective neuronal nitric oxide synthase inhibitors. Bioorg Med Chem Lett. 2007 May 1;17(9):2540-4.
DMAE8BF	RU	https://pubmed.ncbi.nlm.nih.gov/17317165

DMAE8BF	DI	DMAE8BF
DMAE8BF	DN	1-(2-amino-benzothiazol-5-yl)-2-ethyl-isothiourea
DMAE8BF	MI	TTCM4B3
DMAE8BF	MN	Nitric-oxide synthase endothelial (NOS3)
DMAE8BF	MT	DTT
DMAE8BF	MA	Inhibitor
DMAE8BF	RN	Novel 2-aminobenzothiazoles as selective neuronal nitric oxide synthase inhibitors. Bioorg Med Chem Lett. 2007 May 1;17(9):2540-4.
DMAE8BF	RU	https://pubmed.ncbi.nlm.nih.gov/17317165

DMCSHRL	DI	DMCSHRL
DMCSHRL	DN	1-(2-amino-benzothiazol-6-yl)-2-ethyl-isothiourea
DMCSHRL	MI	TTZUFI5
DMCSHRL	MN	Nitric-oxide synthase brain (NOS1)
DMCSHRL	MT	DTT
DMCSHRL	MA	Inhibitor
DMCSHRL	RN	Novel 2-aminobenzothiazoles as selective neuronal nitric oxide synthase inhibitors. Bioorg Med Chem Lett. 2007 May 1;17(9):2540-4.
DMCSHRL	RU	https://pubmed.ncbi.nlm.nih.gov/17317165

DMCSHRL	DI	DMCSHRL
DMCSHRL	DN	1-(2-amino-benzothiazol-6-yl)-2-ethyl-isothiourea
DMCSHRL	MI	TTCM4B3
DMCSHRL	MN	Nitric-oxide synthase endothelial (NOS3)
DMCSHRL	MT	DTT
DMCSHRL	MA	Inhibitor
DMCSHRL	RN	Novel 2-aminobenzothiazoles as selective neuronal nitric oxide synthase inhibitors. Bioorg Med Chem Lett. 2007 May 1;17(9):2540-4.
DMCSHRL	RU	https://pubmed.ncbi.nlm.nih.gov/17317165

DMKWO6A	DI	DMKWO6A
DMKWO6A	DN	1-(2-aminoethyl)-1H-indazol-6-ol
DMKWO6A	MI	TTJQOD7
DMKWO6A	MN	5-HT 2A receptor (HTR2A)
DMKWO6A	MT	DTT
DMKWO6A	MA	Inhibitor
DMKWO6A	RN	1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28.
DMKWO6A	RU	https://pubmed.ncbi.nlm.nih.gov/16392816

DMKWO6A	DI	DMKWO6A
DMKWO6A	DN	1-(2-aminoethyl)-1H-indazol-6-ol
DMKWO6A	MI	TT0K1SC
DMKWO6A	MN	5-HT 2B receptor (HTR2B)
DMKWO6A	MT	DTT
DMKWO6A	MA	Inhibitor
DMKWO6A	RN	1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28.
DMKWO6A	RU	https://pubmed.ncbi.nlm.nih.gov/16392816

DMKWO6A	DI	DMKWO6A
DMKWO6A	DN	1-(2-aminoethyl)-1H-indazol-6-ol
DMKWO6A	MI	TTWJBZ5
DMKWO6A	MN	5-HT 2C receptor (HTR2C)
DMKWO6A	MT	DTT
DMKWO6A	MA	Inhibitor
DMKWO6A	RN	1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28.
DMKWO6A	RU	https://pubmed.ncbi.nlm.nih.gov/16392816

DMYF8ES	DI	DMYF8ES
DMYF8ES	DN	1-(2-bromoethyl)-1H-indole-2,3-dione
DMYF8ES	MI	TTMF541
DMYF8ES	MN	Liver carboxylesterase (CES1)
DMYF8ES	MT	DTT
DMYF8ES	MA	Inhibitor
DMYF8ES	RN	Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85.
DMYF8ES	RU	https://pubmed.ncbi.nlm.nih.gov/17378546

DMUSEOW	DI	DMUSEOW
DMUSEOW	DN	1-(2-Bromo-phenyl)-3-(2,4-dihydroxy-phenyl)-urea
DMUSEOW	MI	TTMWT8Z
DMUSEOW	MN	C-X-C chemokine receptor type 1 (CXCR1)
DMUSEOW	MT	DTT
DMUSEOW	MA	Inhibitor
DMUSEOW	RN	Synthesis and structure-activity relationships of 3,5-diarylisoxazoles and 3,5-diaryl-1,2,4-oxadiazoles, novel classes of small molecule interleuki... Bioorg Med Chem Lett. 2004 Aug 16;14(16):4307-11.
DMUSEOW	RU	https://pubmed.ncbi.nlm.nih.gov/15261292

DMU9T3A	DI	DMU9T3A
DMU9T3A	DN	1-(2-bromophenyl)-3-(4-cyano-2-hydroxyphenyl)urea
DMU9T3A	MI	TT30C9G
DMU9T3A	MN	C-X-C chemokine receptor type 2 (CXCR2)
DMU9T3A	MT	DTT
DMU9T3A	MA	Inhibitor
DMU9T3A	RN	Comparison of N,N'-diarylsquaramides and N,N'-diarylureas as antagonists of the CXCR2 chemokine receptor. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1713-7.
DMU9T3A	RU	https://pubmed.ncbi.nlm.nih.gov/17236763

DMT5S2O	DI	DMT5S2O
DMT5S2O	DN	1-(2-Butoxy-phenyl)-piperazine
DMT5S2O	MI	TTSQIFT
DMT5S2O	MN	5-HT 1A receptor (HTR1A)
DMT5S2O	MT	DTT
DMT5S2O	MA	Inhibitor
DMT5S2O	RN	Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. J Med Chem. 1989 May;32(5):1052-6.
DMT5S2O	RU	https://pubmed.ncbi.nlm.nih.gov/2565400

DMT5S2O	DI	DMT5S2O
DMT5S2O	DN	1-(2-Butoxy-phenyl)-piperazine
DMT5S2O	MI	TT6MSOK
DMT5S2O	MN	5-HT 1D receptor (HTR1D)
DMT5S2O	MT	DTT
DMT5S2O	MA	Inhibitor
DMT5S2O	RN	Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. J Med Chem. 1989 May;32(5):1052-6.
DMT5S2O	RU	https://pubmed.ncbi.nlm.nih.gov/2565400

DMGSKAO	DI	DMGSKAO
DMGSKAO	DN	1-(2-chlorophenyl)-3-(pyridin-2-yl)thiourea
DMGSKAO	MI	TT6804T
DMGSKAO	MN	MIF messenger RNA (MIF mRNA)
DMGSKAO	MT	DTT
DMGSKAO	MA	Inhibitor
DMGSKAO	RN	An integrative in silico methodology for the identification of modulators of macrophage migration inhibitory factor (MIF) tautomerase activity. Bioorg Med Chem. 2010 Jul 15;18(14):5425-40. 
DMGSKAO	RU	https://pubmed.ncbi.nlm.nih.gov/20639113

DMKTZSY	DI	DMKTZSY
DMKTZSY	DN	1-(2'-chlorophenyl)penta-1,4-dien-3-one
DMKTZSY	MI	TTEP6RV
DMKTZSY	MN	Glutathione reductase (GR)
DMKTZSY	MT	DTT
DMKTZSY	MA	Inhibitor
DMKTZSY	RN	Irreversible inactivation of trypanothione reductase by unsaturated Mannich bases: a divinyl ketone as key intermediate. J Med Chem. 2005 Nov 17;48(23):7400-10.
DMKTZSY	RU	https://pubmed.ncbi.nlm.nih.gov/16279799

DMKTZSY	DI	DMKTZSY
DMKTZSY	DN	1-(2'-chlorophenyl)penta-1,4-dien-3-one
DMKTZSY	MI	TTRTKPV
DMKTZSY	MN	Trypanosoma Trypanothione reductase (Trypano TPR)
DMKTZSY	MT	DTT
DMKTZSY	MA	Inhibitor
DMKTZSY	RN	Irreversible inactivation of trypanothione reductase by unsaturated Mannich bases: a divinyl ketone as key intermediate. J Med Chem. 2005 Nov 17;48(23):7400-10.
DMKTZSY	RU	https://pubmed.ncbi.nlm.nih.gov/16279799

DM5RE71	DI	DM5RE71
DM5RE71	DN	1-(2-Chloro-phenyl)-piperazine
DM5RE71	MI	TTSQIFT
DM5RE71	MN	5-HT 1A receptor (HTR1A)
DM5RE71	MT	DTT
DM5RE71	MA	Inhibitor
DM5RE71	RN	Pyrimido[5,4-b]indole derivatives. 1. A new class of potent and selective alpha 1 adrenoceptor ligands. J Med Chem. 1991 Jun;34(6):1850-4.
DM5RE71	RU	https://pubmed.ncbi.nlm.nih.gov/1648138

DM5RE71	DI	DM5RE71
DM5RE71	DN	1-(2-Chloro-phenyl)-piperazine
DM5RE71	MI	TTNGILX
DM5RE71	MN	Adrenergic receptor alpha-1A (ADRA1A)
DM5RE71	MT	DTT
DM5RE71	MA	Inhibitor
DM5RE71	RN	Pyrimido[5,4-b]indole derivatives. 1. A new class of potent and selective alpha 1 adrenoceptor ligands. J Med Chem. 1991 Jun;34(6):1850-4.
DM5RE71	RU	https://pubmed.ncbi.nlm.nih.gov/1648138

DM5RE71	DI	DM5RE71
DM5RE71	DN	1-(2-Chloro-phenyl)-piperazine
DM5RE71	MI	TT34BHT
DM5RE71	MN	Adrenergic receptor alpha-1D (ADRA1D)
DM5RE71	MT	DTT
DM5RE71	MA	Inhibitor
DM5RE71	RN	Pyrimido[5,4-b]indole derivatives. 1. A new class of potent and selective alpha 1 adrenoceptor ligands. J Med Chem. 1991 Jun;34(6):1850-4.
DM5RE71	RU	https://pubmed.ncbi.nlm.nih.gov/1648138

DMM3LET	DI	DMM3LET
DMM3LET	DN	1-(2-Dimethylamino-ethyl)-1H-indol-4-ol
DMM3LET	MI	TTWJBZ5
DMM3LET	MN	5-HT 2C receptor (HTR2C)
DMM3LET	MT	DTT
DMM3LET	MA	Inhibitor
DMM3LET	RN	SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.
DMM3LET	RU	https://pubmed.ncbi.nlm.nih.gov/16061378

DMV3FSH	DI	DMV3FSH
DMV3FSH	DN	1-(2-ethoxy-1-phenylethyl)-4-phenylpiperidin-4-ol
DMV3FSH	MI	TTNT7K8
DMV3FSH	MN	Nociceptin receptor (OPRL1)
DMV3FSH	MT	DTT
DMV3FSH	MA	Inhibitor
DMV3FSH	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMV3FSH	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMV3FSH	DI	DMV3FSH
DMV3FSH	DN	1-(2-ethoxy-1-phenylethyl)-4-phenylpiperidin-4-ol
DMV3FSH	MI	TT27RFC
DMV3FSH	MN	Opioid receptor delta (OPRD1)
DMV3FSH	MT	DTT
DMV3FSH	MA	Inhibitor
DMV3FSH	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMV3FSH	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMV3FSH	DI	DMV3FSH
DMV3FSH	DN	1-(2-ethoxy-1-phenylethyl)-4-phenylpiperidin-4-ol
DMV3FSH	MI	TTQW87Y
DMV3FSH	MN	Opioid receptor kappa (OPRK1)
DMV3FSH	MT	DTT
DMV3FSH	MA	Inhibitor
DMV3FSH	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMV3FSH	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMV3FSH	DI	DMV3FSH
DMV3FSH	DN	1-(2-ethoxy-1-phenylethyl)-4-phenylpiperidin-4-ol
DMV3FSH	MI	TTKWM86
DMV3FSH	MN	Opioid receptor mu (MOP)
DMV3FSH	MT	DTT
DMV3FSH	MA	Inhibitor
DMV3FSH	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMV3FSH	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DM2P7YX	DI	DM2P7YX
DM2P7YX	DN	1-(2-Ethoxy-phenyl)-piperazine
DM2P7YX	MI	TTSQIFT
DM2P7YX	MN	5-HT 1A receptor (HTR1A)
DM2P7YX	MT	DTT
DM2P7YX	MA	Inhibitor
DM2P7YX	RN	Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. J Med Chem. 1989 May;32(5):1052-6.
DM2P7YX	RU	https://pubmed.ncbi.nlm.nih.gov/2565400

DM2P7YX	DI	DM2P7YX
DM2P7YX	DN	1-(2-Ethoxy-phenyl)-piperazine
DM2P7YX	MI	TT6MSOK
DM2P7YX	MN	5-HT 1D receptor (HTR1D)
DM2P7YX	MT	DTT
DM2P7YX	MA	Inhibitor
DM2P7YX	RN	Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. J Med Chem. 1989 May;32(5):1052-6.
DM2P7YX	RU	https://pubmed.ncbi.nlm.nih.gov/2565400

DM94LID	DI	DM94LID
DM94LID	DN	1-(2-Fluoro-phenyl)-piperazine
DM94LID	MI	TTSQIFT
DM94LID	MN	5-HT 1A receptor (HTR1A)
DM94LID	MT	DTT
DM94LID	MA	Inhibitor
DM94LID	RN	Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. J Med Chem. 1989 May;32(5):1052-6.
DM94LID	RU	https://pubmed.ncbi.nlm.nih.gov/2565400

DM94LID	DI	DM94LID
DM94LID	DN	1-(2-Fluoro-phenyl)-piperazine
DM94LID	MI	TT6MSOK
DM94LID	MN	5-HT 1D receptor (HTR1D)
DM94LID	MT	DTT
DM94LID	MA	Inhibitor
DM94LID	RN	Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. J Med Chem. 1989 May;32(5):1052-6.
DM94LID	RU	https://pubmed.ncbi.nlm.nih.gov/2565400

DM0K2T1	DI	DM0K2T1
DM0K2T1	DN	1-(2-Furan-2-yl-ethyl)-3-thiazol-2-yl-thiourea
DM0K2T1	MI	TT84ETX
DM0K2T1	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM0K2T1	MT	DTT
DM0K2T1	MA	Inhibitor
DM0K2T1	RN	Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36.
DM0K2T1	RU	https://pubmed.ncbi.nlm.nih.gov/8523406

DM3WXET	DI	DM3WXET
DM3WXET	DN	1-(2-Hydroxy-3-nitro-phenyl)-3-phenyl-urea
DM3WXET	MI	TT30C9G
DM3WXET	MN	C-X-C chemokine receptor type 2 (CXCR2)
DM3WXET	MT	DTT
DM3WXET	MA	Inhibitor
DM3WXET	RN	Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor. J Med Chem. 2004 Mar 11;47(6):1319-21.
DM3WXET	RU	https://pubmed.ncbi.nlm.nih.gov/14998320

DMN4G7U	DI	DMN4G7U
DMN4G7U	DN	1-(2-hydroxy-4-nitrophenyl)-3-phenylurea
DMN4G7U	MI	TTMWT8Z
DMN4G7U	MN	C-X-C chemokine receptor type 1 (CXCR1)
DMN4G7U	MT	DTT
DMN4G7U	MA	Inhibitor
DMN4G7U	RN	Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor. J Med Chem. 2004 Mar 11;47(6):1319-21.
DMN4G7U	RU	https://pubmed.ncbi.nlm.nih.gov/14998320

DMN4G7U	DI	DMN4G7U
DMN4G7U	DN	1-(2-hydroxy-4-nitrophenyl)-3-phenylurea
DMN4G7U	MI	TT30C9G
DMN4G7U	MN	C-X-C chemokine receptor type 2 (CXCR2)
DMN4G7U	MT	DTT
DMN4G7U	MA	Inhibitor
DMN4G7U	RN	Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem. 1998 Apr 24;273(17):10095-8.
DMN4G7U	RU	https://pubmed.ncbi.nlm.nih.gov/9553055

DMPLHEY	DI	DMPLHEY
DMPLHEY	DN	1-(2-Hydroxy-5-nitro-phenyl)-3-phenyl-urea
DMPLHEY	MI	TT30C9G
DMPLHEY	MN	C-X-C chemokine receptor type 2 (CXCR2)
DMPLHEY	MT	DTT
DMPLHEY	MA	Inhibitor
DMPLHEY	RN	Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor. J Med Chem. 2004 Mar 11;47(6):1319-21.
DMPLHEY	RU	https://pubmed.ncbi.nlm.nih.gov/14998320

DMAFS7J	DI	DMAFS7J
DMAFS7J	DN	1-(2-hydroxyphenyl)-3-p-tolylprop-2-en-1-one
DMAFS7J	MI	TTVKILB
DMAFS7J	MN	Prostaglandin G/H synthase 2 (COX-2)
DMAFS7J	MT	DTT
DMAFS7J	MA	Inhibitor
DMAFS7J	RN	Inhibitory activity of prostaglandin E2 production by the synthetic 2'-hydroxychalcone analogues: Synthesis and SAR study. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1650-3.
DMAFS7J	RU	https://pubmed.ncbi.nlm.nih.gov/19233646

DM1MSAC	DI	DM1MSAC
DM1MSAC	DN	1-(2-iodoethyl)-1H-indole-2,3-dione
DM1MSAC	MI	TTMF541
DM1MSAC	MN	Liver carboxylesterase (CES1)
DM1MSAC	MT	DTT
DM1MSAC	MA	Inhibitor
DM1MSAC	RN	Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85.
DM1MSAC	RU	https://pubmed.ncbi.nlm.nih.gov/17378546

DM5KAH6	DI	DM5KAH6
DM5KAH6	DN	1-(2-Isopropoxy-phenyl)-piperazine
DM5KAH6	MI	TTSQIFT
DM5KAH6	MN	5-HT 1A receptor (HTR1A)
DM5KAH6	MT	DTT
DM5KAH6	MA	Inhibitor
DM5KAH6	RN	Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. J Med Chem. 1989 May;32(5):1052-6.
DM5KAH6	RU	https://pubmed.ncbi.nlm.nih.gov/2565400

DM5KAH6	DI	DM5KAH6
DM5KAH6	DN	1-(2-Isopropoxy-phenyl)-piperazine
DM5KAH6	MI	TT6MSOK
DM5KAH6	MN	5-HT 1D receptor (HTR1D)
DM5KAH6	MT	DTT
DM5KAH6	MA	Inhibitor
DM5KAH6	RN	Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. J Med Chem. 1989 May;32(5):1052-6.
DM5KAH6	RU	https://pubmed.ncbi.nlm.nih.gov/2565400

DMK209P	DI	DMK209P
DMK209P	DN	1-(2-isopropylphenoxy)-3-morpholinopropan-2-ol
DMK209P	MI	TTR6W5O
DMK209P	MN	Adrenergic receptor beta-1 (ADRB1)
DMK209P	MT	DTT
DMK209P	MA	Inhibitor
DMK209P	RN	A vHTS approach for the identification of beta-adrenoceptor ligands. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3399-404.
DMK209P	RU	https://pubmed.ncbi.nlm.nih.gov/20434333

DMK209P	DI	DMK209P
DMK209P	DN	1-(2-isopropylphenoxy)-3-morpholinopropan-2-ol
DMK209P	MI	TT2CJVK
DMK209P	MN	Adrenergic receptor beta-2 (ADRB2)
DMK209P	MT	DTT
DMK209P	MA	Inhibitor
DMK209P	RN	A vHTS approach for the identification of beta-adrenoceptor ligands. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3399-404.
DMK209P	RU	https://pubmed.ncbi.nlm.nih.gov/20434333

DMK209P	DI	DMK209P
DMK209P	DN	1-(2-isopropylphenoxy)-3-morpholinopropan-2-ol
DMK209P	MI	TTMXGCW
DMK209P	MN	Adrenergic receptor beta-3 (ADRB3)
DMK209P	MT	DTT
DMK209P	MA	Inhibitor
DMK209P	RN	A vHTS approach for the identification of beta-adrenoceptor ligands. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3399-404.
DMK209P	RU	https://pubmed.ncbi.nlm.nih.gov/20434333

DMIPAMW	DI	DMIPAMW
DMIPAMW	DN	1-(2-mercaptoethyl)-3-(m-tolylsulfonyl)urea
DMIPAMW	MI	TTWHDVK
DMIPAMW	MN	Fructose-1,6-bisphosphatase (FBP)
DMIPAMW	MT	DTT
DMIPAMW	MA	Inhibitor
DMIPAMW	RN	Allosteric FBPase inhibitors gain 10(5) times in potency when simultaneously binding two neighboring AMP sites. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4708-12.
DMIPAMW	RU	https://pubmed.ncbi.nlm.nih.gov/18650089

DMDQVSU	DI	DMDQVSU
DMDQVSU	DN	1-(2-methoxyphenethyl)pyrrolidine
DMDQVSU	MI	TT9JNIC
DMDQVSU	MN	Histamine H3 receptor (H3R)
DMDQVSU	MT	DTT
DMDQVSU	MA	Inhibitor
DMDQVSU	RN	In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9.
DMDQVSU	RU	https://pubmed.ncbi.nlm.nih.gov/18077160

DM0EZSR	DI	DM0EZSR
DM0EZSR	DN	1-(2-methoxyphenyl)-4-pentylpiperazine
DM0EZSR	MI	TTSQIFT
DM0EZSR	MN	5-HT 1A receptor (HTR1A)
DM0EZSR	MT	DTT
DM0EZSR	MA	Inhibitor
DM0EZSR	RN	Identification of a red-emitting fluorescent ligand for in vitro visualization of human serotonin 5-HT(1A) receptors. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6628-32.
DM0EZSR	RU	https://pubmed.ncbi.nlm.nih.gov/20888762

DMCADRI	DI	DMCADRI
DMCADRI	DN	1-(2-Methoxy-phenyl)-4-propyl-piperazine
DMCADRI	MI	TTSQIFT
DMCADRI	MN	5-HT 1A receptor (HTR1A)
DMCADRI	MT	DTT
DMCADRI	MA	Inhibitor
DMCADRI	RN	Structure-activity relationship studies of central nervous system agents. 13. 4-[3-(Benzotriazol-1-yl)propyl]-1-(2-methoxyphenyl)piperazine, a new ... J Med Chem. 1994 Aug 19;37(17):2754-60.
DMCADRI	RU	https://pubmed.ncbi.nlm.nih.gov/8064802

DMCADRI	DI	DMCADRI
DMCADRI	DN	1-(2-Methoxy-phenyl)-4-propyl-piperazine
DMCADRI	MI	TTJQOD7
DMCADRI	MN	5-HT 2A receptor (HTR2A)
DMCADRI	MT	DTT
DMCADRI	MA	Inhibitor
DMCADRI	RN	Structure-activity relationship studies of central nervous system agents. 13. 4-[3-(Benzotriazol-1-yl)propyl]-1-(2-methoxyphenyl)piperazine, a new ... J Med Chem. 1994 Aug 19;37(17):2754-60.
DMCADRI	RU	https://pubmed.ncbi.nlm.nih.gov/8064802

DM3M4RA	DI	DM3M4RA
DM3M4RA	DN	1-(2-Methoxy-phenyl)-piperazine
DM3M4RA	MI	TTSQIFT
DM3M4RA	MN	5-HT 1A receptor (HTR1A)
DM3M4RA	MT	DTT
DM3M4RA	MA	Inhibitor
DM3M4RA	RN	Pyrimido[5,4-b]indole derivatives. 1. A new class of potent and selective alpha 1 adrenoceptor ligands. J Med Chem. 1991 Jun;34(6):1850-4.
DM3M4RA	RU	https://pubmed.ncbi.nlm.nih.gov/1648138

DM3M4RA	DI	DM3M4RA
DM3M4RA	DN	1-(2-Methoxy-phenyl)-piperazine
DM3M4RA	MI	TT6MSOK
DM3M4RA	MN	5-HT 1D receptor (HTR1D)
DM3M4RA	MT	DTT
DM3M4RA	MA	Inhibitor
DM3M4RA	RN	Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. J Med Chem. 1989 May;32(5):1052-6.
DM3M4RA	RU	https://pubmed.ncbi.nlm.nih.gov/2565400

DM3M4RA	DI	DM3M4RA
DM3M4RA	DN	1-(2-Methoxy-phenyl)-piperazine
DM3M4RA	MI	TTJQOD7
DM3M4RA	MN	5-HT 2A receptor (HTR2A)
DM3M4RA	MT	DTT
DM3M4RA	MA	Inhibitor
DM3M4RA	RN	Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents. J Med Chem. 1986 May;29(5):630-4.
DM3M4RA	RU	https://pubmed.ncbi.nlm.nih.gov/3701781

DM3M4RA	DI	DM3M4RA
DM3M4RA	DN	1-(2-Methoxy-phenyl)-piperazine
DM3M4RA	MI	TTJS8PY
DM3M4RA	MN	5-HT 6 receptor (HTR6)
DM3M4RA	MT	DTT
DM3M4RA	MA	Inhibitor
DM3M4RA	RN	1-(1-Naphthyl)piperazine as a novel template for 5-HT6 serotonin receptor ligands. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1707-11.
DM3M4RA	RU	https://pubmed.ncbi.nlm.nih.gov/15745826

DM3M4RA	DI	DM3M4RA
DM3M4RA	DN	1-(2-Methoxy-phenyl)-piperazine
DM3M4RA	MI	TTO9X1H
DM3M4RA	MN	5-HT 7 receptor (HTR7)
DM3M4RA	MT	DTT
DM3M4RA	MA	Agonist
DM3M4RA	RN	Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype. J Biol Chem. 1993 Aug 25;268(24):18200-4.
DM3M4RA	RU	https://pubmed.ncbi.nlm.nih.gov/8394362

DM3M4RA	DI	DM3M4RA
DM3M4RA	DN	1-(2-Methoxy-phenyl)-piperazine
DM3M4RA	MI	TTNGILX
DM3M4RA	MN	Adrenergic receptor alpha-1A (ADRA1A)
DM3M4RA	MT	DTT
DM3M4RA	MA	Inhibitor
DM3M4RA	RN	Pyrimido[5,4-b]indole derivatives. 1. A new class of potent and selective alpha 1 adrenoceptor ligands. J Med Chem. 1991 Jun;34(6):1850-4.
DM3M4RA	RU	https://pubmed.ncbi.nlm.nih.gov/1648138

DM3M4RA	DI	DM3M4RA
DM3M4RA	DN	1-(2-Methoxy-phenyl)-piperazine
DM3M4RA	MI	TT34BHT
DM3M4RA	MN	Adrenergic receptor alpha-1D (ADRA1D)
DM3M4RA	MT	DTT
DM3M4RA	MA	Inhibitor
DM3M4RA	RN	Pyrimido[5,4-b]indole derivatives. 1. A new class of potent and selective alpha 1 adrenoceptor ligands. J Med Chem. 1991 Jun;34(6):1850-4.
DM3M4RA	RU	https://pubmed.ncbi.nlm.nih.gov/1648138

DMBWCOZ	DI	DMBWCOZ
DMBWCOZ	DN	1-(2-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one
DMBWCOZ	MI	TTVBI8W
DMBWCOZ	MN	Dopamine transporter (DAT)
DMBWCOZ	MT	DTT
DMBWCOZ	MA	Inhibitor
DMBWCOZ	RN	1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32.
DMBWCOZ	RU	https://pubmed.ncbi.nlm.nih.gov/16480278

DMBWCOZ	DI	DMBWCOZ
DMBWCOZ	DN	1-(2-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one
DMBWCOZ	MI	TTAWNKZ
DMBWCOZ	MN	Norepinephrine transporter (NET)
DMBWCOZ	MT	DTT
DMBWCOZ	MA	Inhibitor
DMBWCOZ	RN	1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32.
DMBWCOZ	RU	https://pubmed.ncbi.nlm.nih.gov/16480278

DMBWCOZ	DI	DMBWCOZ
DMBWCOZ	DN	1-(2-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one
DMBWCOZ	MI	TT3ROYC
DMBWCOZ	MN	Serotonin transporter (SERT)
DMBWCOZ	MT	DTT
DMBWCOZ	MA	Inhibitor
DMBWCOZ	RN	1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32.
DMBWCOZ	RU	https://pubmed.ncbi.nlm.nih.gov/16480278

DMZF0D3	DI	DMZF0D3
DMZF0D3	DN	1-(2-morpholinoethyl)-1H-indol-3-yl acetate
DMZF0D3	MI	TT6OEDT
DMZF0D3	MN	Cannabinoid receptor 1 (CB1)
DMZF0D3	MT	DTT
DMZF0D3	MA	Inhibitor
DMZF0D3	RN	Synthesis and cannabinoid activity of 1-substituted-indole-3-oxadiazole derivatives: novel agonists for the CB1 receptor. Eur J Med Chem. 2008 Mar;43(3):513-39.
DMZF0D3	RU	https://pubmed.ncbi.nlm.nih.gov/17582659

DMKITY6	DI	DMKITY6
DMKITY6	DN	1-(2-m-tolyl-ethyl)-pyrrolidine
DMKITY6	MI	TT9JNIC
DMKITY6	MN	Histamine H3 receptor (H3R)
DMKITY6	MT	DTT
DMKITY6	MA	Inhibitor
DMKITY6	RN	In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9.
DMKITY6	RU	https://pubmed.ncbi.nlm.nih.gov/18077160

DMBNZKH	DI	DMBNZKH
DMBNZKH	DN	1-(2-Naphthyl)-2-aminopropane
DMBNZKH	MI	TT3WG5C
DMBNZKH	MN	Monoamine oxidase type A (MAO-A)
DMBNZKH	MT	DTT
DMBNZKH	MA	Inhibitor
DMBNZKH	RN	Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg Med Chem. 2009 Mar 15;17(6):2452-60.
DMBNZKH	RU	https://pubmed.ncbi.nlm.nih.gov/19243954

DMR12KP	DI	DMR12KP
DMR12KP	DN	1-(2-nitrophenethyl)-1H-pyrrolo[3,2-b]pyridine
DMR12KP	MI	TTNDSF4
DMR12KP	MN	Proto-oncogene c-Met (MET)
DMR12KP	MT	DTT
DMR12KP	MA	Inhibitor
DMR12KP	RN	Discovery of 4-azaindoles as novel inhibitors of c-Met kinase. Bioorg Med Chem Lett. 2009 May 15;19(10):2780-4.
DMR12KP	RU	https://pubmed.ncbi.nlm.nih.gov/19369077

DM69T3A	DI	DM69T3A
DM69T3A	DN	1-(2-Oxo-2-p-tolyl-ethyl)-1H-indole-2,3-dione
DM69T3A	MI	TTP86E2
DM69T3A	MN	Plasminogen (PLG)
DM69T3A	MT	DTT
DM69T3A	MA	Inhibitor
DM69T3A	RN	Parallel synthesis of isatin-based serine protease inhibitors. Bioorg Med Chem Lett. 2000 Nov 20;10(22):2501-4.
DM69T3A	RU	https://pubmed.ncbi.nlm.nih.gov/11086715

DMLY4ER	DI	DMLY4ER
DMLY4ER	DN	1-(2-phenoxybenzyl)-1H-imidazole
DMLY4ER	MI	TTSZLWK
DMLY4ER	MN	Aromatase (CYP19A1)
DMLY4ER	MT	DTT
DMLY4ER	MA	Inhibitor
DMLY4ER	RN	Novel highly potent and selective nonsteroidal aromatase inhibitors: synthesis, biological evaluation and structure-activity relationships investigation. J Med Chem. 2010 Jul 22;53(14):5347-51. 
DMLY4ER	RU	https://pubmed.ncbi.nlm.nih.gov/20568782

DMOMAXJ	DI	DMOMAXJ
DMOMAXJ	DN	1-(2-Phenoxy-ethyl)-1H-imidazole
DMOMAXJ	MI	TTIQUX7
DMOMAXJ	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMOMAXJ	MT	DTT
DMOMAXJ	MA	Inhibitor
DMOMAXJ	RN	Selective thromboxane synthetase inhibitors. 1. 1-[(Aryloxy)alkyl]-1H-imidazoles. J Med Chem. 1985 Oct;28(10):1427-32.
DMOMAXJ	RU	https://pubmed.ncbi.nlm.nih.gov/3930740

DMC1IKP	DI	DMC1IKP
DMC1IKP	DN	1-(2-Phenoxy-ethyl)-3-thiazol-2-yl-thiourea
DMC1IKP	MI	TT84ETX
DMC1IKP	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMC1IKP	MT	DTT
DMC1IKP	MA	Inhibitor
DMC1IKP	RN	Anti-HIV activity of aromatic and heterocyclic thiazolyl thiourea compounds. Bioorg Med Chem Lett. 2001 Feb 26;11(4):523-8.
DMC1IKP	RU	https://pubmed.ncbi.nlm.nih.gov/11229762

DMWFCYN	DI	DMWFCYN
DMWFCYN	DN	1-(2-phenoxyphenyl)piperazine
DMWFCYN	MI	TTSQIFT
DMWFCYN	MN	5-HT 1A receptor (HTR1A)
DMWFCYN	MT	DTT
DMWFCYN	MA	Inhibitor
DMWFCYN	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMWFCYN	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMWFCYN	DI	DMWFCYN
DMWFCYN	DN	1-(2-phenoxyphenyl)piperazine
DMWFCYN	MI	TTVBI8W
DMWFCYN	MN	Dopamine transporter (DAT)
DMWFCYN	MT	DTT
DMWFCYN	MA	Inhibitor
DMWFCYN	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMWFCYN	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMWFCYN	DI	DMWFCYN
DMWFCYN	DN	1-(2-phenoxyphenyl)piperazine
DMWFCYN	MI	TTAWNKZ
DMWFCYN	MN	Norepinephrine transporter (NET)
DMWFCYN	MT	DTT
DMWFCYN	MA	Inhibitor
DMWFCYN	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMWFCYN	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMWFCYN	DI	DMWFCYN
DMWFCYN	DN	1-(2-phenoxyphenyl)piperazine
DMWFCYN	MI	TT3ROYC
DMWFCYN	MN	Serotonin transporter (SERT)
DMWFCYN	MT	DTT
DMWFCYN	MA	Inhibitor
DMWFCYN	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMWFCYN	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMXG10E	DI	DMXG10E
DMXG10E	DN	1-(2-Phenyl-propyl)-3-thiazol-2-yl-thiourea
DMXG10E	MI	TT84ETX
DMXG10E	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMXG10E	MT	DTT
DMXG10E	MA	Inhibitor
DMXG10E	RN	Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36.
DMXG10E	RU	https://pubmed.ncbi.nlm.nih.gov/8523406

DMDLKPI	DI	DMDLKPI
DMDLKPI	DN	1-(2-p-tolyl-ethyl)-pyrrolidine
DMDLKPI	MI	TT9JNIC
DMDLKPI	MN	Histamine H3 receptor (H3R)
DMDLKPI	MT	DTT
DMDLKPI	MA	Inhibitor
DMDLKPI	RN	In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9.
DMDLKPI	RU	https://pubmed.ncbi.nlm.nih.gov/18077160

DM4B2EN	DI	DM4B2EN
DM4B2EN	DN	1-(2-Pyridin-2-yl-ethyl)-3-thiazol-2-yl-thiourea
DM4B2EN	MI	TT84ETX
DM4B2EN	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM4B2EN	MT	DTT
DM4B2EN	MA	Inhibitor
DM4B2EN	RN	Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36.
DM4B2EN	RU	https://pubmed.ncbi.nlm.nih.gov/8523406

DMEDSLZ	DI	DMEDSLZ
DMEDSLZ	DN	1-(3-(2-(3-methoxyphenoxy)ethoxy)propyl)azepane
DMEDSLZ	MI	TT9JNIC
DMEDSLZ	MN	Histamine H3 receptor (H3R)
DMEDSLZ	MT	DTT
DMEDSLZ	MA	Inhibitor
DMEDSLZ	RN	Diether derivatives of homo- or substituted piperidines as non-imidazole histamine H3 receptor ligands. Bioorg Med Chem. 2009 Apr 15;17(8):3037-42.
DMEDSLZ	RU	https://pubmed.ncbi.nlm.nih.gov/19329325

DMD25N9	DI	DMD25N9
DMD25N9	DN	1-(3-(2-methylquinolin-7-yl)phenyl)ethanone
DMD25N9	MI	TTHS256
DMD25N9	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMD25N9	MT	DTT
DMD25N9	MA	Inhibitor
DMD25N9	RN	Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8.
DMD25N9	RU	https://pubmed.ncbi.nlm.nih.gov/17590335

DM3EBFS	DI	DM3EBFS
DM3EBFS	DN	1-(3-(3-morpholinopropoxy)phenyl)-3-phenylurea
DM3EBFS	MI	TT7WVHI
DM3EBFS	MN	Soluble epoxide hydrolase (EPHX2)
DM3EBFS	MT	DTT
DM3EBFS	MA	Inhibitor
DM3EBFS	RN	Unsymmetrical non-adamantyl N,N'-diaryl urea and amide inhibitors of soluble expoxide hydrolase. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4259-63.
DM3EBFS	RU	https://pubmed.ncbi.nlm.nih.gov/19520575

DM3EYOL	DI	DM3EYOL
DM3EYOL	DN	1-(3-(3-phenylpropoxy)propyl)piperidine
DM3EYOL	MI	TT9JNIC
DM3EYOL	MN	Histamine H3 receptor (H3R)
DM3EYOL	MT	DTT
DM3EYOL	MA	Inhibitor
DM3EYOL	RN	Piperidine variations in search for non-imidazole histamine H(3) receptor ligands. Bioorg Med Chem. 2008 Sep 15;16(18):8729-36.
DM3EYOL	RU	https://pubmed.ncbi.nlm.nih.gov/18774720

DMHEIKQ	DI	DMHEIKQ
DMHEIKQ	DN	1-(3-(4-(2-fluoroethyl)phenoxy)propyl)piperidine
DMHEIKQ	MI	TT9JNIC
DMHEIKQ	MN	Histamine H3 receptor (H3R)
DMHEIKQ	MT	DTT
DMHEIKQ	MA	Inhibitor
DMHEIKQ	RN	Fluorinated non-imidazole histamine H3 receptor antagonists. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2172-5.
DMHEIKQ	RU	https://pubmed.ncbi.nlm.nih.gov/19286376

DMVXCPE	DI	DMVXCPE
DMVXCPE	DN	1-(3-(4-(fluoromethyl)phenoxy)propyl)piperidine
DMVXCPE	MI	TT9JNIC
DMVXCPE	MN	Histamine H3 receptor (H3R)
DMVXCPE	MT	DTT
DMVXCPE	MA	Inhibitor
DMVXCPE	RN	Fluorinated non-imidazole histamine H3 receptor antagonists. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2172-5.
DMVXCPE	RU	https://pubmed.ncbi.nlm.nih.gov/19286376

DMM36DE	DI	DMM36DE
DMM36DE	DN	1-(3-(4-chlorobenzyl)quinoxalin-2-yl)hydrazine
DMM36DE	MI	TT3WG5C
DMM36DE	MN	Monoamine oxidase type A (MAO-A)
DMM36DE	MT	DTT
DMM36DE	MA	Inhibitor
DMM36DE	RN	Synthesis of 3-benzyl-2-substituted quinoxalines as novel monoamine oxidase A inhibitors. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1753-6.
DMM36DE	RU	https://pubmed.ncbi.nlm.nih.gov/16356714

DMIFARP	DI	DMIFARP
DMIFARP	DN	1-(3-(4-chlorophenyl)propyl)-1H-imidazole
DMIFARP	MI	TTRA5BZ
DMIFARP	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMIFARP	MT	DTT
DMIFARP	MA	Inhibitor
DMIFARP	RN	Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-substituted phenyl alkyl imidazole-based inhibitor... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4752-6.
DMIFARP	RU	https://pubmed.ncbi.nlm.nih.gov/16870430

DMWKXZ2	DI	DMWKXZ2
DMWKXZ2	DN	1-(3-(4-fluorophenyl)propyl)-1H-imidazole
DMWKXZ2	MI	TTSZLWK
DMWKXZ2	MN	Aromatase (CYP19A1)
DMWKXZ2	MT	DTT
DMWKXZ2	MA	Inhibitor
DMWKXZ2	RN	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
DMWKXZ2	RU	https://pubmed.ncbi.nlm.nih.gov/20413308

DMWKXZ2	DI	DMWKXZ2
DMWKXZ2	DN	1-(3-(4-fluorophenyl)propyl)-1H-imidazole
DMWKXZ2	MI	TTRA5BZ
DMWKXZ2	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMWKXZ2	MT	DTT
DMWKXZ2	MA	Inhibitor
DMWKXZ2	RN	Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-substituted phenyl alkyl imidazole-based inhibitor... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4752-6.
DMWKXZ2	RU	https://pubmed.ncbi.nlm.nih.gov/16870430

DMQ4MUF	DI	DMQ4MUF
DMQ4MUF	DN	1-(3-(benzyloxy)-2-methylphenyl)piperazine
DMQ4MUF	MI	TTJS8PY
DMQ4MUF	MN	5-HT 6 receptor (HTR6)
DMQ4MUF	MT	DTT
DMQ4MUF	MA	Inhibitor
DMQ4MUF	RN	Synthesis and SAR of tolylamine 5-HT6 antagonists. Bioorg Med Chem Lett. 2009 May 1;19(9):2409-12.
DMQ4MUF	RU	https://pubmed.ncbi.nlm.nih.gov/19346128

DMX5N3V	DI	DMX5N3V
DMX5N3V	DN	1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine
DMX5N3V	MI	TTSQIFT
DMX5N3V	MN	5-HT 1A receptor (HTR1A)
DMX5N3V	MT	DTT
DMX5N3V	MA	Inhibitor
DMX5N3V	RN	The synthesis and biological activity of pentafluorosulfanyl analogs of fluoxetine, fenfluramine, and norfenfluramine. Bioorg Med Chem. 2007 Nov 1;15(21):6659-66.
DMX5N3V	RU	https://pubmed.ncbi.nlm.nih.gov/17765553

DMX5N3V	DI	DMX5N3V
DMX5N3V	DN	1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine
DMX5N3V	MI	TTK8CXU
DMX5N3V	MN	5-HT 1B receptor (HTR1B)
DMX5N3V	MT	DTT
DMX5N3V	MA	Inhibitor
DMX5N3V	RN	The synthesis and biological activity of pentafluorosulfanyl analogs of fluoxetine, fenfluramine, and norfenfluramine. Bioorg Med Chem. 2007 Nov 1;15(21):6659-66.
DMX5N3V	RU	https://pubmed.ncbi.nlm.nih.gov/17765553

DMX5N3V	DI	DMX5N3V
DMX5N3V	DN	1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine
DMX5N3V	MI	TT6MSOK
DMX5N3V	MN	5-HT 1D receptor (HTR1D)
DMX5N3V	MT	DTT
DMX5N3V	MA	Inhibitor
DMX5N3V	RN	The synthesis and biological activity of pentafluorosulfanyl analogs of fluoxetine, fenfluramine, and norfenfluramine. Bioorg Med Chem. 2007 Nov 1;15(21):6659-66.
DMX5N3V	RU	https://pubmed.ncbi.nlm.nih.gov/17765553

DMX5N3V	DI	DMX5N3V
DMX5N3V	DN	1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine
DMX5N3V	MI	TTJQOD7
DMX5N3V	MN	5-HT 2A receptor (HTR2A)
DMX5N3V	MT	DTT
DMX5N3V	MA	Inhibitor
DMX5N3V	RN	The synthesis and biological activity of pentafluorosulfanyl analogs of fluoxetine, fenfluramine, and norfenfluramine. Bioorg Med Chem. 2007 Nov 1;15(21):6659-66.
DMX5N3V	RU	https://pubmed.ncbi.nlm.nih.gov/17765553

DMX5N3V	DI	DMX5N3V
DMX5N3V	DN	1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine
DMX5N3V	MI	TT0K1SC
DMX5N3V	MN	5-HT 2B receptor (HTR2B)
DMX5N3V	MT	DTT
DMX5N3V	MA	Inhibitor
DMX5N3V	RN	The synthesis and biological activity of pentafluorosulfanyl analogs of fluoxetine, fenfluramine, and norfenfluramine. Bioorg Med Chem. 2007 Nov 1;15(21):6659-66.
DMX5N3V	RU	https://pubmed.ncbi.nlm.nih.gov/17765553

DMX5N3V	DI	DMX5N3V
DMX5N3V	DN	1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine
DMX5N3V	MI	TTJS8PY
DMX5N3V	MN	5-HT 6 receptor (HTR6)
DMX5N3V	MT	DTT
DMX5N3V	MA	Inhibitor
DMX5N3V	RN	The synthesis and biological activity of pentafluorosulfanyl analogs of fluoxetine, fenfluramine, and norfenfluramine. Bioorg Med Chem. 2007 Nov 1;15(21):6659-66.
DMX5N3V	RU	https://pubmed.ncbi.nlm.nih.gov/17765553

DMX5N3V	DI	DMX5N3V
DMX5N3V	DN	1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine
DMX5N3V	MI	TTO9X1H
DMX5N3V	MN	5-HT 7 receptor (HTR7)
DMX5N3V	MT	DTT
DMX5N3V	MA	Inhibitor
DMX5N3V	RN	The synthesis and biological activity of pentafluorosulfanyl analogs of fluoxetine, fenfluramine, and norfenfluramine. Bioorg Med Chem. 2007 Nov 1;15(21):6659-66.
DMX5N3V	RU	https://pubmed.ncbi.nlm.nih.gov/17765553

DMXUNMW	DI	DMXUNMW
DMXUNMW	DN	1-(3-(phenylthio)propyl)-4-m-tolylpiperazine
DMXUNMW	MI	TTJQOD7
DMXUNMW	MN	5-HT 2A receptor (HTR2A)
DMXUNMW	MT	DTT
DMXUNMW	MA	Inhibitor
DMXUNMW	RN	Synthesis and QSAR studies on hypotensive 1-[3-(4-substituted phenylthio) propyl]-4-(substituted phenyl) piperazines. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1708-12.
DMXUNMW	RU	https://pubmed.ncbi.nlm.nih.gov/17234413

DMNZYWR	DI	DMNZYWR
DMNZYWR	DN	1-(3,3-Dimethyl-2-oxo-butyl)-1H-indole-2,3-dione
DMNZYWR	MI	TTPLTSQ
DMNZYWR	MN	Neutrophil elastase (NE)
DMNZYWR	MT	DTT
DMNZYWR	MA	Inhibitor
DMNZYWR	RN	Parallel synthesis of isatin-based serine protease inhibitors. Bioorg Med Chem Lett. 2000 Nov 20;10(22):2501-4.
DMNZYWR	RU	https://pubmed.ncbi.nlm.nih.gov/11086715

DMNZYWR	DI	DMNZYWR
DMNZYWR	DN	1-(3,3-Dimethyl-2-oxo-butyl)-1H-indole-2,3-dione
DMNZYWR	MI	TTP86E2
DMNZYWR	MN	Plasminogen (PLG)
DMNZYWR	MT	DTT
DMNZYWR	MA	Inhibitor
DMNZYWR	RN	Parallel synthesis of isatin-based serine protease inhibitors. Bioorg Med Chem Lett. 2000 Nov 20;10(22):2501-4.
DMNZYWR	RU	https://pubmed.ncbi.nlm.nih.gov/11086715

DM6RO2L	DI	DM6RO2L
DM6RO2L	DN	1-(3,3-Diphenyl-allyl)-3-m-tolyl-urea
DM6RO2L	MI	TTCG0AL
DM6RO2L	MN	Cholecystokinin receptor type A (CCKAR)
DM6RO2L	MT	DTT
DM6RO2L	MA	Inhibitor
DM6RO2L	RN	Hybrid cholecystokinin-A antagonists based on molecular modeling of lorglumide and L-364,718. J Med Chem. 1992 Mar 20;35(6):1042-9.
DM6RO2L	RU	https://pubmed.ncbi.nlm.nih.gov/1552499

DMJDK7Z	DI	DMJDK7Z
DMJDK7Z	DN	1-(3,3-diphenylpropyl)-4-phenylpiperidin-4-ol
DMJDK7Z	MI	TTNT7K8
DMJDK7Z	MN	Nociceptin receptor (OPRL1)
DMJDK7Z	MT	DTT
DMJDK7Z	MA	Inhibitor
DMJDK7Z	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMJDK7Z	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMX6PKO	DI	DMX6PKO
DMX6PKO	DN	1-(3,4-dichlorobenzyl)-1H-imidazole
DMX6PKO	MI	TTRA5BZ
DMX6PKO	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMX6PKO	MT	DTT
DMX6PKO	MA	Inhibitor
DMX6PKO	RN	Synthesis and biochemical evaluation of a range of potent benzyl imidazole-based compounds as potential inhibitors of the enzyme complex 17alpha-hy... Bioorg Med Chem Lett. 2006 Aug 1;16(15):4011-5.
DMX6PKO	RU	https://pubmed.ncbi.nlm.nih.gov/16750362

DMX71K9	DI	DMX71K9
DMX71K9	DN	1-(3,4-dichlorobenzyl)-1H-indole-2,3-dione
DMX71K9	MI	TTEB0GD
DMX71K9	MN	Cholinesterase (BCHE)
DMX71K9	MT	DTT
DMX71K9	MA	Inhibitor
DMX71K9	RN	Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85.
DMX71K9	RU	https://pubmed.ncbi.nlm.nih.gov/17378546

DMX71K9	DI	DMX71K9
DMX71K9	DN	1-(3,4-dichlorobenzyl)-1H-indole-2,3-dione
DMX71K9	MI	TTMF541
DMX71K9	MN	Liver carboxylesterase (CES1)
DMX71K9	MT	DTT
DMX71K9	MA	Inhibitor
DMX71K9	RN	Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85.
DMX71K9	RU	https://pubmed.ncbi.nlm.nih.gov/17378546

DM4YWEL	DI	DM4YWEL
DM4YWEL	DN	1-(3,4-dichlorophenyl)-2-(phenylsulfonyl)ethanone
DM4YWEL	MI	TTN7BL9
DM4YWEL	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DM4YWEL	MT	DTT
DM4YWEL	MA	Inhibitor
DM4YWEL	RN	beta-Keto sulfones as inhibitors of 11beta-hydroxysteroid dehydrogenase type I and the mechanism of action. Bioorg Med Chem. 2007 Jul 1;15(13):4396-405.
DM4YWEL	RU	https://pubmed.ncbi.nlm.nih.gov/17490884

DMNOQ49	DI	DMNOQ49
DMNOQ49	DN	1-(3,4-dichlorophenyl)-3-(3,5-dichlorophenyl)urea
DMNOQ49	MI	TTA93TL
DMNOQ49	MN	P2Y purinoceptor 1 (P2RY1)
DMNOQ49	MT	DTT
DMNOQ49	MA	Inhibitor
DMNOQ49	RN	P2Y1 receptor antagonists as novel antithrombotic agents. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3338-43.
DMNOQ49	RU	https://pubmed.ncbi.nlm.nih.gov/18445527

DMN4JU0	DI	DMN4JU0
DMN4JU0	DN	1-(3,4-Dichloro-phenyl)-3-diethylamino-indan-5-ol
DMN4JU0	MI	TTVBI8W
DMN4JU0	MN	Dopamine transporter (DAT)
DMN4JU0	MT	DTT
DMN4JU0	MA	Inhibitor
DMN4JU0	RN	Synthesis and pharmacological evaluation of 3-(3,4-dichlorophenyl)-1-indanamine derivatives as nonselective ligands for biogenic amine transporters. J Med Chem. 2004 May 6;47(10):2624-34.
DMN4JU0	RU	https://pubmed.ncbi.nlm.nih.gov/15115403

DMN4JU0	DI	DMN4JU0
DMN4JU0	DN	1-(3,4-Dichloro-phenyl)-3-diethylamino-indan-5-ol
DMN4JU0	MI	TTAWNKZ
DMN4JU0	MN	Norepinephrine transporter (NET)
DMN4JU0	MT	DTT
DMN4JU0	MA	Inhibitor
DMN4JU0	RN	Synthesis and pharmacological evaluation of 3-(3,4-dichlorophenyl)-1-indanamine derivatives as nonselective ligands for biogenic amine transporters. J Med Chem. 2004 May 6;47(10):2624-34.
DMN4JU0	RU	https://pubmed.ncbi.nlm.nih.gov/15115403

DMN4JU0	DI	DMN4JU0
DMN4JU0	DN	1-(3,4-Dichloro-phenyl)-3-diethylamino-indan-5-ol
DMN4JU0	MI	TT3ROYC
DMN4JU0	MN	Serotonin transporter (SERT)
DMN4JU0	MT	DTT
DMN4JU0	MA	Inhibitor
DMN4JU0	RN	Synthesis and pharmacological evaluation of 3-(3,4-dichlorophenyl)-1-indanamine derivatives as nonselective ligands for biogenic amine transporters. J Med Chem. 2004 May 6;47(10):2624-34.
DMN4JU0	RU	https://pubmed.ncbi.nlm.nih.gov/15115403

DMVOJ7K	DI	DMVOJ7K
DMVOJ7K	DN	1-(3,4-dichlorophenyl)-3-hydroxyurea
DMVOJ7K	MI	TTUNARX
DMVOJ7K	MN	Carbonic anhydrase (CA)
DMVOJ7K	MT	DTT
DMVOJ7K	MA	Inhibitor
DMVOJ7K	RN	N-hydroxyurea--a versatile zinc binding function in the design of metalloenzyme inhibitors. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4316-20.
DMVOJ7K	RU	https://pubmed.ncbi.nlm.nih.gov/16759856

DMVOJ7K	DI	DMVOJ7K
DMVOJ7K	DN	1-(3,4-dichlorophenyl)-3-hydroxyurea
DMVOJ7K	MI	TTANPDJ
DMVOJ7K	MN	Carbonic anhydrase II (CA-II)
DMVOJ7K	MT	DTT
DMVOJ7K	MA	Inhibitor
DMVOJ7K	RN	N-hydroxyurea--a versatile zinc binding function in the design of metalloenzyme inhibitors. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4316-20.
DMVOJ7K	RU	https://pubmed.ncbi.nlm.nih.gov/16759856

DMVOJ7K	DI	DMVOJ7K
DMVOJ7K	DN	1-(3,4-dichlorophenyl)-3-hydroxyurea
DMVOJ7K	MI	TTZHA0O
DMVOJ7K	MN	Carbonic anhydrase IV (CA-IV)
DMVOJ7K	MT	DTT
DMVOJ7K	MA	Inhibitor
DMVOJ7K	RN	N-hydroxyurea--a versatile zinc binding function in the design of metalloenzyme inhibitors. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4316-20.
DMVOJ7K	RU	https://pubmed.ncbi.nlm.nih.gov/16759856

DMVOJ7K	DI	DMVOJ7K
DMVOJ7K	DN	1-(3,4-dichlorophenyl)-3-hydroxyurea
DMVOJ7K	MI	TT2LVK8
DMVOJ7K	MN	Carbonic anhydrase IX (CA-IX)
DMVOJ7K	MT	DTT
DMVOJ7K	MA	Inhibitor
DMVOJ7K	RN	N-hydroxyurea--a versatile zinc binding function in the design of metalloenzyme inhibitors. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4316-20.
DMVOJ7K	RU	https://pubmed.ncbi.nlm.nih.gov/16759856

DMWIEDN	DI	DMWIEDN
DMWIEDN	DN	1-(3,4-Dichloro-phenyl)-3-methylamino-indan-5-ol
DMWIEDN	MI	TTVBI8W
DMWIEDN	MN	Dopamine transporter (DAT)
DMWIEDN	MT	DTT
DMWIEDN	MA	Inhibitor
DMWIEDN	RN	Synthesis and pharmacological evaluation of 3-(3,4-dichlorophenyl)-1-indanamine derivatives as nonselective ligands for biogenic amine transporters. J Med Chem. 2004 May 6;47(10):2624-34.
DMWIEDN	RU	https://pubmed.ncbi.nlm.nih.gov/15115403

DMWIEDN	DI	DMWIEDN
DMWIEDN	DN	1-(3,4-Dichloro-phenyl)-3-methylamino-indan-5-ol
DMWIEDN	MI	TTAWNKZ
DMWIEDN	MN	Norepinephrine transporter (NET)
DMWIEDN	MT	DTT
DMWIEDN	MA	Inhibitor
DMWIEDN	RN	Synthesis and pharmacological evaluation of 3-(3,4-dichlorophenyl)-1-indanamine derivatives as nonselective ligands for biogenic amine transporters. J Med Chem. 2004 May 6;47(10):2624-34.
DMWIEDN	RU	https://pubmed.ncbi.nlm.nih.gov/15115403

DMWIEDN	DI	DMWIEDN
DMWIEDN	DN	1-(3,4-Dichloro-phenyl)-3-methylamino-indan-5-ol
DMWIEDN	MI	TT3ROYC
DMWIEDN	MN	Serotonin transporter (SERT)
DMWIEDN	MT	DTT
DMWIEDN	MA	Inhibitor
DMWIEDN	RN	Synthesis and pharmacological evaluation of 3-(3,4-dichlorophenyl)-1-indanamine derivatives as nonselective ligands for biogenic amine transporters. J Med Chem. 2004 May 6;47(10):2624-34.
DMWIEDN	RU	https://pubmed.ncbi.nlm.nih.gov/15115403

DMYZ548	DI	DMYZ548
DMYZ548	DN	1-(3,4-DICHLOROPHENYL)-6-(METHOXYMETHYL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX)
DMYZ548	MI	TTXV4FI
DMYZ548	MN	Albendazole monooxygenase (CYP3A4)
DMYZ548	MT	DTT
DMYZ548	MA	Inhibitor
DMYZ548	RN	6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor. J Med Chem. 2010 Jul 8;53(13):4989-5001.
DMYZ548	RU	https://pubmed.ncbi.nlm.nih.gov/20527970

DMYZ548	DI	DMYZ548
DMYZ548	DN	1-(3,4-DICHLOROPHENYL)-6-(METHOXYMETHYL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX)
DMYZ548	MI	TTVG215
DMYZ548	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DMYZ548	MT	DTT
DMYZ548	MA	Inhibitor
DMYZ548	RN	6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor. J Med Chem. 2010 Jul 8;53(13):4989-5001.
DMYZ548	RU	https://pubmed.ncbi.nlm.nih.gov/20527970

DMRXD2P	DI	DMRXD2P
DMRXD2P	DN	1-(3,4-difluorobenzyl)-1H-imidazole
DMRXD2P	MI	TTRA5BZ
DMRXD2P	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMRXD2P	MT	DTT
DMRXD2P	MA	Inhibitor
DMRXD2P	RN	Synthesis and biochemical evaluation of a range of potent benzyl imidazole-based compounds as potential inhibitors of the enzyme complex 17alpha-hy... Bioorg Med Chem Lett. 2006 Aug 1;16(15):4011-5.
DMRXD2P	RU	https://pubmed.ncbi.nlm.nih.gov/16750362

DM5C7I8	DI	DM5C7I8
DM5C7I8	DN	1-(3,4-dihydronaphthalen-1-yl)ethanone
DM5C7I8	MI	TTEAID7
DM5C7I8	MN	Trypanosoma Cruzipain (Trypano CYSP)
DM5C7I8	MT	DTT
DM5C7I8	MA	Inhibitor
DM5C7I8	RN	Design, synthesis, and biochemical evaluation of novel cruzain inhibitors with potential application in the treatment of Chagas' disease. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4405-9.
DM5C7I8	RU	https://pubmed.ncbi.nlm.nih.gov/16781147

DMP93HZ	DI	DMP93HZ
DMP93HZ	DN	1-(3,4-dihydronaphthalen-2-yl)-1H-imidazole
DMP93HZ	MI	TTIQUX7
DMP93HZ	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMP93HZ	MT	DTT
DMP93HZ	MA	Inhibitor
DMP93HZ	RN	Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31.
DMP93HZ	RU	https://pubmed.ncbi.nlm.nih.gov/16570918

DM9M5D1	DI	DM9M5D1
DM9M5D1	DN	1-(3,4-dihydroxy-2-nitrophenyl)-2-phenylethanone
DM9M5D1	MI	TTKWFB8
DM9M5D1	MN	Catechol-O-methyl-transferase (COMT)
DM9M5D1	MT	DTT
DM9M5D1	MA	Inhibitor
DM9M5D1	RN	Synthesis and biological evaluation of a novel series of "ortho-nitrated" inhibitors of catechol-O-methyltransferase. J Med Chem. 2005 Dec 15;48(25):8070-8.
DM9M5D1	RU	https://pubmed.ncbi.nlm.nih.gov/16335931

DMKI719	DI	DMKI719
DMKI719	DN	1-(3,4-dihydroxy-5-nitrophenyl)-2-phenoxyethanone
DMKI719	MI	TTKWFB8
DMKI719	MN	Catechol-O-methyl-transferase (COMT)
DMKI719	MT	DTT
DMKI719	MA	Inhibitor
DMKI719	RN	Synthesis, biological evaluation, and molecular modeling studies of a novel, peripherally selective inhibitor of catechol-O-methyltransferase. J Med Chem. 2004 Dec 2;47(25):6207-17.
DMKI719	RU	https://pubmed.ncbi.nlm.nih.gov/15566291

DMCHILK	DI	DMCHILK
DMCHILK	DN	1-(3,4-Dimethyl-phenyl)-2-phenyl-ethane-1,2-dione
DMCHILK	MI	TTMF541
DMCHILK	MN	Liver carboxylesterase (CES1)
DMCHILK	MT	DTT
DMCHILK	MA	Inhibitor
DMCHILK	RN	Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15.
DMCHILK	RU	https://pubmed.ncbi.nlm.nih.gov/15828829

DM5WOK8	DI	DM5WOK8
DM5WOK8	DN	1-(3,5-bis(trifluoromethyl)benzyl)-1H-imidazole
DM5WOK8	MI	TTRA5BZ
DM5WOK8	MN	Steroid 17-alpha-monooxygenase (S17AH)
DM5WOK8	MT	DTT
DM5WOK8	MA	Inhibitor
DM5WOK8	RN	Synthesis and biochemical evaluation of a range of potent benzyl imidazole-based compounds as potential inhibitors of the enzyme complex 17alpha-hy... Bioorg Med Chem Lett. 2006 Aug 1;16(15):4011-5.
DM5WOK8	RU	https://pubmed.ncbi.nlm.nih.gov/16750362

DMNRCM0	DI	DMNRCM0
DMNRCM0	DN	1-(3,5-dibromobenzyl)-1H-imidazole
DMNRCM0	MI	TTRA5BZ
DMNRCM0	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMNRCM0	MT	DTT
DMNRCM0	MA	Inhibitor
DMNRCM0	RN	Synthesis and biochemical evaluation of a range of potent benzyl imidazole-based compounds as potential inhibitors of the enzyme complex 17alpha-hy... Bioorg Med Chem Lett. 2006 Aug 1;16(15):4011-5.
DMNRCM0	RU	https://pubmed.ncbi.nlm.nih.gov/16750362

DMLSWHP	DI	DMLSWHP
DMLSWHP	DN	1-(3,5-dichlorobenzyl)-1H-imidazole
DMLSWHP	MI	TTRA5BZ
DMLSWHP	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMLSWHP	MT	DTT
DMLSWHP	MA	Inhibitor
DMLSWHP	RN	Synthesis and biochemical evaluation of a range of potent benzyl imidazole-based compounds as potential inhibitors of the enzyme complex 17alpha-hy... Bioorg Med Chem Lett. 2006 Aug 1;16(15):4011-5.
DMLSWHP	RU	https://pubmed.ncbi.nlm.nih.gov/16750362

DMEAI6V	DI	DMEAI6V
DMEAI6V	DN	1-(3,5-difluorobenzyl)-1H-imidazole
DMEAI6V	MI	TTRA5BZ
DMEAI6V	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMEAI6V	MT	DTT
DMEAI6V	MA	Inhibitor
DMEAI6V	RN	Synthesis and biochemical evaluation of a range of potent benzyl imidazole-based compounds as potential inhibitors of the enzyme complex 17alpha-hy... Bioorg Med Chem Lett. 2006 Aug 1;16(15):4011-5.
DMEAI6V	RU	https://pubmed.ncbi.nlm.nih.gov/16750362

DMYJ4EG	DI	DMYJ4EG
DMYJ4EG	DN	1-(3,5-dimethylphenyl)-2-(phenylsulfonyl)ethanone
DMYJ4EG	MI	TTN7BL9
DMYJ4EG	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMYJ4EG	MT	DTT
DMYJ4EG	MA	Inhibitor
DMYJ4EG	RN	beta-Keto sulfones as inhibitors of 11beta-hydroxysteroid dehydrogenase type I and the mechanism of action. Bioorg Med Chem. 2007 Jul 1;15(13):4396-405.
DMYJ4EG	RU	https://pubmed.ncbi.nlm.nih.gov/17490884

DMEJZAC	DI	DMEJZAC
DMEJZAC	DN	1-(3-Amino-benzyl)-1H-indole-5-carboxamidine
DMEJZAC	MI	TT2WR1T
DMEJZAC	MN	Cationic trypsinogen (PRSS1)
DMEJZAC	MT	DTT
DMEJZAC	MA	Inhibitor
DMEJZAC	RN	Aromatic amidines: comparison of their ability to block respiratory syncytial virus induced cell fusion and to inhibit plasmin, urokinase, thrombin... J Med Chem. 1983 Feb;26(2):294-8.
DMEJZAC	RU	https://pubmed.ncbi.nlm.nih.gov/6219223

DMTY41F	DI	DMTY41F
DMTY41F	DN	1-(3-benzyl-6,7-dichloroquinoxalin-2-yl)hydrazine
DMTY41F	MI	TT3WG5C
DMTY41F	MN	Monoamine oxidase type A (MAO-A)
DMTY41F	MT	DTT
DMTY41F	MA	Inhibitor
DMTY41F	RN	Synthesis of 3-benzyl-2-substituted quinoxalines as novel monoamine oxidase A inhibitors. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1753-6.
DMTY41F	RU	https://pubmed.ncbi.nlm.nih.gov/16356714

DMDZAVU	DI	DMDZAVU
DMDZAVU	DN	1-(3-benzyloxy-pyridin-2-yl)-3-phenyl-urea
DMDZAVU	MI	TTL2ADK
DMDZAVU	MN	Rotamase A (PPIA)
DMDZAVU	MT	DTT
DMDZAVU	MA	Inhibitor
DMDZAVU	RN	Structure-based design, synthesis, and biological evaluation of novel inhibitors of human cyclophilin A. J Med Chem. 2006 Feb 9;49(3):900-10.
DMDZAVU	RU	https://pubmed.ncbi.nlm.nih.gov/16451056

DMJCVQN	DI	DMJCVQN
DMJCVQN	DN	1-(3-benzylquinoxalin-2-yl)hydrazine
DMJCVQN	MI	TT3WG5C
DMJCVQN	MN	Monoamine oxidase type A (MAO-A)
DMJCVQN	MT	DTT
DMJCVQN	MA	Inhibitor
DMJCVQN	RN	Synthesis of 3-benzyl-2-substituted quinoxalines as novel monoamine oxidase A inhibitors. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1753-6.
DMJCVQN	RU	https://pubmed.ncbi.nlm.nih.gov/16356714

DMA59TP	DI	DMA59TP
DMA59TP	DN	1-(3-Bromobenzyl)-1H-imidazole
DMA59TP	MI	TTIQUX7
DMA59TP	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMA59TP	MT	DTT
DMA59TP	MA	Inhibitor
DMA59TP	RN	Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25.
DMA59TP	RU	https://pubmed.ncbi.nlm.nih.gov/20121113

DM58S47	DI	DM58S47
DM58S47	DN	1-(3-Bromomethyl-phenyl)-2,2,2-trifluoro-ethanone
DM58S47	MI	TT1RS9F
DM58S47	MN	Acetylcholinesterase (AChE)
DM58S47	MT	DTT
DM58S47	MA	Inhibitor
DM58S47	RN	A structure-based design approach to the development of novel, reversible AChE inhibitors. J Med Chem. 2001 Sep 27;44(20):3203-15.
DM58S47	RU	https://pubmed.ncbi.nlm.nih.gov/11563919

DM2SEXH	DI	DM2SEXH
DM2SEXH	DN	1-(3-bromophenyl)-2-(tert-butylamino)propan-1-one
DM2SEXH	MI	TTVBI8W
DM2SEXH	MN	Dopamine transporter (DAT)
DM2SEXH	MT	DTT
DM2SEXH	MA	Inhibitor
DM2SEXH	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14.
DM2SEXH	RU	https://pubmed.ncbi.nlm.nih.gov/20158204

DM2SEXH	DI	DM2SEXH
DM2SEXH	DN	1-(3-bromophenyl)-2-(tert-butylamino)propan-1-one
DM2SEXH	MI	TTAWNKZ
DM2SEXH	MN	Norepinephrine transporter (NET)
DM2SEXH	MT	DTT
DM2SEXH	MA	Inhibitor
DM2SEXH	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14.
DM2SEXH	RU	https://pubmed.ncbi.nlm.nih.gov/20158204

DMJXOUK	DI	DMJXOUK
DMJXOUK	DN	1-(3-CHLORO-4-FLUOROPHENYL)-2,2,2-TRIFLUORO-1-(1-(4-FLUOROPHENYL)-1H-INDAZOL-5-YL)ETHANOL (ENANTIOMERIC MIX)
DMJXOUK	MI	TTOZRK6
DMJXOUK	MN	Glucocorticoid receptor messenger RNA (GCR mRNA)
DMJXOUK	MT	DTT
DMJXOUK	MA	Inhibitor
DMJXOUK	RN	5-Functionalized indazoles as glucocorticoid receptor agonists. Bioorg Med Chem Lett. 2010 May 15;20(10):3017-20.
DMJXOUK	RU	https://pubmed.ncbi.nlm.nih.gov/20427184

DM3SQBH	DI	DM3SQBH
DM3SQBH	DN	1-(3-Chlorobenzyl)-1H-imidazole
DM3SQBH	MI	TTIQUX7
DM3SQBH	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM3SQBH	MT	DTT
DM3SQBH	MA	Inhibitor
DM3SQBH	RN	Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25.
DM3SQBH	RU	https://pubmed.ncbi.nlm.nih.gov/20121113

DMFYJ5V	DI	DMFYJ5V
DMFYJ5V	DN	1-(3-chlorophenyl)-2-(dimethylamino)propan-1-one
DMFYJ5V	MI	TTVBI8W
DMFYJ5V	MN	Dopamine transporter (DAT)
DMFYJ5V	MT	DTT
DMFYJ5V	MA	Inhibitor
DMFYJ5V	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14.
DMFYJ5V	RU	https://pubmed.ncbi.nlm.nih.gov/20158204

DMFYJ5V	DI	DMFYJ5V
DMFYJ5V	DN	1-(3-chlorophenyl)-2-(dimethylamino)propan-1-one
DMFYJ5V	MI	TTAWNKZ
DMFYJ5V	MN	Norepinephrine transporter (NET)
DMFYJ5V	MT	DTT
DMFYJ5V	MA	Inhibitor
DMFYJ5V	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14.
DMFYJ5V	RU	https://pubmed.ncbi.nlm.nih.gov/20158204

DMPOVUY	DI	DMPOVUY
DMPOVUY	DN	1-(3-chlorophenyl)-2-(piperidin-1-yl)propan-1-one
DMPOVUY	MI	TTVBI8W
DMPOVUY	MN	Dopamine transporter (DAT)
DMPOVUY	MT	DTT
DMPOVUY	MA	Inhibitor
DMPOVUY	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14.
DMPOVUY	RU	https://pubmed.ncbi.nlm.nih.gov/20158204

DMPOVUY	DI	DMPOVUY
DMPOVUY	DN	1-(3-chlorophenyl)-2-(piperidin-1-yl)propan-1-one
DMPOVUY	MI	TTAWNKZ
DMPOVUY	MN	Norepinephrine transporter (NET)
DMPOVUY	MT	DTT
DMPOVUY	MA	Inhibitor
DMPOVUY	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14.
DMPOVUY	RU	https://pubmed.ncbi.nlm.nih.gov/20158204

DMPOVUY	DI	DMPOVUY
DMPOVUY	DN	1-(3-chlorophenyl)-2-(piperidin-1-yl)propan-1-one
DMPOVUY	MI	TT3ROYC
DMPOVUY	MN	Serotonin transporter (SERT)
DMPOVUY	MT	DTT
DMPOVUY	MA	Inhibitor
DMPOVUY	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81.
DMPOVUY	RU	https://pubmed.ncbi.nlm.nih.gov/19821577

DMC5PI4	DI	DMC5PI4
DMC5PI4	DN	1-(3-Chloro-phenyl)-3-(4-hydroxy-decyl)-urea
DMC5PI4	MI	TT7WVHI
DMC5PI4	MN	Soluble epoxide hydrolase (EPHX2)
DMC5PI4	MT	DTT
DMC5PI4	MA	Inhibitor
DMC5PI4	RN	Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem. 2005 May 19;48(10):3621-9.
DMC5PI4	RU	https://pubmed.ncbi.nlm.nih.gov/15887969

DM1VLMC	DI	DM1VLMC
DM1VLMC	DN	1-(3-Chloro-phenyl)-3-cyclohexyl-urea
DM1VLMC	MI	TT7WVHI
DM1VLMC	MN	Soluble epoxide hydrolase (EPHX2)
DM1VLMC	MT	DTT
DM1VLMC	MA	Inhibitor
DM1VLMC	RN	Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem. 2005 May 19;48(10):3621-9.
DM1VLMC	RU	https://pubmed.ncbi.nlm.nih.gov/15887969

DM6LWR2	DI	DM6LWR2
DM6LWR2	DN	1-(3-chloropyridin-2-yl)-4-tosylpiperazine
DM6LWR2	MI	TTN7BL9
DM6LWR2	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DM6LWR2	MT	DTT
DM6LWR2	MA	Inhibitor
DM6LWR2	RN	Discovery and initial SAR of arylsulfonylpiperazine inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1). Bioorg Med Chem Lett. 2008 Jun 15;18(12):3513-6.
DM6LWR2	RU	https://pubmed.ncbi.nlm.nih.gov/18511278

DM8DR1B	DI	DM8DR1B
DM8DR1B	DN	1-(3-cyano-1-methyl-1H-indol-6-yl)-3-phenylurea
DM8DR1B	MI	TTTB4UP
DM8DR1B	MN	Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2)
DM8DR1B	MT	DTT
DM8DR1B	MA	Inhibitor
DM8DR1B	RN	Novel indole inhibitors of IMPDH from fragments: synthesis and initial structure-activity relationships. Bioorg Med Chem Lett. 2006 May 1;16(9):2539-42.
DM8DR1B	RU	https://pubmed.ncbi.nlm.nih.gov/16483773

DM9KTH6	DI	DM9KTH6
DM9KTH6	DN	1-(3-cyano-2-hydroxyphenyl)-3-phenylurea
DM9KTH6	MI	TT30C9G
DM9KTH6	MN	C-X-C chemokine receptor type 2 (CXCR2)
DM9KTH6	MT	DTT
DM9KTH6	MA	Inhibitor
DM9KTH6	RN	Comparison of N,N'-diarylsquaramides and N,N'-diarylureas as antagonists of the CXCR2 chemokine receptor. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1713-7.
DM9KTH6	RU	https://pubmed.ncbi.nlm.nih.gov/17236763

DMVTCGP	DI	DMVTCGP
DMVTCGP	DN	1-(3-Cyano-phenyl)-1H-pyrazole-4-carboxylic acid
DMVTCGP	MI	TT7RJY8
DMVTCGP	MN	Xanthine dehydrogenase/oxidase (XDH)
DMVTCGP	MT	DTT
DMVTCGP	MA	Inhibitor
DMVTCGP	RN	Synthesis and structure-activity relationships of 1-phenylpyrazoles as xanthine oxidase inhibitors. Bioorg Med Chem Lett. 2001 Apr 9;11(7):879-82.
DMVTCGP	RU	https://pubmed.ncbi.nlm.nih.gov/11294382

DM18DB3	DI	DM18DB3
DM18DB3	DN	1-(3-Fluorobenzyl)-1H-imidazole
DM18DB3	MI	TTIQUX7
DM18DB3	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM18DB3	MT	DTT
DM18DB3	MA	Inhibitor
DM18DB3	RN	Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25.
DM18DB3	RU	https://pubmed.ncbi.nlm.nih.gov/20121113

DM2SNR0	DI	DM2SNR0
DM2SNR0	DN	1-(3-Fluoro-phenyl)-piperazine
DM2SNR0	MI	TTSQIFT
DM2SNR0	MN	5-HT 1A receptor (HTR1A)
DM2SNR0	MT	DTT
DM2SNR0	MA	Inhibitor
DM2SNR0	RN	Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. J Med Chem. 1989 May;32(5):1052-6.
DM2SNR0	RU	https://pubmed.ncbi.nlm.nih.gov/2565400

DM2SNR0	DI	DM2SNR0
DM2SNR0	DN	1-(3-Fluoro-phenyl)-piperazine
DM2SNR0	MI	TT6MSOK
DM2SNR0	MN	5-HT 1D receptor (HTR1D)
DM2SNR0	MT	DTT
DM2SNR0	MA	Inhibitor
DM2SNR0	RN	Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. J Med Chem. 1989 May;32(5):1052-6.
DM2SNR0	RU	https://pubmed.ncbi.nlm.nih.gov/2565400

DMWFU3T	DI	DMWFU3T
DMWFU3T	DN	1-(3-Fluoro-pyridin-2-yl)-4-methyl-piperazine
DMWFU3T	MI	TTNGILX
DMWFU3T	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMWFU3T	MT	DTT
DMWFU3T	MA	Inhibitor
DMWFU3T	RN	Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines. J Med Chem. 1984 Sep;27(9):1182-5.
DMWFU3T	RU	https://pubmed.ncbi.nlm.nih.gov/6088770

DMWFU3T	DI	DMWFU3T
DMWFU3T	DN	1-(3-Fluoro-pyridin-2-yl)-4-methyl-piperazine
DMWFU3T	MI	TT34BHT
DMWFU3T	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMWFU3T	MT	DTT
DMWFU3T	MA	Inhibitor
DMWFU3T	RN	Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines. J Med Chem. 1984 Sep;27(9):1182-5.
DMWFU3T	RU	https://pubmed.ncbi.nlm.nih.gov/6088770

DMWFU3T	DI	DMWFU3T
DMWFU3T	DN	1-(3-Fluoro-pyridin-2-yl)-4-methyl-piperazine
DMWFU3T	MI	TTWG9A4
DMWFU3T	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMWFU3T	MT	DTT
DMWFU3T	MA	Inhibitor
DMWFU3T	RN	Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines. J Med Chem. 1984 Sep;27(9):1182-5.
DMWFU3T	RU	https://pubmed.ncbi.nlm.nih.gov/6088770

DMWFU3T	DI	DMWFU3T
DMWFU3T	DN	1-(3-Fluoro-pyridin-2-yl)-4-methyl-piperazine
DMWFU3T	MI	TTWM4TY
DMWFU3T	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMWFU3T	MT	DTT
DMWFU3T	MA	Inhibitor
DMWFU3T	RN	Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines. J Med Chem. 1984 Sep;27(9):1182-5.
DMWFU3T	RU	https://pubmed.ncbi.nlm.nih.gov/6088770

DMQHFOX	DI	DMQHFOX
DMQHFOX	DN	1-(3-Hydroxyphenyl)-4-propylpiperazine
DMQHFOX	MI	TTEX248
DMQHFOX	MN	Dopamine D2 receptor (D2R)
DMQHFOX	MT	DTT
DMQHFOX	MA	Inhibitor
DMQHFOX	RN	Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabi... J Med Chem. 2010 Mar 25;53(6):2510-20.
DMQHFOX	RU	https://pubmed.ncbi.nlm.nih.gov/20155917

DMPEZ1V	DI	DMPEZ1V
DMPEZ1V	DN	1-(3-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one
DMPEZ1V	MI	TTVBI8W
DMPEZ1V	MN	Dopamine transporter (DAT)
DMPEZ1V	MT	DTT
DMPEZ1V	MA	Inhibitor
DMPEZ1V	RN	1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32.
DMPEZ1V	RU	https://pubmed.ncbi.nlm.nih.gov/16480278

DMPEZ1V	DI	DMPEZ1V
DMPEZ1V	DN	1-(3-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one
DMPEZ1V	MI	TTAWNKZ
DMPEZ1V	MN	Norepinephrine transporter (NET)
DMPEZ1V	MT	DTT
DMPEZ1V	MA	Inhibitor
DMPEZ1V	RN	1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32.
DMPEZ1V	RU	https://pubmed.ncbi.nlm.nih.gov/16480278

DMPEZ1V	DI	DMPEZ1V
DMPEZ1V	DN	1-(3-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one
DMPEZ1V	MI	TT3ROYC
DMPEZ1V	MN	Serotonin transporter (SERT)
DMPEZ1V	MT	DTT
DMPEZ1V	MA	Inhibitor
DMPEZ1V	RN	1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32.
DMPEZ1V	RU	https://pubmed.ncbi.nlm.nih.gov/16480278

DM30M9H	DI	DM30M9H
DM30M9H	DN	1-(3-Methoxy-benzyl)-5-methyl-1H-indole-2,3-dione
DM30M9H	MI	TTEAID7
DM30M9H	MN	Trypanosoma Cruzipain (Trypano CYSP)
DM30M9H	MT	DTT
DM30M9H	MA	Inhibitor
DM30M9H	RN	Synthesis and evaluation of isatins and thiosemicarbazone derivatives against cruzain, falcipain-2 and rhodesain. Bioorg Med Chem Lett. 2003 Oct 20;13(20):3527-30.
DM30M9H	RU	https://pubmed.ncbi.nlm.nih.gov/14505663

DM16U5F	DI	DM16U5F
DM16U5F	DN	1-(3-Methoxy-naphthalen-2-yl)-1H-imidazole
DM16U5F	MI	TTSZLWK
DM16U5F	MN	Aromatase (CYP19A1)
DM16U5F	MT	DTT
DM16U5F	MA	Inhibitor
DM16U5F	RN	Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42.
DM16U5F	RU	https://pubmed.ncbi.nlm.nih.gov/16220979

DM16U5F	DI	DM16U5F
DM16U5F	DN	1-(3-Methoxy-naphthalen-2-yl)-1H-imidazole
DM16U5F	MI	TTIQUX7
DM16U5F	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM16U5F	MT	DTT
DM16U5F	MA	Inhibitor
DM16U5F	RN	Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42.
DM16U5F	RU	https://pubmed.ncbi.nlm.nih.gov/16220979

DMGU7MO	DI	DMGU7MO
DMGU7MO	DN	1-(3-methoxyphenethyl)pyrrolidine
DMGU7MO	MI	TT9JNIC
DMGU7MO	MN	Histamine H3 receptor (H3R)
DMGU7MO	MT	DTT
DMGU7MO	MA	Inhibitor
DMGU7MO	RN	In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9.
DMGU7MO	RU	https://pubmed.ncbi.nlm.nih.gov/18077160

DMR0ICB	DI	DMR0ICB
DMR0ICB	DN	1-(3-methoxyphenyl)-2-(phenylsulfonyl)ethanone
DMR0ICB	MI	TTN7BL9
DMR0ICB	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMR0ICB	MT	DTT
DMR0ICB	MA	Inhibitor
DMR0ICB	RN	beta-Keto sulfones as inhibitors of 11beta-hydroxysteroid dehydrogenase type I and the mechanism of action. Bioorg Med Chem. 2007 Jul 1;15(13):4396-405.
DMR0ICB	RU	https://pubmed.ncbi.nlm.nih.gov/17490884

DMI15LJ	DI	DMI15LJ
DMI15LJ	DN	1-(3-Methylbutylidene)thiosemicarbazide
DMI15LJ	MI	TTULVH8
DMI15LJ	MN	Tyrosinase (TYR)
DMI15LJ	MT	DTT
DMI15LJ	MA	Inhibitor
DMI15LJ	RN	A class of potent tyrosinase inhibitors: alkylidenethiosemicarbazide compounds. Eur J Med Chem. 2009 Apr;44(4):1773-8.
DMI15LJ	RU	https://pubmed.ncbi.nlm.nih.gov/18524420

DMB9T6F	DI	DMB9T6F
DMB9T6F	DN	1-(3-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one
DMB9T6F	MI	TTVBI8W
DMB9T6F	MN	Dopamine transporter (DAT)
DMB9T6F	MT	DTT
DMB9T6F	MA	Inhibitor
DMB9T6F	RN	1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32.
DMB9T6F	RU	https://pubmed.ncbi.nlm.nih.gov/16480278

DMB9T6F	DI	DMB9T6F
DMB9T6F	DN	1-(3-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one
DMB9T6F	MI	TTAWNKZ
DMB9T6F	MN	Norepinephrine transporter (NET)
DMB9T6F	MT	DTT
DMB9T6F	MA	Inhibitor
DMB9T6F	RN	1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32.
DMB9T6F	RU	https://pubmed.ncbi.nlm.nih.gov/16480278

DMB9T6F	DI	DMB9T6F
DMB9T6F	DN	1-(3-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one
DMB9T6F	MI	TT3ROYC
DMB9T6F	MN	Serotonin transporter (SERT)
DMB9T6F	MT	DTT
DMB9T6F	MA	Inhibitor
DMB9T6F	RN	1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32.
DMB9T6F	RU	https://pubmed.ncbi.nlm.nih.gov/16480278

DMYH9M0	DI	DMYH9M0
DMYH9M0	DN	1-(3-methylpyridin-2-yl)-4-tosylpiperazine
DMYH9M0	MI	TTN7BL9
DMYH9M0	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMYH9M0	MT	DTT
DMYH9M0	MA	Inhibitor
DMYH9M0	RN	Discovery and initial SAR of arylsulfonylpiperazine inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1). Bioorg Med Chem Lett. 2008 Jun 15;18(12):3513-6.
DMYH9M0	RU	https://pubmed.ncbi.nlm.nih.gov/18511278

DM3RGLE	DI	DM3RGLE
DM3RGLE	DN	1-(3-Nitro-benzyl)-1H-indole-5-carboxamidine
DM3RGLE	MI	TT2WR1T
DM3RGLE	MN	Cationic trypsinogen (PRSS1)
DM3RGLE	MT	DTT
DM3RGLE	MA	Inhibitor
DM3RGLE	RN	Aromatic amidines: comparison of their ability to block respiratory syncytial virus induced cell fusion and to inhibit plasmin, urokinase, thrombin... J Med Chem. 1983 Feb;26(2):294-8.
DM3RGLE	RU	https://pubmed.ncbi.nlm.nih.gov/6219223

DMMJC5E	DI	DMMJC5E
DMMJC5E	DN	1-(3-Nitro-phenyl)-piperazine
DMMJC5E	MI	TTSQIFT
DMMJC5E	MN	5-HT 1A receptor (HTR1A)
DMMJC5E	MT	DTT
DMMJC5E	MA	Inhibitor
DMMJC5E	RN	Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. J Med Chem. 1989 May;32(5):1052-6.
DMMJC5E	RU	https://pubmed.ncbi.nlm.nih.gov/2565400

DMMJC5E	DI	DMMJC5E
DMMJC5E	DN	1-(3-Nitro-phenyl)-piperazine
DMMJC5E	MI	TT6MSOK
DMMJC5E	MN	5-HT 1D receptor (HTR1D)
DMMJC5E	MT	DTT
DMMJC5E	MA	Inhibitor
DMMJC5E	RN	Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. J Med Chem. 1989 May;32(5):1052-6.
DMMJC5E	RU	https://pubmed.ncbi.nlm.nih.gov/2565400

DM3FP6J	DI	DM3FP6J
DM3FP6J	DN	1-(3-nitropyridin-2-yl)-4-tosylpiperazine
DM3FP6J	MI	TTN7BL9
DM3FP6J	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DM3FP6J	MT	DTT
DM3FP6J	MA	Inhibitor
DM3FP6J	RN	Discovery and initial SAR of arylsulfonylpiperazine inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1). Bioorg Med Chem Lett. 2008 Jun 15;18(12):3513-6.
DM3FP6J	RU	https://pubmed.ncbi.nlm.nih.gov/18511278

DMEMHIF	DI	DMEMHIF
DMEMHIF	DN	1-(3-Oxocyclohexylidene)thiosemicarbazide
DMEMHIF	MI	TTULVH8
DMEMHIF	MN	Tyrosinase (TYR)
DMEMHIF	MT	DTT
DMEMHIF	MA	Inhibitor
DMEMHIF	RN	A class of potent tyrosinase inhibitors: alkylidenethiosemicarbazide compounds. Eur J Med Chem. 2009 Apr;44(4):1773-8.
DMEMHIF	RU	https://pubmed.ncbi.nlm.nih.gov/18524420

DMG8DLM	DI	DMG8DLM
DMG8DLM	DN	1-(3-phenoxypropyl)-4-(piperidin-1-yl)piperidine
DMG8DLM	MI	TTULVH8
DMG8DLM	MN	Tyrosinase (TYR)
DMG8DLM	MT	DTT
DMG8DLM	MA	Inhibitor
DMG8DLM	RN	Dragon method for finding novel tyrosinase inhibitors: Biosilico identification and experimental in vitro assays. Eur J Med Chem. 2007 Nov-Dec;42(11-12):1370-81.
DMG8DLM	RU	https://pubmed.ncbi.nlm.nih.gov/17637486

DMFPUGV	DI	DMFPUGV
DMFPUGV	DN	1-(3-Phenylallylidene)thiosemicarbazide
DMFPUGV	MI	TTULVH8
DMFPUGV	MN	Tyrosinase (TYR)
DMFPUGV	MT	DTT
DMFPUGV	MA	Inhibitor
DMFPUGV	RN	A class of potent tyrosinase inhibitors: alkylidenethiosemicarbazide compounds. Eur J Med Chem. 2009 Apr;44(4):1773-8.
DMFPUGV	RU	https://pubmed.ncbi.nlm.nih.gov/18524420

DMPAWFJ	DI	DMPAWFJ
DMPAWFJ	DN	1-(3-phenylpropyl)-1H-imidazole
DMPAWFJ	MI	TTRA5BZ
DMPAWFJ	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMPAWFJ	MT	DTT
DMPAWFJ	MA	Inhibitor
DMPAWFJ	RN	Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-substituted phenyl alkyl imidazole-based inhibitor... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4752-6.
DMPAWFJ	RU	https://pubmed.ncbi.nlm.nih.gov/16870430

DM37RI9	DI	DM37RI9
DM37RI9	DN	1-(3-Phenyl-propyl)-3-thiazol-2-yl-thiourea
DM37RI9	MI	TT84ETX
DM37RI9	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM37RI9	MT	DTT
DM37RI9	MA	Inhibitor
DM37RI9	RN	Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36.
DM37RI9	RU	https://pubmed.ncbi.nlm.nih.gov/8523406

DMZPJM4	DI	DMZPJM4
DMZPJM4	DN	1-(3-tritylaminopropyl)uracil
DMZPJM4	MI	TTY8KJS
DMZPJM4	MN	Bacterial Deoxyuridine triphosphate nucleotidohydrolase (Bact dut)
DMZPJM4	MT	DTT
DMZPJM4	MA	Inhibitor
DMZPJM4	RN	Acyclic nucleoside analogues as inhibitors of Plasmodium falciparum dUTPase. J Med Chem. 2006 Jul 13;49(14):4183-95.
DMZPJM4	RU	https://pubmed.ncbi.nlm.nih.gov/16821778

DMUDVRM	DI	DMUDVRM
DMUDVRM	DN	1-(4-(1H-pyrazol-1-yl)benzyl)-4-phenylpiperazine
DMUDVRM	MI	TTZFYLI
DMUDVRM	MN	Dopamine D1 receptor (D1R)
DMUDVRM	MT	DTT
DMUDVRM	MA	Inhibitor
DMUDVRM	RN	Synthesis and biological investigations of dopaminergic partial agonists preferentially recognizing the D4 receptor subtype. Bioorg Med Chem Lett. 2006 Jun 1;16(11):2955-9.
DMUDVRM	RU	https://pubmed.ncbi.nlm.nih.gov/16563764

DMUDVRM	DI	DMUDVRM
DMUDVRM	DN	1-(4-(1H-pyrazol-1-yl)benzyl)-4-phenylpiperazine
DMUDVRM	MI	TTEX248
DMUDVRM	MN	Dopamine D2 receptor (D2R)
DMUDVRM	MT	DTT
DMUDVRM	MA	Inhibitor
DMUDVRM	RN	Synthesis and biological investigations of dopaminergic partial agonists preferentially recognizing the D4 receptor subtype. Bioorg Med Chem Lett. 2006 Jun 1;16(11):2955-9.
DMUDVRM	RU	https://pubmed.ncbi.nlm.nih.gov/16563764

DMUDVRM	DI	DMUDVRM
DMUDVRM	DN	1-(4-(1H-pyrazol-1-yl)benzyl)-4-phenylpiperazine
DMUDVRM	MI	TT4C8EA
DMUDVRM	MN	Dopamine D3 receptor (D3R)
DMUDVRM	MT	DTT
DMUDVRM	MA	Inhibitor
DMUDVRM	RN	Synthesis and biological investigations of dopaminergic partial agonists preferentially recognizing the D4 receptor subtype. Bioorg Med Chem Lett. 2006 Jun 1;16(11):2955-9.
DMUDVRM	RU	https://pubmed.ncbi.nlm.nih.gov/16563764

DMUDVRM	DI	DMUDVRM
DMUDVRM	DN	1-(4-(1H-pyrazol-1-yl)benzyl)-4-phenylpiperazine
DMUDVRM	MI	TTE0A2F
DMUDVRM	MN	Dopamine D4 receptor (D4R)
DMUDVRM	MT	DTT
DMUDVRM	MA	Inhibitor
DMUDVRM	RN	Synthesis and biological investigations of dopaminergic partial agonists preferentially recognizing the D4 receptor subtype. Bioorg Med Chem Lett. 2006 Jun 1;16(11):2955-9.
DMUDVRM	RU	https://pubmed.ncbi.nlm.nih.gov/16563764

DMYIK9W	DI	DMYIK9W
DMYIK9W	DN	1-(4-(3-morpholinopropoxy)phenyl)-3-phenylurea
DMYIK9W	MI	TT7WVHI
DMYIK9W	MN	Soluble epoxide hydrolase (EPHX2)
DMYIK9W	MT	DTT
DMYIK9W	MA	Inhibitor
DMYIK9W	RN	Unsymmetrical non-adamantyl N,N'-diaryl urea and amide inhibitors of soluble expoxide hydrolase. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4259-63.
DMYIK9W	RU	https://pubmed.ncbi.nlm.nih.gov/19520575

DMM18AQ	DI	DMM18AQ
DMM18AQ	DN	1-(4-(4-phenyl-1-piperazinyl)butyl)indolin-2-one
DMM18AQ	MI	TTEX248
DMM18AQ	MN	Dopamine D2 receptor (D2R)
DMM18AQ	MT	DTT
DMM18AQ	MA	Inhibitor
DMM18AQ	RN	Synthesis of novel lactam derivatives and their evaluation as ligands for the dopamine receptors, leading to a D(4)-selective ligand. Bioorg Med Chem. 2007 Sep 1;15(17):5811-8.
DMM18AQ	RU	https://pubmed.ncbi.nlm.nih.gov/17576067

DMM18AQ	DI	DMM18AQ
DMM18AQ	DN	1-(4-(4-phenyl-1-piperazinyl)butyl)indolin-2-one
DMM18AQ	MI	TT4C8EA
DMM18AQ	MN	Dopamine D3 receptor (D3R)
DMM18AQ	MT	DTT
DMM18AQ	MA	Inhibitor
DMM18AQ	RN	Synthesis of novel lactam derivatives and their evaluation as ligands for the dopamine receptors, leading to a D(4)-selective ligand. Bioorg Med Chem. 2007 Sep 1;15(17):5811-8.
DMM18AQ	RU	https://pubmed.ncbi.nlm.nih.gov/17576067

DMM18AQ	DI	DMM18AQ
DMM18AQ	DN	1-(4-(4-phenyl-1-piperazinyl)butyl)indolin-2-one
DMM18AQ	MI	TTS2PH3
DMM18AQ	MN	Dopamine D5 receptor (D5R)
DMM18AQ	MT	DTT
DMM18AQ	MA	Inhibitor
DMM18AQ	RN	Synthesis of novel lactam derivatives and their evaluation as ligands for the dopamine receptors, leading to a D(4)-selective ligand. Bioorg Med Chem. 2007 Sep 1;15(17):5811-8.
DMM18AQ	RU	https://pubmed.ncbi.nlm.nih.gov/17576067

DMT3H0K	DI	DMT3H0K
DMT3H0K	DN	1-(4-(benzyloxy)phenethyl)pyrrolidine
DMT3H0K	MI	TT9JNIC
DMT3H0K	MN	Histamine H3 receptor (H3R)
DMT3H0K	MT	DTT
DMT3H0K	MA	Inhibitor
DMT3H0K	RN	In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9.
DMT3H0K	RU	https://pubmed.ncbi.nlm.nih.gov/18077160

DM7FWK8	DI	DM7FWK8
DM7FWK8	DN	1-(4-(benzyloxy)phenyl)-3-hydroxyurea
DM7FWK8	MI	TTULVH8
DM7FWK8	MN	Tyrosinase (TYR)
DM7FWK8	MT	DTT
DM7FWK8	MA	Inhibitor
DM7FWK8	RN	Analogues of N-hydroxy-N'-phenylthiourea and N-hydroxy-N'-phenylurea as inhibitors of tyrosinase and melanin formation. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3607-10.
DM7FWK8	RU	https://pubmed.ncbi.nlm.nih.gov/18501598

DMT81N3	DI	DMT81N3
DMT81N3	DN	1-(4-(benzyloxy)phenyl)propan-2-amine
DMT81N3	MI	TT3WG5C
DMT81N3	MN	Monoamine oxidase type A (MAO-A)
DMT81N3	MT	DTT
DMT81N3	MA	Inhibitor
DMT81N3	RN	Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg Med Chem. 2009 Mar 15;17(6):2452-60.
DMT81N3	RU	https://pubmed.ncbi.nlm.nih.gov/19243954

DMT81N3	DI	DMT81N3
DMT81N3	DN	1-(4-(benzyloxy)phenyl)propan-2-amine
DMT81N3	MI	TTGP7BY
DMT81N3	MN	Monoamine oxidase type B (MAO-B)
DMT81N3	MT	DTT
DMT81N3	MA	Inhibitor
DMT81N3	RN	Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg Med Chem. 2009 Mar 15;17(6):2452-60.
DMT81N3	RU	https://pubmed.ncbi.nlm.nih.gov/19243954

DMLODAM	DI	DMLODAM
DMLODAM	DN	1-(4-(Hexyloxy)phenyl)-3-morpholinopropan-1-one
DMLODAM	MI	TTGER3L
DMLODAM	MN	Thyroid hormone receptor beta (THRB)
DMLODAM	MT	DTT
DMLODAM	MA	Inhibitor
DMLODAM	RN	Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors. J Med Chem. 2009 Jul 9;52(13):3892-901.
DMLODAM	RU	https://pubmed.ncbi.nlm.nih.gov/19469546

DMCE7G0	DI	DMCE7G0
DMCE7G0	DN	1-(4-(methylsulfonyl)phenyl)-1H-indole
DMCE7G0	MI	TTVKILB
DMCE7G0	MN	Prostaglandin G/H synthase 2 (COX-2)
DMCE7G0	MT	DTT
DMCE7G0	MA	Inhibitor
DMCE7G0	RN	Synthesis, anti-inflammatory activity, and in vitro antitumor effect of a novel class of cyclooxygenase inhibitors: 4-(aryloyl)phenyl methyl sulfones. J Med Chem. 2010 Sep 23;53(18):6560-71.
DMCE7G0	RU	https://pubmed.ncbi.nlm.nih.gov/20804197

DMYFBRQ	DI	DMYFBRQ
DMYFBRQ	DN	1-(4-(methylsulfonyl)phenyl)-1H-pyrrole
DMYFBRQ	MI	TTVKILB
DMYFBRQ	MN	Prostaglandin G/H synthase 2 (COX-2)
DMYFBRQ	MT	DTT
DMYFBRQ	MA	Inhibitor
DMYFBRQ	RN	Synthesis, anti-inflammatory activity, and in vitro antitumor effect of a novel class of cyclooxygenase inhibitors: 4-(aryloyl)phenyl methyl sulfones. J Med Chem. 2010 Sep 23;53(18):6560-71.
DMYFBRQ	RU	https://pubmed.ncbi.nlm.nih.gov/20804197

DMH7RY0	DI	DMH7RY0
DMH7RY0	DN	1-(4-(methylsulfonyl)phenyl)-3-phenylurea
DMH7RY0	MI	TT8NGED
DMH7RY0	MN	Prostaglandin G/H synthase 1 (COX-1)
DMH7RY0	MT	DTT
DMH7RY0	MA	Inhibitor
DMH7RY0	RN	Design and synthesis of 1,3-diarylurea derivatives as selective cyclooxygenase (COX-2) inhibitors. Bioorg Med Chem Lett. 2008 Feb 15;18(4):1336-9.
DMH7RY0	RU	https://pubmed.ncbi.nlm.nih.gov/18226898

DMH7RY0	DI	DMH7RY0
DMH7RY0	DN	1-(4-(methylsulfonyl)phenyl)-3-phenylurea
DMH7RY0	MI	TTVKILB
DMH7RY0	MN	Prostaglandin G/H synthase 2 (COX-2)
DMH7RY0	MT	DTT
DMH7RY0	MA	Inhibitor
DMH7RY0	RN	Design and synthesis of 1,3-diarylurea derivatives as selective cyclooxygenase (COX-2) inhibitors. Bioorg Med Chem Lett. 2008 Feb 15;18(4):1336-9.
DMH7RY0	RU	https://pubmed.ncbi.nlm.nih.gov/18226898

DMMSQLC	DI	DMMSQLC
DMMSQLC	DN	1-(4-(methylsulfonyl)phenyl)-3-p-tolylurea
DMMSQLC	MI	TT8NGED
DMMSQLC	MN	Prostaglandin G/H synthase 1 (COX-1)
DMMSQLC	MT	DTT
DMMSQLC	MA	Inhibitor
DMMSQLC	RN	Design and synthesis of 1,3-diarylurea derivatives as selective cyclooxygenase (COX-2) inhibitors. Bioorg Med Chem Lett. 2008 Feb 15;18(4):1336-9.
DMMSQLC	RU	https://pubmed.ncbi.nlm.nih.gov/18226898

DMMSQLC	DI	DMMSQLC
DMMSQLC	DN	1-(4-(methylsulfonyl)phenyl)-3-p-tolylurea
DMMSQLC	MI	TTVKILB
DMMSQLC	MN	Prostaglandin G/H synthase 2 (COX-2)
DMMSQLC	MT	DTT
DMMSQLC	MA	Inhibitor
DMMSQLC	RN	Design and synthesis of 1,3-diarylurea derivatives as selective cyclooxygenase (COX-2) inhibitors. Bioorg Med Chem Lett. 2008 Feb 15;18(4):1336-9.
DMMSQLC	RU	https://pubmed.ncbi.nlm.nih.gov/18226898

DM170BV	DI	DM170BV
DM170BV	DN	1-(4-acetyloxazol-2-yl)-7-phenylheptan-1-one
DM170BV	MI	TTDP1UC
DM170BV	MN	Fatty acid amide hydrolase (FAAH)
DM170BV	MT	DTT
DM170BV	MA	Inhibitor
DM170BV	RN	Exploration of a fundamental substituent effect of alpha-ketoheterocycle enzyme inhibitors: Potent and selective inhibitors of fatty acid amide hyd... Bioorg Med Chem Lett. 2008 Nov 15;18(22):5842-6.
DM170BV	RU	https://pubmed.ncbi.nlm.nih.gov/18639454

DMOZAM6	DI	DMOZAM6
DMOZAM6	DN	1-(4-Aminobenzyl)-1H-imidazole
DMOZAM6	MI	TTIQUX7
DMOZAM6	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMOZAM6	MT	DTT
DMOZAM6	MA	Inhibitor
DMOZAM6	RN	Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25.
DMOZAM6	RU	https://pubmed.ncbi.nlm.nih.gov/20121113

DMMYT4W	DI	DMMYT4W
DMMYT4W	DN	1-(4-Aminophenyl)-2-(1H-imidazol-1-yl)ethanone
DMMYT4W	MI	TTSZLWK
DMMYT4W	MN	Aromatase (CYP19A1)
DMMYT4W	MT	DTT
DMMYT4W	MA	Inhibitor
DMMYT4W	RN	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
DMMYT4W	RU	https://pubmed.ncbi.nlm.nih.gov/20558073

DMY7TDZ	DI	DMY7TDZ
DMY7TDZ	DN	1-(4-aminophenyl)-2-pyrrolidin-1-yl-pentan-1-one
DMY7TDZ	MI	TTVBI8W
DMY7TDZ	MN	Dopamine transporter (DAT)
DMY7TDZ	MT	DTT
DMY7TDZ	MA	Inhibitor
DMY7TDZ	RN	A novel photoaffinity ligand for the dopamine transporter based on pyrovalerone. Bioorg Med Chem. 2009 Jun 1;17(11):3770-4.
DMY7TDZ	RU	https://pubmed.ncbi.nlm.nih.gov/19442525

DM4G0NH	DI	DM4G0NH
DM4G0NH	DN	1-(4-aminophenylsulfonyl)-3-(2-mercaptoethyl)urea
DM4G0NH	MI	TTWHDVK
DM4G0NH	MN	Fructose-1,6-bisphosphatase (FBP)
DM4G0NH	MT	DTT
DM4G0NH	MA	Inhibitor
DM4G0NH	RN	Allosteric FBPase inhibitors gain 10(5) times in potency when simultaneously binding two neighboring AMP sites. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4708-12.
DM4G0NH	RU	https://pubmed.ncbi.nlm.nih.gov/18650089

DMWA6G1	DI	DMWA6G1
DMWA6G1	DN	1-(4-aminosulfonylphenyl)-2-(2-pyridyl)acetylene
DMWA6G1	MI	TT8NGED
DMWA6G1	MN	Prostaglandin G/H synthase 1 (COX-1)
DMWA6G1	MT	DTT
DMWA6G1	MA	Inhibitor
DMWA6G1	RN	Synthesis and cyclooxygenase inhibitory activities of linear 1-(methanesulfonylphenyl or benzenesulfonamido)-2-(pyridyl)acetylene regioisomers. Bioorg Med Chem. 2008 Feb 15;16(4):1948-56.
DMWA6G1	RU	https://pubmed.ncbi.nlm.nih.gov/18023187

DMWA6G1	DI	DMWA6G1
DMWA6G1	DN	1-(4-aminosulfonylphenyl)-2-(2-pyridyl)acetylene
DMWA6G1	MI	TTVKILB
DMWA6G1	MN	Prostaglandin G/H synthase 2 (COX-2)
DMWA6G1	MT	DTT
DMWA6G1	MA	Inhibitor
DMWA6G1	RN	Synthesis and cyclooxygenase inhibitory activities of linear 1-(methanesulfonylphenyl or benzenesulfonamido)-2-(pyridyl)acetylene regioisomers. Bioorg Med Chem. 2008 Feb 15;16(4):1948-56.
DMWA6G1	RU	https://pubmed.ncbi.nlm.nih.gov/18023187

DMP93E2	DI	DMP93E2
DMP93E2	DN	1-(4-aminosulfonylphenyl)-2-(4-pyridyl)acetylene
DMP93E2	MI	TT8NGED
DMP93E2	MN	Prostaglandin G/H synthase 1 (COX-1)
DMP93E2	MT	DTT
DMP93E2	MA	Inhibitor
DMP93E2	RN	Synthesis and cyclooxygenase inhibitory activities of linear 1-(methanesulfonylphenyl or benzenesulfonamido)-2-(pyridyl)acetylene regioisomers. Bioorg Med Chem. 2008 Feb 15;16(4):1948-56.
DMP93E2	RU	https://pubmed.ncbi.nlm.nih.gov/18023187

DMXV9S7	DI	DMXV9S7
DMXV9S7	DN	1-(4-Benzylsulfanyl-phenyl)-propylamine
DMXV9S7	MI	TT3ROYC
DMXV9S7	MN	Serotonin transporter (SERT)
DMXV9S7	MT	DTT
DMXV9S7	MA	Inhibitor
DMXV9S7	RN	Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88.
DMXV9S7	RU	https://pubmed.ncbi.nlm.nih.gov/19717215

DMMLCSG	DI	DMMLCSG
DMMLCSG	DN	1-(4-Bromo-2,5-difluorophenyl)-2-aminopropane
DMMLCSG	MI	TTJQOD7
DMMLCSG	MN	5-HT 2A receptor (HTR2A)
DMMLCSG	MT	DTT
DMMLCSG	MA	Inhibitor
DMMLCSG	RN	The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands. Bioorg Med Chem. 2008 Apr 15;16(8):4661-9.
DMMLCSG	RU	https://pubmed.ncbi.nlm.nih.gov/18296055

DMCH6R1	DI	DMCH6R1
DMCH6R1	DN	1-(4-Bromo-2,5-dimethoxy-phenyl)-piperazine
DMCH6R1	MI	TTSQIFT
DMCH6R1	MN	5-HT 1A receptor (HTR1A)
DMCH6R1	MT	DTT
DMCH6R1	MA	Inhibitor
DMCH6R1	RN	Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents. J Med Chem. 1986 May;29(5):630-4.
DMCH6R1	RU	https://pubmed.ncbi.nlm.nih.gov/3701781

DMCH6R1	DI	DMCH6R1
DMCH6R1	DN	1-(4-Bromo-2,5-dimethoxy-phenyl)-piperazine
DMCH6R1	MI	TT6MSOK
DMCH6R1	MN	5-HT 1D receptor (HTR1D)
DMCH6R1	MT	DTT
DMCH6R1	MA	Inhibitor
DMCH6R1	RN	Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents. J Med Chem. 1986 May;29(5):630-4.
DMCH6R1	RU	https://pubmed.ncbi.nlm.nih.gov/3701781

DMCH6R1	DI	DMCH6R1
DMCH6R1	DN	1-(4-Bromo-2,5-dimethoxy-phenyl)-piperazine
DMCH6R1	MI	TTJQOD7
DMCH6R1	MN	5-HT 2A receptor (HTR2A)
DMCH6R1	MT	DTT
DMCH6R1	MA	Inhibitor
DMCH6R1	RN	Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents. J Med Chem. 1986 May;29(5):630-4.
DMCH6R1	RU	https://pubmed.ncbi.nlm.nih.gov/3701781

DM2C7U0	DI	DM2C7U0
DM2C7U0	DN	1-(4-Bromobenzyl)-1H-imidazole
DM2C7U0	MI	TTIQUX7
DM2C7U0	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM2C7U0	MT	DTT
DM2C7U0	MA	Inhibitor
DM2C7U0	RN	Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25.
DM2C7U0	RU	https://pubmed.ncbi.nlm.nih.gov/20121113

DM2C7U0	DI	DM2C7U0
DM2C7U0	DN	1-(4-Bromobenzyl)-1H-imidazole
DM2C7U0	MI	TTRA5BZ
DM2C7U0	MN	Steroid 17-alpha-monooxygenase (S17AH)
DM2C7U0	MT	DTT
DM2C7U0	MA	Inhibitor
DM2C7U0	RN	Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-substituted phenyl alkyl imidazole-based inhibitor... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4752-6.
DM2C7U0	RU	https://pubmed.ncbi.nlm.nih.gov/16870430

DMTPD4R	DI	DMTPD4R
DMTPD4R	DN	1-(4-Bromo-benzyl)-3-quinazolin-8-yl-urea
DMTPD4R	MI	TTMI6F5
DMTPD4R	MN	Transient receptor potential cation channel V1 (TRPV1)
DMTPD4R	MT	DTT
DMTPD4R	MA	Inhibitor
DMTPD4R	RN	Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain: structure-activity relationships for ureas with quin... J Med Chem. 2005 Feb 10;48(3):744-52.
DMTPD4R	RU	https://pubmed.ncbi.nlm.nih.gov/15689158

DMCW8RT	DI	DMCW8RT
DMCW8RT	DN	1-(4-Bromobenzyl)-5-phenyl-1H-imidazole
DMCW8RT	MI	TTIQUX7
DMCW8RT	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMCW8RT	MT	DTT
DMCW8RT	MA	Inhibitor
DMCW8RT	RN	Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25.
DMCW8RT	RU	https://pubmed.ncbi.nlm.nih.gov/20121113

DMUMNYZ	DI	DMUMNYZ
DMUMNYZ	DN	1-(4-bromooxazol-2-yl)-7-phenylheptan-1-one
DMUMNYZ	MI	TTDP1UC
DMUMNYZ	MN	Fatty acid amide hydrolase (FAAH)
DMUMNYZ	MT	DTT
DMUMNYZ	MA	Inhibitor
DMUMNYZ	RN	Exploration of a fundamental substituent effect of alpha-ketoheterocycle enzyme inhibitors: Potent and selective inhibitors of fatty acid amide hyd... Bioorg Med Chem Lett. 2008 Nov 15;18(22):5842-6.
DMUMNYZ	RU	https://pubmed.ncbi.nlm.nih.gov/18639454

DME8B15	DI	DME8B15
DME8B15	DN	1-(4-bromophenethyl)-1H-imidazole
DME8B15	MI	TTRA5BZ
DME8B15	MN	Steroid 17-alpha-monooxygenase (S17AH)
DME8B15	MT	DTT
DME8B15	MA	Inhibitor
DME8B15	RN	Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-substituted phenyl alkyl imidazole-based inhibitor... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4752-6.
DME8B15	RU	https://pubmed.ncbi.nlm.nih.gov/16870430

DMW6YDK	DI	DMW6YDK
DMW6YDK	DN	1-(4-bromophenyl)-2-(tert-butylamino)propan-1-one
DMW6YDK	MI	TTVBI8W
DMW6YDK	MN	Dopamine transporter (DAT)
DMW6YDK	MT	DTT
DMW6YDK	MA	Inhibitor
DMW6YDK	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14.
DMW6YDK	RU	https://pubmed.ncbi.nlm.nih.gov/20158204

DMW6YDK	DI	DMW6YDK
DMW6YDK	DN	1-(4-bromophenyl)-2-(tert-butylamino)propan-1-one
DMW6YDK	MI	TTAWNKZ
DMW6YDK	MN	Norepinephrine transporter (NET)
DMW6YDK	MT	DTT
DMW6YDK	MA	Inhibitor
DMW6YDK	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14.
DMW6YDK	RU	https://pubmed.ncbi.nlm.nih.gov/20158204

DMW6YDK	DI	DMW6YDK
DMW6YDK	DN	1-(4-bromophenyl)-2-(tert-butylamino)propan-1-one
DMW6YDK	MI	TT3ROYC
DMW6YDK	MN	Serotonin transporter (SERT)
DMW6YDK	MT	DTT
DMW6YDK	MA	Inhibitor
DMW6YDK	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14.
DMW6YDK	RU	https://pubmed.ncbi.nlm.nih.gov/20158204

DMPLEC0	DI	DMPLEC0
DMPLEC0	DN	1-(4-bromophenyl)-2-pyrrolidin-1-yl-pentan-1-one
DMPLEC0	MI	TTVBI8W
DMPLEC0	MN	Dopamine transporter (DAT)
DMPLEC0	MT	DTT
DMPLEC0	MA	Inhibitor
DMPLEC0	RN	1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32.
DMPLEC0	RU	https://pubmed.ncbi.nlm.nih.gov/16480278

DMPLEC0	DI	DMPLEC0
DMPLEC0	DN	1-(4-bromophenyl)-2-pyrrolidin-1-yl-pentan-1-one
DMPLEC0	MI	TTAWNKZ
DMPLEC0	MN	Norepinephrine transporter (NET)
DMPLEC0	MT	DTT
DMPLEC0	MA	Inhibitor
DMPLEC0	RN	1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32.
DMPLEC0	RU	https://pubmed.ncbi.nlm.nih.gov/16480278

DMPLEC0	DI	DMPLEC0
DMPLEC0	DN	1-(4-bromophenyl)-2-pyrrolidin-1-yl-pentan-1-one
DMPLEC0	MI	TT3ROYC
DMPLEC0	MN	Serotonin transporter (SERT)
DMPLEC0	MT	DTT
DMPLEC0	MA	Inhibitor
DMPLEC0	RN	1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32.
DMPLEC0	RU	https://pubmed.ncbi.nlm.nih.gov/16480278

DMEUHDL	DI	DMEUHDL
DMEUHDL	DN	1-(4-bromophenyl)-3-hydroxyurea
DMEUHDL	MI	TTULVH8
DMEUHDL	MN	Tyrosinase (TYR)
DMEUHDL	MT	DTT
DMEUHDL	MA	Inhibitor
DMEUHDL	RN	Analogues of N-hydroxy-N'-phenylthiourea and N-hydroxy-N'-phenylurea as inhibitors of tyrosinase and melanin formation. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3607-10.
DMEUHDL	RU	https://pubmed.ncbi.nlm.nih.gov/18501598

DMOEGZV	DI	DMOEGZV
DMOEGZV	DN	1-(4-Butoxy-phenyl)-1H-imidazole
DMOEGZV	MI	TTXV4FI
DMOEGZV	MN	Albendazole monooxygenase (CYP3A4)
DMOEGZV	MT	DTT
DMOEGZV	MA	Inhibitor
DMOEGZV	RN	Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):333-6.
DMOEGZV	RU	https://pubmed.ncbi.nlm.nih.gov/14698153

DMOEGZV	DI	DMOEGZV
DMOEGZV	DN	1-(4-Butoxy-phenyl)-1H-imidazole
DMOEGZV	MI	TTVG215
DMOEGZV	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DMOEGZV	MT	DTT
DMOEGZV	MA	Inhibitor
DMOEGZV	RN	Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):333-6.
DMOEGZV	RU	https://pubmed.ncbi.nlm.nih.gov/14698153

DM7GIZL	DI	DM7GIZL
DM7GIZL	DN	1-(4-butoxyphenyl)propan-2-amine
DM7GIZL	MI	TT3WG5C
DM7GIZL	MN	Monoamine oxidase type A (MAO-A)
DM7GIZL	MT	DTT
DM7GIZL	MA	Inhibitor
DM7GIZL	RN	Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg Med Chem. 2009 Mar 15;17(6):2452-60.
DM7GIZL	RU	https://pubmed.ncbi.nlm.nih.gov/19243954

DMIGDCK	DI	DMIGDCK
DMIGDCK	DN	1-(4-Butyl-thiazol-2-yl)-3-phenethyl-thiourea
DMIGDCK	MI	TT84ETX
DMIGDCK	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMIGDCK	MT	DTT
DMIGDCK	MA	Inhibitor
DMIGDCK	RN	Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36.
DMIGDCK	RU	https://pubmed.ncbi.nlm.nih.gov/8523406

DMBR9TQ	DI	DMBR9TQ
DMBR9TQ	DN	1-(4-chlorobenzyl)-1H-imidazole
DMBR9TQ	MI	TTRA5BZ
DMBR9TQ	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMBR9TQ	MT	DTT
DMBR9TQ	MA	Inhibitor
DMBR9TQ	RN	Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-substituted phenyl alkyl imidazole-based inhibitor... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4752-6.
DMBR9TQ	RU	https://pubmed.ncbi.nlm.nih.gov/16870430

DMOUPNT	DI	DMOUPNT
DMOUPNT	DN	1-(4-chlorobenzyl)-1H-indole-2,3-dione
DMOUPNT	MI	TTMF541
DMOUPNT	MN	Liver carboxylesterase (CES1)
DMOUPNT	MT	DTT
DMOUPNT	MA	Inhibitor
DMOUPNT	RN	Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85.
DMOUPNT	RU	https://pubmed.ncbi.nlm.nih.gov/17378546

DMASLUF	DI	DMASLUF
DMASLUF	DN	1-(4-Chlorobenzyl)-5-phenyl-1H-imidazole
DMASLUF	MI	TTIQUX7
DMASLUF	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMASLUF	MT	DTT
DMASLUF	MA	Inhibitor
DMASLUF	RN	Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25.
DMASLUF	RU	https://pubmed.ncbi.nlm.nih.gov/20121113

DMXGB38	DI	DMXGB38
DMXGB38	DN	1-(4-chlorooxazol-2-yl)-7-phenylheptan-1-one
DMXGB38	MI	TTDP1UC
DMXGB38	MN	Fatty acid amide hydrolase (FAAH)
DMXGB38	MT	DTT
DMXGB38	MA	Inhibitor
DMXGB38	RN	Exploration of a fundamental substituent effect of alpha-ketoheterocycle enzyme inhibitors: Potent and selective inhibitors of fatty acid amide hyd... Bioorg Med Chem Lett. 2008 Nov 15;18(22):5842-6.
DMXGB38	RU	https://pubmed.ncbi.nlm.nih.gov/18639454

DM9MDZG	DI	DM9MDZG
DM9MDZG	DN	1-(4-chlorophenethyl)-1H-imidazole
DM9MDZG	MI	TTRA5BZ
DM9MDZG	MN	Steroid 17-alpha-monooxygenase (S17AH)
DM9MDZG	MT	DTT
DM9MDZG	MA	Inhibitor
DM9MDZG	RN	Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-substituted phenyl alkyl imidazole-based inhibitor... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4752-6.
DM9MDZG	RU	https://pubmed.ncbi.nlm.nih.gov/16870430

DMV8C7I	DI	DMV8C7I
DMV8C7I	DN	1-(4-CHLOROPHENYL)-2-(2,4-DICHLOROPHENYL)-5-(METHYLSULFINYL)-N-(PIPERIDIN-1-YL)-1H-IMIDAZOLE-4-CARBOXAMIDE (ENANTIOMERIC MIX)
DMV8C7I	MI	TT6OEDT
DMV8C7I	MN	Cannabinoid receptor 1 (CB1)
DMV8C7I	MT	DTT
DMV8C7I	MA	Inhibitor
DMV8C7I	RN	Probing the cannabinoid CB1/CB2 receptor subtype selectivity limits of 1,2-diarylimidazole-4-carboxamides by fine-tuning their 5-substitution pattern. Bioorg Med Chem Lett. 2010 May 1;20(9):2770-5.
DMV8C7I	RU	https://pubmed.ncbi.nlm.nih.gov/20363132

DMQHTR4	DI	DMQHTR4
DMQHTR4	DN	1-(4-chlorophenyl)-2-(phenylsulfonyl)ethanone
DMQHTR4	MI	TTN7BL9
DMQHTR4	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMQHTR4	MT	DTT
DMQHTR4	MA	Inhibitor
DMQHTR4	RN	beta-Keto sulfones as inhibitors of 11beta-hydroxysteroid dehydrogenase type I and the mechanism of action. Bioorg Med Chem. 2007 Jul 1;15(13):4396-405.
DMQHTR4	RU	https://pubmed.ncbi.nlm.nih.gov/17490884

DMCDV1O	DI	DMCDV1O
DMCDV1O	DN	1-(4-Chloro-phenyl)-2-phenyl-ethane-1,2-dione
DMCDV1O	MI	TTMF541
DMCDV1O	MN	Liver carboxylesterase (CES1)
DMCDV1O	MT	DTT
DMCDV1O	MA	Inhibitor
DMCDV1O	RN	Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15.
DMCDV1O	RU	https://pubmed.ncbi.nlm.nih.gov/15828829

DMOGVZ2	DI	DMOGVZ2
DMOGVZ2	DN	1-(4-Chloro-phenyl)-2-p-tolyl-ethane-1,2-dione
DMOGVZ2	MI	TTMF541
DMOGVZ2	MN	Liver carboxylesterase (CES1)
DMOGVZ2	MT	DTT
DMOGVZ2	MA	Inhibitor
DMOGVZ2	RN	Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15.
DMOGVZ2	RU	https://pubmed.ncbi.nlm.nih.gov/15828829

DM3YI5G	DI	DM3YI5G
DM3YI5G	DN	1-(4-Chloro-phenyl)-3-(3,3-diphenyl-allyl)-urea
DM3YI5G	MI	TTCG0AL
DM3YI5G	MN	Cholecystokinin receptor type A (CCKAR)
DM3YI5G	MT	DTT
DM3YI5G	MA	Inhibitor
DM3YI5G	RN	Hybrid cholecystokinin-A antagonists based on molecular modeling of lorglumide and L-364,718. J Med Chem. 1992 Mar 20;35(6):1042-9.
DM3YI5G	RU	https://pubmed.ncbi.nlm.nih.gov/1552499

DMUW1GI	DI	DMUW1GI
DMUW1GI	DN	1-(4-Chloro-phenyl)-3-(3-pentyl-oct-2-enyl)-urea
DMUW1GI	MI	TTCG0AL
DMUW1GI	MN	Cholecystokinin receptor type A (CCKAR)
DMUW1GI	MT	DTT
DMUW1GI	MA	Inhibitor
DMUW1GI	RN	Hybrid cholecystokinin-A antagonists based on molecular modeling of lorglumide and L-364,718. J Med Chem. 1992 Mar 20;35(6):1042-9.
DMUW1GI	RU	https://pubmed.ncbi.nlm.nih.gov/1552499

DMVCHSI	DI	DMVCHSI
DMVCHSI	DN	1-(4-chlorophenyl)-4-phenyl-1H-imidazole
DMVCHSI	MI	TT1MPAY
DMVCHSI	MN	GABA(A) receptor alpha-1 (GABRA1)
DMVCHSI	MT	DTT
DMVCHSI	MA	Inhibitor
DMVCHSI	RN	Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors. J Med Chem. 2006 Mar 23;49(6):1855-66.
DMVCHSI	RU	https://pubmed.ncbi.nlm.nih.gov/16539371

DMVCHSI	DI	DMVCHSI
DMVCHSI	DN	1-(4-chlorophenyl)-4-phenyl-1H-imidazole
DMVCHSI	MI	TTZA1NY
DMVCHSI	MN	GABA(A) receptor beta-2 (GABRB2)
DMVCHSI	MT	DTT
DMVCHSI	MA	Inhibitor
DMVCHSI	RN	Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors. J Med Chem. 2006 Mar 23;49(6):1855-66.
DMVCHSI	RU	https://pubmed.ncbi.nlm.nih.gov/16539371

DMVCHSI	DI	DMVCHSI
DMVCHSI	DN	1-(4-chlorophenyl)-4-phenyl-1H-imidazole
DMVCHSI	MI	TT06RH5
DMVCHSI	MN	GABA(A) receptor gamma-2 (GABRG2)
DMVCHSI	MT	DTT
DMVCHSI	MA	Inhibitor
DMVCHSI	RN	Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors. J Med Chem. 2006 Mar 23;49(6):1855-66.
DMVCHSI	RU	https://pubmed.ncbi.nlm.nih.gov/16539371

DMVCHSI	DI	DMVCHSI
DMVCHSI	DN	1-(4-chlorophenyl)-4-phenyl-1H-imidazole
DMVCHSI	MI	TTNJYV2
DMVCHSI	MN	Gamma-aminobutyric acid receptor (GAR)
DMVCHSI	MT	DTT
DMVCHSI	MA	Inhibitor
DMVCHSI	RN	Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors. J Med Chem. 2006 Mar 23;49(6):1855-66.
DMVCHSI	RU	https://pubmed.ncbi.nlm.nih.gov/16539371

DMEJXWG	DI	DMEJXWG
DMEJXWG	DN	1-(4-chlorophenylsulfonyl)-4-phenylazepan-4-ol
DMEJXWG	MI	TTN7BL9
DMEJXWG	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMEJXWG	MT	DTT
DMEJXWG	MA	Inhibitor
DMEJXWG	RN	The discovery of azepane sulfonamides as potent 11beta-HSD1 inhibitors. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4563-5.
DMEJXWG	RU	https://pubmed.ncbi.nlm.nih.gov/19625185

DMIU3C8	DI	DMIU3C8
DMIU3C8	DN	1-(4-cyano-2-hydroxyphenyl)-3-phenylurea
DMIU3C8	MI	TT30C9G
DMIU3C8	MN	C-X-C chemokine receptor type 2 (CXCR2)
DMIU3C8	MT	DTT
DMIU3C8	MA	Inhibitor
DMIU3C8	RN	Comparison of N,N'-diarylsquaramides and N,N'-diarylureas as antagonists of the CXCR2 chemokine receptor. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1713-7.
DMIU3C8	RU	https://pubmed.ncbi.nlm.nih.gov/17236763

DMKDAJ2	DI	DMKDAJ2
DMKDAJ2	DN	1-(4-Cyanobenzyl)-5-(2-fluorophenyl)-1H-imidazole
DMKDAJ2	MI	TTIQUX7
DMKDAJ2	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMKDAJ2	MT	DTT
DMKDAJ2	MA	Inhibitor
DMKDAJ2	RN	Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25.
DMKDAJ2	RU	https://pubmed.ncbi.nlm.nih.gov/20121113

DMAJXYO	DI	DMAJXYO
DMAJXYO	DN	1-(4-Cyanobenzyl)-5-(2-methylphenyl)-1H-imidazole
DMAJXYO	MI	TTIQUX7
DMAJXYO	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMAJXYO	MT	DTT
DMAJXYO	MA	Inhibitor
DMAJXYO	RN	Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25.
DMAJXYO	RU	https://pubmed.ncbi.nlm.nih.gov/20121113

DMVS4D5	DI	DMVS4D5
DMVS4D5	DN	1-(4-Cyanobenzyl)-5-(3-fluorophenyl)-1H-imidazole
DMVS4D5	MI	TTIQUX7
DMVS4D5	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMVS4D5	MT	DTT
DMVS4D5	MA	Inhibitor
DMVS4D5	RN	Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25.
DMVS4D5	RU	https://pubmed.ncbi.nlm.nih.gov/20121113

DMI8UC7	DI	DMI8UC7
DMI8UC7	DN	1-(4-Cyanobenzyl)-5-(3-methylphenyl)-1H-imidazole
DMI8UC7	MI	TTIQUX7
DMI8UC7	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMI8UC7	MT	DTT
DMI8UC7	MA	Inhibitor
DMI8UC7	RN	Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25.
DMI8UC7	RU	https://pubmed.ncbi.nlm.nih.gov/20121113

DM7C3VD	DI	DM7C3VD
DM7C3VD	DN	1-(4-Cyanobenzyl)-5-(4-fluorophenyl)-1H-imidazole
DM7C3VD	MI	TTIQUX7
DM7C3VD	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM7C3VD	MT	DTT
DM7C3VD	MA	Inhibitor
DM7C3VD	RN	Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25.
DM7C3VD	RU	https://pubmed.ncbi.nlm.nih.gov/20121113

DMQX37R	DI	DMQX37R
DMQX37R	DN	1-(4-Cyanobenzyl)-5-(4-methylphenyl)-1H-imidazole
DMQX37R	MI	TTIQUX7
DMQX37R	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMQX37R	MT	DTT
DMQX37R	MA	Inhibitor
DMQX37R	RN	Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25.
DMQX37R	RU	https://pubmed.ncbi.nlm.nih.gov/20121113

DM372EG	DI	DM372EG
DM372EG	DN	1-(4-Cyanobenzyl)-5-(4-pyridyl)-1H-imidazole
DM372EG	MI	TTIQUX7
DM372EG	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM372EG	MT	DTT
DM372EG	MA	Inhibitor
DM372EG	RN	Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25.
DM372EG	RU	https://pubmed.ncbi.nlm.nih.gov/20121113

DMBUMDG	DI	DMBUMDG
DMBUMDG	DN	1-(4-Cyanobenzyl)-5-bromo-1H-imidazole
DMBUMDG	MI	TTIQUX7
DMBUMDG	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMBUMDG	MT	DTT
DMBUMDG	MA	Inhibitor
DMBUMDG	RN	Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25.
DMBUMDG	RU	https://pubmed.ncbi.nlm.nih.gov/20121113

DM2THVK	DI	DM2THVK
DM2THVK	DN	1-(4-Cyanobenzyl)-5-formyl-1H-imidazole
DM2THVK	MI	TTIQUX7
DM2THVK	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM2THVK	MT	DTT
DM2THVK	MA	Inhibitor
DM2THVK	RN	Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25.
DM2THVK	RU	https://pubmed.ncbi.nlm.nih.gov/20121113

DMCUE25	DI	DMCUE25
DMCUE25	DN	1-(4-Cyanobenzyl)-5-hydroxymethyl-1H-imidazole
DMCUE25	MI	TTIQUX7
DMCUE25	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMCUE25	MT	DTT
DMCUE25	MA	Inhibitor
DMCUE25	RN	Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25.
DMCUE25	RU	https://pubmed.ncbi.nlm.nih.gov/20121113

DMKC52N	DI	DMKC52N
DMKC52N	DN	1-(4-Cyanobenzyl)-5-methyl-1H-imidazole
DMKC52N	MI	TTSZLWK
DMKC52N	MN	Aromatase (CYP19A1)
DMKC52N	MT	DTT
DMKC52N	MA	Inhibitor
DMKC52N	RN	Fadrozole hydrochloride: a potent, selective, nonsteroidal inhibitor of aromatase for the treatment of estrogen-dependent disease. J Med Chem. 1991 Feb;34(2):725-36.
DMKC52N	RU	https://pubmed.ncbi.nlm.nih.gov/1825337

DMKC52N	DI	DMKC52N
DMKC52N	DN	1-(4-Cyanobenzyl)-5-methyl-1H-imidazole
DMKC52N	MI	TTIQUX7
DMKC52N	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMKC52N	MT	DTT
DMKC52N	MA	Inhibitor
DMKC52N	RN	Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25.
DMKC52N	RU	https://pubmed.ncbi.nlm.nih.gov/20121113

DMQF8DY	DI	DMQF8DY
DMQF8DY	DN	1-(4-Cyanobenzyl)-5-phenyl-1H-imidazole
DMQF8DY	MI	TTIQUX7
DMQF8DY	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMQF8DY	MT	DTT
DMQF8DY	MA	Inhibitor
DMQF8DY	RN	Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25.
DMQF8DY	RU	https://pubmed.ncbi.nlm.nih.gov/20121113

DM9EK3T	DI	DM9EK3T
DM9EK3T	DN	1-(4-Cyano-thiazol-2-yl)-3-phenethyl-thiourea
DM9EK3T	MI	TT84ETX
DM9EK3T	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM9EK3T	MT	DTT
DM9EK3T	MA	Inhibitor
DM9EK3T	RN	Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36.
DM9EK3T	RU	https://pubmed.ncbi.nlm.nih.gov/8523406

DMZR94D	DI	DMZR94D
DMZR94D	DN	1-(4-ethoxyphenyl)propan-2-amine
DMZR94D	MI	TT3WG5C
DMZR94D	MN	Monoamine oxidase type A (MAO-A)
DMZR94D	MT	DTT
DMZR94D	MA	Inhibitor
DMZR94D	RN	Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg Med Chem. 2009 Mar 15;17(6):2452-60.
DMZR94D	RU	https://pubmed.ncbi.nlm.nih.gov/19243954

DMIYLXU	DI	DMIYLXU
DMIYLXU	DN	1-(4-ethyl-2,5-dimethoxyphenyl)propan-2-amine
DMIYLXU	MI	TTJQOD7
DMIYLXU	MN	5-HT 2A receptor (HTR2A)
DMIYLXU	MT	DTT
DMIYLXU	MA	Inhibitor
DMIYLXU	RN	The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands. Bioorg Med Chem. 2008 Apr 15;16(8):4661-9.
DMIYLXU	RU	https://pubmed.ncbi.nlm.nih.gov/18296055

DMXUIS2	DI	DMXUIS2
DMXUIS2	DN	1-(4-ethylphenylsulfonyl)-4-phenylazepan-4-ol
DMXUIS2	MI	TTN7BL9
DMXUIS2	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMXUIS2	MT	DTT
DMXUIS2	MA	Inhibitor
DMXUIS2	RN	The discovery of azepane sulfonamides as potent 11beta-HSD1 inhibitors. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4563-5.
DMXUIS2	RU	https://pubmed.ncbi.nlm.nih.gov/19625185

DMRK0Z1	DI	DMRK0Z1
DMRK0Z1	DN	1-(4-ethylpiperazin-1-yl)-2-phenylethanone
DMRK0Z1	MI	TTN7BL9
DMRK0Z1	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMRK0Z1	MT	DTT
DMRK0Z1	MA	Inhibitor
DMRK0Z1	RN	Discovery and biological evaluation of adamantyl amide 11beta-HSD1 inhibitors. Bioorg Med Chem Lett. 2007 May 15;17(10):2838-43.
DMRK0Z1	RU	https://pubmed.ncbi.nlm.nih.gov/17350260

DMBJCGA	DI	DMBJCGA
DMBJCGA	DN	1-(4-fluorobenzyl)-1H-imidazole
DMBJCGA	MI	TTIQUX7
DMBJCGA	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMBJCGA	MT	DTT
DMBJCGA	MA	Inhibitor
DMBJCGA	RN	Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25.
DMBJCGA	RU	https://pubmed.ncbi.nlm.nih.gov/20121113

DMBJCGA	DI	DMBJCGA
DMBJCGA	DN	1-(4-fluorobenzyl)-1H-imidazole
DMBJCGA	MI	TTRA5BZ
DMBJCGA	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMBJCGA	MT	DTT
DMBJCGA	MA	Inhibitor
DMBJCGA	RN	Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-substituted phenyl alkyl imidazole-based inhibitor... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4752-6.
DMBJCGA	RU	https://pubmed.ncbi.nlm.nih.gov/16870430

DMT2ZSV	DI	DMT2ZSV
DMT2ZSV	DN	1-(4-Fluorobenzyl)-5-phenyl-1H-imidazole
DMT2ZSV	MI	TTIQUX7
DMT2ZSV	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMT2ZSV	MT	DTT
DMT2ZSV	MA	Inhibitor
DMT2ZSV	RN	Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25.
DMT2ZSV	RU	https://pubmed.ncbi.nlm.nih.gov/20121113

DMZLNAP	DI	DMZLNAP
DMZLNAP	DN	1-(4-fluorophenyl)-2-(phenylsulfonyl)ethanone
DMZLNAP	MI	TTN7BL9
DMZLNAP	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMZLNAP	MT	DTT
DMZLNAP	MA	Inhibitor
DMZLNAP	RN	beta-Keto sulfones as inhibitors of 11beta-hydroxysteroid dehydrogenase type I and the mechanism of action. Bioorg Med Chem. 2007 Jul 1;15(13):4396-405.
DMZLNAP	RU	https://pubmed.ncbi.nlm.nih.gov/17490884

DM6ARQF	DI	DM6ARQF
DM6ARQF	DN	1-(4-fluorophenyl)-2-pyrrolidin-1-yl-pentan-1-one
DM6ARQF	MI	TTVBI8W
DM6ARQF	MN	Dopamine transporter (DAT)
DM6ARQF	MT	DTT
DM6ARQF	MA	Inhibitor
DM6ARQF	RN	1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32.
DM6ARQF	RU	https://pubmed.ncbi.nlm.nih.gov/16480278

DM6ARQF	DI	DM6ARQF
DM6ARQF	DN	1-(4-fluorophenyl)-2-pyrrolidin-1-yl-pentan-1-one
DM6ARQF	MI	TTAWNKZ
DM6ARQF	MN	Norepinephrine transporter (NET)
DM6ARQF	MT	DTT
DM6ARQF	MA	Inhibitor
DM6ARQF	RN	1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32.
DM6ARQF	RU	https://pubmed.ncbi.nlm.nih.gov/16480278

DMKATOJ	DI	DMKATOJ
DMKATOJ	DN	1-(4-fluorophenyl)-3-(phenylsulfonyl)propan-1-one
DMKATOJ	MI	TTN7BL9
DMKATOJ	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMKATOJ	MT	DTT
DMKATOJ	MA	Inhibitor
DMKATOJ	RN	beta-Keto sulfones as inhibitors of 11beta-hydroxysteroid dehydrogenase type I and the mechanism of action. Bioorg Med Chem. 2007 Jul 1;15(13):4396-405.
DMKATOJ	RU	https://pubmed.ncbi.nlm.nih.gov/17490884

DMIQ0VA	DI	DMIQ0VA
DMIQ0VA	DN	1-(4-heptylphenyl)prop-2-en-1-one
DMIQ0VA	MI	TTGER3L
DMIQ0VA	MN	Thyroid hormone receptor beta (THRB)
DMIQ0VA	MT	DTT
DMIQ0VA	MA	Inhibitor
DMIQ0VA	RN	Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80.
DMIQ0VA	RU	https://pubmed.ncbi.nlm.nih.gov/17918822

DM5QLGH	DI	DM5QLGH
DM5QLGH	DN	1-(4-hexylphenyl)-3-(propylamino)propan-1-one
DM5QLGH	MI	TTGER3L
DM5QLGH	MN	Thyroid hormone receptor beta (THRB)
DM5QLGH	MT	DTT
DM5QLGH	MA	Inhibitor
DM5QLGH	RN	Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80.
DM5QLGH	RU	https://pubmed.ncbi.nlm.nih.gov/17918822

DMFN8T6	DI	DMFN8T6
DMFN8T6	DN	1-(4-hexylphenyl)-3-morpholinopropan-1-one
DMFN8T6	MI	TTTSEPU
DMFN8T6	MN	Thyroid hormone receptor alpha (THRA)
DMFN8T6	MT	DTT
DMFN8T6	MA	Inhibitor
DMFN8T6	RN	Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80.
DMFN8T6	RU	https://pubmed.ncbi.nlm.nih.gov/17918822

DMFN8T6	DI	DMFN8T6
DMFN8T6	DN	1-(4-hexylphenyl)-3-morpholinopropan-1-one
DMFN8T6	MI	TTGER3L
DMFN8T6	MN	Thyroid hormone receptor beta (THRB)
DMFN8T6	MT	DTT
DMFN8T6	MA	Inhibitor
DMFN8T6	RN	Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80.
DMFN8T6	RU	https://pubmed.ncbi.nlm.nih.gov/17918822

DMX7PJH	DI	DMX7PJH
DMX7PJH	DN	1-(4-HEXYLPHENYL)PROP-2-EN-1-ONE
DMX7PJH	MI	TTGER3L
DMX7PJH	MN	Thyroid hormone receptor beta (THRB)
DMX7PJH	MT	DTT
DMX7PJH	MA	Inhibitor
DMX7PJH	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMX7PJH	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM145QS	DI	DM145QS
DM145QS	DN	1-(4-hydroxyphenyl)prop-2-en-1-one
DM145QS	MI	TTT2LD9
DM145QS	MN	GABA transaminase (ABAT)
DM145QS	MT	DTT
DM145QS	MA	Inhibitor
DM145QS	RN	Inhibition of GABA shunt enzymes' activity by 4-hydroxybenzaldehyde derivatives. Bioorg Med Chem Lett. 2006 Feb;16(3):592-5.
DM145QS	RU	https://pubmed.ncbi.nlm.nih.gov/16290145

DM145QS	DI	DM145QS
DM145QS	DN	1-(4-hydroxyphenyl)prop-2-en-1-one
DM145QS	MI	TTJUWVB
DM145QS	MN	Succinate-semialdehyde dehydrogenase (ALDH5A1)
DM145QS	MT	DTT
DM145QS	MA	Inhibitor
DM145QS	RN	Inhibition of GABA shunt enzymes' activity by 4-hydroxybenzaldehyde derivatives. Bioorg Med Chem Lett. 2006 Feb;16(3):592-5.
DM145QS	RU	https://pubmed.ncbi.nlm.nih.gov/16290145

DMM17I0	DI	DMM17I0
DMM17I0	DN	1-(4-iodobenzyl)-1H-imidazole
DMM17I0	MI	TTRA5BZ
DMM17I0	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMM17I0	MT	DTT
DMM17I0	MA	Inhibitor
DMM17I0	RN	Synthesis and biochemical evaluation of a range of (4-substituted phenyl)sulfonate derivatives of 4-hydroxybenzyl imidazole-based compounds as pote... Bioorg Med Chem Lett. 2010 Sep 1;20(17):5345-8.
DMM17I0	RU	https://pubmed.ncbi.nlm.nih.gov/20675132

DMDY93H	DI	DMDY93H
DMDY93H	DN	1-(4-iodooxazol-2-yl)-7-phenylheptan-1-one
DMDY93H	MI	TTDP1UC
DMDY93H	MN	Fatty acid amide hydrolase (FAAH)
DMDY93H	MT	DTT
DMDY93H	MA	Inhibitor
DMDY93H	RN	Exploration of a fundamental substituent effect of alpha-ketoheterocycle enzyme inhibitors: Potent and selective inhibitors of fatty acid amide hyd... Bioorg Med Chem Lett. 2008 Nov 15;18(22):5842-6.
DMDY93H	RU	https://pubmed.ncbi.nlm.nih.gov/18639454

DMBV8PT	DI	DMBV8PT
DMBV8PT	DN	1-(4-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one
DMBV8PT	MI	TTVBI8W
DMBV8PT	MN	Dopamine transporter (DAT)
DMBV8PT	MT	DTT
DMBV8PT	MA	Inhibitor
DMBV8PT	RN	1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32.
DMBV8PT	RU	https://pubmed.ncbi.nlm.nih.gov/16480278

DMBV8PT	DI	DMBV8PT
DMBV8PT	DN	1-(4-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one
DMBV8PT	MI	TTAWNKZ
DMBV8PT	MN	Norepinephrine transporter (NET)
DMBV8PT	MT	DTT
DMBV8PT	MA	Inhibitor
DMBV8PT	RN	1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32.
DMBV8PT	RU	https://pubmed.ncbi.nlm.nih.gov/16480278

DMBV8PT	DI	DMBV8PT
DMBV8PT	DN	1-(4-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one
DMBV8PT	MI	TT3ROYC
DMBV8PT	MN	Serotonin transporter (SERT)
DMBV8PT	MT	DTT
DMBV8PT	MA	Inhibitor
DMBV8PT	RN	1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32.
DMBV8PT	RU	https://pubmed.ncbi.nlm.nih.gov/16480278

DMZWRU7	DI	DMZWRU7
DMZWRU7	DN	1-(4-Methoxy-benzenesulfonyl)-heptane-3-thiol
DMZWRU7	MI	TTHY57M
DMZWRU7	MN	Matrix metalloproteinase-13 (MMP-13)
DMZWRU7	MT	DTT
DMZWRU7	MA	Inhibitor
DMZWRU7	RN	Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols. Bioorg Med Chem Lett. 1999 Apr 5;9(7):943-8.
DMZWRU7	RU	https://pubmed.ncbi.nlm.nih.gov/10230616

DMSWJKZ	DI	DMSWJKZ
DMSWJKZ	DN	1-(4-Methoxybenzyl)-5-phenyl-1H-imidazole
DMSWJKZ	MI	TTIQUX7
DMSWJKZ	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMSWJKZ	MT	DTT
DMSWJKZ	MA	Inhibitor
DMSWJKZ	RN	Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25.
DMSWJKZ	RU	https://pubmed.ncbi.nlm.nih.gov/20121113

DMEPJRD	DI	DMEPJRD
DMEPJRD	DN	1-(4-methoxyoxazol-2-yl)-7-phenylheptan-1-one
DMEPJRD	MI	TTDP1UC
DMEPJRD	MN	Fatty acid amide hydrolase (FAAH)
DMEPJRD	MT	DTT
DMEPJRD	MA	Inhibitor
DMEPJRD	RN	Exploration of a fundamental substituent effect of alpha-ketoheterocycle enzyme inhibitors: Potent and selective inhibitors of fatty acid amide hyd... Bioorg Med Chem Lett. 2008 Nov 15;18(22):5842-6.
DMEPJRD	RU	https://pubmed.ncbi.nlm.nih.gov/18639454

DMAW78K	DI	DMAW78K
DMAW78K	DN	1-(4-methoxyphenethyl)pyrrolidine
DMAW78K	MI	TT9JNIC
DMAW78K	MN	Histamine H3 receptor (H3R)
DMAW78K	MT	DTT
DMAW78K	MA	Inhibitor
DMAW78K	RN	In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9.
DMAW78K	RU	https://pubmed.ncbi.nlm.nih.gov/18077160

DMRC7V8	DI	DMRC7V8
DMRC7V8	DN	1-(4-methoxyphenyl)-2-(phenylsulfonyl)ethanone
DMRC7V8	MI	TTN7BL9
DMRC7V8	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMRC7V8	MT	DTT
DMRC7V8	MA	Inhibitor
DMRC7V8	RN	beta-Keto sulfones as inhibitors of 11beta-hydroxysteroid dehydrogenase type I and the mechanism of action. Bioorg Med Chem. 2007 Jul 1;15(13):4396-405.
DMRC7V8	RU	https://pubmed.ncbi.nlm.nih.gov/17490884

DM5R8KU	DI	DM5R8KU
DM5R8KU	DN	1-(4-Methoxy-phenyl)-2-phenyl-ethane-1,2-dione
DM5R8KU	MI	TTMF541
DM5R8KU	MN	Liver carboxylesterase (CES1)
DM5R8KU	MT	DTT
DM5R8KU	MA	Inhibitor
DM5R8KU	RN	Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15.
DM5R8KU	RU	https://pubmed.ncbi.nlm.nih.gov/15828829

DMNJ2CS	DI	DMNJ2CS
DMNJ2CS	DN	1-(4-methoxyphenyl)-3-(1,3,4-thiadiazol-2-yl)urea
DMNJ2CS	MI	TTSJ6Q4
DMNJ2CS	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DMNJ2CS	MT	DTT
DMNJ2CS	MA	Inhibitor
DMNJ2CS	RN	Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. J Med Chem. 2007 May 31;50(11):2640-6.
DMNJ2CS	RU	https://pubmed.ncbi.nlm.nih.gov/17461565

DMYPC0W	DI	DMYPC0W
DMYPC0W	DN	1-(4-methoxyphenyl)-3-(4-methylthiazol-2-yl)urea
DMYPC0W	MI	TTSJ6Q4
DMYPC0W	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DMYPC0W	MT	DTT
DMYPC0W	MA	Inhibitor
DMYPC0W	RN	Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. J Med Chem. 2007 May 31;50(11):2640-6.
DMYPC0W	RU	https://pubmed.ncbi.nlm.nih.gov/17461565

DMVWIE5	DI	DMVWIE5
DMVWIE5	DN	1-(4-methoxyphenyl)-3-(5-methylthiazol-2-yl)urea
DMVWIE5	MI	TTSJ6Q4
DMVWIE5	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DMVWIE5	MT	DTT
DMVWIE5	MA	Inhibitor
DMVWIE5	RN	Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. J Med Chem. 2007 May 31;50(11):2640-6.
DMVWIE5	RU	https://pubmed.ncbi.nlm.nih.gov/17461565

DMG7PKA	DI	DMG7PKA
DMG7PKA	DN	1-(4-methoxyphenylsulfonyl)-4-phenylazepan-4-ol
DMG7PKA	MI	TTN7BL9
DMG7PKA	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMG7PKA	MT	DTT
DMG7PKA	MA	Inhibitor
DMG7PKA	RN	The discovery of azepane sulfonamides as potent 11beta-HSD1 inhibitors. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4563-5.
DMG7PKA	RU	https://pubmed.ncbi.nlm.nih.gov/19625185

DMNDJTL	DI	DMNDJTL
DMNDJTL	DN	1'-(4-Methyl-benzyl)-[1,4']bipiperidinyl
DMNDJTL	MI	TTULVH8
DMNDJTL	MN	Tyrosinase (TYR)
DMNDJTL	MT	DTT
DMNDJTL	MA	Inhibitor
DMNDJTL	RN	Dragon method for finding novel tyrosinase inhibitors: Biosilico identification and experimental in vitro assays. Eur J Med Chem. 2007 Nov-Dec;42(11-12):1370-81.
DMNDJTL	RU	https://pubmed.ncbi.nlm.nih.gov/17637486

DM48ISZ	DI	DM48ISZ
DM48ISZ	DN	1-(4-methyl-benzyl)-1H-imidazole
DM48ISZ	MI	TTRA5BZ
DM48ISZ	MN	Steroid 17-alpha-monooxygenase (S17AH)
DM48ISZ	MT	DTT
DM48ISZ	MA	Inhibitor
DM48ISZ	RN	Synthesis and biochemical evaluation of a range of potent benzyl imidazole-based compounds as potential inhibitors of the enzyme complex 17alpha-hy... Bioorg Med Chem Lett. 2006 Aug 1;16(15):4011-5.
DM48ISZ	RU	https://pubmed.ncbi.nlm.nih.gov/16750362

DMVI2PM	DI	DMVI2PM
DMVI2PM	DN	1-(4-methyloxazol-2-yl)-7-phenylheptan-1-one
DMVI2PM	MI	TTDP1UC
DMVI2PM	MN	Fatty acid amide hydrolase (FAAH)
DMVI2PM	MT	DTT
DMVI2PM	MA	Inhibitor
DMVI2PM	RN	Exploration of a fundamental substituent effect of alpha-ketoheterocycle enzyme inhibitors: Potent and selective inhibitors of fatty acid amide hyd... Bioorg Med Chem Lett. 2008 Nov 15;18(22):5842-6.
DMVI2PM	RU	https://pubmed.ncbi.nlm.nih.gov/18639454

DM3NVLB	DI	DM3NVLB
DM3NVLB	DN	1-(4-Methylpent-3-en-2-ylidene)thiosemicarbazide
DM3NVLB	MI	TTULVH8
DM3NVLB	MN	Tyrosinase (TYR)
DM3NVLB	MT	DTT
DM3NVLB	MA	Inhibitor
DM3NVLB	RN	A class of potent tyrosinase inhibitors: alkylidenethiosemicarbazide compounds. Eur J Med Chem. 2009 Apr;44(4):1773-8.
DM3NVLB	RU	https://pubmed.ncbi.nlm.nih.gov/18524420

DMSRBUE	DI	DMSRBUE
DMSRBUE	DN	1-(4-nitro-2-phenoxybenzyl)-1H-imidazole
DMSRBUE	MI	TTSZLWK
DMSRBUE	MN	Aromatase (CYP19A1)
DMSRBUE	MT	DTT
DMSRBUE	MA	Inhibitor
DMSRBUE	RN	Novel highly potent and selective nonsteroidal aromatase inhibitors: synthesis, biological evaluation and structure-activity relationships investigation. J Med Chem. 2010 Jul 22;53(14):5347-51. 
DMSRBUE	RU	https://pubmed.ncbi.nlm.nih.gov/20568782

DMCP089	DI	DMCP089
DMCP089	DN	1-(4-Nitro-2-phenylsulfanylbenzyl)-1H-imidazole
DMCP089	MI	TTSZLWK
DMCP089	MN	Aromatase (CYP19A1)
DMCP089	MT	DTT
DMCP089	MA	Inhibitor
DMCP089	RN	Novel highly potent and selective nonsteroidal aromatase inhibitors: synthesis, biological evaluation and structure-activity relationships investigation. J Med Chem. 2010 Jul 22;53(14):5347-51. 
DMCP089	RU	https://pubmed.ncbi.nlm.nih.gov/20568782

DMKT2MB	DI	DMKT2MB
DMKT2MB	DN	1-(4-nitrobenzyl)-1H-imidazole
DMKT2MB	MI	TTRA5BZ
DMKT2MB	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMKT2MB	MT	DTT
DMKT2MB	MA	Inhibitor
DMKT2MB	RN	Synthesis and biochemical evaluation of a range of potent benzyl imidazole-based compounds as potential inhibitors of the enzyme complex 17alpha-hy... Bioorg Med Chem Lett. 2006 Aug 1;16(15):4011-5.
DMKT2MB	RU	https://pubmed.ncbi.nlm.nih.gov/16750362

DMKR8BI	DI	DMKR8BI
DMKR8BI	DN	1-(4-nitrophenethyl)pyrrolidine
DMKR8BI	MI	TT9JNIC
DMKR8BI	MN	Histamine H3 receptor (H3R)
DMKR8BI	MT	DTT
DMKR8BI	MA	Inhibitor
DMKR8BI	RN	In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9.
DMKR8BI	RU	https://pubmed.ncbi.nlm.nih.gov/18077160

DM1M67Q	DI	DM1M67Q
DM1M67Q	DN	1-(4-nitrophenyl)-2-(phenylsulfonyl)ethanone
DM1M67Q	MI	TTN7BL9
DM1M67Q	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DM1M67Q	MT	DTT
DM1M67Q	MA	Inhibitor
DM1M67Q	RN	beta-Keto sulfones as inhibitors of 11beta-hydroxysteroid dehydrogenase type I and the mechanism of action. Bioorg Med Chem. 2007 Jul 1;15(13):4396-405.
DM1M67Q	RU	https://pubmed.ncbi.nlm.nih.gov/17490884

DMOC67J	DI	DMOC67J
DMOC67J	DN	1-(4-Nitro-phenyl)-2-phenyl-ethane-1,2-dione
DMOC67J	MI	TTMF541
DMOC67J	MN	Liver carboxylesterase (CES1)
DMOC67J	MT	DTT
DMOC67J	MA	Inhibitor
DMOC67J	RN	Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15.
DMOC67J	RU	https://pubmed.ncbi.nlm.nih.gov/15828829

DME435S	DI	DME435S
DME435S	DN	1-(4-nitrophenyl)-2-pyrrolidin-1-yl-pentan-1-one
DME435S	MI	TTVBI8W
DME435S	MN	Dopamine transporter (DAT)
DME435S	MT	DTT
DME435S	MA	Inhibitor
DME435S	RN	1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32.
DME435S	RU	https://pubmed.ncbi.nlm.nih.gov/16480278

DME435S	DI	DME435S
DME435S	DN	1-(4-nitrophenyl)-2-pyrrolidin-1-yl-pentan-1-one
DME435S	MI	TTAWNKZ
DME435S	MN	Norepinephrine transporter (NET)
DME435S	MT	DTT
DME435S	MA	Inhibitor
DME435S	RN	1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32.
DME435S	RU	https://pubmed.ncbi.nlm.nih.gov/16480278

DME435S	DI	DME435S
DME435S	DN	1-(4-nitrophenyl)-2-pyrrolidin-1-yl-pentan-1-one
DME435S	MI	TT3ROYC
DME435S	MN	Serotonin transporter (SERT)
DME435S	MT	DTT
DME435S	MA	Inhibitor
DME435S	RN	1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32.
DME435S	RU	https://pubmed.ncbi.nlm.nih.gov/16480278

DMQKMCG	DI	DMQKMCG
DMQKMCG	DN	1-(4-nonylbenzyl)azetidine-3-carboxylic acid
DMQKMCG	MI	TT9JZCK
DMQKMCG	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMQKMCG	MT	DTT
DMQKMCG	MA	Inhibitor
DMQKMCG	RN	A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 re... J Med Chem. 2004 Dec 30;47(27):6662-5.
DMQKMCG	RU	https://pubmed.ncbi.nlm.nih.gov/15615513

DM8U2HP	DI	DM8U2HP
DM8U2HP	DN	1-(4-nonylbenzyl)pyrrolidin-3-ylphosphonic acid
DM8U2HP	MI	TT9JZCK
DM8U2HP	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DM8U2HP	MT	DTT
DM8U2HP	MA	Inhibitor
DM8U2HP	RN	A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 re... J Med Chem. 2004 Dec 30;47(27):6662-5.
DM8U2HP	RU	https://pubmed.ncbi.nlm.nih.gov/15615513

DMAR39L	DI	DMAR39L
DMAR39L	DN	1-(4-nonylbenzyl)pyrrolidine-3-carboxylic acid
DMAR39L	MI	TT9JZCK
DMAR39L	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMAR39L	MT	DTT
DMAR39L	MA	Inhibitor
DMAR39L	RN	A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 re... J Med Chem. 2004 Dec 30;47(27):6662-5.
DMAR39L	RU	https://pubmed.ncbi.nlm.nih.gov/15615513

DM9KVBJ	DI	DM9KVBJ
DM9KVBJ	DN	1-(4-octylphenyl)prop-2-en-1-one
DM9KVBJ	MI	TTGER3L
DM9KVBJ	MN	Thyroid hormone receptor beta (THRB)
DM9KVBJ	MT	DTT
DM9KVBJ	MA	Inhibitor
DM9KVBJ	RN	Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80.
DM9KVBJ	RU	https://pubmed.ncbi.nlm.nih.gov/17918822

DMVCM0I	DI	DMVCM0I
DMVCM0I	DN	1-(4-Phenoxyphenyl)piperazine
DMVCM0I	MI	TTXZEAJ
DMVCM0I	MN	Leukotriene A-4 hydrolase (LTA4H)
DMVCM0I	MT	DTT
DMVCM0I	MA	Inhibitor
DMVCM0I	RN	Discovery of 4-[(2S)-2-{[4-(4-chlorophenoxy)phenoxy]methyl}-1-pyrrolidinyl]butanoic acid (DG-051) as a novel leukotriene A4 hydrolase inhibitor of ... J Med Chem. 2010 Jan 28;53(2):573-85.
DMVCM0I	RU	https://pubmed.ncbi.nlm.nih.gov/19950900

DMKNA5U	DI	DMKNA5U
DMKNA5U	DN	1-(4-propoxyphenyl)propan-2-amine
DMKNA5U	MI	TT3WG5C
DMKNA5U	MN	Monoamine oxidase type A (MAO-A)
DMKNA5U	MT	DTT
DMKNA5U	MA	Inhibitor
DMKNA5U	RN	Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg Med Chem. 2009 Mar 15;17(6):2452-60.
DMKNA5U	RU	https://pubmed.ncbi.nlm.nih.gov/19243954

DMFYK6T	DI	DMFYK6T
DMFYK6T	DN	1-(4-p-Tolyl-butyl)-piperidine
DMFYK6T	MI	TTTIBOJ
DMFYK6T	MN	Histamine H1 receptor (H1R)
DMFYK6T	MT	DTT
DMFYK6T	MA	Inhibitor
DMFYK6T	RN	Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs. Bioorg Med Chem Lett. 2009 Sep 1;19(17):5043-7.
DMFYK6T	RU	https://pubmed.ncbi.nlm.nih.gov/19660947

DMFYK6T	DI	DMFYK6T
DMFYK6T	DN	1-(4-p-Tolyl-butyl)-piperidine
DMFYK6T	MI	TTQ6VDM
DMFYK6T	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMFYK6T	MT	DTT
DMFYK6T	MA	Inhibitor
DMFYK6T	RN	Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs. Bioorg Med Chem Lett. 2009 Sep 1;19(17):5043-7.
DMFYK6T	RU	https://pubmed.ncbi.nlm.nih.gov/19660947

DMM7IJZ	DI	DMM7IJZ
DMM7IJZ	DN	1-(4-tert-butylphenylsulfonyl)-4-methoxyazepane
DMM7IJZ	MI	TTN7BL9
DMM7IJZ	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMM7IJZ	MT	DTT
DMM7IJZ	MA	Inhibitor
DMM7IJZ	RN	The discovery of azepane sulfonamides as potent 11beta-HSD1 inhibitors. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4563-5.
DMM7IJZ	RU	https://pubmed.ncbi.nlm.nih.gov/19625185

DMQECWT	DI	DMQECWT
DMQECWT	DN	1-(4-tert-butylphenylsulfonyl)azepan-4-ol
DMQECWT	MI	TTN7BL9
DMQECWT	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMQECWT	MT	DTT
DMQECWT	MA	Inhibitor
DMQECWT	RN	The discovery of azepane sulfonamides as potent 11beta-HSD1 inhibitors. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4563-5.
DMQECWT	RU	https://pubmed.ncbi.nlm.nih.gov/19625185

DMPL3UZ	DI	DMPL3UZ
DMPL3UZ	DN	1-(5-(furan-2-yl)oxazol-2-yl)octadec-9-en-1-one
DMPL3UZ	MI	TTDP1UC
DMPL3UZ	MN	Fatty acid amide hydrolase (FAAH)
DMPL3UZ	MT	DTT
DMPL3UZ	MA	Inhibitor
DMPL3UZ	RN	Optimization of the central heterocycle of alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Aug 14;51(15):4392-403.
DMPL3UZ	RU	https://pubmed.ncbi.nlm.nih.gov/18630870

DM4V9IB	DI	DM4V9IB
DM4V9IB	DN	1-(5-(pyridin-2-yl)oxazol-2-yl)dodecan-1-one
DM4V9IB	MI	TTDP1UC
DM4V9IB	MN	Fatty acid amide hydrolase (FAAH)
DM4V9IB	MT	DTT
DM4V9IB	MA	Inhibitor
DM4V9IB	RN	Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. Bioorg Med Chem. 2008 Feb 15;16(4):1562-95.
DM4V9IB	RU	https://pubmed.ncbi.nlm.nih.gov/18053726

DMICZK0	DI	DMICZK0
DMICZK0	DN	1-(5-(pyridin-2-yl)oxazol-2-yl)octadec-9-en-1-one
DMICZK0	MI	TTDP1UC
DMICZK0	MN	Fatty acid amide hydrolase (FAAH)
DMICZK0	MT	DTT
DMICZK0	MA	Inhibitor
DMICZK0	RN	Optimization of the central heterocycle of alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Aug 14;51(15):4392-403.
DMICZK0	RU	https://pubmed.ncbi.nlm.nih.gov/18630870

DMZNEIB	DI	DMZNEIB
DMZNEIB	DN	1-(5-(pyridin-2-yl)oxazol-2-yl)octan-1-one
DMZNEIB	MI	TTDP1UC
DMZNEIB	MN	Fatty acid amide hydrolase (FAAH)
DMZNEIB	MT	DTT
DMZNEIB	MA	Inhibitor
DMZNEIB	RN	Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. Bioorg Med Chem. 2008 Feb 15;16(4):1562-95.
DMZNEIB	RU	https://pubmed.ncbi.nlm.nih.gov/18053726

DM6FDAY	DI	DM6FDAY
DM6FDAY	DN	1-(5-(pyridin-2-yl)oxazol-2-yl)pentan-1-one
DM6FDAY	MI	TTDP1UC
DM6FDAY	MN	Fatty acid amide hydrolase (FAAH)
DM6FDAY	MT	DTT
DM6FDAY	MA	Inhibitor
DM6FDAY	RN	Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. Bioorg Med Chem. 2008 Feb 15;16(4):1562-95.
DM6FDAY	RU	https://pubmed.ncbi.nlm.nih.gov/18053726

DMDTYAF	DI	DMDTYAF
DMDTYAF	DN	1-(5-chloro-2-hydroxy-4-nitrophenyl)-3-phenylurea
DMDTYAF	MI	TT30C9G
DMDTYAF	MN	C-X-C chemokine receptor type 2 (CXCR2)
DMDTYAF	MT	DTT
DMDTYAF	MA	Inhibitor
DMDTYAF	RN	Comparison of N,N'-diarylsquaramides and N,N'-diarylureas as antagonists of the CXCR2 chemokine receptor. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1713-7.
DMDTYAF	RU	https://pubmed.ncbi.nlm.nih.gov/17236763

DMD8IYZ	DI	DMD8IYZ
DMD8IYZ	DN	1-(5-fluorooxazol-2-yl)-7-phenylheptan-1-one
DMD8IYZ	MI	TTDP1UC
DMD8IYZ	MN	Fatty acid amide hydrolase (FAAH)
DMD8IYZ	MT	DTT
DMD8IYZ	MA	Inhibitor
DMD8IYZ	RN	Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. Bioorg Med Chem. 2008 Feb 15;16(4):1562-95.
DMD8IYZ	RU	https://pubmed.ncbi.nlm.nih.gov/18053726

DMWQ9ZP	DI	DMWQ9ZP
DMWQ9ZP	DN	1-(5-methyloxazol-2-yl)-7-phenylheptan-1-one
DMWQ9ZP	MI	TTDP1UC
DMWQ9ZP	MN	Fatty acid amide hydrolase (FAAH)
DMWQ9ZP	MT	DTT
DMWQ9ZP	MA	Inhibitor
DMWQ9ZP	RN	Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. Bioorg Med Chem. 2008 Feb 15;16(4):1562-95.
DMWQ9ZP	RU	https://pubmed.ncbi.nlm.nih.gov/18053726

DMRITHA	DI	DMRITHA
DMRITHA	DN	1-(5-phenyloxazol-2-yl)octadec-9-en-1-one
DMRITHA	MI	TTDP1UC
DMRITHA	MN	Fatty acid amide hydrolase (FAAH)
DMRITHA	MT	DTT
DMRITHA	MA	Inhibitor
DMRITHA	RN	Optimization of the central heterocycle of alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Aug 14;51(15):4392-403.
DMRITHA	RU	https://pubmed.ncbi.nlm.nih.gov/18630870

DM4IMON	DI	DM4IMON
DM4IMON	DN	1-(5-Pyridin-2-yl-oxazol-2-yl)-octadec-9-yn-1-one
DM4IMON	MI	TTDP1UC
DM4IMON	MN	Fatty acid amide hydrolase (FAAH)
DM4IMON	MT	DTT
DM4IMON	MA	Inhibitor
DM4IMON	RN	Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as a... J Med Chem. 2005 Mar 24;48(6):1849-56.
DM4IMON	RU	https://pubmed.ncbi.nlm.nih.gov/15771430

DMUS9Z3	DI	DMUS9Z3
DMUS9Z3	DN	1-(6-Amino-4-methylpyridin-2-yl)propan-2-ol
DMUS9Z3	MI	TTF10I9
DMUS9Z3	MN	Nitric-oxide synthase inducible (NOS2)
DMUS9Z3	MT	DTT
DMUS9Z3	MA	Inhibitor
DMUS9Z3	RN	Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [18F]6-(2-fl... J Med Chem. 2009 Apr 23;52(8):2443-53.
DMUS9Z3	RU	https://pubmed.ncbi.nlm.nih.gov/19323559

DMEHK4F	DI	DMEHK4F
DMEHK4F	DN	1-(6-Methoxy-naphthalen-2-yl)-1H-imidazole
DMEHK4F	MI	TTIQUX7
DMEHK4F	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMEHK4F	MT	DTT
DMEHK4F	MA	Inhibitor
DMEHK4F	RN	Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42.
DMEHK4F	RU	https://pubmed.ncbi.nlm.nih.gov/16220979

DM7OGLI	DI	DM7OGLI
DM7OGLI	DN	1-(7-Hydroxy-naphthalen-1-yl)-3-pyridin-2-yl-urea
DM7OGLI	MI	TT0PG8F
DM7OGLI	MN	Cyclin-dependent kinase 4 (CDK4)
DM7OGLI	MT	DTT
DM7OGLI	MA	Inhibitor
DM7OGLI	RN	Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. J Med Chem. 2001 Dec 20;44(26):4615-27.
DM7OGLI	RU	https://pubmed.ncbi.nlm.nih.gov/11741479

DMLHDE3	DI	DMLHDE3
DMLHDE3	DN	1-(7-Methoxy-2-phenyl-chroman-4-yl)-1H-imidazole
DMLHDE3	MI	TTSZLWK
DMLHDE3	MN	Aromatase (CYP19A1)
DMLHDE3	MT	DTT
DMLHDE3	MA	Inhibitor
DMLHDE3	RN	Synthesis and evaluation of 4-triazolylflavans as new aromatase inhibitors. Bioorg Med Chem Lett. 2004 Oct 18;14(20):5215-8.
DMLHDE3	RU	https://pubmed.ncbi.nlm.nih.gov/15380230

DM1MJCE	DI	DM1MJCE
DM1MJCE	DN	1-(7-Methoxy-naphthalen-2-yl)-piperazine
DM1MJCE	MI	TTSQIFT
DM1MJCE	MN	5-HT 1A receptor (HTR1A)
DM1MJCE	MT	DTT
DM1MJCE	MA	Inhibitor
DM1MJCE	RN	5-HT1B receptor antagonist properties of novel arylpiperazide derivatives of 1-naphthylpiperazine. J Med Chem. 1997 Nov 21;40(24):3974-8.
DM1MJCE	RU	https://pubmed.ncbi.nlm.nih.gov/9397179

DM1MJCE	DI	DM1MJCE
DM1MJCE	DN	1-(7-Methoxy-naphthalen-2-yl)-piperazine
DM1MJCE	MI	TTK8CXU
DM1MJCE	MN	5-HT 1B receptor (HTR1B)
DM1MJCE	MT	DTT
DM1MJCE	MA	Inhibitor
DM1MJCE	RN	5-HT1B receptor antagonist properties of novel arylpiperazide derivatives of 1-naphthylpiperazine. J Med Chem. 1997 Nov 21;40(24):3974-8.
DM1MJCE	RU	https://pubmed.ncbi.nlm.nih.gov/9397179

DM1MJCE	DI	DM1MJCE
DM1MJCE	DN	1-(7-Methoxy-naphthalen-2-yl)-piperazine
DM1MJCE	MI	TT6MSOK
DM1MJCE	MN	5-HT 1D receptor (HTR1D)
DM1MJCE	MT	DTT
DM1MJCE	MA	Inhibitor
DM1MJCE	RN	5-HT1B receptor antagonist properties of novel arylpiperazide derivatives of 1-naphthylpiperazine. J Med Chem. 1997 Nov 21;40(24):3974-8.
DM1MJCE	RU	https://pubmed.ncbi.nlm.nih.gov/9397179

DMKHJBI	DI	DMKHJBI
DMKHJBI	DN	1-(7-methyl-9H-carbazol-3-yl)ethanone
DMKHJBI	MI	TTBGTCW
DMKHJBI	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DMKHJBI	MT	DTT
DMKHJBI	MA	Inhibitor
DMKHJBI	RN	Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8.
DMKHJBI	RU	https://pubmed.ncbi.nlm.nih.gov/20521839

DMC3PYM	DI	DMC3PYM
DMC3PYM	DN	1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine
DMC3PYM	MI	TT7SBF5
DMC3PYM	MN	Cellular tumor antigen p53 (TP53)
DMC3PYM	MT	DTT
DMC3PYM	MA	Inhibitor
DMC3PYM	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMC3PYM	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMA96U5	DI	DMA96U5
DMA96U5	DN	1-(9H-beta-Carbolin-3-yl)-butan-1-one
DMA96U5	MI	TT1MPAY
DMA96U5	MN	GABA(A) receptor alpha-1 (GABRA1)
DMA96U5	MT	DTT
DMA96U5	MA	Inhibitor
DMA96U5	RN	Predictive binding of beta-carboline inverse agonists and antagonists via the CoMFA/GOLPE approach. J Med Chem. 1992 Oct 30;35(22):4001-10.
DMA96U5	RU	https://pubmed.ncbi.nlm.nih.gov/1331452

DMA96U5	DI	DMA96U5
DMA96U5	DN	1-(9H-beta-Carbolin-3-yl)-butan-1-one
DMA96U5	MI	TTNJYV2
DMA96U5	MN	Gamma-aminobutyric acid receptor (GAR)
DMA96U5	MT	DTT
DMA96U5	MA	Inhibitor
DMA96U5	RN	Predictive binding of beta-carboline inverse agonists and antagonists via the CoMFA/GOLPE approach. J Med Chem. 1992 Oct 30;35(22):4001-10.
DMA96U5	RU	https://pubmed.ncbi.nlm.nih.gov/1331452

DMFOD2L	DI	DMFOD2L
DMFOD2L	DN	1-(9H-beta-Carbolin-3-yl)-ethanone
DMFOD2L	MI	TT1MPAY
DMFOD2L	MN	GABA(A) receptor alpha-1 (GABRA1)
DMFOD2L	MT	DTT
DMFOD2L	MA	Inhibitor
DMFOD2L	RN	Synthesis of 6-substituted beta-carbolines that behave as benzodiazepine receptor antagonists or inverse agonists. J Med Chem. 1987 Apr;30(4):750-3.
DMFOD2L	RU	https://pubmed.ncbi.nlm.nih.gov/3031296

DMFOD2L	DI	DMFOD2L
DMFOD2L	DN	1-(9H-beta-Carbolin-3-yl)-ethanone
DMFOD2L	MI	TTNJYV2
DMFOD2L	MN	Gamma-aminobutyric acid receptor (GAR)
DMFOD2L	MT	DTT
DMFOD2L	MA	Inhibitor
DMFOD2L	RN	Synthesis of 6-substituted beta-carbolines that behave as benzodiazepine receptor antagonists or inverse agonists. J Med Chem. 1987 Apr;30(4):750-3.
DMFOD2L	RU	https://pubmed.ncbi.nlm.nih.gov/3031296

DMH49OD	DI	DMH49OD
DMH49OD	DN	1-(9H-fluoren-9-yl)-1H-imidazole
DMH49OD	MI	TTSZLWK
DMH49OD	MN	Aromatase (CYP19A1)
DMH49OD	MT	DTT
DMH49OD	MA	Inhibitor
DMH49OD	RN	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
DMH49OD	RU	https://pubmed.ncbi.nlm.nih.gov/19072235

DM30FNL	DI	DM30FNL
DM30FNL	DN	1-(9-Oxo-9H-fluoren-4-yl)-3-pyridin-2-yl-urea
DM30FNL	MI	TT0PG8F
DM30FNL	MN	Cyclin-dependent kinase 4 (CDK4)
DM30FNL	MT	DTT
DM30FNL	MA	Inhibitor
DM30FNL	RN	Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. J Med Chem. 2001 Dec 20;44(26):4615-27.
DM30FNL	RU	https://pubmed.ncbi.nlm.nih.gov/11741479

DMVJZ0C	DI	DMVJZ0C
DMVJZ0C	DN	1-(9-phenyl-9H-fluoren-9-yl)-1H-1,2,4-triazole
DMVJZ0C	MI	TTSZLWK
DMVJZ0C	MN	Aromatase (CYP19A1)
DMVJZ0C	MT	DTT
DMVJZ0C	MA	Inhibitor
DMVJZ0C	RN	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
DMVJZ0C	RU	https://pubmed.ncbi.nlm.nih.gov/19072235

DMLIJYS	DI	DMLIJYS
DMLIJYS	DN	1-(9-Phenyl-9H-fluoren-9-yl)1H-imidazole
DMLIJYS	MI	TTSZLWK
DMLIJYS	MN	Aromatase (CYP19A1)
DMLIJYS	MT	DTT
DMLIJYS	MA	Inhibitor
DMLIJYS	RN	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
DMLIJYS	RU	https://pubmed.ncbi.nlm.nih.gov/20413308

DMOTJWZ	DI	DMOTJWZ
DMOTJWZ	DN	1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanone
DMOTJWZ	MI	TTI6V2A
DMOTJWZ	MN	Heme oxygenase 1 (HMOX1)
DMOTJWZ	MT	DTT
DMOTJWZ	MA	Inhibitor
DMOTJWZ	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMOTJWZ	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMOJC9Z	DI	DMOJC9Z
DMOJC9Z	DN	1-(Benzhydrylamino)ethaniminium bromide
DMOJC9Z	MI	TTZUFI5
DMOJC9Z	MN	Nitric-oxide synthase brain (NOS1)
DMOJC9Z	MT	DTT
DMOJC9Z	MA	Inhibitor
DMOJC9Z	RN	N-Substituted acetamidines and 2-methylimidazole derivatives as selective inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6495-9.
DMOJC9Z	RU	https://pubmed.ncbi.nlm.nih.gov/20933416

DMGNL2A	DI	DMGNL2A
DMGNL2A	DN	1-(benzofuran-2-yl)-3-aza-bicyclo[3.1.0]hexane
DMGNL2A	MI	TTVBI8W
DMGNL2A	MN	Dopamine transporter (DAT)
DMGNL2A	MT	DTT
DMGNL2A	MA	Inhibitor
DMGNL2A	RN	Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3682-6.
DMGNL2A	RU	https://pubmed.ncbi.nlm.nih.gov/18539031

DMGNL2A	DI	DMGNL2A
DMGNL2A	DN	1-(benzofuran-2-yl)-3-aza-bicyclo[3.1.0]hexane
DMGNL2A	MI	TT3ROYC
DMGNL2A	MN	Serotonin transporter (SERT)
DMGNL2A	MT	DTT
DMGNL2A	MA	Inhibitor
DMGNL2A	RN	Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3682-6.
DMGNL2A	RU	https://pubmed.ncbi.nlm.nih.gov/18539031

DMVSC3O	DI	DMVSC3O
DMVSC3O	DN	1-(benzyloxy)-2-(2-phenylethyl)benzene
DMVSC3O	MI	TTSQIFT
DMVSC3O	MN	5-HT 1A receptor (HTR1A)
DMVSC3O	MT	DTT
DMVSC3O	MA	Inhibitor
DMVSC3O	RN	Arylmethyloxyphenyl derivatives: small molecules displaying P-glycoprotein inhibition. J Med Chem. 2006 Nov 2;49(22):6607-13.
DMVSC3O	RU	https://pubmed.ncbi.nlm.nih.gov/17064079

DMVSC3O	DI	DMVSC3O
DMVSC3O	DN	1-(benzyloxy)-2-(2-phenylethyl)benzene
DMVSC3O	MI	TTEX248
DMVSC3O	MN	Dopamine D2 receptor (D2R)
DMVSC3O	MT	DTT
DMVSC3O	MA	Inhibitor
DMVSC3O	RN	Arylmethyloxyphenyl derivatives: small molecules displaying P-glycoprotein inhibition. J Med Chem. 2006 Nov 2;49(22):6607-13.
DMVSC3O	RU	https://pubmed.ncbi.nlm.nih.gov/17064079

DMVB7P3	DI	DMVB7P3
DMVB7P3	DN	1-(benzyloxy)-2-[2-(3-methoxyphenyl)ethyl]benzene
DMVB7P3	MI	TTSQIFT
DMVB7P3	MN	5-HT 1A receptor (HTR1A)
DMVB7P3	MT	DTT
DMVB7P3	MA	Inhibitor
DMVB7P3	RN	Arylmethyloxyphenyl derivatives: small molecules displaying P-glycoprotein inhibition. J Med Chem. 2006 Nov 2;49(22):6607-13.
DMVB7P3	RU	https://pubmed.ncbi.nlm.nih.gov/17064079

DMVB7P3	DI	DMVB7P3
DMVB7P3	DN	1-(benzyloxy)-2-[2-(3-methoxyphenyl)ethyl]benzene
DMVB7P3	MI	TTEX248
DMVB7P3	MN	Dopamine D2 receptor (D2R)
DMVB7P3	MT	DTT
DMVB7P3	MA	Inhibitor
DMVB7P3	RN	Arylmethyloxyphenyl derivatives: small molecules displaying P-glycoprotein inhibition. J Med Chem. 2006 Nov 2;49(22):6607-13.
DMVB7P3	RU	https://pubmed.ncbi.nlm.nih.gov/17064079

DMA15X9	DI	DMA15X9
DMA15X9	DN	1(beta)-O-galloylpedunculagin
DMA15X9	MI	TTE14XG
DMA15X9	MN	Squalene monooxygenase (SQLE)
DMA15X9	MT	DTT
DMA15X9	MA	Inhibitor
DMA15X9	RN	Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4.
DMA15X9	RU	https://pubmed.ncbi.nlm.nih.gov/11520216

DMGVPMT	DI	DMGVPMT
DMGVPMT	DN	1-(biphenyl-3-ylmethyl)-1H-1,2,4-triazole
DMGVPMT	MI	TTSZLWK
DMGVPMT	MN	Aromatase (CYP19A1)
DMGVPMT	MT	DTT
DMGVPMT	MA	Inhibitor
DMGVPMT	RN	Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template. J Med Chem. 2010 Mar 11;53(5):2155-70.
DMGVPMT	RU	https://pubmed.ncbi.nlm.nih.gov/20148564

DM5KZ74	DI	DM5KZ74
DM5KZ74	DN	1-(biphenyl-4-yl)-3-(4-(piperidin-1-yl)butyl)urea
DM5KZ74	MI	TTPC4TU
DM5KZ74	MN	5-HT 3A receptor (HTR3A)
DM5KZ74	MT	DTT
DM5KZ74	MA	Inhibitor
DM5KZ74	RN	Novel alpha-7 nicotinic acetylcholine receptor agonists containing a urea moiety: identification and characterization of the potent, selective, and... J Med Chem. 2010 Jun 10;53(11):4379-89.
DM5KZ74	RU	https://pubmed.ncbi.nlm.nih.gov/20465311

DMTZ71K	DI	DMTZ71K
DMTZ71K	DN	1-(bis(3-bromophenyl)methylene)thiosemicarbazide
DMTZ71K	MI	TTEAID7
DMTZ71K	MN	Trypanosoma Cruzipain (Trypano CYSP)
DMTZ71K	MT	DTT
DMTZ71K	MA	Inhibitor
DMTZ71K	RN	Design, synthesis, and biochemical evaluation of novel cruzain inhibitors with potential application in the treatment of Chagas' disease. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4405-9.
DMTZ71K	RU	https://pubmed.ncbi.nlm.nih.gov/16781147

DMYO8D3	DI	DMYO8D3
DMYO8D3	DN	1-(bis(4-bromophenyl)methyl)-3-phenylurea
DMYO8D3	MI	TT6OEDT
DMYO8D3	MN	Cannabinoid receptor 1 (CB1)
DMYO8D3	MT	DTT
DMYO8D3	MA	Inhibitor
DMYO8D3	RN	1-Benzhydryl-3-phenylurea and 1-benzhydryl-3-phenylthiourea derivatives: new templates among the CB1 cannabinoid receptor inverse agonists. J Med Chem. 2005 Nov 17;48(23):7486-90.
DMYO8D3	RU	https://pubmed.ncbi.nlm.nih.gov/16279809

DMTVNO3	DI	DMTVNO3
DMTVNO3	DN	1-(bis(4-chlorophenyl)methyl)-3-phenylurea
DMTVNO3	MI	TT6OEDT
DMTVNO3	MN	Cannabinoid receptor 1 (CB1)
DMTVNO3	MT	DTT
DMTVNO3	MA	Inhibitor
DMTVNO3	RN	1-Benzhydryl-3-phenylurea and 1-benzhydryl-3-phenylthiourea derivatives: new templates among the CB1 cannabinoid receptor inverse agonists. J Med Chem. 2005 Nov 17;48(23):7486-90.
DMTVNO3	RU	https://pubmed.ncbi.nlm.nih.gov/16279809

DMF3D5R	DI	DMF3D5R
DMF3D5R	DN	1-(Bis-biphenyl-4-yl-methyl)-1H-imidazole
DMF3D5R	MI	TTRA5BZ
DMF3D5R	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMF3D5R	MT	DTT
DMF3D5R	MA	Inhibitor
DMF3D5R	RN	Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxyl... Bioorg Med Chem. 2008 Aug 15;16(16):7715-27.
DMF3D5R	RU	https://pubmed.ncbi.nlm.nih.gov/18674917

DMEULBF	DI	DMEULBF
DMEULBF	DN	1-(But-2-enylidene)thiosemicarbazide
DMEULBF	MI	TTULVH8
DMEULBF	MN	Tyrosinase (TYR)
DMEULBF	MT	DTT
DMEULBF	MA	Inhibitor
DMEULBF	RN	A class of potent tyrosinase inhibitors: alkylidenethiosemicarbazide compounds. Eur J Med Chem. 2009 Apr;44(4):1773-8.
DMEULBF	RU	https://pubmed.ncbi.nlm.nih.gov/18524420

DMTMZAJ	DI	DMTMZAJ
DMTMZAJ	DN	1-(but-2-ylamino)ethyl 1,I-bisphosphonic acid
DMTMZAJ	MI	TTIKWV4
DMTMZAJ	MN	Geranyltranstransferase (FDPS)
DMTMZAJ	MT	DTT
DMTMZAJ	MA	Inhibitor
DMTMZAJ	RN	Synthesis and biological evaluation of 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl... Bioorg Med Chem. 2008 Mar 15;16(6):3283-90.
DMTMZAJ	RU	https://pubmed.ncbi.nlm.nih.gov/18096393

DMXU1EF	DI	DMXU1EF
DMXU1EF	DN	1-(Butan-2-ylidene)thiosemicarbazide
DMXU1EF	MI	TTULVH8
DMXU1EF	MN	Tyrosinase (TYR)
DMXU1EF	MT	DTT
DMXU1EF	MA	Inhibitor
DMXU1EF	RN	A class of potent tyrosinase inhibitors: alkylidenethiosemicarbazide compounds. Eur J Med Chem. 2009 Apr;44(4):1773-8.
DMXU1EF	RU	https://pubmed.ncbi.nlm.nih.gov/18524420

DMS3XUC	DI	DMS3XUC
DMS3XUC	DN	1-(cyclohexyl)methyl-5'-O-tritylinosine
DMS3XUC	MI	TTO0IB8
DMS3XUC	MN	Thymidine phosphorylase (TYMP)
DMS3XUC	MT	DTT
DMS3XUC	MA	Inhibitor
DMS3XUC	RN	5'-O-tritylinosine and analogues as allosteric inhibitors of human thymidine phosphorylase. J Med Chem. 2006 Sep 7;49(18):5562-70.
DMS3XUC	RU	https://pubmed.ncbi.nlm.nih.gov/16942029

DMDU3X7	DI	DMDU3X7
DMDU3X7	DN	1-(cyclopropyl)methyl-5'-O-tritylinosine
DMDU3X7	MI	TTO0IB8
DMDU3X7	MN	Thymidine phosphorylase (TYMP)
DMDU3X7	MT	DTT
DMDU3X7	MA	Inhibitor
DMDU3X7	RN	5'-O-tritylinosine and analogues as allosteric inhibitors of human thymidine phosphorylase. J Med Chem. 2006 Sep 7;49(18):5562-70.
DMDU3X7	RU	https://pubmed.ncbi.nlm.nih.gov/16942029

DMLYO8P	DI	DMLYO8P
DMLYO8P	DN	1-(dio-tolylmethyl)-4-phenylpiperidin-4-ol
DMLYO8P	MI	TTNT7K8
DMLYO8P	MN	Nociceptin receptor (OPRL1)
DMLYO8P	MT	DTT
DMLYO8P	MA	Inhibitor
DMLYO8P	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMLYO8P	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMLYO8P	DI	DMLYO8P
DMLYO8P	DN	1-(dio-tolylmethyl)-4-phenylpiperidin-4-ol
DMLYO8P	MI	TT27RFC
DMLYO8P	MN	Opioid receptor delta (OPRD1)
DMLYO8P	MT	DTT
DMLYO8P	MA	Inhibitor
DMLYO8P	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMLYO8P	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMLYO8P	DI	DMLYO8P
DMLYO8P	DN	1-(dio-tolylmethyl)-4-phenylpiperidin-4-ol
DMLYO8P	MI	TTQW87Y
DMLYO8P	MN	Opioid receptor kappa (OPRK1)
DMLYO8P	MT	DTT
DMLYO8P	MA	Inhibitor
DMLYO8P	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMLYO8P	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMLYO8P	DI	DMLYO8P
DMLYO8P	DN	1-(dio-tolylmethyl)-4-phenylpiperidin-4-ol
DMLYO8P	MI	TTKWM86
DMLYO8P	MN	Opioid receptor mu (MOP)
DMLYO8P	MT	DTT
DMLYO8P	MA	Inhibitor
DMLYO8P	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMLYO8P	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMBTLIJ	DI	DMBTLIJ
DMBTLIJ	DN	1-(HYDROXYMETHYLENEAMINO)-8-HYDROXY-OCTANE
DMBTLIJ	MI	TT6L509
DMBTLIJ	MN	Coagulation factor IIa (F2)
DMBTLIJ	MT	DTT
DMBTLIJ	MA	Inhibitor
DMBTLIJ	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMBTLIJ	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMOTICP	DI	DMOTICP
DMOTICP	DN	1-(isoquinolin-5-yl)-3-(1-phenylpropyl)urea
DMOTICP	MI	TTMI6F5
DMOTICP	MN	Transient receptor potential cation channel V1 (TRPV1)
DMOTICP	MT	DTT
DMOTICP	MA	Inhibitor
DMOTICP	RN	Alpha-methylation at benzylic fragment of N-aryl-N'-benzyl ureas provides TRPV1 antagonists with better pharmacokinetic properties and higher effic... Bioorg Med Chem Lett. 2007 Jul 15;17(14):3894-9.
DMOTICP	RU	https://pubmed.ncbi.nlm.nih.gov/17507218

DMHWITR	DI	DMHWITR
DMHWITR	DN	1-(isoquinolin-5-yl)-3-(4-morpholinobenzyl)urea
DMHWITR	MI	TTMI6F5
DMHWITR	MN	Transient receptor potential cation channel V1 (TRPV1)
DMHWITR	MT	DTT
DMHWITR	MA	Inhibitor
DMHWITR	RN	In vitro structure-activity relationship and in vivo characterization of 1-(aryl)-3-(4-(amino)benzyl)urea transient receptor potential vanilloid 1 ... J Med Chem. 2007 Jul 26;50(15):3651-60.
DMHWITR	RU	https://pubmed.ncbi.nlm.nih.gov/17583335

DMI479T	DI	DMI479T
DMI479T	DN	1-(METHOXYMETHYL)-6-(NAPHTHALEN-2-YL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX)
DMI479T	MI	TTXV4FI
DMI479T	MN	Albendazole monooxygenase (CYP3A4)
DMI479T	MT	DTT
DMI479T	MA	Inhibitor
DMI479T	RN	6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor. J Med Chem. 2010 Jul 8;53(13):4989-5001.
DMI479T	RU	https://pubmed.ncbi.nlm.nih.gov/20527970

DMI479T	DI	DMI479T
DMI479T	DN	1-(METHOXYMETHYL)-6-(NAPHTHALEN-2-YL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX)
DMI479T	MI	TTVG215
DMI479T	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DMI479T	MT	DTT
DMI479T	MA	Inhibitor
DMI479T	RN	6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor. J Med Chem. 2010 Jul 8;53(13):4989-5001.
DMI479T	RU	https://pubmed.ncbi.nlm.nih.gov/20527970

DMUEQC8	DI	DMUEQC8
DMUEQC8	DN	1-(naphthalen-2-yl)-3-aza-bicyclo[3.1.0]hexane
DMUEQC8	MI	TTVBI8W
DMUEQC8	MN	Dopamine transporter (DAT)
DMUEQC8	MT	DTT
DMUEQC8	MA	Inhibitor
DMUEQC8	RN	Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3682-6.
DMUEQC8	RU	https://pubmed.ncbi.nlm.nih.gov/18539031

DMUEQC8	DI	DMUEQC8
DMUEQC8	DN	1-(naphthalen-2-yl)-3-aza-bicyclo[3.1.0]hexane
DMUEQC8	MI	TT3ROYC
DMUEQC8	MN	Serotonin transporter (SERT)
DMUEQC8	MT	DTT
DMUEQC8	MA	Inhibitor
DMUEQC8	RN	Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3682-6.
DMUEQC8	RU	https://pubmed.ncbi.nlm.nih.gov/18539031

DMXT2ZL	DI	DMXT2ZL
DMXT2ZL	DN	1-(oxazol-2-yl)-3-(4-phenoxyphenyl)propan-1-one
DMXT2ZL	MI	TTDP1UC
DMXT2ZL	MN	Fatty acid amide hydrolase (FAAH)
DMXT2ZL	MT	DTT
DMXT2ZL	MA	Inhibitor
DMXT2ZL	RN	Optimization of alpha-ketooxazole inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Feb 28;51(4):937-47.
DMXT2ZL	RU	https://pubmed.ncbi.nlm.nih.gov/18247553

DMEOS8P	DI	DMEOS8P
DMEOS8P	DN	1-(oxazol-2-yl)-4-(piperidin-4-yl)butan-1-one
DMEOS8P	MI	TTDP1UC
DMEOS8P	MN	Fatty acid amide hydrolase (FAAH)
DMEOS8P	MT	DTT
DMEOS8P	MA	Inhibitor
DMEOS8P	RN	Novel ketooxazole based inhibitors of fatty acid amide hydrolase (FAAH). Bioorg Med Chem Lett. 2008 Mar 15;18(6):2109-13.
DMEOS8P	RU	https://pubmed.ncbi.nlm.nih.gov/18289847

DMLKA5O	DI	DMLKA5O
DMLKA5O	DN	1-(oxazol-2-yl)-7-phenylheptan-1-one
DMLKA5O	MI	TTDP1UC
DMLKA5O	MN	Fatty acid amide hydrolase (FAAH)
DMLKA5O	MT	DTT
DMLKA5O	MA	Inhibitor
DMLKA5O	RN	Exploration of a fundamental substituent effect of alpha-ketoheterocycle enzyme inhibitors: Potent and selective inhibitors of fatty acid amide hyd... Bioorg Med Chem Lett. 2008 Nov 15;18(22):5842-6.
DMLKA5O	RU	https://pubmed.ncbi.nlm.nih.gov/18639454

DM1ATS3	DI	DM1ATS3
DM1ATS3	DN	1-(oxazol-2-yl)octadec-9-en-1-one
DM1ATS3	MI	TTDP1UC
DM1ATS3	MN	Fatty acid amide hydrolase (FAAH)
DM1ATS3	MT	DTT
DM1ATS3	MA	Inhibitor
DM1ATS3	RN	Optimization of the central heterocycle of alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Aug 14;51(15):4392-403.
DM1ATS3	RU	https://pubmed.ncbi.nlm.nih.gov/18630870

DMT7P2Z	DI	DMT7P2Z
DMT7P2Z	DN	1-(oxazolo[4,5-b]pyridin-2-yl)dodecan-1-one
DMT7P2Z	MI	TTDP1UC
DMT7P2Z	MN	Fatty acid amide hydrolase (FAAH)
DMT7P2Z	MT	DTT
DMT7P2Z	MA	Inhibitor
DMT7P2Z	RN	Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. Bioorg Med Chem. 2008 Feb 15;16(4):1562-95.
DMT7P2Z	RU	https://pubmed.ncbi.nlm.nih.gov/18053726

DMFGUXZ	DI	DMFGUXZ
DMFGUXZ	DN	1-(oxazolo[4,5-b]pyridin-2-yl)octan-1-one
DMFGUXZ	MI	TTDP1UC
DMFGUXZ	MN	Fatty acid amide hydrolase (FAAH)
DMFGUXZ	MT	DTT
DMFGUXZ	MA	Inhibitor
DMFGUXZ	RN	Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. Bioorg Med Chem. 2008 Feb 15;16(4):1562-95.
DMFGUXZ	RU	https://pubmed.ncbi.nlm.nih.gov/18053726

DMH2G13	DI	DMH2G13
DMH2G13	DN	1-(oxazolo[4,5-b]pyridin-2-yl)pentan-1-one
DMH2G13	MI	TTDP1UC
DMH2G13	MN	Fatty acid amide hydrolase (FAAH)
DMH2G13	MT	DTT
DMH2G13	MA	Inhibitor
DMH2G13	RN	Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. Bioorg Med Chem. 2008 Feb 15;16(4):1562-95.
DMH2G13	RU	https://pubmed.ncbi.nlm.nih.gov/18053726

DMJQ7T0	DI	DMJQ7T0
DMJQ7T0	DN	1-(pentyloxy)-4-phenoxybenzene
DMJQ7T0	MI	TTXZEAJ
DMJQ7T0	MN	Leukotriene A-4 hydrolase (LTA4H)
DMJQ7T0	MT	DTT
DMJQ7T0	MA	Inhibitor
DMJQ7T0	RN	Activation and inhibition of leukotriene A4 hydrolase aminopeptidase activity by diphenyl ether and derivatives. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6549-52.
DMJQ7T0	RU	https://pubmed.ncbi.nlm.nih.gov/18952425

DMU10CY	DI	DMU10CY
DMU10CY	DN	1-(phenyl(p-tolyl)methylene)thiosemicarbazide
DMU10CY	MI	TTF2LRI
DMU10CY	MN	Cathepsin B (CTSB)
DMU10CY	MT	DTT
DMU10CY	MA	Inhibitor
DMU10CY	RN	Discovery of trypanocidal thiosemicarbazone inhibitors of rhodesain and TbcatB. Bioorg Med Chem Lett. 2008 May 1;18(9):2883-5.
DMU10CY	RU	https://pubmed.ncbi.nlm.nih.gov/18420405

DMU10CY	DI	DMU10CY
DMU10CY	DN	1-(phenyl(p-tolyl)methylene)thiosemicarbazide
DMU10CY	MI	TT36ETB
DMU10CY	MN	Cathepsin L (CTSL)
DMU10CY	MT	DTT
DMU10CY	MA	Inhibitor
DMU10CY	RN	Discovery of trypanocidal thiosemicarbazone inhibitors of rhodesain and TbcatB. Bioorg Med Chem Lett. 2008 May 1;18(9):2883-5.
DMU10CY	RU	https://pubmed.ncbi.nlm.nih.gov/18420405

DM8APLN	DI	DM8APLN
DM8APLN	DN	1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine
DM8APLN	MI	TTNDSF4
DM8APLN	MN	Proto-oncogene c-Met (MET)
DM8APLN	MT	DTT
DM8APLN	MA	Inhibitor
DM8APLN	RN	Discovery of 4-azaindoles as novel inhibitors of c-Met kinase. Bioorg Med Chem Lett. 2009 May 15;19(10):2780-4.
DM8APLN	RU	https://pubmed.ncbi.nlm.nih.gov/19369077

DM7W25U	DI	DM7W25U
DM7W25U	DN	1-(phenylsulfonyl)-4-(piperazin-1-yl)-1H-indole
DM7W25U	MI	TTJS8PY
DM7W25U	MN	5-HT 6 receptor (HTR6)
DM7W25U	MT	DTT
DM7W25U	MA	Inhibitor
DM7W25U	RN	Binding of amine-substituted N1-benzenesulfonylindoles at human 5-HT6 serotonin receptors. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5298-302.
DM7W25U	RU	https://pubmed.ncbi.nlm.nih.gov/16183286

DMRGD8W	DI	DMRGD8W
DMRGD8W	DN	1-(phenylsulfonyl)butan-2-one
DMRGD8W	MI	TTN7BL9
DMRGD8W	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMRGD8W	MT	DTT
DMRGD8W	MA	Inhibitor
DMRGD8W	RN	beta-Keto sulfones as inhibitors of 11beta-hydroxysteroid dehydrogenase type I and the mechanism of action. Bioorg Med Chem. 2007 Jul 1;15(13):4396-405.
DMRGD8W	RU	https://pubmed.ncbi.nlm.nih.gov/17490884

DMEP80C	DI	DMEP80C
DMEP80C	DN	1-(piperazin-1-yl)isoquinoline
DMEP80C	MI	TTWJBZ5
DMEP80C	MN	5-HT 2C receptor (HTR2C)
DMEP80C	MT	DTT
DMEP80C	MA	Inhibitor
DMEP80C	RN	Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity. Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71.
DMEP80C	RU	https://pubmed.ncbi.nlm.nih.gov/19914063

DMVRN0I	DI	DMVRN0I
DMVRN0I	DN	1-(piperidin-3-ylmethyl)pyridin-2(1H)-one
DMVRN0I	MI	TTF4E0J
DMVRN0I	MN	Neuronal acetylcholine receptor alpha-2 (CHRNA2)
DMVRN0I	MT	DTT
DMVRN0I	MA	Inhibitor
DMVRN0I	RN	Synthesis and pharmacological evaluation of novel 9- and 10-substituted cytisine derivatives. Nicotinic ligands of enhanced subtype selectivity. J Med Chem. 2006 May 4;49(9):2673-6.
DMVRN0I	RU	https://pubmed.ncbi.nlm.nih.gov/16640326

DMKQZB7	DI	DMKQZB7
DMKQZB7	DN	1-(piperidin-4-ylmethyl)pyridin-2(1H)-one
DMKQZB7	MI	TTF4E0J
DMKQZB7	MN	Neuronal acetylcholine receptor alpha-2 (CHRNA2)
DMKQZB7	MT	DTT
DMKQZB7	MA	Inhibitor
DMKQZB7	RN	Synthesis and pharmacological evaluation of novel 9- and 10-substituted cytisine derivatives. Nicotinic ligands of enhanced subtype selectivity. J Med Chem. 2006 May 4;49(9):2673-6.
DMKQZB7	RU	https://pubmed.ncbi.nlm.nih.gov/16640326

DMO10FD	DI	DMO10FD
DMO10FD	DN	1-(Propan-2-ylidene)thiosemicarbazide
DMO10FD	MI	TTULVH8
DMO10FD	MN	Tyrosinase (TYR)
DMO10FD	MT	DTT
DMO10FD	MA	Inhibitor
DMO10FD	RN	A class of potent tyrosinase inhibitors: alkylidenethiosemicarbazide compounds. Eur J Med Chem. 2009 Apr;44(4):1773-8.
DMO10FD	RU	https://pubmed.ncbi.nlm.nih.gov/18524420

DMKE7FG	DI	DMKE7FG
DMKE7FG	DN	1-(pyridin-2-yl)piperazine
DMKE7FG	MI	TTNGILX
DMKE7FG	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMKE7FG	MT	DTT
DMKE7FG	MA	Inhibitor
DMKE7FG	RN	Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines. J Med Chem. 1984 Sep;27(9):1182-5.
DMKE7FG	RU	https://pubmed.ncbi.nlm.nih.gov/6088770

DMKE7FG	DI	DMKE7FG
DMKE7FG	DN	1-(pyridin-2-yl)piperazine
DMKE7FG	MI	TT34BHT
DMKE7FG	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMKE7FG	MT	DTT
DMKE7FG	MA	Inhibitor
DMKE7FG	RN	Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines. J Med Chem. 1984 Sep;27(9):1182-5.
DMKE7FG	RU	https://pubmed.ncbi.nlm.nih.gov/6088770

DMKE7FG	DI	DMKE7FG
DMKE7FG	DN	1-(pyridin-2-yl)piperazine
DMKE7FG	MI	TTWG9A4
DMKE7FG	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMKE7FG	MT	DTT
DMKE7FG	MA	Inhibitor
DMKE7FG	RN	Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines. J Med Chem. 1984 Sep;27(9):1182-5.
DMKE7FG	RU	https://pubmed.ncbi.nlm.nih.gov/6088770

DMKE7FG	DI	DMKE7FG
DMKE7FG	DN	1-(pyridin-2-yl)piperazine
DMKE7FG	MI	TTWM4TY
DMKE7FG	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMKE7FG	MT	DTT
DMKE7FG	MA	Inhibitor
DMKE7FG	RN	Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines. J Med Chem. 1984 Sep;27(9):1182-5.
DMKE7FG	RU	https://pubmed.ncbi.nlm.nih.gov/6088770

DMKE7FG	DI	DMKE7FG
DMKE7FG	DN	1-(pyridin-2-yl)piperazine
DMKE7FG	MI	TT3T17P
DMKE7FG	MN	Phospholipase D1 (PLD1)
DMKE7FG	MT	DTT
DMKE7FG	MA	Inhibitor
DMKE7FG	RN	Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part II. Identification of the 1,3,8-triazaspiro[4,5]decan-4-one privil... Bioorg Med Chem Lett. 2009 Apr 15;19(8):2240-3.
DMKE7FG	RU	https://pubmed.ncbi.nlm.nih.gov/19299128

DM78AJ1	DI	DM78AJ1
DM78AJ1	DN	1-(pyridin-4-yl)piperazine
DM78AJ1	MI	TT3T17P
DM78AJ1	MN	Phospholipase D1 (PLD1)
DM78AJ1	MT	DTT
DM78AJ1	MA	Inhibitor
DM78AJ1	RN	Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part II. Identification of the 1,3,8-triazaspiro[4,5]decan-4-one privil... Bioorg Med Chem Lett. 2009 Apr 15;19(8):2240-3.
DM78AJ1	RU	https://pubmed.ncbi.nlm.nih.gov/19299128

DM6J1AK	DI	DM6J1AK
DM6J1AK	DN	1-(thiophen-2-yl)-3-aza-bicyclo[3.1.0]hexane
DM6J1AK	MI	TTVBI8W
DM6J1AK	MN	Dopamine transporter (DAT)
DM6J1AK	MT	DTT
DM6J1AK	MA	Inhibitor
DM6J1AK	RN	Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3682-6.
DM6J1AK	RU	https://pubmed.ncbi.nlm.nih.gov/18539031

DM6J1AK	DI	DM6J1AK
DM6J1AK	DN	1-(thiophen-2-yl)-3-aza-bicyclo[3.1.0]hexane
DM6J1AK	MI	TT3ROYC
DM6J1AK	MN	Serotonin transporter (SERT)
DM6J1AK	MT	DTT
DM6J1AK	MA	Inhibitor
DM6J1AK	RN	Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3682-6.
DM6J1AK	RU	https://pubmed.ncbi.nlm.nih.gov/18539031

DMD6CHB	DI	DMD6CHB
DMD6CHB	DN	1-(trifluoromethyl)-9H-carbazole
DMD6CHB	MI	TTBGTCW
DMD6CHB	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DMD6CHB	MT	DTT
DMD6CHB	MA	Inhibitor
DMD6CHB	RN	Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8.
DMD6CHB	RU	https://pubmed.ncbi.nlm.nih.gov/20521839

DMWHN2J	DI	DMWHN2J
DMWHN2J	DN	1,1,1,2,2,3,3,5-octafluoro-8-phenyloctan-4-one
DMWHN2J	MI	TTT1JVS
DMWHN2J	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DMWHN2J	MT	DTT
DMWHN2J	MA	Inhibitor
DMWHN2J	RN	Potent and selective fluoroketone inhibitors of group VIA calcium-independent phospholipase A2. J Med Chem. 2010 May 13;53(9):3602-10.
DMWHN2J	RU	https://pubmed.ncbi.nlm.nih.gov/20369880

DM45NF1	DI	DM45NF1
DM45NF1	DN	1,1,1,2,2,3,3-heptafluoro-8-phenyloctan-4-ol
DM45NF1	MI	TTT1JVS
DM45NF1	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DM45NF1	MT	DTT
DM45NF1	MA	Inhibitor
DM45NF1	RN	Potent and selective fluoroketone inhibitors of group VIA calcium-independent phospholipase A2. J Med Chem. 2010 May 13;53(9):3602-10.
DM45NF1	RU	https://pubmed.ncbi.nlm.nih.gov/20369880

DMN68K4	DI	DMN68K4
DMN68K4	DN	1,1,1,2,2,4-hexafluoro-7-phenylheptan-3-one
DMN68K4	MI	TTT1JVS
DMN68K4	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DMN68K4	MT	DTT
DMN68K4	MA	Inhibitor
DMN68K4	RN	Potent and selective fluoroketone inhibitors of group VIA calcium-independent phospholipase A2. J Med Chem. 2010 May 13;53(9):3602-10.
DMN68K4	RU	https://pubmed.ncbi.nlm.nih.gov/20369880

DM7U8LD	DI	DM7U8LD
DM7U8LD	DN	1,1,1,2,2-Pentafluoro-8-phenyl-octan-3-one
DM7U8LD	MI	TTT1JVS
DM7U8LD	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DM7U8LD	MT	DTT
DM7U8LD	MA	Inhibitor
DM7U8LD	RN	Synthesis of polyfluoro ketones for selective inhibition of human phospholipase A2 enzymes. J Med Chem. 2008 Dec 25;51(24):8027-37.
DM7U8LD	RU	https://pubmed.ncbi.nlm.nih.gov/19053783

DMSEHNV	DI	DMSEHNV
DMSEHNV	DN	1,1,1,2,2-Pentafluoro-9-phenyl-nonan-3-one
DMSEHNV	MI	TTT1JVS
DMSEHNV	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DMSEHNV	MT	DTT
DMSEHNV	MA	Inhibitor
DMSEHNV	RN	Synthesis of polyfluoro ketones for selective inhibition of human phospholipase A2 enzymes. J Med Chem. 2008 Dec 25;51(24):8027-37.
DMSEHNV	RU	https://pubmed.ncbi.nlm.nih.gov/19053783

DMLDH4Z	DI	DMLDH4Z
DMLDH4Z	DN	1,1,1,3-Tetrafluoro-6-phenylhexan-2-one
DMLDH4Z	MI	TTT1JVS
DMLDH4Z	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DMLDH4Z	MT	DTT
DMLDH4Z	MA	Inhibitor
DMLDH4Z	RN	Potent and selective fluoroketone inhibitors of group VIA calcium-independent phospholipase A2. J Med Chem. 2010 May 13;53(9):3602-10.
DMLDH4Z	RU	https://pubmed.ncbi.nlm.nih.gov/20369880

DMV0CXN	DI	DMV0CXN
DMV0CXN	DN	1,1,1,3-Tetrafluoro-7-phenylheptan-2-one
DMV0CXN	MI	TTT1JVS
DMV0CXN	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DMV0CXN	MT	DTT
DMV0CXN	MA	Inhibitor
DMV0CXN	RN	Potent and selective fluoroketone inhibitors of group VIA calcium-independent phospholipase A2. J Med Chem. 2010 May 13;53(9):3602-10.
DMV0CXN	RU	https://pubmed.ncbi.nlm.nih.gov/20369880

DMD36WS	DI	DMD36WS
DMD36WS	DN	1,1,1,3-Tetrafluoro-heptadecan-2-one
DMD36WS	MI	TTT1JVS
DMD36WS	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DMD36WS	MT	DTT
DMD36WS	MA	Inhibitor
DMD36WS	RN	Synthesis of polyfluoro ketones for selective inhibition of human phospholipase A2 enzymes. J Med Chem. 2008 Dec 25;51(24):8027-37.
DMD36WS	RU	https://pubmed.ncbi.nlm.nih.gov/19053783

DMJ0ZMT	DI	DMJ0ZMT
DMJ0ZMT	DN	1,1,1-trifluoro-3-(hexylsulfinyl)propan-2-one
DMJ0ZMT	MI	TTMF541
DMJ0ZMT	MN	Liver carboxylesterase (CES1)
DMJ0ZMT	MT	DTT
DMJ0ZMT	MA	Inhibitor
DMJ0ZMT	RN	Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30.
DMJ0ZMT	RU	https://pubmed.ncbi.nlm.nih.gov/18023188

DMWDUCH	DI	DMWDUCH
DMWDUCH	DN	1,1,1-trifluoro-3-(hexylsulfonyl)propan-2-one
DMWDUCH	MI	TTMF541
DMWDUCH	MN	Liver carboxylesterase (CES1)
DMWDUCH	MT	DTT
DMWDUCH	MA	Inhibitor
DMWDUCH	RN	Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30.
DMWDUCH	RU	https://pubmed.ncbi.nlm.nih.gov/18023188

DMWGSP6	DI	DMWGSP6
DMWGSP6	DN	1,1,1-trifluoro-3-(hexylthio)propan-2-one
DMWGSP6	MI	TTDP1UC
DMWGSP6	MN	Fatty acid amide hydrolase (FAAH)
DMWGSP6	MT	DTT
DMWGSP6	MA	Inhibitor
DMWGSP6	RN	Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30.
DMWGSP6	RU	https://pubmed.ncbi.nlm.nih.gov/18023188

DMWGSP6	DI	DMWGSP6
DMWGSP6	DN	1,1,1-trifluoro-3-(hexylthio)propan-2-one
DMWGSP6	MI	TTMF541
DMWGSP6	MN	Liver carboxylesterase (CES1)
DMWGSP6	MT	DTT
DMWGSP6	MA	Inhibitor
DMWGSP6	RN	Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30.
DMWGSP6	RU	https://pubmed.ncbi.nlm.nih.gov/18023188

DMLBT0E	DI	DMLBT0E
DMLBT0E	DN	1,1,1-trifluoro-3-(octylsulfinyl)propan-2-one
DMLBT0E	MI	TTDP1UC
DMLBT0E	MN	Fatty acid amide hydrolase (FAAH)
DMLBT0E	MT	DTT
DMLBT0E	MA	Inhibitor
DMLBT0E	RN	Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30.
DMLBT0E	RU	https://pubmed.ncbi.nlm.nih.gov/18023188

DMLBT0E	DI	DMLBT0E
DMLBT0E	DN	1,1,1-trifluoro-3-(octylsulfinyl)propan-2-one
DMLBT0E	MI	TTMF541
DMLBT0E	MN	Liver carboxylesterase (CES1)
DMLBT0E	MT	DTT
DMLBT0E	MA	Inhibitor
DMLBT0E	RN	Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30.
DMLBT0E	RU	https://pubmed.ncbi.nlm.nih.gov/18023188

DMT29SN	DI	DMT29SN
DMT29SN	DN	1,1,1-trifluoro-3-(octylsulfonyl)propan-2-one
DMT29SN	MI	TTDP1UC
DMT29SN	MN	Fatty acid amide hydrolase (FAAH)
DMT29SN	MT	DTT
DMT29SN	MA	Inhibitor
DMT29SN	RN	Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30.
DMT29SN	RU	https://pubmed.ncbi.nlm.nih.gov/18023188

DMT29SN	DI	DMT29SN
DMT29SN	DN	1,1,1-trifluoro-3-(octylsulfonyl)propan-2-one
DMT29SN	MI	TTMF541
DMT29SN	MN	Liver carboxylesterase (CES1)
DMT29SN	MT	DTT
DMT29SN	MA	Inhibitor
DMT29SN	RN	Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30.
DMT29SN	RU	https://pubmed.ncbi.nlm.nih.gov/18023188

DMU4EJW	DI	DMU4EJW
DMU4EJW	DN	1,1,1-trifluoro-3-(octylthio)propan-2-one
DMU4EJW	MI	TTDP1UC
DMU4EJW	MN	Fatty acid amide hydrolase (FAAH)
DMU4EJW	MT	DTT
DMU4EJW	MA	Inhibitor
DMU4EJW	RN	Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30.
DMU4EJW	RU	https://pubmed.ncbi.nlm.nih.gov/18023188

DMU4EJW	DI	DMU4EJW
DMU4EJW	DN	1,1,1-trifluoro-3-(octylthio)propan-2-one
DMU4EJW	MI	TTMF541
DMU4EJW	MN	Liver carboxylesterase (CES1)
DMU4EJW	MT	DTT
DMU4EJW	MA	Inhibitor
DMU4EJW	RN	Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30.
DMU4EJW	RU	https://pubmed.ncbi.nlm.nih.gov/18023188

DMODCAM	DI	DMODCAM
DMODCAM	DN	1,1,1-Trifluoro-4-(4-hexyloxy-phenyl)-butan-2-one
DMODCAM	MI	TTT1JVS
DMODCAM	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DMODCAM	MT	DTT
DMODCAM	MA	Inhibitor
DMODCAM	RN	Synthesis of polyfluoro ketones for selective inhibition of human phospholipase A2 enzymes. J Med Chem. 2008 Dec 25;51(24):8027-37.
DMODCAM	RU	https://pubmed.ncbi.nlm.nih.gov/19053783

DMI2XWY	DI	DMI2XWY
DMI2XWY	DN	1,1,1-Trifluoro-5-(4-octylphenoxy)pentan-2-one
DMI2XWY	MI	TTT1JVS
DMI2XWY	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DMI2XWY	MT	DTT
DMI2XWY	MA	Inhibitor
DMI2XWY	RN	Potent and selective fluoroketone inhibitors of group VIA calcium-independent phospholipase A2. J Med Chem. 2010 May 13;53(9):3602-10.
DMI2XWY	RU	https://pubmed.ncbi.nlm.nih.gov/20369880

DMCAQ5T	DI	DMCAQ5T
DMCAQ5T	DN	1,1,1-Trifluoro-6-(4-hexyloxy-phenyl)-hexan-2-one
DMCAQ5T	MI	TTT1JVS
DMCAQ5T	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DMCAQ5T	MT	DTT
DMCAQ5T	MA	Inhibitor
DMCAQ5T	RN	Synthesis of polyfluoro ketones for selective inhibition of human phospholipase A2 enzymes. J Med Chem. 2008 Dec 25;51(24):8027-37.
DMCAQ5T	RU	https://pubmed.ncbi.nlm.nih.gov/19053783

DMZ2VE3	DI	DMZ2VE3
DMZ2VE3	DN	1,1,1-Trifluoro-6-(naphthalen-2-yl)hexan-2-one
DMZ2VE3	MI	TTT1JVS
DMZ2VE3	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DMZ2VE3	MT	DTT
DMZ2VE3	MA	Inhibitor
DMZ2VE3	RN	Potent and selective fluoroketone inhibitors of group VIA calcium-independent phospholipase A2. J Med Chem. 2010 May 13;53(9):3602-10.
DMZ2VE3	RU	https://pubmed.ncbi.nlm.nih.gov/20369880

DMLHVWP	DI	DMLHVWP
DMLHVWP	DN	1,1,1-Trifluoro-7-phenylheptan-2-one
DMLHVWP	MI	TTT1JVS
DMLHVWP	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DMLHVWP	MT	DTT
DMLHVWP	MA	Inhibitor
DMLHVWP	RN	Synthesis of polyfluoro ketones for selective inhibition of human phospholipase A2 enzymes. J Med Chem. 2008 Dec 25;51(24):8027-37.
DMLHVWP	RU	https://pubmed.ncbi.nlm.nih.gov/19053783

DMLHVWP	DI	DMLHVWP
DMLHVWP	DN	1,1,1-Trifluoro-7-phenylheptan-2-one
DMLHVWP	MI	TTDP1UC
DMLHVWP	MN	Fatty acid amide hydrolase (FAAH)
DMLHVWP	MT	DTT
DMLHVWP	MA	Inhibitor
DMLHVWP	RN	Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as a... J Med Chem. 2005 Mar 24;48(6):1849-56.
DMLHVWP	RU	https://pubmed.ncbi.nlm.nih.gov/15771430

DM6GI4Z	DI	DM6GI4Z
DM6GI4Z	DN	1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one
DM6GI4Z	MI	TT6R7JZ
DM6GI4Z	MN	Histone deacetylase 1 (HDAC1)
DM6GI4Z	MT	DTT
DM6GI4Z	MA	Inhibitor
DM6GI4Z	RN	Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3443-7.
DM6GI4Z	RU	https://pubmed.ncbi.nlm.nih.gov/12419380

DM6GI4Z	DI	DM6GI4Z
DM6GI4Z	DN	1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one
DM6GI4Z	MI	TTSHTOI
DM6GI4Z	MN	Histone deacetylase 2 (HDAC2)
DM6GI4Z	MT	DTT
DM6GI4Z	MA	Inhibitor
DM6GI4Z	RN	Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3443-7.
DM6GI4Z	RU	https://pubmed.ncbi.nlm.nih.gov/12419380

DM41R2O	DI	DM41R2O
DM41R2O	DN	1,1,1-Trifluoro-8-phenoxy-octan-2-one
DM41R2O	MI	TT6R7JZ
DM41R2O	MN	Histone deacetylase 1 (HDAC1)
DM41R2O	MT	DTT
DM41R2O	MA	Inhibitor
DM41R2O	RN	Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3443-7.
DM41R2O	RU	https://pubmed.ncbi.nlm.nih.gov/12419380

DM41R2O	DI	DM41R2O
DM41R2O	DN	1,1,1-Trifluoro-8-phenoxy-octan-2-one
DM41R2O	MI	TTSHTOI
DM41R2O	MN	Histone deacetylase 2 (HDAC2)
DM41R2O	MT	DTT
DM41R2O	MA	Inhibitor
DM41R2O	RN	Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3443-7.
DM41R2O	RU	https://pubmed.ncbi.nlm.nih.gov/12419380

DMYENI7	DI	DMYENI7
DMYENI7	DN	1,1,1-Trifluoro-8-phenyl-octan-2-one
DMYENI7	MI	TTT1JVS
DMYENI7	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DMYENI7	MT	DTT
DMYENI7	MA	Inhibitor
DMYENI7	RN	Synthesis of polyfluoro ketones for selective inhibition of human phospholipase A2 enzymes. J Med Chem. 2008 Dec 25;51(24):8027-37.
DMYENI7	RU	https://pubmed.ncbi.nlm.nih.gov/19053783

DMYENI7	DI	DMYENI7
DMYENI7	DN	1,1,1-Trifluoro-8-phenyl-octan-2-one
DMYENI7	MI	TTDP1UC
DMYENI7	MN	Fatty acid amide hydrolase (FAAH)
DMYENI7	MT	DTT
DMYENI7	MA	Inhibitor
DMYENI7	RN	Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as a... J Med Chem. 2005 Mar 24;48(6):1849-56.
DMYENI7	RU	https://pubmed.ncbi.nlm.nih.gov/15771430

DM7DWVL	DI	DM7DWVL
DM7DWVL	DN	1,1,1-Trifluoro-9-phenyl-nonan-2-one
DM7DWVL	MI	TTDP1UC
DM7DWVL	MN	Fatty acid amide hydrolase (FAAH)
DM7DWVL	MT	DTT
DM7DWVL	MA	Inhibitor
DM7DWVL	RN	Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as a... J Med Chem. 2005 Mar 24;48(6):1849-56.
DM7DWVL	RU	https://pubmed.ncbi.nlm.nih.gov/15771430

DMW6CQV	DI	DMW6CQV
DMW6CQV	DN	1,1,1-trifluorododecan-2-one
DMW6CQV	MI	TTDP1UC
DMW6CQV	MN	Fatty acid amide hydrolase (FAAH)
DMW6CQV	MT	DTT
DMW6CQV	MA	Inhibitor
DMW6CQV	RN	Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30.
DMW6CQV	RU	https://pubmed.ncbi.nlm.nih.gov/18023188

DMW6CQV	DI	DMW6CQV
DMW6CQV	DN	1,1,1-trifluorododecan-2-one
DMW6CQV	MI	TTMF541
DMW6CQV	MN	Liver carboxylesterase (CES1)
DMW6CQV	MT	DTT
DMW6CQV	MA	Inhibitor
DMW6CQV	RN	Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30.
DMW6CQV	RU	https://pubmed.ncbi.nlm.nih.gov/18023188

DMB5U3P	DI	DMB5U3P
DMB5U3P	DN	1,1,1-trifluoroheptadecan-2-one
DMB5U3P	MI	TTT1JVS
DMB5U3P	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DMB5U3P	MT	DTT
DMB5U3P	MA	Inhibitor
DMB5U3P	RN	Synthesis of polyfluoro ketones for selective inhibition of human phospholipase A2 enzymes. J Med Chem. 2008 Dec 25;51(24):8027-37.
DMB5U3P	RU	https://pubmed.ncbi.nlm.nih.gov/19053783

DM8TWY7	DI	DM8TWY7
DM8TWY7	DN	1,1,1-Trifluoro-nonadecan-2-one
DM8TWY7	MI	TTDP1UC
DM8TWY7	MN	Fatty acid amide hydrolase (FAAH)
DM8TWY7	MT	DTT
DM8TWY7	MA	Inhibitor
DM8TWY7	RN	Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as a... J Med Chem. 2005 Mar 24;48(6):1849-56.
DM8TWY7	RU	https://pubmed.ncbi.nlm.nih.gov/15771430

DM4CEQP	DI	DM4CEQP
DM4CEQP	DN	1,1,1-Trifluoro-tridecan-2-one
DM4CEQP	MI	TTDP1UC
DM4CEQP	MN	Fatty acid amide hydrolase (FAAH)
DM4CEQP	MT	DTT
DM4CEQP	MA	Inhibitor
DM4CEQP	RN	Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as a... J Med Chem. 2005 Mar 24;48(6):1849-56.
DM4CEQP	RU	https://pubmed.ncbi.nlm.nih.gov/15771430

DMX2SFW	DI	DMX2SFW
DMX2SFW	DN	1,1,1-Trifluoro-undecan-2-one
DMX2SFW	MI	TTDP1UC
DMX2SFW	MN	Fatty acid amide hydrolase (FAAH)
DMX2SFW	MT	DTT
DMX2SFW	MA	Inhibitor
DMX2SFW	RN	Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as a... J Med Chem. 2005 Mar 24;48(6):1849-56.
DMX2SFW	RU	https://pubmed.ncbi.nlm.nih.gov/15771430

DMGHAC7	DI	DMGHAC7
DMGHAC7	DN	1,1':4',1''-terphenyl-3,3''-diol
DMGHAC7	MI	TTXV4FI
DMGHAC7	MN	Albendazole monooxygenase (CYP3A4)
DMGHAC7	MT	DTT
DMGHAC7	MA	Inhibitor
DMGHAC7	RN	Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as p... J Med Chem. 2008 Nov 13;51(21):6725-39.
DMGHAC7	RU	https://pubmed.ncbi.nlm.nih.gov/18855374

DMGHAC7	DI	DMGHAC7
DMGHAC7	DN	1,1':4',1''-terphenyl-3,3''-diol
DMGHAC7	MI	TTIWB6L
DMGHAC7	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMGHAC7	MT	DTT
DMGHAC7	MA	Inhibitor
DMGHAC7	RN	New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43.
DMGHAC7	RU	https://pubmed.ncbi.nlm.nih.gov/19831396

DMA3LZ9	DI	DMA3LZ9
DMA3LZ9	DN	1,1':4',1''-terphenyl-3,4''-diol
DMA3LZ9	MI	TTIWB6L
DMA3LZ9	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMA3LZ9	MT	DTT
DMA3LZ9	MA	Inhibitor
DMA3LZ9	RN	New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43.
DMA3LZ9	RU	https://pubmed.ncbi.nlm.nih.gov/19831396

DMYVBD2	DI	DMYVBD2
DMYVBD2	DN	1,10-(methylenedi-4,1-phenylene)bismaleimide
DMYVBD2	MI	TTDP1UC
DMYVBD2	MN	Fatty acid amide hydrolase (FAAH)
DMYVBD2	MT	DTT
DMYVBD2	MA	Inhibitor
DMYVBD2	RN	Synthesis and in vitro evaluation of N-substituted maleimide derivatives as selective monoglyceride lipase inhibitors. J Med Chem. 2009 Dec 10;52(23):7410-20.
DMYVBD2	RU	https://pubmed.ncbi.nlm.nih.gov/19583260

DM9UGFQ	DI	DM9UGFQ
DM9UGFQ	DN	1,10-bis-(Dmt-Tic-amino)decane
DM9UGFQ	MI	TT27RFC
DM9UGFQ	MN	Opioid receptor delta (OPRD1)
DM9UGFQ	MT	DTT
DM9UGFQ	MA	Inhibitor
DM9UGFQ	RN	Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists. J Med Chem. 2005 Dec 15;48(25):8035-44.
DM9UGFQ	RU	https://pubmed.ncbi.nlm.nih.gov/16335927

DM9UGFQ	DI	DM9UGFQ
DM9UGFQ	DN	1,10-bis-(Dmt-Tic-amino)decane
DM9UGFQ	MI	TTKWM86
DM9UGFQ	MN	Opioid receptor mu (MOP)
DM9UGFQ	MT	DTT
DM9UGFQ	MA	Inhibitor
DM9UGFQ	RN	Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists. J Med Chem. 2005 Dec 15;48(25):8035-44.
DM9UGFQ	RU	https://pubmed.ncbi.nlm.nih.gov/16335927

DM6VCI3	DI	DM6VCI3
DM6VCI3	DN	1,10-bis(pyridinium)-decane dibromide
DM6VCI3	MI	TT1RS9F
DM6VCI3	MN	Acetylcholinesterase (AChE)
DM6VCI3	MT	DTT
DM6VCI3	MA	Inhibitor
DM6VCI3	RN	Preparation and in vitro screening of symmetrical bispyridinium cholinesterase inhibitors bearing different connecting linkage-initial study for My... Bioorg Med Chem Lett. 2010 Mar 1;20(5):1763-6.
DM6VCI3	RU	https://pubmed.ncbi.nlm.nih.gov/20138518

DM6VCI3	DI	DM6VCI3
DM6VCI3	DN	1,10-bis(pyridinium)-decane dibromide
DM6VCI3	MI	TTEB0GD
DM6VCI3	MN	Cholinesterase (BCHE)
DM6VCI3	MT	DTT
DM6VCI3	MA	Inhibitor
DM6VCI3	RN	Preparation and in vitro screening of symmetrical bispyridinium cholinesterase inhibitors bearing different connecting linkage-initial study for My... Bioorg Med Chem Lett. 2010 Mar 1;20(5):1763-6.
DM6VCI3	RU	https://pubmed.ncbi.nlm.nih.gov/20138518

DM5LVD2	DI	DM5LVD2
DM5LVD2	DN	1,10-phenanthroline-5,6-dione
DM5LVD2	MI	TTMF541
DM5LVD2	MN	Liver carboxylesterase (CES1)
DM5LVD2	MT	DTT
DM5LVD2	MA	Inhibitor
DM5LVD2	RN	Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34.
DM5LVD2	RU	https://pubmed.ncbi.nlm.nih.gov/17941623

DMVXYZL	DI	DMVXYZL
DMVXYZL	DN	1,11-bis(pyridinium)-undecane dibromide
DMVXYZL	MI	TT1RS9F
DMVXYZL	MN	Acetylcholinesterase (AChE)
DMVXYZL	MT	DTT
DMVXYZL	MA	Inhibitor
DMVXYZL	RN	Preparation and in vitro screening of symmetrical bispyridinium cholinesterase inhibitors bearing different connecting linkage-initial study for My... Bioorg Med Chem Lett. 2010 Mar 1;20(5):1763-6.
DMVXYZL	RU	https://pubmed.ncbi.nlm.nih.gov/20138518

DMVXYZL	DI	DMVXYZL
DMVXYZL	DN	1,11-bis(pyridinium)-undecane dibromide
DMVXYZL	MI	TTEB0GD
DMVXYZL	MN	Cholinesterase (BCHE)
DMVXYZL	MT	DTT
DMVXYZL	MA	Inhibitor
DMVXYZL	RN	Preparation and in vitro screening of symmetrical bispyridinium cholinesterase inhibitors bearing different connecting linkage-initial study for My... Bioorg Med Chem Lett. 2010 Mar 1;20(5):1763-6.
DMVXYZL	RU	https://pubmed.ncbi.nlm.nih.gov/20138518

DMG362U	DI	DMG362U
DMG362U	DN	1,1-bisphosphonate esters
DMG362U	MI	TTS4UGC
DMG362U	MN	Farnesoid X-activated receptor (FXR)
DMG362U	MT	DTT
DMG362U	MA	Agonist
DMG362U	RN	The nuclear receptors FXR and LXRalpha: potential targets for the development of drugs affecting lipid metabolism and neoplastic diseases. Curr Pharm Des. 2001 Mar;7(4):231-59.
DMG362U	RU	https://pubmed.ncbi.nlm.nih.gov/11254888

DM9XTY7	DI	DM9XTY7
DM9XTY7	DN	1,1-Dimethyl-4-phenyl-piperazin-1-ium iodide
DM9XTY7	MI	TTF4E0J
DM9XTY7	MN	Neuronal acetylcholine receptor alpha-2 (CHRNA2)
DM9XTY7	MT	DTT
DM9XTY7	MA	Inhibitor
DM9XTY7	RN	Pharmacology of the agonist binding sites of rat neuronal nicotinic receptor subtypes expressed in HEK 293 cells. Bioorg Med Chem Lett. 2004 Apr 19;14(8):1845-8.
DM9XTY7	RU	https://pubmed.ncbi.nlm.nih.gov/15050613

DMOGHRS	DI	DMOGHRS
DMOGHRS	DN	1,1-Dimethyl-5-oxa-spiro[2.4]heptan-4-one
DMOGHRS	MI	TT1MPAY
DMOGHRS	MN	GABA(A) receptor alpha-1 (GABRA1)
DMOGHRS	MT	DTT
DMOGHRS	MA	Inhibitor
DMOGHRS	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DMOGHRS	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DMOGHRS	DI	DMOGHRS
DMOGHRS	DN	1,1-Dimethyl-5-oxa-spiro[2.4]heptan-4-one
DMOGHRS	MI	TTZA1NY
DMOGHRS	MN	GABA(A) receptor beta-2 (GABRB2)
DMOGHRS	MT	DTT
DMOGHRS	MA	Inhibitor
DMOGHRS	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DMOGHRS	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DMOGHRS	DI	DMOGHRS
DMOGHRS	DN	1,1-Dimethyl-5-oxa-spiro[2.4]heptan-4-one
DMOGHRS	MI	TT06RH5
DMOGHRS	MN	GABA(A) receptor gamma-2 (GABRG2)
DMOGHRS	MT	DTT
DMOGHRS	MA	Inhibitor
DMOGHRS	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DMOGHRS	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DMOGHRS	DI	DMOGHRS
DMOGHRS	DN	1,1-Dimethyl-5-oxa-spiro[2.4]heptan-4-one
DMOGHRS	MI	TTNJYV2
DMOGHRS	MN	Gamma-aminobutyric acid receptor (GAR)
DMOGHRS	MT	DTT
DMOGHRS	MA	Inhibitor
DMOGHRS	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DMOGHRS	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DMZDUSA	DI	DMZDUSA
DMZDUSA	DN	1,1-diphenyl-2-(3-tropanyl)ethanol
DMZDUSA	MI	TTZ9SOR
DMZDUSA	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMZDUSA	MT	DTT
DMZDUSA	MA	Inhibitor
DMZDUSA	RN	Discovery of (3-endo)-3-(2-cyano-2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide as an efficacious inhaled muscarinic acetylch... Bioorg Med Chem Lett. 2009 Aug 15;19(16):4560-2.
DMZDUSA	RU	https://pubmed.ncbi.nlm.nih.gov/19616944

DMZDUSA	DI	DMZDUSA
DMZDUSA	DN	1,1-diphenyl-2-(3-tropanyl)ethanol
DMZDUSA	MI	TTYEG6Q
DMZDUSA	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMZDUSA	MT	DTT
DMZDUSA	MA	Inhibitor
DMZDUSA	RN	Discovery of (3-endo)-3-(2-cyano-2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide as an efficacious inhaled muscarinic acetylch... Bioorg Med Chem Lett. 2009 Aug 15;19(16):4560-2.
DMZDUSA	RU	https://pubmed.ncbi.nlm.nih.gov/19616944

DMZDUSA	DI	DMZDUSA
DMZDUSA	DN	1,1-diphenyl-2-(3-tropanyl)ethanol
DMZDUSA	MI	TTQ13Z5
DMZDUSA	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMZDUSA	MT	DTT
DMZDUSA	MA	Inhibitor
DMZDUSA	RN	Discovery of (3-endo)-3-(2-cyano-2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide as an efficacious inhaled muscarinic acetylch... Bioorg Med Chem Lett. 2009 Aug 15;19(16):4560-2.
DMZDUSA	RU	https://pubmed.ncbi.nlm.nih.gov/19616944

DM7SQ4H	DI	DM7SQ4H
DM7SQ4H	DN	1,1-diphenyl-3-(phenylsulfonyl)propan-2-one
DM7SQ4H	MI	TTN7BL9
DM7SQ4H	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DM7SQ4H	MT	DTT
DM7SQ4H	MA	Inhibitor
DM7SQ4H	RN	beta-Keto sulfones as inhibitors of 11beta-hydroxysteroid dehydrogenase type I and the mechanism of action. Bioorg Med Chem. 2007 Jul 1;15(13):4396-405.
DM7SQ4H	RU	https://pubmed.ncbi.nlm.nih.gov/17490884

DMDYX7P	DI	DMDYX7P
DMDYX7P	DN	1,2,3,4,4a,5,10,10a-Octahydro-benzo[g]quinoline
DMDYX7P	MI	TTWG9A4
DMDYX7P	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMDYX7P	MT	DTT
DMDYX7P	MA	Inhibitor
DMDYX7P	RN	N-(Iodopropenyl)-octahydrobenzo[f]- and -[g]quinolines: synthesis and adrenergic and dopaminergic activity studies. J Med Chem. 1998 Oct 8;41(21):4165-70.
DMDYX7P	RU	https://pubmed.ncbi.nlm.nih.gov/9767652

DMDYX7P	DI	DMDYX7P
DMDYX7P	DN	1,2,3,4,4a,5,10,10a-Octahydro-benzo[g]quinoline
DMDYX7P	MI	TTWM4TY
DMDYX7P	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMDYX7P	MT	DTT
DMDYX7P	MA	Inhibitor
DMDYX7P	RN	N-(Iodopropenyl)-octahydrobenzo[f]- and -[g]quinolines: synthesis and adrenergic and dopaminergic activity studies. J Med Chem. 1998 Oct 8;41(21):4165-70.
DMDYX7P	RU	https://pubmed.ncbi.nlm.nih.gov/9767652

DMDYX7P	DI	DMDYX7P
DMDYX7P	DN	1,2,3,4,4a,5,10,10a-Octahydro-benzo[g]quinoline
DMDYX7P	MI	TT2NUT5
DMDYX7P	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMDYX7P	MT	DTT
DMDYX7P	MA	Inhibitor
DMDYX7P	RN	N-(Iodopropenyl)-octahydrobenzo[f]- and -[g]quinolines: synthesis and adrenergic and dopaminergic activity studies. J Med Chem. 1998 Oct 8;41(21):4165-70.
DMDYX7P	RU	https://pubmed.ncbi.nlm.nih.gov/9767652

DM7JMCI	DI	DM7JMCI
DM7JMCI	DN	1,2,3,4,4a,5-hexahydrophenanthridin-6(10bH)-one
DM7JMCI	MI	TTVDSZ0
DM7JMCI	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DM7JMCI	MT	DTT
DM7JMCI	MA	Inhibitor
DM7JMCI	RN	Design, synthesis, and cytoprotective effect of 2-aminothiazole analogues as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2009 Feb 12;52(3):718-25.
DM7JMCI	RU	https://pubmed.ncbi.nlm.nih.gov/19125579

DMVD702	DI	DMVD702
DMVD702	DN	1,2,3,4,5,6-hexabromocyclohexane
DMVD702	MI	TTRMX3V
DMVD702	MN	Janus kinase 2 (JAK-2)
DMVD702	MT	DTT
DMVD702	MA	Inhibitor
DMVD702	RN	Identification of 1,2,3,4,5,6-hexabromocyclohexane as a small molecule inhibitor of jak2 tyrosine kinase autophosphorylation [correction of autophophorylation]. J Med Chem. 2005 Apr 7;48(7):2526-33.
DMVD702	RU	https://pubmed.ncbi.nlm.nih.gov/15801842

DMTKYFE	DI	DMTKYFE
DMTKYFE	DN	1,2,3,4,5,6-Hexahydro-benzo[c]azocine
DMTKYFE	MI	TTWG9A4
DMTKYFE	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMTKYFE	MT	DTT
DMTKYFE	MA	Inhibitor
DMTKYFE	RN	Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46.
DMTKYFE	RU	https://pubmed.ncbi.nlm.nih.gov/8784452

DMTKYFE	DI	DMTKYFE
DMTKYFE	DN	1,2,3,4,5,6-Hexahydro-benzo[c]azocine
DMTKYFE	MI	TTWM4TY
DMTKYFE	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMTKYFE	MT	DTT
DMTKYFE	MA	Inhibitor
DMTKYFE	RN	Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46.
DMTKYFE	RU	https://pubmed.ncbi.nlm.nih.gov/8784452

DMTKYFE	DI	DMTKYFE
DMTKYFE	DN	1,2,3,4,5,6-Hexahydro-benzo[c]azocine
DMTKYFE	MI	TT2NUT5
DMTKYFE	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMTKYFE	MT	DTT
DMTKYFE	MA	Inhibitor
DMTKYFE	RN	Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46.
DMTKYFE	RU	https://pubmed.ncbi.nlm.nih.gov/8784452

DMTK650	DI	DMTK650
DMTK650	DN	1,2,3,4,6-penta-O-galloyl-beta-D-glucose
DMTK650	MI	TT6L509
DMTK650	MN	Coagulation factor IIa (F2)
DMTK650	MT	DTT
DMTK650	MA	Inhibitor
DMTK650	RN	Effects of tannins from Geum japonicum on the catalytic activity of thrombin and factor Xa of blood coagulation cascade. J Nat Prod. 1998 Nov;61(11):1356-60.
DMTK650	RU	https://pubmed.ncbi.nlm.nih.gov/9834152

DMTK650	DI	DMTK650
DMTK650	DN	1,2,3,4,6-penta-O-galloyl-beta-D-glucose
DMTK650	MI	TTCIHJA
DMTK650	MN	Coagulation factor Xa (F10)
DMTK650	MT	DTT
DMTK650	MA	Inhibitor
DMTK650	RN	Effects of tannins from Geum japonicum on the catalytic activity of thrombin and factor Xa of blood coagulation cascade. J Nat Prod. 1998 Nov;61(11):1356-60.
DMTK650	RU	https://pubmed.ncbi.nlm.nih.gov/9834152

DMTK650	DI	DMTK650
DMTK650	DN	1,2,3,4,6-penta-O-galloyl-beta-D-glucose
DMTK650	MI	TTE14XG
DMTK650	MN	Squalene monooxygenase (SQLE)
DMTK650	MT	DTT
DMTK650	MA	Inhibitor
DMTK650	RN	Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4.
DMTK650	RU	https://pubmed.ncbi.nlm.nih.gov/11520216

DMTK650	DI	DMTK650
DMTK650	DN	1,2,3,4,6-penta-O-galloyl-beta-D-glucose
DMTK650	MI	TT7RJY8
DMTK650	MN	Xanthine dehydrogenase/oxidase (XDH)
DMTK650	MT	DTT
DMTK650	MA	Inhibitor
DMTK650	RN	Pentagalloylglucose, a xanthine oxidase inhibitor from a Paraguayan crude drug, "Molle-i" (Schinus terebinthifolius). J Nat Prod. 1989 Jan-Feb;52(1):210-1.
DMTK650	RU	https://pubmed.ncbi.nlm.nih.gov/2723668

DM9ICSA	DI	DM9ICSA
DM9ICSA	DN	1,2,3,4,6-penta-O-galloyl-D-glucopyranose
DM9ICSA	MI	TTELIN2
DM9ICSA	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DM9ICSA	MT	DTT
DM9ICSA	MA	Inhibitor
DM9ICSA	RN	Bioactivity-guided isolation of 1,2,3,4,6-Penta-O-galloyl-D-glucopyranose from Paeonia lactiflora roots as a PTP1B inhibitor. J Nat Prod. 2010 Sep 24;73(9):1578-81.
DM9ICSA	RU	https://pubmed.ncbi.nlm.nih.gov/20806783

DMHKANE	DI	DMHKANE
DMHKANE	DN	1,2,3,4-Tetrahydro-benzo[h]isoquinolin-8-ol
DMHKANE	MI	TTWG9A4
DMHKANE	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMHKANE	MT	DTT
DMHKANE	MA	Inhibitor
DMHKANE	RN	Examination of the role of the acidic hydrogen in imparting selectivity of 7-(aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline (SK&amp;F 29661) toward inh... J Med Chem. 1997 Dec 5;40(25):3997-4005.
DMHKANE	RU	https://pubmed.ncbi.nlm.nih.gov/9406590

DMHKANE	DI	DMHKANE
DMHKANE	DN	1,2,3,4-Tetrahydro-benzo[h]isoquinolin-8-ol
DMHKANE	MI	TTWM4TY
DMHKANE	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMHKANE	MT	DTT
DMHKANE	MA	Inhibitor
DMHKANE	RN	Examination of the role of the acidic hydrogen in imparting selectivity of 7-(aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline (SK&amp;F 29661) toward inh... J Med Chem. 1997 Dec 5;40(25):3997-4005.
DMHKANE	RU	https://pubmed.ncbi.nlm.nih.gov/9406590

DMHKANE	DI	DMHKANE
DMHKANE	DN	1,2,3,4-Tetrahydro-benzo[h]isoquinolin-8-ol
DMHKANE	MI	TT2NUT5
DMHKANE	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMHKANE	MT	DTT
DMHKANE	MA	Inhibitor
DMHKANE	RN	Examination of the role of the acidic hydrogen in imparting selectivity of 7-(aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline (SK&amp;F 29661) toward inh... J Med Chem. 1997 Dec 5;40(25):3997-4005.
DMHKANE	RU	https://pubmed.ncbi.nlm.nih.gov/9406590

DM5VLIE	DI	DM5VLIE
DM5VLIE	DN	1,2,3,4-Tetrahydro-isoquinolin-7-ol
DM5VLIE	MI	TTWG9A4
DM5VLIE	MN	Adrenergic receptor alpha-2A (ADRA2A)
DM5VLIE	MT	DTT
DM5VLIE	MA	Inhibitor
DM5VLIE	RN	Examination of the role of the acidic hydrogen in imparting selectivity of 7-(aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline (SK&amp;F 29661) toward inh... J Med Chem. 1997 Dec 5;40(25):3997-4005.
DM5VLIE	RU	https://pubmed.ncbi.nlm.nih.gov/9406590

DM5VLIE	DI	DM5VLIE
DM5VLIE	DN	1,2,3,4-Tetrahydro-isoquinolin-7-ol
DM5VLIE	MI	TTWM4TY
DM5VLIE	MN	Adrenergic receptor alpha-2B (ADRA2B)
DM5VLIE	MT	DTT
DM5VLIE	MA	Inhibitor
DM5VLIE	RN	Examination of the role of the acidic hydrogen in imparting selectivity of 7-(aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline (SK&amp;F 29661) toward inh... J Med Chem. 1997 Dec 5;40(25):3997-4005.
DM5VLIE	RU	https://pubmed.ncbi.nlm.nih.gov/9406590

DM5VLIE	DI	DM5VLIE
DM5VLIE	DN	1,2,3,4-Tetrahydro-isoquinolin-7-ol
DM5VLIE	MI	TT2NUT5
DM5VLIE	MN	Adrenergic receptor alpha-2C (ADRA2C)
DM5VLIE	MT	DTT
DM5VLIE	MA	Inhibitor
DM5VLIE	RN	Examination of the role of the acidic hydrogen in imparting selectivity of 7-(aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline (SK&amp;F 29661) toward inh... J Med Chem. 1997 Dec 5;40(25):3997-4005.
DM5VLIE	RU	https://pubmed.ncbi.nlm.nih.gov/9406590

DMZGCEQ	DI	DMZGCEQ
DMZGCEQ	DN	1,2,3,4-tetrahydroisoquinoline
DMZGCEQ	MI	TTWG9A4
DMZGCEQ	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMZGCEQ	MT	DTT
DMZGCEQ	MA	Inhibitor
DMZGCEQ	RN	Comparison of the binding of 3-fluoromethyl-7-sulfonyl-1,2,3,4-tetrahydroisoquinolines with their isosteric sulfonamides to the active site of phen... J Med Chem. 2006 Sep 7;49(18):5424-33.
DMZGCEQ	RU	https://pubmed.ncbi.nlm.nih.gov/16942016

DMZGCEQ	DI	DMZGCEQ
DMZGCEQ	DN	1,2,3,4-tetrahydroisoquinoline
DMZGCEQ	MI	TTWM4TY
DMZGCEQ	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMZGCEQ	MT	DTT
DMZGCEQ	MA	Inhibitor
DMZGCEQ	RN	Comparison of the binding of 3-fluoromethyl-7-sulfonyl-1,2,3,4-tetrahydroisoquinolines with their isosteric sulfonamides to the active site of phen... J Med Chem. 2006 Sep 7;49(18):5424-33.
DMZGCEQ	RU	https://pubmed.ncbi.nlm.nih.gov/16942016

DMZGCEQ	DI	DMZGCEQ
DMZGCEQ	DN	1,2,3,4-tetrahydroisoquinoline
DMZGCEQ	MI	TT2NUT5
DMZGCEQ	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMZGCEQ	MT	DTT
DMZGCEQ	MA	Inhibitor
DMZGCEQ	RN	Comparison of the binding of 3-fluoromethyl-7-sulfonyl-1,2,3,4-tetrahydroisoquinolines with their isosteric sulfonamides to the active site of phen... J Med Chem. 2006 Sep 7;49(18):5424-33.
DMZGCEQ	RU	https://pubmed.ncbi.nlm.nih.gov/16942016

DMNXQ7Z	DI	DMNXQ7Z
DMNXQ7Z	DN	1,2,3,4-Tetrahydro-naphthalen-1-ylamine
DMNXQ7Z	MI	TTGP7BY
DMNXQ7Z	MN	Monoamine oxidase type B (MAO-B)
DMNXQ7Z	MT	DTT
DMNXQ7Z	MA	Inhibitor
DMNXQ7Z	RN	Stereoisomers of allenic amines as inactivators of monoamine oxidase type B. Stereochemical probes of the active site. J Med Chem. 1988 Aug;31(8):1558-66.
DMNXQ7Z	RU	https://pubmed.ncbi.nlm.nih.gov/3397993

DMP4DLV	DI	DMP4DLV
DMP4DLV	DN	1,2,3,4-Tetrahydro-naphthalen-2-ylamine
DMP4DLV	MI	TTSQIFT
DMP4DLV	MN	5-HT 1A receptor (HTR1A)
DMP4DLV	MT	DTT
DMP4DLV	MA	Inhibitor
DMP4DLV	RN	5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80.
DMP4DLV	RU	https://pubmed.ncbi.nlm.nih.gov/3783595

DMP4DLV	DI	DMP4DLV
DMP4DLV	DN	1,2,3,4-Tetrahydro-naphthalen-2-ylamine
DMP4DLV	MI	TT6MSOK
DMP4DLV	MN	5-HT 1D receptor (HTR1D)
DMP4DLV	MT	DTT
DMP4DLV	MA	Inhibitor
DMP4DLV	RN	5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80.
DMP4DLV	RU	https://pubmed.ncbi.nlm.nih.gov/3783595

DMP4DLV	DI	DMP4DLV
DMP4DLV	DN	1,2,3,4-Tetrahydro-naphthalen-2-ylamine
DMP4DLV	MI	TTJQOD7
DMP4DLV	MN	5-HT 2A receptor (HTR2A)
DMP4DLV	MT	DTT
DMP4DLV	MA	Inhibitor
DMP4DLV	RN	5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80.
DMP4DLV	RU	https://pubmed.ncbi.nlm.nih.gov/3783595

DM3JGVF	DI	DM3JGVF
DM3JGVF	DN	1,2,3,4-Tetrahydro-pyrazino[1,2-a]indole
DM3JGVF	MI	TTJQOD7
DM3JGVF	MN	5-HT 2A receptor (HTR2A)
DM3JGVF	MT	DTT
DM3JGVF	MA	Inhibitor
DM3JGVF	RN	Evaluation of isotryptamine derivatives at 5-HT(2) serotonin receptors. Bioorg Med Chem Lett. 2002 Jan 21;12(2):155-8.
DM3JGVF	RU	https://pubmed.ncbi.nlm.nih.gov/11755343

DM3JGVF	DI	DM3JGVF
DM3JGVF	DN	1,2,3,4-Tetrahydro-pyrazino[1,2-a]indole
DM3JGVF	MI	TTWG9A4
DM3JGVF	MN	Adrenergic receptor alpha-2A (ADRA2A)
DM3JGVF	MT	DTT
DM3JGVF	MA	Inhibitor
DM3JGVF	RN	Pyrazino[1,2-a]indoles as novel high-affinity and selective imidazoline I(2) receptor ligands. Bioorg Med Chem Lett. 2004 Feb 23;14(4):1003-5.
DM3JGVF	RU	https://pubmed.ncbi.nlm.nih.gov/15013010

DM3JGVF	DI	DM3JGVF
DM3JGVF	DN	1,2,3,4-Tetrahydro-pyrazino[1,2-a]indole
DM3JGVF	MI	TTWM4TY
DM3JGVF	MN	Adrenergic receptor alpha-2B (ADRA2B)
DM3JGVF	MT	DTT
DM3JGVF	MA	Inhibitor
DM3JGVF	RN	Pyrazino[1,2-a]indoles as novel high-affinity and selective imidazoline I(2) receptor ligands. Bioorg Med Chem Lett. 2004 Feb 23;14(4):1003-5.
DM3JGVF	RU	https://pubmed.ncbi.nlm.nih.gov/15013010

DM3JGVF	DI	DM3JGVF
DM3JGVF	DN	1,2,3,4-Tetrahydro-pyrazino[1,2-a]indole
DM3JGVF	MI	TT2NUT5
DM3JGVF	MN	Adrenergic receptor alpha-2C (ADRA2C)
DM3JGVF	MT	DTT
DM3JGVF	MA	Inhibitor
DM3JGVF	RN	Pyrazino[1,2-a]indoles as novel high-affinity and selective imidazoline I(2) receptor ligands. Bioorg Med Chem Lett. 2004 Feb 23;14(4):1003-5.
DM3JGVF	RU	https://pubmed.ncbi.nlm.nih.gov/15013010

DM3JGVF	DI	DM3JGVF
DM3JGVF	DN	1,2,3,4-Tetrahydro-pyrazino[1,2-a]indole
DM3JGVF	MI	TT3WG5C
DM3JGVF	MN	Monoamine oxidase type A (MAO-A)
DM3JGVF	MT	DTT
DM3JGVF	MA	Inhibitor
DM3JGVF	RN	Pyrazino[1,2-a]indoles as novel high-affinity and selective imidazoline I(2) receptor ligands. Bioorg Med Chem Lett. 2004 Feb 23;14(4):1003-5.
DM3JGVF	RU	https://pubmed.ncbi.nlm.nih.gov/15013010

DM3JGVF	DI	DM3JGVF
DM3JGVF	DN	1,2,3,4-Tetrahydro-pyrazino[1,2-a]indole
DM3JGVF	MI	TTGP7BY
DM3JGVF	MN	Monoamine oxidase type B (MAO-B)
DM3JGVF	MT	DTT
DM3JGVF	MA	Inhibitor
DM3JGVF	RN	Pyrazino[1,2-a]indoles as novel high-affinity and selective imidazoline I(2) receptor ligands. Bioorg Med Chem Lett. 2004 Feb 23;14(4):1003-5.
DM3JGVF	RU	https://pubmed.ncbi.nlm.nih.gov/15013010

DMFDK4N	DI	DMFDK4N
DMFDK4N	DN	1',2',3',6'-Tetrahydro-[2,4']bipyridinyl
DMFDK4N	MI	TTNGILX
DMFDK4N	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMFDK4N	MT	DTT
DMFDK4N	MA	Inhibitor
DMFDK4N	RN	Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines. J Med Chem. 1984 Sep;27(9):1182-5.
DMFDK4N	RU	https://pubmed.ncbi.nlm.nih.gov/6088770

DMFDK4N	DI	DMFDK4N
DMFDK4N	DN	1',2',3',6'-Tetrahydro-[2,4']bipyridinyl
DMFDK4N	MI	TT34BHT
DMFDK4N	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMFDK4N	MT	DTT
DMFDK4N	MA	Inhibitor
DMFDK4N	RN	Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines. J Med Chem. 1984 Sep;27(9):1182-5.
DMFDK4N	RU	https://pubmed.ncbi.nlm.nih.gov/6088770

DMFDK4N	DI	DMFDK4N
DMFDK4N	DN	1',2',3',6'-Tetrahydro-[2,4']bipyridinyl
DMFDK4N	MI	TTWG9A4
DMFDK4N	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMFDK4N	MT	DTT
DMFDK4N	MA	Inhibitor
DMFDK4N	RN	Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines. J Med Chem. 1984 Sep;27(9):1182-5.
DMFDK4N	RU	https://pubmed.ncbi.nlm.nih.gov/6088770

DMFDK4N	DI	DMFDK4N
DMFDK4N	DN	1',2',3',6'-Tetrahydro-[2,4']bipyridinyl
DMFDK4N	MI	TTWM4TY
DMFDK4N	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMFDK4N	MT	DTT
DMFDK4N	MA	Inhibitor
DMFDK4N	RN	Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines. J Med Chem. 1984 Sep;27(9):1182-5.
DMFDK4N	RU	https://pubmed.ncbi.nlm.nih.gov/6088770

DMYDGAZ	DI	DMYDGAZ
DMYDGAZ	DN	1,2,3,7,12,12a-hexahydro-1-aza-pleiaden-5-ol
DMYDGAZ	MI	TTZFYLI
DMYDGAZ	MN	Dopamine D1 receptor (D1R)
DMYDGAZ	MT	DTT
DMYDGAZ	MA	Inhibitor
DMYDGAZ	RN	Advances in development of dopaminergic aporphinoids. J Med Chem. 2007 Jan 25;50(2):171-81.
DMYDGAZ	RU	https://pubmed.ncbi.nlm.nih.gov/17228858

DMAJ0B4	DI	DMAJ0B4
DMAJ0B4	DN	1,2,3,7,12,12a-hexahydro-1-aza-pleiadene-5,6-diol
DMAJ0B4	MI	TTZFYLI
DMAJ0B4	MN	Dopamine D1 receptor (D1R)
DMAJ0B4	MT	DTT
DMAJ0B4	MA	Inhibitor
DMAJ0B4	RN	Advances in development of dopaminergic aporphinoids. J Med Chem. 2007 Jan 25;50(2):171-81.
DMAJ0B4	RU	https://pubmed.ncbi.nlm.nih.gov/17228858

DMAJ0B4	DI	DMAJ0B4
DMAJ0B4	DN	1,2,3,7,12,12a-hexahydro-1-aza-pleiadene-5,6-diol
DMAJ0B4	MI	TTEX248
DMAJ0B4	MN	Dopamine D2 receptor (D2R)
DMAJ0B4	MT	DTT
DMAJ0B4	MA	Inhibitor
DMAJ0B4	RN	Advances in development of dopaminergic aporphinoids. J Med Chem. 2007 Jan 25;50(2):171-81.
DMAJ0B4	RU	https://pubmed.ncbi.nlm.nih.gov/17228858

DMXL5R7	DI	DMXL5R7
DMXL5R7	DN	1,2,3-benzenetricarboxylic acid
DMXL5R7	MI	TTTD730
DMXL5R7	MN	Mitochondrial citrate transporter (SLC25A1)
DMXL5R7	MT	DTT
DMXL5R7	MA	Inhibitor
DMXL5R7	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1051).
DMXL5R7	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1051

DM73F5A	DI	DM73F5A
DM73F5A	DN	1,2,4-Triazole
DM73F5A	MI	TTANPDJ
DM73F5A	MN	Carbonic anhydrase II (CA-II)
DM73F5A	MT	DTT
DM73F5A	MA	Inhibitor
DM73F5A	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM73F5A	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMOXLHT	DI	DMOXLHT
DMOXLHT	DN	1,2,4-Triazole-Carboxamidine
DMOXLHT	MI	TTCM4B3
DMOXLHT	MN	Nitric-oxide synthase endothelial (NOS3)
DMOXLHT	MT	DTT
DMOXLHT	MA	Inhibitor
DMOXLHT	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMOXLHT	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM7BAU2	DI	DM7BAU2
DM7BAU2	DN	1,2,5,6-tetrahydro pyrido[1,2-a]quinolin-3-one
DM7BAU2	MI	TTTU72V
DM7BAU2	MN	Steroid 5-alpha-reductase 1 (SRD5A1)
DM7BAU2	MT	DTT
DM7BAU2	MA	Inhibitor
DM7BAU2	RN	Benzo[c]quinolizin-3-ones: a novel class of potent and selective nonsteroidal inhibitors of human steroid 5alpha-reductase 1. J Med Chem. 2000 Oct 5;43(20):3718-35.
DM7BAU2	RU	https://pubmed.ncbi.nlm.nih.gov/11020287

DM9VYOI	DI	DM9VYOI
DM9VYOI	DN	1,2,5-THIADIAZOLIDIN-3-ONE-1,1-DIOXIDE
DM9VYOI	MI	TTELIN2
DM9VYOI	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DM9VYOI	MT	DTT
DM9VYOI	MA	Inhibitor
DM9VYOI	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM9VYOI	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMWGN3F	DI	DMWGN3F
DMWGN3F	DN	1,2,6-tri-O-galloyl-beta-D-glucose
DMWGN3F	MI	TTE14XG
DMWGN3F	MN	Squalene monooxygenase (SQLE)
DMWGN3F	MT	DTT
DMWGN3F	MA	Inhibitor
DMWGN3F	RN	Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4.
DMWGN3F	RU	https://pubmed.ncbi.nlm.nih.gov/11520216

DMZSL7H	DI	DMZSL7H
DMZSL7H	DN	1,2-bis(2,3,4-trifluorophenyl)-2-hydroxyethanone
DMZSL7H	MI	TTMF541
DMZSL7H	MN	Liver carboxylesterase (CES1)
DMZSL7H	MT	DTT
DMZSL7H	MA	Inhibitor
DMZSL7H	RN	Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17.
DMZSL7H	RU	https://pubmed.ncbi.nlm.nih.gov/17399985

DML5ECR	DI	DML5ECR
DML5ECR	DN	1,2-bis(2,3,4-trifluorophenyl)ethane-1,2-dione
DML5ECR	MI	TTMF541
DML5ECR	MN	Liver carboxylesterase (CES1)
DML5ECR	MT	DTT
DML5ECR	MA	Inhibitor
DML5ECR	RN	Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17.
DML5ECR	RU	https://pubmed.ncbi.nlm.nih.gov/17399985

DMD9HP8	DI	DMD9HP8
DMD9HP8	DN	1,2-bis(2,3,5-trifluorophenyl)-2-hydroxyethanone
DMD9HP8	MI	TTMF541
DMD9HP8	MN	Liver carboxylesterase (CES1)
DMD9HP8	MT	DTT
DMD9HP8	MA	Inhibitor
DMD9HP8	RN	Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17.
DMD9HP8	RU	https://pubmed.ncbi.nlm.nih.gov/17399985

DMZHWAV	DI	DMZHWAV
DMZHWAV	DN	1,2-bis(2,3,5-trifluorophenyl)ethane-1,2-dione
DMZHWAV	MI	TTMF541
DMZHWAV	MN	Liver carboxylesterase (CES1)
DMZHWAV	MT	DTT
DMZHWAV	MA	Inhibitor
DMZHWAV	RN	Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17.
DMZHWAV	RU	https://pubmed.ncbi.nlm.nih.gov/17399985

DMWS2HL	DI	DMWS2HL
DMWS2HL	DN	1,2-bis(2,3,6-trifluorophenyl)ethane-1,2-dione
DMWS2HL	MI	TTMF541
DMWS2HL	MN	Liver carboxylesterase (CES1)
DMWS2HL	MT	DTT
DMWS2HL	MA	Inhibitor
DMWS2HL	RN	Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17.
DMWS2HL	RU	https://pubmed.ncbi.nlm.nih.gov/17399985

DMZ0D5W	DI	DMZ0D5W
DMZ0D5W	DN	1,2-bis(2,3-difluorophenyl)-2-hydroxyethanone
DMZ0D5W	MI	TTMF541
DMZ0D5W	MN	Liver carboxylesterase (CES1)
DMZ0D5W	MT	DTT
DMZ0D5W	MA	Inhibitor
DMZ0D5W	RN	Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17.
DMZ0D5W	RU	https://pubmed.ncbi.nlm.nih.gov/17399985

DM9Z1NY	DI	DM9Z1NY
DM9Z1NY	DN	1,2-bis(2,3-fluorophenyl)ethane-1,2-dione
DM9Z1NY	MI	TTEB0GD
DM9Z1NY	MN	Cholinesterase (BCHE)
DM9Z1NY	MT	DTT
DM9Z1NY	MA	Inhibitor
DM9Z1NY	RN	Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17.
DM9Z1NY	RU	https://pubmed.ncbi.nlm.nih.gov/17399985

DM9Z1NY	DI	DM9Z1NY
DM9Z1NY	DN	1,2-bis(2,3-fluorophenyl)ethane-1,2-dione
DM9Z1NY	MI	TTMF541
DM9Z1NY	MN	Liver carboxylesterase (CES1)
DM9Z1NY	MT	DTT
DM9Z1NY	MA	Inhibitor
DM9Z1NY	RN	Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17.
DM9Z1NY	RU	https://pubmed.ncbi.nlm.nih.gov/17399985

DMLMCBW	DI	DMLMCBW
DMLMCBW	DN	1,2-bis(2,4-difluorophenyl)-2-hydroxyethanone
DMLMCBW	MI	TTMF541
DMLMCBW	MN	Liver carboxylesterase (CES1)
DMLMCBW	MT	DTT
DMLMCBW	MA	Inhibitor
DMLMCBW	RN	Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17.
DMLMCBW	RU	https://pubmed.ncbi.nlm.nih.gov/17399985

DMUZHPS	DI	DMUZHPS
DMUZHPS	DN	1,2-bis(2,4-difluorophenyl)ethane-1,2-dione
DMUZHPS	MI	TTMF541
DMUZHPS	MN	Liver carboxylesterase (CES1)
DMUZHPS	MT	DTT
DMUZHPS	MA	Inhibitor
DMUZHPS	RN	Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17.
DMUZHPS	RU	https://pubmed.ncbi.nlm.nih.gov/17399985

DM9EW2F	DI	DM9EW2F
DM9EW2F	DN	1,2-bis(2,5-difluorophenyl)-2-hydroxyethanone
DM9EW2F	MI	TTMF541
DM9EW2F	MN	Liver carboxylesterase (CES1)
DM9EW2F	MT	DTT
DM9EW2F	MA	Inhibitor
DM9EW2F	RN	Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17.
DM9EW2F	RU	https://pubmed.ncbi.nlm.nih.gov/17399985

DMVLMBQ	DI	DMVLMBQ
DMVLMBQ	DN	1,2-bis(2,5-difluorophenyl)ethane-1,2-dione
DMVLMBQ	MI	TTMF541
DMVLMBQ	MN	Liver carboxylesterase (CES1)
DMVLMBQ	MT	DTT
DMVLMBQ	MA	Inhibitor
DMVLMBQ	RN	Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17.
DMVLMBQ	RU	https://pubmed.ncbi.nlm.nih.gov/17399985

DMSMVCH	DI	DMSMVCH
DMSMVCH	DN	1,2-bis(2,6-difluorophenyl)-2-hydroxyethanone
DMSMVCH	MI	TTMF541
DMSMVCH	MN	Liver carboxylesterase (CES1)
DMSMVCH	MT	DTT
DMSMVCH	MA	Inhibitor
DMSMVCH	RN	Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17.
DMSMVCH	RU	https://pubmed.ncbi.nlm.nih.gov/17399985

DM351EA	DI	DM351EA
DM351EA	DN	1,2-bis(2,6-difluorophenyl)ethane-1,2-dione
DM351EA	MI	TTMF541
DM351EA	MN	Liver carboxylesterase (CES1)
DM351EA	MT	DTT
DM351EA	MA	Inhibitor
DM351EA	RN	Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17.
DM351EA	RU	https://pubmed.ncbi.nlm.nih.gov/17399985

DMZF4IC	DI	DMZF4IC
DMZF4IC	DN	1,2-Bis-(2-chloro-phenyl)-ethane-1,2-dione
DMZF4IC	MI	TTMF541
DMZF4IC	MN	Liver carboxylesterase (CES1)
DMZF4IC	MT	DTT
DMZF4IC	MA	Inhibitor
DMZF4IC	RN	Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15.
DMZF4IC	RU	https://pubmed.ncbi.nlm.nih.gov/15828829

DMNWM5S	DI	DMNWM5S
DMNWM5S	DN	1,2-bis(2-fluorophenyl)-2-hydroxyethanone
DMNWM5S	MI	TTMF541
DMNWM5S	MN	Liver carboxylesterase (CES1)
DMNWM5S	MT	DTT
DMNWM5S	MA	Inhibitor
DMNWM5S	RN	Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17.
DMNWM5S	RU	https://pubmed.ncbi.nlm.nih.gov/17399985

DM9FMUE	DI	DM9FMUE
DM9FMUE	DN	1,2-bis(2-fluorophenyl)ethane-1,2-dione
DM9FMUE	MI	TTMF541
DM9FMUE	MN	Liver carboxylesterase (CES1)
DM9FMUE	MT	DTT
DM9FMUE	MA	Inhibitor
DM9FMUE	RN	Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17.
DM9FMUE	RU	https://pubmed.ncbi.nlm.nih.gov/17399985

DM0LWAV	DI	DM0LWAV
DM0LWAV	DN	1,2-bis(3,4,5-trifluorophenyl)-2-hydroxyethanone
DM0LWAV	MI	TTMF541
DM0LWAV	MN	Liver carboxylesterase (CES1)
DM0LWAV	MT	DTT
DM0LWAV	MA	Inhibitor
DM0LWAV	RN	Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17.
DM0LWAV	RU	https://pubmed.ncbi.nlm.nih.gov/17399985

DMPJT3V	DI	DMPJT3V
DMPJT3V	DN	1,2-bis(3,4,5-trifluorophenyl)ethane-1,2-dione
DMPJT3V	MI	TTMF541
DMPJT3V	MN	Liver carboxylesterase (CES1)
DMPJT3V	MT	DTT
DMPJT3V	MA	Inhibitor
DMPJT3V	RN	Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17.
DMPJT3V	RU	https://pubmed.ncbi.nlm.nih.gov/17399985

DMRCUKJ	DI	DMRCUKJ
DMRCUKJ	DN	1,2-bis(3,4-difluorophenyl)-2-hydroxyethanone
DMRCUKJ	MI	TTMF541
DMRCUKJ	MN	Liver carboxylesterase (CES1)
DMRCUKJ	MT	DTT
DMRCUKJ	MA	Inhibitor
DMRCUKJ	RN	Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17.
DMRCUKJ	RU	https://pubmed.ncbi.nlm.nih.gov/17399985

DMBZ5RN	DI	DMBZ5RN
DMBZ5RN	DN	1,2-bis(3,4-difluorophenyl)ethane-1,2-dione
DMBZ5RN	MI	TTMF541
DMBZ5RN	MN	Liver carboxylesterase (CES1)
DMBZ5RN	MT	DTT
DMBZ5RN	MA	Inhibitor
DMBZ5RN	RN	Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17.
DMBZ5RN	RU	https://pubmed.ncbi.nlm.nih.gov/17399985

DMQTPX2	DI	DMQTPX2
DMQTPX2	DN	1,2-bis(3,5-difluorophenyl)-2-hydroxyethanone
DMQTPX2	MI	TTMF541
DMQTPX2	MN	Liver carboxylesterase (CES1)
DMQTPX2	MT	DTT
DMQTPX2	MA	Inhibitor
DMQTPX2	RN	Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17.
DMQTPX2	RU	https://pubmed.ncbi.nlm.nih.gov/17399985

DM3K5RI	DI	DM3K5RI
DM3K5RI	DN	1,2-bis(3,5-difluorophenyl)ethane-1,2-dione
DM3K5RI	MI	TTMF541
DM3K5RI	MN	Liver carboxylesterase (CES1)
DM3K5RI	MT	DTT
DM3K5RI	MA	Inhibitor
DM3K5RI	RN	Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17.
DM3K5RI	RU	https://pubmed.ncbi.nlm.nih.gov/17399985

DM8XGD0	DI	DM8XGD0
DM8XGD0	DN	1,2-bis(3-fluorophenyl)-2-hydroxyethanon
DM8XGD0	MI	TTMF541
DM8XGD0	MN	Liver carboxylesterase (CES1)
DM8XGD0	MT	DTT
DM8XGD0	MA	Inhibitor
DM8XGD0	RN	Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17.
DM8XGD0	RU	https://pubmed.ncbi.nlm.nih.gov/17399985

DMM3I1P	DI	DMM3I1P
DMM3I1P	DN	1,2-bis(3-fluorophenyl)ethane-1,2-dione
DMM3I1P	MI	TTMF541
DMM3I1P	MN	Liver carboxylesterase (CES1)
DMM3I1P	MT	DTT
DMM3I1P	MA	Inhibitor
DMM3I1P	RN	Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17.
DMM3I1P	RU	https://pubmed.ncbi.nlm.nih.gov/17399985

DMWY1QN	DI	DMWY1QN
DMWY1QN	DN	1,2-Bis-(3-methoxy-phenyl)-ethane-1,2-dione
DMWY1QN	MI	TTMF541
DMWY1QN	MN	Liver carboxylesterase (CES1)
DMWY1QN	MT	DTT
DMWY1QN	MA	Inhibitor
DMWY1QN	RN	Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15.
DMWY1QN	RU	https://pubmed.ncbi.nlm.nih.gov/15828829

DMGSTKZ	DI	DMGSTKZ
DMGSTKZ	DN	1,2-Bis-(3-nitro-phenyl)-ethane-1,2-dione
DMGSTKZ	MI	TTMF541
DMGSTKZ	MN	Liver carboxylesterase (CES1)
DMGSTKZ	MT	DTT
DMGSTKZ	MA	Inhibitor
DMGSTKZ	RN	Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15.
DMGSTKZ	RU	https://pubmed.ncbi.nlm.nih.gov/15828829

DMUW2EJ	DI	DMUW2EJ
DMUW2EJ	DN	1,2-Bis-(4-bromo-phenyl)-ethane-1,2-dione
DMUW2EJ	MI	TTMF541
DMUW2EJ	MN	Liver carboxylesterase (CES1)
DMUW2EJ	MT	DTT
DMUW2EJ	MA	Inhibitor
DMUW2EJ	RN	Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15.
DMUW2EJ	RU	https://pubmed.ncbi.nlm.nih.gov/15828829

DM0E5FH	DI	DM0E5FH
DM0E5FH	DN	1,2-Bis-(4-chloro-phenyl)-ethane-1,2-dione
DM0E5FH	MI	TTMF541
DM0E5FH	MN	Liver carboxylesterase (CES1)
DM0E5FH	MT	DTT
DM0E5FH	MA	Inhibitor
DM0E5FH	RN	Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15.
DM0E5FH	RU	https://pubmed.ncbi.nlm.nih.gov/15828829

DM38Q7W	DI	DM38Q7W
DM38Q7W	DN	1,2-bis(4-fluorophenyl)ethane-1,2-dione
DM38Q7W	MI	TTMF541
DM38Q7W	MN	Liver carboxylesterase (CES1)
DM38Q7W	MT	DTT
DM38Q7W	MA	Inhibitor
DM38Q7W	RN	Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17.
DM38Q7W	RU	https://pubmed.ncbi.nlm.nih.gov/17399985

DM9RF1T	DI	DM9RF1T
DM9RF1T	DN	1,2-Bis-(4-hydroxy-phenyl)-3H-inden-5-ol
DM9RF1T	MI	TTZAYWL
DM9RF1T	MN	Estrogen receptor (ESR)
DM9RF1T	MT	DTT
DM9RF1T	MA	Inhibitor
DM9RF1T	RN	Differential response of estrogen receptor subtypes to 1,3-diarylindene and 2,3-diarylindene ligands. J Med Chem. 2005 Sep 22;48(19):5989-6003.
DM9RF1T	RU	https://pubmed.ncbi.nlm.nih.gov/16162002

DM9RF1T	DI	DM9RF1T
DM9RF1T	DN	1,2-Bis-(4-hydroxy-phenyl)-3H-inden-5-ol
DM9RF1T	MI	TTOM3J0
DM9RF1T	MN	Estrogen receptor beta (ESR2)
DM9RF1T	MT	DTT
DM9RF1T	MA	Inhibitor
DM9RF1T	RN	Differential response of estrogen receptor subtypes to 1,3-diarylindene and 2,3-diarylindene ligands. J Med Chem. 2005 Sep 22;48(19):5989-6003.
DM9RF1T	RU	https://pubmed.ncbi.nlm.nih.gov/16162002

DMCGRV7	DI	DMCGRV7
DMCGRV7	DN	1,2-Bis-(4-methoxy-phenyl)-ethane-1,2-dione
DMCGRV7	MI	TTMF541
DMCGRV7	MN	Liver carboxylesterase (CES1)
DMCGRV7	MT	DTT
DMCGRV7	MA	Inhibitor
DMCGRV7	RN	Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15.
DMCGRV7	RU	https://pubmed.ncbi.nlm.nih.gov/15828829

DM9ENXO	DI	DM9ENXO
DM9ENXO	DN	1,2-Bis-[R-(-)-apomorphine-2'-oxy]ethane
DM9ENXO	MI	TTZFYLI
DM9ENXO	MN	Dopamine D1 receptor (D1R)
DM9ENXO	MT	DTT
DM9ENXO	MA	Inhibitor
DM9ENXO	RN	Synthesis and neuropharmacological characterization of 2-O-substituted apomorphines. Bioorg Med Chem. 2008 Apr 15;16(8):4563-8.
DM9ENXO	RU	https://pubmed.ncbi.nlm.nih.gov/18313931

DM9ENXO	DI	DM9ENXO
DM9ENXO	DN	1,2-Bis-[R-(-)-apomorphine-2'-oxy]ethane
DM9ENXO	MI	TTEX248
DM9ENXO	MN	Dopamine D2 receptor (D2R)
DM9ENXO	MT	DTT
DM9ENXO	MA	Inhibitor
DM9ENXO	RN	Synthesis and neuropharmacological characterization of 2-O-substituted apomorphines. Bioorg Med Chem. 2008 Apr 15;16(8):4563-8.
DM9ENXO	RU	https://pubmed.ncbi.nlm.nih.gov/18313931

DMJAK0E	DI	DMJAK0E
DMJAK0E	DN	1,2-di(10H-phenothiazin-10-yl)ethane-1,2-dione
DMJAK0E	MI	TTEB0GD
DMJAK0E	MN	Cholinesterase (BCHE)
DMJAK0E	MT	DTT
DMJAK0E	MA	Inhibitor
DMJAK0E	RN	Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. Bioorg Med Chem. 2007 Oct 1;15(19):6367-78.
DMJAK0E	RU	https://pubmed.ncbi.nlm.nih.gov/17681768

DM7S1D5	DI	DM7S1D5
DM7S1D5	DN	1,2-Di(berberine-9-O-yl)ethane dibromide
DM7S1D5	MI	TT1RS9F
DM7S1D5	MN	Acetylcholinesterase (AChE)
DM7S1D5	MT	DTT
DM7S1D5	MA	Inhibitor
DM7S1D5	RN	Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase. Bioorg Med Chem. 2010 Jun 15;18(12):4475-84.
DM7S1D5	RU	https://pubmed.ncbi.nlm.nih.gov/20471843

DM7S1D5	DI	DM7S1D5
DM7S1D5	DN	1,2-Di(berberine-9-O-yl)ethane dibromide
DM7S1D5	MI	TTEB0GD
DM7S1D5	MN	Cholinesterase (BCHE)
DM7S1D5	MT	DTT
DM7S1D5	MA	Inhibitor
DM7S1D5	RN	Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase. Bioorg Med Chem. 2010 Jun 15;18(12):4475-84.
DM7S1D5	RU	https://pubmed.ncbi.nlm.nih.gov/20471843

DMBAX2L	DI	DMBAX2L
DMBAX2L	DN	1,2-Diacetoxylycorine
DMBAX2L	MI	TTXV4FI
DMBAX2L	MN	Albendazole monooxygenase (CYP3A4)
DMBAX2L	MT	DTT
DMBAX2L	MA	Inhibitor
DMBAX2L	RN	Selective cytochrome P450 3A4 inhibitory activity of Amaryllidaceae alkaloids. Bioorg Med Chem Lett. 2009 Jun 15;19(12):3233-7.
DMBAX2L	RU	https://pubmed.ncbi.nlm.nih.gov/19428250

DMDJYHK	DI	DMDJYHK
DMDJYHK	DN	1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane
DMDJYHK	MI	TTS64P2
DMDJYHK	MN	Androgen receptor (AR)
DMDJYHK	MT	DTT
DMDJYHK	MA	Inhibitor
DMDJYHK	RN	Identification of the brominated flame retardant 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane as an androgen agonist. J Med Chem. 2006 Dec 14;49(25):7366-72.
DMDJYHK	RU	https://pubmed.ncbi.nlm.nih.gov/17149866

DMDJYHK	DI	DMDJYHK
DMDJYHK	DN	1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane
DMDJYHK	MI	TTKPW01
DMDJYHK	MN	Androgen receptor messenger RNA (AR mRNA)
DMDJYHK	MT	DTT
DMDJYHK	MA	Inhibitor
DMDJYHK	RN	Identification of the brominated flame retardant 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane as an androgen agonist. J Med Chem. 2006 Dec 14;49(25):7366-72.
DMDJYHK	RU	https://pubmed.ncbi.nlm.nih.gov/17149866

DM75OR8	DI	DM75OR8
DM75OR8	DN	1,2-dicyclohexylethane-1,2-dione
DM75OR8	MI	TTMF541
DM75OR8	MN	Liver carboxylesterase (CES1)
DM75OR8	MT	DTT
DM75OR8	MA	Inhibitor
DM75OR8	RN	Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34.
DM75OR8	RU	https://pubmed.ncbi.nlm.nih.gov/17941623

DM542I9	DI	DM542I9
DM542I9	DN	1,2-dihydro-2-oxoquinazoline-4-carboxyanilide
DM542I9	MI	TTJFY5U
DM542I9	MN	Adenosine A3 receptor (ADORA3)
DM542I9	MT	DTT
DM542I9	MA	Inhibitor
DM542I9	RN	Scouting human A3 adenosine receptor antagonist binding mode using a molecular simplification approach: from triazoloquinoxaline to a pyrimidine sk... J Med Chem. 2007 Dec 27;50(26):6596-606.
DM542I9	RU	https://pubmed.ncbi.nlm.nih.gov/18047262

DMST60D	DI	DMST60D
DMST60D	DN	1,2-dihydro-3-(2,3,4-trimethoxyphenyl)naphthalene
DMST60D	MI	TT8NGED
DMST60D	MN	Prostaglandin G/H synthase 1 (COX-1)
DMST60D	MT	DTT
DMST60D	MA	Inhibitor
DMST60D	RN	'Bridged' stilbene derivatives as selective cyclooxygenase-1 inhibitors. Bioorg Med Chem. 2007 Sep 15;15(18):6109-18.
DMST60D	RU	https://pubmed.ncbi.nlm.nih.gov/17604631

DMST60D	DI	DMST60D
DMST60D	DN	1,2-dihydro-3-(2,3,4-trimethoxyphenyl)naphthalene
DMST60D	MI	TTVKILB
DMST60D	MN	Prostaglandin G/H synthase 2 (COX-2)
DMST60D	MT	DTT
DMST60D	MA	Inhibitor
DMST60D	RN	'Bridged' stilbene derivatives as selective cyclooxygenase-1 inhibitors. Bioorg Med Chem. 2007 Sep 15;15(18):6109-18.
DMST60D	RU	https://pubmed.ncbi.nlm.nih.gov/17604631

DM9G7DT	DI	DM9G7DT
DM9G7DT	DN	1,2-Dihydro-indazol-3-one
DM9G7DT	MI	TT2J34L
DM9G7DT	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM9G7DT	MT	DTT
DM9G7DT	MA	Inhibitor
DM9G7DT	RN	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
DM9G7DT	RU	https://pubmed.ncbi.nlm.nih.gov/1848292

DMASC8K	DI	DMASC8K
DMASC8K	DN	1,2-Dihydroxy-10H-anthracen-9-one
DMASC8K	MI	TT2J34L
DMASC8K	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMASC8K	MT	DTT
DMASC8K	MA	Inhibitor
DMASC8K	RN	Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80.
DMASC8K	RU	https://pubmed.ncbi.nlm.nih.gov/9371243

DMGXMF0	DI	DMGXMF0
DMGXMF0	DN	1,2-Di-naphthalen-2-yl-ethane-1,2-dione
DMGXMF0	MI	TTMF541
DMGXMF0	MN	Liver carboxylesterase (CES1)
DMGXMF0	MT	DTT
DMGXMF0	MA	Inhibitor
DMGXMF0	RN	Inhibition of carboxylesterases by benzil (diphenylethane-1,2-dione) and heterocyclic analogues is dependent upon the aromaticity of the ring and t... J Med Chem. 2005 Aug 25;48(17):5543-50.
DMGXMF0	RU	https://pubmed.ncbi.nlm.nih.gov/16107154

DMEAB03	DI	DMEAB03
DMEAB03	DN	1,2-dioctanoyl-sn-glycerol
DMEAB03	MI	TTFJ8Q1
DMEAB03	MN	Protein kinase C alpha (PRKCA)
DMEAB03	MT	DTT
DMEAB03	MA	Inhibitor
DMEAB03	RN	Design, synthesis, and biological activity of isophthalic acid derivatives targeted to the C1 domain of protein kinase C. J Med Chem. 2009 Jul 9;52(13):3969-81.
DMEAB03	RU	https://pubmed.ncbi.nlm.nih.gov/19438240

DMFXB21	DI	DMFXB21
DMFXB21	DN	1,2-Di-p-tolyl-ethane-1,2-dione
DMFXB21	MI	TTMF541
DMFXB21	MN	Liver carboxylesterase (CES1)
DMFXB21	MT	DTT
DMFXB21	MA	Inhibitor
DMFXB21	RN	Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15.
DMFXB21	RU	https://pubmed.ncbi.nlm.nih.gov/15828829

DMV275G	DI	DMV275G
DMV275G	DN	1,2-indanedione
DMV275G	MI	TTEB0GD
DMV275G	MN	Cholinesterase (BCHE)
DMV275G	MT	DTT
DMV275G	MA	Inhibitor
DMV275G	RN	Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34.
DMV275G	RU	https://pubmed.ncbi.nlm.nih.gov/17941623

DMV275G	DI	DMV275G
DMV275G	DN	1,2-indanedione
DMV275G	MI	TTMF541
DMV275G	MN	Liver carboxylesterase (CES1)
DMV275G	MT	DTT
DMV275G	MA	Inhibitor
DMV275G	RN	Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34.
DMV275G	RU	https://pubmed.ncbi.nlm.nih.gov/17941623

DMYXELH	DI	DMYXELH
DMYXELH	DN	1,2-NAPHTHOQUINONE
DMYXELH	MI	TT1RS9F
DMYXELH	MN	Acetylcholinesterase (AChE)
DMYXELH	MT	DTT
DMYXELH	MA	Inhibitor
DMYXELH	RN	Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34.
DMYXELH	RU	https://pubmed.ncbi.nlm.nih.gov/17941623

DMYXELH	DI	DMYXELH
DMYXELH	DN	1,2-NAPHTHOQUINONE
DMYXELH	MI	TTEB0GD
DMYXELH	MN	Cholinesterase (BCHE)
DMYXELH	MT	DTT
DMYXELH	MA	Inhibitor
DMYXELH	RN	Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34.
DMYXELH	RU	https://pubmed.ncbi.nlm.nih.gov/17941623

DMYXELH	DI	DMYXELH
DMYXELH	DN	1,2-NAPHTHOQUINONE
DMYXELH	MI	DE3FEV8
DMYXELH	MN	Dicarbonyl/L-xylulose reductase (DCXR)
DMYXELH	MT	DME
DMYXELH	MA	Metabolism
DMYXELH	RN	Diacetyl/l-xylulose reductase mediates chemical redox cycling in lung epithelial cells. Chem Res Toxicol. 2017 Jul 17;30(7):1406-1418.
DMYXELH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28595002

DMYXELH	DI	DMYXELH
DMYXELH	DN	1,2-NAPHTHOQUINONE
DMYXELH	MI	TTZJYKH
DMYXELH	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMYXELH	MT	DTT
DMYXELH	MA	Inhibitor
DMYXELH	RN	Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem. 2008 Mar 27;51(6):1706-18.
DMYXELH	RU	https://pubmed.ncbi.nlm.nih.gov/18318466

DMYXELH	DI	DMYXELH
DMYXELH	DN	1,2-NAPHTHOQUINONE
DMYXELH	MI	TTMF541
DMYXELH	MN	Liver carboxylesterase (CES1)
DMYXELH	MT	DTT
DMYXELH	MA	Inhibitor
DMYXELH	RN	Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34.
DMYXELH	RU	https://pubmed.ncbi.nlm.nih.gov/17941623

DMYXELH	DI	DMYXELH
DMYXELH	DN	1,2-NAPHTHOQUINONE
DMYXELH	MI	DE8RYV5
DMYXELH	MN	NADPH:quinone reductase (CRYZ)
DMYXELH	MT	DME
DMYXELH	MA	Metabolism
DMYXELH	RN	Effect of superoxide dismutase on the autoxidation of various hydroquinones--a possible role of superoxide dismutase as a superoxide:semiquinone oxidoreductase. Free Radic Biol Med. 1988;5(2):71-9.
DMYXELH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=2855420

DMYXELH	DI	DMYXELH
DMYXELH	DN	1,2-NAPHTHOQUINONE
DMYXELH	MI	TTELIN2
DMYXELH	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMYXELH	MT	DTT
DMYXELH	MA	Inhibitor
DMYXELH	RN	Synthesis and PTP1B inhibition of 1,2-naphthoquinone derivatives as potent anti-diabetic agents. Bioorg Med Chem Lett. 2002 Aug 5;12(15):1941-6.
DMYXELH	RU	https://pubmed.ncbi.nlm.nih.gov/12113814

DMYXELH	DI	DMYXELH
DMYXELH	DN	1,2-NAPHTHOQUINONE
DMYXELH	MI	DEJVDAT
DMYXELH	MN	Sepiapterin reductase (SPR)
DMYXELH	MT	DME
DMYXELH	MA	Metabolism
DMYXELH	RN	Sepiapterin reductase mediates chemical redox cycling in lung epithelial cells. J Biol Chem. 2013 Jun 28;288(26):19221-37.
DMYXELH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23640889

DMNCWXZ	DI	DMNCWXZ
DMNCWXZ	DN	1,3,5-BENZENETRICARBOXYLIC ACID
DMNCWXZ	MI	TTQO71U
DMNCWXZ	MN	Hemoglobin (HB)
DMNCWXZ	MT	DTT
DMNCWXZ	MA	Inhibitor
DMNCWXZ	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMNCWXZ	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM7U6S0	DI	DM7U6S0
DM7U6S0	DN	1,3,5-triphenylimidazolidine-2,4-dione
DM7U6S0	MI	TT6OEDT
DM7U6S0	MN	Cannabinoid receptor 1 (CB1)
DM7U6S0	MT	DTT
DM7U6S0	MA	Inhibitor
DM7U6S0	RN	Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: characterization of new CB1 cann... J Med Chem. 2006 Feb 9;49(3):872-82.
DM7U6S0	RU	https://pubmed.ncbi.nlm.nih.gov/16451053

DMDNM05	DI	DMDNM05
DMDNM05	DN	1,3,5-tris(4-chlorophenyl)imidazolidine-2,4-dione
DMDNM05	MI	TT6OEDT
DMDNM05	MN	Cannabinoid receptor 1 (CB1)
DMDNM05	MT	DTT
DMDNM05	MA	Inhibitor
DMDNM05	RN	Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: characterization of new CB1 cann... J Med Chem. 2006 Feb 9;49(3):872-82.
DMDNM05	RU	https://pubmed.ncbi.nlm.nih.gov/16451053

DMFA8CW	DI	DMFA8CW
DMFA8CW	DN	1,3,7-trihydroxyacridone
DMFA8CW	MI	TT0IHXV
DMFA8CW	MN	DNA topoisomerase II (TOP2)
DMFA8CW	MT	DTT
DMFA8CW	MA	Inhibitor
DMFA8CW	RN	1,3-Dihydroxyacridone derivatives as inhibitors of herpes virus replication. Antiviral Res. 2000 Feb;45(2):123-34.
DMFA8CW	RU	https://pubmed.ncbi.nlm.nih.gov/10809021

DMNCJ5R	DI	DMNCJ5R
DMNCJ5R	DN	1,3,7-Tripropyl-3,7-dihydro-purine-2,6-dione
DMNCJ5R	MI	TTM2AOE
DMNCJ5R	MN	Adenosine A2a receptor (ADORA2A)
DMNCJ5R	MT	DTT
DMNCJ5R	MA	Inhibitor
DMNCJ5R	RN	Analogues of caffeine and theophylline: effect of structural alterations on affinity at adenosine receptors. J Med Chem. 1986 Jul;29(7):1305-8.
DMNCJ5R	RU	https://pubmed.ncbi.nlm.nih.gov/3806581

DMRP03X	DI	DMRP03X
DMRP03X	DN	1,3,8-Trihydroxy-6-methyl-10H-anthracen-9-one
DMRP03X	MI	TT2J34L
DMRP03X	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMRP03X	MT	DTT
DMRP03X	MA	Inhibitor
DMRP03X	RN	Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80.
DMRP03X	RU	https://pubmed.ncbi.nlm.nih.gov/9371243

DMOZEKU	DI	DMOZEKU
DMOZEKU	DN	1,3,8-Trimethyl-3,7-dihydro-purine-2,6-dione
DMOZEKU	MI	TTM2AOE
DMOZEKU	MN	Adenosine A2a receptor (ADORA2A)
DMOZEKU	MT	DTT
DMOZEKU	MA	Inhibitor
DMOZEKU	RN	1,3-Dialkyl-8-(p-sulfophenyl)xanthines: potent water-soluble antagonists for A1- and A2-adenosine receptors. J Med Chem. 1985 Apr;28(4):487-92.
DMOZEKU	RU	https://pubmed.ncbi.nlm.nih.gov/2984420

DM7U31Q	DI	DM7U31Q
DM7U31Q	DN	1,3,9,9a-Tetrahydro-imidazo[4,5-b]quinolin-2-one
DM7U31Q	MI	TT06AWU
DM7U31Q	MN	Phosphodiesterase 3A (PDE3A)
DM7U31Q	MT	DTT
DM7U31Q	MA	Inhibitor
DM7U31Q	RN	1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-ones--inhibitors of blood platelet cAMP phosphodiesterase and induced aggregation. J Med Chem. 1991 Sep;34(9):2906-16.
DM7U31Q	RU	https://pubmed.ncbi.nlm.nih.gov/1654430

DMP86R3	DI	DMP86R3
DMP86R3	DN	1,3-bis(1,3-benzothiazol-2-ylthio)acetone
DMP86R3	MI	TTHGL48
DMP86R3	MN	AP endonuclease 1 (APEX1)
DMP86R3	MT	DTT
DMP86R3	MA	Inhibitor
DMP86R3	RN	Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines. Br J Cancer. 2011 Feb 15;104(4):653-63.
DMP86R3	RU	https://pubmed.ncbi.nlm.nih.gov/21266972

DMELSV1	DI	DMELSV1
DMELSV1	DN	1,3-bis(3,4-dihydroxyphenyl)prop-2-en-1-one
DMELSV1	MI	TTQY2EJ
DMELSV1	MN	TERT messenger RNA (TERT mRNA)
DMELSV1	MT	DTT
DMELSV1	MA	Inhibitor
DMELSV1	RN	Catecholic flavonoids acting as telomerase inhibitors. J Med Chem. 2004 Dec 16;47(26):6466-75.
DMELSV1	RU	https://pubmed.ncbi.nlm.nih.gov/15588081

DM78UPQ	DI	DM78UPQ
DM78UPQ	DN	1,3-Bis-(3-imidazolidin-2-yl-phenyl)-urea
DM78UPQ	MI	TT1RS9F
DM78UPQ	MN	Acetylcholinesterase (AChE)
DM78UPQ	MT	DTT
DM78UPQ	MA	Inhibitor
DM78UPQ	RN	Efficient method for high-throughput virtual screening based on flexible docking: discovery of novel acetylcholinesterase inhibitors. J Med Chem. 2004 Sep 23;47(20):4818-28.
DM78UPQ	RU	https://pubmed.ncbi.nlm.nih.gov/15369385

DMIK7XV	DI	DMIK7XV
DMIK7XV	DN	1,3-bis(nitrooxy)propan-2-yl 2-acetoxybenzoate
DMIK7XV	MI	TTVKILB
DMIK7XV	MN	Prostaglandin G/H synthase 2 (COX-2)
DMIK7XV	MT	DTT
DMIK7XV	MA	Inhibitor
DMIK7XV	RN	Dinitroglyceryl and diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of aspirin, indomethacin and ibuprofen: synthesis, biological evalu... Bioorg Med Chem Lett. 2009 Jun 1;19(11):3014-8.
DMIK7XV	RU	https://pubmed.ncbi.nlm.nih.gov/19419861

DMZKUOX	DI	DMZKUOX
DMZKUOX	DN	1,3-Di(berberine-9-O-yl)ethane dibromide
DMZKUOX	MI	TT1RS9F
DMZKUOX	MN	Acetylcholinesterase (AChE)
DMZKUOX	MT	DTT
DMZKUOX	MA	Inhibitor
DMZKUOX	RN	Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase. Bioorg Med Chem. 2010 Jun 15;18(12):4475-84.
DMZKUOX	RU	https://pubmed.ncbi.nlm.nih.gov/20471843

DMZKUOX	DI	DMZKUOX
DMZKUOX	DN	1,3-Di(berberine-9-O-yl)ethane dibromide
DMZKUOX	MI	TTEB0GD
DMZKUOX	MN	Cholinesterase (BCHE)
DMZKUOX	MT	DTT
DMZKUOX	MA	Inhibitor
DMZKUOX	RN	Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase. Bioorg Med Chem. 2010 Jun 15;18(12):4475-84.
DMZKUOX	RU	https://pubmed.ncbi.nlm.nih.gov/20471843

DMEV8G2	DI	DMEV8G2
DMEV8G2	DN	1,3-Diallyl-3,7-dihydro-purine-2,6-dione
DMEV8G2	MI	TTK25J1
DMEV8G2	MN	Adenosine A1 receptor (ADORA1)
DMEV8G2	MT	DTT
DMEV8G2	MA	Inhibitor
DMEV8G2	RN	Benzo[1,2-c:5,4-c']dipyrazoles: non-xanthine adenosine antagonists. J Med Chem. 1988 Oct;31(10):2034-9.
DMEV8G2	RU	https://pubmed.ncbi.nlm.nih.gov/3172141

DMEV8G2	DI	DMEV8G2
DMEV8G2	DN	1,3-Diallyl-3,7-dihydro-purine-2,6-dione
DMEV8G2	MI	TTM2AOE
DMEV8G2	MN	Adenosine A2a receptor (ADORA2A)
DMEV8G2	MT	DTT
DMEV8G2	MA	Inhibitor
DMEV8G2	RN	Benzo[1,2-c:5,4-c']dipyrazoles: non-xanthine adenosine antagonists. J Med Chem. 1988 Oct;31(10):2034-9.
DMEV8G2	RU	https://pubmed.ncbi.nlm.nih.gov/3172141

DMEV8G2	DI	DMEV8G2
DMEV8G2	DN	1,3-Diallyl-3,7-dihydro-purine-2,6-dione
DMEV8G2	MI	TTNE7KG
DMEV8G2	MN	Adenosine A2b receptor (ADORA2B)
DMEV8G2	MT	DTT
DMEV8G2	MA	Inhibitor
DMEV8G2	RN	Benzo[1,2-c:5,4-c']dipyrazoles: non-xanthine adenosine antagonists. J Med Chem. 1988 Oct;31(10):2034-9.
DMEV8G2	RU	https://pubmed.ncbi.nlm.nih.gov/3172141

DM4G2IE	DI	DM4G2IE
DM4G2IE	DN	1,3-Diallyl-7-methyl-3,7-dihydro-purine-2,6-dione
DM4G2IE	MI	TTM2AOE
DM4G2IE	MN	Adenosine A2a receptor (ADORA2A)
DM4G2IE	MT	DTT
DM4G2IE	MA	Inhibitor
DM4G2IE	RN	Analogues of caffeine and theophylline: effect of structural alterations on affinity at adenosine receptors. J Med Chem. 1986 Jul;29(7):1305-8.
DM4G2IE	RU	https://pubmed.ncbi.nlm.nih.gov/3806581

DMMOBPN	DI	DMMOBPN
DMMOBPN	DN	1,3-dibenzyl urea
DMMOBPN	MI	TTMI6F5
DMMOBPN	MN	Transient receptor potential cation channel V1 (TRPV1)
DMMOBPN	MT	DTT
DMMOBPN	MA	Inhibitor
DMMOBPN	RN	Rare dipeptide and urea derivatives from roots of Moringa oleifera as potential anti-inflammatory and antinociceptive agents. Eur J Med Chem. 2009 Jan;44(1):432-6.
DMMOBPN	RU	https://pubmed.ncbi.nlm.nih.gov/18243423

DM8NARQ	DI	DM8NARQ
DM8NARQ	DN	1,3-Dibenzyl-[1,3]diazetidine-2,4-dione
DM8NARQ	MI	TTQAJF1
DM8NARQ	MN	Cathepsin G (CTSG)
DM8NARQ	MT	DTT
DM8NARQ	MA	Inhibitor
DM8NARQ	RN	Inhibition of serine proteases: activity of 1,3-diazetidine-2,4-diones. Bioorg Med Chem Lett. 2001 Jul 9;11(13):1691-4.
DM8NARQ	RU	https://pubmed.ncbi.nlm.nih.gov/11425539

DM8NARQ	DI	DM8NARQ
DM8NARQ	DN	1,3-Dibenzyl-[1,3]diazetidine-2,4-dione
DM8NARQ	MI	TT2WR1T
DM8NARQ	MN	Cationic trypsinogen (PRSS1)
DM8NARQ	MT	DTT
DM8NARQ	MA	Inhibitor
DM8NARQ	RN	Inhibition of serine proteases: activity of 1,3-diazetidine-2,4-diones. Bioorg Med Chem Lett. 2001 Jul 9;11(13):1691-4.
DM8NARQ	RU	https://pubmed.ncbi.nlm.nih.gov/11425539

DM2WSG5	DI	DM2WSG5
DM2WSG5	DN	1,3-Dibenzyl-3,7-dihydro-purine-2,6-dione
DM2WSG5	MI	TTM2AOE
DM2WSG5	MN	Adenosine A2a receptor (ADORA2A)
DM2WSG5	MT	DTT
DM2WSG5	MA	Inhibitor
DM2WSG5	RN	Analogues of caffeine and theophylline: effect of structural alterations on affinity at adenosine receptors. J Med Chem. 1986 Jul;29(7):1305-8.
DM2WSG5	RU	https://pubmed.ncbi.nlm.nih.gov/3806581

DMKYE16	DI	DMKYE16
DMKYE16	DN	1,3-Diethyl-3,7-dihydro-purine-2,6-dione
DMKYE16	MI	TTK25J1
DMKYE16	MN	Adenosine A1 receptor (ADORA1)
DMKYE16	MT	DTT
DMKYE16	MA	Inhibitor
DMKYE16	RN	Benzo[1,2-c:5,4-c']dipyrazoles: non-xanthine adenosine antagonists. J Med Chem. 1988 Oct;31(10):2034-9.
DMKYE16	RU	https://pubmed.ncbi.nlm.nih.gov/3172141

DMKYE16	DI	DMKYE16
DMKYE16	DN	1,3-Diethyl-3,7-dihydro-purine-2,6-dione
DMKYE16	MI	TTM2AOE
DMKYE16	MN	Adenosine A2a receptor (ADORA2A)
DMKYE16	MT	DTT
DMKYE16	MA	Inhibitor
DMKYE16	RN	Benzo[1,2-c:5,4-c']dipyrazoles: non-xanthine adenosine antagonists. J Med Chem. 1988 Oct;31(10):2034-9.
DMKYE16	RU	https://pubmed.ncbi.nlm.nih.gov/3172141

DMKYE16	DI	DMKYE16
DMKYE16	DN	1,3-Diethyl-3,7-dihydro-purine-2,6-dione
DMKYE16	MI	TTNE7KG
DMKYE16	MN	Adenosine A2b receptor (ADORA2B)
DMKYE16	MT	DTT
DMKYE16	MA	Inhibitor
DMKYE16	RN	Benzo[1,2-c:5,4-c']dipyrazoles: non-xanthine adenosine antagonists. J Med Chem. 1988 Oct;31(10):2034-9.
DMKYE16	RU	https://pubmed.ncbi.nlm.nih.gov/3172141

DMB9XR5	DI	DMB9XR5
DMB9XR5	DN	1,3-Dihydro-imidazo[4,5-b]quinolin-2-one
DMB9XR5	MI	TT06AWU
DMB9XR5	MN	Phosphodiesterase 3A (PDE3A)
DMB9XR5	MT	DTT
DMB9XR5	MA	Inhibitor
DMB9XR5	RN	1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-ones--inhibitors of blood platelet cAMP phosphodiesterase and induced aggregation. J Med Chem. 1991 Sep;34(9):2906-16.
DMB9XR5	RU	https://pubmed.ncbi.nlm.nih.gov/1654430

DM8CYOP	DI	DM8CYOP
DM8CYOP	DN	1,3-Dihydro-naphtho[2,3-d]imidazol-2-one
DM8CYOP	MI	TT06AWU
DM8CYOP	MN	Phosphodiesterase 3A (PDE3A)
DM8CYOP	MT	DTT
DM8CYOP	MA	Inhibitor
DM8CYOP	RN	1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-ones--inhibitors of blood platelet cAMP phosphodiesterase and induced aggregation. J Med Chem. 1991 Sep;34(9):2906-16.
DM8CYOP	RU	https://pubmed.ncbi.nlm.nih.gov/1654430

DMZ80CT	DI	DMZ80CT
DMZ80CT	DN	1,3-Diisobutyl-3,7-dihydro-purine-2,6-dione
DMZ80CT	MI	TTK25J1
DMZ80CT	MN	Adenosine A1 receptor (ADORA1)
DMZ80CT	MT	DTT
DMZ80CT	MA	Inhibitor
DMZ80CT	RN	Benzo[1,2-c:5,4-c']dipyrazoles: non-xanthine adenosine antagonists. J Med Chem. 1988 Oct;31(10):2034-9.
DMZ80CT	RU	https://pubmed.ncbi.nlm.nih.gov/3172141

DMZ80CT	DI	DMZ80CT
DMZ80CT	DN	1,3-Diisobutyl-3,7-dihydro-purine-2,6-dione
DMZ80CT	MI	TTM2AOE
DMZ80CT	MN	Adenosine A2a receptor (ADORA2A)
DMZ80CT	MT	DTT
DMZ80CT	MA	Inhibitor
DMZ80CT	RN	Analogues of caffeine and theophylline: effect of structural alterations on affinity at adenosine receptors. J Med Chem. 1986 Jul;29(7):1305-8.
DMZ80CT	RU	https://pubmed.ncbi.nlm.nih.gov/3806581

DM1KND6	DI	DM1KND6
DM1KND6	DN	1,3-Diphenyl-1H-chromeno[4,3-c]pyrazol-4-one
DM1KND6	MI	TT1MPAY
DM1KND6	MN	GABA(A) receptor alpha-1 (GABRA1)
DM1KND6	MT	DTT
DM1KND6	MA	Inhibitor
DM1KND6	RN	Synthesis, binding studies, and structure-activity relationships of 1-aryl-and 2-aryl[1]benzopyranopyrazol-4-ones, central benzodiazepine receptor ... J Med Chem. 1988 Jan;31(1):1-3.
DM1KND6	RU	https://pubmed.ncbi.nlm.nih.gov/2826782

DM1KND6	DI	DM1KND6
DM1KND6	DN	1,3-Diphenyl-1H-chromeno[4,3-c]pyrazol-4-one
DM1KND6	MI	TT06RH5
DM1KND6	MN	GABA(A) receptor gamma-2 (GABRG2)
DM1KND6	MT	DTT
DM1KND6	MA	Inhibitor
DM1KND6	RN	Synthesis, binding studies, and structure-activity relationships of 1-aryl-and 2-aryl[1]benzopyranopyrazol-4-ones, central benzodiazepine receptor ... J Med Chem. 1988 Jan;31(1):1-3.
DM1KND6	RU	https://pubmed.ncbi.nlm.nih.gov/2826782

DM1KND6	DI	DM1KND6
DM1KND6	DN	1,3-Diphenyl-1H-chromeno[4,3-c]pyrazol-4-one
DM1KND6	MI	TTNJYV2
DM1KND6	MN	Gamma-aminobutyric acid receptor (GAR)
DM1KND6	MT	DTT
DM1KND6	MA	Inhibitor
DM1KND6	RN	Synthesis, binding studies, and structure-activity relationships of 1-aryl-and 2-aryl[1]benzopyranopyrazol-4-ones, central benzodiazepine receptor ... J Med Chem. 1988 Jan;31(1):1-3.
DM1KND6	RU	https://pubmed.ncbi.nlm.nih.gov/2826782

DMI4H05	DI	DMI4H05
DMI4H05	DN	1,3-DIPHENYLUREA
DMI4H05	MI	TT7WVHI
DMI4H05	MN	Soluble epoxide hydrolase (EPHX2)
DMI4H05	MT	DTT
DMI4H05	MA	Inhibitor
DMI4H05	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMI4H05	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMUL2B3	DI	DMUL2B3
DMUL2B3	DN	1,3-Dipropyl-3,7-dihydro-purine-2,6-dione
DMUL2B3	MI	TTK25J1
DMUL2B3	MN	Adenosine A1 receptor (ADORA1)
DMUL2B3	MT	DTT
DMUL2B3	MA	Inhibitor
DMUL2B3	RN	Benzo[1,2-c:5,4-c']dipyrazoles: non-xanthine adenosine antagonists. J Med Chem. 1988 Oct;31(10):2034-9.
DMUL2B3	RU	https://pubmed.ncbi.nlm.nih.gov/3172141

DMUL2B3	DI	DMUL2B3
DMUL2B3	DN	1,3-Dipropyl-3,7-dihydro-purine-2,6-dione
DMUL2B3	MI	TTM2AOE
DMUL2B3	MN	Adenosine A2a receptor (ADORA2A)
DMUL2B3	MT	DTT
DMUL2B3	MA	Inhibitor
DMUL2B3	RN	Benzo[1,2-c:5,4-c']dipyrazoles: non-xanthine adenosine antagonists. J Med Chem. 1988 Oct;31(10):2034-9.
DMUL2B3	RU	https://pubmed.ncbi.nlm.nih.gov/3172141

DMUL2B3	DI	DMUL2B3
DMUL2B3	DN	1,3-Dipropyl-3,7-dihydro-purine-2,6-dione
DMUL2B3	MI	TTNE7KG
DMUL2B3	MN	Adenosine A2b receptor (ADORA2B)
DMUL2B3	MT	DTT
DMUL2B3	MA	Inhibitor
DMUL2B3	RN	Benzo[1,2-c:5,4-c']dipyrazoles: non-xanthine adenosine antagonists. J Med Chem. 1988 Oct;31(10):2034-9.
DMUL2B3	RU	https://pubmed.ncbi.nlm.nih.gov/3172141

DMHNUWG	DI	DMHNUWG
DMHNUWG	DN	1,3-Di-p-tolyl-[1,3]diazetidine-2,4-dione
DMHNUWG	MI	TT2WR1T
DMHNUWG	MN	Cationic trypsinogen (PRSS1)
DMHNUWG	MT	DTT
DMHNUWG	MA	Inhibitor
DMHNUWG	RN	Inhibition of serine proteases: activity of 1,3-diazetidine-2,4-diones. Bioorg Med Chem Lett. 2001 Jul 9;11(13):1691-4.
DMHNUWG	RU	https://pubmed.ncbi.nlm.nih.gov/11425539

DM04KS1	DI	DM04KS1
DM04KS1	DN	1,3-ditolylguanidine
DM04KS1	MI	TTLD29N
DM04KS1	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DM04KS1	MT	DTT
DM04KS1	MA	Inhibitor
DM04KS1	RN	Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302.
DM04KS1	RU	https://pubmed.ncbi.nlm.nih.gov/9703475

DM04KS1	DI	DM04KS1
DM04KS1	DN	1,3-ditolylguanidine
DM04KS1	MI	TTKJEMQ
DM04KS1	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DM04KS1	MT	DTT
DM04KS1	MA	Inhibitor
DM04KS1	RN	Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302.
DM04KS1	RU	https://pubmed.ncbi.nlm.nih.gov/9703475

DM04KS1	DI	DM04KS1
DM04KS1	DN	1,3-ditolylguanidine
DM04KS1	MI	TTN9D8E
DM04KS1	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DM04KS1	MT	DTT
DM04KS1	MA	Inhibitor
DM04KS1	RN	Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302.
DM04KS1	RU	https://pubmed.ncbi.nlm.nih.gov/9703475

DM04KS1	DI	DM04KS1
DM04KS1	DN	1,3-ditolylguanidine
DM04KS1	MI	TT5TPI6
DM04KS1	MN	Opioid receptor sigma 1 (OPRS1)
DM04KS1	MT	DTT
DM04KS1	MA	Agonist
DM04KS1	RN	Sigma1 and sigma2 receptor binding affinity and selectivity of SA4503 and fluoroethyl SA4503. Synapse. 2006 May;59(6):350-8.
DM04KS1	RU	https://pubmed.ncbi.nlm.nih.gov/16463398

DM04KS1	DI	DM04KS1
DM04KS1	DN	1,3-ditolylguanidine
DM04KS1	MI	TT9NXW4
DM04KS1	MN	Sigma intracellular receptor 2 (TMEM97)
DM04KS1	MT	DTT
DM04KS1	MA	Agonist
DM04KS1	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2553).
DM04KS1	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2553

DMVBI2C	DI	DMVBI2C
DMVBI2C	DN	1,3-propanediphosphonic acid
DMVBI2C	MI	TTU6BFZ
DMVBI2C	MN	Candida Thymidylate synthase (Candi TMP1)
DMVBI2C	MT	DTT
DMVBI2C	MA	Inhibitor
DMVBI2C	RN	Novel approaches for targeting thymidylate synthase to overcome the resistance and toxicity of anticancer drugs. J Med Chem. 2010 Sep 23;53(18):6539-49.
DMVBI2C	RU	https://pubmed.ncbi.nlm.nih.gov/20527892

DMLBHXN	DI	DMLBHXN
DMLBHXN	DN	1,4-bis-(Dmt-Tic-amino)butane
DMLBHXN	MI	TT27RFC
DMLBHXN	MN	Opioid receptor delta (OPRD1)
DMLBHXN	MT	DTT
DMLBHXN	MA	Inhibitor
DMLBHXN	RN	Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists. J Med Chem. 2005 Dec 15;48(25):8035-44.
DMLBHXN	RU	https://pubmed.ncbi.nlm.nih.gov/16335927

DMLBHXN	DI	DMLBHXN
DMLBHXN	DN	1,4-bis-(Dmt-Tic-amino)butane
DMLBHXN	MI	TTKWM86
DMLBHXN	MN	Opioid receptor mu (MOP)
DMLBHXN	MT	DTT
DMLBHXN	MA	Inhibitor
DMLBHXN	RN	Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists. J Med Chem. 2005 Dec 15;48(25):8035-44.
DMLBHXN	RU	https://pubmed.ncbi.nlm.nih.gov/16335927

DMC4LMT	DI	DMC4LMT
DMC4LMT	DN	1,4-bis(malimido)xylene
DMC4LMT	MI	TTDP1UC
DMC4LMT	MN	Fatty acid amide hydrolase (FAAH)
DMC4LMT	MT	DTT
DMC4LMT	MA	Inhibitor
DMC4LMT	RN	Synthesis and in vitro evaluation of N-substituted maleimide derivatives as selective monoglyceride lipase inhibitors. J Med Chem. 2009 Dec 10;52(23):7410-20.
DMC4LMT	RU	https://pubmed.ncbi.nlm.nih.gov/19583260

DMVHKZT	DI	DMVHKZT
DMVHKZT	DN	1,4-Butanediol
DMVHKZT	MI	TTO8QRU
DMVHKZT	MN	Group IIA phospholipase A2 (GIIA sPLA2)
DMVHKZT	MT	DTT
DMVHKZT	MA	Inhibitor
DMVHKZT	RN	Drosophila metabolize 1,4-butanediol into gamma-hydroxybutyric acid in vivo. Eur J Pharmacol. 2003 Jul 25;473(2-3):149-52.
DMVHKZT	RU	https://pubmed.ncbi.nlm.nih.gov/12892832

DM87MWN	DI	DM87MWN
DM87MWN	DN	1,4-Di(berberine-9-O-yl)ethane dibromide
DM87MWN	MI	TT1RS9F
DM87MWN	MN	Acetylcholinesterase (AChE)
DM87MWN	MT	DTT
DM87MWN	MA	Inhibitor
DM87MWN	RN	Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase. Bioorg Med Chem. 2010 Jun 15;18(12):4475-84.
DM87MWN	RU	https://pubmed.ncbi.nlm.nih.gov/20471843

DM87MWN	DI	DM87MWN
DM87MWN	DN	1,4-Di(berberine-9-O-yl)ethane dibromide
DM87MWN	MI	TTEB0GD
DM87MWN	MN	Cholinesterase (BCHE)
DM87MWN	MT	DTT
DM87MWN	MA	Inhibitor
DM87MWN	RN	Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase. Bioorg Med Chem. 2010 Jun 15;18(12):4475-84.
DM87MWN	RU	https://pubmed.ncbi.nlm.nih.gov/20471843

DMIHYKG	DI	DMIHYKG
DMIHYKG	DN	1,4-diaminoanthracene-9,10-dione
DMIHYKG	MI	TTM2AOE
DMIHYKG	MN	Adenosine A2a receptor (ADORA2A)
DMIHYKG	MT	DTT
DMIHYKG	MA	Inhibitor
DMIHYKG	RN	Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. J Med Chem. 2010 Feb 25;53(4):1799-809.
DMIHYKG	RU	https://pubmed.ncbi.nlm.nih.gov/20095623

DMB5VQK	DI	DMB5VQK
DMB5VQK	DN	1,4-dideoxy-1,4-imino-D-arabinito
DMB5VQK	MI	TTXWASR
DMB5VQK	MN	Intestinal maltase-glucoamylase (MGAM)
DMB5VQK	MT	DTT
DMB5VQK	MA	Inhibitor
DMB5VQK	RN	New sugar-mimic alkaloids from the pods of Angylocalyx pynaertii. J Nat Prod. 2002 Feb;65(2):198-202.
DMB5VQK	RU	https://pubmed.ncbi.nlm.nih.gov/11858756

DM4RD2S	DI	DM4RD2S
DM4RD2S	DN	1,4-Dideoxy-5-Dehydro-O2-Sulfo-Glucuronic Acid
DM4RD2S	MI	TTGKIED
DM4RD2S	MN	Fibroblast growth factor-2 (FGF2)
DM4RD2S	MT	DTT
DM4RD2S	MA	Inhibitor
DM4RD2S	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM4RD2S	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9KUQZ	DI	DM9KUQZ
DM9KUQZ	DN	1,4-Dideoxy-O2-Sulfo-Glucuronic Acid
DM9KUQZ	MI	TTGKIED
DM9KUQZ	MN	Fibroblast growth factor-2 (FGF2)
DM9KUQZ	MT	DTT
DM9KUQZ	MA	Inhibitor
DM9KUQZ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9KUQZ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMI36WC	DI	DMI36WC
DMI36WC	DN	1,4-Diethylene Dioxide
DMI36WC	MI	TTWMIDN
DMI36WC	MN	B-cell-activating factor (TNFSF13B)
DMI36WC	MT	DTT
DMI36WC	MA	Inhibitor
DMI36WC	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMI36WC	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMNHGVD	DI	DMNHGVD
DMNHGVD	DN	1,4-Dihydro-1-methyl-4-oxo-3-pyridinesulfonamide
DMNHGVD	MI	TTHQPL7
DMNHGVD	MN	Carbonic anhydrase I (CA-I)
DMNHGVD	MT	DTT
DMNHGVD	MA	Inhibitor
DMNHGVD	RN	Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the... Eur J Med Chem. 2010 Sep;45(9):3656-61.
DMNHGVD	RU	https://pubmed.ncbi.nlm.nih.gov/20554082

DMNHGVD	DI	DMNHGVD
DMNHGVD	DN	1,4-Dihydro-1-methyl-4-oxo-3-pyridinesulfonamide
DMNHGVD	MI	TTANPDJ
DMNHGVD	MN	Carbonic anhydrase II (CA-II)
DMNHGVD	MT	DTT
DMNHGVD	MA	Inhibitor
DMNHGVD	RN	Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the... Eur J Med Chem. 2010 Sep;45(9):3656-61.
DMNHGVD	RU	https://pubmed.ncbi.nlm.nih.gov/20554082

DMNHGVD	DI	DMNHGVD
DMNHGVD	DN	1,4-Dihydro-1-methyl-4-oxo-3-pyridinesulfonamide
DMNHGVD	MI	TT2LVK8
DMNHGVD	MN	Carbonic anhydrase IX (CA-IX)
DMNHGVD	MT	DTT
DMNHGVD	MA	Inhibitor
DMNHGVD	RN	Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the... Eur J Med Chem. 2010 Sep;45(9):3656-61.
DMNHGVD	RU	https://pubmed.ncbi.nlm.nih.gov/20554082

DMNHGVD	DI	DMNHGVD
DMNHGVD	DN	1,4-Dihydro-1-methyl-4-oxo-3-pyridinesulfonamide
DMNHGVD	MI	TTSYM0R
DMNHGVD	MN	Carbonic anhydrase XII (CA-XII)
DMNHGVD	MT	DTT
DMNHGVD	MA	Inhibitor
DMNHGVD	RN	Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the... Eur J Med Chem. 2010 Sep;45(9):3656-61.
DMNHGVD	RU	https://pubmed.ncbi.nlm.nih.gov/20554082

DMMGP9X	DI	DMMGP9X
DMMGP9X	DN	1,4-dihydroindeno[1,2-c]-pyrazole
DMMGP9X	MI	TT6OEDT
DMMGP9X	MN	Cannabinoid receptor 1 (CB1)
DMMGP9X	MT	DTT
DMMGP9X	MA	Inhibitor
DMMGP9X	RN	Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2',4'-dichl... J Med Chem. 2005 Nov 17;48(23):7351-62.
DMMGP9X	RU	https://pubmed.ncbi.nlm.nih.gov/16279795

DMMGP9X	DI	DMMGP9X
DMMGP9X	DN	1,4-dihydroindeno[1,2-c]-pyrazole
DMMGP9X	MI	TTMSFAW
DMMGP9X	MN	Cannabinoid receptor 2 (CB2)
DMMGP9X	MT	DTT
DMMGP9X	MA	Inhibitor
DMMGP9X	RN	Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2',4'-dichl... J Med Chem. 2005 Nov 17;48(23):7351-62.
DMMGP9X	RU	https://pubmed.ncbi.nlm.nih.gov/16279795

DMRT13B	DI	DMRT13B
DMRT13B	DN	1,4-Dimethylquinolin-2(1H)-one
DMRT13B	MI	TTJLP0R
DMRT13B	MN	Quinone reductase 2 (NQO2)
DMRT13B	MT	DTT
DMRT13B	MA	Inhibitor
DMRT13B	RN	Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities. J Med Chem. 2009 Apr 9;52(7):1873-84.
DMRT13B	RU	https://pubmed.ncbi.nlm.nih.gov/19265439

DMFY3VS	DI	DMFY3VS
DMFY3VS	DN	1,4-diphenyl-(1E,3E)-1,3-butadiene
DMFY3VS	MI	TTGP7BY
DMFY3VS	MN	Monoamine oxidase type B (MAO-B)
DMFY3VS	MT	DTT
DMFY3VS	MA	Inhibitor
DMFY3VS	RN	Docking studies on monoamine oxidase-B inhibitors: estimation of inhibition constants (K(i)) of a series of experimentally tested compounds. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4438-46.
DMFY3VS	RU	https://pubmed.ncbi.nlm.nih.gov/16137882

DMIFOXE	DI	DMIFOXE
DMIFOXE	DN	1,4-Dithiothreitol
DMIFOXE	MI	TTU6BFZ
DMIFOXE	MN	Candida Thymidylate synthase (Candi TMP1)
DMIFOXE	MT	DTT
DMIFOXE	MA	Inhibitor
DMIFOXE	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMIFOXE	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMIFOXE	DI	DMIFOXE
DMIFOXE	DN	1,4-Dithiothreitol
DMIFOXE	MI	TTPADOQ
DMIFOXE	MN	HMG-CoA reductase (HMGCR)
DMIFOXE	MT	DTT
DMIFOXE	MA	Inhibitor
DMIFOXE	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMIFOXE	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMIFOXE	DI	DMIFOXE
DMIFOXE	DN	1,4-Dithiothreitol
DMIFOXE	MI	TT6ZFQ4
DMIFOXE	MN	Rotamase B (PPIB)
DMIFOXE	MT	DTT
DMIFOXE	MA	Inhibitor
DMIFOXE	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMIFOXE	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMTCMH7	DI	DMTCMH7
DMTCMH7	DN	1,4-Naphthoquinone
DMTCMH7	MI	TTZJYKH
DMTCMH7	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMTCMH7	MT	DTT
DMTCMH7	MA	Inhibitor
DMTCMH7	RN	Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem. 2008 Mar 27;51(6):1706-18.
DMTCMH7	RU	https://pubmed.ncbi.nlm.nih.gov/18318466

DMTCMH7	DI	DMTCMH7
DMTCMH7	DN	1,4-Naphthoquinone
DMTCMH7	MI	TT3PQ2Y
DMTCMH7	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DMTCMH7	MT	DTT
DMTCMH7	MA	Inhibitor
DMTCMH7	RN	Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Chem Biol Interact. 2000 Jan 3;124(1):61-76.
DMTCMH7	RU	https://pubmed.ncbi.nlm.nih.gov/10658902

DMTCMH7	DI	DMTCMH7
DMTCMH7	DN	1,4-Naphthoquinone
DMTCMH7	MI	DEGLTNR
DMTCMH7	MN	Sulfide-quinone reductase (SQR)
DMTCMH7	MT	DME
DMTCMH7	MA	Metabolism
DMTCMH7	RN	The quinone-binding site of Acidithiobacillus ferrooxidans sulfide: quinone oxidoreductase controls both sulfide oxidation and quinone reduction. Biochem Cell Biol. 2016 Apr;94(2):159-66.
DMTCMH7	RU	https://pubmed.ncbi.nlm.nih.gov/26914540

DMEDBO2	DI	DMEDBO2
DMEDBO2	DN	1,4-phenylene disulfamate
DMEDBO2	MI	TTANPDJ
DMEDBO2	MN	Carbonic anhydrase II (CA-II)
DMEDBO2	MT	DTT
DMEDBO2	MA	Inhibitor
DMEDBO2	RN	Ligand-based and structure-based virtual screening to identify carbonic anhydrase IX inhibitors. Bioorg Med Chem. 2009 Jan 15;17(2):553-7.
DMEDBO2	RU	https://pubmed.ncbi.nlm.nih.gov/19097911

DMEDBO2	DI	DMEDBO2
DMEDBO2	DN	1,4-phenylene disulfamate
DMEDBO2	MI	TT2LVK8
DMEDBO2	MN	Carbonic anhydrase IX (CA-IX)
DMEDBO2	MT	DTT
DMEDBO2	MA	Inhibitor
DMEDBO2	RN	Ligand-based and structure-based virtual screening to identify carbonic anhydrase IX inhibitors. Bioorg Med Chem. 2009 Jan 15;17(2):553-7.
DMEDBO2	RU	https://pubmed.ncbi.nlm.nih.gov/19097911

DMF0RXK	DI	DMF0RXK
DMF0RXK	DN	1,5-bis(4-chlorophenyl)-1H-1,2,3-triazole
DMF0RXK	MI	TT6OEDT
DMF0RXK	MN	Cannabinoid receptor 1 (CB1)
DMF0RXK	MT	DTT
DMF0RXK	MA	Inhibitor
DMF0RXK	RN	Synthesis and CB1 cannabinoid receptor affinity of 4-alkoxycarbonyl-1,5-diaryl-1,2,3-triazoles. Bioorg Med Chem Lett. 2009 Feb 1;19(3):891-3.
DMF0RXK	RU	https://pubmed.ncbi.nlm.nih.gov/19097888

DMPOAB7	DI	DMPOAB7
DMPOAB7	DN	1,5-bis(4-hydroxyphenyl)penta-1,4-dien-3-one
DMPOAB7	MI	TTVG215
DMPOAB7	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DMPOAB7	MT	DTT
DMPOAB7	MA	Inhibitor
DMPOAB7	RN	Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues. Eur J Med Chem. 2008 Aug;43(8):1621-31.
DMPOAB7	RU	https://pubmed.ncbi.nlm.nih.gov/18249473

DMZU1GD	DI	DMZU1GD
DMZU1GD	DN	1,5-Dideoxy-1,5-imino-D-xylitol
DMZU1GD	MI	TT1B5PU
DMZU1GD	MN	Glucosylceramidase (GBA)
DMZU1GD	MT	DTT
DMZU1GD	MA	Inhibitor
DMZU1GD	RN	In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures. Bioorg Med Chem. 2008 Aug 1;16(15):7330-6.
DMZU1GD	RU	https://pubmed.ncbi.nlm.nih.gov/18595718

DMYA25G	DI	DMYA25G
DMYA25G	DN	1,5-Dihydro-imidazo[2,1-b]quinazolin-2-one
DMYA25G	MI	TT06AWU
DMYA25G	MN	Phosphodiesterase 3A (PDE3A)
DMYA25G	MT	DTT
DMYA25G	MA	Inhibitor
DMYA25G	RN	Inhibitors of cyclic AMP phosphodiesterase. 3. Synthesis and biological evaluation of pyrido and imidazolyl analogues of 1,2,3,5-tetrahydro-2-oxoim... J Med Chem. 1988 Nov;31(11):2136-45.
DMYA25G	RU	https://pubmed.ncbi.nlm.nih.gov/2846839

DMC7FLT	DI	DMC7FLT
DMC7FLT	DN	1,5-Dihydroxy-10H-anthracen-9-one
DMC7FLT	MI	TT2J34L
DMC7FLT	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMC7FLT	MT	DTT
DMC7FLT	MA	Inhibitor
DMC7FLT	RN	Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80.
DMC7FLT	RU	https://pubmed.ncbi.nlm.nih.gov/9371243

DMDFU6S	DI	DMDFU6S
DMDFU6S	DN	1,6-bis(4-(3-chlorophenyl)piperazin-1-yl)hexane
DMDFU6S	MI	TTSQIFT
DMDFU6S	MN	5-HT 1A receptor (HTR1A)
DMDFU6S	MT	DTT
DMDFU6S	MA	Inhibitor
DMDFU6S	RN	Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. J Med Chem. 2010 Jun 24;53(12):4803-7.
DMDFU6S	RU	https://pubmed.ncbi.nlm.nih.gov/20481570

DMDFU6S	DI	DMDFU6S
DMDFU6S	DN	1,6-bis(4-(3-chlorophenyl)piperazin-1-yl)hexane
DMDFU6S	MI	TTJQOD7
DMDFU6S	MN	5-HT 2A receptor (HTR2A)
DMDFU6S	MT	DTT
DMDFU6S	MA	Inhibitor
DMDFU6S	RN	Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. J Med Chem. 2010 Jun 24;53(12):4803-7.
DMDFU6S	RU	https://pubmed.ncbi.nlm.nih.gov/20481570

DMDFU6S	DI	DMDFU6S
DMDFU6S	DN	1,6-bis(4-(3-chlorophenyl)piperazin-1-yl)hexane
DMDFU6S	MI	TTEX248
DMDFU6S	MN	Dopamine D2 receptor (D2R)
DMDFU6S	MT	DTT
DMDFU6S	MA	Inhibitor
DMDFU6S	RN	Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. J Med Chem. 2010 Jun 24;53(12):4803-7.
DMDFU6S	RU	https://pubmed.ncbi.nlm.nih.gov/20481570

DMDFU6S	DI	DMDFU6S
DMDFU6S	DN	1,6-bis(4-(3-chlorophenyl)piperazin-1-yl)hexane
DMDFU6S	MI	TTQ6VDM
DMDFU6S	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMDFU6S	MT	DTT
DMDFU6S	MA	Inhibitor
DMDFU6S	RN	Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. J Med Chem. 2010 Jun 24;53(12):4803-7.
DMDFU6S	RU	https://pubmed.ncbi.nlm.nih.gov/20481570

DMNLUKS	DI	DMNLUKS
DMNLUKS	DN	1,6-bis(4-(3-methoxyphenyl)piperazin-1-yl)hexane
DMNLUKS	MI	TTSQIFT
DMNLUKS	MN	5-HT 1A receptor (HTR1A)
DMNLUKS	MT	DTT
DMNLUKS	MA	Inhibitor
DMNLUKS	RN	Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. J Med Chem. 2010 Jun 24;53(12):4803-7.
DMNLUKS	RU	https://pubmed.ncbi.nlm.nih.gov/20481570

DMNLUKS	DI	DMNLUKS
DMNLUKS	DN	1,6-bis(4-(3-methoxyphenyl)piperazin-1-yl)hexane
DMNLUKS	MI	TTJQOD7
DMNLUKS	MN	5-HT 2A receptor (HTR2A)
DMNLUKS	MT	DTT
DMNLUKS	MA	Inhibitor
DMNLUKS	RN	Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. J Med Chem. 2010 Jun 24;53(12):4803-7.
DMNLUKS	RU	https://pubmed.ncbi.nlm.nih.gov/20481570

DMNLUKS	DI	DMNLUKS
DMNLUKS	DN	1,6-bis(4-(3-methoxyphenyl)piperazin-1-yl)hexane
DMNLUKS	MI	TTEX248
DMNLUKS	MN	Dopamine D2 receptor (D2R)
DMNLUKS	MT	DTT
DMNLUKS	MA	Inhibitor
DMNLUKS	RN	Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. J Med Chem. 2010 Jun 24;53(12):4803-7.
DMNLUKS	RU	https://pubmed.ncbi.nlm.nih.gov/20481570

DMNLUKS	DI	DMNLUKS
DMNLUKS	DN	1,6-bis(4-(3-methoxyphenyl)piperazin-1-yl)hexane
DMNLUKS	MI	TTQ6VDM
DMNLUKS	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMNLUKS	MT	DTT
DMNLUKS	MA	Inhibitor
DMNLUKS	RN	Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. J Med Chem. 2010 Jun 24;53(12):4803-7.
DMNLUKS	RU	https://pubmed.ncbi.nlm.nih.gov/20481570

DM0GRMD	DI	DM0GRMD
DM0GRMD	DN	1,6-bis(4-(pyridin-2-yl)piperazin-1-yl)hexane
DM0GRMD	MI	TTSQIFT
DM0GRMD	MN	5-HT 1A receptor (HTR1A)
DM0GRMD	MT	DTT
DM0GRMD	MA	Inhibitor
DM0GRMD	RN	Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. J Med Chem. 2010 Jun 24;53(12):4803-7.
DM0GRMD	RU	https://pubmed.ncbi.nlm.nih.gov/20481570

DM0GRMD	DI	DM0GRMD
DM0GRMD	DN	1,6-bis(4-(pyridin-2-yl)piperazin-1-yl)hexane
DM0GRMD	MI	TTJQOD7
DM0GRMD	MN	5-HT 2A receptor (HTR2A)
DM0GRMD	MT	DTT
DM0GRMD	MA	Inhibitor
DM0GRMD	RN	Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. J Med Chem. 2010 Jun 24;53(12):4803-7.
DM0GRMD	RU	https://pubmed.ncbi.nlm.nih.gov/20481570

DM0GRMD	DI	DM0GRMD
DM0GRMD	DN	1,6-bis(4-(pyridin-2-yl)piperazin-1-yl)hexane
DM0GRMD	MI	TTEX248
DM0GRMD	MN	Dopamine D2 receptor (D2R)
DM0GRMD	MT	DTT
DM0GRMD	MA	Inhibitor
DM0GRMD	RN	Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. J Med Chem. 2010 Jun 24;53(12):4803-7.
DM0GRMD	RU	https://pubmed.ncbi.nlm.nih.gov/20481570

DM70ODN	DI	DM70ODN
DM70ODN	DN	1,6-bis(4'-aminophenyl)-hexa-1,3,5-triene
DM70ODN	MI	TTE4KHA
DM70ODN	MN	Amyloid beta A4 protein (APP)
DM70ODN	MT	DTT
DM70ODN	MA	Inhibitor
DM70ODN	RN	Synthesis of biphenyltrienes as probes for beta-amyloid plaques. J Med Chem. 2006 May 4;49(9):2841-4.
DM70ODN	RU	https://pubmed.ncbi.nlm.nih.gov/16640346

DMBCU6W	DI	DMBCU6W
DMBCU6W	DN	1,6-bis(4'-dimethylaminophenyl)-hexa-1,3,5-triene
DMBCU6W	MI	TTE4KHA
DMBCU6W	MN	Amyloid beta A4 protein (APP)
DMBCU6W	MT	DTT
DMBCU6W	MA	Inhibitor
DMBCU6W	RN	Synthesis of biphenyltrienes as probes for beta-amyloid plaques. J Med Chem. 2006 May 4;49(9):2841-4.
DMBCU6W	RU	https://pubmed.ncbi.nlm.nih.gov/16640346

DMEU3MN	DI	DMEU3MN
DMEU3MN	DN	1,6-Bis(4'-hydroxyphenyl)-hexa-1,3,5-triene
DMEU3MN	MI	TTE4KHA
DMEU3MN	MN	Amyloid beta A4 protein (APP)
DMEU3MN	MT	DTT
DMEU3MN	MA	Inhibitor
DMEU3MN	RN	Synthesis of biphenyltrienes as probes for beta-amyloid plaques. J Med Chem. 2006 May 4;49(9):2841-4.
DMEU3MN	RU	https://pubmed.ncbi.nlm.nih.gov/16640346

DM0D6JN	DI	DM0D6JN
DM0D6JN	DN	1,6-bis(4'-methylaminophenyl)-hexa-1,3,5-triene
DM0D6JN	MI	TTE4KHA
DM0D6JN	MN	Amyloid beta A4 protein (APP)
DM0D6JN	MT	DTT
DM0D6JN	MA	Inhibitor
DM0D6JN	RN	Synthesis of biphenyltrienes as probes for beta-amyloid plaques. J Med Chem. 2006 May 4;49(9):2841-4.
DM0D6JN	RU	https://pubmed.ncbi.nlm.nih.gov/16640346

DM5Z6XG	DI	DM5Z6XG
DM5Z6XG	DN	1,6-bis(4-m-tolylpiperazin-1-yl)hexane
DM5Z6XG	MI	TTSQIFT
DM5Z6XG	MN	5-HT 1A receptor (HTR1A)
DM5Z6XG	MT	DTT
DM5Z6XG	MA	Inhibitor
DM5Z6XG	RN	Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. J Med Chem. 2010 Jun 24;53(12):4803-7.
DM5Z6XG	RU	https://pubmed.ncbi.nlm.nih.gov/20481570

DM5Z6XG	DI	DM5Z6XG
DM5Z6XG	DN	1,6-bis(4-m-tolylpiperazin-1-yl)hexane
DM5Z6XG	MI	TTJQOD7
DM5Z6XG	MN	5-HT 2A receptor (HTR2A)
DM5Z6XG	MT	DTT
DM5Z6XG	MA	Inhibitor
DM5Z6XG	RN	Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. J Med Chem. 2010 Jun 24;53(12):4803-7.
DM5Z6XG	RU	https://pubmed.ncbi.nlm.nih.gov/20481570

DM5Z6XG	DI	DM5Z6XG
DM5Z6XG	DN	1,6-bis(4-m-tolylpiperazin-1-yl)hexane
DM5Z6XG	MI	TTEX248
DM5Z6XG	MN	Dopamine D2 receptor (D2R)
DM5Z6XG	MT	DTT
DM5Z6XG	MA	Inhibitor
DM5Z6XG	RN	Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. J Med Chem. 2010 Jun 24;53(12):4803-7.
DM5Z6XG	RU	https://pubmed.ncbi.nlm.nih.gov/20481570

DM5Z6XG	DI	DM5Z6XG
DM5Z6XG	DN	1,6-bis(4-m-tolylpiperazin-1-yl)hexane
DM5Z6XG	MI	TTQ6VDM
DM5Z6XG	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DM5Z6XG	MT	DTT
DM5Z6XG	MA	Inhibitor
DM5Z6XG	RN	Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. J Med Chem. 2010 Jun 24;53(12):4803-7.
DM5Z6XG	RU	https://pubmed.ncbi.nlm.nih.gov/20481570

DMQY75B	DI	DMQY75B
DMQY75B	DN	1,6-bis(4'-nitrophenyl)-hexa-1,3,5-triene
DMQY75B	MI	TTE4KHA
DMQY75B	MN	Amyloid beta A4 protein (APP)
DMQY75B	MT	DTT
DMQY75B	MA	Inhibitor
DMQY75B	RN	Synthesis of biphenyltrienes as probes for beta-amyloid plaques. J Med Chem. 2006 May 4;49(9):2841-4.
DMQY75B	RU	https://pubmed.ncbi.nlm.nih.gov/16640346

DMD3EUI	DI	DMD3EUI
DMD3EUI	DN	1,6-bis(4-phenylpiperazin-1-yl)hexane
DMD3EUI	MI	TTSQIFT
DMD3EUI	MN	5-HT 1A receptor (HTR1A)
DMD3EUI	MT	DTT
DMD3EUI	MA	Inhibitor
DMD3EUI	RN	Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. J Med Chem. 2010 Jun 24;53(12):4803-7.
DMD3EUI	RU	https://pubmed.ncbi.nlm.nih.gov/20481570

DMD3EUI	DI	DMD3EUI
DMD3EUI	DN	1,6-bis(4-phenylpiperazin-1-yl)hexane
DMD3EUI	MI	TTJQOD7
DMD3EUI	MN	5-HT 2A receptor (HTR2A)
DMD3EUI	MT	DTT
DMD3EUI	MA	Inhibitor
DMD3EUI	RN	Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. J Med Chem. 2010 Jun 24;53(12):4803-7.
DMD3EUI	RU	https://pubmed.ncbi.nlm.nih.gov/20481570

DMD3EUI	DI	DMD3EUI
DMD3EUI	DN	1,6-bis(4-phenylpiperazin-1-yl)hexane
DMD3EUI	MI	TTEX248
DMD3EUI	MN	Dopamine D2 receptor (D2R)
DMD3EUI	MT	DTT
DMD3EUI	MA	Inhibitor
DMD3EUI	RN	Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. J Med Chem. 2010 Jun 24;53(12):4803-7.
DMD3EUI	RU	https://pubmed.ncbi.nlm.nih.gov/20481570

DMD3EUI	DI	DMD3EUI
DMD3EUI	DN	1,6-bis(4-phenylpiperazin-1-yl)hexane
DMD3EUI	MI	TTQ6VDM
DMD3EUI	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMD3EUI	MT	DTT
DMD3EUI	MA	Inhibitor
DMD3EUI	RN	Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. J Med Chem. 2010 Jun 24;53(12):4803-7.
DMD3EUI	RU	https://pubmed.ncbi.nlm.nih.gov/20481570

DMRG2CU	DI	DMRG2CU
DMRG2CU	DN	1,6-bis-(Dmt-Tic-amino)hexane
DMRG2CU	MI	TT27RFC
DMRG2CU	MN	Opioid receptor delta (OPRD1)
DMRG2CU	MT	DTT
DMRG2CU	MA	Inhibitor
DMRG2CU	RN	Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists. J Med Chem. 2005 Dec 15;48(25):8035-44.
DMRG2CU	RU	https://pubmed.ncbi.nlm.nih.gov/16335927

DMRG2CU	DI	DMRG2CU
DMRG2CU	DN	1,6-bis-(Dmt-Tic-amino)hexane
DMRG2CU	MI	TTKWM86
DMRG2CU	MN	Opioid receptor mu (MOP)
DMRG2CU	MT	DTT
DMRG2CU	MA	Inhibitor
DMRG2CU	RN	Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists. J Med Chem. 2005 Dec 15;48(25):8035-44.
DMRG2CU	RU	https://pubmed.ncbi.nlm.nih.gov/16335927

DMMUZK9	DI	DMMUZK9
DMMUZK9	DN	1,6-bis-(N,N-dimethyl-Dmt-Tic-NH)hexane
DMMUZK9	MI	TT27RFC
DMMUZK9	MN	Opioid receptor delta (OPRD1)
DMMUZK9	MT	DTT
DMMUZK9	MA	Inhibitor
DMMUZK9	RN	Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists. J Med Chem. 2005 Dec 15;48(25):8035-44.
DMMUZK9	RU	https://pubmed.ncbi.nlm.nih.gov/16335927

DMMUZK9	DI	DMMUZK9
DMMUZK9	DN	1,6-bis-(N,N-dimethyl-Dmt-Tic-NH)hexane
DMMUZK9	MI	TTKWM86
DMMUZK9	MN	Opioid receptor mu (MOP)
DMMUZK9	MT	DTT
DMMUZK9	MA	Inhibitor
DMMUZK9	RN	Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists. J Med Chem. 2005 Dec 15;48(25):8035-44.
DMMUZK9	RU	https://pubmed.ncbi.nlm.nih.gov/16335927

DMLB3RT	DI	DMLB3RT
DMLB3RT	DN	1,6-hexamethylene diisocyanate
DMLB3RT	MI	TTELV3W
DMLB3RT	MN	Transformation-sensitive protein p120 (TRPA1)
DMLB3RT	MT	DTT
DMLB3RT	MA	Activator
DMLB3RT	RN	Transient receptor potential ankyrin 1 antagonists block the noxious effects of toxic industrial isocyanates and tear gases. FASEB J. 2009 Apr;23(4):1102-14.
DMLB3RT	RU	https://pubmed.ncbi.nlm.nih.gov/19036859

DMBU796	DI	DMBU796
DMBU796	DN	1,7,8,9-tetrahydro-1,5-diaza-trindene-4,6-dione
DMBU796	MI	TTVDSZ0
DMBU796	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMBU796	MT	DTT
DMBU796	MA	Inhibitor
DMBU796	RN	Synthesis and structure-activity relationships of novel poly(ADP-ribose) polymerase-1 inhibitors. Bioorg Med Chem Lett. 2006 Feb 15;16(4):938-42.
DMBU796	RU	https://pubmed.ncbi.nlm.nih.gov/16290935

DMVHE1P	DI	DMVHE1P
DMVHE1P	DN	1,8,9-Trimethoxy-9,10-dihydro-anthracene
DMVHE1P	MI	TT2J34L
DMVHE1P	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMVHE1P	MT	DTT
DMVHE1P	MA	Inhibitor
DMVHE1P	RN	Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80.
DMVHE1P	RU	https://pubmed.ncbi.nlm.nih.gov/9371243

DMKJGTH	DI	DMKJGTH
DMKJGTH	DN	1,8-bis-maleimidodiethyleneglycol
DMKJGTH	MI	TTDP1UC
DMKJGTH	MN	Fatty acid amide hydrolase (FAAH)
DMKJGTH	MT	DTT
DMKJGTH	MA	Inhibitor
DMKJGTH	RN	Synthesis and in vitro evaluation of N-substituted maleimide derivatives as selective monoglyceride lipase inhibitors. J Med Chem. 2009 Dec 10;52(23):7410-20.
DMKJGTH	RU	https://pubmed.ncbi.nlm.nih.gov/19583260

DMZK4DL	DI	DMZK4DL
DMZK4DL	DN	1,8-Dichloro-10H-anthracen-9-one
DMZK4DL	MI	TT2J34L
DMZK4DL	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMZK4DL	MT	DTT
DMZK4DL	MA	Inhibitor
DMZK4DL	RN	Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80.
DMZK4DL	RU	https://pubmed.ncbi.nlm.nih.gov/9371243

DMKJBRZ	DI	DMKJBRZ
DMKJBRZ	DN	1,8-Dichloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol
DMKJBRZ	MI	TTZAYWL
DMKJBRZ	MN	Estrogen receptor (ESR)
DMKJBRZ	MT	DTT
DMKJBRZ	MA	Inhibitor
DMKJBRZ	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DMKJBRZ	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMKJBRZ	DI	DMKJBRZ
DMKJBRZ	DN	1,8-Dichloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol
DMKJBRZ	MI	TTOM3J0
DMKJBRZ	MN	Estrogen receptor beta (ESR2)
DMKJBRZ	MT	DTT
DMKJBRZ	MA	Inhibitor
DMKJBRZ	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DMKJBRZ	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMDFBSX	DI	DMDFBSX
DMDFBSX	DN	1,8-Dihydroxy-2-propionyl-10H-anthracen-9-one
DMDFBSX	MI	TT2J34L
DMDFBSX	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMDFBSX	MT	DTT
DMDFBSX	MA	Inhibitor
DMDFBSX	RN	Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80.
DMDFBSX	RU	https://pubmed.ncbi.nlm.nih.gov/9371243

DMWC7QE	DI	DMWC7QE
DMWC7QE	DN	1,9-bis(pyridinium)-nonane dibromide
DMWC7QE	MI	TT1RS9F
DMWC7QE	MN	Acetylcholinesterase (AChE)
DMWC7QE	MT	DTT
DMWC7QE	MA	Inhibitor
DMWC7QE	RN	Preparation and in vitro screening of symmetrical bispyridinium cholinesterase inhibitors bearing different connecting linkage-initial study for My... Bioorg Med Chem Lett. 2010 Mar 1;20(5):1763-6.
DMWC7QE	RU	https://pubmed.ncbi.nlm.nih.gov/20138518

DMWC7QE	DI	DMWC7QE
DMWC7QE	DN	1,9-bis(pyridinium)-nonane dibromide
DMWC7QE	MI	TTEB0GD
DMWC7QE	MN	Cholinesterase (BCHE)
DMWC7QE	MT	DTT
DMWC7QE	MA	Inhibitor
DMWC7QE	RN	Preparation and in vitro screening of symmetrical bispyridinium cholinesterase inhibitors bearing different connecting linkage-initial study for My... Bioorg Med Chem Lett. 2010 Mar 1;20(5):1763-6.
DMWC7QE	RU	https://pubmed.ncbi.nlm.nih.gov/20138518

DMW613U	DI	DMW613U
DMW613U	DN	1,9-dideoxyforskolin
DMW613U	MI	TT0FC1V
DMW613U	MN	Volume regulated chloride channel (VRAC)
DMW613U	MT	DTT
DMW613U	MA	Blocker (channel blocker)
DMW613U	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 710).
DMW613U	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=710

DM7U0XW	DI	DM7U0XW
DM7U0XW	DN	1-[(3-Methoxybenzyl)amino]ethaniminium chloride
DM7U0XW	MI	TTZUFI5
DM7U0XW	MN	Nitric-oxide synthase brain (NOS1)
DM7U0XW	MT	DTT
DM7U0XW	MA	Inhibitor
DM7U0XW	RN	N-Substituted acetamidines and 2-methylimidazole derivatives as selective inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6495-9.
DM7U0XW	RU	https://pubmed.ncbi.nlm.nih.gov/20933416

DM3UHDW	DI	DM3UHDW
DM3UHDW	DN	1-[(3-methoxybenzyl)oxy]-2-(2-phenylethyl)benzene
DM3UHDW	MI	TTSQIFT
DM3UHDW	MN	5-HT 1A receptor (HTR1A)
DM3UHDW	MT	DTT
DM3UHDW	MA	Inhibitor
DM3UHDW	RN	Arylmethyloxyphenyl derivatives: small molecules displaying P-glycoprotein inhibition. J Med Chem. 2006 Nov 2;49(22):6607-13.
DM3UHDW	RU	https://pubmed.ncbi.nlm.nih.gov/17064079

DM3UHDW	DI	DM3UHDW
DM3UHDW	DN	1-[(3-methoxybenzyl)oxy]-2-(2-phenylethyl)benzene
DM3UHDW	MI	TTEX248
DM3UHDW	MN	Dopamine D2 receptor (D2R)
DM3UHDW	MT	DTT
DM3UHDW	MA	Inhibitor
DM3UHDW	RN	Arylmethyloxyphenyl derivatives: small molecules displaying P-glycoprotein inhibition. J Med Chem. 2006 Nov 2;49(22):6607-13.
DM3UHDW	RU	https://pubmed.ncbi.nlm.nih.gov/17064079

DMNJMGK	DI	DMNJMGK
DMNJMGK	DN	1-[(7-Fluoronaphth-2-yl)methyl]-1H-imidazole
DMNJMGK	MI	TTSZLWK
DMNJMGK	MN	Aromatase (CYP19A1)
DMNJMGK	MT	DTT
DMNJMGK	MA	Inhibitor
DMNJMGK	RN	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
DMNJMGK	RU	https://pubmed.ncbi.nlm.nih.gov/20413308

DM1JQPW	DI	DM1JQPW
DM1JQPW	DN	1-[(cyclohexylamino)ethyl]-1,1-bisphosphonicacid
DM1JQPW	MI	TTIKWV4
DM1JQPW	MN	Geranyltranstransferase (FDPS)
DM1JQPW	MT	DTT
DM1JQPW	MA	Inhibitor
DM1JQPW	RN	Synthesis and biological evaluation of 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl... Bioorg Med Chem. 2008 Mar 15;16(6):3283-90.
DM1JQPW	RU	https://pubmed.ncbi.nlm.nih.gov/18096393

DMQPFT3	DI	DMQPFT3
DMQPFT3	DN	1-[(Furan-2(5H)-one)-4-methyl]-desloratadine
DMQPFT3	MI	TTTIBOJ
DMQPFT3	MN	Histamine H1 receptor (H1R)
DMQPFT3	MT	DTT
DMQPFT3	MA	Inhibitor
DMQPFT3	RN	Stereoselective synthesis of desloratadine derivatives as antagonist of histamine. Bioorg Med Chem. 2010 Feb 15;18(4):1626-32.
DMQPFT3	RU	https://pubmed.ncbi.nlm.nih.gov/20110173

DM8VNYA	DI	DM8VNYA
DM8VNYA	DN	1-[(n-but-1-ylamino)ethyl]-1,1-bisphosphonic acid
DM8VNYA	MI	TTIKWV4
DM8VNYA	MN	Geranyltranstransferase (FDPS)
DM8VNYA	MT	DTT
DM8VNYA	MA	Inhibitor
DM8VNYA	RN	Synthesis and biological evaluation of 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl... Bioorg Med Chem. 2008 Mar 15;16(6):3283-90.
DM8VNYA	RU	https://pubmed.ncbi.nlm.nih.gov/18096393

DM4ABTN	DI	DM4ABTN
DM4ABTN	DN	1-[(n-hex-1-ylamino)ethyl]-1,1-bisphosphonic acid
DM4ABTN	MI	TTIKWV4
DM4ABTN	MN	Geranyltranstransferase (FDPS)
DM4ABTN	MT	DTT
DM4ABTN	MA	Inhibitor
DM4ABTN	RN	Synthesis and biological evaluation of 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl... Bioorg Med Chem. 2008 Mar 15;16(6):3283-90.
DM4ABTN	RU	https://pubmed.ncbi.nlm.nih.gov/18096393

DM9ZK0D	DI	DM9ZK0D
DM9ZK0D	DN	1-[(n-oct-1-ylamino)ethyl]-1,1-bisphosphonic acid
DM9ZK0D	MI	TTIKWV4
DM9ZK0D	MN	Geranyltranstransferase (FDPS)
DM9ZK0D	MT	DTT
DM9ZK0D	MA	Inhibitor
DM9ZK0D	RN	Synthesis and biological evaluation of 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl... Bioorg Med Chem. 2008 Mar 15;16(6):3283-90.
DM9ZK0D	RU	https://pubmed.ncbi.nlm.nih.gov/18096393

DMCRHVI	DI	DMCRHVI
DMCRHVI	DN	1-[(prop-1-ylamino)ethyl]-1,1-bisphosphonic acid
DMCRHVI	MI	TTIKWV4
DMCRHVI	MN	Geranyltranstransferase (FDPS)
DMCRHVI	MT	DTT
DMCRHVI	MA	Inhibitor
DMCRHVI	RN	Synthesis and biological evaluation of 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl... Bioorg Med Chem. 2008 Mar 15;16(6):3283-90.
DMCRHVI	RU	https://pubmed.ncbi.nlm.nih.gov/18096393

DMSCN8J	DI	DMSCN8J
DMSCN8J	DN	1-[(prop-2-ylamino)ethyl]-1,1-bisphosphonicacid
DMSCN8J	MI	TTIKWV4
DMSCN8J	MN	Geranyltranstransferase (FDPS)
DMSCN8J	MT	DTT
DMSCN8J	MA	Inhibitor
DMSCN8J	RN	Synthesis and biological evaluation of 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl... Bioorg Med Chem. 2008 Mar 15;16(6):3283-90.
DMSCN8J	RU	https://pubmed.ncbi.nlm.nih.gov/18096393

DMLDY3H	DI	DMLDY3H
DMLDY3H	DN	1-[(tert-butylamino)ethyl]-1,1-bisphosphonicacid
DMLDY3H	MI	TTIKWV4
DMLDY3H	MN	Geranyltranstransferase (FDPS)
DMLDY3H	MT	DTT
DMLDY3H	MA	Inhibitor
DMLDY3H	RN	Synthesis and biological evaluation of 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl... Bioorg Med Chem. 2008 Mar 15;16(6):3283-90.
DMLDY3H	RU	https://pubmed.ncbi.nlm.nih.gov/18096393

DMU3VWA	DI	DMU3VWA
DMU3VWA	DN	1-[(Z)-4-(triphenylmethoxy)-2-butenyl]thymine
DMU3VWA	MI	TTP3QRF
DMU3VWA	MN	Thymidine kinase 1 (TK1)
DMU3VWA	MT	DTT
DMU3VWA	MA	Inhibitor
DMU3VWA	RN	N1-substituted thymine derivatives as mitochondrial thymidine kinase (TK-2) inhibitors. J Med Chem. 2006 Dec 28;49(26):7766-73.
DMU3VWA	RU	https://pubmed.ncbi.nlm.nih.gov/17181158

DMU3VWA	DI	DMU3VWA
DMU3VWA	DN	1-[(Z)-4-(triphenylmethoxy)-2-butenyl]thymine
DMU3VWA	MI	TT7KNZQ
DMU3VWA	MN	Thymidine kinase 2 (Mt-TK2)
DMU3VWA	MT	DTT
DMU3VWA	MA	Inhibitor
DMU3VWA	RN	N1-substituted thymine derivatives as mitochondrial thymidine kinase (TK-2) inhibitors. J Med Chem. 2006 Dec 28;49(26):7766-73.
DMU3VWA	RU	https://pubmed.ncbi.nlm.nih.gov/17181158

DMIHBFO	DI	DMIHBFO
DMIHBFO	DN	1-[(Z)-4-trityloxy-2-butenyl]uracil
DMIHBFO	MI	TTY8KJS
DMIHBFO	MN	Bacterial Deoxyuridine triphosphate nucleotidohydrolase (Bact dut)
DMIHBFO	MT	DTT
DMIHBFO	MA	Inhibitor
DMIHBFO	RN	Acyclic nucleoside analogues as inhibitors of Plasmodium falciparum dUTPase. J Med Chem. 2006 Jul 13;49(14):4183-95.
DMIHBFO	RU	https://pubmed.ncbi.nlm.nih.gov/16821778

DMEHP8M	DI	DMEHP8M
DMEHP8M	DN	1-[2-(2,4,6-trimethyl-phenyl)-ethyl]-pyrrolidine
DMEHP8M	MI	TT9JNIC
DMEHP8M	MN	Histamine H3 receptor (H3R)
DMEHP8M	MT	DTT
DMEHP8M	MA	Inhibitor
DMEHP8M	RN	In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9.
DMEHP8M	RU	https://pubmed.ncbi.nlm.nih.gov/18077160

DMTNRG7	DI	DMTNRG7
DMTNRG7	DN	1-[2-(2-Benzyl-phenoxy)-ethyl]-piperidine
DMTNRG7	MI	TTZFYLI
DMTNRG7	MN	Dopamine D1 receptor (D1R)
DMTNRG7	MT	DTT
DMTNRG7	MA	Inhibitor
DMTNRG7	RN	Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
DMTNRG7	RU	https://pubmed.ncbi.nlm.nih.gov/15293986

DMTNRG7	DI	DMTNRG7
DMTNRG7	DN	1-[2-(2-Benzyl-phenoxy)-ethyl]-piperidine
DMTNRG7	MI	TTEX248
DMTNRG7	MN	Dopamine D2 receptor (D2R)
DMTNRG7	MT	DTT
DMTNRG7	MA	Inhibitor
DMTNRG7	RN	Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
DMTNRG7	RU	https://pubmed.ncbi.nlm.nih.gov/15293986

DMTNRG7	DI	DMTNRG7
DMTNRG7	DN	1-[2-(2-Benzyl-phenoxy)-ethyl]-piperidine
DMTNRG7	MI	TT4C8EA
DMTNRG7	MN	Dopamine D3 receptor (D3R)
DMTNRG7	MT	DTT
DMTNRG7	MA	Inhibitor
DMTNRG7	RN	Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
DMTNRG7	RU	https://pubmed.ncbi.nlm.nih.gov/15293986

DMTNRG7	DI	DMTNRG7
DMTNRG7	DN	1-[2-(2-Benzyl-phenoxy)-ethyl]-piperidine
DMTNRG7	MI	TTE0A2F
DMTNRG7	MN	Dopamine D4 receptor (D4R)
DMTNRG7	MT	DTT
DMTNRG7	MA	Inhibitor
DMTNRG7	RN	Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
DMTNRG7	RU	https://pubmed.ncbi.nlm.nih.gov/15293986

DMTNRG7	DI	DMTNRG7
DMTNRG7	DN	1-[2-(2-Benzyl-phenoxy)-ethyl]-piperidine
DMTNRG7	MI	TTS2PH3
DMTNRG7	MN	Dopamine D5 receptor (D5R)
DMTNRG7	MT	DTT
DMTNRG7	MA	Inhibitor
DMTNRG7	RN	Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
DMTNRG7	RU	https://pubmed.ncbi.nlm.nih.gov/15293986

DMLSU30	DI	DMLSU30
DMLSU30	DN	1-[2-(2-Benzyl-phenoxy)-ethyl]-pyrrolidine
DMLSU30	MI	TTZFYLI
DMLSU30	MN	Dopamine D1 receptor (D1R)
DMLSU30	MT	DTT
DMLSU30	MA	Inhibitor
DMLSU30	RN	Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
DMLSU30	RU	https://pubmed.ncbi.nlm.nih.gov/15293986

DMLSU30	DI	DMLSU30
DMLSU30	DN	1-[2-(2-Benzyl-phenoxy)-ethyl]-pyrrolidine
DMLSU30	MI	TT4C8EA
DMLSU30	MN	Dopamine D3 receptor (D3R)
DMLSU30	MT	DTT
DMLSU30	MA	Inhibitor
DMLSU30	RN	Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
DMLSU30	RU	https://pubmed.ncbi.nlm.nih.gov/15293986

DMLSU30	DI	DMLSU30
DMLSU30	DN	1-[2-(2-Benzyl-phenoxy)-ethyl]-pyrrolidine
DMLSU30	MI	TTE0A2F
DMLSU30	MN	Dopamine D4 receptor (D4R)
DMLSU30	MT	DTT
DMLSU30	MA	Inhibitor
DMLSU30	RN	Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
DMLSU30	RU	https://pubmed.ncbi.nlm.nih.gov/15293986

DMLSU30	DI	DMLSU30
DMLSU30	DN	1-[2-(2-Benzyl-phenoxy)-ethyl]-pyrrolidine
DMLSU30	MI	TTS2PH3
DMLSU30	MN	Dopamine D5 receptor (D5R)
DMLSU30	MT	DTT
DMLSU30	MA	Inhibitor
DMLSU30	RN	Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
DMLSU30	RU	https://pubmed.ncbi.nlm.nih.gov/15293986

DMDZA83	DI	DMDZA83
DMDZA83	DN	1-[2-(2-triphenylmethoxyethoxy)ethyl]thymine
DMDZA83	MI	TTP3QRF
DMDZA83	MN	Thymidine kinase 1 (TK1)
DMDZA83	MT	DTT
DMDZA83	MA	Inhibitor
DMDZA83	RN	N1-substituted thymine derivatives as mitochondrial thymidine kinase (TK-2) inhibitors. J Med Chem. 2006 Dec 28;49(26):7766-73.
DMDZA83	RU	https://pubmed.ncbi.nlm.nih.gov/17181158

DM98F0U	DI	DM98F0U
DM98F0U	DN	1-[2-(trityloxy)ethoxymethyl]uracil
DM98F0U	MI	TTY8KJS
DM98F0U	MN	Bacterial Deoxyuridine triphosphate nucleotidohydrolase (Bact dut)
DM98F0U	MT	DTT
DM98F0U	MA	Inhibitor
DM98F0U	RN	Acyclic nucleoside analogues as inhibitors of Plasmodium falciparum dUTPase. J Med Chem. 2006 Jul 13;49(14):4183-95.
DM98F0U	RU	https://pubmed.ncbi.nlm.nih.gov/16821778

DMD2NXL	DI	DMD2NXL
DMD2NXL	DN	1-[3-(2-Benzyl-phenoxy)-propyl]-pyrrolidine
DMD2NXL	MI	TTZFYLI
DMD2NXL	MN	Dopamine D1 receptor (D1R)
DMD2NXL	MT	DTT
DMD2NXL	MA	Inhibitor
DMD2NXL	RN	Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
DMD2NXL	RU	https://pubmed.ncbi.nlm.nih.gov/15293986

DMD2NXL	DI	DMD2NXL
DMD2NXL	DN	1-[3-(2-Benzyl-phenoxy)-propyl]-pyrrolidine
DMD2NXL	MI	TTEX248
DMD2NXL	MN	Dopamine D2 receptor (D2R)
DMD2NXL	MT	DTT
DMD2NXL	MA	Inhibitor
DMD2NXL	RN	Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
DMD2NXL	RU	https://pubmed.ncbi.nlm.nih.gov/15293986

DMD2NXL	DI	DMD2NXL
DMD2NXL	DN	1-[3-(2-Benzyl-phenoxy)-propyl]-pyrrolidine
DMD2NXL	MI	TT4C8EA
DMD2NXL	MN	Dopamine D3 receptor (D3R)
DMD2NXL	MT	DTT
DMD2NXL	MA	Inhibitor
DMD2NXL	RN	Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
DMD2NXL	RU	https://pubmed.ncbi.nlm.nih.gov/15293986

DMD2NXL	DI	DMD2NXL
DMD2NXL	DN	1-[3-(2-Benzyl-phenoxy)-propyl]-pyrrolidine
DMD2NXL	MI	TTE0A2F
DMD2NXL	MN	Dopamine D4 receptor (D4R)
DMD2NXL	MT	DTT
DMD2NXL	MA	Inhibitor
DMD2NXL	RN	Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
DMD2NXL	RU	https://pubmed.ncbi.nlm.nih.gov/15293986

DMD2NXL	DI	DMD2NXL
DMD2NXL	DN	1-[3-(2-Benzyl-phenoxy)-propyl]-pyrrolidine
DMD2NXL	MI	TTS2PH3
DMD2NXL	MN	Dopamine D5 receptor (D5R)
DMD2NXL	MT	DTT
DMD2NXL	MA	Inhibitor
DMD2NXL	RN	Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
DMD2NXL	RU	https://pubmed.ncbi.nlm.nih.gov/15293986

DMLRS8I	DI	DMLRS8I
DMLRS8I	DN	1-[3-(3-biphenyl)-(1,2,4-triazol-4-yl) ]-3-phenol
DMLRS8I	MI	TT27RFC
DMLRS8I	MN	Opioid receptor delta (OPRD1)
DMLRS8I	MT	DTT
DMLRS8I	MA	Inhibitor
DMLRS8I	RN	Discovery of novel triazole-based opioid receptor antagonists. J Med Chem. 2006 Jul 13;49(14):4044-7.
DMLRS8I	RU	https://pubmed.ncbi.nlm.nih.gov/16821764

DMLRS8I	DI	DMLRS8I
DMLRS8I	DN	1-[3-(3-biphenyl)-(1,2,4-triazol-4-yl) ]-3-phenol
DMLRS8I	MI	TTKWM86
DMLRS8I	MN	Opioid receptor mu (MOP)
DMLRS8I	MT	DTT
DMLRS8I	MA	Inhibitor
DMLRS8I	RN	Discovery of novel triazole-based opioid receptor antagonists. J Med Chem. 2006 Jul 13;49(14):4044-7.
DMLRS8I	RU	https://pubmed.ncbi.nlm.nih.gov/16821764

DMB1NF0	DI	DMB1NF0
DMB1NF0	DN	1-[3-(4-biphenyl)-(1,2,4-triazol-4-yl) ]-3-phenol
DMB1NF0	MI	TT27RFC
DMB1NF0	MN	Opioid receptor delta (OPRD1)
DMB1NF0	MT	DTT
DMB1NF0	MA	Inhibitor
DMB1NF0	RN	Discovery of novel triazole-based opioid receptor antagonists. J Med Chem. 2006 Jul 13;49(14):4044-7.
DMB1NF0	RU	https://pubmed.ncbi.nlm.nih.gov/16821764

DMB1NF0	DI	DMB1NF0
DMB1NF0	DN	1-[3-(4-biphenyl)-(1,2,4-triazol-4-yl) ]-3-phenol
DMB1NF0	MI	TTKWM86
DMB1NF0	MN	Opioid receptor mu (MOP)
DMB1NF0	MT	DTT
DMB1NF0	MA	Inhibitor
DMB1NF0	RN	Discovery of novel triazole-based opioid receptor antagonists. J Med Chem. 2006 Jul 13;49(14):4044-7.
DMB1NF0	RU	https://pubmed.ncbi.nlm.nih.gov/16821764

DMS192I	DI	DMS192I
DMS192I	DN	1-[3-(Methylsulfonyl)phenyl]-4-propylpiperazine
DMS192I	MI	TTEX248
DMS192I	MN	Dopamine D2 receptor (D2R)
DMS192I	MT	DTT
DMS192I	MA	Inhibitor
DMS192I	RN	Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabi... J Med Chem. 2010 Mar 25;53(6):2510-20.
DMS192I	RU	https://pubmed.ncbi.nlm.nih.gov/20155917

DME1R96	DI	DME1R96
DME1R96	DN	1-[4-(2-oxo-2-phenylethyl)phenyl]guanidine
DME1R96	MI	TTGY7WI
DME1R96	MN	Urokinase-type plasminogen activator (PLAU)
DME1R96	MT	DTT
DME1R96	MA	Inhibitor
DME1R96	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DME1R96	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM0I2RH	DI	DM0I2RH
DM0I2RH	DN	1-[4-(4-Iodophenoxy)phenyl]piperazine
DM0I2RH	MI	TTXZEAJ
DM0I2RH	MN	Leukotriene A-4 hydrolase (LTA4H)
DM0I2RH	MT	DTT
DM0I2RH	MA	Inhibitor
DM0I2RH	RN	Discovery of 4-[(2S)-2-{[4-(4-chlorophenoxy)phenoxy]methyl}-1-pyrrolidinyl]butanoic acid (DG-051) as a novel leukotriene A4 hydrolase inhibitor of ... J Med Chem. 2010 Jan 28;53(2):573-85.
DM0I2RH	RU	https://pubmed.ncbi.nlm.nih.gov/19950900

DM4F1GJ	DI	DM4F1GJ
DM4F1GJ	DN	1-[4-(Benzothiazol-2-yloxy)benzyl]piperidin-4-ol
DM4F1GJ	MI	TTXZEAJ
DM4F1GJ	MN	Leukotriene A-4 hydrolase (LTA4H)
DM4F1GJ	MT	DTT
DM4F1GJ	MA	Inhibitor
DM4F1GJ	RN	Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69.
DM4F1GJ	RU	https://pubmed.ncbi.nlm.nih.gov/18588282

DMHXAMR	DI	DMHXAMR
DMHXAMR	DN	1-[4-hydroxy-3-(tritylaminomethyl)butyl]uracil
DMHXAMR	MI	TTY8KJS
DMHXAMR	MN	Bacterial Deoxyuridine triphosphate nucleotidohydrolase (Bact dut)
DMHXAMR	MT	DTT
DMHXAMR	MA	Inhibitor
DMHXAMR	RN	Acyclic nucleoside analogues as inhibitors of Plasmodium falciparum dUTPase. J Med Chem. 2006 Jul 13;49(14):4183-95.
DMHXAMR	RU	https://pubmed.ncbi.nlm.nih.gov/16821778

DM8NMAV	DI	DM8NMAV
DM8NMAV	DN	1-[5-(4-Chlorophenyl)-2-furoyl]piperazine
DM8NMAV	MI	TTZOVE0
DM8NMAV	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DM8NMAV	MT	DTT
DM8NMAV	MA	Inhibitor
DM8NMAV	RN	Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain. Bioorg Med Chem. 2008 Jun 15;16(12):6379-86.
DM8NMAV	RU	https://pubmed.ncbi.nlm.nih.gov/18501613

DM8NMAV	DI	DM8NMAV
DM8NMAV	DN	1-[5-(4-Chlorophenyl)-2-furoyl]piperazine
DM8NMAV	MI	TT90XZ8
DM8NMAV	MN	Voltage-gated sodium channel alpha Nav1.8 (SCN10A)
DM8NMAV	MT	DTT
DM8NMAV	MA	Inhibitor
DM8NMAV	RN	Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain. Bioorg Med Chem. 2008 Jun 15;16(12):6379-86.
DM8NMAV	RU	https://pubmed.ncbi.nlm.nih.gov/18501613

DMFHBJM	DI	DMFHBJM
DMFHBJM	DN	1-[5-(triphenylmethoxy)pentyl]thymine
DMFHBJM	MI	TTP3QRF
DMFHBJM	MN	Thymidine kinase 1 (TK1)
DMFHBJM	MT	DTT
DMFHBJM	MA	Inhibitor
DMFHBJM	RN	N1-substituted thymine derivatives as mitochondrial thymidine kinase (TK-2) inhibitors. J Med Chem. 2006 Dec 28;49(26):7766-73.
DMFHBJM	RU	https://pubmed.ncbi.nlm.nih.gov/17181158

DMFHBJM	DI	DMFHBJM
DMFHBJM	DN	1-[5-(triphenylmethoxy)pentyl]thymine
DMFHBJM	MI	TT7KNZQ
DMFHBJM	MN	Thymidine kinase 2 (Mt-TK2)
DMFHBJM	MT	DTT
DMFHBJM	MA	Inhibitor
DMFHBJM	RN	N1-substituted thymine derivatives as mitochondrial thymidine kinase (TK-2) inhibitors. J Med Chem. 2006 Dec 28;49(26):7766-73.
DMFHBJM	RU	https://pubmed.ncbi.nlm.nih.gov/17181158

DM5NVHO	DI	DM5NVHO
DM5NVHO	DN	1-[6-(triphenylmethoxy)hexyl]thymine
DM5NVHO	MI	TTP3QRF
DM5NVHO	MN	Thymidine kinase 1 (TK1)
DM5NVHO	MT	DTT
DM5NVHO	MA	Inhibitor
DM5NVHO	RN	N1-substituted thymine derivatives as mitochondrial thymidine kinase (TK-2) inhibitors. J Med Chem. 2006 Dec 28;49(26):7766-73.
DM5NVHO	RU	https://pubmed.ncbi.nlm.nih.gov/17181158

DM5NVHO	DI	DM5NVHO
DM5NVHO	DN	1-[6-(triphenylmethoxy)hexyl]thymine
DM5NVHO	MI	TT7KNZQ
DM5NVHO	MN	Thymidine kinase 2 (Mt-TK2)
DM5NVHO	MT	DTT
DM5NVHO	MA	Inhibitor
DM5NVHO	RN	N1-substituted thymine derivatives as mitochondrial thymidine kinase (TK-2) inhibitors. J Med Chem. 2006 Dec 28;49(26):7766-73.
DM5NVHO	RU	https://pubmed.ncbi.nlm.nih.gov/17181158

DMQ05F2	DI	DMQ05F2
DMQ05F2	DN	1-[7-(triphenylmethoxy)heptyl]thymine
DMQ05F2	MI	TTP3QRF
DMQ05F2	MN	Thymidine kinase 1 (TK1)
DMQ05F2	MT	DTT
DMQ05F2	MA	Inhibitor
DMQ05F2	RN	N1-substituted thymine derivatives as mitochondrial thymidine kinase (TK-2) inhibitors. J Med Chem. 2006 Dec 28;49(26):7766-73.
DMQ05F2	RU	https://pubmed.ncbi.nlm.nih.gov/17181158

DM13D4E	DI	DM13D4E
DM13D4E	DN	1-[bis(4-bromophenyl)methyl]-3-phenylthiourea
DM13D4E	MI	TT6OEDT
DM13D4E	MN	Cannabinoid receptor 1 (CB1)
DM13D4E	MT	DTT
DM13D4E	MA	Inhibitor
DM13D4E	RN	1-Benzhydryl-3-phenylurea and 1-benzhydryl-3-phenylthiourea derivatives: new templates among the CB1 cannabinoid receptor inverse agonists. J Med Chem. 2005 Nov 17;48(23):7486-90.
DM13D4E	RU	https://pubmed.ncbi.nlm.nih.gov/16279809

DMN2LHM	DI	DMN2LHM
DMN2LHM	DN	1-[bis(4-chlorophenyl)methyl]-3-(4-chlorophenyl)-
DMN2LHM	MI	TT6OEDT
DMN2LHM	MN	Cannabinoid receptor 1 (CB1)
DMN2LHM	MT	DTT
DMN2LHM	MA	Inhibitor
DMN2LHM	RN	1-Benzhydryl-3-phenylurea and 1-benzhydryl-3-phenylthiourea derivatives: new templates among the CB1 cannabinoid receptor inverse agonists. J Med Chem. 2005 Nov 17;48(23):7486-90.
DMN2LHM	RU	https://pubmed.ncbi.nlm.nih.gov/16279809

DMFMR2N	DI	DMFMR2N
DMFMR2N	DN	1-[bis(4-chlorophenyl)methyl]-3-phenylthiourea
DMFMR2N	MI	TT6OEDT
DMFMR2N	MN	Cannabinoid receptor 1 (CB1)
DMFMR2N	MT	DTT
DMFMR2N	MA	Inhibitor
DMFMR2N	RN	1-Benzhydryl-3-phenylurea and 1-benzhydryl-3-phenylthiourea derivatives: new templates among the CB1 cannabinoid receptor inverse agonists. J Med Chem. 2005 Nov 17;48(23):7486-90.
DMFMR2N	RU	https://pubmed.ncbi.nlm.nih.gov/16279809

DMJT7VI	DI	DMJT7VI
DMJT7VI	DN	1-[bis(4-iodophenyl)methyl]-3-(4-bromophenyl)urea
DMJT7VI	MI	TT6OEDT
DMJT7VI	MN	Cannabinoid receptor 1 (CB1)
DMJT7VI	MT	DTT
DMJT7VI	MA	Inhibitor
DMJT7VI	RN	1-Benzhydryl-3-phenylurea and 1-benzhydryl-3-phenylthiourea derivatives: new templates among the CB1 cannabinoid receptor inverse agonists. J Med Chem. 2005 Nov 17;48(23):7486-90.
DMJT7VI	RU	https://pubmed.ncbi.nlm.nih.gov/16279809

DML745Y	DI	DML745Y
DML745Y	DN	10,10-difluoro TXA2
DML745Y	MI	TT2O84V
DML745Y	MN	Thromboxane A2 receptor (TBXA2R)
DML745Y	MT	DTT
DML745Y	MA	Agonist
DML745Y	RN	Difluorothromboxane A2 and stereoisomers: stable derivatives of thromboxane A2 with differential effects on platelets and blood vessels. Proc Natl Acad Sci U S A. 1989 Jul;86(14):5600-4.
DML745Y	RU	https://pubmed.ncbi.nlm.nih.gov/2748606

DMS5ICY	DI	DMS5ICY
DMS5ICY	DN	10,11-dihydro-5H-dibenzo[b,f]azepine
DMS5ICY	MI	TTPC4TU
DMS5ICY	MN	5-HT 3A receptor (HTR3A)
DMS5ICY	MT	DTT
DMS5ICY	MA	Inhibitor
DMS5ICY	RN	Molecular properties of psychopharmacological drugs determining non-competitive inhibition of 5-HT3A receptors. Eur J Med Chem. 2009 Jun;44(6):2667-72.
DMS5ICY	RU	https://pubmed.ncbi.nlm.nih.gov/19144451

DM5BUXZ	DI	DM5BUXZ
DM5BUXZ	DN	10-Acetyl-1,8-dihydroxy-10H-anthracen-9-one
DM5BUXZ	MI	TT2J34L
DM5BUXZ	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM5BUXZ	MT	DTT
DM5BUXZ	MA	Inhibitor
DM5BUXZ	RN	Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80.
DM5BUXZ	RU	https://pubmed.ncbi.nlm.nih.gov/9371243

DM1JLUV	DI	DM1JLUV
DM1JLUV	DN	10-Allyl-10H-dibenzo[b,f][1,4]oxazepin-11-one
DM1JLUV	MI	TT84ETX
DM1JLUV	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM1JLUV	MT	DTT
DM1JLUV	MA	Inhibitor
DM1JLUV	RN	Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 2. Tricyclic pyridobenzoxazepinones and dibenzoxazepinones. J Med Chem. 1992 May 15;35(10):1887-97.
DM1JLUV	RU	https://pubmed.ncbi.nlm.nih.gov/1375293

DM4M2VU	DI	DM4M2VU
DM4M2VU	DN	10-Benzoyl-1,8-dihydroxy-10H-anthracen-9-one
DM4M2VU	MI	TT2J34L
DM4M2VU	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM4M2VU	MT	DTT
DM4M2VU	MA	Inhibitor
DM4M2VU	RN	Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80.
DM4M2VU	RU	https://pubmed.ncbi.nlm.nih.gov/9371243

DMQOUJ7	DI	DMQOUJ7
DMQOUJ7	DN	10-CF3C(OH)2-DDACTHF
DMQOUJ7	MI	TTEXB9Z
DMQOUJ7	MN	Glycinamide ribonucleotide formyltransferase (GART)
DMQOUJ7	MT	DTT
DMQOUJ7	MA	Inhibitor
DMQOUJ7	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMQOUJ7	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMDQ7Z9	DI	DMDQ7Z9
DMDQ7Z9	DN	10-EPI-8-DEOXY-CUMAMBRIN B
DMDQ7Z9	MI	TTSZLWK
DMDQ7Z9	MN	Aromatase (CYP19A1)
DMDQ7Z9	MT	DTT
DMDQ7Z9	MA	Inhibitor
DMDQ7Z9	RN	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
DMDQ7Z9	RU	https://pubmed.ncbi.nlm.nih.gov/20413308

DMGT82V	DI	DMGT82V
DMGT82V	DN	10-Ethyl-10H-dibenzo[b,f][1,4]oxazepin-11-one
DMGT82V	MI	TT84ETX
DMGT82V	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMGT82V	MT	DTT
DMGT82V	MA	Inhibitor
DMGT82V	RN	Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 2. Tricyclic pyridobenzoxazepinones and dibenzoxazepinones. J Med Chem. 1992 May 15;35(10):1887-97.
DMGT82V	RU	https://pubmed.ncbi.nlm.nih.gov/1375293

DMEBHML	DI	DMEBHML
DMEBHML	DN	10-Formyl-5,8,10-Trideazafolic Acid
DMEBHML	MI	TTEXB9Z
DMEBHML	MN	Glycinamide ribonucleotide formyltransferase (GART)
DMEBHML	MT	DTT
DMEBHML	MA	Inhibitor
DMEBHML	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMEBHML	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM4R7X8	DI	DM4R7X8
DM4R7X8	DN	10-hydroxy-18-methoxybetaenone
DM4R7X8	MI	TT0PG8F
DM4R7X8	MN	Cyclin-dependent kinase 4 (CDK4)
DM4R7X8	MT	DTT
DM4R7X8	MA	Inhibitor
DM4R7X8	RN	Anthraquinones and betaenone derivatives from the sponge-associated fungus Microsphaeropsis species: novel inhibitors of protein kinases. J Nat Prod. 2000 Jun;63(6):739-45.
DM4R7X8	RU	https://pubmed.ncbi.nlm.nih.gov/10869191

DM4R7X8	DI	DM4R7X8
DM4R7X8	DN	10-hydroxy-18-methoxybetaenone
DM4R7X8	MI	TTGKNB4
DM4R7X8	MN	Epidermal growth factor receptor (EGFR)
DM4R7X8	MT	DTT
DM4R7X8	MA	Inhibitor
DM4R7X8	RN	Anthraquinones and betaenone derivatives from the sponge-associated fungus Microsphaeropsis species: novel inhibitors of protein kinases. J Nat Prod. 2000 Jun;63(6):739-45.
DM4R7X8	RU	https://pubmed.ncbi.nlm.nih.gov/10869191

DM9WLN4	DI	DM9WLN4
DM9WLN4	DN	10-hydroxycamptothecin
DM9WLN4	MI	TTGTQHC
DM9WLN4	MN	DNA topoisomerase I (TOP1)
DM9WLN4	MT	DTT
DM9WLN4	MA	Inhibitor
DM9WLN4	RN	Upregulation of p21WAF1/CIP1 in human breast cancer cell lines MCF-7 and MDA-MB-468 undergoing apoptosis induced by natural product anticancer drugs 10-hydroxycamptothecin and camptothecin through p53-dependent and independent pathways. Int J Oncol. 1998 Apr;12(4):793-804.
DM9WLN4	RU	https://pubmed.ncbi.nlm.nih.gov/9499438

DM9WLN4	DI	DM9WLN4
DM9WLN4	DN	10-hydroxycamptothecin
DM9WLN4	MI	DTCSGPB
DM9WLN4	MN	Multidrug resistance-associated protein 4 (ABCC4)
DM9WLN4	MT	DTP
DM9WLN4	MA	Substrate
DM9WLN4	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM9WLN4	RU	https://doi.org/10.1007/s11095-012-0935-x

DM5H73W	DI	DM5H73W
DM5H73W	DN	10-Hydroxy-infractopicrin
DM5H73W	MI	TT1RS9F
DM5H73W	MN	Acetylcholinesterase (AChE)
DM5H73W	MT	DTT
DM5H73W	MA	Inhibitor
DM5H73W	RN	Acetylcholinesterase inhibitors from the toadstool Cortinarius infractus. Bioorg Med Chem. 2010 Mar 15;18(6):2173-2177.
DM5H73W	RU	https://pubmed.ncbi.nlm.nih.gov/20176490

DMCXA1Y	DI	DMCXA1Y
DMCXA1Y	DN	10-Isopropyl-10H-dibenzo[b,f][1,4]oxazepin-11-one
DMCXA1Y	MI	TT84ETX
DMCXA1Y	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMCXA1Y	MT	DTT
DMCXA1Y	MA	Inhibitor
DMCXA1Y	RN	Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 2. Tricyclic pyridobenzoxazepinones and dibenzoxazepinones. J Med Chem. 1992 May 15;35(10):1887-97.
DMCXA1Y	RU	https://pubmed.ncbi.nlm.nih.gov/1375293

DM2H6KD	DI	DM2H6KD
DM2H6KD	DN	10-methoxy-ginkgolide C
DM2H6KD	MI	TTZ8EM9
DM2H6KD	MN	Glycine receptor (GlyR)
DM2H6KD	MT	DTT
DM2H6KD	MA	Inhibitor
DM2H6KD	RN	Probing the pharmacophore of ginkgolides as glycine receptor antagonists. J Med Chem. 2007 Apr 5;50(7):1610-7.
DM2H6KD	RU	https://pubmed.ncbi.nlm.nih.gov/17352465

DM2H6KD	DI	DM2H6KD
DM2H6KD	DN	10-methoxy-ginkgolide C
DM2H6KD	MI	TTF45NW
DM2H6KD	MN	Strychnine-binding glycine receptor (GLRA1)
DM2H6KD	MT	DTT
DM2H6KD	MA	Inhibitor
DM2H6KD	RN	Probing the pharmacophore of ginkgolides as glycine receptor antagonists. J Med Chem. 2007 Apr 5;50(7):1610-7.
DM2H6KD	RU	https://pubmed.ncbi.nlm.nih.gov/17352465

DMJW25X	DI	DMJW25X
DMJW25X	DN	10-methoxy-N(1)-methylburnamine-17-O-veratrate
DMJW25X	MI	TTF8JAT
DMJW25X	MN	SLC5A2 messenger RNA (SLC5A2 mRNA)
DMJW25X	MT	DTT
DMJW25X	MA	Inhibitor
DMJW25X	RN	Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter. Bioorg Med Chem. 2010 Mar 15;18(6):2152-2158.
DMJW25X	RU	https://pubmed.ncbi.nlm.nih.gov/20189404

DMJW25X	DI	DMJW25X
DMJW25X	DN	10-methoxy-N(1)-methylburnamine-17-O-veratrate
DMJW25X	MI	TT2UE56
DMJW25X	MN	Sodium/glucose cotransporter 1 (SGLT1)
DMJW25X	MT	DTT
DMJW25X	MA	Inhibitor
DMJW25X	RN	Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter. Bioorg Med Chem. 2010 Mar 15;18(6):2152-2158.
DMJW25X	RU	https://pubmed.ncbi.nlm.nih.gov/20189404

DMM9GEA	DI	DMM9GEA
DMM9GEA	DN	10-OBn-7alpha-F-gingkolide B
DMM9GEA	MI	TTQL5VC
DMM9GEA	MN	Platelet-activating factor receptor (PTAFR)
DMM9GEA	MT	DTT
DMM9GEA	MA	Antagonist
DMM9GEA	RN	Preparation of 7-substituted ginkgolide derivatives: potent platelet activating factor (PAF) receptor antagonists. J Med Chem. 2003 Feb 13;46(4):601-8.
DMM9GEA	RU	https://pubmed.ncbi.nlm.nih.gov/12570381

DMAM5WJ	DI	DMAM5WJ
DMAM5WJ	DN	10-OBn-epi-ginkgolide C
DMAM5WJ	MI	TTQL5VC
DMAM5WJ	MN	Platelet-activating factor receptor (PTAFR)
DMAM5WJ	MT	DTT
DMAM5WJ	MA	Antagonist
DMAM5WJ	RN	Preparation of 7-substituted ginkgolide derivatives: potent platelet activating factor (PAF) receptor antagonists. J Med Chem. 2003 Feb 13;46(4):601-8.
DMAM5WJ	RU	https://pubmed.ncbi.nlm.nih.gov/12570381

DMS0I5V	DI	DMS0I5V
DMS0I5V	DN	10-OBn-ginkgolide B
DMS0I5V	MI	TTQL5VC
DMS0I5V	MN	Platelet-activating factor receptor (PTAFR)
DMS0I5V	MT	DTT
DMS0I5V	MA	Antagonist
DMS0I5V	RN	Preparation of 7-substituted ginkgolide derivatives: potent platelet activating factor (PAF) receptor antagonists. J Med Chem. 2003 Feb 13;46(4):601-8.
DMS0I5V	RU	https://pubmed.ncbi.nlm.nih.gov/12570381

DMOXKLH	DI	DMOXKLH
DMOXKLH	DN	10-OBn-ginkgolide C
DMOXKLH	MI	TTQL5VC
DMOXKLH	MN	Platelet-activating factor receptor (PTAFR)
DMOXKLH	MT	DTT
DMOXKLH	MA	Antagonist
DMOXKLH	RN	Preparation of 7-substituted ginkgolide derivatives: potent platelet activating factor (PAF) receptor antagonists. J Med Chem. 2003 Feb 13;46(4):601-8.
DMOXKLH	RU	https://pubmed.ncbi.nlm.nih.gov/12570381

DMR3A5N	DI	DMR3A5N
DMR3A5N	DN	10-Propargyl-5,8-Dideazafolic Acid
DMR3A5N	MI	TTU6BFZ
DMR3A5N	MN	Candida Thymidylate synthase (Candi TMP1)
DMR3A5N	MT	DTT
DMR3A5N	MA	Inhibitor
DMR3A5N	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMR3A5N	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMR3A5N	DI	DMR3A5N
DMR3A5N	DN	10-Propargyl-5,8-Dideazafolic Acid
DMR3A5N	MI	TTJLP0R
DMR3A5N	MN	Quinone reductase 2 (NQO2)
DMR3A5N	MT	DTT
DMR3A5N	MA	Inhibitor
DMR3A5N	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMR3A5N	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD1258	DI	DMD1258
DMD1258	DN	10-Propyl-10H-dibenzo[b,f][1,4]oxazepin-11-one
DMD1258	MI	TT84ETX
DMD1258	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMD1258	MT	DTT
DMD1258	MA	Inhibitor
DMD1258	RN	Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 2. Tricyclic pyridobenzoxazepinones and dibenzoxazepinones. J Med Chem. 1992 May 15;35(10):1887-97.
DMD1258	RU	https://pubmed.ncbi.nlm.nih.gov/1375293

DMZ3N8A	DI	DMZ3N8A
DMZ3N8A	DN	10-Propyl-10H-dibenzo[b,f][1,4]thiazepin-11-one
DMZ3N8A	MI	TT84ETX
DMZ3N8A	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMZ3N8A	MT	DTT
DMZ3N8A	MA	Inhibitor
DMZ3N8A	RN	Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 2. Tricyclic pyridobenzoxazepinones and dibenzoxazepinones. J Med Chem. 1992 May 15;35(10):1887-97.
DMZ3N8A	RU	https://pubmed.ncbi.nlm.nih.gov/1375293

DM8XRCT	DI	DM8XRCT
DM8XRCT	DN	10R-hydroxylobel-7-ene
DM8XRCT	MI	TTVBI8W
DM8XRCT	MN	Dopamine transporter (DAT)
DM8XRCT	MT	DTT
DM8XRCT	MA	Inhibitor
DM8XRCT	RN	Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5018-21.
DM8XRCT	RU	https://pubmed.ncbi.nlm.nih.gov/16905316

DM8XRCT	DI	DM8XRCT
DM8XRCT	DN	10R-hydroxylobel-7-ene
DM8XRCT	MI	TT3ROYC
DM8XRCT	MN	Serotonin transporter (SERT)
DM8XRCT	MT	DTT
DM8XRCT	MA	Inhibitor
DM8XRCT	RN	Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5018-21.
DM8XRCT	RU	https://pubmed.ncbi.nlm.nih.gov/16905316

DMN93QT	DI	DMN93QT
DMN93QT	DN	10R-hydroxylobelane
DMN93QT	MI	TTVBI8W
DMN93QT	MN	Dopamine transporter (DAT)
DMN93QT	MT	DTT
DMN93QT	MA	Inhibitor
DMN93QT	RN	Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5018-21.
DMN93QT	RU	https://pubmed.ncbi.nlm.nih.gov/16905316

DMN93QT	DI	DMN93QT
DMN93QT	DN	10R-hydroxylobelane
DMN93QT	MI	TT3ROYC
DMN93QT	MN	Serotonin transporter (SERT)
DMN93QT	MT	DTT
DMN93QT	MA	Inhibitor
DMN93QT	RN	Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5018-21.
DMN93QT	RU	https://pubmed.ncbi.nlm.nih.gov/16905316

DMN1YQ6	DI	DMN1YQ6
DMN1YQ6	DN	10S-hydroxylobel-7-ene
DMN1YQ6	MI	TTVBI8W
DMN1YQ6	MN	Dopamine transporter (DAT)
DMN1YQ6	MT	DTT
DMN1YQ6	MA	Inhibitor
DMN1YQ6	RN	Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5018-21.
DMN1YQ6	RU	https://pubmed.ncbi.nlm.nih.gov/16905316

DMN1YQ6	DI	DMN1YQ6
DMN1YQ6	DN	10S-hydroxylobel-7-ene
DMN1YQ6	MI	TT3ROYC
DMN1YQ6	MN	Serotonin transporter (SERT)
DMN1YQ6	MT	DTT
DMN1YQ6	MA	Inhibitor
DMN1YQ6	RN	Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5018-21.
DMN1YQ6	RU	https://pubmed.ncbi.nlm.nih.gov/16905316

DM54AKV	DI	DM54AKV
DM54AKV	DN	10S-hydroxylobelane
DM54AKV	MI	TTVBI8W
DM54AKV	MN	Dopamine transporter (DAT)
DM54AKV	MT	DTT
DM54AKV	MA	Inhibitor
DM54AKV	RN	Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5018-21.
DM54AKV	RU	https://pubmed.ncbi.nlm.nih.gov/16905316

DM54AKV	DI	DM54AKV
DM54AKV	DN	10S-hydroxylobelane
DM54AKV	MI	TT3ROYC
DM54AKV	MN	Serotonin transporter (SERT)
DM54AKV	MT	DTT
DM54AKV	MA	Inhibitor
DM54AKV	RN	Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5018-21.
DM54AKV	RU	https://pubmed.ncbi.nlm.nih.gov/16905316

DMEAGI6	DI	DMEAGI6
DMEAGI6	DN	10-trifluoroacetyl-DDACTHF
DMEAGI6	MI	TTEXB9Z
DMEAGI6	MN	Glycinamide ribonucleotide formyltransferase (GART)
DMEAGI6	MT	DTT
DMEAGI6	MA	Inhibitor
DMEAGI6	RN	Discovery of a potent, nonpolyglutamatable inhibitor of glycinamide ribonucleotide transformylase. J Med Chem. 2006 May 18;49(10):2998-3002.
DMEAGI6	RU	https://pubmed.ncbi.nlm.nih.gov/16686541

DMIRSA5	DI	DMIRSA5
DMIRSA5	DN	10Z-Hymenialdisine
DMIRSA5	MI	TTH6V3D
DMIRSA5	MN	Cyclin-dependent kinase 1 (CDK1)
DMIRSA5	MT	DTT
DMIRSA5	MA	Binder
DMIRSA5	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DMIRSA5	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DMIRSA5	DI	DMIRSA5
DMIRSA5	DN	10Z-Hymenialdisine
DMIRSA5	MI	TT7HF4W
DMIRSA5	MN	Cyclin-dependent kinase 2 (CDK2)
DMIRSA5	MT	DTT
DMIRSA5	MA	Inhibitor
DMIRSA5	RN	Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
DMIRSA5	RU	https://pubmed.ncbi.nlm.nih.gov/12237154

DMIRSA5	DI	DMIRSA5
DMIRSA5	DN	10Z-Hymenialdisine
DMIRSA5	MI	TTL4Q97
DMIRSA5	MN	Cyclin-dependent kinase 5 (CDK5)
DMIRSA5	MT	DTT
DMIRSA5	MA	Inhibitor
DMIRSA5	RN	Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
DMIRSA5	RU	https://pubmed.ncbi.nlm.nih.gov/12237154

DME0OGM	DI	DME0OGM
DME0OGM	DN	11,12-dihydro-dibenzo[a,e]cyclooctene-5,6-dione
DME0OGM	MI	TTMF541
DME0OGM	MN	Liver carboxylesterase (CES1)
DME0OGM	MT	DTT
DME0OGM	MA	Inhibitor
DME0OGM	RN	Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34.
DME0OGM	RU	https://pubmed.ncbi.nlm.nih.gov/17941623

DMFVP6K	DI	DMFVP6K
DMFVP6K	DN	11A1
DMFVP6K	MI	TTE4KHA
DMFVP6K	MN	Amyloid beta A4 protein (APP)
DMFVP6K	MT	DTT
DMFVP6K	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
DMFVP6K	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402

DM0EPJT	DI	DM0EPJT
DM0EPJT	DN	11BETA,13-DIHYDRO-10-EPI-8-DEOXYCUMAM-BRIN B
DM0EPJT	MI	TTSZLWK
DM0EPJT	MN	Aromatase (CYP19A1)
DM0EPJT	MT	DTT
DM0EPJT	MA	Inhibitor
DM0EPJT	RN	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
DM0EPJT	RU	https://pubmed.ncbi.nlm.nih.gov/20413308

DMH5QEA	DI	DMH5QEA
DMH5QEA	DN	11-Butyryloxy-N-n-propylnoraporphine
DMH5QEA	MI	TTJQOD7
DMH5QEA	MN	5-HT 2A receptor (HTR2A)
DMH5QEA	MT	DTT
DMH5QEA	MA	Inhibitor
DMH5QEA	RN	N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D(2) and serotonin 5-HT(1A) receptor dual ligands. Bioorg Med Chem. 2008 Sep 15;16(18):8335-8.
DMH5QEA	RU	https://pubmed.ncbi.nlm.nih.gov/18783955

DMH5QEA	DI	DMH5QEA
DMH5QEA	DN	11-Butyryloxy-N-n-propylnoraporphine
DMH5QEA	MI	TTZFYLI
DMH5QEA	MN	Dopamine D1 receptor (D1R)
DMH5QEA	MT	DTT
DMH5QEA	MA	Inhibitor
DMH5QEA	RN	N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D(2) and serotonin 5-HT(1A) receptor dual ligands. Bioorg Med Chem. 2008 Sep 15;16(18):8335-8.
DMH5QEA	RU	https://pubmed.ncbi.nlm.nih.gov/18783955

DMYGE3K	DI	DMYGE3K
DMYGE3K	DN	11C-PBR-170
DMYGE3K	MI	TTPTXIN
DMYGE3K	MN	Translocator protein (TSPO)
DMYGE3K	MT	DTT
DMYGE3K	MA	Binder
DMYGE3K	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2879).
DMYGE3K	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2879

DM1ERJC	DI	DM1ERJC
DM1ERJC	DN	11-deoxy-PGE1
DM1ERJC	MI	TT1ZAVI
DM1ERJC	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DM1ERJC	MT	DTT
DM1ERJC	MA	Agonist
DM1ERJC	RN	Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
DM1ERJC	RU	https://pubmed.ncbi.nlm.nih.gov/9313928

DM1ERJC	DI	DM1ERJC
DM1ERJC	DN	11-deoxy-PGE1
DM1ERJC	MI	TTPNGDE
DM1ERJC	MN	Prostaglandin E2 receptor EP3 (PTGER3)
DM1ERJC	MT	DTT
DM1ERJC	MA	Agonist
DM1ERJC	RN	Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41.
DM1ERJC	RU	https://pubmed.ncbi.nlm.nih.gov/9537820

DM1ERJC	DI	DM1ERJC
DM1ERJC	DN	11-deoxy-PGE1
DM1ERJC	MI	TT79WV3
DM1ERJC	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DM1ERJC	MT	DTT
DM1ERJC	MA	Agonist
DM1ERJC	RN	Pharmacological characterization of [(3)H]-prostaglandin E(2) binding to the cloned human EP(4) prostanoid receptor. Br J Pharmacol. 2000 Aug;130(8):1919-26.
DM1ERJC	RU	https://pubmed.ncbi.nlm.nih.gov/10952683

DMXLWOK	DI	DMXLWOK
DMXLWOK	DN	11-deoxy-PGE2
DMXLWOK	MI	TT79WV3
DMXLWOK	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DMXLWOK	MT	DTT
DMXLWOK	MA	Agonist
DMXLWOK	RN	Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41.
DMXLWOK	RU	https://pubmed.ncbi.nlm.nih.gov/9537820

DMK41DJ	DI	DMK41DJ
DMK41DJ	DN	11H-benzo[a]carbazole
DMK41DJ	MI	TTBGTCW
DMK41DJ	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DMK41DJ	MT	DTT
DMK41DJ	MA	Inhibitor
DMK41DJ	RN	Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8.
DMK41DJ	RU	https://pubmed.ncbi.nlm.nih.gov/20521839

DMX4I9D	DI	DMX4I9D
DMX4I9D	DN	11-Heptanoyloxy-N-n-propylnoraporphine
DMX4I9D	MI	TTJQOD7
DMX4I9D	MN	5-HT 2A receptor (HTR2A)
DMX4I9D	MT	DTT
DMX4I9D	MA	Inhibitor
DMX4I9D	RN	N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D(2) and serotonin 5-HT(1A) receptor dual ligands. Bioorg Med Chem. 2008 Sep 15;16(18):8335-8.
DMX4I9D	RU	https://pubmed.ncbi.nlm.nih.gov/18783955

DMX4I9D	DI	DMX4I9D
DMX4I9D	DN	11-Heptanoyloxy-N-n-propylnoraporphine
DMX4I9D	MI	TTZFYLI
DMX4I9D	MN	Dopamine D1 receptor (D1R)
DMX4I9D	MT	DTT
DMX4I9D	MA	Inhibitor
DMX4I9D	RN	N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D(2) and serotonin 5-HT(1A) receptor dual ligands. Bioorg Med Chem. 2008 Sep 15;16(18):8335-8.
DMX4I9D	RU	https://pubmed.ncbi.nlm.nih.gov/18783955

DMRYV9E	DI	DMRYV9E
DMRYV9E	DN	11-Hexanoyloxy-N-n-propylnoraporphine
DMRYV9E	MI	TTJQOD7
DMRYV9E	MN	5-HT 2A receptor (HTR2A)
DMRYV9E	MT	DTT
DMRYV9E	MA	Inhibitor
DMRYV9E	RN	N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D(2) and serotonin 5-HT(1A) receptor dual ligands. Bioorg Med Chem. 2008 Sep 15;16(18):8335-8.
DMRYV9E	RU	https://pubmed.ncbi.nlm.nih.gov/18783955

DMRYV9E	DI	DMRYV9E
DMRYV9E	DN	11-Hexanoyloxy-N-n-propylnoraporphine
DMRYV9E	MI	TTZFYLI
DMRYV9E	MN	Dopamine D1 receptor (D1R)
DMRYV9E	MT	DTT
DMRYV9E	MA	Inhibitor
DMRYV9E	RN	N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D(2) and serotonin 5-HT(1A) receptor dual ligands. Bioorg Med Chem. 2008 Sep 15;16(18):8335-8.
DMRYV9E	RU	https://pubmed.ncbi.nlm.nih.gov/18783955

DMM6CJI	DI	DMM6CJI
DMM6CJI	DN	11-keto-beta-boswellicacid
DMM6CJI	MI	TTN7BL9
DMM6CJI	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMM6CJI	MT	DTT
DMM6CJI	MA	Inhibitor
DMM6CJI	RN	11beta-Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational a... Bioorg Med Chem. 2010 Feb 15;18(4):1507-15.
DMM6CJI	RU	https://pubmed.ncbi.nlm.nih.gov/20100662

DMM6CJI	DI	DMM6CJI
DMM6CJI	DN	11-keto-beta-boswellicacid
DMM6CJI	MI	TT9H85R
DMM6CJI	MN	Corticosteroid 11-beta-dehydrogenase 2 (HSD11B2)
DMM6CJI	MT	DTT
DMM6CJI	MA	Inhibitor
DMM6CJI	RN	11beta-Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational a... Bioorg Med Chem. 2010 Feb 15;18(4):1507-15.
DMM6CJI	RU	https://pubmed.ncbi.nlm.nih.gov/20100662

DM1WPE3	DI	DM1WPE3
DM1WPE3	DN	11-keto-ursolic acid
DM1WPE3	MI	TTN7BL9
DM1WPE3	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DM1WPE3	MT	DTT
DM1WPE3	MA	Inhibitor
DM1WPE3	RN	11beta-Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational a... Bioorg Med Chem. 2010 Feb 15;18(4):1507-15.
DM1WPE3	RU	https://pubmed.ncbi.nlm.nih.gov/20100662

DM9IHFY	DI	DM9IHFY
DM9IHFY	DN	11-methyl-6,11-dihydro-5H-benzo[a]carbazol-9-ol
DM9IHFY	MI	TTS64P2
DM9IHFY	MN	Androgen receptor (AR)
DM9IHFY	MT	DTT
DM9IHFY	MA	Inhibitor
DM9IHFY	RN	Discovery of indole-containing tetracycles as a new scaffold for androgen receptor ligands. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3233-7.
DM9IHFY	RU	https://pubmed.ncbi.nlm.nih.gov/16603353

DM62FEH	DI	DM62FEH
DM62FEH	DN	11-Propionyloxy-N-n-propylnoraporphine
DM62FEH	MI	TTJQOD7
DM62FEH	MN	5-HT 2A receptor (HTR2A)
DM62FEH	MT	DTT
DM62FEH	MA	Inhibitor
DM62FEH	RN	N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D(2) and serotonin 5-HT(1A) receptor dual ligands. Bioorg Med Chem. 2008 Sep 15;16(18):8335-8.
DM62FEH	RU	https://pubmed.ncbi.nlm.nih.gov/18783955

DM62FEH	DI	DM62FEH
DM62FEH	DN	11-Propionyloxy-N-n-propylnoraporphine
DM62FEH	MI	TTZFYLI
DM62FEH	MN	Dopamine D1 receptor (D1R)
DM62FEH	MT	DTT
DM62FEH	MA	Inhibitor
DM62FEH	RN	N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D(2) and serotonin 5-HT(1A) receptor dual ligands. Bioorg Med Chem. 2008 Sep 15;16(18):8335-8.
DM62FEH	RU	https://pubmed.ncbi.nlm.nih.gov/18783955

DMM91WE	DI	DMM91WE
DMM91WE	DN	11-valeryloxynoraporphine
DMM91WE	MI	TTJQOD7
DMM91WE	MN	5-HT 2A receptor (HTR2A)
DMM91WE	MT	DTT
DMM91WE	MA	Inhibitor
DMM91WE	RN	N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D(2) and serotonin 5-HT(1A) receptor dual ligands. Bioorg Med Chem. 2008 Sep 15;16(18):8335-8.
DMM91WE	RU	https://pubmed.ncbi.nlm.nih.gov/18783955

DMM91WE	DI	DMM91WE
DMM91WE	DN	11-valeryloxynoraporphine
DMM91WE	MI	TTZFYLI
DMM91WE	MN	Dopamine D1 receptor (D1R)
DMM91WE	MT	DTT
DMM91WE	MA	Inhibitor
DMM91WE	RN	N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D(2) and serotonin 5-HT(1A) receptor dual ligands. Bioorg Med Chem. 2008 Sep 15;16(18):8335-8.
DMM91WE	RU	https://pubmed.ncbi.nlm.nih.gov/18783955

DM84YCI	DI	DM84YCI
DM84YCI	DN	12-(3-Adamantan-1-yl-ureido)-dodeca noic acid
DM84YCI	MI	TT7WVHI
DM84YCI	MN	Soluble epoxide hydrolase (EPHX2)
DM84YCI	MT	DTT
DM84YCI	MA	Inhibitor
DM84YCI	RN	Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement. J Med Chem. 2009 Aug 27;52(16):5009-12.
DM84YCI	RU	https://pubmed.ncbi.nlm.nih.gov/19645482

DM0F3SR	DI	DM0F3SR
DM0F3SR	DN	12-(3-n-Hexylureido)dodec-8(Z)-enoic acid
DM0F3SR	MI	TT7WVHI
DM0F3SR	MN	Soluble epoxide hydrolase (EPHX2)
DM0F3SR	MT	DTT
DM0F3SR	MA	Inhibitor
DM0F3SR	RN	14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxi... J Med Chem. 2009 Aug 27;52(16):5069-75.
DM0F3SR	RU	https://pubmed.ncbi.nlm.nih.gov/19653681

DMAFNXZ	DI	DMAFNXZ
DMAFNXZ	DN	12-(3-n-Pentylureidooxy)dodec-8(Z)-enoic acid
DMAFNXZ	MI	TT7WVHI
DMAFNXZ	MN	Soluble epoxide hydrolase (EPHX2)
DMAFNXZ	MT	DTT
DMAFNXZ	MA	Inhibitor
DMAFNXZ	RN	14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxi... J Med Chem. 2009 Aug 27;52(16):5069-75.
DMAFNXZ	RU	https://pubmed.ncbi.nlm.nih.gov/19653681

DMVP39I	DI	DMVP39I
DMVP39I	DN	12,13-DEHYDRO-8-O-ACETYLMANZAMINE A
DMVP39I	MI	TTRSMW9
DMVP39I	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMVP39I	MT	DTT
DMVP39I	MA	Inhibitor
DMVP39I	RN	Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for ... J Nat Prod. 2007 Sep;70(9):1397-405.
DMVP39I	RU	https://pubmed.ncbi.nlm.nih.gov/17708655

DM8XAWU	DI	DM8XAWU
DM8XAWU	DN	12,13-DEHYDROMANZAMINE A
DM8XAWU	MI	TTRSMW9
DM8XAWU	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DM8XAWU	MT	DTT
DM8XAWU	MA	Inhibitor
DM8XAWU	RN	Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for ... J Nat Prod. 2007 Sep;70(9):1397-405.
DM8XAWU	RU	https://pubmed.ncbi.nlm.nih.gov/17708655

DMAUPQR	DI	DMAUPQR
DMAUPQR	DN	12,17-dehydroxyriccardin C
DMAUPQR	MI	TTECBXN
DMAUPQR	MN	Oxysterols receptor LXR-alpha (NR1H3)
DMAUPQR	MT	DTT
DMAUPQR	MA	Inhibitor
DMAUPQR	RN	Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85.
DMAUPQR	RU	https://pubmed.ncbi.nlm.nih.gov/18343126

DMAUPQR	DI	DMAUPQR
DMAUPQR	DN	12,17-dehydroxyriccardin C
DMAUPQR	MI	TTXA6PH
DMAUPQR	MN	Oxysterols receptor LXR-beta (NR1H2)
DMAUPQR	MT	DTT
DMAUPQR	MA	Inhibitor
DMAUPQR	RN	Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85.
DMAUPQR	RU	https://pubmed.ncbi.nlm.nih.gov/18343126

DMW172Q	DI	DMW172Q
DMW172Q	DN	123I-DRM-106
DMW172Q	MI	TTE4KHA
DMW172Q	MN	Amyloid beta A4 protein (APP)
DMW172Q	MT	DTT
DMW172Q	MA	Modulator
DMW172Q	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
DMW172Q	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402

DMTOSXF	DI	DMTOSXF
DMTOSXF	DN	12-dehydroxyriccardin C
DMTOSXF	MI	TTECBXN
DMTOSXF	MN	Oxysterols receptor LXR-alpha (NR1H3)
DMTOSXF	MT	DTT
DMTOSXF	MA	Inhibitor
DMTOSXF	RN	Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85.
DMTOSXF	RU	https://pubmed.ncbi.nlm.nih.gov/18343126

DMTOSXF	DI	DMTOSXF
DMTOSXF	DN	12-dehydroxyriccardin C
DMTOSXF	MI	TTXA6PH
DMTOSXF	MN	Oxysterols receptor LXR-beta (NR1H2)
DMTOSXF	MT	DTT
DMTOSXF	MA	Inhibitor
DMTOSXF	RN	Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85.
DMTOSXF	RU	https://pubmed.ncbi.nlm.nih.gov/18343126

DM9JI8C	DI	DM9JI8C
DM9JI8C	DN	12-epi LTB4
DM9JI8C	MI	TTVJX54
DM9JI8C	MN	Leukotriene B4 receptor 2 (LTB4R2)
DM9JI8C	MT	DTT
DM9JI8C	MA	Agonist
DM9JI8C	RN	Hydroxyeicosanoids bind to and activate the low affinity leukotriene B4 receptor, BLT2. J Biol Chem. 2001 Apr 13;276(15):12454-9.
DM9JI8C	RU	https://pubmed.ncbi.nlm.nih.gov/11278893

DMZ9PW3	DI	DMZ9PW3
DMZ9PW3	DN	12-EPI-SALVINORIN A
DMZ9PW3	MI	TTQW87Y
DMZ9PW3	MN	Opioid receptor kappa (OPRK1)
DMZ9PW3	MT	DTT
DMZ9PW3	MA	Inhibitor
DMZ9PW3	RN	Modification of the furan ring of salvinorin A: identification of a selective partial agonist at the kappa opioid receptor. Bioorg Med Chem. 2009 Feb 1;17(3):1370-80.
DMZ9PW3	RU	https://pubmed.ncbi.nlm.nih.gov/19147366

DMA2EIK	DI	DMA2EIK
DMA2EIK	DN	12-hydroxyheptadecatrienoic acid
DMA2EIK	MI	TTVJX54
DMA2EIK	MN	Leukotriene B4 receptor 2 (LTB4R2)
DMA2EIK	MT	DTT
DMA2EIK	MA	Agonist
DMA2EIK	RN	12(S)-Hydroxyheptadeca-5Z, 8E, 10E-trienoic acid is a natural ligand for leukotriene B4 receptor 2. J Exp Med. 2008 Apr 14;205(4):759-66.
DMA2EIK	RU	https://pubmed.ncbi.nlm.nih.gov/18378794

DMKH0OC	DI	DMKH0OC
DMKH0OC	DN	12-O-deacetyl-12-epi-19-deoxy-21-hydroxyscalarin
DMKH0OC	MI	TTS4UGC
DMKH0OC	MN	Farnesoid X-activated receptor (FXR)
DMKH0OC	MT	DTT
DMKH0OC	MA	Inhibitor
DMKH0OC	RN	Scalarane sesterterpenes from a marine sponge of the genus Spongia and their FXR antagonistic activity. J Nat Prod. 2007 Nov;70(11):1691-5.
DMKH0OC	RU	https://pubmed.ncbi.nlm.nih.gov/17988093

DMLR2FB	DI	DMLR2FB
DMLR2FB	DN	12-Phenylheme
DMLR2FB	MI	TTI6V2A
DMLR2FB	MN	Heme oxygenase 1 (HMOX1)
DMLR2FB	MT	DTT
DMLR2FB	MA	Inhibitor
DMLR2FB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMLR2FB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMK0GJ3	DI	DMK0GJ3
DMK0GJ3	DN	12R-HETE
DMK0GJ3	MI	TTVJX54
DMK0GJ3	MN	Leukotriene B4 receptor 2 (LTB4R2)
DMK0GJ3	MT	DTT
DMK0GJ3	MA	Agonist
DMK0GJ3	RN	A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature. 1997 Jun 5;387(6633):620-4.
DMK0GJ3	RU	https://pubmed.ncbi.nlm.nih.gov/9177352

DMBEZ09	DI	DMBEZ09
DMBEZ09	DN	12S-HETE
DMBEZ09	MI	TT71ZLK
DMBEZ09	MN	G-protein coupled receptor 31 (GPR31)
DMBEZ09	MT	DTT
DMBEZ09	MA	Agonist
DMBEZ09	RN	Identification of the orphan G protein-coupled receptor GPR31 as a receptor for 12-(S)-hydroxyeicosatetraenoic acid. J Biol Chem. 2011 Sep 30;286(39):33832-40.
DMBEZ09	RU	https://pubmed.ncbi.nlm.nih.gov/21712392

DMBEZ09	DI	DMBEZ09
DMBEZ09	DN	12S-HETE
DMBEZ09	MI	TTVJX54
DMBEZ09	MN	Leukotriene B4 receptor 2 (LTB4R2)
DMBEZ09	MT	DTT
DMBEZ09	MA	Agonist
DMBEZ09	RN	Hydroxyeicosanoids bind to and activate the low affinity leukotriene B4 receptor, BLT2. J Biol Chem. 2001 Apr 13;276(15):12454-9.
DMBEZ09	RU	https://pubmed.ncbi.nlm.nih.gov/11278893

DM6ZX1O	DI	DM6ZX1O
DM6ZX1O	DN	12S-HPETE
DM6ZX1O	MI	TTMI6F5
DM6ZX1O	MN	Transient receptor potential cation channel V1 (TRPV1)
DM6ZX1O	MT	DTT
DM6ZX1O	MA	Activator
DM6ZX1O	RN	Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc Natl Acad Sci U S A. 2000 May 23;97(11):6155-60.
DM6ZX1O	RU	https://pubmed.ncbi.nlm.nih.gov/10823958

DMRO1IU	DI	DMRO1IU
DMRO1IU	DN	1-3 Sugar Ring of Pentamannosyl 6-Phosphate
DMRO1IU	MI	TT95ICL
DMRO1IU	MN	Mannose-6-phosphate receptor (M6PR)
DMRO1IU	MT	DTT
DMRO1IU	MA	Inhibitor
DMRO1IU	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMRO1IU	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMIY9DB	DI	DMIY9DB
DMIY9DB	DN	13-(3-n-Pentylthioureido)tridec-8(Z)-enoic Acid
DMIY9DB	MI	TT7WVHI
DMIY9DB	MN	Soluble epoxide hydrolase (EPHX2)
DMIY9DB	MT	DTT
DMIY9DB	MA	Inhibitor
DMIY9DB	RN	14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxi... J Med Chem. 2009 Aug 27;52(16):5069-75.
DMIY9DB	RU	https://pubmed.ncbi.nlm.nih.gov/19653681

DM0NRJG	DI	DM0NRJG
DM0NRJG	DN	13-(3-n-Pentylureido)tridec-5(Z)-enoic acid
DM0NRJG	MI	TT7WVHI
DM0NRJG	MN	Soluble epoxide hydrolase (EPHX2)
DM0NRJG	MT	DTT
DM0NRJG	MA	Inhibitor
DM0NRJG	RN	14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxi... J Med Chem. 2009 Aug 27;52(16):5069-75.
DM0NRJG	RU	https://pubmed.ncbi.nlm.nih.gov/19653681

DM17DY6	DI	DM17DY6
DM17DY6	DN	13-(3-n-Pentylureido)tridec-8(E)-enoic acid
DM17DY6	MI	TT7WVHI
DM17DY6	MN	Soluble epoxide hydrolase (EPHX2)
DM17DY6	MT	DTT
DM17DY6	MA	Inhibitor
DM17DY6	RN	14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxi... J Med Chem. 2009 Aug 27;52(16):5069-75.
DM17DY6	RU	https://pubmed.ncbi.nlm.nih.gov/19653681

DM9VDOG	DI	DM9VDOG
DM9VDOG	DN	13-(3-n-Pentylureido)tridec-8-ynoic acid
DM9VDOG	MI	TT7WVHI
DM9VDOG	MN	Soluble epoxide hydrolase (EPHX2)
DM9VDOG	MT	DTT
DM9VDOG	MA	Inhibitor
DM9VDOG	RN	14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxi... J Med Chem. 2009 Aug 27;52(16):5069-75.
DM9VDOG	RU	https://pubmed.ncbi.nlm.nih.gov/19653681

DM3I6PS	DI	DM3I6PS
DM3I6PS	DN	13-(3-Pentyluredo)tridec-8(Z)-enoic acid
DM3I6PS	MI	TT7WVHI
DM3I6PS	MN	Soluble epoxide hydrolase (EPHX2)
DM3I6PS	MT	DTT
DM3I6PS	MA	Inhibitor
DM3I6PS	RN	14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxi... J Med Chem. 2009 Aug 27;52(16):5069-75.
DM3I6PS	RU	https://pubmed.ncbi.nlm.nih.gov/19653681

DM8HRTC	DI	DM8HRTC
DM8HRTC	DN	13-(5-n-Pentylfuran-2-yl)tridec-8(Z)-enoic acid
DM8HRTC	MI	TT7WVHI
DM8HRTC	MN	Soluble epoxide hydrolase (EPHX2)
DM8HRTC	MT	DTT
DM8HRTC	MA	Inhibitor
DM8HRTC	RN	14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxi... J Med Chem. 2009 Aug 27;52(16):5069-75.
DM8HRTC	RU	https://pubmed.ncbi.nlm.nih.gov/19653681

DMXK6D2	DI	DMXK6D2
DMXK6D2	DN	13-(N-Isopropylheptanamido)tridec-8(Z)-enoic acid
DMXK6D2	MI	TT7WVHI
DMXK6D2	MN	Soluble epoxide hydrolase (EPHX2)
DMXK6D2	MT	DTT
DMXK6D2	MA	Inhibitor
DMXK6D2	RN	14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxi... J Med Chem. 2009 Aug 27;52(16):5069-75.
DMXK6D2	RU	https://pubmed.ncbi.nlm.nih.gov/19653681

DM689TH	DI	DM689TH
DM689TH	DN	13-(N-Methyl-n-heptnamido)tridec-8(Z)-enoic acid
DM689TH	MI	TT7WVHI
DM689TH	MN	Soluble epoxide hydrolase (EPHX2)
DM689TH	MT	DTT
DM689TH	MA	Inhibitor
DM689TH	RN	14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxi... J Med Chem. 2009 Aug 27;52(16):5069-75.
DM689TH	RU	https://pubmed.ncbi.nlm.nih.gov/19653681

DMSF3C8	DI	DMSF3C8
DMSF3C8	DN	13-(n-Pentylcarbamoyloxy)tridec-8(Z)-enoic acid
DMSF3C8	MI	TT7WVHI
DMSF3C8	MN	Soluble epoxide hydrolase (EPHX2)
DMSF3C8	MT	DTT
DMSF3C8	MA	Inhibitor
DMSF3C8	RN	14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxi... J Med Chem. 2009 Aug 27;52(16):5069-75.
DMSF3C8	RU	https://pubmed.ncbi.nlm.nih.gov/19653681

DMZVWCG	DI	DMZVWCG
DMZVWCG	DN	13,14-dihydro-15-keto-PGD2
DMZVWCG	MI	TTQDMX5
DMZVWCG	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMZVWCG	MT	DTT
DMZVWCG	MA	Agonist
DMZVWCG	RN	CRTH2-specific binding characteristics of [3H]ramatroban and its effects on PGD2-, 15-deoxy-Delta12, 14-PGJ2- and indomethacin-induced agonist resp... Eur J Pharmacol. 2005 Nov 7;524(1-3):30-7.
DMZVWCG	RU	https://pubmed.ncbi.nlm.nih.gov/16256979

DMNT1XI	DI	DMNT1XI
DMNT1XI	DN	13,14-dihydro-15-keto-PGF2alpha
DMNT1XI	MI	TTQDMX5
DMNT1XI	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMNT1XI	MT	DTT
DMNT1XI	MA	Agonist
DMNT1XI	RN	Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2. Br J Pharmacol. 2002 Dec;137(8):1163-72.
DMNT1XI	RU	https://pubmed.ncbi.nlm.nih.gov/12466225

DMNRMTX	DI	DMNRMTX
DMNRMTX	DN	13,14-dihydro-16-m-chlorophenoxy-w-tetranor-PGF1alpha
DMNRMTX	MI	TTT2ZAR
DMNRMTX	MN	Prostaglandin F2-alpha receptor (PTGFR)
DMNRMTX	MT	DTT
DMNRMTX	MA	Agonist
DMNRMTX	RN	Design and synthesis of 13,14-dihydro prostaglandin F(1alpha) analogues as potent and selective ligands for the human FP receptor. J Med Chem. 2000 Mar 9;43(5):945-52.
DMNRMTX	RU	https://pubmed.ncbi.nlm.nih.gov/10715159

DMTEACQ	DI	DMTEACQ
DMTEACQ	DN	13,14-dihydro-PGE1
DMTEACQ	MI	TT79WV3
DMTEACQ	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DMTEACQ	MT	DTT
DMTEACQ	MA	Agonist
DMTEACQ	RN	Pharmacological characterization of [(3)H]-prostaglandin E(2) binding to the cloned human EP(4) prostanoid receptor. Br J Pharmacol. 2000 Aug;130(8):1919-26.
DMTEACQ	RU	https://pubmed.ncbi.nlm.nih.gov/10952683

DMMTPK3	DI	DMMTPK3
DMMTPK3	DN	135PAM1
DMMTPK3	MI	TT64ZVP
DMMTPK3	MN	Relaxin-3 receptor 1 (RXFP3)
DMMTPK3	MT	DTT
DMMTPK3	MA	Modulator (allosteric modulator)
DMMTPK3	RN	In vitro pharmacological characterization of RXFP3 allosterism: an example of probe dependency. PLoS One. 2012;7(2):e30792.
DMMTPK3	RU	https://pubmed.ncbi.nlm.nih.gov/22347403

DMJ2T7P	DI	DMJ2T7P
DMJ2T7P	DN	13-Acetylphorbol
DMJ2T7P	MI	TT9WJ8U
DMJ2T7P	MN	Protein kinase C delta (PRKCD)
DMJ2T7P	MT	DTT
DMJ2T7P	MA	Inhibitor
DMJ2T7P	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMJ2T7P	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMRVQCB	DI	DMRVQCB
DMRVQCB	DN	13-n-Heptanamidotridec-5-ynoic acid
DMRVQCB	MI	TT7WVHI
DMRVQCB	MN	Soluble epoxide hydrolase (EPHX2)
DMRVQCB	MT	DTT
DMRVQCB	MA	Inhibitor
DMRVQCB	RN	14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxi... J Med Chem. 2009 Aug 27;52(16):5069-75.
DMRVQCB	RU	https://pubmed.ncbi.nlm.nih.gov/19653681

DM0LGWJ	DI	DM0LGWJ
DM0LGWJ	DN	13-n-Heptanamidotridec-8(Z)-enoic acid
DM0LGWJ	MI	TT7WVHI
DM0LGWJ	MN	Soluble epoxide hydrolase (EPHX2)
DM0LGWJ	MT	DTT
DM0LGWJ	MA	Inhibitor
DM0LGWJ	RN	14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxi... J Med Chem. 2009 Aug 27;52(16):5069-75.
DM0LGWJ	RU	https://pubmed.ncbi.nlm.nih.gov/19653681

DM5NFB6	DI	DM5NFB6
DM5NFB6	DN	14-(n-Hexylamino)-14-oxotetradec-8(Z)-enoic acid
DM5NFB6	MI	TT7WVHI
DM5NFB6	MN	Soluble epoxide hydrolase (EPHX2)
DM5NFB6	MT	DTT
DM5NFB6	MA	Inhibitor
DM5NFB6	RN	14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxi... J Med Chem. 2009 Aug 27;52(16):5069-75.
DM5NFB6	RU	https://pubmed.ncbi.nlm.nih.gov/19653681

DMLZT64	DI	DMLZT64
DMLZT64	DN	1400W
DMLZT64	MI	TTZUFI5
DMLZT64	MN	Nitric-oxide synthase brain (NOS1)
DMLZT64	MT	DTT
DMLZT64	MA	Inhibitor
DMLZT64	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMLZT64	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMLZT64	DI	DMLZT64
DMLZT64	DN	1400W
DMLZT64	MI	TTCM4B3
DMLZT64	MN	Nitric-oxide synthase endothelial (NOS3)
DMLZT64	MT	DTT
DMLZT64	MA	Inhibitor
DMLZT64	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMLZT64	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMLZT64	DI	DMLZT64
DMLZT64	DN	1400W
DMLZT64	MI	TTF10I9
DMLZT64	MN	Nitric-oxide synthase inducible (NOS2)
DMLZT64	MT	DTT
DMLZT64	MA	Inhibitor
DMLZT64	RN	1400W is a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo. J Biol Chem. 1997 Feb 21;272(8):4959-63.
DMLZT64	RU	https://pubmed.ncbi.nlm.nih.gov/9030556

DMI7LXH	DI	DMI7LXH
DMI7LXH	DN	14-O-phenylpropylnaltrexone
DMI7LXH	MI	TT27RFC
DMI7LXH	MN	Opioid receptor delta (OPRD1)
DMI7LXH	MT	DTT
DMI7LXH	MA	Inhibitor
DMI7LXH	RN	14 beta-O-cinnamoylnaltrexone and related dihydrocodeinones are mu opioid receptor partial agonists with predominant antagonist activity. J Med Chem. 2009 Mar 26;52(6):1553-7.
DMI7LXH	RU	https://pubmed.ncbi.nlm.nih.gov/19253983

DMI7LXH	DI	DMI7LXH
DMI7LXH	DN	14-O-phenylpropylnaltrexone
DMI7LXH	MI	TTQW87Y
DMI7LXH	MN	Opioid receptor kappa (OPRK1)
DMI7LXH	MT	DTT
DMI7LXH	MA	Inhibitor
DMI7LXH	RN	14 beta-O-cinnamoylnaltrexone and related dihydrocodeinones are mu opioid receptor partial agonists with predominant antagonist activity. J Med Chem. 2009 Mar 26;52(6):1553-7.
DMI7LXH	RU	https://pubmed.ncbi.nlm.nih.gov/19253983

DMI7LXH	DI	DMI7LXH
DMI7LXH	DN	14-O-phenylpropylnaltrexone
DMI7LXH	MI	TTKWM86
DMI7LXH	MN	Opioid receptor mu (MOP)
DMI7LXH	MT	DTT
DMI7LXH	MA	Inhibitor
DMI7LXH	RN	14 beta-O-cinnamoylnaltrexone and related dihydrocodeinones are mu opioid receptor partial agonists with predominant antagonist activity. J Med Chem. 2009 Mar 26;52(6):1553-7.
DMI7LXH	RU	https://pubmed.ncbi.nlm.nih.gov/19253983

DMY9ZT8	DI	DMY9ZT8
DMY9ZT8	DN	15(R)-15-methyl-PGD2
DMY9ZT8	MI	TTQDMX5
DMY9ZT8	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMY9ZT8	MT	DTT
DMY9ZT8	MA	Agonist
DMY9ZT8	RN	CRTH2-specific binding characteristics of [3H]ramatroban and its effects on PGD2-, 15-deoxy-Delta12, 14-PGJ2- and indomethacin-induced agonist resp... Eur J Pharmacol. 2005 Nov 7;524(1-3):30-7.
DMY9ZT8	RU	https://pubmed.ncbi.nlm.nih.gov/16256979

DMG273T	DI	DMG273T
DMG273T	DN	15(S)-15-methyl-PGD2
DMG273T	MI	TTQDMX5
DMG273T	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMG273T	MT	DTT
DMG273T	MA	Agonist
DMG273T	RN	Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2. Br J Pharmacol. 2002 Dec;137(8):1163-72.
DMG273T	RU	https://pubmed.ncbi.nlm.nih.gov/12466225

DMLSZW2	DI	DMLSZW2
DMLSZW2	DN	15-ACETOXY-EREMANTHOLIDE B
DMLSZW2	MI	TTSXVID
DMLSZW2	MN	Nuclear factor NF-kappa-B (NFKB)
DMLSZW2	MT	DTT
DMLSZW2	MA	Inhibitor
DMLSZW2	RN	Quantitative structure-activity relationship of sesquiterpene lactones as inhibitors of the transcription factor NF-kappaB. J Med Chem. 2004 Nov 18;47(24):6042-54.
DMLSZW2	RU	https://pubmed.ncbi.nlm.nih.gov/15537359

DMJC0NQ	DI	DMJC0NQ
DMJC0NQ	DN	15-DEOXYBUDLEIN A
DMJC0NQ	MI	TTSXVID
DMJC0NQ	MN	Nuclear factor NF-kappa-B (NFKB)
DMJC0NQ	MT	DTT
DMJC0NQ	MA	Inhibitor
DMJC0NQ	RN	Quantitative structure-activity relationship of sesquiterpene lactones as inhibitors of the transcription factor NF-kappaB. J Med Chem. 2004 Nov 18;47(24):6042-54.
DMJC0NQ	RU	https://pubmed.ncbi.nlm.nih.gov/15537359

DM8VUX3	DI	DM8VUX3
DM8VUX3	DN	15-deoxy-Delta(12, 14)-prostaglandin J(2)
DM8VUX3	MI	TTZMAO3
DM8VUX3	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DM8VUX3	MT	DTT
DM8VUX3	MA	Agonist
DM8VUX3	RN	Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer. 2003 May 1;104(5):597-602.
DM8VUX3	RU	https://pubmed.ncbi.nlm.nih.gov/12594814

DMJ27QT	DI	DMJ27QT
DMJ27QT	DN	15-deoxy-Delta12,14-PGD2
DMJ27QT	MI	TTQDMX5
DMJ27QT	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMJ27QT	MT	DTT
DMJ27QT	MA	Agonist
DMJ27QT	RN	Expression and molecular pharmacology of the mouse CRTH2 receptor. J Pharmacol Exp Ther. 2003 Aug;306(2):463-70.
DMJ27QT	RU	https://pubmed.ncbi.nlm.nih.gov/12721327

DMNDECA	DI	DMNDECA
DMNDECA	DN	15-deoxy-Delta12,14-PGJ2
DMNDECA	MI	TTNVEIR
DMNDECA	MN	Prostaglandin D2 receptor (PTGDR)
DMNDECA	MT	DTT
DMNDECA	MA	Agonist
DMNDECA	RN	Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist. Br J Pharmacol. 1998 Apr;123(7):1317-24.
DMNDECA	RU	https://pubmed.ncbi.nlm.nih.gov/9579725

DMNDECA	DI	DMNDECA
DMNDECA	DN	15-deoxy-Delta12,14-PGJ2
DMNDECA	MI	TTQDMX5
DMNDECA	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMNDECA	MT	DTT
DMNDECA	MA	Agonist
DMNDECA	RN	Expression and molecular pharmacology of the mouse CRTH2 receptor. J Pharmacol Exp Ther. 2003 Aug;306(2):463-70.
DMNDECA	RU	https://pubmed.ncbi.nlm.nih.gov/12721327

DMR9SFM	DI	DMR9SFM
DMR9SFM	DN	15-deoxygoiazensolide
DMR9SFM	MI	TTSXVID
DMR9SFM	MN	Nuclear factor NF-kappa-B (NFKB)
DMR9SFM	MT	DTT
DMR9SFM	MA	Inhibitor
DMR9SFM	RN	Development of a structural model for NF-kappaB inhibition of sesquiterpene lactones using self-organizing neural networks. J Med Chem. 2006 Apr 6;49(7):2241-52.
DMR9SFM	RU	https://pubmed.ncbi.nlm.nih.gov/16570920

DMEML8B	DI	DMEML8B
DMEML8B	DN	15-hydroxyeicosatetraenoic acid
DMEML8B	MI	TT2J34L
DMEML8B	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMEML8B	MT	DTT
DMEML8B	MA	Inhibitor
DMEML8B	RN	Preview of potential therapeutic applications of leukotriene B4 inhibitors in dermatology. Skin Pharmacol Appl Skin Physiol. 2000 Sep-Oct;13(5):235-45.
DMEML8B	RU	https://pubmed.ncbi.nlm.nih.gov/10940813

DMQCRUG	DI	DMQCRUG
DMQCRUG	DN	15-isobutyrylmiguanin
DMQCRUG	MI	TTSXVID
DMQCRUG	MN	Nuclear factor NF-kappa-B (NFKB)
DMQCRUG	MT	DTT
DMQCRUG	MA	Inhibitor
DMQCRUG	RN	Development of a structural model for NF-kappaB inhibition of sesquiterpene lactones using self-organizing neural networks. J Med Chem. 2006 Apr 6;49(7):2241-52.
DMQCRUG	RU	https://pubmed.ncbi.nlm.nih.gov/16570920

DMDKFGX	DI	DMDKFGX
DMDKFGX	DN	15-nor-18-Methoxycornaridine
DMDKFGX	MI	TTTVAFQ
DMDKFGX	MN	Neuronal acetylcholine receptor beta-4 (CHRNB4)
DMDKFGX	MT	DTT
DMDKFGX	MA	Inhibitor
DMDKFGX	RN	Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents. J Med Chem. 2003 Jun 19;46(13):2716-30.
DMDKFGX	RU	https://pubmed.ncbi.nlm.nih.gov/12801235

DM41LV6	DI	DM41LV6
DM41LV6	DN	15S-HPETE
DM41LV6	MI	TTMI6F5
DM41LV6	MN	Transient receptor potential cation channel V1 (TRPV1)
DM41LV6	MT	DTT
DM41LV6	MA	Activator
DM41LV6	RN	Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc Natl Acad Sci U S A. 2000 May 23;97(11):6155-60.
DM41LV6	RU	https://pubmed.ncbi.nlm.nih.gov/10823958

DMK4N2F	DI	DMK4N2F
DMK4N2F	DN	16-(2',2'-Dimethyl)-propylidene-estradiol
DMK4N2F	MI	TTIWB6L
DMK4N2F	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMK4N2F	MT	DTT
DMK4N2F	MA	Inhibitor
DMK4N2F	RN	Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45.
DMK4N2F	RU	https://pubmed.ncbi.nlm.nih.gov/16480268

DMQYJB1	DI	DMQYJB1
DMQYJB1	DN	16-(2',2'-Dimethyl)-propylidene-estrone
DMQYJB1	MI	TTIWB6L
DMQYJB1	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMQYJB1	MT	DTT
DMQYJB1	MA	Inhibitor
DMQYJB1	RN	Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45.
DMQYJB1	RU	https://pubmed.ncbi.nlm.nih.gov/16480268

DMCHMNF	DI	DMCHMNF
DMCHMNF	DN	16-(3-Ethylureido)hexadec-11(Z)-enoic acid
DMCHMNF	MI	TT7WVHI
DMCHMNF	MN	Soluble epoxide hydrolase (EPHX2)
DMCHMNF	MT	DTT
DMCHMNF	MA	Inhibitor
DMCHMNF	RN	14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxi... J Med Chem. 2009 Aug 27;52(16):5069-75.
DMCHMNF	RU	https://pubmed.ncbi.nlm.nih.gov/19653681

DMTAXZI	DI	DMTAXZI
DMTAXZI	DN	16-(4-cyano-benzylidene)-estradiol
DMTAXZI	MI	TTIWB6L
DMTAXZI	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMTAXZI	MT	DTT
DMTAXZI	MA	Inhibitor
DMTAXZI	RN	Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45.
DMTAXZI	RU	https://pubmed.ncbi.nlm.nih.gov/16480268

DMEH8I0	DI	DMEH8I0
DMEH8I0	DN	16-(4-dimethylamino-benzylidene)-estradiol
DMEH8I0	MI	TTIWB6L
DMEH8I0	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMEH8I0	MT	DTT
DMEH8I0	MA	Inhibitor
DMEH8I0	RN	Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45.
DMEH8I0	RU	https://pubmed.ncbi.nlm.nih.gov/16480268

DMX8YCK	DI	DMX8YCK
DMX8YCK	DN	16-(4-dimethylamino-benzylidene)-estrone
DMX8YCK	MI	TTIWB6L
DMX8YCK	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMX8YCK	MT	DTT
DMX8YCK	MA	Inhibitor
DMX8YCK	RN	Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45.
DMX8YCK	RU	https://pubmed.ncbi.nlm.nih.gov/16480268

DMIC0OU	DI	DMIC0OU
DMIC0OU	DN	16-(pyridin-2-yl)methylene-estradiol
DMIC0OU	MI	TTIWB6L
DMIC0OU	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMIC0OU	MT	DTT
DMIC0OU	MA	Inhibitor
DMIC0OU	RN	Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45.
DMIC0OU	RU	https://pubmed.ncbi.nlm.nih.gov/16480268

DMSXFG0	DI	DMSXFG0
DMSXFG0	DN	16-(pyridin-2-yl)methyl-estradiol
DMSXFG0	MI	TTIWB6L
DMSXFG0	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMSXFG0	MT	DTT
DMSXFG0	MA	Inhibitor
DMSXFG0	RN	Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45.
DMSXFG0	RU	https://pubmed.ncbi.nlm.nih.gov/16480268

DMIMZ21	DI	DMIMZ21
DMIMZ21	DN	16-(pyridin-3-yl)methylene-estradiol
DMIMZ21	MI	TTIWB6L
DMIMZ21	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMIMZ21	MT	DTT
DMIMZ21	MA	Inhibitor
DMIMZ21	RN	Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45.
DMIMZ21	RU	https://pubmed.ncbi.nlm.nih.gov/16480268

DMTD5AO	DI	DMTD5AO
DMTD5AO	DN	16-(pyridin-3-yl)methyl-estradiol
DMTD5AO	MI	TTIWB6L
DMTD5AO	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMTD5AO	MT	DTT
DMTD5AO	MA	Inhibitor
DMTD5AO	RN	Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45.
DMTD5AO	RU	https://pubmed.ncbi.nlm.nih.gov/16480268

DMOTNPC	DI	DMOTNPC
DMOTNPC	DN	16-(pyridin-4-yl)methylene-estradiol
DMOTNPC	MI	TTIWB6L
DMOTNPC	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMOTNPC	MT	DTT
DMOTNPC	MA	Inhibitor
DMOTNPC	RN	Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45.
DMOTNPC	RU	https://pubmed.ncbi.nlm.nih.gov/16480268

DM7NSRI	DI	DM7NSRI
DM7NSRI	DN	16-(pyridin-4-yl)methyl-estradiol
DM7NSRI	MI	TTIWB6L
DM7NSRI	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DM7NSRI	MT	DTT
DM7NSRI	MA	Inhibitor
DM7NSRI	RN	Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45.
DM7NSRI	RU	https://pubmed.ncbi.nlm.nih.gov/16480268

DME3XS4	DI	DME3XS4
DME3XS4	DN	16-(thiophen-2-yl)methylene-estrone
DME3XS4	MI	TTIWB6L
DME3XS4	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DME3XS4	MT	DTT
DME3XS4	MA	Inhibitor
DME3XS4	RN	Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45.
DME3XS4	RU	https://pubmed.ncbi.nlm.nih.gov/16480268

DMI49D0	DI	DMI49D0
DMI49D0	DN	16-alphaH,17-isovaleryloxy-ent-kauran-19-oic acid
DMI49D0	MI	TTELIN2
DMI49D0	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMI49D0	MT	DTT
DMI49D0	MA	Inhibitor
DMI49D0	RN	Inhibition of protein tyrosine phosphatase 1B by diterpenoids isolated from Acanthopanax koreanum. Bioorg Med Chem Lett. 2006 Jun 1;16(11):3061-4.
DMI49D0	RU	https://pubmed.ncbi.nlm.nih.gov/16545563

DMCMP9B	DI	DMCMP9B
DMCMP9B	DN	16beta-cyano-estradiol
DMCMP9B	MI	TTIWB6L
DMCMP9B	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMCMP9B	MT	DTT
DMCMP9B	MA	Inhibitor
DMCMP9B	RN	Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45.
DMCMP9B	RU	https://pubmed.ncbi.nlm.nih.gov/16480268

DMWJNV5	DI	DMWJNV5
DMWJNV5	DN	16-beta-ethoxymethyl-estrone
DMWJNV5	MI	TTIWB6L
DMWJNV5	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMWJNV5	MT	DTT
DMWJNV5	MA	Inhibitor
DMWJNV5	RN	Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45.
DMWJNV5	RU	https://pubmed.ncbi.nlm.nih.gov/16480268

DMUW07J	DI	DMUW07J
DMUW07J	DN	16-beta-hydroxymethyl-estradiol
DMUW07J	MI	TTIWB6L
DMUW07J	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMUW07J	MT	DTT
DMUW07J	MA	Inhibitor
DMUW07J	RN	Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45.
DMUW07J	RU	https://pubmed.ncbi.nlm.nih.gov/16480268

DMTZG68	DI	DMTZG68
DMTZG68	DN	16-isobutylidene-estradiol
DMTZG68	MI	TTIWB6L
DMTZG68	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMTZG68	MT	DTT
DMTZG68	MA	Inhibitor
DMTZG68	RN	Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45.
DMTZG68	RU	https://pubmed.ncbi.nlm.nih.gov/16480268

DMS7PL3	DI	DMS7PL3
DMS7PL3	DN	16-isobutylidene-estrone
DMS7PL3	MI	TTIWB6L
DMS7PL3	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMS7PL3	MT	DTT
DMS7PL3	MA	Inhibitor
DMS7PL3	RN	Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45.
DMS7PL3	RU	https://pubmed.ncbi.nlm.nih.gov/16480268

DMDR1M6	DI	DMDR1M6
DMDR1M6	DN	17 beta-N,N-diethylcarbamoyl-4-aza-5 alpha-androstan-3-one (4MA)
DMDR1M6	MI	TTZT9R2
DMDR1M6	MN	Hydroxysteroid dehydrogenase 3-beta (HSD3B)
DMDR1M6	MT	DTT
DMDR1M6	MA	Inhibitor
DMDR1M6	RN	Inhibition of 3 beta-hydroxysteroid-dehydrogenase: an approach for prostate cancer treatment Anticancer Res. 1995 Jul-Aug;15(4):1349-54.
DMDR1M6	RU	https://pubmed.ncbi.nlm.nih.gov/7654020

DMUQWPZ	DI	DMUQWPZ
DMUQWPZ	DN	17-(Cyclobutylmethyl)-N-phenylmorphinan-3-amine
DMUQWPZ	MI	TT27RFC
DMUQWPZ	MN	Opioid receptor delta (OPRD1)
DMUQWPZ	MT	DTT
DMUQWPZ	MA	Inhibitor
DMUQWPZ	RN	Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18.
DMUQWPZ	RU	https://pubmed.ncbi.nlm.nih.gov/19928862

DMUQWPZ	DI	DMUQWPZ
DMUQWPZ	DN	17-(Cyclobutylmethyl)-N-phenylmorphinan-3-amine
DMUQWPZ	MI	TTQW87Y
DMUQWPZ	MN	Opioid receptor kappa (OPRK1)
DMUQWPZ	MT	DTT
DMUQWPZ	MA	Inhibitor
DMUQWPZ	RN	Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18.
DMUQWPZ	RU	https://pubmed.ncbi.nlm.nih.gov/19928862

DMUQWPZ	DI	DMUQWPZ
DMUQWPZ	DN	17-(Cyclobutylmethyl)-N-phenylmorphinan-3-amine
DMUQWPZ	MI	TTKWM86
DMUQWPZ	MN	Opioid receptor mu (MOP)
DMUQWPZ	MT	DTT
DMUQWPZ	MA	Inhibitor
DMUQWPZ	RN	Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18.
DMUQWPZ	RU	https://pubmed.ncbi.nlm.nih.gov/19928862

DM174HN	DI	DM174HN
DM174HN	DN	17-(Cyclopropylmethyl)-N-phenylmorphinan-3-amine
DM174HN	MI	TT27RFC
DM174HN	MN	Opioid receptor delta (OPRD1)
DM174HN	MT	DTT
DM174HN	MA	Inhibitor
DM174HN	RN	Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18.
DM174HN	RU	https://pubmed.ncbi.nlm.nih.gov/19928862

DM174HN	DI	DM174HN
DM174HN	DN	17-(Cyclopropylmethyl)-N-phenylmorphinan-3-amine
DM174HN	MI	TTQW87Y
DM174HN	MN	Opioid receptor kappa (OPRK1)
DM174HN	MT	DTT
DM174HN	MA	Inhibitor
DM174HN	RN	Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18.
DM174HN	RU	https://pubmed.ncbi.nlm.nih.gov/19928862

DM174HN	DI	DM174HN
DM174HN	DN	17-(Cyclopropylmethyl)-N-phenylmorphinan-3-amine
DM174HN	MI	TTKWM86
DM174HN	MN	Opioid receptor mu (MOP)
DM174HN	MT	DTT
DM174HN	MA	Inhibitor
DM174HN	RN	Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18.
DM174HN	RU	https://pubmed.ncbi.nlm.nih.gov/19928862

DMLC2VE	DI	DMLC2VE
DMLC2VE	DN	177Lu-labelled RM2
DMLC2VE	MI	TTC1MVT
DMLC2VE	MN	Gastrin-releasing peptide receptor (GRPR)
DMLC2VE	MT	DTT
DMLC2VE	MA	Antagonist
DMLC2VE	RN	Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608.
DMLC2VE	RU	https://pubmed.ncbi.nlm.nih.gov/32728208

DMT2EPG	DI	DMT2EPG
DMT2EPG	DN	17alpha-hydroxypregnenolone
DMT2EPG	MI	DEN0GVQ
DMT2EPG	MN	Beta-HSD adrenal and gonadal type (HSD3B2)
DMT2EPG	MT	DME
DMT2EPG	MA	Metabolism
DMT2EPG	RN	Structure/function relationships responsible for the kinetic differences between human type 1 and type 2 3beta-hydroxysteroid dehydrogenase and for the catalysis of the type 1 activity. J Biol Chem. 2002 Nov 8;277(45):42795-801.
DMT2EPG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12205101

DMT2EPG	DI	DMT2EPG
DMT2EPG	DN	17alpha-hydroxypregnenolone
DMT2EPG	MI	DERDQWN
DMT2EPG	MN	Dihydrotestosterone oxidoreductase (HSD3B1)
DMT2EPG	MT	DME
DMT2EPG	MA	Metabolism
DMT2EPG	RN	Structure/function relationships responsible for the kinetic differences between human type 1 and type 2 3beta-hydroxysteroid dehydrogenase and for the catalysis of the type 1 activity. J Biol Chem. 2002 Nov 8;277(45):42795-801.
DMT2EPG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12205101

DM7UHJS	DI	DM7UHJS
DM7UHJS	DN	17-dehydroxyriccardin C
DM7UHJS	MI	TTECBXN
DM7UHJS	MN	Oxysterols receptor LXR-alpha (NR1H3)
DM7UHJS	MT	DTT
DM7UHJS	MA	Inhibitor
DM7UHJS	RN	Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85.
DM7UHJS	RU	https://pubmed.ncbi.nlm.nih.gov/18343126

DM7UHJS	DI	DM7UHJS
DM7UHJS	DN	17-dehydroxyriccardin C
DM7UHJS	MI	TTXA6PH
DM7UHJS	MN	Oxysterols receptor LXR-beta (NR1H2)
DM7UHJS	MT	DTT
DM7UHJS	MA	Inhibitor
DM7UHJS	RN	Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85.
DM7UHJS	RU	https://pubmed.ncbi.nlm.nih.gov/18343126

DMCALYO	DI	DMCALYO
DMCALYO	DN	17-desmethoxy-17-aminogeldanamycin
DMCALYO	MI	TT78R5H
DMCALYO	MN	Heat shock protein 90 alpha (HSP90A)
DMCALYO	MT	DTT
DMCALYO	MA	Inhibitor
DMCALYO	RN	Heat shock protein 90: inhibitors in clinical trials. J Med Chem. 2010 Jan 14;53(1):3-17.
DMCALYO	RU	https://pubmed.ncbi.nlm.nih.gov/20055425

DMKUGH1	DI	DMKUGH1
DMKUGH1	DN	17-METHYL-17-ALPHA-DIHYDROEQUILENIN
DMKUGH1	MI	TTZAYWL
DMKUGH1	MN	Estrogen receptor (ESR)
DMKUGH1	MT	DTT
DMKUGH1	MA	Inhibitor
DMKUGH1	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMKUGH1	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMMEB64	DI	DMMEB64
DMMEB64	DN	17-methyl-4'-methyldihydromorphinone
DMMEB64	MI	TT27RFC
DMMEB64	MN	Opioid receptor delta (OPRD1)
DMMEB64	MT	DTT
DMMEB64	MA	Inhibitor
DMMEB64	RN	Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effect of substitution in the aromatic ring of cinnamoylaminomorp... J Med Chem. 2006 Aug 24;49(17):5333-8.
DMMEB64	RU	https://pubmed.ncbi.nlm.nih.gov/16913723

DMMEB64	DI	DMMEB64
DMMEB64	DN	17-methyl-4'-methyldihydromorphinone
DMMEB64	MI	TTQW87Y
DMMEB64	MN	Opioid receptor kappa (OPRK1)
DMMEB64	MT	DTT
DMMEB64	MA	Inhibitor
DMMEB64	RN	Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effect of substitution in the aromatic ring of cinnamoylaminomorp... J Med Chem. 2006 Aug 24;49(17):5333-8.
DMMEB64	RU	https://pubmed.ncbi.nlm.nih.gov/16913723

DMMEB64	DI	DMMEB64
DMMEB64	DN	17-methyl-4'-methyldihydromorphinone
DMMEB64	MI	TTKWM86
DMMEB64	MN	Opioid receptor mu (MOP)
DMMEB64	MT	DTT
DMMEB64	MA	Inhibitor
DMMEB64	RN	Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effect of substitution in the aromatic ring of cinnamoylaminomorp... J Med Chem. 2006 Aug 24;49(17):5333-8.
DMMEB64	RU	https://pubmed.ncbi.nlm.nih.gov/16913723

DMI4WCQ	DI	DMI4WCQ
DMI4WCQ	DN	17-Methylmorphinan-3-yl 4-Iodophenyl Carbamate
DMI4WCQ	MI	TT27RFC
DMI4WCQ	MN	Opioid receptor delta (OPRD1)
DMI4WCQ	MT	DTT
DMI4WCQ	MA	Inhibitor
DMI4WCQ	RN	Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18.
DMI4WCQ	RU	https://pubmed.ncbi.nlm.nih.gov/19928862

DMI4WCQ	DI	DMI4WCQ
DMI4WCQ	DN	17-Methylmorphinan-3-yl 4-Iodophenyl Carbamate
DMI4WCQ	MI	TTQW87Y
DMI4WCQ	MN	Opioid receptor kappa (OPRK1)
DMI4WCQ	MT	DTT
DMI4WCQ	MA	Inhibitor
DMI4WCQ	RN	Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18.
DMI4WCQ	RU	https://pubmed.ncbi.nlm.nih.gov/19928862

DMI4WCQ	DI	DMI4WCQ
DMI4WCQ	DN	17-Methylmorphinan-3-yl 4-Iodophenyl Carbamate
DMI4WCQ	MI	TTKWM86
DMI4WCQ	MN	Opioid receptor mu (MOP)
DMI4WCQ	MT	DTT
DMI4WCQ	MA	Inhibitor
DMI4WCQ	RN	Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18.
DMI4WCQ	RU	https://pubmed.ncbi.nlm.nih.gov/19928862

DM9OMI3	DI	DM9OMI3
DM9OMI3	DN	17-phenyl-omega-trinor-PGE2
DM9OMI3	MI	TTG1QMU
DM9OMI3	MN	Prostaglandin E2 receptor EP1 (PTGER1)
DM9OMI3	MT	DTT
DM9OMI3	MA	Agonist
DM9OMI3	RN	Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41.
DM9OMI3	RU	https://pubmed.ncbi.nlm.nih.gov/9537820

DM9OMI3	DI	DM9OMI3
DM9OMI3	DN	17-phenyl-omega-trinor-PGE2
DM9OMI3	MI	TT1ZAVI
DM9OMI3	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DM9OMI3	MT	DTT
DM9OMI3	MA	Agonist
DM9OMI3	RN	Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41.
DM9OMI3	RU	https://pubmed.ncbi.nlm.nih.gov/9537820

DM9OMI3	DI	DM9OMI3
DM9OMI3	DN	17-phenyl-omega-trinor-PGE2
DM9OMI3	MI	TTPNGDE
DM9OMI3	MN	Prostaglandin E2 receptor EP3 (PTGER3)
DM9OMI3	MT	DTT
DM9OMI3	MA	Agonist
DM9OMI3	RN	Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
DM9OMI3	RU	https://pubmed.ncbi.nlm.nih.gov/9313928

DMYS6DB	DI	DMYS6DB
DMYS6DB	DN	18alpha-Glycyrrhetic acid
DMYS6DB	MI	TTELIN2
DMYS6DB	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMYS6DB	MT	DTT
DMYS6DB	MA	Inhibitor
DMYS6DB	RN	Protein tyrosine phosphatase 1B inhibitory activity of triterpenes isolated from Astilbe koreana. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3273-6.
DMYS6DB	RU	https://pubmed.ncbi.nlm.nih.gov/16580200

DMFMRN8	DI	DMFMRN8
DMFMRN8	DN	18beta-Glycyrrhetic acid
DMFMRN8	MI	TTELIN2
DMFMRN8	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMFMRN8	MT	DTT
DMFMRN8	MA	Inhibitor
DMFMRN8	RN	Protein tyrosine phosphatase 1B inhibitory activity of triterpenes isolated from Astilbe koreana. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3273-6.
DMFMRN8	RU	https://pubmed.ncbi.nlm.nih.gov/16580200

DM0JEQ6	DI	DM0JEQ6
DM0JEQ6	DN	18-Dimethylaminocoronaridine
DM0JEQ6	MI	TTTVAFQ
DM0JEQ6	MN	Neuronal acetylcholine receptor beta-4 (CHRNB4)
DM0JEQ6	MT	DTT
DM0JEQ6	MA	Inhibitor
DM0JEQ6	RN	Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents. J Med Chem. 2003 Jun 19;46(13):2716-30.
DM0JEQ6	RU	https://pubmed.ncbi.nlm.nih.gov/12801235

DMAPI2G	DI	DMAPI2G
DMAPI2G	DN	18F-AV-45 dimer
DMAPI2G	MI	TTE4KHA
DMAPI2G	MN	Amyloid beta A4 protein (APP)
DMAPI2G	MT	DTT
DMAPI2G	MA	Modulator
DMAPI2G	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
DMAPI2G	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402

DM2VZMC	DI	DM2VZMC
DM2VZMC	DN	18F-SMIBR-K5
DM2VZMC	MI	TT69TQN
DM2VZMC	MN	Integrin alpha-V/beta-3 (ITGAV/B3)
DM2VZMC	MT	DTT
DM2VZMC	MA	Modulator
DM2VZMC	RN	Synthesis of [18F]RGD-K5 by catalyzed [3 + 2] cycloaddition for imaging integrin alphavbeta3 expression in vivo. Nucl Med Biol. 2013 Jul;40(5):710-6.
DM2VZMC	RU	https://pubmed.ncbi.nlm.nih.gov/23706550

DMBG9Z3	DI	DMBG9Z3
DMBG9Z3	DN	18-methoxycoronaridinate 2-Hydroxyethylamide
DMBG9Z3	MI	TTTVAFQ
DMBG9Z3	MN	Neuronal acetylcholine receptor beta-4 (CHRNB4)
DMBG9Z3	MT	DTT
DMBG9Z3	MA	Inhibitor
DMBG9Z3	RN	Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents. J Med Chem. 2003 Jun 19;46(13):2716-30.
DMBG9Z3	RU	https://pubmed.ncbi.nlm.nih.gov/12801235

DMSBAC0	DI	DMSBAC0
DMSBAC0	DN	18-methoxycoronaridinate 2-methoxyethylamide
DMSBAC0	MI	TTTVAFQ
DMSBAC0	MN	Neuronal acetylcholine receptor beta-4 (CHRNB4)
DMSBAC0	MT	DTT
DMSBAC0	MA	Inhibitor
DMSBAC0	RN	Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents. J Med Chem. 2003 Jun 19;46(13):2716-30.
DMSBAC0	RU	https://pubmed.ncbi.nlm.nih.gov/12801235

DMTJ384	DI	DMTJ384
DMTJ384	DN	18-Methoxycoronaridine
DMTJ384	MI	TTMT0HG
DMTJ384	MN	Neuronal acetylcholine receptor alpha-2/alpha-3 (CHRNA2/A3)
DMTJ384	MT	DTT
DMTJ384	MA	Antagonist
DMTJ384	RN	Antagonism of alpha 3 beta 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration. Eur J Pharmacol. 2002 Mar 1;438(1-2):99-105.
DMTJ384	RU	https://pubmed.ncbi.nlm.nih.gov/11906717

DMOYC0U	DI	DMOYC0U
DMOYC0U	DN	18-Methylaminocoronaridine
DMOYC0U	MI	TTTVAFQ
DMOYC0U	MN	Neuronal acetylcholine receptor beta-4 (CHRNB4)
DMOYC0U	MT	DTT
DMOYC0U	MA	Inhibitor
DMOYC0U	RN	Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents. J Med Chem. 2003 Jun 19;46(13):2716-30.
DMOYC0U	RU	https://pubmed.ncbi.nlm.nih.gov/12801235

DMGUKCF	DI	DMGUKCF
DMGUKCF	DN	19(R)-OH-PGE2
DMGUKCF	MI	TT1ZAVI
DMGUKCF	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DMGUKCF	MT	DTT
DMGUKCF	MA	Agonist
DMGUKCF	RN	Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41.
DMGUKCF	RU	https://pubmed.ncbi.nlm.nih.gov/9537820

DMGUKCF	DI	DMGUKCF
DMGUKCF	DN	19(R)-OH-PGE2
DMGUKCF	MI	TT79WV3
DMGUKCF	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DMGUKCF	MT	DTT
DMGUKCF	MA	Agonist
DMGUKCF	RN	Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41.
DMGUKCF	RU	https://pubmed.ncbi.nlm.nih.gov/9537820

DMP168O	DI	DMP168O
DMP168O	DN	19alpha,24-dihydroxyurs-12-en-3-on-28-oic acid
DMP168O	MI	TTELIN2
DMP168O	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMP168O	MT	DTT
DMP168O	MA	Inhibitor
DMP168O	RN	Triterpenoids from the leaves of Diospyros kaki (persimmon) and their inhibitory effects on protein tyrosine phosphatase 1B. J Nat Prod. 2008 Oct;71(10):1775-8.
DMP168O	RU	https://pubmed.ncbi.nlm.nih.gov/18798681

DM92ZCU	DI	DM92ZCU
DM92ZCU	DN	1-acetamido-5-sulfonamidoindane
DM92ZCU	MI	TTHQPL7
DM92ZCU	MN	Carbonic anhydrase I (CA-I)
DM92ZCU	MT	DTT
DM92ZCU	MA	Inhibitor
DM92ZCU	RN	Carbonic anhydrase inhibitors. Design of anticonvulsant sulfonamides incorporating indane moieties. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5781-6.
DM92ZCU	RU	https://pubmed.ncbi.nlm.nih.gov/15501040

DM92ZCU	DI	DM92ZCU
DM92ZCU	DN	1-acetamido-5-sulfonamidoindane
DM92ZCU	MI	TTANPDJ
DM92ZCU	MN	Carbonic anhydrase II (CA-II)
DM92ZCU	MT	DTT
DM92ZCU	MA	Inhibitor
DM92ZCU	RN	Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9.
DM92ZCU	RU	https://pubmed.ncbi.nlm.nih.gov/16640335

DM92ZCU	DI	DM92ZCU
DM92ZCU	DN	1-acetamido-5-sulfonamidoindane
DM92ZCU	MI	TT2LVK8
DM92ZCU	MN	Carbonic anhydrase IX (CA-IX)
DM92ZCU	MT	DTT
DM92ZCU	MA	Inhibitor
DM92ZCU	RN	Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9.
DM92ZCU	RU	https://pubmed.ncbi.nlm.nih.gov/16640335

DM7DL03	DI	DM7DL03
DM7DL03	DN	1-Acetoxy-2-tert-butyldimethylsilyl-oxylycorine
DM7DL03	MI	TTXV4FI
DM7DL03	MN	Albendazole monooxygenase (CYP3A4)
DM7DL03	MT	DTT
DM7DL03	MA	Inhibitor
DM7DL03	RN	Selective cytochrome P450 3A4 inhibitory activity of Amaryllidaceae alkaloids. Bioorg Med Chem Lett. 2009 Jun 15;19(12):3233-7.
DM7DL03	RU	https://pubmed.ncbi.nlm.nih.gov/19428250

DMMP7HU	DI	DMMP7HU
DMMP7HU	DN	1'-acetoxychavicol acetate
DMMP7HU	MI	TTELV3W
DMMP7HU	MN	Transformation-sensitive protein p120 (TRPA1)
DMMP7HU	MT	DTT
DMMP7HU	MA	Activator
DMMP7HU	RN	Galangal pungent component, 1'-acetoxychavicol acetate, activates TRPA1. Biosci Biotechnol Biochem. 2010;74(8):1694-6.
DMMP7HU	RU	https://pubmed.ncbi.nlm.nih.gov/20699565

DMQH1MS	DI	DMQH1MS
DMQH1MS	DN	1-Acetoxylycorine
DMQH1MS	MI	TTXV4FI
DMQH1MS	MN	Albendazole monooxygenase (CYP3A4)
DMQH1MS	MT	DTT
DMQH1MS	MA	Inhibitor
DMQH1MS	RN	Selective cytochrome P450 3A4 inhibitory activity of Amaryllidaceae alkaloids. Bioorg Med Chem Lett. 2009 Jun 15;19(12):3233-7.
DMQH1MS	RU	https://pubmed.ncbi.nlm.nih.gov/19428250

DMRJSG7	DI	DMRJSG7
DMRJSG7	DN	1-adamantan-1-yl-3-((R)-1-phenyl-ethyl)-urea
DMRJSG7	MI	TT7WVHI
DMRJSG7	MN	Soluble epoxide hydrolase (EPHX2)
DMRJSG7	MT	DTT
DMRJSG7	MA	Inhibitor
DMRJSG7	RN	Solid-phase combinatorial approach for the optimization of soluble epoxide hydrolase inhibitors. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5773-7.
DMRJSG7	RU	https://pubmed.ncbi.nlm.nih.gov/16949285

DMNXU1O	DI	DMNXU1O
DMNXU1O	DN	1-adamantan-1-yl-3-(1-benzyl-piperidin-4-yl)-urea
DMNXU1O	MI	TT7WVHI
DMNXU1O	MN	Soluble epoxide hydrolase (EPHX2)
DMNXU1O	MT	DTT
DMNXU1O	MA	Inhibitor
DMNXU1O	RN	Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5212-6.
DMNXU1O	RU	https://pubmed.ncbi.nlm.nih.gov/16870439

DMAJC42	DI	DMAJC42
DMAJC42	DN	1-adamantan-1-yl-3-(1-butyl-piperidin-4-yl)-urea
DMAJC42	MI	TT7WVHI
DMAJC42	MN	Soluble epoxide hydrolase (EPHX2)
DMAJC42	MT	DTT
DMAJC42	MA	Inhibitor
DMAJC42	RN	Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5212-6.
DMAJC42	RU	https://pubmed.ncbi.nlm.nih.gov/16870439

DMY1Z2X	DI	DMY1Z2X
DMY1Z2X	DN	1-adamantan-1-yl-3-(1-ethyl-piperidin-4-yl)-urea
DMY1Z2X	MI	TT7WVHI
DMY1Z2X	MN	Soluble epoxide hydrolase (EPHX2)
DMY1Z2X	MT	DTT
DMY1Z2X	MA	Inhibitor
DMY1Z2X	RN	Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5212-6.
DMY1Z2X	RU	https://pubmed.ncbi.nlm.nih.gov/16870439

DM2K7TX	DI	DM2K7TX
DM2K7TX	DN	1-adamantan-1-yl-3-(1-propyl-piperidin-4-yl)-urea
DM2K7TX	MI	TT7WVHI
DM2K7TX	MN	Soluble epoxide hydrolase (EPHX2)
DM2K7TX	MT	DTT
DM2K7TX	MA	Inhibitor
DM2K7TX	RN	Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5212-6.
DM2K7TX	RU	https://pubmed.ncbi.nlm.nih.gov/16870439

DMRIYX9	DI	DMRIYX9
DMRIYX9	DN	1-adamantan-1-yl-3-(2-heptyloxyethyl)urea
DMRIYX9	MI	TT7WVHI
DMRIYX9	MN	Soluble epoxide hydrolase (EPHX2)
DMRIYX9	MT	DTT
DMRIYX9	MA	Inhibitor
DMRIYX9	RN	1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic prope... J Med Chem. 2007 Oct 18;50(21):5217-26.
DMRIYX9	RU	https://pubmed.ncbi.nlm.nih.gov/17894481

DMDO9YM	DI	DMDO9YM
DMDO9YM	DN	1-adamantan-1-yl-3-(2-hydroxyethyl)urea
DMDO9YM	MI	TT7WVHI
DMDO9YM	MN	Soluble epoxide hydrolase (EPHX2)
DMDO9YM	MT	DTT
DMDO9YM	MA	Inhibitor
DMDO9YM	RN	1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic prope... J Med Chem. 2007 Oct 18;50(21):5217-26.
DMDO9YM	RU	https://pubmed.ncbi.nlm.nih.gov/17894481

DMJ8ZS6	DI	DMJ8ZS6
DMJ8ZS6	DN	1-Adamantan-1-yl-3-(2-hydroxy-phenyl)-urea
DMJ8ZS6	MI	TT7WVHI
DMJ8ZS6	MN	Soluble epoxide hydrolase (EPHX2)
DMJ8ZS6	MT	DTT
DMJ8ZS6	MA	Inhibitor
DMJ8ZS6	RN	Salicylate-urea-based soluble epoxide hydrolase inhibitors with high metabolic and chemical stabilities. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1784-9.
DMJ8ZS6	RU	https://pubmed.ncbi.nlm.nih.gov/19216074

DMRBVFO	DI	DMRBVFO
DMRBVFO	DN	1-Adamantan-1-yl-3-(2-methoxy-phenyl)-urea
DMRBVFO	MI	TT7WVHI
DMRBVFO	MN	Soluble epoxide hydrolase (EPHX2)
DMRBVFO	MT	DTT
DMRBVFO	MA	Inhibitor
DMRBVFO	RN	Salicylate-urea-based soluble epoxide hydrolase inhibitors with high metabolic and chemical stabilities. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1784-9.
DMRBVFO	RU	https://pubmed.ncbi.nlm.nih.gov/19216074

DMGEXOZ	DI	DMGEXOZ
DMGEXOZ	DN	1-adamantan-1-yl-3-(3-hexyloxypropyl)urea
DMGEXOZ	MI	TT7WVHI
DMGEXOZ	MN	Soluble epoxide hydrolase (EPHX2)
DMGEXOZ	MT	DTT
DMGEXOZ	MA	Inhibitor
DMGEXOZ	RN	1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic prope... J Med Chem. 2007 Oct 18;50(21):5217-26.
DMGEXOZ	RU	https://pubmed.ncbi.nlm.nih.gov/17894481

DM8SEJP	DI	DM8SEJP
DM8SEJP	DN	1-Adamantan-1-yl-3-(3-hydroxy-phenyl)-urea
DM8SEJP	MI	TT7WVHI
DM8SEJP	MN	Soluble epoxide hydrolase (EPHX2)
DM8SEJP	MT	DTT
DM8SEJP	MA	Inhibitor
DM8SEJP	RN	Salicylate-urea-based soluble epoxide hydrolase inhibitors with high metabolic and chemical stabilities. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1784-9.
DM8SEJP	RU	https://pubmed.ncbi.nlm.nih.gov/19216074

DMZX72E	DI	DMZX72E
DMZX72E	DN	1-adamantan-1-yl-3-(3-hydroxypropyl)urea
DMZX72E	MI	TT7WVHI
DMZX72E	MN	Soluble epoxide hydrolase (EPHX2)
DMZX72E	MT	DTT
DMZX72E	MA	Inhibitor
DMZX72E	RN	1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic prope... J Med Chem. 2007 Oct 18;50(21):5217-26.
DMZX72E	RU	https://pubmed.ncbi.nlm.nih.gov/17894481

DMHAS3G	DI	DMHAS3G
DMHAS3G	DN	1-Adamantan-1-yl-3-(3-methoxy-phenyl)-urea
DMHAS3G	MI	TT7WVHI
DMHAS3G	MN	Soluble epoxide hydrolase (EPHX2)
DMHAS3G	MT	DTT
DMHAS3G	MA	Inhibitor
DMHAS3G	RN	Salicylate-urea-based soluble epoxide hydrolase inhibitors with high metabolic and chemical stabilities. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1784-9.
DMHAS3G	RU	https://pubmed.ncbi.nlm.nih.gov/19216074

DM53G1V	DI	DM53G1V
DM53G1V	DN	1-adamantan-1-yl-3-(4-hydroxybutyl)urea
DM53G1V	MI	TT7WVHI
DM53G1V	MN	Soluble epoxide hydrolase (EPHX2)
DM53G1V	MT	DTT
DM53G1V	MA	Inhibitor
DM53G1V	RN	1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic prope... J Med Chem. 2007 Oct 18;50(21):5217-26.
DM53G1V	RU	https://pubmed.ncbi.nlm.nih.gov/17894481

DMHKG89	DI	DMHKG89
DMHKG89	DN	1-Adamantan-1-yl-3-(4-hydroxy-decyl)-urea
DMHKG89	MI	TT7WVHI
DMHKG89	MN	Soluble epoxide hydrolase (EPHX2)
DMHKG89	MT	DTT
DMHKG89	MA	Inhibitor
DMHKG89	RN	Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem. 2005 May 19;48(10):3621-9.
DMHKG89	RU	https://pubmed.ncbi.nlm.nih.gov/15887969

DMUPAR1	DI	DMUPAR1
DMUPAR1	DN	1-Adamantan-1-yl-3-(4-hydroxy-phenyl)-urea
DMUPAR1	MI	TT7WVHI
DMUPAR1	MN	Soluble epoxide hydrolase (EPHX2)
DMUPAR1	MT	DTT
DMUPAR1	MA	Inhibitor
DMUPAR1	RN	Salicylate-urea-based soluble epoxide hydrolase inhibitors with high metabolic and chemical stabilities. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1784-9.
DMUPAR1	RU	https://pubmed.ncbi.nlm.nih.gov/19216074

DMMBYOD	DI	DMMBYOD
DMMBYOD	DN	1-Adamantan-1-yl-3-(4-methoxy-phenyl)-urea
DMMBYOD	MI	TT7WVHI
DMMBYOD	MN	Soluble epoxide hydrolase (EPHX2)
DMMBYOD	MT	DTT
DMMBYOD	MA	Inhibitor
DMMBYOD	RN	Salicylate-urea-based soluble epoxide hydrolase inhibitors with high metabolic and chemical stabilities. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1784-9.
DMMBYOD	RU	https://pubmed.ncbi.nlm.nih.gov/19216074

DM3RE2D	DI	DM3RE2D
DM3RE2D	DN	1-adamantan-1-yl-3-(4-pentyloxybutyl)urea
DM3RE2D	MI	TT7WVHI
DM3RE2D	MN	Soluble epoxide hydrolase (EPHX2)
DM3RE2D	MT	DTT
DM3RE2D	MA	Inhibitor
DM3RE2D	RN	1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic prope... J Med Chem. 2007 Oct 18;50(21):5217-26.
DM3RE2D	RU	https://pubmed.ncbi.nlm.nih.gov/17894481

DMUZ3OS	DI	DMUZ3OS
DMUZ3OS	DN	1-adamantan-1-yl-3-(4-pentyloxycylclohexyl)urea
DMUZ3OS	MI	TT7WVHI
DMUZ3OS	MN	Soluble epoxide hydrolase (EPHX2)
DMUZ3OS	MT	DTT
DMUZ3OS	MA	Inhibitor
DMUZ3OS	RN	1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic prope... J Med Chem. 2007 Oct 18;50(21):5217-26.
DMUZ3OS	RU	https://pubmed.ncbi.nlm.nih.gov/17894481

DMEDQVX	DI	DMEDQVX
DMEDQVX	DN	1-adamantan-1-yl-3-(5-butoxypentyl)urea
DMEDQVX	MI	TT7WVHI
DMEDQVX	MN	Soluble epoxide hydrolase (EPHX2)
DMEDQVX	MT	DTT
DMEDQVX	MA	Inhibitor
DMEDQVX	RN	1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic prope... J Med Chem. 2007 Oct 18;50(21):5217-26.
DMEDQVX	RU	https://pubmed.ncbi.nlm.nih.gov/17894481

DMV6824	DI	DMV6824
DMV6824	DN	1-adamantan-1-yl-3-(5-hydroxypentyl)urea
DMV6824	MI	TT7WVHI
DMV6824	MN	Soluble epoxide hydrolase (EPHX2)
DMV6824	MT	DTT
DMV6824	MA	Inhibitor
DMV6824	RN	1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic prope... J Med Chem. 2007 Oct 18;50(21):5217-26.
DMV6824	RU	https://pubmed.ncbi.nlm.nih.gov/17894481

DMOX5MC	DI	DMOX5MC
DMOX5MC	DN	1-adamantan-1-yl-3-(6-hydroxyhexyl)urea
DMOX5MC	MI	TT7WVHI
DMOX5MC	MN	Soluble epoxide hydrolase (EPHX2)
DMOX5MC	MT	DTT
DMOX5MC	MA	Inhibitor
DMOX5MC	RN	1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic prope... J Med Chem. 2007 Oct 18;50(21):5217-26.
DMOX5MC	RU	https://pubmed.ncbi.nlm.nih.gov/17894481

DMO1L3I	DI	DMO1L3I
DMO1L3I	DN	1-adamantan-1-yl-3-(6-propyloxyhexyl)urea
DMO1L3I	MI	TT7WVHI
DMO1L3I	MN	Soluble epoxide hydrolase (EPHX2)
DMO1L3I	MT	DTT
DMO1L3I	MA	Inhibitor
DMO1L3I	RN	1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic prope... J Med Chem. 2007 Oct 18;50(21):5217-26.
DMO1L3I	RU	https://pubmed.ncbi.nlm.nih.gov/17894481

DMXRHKQ	DI	DMXRHKQ
DMXRHKQ	DN	1-adamantan-1-yl-3-[4-(4-fluorophenoxy)butyl]urea
DMXRHKQ	MI	TT7WVHI
DMXRHKQ	MN	Soluble epoxide hydrolase (EPHX2)
DMXRHKQ	MT	DTT
DMXRHKQ	MA	Inhibitor
DMXRHKQ	RN	Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem. 2007 Aug 9;50(16):3825-40.
DMXRHKQ	RU	https://pubmed.ncbi.nlm.nih.gov/17616115

DMLD2G3	DI	DMLD2G3
DMLD2G3	DN	1-Adamantan-1-yl-3-decyl-urea
DMLD2G3	MI	TT7WVHI
DMLD2G3	MN	Soluble epoxide hydrolase (EPHX2)
DMLD2G3	MT	DTT
DMLD2G3	MA	Inhibitor
DMLD2G3	RN	Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem. 2005 May 19;48(10):3621-9.
DMLD2G3	RU	https://pubmed.ncbi.nlm.nih.gov/15887969

DMCFKX0	DI	DMCFKX0
DMCFKX0	DN	1-Adamantan-1-yl-3-phenyl-urea
DMCFKX0	MI	TT7WVHI
DMCFKX0	MN	Soluble epoxide hydrolase (EPHX2)
DMCFKX0	MT	DTT
DMCFKX0	MA	Inhibitor
DMCFKX0	RN	Salicylate-urea-based soluble epoxide hydrolase inhibitors with high metabolic and chemical stabilities. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1784-9.
DMCFKX0	RU	https://pubmed.ncbi.nlm.nih.gov/19216074

DMGPIL0	DI	DMGPIL0
DMGPIL0	DN	1-adamantan-1-yl-3-piperidin-4-ylmethyl-urea
DMGPIL0	MI	TT7WVHI
DMGPIL0	MN	Soluble epoxide hydrolase (EPHX2)
DMGPIL0	MT	DTT
DMGPIL0	MA	Inhibitor
DMGPIL0	RN	Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5212-6.
DMGPIL0	RU	https://pubmed.ncbi.nlm.nih.gov/16870439

DMTNPBH	DI	DMTNPBH
DMTNPBH	DN	1-adamantan-1-yl-3-piperidin-4-yl-urea
DMTNPBH	MI	TT7WVHI
DMTNPBH	MN	Soluble epoxide hydrolase (EPHX2)
DMTNPBH	MT	DTT
DMTNPBH	MA	Inhibitor
DMTNPBH	RN	Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5212-6.
DMTNPBH	RU	https://pubmed.ncbi.nlm.nih.gov/16870439

DM60Y8M	DI	DM60Y8M
DM60Y8M	DN	1-Adamantan-1-ylmethyl-3-thiazol-2-yl-thiourea
DM60Y8M	MI	TT84ETX
DM60Y8M	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM60Y8M	MT	DTT
DM60Y8M	MA	Inhibitor
DM60Y8M	RN	Anti-HIV activity of aromatic and heterocyclic thiazolyl thiourea compounds. Bioorg Med Chem Lett. 2001 Feb 26;11(4):523-8.
DM60Y8M	RU	https://pubmed.ncbi.nlm.nih.gov/11229762

DMQJ9RZ	DI	DMQJ9RZ
DMQJ9RZ	DN	1-allyl-2-[3-(isopropylamino)propoxy]-9H-carbazole
DMQJ9RZ	MI	TTFQEO5
DMQJ9RZ	MN	Squalene synthetase (FDFT1)
DMQJ9RZ	MT	DTT
DMQJ9RZ	MA	Inhibitor
DMQJ9RZ	RN	Synthesis and biological evaluation of novel propylamine derivatives as orally active squalene synthase inhibitors. Bioorg Med Chem. 2004 Nov 15;12(22):5899-908.
DMQJ9RZ	RU	https://pubmed.ncbi.nlm.nih.gov/15498666

DMNDW4J	DI	DMNDW4J
DMNDW4J	DN	1-allyl-2-[3-(isopropylamino)propoxy]-9H-xanthen-9-one
DMNDW4J	MI	TTFQEO5
DMNDW4J	MN	Squalene synthetase (FDFT1)
DMNDW4J	MT	DTT
DMNDW4J	MA	Inhibitor
DMNDW4J	RN	Synthesis and biological evaluation of novel propylamine derivatives as orally active squalene synthase inhibitors. Bioorg Med Chem. 2004 Nov 15;12(22):5899-908.
DMNDW4J	RU	https://pubmed.ncbi.nlm.nih.gov/15498666

DML54H2	DI	DML54H2
DML54H2	DN	1-Allyl-3,7-dihydro-purine-2,6-dione
DML54H2	MI	TTJFY5U
DML54H2	MN	Adenosine A3 receptor (ADORA3)
DML54H2	MT	DTT
DML54H2	MA	Inhibitor
DML54H2	RN	Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. J Med Chem. 2002 May 23;45(11):2131-8.
DML54H2	RU	https://pubmed.ncbi.nlm.nih.gov/12014951

DMZE5GX	DI	DMZE5GX
DMZE5GX	DN	1-Allyl-3,7-dimethyl-3,7-dihydro-purine-2,6-dione
DMZE5GX	MI	TTM2AOE
DMZE5GX	MN	Adenosine A2a receptor (ADORA2A)
DMZE5GX	MT	DTT
DMZE5GX	MA	Inhibitor
DMZE5GX	RN	Analogues of caffeine and theophylline: effect of structural alterations on affinity at adenosine receptors. J Med Chem. 1986 Jul;29(7):1305-8.
DMZE5GX	RU	https://pubmed.ncbi.nlm.nih.gov/3806581

DM2J5WH	DI	DM2J5WH
DM2J5WH	DN	1-allyl-5'-O-tritylinosine
DM2J5WH	MI	TTO0IB8
DM2J5WH	MN	Thymidine phosphorylase (TYMP)
DM2J5WH	MT	DTT
DM2J5WH	MA	Inhibitor
DM2J5WH	RN	5'-O-tritylinosine and analogues as allosteric inhibitors of human thymidine phosphorylase. J Med Chem. 2006 Sep 7;49(18):5562-70.
DM2J5WH	RU	https://pubmed.ncbi.nlm.nih.gov/16942029

DMRAN9T	DI	DMRAN9T
DMRAN9T	DN	1-amino-2,4-bis(phenylthio)anthracene-9,10-dione
DMRAN9T	MI	TTM2AOE
DMRAN9T	MN	Adenosine A2a receptor (ADORA2A)
DMRAN9T	MT	DTT
DMRAN9T	MA	Inhibitor
DMRAN9T	RN	Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. J Med Chem. 2010 Feb 25;53(4):1799-809.
DMRAN9T	RU	https://pubmed.ncbi.nlm.nih.gov/20095623

DMWCXM4	DI	DMWCXM4
DMWCXM4	DN	1-amino-2-phenoxyanthracene-9,10-dione
DMWCXM4	MI	TTM2AOE
DMWCXM4	MN	Adenosine A2a receptor (ADORA2A)
DMWCXM4	MT	DTT
DMWCXM4	MA	Inhibitor
DMWCXM4	RN	Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. J Med Chem. 2010 Feb 25;53(4):1799-809.
DMWCXM4	RU	https://pubmed.ncbi.nlm.nih.gov/20095623

DMOAQC4	DI	DMOAQC4
DMOAQC4	DN	1-Amino-3-(aminoxy)-2-propanol Dihydrochloride
DMOAQC4	MI	TTUMGNO
DMOAQC4	MN	Ornithine decarboxylase (ODC1)
DMOAQC4	MT	DTT
DMOAQC4	MA	Inhibitor
DMOAQC4	RN	Selective delivery of 2-hydroxy APA to Trypanosoma brucei using the melamine motif. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4364-6.
DMOAQC4	RU	https://pubmed.ncbi.nlm.nih.gov/20615694

DMJMDNX	DI	DMJMDNX
DMJMDNX	DN	1-amino-4-chloroanthracene-9,10-dione
DMJMDNX	MI	TTM2AOE
DMJMDNX	MN	Adenosine A2a receptor (ADORA2A)
DMJMDNX	MT	DTT
DMJMDNX	MA	Inhibitor
DMJMDNX	RN	Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. J Med Chem. 2010 Feb 25;53(4):1799-809.
DMJMDNX	RU	https://pubmed.ncbi.nlm.nih.gov/20095623

DM7X5BP	DI	DM7X5BP
DM7X5BP	DN	1-amino-4-methoxyanthracene-9,10-dione
DM7X5BP	MI	TTM2AOE
DM7X5BP	MN	Adenosine A2a receptor (ADORA2A)
DM7X5BP	MT	DTT
DM7X5BP	MA	Inhibitor
DM7X5BP	RN	Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. J Med Chem. 2010 Feb 25;53(4):1799-809.
DM7X5BP	RU	https://pubmed.ncbi.nlm.nih.gov/20095623

DM6AV2S	DI	DM6AV2S
DM6AV2S	DN	1-Amino-6-Cyclohex-3-Enylmethyloxypurine
DM6AV2S	MI	TT7HF4W
DM6AV2S	MN	Cyclin-dependent kinase 2 (CDK2)
DM6AV2S	MT	DTT
DM6AV2S	MA	Inhibitor
DM6AV2S	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM6AV2S	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMGU76I	DI	DMGU76I
DMGU76I	DN	1-aminoanthracene-9,10-dione
DMGU76I	MI	TTM2AOE
DMGU76I	MN	Adenosine A2a receptor (ADORA2A)
DMGU76I	MT	DTT
DMGU76I	MA	Inhibitor
DMGU76I	RN	Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. J Med Chem. 2010 Feb 25;53(4):1799-809.
DMGU76I	RU	https://pubmed.ncbi.nlm.nih.gov/20095623

DM4TFN6	DI	DM4TFN6
DM4TFN6	DN	1-aminobutylphosphonic acid
DM4TFN6	MI	TTPHMWB
DM4TFN6	MN	Aminopeptidase N (ANPEP)
DM4TFN6	MT	DTT
DM4TFN6	MA	Inhibitor
DM4TFN6	RN	New aromatic monoesters of alpha-aminoaralkylphosphonic acids as inhibitors of aminopeptidase N/CD13. Bioorg Med Chem. 2010 Apr 15;18(8):2930-6.
DM4TFN6	RU	https://pubmed.ncbi.nlm.nih.gov/20347318

DMFUABI	DI	DMFUABI
DMFUABI	DN	1-aminohexylphosphonic acid
DMFUABI	MI	TTPHMWB
DMFUABI	MN	Aminopeptidase N (ANPEP)
DMFUABI	MT	DTT
DMFUABI	MA	Inhibitor
DMFUABI	RN	New aromatic monoesters of alpha-aminoaralkylphosphonic acids as inhibitors of aminopeptidase N/CD13. Bioorg Med Chem. 2010 Apr 15;18(8):2930-6.
DMFUABI	RU	https://pubmed.ncbi.nlm.nih.gov/20347318

DML6UJM	DI	DML6UJM
DML6UJM	DN	1-aminohexylphosphonic acid monophenyl ester
DML6UJM	MI	TTPHMWB
DML6UJM	MN	Aminopeptidase N (ANPEP)
DML6UJM	MT	DTT
DML6UJM	MA	Inhibitor
DML6UJM	RN	New aromatic monoesters of alpha-aminoaralkylphosphonic acids as inhibitors of aminopeptidase N/CD13. Bioorg Med Chem. 2010 Apr 15;18(8):2930-6.
DML6UJM	RU	https://pubmed.ncbi.nlm.nih.gov/20347318

DMBWNL6	DI	DMBWNL6
DMBWNL6	DN	1-Aminomethyl-3-cyclohexyl-isochroman-5,6-diol
DMBWNL6	MI	TTZFYLI
DMBWNL6	MN	Dopamine D1 receptor (D1R)
DMBWNL6	MT	DTT
DMBWNL6	MA	Inhibitor
DMBWNL6	RN	Synthesis and pharmacological evaluation of 1-(aminomethyl)-3,4-dihydro-5-hydroxy-1H-2-benzopyrans as dopamine D1 selective ligands. J Med Chem. 1991 Oct;34(10):2946-53.
DMBWNL6	RU	https://pubmed.ncbi.nlm.nih.gov/1833546

DMBWNL6	DI	DMBWNL6
DMBWNL6	DN	1-Aminomethyl-3-cyclohexyl-isochroman-5,6-diol
DMBWNL6	MI	TTEX248
DMBWNL6	MN	Dopamine D2 receptor (D2R)
DMBWNL6	MT	DTT
DMBWNL6	MA	Inhibitor
DMBWNL6	RN	Synthesis and pharmacological evaluation of 1-(aminomethyl)-3,4-dihydro-5-hydroxy-1H-2-benzopyrans as dopamine D1 selective ligands. J Med Chem. 1991 Oct;34(10):2946-53.
DMBWNL6	RU	https://pubmed.ncbi.nlm.nih.gov/1833546

DMJNG8A	DI	DMJNG8A
DMJNG8A	DN	1-Aminomethyl-3-phenyl-isochroman-5,6-diol
DMJNG8A	MI	TTZFYLI
DMJNG8A	MN	Dopamine D1 receptor (D1R)
DMJNG8A	MT	DTT
DMJNG8A	MA	Inhibitor
DMJNG8A	RN	(1R,3S)-1-(aminomethyl)-3,4-dihydro-5,6-dihydroxy-3-phenyl-1H-2-benzopyran: a potent and selective D1 agonist. J Med Chem. 1990 Nov;33(11):2948-50.
DMJNG8A	RU	https://pubmed.ncbi.nlm.nih.gov/1977907

DM50GS7	DI	DM50GS7
DM50GS7	DN	1-Aminomethyl-isochroman-5,6-diol
DM50GS7	MI	TTZFYLI
DM50GS7	MN	Dopamine D1 receptor (D1R)
DM50GS7	MT	DTT
DM50GS7	MA	Inhibitor
DM50GS7	RN	(1R,3S)-1-(aminomethyl)-3,4-dihydro-5,6-dihydroxy-3-phenyl-1H-2-benzopyran: a potent and selective D1 agonist. J Med Chem. 1990 Nov;33(11):2948-50.
DM50GS7	RU	https://pubmed.ncbi.nlm.nih.gov/1977907

DM50GS7	DI	DM50GS7
DM50GS7	DN	1-Aminomethyl-isochroman-5,6-diol
DM50GS7	MI	TTEX248
DM50GS7	MN	Dopamine D2 receptor (D2R)
DM50GS7	MT	DTT
DM50GS7	MA	Inhibitor
DM50GS7	RN	(1R,3S)-1-(aminomethyl)-3,4-dihydro-5,6-dihydroxy-3-phenyl-1H-2-benzopyran: a potent and selective D1 agonist. J Med Chem. 1990 Nov;33(11):2948-50.
DM50GS7	RU	https://pubmed.ncbi.nlm.nih.gov/1977907

DMMV30B	DI	DMMV30B
DMMV30B	DN	1-aminopentylphosphonic acid monophenyl ester
DMMV30B	MI	TTPHMWB
DMMV30B	MN	Aminopeptidase N (ANPEP)
DMMV30B	MT	DTT
DMMV30B	MA	Inhibitor
DMMV30B	RN	New aromatic monoesters of alpha-aminoaralkylphosphonic acids as inhibitors of aminopeptidase N/CD13. Bioorg Med Chem. 2010 Apr 15;18(8):2930-6.
DMMV30B	RU	https://pubmed.ncbi.nlm.nih.gov/20347318

DMPYCK5	DI	DMPYCK5
DMPYCK5	DN	1-Aminopropane-1,2,3-tricarboxylic acid
DMPYCK5	MI	TTHI19T
DMPYCK5	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMPYCK5	MT	DTT
DMPYCK5	MA	Inhibitor
DMPYCK5	RN	Discovery of novel lipophilic inhibitors of OXA-10 enzyme (class D beta-lactamase) by screening amino analogs and homologs of citrate and isocitrate. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3593-7.
DMPYCK5	RU	https://pubmed.ncbi.nlm.nih.gov/19467869

DMNGY0E	DI	DMNGY0E
DMNGY0E	DN	1-anilinonaphthalene-8-sulfonic acid
DMNGY0E	MI	TTIV96N
DMNGY0E	MN	Fatty acid-binding protein 1 (FABP1)
DMNGY0E	MT	DTT
DMNGY0E	MA	Inhibitor
DMNGY0E	RN	Characterization of the drug binding specificity of rat liver fatty acid binding protein. J Med Chem. 2008 Jul 10;51(13):3755-64.
DMNGY0E	RU	https://pubmed.ncbi.nlm.nih.gov/18533710

DMJD1QF	DI	DMJD1QF
DMJD1QF	DN	1-arylmethylpyrrolidin-2-yl ethanol amine
DMJD1QF	MI	TTBUYHA
DMJD1QF	MN	Extracellular calcium-sensing receptor (CASR)
DMJD1QF	MT	DTT
DMJD1QF	MA	Antagonist
DMJD1QF	RN	Discovery of novel 1-arylmethyl pyrrolidin-2-yl ethanol amines as calcium-sensing receptor antagonists. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5478-82.
DMJD1QF	RU	https://pubmed.ncbi.nlm.nih.gov/16216508

DMQ1EVT	DI	DMQ1EVT
DMQ1EVT	DN	1-benzene sulfonyl-cis-2,6-dimethyl piperidine
DMQ1EVT	MI	TT1RS9F
DMQ1EVT	MN	Acetylcholinesterase (AChE)
DMQ1EVT	MT	DTT
DMQ1EVT	MA	Inhibitor
DMQ1EVT	RN	Active site directed docking studies: synthesis and pharmacological evaluation of cis-2,6-dimethyl piperidine sulfonamides as inhibitors of acetylc... Eur J Med Chem. 2009 Oct;44(10):4057-62.
DMQ1EVT	RU	https://pubmed.ncbi.nlm.nih.gov/19493592

DM781L6	DI	DM781L6
DM781L6	DN	1-Benzenesulfonyl-2-nitro-benzene
DM781L6	MI	TT84ETX
DM781L6	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM781L6	MT	DTT
DM781L6	MA	Inhibitor
DM781L6	RN	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82.
DM781L6	RU	https://pubmed.ncbi.nlm.nih.gov/11384233

DM1N4LK	DI	DM1N4LK
DM1N4LK	DN	1-Benzenesulfonyl-3-piperidin-3-yl-1H-indole
DM1N4LK	MI	TTJS8PY
DM1N4LK	MN	5-HT 6 receptor (HTR6)
DM1N4LK	MT	DTT
DM1N4LK	MA	Inhibitor
DM1N4LK	RN	Conformationally constrained N1-arylsulfonyltryptamine derivatives as 5-HT6 receptor antagonists. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4780-5.
DM1N4LK	RU	https://pubmed.ncbi.nlm.nih.gov/16125933

DMRA9VG	DI	DMRA9VG
DMRA9VG	DN	1-Benzenesulfonyl-3-piperidin-4-yl-1H-indole
DMRA9VG	MI	TTJS8PY
DMRA9VG	MN	5-HT 6 receptor (HTR6)
DMRA9VG	MT	DTT
DMRA9VG	MA	Inhibitor
DMRA9VG	RN	N1-arylsulfonyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole derivatives are potent and selective 5-HT6 receptor antagonists. Bioorg Med Chem Lett. 2005 Jan 17;15(2):379-83.
DMRA9VG	RU	https://pubmed.ncbi.nlm.nih.gov/15603958

DMQSK3H	DI	DMQSK3H
DMQSK3H	DN	1-benzhydryl-3-(isoquinolin-5-yl)urea
DMQSK3H	MI	TTMI6F5
DMQSK3H	MN	Transient receptor potential cation channel V1 (TRPV1)
DMQSK3H	MT	DTT
DMQSK3H	MA	Inhibitor
DMQSK3H	RN	Alpha-methylation at benzylic fragment of N-aryl-N'-benzyl ureas provides TRPV1 antagonists with better pharmacokinetic properties and higher effic... Bioorg Med Chem Lett. 2007 Jul 15;17(14):3894-9.
DMQSK3H	RU	https://pubmed.ncbi.nlm.nih.gov/17507218

DMBAZG3	DI	DMBAZG3
DMBAZG3	DN	1-benzhydryl-3-butylpiperidin-4-amine
DMBAZG3	MI	TTDIGC1
DMBAZG3	MN	Dipeptidyl peptidase 4 (DPP-4)
DMBAZG3	MT	DTT
DMBAZG3	MA	Inhibitor
DMBAZG3	RN	1,3-disubstituted 4-aminopiperidines as useful tools in the optimization of the 2-aminobenzo[a]quinolizine dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett. 2007 Jun 1;17(11):2966-70.
DMBAZG3	RU	https://pubmed.ncbi.nlm.nih.gov/17418568

DMTANPG	DI	DMTANPG
DMTANPG	DN	1-benzhydryl-4-(2-fluorophenyl)piperidin-4-ol
DMTANPG	MI	TTNT7K8
DMTANPG	MN	Nociceptin receptor (OPRL1)
DMTANPG	MT	DTT
DMTANPG	MA	Inhibitor
DMTANPG	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMTANPG	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMTANPG	DI	DMTANPG
DMTANPG	DN	1-benzhydryl-4-(2-fluorophenyl)piperidin-4-ol
DMTANPG	MI	TT27RFC
DMTANPG	MN	Opioid receptor delta (OPRD1)
DMTANPG	MT	DTT
DMTANPG	MA	Inhibitor
DMTANPG	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMTANPG	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMTANPG	DI	DMTANPG
DMTANPG	DN	1-benzhydryl-4-(2-fluorophenyl)piperidin-4-ol
DMTANPG	MI	TTQW87Y
DMTANPG	MN	Opioid receptor kappa (OPRK1)
DMTANPG	MT	DTT
DMTANPG	MA	Inhibitor
DMTANPG	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMTANPG	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMTANPG	DI	DMTANPG
DMTANPG	DN	1-benzhydryl-4-(2-fluorophenyl)piperidin-4-ol
DMTANPG	MI	TTKWM86
DMTANPG	MN	Opioid receptor mu (MOP)
DMTANPG	MT	DTT
DMTANPG	MA	Inhibitor
DMTANPG	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMTANPG	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMWHMNY	DI	DMWHMNY
DMWHMNY	DN	1-benzhydryl-4-(2-methoxyphenyl)piperidin-4-ol
DMWHMNY	MI	TTNT7K8
DMWHMNY	MN	Nociceptin receptor (OPRL1)
DMWHMNY	MT	DTT
DMWHMNY	MA	Inhibitor
DMWHMNY	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMWHMNY	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMWHMNY	DI	DMWHMNY
DMWHMNY	DN	1-benzhydryl-4-(2-methoxyphenyl)piperidin-4-ol
DMWHMNY	MI	TT27RFC
DMWHMNY	MN	Opioid receptor delta (OPRD1)
DMWHMNY	MT	DTT
DMWHMNY	MA	Inhibitor
DMWHMNY	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMWHMNY	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMWHMNY	DI	DMWHMNY
DMWHMNY	DN	1-benzhydryl-4-(2-methoxyphenyl)piperidin-4-ol
DMWHMNY	MI	TTQW87Y
DMWHMNY	MN	Opioid receptor kappa (OPRK1)
DMWHMNY	MT	DTT
DMWHMNY	MA	Inhibitor
DMWHMNY	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMWHMNY	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMWHMNY	DI	DMWHMNY
DMWHMNY	DN	1-benzhydryl-4-(2-methoxyphenyl)piperidin-4-ol
DMWHMNY	MI	TTKWM86
DMWHMNY	MN	Opioid receptor mu (MOP)
DMWHMNY	MT	DTT
DMWHMNY	MA	Inhibitor
DMWHMNY	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMWHMNY	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMTYKMR	DI	DMTYKMR
DMTYKMR	DN	1-benzhydryl-4-(3,3-diphenylpropyl)piperazine
DMTYKMR	MI	TTFK1JQ
DMTYKMR	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMTYKMR	MT	DTT
DMTYKMR	MA	Inhibitor
DMTYKMR	RN	Scaffold-based design and synthesis of potent N-type calcium channel blockers. Bioorg Med Chem Lett. 2009 Nov 15;19(22):6467-72.
DMTYKMR	RU	https://pubmed.ncbi.nlm.nih.gov/19815411

DMXZFPB	DI	DMXZFPB
DMXZFPB	DN	1-benzhydryl-4-(3-fluorophenyl)piperidin-4-ol
DMXZFPB	MI	TTNT7K8
DMXZFPB	MN	Nociceptin receptor (OPRL1)
DMXZFPB	MT	DTT
DMXZFPB	MA	Inhibitor
DMXZFPB	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMXZFPB	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMXZFPB	DI	DMXZFPB
DMXZFPB	DN	1-benzhydryl-4-(3-fluorophenyl)piperidin-4-ol
DMXZFPB	MI	TT27RFC
DMXZFPB	MN	Opioid receptor delta (OPRD1)
DMXZFPB	MT	DTT
DMXZFPB	MA	Inhibitor
DMXZFPB	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMXZFPB	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMXZFPB	DI	DMXZFPB
DMXZFPB	DN	1-benzhydryl-4-(3-fluorophenyl)piperidin-4-ol
DMXZFPB	MI	TTQW87Y
DMXZFPB	MN	Opioid receptor kappa (OPRK1)
DMXZFPB	MT	DTT
DMXZFPB	MA	Inhibitor
DMXZFPB	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMXZFPB	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMXZFPB	DI	DMXZFPB
DMXZFPB	DN	1-benzhydryl-4-(3-fluorophenyl)piperidin-4-ol
DMXZFPB	MI	TTKWM86
DMXZFPB	MN	Opioid receptor mu (MOP)
DMXZFPB	MT	DTT
DMXZFPB	MA	Inhibitor
DMXZFPB	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMXZFPB	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DM1QYS8	DI	DM1QYS8
DM1QYS8	DN	1-benzhydryl-4-(3-methoxyphenyl)piperidin-4-ol
DM1QYS8	MI	TTNT7K8
DM1QYS8	MN	Nociceptin receptor (OPRL1)
DM1QYS8	MT	DTT
DM1QYS8	MA	Inhibitor
DM1QYS8	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DM1QYS8	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DM1QYS8	DI	DM1QYS8
DM1QYS8	DN	1-benzhydryl-4-(3-methoxyphenyl)piperidin-4-ol
DM1QYS8	MI	TT27RFC
DM1QYS8	MN	Opioid receptor delta (OPRD1)
DM1QYS8	MT	DTT
DM1QYS8	MA	Inhibitor
DM1QYS8	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DM1QYS8	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DM1QYS8	DI	DM1QYS8
DM1QYS8	DN	1-benzhydryl-4-(3-methoxyphenyl)piperidin-4-ol
DM1QYS8	MI	TTQW87Y
DM1QYS8	MN	Opioid receptor kappa (OPRK1)
DM1QYS8	MT	DTT
DM1QYS8	MA	Inhibitor
DM1QYS8	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DM1QYS8	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DM1QYS8	DI	DM1QYS8
DM1QYS8	DN	1-benzhydryl-4-(3-methoxyphenyl)piperidin-4-ol
DM1QYS8	MI	TTKWM86
DM1QYS8	MN	Opioid receptor mu (MOP)
DM1QYS8	MT	DTT
DM1QYS8	MA	Inhibitor
DM1QYS8	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DM1QYS8	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMIT7SH	DI	DMIT7SH
DMIT7SH	DN	1-benzhydryl-4-(3-phenylpropyl)piperidin-4-ol
DMIT7SH	MI	TTNT7K8
DMIT7SH	MN	Nociceptin receptor (OPRL1)
DMIT7SH	MT	DTT
DMIT7SH	MA	Inhibitor
DMIT7SH	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMIT7SH	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMIT7SH	DI	DMIT7SH
DMIT7SH	DN	1-benzhydryl-4-(3-phenylpropyl)piperidin-4-ol
DMIT7SH	MI	TT27RFC
DMIT7SH	MN	Opioid receptor delta (OPRD1)
DMIT7SH	MT	DTT
DMIT7SH	MA	Inhibitor
DMIT7SH	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMIT7SH	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMIT7SH	DI	DMIT7SH
DMIT7SH	DN	1-benzhydryl-4-(3-phenylpropyl)piperidin-4-ol
DMIT7SH	MI	TTQW87Y
DMIT7SH	MN	Opioid receptor kappa (OPRK1)
DMIT7SH	MT	DTT
DMIT7SH	MA	Inhibitor
DMIT7SH	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMIT7SH	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMIT7SH	DI	DMIT7SH
DMIT7SH	DN	1-benzhydryl-4-(3-phenylpropyl)piperidin-4-ol
DMIT7SH	MI	TTKWM86
DMIT7SH	MN	Opioid receptor mu (MOP)
DMIT7SH	MT	DTT
DMIT7SH	MA	Inhibitor
DMIT7SH	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMIT7SH	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DM5SWL7	DI	DM5SWL7
DM5SWL7	DN	1-benzhydryl-4-(4,4-diphenylbutyl)piperazine
DM5SWL7	MI	TTFK1JQ
DM5SWL7	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DM5SWL7	MT	DTT
DM5SWL7	MA	Inhibitor
DM5SWL7	RN	Scaffold-based design and synthesis of potent N-type calcium channel blockers. Bioorg Med Chem Lett. 2009 Nov 15;19(22):6467-72.
DM5SWL7	RU	https://pubmed.ncbi.nlm.nih.gov/19815411

DM0BQYX	DI	DM0BQYX
DM0BQYX	DN	1-benzhydryl-4-(4-bromophenyl)piperidin-4-ol
DM0BQYX	MI	TTNT7K8
DM0BQYX	MN	Nociceptin receptor (OPRL1)
DM0BQYX	MT	DTT
DM0BQYX	MA	Inhibitor
DM0BQYX	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DM0BQYX	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DM0BQYX	DI	DM0BQYX
DM0BQYX	DN	1-benzhydryl-4-(4-bromophenyl)piperidin-4-ol
DM0BQYX	MI	TT27RFC
DM0BQYX	MN	Opioid receptor delta (OPRD1)
DM0BQYX	MT	DTT
DM0BQYX	MA	Inhibitor
DM0BQYX	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DM0BQYX	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DM0BQYX	DI	DM0BQYX
DM0BQYX	DN	1-benzhydryl-4-(4-bromophenyl)piperidin-4-ol
DM0BQYX	MI	TTQW87Y
DM0BQYX	MN	Opioid receptor kappa (OPRK1)
DM0BQYX	MT	DTT
DM0BQYX	MA	Inhibitor
DM0BQYX	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DM0BQYX	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DM0BQYX	DI	DM0BQYX
DM0BQYX	DN	1-benzhydryl-4-(4-bromophenyl)piperidin-4-ol
DM0BQYX	MI	TTKWM86
DM0BQYX	MN	Opioid receptor mu (MOP)
DM0BQYX	MT	DTT
DM0BQYX	MA	Inhibitor
DM0BQYX	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DM0BQYX	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMMAJW9	DI	DMMAJW9
DMMAJW9	DN	1-benzhydryl-4-(4-butylphenyl)piperidin-4-ol
DMMAJW9	MI	TTNT7K8
DMMAJW9	MN	Nociceptin receptor (OPRL1)
DMMAJW9	MT	DTT
DMMAJW9	MA	Inhibitor
DMMAJW9	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMMAJW9	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMWYG8K	DI	DMWYG8K
DMWYG8K	DN	1-benzhydryl-4-(4-chlorophenyl)piperidin-4-ol
DMWYG8K	MI	TTNT7K8
DMWYG8K	MN	Nociceptin receptor (OPRL1)
DMWYG8K	MT	DTT
DMWYG8K	MA	Inhibitor
DMWYG8K	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMWYG8K	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMWYG8K	DI	DMWYG8K
DMWYG8K	DN	1-benzhydryl-4-(4-chlorophenyl)piperidin-4-ol
DMWYG8K	MI	TT27RFC
DMWYG8K	MN	Opioid receptor delta (OPRD1)
DMWYG8K	MT	DTT
DMWYG8K	MA	Inhibitor
DMWYG8K	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMWYG8K	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMWYG8K	DI	DMWYG8K
DMWYG8K	DN	1-benzhydryl-4-(4-chlorophenyl)piperidin-4-ol
DMWYG8K	MI	TTQW87Y
DMWYG8K	MN	Opioid receptor kappa (OPRK1)
DMWYG8K	MT	DTT
DMWYG8K	MA	Inhibitor
DMWYG8K	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMWYG8K	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMWYG8K	DI	DMWYG8K
DMWYG8K	DN	1-benzhydryl-4-(4-chlorophenyl)piperidin-4-ol
DMWYG8K	MI	TTKWM86
DMWYG8K	MN	Opioid receptor mu (MOP)
DMWYG8K	MT	DTT
DMWYG8K	MA	Inhibitor
DMWYG8K	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMWYG8K	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DME0BJD	DI	DME0BJD
DME0BJD	DN	1-benzhydryl-4-(4-ethylphenyl)piperidin-4-ol
DME0BJD	MI	TTNT7K8
DME0BJD	MN	Nociceptin receptor (OPRL1)
DME0BJD	MT	DTT
DME0BJD	MA	Inhibitor
DME0BJD	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DME0BJD	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DME0BJD	DI	DME0BJD
DME0BJD	DN	1-benzhydryl-4-(4-ethylphenyl)piperidin-4-ol
DME0BJD	MI	TTQW87Y
DME0BJD	MN	Opioid receptor kappa (OPRK1)
DME0BJD	MT	DTT
DME0BJD	MA	Inhibitor
DME0BJD	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DME0BJD	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DME0BJD	DI	DME0BJD
DME0BJD	DN	1-benzhydryl-4-(4-ethylphenyl)piperidin-4-ol
DME0BJD	MI	TTKWM86
DME0BJD	MN	Opioid receptor mu (MOP)
DME0BJD	MT	DTT
DME0BJD	MA	Inhibitor
DME0BJD	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DME0BJD	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMRNZD6	DI	DMRNZD6
DMRNZD6	DN	1-benzhydryl-4-(4-fluorophenyl)piperidin-4-ol
DMRNZD6	MI	TTNT7K8
DMRNZD6	MN	Nociceptin receptor (OPRL1)
DMRNZD6	MT	DTT
DMRNZD6	MA	Inhibitor
DMRNZD6	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMRNZD6	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMRNZD6	DI	DMRNZD6
DMRNZD6	DN	1-benzhydryl-4-(4-fluorophenyl)piperidin-4-ol
DMRNZD6	MI	TT27RFC
DMRNZD6	MN	Opioid receptor delta (OPRD1)
DMRNZD6	MT	DTT
DMRNZD6	MA	Inhibitor
DMRNZD6	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMRNZD6	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMRNZD6	DI	DMRNZD6
DMRNZD6	DN	1-benzhydryl-4-(4-fluorophenyl)piperidin-4-ol
DMRNZD6	MI	TTQW87Y
DMRNZD6	MN	Opioid receptor kappa (OPRK1)
DMRNZD6	MT	DTT
DMRNZD6	MA	Inhibitor
DMRNZD6	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMRNZD6	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMRNZD6	DI	DMRNZD6
DMRNZD6	DN	1-benzhydryl-4-(4-fluorophenyl)piperidin-4-ol
DMRNZD6	MI	TTKWM86
DMRNZD6	MN	Opioid receptor mu (MOP)
DMRNZD6	MT	DTT
DMRNZD6	MA	Inhibitor
DMRNZD6	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMRNZD6	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMXT894	DI	DMXT894
DMXT894	DN	1-benzhydryl-4-(4-methoxyphenyl)piperidin-4-ol
DMXT894	MI	TTNT7K8
DMXT894	MN	Nociceptin receptor (OPRL1)
DMXT894	MT	DTT
DMXT894	MA	Inhibitor
DMXT894	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMXT894	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMXT894	DI	DMXT894
DMXT894	DN	1-benzhydryl-4-(4-methoxyphenyl)piperidin-4-ol
DMXT894	MI	TT27RFC
DMXT894	MN	Opioid receptor delta (OPRD1)
DMXT894	MT	DTT
DMXT894	MA	Inhibitor
DMXT894	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMXT894	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMXT894	DI	DMXT894
DMXT894	DN	1-benzhydryl-4-(4-methoxyphenyl)piperidin-4-ol
DMXT894	MI	TTQW87Y
DMXT894	MN	Opioid receptor kappa (OPRK1)
DMXT894	MT	DTT
DMXT894	MA	Inhibitor
DMXT894	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMXT894	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMXT894	DI	DMXT894
DMXT894	DN	1-benzhydryl-4-(4-methoxyphenyl)piperidin-4-ol
DMXT894	MI	TTKWM86
DMXT894	MN	Opioid receptor mu (MOP)
DMXT894	MT	DTT
DMXT894	MA	Inhibitor
DMXT894	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMXT894	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMJDUM5	DI	DMJDUM5
DMJDUM5	DN	1-benzhydryl-4-(4-propylphenyl)piperidin-4-ol
DMJDUM5	MI	TTNT7K8
DMJDUM5	MN	Nociceptin receptor (OPRL1)
DMJDUM5	MT	DTT
DMJDUM5	MA	Inhibitor
DMJDUM5	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMJDUM5	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMJDUM5	DI	DMJDUM5
DMJDUM5	DN	1-benzhydryl-4-(4-propylphenyl)piperidin-4-ol
DMJDUM5	MI	TTQW87Y
DMJDUM5	MN	Opioid receptor kappa (OPRK1)
DMJDUM5	MT	DTT
DMJDUM5	MA	Inhibitor
DMJDUM5	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMJDUM5	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMJDUM5	DI	DMJDUM5
DMJDUM5	DN	1-benzhydryl-4-(4-propylphenyl)piperidin-4-ol
DMJDUM5	MI	TTKWM86
DMJDUM5	MN	Opioid receptor mu (MOP)
DMJDUM5	MT	DTT
DMJDUM5	MA	Inhibitor
DMJDUM5	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMJDUM5	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMDRUBL	DI	DMDRUBL
DMDRUBL	DN	1-benzhydryl-4-(benzyloxy)-4-phenylpiperidine
DMDRUBL	MI	TTNT7K8
DMDRUBL	MN	Nociceptin receptor (OPRL1)
DMDRUBL	MT	DTT
DMDRUBL	MA	Inhibitor
DMDRUBL	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMDRUBL	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMDRUBL	DI	DMDRUBL
DMDRUBL	DN	1-benzhydryl-4-(benzyloxy)-4-phenylpiperidine
DMDRUBL	MI	TT27RFC
DMDRUBL	MN	Opioid receptor delta (OPRD1)
DMDRUBL	MT	DTT
DMDRUBL	MA	Inhibitor
DMDRUBL	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMDRUBL	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMDRUBL	DI	DMDRUBL
DMDRUBL	DN	1-benzhydryl-4-(benzyloxy)-4-phenylpiperidine
DMDRUBL	MI	TTQW87Y
DMDRUBL	MN	Opioid receptor kappa (OPRK1)
DMDRUBL	MT	DTT
DMDRUBL	MA	Inhibitor
DMDRUBL	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMDRUBL	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMMB2GV	DI	DMMB2GV
DMMB2GV	DN	1-benzhydryl-4-(furan-2-yl)piperidin-4-ol
DMMB2GV	MI	TTNT7K8
DMMB2GV	MN	Nociceptin receptor (OPRL1)
DMMB2GV	MT	DTT
DMMB2GV	MA	Inhibitor
DMMB2GV	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMMB2GV	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMMB2GV	DI	DMMB2GV
DMMB2GV	DN	1-benzhydryl-4-(furan-2-yl)piperidin-4-ol
DMMB2GV	MI	TT27RFC
DMMB2GV	MN	Opioid receptor delta (OPRD1)
DMMB2GV	MT	DTT
DMMB2GV	MA	Inhibitor
DMMB2GV	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMMB2GV	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMMB2GV	DI	DMMB2GV
DMMB2GV	DN	1-benzhydryl-4-(furan-2-yl)piperidin-4-ol
DMMB2GV	MI	TTQW87Y
DMMB2GV	MN	Opioid receptor kappa (OPRK1)
DMMB2GV	MT	DTT
DMMB2GV	MA	Inhibitor
DMMB2GV	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMMB2GV	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMMB2GV	DI	DMMB2GV
DMMB2GV	DN	1-benzhydryl-4-(furan-2-yl)piperidin-4-ol
DMMB2GV	MI	TTKWM86
DMMB2GV	MN	Opioid receptor mu (MOP)
DMMB2GV	MT	DTT
DMMB2GV	MA	Inhibitor
DMMB2GV	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMMB2GV	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMJ8F60	DI	DMJ8F60
DMJ8F60	DN	1-benzhydryl-4-(pyridin-2-yl)piperidin-4-ol
DMJ8F60	MI	TTNT7K8
DMJ8F60	MN	Nociceptin receptor (OPRL1)
DMJ8F60	MT	DTT
DMJ8F60	MA	Inhibitor
DMJ8F60	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMJ8F60	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMJ8F60	DI	DMJ8F60
DMJ8F60	DN	1-benzhydryl-4-(pyridin-2-yl)piperidin-4-ol
DMJ8F60	MI	TTQW87Y
DMJ8F60	MN	Opioid receptor kappa (OPRK1)
DMJ8F60	MT	DTT
DMJ8F60	MA	Inhibitor
DMJ8F60	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMJ8F60	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMJ8F60	DI	DMJ8F60
DMJ8F60	DN	1-benzhydryl-4-(pyridin-2-yl)piperidin-4-ol
DMJ8F60	MI	TTKWM86
DMJ8F60	MN	Opioid receptor mu (MOP)
DMJ8F60	MT	DTT
DMJ8F60	MA	Inhibitor
DMJ8F60	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMJ8F60	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMNOZR2	DI	DMNOZR2
DMNOZR2	DN	1-benzhydryl-4-(thiophen-2-yl)piperidin-4-ol
DMNOZR2	MI	TTNT7K8
DMNOZR2	MN	Nociceptin receptor (OPRL1)
DMNOZR2	MT	DTT
DMNOZR2	MA	Inhibitor
DMNOZR2	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMNOZR2	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMNOZR2	DI	DMNOZR2
DMNOZR2	DN	1-benzhydryl-4-(thiophen-2-yl)piperidin-4-ol
DMNOZR2	MI	TT27RFC
DMNOZR2	MN	Opioid receptor delta (OPRD1)
DMNOZR2	MT	DTT
DMNOZR2	MA	Inhibitor
DMNOZR2	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMNOZR2	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMNOZR2	DI	DMNOZR2
DMNOZR2	DN	1-benzhydryl-4-(thiophen-2-yl)piperidin-4-ol
DMNOZR2	MI	TTQW87Y
DMNOZR2	MN	Opioid receptor kappa (OPRK1)
DMNOZR2	MT	DTT
DMNOZR2	MA	Inhibitor
DMNOZR2	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMNOZR2	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMNOZR2	DI	DMNOZR2
DMNOZR2	DN	1-benzhydryl-4-(thiophen-2-yl)piperidin-4-ol
DMNOZR2	MI	TTKWM86
DMNOZR2	MN	Opioid receptor mu (MOP)
DMNOZR2	MT	DTT
DMNOZR2	MA	Inhibitor
DMNOZR2	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMNOZR2	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMVBR36	DI	DMVBR36
DMVBR36	DN	1-benzhydryl-4-benzylpiperidin-4-ol
DMVBR36	MI	TTNT7K8
DMVBR36	MN	Nociceptin receptor (OPRL1)
DMVBR36	MT	DTT
DMVBR36	MA	Inhibitor
DMVBR36	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMVBR36	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMVBR36	DI	DMVBR36
DMVBR36	DN	1-benzhydryl-4-benzylpiperidin-4-ol
DMVBR36	MI	TT27RFC
DMVBR36	MN	Opioid receptor delta (OPRD1)
DMVBR36	MT	DTT
DMVBR36	MA	Inhibitor
DMVBR36	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMVBR36	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMVBR36	DI	DMVBR36
DMVBR36	DN	1-benzhydryl-4-benzylpiperidin-4-ol
DMVBR36	MI	TTQW87Y
DMVBR36	MN	Opioid receptor kappa (OPRK1)
DMVBR36	MT	DTT
DMVBR36	MA	Inhibitor
DMVBR36	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMVBR36	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMVBR36	DI	DMVBR36
DMVBR36	DN	1-benzhydryl-4-benzylpiperidin-4-ol
DMVBR36	MI	TTKWM86
DMVBR36	MN	Opioid receptor mu (MOP)
DMVBR36	MT	DTT
DMVBR36	MA	Inhibitor
DMVBR36	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMVBR36	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMRN7SC	DI	DMRN7SC
DMRN7SC	DN	1-benzhydryl-4-butylpiperidin-4-ol
DMRN7SC	MI	TTNT7K8
DMRN7SC	MN	Nociceptin receptor (OPRL1)
DMRN7SC	MT	DTT
DMRN7SC	MA	Inhibitor
DMRN7SC	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMRN7SC	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMRN7SC	DI	DMRN7SC
DMRN7SC	DN	1-benzhydryl-4-butylpiperidin-4-ol
DMRN7SC	MI	TT27RFC
DMRN7SC	MN	Opioid receptor delta (OPRD1)
DMRN7SC	MT	DTT
DMRN7SC	MA	Inhibitor
DMRN7SC	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMRN7SC	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMRN7SC	DI	DMRN7SC
DMRN7SC	DN	1-benzhydryl-4-butylpiperidin-4-ol
DMRN7SC	MI	TTQW87Y
DMRN7SC	MN	Opioid receptor kappa (OPRK1)
DMRN7SC	MT	DTT
DMRN7SC	MA	Inhibitor
DMRN7SC	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMRN7SC	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMRN7SC	DI	DMRN7SC
DMRN7SC	DN	1-benzhydryl-4-butylpiperidin-4-ol
DMRN7SC	MI	TTKWM86
DMRN7SC	MN	Opioid receptor mu (MOP)
DMRN7SC	MT	DTT
DMRN7SC	MA	Inhibitor
DMRN7SC	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMRN7SC	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMZVSYD	DI	DMZVSYD
DMZVSYD	DN	1-benzhydryl-4-cyclohexylpiperidin-4-ol
DMZVSYD	MI	TTNT7K8
DMZVSYD	MN	Nociceptin receptor (OPRL1)
DMZVSYD	MT	DTT
DMZVSYD	MA	Inhibitor
DMZVSYD	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMZVSYD	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMZVSYD	DI	DMZVSYD
DMZVSYD	DN	1-benzhydryl-4-cyclohexylpiperidin-4-ol
DMZVSYD	MI	TT27RFC
DMZVSYD	MN	Opioid receptor delta (OPRD1)
DMZVSYD	MT	DTT
DMZVSYD	MA	Inhibitor
DMZVSYD	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMZVSYD	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMZVSYD	DI	DMZVSYD
DMZVSYD	DN	1-benzhydryl-4-cyclohexylpiperidin-4-ol
DMZVSYD	MI	TTQW87Y
DMZVSYD	MN	Opioid receptor kappa (OPRK1)
DMZVSYD	MT	DTT
DMZVSYD	MA	Inhibitor
DMZVSYD	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMZVSYD	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMZVSYD	DI	DMZVSYD
DMZVSYD	DN	1-benzhydryl-4-cyclohexylpiperidin-4-ol
DMZVSYD	MI	TTKWM86
DMZVSYD	MN	Opioid receptor mu (MOP)
DMZVSYD	MT	DTT
DMZVSYD	MA	Inhibitor
DMZVSYD	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMZVSYD	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMM94Y2	DI	DMM94Y2
DMM94Y2	DN	1-benzhydryl-4-cyclopropylpiperidin-4-ol
DMM94Y2	MI	TTNT7K8
DMM94Y2	MN	Nociceptin receptor (OPRL1)
DMM94Y2	MT	DTT
DMM94Y2	MA	Inhibitor
DMM94Y2	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMM94Y2	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMM94Y2	DI	DMM94Y2
DMM94Y2	DN	1-benzhydryl-4-cyclopropylpiperidin-4-ol
DMM94Y2	MI	TTKWM86
DMM94Y2	MN	Opioid receptor mu (MOP)
DMM94Y2	MT	DTT
DMM94Y2	MA	Inhibitor
DMM94Y2	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMM94Y2	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DM6PIL2	DI	DM6PIL2
DM6PIL2	DN	1-benzhydryl-4-ethoxy-4-phenylpiperidine
DM6PIL2	MI	TTNT7K8
DM6PIL2	MN	Nociceptin receptor (OPRL1)
DM6PIL2	MT	DTT
DM6PIL2	MA	Inhibitor
DM6PIL2	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DM6PIL2	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DM6PIL2	DI	DM6PIL2
DM6PIL2	DN	1-benzhydryl-4-ethoxy-4-phenylpiperidine
DM6PIL2	MI	TT27RFC
DM6PIL2	MN	Opioid receptor delta (OPRD1)
DM6PIL2	MT	DTT
DM6PIL2	MA	Inhibitor
DM6PIL2	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DM6PIL2	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DM6PIL2	DI	DM6PIL2
DM6PIL2	DN	1-benzhydryl-4-ethoxy-4-phenylpiperidine
DM6PIL2	MI	TTQW87Y
DM6PIL2	MN	Opioid receptor kappa (OPRK1)
DM6PIL2	MT	DTT
DM6PIL2	MA	Inhibitor
DM6PIL2	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DM6PIL2	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DM6PIL2	DI	DM6PIL2
DM6PIL2	DN	1-benzhydryl-4-ethoxy-4-phenylpiperidine
DM6PIL2	MI	TTKWM86
DM6PIL2	MN	Opioid receptor mu (MOP)
DM6PIL2	MT	DTT
DM6PIL2	MA	Inhibitor
DM6PIL2	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DM6PIL2	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMUK95S	DI	DMUK95S
DMUK95S	DN	1-benzhydryl-4-hexylpiperidin-4-ol
DMUK95S	MI	TTNT7K8
DMUK95S	MN	Nociceptin receptor (OPRL1)
DMUK95S	MT	DTT
DMUK95S	MA	Inhibitor
DMUK95S	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMUK95S	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMUK95S	DI	DMUK95S
DMUK95S	DN	1-benzhydryl-4-hexylpiperidin-4-ol
DMUK95S	MI	TT27RFC
DMUK95S	MN	Opioid receptor delta (OPRD1)
DMUK95S	MT	DTT
DMUK95S	MA	Inhibitor
DMUK95S	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMUK95S	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMUK95S	DI	DMUK95S
DMUK95S	DN	1-benzhydryl-4-hexylpiperidin-4-ol
DMUK95S	MI	TTQW87Y
DMUK95S	MN	Opioid receptor kappa (OPRK1)
DMUK95S	MT	DTT
DMUK95S	MA	Inhibitor
DMUK95S	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMUK95S	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMUK95S	DI	DMUK95S
DMUK95S	DN	1-benzhydryl-4-hexylpiperidin-4-ol
DMUK95S	MI	TTKWM86
DMUK95S	MN	Opioid receptor mu (MOP)
DMUK95S	MT	DTT
DMUK95S	MA	Inhibitor
DMUK95S	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMUK95S	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMGYCQ3	DI	DMGYCQ3
DMGYCQ3	DN	1-benzhydryl-4-isopropylpiperidin-4-ol
DMGYCQ3	MI	TTNT7K8
DMGYCQ3	MN	Nociceptin receptor (OPRL1)
DMGYCQ3	MT	DTT
DMGYCQ3	MA	Inhibitor
DMGYCQ3	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMGYCQ3	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMGYCQ3	DI	DMGYCQ3
DMGYCQ3	DN	1-benzhydryl-4-isopropylpiperidin-4-ol
DMGYCQ3	MI	TTQW87Y
DMGYCQ3	MN	Opioid receptor kappa (OPRK1)
DMGYCQ3	MT	DTT
DMGYCQ3	MA	Inhibitor
DMGYCQ3	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMGYCQ3	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMGYCQ3	DI	DMGYCQ3
DMGYCQ3	DN	1-benzhydryl-4-isopropylpiperidin-4-ol
DMGYCQ3	MI	TTKWM86
DMGYCQ3	MN	Opioid receptor mu (MOP)
DMGYCQ3	MT	DTT
DMGYCQ3	MA	Inhibitor
DMGYCQ3	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMGYCQ3	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMBG0N8	DI	DMBG0N8
DMBG0N8	DN	1-benzhydryl-4-methoxy-4-phenylpiperidine
DMBG0N8	MI	TTNT7K8
DMBG0N8	MN	Nociceptin receptor (OPRL1)
DMBG0N8	MT	DTT
DMBG0N8	MA	Inhibitor
DMBG0N8	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMBG0N8	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMBG0N8	DI	DMBG0N8
DMBG0N8	DN	1-benzhydryl-4-methoxy-4-phenylpiperidine
DMBG0N8	MI	TT27RFC
DMBG0N8	MN	Opioid receptor delta (OPRD1)
DMBG0N8	MT	DTT
DMBG0N8	MA	Inhibitor
DMBG0N8	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMBG0N8	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMBG0N8	DI	DMBG0N8
DMBG0N8	DN	1-benzhydryl-4-methoxy-4-phenylpiperidine
DMBG0N8	MI	TTQW87Y
DMBG0N8	MN	Opioid receptor kappa (OPRK1)
DMBG0N8	MT	DTT
DMBG0N8	MA	Inhibitor
DMBG0N8	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMBG0N8	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMBG0N8	DI	DMBG0N8
DMBG0N8	DN	1-benzhydryl-4-methoxy-4-phenylpiperidine
DMBG0N8	MI	TTKWM86
DMBG0N8	MN	Opioid receptor mu (MOP)
DMBG0N8	MT	DTT
DMBG0N8	MA	Inhibitor
DMBG0N8	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMBG0N8	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMVJH1S	DI	DMVJH1S
DMVJH1S	DN	1-benzhydryl-4-m-tolylpiperidin-4-ol
DMVJH1S	MI	TTNT7K8
DMVJH1S	MN	Nociceptin receptor (OPRL1)
DMVJH1S	MT	DTT
DMVJH1S	MA	Inhibitor
DMVJH1S	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMVJH1S	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMVJH1S	DI	DMVJH1S
DMVJH1S	DN	1-benzhydryl-4-m-tolylpiperidin-4-ol
DMVJH1S	MI	TT27RFC
DMVJH1S	MN	Opioid receptor delta (OPRD1)
DMVJH1S	MT	DTT
DMVJH1S	MA	Inhibitor
DMVJH1S	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMVJH1S	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMVJH1S	DI	DMVJH1S
DMVJH1S	DN	1-benzhydryl-4-m-tolylpiperidin-4-ol
DMVJH1S	MI	TTQW87Y
DMVJH1S	MN	Opioid receptor kappa (OPRK1)
DMVJH1S	MT	DTT
DMVJH1S	MA	Inhibitor
DMVJH1S	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMVJH1S	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMVJH1S	DI	DMVJH1S
DMVJH1S	DN	1-benzhydryl-4-m-tolylpiperidin-4-ol
DMVJH1S	MI	TTKWM86
DMVJH1S	MN	Opioid receptor mu (MOP)
DMVJH1S	MT	DTT
DMVJH1S	MA	Inhibitor
DMVJH1S	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMVJH1S	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMVUMSF	DI	DMVUMSF
DMVUMSF	DN	1-benzhydryl-4-o-tolylpiperidin-4-ol
DMVUMSF	MI	TTNT7K8
DMVUMSF	MN	Nociceptin receptor (OPRL1)
DMVUMSF	MT	DTT
DMVUMSF	MA	Inhibitor
DMVUMSF	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMVUMSF	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMVUMSF	DI	DMVUMSF
DMVUMSF	DN	1-benzhydryl-4-o-tolylpiperidin-4-ol
DMVUMSF	MI	TT27RFC
DMVUMSF	MN	Opioid receptor delta (OPRD1)
DMVUMSF	MT	DTT
DMVUMSF	MA	Inhibitor
DMVUMSF	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMVUMSF	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMVUMSF	DI	DMVUMSF
DMVUMSF	DN	1-benzhydryl-4-o-tolylpiperidin-4-ol
DMVUMSF	MI	TTQW87Y
DMVUMSF	MN	Opioid receptor kappa (OPRK1)
DMVUMSF	MT	DTT
DMVUMSF	MA	Inhibitor
DMVUMSF	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMVUMSF	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMVUMSF	DI	DMVUMSF
DMVUMSF	DN	1-benzhydryl-4-o-tolylpiperidin-4-ol
DMVUMSF	MI	TTKWM86
DMVUMSF	MN	Opioid receptor mu (MOP)
DMVUMSF	MT	DTT
DMVUMSF	MA	Inhibitor
DMVUMSF	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMVUMSF	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMEB968	DI	DMEB968
DMEB968	DN	1-benzhydryl-4-phenyl-4-propoxypiperidine
DMEB968	MI	TTNT7K8
DMEB968	MN	Nociceptin receptor (OPRL1)
DMEB968	MT	DTT
DMEB968	MA	Inhibitor
DMEB968	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMEB968	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMEB968	DI	DMEB968
DMEB968	DN	1-benzhydryl-4-phenyl-4-propoxypiperidine
DMEB968	MI	TT27RFC
DMEB968	MN	Opioid receptor delta (OPRD1)
DMEB968	MT	DTT
DMEB968	MA	Inhibitor
DMEB968	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMEB968	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMEB968	DI	DMEB968
DMEB968	DN	1-benzhydryl-4-phenyl-4-propoxypiperidine
DMEB968	MI	TTQW87Y
DMEB968	MN	Opioid receptor kappa (OPRK1)
DMEB968	MT	DTT
DMEB968	MA	Inhibitor
DMEB968	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMEB968	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMEB968	DI	DMEB968
DMEB968	DN	1-benzhydryl-4-phenyl-4-propoxypiperidine
DMEB968	MI	TTKWM86
DMEB968	MN	Opioid receptor mu (MOP)
DMEB968	MT	DTT
DMEB968	MA	Inhibitor
DMEB968	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMEB968	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DM7KU1X	DI	DM7KU1X
DM7KU1X	DN	1-benzhydryl-4-phenylpiperidin-4-ol
DM7KU1X	MI	TTNT7K8
DM7KU1X	MN	Nociceptin receptor (OPRL1)
DM7KU1X	MT	DTT
DM7KU1X	MA	Inhibitor
DM7KU1X	RN	The discovery of tropane derivatives as nociceptin receptor ligands for the management of cough and anxiety. Bioorg Med Chem Lett. 2009 May 1;19(9):2519-23.
DM7KU1X	RU	https://pubmed.ncbi.nlm.nih.gov/19339177

DM7KU1X	DI	DM7KU1X
DM7KU1X	DN	1-benzhydryl-4-phenylpiperidin-4-ol
DM7KU1X	MI	TT27RFC
DM7KU1X	MN	Opioid receptor delta (OPRD1)
DM7KU1X	MT	DTT
DM7KU1X	MA	Inhibitor
DM7KU1X	RN	The discovery of tropane derivatives as nociceptin receptor ligands for the management of cough and anxiety. Bioorg Med Chem Lett. 2009 May 1;19(9):2519-23.
DM7KU1X	RU	https://pubmed.ncbi.nlm.nih.gov/19339177

DM7KU1X	DI	DM7KU1X
DM7KU1X	DN	1-benzhydryl-4-phenylpiperidin-4-ol
DM7KU1X	MI	TTQW87Y
DM7KU1X	MN	Opioid receptor kappa (OPRK1)
DM7KU1X	MT	DTT
DM7KU1X	MA	Inhibitor
DM7KU1X	RN	The discovery of tropane derivatives as nociceptin receptor ligands for the management of cough and anxiety. Bioorg Med Chem Lett. 2009 May 1;19(9):2519-23.
DM7KU1X	RU	https://pubmed.ncbi.nlm.nih.gov/19339177

DM7KU1X	DI	DM7KU1X
DM7KU1X	DN	1-benzhydryl-4-phenylpiperidin-4-ol
DM7KU1X	MI	TTKWM86
DM7KU1X	MN	Opioid receptor mu (MOP)
DM7KU1X	MT	DTT
DM7KU1X	MA	Inhibitor
DM7KU1X	RN	The discovery of tropane derivatives as nociceptin receptor ligands for the management of cough and anxiety. Bioorg Med Chem Lett. 2009 May 1;19(9):2519-23.
DM7KU1X	RU	https://pubmed.ncbi.nlm.nih.gov/19339177

DM679RC	DI	DM679RC
DM679RC	DN	1-benzhydryl-4-p-tolylpiperidin-4-ol
DM679RC	MI	TTNT7K8
DM679RC	MN	Nociceptin receptor (OPRL1)
DM679RC	MT	DTT
DM679RC	MA	Inhibitor
DM679RC	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DM679RC	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DM679RC	DI	DM679RC
DM679RC	DN	1-benzhydryl-4-p-tolylpiperidin-4-ol
DM679RC	MI	TT27RFC
DM679RC	MN	Opioid receptor delta (OPRD1)
DM679RC	MT	DTT
DM679RC	MA	Inhibitor
DM679RC	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DM679RC	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DM679RC	DI	DM679RC
DM679RC	DN	1-benzhydryl-4-p-tolylpiperidin-4-ol
DM679RC	MI	TTQW87Y
DM679RC	MN	Opioid receptor kappa (OPRK1)
DM679RC	MT	DTT
DM679RC	MA	Inhibitor
DM679RC	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DM679RC	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DM679RC	DI	DM679RC
DM679RC	DN	1-benzhydryl-4-p-tolylpiperidin-4-ol
DM679RC	MI	TTKWM86
DM679RC	MN	Opioid receptor mu (MOP)
DM679RC	MT	DTT
DM679RC	MA	Inhibitor
DM679RC	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DM679RC	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMM5DTF	DI	DMM5DTF
DMM5DTF	DN	1-benzhydryl-4-tert-butylpiperidin-4-ol
DMM5DTF	MI	TTNT7K8
DMM5DTF	MN	Nociceptin receptor (OPRL1)
DMM5DTF	MT	DTT
DMM5DTF	MA	Inhibitor
DMM5DTF	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMM5DTF	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMM5DTF	DI	DMM5DTF
DMM5DTF	DN	1-benzhydryl-4-tert-butylpiperidin-4-ol
DMM5DTF	MI	TTQW87Y
DMM5DTF	MN	Opioid receptor kappa (OPRK1)
DMM5DTF	MT	DTT
DMM5DTF	MA	Inhibitor
DMM5DTF	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMM5DTF	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMM5DTF	DI	DMM5DTF
DMM5DTF	DN	1-benzhydryl-4-tert-butylpiperidin-4-ol
DMM5DTF	MI	TTKWM86
DMM5DTF	MN	Opioid receptor mu (MOP)
DMM5DTF	MT	DTT
DMM5DTF	MA	Inhibitor
DMM5DTF	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMM5DTF	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMMN5TA	DI	DMMN5TA
DMMN5TA	DN	1-Benzo[b]thiophen-2-yl-cycloheptylamine
DMMN5TA	MI	TTVBI8W
DMMN5TA	MN	Dopamine transporter (DAT)
DMMN5TA	MT	DTT
DMMN5TA	MA	Inhibitor
DMMN5TA	RN	Synthesis and biological evaluation of 1-[1-(2-benzo[b]thienyl)cyclohexyl]piperidine homologues at dopamine-uptake and phencyclidine- and sigma-bin... J Med Chem. 1993 Apr 30;36(9):1188-93.
DMMN5TA	RU	https://pubmed.ncbi.nlm.nih.gov/8098066

DMR97FU	DI	DMR97FU
DMR97FU	DN	1-Benzo[b]thiophen-2-yl-cyclohexylamine
DMR97FU	MI	TTVBI8W
DMR97FU	MN	Dopamine transporter (DAT)
DMR97FU	MT	DTT
DMR97FU	MA	Inhibitor
DMR97FU	RN	Synthesis and biological evaluation of 1-[1-(2-benzo[b]thienyl)cyclohexyl]piperidine homologues at dopamine-uptake and phencyclidine- and sigma-bin... J Med Chem. 1993 Apr 30;36(9):1188-93.
DMR97FU	RU	https://pubmed.ncbi.nlm.nih.gov/8098066

DM6EF1L	DI	DM6EF1L
DM6EF1L	DN	1-Benzo[b]thiophen-2-yl-cyclopentylamine
DM6EF1L	MI	TTVBI8W
DM6EF1L	MN	Dopamine transporter (DAT)
DM6EF1L	MT	DTT
DM6EF1L	MA	Inhibitor
DM6EF1L	RN	Synthesis and biological evaluation of 1-[1-(2-benzo[b]thienyl)cyclohexyl]piperidine homologues at dopamine-uptake and phencyclidine- and sigma-bin... J Med Chem. 1993 Apr 30;36(9):1188-93.
DM6EF1L	RU	https://pubmed.ncbi.nlm.nih.gov/8098066

DM153Y8	DI	DM153Y8
DM153Y8	DN	1-Benzooxazol-2-yl-6-phenyl-hexan-1-one
DM153Y8	MI	TTDP1UC
DM153Y8	MN	Fatty acid amide hydrolase (FAAH)
DM153Y8	MT	DTT
DM153Y8	MA	Inhibitor
DM153Y8	RN	Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as a... J Med Chem. 2005 Mar 24;48(6):1849-56.
DM153Y8	RU	https://pubmed.ncbi.nlm.nih.gov/15771430

DMEZPC8	DI	DMEZPC8
DMEZPC8	DN	1-Benzothiazol-2-yl-3-phenethyl-thiourea
DMEZPC8	MI	TT84ETX
DMEZPC8	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMEZPC8	MT	DTT
DMEZPC8	MA	Inhibitor
DMEZPC8	RN	Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36.
DMEZPC8	RU	https://pubmed.ncbi.nlm.nih.gov/8523406

DMF9X2T	DI	DMF9X2T
DMF9X2T	DN	1-benzoyl-2-benzyl-1,2-dihydropyridin-3(6H)-one
DMF9X2T	MI	TT9W8GU
DMF9X2T	MN	Gamma-secretase (GS)
DMF9X2T	MT	DTT
DMF9X2T	MA	Inhibitor
DMF9X2T	RN	Novel gamma-secretase inhibitors discovered by library screening of in-house synthetic natural product intermediates. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3813-6.
DMF9X2T	RU	https://pubmed.ncbi.nlm.nih.gov/16682195

DMF9X2T	DI	DMF9X2T
DMF9X2T	DN	1-benzoyl-2-benzyl-1,2-dihydropyridin-3(6H)-one
DMF9X2T	MI	TTZ3S8C
DMF9X2T	MN	Presenilin 1 (PSEN1)
DMF9X2T	MT	DTT
DMF9X2T	MA	Inhibitor
DMF9X2T	RN	Novel gamma-secretase inhibitors discovered by library screening of in-house synthetic natural product intermediates. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3813-6.
DMF9X2T	RU	https://pubmed.ncbi.nlm.nih.gov/16682195

DMF9X2T	DI	DMF9X2T
DMF9X2T	DN	1-benzoyl-2-benzyl-1,2-dihydropyridin-3(6H)-one
DMF9X2T	MI	TTWN3F4
DMF9X2T	MN	Presenilin 2 (PSEN2)
DMF9X2T	MT	DTT
DMF9X2T	MA	Inhibitor
DMF9X2T	RN	Novel gamma-secretase inhibitors discovered by library screening of in-house synthetic natural product intermediates. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3813-6.
DMF9X2T	RU	https://pubmed.ncbi.nlm.nih.gov/16682195

DMG5MNZ	DI	DMG5MNZ
DMG5MNZ	DN	1-benzoyl-N-phenyl-1H-pyrazole-3-carboxamide
DMG5MNZ	MI	TT6L509
DMG5MNZ	MN	Coagulation factor IIa (F2)
DMG5MNZ	MT	DTT
DMG5MNZ	MA	Inhibitor
DMG5MNZ	RN	N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
DMG5MNZ	RU	https://pubmed.ncbi.nlm.nih.gov/17850059

DMG5MNZ	DI	DMG5MNZ
DMG5MNZ	DN	1-benzoyl-N-phenyl-1H-pyrazole-3-carboxamide
DMG5MNZ	MI	TTPLTSQ
DMG5MNZ	MN	Neutrophil elastase (NE)
DMG5MNZ	MT	DTT
DMG5MNZ	MA	Inhibitor
DMG5MNZ	RN	N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
DMG5MNZ	RU	https://pubmed.ncbi.nlm.nih.gov/17850059

DMG5MNZ	DI	DMG5MNZ
DMG5MNZ	DN	1-benzoyl-N-phenyl-1H-pyrazole-3-carboxamide
DMG5MNZ	MI	TTMF8H9
DMG5MNZ	MN	Plasma kallikrein (KLKB1)
DMG5MNZ	MT	DTT
DMG5MNZ	MA	Inhibitor
DMG5MNZ	RN	N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
DMG5MNZ	RU	https://pubmed.ncbi.nlm.nih.gov/17850059

DMG5MNZ	DI	DMG5MNZ
DMG5MNZ	DN	1-benzoyl-N-phenyl-1H-pyrazole-3-carboxamide
DMG5MNZ	MI	TTGY7WI
DMG5MNZ	MN	Urokinase-type plasminogen activator (PLAU)
DMG5MNZ	MT	DTT
DMG5MNZ	MA	Inhibitor
DMG5MNZ	RN	N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
DMG5MNZ	RU	https://pubmed.ncbi.nlm.nih.gov/17850059

DM17TIX	DI	DM17TIX
DM17TIX	DN	1-Benzyl-1,2-dihydro-indazol-3-one
DM17TIX	MI	TT2J34L
DM17TIX	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM17TIX	MT	DTT
DM17TIX	MA	Inhibitor
DM17TIX	RN	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
DM17TIX	RU	https://pubmed.ncbi.nlm.nih.gov/1848292

DMUXSH5	DI	DMUXSH5
DMUXSH5	DN	1-Benzyl-1,4-dihydro-4-oxo-3-pyridinesulfonamide
DMUXSH5	MI	TTHQPL7
DMUXSH5	MN	Carbonic anhydrase I (CA-I)
DMUXSH5	MT	DTT
DMUXSH5	MA	Inhibitor
DMUXSH5	RN	Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the... Eur J Med Chem. 2010 Sep;45(9):3656-61.
DMUXSH5	RU	https://pubmed.ncbi.nlm.nih.gov/20554082

DMUXSH5	DI	DMUXSH5
DMUXSH5	DN	1-Benzyl-1,4-dihydro-4-oxo-3-pyridinesulfonamide
DMUXSH5	MI	TTANPDJ
DMUXSH5	MN	Carbonic anhydrase II (CA-II)
DMUXSH5	MT	DTT
DMUXSH5	MA	Inhibitor
DMUXSH5	RN	Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the... Eur J Med Chem. 2010 Sep;45(9):3656-61.
DMUXSH5	RU	https://pubmed.ncbi.nlm.nih.gov/20554082

DMUXSH5	DI	DMUXSH5
DMUXSH5	DN	1-Benzyl-1,4-dihydro-4-oxo-3-pyridinesulfonamide
DMUXSH5	MI	TT2LVK8
DMUXSH5	MN	Carbonic anhydrase IX (CA-IX)
DMUXSH5	MT	DTT
DMUXSH5	MA	Inhibitor
DMUXSH5	RN	Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the... Eur J Med Chem. 2010 Sep;45(9):3656-61.
DMUXSH5	RU	https://pubmed.ncbi.nlm.nih.gov/20554082

DMUXSH5	DI	DMUXSH5
DMUXSH5	DN	1-Benzyl-1,4-dihydro-4-oxo-3-pyridinesulfonamide
DMUXSH5	MI	TTSYM0R
DMUXSH5	MN	Carbonic anhydrase XII (CA-XII)
DMUXSH5	MT	DTT
DMUXSH5	MA	Inhibitor
DMUXSH5	RN	Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the... Eur J Med Chem. 2010 Sep;45(9):3656-61.
DMUXSH5	RU	https://pubmed.ncbi.nlm.nih.gov/20554082

DMYGZ8V	DI	DMYGZ8V
DMYGZ8V	DN	1-Benzyl-1H-1,3,4b,9-tetraaza-fluorene-2,4-dione
DMYGZ8V	MI	TTJFY5U
DMYGZ8V	MN	Adenosine A3 receptor (ADORA3)
DMYGZ8V	MT	DTT
DMYGZ8V	MA	Inhibitor
DMYGZ8V	RN	Pyrido[2,1-f]purine-2,4-dione derivatives as a novel class of highly potent human A(3) adenosine receptor antagonists. J Med Chem. 2002 Aug 1;45(16):3337-44.
DMYGZ8V	RU	https://pubmed.ncbi.nlm.nih.gov/12139445

DM2UFXE	DI	DM2UFXE
DM2UFXE	DN	1-benzyl-1H-indole-2,3-dione
DM2UFXE	MI	TTMF541
DM2UFXE	MN	Liver carboxylesterase (CES1)
DM2UFXE	MT	DTT
DM2UFXE	MA	Inhibitor
DM2UFXE	RN	Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85.
DM2UFXE	RU	https://pubmed.ncbi.nlm.nih.gov/17378546

DMW0Y92	DI	DMW0Y92
DMW0Y92	DN	1-Benzyl-1H-indole-5-carboxamidine
DMW0Y92	MI	TT2WR1T
DMW0Y92	MN	Cationic trypsinogen (PRSS1)
DMW0Y92	MT	DTT
DMW0Y92	MA	Inhibitor
DMW0Y92	RN	Aromatic amidines: comparison of their ability to block respiratory syncytial virus induced cell fusion and to inhibit plasmin, urokinase, thrombin... J Med Chem. 1983 Feb;26(2):294-8.
DMW0Y92	RU	https://pubmed.ncbi.nlm.nih.gov/6219223

DMEVSFY	DI	DMEVSFY
DMEVSFY	DN	1-benzyl-1H-pyrrolo[3,2-b]pyridine
DMEVSFY	MI	TTNDSF4
DMEVSFY	MN	Proto-oncogene c-Met (MET)
DMEVSFY	MT	DTT
DMEVSFY	MA	Inhibitor
DMEVSFY	RN	Discovery of 4-azaindoles as novel inhibitors of c-Met kinase. Bioorg Med Chem Lett. 2009 May 15;19(10):2780-4.
DMEVSFY	RU	https://pubmed.ncbi.nlm.nih.gov/19369077

DMQFS2D	DI	DMQFS2D
DMQFS2D	DN	1-benzyl-2,3-dimethyl-1H-indole-7-carboxylic acid
DMQFS2D	MI	TTHWMFZ
DMQFS2D	MN	Fatty acid-binding protein 4 (FABP4)
DMQFS2D	MT	DTT
DMQFS2D	MA	Inhibitor
DMQFS2D	RN	N-Benzyl-indolo carboxylic acids: Design and synthesis of potent and selective adipocyte fatty-acid binding protein (A-FABP) inhibitors. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1745-8.
DMQFS2D	RU	https://pubmed.ncbi.nlm.nih.gov/19217286

DMEVO6M	DI	DMEVO6M
DMEVO6M	DN	1-Benzyl-2-methyl-1H-imidazole
DMEVO6M	MI	TTZUFI5
DMEVO6M	MN	Nitric-oxide synthase brain (NOS1)
DMEVO6M	MT	DTT
DMEVO6M	MA	Inhibitor
DMEVO6M	RN	N-Substituted acetamidines and 2-methylimidazole derivatives as selective inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6495-9.
DMEVO6M	RU	https://pubmed.ncbi.nlm.nih.gov/20933416

DMPTMKU	DI	DMPTMKU
DMPTMKU	DN	1-benzyl-3,3-diethylazetidine-2,4-dione
DMPTMKU	MI	TTPLTSQ
DMPTMKU	MN	Neutrophil elastase (NE)
DMPTMKU	MT	DTT
DMPTMKU	MA	Inhibitor
DMPTMKU	RN	4-Oxo-beta-lactams (azetidine-2,4-diones) are potent and selective inhibitors of human leukocyte elastase. J Med Chem. 2010 Jan 14;53(1):241-53.
DMPTMKU	RU	https://pubmed.ncbi.nlm.nih.gov/19904934

DMW59XA	DI	DMW59XA
DMW59XA	DN	1-benzyl-3,3-dimethylazetidine-2,4-dione
DMW59XA	MI	TTPLTSQ
DMW59XA	MN	Neutrophil elastase (NE)
DMW59XA	MT	DTT
DMW59XA	MA	Inhibitor
DMW59XA	RN	4-Oxo-beta-lactams (azetidine-2,4-diones) are potent and selective inhibitors of human leukocyte elastase. J Med Chem. 2010 Jan 14;53(1):241-53.
DMW59XA	RU	https://pubmed.ncbi.nlm.nih.gov/19904934

DMMRV21	DI	DMMRV21
DMMRV21	DN	1-Benzyl-3-methyl-3,7-dihydro-purine-2,6-dione
DMMRV21	MI	TTNE7KG
DMMRV21	MN	Adenosine A2b receptor (ADORA2B)
DMMRV21	MT	DTT
DMMRV21	MA	Inhibitor
DMMRV21	RN	Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. J Med Chem. 2002 May 23;45(11):2131-8.
DMMRV21	RU	https://pubmed.ncbi.nlm.nih.gov/12014951

DMMRV21	DI	DMMRV21
DMMRV21	DN	1-Benzyl-3-methyl-3,7-dihydro-purine-2,6-dione
DMMRV21	MI	TTJFY5U
DMMRV21	MN	Adenosine A3 receptor (ADORA3)
DMMRV21	MT	DTT
DMMRV21	MA	Inhibitor
DMMRV21	RN	Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. J Med Chem. 2002 May 23;45(11):2131-8.
DMMRV21	RU	https://pubmed.ncbi.nlm.nih.gov/12014951

DMMNH4K	DI	DMMNH4K
DMMNH4K	DN	1'-Benzyl-3-phenyl-[3,4']bipiperidinyl-2,6-dione
DMMNH4K	MI	TTZ9SOR
DMMNH4K	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMMNH4K	MT	DTT
DMMNH4K	MA	Inhibitor
DMMNH4K	RN	Synthesis and biological evaluation of [125I]- and [123I]-4-iododexetimide, a potent muscarinic cholinergic receptor antagonist. J Med Chem. 1989 May;32(5):1057-62.
DMMNH4K	RU	https://pubmed.ncbi.nlm.nih.gov/2785211

DMMNH4K	DI	DMMNH4K
DMMNH4K	DN	1'-Benzyl-3-phenyl-[3,4']bipiperidinyl-2,6-dione
DMMNH4K	MI	TTYEG6Q
DMMNH4K	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMMNH4K	MT	DTT
DMMNH4K	MA	Inhibitor
DMMNH4K	RN	Synthesis and biological evaluation of [125I]- and [123I]-4-iododexetimide, a potent muscarinic cholinergic receptor antagonist. J Med Chem. 1989 May;32(5):1057-62.
DMMNH4K	RU	https://pubmed.ncbi.nlm.nih.gov/2785211

DMMNH4K	DI	DMMNH4K
DMMNH4K	DN	1'-Benzyl-3-phenyl-[3,4']bipiperidinyl-2,6-dione
DMMNH4K	MI	TTQ13Z5
DMMNH4K	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMMNH4K	MT	DTT
DMMNH4K	MA	Inhibitor
DMMNH4K	RN	Synthesis and biological evaluation of [125I]- and [123I]-4-iododexetimide, a potent muscarinic cholinergic receptor antagonist. J Med Chem. 1989 May;32(5):1057-62.
DMMNH4K	RU	https://pubmed.ncbi.nlm.nih.gov/2785211

DMMNH4K	DI	DMMNH4K
DMMNH4K	DN	1'-Benzyl-3-phenyl-[3,4']bipiperidinyl-2,6-dione
DMMNH4K	MI	TTQ3JTF
DMMNH4K	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DMMNH4K	MT	DTT
DMMNH4K	MA	Inhibitor
DMMNH4K	RN	Synthesis and biological evaluation of [125I]- and [123I]-4-iododexetimide, a potent muscarinic cholinergic receptor antagonist. J Med Chem. 1989 May;32(5):1057-62.
DMMNH4K	RU	https://pubmed.ncbi.nlm.nih.gov/2785211

DMMNH4K	DI	DMMNH4K
DMMNH4K	DN	1'-Benzyl-3-phenyl-[3,4']bipiperidinyl-2,6-dione
DMMNH4K	MI	TTH18TF
DMMNH4K	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMMNH4K	MT	DTT
DMMNH4K	MA	Inhibitor
DMMNH4K	RN	Synthesis and biological evaluation of [125I]- and [123I]-4-iododexetimide, a potent muscarinic cholinergic receptor antagonist. J Med Chem. 1989 May;32(5):1057-62.
DMMNH4K	RU	https://pubmed.ncbi.nlm.nih.gov/2785211

DMV7UC0	DI	DMV7UC0
DMV7UC0	DN	1-Benzyl-3-phenylquinazoline-2,4(1H,3H)-dione
DMV7UC0	MI	TTUV8G9
DMV7UC0	MN	Progesterone receptor (PGR)
DMV7UC0	MT	DTT
DMV7UC0	MA	Inhibitor
DMV7UC0	RN	Progesterone receptor antagonists with a 3-phenylquinazoline-2,4-dione/2-phenylisoquinoline-1,3-dione skeleton. Bioorg Med Chem. 2008 Jul 15;16(14):7046-54.
DMV7UC0	RU	https://pubmed.ncbi.nlm.nih.gov/18586498

DMNWGOE	DI	DMNWGOE
DMNWGOE	DN	1-Benzyl-3-thiazol-2-yl-thiourea
DMNWGOE	MI	TT84ETX
DMNWGOE	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMNWGOE	MT	DTT
DMNWGOE	MA	Inhibitor
DMNWGOE	RN	Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36.
DMNWGOE	RU	https://pubmed.ncbi.nlm.nih.gov/8523406

DMGDY4X	DI	DMGDY4X
DMGDY4X	DN	1-benzyl-4-(2,4-dichlorophenyl)pyrrolidin-3-amine
DMGDY4X	MI	TTDIGC1
DMGDY4X	MN	Dipeptidyl peptidase 4 (DPP-4)
DMGDY4X	MT	DTT
DMGDY4X	MA	Inhibitor
DMGDY4X	RN	Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibito... Bioorg Med Chem Lett. 2007 Apr 1;17(7):2005-12.
DMGDY4X	RU	https://pubmed.ncbi.nlm.nih.gov/17276063

DMF0GXD	DI	DMF0GXD
DMF0GXD	DN	1-Benzyl-4-(2-ethynyl-pyrrol-1-yl)-piperidine
DMF0GXD	MI	TTZFYLI
DMF0GXD	MN	Dopamine D1 receptor (D1R)
DMF0GXD	MT	DTT
DMF0GXD	MA	Inhibitor
DMF0GXD	RN	Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6.
DMF0GXD	RU	https://pubmed.ncbi.nlm.nih.gov/10560741

DMF0GXD	DI	DMF0GXD
DMF0GXD	DN	1-Benzyl-4-(2-ethynyl-pyrrol-1-yl)-piperidine
DMF0GXD	MI	TTEX248
DMF0GXD	MN	Dopamine D2 receptor (D2R)
DMF0GXD	MT	DTT
DMF0GXD	MA	Inhibitor
DMF0GXD	RN	Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6.
DMF0GXD	RU	https://pubmed.ncbi.nlm.nih.gov/10560741

DMF0GXD	DI	DMF0GXD
DMF0GXD	DN	1-Benzyl-4-(2-ethynyl-pyrrol-1-yl)-piperidine
DMF0GXD	MI	TT4C8EA
DMF0GXD	MN	Dopamine D3 receptor (D3R)
DMF0GXD	MT	DTT
DMF0GXD	MA	Inhibitor
DMF0GXD	RN	Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6.
DMF0GXD	RU	https://pubmed.ncbi.nlm.nih.gov/10560741

DMF0GXD	DI	DMF0GXD
DMF0GXD	DN	1-Benzyl-4-(2-ethynyl-pyrrol-1-yl)-piperidine
DMF0GXD	MI	TTE0A2F
DMF0GXD	MN	Dopamine D4 receptor (D4R)
DMF0GXD	MT	DTT
DMF0GXD	MA	Inhibitor
DMF0GXD	RN	Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6.
DMF0GXD	RU	https://pubmed.ncbi.nlm.nih.gov/10560741

DMBRJ5S	DI	DMBRJ5S
DMBRJ5S	DN	1-Benzyl-4-(2-iodo-pyrrol-1-yl)-piperidine
DMBRJ5S	MI	TTZFYLI
DMBRJ5S	MN	Dopamine D1 receptor (D1R)
DMBRJ5S	MT	DTT
DMBRJ5S	MA	Inhibitor
DMBRJ5S	RN	Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6.
DMBRJ5S	RU	https://pubmed.ncbi.nlm.nih.gov/10560741

DMBRJ5S	DI	DMBRJ5S
DMBRJ5S	DN	1-Benzyl-4-(2-iodo-pyrrol-1-yl)-piperidine
DMBRJ5S	MI	TTEX248
DMBRJ5S	MN	Dopamine D2 receptor (D2R)
DMBRJ5S	MT	DTT
DMBRJ5S	MA	Inhibitor
DMBRJ5S	RN	Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6.
DMBRJ5S	RU	https://pubmed.ncbi.nlm.nih.gov/10560741

DMBRJ5S	DI	DMBRJ5S
DMBRJ5S	DN	1-Benzyl-4-(2-iodo-pyrrol-1-yl)-piperidine
DMBRJ5S	MI	TT4C8EA
DMBRJ5S	MN	Dopamine D3 receptor (D3R)
DMBRJ5S	MT	DTT
DMBRJ5S	MA	Inhibitor
DMBRJ5S	RN	Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6.
DMBRJ5S	RU	https://pubmed.ncbi.nlm.nih.gov/10560741

DMBRJ5S	DI	DMBRJ5S
DMBRJ5S	DN	1-Benzyl-4-(2-iodo-pyrrol-1-yl)-piperidine
DMBRJ5S	MI	TTE0A2F
DMBRJ5S	MN	Dopamine D4 receptor (D4R)
DMBRJ5S	MT	DTT
DMBRJ5S	MA	Inhibitor
DMBRJ5S	RN	Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6.
DMBRJ5S	RU	https://pubmed.ncbi.nlm.nih.gov/10560741

DMSBNY8	DI	DMSBNY8
DMSBNY8	DN	1-Benzyl-4-(2-oxazol-5-yl-pyrrol-1-yl)-piperidine
DMSBNY8	MI	TTZFYLI
DMSBNY8	MN	Dopamine D1 receptor (D1R)
DMSBNY8	MT	DTT
DMSBNY8	MA	Inhibitor
DMSBNY8	RN	Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6.
DMSBNY8	RU	https://pubmed.ncbi.nlm.nih.gov/10560741

DMSBNY8	DI	DMSBNY8
DMSBNY8	DN	1-Benzyl-4-(2-oxazol-5-yl-pyrrol-1-yl)-piperidine
DMSBNY8	MI	TTEX248
DMSBNY8	MN	Dopamine D2 receptor (D2R)
DMSBNY8	MT	DTT
DMSBNY8	MA	Inhibitor
DMSBNY8	RN	Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6.
DMSBNY8	RU	https://pubmed.ncbi.nlm.nih.gov/10560741

DMSBNY8	DI	DMSBNY8
DMSBNY8	DN	1-Benzyl-4-(2-oxazol-5-yl-pyrrol-1-yl)-piperidine
DMSBNY8	MI	TT4C8EA
DMSBNY8	MN	Dopamine D3 receptor (D3R)
DMSBNY8	MT	DTT
DMSBNY8	MA	Inhibitor
DMSBNY8	RN	Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6.
DMSBNY8	RU	https://pubmed.ncbi.nlm.nih.gov/10560741

DMSBNY8	DI	DMSBNY8
DMSBNY8	DN	1-Benzyl-4-(2-oxazol-5-yl-pyrrol-1-yl)-piperidine
DMSBNY8	MI	TTE0A2F
DMSBNY8	MN	Dopamine D4 receptor (D4R)
DMSBNY8	MT	DTT
DMSBNY8	MA	Inhibitor
DMSBNY8	RN	Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6.
DMSBNY8	RU	https://pubmed.ncbi.nlm.nih.gov/10560741

DMCO0JU	DI	DMCO0JU
DMCO0JU	DN	1-Benzyl-4-(3-hydroxyphenyl)piperidine
DMCO0JU	MI	TTEX248
DMCO0JU	MN	Dopamine D2 receptor (D2R)
DMCO0JU	MT	DTT
DMCO0JU	MA	Inhibitor
DMCO0JU	RN	Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabi... J Med Chem. 2010 Mar 25;53(6):2510-20.
DMCO0JU	RU	https://pubmed.ncbi.nlm.nih.gov/20155917

DMCJZVA	DI	DMCJZVA
DMCJZVA	DN	1-Benzyl-4-(3-oxazol-5-yl-pyrrol-1-yl)-piperidine
DMCJZVA	MI	TTEX248
DMCJZVA	MN	Dopamine D2 receptor (D2R)
DMCJZVA	MT	DTT
DMCJZVA	MA	Inhibitor
DMCJZVA	RN	Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6.
DMCJZVA	RU	https://pubmed.ncbi.nlm.nih.gov/10560741

DMCJZVA	DI	DMCJZVA
DMCJZVA	DN	1-Benzyl-4-(3-oxazol-5-yl-pyrrol-1-yl)-piperidine
DMCJZVA	MI	TT4C8EA
DMCJZVA	MN	Dopamine D3 receptor (D3R)
DMCJZVA	MT	DTT
DMCJZVA	MA	Inhibitor
DMCJZVA	RN	Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6.
DMCJZVA	RU	https://pubmed.ncbi.nlm.nih.gov/10560741

DMCJZVA	DI	DMCJZVA
DMCJZVA	DN	1-Benzyl-4-(3-oxazol-5-yl-pyrrol-1-yl)-piperidine
DMCJZVA	MI	TTE0A2F
DMCJZVA	MN	Dopamine D4 receptor (D4R)
DMCJZVA	MT	DTT
DMCJZVA	MA	Inhibitor
DMCJZVA	RN	Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6.
DMCJZVA	RU	https://pubmed.ncbi.nlm.nih.gov/10560741

DM4NGUL	DI	DM4NGUL
DM4NGUL	DN	1-Benzyl-4-(4-phenylpiperazin-1-yl)phthalazine
DM4NGUL	MI	TT8J1S3
DM4NGUL	MN	Smoothened homolog (SMO)
DM4NGUL	MT	DTT
DM4NGUL	MA	Inhibitor
DM4NGUL	RN	1-amino-4-benzylphthalazines as orally bioavailable smoothened antagonists with antitumor activity. J Med Chem. 2009 Jul 9;52(13):3954-68.
DM4NGUL	RU	https://pubmed.ncbi.nlm.nih.gov/19469545

DMOF07G	DI	DMOF07G
DMOF07G	DN	1-Benzyl-4-[3-(methylsulfonyl)phenyl]piperazine
DMOF07G	MI	TTEX248
DMOF07G	MN	Dopamine D2 receptor (D2R)
DMOF07G	MT	DTT
DMOF07G	MA	Inhibitor
DMOF07G	RN	Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabi... J Med Chem. 2010 Mar 25;53(6):2510-20.
DMOF07G	RU	https://pubmed.ncbi.nlm.nih.gov/20155917

DME0MDL	DI	DME0MDL
DME0MDL	DN	1-Benzyl-4-[3-(methylsulfonyl)phenyl]piperidine
DME0MDL	MI	TTEX248
DME0MDL	MN	Dopamine D2 receptor (D2R)
DME0MDL	MT	DTT
DME0MDL	MA	Inhibitor
DME0MDL	RN	Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabi... J Med Chem. 2010 Mar 25;53(6):2510-20.
DME0MDL	RU	https://pubmed.ncbi.nlm.nih.gov/20155917

DMAQSBV	DI	DMAQSBV
DMAQSBV	DN	1-Benzyl-4-chroman-2-ylmethyl-piperazine
DMAQSBV	MI	TTSQIFT
DMAQSBV	MN	5-HT 1A receptor (HTR1A)
DMAQSBV	MT	DTT
DMAQSBV	MA	Inhibitor
DMAQSBV	RN	Synthesis and structure-activity relationships of 1-aralkyl-4-benzylpiperidine and 1-aralkyl-4-benzylpiperazine derivatives as potent sigma ligands. J Med Chem. 2005 Jan 13;48(1):266-73.
DMAQSBV	RU	https://pubmed.ncbi.nlm.nih.gov/15634021

DMETDQC	DI	DMETDQC
DMETDQC	DN	1-Benzyl-4-methyl-piperazine
DMETDQC	MI	TTD0CIQ
DMETDQC	MN	Melanocortin receptor 4 (MC4R)
DMETDQC	MT	DTT
DMETDQC	MA	Inhibitor
DMETDQC	RN	Privileged structure based ligands for melanocortin receptors--substituted benzylic piperazine derivatives. Bioorg Med Chem Lett. 2005 Nov 15;15(22):4973-8.
DMETDQC	RU	https://pubmed.ncbi.nlm.nih.gov/16169215

DMNTELW	DI	DMNTELW
DMNTELW	DN	1-benzyl-4-phenylpiperidin-4-ol
DMNTELW	MI	TTNT7K8
DMNTELW	MN	Nociceptin receptor (OPRL1)
DMNTELW	MT	DTT
DMNTELW	MA	Inhibitor
DMNTELW	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMNTELW	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMNWEC9	DI	DMNWEC9
DMNWEC9	DN	1-Benzyl-4-pyrrol-1-yl-piperidine
DMNWEC9	MI	TTEX248
DMNWEC9	MN	Dopamine D2 receptor (D2R)
DMNWEC9	MT	DTT
DMNWEC9	MA	Inhibitor
DMNWEC9	RN	Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6.
DMNWEC9	RU	https://pubmed.ncbi.nlm.nih.gov/10560741

DMNWEC9	DI	DMNWEC9
DMNWEC9	DN	1-Benzyl-4-pyrrol-1-yl-piperidine
DMNWEC9	MI	TT4C8EA
DMNWEC9	MN	Dopamine D3 receptor (D3R)
DMNWEC9	MT	DTT
DMNWEC9	MA	Inhibitor
DMNWEC9	RN	Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6.
DMNWEC9	RU	https://pubmed.ncbi.nlm.nih.gov/10560741

DMNWEC9	DI	DMNWEC9
DMNWEC9	DN	1-Benzyl-4-pyrrol-1-yl-piperidine
DMNWEC9	MI	TTE0A2F
DMNWEC9	MN	Dopamine D4 receptor (D4R)
DMNWEC9	MT	DTT
DMNWEC9	MA	Inhibitor
DMNWEC9	RN	Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6.
DMNWEC9	RU	https://pubmed.ncbi.nlm.nih.gov/10560741

DMH0ZVR	DI	DMH0ZVR
DMH0ZVR	DN	1-benzyl-5'-O-tritylinosine
DMH0ZVR	MI	TTO0IB8
DMH0ZVR	MN	Thymidine phosphorylase (TYMP)
DMH0ZVR	MT	DTT
DMH0ZVR	MA	Inhibitor
DMH0ZVR	RN	5'-O-tritylinosine and analogues as allosteric inhibitors of human thymidine phosphorylase. J Med Chem. 2006 Sep 7;49(18):5562-70.
DMH0ZVR	RU	https://pubmed.ncbi.nlm.nih.gov/16942029

DM8GUN9	DI	DM8GUN9
DM8GUN9	DN	1-Benzyl-5-phenyl-1H-imidazole
DM8GUN9	MI	TTIQUX7
DM8GUN9	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM8GUN9	MT	DTT
DM8GUN9	MA	Inhibitor
DM8GUN9	RN	Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25.
DM8GUN9	RU	https://pubmed.ncbi.nlm.nih.gov/20121113

DMCX3N1	DI	DMCX3N1
DMCX3N1	DN	1-Benzyl-7-chloro-4-hexyloxy-quinolinium
DMCX3N1	MI	TTY3UE6
DMCX3N1	MN	Voltage-gated potassium channel Kv1.3 (KCNA3)
DMCX3N1	MT	DTT
DMCX3N1	MA	Inhibitor
DMCX3N1	RN	Novel inhibitors of potassium ion channels on human T lymphocytes. J Med Chem. 1995 May 26;38(11):1877-83.
DMCX3N1	RU	https://pubmed.ncbi.nlm.nih.gov/7540207

DMJHXMY	DI	DMJHXMY
DMJHXMY	DN	1-benzyl-APDC
DMJHXMY	MI	TTWRP2F
DMJHXMY	MN	Metabotropic glutamate receptor 6 (mGluR6)
DMJHXMY	MT	DTT
DMJHXMY	MA	Agonist
DMJHXMY	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 294).
DMJHXMY	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=294

DM7GDEK	DI	DM7GDEK
DM7GDEK	DN	1-benzylpiperidine hydrochloride
DM7GDEK	MI	TTVBI8W
DM7GDEK	MN	Dopamine transporter (DAT)
DM7GDEK	MT	DTT
DM7GDEK	MA	Inhibitor
DM7GDEK	RN	Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31.
DM7GDEK	RU	https://pubmed.ncbi.nlm.nih.gov/17489581

DM7GDEK	DI	DM7GDEK
DM7GDEK	DN	1-benzylpiperidine hydrochloride
DM7GDEK	MI	TT3ROYC
DM7GDEK	MN	Serotonin transporter (SERT)
DM7GDEK	MT	DTT
DM7GDEK	MA	Inhibitor
DM7GDEK	RN	Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31.
DM7GDEK	RU	https://pubmed.ncbi.nlm.nih.gov/17489581

DMHR90S	DI	DMHR90S
DMHR90S	DN	1beta-methoxy-miller-9Z-enolide
DMHR90S	MI	TTSXVID
DMHR90S	MN	Nuclear factor NF-kappa-B (NFKB)
DMHR90S	MT	DTT
DMHR90S	MA	Inhibitor
DMHR90S	RN	Development of a structural model for NF-kappaB inhibition of sesquiterpene lactones using self-organizing neural networks. J Med Chem. 2006 Apr 6;49(7):2241-52.
DMHR90S	RU	https://pubmed.ncbi.nlm.nih.gov/16570920

DMKJYCU	DI	DMKJYCU
DMKJYCU	DN	1-biphenyl-2-ylmethanamine
DMKJYCU	MI	TTDIGC1
DMKJYCU	MN	Dipeptidyl peptidase 4 (DPP-4)
DMKJYCU	MT	DTT
DMKJYCU	MA	Inhibitor
DMKJYCU	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMKJYCU	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM6E7TA	DI	DM6E7TA
DM6E7TA	DN	1-Biphenyl-4-yl-3-aza-bicyclo[3.1.0]hexane
DM6E7TA	MI	TTVBI8W
DM6E7TA	MN	Dopamine transporter (DAT)
DM6E7TA	MT	DTT
DM6E7TA	MA	Inhibitor
DM6E7TA	RN	Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3682-6.
DM6E7TA	RU	https://pubmed.ncbi.nlm.nih.gov/18539031

DM6E7TA	DI	DM6E7TA
DM6E7TA	DN	1-Biphenyl-4-yl-3-aza-bicyclo[3.1.0]hexane
DM6E7TA	MI	TT3ROYC
DM6E7TA	MN	Serotonin transporter (SERT)
DM6E7TA	MT	DTT
DM6E7TA	MA	Inhibitor
DM6E7TA	RN	Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3682-6.
DM6E7TA	RU	https://pubmed.ncbi.nlm.nih.gov/18539031

DM9QTWB	DI	DM9QTWB
DM9QTWB	DN	1-Biphenyl-4-ylmaleimide
DM9QTWB	MI	TTDP1UC
DM9QTWB	MN	Fatty acid amide hydrolase (FAAH)
DM9QTWB	MT	DTT
DM9QTWB	MA	Inhibitor
DM9QTWB	RN	Synthesis and in vitro evaluation of N-substituted maleimide derivatives as selective monoglyceride lipase inhibitors. J Med Chem. 2009 Dec 10;52(23):7410-20.
DM9QTWB	RU	https://pubmed.ncbi.nlm.nih.gov/19583260

DMKL201	DI	DMKL201
DMKL201	DN	1-Biphenyl-4-ylmethylmaleimide
DMKL201	MI	TTDP1UC
DMKL201	MN	Fatty acid amide hydrolase (FAAH)
DMKL201	MT	DTT
DMKL201	MA	Inhibitor
DMKL201	RN	Synthesis and in vitro evaluation of N-substituted maleimide derivatives as selective monoglyceride lipase inhibitors. J Med Chem. 2009 Dec 10;52(23):7410-20.
DMKL201	RU	https://pubmed.ncbi.nlm.nih.gov/19583260

DMGL4MJ	DI	DMGL4MJ
DMGL4MJ	DN	1-Bromo-4-imidazol-1-ylmethyl-xanthen-9-one
DMGL4MJ	MI	TTSZLWK
DMGL4MJ	MN	Aromatase (CYP19A1)
DMGL4MJ	MT	DTT
DMGL4MJ	MA	Inhibitor
DMGL4MJ	RN	A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase. J Med Chem. 2001 Mar 1;44(5):672-80.
DMGL4MJ	RU	https://pubmed.ncbi.nlm.nih.gov/11262078

DMU2PSQ	DI	DMU2PSQ
DMU2PSQ	DN	1-Bromo-6-(3-hydroxyphenyl)-2-naphthol
DMU2PSQ	MI	TTIWB6L
DMU2PSQ	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMU2PSQ	MT	DTT
DMU2PSQ	MA	Inhibitor
DMU2PSQ	RN	Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design,... J Med Chem. 2008 Aug 14;51(15):4685-98.
DMU2PSQ	RU	https://pubmed.ncbi.nlm.nih.gov/18630892

DM2T4NL	DI	DM2T4NL
DM2T4NL	DN	1-Bromo-6-(4-hydroxy-phenyl)-naphthalen-2-ol
DM2T4NL	MI	TTZAYWL
DM2T4NL	MN	Estrogen receptor (ESR)
DM2T4NL	MT	DTT
DM2T4NL	MA	Inhibitor
DM2T4NL	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DM2T4NL	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DM2T4NL	DI	DM2T4NL
DM2T4NL	DN	1-Bromo-6-(4-hydroxy-phenyl)-naphthalen-2-ol
DM2T4NL	MI	TTOM3J0
DM2T4NL	MN	Estrogen receptor beta (ESR2)
DM2T4NL	MT	DTT
DM2T4NL	MA	Inhibitor
DM2T4NL	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DM2T4NL	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMXMATS	DI	DMXMATS
DMXMATS	DN	1-butoxy-4-phenoxybenzene
DMXMATS	MI	TTXZEAJ
DMXMATS	MN	Leukotriene A-4 hydrolase (LTA4H)
DMXMATS	MT	DTT
DMXMATS	MA	Inhibitor
DMXMATS	RN	Activation and inhibition of leukotriene A4 hydrolase aminopeptidase activity by diphenyl ether and derivatives. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6549-52.
DMXMATS	RU	https://pubmed.ncbi.nlm.nih.gov/18952425

DMO7NXE	DI	DMO7NXE
DMO7NXE	DN	1-Butyl-3-(2-dimethylamino-ethyl)-1H-indol-4-ol
DMO7NXE	MI	TTJQOD7
DMO7NXE	MN	5-HT 2A receptor (HTR2A)
DMO7NXE	MT	DTT
DMO7NXE	MA	Inhibitor
DMO7NXE	RN	SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.
DMO7NXE	RU	https://pubmed.ncbi.nlm.nih.gov/16061378

DMO7NXE	DI	DMO7NXE
DMO7NXE	DN	1-Butyl-3-(2-dimethylamino-ethyl)-1H-indol-4-ol
DMO7NXE	MI	TT0K1SC
DMO7NXE	MN	5-HT 2B receptor (HTR2B)
DMO7NXE	MT	DTT
DMO7NXE	MA	Inhibitor
DMO7NXE	RN	SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.
DMO7NXE	RU	https://pubmed.ncbi.nlm.nih.gov/16061378

DMO7NXE	DI	DMO7NXE
DMO7NXE	DN	1-Butyl-3-(2-dimethylamino-ethyl)-1H-indol-4-ol
DMO7NXE	MI	TTWJBZ5
DMO7NXE	MN	5-HT 2C receptor (HTR2C)
DMO7NXE	MT	DTT
DMO7NXE	MA	Inhibitor
DMO7NXE	RN	SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.
DMO7NXE	RU	https://pubmed.ncbi.nlm.nih.gov/16061378

DMOE2ZV	DI	DMOE2ZV
DMOE2ZV	DN	1-Butyl-3,7-dihydro-purine-2,6-dione
DMOE2ZV	MI	TTJFY5U
DMOE2ZV	MN	Adenosine A3 receptor (ADORA3)
DMOE2ZV	MT	DTT
DMOE2ZV	MA	Inhibitor
DMOE2ZV	RN	Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. J Med Chem. 2002 May 23;45(11):2131-8.
DMOE2ZV	RU	https://pubmed.ncbi.nlm.nih.gov/12014951

DM9GRN8	DI	DM9GRN8
DM9GRN8	DN	1-Butyl-3-methyl-3,7-dihydro-purine-2,6-dione
DM9GRN8	MI	TTZ97H5
DM9GRN8	MN	Phosphodiesterase 4A (PDE4A)
DM9GRN8	MT	DTT
DM9GRN8	MA	Inhibitor
DM9GRN8	RN	Effects of alkyl substitutions of xanthine skeleton on bronchodilation. J Med Chem. 1992 Oct 30;35(22):4039-44.
DM9GRN8	RU	https://pubmed.ncbi.nlm.nih.gov/1331453

DM9GRN8	DI	DM9GRN8
DM9GRN8	DN	1-Butyl-3-methyl-3,7-dihydro-purine-2,6-dione
DM9GRN8	MI	TTSKMI8
DM9GRN8	MN	Phosphodiesterase 4D (PDE4D)
DM9GRN8	MT	DTT
DM9GRN8	MA	Inhibitor
DM9GRN8	RN	Effects of alkyl substitutions of xanthine skeleton on bronchodilation. J Med Chem. 1992 Oct 30;35(22):4039-44.
DM9GRN8	RU	https://pubmed.ncbi.nlm.nih.gov/1331453

DM6QULO	DI	DM6QULO
DM6QULO	DN	1-Butyl-4-(2-methoxy-phenyl)-piperazine
DM6QULO	MI	TTSQIFT
DM6QULO	MN	5-HT 1A receptor (HTR1A)
DM6QULO	MT	DTT
DM6QULO	MA	Inhibitor
DM6QULO	RN	Structure-activity relationship studies of central nervous system agents. 13. 4-[3-(Benzotriazol-1-yl)propyl]-1-(2-methoxyphenyl)piperazine, a new ... J Med Chem. 1994 Aug 19;37(17):2754-60.
DM6QULO	RU	https://pubmed.ncbi.nlm.nih.gov/8064802

DM6QULO	DI	DM6QULO
DM6QULO	DN	1-Butyl-4-(2-methoxy-phenyl)-piperazine
DM6QULO	MI	TTJQOD7
DM6QULO	MN	5-HT 2A receptor (HTR2A)
DM6QULO	MT	DTT
DM6QULO	MA	Inhibitor
DM6QULO	RN	Structure-activity relationship studies of central nervous system agents. 13. 4-[3-(Benzotriazol-1-yl)propyl]-1-(2-methoxyphenyl)piperazine, a new ... J Med Chem. 1994 Aug 19;37(17):2754-60.
DM6QULO	RU	https://pubmed.ncbi.nlm.nih.gov/8064802

DMSNK98	DI	DMSNK98
DMSNK98	DN	1-Butyl-8-phenyl-3,7-dihydro-purine-2,6-dione
DMSNK98	MI	TTK25J1
DMSNK98	MN	Adenosine A1 receptor (ADORA1)
DMSNK98	MT	DTT
DMSNK98	MA	Inhibitor
DMSNK98	RN	Preparation, properties, reactions, and adenosine receptor affinities of sulfophenylxanthine nitrophenyl esters: toward the development of sulfonic... J Med Chem. 2004 Feb 12;47(4):1031-43.
DMSNK98	RU	https://pubmed.ncbi.nlm.nih.gov/14761205

DMSNK98	DI	DMSNK98
DMSNK98	DN	1-Butyl-8-phenyl-3,7-dihydro-purine-2,6-dione
DMSNK98	MI	TTM2AOE
DMSNK98	MN	Adenosine A2a receptor (ADORA2A)
DMSNK98	MT	DTT
DMSNK98	MA	Inhibitor
DMSNK98	RN	Preparation, properties, reactions, and adenosine receptor affinities of sulfophenylxanthine nitrophenyl esters: toward the development of sulfonic... J Med Chem. 2004 Feb 12;47(4):1031-43.
DMSNK98	RU	https://pubmed.ncbi.nlm.nih.gov/14761205

DMSNK98	DI	DMSNK98
DMSNK98	DN	1-Butyl-8-phenyl-3,7-dihydro-purine-2,6-dione
DMSNK98	MI	TTNE7KG
DMSNK98	MN	Adenosine A2b receptor (ADORA2B)
DMSNK98	MT	DTT
DMSNK98	MA	Inhibitor
DMSNK98	RN	Preparation, properties, reactions, and adenosine receptor affinities of sulfophenylxanthine nitrophenyl esters: toward the development of sulfonic... J Med Chem. 2004 Feb 12;47(4):1031-43.
DMSNK98	RU	https://pubmed.ncbi.nlm.nih.gov/14761205

DMVFCLO	DI	DMVFCLO
DMVFCLO	DN	1-butyryl-1H-indole-2,3-dione
DMVFCLO	MI	TTMF541
DMVFCLO	MN	Liver carboxylesterase (CES1)
DMVFCLO	MT	DTT
DMVFCLO	MA	Inhibitor
DMVFCLO	RN	Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85.
DMVFCLO	RU	https://pubmed.ncbi.nlm.nih.gov/17378546

DM13HGN	DI	DM13HGN
DM13HGN	DN	1-Chloro-4-(1-phenyl-cyclohexanesulfonyl)-benzene
DM13HGN	MI	TTZ3S8C
DM13HGN	MN	Presenilin 1 (PSEN1)
DM13HGN	MT	DTT
DM13HGN	MA	Inhibitor
DM13HGN	RN	Aryl sulfones: a new class of gamma-secretase inhibitors. Bioorg Med Chem Lett. 2005 May 16;15(10):2685-8.
DM13HGN	RU	https://pubmed.ncbi.nlm.nih.gov/15863342

DM13HGN	DI	DM13HGN
DM13HGN	DN	1-Chloro-4-(1-phenyl-cyclohexanesulfonyl)-benzene
DM13HGN	MI	TTWN3F4
DM13HGN	MN	Presenilin 2 (PSEN2)
DM13HGN	MT	DTT
DM13HGN	MA	Inhibitor
DM13HGN	RN	Aryl sulfones: a new class of gamma-secretase inhibitors. Bioorg Med Chem Lett. 2005 May 16;15(10):2685-8.
DM13HGN	RU	https://pubmed.ncbi.nlm.nih.gov/15863342

DM0MGFQ	DI	DM0MGFQ
DM0MGFQ	DN	1-CHLORO-6-(4-HYDROXYPHENYL)-2-NAPHTHOL
DM0MGFQ	MI	TTZAYWL
DM0MGFQ	MN	Estrogen receptor (ESR)
DM0MGFQ	MT	DTT
DM0MGFQ	MA	Inhibitor
DM0MGFQ	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DM0MGFQ	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DM0MGFQ	DI	DM0MGFQ
DM0MGFQ	DN	1-CHLORO-6-(4-HYDROXYPHENYL)-2-NAPHTHOL
DM0MGFQ	MI	TTOM3J0
DM0MGFQ	MN	Estrogen receptor beta (ESR2)
DM0MGFQ	MT	DTT
DM0MGFQ	MA	Inhibitor
DM0MGFQ	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM0MGFQ	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMA2607	DI	DMA2607
DMA2607	DN	1-Cycloheptyl-3-(1-propionylpiperidin-4-yl)urea
DMA2607	MI	TT7WVHI
DMA2607	MN	Soluble epoxide hydrolase (EPHX2)
DMA2607	MT	DTT
DMA2607	MA	Inhibitor
DMA2607	RN	1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, a... J Med Chem. 2010 Oct 14;53(19):7067-75.
DMA2607	RU	https://pubmed.ncbi.nlm.nih.gov/20812725

DMS10LE	DI	DMS10LE
DMS10LE	DN	1-cyclohexyl-1-isopropyl-3,3-dimethylselenourea
DMS10LE	MI	TTAS2UO
DMS10LE	MN	Bacterial Urease (Bact ureC)
DMS10LE	MT	DTT
DMS10LE	MA	Inhibitor
DMS10LE	RN	Facile one-pot synthesis of thio and selenourea derivatives: a new class of potent urease inhibitors. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6387-91.
DMS10LE	RU	https://pubmed.ncbi.nlm.nih.gov/17889535

DMAZYCD	DI	DMAZYCD
DMAZYCD	DN	1-Cyclohexyl-3-(1-propionylpiperidin-4-yl)urea
DMAZYCD	MI	TT7WVHI
DMAZYCD	MN	Soluble epoxide hydrolase (EPHX2)
DMAZYCD	MT	DTT
DMAZYCD	MA	Inhibitor
DMAZYCD	RN	1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, a... J Med Chem. 2010 Oct 14;53(19):7067-75.
DMAZYCD	RU	https://pubmed.ncbi.nlm.nih.gov/20812725

DMESUD7	DI	DMESUD7
DMESUD7	DN	1-Cyclohexyl-3-(4-methoxy-phenyl)-urea
DMESUD7	MI	TT7WVHI
DMESUD7	MN	Soluble epoxide hydrolase (EPHX2)
DMESUD7	MT	DTT
DMESUD7	MA	Inhibitor
DMESUD7	RN	Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem. 2005 May 19;48(10):3621-9.
DMESUD7	RU	https://pubmed.ncbi.nlm.nih.gov/15887969

DMH9O6V	DI	DMH9O6V
DMH9O6V	DN	1-Cyclohexyl-3-phenethyl-urea
DMH9O6V	MI	TT7WVHI
DMH9O6V	MN	Soluble epoxide hydrolase (EPHX2)
DMH9O6V	MT	DTT
DMH9O6V	MA	Inhibitor
DMH9O6V	RN	Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem. 2005 May 19;48(10):3621-9.
DMH9O6V	RU	https://pubmed.ncbi.nlm.nih.gov/15887969

DM9K8HA	DI	DM9K8HA
DM9K8HA	DN	1-Cyclohexyl-3-phenyl-urea
DM9K8HA	MI	TT7WVHI
DM9K8HA	MN	Soluble epoxide hydrolase (EPHX2)
DM9K8HA	MT	DTT
DM9K8HA	MA	Inhibitor
DM9K8HA	RN	Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem. 2005 May 19;48(10):3621-9.
DM9K8HA	RU	https://pubmed.ncbi.nlm.nih.gov/15887969

DMFPQME	DI	DMFPQME
DMFPQME	DN	1-cyclohexylamido-5-sulfonamidoindane
DMFPQME	MI	TTHQPL7
DMFPQME	MN	Carbonic anhydrase I (CA-I)
DMFPQME	MT	DTT
DMFPQME	MA	Inhibitor
DMFPQME	RN	Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9.
DMFPQME	RU	https://pubmed.ncbi.nlm.nih.gov/16640335

DMFPQME	DI	DMFPQME
DMFPQME	DN	1-cyclohexylamido-5-sulfonamidoindane
DMFPQME	MI	TTANPDJ
DMFPQME	MN	Carbonic anhydrase II (CA-II)
DMFPQME	MT	DTT
DMFPQME	MA	Inhibitor
DMFPQME	RN	Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9.
DMFPQME	RU	https://pubmed.ncbi.nlm.nih.gov/16640335

DMFPQME	DI	DMFPQME
DMFPQME	DN	1-cyclohexylamido-5-sulfonamidoindane
DMFPQME	MI	TT2LVK8
DMFPQME	MN	Carbonic anhydrase IX (CA-IX)
DMFPQME	MT	DTT
DMFPQME	MA	Inhibitor
DMFPQME	RN	Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9.
DMFPQME	RU	https://pubmed.ncbi.nlm.nih.gov/16640335

DM7A50Z	DI	DM7A50Z
DM7A50Z	DN	1-Cyclohexylidenethiosemicarbazide
DM7A50Z	MI	TTULVH8
DM7A50Z	MN	Tyrosinase (TYR)
DM7A50Z	MT	DTT
DM7A50Z	MA	Inhibitor
DM7A50Z	RN	A class of potent tyrosinase inhibitors: alkylidenethiosemicarbazide compounds. Eur J Med Chem. 2009 Apr;44(4):1773-8.
DM7A50Z	RU	https://pubmed.ncbi.nlm.nih.gov/18524420

DMEMQFH	DI	DMEMQFH
DMEMQFH	DN	1-Cyclopentyl-3,7-dihydro-purine-2,6-dione
DMEMQFH	MI	TTJFY5U
DMEMQFH	MN	Adenosine A3 receptor (ADORA3)
DMEMQFH	MT	DTT
DMEMQFH	MA	Inhibitor
DMEMQFH	RN	Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. J Med Chem. 2002 May 23;45(11):2131-8.
DMEMQFH	RU	https://pubmed.ncbi.nlm.nih.gov/12014951

DMDGWAY	DI	DMDGWAY
DMDGWAY	DN	1-Cyclopentylidenethiosemicarbazide
DMDGWAY	MI	TTULVH8
DMDGWAY	MN	Tyrosinase (TYR)
DMDGWAY	MT	DTT
DMDGWAY	MA	Inhibitor
DMDGWAY	RN	A class of potent tyrosinase inhibitors: alkylidenethiosemicarbazide compounds. Eur J Med Chem. 2009 Apr;44(4):1773-8.
DMDGWAY	RU	https://pubmed.ncbi.nlm.nih.gov/18524420

DMGSQTK	DI	DMGSQTK
DMGSQTK	DN	1D05
DMGSQTK	MI	TTBRG7E
DMGSQTK	MN	Proprotein convertase subtilisin/kexin type 9 (PCSK9)
DMGSQTK	MT	DTT
DMGSQTK	RN	A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo. J Lipid Res. 2011 Jan;52(1):78-86.
DMGSQTK	RU	https://pubmed.ncbi.nlm.nih.gov/20959675

DMG0VN6	DI	DMG0VN6
DMG0VN6	DN	1-Deaza-Adenosine
DMG0VN6	MI	TTLP57V
DMG0VN6	MN	Adenosine deaminase (ADA)
DMG0VN6	MT	DTT
DMG0VN6	MA	Inhibitor
DMG0VN6	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMG0VN6	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMOEQDP	DI	DMOEQDP
DMOEQDP	DN	1-Deoxy-1-Methoxycarbamido-Beta-D-Glucopyranose
DMOEQDP	MI	TTZHY6R
DMOEQDP	MN	Glycogen phosphorylase muscle form (GP)
DMOEQDP	MT	DTT
DMOEQDP	MA	Inhibitor
DMOEQDP	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMOEQDP	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMAEWHB	DI	DMAEWHB
DMAEWHB	DN	1-Deoxy-1-Thio-Heptaethylene Glycol
DMAEWHB	MI	TT1RS9F
DMAEWHB	MN	Acetylcholinesterase (AChE)
DMAEWHB	MT	DTT
DMAEWHB	MA	Inhibitor
DMAEWHB	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMAEWHB	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMCSPU4	DI	DMCSPU4
DMCSPU4	DN	1-Deoxy-D-Xylulose-5-Phosphate
DMCSPU4	MI	TTHB48R
DMCSPU4	MN	Bacterial Pyridoxal phosphate biosynthetic pdxJ (Bact pdxJ)
DMCSPU4	MT	DTT
DMCSPU4	MA	Inhibitor
DMCSPU4	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMCSPU4	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMH9WFD	DI	DMH9WFD
DMH9WFD	DN	1-Deoxy-Ribofuranose-5'-Phosphate
DMH9WFD	MI	TTVNA43
DMH9WFD	MN	Bacterial Deoxy-D-manno-octulosonate 8-phosphate synthase (Bact kdsA)
DMH9WFD	MT	DTT
DMH9WFD	MA	Inhibitor
DMH9WFD	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMH9WFD	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM4NBUH	DI	DM4NBUH
DM4NBUH	DN	1-D-glucopyranosyl cytosine
DM4NBUH	MI	TTZHY6R
DM4NBUH	MN	Glycogen phosphorylase muscle form (GP)
DM4NBUH	MT	DTT
DM4NBUH	MA	Inhibitor
DM4NBUH	RN	1-(3-Deoxy-3-fluoro-beta-d-glucopyranosyl) pyrimidine derivatives as inhibitors of glycogen phosphorylase b: Kinetic, crystallographic and modellin... Bioorg Med Chem. 2010 May 15;18(10):3413-25.
DM4NBUH	RU	https://pubmed.ncbi.nlm.nih.gov/20430629

DM90ULM	DI	DM90ULM
DM90ULM	DN	1-D-glucopyranosyl uracil
DM90ULM	MI	TTZHY6R
DM90ULM	MN	Glycogen phosphorylase muscle form (GP)
DM90ULM	MT	DTT
DM90ULM	MA	Inhibitor
DM90ULM	RN	1-(3-Deoxy-3-fluoro-beta-d-glucopyranosyl) pyrimidine derivatives as inhibitors of glycogen phosphorylase b: Kinetic, crystallographic and modellin... Bioorg Med Chem. 2010 May 15;18(10):3413-25.
DM90ULM	RU	https://pubmed.ncbi.nlm.nih.gov/20430629

DMOL2Y0	DI	DMOL2Y0
DMOL2Y0	DN	1-Dibenzo[b,f]oxepin-10-yl-4-methyl-piperazine
DMOL2Y0	MI	TTZFYLI
DMOL2Y0	MN	Dopamine D1 receptor (D1R)
DMOL2Y0	MT	DTT
DMOL2Y0	MA	Inhibitor
DMOL2Y0	RN	Affinity of 10-(4-methylpiperazino)dibenz[b,f]oxepins for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1982 Jul;25(7):855-8.
DMOL2Y0	RU	https://pubmed.ncbi.nlm.nih.gov/7108902

DMOL2Y0	DI	DMOL2Y0
DMOL2Y0	DN	1-Dibenzo[b,f]oxepin-10-yl-4-methyl-piperazine
DMOL2Y0	MI	TTEX248
DMOL2Y0	MN	Dopamine D2 receptor (D2R)
DMOL2Y0	MT	DTT
DMOL2Y0	MA	Inhibitor
DMOL2Y0	RN	Affinity of 10-(4-methylpiperazino)dibenz[b,f]oxepins for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1982 Jul;25(7):855-8.
DMOL2Y0	RU	https://pubmed.ncbi.nlm.nih.gov/7108902

DMOL2Y0	DI	DMOL2Y0
DMOL2Y0	DN	1-Dibenzo[b,f]oxepin-10-yl-4-methyl-piperazine
DMOL2Y0	MI	TT4C8EA
DMOL2Y0	MN	Dopamine D3 receptor (D3R)
DMOL2Y0	MT	DTT
DMOL2Y0	MA	Inhibitor
DMOL2Y0	RN	Affinity of 10-(4-methylpiperazino)dibenz[b,f]oxepins for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1982 Jul;25(7):855-8.
DMOL2Y0	RU	https://pubmed.ncbi.nlm.nih.gov/7108902

DMOL2Y0	DI	DMOL2Y0
DMOL2Y0	DN	1-Dibenzo[b,f]oxepin-10-yl-4-methyl-piperazine
DMOL2Y0	MI	TTE0A2F
DMOL2Y0	MN	Dopamine D4 receptor (D4R)
DMOL2Y0	MT	DTT
DMOL2Y0	MA	Inhibitor
DMOL2Y0	RN	Affinity of 10-(4-methylpiperazino)dibenz[b,f]oxepins for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1982 Jul;25(7):855-8.
DMOL2Y0	RU	https://pubmed.ncbi.nlm.nih.gov/7108902

DMOL2Y0	DI	DMOL2Y0
DMOL2Y0	DN	1-Dibenzo[b,f]oxepin-10-yl-4-methyl-piperazine
DMOL2Y0	MI	TTS2PH3
DMOL2Y0	MN	Dopamine D5 receptor (D5R)
DMOL2Y0	MT	DTT
DMOL2Y0	MA	Inhibitor
DMOL2Y0	RN	Affinity of 10-(4-methylpiperazino)dibenz[b,f]oxepins for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1982 Jul;25(7):855-8.
DMOL2Y0	RU	https://pubmed.ncbi.nlm.nih.gov/7108902

DMOSRET	DI	DMOSRET
DMOSRET	DN	1DMe
DMOSRET	MI	TTEP027
DMOSRET	MN	Neuropeptide FF receptor 1 (NPFFR1)
DMOSRET	MT	DTT
DMOSRET	MA	Agonist
DMOSRET	RN	Quantitative autoradiographic distribution of NPFF1 neuropeptide FF receptor in the rat brain and comparison with NPFF2 receptor by using [125I]YVP and [(125I]EYF as selective radioligands. Neuroscience. 2002;115(2):349-61.
DMOSRET	RU	https://pubmed.ncbi.nlm.nih.gov/12421602

DMOSRET	DI	DMOSRET
DMOSRET	DN	1DMe
DMOSRET	MI	TTXYNDJ
DMOSRET	MN	Neuropeptide FF receptor 2 (NPFFR2)
DMOSRET	MT	DTT
DMOSRET	MA	Agonist
DMOSRET	RN	Quantitative autoradiographic distribution of NPFF1 neuropeptide FF receptor in the rat brain and comparison with NPFF2 receptor by using [125I]YVP and [(125I]EYF as selective radioligands. Neuroscience. 2002;115(2):349-61.
DMOSRET	RU	https://pubmed.ncbi.nlm.nih.gov/12421602

DM7P3N5	DI	DM7P3N5
DM7P3N5	DN	1-DODECANOL
DM7P3N5	MI	TTDP1UC
DM7P3N5	MN	Fatty acid amide hydrolase (FAAH)
DM7P3N5	MT	DTT
DM7P3N5	MA	Inhibitor
DM7P3N5	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM7P3N5	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMK6BWV	DI	DMK6BWV
DMK6BWV	DN	1-dodecyl-1H-indole-2,3-dione
DMK6BWV	MI	TTMF541
DMK6BWV	MN	Liver carboxylesterase (CES1)
DMK6BWV	MT	DTT
DMK6BWV	MA	Inhibitor
DMK6BWV	RN	Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85.
DMK6BWV	RU	https://pubmed.ncbi.nlm.nih.gov/17378546

DMK6BWV	DI	DMK6BWV
DMK6BWV	DN	1-dodecyl-1H-indole-2,3-dione
DMK6BWV	MI	TTLZS4Q
DMK6BWV	MN	M-phase inducer phosphatase 1 (MPIP1)
DMK6BWV	MT	DTT
DMK6BWV	MA	Inhibitor
DMK6BWV	RN	Design and synthesis of N-alkyl oxindolylidene acetic acids as a new class of potent Cdc25A inhibitors. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3350-3.
DMK6BWV	RU	https://pubmed.ncbi.nlm.nih.gov/18442908

DMJBFN0	DI	DMJBFN0
DMJBFN0	DN	1-ETHOXY-2-(2-ETHOXYETHOXY)ETHANE
DMJBFN0	MI	TT1RS9F
DMJBFN0	MN	Acetylcholinesterase (AChE)
DMJBFN0	MT	DTT
DMJBFN0	MA	Inhibitor
DMJBFN0	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMJBFN0	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMJBFN0	DI	DMJBFN0
DMJBFN0	DN	1-ETHOXY-2-(2-ETHOXYETHOXY)ETHANE
DMJBFN0	MI	TTFGVKC
DMJBFN0	MN	Bacterial Phosphoenolpyruvate transferase (Bact ptsI)
DMJBFN0	MT	DTT
DMJBFN0	MA	Inhibitor
DMJBFN0	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMJBFN0	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM5UWH9	DI	DM5UWH9
DM5UWH9	DN	1-Ethyl-3-imidazol-1-ylmethyl-1H-indole
DM5UWH9	MI	TTIQUX7
DM5UWH9	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM5UWH9	MT	DTT
DM5UWH9	MA	Inhibitor
DM5UWH9	RN	Selective thromboxane synthetase inhibitors. 2. 3-(1H-imidazol-1-ylmethyl)-2-methyl-1H-indole-1-propanoic acid and analogues. J Med Chem. 1986 Mar;29(3):342-6.
DM5UWH9	RU	https://pubmed.ncbi.nlm.nih.gov/3081722

DMSFINY	DI	DMSFINY
DMSFINY	DN	1-Ethyl-3-methyl-3,7-dihydro-purine-2,6-dione
DMSFINY	MI	TTM2AOE
DMSFINY	MN	Adenosine A2a receptor (ADORA2A)
DMSFINY	MT	DTT
DMSFINY	MA	Inhibitor
DMSFINY	RN	Analogues of caffeine and theophylline: effect of structural alterations on affinity at adenosine receptors. J Med Chem. 1986 Jul;29(7):1305-8.
DMSFINY	RU	https://pubmed.ncbi.nlm.nih.gov/3806581

DMGKP9Y	DI	DMGKP9Y
DMGKP9Y	DN	1-Ethyl-4-(2-methoxy-phenyl)-piperazine
DMGKP9Y	MI	TTSQIFT
DMGKP9Y	MN	5-HT 1A receptor (HTR1A)
DMGKP9Y	MT	DTT
DMGKP9Y	MA	Inhibitor
DMGKP9Y	RN	Structure-activity relationship studies of central nervous system agents. 13. 4-[3-(Benzotriazol-1-yl)propyl]-1-(2-methoxyphenyl)piperazine, a new ... J Med Chem. 1994 Aug 19;37(17):2754-60.
DMGKP9Y	RU	https://pubmed.ncbi.nlm.nih.gov/8064802

DMGKP9Y	DI	DMGKP9Y
DMGKP9Y	DN	1-Ethyl-4-(2-methoxy-phenyl)-piperazine
DMGKP9Y	MI	TTJQOD7
DMGKP9Y	MN	5-HT 2A receptor (HTR2A)
DMGKP9Y	MT	DTT
DMGKP9Y	MA	Inhibitor
DMGKP9Y	RN	Structure-activity relationship studies of central nervous system agents. 13. 4-[3-(Benzotriazol-1-yl)propyl]-1-(2-methoxyphenyl)piperazine, a new ... J Med Chem. 1994 Aug 19;37(17):2754-60.
DMGKP9Y	RU	https://pubmed.ncbi.nlm.nih.gov/8064802

DMUOSJG	DI	DMUOSJG
DMUOSJG	DN	1-Ethyl-5-(imidazol-1-yl-phenyl-methyl)-1H-indole
DMUOSJG	MI	TTSZLWK
DMUOSJG	MN	Aromatase (CYP19A1)
DMUOSJG	MT	DTT
DMUOSJG	MA	Inhibitor
DMUOSJG	RN	New selective nonsteroidal aromatase inhibitors: synthesis and inhibitory activity of 2,3 or 5-(alpha-azolylbenzyl)-1H-indoles. Bioorg Med Chem Lett. 1999 Feb 8;9(3):333-6.
DMUOSJG	RU	https://pubmed.ncbi.nlm.nih.gov/10091679

DMUOSJG	DI	DMUOSJG
DMUOSJG	DN	1-Ethyl-5-(imidazol-1-yl-phenyl-methyl)-1H-indole
DMUOSJG	MI	TTRA5BZ
DMUOSJG	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMUOSJG	MT	DTT
DMUOSJG	MA	Inhibitor
DMUOSJG	RN	New selective nonsteroidal aromatase inhibitors: synthesis and inhibitory activity of 2,3 or 5-(alpha-azolylbenzyl)-1H-indoles. Bioorg Med Chem Lett. 1999 Feb 8;9(3):333-6.
DMUOSJG	RU	https://pubmed.ncbi.nlm.nih.gov/10091679

DMQRKZO	DI	DMQRKZO
DMQRKZO	DN	1-Ethylidenethiosemicarbazide
DMQRKZO	MI	TTULVH8
DMQRKZO	MN	Tyrosinase (TYR)
DMQRKZO	MT	DTT
DMQRKZO	MA	Inhibitor
DMQRKZO	RN	A class of potent tyrosinase inhibitors: alkylidenethiosemicarbazide compounds. Eur J Med Chem. 2009 Apr;44(4):1773-8.
DMQRKZO	RU	https://pubmed.ncbi.nlm.nih.gov/18524420

DM0Q46C	DI	DM0Q46C
DM0Q46C	DN	1-fluoro-5-phenyl-3-aza-bicyclo[3.1.0]hexane
DM0Q46C	MI	TT3ROYC
DM0Q46C	MN	Serotonin transporter (SERT)
DM0Q46C	MT	DTT
DM0Q46C	MA	Inhibitor
DM0Q46C	RN	Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3682-6.
DM0Q46C	RU	https://pubmed.ncbi.nlm.nih.gov/18539031

DM8BC1M	DI	DM8BC1M
DM8BC1M	DN	1-Fluoro-6-(4-hydroxy-phenyl)-naphthalen-2-ol
DM8BC1M	MI	TTZAYWL
DM8BC1M	MN	Estrogen receptor (ESR)
DM8BC1M	MT	DTT
DM8BC1M	MA	Inhibitor
DM8BC1M	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DM8BC1M	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DM8BC1M	DI	DM8BC1M
DM8BC1M	DN	1-Fluoro-6-(4-hydroxy-phenyl)-naphthalen-2-ol
DM8BC1M	MI	TTOM3J0
DM8BC1M	MN	Estrogen receptor beta (ESR2)
DM8BC1M	MT	DTT
DM8BC1M	MA	Inhibitor
DM8BC1M	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DM8BC1M	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DM7UK56	DI	DM7UK56
DM7UK56	DN	1-furan-2-yl-3-pyridin-2-yl-propenone (FPP-3)
DM7UK56	MI	TT2J34L
DM7UK56	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM7UK56	MT	DTT
DM7UK56	MA	Inhibitor
DM7UK56	RN	The anti-angiogenic effects of 1-furan-2-yl-3-pyridin-2-yl-propenone are mediated through the suppression of both VEGF production and VEGF-induced ... Vascul Pharmacol. 2009 Mar-Apr;50(3-4):123-31.
DM7UK56	RU	https://pubmed.ncbi.nlm.nih.gov/19068239

DMF4BCP	DI	DMF4BCP
DMF4BCP	DN	1-Furan-2-ylmethyl-3-thiazol-2-yl-thiourea
DMF4BCP	MI	TT84ETX
DMF4BCP	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMF4BCP	MT	DTT
DMF4BCP	MA	Inhibitor
DMF4BCP	RN	Anti-HIV activity of aromatic and heterocyclic thiazolyl thiourea compounds. Bioorg Med Chem Lett. 2001 Feb 26;11(4):523-8.
DMF4BCP	RU	https://pubmed.ncbi.nlm.nih.gov/11229762

DMEB8CG	DI	DMEB8CG
DMEB8CG	DN	1G244
DMEB8CG	MI	TTJGLZF
DMEB8CG	MN	Dipeptidyl peptidase 8 (DPP-8)
DMEB8CG	MT	DTT
DMEB8CG	MA	Inhibitor
DMEB8CG	RN	Biochemistry, pharmacokinetics, and toxicology of a potent and selective DPP8/9 inhibitor. Biochem Pharmacol. 2009 Jul 15;78(2):203-10.
DMEB8CG	RU	https://pubmed.ncbi.nlm.nih.gov/19439267

DMEB8CG	DI	DMEB8CG
DMEB8CG	DN	1G244
DMEB8CG	MI	TTNDUL7
DMEB8CG	MN	Dipeptidyl peptidase 9 (DPP-9)
DMEB8CG	MT	DTT
DMEB8CG	MA	Inhibitor
DMEB8CG	RN	Biochemistry, pharmacokinetics, and toxicology of a potent and selective DPP8/9 inhibitor. Biochem Pharmacol. 2009 Jul 15;78(2):203-10.
DMEB8CG	RU	https://pubmed.ncbi.nlm.nih.gov/19439267

DM42IY7	DI	DM42IY7
DM42IY7	DN	1-Guanidinium-7-Aminoheptane
DM42IY7	MI	TTBO2A9
DM42IY7	MN	Deoxyhypusine synthase (DHPS)
DM42IY7	MT	DTT
DM42IY7	MA	Inhibitor
DM42IY7	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM42IY7	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM48TIN	DI	DM48TIN
DM48TIN	DN	1-guanidino-7-isoquinolinesulphonamide
DM48TIN	MI	TTP86E2
DM48TIN	MN	Plasminogen (PLG)
DM48TIN	MT	DTT
DM48TIN	MA	Inhibitor
DM48TIN	RN	Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-sulfonamidoisoquinolinyl)guanidines. J Med Chem. 2007 May 17;50(10):2341-51.
DM48TIN	RU	https://pubmed.ncbi.nlm.nih.gov/17447747

DM48TIN	DI	DM48TIN
DM48TIN	DN	1-guanidino-7-isoquinolinesulphonamide
DM48TIN	MI	TTGY7WI
DM48TIN	MN	Urokinase-type plasminogen activator (PLAU)
DM48TIN	MT	DTT
DM48TIN	MA	Inhibitor
DM48TIN	RN	Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-sulfonamidoisoquinolinyl)guanidines. J Med Chem. 2007 May 17;50(10):2341-51.
DM48TIN	RU	https://pubmed.ncbi.nlm.nih.gov/17447747

DMTF1HL	DI	DMTF1HL
DMTF1HL	DN	1-guanidino-N-phenyl-7-isoquinolinesulphonamide
DMTF1HL	MI	TTP86E2
DMTF1HL	MN	Plasminogen (PLG)
DMTF1HL	MT	DTT
DMTF1HL	MA	Inhibitor
DMTF1HL	RN	Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-sulfonamidoisoquinolinyl)guanidines. J Med Chem. 2007 May 17;50(10):2341-51.
DMTF1HL	RU	https://pubmed.ncbi.nlm.nih.gov/17447747

DMTF1HL	DI	DMTF1HL
DMTF1HL	DN	1-guanidino-N-phenyl-7-isoquinolinesulphonamide
DMTF1HL	MI	TTXAGYU
DMTF1HL	MN	Tissue-type plasminogen activator (PLAT)
DMTF1HL	MT	DTT
DMTF1HL	MA	Inhibitor
DMTF1HL	RN	Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-sulfonamidoisoquinolinyl)guanidines. J Med Chem. 2007 May 17;50(10):2341-51.
DMTF1HL	RU	https://pubmed.ncbi.nlm.nih.gov/17447747

DMTF1HL	DI	DMTF1HL
DMTF1HL	DN	1-guanidino-N-phenyl-7-isoquinolinesulphonamide
DMTF1HL	MI	TTGY7WI
DMTF1HL	MN	Urokinase-type plasminogen activator (PLAU)
DMTF1HL	MT	DTT
DMTF1HL	MA	Inhibitor
DMTF1HL	RN	Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-sulfonamidoisoquinolinyl)guanidines. J Med Chem. 2007 May 17;50(10):2341-51.
DMTF1HL	RU	https://pubmed.ncbi.nlm.nih.gov/17447747

DM9KAI5	DI	DM9KAI5
DM9KAI5	DN	1H-1,2,3-benzotriazol-1-amine
DM9KAI5	MI	TTXV4FI
DM9KAI5	MN	Albendazole monooxygenase (CYP3A4)
DM9KAI5	MT	DTT
DM9KAI5	MA	Inhibitor
DM9KAI5	RN	Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor. Bioorg Med Chem Lett. 2001 Dec 3;11(23):2993-5.
DM9KAI5	RU	https://pubmed.ncbi.nlm.nih.gov/11714595

DM9KAI5	DI	DM9KAI5
DM9KAI5	DN	1H-1,2,3-benzotriazol-1-amine
DM9KAI5	MI	TTVG215
DM9KAI5	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DM9KAI5	MT	DTT
DM9KAI5	MA	Inhibitor
DM9KAI5	RN	Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor. Bioorg Med Chem Lett. 2001 Dec 3;11(23):2993-5.
DM9KAI5	RU	https://pubmed.ncbi.nlm.nih.gov/11714595

DMNZAVE	DI	DMNZAVE
DMNZAVE	DN	1h-Benoximidazole-2-Carboxylic Acid
DMNZAVE	MI	TTPT2QI
DMNZAVE	MN	Cathepsin D (CTSD)
DMNZAVE	MT	DTT
DMNZAVE	MA	Inhibitor
DMNZAVE	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMNZAVE	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM4OWM6	DI	DM4OWM6
DM4OWM6	DN	1-hexadecyl-1H-indole-2,3-dione
DM4OWM6	MI	TTMF541
DM4OWM6	MN	Liver carboxylesterase (CES1)
DM4OWM6	MT	DTT
DM4OWM6	MA	Inhibitor
DM4OWM6	RN	Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85.
DM4OWM6	RU	https://pubmed.ncbi.nlm.nih.gov/17378546

DMME09C	DI	DMME09C
DMME09C	DN	1H-Imidazo[4,5-c]quinolin-4-ylamine HCl
DMME09C	MI	TTK25J1
DMME09C	MN	Adenosine A1 receptor (ADORA1)
DMME09C	MT	DTT
DMME09C	MA	Inhibitor
DMME09C	RN	1H-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists. J Med Chem. 1991 Mar;34(3):1202-6.
DMME09C	RU	https://pubmed.ncbi.nlm.nih.gov/2002461

DMME09C	DI	DMME09C
DMME09C	DN	1H-Imidazo[4,5-c]quinolin-4-ylamine HCl
DMME09C	MI	TTM2AOE
DMME09C	MN	Adenosine A2a receptor (ADORA2A)
DMME09C	MT	DTT
DMME09C	MA	Inhibitor
DMME09C	RN	1H-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists. J Med Chem. 1991 Mar;34(3):1202-6.
DMME09C	RU	https://pubmed.ncbi.nlm.nih.gov/2002461

DMME09C	DI	DMME09C
DMME09C	DN	1H-Imidazo[4,5-c]quinolin-4-ylamine HCl
DMME09C	MI	TTNE7KG
DMME09C	MN	Adenosine A2b receptor (ADORA2B)
DMME09C	MT	DTT
DMME09C	MA	Inhibitor
DMME09C	RN	1H-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists. J Med Chem. 1991 Mar;34(3):1202-6.
DMME09C	RU	https://pubmed.ncbi.nlm.nih.gov/2002461

DMOZ91H	DI	DMOZ91H
DMOZ91H	DN	1H-Indole-2,3-dione
DMOZ91H	MI	TTGP7BY
DMOZ91H	MN	Monoamine oxidase type B (MAO-B)
DMOZ91H	MT	DTT
DMOZ91H	MA	Inhibitor
DMOZ91H	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMOZ91H	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMOZ91H	DI	DMOZ91H
DMOZ91H	DN	1H-Indole-2,3-dione
DMOZ91H	MI	DEIVKZ8
DMOZ91H	MN	NADPH-dependent carbonyl reductase 3 (CBR3)
DMOZ91H	MT	DME
DMOZ91H	MA	Metabolism
DMOZ91H	RN	Analysis of the substrate-binding site of human carbonyl reductases CBR1 and CBR3 by site-directed mutagenesis. Chem Biol Interact. 2009 Mar 16;178(1-3):234-41.
DMOZ91H	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19061875

DMNDVMH	DI	DMNDVMH
DMNDVMH	DN	1H-indole-4,7-dione
DMNDVMH	MI	TTZJYKH
DMNDVMH	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMNDVMH	MT	DTT
DMNDVMH	MA	Inhibitor
DMNDVMH	RN	Synthesis of indoleamine 2,3-dioxygenase inhibitory analogues of the sponge alkaloid exiguamine A. J Med Chem. 2008 May 8;51(9):2634-7.
DMNDVMH	RU	https://pubmed.ncbi.nlm.nih.gov/18393489

DM4V6JE	DI	DM4V6JE
DM4V6JE	DN	1H-Pyrazole-3-carboxylic acid
DM4V6JE	MI	TTWNV8U
DM4V6JE	MN	Nicotinic acid receptor (HCAR2)
DM4V6JE	MT	DTT
DM4V6JE	MA	Inhibitor
DM4V6JE	RN	Pyrazole derivatives as partial agonists for the nicotinic acid receptor. J Med Chem. 2003 Aug 28;46(18):3945-51.
DM4V6JE	RU	https://pubmed.ncbi.nlm.nih.gov/12930155

DM235CQ	DI	DM235CQ
DM235CQ	DN	1-Hydroxy-10H-anthracen-9-one
DM235CQ	MI	TT2J34L
DM235CQ	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM235CQ	MT	DTT
DM235CQ	MA	Inhibitor
DM235CQ	RN	Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80.
DM235CQ	RU	https://pubmed.ncbi.nlm.nih.gov/9371243

DMIOTQ8	DI	DMIOTQ8
DMIOTQ8	DN	1-Hydroxy-1-Thio-Glycerol
DMIOTQ8	MI	TTNGKET
DMIOTQ8	MN	Prolyl endopeptidase (PREP)
DMIOTQ8	MT	DTT
DMIOTQ8	MA	Inhibitor
DMIOTQ8	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMIOTQ8	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9EWN8	DI	DM9EWN8
DM9EWN8	DN	1-Hydroxy-2-Amino-3-Cyclohexylpropane
DM9EWN8	MI	TTB2MXP
DM9EWN8	MN	Angiotensinogenase renin (REN)
DM9EWN8	MT	DTT
DM9EWN8	MA	Inhibitor
DM9EWN8	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9EWN8	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMGBSWP	DI	DMGBSWP
DMGBSWP	DN	1-hydroxy-2-dodecyl-4(1H)quinolone
DMGBSWP	MI	TT3PQ2Y
DMGBSWP	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DMGBSWP	MT	DTT
DMGBSWP	MA	Inhibitor
DMGBSWP	RN	Type II NADH dehydrogenase of the respiratory chain of Plasmodium falciparum and its inhibitors. Bioorg Med Chem Lett. 2009 Feb 1;19(3):972-5.
DMGBSWP	RU	https://pubmed.ncbi.nlm.nih.gov/19097788

DMGNVEF	DI	DMGNVEF
DMGNVEF	DN	1-hydroxy-3-(4-(trifluoromethyl)phenyl)urea
DMGNVEF	MI	TTULVH8
DMGNVEF	MN	Tyrosinase (TYR)
DMGNVEF	MT	DTT
DMGNVEF	MA	Inhibitor
DMGNVEF	RN	Analogues of N-hydroxy-N'-phenylthiourea and N-hydroxy-N'-phenylurea as inhibitors of tyrosinase and melanin formation. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3607-10.
DMGNVEF	RU	https://pubmed.ncbi.nlm.nih.gov/18501598

DMZ7GUP	DI	DMZ7GUP
DMZ7GUP	DN	1-hydroxy-3-(4-nitrophenyl)urea
DMZ7GUP	MI	TTULVH8
DMZ7GUP	MN	Tyrosinase (TYR)
DMZ7GUP	MT	DTT
DMZ7GUP	MA	Inhibitor
DMZ7GUP	RN	Analogues of N-hydroxy-N'-phenylthiourea and N-hydroxy-N'-phenylurea as inhibitors of tyrosinase and melanin formation. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3607-10.
DMZ7GUP	RU	https://pubmed.ncbi.nlm.nih.gov/18501598

DMZ8IL9	DI	DMZ8IL9
DMZ8IL9	DN	1-Hydroxy-3-Methylbutane
DMZ8IL9	MI	TTB2MXP
DMZ8IL9	MN	Angiotensinogenase renin (REN)
DMZ8IL9	MT	DTT
DMZ8IL9	MA	Inhibitor
DMZ8IL9	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMZ8IL9	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM4TSVC	DI	DM4TSVC
DM4TSVC	DN	1-hydroxy-3-phenylurea
DM4TSVC	MI	TTULVH8
DM4TSVC	MN	Tyrosinase (TYR)
DM4TSVC	MT	DTT
DM4TSVC	MA	Inhibitor
DM4TSVC	RN	Analogues of N-hydroxy-N'-phenylthiourea and N-hydroxy-N'-phenylurea as inhibitors of tyrosinase and melanin formation. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3607-10.
DM4TSVC	RU	https://pubmed.ncbi.nlm.nih.gov/18501598

DMRNO5U	DI	DMRNO5U
DMRNO5U	DN	1-Hydroxy-8-methoxy-10H-anthracen-9-one
DMRNO5U	MI	TT2J34L
DMRNO5U	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMRNO5U	MT	DTT
DMRNO5U	MA	Inhibitor
DMRNO5U	RN	Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80.
DMRNO5U	RU	https://pubmed.ncbi.nlm.nih.gov/9371243

DM6FLXW	DI	DM6FLXW
DM6FLXW	DN	1-Hydroxyamine-2-Isobutylmalonic Acid
DM6FLXW	MI	TTGA1IV
DM6FLXW	MN	Matrix metalloproteinase-8 (MMP-8)
DM6FLXW	MT	DTT
DM6FLXW	MA	Inhibitor
DM6FLXW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM6FLXW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM3JHVL	DI	DM3JHVL
DM3JHVL	DN	1-Imidazol-1-yl-3-(4-octylphenoxy)propan-2-one
DM3JHVL	MI	TTT1JVS
DM3JHVL	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DM3JHVL	MT	DTT
DM3JHVL	MA	Inhibitor
DM3JHVL	RN	1-Indol-1-yl-propan-2-ones and related heterocyclic compounds as dual inhibitors of cytosolic phospholipase A(2)alpha and fatty acid amide hydrolase. Bioorg Med Chem. 2010 Jan 15;18(2):945-52.
DM3JHVL	RU	https://pubmed.ncbi.nlm.nih.gov/20005725

DM3JHVL	DI	DM3JHVL
DM3JHVL	DN	1-Imidazol-1-yl-3-(4-octylphenoxy)propan-2-one
DM3JHVL	MI	TTDP1UC
DM3JHVL	MN	Fatty acid amide hydrolase (FAAH)
DM3JHVL	MT	DTT
DM3JHVL	MA	Inhibitor
DM3JHVL	RN	1-Indol-1-yl-propan-2-ones and related heterocyclic compounds as dual inhibitors of cytosolic phospholipase A(2)alpha and fatty acid amide hydrolase. Bioorg Med Chem. 2010 Jan 15;18(2):945-52.
DM3JHVL	RU	https://pubmed.ncbi.nlm.nih.gov/20005725

DMN7KHS	DI	DMN7KHS
DMN7KHS	DN	1-Imidazol-1-ylmethyl-4-nitro-xanthen-9-one
DMN7KHS	MI	TTSZLWK
DMN7KHS	MN	Aromatase (CYP19A1)
DMN7KHS	MT	DTT
DMN7KHS	MA	Inhibitor
DMN7KHS	RN	A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase. J Med Chem. 2001 Mar 1;44(5):672-80.
DMN7KHS	RU	https://pubmed.ncbi.nlm.nih.gov/11262078

DMN7KHS	DI	DMN7KHS
DMN7KHS	DN	1-Imidazol-1-ylmethyl-4-nitro-xanthen-9-one
DMN7KHS	MI	TTRA5BZ
DMN7KHS	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMN7KHS	MT	DTT
DMN7KHS	MA	Inhibitor
DMN7KHS	RN	A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase. J Med Chem. 2001 Mar 1;44(5):672-80.
DMN7KHS	RU	https://pubmed.ncbi.nlm.nih.gov/11262078

DMIDX7P	DI	DMIDX7P
DMIDX7P	DN	1-Imidazol-1-ylmethylxanthen-9-one
DMIDX7P	MI	TTSZLWK
DMIDX7P	MN	Aromatase (CYP19A1)
DMIDX7P	MT	DTT
DMIDX7P	MA	Inhibitor
DMIDX7P	RN	Novel highly potent and selective nonsteroidal aromatase inhibitors: synthesis, biological evaluation and structure-activity relationships investigation. J Med Chem. 2010 Jul 22;53(14):5347-51. 
DMIDX7P	RU	https://pubmed.ncbi.nlm.nih.gov/20568782

DMIDX7P	DI	DMIDX7P
DMIDX7P	DN	1-Imidazol-1-ylmethylxanthen-9-one
DMIDX7P	MI	TTRA5BZ
DMIDX7P	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMIDX7P	MT	DTT
DMIDX7P	MA	Inhibitor
DMIDX7P	RN	Novel highly potent and selective nonsteroidal aromatase inhibitors: synthesis, biological evaluation and structure-activity relationships investigation. J Med Chem. 2010 Jul 22;53(14):5347-51. 
DMIDX7P	RU	https://pubmed.ncbi.nlm.nih.gov/20568782

DMYIQDE	DI	DMYIQDE
DMYIQDE	DN	1-Iodyl-3-nitro-benzene
DMYIQDE	MI	TTELIN2
DMYIQDE	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMYIQDE	MT	DTT
DMYIQDE	MA	Inhibitor
DMYIQDE	RN	Periodinates: a new class of protein tyrosine phosphatase inhibitors. Bioorg Med Chem Lett. 1999 Feb 8;9(3):353-6.
DMYIQDE	RU	https://pubmed.ncbi.nlm.nih.gov/10091683

DMF1WA6	DI	DMF1WA6
DMF1WA6	DN	1-Iodyl-4-nitro-benzene
DMF1WA6	MI	TTELIN2
DMF1WA6	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMF1WA6	MT	DTT
DMF1WA6	MA	Inhibitor
DMF1WA6	RN	Periodinates: a new class of protein tyrosine phosphatase inhibitors. Bioorg Med Chem Lett. 1999 Feb 8;9(3):353-6.
DMF1WA6	RU	https://pubmed.ncbi.nlm.nih.gov/10091683

DMD7WNV	DI	DMD7WNV
DMD7WNV	DN	1-Methoxy-2-[2-(2-Methoxy-Ethoxy]-Ethane
DMD7WNV	MI	TT2B9KF
DMD7WNV	MN	Fyn tyrosine protein kinase (FYN)
DMD7WNV	MT	DTT
DMD7WNV	MA	Inhibitor
DMD7WNV	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD7WNV	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD7WNV	DI	DMD7WNV
DMD7WNV	DN	1-Methoxy-2-[2-(2-Methoxy-Ethoxy]-Ethane
DMD7WNV	MI	TT04R7I
DMD7WNV	MN	Transketolase (TK)
DMD7WNV	MT	DTT
DMD7WNV	MA	Inhibitor
DMD7WNV	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD7WNV	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM7DTRM	DI	DM7DTRM
DM7DTRM	DN	1-methoxy-3-(3-(pyridin-4-yl)-1H-indol-6-yl)urea
DM7DTRM	MI	TTTB4UP
DM7DTRM	MN	Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2)
DM7DTRM	MT	DTT
DM7DTRM	MA	Inhibitor
DM7DTRM	RN	Novel indole inhibitors of IMPDH from fragments: synthesis and initial structure-activity relationships. Bioorg Med Chem Lett. 2006 May 1;16(9):2539-42.
DM7DTRM	RU	https://pubmed.ncbi.nlm.nih.gov/16483773

DMFVSBK	DI	DMFVSBK
DMFVSBK	DN	1-Methoxy-3-(oxiran-2-ylmethoxy)-9H-xanthen-9-one
DMFVSBK	MI	TT0IHXV
DMFVSBK	MN	DNA topoisomerase II (TOP2)
DMFVSBK	MT	DTT
DMFVSBK	MA	Inhibitor
DMFVSBK	RN	Synthesis and pharmacological evaluation of new methyloxiranylmethoxyxanthone analogues. Eur J Med Chem. 2010 Sep;45(9):4221-8.
DMFVSBK	RU	https://pubmed.ncbi.nlm.nih.gov/20619511

DM8YQ2O	DI	DM8YQ2O
DM8YQ2O	DN	1-Methoxy-6-phenyl-6H-benzo[c]chromen-8-ylamine
DM8YQ2O	MI	TTOZRK6
DM8YQ2O	MN	Glucocorticoid receptor messenger RNA (GCR mRNA)
DM8YQ2O	MT	DTT
DM8YQ2O	MA	Inhibitor
DM8YQ2O	RN	Synthesis and biological evaluation of novel, selective, nonsteroidal glucocorticoid receptor antagonists. Bioorg Med Chem Lett. 2004 May 3;14(9):2079-82.
DM8YQ2O	RU	https://pubmed.ncbi.nlm.nih.gov/15080982

DM2D5HB	DI	DM2D5HB
DM2D5HB	DN	1-Methoxy-6-phenyl-6H-benzo[c]chromene
DM2D5HB	MI	TTOZRK6
DM2D5HB	MN	Glucocorticoid receptor messenger RNA (GCR mRNA)
DM2D5HB	MT	DTT
DM2D5HB	MA	Inhibitor
DM2D5HB	RN	Synthesis and biological evaluation of novel, selective, nonsteroidal glucocorticoid receptor antagonists. Bioorg Med Chem Lett. 2004 May 3;14(9):2079-82.
DM2D5HB	RU	https://pubmed.ncbi.nlm.nih.gov/15080982

DMAUZHJ	DI	DMAUZHJ
DMAUZHJ	DN	1-methoxy-9-aminomethyl-9,10-dihydroanthracene
DMAUZHJ	MI	TTJQOD7
DMAUZHJ	MN	5-HT 2A receptor (HTR2A)
DMAUZHJ	MT	DTT
DMAUZHJ	MA	Inhibitor
DMAUZHJ	RN	Methoxy-substituted 9-aminomethyl-9,10-dihydroanthracene (AMDA) derivatives exhibit differential binding affinities at the 5-HT(2A) receptor. Bioorg Med Chem Lett. 2008 Oct 1;18(19):5268-71.
DMAUZHJ	RU	https://pubmed.ncbi.nlm.nih.gov/18774714

DM9KCXI	DI	DM9KCXI
DM9KCXI	DN	1-Methyl-1-(4-pyrrolidin-1-yl-but-2-ynyl)-urea
DM9KCXI	MI	TTZ9SOR
DM9KCXI	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DM9KCXI	MT	DTT
DM9KCXI	MA	Inhibitor
DM9KCXI	RN	Urea and 2-imidazolidone derivatives of the muscarinic agents oxotremorine and N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide. J Med Chem. 1992 Aug 21;35(17):3270-9.
DM9KCXI	RU	https://pubmed.ncbi.nlm.nih.gov/1507212

DM9KCXI	DI	DM9KCXI
DM9KCXI	DN	1-Methyl-1-(4-pyrrolidin-1-yl-but-2-ynyl)-urea
DM9KCXI	MI	TTYEG6Q
DM9KCXI	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DM9KCXI	MT	DTT
DM9KCXI	MA	Inhibitor
DM9KCXI	RN	Urea and 2-imidazolidone derivatives of the muscarinic agents oxotremorine and N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide. J Med Chem. 1992 Aug 21;35(17):3270-9.
DM9KCXI	RU	https://pubmed.ncbi.nlm.nih.gov/1507212

DM9KCXI	DI	DM9KCXI
DM9KCXI	DN	1-Methyl-1-(4-pyrrolidin-1-yl-but-2-ynyl)-urea
DM9KCXI	MI	TTQ13Z5
DM9KCXI	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DM9KCXI	MT	DTT
DM9KCXI	MA	Inhibitor
DM9KCXI	RN	Urea and 2-imidazolidone derivatives of the muscarinic agents oxotremorine and N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide. J Med Chem. 1992 Aug 21;35(17):3270-9.
DM9KCXI	RU	https://pubmed.ncbi.nlm.nih.gov/1507212

DM9KCXI	DI	DM9KCXI
DM9KCXI	DN	1-Methyl-1-(4-pyrrolidin-1-yl-but-2-ynyl)-urea
DM9KCXI	MI	TTQ3JTF
DM9KCXI	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DM9KCXI	MT	DTT
DM9KCXI	MA	Inhibitor
DM9KCXI	RN	Urea and 2-imidazolidone derivatives of the muscarinic agents oxotremorine and N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide. J Med Chem. 1992 Aug 21;35(17):3270-9.
DM9KCXI	RU	https://pubmed.ncbi.nlm.nih.gov/1507212

DM9KCXI	DI	DM9KCXI
DM9KCXI	DN	1-Methyl-1-(4-pyrrolidin-1-yl-but-2-ynyl)-urea
DM9KCXI	MI	TTH18TF
DM9KCXI	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DM9KCXI	MT	DTT
DM9KCXI	MA	Inhibitor
DM9KCXI	RN	Urea and 2-imidazolidone derivatives of the muscarinic agents oxotremorine and N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide. J Med Chem. 1992 Aug 21;35(17):3270-9.
DM9KCXI	RU	https://pubmed.ncbi.nlm.nih.gov/1507212

DMI6P91	DI	DMI6P91
DMI6P91	DN	1-Methyl-1,2,3,4-tetrahydro-isoquinoline-6,7-diol
DMI6P91	MI	TTEX248
DMI6P91	MN	Dopamine D2 receptor (D2R)
DMI6P91	MT	DTT
DMI6P91	MA	Inhibitor
DMI6P91	RN	D4 dopamine receptor-selective compounds from the Chinese plant Phoebe chekiangensis, Bioorg. Med. Chem. Lett. 7(9):1207-1212 (1997).
DMI6P91	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97001947

DM1BGQN	DI	DM1BGQN
DM1BGQN	DN	1-Methyl-1,2-dihydro-indazol-3-one
DM1BGQN	MI	TT2J34L
DM1BGQN	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM1BGQN	MT	DTT
DM1BGQN	MA	Inhibitor
DM1BGQN	RN	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
DM1BGQN	RU	https://pubmed.ncbi.nlm.nih.gov/1848292

DMMX7V8	DI	DMMX7V8
DMMX7V8	DN	1-Methyl-1,3-dihydro-indol-2-one
DMMX7V8	MI	TTSQIFT
DMMX7V8	MN	5-HT 1A receptor (HTR1A)
DMMX7V8	MT	DTT
DMMX7V8	MA	Inhibitor
DMMX7V8	RN	Influence of the terminal amide fragment geometry in some 3-arylideneindolin-2(1H)-ones on their 5-HT1A/5-HT2A receptor activity. Bioorg Med Chem Lett. 2001 May 7;11(9):1229-31.
DMMX7V8	RU	https://pubmed.ncbi.nlm.nih.gov/11354383

DMMX7V8	DI	DMMX7V8
DMMX7V8	DN	1-Methyl-1,3-dihydro-indol-2-one
DMMX7V8	MI	TTJQOD7
DMMX7V8	MN	5-HT 2A receptor (HTR2A)
DMMX7V8	MT	DTT
DMMX7V8	MA	Inhibitor
DMMX7V8	RN	Influence of the terminal amide fragment geometry in some 3-arylideneindolin-2(1H)-ones on their 5-HT1A/5-HT2A receptor activity. Bioorg Med Chem Lett. 2001 May 7;11(9):1229-31.
DMMX7V8	RU	https://pubmed.ncbi.nlm.nih.gov/11354383

DMPW75L	DI	DMPW75L
DMPW75L	DN	1-methyl-1H-indole-2,3-dione
DMPW75L	MI	TTMF541
DMPW75L	MN	Liver carboxylesterase (CES1)
DMPW75L	MT	DTT
DMPW75L	MA	Inhibitor
DMPW75L	RN	Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85.
DMPW75L	RU	https://pubmed.ncbi.nlm.nih.gov/17378546

DMDZ1FR	DI	DMDZ1FR
DMDZ1FR	DN	1-methyl-1H-indole-3-carbaldehyde
DMDZ1FR	MI	TTTB4UP
DMDZ1FR	MN	Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2)
DMDZ1FR	MT	DTT
DMDZ1FR	MA	Inhibitor
DMDZ1FR	RN	Low molecular weight indole fragments as IMPDH inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2535-8.
DMDZ1FR	RU	https://pubmed.ncbi.nlm.nih.gov/16483769

DML5FQT	DI	DML5FQT
DML5FQT	DN	1-methyl-1H-indole-3-carbonitrile
DML5FQT	MI	TTTB4UP
DML5FQT	MN	Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2)
DML5FQT	MT	DTT
DML5FQT	MA	Inhibitor
DML5FQT	RN	Novel indole inhibitors of IMPDH from fragments: synthesis and initial structure-activity relationships. Bioorg Med Chem Lett. 2006 May 1;16(9):2539-42.
DML5FQT	RU	https://pubmed.ncbi.nlm.nih.gov/16483773

DMUKAH6	DI	DMUKAH6
DMUKAH6	DN	1-methyl-1H-indole-3-carboxamide
DMUKAH6	MI	TTTB4UP
DMUKAH6	MN	Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2)
DMUKAH6	MT	DTT
DMUKAH6	MA	Inhibitor
DMUKAH6	RN	Low molecular weight indole fragments as IMPDH inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2535-8.
DMUKAH6	RU	https://pubmed.ncbi.nlm.nih.gov/16483769

DMYU348	DI	DMYU348
DMYU348	DN	1-Methyl-2-(4-phenylsulfanyl-phenyl)-ethylamine
DMYU348	MI	TT3ROYC
DMYU348	MN	Serotonin transporter (SERT)
DMYU348	MT	DTT
DMYU348	MA	Inhibitor
DMYU348	RN	Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88.
DMYU348	RU	https://pubmed.ncbi.nlm.nih.gov/19717215

DM5GELS	DI	DM5GELS
DM5GELS	DN	1-Methyl-2-Oxy-5,5-Dimethyl Pyrrolidine
DM5GELS	MI	TTB2MXP
DM5GELS	MN	Angiotensinogenase renin (REN)
DM5GELS	MT	DTT
DM5GELS	MA	Inhibitor
DM5GELS	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM5GELS	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMC3IGK	DI	DMC3IGK
DMC3IGK	DN	1-methyl-3-(phenylcarbamoyloxy)pyridinium bromide
DMC3IGK	MI	TTEB0GD
DMC3IGK	MN	Cholinesterase (BCHE)
DMC3IGK	MT	DTT
DMC3IGK	MA	Inhibitor
DMC3IGK	RN	Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. Bioorg Med Chem. 2010 Jul 1;18(13):4687-93. 
DMC3IGK	RU	https://pubmed.ncbi.nlm.nih.gov/20627738

DMICQWN	DI	DMICQWN
DMICQWN	DN	1-METHYL-3-PHENYL-1H-PYRAZOL-5-YLSULFAMIC ACID
DMICQWN	MI	TTELIN2
DMICQWN	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMICQWN	MT	DTT
DMICQWN	MA	Inhibitor
DMICQWN	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMICQWN	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DM90LWT	DI	DM90LWT
DM90LWT	DN	1-Methyl-3-propyl-3,7-dihydro-purine-2,6-dione
DM90LWT	MI	TTZ97H5
DM90LWT	MN	Phosphodiesterase 4A (PDE4A)
DM90LWT	MT	DTT
DM90LWT	MA	Inhibitor
DM90LWT	RN	Effects of alkyl substitutions of xanthine skeleton on bronchodilation. J Med Chem. 1992 Oct 30;35(22):4039-44.
DM90LWT	RU	https://pubmed.ncbi.nlm.nih.gov/1331453

DM90LWT	DI	DM90LWT
DM90LWT	DN	1-Methyl-3-propyl-3,7-dihydro-purine-2,6-dione
DM90LWT	MI	TTSKMI8
DM90LWT	MN	Phosphodiesterase 4D (PDE4D)
DM90LWT	MT	DTT
DM90LWT	MA	Inhibitor
DM90LWT	RN	Effects of alkyl substitutions of xanthine skeleton on bronchodilation. J Med Chem. 1992 Oct 30;35(22):4039-44.
DM90LWT	RU	https://pubmed.ncbi.nlm.nih.gov/1331453

DMBWSCR	DI	DMBWSCR
DMBWSCR	DN	1-Methyl-4-(1-phenyl-ethyl)-piperazine
DMBWSCR	MI	TTD0CIQ
DMBWSCR	MN	Melanocortin receptor 4 (MC4R)
DMBWSCR	MT	DTT
DMBWSCR	MA	Inhibitor
DMBWSCR	RN	Privileged structure based ligands for melanocortin receptors--substituted benzylic piperazine derivatives. Bioorg Med Chem Lett. 2005 Nov 15;15(22):4973-8.
DMBWSCR	RU	https://pubmed.ncbi.nlm.nih.gov/16169215

DMPWB8G	DI	DMPWB8G
DMPWB8G	DN	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
DMPWB8G	MI	TTGP7BY
DMPWB8G	MN	Monoamine oxidase type B (MAO-B)
DMPWB8G	MT	DTT
DMPWB8G	MA	Inhibitor
DMPWB8G	RN	Further explorations of unnatural alkaloids. J Nat Prod. 1985 Nov-Dec;48(6):878-93.
DMPWB8G	RU	https://pubmed.ncbi.nlm.nih.gov/3879267

DM6XFMT	DI	DM6XFMT
DM6XFMT	DN	1-Methyl-4-p-tolyl-piperidine-4-carbonitrile
DM6XFMT	MI	TT3ROYC
DM6XFMT	MN	Serotonin transporter (SERT)
DM6XFMT	MT	DTT
DM6XFMT	MA	Inhibitor
DM6XFMT	RN	Synthesis, dopamine and serotonin transporter binding affinities of novel analogues of meperidine. Bioorg Med Chem Lett. 1999 Dec 6;9(23):3273-6.
DM6XFMT	RU	https://pubmed.ncbi.nlm.nih.gov/10612583

DM4HS92	DI	DM4HS92
DM4HS92	DN	1-Methyl-5-(4-phenylazo-phenyl)-piperidin-2-one
DM4HS92	MI	TTTU72V
DM4HS92	MN	Steroid 5-alpha-reductase 1 (SRD5A1)
DM4HS92	MT	DTT
DM4HS92	MA	Inhibitor
DM4HS92	RN	Simple bi- and tricyclic inhibitors of human steroid 5alpha-reductase. Bioorg Med Chem Lett. 2000 Sep 4;10(17):1909-11.
DM4HS92	RU	https://pubmed.ncbi.nlm.nih.gov/10987415

DMX2FWN	DI	DMX2FWN
DMX2FWN	DN	1-Methyl-5-oxa-spiro[2.4]heptan-4-one
DMX2FWN	MI	TT1MPAY
DMX2FWN	MN	GABA(A) receptor alpha-1 (GABRA1)
DMX2FWN	MT	DTT
DMX2FWN	MA	Inhibitor
DMX2FWN	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DMX2FWN	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DMX2FWN	DI	DMX2FWN
DMX2FWN	DN	1-Methyl-5-oxa-spiro[2.4]heptan-4-one
DMX2FWN	MI	TTZA1NY
DMX2FWN	MN	GABA(A) receptor beta-2 (GABRB2)
DMX2FWN	MT	DTT
DMX2FWN	MA	Inhibitor
DMX2FWN	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DMX2FWN	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DMX2FWN	DI	DMX2FWN
DMX2FWN	DN	1-Methyl-5-oxa-spiro[2.4]heptan-4-one
DMX2FWN	MI	TT06RH5
DMX2FWN	MN	GABA(A) receptor gamma-2 (GABRG2)
DMX2FWN	MT	DTT
DMX2FWN	MA	Inhibitor
DMX2FWN	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DMX2FWN	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DMX2FWN	DI	DMX2FWN
DMX2FWN	DN	1-Methyl-5-oxa-spiro[2.4]heptan-4-one
DMX2FWN	MI	TTNJYV2
DMX2FWN	MN	Gamma-aminobutyric acid receptor (GAR)
DMX2FWN	MT	DTT
DMX2FWN	MA	Inhibitor
DMX2FWN	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DMX2FWN	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DMB3JO2	DI	DMB3JO2
DMB3JO2	DN	1-Methyl-5-phenyl-piperidin-2-one
DMB3JO2	MI	TTTU72V
DMB3JO2	MN	Steroid 5-alpha-reductase 1 (SRD5A1)
DMB3JO2	MT	DTT
DMB3JO2	MA	Inhibitor
DMB3JO2	RN	Simple bi- and tricyclic inhibitors of human steroid 5alpha-reductase. Bioorg Med Chem Lett. 2000 Sep 4;10(17):1909-11.
DMB3JO2	RU	https://pubmed.ncbi.nlm.nih.gov/10987415

DMSTH24	DI	DMSTH24
DMSTH24	DN	1-Methyl-8-phenyl-3,7-dihydro-purine-2,6-dione
DMSTH24	MI	TTK25J1
DMSTH24	MN	Adenosine A1 receptor (ADORA1)
DMSTH24	MT	DTT
DMSTH24	MA	Inhibitor
DMSTH24	RN	Effects of 8-phenyl and 8-cycloalkyl substituents on the activity of mono-, di-, and trisubstituted alkylxanthines with substitution at the 1-, 3-,... J Med Chem. 1989 Jun;32(6):1231-7.
DMSTH24	RU	https://pubmed.ncbi.nlm.nih.gov/2724296

DMSTH24	DI	DMSTH24
DMSTH24	DN	1-Methyl-8-phenyl-3,7-dihydro-purine-2,6-dione
DMSTH24	MI	TTM2AOE
DMSTH24	MN	Adenosine A2a receptor (ADORA2A)
DMSTH24	MT	DTT
DMSTH24	MA	Inhibitor
DMSTH24	RN	Preparation, properties, reactions, and adenosine receptor affinities of sulfophenylxanthine nitrophenyl esters: toward the development of sulfonic... J Med Chem. 2004 Feb 12;47(4):1031-43.
DMSTH24	RU	https://pubmed.ncbi.nlm.nih.gov/14761205

DMDIH07	DI	DMDIH07
DMDIH07	DN	1-methylcyclopropanecarboxylic acid
DMDIH07	MI	TT0FYAN
DMDIH07	MN	Free fatty acid receptor 2 (FFAR2)
DMDIH07	MT	DTT
DMDIH07	MA	Agonist
DMDIH07	RN	Selective orthosteric free fatty acid receptor 2 (FFA2) agonists: identification of the structural and chemical requirements for selective activation of FFA2 versus FFA3. J Biol Chem. 2011 Mar 25;286(12):10628-40.
DMDIH07	RU	https://pubmed.ncbi.nlm.nih.gov/21220428

DMDIH07	DI	DMDIH07
DMDIH07	DN	1-methylcyclopropanecarboxylic acid
DMDIH07	MI	TTXDOHN
DMDIH07	MN	Free fatty acid receptor 3 (FFAR3)
DMDIH07	MT	DTT
DMDIH07	MA	Agonist
DMDIH07	RN	Selective orthosteric free fatty acid receptor 2 (FFA2) agonists: identification of the structural and chemical requirements for selective activation of FFA2 versus FFA3. J Biol Chem. 2011 Mar 25;286(12):10628-40.
DMDIH07	RU	https://pubmed.ncbi.nlm.nih.gov/21220428

DMFR7JW	DI	DMFR7JW
DMFR7JW	DN	1-Methyloxy-4-Sulfone-Benzene
DMFR7JW	MI	TTHY57M
DMFR7JW	MN	Matrix metalloproteinase-13 (MMP-13)
DMFR7JW	MT	DTT
DMFR7JW	MA	Inhibitor
DMFR7JW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMFR7JW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMFR7JW	DI	DMFR7JW
DMFR7JW	DN	1-Methyloxy-4-Sulfone-Benzene
DMFR7JW	MI	TTUZ2L5
DMFR7JW	MN	Matrix metalloproteinase-3 (MMP-3)
DMFR7JW	MT	DTT
DMFR7JW	MA	Inhibitor
DMFR7JW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMFR7JW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM2WQ1E	DI	DM2WQ1E
DM2WQ1E	DN	1-METHYLXANTHINE
DM2WQ1E	MI	TTK25J1
DM2WQ1E	MN	Adenosine A1 receptor (ADORA1)
DM2WQ1E	MT	DTT
DM2WQ1E	MA	Inhibitor
DM2WQ1E	RN	Benzo[1,2-c:5,4-c']dipyrazoles: non-xanthine adenosine antagonists. J Med Chem. 1988 Oct;31(10):2034-9.
DM2WQ1E	RU	https://pubmed.ncbi.nlm.nih.gov/3172141

DM2WQ1E	DI	DM2WQ1E
DM2WQ1E	DN	1-METHYLXANTHINE
DM2WQ1E	MI	TTM2AOE
DM2WQ1E	MN	Adenosine A2a receptor (ADORA2A)
DM2WQ1E	MT	DTT
DM2WQ1E	MA	Inhibitor
DM2WQ1E	RN	Benzo[1,2-c:5,4-c']dipyrazoles: non-xanthine adenosine antagonists. J Med Chem. 1988 Oct;31(10):2034-9.
DM2WQ1E	RU	https://pubmed.ncbi.nlm.nih.gov/3172141

DM2WQ1E	DI	DM2WQ1E
DM2WQ1E	DN	1-METHYLXANTHINE
DM2WQ1E	MI	TTNE7KG
DM2WQ1E	MN	Adenosine A2b receptor (ADORA2B)
DM2WQ1E	MT	DTT
DM2WQ1E	MA	Inhibitor
DM2WQ1E	RN	Benzo[1,2-c:5,4-c']dipyrazoles: non-xanthine adenosine antagonists. J Med Chem. 1988 Oct;31(10):2034-9.
DM2WQ1E	RU	https://pubmed.ncbi.nlm.nih.gov/3172141

DMYOJ01	DI	DMYOJ01
DMYOJ01	DN	1-Morpholin-4-yl-benzo[f]chromen-3-one
DMYOJ01	MI	TTK3PY9
DMYOJ01	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMYOJ01	MT	DTT
DMYOJ01	MA	Inhibitor
DMYOJ01	RN	Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85.
DMYOJ01	RU	https://pubmed.ncbi.nlm.nih.gov/15658870

DM0A1YI	DI	DM0A1YI
DM0A1YI	DN	1na
DM0A1YI	MI	TTAU4D6
DM0A1YI	MN	E-selectin (SELE)
DM0A1YI	MT	DTT
DM0A1YI	MA	Inhibitor
DM0A1YI	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM0A1YI	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM0A1YI	DI	DM0A1YI
DM0A1YI	DN	1na
DM0A1YI	MI	TTE5VG0
DM0A1YI	MN	P-selectin (SELP)
DM0A1YI	MT	DTT
DM0A1YI	MA	Inhibitor
DM0A1YI	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM0A1YI	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMF87Z5	DI	DMF87Z5
DMF87Z5	DN	1-N-Acetyl-Beta-D-Glucosamine
DMF87Z5	MI	TTZHY6R
DMF87Z5	MN	Glycogen phosphorylase muscle form (GP)
DMF87Z5	MT	DTT
DMF87Z5	MA	Inhibitor
DMF87Z5	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMF87Z5	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMTBZJL	DI	DMTBZJL
DMTBZJL	DN	1-Naphthalen-2-yl-1H-imidazole
DMTBZJL	MI	TTSZLWK
DMTBZJL	MN	Aromatase (CYP19A1)
DMTBZJL	MT	DTT
DMTBZJL	MA	Inhibitor
DMTBZJL	RN	Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42.
DMTBZJL	RU	https://pubmed.ncbi.nlm.nih.gov/16220979

DMTBZJL	DI	DMTBZJL
DMTBZJL	DN	1-Naphthalen-2-yl-1H-imidazole
DMTBZJL	MI	TTIQUX7
DMTBZJL	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMTBZJL	MT	DTT
DMTBZJL	MA	Inhibitor
DMTBZJL	RN	Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42.
DMTBZJL	RU	https://pubmed.ncbi.nlm.nih.gov/16220979

DMU04ZQ	DI	DMU04ZQ
DMU04ZQ	DN	1-naphthalen-2-yl-2-pyrrolidin-1-yl-pentan-1-one
DMU04ZQ	MI	TTVBI8W
DMU04ZQ	MN	Dopamine transporter (DAT)
DMU04ZQ	MT	DTT
DMU04ZQ	MA	Inhibitor
DMU04ZQ	RN	1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32.
DMU04ZQ	RU	https://pubmed.ncbi.nlm.nih.gov/16480278

DMU04ZQ	DI	DMU04ZQ
DMU04ZQ	DN	1-naphthalen-2-yl-2-pyrrolidin-1-yl-pentan-1-one
DMU04ZQ	MI	TTAWNKZ
DMU04ZQ	MN	Norepinephrine transporter (NET)
DMU04ZQ	MT	DTT
DMU04ZQ	MA	Inhibitor
DMU04ZQ	RN	1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32.
DMU04ZQ	RU	https://pubmed.ncbi.nlm.nih.gov/16480278

DMU04ZQ	DI	DMU04ZQ
DMU04ZQ	DN	1-naphthalen-2-yl-2-pyrrolidin-1-yl-pentan-1-one
DMU04ZQ	MI	TT3ROYC
DMU04ZQ	MN	Serotonin transporter (SERT)
DMU04ZQ	MT	DTT
DMU04ZQ	MA	Inhibitor
DMU04ZQ	RN	1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32.
DMU04ZQ	RU	https://pubmed.ncbi.nlm.nih.gov/16480278

DMJK0MF	DI	DMJK0MF
DMJK0MF	DN	1-Naphthalen-2-yl-piperazine
DMJK0MF	MI	TTSQIFT
DMJK0MF	MN	5-HT 1A receptor (HTR1A)
DMJK0MF	MT	DTT
DMJK0MF	MA	Inhibitor
DMJK0MF	RN	5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80.
DMJK0MF	RU	https://pubmed.ncbi.nlm.nih.gov/3783595

DMJK0MF	DI	DMJK0MF
DMJK0MF	DN	1-Naphthalen-2-yl-piperazine
DMJK0MF	MI	TTK8CXU
DMJK0MF	MN	5-HT 1B receptor (HTR1B)
DMJK0MF	MT	DTT
DMJK0MF	MA	Inhibitor
DMJK0MF	RN	5-HT1B receptor antagonist properties of novel arylpiperazide derivatives of 1-naphthylpiperazine. J Med Chem. 1997 Nov 21;40(24):3974-8.
DMJK0MF	RU	https://pubmed.ncbi.nlm.nih.gov/9397179

DMJK0MF	DI	DMJK0MF
DMJK0MF	DN	1-Naphthalen-2-yl-piperazine
DMJK0MF	MI	TT6MSOK
DMJK0MF	MN	5-HT 1D receptor (HTR1D)
DMJK0MF	MT	DTT
DMJK0MF	MA	Inhibitor
DMJK0MF	RN	5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80.
DMJK0MF	RU	https://pubmed.ncbi.nlm.nih.gov/3783595

DMJK0MF	DI	DMJK0MF
DMJK0MF	DN	1-Naphthalen-2-yl-piperazine
DMJK0MF	MI	TTJQOD7
DMJK0MF	MN	5-HT 2A receptor (HTR2A)
DMJK0MF	MT	DTT
DMJK0MF	MA	Inhibitor
DMJK0MF	RN	5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80.
DMJK0MF	RU	https://pubmed.ncbi.nlm.nih.gov/3783595

DM6BIWK	DI	DM6BIWK
DM6BIWK	DN	1-naphthylpiperazine
DM6BIWK	MI	TTSQIFT
DM6BIWK	MN	5-HT 1A receptor (HTR1A)
DM6BIWK	MT	DTT
DM6BIWK	MA	Agonist
DM6BIWK	RN	5-HT1B receptor antagonist properties of novel arylpiperazide derivatives of 1-naphthylpiperazine. J Med Chem. 1997 Nov 21;40(24):3974-8.
DM6BIWK	RU	https://pubmed.ncbi.nlm.nih.gov/9397179

DM6BIWK	DI	DM6BIWK
DM6BIWK	DN	1-naphthylpiperazine
DM6BIWK	MI	TTK8CXU
DM6BIWK	MN	5-HT 1B receptor (HTR1B)
DM6BIWK	MT	DTT
DM6BIWK	MA	Agonist
DM6BIWK	RN	Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors. J Neurochem. 1996 Nov;67(5):2096-103.
DM6BIWK	RU	https://pubmed.ncbi.nlm.nih.gov/8863519

DM6BIWK	DI	DM6BIWK
DM6BIWK	DN	1-naphthylpiperazine
DM6BIWK	MI	TT6MSOK
DM6BIWK	MN	5-HT 1D receptor (HTR1D)
DM6BIWK	MT	DTT
DM6BIWK	MA	Agonist
DM6BIWK	RN	Human serotonin 1D receptor is encoded by a subfamily of two distinct genes: 5-HT1D alpha and 5-HT1D beta. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3630-4.
DM6BIWK	RU	https://pubmed.ncbi.nlm.nih.gov/1565658

DM6BIWK	DI	DM6BIWK
DM6BIWK	DN	1-naphthylpiperazine
DM6BIWK	MI	TTCPG9S
DM6BIWK	MN	5-HT 1E receptor (HTR1E)
DM6BIWK	MT	DTT
DM6BIWK	MA	Antagonist
DM6BIWK	RN	Molecular cloning and pharmacological characterization of the guinea pig 5-HT1E receptor. Eur J Pharmacol. 2004 Jan 26;484(2-3):127-39.
DM6BIWK	RU	https://pubmed.ncbi.nlm.nih.gov/14744596

DM6BIWK	DI	DM6BIWK
DM6BIWK	DN	1-naphthylpiperazine
DM6BIWK	MI	TT0MI3F
DM6BIWK	MN	5-HT 1F receptor (HTR1F)
DM6BIWK	MT	DTT
DM6BIWK	MA	Antagonist
DM6BIWK	RN	Cloning and characterization of the guinea pig 5-HT1F receptor subtype: a comparison of the pharmacological profile to the human species homolog. Neuropharmacology. 1997 Apr-May;36(4-5):569-76.
DM6BIWK	RU	https://pubmed.ncbi.nlm.nih.gov/9225282

DM6BIWK	DI	DM6BIWK
DM6BIWK	DN	1-naphthylpiperazine
DM6BIWK	MI	TTJQOD7
DM6BIWK	MN	5-HT 2A receptor (HTR2A)
DM6BIWK	MT	DTT
DM6BIWK	MA	Inhibitor
DM6BIWK	RN	5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80.
DM6BIWK	RU	https://pubmed.ncbi.nlm.nih.gov/3783595

DM6BIWK	DI	DM6BIWK
DM6BIWK	DN	1-naphthylpiperazine
DM6BIWK	MI	TT0K1SC
DM6BIWK	MN	5-HT 2B receptor (HTR2B)
DM6BIWK	MT	DTT
DM6BIWK	MA	Antagonist
DM6BIWK	RN	Pharmacological characteristics of the newly cloned rat 5-hydroxytryptamine2F receptor. Mol Pharmacol. 1993 Mar;43(3):419-26.
DM6BIWK	RU	https://pubmed.ncbi.nlm.nih.gov/8450835

DM6BIWK	DI	DM6BIWK
DM6BIWK	DN	1-naphthylpiperazine
DM6BIWK	MI	TTJS8PY
DM6BIWK	MN	5-HT 6 receptor (HTR6)
DM6BIWK	MT	DTT
DM6BIWK	MA	Agonist
DM6BIWK	RN	Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol. 1993 Mar;43(3):320-7.
DM6BIWK	RU	https://pubmed.ncbi.nlm.nih.gov/7680751

DM6BIWK	DI	DM6BIWK
DM6BIWK	DN	1-naphthylpiperazine
DM6BIWK	MI	TTO9X1H
DM6BIWK	MN	5-HT 7 receptor (HTR7)
DM6BIWK	MT	DTT
DM6BIWK	MA	Agonist
DM6BIWK	RN	Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase. J Biol Chem. 1993 Nov 5;268(31):23422-6.
DM6BIWK	RU	https://pubmed.ncbi.nlm.nih.gov/8226867

DMP6VOK	DI	DMP6VOK
DMP6VOK	DN	1-nitro-2-(2-nitrophenylsulfonyl)benzene
DMP6VOK	MI	TT84ETX
DMP6VOK	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMP6VOK	MT	DTT
DMP6VOK	MA	Inhibitor
DMP6VOK	RN	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82.
DMP6VOK	RU	https://pubmed.ncbi.nlm.nih.gov/11384233

DM9OJ7T	DI	DM9OJ7T
DM9OJ7T	DN	1-Octyl-3-(1-propionylpiperidin-4-yl)urea
DM9OJ7T	MI	TT7WVHI
DM9OJ7T	MN	Soluble epoxide hydrolase (EPHX2)
DM9OJ7T	MT	DTT
DM9OJ7T	MA	Inhibitor
DM9OJ7T	RN	1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, a... J Med Chem. 2010 Oct 14;53(19):7067-75.
DM9OJ7T	RU	https://pubmed.ncbi.nlm.nih.gov/20812725

DMYHMEK	DI	DMYHMEK
DMYHMEK	DN	1-OH-PGE1
DMYHMEK	MI	TT79WV3
DMYHMEK	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DMYHMEK	MT	DTT
DMYHMEK	MA	Agonist
DMYHMEK	RN	Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
DMYHMEK	RU	https://pubmed.ncbi.nlm.nih.gov/9313928

DM5KU8S	DI	DM5KU8S
DM5KU8S	DN	1-oleoyl glycerol
DM5KU8S	MI	TT7QNVC
DM5KU8S	MN	Glucose-dependent insulinotropic receptor (GPR119)
DM5KU8S	MT	DTT
DM5KU8S	MA	Agonist
DM5KU8S	RN	2-Oleoyl glycerol is a GPR119 agonist and signals GLP-1 release in humans. J Clin Endocrinol Metab. 2011 Sep;96(9):E1409-17.
DM5KU8S	RU	https://pubmed.ncbi.nlm.nih.gov/21778222

DMPMGLO	DI	DMPMGLO
DMPMGLO	DN	1-Oxazolo[4,5-b]pyridin-2-yl-6-phenyl-hexan-1-one
DMPMGLO	MI	TTDP1UC
DMPMGLO	MN	Fatty acid amide hydrolase (FAAH)
DMPMGLO	MT	DTT
DMPMGLO	MA	Inhibitor
DMPMGLO	RN	The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J Med Chem. 2005 Aug 11;48(16):5059-87.
DMPMGLO	RU	https://pubmed.ncbi.nlm.nih.gov/16078824

DM9BY8D	DI	DM9BY8D
DM9BY8D	DN	1-Oxazolo[4,5-b]pyridin-2-yl-octadec-9-yn-1-one
DM9BY8D	MI	TTDP1UC
DM9BY8D	MN	Fatty acid amide hydrolase (FAAH)
DM9BY8D	MT	DTT
DM9BY8D	MA	Inhibitor
DM9BY8D	RN	Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as a... J Med Chem. 2005 Mar 24;48(6):1849-56.
DM9BY8D	RU	https://pubmed.ncbi.nlm.nih.gov/15771430

DM9ZK0M	DI	DM9ZK0M
DM9ZK0M	DN	1-palmitoyl-lysophosphatidylcholine
DM9ZK0M	MI	TT7QNVC
DM9ZK0M	MN	Glucose-dependent insulinotropic receptor (GPR119)
DM9ZK0M	MT	DTT
DM9ZK0M	MA	Agonist
DM9ZK0M	RN	Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem Biophys Res Commun. 2005 Jan 28;326(4):744-51.
DM9ZK0M	RU	https://pubmed.ncbi.nlm.nih.gov/15607732

DM9PNTQ	DI	DM9PNTQ
DM9PNTQ	DN	1-pentafluorophenylamido-5-sulfonamidoindane
DM9PNTQ	MI	TTHQPL7
DM9PNTQ	MN	Carbonic anhydrase I (CA-I)
DM9PNTQ	MT	DTT
DM9PNTQ	MA	Inhibitor
DM9PNTQ	RN	Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9.
DM9PNTQ	RU	https://pubmed.ncbi.nlm.nih.gov/16640335

DM9PNTQ	DI	DM9PNTQ
DM9PNTQ	DN	1-pentafluorophenylamido-5-sulfonamidoindane
DM9PNTQ	MI	TTANPDJ
DM9PNTQ	MN	Carbonic anhydrase II (CA-II)
DM9PNTQ	MT	DTT
DM9PNTQ	MA	Inhibitor
DM9PNTQ	RN	Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9.
DM9PNTQ	RU	https://pubmed.ncbi.nlm.nih.gov/16640335

DM9PNTQ	DI	DM9PNTQ
DM9PNTQ	DN	1-pentafluorophenylamido-5-sulfonamidoindane
DM9PNTQ	MI	TT2LVK8
DM9PNTQ	MN	Carbonic anhydrase IX (CA-IX)
DM9PNTQ	MT	DTT
DM9PNTQ	MA	Inhibitor
DM9PNTQ	RN	Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9.
DM9PNTQ	RU	https://pubmed.ncbi.nlm.nih.gov/16640335

DMNUAB9	DI	DMNUAB9
DMNUAB9	DN	1-pentenyl-4-(aminosulfonyl)benzoate
DMNUAB9	MI	TTANPDJ
DMNUAB9	MN	Carbonic anhydrase II (CA-II)
DMNUAB9	MT	DTT
DMNUAB9	MA	Inhibitor
DMNUAB9	RN	Synthesis and structure-activity relationships of novel benzene sulfonamides with potent binding affinity for bovine carbonic anhydrase II. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5429-33.
DMNUAB9	RU	https://pubmed.ncbi.nlm.nih.gov/16213706

DMA29SX	DI	DMA29SX
DMA29SX	DN	1-Phenethyl-3,7-dihydro-purine-2,6-dione
DMA29SX	MI	TTJFY5U
DMA29SX	MN	Adenosine A3 receptor (ADORA3)
DMA29SX	MT	DTT
DMA29SX	MA	Inhibitor
DMA29SX	RN	Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. J Med Chem. 2002 May 23;45(11):2131-8.
DMA29SX	RU	https://pubmed.ncbi.nlm.nih.gov/12014951

DM32WSM	DI	DM32WSM
DM32WSM	DN	1-Phenethyl-3-[1,3,4]thiadiazol-2-yl-thiourea
DM32WSM	MI	TT84ETX
DM32WSM	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM32WSM	MT	DTT
DM32WSM	MA	Inhibitor
DM32WSM	RN	Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36.
DM32WSM	RU	https://pubmed.ncbi.nlm.nih.gov/8523406

DM0DH98	DI	DM0DH98
DM0DH98	DN	1-phenyl-1-(piperidin-2-yl)propan-2-one
DM0DH98	MI	TTVBI8W
DM0DH98	MN	Dopamine transporter (DAT)
DM0DH98	MT	DTT
DM0DH98	MA	Inhibitor
DM0DH98	RN	Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter. J Med Chem. 2007 Jan 25;50(2):219-32.
DM0DH98	RU	https://pubmed.ncbi.nlm.nih.gov/17228864

DMGV6BI	DI	DMGV6BI
DMGV6BI	DN	1-Phenyl-1H-benzoimidazol-5-ol
DMGV6BI	MI	TT8FYO9
DMGV6BI	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMGV6BI	MT	DTT
DMGV6BI	MA	Inhibitor
DMGV6BI	RN	Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor. J Med Chem. 1998 Dec 31;41(27):5457-65.
DMGV6BI	RU	https://pubmed.ncbi.nlm.nih.gov/9876115

DMGV6BI	DI	DMGV6BI
DMGV6BI	DN	1-Phenyl-1H-benzoimidazol-5-ol
DMGV6BI	MI	TTI7421
DMGV6BI	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMGV6BI	MT	DTT
DMGV6BI	MA	Inhibitor
DMGV6BI	RN	Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor. J Med Chem. 1998 Dec 31;41(27):5457-65.
DMGV6BI	RU	https://pubmed.ncbi.nlm.nih.gov/9876115

DM8YPH0	DI	DM8YPH0
DM8YPH0	DN	1-Phenyl-1H-benzoimidazole
DM8YPH0	MI	TT8FYO9
DM8YPH0	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DM8YPH0	MT	DTT
DM8YPH0	MA	Inhibitor
DM8YPH0	RN	Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor. J Med Chem. 1998 Dec 31;41(27):5457-65.
DM8YPH0	RU	https://pubmed.ncbi.nlm.nih.gov/9876115

DM8YPH0	DI	DM8YPH0
DM8YPH0	DN	1-Phenyl-1H-benzoimidazole
DM8YPH0	MI	TTI7421
DM8YPH0	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM8YPH0	MT	DTT
DM8YPH0	MA	Inhibitor
DM8YPH0	RN	Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor. J Med Chem. 1998 Dec 31;41(27):5457-65.
DM8YPH0	RU	https://pubmed.ncbi.nlm.nih.gov/9876115

DM74RMP	DI	DM74RMP
DM74RMP	DN	1-phenyl-1H-indole-2,3-dione
DM74RMP	MI	TTMF541
DM74RMP	MN	Liver carboxylesterase (CES1)
DM74RMP	MT	DTT
DM74RMP	MA	Inhibitor
DM74RMP	RN	Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85.
DM74RMP	RU	https://pubmed.ncbi.nlm.nih.gov/17378546

DMZM9AI	DI	DMZM9AI
DMZM9AI	DN	1-phenyl-2-(1-phenyl-1H-tetrazol-5-yloxy)ethanone
DMZM9AI	MI	TTN7BL9
DMZM9AI	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMZM9AI	MT	DTT
DMZM9AI	MA	Inhibitor
DMZM9AI	RN	Modulation of 11beta-hydroxysteroid dehydrogenase type 1 activity by 1,5-substituted 1H-tetrazoles. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3265-71.
DMZM9AI	RU	https://pubmed.ncbi.nlm.nih.gov/20452767

DMW9CRT	DI	DMW9CRT
DMW9CRT	DN	1-Phenyl-2-p-tolyl-ethane-1,2-dione
DMW9CRT	MI	TTMF541
DMW9CRT	MN	Liver carboxylesterase (CES1)
DMW9CRT	MT	DTT
DMW9CRT	MA	Inhibitor
DMW9CRT	RN	Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15.
DMW9CRT	RU	https://pubmed.ncbi.nlm.nih.gov/15828829

DM8EDI7	DI	DM8EDI7
DM8EDI7	DN	1-Phenyl-2-pyridin-3-yl-propan-1-one
DM8EDI7	MI	TTIQUX7
DM8EDI7	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM8EDI7	MT	DTT
DM8EDI7	MA	Inhibitor
DM8EDI7	RN	Structure-activity relationship study of the inhibition of adrenal cortical 11 beta-hydroxylase by new metyrapone analogues. J Med Chem. 1984 Jan;27(1):15-9.
DM8EDI7	RU	https://pubmed.ncbi.nlm.nih.gov/6606707

DM6QU5B	DI	DM6QU5B
DM6QU5B	DN	1-phenyl-3-(1,3,4-thiadiazol-2-yl)thiourea
DM6QU5B	MI	TT6804T
DM6QU5B	MN	MIF messenger RNA (MIF mRNA)
DM6QU5B	MT	DTT
DM6QU5B	MA	Inhibitor
DM6QU5B	RN	An integrative in silico methodology for the identification of modulators of macrophage migration inhibitory factor (MIF) tautomerase activity. Bioorg Med Chem. 2010 Jul 15;18(14):5425-40. 
DM6QU5B	RU	https://pubmed.ncbi.nlm.nih.gov/20639113

DMCHOFK	DI	DMCHOFK
DMCHOFK	DN	1-Phenyl-3-(1-propionylpiperidin-4-yl)urea
DMCHOFK	MI	TT7WVHI
DMCHOFK	MN	Soluble epoxide hydrolase (EPHX2)
DMCHOFK	MT	DTT
DMCHOFK	MA	Inhibitor
DMCHOFK	RN	1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, a... J Med Chem. 2010 Oct 14;53(19):7067-75.
DMCHOFK	RU	https://pubmed.ncbi.nlm.nih.gov/20812725

DM9SKYC	DI	DM9SKYC
DM9SKYC	DN	1-phenyl-3-(2-(pyridin-2-yl)quinazolin-4-yl)urea
DM9SKYC	MI	TTJFY5U
DM9SKYC	MN	Adenosine A3 receptor (ADORA3)
DM9SKYC	MT	DTT
DM9SKYC	MA	Inhibitor
DM9SKYC	RN	Pharmacophore based receptor modeling: the case of adenosine A3 receptor antagonists. An approach to the optimization of protein models. J Med Chem. 2006 Jul 13;49(14):4085-97.
DM9SKYC	RU	https://pubmed.ncbi.nlm.nih.gov/16821770

DMQKB6W	DI	DMQKB6W
DMQKB6W	DN	1-phenyl-3-(2-(pyridin-3-yl)quinazolin-4-yl)urea
DMQKB6W	MI	TTJFY5U
DMQKB6W	MN	Adenosine A3 receptor (ADORA3)
DMQKB6W	MT	DTT
DMQKB6W	MA	Inhibitor
DMQKB6W	RN	Pharmacophore based receptor modeling: the case of adenosine A3 receptor antagonists. An approach to the optimization of protein models. J Med Chem. 2006 Jul 13;49(14):4085-97.
DMQKB6W	RU	https://pubmed.ncbi.nlm.nih.gov/16821770

DMJVITG	DI	DMJVITG
DMJVITG	DN	1-phenyl-3-(2-(pyridin-4-yl)thiazol-4-yl)urea
DMJVITG	MI	TTL4Q97
DMJVITG	MN	Cyclin-dependent kinase 5 (CDK5)
DMJVITG	MT	DTT
DMJVITG	MA	Inhibitor
DMJVITG	RN	Structure-activity relationships of 3,4-dihydro-1H-quinazolin-2-one derivatives as potential CDK5 inhibitors. Bioorg Med Chem. 2007 Oct 15;15(20):6574-95.
DMJVITG	RU	https://pubmed.ncbi.nlm.nih.gov/17697781

DMJNAX5	DI	DMJNAX5
DMJNAX5	DN	1-phenyl-3-(3-(pyridin-2-yl)isoquinolin-1-yl)urea
DMJNAX5	MI	TTJFY5U
DMJNAX5	MN	Adenosine A3 receptor (ADORA3)
DMJNAX5	MT	DTT
DMJNAX5	MA	Inhibitor
DMJNAX5	RN	Pharmacophore based receptor modeling: the case of adenosine A3 receptor antagonists. An approach to the optimization of protein models. J Med Chem. 2006 Jul 13;49(14):4085-97.
DMJNAX5	RU	https://pubmed.ncbi.nlm.nih.gov/16821770

DMJ723D	DI	DMJ723D
DMJ723D	DN	1-Phenyl-3-(4-pyridin-2-yl-thiazol-2-yl)-urea
DMJ723D	MI	TTM2AOE
DMJ723D	MN	Adenosine A2a receptor (ADORA2A)
DMJ723D	MT	DTT
DMJ723D	MA	Inhibitor
DMJ723D	RN	Thiazole and thiadiazole analogues as a novel class of adenosine receptor antagonists. J Med Chem. 2001 Mar 1;44(5):749-62.
DMJ723D	RU	https://pubmed.ncbi.nlm.nih.gov/11262085

DM8ZBHF	DI	DM8ZBHF
DM8ZBHF	DN	1-phenyl-3-(phenylsulfonyl)propan-1-one
DM8ZBHF	MI	TTN7BL9
DM8ZBHF	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DM8ZBHF	MT	DTT
DM8ZBHF	MA	Inhibitor
DM8ZBHF	RN	beta-Keto sulfones as inhibitors of 11beta-hydroxysteroid dehydrogenase type I and the mechanism of action. Bioorg Med Chem. 2007 Jul 1;15(13):4396-405.
DM8ZBHF	RU	https://pubmed.ncbi.nlm.nih.gov/17490884

DMZOEQY	DI	DMZOEQY
DMZOEQY	DN	1-phenyl-3-(quinazolin-4-yl)urea
DMZOEQY	MI	TTJFY5U
DMZOEQY	MN	Adenosine A3 receptor (ADORA3)
DMZOEQY	MT	DTT
DMZOEQY	MA	Inhibitor
DMZOEQY	RN	Pharmacophore based receptor modeling: the case of adenosine A3 receptor antagonists. An approach to the optimization of protein models. J Med Chem. 2006 Jul 13;49(14):4085-97.
DMZOEQY	RU	https://pubmed.ncbi.nlm.nih.gov/16821770

DMUA72F	DI	DMUA72F
DMUA72F	DN	1-phenyl-3-aza-bicyclo[3.1.0]hexane
DMUA72F	MI	TTVBI8W
DMUA72F	MN	Dopamine transporter (DAT)
DMUA72F	MT	DTT
DMUA72F	MA	Inhibitor
DMUA72F	RN	Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3682-6.
DMUA72F	RU	https://pubmed.ncbi.nlm.nih.gov/18539031

DMUA72F	DI	DMUA72F
DMUA72F	DN	1-phenyl-3-aza-bicyclo[3.1.0]hexane
DMUA72F	MI	TT3ROYC
DMUA72F	MN	Serotonin transporter (SERT)
DMUA72F	MT	DTT
DMUA72F	MA	Inhibitor
DMUA72F	RN	Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3682-6.
DMUA72F	RU	https://pubmed.ncbi.nlm.nih.gov/18539031

DMKV17L	DI	DMKV17L
DMKV17L	DN	1-phenyl-4-(1-phenyl-1H-tetrazol-5-yl)butan-2-one
DMKV17L	MI	TTN7BL9
DMKV17L	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMKV17L	MT	DTT
DMKV17L	MA	Inhibitor
DMKV17L	RN	Modulation of 11beta-hydroxysteroid dehydrogenase type 1 activity by 1,5-substituted 1H-tetrazoles. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3265-71.
DMKV17L	RU	https://pubmed.ncbi.nlm.nih.gov/20452767

DMA4XGL	DI	DMA4XGL
DMA4XGL	DN	1-phenylbiguanide
DMA4XGL	MI	TTPC4TU
DMA4XGL	MN	5-HT 3A receptor (HTR3A)
DMA4XGL	MT	DTT
DMA4XGL	MA	Agonist
DMA4XGL	RN	Allosteric interactions among agonists and antagonists at 5-hydroxytryptamine3 receptors. J Neurochem. 1995 Jul;65(1):104-10.
DMA4XGL	RU	https://pubmed.ncbi.nlm.nih.gov/7790853

DMA4XGL	DI	DMA4XGL
DMA4XGL	DN	1-phenylbiguanide
DMA4XGL	MI	TTR6K75
DMA4XGL	MN	5-HT 3B receptor (HTR3B)
DMA4XGL	MT	DTT
DMA4XGL	MA	Agonist
DMA4XGL	RN	Pharmacological comparison of human homomeric 5-HT3A receptors versus heteromeric 5-HT3A/3B receptors. Neuropharmacology. 2001 Aug;41(2):282-4.
DMA4XGL	RU	https://pubmed.ncbi.nlm.nih.gov/11489465

DM04SWY	DI	DM04SWY
DM04SWY	DN	1-Phenyl-propane-1,2-dione
DM04SWY	MI	TTMF541
DM04SWY	MN	Liver carboxylesterase (CES1)
DM04SWY	MT	DTT
DM04SWY	MA	Inhibitor
DM04SWY	RN	Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15.
DM04SWY	RU	https://pubmed.ncbi.nlm.nih.gov/15828829

DM5REQ9	DI	DM5REQ9
DM5REQ9	DN	1-phenylthio-N,N-dimethyltryptamine
DM5REQ9	MI	TTJS8PY
DM5REQ9	MN	5-HT 6 receptor (HTR6)
DM5REQ9	MT	DTT
DM5REQ9	MA	Inhibitor
DM5REQ9	RN	Binding of serotonin and N1-benzenesulfonyltryptamine-related analogs at human 5-HT6 serotonin receptors: receptor modeling studies. J Med Chem. 2008 Feb 14;51(3):603-11.
DM5REQ9	RU	https://pubmed.ncbi.nlm.nih.gov/18201064

DMCBX7R	DI	DMCBX7R
DMCBX7R	DN	1-Prop-2-ynyl-3,7-dihydro-purine-2,6-dione
DMCBX7R	MI	TTJFY5U
DMCBX7R	MN	Adenosine A3 receptor (ADORA3)
DMCBX7R	MT	DTT
DMCBX7R	MA	Inhibitor
DMCBX7R	RN	Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. J Med Chem. 2002 May 23;45(11):2131-8.
DMCBX7R	RU	https://pubmed.ncbi.nlm.nih.gov/12014951

DM1TNWG	DI	DM1TNWG
DM1TNWG	DN	1-propionyl-1H-indole-2,3-dione
DM1TNWG	MI	TTMF541
DM1TNWG	MN	Liver carboxylesterase (CES1)
DM1TNWG	MT	DTT
DM1TNWG	MA	Inhibitor
DM1TNWG	RN	Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85.
DM1TNWG	RU	https://pubmed.ncbi.nlm.nih.gov/17378546

DMOCAUL	DI	DMOCAUL
DMOCAUL	DN	1-Propyl-3-(3-trifluoromethyl-phenyl)-pyrrolidine
DMOCAUL	MI	TTSQIFT
DMOCAUL	MN	5-HT 1A receptor (HTR1A)
DMOCAUL	MT	DTT
DMOCAUL	MA	Inhibitor
DMOCAUL	RN	Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity, Bioorg. Med. Chem. Lett. 7(3):241-246 (1997).
DMOCAUL	RU	http://www.sciencedirect.com/science/article/pii/S0960894X9600618X

DMOCAUL	DI	DMOCAUL
DMOCAUL	DN	1-Propyl-3-(3-trifluoromethyl-phenyl)-pyrrolidine
DMOCAUL	MI	TTJQOD7
DMOCAUL	MN	5-HT 2A receptor (HTR2A)
DMOCAUL	MT	DTT
DMOCAUL	MA	Inhibitor
DMOCAUL	RN	Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity, Bioorg. Med. Chem. Lett. 7(3):241-246 (1997).
DMOCAUL	RU	http://www.sciencedirect.com/science/article/pii/S0960894X9600618X

DMOCAUL	DI	DMOCAUL
DMOCAUL	DN	1-Propyl-3-(3-trifluoromethyl-phenyl)-pyrrolidine
DMOCAUL	MI	TTEX248
DMOCAUL	MN	Dopamine D2 receptor (D2R)
DMOCAUL	MT	DTT
DMOCAUL	MA	Inhibitor
DMOCAUL	RN	Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity, Bioorg. Med. Chem. Lett. 7(3):241-246 (1997).
DMOCAUL	RU	http://www.sciencedirect.com/science/article/pii/S0960894X9600618X

DMOCAUL	DI	DMOCAUL
DMOCAUL	DN	1-Propyl-3-(3-trifluoromethyl-phenyl)-pyrrolidine
DMOCAUL	MI	TT4C8EA
DMOCAUL	MN	Dopamine D3 receptor (D3R)
DMOCAUL	MT	DTT
DMOCAUL	MA	Inhibitor
DMOCAUL	RN	Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity, Bioorg. Med. Chem. Lett. 7(3):241-246 (1997).
DMOCAUL	RU	http://www.sciencedirect.com/science/article/pii/S0960894X9600618X

DML5J94	DI	DML5J94
DML5J94	DN	1-Propyl-3,7-dihydro-purine-2,6-dione
DML5J94	MI	TTK25J1
DML5J94	MN	Adenosine A1 receptor (ADORA1)
DML5J94	MT	DTT
DML5J94	MA	Inhibitor
DML5J94	RN	Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. J Med Chem. 2002 May 23;45(11):2131-8.
DML5J94	RU	https://pubmed.ncbi.nlm.nih.gov/12014951

DML5J94	DI	DML5J94
DML5J94	DN	1-Propyl-3,7-dihydro-purine-2,6-dione
DML5J94	MI	TTNE7KG
DML5J94	MN	Adenosine A2b receptor (ADORA2B)
DML5J94	MT	DTT
DML5J94	MA	Inhibitor
DML5J94	RN	Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. J Med Chem. 2002 May 23;45(11):2131-8.
DML5J94	RU	https://pubmed.ncbi.nlm.nih.gov/12014951

DML5J94	DI	DML5J94
DML5J94	DN	1-Propyl-3,7-dihydro-purine-2,6-dione
DML5J94	MI	TTJFY5U
DML5J94	MN	Adenosine A3 receptor (ADORA3)
DML5J94	MT	DTT
DML5J94	MA	Inhibitor
DML5J94	RN	Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. J Med Chem. 2002 May 23;45(11):2131-8.
DML5J94	RU	https://pubmed.ncbi.nlm.nih.gov/12014951

DM1387P	DI	DM1387P
DM1387P	DN	1-Propyl-3-m-tolyl-piperidine hydrochloride
DM1387P	MI	TTEX248
DM1387P	MN	Dopamine D2 receptor (D2R)
DM1387P	MT	DTT
DM1387P	MA	Inhibitor
DM1387P	RN	New N-n-propyl-substituted 3-aryl- and 3-cyclohexylpiperidines as partial agonists at the D4 dopamine receptor. J Med Chem. 2003 Jan 2;46(1):161-8.
DM1387P	RU	https://pubmed.ncbi.nlm.nih.gov/12502370

DM1O6KQ	DI	DM1O6KQ
DM1O6KQ	DN	1-Propyl-3-o-tolyl-piperidine hydrochloride
DM1O6KQ	MI	TTEX248
DM1O6KQ	MN	Dopamine D2 receptor (D2R)
DM1O6KQ	MT	DTT
DM1O6KQ	MA	Inhibitor
DM1O6KQ	RN	New N-n-propyl-substituted 3-aryl- and 3-cyclohexylpiperidines as partial agonists at the D4 dopamine receptor. J Med Chem. 2003 Jan 2;46(1):161-8.
DM1O6KQ	RU	https://pubmed.ncbi.nlm.nih.gov/12502370

DMPMIN9	DI	DMPMIN9
DMPMIN9	DN	1-Propyl-3-p-tolyl-piperidine hydrochloride
DMPMIN9	MI	TTEX248
DMPMIN9	MN	Dopamine D2 receptor (D2R)
DMPMIN9	MT	DTT
DMPMIN9	MA	Inhibitor
DMPMIN9	RN	New N-n-propyl-substituted 3-aryl- and 3-cyclohexylpiperidines as partial agonists at the D4 dopamine receptor. J Med Chem. 2003 Jan 2;46(1):161-8.
DMPMIN9	RU	https://pubmed.ncbi.nlm.nih.gov/12502370

DM5P01L	DI	DM5P01L
DM5P01L	DN	1-propyl-5'-O-tritylinosine
DM5P01L	MI	TTO0IB8
DM5P01L	MN	Thymidine phosphorylase (TYMP)
DM5P01L	MT	DTT
DM5P01L	MA	Inhibitor
DM5P01L	RN	5'-O-tritylinosine and analogues as allosteric inhibitors of human thymidine phosphorylase. J Med Chem. 2006 Sep 7;49(18):5562-70.
DM5P01L	RU	https://pubmed.ncbi.nlm.nih.gov/16942029

DMXOUFI	DI	DMXOUFI
DMXOUFI	DN	1-Propylidenethiosemicarbazide
DMXOUFI	MI	TTULVH8
DMXOUFI	MN	Tyrosinase (TYR)
DMXOUFI	MT	DTT
DMXOUFI	MA	Inhibitor
DMXOUFI	RN	A class of potent tyrosinase inhibitors: alkylidenethiosemicarbazide compounds. Eur J Med Chem. 2009 Apr;44(4):1773-8.
DMXOUFI	RU	https://pubmed.ncbi.nlm.nih.gov/18524420

DMTMXN4	DI	DMTMXN4
DMTMXN4	DN	1-Pyridin-2-yl-3-quinolin-5-yl-urea
DMTMXN4	MI	TT0PG8F
DMTMXN4	MN	Cyclin-dependent kinase 4 (CDK4)
DMTMXN4	MT	DTT
DMTMXN4	MA	Inhibitor
DMTMXN4	RN	Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. J Med Chem. 2001 Dec 20;44(26):4615-27.
DMTMXN4	RU	https://pubmed.ncbi.nlm.nih.gov/11741479

DM7Y5AN	DI	DM7Y5AN
DM7Y5AN	DN	1S,2R-milnacipran
DM7Y5AN	MI	TTVBI8W
DM7Y5AN	MN	Dopamine transporter (DAT)
DM7Y5AN	MT	DTT
DM7Y5AN	MA	Inhibitor
DM7Y5AN	RN	Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropath... J Med Chem. 2008 Nov 27;51(22):7265-72.
DM7Y5AN	RU	https://pubmed.ncbi.nlm.nih.gov/18954038

DM7Y5AN	DI	DM7Y5AN
DM7Y5AN	DN	1S,2R-milnacipran
DM7Y5AN	MI	TTAWNKZ
DM7Y5AN	MN	Norepinephrine transporter (NET)
DM7Y5AN	MT	DTT
DM7Y5AN	MA	Inhibitor
DM7Y5AN	RN	Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropath... J Med Chem. 2008 Nov 27;51(22):7265-72.
DM7Y5AN	RU	https://pubmed.ncbi.nlm.nih.gov/18954038

DM7Y5AN	DI	DM7Y5AN
DM7Y5AN	DN	1S,2R-milnacipran
DM7Y5AN	MI	TT3ROYC
DM7Y5AN	MN	Serotonin transporter (SERT)
DM7Y5AN	MT	DTT
DM7Y5AN	MA	Inhibitor
DM7Y5AN	RN	Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropath... J Med Chem. 2008 Nov 27;51(22):7265-72.
DM7Y5AN	RU	https://pubmed.ncbi.nlm.nih.gov/18954038

DM7K0B3	DI	DM7K0B3
DM7K0B3	DN	1-stearoyl-lysophosphatidylcholine
DM7K0B3	MI	TT7QNVC
DM7K0B3	MN	Glucose-dependent insulinotropic receptor (GPR119)
DM7K0B3	MT	DTT
DM7K0B3	MA	Agonist
DM7K0B3	RN	Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem Biophys Res Commun. 2005 Jan 28;326(4):744-51.
DM7K0B3	RU	https://pubmed.ncbi.nlm.nih.gov/15607732

DMPSM4O	DI	DMPSM4O
DMPSM4O	DN	1-tert-butyl-9H-carbazole
DMPSM4O	MI	TTBGTCW
DMPSM4O	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DMPSM4O	MT	DTT
DMPSM4O	MA	Inhibitor
DMPSM4O	RN	Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8.
DMPSM4O	RU	https://pubmed.ncbi.nlm.nih.gov/20521839

DMAQKO1	DI	DMAQKO1
DMAQKO1	DN	1-Thiazol-2-yl-3-(2-o-tolyl-ethyl)-thiourea
DMAQKO1	MI	TT84ETX
DMAQKO1	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMAQKO1	MT	DTT
DMAQKO1	MA	Inhibitor
DMAQKO1	RN	Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36.
DMAQKO1	RU	https://pubmed.ncbi.nlm.nih.gov/8523406

DMCIA40	DI	DMCIA40
DMCIA40	DN	1-Thiazol-2-yl-3-(2-p-tolyl-ethyl)-thiourea
DMCIA40	MI	TT84ETX
DMCIA40	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMCIA40	MT	DTT
DMCIA40	MA	Inhibitor
DMCIA40	RN	Anti-HIV activity of aromatic and heterocyclic thiazolyl thiourea compounds. Bioorg Med Chem Lett. 2001 Feb 26;11(4):523-8.
DMCIA40	RU	https://pubmed.ncbi.nlm.nih.gov/11229762

DM9SYEP	DI	DM9SYEP
DM9SYEP	DN	1'-tosylspiro[indene-1,4'-piperidine]
DM9SYEP	MI	TTSCIUP
DM9SYEP	MN	Oxytocin receptor (OTR)
DM9SYEP	MT	DTT
DM9SYEP	MA	Inhibitor
DM9SYEP	RN	Oral oxytocin antagonists. J Med Chem. 2010 Sep 23;53(18):6525-38.
DM9SYEP	RU	https://pubmed.ncbi.nlm.nih.gov/20550119

DM9SYEP	DI	DM9SYEP
DM9SYEP	DN	1'-tosylspiro[indene-1,4'-piperidine]
DM9SYEP	MI	TT4TFGN
DM9SYEP	MN	Vasopressin V1a receptor (V1AR)
DM9SYEP	MT	DTT
DM9SYEP	MA	Inhibitor
DM9SYEP	RN	Oral oxytocin antagonists. J Med Chem. 2010 Sep 23;53(18):6525-38.
DM9SYEP	RU	https://pubmed.ncbi.nlm.nih.gov/20550119

DM9ZRU2	DI	DM9ZRU2
DM9ZRU2	DN	1-valproylamido-5-sulfonamidoindane
DM9ZRU2	MI	TTHQPL7
DM9ZRU2	MN	Carbonic anhydrase I (CA-I)
DM9ZRU2	MT	DTT
DM9ZRU2	MA	Inhibitor
DM9ZRU2	RN	Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9.
DM9ZRU2	RU	https://pubmed.ncbi.nlm.nih.gov/16640335

DM9ZRU2	DI	DM9ZRU2
DM9ZRU2	DN	1-valproylamido-5-sulfonamidoindane
DM9ZRU2	MI	TTANPDJ
DM9ZRU2	MN	Carbonic anhydrase II (CA-II)
DM9ZRU2	MT	DTT
DM9ZRU2	MA	Inhibitor
DM9ZRU2	RN	Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9.
DM9ZRU2	RU	https://pubmed.ncbi.nlm.nih.gov/16640335

DM9ZRU2	DI	DM9ZRU2
DM9ZRU2	DN	1-valproylamido-5-sulfonamidoindane
DM9ZRU2	MI	TT2LVK8
DM9ZRU2	MN	Carbonic anhydrase IX (CA-IX)
DM9ZRU2	MT	DTT
DM9ZRU2	MA	Inhibitor
DM9ZRU2	RN	Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9.
DM9ZRU2	RU	https://pubmed.ncbi.nlm.nih.gov/16640335

DM1TK45	DI	DM1TK45
DM1TK45	DN	2-((1H-imidazol-4-yl)methyl)pyridine
DM1TK45	MI	TT9JNIC
DM1TK45	MN	Histamine H3 receptor (H3R)
DM1TK45	MT	DTT
DM1TK45	MA	Inhibitor
DM1TK45	RN	Investigation of the histamine H3 receptor binding site. Design and synthesis of hybrid agonists with a lipophilic side chain. J Med Chem. 2010 Sep 9;53(17):6445-56.
DM1TK45	RU	https://pubmed.ncbi.nlm.nih.gov/20690643

DM91PA5	DI	DM91PA5
DM91PA5	DN	2-((2-ethoxyphenoxy)methyl)-4-isopropylmorpholine
DM91PA5	MI	TT9JNIC
DM91PA5	MN	Histamine H3 receptor (H3R)
DM91PA5	MT	DTT
DM91PA5	MA	Inhibitor
DM91PA5	RN	2-Aryloxymethylmorpholine histamine H(3) antagonists. Bioorg Med Chem Lett. 2008 Nov 1;18(21):5796-9.
DM91PA5	RU	https://pubmed.ncbi.nlm.nih.gov/18922693

DMS1AOK	DI	DMS1AOK
DMS1AOK	DN	2-((2-iodophenoxy)(phenyl)methyl)morpholine
DMS1AOK	MI	TTVBI8W
DMS1AOK	MN	Dopamine transporter (DAT)
DMS1AOK	MT	DTT
DMS1AOK	MA	Inhibitor
DMS1AOK	RN	Development of SPECT imaging agents for the norepinephrine transporters: [123I]INER. Bioorg Med Chem Lett. 2007 Jan 15;17(2):533-7.
DMS1AOK	RU	https://pubmed.ncbi.nlm.nih.gov/17095215

DMS1AOK	DI	DMS1AOK
DMS1AOK	DN	2-((2-iodophenoxy)(phenyl)methyl)morpholine
DMS1AOK	MI	TTAWNKZ
DMS1AOK	MN	Norepinephrine transporter (NET)
DMS1AOK	MT	DTT
DMS1AOK	MA	Inhibitor
DMS1AOK	RN	Development of SPECT imaging agents for the norepinephrine transporters: [123I]INER. Bioorg Med Chem Lett. 2007 Jan 15;17(2):533-7.
DMS1AOK	RU	https://pubmed.ncbi.nlm.nih.gov/17095215

DM1BI65	DI	DM1BI65
DM1BI65	DN	2-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol
DM1BI65	MI	TT7HF4W
DM1BI65	MN	Cyclin-dependent kinase 2 (CDK2)
DM1BI65	MT	DTT
DM1BI65	MA	Inhibitor
DM1BI65	RN	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
DM1BI65	RU	https://pubmed.ncbi.nlm.nih.gov/17064068

DM1BI65	DI	DM1BI65
DM1BI65	DN	2-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol
DM1BI65	MI	TTCEJ4F
DM1BI65	MN	G1/S-specific cyclin-E1 (CCNE1)
DM1BI65	MT	DTT
DM1BI65	MA	Inhibitor
DM1BI65	RN	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
DM1BI65	RU	https://pubmed.ncbi.nlm.nih.gov/17064068

DMS21CR	DI	DMS21CR
DMS21CR	DN	2-((3-iodophenyl)(o-tolyloxy)methyl)morpholine
DMS21CR	MI	TTVBI8W
DMS21CR	MN	Dopamine transporter (DAT)
DMS21CR	MT	DTT
DMS21CR	MA	Inhibitor
DMS21CR	RN	Development of SPECT imaging agents for the norepinephrine transporters: [123I]INER. Bioorg Med Chem Lett. 2007 Jan 15;17(2):533-7.
DMS21CR	RU	https://pubmed.ncbi.nlm.nih.gov/17095215

DMS21CR	DI	DMS21CR
DMS21CR	DN	2-((3-iodophenyl)(o-tolyloxy)methyl)morpholine
DMS21CR	MI	TTAWNKZ
DMS21CR	MN	Norepinephrine transporter (NET)
DMS21CR	MT	DTT
DMS21CR	MA	Inhibitor
DMS21CR	RN	Development of SPECT imaging agents for the norepinephrine transporters: [123I]INER. Bioorg Med Chem Lett. 2007 Jan 15;17(2):533-7.
DMS21CR	RU	https://pubmed.ncbi.nlm.nih.gov/17095215

DMFXDY3	DI	DMFXDY3
DMFXDY3	DN	2-(1-(aminomethyl)-3-butylcyclopentyl)acetic acid
DMFXDY3	MI	TTFK1JQ
DMFXDY3	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMFXDY3	MT	DTT
DMFXDY3	MA	Inhibitor
DMFXDY3	RN	Synthesis and in vivo evaluation of 3-substituted gababutins. Bioorg Med Chem Lett. 2010 Jan 1;20(1):362-5.
DMFXDY3	RU	https://pubmed.ncbi.nlm.nih.gov/19897364

DM1ASK6	DI	DM1ASK6
DM1ASK6	DN	2-(1-(aminomethyl)-3-ethylcyclopentyl)acetic acid
DM1ASK6	MI	TTFK1JQ
DM1ASK6	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DM1ASK6	MT	DTT
DM1ASK6	MA	Inhibitor
DM1ASK6	RN	Synthesis and in vivo evaluation of 3-substituted gababutins. Bioorg Med Chem Lett. 2010 Jan 1;20(1):362-5.
DM1ASK6	RU	https://pubmed.ncbi.nlm.nih.gov/19897364

DM3D8WI	DI	DM3D8WI
DM3D8WI	DN	2-(1-(phenylsulfonyl)-1H-indol-3-yl)ethanamine
DM3D8WI	MI	TTJS8PY
DM3D8WI	MN	5-HT 6 receptor (HTR6)
DM3D8WI	MT	DTT
DM3D8WI	MA	Inhibitor
DM3D8WI	RN	Discovery of N1-(6-chloroimidazo[2,1-b][1,3]thiazole-5-sulfonyl)tryptamine as a potent, selective, and orally active 5-HT(6) receptor agonist. J Med Chem. 2007 Nov 15;50(23):5535-8.
DM3D8WI	RU	https://pubmed.ncbi.nlm.nih.gov/17948978

DMUE0D6	DI	DMUE0D6
DMUE0D6	DN	2-(1,1'-Biphenyl-4-Yl)Propanoic Acid
DMUE0D6	MI	TT8NGED
DMUE0D6	MN	Prostaglandin G/H synthase 1 (COX-1)
DMUE0D6	MT	DTT
DMUE0D6	MA	Inhibitor
DMUE0D6	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMUE0D6	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMZ83G9	DI	DMZ83G9
DMZ83G9	DN	2-(1,4'-bipiperidin-1'-yl)thiazolo[4,5-b]pyridine
DMZ83G9	MI	TT9JNIC
DMZ83G9	MN	Histamine H3 receptor (H3R)
DMZ83G9	MT	DTT
DMZ83G9	MA	Inhibitor
DMZ83G9	RN	Synthesis and structure-activity relationships of 2-(1,4'-bipiperidin-1'-yl)thiazolopyridine as H3 receptor antagonists. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6176-80.
DMZ83G9	RU	https://pubmed.ncbi.nlm.nih.gov/19773164

DMEKSAZ	DI	DMEKSAZ
DMEKSAZ	DN	2-(1,4'-bipiperidin-1'-yl)thiazolo[4,5-c]pyridine
DMEKSAZ	MI	TT9JNIC
DMEKSAZ	MN	Histamine H3 receptor (H3R)
DMEKSAZ	MT	DTT
DMEKSAZ	MA	Inhibitor
DMEKSAZ	RN	Synthesis and structure-activity relationships of 2-(1,4'-bipiperidin-1'-yl)thiazolopyridine as H3 receptor antagonists. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6176-80.
DMEKSAZ	RU	https://pubmed.ncbi.nlm.nih.gov/19773164

DMVXN01	DI	DMVXN01
DMVXN01	DN	2-(10-Imidazol-1-yl-decyl)-isoindole-1,3-dione
DMVXN01	MI	TTKNWZ4
DMVXN01	MN	Thromboxane-A synthase (TBXAS1)
DMVXN01	MT	DTT
DMVXN01	MA	Inhibitor
DMVXN01	RN	Thromboxane synthetase inhibitors and antihypertensive agents. 2. N-[(1H-imidazol-1-yl)alkyl]-1H-isoindole-1,3(2H)-diones and N-[(1H-1,2,4-triazol-... J Med Chem. 1986 May;29(5):816-9.
DMVXN01	RU	https://pubmed.ncbi.nlm.nih.gov/3517332

DM05OJD	DI	DM05OJD
DM05OJD	DN	2-(1-adamantyl) piperidine
DM05OJD	MI	TTXT3PU
DM05OJD	MN	Influenza M2 protein (Influ M)
DM05OJD	MT	DTT
DM05OJD	MA	Inhibitor
DM05OJD	RN	Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25.
DM05OJD	RU	https://pubmed.ncbi.nlm.nih.gov/17139286

DMMSFEU	DI	DMMSFEU
DMMSFEU	DN	2-(1-adamantyl) pyrrolidine
DMMSFEU	MI	TTXT3PU
DMMSFEU	MN	Influenza M2 protein (Influ M)
DMMSFEU	MT	DTT
DMMSFEU	MA	Inhibitor
DMMSFEU	RN	Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25.
DMMSFEU	RU	https://pubmed.ncbi.nlm.nih.gov/17139286

DMIGRMV	DI	DMIGRMV
DMIGRMV	DN	2-(1-adamantyl)-2-methyl-pyrrolidine
DMIGRMV	MI	TTXT3PU
DMIGRMV	MN	Influenza M2 protein (Influ M)
DMIGRMV	MT	DTT
DMIGRMV	MA	Inhibitor
DMIGRMV	RN	Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25.
DMIGRMV	RU	https://pubmed.ncbi.nlm.nih.gov/17139286

DMB5LHA	DI	DMB5LHA
DMB5LHA	DN	2-(1-benzyl-1H-inden-3-yl)-N,N-dimethylethanamine
DMB5LHA	MI	TTJS8PY
DMB5LHA	MN	5-HT 6 receptor (HTR6)
DMB5LHA	MT	DTT
DMB5LHA	MA	Inhibitor
DMB5LHA	RN	Indene-based scaffolds. 2. An indole-indene switch: discovery of novel indenylsulfonamides as 5-HT6 serotonin receptor agonists. J Med Chem. 2009 Feb 12;52(3):675-87.
DMB5LHA	RU	https://pubmed.ncbi.nlm.nih.gov/19159187

DMML3XI	DI	DMML3XI
DMML3XI	DN	2-(1-benzyl-1H-indol-3-yl)-N,N-dimethylethanamine
DMML3XI	MI	TTJS8PY
DMML3XI	MN	5-HT 6 receptor (HTR6)
DMML3XI	MT	DTT
DMML3XI	MA	Inhibitor
DMML3XI	RN	Indene-based scaffolds. 2. An indole-indene switch: discovery of novel indenylsulfonamides as 5-HT6 serotonin receptor agonists. J Med Chem. 2009 Feb 12;52(3):675-87.
DMML3XI	RU	https://pubmed.ncbi.nlm.nih.gov/19159187

DMF2XHZ	DI	DMF2XHZ
DMF2XHZ	DN	2-(1-dodecyl-1H-indol-3-yl)acetic acid
DMF2XHZ	MI	TTLZS4Q
DMF2XHZ	MN	M-phase inducer phosphatase 1 (MPIP1)
DMF2XHZ	MT	DTT
DMF2XHZ	MA	Inhibitor
DMF2XHZ	RN	Design and synthesis of N-alkyl oxindolylidene acetic acids as a new class of potent Cdc25A inhibitors. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3350-3.
DMF2XHZ	RU	https://pubmed.ncbi.nlm.nih.gov/18442908

DM0Y2P1	DI	DM0Y2P1
DM0Y2P1	DN	2-(1H-benzo[d]imidazol-2-yl)quinoxaline
DM0Y2P1	MI	TTK25J1
DM0Y2P1	MN	Adenosine A1 receptor (ADORA1)
DM0Y2P1	MT	DTT
DM0Y2P1	MA	Inhibitor
DM0Y2P1	RN	Derivatives of 4-amino-6-hydroxy-2-mercaptopyrimidine as novel, potent, and selective A3 adenosine receptor antagonists. J Med Chem. 2008 Mar 27;51(6):1764-70.
DM0Y2P1	RU	https://pubmed.ncbi.nlm.nih.gov/18269230

DM0Y2P1	DI	DM0Y2P1
DM0Y2P1	DN	2-(1H-benzo[d]imidazol-2-yl)quinoxaline
DM0Y2P1	MI	TTM2AOE
DM0Y2P1	MN	Adenosine A2a receptor (ADORA2A)
DM0Y2P1	MT	DTT
DM0Y2P1	MA	Inhibitor
DM0Y2P1	RN	Derivatives of 4-amino-6-hydroxy-2-mercaptopyrimidine as novel, potent, and selective A3 adenosine receptor antagonists. J Med Chem. 2008 Mar 27;51(6):1764-70.
DM0Y2P1	RU	https://pubmed.ncbi.nlm.nih.gov/18269230

DM0Y2P1	DI	DM0Y2P1
DM0Y2P1	DN	2-(1H-benzo[d]imidazol-2-yl)quinoxaline
DM0Y2P1	MI	TTJFY5U
DM0Y2P1	MN	Adenosine A3 receptor (ADORA3)
DM0Y2P1	MT	DTT
DM0Y2P1	MA	Inhibitor
DM0Y2P1	RN	Derivatives of 4-amino-6-hydroxy-2-mercaptopyrimidine as novel, potent, and selective A3 adenosine receptor antagonists. J Med Chem. 2008 Mar 27;51(6):1764-70.
DM0Y2P1	RU	https://pubmed.ncbi.nlm.nih.gov/18269230

DMXA20E	DI	DMXA20E
DMXA20E	DN	2-(1H-imidazo[4,5-c]pyridin-2-yl)quinoxaline
DMXA20E	MI	TTJFY5U
DMXA20E	MN	Adenosine A3 receptor (ADORA3)
DMXA20E	MT	DTT
DMXA20E	MA	Inhibitor
DMXA20E	RN	2-(Benzimidazol-2-yl)quinoxalines: a novel class of selective antagonists at human A(1) and A(3) adenosine receptors designed by 3D database search... J Med Chem. 2005 Dec 29;48(26):8253-60.
DMXA20E	RU	https://pubmed.ncbi.nlm.nih.gov/16366607

DMFK9GA	DI	DMFK9GA
DMFK9GA	DN	2-(1H-Imidazol-1-yl)-1-(4-nitrophenyl)ethanone
DMFK9GA	MI	TTSZLWK
DMFK9GA	MN	Aromatase (CYP19A1)
DMFK9GA	MT	DTT
DMFK9GA	MA	Inhibitor
DMFK9GA	RN	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
DMFK9GA	RU	https://pubmed.ncbi.nlm.nih.gov/20558073

DM2PZ1B	DI	DM2PZ1B
DM2PZ1B	DN	2-(1H-Imidazol-4-yl)benzene-1,3-diol
DM2PZ1B	MI	TTZJYKH
DM2PZ1B	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DM2PZ1B	MT	DTT
DM2PZ1B	MA	Inhibitor
DM2PZ1B	RN	Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase. J Med Chem. 2008 Aug 28;51(16):4968-77.
DM2PZ1B	RU	https://pubmed.ncbi.nlm.nih.gov/18665584

DM6MR82	DI	DM6MR82
DM6MR82	DN	2-(1H-Imidazol-4-yl)phenol
DM6MR82	MI	TTZJYKH
DM6MR82	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DM6MR82	MT	DTT
DM6MR82	MA	Inhibitor
DM6MR82	RN	Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase. J Med Chem. 2008 Aug 28;51(16):4968-77.
DM6MR82	RU	https://pubmed.ncbi.nlm.nih.gov/18665584

DMCG1HE	DI	DMCG1HE
DMCG1HE	DN	2-(1H-Imidazol-4-ylmethyl)-4-phenyl-thiazole
DMCG1HE	MI	TTPC4TU
DMCG1HE	MN	5-HT 3A receptor (HTR3A)
DMCG1HE	MT	DTT
DMCG1HE	MA	Inhibitor
DMCG1HE	RN	Aromatic thiazole derivatives: structurally novel and selective serotonin-3 receptor antagonists. J Med Chem. 1990 Jan;33(1):13-6.
DMCG1HE	RU	https://pubmed.ncbi.nlm.nih.gov/2296012

DMCG1HE	DI	DMCG1HE
DMCG1HE	DN	2-(1H-Imidazol-4-ylmethyl)-4-phenyl-thiazole
DMCG1HE	MI	TTR6K75
DMCG1HE	MN	5-HT 3B receptor (HTR3B)
DMCG1HE	MT	DTT
DMCG1HE	MA	Inhibitor
DMCG1HE	RN	Aromatic thiazole derivatives: structurally novel and selective serotonin-3 receptor antagonists. J Med Chem. 1990 Jan;33(1):13-6.
DMCG1HE	RU	https://pubmed.ncbi.nlm.nih.gov/2296012

DM0CSH8	DI	DM0CSH8
DM0CSH8	DN	2-(1H-indazol-3-yl)-1H-benzo[d]imidazole
DM0CSH8	MI	TTTU902
DM0CSH8	MN	Checkpoint kinase-1 (CHK1)
DM0CSH8	MT	DTT
DM0CSH8	MA	Inhibitor
DM0CSH8	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM0CSH8	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM0CSH8	DI	DM0CSH8
DM0CSH8	DN	2-(1H-indazol-3-yl)-1H-benzo[d]imidazole
DM0CSH8	MI	TTRLW2X
DM0CSH8	MN	Fibroblast growth factor receptor 1 (FGFR1)
DM0CSH8	MT	DTT
DM0CSH8	MA	Inhibitor
DM0CSH8	RN	Design and structure-activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3595-9.
DM0CSH8	RU	https://pubmed.ncbi.nlm.nih.gov/16603352

DM0CSH8	DI	DM0CSH8
DM0CSH8	DN	2-(1H-indazol-3-yl)-1H-benzo[d]imidazole
DM0CSH8	MI	TTI7421
DM0CSH8	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM0CSH8	MT	DTT
DM0CSH8	MA	Inhibitor
DM0CSH8	RN	Design and structure-activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3595-9.
DM0CSH8	RU	https://pubmed.ncbi.nlm.nih.gov/16603352

DM0CSH8	DI	DM0CSH8
DM0CSH8	DN	2-(1H-indazol-3-yl)-1H-benzo[d]imidazole
DM0CSH8	MI	TTUTJGQ
DM0CSH8	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM0CSH8	MT	DTT
DM0CSH8	MA	Inhibitor
DM0CSH8	RN	Design and structure-activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3595-9.
DM0CSH8	RU	https://pubmed.ncbi.nlm.nih.gov/16603352

DM0CSH8	DI	DM0CSH8
DM0CSH8	DN	2-(1H-indazol-3-yl)-1H-benzo[d]imidazole
DM0CSH8	MI	TT1VAUK
DM0CSH8	MN	VEGFR1 messenger RNA (VEGFR1 mRNA)
DM0CSH8	MT	DTT
DM0CSH8	MA	Inhibitor
DM0CSH8	RN	Design and structure-activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3595-9.
DM0CSH8	RU	https://pubmed.ncbi.nlm.nih.gov/16603352

DMFAME4	DI	DMFAME4
DMFAME4	DN	2-(1H-Indol-3-yl)-2-oxo-N-phenethyl-acetamide
DMFAME4	MI	TT1MPAY
DMFAME4	MN	GABA(A) receptor alpha-1 (GABRA1)
DMFAME4	MT	DTT
DMFAME4	MA	Inhibitor
DMFAME4	RN	Benzodiazepine receptor affinity and interaction of some N-(indol-3-ylglyoxylyl)amine derivatives. J Med Chem. 1992 Jun 12;35(12):2214-20.
DMFAME4	RU	https://pubmed.ncbi.nlm.nih.gov/1319492

DMFAME4	DI	DMFAME4
DMFAME4	DN	2-(1H-Indol-3-yl)-2-oxo-N-phenethyl-acetamide
DMFAME4	MI	TT06RH5
DMFAME4	MN	GABA(A) receptor gamma-2 (GABRG2)
DMFAME4	MT	DTT
DMFAME4	MA	Inhibitor
DMFAME4	RN	Benzodiazepine receptor affinity and interaction of some N-(indol-3-ylglyoxylyl)amine derivatives. J Med Chem. 1992 Jun 12;35(12):2214-20.
DMFAME4	RU	https://pubmed.ncbi.nlm.nih.gov/1319492

DMFAME4	DI	DMFAME4
DMFAME4	DN	2-(1H-Indol-3-yl)-2-oxo-N-phenethyl-acetamide
DMFAME4	MI	TTNJYV2
DMFAME4	MN	Gamma-aminobutyric acid receptor (GAR)
DMFAME4	MT	DTT
DMFAME4	MA	Inhibitor
DMFAME4	RN	Benzodiazepine receptor affinity and interaction of some N-(indol-3-ylglyoxylyl)amine derivatives. J Med Chem. 1992 Jun 12;35(12):2214-20.
DMFAME4	RU	https://pubmed.ncbi.nlm.nih.gov/1319492

DMR9Q4Y	DI	DMR9Q4Y
DMR9Q4Y	DN	2-(1H-indol-3-yl)-N,N-dimethylethanamine
DMR9Q4Y	MI	TTJQOD7
DMR9Q4Y	MN	5-HT 2A receptor (HTR2A)
DMR9Q4Y	MT	DTT
DMR9Q4Y	MA	Inhibitor
DMR9Q4Y	RN	Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects. Arch Gen Psychiatry. 1994 Feb;51(2):85-97.
DMR9Q4Y	RU	https://pubmed.ncbi.nlm.nih.gov/8297216

DMR9Q4Y	DI	DMR9Q4Y
DMR9Q4Y	DN	2-(1H-indol-3-yl)-N,N-dimethylethanamine
DMR9Q4Y	MI	TTJS8PY
DMR9Q4Y	MN	5-HT 6 receptor (HTR6)
DMR9Q4Y	MT	DTT
DMR9Q4Y	MA	Inhibitor
DMR9Q4Y	RN	Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects. Arch Gen Psychiatry. 1994 Feb;51(2):85-97.
DMR9Q4Y	RU	https://pubmed.ncbi.nlm.nih.gov/8297216

DMR9Q4Y	DI	DMR9Q4Y
DMR9Q4Y	DN	2-(1H-indol-3-yl)-N,N-dimethylethanamine
DMR9Q4Y	MI	TT5TPI6
DMR9Q4Y	MN	Opioid receptor sigma 1 (OPRS1)
DMR9Q4Y	MT	DTT
DMR9Q4Y	MA	Inhibitor
DMR9Q4Y	RN	Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects. Arch Gen Psychiatry. 1994 Feb;51(2):85-97.
DMR9Q4Y	RU	https://pubmed.ncbi.nlm.nih.gov/8297216

DMB7AU5	DI	DMB7AU5
DMB7AU5	DN	2-(1H-Indol-3-ylmethyl)-1,2-dihydro-indazol-3-one
DMB7AU5	MI	TT2J34L
DMB7AU5	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMB7AU5	MT	DTT
DMB7AU5	MA	Inhibitor
DMB7AU5	RN	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
DMB7AU5	RU	https://pubmed.ncbi.nlm.nih.gov/1848292

DMZNML4	DI	DMZNML4
DMZNML4	DN	2-(1H-indol-5-yl)-6-morpholino-4H-pyran-4-one
DMZNML4	MI	TTK3PY9
DMZNML4	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMZNML4	MT	DTT
DMZNML4	MA	Inhibitor
DMZNML4	RN	Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72.
DMZNML4	RU	https://pubmed.ncbi.nlm.nih.gov/17371003

DMHSORL	DI	DMHSORL
DMHSORL	DN	2-(1H-pyrazol-3-yl)-1H-benzimidazole
DMHSORL	MI	TTPS3C0
DMHSORL	MN	Aurora kinase A (AURKA)
DMHSORL	MT	DTT
DMHSORL	MA	Inhibitor
DMHSORL	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMHSORL	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMUY75A	DI	DMUY75A
DMUY75A	DN	2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol
DMUY75A	MI	TT78R5H
DMUY75A	MN	Heat shock protein 90 alpha (HSP90A)
DMUY75A	MT	DTT
DMUY75A	MA	Inhibitor
DMUY75A	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMUY75A	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM4MIXK	DI	DM4MIXK
DM4MIXK	DN	2-(1-Imidazol-1-yl-ethyl)-9H-carbazole
DM4MIXK	MI	TTRA5BZ
DM4MIXK	MN	Steroid 17-alpha-monooxygenase (S17AH)
DM4MIXK	MT	DTT
DM4MIXK	MA	Inhibitor
DM4MIXK	RN	Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxyl... Bioorg Med Chem. 2008 Aug 15;16(16):7715-27.
DM4MIXK	RU	https://pubmed.ncbi.nlm.nih.gov/18674917

DMY35HG	DI	DMY35HG
DMY35HG	DN	2-(1-o-tolyl-1H-pyrrol-3-yl)ethanamine
DMY35HG	MI	TTO9X1H
DMY35HG	MN	5-HT 7 receptor (HTR7)
DMY35HG	MT	DTT
DMY35HG	MA	Inhibitor
DMY35HG	RN	Novel aminoethylbiphenyls as 5-HT7 receptor ligands. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3018-22.
DMY35HG	RU	https://pubmed.ncbi.nlm.nih.gov/17419056

DMR0HDF	DI	DMR0HDF
DMR0HDF	DN	2-(1-Pentyl-hexyl)-4-phenyl-1H-imidazole
DMR0HDF	MI	TTRK8B9
DMR0HDF	MN	Sodium channel unspecific (NaC)
DMR0HDF	MT	DTT
DMR0HDF	MA	Inhibitor
DMR0HDF	RN	2-Alkyl-4-arylimidazoles: structurally novel sodium channel modulators. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3521-3.
DMR0HDF	RU	https://pubmed.ncbi.nlm.nih.gov/15177465

DMR0HDF	DI	DMR0HDF
DMR0HDF	DN	2-(1-Pentyl-hexyl)-4-phenyl-1H-imidazole
DMR0HDF	MI	TTAXZ0K
DMR0HDF	MN	Voltage-gated sodium channel alpha Nav1.3 (SCN3A)
DMR0HDF	MT	DTT
DMR0HDF	MA	Inhibitor
DMR0HDF	RN	2-Alkyl-4-arylimidazoles: structurally novel sodium channel modulators. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3521-3.
DMR0HDF	RU	https://pubmed.ncbi.nlm.nih.gov/15177465

DMXCID6	DI	DMXCID6
DMXCID6	DN	2-(1-tosyl-1H-indol-3-yl)ethanamine
DMXCID6	MI	TTJS8PY
DMXCID6	MN	5-HT 6 receptor (HTR6)
DMXCID6	MT	DTT
DMXCID6	MA	Inhibitor
DMXCID6	RN	Discovery of N1-(6-chloroimidazo[2,1-b][1,3]thiazole-5-sulfonyl)tryptamine as a potent, selective, and orally active 5-HT(6) receptor agonist. J Med Chem. 2007 Nov 15;50(23):5535-8.
DMXCID6	RU	https://pubmed.ncbi.nlm.nih.gov/17948978

DMGZKCT	DI	DMGZKCT
DMGZKCT	DN	2-(2-((benzylamino)methyl)phenoxy)-5-chlorophenol
DMGZKCT	MI	TTNX2CS
DMGZKCT	MN	Plasmodium Enoyl-ACP reductase (Malaria fabI)
DMGZKCT	MT	DTT
DMGZKCT	MA	Inhibitor
DMGZKCT	RN	Synthesis and biological activity of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 2: 2'-substituted triclosan der... Bioorg Med Chem Lett. 2006 Apr 15;16(8):2163-9.
DMGZKCT	RU	https://pubmed.ncbi.nlm.nih.gov/16466916

DM54M6C	DI	DM54M6C
DM54M6C	DN	2-(2-(2,5-dichlorophenylamino)phenyl)acetic acid
DM54M6C	MI	TTCTE1G
DM54M6C	MN	Interleukin-8 (IL8)
DM54M6C	MT	DTT
DM54M6C	MA	Inhibitor
DM54M6C	RN	Structure-Activity Relationship of novel phenylacetic CXCR1 inhibitors. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4026-30.
DM54M6C	RU	https://pubmed.ncbi.nlm.nih.gov/19560921

DMJ2DE4	DI	DMJ2DE4
DMJ2DE4	DN	2-(2-(2,6-dimethylphenylamino)phenyl)acetic acid
DMJ2DE4	MI	TT8NGED
DMJ2DE4	MN	Prostaglandin G/H synthase 1 (COX-1)
DMJ2DE4	MT	DTT
DMJ2DE4	MA	Inhibitor
DMJ2DE4	RN	Molecular determinants for the selective inhibition of cyclooxygenase-2 by lumiracoxib. J Biol Chem. 2007 Jun 1;282(22):16379-90.
DMJ2DE4	RU	https://pubmed.ncbi.nlm.nih.gov/17434872

DMJ2DE4	DI	DMJ2DE4
DMJ2DE4	DN	2-(2-(2,6-dimethylphenylamino)phenyl)acetic acid
DMJ2DE4	MI	TTVKILB
DMJ2DE4	MN	Prostaglandin G/H synthase 2 (COX-2)
DMJ2DE4	MT	DTT
DMJ2DE4	MA	Inhibitor
DMJ2DE4	RN	Molecular determinants for the selective inhibition of cyclooxygenase-2 by lumiracoxib. J Biol Chem. 2007 Jun 1;282(22):16379-90.
DMJ2DE4	RU	https://pubmed.ncbi.nlm.nih.gov/17434872

DMBP1TQ	DI	DMBP1TQ
DMBP1TQ	DN	2-(2-(2-chlorophenoxy)phenyl)acetic acid
DMBP1TQ	MI	TTCTE1G
DMBP1TQ	MN	Interleukin-8 (IL8)
DMBP1TQ	MT	DTT
DMBP1TQ	MA	Inhibitor
DMBP1TQ	RN	Structure-Activity Relationship of novel phenylacetic CXCR1 inhibitors. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4026-30.
DMBP1TQ	RU	https://pubmed.ncbi.nlm.nih.gov/19560921

DMPLV3A	DI	DMPLV3A
DMPLV3A	DN	2-(2-(2-chlorophenylamino)phenyl)acetic acid
DMPLV3A	MI	TTCTE1G
DMPLV3A	MN	Interleukin-8 (IL8)
DMPLV3A	MT	DTT
DMPLV3A	MA	Inhibitor
DMPLV3A	RN	Structure-Activity Relationship of novel phenylacetic CXCR1 inhibitors. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4026-30.
DMPLV3A	RU	https://pubmed.ncbi.nlm.nih.gov/19560921

DMDSUR2	DI	DMDSUR2
DMDSUR2	DN	2-(2-(2-fluorophenoxy)phenyl)acetic acid
DMDSUR2	MI	TTCTE1G
DMDSUR2	MN	Interleukin-8 (IL8)
DMDSUR2	MT	DTT
DMDSUR2	MA	Inhibitor
DMDSUR2	RN	Structure-Activity Relationship of novel phenylacetic CXCR1 inhibitors. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4026-30.
DMDSUR2	RU	https://pubmed.ncbi.nlm.nih.gov/19560921

DMVQ68F	DI	DMVQ68F
DMVQ68F	DN	2-(2-(2-fluorophenylamino)phenyl)acetic acid
DMVQ68F	MI	TTCTE1G
DMVQ68F	MN	Interleukin-8 (IL8)
DMVQ68F	MT	DTT
DMVQ68F	MA	Inhibitor
DMVQ68F	RN	Structure-Activity Relationship of novel phenylacetic CXCR1 inhibitors. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4026-30.
DMVQ68F	RU	https://pubmed.ncbi.nlm.nih.gov/19560921

DMKT51Z	DI	DMKT51Z
DMKT51Z	DN	2-(2-(4-tert-butylphenoxy)acetamido)benzoic acid
DMKT51Z	MI	TTWNV8U
DMKT51Z	MN	Nicotinic acid receptor (HCAR2)
DMKT51Z	MT	DTT
DMKT51Z	MA	Inhibitor
DMKT51Z	RN	Molecular modeling aided design of nicotinic acid receptor GPR109A agonists. Bioorg Med Chem Lett. 2008 Sep 15;18(18):4963-7.
DMKT51Z	RU	https://pubmed.ncbi.nlm.nih.gov/18760600

DMZVBPG	DI	DMZVBPG
DMZVBPG	DN	2-(2-(4-tert-Butylphenylthio)ethyl)-1H-imidazole
DMZVBPG	MI	TTXV4FI
DMZVBPG	MN	Albendazole monooxygenase (CYP3A4)
DMZVBPG	MT	DTT
DMZVBPG	MA	Inhibitor
DMZVBPG	RN	Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active hi... J Med Chem. 2010 May 13;53(9):3840-4.
DMZVBPG	RU	https://pubmed.ncbi.nlm.nih.gov/20384344

DMZVBPG	DI	DMZVBPG
DMZVBPG	DN	2-(2-(4-tert-Butylphenylthio)ethyl)-1H-imidazole
DMZVBPG	MI	TTVG215
DMZVBPG	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DMZVBPG	MT	DTT
DMZVBPG	MA	Inhibitor
DMZVBPG	RN	Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active hi... J Med Chem. 2010 May 13;53(9):3840-4.
DMZVBPG	RU	https://pubmed.ncbi.nlm.nih.gov/20384344

DMZVBPG	DI	DMZVBPG
DMZVBPG	DN	2-(2-(4-tert-Butylphenylthio)ethyl)-1H-imidazole
DMZVBPG	MI	TT9JNIC
DMZVBPG	MN	Histamine H3 receptor (H3R)
DMZVBPG	MT	DTT
DMZVBPG	MA	Inhibitor
DMZVBPG	RN	Investigation of the histamine H3 receptor binding site. Design and synthesis of hybrid agonists with a lipophilic side chain. J Med Chem. 2010 Sep 9;53(17):6445-56.
DMZVBPG	RU	https://pubmed.ncbi.nlm.nih.gov/20690643

DMZVBPG	DI	DMZVBPG
DMZVBPG	DN	2-(2-(4-tert-Butylphenylthio)ethyl)-1H-imidazole
DMZVBPG	MI	TTXJ178
DMZVBPG	MN	Histamine H4 receptor (H4R)
DMZVBPG	MT	DTT
DMZVBPG	MA	Inhibitor
DMZVBPG	RN	Synthesis and structure-activity relationships of N-aryl-piperidine derivatives as potent (partial) agonists for human histamine H3 receptor. Bioorg Med Chem. 2010 Jul 15;18(14):5441-8. 
DMZVBPG	RU	https://pubmed.ncbi.nlm.nih.gov/20541426

DMDR50V	DI	DMDR50V
DMDR50V	DN	2-(2-(biphenyl-4-yl)ethylsulfinyl)acetic acid
DMDR50V	MI	TTXZ0KQ
DMDR50V	MN	Matrix metalloproteinase-12 (MMP-12)
DMDR50V	MT	DTT
DMDR50V	MA	Inhibitor
DMDR50V	RN	The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3.
DMDR50V	RU	https://pubmed.ncbi.nlm.nih.gov/19703773

DM95B4J	DI	DM95B4J
DM95B4J	DN	2-(2-(biphenyl-4-yl)ethylsulfonyl)acetic acid
DM95B4J	MI	TTXZ0KQ
DM95B4J	MN	Matrix metalloproteinase-12 (MMP-12)
DM95B4J	MT	DTT
DM95B4J	MA	Inhibitor
DM95B4J	RN	The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3.
DM95B4J	RU	https://pubmed.ncbi.nlm.nih.gov/19703773

DM95B4J	DI	DM95B4J
DM95B4J	DN	2-(2-(biphenyl-4-yl)ethylsulfonyl)acetic acid
DM95B4J	MI	TTHY57M
DM95B4J	MN	Matrix metalloproteinase-13 (MMP-13)
DM95B4J	MT	DTT
DM95B4J	MA	Inhibitor
DM95B4J	RN	The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3.
DM95B4J	RU	https://pubmed.ncbi.nlm.nih.gov/19703773

DMBZIUC	DI	DMBZIUC
DMBZIUC	DN	2-(2-(biphenyl-4-yl)ethylthio)acetic acid
DMBZIUC	MI	TTXZ0KQ
DMBZIUC	MN	Matrix metalloproteinase-12 (MMP-12)
DMBZIUC	MT	DTT
DMBZIUC	MA	Inhibitor
DMBZIUC	RN	The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3.
DMBZIUC	RU	https://pubmed.ncbi.nlm.nih.gov/19703773

DMZA8M7	DI	DMZA8M7
DMZA8M7	DN	2-(2-(butylamino)pyrimidin-4-ylamino)benzoic acid
DMZA8M7	MI	TT0K6EO
DMZA8M7	MN	Stress-activated protein kinase JNK1 (JNK1)
DMZA8M7	MT	DTT
DMZA8M7	MA	Inhibitor
DMZA8M7	RN	Discovery of a new class of 4-anilinopyrimidines as potent c-Jun N-terminal kinase inhibitors: Synthesis and SAR studies. Bioorg Med Chem Lett. 2007 Feb 1;17(3):668-72.
DMZA8M7	RU	https://pubmed.ncbi.nlm.nih.gov/17107797

DM4KS27	DI	DM4KS27
DM4KS27	DN	2-(2-(pentyloxy)pyrimidin-4-ylamino)benzoic acid
DM4KS27	MI	TT0K6EO
DM4KS27	MN	Stress-activated protein kinase JNK1 (JNK1)
DM4KS27	MT	DTT
DM4KS27	MA	Inhibitor
DM4KS27	RN	Discovery of a new class of 4-anilinopyrimidines as potent c-Jun N-terminal kinase inhibitors: Synthesis and SAR studies. Bioorg Med Chem Lett. 2007 Feb 1;17(3):668-72.
DM4KS27	RU	https://pubmed.ncbi.nlm.nih.gov/17107797

DM5GAOZ	DI	DM5GAOZ
DM5GAOZ	DN	2-(2-(phenylamino)pyrimidin-4-ylamino)benzamide
DM5GAOZ	MI	TT0K6EO
DM5GAOZ	MN	Stress-activated protein kinase JNK1 (JNK1)
DM5GAOZ	MT	DTT
DM5GAOZ	MA	Inhibitor
DM5GAOZ	RN	Discovery of a new class of 4-anilinopyrimidines as potent c-Jun N-terminal kinase inhibitors: Synthesis and SAR studies. Bioorg Med Chem Lett. 2007 Feb 1;17(3):668-72.
DM5GAOZ	RU	https://pubmed.ncbi.nlm.nih.gov/17107797

DMCHZ8J	DI	DMCHZ8J
DMCHZ8J	DN	2-(2-(pyrrolidin-1-yl)ethyl)-1H-indole
DMCHZ8J	MI	TT9JNIC
DMCHZ8J	MN	Histamine H3 receptor (H3R)
DMCHZ8J	MT	DTT
DMCHZ8J	MA	Inhibitor
DMCHZ8J	RN	In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9.
DMCHZ8J	RU	https://pubmed.ncbi.nlm.nih.gov/18077160

DMQ0WKA	DI	DMQ0WKA
DMQ0WKA	DN	2-(2-(pyrrolidin-1-yl)ethyl)phenol
DMQ0WKA	MI	TT9JNIC
DMQ0WKA	MN	Histamine H3 receptor (H3R)
DMQ0WKA	MT	DTT
DMQ0WKA	MA	Inhibitor
DMQ0WKA	RN	In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9.
DMQ0WKA	RU	https://pubmed.ncbi.nlm.nih.gov/18077160

DMGQC2F	DI	DMGQC2F
DMGQC2F	DN	2-(2-(pyrrolidin-1-yl)ethyl)pyridine
DMGQC2F	MI	TT9JNIC
DMGQC2F	MN	Histamine H3 receptor (H3R)
DMGQC2F	MT	DTT
DMGQC2F	MA	Inhibitor
DMGQC2F	RN	In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9.
DMGQC2F	RU	https://pubmed.ncbi.nlm.nih.gov/18077160

DMFU1PK	DI	DMFU1PK
DMFU1PK	DN	2-(2,3,4-trimethoxyphenyl)-1H-indene
DMFU1PK	MI	TT8NGED
DMFU1PK	MN	Prostaglandin G/H synthase 1 (COX-1)
DMFU1PK	MT	DTT
DMFU1PK	MA	Inhibitor
DMFU1PK	RN	'Bridged' stilbene derivatives as selective cyclooxygenase-1 inhibitors. Bioorg Med Chem. 2007 Sep 15;15(18):6109-18.
DMFU1PK	RU	https://pubmed.ncbi.nlm.nih.gov/17604631

DMFU1PK	DI	DMFU1PK
DMFU1PK	DN	2-(2,3,4-trimethoxyphenyl)-1H-indene
DMFU1PK	MI	TTVKILB
DMFU1PK	MN	Prostaglandin G/H synthase 2 (COX-2)
DMFU1PK	MT	DTT
DMFU1PK	MA	Inhibitor
DMFU1PK	RN	'Bridged' stilbene derivatives as selective cyclooxygenase-1 inhibitors. Bioorg Med Chem. 2007 Sep 15;15(18):6109-18.
DMFU1PK	RU	https://pubmed.ncbi.nlm.nih.gov/17604631

DM1T8IP	DI	DM1T8IP
DM1T8IP	DN	2-(2,3-bis(2-chlorobenzyloxy)phenyl)acetic acid
DM1T8IP	MI	TTHWMFZ
DM1T8IP	MN	Fatty acid-binding protein 4 (FABP4)
DM1T8IP	MT	DTT
DM1T8IP	MA	Inhibitor
DM1T8IP	RN	NMR structure of a potent small molecule inhibitor bound to human keratinocyte fatty acid-binding protein. J Med Chem. 2006 Aug 10;49(16):5013-7.
DM1T8IP	RU	https://pubmed.ncbi.nlm.nih.gov/16884313

DM1T8IP	DI	DM1T8IP
DM1T8IP	DN	2-(2,3-bis(2-chlorobenzyloxy)phenyl)acetic acid
DM1T8IP	MI	TTNT2S6
DM1T8IP	MN	Fatty acid-binding protein 5 (FABP5)
DM1T8IP	MT	DTT
DM1T8IP	MA	Inhibitor
DM1T8IP	RN	NMR structure of a potent small molecule inhibitor bound to human keratinocyte fatty acid-binding protein. J Med Chem. 2006 Aug 10;49(16):5013-7.
DM1T8IP	RU	https://pubmed.ncbi.nlm.nih.gov/16884313

DM56NK4	DI	DM56NK4
DM56NK4	DN	2-(2,3-Dihydro-1H-indol-5-yl)-1-methyl-ethylamine
DM56NK4	MI	TTVBI8W
DM56NK4	MN	Dopamine transporter (DAT)
DM56NK4	MT	DTT
DM56NK4	MA	Inhibitor
DM56NK4	RN	Selective monoamine oxidase inhibitors. 3. Cyclic compounds related to 4-aminophenethylamine. Preparation and neuron-selective action of some 5-(2-... J Med Chem. 1986 Aug;29(8):1406-12.
DM56NK4	RU	https://pubmed.ncbi.nlm.nih.gov/3735309

DM56NK4	DI	DM56NK4
DM56NK4	DN	2-(2,3-Dihydro-1H-indol-5-yl)-1-methyl-ethylamine
DM56NK4	MI	TTAWNKZ
DM56NK4	MN	Norepinephrine transporter (NET)
DM56NK4	MT	DTT
DM56NK4	MA	Inhibitor
DM56NK4	RN	Selective monoamine oxidase inhibitors. 3. Cyclic compounds related to 4-aminophenethylamine. Preparation and neuron-selective action of some 5-(2-... J Med Chem. 1986 Aug;29(8):1406-12.
DM56NK4	RU	https://pubmed.ncbi.nlm.nih.gov/3735309

DM4XL8Z	DI	DM4XL8Z
DM4XL8Z	DN	2-(2,4-dichlorophenoxy)-5-(2-methylbutyl)phenol
DM4XL8Z	MI	TTNX2CS
DM4XL8Z	MN	Plasmodium Enoyl-ACP reductase (Malaria fabI)
DM4XL8Z	MT	DTT
DM4XL8Z	MA	Inhibitor
DM4XL8Z	RN	Design and in silico screening of combinatorial library of antimalarial analogs of triclosan inhibiting Plasmodium falciparum enoyl-acyl carrier pr... Eur J Med Chem. 2009 Jul;44(7):3009-19.
DM4XL8Z	RU	https://pubmed.ncbi.nlm.nih.gov/19217192

DME3FUD	DI	DME3FUD
DME3FUD	DN	2-(2,4-dichlorophenoxy)-5-(3-phenylpropyl)phenol
DME3FUD	MI	TTNX2CS
DME3FUD	MN	Plasmodium Enoyl-ACP reductase (Malaria fabI)
DME3FUD	MT	DTT
DME3FUD	MA	Inhibitor
DME3FUD	RN	X-ray structural analysis of Plasmodium falciparum enoyl acyl carrier protein reductase as a pathway toward the optimization of triclosan antimalar... J Biol Chem. 2007 Aug 31;282(35):25436-44.
DME3FUD	RU	https://pubmed.ncbi.nlm.nih.gov/17567585

DMPSR1O	DI	DMPSR1O
DMPSR1O	DN	2-(2,4-dichlorophenoxy)-5-ethylphenol
DMPSR1O	MI	TTNX2CS
DMPSR1O	MN	Plasmodium Enoyl-ACP reductase (Malaria fabI)
DMPSR1O	MT	DTT
DMPSR1O	MA	Inhibitor
DMPSR1O	RN	X-ray structural analysis of Plasmodium falciparum enoyl acyl carrier protein reductase as a pathway toward the optimization of triclosan antimalar... J Biol Chem. 2007 Aug 31;282(35):25436-44.
DMPSR1O	RU	https://pubmed.ncbi.nlm.nih.gov/17567585

DMKOFRE	DI	DMKOFRE
DMKOFRE	DN	2-(2,4-dichlorophenoxy)-5-isobutylphenol
DMKOFRE	MI	TTNX2CS
DMKOFRE	MN	Plasmodium Enoyl-ACP reductase (Malaria fabI)
DMKOFRE	MT	DTT
DMKOFRE	MA	Inhibitor
DMKOFRE	RN	Design and in silico screening of combinatorial library of antimalarial analogs of triclosan inhibiting Plasmodium falciparum enoyl-acyl carrier pr... Eur J Med Chem. 2009 Jul;44(7):3009-19.
DMKOFRE	RU	https://pubmed.ncbi.nlm.nih.gov/19217192

DME0LZ2	DI	DME0LZ2
DME0LZ2	DN	2-(2,4-dichlorophenoxy)-5-isopentylphenol
DME0LZ2	MI	TTNX2CS
DME0LZ2	MN	Plasmodium Enoyl-ACP reductase (Malaria fabI)
DME0LZ2	MT	DTT
DME0LZ2	MA	Inhibitor
DME0LZ2	RN	Design and in silico screening of combinatorial library of antimalarial analogs of triclosan inhibiting Plasmodium falciparum enoyl-acyl carrier pr... Eur J Med Chem. 2009 Jul;44(7):3009-19.
DME0LZ2	RU	https://pubmed.ncbi.nlm.nih.gov/19217192

DM1L3US	DI	DM1L3US
DM1L3US	DN	2-(2,4-dichlorophenoxy)-5-methylphenol
DM1L3US	MI	TTNX2CS
DM1L3US	MN	Plasmodium Enoyl-ACP reductase (Malaria fabI)
DM1L3US	MT	DTT
DM1L3US	MA	Inhibitor
DM1L3US	RN	X-ray structural analysis of Plasmodium falciparum enoyl acyl carrier protein reductase as a pathway toward the optimization of triclosan antimalar... J Biol Chem. 2007 Aug 31;282(35):25436-44.
DM1L3US	RU	https://pubmed.ncbi.nlm.nih.gov/17567585

DM6ZNR3	DI	DM6ZNR3
DM6ZNR3	DN	2-(2,4-dichlorophenoxy)-5-phenethylphenol
DM6ZNR3	MI	TTNX2CS
DM6ZNR3	MN	Plasmodium Enoyl-ACP reductase (Malaria fabI)
DM6ZNR3	MT	DTT
DM6ZNR3	MA	Inhibitor
DM6ZNR3	RN	Design and in silico screening of combinatorial library of antimalarial analogs of triclosan inhibiting Plasmodium falciparum enoyl-acyl carrier pr... Eur J Med Chem. 2009 Jul;44(7):3009-19.
DM6ZNR3	RU	https://pubmed.ncbi.nlm.nih.gov/19217192

DMKP974	DI	DMKP974
DMKP974	DN	2-(2,4-dichlorophenoxy)-5-propylphenol
DMKP974	MI	TTNX2CS
DMKP974	MN	Plasmodium Enoyl-ACP reductase (Malaria fabI)
DMKP974	MT	DTT
DMKP974	MA	Inhibitor
DMKP974	RN	X-ray structural analysis of Plasmodium falciparum enoyl acyl carrier protein reductase as a pathway toward the optimization of triclosan antimalar... J Biol Chem. 2007 Aug 31;282(35):25436-44.
DMKP974	RU	https://pubmed.ncbi.nlm.nih.gov/17567585

DMDUF21	DI	DMDUF21
DMDUF21	DN	2-(2,4-dichlorophenyl)-4,5-dihydro-1H-imidazole
DMDUF21	MI	TTGP7BY
DMDUF21	MN	Monoamine oxidase type B (MAO-B)
DMDUF21	MT	DTT
DMDUF21	MA	Inhibitor
DMDUF21	RN	Ultrasound promoted synthesis of 2-imidazolines in water: a greener approach toward monoamine oxidase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):546-9.
DMDUF21	RU	https://pubmed.ncbi.nlm.nih.gov/19064321

DMSND8U	DI	DMSND8U
DMSND8U	DN	2-(2,4-difluorophenyl)-2,2-diphenylacetamide
DMSND8U	MI	TTMNI76
DMSND8U	MN	Calcium-activated potassium channel (KCN)
DMSND8U	MT	DTT
DMSND8U	MA	Inhibitor
DMSND8U	RN	Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82.
DMSND8U	RU	https://pubmed.ncbi.nlm.nih.gov/18232633

DMG49N2	DI	DMG49N2
DMG49N2	DN	2-(2,4-diphenylthiazol-5-yl)acetic acid
DMG49N2	MI	TTQDMX5
DMG49N2	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMG49N2	MT	DTT
DMG49N2	MA	Inhibitor
DMG49N2	RN	Novel selective thiazoleacetic acids as CRTH2 antagonists developed from in silico derived hits. Part 1. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1177-80.
DMG49N2	RU	https://pubmed.ncbi.nlm.nih.gov/20031403

DM7JUK0	DI	DM7JUK0
DM7JUK0	DN	2-(2,6-Dimethyl-benzyl)-4,5-dihydro-1H-imidazole
DM7JUK0	MI	TT6MSOK
DM7JUK0	MN	5-HT 1D receptor (HTR1D)
DM7JUK0	MT	DTT
DM7JUK0	MA	Inhibitor
DM7JUK0	RN	2-(Anilino)imidazolines and 2-(benzyl)imidazoline derivatives as h5-HT1D serotonin receptor ligands. Bioorg Med Chem Lett. 2004 Sep 20;14(18):4697-9.
DM7JUK0	RU	https://pubmed.ncbi.nlm.nih.gov/15324890

DMITKZY	DI	DMITKZY
DMITKZY	DN	2-(2-acetyl-4-bromophenoxy)acetic acid
DMITKZY	MI	TTQDMX5
DMITKZY	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMITKZY	MT	DTT
DMITKZY	MA	Inhibitor
DMITKZY	RN	Novel selective orally active CRTH2 antagonists for allergic inflammation developed from in silico derived hits. J Med Chem. 2006 Nov 16;49(23):6638-41.
DMITKZY	RU	https://pubmed.ncbi.nlm.nih.gov/17154491

DMP1KZW	DI	DMP1KZW
DMP1KZW	DN	2-(2-adamantyl) piperidine
DMP1KZW	MI	TTXT3PU
DMP1KZW	MN	Influenza M2 protein (Influ M)
DMP1KZW	MT	DTT
DMP1KZW	MA	Inhibitor
DMP1KZW	RN	Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25.
DMP1KZW	RU	https://pubmed.ncbi.nlm.nih.gov/17139286

DMXDGEF	DI	DMXDGEF
DMXDGEF	DN	2-(2-allyl-4-chlorophenoxy)acetic acid
DMXDGEF	MI	TTQDMX5
DMXDGEF	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMXDGEF	MT	DTT
DMXDGEF	MA	Inhibitor
DMXDGEF	RN	2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4347-50.
DMXDGEF	RU	https://pubmed.ncbi.nlm.nih.gov/17531480

DMVTD1F	DI	DMVTD1F
DMVTD1F	DN	2-(2'-Aminoethyl)-5-benzyltetrahydrofuran
DMVTD1F	MI	TTVBI8W
DMVTD1F	MN	Dopamine transporter (DAT)
DMVTD1F	MT	DTT
DMVTD1F	MA	Inhibitor
DMVTD1F	RN	2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68.
DMVTD1F	RU	https://pubmed.ncbi.nlm.nih.gov/19201198

DMVTD1F	DI	DMVTD1F
DMVTD1F	DN	2-(2'-Aminoethyl)-5-benzyltetrahydrofuran
DMVTD1F	MI	TTAWNKZ
DMVTD1F	MN	Norepinephrine transporter (NET)
DMVTD1F	MT	DTT
DMVTD1F	MA	Inhibitor
DMVTD1F	RN	2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68.
DMVTD1F	RU	https://pubmed.ncbi.nlm.nih.gov/19201198

DMVTD1F	DI	DMVTD1F
DMVTD1F	DN	2-(2'-Aminoethyl)-5-benzyltetrahydrofuran
DMVTD1F	MI	TT3ROYC
DMVTD1F	MN	Serotonin transporter (SERT)
DMVTD1F	MT	DTT
DMVTD1F	MA	Inhibitor
DMVTD1F	RN	2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68.
DMVTD1F	RU	https://pubmed.ncbi.nlm.nih.gov/19201198

DM3JM7V	DI	DM3JM7V
DM3JM7V	DN	2-(2-Amino-ethyl)-7-imino-azepane
DM3JM7V	MI	TTZUFI5
DM3JM7V	MN	Nitric-oxide synthase brain (NOS1)
DM3JM7V	MT	DTT
DM3JM7V	MA	Inhibitor
DM3JM7V	RN	Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3.
DM3JM7V	RU	https://pubmed.ncbi.nlm.nih.gov/11551770

DM3JM7V	DI	DM3JM7V
DM3JM7V	DN	2-(2-Amino-ethyl)-7-imino-azepane
DM3JM7V	MI	TTF10I9
DM3JM7V	MN	Nitric-oxide synthase inducible (NOS2)
DM3JM7V	MT	DTT
DM3JM7V	MA	Inhibitor
DM3JM7V	RN	Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3.
DM3JM7V	RU	https://pubmed.ncbi.nlm.nih.gov/11551770

DMDFYJR	DI	DMDFYJR
DMDFYJR	DN	2-(2-Aminoethyl)anthra[1,9-cd]pyrazol-6(2H)-one
DMDFYJR	MI	TT0IHXV
DMDFYJR	MN	DNA topoisomerase II (TOP2)
DMDFYJR	MT	DTT
DMDFYJR	MA	Inhibitor
DMDFYJR	RN	Design, synthesis and biological evaluation of a novel series of anthrapyrazoles linked with netropsin-like oligopyrrole carboxamides as anticancer... Bioorg Med Chem. 2010 Jun 1;18(11):3974-84.
DMDFYJR	RU	https://pubmed.ncbi.nlm.nih.gov/20471276

DMM9A8G	DI	DMM9A8G
DMM9A8G	DN	2-(2-aminophenoxy)-5-hexylphenol
DMM9A8G	MI	TTVTX4N
DMM9A8G	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DMM9A8G	MT	DTT
DMM9A8G	MA	Inhibitor
DMM9A8G	RN	Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33.
DMM9A8G	RU	https://pubmed.ncbi.nlm.nih.gov/18457948

DM0CWHT	DI	DM0CWHT
DM0CWHT	DN	2-(2-Amino-phenyl)-6-methyl-chromen-4-one
DM0CWHT	MI	TTNJYV2
DM0CWHT	MN	Gamma-aminobutyric acid receptor (GAR)
DM0CWHT	MT	DTT
DM0CWHT	MA	Inhibitor
DM0CWHT	RN	Refinement and evaluation of a pharmacophore model for flavone derivatives binding to the benzodiazepine site of the GABA(A) receptor. J Med Chem. 2002 Sep 12;45(19):4188-201.
DM0CWHT	RU	https://pubmed.ncbi.nlm.nih.gov/12213060

DMCLSJZ	DI	DMCLSJZ
DMCLSJZ	DN	2-(2-aminophenyl)-6-morpholino-4H-pyran-4-one
DMCLSJZ	MI	TTK3PY9
DMCLSJZ	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMCLSJZ	MT	DTT
DMCLSJZ	MA	Inhibitor
DMCLSJZ	RN	Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72.
DMCLSJZ	RU	https://pubmed.ncbi.nlm.nih.gov/17371003

DMZNRFG	DI	DMZNRFG
DMZNRFG	DN	2-(2-Amino-propyl)-5-bromo-4-methoxy-phenol
DMZNRFG	MI	TTSQIFT
DMZNRFG	MN	5-HT 1A receptor (HTR1A)
DMZNRFG	MT	DTT
DMZNRFG	MA	Inhibitor
DMZNRFG	RN	5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. J Med Chem. 1986 Feb;29(2):194-9.
DMZNRFG	RU	https://pubmed.ncbi.nlm.nih.gov/3950904

DMZNRFG	DI	DMZNRFG
DMZNRFG	DN	2-(2-Amino-propyl)-5-bromo-4-methoxy-phenol
DMZNRFG	MI	TT6MSOK
DMZNRFG	MN	5-HT 1D receptor (HTR1D)
DMZNRFG	MT	DTT
DMZNRFG	MA	Inhibitor
DMZNRFG	RN	5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. J Med Chem. 1986 Feb;29(2):194-9.
DMZNRFG	RU	https://pubmed.ncbi.nlm.nih.gov/3950904

DMZNRFG	DI	DMZNRFG
DMZNRFG	DN	2-(2-Amino-propyl)-5-bromo-4-methoxy-phenol
DMZNRFG	MI	TTJQOD7
DMZNRFG	MN	5-HT 2A receptor (HTR2A)
DMZNRFG	MT	DTT
DMZNRFG	MA	Inhibitor
DMZNRFG	RN	5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. J Med Chem. 1986 Feb;29(2):194-9.
DMZNRFG	RU	https://pubmed.ncbi.nlm.nih.gov/3950904

DMN6IV2	DI	DMN6IV2
DMN6IV2	DN	2-(2-benzhydryl-4-phenylthiazol-5-yl)acetic acid
DMN6IV2	MI	TTQDMX5
DMN6IV2	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMN6IV2	MT	DTT
DMN6IV2	MA	Inhibitor
DMN6IV2	RN	Novel selective thiazoleacetic acids as CRTH2 antagonists developed from in silico derived hits. Part 2. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1181-5.
DMN6IV2	RU	https://pubmed.ncbi.nlm.nih.gov/20022749

DMLOD2Y	DI	DMLOD2Y
DMLOD2Y	DN	2-(2-benzoyl-4-bromophenoxy)acetic acid
DMLOD2Y	MI	TTQDMX5
DMLOD2Y	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMLOD2Y	MT	DTT
DMLOD2Y	MA	Inhibitor
DMLOD2Y	RN	Novel selective orally active CRTH2 antagonists for allergic inflammation developed from in silico derived hits. J Med Chem. 2006 Nov 16;49(23):6638-41.
DMLOD2Y	RU	https://pubmed.ncbi.nlm.nih.gov/17154491

DMFK0GM	DI	DMFK0GM
DMFK0GM	DN	2-(2-bromo-2-naphthamido)benzoic acid
DMFK0GM	MI	TT3PQ2Y
DMFK0GM	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DMFK0GM	MT	DTT
DMFK0GM	MA	Inhibitor
DMFK0GM	RN	The first de novo designed inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. Bioorg Med Chem Lett. 2006 Jan 1;16(1):88-92.
DMFK0GM	RU	https://pubmed.ncbi.nlm.nih.gov/16236496

DM3VH7F	DI	DM3VH7F
DM3VH7F	DN	2-(2-Bromo-benzoyl)-cyclohexane-1,3-dione
DM3VH7F	MI	TT8DSFC
DM3VH7F	MN	Hydroxyphenylpyruvate dioxygenase (HPD)
DM3VH7F	MT	DTT
DM3VH7F	MA	Inhibitor
DM3VH7F	RN	SAR studies of 2-o-substituted-benzoyl- and 2-alkanoyl-cyclohexane-1,3-diones as inhibitors of 4-hydroxyphenylpyruvate dioxygenase. Bioorg Med Chem Lett. 2000 May 1;10(9):843-5.
DM3VH7F	RU	https://pubmed.ncbi.nlm.nih.gov/10853644

DMHBE0X	DI	DMHBE0X
DMHBE0X	DN	2-(2-Bromophenoxy)-N,N-dimethylethanamine
DMHBE0X	MI	TTO9X1H
DMHBE0X	MN	5-HT 7 receptor (HTR7)
DMHBE0X	MT	DTT
DMHBE0X	MA	Inhibitor
DMHBE0X	RN	SAR studies on new bis-aryls 5-HT7 ligands: Synthesis and molecular modeling. Bioorg Med Chem. 2010 Mar 1;18(5):1958-67.
DMHBE0X	RU	https://pubmed.ncbi.nlm.nih.gov/20138771

DMHJMUX	DI	DMHJMUX
DMHJMUX	DN	2-(2-Bromophenylthio)-N,N-dimethylethanamine
DMHJMUX	MI	TTO9X1H
DMHJMUX	MN	5-HT 7 receptor (HTR7)
DMHJMUX	MT	DTT
DMHJMUX	MA	Inhibitor
DMHJMUX	RN	SAR studies on new bis-aryls 5-HT7 ligands: Synthesis and molecular modeling. Bioorg Med Chem. 2010 Mar 1;18(5):1958-67.
DMHJMUX	RU	https://pubmed.ncbi.nlm.nih.gov/20138771

DMLTU3J	DI	DMLTU3J
DMLTU3J	DN	2-(2-butoxypyrimidin-4-ylamino)benzoic acid
DMLTU3J	MI	TT0K6EO
DMLTU3J	MN	Stress-activated protein kinase JNK1 (JNK1)
DMLTU3J	MT	DTT
DMLTU3J	MA	Inhibitor
DMLTU3J	RN	Discovery of a new class of 4-anilinopyrimidines as potent c-Jun N-terminal kinase inhibitors: Synthesis and SAR studies. Bioorg Med Chem Lett. 2007 Feb 1;17(3):668-72.
DMLTU3J	RU	https://pubmed.ncbi.nlm.nih.gov/17107797

DMEGY0T	DI	DMEGY0T
DMEGY0T	DN	2-(2-carboxy-5-mercaptopentyl)benzoic acid
DMEGY0T	MI	TT9G4N0
DMEGY0T	MN	Glutamate carboxypeptidase II (GCPII)
DMEGY0T	MT	DTT
DMEGY0T	MA	Inhibitor
DMEGY0T	RN	Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1' side chain. J Med Chem. 2006 May 18;49(10):2876-85.
DMEGY0T	RU	https://pubmed.ncbi.nlm.nih.gov/16686531

DMR98ML	DI	DMR98ML
DMR98ML	DN	2-(2-carboxy-7-mercaptoheptyl)benzoic acid
DMR98ML	MI	TT9G4N0
DMR98ML	MN	Glutamate carboxypeptidase II (GCPII)
DMR98ML	MT	DTT
DMR98ML	MA	Inhibitor
DMR98ML	RN	Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1' side chain. J Med Chem. 2006 May 18;49(10):2876-85.
DMR98ML	RU	https://pubmed.ncbi.nlm.nih.gov/16686531

DMWDV71	DI	DMWDV71
DMWDV71	DN	2-(2-Chloro-4-hydroxy-phenyl)-benzooxazol-5-ol
DMWDV71	MI	TTZAYWL
DMWDV71	MN	Estrogen receptor (ESR)
DMWDV71	MT	DTT
DMWDV71	MA	Inhibitor
DMWDV71	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMWDV71	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMWDV71	DI	DMWDV71
DMWDV71	DN	2-(2-Chloro-4-hydroxy-phenyl)-benzooxazol-5-ol
DMWDV71	MI	TTOM3J0
DMWDV71	MN	Estrogen receptor beta (ESR2)
DMWDV71	MT	DTT
DMWDV71	MA	Inhibitor
DMWDV71	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMWDV71	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMG6ABE	DI	DMG6ABE
DMG6ABE	DN	2-(2-Chloro-benzoyl)-cyclohexane-1,3-dione
DMG6ABE	MI	TT8DSFC
DMG6ABE	MN	Hydroxyphenylpyruvate dioxygenase (HPD)
DMG6ABE	MT	DTT
DMG6ABE	MA	Inhibitor
DMG6ABE	RN	SAR studies of 2-o-substituted-benzoyl- and 2-alkanoyl-cyclohexane-1,3-diones as inhibitors of 4-hydroxyphenylpyruvate dioxygenase. Bioorg Med Chem Lett. 2000 May 1;10(9):843-5.
DMG6ABE	RU	https://pubmed.ncbi.nlm.nih.gov/10853644

DM1ULEX	DI	DM1ULEX
DM1ULEX	DN	2-(2-chlorophenoxy)-3-(piperidin-4-yl)pyridine
DM1ULEX	MI	TTSQIFT
DM1ULEX	MN	5-HT 1A receptor (HTR1A)
DM1ULEX	MT	DTT
DM1ULEX	MA	Inhibitor
DM1ULEX	RN	Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7.
DM1ULEX	RU	https://pubmed.ncbi.nlm.nih.gov/20031410

DM1ULEX	DI	DM1ULEX
DM1ULEX	DN	2-(2-chlorophenoxy)-3-(piperidin-4-yl)pyridine
DM1ULEX	MI	TTVBI8W
DM1ULEX	MN	Dopamine transporter (DAT)
DM1ULEX	MT	DTT
DM1ULEX	MA	Inhibitor
DM1ULEX	RN	Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7.
DM1ULEX	RU	https://pubmed.ncbi.nlm.nih.gov/20031410

DM1ULEX	DI	DM1ULEX
DM1ULEX	DN	2-(2-chlorophenoxy)-3-(piperidin-4-yl)pyridine
DM1ULEX	MI	TTAWNKZ
DM1ULEX	MN	Norepinephrine transporter (NET)
DM1ULEX	MT	DTT
DM1ULEX	MA	Inhibitor
DM1ULEX	RN	Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7.
DM1ULEX	RU	https://pubmed.ncbi.nlm.nih.gov/20031410

DM1ULEX	DI	DM1ULEX
DM1ULEX	DN	2-(2-chlorophenoxy)-3-(piperidin-4-yl)pyridine
DM1ULEX	MI	TT3ROYC
DM1ULEX	MN	Serotonin transporter (SERT)
DM1ULEX	MT	DTT
DM1ULEX	MA	Inhibitor
DM1ULEX	RN	Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7.
DM1ULEX	RU	https://pubmed.ncbi.nlm.nih.gov/20031410

DM60RWZ	DI	DM60RWZ
DM60RWZ	DN	2-(2-chlorophenyl)-2,2-diphenylethanamide
DM60RWZ	MI	TTMNI76
DM60RWZ	MN	Calcium-activated potassium channel (KCN)
DM60RWZ	MT	DTT
DM60RWZ	MA	Inhibitor
DM60RWZ	RN	Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82.
DM60RWZ	RU	https://pubmed.ncbi.nlm.nih.gov/18232633

DMTYDX2	DI	DMTYDX2
DMTYDX2	DN	2-(2-Chlorophenyl)-2H-indazole-7-carboxamide
DMTYDX2	MI	TTVDSZ0
DMTYDX2	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMTYDX2	MT	DTT
DMTYDX2	MA	Inhibitor
DMTYDX2	RN	Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor effica... J Med Chem. 2009 Nov 26;52(22):7170-85.
DMTYDX2	RU	https://pubmed.ncbi.nlm.nih.gov/19873981

DMFG2S5	DI	DMFG2S5
DMFG2S5	DN	2-(2-chlorophenyl)-2-morpholinoethanamine
DMFG2S5	MI	TTDIGC1
DMFG2S5	MN	Dipeptidyl peptidase 4 (DPP-4)
DMFG2S5	MT	DTT
DMFG2S5	MA	Inhibitor
DMFG2S5	RN	In silico fragment-based discovery of DPP-IV S1 pocket binders. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1405-9.
DMFG2S5	RU	https://pubmed.ncbi.nlm.nih.gov/16321524

DMJ38LE	DI	DMJ38LE
DMJ38LE	DN	2-(2-chlorophenylamino)-5-methylthiazol-4(5H)-one
DMJ38LE	MI	TTN7BL9
DMJ38LE	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMJ38LE	MT	DTT
DMJ38LE	MA	Inhibitor
DMJ38LE	RN	The discovery of 2-anilinothiazolones as 11beta-HSD1 inhibitors. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6056-61.
DMJ38LE	RU	https://pubmed.ncbi.nlm.nih.gov/17919905

DM187UQ	DI	DM187UQ
DM187UQ	DN	2-(2-cycloheptylidenehydrazinyl)-4-phenylthiazole
DM187UQ	MI	TT3WG5C
DM187UQ	MN	Monoamine oxidase type A (MAO-A)
DM187UQ	MT	DTT
DM187UQ	MA	Inhibitor
DM187UQ	RN	Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Jul 15;18(14):5063-70. 
DM187UQ	RU	https://pubmed.ncbi.nlm.nih.gov/20579890

DM187UQ	DI	DM187UQ
DM187UQ	DN	2-(2-cycloheptylidenehydrazinyl)-4-phenylthiazole
DM187UQ	MI	TTGP7BY
DM187UQ	MN	Monoamine oxidase type B (MAO-B)
DM187UQ	MT	DTT
DM187UQ	MA	Inhibitor
DM187UQ	RN	Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Jul 15;18(14):5063-70. 
DM187UQ	RU	https://pubmed.ncbi.nlm.nih.gov/20579890

DMUN2CS	DI	DMUN2CS
DMUN2CS	DN	2-(2-cyclohexyl-4-fluorophenoxy)acetic acid
DMUN2CS	MI	TTQDMX5
DMUN2CS	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMUN2CS	MT	DTT
DMUN2CS	MA	Inhibitor
DMUN2CS	RN	2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4347-50.
DMUN2CS	RU	https://pubmed.ncbi.nlm.nih.gov/17531480

DMSI07M	DI	DMSI07M
DMSI07M	DN	2-(2-cyclohexyl-4-methoxyphenoxy)acetic acid
DMSI07M	MI	TTQDMX5
DMSI07M	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMSI07M	MT	DTT
DMSI07M	MA	Inhibitor
DMSI07M	RN	2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4347-50.
DMSI07M	RU	https://pubmed.ncbi.nlm.nih.gov/17531480

DMVCY42	DI	DMVCY42
DMVCY42	DN	2-(2-cyclohexyl-4-methylphenoxy)acetic acid
DMVCY42	MI	TTQDMX5
DMVCY42	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMVCY42	MT	DTT
DMVCY42	MA	Inhibitor
DMVCY42	RN	2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4347-50.
DMVCY42	RU	https://pubmed.ncbi.nlm.nih.gov/17531480

DMPNGXE	DI	DMPNGXE
DMPNGXE	DN	2-(2-cyclohexylidenehydrazinyl)-4-phenylthiazole
DMPNGXE	MI	TTGP7BY
DMPNGXE	MN	Monoamine oxidase type B (MAO-B)
DMPNGXE	MT	DTT
DMPNGXE	MA	Inhibitor
DMPNGXE	RN	Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Jul 15;18(14):5063-70. 
DMPNGXE	RU	https://pubmed.ncbi.nlm.nih.gov/20579890

DMTFWAQ	DI	DMTFWAQ
DMTFWAQ	DN	2-(2-cyclohexylidenehydrazinyl)-4-p-tolylthiazole
DMTFWAQ	MI	TTGP7BY
DMTFWAQ	MN	Monoamine oxidase type B (MAO-B)
DMTFWAQ	MT	DTT
DMTFWAQ	MA	Inhibitor
DMTFWAQ	RN	Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Jul 15;18(14):5063-70. 
DMTFWAQ	RU	https://pubmed.ncbi.nlm.nih.gov/20579890

DM81WJK	DI	DM81WJK
DM81WJK	DN	2-(2-cyclohexylphenoxy)acetic acid
DM81WJK	MI	TTQDMX5
DM81WJK	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DM81WJK	MT	DTT
DM81WJK	MA	Inhibitor
DM81WJK	RN	2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4347-50.
DM81WJK	RU	https://pubmed.ncbi.nlm.nih.gov/17531480

DMH1VCE	DI	DMH1VCE
DMH1VCE	DN	2-(2-cyclopentylidenehydrazinyl)-4-phenylthiazole
DMH1VCE	MI	TT3WG5C
DMH1VCE	MN	Monoamine oxidase type A (MAO-A)
DMH1VCE	MT	DTT
DMH1VCE	MA	Inhibitor
DMH1VCE	RN	Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Jul 15;18(14):5063-70. 
DMH1VCE	RU	https://pubmed.ncbi.nlm.nih.gov/20579890

DMH1VCE	DI	DMH1VCE
DMH1VCE	DN	2-(2-cyclopentylidenehydrazinyl)-4-phenylthiazole
DMH1VCE	MI	TTGP7BY
DMH1VCE	MN	Monoamine oxidase type B (MAO-B)
DMH1VCE	MT	DTT
DMH1VCE	MA	Inhibitor
DMH1VCE	RN	Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Jul 15;18(14):5063-70. 
DMH1VCE	RU	https://pubmed.ncbi.nlm.nih.gov/20579890

DM1SN37	DI	DM1SN37
DM1SN37	DN	2-(2-fluorophenoxy)-3-(piperidin-4-yl)pyridine
DM1SN37	MI	TTSQIFT
DM1SN37	MN	5-HT 1A receptor (HTR1A)
DM1SN37	MT	DTT
DM1SN37	MA	Inhibitor
DM1SN37	RN	Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7.
DM1SN37	RU	https://pubmed.ncbi.nlm.nih.gov/20031410

DM1SN37	DI	DM1SN37
DM1SN37	DN	2-(2-fluorophenoxy)-3-(piperidin-4-yl)pyridine
DM1SN37	MI	TTAWNKZ
DM1SN37	MN	Norepinephrine transporter (NET)
DM1SN37	MT	DTT
DM1SN37	MA	Inhibitor
DM1SN37	RN	Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7.
DM1SN37	RU	https://pubmed.ncbi.nlm.nih.gov/20031410

DM1SN37	DI	DM1SN37
DM1SN37	DN	2-(2-fluorophenoxy)-3-(piperidin-4-yl)pyridine
DM1SN37	MI	TT3ROYC
DM1SN37	MN	Serotonin transporter (SERT)
DM1SN37	MT	DTT
DM1SN37	MA	Inhibitor
DM1SN37	RN	Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7.
DM1SN37	RU	https://pubmed.ncbi.nlm.nih.gov/20031410

DMDUG9M	DI	DMDUG9M
DMDUG9M	DN	2-(2-Fluoro-phenyl)-benzo[h]chromen-4-one
DMDUG9M	MI	TTK3PY9
DMDUG9M	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMDUG9M	MT	DTT
DMDUG9M	MA	Inhibitor
DMDUG9M	RN	Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85.
DMDUG9M	RU	https://pubmed.ncbi.nlm.nih.gov/15658870

DMMEBH3	DI	DMMEBH3
DMMEBH3	DN	2-(2-formylphenoxy)acetic acid
DMMEBH3	MI	TTQDMX5
DMMEBH3	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMMEBH3	MT	DTT
DMMEBH3	MA	Inhibitor
DMMEBH3	RN	Novel selective orally active CRTH2 antagonists for allergic inflammation developed from in silico derived hits. J Med Chem. 2006 Nov 16;49(23):6638-41.
DMMEBH3	RU	https://pubmed.ncbi.nlm.nih.gov/17154491

DMXGWOT	DI	DMXGWOT
DMXGWOT	DN	2-(2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-amine
DMXGWOT	MI	TTK25J1
DMXGWOT	MN	Adenosine A1 receptor (ADORA1)
DMXGWOT	MT	DTT
DMXGWOT	MA	Inhibitor
DMXGWOT	RN	Identification of novel, water-soluble, 2-amino-N-pyrimidin-4-yl acetamides as A2A receptor antagonists with in vivo efficacy. J Med Chem. 2008 Feb 14;51(3):400-6.
DMXGWOT	RU	https://pubmed.ncbi.nlm.nih.gov/18189346

DMXGWOT	DI	DMXGWOT
DMXGWOT	DN	2-(2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-amine
DMXGWOT	MI	TTM2AOE
DMXGWOT	MN	Adenosine A2a receptor (ADORA2A)
DMXGWOT	MT	DTT
DMXGWOT	MA	Inhibitor
DMXGWOT	RN	Identification of novel, water-soluble, 2-amino-N-pyrimidin-4-yl acetamides as A2A receptor antagonists with in vivo efficacy. J Med Chem. 2008 Feb 14;51(3):400-6.
DMXGWOT	RU	https://pubmed.ncbi.nlm.nih.gov/18189346

DMSI41E	DI	DMSI41E
DMSI41E	DN	2-(2-hexylphenyl)isoindoline-1,3-dione
DMSI41E	MI	TTECBXN
DMSI41E	MN	Oxysterols receptor LXR-alpha (NR1H3)
DMSI41E	MT	DTT
DMSI41E	MA	Inhibitor
DMSI41E	RN	Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85.
DMSI41E	RU	https://pubmed.ncbi.nlm.nih.gov/18343126

DMMEL39	DI	DMMEL39
DMMEL39	DN	2-(2-Hydroxycarbamoyl-ethyl)-pentanedioic acid
DMMEL39	MI	TT9G4N0
DMMEL39	MN	Glutamate carboxypeptidase II (GCPII)
DMMEL39	MT	DTT
DMMEL39	MA	Inhibitor
DMMEL39	RN	Synthesis and biological evaluation of hydroxamate-Based inhibitors of glutamate carboxypeptidase II. Bioorg Med Chem Lett. 2003 Jul 7;13(13):2097-100.
DMMEL39	RU	https://pubmed.ncbi.nlm.nih.gov/12798312

DMRPCL7	DI	DMRPCL7
DMRPCL7	DN	2-(2-Hydroxyethyl)anthra[1,9-cd]pyrazol-6(2H)-one
DMRPCL7	MI	TT0IHXV
DMRPCL7	MN	DNA topoisomerase II (TOP2)
DMRPCL7	MT	DTT
DMRPCL7	MA	Inhibitor
DMRPCL7	RN	Design, synthesis and biological evaluation of a novel series of anthrapyrazoles linked with netropsin-like oligopyrrole carboxamides as anticancer... Bioorg Med Chem. 2010 Jun 1;18(11):3974-84.
DMRPCL7	RU	https://pubmed.ncbi.nlm.nih.gov/20471276

DM3UMYD	DI	DM3UMYD
DM3UMYD	DN	2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine
DM3UMYD	MI	TT2WR1T
DM3UMYD	MN	Cationic trypsinogen (PRSS1)
DM3UMYD	MT	DTT
DM3UMYD	MA	Inhibitor
DM3UMYD	RN	Development of serine protease inhibitors displaying a multicentered short (&lt;2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasmi... J Med Chem. 2001 Aug 16;44(17):2753-71.
DM3UMYD	RU	https://pubmed.ncbi.nlm.nih.gov/11495587

DM3UMYD	DI	DM3UMYD
DM3UMYD	DN	2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine
DM3UMYD	MI	TT6L509
DM3UMYD	MN	Coagulation factor IIa (F2)
DM3UMYD	MT	DTT
DM3UMYD	MA	Inhibitor
DM3UMYD	RN	Development of serine protease inhibitors displaying a multicentered short (&lt;2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasmi... J Med Chem. 2001 Aug 16;44(17):2753-71.
DM3UMYD	RU	https://pubmed.ncbi.nlm.nih.gov/11495587

DM3UMYD	DI	DM3UMYD
DM3UMYD	DN	2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine
DM3UMYD	MI	TTP86E2
DM3UMYD	MN	Plasminogen (PLG)
DM3UMYD	MT	DTT
DM3UMYD	MA	Inhibitor
DM3UMYD	RN	Development of serine protease inhibitors displaying a multicentered short (&lt;2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasmi... J Med Chem. 2001 Aug 16;44(17):2753-71.
DM3UMYD	RU	https://pubmed.ncbi.nlm.nih.gov/11495587

DM3UMYD	DI	DM3UMYD
DM3UMYD	DN	2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine
DM3UMYD	MI	TTXAGYU
DM3UMYD	MN	Tissue-type plasminogen activator (PLAT)
DM3UMYD	MT	DTT
DM3UMYD	MA	Inhibitor
DM3UMYD	RN	Development of serine protease inhibitors displaying a multicentered short (&lt;2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasmi... J Med Chem. 2001 Aug 16;44(17):2753-71.
DM3UMYD	RU	https://pubmed.ncbi.nlm.nih.gov/11495587

DM3UMYD	DI	DM3UMYD
DM3UMYD	DN	2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine
DM3UMYD	MI	TTGY7WI
DM3UMYD	MN	Urokinase-type plasminogen activator (PLAU)
DM3UMYD	MT	DTT
DM3UMYD	MA	Inhibitor
DM3UMYD	RN	Development of serine protease inhibitors displaying a multicentered short (&lt;2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasmi... J Med Chem. 2001 Aug 16;44(17):2753-71.
DM3UMYD	RU	https://pubmed.ncbi.nlm.nih.gov/11495587

DMOANXP	DI	DMOANXP
DMOANXP	DN	2-(2-Hydroxy-phenyl)-6-methyl-chromen-4-one
DMOANXP	MI	TTNJYV2
DMOANXP	MN	Gamma-aminobutyric acid receptor (GAR)
DMOANXP	MT	DTT
DMOANXP	MA	Inhibitor
DMOANXP	RN	Refinement and evaluation of a pharmacophore model for flavone derivatives binding to the benzodiazepine site of the GABA(A) receptor. J Med Chem. 2002 Sep 12;45(19):4188-201.
DMOANXP	RU	https://pubmed.ncbi.nlm.nih.gov/12213060

DMCLIN8	DI	DMCLIN8
DMCLIN8	DN	2-(2''-indolylethyloxy)adenosine
DMCLIN8	MI	TTK25J1
DMCLIN8	MN	Adenosine A1 receptor (ADORA1)
DMCLIN8	MT	DTT
DMCLIN8	MA	Inhibitor
DMCLIN8	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DMCLIN8	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DMCLIN8	DI	DMCLIN8
DMCLIN8	DN	2-(2''-indolylethyloxy)adenosine
DMCLIN8	MI	TTM2AOE
DMCLIN8	MN	Adenosine A2a receptor (ADORA2A)
DMCLIN8	MT	DTT
DMCLIN8	MA	Inhibitor
DMCLIN8	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DMCLIN8	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DMCLIN8	DI	DMCLIN8
DMCLIN8	DN	2-(2''-indolylethyloxy)adenosine
DMCLIN8	MI	TTJFY5U
DMCLIN8	MN	Adenosine A3 receptor (ADORA3)
DMCLIN8	MT	DTT
DMCLIN8	MA	Inhibitor
DMCLIN8	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DMCLIN8	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DMSVHU9	DI	DMSVHU9
DMSVHU9	DN	2-(2-Iodo-benzoyl)-cyclohexane-1,3-dione
DMSVHU9	MI	TT8DSFC
DMSVHU9	MN	Hydroxyphenylpyruvate dioxygenase (HPD)
DMSVHU9	MT	DTT
DMSVHU9	MA	Inhibitor
DMSVHU9	RN	SAR studies of 2-o-substituted-benzoyl- and 2-alkanoyl-cyclohexane-1,3-diones as inhibitors of 4-hydroxyphenylpyruvate dioxygenase. Bioorg Med Chem Lett. 2000 May 1;10(9):843-5.
DMSVHU9	RU	https://pubmed.ncbi.nlm.nih.gov/10853644

DMPA4S0	DI	DMPA4S0
DMPA4S0	DN	2-(2-Iodo-phenyl)-benzo[d][1,3]oxazin-4-one
DMPA4S0	MI	TT2WR1T
DMPA4S0	MN	Cationic trypsinogen (PRSS1)
DMPA4S0	MT	DTT
DMPA4S0	MA	Inhibitor
DMPA4S0	RN	2-amino-4H-3,1-benzoxazin-4-ones as inhibitors of C1r serine protease. J Med Chem. 1998 Mar 26;41(7):1060-7.
DMPA4S0	RU	https://pubmed.ncbi.nlm.nih.gov/9544206

DMGELY0	DI	DMGELY0
DMGELY0	DN	2-(2-Mercapto-ethyl)-pentanedioic acid
DMGELY0	MI	TT9G4N0
DMGELY0	MN	Glutamate carboxypeptidase II (GCPII)
DMGELY0	MT	DTT
DMGELY0	MA	Inhibitor
DMGELY0	RN	Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. J Med Chem. 2003 May 8;46(10):1989-96.
DMGELY0	RU	https://pubmed.ncbi.nlm.nih.gov/12723961

DMESMBO	DI	DMESMBO
DMESMBO	DN	2-(2-Methoxy-benzoyl)-cyclohexane-1,3-dione
DMESMBO	MI	TT8DSFC
DMESMBO	MN	Hydroxyphenylpyruvate dioxygenase (HPD)
DMESMBO	MT	DTT
DMESMBO	MA	Inhibitor
DMESMBO	RN	SAR studies of 2-o-substituted-benzoyl- and 2-alkanoyl-cyclohexane-1,3-diones as inhibitors of 4-hydroxyphenylpyruvate dioxygenase. Bioorg Med Chem Lett. 2000 May 1;10(9):843-5.
DMESMBO	RU	https://pubmed.ncbi.nlm.nih.gov/10853644

DM9Z8V5	DI	DM9Z8V5
DM9Z8V5	DN	2-(2-Methoxybenzyl)-3H-benzo[f]chromen-3-one
DM9Z8V5	MI	TTMSFAW
DM9Z8V5	MN	Cannabinoid receptor 2 (CB2)
DM9Z8V5	MT	DTT
DM9Z8V5	MA	Inhibitor
DM9Z8V5	RN	Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists. Bioorg Med Chem. 2009 Apr 1;17(7):2842-51.
DM9Z8V5	RU	https://pubmed.ncbi.nlm.nih.gov/19278853

DMYVDJQ	DI	DMYVDJQ
DMYVDJQ	DN	2-(2-methoxyphenoxy)-3-(piperidin-4-yl)pyridine
DMYVDJQ	MI	TTSQIFT
DMYVDJQ	MN	5-HT 1A receptor (HTR1A)
DMYVDJQ	MT	DTT
DMYVDJQ	MA	Inhibitor
DMYVDJQ	RN	Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7.
DMYVDJQ	RU	https://pubmed.ncbi.nlm.nih.gov/20031410

DMYVDJQ	DI	DMYVDJQ
DMYVDJQ	DN	2-(2-methoxyphenoxy)-3-(piperidin-4-yl)pyridine
DMYVDJQ	MI	TTVBI8W
DMYVDJQ	MN	Dopamine transporter (DAT)
DMYVDJQ	MT	DTT
DMYVDJQ	MA	Inhibitor
DMYVDJQ	RN	Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7.
DMYVDJQ	RU	https://pubmed.ncbi.nlm.nih.gov/20031410

DMYVDJQ	DI	DMYVDJQ
DMYVDJQ	DN	2-(2-methoxyphenoxy)-3-(piperidin-4-yl)pyridine
DMYVDJQ	MI	TTAWNKZ
DMYVDJQ	MN	Norepinephrine transporter (NET)
DMYVDJQ	MT	DTT
DMYVDJQ	MA	Inhibitor
DMYVDJQ	RN	Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7.
DMYVDJQ	RU	https://pubmed.ncbi.nlm.nih.gov/20031410

DMYVDJQ	DI	DMYVDJQ
DMYVDJQ	DN	2-(2-methoxyphenoxy)-3-(piperidin-4-yl)pyridine
DMYVDJQ	MI	TT3ROYC
DMYVDJQ	MN	Serotonin transporter (SERT)
DMYVDJQ	MT	DTT
DMYVDJQ	MA	Inhibitor
DMYVDJQ	RN	Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7.
DMYVDJQ	RU	https://pubmed.ncbi.nlm.nih.gov/20031410

DMXFYN8	DI	DMXFYN8
DMXFYN8	DN	2-(2-methoxyphenyl)-1H-indene
DMXFYN8	MI	TT8NGED
DMXFYN8	MN	Prostaglandin G/H synthase 1 (COX-1)
DMXFYN8	MT	DTT
DMXFYN8	MA	Inhibitor
DMXFYN8	RN	'Bridged' stilbene derivatives as selective cyclooxygenase-1 inhibitors. Bioorg Med Chem. 2007 Sep 15;15(18):6109-18.
DMXFYN8	RU	https://pubmed.ncbi.nlm.nih.gov/17604631

DMDI98B	DI	DMDI98B
DMDI98B	DN	2-(2-Methoxy-phenyl)-1-methyl-ethylamine
DMDI98B	MI	TTSQIFT
DMDI98B	MN	5-HT 1A receptor (HTR1A)
DMDI98B	MT	DTT
DMDI98B	MA	Inhibitor
DMDI98B	RN	5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. J Med Chem. 1986 Feb;29(2):194-9.
DMDI98B	RU	https://pubmed.ncbi.nlm.nih.gov/3950904

DMDI98B	DI	DMDI98B
DMDI98B	DN	2-(2-Methoxy-phenyl)-1-methyl-ethylamine
DMDI98B	MI	TT6MSOK
DMDI98B	MN	5-HT 1D receptor (HTR1D)
DMDI98B	MT	DTT
DMDI98B	MA	Inhibitor
DMDI98B	RN	5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. J Med Chem. 1986 Feb;29(2):194-9.
DMDI98B	RU	https://pubmed.ncbi.nlm.nih.gov/3950904

DMDI98B	DI	DMDI98B
DMDI98B	DN	2-(2-Methoxy-phenyl)-1-methyl-ethylamine
DMDI98B	MI	TTJQOD7
DMDI98B	MN	5-HT 2A receptor (HTR2A)
DMDI98B	MT	DTT
DMDI98B	MA	Inhibitor
DMDI98B	RN	5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. J Med Chem. 1986 Feb;29(2):194-9.
DMDI98B	RU	https://pubmed.ncbi.nlm.nih.gov/3950904

DMPVCDN	DI	DMPVCDN
DMPVCDN	DN	2-(2-Methoxy-phenyl)-6-methyl-chromen-4-one
DMPVCDN	MI	TTNJYV2
DMPVCDN	MN	Gamma-aminobutyric acid receptor (GAR)
DMPVCDN	MT	DTT
DMPVCDN	MA	Inhibitor
DMPVCDN	RN	Refinement and evaluation of a pharmacophore model for flavone derivatives binding to the benzodiazepine site of the GABA(A) receptor. J Med Chem. 2002 Sep 12;45(19):4188-201.
DMPVCDN	RU	https://pubmed.ncbi.nlm.nih.gov/12213060

DMXVCL0	DI	DMXVCL0
DMXVCL0	DN	2-(2-methoxyphenyl)-6-morpholino-4H-pyran-4-one
DMXVCL0	MI	TTK3PY9
DMXVCL0	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMXVCL0	MT	DTT
DMXVCL0	MA	Inhibitor
DMXVCL0	RN	Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72.
DMXVCL0	RU	https://pubmed.ncbi.nlm.nih.gov/17371003

DM4GN0E	DI	DM4GN0E
DM4GN0E	DN	2-(2-Methyl-benzoyl)-cyclohexane-1,3-dione
DM4GN0E	MI	TT8DSFC
DM4GN0E	MN	Hydroxyphenylpyruvate dioxygenase (HPD)
DM4GN0E	MT	DTT
DM4GN0E	MA	Inhibitor
DM4GN0E	RN	SAR studies of 2-o-substituted-benzoyl- and 2-alkanoyl-cyclohexane-1,3-diones as inhibitors of 4-hydroxyphenylpyruvate dioxygenase. Bioorg Med Chem Lett. 2000 May 1;10(9):843-5.
DM4GN0E	RU	https://pubmed.ncbi.nlm.nih.gov/10853644

DM7HN4Z	DI	DM7HN4Z
DM7HN4Z	DN	2-(2'-methyl-biphenyl-3-yl)-ethylamine
DM7HN4Z	MI	TTSQIFT
DM7HN4Z	MN	5-HT 1A receptor (HTR1A)
DM7HN4Z	MT	DTT
DM7HN4Z	MA	Inhibitor
DM7HN4Z	RN	Novel aminoethylbiphenyls as 5-HT7 receptor ligands. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3018-22.
DM7HN4Z	RU	https://pubmed.ncbi.nlm.nih.gov/17419056

DM7HN4Z	DI	DM7HN4Z
DM7HN4Z	DN	2-(2'-methyl-biphenyl-3-yl)-ethylamine
DM7HN4Z	MI	TTO9X1H
DM7HN4Z	MN	5-HT 7 receptor (HTR7)
DM7HN4Z	MT	DTT
DM7HN4Z	MA	Inhibitor
DM7HN4Z	RN	Novel aminoethylbiphenyls as 5-HT7 receptor ligands. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3018-22.
DM7HN4Z	RU	https://pubmed.ncbi.nlm.nih.gov/17419056

DMAHZR9	DI	DMAHZR9
DMAHZR9	DN	2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one
DMAHZR9	MI	TTK3PY9
DMAHZR9	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMAHZR9	MT	DTT
DMAHZR9	MA	Inhibitor
DMAHZR9	RN	Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6083-7.
DMAHZR9	RU	https://pubmed.ncbi.nlm.nih.gov/15546735

DMAHZR9	DI	DMAHZR9
DMAHZR9	DN	2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one
DMAHZR9	MI	TTCJG29
DMAHZR9	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMAHZR9	MT	DTT
DMAHZR9	MA	Inhibitor
DMAHZR9	RN	Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85.
DMAHZR9	RU	https://pubmed.ncbi.nlm.nih.gov/15658870

DMPH63G	DI	DMPH63G
DMPH63G	DN	2-(2-Methylpropanoyl)-1,3,5-benzenetriol
DMPH63G	MI	TT8NGED
DMPH63G	MN	Prostaglandin G/H synthase 1 (COX-1)
DMPH63G	MT	DTT
DMPH63G	MA	Inhibitor
DMPH63G	RN	Anti-inflammatory acylphloroglucinol derivatives from Hops (Humulus lupulus). J Nat Prod. 2005 Oct;68(10):1545-8.
DMPH63G	RU	https://pubmed.ncbi.nlm.nih.gov/16252923

DMW75IF	DI	DMW75IF
DMW75IF	DN	2-(2-methylquinolin-4-ylamino)-N-phenylacetamide
DMW75IF	MI	TTQW87Y
DMW75IF	MN	Opioid receptor kappa (OPRK1)
DMW75IF	MT	DTT
DMW75IF	MA	Inhibitor
DMW75IF	RN	Synthesis and characterizations of novel quinoline derivatives having mixed ligand activities at the kappa and mu receptors: Potential therapeutic ... Bioorg Med Chem. 2009 Aug 15;17(16):5782-90.
DMW75IF	RU	https://pubmed.ncbi.nlm.nih.gov/19640720

DMW75IF	DI	DMW75IF
DMW75IF	DN	2-(2-methylquinolin-4-ylamino)-N-phenylacetamide
DMW75IF	MI	TTKWM86
DMW75IF	MN	Opioid receptor mu (MOP)
DMW75IF	MT	DTT
DMW75IF	MA	Inhibitor
DMW75IF	RN	Synthesis and characterizations of novel quinoline derivatives having mixed ligand activities at the kappa and mu receptors: Potential therapeutic ... Bioorg Med Chem. 2009 Aug 15;17(16):5782-90.
DMW75IF	RU	https://pubmed.ncbi.nlm.nih.gov/19640720

DMENUIH	DI	DMENUIH
DMENUIH	DN	2-(2-methylquinolin-7-yl)benzonitrile
DMENUIH	MI	TTHS256
DMENUIH	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMENUIH	MT	DTT
DMENUIH	MA	Inhibitor
DMENUIH	RN	Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8.
DMENUIH	RU	https://pubmed.ncbi.nlm.nih.gov/17590335

DMIHTL0	DI	DMIHTL0
DMIHTL0	DN	2-(2-Methyl-thiazol-4-ylethynyl)-pyridine
DMIHTL0	MI	TTHS256
DMIHTL0	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMIHTL0	MT	DTT
DMIHTL0	MA	Inhibitor
DMIHTL0	RN	5-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-2,3'-bipyridine: a highly potent, orally active metabotropic glutamate subtype 5 (mGlu5) receptor antagonist... Bioorg Med Chem Lett. 2004 Aug 2;14(15):3993-6.
DMIHTL0	RU	https://pubmed.ncbi.nlm.nih.gov/15225713

DMN176Y	DI	DMN176Y
DMN176Y	DN	2-(2-naphthamido)benzoic acid
DMN176Y	MI	TT3PQ2Y
DMN176Y	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DMN176Y	MT	DTT
DMN176Y	MA	Inhibitor
DMN176Y	RN	The first de novo designed inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. Bioorg Med Chem Lett. 2006 Jan 1;16(1):88-92.
DMN176Y	RU	https://pubmed.ncbi.nlm.nih.gov/16236496

DMUJQX1	DI	DMUJQX1
DMUJQX1	DN	2-(2-Nitro-benzoyl)-cyclohexane-1,3-dione
DMUJQX1	MI	TT8DSFC
DMUJQX1	MN	Hydroxyphenylpyruvate dioxygenase (HPD)
DMUJQX1	MT	DTT
DMUJQX1	MA	Inhibitor
DMUJQX1	RN	SAR studies of 2-o-substituted-benzoyl- and 2-alkanoyl-cyclohexane-1,3-diones as inhibitors of 4-hydroxyphenylpyruvate dioxygenase. Bioorg Med Chem Lett. 2000 May 1;10(9):843-5.
DMUJQX1	RU	https://pubmed.ncbi.nlm.nih.gov/10853644

DM5NLQE	DI	DM5NLQE
DM5NLQE	DN	2-(2-phenethylphenyl)isoindoline-1,3-dione
DM5NLQE	MI	TTECBXN
DM5NLQE	MN	Oxysterols receptor LXR-alpha (NR1H3)
DM5NLQE	MT	DTT
DM5NLQE	MA	Inhibitor
DM5NLQE	RN	Separation of alpha-glucosidase-inhibitory and liver X receptor-antagonistic activities of phenethylphenyl phthalimide analogs and generation of LX... Bioorg Med Chem. 2009 Jul 15;17(14):5001-14.
DM5NLQE	RU	https://pubmed.ncbi.nlm.nih.gov/19539483

DME0HPA	DI	DME0HPA
DME0HPA	DN	2-(2-phenoxypyrimidin-4-ylamino)benzoic acid
DME0HPA	MI	TT0K6EO
DME0HPA	MN	Stress-activated protein kinase JNK1 (JNK1)
DME0HPA	MT	DTT
DME0HPA	MA	Inhibitor
DME0HPA	RN	Discovery of a new class of 4-anilinopyrimidines as potent c-Jun N-terminal kinase inhibitors: Synthesis and SAR studies. Bioorg Med Chem Lett. 2007 Feb 1;17(3):668-72.
DME0HPA	RU	https://pubmed.ncbi.nlm.nih.gov/17107797

DM1K0U5	DI	DM1K0U5
DM1K0U5	DN	2-(2-Phenyl-1H-indol-3-yl)-N,N-dipropyl-acetamide
DM1K0U5	MI	TTPTXIN
DM1K0U5	MN	Translocator protein (TSPO)
DM1K0U5	MT	DTT
DM1K0U5	MA	Inhibitor
DM1K0U5	RN	Chemistry, binding affinities, and behavioral properties of a new class of "antineophobic" mitochondrial DBI receptor complex (mDRC) ligands. J Med Chem. 1993 Oct 1;36(20):2908-20.
DM1K0U5	RU	https://pubmed.ncbi.nlm.nih.gov/8411007

DMO9SP1	DI	DMO9SP1
DMO9SP1	DN	2-(2-phenyl-2-(piperazin-1-yl)ethyl)benzonitrile
DMO9SP1	MI	TTAWNKZ
DMO9SP1	MN	Norepinephrine transporter (NET)
DMO9SP1	MT	DTT
DMO9SP1	MA	Inhibitor
DMO9SP1	RN	N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8.
DMO9SP1	RU	https://pubmed.ncbi.nlm.nih.gov/16750359

DMO9SP1	DI	DMO9SP1
DMO9SP1	DN	2-(2-phenyl-2-(piperazin-1-yl)ethyl)benzonitrile
DMO9SP1	MI	TT3ROYC
DMO9SP1	MN	Serotonin transporter (SERT)
DMO9SP1	MT	DTT
DMO9SP1	MA	Inhibitor
DMO9SP1	RN	N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8.
DMO9SP1	RU	https://pubmed.ncbi.nlm.nih.gov/16750359

DMQM6IA	DI	DMQM6IA
DMQM6IA	DN	2-(2-Phosphonooxy-ethyl)-pentanedioic acid
DMQM6IA	MI	TT9G4N0
DMQM6IA	MN	Glutamate carboxypeptidase II (GCPII)
DMQM6IA	MT	DTT
DMQM6IA	MA	Inhibitor
DMQM6IA	RN	Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. J Med Chem. 2003 May 8;46(10):1989-96.
DMQM6IA	RU	https://pubmed.ncbi.nlm.nih.gov/12723961

DMGVCKZ	DI	DMGVCKZ
DMGVCKZ	DN	2-(2-propoxypyrimidin-4-ylamino)benzoic acid
DMGVCKZ	MI	TT0K6EO
DMGVCKZ	MN	Stress-activated protein kinase JNK1 (JNK1)
DMGVCKZ	MT	DTT
DMGVCKZ	MA	Inhibitor
DMGVCKZ	RN	Discovery of a new class of 4-anilinopyrimidines as potent c-Jun N-terminal kinase inhibitors: Synthesis and SAR studies. Bioorg Med Chem Lett. 2007 Feb 1;17(3):668-72.
DMGVCKZ	RU	https://pubmed.ncbi.nlm.nih.gov/17107797

DMB4W68	DI	DMB4W68
DMB4W68	DN	2-(2-sec-butoxypyrimidin-4-ylamino)benzoic acid
DMB4W68	MI	TT0K6EO
DMB4W68	MN	Stress-activated protein kinase JNK1 (JNK1)
DMB4W68	MT	DTT
DMB4W68	MA	Inhibitor
DMB4W68	RN	Discovery of a new class of 4-anilinopyrimidines as potent c-Jun N-terminal kinase inhibitors: Synthesis and SAR studies. Bioorg Med Chem Lett. 2007 Feb 1;17(3):668-72.
DMB4W68	RU	https://pubmed.ncbi.nlm.nih.gov/17107797

DMRL65E	DI	DMRL65E
DMRL65E	DN	2-(2-thiazolyl)ethanamine
DMRL65E	MI	TTTIBOJ
DMRL65E	MN	Histamine H1 receptor (H1R)
DMRL65E	MT	DTT
DMRL65E	MA	Agonist
DMRL65E	RN	Multiple differences in agonist and antagonist pharmacology between human and guinea pig histamine H1-receptor. J Pharmacol Exp Ther. 2003 Jun;305(3):1104-15.
DMRL65E	RU	https://pubmed.ncbi.nlm.nih.gov/12626648

DMLJH92	DI	DMLJH92
DMLJH92	DN	2-(3-(2-methylquinolin-7-yl)phenyl)acetonitrile
DMLJH92	MI	TTHS256
DMLJH92	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMLJH92	MT	DTT
DMLJH92	MA	Inhibitor
DMLJH92	RN	Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8.
DMLJH92	RU	https://pubmed.ncbi.nlm.nih.gov/17590335

DMM9WB0	DI	DMM9WB0
DMM9WB0	DN	2-(3-(3,5-dichlorophenyl)ureido)benzoic acid
DMM9WB0	MI	TT3PQ2Y
DMM9WB0	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DMM9WB0	MT	DTT
DMM9WB0	MA	Inhibitor
DMM9WB0	RN	Discovery of novel inhibitors for DHODH via virtual screening and X-ray crystallographic structures. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1981-4.
DMM9WB0	RU	https://pubmed.ncbi.nlm.nih.gov/20153645

DMRX4HM	DI	DMRX4HM
DMRX4HM	DN	2-(3-(3-bromophenyl)ureido)-4-chlorobenzoic acid
DMRX4HM	MI	TT0MYE2
DMRX4HM	MN	Glutamate receptor ionotropic kainate 1 (GRIK1)
DMRX4HM	MT	DTT
DMRX4HM	MA	Inhibitor
DMRX4HM	RN	Bioisosteric modifications of 2-arylureidobenzoic acids: selective noncompetitive antagonists for the homomeric kainate receptor subtype GluR5. J Med Chem. 2004 Dec 30;47(27):6948-57.
DMRX4HM	RU	https://pubmed.ncbi.nlm.nih.gov/15615543

DM1VSOK	DI	DM1VSOK
DM1VSOK	DN	2-(3-(3-methoxyphenoxy)prop-1-ynyl)pyridine
DM1VSOK	MI	TTHS256
DM1VSOK	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM1VSOK	MT	DTT
DM1VSOK	MA	Inhibitor
DM1VSOK	RN	A new series of pyridinyl-alkynes as antagonists of the metabotropic glutamate receptor 5 (mGluR5). Bioorg Med Chem Lett. 2006 Sep 15;16(18):4792-5.
DM1VSOK	RU	https://pubmed.ncbi.nlm.nih.gov/16839764

DMXRHOY	DI	DMXRHOY
DMXRHOY	DN	2-(3''-(4''-bromo-indolyl)ethyloxy)adenosine
DMXRHOY	MI	TTK25J1
DMXRHOY	MN	Adenosine A1 receptor (ADORA1)
DMXRHOY	MT	DTT
DMXRHOY	MA	Inhibitor
DMXRHOY	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DMXRHOY	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DMXRHOY	DI	DMXRHOY
DMXRHOY	DN	2-(3''-(4''-bromo-indolyl)ethyloxy)adenosine
DMXRHOY	MI	TTM2AOE
DMXRHOY	MN	Adenosine A2a receptor (ADORA2A)
DMXRHOY	MT	DTT
DMXRHOY	MA	Inhibitor
DMXRHOY	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DMXRHOY	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DMXRHOY	DI	DMXRHOY
DMXRHOY	DN	2-(3''-(4''-bromo-indolyl)ethyloxy)adenosine
DMXRHOY	MI	TTJFY5U
DMXRHOY	MN	Adenosine A3 receptor (ADORA3)
DMXRHOY	MT	DTT
DMXRHOY	MA	Inhibitor
DMXRHOY	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DMXRHOY	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DMR8PGZ	DI	DMR8PGZ
DMR8PGZ	DN	2-(3''-(5''-bromo-indolyl)ethyloxy)adenosine
DMR8PGZ	MI	TTK25J1
DMR8PGZ	MN	Adenosine A1 receptor (ADORA1)
DMR8PGZ	MT	DTT
DMR8PGZ	MA	Inhibitor
DMR8PGZ	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DMR8PGZ	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DMR8PGZ	DI	DMR8PGZ
DMR8PGZ	DN	2-(3''-(5''-bromo-indolyl)ethyloxy)adenosine
DMR8PGZ	MI	TTM2AOE
DMR8PGZ	MN	Adenosine A2a receptor (ADORA2A)
DMR8PGZ	MT	DTT
DMR8PGZ	MA	Inhibitor
DMR8PGZ	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DMR8PGZ	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DMR8PGZ	DI	DMR8PGZ
DMR8PGZ	DN	2-(3''-(5''-bromo-indolyl)ethyloxy)adenosine
DMR8PGZ	MI	TTJFY5U
DMR8PGZ	MN	Adenosine A3 receptor (ADORA3)
DMR8PGZ	MT	DTT
DMR8PGZ	MA	Inhibitor
DMR8PGZ	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DMR8PGZ	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DMD8Q3E	DI	DMD8Q3E
DMD8Q3E	DN	2-(3''(5''-chloro-indolyl)ethyloxy)adenosine
DMD8Q3E	MI	TTK25J1
DMD8Q3E	MN	Adenosine A1 receptor (ADORA1)
DMD8Q3E	MT	DTT
DMD8Q3E	MA	Inhibitor
DMD8Q3E	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DMD8Q3E	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DMD8Q3E	DI	DMD8Q3E
DMD8Q3E	DN	2-(3''(5''-chloro-indolyl)ethyloxy)adenosine
DMD8Q3E	MI	TTM2AOE
DMD8Q3E	MN	Adenosine A2a receptor (ADORA2A)
DMD8Q3E	MT	DTT
DMD8Q3E	MA	Inhibitor
DMD8Q3E	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DMD8Q3E	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DMD8Q3E	DI	DMD8Q3E
DMD8Q3E	DN	2-(3''(5''-chloro-indolyl)ethyloxy)adenosine
DMD8Q3E	MI	TTJFY5U
DMD8Q3E	MN	Adenosine A3 receptor (ADORA3)
DMD8Q3E	MT	DTT
DMD8Q3E	MA	Inhibitor
DMD8Q3E	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DMD8Q3E	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DME3IN1	DI	DME3IN1
DME3IN1	DN	2-(3''-(5''-fluoro-indolyl)ethyloxy)adenosine
DME3IN1	MI	TTK25J1
DME3IN1	MN	Adenosine A1 receptor (ADORA1)
DME3IN1	MT	DTT
DME3IN1	MA	Inhibitor
DME3IN1	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DME3IN1	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DME3IN1	DI	DME3IN1
DME3IN1	DN	2-(3''-(5''-fluoro-indolyl)ethyloxy)adenosine
DME3IN1	MI	TTM2AOE
DME3IN1	MN	Adenosine A2a receptor (ADORA2A)
DME3IN1	MT	DTT
DME3IN1	MA	Inhibitor
DME3IN1	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DME3IN1	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DME3IN1	DI	DME3IN1
DME3IN1	DN	2-(3''-(5''-fluoro-indolyl)ethyloxy)adenosine
DME3IN1	MI	TTJFY5U
DME3IN1	MN	Adenosine A3 receptor (ADORA3)
DME3IN1	MT	DTT
DME3IN1	MA	Inhibitor
DME3IN1	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DME3IN1	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DM6BIOP	DI	DM6BIOP
DM6BIOP	DN	2-(3''-(5''-hydroxyindolyl)ethyloxy)adenosine
DM6BIOP	MI	TTK25J1
DM6BIOP	MN	Adenosine A1 receptor (ADORA1)
DM6BIOP	MT	DTT
DM6BIOP	MA	Inhibitor
DM6BIOP	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DM6BIOP	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DM6BIOP	DI	DM6BIOP
DM6BIOP	DN	2-(3''-(5''-hydroxyindolyl)ethyloxy)adenosine
DM6BIOP	MI	TTM2AOE
DM6BIOP	MN	Adenosine A2a receptor (ADORA2A)
DM6BIOP	MT	DTT
DM6BIOP	MA	Inhibitor
DM6BIOP	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DM6BIOP	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DM6BIOP	DI	DM6BIOP
DM6BIOP	DN	2-(3''-(5''-hydroxyindolyl)ethyloxy)adenosine
DM6BIOP	MI	TTJFY5U
DM6BIOP	MN	Adenosine A3 receptor (ADORA3)
DM6BIOP	MT	DTT
DM6BIOP	MA	Inhibitor
DM6BIOP	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DM6BIOP	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DMFP0IW	DI	DMFP0IW
DMFP0IW	DN	2-(3''-(5''-iodo-indolyl)ethyloxy)adenosine
DMFP0IW	MI	TTK25J1
DMFP0IW	MN	Adenosine A1 receptor (ADORA1)
DMFP0IW	MT	DTT
DMFP0IW	MA	Inhibitor
DMFP0IW	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DMFP0IW	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DMFP0IW	DI	DMFP0IW
DMFP0IW	DN	2-(3''-(5''-iodo-indolyl)ethyloxy)adenosine
DMFP0IW	MI	TTM2AOE
DMFP0IW	MN	Adenosine A2a receptor (ADORA2A)
DMFP0IW	MT	DTT
DMFP0IW	MA	Inhibitor
DMFP0IW	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DMFP0IW	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DMFP0IW	DI	DMFP0IW
DMFP0IW	DN	2-(3''-(5''-iodo-indolyl)ethyloxy)adenosine
DMFP0IW	MI	TTJFY5U
DMFP0IW	MN	Adenosine A3 receptor (ADORA3)
DMFP0IW	MT	DTT
DMFP0IW	MA	Inhibitor
DMFP0IW	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DMFP0IW	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DMWA0MN	DI	DMWA0MN
DMWA0MN	DN	2-(3''-(5''-methoxy-indolyl)ethyloxy)adenosine
DMWA0MN	MI	TTK25J1
DMWA0MN	MN	Adenosine A1 receptor (ADORA1)
DMWA0MN	MT	DTT
DMWA0MN	MA	Inhibitor
DMWA0MN	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DMWA0MN	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DMWA0MN	DI	DMWA0MN
DMWA0MN	DN	2-(3''-(5''-methoxy-indolyl)ethyloxy)adenosine
DMWA0MN	MI	TTM2AOE
DMWA0MN	MN	Adenosine A2a receptor (ADORA2A)
DMWA0MN	MT	DTT
DMWA0MN	MA	Inhibitor
DMWA0MN	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DMWA0MN	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DMWA0MN	DI	DMWA0MN
DMWA0MN	DN	2-(3''-(5''-methoxy-indolyl)ethyloxy)adenosine
DMWA0MN	MI	TTJFY5U
DMWA0MN	MN	Adenosine A3 receptor (ADORA3)
DMWA0MN	MT	DTT
DMWA0MN	MA	Inhibitor
DMWA0MN	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DMWA0MN	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DMGRC24	DI	DMGRC24
DMGRC24	DN	2-(3''-(6''-bromo-indolyl)ethyloxy)adenosine
DMGRC24	MI	TTK25J1
DMGRC24	MN	Adenosine A1 receptor (ADORA1)
DMGRC24	MT	DTT
DMGRC24	MA	Inhibitor
DMGRC24	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DMGRC24	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DMGRC24	DI	DMGRC24
DMGRC24	DN	2-(3''-(6''-bromo-indolyl)ethyloxy)adenosine
DMGRC24	MI	TTM2AOE
DMGRC24	MN	Adenosine A2a receptor (ADORA2A)
DMGRC24	MT	DTT
DMGRC24	MA	Inhibitor
DMGRC24	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DMGRC24	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DMGRC24	DI	DMGRC24
DMGRC24	DN	2-(3''-(6''-bromo-indolyl)ethyloxy)adenosine
DMGRC24	MI	TTJFY5U
DMGRC24	MN	Adenosine A3 receptor (ADORA3)
DMGRC24	MT	DTT
DMGRC24	MA	Inhibitor
DMGRC24	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DMGRC24	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DML39UW	DI	DML39UW
DML39UW	DN	2-(3''-(6''-chloro-indolyl)ethyloxy)adenosine
DML39UW	MI	TTK25J1
DML39UW	MN	Adenosine A1 receptor (ADORA1)
DML39UW	MT	DTT
DML39UW	MA	Inhibitor
DML39UW	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DML39UW	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DML39UW	DI	DML39UW
DML39UW	DN	2-(3''-(6''-chloro-indolyl)ethyloxy)adenosine
DML39UW	MI	TTM2AOE
DML39UW	MN	Adenosine A2a receptor (ADORA2A)
DML39UW	MT	DTT
DML39UW	MA	Inhibitor
DML39UW	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DML39UW	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DML39UW	DI	DML39UW
DML39UW	DN	2-(3''-(6''-chloro-indolyl)ethyloxy)adenosine
DML39UW	MI	TTJFY5U
DML39UW	MN	Adenosine A3 receptor (ADORA3)
DML39UW	MT	DTT
DML39UW	MA	Inhibitor
DML39UW	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DML39UW	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DMITEND	DI	DMITEND
DMITEND	DN	2-(3''(7''-bromo-indolyl)ethyloxy)adenosine
DMITEND	MI	TTK25J1
DMITEND	MN	Adenosine A1 receptor (ADORA1)
DMITEND	MT	DTT
DMITEND	MA	Inhibitor
DMITEND	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DMITEND	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DMITEND	DI	DMITEND
DMITEND	DN	2-(3''(7''-bromo-indolyl)ethyloxy)adenosine
DMITEND	MI	TTM2AOE
DMITEND	MN	Adenosine A2a receptor (ADORA2A)
DMITEND	MT	DTT
DMITEND	MA	Inhibitor
DMITEND	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DMITEND	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DMITEND	DI	DMITEND
DMITEND	DN	2-(3''(7''-bromo-indolyl)ethyloxy)adenosine
DMITEND	MI	TTJFY5U
DMITEND	MN	Adenosine A3 receptor (ADORA3)
DMITEND	MT	DTT
DMITEND	MA	Inhibitor
DMITEND	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DMITEND	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DMLDOH6	DI	DMLDOH6
DMLDOH6	DN	2-(3''-(benzoimidazole-1''-yl)ethyloxy)adenosine
DMLDOH6	MI	TTM2AOE
DMLDOH6	MN	Adenosine A2a receptor (ADORA2A)
DMLDOH6	MT	DTT
DMLDOH6	MA	Inhibitor
DMLDOH6	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DMLDOH6	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DMLDOH6	DI	DMLDOH6
DMLDOH6	DN	2-(3''-(benzoimidazole-1''-yl)ethyloxy)adenosine
DMLDOH6	MI	TTJFY5U
DMLDOH6	MN	Adenosine A3 receptor (ADORA3)
DMLDOH6	MT	DTT
DMLDOH6	MA	Inhibitor
DMLDOH6	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DMLDOH6	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DM1KCUV	DI	DM1KCUV
DM1KCUV	DN	2-(3''-(benzotriazole-1''-yl)ethyloxy)adenosine
DM1KCUV	MI	TTJFY5U
DM1KCUV	MN	Adenosine A3 receptor (ADORA3)
DM1KCUV	MT	DTT
DM1KCUV	MA	Inhibitor
DM1KCUV	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DM1KCUV	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DM0R5U6	DI	DM0R5U6
DM0R5U6	DN	2-(3-(benzyloxy)phenyl)isoindoline-1,3-dione
DM0R5U6	MI	TTHS256
DM0R5U6	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM0R5U6	MT	DTT
DM0R5U6	MA	Inhibitor
DM0R5U6	RN	Arylmethoxypyridines as novel, potent and orally active mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1892-7.
DM0R5U6	RU	https://pubmed.ncbi.nlm.nih.gov/16439120

DMKEY9V	DI	DMKEY9V
DMKEY9V	DN	2-(3-(naphthalen-2-yl)propanamido)benzoic acid
DMKEY9V	MI	TTWNV8U
DMKEY9V	MN	Nicotinic acid receptor (HCAR2)
DMKEY9V	MT	DTT
DMKEY9V	MA	Inhibitor
DMKEY9V	RN	Molecular modeling aided design of nicotinic acid receptor GPR109A agonists. Bioorg Med Chem Lett. 2008 Sep 15;18(18):4963-7.
DMKEY9V	RU	https://pubmed.ncbi.nlm.nih.gov/18760600

DM94B7N	DI	DM94B7N
DM94B7N	DN	2-(3-(phenylsulfonyl)-1H-indol-1-yl)ethanamine
DM94B7N	MI	TTJS8PY
DM94B7N	MN	5-HT 6 receptor (HTR6)
DM94B7N	MT	DTT
DM94B7N	MA	Inhibitor
DM94B7N	RN	Novel 1-aminoethyl-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines are potent 5-HT(6) agonists. Bioorg Med Chem. 2009 Jul 15;17(14):5153-63.
DM94B7N	RU	https://pubmed.ncbi.nlm.nih.gov/19523834

DM1I6SO	DI	DM1I6SO
DM1I6SO	DN	2-(3,4,5-Trihydroxy-benzylidene)-malononitrile
DM1I6SO	MI	TT860QF
DM1I6SO	MN	LCK tyrosine protein kinase (LCK)
DM1I6SO	MT	DTT
DM1I6SO	MA	Inhibitor
DM1I6SO	RN	Tyrphostins. 3. Structure-activity relationship studies of alpha-substituted benzylidenemalononitrile 5-S-aryltyrphostins. J Med Chem. 1993 Nov 12;36(23):3556-64.
DM1I6SO	RU	https://pubmed.ncbi.nlm.nih.gov/7902440

DMJKVZ3	DI	DMJKVZ3
DMJKVZ3	DN	2-(3,4-Difluorophenyl)-2,2-diphenylacetamide
DMJKVZ3	MI	TTMNI76
DMJKVZ3	MN	Calcium-activated potassium channel (KCN)
DMJKVZ3	MT	DTT
DMJKVZ3	MA	Inhibitor
DMJKVZ3	RN	Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82.
DMJKVZ3	RU	https://pubmed.ncbi.nlm.nih.gov/18232633

DMAOD0K	DI	DMAOD0K
DMAOD0K	DN	2-(3,4-Dihydroxy-benzyl)-7-hydroxy-chromen-4-one
DMAOD0K	MI	TTFBNVI
DMAOD0K	MN	Aldose reductase (AKR1B1)
DMAOD0K	MT	DTT
DMAOD0K	MA	Inhibitor
DMAOD0K	RN	1-Benzopyran-4-one antioxidants as aldose reductase inhibitors. J Med Chem. 1999 Jun 3;42(11):1881-93.
DMAOD0K	RU	https://pubmed.ncbi.nlm.nih.gov/10354396

DM5MKEI	DI	DM5MKEI
DM5MKEI	DN	2-(3,4-Dihydroxy-phenyl)-7-hydroxy-chromen-4-one
DM5MKEI	MI	TTFBNVI
DM5MKEI	MN	Aldose reductase (AKR1B1)
DM5MKEI	MT	DTT
DM5MKEI	MA	Inhibitor
DM5MKEI	RN	1-Benzopyran-4-one antioxidants as aldose reductase inhibitors. J Med Chem. 1999 Jun 3;42(11):1881-93.
DM5MKEI	RU	https://pubmed.ncbi.nlm.nih.gov/10354396

DMSZ0H9	DI	DMSZ0H9
DMSZ0H9	DN	2-(3,4-Dihydroxyphenyl)Acetic Acid
DMSZ0H9	MI	TTUTN1I
DMSZ0H9	MN	Human Deoxyribonucleic acid (hDNA)
DMSZ0H9	MT	DTT
DMSZ0H9	MA	Inhibitor
DMSZ0H9	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMSZ0H9	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM3S26I	DI	DM3S26I
DM3S26I	DN	2-(3,4-dimethoxybenzamido)thiophene-3-carboxamide
DM3S26I	MI	TTGJCWZ
DM3S26I	MN	Fms-like tyrosine kinase 3 (FLT-3)
DM3S26I	MT	DTT
DM3S26I	MA	Inhibitor
DM3S26I	RN	Identification of 2-acylaminothiophene-3-carboxamides as potent inhibitors of FLT3. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3282-6.
DM3S26I	RU	https://pubmed.ncbi.nlm.nih.gov/16580199

DMLOX0Y	DI	DMLOX0Y
DMLOX0Y	DN	2-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-imidazole
DMLOX0Y	MI	TT3WG5C
DMLOX0Y	MN	Monoamine oxidase type A (MAO-A)
DMLOX0Y	MT	DTT
DMLOX0Y	MA	Inhibitor
DMLOX0Y	RN	Ultrasound promoted synthesis of 2-imidazolines in water: a greener approach toward monoamine oxidase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):546-9.
DMLOX0Y	RU	https://pubmed.ncbi.nlm.nih.gov/19064321

DMDGRWM	DI	DMDGRWM
DMDGRWM	DN	2-(3,4-dimethylphenyl)-1,8-naphthyridine
DMDGRWM	MI	TTHS256
DMDGRWM	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMDGRWM	MT	DTT
DMDGRWM	MA	Inhibitor
DMDGRWM	RN	Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8.
DMDGRWM	RU	https://pubmed.ncbi.nlm.nih.gov/17936624

DM8KM1Q	DI	DM8KM1Q
DM8KM1Q	DN	2-(3,5-dichlorophenyl)pyrido[2,3-d]pyrimidine
DM8KM1Q	MI	TTHS256
DM8KM1Q	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM8KM1Q	MT	DTT
DM8KM1Q	MA	Inhibitor
DM8KM1Q	RN	Synthesis and SAR of 2-aryl pyrido[2,3-d]pyrimidines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5396-9.
DM8KM1Q	RU	https://pubmed.ncbi.nlm.nih.gov/17723296

DMGJPYO	DI	DMGJPYO
DMGJPYO	DN	2-(3,5-difluorophenyl)-7-methyl-1,8-naphthyridine
DMGJPYO	MI	TTHS256
DMGJPYO	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMGJPYO	MT	DTT
DMGJPYO	MA	Inhibitor
DMGJPYO	RN	Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8.
DMGJPYO	RU	https://pubmed.ncbi.nlm.nih.gov/17936624

DMIEB8R	DI	DMIEB8R
DMIEB8R	DN	2-(3,5-dimethoxy-4-phenethoxyphenyl)ethanamine
DMIEB8R	MI	TTJQOD7
DMIEB8R	MN	5-HT 2A receptor (HTR2A)
DMIEB8R	MT	DTT
DMIEB8R	MA	Inhibitor
DMIEB8R	RN	The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands. Bioorg Med Chem. 2008 Apr 15;16(8):4661-9.
DMIEB8R	RU	https://pubmed.ncbi.nlm.nih.gov/18296055

DMKND0T	DI	DMKND0T
DMKND0T	DN	2-(3,5-dimethoxyphenyl)-1,8-naphthyridine
DMKND0T	MI	TTHS256
DMKND0T	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMKND0T	MT	DTT
DMKND0T	MA	Inhibitor
DMKND0T	RN	Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8.
DMKND0T	RU	https://pubmed.ncbi.nlm.nih.gov/17936624

DMJ2NPY	DI	DMJ2NPY
DMJ2NPY	DN	2-(3-acetylphenyl)-6-morpholino-4H-pyran-4-one
DMJ2NPY	MI	TTK3PY9
DMJ2NPY	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMJ2NPY	MT	DTT
DMJ2NPY	MA	Inhibitor
DMJ2NPY	RN	Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72.
DMJ2NPY	RU	https://pubmed.ncbi.nlm.nih.gov/17371003

DMAGFUH	DI	DMAGFUH
DMAGFUH	DN	2-(3'-Allyl-biphenyl-4-yl)-propionic acid
DMAGFUH	MI	TT8NGED
DMAGFUH	MN	Prostaglandin G/H synthase 1 (COX-1)
DMAGFUH	MT	DTT
DMAGFUH	MA	Inhibitor
DMAGFUH	RN	Structure-based design of COX-2 selectivity into flurbiprofen. Bioorg Med Chem Lett. 1999 Feb 8;9(3):307-12.
DMAGFUH	RU	https://pubmed.ncbi.nlm.nih.gov/10091674

DMC6E8R	DI	DMC6E8R
DMC6E8R	DN	2-(3-aminophenoxy)-5-hexylphenol
DMC6E8R	MI	TTVTX4N
DMC6E8R	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DMC6E8R	MT	DTT
DMC6E8R	MA	Inhibitor
DMC6E8R	RN	Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33.
DMC6E8R	RU	https://pubmed.ncbi.nlm.nih.gov/18457948

DMQB9SC	DI	DMQB9SC
DMQB9SC	DN	2-(3-aminophenyl)-3-mercaptopropanoic acid
DMQB9SC	MI	TTP18AY
DMQB9SC	MN	Carboxypeptidase B2 (CPB2)
DMQB9SC	MT	DTT
DMQB9SC	MA	Inhibitor
DMQB9SC	RN	3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa). Bioorg Med Chem Lett. 2007 Mar 1;17(5):1349-54.
DMQB9SC	RU	https://pubmed.ncbi.nlm.nih.gov/17189688

DMAP37I	DI	DMAP37I
DMAP37I	DN	2-(3-Amino-phenyl)-6-methyl-chromen-4-one
DMAP37I	MI	TTNJYV2
DMAP37I	MN	Gamma-aminobutyric acid receptor (GAR)
DMAP37I	MT	DTT
DMAP37I	MA	Inhibitor
DMAP37I	RN	Refinement and evaluation of a pharmacophore model for flavone derivatives binding to the benzodiazepine site of the GABA(A) receptor. J Med Chem. 2002 Sep 12;45(19):4188-201.
DMAP37I	RU	https://pubmed.ncbi.nlm.nih.gov/12213060

DM3FBLT	DI	DM3FBLT
DM3FBLT	DN	2-(3-benzenesulfonyl)phenyl-1-aminoethane
DM3FBLT	MI	TTJS8PY
DM3FBLT	MN	5-HT 6 receptor (HTR6)
DM3FBLT	MT	DTT
DM3FBLT	MA	Inhibitor
DM3FBLT	RN	Binding of sulfonyl-containing arylalkylamines at human 5-HT6 serotonin receptors. J Med Chem. 2006 Aug 24;49(17):5217-25.
DM3FBLT	RU	https://pubmed.ncbi.nlm.nih.gov/16913710

DMDB4LZ	DI	DMDB4LZ
DMDB4LZ	DN	2-(3-benzoyl-1H-pyrrol-1-yl)acetic acid
DMDB4LZ	MI	TTFBNVI
DMDB4LZ	MN	Aldose reductase (AKR1B1)
DMDB4LZ	MT	DTT
DMDB4LZ	MA	Inhibitor
DMDB4LZ	RN	Design and synthesis of novel series of pyrrole based chemotypes and their evaluation as selective aldose reductase inhibitors. A case of bioisoste... Bioorg Med Chem. 2010 Mar 15;18(6):2107-2114.
DMDB4LZ	RU	https://pubmed.ncbi.nlm.nih.gov/20189816

DMWMFTJ	DI	DMWMFTJ
DMWMFTJ	DN	2-(3-BENZOYLPHENOXY)ETHYL(HYDROXY)FORMAMIDE
DMWMFTJ	MI	TTICO5G
DMWMFTJ	MN	Staphylococcus Peptide deformylase (Stap-coc def)
DMWMFTJ	MT	DTT
DMWMFTJ	MA	Inhibitor
DMWMFTJ	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMWMFTJ	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM6V91D	DI	DM6V91D
DM6V91D	DN	2-(3-benzylquinoxalin-2-ylamino)ethanol
DM6V91D	MI	TT3WG5C
DM6V91D	MN	Monoamine oxidase type A (MAO-A)
DM6V91D	MT	DTT
DM6V91D	MA	Inhibitor
DM6V91D	RN	Synthesis of 3-benzyl-2-substituted quinoxalines as novel monoamine oxidase A inhibitors. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1753-6.
DM6V91D	RU	https://pubmed.ncbi.nlm.nih.gov/16356714

DMY60K3	DI	DMY60K3
DMY60K3	DN	2-(3-biphenyl-4-yl-propionylamino)-benzoic acid
DMY60K3	MI	TTWNV8U
DMY60K3	MN	Nicotinic acid receptor (HCAR2)
DMY60K3	MT	DTT
DMY60K3	MA	Inhibitor
DMY60K3	RN	Discovery of biaryl anthranilides as full agonists for the high affinity niacin receptor. J Med Chem. 2007 Dec 13;50(25):6303-6.
DMY60K3	RU	https://pubmed.ncbi.nlm.nih.gov/17994679

DMX4DUR	DI	DMX4DUR
DMX4DUR	DN	2-(3-bromobenzoylamino)-4-chlorobenzoic acid
DMX4DUR	MI	TT0MYE2
DMX4DUR	MN	Glutamate receptor ionotropic kainate 1 (GRIK1)
DMX4DUR	MT	DTT
DMX4DUR	MA	Inhibitor
DMX4DUR	RN	Bioisosteric modifications of 2-arylureidobenzoic acids: selective noncompetitive antagonists for the homomeric kainate receptor subtype GluR5. J Med Chem. 2004 Dec 30;47(27):6948-57.
DMX4DUR	RU	https://pubmed.ncbi.nlm.nih.gov/15615543

DM9G7B6	DI	DM9G7B6
DM9G7B6	DN	2-(3-Bromo-phenyl)-6-methyl-chromen-4-one
DM9G7B6	MI	TTNJYV2
DM9G7B6	MN	Gamma-aminobutyric acid receptor (GAR)
DM9G7B6	MT	DTT
DM9G7B6	MA	Inhibitor
DM9G7B6	RN	Refinement and evaluation of a pharmacophore model for flavone derivatives binding to the benzodiazepine site of the GABA(A) receptor. J Med Chem. 2002 Sep 12;45(19):4188-201.
DM9G7B6	RU	https://pubmed.ncbi.nlm.nih.gov/12213060

DM9RAYC	DI	DM9RAYC
DM9RAYC	DN	2-(3-Bromo-phenyl)-6-nitro-chromen-4-one
DM9RAYC	MI	TT1MPAY
DM9RAYC	MN	GABA(A) receptor alpha-1 (GABRA1)
DM9RAYC	MT	DTT
DM9RAYC	MA	Inhibitor
DM9RAYC	RN	Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997).
DM9RAYC	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97003430

DM9RAYC	DI	DM9RAYC
DM9RAYC	DN	2-(3-Bromo-phenyl)-6-nitro-chromen-4-one
DM9RAYC	MI	TTNJYV2
DM9RAYC	MN	Gamma-aminobutyric acid receptor (GAR)
DM9RAYC	MT	DTT
DM9RAYC	MA	Inhibitor
DM9RAYC	RN	Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997).
DM9RAYC	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97003430

DMYSM9L	DI	DMYSM9L
DMYSM9L	DN	2-(3-bromophenyl)-7-methyl-1,8-naphthyridine
DMYSM9L	MI	TTHS256
DMYSM9L	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMYSM9L	MT	DTT
DMYSM9L	MA	Inhibitor
DMYSM9L	RN	Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8.
DMYSM9L	RU	https://pubmed.ncbi.nlm.nih.gov/17936624

DMANS5X	DI	DMANS5X
DMANS5X	DN	2-(3-bromophenyl)-7-methylpyrido[2,3-d]pyrimidine
DMANS5X	MI	TTHS256
DMANS5X	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMANS5X	MT	DTT
DMANS5X	MA	Inhibitor
DMANS5X	RN	Synthesis and SAR of 2-aryl pyrido[2,3-d]pyrimidines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5396-9.
DMANS5X	RU	https://pubmed.ncbi.nlm.nih.gov/17723296

DM7XDLO	DI	DM7XDLO
DM7XDLO	DN	2-(3-Bromo-phenyl)-chromen-4-one
DM7XDLO	MI	TT1MPAY
DM7XDLO	MN	GABA(A) receptor alpha-1 (GABRA1)
DM7XDLO	MT	DTT
DM7XDLO	MA	Inhibitor
DM7XDLO	RN	Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997).
DM7XDLO	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97003430

DM7XDLO	DI	DM7XDLO
DM7XDLO	DN	2-(3-Bromo-phenyl)-chromen-4-one
DM7XDLO	MI	TTNJYV2
DM7XDLO	MN	Gamma-aminobutyric acid receptor (GAR)
DM7XDLO	MT	DTT
DM7XDLO	MA	Inhibitor
DM7XDLO	RN	Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997).
DM7XDLO	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97003430

DM260RG	DI	DM260RG
DM260RG	DN	2-(3-bromophenyl)histamine
DM260RG	MI	TTTIBOJ
DM260RG	MN	Histamine H1 receptor (H1R)
DM260RG	MT	DTT
DM260RG	MA	Agonist
DM260RG	RN	Multiple differences in agonist and antagonist pharmacology between human and guinea pig histamine H1-receptor. J Pharmacol Exp Ther. 2003 Jun;305(3):1104-15.
DM260RG	RU	https://pubmed.ncbi.nlm.nih.gov/12626648

DM260RG	DI	DM260RG
DM260RG	DN	2-(3-bromophenyl)histamine
DM260RG	MI	TTXJ178
DM260RG	MN	Histamine H4 receptor (H4R)
DM260RG	MT	DTT
DM260RG	MA	Agonist
DM260RG	RN	Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first pote... J Pharmacol Exp Ther. 2005 Sep;314(3):1310-21.
DM260RG	RU	https://pubmed.ncbi.nlm.nih.gov/15947036

DMVA4XC	DI	DMVA4XC
DMVA4XC	DN	2-(3-bromophenyl)pyrido[2,3-d]pyrimidine
DMVA4XC	MI	TTHS256
DMVA4XC	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMVA4XC	MT	DTT
DMVA4XC	MA	Inhibitor
DMVA4XC	RN	Synthesis and SAR of 2-aryl pyrido[2,3-d]pyrimidines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5396-9.
DMVA4XC	RU	https://pubmed.ncbi.nlm.nih.gov/17723296

DMFETRH	DI	DMFETRH
DMFETRH	DN	2-(3-Bromophenylthio)-N,N-dimethylethanamine
DMFETRH	MI	TTSQIFT
DMFETRH	MN	5-HT 1A receptor (HTR1A)
DMFETRH	MT	DTT
DMFETRH	MA	Inhibitor
DMFETRH	RN	SAR studies on new bis-aryls 5-HT7 ligands: Synthesis and molecular modeling. Bioorg Med Chem. 2010 Mar 1;18(5):1958-67.
DMFETRH	RU	https://pubmed.ncbi.nlm.nih.gov/20138771

DMJM5VW	DI	DMJM5VW
DMJM5VW	DN	2-(3-Butoxy-4-hydroxy-phenyl)-benzooxazol-6-ol
DMJM5VW	MI	TTZAYWL
DMJM5VW	MN	Estrogen receptor (ESR)
DMJM5VW	MT	DTT
DMJM5VW	MA	Inhibitor
DMJM5VW	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMJM5VW	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMJM5VW	DI	DMJM5VW
DMJM5VW	DN	2-(3-Butoxy-4-hydroxy-phenyl)-benzooxazol-6-ol
DMJM5VW	MI	TTOM3J0
DMJM5VW	MN	Estrogen receptor beta (ESR2)
DMJM5VW	MT	DTT
DMJM5VW	MA	Inhibitor
DMJM5VW	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMJM5VW	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMSZT9G	DI	DMSZT9G
DMSZT9G	DN	2-(3-Butoxy-phenyl)-6-methyl-chromen-4-one
DMSZT9G	MI	TTNJYV2
DMSZT9G	MN	Gamma-aminobutyric acid receptor (GAR)
DMSZT9G	MT	DTT
DMSZT9G	MA	Inhibitor
DMSZT9G	RN	Refinement and evaluation of a pharmacophore model for flavone derivatives binding to the benzodiazepine site of the GABA(A) receptor. J Med Chem. 2002 Sep 12;45(19):4188-201.
DMSZT9G	RU	https://pubmed.ncbi.nlm.nih.gov/12213060

DMHXVNZ	DI	DMHXVNZ
DMHXVNZ	DN	2-(3-carbamoylbenzyl)-5-mercaptopentanoic acid
DMHXVNZ	MI	TT9G4N0
DMHXVNZ	MN	Glutamate carboxypeptidase II (GCPII)
DMHXVNZ	MT	DTT
DMHXVNZ	MA	Inhibitor
DMHXVNZ	RN	Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1' side chain. J Med Chem. 2006 May 18;49(10):2876-85.
DMHXVNZ	RU	https://pubmed.ncbi.nlm.nih.gov/16686531

DMI6AZ5	DI	DMI6AZ5
DMI6AZ5	DN	2-(3-carboxybenzyl)succinic acid
DMI6AZ5	MI	TT9G4N0
DMI6AZ5	MN	Glutamate carboxypeptidase II (GCPII)
DMI6AZ5	MT	DTT
DMI6AZ5	MA	Inhibitor
DMI6AZ5	RN	Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1' side chain. J Med Chem. 2006 May 18;49(10):2876-85.
DMI6AZ5	RU	https://pubmed.ncbi.nlm.nih.gov/16686531

DMBONUV	DI	DMBONUV
DMBONUV	DN	2-(3-Chloro-4-hydroxy-phenyl)-benzooxazol-5-ol
DMBONUV	MI	TTZAYWL
DMBONUV	MN	Estrogen receptor (ESR)
DMBONUV	MT	DTT
DMBONUV	MA	Inhibitor
DMBONUV	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMBONUV	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMBONUV	DI	DMBONUV
DMBONUV	DN	2-(3-Chloro-4-hydroxy-phenyl)-benzooxazol-5-ol
DMBONUV	MI	TTOM3J0
DMBONUV	MN	Estrogen receptor beta (ESR2)
DMBONUV	MT	DTT
DMBONUV	MA	Inhibitor
DMBONUV	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMBONUV	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DM3B6IN	DI	DM3B6IN
DM3B6IN	DN	2-(3-Chloro-4-hydroxy-phenyl)-benzooxazol-6-ol
DM3B6IN	MI	TTZAYWL
DM3B6IN	MN	Estrogen receptor (ESR)
DM3B6IN	MT	DTT
DM3B6IN	MA	Inhibitor
DM3B6IN	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DM3B6IN	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DM3B6IN	DI	DM3B6IN
DM3B6IN	DN	2-(3-Chloro-4-hydroxy-phenyl)-benzooxazol-6-ol
DM3B6IN	MI	TTOM3J0
DM3B6IN	MN	Estrogen receptor beta (ESR2)
DM3B6IN	MT	DTT
DM3B6IN	MA	Inhibitor
DM3B6IN	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DM3B6IN	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DM1VDC3	DI	DM1VDC3
DM1VDC3	DN	2-(3-chlorobenzyloxy)-6-chloroisonicotinonitrile
DM1VDC3	MI	TTHS256
DM1VDC3	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM1VDC3	MT	DTT
DM1VDC3	MA	Inhibitor
DM1VDC3	RN	Arylmethoxypyridines as novel, potent and orally active mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1892-7.
DM1VDC3	RU	https://pubmed.ncbi.nlm.nih.gov/16439120

DMK6CD9	DI	DMK6CD9
DMK6CD9	DN	2-(3-Chloro-phenyl)-1H-[1,8]naphthyridin-4-one
DMK6CD9	MI	TTML2WA
DMK6CD9	MN	Tubulin (TUB)
DMK6CD9	MT	DTT
DMK6CD9	MA	Inhibitor
DMK6CD9	RN	Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubul... J Med Chem. 1997 Sep 12;40(19):3049-56.
DMK6CD9	RU	https://pubmed.ncbi.nlm.nih.gov/9301667

DMK6CD9	DI	DMK6CD9
DMK6CD9	DN	2-(3-Chloro-phenyl)-1H-[1,8]naphthyridin-4-one
DMK6CD9	MI	TTYFKSZ
DMK6CD9	MN	Tubulin beta (TUBB)
DMK6CD9	MT	DTT
DMK6CD9	MA	Inhibitor
DMK6CD9	RN	Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubul... J Med Chem. 1997 Sep 12;40(19):3049-56.
DMK6CD9	RU	https://pubmed.ncbi.nlm.nih.gov/9301667

DMYQBSV	DI	DMYQBSV
DMYQBSV	DN	2-(3-Chlorophenyl)-2H-indazole-7-carboxamide
DMYQBSV	MI	TTVDSZ0
DMYQBSV	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMYQBSV	MT	DTT
DMYQBSV	MA	Inhibitor
DMYQBSV	RN	Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor effica... J Med Chem. 2009 Nov 26;52(22):7170-85.
DMYQBSV	RU	https://pubmed.ncbi.nlm.nih.gov/19873981

DM7BC50	DI	DM7BC50
DM7BC50	DN	2-(3-chlorophenyl)-7-methyl-1,8-naphthyridine
DM7BC50	MI	TTHS256
DM7BC50	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM7BC50	MT	DTT
DM7BC50	MA	Inhibitor
DM7BC50	RN	Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8.
DM7BC50	RU	https://pubmed.ncbi.nlm.nih.gov/17936624

DML83DM	DI	DML83DM
DML83DM	DN	2-(3-Chloro-phenyl)-chromen-4-one
DML83DM	MI	TT1MPAY
DML83DM	MN	GABA(A) receptor alpha-1 (GABRA1)
DML83DM	MT	DTT
DML83DM	MA	Inhibitor
DML83DM	RN	Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997).
DML83DM	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97003430

DML83DM	DI	DML83DM
DML83DM	DN	2-(3-Chloro-phenyl)-chromen-4-one
DML83DM	MI	TTNJYV2
DML83DM	MN	Gamma-aminobutyric acid receptor (GAR)
DML83DM	MT	DTT
DML83DM	MA	Inhibitor
DML83DM	RN	Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997).
DML83DM	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97003430

DMO0Y79	DI	DMO0Y79
DMO0Y79	DN	2-(3-chlorophenyl)histamine
DMO0Y79	MI	TTTIBOJ
DMO0Y79	MN	Histamine H1 receptor (H1R)
DMO0Y79	MT	DTT
DMO0Y79	MA	Agonist
DMO0Y79	RN	Multiple differences in agonist and antagonist pharmacology between human and guinea pig histamine H1-receptor. J Pharmacol Exp Ther. 2003 Jun;305(3):1104-15.
DMO0Y79	RU	https://pubmed.ncbi.nlm.nih.gov/12626648

DMVB5U0	DI	DMVB5U0
DMVB5U0	DN	2-(3-cyanobenzyl)-5-mercaptopentanoic acid
DMVB5U0	MI	TT9G4N0
DMVB5U0	MN	Glutamate carboxypeptidase II (GCPII)
DMVB5U0	MT	DTT
DMVB5U0	MA	Inhibitor
DMVB5U0	RN	Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1' side chain. J Med Chem. 2006 May 18;49(10):2876-85.
DMVB5U0	RU	https://pubmed.ncbi.nlm.nih.gov/16686531

DMPLN58	DI	DMPLN58
DMPLN58	DN	2-(3'-Ethyl-biphenyl-4-yl)-propionic acid
DMPLN58	MI	TT8NGED
DMPLN58	MN	Prostaglandin G/H synthase 1 (COX-1)
DMPLN58	MT	DTT
DMPLN58	MA	Inhibitor
DMPLN58	RN	Structure-based design of COX-2 selectivity into flurbiprofen. Bioorg Med Chem Lett. 1999 Feb 8;9(3):307-12.
DMPLN58	RU	https://pubmed.ncbi.nlm.nih.gov/10091674

DMPGYDA	DI	DMPGYDA
DMPGYDA	DN	2-(3'-Ethylsulfanyl-biphenyl-4-yl)-propionic acid
DMPGYDA	MI	TT8NGED
DMPGYDA	MN	Prostaglandin G/H synthase 1 (COX-1)
DMPGYDA	MT	DTT
DMPGYDA	MA	Inhibitor
DMPGYDA	RN	Structure-based design of COX-2 selectivity into flurbiprofen. Bioorg Med Chem Lett. 1999 Feb 8;9(3):307-12.
DMPGYDA	RU	https://pubmed.ncbi.nlm.nih.gov/10091674

DMNTHK5	DI	DMNTHK5
DMNTHK5	DN	2-(3-Fluoro-4-hydroxy-phenyl)-benzooxazol-5-ol
DMNTHK5	MI	TTZAYWL
DMNTHK5	MN	Estrogen receptor (ESR)
DMNTHK5	MT	DTT
DMNTHK5	MA	Inhibitor
DMNTHK5	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMNTHK5	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMNTHK5	DI	DMNTHK5
DMNTHK5	DN	2-(3-Fluoro-4-hydroxy-phenyl)-benzooxazol-5-ol
DMNTHK5	MI	TTOM3J0
DMNTHK5	MN	Estrogen receptor beta (ESR2)
DMNTHK5	MT	DTT
DMNTHK5	MA	Inhibitor
DMNTHK5	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMNTHK5	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DM50FW1	DI	DM50FW1
DM50FW1	DN	2-(3-Fluoro-4-hydroxy-phenyl)-benzooxazol-6-ol
DM50FW1	MI	TTZAYWL
DM50FW1	MN	Estrogen receptor (ESR)
DM50FW1	MT	DTT
DM50FW1	MA	Inhibitor
DM50FW1	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DM50FW1	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DM50FW1	DI	DM50FW1
DM50FW1	DN	2-(3-Fluoro-4-hydroxy-phenyl)-benzooxazol-6-ol
DM50FW1	MI	TTOM3J0
DM50FW1	MN	Estrogen receptor beta (ESR2)
DM50FW1	MT	DTT
DM50FW1	MA	Inhibitor
DM50FW1	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DM50FW1	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMNYWAT	DI	DMNYWAT
DMNYWAT	DN	2-(3-Fluoro-phenyl)-benzo[h]chromen-4-one
DMNYWAT	MI	TTK3PY9
DMNYWAT	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMNYWAT	MT	DTT
DMNYWAT	MA	Inhibitor
DMNYWAT	RN	Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85.
DMNYWAT	RU	https://pubmed.ncbi.nlm.nih.gov/15658870

DMZX2GE	DI	DMZX2GE
DMZX2GE	DN	2-(3-guanidinophenyl)-3-mercaptopropanoic acid
DMZX2GE	MI	TTP18AY
DMZX2GE	MN	Carboxypeptidase B2 (CPB2)
DMZX2GE	MT	DTT
DMZX2GE	MA	Inhibitor
DMZX2GE	RN	3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa). Bioorg Med Chem Lett. 2007 Mar 1;17(5):1349-54.
DMZX2GE	RU	https://pubmed.ncbi.nlm.nih.gov/17189688

DMFVITM	DI	DMFVITM
DMFVITM	DN	2-(3-Hydroxycarbamoyl-propyl)-pentanedioic acid
DMFVITM	MI	TT9G4N0
DMFVITM	MN	Glutamate carboxypeptidase II (GCPII)
DMFVITM	MT	DTT
DMFVITM	MA	Inhibitor
DMFVITM	RN	Synthesis and biological evaluation of hydroxamate-Based inhibitors of glutamate carboxypeptidase II. Bioorg Med Chem Lett. 2003 Jul 7;13(13):2097-100.
DMFVITM	RU	https://pubmed.ncbi.nlm.nih.gov/12798312

DMZCE18	DI	DMZCE18
DMZCE18	DN	2-(3-hydroxyphenyl)-1,2'-spirobi[1H-indene]-5-ol
DMZCE18	MI	TTZAYWL
DMZCE18	MN	Estrogen receptor (ESR)
DMZCE18	MT	DTT
DMZCE18	MA	Inhibitor
DMZCE18	RN	2-Phenylspiroindenes: a novel class of selective estrogen receptor modulators (SERMs). Bioorg Med Chem Lett. 2003 Feb 10;13(3):479-83.
DMZCE18	RU	https://pubmed.ncbi.nlm.nih.gov/12565955

DMZCE18	DI	DMZCE18
DMZCE18	DN	2-(3-hydroxyphenyl)-1,2'-spirobi[1H-indene]-5-ol
DMZCE18	MI	TTOM3J0
DMZCE18	MN	Estrogen receptor beta (ESR2)
DMZCE18	MT	DTT
DMZCE18	MA	Inhibitor
DMZCE18	RN	2-Phenylspiroindenes: a novel class of selective estrogen receptor modulators (SERMs). Bioorg Med Chem Lett. 2003 Feb 10;13(3):479-83.
DMZCE18	RU	https://pubmed.ncbi.nlm.nih.gov/12565955

DMIGXRJ	DI	DMIGXRJ
DMIGXRJ	DN	2-(3-hydroxyphenyl)-1,2'-spirobi[1H-indene]-6-ol
DMIGXRJ	MI	TTZAYWL
DMIGXRJ	MN	Estrogen receptor (ESR)
DMIGXRJ	MT	DTT
DMIGXRJ	MA	Inhibitor
DMIGXRJ	RN	2-Phenylspiroindenes: a novel class of selective estrogen receptor modulators (SERMs). Bioorg Med Chem Lett. 2003 Feb 10;13(3):479-83.
DMIGXRJ	RU	https://pubmed.ncbi.nlm.nih.gov/12565955

DMIGXRJ	DI	DMIGXRJ
DMIGXRJ	DN	2-(3-hydroxyphenyl)-1,2'-spirobi[1H-indene]-6-ol
DMIGXRJ	MI	TTOM3J0
DMIGXRJ	MN	Estrogen receptor beta (ESR2)
DMIGXRJ	MT	DTT
DMIGXRJ	MA	Inhibitor
DMIGXRJ	RN	2-Phenylspiroindenes: a novel class of selective estrogen receptor modulators (SERMs). Bioorg Med Chem Lett. 2003 Feb 10;13(3):479-83.
DMIGXRJ	RU	https://pubmed.ncbi.nlm.nih.gov/12565955

DM40RS3	DI	DM40RS3
DM40RS3	DN	2-(3-Hydroxy-phenyl)-6-methyl-chromen-4-one
DM40RS3	MI	TTNJYV2
DM40RS3	MN	Gamma-aminobutyric acid receptor (GAR)
DM40RS3	MT	DTT
DM40RS3	MA	Inhibitor
DM40RS3	RN	Refinement and evaluation of a pharmacophore model for flavone derivatives binding to the benzodiazepine site of the GABA(A) receptor. J Med Chem. 2002 Sep 12;45(19):4188-201.
DM40RS3	RU	https://pubmed.ncbi.nlm.nih.gov/12213060

DMAH0ZG	DI	DMAH0ZG
DMAH0ZG	DN	2-(3-hydroxyphenyl)-7-methoxychroman-4-one
DMAH0ZG	MI	TTSZLWK
DMAH0ZG	MN	Aromatase (CYP19A1)
DMAH0ZG	MT	DTT
DMAH0ZG	MA	Inhibitor
DMAH0ZG	RN	New 7,8-benzoflavanones as potent aromatase inhibitors: synthesis and biological evaluation. Bioorg Med Chem. 2008 Feb 1;16(3):1474-80.
DMAH0ZG	RU	https://pubmed.ncbi.nlm.nih.gov/18042388

DMV9M57	DI	DMV9M57
DMV9M57	DN	2-(3-hydroxyphenyl)quinolin-6-ol
DMV9M57	MI	TTIWB6L
DMV9M57	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMV9M57	MT	DTT
DMV9M57	MA	Inhibitor
DMV9M57	RN	Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors... J Med Chem. 2008 Apr 10;51(7):2158-69.
DMV9M57	RU	https://pubmed.ncbi.nlm.nih.gov/18324762

DMXRAE3	DI	DMXRAE3
DMXRAE3	DN	2-(3''-indolylethyloxy)adenosine
DMXRAE3	MI	TTK25J1
DMXRAE3	MN	Adenosine A1 receptor (ADORA1)
DMXRAE3	MT	DTT
DMXRAE3	MA	Inhibitor
DMXRAE3	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DMXRAE3	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DMXRAE3	DI	DMXRAE3
DMXRAE3	DN	2-(3''-indolylethyloxy)adenosine
DMXRAE3	MI	TTM2AOE
DMXRAE3	MN	Adenosine A2a receptor (ADORA2A)
DMXRAE3	MT	DTT
DMXRAE3	MA	Inhibitor
DMXRAE3	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DMXRAE3	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DMXRAE3	DI	DMXRAE3
DMXRAE3	DN	2-(3''-indolylethyloxy)adenosine
DMXRAE3	MI	TTJFY5U
DMXRAE3	MN	Adenosine A3 receptor (ADORA3)
DMXRAE3	MT	DTT
DMXRAE3	MA	Inhibitor
DMXRAE3	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DMXRAE3	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DMML0VP	DI	DMML0VP
DMML0VP	DN	2-(3-iodophenyl)histamine
DMML0VP	MI	TTTIBOJ
DMML0VP	MN	Histamine H1 receptor (H1R)
DMML0VP	MT	DTT
DMML0VP	MA	Agonist
DMML0VP	RN	Multiple differences in agonist and antagonist pharmacology between human and guinea pig histamine H1-receptor. J Pharmacol Exp Ther. 2003 Jun;305(3):1104-15.
DMML0VP	RU	https://pubmed.ncbi.nlm.nih.gov/12626648

DM59VBG	DI	DM59VBG
DM59VBG	DN	2-(3-Isobutyl-phenyl)-propionic acid
DM59VBG	MI	TTMWT8Z
DM59VBG	MN	C-X-C chemokine receptor type 1 (CXCR1)
DM59VBG	MT	DTT
DM59VBG	MA	Inhibitor
DM59VBG	RN	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
DM59VBG	RU	https://pubmed.ncbi.nlm.nih.gov/15974585

DM59VBG	DI	DM59VBG
DM59VBG	DN	2-(3-Isobutyl-phenyl)-propionic acid
DM59VBG	MI	TT30C9G
DM59VBG	MN	C-X-C chemokine receptor type 2 (CXCR2)
DM59VBG	MT	DTT
DM59VBG	MA	Inhibitor
DM59VBG	RN	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
DM59VBG	RU	https://pubmed.ncbi.nlm.nih.gov/15974585

DMUOWNE	DI	DMUOWNE
DMUOWNE	DN	2-(3-Isopropyl-phenyl)-propionic acid
DMUOWNE	MI	TTMWT8Z
DMUOWNE	MN	C-X-C chemokine receptor type 1 (CXCR1)
DMUOWNE	MT	DTT
DMUOWNE	MA	Inhibitor
DMUOWNE	RN	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
DMUOWNE	RU	https://pubmed.ncbi.nlm.nih.gov/15974585

DMUOWNE	DI	DMUOWNE
DMUOWNE	DN	2-(3-Isopropyl-phenyl)-propionic acid
DMUOWNE	MI	TT30C9G
DMUOWNE	MN	C-X-C chemokine receptor type 2 (CXCR2)
DMUOWNE	MT	DTT
DMUOWNE	MA	Inhibitor
DMUOWNE	RN	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
DMUOWNE	RU	https://pubmed.ncbi.nlm.nih.gov/15974585

DMMDNA8	DI	DMMDNA8
DMMDNA8	DN	2-(3-Mercapto-propyl)-pentanedioic acid
DMMDNA8	MI	TT9G4N0
DMMDNA8	MN	Glutamate carboxypeptidase II (GCPII)
DMMDNA8	MT	DTT
DMMDNA8	MA	Inhibitor
DMMDNA8	RN	Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. J Med Chem. 2003 May 8;46(10):1989-96.
DMMDNA8	RU	https://pubmed.ncbi.nlm.nih.gov/12723961

DM21MAU	DI	DM21MAU
DM21MAU	DN	2-(3-methoxybenzylthio)-2-phenylacetic acid
DM21MAU	MI	TTLUQ8E
DM21MAU	MN	Hormone sensitive lipase (LIPE)
DM21MAU	MT	DTT
DM21MAU	MA	Inhibitor
DM21MAU	RN	Combining ligand-based pharmacophore modeling, quantitative structure-activity relationship analysis and in silico screening for the discovery of n... J Med Chem. 2008 Oct 23;51(20):6478-94.
DM21MAU	RU	https://pubmed.ncbi.nlm.nih.gov/18808096

DMCDGAU	DI	DMCDGAU
DMCDGAU	DN	2-(3'-Methoxyphenyl) Benzimidazole-4-Carboxamide
DMCDGAU	MI	TTVDSZ0
DMCDGAU	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMCDGAU	MT	DTT
DMCDGAU	MA	Inhibitor
DMCDGAU	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMCDGAU	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM4C9H2	DI	DM4C9H2
DM4C9H2	DN	2-(3-Methoxy-phenyl)-1-methyl-ethylamine
DM4C9H2	MI	TTSQIFT
DM4C9H2	MN	5-HT 1A receptor (HTR1A)
DM4C9H2	MT	DTT
DM4C9H2	MA	Inhibitor
DM4C9H2	RN	5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. J Med Chem. 1986 Feb;29(2):194-9.
DM4C9H2	RU	https://pubmed.ncbi.nlm.nih.gov/3950904

DM4C9H2	DI	DM4C9H2
DM4C9H2	DN	2-(3-Methoxy-phenyl)-1-methyl-ethylamine
DM4C9H2	MI	TT6MSOK
DM4C9H2	MN	5-HT 1D receptor (HTR1D)
DM4C9H2	MT	DTT
DM4C9H2	MA	Inhibitor
DM4C9H2	RN	5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. J Med Chem. 1986 Feb;29(2):194-9.
DM4C9H2	RU	https://pubmed.ncbi.nlm.nih.gov/3950904

DM4C9H2	DI	DM4C9H2
DM4C9H2	DN	2-(3-Methoxy-phenyl)-1-methyl-ethylamine
DM4C9H2	MI	TTJQOD7
DM4C9H2	MN	5-HT 2A receptor (HTR2A)
DM4C9H2	MT	DTT
DM4C9H2	MA	Inhibitor
DM4C9H2	RN	5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. J Med Chem. 1986 Feb;29(2):194-9.
DM4C9H2	RU	https://pubmed.ncbi.nlm.nih.gov/3950904

DMBGVEK	DI	DMBGVEK
DMBGVEK	DN	2-(3-Methoxy-phenyl)-6-methyl-chromen-4-one
DMBGVEK	MI	TTNJYV2
DMBGVEK	MN	Gamma-aminobutyric acid receptor (GAR)
DMBGVEK	MT	DTT
DMBGVEK	MA	Inhibitor
DMBGVEK	RN	Refinement and evaluation of a pharmacophore model for flavone derivatives binding to the benzodiazepine site of the GABA(A) receptor. J Med Chem. 2002 Sep 12;45(19):4188-201.
DMBGVEK	RU	https://pubmed.ncbi.nlm.nih.gov/12213060

DMASH36	DI	DMASH36
DMASH36	DN	2-(3-methoxyphenyl)-6-morpholino-4H-pyran-4-one
DMASH36	MI	TTK3PY9
DMASH36	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMASH36	MT	DTT
DMASH36	MA	Inhibitor
DMASH36	RN	Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72.
DMASH36	RU	https://pubmed.ncbi.nlm.nih.gov/17371003

DME09J2	DI	DME09J2
DME09J2	DN	2-(3-Methyl-3H-imidazol-4-yl)-ethylamine
DME09J2	MI	TT9JNIC
DME09J2	MN	Histamine H3 receptor (H3R)
DME09J2	MT	DTT
DME09J2	MA	Inhibitor
DME09J2	RN	New acetylene based histamine H3 receptor antagonists derived from the marine natural product verongamine. Bioorg Med Chem Lett. 1998 May 19;8(10):1133-8.
DME09J2	RU	https://pubmed.ncbi.nlm.nih.gov/9871722

DMFOA6R	DI	DMFOA6R
DMFOA6R	DN	2-(3-Methyl-indole-1-sulfonyl)-benzoic acid
DMFOA6R	MI	TTHWMFZ
DMFOA6R	MN	Fatty acid-binding protein 4 (FABP4)
DMFOA6R	MT	DTT
DMFOA6R	MA	Inhibitor
DMFOA6R	RN	Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4445-8.
DMFOA6R	RU	https://pubmed.ncbi.nlm.nih.gov/15357969

DM1J4MT	DI	DM1J4MT
DM1J4MT	DN	2-(3-Methyl-piperazin-1-yl)-6-nitro-quinoline
DM1J4MT	MI	TT3ROYC
DM1J4MT	MN	Serotonin transporter (SERT)
DM1J4MT	MT	DTT
DM1J4MT	MA	Inhibitor
DM1J4MT	RN	Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 1. Bioorg Med Chem Lett. 2000 Jul 17;10(14):1559-62.
DM1J4MT	RU	https://pubmed.ncbi.nlm.nih.gov/10915050

DM4D1UT	DI	DM4D1UT
DM4D1UT	DN	2-(3-Methylsulfanyl-propyl)-pentanedioic acid
DM4D1UT	MI	TT9G4N0
DM4D1UT	MN	Glutamate carboxypeptidase II (GCPII)
DM4D1UT	MT	DTT
DM4D1UT	MA	Inhibitor
DM4D1UT	RN	Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. J Med Chem. 2003 May 8;46(10):1989-96.
DM4D1UT	RU	https://pubmed.ncbi.nlm.nih.gov/12723961

DMMYQ9R	DI	DMMYQ9R
DMMYQ9R	DN	2-(3-nitrophenyl)-4,5-dihydro-1H-imidazole
DMMYQ9R	MI	TTGP7BY
DMMYQ9R	MN	Monoamine oxidase type B (MAO-B)
DMMYQ9R	MT	DTT
DMMYQ9R	MA	Inhibitor
DMMYQ9R	RN	Ultrasound promoted synthesis of 2-imidazolines in water: a greener approach toward monoamine oxidase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):546-9.
DMMYQ9R	RU	https://pubmed.ncbi.nlm.nih.gov/19064321

DM6GLEA	DI	DM6GLEA
DM6GLEA	DN	2-(3-Phenoxy-benzoylamino)-benzoic acid
DM6GLEA	MI	TTRVTMX
DM6GLEA	MN	Bacterial Beta-ketoacyl-ACP synthase III (Bact fabH)
DM6GLEA	MT	DTT
DM6GLEA	MA	Inhibitor
DM6GLEA	RN	Structure-based design, synthesis, and study of potent inhibitors of beta-ketoacyl-acyl carrier protein synthase III as potential antimicrobial age... J Med Chem. 2005 Mar 10;48(5):1596-609.
DM6GLEA	RU	https://pubmed.ncbi.nlm.nih.gov/15743201

DMIQBXD	DI	DMIQBXD
DMIQBXD	DN	2-(3-Phenyl-propyl)-1,2-dihydro-indazol-3-one
DMIQBXD	MI	TT2J34L
DMIQBXD	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMIQBXD	MT	DTT
DMIQBXD	MA	Inhibitor
DMIQBXD	RN	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
DMIQBXD	RU	https://pubmed.ncbi.nlm.nih.gov/1848292

DMIQBXD	DI	DMIQBXD
DMIQBXD	DN	2-(3-Phenyl-propyl)-1,2-dihydro-indazol-3-one
DMIQBXD	MI	TT8NGED
DMIQBXD	MN	Prostaglandin G/H synthase 1 (COX-1)
DMIQBXD	MT	DTT
DMIQBXD	MA	Inhibitor
DMIQBXD	RN	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
DMIQBXD	RU	https://pubmed.ncbi.nlm.nih.gov/1848292

DMIQBXD	DI	DMIQBXD
DMIQBXD	DN	2-(3-Phenyl-propyl)-1,2-dihydro-indazol-3-one
DMIQBXD	MI	TTVKILB
DMIQBXD	MN	Prostaglandin G/H synthase 2 (COX-2)
DMIQBXD	MT	DTT
DMIQBXD	MA	Inhibitor
DMIQBXD	RN	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
DMIQBXD	RU	https://pubmed.ncbi.nlm.nih.gov/1848292

DM4WOT6	DI	DM4WOT6
DM4WOT6	DN	2-(3-phenylthio)phenyl)-1-aminoethane
DM4WOT6	MI	TTJS8PY
DM4WOT6	MN	5-HT 6 receptor (HTR6)
DM4WOT6	MT	DTT
DM4WOT6	MA	Inhibitor
DM4WOT6	RN	Binding of sulfonyl-containing arylalkylamines at human 5-HT6 serotonin receptors. J Med Chem. 2006 Aug 24;49(17):5217-25.
DM4WOT6	RU	https://pubmed.ncbi.nlm.nih.gov/16913710

DMZ5H8O	DI	DMZ5H8O
DMZ5H8O	DN	2-(3-Piperidin-1-yl-propyl)-3H-quinazolin-4-one
DMZ5H8O	MI	TTVDSZ0
DMZ5H8O	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMZ5H8O	MT	DTT
DMZ5H8O	MA	Inhibitor
DMZ5H8O	RN	Rational approaches to discovery of orally active and brain-penetrable quinazolinone inhibitors of poly(ADP-ribose)polymerase. J Med Chem. 2004 Aug 12;47(17):4151-4.
DMZ5H8O	RU	https://pubmed.ncbi.nlm.nih.gov/15293985

DMNCP8Y	DI	DMNCP8Y
DMNCP8Y	DN	2-(3''-pyrrolylethyloxy)adenosine
DMNCP8Y	MI	TTK25J1
DMNCP8Y	MN	Adenosine A1 receptor (ADORA1)
DMNCP8Y	MT	DTT
DMNCP8Y	MA	Inhibitor
DMNCP8Y	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DMNCP8Y	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DMNCP8Y	DI	DMNCP8Y
DMNCP8Y	DN	2-(3''-pyrrolylethyloxy)adenosine
DMNCP8Y	MI	TTM2AOE
DMNCP8Y	MN	Adenosine A2a receptor (ADORA2A)
DMNCP8Y	MT	DTT
DMNCP8Y	MA	Inhibitor
DMNCP8Y	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DMNCP8Y	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DMNCP8Y	DI	DMNCP8Y
DMNCP8Y	DN	2-(3''-pyrrolylethyloxy)adenosine
DMNCP8Y	MI	TTJFY5U
DMNCP8Y	MN	Adenosine A3 receptor (ADORA3)
DMNCP8Y	MT	DTT
DMNCP8Y	MA	Inhibitor
DMNCP8Y	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DMNCP8Y	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DM7NGV1	DI	DM7NGV1
DM7NGV1	DN	2-(3'-Vinyl-biphenyl-4-yl)-propionic acid
DM7NGV1	MI	TT8NGED
DM7NGV1	MN	Prostaglandin G/H synthase 1 (COX-1)
DM7NGV1	MT	DTT
DM7NGV1	MA	Inhibitor
DM7NGV1	RN	Structure-based design of COX-2 selectivity into flurbiprofen. Bioorg Med Chem Lett. 1999 Feb 8;9(3):307-12.
DM7NGV1	RU	https://pubmed.ncbi.nlm.nih.gov/10091674

DM27CQJ	DI	DM27CQJ
DM27CQJ	DN	2-(4-(3-chlorophenyl)but-1-ynyl)-6-methylpyridine
DM27CQJ	MI	TTHS256
DM27CQJ	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM27CQJ	MT	DTT
DM27CQJ	MA	Inhibitor
DM27CQJ	RN	Structure-activity relationships for the linker in a series of pyridinyl-alkynes that are antagonists of the metabotropic glutamate receptor 5 (mGl... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4788-91.
DM27CQJ	RU	https://pubmed.ncbi.nlm.nih.gov/16837196

DMOYT8I	DI	DMOYT8I
DMOYT8I	DN	2-(4-(4-Hydroxyphenyl)thiazol-2-ylamino)phenol
DMOYT8I	MI	TTWHDVK
DMOYT8I	MN	Fructose-1,6-bisphosphatase (FBP)
DMOYT8I	MT	DTT
DMOYT8I	MA	Inhibitor
DMOYT8I	RN	A library of novel allosteric inhibitors against fructose 1,6-bisphosphatase. Bioorg Med Chem. 2009 Jun 1;17(11):3916-22.
DMOYT8I	RU	https://pubmed.ncbi.nlm.nih.gov/19419876

DMDAO5T	DI	DMDAO5T
DMDAO5T	DN	2-(4-(benzenesulfonyl)phenyl)-1-aminoethane
DMDAO5T	MI	TTJS8PY
DMDAO5T	MN	5-HT 6 receptor (HTR6)
DMDAO5T	MT	DTT
DMDAO5T	MA	Inhibitor
DMDAO5T	RN	Binding of sulfonyl-containing arylalkylamines at human 5-HT6 serotonin receptors. J Med Chem. 2006 Aug 24;49(17):5217-25.
DMDAO5T	RU	https://pubmed.ncbi.nlm.nih.gov/16913710

DMFNQZS	DI	DMFNQZS
DMFNQZS	DN	2-(4-(methylamino)phenyl)benzo[d]thiazol-6-ol
DMFNQZS	MI	TTE4KHA
DMFNQZS	MN	Amyloid beta A4 protein (APP)
DMFNQZS	MT	DTT
DMFNQZS	MA	Inhibitor
DMFNQZS	RN	Synthesis of biphenyltrienes as probes for beta-amyloid plaques. J Med Chem. 2006 May 4;49(9):2841-4.
DMFNQZS	RU	https://pubmed.ncbi.nlm.nih.gov/16640346

DMVD6HE	DI	DMVD6HE
DMVD6HE	DN	2-(4-(methylsulfonyl)phenyl)-3-phenylquinoline
DMVD6HE	MI	TTVKILB
DMVD6HE	MN	Prostaglandin G/H synthase 2 (COX-2)
DMVD6HE	MT	DTT
DMVD6HE	MA	Inhibitor
DMVD6HE	RN	Design, synthesis and biological evaluation of new 2,3-diarylquinoline derivatives as selective cyclooxygenase-2 inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1029-33.
DMVD6HE	RU	https://pubmed.ncbi.nlm.nih.gov/20061161

DM1TZNK	DI	DM1TZNK
DM1TZNK	DN	2-(4-(methylsulfonyl)phenyl)pyridine
DM1TZNK	MI	TTVKILB
DM1TZNK	MN	Prostaglandin G/H synthase 2 (COX-2)
DM1TZNK	MT	DTT
DM1TZNK	MA	Inhibitor
DM1TZNK	RN	Synthesis, anti-inflammatory activity, and in vitro antitumor effect of a novel class of cyclooxygenase inhibitors: 4-(aryloyl)phenyl methyl sulfones. J Med Chem. 2010 Sep 23;53(18):6560-71.
DM1TZNK	RU	https://pubmed.ncbi.nlm.nih.gov/20804197

DM4X0SJ	DI	DM4X0SJ
DM4X0SJ	DN	2-(4,5-dihydro-1H-imidazol-2-yl)quinoline
DM4X0SJ	MI	TT3WG5C
DM4X0SJ	MN	Monoamine oxidase type A (MAO-A)
DM4X0SJ	MT	DTT
DM4X0SJ	MA	Inhibitor
DM4X0SJ	RN	Ultrasound promoted synthesis of 2-imidazolines in water: a greener approach toward monoamine oxidase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):546-9.
DM4X0SJ	RU	https://pubmed.ncbi.nlm.nih.gov/19064321

DM4X0SJ	DI	DM4X0SJ
DM4X0SJ	DN	2-(4,5-dihydro-1H-imidazol-2-yl)quinoline
DM4X0SJ	MI	TTGP7BY
DM4X0SJ	MN	Monoamine oxidase type B (MAO-B)
DM4X0SJ	MT	DTT
DM4X0SJ	MA	Inhibitor
DM4X0SJ	RN	Ultrasound promoted synthesis of 2-imidazolines in water: a greener approach toward monoamine oxidase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):546-9.
DM4X0SJ	RU	https://pubmed.ncbi.nlm.nih.gov/19064321

DM4BFHR	DI	DM4BFHR
DM4BFHR	DN	2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile
DM4BFHR	MI	TTGKNB4
DM4BFHR	MN	Epidermal growth factor receptor (EGFR)
DM4BFHR	MT	DTT
DM4BFHR	MA	Inhibitor
DM4BFHR	RN	Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine... J Med Chem. 1991 Jun;34(6):1896-907.
DM4BFHR	RU	https://pubmed.ncbi.nlm.nih.gov/1676428

DM1UBGQ	DI	DM1UBGQ
DM1UBGQ	DN	2-(4,6-dimethoxypyrimidin-2-yloxy)-5-hexylphenol
DM1UBGQ	MI	TTVTX4N
DM1UBGQ	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DM1UBGQ	MT	DTT
DM1UBGQ	MA	Inhibitor
DM1UBGQ	RN	Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33.
DM1UBGQ	RU	https://pubmed.ncbi.nlm.nih.gov/18457948

DMUANX1	DI	DMUANX1
DMUANX1	DN	2-(4-amino-2-chlorophenoxy)-5-chlorophenol
DMUANX1	MI	TTNX2CS
DMUANX1	MN	Plasmodium Enoyl-ACP reductase (Malaria fabI)
DMUANX1	MT	DTT
DMUANX1	MA	Inhibitor
DMUANX1	RN	Synthesis, biological activity, and X-ray crystal structural analysis of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. ... Bioorg Med Chem Lett. 2005 Dec 1;15(23):5247-52.
DMUANX1	RU	https://pubmed.ncbi.nlm.nih.gov/16198563

DMSHPCW	DI	DMSHPCW
DMSHPCW	DN	2-(4-Amino-3'-chloro-biphenyl-3-yl)-propan-2-ol
DMSHPCW	MI	TTUV8G9
DMSHPCW	MN	Progesterone receptor (PGR)
DMSHPCW	MT	DTT
DMSHPCW	MA	Inhibitor
DMSHPCW	RN	Potent nonsteroidal progesterone receptor agonists: synthesis and SAR study of 6-aryl benzoxazines. Bioorg Med Chem Lett. 2002 Mar 11;12(5):787-90.
DMSHPCW	RU	https://pubmed.ncbi.nlm.nih.gov/11859003

DMP0GI8	DI	DMP0GI8
DMP0GI8	DN	2-(4-aminophenoxy)-5-hexylphenol
DMP0GI8	MI	TTVTX4N
DMP0GI8	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DMP0GI8	MT	DTT
DMP0GI8	MA	Inhibitor
DMP0GI8	RN	Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33.
DMP0GI8	RU	https://pubmed.ncbi.nlm.nih.gov/18457948

DMGQHBU	DI	DMGQHBU
DMGQHBU	DN	2-(4-Amino-phenyl)-6-methyl-chromen-4-one
DMGQHBU	MI	TTNJYV2
DMGQHBU	MN	Gamma-aminobutyric acid receptor (GAR)
DMGQHBU	MT	DTT
DMGQHBU	MA	Inhibitor
DMGQHBU	RN	Refinement and evaluation of a pharmacophore model for flavone derivatives binding to the benzodiazepine site of the GABA(A) receptor. J Med Chem. 2002 Sep 12;45(19):4188-201.
DMGQHBU	RU	https://pubmed.ncbi.nlm.nih.gov/12213060

DM7LBEG	DI	DM7LBEG
DM7LBEG	DN	2-(4-Amino-phenyl)-8-hydroxy-3H-quinazolin-4-one
DM7LBEG	MI	TTVDSZ0
DM7LBEG	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DM7LBEG	MT	DTT
DM7LBEG	MA	Inhibitor
DM7LBEG	RN	Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56.
DM7LBEG	RU	https://pubmed.ncbi.nlm.nih.gov/9857092

DMJRDAQ	DI	DMJRDAQ
DMJRDAQ	DN	2-(4-Amino-phenyl)-8-methyl-3H-quinazolin-4-one
DMJRDAQ	MI	TTVDSZ0
DMJRDAQ	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMJRDAQ	MT	DTT
DMJRDAQ	MA	Inhibitor
DMJRDAQ	RN	Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56.
DMJRDAQ	RU	https://pubmed.ncbi.nlm.nih.gov/9857092

DM2P9L5	DI	DM2P9L5
DM2P9L5	DN	2-(4-Amino-phenyl)-benzo[h]chromen-4-one
DM2P9L5	MI	TTK3PY9
DM2P9L5	MN	DNA-dependent protein kinase catalytic (PRKDC)
DM2P9L5	MT	DTT
DM2P9L5	MA	Inhibitor
DM2P9L5	RN	Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85.
DM2P9L5	RU	https://pubmed.ncbi.nlm.nih.gov/15658870

DMMU2BZ	DI	DMMU2BZ
DMMU2BZ	DN	2-(4-aminophenylsulfonamido)acetic acid
DMMU2BZ	MI	TTFBNVI
DMMU2BZ	MN	Aldose reductase (AKR1B1)
DMMU2BZ	MT	DTT
DMMU2BZ	MA	Inhibitor
DMMU2BZ	RN	Design and synthesis of N-(3,5-difluoro-4-hydroxyphenyl)benzenesulfonamides as aldose reductase inhibitors. Bioorg Med Chem. 2008 Apr 1;16(7):3926-32.
DMMU2BZ	RU	https://pubmed.ncbi.nlm.nih.gov/18267362

DM2JG49	DI	DM2JG49
DM2JG49	DN	2-(4-Azido-phenyl)-8-methoxy-3H-quinazolin-4-one
DM2JG49	MI	TTVDSZ0
DM2JG49	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DM2JG49	MT	DTT
DM2JG49	MA	Inhibitor
DM2JG49	RN	Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56.
DM2JG49	RU	https://pubmed.ncbi.nlm.nih.gov/9857092

DMJA5Y4	DI	DMJA5Y4
DMJA5Y4	DN	2-(4-benzoylpiperazin-1-yl)thiazole-5-carboxamide
DMJA5Y4	MI	TT6RIOV
DMJA5Y4	MN	Acyl-CoA desaturase (SCD)
DMJA5Y4	MT	DTT
DMJA5Y4	MA	Inhibitor
DMJA5Y4	RN	Thiazole analog as stearoyl-CoA desaturase 1 inhibitor. Bioorg Med Chem Lett. 2009 Sep 1;19(17):5214-7.
DMJA5Y4	RU	https://pubmed.ncbi.nlm.nih.gov/19632834

DMGMZV9	DI	DMGMZV9
DMGMZV9	DN	2-(4-benzoylpiperidine-1-carbonyl)benzoic acid
DMGMZV9	MI	TTP18AY
DMGMZV9	MN	Carboxypeptidase B2 (CPB2)
DMGMZV9	MT	DTT
DMGMZV9	MA	Inhibitor
DMGMZV9	RN	A new type of five-membered heterocyclic inhibitors of basic metallocarboxypeptidases. Eur J Med Chem. 2009 Aug;44(8):3266-71.
DMGMZV9	RU	https://pubmed.ncbi.nlm.nih.gov/19386397

DM6R4MG	DI	DM6R4MG
DM6R4MG	DN	2-(4-benzylphenoxy)ethanamine
DM6R4MG	MI	TTXZEAJ
DM6R4MG	MN	Leukotriene A-4 hydrolase (LTA4H)
DM6R4MG	MT	DTT
DM6R4MG	MA	Inhibitor
DM6R4MG	RN	Activation and inhibition of leukotriene A4 hydrolase aminopeptidase activity by diphenyl ether and derivatives. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6549-52.
DM6R4MG	RU	https://pubmed.ncbi.nlm.nih.gov/18952425

DM1V7EF	DI	DM1V7EF
DM1V7EF	DN	2-(4-Benzyl-piperazin-1-yl)-benzothiazole
DM1V7EF	MI	TTPC4TU
DM1V7EF	MN	5-HT 3A receptor (HTR3A)
DM1V7EF	MT	DTT
DM1V7EF	MA	Inhibitor
DM1V7EF	RN	Synthesis of 2-piperazinylbenzothiazole and 2-piperazinylbenzoxazole derivatives with 5-HT3 antagonist and 5-HT4 agonist properties. J Med Chem. 1994 Apr 29;37(9):1320-5.
DM1V7EF	RU	https://pubmed.ncbi.nlm.nih.gov/8176710

DM1V7EF	DI	DM1V7EF
DM1V7EF	DN	2-(4-Benzyl-piperazin-1-yl)-benzothiazole
DM1V7EF	MI	TTR6K75
DM1V7EF	MN	5-HT 3B receptor (HTR3B)
DM1V7EF	MT	DTT
DM1V7EF	MA	Inhibitor
DM1V7EF	RN	Synthesis of 2-piperazinylbenzothiazole and 2-piperazinylbenzoxazole derivatives with 5-HT3 antagonist and 5-HT4 agonist properties. J Med Chem. 1994 Apr 29;37(9):1320-5.
DM1V7EF	RU	https://pubmed.ncbi.nlm.nih.gov/8176710

DMFGCS1	DI	DMFGCS1
DMFGCS1	DN	2-(4-benzyl-piperidin-1-ylmethyl)-1H-indol-6-ol
DMFGCS1	MI	TTN9D8E
DMFGCS1	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMFGCS1	MT	DTT
DMFGCS1	MA	Inhibitor
DMFGCS1	RN	Selective NR1/2B N-methyl-D-aspartate receptor antagonists among indole-2-carboxamides and benzimidazole-2-carboxamides. J Med Chem. 2007 Mar 8;50(5):901-14.
DMFGCS1	RU	https://pubmed.ncbi.nlm.nih.gov/17290978

DMID9YA	DI	DMID9YA
DMID9YA	DN	2-(4-Benzyl-piperidin-1-ylmethyl)-chroman-4-one
DMID9YA	MI	TTSQIFT
DMID9YA	MN	5-HT 1A receptor (HTR1A)
DMID9YA	MT	DTT
DMID9YA	MA	Inhibitor
DMID9YA	RN	Synthesis and structure-activity relationships of 1-aralkyl-4-benzylpiperidine and 1-aralkyl-4-benzylpiperazine derivatives as potent sigma ligands. J Med Chem. 2005 Jan 13;48(1):266-73.
DMID9YA	RU	https://pubmed.ncbi.nlm.nih.gov/15634021

DM7QK5C	DI	DM7QK5C
DM7QK5C	DN	2-(4-bromo-2-(hydroxymethyl)phenoxy)acetic acid
DM7QK5C	MI	TTQDMX5
DM7QK5C	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DM7QK5C	MT	DTT
DM7QK5C	MA	Inhibitor
DM7QK5C	RN	Novel selective orally active CRTH2 antagonists for allergic inflammation developed from in silico derived hits. J Med Chem. 2006 Nov 16;49(23):6638-41.
DM7QK5C	RU	https://pubmed.ncbi.nlm.nih.gov/17154491

DM6I1NQ	DI	DM6I1NQ
DM6I1NQ	DN	2-(4-bromo-2-cyclohexylphenoxy)acetic acid
DM6I1NQ	MI	TTQDMX5
DM6I1NQ	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DM6I1NQ	MT	DTT
DM6I1NQ	MA	Inhibitor
DM6I1NQ	RN	2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4347-50.
DM6I1NQ	RU	https://pubmed.ncbi.nlm.nih.gov/17531480

DMQVUZP	DI	DMQVUZP
DMQVUZP	DN	2-(4-bromo-2-formylphenoxy)acetic acid
DMQVUZP	MI	TTQDMX5
DMQVUZP	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMQVUZP	MT	DTT
DMQVUZP	MA	Inhibitor
DMQVUZP	RN	Novel selective orally active CRTH2 antagonists for allergic inflammation developed from in silico derived hits. J Med Chem. 2006 Nov 16;49(23):6638-41.
DMQVUZP	RU	https://pubmed.ncbi.nlm.nih.gov/17154491

DM79JVK	DI	DM79JVK
DM79JVK	DN	2-(4-Bromo-2-methoxy-phenyl)-1-methyl-ethylamine
DM79JVK	MI	TTSQIFT
DM79JVK	MN	5-HT 1A receptor (HTR1A)
DM79JVK	MT	DTT
DM79JVK	MA	Inhibitor
DM79JVK	RN	5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. J Med Chem. 1986 Feb;29(2):194-9.
DM79JVK	RU	https://pubmed.ncbi.nlm.nih.gov/3950904

DM79JVK	DI	DM79JVK
DM79JVK	DN	2-(4-Bromo-2-methoxy-phenyl)-1-methyl-ethylamine
DM79JVK	MI	TT6MSOK
DM79JVK	MN	5-HT 1D receptor (HTR1D)
DM79JVK	MT	DTT
DM79JVK	MA	Inhibitor
DM79JVK	RN	5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. J Med Chem. 1986 Feb;29(2):194-9.
DM79JVK	RU	https://pubmed.ncbi.nlm.nih.gov/3950904

DM79JVK	DI	DM79JVK
DM79JVK	DN	2-(4-Bromo-2-methoxy-phenyl)-1-methyl-ethylamine
DM79JVK	MI	TTJQOD7
DM79JVK	MN	5-HT 2A receptor (HTR2A)
DM79JVK	MT	DTT
DM79JVK	MA	Inhibitor
DM79JVK	RN	5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. J Med Chem. 1986 Feb;29(2):194-9.
DM79JVK	RU	https://pubmed.ncbi.nlm.nih.gov/3950904

DMXAQZ0	DI	DMXAQZ0
DMXAQZ0	DN	2-(4-bromo-2-tert-butylphenoxy)acetic acid
DMXAQZ0	MI	TTQDMX5
DMXAQZ0	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMXAQZ0	MT	DTT
DMXAQZ0	MA	Inhibitor
DMXAQZ0	RN	Novel selective orally active CRTH2 antagonists for allergic inflammation developed from in silico derived hits. J Med Chem. 2006 Nov 16;49(23):6638-41.
DMXAQZ0	RU	https://pubmed.ncbi.nlm.nih.gov/17154491

DMY8GZP	DI	DMY8GZP
DMY8GZP	DN	2-(4-Bromo-3-phenoxy-benzoylamino)-benzoic acid
DMY8GZP	MI	TTRVTMX
DMY8GZP	MN	Bacterial Beta-ketoacyl-ACP synthase III (Bact fabH)
DMY8GZP	MT	DTT
DMY8GZP	MA	Inhibitor
DMY8GZP	RN	Structure-based design, synthesis, and study of potent inhibitors of beta-ketoacyl-acyl carrier protein synthase III as potential antimicrobial age... J Med Chem. 2005 Mar 10;48(5):1596-609.
DMY8GZP	RU	https://pubmed.ncbi.nlm.nih.gov/15743201

DMB49UP	DI	DMB49UP
DMB49UP	DN	2-(4-Bromo-phenyl)-1-methyl-ethylamine
DMB49UP	MI	TTSQIFT
DMB49UP	MN	5-HT 1A receptor (HTR1A)
DMB49UP	MT	DTT
DMB49UP	MA	Inhibitor
DMB49UP	RN	5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. J Med Chem. 1986 Feb;29(2):194-9.
DMB49UP	RU	https://pubmed.ncbi.nlm.nih.gov/3950904

DMB49UP	DI	DMB49UP
DMB49UP	DN	2-(4-Bromo-phenyl)-1-methyl-ethylamine
DMB49UP	MI	TT6MSOK
DMB49UP	MN	5-HT 1D receptor (HTR1D)
DMB49UP	MT	DTT
DMB49UP	MA	Inhibitor
DMB49UP	RN	5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. J Med Chem. 1986 Feb;29(2):194-9.
DMB49UP	RU	https://pubmed.ncbi.nlm.nih.gov/3950904

DMB49UP	DI	DMB49UP
DMB49UP	DN	2-(4-Bromo-phenyl)-1-methyl-ethylamine
DMB49UP	MI	TTJQOD7
DMB49UP	MN	5-HT 2A receptor (HTR2A)
DMB49UP	MT	DTT
DMB49UP	MA	Inhibitor
DMB49UP	RN	5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. J Med Chem. 1986 Feb;29(2):194-9.
DMB49UP	RU	https://pubmed.ncbi.nlm.nih.gov/3950904

DMY5STK	DI	DMY5STK
DMY5STK	DN	2-(4-bromophenylsulfonamido)-N-hydroxyacetamide
DMY5STK	MI	TTJ4QE7
DMY5STK	MN	Matrix metalloproteinase-14 (MMP-14)
DMY5STK	MT	DTT
DMY5STK	MA	Inhibitor
DMY5STK	RN	Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule sheddi... J Med Chem. 2010 Mar 25;53(6):2622-35.
DMY5STK	RU	https://pubmed.ncbi.nlm.nih.gov/20180536

DMY5STK	DI	DMY5STK
DMY5STK	DN	2-(4-bromophenylsulfonamido)-N-hydroxyacetamide
DMY5STK	MI	TT6AZXG
DMY5STK	MN	TNF alpha converting enzyme (ADAM17)
DMY5STK	MT	DTT
DMY5STK	MA	Inhibitor
DMY5STK	RN	Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule sheddi... J Med Chem. 2010 Mar 25;53(6):2622-35.
DMY5STK	RU	https://pubmed.ncbi.nlm.nih.gov/20180536

DMG32HQ	DI	DMG32HQ
DMG32HQ	DN	2-(4-Butoxy-phenoxy)-N-hydroxy-acetamide
DMG32HQ	MI	TT2J34L
DMG32HQ	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMG32HQ	MT	DTT
DMG32HQ	MA	Inhibitor
DMG32HQ	RN	Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8.
DMG32HQ	RU	https://pubmed.ncbi.nlm.nih.gov/2308149

DMEKNZW	DI	DMEKNZW
DMEKNZW	DN	2-(4-Butoxy-phenoxy)-N-hydroxy-N-methyl-acetamide
DMEKNZW	MI	TT2J34L
DMEKNZW	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMEKNZW	MT	DTT
DMEKNZW	MA	Inhibitor
DMEKNZW	RN	Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8.
DMEKNZW	RU	https://pubmed.ncbi.nlm.nih.gov/2308149

DMO5IM0	DI	DMO5IM0
DMO5IM0	DN	2-(4-Butoxy-phenoxy)-N-hydroxy-propionamide
DMO5IM0	MI	TT2J34L
DMO5IM0	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMO5IM0	MT	DTT
DMO5IM0	MA	Inhibitor
DMO5IM0	RN	Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8.
DMO5IM0	RU	https://pubmed.ncbi.nlm.nih.gov/2308149

DMP7CF8	DI	DMP7CF8
DMP7CF8	DN	2-(4-Butoxy-phenyl)-N-hydroxy-N-methyl-acetamide
DMP7CF8	MI	TT2J34L
DMP7CF8	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMP7CF8	MT	DTT
DMP7CF8	MA	Inhibitor
DMP7CF8	RN	Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8.
DMP7CF8	RU	https://pubmed.ncbi.nlm.nih.gov/2308149

DM2XFGJ	DI	DM2XFGJ
DM2XFGJ	DN	2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
DM2XFGJ	MI	TT6PKBN
DM2XFGJ	MN	Proto-oncogene c-Src (SRC)
DM2XFGJ	MT	DTT
DM2XFGJ	MA	Inhibitor
DM2XFGJ	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM2XFGJ	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM7BHYS	DI	DM7BHYS
DM7BHYS	DN	2-(4-chloro-1H-benzo[d]imidazol-2-yl)quinoxaline
DM7BHYS	MI	TTK25J1
DM7BHYS	MN	Adenosine A1 receptor (ADORA1)
DM7BHYS	MT	DTT
DM7BHYS	MA	Inhibitor
DM7BHYS	RN	2-(Benzimidazol-2-yl)quinoxalines: a novel class of selective antagonists at human A(1) and A(3) adenosine receptors designed by 3D database search... J Med Chem. 2005 Dec 29;48(26):8253-60.
DM7BHYS	RU	https://pubmed.ncbi.nlm.nih.gov/16366607

DM7BHYS	DI	DM7BHYS
DM7BHYS	DN	2-(4-chloro-1H-benzo[d]imidazol-2-yl)quinoxaline
DM7BHYS	MI	TTJFY5U
DM7BHYS	MN	Adenosine A3 receptor (ADORA3)
DM7BHYS	MT	DTT
DM7BHYS	MA	Inhibitor
DM7BHYS	RN	2-(Benzimidazol-2-yl)quinoxalines: a novel class of selective antagonists at human A(1) and A(3) adenosine receptors designed by 3D database search... J Med Chem. 2005 Dec 29;48(26):8253-60.
DM7BHYS	RU	https://pubmed.ncbi.nlm.nih.gov/16366607

DM15YM7	DI	DM15YM7
DM15YM7	DN	2-(4-chloro-2-cycloheptylphenoxy)acetic acid
DM15YM7	MI	TTQDMX5
DM15YM7	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DM15YM7	MT	DTT
DM15YM7	MA	Inhibitor
DM15YM7	RN	7-Azaindole-3-acetic acid derivatives: potent and selective CRTh2 receptor antagonists. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4794-8.
DM15YM7	RU	https://pubmed.ncbi.nlm.nih.gov/19592244

DMGYZ8D	DI	DMGYZ8D
DMGYZ8D	DN	2-(4-chloro-2-cyclohexylphenoxy)acetic acid
DMGYZ8D	MI	TTQDMX5
DMGYZ8D	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMGYZ8D	MT	DTT
DMGYZ8D	MA	Inhibitor
DMGYZ8D	RN	2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4347-50.
DMGYZ8D	RU	https://pubmed.ncbi.nlm.nih.gov/17531480

DMA6KQU	DI	DMA6KQU
DMA6KQU	DN	2-(4-chloro-2-cyclopentylphenoxy)acetic acid
DMA6KQU	MI	TTQDMX5
DMA6KQU	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMA6KQU	MT	DTT
DMA6KQU	MA	Inhibitor
DMA6KQU	RN	2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4347-50.
DMA6KQU	RU	https://pubmed.ncbi.nlm.nih.gov/17531480

DMBHFIM	DI	DMBHFIM
DMBHFIM	DN	2-(4-chloro-2-hydroxyphenoxy)benzenaminium
DMBHFIM	MI	TTNX2CS
DMBHFIM	MN	Plasmodium Enoyl-ACP reductase (Malaria fabI)
DMBHFIM	MT	DTT
DMBHFIM	MA	Inhibitor
DMBHFIM	RN	Design and in silico screening of combinatorial library of antimalarial analogs of triclosan inhibiting Plasmodium falciparum enoyl-acyl carrier pr... Eur J Med Chem. 2009 Jul;44(7):3009-19.
DMBHFIM	RU	https://pubmed.ncbi.nlm.nih.gov/19217192

DMOH2YC	DI	DMOH2YC
DMOH2YC	DN	2-(4-Chlorobenzylidene)cyclopentanone
DMOH2YC	MI	TT5ZWB6
DMOH2YC	MN	Dihydrodiol dehydrogenase type I (AKR1C3)
DMOH2YC	MT	DTT
DMOH2YC	MA	Inhibitor
DMOH2YC	RN	New cyclopentane derivatives as inhibitors of steroid metabolizing enzymes AKR1C1 and AKR1C3. Eur J Med Chem. 2009 Jun;44(6):2563-71.
DMOH2YC	RU	https://pubmed.ncbi.nlm.nih.gov/19237229

DMFE93N	DI	DMFE93N
DMFE93N	DN	2-(4-chlorobenzylidene)cyclopentyl ethyl ether
DMFE93N	MI	TT5ZWB6
DMFE93N	MN	Dihydrodiol dehydrogenase type I (AKR1C3)
DMFE93N	MT	DTT
DMFE93N	MA	Inhibitor
DMFE93N	RN	New cyclopentane derivatives as inhibitors of steroid metabolizing enzymes AKR1C1 and AKR1C3. Eur J Med Chem. 2009 Jun;44(6):2563-71.
DMFE93N	RU	https://pubmed.ncbi.nlm.nih.gov/19237229

DMTW9B7	DI	DMTW9B7
DMTW9B7	DN	2-(4-chlorobenzylidene)cyclopentylmethyl ether
DMTW9B7	MI	TT5ZWB6
DMTW9B7	MN	Dihydrodiol dehydrogenase type I (AKR1C3)
DMTW9B7	MT	DTT
DMTW9B7	MA	Inhibitor
DMTW9B7	RN	New cyclopentane derivatives as inhibitors of steroid metabolizing enzymes AKR1C1 and AKR1C3. Eur J Med Chem. 2009 Jun;44(6):2563-71.
DMTW9B7	RU	https://pubmed.ncbi.nlm.nih.gov/19237229

DM1JKWL	DI	DM1JKWL
DM1JKWL	DN	2-(4-chlorobenzyloxyamino)-N-hydroxyacetamide
DM1JKWL	MI	TTHQPL7
DM1JKWL	MN	Carbonic anhydrase I (CA-I)
DM1JKWL	MT	DTT
DM1JKWL	MA	Inhibitor
DM1JKWL	RN	Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with su... Bioorg Med Chem. 2007 Mar 15;15(6):2298-311.
DM1JKWL	RU	https://pubmed.ncbi.nlm.nih.gov/17276072

DM1JKWL	DI	DM1JKWL
DM1JKWL	DN	2-(4-chlorobenzyloxyamino)-N-hydroxyacetamide
DM1JKWL	MI	TTANPDJ
DM1JKWL	MN	Carbonic anhydrase II (CA-II)
DM1JKWL	MT	DTT
DM1JKWL	MA	Inhibitor
DM1JKWL	RN	Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with su... Bioorg Med Chem. 2007 Mar 15;15(6):2298-311.
DM1JKWL	RU	https://pubmed.ncbi.nlm.nih.gov/17276072

DM1JKWL	DI	DM1JKWL
DM1JKWL	DN	2-(4-chlorobenzyloxyamino)-N-hydroxyacetamide
DM1JKWL	MI	TT2LVK8
DM1JKWL	MN	Carbonic anhydrase IX (CA-IX)
DM1JKWL	MT	DTT
DM1JKWL	MA	Inhibitor
DM1JKWL	RN	Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with su... Bioorg Med Chem. 2007 Mar 15;15(6):2298-311.
DM1JKWL	RU	https://pubmed.ncbi.nlm.nih.gov/17276072

DMFGQ7K	DI	DMFGQ7K
DMFGQ7K	DN	2-(4-chlorobenzyloxyamino)-N-hydroxyhexanamide
DMFGQ7K	MI	TTHQPL7
DMFGQ7K	MN	Carbonic anhydrase I (CA-I)
DMFGQ7K	MT	DTT
DMFGQ7K	MA	Inhibitor
DMFGQ7K	RN	Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with su... Bioorg Med Chem. 2007 Mar 15;15(6):2298-311.
DMFGQ7K	RU	https://pubmed.ncbi.nlm.nih.gov/17276072

DMFGQ7K	DI	DMFGQ7K
DMFGQ7K	DN	2-(4-chlorobenzyloxyamino)-N-hydroxyhexanamide
DMFGQ7K	MI	TTANPDJ
DMFGQ7K	MN	Carbonic anhydrase II (CA-II)
DMFGQ7K	MT	DTT
DMFGQ7K	MA	Inhibitor
DMFGQ7K	RN	Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with su... Bioorg Med Chem. 2007 Mar 15;15(6):2298-311.
DMFGQ7K	RU	https://pubmed.ncbi.nlm.nih.gov/17276072

DMFGQ7K	DI	DMFGQ7K
DMFGQ7K	DN	2-(4-chlorobenzyloxyamino)-N-hydroxyhexanamide
DMFGQ7K	MI	TT2LVK8
DMFGQ7K	MN	Carbonic anhydrase IX (CA-IX)
DMFGQ7K	MT	DTT
DMFGQ7K	MA	Inhibitor
DMFGQ7K	RN	Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with su... Bioorg Med Chem. 2007 Mar 15;15(6):2298-311.
DMFGQ7K	RU	https://pubmed.ncbi.nlm.nih.gov/17276072

DMRADWB	DI	DMRADWB
DMRADWB	DN	2-(4-chlorobenzyloxyamino)-N-hydroxypropanamide
DMRADWB	MI	TTHQPL7
DMRADWB	MN	Carbonic anhydrase I (CA-I)
DMRADWB	MT	DTT
DMRADWB	MA	Inhibitor
DMRADWB	RN	Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with su... Bioorg Med Chem. 2007 Mar 15;15(6):2298-311.
DMRADWB	RU	https://pubmed.ncbi.nlm.nih.gov/17276072

DMRADWB	DI	DMRADWB
DMRADWB	DN	2-(4-chlorobenzyloxyamino)-N-hydroxypropanamide
DMRADWB	MI	TTANPDJ
DMRADWB	MN	Carbonic anhydrase II (CA-II)
DMRADWB	MT	DTT
DMRADWB	MA	Inhibitor
DMRADWB	RN	Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with su... Bioorg Med Chem. 2007 Mar 15;15(6):2298-311.
DMRADWB	RU	https://pubmed.ncbi.nlm.nih.gov/17276072

DMRADWB	DI	DMRADWB
DMRADWB	DN	2-(4-chlorobenzyloxyamino)-N-hydroxypropanamide
DMRADWB	MI	TT2LVK8
DMRADWB	MN	Carbonic anhydrase IX (CA-IX)
DMRADWB	MT	DTT
DMRADWB	MA	Inhibitor
DMRADWB	RN	Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with su... Bioorg Med Chem. 2007 Mar 15;15(6):2298-311.
DMRADWB	RU	https://pubmed.ncbi.nlm.nih.gov/17276072

DMQAVM4	DI	DMQAVM4
DMQAVM4	DN	2-(4'-chloro-biphenyl-4-sulfonyl)-pentanoic acid
DMQAVM4	MI	TTLM12X
DMQAVM4	MN	Matrix metalloproteinase-2 (MMP-2)
DMQAVM4	MT	DTT
DMQAVM4	MA	Inhibitor
DMQAVM4	RN	Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3096-100.
DMQAVM4	RU	https://pubmed.ncbi.nlm.nih.gov/16632358

DMQAVM4	DI	DMQAVM4
DMQAVM4	DN	2-(4'-chloro-biphenyl-4-sulfonyl)-pentanoic acid
DMQAVM4	MI	TT6X50U
DMQAVM4	MN	Matrix metalloproteinase-9 (MMP-9)
DMQAVM4	MT	DTT
DMQAVM4	MA	Inhibitor
DMQAVM4	RN	Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3096-100.
DMQAVM4	RU	https://pubmed.ncbi.nlm.nih.gov/16632358

DM6Z9U4	DI	DM6Z9U4
DM6Z9U4	DN	2-(4-Chlorophenyl)-2H-indazole-7-carboxamide
DM6Z9U4	MI	TTVDSZ0
DM6Z9U4	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DM6Z9U4	MT	DTT
DM6Z9U4	MA	Inhibitor
DM6Z9U4	RN	Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor effica... J Med Chem. 2009 Nov 26;52(22):7170-85.
DM6Z9U4	RU	https://pubmed.ncbi.nlm.nih.gov/19873981

DMSB0JA	DI	DMSB0JA
DMSB0JA	DN	2-(4-Chloro-phenyl)-3H-imidazo[4,5-c]quinoline
DMSB0JA	MI	TT1MPAY
DMSB0JA	MN	GABA(A) receptor alpha-1 (GABRA1)
DMSB0JA	MT	DTT
DMSB0JA	MA	Inhibitor
DMSB0JA	RN	Synthesis and structure--activity relationships of fused imidazopyridines: a new series of benzodiazepine receptor ligands. J Med Chem. 1996 Jul 5;39(14):2844-51.
DMSB0JA	RU	https://pubmed.ncbi.nlm.nih.gov/8709114

DMSB0JA	DI	DMSB0JA
DMSB0JA	DN	2-(4-Chloro-phenyl)-3H-imidazo[4,5-c]quinoline
DMSB0JA	MI	TTNJYV2
DMSB0JA	MN	Gamma-aminobutyric acid receptor (GAR)
DMSB0JA	MT	DTT
DMSB0JA	MA	Inhibitor
DMSB0JA	RN	Synthesis and structure--activity relationships of fused imidazopyridines: a new series of benzodiazepine receptor ligands. J Med Chem. 1996 Jul 5;39(14):2844-51.
DMSB0JA	RU	https://pubmed.ncbi.nlm.nih.gov/8709114

DMFQI4C	DI	DMFQI4C
DMFQI4C	DN	2-(4-chlorophenyl)-4,5-dihydro-1H-imidazole
DMFQI4C	MI	TTGP7BY
DMFQI4C	MN	Monoamine oxidase type B (MAO-B)
DMFQI4C	MT	DTT
DMFQI4C	MA	Inhibitor
DMFQI4C	RN	Ultrasound promoted synthesis of 2-imidazolines in water: a greener approach toward monoamine oxidase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):546-9.
DMFQI4C	RU	https://pubmed.ncbi.nlm.nih.gov/19064321

DMYGRS9	DI	DMYGRS9
DMYGRS9	DN	2-(4-chlorophenyl)-5-phenyl-4-isoxazolin-3-one
DMYGRS9	MI	TT1MPAY
DMYGRS9	MN	GABA(A) receptor alpha-1 (GABRA1)
DMYGRS9	MT	DTT
DMYGRS9	MA	Inhibitor
DMYGRS9	RN	Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors. J Med Chem. 2006 Mar 23;49(6):1855-66.
DMYGRS9	RU	https://pubmed.ncbi.nlm.nih.gov/16539371

DMYGRS9	DI	DMYGRS9
DMYGRS9	DN	2-(4-chlorophenyl)-5-phenyl-4-isoxazolin-3-one
DMYGRS9	MI	TTZA1NY
DMYGRS9	MN	GABA(A) receptor beta-2 (GABRB2)
DMYGRS9	MT	DTT
DMYGRS9	MA	Inhibitor
DMYGRS9	RN	Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors. J Med Chem. 2006 Mar 23;49(6):1855-66.
DMYGRS9	RU	https://pubmed.ncbi.nlm.nih.gov/16539371

DMYGRS9	DI	DMYGRS9
DMYGRS9	DN	2-(4-chlorophenyl)-5-phenyl-4-isoxazolin-3-one
DMYGRS9	MI	TT06RH5
DMYGRS9	MN	GABA(A) receptor gamma-2 (GABRG2)
DMYGRS9	MT	DTT
DMYGRS9	MA	Inhibitor
DMYGRS9	RN	Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors. J Med Chem. 2006 Mar 23;49(6):1855-66.
DMYGRS9	RU	https://pubmed.ncbi.nlm.nih.gov/16539371

DMYGRS9	DI	DMYGRS9
DMYGRS9	DN	2-(4-chlorophenyl)-5-phenyl-4-isoxazolin-3-one
DMYGRS9	MI	TTNJYV2
DMYGRS9	MN	Gamma-aminobutyric acid receptor (GAR)
DMYGRS9	MT	DTT
DMYGRS9	MA	Inhibitor
DMYGRS9	RN	Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors. J Med Chem. 2006 Mar 23;49(6):1855-66.
DMYGRS9	RU	https://pubmed.ncbi.nlm.nih.gov/16539371

DM9SGBO	DI	DM9SGBO
DM9SGBO	DN	2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide
DM9SGBO	MI	TTVDSZ0
DM9SGBO	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DM9SGBO	MT	DTT
DM9SGBO	MA	Inhibitor
DM9SGBO	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9SGBO	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM7EUOX	DI	DM7EUOX
DM7EUOX	DN	2-(4-chlorophenyl)-6-morpholino-4H-pyran-4-one
DM7EUOX	MI	TTK3PY9
DM7EUOX	MN	DNA-dependent protein kinase catalytic (PRKDC)
DM7EUOX	MT	DTT
DM7EUOX	MA	Inhibitor
DM7EUOX	RN	Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72.
DM7EUOX	RU	https://pubmed.ncbi.nlm.nih.gov/17371003

DMAPWNR	DI	DMAPWNR
DMAPWNR	DN	2-(4-chlorophenyl)-6-phenyl-9H-purine
DMAPWNR	MI	TTK25J1
DMAPWNR	MN	Adenosine A1 receptor (ADORA1)
DMAPWNR	MT	DTT
DMAPWNR	MA	Inhibitor
DMAPWNR	RN	2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7.
DMAPWNR	RU	https://pubmed.ncbi.nlm.nih.gov/16686529

DMAPWNR	DI	DMAPWNR
DMAPWNR	DN	2-(4-chlorophenyl)-6-phenyl-9H-purine
DMAPWNR	MI	TTM2AOE
DMAPWNR	MN	Adenosine A2a receptor (ADORA2A)
DMAPWNR	MT	DTT
DMAPWNR	MA	Inhibitor
DMAPWNR	RN	2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7.
DMAPWNR	RU	https://pubmed.ncbi.nlm.nih.gov/16686529

DMAPWNR	DI	DMAPWNR
DMAPWNR	DN	2-(4-chlorophenyl)-6-phenyl-9H-purine
DMAPWNR	MI	TTJFY5U
DMAPWNR	MN	Adenosine A3 receptor (ADORA3)
DMAPWNR	MT	DTT
DMAPWNR	MA	Inhibitor
DMAPWNR	RN	2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7.
DMAPWNR	RU	https://pubmed.ncbi.nlm.nih.gov/16686529

DMJORCV	DI	DMJORCV
DMJORCV	DN	2-(4-chlorophenylsulfonyl)naphthalene-1,4-diol
DMJORCV	MI	TTRVTMX
DMJORCV	MN	Bacterial Beta-ketoacyl-ACP synthase III (Bact fabH)
DMJORCV	MT	DTT
DMJORCV	MA	Inhibitor
DMJORCV	RN	Synthesis and biological evaluation of novel sulfonyl-naphthalene-1,4-diols as FabH inhibitors. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6402-5.
DMJORCV	RU	https://pubmed.ncbi.nlm.nih.gov/18996691

DM4XFJI	DI	DM4XFJI
DM4XFJI	DN	2-(4-cyano-2-cyclohexylphenoxy)acetic acid
DM4XFJI	MI	TTQDMX5
DM4XFJI	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DM4XFJI	MT	DTT
DM4XFJI	MA	Inhibitor
DM4XFJI	RN	2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4347-50.
DM4XFJI	RU	https://pubmed.ncbi.nlm.nih.gov/17531480

DMOH46C	DI	DMOH46C
DMOH46C	DN	2-(4-cyclohexylthiosemicarbazono)methyl-phenol
DMOH46C	MI	TTHM0R1
DMOH46C	MN	Steryl-sulfatase (STS)
DMOH46C	MT	DTT
DMOH46C	MA	Inhibitor
DMOH46C	RN	Thiosemicarbazones of formyl benzoic acids as novel potent inhibitors of estrone sulfatase. J Med Chem. 2007 Jul 26;50(15):3661-6.
DMOH46C	RU	https://pubmed.ncbi.nlm.nih.gov/17580843

DM6VQEO	DI	DM6VQEO
DM6VQEO	DN	2-(4-Cyclopentyl-piperazin-1-yl)-quinoline
DM6VQEO	MI	TT9JNIC
DM6VQEO	MN	Histamine H3 receptor (H3R)
DM6VQEO	MT	DTT
DM6VQEO	MA	Inhibitor
DM6VQEO	RN	2-(4-alkylpiperazin-1-yl)quinolines as a new class of imidazole-free histamine H3 receptor antagonists. J Med Chem. 2005 Jan 13;48(1):306-11.
DM6VQEO	RU	https://pubmed.ncbi.nlm.nih.gov/15634025

DMPU90E	DI	DMPU90E
DMPU90E	DN	2-(4-Cyclopropyl-piperazin-1-yl)-quinoline
DMPU90E	MI	TT9JNIC
DMPU90E	MN	Histamine H3 receptor (H3R)
DMPU90E	MT	DTT
DMPU90E	MA	Inhibitor
DMPU90E	RN	2-(4-alkylpiperazin-1-yl)quinolines as a new class of imidazole-free histamine H3 receptor antagonists. J Med Chem. 2005 Jan 13;48(1):306-11.
DMPU90E	RU	https://pubmed.ncbi.nlm.nih.gov/15634025

DM823CD	DI	DM823CD
DM823CD	DN	2-(4-Diethylamino-but-2-ynyl)-isoindole-1,3-dione
DM823CD	MI	TTZ9SOR
DM823CD	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DM823CD	MT	DTT
DM823CD	MA	Inhibitor
DM823CD	RN	Design of dual acting anticonvulsant-antimuscarinic succinimide and hydantoin derivatives, Bioorg. Med. Chem. Lett. 7(8):979-984 (1997).
DM823CD	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97001431

DM823CD	DI	DM823CD
DM823CD	DN	2-(4-Diethylamino-but-2-ynyl)-isoindole-1,3-dione
DM823CD	MI	TTYEG6Q
DM823CD	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DM823CD	MT	DTT
DM823CD	MA	Inhibitor
DM823CD	RN	Design of dual acting anticonvulsant-antimuscarinic succinimide and hydantoin derivatives, Bioorg. Med. Chem. Lett. 7(8):979-984 (1997).
DM823CD	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97001431

DMXH0FO	DI	DMXH0FO
DMXH0FO	DN	2-(4-Dipropylamino-cyclohexylidene)-malononitrile
DMXH0FO	MI	TTEX248
DMXH0FO	MN	Dopamine D2 receptor (D2R)
DMXH0FO	MT	DTT
DMXH0FO	MA	Inhibitor
DMXH0FO	RN	Conjugated enynes as nonaromatic catechol bioisosteres: synthesis, binding experiments, and computational studies of novel dopamine receptor agonis... J Med Chem. 2000 Feb 24;43(4):756-62.
DMXH0FO	RU	https://pubmed.ncbi.nlm.nih.gov/10691700

DMXH0FO	DI	DMXH0FO
DMXH0FO	DN	2-(4-Dipropylamino-cyclohexylidene)-malononitrile
DMXH0FO	MI	TT4C8EA
DMXH0FO	MN	Dopamine D3 receptor (D3R)
DMXH0FO	MT	DTT
DMXH0FO	MA	Inhibitor
DMXH0FO	RN	Conjugated enynes as nonaromatic catechol bioisosteres: synthesis, binding experiments, and computational studies of novel dopamine receptor agonis... J Med Chem. 2000 Feb 24;43(4):756-62.
DMXH0FO	RU	https://pubmed.ncbi.nlm.nih.gov/10691700

DMTAVU5	DI	DMTAVU5
DMTAVU5	DN	2-(4-ethylthiobenzimidazol-2-yl)quinoxaline
DMTAVU5	MI	TTK25J1
DMTAVU5	MN	Adenosine A1 receptor (ADORA1)
DMTAVU5	MT	DTT
DMTAVU5	MA	Inhibitor
DMTAVU5	RN	2-(Benzimidazol-2-yl)quinoxalines: a novel class of selective antagonists at human A(1) and A(3) adenosine receptors designed by 3D database search... J Med Chem. 2005 Dec 29;48(26):8253-60.
DMTAVU5	RU	https://pubmed.ncbi.nlm.nih.gov/16366607

DMTAVU5	DI	DMTAVU5
DMTAVU5	DN	2-(4-ethylthiobenzimidazol-2-yl)quinoxaline
DMTAVU5	MI	TTM2AOE
DMTAVU5	MN	Adenosine A2a receptor (ADORA2A)
DMTAVU5	MT	DTT
DMTAVU5	MA	Inhibitor
DMTAVU5	RN	2-(Benzimidazol-2-yl)quinoxalines: a novel class of selective antagonists at human A(1) and A(3) adenosine receptors designed by 3D database search... J Med Chem. 2005 Dec 29;48(26):8253-60.
DMTAVU5	RU	https://pubmed.ncbi.nlm.nih.gov/16366607

DMTAVU5	DI	DMTAVU5
DMTAVU5	DN	2-(4-ethylthiobenzimidazol-2-yl)quinoxaline
DMTAVU5	MI	TTJFY5U
DMTAVU5	MN	Adenosine A3 receptor (ADORA3)
DMTAVU5	MT	DTT
DMTAVU5	MA	Inhibitor
DMTAVU5	RN	2-(Benzimidazol-2-yl)quinoxalines: a novel class of selective antagonists at human A(1) and A(3) adenosine receptors designed by 3D database search... J Med Chem. 2005 Dec 29;48(26):8253-60.
DMTAVU5	RU	https://pubmed.ncbi.nlm.nih.gov/16366607

DMGLEX5	DI	DMGLEX5
DMGLEX5	DN	2-(4-Fluoro-3-phenoxy-benzoylamino)-benzoic acid
DMGLEX5	MI	TTRVTMX
DMGLEX5	MN	Bacterial Beta-ketoacyl-ACP synthase III (Bact fabH)
DMGLEX5	MT	DTT
DMGLEX5	MA	Inhibitor
DMGLEX5	RN	Structure-based design, synthesis, and study of potent inhibitors of beta-ketoacyl-acyl carrier protein synthase III as potential antimicrobial age... J Med Chem. 2005 Mar 10;48(5):1596-609.
DMGLEX5	RU	https://pubmed.ncbi.nlm.nih.gov/15743201

DMZSHDR	DI	DMZSHDR
DMZSHDR	DN	2-(4-fluoro-benzyl)isoquinoline-1,3,4-trione
DMZSHDR	MI	TTPF2QI
DMZSHDR	MN	Caspase-3 (CASP3)
DMZSHDR	MT	DTT
DMZSHDR	MA	Inhibitor
DMZSHDR	RN	Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors. J Med Chem. 2006 Mar 9;49(5):1613-23.
DMZSHDR	RU	https://pubmed.ncbi.nlm.nih.gov/16509578

DMKFIEY	DI	DMKFIEY
DMKFIEY	DN	2-(4-Fluoro-indole-1-sulfonyl)-benzoic acid
DMKFIEY	MI	TTHWMFZ
DMKFIEY	MN	Fatty acid-binding protein 4 (FABP4)
DMKFIEY	MT	DTT
DMKFIEY	MA	Inhibitor
DMKFIEY	RN	Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4445-8.
DMKFIEY	RU	https://pubmed.ncbi.nlm.nih.gov/15357969

DMECX8S	DI	DMECX8S
DMECX8S	DN	2-(4-fluorophenyl)-6-morpholino-4H-pyran-4-one
DMECX8S	MI	TTK3PY9
DMECX8S	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMECX8S	MT	DTT
DMECX8S	MA	Inhibitor
DMECX8S	RN	Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72.
DMECX8S	RU	https://pubmed.ncbi.nlm.nih.gov/17371003

DMZDGB3	DI	DMZDGB3
DMZDGB3	DN	2-(4-fluorophenyl)-7-methoxy-4H-chromen-4-one
DMZDGB3	MI	TTGP7BY
DMZDGB3	MN	Monoamine oxidase type B (MAO-B)
DMZDGB3	MT	DTT
DMZDGB3	MA	Inhibitor
DMZDGB3	RN	A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9.
DMZDGB3	RU	https://pubmed.ncbi.nlm.nih.gov/20045650

DM0CDRP	DI	DM0CDRP
DM0CDRP	DN	2-(4-fluorophenylsulfonamido)-1-naphthoic acid
DM0CDRP	MI	TTZL0OI
DM0CDRP	MN	Methionine aminopeptidase 2 (METAP2)
DM0CDRP	MT	DTT
DM0CDRP	MA	Inhibitor
DM0CDRP	RN	Development of sulfonamide compounds as potent methionine aminopeptidase type II inhibitors with antiproliferative properties. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3574-7.
DM0CDRP	RU	https://pubmed.ncbi.nlm.nih.gov/16632353

DM05HBC	DI	DM05HBC
DM05HBC	DN	2-(4-hexyl-2-methoxyphenoxy)pyrimidine
DM05HBC	MI	TTVTX4N
DM05HBC	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DM05HBC	MT	DTT
DM05HBC	MA	Inhibitor
DM05HBC	RN	Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33.
DM05HBC	RU	https://pubmed.ncbi.nlm.nih.gov/18457948

DMCPN7V	DI	DMCPN7V
DMCPN7V	DN	2-(4-hydroxybenzylideneamino)ethanesulfonamide
DMCPN7V	MI	TTANPDJ
DMCPN7V	MN	Carbonic anhydrase II (CA-II)
DMCPN7V	MT	DTT
DMCPN7V	MA	Inhibitor
DMCPN7V	RN	Carbonic anhydrase II-induced selection of inhibitors from a dynamic combinatorial library of Schiff's bases. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6014-7.
DMCPN7V	RU	https://pubmed.ncbi.nlm.nih.gov/19796939

DMM4S1R	DI	DMM4S1R
DMM4S1R	DN	2-(4-hydroxylphenyl)-3-(3,5-dihydroxylphenyl) propenoic acid (NNU-hdpa)
DMM4S1R	MI	TT2J34L
DMM4S1R	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMM4S1R	MT	DTT
DMM4S1R	MA	Inhibitor
DMM4S1R	RN	Anti-inflammatory effects and gastrointestinal safety of NNU-hdpa, a novel dual COX/5-LOX inhibitor. Eur J Pharmacol. 2009 Jun 2;611(1-3):100-6.
DMM4S1R	RU	https://pubmed.ncbi.nlm.nih.gov/19345206

DMUGHF6	DI	DMUGHF6
DMUGHF6	DN	2-(4-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol
DMUGHF6	MI	TTZAYWL
DMUGHF6	MN	Estrogen receptor (ESR)
DMUGHF6	MT	DTT
DMUGHF6	MA	Inhibitor
DMUGHF6	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMUGHF6	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMUGHF6	DI	DMUGHF6
DMUGHF6	DN	2-(4-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol
DMUGHF6	MI	TTOM3J0
DMUGHF6	MN	Estrogen receptor beta (ESR2)
DMUGHF6	MT	DTT
DMUGHF6	MA	Inhibitor
DMUGHF6	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMUGHF6	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DM1C864	DI	DM1C864
DM1C864	DN	2-(4-hydroxypent-1-yl)-N6-methoxyadenosine
DM1C864	MI	TTK25J1
DM1C864	MN	Adenosine A1 receptor (ADORA1)
DM1C864	MT	DTT
DM1C864	MA	Inhibitor
DM1C864	RN	N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
DM1C864	RU	https://pubmed.ncbi.nlm.nih.gov/17309246

DM1C864	DI	DM1C864
DM1C864	DN	2-(4-hydroxypent-1-yl)-N6-methoxyadenosine
DM1C864	MI	TTM2AOE
DM1C864	MN	Adenosine A2a receptor (ADORA2A)
DM1C864	MT	DTT
DM1C864	MA	Inhibitor
DM1C864	RN	N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
DM1C864	RU	https://pubmed.ncbi.nlm.nih.gov/17309246

DM1C864	DI	DM1C864
DM1C864	DN	2-(4-hydroxypent-1-yl)-N6-methoxyadenosine
DM1C864	MI	TTJFY5U
DM1C864	MN	Adenosine A3 receptor (ADORA3)
DM1C864	MT	DTT
DM1C864	MA	Inhibitor
DM1C864	RN	N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
DM1C864	RU	https://pubmed.ncbi.nlm.nih.gov/17309246

DMW6L38	DI	DMW6L38
DMW6L38	DN	2-(4-hydroxyphenyl)-1,2'-spirobi[1H-indene]-5-ol
DMW6L38	MI	TTZAYWL
DMW6L38	MN	Estrogen receptor (ESR)
DMW6L38	MT	DTT
DMW6L38	MA	Inhibitor
DMW6L38	RN	2-Phenylspiroindenes: a novel class of selective estrogen receptor modulators (SERMs). Bioorg Med Chem Lett. 2003 Feb 10;13(3):479-83.
DMW6L38	RU	https://pubmed.ncbi.nlm.nih.gov/12565955

DMW6L38	DI	DMW6L38
DMW6L38	DN	2-(4-hydroxyphenyl)-1,2'-spirobi[1H-indene]-5-ol
DMW6L38	MI	TTOM3J0
DMW6L38	MN	Estrogen receptor beta (ESR2)
DMW6L38	MT	DTT
DMW6L38	MA	Inhibitor
DMW6L38	RN	2-Phenylspiroindenes: a novel class of selective estrogen receptor modulators (SERMs). Bioorg Med Chem Lett. 2003 Feb 10;13(3):479-83.
DMW6L38	RU	https://pubmed.ncbi.nlm.nih.gov/12565955

DMBIV8F	DI	DMBIV8F
DMBIV8F	DN	2-(4-Hydroxy-phenyl)-1-p-tolyl-3H-inden-5-ol
DMBIV8F	MI	TTOM3J0
DMBIV8F	MN	Estrogen receptor beta (ESR2)
DMBIV8F	MT	DTT
DMBIV8F	MA	Inhibitor
DMBIV8F	RN	Differential response of estrogen receptor subtypes to 1,3-diarylindene and 2,3-diarylindene ligands. J Med Chem. 2005 Sep 22;48(19):5989-6003.
DMBIV8F	RU	https://pubmed.ncbi.nlm.nih.gov/16162002

DMNGW1A	DI	DMNGW1A
DMNGW1A	DN	2-(4-Hydroxy-phenyl)-3,3-diphenyl-acrylonitrile
DMNGW1A	MI	TTFJ8Q1
DMNGW1A	MN	Protein kinase C alpha (PRKCA)
DMNGW1A	MT	DTT
DMNGW1A	MA	Inhibitor
DMNGW1A	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DMNGW1A	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DMNGW1A	DI	DMNGW1A
DMNGW1A	DN	2-(4-Hydroxy-phenyl)-3,3-diphenyl-acrylonitrile
DMNGW1A	MI	TTYPXQF
DMNGW1A	MN	Protein kinase C beta (PRKCB)
DMNGW1A	MT	DTT
DMNGW1A	MA	Inhibitor
DMNGW1A	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DMNGW1A	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DMNGW1A	DI	DMNGW1A
DMNGW1A	DN	2-(4-Hydroxy-phenyl)-3,3-diphenyl-acrylonitrile
DMNGW1A	MI	TT9WJ8U
DMNGW1A	MN	Protein kinase C delta (PRKCD)
DMNGW1A	MT	DTT
DMNGW1A	MA	Inhibitor
DMNGW1A	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DMNGW1A	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DMNGW1A	DI	DMNGW1A
DMNGW1A	DN	2-(4-Hydroxy-phenyl)-3,3-diphenyl-acrylonitrile
DMNGW1A	MI	TTBZ7OD
DMNGW1A	MN	Protein kinase C epsilon (PRKCE)
DMNGW1A	MT	DTT
DMNGW1A	MA	Inhibitor
DMNGW1A	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DMNGW1A	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DMNGW1A	DI	DMNGW1A
DMNGW1A	DN	2-(4-Hydroxy-phenyl)-3,3-diphenyl-acrylonitrile
DMNGW1A	MI	TTRFOXJ
DMNGW1A	MN	Protein kinase C gamma (PRKCG)
DMNGW1A	MT	DTT
DMNGW1A	MA	Inhibitor
DMNGW1A	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DMNGW1A	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DMNGW1A	DI	DMNGW1A
DMNGW1A	DN	2-(4-Hydroxy-phenyl)-3,3-diphenyl-acrylonitrile
DMNGW1A	MI	TT8QL1J
DMNGW1A	MN	Protein kinase C theta (PRKCQ)
DMNGW1A	MT	DTT
DMNGW1A	MA	Inhibitor
DMNGW1A	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DMNGW1A	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DMNGW1A	DI	DMNGW1A
DMNGW1A	DN	2-(4-Hydroxy-phenyl)-3,3-diphenyl-acrylonitrile
DMNGW1A	MI	TTUWGRA
DMNGW1A	MN	Protein kinase C zeta (PRKCZ)
DMNGW1A	MT	DTT
DMNGW1A	MA	Inhibitor
DMNGW1A	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DMNGW1A	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DM4N0LB	DI	DM4N0LB
DM4N0LB	DN	2-(4-Hydroxy-phenyl)-4-methoxy-quinolin-6-ol
DM4N0LB	MI	TTZAYWL
DM4N0LB	MN	Estrogen receptor (ESR)
DM4N0LB	MT	DTT
DM4N0LB	MA	Inhibitor
DM4N0LB	RN	ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5.
DM4N0LB	RU	https://pubmed.ncbi.nlm.nih.gov/16098741

DM4N0LB	DI	DM4N0LB
DM4N0LB	DN	2-(4-Hydroxy-phenyl)-4-methoxy-quinolin-6-ol
DM4N0LB	MI	TTOM3J0
DM4N0LB	MN	Estrogen receptor beta (ESR2)
DM4N0LB	MT	DTT
DM4N0LB	MA	Inhibitor
DM4N0LB	RN	ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5.
DM4N0LB	RU	https://pubmed.ncbi.nlm.nih.gov/16098741

DM81G2U	DI	DM81G2U
DM81G2U	DN	2-(4-Hydroxy-phenyl)-4-vinyl-quinolin-6-ol
DM81G2U	MI	TTZAYWL
DM81G2U	MN	Estrogen receptor (ESR)
DM81G2U	MT	DTT
DM81G2U	MA	Inhibitor
DM81G2U	RN	ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5.
DM81G2U	RU	https://pubmed.ncbi.nlm.nih.gov/16098741

DM81G2U	DI	DM81G2U
DM81G2U	DN	2-(4-Hydroxy-phenyl)-4-vinyl-quinolin-6-ol
DM81G2U	MI	TTOM3J0
DM81G2U	MN	Estrogen receptor beta (ESR2)
DM81G2U	MT	DTT
DM81G2U	MA	Inhibitor
DM81G2U	RN	ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5.
DM81G2U	RU	https://pubmed.ncbi.nlm.nih.gov/16098741

DM81G2U	DI	DM81G2U
DM81G2U	DN	2-(4-Hydroxy-phenyl)-4-vinyl-quinolin-6-ol
DM81G2U	MI	TTPNQAC
DM81G2U	MN	Estrogen-related receptor-alpha (ESRRA)
DM81G2U	MT	DTT
DM81G2U	MA	Inhibitor
DM81G2U	RN	ERbeta ligands. Part 6: 6H-Chromeno[4,3-b]quinolines as a new series of estrogen receptor beta-selective ligands. Bioorg Med Chem Lett. 2007 Jul 15;17(14):4053-6.
DM81G2U	RU	https://pubmed.ncbi.nlm.nih.gov/17482813

DMFWOMY	DI	DMFWOMY
DMFWOMY	DN	2-(4-Hydroxy-phenyl)-7-isopropyl-benzooxazol-5-ol
DMFWOMY	MI	TTZAYWL
DMFWOMY	MN	Estrogen receptor (ESR)
DMFWOMY	MT	DTT
DMFWOMY	MA	Inhibitor
DMFWOMY	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMFWOMY	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMFWOMY	DI	DMFWOMY
DMFWOMY	DN	2-(4-Hydroxy-phenyl)-7-isopropyl-benzooxazol-5-ol
DMFWOMY	MI	TTOM3J0
DMFWOMY	MN	Estrogen receptor beta (ESR2)
DMFWOMY	MT	DTT
DMFWOMY	MA	Inhibitor
DMFWOMY	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMFWOMY	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMY0I8P	DI	DMY0I8P
DMY0I8P	DN	2-(4-Hydroxy-phenyl)-7-methoxy-benzofuran-5-ol
DMY0I8P	MI	TTZAYWL
DMY0I8P	MN	Estrogen receptor (ESR)
DMY0I8P	MT	DTT
DMY0I8P	MA	Inhibitor
DMY0I8P	RN	7-Substituted 2-phenyl-benzofurans as ER beta selective ligands. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4925-9.
DMY0I8P	RU	https://pubmed.ncbi.nlm.nih.gov/15341953

DMY0I8P	DI	DMY0I8P
DMY0I8P	DN	2-(4-Hydroxy-phenyl)-7-methoxy-benzofuran-5-ol
DMY0I8P	MI	TTOM3J0
DMY0I8P	MN	Estrogen receptor beta (ESR2)
DMY0I8P	MT	DTT
DMY0I8P	MA	Inhibitor
DMY0I8P	RN	7-Substituted 2-phenyl-benzofurans as ER beta selective ligands. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4925-9.
DMY0I8P	RU	https://pubmed.ncbi.nlm.nih.gov/15341953

DMCNITS	DI	DMCNITS
DMCNITS	DN	2-(4-Hydroxy-phenyl)-7-methoxy-benzooxazol-5-ol
DMCNITS	MI	TTZAYWL
DMCNITS	MN	Estrogen receptor (ESR)
DMCNITS	MT	DTT
DMCNITS	MA	Inhibitor
DMCNITS	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMCNITS	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMCNITS	DI	DMCNITS
DMCNITS	DN	2-(4-Hydroxy-phenyl)-7-methoxy-benzooxazol-5-ol
DMCNITS	MI	TTOM3J0
DMCNITS	MN	Estrogen receptor beta (ESR2)
DMCNITS	MT	DTT
DMCNITS	MA	Inhibitor
DMCNITS	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMCNITS	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMT847Y	DI	DMT847Y
DMT847Y	DN	2-(4-hydroxyphenyl)-7-methoxychroman-4-one
DMT847Y	MI	TTSZLWK
DMT847Y	MN	Aromatase (CYP19A1)
DMT847Y	MT	DTT
DMT847Y	MA	Inhibitor
DMT847Y	RN	New 7,8-benzoflavanones as potent aromatase inhibitors: synthesis and biological evaluation. Bioorg Med Chem. 2008 Feb 1;16(3):1474-80.
DMT847Y	RU	https://pubmed.ncbi.nlm.nih.gov/18042388

DMQ2KPI	DI	DMQ2KPI
DMQ2KPI	DN	2-(4-Hydroxy-phenyl)-7-methyl-benzofuran-5-ol
DMQ2KPI	MI	TTZAYWL
DMQ2KPI	MN	Estrogen receptor (ESR)
DMQ2KPI	MT	DTT
DMQ2KPI	MA	Inhibitor
DMQ2KPI	RN	7-Substituted 2-phenyl-benzofurans as ER beta selective ligands. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4925-9.
DMQ2KPI	RU	https://pubmed.ncbi.nlm.nih.gov/15341953

DMQ2KPI	DI	DMQ2KPI
DMQ2KPI	DN	2-(4-Hydroxy-phenyl)-7-methyl-benzofuran-5-ol
DMQ2KPI	MI	TTOM3J0
DMQ2KPI	MN	Estrogen receptor beta (ESR2)
DMQ2KPI	MT	DTT
DMQ2KPI	MA	Inhibitor
DMQ2KPI	RN	7-Substituted 2-phenyl-benzofurans as ER beta selective ligands. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4925-9.
DMQ2KPI	RU	https://pubmed.ncbi.nlm.nih.gov/15341953

DMUB7KH	DI	DMUB7KH
DMUB7KH	DN	2-(4-Hydroxy-phenyl)-7-phenyl-benzooxazol-5-ol
DMUB7KH	MI	TTZAYWL
DMUB7KH	MN	Estrogen receptor (ESR)
DMUB7KH	MT	DTT
DMUB7KH	MA	Inhibitor
DMUB7KH	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMUB7KH	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMUB7KH	DI	DMUB7KH
DMUB7KH	DN	2-(4-Hydroxy-phenyl)-7-phenyl-benzooxazol-5-ol
DMUB7KH	MI	TTOM3J0
DMUB7KH	MN	Estrogen receptor beta (ESR2)
DMUB7KH	MT	DTT
DMUB7KH	MA	Inhibitor
DMUB7KH	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMUB7KH	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMND63Z	DI	DMND63Z
DMND63Z	DN	2-(4-Hydroxy-phenyl)-7-propenyl-benzooxazol-5-ol
DMND63Z	MI	TTZAYWL
DMND63Z	MN	Estrogen receptor (ESR)
DMND63Z	MT	DTT
DMND63Z	MA	Inhibitor
DMND63Z	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMND63Z	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMND63Z	DI	DMND63Z
DMND63Z	DN	2-(4-Hydroxy-phenyl)-7-propenyl-benzooxazol-5-ol
DMND63Z	MI	TTOM3J0
DMND63Z	MN	Estrogen receptor beta (ESR2)
DMND63Z	MT	DTT
DMND63Z	MA	Inhibitor
DMND63Z	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMND63Z	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMONT2D	DI	DMONT2D
DMONT2D	DN	2-(4-Hydroxy-phenyl)-7-propyl-benzooxazol-5-ol
DMONT2D	MI	TTZAYWL
DMONT2D	MN	Estrogen receptor (ESR)
DMONT2D	MT	DTT
DMONT2D	MA	Inhibitor
DMONT2D	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMONT2D	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMONT2D	DI	DMONT2D
DMONT2D	DN	2-(4-Hydroxy-phenyl)-7-propyl-benzooxazol-5-ol
DMONT2D	MI	TTOM3J0
DMONT2D	MN	Estrogen receptor beta (ESR2)
DMONT2D	MT	DTT
DMONT2D	MA	Inhibitor
DMONT2D	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMONT2D	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DM2F6U3	DI	DM2F6U3
DM2F6U3	DN	2-(4-Hydroxy-phenyl)-7-vinyl-benzooxazol-5-ol
DM2F6U3	MI	TTZAYWL
DM2F6U3	MN	Estrogen receptor (ESR)
DM2F6U3	MT	DTT
DM2F6U3	MA	Inhibitor
DM2F6U3	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DM2F6U3	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DM2F6U3	DI	DM2F6U3
DM2F6U3	DN	2-(4-Hydroxy-phenyl)-7-vinyl-benzooxazol-5-ol
DM2F6U3	MI	TTOM3J0
DM2F6U3	MN	Estrogen receptor beta (ESR2)
DM2F6U3	MT	DTT
DM2F6U3	MA	Inhibitor
DM2F6U3	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DM2F6U3	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMVHQM9	DI	DMVHQM9
DMVHQM9	DN	2-(4-Hydroxy-phenyl)-8-methyl-3H-quinazolin-4-one
DMVHQM9	MI	TTVDSZ0
DMVHQM9	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMVHQM9	MT	DTT
DMVHQM9	MA	Inhibitor
DMVHQM9	RN	Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56.
DMVHQM9	RU	https://pubmed.ncbi.nlm.nih.gov/9857092

DMN6S3F	DI	DMN6S3F
DMN6S3F	DN	2-(4-HYDROXY-PHENYL)BENZOFURAN-5-OL
DMN6S3F	MI	TTZAYWL
DMN6S3F	MN	Estrogen receptor (ESR)
DMN6S3F	MT	DTT
DMN6S3F	MA	Inhibitor
DMN6S3F	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMN6S3F	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMN6S3F	DI	DMN6S3F
DMN6S3F	DN	2-(4-HYDROXY-PHENYL)BENZOFURAN-5-OL
DMN6S3F	MI	TTOM3J0
DMN6S3F	MN	Estrogen receptor beta (ESR2)
DMN6S3F	MT	DTT
DMN6S3F	MA	Inhibitor
DMN6S3F	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMN6S3F	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMMUNA7	DI	DMMUNA7
DMMUNA7	DN	2-(4-Hydroxy-phenyl)-benzooxazol-5-ol
DMMUNA7	MI	TTZAYWL
DMMUNA7	MN	Estrogen receptor (ESR)
DMMUNA7	MT	DTT
DMMUNA7	MA	Inhibitor
DMMUNA7	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMMUNA7	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMMUNA7	DI	DMMUNA7
DMMUNA7	DN	2-(4-Hydroxy-phenyl)-benzooxazol-5-ol
DMMUNA7	MI	TTOM3J0
DMMUNA7	MN	Estrogen receptor beta (ESR2)
DMMUNA7	MT	DTT
DMMUNA7	MA	Inhibitor
DMMUNA7	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMMUNA7	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DM31MY0	DI	DM31MY0
DM31MY0	DN	2-(4-Hydroxy-phenyl)-benzooxazol-6-ol
DM31MY0	MI	TTZAYWL
DM31MY0	MN	Estrogen receptor (ESR)
DM31MY0	MT	DTT
DM31MY0	MA	Inhibitor
DM31MY0	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DM31MY0	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DM31MY0	DI	DM31MY0
DM31MY0	DN	2-(4-Hydroxy-phenyl)-benzooxazol-6-ol
DM31MY0	MI	TTOM3J0
DM31MY0	MN	Estrogen receptor beta (ESR2)
DM31MY0	MT	DTT
DM31MY0	MA	Inhibitor
DM31MY0	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DM31MY0	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMCWFUZ	DI	DMCWFUZ
DMCWFUZ	DN	2-(4-Hydroxy-phenyl)-quinolin-6-ol
DMCWFUZ	MI	TTZAYWL
DMCWFUZ	MN	Estrogen receptor (ESR)
DMCWFUZ	MT	DTT
DMCWFUZ	MA	Inhibitor
DMCWFUZ	RN	ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5.
DMCWFUZ	RU	https://pubmed.ncbi.nlm.nih.gov/16098741

DMCWFUZ	DI	DMCWFUZ
DMCWFUZ	DN	2-(4-Hydroxy-phenyl)-quinolin-6-ol
DMCWFUZ	MI	TTOM3J0
DMCWFUZ	MN	Estrogen receptor beta (ESR2)
DMCWFUZ	MT	DTT
DMCWFUZ	MA	Inhibitor
DMCWFUZ	RN	ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5.
DMCWFUZ	RU	https://pubmed.ncbi.nlm.nih.gov/16098741

DM8GBH4	DI	DM8GBH4
DM8GBH4	DN	2-(4-hydroxystyryl)quinolin-8-ol
DM8GBH4	MI	TT6804T
DM8GBH4	MN	MIF messenger RNA (MIF mRNA)
DM8GBH4	MT	DTT
DM8GBH4	MA	Inhibitor
DM8GBH4	RN	Discovery of human macrophage migration inhibitory factor (MIF)-CD74 antagonists via virtual screening. J Med Chem. 2009 Jan 22;52(2):416-24.
DM8GBH4	RU	https://pubmed.ncbi.nlm.nih.gov/19090668

DMUIVS9	DI	DMUIVS9
DMUIVS9	DN	2-(4-Imidazol-1-yl-phenoxymethyl)-pyridine
DMUIVS9	MI	TTXV4FI
DMUIVS9	MN	Albendazole monooxygenase (CYP3A4)
DMUIVS9	MT	DTT
DMUIVS9	MA	Inhibitor
DMUIVS9	RN	Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):333-6.
DMUIVS9	RU	https://pubmed.ncbi.nlm.nih.gov/14698153

DMUIVS9	DI	DMUIVS9
DMUIVS9	DN	2-(4-Imidazol-1-yl-phenoxymethyl)-pyridine
DMUIVS9	MI	TTVG215
DMUIVS9	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DMUIVS9	MT	DTT
DMUIVS9	MA	Inhibitor
DMUIVS9	RN	Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):333-6.
DMUIVS9	RU	https://pubmed.ncbi.nlm.nih.gov/14698153

DMSH4WP	DI	DMSH4WP
DMSH4WP	DN	2-(4-Isopropyl-piperazin-1-yl)-quinoline
DMSH4WP	MI	TT9JNIC
DMSH4WP	MN	Histamine H3 receptor (H3R)
DMSH4WP	MT	DTT
DMSH4WP	MA	Inhibitor
DMSH4WP	RN	2-(4-alkylpiperazin-1-yl)quinolines as a new class of imidazole-free histamine H3 receptor antagonists. J Med Chem. 2005 Jan 13;48(1):306-11.
DMSH4WP	RU	https://pubmed.ncbi.nlm.nih.gov/15634025

DMXPJF3	DI	DMXPJF3
DMXPJF3	DN	2-(4-Mercapto-butyl)-pentanedioic acid
DMXPJF3	MI	TT9G4N0
DMXPJF3	MN	Glutamate carboxypeptidase II (GCPII)
DMXPJF3	MT	DTT
DMXPJF3	MA	Inhibitor
DMXPJF3	RN	Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. J Med Chem. 2003 May 8;46(10):1989-96.
DMXPJF3	RU	https://pubmed.ncbi.nlm.nih.gov/12723961

DMHAE31	DI	DMHAE31
DMHAE31	DN	2-(4-methoxy-benzyl)isoquinoline-1,3,4-trione
DMHAE31	MI	TTPF2QI
DMHAE31	MN	Caspase-3 (CASP3)
DMHAE31	MT	DTT
DMHAE31	MA	Inhibitor
DMHAE31	RN	Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors. J Med Chem. 2006 Mar 9;49(5):1613-23.
DMHAE31	RU	https://pubmed.ncbi.nlm.nih.gov/16509578

DMZNPMQ	DI	DMZNPMQ
DMZNPMQ	DN	2-(4-methoxybenzylthio)-6-methylpyrimidin-4-ol
DMZNPMQ	MI	TTHY57M
DMZNPMQ	MN	Matrix metalloproteinase-13 (MMP-13)
DMZNPMQ	MT	DTT
DMZNPMQ	MA	Inhibitor
DMZNPMQ	RN	Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study. Bioorg Med Chem. 2009 Feb 1;17(3):1101-8.
DMZNPMQ	RU	https://pubmed.ncbi.nlm.nih.gov/18364257

DMTEQU8	DI	DMTEQU8
DMTEQU8	DN	2-(4-Methoxy-phenyl)-1H-indole-3-carbaldehyde
DMTEQU8	MI	TTML2WA
DMTEQU8	MN	Tubulin (TUB)
DMTEQU8	MT	DTT
DMTEQU8	MA	Inhibitor
DMTEQU8	RN	Methoxy-substituted 3-formyl-2-phenylindoles inhibit tubulin polymerization. J Med Chem. 1998 Dec 3;41(25):4965-72.
DMTEQU8	RU	https://pubmed.ncbi.nlm.nih.gov/9836614

DMTEQU8	DI	DMTEQU8
DMTEQU8	DN	2-(4-Methoxy-phenyl)-1H-indole-3-carbaldehyde
DMTEQU8	MI	TTYFKSZ
DMTEQU8	MN	Tubulin beta (TUBB)
DMTEQU8	MT	DTT
DMTEQU8	MA	Inhibitor
DMTEQU8	RN	Methoxy-substituted 3-formyl-2-phenylindoles inhibit tubulin polymerization. J Med Chem. 1998 Dec 3;41(25):4965-72.
DMTEQU8	RU	https://pubmed.ncbi.nlm.nih.gov/9836614

DM0KUMX	DI	DM0KUMX
DM0KUMX	DN	2-(4-methoxyphenyl)-4,5-dihydro-1H-imidazole
DM0KUMX	MI	TT3WG5C
DM0KUMX	MN	Monoamine oxidase type A (MAO-A)
DM0KUMX	MT	DTT
DM0KUMX	MA	Inhibitor
DM0KUMX	RN	Ultrasound promoted synthesis of 2-imidazolines in water: a greener approach toward monoamine oxidase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):546-9.
DM0KUMX	RU	https://pubmed.ncbi.nlm.nih.gov/19064321

DMIDXTR	DI	DMIDXTR
DMIDXTR	DN	2-(4-methoxyphenyl)-4H-chromene-4-thione
DMIDXTR	MI	TTGP7BY
DMIDXTR	MN	Monoamine oxidase type B (MAO-B)
DMIDXTR	MT	DTT
DMIDXTR	MA	Inhibitor
DMIDXTR	RN	A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9.
DMIDXTR	RU	https://pubmed.ncbi.nlm.nih.gov/20045650

DMZ9A6U	DI	DMZ9A6U
DMZ9A6U	DN	2-(4-Methoxy-phenyl)-5-phenyl-thiazol-4-ol
DMZ9A6U	MI	TT2J34L
DMZ9A6U	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMZ9A6U	MT	DTT
DMZ9A6U	MA	Inhibitor
DMZ9A6U	RN	4-hydroxythiazole inhibitors of 5-lipoxygenase. J Med Chem. 1991 Jul;34(7):2158-65.
DMZ9A6U	RU	https://pubmed.ncbi.nlm.nih.gov/2066989

DMVQU1M	DI	DMVQU1M
DMVQU1M	DN	2-(4-methoxyphenyl)-6-morpholino-4H-pyran-4-one
DMVQU1M	MI	TTK3PY9
DMVQU1M	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMVQU1M	MT	DTT
DMVQU1M	MA	Inhibitor
DMVQU1M	RN	Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72.
DMVQU1M	RU	https://pubmed.ncbi.nlm.nih.gov/17371003

DMXTHOV	DI	DMXTHOV
DMXTHOV	DN	2-(4-methoxyphenyl)-6-phenyl-9H-purine
DMXTHOV	MI	TTK25J1
DMXTHOV	MN	Adenosine A1 receptor (ADORA1)
DMXTHOV	MT	DTT
DMXTHOV	MA	Inhibitor
DMXTHOV	RN	2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7.
DMXTHOV	RU	https://pubmed.ncbi.nlm.nih.gov/16686529

DMXTHOV	DI	DMXTHOV
DMXTHOV	DN	2-(4-methoxyphenyl)-6-phenyl-9H-purine
DMXTHOV	MI	TTJFY5U
DMXTHOV	MN	Adenosine A3 receptor (ADORA3)
DMXTHOV	MT	DTT
DMXTHOV	MA	Inhibitor
DMXTHOV	RN	2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7.
DMXTHOV	RU	https://pubmed.ncbi.nlm.nih.gov/16686529

DMS572H	DI	DMS572H
DMS572H	DN	2-(4-Methoxy-phenyl)-8-methyl-3H-quinazolin-4-one
DMS572H	MI	TTVDSZ0
DMS572H	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMS572H	MT	DTT
DMS572H	MA	Inhibitor
DMS572H	RN	Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56.
DMS572H	RU	https://pubmed.ncbi.nlm.nih.gov/9857092

DM1N08O	DI	DM1N08O
DM1N08O	DN	2-(4-methoxyphenyl)-N-(thiazol-2-yl)acetamide
DM1N08O	MI	TTSJ6Q4
DM1N08O	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DM1N08O	MT	DTT
DM1N08O	MA	Inhibitor
DM1N08O	RN	Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. J Med Chem. 2007 May 31;50(11):2640-6.
DM1N08O	RU	https://pubmed.ncbi.nlm.nih.gov/17461565

DMBRETS	DI	DMBRETS
DMBRETS	DN	2-(4-methoxyphenyl)quinoline-8-carboxamide
DMBRETS	MI	TTVDSZ0
DMBRETS	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMBRETS	MT	DTT
DMBRETS	MA	Inhibitor
DMBRETS	RN	Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhi... J Med Chem. 2009 Feb 12;52(3):868-77.
DMBRETS	RU	https://pubmed.ncbi.nlm.nih.gov/19117416

DMDXIN1	DI	DMDXIN1
DMDXIN1	DN	2-(4-methyl-1H-benzo[d]imidazol-2-yl)quinoxaline
DMDXIN1	MI	TTK25J1
DMDXIN1	MN	Adenosine A1 receptor (ADORA1)
DMDXIN1	MT	DTT
DMDXIN1	MA	Inhibitor
DMDXIN1	RN	Derivatives of 4-amino-6-hydroxy-2-mercaptopyrimidine as novel, potent, and selective A3 adenosine receptor antagonists. J Med Chem. 2008 Mar 27;51(6):1764-70.
DMDXIN1	RU	https://pubmed.ncbi.nlm.nih.gov/18269230

DMDXIN1	DI	DMDXIN1
DMDXIN1	DN	2-(4-methyl-1H-benzo[d]imidazol-2-yl)quinoxaline
DMDXIN1	MI	TTM2AOE
DMDXIN1	MN	Adenosine A2a receptor (ADORA2A)
DMDXIN1	MT	DTT
DMDXIN1	MA	Inhibitor
DMDXIN1	RN	Derivatives of 4-amino-6-hydroxy-2-mercaptopyrimidine as novel, potent, and selective A3 adenosine receptor antagonists. J Med Chem. 2008 Mar 27;51(6):1764-70.
DMDXIN1	RU	https://pubmed.ncbi.nlm.nih.gov/18269230

DMDXIN1	DI	DMDXIN1
DMDXIN1	DN	2-(4-methyl-1H-benzo[d]imidazol-2-yl)quinoxaline
DMDXIN1	MI	TTJFY5U
DMDXIN1	MN	Adenosine A3 receptor (ADORA3)
DMDXIN1	MT	DTT
DMDXIN1	MA	Inhibitor
DMDXIN1	RN	Derivatives of 4-amino-6-hydroxy-2-mercaptopyrimidine as novel, potent, and selective A3 adenosine receptor antagonists. J Med Chem. 2008 Mar 27;51(6):1764-70.
DMDXIN1	RU	https://pubmed.ncbi.nlm.nih.gov/18269230

DM943YL	DI	DM943YL
DM943YL	DN	2-(4-Methyl-indole-1-sulfonyl)-benzoic acid
DM943YL	MI	TTHWMFZ
DM943YL	MN	Fatty acid-binding protein 4 (FABP4)
DM943YL	MT	DTT
DM943YL	MA	Inhibitor
DM943YL	RN	Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4445-8.
DM943YL	RU	https://pubmed.ncbi.nlm.nih.gov/15357969

DMDHFU9	DI	DMDHFU9
DMDHFU9	DN	2-(4-Methyl-piperazin-1-yl)-4-phenyl-pyrimidine
DMDHFU9	MI	TTSQIFT
DMDHFU9	MN	5-HT 1A receptor (HTR1A)
DMDHFU9	MT	DTT
DMDHFU9	MA	Inhibitor
DMDHFU9	RN	4-(3-furyl)-2-(4-methylpiperazino)pyrimidines: Potent 5-HT2A receptor antagonists, Bioorg. Med. Chem. Lett. 7(13):1635-1638 (1997).
DMDHFU9	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97002916

DMDHFU9	DI	DMDHFU9
DMDHFU9	DN	2-(4-Methyl-piperazin-1-yl)-4-phenyl-pyrimidine
DMDHFU9	MI	TTJQOD7
DMDHFU9	MN	5-HT 2A receptor (HTR2A)
DMDHFU9	MT	DTT
DMDHFU9	MA	Inhibitor
DMDHFU9	RN	4-(3-furyl)-2-(4-methylpiperazino)pyrimidines: Potent 5-HT2A receptor antagonists, Bioorg. Med. Chem. Lett. 7(13):1635-1638 (1997).
DMDHFU9	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97002916

DMB8OY6	DI	DMB8OY6
DMB8OY6	DN	2-(4-Methyl-piperazin-1-yl)-quinoline
DMB8OY6	MI	TTPC4TU
DMB8OY6	MN	5-HT 3A receptor (HTR3A)
DMB8OY6	MT	DTT
DMB8OY6	MA	Inhibitor
DMB8OY6	RN	Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy ... J Med Chem. 1999 May 6;42(9):1556-75.
DMB8OY6	RU	https://pubmed.ncbi.nlm.nih.gov/10229626

DMB8OY6	DI	DMB8OY6
DMB8OY6	DN	2-(4-Methyl-piperazin-1-yl)-quinoline
DMB8OY6	MI	TTR6K75
DMB8OY6	MN	5-HT 3B receptor (HTR3B)
DMB8OY6	MT	DTT
DMB8OY6	MA	Inhibitor
DMB8OY6	RN	Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy ... J Med Chem. 1999 May 6;42(9):1556-75.
DMB8OY6	RU	https://pubmed.ncbi.nlm.nih.gov/10229626

DMB8OY6	DI	DMB8OY6
DMB8OY6	DN	2-(4-Methyl-piperazin-1-yl)-quinoline
DMB8OY6	MI	TT9JNIC
DMB8OY6	MN	Histamine H3 receptor (H3R)
DMB8OY6	MT	DTT
DMB8OY6	MA	Inhibitor
DMB8OY6	RN	2-(4-alkylpiperazin-1-yl)quinolines as a new class of imidazole-free histamine H3 receptor antagonists. J Med Chem. 2005 Jan 13;48(1):306-11.
DMB8OY6	RU	https://pubmed.ncbi.nlm.nih.gov/15634025

DMBJICP	DI	DMBJICP
DMBJICP	DN	2-(4-nitro-1H-benzo[d]imidazol-2-yl)quinoxaline
DMBJICP	MI	TTJFY5U
DMBJICP	MN	Adenosine A3 receptor (ADORA3)
DMBJICP	MT	DTT
DMBJICP	MA	Inhibitor
DMBJICP	RN	2-(Benzimidazol-2-yl)quinoxalines: a novel class of selective antagonists at human A(1) and A(3) adenosine receptors designed by 3D database search... J Med Chem. 2005 Dec 29;48(26):8253-60.
DMBJICP	RU	https://pubmed.ncbi.nlm.nih.gov/16366607

DMX8U32	DI	DMX8U32
DMX8U32	DN	2-(4-nitrophenyl)-5-(4-methoxyphenyl)thiophene
DMX8U32	MI	TTE4KHA
DMX8U32	MN	Amyloid beta A4 protein (APP)
DMX8U32	MT	DTT
DMX8U32	MA	Inhibitor
DMX8U32	RN	Design, synthesis, and structure-activity relationship of novel thiophene derivatives for beta-amyloid plaque imaging. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1350-2.
DMX8U32	RU	https://pubmed.ncbi.nlm.nih.gov/16325402

DMR54SW	DI	DMR54SW
DMR54SW	DN	2-(4-pentylphenyl)-N-(pyridin-3-yl)acetamide
DMR54SW	MI	TTMI6F5
DMR54SW	MN	Transient receptor potential cation channel V1 (TRPV1)
DMR54SW	MT	DTT
DMR54SW	MA	Inhibitor
DMR54SW	RN	N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4.
DMR54SW	RU	https://pubmed.ncbi.nlm.nih.gov/18359227

DM65IF1	DI	DM65IF1
DM65IF1	DN	2-(4-Phenoxy-benzyl)-1H-benzoimidazole
DM65IF1	MI	TTLD29N
DM65IF1	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DM65IF1	MT	DTT
DM65IF1	MA	Inhibitor
DM65IF1	RN	NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J Med Chem. 2004 Apr 8;47(8):2089-96.
DM65IF1	RU	https://pubmed.ncbi.nlm.nih.gov/15056006

DM65IF1	DI	DM65IF1
DM65IF1	DN	2-(4-Phenoxy-benzyl)-1H-benzoimidazole
DM65IF1	MI	TTN9D8E
DM65IF1	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DM65IF1	MT	DTT
DM65IF1	MA	Inhibitor
DM65IF1	RN	NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J Med Chem. 2004 Apr 8;47(8):2089-96.
DM65IF1	RU	https://pubmed.ncbi.nlm.nih.gov/15056006

DM3HANW	DI	DM3HANW
DM3HANW	DN	2-(4-Phenoxy-benzyl)-3H-benzoimidazol-4-ol
DM3HANW	MI	TTLD29N
DM3HANW	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DM3HANW	MT	DTT
DM3HANW	MA	Inhibitor
DM3HANW	RN	NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J Med Chem. 2004 Apr 8;47(8):2089-96.
DM3HANW	RU	https://pubmed.ncbi.nlm.nih.gov/15056006

DM3HANW	DI	DM3HANW
DM3HANW	DN	2-(4-Phenoxy-benzyl)-3H-benzoimidazol-4-ol
DM3HANW	MI	TTN9D8E
DM3HANW	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DM3HANW	MT	DTT
DM3HANW	MA	Inhibitor
DM3HANW	RN	NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J Med Chem. 2004 Apr 8;47(8):2089-96.
DM3HANW	RU	https://pubmed.ncbi.nlm.nih.gov/15056006

DMFO19B	DI	DMFO19B
DMFO19B	DN	2-(4-Phenoxy-benzyl)-3H-benzoimidazol-5-ol
DMFO19B	MI	TTLD29N
DMFO19B	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMFO19B	MT	DTT
DMFO19B	MA	Inhibitor
DMFO19B	RN	NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J Med Chem. 2004 Apr 8;47(8):2089-96.
DMFO19B	RU	https://pubmed.ncbi.nlm.nih.gov/15056006

DMFO19B	DI	DMFO19B
DMFO19B	DN	2-(4-Phenoxy-benzyl)-3H-benzoimidazol-5-ol
DMFO19B	MI	TTN9D8E
DMFO19B	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMFO19B	MT	DTT
DMFO19B	MA	Inhibitor
DMFO19B	RN	NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J Med Chem. 2004 Apr 8;47(8):2089-96.
DMFO19B	RU	https://pubmed.ncbi.nlm.nih.gov/15056006

DMJSBFU	DI	DMJSBFU
DMJSBFU	DN	2-(4-Phenoxy-benzyl)-3H-benzoimidazol-5-ylamine
DMJSBFU	MI	TTLD29N
DMJSBFU	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMJSBFU	MT	DTT
DMJSBFU	MA	Inhibitor
DMJSBFU	RN	NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J Med Chem. 2004 Apr 8;47(8):2089-96.
DMJSBFU	RU	https://pubmed.ncbi.nlm.nih.gov/15056006

DMJSBFU	DI	DMJSBFU
DMJSBFU	DN	2-(4-Phenoxy-benzyl)-3H-benzoimidazol-5-ylamine
DMJSBFU	MI	TTN9D8E
DMJSBFU	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMJSBFU	MT	DTT
DMJSBFU	MA	Inhibitor
DMJSBFU	RN	NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J Med Chem. 2004 Apr 8;47(8):2089-96.
DMJSBFU	RU	https://pubmed.ncbi.nlm.nih.gov/15056006

DM7TBUJ	DI	DM7TBUJ
DM7TBUJ	DN	2-(4-phenoxyphenoxy)ethanamine
DM7TBUJ	MI	TTO8QRU
DM7TBUJ	MN	Group IIA phospholipase A2 (GIIA sPLA2)
DM7TBUJ	MT	DTT
DM7TBUJ	MA	Inhibitor
DM7TBUJ	RN	Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. J Med Chem. 2008 Dec 25;51(24):7882-8.
DM7TBUJ	RU	https://pubmed.ncbi.nlm.nih.gov/19090779

DM7TBUJ	DI	DM7TBUJ
DM7TBUJ	DN	2-(4-phenoxyphenoxy)ethanamine
DM7TBUJ	MI	TTXZEAJ
DM7TBUJ	MN	Leukotriene A-4 hydrolase (LTA4H)
DM7TBUJ	MT	DTT
DM7TBUJ	MA	Inhibitor
DM7TBUJ	RN	Activation and inhibition of leukotriene A4 hydrolase aminopeptidase activity by diphenyl ether and derivatives. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6549-52.
DM7TBUJ	RU	https://pubmed.ncbi.nlm.nih.gov/18952425

DMSPOAT	DI	DMSPOAT
DMSPOAT	DN	2-(4-Phenoxy-phenyl)-1H-benzoimidazol-5-ylamine
DMSPOAT	MI	TT9ABMF
DMSPOAT	MN	Serine/threonine-protein kinase Chk2 (RAD53)
DMSPOAT	MT	DTT
DMSPOAT	MA	Inhibitor
DMSPOAT	RN	Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. J Med Chem. 2005 Mar 24;48(6):1873-85.
DMSPOAT	RU	https://pubmed.ncbi.nlm.nih.gov/15771432

DMEQ063	DI	DMEQ063
DMEQ063	DN	2-(4-Phenyl-butyl)-1,2-dihydro-indazol-3-one
DMEQ063	MI	TT2J34L
DMEQ063	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMEQ063	MT	DTT
DMEQ063	MA	Inhibitor
DMEQ063	RN	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
DMEQ063	RU	https://pubmed.ncbi.nlm.nih.gov/1848292

DMNJAV1	DI	DMNJAV1
DMNJAV1	DN	2-(4-phenylbutyl)pyrido[2,3-d]pyrimidin-4(3H)-one
DMNJAV1	MI	TTWNV8U
DMNJAV1	MN	Nicotinic acid receptor (HCAR2)
DMNJAV1	MT	DTT
DMNJAV1	MA	Inhibitor
DMNJAV1	RN	Pyrido pyrimidinones as selective agonists of the high affinity niacin receptor GPR109A: optimization of in vitro activity. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5426-30.
DMNJAV1	RU	https://pubmed.ncbi.nlm.nih.gov/20724150

DM98WVL	DI	DM98WVL
DM98WVL	DN	2-(4-Piperidin-1-ylmethylphenoxy)benzothiazole
DM98WVL	MI	TTXZEAJ
DM98WVL	MN	Leukotriene A-4 hydrolase (LTA4H)
DM98WVL	MT	DTT
DM98WVL	MA	Inhibitor
DM98WVL	RN	Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69.
DM98WVL	RU	https://pubmed.ncbi.nlm.nih.gov/18588282

DMXC20R	DI	DMXC20R
DMXC20R	DN	2-(4-propylphenylsulfonyl)naphthalene-1,4-diol
DMXC20R	MI	TTRVTMX
DMXC20R	MN	Bacterial Beta-ketoacyl-ACP synthase III (Bact fabH)
DMXC20R	MT	DTT
DMXC20R	MA	Inhibitor
DMXC20R	RN	Synthesis and biological evaluation of novel sulfonyl-naphthalene-1,4-diols as FabH inhibitors. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6402-5.
DMXC20R	RU	https://pubmed.ncbi.nlm.nih.gov/18996691

DMWPM9L	DI	DMWPM9L
DMWPM9L	DN	2-(4-Propyl-piperazin-1-yl)-quinoline
DMWPM9L	MI	TT9JNIC
DMWPM9L	MN	Histamine H3 receptor (H3R)
DMWPM9L	MT	DTT
DMWPM9L	MA	Inhibitor
DMWPM9L	RN	2-(4-alkylpiperazin-1-yl)quinolines as a new class of imidazole-free histamine H3 receptor antagonists. J Med Chem. 2005 Jan 13;48(1):306-11.
DMWPM9L	RU	https://pubmed.ncbi.nlm.nih.gov/15634025

DMIOW3D	DI	DMIOW3D
DMIOW3D	DN	2-(4-tert-butylbenzylideneamino)ethanesulfonamide
DMIOW3D	MI	TTANPDJ
DMIOW3D	MN	Carbonic anhydrase II (CA-II)
DMIOW3D	MT	DTT
DMIOW3D	MA	Inhibitor
DMIOW3D	RN	Carbonic anhydrase II-induced selection of inhibitors from a dynamic combinatorial library of Schiff's bases. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6014-7.
DMIOW3D	RU	https://pubmed.ncbi.nlm.nih.gov/19796939

DM1A4BS	DI	DM1A4BS
DM1A4BS	DN	2-(4-tert-Butyl-phenyl)-4,5-dihydro-1H-imidazole
DM1A4BS	MI	TT6MSOK
DM1A4BS	MN	5-HT 1D receptor (HTR1D)
DM1A4BS	MT	DTT
DM1A4BS	MA	Inhibitor
DM1A4BS	RN	2-(Anilino)imidazolines and 2-(benzyl)imidazoline derivatives as h5-HT1D serotonin receptor ligands. Bioorg Med Chem Lett. 2004 Sep 20;14(18):4697-9.
DM1A4BS	RU	https://pubmed.ncbi.nlm.nih.gov/15324890

DM1A4BS	DI	DM1A4BS
DM1A4BS	DN	2-(4-tert-Butyl-phenyl)-4,5-dihydro-1H-imidazole
DM1A4BS	MI	TTNGILX
DM1A4BS	MN	Adrenergic receptor alpha-1A (ADRA1A)
DM1A4BS	MT	DTT
DM1A4BS	MA	Inhibitor
DM1A4BS	RN	2-(Anilino)imidazolines and 2-(benzyl)imidazoline derivatives as h5-HT1D serotonin receptor ligands. Bioorg Med Chem Lett. 2004 Sep 20;14(18):4697-9.
DM1A4BS	RU	https://pubmed.ncbi.nlm.nih.gov/15324890

DMED9FL	DI	DMED9FL
DMED9FL	DN	2-(4-tosylpiperazin-1-yl)nicotinonitrile
DMED9FL	MI	TTN7BL9
DMED9FL	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMED9FL	MT	DTT
DMED9FL	MA	Inhibitor
DMED9FL	RN	Discovery and initial SAR of arylsulfonylpiperazine inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1). Bioorg Med Chem Lett. 2008 Jun 15;18(12):3513-6.
DMED9FL	RU	https://pubmed.ncbi.nlm.nih.gov/18511278

DMTC5Y9	DI	DMTC5Y9
DMTC5Y9	DN	2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile
DMTC5Y9	MI	TTGKNB4
DMTC5Y9	MN	Epidermal growth factor receptor (EGFR)
DMTC5Y9	MT	DTT
DMTC5Y9	MA	Inhibitor
DMTC5Y9	RN	Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine... J Med Chem. 1991 Jun;34(6):1896-907.
DMTC5Y9	RU	https://pubmed.ncbi.nlm.nih.gov/1676428

DMXRYDL	DI	DMXRYDL
DMXRYDL	DN	2-(5-Bromo-indole-1-sulfonyl)-benzoic acid
DMXRYDL	MI	TTHWMFZ
DMXRYDL	MN	Fatty acid-binding protein 4 (FABP4)
DMXRYDL	MT	DTT
DMXRYDL	MA	Inhibitor
DMXRYDL	RN	Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4445-8.
DMXRYDL	RU	https://pubmed.ncbi.nlm.nih.gov/15357969

DM0ZB89	DI	DM0ZB89
DM0ZB89	DN	2-(5-chloro-1H-benzo[d]imidazol-2-yl)quinoxaline
DM0ZB89	MI	TTJFY5U
DM0ZB89	MN	Adenosine A3 receptor (ADORA3)
DM0ZB89	MT	DTT
DM0ZB89	MA	Inhibitor
DM0ZB89	RN	2-(Benzimidazol-2-yl)quinoxalines: a novel class of selective antagonists at human A(1) and A(3) adenosine receptors designed by 3D database search... J Med Chem. 2005 Dec 29;48(26):8253-60.
DM0ZB89	RU	https://pubmed.ncbi.nlm.nih.gov/16366607

DMSIJ17	DI	DMSIJ17
DMSIJ17	DN	2-(5-cyano-1-pent-1-ynyl)-N6-methoxyadenosine
DMSIJ17	MI	TTK25J1
DMSIJ17	MN	Adenosine A1 receptor (ADORA1)
DMSIJ17	MT	DTT
DMSIJ17	MA	Inhibitor
DMSIJ17	RN	N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
DMSIJ17	RU	https://pubmed.ncbi.nlm.nih.gov/17309246

DMSIJ17	DI	DMSIJ17
DMSIJ17	DN	2-(5-cyano-1-pent-1-ynyl)-N6-methoxyadenosine
DMSIJ17	MI	TTM2AOE
DMSIJ17	MN	Adenosine A2a receptor (ADORA2A)
DMSIJ17	MT	DTT
DMSIJ17	MA	Inhibitor
DMSIJ17	RN	N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
DMSIJ17	RU	https://pubmed.ncbi.nlm.nih.gov/17309246

DMSIJ17	DI	DMSIJ17
DMSIJ17	DN	2-(5-cyano-1-pent-1-ynyl)-N6-methoxyadenosine
DMSIJ17	MI	TTJFY5U
DMSIJ17	MN	Adenosine A3 receptor (ADORA3)
DMSIJ17	MT	DTT
DMSIJ17	MA	Inhibitor
DMSIJ17	RN	N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
DMSIJ17	RU	https://pubmed.ncbi.nlm.nih.gov/17309246

DMHW5FT	DI	DMHW5FT
DMHW5FT	DN	2-(5-fluoro-1H-indol-3-yl)ethanamine
DMHW5FT	MI	TTCPG9S
DMHW5FT	MN	5-HT 1E receptor (HTR1E)
DMHW5FT	MT	DTT
DMHW5FT	MA	Agonist
DMHW5FT	RN	Molecular cloning and pharmacological characterization of the guinea pig 5-HT1E receptor. Eur J Pharmacol. 2004 Jan 26;484(2-3):127-39.
DMHW5FT	RU	https://pubmed.ncbi.nlm.nih.gov/14744596

DMHW5FT	DI	DMHW5FT
DMHW5FT	DN	2-(5-fluoro-1H-indol-3-yl)ethanamine
DMHW5FT	MI	TTXDKTO
DMHW5FT	MN	Long transient receptor potential channel 8 (TRPM8)
DMHW5FT	MT	DTT
DMHW5FT	MA	Inhibitor
DMHW5FT	RN	5-benzyloxytryptamine as an antagonist of TRPM8. Bioorg Med Chem Lett. 2010 Dec 1;20(23):7076-9.
DMHW5FT	RU	https://pubmed.ncbi.nlm.nih.gov/20965726

DMB3JG0	DI	DMB3JG0
DMB3JG0	DN	2-(5-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol
DMB3JG0	MI	TTZAYWL
DMB3JG0	MN	Estrogen receptor (ESR)
DMB3JG0	MT	DTT
DMB3JG0	MA	Inhibitor
DMB3JG0	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMB3JG0	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMB3JG0	DI	DMB3JG0
DMB3JG0	DN	2-(5-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol
DMB3JG0	MI	TTOM3J0
DMB3JG0	MN	Estrogen receptor beta (ESR2)
DMB3JG0	MT	DTT
DMB3JG0	MA	Inhibitor
DMB3JG0	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMB3JG0	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DM0P6A3	DI	DM0P6A3
DM0P6A3	DN	2-(5-Mercapto-pentyl)-pentanedioic acid
DM0P6A3	MI	TT9G4N0
DM0P6A3	MN	Glutamate carboxypeptidase II (GCPII)
DM0P6A3	MT	DTT
DM0P6A3	MA	Inhibitor
DM0P6A3	RN	Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. J Med Chem. 2003 May 8;46(10):1989-96.
DM0P6A3	RU	https://pubmed.ncbi.nlm.nih.gov/12723961

DM1O0JD	DI	DM1O0JD
DM1O0JD	DN	2-(5-Methoxy-1H-indol-3-yl)-1-methyl-ethylamine
DM1O0JD	MI	TTSQIFT
DM1O0JD	MN	5-HT 1A receptor (HTR1A)
DM1O0JD	MT	DTT
DM1O0JD	MA	Inhibitor
DM1O0JD	RN	A novel and selective 5-HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano[3,2-e]indole. J Med Chem. 2003 Sep 11;46(19):4188-95.
DM1O0JD	RU	https://pubmed.ncbi.nlm.nih.gov/12954071

DM1O0JD	DI	DM1O0JD
DM1O0JD	DN	2-(5-Methoxy-1H-indol-3-yl)-1-methyl-ethylamine
DM1O0JD	MI	TTJQOD7
DM1O0JD	MN	5-HT 2A receptor (HTR2A)
DM1O0JD	MT	DTT
DM1O0JD	MA	Inhibitor
DM1O0JD	RN	1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28.
DM1O0JD	RU	https://pubmed.ncbi.nlm.nih.gov/16392816

DM1O0JD	DI	DM1O0JD
DM1O0JD	DN	2-(5-Methoxy-1H-indol-3-yl)-1-methyl-ethylamine
DM1O0JD	MI	TT0K1SC
DM1O0JD	MN	5-HT 2B receptor (HTR2B)
DM1O0JD	MT	DTT
DM1O0JD	MA	Inhibitor
DM1O0JD	RN	1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28.
DM1O0JD	RU	https://pubmed.ncbi.nlm.nih.gov/16392816

DM1O0JD	DI	DM1O0JD
DM1O0JD	DN	2-(5-Methoxy-1H-indol-3-yl)-1-methyl-ethylamine
DM1O0JD	MI	TTWJBZ5
DM1O0JD	MN	5-HT 2C receptor (HTR2C)
DM1O0JD	MT	DTT
DM1O0JD	MA	Inhibitor
DM1O0JD	RN	1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28.
DM1O0JD	RU	https://pubmed.ncbi.nlm.nih.gov/16392816

DM2TU6W	DI	DM2TU6W
DM2TU6W	DN	2-(5-Nonyloxy-1H-indol-3-yl)-ethylamine
DM2TU6W	MI	TTK8CXU
DM2TU6W	MN	5-HT 1B receptor (HTR1B)
DM2TU6W	MT	DTT
DM2TU6W	MA	Agonist
DM2TU6W	RN	Identification of an amino acid residue important for binding of methiothepin and sumatriptan to the human 5-HT(1B) receptor. Eur J Pharmacol. 1999 Sep 10;380(2-3):171-81.
DM2TU6W	RU	https://pubmed.ncbi.nlm.nih.gov/10513577

DM2TU6W	DI	DM2TU6W
DM2TU6W	DN	2-(5-Nonyloxy-1H-indol-3-yl)-ethylamine
DM2TU6W	MI	TT6MSOK
DM2TU6W	MN	5-HT 1D receptor (HTR1D)
DM2TU6W	MT	DTT
DM2TU6W	MA	Inhibitor
DM2TU6W	RN	5-(Nonyloxy)tryptamine: a novel high-affinity 5-HT1D beta serotonin receptor agonist. J Med Chem. 1994 Sep 2;37(18):2828-30.
DM2TU6W	RU	https://pubmed.ncbi.nlm.nih.gov/8071931

DMDZ9RK	DI	DMDZ9RK
DMDZ9RK	DN	2-(5-phenyl-furan-2-yl)-4,5-dihydro-1H-imidazole
DMDZ9RK	MI	TT3WG5C
DMDZ9RK	MN	Monoamine oxidase type A (MAO-A)
DMDZ9RK	MT	DTT
DMDZ9RK	MA	Inhibitor
DMDZ9RK	RN	3-[5-(4,5-dihydro-1H-imidazol-2-yl)-furan-2-yl]phenylamine (Amifuraline), a promising reversible and selective peripheral MAO-A inhibitor. J Med Chem. 2006 Sep 7;49(18):5578-86.
DMDZ9RK	RU	https://pubmed.ncbi.nlm.nih.gov/16942031

DMDZ9RK	DI	DMDZ9RK
DMDZ9RK	DN	2-(5-phenyl-furan-2-yl)-4,5-dihydro-1H-imidazole
DMDZ9RK	MI	TTGP7BY
DMDZ9RK	MN	Monoamine oxidase type B (MAO-B)
DMDZ9RK	MT	DTT
DMDZ9RK	MA	Inhibitor
DMDZ9RK	RN	3-[5-(4,5-dihydro-1H-imidazol-2-yl)-furan-2-yl]phenylamine (Amifuraline), a promising reversible and selective peripheral MAO-A inhibitor. J Med Chem. 2006 Sep 7;49(18):5578-86.
DMDZ9RK	RU	https://pubmed.ncbi.nlm.nih.gov/16942031

DMX6QMT	DI	DMX6QMT
DMX6QMT	DN	2-(5-Phenyl-oxazol-2-ylamino)-benzonitrile
DMX6QMT	MI	TTUTJGQ
DMX6QMT	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMX6QMT	MT	DTT
DMX6QMT	MA	Inhibitor
DMX6QMT	RN	Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9.
DMX6QMT	RU	https://pubmed.ncbi.nlm.nih.gov/15743202

DMX6QMT	DI	DMX6QMT
DMX6QMT	DN	2-(5-Phenyl-oxazol-2-ylamino)-benzonitrile
DMX6QMT	MI	TTDCBX5
DMX6QMT	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DMX6QMT	MT	DTT
DMX6QMT	MA	Inhibitor
DMX6QMT	RN	Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9.
DMX6QMT	RU	https://pubmed.ncbi.nlm.nih.gov/15743202

DMX6QMT	DI	DMX6QMT
DMX6QMT	DN	2-(5-Phenyl-oxazol-2-ylamino)-benzonitrile
DMX6QMT	MI	TT1VAUK
DMX6QMT	MN	VEGFR1 messenger RNA (VEGFR1 mRNA)
DMX6QMT	MT	DTT
DMX6QMT	MA	Inhibitor
DMX6QMT	RN	Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9.
DMX6QMT	RU	https://pubmed.ncbi.nlm.nih.gov/15743202

DM1AEK4	DI	DM1AEK4
DM1AEK4	DN	2-(5-Thiophen-2-yl-1H-indol-3-yl)-ethylamine
DM1AEK4	MI	TTK8CXU
DM1AEK4	MN	5-HT 1B receptor (HTR1B)
DM1AEK4	MT	DTT
DM1AEK4	MA	Inhibitor
DM1AEK4	RN	5-Thienyltryptamine derivatives as serotonin 5-HT1B/1D receptor agonists: potential treatments for migraine. Bioorg Med Chem Lett. 2000 May 1;10(9):903-5.
DM1AEK4	RU	https://pubmed.ncbi.nlm.nih.gov/10853656

DM1AEK4	DI	DM1AEK4
DM1AEK4	DN	2-(5-Thiophen-2-yl-1H-indol-3-yl)-ethylamine
DM1AEK4	MI	TT6MSOK
DM1AEK4	MN	5-HT 1D receptor (HTR1D)
DM1AEK4	MT	DTT
DM1AEK4	MA	Inhibitor
DM1AEK4	RN	5-Thienyltryptamine derivatives as serotonin 5-HT1B/1D receptor agonists: potential treatments for migraine. Bioorg Med Chem Lett. 2000 May 1;10(9):903-5.
DM1AEK4	RU	https://pubmed.ncbi.nlm.nih.gov/10853656

DMRBX1D	DI	DMRBX1D
DMRBX1D	DN	2-(6-amino-8-bromo-9H-purin-9-yl)ethanol
DMRBX1D	MI	TTK25J1
DMRBX1D	MN	Adenosine A1 receptor (ADORA1)
DMRBX1D	MT	DTT
DMRBX1D	MA	Inhibitor
DMRBX1D	RN	Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods. Eur J Med Chem. 2010 Aug;45(8):3459-71.
DMRBX1D	RU	https://pubmed.ncbi.nlm.nih.gov/20537438

DMRBX1D	DI	DMRBX1D
DMRBX1D	DN	2-(6-amino-8-bromo-9H-purin-9-yl)ethanol
DMRBX1D	MI	TTM2AOE
DMRBX1D	MN	Adenosine A2a receptor (ADORA2A)
DMRBX1D	MT	DTT
DMRBX1D	MA	Inhibitor
DMRBX1D	RN	Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods. Eur J Med Chem. 2010 Aug;45(8):3459-71.
DMRBX1D	RU	https://pubmed.ncbi.nlm.nih.gov/20537438

DMRBX1D	DI	DMRBX1D
DMRBX1D	DN	2-(6-amino-8-bromo-9H-purin-9-yl)ethanol
DMRBX1D	MI	TTNE7KG
DMRBX1D	MN	Adenosine A2b receptor (ADORA2B)
DMRBX1D	MT	DTT
DMRBX1D	MA	Inhibitor
DMRBX1D	RN	Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods. Eur J Med Chem. 2010 Aug;45(8):3459-71.
DMRBX1D	RU	https://pubmed.ncbi.nlm.nih.gov/20537438

DMTI1VO	DI	DMTI1VO
DMTI1VO	DN	2-(6-Cyclopentylamino-purin-9-yl)-ethanol
DMTI1VO	MI	TTK25J1
DMTI1VO	MN	Adenosine A1 receptor (ADORA1)
DMTI1VO	MT	DTT
DMTI1VO	MA	Inhibitor
DMTI1VO	RN	N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor. J Med Chem. 1991 Sep;34(9):2877-82.
DMTI1VO	RU	https://pubmed.ncbi.nlm.nih.gov/1895305

DMXAVHT	DI	DMXAVHT
DMXAVHT	DN	2-(6-Hydroxy-naphthalen-1-yl)-benzooxazol-5-ol
DMXAVHT	MI	TTZAYWL
DMXAVHT	MN	Estrogen receptor (ESR)
DMXAVHT	MT	DTT
DMXAVHT	MA	Inhibitor
DMXAVHT	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMXAVHT	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMXAVHT	DI	DMXAVHT
DMXAVHT	DN	2-(6-Hydroxy-naphthalen-1-yl)-benzooxazol-5-ol
DMXAVHT	MI	TTOM3J0
DMXAVHT	MN	Estrogen receptor beta (ESR2)
DMXAVHT	MT	DTT
DMXAVHT	MA	Inhibitor
DMXAVHT	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMXAVHT	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DM3GQN2	DI	DM3GQN2
DM3GQN2	DN	2-(6-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol
DM3GQN2	MI	TTZAYWL
DM3GQN2	MN	Estrogen receptor (ESR)
DM3GQN2	MT	DTT
DM3GQN2	MA	Inhibitor
DM3GQN2	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DM3GQN2	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DM3GQN2	DI	DM3GQN2
DM3GQN2	DN	2-(6-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol
DM3GQN2	MI	TTOM3J0
DM3GQN2	MN	Estrogen receptor beta (ESR2)
DM3GQN2	MT	DTT
DM3GQN2	MA	Inhibitor
DM3GQN2	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DM3GQN2	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DM715EC	DI	DM715EC
DM715EC	DN	2-(6-Hydroxy-naphthalen-2-yl)-benzooxazol-5-ol
DM715EC	MI	TTZAYWL
DM715EC	MN	Estrogen receptor (ESR)
DM715EC	MT	DTT
DM715EC	MA	Inhibitor
DM715EC	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DM715EC	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DM715EC	DI	DM715EC
DM715EC	DN	2-(6-Hydroxy-naphthalen-2-yl)-benzooxazol-5-ol
DM715EC	MI	TTOM3J0
DM715EC	MN	Estrogen receptor beta (ESR2)
DM715EC	MT	DTT
DM715EC	MA	Inhibitor
DM715EC	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DM715EC	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMANHOT	DI	DMANHOT
DMANHOT	DN	2-(6-Hydroxy-naphthalen-2-yl)-benzooxazol-6-ol
DMANHOT	MI	TTZAYWL
DMANHOT	MN	Estrogen receptor (ESR)
DMANHOT	MT	DTT
DMANHOT	MA	Inhibitor
DMANHOT	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMANHOT	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMANHOT	DI	DMANHOT
DMANHOT	DN	2-(6-Hydroxy-naphthalen-2-yl)-benzooxazol-6-ol
DMANHOT	MI	TTOM3J0
DMANHOT	MN	Estrogen receptor beta (ESR2)
DMANHOT	MT	DTT
DMANHOT	MA	Inhibitor
DMANHOT	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMANHOT	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMKI6GQ	DI	DMKI6GQ
DMKI6GQ	DN	2-(6-Imidazol-1-yl-hexyl)-isoindole-1,3-dione
DMKI6GQ	MI	TTKNWZ4
DMKI6GQ	MN	Thromboxane-A synthase (TBXAS1)
DMKI6GQ	MT	DTT
DMKI6GQ	MA	Inhibitor
DMKI6GQ	RN	Thromboxane synthetase inhibitors and antihypertensive agents. 2. N-[(1H-imidazol-1-yl)alkyl]-1H-isoindole-1,3(2H)-diones and N-[(1H-1,2,4-triazol-... J Med Chem. 1986 May;29(5):816-9.
DMKI6GQ	RU	https://pubmed.ncbi.nlm.nih.gov/3517332

DM41UYN	DI	DM41UYN
DM41UYN	DN	2-(6-Methoxy-indole-1-sulfonyl)-benzoic acid
DM41UYN	MI	TTHWMFZ
DM41UYN	MN	Fatty acid-binding protein 4 (FABP4)
DM41UYN	MT	DTT
DM41UYN	MA	Inhibitor
DM41UYN	RN	Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4445-8.
DM41UYN	RU	https://pubmed.ncbi.nlm.nih.gov/15357969

DMZDNHQ	DI	DMZDNHQ
DMZDNHQ	DN	2-(6-morpholino-9H-purin-2-yl)phenol
DMZDNHQ	MI	TTCJG29
DMZDNHQ	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMZDNHQ	MT	DTT
DMZDNHQ	MA	Inhibitor
DMZDNHQ	RN	Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-alpha: Hit to lead studies. Bioorg Med Chem Lett. 2010 Jan 15;20(2):636-9.
DMZDNHQ	RU	https://pubmed.ncbi.nlm.nih.gov/19969455

DMR3Z1D	DI	DMR3Z1D
DMR3Z1D	DN	2-(6-phenylhexyl)pyrido[2,3-d]pyrimidin-4(3H)-one
DMR3Z1D	MI	TTWNV8U
DMR3Z1D	MN	Nicotinic acid receptor (HCAR2)
DMR3Z1D	MT	DTT
DMR3Z1D	MA	Inhibitor
DMR3Z1D	RN	Pyrido pyrimidinones as selective agonists of the high affinity niacin receptor GPR109A: optimization of in vitro activity. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5426-30.
DMR3Z1D	RU	https://pubmed.ncbi.nlm.nih.gov/20724150

DMD2QVO	DI	DMD2QVO
DMD2QVO	DN	2-(7-(benzyloxy)-1H-indol-3-yl)ethanamine
DMD2QVO	MI	TTXZEAJ
DMD2QVO	MN	Leukotriene A-4 hydrolase (LTA4H)
DMD2QVO	MT	DTT
DMD2QVO	MA	Inhibitor
DMD2QVO	RN	Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. J Med Chem. 2008 Dec 25;51(24):7882-8.
DMD2QVO	RU	https://pubmed.ncbi.nlm.nih.gov/19090779

DMD2QVO	DI	DMD2QVO
DMD2QVO	DN	2-(7-(benzyloxy)-1H-indol-3-yl)ethanamine
DMD2QVO	MI	TTXDKTO
DMD2QVO	MN	Long transient receptor potential channel 8 (TRPM8)
DMD2QVO	MT	DTT
DMD2QVO	MA	Inhibitor
DMD2QVO	RN	5-benzyloxytryptamine as an antagonist of TRPM8. Bioorg Med Chem Lett. 2010 Dec 1;20(23):7076-9.
DMD2QVO	RU	https://pubmed.ncbi.nlm.nih.gov/20965726

DMJAEZ8	DI	DMJAEZ8
DMJAEZ8	DN	2-(7-phenylheptanoyl)oxazole-4-carbaldehyde
DMJAEZ8	MI	TTDP1UC
DMJAEZ8	MN	Fatty acid amide hydrolase (FAAH)
DMJAEZ8	MT	DTT
DMJAEZ8	MA	Inhibitor
DMJAEZ8	RN	Exploration of a fundamental substituent effect of alpha-ketoheterocycle enzyme inhibitors: Potent and selective inhibitors of fatty acid amide hyd... Bioorg Med Chem Lett. 2008 Nov 15;18(22):5842-6.
DMJAEZ8	RU	https://pubmed.ncbi.nlm.nih.gov/18639454

DMVSL49	DI	DMVSL49
DMVSL49	DN	2-(7-phenylheptanoyl)oxazole-4-carbonitrile
DMVSL49	MI	TTDP1UC
DMVSL49	MN	Fatty acid amide hydrolase (FAAH)
DMVSL49	MT	DTT
DMVSL49	MA	Inhibitor
DMVSL49	RN	Exploration of a fundamental substituent effect of alpha-ketoheterocycle enzyme inhibitors: Potent and selective inhibitors of fatty acid amide hyd... Bioorg Med Chem Lett. 2008 Nov 15;18(22):5842-6.
DMVSL49	RU	https://pubmed.ncbi.nlm.nih.gov/18639454

DM9JMF2	DI	DM9JMF2
DM9JMF2	DN	2-(7-phenylheptanoyl)oxazole-4-carboxamide
DM9JMF2	MI	TTDP1UC
DM9JMF2	MN	Fatty acid amide hydrolase (FAAH)
DM9JMF2	MT	DTT
DM9JMF2	MA	Inhibitor
DM9JMF2	RN	Exploration of a fundamental substituent effect of alpha-ketoheterocycle enzyme inhibitors: Potent and selective inhibitors of fatty acid amide hyd... Bioorg Med Chem Lett. 2008 Nov 15;18(22):5842-6.
DM9JMF2	RU	https://pubmed.ncbi.nlm.nih.gov/18639454

DM9BE2S	DI	DM9BE2S
DM9BE2S	DN	2-(7-phenylheptanoyl)oxazole-4-carboxylic acid
DM9BE2S	MI	TTDP1UC
DM9BE2S	MN	Fatty acid amide hydrolase (FAAH)
DM9BE2S	MT	DTT
DM9BE2S	MA	Inhibitor
DM9BE2S	RN	Exploration of a fundamental substituent effect of alpha-ketoheterocycle enzyme inhibitors: Potent and selective inhibitors of fatty acid amide hyd... Bioorg Med Chem Lett. 2008 Nov 15;18(22):5842-6.
DM9BE2S	RU	https://pubmed.ncbi.nlm.nih.gov/18639454

DM89RYN	DI	DM89RYN
DM89RYN	DN	2-(7-phenylheptanoyl)oxazole-5-carbonitrile
DM89RYN	MI	TTDP1UC
DM89RYN	MN	Fatty acid amide hydrolase (FAAH)
DM89RYN	MT	DTT
DM89RYN	MA	Inhibitor
DM89RYN	RN	Exploration of a fundamental substituent effect of alpha-ketoheterocycle enzyme inhibitors: Potent and selective inhibitors of fatty acid amide hyd... Bioorg Med Chem Lett. 2008 Nov 15;18(22):5842-6.
DM89RYN	RU	https://pubmed.ncbi.nlm.nih.gov/18639454

DMB53ML	DI	DMB53ML
DMB53ML	DN	2-(7-phenylheptanoyl)oxazole-5-carboxylic acid
DMB53ML	MI	TTDP1UC
DMB53ML	MN	Fatty acid amide hydrolase (FAAH)
DMB53ML	MT	DTT
DMB53ML	MA	Inhibitor
DMB53ML	RN	Exploration of a fundamental substituent effect of alpha-ketoheterocycle enzyme inhibitors: Potent and selective inhibitors of fatty acid amide hyd... Bioorg Med Chem Lett. 2008 Nov 15;18(22):5842-6.
DMB53ML	RU	https://pubmed.ncbi.nlm.nih.gov/18639454

DMLQ9WD	DI	DMLQ9WD
DMLQ9WD	DN	2-(8-Imidazol-1-yl-octyl)-isoindole-1,3-dione
DMLQ9WD	MI	TTKNWZ4
DMLQ9WD	MN	Thromboxane-A synthase (TBXAS1)
DMLQ9WD	MT	DTT
DMLQ9WD	MA	Inhibitor
DMLQ9WD	RN	Thromboxane synthetase inhibitors and antihypertensive agents. 2. N-[(1H-imidazol-1-yl)alkyl]-1H-isoindole-1,3(2H)-diones and N-[(1H-1,2,4-triazol-... J Med Chem. 1986 May;29(5):816-9.
DMLQ9WD	RU	https://pubmed.ncbi.nlm.nih.gov/3517332

DMRW475	DI	DMRW475
DMRW475	DN	2-(9,10-dihydroanthracen-9-yl)-N-methylethanamine
DMRW475	MI	TTJQOD7
DMRW475	MN	5-HT 2A receptor (HTR2A)
DMRW475	MT	DTT
DMRW475	MA	Inhibitor
DMRW475	RN	Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504.
DMRW475	RU	https://pubmed.ncbi.nlm.nih.gov/19700330

DMRW475	DI	DMRW475
DMRW475	DN	2-(9,10-dihydroanthracen-9-yl)-N-methylethanamine
DMRW475	MI	TTTIBOJ
DMRW475	MN	Histamine H1 receptor (H1R)
DMRW475	MT	DTT
DMRW475	MA	Inhibitor
DMRW475	RN	Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504.
DMRW475	RU	https://pubmed.ncbi.nlm.nih.gov/19700330

DMPJ0O6	DI	DMPJ0O6
DMPJ0O6	DN	2-(9-Benzyl-9H-purin-6-ylamino)-ethanol
DMPJ0O6	MI	TT1MPAY
DMPJ0O6	MN	GABA(A) receptor alpha-1 (GABRA1)
DMPJ0O6	MT	DTT
DMPJ0O6	MA	Inhibitor
DMPJ0O6	RN	Benzodiazepine receptor binding activity of 6,9-disubstituted purines. J Med Chem. 1989 May;32(5):1020-4.
DMPJ0O6	RU	https://pubmed.ncbi.nlm.nih.gov/2540330

DMPJ0O6	DI	DMPJ0O6
DMPJ0O6	DN	2-(9-Benzyl-9H-purin-6-ylamino)-ethanol
DMPJ0O6	MI	TTZA1NY
DMPJ0O6	MN	GABA(A) receptor beta-2 (GABRB2)
DMPJ0O6	MT	DTT
DMPJ0O6	MA	Inhibitor
DMPJ0O6	RN	Benzodiazepine receptor binding activity of 6,9-disubstituted purines. J Med Chem. 1989 May;32(5):1020-4.
DMPJ0O6	RU	https://pubmed.ncbi.nlm.nih.gov/2540330

DMPJ0O6	DI	DMPJ0O6
DMPJ0O6	DN	2-(9-Benzyl-9H-purin-6-ylamino)-ethanol
DMPJ0O6	MI	TT06RH5
DMPJ0O6	MN	GABA(A) receptor gamma-2 (GABRG2)
DMPJ0O6	MT	DTT
DMPJ0O6	MA	Inhibitor
DMPJ0O6	RN	Benzodiazepine receptor binding activity of 6,9-disubstituted purines. J Med Chem. 1989 May;32(5):1020-4.
DMPJ0O6	RU	https://pubmed.ncbi.nlm.nih.gov/2540330

DMPJ0O6	DI	DMPJ0O6
DMPJ0O6	DN	2-(9-Benzyl-9H-purin-6-ylamino)-ethanol
DMPJ0O6	MI	TTNJYV2
DMPJ0O6	MN	Gamma-aminobutyric acid receptor (GAR)
DMPJ0O6	MT	DTT
DMPJ0O6	MA	Inhibitor
DMPJ0O6	RN	Benzodiazepine receptor binding activity of 6,9-disubstituted purines. J Med Chem. 1989 May;32(5):1020-4.
DMPJ0O6	RU	https://pubmed.ncbi.nlm.nih.gov/2540330

DMOUG6Y	DI	DMOUG6Y
DMOUG6Y	DN	2-(Acetylamino)-2-Deoxy-a-D-Glucopyranose
DMOUG6Y	MI	TT1RS9F
DMOUG6Y	MN	Acetylcholinesterase (AChE)
DMOUG6Y	MT	DTT
DMOUG6Y	MA	Inhibitor
DMOUG6Y	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMOUG6Y	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMOUG6Y	DI	DMOUG6Y
DMOUG6Y	DN	2-(Acetylamino)-2-Deoxy-a-D-Glucopyranose
DMOUG6Y	MI	TTL69WB
DMOUG6Y	MN	Angiotensin-converting enzyme (ACE)
DMOUG6Y	MT	DTT
DMOUG6Y	MA	Inhibitor
DMOUG6Y	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMOUG6Y	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMOUG6Y	DI	DMOUG6Y
DMOUG6Y	DN	2-(Acetylamino)-2-Deoxy-a-D-Glucopyranose
DMOUG6Y	MI	TT1B5PU
DMOUG6Y	MN	Glucosylceramidase (GBA)
DMOUG6Y	MT	DTT
DMOUG6Y	MA	Inhibitor
DMOUG6Y	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMOUG6Y	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMB3YXG	DI	DMB3YXG
DMB3YXG	DN	2-(adamantan-1-ylamino)-5,5-diethyl-oxazol-4-one
DMB3YXG	MI	TTN7BL9
DMB3YXG	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMB3YXG	MT	DTT
DMB3YXG	MA	Inhibitor
DMB3YXG	RN	Oxazolones as potent inhibitors of 11beta-hydroxysteroid dehydrogenase type 1. Bioorg Med Chem Lett. 2007 Sep 1;17(17):4837-40.
DMB3YXG	RU	https://pubmed.ncbi.nlm.nih.gov/17600707

DM6P20R	DI	DM6P20R
DM6P20R	DN	2-(allyloxy)-N8-hydroxy-N1-phenyloctanediamide
DM6P20R	MI	TTSHTOI
DM6P20R	MN	Histone deacetylase 2 (HDAC2)
DM6P20R	MT	DTT
DM6P20R	MA	Inhibitor
DM6P20R	RN	Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6261-5.
DM6P20R	RU	https://pubmed.ncbi.nlm.nih.gov/17892933

DMU4MIC	DI	DMU4MIC
DMU4MIC	DN	2-(Aminomethyl)-5-(1'-naphthethyl)tetrahydrofuran
DMU4MIC	MI	TTAWNKZ
DMU4MIC	MN	Norepinephrine transporter (NET)
DMU4MIC	MT	DTT
DMU4MIC	MA	Inhibitor
DMU4MIC	RN	2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68.
DMU4MIC	RU	https://pubmed.ncbi.nlm.nih.gov/19201198

DMU4MIC	DI	DMU4MIC
DMU4MIC	DN	2-(Aminomethyl)-5-(1'-naphthethyl)tetrahydrofuran
DMU4MIC	MI	TT3ROYC
DMU4MIC	MN	Serotonin transporter (SERT)
DMU4MIC	MT	DTT
DMU4MIC	MA	Inhibitor
DMU4MIC	RN	2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68.
DMU4MIC	RU	https://pubmed.ncbi.nlm.nih.gov/19201198

DMCUTY9	DI	DMCUTY9
DMCUTY9	DN	2-(Aminomethyl)-5-(1'-naphthyl)tetrahydrofuran
DMCUTY9	MI	TTVBI8W
DMCUTY9	MN	Dopamine transporter (DAT)
DMCUTY9	MT	DTT
DMCUTY9	MA	Inhibitor
DMCUTY9	RN	2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68.
DMCUTY9	RU	https://pubmed.ncbi.nlm.nih.gov/19201198

DMCUTY9	DI	DMCUTY9
DMCUTY9	DN	2-(Aminomethyl)-5-(1'-naphthyl)tetrahydrofuran
DMCUTY9	MI	TTAWNKZ
DMCUTY9	MN	Norepinephrine transporter (NET)
DMCUTY9	MT	DTT
DMCUTY9	MA	Inhibitor
DMCUTY9	RN	2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68.
DMCUTY9	RU	https://pubmed.ncbi.nlm.nih.gov/19201198

DMCUTY9	DI	DMCUTY9
DMCUTY9	DN	2-(Aminomethyl)-5-(1'-naphthyl)tetrahydrofuran
DMCUTY9	MI	TT3ROYC
DMCUTY9	MN	Serotonin transporter (SERT)
DMCUTY9	MT	DTT
DMCUTY9	MA	Inhibitor
DMCUTY9	RN	2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68.
DMCUTY9	RU	https://pubmed.ncbi.nlm.nih.gov/19201198

DM157SO	DI	DM157SO
DM157SO	DN	2-(Aminomethyl)-5-(2'-naphthyl)tetrahydrofuran
DM157SO	MI	TTVBI8W
DM157SO	MN	Dopamine transporter (DAT)
DM157SO	MT	DTT
DM157SO	MA	Inhibitor
DM157SO	RN	2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68.
DM157SO	RU	https://pubmed.ncbi.nlm.nih.gov/19201198

DM157SO	DI	DM157SO
DM157SO	DN	2-(Aminomethyl)-5-(2'-naphthyl)tetrahydrofuran
DM157SO	MI	TTAWNKZ
DM157SO	MN	Norepinephrine transporter (NET)
DM157SO	MT	DTT
DM157SO	MA	Inhibitor
DM157SO	RN	2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68.
DM157SO	RU	https://pubmed.ncbi.nlm.nih.gov/19201198

DM157SO	DI	DM157SO
DM157SO	DN	2-(Aminomethyl)-5-(2'-naphthyl)tetrahydrofuran
DM157SO	MI	TT3ROYC
DM157SO	MN	Serotonin transporter (SERT)
DM157SO	MT	DTT
DM157SO	MA	Inhibitor
DM157SO	RN	2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68.
DM157SO	RU	https://pubmed.ncbi.nlm.nih.gov/19201198

DMEZ7O2	DI	DMEZ7O2
DMEZ7O2	DN	2-(Aminomethyl)-5-phenethyltetrahydrofuran
DMEZ7O2	MI	TTVBI8W
DMEZ7O2	MN	Dopamine transporter (DAT)
DMEZ7O2	MT	DTT
DMEZ7O2	MA	Inhibitor
DMEZ7O2	RN	2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68.
DMEZ7O2	RU	https://pubmed.ncbi.nlm.nih.gov/19201198

DMEZ7O2	DI	DMEZ7O2
DMEZ7O2	DN	2-(Aminomethyl)-5-phenethyltetrahydrofuran
DMEZ7O2	MI	TTAWNKZ
DMEZ7O2	MN	Norepinephrine transporter (NET)
DMEZ7O2	MT	DTT
DMEZ7O2	MA	Inhibitor
DMEZ7O2	RN	2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68.
DMEZ7O2	RU	https://pubmed.ncbi.nlm.nih.gov/19201198

DMEZ7O2	DI	DMEZ7O2
DMEZ7O2	DN	2-(Aminomethyl)-5-phenethyltetrahydrofuran
DMEZ7O2	MI	TT3ROYC
DMEZ7O2	MN	Serotonin transporter (SERT)
DMEZ7O2	MT	DTT
DMEZ7O2	MA	Inhibitor
DMEZ7O2	RN	2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68.
DMEZ7O2	RU	https://pubmed.ncbi.nlm.nih.gov/19201198

DMO3G6Q	DI	DMO3G6Q
DMO3G6Q	DN	2-(benzofuran-2-yl)-6-morpholino-4H-pyran-4-one
DMO3G6Q	MI	TTK3PY9
DMO3G6Q	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMO3G6Q	MT	DTT
DMO3G6Q	MA	Inhibitor
DMO3G6Q	RN	Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72.
DMO3G6Q	RU	https://pubmed.ncbi.nlm.nih.gov/17371003

DMW27AC	DI	DMW27AC
DMW27AC	DN	2-(benzylamino)-5,5-diethyloxazol-4(5H)-one
DMW27AC	MI	TTN7BL9
DMW27AC	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMW27AC	MT	DTT
DMW27AC	MA	Inhibitor
DMW27AC	RN	Oxazolones as potent inhibitors of 11beta-hydroxysteroid dehydrogenase type 1. Bioorg Med Chem Lett. 2007 Sep 1;17(17):4837-40.
DMW27AC	RU	https://pubmed.ncbi.nlm.nih.gov/17600707

DM4X6I9	DI	DM4X6I9
DM4X6I9	DN	2-(Benzylamino)-6-(3-acetamidophenyl)pyrazine
DM4X6I9	MI	TT0EOB8
DM4X6I9	MN	B-Raf messenger RNA (BRAF mRNA)
DM4X6I9	MT	DTT
DM4X6I9	MA	Inhibitor
DM4X6I9	RN	Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead. J Med Chem. 2006 Jan 12;49(1):407-16.
DM4X6I9	RU	https://pubmed.ncbi.nlm.nih.gov/16392826

DM3VJLZ	DI	DM3VJLZ
DM3VJLZ	DN	2-(benzylideneamino)ethanesulfonamide
DM3VJLZ	MI	TTANPDJ
DM3VJLZ	MN	Carbonic anhydrase II (CA-II)
DM3VJLZ	MT	DTT
DM3VJLZ	MA	Inhibitor
DM3VJLZ	RN	Carbonic anhydrase II-induced selection of inhibitors from a dynamic combinatorial library of Schiff's bases. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6014-7.
DM3VJLZ	RU	https://pubmed.ncbi.nlm.nih.gov/19796939

DM48C7G	DI	DM48C7G
DM48C7G	DN	2-(benzyloxy)-N7-hydroxy-N1-phenylheptanediamide
DM48C7G	MI	TTSHTOI
DM48C7G	MN	Histone deacetylase 2 (HDAC2)
DM48C7G	MT	DTT
DM48C7G	MA	Inhibitor
DM48C7G	RN	Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6261-5.
DM48C7G	RU	https://pubmed.ncbi.nlm.nih.gov/17892933

DME50RZ	DI	DME50RZ
DME50RZ	DN	2-(benzyloxy)naphthalene
DME50RZ	MI	TTSJ6Q4
DME50RZ	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DME50RZ	MT	DTT
DME50RZ	MA	Inhibitor
DME50RZ	RN	Bioactivity-guided mapping and navigation of chemical space. Nat Chem Biol. 2009 Aug;5(8):585-92.
DME50RZ	RU	https://pubmed.ncbi.nlm.nih.gov/19561619

DMSNCOW	DI	DMSNCOW
DMSNCOW	DN	2-(benzyloxyamino)-N-hydroxy-3-methylpentanamide
DMSNCOW	MI	TT2LVK8
DMSNCOW	MN	Carbonic anhydrase IX (CA-IX)
DMSNCOW	MT	DTT
DMSNCOW	MA	Inhibitor
DMSNCOW	RN	Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with su... Bioorg Med Chem. 2007 Mar 15;15(6):2298-311.
DMSNCOW	RU	https://pubmed.ncbi.nlm.nih.gov/17276072

DMHZJXG	DI	DMHZJXG
DMHZJXG	DN	2-(benzyloxyamino)-N-hydroxyacetamide
DMHZJXG	MI	TT2LVK8
DMHZJXG	MN	Carbonic anhydrase IX (CA-IX)
DMHZJXG	MT	DTT
DMHZJXG	MA	Inhibitor
DMHZJXG	RN	Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with su... Bioorg Med Chem. 2007 Mar 15;15(6):2298-311.
DMHZJXG	RU	https://pubmed.ncbi.nlm.nih.gov/17276072

DMOUKTH	DI	DMOUKTH
DMOUKTH	DN	2-(benzyloxyamino)-N-hydroxyhexanamide
DMOUKTH	MI	TTANPDJ
DMOUKTH	MN	Carbonic anhydrase II (CA-II)
DMOUKTH	MT	DTT
DMOUKTH	MA	Inhibitor
DMOUKTH	RN	Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with su... Bioorg Med Chem. 2007 Mar 15;15(6):2298-311.
DMOUKTH	RU	https://pubmed.ncbi.nlm.nih.gov/17276072

DMOUKTH	DI	DMOUKTH
DMOUKTH	DN	2-(benzyloxyamino)-N-hydroxyhexanamide
DMOUKTH	MI	TT2LVK8
DMOUKTH	MN	Carbonic anhydrase IX (CA-IX)
DMOUKTH	MT	DTT
DMOUKTH	MA	Inhibitor
DMOUKTH	RN	Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with su... Bioorg Med Chem. 2007 Mar 15;15(6):2298-311.
DMOUKTH	RU	https://pubmed.ncbi.nlm.nih.gov/17276072

DM0C5O3	DI	DM0C5O3
DM0C5O3	DN	2-(Biphenyl-2-yloxy)-N,N-dimethylethanamine
DM0C5O3	MI	TTO9X1H
DM0C5O3	MN	5-HT 7 receptor (HTR7)
DM0C5O3	MT	DTT
DM0C5O3	MA	Inhibitor
DM0C5O3	RN	SAR studies on new bis-aryls 5-HT7 ligands: Synthesis and molecular modeling. Bioorg Med Chem. 2010 Mar 1;18(5):1958-67.
DM0C5O3	RU	https://pubmed.ncbi.nlm.nih.gov/20138771

DM9XZSC	DI	DM9XZSC
DM9XZSC	DN	2-(Biphenyl-2-ylthio)-N,N-dimethylethanamine
DM9XZSC	MI	TTO9X1H
DM9XZSC	MN	5-HT 7 receptor (HTR7)
DM9XZSC	MT	DTT
DM9XZSC	MA	Inhibitor
DM9XZSC	RN	SAR studies on new bis-aryls 5-HT7 ligands: Synthesis and molecular modeling. Bioorg Med Chem. 2010 Mar 1;18(5):1958-67.
DM9XZSC	RU	https://pubmed.ncbi.nlm.nih.gov/20138771

DMU0GDY	DI	DMU0GDY
DMU0GDY	DN	2-(Biphenyl-3-ylthio)-N,N-dimethylethanamine
DMU0GDY	MI	TTSQIFT
DMU0GDY	MN	5-HT 1A receptor (HTR1A)
DMU0GDY	MT	DTT
DMU0GDY	MA	Inhibitor
DMU0GDY	RN	SAR studies on new bis-aryls 5-HT7 ligands: Synthesis and molecular modeling. Bioorg Med Chem. 2010 Mar 1;18(5):1958-67.
DMU0GDY	RU	https://pubmed.ncbi.nlm.nih.gov/20138771

DMRQOKB	DI	DMRQOKB
DMRQOKB	DN	2-(biphenyl-4-yl)vinylboronic acid
DMRQOKB	MI	TTHQPL7
DMRQOKB	MN	Carbonic anhydrase I (CA-I)
DMRQOKB	MT	DTT
DMRQOKB	MA	Inhibitor
DMRQOKB	RN	Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5.
DMRQOKB	RU	https://pubmed.ncbi.nlm.nih.gov/19375309

DMRQOKB	DI	DMRQOKB
DMRQOKB	DN	2-(biphenyl-4-yl)vinylboronic acid
DMRQOKB	MI	TTDP1UC
DMRQOKB	MN	Fatty acid amide hydrolase (FAAH)
DMRQOKB	MT	DTT
DMRQOKB	MA	Inhibitor
DMRQOKB	RN	Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Nov 27;51(22):7057-60.
DMRQOKB	RU	https://pubmed.ncbi.nlm.nih.gov/18983140

DM3PWK7	DI	DM3PWK7
DM3PWK7	DN	2-(biphenyl-4-ylsulfonamido)-N-hydroxyacetamide
DM3PWK7	MI	TTJ4QE7
DM3PWK7	MN	Matrix metalloproteinase-14 (MMP-14)
DM3PWK7	MT	DTT
DM3PWK7	MA	Inhibitor
DM3PWK7	RN	Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule sheddi... J Med Chem. 2010 Mar 25;53(6):2622-35.
DM3PWK7	RU	https://pubmed.ncbi.nlm.nih.gov/20180536

DM3PWK7	DI	DM3PWK7
DM3PWK7	DN	2-(biphenyl-4-ylsulfonamido)-N-hydroxyacetamide
DM3PWK7	MI	TT6AZXG
DM3PWK7	MN	TNF alpha converting enzyme (ADAM17)
DM3PWK7	MT	DTT
DM3PWK7	MA	Inhibitor
DM3PWK7	RN	Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule sheddi... J Med Chem. 2010 Mar 25;53(6):2622-35.
DM3PWK7	RU	https://pubmed.ncbi.nlm.nih.gov/20180536

DMH3YBR	DI	DMH3YBR
DMH3YBR	DN	2-(biphenyl-4-ylsulfonamido)pentanedioic acid
DMH3YBR	MI	TTHY57M
DMH3YBR	MN	Matrix metalloproteinase-13 (MMP-13)
DMH3YBR	MT	DTT
DMH3YBR	MA	Inhibitor
DMH3YBR	RN	Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study. Bioorg Med Chem. 2009 Feb 1;17(3):1101-8.
DMH3YBR	RU	https://pubmed.ncbi.nlm.nih.gov/18364257

DMH3YBR	DI	DMH3YBR
DMH3YBR	DN	2-(biphenyl-4-ylsulfonamido)pentanedioic acid
DMH3YBR	MI	TTGA1IV
DMH3YBR	MN	Matrix metalloproteinase-8 (MMP-8)
DMH3YBR	MT	DTT
DMH3YBR	MA	Inhibitor
DMH3YBR	RN	Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study. Bioorg Med Chem. 2009 Feb 1;17(3):1101-8.
DMH3YBR	RU	https://pubmed.ncbi.nlm.nih.gov/18364257

DMH3YBR	DI	DMH3YBR
DMH3YBR	DN	2-(biphenyl-4-ylsulfonamido)pentanedioic acid
DMH3YBR	MI	TT6X50U
DMH3YBR	MN	Matrix metalloproteinase-9 (MMP-9)
DMH3YBR	MT	DTT
DMH3YBR	MA	Inhibitor
DMH3YBR	RN	Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study. Bioorg Med Chem. 2009 Feb 1;17(3):1101-8.
DMH3YBR	RU	https://pubmed.ncbi.nlm.nih.gov/18364257

DMCNV5J	DI	DMCNV5J
DMCNV5J	DN	2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide
DMCNV5J	MI	TTXZ0KQ
DMCNV5J	MN	Matrix metalloproteinase-12 (MMP-12)
DMCNV5J	MT	DTT
DMCNV5J	MA	Inhibitor
DMCNV5J	RN	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
DMCNV5J	RU	https://pubmed.ncbi.nlm.nih.gov/19775099

DMCNV5J	DI	DMCNV5J
DMCNV5J	DN	2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide
DMCNV5J	MI	TTHY57M
DMCNV5J	MN	Matrix metalloproteinase-13 (MMP-13)
DMCNV5J	MT	DTT
DMCNV5J	MA	Inhibitor
DMCNV5J	RN	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
DMCNV5J	RU	https://pubmed.ncbi.nlm.nih.gov/19775099

DMCNV5J	DI	DMCNV5J
DMCNV5J	DN	2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide
DMCNV5J	MI	TTJ4QE7
DMCNV5J	MN	Matrix metalloproteinase-14 (MMP-14)
DMCNV5J	MT	DTT
DMCNV5J	MA	Inhibitor
DMCNV5J	RN	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
DMCNV5J	RU	https://pubmed.ncbi.nlm.nih.gov/19775099

DMCNV5J	DI	DMCNV5J
DMCNV5J	DN	2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide
DMCNV5J	MI	TTLM12X
DMCNV5J	MN	Matrix metalloproteinase-2 (MMP-2)
DMCNV5J	MT	DTT
DMCNV5J	MA	Inhibitor
DMCNV5J	RN	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
DMCNV5J	RU	https://pubmed.ncbi.nlm.nih.gov/19775099

DMCNV5J	DI	DMCNV5J
DMCNV5J	DN	2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide
DMCNV5J	MI	TTYRF5E
DMCNV5J	MN	Matrix metalloproteinase-21 (MMP-21)
DMCNV5J	MT	DTT
DMCNV5J	MA	Inhibitor
DMCNV5J	RN	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
DMCNV5J	RU	https://pubmed.ncbi.nlm.nih.gov/19775099

DMCNV5J	DI	DMCNV5J
DMCNV5J	DN	2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide
DMCNV5J	MI	TTGA1IV
DMCNV5J	MN	Matrix metalloproteinase-8 (MMP-8)
DMCNV5J	MT	DTT
DMCNV5J	MA	Inhibitor
DMCNV5J	RN	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
DMCNV5J	RU	https://pubmed.ncbi.nlm.nih.gov/19775099

DMCNV5J	DI	DMCNV5J
DMCNV5J	DN	2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide
DMCNV5J	MI	TT6X50U
DMCNV5J	MN	Matrix metalloproteinase-9 (MMP-9)
DMCNV5J	MT	DTT
DMCNV5J	MA	Inhibitor
DMCNV5J	RN	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
DMCNV5J	RU	https://pubmed.ncbi.nlm.nih.gov/19775099

DMFO7CH	DI	DMFO7CH
DMFO7CH	DN	2-(butylthiomethyl)-5-hydroxy-4H-pyran-4-one
DMFO7CH	MI	TTULVH8
DMFO7CH	MN	Tyrosinase (TYR)
DMFO7CH	MT	DTT
DMFO7CH	MA	Inhibitor
DMFO7CH	RN	Kojyl thioether derivatives having both tyrosinase inhibitory and anti-inflammatory properties. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6569-71.
DMFO7CH	RU	https://pubmed.ncbi.nlm.nih.gov/20934336

DMA6P4J	DI	DMA6P4J
DMA6P4J	DN	2-(Carbazole-9-sulfonyl)-benzoic acid
DMA6P4J	MI	TTHWMFZ
DMA6P4J	MN	Fatty acid-binding protein 4 (FABP4)
DMA6P4J	MT	DTT
DMA6P4J	MA	Inhibitor
DMA6P4J	RN	Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4445-8.
DMA6P4J	RU	https://pubmed.ncbi.nlm.nih.gov/15357969

DMA6P4J	DI	DMA6P4J
DMA6P4J	DN	2-(Carbazole-9-sulfonyl)-benzoic acid
DMA6P4J	MI	TTNT2S6
DMA6P4J	MN	Fatty acid-binding protein 5 (FABP5)
DMA6P4J	MT	DTT
DMA6P4J	MA	Inhibitor
DMA6P4J	RN	Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4445-8.
DMA6P4J	RU	https://pubmed.ncbi.nlm.nih.gov/15357969

DMQ2SNL	DI	DMQ2SNL
DMQ2SNL	DN	2-(carboxymethylamino)-2-oxoacetic acid
DMQ2SNL	MI	TTMHFRY
DMQ2SNL	MN	HIF-prolyl hydroxylase 1 (HPH-1)
DMQ2SNL	MT	DTT
DMQ2SNL	MA	Inhibitor
DMQ2SNL	RN	Design, synthesis, enzyme-inhibitory activity, and effect on human cancer cells of a novel series of jumonji domain-containing protein 2 histone de... J Med Chem. 2010 Aug 12;53(15):5629-38.
DMQ2SNL	RU	https://pubmed.ncbi.nlm.nih.gov/20684604

DM0PA6I	DI	DM0PA6I
DM0PA6I	DN	2-(cinnamyloxy)pyrido[2,3-d]pyrimidin-4(3H)-one
DM0PA6I	MI	TTWNV8U
DM0PA6I	MN	Nicotinic acid receptor (HCAR2)
DM0PA6I	MT	DTT
DM0PA6I	MA	Inhibitor
DM0PA6I	RN	Pyrido pyrimidinones as selective agonists of the high affinity niacin receptor GPR109A: optimization of in vitro activity. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5426-30.
DM0PA6I	RU	https://pubmed.ncbi.nlm.nih.gov/20724150

DMQ9ODG	DI	DMQ9ODG
DMQ9ODG	DN	2-(cycloheptylamino)-2-oxoethyl 2-aminonicotinate
DMQ9ODG	MI	TTEAID7
DMQ9ODG	MN	Trypanosoma Cruzipain (Trypano CYSP)
DMQ9ODG	MT	DTT
DMQ9ODG	MA	Inhibitor
DMQ9ODG	RN	Divergent modes of enzyme inhibition in a homologous structure-activity series. J Med Chem. 2009 Aug 27;52(16):5005-8.
DMQ9ODG	RU	https://pubmed.ncbi.nlm.nih.gov/19637873

DMPT0MB	DI	DMPT0MB
DMPT0MB	DN	2-(cyclohexylamino)benzoic acid
DMPT0MB	MI	TTTU902
DMPT0MB	MN	Checkpoint kinase-1 (CHK1)
DMPT0MB	MT	DTT
DMPT0MB	MA	Inhibitor
DMPT0MB	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMPT0MB	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM2CAI1	DI	DM2CAI1
DM2CAI1	DN	2-(cyclohexylthiomethyl)-5-hydroxy-4H-pyran-4-one
DM2CAI1	MI	TTULVH8
DM2CAI1	MN	Tyrosinase (TYR)
DM2CAI1	MT	DTT
DM2CAI1	MA	Inhibitor
DM2CAI1	RN	Kojyl thioether derivatives having both tyrosinase inhibitory and anti-inflammatory properties. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6569-71.
DM2CAI1	RU	https://pubmed.ncbi.nlm.nih.gov/20934336

DMAPW5K	DI	DMAPW5K
DMAPW5K	DN	2-(cyclooctylamino)-5,5-diethyloxazol-4(5H)-one
DMAPW5K	MI	TTN7BL9
DMAPW5K	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMAPW5K	MT	DTT
DMAPW5K	MA	Inhibitor
DMAPW5K	RN	Oxazolones as potent inhibitors of 11beta-hydroxysteroid dehydrogenase type 1. Bioorg Med Chem Lett. 2007 Sep 1;17(17):4837-40.
DMAPW5K	RU	https://pubmed.ncbi.nlm.nih.gov/17600707

DMZVMDO	DI	DMZVMDO
DMZVMDO	DN	2-(difluoromethyl)-9H-carbazole
DMZVMDO	MI	TTBGTCW
DMZVMDO	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DMZVMDO	MT	DTT
DMZVMDO	MA	Inhibitor
DMZVMDO	RN	Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8.
DMZVMDO	RU	https://pubmed.ncbi.nlm.nih.gov/20521839

DMS7WQD	DI	DMS7WQD
DMS7WQD	DN	2-(ethoxycarbonyl)-1H-indole-5-carboxylic acid
DMS7WQD	MI	TT9JNIC
DMS7WQD	MN	Histamine H3 receptor (H3R)
DMS7WQD	MT	DTT
DMS7WQD	MA	Inhibitor
DMS7WQD	RN	5-hydroxyindole-2-carboxylic acid amides: novel histamine-3 receptor inverse agonists for the treatment of obesity. J Med Chem. 2009 Jul 9;52(13):3855-68.
DMS7WQD	RU	https://pubmed.ncbi.nlm.nih.gov/19456097

DM8GJCU	DI	DM8GJCU
DM8GJCU	DN	2-(ethylthiomethyl)-5-hydroxy-4H-pyran-4-one
DM8GJCU	MI	TTULVH8
DM8GJCU	MN	Tyrosinase (TYR)
DM8GJCU	MT	DTT
DM8GJCU	MA	Inhibitor
DM8GJCU	RN	Kojyl thioether derivatives having both tyrosinase inhibitory and anti-inflammatory properties. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6569-71.
DM8GJCU	RU	https://pubmed.ncbi.nlm.nih.gov/20934336

DM6BHUF	DI	DM6BHUF
DM6BHUF	DN	2-(furan-2-yl)-6-morpholino-4H-pyran-4-one
DM6BHUF	MI	TTK3PY9
DM6BHUF	MN	DNA-dependent protein kinase catalytic (PRKDC)
DM6BHUF	MT	DTT
DM6BHUF	MA	Inhibitor
DM6BHUF	RN	Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72.
DM6BHUF	RU	https://pubmed.ncbi.nlm.nih.gov/17371003

DM490BL	DI	DM490BL
DM490BL	DN	2-(heptylthiomethyl)-5-hydroxy-4H-pyran-4-one
DM490BL	MI	TTULVH8
DM490BL	MN	Tyrosinase (TYR)
DM490BL	MT	DTT
DM490BL	MA	Inhibitor
DM490BL	RN	Kojyl thioether derivatives having both tyrosinase inhibitory and anti-inflammatory properties. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6569-71.
DM490BL	RU	https://pubmed.ncbi.nlm.nih.gov/20934336

DM7YLTS	DI	DM7YLTS
DM7YLTS	DN	2-(hex-1-ynyl)-N6-methoxyadenosine
DM7YLTS	MI	TTK25J1
DM7YLTS	MN	Adenosine A1 receptor (ADORA1)
DM7YLTS	MT	DTT
DM7YLTS	MA	Inhibitor
DM7YLTS	RN	N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
DM7YLTS	RU	https://pubmed.ncbi.nlm.nih.gov/17309246

DM7YLTS	DI	DM7YLTS
DM7YLTS	DN	2-(hex-1-ynyl)-N6-methoxyadenosine
DM7YLTS	MI	TTM2AOE
DM7YLTS	MN	Adenosine A2a receptor (ADORA2A)
DM7YLTS	MT	DTT
DM7YLTS	MA	Inhibitor
DM7YLTS	RN	N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
DM7YLTS	RU	https://pubmed.ncbi.nlm.nih.gov/17309246

DM7YLTS	DI	DM7YLTS
DM7YLTS	DN	2-(hex-1-ynyl)-N6-methoxyadenosine
DM7YLTS	MI	TTJFY5U
DM7YLTS	MN	Adenosine A3 receptor (ADORA3)
DM7YLTS	MT	DTT
DM7YLTS	MA	Inhibitor
DM7YLTS	RN	N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
DM7YLTS	RU	https://pubmed.ncbi.nlm.nih.gov/17309246

DM235Q4	DI	DM235Q4
DM235Q4	DN	2-(hexylthiomethyl)-5-hydroxy-4H-pyran-4-one
DM235Q4	MI	TTULVH8
DM235Q4	MN	Tyrosinase (TYR)
DM235Q4	MT	DTT
DM235Q4	MA	Inhibitor
DM235Q4	RN	Kojyl thioether derivatives having both tyrosinase inhibitory and anti-inflammatory properties. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6569-71.
DM235Q4	RU	https://pubmed.ncbi.nlm.nih.gov/20934336

DMOVYXT	DI	DMOVYXT
DMOVYXT	DN	2-(indolin-1yl)-melatonin
DMOVYXT	MI	TT0WAIE
DMOVYXT	MN	Melatonin receptor type 1A (MTNR1A)
DMOVYXT	MT	DTT
DMOVYXT	MA	Antagonist
DMOVYXT	RN	2-[(2,3-dihydro-1H-indol-1-yl)methyl]melatonin analogues: a novel class of MT2-selective melatonin receptor antagonists. J Med Chem. 2009 Feb 12;52(3):826-33.
DMOVYXT	RU	https://pubmed.ncbi.nlm.nih.gov/19193160

DM1SIQD	DI	DM1SIQD
DM1SIQD	DN	2-(methylsulfonyl)naphthalene-1,4-diol
DM1SIQD	MI	TTRVTMX
DM1SIQD	MN	Bacterial Beta-ketoacyl-ACP synthase III (Bact fabH)
DM1SIQD	MT	DTT
DM1SIQD	MA	Inhibitor
DM1SIQD	RN	Synthesis and biological evaluation of novel sulfonyl-naphthalene-1,4-diols as FabH inhibitors. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6402-5.
DM1SIQD	RU	https://pubmed.ncbi.nlm.nih.gov/18996691

DMM52D3	DI	DMM52D3
DMM52D3	DN	2-(methylsulfonylthio)ethyl 2-propylpentanoate
DMM52D3	MI	TTBH0VX
DMM52D3	MN	Histone deacetylase (HDAC)
DMM52D3	MT	DTT
DMM52D3	MA	Inhibitor
DMM52D3	RN	New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7.
DMM52D3	RU	https://pubmed.ncbi.nlm.nih.gov/18294844

DMM52D3	DI	DMM52D3
DMM52D3	DN	2-(methylsulfonylthio)ethyl 2-propylpentanoate
DMM52D3	MI	TT6R7JZ
DMM52D3	MN	Histone deacetylase 1 (HDAC1)
DMM52D3	MT	DTT
DMM52D3	MA	Inhibitor
DMM52D3	RN	New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7.
DMM52D3	RU	https://pubmed.ncbi.nlm.nih.gov/18294844

DMM52D3	DI	DMM52D3
DMM52D3	DN	2-(methylsulfonylthio)ethyl 2-propylpentanoate
DMM52D3	MI	TTYHPU6
DMM52D3	MN	Histone deacetylase 10 (HDAC10)
DMM52D3	MT	DTT
DMM52D3	MA	Inhibitor
DMM52D3	RN	New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7.
DMM52D3	RU	https://pubmed.ncbi.nlm.nih.gov/18294844

DMM52D3	DI	DMM52D3
DMM52D3	DN	2-(methylsulfonylthio)ethyl 2-propylpentanoate
DMM52D3	MI	TTSHTOI
DMM52D3	MN	Histone deacetylase 2 (HDAC2)
DMM52D3	MT	DTT
DMM52D3	MA	Inhibitor
DMM52D3	RN	New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7.
DMM52D3	RU	https://pubmed.ncbi.nlm.nih.gov/18294844

DMM52D3	DI	DMM52D3
DMM52D3	DN	2-(methylsulfonylthio)ethyl 2-propylpentanoate
DMM52D3	MI	TTTQGH8
DMM52D3	MN	Histone deacetylase 4 (HDAC4)
DMM52D3	MT	DTT
DMM52D3	MA	Inhibitor
DMM52D3	RN	New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7.
DMM52D3	RU	https://pubmed.ncbi.nlm.nih.gov/18294844

DMM52D3	DI	DMM52D3
DMM52D3	DN	2-(methylsulfonylthio)ethyl 2-propylpentanoate
DMM52D3	MI	TT5ZKDI
DMM52D3	MN	Histone deacetylase 6 (HDAC6)
DMM52D3	MT	DTT
DMM52D3	MA	Inhibitor
DMM52D3	RN	New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7.
DMM52D3	RU	https://pubmed.ncbi.nlm.nih.gov/18294844

DMM52D3	DI	DMM52D3
DMM52D3	DN	2-(methylsulfonylthio)ethyl 2-propylpentanoate
DMM52D3	MI	TTT6LFV
DMM52D3	MN	Histone deacetylase 8 (HDAC8)
DMM52D3	MT	DTT
DMM52D3	MA	Inhibitor
DMM52D3	RN	New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7.
DMM52D3	RU	https://pubmed.ncbi.nlm.nih.gov/18294844

DM15BA7	DI	DM15BA7
DM15BA7	DN	2-(m-tolylethynyl)pyrimidine
DM15BA7	MI	TTHS256
DM15BA7	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM15BA7	MT	DTT
DM15BA7	MA	Inhibitor
DM15BA7	RN	Discovery of molecular switches that modulate modes of metabotropic glutamate receptor subtype 5 (mGlu5) pharmacology in vitro and in vivo within a... J Med Chem. 2009 Jul 23;52(14):4103-6.
DM15BA7	RU	https://pubmed.ncbi.nlm.nih.gov/19537763

DMRNOM6	DI	DMRNOM6
DMRNOM6	DN	2-(N-(2-Ffuorophenyl)pyrrol-3-yl) acetic acid
DMRNOM6	MI	TT8NGED
DMRNOM6	MN	Prostaglandin G/H synthase 1 (COX-1)
DMRNOM6	MT	DTT
DMRNOM6	MA	Inhibitor
DMRNOM6	RN	Synthesis and biological activity of new anti-inflammatory compounds containing the 1,4-benzodioxine and/or pyrrole system. Bioorg Med Chem. 2007 Jul 15;15(14):4876-90.
DMRNOM6	RU	https://pubmed.ncbi.nlm.nih.gov/17517512

DMRNOM6	DI	DMRNOM6
DMRNOM6	DN	2-(N-(2-Ffuorophenyl)pyrrol-3-yl) acetic acid
DMRNOM6	MI	TTVKILB
DMRNOM6	MN	Prostaglandin G/H synthase 2 (COX-2)
DMRNOM6	MT	DTT
DMRNOM6	MA	Inhibitor
DMRNOM6	RN	Synthesis and biological activity of new anti-inflammatory compounds containing the 1,4-benzodioxine and/or pyrrole system. Bioorg Med Chem. 2007 Jul 15;15(14):4876-90.
DMRNOM6	RU	https://pubmed.ncbi.nlm.nih.gov/17517512

DMCL9E6	DI	DMCL9E6
DMCL9E6	DN	2-(N-(2-fluorophenyl)pyrrol-2-yl) acetic acid
DMCL9E6	MI	TT8NGED
DMCL9E6	MN	Prostaglandin G/H synthase 1 (COX-1)
DMCL9E6	MT	DTT
DMCL9E6	MA	Inhibitor
DMCL9E6	RN	Synthesis and biological activity of new anti-inflammatory compounds containing the 1,4-benzodioxine and/or pyrrole system. Bioorg Med Chem. 2007 Jul 15;15(14):4876-90.
DMCL9E6	RU	https://pubmed.ncbi.nlm.nih.gov/17517512

DMCL9E6	DI	DMCL9E6
DMCL9E6	DN	2-(N-(2-fluorophenyl)pyrrol-2-yl) acetic acid
DMCL9E6	MI	TTVKILB
DMCL9E6	MN	Prostaglandin G/H synthase 2 (COX-2)
DMCL9E6	MT	DTT
DMCL9E6	MA	Inhibitor
DMCL9E6	RN	Synthesis and biological activity of new anti-inflammatory compounds containing the 1,4-benzodioxine and/or pyrrole system. Bioorg Med Chem. 2007 Jul 15;15(14):4876-90.
DMCL9E6	RU	https://pubmed.ncbi.nlm.nih.gov/17517512

DMVR248	DI	DMVR248
DMVR248	DN	2-(N,N-Diethylamino)-3'-chloropropiophenone
DMVR248	MI	TTVBI8W
DMVR248	MN	Dopamine transporter (DAT)
DMVR248	MT	DTT
DMVR248	MA	Inhibitor
DMVR248	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81.
DMVR248	RU	https://pubmed.ncbi.nlm.nih.gov/19821577

DMVR248	DI	DMVR248
DMVR248	DN	2-(N,N-Diethylamino)-3'-chloropropiophenone
DMVR248	MI	TTAWNKZ
DMVR248	MN	Norepinephrine transporter (NET)
DMVR248	MT	DTT
DMVR248	MA	Inhibitor
DMVR248	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81.
DMVR248	RU	https://pubmed.ncbi.nlm.nih.gov/19821577

DMHYKR8	DI	DMHYKR8
DMHYKR8	DN	2-(N''-Acetyl-hydrazino)-benzenesulfonamide
DMHYKR8	MI	TTANPDJ
DMHYKR8	MN	Carbonic anhydrase II (CA-II)
DMHYKR8	MT	DTT
DMHYKR8	MA	Inhibitor
DMHYKR8	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamide... J Med Chem. 2005 Mar 24;48(6):2121-5.
DMHYKR8	RU	https://pubmed.ncbi.nlm.nih.gov/15771455

DMHYKR8	DI	DMHYKR8
DMHYKR8	DN	2-(N''-Acetyl-hydrazino)-benzenesulfonamide
DMHYKR8	MI	TT2LVK8
DMHYKR8	MN	Carbonic anhydrase IX (CA-IX)
DMHYKR8	MT	DTT
DMHYKR8	MA	Inhibitor
DMHYKR8	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamide... J Med Chem. 2005 Mar 24;48(6):2121-5.
DMHYKR8	RU	https://pubmed.ncbi.nlm.nih.gov/15771455

DMKY71Z	DI	DMKY71Z
DMKY71Z	DN	2-(naphthalen-2-yl)-4,5-dihydro-1H-imidazole
DMKY71Z	MI	TT3WG5C
DMKY71Z	MN	Monoamine oxidase type A (MAO-A)
DMKY71Z	MT	DTT
DMKY71Z	MA	Inhibitor
DMKY71Z	RN	Ultrasound promoted synthesis of 2-imidazolines in water: a greener approach toward monoamine oxidase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):546-9.
DMKY71Z	RU	https://pubmed.ncbi.nlm.nih.gov/19064321

DMKY71Z	DI	DMKY71Z
DMKY71Z	DN	2-(naphthalen-2-yl)-4,5-dihydro-1H-imidazole
DMKY71Z	MI	TTGP7BY
DMKY71Z	MN	Monoamine oxidase type B (MAO-B)
DMKY71Z	MT	DTT
DMKY71Z	MA	Inhibitor
DMKY71Z	RN	Ultrasound promoted synthesis of 2-imidazolines in water: a greener approach toward monoamine oxidase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):546-9.
DMKY71Z	RU	https://pubmed.ncbi.nlm.nih.gov/19064321

DMEXBUF	DI	DMEXBUF
DMEXBUF	DN	2-(naphthalen-2-ylsulfonyl)naphthalene-1,4-diol
DMEXBUF	MI	TTRVTMX
DMEXBUF	MN	Bacterial Beta-ketoacyl-ACP synthase III (Bact fabH)
DMEXBUF	MT	DTT
DMEXBUF	MA	Inhibitor
DMEXBUF	RN	Synthesis and biological evaluation of novel sulfonyl-naphthalene-1,4-diols as FabH inhibitors. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6402-5.
DMEXBUF	RU	https://pubmed.ncbi.nlm.nih.gov/18996691

DML4GHA	DI	DML4GHA
DML4GHA	DN	2-(N-Cyclopentylamino)-3'-bromopropiophenone
DML4GHA	MI	TTVBI8W
DML4GHA	MN	Dopamine transporter (DAT)
DML4GHA	MT	DTT
DML4GHA	MA	Inhibitor
DML4GHA	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14.
DML4GHA	RU	https://pubmed.ncbi.nlm.nih.gov/20158204

DML4GHA	DI	DML4GHA
DML4GHA	DN	2-(N-Cyclopentylamino)-3'-bromopropiophenone
DML4GHA	MI	TTAWNKZ
DML4GHA	MN	Norepinephrine transporter (NET)
DML4GHA	MT	DTT
DML4GHA	MA	Inhibitor
DML4GHA	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14.
DML4GHA	RU	https://pubmed.ncbi.nlm.nih.gov/20158204

DMP68CE	DI	DMP68CE
DMP68CE	DN	2-(N-Cyclopentylamino)-3'-chloropropiophenone
DMP68CE	MI	TTVBI8W
DMP68CE	MN	Dopamine transporter (DAT)
DMP68CE	MT	DTT
DMP68CE	MA	Inhibitor
DMP68CE	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81.
DMP68CE	RU	https://pubmed.ncbi.nlm.nih.gov/19821577

DMP68CE	DI	DMP68CE
DMP68CE	DN	2-(N-Cyclopentylamino)-3'-chloropropiophenone
DMP68CE	MI	TTAWNKZ
DMP68CE	MN	Norepinephrine transporter (NET)
DMP68CE	MT	DTT
DMP68CE	MA	Inhibitor
DMP68CE	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81.
DMP68CE	RU	https://pubmed.ncbi.nlm.nih.gov/19821577

DMH6FKX	DI	DMH6FKX
DMH6FKX	DN	2-(N-Cyclopentylamino)-3'-fluoropropiophenone
DMH6FKX	MI	TTVBI8W
DMH6FKX	MN	Dopamine transporter (DAT)
DMH6FKX	MT	DTT
DMH6FKX	MA	Inhibitor
DMH6FKX	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14.
DMH6FKX	RU	https://pubmed.ncbi.nlm.nih.gov/20158204

DMH6FKX	DI	DMH6FKX
DMH6FKX	DN	2-(N-Cyclopentylamino)-3'-fluoropropiophenone
DMH6FKX	MI	TTAWNKZ
DMH6FKX	MN	Norepinephrine transporter (NET)
DMH6FKX	MT	DTT
DMH6FKX	MA	Inhibitor
DMH6FKX	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14.
DMH6FKX	RU	https://pubmed.ncbi.nlm.nih.gov/20158204

DMVN1UI	DI	DMVN1UI
DMVN1UI	DN	2-(N-Cyclopentylamino)-3'-methoxypropiophenone
DMVN1UI	MI	TTVBI8W
DMVN1UI	MN	Dopamine transporter (DAT)
DMVN1UI	MT	DTT
DMVN1UI	MA	Inhibitor
DMVN1UI	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14.
DMVN1UI	RU	https://pubmed.ncbi.nlm.nih.gov/20158204

DMVN1UI	DI	DMVN1UI
DMVN1UI	DN	2-(N-Cyclopentylamino)-3'-methoxypropiophenone
DMVN1UI	MI	TTAWNKZ
DMVN1UI	MN	Norepinephrine transporter (NET)
DMVN1UI	MT	DTT
DMVN1UI	MA	Inhibitor
DMVN1UI	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14.
DMVN1UI	RU	https://pubmed.ncbi.nlm.nih.gov/20158204

DMVN1UI	DI	DMVN1UI
DMVN1UI	DN	2-(N-Cyclopentylamino)-3'-methoxypropiophenone
DMVN1UI	MI	TT3ROYC
DMVN1UI	MN	Serotonin transporter (SERT)
DMVN1UI	MT	DTT
DMVN1UI	MA	Inhibitor
DMVN1UI	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14.
DMVN1UI	RU	https://pubmed.ncbi.nlm.nih.gov/20158204

DMG87RK	DI	DMG87RK
DMG87RK	DN	2-(N-Cyclopentylamino)-3'-methylpropiophenone
DMG87RK	MI	TTVBI8W
DMG87RK	MN	Dopamine transporter (DAT)
DMG87RK	MT	DTT
DMG87RK	MA	Inhibitor
DMG87RK	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14.
DMG87RK	RU	https://pubmed.ncbi.nlm.nih.gov/20158204

DMG87RK	DI	DMG87RK
DMG87RK	DN	2-(N-Cyclopentylamino)-3'-methylpropiophenone
DMG87RK	MI	TTAWNKZ
DMG87RK	MN	Norepinephrine transporter (NET)
DMG87RK	MT	DTT
DMG87RK	MA	Inhibitor
DMG87RK	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14.
DMG87RK	RU	https://pubmed.ncbi.nlm.nih.gov/20158204

DMNMES3	DI	DMNMES3
DMNMES3	DN	2-(N-Cyclopropylamino)-3-chloropropiophenone
DMNMES3	MI	TTVBI8W
DMNMES3	MN	Dopamine transporter (DAT)
DMNMES3	MT	DTT
DMNMES3	MA	Inhibitor
DMNMES3	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81.
DMNMES3	RU	https://pubmed.ncbi.nlm.nih.gov/19821577

DMNMES3	DI	DMNMES3
DMNMES3	DN	2-(N-Cyclopropylamino)-3-chloropropiophenone
DMNMES3	MI	TTAWNKZ
DMNMES3	MN	Norepinephrine transporter (NET)
DMNMES3	MT	DTT
DMNMES3	MA	Inhibitor
DMNMES3	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81.
DMNMES3	RU	https://pubmed.ncbi.nlm.nih.gov/19821577

DMNMES3	DI	DMNMES3
DMNMES3	DN	2-(N-Cyclopropylamino)-3-chloropropiophenone
DMNMES3	MI	TT3ROYC
DMNMES3	MN	Serotonin transporter (SERT)
DMNMES3	MT	DTT
DMNMES3	MA	Inhibitor
DMNMES3	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81.
DMNMES3	RU	https://pubmed.ncbi.nlm.nih.gov/19821577

DMCK7SV	DI	DMCK7SV
DMCK7SV	DN	2-(N-Isopropylamino)-3'-chloropropiophenone
DMCK7SV	MI	TTVBI8W
DMCK7SV	MN	Dopamine transporter (DAT)
DMCK7SV	MT	DTT
DMCK7SV	MA	Inhibitor
DMCK7SV	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81.
DMCK7SV	RU	https://pubmed.ncbi.nlm.nih.gov/19821577

DMZVHSB	DI	DMZVHSB
DMZVHSB	DN	2-(N-Morpholino)-Ethanesulfonic Acid
DMZVHSB	MI	TT1RS9F
DMZVHSB	MN	Acetylcholinesterase (AChE)
DMZVHSB	MT	DTT
DMZVHSB	MA	Inhibitor
DMZVHSB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMZVHSB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMZVHSB	DI	DMZVHSB
DMZVHSB	DN	2-(N-Morpholino)-Ethanesulfonic Acid
DMZVHSB	MI	TTNAW8S
DMZVHSB	MN	Bacterial Flavohemoglobin (Bact hmp)
DMZVHSB	MT	DTT
DMZVHSB	MA	Inhibitor
DMZVHSB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMZVHSB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMZVHSB	DI	DMZVHSB
DMZVHSB	DN	2-(N-Morpholino)-Ethanesulfonic Acid
DMZVHSB	MI	TTC67I0
DMZVHSB	MN	Bacterial Glucosamine-6-phosphate synthase (Bact glmS)
DMZVHSB	MT	DTT
DMZVHSB	MA	Inhibitor
DMZVHSB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMZVHSB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMZVHSB	DI	DMZVHSB
DMZVHSB	DN	2-(N-Morpholino)-Ethanesulfonic Acid
DMZVHSB	MI	TTEB0GD
DMZVHSB	MN	Cholinesterase (BCHE)
DMZVHSB	MT	DTT
DMZVHSB	MA	Inhibitor
DMZVHSB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMZVHSB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMZVHSB	DI	DMZVHSB
DMZVHSB	DN	2-(N-Morpholino)-Ethanesulfonic Acid
DMZVHSB	MI	TT8VUE0
DMZVHSB	MN	Chymase (CYM)
DMZVHSB	MT	DTT
DMZVHSB	MA	Inhibitor
DMZVHSB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMZVHSB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMZVHSB	DI	DMZVHSB
DMZVHSB	DN	2-(N-Morpholino)-Ethanesulfonic Acid
DMZVHSB	MI	TTN7BL9
DMZVHSB	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMZVHSB	MT	DTT
DMZVHSB	MA	Inhibitor
DMZVHSB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMZVHSB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMZVHSB	DI	DMZVHSB
DMZVHSB	DN	2-(N-Morpholino)-Ethanesulfonic Acid
DMZVHSB	MI	TT9SL3Q
DMZVHSB	MN	Polypeptide deformylase (PDF)
DMZVHSB	MT	DTT
DMZVHSB	MA	Inhibitor
DMZVHSB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMZVHSB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMZVHSB	DI	DMZVHSB
DMZVHSB	DN	2-(N-Morpholino)-Ethanesulfonic Acid
DMZVHSB	MI	TTHI19T
DMZVHSB	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMZVHSB	MT	DTT
DMZVHSB	MA	Inhibitor
DMZVHSB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMZVHSB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM85ZCW	DI	DM85ZCW
DM85ZCW	DN	2-(N-Pyrrolidinyl)-3'-bromopropiophenone
DM85ZCW	MI	TTVBI8W
DM85ZCW	MN	Dopamine transporter (DAT)
DM85ZCW	MT	DTT
DM85ZCW	MA	Inhibitor
DM85ZCW	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14.
DM85ZCW	RU	https://pubmed.ncbi.nlm.nih.gov/20158204

DM85ZCW	DI	DM85ZCW
DM85ZCW	DN	2-(N-Pyrrolidinyl)-3'-bromopropiophenone
DM85ZCW	MI	TTAWNKZ
DM85ZCW	MN	Norepinephrine transporter (NET)
DM85ZCW	MT	DTT
DM85ZCW	MA	Inhibitor
DM85ZCW	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14.
DM85ZCW	RU	https://pubmed.ncbi.nlm.nih.gov/20158204

DMYPOC5	DI	DMYPOC5
DMYPOC5	DN	2-(N-Pyrrolidinyl)-3'-fluoropropiophenone
DMYPOC5	MI	TTVBI8W
DMYPOC5	MN	Dopamine transporter (DAT)
DMYPOC5	MT	DTT
DMYPOC5	MA	Inhibitor
DMYPOC5	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14.
DMYPOC5	RU	https://pubmed.ncbi.nlm.nih.gov/20158204

DMYPOC5	DI	DMYPOC5
DMYPOC5	DN	2-(N-Pyrrolidinyl)-3'-fluoropropiophenone
DMYPOC5	MI	TTAWNKZ
DMYPOC5	MN	Norepinephrine transporter (NET)
DMYPOC5	MT	DTT
DMYPOC5	MA	Inhibitor
DMYPOC5	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14.
DMYPOC5	RU	https://pubmed.ncbi.nlm.nih.gov/20158204

DM1W3L9	DI	DM1W3L9
DM1W3L9	DN	2-(N-Pyrrolidinyl)-3'-methoxypropiophenone
DM1W3L9	MI	TTVBI8W
DM1W3L9	MN	Dopamine transporter (DAT)
DM1W3L9	MT	DTT
DM1W3L9	MA	Inhibitor
DM1W3L9	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14.
DM1W3L9	RU	https://pubmed.ncbi.nlm.nih.gov/20158204

DM1W3L9	DI	DM1W3L9
DM1W3L9	DN	2-(N-Pyrrolidinyl)-3'-methoxypropiophenone
DM1W3L9	MI	TTAWNKZ
DM1W3L9	MN	Norepinephrine transporter (NET)
DM1W3L9	MT	DTT
DM1W3L9	MA	Inhibitor
DM1W3L9	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14.
DM1W3L9	RU	https://pubmed.ncbi.nlm.nih.gov/20158204

DMGKXOI	DI	DMGKXOI
DMGKXOI	DN	2-(N-Pyrrolidinyl)-3'-methylpropiophenone
DMGKXOI	MI	TTVBI8W
DMGKXOI	MN	Dopamine transporter (DAT)
DMGKXOI	MT	DTT
DMGKXOI	MA	Inhibitor
DMGKXOI	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14.
DMGKXOI	RU	https://pubmed.ncbi.nlm.nih.gov/20158204

DMGKXOI	DI	DMGKXOI
DMGKXOI	DN	2-(N-Pyrrolidinyl)-3'-methylpropiophenone
DMGKXOI	MI	TTAWNKZ
DMGKXOI	MN	Norepinephrine transporter (NET)
DMGKXOI	MT	DTT
DMGKXOI	MA	Inhibitor
DMGKXOI	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14.
DMGKXOI	RU	https://pubmed.ncbi.nlm.nih.gov/20158204

DM1I9LQ	DI	DM1I9LQ
DM1I9LQ	DN	2-(N-Pyrrolidinyl)-3'-nitropropiophenone
DM1I9LQ	MI	TTVBI8W
DM1I9LQ	MN	Dopamine transporter (DAT)
DM1I9LQ	MT	DTT
DM1I9LQ	MA	Inhibitor
DM1I9LQ	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14.
DM1I9LQ	RU	https://pubmed.ncbi.nlm.nih.gov/20158204

DM1I9LQ	DI	DM1I9LQ
DM1I9LQ	DN	2-(N-Pyrrolidinyl)-3'-nitropropiophenone
DM1I9LQ	MI	TTAWNKZ
DM1I9LQ	MN	Norepinephrine transporter (NET)
DM1I9LQ	MT	DTT
DM1I9LQ	MA	Inhibitor
DM1I9LQ	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14.
DM1I9LQ	RU	https://pubmed.ncbi.nlm.nih.gov/20158204

DMKIEVP	DI	DMKIEVP
DMKIEVP	DN	2-(N-tert-Butylamino)-3',4'-dichloropropiophenone
DMKIEVP	MI	TTVBI8W
DMKIEVP	MN	Dopamine transporter (DAT)
DMKIEVP	MT	DTT
DMKIEVP	MA	Inhibitor
DMKIEVP	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81.
DMKIEVP	RU	https://pubmed.ncbi.nlm.nih.gov/19821577

DMKIEVP	DI	DMKIEVP
DMKIEVP	DN	2-(N-tert-Butylamino)-3',4'-dichloropropiophenone
DMKIEVP	MI	TTAWNKZ
DMKIEVP	MN	Norepinephrine transporter (NET)
DMKIEVP	MT	DTT
DMKIEVP	MA	Inhibitor
DMKIEVP	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81.
DMKIEVP	RU	https://pubmed.ncbi.nlm.nih.gov/19821577

DMKIEVP	DI	DMKIEVP
DMKIEVP	DN	2-(N-tert-Butylamino)-3',4'-dichloropropiophenone
DMKIEVP	MI	TT3ROYC
DMKIEVP	MN	Serotonin transporter (SERT)
DMKIEVP	MT	DTT
DMKIEVP	MA	Inhibitor
DMKIEVP	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81.
DMKIEVP	RU	https://pubmed.ncbi.nlm.nih.gov/19821577

DMY2PBO	DI	DMY2PBO
DMY2PBO	DN	2-(N-tert-Butylamino)-3'-chloroheptanophenone
DMY2PBO	MI	TTVBI8W
DMY2PBO	MN	Dopamine transporter (DAT)
DMY2PBO	MT	DTT
DMY2PBO	MA	Inhibitor
DMY2PBO	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81.
DMY2PBO	RU	https://pubmed.ncbi.nlm.nih.gov/19821577

DMY2PBO	DI	DMY2PBO
DMY2PBO	DN	2-(N-tert-Butylamino)-3'-chloroheptanophenone
DMY2PBO	MI	TTAWNKZ
DMY2PBO	MN	Norepinephrine transporter (NET)
DMY2PBO	MT	DTT
DMY2PBO	MA	Inhibitor
DMY2PBO	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81.
DMY2PBO	RU	https://pubmed.ncbi.nlm.nih.gov/19821577

DMPO3CJ	DI	DMPO3CJ
DMPO3CJ	DN	2-(N-tert-Butylamino)-3'-chlorohexanophenone
DMPO3CJ	MI	TTVBI8W
DMPO3CJ	MN	Dopamine transporter (DAT)
DMPO3CJ	MT	DTT
DMPO3CJ	MA	Inhibitor
DMPO3CJ	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81.
DMPO3CJ	RU	https://pubmed.ncbi.nlm.nih.gov/19821577

DMPO3CJ	DI	DMPO3CJ
DMPO3CJ	DN	2-(N-tert-Butylamino)-3'-chlorohexanophenone
DMPO3CJ	MI	TTAWNKZ
DMPO3CJ	MN	Norepinephrine transporter (NET)
DMPO3CJ	MT	DTT
DMPO3CJ	MA	Inhibitor
DMPO3CJ	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81.
DMPO3CJ	RU	https://pubmed.ncbi.nlm.nih.gov/19821577

DMW47VA	DI	DMW47VA
DMW47VA	DN	2-(N-tert-Butylamino)-3'-chlorooctanophenone
DMW47VA	MI	TTVBI8W
DMW47VA	MN	Dopamine transporter (DAT)
DMW47VA	MT	DTT
DMW47VA	MA	Inhibitor
DMW47VA	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81.
DMW47VA	RU	https://pubmed.ncbi.nlm.nih.gov/19821577

DMW47VA	DI	DMW47VA
DMW47VA	DN	2-(N-tert-Butylamino)-3'-chlorooctanophenone
DMW47VA	MI	TTAWNKZ
DMW47VA	MN	Norepinephrine transporter (NET)
DMW47VA	MT	DTT
DMW47VA	MA	Inhibitor
DMW47VA	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81.
DMW47VA	RU	https://pubmed.ncbi.nlm.nih.gov/19821577

DMTZ540	DI	DMTZ540
DMTZ540	DN	2-(N-tert-Butylamino)-3'-chloropentanophenone
DMTZ540	MI	TTVBI8W
DMTZ540	MN	Dopamine transporter (DAT)
DMTZ540	MT	DTT
DMTZ540	MA	Inhibitor
DMTZ540	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81.
DMTZ540	RU	https://pubmed.ncbi.nlm.nih.gov/19821577

DMTZ540	DI	DMTZ540
DMTZ540	DN	2-(N-tert-Butylamino)-3'-chloropentanophenone
DMTZ540	MI	TTAWNKZ
DMTZ540	MN	Norepinephrine transporter (NET)
DMTZ540	MT	DTT
DMTZ540	MA	Inhibitor
DMTZ540	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81.
DMTZ540	RU	https://pubmed.ncbi.nlm.nih.gov/19821577

DME1SP4	DI	DME1SP4
DME1SP4	DN	2-(N-tert-Butylamino)-4'-chloropropiophenone
DME1SP4	MI	TTVBI8W
DME1SP4	MN	Dopamine transporter (DAT)
DME1SP4	MT	DTT
DME1SP4	MA	Inhibitor
DME1SP4	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81.
DME1SP4	RU	https://pubmed.ncbi.nlm.nih.gov/19821577

DM9E5LT	DI	DM9E5LT
DM9E5LT	DN	2-(N-tert-Butylamino)propiophenone
DM9E5LT	MI	TTVBI8W
DM9E5LT	MN	Dopamine transporter (DAT)
DM9E5LT	MT	DTT
DM9E5LT	MA	Inhibitor
DM9E5LT	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81.
DM9E5LT	RU	https://pubmed.ncbi.nlm.nih.gov/19821577

DM9E5LT	DI	DM9E5LT
DM9E5LT	DN	2-(N-tert-Butylamino)propiophenone
DM9E5LT	MI	TTAWNKZ
DM9E5LT	MN	Norepinephrine transporter (NET)
DM9E5LT	MT	DTT
DM9E5LT	MA	Inhibitor
DM9E5LT	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81.
DM9E5LT	RU	https://pubmed.ncbi.nlm.nih.gov/19821577

DM3RCA9	DI	DM3RCA9
DM3RCA9	DN	2-(o-toluidino)-5-ethylthiazol-4(5H)-one
DM3RCA9	MI	TTN7BL9
DM3RCA9	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DM3RCA9	MT	DTT
DM3RCA9	MA	Inhibitor
DM3RCA9	RN	2-amino-1,3-thiazol-4(5H)-ones as potent and selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: enzyme-ligand co-crystal structure an... J Med Chem. 2008 May 22;51(10):2933-43.
DM3RCA9	RU	https://pubmed.ncbi.nlm.nih.gov/18419108

DMYTJX4	DI	DMYTJX4
DMYTJX4	DN	2-(o-toluidino)-5-isopropylthiazol-4(5H)-one
DMYTJX4	MI	TTN7BL9
DMYTJX4	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMYTJX4	MT	DTT
DMYTJX4	MA	Inhibitor
DMYTJX4	RN	The discovery of 2-anilinothiazolones as 11beta-HSD1 inhibitors. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6056-61.
DMYTJX4	RU	https://pubmed.ncbi.nlm.nih.gov/17919905

DM7LOHK	DI	DM7LOHK
DM7LOHK	DN	2-(Oxalyl-Amino)-Benzoic Acid
DM7LOHK	MI	TTELIN2
DM7LOHK	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DM7LOHK	MT	DTT
DM7LOHK	MA	Inhibitor
DM7LOHK	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM7LOHK	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMPUARE	DI	DMPUARE
DMPUARE	DN	2-(Phenylamino)-6-(3-acetamidophenyl)pyrazine
DMPUARE	MI	TT0EOB8
DMPUARE	MN	B-Raf messenger RNA (BRAF mRNA)
DMPUARE	MT	DTT
DMPUARE	MA	Inhibitor
DMPUARE	RN	Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead. J Med Chem. 2006 Jan 12;49(1):407-16.
DMPUARE	RU	https://pubmed.ncbi.nlm.nih.gov/16392826

DMRIFCW	DI	DMRIFCW
DMRIFCW	DN	2-(phenylethynyl)pyrimidine
DMRIFCW	MI	TTHS256
DMRIFCW	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMRIFCW	MT	DTT
DMRIFCW	MA	Inhibitor
DMRIFCW	RN	Discovery of molecular switches that modulate modes of metabotropic glutamate receptor subtype 5 (mGlu5) pharmacology in vitro and in vivo within a... J Med Chem. 2009 Jul 23;52(14):4103-6.
DMRIFCW	RU	https://pubmed.ncbi.nlm.nih.gov/19537763

DMFBTM2	DI	DMFBTM2
DMFBTM2	DN	2-(phenylsulfonamido)-1-naphthoic acid
DMFBTM2	MI	TTZL0OI
DMFBTM2	MN	Methionine aminopeptidase 2 (METAP2)
DMFBTM2	MT	DTT
DMFBTM2	MA	Inhibitor
DMFBTM2	RN	Development of sulfonamide compounds as potent methionine aminopeptidase type II inhibitors with antiproliferative properties. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3574-7.
DMFBTM2	RU	https://pubmed.ncbi.nlm.nih.gov/16632353

DMDGAHO	DI	DMDGAHO
DMDGAHO	DN	2-(phenylsulfonamido)-5-propylbenzoic acid
DMDGAHO	MI	TTZL0OI
DMDGAHO	MN	Methionine aminopeptidase 2 (METAP2)
DMDGAHO	MT	DTT
DMDGAHO	MA	Inhibitor
DMDGAHO	RN	Development of sulfonamide compounds as potent methionine aminopeptidase type II inhibitors with antiproliferative properties. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3574-7.
DMDGAHO	RU	https://pubmed.ncbi.nlm.nih.gov/16632353

DMMSI67	DI	DMMSI67
DMMSI67	DN	2-(Phenylsulfonamido)acetic Acid
DMMSI67	MI	TTFBNVI
DMMSI67	MN	Aldose reductase (AKR1B1)
DMMSI67	MT	DTT
DMMSI67	MA	Inhibitor
DMMSI67	RN	A diverse series of substituted benzenesulfonamides as aldose reductase inhibitors with antioxidant activity: design, synthesis, and in vitro activ... J Med Chem. 2010 Nov 11;53(21):7756-66.
DMMSI67	RU	https://pubmed.ncbi.nlm.nih.gov/20936791

DMCF75U	DI	DMCF75U
DMCF75U	DN	2-(phenylsulfonyl)-1-(thiophen-3-yl)ethanone
DMCF75U	MI	TTN7BL9
DMCF75U	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMCF75U	MT	DTT
DMCF75U	MA	Inhibitor
DMCF75U	RN	beta-Keto sulfones as inhibitors of 11beta-hydroxysteroid dehydrogenase type I and the mechanism of action. Bioorg Med Chem. 2007 Jul 1;15(13):4396-405.
DMCF75U	RU	https://pubmed.ncbi.nlm.nih.gov/17490884

DM93XJT	DI	DM93XJT
DM93XJT	DN	2-(phenylsulfonyl)-1-p-tolylethanone
DM93XJT	MI	TTN7BL9
DM93XJT	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DM93XJT	MT	DTT
DM93XJT	MA	Inhibitor
DM93XJT	RN	beta-Keto sulfones as inhibitors of 11beta-hydroxysteroid dehydrogenase type I and the mechanism of action. Bioorg Med Chem. 2007 Jul 1;15(13):4396-405.
DM93XJT	RU	https://pubmed.ncbi.nlm.nih.gov/17490884

DMAKR2E	DI	DMAKR2E
DMAKR2E	DN	2-(phenylsulfonyl)naphthalene-1,4-diol
DMAKR2E	MI	TTRVTMX
DMAKR2E	MN	Bacterial Beta-ketoacyl-ACP synthase III (Bact fabH)
DMAKR2E	MT	DTT
DMAKR2E	MA	Inhibitor
DMAKR2E	RN	Synthesis and biological evaluation of novel sulfonyl-naphthalene-1,4-diols as FabH inhibitors. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6402-5.
DMAKR2E	RU	https://pubmed.ncbi.nlm.nih.gov/18996691

DM4V2ZO	DI	DM4V2ZO
DM4V2ZO	DN	2-(Phosphonooxy)Butanoic Acid
DM4V2ZO	MI	TTVNA43
DM4V2ZO	MN	Bacterial Deoxy-D-manno-octulosonate 8-phosphate synthase (Bact kdsA)
DM4V2ZO	MT	DTT
DM4V2ZO	MA	Inhibitor
DM4V2ZO	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DM4V2ZO	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DML6HSE	DI	DML6HSE
DML6HSE	DN	2-(piperazin-1-yl)-5,6,7,8-tetrahydroquinoline
DML6HSE	MI	TTJQOD7
DML6HSE	MN	5-HT 2A receptor (HTR2A)
DML6HSE	MT	DTT
DML6HSE	MA	Inhibitor
DML6HSE	RN	Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity. Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71.
DML6HSE	RU	https://pubmed.ncbi.nlm.nih.gov/19914063

DML6HSE	DI	DML6HSE
DML6HSE	DN	2-(piperazin-1-yl)-5,6,7,8-tetrahydroquinoline
DML6HSE	MI	TTWJBZ5
DML6HSE	MN	5-HT 2C receptor (HTR2C)
DML6HSE	MT	DTT
DML6HSE	MA	Inhibitor
DML6HSE	RN	Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity. Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71.
DML6HSE	RU	https://pubmed.ncbi.nlm.nih.gov/19914063

DMGQX1I	DI	DMGQX1I
DMGQX1I	DN	2-(piperidin-1-yl)-4H-benzo[h]chromen-4-one
DMGQX1I	MI	TTK3PY9
DMGQX1I	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMGQX1I	MT	DTT
DMGQX1I	MA	Inhibitor
DMGQX1I	RN	Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46.
DMGQX1I	RU	https://pubmed.ncbi.nlm.nih.gov/16302822

DMLT635	DI	DMLT635
DMLT635	DN	2-(p-Methylsulfonylbenzoyl)furan
DMLT635	MI	TT8NGED
DMLT635	MN	Prostaglandin G/H synthase 1 (COX-1)
DMLT635	MT	DTT
DMLT635	MA	Inhibitor
DMLT635	RN	Synthesis, anti-inflammatory activity, and in vitro antitumor effect of a novel class of cyclooxygenase inhibitors: 4-(aryloyl)phenyl methyl sulfones. J Med Chem. 2010 Sep 23;53(18):6560-71.
DMLT635	RU	https://pubmed.ncbi.nlm.nih.gov/20804197

DMLT635	DI	DMLT635
DMLT635	DN	2-(p-Methylsulfonylbenzoyl)furan
DMLT635	MI	TTVKILB
DMLT635	MN	Prostaglandin G/H synthase 2 (COX-2)
DMLT635	MT	DTT
DMLT635	MA	Inhibitor
DMLT635	RN	Synthesis, anti-inflammatory activity, and in vitro antitumor effect of a novel class of cyclooxygenase inhibitors: 4-(aryloyl)phenyl methyl sulfones. J Med Chem. 2010 Sep 23;53(18):6560-71.
DMLT635	RU	https://pubmed.ncbi.nlm.nih.gov/20804197

DM27YTF	DI	DM27YTF
DM27YTF	DN	2-(p-toluidino)-4-phenylpyrimidine-5-carbonitrile
DM27YTF	MI	TTH6V3D
DM27YTF	MN	Cyclin-dependent kinase 1 (CDK1)
DM27YTF	MT	DTT
DM27YTF	MA	Inhibitor
DM27YTF	RN	4-Aryl-5-cyano-2-aminopyrimidines as VEGF-R2 inhibitors: synthesis and biological evaluation. Bioorg Med Chem Lett. 2007 Jun 15;17(12):3266-70.
DM27YTF	RU	https://pubmed.ncbi.nlm.nih.gov/17481894

DM27YTF	DI	DM27YTF
DM27YTF	DN	2-(p-toluidino)-4-phenylpyrimidine-5-carbonitrile
DM27YTF	MI	TTUTJGQ
DM27YTF	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM27YTF	MT	DTT
DM27YTF	MA	Inhibitor
DM27YTF	RN	4-Aryl-5-cyano-2-aminopyrimidines as VEGF-R2 inhibitors: synthesis and biological evaluation. Bioorg Med Chem Lett. 2007 Jun 15;17(12):3266-70.
DM27YTF	RU	https://pubmed.ncbi.nlm.nih.gov/17481894

DMON1A5	DI	DMON1A5
DMON1A5	DN	2-(p-tolylthio)naphthalene-1,4-dione
DMON1A5	MI	TTRVTMX
DMON1A5	MN	Bacterial Beta-ketoacyl-ACP synthase III (Bact fabH)
DMON1A5	MT	DTT
DMON1A5	MA	Inhibitor
DMON1A5	RN	Synthesis and biological evaluation of novel sulfonyl-naphthalene-1,4-diols as FabH inhibitors. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6402-5.
DMON1A5	RU	https://pubmed.ncbi.nlm.nih.gov/18996691

DMST2LX	DI	DMST2LX
DMST2LX	DN	2-(pyridin-2-yl)-1H-benzo[d]imidazol-5-amine
DMST2LX	MI	TTZL0OI
DMST2LX	MN	Methionine aminopeptidase 2 (METAP2)
DMST2LX	MT	DTT
DMST2LX	MA	Inhibitor
DMST2LX	RN	Subtype-selectivity of metal-dependent methionine aminopeptidase inhibitors, Bioorg. Med. Chem. Lett. 20(14):4038-4044 (2010).
DMST2LX	RU	http://www.sciencedirect.com/science/article/pii/S0960894X10007468

DMRUTDY	DI	DMRUTDY
DMRUTDY	DN	2-(pyridin-2-yl)-1H-benzo[d]imidazole
DMRUTDY	MI	TTZL0OI
DMRUTDY	MN	Methionine aminopeptidase 2 (METAP2)
DMRUTDY	MT	DTT
DMRUTDY	MA	Inhibitor
DMRUTDY	RN	Subtype-selectivity of metal-dependent methionine aminopeptidase inhibitors, Bioorg. Med. Chem. Lett. 20(14):4038-4044 (2010).
DMRUTDY	RU	http://www.sciencedirect.com/science/article/pii/S0960894X10007468

DMHFGMQ	DI	DMHFGMQ
DMHFGMQ	DN	2-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridine
DMHFGMQ	MI	TTZL0OI
DMHFGMQ	MN	Methionine aminopeptidase 2 (METAP2)
DMHFGMQ	MT	DTT
DMHFGMQ	MA	Inhibitor
DMHFGMQ	RN	Subtype-selectivity of metal-dependent methionine aminopeptidase inhibitors, Bioorg. Med. Chem. Lett. 20(14):4038-4044 (2010).
DMHFGMQ	RU	http://www.sciencedirect.com/science/article/pii/S0960894X10007468

DM3EBYD	DI	DM3EBYD
DM3EBYD	DN	2-(pyridin-2-yl)-4-(m-tolylthio)pyrimidine
DM3EBYD	MI	TTHS256
DM3EBYD	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM3EBYD	MT	DTT
DM3EBYD	MA	Inhibitor
DM3EBYD	RN	Structure-activity relationship of thiopyrimidines as mGluR5 antagonists. Bioorg Med Chem Lett. 2006 May 1;16(9):2467-9.
DM3EBYD	RU	https://pubmed.ncbi.nlm.nih.gov/16481165

DMET46L	DI	DMET46L
DMET46L	DN	2-(pyrimidin-4-ylamino)thiazole-5-carbonitrile
DMET46L	MI	TTUTJGQ
DMET46L	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMET46L	MT	DTT
DMET46L	MA	Inhibitor
DMET46L	RN	Potent 2-[(pyrimidin-4-yl)amine}-1,3-thiazole-5-carbonitrile-based inhibitors of VEGFR-2 (KDR) kinase. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1146-50.
DMET46L	RU	https://pubmed.ncbi.nlm.nih.gov/16368234

DM5CEG8	DI	DM5CEG8
DM5CEG8	DN	2-(Sulfanylmethyl)phenylphosphonic acid
DM5CEG8	MI	TTHI19T
DM5CEG8	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DM5CEG8	MT	DTT
DM5CEG8	MA	Inhibitor
DM5CEG8	RN	Mercaptophosphonate compounds as broad-spectrum inhibitors of the metallo-beta-lactamases. J Med Chem. 2010 Jul 8;53(13):4862-76.
DM5CEG8	RU	https://pubmed.ncbi.nlm.nih.gov/20527888

DMI457Y	DI	DMI457Y
DMI457Y	DN	2-(tert-butylamino)-1-(3-chlorophenyl)butan-1-one
DMI457Y	MI	TTVBI8W
DMI457Y	MN	Dopamine transporter (DAT)
DMI457Y	MT	DTT
DMI457Y	MA	Inhibitor
DMI457Y	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14.
DMI457Y	RU	https://pubmed.ncbi.nlm.nih.gov/20158204

DMI457Y	DI	DMI457Y
DMI457Y	DN	2-(tert-butylamino)-1-(3-chlorophenyl)butan-1-one
DMI457Y	MI	TTAWNKZ
DMI457Y	MN	Norepinephrine transporter (NET)
DMI457Y	MT	DTT
DMI457Y	MA	Inhibitor
DMI457Y	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14.
DMI457Y	RU	https://pubmed.ncbi.nlm.nih.gov/20158204

DMI457Y	DI	DMI457Y
DMI457Y	DN	2-(tert-butylamino)-1-(3-chlorophenyl)butan-1-one
DMI457Y	MI	TT3ROYC
DMI457Y	MN	Serotonin transporter (SERT)
DMI457Y	MT	DTT
DMI457Y	MA	Inhibitor
DMI457Y	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14.
DMI457Y	RU	https://pubmed.ncbi.nlm.nih.gov/20158204

DM6PV4W	DI	DM6PV4W
DM6PV4W	DN	2-(tert-butylamino)-1-m-tolylpropan-1-one
DM6PV4W	MI	TTVBI8W
DM6PV4W	MN	Dopamine transporter (DAT)
DM6PV4W	MT	DTT
DM6PV4W	MA	Inhibitor
DM6PV4W	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14.
DM6PV4W	RU	https://pubmed.ncbi.nlm.nih.gov/20158204

DM6PV4W	DI	DM6PV4W
DM6PV4W	DN	2-(tert-butylamino)-1-m-tolylpropan-1-one
DM6PV4W	MI	TTAWNKZ
DM6PV4W	MN	Norepinephrine transporter (NET)
DM6PV4W	MT	DTT
DM6PV4W	MA	Inhibitor
DM6PV4W	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14.
DM6PV4W	RU	https://pubmed.ncbi.nlm.nih.gov/20158204

DMYFQDT	DI	DMYFQDT
DMYFQDT	DN	2-(tert-butylamino)-1-p-tolylpropan-1-one
DMYFQDT	MI	TTVBI8W
DMYFQDT	MN	Dopamine transporter (DAT)
DMYFQDT	MT	DTT
DMYFQDT	MA	Inhibitor
DMYFQDT	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14.
DMYFQDT	RU	https://pubmed.ncbi.nlm.nih.gov/20158204

DMYFQDT	DI	DMYFQDT
DMYFQDT	DN	2-(tert-butylamino)-1-p-tolylpropan-1-one
DMYFQDT	MI	TTAWNKZ
DMYFQDT	MN	Norepinephrine transporter (NET)
DMYFQDT	MT	DTT
DMYFQDT	MA	Inhibitor
DMYFQDT	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14.
DMYFQDT	RU	https://pubmed.ncbi.nlm.nih.gov/20158204

DMOJK8Y	DI	DMOJK8Y
DMOJK8Y	DN	2-(tert-Butylamino)-3',4'-dichlorobutyrophenone
DMOJK8Y	MI	TTVBI8W
DMOJK8Y	MN	Dopamine transporter (DAT)
DMOJK8Y	MT	DTT
DMOJK8Y	MA	Inhibitor
DMOJK8Y	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81.
DMOJK8Y	RU	https://pubmed.ncbi.nlm.nih.gov/19821577

DMOJK8Y	DI	DMOJK8Y
DMOJK8Y	DN	2-(tert-Butylamino)-3',4'-dichlorobutyrophenone
DMOJK8Y	MI	TTAWNKZ
DMOJK8Y	MN	Norepinephrine transporter (NET)
DMOJK8Y	MT	DTT
DMOJK8Y	MA	Inhibitor
DMOJK8Y	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81.
DMOJK8Y	RU	https://pubmed.ncbi.nlm.nih.gov/19821577

DMOJK8Y	DI	DMOJK8Y
DMOJK8Y	DN	2-(tert-Butylamino)-3',4'-dichlorobutyrophenone
DMOJK8Y	MI	TT3ROYC
DMOJK8Y	MN	Serotonin transporter (SERT)
DMOJK8Y	MT	DTT
DMOJK8Y	MA	Inhibitor
DMOJK8Y	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81.
DMOJK8Y	RU	https://pubmed.ncbi.nlm.nih.gov/19821577

DMMUDQ7	DI	DMMUDQ7
DMMUDQ7	DN	2-(tert-Butylamino)-3',4'-dichloropentanophenone
DMMUDQ7	MI	TTVBI8W
DMMUDQ7	MN	Dopamine transporter (DAT)
DMMUDQ7	MT	DTT
DMMUDQ7	MA	Inhibitor
DMMUDQ7	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81.
DMMUDQ7	RU	https://pubmed.ncbi.nlm.nih.gov/19821577

DMMUDQ7	DI	DMMUDQ7
DMMUDQ7	DN	2-(tert-Butylamino)-3',4'-dichloropentanophenone
DMMUDQ7	MI	TTAWNKZ
DMMUDQ7	MN	Norepinephrine transporter (NET)
DMMUDQ7	MT	DTT
DMMUDQ7	MA	Inhibitor
DMMUDQ7	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81.
DMMUDQ7	RU	https://pubmed.ncbi.nlm.nih.gov/19821577

DMMUDQ7	DI	DMMUDQ7
DMMUDQ7	DN	2-(tert-Butylamino)-3',4'-dichloropentanophenone
DMMUDQ7	MI	TT3ROYC
DMMUDQ7	MN	Serotonin transporter (SERT)
DMMUDQ7	MT	DTT
DMMUDQ7	MA	Inhibitor
DMMUDQ7	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81.
DMMUDQ7	RU	https://pubmed.ncbi.nlm.nih.gov/19821577

DMH3QLF	DI	DMH3QLF
DMH3QLF	DN	2-(tert-Butylamino)-3',5'-difluoropropiophenone
DMH3QLF	MI	TTVBI8W
DMH3QLF	MN	Dopamine transporter (DAT)
DMH3QLF	MT	DTT
DMH3QLF	MA	Inhibitor
DMH3QLF	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81.
DMH3QLF	RU	https://pubmed.ncbi.nlm.nih.gov/19821577

DM5YJP3	DI	DM5YJP3
DM5YJP3	DN	2-(tert-Butylamino)-3'-fluoropropiophenone
DM5YJP3	MI	TTVBI8W
DM5YJP3	MN	Dopamine transporter (DAT)
DM5YJP3	MT	DTT
DM5YJP3	MA	Inhibitor
DM5YJP3	RN	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81.
DM5YJP3	RU	https://pubmed.ncbi.nlm.nih.gov/19821577

DMH4IRP	DI	DMH4IRP
DMH4IRP	DN	2-(thiazol-4-yl)-1H-benzo[d]imidazol-5-amine
DMH4IRP	MI	TTZL0OI
DMH4IRP	MN	Methionine aminopeptidase 2 (METAP2)
DMH4IRP	MT	DTT
DMH4IRP	MA	Inhibitor
DMH4IRP	RN	Subtype-selectivity of metal-dependent methionine aminopeptidase inhibitors, Bioorg. Med. Chem. Lett. 20(14):4038-4044 (2010).
DMH4IRP	RU	http://www.sciencedirect.com/science/article/pii/S0960894X10007468

DMDL8KY	DI	DMDL8KY
DMDL8KY	DN	2-(trifluoromethoxy)-9H-carbazole
DMDL8KY	MI	TTBGTCW
DMDL8KY	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DMDL8KY	MT	DTT
DMDL8KY	MA	Inhibitor
DMDL8KY	RN	Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8.
DMDL8KY	RU	https://pubmed.ncbi.nlm.nih.gov/20521839

DM7M6T3	DI	DM7M6T3
DM7M6T3	DN	2-(trifluoromethyl)-9H-carbazole
DM7M6T3	MI	TTBGTCW
DM7M6T3	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DM7M6T3	MT	DTT
DM7M6T3	MA	Inhibitor
DM7M6T3	RN	Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8.
DM7M6T3	RU	https://pubmed.ncbi.nlm.nih.gov/20521839

DMWAKFM	DI	DMWAKFM
DMWAKFM	DN	2-(trifluoromethyl)benzaldehyde thiosemicarbazone
DMWAKFM	MI	TTEAID7
DMWAKFM	MN	Trypanosoma Cruzipain (Trypano CYSP)
DMWAKFM	MT	DTT
DMWAKFM	MA	Inhibitor
DMWAKFM	RN	Synthesis and structure-activity relationship study of potent trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine protease cruz... J Med Chem. 2002 Jun 20;45(13):2695-707.
DMWAKFM	RU	https://pubmed.ncbi.nlm.nih.gov/12061873

DMBLXOG	DI	DMBLXOG
DMBLXOG	DN	2,2,2-TRIFLUORO-1-(4-FLUOROPHENYL)-1-(1-(4-FLUOROPHENYL)-1H-INDAZOL-5-YL)ETHANOL (DIASTEREOMERIC MIX)
DMBLXOG	MI	TTOZRK6
DMBLXOG	MN	Glucocorticoid receptor messenger RNA (GCR mRNA)
DMBLXOG	MT	DTT
DMBLXOG	MA	Inhibitor
DMBLXOG	RN	5-Functionalized indazoles as glucocorticoid receptor agonists. Bioorg Med Chem Lett. 2010 May 15;20(10):3017-20.
DMBLXOG	RU	https://pubmed.ncbi.nlm.nih.gov/20427184

DMG4ITB	DI	DMG4ITB
DMG4ITB	DN	2,2,2-Trifluoro-N-(4-sulfamoyl-phenyl)-acetamide
DMG4ITB	MI	TTHQPL7
DMG4ITB	MN	Carbonic anhydrase I (CA-I)
DMG4ITB	MT	DTT
DMG4ITB	MA	Inhibitor
DMG4ITB	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DMG4ITB	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DMG4ITB	DI	DMG4ITB
DMG4ITB	DN	2,2,2-Trifluoro-N-(4-sulfamoyl-phenyl)-acetamide
DMG4ITB	MI	TTANPDJ
DMG4ITB	MN	Carbonic anhydrase II (CA-II)
DMG4ITB	MT	DTT
DMG4ITB	MA	Inhibitor
DMG4ITB	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DMG4ITB	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DMG4ITB	DI	DMG4ITB
DMG4ITB	DN	2,2,2-Trifluoro-N-(4-sulfamoyl-phenyl)-acetamide
DMG4ITB	MI	TT2LVK8
DMG4ITB	MN	Carbonic anhydrase IX (CA-IX)
DMG4ITB	MT	DTT
DMG4ITB	MA	Inhibitor
DMG4ITB	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DMG4ITB	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DMG4ITB	DI	DMG4ITB
DMG4ITB	DN	2,2,2-Trifluoro-N-(4-sulfamoyl-phenyl)-acetamide
DMG4ITB	MI	TTSYM0R
DMG4ITB	MN	Carbonic anhydrase XII (CA-XII)
DMG4ITB	MT	DTT
DMG4ITB	MA	Inhibitor
DMG4ITB	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DMG4ITB	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DMJXAF7	DI	DMJXAF7
DMJXAF7	DN	2,2,2-tris-(3-fluorophenyl)-acetamide
DMJXAF7	MI	TTMNI76
DMJXAF7	MN	Calcium-activated potassium channel (KCN)
DMJXAF7	MT	DTT
DMJXAF7	MA	Inhibitor
DMJXAF7	RN	Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82.
DMJXAF7	RU	https://pubmed.ncbi.nlm.nih.gov/18232633

DMCZHEN	DI	DMCZHEN
DMCZHEN	DN	2,2,2-tris-(4-fluorophenyl)-acetamide
DMCZHEN	MI	TTMNI76
DMCZHEN	MN	Calcium-activated potassium channel (KCN)
DMCZHEN	MT	DTT
DMCZHEN	MA	Inhibitor
DMCZHEN	RN	Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82.
DMCZHEN	RU	https://pubmed.ncbi.nlm.nih.gov/18232633

DMG7EPF	DI	DMG7EPF
DMG7EPF	DN	2,2',3-Tribromo-4,4',5,5'-tetrahydroxybibenzyl
DMG7EPF	MI	TT58ZYW
DMG7EPF	MN	Mycobacterium Isocitrate lyase (MycB icl)
DMG7EPF	MT	DTT
DMG7EPF	MA	Inhibitor
DMG7EPF	RN	Bromophenols as Candida albicans isocitrate lyase inhibitors. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6644-8.
DMG7EPF	RU	https://pubmed.ncbi.nlm.nih.gov/20888765

DMAYXUR	DI	DMAYXUR
DMAYXUR	DN	2,2',4,4',6'-pentahydroxychalcone
DMAYXUR	MI	TTULVH8
DMAYXUR	MN	Tyrosinase (TYR)
DMAYXUR	MT	DTT
DMAYXUR	MA	Inhibitor
DMAYXUR	RN	Synthesis and evaluation of 2',4',6'-trihydroxychalcones as a new class of tyrosinase inhibitors. Bioorg Med Chem. 2007 Mar 15;15(6):2396-402.
DMAYXUR	RU	https://pubmed.ncbi.nlm.nih.gov/17267225

DMMJ613	DI	DMMJ613
DMMJ613	DN	2,2',4,4'-tetrahydroxy-6'-methoxychalcone
DMMJ613	MI	TTULVH8
DMMJ613	MN	Tyrosinase (TYR)
DMMJ613	MT	DTT
DMMJ613	MA	Inhibitor
DMMJ613	RN	Synthesis and evaluation of 2',4',6'-trihydroxychalcones as a new class of tyrosinase inhibitors. Bioorg Med Chem. 2007 Mar 15;15(6):2396-402.
DMMJ613	RU	https://pubmed.ncbi.nlm.nih.gov/17267225

DMM6KBD	DI	DMM6KBD
DMM6KBD	DN	2,2',4,4'-tetrahydroxychalcone
DMM6KBD	MI	TTULVH8
DMM6KBD	MN	Tyrosinase (TYR)
DMM6KBD	MT	DTT
DMM6KBD	MA	Inhibitor
DMM6KBD	RN	Synthesis and evaluation of 2',4',6'-trihydroxychalcones as a new class of tyrosinase inhibitors. Bioorg Med Chem. 2007 Mar 15;15(6):2396-402.
DMM6KBD	RU	https://pubmed.ncbi.nlm.nih.gov/17267225

DMP9ECK	DI	DMP9ECK
DMP9ECK	DN	2,2,4-Trimethyl-6-phenyl-1,2-dihydro-quinoline
DMP9ECK	MI	TTUV8G9
DMP9ECK	MN	Progesterone receptor (PGR)
DMP9ECK	MT	DTT
DMP9ECK	MA	Inhibitor
DMP9ECK	RN	Discovery and preliminary SAR studies of a novel, nonsteroidal progesterone receptor antagonist pharmacophore. J Med Chem. 1998 Aug 27;41(18):3461-6.
DMP9ECK	RU	https://pubmed.ncbi.nlm.nih.gov/9719599

DMPMOHQ	DI	DMPMOHQ
DMPMOHQ	DN	2,2'-bi(1,3,4-thiadiazole)-5,5'(4H,4'H)-dithione
DMPMOHQ	MI	TTULVH8
DMPMOHQ	MN	Tyrosinase (TYR)
DMPMOHQ	MT	DTT
DMPMOHQ	MA	Inhibitor
DMPMOHQ	RN	New potent inhibitors of tyrosinase: novel clues to binding of 1,3,4-thiadiazole-2(3H)-thiones, 1,3,4-oxadiazole-2(3H)-thiones, 4-amino-1,2,4-triaz... Bioorg Med Chem. 2010 Jun 1;18(11):4042-8.
DMPMOHQ	RU	https://pubmed.ncbi.nlm.nih.gov/20452224

DMDIX40	DI	DMDIX40
DMDIX40	DN	2,2-bis-(2-fluorophenyl)-2-phenylacetamide
DMDIX40	MI	TTMNI76
DMDIX40	MN	Calcium-activated potassium channel (KCN)
DMDIX40	MT	DTT
DMDIX40	MA	Inhibitor
DMDIX40	RN	Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82.
DMDIX40	RU	https://pubmed.ncbi.nlm.nih.gov/18232633

DM6ICRJ	DI	DM6ICRJ
DM6ICRJ	DN	2,2-bis-(3-fluorophenyl)-2-phenylacetamide
DM6ICRJ	MI	TTMNI76
DM6ICRJ	MN	Calcium-activated potassium channel (KCN)
DM6ICRJ	MT	DTT
DM6ICRJ	MA	Inhibitor
DM6ICRJ	RN	Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82.
DM6ICRJ	RU	https://pubmed.ncbi.nlm.nih.gov/18232633

DMTODR2	DI	DMTODR2
DMTODR2	DN	2,2-bis(3-fluorophenyl)-N-hydroxyacetamide
DMTODR2	MI	TTBH0VX
DMTODR2	MN	Histone deacetylase (HDAC)
DMTODR2	MT	DTT
DMTODR2	MA	Inhibitor
DMTODR2	RN	Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5684-8.
DMTODR2	RU	https://pubmed.ncbi.nlm.nih.gov/19699639

DMTODR2	DI	DMTODR2
DMTODR2	DN	2,2-bis(3-fluorophenyl)-N-hydroxyacetamide
DMTODR2	MI	TTTQGH8
DMTODR2	MN	Histone deacetylase 4 (HDAC4)
DMTODR2	MT	DTT
DMTODR2	MA	Inhibitor
DMTODR2	RN	Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5684-8.
DMTODR2	RU	https://pubmed.ncbi.nlm.nih.gov/19699639

DM2RKD6	DI	DM2RKD6
DM2RKD6	DN	2,2-bis(4-chlorophenyl)-N-hydroxyacetamide
DM2RKD6	MI	TTBH0VX
DM2RKD6	MN	Histone deacetylase (HDAC)
DM2RKD6	MT	DTT
DM2RKD6	MA	Inhibitor
DM2RKD6	RN	Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5684-8.
DM2RKD6	RU	https://pubmed.ncbi.nlm.nih.gov/19699639

DM2RKD6	DI	DM2RKD6
DM2RKD6	DN	2,2-bis(4-chlorophenyl)-N-hydroxyacetamide
DM2RKD6	MI	TTTQGH8
DM2RKD6	MN	Histone deacetylase 4 (HDAC4)
DM2RKD6	MT	DTT
DM2RKD6	MA	Inhibitor
DM2RKD6	RN	Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5684-8.
DM2RKD6	RU	https://pubmed.ncbi.nlm.nih.gov/19699639

DM5PWQM	DI	DM5PWQM
DM5PWQM	DN	2,2-bis(4-fluorophenyl)-N-hydroxyacetamide
DM5PWQM	MI	TTBH0VX
DM5PWQM	MN	Histone deacetylase (HDAC)
DM5PWQM	MT	DTT
DM5PWQM	MA	Inhibitor
DM5PWQM	RN	Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5684-8.
DM5PWQM	RU	https://pubmed.ncbi.nlm.nih.gov/19699639

DM5PWQM	DI	DM5PWQM
DM5PWQM	DN	2,2-bis(4-fluorophenyl)-N-hydroxyacetamide
DM5PWQM	MI	TTTQGH8
DM5PWQM	MN	Histone deacetylase 4 (HDAC4)
DM5PWQM	MT	DTT
DM5PWQM	MA	Inhibitor
DM5PWQM	RN	Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5684-8.
DM5PWQM	RU	https://pubmed.ncbi.nlm.nih.gov/19699639

DMFPYU8	DI	DMFPYU8
DMFPYU8	DN	2,2-Dibenzylcyclopentanol
DMFPYU8	MI	TT5ZWB6
DMFPYU8	MN	Dihydrodiol dehydrogenase type I (AKR1C3)
DMFPYU8	MT	DTT
DMFPYU8	MA	Inhibitor
DMFPYU8	RN	New cyclopentane derivatives as inhibitors of steroid metabolizing enzymes AKR1C1 and AKR1C3. Eur J Med Chem. 2009 Jun;44(6):2563-71.
DMFPYU8	RU	https://pubmed.ncbi.nlm.nih.gov/19237229

DMKXFDA	DI	DMKXFDA
DMKXFDA	DN	2,2-difluoromevalonate 5-diphosphate
DMKXFDA	MI	TTE5J6X
DMKXFDA	MN	Diphosphomevalonate decarboxylase (MVD)
DMKXFDA	MT	DTT
DMKXFDA	MA	Inhibitor
DMKXFDA	RN	Mutation and inhibition studies of mevalonate 5-diphosphate decarboxylase. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6164-8.
DMKXFDA	RU	https://pubmed.ncbi.nlm.nih.gov/17888661

DMPX642	DI	DMPX642
DMPX642	DN	2,2-diMeBut-RYYRIK-NH2
DMPX642	MI	TTNT7K8
DMPX642	MN	Nociceptin receptor (OPRL1)
DMPX642	MT	DTT
DMPX642	MA	Inhibitor
DMPX642	RN	Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist. Bioorg Med Chem. 2008 Mar 1;16(5):2635-44.
DMPX642	RU	https://pubmed.ncbi.nlm.nih.gov/18068993

DM34IX5	DI	DM34IX5
DM34IX5	DN	2,2-Dimethoxy-1,2-diphenyl-ethanone
DM34IX5	MI	TTMF541
DM34IX5	MN	Liver carboxylesterase (CES1)
DM34IX5	MT	DTT
DM34IX5	MA	Inhibitor
DM34IX5	RN	Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15.
DM34IX5	RU	https://pubmed.ncbi.nlm.nih.gov/15828829

DMQYCFI	DI	DMQYCFI
DMQYCFI	DN	2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
DMQYCFI	MI	TTZJYKH
DMQYCFI	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMQYCFI	MT	DTT
DMQYCFI	MA	Inhibitor
DMQYCFI	RN	Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem. 2008 Mar 27;51(6):1706-18.
DMQYCFI	RU	https://pubmed.ncbi.nlm.nih.gov/18318466

DM7BL04	DI	DM7BL04
DM7BL04	DN	2,2-dimethyl-3-methyleneheptadecane
DM7BL04	MI	TTDP1UC
DM7BL04	MN	Fatty acid amide hydrolase (FAAH)
DM7BL04	MT	DTT
DM7BL04	MA	Inhibitor
DM7BL04	RN	Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30.
DM7BL04	RU	https://pubmed.ncbi.nlm.nih.gov/18023188

DM7BL04	DI	DM7BL04
DM7BL04	DN	2,2-dimethyl-3-methyleneheptadecane
DM7BL04	MI	TTMF541
DM7BL04	MN	Liver carboxylesterase (CES1)
DM7BL04	MT	DTT
DM7BL04	MA	Inhibitor
DM7BL04	RN	Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30.
DM7BL04	RU	https://pubmed.ncbi.nlm.nih.gov/18023188

DMATB8H	DI	DMATB8H
DMATB8H	DN	2,2-Dimethyl-N-(4-sulfamoyl-phenyl)-propionamide
DMATB8H	MI	TTANPDJ
DMATB8H	MN	Carbonic anhydrase II (CA-II)
DMATB8H	MT	DTT
DMATB8H	MA	Inhibitor
DMATB8H	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DMATB8H	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DMATB8H	DI	DMATB8H
DMATB8H	DN	2,2-Dimethyl-N-(4-sulfamoyl-phenyl)-propionamide
DMATB8H	MI	TT2LVK8
DMATB8H	MN	Carbonic anhydrase IX (CA-IX)
DMATB8H	MT	DTT
DMATB8H	MA	Inhibitor
DMATB8H	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DMATB8H	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DMATB8H	DI	DMATB8H
DMATB8H	DN	2,2-Dimethyl-N-(4-sulfamoyl-phenyl)-propionamide
DMATB8H	MI	TTSYM0R
DMATB8H	MN	Carbonic anhydrase XII (CA-XII)
DMATB8H	MT	DTT
DMATB8H	MA	Inhibitor
DMATB8H	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DMATB8H	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DMTBAUG	DI	DMTBAUG
DMTBAUG	DN	2,2-Diphenyl-ethylamine
DMTBAUG	MI	TTJQOD7
DMTBAUG	MN	5-HT 2A receptor (HTR2A)
DMTBAUG	MT	DTT
DMTBAUG	MA	Inhibitor
DMTBAUG	RN	Exploring the relationship between binding modes of 9-(aminomethyl)-9,10-dihydroanthracene and cyproheptadine analogues at the 5-HT2A serotonin rec... Bioorg Med Chem Lett. 2001 Feb 26;11(4):563-6.
DMTBAUG	RU	https://pubmed.ncbi.nlm.nih.gov/11229772

DMOQDBA	DI	DMOQDBA
DMOQDBA	DN	2,2'-pyridylisatogen tosylate
DMOQDBA	MI	TTA93TL
DMOQDBA	MN	P2Y purinoceptor 1 (P2RY1)
DMOQDBA	MT	DTT
DMOQDBA	MA	Modulator (allosteric modulator)
DMOQDBA	RN	2,2'-Pyridylisatogen tosylate antagonizes P2Y1 receptor signaling without affecting nucleotide binding. Biochem Pharmacol. 2004 Jul 15;68(2):231-7.
DMOQDBA	RU	https://pubmed.ncbi.nlm.nih.gov/15193995

DM7H34U	DI	DM7H34U
DM7H34U	DN	2,3,3-Triphenyl-acrylonitrile
DM7H34U	MI	TTFJ8Q1
DM7H34U	MN	Protein kinase C alpha (PRKCA)
DM7H34U	MT	DTT
DM7H34U	MA	Inhibitor
DM7H34U	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DM7H34U	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DM7H34U	DI	DM7H34U
DM7H34U	DN	2,3,3-Triphenyl-acrylonitrile
DM7H34U	MI	TTYPXQF
DM7H34U	MN	Protein kinase C beta (PRKCB)
DM7H34U	MT	DTT
DM7H34U	MA	Inhibitor
DM7H34U	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DM7H34U	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DM7H34U	DI	DM7H34U
DM7H34U	DN	2,3,3-Triphenyl-acrylonitrile
DM7H34U	MI	TT9WJ8U
DM7H34U	MN	Protein kinase C delta (PRKCD)
DM7H34U	MT	DTT
DM7H34U	MA	Inhibitor
DM7H34U	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DM7H34U	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DM7H34U	DI	DM7H34U
DM7H34U	DN	2,3,3-Triphenyl-acrylonitrile
DM7H34U	MI	TTBZ7OD
DM7H34U	MN	Protein kinase C epsilon (PRKCE)
DM7H34U	MT	DTT
DM7H34U	MA	Inhibitor
DM7H34U	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DM7H34U	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DM7H34U	DI	DM7H34U
DM7H34U	DN	2,3,3-Triphenyl-acrylonitrile
DM7H34U	MI	TTRFOXJ
DM7H34U	MN	Protein kinase C gamma (PRKCG)
DM7H34U	MT	DTT
DM7H34U	MA	Inhibitor
DM7H34U	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DM7H34U	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DM7H34U	DI	DM7H34U
DM7H34U	DN	2,3,3-Triphenyl-acrylonitrile
DM7H34U	MI	TT8QL1J
DM7H34U	MN	Protein kinase C theta (PRKCQ)
DM7H34U	MT	DTT
DM7H34U	MA	Inhibitor
DM7H34U	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DM7H34U	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DM7H34U	DI	DM7H34U
DM7H34U	DN	2,3,3-Triphenyl-acrylonitrile
DM7H34U	MI	TTUWGRA
DM7H34U	MN	Protein kinase C zeta (PRKCZ)
DM7H34U	MT	DTT
DM7H34U	MA	Inhibitor
DM7H34U	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DM7H34U	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DMV1CX0	DI	DMV1CX0
DMV1CX0	DN	2,3,4,11-tetrahydro-1H-benzo[a]carbazole
DMV1CX0	MI	TTBGTCW
DMV1CX0	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DMV1CX0	MT	DTT
DMV1CX0	MA	Inhibitor
DMV1CX0	RN	Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8.
DMV1CX0	RU	https://pubmed.ncbi.nlm.nih.gov/20521839

DMK4LTB	DI	DMK4LTB
DMK4LTB	DN	2,3,4,5-Tetrabromo-6-(2,4-dibromo-phenoxy)-phenol
DMK4LTB	MI	TT12ABZ
DMK4LTB	MN	Arachidonate 12-lipoxygenase (12-LOX)
DMK4LTB	MT	DTT
DMK4LTB	MA	Inhibitor
DMK4LTB	RN	Probing the activity differences of simple and complex brominated aryl compounds against 15-soybean, 15-human, and 12-human lipoxygenase. J Med Chem. 2004 Jul 29;47(16):4060-5.
DMK4LTB	RU	https://pubmed.ncbi.nlm.nih.gov/15267244

DMK4LTB	DI	DMK4LTB
DMK4LTB	DN	2,3,4,5-Tetrabromo-6-(2,4-dibromo-phenoxy)-phenol
DMK4LTB	MI	TTN9T81
DMK4LTB	MN	Arachidonate 15-lipoxygenase (15-LOX)
DMK4LTB	MT	DTT
DMK4LTB	MA	Inhibitor
DMK4LTB	RN	Probing the activity differences of simple and complex brominated aryl compounds against 15-soybean, 15-human, and 12-human lipoxygenase. J Med Chem. 2004 Jul 29;47(16):4060-5.
DMK4LTB	RU	https://pubmed.ncbi.nlm.nih.gov/15267244

DMGQE4B	DI	DMGQE4B
DMGQE4B	DN	2,3,4,5-Tetrafluoro-6-pentafluorophenylazo-phenol
DMGQE4B	MI	TTRA5BZ
DMGQE4B	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMGQE4B	MT	DTT
DMGQE4B	MA	Inhibitor
DMGQE4B	RN	Hydroxyperfluoroazobenzenes: novel inhibitors of enzymes of androgen biosynthesis. J Med Chem. 1990 Sep;33(9):2452-5.
DMGQE4B	RU	https://pubmed.ncbi.nlm.nih.gov/2391687

DM1RE9Q	DI	DM1RE9Q
DM1RE9Q	DN	2,3,4,5-Tetrahydro-1H-benzo[c]azepine
DM1RE9Q	MI	TTWG9A4
DM1RE9Q	MN	Adrenergic receptor alpha-2A (ADRA2A)
DM1RE9Q	MT	DTT
DM1RE9Q	MA	Inhibitor
DM1RE9Q	RN	Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46.
DM1RE9Q	RU	https://pubmed.ncbi.nlm.nih.gov/8784452

DM1RE9Q	DI	DM1RE9Q
DM1RE9Q	DN	2,3,4,5-Tetrahydro-1H-benzo[c]azepine
DM1RE9Q	MI	TTWM4TY
DM1RE9Q	MN	Adrenergic receptor alpha-2B (ADRA2B)
DM1RE9Q	MT	DTT
DM1RE9Q	MA	Inhibitor
DM1RE9Q	RN	Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46.
DM1RE9Q	RU	https://pubmed.ncbi.nlm.nih.gov/8784452

DM1RE9Q	DI	DM1RE9Q
DM1RE9Q	DN	2,3,4,5-Tetrahydro-1H-benzo[c]azepine
DM1RE9Q	MI	TT2NUT5
DM1RE9Q	MN	Adrenergic receptor alpha-2C (ADRA2C)
DM1RE9Q	MT	DTT
DM1RE9Q	MA	Inhibitor
DM1RE9Q	RN	Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46.
DM1RE9Q	RU	https://pubmed.ncbi.nlm.nih.gov/8784452

DM4EZOB	DI	DM4EZOB
DM4EZOB	DN	2,3,4,5-Tetrahydro-1H-benzo[e][1,4]diazepine
DM4EZOB	MI	TTWG9A4
DM4EZOB	MN	Adrenergic receptor alpha-2A (ADRA2A)
DM4EZOB	MT	DTT
DM4EZOB	MA	Inhibitor
DM4EZOB	RN	Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46.
DM4EZOB	RU	https://pubmed.ncbi.nlm.nih.gov/8784452

DM4EZOB	DI	DM4EZOB
DM4EZOB	DN	2,3,4,5-Tetrahydro-1H-benzo[e][1,4]diazepine
DM4EZOB	MI	TTWM4TY
DM4EZOB	MN	Adrenergic receptor alpha-2B (ADRA2B)
DM4EZOB	MT	DTT
DM4EZOB	MA	Inhibitor
DM4EZOB	RN	Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46.
DM4EZOB	RU	https://pubmed.ncbi.nlm.nih.gov/8784452

DM4EZOB	DI	DM4EZOB
DM4EZOB	DN	2,3,4,5-Tetrahydro-1H-benzo[e][1,4]diazepine
DM4EZOB	MI	TT2NUT5
DM4EZOB	MN	Adrenergic receptor alpha-2C (ADRA2C)
DM4EZOB	MT	DTT
DM4EZOB	MA	Inhibitor
DM4EZOB	RN	Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46.
DM4EZOB	RU	https://pubmed.ncbi.nlm.nih.gov/8784452

DMX8NYD	DI	DMX8NYD
DMX8NYD	DN	2,3,4,5-Tetrahydro-1H-pyrido[4,3-b]indole
DMX8NYD	MI	TT3WG5C
DMX8NYD	MN	Monoamine oxidase type A (MAO-A)
DMX8NYD	MT	DTT
DMX8NYD	MA	Inhibitor
DMX8NYD	RN	Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
DMX8NYD	RU	https://pubmed.ncbi.nlm.nih.gov/15013009

DMX8NYD	DI	DMX8NYD
DMX8NYD	DN	2,3,4,5-Tetrahydro-1H-pyrido[4,3-b]indole
DMX8NYD	MI	TTGP7BY
DMX8NYD	MN	Monoamine oxidase type B (MAO-B)
DMX8NYD	MT	DTT
DMX8NYD	MA	Inhibitor
DMX8NYD	RN	Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
DMX8NYD	RU	https://pubmed.ncbi.nlm.nih.gov/15013009

DMOFG4M	DI	DMOFG4M
DMOFG4M	DN	2,3,4,5-Tetrahydro-benzo[f][1,4]oxazepine
DMOFG4M	MI	TTWG9A4
DMOFG4M	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMOFG4M	MT	DTT
DMOFG4M	MA	Inhibitor
DMOFG4M	RN	Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46.
DMOFG4M	RU	https://pubmed.ncbi.nlm.nih.gov/8784452

DMOFG4M	DI	DMOFG4M
DMOFG4M	DN	2,3,4,5-Tetrahydro-benzo[f][1,4]oxazepine
DMOFG4M	MI	TTWM4TY
DMOFG4M	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMOFG4M	MT	DTT
DMOFG4M	MA	Inhibitor
DMOFG4M	RN	Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46.
DMOFG4M	RU	https://pubmed.ncbi.nlm.nih.gov/8784452

DMOFG4M	DI	DMOFG4M
DMOFG4M	DN	2,3,4,5-Tetrahydro-benzo[f][1,4]oxazepine
DMOFG4M	MI	TT2NUT5
DMOFG4M	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMOFG4M	MT	DTT
DMOFG4M	MA	Inhibitor
DMOFG4M	RN	Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46.
DMOFG4M	RU	https://pubmed.ncbi.nlm.nih.gov/8784452

DMXAS25	DI	DMXAS25
DMXAS25	DN	2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide
DMXAS25	MI	TTUF2HO
DMXAS25	MN	NAD-dependent deacetylase sirtuin-1 (SIRT1)
DMXAS25	MT	DTT
DMXAS25	MA	Inhibitor
DMXAS25	RN	Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J Med Chem. 2005 Dec 15;48(25):8045-54.
DMXAS25	RU	https://pubmed.ncbi.nlm.nih.gov/16335928

DMQYEZP	DI	DMQYEZP
DMQYEZP	DN	2,3,4-tribromo-6-(2,4-dibromophenoxy)phenol
DMQYEZP	MI	TTCFP0V
DMQYEZP	MN	Glutamine amidotransferase (GMPS)
DMQYEZP	MT	DTT
DMQYEZP	MA	Inhibitor
DMQYEZP	RN	Enzyme inhibitors: new and known polybrominated phenols and diphenyl ethers from four Indo-Pacific Dysidea sponges. J Nat Prod. 1995 Sep;58(9):1384-91.
DMQYEZP	RU	https://pubmed.ncbi.nlm.nih.gov/7494145

DMCAZ32	DI	DMCAZ32
DMCAZ32	DN	2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide
DMCAZ32	MI	TTJGNVC
DMCAZ32	MN	Apoptosis regulator Bcl-2 (BCL-2)
DMCAZ32	MT	DTT
DMCAZ32	MA	Inhibitor
DMCAZ32	RN	Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem. 2006 Oct 19;49(21):6139-42.
DMCAZ32	RU	https://pubmed.ncbi.nlm.nih.gov/17034116

DMWHK35	DI	DMWHK35
DMWHK35	DN	2,3,4-trihydroxybenzoic acid
DMWHK35	MI	TT2IYXF
DMWHK35	MN	L-selectin (SELL)
DMWHK35	MT	DTT
DMWHK35	MA	Inhibitor
DMWHK35	RN	Rational design of novel, potent small molecule pan-selectin antagonists. J Med Chem. 2007 Mar 22;50(6):1101-15.
DMWHK35	RU	https://pubmed.ncbi.nlm.nih.gov/17302397

DMWHK35	DI	DMWHK35
DMWHK35	DN	2,3,4-trihydroxybenzoic acid
DMWHK35	MI	TTE5VG0
DMWHK35	MN	P-selectin (SELP)
DMWHK35	MT	DTT
DMWHK35	MA	Inhibitor
DMWHK35	RN	Rational design of novel, potent small molecule pan-selectin antagonists. J Med Chem. 2007 Mar 22;50(6):1101-15.
DMWHK35	RU	https://pubmed.ncbi.nlm.nih.gov/17302397

DMPRF1X	DI	DMPRF1X
DMPRF1X	DN	2,3,4-Trimethoxy-4'-amino-trans-stilbene
DMPRF1X	MI	TTSZLWK
DMPRF1X	MN	Aromatase (CYP19A1)
DMPRF1X	MT	DTT
DMPRF1X	MA	Inhibitor
DMPRF1X	RN	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
DMPRF1X	RU	https://pubmed.ncbi.nlm.nih.gov/20558073

DM592YS	DI	DM592YS
DM592YS	DN	2,3,5,6-Tetrafluoro-4-Methoxy-Benzamide
DM592YS	MI	TTFPQV7
DM592YS	MN	Galectin-3 (LGALS3)
DM592YS	MT	DTT
DM592YS	MA	Inhibitor
DM592YS	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM592YS	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMRVYKQ	DI	DMRVYKQ
DMRVYKQ	DN	2,3,5,6-Tetrafluoro-4-pentafluorophenylazo-phenol
DMRVYKQ	MI	TTRA5BZ
DMRVYKQ	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMRVYKQ	MT	DTT
DMRVYKQ	MA	Inhibitor
DMRVYKQ	RN	Hydroxyperfluoroazobenzenes: novel inhibitors of enzymes of androgen biosynthesis. J Med Chem. 1990 Sep;33(9):2452-5.
DMRVYKQ	RU	https://pubmed.ncbi.nlm.nih.gov/2391687

DMRVYKQ	DI	DMRVYKQ
DMRVYKQ	DN	2,3,5,6-Tetrafluoro-4-pentafluorophenylazo-phenol
DMRVYKQ	MI	TTTU72V
DMRVYKQ	MN	Steroid 5-alpha-reductase 1 (SRD5A1)
DMRVYKQ	MT	DTT
DMRVYKQ	MA	Inhibitor
DMRVYKQ	RN	Hydroxyperfluoroazobenzenes: novel inhibitors of enzymes of androgen biosynthesis. J Med Chem. 1990 Sep;33(9):2452-5.
DMRVYKQ	RU	https://pubmed.ncbi.nlm.nih.gov/2391687

DMRVYKQ	DI	DMRVYKQ
DMRVYKQ	DN	2,3,5,6-Tetrafluoro-4-pentafluorophenylazo-phenol
DMRVYKQ	MI	TTT02K8
DMRVYKQ	MN	Steroid 5-alpha-reductase 2 (SRD5A2)
DMRVYKQ	MT	DTT
DMRVYKQ	MA	Inhibitor
DMRVYKQ	RN	Hydroxyperfluoroazobenzenes: novel inhibitors of enzymes of androgen biosynthesis. J Med Chem. 1990 Sep;33(9):2452-5.
DMRVYKQ	RU	https://pubmed.ncbi.nlm.nih.gov/2391687

DMLI5UT	DI	DMLI5UT
DMLI5UT	DN	2,3,5-Trimethoxy-4'-amino-trans-stilbene
DMLI5UT	MI	TTSZLWK
DMLI5UT	MN	Aromatase (CYP19A1)
DMLI5UT	MT	DTT
DMLI5UT	MA	Inhibitor
DMLI5UT	RN	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
DMLI5UT	RU	https://pubmed.ncbi.nlm.nih.gov/20558073

DMCKO6T	DI	DMCKO6T
DMCKO6T	DN	2,3,7-trichloro-5-nitroquinoxaline (TNQX)
DMCKO6T	MI	TTUJFD0
DMCKO6T	MN	Telomerase reverse transcriptase (TERT)
DMCKO6T	MT	DTT
DMCKO6T	MA	Inhibitor
DMCKO6T	RN	Identification of a quinoxaline derivative that is a potent telomerase inhibitor leading to cellular senescence of human cancer cells. Biochem J. 2003 Jul 15;373(Pt 2):523-9.
DMCKO6T	RU	https://pubmed.ncbi.nlm.nih.gov/12689331

DMOB7P6	DI	DMOB7P6
DMOB7P6	DN	2',3'-ddATP
DMOB7P6	MI	TT84ETX
DMOB7P6	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMOB7P6	MT	DTT
DMOB7P6	MA	Inhibitor
DMOB7P6	RN	Synthesis of 2',3'-dideoxynucleoside 5'-alpha-P-borano-beta,gamma-(difluoromethylene)triphosphates and their inhibition of HIV-1 reverse transcript... J Med Chem. 2005 Apr 7;48(7):2695-700.
DMOB7P6	RU	https://pubmed.ncbi.nlm.nih.gov/15801860

DMOB7P6	DI	DMOB7P6
DMOB7P6	DN	2',3'-ddATP
DMOB7P6	MI	TTA93TL
DMOB7P6	MN	P2Y purinoceptor 1 (P2RY1)
DMOB7P6	MT	DTT
DMOB7P6	MA	Agonist
DMOB7P6	RN	An examination of deoxyadenosine 5'(alpha-thio)triphosphate as a ligand to define P2Y receptors and its selectivity as a low potency partial agonist of the P2Y1 receptor. Br J Pharmacol. 1997 May;121(2):338-44.
DMOB7P6	RU	https://pubmed.ncbi.nlm.nih.gov/9154346

DM2UWDR	DI	DM2UWDR
DM2UWDR	DN	2,3'-diamino-3,4,4',5-tetramethoxy-(Z)-stillbene
DM2UWDR	MI	TTYFKSZ
DM2UWDR	MN	Tubulin beta (TUBB)
DM2UWDR	MT	DTT
DM2UWDR	MA	Inhibitor
DM2UWDR	RN	2-amino and 2'-aminocombretastatin derivatives as potent antimitotic agents. J Med Chem. 2006 Oct 19;49(21):6412-5.
DM2UWDR	RU	https://pubmed.ncbi.nlm.nih.gov/17034147

DM2UWDR	DI	DM2UWDR
DM2UWDR	DN	2,3'-diamino-3,4,4',5-tetramethoxy-(Z)-stillbene
DM2UWDR	MI	TTJ2PTI
DM2UWDR	MN	Tubulin beta-2 chain (TUBB2)
DM2UWDR	MT	DTT
DM2UWDR	MA	Inhibitor
DM2UWDR	RN	2-amino and 2'-aminocombretastatin derivatives as potent antimitotic agents. J Med Chem. 2006 Oct 19;49(21):6412-5.
DM2UWDR	RU	https://pubmed.ncbi.nlm.nih.gov/17034147

DMPCGSD	DI	DMPCGSD
DMPCGSD	DN	2,3-dichloro-1,4-naphthoquinone
DMPCGSD	MI	TTZJYKH
DMPCGSD	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMPCGSD	MT	DTT
DMPCGSD	MA	Inhibitor
DMPCGSD	RN	Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem. 2008 Mar 27;51(6):1706-18.
DMPCGSD	RU	https://pubmed.ncbi.nlm.nih.gov/18318466

DM6SBPI	DI	DM6SBPI
DM6SBPI	DN	2,3-Didehydroalanine
DM6SBPI	MI	TT3DQUT
DM6SBPI	MN	Bacterial Lantibiotic mersacidin (Bact glmM)
DM6SBPI	MT	DTT
DM6SBPI	MA	Inhibitor
DM6SBPI	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DM6SBPI	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMCXR4M	DI	DMCXR4M
DMCXR4M	DN	2',3'-Dideoxycytidine-5'-Monophosphate
DMCXR4M	MI	TTMFYEC
DMCXR4M	MN	Streptococcus Cytidylate kinase (Stre-coc cmk)
DMCXR4M	MT	DTT
DMCXR4M	MA	Inhibitor
DMCXR4M	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMCXR4M	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMEQXUD	DI	DMEQXUD
DMEQXUD	DN	2',3'-Dideoxythymidine-5'-Monophosphate
DMEQXUD	MI	TT5B8AX
DMEQXUD	MN	Mycobacterium Thymidine monophosphate kinase (MycB tmk)
DMEQXUD	MT	DTT
DMEQXUD	MA	Inhibitor
DMEQXUD	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMEQXUD	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMJB7W1	DI	DMJB7W1
DMJB7W1	DN	2,3-dihydro-1,4-dithiin-1,1,4,4-tetroxide
DMJB7W1	MI	TTOPAY7
DMJB7W1	MN	Galanin receptor (GAL-R)
DMJB7W1	MT	DTT
DMJB7W1	MA	Antagonist
DMJB7W1	RN	2,3-Dihydro-dithiin and -dithiepine-1,1,4,4-tetroxides: small molecule non-peptide antagonists of the human galanin hGAL-1 receptor. Bioorg Med Chem. 2000 Jun;8(6):1383-91.
DMJB7W1	RU	https://pubmed.ncbi.nlm.nih.gov/10896115

DMB3WI8	DI	DMB3WI8
DMB3WI8	DN	2,3-dihydro-1H-benzo[de]isoquinolin-1-one
DMB3WI8	MI	TTVDSZ0
DMB3WI8	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMB3WI8	MT	DTT
DMB3WI8	MA	Inhibitor
DMB3WI8	RN	Discovery and SAR of novel, potent and selective hexahydrobenzonaphthyridinone inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1). Bioorg Med Chem Lett. 2010 Jan 15;20(2):448-52.
DMB3WI8	RU	https://pubmed.ncbi.nlm.nih.gov/20015648

DM46MKY	DI	DM46MKY
DM46MKY	DN	2,3-dihydro-1H-indene-5-sulfonamide
DM46MKY	MI	TTUNARX
DM46MKY	MN	Carbonic anhydrase (CA)
DM46MKY	MT	DTT
DM46MKY	MA	Inhibitor
DM46MKY	RN	Indanesulfonamides as carbonic anhydrase inhibitors and anticonvulsant agents: structure-activity relationship and pharmacological evaluation. Eur J Med Chem. 2008 Dec;43(12):2853-60.
DM46MKY	RU	https://pubmed.ncbi.nlm.nih.gov/18406497

DM46MKY	DI	DM46MKY
DM46MKY	DN	2,3-dihydro-1H-indene-5-sulfonamide
DM46MKY	MI	TTHQPL7
DM46MKY	MN	Carbonic anhydrase I (CA-I)
DM46MKY	MT	DTT
DM46MKY	MA	Inhibitor
DM46MKY	RN	Carbonic anhydrase inhibitors. Design of anticonvulsant sulfonamides incorporating indane moieties. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5781-6.
DM46MKY	RU	https://pubmed.ncbi.nlm.nih.gov/15501040

DM46MKY	DI	DM46MKY
DM46MKY	DN	2,3-dihydro-1H-indene-5-sulfonamide
DM46MKY	MI	TTANPDJ
DM46MKY	MN	Carbonic anhydrase II (CA-II)
DM46MKY	MT	DTT
DM46MKY	MA	Inhibitor
DM46MKY	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM46MKY	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM46MKY	DI	DM46MKY
DM46MKY	DN	2,3-dihydro-1H-indene-5-sulfonamide
DM46MKY	MI	TTSYM0R
DM46MKY	MN	Carbonic anhydrase XII (CA-XII)
DM46MKY	MT	DTT
DM46MKY	MA	Inhibitor
DM46MKY	RN	Indanesulfonamides as carbonic anhydrase inhibitors and anticonvulsant agents: structure-activity relationship and pharmacological evaluation. Eur J Med Chem. 2008 Dec;43(12):2853-60.
DM46MKY	RU	https://pubmed.ncbi.nlm.nih.gov/18406497

DM46MKY	DI	DM46MKY
DM46MKY	DN	2,3-dihydro-1H-indene-5-sulfonamide
DM46MKY	MI	TTEYTKG
DM46MKY	MN	Carbonic anhydrase XIV (CA-XIV)
DM46MKY	MT	DTT
DM46MKY	MA	Inhibitor
DM46MKY	RN	Indanesulfonamides as carbonic anhydrase inhibitors and anticonvulsant agents: structure-activity relationship and pharmacological evaluation. Eur J Med Chem. 2008 Dec;43(12):2853-60.
DM46MKY	RU	https://pubmed.ncbi.nlm.nih.gov/18406497

DM3URJG	DI	DM3URJG
DM3URJG	DN	2,3-Dihydro-1H-indol-5-ol
DM3URJG	MI	TTEX248
DM3URJG	MN	Dopamine D2 receptor (D2R)
DM3URJG	MT	DTT
DM3URJG	MA	Inhibitor
DM3URJG	RN	D4 dopamine receptor-selective compounds from the Chinese plant Phoebe chekiangensis, Bioorg. Med. Chem. Lett. 7(9):1207-1212 (1997).
DM3URJG	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97001947

DMWI9XS	DI	DMWI9XS
DMWI9XS	DN	2,3-Dihydro-1H-isoindole
DMWI9XS	MI	TTWG9A4
DMWI9XS	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMWI9XS	MT	DTT
DMWI9XS	MA	Inhibitor
DMWI9XS	RN	Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46.
DMWI9XS	RU	https://pubmed.ncbi.nlm.nih.gov/8784452

DMWI9XS	DI	DMWI9XS
DMWI9XS	DN	2,3-Dihydro-1H-isoindole
DMWI9XS	MI	TTWM4TY
DMWI9XS	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMWI9XS	MT	DTT
DMWI9XS	MA	Inhibitor
DMWI9XS	RN	Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46.
DMWI9XS	RU	https://pubmed.ncbi.nlm.nih.gov/8784452

DMWI9XS	DI	DMWI9XS
DMWI9XS	DN	2,3-Dihydro-1H-isoindole
DMWI9XS	MI	TT2NUT5
DMWI9XS	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMWI9XS	MT	DTT
DMWI9XS	MA	Inhibitor
DMWI9XS	RN	Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46.
DMWI9XS	RU	https://pubmed.ncbi.nlm.nih.gov/8784452

DMUW94S	DI	DMUW94S
DMUW94S	DN	2,3-dihydrobenzo[d]thiazole-2-thiol
DMUW94S	MI	TTZJYKH
DMUW94S	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMUW94S	MT	DTT
DMUW94S	MA	Inhibitor
DMUW94S	RN	Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2010 Feb 11;53(3):1172-89.
DMUW94S	RU	https://pubmed.ncbi.nlm.nih.gov/20055453

DMYHFUO	DI	DMYHFUO
DMYHFUO	DN	2,3-dihydropyrrolo[2,1-b]quinazolin-9(1H)-imine
DMYHFUO	MI	TT1RS9F
DMYHFUO	MN	Acetylcholinesterase (AChE)
DMYHFUO	MT	DTT
DMYHFUO	MA	Inhibitor
DMYHFUO	RN	Homobivalent quinazolinimines as novel nanomolar inhibitors of cholinesterases with dirigible selectivity toward butyrylcholinesterase. J Med Chem. 2006 Sep 7;49(18):5411-3.
DMYHFUO	RU	https://pubmed.ncbi.nlm.nih.gov/16942014

DMYHFUO	DI	DMYHFUO
DMYHFUO	DN	2,3-dihydropyrrolo[2,1-b]quinazolin-9(1H)-imine
DMYHFUO	MI	TTEB0GD
DMYHFUO	MN	Cholinesterase (BCHE)
DMYHFUO	MT	DTT
DMYHFUO	MA	Inhibitor
DMYHFUO	RN	Homobivalent quinazolinimines as novel nanomolar inhibitors of cholinesterases with dirigible selectivity toward butyrylcholinesterase. J Med Chem. 2006 Sep 7;49(18):5411-3.
DMYHFUO	RU	https://pubmed.ncbi.nlm.nih.gov/16942014

DMOWNB4	DI	DMOWNB4
DMOWNB4	DN	2,3-dihydroxypropanal
DMOWNB4	MI	DED2FW3
DMOWNB4	MN	Aldo-keto reductase 1A1 (AKR1A1)
DMOWNB4	MT	DME
DMOWNB4	MA	Metabolism
DMOWNB4	RN	The C-terminal loop of aldehyde reductase determines the substrate and inhibitor specificity. Biochemistry. 1996 Nov 12;35(45):14276-80.
DMOWNB4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8916913

DMOWNB4	DI	DMOWNB4
DMOWNB4	DN	2,3-dihydroxypropanal
DMOWNB4	MI	TTFBNVI
DMOWNB4	MN	Aldose reductase (AKR1B1)
DMOWNB4	MT	DTT
DMOWNB4	MA	Inhibitor
DMOWNB4	RN	Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10. Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20764-9.
DMOWNB4	RU	https://pubmed.ncbi.nlm.nih.gov/18087047

DML92OK	DI	DML92OK
DML92OK	DN	2,3-dimethoxy-2'-hydroxychalcone
DML92OK	MI	TTVKILB
DML92OK	MN	Prostaglandin G/H synthase 2 (COX-2)
DML92OK	MT	DTT
DML92OK	MA	Inhibitor
DML92OK	RN	Inhibitory activity of prostaglandin E2 production by the synthetic 2'-hydroxychalcone analogues: Synthesis and SAR study. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1650-3.
DML92OK	RU	https://pubmed.ncbi.nlm.nih.gov/19233646

DM9C0YZ	DI	DM9C0YZ
DM9C0YZ	DN	2,3-Dimethoxy-4'-amino-trans-stilbene
DM9C0YZ	MI	TTSZLWK
DM9C0YZ	MN	Aromatase (CYP19A1)
DM9C0YZ	MT	DTT
DM9C0YZ	MA	Inhibitor
DM9C0YZ	RN	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
DM9C0YZ	RU	https://pubmed.ncbi.nlm.nih.gov/20558073

DMEB47J	DI	DMEB47J
DMEB47J	DN	2,3-Dimethoxybenzo[i]phenanthridines
DMEB47J	MI	TTGTQHC
DMEB47J	MN	DNA topoisomerase I (TOP1)
DMEB47J	MT	DTT
DMEB47J	MA	Activator
DMEB47J	RN	2,3-Dimethoxybenzo[i]phenanthridines: topoisomerase I-targeting anticancer agents. Bioorg Med Chem. 2003 Feb 20;11(4):521-8.
DMEB47J	RU	https://pubmed.ncbi.nlm.nih.gov/12538017

DMGXVBA	DI	DMGXVBA
DMGXVBA	DN	2,3-DIMETHYL-1,4-NAPHTHOQUINONE
DMGXVBA	MI	TTHDSE2
DMGXVBA	MN	Bacterial Fumarate reductase flavoprotein (Bact frdA)
DMGXVBA	MT	DTT
DMGXVBA	MA	Inhibitor
DMGXVBA	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMGXVBA	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMKV9EZ	DI	DMKV9EZ
DMKV9EZ	DN	2,3-Dimethylnaphtho[2,3-f]quinoxaline-7,12-dione
DMKV9EZ	MI	TTQY2EJ
DMKV9EZ	MN	TERT messenger RNA (TERT mRNA)
DMKV9EZ	MT	DTT
DMKV9EZ	MA	Inhibitor
DMKV9EZ	RN	Synthesis, cytotoxicity and human telomerase inhibition activities of a series of 1,2-heteroannelated anthraquinones and anthra[1,2-d]imidazole-6,1... Bioorg Med Chem. 2009 Nov 1;17(21):7418-28.
DMKV9EZ	RU	https://pubmed.ncbi.nlm.nih.gov/19804981

DM8C43L	DI	DM8C43L
DM8C43L	DN	2,3-dioxoindoline-7-carboxylic acid
DM8C43L	MI	TTGX0HR
DM8C43L	MN	Bacterial DNA ligase (Bact ligA)
DM8C43L	MT	DTT
DM8C43L	MA	Inhibitor
DM8C43L	RN	Identification and validation of human DNA ligase inhibitors using computer-aided drug design. J Med Chem. 2008 Aug 14;51(15):4553-62.
DM8C43L	RU	https://pubmed.ncbi.nlm.nih.gov/18630893

DMC3UYH	DI	DMC3UYH
DMC3UYH	DN	2,3-diphenyl-1H-indole
DMC3UYH	MI	TTZAYWL
DMC3UYH	MN	Estrogen receptor (ESR)
DMC3UYH	MT	DTT
DMC3UYH	MA	Inhibitor
DMC3UYH	RN	Estrogen receptor beta selective ligands: discovery and SAR of novel heterocyclic ligands. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5562-6.
DMC3UYH	RU	https://pubmed.ncbi.nlm.nih.gov/16219463

DMC3UYH	DI	DMC3UYH
DMC3UYH	DN	2,3-diphenyl-1H-indole
DMC3UYH	MI	TTOM3J0
DMC3UYH	MN	Estrogen receptor beta (ESR2)
DMC3UYH	MT	DTT
DMC3UYH	MA	Inhibitor
DMC3UYH	RN	Estrogen receptor beta selective ligands: discovery and SAR of novel heterocyclic ligands. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5562-6.
DMC3UYH	RU	https://pubmed.ncbi.nlm.nih.gov/16219463

DMI2PY7	DI	DMI2PY7
DMI2PY7	DN	2,4,3',5'-tetrahydroxybibenzyl
DMI2PY7	MI	TTULVH8
DMI2PY7	MN	Tyrosinase (TYR)
DMI2PY7	MT	DTT
DMI2PY7	MA	Inhibitor
DMI2PY7	RN	Chemical transformations of oxyresveratrol (trans-2,4,3',5'-tetrahydroxystilbene) into a potent tyrosinase inhibitor and a strong cytotoxic agent. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5650-3.
DMI2PY7	RU	https://pubmed.ncbi.nlm.nih.gov/16919455

DMS8I1E	DI	DMS8I1E
DMS8I1E	DN	2,4,4-triphenylimidazoline
DMS8I1E	MI	TTY6EWA
DMS8I1E	MN	Neuropeptide Y receptor type 5 (NPY5R)
DMS8I1E	MT	DTT
DMS8I1E	MA	Inhibitor
DMS8I1E	RN	Discovery of substituted 2,4,4-triarylimidazoline derivatives as potent and selective neuropeptide Y Y5 receptor antagonists. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1670-4.
DMS8I1E	RU	https://pubmed.ncbi.nlm.nih.gov/19233647

DMSJBEH	DI	DMSJBEH
DMSJBEH	DN	2,4,5-Triarylimidazole analogue
DMSJBEH	MI	TTSJ6Q4
DMSJBEH	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DMSJBEH	MT	DTT
DMSJBEH	MA	Inhibitor
DMSJBEH	RN	2,4,5- triarylimidazole inhibitors of IL-1 biosynthesis, Bioorg. Med. Chem. Lett. 5(11):1171-1176 (1995).
DMSJBEH	RU	http://www.sciencedirect.com/science/article/pii/0960894X9500189Z

DMTA152	DI	DMTA152
DMTA152	DN	2,4,6 trinitrobenzene sulfonate 1,3-bis (2-chlorethyl)-1-nitrosourea
DMTA152	MI	TTEP6RV
DMTA152	MN	Glutathione reductase (GR)
DMTA152	MT	DTT
DMTA152	MA	Inhibitor
DMTA152	RN	The purification and properties of glutathione reductase from the cestode Moniezia expansa. Int J Biochem Cell Biol. 1995 Apr;27(4):393-401.
DMTA152	RU	https://pubmed.ncbi.nlm.nih.gov/7788561

DMTVL9N	DI	DMTVL9N
DMTVL9N	DN	2,4,6-Trihydroxy-3-nitro-N-tridecyl-benzamide
DMTVL9N	MI	TTWXB3E
DMTVL9N	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DMTVL9N	MT	DTT
DMTVL9N	MA	Inhibitor
DMTVL9N	RN	Control of hepatitis C: a medicinal chemistry perspective. J Med Chem. 2005 Jan 13;48(1):1-20.
DMTVL9N	RU	https://pubmed.ncbi.nlm.nih.gov/15633995

DM90TSI	DI	DM90TSI
DM90TSI	DN	2,4-bis-docosanoylamino-benzenesulfonate
DM90TSI	MI	TT2TDH9
DM90TSI	MN	Scavenger receptor A1 (MSR1)
DM90TSI	MT	DTT
DM90TSI	MA	Inhibitor
DM90TSI	RN	2,4-Bis(octadecanoylamino)benzenesulfonic acid sodium salt as a novel scavenger receptor inhibitor with low molecular weight. Bioorg Med Chem Lett. 2004 Jun 7;14(11):2791-5.
DM90TSI	RU	https://pubmed.ncbi.nlm.nih.gov/15125934

DMZO0EI	DI	DMZO0EI
DMZO0EI	DN	2,4-Deoxy-4-Guanidino-5-N-Acetyl-Neuraminic Acid
DMZO0EI	MI	TT50QJ3
DMZO0EI	MN	Influenza Neuraminidase (Influ NA)
DMZO0EI	MT	DTT
DMZO0EI	MA	Inhibitor
DMZO0EI	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMZO0EI	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMVPWML	DI	DMVPWML
DMVPWML	DN	2,4'-Diacetoxy-5,3'-di-(2-propenyl)-biphenyl
DMVPWML	MI	TTSJ6Q4
DMVPWML	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DMVPWML	MT	DTT
DMVPWML	MA	Inhibitor
DMVPWML	RN	Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxyge... Bioorg Med Chem. 2009 Jul 1;17(13):4459-65.
DMVPWML	RU	https://pubmed.ncbi.nlm.nih.gov/19481465

DMQPKWM	DI	DMQPKWM
DMQPKWM	DN	2,4-Diamino-6-Phenyl-5,6,7,8,-Tetrahydropteridine
DMQPKWM	MI	TTCM4B3
DMQPKWM	MN	Nitric-oxide synthase endothelial (NOS3)
DMQPKWM	MT	DTT
DMQPKWM	MA	Inhibitor
DMQPKWM	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMQPKWM	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMAOGBP	DI	DMAOGBP
DMAOGBP	DN	2,4-Diamino-butyric acid(GABA)
DMAOGBP	MI	TTPRKM0
DMAOGBP	MN	GABA transporter GAT-1 (SLC6A1)
DMAOGBP	MT	DTT
DMAOGBP	MA	Inhibitor
DMAOGBP	RN	Glycine antagonists. Synthesis, structure, and biological effects of some bicyclic 5-isoxazolol zwitterions. J Med Chem. 1986 Feb;29(2):224-9.
DMAOGBP	RU	https://pubmed.ncbi.nlm.nih.gov/3005567

DMAOGBP	DI	DMAOGBP
DMAOGBP	DN	2,4-Diamino-butyric acid(GABA)
DMAOGBP	MI	TT8RXO5
DMAOGBP	MN	GABA transporter-3 (SLC6A11)
DMAOGBP	MT	DTT
DMAOGBP	MA	Inhibitor
DMAOGBP	RN	Glycine antagonists. Synthesis, structure, and biological effects of some bicyclic 5-isoxazolol zwitterions. J Med Chem. 1986 Feb;29(2):224-9.
DMAOGBP	RU	https://pubmed.ncbi.nlm.nih.gov/3005567

DMAOGBP	DI	DMAOGBP
DMAOGBP	DN	2,4-Diamino-butyric acid(GABA)
DMAOGBP	MI	TTNJYV2
DMAOGBP	MN	Gamma-aminobutyric acid receptor (GAR)
DMAOGBP	MT	DTT
DMAOGBP	MA	Inhibitor
DMAOGBP	RN	Glycine antagonists. Synthesis, structure, and biological effects of some bicyclic 5-isoxazolol zwitterions. J Med Chem. 1986 Feb;29(2):224-9.
DMAOGBP	RU	https://pubmed.ncbi.nlm.nih.gov/3005567

DMS1YXL	DI	DMS1YXL
DMS1YXL	DN	2,4-diaminoquinozalines and quinoxaline-2,3-diones
DMS1YXL	MI	TTNSXG2
DMS1YXL	MN	Human immunodeficiency virus TAR RNA (HIV TAR-RNA)
DMS1YXL	MT	DTT
DMS1YXL	MA	Inhibitor
DMS1YXL	RN	RNA as a target for small molecules. Curr Opin Chem Biol. 2000 Dec;4(6):678-86.
DMS1YXL	RU	https://pubmed.ncbi.nlm.nih.gov/11102874

DMQ385U	DI	DMQ385U
DMQ385U	DN	2,4-Dibenzylamino-6-isopentylpyrimidine
DMQ385U	MI	TTZAYWL
DMQ385U	MN	Estrogen receptor (ESR)
DMQ385U	MT	DTT
DMQ385U	MA	Inhibitor
DMQ385U	RN	Blocking estrogen signaling after the hormone: pyrimidine-core inhibitors of estrogen receptor-coactivator binding. J Med Chem. 2008 Oct 23;51(20):6512-30.
DMQ385U	RU	https://pubmed.ncbi.nlm.nih.gov/18785725

DM4EY5S	DI	DM4EY5S
DM4EY5S	DN	2,4-dichloro-5-sulfamoylbenzoic acid
DM4EY5S	MI	TTHQPL7
DM4EY5S	MN	Carbonic anhydrase I (CA-I)
DM4EY5S	MT	DTT
DM4EY5S	MA	Inhibitor
DM4EY5S	RN	Synthesis, characterization and antiglaucoma activity of a novel proton transfer compound and a mixed-ligand Zn(II) complex. Bioorg Med Chem. 2010 Jan 15;18(2):930-8.
DM4EY5S	RU	https://pubmed.ncbi.nlm.nih.gov/20006931

DM4EY5S	DI	DM4EY5S
DM4EY5S	DN	2,4-dichloro-5-sulfamoylbenzoic acid
DM4EY5S	MI	TTANPDJ
DM4EY5S	MN	Carbonic anhydrase II (CA-II)
DM4EY5S	MT	DTT
DM4EY5S	MA	Inhibitor
DM4EY5S	RN	Synthesis, characterization and antiglaucoma activity of a novel proton transfer compound and a mixed-ligand Zn(II) complex. Bioorg Med Chem. 2010 Jan 15;18(2):930-8.
DM4EY5S	RU	https://pubmed.ncbi.nlm.nih.gov/20006931

DMR5DYK	DI	DMR5DYK
DMR5DYK	DN	2,4-Dichlorobenzenemethanethiol
DMR5DYK	MI	TTZJYKH
DMR5DYK	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMR5DYK	MT	DTT
DMR5DYK	MA	Inhibitor
DMR5DYK	RN	S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9.
DMR5DYK	RU	https://pubmed.ncbi.nlm.nih.gov/20688518

DMO4FSH	DI	DMO4FSH
DMO4FSH	DN	2,4-Dichloro-N-(4-phenyl-thiazol-2-yl)-benzamide
DMO4FSH	MI	TTK25J1
DMO4FSH	MN	Adenosine A1 receptor (ADORA1)
DMO4FSH	MT	DTT
DMO4FSH	MA	Inhibitor
DMO4FSH	RN	Substituted 4-phenyl-2-(phenylcarboxamido)-1,3-thiazole derivatives as antagonists for the adenosine A(1) receptor. Bioorg Med Chem Lett. 2001 Aug 6;11(15):2017-9.
DMO4FSH	RU	https://pubmed.ncbi.nlm.nih.gov/11454470

DM4QDZV	DI	DM4QDZV
DM4QDZV	DN	2',4'-dicyanobiphenyl-4-yl sulfamate
DM4QDZV	MI	TTHM0R1
DM4QDZV	MN	Steryl-sulfatase (STS)
DM4QDZV	MT	DTT
DM4QDZV	MA	Inhibitor
DM4QDZV	RN	Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template. J Med Chem. 2010 Mar 11;53(5):2155-70.
DM4QDZV	RU	https://pubmed.ncbi.nlm.nih.gov/20148564

DM75TJ1	DI	DM75TJ1
DM75TJ1	DN	2,4-difluorophenyl 4-butoxybenzylcarbamate
DM75TJ1	MI	TTDP1UC
DM75TJ1	MN	Fatty acid amide hydrolase (FAAH)
DM75TJ1	MT	DTT
DM75TJ1	MA	Inhibitor
DM75TJ1	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DM75TJ1	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DM0URFY	DI	DM0URFY
DM0URFY	DN	2,4-diisobutylamino-6-isopentylpyrimidine
DM0URFY	MI	TTZAYWL
DM0URFY	MN	Estrogen receptor (ESR)
DM0URFY	MT	DTT
DM0URFY	MA	Inhibitor
DM0URFY	RN	Blocking estrogen signaling after the hormone: pyrimidine-core inhibitors of estrogen receptor-coactivator binding. J Med Chem. 2008 Oct 23;51(20):6512-30.
DM0URFY	RU	https://pubmed.ncbi.nlm.nih.gov/18785725

DMP9BZU	DI	DMP9BZU
DMP9BZU	DN	2,4-dimethoxy-2'-hydroxychalcone
DMP9BZU	MI	TTVKILB
DMP9BZU	MN	Prostaglandin G/H synthase 2 (COX-2)
DMP9BZU	MT	DTT
DMP9BZU	MA	Inhibitor
DMP9BZU	RN	Inhibitory activity of prostaglandin E2 production by the synthetic 2'-hydroxychalcone analogues: Synthesis and SAR study. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1650-3.
DMP9BZU	RU	https://pubmed.ncbi.nlm.nih.gov/19233646

DMHSLXI	DI	DMHSLXI
DMHSLXI	DN	2,4-Dimethoxy-3'-amino-trans-stilbene
DMHSLXI	MI	TTSZLWK
DMHSLXI	MN	Aromatase (CYP19A1)
DMHSLXI	MT	DTT
DMHSLXI	MA	Inhibitor
DMHSLXI	RN	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
DMHSLXI	RU	https://pubmed.ncbi.nlm.nih.gov/20558073

DMMZ643	DI	DMMZ643
DMMZ643	DN	2,4-Dimethoxy-4'-amino-trans-stilbene
DMMZ643	MI	TTSZLWK
DMMZ643	MN	Aromatase (CYP19A1)
DMMZ643	MT	DTT
DMMZ643	MA	Inhibitor
DMMZ643	RN	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
DMMZ643	RU	https://pubmed.ncbi.nlm.nih.gov/20558073

DMWNJ84	DI	DMWNJ84
DMWNJ84	DN	2,4'-Dimethoxy-5,3'-di-(2-propenyl)-biphenyl
DMWNJ84	MI	TTSJ6Q4
DMWNJ84	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DMWNJ84	MT	DTT
DMWNJ84	MA	Inhibitor
DMWNJ84	RN	Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxyge... Bioorg Med Chem. 2009 Jul 1;17(13):4459-65.
DMWNJ84	RU	https://pubmed.ncbi.nlm.nih.gov/19481465

DMWNJ84	DI	DMWNJ84
DMWNJ84	DN	2,4'-Dimethoxy-5,3'-di-(2-propenyl)-biphenyl
DMWNJ84	MI	TT8NGED
DMWNJ84	MN	Prostaglandin G/H synthase 1 (COX-1)
DMWNJ84	MT	DTT
DMWNJ84	MA	Inhibitor
DMWNJ84	RN	Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxyge... Bioorg Med Chem. 2009 Jul 1;17(13):4459-65.
DMWNJ84	RU	https://pubmed.ncbi.nlm.nih.gov/19481465

DMWNJ84	DI	DMWNJ84
DMWNJ84	DN	2,4'-Dimethoxy-5,3'-di-(2-propenyl)-biphenyl
DMWNJ84	MI	TTVKILB
DMWNJ84	MN	Prostaglandin G/H synthase 2 (COX-2)
DMWNJ84	MT	DTT
DMWNJ84	MA	Inhibitor
DMWNJ84	RN	Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxyge... Bioorg Med Chem. 2009 Jul 1;17(13):4459-65.
DMWNJ84	RU	https://pubmed.ncbi.nlm.nih.gov/19481465

DM94NM7	DI	DM94NM7
DM94NM7	DN	2,4'-Dimethoxy-5,3'-dipropyl-biphenyl
DM94NM7	MI	TTVKILB
DM94NM7	MN	Prostaglandin G/H synthase 2 (COX-2)
DM94NM7	MT	DTT
DM94NM7	MA	Inhibitor
DM94NM7	RN	Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxyge... Bioorg Med Chem. 2009 Jul 1;17(13):4459-65.
DM94NM7	RU	https://pubmed.ncbi.nlm.nih.gov/19481465

DM2AW0Z	DI	DM2AW0Z
DM2AW0Z	DN	2,4-Disulfamyltrifluoromethylaniline
DM2AW0Z	MI	TTUNARX
DM2AW0Z	MN	Carbonic anhydrase (CA)
DM2AW0Z	MT	DTT
DM2AW0Z	MA	Inhibitor
DM2AW0Z	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DM2AW0Z	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DM2AW0Z	DI	DM2AW0Z
DM2AW0Z	DN	2,4-Disulfamyltrifluoromethylaniline
DM2AW0Z	MI	TTHQPL7
DM2AW0Z	MN	Carbonic anhydrase I (CA-I)
DM2AW0Z	MT	DTT
DM2AW0Z	MA	Inhibitor
DM2AW0Z	RN	Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorg Med Chem. 2009 Jul 15;17(14):5054-8.
DM2AW0Z	RU	https://pubmed.ncbi.nlm.nih.gov/19520577

DM2AW0Z	DI	DM2AW0Z
DM2AW0Z	DN	2,4-Disulfamyltrifluoromethylaniline
DM2AW0Z	MI	TTANPDJ
DM2AW0Z	MN	Carbonic anhydrase II (CA-II)
DM2AW0Z	MT	DTT
DM2AW0Z	MA	Inhibitor
DM2AW0Z	RN	Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, ... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6649-54.
DM2AW0Z	RU	https://pubmed.ncbi.nlm.nih.gov/19846301

DM2AW0Z	DI	DM2AW0Z
DM2AW0Z	DN	2,4-Disulfamyltrifluoromethylaniline
DM2AW0Z	MI	TTZHA0O
DM2AW0Z	MN	Carbonic anhydrase IV (CA-IV)
DM2AW0Z	MT	DTT
DM2AW0Z	MA	Inhibitor
DM2AW0Z	RN	Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1149-54.
DM2AW0Z	RU	https://pubmed.ncbi.nlm.nih.gov/15686931

DM2AW0Z	DI	DM2AW0Z
DM2AW0Z	DN	2,4-Disulfamyltrifluoromethylaniline
DM2AW0Z	MI	TT2LVK8
DM2AW0Z	MN	Carbonic anhydrase IX (CA-IX)
DM2AW0Z	MT	DTT
DM2AW0Z	MA	Inhibitor
DM2AW0Z	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DM2AW0Z	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DM2AW0Z	DI	DM2AW0Z
DM2AW0Z	DN	2,4-Disulfamyltrifluoromethylaniline
DM2AW0Z	MI	TTCFSPE
DM2AW0Z	MN	Carbonic anhydrase VI (CA-VI)
DM2AW0Z	MT	DTT
DM2AW0Z	MA	Inhibitor
DM2AW0Z	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DM2AW0Z	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DM2AW0Z	DI	DM2AW0Z
DM2AW0Z	DN	2,4-Disulfamyltrifluoromethylaniline
DM2AW0Z	MI	TTSYM0R
DM2AW0Z	MN	Carbonic anhydrase XII (CA-XII)
DM2AW0Z	MT	DTT
DM2AW0Z	MA	Inhibitor
DM2AW0Z	RN	Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglauc... Bioorg Med Chem Lett. 2005 Feb 15;15(4):963-9.
DM2AW0Z	RU	https://pubmed.ncbi.nlm.nih.gov/15686894

DM2AW0Z	DI	DM2AW0Z
DM2AW0Z	DN	2,4-Disulfamyltrifluoromethylaniline
DM2AW0Z	MI	TTEYTKG
DM2AW0Z	MN	Carbonic anhydrase XIV (CA-XIV)
DM2AW0Z	MT	DTT
DM2AW0Z	MA	Inhibitor
DM2AW0Z	RN	Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33.
DM2AW0Z	RU	https://pubmed.ncbi.nlm.nih.gov/16039848

DMZRY0Q	DI	DMZRY0Q
DMZRY0Q	DN	2,4-epi-neodysiherbaine
DMZRY0Q	MI	TT0MYE2
DMZRY0Q	MN	Glutamate receptor ionotropic kainate 1 (GRIK1)
DMZRY0Q	MT	DTT
DMZRY0Q	MA	Antagonist
DMZRY0Q	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 450).
DMZRY0Q	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=450

DMZRY0Q	DI	DMZRY0Q
DMZRY0Q	DN	2,4-epi-neodysiherbaine
DMZRY0Q	MI	TT0K5RG
DMZRY0Q	MN	Glutamate receptor ionotropic kainate 2 (GRIK2)
DMZRY0Q	MT	DTT
DMZRY0Q	MA	Antagonist
DMZRY0Q	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 451).
DMZRY0Q	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=451

DMLDHMB	DI	DMLDHMB
DMLDHMB	DN	2,5-Anhydroglucitol-1,6-Biphosphate
DMLDHMB	MI	TTWHDVK
DMLDHMB	MN	Fructose-1,6-bisphosphatase (FBP)
DMLDHMB	MT	DTT
DMLDHMB	MA	Inhibitor
DMLDHMB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMLDHMB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMU5GKN	DI	DMU5GKN
DMU5GKN	DN	2,5-bis(2-methoxyphenyl)thiophene
DMU5GKN	MI	TTE4KHA
DMU5GKN	MN	Amyloid beta A4 protein (APP)
DMU5GKN	MT	DTT
DMU5GKN	MA	Inhibitor
DMU5GKN	RN	Design, synthesis, and structure-activity relationship of novel thiophene derivatives for beta-amyloid plaque imaging. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1350-2.
DMU5GKN	RU	https://pubmed.ncbi.nlm.nih.gov/16325402

DMH6RDL	DI	DMH6RDL
DMH6RDL	DN	2,5-Bis-(3,4-dimethoxy-phenyl)-furan
DMH6RDL	MI	TTZ97H5
DMH6RDL	MN	Phosphodiesterase 4A (PDE4A)
DMH6RDL	MT	DTT
DMH6RDL	MA	Inhibitor
DMH6RDL	RN	Substituted furans as inhibitors of the PDE4 enzyme. Bioorg Med Chem Lett. 1999 Feb 8;9(3):323-6.
DMH6RDL	RU	https://pubmed.ncbi.nlm.nih.gov/10091677

DM28GQS	DI	DM28GQS
DM28GQS	DN	2,5-Bis-(3-cyclopentyloxy-4-methoxy-phenyl)-furan
DM28GQS	MI	TTZ97H5
DM28GQS	MN	Phosphodiesterase 4A (PDE4A)
DM28GQS	MT	DTT
DM28GQS	MA	Inhibitor
DM28GQS	RN	Substituted furans as inhibitors of the PDE4 enzyme. Bioorg Med Chem Lett. 1999 Feb 8;9(3):323-6.
DM28GQS	RU	https://pubmed.ncbi.nlm.nih.gov/10091677

DMOQPHK	DI	DMOQPHK
DMOQPHK	DN	2,5-bis(4-hydroxybenzylidene)cyclopentanone
DMOQPHK	MI	TTXV4FI
DMOQPHK	MN	Albendazole monooxygenase (CYP3A4)
DMOQPHK	MT	DTT
DMOQPHK	MA	Inhibitor
DMOQPHK	RN	Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues. Eur J Med Chem. 2008 Aug;43(8):1621-31.
DMOQPHK	RU	https://pubmed.ncbi.nlm.nih.gov/18249473

DMNQIGZ	DI	DMNQIGZ
DMNQIGZ	DN	2,5-bis(4-Hydroxyphenyl)thiophene
DMNQIGZ	MI	TTE4KHA
DMNQIGZ	MN	Amyloid beta A4 protein (APP)
DMNQIGZ	MT	DTT
DMNQIGZ	MA	Inhibitor
DMNQIGZ	RN	Design, synthesis, and structure-activity relationship of novel thiophene derivatives for beta-amyloid plaque imaging. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1350-2.
DMNQIGZ	RU	https://pubmed.ncbi.nlm.nih.gov/16325402

DM30RNY	DI	DM30RNY
DM30RNY	DN	2,5-bis(4-methoxyphenyl)thiophene
DM30RNY	MI	TTE4KHA
DM30RNY	MN	Amyloid beta A4 protein (APP)
DM30RNY	MT	DTT
DM30RNY	MA	Inhibitor
DM30RNY	RN	Design, synthesis, and structure-activity relationship of novel thiophene derivatives for beta-amyloid plaque imaging. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1350-2.
DM30RNY	RU	https://pubmed.ncbi.nlm.nih.gov/16325402

DM3USOR	DI	DM3USOR
DM3USOR	DN	2,5-bis(4-nitrophenyl)thiophene
DM3USOR	MI	TTE4KHA
DM3USOR	MN	Amyloid beta A4 protein (APP)
DM3USOR	MT	DTT
DM3USOR	MA	Inhibitor
DM3USOR	RN	Design, synthesis, and structure-activity relationship of novel thiophene derivatives for beta-amyloid plaque imaging. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1350-2.
DM3USOR	RU	https://pubmed.ncbi.nlm.nih.gov/16325402

DMMESIU	DI	DMMESIU
DMMESIU	DN	2,5'-dichloro-5'-deoxy-N6-cyclopentyladenosine
DMMESIU	MI	TTK25J1
DMMESIU	MN	Adenosine A1 receptor (ADORA1)
DMMESIU	MT	DTT
DMMESIU	MA	Inhibitor
DMMESIU	RN	N6-Cycloalkyl- and N6-bicycloalkyl-C5'(C2')-modified adenosine derivatives as high-affinity and selective agonists at the human A1 adenosine recept... J Med Chem. 2009 Apr 23;52(8):2393-406.
DMMESIU	RU	https://pubmed.ncbi.nlm.nih.gov/19317449

DMMESIU	DI	DMMESIU
DMMESIU	DN	2,5'-dichloro-5'-deoxy-N6-cyclopentyladenosine
DMMESIU	MI	TTM2AOE
DMMESIU	MN	Adenosine A2a receptor (ADORA2A)
DMMESIU	MT	DTT
DMMESIU	MA	Inhibitor
DMMESIU	RN	N6-Cycloalkyl- and N6-bicycloalkyl-C5'(C2')-modified adenosine derivatives as high-affinity and selective agonists at the human A1 adenosine recept... J Med Chem. 2009 Apr 23;52(8):2393-406.
DMMESIU	RU	https://pubmed.ncbi.nlm.nih.gov/19317449

DMMESIU	DI	DMMESIU
DMMESIU	DN	2,5'-dichloro-5'-deoxy-N6-cyclopentyladenosine
DMMESIU	MI	TTNE7KG
DMMESIU	MN	Adenosine A2b receptor (ADORA2B)
DMMESIU	MT	DTT
DMMESIU	MA	Inhibitor
DMMESIU	RN	N6-Cycloalkyl- and N6-bicycloalkyl-C5'(C2')-modified adenosine derivatives as high-affinity and selective agonists at the human A1 adenosine recept... J Med Chem. 2009 Apr 23;52(8):2393-406.
DMMESIU	RU	https://pubmed.ncbi.nlm.nih.gov/19317449

DMMESIU	DI	DMMESIU
DMMESIU	DN	2,5'-dichloro-5'-deoxy-N6-cyclopentyladenosine
DMMESIU	MI	TTJFY5U
DMMESIU	MN	Adenosine A3 receptor (ADORA3)
DMMESIU	MT	DTT
DMMESIU	MA	Inhibitor
DMMESIU	RN	N6-Cycloalkyl- and N6-bicycloalkyl-C5'(C2')-modified adenosine derivatives as high-affinity and selective agonists at the human A1 adenosine recept... J Med Chem. 2009 Apr 23;52(8):2393-406.
DMMESIU	RU	https://pubmed.ncbi.nlm.nih.gov/19317449

DM9PK1R	DI	DM9PK1R
DM9PK1R	DN	2,5-dichloro-N-phenylthiophene-3-sulfonamide
DM9PK1R	MI	TTSFWA7
DM9PK1R	MN	Plasmodium CDK Pfmrk (Malaria Pfmrk)
DM9PK1R	MT	DTT
DM9PK1R	MA	Inhibitor
DM9PK1R	RN	Activity of substituted thiophene sulfonamides against malarial and mammalian cyclin dependent protein kinases, Bioorg. Med. Chem. Lett. 20(13):3863-3867 (2010).
DM9PK1R	RU	http://www.sciencedirect.com/science/article/pii/S0960894X10006803

DMU5J8Y	DI	DMU5J8Y
DMU5J8Y	DN	2,5-dichloro-N-p-tolylthiophene-3-sulfonamide
DMU5J8Y	MI	TTAMQ62
DMU5J8Y	MN	Cyclin A2 (CCNA2)
DMU5J8Y	MT	DTT
DMU5J8Y	MA	Inhibitor
DMU5J8Y	RN	Activity of substituted thiophene sulfonamides against malarial and mammalian cyclin dependent protein kinases, Bioorg. Med. Chem. Lett. 20(13):3863-3867 (2010).
DMU5J8Y	RU	http://www.sciencedirect.com/science/article/pii/S0960894X10006803

DMU5J8Y	DI	DMU5J8Y
DMU5J8Y	DN	2,5-dichloro-N-p-tolylthiophene-3-sulfonamide
DMU5J8Y	MI	TTQYF7G
DMU5J8Y	MN	Cyclin-dependent kinase 7 (CDK7)
DMU5J8Y	MT	DTT
DMU5J8Y	MA	Inhibitor
DMU5J8Y	RN	Activity of substituted thiophene sulfonamides against malarial and mammalian cyclin dependent protein kinases, Bioorg. Med. Chem. Lett. 20(13):3863-3867 (2010).
DMU5J8Y	RU	http://www.sciencedirect.com/science/article/pii/S0960894X10006803

DMU5J8Y	DI	DMU5J8Y
DMU5J8Y	DN	2,5-dichloro-N-p-tolylthiophene-3-sulfonamide
DMU5J8Y	MI	TTSFWA7
DMU5J8Y	MN	Plasmodium CDK Pfmrk (Malaria Pfmrk)
DMU5J8Y	MT	DTT
DMU5J8Y	MA	Inhibitor
DMU5J8Y	RN	Activity of substituted thiophene sulfonamides against malarial and mammalian cyclin dependent protein kinases, Bioorg. Med. Chem. Lett. 20(13):3863-3867 (2010).
DMU5J8Y	RU	http://www.sciencedirect.com/science/article/pii/S0960894X10006803

DMI1O54	DI	DMI1O54
DMI1O54	DN	2,5-dideoxy-2,5-imino-D-altritol
DMI1O54	MI	TTIS03D
DMI1O54	MN	Alpha-galactosidase A (GLA)
DMI1O54	MT	DTT
DMI1O54	MA	Inhibitor
DMI1O54	RN	2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease. Bioorg Med Chem. 2010 Jun 1;18(11):3790-4.
DMI1O54	RU	https://pubmed.ncbi.nlm.nih.gov/20457528

DMI1O54	DI	DMI1O54
DMI1O54	DN	2,5-dideoxy-2,5-imino-D-altritol
DMI1O54	MI	TTA0OSE
DMI1O54	MN	Lactase-phlorizin hydrolase (LCT)
DMI1O54	MT	DTT
DMI1O54	MA	Inhibitor
DMI1O54	RN	2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease. Bioorg Med Chem. 2010 Jun 1;18(11):3790-4.
DMI1O54	RU	https://pubmed.ncbi.nlm.nih.gov/20457528

DMKP7O0	DI	DMKP7O0
DMKP7O0	DN	2,5-dideoxy-2,5-imino-dl-glycero-D-manno-heptitol
DMKP7O0	MI	TTA0OSE
DMKP7O0	MN	Lactase-phlorizin hydrolase (LCT)
DMKP7O0	MT	DTT
DMKP7O0	MA	Inhibitor
DMKP7O0	RN	Nitrogen-containing furanose and pyranose analogues from Hyacinthus orientalis. J Nat Prod. 1998 May;61(5):625-8.
DMKP7O0	RU	https://pubmed.ncbi.nlm.nih.gov/9599261

DMGQVF5	DI	DMGQVF5
DMGQVF5	DN	2,5-Dideoxy-2,5-imino-D-mannitol
DMGQVF5	MI	TTXWASR
DMGQVF5	MN	Intestinal maltase-glucoamylase (MGAM)
DMGQVF5	MT	DTT
DMGQVF5	MA	Inhibitor
DMGQVF5	RN	New sugar-mimic alkaloids from the pods of Angylocalyx pynaertii. J Nat Prod. 2002 Feb;65(2):198-202.
DMGQVF5	RU	https://pubmed.ncbi.nlm.nih.gov/11858756

DM5OYWF	DI	DM5OYWF
DM5OYWF	DN	2',5'-DIDEOXY-ADENOSINE 3'-MONOPHOSPHATE
DM5OYWF	MI	TTBQ9IM
DM5OYWF	MN	Adenylate cyclase type 2 (ADCY2)
DM5OYWF	MT	DTT
DM5OYWF	MA	Inhibitor
DM5OYWF	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM5OYWF	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM5CWM0	DI	DM5CWM0
DM5CWM0	DN	2,5-didesoxy-3-ATP
DM5CWM0	MI	TT2QM9D
DM5CWM0	MN	Adenylate cyclase (ADCY)
DM5CWM0	MT	DTT
DM5CWM0	MA	Inhibitor
DM5CWM0	RN	Structure-based development of novel adenylyl cyclase inhibitors. J Med Chem. 2008 Aug 14;51(15):4456-64.
DM5CWM0	RU	https://pubmed.ncbi.nlm.nih.gov/18630896

DMIGFX6	DI	DMIGFX6
DMIGFX6	DN	2,5-difluorophenol
DMIGFX6	MI	TTUNARX
DMIGFX6	MN	Carbonic anhydrase (CA)
DMIGFX6	MT	DTT
DMIGFX6	MA	Inhibitor
DMIGFX6	RN	Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8.
DMIGFX6	RU	https://pubmed.ncbi.nlm.nih.gov/18579385

DMV0UIR	DI	DMV0UIR
DMV0UIR	DN	2,5-Dimethoxy-4'-amino-trans-stilbene
DMV0UIR	MI	TTSZLWK
DMV0UIR	MN	Aromatase (CYP19A1)
DMV0UIR	MT	DTT
DMV0UIR	MA	Inhibitor
DMV0UIR	RN	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
DMV0UIR	RU	https://pubmed.ncbi.nlm.nih.gov/20558073

DM50ZQP	DI	DM50ZQP
DM50ZQP	DN	2,5-dimethoxy-4-bromophenethylamine
DM50ZQP	MI	TTJQOD7
DM50ZQP	MN	5-HT 2A receptor (HTR2A)
DM50ZQP	MT	DTT
DM50ZQP	MA	Inhibitor
DM50ZQP	RN	1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agoni... J Med Chem. 2006 Sep 21;49(19):5794-803.
DM50ZQP	RU	https://pubmed.ncbi.nlm.nih.gov/16970404

DM5IJSW	DI	DM5IJSW
DM5IJSW	DN	2,5-imino-2,5,6-trideoxy-D-manno-heptitol
DM5IJSW	MI	TTLPC70
DM5IJSW	MN	Lysosomal alpha-glucosidase (GAA)
DM5IJSW	MT	DTT
DM5IJSW	MA	Inhibitor
DM5IJSW	RN	Nitrogen-containing furanose and pyranose analogues from Hyacinthus orientalis. J Nat Prod. 1998 May;61(5):625-8.
DM5IJSW	RU	https://pubmed.ncbi.nlm.nih.gov/9599261

DM4IFPQ	DI	DM4IFPQ
DM4IFPQ	DN	2,6,8-triphenyl-9H-purine
DM4IFPQ	MI	TTK25J1
DM4IFPQ	MN	Adenosine A1 receptor (ADORA1)
DM4IFPQ	MT	DTT
DM4IFPQ	MA	Inhibitor
DM4IFPQ	RN	2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7.
DM4IFPQ	RU	https://pubmed.ncbi.nlm.nih.gov/16686529

DM4IFPQ	DI	DM4IFPQ
DM4IFPQ	DN	2,6,8-triphenyl-9H-purine
DM4IFPQ	MI	TTM2AOE
DM4IFPQ	MN	Adenosine A2a receptor (ADORA2A)
DM4IFPQ	MT	DTT
DM4IFPQ	MA	Inhibitor
DM4IFPQ	RN	2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7.
DM4IFPQ	RU	https://pubmed.ncbi.nlm.nih.gov/16686529

DM4IFPQ	DI	DM4IFPQ
DM4IFPQ	DN	2,6,8-triphenyl-9H-purine
DM4IFPQ	MI	TTJFY5U
DM4IFPQ	MN	Adenosine A3 receptor (ADORA3)
DM4IFPQ	MT	DTT
DM4IFPQ	MA	Inhibitor
DM4IFPQ	RN	2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7.
DM4IFPQ	RU	https://pubmed.ncbi.nlm.nih.gov/16686529

DMYQNK0	DI	DMYQNK0
DMYQNK0	DN	2,6-bis(4-chlorophenyl)-9H-purine
DMYQNK0	MI	TTJFY5U
DMYQNK0	MN	Adenosine A3 receptor (ADORA3)
DMYQNK0	MT	DTT
DMYQNK0	MA	Inhibitor
DMYQNK0	RN	2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7.
DMYQNK0	RU	https://pubmed.ncbi.nlm.nih.gov/16686529

DMC2N80	DI	DMC2N80
DMC2N80	DN	2,6-bis(4-methoxyphenyl)-9H-purine
DMC2N80	MI	TTJFY5U
DMC2N80	MN	Adenosine A3 receptor (ADORA3)
DMC2N80	MT	DTT
DMC2N80	MA	Inhibitor
DMC2N80	RN	2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7.
DMC2N80	RU	https://pubmed.ncbi.nlm.nih.gov/16686529

DM41RZX	DI	DM41RZX
DM41RZX	DN	2,6-bis(4-tolyl)-9H-purine
DM41RZX	MI	TTK25J1
DM41RZX	MN	Adenosine A1 receptor (ADORA1)
DM41RZX	MT	DTT
DM41RZX	MA	Inhibitor
DM41RZX	RN	2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7.
DM41RZX	RU	https://pubmed.ncbi.nlm.nih.gov/16686529

DM41RZX	DI	DM41RZX
DM41RZX	DN	2,6-bis(4-tolyl)-9H-purine
DM41RZX	MI	TTJFY5U
DM41RZX	MN	Adenosine A3 receptor (ADORA3)
DM41RZX	MT	DTT
DM41RZX	MA	Inhibitor
DM41RZX	RN	2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7.
DM41RZX	RU	https://pubmed.ncbi.nlm.nih.gov/16686529

DMREF31	DI	DMREF31
DMREF31	DN	2,6-diamino-5-nitropyrimidin-4(3H)-one
DMREF31	MI	TT4ILYC
DMREF31	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMREF31	MT	DTT
DMREF31	MA	Inhibitor
DMREF31	RN	Structural studies of pterin-based inhibitors of dihydropteroate synthase. J Med Chem. 2010 Jan 14;53(1):166-77.
DMREF31	RU	https://pubmed.ncbi.nlm.nih.gov/19899766

DM4RS9N	DI	DM4RS9N
DM4RS9N	DN	2,6-diamino-5-nitrosopyrimidin-4(3H)-one
DM4RS9N	MI	TT4ILYC
DM4RS9N	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DM4RS9N	MT	DTT
DM4RS9N	MA	Inhibitor
DM4RS9N	RN	Structural studies of pterin-based inhibitors of dihydropteroate synthase. J Med Chem. 2010 Jan 14;53(1):166-77.
DM4RS9N	RU	https://pubmed.ncbi.nlm.nih.gov/19899766

DM8JFNU	DI	DM8JFNU
DM8JFNU	DN	2,6-DICARBOXYNAPHTHALENE
DM8JFNU	MI	TTQO71U
DM8JFNU	MN	Hemoglobin (HB)
DM8JFNU	MT	DTT
DM8JFNU	MA	Inhibitor
DM8JFNU	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM8JFNU	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMGEYAK	DI	DMGEYAK
DMGEYAK	DN	2,6-Difluorobenzenesulfonamide
DMGEYAK	MI	TTANPDJ
DMGEYAK	MN	Carbonic anhydrase II (CA-II)
DMGEYAK	MT	DTT
DMGEYAK	MA	Inhibitor
DMGEYAK	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMGEYAK	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMDN12L	DI	DMDN12L
DMDN12L	DN	2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One
DMDN12L	MI	TTP7EGM
DMDN12L	MN	Dual specificity protein kinase TTK (MPS1)
DMDN12L	MT	DTT
DMDN12L	MA	Inhibitor
DMDN12L	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMDN12L	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMDN12L	DI	DMDN12L
DMDN12L	DN	2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One
DMDN12L	MI	TTR2TXZ
DMDN12L	MN	Jun N terminal kinase (JNK)
DMDN12L	MT	DTT
DMDN12L	MA	Inhibitor
DMDN12L	RN	c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest. 2001 Jul;108(1):73-81.
DMDN12L	RU	https://pubmed.ncbi.nlm.nih.gov/11435459

DMDN12L	DI	DMDN12L
DMDN12L	DN	2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One
DMDN12L	MI	TT0K6EO
DMDN12L	MN	Stress-activated protein kinase JNK1 (JNK1)
DMDN12L	MT	DTT
DMDN12L	MA	Inhibitor
DMDN12L	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMDN12L	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMDN12L	DI	DMDN12L
DMDN12L	DN	2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One
DMDN12L	MI	TTHS0U8
DMDN12L	MN	Stress-activated protein kinase JNK2 (JNK2)
DMDN12L	MT	DTT
DMDN12L	MA	Inhibitor
DMDN12L	RN	Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
DMDN12L	RU	https://pubmed.ncbi.nlm.nih.gov/11804650

DMDN12L	DI	DMDN12L
DMDN12L	DN	2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One
DMDN12L	MI	TT056SO
DMDN12L	MN	Stress-activated protein kinase JNK3 (JNK3)
DMDN12L	MT	DTT
DMDN12L	MA	Inhibitor
DMDN12L	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMDN12L	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM5QEUC	DI	DM5QEUC
DM5QEUC	DN	2,6-dihydroxy-1,7-dimethoxyxanthone
DM5QEUC	MI	TTVKILB
DM5QEUC	MN	Prostaglandin G/H synthase 2 (COX-2)
DM5QEUC	MT	DTT
DM5QEUC	MA	Inhibitor
DM5QEUC	RN	Selective cyclooxygenase-2 inhibitors from Calophyllum membranaceum. J Nat Prod. 2005 Oct;68(10):1514-8.
DM5QEUC	RU	https://pubmed.ncbi.nlm.nih.gov/16252917

DMD51I4	DI	DMD51I4
DMD51I4	DN	2,6-Diisopropyl-4-nitro-phenol
DMD51I4	MI	TTNJYV2
DMD51I4	MN	Gamma-aminobutyric acid receptor (GAR)
DMD51I4	MT	DTT
DMD51I4	MA	Inhibitor
DMD51I4	RN	Propofol analogues. Synthesis, relationships between structure and affinity at GABAA receptor in rat brain, and differential electrophysiological p... J Med Chem. 1998 May 21;41(11):1846-54.
DMD51I4	RU	https://pubmed.ncbi.nlm.nih.gov/9599235

DMRZJU5	DI	DMRZJU5
DMRZJU5	DN	2,6-dimethyl-8-ethyl-1-deazapurine
DMRZJU5	MI	TTK25J1
DMRZJU5	MN	Adenosine A1 receptor (ADORA1)
DMRZJU5	MT	DTT
DMRZJU5	MA	Inhibitor
DMRZJU5	RN	2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34.
DMRZJU5	RU	https://pubmed.ncbi.nlm.nih.gov/17300165

DMW2VZ1	DI	DMW2VZ1
DMW2VZ1	DN	2,6-diphenyl-1-deazapurine
DMW2VZ1	MI	TTK25J1
DMW2VZ1	MN	Adenosine A1 receptor (ADORA1)
DMW2VZ1	MT	DTT
DMW2VZ1	MA	Inhibitor
DMW2VZ1	RN	2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34.
DMW2VZ1	RU	https://pubmed.ncbi.nlm.nih.gov/17300165

DMW2VZ1	DI	DMW2VZ1
DMW2VZ1	DN	2,6-diphenyl-1-deazapurine
DMW2VZ1	MI	TTM2AOE
DMW2VZ1	MN	Adenosine A2a receptor (ADORA2A)
DMW2VZ1	MT	DTT
DMW2VZ1	MA	Inhibitor
DMW2VZ1	RN	2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34.
DMW2VZ1	RU	https://pubmed.ncbi.nlm.nih.gov/17300165

DMW2VZ1	DI	DMW2VZ1
DMW2VZ1	DN	2,6-diphenyl-1-deazapurine
DMW2VZ1	MI	TTJFY5U
DMW2VZ1	MN	Adenosine A3 receptor (ADORA3)
DMW2VZ1	MT	DTT
DMW2VZ1	MA	Inhibitor
DMW2VZ1	RN	2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34.
DMW2VZ1	RU	https://pubmed.ncbi.nlm.nih.gov/17300165

DMY3C78	DI	DMY3C78
DMY3C78	DN	2,6-diphenyl-8-(1-ethylpropyl)-1-deazapurine
DMY3C78	MI	TTK25J1
DMY3C78	MN	Adenosine A1 receptor (ADORA1)
DMY3C78	MT	DTT
DMY3C78	MA	Inhibitor
DMY3C78	RN	2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34.
DMY3C78	RU	https://pubmed.ncbi.nlm.nih.gov/17300165

DMY3C78	DI	DMY3C78
DMY3C78	DN	2,6-diphenyl-8-(1-ethylpropyl)-1-deazapurine
DMY3C78	MI	TTM2AOE
DMY3C78	MN	Adenosine A2a receptor (ADORA2A)
DMY3C78	MT	DTT
DMY3C78	MA	Inhibitor
DMY3C78	RN	2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34.
DMY3C78	RU	https://pubmed.ncbi.nlm.nih.gov/17300165

DMY3C78	DI	DMY3C78
DMY3C78	DN	2,6-diphenyl-8-(1-ethylpropyl)-1-deazapurine
DMY3C78	MI	TTNE7KG
DMY3C78	MN	Adenosine A2b receptor (ADORA2B)
DMY3C78	MT	DTT
DMY3C78	MA	Inhibitor
DMY3C78	RN	2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34.
DMY3C78	RU	https://pubmed.ncbi.nlm.nih.gov/17300165

DMY3C78	DI	DMY3C78
DMY3C78	DN	2,6-diphenyl-8-(1-ethylpropyl)-1-deazapurine
DMY3C78	MI	TTJFY5U
DMY3C78	MN	Adenosine A3 receptor (ADORA3)
DMY3C78	MT	DTT
DMY3C78	MA	Inhibitor
DMY3C78	RN	2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34.
DMY3C78	RU	https://pubmed.ncbi.nlm.nih.gov/17300165

DM0C8BW	DI	DM0C8BW
DM0C8BW	DN	2,6-diphenyl-8-ethyl-1-deazapurine
DM0C8BW	MI	TTK25J1
DM0C8BW	MN	Adenosine A1 receptor (ADORA1)
DM0C8BW	MT	DTT
DM0C8BW	MA	Inhibitor
DM0C8BW	RN	2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34.
DM0C8BW	RU	https://pubmed.ncbi.nlm.nih.gov/17300165

DM0C8BW	DI	DM0C8BW
DM0C8BW	DN	2,6-diphenyl-8-ethyl-1-deazapurine
DM0C8BW	MI	TTM2AOE
DM0C8BW	MN	Adenosine A2a receptor (ADORA2A)
DM0C8BW	MT	DTT
DM0C8BW	MA	Inhibitor
DM0C8BW	RN	2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34.
DM0C8BW	RU	https://pubmed.ncbi.nlm.nih.gov/17300165

DM0C8BW	DI	DM0C8BW
DM0C8BW	DN	2,6-diphenyl-8-ethyl-1-deazapurine
DM0C8BW	MI	TTJFY5U
DM0C8BW	MN	Adenosine A3 receptor (ADORA3)
DM0C8BW	MT	DTT
DM0C8BW	MA	Inhibitor
DM0C8BW	RN	2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34.
DM0C8BW	RU	https://pubmed.ncbi.nlm.nih.gov/17300165

DMI79FV	DI	DMI79FV
DMI79FV	DN	2,6-diphenyl-8-methyl-1-deazapurine
DMI79FV	MI	TTK25J1
DMI79FV	MN	Adenosine A1 receptor (ADORA1)
DMI79FV	MT	DTT
DMI79FV	MA	Inhibitor
DMI79FV	RN	2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34.
DMI79FV	RU	https://pubmed.ncbi.nlm.nih.gov/17300165

DMI79FV	DI	DMI79FV
DMI79FV	DN	2,6-diphenyl-8-methyl-1-deazapurine
DMI79FV	MI	TTM2AOE
DMI79FV	MN	Adenosine A2a receptor (ADORA2A)
DMI79FV	MT	DTT
DMI79FV	MA	Inhibitor
DMI79FV	RN	2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34.
DMI79FV	RU	https://pubmed.ncbi.nlm.nih.gov/17300165

DMI79FV	DI	DMI79FV
DMI79FV	DN	2,6-diphenyl-8-methyl-1-deazapurine
DMI79FV	MI	TTJFY5U
DMI79FV	MN	Adenosine A3 receptor (ADORA3)
DMI79FV	MT	DTT
DMI79FV	MA	Inhibitor
DMI79FV	RN	2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34.
DMI79FV	RU	https://pubmed.ncbi.nlm.nih.gov/17300165

DM6D1BQ	DI	DM6D1BQ
DM6D1BQ	DN	2,6-diphenyl-8-tButyl-1-deazapurine
DM6D1BQ	MI	TTK25J1
DM6D1BQ	MN	Adenosine A1 receptor (ADORA1)
DM6D1BQ	MT	DTT
DM6D1BQ	MA	Inhibitor
DM6D1BQ	RN	2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34.
DM6D1BQ	RU	https://pubmed.ncbi.nlm.nih.gov/17300165

DM6D1BQ	DI	DM6D1BQ
DM6D1BQ	DN	2,6-diphenyl-8-tButyl-1-deazapurine
DM6D1BQ	MI	TTM2AOE
DM6D1BQ	MN	Adenosine A2a receptor (ADORA2A)
DM6D1BQ	MT	DTT
DM6D1BQ	MA	Inhibitor
DM6D1BQ	RN	2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34.
DM6D1BQ	RU	https://pubmed.ncbi.nlm.nih.gov/17300165

DM6D1BQ	DI	DM6D1BQ
DM6D1BQ	DN	2,6-diphenyl-8-tButyl-1-deazapurine
DM6D1BQ	MI	TTJFY5U
DM6D1BQ	MN	Adenosine A3 receptor (ADORA3)
DM6D1BQ	MT	DTT
DM6D1BQ	MA	Inhibitor
DM6D1BQ	RN	2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34.
DM6D1BQ	RU	https://pubmed.ncbi.nlm.nih.gov/17300165

DM5SXYI	DI	DM5SXYI
DM5SXYI	DN	2,6-diphenyl-9H-purine
DM5SXYI	MI	TTK25J1
DM5SXYI	MN	Adenosine A1 receptor (ADORA1)
DM5SXYI	MT	DTT
DM5SXYI	MA	Inhibitor
DM5SXYI	RN	2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7.
DM5SXYI	RU	https://pubmed.ncbi.nlm.nih.gov/16686529

DM5SXYI	DI	DM5SXYI
DM5SXYI	DN	2,6-diphenyl-9H-purine
DM5SXYI	MI	TTM2AOE
DM5SXYI	MN	Adenosine A2a receptor (ADORA2A)
DM5SXYI	MT	DTT
DM5SXYI	MA	Inhibitor
DM5SXYI	RN	2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7.
DM5SXYI	RU	https://pubmed.ncbi.nlm.nih.gov/16686529

DM5SXYI	DI	DM5SXYI
DM5SXYI	DN	2,6-diphenyl-9H-purine
DM5SXYI	MI	TTJFY5U
DM5SXYI	MN	Adenosine A3 receptor (ADORA3)
DM5SXYI	MT	DTT
DM5SXYI	MA	Inhibitor
DM5SXYI	RN	2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7.
DM5SXYI	RU	https://pubmed.ncbi.nlm.nih.gov/16686529

DM3JURW	DI	DM3JURW
DM3JURW	DN	2,6-Diphenyl-pyrimidin-4-ylamine
DM3JURW	MI	TTK25J1
DM3JURW	MN	Adenosine A1 receptor (ADORA1)
DM3JURW	MT	DTT
DM3JURW	MA	Inhibitor
DM3JURW	RN	A new generation of adenosine receptor antagonists: from di- to trisubstituted aminopyrimidines. Bioorg Med Chem. 2008 Mar 15;16(6):2741-52.
DM3JURW	RU	https://pubmed.ncbi.nlm.nih.gov/18258439

DM3JURW	DI	DM3JURW
DM3JURW	DN	2,6-Diphenyl-pyrimidin-4-ylamine
DM3JURW	MI	TTM2AOE
DM3JURW	MN	Adenosine A2a receptor (ADORA2A)
DM3JURW	MT	DTT
DM3JURW	MA	Inhibitor
DM3JURW	RN	A new generation of adenosine receptor antagonists: from di- to trisubstituted aminopyrimidines. Bioorg Med Chem. 2008 Mar 15;16(6):2741-52.
DM3JURW	RU	https://pubmed.ncbi.nlm.nih.gov/18258439

DMY8LDT	DI	DMY8LDT
DMY8LDT	DN	2,6-di-t-butylphenol
DMY8LDT	MI	TTANPDJ
DMY8LDT	MN	Carbonic anhydrase II (CA-II)
DMY8LDT	MT	DTT
DMY8LDT	MA	Inhibitor
DMY8LDT	RN	Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols. Bioorg Med Chem. 2009 Apr 15;17(8):3207-11.
DMY8LDT	RU	https://pubmed.ncbi.nlm.nih.gov/19231207

DMFO1H2	DI	DMFO1H2
DMFO1H2	DN	2,6-di-tert-butyl-4-methoxyphenol
DMFO1H2	MI	TTANPDJ
DMFO1H2	MN	Carbonic anhydrase II (CA-II)
DMFO1H2	MT	DTT
DMFO1H2	MA	Inhibitor
DMFO1H2	RN	Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols. Bioorg Med Chem. 2009 Apr 15;17(8):3207-11.
DMFO1H2	RU	https://pubmed.ncbi.nlm.nih.gov/19231207

DM8F9KO	DI	DM8F9KO
DM8F9KO	DN	2,6-dphenyl-8-propyl-1-deazapurine
DM8F9KO	MI	TTK25J1
DM8F9KO	MN	Adenosine A1 receptor (ADORA1)
DM8F9KO	MT	DTT
DM8F9KO	MA	Inhibitor
DM8F9KO	RN	2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34.
DM8F9KO	RU	https://pubmed.ncbi.nlm.nih.gov/17300165

DM8F9KO	DI	DM8F9KO
DM8F9KO	DN	2,6-dphenyl-8-propyl-1-deazapurine
DM8F9KO	MI	TTM2AOE
DM8F9KO	MN	Adenosine A2a receptor (ADORA2A)
DM8F9KO	MT	DTT
DM8F9KO	MA	Inhibitor
DM8F9KO	RN	2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34.
DM8F9KO	RU	https://pubmed.ncbi.nlm.nih.gov/17300165

DM8F9KO	DI	DM8F9KO
DM8F9KO	DN	2,6-dphenyl-8-propyl-1-deazapurine
DM8F9KO	MI	TTJFY5U
DM8F9KO	MN	Adenosine A3 receptor (ADORA3)
DM8F9KO	MT	DTT
DM8F9KO	MA	Inhibitor
DM8F9KO	RN	2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34.
DM8F9KO	RU	https://pubmed.ncbi.nlm.nih.gov/17300165

DMT9JHV	DI	DMT9JHV
DMT9JHV	DN	2,7-Bis(3-chloropropionamido)anthraquinone
DMT9JHV	MI	TTQY2EJ
DMT9JHV	MN	TERT messenger RNA (TERT mRNA)
DMT9JHV	MT	DTT
DMT9JHV	MA	Inhibitor
DMT9JHV	RN	Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86.
DMT9JHV	RU	https://pubmed.ncbi.nlm.nih.gov/18571928

DM8VWQ2	DI	DM8VWQ2
DM8VWQ2	DN	2,7-Bis(4-chlorobutyramido)anthraquinone
DM8VWQ2	MI	TTQY2EJ
DM8VWQ2	MN	TERT messenger RNA (TERT mRNA)
DM8VWQ2	MT	DTT
DM8VWQ2	MA	Inhibitor
DM8VWQ2	RN	Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86.
DM8VWQ2	RU	https://pubmed.ncbi.nlm.nih.gov/18571928

DM2EPM4	DI	DM2EPM4
DM2EPM4	DN	2,7-Bis(acetamido)anthraquinone
DM2EPM4	MI	TTQY2EJ
DM2EPM4	MN	TERT messenger RNA (TERT mRNA)
DM2EPM4	MT	DTT
DM2EPM4	MA	Inhibitor
DM2EPM4	RN	Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86.
DM2EPM4	RU	https://pubmed.ncbi.nlm.nih.gov/18571928

DMEQC4X	DI	DMEQC4X
DMEQC4X	DN	2,7-Bis(benzoamido)anthraquinone
DMEQC4X	MI	TTQY2EJ
DMEQC4X	MN	TERT messenger RNA (TERT mRNA)
DMEQC4X	MT	DTT
DMEQC4X	MA	Inhibitor
DMEQC4X	RN	Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86.
DMEQC4X	RU	https://pubmed.ncbi.nlm.nih.gov/18571928

DM9S8LY	DI	DM9S8LY
DM9S8LY	DN	2,7-Bis(butyramido)anthraquinone
DM9S8LY	MI	TTQY2EJ
DM9S8LY	MN	TERT messenger RNA (TERT mRNA)
DM9S8LY	MT	DTT
DM9S8LY	MA	Inhibitor
DM9S8LY	RN	Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86.
DM9S8LY	RU	https://pubmed.ncbi.nlm.nih.gov/18571928

DM4MYAR	DI	DM4MYAR
DM4MYAR	DN	2,7-Bis(chloroacetamido)anthraquinone
DM4MYAR	MI	TTQY2EJ
DM4MYAR	MN	TERT messenger RNA (TERT mRNA)
DM4MYAR	MT	DTT
DM4MYAR	MA	Inhibitor
DM4MYAR	RN	Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86.
DM4MYAR	RU	https://pubmed.ncbi.nlm.nih.gov/18571928

DMTPZ8D	DI	DMTPZ8D
DMTPZ8D	DN	2,7-Bis(cyclohexanecarbonamido)anthraquinone
DMTPZ8D	MI	TTQY2EJ
DMTPZ8D	MN	TERT messenger RNA (TERT mRNA)
DMTPZ8D	MT	DTT
DMTPZ8D	MA	Inhibitor
DMTPZ8D	RN	Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86.
DMTPZ8D	RU	https://pubmed.ncbi.nlm.nih.gov/18571928

DMP3EZ8	DI	DMP3EZ8
DMP3EZ8	DN	2,7-Bis(cyclopentanecarbonamido)anthraquinone
DMP3EZ8	MI	TTQY2EJ
DMP3EZ8	MN	TERT messenger RNA (TERT mRNA)
DMP3EZ8	MT	DTT
DMP3EZ8	MA	Inhibitor
DMP3EZ8	RN	Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86.
DMP3EZ8	RU	https://pubmed.ncbi.nlm.nih.gov/18571928

DMY3V2B	DI	DMY3V2B
DMY3V2B	DN	2,7-Bis(cyclopropanecarbonamido)anthraquinone
DMY3V2B	MI	TTQY2EJ
DMY3V2B	MN	TERT messenger RNA (TERT mRNA)
DMY3V2B	MT	DTT
DMY3V2B	MA	Inhibitor
DMY3V2B	RN	Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86.
DMY3V2B	RU	https://pubmed.ncbi.nlm.nih.gov/18571928

DMEVIBT	DI	DMEVIBT
DMEVIBT	DN	2,7-Bis(phenylacetamido)anthraquinone
DMEVIBT	MI	TTQY2EJ
DMEVIBT	MN	TERT messenger RNA (TERT mRNA)
DMEVIBT	MT	DTT
DMEVIBT	MA	Inhibitor
DMEVIBT	RN	Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86.
DMEVIBT	RU	https://pubmed.ncbi.nlm.nih.gov/18571928

DMDKXEY	DI	DMDKXEY
DMDKXEY	DN	2,7-Bis(phenylpropionamido)anthraquinone
DMDKXEY	MI	TTQY2EJ
DMDKXEY	MN	TERT messenger RNA (TERT mRNA)
DMDKXEY	MT	DTT
DMDKXEY	MA	Inhibitor
DMDKXEY	RN	Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86.
DMDKXEY	RU	https://pubmed.ncbi.nlm.nih.gov/18571928

DM2D1EJ	DI	DM2D1EJ
DM2D1EJ	DN	2,7-Bis(propionamido)anthraquinone
DM2D1EJ	MI	TTQY2EJ
DM2D1EJ	MN	TERT messenger RNA (TERT mRNA)
DM2D1EJ	MT	DTT
DM2D1EJ	MA	Inhibitor
DM2D1EJ	RN	Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86.
DM2D1EJ	RU	https://pubmed.ncbi.nlm.nih.gov/18571928

DM3GTV0	DI	DM3GTV0
DM3GTV0	DN	2,7-Bis[2-(butylamino)acetamido]anthraquinone
DM3GTV0	MI	TTQY2EJ
DM3GTV0	MN	TERT messenger RNA (TERT mRNA)
DM3GTV0	MT	DTT
DM3GTV0	MA	Inhibitor
DM3GTV0	RN	Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86.
DM3GTV0	RU	https://pubmed.ncbi.nlm.nih.gov/18571928

DMKDSGE	DI	DMKDSGE
DMKDSGE	DN	2,7-Bis[2-(diethylamino)acetamido]anthraquinone
DMKDSGE	MI	TTQY2EJ
DMKDSGE	MN	TERT messenger RNA (TERT mRNA)
DMKDSGE	MT	DTT
DMKDSGE	MA	Inhibitor
DMKDSGE	RN	Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86.
DMKDSGE	RU	https://pubmed.ncbi.nlm.nih.gov/18571928

DMNW5PL	DI	DMNW5PL
DMNW5PL	DN	2,7-Bis[2-(dimethylamino)acetamido]anthraquinone
DMNW5PL	MI	TTQY2EJ
DMNW5PL	MN	TERT messenger RNA (TERT mRNA)
DMNW5PL	MT	DTT
DMNW5PL	MA	Inhibitor
DMNW5PL	RN	Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86.
DMNW5PL	RU	https://pubmed.ncbi.nlm.nih.gov/18571928

DMZ7EAC	DI	DMZ7EAC
DMZ7EAC	DN	2,7-Bis[2-(ethylamino)acetamido]anthraquinone
DMZ7EAC	MI	TTQY2EJ
DMZ7EAC	MN	TERT messenger RNA (TERT mRNA)
DMZ7EAC	MT	DTT
DMZ7EAC	MA	Inhibitor
DMZ7EAC	RN	Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86.
DMZ7EAC	RU	https://pubmed.ncbi.nlm.nih.gov/18571928

DMM4T1Q	DI	DMM4T1Q
DMM4T1Q	DN	2,7-Bis[2-(isobutylamino)acetamido]anthraquinone
DMM4T1Q	MI	TTQY2EJ
DMM4T1Q	MN	TERT messenger RNA (TERT mRNA)
DMM4T1Q	MT	DTT
DMM4T1Q	MA	Inhibitor
DMM4T1Q	RN	Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86.
DMM4T1Q	RU	https://pubmed.ncbi.nlm.nih.gov/18571928

DMRQGWX	DI	DMRQGWX
DMRQGWX	DN	2,7-Bis[2-(isopropylamino)acetamido]anthraquinone
DMRQGWX	MI	TTQY2EJ
DMRQGWX	MN	TERT messenger RNA (TERT mRNA)
DMRQGWX	MT	DTT
DMRQGWX	MA	Inhibitor
DMRQGWX	RN	Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86.
DMRQGWX	RU	https://pubmed.ncbi.nlm.nih.gov/18571928

DMPE8GX	DI	DMPE8GX
DMPE8GX	DN	2,7-Bis[2-(piperazino)acetamido]anthraquinone
DMPE8GX	MI	TTQY2EJ
DMPE8GX	MN	TERT messenger RNA (TERT mRNA)
DMPE8GX	MT	DTT
DMPE8GX	MA	Inhibitor
DMPE8GX	RN	Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86.
DMPE8GX	RU	https://pubmed.ncbi.nlm.nih.gov/18571928

DMITF0P	DI	DMITF0P
DMITF0P	DN	2,7-Bis[2-(piperidino)acetamido]anthraquinone
DMITF0P	MI	TTQY2EJ
DMITF0P	MN	TERT messenger RNA (TERT mRNA)
DMITF0P	MT	DTT
DMITF0P	MA	Inhibitor
DMITF0P	RN	Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86.
DMITF0P	RU	https://pubmed.ncbi.nlm.nih.gov/18571928

DMH89TO	DI	DMH89TO
DMH89TO	DN	2,7-Bis[2-(propylamino)acetamido]anthraquinone
DMH89TO	MI	TTQY2EJ
DMH89TO	MN	TERT messenger RNA (TERT mRNA)
DMH89TO	MT	DTT
DMH89TO	MA	Inhibitor
DMH89TO	RN	Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86.
DMH89TO	RU	https://pubmed.ncbi.nlm.nih.gov/18571928

DMHVKIJ	DI	DMHVKIJ
DMHVKIJ	DN	2,7-Bis[2-(pyrrolidino)acetamido]anthraquinone
DMHVKIJ	MI	TTQY2EJ
DMHVKIJ	MN	TERT messenger RNA (TERT mRNA)
DMHVKIJ	MT	DTT
DMHVKIJ	MA	Inhibitor
DMHVKIJ	RN	Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86.
DMHVKIJ	RU	https://pubmed.ncbi.nlm.nih.gov/18571928

DM4V63W	DI	DM4V63W
DM4V63W	DN	2,7-Bis[3-(butylamino)propionamido]anthraquinone
DM4V63W	MI	TTQY2EJ
DM4V63W	MN	TERT messenger RNA (TERT mRNA)
DM4V63W	MT	DTT
DM4V63W	MA	Inhibitor
DM4V63W	RN	Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86.
DM4V63W	RU	https://pubmed.ncbi.nlm.nih.gov/18571928

DMC537F	DI	DMC537F
DMC537F	DN	2,7-Bis[3-(ethylamino)propionamido]anthraquinone
DMC537F	MI	TTQY2EJ
DMC537F	MN	TERT messenger RNA (TERT mRNA)
DMC537F	MT	DTT
DMC537F	MA	Inhibitor
DMC537F	RN	Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86.
DMC537F	RU	https://pubmed.ncbi.nlm.nih.gov/18571928

DMOZEKQ	DI	DMOZEKQ
DMOZEKQ	DN	2,7-Bis[3-(piperazino)propionamido]anthraquinone
DMOZEKQ	MI	TTQY2EJ
DMOZEKQ	MN	TERT messenger RNA (TERT mRNA)
DMOZEKQ	MT	DTT
DMOZEKQ	MA	Inhibitor
DMOZEKQ	RN	Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86.
DMOZEKQ	RU	https://pubmed.ncbi.nlm.nih.gov/18571928

DMET693	DI	DMET693
DMET693	DN	2,7-Bis[3-(piperidino)propionamido]anthraquinone
DMET693	MI	TTQY2EJ
DMET693	MN	TERT messenger RNA (TERT mRNA)
DMET693	MT	DTT
DMET693	MA	Inhibitor
DMET693	RN	Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86.
DMET693	RU	https://pubmed.ncbi.nlm.nih.gov/18571928

DM6I90F	DI	DM6I90F
DM6I90F	DN	2,7-Bis[3-(propylamino)propionamido]anthraquinone
DM6I90F	MI	TTQY2EJ
DM6I90F	MN	TERT messenger RNA (TERT mRNA)
DM6I90F	MT	DTT
DM6I90F	MA	Inhibitor
DM6I90F	RN	Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86.
DM6I90F	RU	https://pubmed.ncbi.nlm.nih.gov/18571928

DMD6ZV5	DI	DMD6ZV5
DMD6ZV5	DN	2,7-Bis[3-(pyrrolidino)propionamido]anthraquinone
DMD6ZV5	MI	TTQY2EJ
DMD6ZV5	MN	TERT messenger RNA (TERT mRNA)
DMD6ZV5	MT	DTT
DMD6ZV5	MA	Inhibitor
DMD6ZV5	RN	Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86.
DMD6ZV5	RU	https://pubmed.ncbi.nlm.nih.gov/18571928

DME0TZU	DI	DME0TZU
DME0TZU	DN	2,7-diaminoanthraquinone
DME0TZU	MI	TTQY2EJ
DME0TZU	MN	TERT messenger RNA (TERT mRNA)
DME0TZU	MT	DTT
DME0TZU	MA	Inhibitor
DME0TZU	RN	Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86.
DME0TZU	RU	https://pubmed.ncbi.nlm.nih.gov/18571928

DMN56VM	DI	DMN56VM
DMN56VM	DN	2,7-Dinitroantraquinone
DMN56VM	MI	TTQY2EJ
DMN56VM	MN	TERT messenger RNA (TERT mRNA)
DMN56VM	MT	DTT
DMN56VM	MA	Inhibitor
DMN56VM	RN	Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86.
DMN56VM	RU	https://pubmed.ncbi.nlm.nih.gov/18571928

DMAKZ43	DI	DMAKZ43
DMAKZ43	DN	2,8-Dimethyl-1-oxa-8-aza-spiro[4.5]decan-3-one
DMAKZ43	MI	TTZ9SOR
DMAKZ43	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMAKZ43	MT	DTT
DMAKZ43	MA	Inhibitor
DMAKZ43	RN	Synthesis and modeling studies of a potent conformationally rigid muscarinic agonist: 1-azabicyclo[2.2.1]heptanespirofuranone. J Med Chem. 1998 Oct 22;41(22):4181-5.
DMAKZ43	RU	https://pubmed.ncbi.nlm.nih.gov/9784090

DMAKZ43	DI	DMAKZ43
DMAKZ43	DN	2,8-Dimethyl-1-oxa-8-aza-spiro[4.5]decan-3-one
DMAKZ43	MI	TTYEG6Q
DMAKZ43	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMAKZ43	MT	DTT
DMAKZ43	MA	Inhibitor
DMAKZ43	RN	Synthesis and modeling studies of a potent conformationally rigid muscarinic agonist: 1-azabicyclo[2.2.1]heptanespirofuranone. J Med Chem. 1998 Oct 22;41(22):4181-5.
DMAKZ43	RU	https://pubmed.ncbi.nlm.nih.gov/9784090

DMAKZ43	DI	DMAKZ43
DMAKZ43	DN	2,8-Dimethyl-1-oxa-8-aza-spiro[4.5]decan-3-one
DMAKZ43	MI	TTQ13Z5
DMAKZ43	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMAKZ43	MT	DTT
DMAKZ43	MA	Inhibitor
DMAKZ43	RN	Synthesis and modeling studies of a potent conformationally rigid muscarinic agonist: 1-azabicyclo[2.2.1]heptanespirofuranone. J Med Chem. 1998 Oct 22;41(22):4181-5.
DMAKZ43	RU	https://pubmed.ncbi.nlm.nih.gov/9784090

DMAKZ43	DI	DMAKZ43
DMAKZ43	DN	2,8-Dimethyl-1-oxa-8-aza-spiro[4.5]decan-3-one
DMAKZ43	MI	TTQ3JTF
DMAKZ43	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DMAKZ43	MT	DTT
DMAKZ43	MA	Inhibitor
DMAKZ43	RN	Synthesis and modeling studies of a potent conformationally rigid muscarinic agonist: 1-azabicyclo[2.2.1]heptanespirofuranone. J Med Chem. 1998 Oct 22;41(22):4181-5.
DMAKZ43	RU	https://pubmed.ncbi.nlm.nih.gov/9784090

DMAKZ43	DI	DMAKZ43
DMAKZ43	DN	2,8-Dimethyl-1-oxa-8-aza-spiro[4.5]decan-3-one
DMAKZ43	MI	TTH18TF
DMAKZ43	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMAKZ43	MT	DTT
DMAKZ43	MA	Inhibitor
DMAKZ43	RN	Synthesis and modeling studies of a potent conformationally rigid muscarinic agonist: 1-azabicyclo[2.2.1]heptanespirofuranone. J Med Chem. 1998 Oct 22;41(22):4181-5.
DMAKZ43	RU	https://pubmed.ncbi.nlm.nih.gov/9784090

DMU2EFH	DI	DMU2EFH
DMU2EFH	DN	2,8-Dimethyl-3H-quinazolin-4-one
DMU2EFH	MI	TTVDSZ0
DMU2EFH	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMU2EFH	MT	DTT
DMU2EFH	MA	Inhibitor
DMU2EFH	RN	Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56.
DMU2EFH	RU	https://pubmed.ncbi.nlm.nih.gov/9857092

DMVSTG7	DI	DMVSTG7
DMVSTG7	DN	2-[(2,2-diphenylacetyl)amino]benzoic acid
DMVSTG7	MI	TT5ZWB6
DMVSTG7	MN	Dihydrodiol dehydrogenase type I (AKR1C3)
DMVSTG7	MT	DTT
DMVSTG7	MA	Inhibitor
DMVSTG7	RN	Nonsteroidal anti-inflammatory drugs and their analogues as inhibitors of aldo-keto reductase AKR1C3: new lead compounds for the development of ant... Bioorg Med Chem Lett. 2005 Dec 1;15(23):5170-5.
DMVSTG7	RU	https://pubmed.ncbi.nlm.nih.gov/16183274

DMR4LJY	DI	DMR4LJY
DMR4LJY	DN	2-[(2',3',4'-TRIFLUOROBIPHENYL-2-YL)OXY]ETHANOL
DMR4LJY	MI	TTUMQVO
DMR4LJY	MN	Cathepsin S (CTSS)
DMR4LJY	MT	DTT
DMR4LJY	MA	Inhibitor
DMR4LJY	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMR4LJY	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMXA1LK	DI	DMXA1LK
DMXA1LK	DN	2-[(2-methoxy-5-methylphenoxy)methyl]pyridine
DMXA1LK	MI	TTQO71U
DMXA1LK	MN	Hemoglobin (HB)
DMXA1LK	MT	DTT
DMXA1LK	MA	Inhibitor
DMXA1LK	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMXA1LK	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM75WN4	DI	DM75WN4
DM75WN4	DN	2-[(2-methyl-4-thiazolyl)ethynyl]pyrazine
DM75WN4	MI	TTHS256
DM75WN4	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM75WN4	MT	DTT
DM75WN4	MA	Inhibitor
DM75WN4	RN	Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100.
DM75WN4	RU	https://pubmed.ncbi.nlm.nih.gov/16451073

DMKC1GI	DI	DMKC1GI
DMKC1GI	DN	2-[(4-acetylphenyl)ethynyl]-N6-methoxyadenosine
DMKC1GI	MI	TTK25J1
DMKC1GI	MN	Adenosine A1 receptor (ADORA1)
DMKC1GI	MT	DTT
DMKC1GI	MA	Inhibitor
DMKC1GI	RN	N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
DMKC1GI	RU	https://pubmed.ncbi.nlm.nih.gov/17309246

DMKC1GI	DI	DMKC1GI
DMKC1GI	DN	2-[(4-acetylphenyl)ethynyl]-N6-methoxyadenosine
DMKC1GI	MI	TTM2AOE
DMKC1GI	MN	Adenosine A2a receptor (ADORA2A)
DMKC1GI	MT	DTT
DMKC1GI	MA	Inhibitor
DMKC1GI	RN	N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
DMKC1GI	RU	https://pubmed.ncbi.nlm.nih.gov/17309246

DMKC1GI	DI	DMKC1GI
DMKC1GI	DN	2-[(4-acetylphenyl)ethynyl]-N6-methoxyadenosine
DMKC1GI	MI	TTJFY5U
DMKC1GI	MN	Adenosine A3 receptor (ADORA3)
DMKC1GI	MT	DTT
DMKC1GI	MA	Inhibitor
DMKC1GI	RN	N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
DMKC1GI	RU	https://pubmed.ncbi.nlm.nih.gov/17309246

DMTNQZU	DI	DMTNQZU
DMTNQZU	DN	2-[(4-fluorophenyl)ethynyl]-N6-methoxyadenosine
DMTNQZU	MI	TTK25J1
DMTNQZU	MN	Adenosine A1 receptor (ADORA1)
DMTNQZU	MT	DTT
DMTNQZU	MA	Inhibitor
DMTNQZU	RN	N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
DMTNQZU	RU	https://pubmed.ncbi.nlm.nih.gov/17309246

DMTNQZU	DI	DMTNQZU
DMTNQZU	DN	2-[(4-fluorophenyl)ethynyl]-N6-methoxyadenosine
DMTNQZU	MI	TTM2AOE
DMTNQZU	MN	Adenosine A2a receptor (ADORA2A)
DMTNQZU	MT	DTT
DMTNQZU	MA	Inhibitor
DMTNQZU	RN	N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
DMTNQZU	RU	https://pubmed.ncbi.nlm.nih.gov/17309246

DMTNQZU	DI	DMTNQZU
DMTNQZU	DN	2-[(4-fluorophenyl)ethynyl]-N6-methoxyadenosine
DMTNQZU	MI	TTJFY5U
DMTNQZU	MN	Adenosine A3 receptor (ADORA3)
DMTNQZU	MT	DTT
DMTNQZU	MA	Inhibitor
DMTNQZU	RN	N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
DMTNQZU	RU	https://pubmed.ncbi.nlm.nih.gov/17309246

DMDT7SK	DI	DMDT7SK
DMDT7SK	DN	2-[(biphenyl-4-carbonyl)-amino]-benzoic acid
DMDT7SK	MI	TT3PQ2Y
DMDT7SK	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DMDT7SK	MT	DTT
DMDT7SK	MA	Inhibitor
DMDT7SK	RN	The first de novo designed inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. Bioorg Med Chem Lett. 2006 Jan 1;16(1):88-92.
DMDT7SK	RU	https://pubmed.ncbi.nlm.nih.gov/16236496

DMVSI6R	DI	DMVSI6R
DMVSI6R	DN	2-[(Dioxidophosphino)Oxy]Benzoate
DMVSI6R	MI	TTLP6GN
DMVSI6R	MN	Bacterial DD-carboxypeptidase (Bact vanYB)
DMVSI6R	MT	DTT
DMVSI6R	MA	Inhibitor
DMVSI6R	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMVSI6R	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMSW89U	DI	DMSW89U
DMSW89U	DN	2-[1-(2-Chloro-phenyl)-1H-pyrrol-2-yl]-ethylamine
DMSW89U	MI	TTO9X1H
DMSW89U	MN	5-HT 7 receptor (HTR7)
DMSW89U	MT	DTT
DMSW89U	MA	Inhibitor
DMSW89U	RN	Phenylpyrroles, a new chemolibrary virtual screening class of 5-HT7 receptor ligands. Bioorg Med Chem Lett. 2005 Aug 15;15(16):3753-7.
DMSW89U	RU	https://pubmed.ncbi.nlm.nih.gov/16002287

DMUZDSC	DI	DMUZDSC
DMUZDSC	DN	2-[1-(4-CHLORO-PHENYL)-ETHYL]-4,6-DINITRO-PHENOL
DMUZDSC	MI	TTHDSE2
DMUZDSC	MN	Bacterial Fumarate reductase flavoprotein (Bact frdA)
DMUZDSC	MT	DTT
DMUZDSC	MA	Inhibitor
DMUZDSC	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMUZDSC	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMEA2SR	DI	DMEA2SR
DMEA2SR	DN	2-[1,4]Diazepan-1-yl-6-nitro-quinoline
DMEA2SR	MI	TT3ROYC
DMEA2SR	MN	Serotonin transporter (SERT)
DMEA2SR	MT	DTT
DMEA2SR	MA	Inhibitor
DMEA2SR	RN	Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 1. Bioorg Med Chem Lett. 2000 Jul 17;10(14):1559-62.
DMEA2SR	RU	https://pubmed.ncbi.nlm.nih.gov/10915050

DMC8IEM	DI	DMC8IEM
DMC8IEM	DN	2-[1,4]Oxazepan-4-yl-benzo[h]chromen-4-one
DMC8IEM	MI	TTK3PY9
DMC8IEM	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMC8IEM	MT	DTT
DMC8IEM	MA	Inhibitor
DMC8IEM	RN	Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85.
DMC8IEM	RU	https://pubmed.ncbi.nlm.nih.gov/15658870

DMFJOHG	DI	DMFJOHG
DMFJOHG	DN	2-[125I]melatonin
DMFJOHG	MI	TT0WAIE
DMFJOHG	MN	Melatonin receptor type 1A (MTNR1A)
DMFJOHG	MT	DTT
DMFJOHG	MA	Agonist
DMFJOHG	RN	Melatonin receptor antagonists that differentiate between the human Mel1a and Mel1b recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML1 presynaptic heteroreceptor. Naunyn Schmiedebergs Arch Pharmacol. 1997 Mar;355(3):365-75.
DMFJOHG	RU	https://pubmed.ncbi.nlm.nih.gov/9089668

DMKEZ5G	DI	DMKEZ5G
DMKEZ5G	DN	2-[2-(1H-Imidazol-4-yl)-cyclopropyl]-ethylamine
DMKEZ5G	MI	TT9JNIC
DMKEZ5G	MN	Histamine H3 receptor (H3R)
DMKEZ5G	MT	DTT
DMKEZ5G	MA	Inhibitor
DMKEZ5G	RN	Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist f... J Med Chem. 2003 May 8;46(10):1980-8.
DMKEZ5G	RU	https://pubmed.ncbi.nlm.nih.gov/12723960

DMX1TIU	DI	DMX1TIU
DMX1TIU	DN	2-[2-(3,5-Dimethoxy-phenyl)-vinyl]-thiophene
DMX1TIU	MI	TTI84H7
DMX1TIU	MN	Cytochrome P450 1B1 (CYP1B1)
DMX1TIU	MT	DTT
DMX1TIU	MA	Inhibitor
DMX1TIU	RN	Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors. J Med Chem. 2002 Jan 3;45(1):160-4.
DMX1TIU	RU	https://pubmed.ncbi.nlm.nih.gov/11754588

DMDT9KG	DI	DMDT9KG
DMDT9KG	DN	2-[3-(1-Hydroxy-propyl)-phenyl]-propionic acid
DMDT9KG	MI	TTMWT8Z
DMDT9KG	MN	C-X-C chemokine receptor type 1 (CXCR1)
DMDT9KG	MT	DTT
DMDT9KG	MA	Inhibitor
DMDT9KG	RN	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
DMDT9KG	RU	https://pubmed.ncbi.nlm.nih.gov/15974585

DMDT9KG	DI	DMDT9KG
DMDT9KG	DN	2-[3-(1-Hydroxy-propyl)-phenyl]-propionic acid
DMDT9KG	MI	TT30C9G
DMDT9KG	MN	C-X-C chemokine receptor type 2 (CXCR2)
DMDT9KG	MT	DTT
DMDT9KG	MA	Inhibitor
DMDT9KG	RN	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
DMDT9KG	RU	https://pubmed.ncbi.nlm.nih.gov/15974585

DMWIUR0	DI	DMWIUR0
DMWIUR0	DN	2-[3-(1-Phenyl-ethyl)-phenyl]-propionic acid
DMWIUR0	MI	TTMWT8Z
DMWIUR0	MN	C-X-C chemokine receptor type 1 (CXCR1)
DMWIUR0	MT	DTT
DMWIUR0	MA	Inhibitor
DMWIUR0	RN	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
DMWIUR0	RU	https://pubmed.ncbi.nlm.nih.gov/15974585

DMWIUR0	DI	DMWIUR0
DMWIUR0	DN	2-[3-(1-Phenyl-ethyl)-phenyl]-propionic acid
DMWIUR0	MI	TT30C9G
DMWIUR0	MN	C-X-C chemokine receptor type 2 (CXCR2)
DMWIUR0	MT	DTT
DMWIUR0	MA	Inhibitor
DMWIUR0	RN	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
DMWIUR0	RU	https://pubmed.ncbi.nlm.nih.gov/15974585

DMKSDT4	DI	DMKSDT4
DMKSDT4	DN	2-[3-(2-Methyl-butyl)-phenyl]-propionic acid
DMKSDT4	MI	TTMWT8Z
DMKSDT4	MN	C-X-C chemokine receptor type 1 (CXCR1)
DMKSDT4	MT	DTT
DMKSDT4	MA	Inhibitor
DMKSDT4	RN	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
DMKSDT4	RU	https://pubmed.ncbi.nlm.nih.gov/15974585

DMKSDT4	DI	DMKSDT4
DMKSDT4	DN	2-[3-(2-Methyl-butyl)-phenyl]-propionic acid
DMKSDT4	MI	TT30C9G
DMKSDT4	MN	C-X-C chemokine receptor type 2 (CXCR2)
DMKSDT4	MT	DTT
DMKSDT4	MA	Inhibitor
DMKSDT4	RN	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
DMKSDT4	RU	https://pubmed.ncbi.nlm.nih.gov/15974585

DM8A3NI	DI	DM8A3NI
DM8A3NI	DN	2-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine
DM8A3NI	MI	TTXV4FI
DM8A3NI	MN	Albendazole monooxygenase (CYP3A4)
DM8A3NI	MT	DTT
DM8A3NI	MA	Inhibitor
DM8A3NI	RN	Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):333-6.
DM8A3NI	RU	https://pubmed.ncbi.nlm.nih.gov/14698153

DM8A3NI	DI	DM8A3NI
DM8A3NI	DN	2-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine
DM8A3NI	MI	TTVG215
DM8A3NI	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DM8A3NI	MT	DTT
DM8A3NI	MA	Inhibitor
DM8A3NI	RN	Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):333-6.
DM8A3NI	RU	https://pubmed.ncbi.nlm.nih.gov/14698153

DM5ETL9	DI	DM5ETL9
DM5ETL9	DN	2-[3-(Pyridin-4-yloxy)-benzoylamino]-benzoic acid
DM5ETL9	MI	TTRVTMX
DM5ETL9	MN	Bacterial Beta-ketoacyl-ACP synthase III (Bact fabH)
DM5ETL9	MT	DTT
DM5ETL9	MA	Inhibitor
DM5ETL9	RN	Structure-based design, synthesis, and study of potent inhibitors of beta-ketoacyl-acyl carrier protein synthase III as potential antimicrobial age... J Med Chem. 2005 Mar 10;48(5):1596-609.
DM5ETL9	RU	https://pubmed.ncbi.nlm.nih.gov/15743201

DMUH526	DI	DMUH526
DMUH526	DN	2-[4-(1-Ethyl-propyl)-piperazin-1-yl]-quinoline
DMUH526	MI	TT9JNIC
DMUH526	MN	Histamine H3 receptor (H3R)
DMUH526	MT	DTT
DMUH526	MA	Inhibitor
DMUH526	RN	2-(4-alkylpiperazin-1-yl)quinolines as a new class of imidazole-free histamine H3 receptor antagonists. J Med Chem. 2005 Jan 13;48(1):306-11.
DMUH526	RU	https://pubmed.ncbi.nlm.nih.gov/15634025

DMUHECR	DI	DMUHECR
DMUHECR	DN	2-[4-(1H-Indol-5-yl)-phenyl]-propionic acid
DMUHECR	MI	TT8NGED
DMUHECR	MN	Prostaglandin G/H synthase 1 (COX-1)
DMUHECR	MT	DTT
DMUHECR	MA	Inhibitor
DMUHECR	RN	Structure-based design of COX-2 selectivity into flurbiprofen. Bioorg Med Chem Lett. 1999 Feb 8;9(3):307-12.
DMUHECR	RU	https://pubmed.ncbi.nlm.nih.gov/10091674

DMWXI06	DI	DMWXI06
DMWXI06	DN	2-[4-(2,4-Dichlorophenoxy)Phenoxy]Propanoic Acid
DMWXI06	MI	TTY84UG
DMWXI06	MN	Acetyl-CoA carboxylase 2 (ACACB)
DMWXI06	MT	DTT
DMWXI06	MA	Inhibitor
DMWXI06	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMWXI06	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMDMK5V	DI	DMDMK5V
DMDMK5V	DN	2-[4-(2-Azepan-1-ylethoxy)phenoxy]benzooxazole
DMDMK5V	MI	TTXZEAJ
DMDMK5V	MN	Leukotriene A-4 hydrolase (LTA4H)
DMDMK5V	MT	DTT
DMDMK5V	MA	Inhibitor
DMDMK5V	RN	Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69.
DMDMK5V	RU	https://pubmed.ncbi.nlm.nih.gov/18588282

DM923WK	DI	DM923WK
DM923WK	DN	2-[4-(2-Azepan-1-ylethoxy)phenoxy]benzothiazole
DM923WK	MI	TTXZEAJ
DM923WK	MN	Leukotriene A-4 hydrolase (LTA4H)
DM923WK	MT	DTT
DM923WK	MA	Inhibitor
DM923WK	RN	Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69.
DM923WK	RU	https://pubmed.ncbi.nlm.nih.gov/18588282

DMECQB4	DI	DMECQB4
DMECQB4	DN	2-[4-(2-Morpholin-4-ylethoxy)phenoxy]benzooxazole
DMECQB4	MI	TTXZEAJ
DMECQB4	MN	Leukotriene A-4 hydrolase (LTA4H)
DMECQB4	MT	DTT
DMECQB4	MA	Inhibitor
DMECQB4	RN	Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69.
DMECQB4	RU	https://pubmed.ncbi.nlm.nih.gov/18588282

DMMYJ3R	DI	DMMYJ3R
DMMYJ3R	DN	2-[4-(2-Piperidin-1-ylethyl)phenoxy]benzothiazole
DMMYJ3R	MI	TTXZEAJ
DMMYJ3R	MN	Leukotriene A-4 hydrolase (LTA4H)
DMMYJ3R	MT	DTT
DMMYJ3R	MA	Inhibitor
DMMYJ3R	RN	Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69.
DMMYJ3R	RU	https://pubmed.ncbi.nlm.nih.gov/18588282

DMMYJ3R	DI	DMMYJ3R
DMMYJ3R	DN	2-[4-(2-Piperidin-1-ylethyl)phenoxy]benzothiazole
DMMYJ3R	MI	TTQ6VDM
DMMYJ3R	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMMYJ3R	MT	DTT
DMMYJ3R	MA	Inhibitor
DMMYJ3R	RN	Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69.
DMMYJ3R	RU	https://pubmed.ncbi.nlm.nih.gov/18588282

DM6R1XH	DI	DM6R1XH
DM6R1XH	DN	2-[4-(2-Thienyl)phenyl]-4-methylmorpholin-2-ol
DM6R1XH	MI	TTFQEO5
DM6R1XH	MN	Squalene synthetase (FDFT1)
DM6R1XH	MT	DTT
DM6R1XH	MA	Inhibitor
DM6R1XH	RN	Lipid-lowering (hetero)aromatic tetrahydro-1,4-oxazine derivatives with antioxidant and squalene synthase inhibitory activity. J Med Chem. 2008 Sep 25;51(18):5861-5.
DM6R1XH	RU	https://pubmed.ncbi.nlm.nih.gov/18754614

DMZFKDW	DI	DMZFKDW
DMZFKDW	DN	2-[7-(Benzyloxy)-2-oxo-2H-chromen-4-yl]acetamide
DMZFKDW	MI	TT3WG5C
DMZFKDW	MN	Monoamine oxidase type A (MAO-A)
DMZFKDW	MT	DTT
DMZFKDW	MA	Inhibitor
DMZFKDW	RN	Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: development and biopharmacological profiling of 7-[(3-chlorobenzyl)ox... J Med Chem. 2009 Nov 12;52(21):6685-706.
DMZFKDW	RU	https://pubmed.ncbi.nlm.nih.gov/19810674

DMZFKDW	DI	DMZFKDW
DMZFKDW	DN	2-[7-(Benzyloxy)-2-oxo-2H-chromen-4-yl]acetamide
DMZFKDW	MI	TTGP7BY
DMZFKDW	MN	Monoamine oxidase type B (MAO-B)
DMZFKDW	MT	DTT
DMZFKDW	MA	Inhibitor
DMZFKDW	RN	Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: development and biopharmacological profiling of 7-[(3-chlorobenzyl)ox... J Med Chem. 2009 Nov 12;52(21):6685-706.
DMZFKDW	RU	https://pubmed.ncbi.nlm.nih.gov/19810674

DM1PSRQ	DI	DM1PSRQ
DM1PSRQ	DN	2-{[2-(2-phenylethyl)phenoxy]methyl}pyridine
DM1PSRQ	MI	TTSQIFT
DM1PSRQ	MN	5-HT 1A receptor (HTR1A)
DM1PSRQ	MT	DTT
DM1PSRQ	MA	Inhibitor
DM1PSRQ	RN	Arylmethyloxyphenyl derivatives: small molecules displaying P-glycoprotein inhibition. J Med Chem. 2006 Nov 2;49(22):6607-13.
DM1PSRQ	RU	https://pubmed.ncbi.nlm.nih.gov/17064079

DM1PSRQ	DI	DM1PSRQ
DM1PSRQ	DN	2-{[2-(2-phenylethyl)phenoxy]methyl}pyridine
DM1PSRQ	MI	TTEX248
DM1PSRQ	MN	Dopamine D2 receptor (D2R)
DM1PSRQ	MT	DTT
DM1PSRQ	MA	Inhibitor
DM1PSRQ	RN	Arylmethyloxyphenyl derivatives: small molecules displaying P-glycoprotein inhibition. J Med Chem. 2006 Nov 2;49(22):6607-13.
DM1PSRQ	RU	https://pubmed.ncbi.nlm.nih.gov/17064079

DM9TCWA	DI	DM9TCWA
DM9TCWA	DN	2-{[R-(-)-Apomorphine-2'-oxy]ethoxy}-ethanol
DM9TCWA	MI	TTZFYLI
DM9TCWA	MN	Dopamine D1 receptor (D1R)
DM9TCWA	MT	DTT
DM9TCWA	MA	Inhibitor
DM9TCWA	RN	Synthesis and neuropharmacological characterization of 2-O-substituted apomorphines. Bioorg Med Chem. 2008 Apr 15;16(8):4563-8.
DM9TCWA	RU	https://pubmed.ncbi.nlm.nih.gov/18313931

DM9TCWA	DI	DM9TCWA
DM9TCWA	DN	2-{[R-(-)-Apomorphine-2'-oxy]ethoxy}-ethanol
DM9TCWA	MI	TTEX248
DM9TCWA	MN	Dopamine D2 receptor (D2R)
DM9TCWA	MT	DTT
DM9TCWA	MA	Inhibitor
DM9TCWA	RN	Synthesis and neuropharmacological characterization of 2-O-substituted apomorphines. Bioorg Med Chem. 2008 Apr 15;16(8):4563-8.
DM9TCWA	RU	https://pubmed.ncbi.nlm.nih.gov/18313931

DM5BAJ9	DI	DM5BAJ9
DM5BAJ9	DN	20-HETE
DM5BAJ9	MI	TTRBT3W
DM5BAJ9	MN	Short transient receptor potential channel 6 (TRPC6)
DM5BAJ9	MT	DTT
DM5BAJ9	MA	Activator
DM5BAJ9	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 491).
DM5BAJ9	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=491

DM84GAQ	DI	DM84GAQ
DM84GAQ	DN	20-hydroxy-LTB4
DM84GAQ	MI	TTVJX54
DM84GAQ	MN	Leukotriene B4 receptor 2 (LTB4R2)
DM84GAQ	MT	DTT
DM84GAQ	MA	Agonist
DM84GAQ	RN	A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature. 1997 Jun 5;387(6633):620-4.
DM84GAQ	RU	https://pubmed.ncbi.nlm.nih.gov/9177352

DMHJM0F	DI	DMHJM0F
DMHJM0F	DN	227Th-rituximab
DMHJM0F	MI	TTUE541
DMHJM0F	MN	Leukocyte surface antigen Leu-16 (CD20)
DMHJM0F	MT	DTT
DMHJM0F	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628).
DMHJM0F	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2628

DME8273	DI	DME8273
DME8273	DN	22R-hydroxycholesterol
DME8273	MI	TTS4UGC
DME8273	MN	Farnesoid X-activated receptor (FXR)
DME8273	MT	DTT
DME8273	MA	Agonist
DME8273	RN	Oxysterol 22(R)-hydroxycholesterol induces the expression of the bile salt export pump through nuclear receptor farsenoid X receptor but not liver ... J Pharmacol Exp Ther. 2006 Apr;317(1):317-25.
DME8273	RU	https://pubmed.ncbi.nlm.nih.gov/16371446

DME8273	DI	DME8273
DME8273	DN	22R-hydroxycholesterol
DME8273	MI	TTECBXN
DME8273	MN	Oxysterols receptor LXR-alpha (NR1H3)
DME8273	MT	DTT
DME8273	MA	Agonist
DME8273	RN	An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature. 1996 Oct 24;383(6602):728-31.
DME8273	RU	https://pubmed.ncbi.nlm.nih.gov/8878485

DME8273	DI	DME8273
DME8273	DN	22R-hydroxycholesterol
DME8273	MI	TTXA6PH
DME8273	MN	Oxysterols receptor LXR-beta (NR1H2)
DME8273	MT	DTT
DME8273	MA	Agonist
DME8273	RN	An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature. 1996 Oct 24;383(6602):728-31.
DME8273	RU	https://pubmed.ncbi.nlm.nih.gov/8878485

DM74X5O	DI	DM74X5O
DM74X5O	DN	2'-3'-dideoxy-7-deaza-guaninetriphosphate
DM74X5O	MI	TT84ETX
DM74X5O	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM74X5O	MT	DTT
DM74X5O	MA	Inhibitor
DM74X5O	RN	Synthesis of 2',3'-dideoxynucleoside 5'-alpha-P-borano-beta,gamma-(difluoromethylene)triphosphates and their inhibition of HIV-1 reverse transcript... J Med Chem. 2005 Apr 7;48(7):2695-700.
DM74X5O	RU	https://pubmed.ncbi.nlm.nih.gov/15801860

DM27GH0	DI	DM27GH0
DM27GH0	DN	23-hydroxybetulinic acid
DM27GH0	MI	TTZHY6R
DM27GH0	MN	Glycogen phosphorylase muscle form (GP)
DM27GH0	MT	DTT
DM27GH0	MA	Inhibitor
DM27GH0	RN	Naturally occurring pentacyclic triterpenes as inhibitors of glycogen phosphorylase: synthesis, structure-activity relationships, and X-ray crystal... J Med Chem. 2008 Jun 26;51(12):3540-54.
DM27GH0	RU	https://pubmed.ncbi.nlm.nih.gov/18517260

DMW2KI5	DI	DMW2KI5
DMW2KI5	DN	24(S), 25-epoxycholesterol
DMW2KI5	MI	TTECBXN
DMW2KI5	MN	Oxysterols receptor LXR-alpha (NR1H3)
DMW2KI5	MT	DTT
DMW2KI5	MA	Agonist
DMW2KI5	RN	Brain endogenous liver X receptor ligands selectively promote midbrain neurogenesis. Nat Chem Biol. 2013 Feb;9(2):126-33.
DMW2KI5	RU	https://pubmed.ncbi.nlm.nih.gov/23292650

DMW2KI5	DI	DMW2KI5
DMW2KI5	DN	24(S), 25-epoxycholesterol
DMW2KI5	MI	TTXA6PH
DMW2KI5	MN	Oxysterols receptor LXR-beta (NR1H2)
DMW2KI5	MT	DTT
DMW2KI5	MA	Agonist
DMW2KI5	RN	Brain endogenous liver X receptor ligands selectively promote midbrain neurogenesis. Nat Chem Biol. 2013 Feb;9(2):126-33.
DMW2KI5	RU	https://pubmed.ncbi.nlm.nih.gov/23292650

DMGMWA6	DI	DMGMWA6
DMGMWA6	DN	24(S)-hydroxycholesterol
DMGMWA6	MI	TTECBXN
DMGMWA6	MN	Oxysterols receptor LXR-alpha (NR1H3)
DMGMWA6	MT	DTT
DMGMWA6	MA	Agonist
DMGMWA6	RN	Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J Biol Chem. 1997 Feb 7;272(6):3137-40.
DMGMWA6	RU	https://pubmed.ncbi.nlm.nih.gov/9013544

DMGMWA6	DI	DMGMWA6
DMGMWA6	DN	24(S)-hydroxycholesterol
DMGMWA6	MI	TTXA6PH
DMGMWA6	MN	Oxysterols receptor LXR-beta (NR1H2)
DMGMWA6	MT	DTT
DMGMWA6	MA	Agonist
DMGMWA6	RN	Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J Biol Chem. 1997 Feb 7;272(6):3137-40.
DMGMWA6	RU	https://pubmed.ncbi.nlm.nih.gov/9013544

DMZIQ56	DI	DMZIQ56
DMZIQ56	DN	24-ethylcholest-6-ene-3,5-diol
DMZIQ56	MI	TT1RS9F
DMZIQ56	MN	Acetylcholinesterase (AChE)
DMZIQ56	MT	DTT
DMZIQ56	MA	Inhibitor
DMZIQ56	RN	Isolation and cholinesterase-inhibition studies of sterols from Haloxylon recurvum. Bioorg Med Chem Lett. 2006 Feb;16(3):573-80.
DMZIQ56	RU	https://pubmed.ncbi.nlm.nih.gov/16274989

DMZIQ56	DI	DMZIQ56
DMZIQ56	DN	24-ethylcholest-6-ene-3,5-diol
DMZIQ56	MI	TTEB0GD
DMZIQ56	MN	Cholinesterase (BCHE)
DMZIQ56	MT	DTT
DMZIQ56	MA	Inhibitor
DMZIQ56	RN	Isolation and cholinesterase-inhibition studies of sterols from Haloxylon recurvum. Bioorg Med Chem Lett. 2006 Feb;16(3):573-80.
DMZIQ56	RU	https://pubmed.ncbi.nlm.nih.gov/16274989

DMQSTYZ	DI	DMQSTYZ
DMQSTYZ	DN	24-ethyl-cholest-7-ene-3,5,6-triol
DMQSTYZ	MI	TT1RS9F
DMQSTYZ	MN	Acetylcholinesterase (AChE)
DMQSTYZ	MT	DTT
DMQSTYZ	MA	Inhibitor
DMQSTYZ	RN	Isolation and cholinesterase-inhibition studies of sterols from Haloxylon recurvum. Bioorg Med Chem Lett. 2006 Feb;16(3):573-80.
DMQSTYZ	RU	https://pubmed.ncbi.nlm.nih.gov/16274989

DMQSTYZ	DI	DMQSTYZ
DMQSTYZ	DN	24-ethyl-cholest-7-ene-3,5,6-triol
DMQSTYZ	MI	TTEB0GD
DMQSTYZ	MN	Cholinesterase (BCHE)
DMQSTYZ	MT	DTT
DMQSTYZ	MA	Inhibitor
DMQSTYZ	RN	Isolation and cholinesterase-inhibition studies of sterols from Haloxylon recurvum. Bioorg Med Chem Lett. 2006 Feb;16(3):573-80.
DMQSTYZ	RU	https://pubmed.ncbi.nlm.nih.gov/16274989

DMVY271	DI	DMVY271
DMVY271	DN	24-hydroxyursolic acid
DMVY271	MI	TTELIN2
DMVY271	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMVY271	MT	DTT
DMVY271	MA	Inhibitor
DMVY271	RN	Triterpenoids from the leaves of Diospyros kaki (persimmon) and their inhibitory effects on protein tyrosine phosphatase 1B. J Nat Prod. 2008 Oct;71(10):1775-8.
DMVY271	RU	https://pubmed.ncbi.nlm.nih.gov/18798681

DM90IRW	DI	DM90IRW
DM90IRW	DN	24-thiacycloartanol
DM90IRW	MI	TTWQ8IY
DM90IRW	MN	Fungal Sterol 24-C-methyltransferase (Fung erg6)
DM90IRW	MT	DTT
DM90IRW	MA	Inhibitor
DM90IRW	RN	Inactivation of soybean sterol 24-C-methyltransferase by elongated sterol side chains at C26. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5902-6.
DM90IRW	RU	https://pubmed.ncbi.nlm.nih.gov/17851075

DM6P3Z8	DI	DM6P3Z8
DM6P3Z8	DN	2'-5'dideoxyuridine
DM6P3Z8	MI	TTU6BFZ
DM6P3Z8	MN	Candida Thymidylate synthase (Candi TMP1)
DM6P3Z8	MT	DTT
DM6P3Z8	MA	Inhibitor
DM6P3Z8	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DM6P3Z8	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMCHAQ7	DI	DMCHAQ7
DMCHAQ7	DN	25-hydroxycholesterol
DMCHAQ7	MI	TTME5YJ
DMCHAQ7	MN	EBV-induced G-protein coupled receptor 2 (GPR183)
DMCHAQ7	MT	DTT
DMCHAQ7	MA	Agonist
DMCHAQ7	RN	Oxysterols direct B-cell migration through EBI2. Nature. 2011 Jul 27;475(7357):519-23.
DMCHAQ7	RU	https://pubmed.ncbi.nlm.nih.gov/21796211

DMCHAQ7	DI	DMCHAQ7
DMCHAQ7	DN	25-hydroxycholesterol
DMCHAQ7	MI	TTGV6LY
DMCHAQ7	MN	Nuclear receptor ROR-gamma (RORG)
DMCHAQ7	MT	DTT
DMCHAQ7	MA	Agonist
DMCHAQ7	RN	Structural basis for hydroxycholesterols as natural ligands of orphan nuclear receptor RORgamma. Mol Endocrinol. 2010 May;24(5):923-9.
DMCHAQ7	RU	https://pubmed.ncbi.nlm.nih.gov/20203100

DM2L6OZ	DI	DM2L6OZ
DM2L6OZ	DN	27-hydroxycholesterol
DM2L6OZ	MI	TTME5YJ
DM2L6OZ	MN	EBV-induced G-protein coupled receptor 2 (GPR183)
DM2L6OZ	MT	DTT
DM2L6OZ	MA	Agonist
DM2L6OZ	RN	Oxysterols direct B-cell migration through EBI2. Nature. 2011 Jul 27;475(7357):519-23.
DM2L6OZ	RU	https://pubmed.ncbi.nlm.nih.gov/21796211

DM2L6OZ	DI	DM2L6OZ
DM2L6OZ	DN	27-hydroxycholesterol
DM2L6OZ	MI	TTECBXN
DM2L6OZ	MN	Oxysterols receptor LXR-alpha (NR1H3)
DM2L6OZ	MT	DTT
DM2L6OZ	MA	Agonist
DM2L6OZ	RN	27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J Biol Chem. 2001 Oct 19;276(42):38378-87.
DM2L6OZ	RU	https://pubmed.ncbi.nlm.nih.gov/11504730

DM2L6OZ	DI	DM2L6OZ
DM2L6OZ	DN	27-hydroxycholesterol
DM2L6OZ	MI	TTXA6PH
DM2L6OZ	MN	Oxysterols receptor LXR-beta (NR1H2)
DM2L6OZ	MT	DTT
DM2L6OZ	MA	Agonist
DM2L6OZ	RN	27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J Biol Chem. 2001 Oct 19;276(42):38378-87.
DM2L6OZ	RU	https://pubmed.ncbi.nlm.nih.gov/11504730

DMUQAP7	DI	DMUQAP7
DMUQAP7	DN	29-methylidene-2,3-oxidosqualene
DMUQAP7	MI	TT7O8ZA
DMUQAP7	MN	Lanosterol synthase (LSS)
DMUQAP7	MT	DTT
DMUQAP7	MA	Inhibitor
DMUQAP7	RN	Synthesis and inhibition studies of sulfur-substituted squalene oxide analogues as mechanism-based inhibitors of 2,3-oxidosqualene-lanosterol cyclase. J Med Chem. 1997 Jan 17;40(2):201-9.
DMUQAP7	RU	https://pubmed.ncbi.nlm.nih.gov/9003518

DMIQM4O	DI	DMIQM4O
DMIQM4O	DN	2-acetamido-2,3-dihydro-1H-indene-5-sulfonic acid
DMIQM4O	MI	TTUNARX
DMIQM4O	MN	Carbonic anhydrase (CA)
DMIQM4O	MT	DTT
DMIQM4O	MA	Inhibitor
DMIQM4O	RN	Indanesulfonamides as carbonic anhydrase inhibitors and anticonvulsant agents: structure-activity relationship and pharmacological evaluation. Eur J Med Chem. 2008 Dec;43(12):2853-60.
DMIQM4O	RU	https://pubmed.ncbi.nlm.nih.gov/18406497

DMIQM4O	DI	DMIQM4O
DMIQM4O	DN	2-acetamido-2,3-dihydro-1H-indene-5-sulfonic acid
DMIQM4O	MI	TTSYM0R
DMIQM4O	MN	Carbonic anhydrase XII (CA-XII)
DMIQM4O	MT	DTT
DMIQM4O	MA	Inhibitor
DMIQM4O	RN	Indanesulfonamides as carbonic anhydrase inhibitors and anticonvulsant agents: structure-activity relationship and pharmacological evaluation. Eur J Med Chem. 2008 Dec;43(12):2853-60.
DMIQM4O	RU	https://pubmed.ncbi.nlm.nih.gov/18406497

DMIQM4O	DI	DMIQM4O
DMIQM4O	DN	2-acetamido-2,3-dihydro-1H-indene-5-sulfonic acid
DMIQM4O	MI	TTEYTKG
DMIQM4O	MN	Carbonic anhydrase XIV (CA-XIV)
DMIQM4O	MT	DTT
DMIQM4O	MA	Inhibitor
DMIQM4O	RN	Indanesulfonamides as carbonic anhydrase inhibitors and anticonvulsant agents: structure-activity relationship and pharmacological evaluation. Eur J Med Chem. 2008 Dec;43(12):2853-60.
DMIQM4O	RU	https://pubmed.ncbi.nlm.nih.gov/18406497

DMPKBVR	DI	DMPKBVR
DMPKBVR	DN	2-acetamido-5-sulfonamidoindane
DMPKBVR	MI	TTHQPL7
DMPKBVR	MN	Carbonic anhydrase I (CA-I)
DMPKBVR	MT	DTT
DMPKBVR	MA	Inhibitor
DMPKBVR	RN	Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9.
DMPKBVR	RU	https://pubmed.ncbi.nlm.nih.gov/16640335

DMPKBVR	DI	DMPKBVR
DMPKBVR	DN	2-acetamido-5-sulfonamidoindane
DMPKBVR	MI	TTANPDJ
DMPKBVR	MN	Carbonic anhydrase II (CA-II)
DMPKBVR	MT	DTT
DMPKBVR	MA	Inhibitor
DMPKBVR	RN	Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9.
DMPKBVR	RU	https://pubmed.ncbi.nlm.nih.gov/16640335

DMPKBVR	DI	DMPKBVR
DMPKBVR	DN	2-acetamido-5-sulfonamidoindane
DMPKBVR	MI	TT2LVK8
DMPKBVR	MN	Carbonic anhydrase IX (CA-IX)
DMPKBVR	MT	DTT
DMPKBVR	MA	Inhibitor
DMPKBVR	RN	Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9.
DMPKBVR	RU	https://pubmed.ncbi.nlm.nih.gov/16640335

DMRKYD6	DI	DMRKYD6
DMRKYD6	DN	2-acetyl-3-hydroxycyclohex-2-enone
DMRKYD6	MI	TT8DSFC
DMRKYD6	MN	Hydroxyphenylpyruvate dioxygenase (HPD)
DMRKYD6	MT	DTT
DMRKYD6	MA	Inhibitor
DMRKYD6	RN	Enzyme inhibition potency enhancement by active site metal chelating and hydrogen bonding induced conformation-restricted cyclopropanecarbonyl deri... Bioorg Med Chem Lett. 2006 Dec 1;16(23):6024-7.
DMRKYD6	RU	https://pubmed.ncbi.nlm.nih.gov/16979340

DM9ZOX4	DI	DM9ZOX4
DM9ZOX4	DN	2-Acetylaminoethyl 18-methoxycoronaridinate
DM9ZOX4	MI	TTTVAFQ
DM9ZOX4	MN	Neuronal acetylcholine receptor beta-4 (CHRNB4)
DM9ZOX4	MT	DTT
DM9ZOX4	MA	Inhibitor
DM9ZOX4	RN	Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents. J Med Chem. 2003 Jun 19;46(13):2716-30.
DM9ZOX4	RU	https://pubmed.ncbi.nlm.nih.gov/12801235

DMEQKIU	DI	DMEQKIU
DMEQKIU	DN	2-Acetylamino-indan-5-sulfonic acid hydrate
DMEQKIU	MI	TTHQPL7
DMEQKIU	MN	Carbonic anhydrase I (CA-I)
DMEQKIU	MT	DTT
DMEQKIU	MA	Inhibitor
DMEQKIU	RN	Carbonic anhydrase inhibitors. Design of anticonvulsant sulfonamides incorporating indane moieties. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5781-6.
DMEQKIU	RU	https://pubmed.ncbi.nlm.nih.gov/15501040

DMEQKIU	DI	DMEQKIU
DMEQKIU	DN	2-Acetylamino-indan-5-sulfonic acid hydrate
DMEQKIU	MI	TTANPDJ
DMEQKIU	MN	Carbonic anhydrase II (CA-II)
DMEQKIU	MT	DTT
DMEQKIU	MA	Inhibitor
DMEQKIU	RN	Carbonic anhydrase inhibitors. Design of anticonvulsant sulfonamides incorporating indane moieties. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5781-6.
DMEQKIU	RU	https://pubmed.ncbi.nlm.nih.gov/15501040

DM0NJYZ	DI	DM0NJYZ
DM0NJYZ	DN	2-acetylaminoquinazoline-4-carboxyanilide
DM0NJYZ	MI	TTJFY5U
DM0NJYZ	MN	Adenosine A3 receptor (ADORA3)
DM0NJYZ	MT	DTT
DM0NJYZ	MA	Inhibitor
DM0NJYZ	RN	Scouting human A3 adenosine receptor antagonist binding mode using a molecular simplification approach: from triazoloquinoxaline to a pyrimidine sk... J Med Chem. 2007 Dec 27;50(26):6596-606.
DM0NJYZ	RU	https://pubmed.ncbi.nlm.nih.gov/18047262

DMN8TVB	DI	DMN8TVB
DMN8TVB	DN	2-Acetyl-cyclohexane-1,3-dione
DMN8TVB	MI	TT8DSFC
DMN8TVB	MN	Hydroxyphenylpyruvate dioxygenase (HPD)
DMN8TVB	MT	DTT
DMN8TVB	MA	Inhibitor
DMN8TVB	RN	SAR studies of 2-o-substituted-benzoyl- and 2-alkanoyl-cyclohexane-1,3-diones as inhibitors of 4-hydroxyphenylpyruvate dioxygenase. Bioorg Med Chem Lett. 2000 May 1;10(9):843-5.
DMN8TVB	RU	https://pubmed.ncbi.nlm.nih.gov/10853644

DMJAUH0	DI	DMJAUH0
DMJAUH0	DN	2-Adamantan-1-yl-N-decyl-acetamide
DMJAUH0	MI	TT7WVHI
DMJAUH0	MN	Soluble epoxide hydrolase (EPHX2)
DMJAUH0	MT	DTT
DMJAUH0	MA	Inhibitor
DMJAUH0	RN	Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem. 2005 May 19;48(10):3621-9.
DMJAUH0	RU	https://pubmed.ncbi.nlm.nih.gov/15887969

DMXG029	DI	DMXG029
DMXG029	DN	2-Adamantan-2-ylidenemethyl-benzooxazol-6-ol
DMXG029	MI	TTHM0R1
DMXG029	MN	Steryl-sulfatase (STS)
DMXG029	MT	DTT
DMXG029	MA	Inhibitor
DMXG029	RN	Estrone formate: a novel type of irreversible inhibitor of human steroid sulfatase. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4999-5002.
DMXG029	RU	https://pubmed.ncbi.nlm.nih.gov/15341968

DM3DE9Z	DI	DM3DE9Z
DM3DE9Z	DN	2-allylisoquinoline-1,3,4-trione
DM3DE9Z	MI	TTPF2QI
DM3DE9Z	MN	Caspase-3 (CASP3)
DM3DE9Z	MT	DTT
DM3DE9Z	MA	Inhibitor
DM3DE9Z	RN	Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors. J Med Chem. 2006 Mar 9;49(5):1613-23.
DM3DE9Z	RU	https://pubmed.ncbi.nlm.nih.gov/16509578

DMTO1EJ	DI	DMTO1EJ
DMTO1EJ	DN	2-Allylthio-3-benzyl-6-nitro-quinazolin-4(3H)-one
DMTO1EJ	MI	TT9SL3Q
DMTO1EJ	MN	Polypeptide deformylase (PDF)
DMTO1EJ	MT	DTT
DMTO1EJ	MA	Inhibitor
DMTO1EJ	RN	Non-classical antifolates. Part 2: synthesis, biological evaluation, and molecular modeling study of some new 2,6-substituted-quinazolin-4-ones. Bioorg Med Chem. 2010 Apr 15;18(8):2849-63.
DMTO1EJ	RU	https://pubmed.ncbi.nlm.nih.gov/20350811

DMBWGCX	DI	DMBWGCX
DMBWGCX	DN	2-Allylthio-6-amino-3-benzyl-quinazolin-4(3H)-one
DMBWGCX	MI	TT9SL3Q
DMBWGCX	MN	Polypeptide deformylase (PDF)
DMBWGCX	MT	DTT
DMBWGCX	MA	Inhibitor
DMBWGCX	RN	Non-classical antifolates. Part 2: synthesis, biological evaluation, and molecular modeling study of some new 2,6-substituted-quinazolin-4-ones. Bioorg Med Chem. 2010 Apr 15;18(8):2849-63.
DMBWGCX	RU	https://pubmed.ncbi.nlm.nih.gov/20350811

DMHY2RA	DI	DMHY2RA
DMHY2RA	DN	2alpha-Hydroxyolean-12-en-28-oic acid
DMHY2RA	MI	TTZHY6R
DMHY2RA	MN	Glycogen phosphorylase muscle form (GP)
DMHY2RA	MT	DTT
DMHY2RA	MA	Inhibitor
DMHY2RA	RN	Synthesis of 3-deoxypentacyclic triterpene derivatives as inhibitors of glycogen phosphorylase. J Nat Prod. 2009 Aug;72(8):1414-8.
DMHY2RA	RU	https://pubmed.ncbi.nlm.nih.gov/19642687

DM1RSCP	DI	DM1RSCP
DM1RSCP	DN	2alpha-Hydroxyurs-12-en-28-oic acid
DM1RSCP	MI	TTZHY6R
DM1RSCP	MN	Glycogen phosphorylase muscle form (GP)
DM1RSCP	MT	DTT
DM1RSCP	MA	Inhibitor
DM1RSCP	RN	Synthesis of 3-deoxypentacyclic triterpene derivatives as inhibitors of glycogen phosphorylase. J Nat Prod. 2009 Aug;72(8):1414-8.
DM1RSCP	RU	https://pubmed.ncbi.nlm.nih.gov/19642687

DM73FWA	DI	DM73FWA
DM73FWA	DN	2-Amino-1-(4-ethylthiophenyl)butane
DM73FWA	MI	TT3ROYC
DM73FWA	MN	Serotonin transporter (SERT)
DM73FWA	MT	DTT
DM73FWA	MA	Inhibitor
DM73FWA	RN	Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88.
DM73FWA	RU	https://pubmed.ncbi.nlm.nih.gov/19717215

DMS5LKR	DI	DMS5LKR
DMS5LKR	DN	2-Amino-1-(4-ethylthiophenyl)propane
DMS5LKR	MI	TT3ROYC
DMS5LKR	MN	Serotonin transporter (SERT)
DMS5LKR	MT	DTT
DMS5LKR	MA	Inhibitor
DMS5LKR	RN	Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88.
DMS5LKR	RU	https://pubmed.ncbi.nlm.nih.gov/19717215

DMW7N3H	DI	DMW7N3H
DMW7N3H	DN	2-Amino-1-(4-methylthiophenyl)butane
DMW7N3H	MI	TT3ROYC
DMW7N3H	MN	Serotonin transporter (SERT)
DMW7N3H	MT	DTT
DMW7N3H	MA	Inhibitor
DMW7N3H	RN	Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88.
DMW7N3H	RU	https://pubmed.ncbi.nlm.nih.gov/19717215

DMJ2Z9G	DI	DMJ2Z9G
DMJ2Z9G	DN	2-Amino-1-(4-methylthiophenyl)propane
DMJ2Z9G	MI	TTVBI8W
DMJ2Z9G	MN	Dopamine transporter (DAT)
DMJ2Z9G	MT	DTT
DMJ2Z9G	MA	Inhibitor
DMJ2Z9G	RN	Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88.
DMJ2Z9G	RU	https://pubmed.ncbi.nlm.nih.gov/19717215

DMJ2Z9G	DI	DMJ2Z9G
DMJ2Z9G	DN	2-Amino-1-(4-methylthiophenyl)propane
DMJ2Z9G	MI	TT3WG5C
DMJ2Z9G	MN	Monoamine oxidase type A (MAO-A)
DMJ2Z9G	MT	DTT
DMJ2Z9G	MA	Inhibitor
DMJ2Z9G	RN	Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg Med Chem. 2009 Mar 15;17(6):2452-60.
DMJ2Z9G	RU	https://pubmed.ncbi.nlm.nih.gov/19243954

DMJ2Z9G	DI	DMJ2Z9G
DMJ2Z9G	DN	2-Amino-1-(4-methylthiophenyl)propane
DMJ2Z9G	MI	TTAWNKZ
DMJ2Z9G	MN	Norepinephrine transporter (NET)
DMJ2Z9G	MT	DTT
DMJ2Z9G	MA	Inhibitor
DMJ2Z9G	RN	Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88.
DMJ2Z9G	RU	https://pubmed.ncbi.nlm.nih.gov/19717215

DMJ2Z9G	DI	DMJ2Z9G
DMJ2Z9G	DN	2-Amino-1-(4-methylthiophenyl)propane
DMJ2Z9G	MI	TT3ROYC
DMJ2Z9G	MN	Serotonin transporter (SERT)
DMJ2Z9G	MT	DTT
DMJ2Z9G	MA	Inhibitor
DMJ2Z9G	RN	Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88.
DMJ2Z9G	RU	https://pubmed.ncbi.nlm.nih.gov/19717215

DMNQL17	DI	DMNQL17
DMNQL17	DN	2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE
DMNQL17	MI	TTZAYWL
DMNQL17	MN	Estrogen receptor (ESR)
DMNQL17	MT	DTT
DMNQL17	MA	Inhibitor
DMNQL17	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMNQL17	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMNQL17	DI	DMNQL17
DMNQL17	DN	2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE
DMNQL17	MI	DE1P7EZ
DMNQL17	MN	Glycerol/diol dehydratase (dhaB)
DMNQL17	MT	DME
DMNQL17	MA	Metabolism
DMNQL17	RN	Gut microbial beta-glucuronidase and glycerol/diol dehydratase activity contribute to dietary heterocyclic amine biotransformation. BMC Microbiol. 2019 May 16;19(1):99.
DMNQL17	RU	https://pubmed.ncbi.nlm.nih.gov/31096909

DMNQL17	DI	DMNQL17
DMNQL17	DN	2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE
DMNQL17	MI	DE4ZRTV
DMNQL17	MN	Glycerol/diol dehydratase (dhaB)
DMNQL17	MT	DME
DMNQL17	MA	Metabolism
DMNQL17	RN	Gut microbial beta-glucuronidase and glycerol/diol dehydratase activity contribute to dietary heterocyclic amine biotransformation. BMC Microbiol. 2019 May 16;19(1):99.
DMNQL17	RU	https://pubmed.ncbi.nlm.nih.gov/31096909

DMNQL17	DI	DMNQL17
DMNQL17	DN	2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE
DMNQL17	MI	DEW0ADP
DMNQL17	MN	Glycerol/diol dehydratase (dhaB)
DMNQL17	MT	DME
DMNQL17	MA	Metabolism
DMNQL17	RN	Gut microbial beta-glucuronidase and glycerol/diol dehydratase activity contribute to dietary heterocyclic amine biotransformation. BMC Microbiol. 2019 May 16;19(1):99.
DMNQL17	RU	https://pubmed.ncbi.nlm.nih.gov/31096909

DMNQL17	DI	DMNQL17
DMNQL17	DN	2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE
DMNQL17	MI	DEIN8FB
DMNQL17	MN	Glycerol/diol dehydratase (dhaB)
DMNQL17	MT	DME
DMNQL17	MA	Metabolism
DMNQL17	RN	Gut microbial beta-glucuronidase and glycerol/diol dehydratase activity contribute to dietary heterocyclic amine biotransformation. BMC Microbiol. 2019 May 16;19(1):99.
DMNQL17	RU	https://pubmed.ncbi.nlm.nih.gov/31096909

DMWDENZ	DI	DMWDENZ
DMWDENZ	DN	2-amino-2-(2,3-difluorophenyl)acetic acid
DMWDENZ	MI	TTFK1JQ
DMWDENZ	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMWDENZ	MT	DTT
DMWDENZ	MA	Inhibitor
DMWDENZ	RN	Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41.
DMWDENZ	RU	https://pubmed.ncbi.nlm.nih.gov/16380257

DMSAFUK	DI	DMSAFUK
DMSAFUK	DN	2-amino-2-(2,4-difluorophenyl)acetic acid
DMSAFUK	MI	TTFK1JQ
DMSAFUK	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMSAFUK	MT	DTT
DMSAFUK	MA	Inhibitor
DMSAFUK	RN	Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41.
DMSAFUK	RU	https://pubmed.ncbi.nlm.nih.gov/16380257

DMLXOHE	DI	DMLXOHE
DMLXOHE	DN	2-amino-2-(2-fluorophenyl)acetic acid
DMLXOHE	MI	TTFK1JQ
DMLXOHE	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMLXOHE	MT	DTT
DMLXOHE	MA	Inhibitor
DMLXOHE	RN	Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41.
DMLXOHE	RU	https://pubmed.ncbi.nlm.nih.gov/16380257

DMEX6AM	DI	DMEX6AM
DMEX6AM	DN	2-amino-2-(3-bromophenyl)acetic acid
DMEX6AM	MI	TTFK1JQ
DMEX6AM	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMEX6AM	MT	DTT
DMEX6AM	MA	Inhibitor
DMEX6AM	RN	Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41.
DMEX6AM	RU	https://pubmed.ncbi.nlm.nih.gov/16380257

DMMU1CQ	DI	DMMU1CQ
DMMU1CQ	DN	2-amino-2-(3-chloro-4-fluorophenyl)acetic acid
DMMU1CQ	MI	TTFK1JQ
DMMU1CQ	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMMU1CQ	MT	DTT
DMMU1CQ	MA	Inhibitor
DMMU1CQ	RN	Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41.
DMMU1CQ	RU	https://pubmed.ncbi.nlm.nih.gov/16380257

DMPZX8U	DI	DMPZX8U
DMPZX8U	DN	2-amino-2-(3-chlorophenyl)acetic acid
DMPZX8U	MI	TTFK1JQ
DMPZX8U	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMPZX8U	MT	DTT
DMPZX8U	MA	Inhibitor
DMPZX8U	RN	Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41.
DMPZX8U	RU	https://pubmed.ncbi.nlm.nih.gov/16380257

DMHQNZD	DI	DMHQNZD
DMHQNZD	DN	2-amino-2-(thiophen-2-yl)acetic acid
DMHQNZD	MI	TTFK1JQ
DMHQNZD	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMHQNZD	MT	DTT
DMHQNZD	MA	Inhibitor
DMHQNZD	RN	Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41.
DMHQNZD	RU	https://pubmed.ncbi.nlm.nih.gov/16380257

DMQOCAY	DI	DMQOCAY
DMQOCAY	DN	2-amino-2,3-dihydro-1H-indene-5-sulfonamide
DMQOCAY	MI	TTUNARX
DMQOCAY	MN	Carbonic anhydrase (CA)
DMQOCAY	MT	DTT
DMQOCAY	MA	Inhibitor
DMQOCAY	RN	Indanesulfonamides as carbonic anhydrase inhibitors and anticonvulsant agents: structure-activity relationship and pharmacological evaluation. Eur J Med Chem. 2008 Dec;43(12):2853-60.
DMQOCAY	RU	https://pubmed.ncbi.nlm.nih.gov/18406497

DMQOCAY	DI	DMQOCAY
DMQOCAY	DN	2-amino-2,3-dihydro-1H-indene-5-sulfonamide
DMQOCAY	MI	TTSYM0R
DMQOCAY	MN	Carbonic anhydrase XII (CA-XII)
DMQOCAY	MT	DTT
DMQOCAY	MA	Inhibitor
DMQOCAY	RN	Indanesulfonamides as carbonic anhydrase inhibitors and anticonvulsant agents: structure-activity relationship and pharmacological evaluation. Eur J Med Chem. 2008 Dec;43(12):2853-60.
DMQOCAY	RU	https://pubmed.ncbi.nlm.nih.gov/18406497

DMQOCAY	DI	DMQOCAY
DMQOCAY	DN	2-amino-2,3-dihydro-1H-indene-5-sulfonamide
DMQOCAY	MI	TTEYTKG
DMQOCAY	MN	Carbonic anhydrase XIV (CA-XIV)
DMQOCAY	MT	DTT
DMQOCAY	MA	Inhibitor
DMQOCAY	RN	Indanesulfonamides as carbonic anhydrase inhibitors and anticonvulsant agents: structure-activity relationship and pharmacological evaluation. Eur J Med Chem. 2008 Dec;43(12):2853-60.
DMQOCAY	RU	https://pubmed.ncbi.nlm.nih.gov/18406497

DM14HCY	DI	DM14HCY
DM14HCY	DN	2-amino-2-phenyl-1,1-di(pyridin-3-yl)ethanol
DM14HCY	MI	TTW0CMT
DM14HCY	MN	Voltage-gated potassium channel Kv1.5 (KCNA5)
DM14HCY	MT	DTT
DM14HCY	MA	Inhibitor
DM14HCY	RN	Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channel. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2493-6.
DM14HCY	RU	https://pubmed.ncbi.nlm.nih.gov/20304642

DMQKGL3	DI	DMQKGL3
DMQKGL3	DN	2-AMINO-3-(4-HYDROXY-1,2,5-OXADIAZOL-3-YL)PROPIONIC ACID (STRUCTURAL MIX)
DMQKGL3	MI	TTAN6JD
DMQKGL3	MN	Glutamate receptor AMPA (GRIA)
DMQKGL3	MT	DTT
DMQKGL3	MA	Inhibitor
DMQKGL3	RN	4-hydroxy-1,2,5-oxadiazol-3-yl moiety as bioisoster of the carboxy function. Synthesis, ionization constants, and molecular pharmacological charact... J Med Chem. 2010 May 27;53(10):4110-8.
DMQKGL3	RU	https://pubmed.ncbi.nlm.nih.gov/20408529

DMQKGL3	DI	DMQKGL3
DMQKGL3	DN	2-AMINO-3-(4-HYDROXY-1,2,5-OXADIAZOL-3-YL)PROPIONIC ACID (STRUCTURAL MIX)
DMQKGL3	MI	TT0MYE2
DMQKGL3	MN	Glutamate receptor ionotropic kainate 1 (GRIK1)
DMQKGL3	MT	DTT
DMQKGL3	MA	Inhibitor
DMQKGL3	RN	4-hydroxy-1,2,5-oxadiazol-3-yl moiety as bioisoster of the carboxy function. Synthesis, ionization constants, and molecular pharmacological charact... J Med Chem. 2010 May 27;53(10):4110-8.
DMQKGL3	RU	https://pubmed.ncbi.nlm.nih.gov/20408529

DM2GJZE	DI	DM2GJZE
DM2GJZE	DN	2-amino-3-(m-tolylamino)naphthalene-1,4-dione
DM2GJZE	MI	TTM2AOE
DM2GJZE	MN	Adenosine A2a receptor (ADORA2A)
DM2GJZE	MT	DTT
DM2GJZE	MA	Inhibitor
DM2GJZE	RN	Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. J Med Chem. 2010 Feb 25;53(4):1799-809.
DM2GJZE	RU	https://pubmed.ncbi.nlm.nih.gov/20095623

DMUYZA8	DI	DMUYZA8
DMUYZA8	DN	2'-amino-3,4,4',5-tetramethoxy-(Z)-stillbene
DMUYZA8	MI	TTYFKSZ
DMUYZA8	MN	Tubulin beta (TUBB)
DMUYZA8	MT	DTT
DMUYZA8	MA	Inhibitor
DMUYZA8	RN	2-amino and 2'-aminocombretastatin derivatives as potent antimitotic agents. J Med Chem. 2006 Oct 19;49(21):6412-5.
DMUYZA8	RU	https://pubmed.ncbi.nlm.nih.gov/17034147

DMUYZA8	DI	DMUYZA8
DMUYZA8	DN	2'-amino-3,4,4',5-tetramethoxy-(Z)-stillbene
DMUYZA8	MI	TTJ2PTI
DMUYZA8	MN	Tubulin beta-2 chain (TUBB2)
DMUYZA8	MT	DTT
DMUYZA8	MA	Inhibitor
DMUYZA8	RN	2-amino and 2'-aminocombretastatin derivatives as potent antimitotic agents. J Med Chem. 2006 Oct 19;49(21):6412-5.
DMUYZA8	RU	https://pubmed.ncbi.nlm.nih.gov/17034147

DMMZ2LI	DI	DMMZ2LI
DMMZ2LI	DN	2-amino-3,4',5-trimethoxy-(Z)-stillbene
DMMZ2LI	MI	TTYFKSZ
DMMZ2LI	MN	Tubulin beta (TUBB)
DMMZ2LI	MT	DTT
DMMZ2LI	MA	Inhibitor
DMMZ2LI	RN	2-amino and 2'-aminocombretastatin derivatives as potent antimitotic agents. J Med Chem. 2006 Oct 19;49(21):6412-5.
DMMZ2LI	RU	https://pubmed.ncbi.nlm.nih.gov/17034147

DMMZ2LI	DI	DMMZ2LI
DMMZ2LI	DN	2-amino-3,4',5-trimethoxy-(Z)-stillbene
DMMZ2LI	MI	TTJ2PTI
DMMZ2LI	MN	Tubulin beta-2 chain (TUBB2)
DMMZ2LI	MT	DTT
DMMZ2LI	MA	Inhibitor
DMMZ2LI	RN	2-amino and 2'-aminocombretastatin derivatives as potent antimitotic agents. J Med Chem. 2006 Oct 19;49(21):6412-5.
DMMZ2LI	RU	https://pubmed.ncbi.nlm.nih.gov/17034147

DM6AYDL	DI	DM6AYDL
DM6AYDL	DN	2-Amino-3-Methyl-1-Pyrrolidin-1-Yl-Butan-1-One
DM6AYDL	MI	TTDIGC1
DM6AYDL	MN	Dipeptidyl peptidase 4 (DPP-4)
DM6AYDL	MT	DTT
DM6AYDL	MA	Inhibitor
DM6AYDL	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM6AYDL	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMXLZUA	DI	DMXLZUA
DMXLZUA	DN	2-Amino-3-Oxo-4-Sulfo-Butyric Acid
DMXLZUA	MI	TTHM0R1
DMXLZUA	MN	Steryl-sulfatase (STS)
DMXLZUA	MT	DTT
DMXLZUA	MA	Inhibitor
DMXLZUA	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMXLZUA	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMTP3LD	DI	DMTP3LD
DMTP3LD	DN	2'-amino-4-(1,1-dimethyl-heptyl)-biphenyl-2-ol
DMTP3LD	MI	TT6OEDT
DMTP3LD	MN	Cannabinoid receptor 1 (CB1)
DMTP3LD	MT	DTT
DMTP3LD	MA	Inhibitor
DMTP3LD	RN	Biaryl cannabinoid mimetics--synthesis and structure-activity relationship. Bioorg Med Chem Lett. 2007 Jul 1;17(13):3652-6.
DMTP3LD	RU	https://pubmed.ncbi.nlm.nih.gov/17507224

DMTP3LD	DI	DMTP3LD
DMTP3LD	DN	2'-amino-4-(1,1-dimethyl-heptyl)-biphenyl-2-ol
DMTP3LD	MI	TTMSFAW
DMTP3LD	MN	Cannabinoid receptor 2 (CB2)
DMTP3LD	MT	DTT
DMTP3LD	MA	Inhibitor
DMTP3LD	RN	Biaryl cannabinoid mimetics--synthesis and structure-activity relationship. Bioorg Med Chem Lett. 2007 Jul 1;17(13):3652-6.
DMTP3LD	RU	https://pubmed.ncbi.nlm.nih.gov/17507224

DMULSNQ	DI	DMULSNQ
DMULSNQ	DN	2-amino-4-(2-methyl-benzylsulfanyl)-butyric acid
DMULSNQ	MI	TTFK1JQ
DMULSNQ	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMULSNQ	MT	DTT
DMULSNQ	MA	Inhibitor
DMULSNQ	RN	Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41.
DMULSNQ	RU	https://pubmed.ncbi.nlm.nih.gov/16380257

DMVN0EC	DI	DMVN0EC
DMVN0EC	DN	2-Amino-4,6-di-furan-2-yl-nicotinonitrile
DMVN0EC	MI	TTK25J1
DMVN0EC	MN	Adenosine A1 receptor (ADORA1)
DMVN0EC	MT	DTT
DMVN0EC	MA	Inhibitor
DMVN0EC	RN	2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem. 2008 Aug 14;51(15):4449-55.
DMVN0EC	RU	https://pubmed.ncbi.nlm.nih.gov/18637670

DMVN0EC	DI	DMVN0EC
DMVN0EC	DN	2-Amino-4,6-di-furan-2-yl-nicotinonitrile
DMVN0EC	MI	TTM2AOE
DMVN0EC	MN	Adenosine A2a receptor (ADORA2A)
DMVN0EC	MT	DTT
DMVN0EC	MA	Inhibitor
DMVN0EC	RN	2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem. 2008 Aug 14;51(15):4449-55.
DMVN0EC	RU	https://pubmed.ncbi.nlm.nih.gov/18637670

DMVN0EC	DI	DMVN0EC
DMVN0EC	DN	2-Amino-4,6-di-furan-2-yl-nicotinonitrile
DMVN0EC	MI	TTNE7KG
DMVN0EC	MN	Adenosine A2b receptor (ADORA2B)
DMVN0EC	MT	DTT
DMVN0EC	MA	Inhibitor
DMVN0EC	RN	2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem. 2008 Aug 14;51(15):4449-55.
DMVN0EC	RU	https://pubmed.ncbi.nlm.nih.gov/18637670

DMVJXQ9	DI	DMVJXQ9
DMVJXQ9	DN	2-amino-4,6-dimethylpyridine
DMVJXQ9	MI	TTZUFI5
DMVJXQ9	MN	Nitric-oxide synthase brain (NOS1)
DMVJXQ9	MT	DTT
DMVJXQ9	MA	Inhibitor
DMVJXQ9	RN	L337H mutant of rat neuronal nitric oxide synthase resembles human neuronal nitric oxide synthase toward inhibitors. J Med Chem. 2009 Jul 23;52(14):4533-7.
DMVJXQ9	RU	https://pubmed.ncbi.nlm.nih.gov/19537690

DMO69TS	DI	DMO69TS
DMO69TS	DN	2-Amino-4,6-diphenyl-nicotinonitrile
DMO69TS	MI	TTK25J1
DMO69TS	MN	Adenosine A1 receptor (ADORA1)
DMO69TS	MT	DTT
DMO69TS	MA	Inhibitor
DMO69TS	RN	2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem. 2008 Aug 14;51(15):4449-55.
DMO69TS	RU	https://pubmed.ncbi.nlm.nih.gov/18637670

DMO69TS	DI	DMO69TS
DMO69TS	DN	2-Amino-4,6-diphenyl-nicotinonitrile
DMO69TS	MI	TTM2AOE
DMO69TS	MN	Adenosine A2a receptor (ADORA2A)
DMO69TS	MT	DTT
DMO69TS	MA	Inhibitor
DMO69TS	RN	2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem. 2008 Aug 14;51(15):4449-55.
DMO69TS	RU	https://pubmed.ncbi.nlm.nih.gov/18637670

DM1MOB9	DI	DM1MOB9
DM1MOB9	DN	2-Amino-4,6-diphenyl-pyrimidin-5-carbonitrile
DM1MOB9	MI	TTK25J1
DM1MOB9	MN	Adenosine A1 receptor (ADORA1)
DM1MOB9	MT	DTT
DM1MOB9	MA	Inhibitor
DM1MOB9	RN	A new generation of adenosine receptor antagonists: from di- to trisubstituted aminopyrimidines. Bioorg Med Chem. 2008 Mar 15;16(6):2741-52.
DM1MOB9	RU	https://pubmed.ncbi.nlm.nih.gov/18258439

DM1MOB9	DI	DM1MOB9
DM1MOB9	DN	2-Amino-4,6-diphenyl-pyrimidin-5-carbonitrile
DM1MOB9	MI	TTM2AOE
DM1MOB9	MN	Adenosine A2a receptor (ADORA2A)
DM1MOB9	MT	DTT
DM1MOB9	MA	Inhibitor
DM1MOB9	RN	A new generation of adenosine receptor antagonists: from di- to trisubstituted aminopyrimidines. Bioorg Med Chem. 2008 Mar 15;16(6):2741-52.
DM1MOB9	RU	https://pubmed.ncbi.nlm.nih.gov/18258439

DMI9YGU	DI	DMI9YGU
DMI9YGU	DN	2-Amino-4,6-diphenyl-pyrimidine
DMI9YGU	MI	TTK25J1
DMI9YGU	MN	Adenosine A1 receptor (ADORA1)
DMI9YGU	MT	DTT
DMI9YGU	MA	Inhibitor
DMI9YGU	RN	A new generation of adenosine receptor antagonists: from di- to trisubstituted aminopyrimidines. Bioorg Med Chem. 2008 Mar 15;16(6):2741-52.
DMI9YGU	RU	https://pubmed.ncbi.nlm.nih.gov/18258439

DMI9YGU	DI	DMI9YGU
DMI9YGU	DN	2-Amino-4,6-diphenyl-pyrimidine
DMI9YGU	MI	TTM2AOE
DMI9YGU	MN	Adenosine A2a receptor (ADORA2A)
DMI9YGU	MT	DTT
DMI9YGU	MA	Inhibitor
DMI9YGU	RN	A new generation of adenosine receptor antagonists: from di- to trisubstituted aminopyrimidines. Bioorg Med Chem. 2008 Mar 15;16(6):2741-52.
DMI9YGU	RU	https://pubmed.ncbi.nlm.nih.gov/18258439

DM53T8Q	DI	DM53T8Q
DM53T8Q	DN	2-Amino-4,6-di-thiophen-2-yl-nicotinonitrile
DM53T8Q	MI	TTK25J1
DM53T8Q	MN	Adenosine A1 receptor (ADORA1)
DM53T8Q	MT	DTT
DM53T8Q	MA	Inhibitor
DM53T8Q	RN	2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem. 2008 Aug 14;51(15):4449-55.
DM53T8Q	RU	https://pubmed.ncbi.nlm.nih.gov/18637670

DM53T8Q	DI	DM53T8Q
DM53T8Q	DN	2-Amino-4,6-di-thiophen-2-yl-nicotinonitrile
DM53T8Q	MI	TTM2AOE
DM53T8Q	MN	Adenosine A2a receptor (ADORA2A)
DM53T8Q	MT	DTT
DM53T8Q	MA	Inhibitor
DM53T8Q	RN	2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem. 2008 Aug 14;51(15):4449-55.
DM53T8Q	RU	https://pubmed.ncbi.nlm.nih.gov/18637670

DMP4NHD	DI	DMP4NHD
DMP4NHD	DN	2-Amino-4-furan-2-yl-6-phenyl-nicotinonitrile
DMP4NHD	MI	TTK25J1
DMP4NHD	MN	Adenosine A1 receptor (ADORA1)
DMP4NHD	MT	DTT
DMP4NHD	MA	Inhibitor
DMP4NHD	RN	2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem. 2008 Aug 14;51(15):4449-55.
DMP4NHD	RU	https://pubmed.ncbi.nlm.nih.gov/18637670

DMP4NHD	DI	DMP4NHD
DMP4NHD	DN	2-Amino-4-furan-2-yl-6-phenyl-nicotinonitrile
DMP4NHD	MI	TTM2AOE
DMP4NHD	MN	Adenosine A2a receptor (ADORA2A)
DMP4NHD	MT	DTT
DMP4NHD	MA	Inhibitor
DMP4NHD	RN	2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem. 2008 Aug 14;51(15):4449-55.
DMP4NHD	RU	https://pubmed.ncbi.nlm.nih.gov/18637670

DMP4NHD	DI	DMP4NHD
DMP4NHD	DN	2-Amino-4-furan-2-yl-6-phenyl-nicotinonitrile
DMP4NHD	MI	TTNE7KG
DMP4NHD	MN	Adenosine A2b receptor (ADORA2B)
DMP4NHD	MT	DTT
DMP4NHD	MA	Inhibitor
DMP4NHD	RN	2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem. 2008 Aug 14;51(15):4449-55.
DMP4NHD	RU	https://pubmed.ncbi.nlm.nih.gov/18637670

DM1OED2	DI	DM1OED2
DM1OED2	DN	2-amino-4-methylpyridine
DM1OED2	MI	TTZUFI5
DM1OED2	MN	Nitric-oxide synthase brain (NOS1)
DM1OED2	MT	DTT
DM1OED2	MA	Inhibitor
DM1OED2	RN	Anchored plasticity opens doors for selective inhibitor design in nitric oxide synthase. Nat Chem Biol. 2008 Nov;4(11):700-7.
DM1OED2	RU	https://pubmed.ncbi.nlm.nih.gov/18849972

DM1OED2	DI	DM1OED2
DM1OED2	DN	2-amino-4-methylpyridine
DM1OED2	MI	TTCM4B3
DM1OED2	MN	Nitric-oxide synthase endothelial (NOS3)
DM1OED2	MT	DTT
DM1OED2	MA	Inhibitor
DM1OED2	RN	Anchored plasticity opens doors for selective inhibitor design in nitric oxide synthase. Nat Chem Biol. 2008 Nov;4(11):700-7.
DM1OED2	RU	https://pubmed.ncbi.nlm.nih.gov/18849972

DM1OED2	DI	DM1OED2
DM1OED2	DN	2-amino-4-methylpyridine
DM1OED2	MI	TTF10I9
DM1OED2	MN	Nitric-oxide synthase inducible (NOS2)
DM1OED2	MT	DTT
DM1OED2	MA	Inhibitor
DM1OED2	RN	2-Amino-4-methylpyridine as a potent inhibitor of inducible NO synthase activity in vitro and in vivo. Br J Pharmacol. 1996 Nov;119(6):1101-8.
DM1OED2	RU	https://pubmed.ncbi.nlm.nih.gov/8937711

DMRVTJ1	DI	DMRVTJ1
DMRVTJ1	DN	2-Amino-4-phenyl-6-thiophen-2-yl-nicotinonitrile
DMRVTJ1	MI	TTK25J1
DMRVTJ1	MN	Adenosine A1 receptor (ADORA1)
DMRVTJ1	MT	DTT
DMRVTJ1	MA	Inhibitor
DMRVTJ1	RN	2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem. 2008 Aug 14;51(15):4449-55.
DMRVTJ1	RU	https://pubmed.ncbi.nlm.nih.gov/18637670

DMRVTJ1	DI	DMRVTJ1
DMRVTJ1	DN	2-Amino-4-phenyl-6-thiophen-2-yl-nicotinonitrile
DMRVTJ1	MI	TTM2AOE
DMRVTJ1	MN	Adenosine A2a receptor (ADORA2A)
DMRVTJ1	MT	DTT
DMRVTJ1	MA	Inhibitor
DMRVTJ1	RN	2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem. 2008 Aug 14;51(15):4449-55.
DMRVTJ1	RU	https://pubmed.ncbi.nlm.nih.gov/18637670

DMOIZY1	DI	DMOIZY1
DMOIZY1	DN	2-Amino-4-phosphono-butyric acid
DMOIZY1	MI	TT0IFKL
DMOIZY1	MN	Metabotropic glutamate receptor 8 (mGluR8)
DMOIZY1	MT	DTT
DMOIZY1	MA	Inhibitor
DMOIZY1	RN	(2S,1'S,2'R,3'R)-2(2'-Carboxy-3'-hydroxymethylcyclopropyl)glycine-[3H], a potent and selective radioligand for labeling group 2 and 3 metabotropic ... Bioorg Med Chem Lett. 2005 Jan 17;15(2):349-51.
DMOIZY1	RU	https://pubmed.ncbi.nlm.nih.gov/15603952

DMDUZ2H	DI	DMDUZ2H
DMDUZ2H	DN	2-Amino-5-(N-nitro-guanidino)-pentanoic acid
DMDUZ2H	MI	TTZUFI5
DMDUZ2H	MN	Nitric-oxide synthase brain (NOS1)
DMDUZ2H	MT	DTT
DMDUZ2H	MA	Inhibitor
DMDUZ2H	RN	2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. J Med Chem. 1996 Feb 2;39(3):669-72.
DMDUZ2H	RU	https://pubmed.ncbi.nlm.nih.gov/8576908

DMDUZ2H	DI	DMDUZ2H
DMDUZ2H	DN	2-Amino-5-(N-nitro-guanidino)-pentanoic acid
DMDUZ2H	MI	TTCM4B3
DMDUZ2H	MN	Nitric-oxide synthase endothelial (NOS3)
DMDUZ2H	MT	DTT
DMDUZ2H	MA	Inhibitor
DMDUZ2H	RN	2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. J Med Chem. 1996 Feb 2;39(3):669-72.
DMDUZ2H	RU	https://pubmed.ncbi.nlm.nih.gov/8576908

DMDUZ2H	DI	DMDUZ2H
DMDUZ2H	DN	2-Amino-5-(N-nitro-guanidino)-pentanoic acid
DMDUZ2H	MI	TTF10I9
DMDUZ2H	MN	Nitric-oxide synthase inducible (NOS2)
DMDUZ2H	MT	DTT
DMDUZ2H	MA	Inhibitor
DMDUZ2H	RN	2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. J Med Chem. 1996 Feb 2;39(3):669-72.
DMDUZ2H	RU	https://pubmed.ncbi.nlm.nih.gov/8576908

DMA7ZOW	DI	DMA7ZOW
DMA7ZOW	DN	2-Amino-5-Hydroxy-Benzimidazole
DMA7ZOW	MI	TTGY7WI
DMA7ZOW	MN	Urokinase-type plasminogen activator (PLAU)
DMA7ZOW	MT	DTT
DMA7ZOW	MA	Inhibitor
DMA7ZOW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMA7ZOW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMOQ2R8	DI	DMOQ2R8
DMOQ2R8	DN	2-amino-5-phenylthiophene-3-carboxamide
DMOQ2R8	MI	TTJ3E9X
DMOQ2R8	MN	Inhibitor of nuclear factor kappa-B kinase beta (IKKB)
DMOQ2R8	MT	DTT
DMOQ2R8	MA	Inhibitor
DMOQ2R8	RN	Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies. J Med Chem. 2006 May 18;49(10):2898-908.
DMOQ2R8	RU	https://pubmed.ncbi.nlm.nih.gov/16686533

DM3VJEZ	DI	DM3VJEZ
DM3VJEZ	DN	2-Amino-6-(2-bromo-benzenesulfonyl)-benzonitrile
DM3VJEZ	MI	TT84ETX
DM3VJEZ	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM3VJEZ	MT	DTT
DM3VJEZ	MA	Inhibitor
DM3VJEZ	RN	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82.
DM3VJEZ	RU	https://pubmed.ncbi.nlm.nih.gov/11384233

DMFW9D3	DI	DMFW9D3
DMFW9D3	DN	2-Amino-6-(2-chloro-benzenesulfonyl)-benzonitrile
DMFW9D3	MI	TT84ETX
DMFW9D3	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMFW9D3	MT	DTT
DMFW9D3	MA	Inhibitor
DMFW9D3	RN	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82.
DMFW9D3	RU	https://pubmed.ncbi.nlm.nih.gov/11384233

DM7391H	DI	DM7391H
DM7391H	DN	2-Amino-6-(2-chloro-phenylsulfanyl)-benzonitrile
DM7391H	MI	TT84ETX
DM7391H	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM7391H	MT	DTT
DM7391H	MA	Inhibitor
DM7391H	RN	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82.
DM7391H	RU	https://pubmed.ncbi.nlm.nih.gov/11384233

DM8O6AC	DI	DM8O6AC
DM8O6AC	DN	2-Amino-6-(2-cyano-benzenesulfinyl)-benzonitrile
DM8O6AC	MI	TT84ETX
DM8O6AC	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM8O6AC	MT	DTT
DM8O6AC	MA	Inhibitor
DM8O6AC	RN	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82.
DM8O6AC	RU	https://pubmed.ncbi.nlm.nih.gov/11384233

DMRKQLV	DI	DMRKQLV
DMRKQLV	DN	2-Amino-6-(2-cyano-benzenesulfonyl)-benzonitrile
DMRKQLV	MI	TT84ETX
DMRKQLV	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMRKQLV	MT	DTT
DMRKQLV	MA	Inhibitor
DMRKQLV	RN	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82.
DMRKQLV	RU	https://pubmed.ncbi.nlm.nih.gov/11384233

DM8UQD5	DI	DM8UQD5
DM8UQD5	DN	2-Amino-6-(2-cyano-phenylsulfanyl)-benzonitrile
DM8UQD5	MI	TT84ETX
DM8UQD5	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM8UQD5	MT	DTT
DM8UQD5	MA	Inhibitor
DM8UQD5	RN	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82.
DM8UQD5	RU	https://pubmed.ncbi.nlm.nih.gov/11384233

DMBMK8S	DI	DMBMK8S
DMBMK8S	DN	2-Amino-6-(2-fluoro-benzenesulfonyl)-benzonitrile
DMBMK8S	MI	TT84ETX
DMBMK8S	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMBMK8S	MT	DTT
DMBMK8S	MA	Inhibitor
DMBMK8S	RN	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82.
DMBMK8S	RU	https://pubmed.ncbi.nlm.nih.gov/11384233

DM0N5J4	DI	DM0N5J4
DM0N5J4	DN	2-Amino-6-(2-methoxy-phenylsulfanyl)-benzonitrile
DM0N5J4	MI	TT84ETX
DM0N5J4	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM0N5J4	MT	DTT
DM0N5J4	MA	Inhibitor
DM0N5J4	RN	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82.
DM0N5J4	RU	https://pubmed.ncbi.nlm.nih.gov/11384233

DM6R98Y	DI	DM6R98Y
DM6R98Y	DN	2-Amino-6-(3-bromo-benzenesulfinyl)-benzonitrile
DM6R98Y	MI	TT84ETX
DM6R98Y	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM6R98Y	MT	DTT
DM6R98Y	MA	Inhibitor
DM6R98Y	RN	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82.
DM6R98Y	RU	https://pubmed.ncbi.nlm.nih.gov/11384233

DMTUM78	DI	DMTUM78
DMTUM78	DN	2-Amino-6-(3-bromo-benzenesulfonyl)-benzonitrile
DMTUM78	MI	TT84ETX
DMTUM78	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMTUM78	MT	DTT
DMTUM78	MA	Inhibitor
DMTUM78	RN	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82.
DMTUM78	RU	https://pubmed.ncbi.nlm.nih.gov/11384233

DMH4TRD	DI	DMH4TRD
DMH4TRD	DN	2-Amino-6-(3-bromo-phenylsulfanyl)-benzonitrile
DMH4TRD	MI	TT84ETX
DMH4TRD	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMH4TRD	MT	DTT
DMH4TRD	MA	Inhibitor
DMH4TRD	RN	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82.
DMH4TRD	RU	https://pubmed.ncbi.nlm.nih.gov/11384233

DM9XKJQ	DI	DM9XKJQ
DM9XKJQ	DN	2-Amino-6-(3-chloro-benzenesulfonyl)-benzonitrile
DM9XKJQ	MI	TT84ETX
DM9XKJQ	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM9XKJQ	MT	DTT
DM9XKJQ	MA	Inhibitor
DM9XKJQ	RN	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82.
DM9XKJQ	RU	https://pubmed.ncbi.nlm.nih.gov/11384233

DMT3KP0	DI	DMT3KP0
DMT3KP0	DN	2-Amino-6-(3-chloro-phenylsulfanyl)-benzonitrile
DMT3KP0	MI	TT84ETX
DMT3KP0	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMT3KP0	MT	DTT
DMT3KP0	MA	Inhibitor
DMT3KP0	RN	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82.
DMT3KP0	RU	https://pubmed.ncbi.nlm.nih.gov/11384233

DM9GQ1U	DI	DM9GQ1U
DM9GQ1U	DN	2-Amino-6-(3-cyano-benzenesulfonyl)-benzonitrile
DM9GQ1U	MI	TT84ETX
DM9GQ1U	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM9GQ1U	MT	DTT
DM9GQ1U	MA	Inhibitor
DM9GQ1U	RN	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82.
DM9GQ1U	RU	https://pubmed.ncbi.nlm.nih.gov/11384233

DM2MCK1	DI	DM2MCK1
DM2MCK1	DN	2-Amino-6-(3-cyano-phenylsulfanyl)-benzonitrile
DM2MCK1	MI	TT84ETX
DM2MCK1	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM2MCK1	MT	DTT
DM2MCK1	MA	Inhibitor
DM2MCK1	RN	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82.
DM2MCK1	RU	https://pubmed.ncbi.nlm.nih.gov/11384233

DMG7HP2	DI	DMG7HP2
DMG7HP2	DN	2-Amino-6-(3-fluoro-phenylsulfanyl)-benzonitrile
DMG7HP2	MI	TT84ETX
DMG7HP2	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMG7HP2	MT	DTT
DMG7HP2	MA	Inhibitor
DMG7HP2	RN	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82.
DMG7HP2	RU	https://pubmed.ncbi.nlm.nih.gov/11384233

DMACYWZ	DI	DMACYWZ
DMACYWZ	DN	2-Amino-6-(3-methoxy-phenylsulfanyl)-benzonitrile
DMACYWZ	MI	TT84ETX
DMACYWZ	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMACYWZ	MT	DTT
DMACYWZ	MA	Inhibitor
DMACYWZ	RN	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82.
DMACYWZ	RU	https://pubmed.ncbi.nlm.nih.gov/11384233

DML6EFV	DI	DML6EFV
DML6EFV	DN	2-Amino-6-(4-chloro-phenylsulfanyl)-benzonitrile
DML6EFV	MI	TT84ETX
DML6EFV	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DML6EFV	MT	DTT
DML6EFV	MA	Inhibitor
DML6EFV	RN	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82.
DML6EFV	RU	https://pubmed.ncbi.nlm.nih.gov/11384233

DMECHD0	DI	DMECHD0
DMECHD0	DN	2-Amino-6-(indan-5-ylamino)-3H-pyrimidin-4-one
DMECHD0	MI	TT2GPK3
DMECHD0	MN	DNA topoisomerase (TOP)
DMECHD0	MT	DTT
DMECHD0	MA	Inhibitor
DMECHD0	RN	Inhibitors of Bacillus subtilis DNA polymerase III. Influence of modifications in the pyrimidine ring of anilino- and (benzylamino)pyrimidines. J Med Chem. 1986 May;29(5):676-81.
DMECHD0	RU	https://pubmed.ncbi.nlm.nih.gov/3084785

DMXPWHF	DI	DMXPWHF
DMXPWHF	DN	2-Amino-6-(naphthalene-1-sulfonyl)-benzonitrile
DMXPWHF	MI	TT84ETX
DMXPWHF	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMXPWHF	MT	DTT
DMXPWHF	MA	Inhibitor
DMXPWHF	RN	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82.
DMXPWHF	RU	https://pubmed.ncbi.nlm.nih.gov/11384233

DMMKJYG	DI	DMMKJYG
DMMKJYG	DN	2-Amino-6-(naphthalene-2-sulfonyl)-benzonitrile
DMMKJYG	MI	TT84ETX
DMMKJYG	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMMKJYG	MT	DTT
DMMKJYG	MA	Inhibitor
DMMKJYG	RN	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82.
DMMKJYG	RU	https://pubmed.ncbi.nlm.nih.gov/11384233

DMWGE3U	DI	DMWGE3U
DMWGE3U	DN	2-Amino-6-(toluene-2-sulfonyl)-benzonitrile
DMWGE3U	MI	TT84ETX
DMWGE3U	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMWGE3U	MT	DTT
DMWGE3U	MA	Inhibitor
DMWGE3U	RN	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82.
DMWGE3U	RU	https://pubmed.ncbi.nlm.nih.gov/11384233

DMJXWH0	DI	DMJXWH0
DMJXWH0	DN	2-Amino-6-(toluene-3-sulfinyl)-benzonitrile
DMJXWH0	MI	TT84ETX
DMJXWH0	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMJXWH0	MT	DTT
DMJXWH0	MA	Inhibitor
DMJXWH0	RN	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82.
DMJXWH0	RU	https://pubmed.ncbi.nlm.nih.gov/11384233

DM1EGP9	DI	DM1EGP9
DM1EGP9	DN	2-Amino-6-(toluene-3-sulfonyl)-benzonitrile
DM1EGP9	MI	TT84ETX
DM1EGP9	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM1EGP9	MT	DTT
DM1EGP9	MA	Inhibitor
DM1EGP9	RN	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82.
DM1EGP9	RU	https://pubmed.ncbi.nlm.nih.gov/11384233

DMB7415	DI	DMB7415
DMB7415	DN	2-Amino-6-(toluene-4-sulfonyl)-benzonitrile
DMB7415	MI	TT84ETX
DMB7415	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMB7415	MT	DTT
DMB7415	MA	Inhibitor
DMB7415	RN	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82.
DMB7415	RU	https://pubmed.ncbi.nlm.nih.gov/11384233

DMJ4H9F	DI	DMJ4H9F
DMJ4H9F	DN	2-Amino-6-benzenesulfonyl-benzonitrile
DMJ4H9F	MI	TT84ETX
DMJ4H9F	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMJ4H9F	MT	DTT
DMJ4H9F	MA	Inhibitor
DMJ4H9F	RN	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82.
DMJ4H9F	RU	https://pubmed.ncbi.nlm.nih.gov/11384233

DMJVG30	DI	DMJVG30
DMJVG30	DN	2-Amino-6-Chloropyrazine
DMJVG30	MI	TT7HF4W
DMJVG30	MN	Cyclin-dependent kinase 2 (CDK2)
DMJVG30	MT	DTT
DMJVG30	MA	Inhibitor
DMJVG30	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMJVG30	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMUYTXS	DI	DMUYTXS
DMUYTXS	DN	2-Amino-6-furan-2-yl-4-phenyl-nicotinonitrile
DMUYTXS	MI	TTK25J1
DMUYTXS	MN	Adenosine A1 receptor (ADORA1)
DMUYTXS	MT	DTT
DMUYTXS	MA	Inhibitor
DMUYTXS	RN	2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem. 2008 Aug 14;51(15):4449-55.
DMUYTXS	RU	https://pubmed.ncbi.nlm.nih.gov/18637670

DMUYTXS	DI	DMUYTXS
DMUYTXS	DN	2-Amino-6-furan-2-yl-4-phenyl-nicotinonitrile
DMUYTXS	MI	TTM2AOE
DMUYTXS	MN	Adenosine A2a receptor (ADORA2A)
DMUYTXS	MT	DTT
DMUYTXS	MA	Inhibitor
DMUYTXS	RN	2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem. 2008 Aug 14;51(15):4449-55.
DMUYTXS	RU	https://pubmed.ncbi.nlm.nih.gov/18637670

DMUYTXS	DI	DMUYTXS
DMUYTXS	DN	2-Amino-6-furan-2-yl-4-phenyl-nicotinonitrile
DMUYTXS	MI	TTNE7KG
DMUYTXS	MN	Adenosine A2b receptor (ADORA2B)
DMUYTXS	MT	DTT
DMUYTXS	MA	Inhibitor
DMUYTXS	RN	2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem. 2008 Aug 14;51(15):4449-55.
DMUYTXS	RU	https://pubmed.ncbi.nlm.nih.gov/18637670

DMQF9H1	DI	DMQF9H1
DMQF9H1	DN	2-Amino-6-m-tolylsulfanyl-benzonitrile
DMQF9H1	MI	TT84ETX
DMQF9H1	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMQF9H1	MT	DTT
DMQF9H1	MA	Inhibitor
DMQF9H1	RN	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82.
DMQF9H1	RU	https://pubmed.ncbi.nlm.nih.gov/11384233

DMAXESK	DI	DMAXESK
DMAXESK	DN	2-amino-6-phenyl-4-p-tolylnicotinonitrile
DMAXESK	MI	TTK25J1
DMAXESK	MN	Adenosine A1 receptor (ADORA1)
DMAXESK	MT	DTT
DMAXESK	MA	Inhibitor
DMAXESK	RN	Identification of non-furan containing A2A antagonists using database mining and molecular similarity approaches. Bioorg Med Chem Lett. 2006 Dec 1;16(23):5993-7.
DMAXESK	RU	https://pubmed.ncbi.nlm.nih.gov/16971117

DMAXESK	DI	DMAXESK
DMAXESK	DN	2-amino-6-phenyl-4-p-tolylnicotinonitrile
DMAXESK	MI	TTM2AOE
DMAXESK	MN	Adenosine A2a receptor (ADORA2A)
DMAXESK	MT	DTT
DMAXESK	MA	Inhibitor
DMAXESK	RN	Identification of non-furan containing A2A antagonists using database mining and molecular similarity approaches. Bioorg Med Chem Lett. 2006 Dec 1;16(23):5993-7.
DMAXESK	RU	https://pubmed.ncbi.nlm.nih.gov/16971117

DM7M9CL	DI	DM7M9CL
DM7M9CL	DN	2-Amino-6-phenyl-4-thiophen-2-yl-nicotinonitrile
DM7M9CL	MI	TTK25J1
DM7M9CL	MN	Adenosine A1 receptor (ADORA1)
DM7M9CL	MT	DTT
DM7M9CL	MA	Inhibitor
DM7M9CL	RN	2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem. 2008 Aug 14;51(15):4449-55.
DM7M9CL	RU	https://pubmed.ncbi.nlm.nih.gov/18637670

DM7M9CL	DI	DM7M9CL
DM7M9CL	DN	2-Amino-6-phenyl-4-thiophen-2-yl-nicotinonitrile
DM7M9CL	MI	TTM2AOE
DM7M9CL	MN	Adenosine A2a receptor (ADORA2A)
DM7M9CL	MT	DTT
DM7M9CL	MA	Inhibitor
DM7M9CL	RN	2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem. 2008 Aug 14;51(15):4449-55.
DM7M9CL	RU	https://pubmed.ncbi.nlm.nih.gov/18637670

DMMBGK0	DI	DMMBGK0
DMMBGK0	DN	2-Amino-6-phenylsulfanyl-benzonitrile
DMMBGK0	MI	TT84ETX
DMMBGK0	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMMBGK0	MT	DTT
DMMBGK0	MA	Inhibitor
DMMBGK0	RN	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82.
DMMBGK0	RU	https://pubmed.ncbi.nlm.nih.gov/11384233

DM4BQ1W	DI	DM4BQ1W
DM4BQ1W	DN	2-Amino-6-p-tolylsulfanyl-benzonitrile
DM4BQ1W	MI	TT84ETX
DM4BQ1W	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM4BQ1W	MT	DTT
DM4BQ1W	MA	Inhibitor
DM4BQ1W	RN	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82.
DM4BQ1W	RU	https://pubmed.ncbi.nlm.nih.gov/11384233

DMRSGC5	DI	DMRSGC5
DMRSGC5	DN	2-amino-8-methyl-7,8-dihydropteridin-4(3H)-one
DMRSGC5	MI	TT4ILYC
DMRSGC5	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMRSGC5	MT	DTT
DMRSGC5	MA	Inhibitor
DMRSGC5	RN	Structural studies of pterin-based inhibitors of dihydropteroate synthase. J Med Chem. 2010 Jan 14;53(1):166-77.
DMRSGC5	RU	https://pubmed.ncbi.nlm.nih.gov/19899766

DMEMANH	DI	DMEMANH
DMEMANH	DN	2-Amino-benzenesulfonamide
DMEMANH	MI	TTUNARX
DMEMANH	MN	Carbonic anhydrase (CA)
DMEMANH	MT	DTT
DMEMANH	MA	Inhibitor
DMEMANH	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DMEMANH	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DMEMANH	DI	DMEMANH
DMEMANH	DN	2-Amino-benzenesulfonamide
DMEMANH	MI	TTANPDJ
DMEMANH	MN	Carbonic anhydrase II (CA-II)
DMEMANH	MT	DTT
DMEMANH	MA	Inhibitor
DMEMANH	RN	Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, ... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6649-54.
DMEMANH	RU	https://pubmed.ncbi.nlm.nih.gov/19846301

DMEMANH	DI	DMEMANH
DMEMANH	DN	2-Amino-benzenesulfonamide
DMEMANH	MI	TT2LVK8
DMEMANH	MN	Carbonic anhydrase IX (CA-IX)
DMEMANH	MT	DTT
DMEMANH	MA	Inhibitor
DMEMANH	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DMEMANH	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DMEMANH	DI	DMEMANH
DMEMANH	DN	2-Amino-benzenesulfonamide
DMEMANH	MI	TTCFSPE
DMEMANH	MN	Carbonic anhydrase VI (CA-VI)
DMEMANH	MT	DTT
DMEMANH	MA	Inhibitor
DMEMANH	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DMEMANH	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DMEMANH	DI	DMEMANH
DMEMANH	DN	2-Amino-benzenesulfonamide
DMEMANH	MI	TTSYM0R
DMEMANH	MN	Carbonic anhydrase XII (CA-XII)
DMEMANH	MT	DTT
DMEMANH	MA	Inhibitor
DMEMANH	RN	Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglauc... Bioorg Med Chem Lett. 2005 Feb 15;15(4):963-9.
DMEMANH	RU	https://pubmed.ncbi.nlm.nih.gov/15686894

DMEMANH	DI	DMEMANH
DMEMANH	DN	2-Amino-benzenesulfonamide
DMEMANH	MI	TTEYTKG
DMEMANH	MN	Carbonic anhydrase XIV (CA-XIV)
DMEMANH	MT	DTT
DMEMANH	MA	Inhibitor
DMEMANH	RN	Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33.
DMEMANH	RU	https://pubmed.ncbi.nlm.nih.gov/16039848

DM2OE1W	DI	DM2OE1W
DM2OE1W	DN	2-Aminoethanimidic Acid
DM2OE1W	MI	TTF2LRI
DM2OE1W	MN	Cathepsin B (CTSB)
DM2OE1W	MT	DTT
DM2OE1W	MA	Inhibitor
DM2OE1W	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM2OE1W	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMUJC2E	DI	DMUJC2E
DMUJC2E	DN	2'-aminoimidazolylmethyluracils
DMUJC2E	MI	TTO0IB8
DMUJC2E	MN	Thymidine phosphorylase (TYMP)
DMUJC2E	MT	DTT
DMUJC2E	MA	Inhibitor
DMUJC2E	RN	Potential tumor-selective nitroimidazolylmethyluracil prodrug derivatives: inhibitors of the angiogenic enzyme thymidine phosphorylase. J Med Chem. 2003 Jan 16;46(2):207-9.
DMUJC2E	RU	https://pubmed.ncbi.nlm.nih.gov/12519058

DMCUSH1	DI	DMCUSH1
DMCUSH1	DN	2-Amino-indan-5-sulfonic acid
DMCUSH1	MI	TTUNARX
DMCUSH1	MN	Carbonic anhydrase (CA)
DMCUSH1	MT	DTT
DMCUSH1	MA	Inhibitor
DMCUSH1	RN	Indanesulfonamides as carbonic anhydrase inhibitors and anticonvulsant agents: structure-activity relationship and pharmacological evaluation. Eur J Med Chem. 2008 Dec;43(12):2853-60.
DMCUSH1	RU	https://pubmed.ncbi.nlm.nih.gov/18406497

DMCUSH1	DI	DMCUSH1
DMCUSH1	DN	2-Amino-indan-5-sulfonic acid
DMCUSH1	MI	TTHQPL7
DMCUSH1	MN	Carbonic anhydrase I (CA-I)
DMCUSH1	MT	DTT
DMCUSH1	MA	Inhibitor
DMCUSH1	RN	Carbonic anhydrase inhibitors. Design of anticonvulsant sulfonamides incorporating indane moieties. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5781-6.
DMCUSH1	RU	https://pubmed.ncbi.nlm.nih.gov/15501040

DMCUSH1	DI	DMCUSH1
DMCUSH1	DN	2-Amino-indan-5-sulfonic acid
DMCUSH1	MI	TTANPDJ
DMCUSH1	MN	Carbonic anhydrase II (CA-II)
DMCUSH1	MT	DTT
DMCUSH1	MA	Inhibitor
DMCUSH1	RN	Carbonic anhydrase inhibitors. Design of anticonvulsant sulfonamides incorporating indane moieties. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5781-6.
DMCUSH1	RU	https://pubmed.ncbi.nlm.nih.gov/15501040

DMCUSH1	DI	DMCUSH1
DMCUSH1	DN	2-Amino-indan-5-sulfonic acid
DMCUSH1	MI	TTSYM0R
DMCUSH1	MN	Carbonic anhydrase XII (CA-XII)
DMCUSH1	MT	DTT
DMCUSH1	MA	Inhibitor
DMCUSH1	RN	Indanesulfonamides as carbonic anhydrase inhibitors and anticonvulsant agents: structure-activity relationship and pharmacological evaluation. Eur J Med Chem. 2008 Dec;43(12):2853-60.
DMCUSH1	RU	https://pubmed.ncbi.nlm.nih.gov/18406497

DMCUSH1	DI	DMCUSH1
DMCUSH1	DN	2-Amino-indan-5-sulfonic acid
DMCUSH1	MI	TTEYTKG
DMCUSH1	MN	Carbonic anhydrase XIV (CA-XIV)
DMCUSH1	MT	DTT
DMCUSH1	MA	Inhibitor
DMCUSH1	RN	Indanesulfonamides as carbonic anhydrase inhibitors and anticonvulsant agents: structure-activity relationship and pharmacological evaluation. Eur J Med Chem. 2008 Dec;43(12):2853-60.
DMCUSH1	RU	https://pubmed.ncbi.nlm.nih.gov/18406497

DMCJUWK	DI	DMCJUWK
DMCJUWK	DN	2-Aminomethyl-5-(p-bromophenyl)tetrahydrofuran
DMCJUWK	MI	TTVBI8W
DMCJUWK	MN	Dopamine transporter (DAT)
DMCJUWK	MT	DTT
DMCJUWK	MA	Inhibitor
DMCJUWK	RN	2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68.
DMCJUWK	RU	https://pubmed.ncbi.nlm.nih.gov/19201198

DMCJUWK	DI	DMCJUWK
DMCJUWK	DN	2-Aminomethyl-5-(p-bromophenyl)tetrahydrofuran
DMCJUWK	MI	TTAWNKZ
DMCJUWK	MN	Norepinephrine transporter (NET)
DMCJUWK	MT	DTT
DMCJUWK	MA	Inhibitor
DMCJUWK	RN	2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68.
DMCJUWK	RU	https://pubmed.ncbi.nlm.nih.gov/19201198

DMCJUWK	DI	DMCJUWK
DMCJUWK	DN	2-Aminomethyl-5-(p-bromophenyl)tetrahydrofuran
DMCJUWK	MI	TT3ROYC
DMCJUWK	MN	Serotonin transporter (SERT)
DMCJUWK	MT	DTT
DMCJUWK	MA	Inhibitor
DMCJUWK	RN	2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68.
DMCJUWK	RU	https://pubmed.ncbi.nlm.nih.gov/19201198

DM3OTZY	DI	DM3OTZY
DM3OTZY	DN	2-Aminomethyl-5-(p-chlorophenyl)tetrahydrofuran
DM3OTZY	MI	TTVBI8W
DM3OTZY	MN	Dopamine transporter (DAT)
DM3OTZY	MT	DTT
DM3OTZY	MA	Inhibitor
DM3OTZY	RN	2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68.
DM3OTZY	RU	https://pubmed.ncbi.nlm.nih.gov/19201198

DM3OTZY	DI	DM3OTZY
DM3OTZY	DN	2-Aminomethyl-5-(p-chlorophenyl)tetrahydrofuran
DM3OTZY	MI	TTAWNKZ
DM3OTZY	MN	Norepinephrine transporter (NET)
DM3OTZY	MT	DTT
DM3OTZY	MA	Inhibitor
DM3OTZY	RN	2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68.
DM3OTZY	RU	https://pubmed.ncbi.nlm.nih.gov/19201198

DM3OTZY	DI	DM3OTZY
DM3OTZY	DN	2-Aminomethyl-5-(p-chlorophenyl)tetrahydrofuran
DM3OTZY	MI	TT3ROYC
DM3OTZY	MN	Serotonin transporter (SERT)
DM3OTZY	MT	DTT
DM3OTZY	MA	Inhibitor
DM3OTZY	RN	2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68.
DM3OTZY	RU	https://pubmed.ncbi.nlm.nih.gov/19201198

DM413ZB	DI	DM413ZB
DM413ZB	DN	2-Aminomethyl-5-(phenyl)tetrahydrofuran
DM413ZB	MI	TTVBI8W
DM413ZB	MN	Dopamine transporter (DAT)
DM413ZB	MT	DTT
DM413ZB	MA	Inhibitor
DM413ZB	RN	2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68.
DM413ZB	RU	https://pubmed.ncbi.nlm.nih.gov/19201198

DM413ZB	DI	DM413ZB
DM413ZB	DN	2-Aminomethyl-5-(phenyl)tetrahydrofuran
DM413ZB	MI	TTAWNKZ
DM413ZB	MN	Norepinephrine transporter (NET)
DM413ZB	MT	DTT
DM413ZB	MA	Inhibitor
DM413ZB	RN	2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68.
DM413ZB	RU	https://pubmed.ncbi.nlm.nih.gov/19201198

DM413ZB	DI	DM413ZB
DM413ZB	DN	2-Aminomethyl-5-(phenyl)tetrahydrofuran
DM413ZB	MI	TT3ROYC
DM413ZB	MN	Serotonin transporter (SERT)
DM413ZB	MT	DTT
DM413ZB	MA	Inhibitor
DM413ZB	RN	2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68.
DM413ZB	RU	https://pubmed.ncbi.nlm.nih.gov/19201198

DMDG8FL	DI	DMDG8FL
DMDG8FL	DN	2-Aminomethyl-5-(p-methoxyphenyl)tetrahydrofuran
DMDG8FL	MI	TTVBI8W
DMDG8FL	MN	Dopamine transporter (DAT)
DMDG8FL	MT	DTT
DMDG8FL	MA	Inhibitor
DMDG8FL	RN	2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68.
DMDG8FL	RU	https://pubmed.ncbi.nlm.nih.gov/19201198

DMDG8FL	DI	DMDG8FL
DMDG8FL	DN	2-Aminomethyl-5-(p-methoxyphenyl)tetrahydrofuran
DMDG8FL	MI	TTAWNKZ
DMDG8FL	MN	Norepinephrine transporter (NET)
DMDG8FL	MT	DTT
DMDG8FL	MA	Inhibitor
DMDG8FL	RN	2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68.
DMDG8FL	RU	https://pubmed.ncbi.nlm.nih.gov/19201198

DMDG8FL	DI	DMDG8FL
DMDG8FL	DN	2-Aminomethyl-5-(p-methoxyphenyl)tetrahydrofuran
DMDG8FL	MI	TT3ROYC
DMDG8FL	MN	Serotonin transporter (SERT)
DMDG8FL	MT	DTT
DMDG8FL	MA	Inhibitor
DMDG8FL	RN	2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68.
DMDG8FL	RU	https://pubmed.ncbi.nlm.nih.gov/19201198

DME4P7K	DI	DME4P7K
DME4P7K	DN	2-Aminomethyl-5-(p-t-butylphenyl)tetrahydrofuran
DME4P7K	MI	TTVBI8W
DME4P7K	MN	Dopamine transporter (DAT)
DME4P7K	MT	DTT
DME4P7K	MA	Inhibitor
DME4P7K	RN	2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68.
DME4P7K	RU	https://pubmed.ncbi.nlm.nih.gov/19201198

DME4P7K	DI	DME4P7K
DME4P7K	DN	2-Aminomethyl-5-(p-t-butylphenyl)tetrahydrofuran
DME4P7K	MI	TTAWNKZ
DME4P7K	MN	Norepinephrine transporter (NET)
DME4P7K	MT	DTT
DME4P7K	MA	Inhibitor
DME4P7K	RN	2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68.
DME4P7K	RU	https://pubmed.ncbi.nlm.nih.gov/19201198

DME4P7K	DI	DME4P7K
DME4P7K	DN	2-Aminomethyl-5-(p-t-butylphenyl)tetrahydrofuran
DME4P7K	MI	TT3ROYC
DME4P7K	MN	Serotonin transporter (SERT)
DME4P7K	MT	DTT
DME4P7K	MA	Inhibitor
DME4P7K	RN	2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68.
DME4P7K	RU	https://pubmed.ncbi.nlm.nih.gov/19201198

DMAN8EH	DI	DMAN8EH
DMAN8EH	DN	2-Aminomethyl-pyrrolidine-3,4-diol
DMAN8EH	MI	TTXWASR
DMAN8EH	MN	Intestinal maltase-glucoamylase (MGAM)
DMAN8EH	MT	DTT
DMAN8EH	MA	Inhibitor
DMAN8EH	RN	Derivatives of (2R,3R,4S)-2-aminomethylpyrrolidine-3,4-diol are selective alpha-mannosidase inhibitors. Bioorg Med Chem Lett. 2001 Sep 17;11(18):2489-93.
DMAN8EH	RU	https://pubmed.ncbi.nlm.nih.gov/11549453

DMESFTW	DI	DMESFTW
DMESFTW	DN	2-amino-N-(quinolin-8-yl)benzenesulfonamide
DMESFTW	MI	TTSXVID
DMESFTW	MN	Nuclear factor NF-kappa-B (NFKB)
DMESFTW	MT	DTT
DMESFTW	MA	Inhibitor
DMESFTW	RN	Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFkappaB activity within two separate high-throughput s... Bioorg Med Chem Lett. 2008 Jan 1;18(1):329-35.
DMESFTW	RU	https://pubmed.ncbi.nlm.nih.gov/18024113

DM3YI9P	DI	DM3YI9P
DM3YI9P	DN	2-Amino-N,3,3-Trimethylbutanamide
DM3YI9P	MI	TT6X50U
DM3YI9P	MN	Matrix metalloproteinase-9 (MMP-9)
DM3YI9P	MT	DTT
DM3YI9P	MA	Inhibitor
DM3YI9P	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM3YI9P	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMRY06D	DI	DMRY06D
DMRY06D	DN	2-Amino-N-[4-(phenylmethoxy)phenyl]-acetamide
DMRY06D	MI	TTXZEAJ
DMRY06D	MN	Leukotriene A-4 hydrolase (LTA4H)
DMRY06D	MT	DTT
DMRY06D	MA	Inhibitor
DMRY06D	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMRY06D	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMQ30UY	DI	DMQ30UY
DMQ30UY	DN	2-amino-N1-benzyl-N3-hydroxymalonamide
DMQ30UY	MI	TTPHMWB
DMQ30UY	MN	Aminopeptidase N (ANPEP)
DMQ30UY	MT	DTT
DMQ30UY	MA	Inhibitor
DMQ30UY	RN	Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents. J Med Chem. 2007 Mar 22;50(6):1322-34.
DMQ30UY	RU	https://pubmed.ncbi.nlm.nih.gov/17326615

DM320RW	DI	DM320RW
DM320RW	DN	2-amino-N-benzyl-6-phenyl-9H-purine-9-carboxamide
DM320RW	MI	TTK25J1
DM320RW	MN	Adenosine A1 receptor (ADORA1)
DM320RW	MT	DTT
DM320RW	MA	Inhibitor
DM320RW	RN	Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpu... Bioorg Med Chem Lett. 2008 May 1;18(9):2924-9.
DM320RW	RU	https://pubmed.ncbi.nlm.nih.gov/18411049

DM320RW	DI	DM320RW
DM320RW	DN	2-amino-N-benzyl-6-phenyl-9H-purine-9-carboxamide
DM320RW	MI	TTM2AOE
DM320RW	MN	Adenosine A2a receptor (ADORA2A)
DM320RW	MT	DTT
DM320RW	MA	Inhibitor
DM320RW	RN	Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpu... Bioorg Med Chem Lett. 2008 May 1;18(9):2924-9.
DM320RW	RU	https://pubmed.ncbi.nlm.nih.gov/18411049

DMBVGAO	DI	DMBVGAO
DMBVGAO	DN	2-aminophenoxazine-3-one
DMBVGAO	MI	TTF0RCZ
DMBVGAO	MN	Apoptosis mediating surface antigen FAS (FAS)
DMBVGAO	MT	DTT
DMBVGAO	MA	Activator
DMBVGAO	RN	Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside. Drug Discov Today. 2020 Jul;25(7):1189-1197.
DMBVGAO	RU	https://pubmed.ncbi.nlm.nih.gov/32389641

DMBVGAO	DI	DMBVGAO
DMBVGAO	DN	2-aminophenoxazine-3-one
DMBVGAO	MI	TTZY5KP
DMBVGAO	MN	Caspase (CASP)
DMBVGAO	MT	DTT
DMBVGAO	MA	Activator
DMBVGAO	RN	Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside. Drug Discov Today. 2020 Jul;25(7):1189-1197.
DMBVGAO	RU	https://pubmed.ncbi.nlm.nih.gov/32389641

DMQIC3L	DI	DMQIC3L
DMQIC3L	DN	2-aminopyridine
DMQIC3L	MI	TTZUFI5
DMQIC3L	MN	Nitric-oxide synthase brain (NOS1)
DMQIC3L	MT	DTT
DMQIC3L	MA	Inhibitor
DMQIC3L	RN	L337H mutant of rat neuronal nitric oxide synthase resembles human neuronal nitric oxide synthase toward inhibitors. J Med Chem. 2009 Jul 23;52(14):4533-7.
DMQIC3L	RU	https://pubmed.ncbi.nlm.nih.gov/19537690

DMJW4CS	DI	DMJW4CS
DMJW4CS	DN	2-aminoquinazoline-4-carboxy-(4-bromophenyl)amide
DMJW4CS	MI	TTJFY5U
DMJW4CS	MN	Adenosine A3 receptor (ADORA3)
DMJW4CS	MT	DTT
DMJW4CS	MA	Inhibitor
DMJW4CS	RN	Scouting human A3 adenosine receptor antagonist binding mode using a molecular simplification approach: from triazoloquinoxaline to a pyrimidine sk... J Med Chem. 2007 Dec 27;50(26):6596-606.
DMJW4CS	RU	https://pubmed.ncbi.nlm.nih.gov/18047262

DMQJYX7	DI	DMQJYX7
DMQJYX7	DN	2-aminoquinazoline-4-carboxyanilide
DMQJYX7	MI	TTJFY5U
DMQJYX7	MN	Adenosine A3 receptor (ADORA3)
DMQJYX7	MT	DTT
DMQJYX7	MA	Inhibitor
DMQJYX7	RN	Scouting human A3 adenosine receptor antagonist binding mode using a molecular simplification approach: from triazoloquinoxaline to a pyrimidine sk... J Med Chem. 2007 Dec 27;50(26):6596-606.
DMQJYX7	RU	https://pubmed.ncbi.nlm.nih.gov/18047262

DME4856	DI	DME4856
DME4856	DN	2-amino-quinoline-3-carboxylic acid amide
DME4856	MI	TTJ3E9X
DME4856	MN	Inhibitor of nuclear factor kappa-B kinase beta (IKKB)
DME4856	MT	DTT
DME4856	MA	Inhibitor
DME4856	RN	Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies. J Med Chem. 2006 May 18;49(10):2898-908.
DME4856	RU	https://pubmed.ncbi.nlm.nih.gov/16686533

DM9YCAH	DI	DM9YCAH
DM9YCAH	DN	2-Aminothiazoline
DM9YCAH	MI	TTZUFI5
DM9YCAH	MN	Nitric-oxide synthase brain (NOS1)
DM9YCAH	MT	DTT
DM9YCAH	MA	Inhibitor
DM9YCAH	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DM9YCAH	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DM9YCAH	DI	DM9YCAH
DM9YCAH	DN	2-Aminothiazoline
DM9YCAH	MI	TTCM4B3
DM9YCAH	MN	Nitric-oxide synthase endothelial (NOS3)
DM9YCAH	MT	DTT
DM9YCAH	MA	Inhibitor
DM9YCAH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9YCAH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9YCAH	DI	DM9YCAH
DM9YCAH	DN	2-Aminothiazoline
DM9YCAH	MI	TTF10I9
DM9YCAH	MN	Nitric-oxide synthase inducible (NOS2)
DM9YCAH	MT	DTT
DM9YCAH	MA	Inhibitor
DM9YCAH	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DM9YCAH	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DMO792L	DI	DMO792L
DMO792L	DN	2-amino-uridine-5'-monophosphate
DMO792L	MI	TT24DGP
DMO792L	MN	P2Y purinoceptor 4 (P2RY4)
DMO792L	MT	DTT
DMO792L	MA	Agonist
DMO792L	RN	Structural modifications of UMP, UDP, and UTP leading to subtype-selective agonists for P2Y2, P2Y4, and P2Y6 receptors. J Med Chem. 2011 Apr 28;54(8):2878-90.
DMO792L	RU	https://pubmed.ncbi.nlm.nih.gov/21417463

DMFNEZW	DI	DMFNEZW
DMFNEZW	DN	2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE
DMFNEZW	MI	TT7HF4W
DMFNEZW	MN	Cyclin-dependent kinase 2 (CDK2)
DMFNEZW	MT	DTT
DMFNEZW	MA	Inhibitor
DMFNEZW	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMFNEZW	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM9AKVR	DI	DM9AKVR
DM9AKVR	DN	2-APB
DM9AKVR	MI	TTEBMN7
DM9AKVR	MN	Long transient receptor potential channel 2 (TRPM2)
DM9AKVR	MT	DTT
DM9AKVR	MA	Blocker (channel blocker)
DM9AKVR	RN	Inhibition of the transient receptor potential cation channel TRPM2 by 2-aminoethoxydiphenyl borate (2-APB). Br J Pharmacol. 2008 Mar;153(6):1324-30.
DM9AKVR	RU	https://pubmed.ncbi.nlm.nih.gov/18204483

DM9AKVR	DI	DM9AKVR
DM9AKVR	DN	2-APB
DM9AKVR	MI	TTO3TD8
DM9AKVR	MN	Long transient receptor potential channel 3 (TRPM3)
DM9AKVR	MT	DTT
DM9AKVR	MA	Inhibitor (gating inhibitor)
DM9AKVR	RN	Block of TRPC5 channels by 2-aminoethoxydiphenyl borate: a differential, extracellular and voltage-dependent effect. Br J Pharmacol. 2005 Jun;145(4):405-14.
DM9AKVR	RU	https://pubmed.ncbi.nlm.nih.gov/15806115

DM9AKVR	DI	DM9AKVR
DM9AKVR	DN	2-APB
DM9AKVR	MI	TTV76RD
DM9AKVR	MN	Long transient receptor potential channel 6 (TRPM6)
DM9AKVR	MT	DTT
DM9AKVR	MA	Activator
DM9AKVR	RN	Functional characterization of homo- and heteromeric channel kinases TRPM6 and TRPM7. J Gen Physiol. 2006 May;127(5):525-37.
DM9AKVR	RU	https://pubmed.ncbi.nlm.nih.gov/16636202

DM9AKVR	DI	DM9AKVR
DM9AKVR	DN	2-APB
DM9AKVR	MI	TTFPVZO
DM9AKVR	MN	Long transient receptor potential channel 7 (TRPM7)
DM9AKVR	MT	DTT
DM9AKVR	MA	Activator
DM9AKVR	RN	LTRPC7 is a Mg.ATP-regulated divalent cation channel required for cell viability. Nature. 2001 May 31;411(6837):590-5.
DM9AKVR	RU	https://pubmed.ncbi.nlm.nih.gov/11385574

DM9AKVR	DI	DM9AKVR
DM9AKVR	DN	2-APB
DM9AKVR	MI	TTXDKTO
DM9AKVR	MN	Long transient receptor potential channel 8 (TRPM8)
DM9AKVR	MT	DTT
DM9AKVR	MA	Blocker (channel blocker)
DM9AKVR	RN	Effects of antagonists and heat on TRPM8 channel currents in dorsal root ganglion neuron activated by nociceptive cold stress and menthol. Neurochem Res. 2012 Feb;37(2):314-20.
DM9AKVR	RU	https://pubmed.ncbi.nlm.nih.gov/21964764

DM9AKVR	DI	DM9AKVR
DM9AKVR	DN	2-APB
DM9AKVR	MI	TTA76X0
DM9AKVR	MN	Short transient receptor potential channel 1 (TRPC1)
DM9AKVR	MT	DTT
DM9AKVR	MA	Blocker (channel blocker)
DM9AKVR	RN	TRPC1 and TRPC5 form a novel cation channel in mammalian brain. Neuron. 2001 Mar;29(3):645-55.
DM9AKVR	RU	https://pubmed.ncbi.nlm.nih.gov/11301024

DM9AKVR	DI	DM9AKVR
DM9AKVR	DN	2-APB
DM9AKVR	MI	TTSJ9E7
DM9AKVR	MN	Short transient receptor potential channel 2 (TRPC2)
DM9AKVR	MT	DTT
DM9AKVR	MA	Blocker (channel blocker)
DM9AKVR	RN	A diacylglycerol-gated cation channel in vomeronasal neuron dendrites is impaired in TRPC2 mutant mice: mechanism of pheromone transduction. Neuron. 2003 Oct 30;40(3):551-61.
DM9AKVR	RU	https://pubmed.ncbi.nlm.nih.gov/14642279

DM9AKVR	DI	DM9AKVR
DM9AKVR	DN	2-APB
DM9AKVR	MI	TTNVC34
DM9AKVR	MN	Short transient receptor potential channel 3 (TRPC3)
DM9AKVR	MT	DTT
DM9AKVR	MA	Blocker (channel blocker)
DM9AKVR	RN	Mechanism of inhibition of TRPC cation channels by 2-aminoethoxydiphenylborane. Mol Pharmacol. 2005 Sep;68(3):758-62.
DM9AKVR	RU	https://pubmed.ncbi.nlm.nih.gov/15933213

DM9AKVR	DI	DM9AKVR
DM9AKVR	DN	2-APB
DM9AKVR	MI	TTX0H5W
DM9AKVR	MN	Short transient receptor potential channel 4 (TRPC4)
DM9AKVR	MT	DTT
DM9AKVR	MA	Blocker (channel blocker)
DM9AKVR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 489).
DM9AKVR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=489

DM9AKVR	DI	DM9AKVR
DM9AKVR	DN	2-APB
DM9AKVR	MI	TT32NQ1
DM9AKVR	MN	Short transient receptor potential channel 5 (TRPC5)
DM9AKVR	MT	DTT
DM9AKVR	MA	Blocker (channel blocker)
DM9AKVR	RN	Block of TRPC5 channels by 2-aminoethoxydiphenyl borate: a differential, extracellular and voltage-dependent effect. Br J Pharmacol. 2005 Jun;145(4):405-14.
DM9AKVR	RU	https://pubmed.ncbi.nlm.nih.gov/15806115

DM9AKVR	DI	DM9AKVR
DM9AKVR	DN	2-APB
DM9AKVR	MI	TTRBT3W
DM9AKVR	MN	Short transient receptor potential channel 6 (TRPC6)
DM9AKVR	MT	DTT
DM9AKVR	MA	Blocker (channel blocker)
DM9AKVR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 491).
DM9AKVR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=491

DM9AKVR	DI	DM9AKVR
DM9AKVR	DN	2-APB
DM9AKVR	MI	TT06GRA
DM9AKVR	MN	Short transient receptor potential channel 7 (TRPC7)
DM9AKVR	MT	DTT
DM9AKVR	MA	Blocker (channel blocker)
DM9AKVR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 492).
DM9AKVR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=492

DM9AKVR	DI	DM9AKVR
DM9AKVR	DN	2-APB
DM9AKVR	MI	TTMI6F5
DM9AKVR	MN	Transient receptor potential cation channel V1 (TRPV1)
DM9AKVR	MT	DTT
DM9AKVR	MA	Activator
DM9AKVR	RN	2-aminoethoxydiphenyl borate is a common activator of TRPV1, TRPV2, and TRPV3. J Biol Chem. 2004 Aug 20;279(34):35741-8.
DM9AKVR	RU	https://pubmed.ncbi.nlm.nih.gov/15194687

DM9AKVR	DI	DM9AKVR
DM9AKVR	DN	2-APB
DM9AKVR	MI	TTBECWA
DM9AKVR	MN	Transient receptor potential cation channel V2 (TRPV2)
DM9AKVR	MT	DTT
DM9AKVR	MA	Activator
DM9AKVR	RN	Pharmacological characterization and molecular determinants of the activation of transient receptor potential V2 channel orthologs by 2-aminoethoxy... Mol Pharmacol. 2007 Nov;72(5):1258-68.
DM9AKVR	RU	https://pubmed.ncbi.nlm.nih.gov/17673572

DM9AKVR	DI	DM9AKVR
DM9AKVR	DN	2-APB
DM9AKVR	MI	TT946IA
DM9AKVR	MN	Transient receptor potential cation channel V3 (TRPV3)
DM9AKVR	MT	DTT
DM9AKVR	MA	Activator
DM9AKVR	RN	2-aminoethoxydiphenyl borate activates and sensitizes the heat-gated ion channel TRPV3. J Neurosci. 2004 Jun 2;24(22):5177-82.
DM9AKVR	RU	https://pubmed.ncbi.nlm.nih.gov/15175387

DM9AKVR	DI	DM9AKVR
DM9AKVR	DN	2-APB
DM9AKVR	MI	TTBK14N
DM9AKVR	MN	Transient receptor potential cation channel V6 (TRPV6)
DM9AKVR	MT	DTT
DM9AKVR	MA	Activator
DM9AKVR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 512).
DM9AKVR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=512

DMM0KOJ	DI	DMM0KOJ
DMM0KOJ	DN	2-arachidonoylglycerol
DMM0KOJ	MI	TTDP1UC
DMM0KOJ	MN	Fatty acid amide hydrolase (FAAH)
DMM0KOJ	MT	DTT
DMM0KOJ	MA	Inhibitor
DMM0KOJ	RN	Conformationally constrained analogues of 2-arachidonoylglycerol. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5959-63.
DMM0KOJ	RU	https://pubmed.ncbi.nlm.nih.gov/17826996

DMICOL3	DI	DMICOL3
DMICOL3	DN	2-arachidonoylglycerolphosphoinositol
DMICOL3	MI	TTNET8J
DMICOL3	MN	G-protein coupled receptor 55 (GPR55)
DMICOL3	MT	DTT
DMICOL3	MA	Agonist
DMICOL3	RN	2-Arachidonoyl-sn-glycero-3-phosphoinositol: a possible natural ligand for GPR55. J Biochem. 2009 Jan;145(1):13-20.
DMICOL3	RU	https://pubmed.ncbi.nlm.nih.gov/18845565

DM2H8TV	DI	DM2H8TV
DM2H8TV	DN	2-arachidonyl glyceryl ether
DM2H8TV	MI	TTNET8J
DM2H8TV	MN	G-protein coupled receptor 55 (GPR55)
DM2H8TV	MT	DTT
DM2H8TV	MA	Agonist
DM2H8TV	RN	The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007 Dec;152(7):1092-101.
DM2H8TV	RU	https://pubmed.ncbi.nlm.nih.gov/17876302

DMBSDIV	DI	DMBSDIV
DMBSDIV	DN	2-azido-N6-methyl-9-(beta-D-ribofuranosyl)adenine
DMBSDIV	MI	TTK25J1
DMBSDIV	MN	Adenosine A1 receptor (ADORA1)
DMBSDIV	MT	DTT
DMBSDIV	MA	Inhibitor
DMBSDIV	RN	2-triazole-substituted adenosines: a new class of selective A3 adenosine receptor agonists, partial agonists, and antagonists. J Med Chem. 2006 Dec 14;49(25):7373-83.
DMBSDIV	RU	https://pubmed.ncbi.nlm.nih.gov/17149867

DMBSDIV	DI	DMBSDIV
DMBSDIV	DN	2-azido-N6-methyl-9-(beta-D-ribofuranosyl)adenine
DMBSDIV	MI	TTJFY5U
DMBSDIV	MN	Adenosine A3 receptor (ADORA3)
DMBSDIV	MT	DTT
DMBSDIV	MA	Inhibitor
DMBSDIV	RN	2-triazole-substituted adenosines: a new class of selective A3 adenosine receptor agonists, partial agonists, and antagonists. J Med Chem. 2006 Dec 14;49(25):7373-83.
DMBSDIV	RU	https://pubmed.ncbi.nlm.nih.gov/17149867

DMXZ1HL	DI	DMXZ1HL
DMXZ1HL	DN	2-Benzhydryl-7-hydroxy-chromen-4-one
DMXZ1HL	MI	TTFBNVI
DMXZ1HL	MN	Aldose reductase (AKR1B1)
DMXZ1HL	MT	DTT
DMXZ1HL	MA	Inhibitor
DMXZ1HL	RN	1-Benzopyran-4-one antioxidants as aldose reductase inhibitors. J Med Chem. 1999 Jun 3;42(11):1881-93.
DMXZ1HL	RU	https://pubmed.ncbi.nlm.nih.gov/10354396

DMQX9PD	DI	DMQX9PD
DMQX9PD	DN	2-Benzoxy-5-(2-methylquinolin-7-yl)benzonitrile
DMQX9PD	MI	TTHS256
DMQX9PD	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMQX9PD	MT	DTT
DMQX9PD	MA	Inhibitor
DMQX9PD	RN	Structure-activity relationships in a novel series of 7-substituted-aryl quinolines and 5-substituted-aryl benzothiazoles at the metabotropic gluta... Bioorg Med Chem. 2010 May 1;18(9):3026-35.
DMQX9PD	RU	https://pubmed.ncbi.nlm.nih.gov/20382541

DMO97FR	DI	DMO97FR
DMO97FR	DN	2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile
DMO97FR	MI	TTGKNB4
DMO97FR	MN	Epidermal growth factor receptor (EGFR)
DMO97FR	MT	DTT
DMO97FR	MA	Inhibitor
DMO97FR	RN	Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J Nat Prod. 1992 Nov;55(11):1529-60.
DMO97FR	RU	https://pubmed.ncbi.nlm.nih.gov/1479375

DMGEFQP	DI	DMGEFQP
DMGEFQP	DN	2-benzoylaminoquinazoline-4-carboxyanilide
DMGEFQP	MI	TTJFY5U
DMGEFQP	MN	Adenosine A3 receptor (ADORA3)
DMGEFQP	MT	DTT
DMGEFQP	MA	Inhibitor
DMGEFQP	RN	Scouting human A3 adenosine receptor antagonist binding mode using a molecular simplification approach: from triazoloquinoxaline to a pyrimidine sk... J Med Chem. 2007 Dec 27;50(26):6596-606.
DMGEFQP	RU	https://pubmed.ncbi.nlm.nih.gov/18047262

DM1CB5J	DI	DM1CB5J
DM1CB5J	DN	2-Benzyl-1,2-dihydro-indazol-3-one
DM1CB5J	MI	TT2J34L
DM1CB5J	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM1CB5J	MT	DTT
DM1CB5J	MA	Inhibitor
DM1CB5J	RN	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
DM1CB5J	RU	https://pubmed.ncbi.nlm.nih.gov/1848292

DM1CB5J	DI	DM1CB5J
DM1CB5J	DN	2-Benzyl-1,2-dihydro-indazol-3-one
DM1CB5J	MI	TT8NGED
DM1CB5J	MN	Prostaglandin G/H synthase 1 (COX-1)
DM1CB5J	MT	DTT
DM1CB5J	MA	Inhibitor
DM1CB5J	RN	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
DM1CB5J	RU	https://pubmed.ncbi.nlm.nih.gov/1848292

DM1CB5J	DI	DM1CB5J
DM1CB5J	DN	2-Benzyl-1,2-dihydro-indazol-3-one
DM1CB5J	MI	TTVKILB
DM1CB5J	MN	Prostaglandin G/H synthase 2 (COX-2)
DM1CB5J	MT	DTT
DM1CB5J	MA	Inhibitor
DM1CB5J	RN	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
DM1CB5J	RU	https://pubmed.ncbi.nlm.nih.gov/1848292

DMV7IWE	DI	DMV7IWE
DMV7IWE	DN	2-Benzyl-1-hydroxy-3H-benzo[f]chromen-3-one
DMV7IWE	MI	TT8XK6L
DMV7IWE	MN	Quinone reductase 1 (NQO1)
DMV7IWE	MT	DTT
DMV7IWE	MA	Inhibitor
DMV7IWE	RN	Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1). J Med Chem. 2009 Nov 26;52(22):7142-56.
DMV7IWE	RU	https://pubmed.ncbi.nlm.nih.gov/19877692

DMPYB93	DI	DMPYB93
DMPYB93	DN	2-Benzyl-2H-indazole-7-carboxamide
DMPYB93	MI	TTVDSZ0
DMPYB93	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMPYB93	MT	DTT
DMPYB93	MA	Inhibitor
DMPYB93	RN	Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor effica... J Med Chem. 2009 Nov 26;52(22):7170-85.
DMPYB93	RU	https://pubmed.ncbi.nlm.nih.gov/19873981

DM6E04T	DI	DM6E04T
DM6E04T	DN	2-benzyl-2H-pyrazolo[3,4-c]quinolin-4(5H)-one
DM6E04T	MI	TTJFY5U
DM6E04T	MN	Adenosine A3 receptor (ADORA3)
DM6E04T	MT	DTT
DM6E04T	MA	Inhibitor
DM6E04T	RN	New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluati... J Med Chem. 2007 Aug 23;50(17):4061-74.
DM6E04T	RU	https://pubmed.ncbi.nlm.nih.gov/17665891

DMANTCY	DI	DMANTCY
DMANTCY	DN	2-Benzyl-3-phenyl-7-(trifluoromethyl)-2H-indazole
DMANTCY	MI	TTECBXN
DMANTCY	MN	Oxysterols receptor LXR-alpha (NR1H3)
DMANTCY	MT	DTT
DMANTCY	MA	Inhibitor
DMANTCY	RN	Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic tr... J Med Chem. 2008 Nov 27;51(22):7161-8.
DMANTCY	RU	https://pubmed.ncbi.nlm.nih.gov/18973288

DMANTCY	DI	DMANTCY
DMANTCY	DN	2-Benzyl-3-phenyl-7-(trifluoromethyl)-2H-indazole
DMANTCY	MI	TTXA6PH
DMANTCY	MN	Oxysterols receptor LXR-beta (NR1H2)
DMANTCY	MT	DTT
DMANTCY	MA	Inhibitor
DMANTCY	RN	Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic tr... J Med Chem. 2008 Nov 27;51(22):7161-8.
DMANTCY	RU	https://pubmed.ncbi.nlm.nih.gov/18973288

DMH76SO	DI	DMH76SO
DMH76SO	DN	2-benzyl-4,5,6,7-tetrachloroisoindoline-1,3-dione
DMH76SO	MI	TTECBXN
DMH76SO	MN	Oxysterols receptor LXR-alpha (NR1H3)
DMH76SO	MT	DTT
DMH76SO	MA	Inhibitor
DMH76SO	RN	Liver X receptor antagonists with a phthalimide skeleton derived from thalidomide-related glucosidase inhibitors. Bioorg Med Chem Lett. 2007 Jul 15;17(14):3957-61.
DMH76SO	RU	https://pubmed.ncbi.nlm.nih.gov/17498949

DMH76SO	DI	DMH76SO
DMH76SO	DN	2-benzyl-4,5,6,7-tetrachloroisoindoline-1,3-dione
DMH76SO	MI	TTXA6PH
DMH76SO	MN	Oxysterols receptor LXR-beta (NR1H2)
DMH76SO	MT	DTT
DMH76SO	MA	Inhibitor
DMH76SO	RN	Liver X receptor antagonists with a phthalimide skeleton derived from thalidomide-related glucosidase inhibitors. Bioorg Med Chem Lett. 2007 Jul 15;17(14):3957-61.
DMH76SO	RU	https://pubmed.ncbi.nlm.nih.gov/17498949

DMYGKW5	DI	DMYGKW5
DMYGKW5	DN	2-Benzyl-4-piperazin-1-yl-1H-benzimidazole
DMYGKW5	MI	TTJS8PY
DMYGKW5	MN	5-HT 6 receptor (HTR6)
DMYGKW5	MT	DTT
DMYGKW5	MA	Inhibitor
DMYGKW5	RN	Benzimidazole derivatives as new serotonin 5-HT6 receptor antagonists. Molecular mechanisms of receptor inactivation. J Med Chem. 2010 Feb 11;53(3):1357-69.
DMYGKW5	RU	https://pubmed.ncbi.nlm.nih.gov/20078106

DM3I7EL	DI	DM3I7EL
DM3I7EL	DN	2-benzyl-5-mercaptopentanoic acid
DM3I7EL	MI	TT9G4N0
DM3I7EL	MN	Glutamate carboxypeptidase II (GCPII)
DM3I7EL	MT	DTT
DM3I7EL	MA	Inhibitor
DM3I7EL	RN	Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1' side chain. J Med Chem. 2006 May 18;49(10):2876-85.
DM3I7EL	RU	https://pubmed.ncbi.nlm.nih.gov/16686531

DMGWRID	DI	DMGWRID
DMGWRID	DN	2-Benzyl-6-methoxy-5-oxazol-5-yl-1H-indole
DMGWRID	MI	TTTB4UP
DMGWRID	MN	Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2)
DMGWRID	MT	DTT
DMGWRID	MA	Inhibitor
DMGWRID	RN	Novel indole-based inhibitors of IMPDH: introduction of hydrogen bond acceptors at indole C-3. Bioorg Med Chem Lett. 2003 Apr 7;13(7):1273-6.
DMGWRID	RU	https://pubmed.ncbi.nlm.nih.gov/12657262

DMAX5TC	DI	DMAX5TC
DMAX5TC	DN	2-Benzyl-7-hydroxy-chromen-4-one
DMAX5TC	MI	TTFBNVI
DMAX5TC	MN	Aldose reductase (AKR1B1)
DMAX5TC	MT	DTT
DMAX5TC	MA	Inhibitor
DMAX5TC	RN	1-Benzopyran-4-one antioxidants as aldose reductase inhibitors. J Med Chem. 1999 Jun 3;42(11):1881-93.
DMAX5TC	RU	https://pubmed.ncbi.nlm.nih.gov/10354396

DM6EMGJ	DI	DM6EMGJ
DM6EMGJ	DN	2-Benzylaminomethyl-3-hydroxymorphinan
DM6EMGJ	MI	TTQW87Y
DM6EMGJ	MN	Opioid receptor kappa (OPRK1)
DM6EMGJ	MT	DTT
DM6EMGJ	MA	Inhibitor
DM6EMGJ	RN	Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18.
DM6EMGJ	RU	https://pubmed.ncbi.nlm.nih.gov/19928862

DM6EMGJ	DI	DM6EMGJ
DM6EMGJ	DN	2-Benzylaminomethyl-3-hydroxymorphinan
DM6EMGJ	MI	TTKWM86
DM6EMGJ	MN	Opioid receptor mu (MOP)
DM6EMGJ	MT	DTT
DM6EMGJ	MA	Inhibitor
DM6EMGJ	RN	Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18.
DM6EMGJ	RU	https://pubmed.ncbi.nlm.nih.gov/19928862

DMM48L6	DI	DMM48L6
DMM48L6	DN	2-Benzylbenzo[f]chromen-3-one
DMM48L6	MI	TT6OEDT
DMM48L6	MN	Cannabinoid receptor 1 (CB1)
DMM48L6	MT	DTT
DMM48L6	MA	Inhibitor
DMM48L6	RN	Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists. Bioorg Med Chem. 2009 Apr 1;17(7):2842-51.
DMM48L6	RU	https://pubmed.ncbi.nlm.nih.gov/19278853

DME7SAV	DI	DME7SAV
DME7SAV	DN	2-benzylisoquinoline-1,3,4-trione
DME7SAV	MI	TTPF2QI
DME7SAV	MN	Caspase-3 (CASP3)
DME7SAV	MT	DTT
DME7SAV	MA	Inhibitor
DME7SAV	RN	Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors. J Med Chem. 2006 Mar 9;49(5):1613-23.
DME7SAV	RU	https://pubmed.ncbi.nlm.nih.gov/16509578

DMF5MGQ	DI	DMF5MGQ
DMF5MGQ	DN	2-benzyl-N1-hydroxy-N3-(3-phenylpropyl)malonamide
DMF5MGQ	MI	TTPHMWB
DMF5MGQ	MN	Aminopeptidase N (ANPEP)
DMF5MGQ	MT	DTT
DMF5MGQ	MA	Inhibitor
DMF5MGQ	RN	Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents. J Med Chem. 2007 Mar 22;50(6):1322-34.
DMF5MGQ	RU	https://pubmed.ncbi.nlm.nih.gov/17326615

DMRVA94	DI	DMRVA94
DMRVA94	DN	2-benzyl-N1-hydroxy-N3-(4-phenylbutyl)malonamide
DMRVA94	MI	TTPHMWB
DMRVA94	MN	Aminopeptidase N (ANPEP)
DMRVA94	MT	DTT
DMRVA94	MA	Inhibitor
DMRVA94	RN	Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents. J Med Chem. 2007 Mar 22;50(6):1322-34.
DMRVA94	RU	https://pubmed.ncbi.nlm.nih.gov/17326615

DM2BPIN	DI	DM2BPIN
DM2BPIN	DN	2-benzyl-N1-hydroxy-N3-phenethylmalonamide
DM2BPIN	MI	TTPHMWB
DM2BPIN	MN	Aminopeptidase N (ANPEP)
DM2BPIN	MT	DTT
DM2BPIN	MA	Inhibitor
DM2BPIN	RN	Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents. J Med Chem. 2007 Mar 22;50(6):1322-34.
DM2BPIN	RU	https://pubmed.ncbi.nlm.nih.gov/17326615

DMCLAXG	DI	DMCLAXG
DMCLAXG	DN	2-benzyloxy-7,8-dihydro-6H-quinolin-5-one
DMCLAXG	MI	TTHS256
DMCLAXG	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMCLAXG	MT	DTT
DMCLAXG	MA	Inhibitor
DMCLAXG	RN	Positive and negative modulation of group I metabotropic glutamate receptors. J Med Chem. 2008 Feb 14;51(3):634-47.
DMCLAXG	RU	https://pubmed.ncbi.nlm.nih.gov/18173231

DM6F0C4	DI	DM6F0C4
DM6F0C4	DN	2-Benzylsulfanyl-6-chloro-pyrimidin-4-ylamine
DM6F0C4	MI	TT84ETX
DM6F0C4	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM6F0C4	MT	DTT
DM6F0C4	MA	Inhibitor
DM6F0C4	RN	Pyrimidine thioethers: a novel class of HIV-1 reverse transcriptase inhibitors with activity against BHAP-resistant HIV. J Med Chem. 1998 Sep 24;41(20):3793-803.
DM6F0C4	RU	https://pubmed.ncbi.nlm.nih.gov/9748354

DMV4OY2	DI	DMV4OY2
DMV4OY2	DN	2beta,3alpha-dihydroxyolean-12-en-28-oic acid
DMV4OY2	MI	TTZHY6R
DMV4OY2	MN	Glycogen phosphorylase muscle form (GP)
DMV4OY2	MT	DTT
DMV4OY2	MA	Inhibitor
DMV4OY2	RN	Practical synthesis of bredemolic acid, a natural inhibitor of glycogen phosphorylase. J Nat Prod. 2008 Nov;71(11):1877-80.
DMV4OY2	RU	https://pubmed.ncbi.nlm.nih.gov/18847277

DMU4Q8C	DI	DMU4Q8C
DMU4Q8C	DN	2beta,3alpha-dihydroxyurs-12-en-28-oic acid
DMU4Q8C	MI	TTZHY6R
DMU4Q8C	MN	Glycogen phosphorylase muscle form (GP)
DMU4Q8C	MT	DTT
DMU4Q8C	MA	Inhibitor
DMU4Q8C	RN	Practical synthesis of bredemolic acid, a natural inhibitor of glycogen phosphorylase. J Nat Prod. 2008 Nov;71(11):1877-80.
DMU4Q8C	RU	https://pubmed.ncbi.nlm.nih.gov/18847277

DMWZ4KN	DI	DMWZ4KN
DMWZ4KN	DN	2beta-methoxy-2-deethoxyphantomolin
DMWZ4KN	MI	TTSXVID
DMWZ4KN	MN	Nuclear factor NF-kappa-B (NFKB)
DMWZ4KN	MT	DTT
DMWZ4KN	MA	Inhibitor
DMWZ4KN	RN	Development of a structural model for NF-kappaB inhibition of sesquiterpene lactones using self-organizing neural networks. J Med Chem. 2006 Apr 6;49(7):2241-52.
DMWZ4KN	RU	https://pubmed.ncbi.nlm.nih.gov/16570920

DMFAW4R	DI	DMFAW4R
DMFAW4R	DN	2-BFi
DMFAW4R	MI	TTWG9A4
DMFAW4R	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMFAW4R	MT	DTT
DMFAW4R	MA	Inhibitor
DMFAW4R	RN	Probes for imidazoline binding sites: synthesis and evaluation of a selective, irreversible I2 ligand. Bioorg Med Chem Lett. 2000 Mar 20;10(6):605-7.
DMFAW4R	RU	https://pubmed.ncbi.nlm.nih.gov/10741563

DMFAW4R	DI	DMFAW4R
DMFAW4R	DN	2-BFi
DMFAW4R	MI	TTWM4TY
DMFAW4R	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMFAW4R	MT	DTT
DMFAW4R	MA	Inhibitor
DMFAW4R	RN	Probes for imidazoline binding sites: synthesis and evaluation of a selective, irreversible I2 ligand. Bioorg Med Chem Lett. 2000 Mar 20;10(6):605-7.
DMFAW4R	RU	https://pubmed.ncbi.nlm.nih.gov/10741563

DMFAW4R	DI	DMFAW4R
DMFAW4R	DN	2-BFi
DMFAW4R	MI	TT2NUT5
DMFAW4R	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMFAW4R	MT	DTT
DMFAW4R	MA	Inhibitor
DMFAW4R	RN	Probes for imidazoline binding sites: synthesis and evaluation of a selective, irreversible I2 ligand. Bioorg Med Chem Lett. 2000 Mar 20;10(6):605-7.
DMFAW4R	RU	https://pubmed.ncbi.nlm.nih.gov/10741563

DMFAW4R	DI	DMFAW4R
DMFAW4R	DN	2-BFi
DMFAW4R	MI	TT3WG5C
DMFAW4R	MN	Monoamine oxidase type A (MAO-A)
DMFAW4R	MT	DTT
DMFAW4R	MA	Inhibitor
DMFAW4R	RN	Probes for imidazoline binding sites: synthesis and evaluation of a selective, irreversible I2 ligand. Bioorg Med Chem Lett. 2000 Mar 20;10(6):605-7.
DMFAW4R	RU	https://pubmed.ncbi.nlm.nih.gov/10741563

DMFAW4R	DI	DMFAW4R
DMFAW4R	DN	2-BFi
DMFAW4R	MI	TTGP7BY
DMFAW4R	MN	Monoamine oxidase type B (MAO-B)
DMFAW4R	MT	DTT
DMFAW4R	MA	Inhibitor
DMFAW4R	RN	Ultrasound promoted synthesis of 2-imidazolines in water: a greener approach toward monoamine oxidase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):546-9.
DMFAW4R	RU	https://pubmed.ncbi.nlm.nih.gov/19064321

DMHS3N6	DI	DMHS3N6
DMHS3N6	DN	2-biphenyl-4-yl-1-phenothiazin-10-yl-ethanone
DMHS3N6	MI	TTEB0GD
DMHS3N6	MN	Cholinesterase (BCHE)
DMHS3N6	MT	DTT
DMHS3N6	MA	Inhibitor
DMHS3N6	RN	Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. Bioorg Med Chem. 2007 Oct 1;15(19):6367-78.
DMHS3N6	RU	https://pubmed.ncbi.nlm.nih.gov/17681768

DML1W5Z	DI	DML1W5Z
DML1W5Z	DN	2-biphenyl-4-yl-6-morpholin-4-yl-pyran-4-one
DML1W5Z	MI	TTK3PY9
DML1W5Z	MN	DNA-dependent protein kinase catalytic (PRKDC)
DML1W5Z	MT	DTT
DML1W5Z	MA	Inhibitor
DML1W5Z	RN	Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72.
DML1W5Z	RU	https://pubmed.ncbi.nlm.nih.gov/17371003

DMWOJ5N	DI	DMWOJ5N
DMWOJ5N	DN	2-Biphenyl-4-yl-N-hydroxy-N-methyl-acetamide
DMWOJ5N	MI	TT2J34L
DMWOJ5N	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMWOJ5N	MT	DTT
DMWOJ5N	MA	Inhibitor
DMWOJ5N	RN	Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8.
DMWOJ5N	RU	https://pubmed.ncbi.nlm.nih.gov/2308149

DMCM01R	DI	DMCM01R
DMCM01R	DN	2-bromo-4-(3-fluorophenylethynyl)thiazole
DMCM01R	MI	TTHS256
DMCM01R	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMCM01R	MT	DTT
DMCM01R	MA	Inhibitor
DMCM01R	RN	Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100.
DMCM01R	RU	https://pubmed.ncbi.nlm.nih.gov/16451073

DMJ0368	DI	DMJ0368
DMJ0368	DN	2-bromo-4-methylphenyl 2-nitrobenzoate
DMJ0368	MI	TTVTX4N
DMJ0368	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DMJ0368	MT	DTT
DMJ0368	MA	Inhibitor
DMJ0368	RN	Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening. Eur J Med Chem. 2009 Sep;44(9):3718-30.
DMJ0368	RU	https://pubmed.ncbi.nlm.nih.gov/19428156

DMIHJSA	DI	DMIHJSA
DMIHJSA	DN	2-Bromoacetyl Group
DMIHJSA	MI	TT8NGED
DMIHJSA	MN	Prostaglandin G/H synthase 1 (COX-1)
DMIHJSA	MT	DTT
DMIHJSA	MA	Inhibitor
DMIHJSA	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMIHJSA	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMOYCWU	DI	DMOYCWU
DMOYCWU	DN	2-bromo-LSD
DMOYCWU	MI	TTJS8PY
DMOYCWU	MN	5-HT 6 receptor (HTR6)
DMOYCWU	MT	DTT
DMOYCWU	MA	Antagonist
DMOYCWU	RN	Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol. 1993 Mar;43(3):320-7.
DMOYCWU	RU	https://pubmed.ncbi.nlm.nih.gov/7680751

DMOYCWU	DI	DMOYCWU
DMOYCWU	DN	2-bromo-LSD
DMOYCWU	MI	TTO9X1H
DMOYCWU	MN	5-HT 7 receptor (HTR7)
DMOYCWU	MT	DTT
DMOYCWU	MA	Antagonist
DMOYCWU	RN	Molecular cloning of a mammalian serotonin receptor that activates adenylate cyclase. Mol Pharmacol. 1993 Aug;44(2):229-36.
DMOYCWU	RU	https://pubmed.ncbi.nlm.nih.gov/8394987

DMYCENM	DI	DMYCENM
DMYCENM	DN	2-Bromo-N-(2-morpholinoethyl)nicotinamide
DMYCENM	MI	TT3WG5C
DMYCENM	MN	Monoamine oxidase type A (MAO-A)
DMYCENM	MT	DTT
DMYCENM	MA	Inhibitor
DMYCENM	RN	Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1659-64.
DMYCENM	RU	https://pubmed.ncbi.nlm.nih.gov/20117937

DMYCENM	DI	DMYCENM
DMYCENM	DN	2-Bromo-N-(2-morpholinoethyl)nicotinamide
DMYCENM	MI	TTGP7BY
DMYCENM	MN	Monoamine oxidase type B (MAO-B)
DMYCENM	MT	DTT
DMYCENM	MA	Inhibitor
DMYCENM	RN	Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1659-64.
DMYCENM	RU	https://pubmed.ncbi.nlm.nih.gov/20117937

DM9NMIO	DI	DM9NMIO
DM9NMIO	DN	2-Bromo-N-(3-morpholinopropyl)nicotinamide
DM9NMIO	MI	TTGP7BY
DM9NMIO	MN	Monoamine oxidase type B (MAO-B)
DM9NMIO	MT	DTT
DM9NMIO	MA	Inhibitor
DM9NMIO	RN	Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1659-64.
DM9NMIO	RU	https://pubmed.ncbi.nlm.nih.gov/20117937

DM6JDIY	DI	DM6JDIY
DM6JDIY	DN	2-bromophenol
DM6JDIY	MI	TTU6BFZ
DM6JDIY	MN	Candida Thymidylate synthase (Candi TMP1)
DM6JDIY	MT	DTT
DM6JDIY	MA	Inhibitor
DM6JDIY	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DM6JDIY	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMY7RM8	DI	DMY7RM8
DMY7RM8	DN	2-Butyl-1(3)H-anthra[1,2-d]imidazole-6,11-dione
DMY7RM8	MI	TTQY2EJ
DMY7RM8	MN	TERT messenger RNA (TERT mRNA)
DMY7RM8	MT	DTT
DMY7RM8	MA	Inhibitor
DMY7RM8	RN	Synthesis, cytotoxicity and human telomerase inhibition activities of a series of 1,2-heteroannelated anthraquinones and anthra[1,2-d]imidazole-6,1... Bioorg Med Chem. 2009 Nov 1;17(21):7418-28.
DMY7RM8	RU	https://pubmed.ncbi.nlm.nih.gov/19804981

DML9MCU	DI	DML9MCU
DML9MCU	DN	2-butylamido-5-sulfonamidoindane
DML9MCU	MI	TTHQPL7
DML9MCU	MN	Carbonic anhydrase I (CA-I)
DML9MCU	MT	DTT
DML9MCU	MA	Inhibitor
DML9MCU	RN	Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9.
DML9MCU	RU	https://pubmed.ncbi.nlm.nih.gov/16640335

DML9MCU	DI	DML9MCU
DML9MCU	DN	2-butylamido-5-sulfonamidoindane
DML9MCU	MI	TTANPDJ
DML9MCU	MN	Carbonic anhydrase II (CA-II)
DML9MCU	MT	DTT
DML9MCU	MA	Inhibitor
DML9MCU	RN	Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9.
DML9MCU	RU	https://pubmed.ncbi.nlm.nih.gov/16640335

DML9MCU	DI	DML9MCU
DML9MCU	DN	2-butylamido-5-sulfonamidoindane
DML9MCU	MI	TT2LVK8
DML9MCU	MN	Carbonic anhydrase IX (CA-IX)
DML9MCU	MT	DTT
DML9MCU	MA	Inhibitor
DML9MCU	RN	Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9.
DML9MCU	RU	https://pubmed.ncbi.nlm.nih.gov/16640335

DMG5SAQ	DI	DMG5SAQ
DMG5SAQ	DN	2-chloro-1-(5-(pyridin-2-yl)oxazol-2-yl)ethanone
DMG5SAQ	MI	TTDP1UC
DMG5SAQ	MN	Fatty acid amide hydrolase (FAAH)
DMG5SAQ	MT	DTT
DMG5SAQ	MA	Inhibitor
DMG5SAQ	RN	Structure-activity relationships of alpha-ketooxazole inhibitors of fatty acid amide hydrolase. J Med Chem. 2007 Jul 12;50(14):3359-68.
DMG5SAQ	RU	https://pubmed.ncbi.nlm.nih.gov/17559203

DMD3ZNP	DI	DMD3ZNP
DMD3ZNP	DN	2-chloro-2'-C-methyl-tecadenoson
DMD3ZNP	MI	TTK25J1
DMD3ZNP	MN	Adenosine A1 receptor (ADORA1)
DMD3ZNP	MT	DTT
DMD3ZNP	MA	Inhibitor
DMD3ZNP	RN	5'-Carbamoyl derivatives of 2'-C-methyl-purine nucleosides as selective A1 adenosine receptor agonists: affinity, efficacy, and selectivity for A1 ... Bioorg Med Chem. 2008 Jan 1;16(1):336-53.
DMD3ZNP	RU	https://pubmed.ncbi.nlm.nih.gov/17933541

DMD3ZNP	DI	DMD3ZNP
DMD3ZNP	DN	2-chloro-2'-C-methyl-tecadenoson
DMD3ZNP	MI	TTNE7KG
DMD3ZNP	MN	Adenosine A2b receptor (ADORA2B)
DMD3ZNP	MT	DTT
DMD3ZNP	MA	Inhibitor
DMD3ZNP	RN	5'-Carbamoyl derivatives of 2'-C-methyl-purine nucleosides as selective A1 adenosine receptor agonists: affinity, efficacy, and selectivity for A1 ... Bioorg Med Chem. 2008 Jan 1;16(1):336-53.
DMD3ZNP	RU	https://pubmed.ncbi.nlm.nih.gov/17933541

DMD3ZNP	DI	DMD3ZNP
DMD3ZNP	DN	2-chloro-2'-C-methyl-tecadenoson
DMD3ZNP	MI	TTJFY5U
DMD3ZNP	MN	Adenosine A3 receptor (ADORA3)
DMD3ZNP	MT	DTT
DMD3ZNP	MA	Inhibitor
DMD3ZNP	RN	5'-Carbamoyl derivatives of 2'-C-methyl-purine nucleosides as selective A1 adenosine receptor agonists: affinity, efficacy, and selectivity for A1 ... Bioorg Med Chem. 2008 Jan 1;16(1):336-53.
DMD3ZNP	RU	https://pubmed.ncbi.nlm.nih.gov/17933541

DMTPKU8	DI	DMTPKU8
DMTPKU8	DN	2-chloro-4-(o-tolyloxy)benzonitrile
DMTPKU8	MI	TTKPW01
DMTPKU8	MN	Androgen receptor messenger RNA (AR mRNA)
DMTPKU8	MT	DTT
DMTPKU8	MA	Inhibitor
DMTPKU8	RN	Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2176-8.
DMTPKU8	RU	https://pubmed.ncbi.nlm.nih.gov/19286380

DMPCRLY	DI	DMPCRLY
DMPCRLY	DN	2-chloro-4-(thiazol-2-yl)thieno[3,2-d]pyrimidine
DMPCRLY	MI	TTK25J1
DMPCRLY	MN	Adenosine A1 receptor (ADORA1)
DMPCRLY	MT	DTT
DMPCRLY	MA	Inhibitor
DMPCRLY	RN	Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2920-3.
DMPCRLY	RU	https://pubmed.ncbi.nlm.nih.gov/18407496

DMPCRLY	DI	DMPCRLY
DMPCRLY	DN	2-chloro-4-(thiazol-2-yl)thieno[3,2-d]pyrimidine
DMPCRLY	MI	TTM2AOE
DMPCRLY	MN	Adenosine A2a receptor (ADORA2A)
DMPCRLY	MT	DTT
DMPCRLY	MA	Inhibitor
DMPCRLY	RN	Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2920-3.
DMPCRLY	RU	https://pubmed.ncbi.nlm.nih.gov/18407496

DMC5OQ3	DI	DMC5OQ3
DMC5OQ3	DN	2-chloro-4-(thiophen-2-yl)thieno[3,2-d]pyrimidine
DMC5OQ3	MI	TTK25J1
DMC5OQ3	MN	Adenosine A1 receptor (ADORA1)
DMC5OQ3	MT	DTT
DMC5OQ3	MA	Inhibitor
DMC5OQ3	RN	Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2920-3.
DMC5OQ3	RU	https://pubmed.ncbi.nlm.nih.gov/18407496

DMC5OQ3	DI	DMC5OQ3
DMC5OQ3	DN	2-chloro-4-(thiophen-2-yl)thieno[3,2-d]pyrimidine
DMC5OQ3	MI	TTM2AOE
DMC5OQ3	MN	Adenosine A2a receptor (ADORA2A)
DMC5OQ3	MT	DTT
DMC5OQ3	MA	Inhibitor
DMC5OQ3	RN	Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2920-3.
DMC5OQ3	RU	https://pubmed.ncbi.nlm.nih.gov/18407496

DM5KR4B	DI	DM5KR4B
DM5KR4B	DN	2-Chloro-5-(2-methylquinolin-7-yl)nicotinonitrile
DM5KR4B	MI	TTHS256
DM5KR4B	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM5KR4B	MT	DTT
DM5KR4B	MA	Inhibitor
DM5KR4B	RN	Structure-activity relationships in a novel series of 7-substituted-aryl quinolines and 5-substituted-aryl benzothiazoles at the metabotropic gluta... Bioorg Med Chem. 2010 May 1;18(9):3026-35.
DM5KR4B	RU	https://pubmed.ncbi.nlm.nih.gov/20382541

DMUGQIV	DI	DMUGQIV
DMUGQIV	DN	2-chloro-5-nitro-N-phenylbenzamide
DMUGQIV	MI	DEX5D46
DMUGQIV	MN	Oxygen-insensitive NADPH nitroreductase A (nfsA)
DMUGQIV	MT	DME
DMUGQIV	MA	Metabolism
DMUGQIV	RN	Effects of bacterial and presystemic nitroreductase metabolism of 2-chloro-5-nitro-N-phenylbenzamide on its mutagenicity and bioavailability. Chem Biol Interact. 2012 Apr 15;197(1):16-22.
DMUGQIV	RU	https://pubmed.ncbi.nlm.nih.gov/22450444

DMUGQIV	DI	DMUGQIV
DMUGQIV	DN	2-chloro-5-nitro-N-phenylbenzamide
DMUGQIV	MI	DEOWDK1
DMUGQIV	MN	Oxygen-insensitive NADPH nitroreductase B (nfsB)
DMUGQIV	MT	DME
DMUGQIV	MA	Metabolism
DMUGQIV	RN	Effects of bacterial and presystemic nitroreductase metabolism of 2-chloro-5-nitro-N-phenylbenzamide on its mutagenicity and bioavailability. Chem Biol Interact. 2012 Apr 15;197(1):16-22.
DMUGQIV	RU	https://pubmed.ncbi.nlm.nih.gov/22450444

DMUGQIV	DI	DMUGQIV
DMUGQIV	DN	2-chloro-5-nitro-N-phenylbenzamide
DMUGQIV	MI	TTZMAO3
DMUGQIV	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMUGQIV	MT	DTT
DMUGQIV	MA	Inhibitor
DMUGQIV	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMUGQIV	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMUGQIV	DI	DMUGQIV
DMUGQIV	DN	2-chloro-5-nitro-N-phenylbenzamide
DMUGQIV	MI	TTT2SVW
DMUGQIV	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DMUGQIV	MT	DTT
DMUGQIV	MA	Inhibitor
DMUGQIV	RN	Tryptophan-containing dipeptide derivatives as potent PPARgamma antagonists: design, synthesis, biological evaluation, and molecular modeling. Eur J Med Chem. 2008 Dec;43(12):2699-716.
DMUGQIV	RU	https://pubmed.ncbi.nlm.nih.gov/18329752

DMUGQIV	DI	DMUGQIV
DMUGQIV	DN	2-chloro-5-nitro-N-phenylbenzamide
DMUGQIV	MI	TT6PEUO
DMUGQIV	MN	Retinoic acid receptor RXR-alpha (RXRA)
DMUGQIV	MT	DTT
DMUGQIV	MA	Inhibitor
DMUGQIV	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMUGQIV	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DML0S8M	DI	DML0S8M
DML0S8M	DN	2-chloro-6(methylamino)purine
DML0S8M	MI	TT7RJY8
DML0S8M	MN	Xanthine dehydrogenase/oxidase (XDH)
DML0S8M	MT	DTT
DML0S8M	MA	Inhibitor
DML0S8M	RN	The screening and characterization of 6-aminopurine-based xanthine oxidase inhibitors. Bioorg Med Chem. 2007 May 15;15(10):3450-6.
DML0S8M	RU	https://pubmed.ncbi.nlm.nih.gov/17379526

DMYPQEW	DI	DMYPQEW
DMYPQEW	DN	2-chloroadenosine
DMYPQEW	MI	TTK25J1
DMYPQEW	MN	Adenosine A1 receptor (ADORA1)
DMYPQEW	MT	DTT
DMYPQEW	MA	Agonist
DMYPQEW	RN	Identification of the adenine binding site of the human A1 adenosine receptor. J Biol Chem. 1999 Feb 5;274(6):3617-21.
DMYPQEW	RU	https://pubmed.ncbi.nlm.nih.gov/9920910

DMYPQEW	DI	DMYPQEW
DMYPQEW	DN	2-chloroadenosine
DMYPQEW	MI	TTNE7KG
DMYPQEW	MN	Adenosine A2b receptor (ADORA2B)
DMYPQEW	MT	DTT
DMYPQEW	MA	Agonist
DMYPQEW	RN	Adenosine receptor activation in human fibroblasts: nucleoside agonists and antagonists. Can J Physiol Pharmacol. 1980 Jun;58(6):673-91.
DMYPQEW	RU	https://pubmed.ncbi.nlm.nih.gov/6253037

DMYPQEW	DI	DMYPQEW
DMYPQEW	DN	2-chloroadenosine
DMYPQEW	MI	TTJFY5U
DMYPQEW	MN	Adenosine A3 receptor (ADORA3)
DMYPQEW	MT	DTT
DMYPQEW	MA	Agonist
DMYPQEW	RN	A binding site model and structure-activity relationships for the rat A3 adenosine receptor. Mol Pharmacol. 1994 Jun;45(6):1101-11.
DMYPQEW	RU	https://pubmed.ncbi.nlm.nih.gov/8022403

DMQUDA9	DI	DMQUDA9
DMQUDA9	DN	2-chloroadenosine-5-triphosphate
DMQUDA9	MI	TTA93TL
DMQUDA9	MN	P2Y purinoceptor 1 (P2RY1)
DMQUDA9	MT	DTT
DMQUDA9	MA	Antagonist
DMQUDA9	RN	ATP derivatives are antagonists of the P2Y1 receptor: similarities to the platelet ADP receptor. Mol Pharmacol. 1998 Apr;53(4):727-33.
DMQUDA9	RU	https://pubmed.ncbi.nlm.nih.gov/9547364

DMI89RL	DI	DMI89RL
DMI89RL	DN	2-Chlorobenzenemethanethiol
DMI89RL	MI	TTZJYKH
DMI89RL	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMI89RL	MT	DTT
DMI89RL	MA	Inhibitor
DMI89RL	RN	S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9.
DMI89RL	RU	https://pubmed.ncbi.nlm.nih.gov/20688518

DMR8M36	DI	DMR8M36
DMR8M36	DN	2-Chloro-N-(2-morpholinoethyl)nicotinamide
DMR8M36	MI	TT3WG5C
DMR8M36	MN	Monoamine oxidase type A (MAO-A)
DMR8M36	MT	DTT
DMR8M36	MA	Inhibitor
DMR8M36	RN	Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1659-64.
DMR8M36	RU	https://pubmed.ncbi.nlm.nih.gov/20117937

DMR8M36	DI	DMR8M36
DMR8M36	DN	2-Chloro-N-(2-morpholinoethyl)nicotinamide
DMR8M36	MI	TTGP7BY
DMR8M36	MN	Monoamine oxidase type B (MAO-B)
DMR8M36	MT	DTT
DMR8M36	MA	Inhibitor
DMR8M36	RN	Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1659-64.
DMR8M36	RU	https://pubmed.ncbi.nlm.nih.gov/20117937

DM2W71L	DI	DM2W71L
DM2W71L	DN	2-chloro-N-(3-(3-chlorobenzamido)phenyl)benzamide
DM2W71L	MI	TTHS256
DM2W71L	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM2W71L	MT	DTT
DM2W71L	MA	Inhibitor
DM2W71L	RN	Synthesis and SAR of novel, non-MPEP chemotype mGluR5 NAMs identified by functional HTS. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6502-6.
DM2W71L	RU	https://pubmed.ncbi.nlm.nih.gov/19875287

DM5S1DW	DI	DM5S1DW
DM5S1DW	DN	2-Chloro-N-(3-morpholinopropyl)nicotinamide
DM5S1DW	MI	TT3WG5C
DM5S1DW	MN	Monoamine oxidase type A (MAO-A)
DM5S1DW	MT	DTT
DM5S1DW	MA	Inhibitor
DM5S1DW	RN	Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1659-64.
DM5S1DW	RU	https://pubmed.ncbi.nlm.nih.gov/20117937

DM5S1DW	DI	DM5S1DW
DM5S1DW	DN	2-Chloro-N-(3-morpholinopropyl)nicotinamide
DM5S1DW	MI	TTGP7BY
DM5S1DW	MN	Monoamine oxidase type B (MAO-B)
DM5S1DW	MT	DTT
DM5S1DW	MA	Inhibitor
DM5S1DW	RN	Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1659-64.
DM5S1DW	RU	https://pubmed.ncbi.nlm.nih.gov/20117937

DMBKVM4	DI	DMBKVM4
DMBKVM4	DN	2-chloro-N-(6-cyanopyridin-3-yl)propanamide
DMBKVM4	MI	TTCJG29
DMBKVM4	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMBKVM4	MT	DTT
DMBKVM4	MA	Inhibitor
DMBKVM4	RN	Synthesis and therapeutic evaluation of pyridyl based novel mTOR inhibitors. Bioorg Med Chem Lett. 2009 Jun 1;19(11):2949-52.
DMBKVM4	RU	https://pubmed.ncbi.nlm.nih.gov/19409777

DMLDQ6I	DI	DMLDQ6I
DMLDQ6I	DN	2-chloro-N-(o-tolylcarbamoyl)benzamide
DMLDQ6I	MI	TTSFWA7
DMLDQ6I	MN	Plasmodium CDK Pfmrk (Malaria Pfmrk)
DMLDQ6I	MT	DTT
DMLDQ6I	MA	Inhibitor
DMLDQ6I	RN	Activity of substituted thiophene sulfonamides against malarial and mammalian cyclin dependent protein kinases, Bioorg. Med. Chem. Lett. 20(13):3863-3867 (2010).
DMLDQ6I	RU	http://www.sciencedirect.com/science/article/pii/S0960894X10006803

DM2E3X5	DI	DM2E3X5
DM2E3X5	DN	2-Chlorophenol
DM2E3X5	MI	TTQBR95
DM2E3X5	MN	Stress-activated protein kinase 2a (p38 alpha)
DM2E3X5	MT	DTT
DM2E3X5	MA	Inhibitor
DM2E3X5	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM2E3X5	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMXYTGU	DI	DMXYTGU
DMXYTGU	DN	2-Cinnamamido-N1-hydroxy-N4-octylsuccinamide
DMXYTGU	MI	TTPHMWB
DMXYTGU	MN	Aminopeptidase N (ANPEP)
DMXYTGU	MT	DTT
DMXYTGU	MA	Inhibitor
DMXYTGU	RN	Design, synthesis, and preliminary studies of the activity of novel derivatives of N-cinnamoyl-L-aspartic acid as inhibitors of aminopeptidase N/CD13. Bioorg Med Chem. 2009 Oct 15;17(20):7398-404.
DMXYTGU	RU	https://pubmed.ncbi.nlm.nih.gov/19782572

DMI6FZN	DI	DMI6FZN
DMI6FZN	DN	2-Cinnamamido-N1-hydroxy-N4-pentylsuccinamide
DMI6FZN	MI	TTPHMWB
DMI6FZN	MN	Aminopeptidase N (ANPEP)
DMI6FZN	MT	DTT
DMI6FZN	MA	Inhibitor
DMI6FZN	RN	Design, synthesis, and preliminary studies of the activity of novel derivatives of N-cinnamoyl-L-aspartic acid as inhibitors of aminopeptidase N/CD13. Bioorg Med Chem. 2009 Oct 15;17(20):7398-404.
DMI6FZN	RU	https://pubmed.ncbi.nlm.nih.gov/19782572

DMRNGK7	DI	DMRNGK7
DMRNGK7	DN	2-Cinnamamido-N4-hexyl-N1-hydroxysuccinamide
DMRNGK7	MI	TTPHMWB
DMRNGK7	MN	Aminopeptidase N (ANPEP)
DMRNGK7	MT	DTT
DMRNGK7	MA	Inhibitor
DMRNGK7	RN	Design, synthesis, and preliminary studies of the activity of novel derivatives of N-cinnamoyl-L-aspartic acid as inhibitors of aminopeptidase N/CD13. Bioorg Med Chem. 2009 Oct 15;17(20):7398-404.
DMRNGK7	RU	https://pubmed.ncbi.nlm.nih.gov/19782572

DM4235F	DI	DM4235F
DM4235F	DN	2-Cl-ADP(alpha-BH3)
DM4235F	MI	TTA93TL
DM4235F	MN	P2Y purinoceptor 1 (P2RY1)
DM4235F	MT	DTT
DM4235F	MA	Agonist
DM4235F	RN	Highly efficient biocompatible neuroprotectants with dual activity as antioxidants and P2Y receptor agonists. J Med Chem. 2013 Jun 27;56(12):4938-52.
DM4235F	RU	https://pubmed.ncbi.nlm.nih.gov/23751098

DMCN6PY	DI	DMCN6PY
DMCN6PY	DN	2-cyano-3-(3,4-dihydroxyphenyl)acrylamide
DMCN6PY	MI	TTGKNB4
DMCN6PY	MN	Epidermal growth factor receptor (EGFR)
DMCN6PY	MT	DTT
DMCN6PY	MA	Inhibitor
DMCN6PY	RN	Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J Nat Prod. 1992 Nov;55(11):1529-60.
DMCN6PY	RU	https://pubmed.ncbi.nlm.nih.gov/1479375

DM2U1N5	DI	DM2U1N5
DM2U1N5	DN	2-Cyclohex-1-enylethynyl-pyridine
DM2U1N5	MI	TTHS256
DM2U1N5	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM2U1N5	MT	DTT
DM2U1N5	MA	Inhibitor
DM2U1N5	RN	Cyclohexenyl- and dehydropiperidinyl-alkynyl pyridines as potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4589-93.
DM2U1N5	RU	https://pubmed.ncbi.nlm.nih.gov/16115767

DMS1T0V	DI	DMS1T0V
DMS1T0V	DN	2-Cyclohexylacetic acidbiphenyl-3-yl ester
DMS1T0V	MI	TTDP1UC
DMS1T0V	MN	Fatty acid amide hydrolase (FAAH)
DMS1T0V	MT	DTT
DMS1T0V	MA	Inhibitor
DMS1T0V	RN	Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl a... J Med Chem. 2008 Jun 26;51(12):3487-98.
DMS1T0V	RU	https://pubmed.ncbi.nlm.nih.gov/18507372

DMFBD3K	DI	DMFBD3K
DMFBD3K	DN	2-cyclohexylamido-5-sulfonamidoindane
DMFBD3K	MI	TTHQPL7
DMFBD3K	MN	Carbonic anhydrase I (CA-I)
DMFBD3K	MT	DTT
DMFBD3K	MA	Inhibitor
DMFBD3K	RN	Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9.
DMFBD3K	RU	https://pubmed.ncbi.nlm.nih.gov/16640335

DMFBD3K	DI	DMFBD3K
DMFBD3K	DN	2-cyclohexylamido-5-sulfonamidoindane
DMFBD3K	MI	TTANPDJ
DMFBD3K	MN	Carbonic anhydrase II (CA-II)
DMFBD3K	MT	DTT
DMFBD3K	MA	Inhibitor
DMFBD3K	RN	Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9.
DMFBD3K	RU	https://pubmed.ncbi.nlm.nih.gov/16640335

DMFBD3K	DI	DMFBD3K
DMFBD3K	DN	2-cyclohexylamido-5-sulfonamidoindane
DMFBD3K	MI	TT2LVK8
DMFBD3K	MN	Carbonic anhydrase IX (CA-IX)
DMFBD3K	MT	DTT
DMFBD3K	MA	Inhibitor
DMFBD3K	RN	Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9.
DMFBD3K	RU	https://pubmed.ncbi.nlm.nih.gov/16640335

DMFMZRB	DI	DMFMZRB
DMFMZRB	DN	2-cyclohexylamino-pyridine-2-carbonitrile
DMFMZRB	MI	TTDZN01
DMFMZRB	MN	Cathepsin K (CTSK)
DMFMZRB	MT	DTT
DMFMZRB	MA	Inhibitor
DMFMZRB	RN	2-Cyano-pyrimidines: a new chemotype for inhibitors of the cysteine protease cathepsin K. J Med Chem. 2007 Feb 22;50(4):591-4.
DMFMZRB	RU	https://pubmed.ncbi.nlm.nih.gov/17256925

DMMIGXO	DI	DMMIGXO
DMMIGXO	DN	2-cyclohexylamino-pyrimidine-4-carbonitrile
DMMIGXO	MI	TTDZN01
DMMIGXO	MN	Cathepsin K (CTSK)
DMMIGXO	MT	DTT
DMMIGXO	MA	Inhibitor
DMMIGXO	RN	2-Cyano-pyrimidines: a new chemotype for inhibitors of the cysteine protease cathepsin K. J Med Chem. 2007 Feb 22;50(4):591-4.
DMMIGXO	RU	https://pubmed.ncbi.nlm.nih.gov/17256925

DM2JZ84	DI	DM2JZ84
DM2JZ84	DN	2-Cyclohexylethynyl-pyridine
DM2JZ84	MI	TTHS256
DM2JZ84	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM2JZ84	MT	DTT
DM2JZ84	MA	Inhibitor
DM2JZ84	RN	Cyclohexenyl- and dehydropiperidinyl-alkynyl pyridines as potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4589-93.
DM2JZ84	RU	https://pubmed.ncbi.nlm.nih.gov/16115767

DMF6PMU	DI	DMF6PMU
DMF6PMU	DN	2-Cyclohexyl-N-(4-methoxy-phenyl)-acetamide
DMF6PMU	MI	TT7WVHI
DMF6PMU	MN	Soluble epoxide hydrolase (EPHX2)
DMF6PMU	MT	DTT
DMF6PMU	MA	Inhibitor
DMF6PMU	RN	Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem. 2005 May 19;48(10):3621-9.
DMF6PMU	RU	https://pubmed.ncbi.nlm.nih.gov/15887969

DM89CLH	DI	DM89CLH
DM89CLH	DN	2-Cyclohexyl-N-phenethyl-acetamide
DM89CLH	MI	TT7WVHI
DM89CLH	MN	Soluble epoxide hydrolase (EPHX2)
DM89CLH	MT	DTT
DM89CLH	MA	Inhibitor
DM89CLH	RN	Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem. 2005 May 19;48(10):3621-9.
DM89CLH	RU	https://pubmed.ncbi.nlm.nih.gov/15887969

DMBJUP5	DI	DMBJUP5
DMBJUP5	DN	2-Cyclohexyl-N-phenyl-acetamide
DMBJUP5	MI	TT7WVHI
DMBJUP5	MN	Soluble epoxide hydrolase (EPHX2)
DMBJUP5	MT	DTT
DMBJUP5	MA	Inhibitor
DMBJUP5	RN	Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem. 2005 May 19;48(10):3621-9.
DMBJUP5	RU	https://pubmed.ncbi.nlm.nih.gov/15887969

DMVP6CW	DI	DMVP6CW
DMVP6CW	DN	2-Cyclopent-1-enylethynyl-pyridine
DMVP6CW	MI	TTHS256
DMVP6CW	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMVP6CW	MT	DTT
DMVP6CW	MA	Inhibitor
DMVP6CW	RN	Cyclohexenyl- and dehydropiperidinyl-alkynyl pyridines as potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4589-93.
DMVP6CW	RU	https://pubmed.ncbi.nlm.nih.gov/16115767

DM6CZAN	DI	DM6CZAN
DM6CZAN	DN	2-Cyclopentyl-1H-imidazo[4,5-c]quinolin-4-ylamine
DM6CZAN	MI	TTK25J1
DM6CZAN	MN	Adenosine A1 receptor (ADORA1)
DM6CZAN	MT	DTT
DM6CZAN	MA	Inhibitor
DM6CZAN	RN	1H-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists. J Med Chem. 1991 Mar;34(3):1202-6.
DM6CZAN	RU	https://pubmed.ncbi.nlm.nih.gov/2002461

DM6CZAN	DI	DM6CZAN
DM6CZAN	DN	2-Cyclopentyl-1H-imidazo[4,5-c]quinolin-4-ylamine
DM6CZAN	MI	TTM2AOE
DM6CZAN	MN	Adenosine A2a receptor (ADORA2A)
DM6CZAN	MT	DTT
DM6CZAN	MA	Inhibitor
DM6CZAN	RN	1H-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists. J Med Chem. 1991 Mar;34(3):1202-6.
DM6CZAN	RU	https://pubmed.ncbi.nlm.nih.gov/2002461

DM6CZAN	DI	DM6CZAN
DM6CZAN	DN	2-Cyclopentyl-1H-imidazo[4,5-c]quinolin-4-ylamine
DM6CZAN	MI	TTNE7KG
DM6CZAN	MN	Adenosine A2b receptor (ADORA2B)
DM6CZAN	MT	DTT
DM6CZAN	MA	Inhibitor
DM6CZAN	RN	1H-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists. J Med Chem. 1991 Mar;34(3):1202-6.
DM6CZAN	RU	https://pubmed.ncbi.nlm.nih.gov/2002461

DMS947W	DI	DMS947W
DMS947W	DN	2-Cyclopentylaminomethyl-pyrrolidine-3,4-diol
DMS947W	MI	TTXWASR
DMS947W	MN	Intestinal maltase-glucoamylase (MGAM)
DMS947W	MT	DTT
DMS947W	MA	Inhibitor
DMS947W	RN	Derivatives of (2R,3R,4S)-2-aminomethylpyrrolidine-3,4-diol are selective alpha-mannosidase inhibitors. Bioorg Med Chem Lett. 2001 Sep 17;11(18):2489-93.
DMS947W	RU	https://pubmed.ncbi.nlm.nih.gov/11549453

DMRS6LH	DI	DMRS6LH
DMRS6LH	DN	2-Cyclopropanecarbonyl-cyclohexane-1,3-dione
DMRS6LH	MI	TT8DSFC
DMRS6LH	MN	Hydroxyphenylpyruvate dioxygenase (HPD)
DMRS6LH	MT	DTT
DMRS6LH	MA	Inhibitor
DMRS6LH	RN	SAR studies of 2-o-substituted-benzoyl- and 2-alkanoyl-cyclohexane-1,3-diones as inhibitors of 4-hydroxyphenylpyruvate dioxygenase. Bioorg Med Chem Lett. 2000 May 1;10(9):843-5.
DMRS6LH	RU	https://pubmed.ncbi.nlm.nih.gov/10853644

DM0W2QB	DI	DM0W2QB
DM0W2QB	DN	2-Cyclopropylmethylenepropanal
DM0W2QB	MI	TTB2MXP
DM0W2QB	MN	Angiotensinogenase renin (REN)
DM0W2QB	MT	DTT
DM0W2QB	MA	Inhibitor
DM0W2QB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM0W2QB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMIAM5L	DI	DMIAM5L
DMIAM5L	DN	2-Deoxy-2,3-Dehydro-N-Acetyl-Neuraminic Acid
DMIAM5L	MI	TT50QJ3
DMIAM5L	MN	Influenza Neuraminidase (Influ NA)
DMIAM5L	MT	DTT
DMIAM5L	MA	Inhibitor
DMIAM5L	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMIAM5L	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMBMK4T	DI	DMBMK4T
DMBMK4T	DN	2-Deoxy-2-Amino Glucitol-6-Phosphate
DMBMK4T	MI	TTC67I0
DMBMK4T	MN	Bacterial Glucosamine-6-phosphate synthase (Bact glmS)
DMBMK4T	MT	DTT
DMBMK4T	MA	Inhibitor
DMBMK4T	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMBMK4T	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMMC8IG	DI	DMMC8IG
DMMC8IG	DN	2-Deoxy-2fluoro-Glucose
DMMC8IG	MI	TTA0OSE
DMMC8IG	MN	Lactase-phlorizin hydrolase (LCT)
DMMC8IG	MT	DTT
DMMC8IG	MA	Inhibitor
DMMC8IG	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMMC8IG	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMG7CAU	DI	DMG7CAU
DMG7CAU	DN	2'-Deoxycytidine-5'-Monophosphate
DMG7CAU	MI	TTU6BFZ
DMG7CAU	MN	Candida Thymidylate synthase (Candi TMP1)
DMG7CAU	MT	DTT
DMG7CAU	MA	Inhibitor
DMG7CAU	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMG7CAU	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMMPL3D	DI	DMMPL3D
DMMPL3D	DN	2-Deoxy-Glucose-6-Phosphate
DMMPL3D	MI	TTZHY6R
DMMPL3D	MN	Glycogen phosphorylase muscle form (GP)
DMMPL3D	MT	DTT
DMMPL3D	MA	Inhibitor
DMMPL3D	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMMPL3D	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMY9FDT	DI	DMY9FDT
DMY9FDT	DN	2'-Deoxyguanosine-5'-Monophosphate
DMY9FDT	MI	TTU6BFZ
DMY9FDT	MN	Candida Thymidylate synthase (Candi TMP1)
DMY9FDT	MT	DTT
DMY9FDT	MA	Inhibitor
DMY9FDT	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMY9FDT	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9OEJT	DI	DM9OEJT
DM9OEJT	DN	2'-deoxythymidine triphosphate
DM9OEJT	MI	TTIU7X1
DM9OEJT	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DM9OEJT	MT	DTT
DM9OEJT	MA	Inhibitor
DM9OEJT	RN	Inhibition of human hepatitis B virus DNA polymerase and duck hepatitis B virus DNA polymerase by triphosphates of thymidine analogs and pharmacokinetic properties of the corresponding nucleosides. JMed Virol. 1988 Dec;26(4):353-62.
DM9OEJT	RU	https://pubmed.ncbi.nlm.nih.gov/3145322

DM9OEJT	DI	DM9OEJT
DM9OEJT	DN	2'-deoxythymidine triphosphate
DM9OEJT	MI	TT84ETX
DM9OEJT	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM9OEJT	MT	DTT
DM9OEJT	MA	Inhibitor
DM9OEJT	RN	Synthesis of 2',3'-dideoxynucleoside 5'-alpha-P-borano-beta,gamma-(difluoromethylene)triphosphates and their inhibition of HIV-1 reverse transcript... J Med Chem. 2005 Apr 7;48(7):2695-700.
DM9OEJT	RU	https://pubmed.ncbi.nlm.nih.gov/15801860

DM9OEJT	DI	DM9OEJT
DM9OEJT	DN	2'-deoxythymidine triphosphate
DM9OEJT	MI	TT5B8AX
DM9OEJT	MN	Mycobacterium Thymidine monophosphate kinase (MycB tmk)
DM9OEJT	MT	DTT
DM9OEJT	MA	Inhibitor
DM9OEJT	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9OEJT	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9OEJT	DI	DM9OEJT
DM9OEJT	DN	2'-deoxythymidine triphosphate
DM9OEJT	MI	TTP3QRF
DM9OEJT	MN	Thymidine kinase 1 (TK1)
DM9OEJT	MT	DTT
DM9OEJT	MA	Inhibitor
DM9OEJT	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9OEJT	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM1HMWA	DI	DM1HMWA
DM1HMWA	DN	2'-Deoxyuridine
DM1HMWA	MI	TTU6BFZ
DM1HMWA	MN	Candida Thymidylate synthase (Candi TMP1)
DM1HMWA	MT	DTT
DM1HMWA	MA	Inhibitor
DM1HMWA	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM1HMWA	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM1HMWA	DI	DM1HMWA
DM1HMWA	DN	2'-Deoxyuridine
DM1HMWA	MI	TTP3QRF
DM1HMWA	MN	Thymidine kinase 1 (TK1)
DM1HMWA	MT	DTT
DM1HMWA	MA	Inhibitor
DM1HMWA	RN	Species- or isozyme-specific enzyme inhibitors. 5. Differential effects of thymidine substituents on affinity for rat thymidine kinase isozymes. J Med Chem. 1982 Jun;25(6):644-9.
DM1HMWA	RU	https://pubmed.ncbi.nlm.nih.gov/7097717

DMXV27U	DI	DMXV27U
DMXV27U	DN	2'-deoxyuridine 5'-alpha,beta-imido-diphosphate
DMXV27U	MI	TTY8KJS
DMXV27U	MN	Bacterial Deoxyuridine triphosphate nucleotidohydrolase (Bact dut)
DMXV27U	MT	DTT
DMXV27U	MA	Inhibitor
DMXV27U	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMXV27U	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMOHABR	DI	DMOHABR
DMOHABR	DN	2'-Deoxyuridine 5'-Alpha,Beta-Imido-Triphosphate
DMOHABR	MI	TTY8KJS
DMOHABR	MN	Bacterial Deoxyuridine triphosphate nucleotidohydrolase (Bact dut)
DMOHABR	MT	DTT
DMOHABR	MA	Inhibitor
DMOHABR	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMOHABR	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMPV1LU	DI	DMPV1LU
DMPV1LU	DN	2'-deoxyuridylic acid
DMPV1LU	MI	TTY8KJS
DMPV1LU	MN	Bacterial Deoxyuridine triphosphate nucleotidohydrolase (Bact dut)
DMPV1LU	MT	DTT
DMPV1LU	MA	Inhibitor
DMPV1LU	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMPV1LU	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMPV1LU	DI	DMPV1LU
DMPV1LU	DN	2'-deoxyuridylic acid
DMPV1LU	MI	TTU6BFZ
DMPV1LU	MN	Candida Thymidylate synthase (Candi TMP1)
DMPV1LU	MT	DTT
DMPV1LU	MA	Inhibitor
DMPV1LU	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMPV1LU	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMPV1LU	DI	DMPV1LU
DMPV1LU	DN	2'-deoxyuridylic acid
DMPV1LU	MI	DEH4O6C
DMPV1LU	MN	Thymidylate synthase (thyA)
DMPV1LU	MT	DME
DMPV1LU	MA	Metabolism
DMPV1LU	RN	Role of the conserved tryptophan 82 of Lactobacillus casei thymidylate synthase. Chem Biol. 1995 Sep;2(9):609-14.
DMPV1LU	RU	https://pubmed.ncbi.nlm.nih.gov/9383465

DMPV1LU	DI	DMPV1LU
DMPV1LU	DN	2'-deoxyuridylic acid
DMPV1LU	MI	DEASG0Q
DMPV1LU	MN	Thymidylate synthase (TYMS)
DMPV1LU	MT	DME
DMPV1LU	MA	Metabolism
DMPV1LU	RN	Distribution of mutations in human thymidylate synthase yielding resistance to 5-fluorodeoxyuridine. J Biol Chem. 2002 Sep 27;277(39):36304-11.
DMPV1LU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12147691

DM4A527	DI	DM4A527
DM4A527	DN	2-dibenzofuran-4-yl-6-morpholin-4-yl-pyran-4-one
DM4A527	MI	TTK3PY9
DM4A527	MN	DNA-dependent protein kinase catalytic (PRKDC)
DM4A527	MT	DTT
DM4A527	MA	Inhibitor
DM4A527	RN	Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72.
DM4A527	RU	https://pubmed.ncbi.nlm.nih.gov/17371003

DMF50YH	DI	DMF50YH
DMF50YH	DN	2-Dipropylamino-1,2,3,4-tetrahydro-anthracen-9-ol
DMF50YH	MI	TTSQIFT
DMF50YH	MN	5-HT 1A receptor (HTR1A)
DMF50YH	MT	DTT
DMF50YH	MA	Inhibitor
DMF50YH	RN	Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993).
DMF50YH	RU	http://www.sciencedirect.com/science/article/pii/S0960894X0181009X

DM2PDGO	DI	DM2PDGO
DM2PDGO	DN	2-EPI-2-THIOSALVINORIN A
DM2PDGO	MI	TTQW87Y
DM2PDGO	MN	Opioid receptor kappa (OPRK1)
DM2PDGO	MT	DTT
DM2PDGO	MA	Inhibitor
DM2PDGO	RN	Convenient synthesis and in vitro pharmacological activity of 2-thioanalogs of salvinorins A and B. Bioorg Med Chem Lett. 2007 Apr 15;17(8):2229-32.
DM2PDGO	RU	https://pubmed.ncbi.nlm.nih.gov/17303418

DMZXIW0	DI	DMZXIW0
DMZXIW0	DN	2-EPI-2-THIOSALVINORIN B
DMZXIW0	MI	TTQW87Y
DMZXIW0	MN	Opioid receptor kappa (OPRK1)
DMZXIW0	MT	DTT
DMZXIW0	MA	Inhibitor
DMZXIW0	RN	Convenient synthesis and in vitro pharmacological activity of 2-thioanalogs of salvinorins A and B. Bioorg Med Chem Lett. 2007 Apr 15;17(8):2229-32.
DMZXIW0	RU	https://pubmed.ncbi.nlm.nih.gov/17303418

DMNVJY0	DI	DMNVJY0
DMNVJY0	DN	2'-epi-guianin
DMNVJY0	MI	TT8NGED
DMNVJY0	MN	Prostaglandin G/H synthase 1 (COX-1)
DMNVJY0	MT	DTT
DMNVJY0	MA	Inhibitor
DMNVJY0	RN	COX, LOX and platelet aggregation inhibitory properties of Lauraceae neolignans. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6922-5.
DMNVJY0	RU	https://pubmed.ncbi.nlm.nih.gov/19880317

DMGRA3T	DI	DMGRA3T
DMGRA3T	DN	2-ethoxy-5-(m-tolylethynyl)pyrimidine
DMGRA3T	MI	TTHS256
DMGRA3T	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMGRA3T	MT	DTT
DMGRA3T	MA	Inhibitor
DMGRA3T	RN	Discovery of molecular switches that modulate modes of metabotropic glutamate receptor subtype 5 (mGlu5) pharmacology in vitro and in vivo within a... J Med Chem. 2009 Jul 23;52(14):4103-6.
DMGRA3T	RU	https://pubmed.ncbi.nlm.nih.gov/19537763

DM0BHKM	DI	DM0BHKM
DM0BHKM	DN	2-ethyl-4-(furan-2-yl)thieno[3,2-d]pyrimidine
DM0BHKM	MI	TTK25J1
DM0BHKM	MN	Adenosine A1 receptor (ADORA1)
DM0BHKM	MT	DTT
DM0BHKM	MA	Inhibitor
DM0BHKM	RN	Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2920-3.
DM0BHKM	RU	https://pubmed.ncbi.nlm.nih.gov/18407496

DM0BHKM	DI	DM0BHKM
DM0BHKM	DN	2-ethyl-4-(furan-2-yl)thieno[3,2-d]pyrimidine
DM0BHKM	MI	TTM2AOE
DM0BHKM	MN	Adenosine A2a receptor (ADORA2A)
DM0BHKM	MT	DTT
DM0BHKM	MA	Inhibitor
DM0BHKM	RN	Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2920-3.
DM0BHKM	RU	https://pubmed.ncbi.nlm.nih.gov/18407496

DMR0IEK	DI	DMR0IEK
DMR0IEK	DN	2-ethyl-4-(furan-3-yl)thieno[3,2-d]pyrimidine
DMR0IEK	MI	TTK25J1
DMR0IEK	MN	Adenosine A1 receptor (ADORA1)
DMR0IEK	MT	DTT
DMR0IEK	MA	Inhibitor
DMR0IEK	RN	Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2920-3.
DMR0IEK	RU	https://pubmed.ncbi.nlm.nih.gov/18407496

DMR0IEK	DI	DMR0IEK
DMR0IEK	DN	2-ethyl-4-(furan-3-yl)thieno[3,2-d]pyrimidine
DMR0IEK	MI	TTM2AOE
DMR0IEK	MN	Adenosine A2a receptor (ADORA2A)
DMR0IEK	MT	DTT
DMR0IEK	MA	Inhibitor
DMR0IEK	RN	Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2920-3.
DMR0IEK	RU	https://pubmed.ncbi.nlm.nih.gov/18407496

DMWFR16	DI	DMWFR16
DMWFR16	DN	2-ethyl-4-(pyridin-2-yl)thieno[3,2-d]pyrimidine
DMWFR16	MI	TTK25J1
DMWFR16	MN	Adenosine A1 receptor (ADORA1)
DMWFR16	MT	DTT
DMWFR16	MA	Inhibitor
DMWFR16	RN	Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2920-3.
DMWFR16	RU	https://pubmed.ncbi.nlm.nih.gov/18407496

DMWFR16	DI	DMWFR16
DMWFR16	DN	2-ethyl-4-(pyridin-2-yl)thieno[3,2-d]pyrimidine
DMWFR16	MI	TTM2AOE
DMWFR16	MN	Adenosine A2a receptor (ADORA2A)
DMWFR16	MT	DTT
DMWFR16	MA	Inhibitor
DMWFR16	RN	Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2920-3.
DMWFR16	RU	https://pubmed.ncbi.nlm.nih.gov/18407496

DMWCGE8	DI	DMWCGE8
DMWCGE8	DN	2-ethyl-4-(thiazol-2-yl)thieno[3,2-d]pyrimidine
DMWCGE8	MI	TTK25J1
DMWCGE8	MN	Adenosine A1 receptor (ADORA1)
DMWCGE8	MT	DTT
DMWCGE8	MA	Inhibitor
DMWCGE8	RN	Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2920-3.
DMWCGE8	RU	https://pubmed.ncbi.nlm.nih.gov/18407496

DMWCGE8	DI	DMWCGE8
DMWCGE8	DN	2-ethyl-4-(thiazol-2-yl)thieno[3,2-d]pyrimidine
DMWCGE8	MI	TTM2AOE
DMWCGE8	MN	Adenosine A2a receptor (ADORA2A)
DMWCGE8	MT	DTT
DMWCGE8	MA	Inhibitor
DMWCGE8	RN	Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2920-3.
DMWCGE8	RU	https://pubmed.ncbi.nlm.nih.gov/18407496

DMWCGE8	DI	DMWCGE8
DMWCGE8	DN	2-ethyl-4-(thiazol-2-yl)thieno[3,2-d]pyrimidine
DMWCGE8	MI	TTNE7KG
DMWCGE8	MN	Adenosine A2b receptor (ADORA2B)
DMWCGE8	MT	DTT
DMWCGE8	MA	Inhibitor
DMWCGE8	RN	Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2920-3.
DMWCGE8	RU	https://pubmed.ncbi.nlm.nih.gov/18407496

DMWCGE8	DI	DMWCGE8
DMWCGE8	DN	2-ethyl-4-(thiazol-2-yl)thieno[3,2-d]pyrimidine
DMWCGE8	MI	TTJFY5U
DMWCGE8	MN	Adenosine A3 receptor (ADORA3)
DMWCGE8	MT	DTT
DMWCGE8	MA	Inhibitor
DMWCGE8	RN	Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2920-3.
DMWCGE8	RU	https://pubmed.ncbi.nlm.nih.gov/18407496

DMIRSQO	DI	DMIRSQO
DMIRSQO	DN	2-ethyl-4-(thiophen-2-yl)thieno[3,2-d]pyrimidine
DMIRSQO	MI	TTK25J1
DMIRSQO	MN	Adenosine A1 receptor (ADORA1)
DMIRSQO	MT	DTT
DMIRSQO	MA	Inhibitor
DMIRSQO	RN	Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2920-3.
DMIRSQO	RU	https://pubmed.ncbi.nlm.nih.gov/18407496

DMIRSQO	DI	DMIRSQO
DMIRSQO	DN	2-ethyl-4-(thiophen-2-yl)thieno[3,2-d]pyrimidine
DMIRSQO	MI	TTM2AOE
DMIRSQO	MN	Adenosine A2a receptor (ADORA2A)
DMIRSQO	MT	DTT
DMIRSQO	MA	Inhibitor
DMIRSQO	RN	Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2920-3.
DMIRSQO	RU	https://pubmed.ncbi.nlm.nih.gov/18407496

DMLC8OB	DI	DMLC8OB
DMLC8OB	DN	2-Ethyl-5-methoxy-3-piperidin-4-yl-1H-indole
DMLC8OB	MI	TTJS8PY
DMLC8OB	MN	5-HT 6 receptor (HTR6)
DMLC8OB	MT	DTT
DMLC8OB	MA	Inhibitor
DMLC8OB	RN	2-Alkyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles as novel 5-HT6 receptor agonists. Bioorg Med Chem Lett. 2005 Oct 1;15(19):4230-4.
DMLC8OB	RU	https://pubmed.ncbi.nlm.nih.gov/16055331

DMN8W1H	DI	DMN8W1H
DMN8W1H	DN	2-ethyl-9H-carbazole
DMN8W1H	MI	TTBGTCW
DMN8W1H	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DMN8W1H	MT	DTT
DMN8W1H	MA	Inhibitor
DMN8W1H	RN	Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8.
DMN8W1H	RU	https://pubmed.ncbi.nlm.nih.gov/20521839

DMDY3JQ	DI	DMDY3JQ
DMDY3JQ	DN	2-ethylamido-5-sulfonamidoindane
DMDY3JQ	MI	TTHQPL7
DMDY3JQ	MN	Carbonic anhydrase I (CA-I)
DMDY3JQ	MT	DTT
DMDY3JQ	MA	Inhibitor
DMDY3JQ	RN	Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9.
DMDY3JQ	RU	https://pubmed.ncbi.nlm.nih.gov/16640335

DMDY3JQ	DI	DMDY3JQ
DMDY3JQ	DN	2-ethylamido-5-sulfonamidoindane
DMDY3JQ	MI	TTANPDJ
DMDY3JQ	MN	Carbonic anhydrase II (CA-II)
DMDY3JQ	MT	DTT
DMDY3JQ	MA	Inhibitor
DMDY3JQ	RN	Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9.
DMDY3JQ	RU	https://pubmed.ncbi.nlm.nih.gov/16640335

DMDY3JQ	DI	DMDY3JQ
DMDY3JQ	DN	2-ethylamido-5-sulfonamidoindane
DMDY3JQ	MI	TT2LVK8
DMDY3JQ	MN	Carbonic anhydrase IX (CA-IX)
DMDY3JQ	MT	DTT
DMDY3JQ	MA	Inhibitor
DMDY3JQ	RN	Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9.
DMDY3JQ	RU	https://pubmed.ncbi.nlm.nih.gov/16640335

DMC10DR	DI	DMC10DR
DMC10DR	DN	2-ethylestradiol 3,17-O,O-bis-sulfamate
DMC10DR	MI	TTHM0R1
DMC10DR	MN	Steryl-sulfatase (STS)
DMC10DR	MT	DTT
DMC10DR	MA	Inhibitor
DMC10DR	RN	2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity. J Med Chem. 2006 Dec 28;49(26):7683-96.
DMC10DR	RU	https://pubmed.ncbi.nlm.nih.gov/17181151

DMKR47X	DI	DMKR47X
DMKR47X	DN	2-ethylquinoline-8-carboxamide
DMKR47X	MI	TTVDSZ0
DMKR47X	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMKR47X	MT	DTT
DMKR47X	MA	Inhibitor
DMKR47X	RN	Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhi... J Med Chem. 2009 Feb 12;52(3):868-77.
DMKR47X	RU	https://pubmed.ncbi.nlm.nih.gov/19117416

DME6VKS	DI	DME6VKS
DME6VKS	DN	2-ethynyl-4-(3-fluorophenylethynyl)thiazole
DME6VKS	MI	TTHS256
DME6VKS	MN	Metabotropic glutamate receptor 5 (mGluR5)
DME6VKS	MT	DTT
DME6VKS	MA	Inhibitor
DME6VKS	RN	Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100.
DME6VKS	RU	https://pubmed.ncbi.nlm.nih.gov/16451073

DM2D78W	DI	DM2D78W
DM2D78W	DN	2-ethynyl-N6-methoxyadenosine
DM2D78W	MI	TTK25J1
DM2D78W	MN	Adenosine A1 receptor (ADORA1)
DM2D78W	MT	DTT
DM2D78W	MA	Inhibitor
DM2D78W	RN	N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
DM2D78W	RU	https://pubmed.ncbi.nlm.nih.gov/17309246

DM2D78W	DI	DM2D78W
DM2D78W	DN	2-ethynyl-N6-methoxyadenosine
DM2D78W	MI	TTM2AOE
DM2D78W	MN	Adenosine A2a receptor (ADORA2A)
DM2D78W	MT	DTT
DM2D78W	MA	Inhibitor
DM2D78W	RN	N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
DM2D78W	RU	https://pubmed.ncbi.nlm.nih.gov/17309246

DM2D78W	DI	DM2D78W
DM2D78W	DN	2-ethynyl-N6-methoxyadenosine
DM2D78W	MI	TTJFY5U
DM2D78W	MN	Adenosine A3 receptor (ADORA3)
DM2D78W	MT	DTT
DM2D78W	MA	Inhibitor
DM2D78W	RN	N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
DM2D78W	RU	https://pubmed.ncbi.nlm.nih.gov/17309246

DMNOAJG	DI	DMNOAJG
DMNOAJG	DN	2ewy
DMNOAJG	MI	TT69DB8
DMNOAJG	MN	Beta-site APP-cleaving enzyme 2 (BACE2)
DMNOAJG	MT	DTT
DMNOAJG	MA	Inhibitor
DMNOAJG	RN	Crystal structure of human BACE2 in complex with a hydroxyethylamine transition-state inhibitor. J Mol Biol. 2006 Jan 13;355(2):249-61.
DMNOAJG	RU	https://pubmed.ncbi.nlm.nih.gov/16305800

DMUGAT8	DI	DMUGAT8
DMUGAT8	DN	2-Fluoro-4-[5-(3-hydroxyphenyl)-2-thienyl]phenol
DMUGAT8	MI	TTXV4FI
DMUGAT8	MN	Albendazole monooxygenase (CYP3A4)
DMUGAT8	MT	DTT
DMUGAT8	MA	Inhibitor
DMUGAT8	RN	New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43.
DMUGAT8	RU	https://pubmed.ncbi.nlm.nih.gov/19831396

DMUGAT8	DI	DMUGAT8
DMUGAT8	DN	2-Fluoro-4-[5-(3-hydroxyphenyl)-2-thienyl]phenol
DMUGAT8	MI	TTVG215
DMUGAT8	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DMUGAT8	MT	DTT
DMUGAT8	MA	Inhibitor
DMUGAT8	RN	New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43.
DMUGAT8	RU	https://pubmed.ncbi.nlm.nih.gov/19831396

DMUGAT8	DI	DMUGAT8
DMUGAT8	DN	2-Fluoro-4-[5-(3-hydroxyphenyl)-2-thienyl]phenol
DMUGAT8	MI	TTIWB6L
DMUGAT8	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMUGAT8	MT	DTT
DMUGAT8	MA	Inhibitor
DMUGAT8	RN	New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43.
DMUGAT8	RU	https://pubmed.ncbi.nlm.nih.gov/19831396

DMGBEFY	DI	DMGBEFY
DMGBEFY	DN	2-Fluoro-4-[5-(3-hydroxyphenyl)-3-thienyl]phenol
DMGBEFY	MI	TTIWB6L
DMGBEFY	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMGBEFY	MT	DTT
DMGBEFY	MA	Inhibitor
DMGBEFY	RN	New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43.
DMGBEFY	RU	https://pubmed.ncbi.nlm.nih.gov/19831396

DMCGI1S	DI	DMCGI1S
DMCGI1S	DN	2-fluoro-5-(3-methylthiophen-2-yl)pyridine
DMCGI1S	MI	TTXV4FI
DMCGI1S	MN	Albendazole monooxygenase (CYP3A4)
DMCGI1S	MT	DTT
DMCGI1S	MA	Inhibitor
DMCGI1S	RN	Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallization. J Med Chem. 2006 Nov 30;49(24):6987-7001.
DMCGI1S	RU	https://pubmed.ncbi.nlm.nih.gov/17125252

DMKOUCM	DI	DMKOUCM
DMKOUCM	DN	2-Fluoro-5-[5-(4-hydroxyphenyl)-2-thienyl]phenol
DMKOUCM	MI	TTIWB6L
DMKOUCM	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMKOUCM	MT	DTT
DMKOUCM	MA	Inhibitor
DMKOUCM	RN	New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43.
DMKOUCM	RU	https://pubmed.ncbi.nlm.nih.gov/19831396

DMP8OXL	DI	DMP8OXL
DMP8OXL	DN	2-Fluoro-6-(3-phenoxy-benzoylamino)-benzoic acid
DMP8OXL	MI	TTRVTMX
DMP8OXL	MN	Bacterial Beta-ketoacyl-ACP synthase III (Bact fabH)
DMP8OXL	MT	DTT
DMP8OXL	MA	Inhibitor
DMP8OXL	RN	Structure-based design, synthesis, and study of potent inhibitors of beta-ketoacyl-acyl carrier protein synthase III as potential antimicrobial age... J Med Chem. 2005 Mar 10;48(5):1596-609.
DMP8OXL	RU	https://pubmed.ncbi.nlm.nih.gov/15743201

DMEQRHY	DI	DMEQRHY
DMEQRHY	DN	2-fluoromevalonate 5-diphosphate
DMEQRHY	MI	TTE5J6X
DMEQRHY	MN	Diphosphomevalonate decarboxylase (MVD)
DMEQRHY	MT	DTT
DMEQRHY	MA	Inhibitor
DMEQRHY	RN	Inhibition of mevalonate 5-diphosphate decarboxylase by fluorinated substrate analogs. Biochim Biophys Acta. 2006 Jul;1760(7):1080-7.
DMEQRHY	RU	https://pubmed.ncbi.nlm.nih.gov/16626865

DMX34TL	DI	DMX34TL
DMX34TL	DN	2-fluoronorepinehprine
DMX34TL	MI	TT2CJVK
DMX34TL	MN	Adrenergic receptor beta-2 (ADRB2)
DMX34TL	MT	DTT
DMX34TL	MA	Inhibitor
DMX34TL	RN	Structural basis of the selectivity of the beta(2)-adrenergic receptor for fluorinated catecholamines. Bioorg Med Chem. 2009 Dec 1;17(23):7987-92.
DMX34TL	RU	https://pubmed.ncbi.nlm.nih.gov/19857969

DM5OW91	DI	DM5OW91
DM5OW91	DN	2-fluorophenyl 1-(4-butoxyphenyl)propylcarbamate
DM5OW91	MI	TTDP1UC
DM5OW91	MN	Fatty acid amide hydrolase (FAAH)
DM5OW91	MT	DTT
DM5OW91	MA	Inhibitor
DM5OW91	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DM5OW91	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DMSFQAZ	DI	DMSFQAZ
DMSFQAZ	DN	2-fluorophenyl 4-(decyloxy)phenylcarbamate
DMSFQAZ	MI	TTDP1UC
DMSFQAZ	MN	Fatty acid amide hydrolase (FAAH)
DMSFQAZ	MT	DTT
DMSFQAZ	MA	Inhibitor
DMSFQAZ	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DMSFQAZ	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DMCEGZU	DI	DMCEGZU
DMCEGZU	DN	2-fluorophenyl 4-(dodecyloxy)phenylcarbamate
DMCEGZU	MI	TTDP1UC
DMCEGZU	MN	Fatty acid amide hydrolase (FAAH)
DMCEGZU	MT	DTT
DMCEGZU	MA	Inhibitor
DMCEGZU	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DMCEGZU	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DMLM2WU	DI	DMLM2WU
DMLM2WU	DN	2-fluorophenyl 4-(heptyloxy)phenylcarbamate
DMLM2WU	MI	TTDP1UC
DMLM2WU	MN	Fatty acid amide hydrolase (FAAH)
DMLM2WU	MT	DTT
DMLM2WU	MA	Inhibitor
DMLM2WU	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DMLM2WU	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DM854ED	DI	DM854ED
DM854ED	DN	2-fluorophenyl 4-(hexyloxy)phenylcarbamate
DM854ED	MI	TTDP1UC
DM854ED	MN	Fatty acid amide hydrolase (FAAH)
DM854ED	MT	DTT
DM854ED	MA	Inhibitor
DM854ED	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DM854ED	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DM81J0O	DI	DM81J0O
DM81J0O	DN	2-fluorophenyl 4-(octyloxy)phenylcarbamate
DM81J0O	MI	TTDP1UC
DM81J0O	MN	Fatty acid amide hydrolase (FAAH)
DM81J0O	MT	DTT
DM81J0O	MA	Inhibitor
DM81J0O	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DM81J0O	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DMTYX5G	DI	DMTYX5G
DMTYX5G	DN	2-fluorophenyl 4-(undecyloxy)phenylcarbamate
DMTYX5G	MI	TTDP1UC
DMTYX5G	MN	Fatty acid amide hydrolase (FAAH)
DMTYX5G	MT	DTT
DMTYX5G	MA	Inhibitor
DMTYX5G	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DMTYX5G	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DM4EIQ3	DI	DM4EIQ3
DM4EIQ3	DN	2-fluorophenyl 4-butoxybenzylcarbamate
DM4EIQ3	MI	TTDP1UC
DM4EIQ3	MN	Fatty acid amide hydrolase (FAAH)
DM4EIQ3	MT	DTT
DM4EIQ3	MA	Inhibitor
DM4EIQ3	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DM4EIQ3	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DMYJ1M4	DI	DMYJ1M4
DMYJ1M4	DN	2-fluorophenyl 4-butoxyphenylcarbamate
DMYJ1M4	MI	TTDP1UC
DMYJ1M4	MN	Fatty acid amide hydrolase (FAAH)
DMYJ1M4	MT	DTT
DMYJ1M4	MA	Inhibitor
DMYJ1M4	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DMYJ1M4	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DMGIKWA	DI	DMGIKWA
DMGIKWA	DN	2-fluorophenyl 4'-ethylbiphenyl-4-ylcarbamate
DMGIKWA	MI	TTDP1UC
DMGIKWA	MN	Fatty acid amide hydrolase (FAAH)
DMGIKWA	MT	DTT
DMGIKWA	MA	Inhibitor
DMGIKWA	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DMGIKWA	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DMSMDQC	DI	DMSMDQC
DMSMDQC	DN	2-fluorophenyl 4-phenoxyphenylcarbamate
DMSMDQC	MI	TTDP1UC
DMSMDQC	MN	Fatty acid amide hydrolase (FAAH)
DMSMDQC	MT	DTT
DMSMDQC	MA	Inhibitor
DMSMDQC	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DMSMDQC	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DMNPGXA	DI	DMNPGXA
DMNPGXA	DN	2-fluorophenyl-2,2-diphenylacetamide
DMNPGXA	MI	TTMNI76
DMNPGXA	MN	Calcium-activated potassium channel (KCN)
DMNPGXA	MT	DTT
DMNPGXA	MA	Inhibitor
DMNPGXA	RN	Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82.
DMNPGXA	RU	https://pubmed.ncbi.nlm.nih.gov/18232633

DMXPFYZ	DI	DMXPFYZ
DMXPFYZ	DN	2-fluorophenylboronic acid
DMXPFYZ	MI	TTDP1UC
DMXPFYZ	MN	Fatty acid amide hydrolase (FAAH)
DMXPFYZ	MT	DTT
DMXPFYZ	MA	Inhibitor
DMXPFYZ	RN	Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Nov 27;51(22):7057-60.
DMXPFYZ	RU	https://pubmed.ncbi.nlm.nih.gov/18983140

DM28XTE	DI	DM28XTE
DM28XTE	DN	2-Furan-2-yl-3-phenethyl-3H-quinazolin-4-one
DM28XTE	MI	TTBUYHA
DM28XTE	MN	Extracellular calcium-sensing receptor (CASR)
DM28XTE	MT	DTT
DM28XTE	MA	Inhibitor
DM28XTE	RN	Design, new synthesis, and calcilytic activity of substituted 3H-pyrimidin-4-ones. Bioorg Med Chem Lett. 2005 May 16;15(10):2537-40.
DM28XTE	RU	https://pubmed.ncbi.nlm.nih.gov/15863312

DMQIFJ9	DI	DMQIFJ9
DMQIFJ9	DN	2-Furan-2-yl-4,5-dihydro-1H-imidazole
DMQIFJ9	MI	TT3WG5C
DMQIFJ9	MN	Monoamine oxidase type A (MAO-A)
DMQIFJ9	MT	DTT
DMQIFJ9	MA	Inhibitor
DMQIFJ9	RN	Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9.
DMQIFJ9	RU	https://pubmed.ncbi.nlm.nih.gov/14698196

DMQIFJ9	DI	DMQIFJ9
DMQIFJ9	DN	2-Furan-2-yl-4,5-dihydro-1H-imidazole
DMQIFJ9	MI	TTGP7BY
DMQIFJ9	MN	Monoamine oxidase type B (MAO-B)
DMQIFJ9	MT	DTT
DMQIFJ9	MA	Inhibitor
DMQIFJ9	RN	Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9.
DMQIFJ9	RU	https://pubmed.ncbi.nlm.nih.gov/14698196

DMHT80R	DI	DMHT80R
DMHT80R	DN	2-Furan-2-yl-6H-pyrazolo[1,5-c]quinazolin-5-one
DMHT80R	MI	TT1MPAY
DMHT80R	MN	GABA(A) receptor alpha-1 (GABRA1)
DMHT80R	MT	DTT
DMHT80R	MA	Inhibitor
DMHT80R	RN	Synthesis and binding activity of some pyrazolo[1,5-c]quinazolines as tools to verify an optional binding site of a benzodiazepine receptor ligand. J Med Chem. 1996 Jul 19;39(15):2915-21.
DMHT80R	RU	https://pubmed.ncbi.nlm.nih.gov/8709126

DMHT80R	DI	DMHT80R
DMHT80R	DN	2-Furan-2-yl-6H-pyrazolo[1,5-c]quinazolin-5-one
DMHT80R	MI	TTNJYV2
DMHT80R	MN	Gamma-aminobutyric acid receptor (GAR)
DMHT80R	MT	DTT
DMHT80R	MA	Inhibitor
DMHT80R	RN	Synthesis and binding activity of some pyrazolo[1,5-c]quinazolines as tools to verify an optional binding site of a benzodiazepine receptor ligand. J Med Chem. 1996 Jul 19;39(15):2915-21.
DMHT80R	RU	https://pubmed.ncbi.nlm.nih.gov/8709126

DMD8ZUH	DI	DMD8ZUH
DMD8ZUH	DN	2-Furan-2-yl-7-methyl-1H-[1,8]naphthyridin-4-one
DMD8ZUH	MI	TTML2WA
DMD8ZUH	MN	Tubulin (TUB)
DMD8ZUH	MT	DTT
DMD8ZUH	MA	Inhibitor
DMD8ZUH	RN	Antitumor agents. 196. Substituted 2-thienyl-1,8-naphthyridin-4-ones: their synthesis, cytotoxicity, and inhibition of tubulin polymerization. J Med Chem. 1999 Oct 7;42(20):4081-7.
DMD8ZUH	RU	https://pubmed.ncbi.nlm.nih.gov/10514278

DMD8ZUH	DI	DMD8ZUH
DMD8ZUH	DN	2-Furan-2-yl-7-methyl-1H-[1,8]naphthyridin-4-one
DMD8ZUH	MI	TTYFKSZ
DMD8ZUH	MN	Tubulin beta (TUBB)
DMD8ZUH	MT	DTT
DMD8ZUH	MA	Inhibitor
DMD8ZUH	RN	Antitumor agents. 196. Substituted 2-thienyl-1,8-naphthyridin-4-ones: their synthesis, cytotoxicity, and inhibition of tubulin polymerization. J Med Chem. 1999 Oct 7;42(20):4081-7.
DMD8ZUH	RU	https://pubmed.ncbi.nlm.nih.gov/10514278

DMQIRY7	DI	DMQIRY7
DMQIRY7	DN	2-Furan-2-ylmethyl-1,2-dihydro-indazol-3-one
DMQIRY7	MI	TT2J34L
DMQIRY7	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMQIRY7	MT	DTT
DMQIRY7	MA	Inhibitor
DMQIRY7	RN	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
DMQIRY7	RU	https://pubmed.ncbi.nlm.nih.gov/1848292

DMQIRY7	DI	DMQIRY7
DMQIRY7	DN	2-Furan-2-ylmethyl-1,2-dihydro-indazol-3-one
DMQIRY7	MI	TT8NGED
DMQIRY7	MN	Prostaglandin G/H synthase 1 (COX-1)
DMQIRY7	MT	DTT
DMQIRY7	MA	Inhibitor
DMQIRY7	RN	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
DMQIRY7	RU	https://pubmed.ncbi.nlm.nih.gov/1848292

DMQIRY7	DI	DMQIRY7
DMQIRY7	DN	2-Furan-2-ylmethyl-1,2-dihydro-indazol-3-one
DMQIRY7	MI	TTVKILB
DMQIRY7	MN	Prostaglandin G/H synthase 2 (COX-2)
DMQIRY7	MT	DTT
DMQIRY7	MA	Inhibitor
DMQIRY7	RN	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
DMQIRY7	RU	https://pubmed.ncbi.nlm.nih.gov/1848292

DMET6FO	DI	DMET6FO
DMET6FO	DN	2H-chromeno[2,3-d]pyrimidine-2,4(3H)-dione
DMET6FO	MI	TTUF2HO
DMET6FO	MN	NAD-dependent deacetylase sirtuin-1 (SIRT1)
DMET6FO	MT	DTT
DMET6FO	MA	Inhibitor
DMET6FO	RN	Characterization of sirtuin inhibitors in nematodes expressing a muscular dystrophy protein reveals muscle cell and behavioral protection by specif... J Med Chem. 2010 Feb 11;53(3):1407-11.
DMET6FO	RU	https://pubmed.ncbi.nlm.nih.gov/20041717

DMX45WE	DI	DMX45WE
DMX45WE	DN	2-Heptyl-1(3)H-anthra[1,2-d]imidazole-6,11-dione
DMX45WE	MI	TTQY2EJ
DMX45WE	MN	TERT messenger RNA (TERT mRNA)
DMX45WE	MT	DTT
DMX45WE	MA	Inhibitor
DMX45WE	RN	Synthesis, cytotoxicity and human telomerase inhibition activities of a series of 1,2-heteroannelated anthraquinones and anthra[1,2-d]imidazole-6,1... Bioorg Med Chem. 2009 Nov 1;17(21):7418-28.
DMX45WE	RU	https://pubmed.ncbi.nlm.nih.gov/19804981

DMJ3ATL	DI	DMJ3ATL
DMJ3ATL	DN	2-HEPTYL-4-HYDROXY QUINOLINE N-OXIDE
DMJ3ATL	MI	TTHDSE2
DMJ3ATL	MN	Bacterial Fumarate reductase flavoprotein (Bact frdA)
DMJ3ATL	MT	DTT
DMJ3ATL	MA	Inhibitor
DMJ3ATL	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMJ3ATL	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMRXW3U	DI	DMRXW3U
DMRXW3U	DN	2-Hex-5-enyl-5-non-8-enyl-3,4-dihydro-2H-pyrrole
DMRXW3U	MI	TT1RS9F
DMRXW3U	MN	Acetylcholinesterase (AChE)
DMRXW3U	MT	DTT
DMRXW3U	MA	Inhibitor
DMRXW3U	RN	Acetylcholinesterase inhibition by alkaloids of the ant's venom Monomorium minutum, Bioorg. Med. Chem. Lett. 5(11):1131-1132 (1995).
DMRXW3U	RU	http://www.sciencedirect.com/science/article/pii/0960894X9500179W

DM7KDQV	DI	DM7KDQV
DM7KDQV	DN	2-Hex-5-enyl-5-non-8-enyl-pyrrolidine
DM7KDQV	MI	TT1RS9F
DM7KDQV	MN	Acetylcholinesterase (AChE)
DM7KDQV	MT	DTT
DM7KDQV	MA	Inhibitor
DM7KDQV	RN	Acetylcholinesterase inhibition by alkaloids of the ant's venom Monomorium minutum, Bioorg. Med. Chem. Lett. 5(11):1131-1132 (1995).
DM7KDQV	RU	http://www.sciencedirect.com/science/article/pii/0960894X9500179W

DMIBRYM	DI	DMIBRYM
DMIBRYM	DN	2-Hex-5-enyl-5-nonyl-pyrrolidine
DMIBRYM	MI	TT1RS9F
DMIBRYM	MN	Acetylcholinesterase (AChE)
DMIBRYM	MT	DTT
DMIBRYM	MA	Inhibitor
DMIBRYM	RN	Acetylcholinesterase inhibition by alkaloids of the ant's venom Monomorium minutum, Bioorg. Med. Chem. Lett. 5(11):1131-1132 (1995).
DMIBRYM	RU	http://www.sciencedirect.com/science/article/pii/0960894X9500179W

DMTFIPZ	DI	DMTFIPZ
DMTFIPZ	DN	2-Hexadecynoic acid
DMTFIPZ	MI	TTVTX4N
DMTFIPZ	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DMTFIPZ	MT	DTT
DMTFIPZ	MA	Inhibitor
DMTFIPZ	RN	2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infections. Bioorg Med Chem. 2010 Nov 1;18(21):7475-85.
DMTFIPZ	RU	https://pubmed.ncbi.nlm.nih.gov/20855214

DMTFIPZ	DI	DMTFIPZ
DMTFIPZ	DN	2-Hexadecynoic acid
DMTFIPZ	MI	TT7AOUD
DMTFIPZ	MN	Fatty acid synthase (FASN)
DMTFIPZ	MT	DTT
DMTFIPZ	MA	Inhibitor
DMTFIPZ	RN	2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infections. Bioorg Med Chem. 2010 Nov 1;18(21):7475-85.
DMTFIPZ	RU	https://pubmed.ncbi.nlm.nih.gov/20855214

DMTFIPZ	DI	DMTFIPZ
DMTFIPZ	DN	2-Hexadecynoic acid
DMTFIPZ	MI	TTHPFTS
DMTFIPZ	MN	Plasmodium Beta-hydroxyacyl-ACP dehydratase (Malaria FabZ)
DMTFIPZ	MT	DTT
DMTFIPZ	MA	Inhibitor
DMTFIPZ	RN	2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infections. Bioorg Med Chem. 2010 Nov 1;18(21):7475-85.
DMTFIPZ	RU	https://pubmed.ncbi.nlm.nih.gov/20855214

DMTFIPZ	DI	DMTFIPZ
DMTFIPZ	DN	2-Hexadecynoic acid
DMTFIPZ	MI	TTBE4IR
DMTFIPZ	MN	Plasmodium Oxoacyl-[acyl-carrier protein] reductase (Malaria fabG)
DMTFIPZ	MT	DTT
DMTFIPZ	MA	Inhibitor
DMTFIPZ	RN	2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infections. Bioorg Med Chem. 2010 Nov 1;18(21):7475-85.
DMTFIPZ	RU	https://pubmed.ncbi.nlm.nih.gov/20855214

DM94PBL	DI	DM94PBL
DM94PBL	DN	2-Hexyl-4-(4-isobutyl-phenyl)-1H-imidazole
DM94PBL	MI	TTRK8B9
DM94PBL	MN	Sodium channel unspecific (NaC)
DM94PBL	MT	DTT
DM94PBL	MA	Inhibitor
DM94PBL	RN	2-Alkyl-4-arylimidazoles: structurally novel sodium channel modulators. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3521-3.
DM94PBL	RU	https://pubmed.ncbi.nlm.nih.gov/15177465

DM94PBL	DI	DM94PBL
DM94PBL	DN	2-Hexyl-4-(4-isobutyl-phenyl)-1H-imidazole
DM94PBL	MI	TTAXZ0K
DM94PBL	MN	Voltage-gated sodium channel alpha Nav1.3 (SCN3A)
DM94PBL	MT	DTT
DM94PBL	MA	Inhibitor
DM94PBL	RN	2-Alkyl-4-arylimidazoles: structurally novel sodium channel modulators. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3521-3.
DM94PBL	RU	https://pubmed.ncbi.nlm.nih.gov/15177465

DMKORTS	DI	DMKORTS
DMKORTS	DN	2-Hexyloxy-5-imidazol-1-yl-pyridine
DMKORTS	MI	TTVG215
DMKORTS	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DMKORTS	MT	DTT
DMKORTS	MA	Inhibitor
DMKORTS	RN	Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):333-6.
DMKORTS	RU	https://pubmed.ncbi.nlm.nih.gov/14698153

DMTD0IG	DI	DMTD0IG
DMTD0IG	DN	2-hexylphenyl acrylate
DMTD0IG	MI	TTGER3L
DMTD0IG	MN	Thyroid hormone receptor beta (THRB)
DMTD0IG	MT	DTT
DMTD0IG	MA	Inhibitor
DMTD0IG	RN	Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80.
DMTD0IG	RU	https://pubmed.ncbi.nlm.nih.gov/17918822

DMHR1UE	DI	DMHR1UE
DMHR1UE	DN	2H-Isoquinolin-1-one
DMHR1UE	MI	TTVDSZ0
DMHR1UE	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMHR1UE	MT	DTT
DMHR1UE	MA	Inhibitor
DMHR1UE	RN	Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56.
DMHR1UE	RU	https://pubmed.ncbi.nlm.nih.gov/9857092

DMOT1LQ	DI	DMOT1LQ
DMOT1LQ	DN	2-Hydrazino-3-methyl-4(3H)-quinazolinone
DMOT1LQ	MI	TTGP7BY
DMOT1LQ	MN	Monoamine oxidase type B (MAO-B)
DMOT1LQ	MT	DTT
DMOT1LQ	MA	Inhibitor
DMOT1LQ	RN	New pyrazoline bearing 4(3H)-quinazolinone inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A ... Bioorg Med Chem. 2009 Jan 15;17(2):675-89.
DMOT1LQ	RU	https://pubmed.ncbi.nlm.nih.gov/19091581

DMG78U2	DI	DMG78U2
DMG78U2	DN	2-Hydrazinocarbonyl-benzenesulfonamide
DMG78U2	MI	TTANPDJ
DMG78U2	MN	Carbonic anhydrase II (CA-II)
DMG78U2	MT	DTT
DMG78U2	MA	Inhibitor
DMG78U2	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamide... J Med Chem. 2005 Mar 24;48(6):2121-5.
DMG78U2	RU	https://pubmed.ncbi.nlm.nih.gov/15771455

DMG78U2	DI	DMG78U2
DMG78U2	DN	2-Hydrazinocarbonyl-benzenesulfonamide
DMG78U2	MI	TT2LVK8
DMG78U2	MN	Carbonic anhydrase IX (CA-IX)
DMG78U2	MT	DTT
DMG78U2	MA	Inhibitor
DMG78U2	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamide... J Med Chem. 2005 Mar 24;48(6):2121-5.
DMG78U2	RU	https://pubmed.ncbi.nlm.nih.gov/15771455

DMCNXZM	DI	DMCNXZM
DMCNXZM	DN	2-hydrazinylbenzenesulfonamide
DMCNXZM	MI	TTUNARX
DMCNXZM	MN	Carbonic anhydrase (CA)
DMCNXZM	MT	DTT
DMCNXZM	MA	Inhibitor
DMCNXZM	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DMCNXZM	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DMCNXZM	DI	DMCNXZM
DMCNXZM	DN	2-hydrazinylbenzenesulfonamide
DMCNXZM	MI	TTANPDJ
DMCNXZM	MN	Carbonic anhydrase II (CA-II)
DMCNXZM	MT	DTT
DMCNXZM	MA	Inhibitor
DMCNXZM	RN	Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorg Med Chem. 2009 Jul 15;17(14):5054-8.
DMCNXZM	RU	https://pubmed.ncbi.nlm.nih.gov/19520577

DMCNXZM	DI	DMCNXZM
DMCNXZM	DN	2-hydrazinylbenzenesulfonamide
DMCNXZM	MI	TT2LVK8
DMCNXZM	MN	Carbonic anhydrase IX (CA-IX)
DMCNXZM	MT	DTT
DMCNXZM	MA	Inhibitor
DMCNXZM	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DMCNXZM	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DMCNXZM	DI	DMCNXZM
DMCNXZM	DN	2-hydrazinylbenzenesulfonamide
DMCNXZM	MI	TTCFSPE
DMCNXZM	MN	Carbonic anhydrase VI (CA-VI)
DMCNXZM	MT	DTT
DMCNXZM	MA	Inhibitor
DMCNXZM	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DMCNXZM	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DMCNXZM	DI	DMCNXZM
DMCNXZM	DN	2-hydrazinylbenzenesulfonamide
DMCNXZM	MI	TTSYM0R
DMCNXZM	MN	Carbonic anhydrase XII (CA-XII)
DMCNXZM	MT	DTT
DMCNXZM	MA	Inhibitor
DMCNXZM	RN	Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglauc... Bioorg Med Chem Lett. 2005 Feb 15;15(4):963-9.
DMCNXZM	RU	https://pubmed.ncbi.nlm.nih.gov/15686894

DMJAN52	DI	DMJAN52
DMJAN52	DN	2-hydroxy capric acid
DMJAN52	MI	TTG0MQD
DMJAN52	MN	Inflammation-related GPCR EX33 (GPR84)
DMJAN52	MT	DTT
DMJAN52	MA	Agonist
DMJAN52	RN	Medium-chain fatty acid-sensing receptor, GPR84, is a proinflammatory receptor. J Biol Chem. 2013 Apr 12;288(15):10684-91.
DMJAN52	RU	https://pubmed.ncbi.nlm.nih.gov/23449982

DMM9Z0B	DI	DMM9Z0B
DMM9Z0B	DN	2-hydroxy-17beta-estradiol
DMM9Z0B	MI	TT2QM9D
DMM9Z0B	MN	Adenylate cyclase (ADCY)
DMM9Z0B	MT	DTT
DMM9Z0B	MA	Inhibitor
DMM9Z0B	RN	Structure-based development of novel adenylyl cyclase inhibitors. J Med Chem. 2008 Aug 14;51(15):4456-64.
DMM9Z0B	RU	https://pubmed.ncbi.nlm.nih.gov/18630896

DMM9Z0B	DI	DMM9Z0B
DMM9Z0B	DN	2-hydroxy-17beta-estradiol
DMM9Z0B	MI	DESD26P
DMM9Z0B	MN	UDP-glucuronosyltransferase 1A6 (UGT1A6)
DMM9Z0B	MT	DME
DMM9Z0B	MA	Metabolism
DMM9Z0B	RN	Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev. 1999 Nov;31(4):817-99.
DMM9Z0B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10575553

DM2GPF6	DI	DM2GPF6
DM2GPF6	DN	2-Hydroxy-2-phenyl-nonanoic acid amide
DM2GPF6	MI	TTRK8B9
DM2GPF6	MN	Sodium channel unspecific (NaC)
DM2GPF6	MT	DTT
DM2GPF6	MA	Inhibitor
DM2GPF6	RN	Comparative molecular field analysis of hydantoin binding to the neuronal voltage-dependent sodium channel. J Med Chem. 1999 May 6;42(9):1537-45.
DM2GPF6	RU	https://pubmed.ncbi.nlm.nih.gov/10229624

DM2GPF6	DI	DM2GPF6
DM2GPF6	DN	2-Hydroxy-2-phenyl-nonanoic acid amide
DM2GPF6	MI	TTAXZ0K
DM2GPF6	MN	Voltage-gated sodium channel alpha Nav1.3 (SCN3A)
DM2GPF6	MT	DTT
DM2GPF6	MA	Inhibitor
DM2GPF6	RN	Comparative molecular field analysis of hydantoin binding to the neuronal voltage-dependent sodium channel. J Med Chem. 1999 May 6;42(9):1537-45.
DM2GPF6	RU	https://pubmed.ncbi.nlm.nih.gov/10229624

DM5ACNU	DI	DM5ACNU
DM5ACNU	DN	2'-hydroxy-3,4,5-trimethoxychalcone
DM5ACNU	MI	TTVKILB
DM5ACNU	MN	Prostaglandin G/H synthase 2 (COX-2)
DM5ACNU	MT	DTT
DM5ACNU	MA	Inhibitor
DM5ACNU	RN	Inhibitory activity of prostaglandin E2 production by the synthetic 2'-hydroxychalcone analogues: Synthesis and SAR study. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1650-3.
DM5ACNU	RU	https://pubmed.ncbi.nlm.nih.gov/19233646

DMDOHRF	DI	DMDOHRF
DMDOHRF	DN	2-HYDROXY-3,5-DIIODOBENZOIC ACID
DMDOHRF	MI	TTKRD0G
DMDOHRF	MN	Endothelin A receptor (EDNRA)
DMDOHRF	MT	DTT
DMDOHRF	MA	Inhibitor
DMDOHRF	RN	Allosteric inhibition of endothelin ETA receptors by 3, 5-dibromosalicylic acid. Mol Pharmacol. 2000 Dec;58(6):1461-9.
DMDOHRF	RU	https://pubmed.ncbi.nlm.nih.gov/11093786

DMK8WUR	DI	DMK8WUR
DMK8WUR	DN	2-hydroxy-3-isopropyl-2,4,6-cycloheptatrien-1-one
DMK8WUR	MI	TTULVH8
DMK8WUR	MN	Tyrosinase (TYR)
DMK8WUR	MT	DTT
DMK8WUR	MA	Inhibitor
DMK8WUR	RN	Structural insights into the hot spot amino acid residues of mushroom tyrosinase for the bindings of thujaplicins. Bioorg Med Chem. 2010 Nov 15;18(22):8112-8.
DMK8WUR	RU	https://pubmed.ncbi.nlm.nih.gov/20947360

DM5QV19	DI	DM5QV19
DM5QV19	DN	2'-Hydroxy-3-methoxy-biphenyl-4-carbonitrile
DM5QV19	MI	TTKPW01
DM5QV19	MN	Androgen receptor messenger RNA (AR mRNA)
DM5QV19	MT	DTT
DM5QV19	MA	Inhibitor
DM5QV19	RN	Rational design and synthesis of 4-((1R,2R)-2-hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a novel, nonsteroidal androgen recepto... J Med Chem. 2008 Nov 13;51(21):7010-4.
DM5QV19	RU	https://pubmed.ncbi.nlm.nih.gov/18921992

DMSDYZQ	DI	DMSDYZQ
DMSDYZQ	DN	2-hydroxy-5-isopropyl-2,4,6-cycloheptatrien-1-one
DMSDYZQ	MI	TTULVH8
DMSDYZQ	MN	Tyrosinase (TYR)
DMSDYZQ	MT	DTT
DMSDYZQ	MA	Inhibitor
DMSDYZQ	RN	Structural insights into the hot spot amino acid residues of mushroom tyrosinase for the bindings of thujaplicins. Bioorg Med Chem. 2010 Nov 15;18(22):8112-8.
DMSDYZQ	RU	https://pubmed.ncbi.nlm.nih.gov/20947360

DMB3Y8H	DI	DMB3Y8H
DMB3Y8H	DN	2-Hydroxy-6-(3-phenoxy-benzoylamino)-benzoic acid
DMB3Y8H	MI	TTRVTMX
DMB3Y8H	MN	Bacterial Beta-ketoacyl-ACP synthase III (Bact fabH)
DMB3Y8H	MT	DTT
DMB3Y8H	MA	Inhibitor
DMB3Y8H	RN	Structure-based design, synthesis, and study of potent inhibitors of beta-ketoacyl-acyl carrier protein synthase III as potential antimicrobial age... J Med Chem. 2005 Mar 10;48(5):1596-609.
DMB3Y8H	RU	https://pubmed.ncbi.nlm.nih.gov/15743201

DMOT6V7	DI	DMOT6V7
DMOT6V7	DN	2-HYDROXYCARBAMOYL-4-METHYL-PENTANOIC ACID
DMOT6V7	MI	TTGA1IV
DMOT6V7	MN	Matrix metalloproteinase-8 (MMP-8)
DMOT6V7	MT	DTT
DMOT6V7	MA	Inhibitor
DMOT6V7	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMOT6V7	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMA8DZT	DI	DMA8DZT
DMA8DZT	DN	2-Hydroxycarbamoylmethyl-pentanedioic acid
DMA8DZT	MI	TT9G4N0
DMA8DZT	MN	Glutamate carboxypeptidase II (GCPII)
DMA8DZT	MT	DTT
DMA8DZT	MA	Inhibitor
DMA8DZT	RN	Synthesis and biological evaluation of hydroxamate-Based inhibitors of glutamate carboxypeptidase II. Bioorg Med Chem Lett. 2003 Jul 7;13(13):2097-100.
DMA8DZT	RU	https://pubmed.ncbi.nlm.nih.gov/12798312

DM412RI	DI	DM412RI
DM412RI	DN	2-Hydroxycarbamoyl-pentanedioic acid
DM412RI	MI	TT9G4N0
DM412RI	MN	Glutamate carboxypeptidase II (GCPII)
DM412RI	MT	DTT
DM412RI	MA	Inhibitor
DM412RI	RN	Synthesis and biological evaluation of hydroxamate-Based inhibitors of glutamate carboxypeptidase II. Bioorg Med Chem Lett. 2003 Jul 7;13(13):2097-100.
DM412RI	RU	https://pubmed.ncbi.nlm.nih.gov/12798312

DM8RTBS	DI	DM8RTBS
DM8RTBS	DN	2'-Hydroxychalcone
DM8RTBS	MI	TTVKILB
DM8RTBS	MN	Prostaglandin G/H synthase 2 (COX-2)
DM8RTBS	MT	DTT
DM8RTBS	MA	Inhibitor
DM8RTBS	RN	Inhibitory activity of prostaglandin E2 production by the synthetic 2'-hydroxychalcone analogues: Synthesis and SAR study. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1650-3.
DM8RTBS	RU	https://pubmed.ncbi.nlm.nih.gov/19233646

DM86HTZ	DI	DM86HTZ
DM86HTZ	DN	2-Hydroxycinnamic acid
DM86HTZ	MI	TTHQPL7
DM86HTZ	MN	Carbonic anhydrase I (CA-I)
DM86HTZ	MT	DTT
DM86HTZ	MA	Inhibitor
DM86HTZ	RN	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
DM86HTZ	RU	https://pubmed.ncbi.nlm.nih.gov/20674354

DM86HTZ	DI	DM86HTZ
DM86HTZ	DN	2-Hydroxycinnamic acid
DM86HTZ	MI	TTANPDJ
DM86HTZ	MN	Carbonic anhydrase II (CA-II)
DM86HTZ	MT	DTT
DM86HTZ	MA	Inhibitor
DM86HTZ	RN	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
DM86HTZ	RU	https://pubmed.ncbi.nlm.nih.gov/20674354

DMT6APV	DI	DMT6APV
DMT6APV	DN	2-Hydroxyethyl 18-methoxycoronaridinate
DMT6APV	MI	TTTVAFQ
DMT6APV	MN	Neuronal acetylcholine receptor beta-4 (CHRNB4)
DMT6APV	MT	DTT
DMT6APV	MA	Inhibitor
DMT6APV	RN	Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents. J Med Chem. 2003 Jun 19;46(13):2716-30.
DMT6APV	RU	https://pubmed.ncbi.nlm.nih.gov/12801235

DM5E1DC	DI	DM5E1DC
DM5E1DC	DN	2-hydroxygarveatin E
DM5E1DC	MI	TTZJYKH
DM5E1DC	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DM5E1DC	MT	DTT
DM5E1DC	MA	Inhibitor
DM5E1DC	RN	Indoleamine 2,3-dioxygenase inhibitors from the Northeastern Pacific Marine Hydroid Garveia annulata. J Nat Prod. 2006 Oct;69(10):1496-9.
DM5E1DC	RU	https://pubmed.ncbi.nlm.nih.gov/17067170

DMK96BL	DI	DMK96BL
DMK96BL	DN	2-HYDROXYGARVIN A
DMK96BL	MI	TTZJYKH
DMK96BL	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMK96BL	MT	DTT
DMK96BL	MA	Inhibitor
DMK96BL	RN	Indoleamine 2,3-dioxygenase inhibitors from the Northeastern Pacific Marine Hydroid Garveia annulata. J Nat Prod. 2006 Oct;69(10):1496-9.
DMK96BL	RU	https://pubmed.ncbi.nlm.nih.gov/17067170

DMNXV2I	DI	DMNXV2I
DMNXV2I	DN	2-Hydroxyiminoolean-12-en-28-oic acid
DMNXV2I	MI	TTZHY6R
DMNXV2I	MN	Glycogen phosphorylase muscle form (GP)
DMNXV2I	MT	DTT
DMNXV2I	MA	Inhibitor
DMNXV2I	RN	Synthesis of 3-deoxypentacyclic triterpene derivatives as inhibitors of glycogen phosphorylase. J Nat Prod. 2009 Aug;72(8):1414-8.
DMNXV2I	RU	https://pubmed.ncbi.nlm.nih.gov/19642687

DMDKF03	DI	DMDKF03
DMDKF03	DN	2-Hydroxyiminours-12-en-28-oic acid
DMDKF03	MI	TTZHY6R
DMDKF03	MN	Glycogen phosphorylase muscle form (GP)
DMDKF03	MT	DTT
DMDKF03	MA	Inhibitor
DMDKF03	RN	Synthesis of 3-deoxypentacyclic triterpene derivatives as inhibitors of glycogen phosphorylase. J Nat Prod. 2009 Aug;72(8):1414-8.
DMDKF03	RU	https://pubmed.ncbi.nlm.nih.gov/19642687

DMTLYDS	DI	DMTLYDS
DMTLYDS	DN	2-hydroxyisoquinoline-1,3(2H,4H)-dione
DMTLYDS	MI	TT37KAF
DMTLYDS	MN	Human immunodeficiency virus Ribonuclease H (HIV RNH)
DMTLYDS	MT	DTT
DMTLYDS	MA	Inhibitor
DMTLYDS	RN	RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: design, biochemical activity, and structural information. J Med Chem. 2009 Oct 8;52(19):5781-4.
DMTLYDS	RU	https://pubmed.ncbi.nlm.nih.gov/19791799

DMCNW3M	DI	DMCNW3M
DMCNW3M	DN	2-hydroxylauric acid
DMCNW3M	MI	TTG0MQD
DMCNW3M	MN	Inflammation-related GPCR EX33 (GPR84)
DMCNW3M	MT	DTT
DMCNW3M	MA	Agonist
DMCNW3M	RN	Medium-chain fatty acid-sensing receptor, GPR84, is a proinflammatory receptor. J Biol Chem. 2013 Apr 12;288(15):10684-91.
DMCNW3M	RU	https://pubmed.ncbi.nlm.nih.gov/23449982

DM4LMPD	DI	DM4LMPD
DM4LMPD	DN	2-Hydroxymethyl-3-hydroxymorphinan
DM4LMPD	MI	TT27RFC
DM4LMPD	MN	Opioid receptor delta (OPRD1)
DM4LMPD	MT	DTT
DM4LMPD	MA	Inhibitor
DM4LMPD	RN	Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18.
DM4LMPD	RU	https://pubmed.ncbi.nlm.nih.gov/19928862

DM4LMPD	DI	DM4LMPD
DM4LMPD	DN	2-Hydroxymethyl-3-hydroxymorphinan
DM4LMPD	MI	TTQW87Y
DM4LMPD	MN	Opioid receptor kappa (OPRK1)
DM4LMPD	MT	DTT
DM4LMPD	MA	Inhibitor
DM4LMPD	RN	Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18.
DM4LMPD	RU	https://pubmed.ncbi.nlm.nih.gov/19928862

DM4LMPD	DI	DM4LMPD
DM4LMPD	DN	2-Hydroxymethyl-3-hydroxymorphinan
DM4LMPD	MI	TTKWM86
DM4LMPD	MN	Opioid receptor mu (MOP)
DM4LMPD	MT	DTT
DM4LMPD	MA	Inhibitor
DM4LMPD	RN	Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18.
DM4LMPD	RU	https://pubmed.ncbi.nlm.nih.gov/19928862

DM7MUZ1	DI	DM7MUZ1
DM7MUZ1	DN	2-Hydroxymethyl-Pyrrolidine-3,4-Diol
DM7MUZ1	MI	TTMCF1Y
DM7MUZ1	MN	Purine nucleoside phosphorylase (PNP)
DM7MUZ1	MT	DTT
DM7MUZ1	MA	Inhibitor
DM7MUZ1	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DM7MUZ1	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMWSR13	DI	DMWSR13
DMWSR13	DN	2-Hydroxy-N-(3-phenyl-propyl)-benzamide
DMWSR13	MI	TT64EPS
DMWSR13	MN	Fungal Scytalone dehydratase (Fung SDH1)
DMWSR13	MT	DTT
DMWSR13	MA	Inhibitor
DMWSR13	RN	A diazine heterocycle replaces a six-membered hydrogen-bonded array in the active site of scytalone dehydratase, Bioorg. Med. Chem. Lett. 3(8):1605-1608 (1993).
DMWSR13	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00800268

DMQ0F96	DI	DMQ0F96
DMQ0F96	DN	2-Hydroxy-N,6-bis(3-hydroxyphenyl)-1-naphthamide
DMQ0F96	MI	TTIWB6L
DMQ0F96	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMQ0F96	MT	DTT
DMQ0F96	MA	Inhibitor
DMQ0F96	RN	Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design,... J Med Chem. 2008 Aug 14;51(15):4685-98.
DMQ0F96	RU	https://pubmed.ncbi.nlm.nih.gov/18630892

DMMILJS	DI	DMMILJS
DMMILJS	DN	2-hydroxyoctanoic acid
DMMILJS	MI	TT8WFXV
DMMILJS	MN	Hydroxycarboxylic acid receptor 3 (HCAR3)
DMMILJS	MT	DTT
DMMILJS	MA	Agonist
DMMILJS	RN	Deorphanization of GPR109B as a receptor for the beta-oxidation intermediate 3-OH-octanoic acid and its role in the regulation of lipolysis. J Biol Chem. 2009 Aug 14;284(33):21928-33.
DMMILJS	RU	https://pubmed.ncbi.nlm.nih.gov/19561068

DMHK2NQ	DI	DMHK2NQ
DMHK2NQ	DN	2-hydroxyphenethyl 3,4,5-trihydroxybenzoate
DMHK2NQ	MI	TTULVH8
DMHK2NQ	MN	Tyrosinase (TYR)
DMHK2NQ	MT	DTT
DMHK2NQ	MA	Inhibitor
DMHK2NQ	RN	Synthetic tyrosyl gallate derivatives as potent melanin formation inhibitors. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5462-4.
DMHK2NQ	RU	https://pubmed.ncbi.nlm.nih.gov/17693086

DMHO8KQ	DI	DMHO8KQ
DMHO8KQ	DN	2-hydroxy-saclofen
DMHO8KQ	MI	TTDCVZW
DMHO8KQ	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMHO8KQ	MT	DTT
DMHO8KQ	MA	Antagonist
DMHO8KQ	RN	Expression cloning of GABA(B) receptors uncovers similarity to metabotropic glutamate receptors. Nature. 1997 Mar 20;386(6622):239-46.
DMHO8KQ	RU	https://pubmed.ncbi.nlm.nih.gov/9069281

DM261B0	DI	DM261B0
DM261B0	DN	2-Imidazol-1-yl-7-methoxy-3-phenyl-chromen-4-one
DM261B0	MI	TTSZLWK
DM261B0	MN	Aromatase (CYP19A1)
DM261B0	MT	DTT
DM261B0	MA	Inhibitor
DM261B0	RN	Synthesis and characterization of azole isoflavone inhibitors of aromatase. Bioorg Med Chem. 2005 Jun 2;13(12):4063-70.
DM261B0	RU	https://pubmed.ncbi.nlm.nih.gov/15911319

DM2GUDZ	DI	DM2GUDZ
DM2GUDZ	DN	2-Imidazol-1-ylmethylxanthen-9-one
DM2GUDZ	MI	TTSZLWK
DM2GUDZ	MN	Aromatase (CYP19A1)
DM2GUDZ	MT	DTT
DM2GUDZ	MA	Inhibitor
DM2GUDZ	RN	Novel highly potent and selective nonsteroidal aromatase inhibitors: synthesis, biological evaluation and structure-activity relationships investigation. J Med Chem. 2010 Jul 22;53(14):5347-51. 
DM2GUDZ	RU	https://pubmed.ncbi.nlm.nih.gov/20568782

DMSEIUP	DI	DMSEIUP
DMSEIUP	DN	2-iodo-melatonin
DMSEIUP	MI	TT0WAIE
DMSEIUP	MN	Melatonin receptor type 1A (MTNR1A)
DMSEIUP	MT	DTT
DMSEIUP	MA	Agonist
DMSEIUP	RN	Characterization of a retinal melatonin receptor. J Pharmacol Exp Ther. 1985 Aug;234(2):395-401.
DMSEIUP	RU	https://pubmed.ncbi.nlm.nih.gov/2991499

DMSEIUP	DI	DMSEIUP
DMSEIUP	DN	2-iodo-melatonin
DMSEIUP	MI	TT32JK8
DMSEIUP	MN	Melatonin receptor type 1B (MTNR1B)
DMSEIUP	MT	DTT
DMSEIUP	MA	Inhibitor
DMSEIUP	RN	Synthesis of nitroindole derivatives with high affinity and selectivity for melatoninergic binding sites MT(3). J Med Chem. 2002 Apr 25;45(9):1853-9.
DMSEIUP	RU	https://pubmed.ncbi.nlm.nih.gov/11960497

DMSEIUP	DI	DMSEIUP
DMSEIUP	DN	2-iodo-melatonin
DMSEIUP	MI	TTJLP0R
DMSEIUP	MN	Quinone reductase 2 (NQO2)
DMSEIUP	MT	DTT
DMSEIUP	MA	Inhibitor
DMSEIUP	RN	Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities. J Med Chem. 2009 Apr 9;52(7):1873-84.
DMSEIUP	RU	https://pubmed.ncbi.nlm.nih.gov/19265439

DMOVRX7	DI	DMOVRX7
DMOVRX7	DN	2-isooleanolic acid
DMOVRX7	MI	TTZHY6R
DMOVRX7	MN	Glycogen phosphorylase muscle form (GP)
DMOVRX7	MT	DTT
DMOVRX7	MA	Inhibitor
DMOVRX7	RN	Synthesis of 3-deoxypentacyclic triterpene derivatives as inhibitors of glycogen phosphorylase. J Nat Prod. 2009 Aug;72(8):1414-8.
DMOVRX7	RU	https://pubmed.ncbi.nlm.nih.gov/19642687

DMSLMAN	DI	DMSLMAN
DMSLMAN	DN	2-isopropyl-9H-carbazole
DMSLMAN	MI	TTBGTCW
DMSLMAN	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DMSLMAN	MT	DTT
DMSLMAN	MA	Inhibitor
DMSLMAN	RN	Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8.
DMSLMAN	RU	https://pubmed.ncbi.nlm.nih.gov/20521839

DMEZFKS	DI	DMEZFKS
DMEZFKS	DN	2-isoursolic acid
DMEZFKS	MI	TTZHY6R
DMEZFKS	MN	Glycogen phosphorylase muscle form (GP)
DMEZFKS	MT	DTT
DMEZFKS	MA	Inhibitor
DMEZFKS	RN	Synthesis of 3-deoxypentacyclic triterpene derivatives as inhibitors of glycogen phosphorylase. J Nat Prod. 2009 Aug;72(8):1414-8.
DMEZFKS	RU	https://pubmed.ncbi.nlm.nih.gov/19642687

DM1F4TN	DI	DM1F4TN
DM1F4TN	DN	2-Isoxazol-3-yl-3H-imidazo[4,5-c]quinoline
DM1F4TN	MI	TT1MPAY
DM1F4TN	MN	GABA(A) receptor alpha-1 (GABRA1)
DM1F4TN	MT	DTT
DM1F4TN	MA	Inhibitor
DM1F4TN	RN	Synthesis and structure--activity relationships of fused imidazopyridines: a new series of benzodiazepine receptor ligands. J Med Chem. 1996 Jul 5;39(14):2844-51.
DM1F4TN	RU	https://pubmed.ncbi.nlm.nih.gov/8709114

DM1F4TN	DI	DM1F4TN
DM1F4TN	DN	2-Isoxazol-3-yl-3H-imidazo[4,5-c]quinoline
DM1F4TN	MI	TTNJYV2
DM1F4TN	MN	Gamma-aminobutyric acid receptor (GAR)
DM1F4TN	MT	DTT
DM1F4TN	MA	Inhibitor
DM1F4TN	RN	Synthesis and structure--activity relationships of fused imidazopyridines: a new series of benzodiazepine receptor ligands. J Med Chem. 1996 Jul 5;39(14):2844-51.
DM1F4TN	RU	https://pubmed.ncbi.nlm.nih.gov/8709114

DMD2ZNA	DI	DMD2ZNA
DMD2ZNA	DN	2-Isoxazol-5-yl-3H-imidazo[4,5-c]quinoline
DMD2ZNA	MI	TT1MPAY
DMD2ZNA	MN	GABA(A) receptor alpha-1 (GABRA1)
DMD2ZNA	MT	DTT
DMD2ZNA	MA	Inhibitor
DMD2ZNA	RN	Synthesis and structure--activity relationships of fused imidazopyridines: a new series of benzodiazepine receptor ligands. J Med Chem. 1996 Jul 5;39(14):2844-51.
DMD2ZNA	RU	https://pubmed.ncbi.nlm.nih.gov/8709114

DMD2ZNA	DI	DMD2ZNA
DMD2ZNA	DN	2-Isoxazol-5-yl-3H-imidazo[4,5-c]quinoline
DMD2ZNA	MI	TTZA1NY
DMD2ZNA	MN	GABA(A) receptor beta-2 (GABRB2)
DMD2ZNA	MT	DTT
DMD2ZNA	MA	Inhibitor
DMD2ZNA	RN	Synthesis and structure--activity relationships of fused imidazopyridines: a new series of benzodiazepine receptor ligands. J Med Chem. 1996 Jul 5;39(14):2844-51.
DMD2ZNA	RU	https://pubmed.ncbi.nlm.nih.gov/8709114

DMD2ZNA	DI	DMD2ZNA
DMD2ZNA	DN	2-Isoxazol-5-yl-3H-imidazo[4,5-c]quinoline
DMD2ZNA	MI	TT06RH5
DMD2ZNA	MN	GABA(A) receptor gamma-2 (GABRG2)
DMD2ZNA	MT	DTT
DMD2ZNA	MA	Inhibitor
DMD2ZNA	RN	Synthesis and structure--activity relationships of fused imidazopyridines: a new series of benzodiazepine receptor ligands. J Med Chem. 1996 Jul 5;39(14):2844-51.
DMD2ZNA	RU	https://pubmed.ncbi.nlm.nih.gov/8709114

DMD2ZNA	DI	DMD2ZNA
DMD2ZNA	DN	2-Isoxazol-5-yl-3H-imidazo[4,5-c]quinoline
DMD2ZNA	MI	TTNJYV2
DMD2ZNA	MN	Gamma-aminobutyric acid receptor (GAR)
DMD2ZNA	MT	DTT
DMD2ZNA	MA	Inhibitor
DMD2ZNA	RN	Synthesis and structure--activity relationships of fused imidazopyridines: a new series of benzodiazepine receptor ligands. J Med Chem. 1996 Jul 5;39(14):2844-51.
DMD2ZNA	RU	https://pubmed.ncbi.nlm.nih.gov/8709114

DMZD348	DI	DMZD348
DMZD348	DN	2LM20-4
DMZD348	MI	TTUE541
DMZD348	MN	Leukocyte surface antigen Leu-16 (CD20)
DMZD348	MT	DTT
DMZD348	MA	Modulator
DMZD348	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628).
DMZD348	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2628

DMPJT1C	DI	DMPJT1C
DMPJT1C	DN	2MD
DMPJT1C	MI	TTK59TV
DMPJT1C	MN	Vitamin D3 receptor (VDR)
DMPJT1C	MT	DTT
DMPJT1C	MA	Agonist
DMPJT1C	RN	New 1alpha,25-dihydroxy-19-norvitamin D3 compounds of high biological activity: synthesis and biological evaluation of 2-hydroxymethyl, 2-methyl, and 2-methylene analogues. J Med Chem. 1998 Nov 5;41(23):4662-74.
DMPJT1C	RU	https://pubmed.ncbi.nlm.nih.gov/9804706

DMDFPGB	DI	DMDFPGB
DMDFPGB	DN	2'-Me-CCPA
DMDFPGB	MI	TTJFY5U
DMDFPGB	MN	Adenosine A3 receptor (ADORA3)
DMDFPGB	MT	DTT
DMDFPGB	MA	Agonist
DMDFPGB	RN	2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies. J Med Chem. 1998 May 7;41(10):1708-15.
DMDFPGB	RU	https://pubmed.ncbi.nlm.nih.gov/9572897

DMDZTU3	DI	DMDZTU3
DMDZTU3	DN	2-MePen-RYYRIK-NH2
DMDZTU3	MI	TTNT7K8
DMDZTU3	MN	Nociceptin receptor (OPRL1)
DMDZTU3	MT	DTT
DMDZTU3	MA	Inhibitor
DMDZTU3	RN	Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist. Bioorg Med Chem. 2008 Mar 1;16(5):2635-44.
DMDZTU3	RU	https://pubmed.ncbi.nlm.nih.gov/18068993

DMHK25N	DI	DMHK25N
DMHK25N	DN	2-Mercaptomethyl-pentanedioic acid
DMHK25N	MI	TT9G4N0
DMHK25N	MN	Glutamate carboxypeptidase II (GCPII)
DMHK25N	MT	DTT
DMHK25N	MA	Inhibitor
DMHK25N	RN	Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. J Med Chem. 2003 May 8;46(10):1989-96.
DMHK25N	RU	https://pubmed.ncbi.nlm.nih.gov/12723961

DMXEUDM	DI	DMXEUDM
DMXEUDM	DN	2-Mercapto-N-(4-sulfamoyl-phenyl)-benzamide
DMXEUDM	MI	TTHQPL7
DMXEUDM	MN	Carbonic anhydrase I (CA-I)
DMXEUDM	MT	DTT
DMXEUDM	MA	Inhibitor
DMXEUDM	RN	Recent developments of carbonic anhydrase inhibitors as potential anticancer drugs. J Med Chem. 2008 Jun 12;51(11):3051-6.
DMXEUDM	RU	https://pubmed.ncbi.nlm.nih.gov/18348513

DMXEUDM	DI	DMXEUDM
DMXEUDM	DN	2-Mercapto-N-(4-sulfamoyl-phenyl)-benzamide
DMXEUDM	MI	TTANPDJ
DMXEUDM	MN	Carbonic anhydrase II (CA-II)
DMXEUDM	MT	DTT
DMXEUDM	MA	Inhibitor
DMXEUDM	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMXEUDM	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMXEUDM	DI	DMXEUDM
DMXEUDM	DN	2-Mercapto-N-(4-sulfamoyl-phenyl)-benzamide
DMXEUDM	MI	TT2LVK8
DMXEUDM	MN	Carbonic anhydrase IX (CA-IX)
DMXEUDM	MT	DTT
DMXEUDM	MA	Inhibitor
DMXEUDM	RN	Recent developments of carbonic anhydrase inhibitors as potential anticancer drugs. J Med Chem. 2008 Jun 12;51(11):3051-6.
DMXEUDM	RU	https://pubmed.ncbi.nlm.nih.gov/18348513

DMRVBCI	DI	DMRVBCI
DMRVBCI	DN	2-Mercapto-pentanedioic acid
DMRVBCI	MI	TT9G4N0
DMRVBCI	MN	Glutamate carboxypeptidase II (GCPII)
DMRVBCI	MT	DTT
DMRVBCI	MA	Inhibitor
DMRVBCI	RN	Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. J Med Chem. 2003 May 8;46(10):1989-96.
DMRVBCI	RU	https://pubmed.ncbi.nlm.nih.gov/12723961

DM8HSBT	DI	DM8HSBT
DM8HSBT	DN	2-mercaptophenylphosphonic acid
DM8HSBT	MI	TTHI19T
DM8HSBT	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DM8HSBT	MT	DTT
DM8HSBT	MA	Inhibitor
DM8HSBT	RN	Mercaptophosphonate compounds as broad-spectrum inhibitors of the metallo-beta-lactamases. J Med Chem. 2010 Jul 8;53(13):4862-76.
DM8HSBT	RU	https://pubmed.ncbi.nlm.nih.gov/20527888

DMGADQ1	DI	DMGADQ1
DMGADQ1	DN	2MeSADP
DMGADQ1	MI	TTA93TL
DMGADQ1	MN	P2Y purinoceptor 1 (P2RY1)
DMGADQ1	MT	DTT
DMGADQ1	MA	Agonist
DMGADQ1	RN	Molecular cloning of the platelet P2T(AC) ADP receptor: pharmacological comparison with another ADP receptor, the P2Y(1) receptor. Mol Pharmacol. 2001 Sep;60(3):432-9.
DMGADQ1	RU	https://pubmed.ncbi.nlm.nih.gov/11502873

DMGADQ1	DI	DMGADQ1
DMGADQ1	DN	2MeSADP
DMGADQ1	MI	TTZ1DT0
DMGADQ1	MN	P2Y purinoceptor 12 (P2RY12)
DMGADQ1	MT	DTT
DMGADQ1	MA	Agonist
DMGADQ1	RN	Molecular cloning of the platelet P2T(AC) ADP receptor: pharmacological comparison with another ADP receptor, the P2Y(1) receptor. Mol Pharmacol. 2001 Sep;60(3):432-9.
DMGADQ1	RU	https://pubmed.ncbi.nlm.nih.gov/11502873

DMGADQ1	DI	DMGADQ1
DMGADQ1	DN	2MeSADP
DMGADQ1	MI	TT1FE3L
DMGADQ1	MN	P2Y purinoceptor 13 (P2RY13)
DMGADQ1	MT	DTT
DMGADQ1	MA	Agonist
DMGADQ1	RN	Pharmacological characterization of the human P2Y13 receptor. Mol Pharmacol. 2003 Jul;64(1):104-12.
DMGADQ1	RU	https://pubmed.ncbi.nlm.nih.gov/12815166

DMBO2DC	DI	DMBO2DC
DMBO2DC	DN	2MeSAMP
DMBO2DC	MI	TTZ1DT0
DMBO2DC	MN	P2Y purinoceptor 12 (P2RY12)
DMBO2DC	MT	DTT
DMBO2DC	MA	Antagonist
DMBO2DC	RN	Molecular cloning of the platelet P2T(AC) ADP receptor: pharmacological comparison with another ADP receptor, the P2Y(1) receptor. Mol Pharmacol. 2001 Sep;60(3):432-9.
DMBO2DC	RU	https://pubmed.ncbi.nlm.nih.gov/11502873

DMBO2DC	DI	DMBO2DC
DMBO2DC	DN	2MeSAMP
DMBO2DC	MI	TT1FE3L
DMBO2DC	MN	P2Y purinoceptor 13 (P2RY13)
DMBO2DC	MT	DTT
DMBO2DC	MA	Antagonist
DMBO2DC	RN	Pharmacological characterization of the human P2Y13 receptor. Mol Pharmacol. 2003 Jul;64(1):104-12.
DMBO2DC	RU	https://pubmed.ncbi.nlm.nih.gov/12815166

DMUE0W6	DI	DMUE0W6
DMUE0W6	DN	2MeSATP
DMUE0W6	MI	TTA93TL
DMUE0W6	MN	P2Y purinoceptor 1 (P2RY1)
DMUE0W6	MT	DTT
DMUE0W6	MA	Agonist
DMUE0W6	RN	Quantitation of the P2Y(1) receptor with a high affinity radiolabeled antagonist. Mol Pharmacol. 2002 Nov;62(5):1249-57.
DMUE0W6	RU	https://pubmed.ncbi.nlm.nih.gov/12391289

DMUE0W6	DI	DMUE0W6
DMUE0W6	DN	2MeSATP
DMUE0W6	MI	TTYXPCO
DMUE0W6	MN	P2Y purinoceptor 11 (P2RY11)
DMUE0W6	MT	DTT
DMUE0W6	MA	Agonist
DMUE0W6	RN	Pharmacological characterization of the human P2Y11 receptor. Br J Pharmacol. 1999 Nov;128(6):1199-206.
DMUE0W6	RU	https://pubmed.ncbi.nlm.nih.gov/10578132

DMUE0W6	DI	DMUE0W6
DMUE0W6	DN	2MeSATP
DMUE0W6	MI	TT1FE3L
DMUE0W6	MN	P2Y purinoceptor 13 (P2RY13)
DMUE0W6	MT	DTT
DMUE0W6	MA	Agonist
DMUE0W6	RN	Pharmacological characterization of the human P2Y13 receptor. Mol Pharmacol. 2003 Jul;64(1):104-12.
DMUE0W6	RU	https://pubmed.ncbi.nlm.nih.gov/12815166

DMUE0W6	DI	DMUE0W6
DMUE0W6	DN	2MeSATP
DMUE0W6	MI	TTNVSKA
DMUE0W6	MN	P2Y purinoceptor 6 (P2RY6)
DMUE0W6	MT	DTT
DMUE0W6	MA	Agonist
DMUE0W6	RN	Cloning, functional expression and tissue distribution of the human P2Y6 receptor. Biochem Biophys Res Commun. 1996 May 15;222(2):303-8.
DMUE0W6	RU	https://pubmed.ncbi.nlm.nih.gov/8670200

DMY2GXT	DI	DMY2GXT
DMY2GXT	DN	2'-Me-tecadenoson
DMY2GXT	MI	TTK25J1
DMY2GXT	MN	Adenosine A1 receptor (ADORA1)
DMY2GXT	MT	DTT
DMY2GXT	MA	Inhibitor
DMY2GXT	RN	5'-Carbamoyl derivatives of 2'-C-methyl-purine nucleosides as selective A1 adenosine receptor agonists: affinity, efficacy, and selectivity for A1 ... Bioorg Med Chem. 2008 Jan 1;16(1):336-53.
DMY2GXT	RU	https://pubmed.ncbi.nlm.nih.gov/17933541

DMY2GXT	DI	DMY2GXT
DMY2GXT	DN	2'-Me-tecadenoson
DMY2GXT	MI	TTNE7KG
DMY2GXT	MN	Adenosine A2b receptor (ADORA2B)
DMY2GXT	MT	DTT
DMY2GXT	MA	Inhibitor
DMY2GXT	RN	5'-Carbamoyl derivatives of 2'-C-methyl-purine nucleosides as selective A1 adenosine receptor agonists: affinity, efficacy, and selectivity for A1 ... Bioorg Med Chem. 2008 Jan 1;16(1):336-53.
DMY2GXT	RU	https://pubmed.ncbi.nlm.nih.gov/17933541

DMA5Q4T	DI	DMA5Q4T
DMA5Q4T	DN	2-methoxy-1,4-naphthoquinone
DMA5Q4T	MI	TTZJYKH
DMA5Q4T	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMA5Q4T	MT	DTT
DMA5Q4T	MA	Inhibitor
DMA5Q4T	RN	Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem. 2008 Mar 27;51(6):1706-18.
DMA5Q4T	RU	https://pubmed.ncbi.nlm.nih.gov/18318466

DMH76C5	DI	DMH76C5
DMH76C5	DN	2-methoxy-1-naphthaldehyde thiosemicarbazone
DMH76C5	MI	TTEAID7
DMH76C5	MN	Trypanosoma Cruzipain (Trypano CYSP)
DMH76C5	MT	DTT
DMH76C5	MA	Inhibitor
DMH76C5	RN	Synthesis and structure-activity relationship study of potent trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine protease cruz... J Med Chem. 2002 Jun 20;45(13):2695-707.
DMH76C5	RU	https://pubmed.ncbi.nlm.nih.gov/12061873

DM93DYT	DI	DM93DYT
DM93DYT	DN	2-methoxy-3,4-methylenedioxybenzophenone
DM93DYT	MI	TTMF541
DM93DYT	MN	Liver carboxylesterase (CES1)
DM93DYT	MT	DTT
DM93DYT	MA	Inhibitor
DM93DYT	RN	Phenolic compounds from the roots of Lindera fruticosa. J Nat Prod. 2006 May;69(5):853-5.
DM93DYT	RU	https://pubmed.ncbi.nlm.nih.gov/16724860

DMF8E5L	DI	DMF8E5L
DMF8E5L	DN	2-methoxy-4-(2-methoxyphenylthio)benzonitrile
DMF8E5L	MI	TTKPW01
DMF8E5L	MN	Androgen receptor messenger RNA (AR mRNA)
DMF8E5L	MT	DTT
DMF8E5L	MA	Inhibitor
DMF8E5L	RN	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
DMF8E5L	RU	https://pubmed.ncbi.nlm.nih.gov/19201190

DMEAVD2	DI	DMEAVD2
DMEAVD2	DN	2-methoxy-4-(2-nitrovinyl)phenol
DMEAVD2	MI	TTGKNB4
DMEAVD2	MN	Epidermal growth factor receptor (EGFR)
DMEAVD2	MT	DTT
DMEAVD2	MA	Inhibitor
DMEAVD2	RN	Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J Nat Prod. 1992 Nov;55(11):1529-60.
DMEAVD2	RU	https://pubmed.ncbi.nlm.nih.gov/1479375

DM1MGQ6	DI	DM1MGQ6
DM1MGQ6	DN	2-methoxy-4-(m-tolyloxy)benzonitrile
DM1MGQ6	MI	TTKPW01
DM1MGQ6	MN	Androgen receptor messenger RNA (AR mRNA)
DM1MGQ6	MT	DTT
DM1MGQ6	MA	Inhibitor
DM1MGQ6	RN	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
DM1MGQ6	RU	https://pubmed.ncbi.nlm.nih.gov/19201190

DMT7YR3	DI	DMT7YR3
DMT7YR3	DN	2-methoxy-4-(o-tolyloxy)benzonitrile
DMT7YR3	MI	TTKPW01
DMT7YR3	MN	Androgen receptor messenger RNA (AR mRNA)
DMT7YR3	MT	DTT
DMT7YR3	MA	Inhibitor
DMT7YR3	RN	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
DMT7YR3	RU	https://pubmed.ncbi.nlm.nih.gov/19201190

DMXGP2I	DI	DMXGP2I
DMXGP2I	DN	2-methoxy-4-(propylthio)benzonitrile
DMXGP2I	MI	TTKPW01
DMXGP2I	MN	Androgen receptor messenger RNA (AR mRNA)
DMXGP2I	MT	DTT
DMXGP2I	MA	Inhibitor
DMXGP2I	RN	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
DMXGP2I	RU	https://pubmed.ncbi.nlm.nih.gov/19201190

DMR5YZG	DI	DMR5YZG
DMR5YZG	DN	2-methoxy-4-(p-tolyloxy)benzonitrile
DMR5YZG	MI	TTKPW01
DMR5YZG	MN	Androgen receptor messenger RNA (AR mRNA)
DMR5YZG	MT	DTT
DMR5YZG	MA	Inhibitor
DMR5YZG	RN	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
DMR5YZG	RU	https://pubmed.ncbi.nlm.nih.gov/19201190

DMCGID6	DI	DMCGID6
DMCGID6	DN	2-Methoxy-5-(3,4,5-trimethoxy-benzyl)-phenol
DMCGID6	MI	TTML2WA
DMCGID6	MN	Tubulin (TUB)
DMCGID6	MT	DTT
DMCGID6	MA	Inhibitor
DMCGID6	RN	Synthesis of alkoxy-substituted diaryl compounds and correlation of ring separation with inhibition of tubulin polymerization: differential enhance... J Med Chem. 1992 Mar 20;35(6):1058-67.
DMCGID6	RU	https://pubmed.ncbi.nlm.nih.gov/1552500

DMCGID6	DI	DMCGID6
DMCGID6	DN	2-Methoxy-5-(3,4,5-trimethoxy-benzyl)-phenol
DMCGID6	MI	TTYFKSZ
DMCGID6	MN	Tubulin beta (TUBB)
DMCGID6	MT	DTT
DMCGID6	MA	Inhibitor
DMCGID6	RN	Synthesis of alkoxy-substituted diaryl compounds and correlation of ring separation with inhibition of tubulin polymerization: differential enhance... J Med Chem. 1992 Mar 20;35(6):1058-67.
DMCGID6	RU	https://pubmed.ncbi.nlm.nih.gov/1552500

DM6CAYV	DI	DM6CAYV
DM6CAYV	DN	2-Methoxy-5-(3,4,5-trimethoxy-phenoxy)-phenol
DM6CAYV	MI	TTML2WA
DM6CAYV	MN	Tubulin (TUB)
DM6CAYV	MT	DTT
DM6CAYV	MA	Inhibitor
DM6CAYV	RN	Antimitotic and cell growth inhibitory properties of combretastatin A-4-like ethers. Bioorg Med Chem Lett. 2001 Jan 8;11(1):51-4.
DM6CAYV	RU	https://pubmed.ncbi.nlm.nih.gov/11140732

DM6CAYV	DI	DM6CAYV
DM6CAYV	DN	2-Methoxy-5-(3,4,5-trimethoxy-phenoxy)-phenol
DM6CAYV	MI	TTYFKSZ
DM6CAYV	MN	Tubulin beta (TUBB)
DM6CAYV	MT	DTT
DM6CAYV	MA	Inhibitor
DM6CAYV	RN	Antimitotic and cell growth inhibitory properties of combretastatin A-4-like ethers. Bioorg Med Chem Lett. 2001 Jan 8;11(1):51-4.
DM6CAYV	RU	https://pubmed.ncbi.nlm.nih.gov/11140732

DM9LY0Z	DI	DM9LY0Z
DM9LY0Z	DN	2-Methoxy-5-(5,6,7-trimethoxy-indan-1-yl)-phenol
DM9LY0Z	MI	TTML2WA
DM9LY0Z	MN	Tubulin (TUB)
DM9LY0Z	MT	DTT
DM9LY0Z	MA	Inhibitor
DM9LY0Z	RN	The synthesis and evaluation of temperature sensitive tubulin toxins. Bioorg Med Chem Lett. 1999 Feb 8;9(3):407-12.
DM9LY0Z	RU	https://pubmed.ncbi.nlm.nih.gov/10091693

DM9LY0Z	DI	DM9LY0Z
DM9LY0Z	DN	2-Methoxy-5-(5,6,7-trimethoxy-indan-1-yl)-phenol
DM9LY0Z	MI	TTYFKSZ
DM9LY0Z	MN	Tubulin beta (TUBB)
DM9LY0Z	MT	DTT
DM9LY0Z	MA	Inhibitor
DM9LY0Z	RN	The synthesis and evaluation of temperature sensitive tubulin toxins. Bioorg Med Chem Lett. 1999 Feb 8;9(3):407-12.
DM9LY0Z	RU	https://pubmed.ncbi.nlm.nih.gov/10091693

DMXCAKO	DI	DMXCAKO
DMXCAKO	DN	2-methoxy-9-aminomethyl-9,10-dihydroanthracene
DMXCAKO	MI	TTJQOD7
DMXCAKO	MN	5-HT 2A receptor (HTR2A)
DMXCAKO	MT	DTT
DMXCAKO	MA	Inhibitor
DMXCAKO	RN	Methoxy-substituted 9-aminomethyl-9,10-dihydroanthracene (AMDA) derivatives exhibit differential binding affinities at the 5-HT(2A) receptor. Bioorg Med Chem Lett. 2008 Oct 1;18(19):5268-71.
DMXCAKO	RU	https://pubmed.ncbi.nlm.nih.gov/18774714

DM4G3FS	DI	DM4G3FS
DM4G3FS	DN	2-methoxy-alpha,beta-didehydro-agomelatine
DM4G3FS	MI	TT0WAIE
DM4G3FS	MN	Melatonin receptor type 1A (MTNR1A)
DM4G3FS	MT	DTT
DM4G3FS	MA	Agonist
DM4G3FS	RN	Synthesis of new N-(arylcyclopropyl)acetamides and N-(arylvinyl)acetamides as conformationally-restricted ligands for melatonin receptors. Bioorg Med Chem Lett. 2013 Jan 15;23(2):430-4.
DM4G3FS	RU	https://pubmed.ncbi.nlm.nih.gov/23265885

DMPG0V7	DI	DMPG0V7
DMPG0V7	DN	2-methoxyapomorphine
DMPG0V7	MI	TTZFYLI
DMPG0V7	MN	Dopamine D1 receptor (D1R)
DMPG0V7	MT	DTT
DMPG0V7	MA	Inhibitor
DMPG0V7	RN	Synthesis and neuropharmacological characterization of 2-O-substituted apomorphines. Bioorg Med Chem. 2008 Apr 15;16(8):4563-8.
DMPG0V7	RU	https://pubmed.ncbi.nlm.nih.gov/18313931

DMPG0V7	DI	DMPG0V7
DMPG0V7	DN	2-methoxyapomorphine
DMPG0V7	MI	TTEX248
DMPG0V7	MN	Dopamine D2 receptor (D2R)
DMPG0V7	MT	DTT
DMPG0V7	MA	Inhibitor
DMPG0V7	RN	Synthesis and neuropharmacological characterization of 2-O-substituted apomorphines. Bioorg Med Chem. 2008 Apr 15;16(8):4563-8.
DMPG0V7	RU	https://pubmed.ncbi.nlm.nih.gov/18313931

DMIBKNZ	DI	DMIBKNZ
DMIBKNZ	DN	2-methoxyestradiol-17-O-sulfamate
DMIBKNZ	MI	TTANPDJ
DMIBKNZ	MN	Carbonic anhydrase II (CA-II)
DMIBKNZ	MT	DTT
DMIBKNZ	MA	Inhibitor
DMIBKNZ	RN	Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents. J Med Chem. 2008 Mar 13;51(5):1295-308.
DMIBKNZ	RU	https://pubmed.ncbi.nlm.nih.gov/18260615

DMD6L7C	DI	DMD6L7C
DMD6L7C	DN	2-methoxyestrrone-3-O-sulfamate
DMD6L7C	MI	TTANPDJ
DMD6L7C	MN	Carbonic anhydrase II (CA-II)
DMD6L7C	MT	DTT
DMD6L7C	MA	Inhibitor
DMD6L7C	RN	Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents. J Med Chem. 2008 Mar 13;51(5):1295-308.
DMD6L7C	RU	https://pubmed.ncbi.nlm.nih.gov/18260615

DM6X8GN	DI	DM6X8GN
DM6X8GN	DN	2-Methoxyethyl 18-methoxycoronaridinate
DM6X8GN	MI	TTTVAFQ
DM6X8GN	MN	Neuronal acetylcholine receptor beta-4 (CHRNB4)
DM6X8GN	MT	DTT
DM6X8GN	MA	Inhibitor
DM6X8GN	RN	Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents. J Med Chem. 2003 Jun 19;46(13):2716-30.
DM6X8GN	RU	https://pubmed.ncbi.nlm.nih.gov/12801235

DM31E6J	DI	DM31E6J
DM31E6J	DN	2-Methoxy-N-(3-methyl-2-phenyl-butyl)-benzamide
DM31E6J	MI	TTY3UE6
DM31E6J	MN	Voltage-gated potassium channel Kv1.3 (KCNA3)
DM31E6J	MT	DTT
DM31E6J	MA	Inhibitor
DM31E6J	RN	Benzamide derivatives as blockers of Kv1.3 ion channel. Bioorg Med Chem Lett. 2003 Mar 24;13(6):1161-4.
DM31E6J	RU	https://pubmed.ncbi.nlm.nih.gov/12643934

DMQS8VE	DI	DMQS8VE
DMQS8VE	DN	2-methoxyphenyl 10H-phenothiazine-10-carboxylate
DMQS8VE	MI	TTEB0GD
DMQS8VE	MN	Cholinesterase (BCHE)
DMQS8VE	MT	DTT
DMQS8VE	MA	Inhibitor
DMQS8VE	RN	Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. J Med Chem. 2008 Jul 24;51(14):4200-12.
DMQS8VE	RU	https://pubmed.ncbi.nlm.nih.gov/18570368

DML5PE9	DI	DML5PE9
DML5PE9	DN	2-methoxyphenylboronic acid
DML5PE9	MI	TTDP1UC
DML5PE9	MN	Fatty acid amide hydrolase (FAAH)
DML5PE9	MT	DTT
DML5PE9	MA	Inhibitor
DML5PE9	RN	Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Nov 27;51(22):7057-60.
DML5PE9	RU	https://pubmed.ncbi.nlm.nih.gov/18983140

DMX1IC4	DI	DMX1IC4
DMX1IC4	DN	2-Methyl-[1,4]thiazepan-(5E)-ylideneamine
DMX1IC4	MI	TTZUFI5
DMX1IC4	MN	Nitric-oxide synthase brain (NOS1)
DMX1IC4	MT	DTT
DMX1IC4	MA	Inhibitor
DMX1IC4	RN	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
DMX1IC4	RU	https://pubmed.ncbi.nlm.nih.gov/15501067

DMX1IC4	DI	DMX1IC4
DMX1IC4	DN	2-Methyl-[1,4]thiazepan-(5E)-ylideneamine
DMX1IC4	MI	TTCM4B3
DMX1IC4	MN	Nitric-oxide synthase endothelial (NOS3)
DMX1IC4	MT	DTT
DMX1IC4	MA	Inhibitor
DMX1IC4	RN	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
DMX1IC4	RU	https://pubmed.ncbi.nlm.nih.gov/15501067

DMX1IC4	DI	DMX1IC4
DMX1IC4	DN	2-Methyl-[1,4]thiazepan-(5E)-ylideneamine
DMX1IC4	MI	TTF10I9
DMX1IC4	MN	Nitric-oxide synthase inducible (NOS2)
DMX1IC4	MT	DTT
DMX1IC4	MA	Inhibitor
DMX1IC4	RN	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
DMX1IC4	RU	https://pubmed.ncbi.nlm.nih.gov/15501067

DMKTQB2	DI	DMKTQB2
DMKTQB2	DN	2-Methyl-1(3)H-anthrasimidazole-6,11-dione
DMKTQB2	MI	TTQY2EJ
DMKTQB2	MN	TERT messenger RNA (TERT mRNA)
DMKTQB2	MT	DTT
DMKTQB2	MA	Inhibitor
DMKTQB2	RN	Synthesis, cytotoxicity and human telomerase inhibition activities of a series of 1,2-heteroannelated anthraquinones and anthra[1,2-d]imidazole-6,1... Bioorg Med Chem. 2009 Nov 1;17(21):7418-28.
DMKTQB2	RU	https://pubmed.ncbi.nlm.nih.gov/19804981

DMRWOQH	DI	DMRWOQH
DMRWOQH	DN	2-methyl-1-(pyridin-3-yl)pent-1-en-3-one oxime
DMRWOQH	MI	TTELV3W
DMRWOQH	MN	Transformation-sensitive protein p120 (TRPA1)
DMRWOQH	MT	DTT
DMRWOQH	MA	Inhibitor
DMRWOQH	RN	Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents. J Med Chem. 2010 Jul 22;53(14):5085-107. 
DMRWOQH	RU	https://pubmed.ncbi.nlm.nih.gov/20356305

DMTQ4FV	DI	DMTQ4FV
DMTQ4FV	DN	2-methyl-1-(pyridin-4-yl)pent-1-en-3-one oxime
DMTQ4FV	MI	TTELV3W
DMTQ4FV	MN	Transformation-sensitive protein p120 (TRPA1)
DMTQ4FV	MT	DTT
DMTQ4FV	MA	Inhibitor
DMTQ4FV	RN	Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents. J Med Chem. 2010 Jul 22;53(14):5085-107. 
DMTQ4FV	RU	https://pubmed.ncbi.nlm.nih.gov/20356305

DMLTJDR	DI	DMLTJDR
DMLTJDR	DN	2-methyl-1-(thiophen-2-yl)pent-1-en-3-one oxime
DMLTJDR	MI	TTELV3W
DMLTJDR	MN	Transformation-sensitive protein p120 (TRPA1)
DMLTJDR	MT	DTT
DMLTJDR	MA	Inhibitor
DMLTJDR	RN	Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents. J Med Chem. 2010 Jul 22;53(14):5085-107. 
DMLTJDR	RU	https://pubmed.ncbi.nlm.nih.gov/20356305

DMQJKSV	DI	DMQJKSV
DMQJKSV	DN	2-methyl-1-(thiophen-3-yl)pent-1-en-3-one oxime
DMQJKSV	MI	TTELV3W
DMQJKSV	MN	Transformation-sensitive protein p120 (TRPA1)
DMQJKSV	MT	DTT
DMQJKSV	MA	Inhibitor
DMQJKSV	RN	Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents. J Med Chem. 2010 Jul 22;53(14):5085-107. 
DMQJKSV	RU	https://pubmed.ncbi.nlm.nih.gov/20356305

DMDJHFQ	DI	DMDJHFQ
DMDJHFQ	DN	2-Methyl-1,2-dihydro-indazol-3-one
DMDJHFQ	MI	TT2J34L
DMDJHFQ	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMDJHFQ	MT	DTT
DMDJHFQ	MA	Inhibitor
DMDJHFQ	RN	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
DMDJHFQ	RU	https://pubmed.ncbi.nlm.nih.gov/1848292

DMDJHFQ	DI	DMDJHFQ
DMDJHFQ	DN	2-Methyl-1,2-dihydro-indazol-3-one
DMDJHFQ	MI	TT8NGED
DMDJHFQ	MN	Prostaglandin G/H synthase 1 (COX-1)
DMDJHFQ	MT	DTT
DMDJHFQ	MA	Inhibitor
DMDJHFQ	RN	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
DMDJHFQ	RU	https://pubmed.ncbi.nlm.nih.gov/1848292

DMDJHFQ	DI	DMDJHFQ
DMDJHFQ	DN	2-Methyl-1,2-dihydro-indazol-3-one
DMDJHFQ	MI	TTVKILB
DMDJHFQ	MN	Prostaglandin G/H synthase 2 (COX-2)
DMDJHFQ	MT	DTT
DMDJHFQ	MA	Inhibitor
DMDJHFQ	RN	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
DMDJHFQ	RU	https://pubmed.ncbi.nlm.nih.gov/1848292

DMIWX21	DI	DMIWX21
DMIWX21	DN	2-Methyl-1,2-di-pyridin-3-yl-1-methoxypropane
DMIWX21	MI	TTIQUX7
DMIWX21	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMIWX21	MT	DTT
DMIWX21	MA	Inhibitor
DMIWX21	RN	Structure-activity relationship study of the inhibition of adrenal cortical 11 beta-hydroxylase by new metyrapone analogues. J Med Chem. 1984 Jan;27(1):15-9.
DMIWX21	RU	https://pubmed.ncbi.nlm.nih.gov/6606707

DMB0NEL	DI	DMB0NEL
DMB0NEL	DN	2-Methyl-1,2-di-pyridin-3-yl-propan-1-one oxime
DMB0NEL	MI	TTIQUX7
DMB0NEL	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMB0NEL	MT	DTT
DMB0NEL	MA	Inhibitor
DMB0NEL	RN	Structure-activity relationship study of the inhibition of adrenal cortical 11 beta-hydroxylase by new metyrapone analogues. J Med Chem. 1984 Jan;27(1):15-9.
DMB0NEL	RU	https://pubmed.ncbi.nlm.nih.gov/6606707

DMC3ET2	DI	DMC3ET2
DMC3ET2	DN	2-Methyl-1,2-di-pyridin-3-yl-propane
DMC3ET2	MI	TTIQUX7
DMC3ET2	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMC3ET2	MT	DTT
DMC3ET2	MA	Inhibitor
DMC3ET2	RN	Structure-activity relationship study of the inhibition of adrenal cortical 11 beta-hydroxylase by new metyrapone analogues. J Med Chem. 1984 Jan;27(1):15-9.
DMC3ET2	RU	https://pubmed.ncbi.nlm.nih.gov/6606707

DMQHM7R	DI	DMQHM7R
DMQHM7R	DN	2-Methyl-1,2-di-pyridin-3-yl-propylchloride
DMQHM7R	MI	TTIQUX7
DMQHM7R	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMQHM7R	MT	DTT
DMQHM7R	MA	Inhibitor
DMQHM7R	RN	Structure-activity relationship study of the inhibition of adrenal cortical 11 beta-hydroxylase by new metyrapone analogues. J Med Chem. 1984 Jan;27(1):15-9.
DMQHM7R	RU	https://pubmed.ncbi.nlm.nih.gov/6606707

DM561MH	DI	DM561MH
DM561MH	DN	2-Methyl-1,2-di-pyridin-3-yl-propyliodide
DM561MH	MI	TTIQUX7
DM561MH	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM561MH	MT	DTT
DM561MH	MA	Inhibitor
DM561MH	RN	Structure-activity relationship study of the inhibition of adrenal cortical 11 beta-hydroxylase by new metyrapone analogues. J Med Chem. 1984 Jan;27(1):15-9.
DM561MH	RU	https://pubmed.ncbi.nlm.nih.gov/6606707

DMLX9RG	DI	DMLX9RG
DMLX9RG	DN	2-Methyl-1-phenyl-2-pyridin-3-yl-propan-1-ol
DMLX9RG	MI	TTIQUX7
DMLX9RG	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMLX9RG	MT	DTT
DMLX9RG	MA	Inhibitor
DMLX9RG	RN	Structure-activity relationship study of the inhibition of adrenal cortical 11 beta-hydroxylase by new metyrapone analogues. J Med Chem. 1984 Jan;27(1):15-9.
DMLX9RG	RU	https://pubmed.ncbi.nlm.nih.gov/6606707

DMZY72I	DI	DMZY72I
DMZY72I	DN	2-Methyl-1-phenyl-2-pyridin-3-yl-propan-1-one
DMZY72I	MI	TTIQUX7
DMZY72I	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMZY72I	MT	DTT
DMZY72I	MA	Inhibitor
DMZY72I	RN	Structure-activity relationship study of the inhibition of adrenal cortical 11 beta-hydroxylase by new metyrapone analogues. J Med Chem. 1984 Jan;27(1):15-9.
DMZY72I	RU	https://pubmed.ncbi.nlm.nih.gov/6606707

DMD45CU	DI	DMD45CU
DMD45CU	DN	2-Methyl-2,4-Pentanediol
DMD45CU	MI	TTC67I0
DMD45CU	MN	Bacterial Glucosamine-6-phosphate synthase (Bact glmS)
DMD45CU	MT	DTT
DMD45CU	MA	Inhibitor
DMD45CU	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD45CU	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD45CU	DI	DMD45CU
DMD45CU	DN	2-Methyl-2,4-Pentanediol
DMD45CU	MI	TTV3NH6
DMD45CU	MN	Calmodulin (CALM)
DMD45CU	MT	DTT
DMD45CU	MA	Inhibitor
DMD45CU	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD45CU	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD45CU	DI	DMD45CU
DMD45CU	DN	2-Methyl-2,4-Pentanediol
DMD45CU	MI	TTN12BZ
DMD45CU	MN	CTP synthase (CTPS1)
DMD45CU	MT	DTT
DMD45CU	MA	Inhibitor
DMD45CU	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD45CU	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD45CU	DI	DMD45CU
DMD45CU	DN	2-Methyl-2,4-Pentanediol
DMD45CU	MI	TT5ZWB6
DMD45CU	MN	Dihydrodiol dehydrogenase type I (AKR1C3)
DMD45CU	MT	DTT
DMD45CU	MA	Inhibitor
DMD45CU	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD45CU	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD45CU	DI	DMD45CU
DMD45CU	DN	2-Methyl-2,4-Pentanediol
DMD45CU	MI	TT78R5H
DMD45CU	MN	Heat shock protein 90 alpha (HSP90A)
DMD45CU	MT	DTT
DMD45CU	MA	Inhibitor
DMD45CU	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD45CU	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD45CU	DI	DMD45CU
DMD45CU	DN	2-Methyl-2,4-Pentanediol
DMD45CU	MI	TTCM4B3
DMD45CU	MN	Nitric-oxide synthase endothelial (NOS3)
DMD45CU	MT	DTT
DMD45CU	MA	Inhibitor
DMD45CU	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD45CU	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD45CU	DI	DMD45CU
DMD45CU	DN	2-Methyl-2,4-Pentanediol
DMD45CU	MI	TT9V5JH
DMD45CU	MN	Phospholipase A2 (PLA2G1B)
DMD45CU	MT	DTT
DMD45CU	MA	Inhibitor
DMD45CU	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD45CU	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD45CU	DI	DMD45CU
DMD45CU	DN	2-Methyl-2,4-Pentanediol
DMD45CU	MI	TT4YO0Z
DMD45CU	MN	Phosphopantetheine adenylyltransferase (PPAT)
DMD45CU	MT	DTT
DMD45CU	MA	Inhibitor
DMD45CU	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD45CU	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD45CU	DI	DMD45CU
DMD45CU	DN	2-Methyl-2,4-Pentanediol
DMD45CU	MI	TT48I1Y
DMD45CU	MN	Placenta growth factor (PlGF)
DMD45CU	MT	DTT
DMD45CU	MA	Inhibitor
DMD45CU	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD45CU	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD45CU	DI	DMD45CU
DMD45CU	DN	2-Methyl-2,4-Pentanediol
DMD45CU	MI	TT9PB26
DMD45CU	MN	Presynaptic density protein 95 (DLG4)
DMD45CU	MT	DTT
DMD45CU	MA	Inhibitor
DMD45CU	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD45CU	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD45CU	DI	DMD45CU
DMD45CU	DN	2-Methyl-2,4-Pentanediol
DMD45CU	MI	TTE5VG0
DMD45CU	MN	P-selectin (SELP)
DMD45CU	MT	DTT
DMD45CU	MA	Inhibitor
DMD45CU	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD45CU	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD45CU	DI	DMD45CU
DMD45CU	DN	2-Methyl-2,4-Pentanediol
DMD45CU	MI	TTELIN2
DMD45CU	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMD45CU	MT	DTT
DMD45CU	MA	Inhibitor
DMD45CU	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD45CU	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD45CU	DI	DMD45CU
DMD45CU	DN	2-Methyl-2,4-Pentanediol
DMD45CU	MI	TTHI19T
DMD45CU	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMD45CU	MT	DTT
DMD45CU	MA	Inhibitor
DMD45CU	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD45CU	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMHM5GJ	DI	DMHM5GJ
DMHM5GJ	DN	2-Methyl-2-Propanol
DMHM5GJ	MI	TTV3NH6
DMHM5GJ	MN	Calmodulin (CALM)
DMHM5GJ	MT	DTT
DMHM5GJ	MA	Inhibitor
DMHM5GJ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMHM5GJ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMHM5GJ	DI	DMHM5GJ
DMHM5GJ	DN	2-Methyl-2-Propanol
DMHM5GJ	MI	TTZL0OI
DMHM5GJ	MN	Methionine aminopeptidase 2 (METAP2)
DMHM5GJ	MT	DTT
DMHM5GJ	MA	Inhibitor
DMHM5GJ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMHM5GJ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM3DNFQ	DI	DM3DNFQ
DM3DNFQ	DN	2-Methyl-3-(2-Aminothiazolo)Propanal
DM3DNFQ	MI	TTB2MXP
DM3DNFQ	MN	Angiotensinogenase renin (REN)
DM3DNFQ	MT	DTT
DM3DNFQ	MA	Inhibitor
DM3DNFQ	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM3DNFQ	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMV8YIZ	DI	DMV8YIZ
DMV8YIZ	DN	2-methyl-3-(pyridin-4-yl)-1H-indol-6-amine
DMV8YIZ	MI	TTTB4UP
DMV8YIZ	MN	Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2)
DMV8YIZ	MT	DTT
DMV8YIZ	MA	Inhibitor
DMV8YIZ	RN	Low molecular weight indole fragments as IMPDH inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2535-8.
DMV8YIZ	RU	https://pubmed.ncbi.nlm.nih.gov/16483769

DM8N54C	DI	DM8N54C
DM8N54C	DN	2-methyl-3-(pyridin-4-yl)-1H-indole
DM8N54C	MI	TTTB4UP
DM8N54C	MN	Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2)
DM8N54C	MT	DTT
DM8N54C	MA	Inhibitor
DM8N54C	RN	Low molecular weight indole fragments as IMPDH inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2535-8.
DM8N54C	RU	https://pubmed.ncbi.nlm.nih.gov/16483769

DMHYA7G	DI	DMHYA7G
DMHYA7G	DN	2-methyl-3-phenethyl-3H-pyrimidin-4-one
DMHYA7G	MI	TTBUYHA
DMHYA7G	MN	Extracellular calcium-sensing receptor (CASR)
DMHYA7G	MT	DTT
DMHYA7G	MA	Antagonist
DMHYA7G	RN	Design, new synthesis, and calcilytic activity of substituted 3H-pyrimidin-4-ones. Bioorg Med Chem Lett. 2005 May 16;15(10):2537-40.
DMHYA7G	RU	https://pubmed.ncbi.nlm.nih.gov/15863312

DMAFPE7	DI	DMAFPE7
DMAFPE7	DN	2-methyl-4-(2-thienylethynyl)thiazole
DMAFPE7	MI	TTHS256
DMAFPE7	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMAFPE7	MT	DTT
DMAFPE7	MA	Inhibitor
DMAFPE7	RN	Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100.
DMAFPE7	RU	https://pubmed.ncbi.nlm.nih.gov/16451073

DMK4A0J	DI	DMK4A0J
DMK4A0J	DN	2-methyl-4-(3-thienylethynyl)thiazole
DMK4A0J	MI	TTHS256
DMK4A0J	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMK4A0J	MT	DTT
DMK4A0J	MA	Inhibitor
DMK4A0J	RN	Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100.
DMK4A0J	RU	https://pubmed.ncbi.nlm.nih.gov/16451073

DM4P3CW	DI	DM4P3CW
DM4P3CW	DN	2-methyl-4-(m-tolylethynyl)thiazole
DM4P3CW	MI	TTHS256
DM4P3CW	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM4P3CW	MT	DTT
DM4P3CW	MA	Inhibitor
DM4P3CW	RN	Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100.
DM4P3CW	RU	https://pubmed.ncbi.nlm.nih.gov/16451073

DMKFBVS	DI	DMKFBVS
DMKFBVS	DN	2-Methyl-4-o-tolylethynyl-thiazole
DMKFBVS	MI	TTHS256
DMKFBVS	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMKFBVS	MT	DTT
DMKFBVS	MA	Inhibitor
DMKFBVS	RN	5-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-2,3'-bipyridine: a highly potent, orally active metabotropic glutamate subtype 5 (mGlu5) receptor antagonist... Bioorg Med Chem Lett. 2004 Aug 2;14(15):3993-6.
DMKFBVS	RU	https://pubmed.ncbi.nlm.nih.gov/15225713

DMRC60A	DI	DMRC60A
DMRC60A	DN	2-Methyl-4-phenylethynyl-thiazole
DMRC60A	MI	TTHS256
DMRC60A	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMRC60A	MT	DTT
DMRC60A	MA	Inhibitor
DMRC60A	RN	5-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-2,3'-bipyridine: a highly potent, orally active metabotropic glutamate subtype 5 (mGlu5) receptor antagonist... Bioorg Med Chem Lett. 2004 Aug 2;14(15):3993-6.
DMRC60A	RU	https://pubmed.ncbi.nlm.nih.gov/15225713

DMWRCFY	DI	DMWRCFY
DMWRCFY	DN	2-Methyl-4-p-tolylethynyl-thiazole
DMWRCFY	MI	TTHS256
DMWRCFY	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMWRCFY	MT	DTT
DMWRCFY	MA	Inhibitor
DMWRCFY	RN	5-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-2,3'-bipyridine: a highly potent, orally active metabotropic glutamate subtype 5 (mGlu5) receptor antagonist... Bioorg Med Chem Lett. 2004 Aug 2;14(15):3993-6.
DMWRCFY	RU	https://pubmed.ncbi.nlm.nih.gov/15225713

DM1S5CB	DI	DM1S5CB
DM1S5CB	DN	2-methyl-5-HT
DM1S5CB	MI	TTK8CXU
DM1S5CB	MN	5-HT 1B receptor (HTR1B)
DM1S5CB	MT	DTT
DM1S5CB	MA	Agonist
DM1S5CB	RN	Human serotonin 1D receptor is encoded by a subfamily of two distinct genes: 5-HT1D alpha and 5-HT1D beta. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3630-4.
DM1S5CB	RU	https://pubmed.ncbi.nlm.nih.gov/1565658

DM1S5CB	DI	DM1S5CB
DM1S5CB	DN	2-methyl-5-HT
DM1S5CB	MI	TT6MSOK
DM1S5CB	MN	5-HT 1D receptor (HTR1D)
DM1S5CB	MT	DTT
DM1S5CB	MA	Agonist
DM1S5CB	RN	Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan. Mol Pharmacol. 1996 Dec;50(6):1567-80.
DM1S5CB	RU	https://pubmed.ncbi.nlm.nih.gov/8967979

DM1S5CB	DI	DM1S5CB
DM1S5CB	DN	2-methyl-5-HT
DM1S5CB	MI	TTCPG9S
DM1S5CB	MN	5-HT 1E receptor (HTR1E)
DM1S5CB	MT	DTT
DM1S5CB	MA	Agonist
DM1S5CB	RN	Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):408-12.
DM1S5CB	RU	https://pubmed.ncbi.nlm.nih.gov/8380639

DM1S5CB	DI	DM1S5CB
DM1S5CB	DN	2-methyl-5-HT
DM1S5CB	MI	TT0MI3F
DM1S5CB	MN	5-HT 1F receptor (HTR1F)
DM1S5CB	MT	DTT
DM1S5CB	MA	Agonist
DM1S5CB	RN	Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):408-12.
DM1S5CB	RU	https://pubmed.ncbi.nlm.nih.gov/8380639

DM1S5CB	DI	DM1S5CB
DM1S5CB	DN	2-methyl-5-HT
DM1S5CB	MI	TT0K1SC
DM1S5CB	MN	5-HT 2B receptor (HTR2B)
DM1S5CB	MT	DTT
DM1S5CB	MA	Agonist
DM1S5CB	RN	Pharmacological characteristics of the newly cloned rat 5-hydroxytryptamine2F receptor. Mol Pharmacol. 1993 Mar;43(3):419-26.
DM1S5CB	RU	https://pubmed.ncbi.nlm.nih.gov/8450835

DM1S5CB	DI	DM1S5CB
DM1S5CB	DN	2-methyl-5-HT
DM1S5CB	MI	TTPC4TU
DM1S5CB	MN	5-HT 3A receptor (HTR3A)
DM1S5CB	MT	DTT
DM1S5CB	MA	Agonist
DM1S5CB	RN	Pharmacological profile of YM-31636, a novel 5-HT3 receptor agonist, in vitro. Eur J Pharmacol. 2000 Dec 8;409(2):195-201.
DM1S5CB	RU	https://pubmed.ncbi.nlm.nih.gov/11104834

DM1S5CB	DI	DM1S5CB
DM1S5CB	DN	2-methyl-5-HT
DM1S5CB	MI	TTR6K75
DM1S5CB	MN	5-HT 3B receptor (HTR3B)
DM1S5CB	MT	DTT
DM1S5CB	MA	Agonist
DM1S5CB	RN	The 5-HT3B subunit is a major determinant of serotonin-receptor function. Nature. 1999 Jan 28;397(6717):359-63.
DM1S5CB	RU	https://pubmed.ncbi.nlm.nih.gov/9950429

DM1S5CB	DI	DM1S5CB
DM1S5CB	DN	2-methyl-5-HT
DM1S5CB	MI	TTJS8PY
DM1S5CB	MN	5-HT 6 receptor (HTR6)
DM1S5CB	MT	DTT
DM1S5CB	MA	Agonist
DM1S5CB	RN	Functional and radioligand binding characterization of rat 5-HT6 receptors stably expressed in HEK293 cells. Neuropharmacology. 1997 Apr-May;36(4-5):713-20.
DM1S5CB	RU	https://pubmed.ncbi.nlm.nih.gov/9225298

DM536IA	DI	DM536IA
DM536IA	DN	2-methyl-6-(3-(phenylthio)prop-1-ynyl)pyridine
DM536IA	MI	TTHS256
DM536IA	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM536IA	MT	DTT
DM536IA	MA	Inhibitor
DM536IA	RN	Structure-activity relationships for the linker in a series of pyridinyl-alkynes that are antagonists of the metabotropic glutamate receptor 5 (mGl... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4788-91.
DM536IA	RU	https://pubmed.ncbi.nlm.nih.gov/16837196

DMGPDYE	DI	DMGPDYE
DMGPDYE	DN	2-methyl-6-(3-(p-tolyloxy)prop-1-ynyl)pyridine
DMGPDYE	MI	TTHS256
DMGPDYE	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMGPDYE	MT	DTT
DMGPDYE	MA	Inhibitor
DMGPDYE	RN	A new series of pyridinyl-alkynes as antagonists of the metabotropic glutamate receptor 5 (mGluR5). Bioorg Med Chem Lett. 2006 Sep 15;16(18):4792-5.
DMGPDYE	RU	https://pubmed.ncbi.nlm.nih.gov/16839764

DM1YK7M	DI	DM1YK7M
DM1YK7M	DN	2-methyl-6-(4-phenylbut-1-ynyl)pyridine
DM1YK7M	MI	TTHS256
DM1YK7M	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM1YK7M	MT	DTT
DM1YK7M	MA	Inhibitor
DM1YK7M	RN	Structure-activity relationships for the linker in a series of pyridinyl-alkynes that are antagonists of the metabotropic glutamate receptor 5 (mGl... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4788-91.
DM1YK7M	RU	https://pubmed.ncbi.nlm.nih.gov/16837196

DM0UNM1	DI	DM0UNM1
DM0UNM1	DN	2-methyl-6-(4-phenylpent-1-ynyl)pyridine
DM0UNM1	MI	TTHS256
DM0UNM1	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM0UNM1	MT	DTT
DM0UNM1	MA	Inhibitor
DM0UNM1	RN	Structure-activity relationships for the linker in a series of pyridinyl-alkynes that are antagonists of the metabotropic glutamate receptor 5 (mGl... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4788-91.
DM0UNM1	RU	https://pubmed.ncbi.nlm.nih.gov/16837196

DMDVO7Z	DI	DMDVO7Z
DMDVO7Z	DN	2-methyl-6-(5-phenylpent-1-ynyl)pyridine
DMDVO7Z	MI	TTHS256
DMDVO7Z	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMDVO7Z	MT	DTT
DMDVO7Z	MA	Inhibitor
DMDVO7Z	RN	Structure-activity relationships for the linker in a series of pyridinyl-alkynes that are antagonists of the metabotropic glutamate receptor 5 (mGl... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4788-91.
DMDVO7Z	RU	https://pubmed.ncbi.nlm.nih.gov/16837196

DMVQK4Y	DI	DMVQK4Y
DMVQK4Y	DN	2-methyl-6-(phenylethynyl)pyridine
DMVQK4Y	MI	TTVBPDM
DMVQK4Y	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMVQK4Y	MT	DTT
DMVQK4Y	MA	Inhibitor
DMVQK4Y	RN	Carbamoyloximes as novel non-competitive mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4371-5.
DMVQK4Y	RU	https://pubmed.ncbi.nlm.nih.gov/20615697

DMVQK4Y	DI	DMVQK4Y
DMVQK4Y	DN	2-methyl-6-(phenylethynyl)pyridine
DMVQK4Y	MI	TTICZ1O
DMVQK4Y	MN	Metabotropic glutamate receptor 4 (mGluR4)
DMVQK4Y	MT	DTT
DMVQK4Y	MA	Modulator (allosteric modulator)
DMVQK4Y	RN	Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP. Br J Pharmacol. 2003 Mar;138(6):1026-30.
DMVQK4Y	RU	https://pubmed.ncbi.nlm.nih.gov/12684257

DMVQK4Y	DI	DMVQK4Y
DMVQK4Y	DN	2-methyl-6-(phenylethynyl)pyridine
DMVQK4Y	MI	TTHS256
DMVQK4Y	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMVQK4Y	MT	DTT
DMVQK4Y	MA	Inhibitor
DMVQK4Y	RN	2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology. 1999 Oct;38(10):1493-503.
DMVQK4Y	RU	https://pubmed.ncbi.nlm.nih.gov/10530811

DMJYSF3	DI	DMJYSF3
DMJYSF3	DN	2-methyl-6-(trifluoromethyl)-9H-carbazole
DMJYSF3	MI	TTBGTCW
DMJYSF3	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DMJYSF3	MT	DTT
DMJYSF3	MA	Inhibitor
DMJYSF3	RN	Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8.
DMJYSF3	RU	https://pubmed.ncbi.nlm.nih.gov/20521839

DM8EV4A	DI	DM8EV4A
DM8EV4A	DN	2-Methyl-6-pyrrolidin-1-yl-hex-4-ynal oxime
DM8EV4A	MI	TTZ9SOR
DM8EV4A	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DM8EV4A	MT	DTT
DM8EV4A	MA	Inhibitor
DM8EV4A	RN	Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992).
DM8EV4A	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805351

DM8EV4A	DI	DM8EV4A
DM8EV4A	DN	2-Methyl-6-pyrrolidin-1-yl-hex-4-ynal oxime
DM8EV4A	MI	TTYEG6Q
DM8EV4A	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DM8EV4A	MT	DTT
DM8EV4A	MA	Inhibitor
DM8EV4A	RN	Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992).
DM8EV4A	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805351

DM8EV4A	DI	DM8EV4A
DM8EV4A	DN	2-Methyl-6-pyrrolidin-1-yl-hex-4-ynal oxime
DM8EV4A	MI	TTQ13Z5
DM8EV4A	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DM8EV4A	MT	DTT
DM8EV4A	MA	Inhibitor
DM8EV4A	RN	Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992).
DM8EV4A	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805351

DM8EV4A	DI	DM8EV4A
DM8EV4A	DN	2-Methyl-6-pyrrolidin-1-yl-hex-4-ynal oxime
DM8EV4A	MI	TTQ3JTF
DM8EV4A	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DM8EV4A	MT	DTT
DM8EV4A	MA	Inhibitor
DM8EV4A	RN	Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992).
DM8EV4A	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805351

DM8EV4A	DI	DM8EV4A
DM8EV4A	DN	2-Methyl-6-pyrrolidin-1-yl-hex-4-ynal oxime
DM8EV4A	MI	TTH18TF
DM8EV4A	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DM8EV4A	MT	DTT
DM8EV4A	MA	Inhibitor
DM8EV4A	RN	Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992).
DM8EV4A	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805351

DM9FZ0B	DI	DM9FZ0B
DM9FZ0B	DN	2-methyl-7-(pyridin-3-yl)quinoline
DM9FZ0B	MI	TTHS256
DM9FZ0B	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM9FZ0B	MT	DTT
DM9FZ0B	MA	Inhibitor
DM9FZ0B	RN	Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8.
DM9FZ0B	RU	https://pubmed.ncbi.nlm.nih.gov/17590335

DMMFKOH	DI	DMMFKOH
DMMFKOH	DN	2-methyl-7-m-tolyl-1,6-naphthyridine
DMMFKOH	MI	TTHS256
DMMFKOH	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMMFKOH	MT	DTT
DMMFKOH	MA	Inhibitor
DMMFKOH	RN	Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8.
DMMFKOH	RU	https://pubmed.ncbi.nlm.nih.gov/17936624

DMZFK4R	DI	DMZFK4R
DMZFK4R	DN	2-methyl-7-m-tolyl-1,8-naphthyridine
DMZFK4R	MI	TTHS256
DMZFK4R	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMZFK4R	MT	DTT
DMZFK4R	MA	Inhibitor
DMZFK4R	RN	Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8.
DMZFK4R	RU	https://pubmed.ncbi.nlm.nih.gov/17936624

DMC02TI	DI	DMC02TI
DMC02TI	DN	2-methyl-7-m-tolylquinoline
DMC02TI	MI	TTHS256
DMC02TI	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMC02TI	MT	DTT
DMC02TI	MA	Inhibitor
DMC02TI	RN	Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8.
DMC02TI	RU	https://pubmed.ncbi.nlm.nih.gov/17590335

DM8RV5X	DI	DM8RV5X
DM8RV5X	DN	2-methyl-7-phenyl-1,8-naphthyridine
DM8RV5X	MI	TTHS256
DM8RV5X	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM8RV5X	MT	DTT
DM8RV5X	MA	Inhibitor
DM8RV5X	RN	Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8.
DM8RV5X	RU	https://pubmed.ncbi.nlm.nih.gov/17936624

DMT7MVD	DI	DMT7MVD
DMT7MVD	DN	2-methyl-7-phenylquinoline
DMT7MVD	MI	TTHS256
DMT7MVD	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMT7MVD	MT	DTT
DMT7MVD	MA	Inhibitor
DMT7MVD	RN	Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8.
DMT7MVD	RU	https://pubmed.ncbi.nlm.nih.gov/17590335

DMY65CX	DI	DMY65CX
DMY65CX	DN	2-Methyl-8-phenyl-1,2,3,4-tetrahydro-isoquinoline
DMY65CX	MI	TTZFYLI
DMY65CX	MN	Dopamine D1 receptor (D1R)
DMY65CX	MT	DTT
DMY65CX	MA	Inhibitor
DMY65CX	RN	Synthesis and evaluation of 1,2,3,4-tetrahydro[1]benzothieno[2,3-h]isoquinolines as dopamine antagonists. J Med Chem. 1981 Sep;24(9):1107-10.
DMY65CX	RU	https://pubmed.ncbi.nlm.nih.gov/7288826

DMY65CX	DI	DMY65CX
DMY65CX	DN	2-Methyl-8-phenyl-1,2,3,4-tetrahydro-isoquinoline
DMY65CX	MI	TTEX248
DMY65CX	MN	Dopamine D2 receptor (D2R)
DMY65CX	MT	DTT
DMY65CX	MA	Inhibitor
DMY65CX	RN	Synthesis and evaluation of 1,2,3,4-tetrahydro[1]benzothieno[2,3-h]isoquinolines as dopamine antagonists. J Med Chem. 1981 Sep;24(9):1107-10.
DMY65CX	RU	https://pubmed.ncbi.nlm.nih.gov/7288826

DM06TZN	DI	DM06TZN
DM06TZN	DN	2-methyl-9H-carbazole
DM06TZN	MI	TTBGTCW
DM06TZN	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DM06TZN	MT	DTT
DM06TZN	MA	Inhibitor
DM06TZN	RN	Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8.
DM06TZN	RU	https://pubmed.ncbi.nlm.nih.gov/20521839

DMEVFJW	DI	DMEVFJW
DMEVFJW	DN	2-methyl-9H-indeno[2,1-d]pyrimidin-9-one
DMEVFJW	MI	TTGP7BY
DMEVFJW	MN	Monoamine oxidase type B (MAO-B)
DMEVFJW	MT	DTT
DMEVFJW	MA	Inhibitor
DMEVFJW	RN	Synthesis and monoamine oxidase inhibitory activity of new pyridazine-, pyrimidine- and 1,2,4-triazine-containing tricyclic derivatives. J Med Chem. 2007 Nov 1;50(22):5364-71.
DMEVFJW	RU	https://pubmed.ncbi.nlm.nih.gov/17910428

DMKP6BM	DI	DMKP6BM
DMKP6BM	DN	2-Methylamino-succinic acid(NMDA)
DMKP6BM	MI	TTLD29N
DMKP6BM	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMKP6BM	MT	DTT
DMKP6BM	MA	Inhibitor
DMKP6BM	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455).
DMKP6BM	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=455

DMKP6BM	DI	DMKP6BM
DMKP6BM	DN	2-Methylamino-succinic acid(NMDA)
DMKP6BM	MI	TTKJEMQ
DMKP6BM	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMKP6BM	MT	DTT
DMKP6BM	MA	Inhibitor
DMKP6BM	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456).
DMKP6BM	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=456

DMKP6BM	DI	DMKP6BM
DMKP6BM	DN	2-Methylamino-succinic acid(NMDA)
DMKP6BM	MI	TTN9D8E
DMKP6BM	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMKP6BM	MT	DTT
DMKP6BM	MA	Inhibitor
DMKP6BM	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457).
DMKP6BM	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=457

DMKP6BM	DI	DMKP6BM
DMKP6BM	DN	2-Methylamino-succinic acid(NMDA)
DMKP6BM	MI	TT1M8OW
DMKP6BM	MN	Glutamate receptor ionotropic NMDA 2C (GluN2C)
DMKP6BM	MT	DTT
DMKP6BM	MA	Agonist
DMKP6BM	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 458).
DMKP6BM	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=458

DMKP6BM	DI	DMKP6BM
DMKP6BM	DN	2-Methylamino-succinic acid(NMDA)
DMKP6BM	MI	TT5POTG
DMKP6BM	MN	Glutamate receptor ionotropic NMDA 2D (GluN2D)
DMKP6BM	MT	DTT
DMKP6BM	MA	Agonist
DMKP6BM	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 459).
DMKP6BM	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=459

DMQBF7J	DI	DMQBF7J
DMQBF7J	DN	2-Methyl-beta-carboline-2-ium iodide
DMQBF7J	MI	TTEB0GD
DMQBF7J	MN	Cholinesterase (BCHE)
DMQBF7J	MT	DTT
DMQBF7J	MA	Inhibitor
DMQBF7J	RN	Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents. J Med Chem. 2010 May 13;53(9):3611-7.
DMQBF7J	RU	https://pubmed.ncbi.nlm.nih.gov/20361801

DMKB2P8	DI	DMKB2P8
DMKB2P8	DN	2-methylbut-3-yn-2-yl 4-methoxybenzoate
DMKB2P8	MI	TTPLTSQ
DMKB2P8	MN	Neutrophil elastase (NE)
DMKB2P8	MT	DTT
DMKB2P8	MA	Inhibitor
DMKB2P8	RN	N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
DMKB2P8	RU	https://pubmed.ncbi.nlm.nih.gov/17850059

DMD8CQS	DI	DMD8CQS
DMD8CQS	DN	2-methylhistamine
DMD8CQS	MI	TTXJ178
DMD8CQS	MN	Histamine H4 receptor (H4R)
DMD8CQS	MT	DTT
DMD8CQS	MA	Agonist
DMD8CQS	RN	Compared pharmacology of human histamine H3 and H4 receptors: structure-activity relationships of histamine derivatives. Br J Pharmacol. 2006 Apr;147(7):744-54.
DMD8CQS	RU	https://pubmed.ncbi.nlm.nih.gov/16432504

DMHW9GL	DI	DMHW9GL
DMHW9GL	DN	2-methylisoquinoline-1,3,4-trione
DMHW9GL	MI	TTPF2QI
DMHW9GL	MN	Caspase-3 (CASP3)
DMHW9GL	MT	DTT
DMHW9GL	MA	Inhibitor
DMHW9GL	RN	Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors. J Med Chem. 2006 Mar 9;49(5):1613-23.
DMHW9GL	RU	https://pubmed.ncbi.nlm.nih.gov/16509578

DMUN3LV	DI	DMUN3LV
DMUN3LV	DN	2-Methylquinoline-8-carboxamide
DMUN3LV	MI	TTVDSZ0
DMUN3LV	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMUN3LV	MT	DTT
DMUN3LV	MA	Inhibitor
DMUN3LV	RN	Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhi... J Med Chem. 2009 Feb 12;52(3):868-77.
DMUN3LV	RU	https://pubmed.ncbi.nlm.nih.gov/19117416

DMM4HXK	DI	DMM4HXK
DMM4HXK	DN	2-methylsulfanylestradiol 3,17-O,O-bis-sulfamate
DMM4HXK	MI	TTHM0R1
DMM4HXK	MN	Steryl-sulfatase (STS)
DMM4HXK	MT	DTT
DMM4HXK	MA	Inhibitor
DMM4HXK	RN	2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity. J Med Chem. 2006 Dec 28;49(26):7683-96.
DMM4HXK	RU	https://pubmed.ncbi.nlm.nih.gov/17181151

DM4IJXW	DI	DM4IJXW
DM4IJXW	DN	2-MOE phosphorothioate gapmers
DM4IJXW	MI	TTZQTY2
DM4IJXW	MN	DMPK messenger RNA (DMPK mRNA)
DM4IJXW	MT	DTT
DM4IJXW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1505).
DM4IJXW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1505

DME9S8M	DI	DME9S8M
DME9S8M	DN	2'-Monophosphoadenosine 5'-Diphosphoribose
DME9S8M	MI	TTFBNVI
DME9S8M	MN	Aldose reductase (AKR1B1)
DME9S8M	MT	DTT
DME9S8M	MA	Inhibitor
DME9S8M	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DME9S8M	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DME9S8M	DI	DME9S8M
DME9S8M	DN	2'-Monophosphoadenosine 5'-Diphosphoribose
DME9S8M	MI	TTQWGU9
DME9S8M	MN	Bacterial Aspartate-semialdehyde dehydrogenase (Bact asd2)
DME9S8M	MT	DTT
DME9S8M	MA	Inhibitor
DME9S8M	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DME9S8M	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DME9S8M	DI	DME9S8M
DME9S8M	DN	2'-Monophosphoadenosine 5'-Diphosphoribose
DME9S8M	MI	TTN7BL9
DME9S8M	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DME9S8M	MT	DTT
DME9S8M	MA	Inhibitor
DME9S8M	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DME9S8M	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DME9S8M	DI	DME9S8M
DME9S8M	DN	2'-Monophosphoadenosine 5'-Diphosphoribose
DME9S8M	MI	TT5ZWB6
DME9S8M	MN	Dihydrodiol dehydrogenase type I (AKR1C3)
DME9S8M	MT	DTT
DME9S8M	MA	Inhibitor
DME9S8M	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DME9S8M	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DME9S8M	DI	DME9S8M
DME9S8M	DN	2'-Monophosphoadenosine 5'-Diphosphoribose
DME9S8M	MI	TTJS7O4
DME9S8M	MN	Entamoeba Alcohol dehydrogenase 2 (Entamo ADH2)
DME9S8M	MT	DTT
DME9S8M	MA	Inhibitor
DME9S8M	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DME9S8M	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DME9S8M	DI	DME9S8M
DME9S8M	DN	2'-Monophosphoadenosine 5'-Diphosphoribose
DME9S8M	MI	TTIWB6L
DME9S8M	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DME9S8M	MT	DTT
DME9S8M	MA	Inhibitor
DME9S8M	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DME9S8M	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DME9S8M	DI	DME9S8M
DME9S8M	DN	2'-Monophosphoadenosine 5'-Diphosphoribose
DME9S8M	MI	TTKN8W0
DME9S8M	MN	Glucose-6-phosphate dehydrogenase (G6PD)
DME9S8M	MT	DTT
DME9S8M	MA	Inhibitor
DME9S8M	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DME9S8M	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DME9S8M	DI	DME9S8M
DME9S8M	DN	2'-Monophosphoadenosine 5'-Diphosphoribose
DME9S8M	MI	TTPADOQ
DME9S8M	MN	HMG-CoA reductase (HMGCR)
DME9S8M	MT	DTT
DME9S8M	MA	Inhibitor
DME9S8M	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DME9S8M	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DME9S8M	DI	DME9S8M
DME9S8M	DN	2'-Monophosphoadenosine 5'-Diphosphoribose
DME9S8M	MI	TTZUFI5
DME9S8M	MN	Nitric-oxide synthase brain (NOS1)
DME9S8M	MT	DTT
DME9S8M	MA	Inhibitor
DME9S8M	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DME9S8M	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DME9S8M	DI	DME9S8M
DME9S8M	DN	2'-Monophosphoadenosine 5'-Diphosphoribose
DME9S8M	MI	TT9SL3Q
DME9S8M	MN	Polypeptide deformylase (PDF)
DME9S8M	MT	DTT
DME9S8M	MA	Inhibitor
DME9S8M	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DME9S8M	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMDYRNF	DI	DMDYRNF
DMDYRNF	DN	2'-Monophosphoadenosine-5'-Diphosphate
DMDYRNF	MI	TT9SL3Q
DMDYRNF	MN	Polypeptide deformylase (PDF)
DMDYRNF	MT	DTT
DMDYRNF	MA	Inhibitor
DMDYRNF	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMDYRNF	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMCVF7R	DI	DMCVF7R
DMCVF7R	DN	2-morpholin-4-yl-6-phenyl-4H-thiopyran-4-one
DMCVF7R	MI	TTK3PY9
DMCVF7R	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMCVF7R	MT	DTT
DMCVF7R	MA	Inhibitor
DMCVF7R	RN	Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72.
DMCVF7R	RU	https://pubmed.ncbi.nlm.nih.gov/17371003

DMTB1KV	DI	DMTB1KV
DMTB1KV	DN	2-Morpholin-4-yl-6-phenyl-chromen-4-one
DMTB1KV	MI	TTK3PY9
DMTB1KV	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMTB1KV	MT	DTT
DMTB1KV	MA	Inhibitor
DMTB1KV	RN	Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85.
DMTB1KV	RU	https://pubmed.ncbi.nlm.nih.gov/15658870

DMC1TWI	DI	DMC1TWI
DMC1TWI	DN	2-morpholin-4-yl-8-naphthalen-2-ylchromen-4-one
DMC1TWI	MI	TTK3PY9
DMC1TWI	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMC1TWI	MT	DTT
DMC1TWI	MA	Inhibitor
DMC1TWI	RN	Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46.
DMC1TWI	RU	https://pubmed.ncbi.nlm.nih.gov/16302822

DMVN38H	DI	DMVN38H
DMVN38H	DN	2-morpholin-4-yl-8-phenoxathiin-4-ylchromen-4-one
DMVN38H	MI	TTK3PY9
DMVN38H	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMVN38H	MT	DTT
DMVN38H	MA	Inhibitor
DMVN38H	RN	Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46.
DMVN38H	RU	https://pubmed.ncbi.nlm.nih.gov/16302822

DMNKHOI	DI	DMNKHOI
DMNKHOI	DN	2-Morpholin-4-yl-8-phenylethynyl-chromen-4-one
DMNKHOI	MI	TTJGW1Z
DMNKHOI	MN	Phosphodiesterase 2A (PDE2A)
DMNKHOI	MT	DTT
DMNKHOI	MA	Inhibitor
DMNKHOI	RN	PDE2 inhibition by the PI3 kinase inhibitor LY294002 and analogues. Bioorg Med Chem Lett. 2004 Jun 7;14(11):2847-51.
DMNKHOI	RU	https://pubmed.ncbi.nlm.nih.gov/15125945

DMNKHOI	DI	DMNKHOI
DMNKHOI	DN	2-Morpholin-4-yl-8-phenylethynyl-chromen-4-one
DMNKHOI	MI	TT06AWU
DMNKHOI	MN	Phosphodiesterase 3A (PDE3A)
DMNKHOI	MT	DTT
DMNKHOI	MA	Inhibitor
DMNKHOI	RN	Analysis of anti-PDE3 activity of 2-morpholinochromone derivatives reveals multiple mechanisms of anti-platelet activity. Bioorg Med Chem Lett. 2006 Feb 15;16(4):969-73.
DMNKHOI	RU	https://pubmed.ncbi.nlm.nih.gov/16290931

DMNHYQ0	DI	DMNHYQ0
DMNHYQ0	DN	2-morpholin-4-yl-8-styrylchromen-4-one
DMNHYQ0	MI	TTK3PY9
DMNHYQ0	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMNHYQ0	MT	DTT
DMNHYQ0	MA	Inhibitor
DMNHYQ0	RN	Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46.
DMNHYQ0	RU	https://pubmed.ncbi.nlm.nih.gov/16302822

DM5JHT6	DI	DM5JHT6
DM5JHT6	DN	2-morpholin-4-yl-8-thiophen-2-ylchromen-4-one
DM5JHT6	MI	TTK3PY9
DM5JHT6	MN	DNA-dependent protein kinase catalytic (PRKDC)
DM5JHT6	MT	DTT
DM5JHT6	MA	Inhibitor
DM5JHT6	RN	Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46.
DM5JHT6	RU	https://pubmed.ncbi.nlm.nih.gov/16302822

DMCY4EP	DI	DMCY4EP
DMCY4EP	DN	2-morpholin-4-yl-8-thiophen-3-ylchromen-4-one
DMCY4EP	MI	TTK3PY9
DMCY4EP	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMCY4EP	MT	DTT
DMCY4EP	MA	Inhibitor
DMCY4EP	RN	Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46.
DMCY4EP	RU	https://pubmed.ncbi.nlm.nih.gov/16302822

DM3ZWNI	DI	DM3ZWNI
DM3ZWNI	DN	2-Morpholin-4-yl-benzo[h]chromene-4-thione
DM3ZWNI	MI	TTK3PY9
DM3ZWNI	MN	DNA-dependent protein kinase catalytic (PRKDC)
DM3ZWNI	MT	DTT
DM3ZWNI	MA	Inhibitor
DM3ZWNI	RN	Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85.
DM3ZWNI	RU	https://pubmed.ncbi.nlm.nih.gov/15658870

DMDTRZ2	DI	DMDTRZ2
DMDTRZ2	DN	2-Morpholin-4-yl-N-(4-sulfamoyl-phenyl)-acetamide
DMDTRZ2	MI	TTHQPL7
DMDTRZ2	MN	Carbonic anhydrase I (CA-I)
DMDTRZ2	MT	DTT
DMDTRZ2	MA	Inhibitor
DMDTRZ2	RN	Carbonic anhydrase inhibitors. Novel sulfanilamide/acetazolamide derivatives obtained by the tail approach and their interaction with the cytosolic... Bioorg Med Chem Lett. 2005 Jan 17;15(2):367-72.
DMDTRZ2	RU	https://pubmed.ncbi.nlm.nih.gov/15603956

DMDTRZ2	DI	DMDTRZ2
DMDTRZ2	DN	2-Morpholin-4-yl-N-(4-sulfamoyl-phenyl)-acetamide
DMDTRZ2	MI	TTANPDJ
DMDTRZ2	MN	Carbonic anhydrase II (CA-II)
DMDTRZ2	MT	DTT
DMDTRZ2	MA	Inhibitor
DMDTRZ2	RN	Carbonic anhydrase inhibitors. Novel sulfanilamide/acetazolamide derivatives obtained by the tail approach and their interaction with the cytosolic... Bioorg Med Chem Lett. 2005 Jan 17;15(2):367-72.
DMDTRZ2	RU	https://pubmed.ncbi.nlm.nih.gov/15603956

DMDTRZ2	DI	DMDTRZ2
DMDTRZ2	DN	2-Morpholin-4-yl-N-(4-sulfamoyl-phenyl)-acetamide
DMDTRZ2	MI	TT2LVK8
DMDTRZ2	MN	Carbonic anhydrase IX (CA-IX)
DMDTRZ2	MT	DTT
DMDTRZ2	MA	Inhibitor
DMDTRZ2	RN	Carbonic anhydrase inhibitors. Novel sulfanilamide/acetazolamide derivatives obtained by the tail approach and their interaction with the cytosolic... Bioorg Med Chem Lett. 2005 Jan 17;15(2):367-72.
DMDTRZ2	RU	https://pubmed.ncbi.nlm.nih.gov/15603956

DMCKSX7	DI	DMCKSX7
DMCKSX7	DN	2-Morpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one
DMCKSX7	MI	TTK3PY9
DMCKSX7	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMCKSX7	MT	DTT
DMCKSX7	MA	Inhibitor
DMCKSX7	RN	Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85.
DMCKSX7	RU	https://pubmed.ncbi.nlm.nih.gov/15658870

DM79ZOV	DI	DM79ZOV
DM79ZOV	DN	2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one
DM79ZOV	MI	TTK3PY9
DM79ZOV	MN	DNA-dependent protein kinase catalytic (PRKDC)
DM79ZOV	MT	DTT
DM79ZOV	MA	Inhibitor
DM79ZOV	RN	Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85.
DM79ZOV	RU	https://pubmed.ncbi.nlm.nih.gov/15658870

DM79ZOV	DI	DM79ZOV
DM79ZOV	DN	2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one
DM79ZOV	MI	TTCJG29
DM79ZOV	MN	Serine/threonine-protein kinase mTOR (mTOR)
DM79ZOV	MT	DTT
DM79ZOV	MA	Inhibitor
DM79ZOV	RN	Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85.
DM79ZOV	RU	https://pubmed.ncbi.nlm.nih.gov/15658870

DMFHTEG	DI	DMFHTEG
DMFHTEG	DN	2-morpholino-1,1,2-triphenylethanol
DMFHTEG	MI	TTW0CMT
DMFHTEG	MN	Voltage-gated potassium channel Kv1.5 (KCNA5)
DMFHTEG	MT	DTT
DMFHTEG	MA	Inhibitor
DMFHTEG	RN	Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channel. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2493-6.
DMFHTEG	RU	https://pubmed.ncbi.nlm.nih.gov/20304642

DMH89O5	DI	DMH89O5
DMH89O5	DN	2-morpholino-1,1-di(pyridin-3-yl)hexan-1-ol
DMH89O5	MI	TTW0CMT
DMH89O5	MN	Voltage-gated potassium channel Kv1.5 (KCNA5)
DMH89O5	MT	DTT
DMH89O5	MA	Inhibitor
DMH89O5	RN	Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channel. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2493-6.
DMH89O5	RU	https://pubmed.ncbi.nlm.nih.gov/20304642

DMDMVA1	DI	DMDMVA1
DMDMVA1	DN	2-morpholino-1,1-di(pyridin-3-yl)octan-1-ol
DMDMVA1	MI	TTW0CMT
DMDMVA1	MN	Voltage-gated potassium channel Kv1.5 (KCNA5)
DMDMVA1	MT	DTT
DMDMVA1	MA	Inhibitor
DMDMVA1	RN	Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channel. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2493-6.
DMDMVA1	RU	https://pubmed.ncbi.nlm.nih.gov/20304642

DM3V5AB	DI	DM3V5AB
DM3V5AB	DN	2-morpholino-2-phenyl-1,1-di(pyridin-3-yl)ethanol
DM3V5AB	MI	TTW0CMT
DM3V5AB	MN	Voltage-gated potassium channel Kv1.5 (KCNA5)
DM3V5AB	MT	DTT
DM3V5AB	MA	Inhibitor
DM3V5AB	RN	Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channel. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2493-6.
DM3V5AB	RU	https://pubmed.ncbi.nlm.nih.gov/20304642

DM5J6IT	DI	DM5J6IT
DM5J6IT	DN	2-morpholino-4H-benzo[g]chromen-4-one
DM5J6IT	MI	TTK3PY9
DM5J6IT	MN	DNA-dependent protein kinase catalytic (PRKDC)
DM5J6IT	MT	DTT
DM5J6IT	MA	Inhibitor
DM5J6IT	RN	Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46.
DM5J6IT	RU	https://pubmed.ncbi.nlm.nih.gov/16302822

DMZL6Q1	DI	DMZL6Q1
DMZL6Q1	DN	2-morpholino-6-(naphthalen-1-yl)-4H-chromen-4-one
DMZL6Q1	MI	TTK3PY9
DMZL6Q1	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMZL6Q1	MT	DTT
DMZL6Q1	MA	Inhibitor
DMZL6Q1	RN	Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46.
DMZL6Q1	RU	https://pubmed.ncbi.nlm.nih.gov/16302822

DMEOI0V	DI	DMEOI0V
DMEOI0V	DN	2-morpholino-6-(naphthalen-1-yl)-4H-pyran-4-one
DMEOI0V	MI	TTK3PY9
DMEOI0V	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMEOI0V	MT	DTT
DMEOI0V	MA	Inhibitor
DMEOI0V	RN	Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72.
DMEOI0V	RU	https://pubmed.ncbi.nlm.nih.gov/17371003

DMO7QCN	DI	DMO7QCN
DMO7QCN	DN	2-morpholino-6-(naphthalen-2-yl)-4H-pyran-4-one
DMO7QCN	MI	TTK3PY9
DMO7QCN	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMO7QCN	MT	DTT
DMO7QCN	MA	Inhibitor
DMO7QCN	RN	Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72.
DMO7QCN	RU	https://pubmed.ncbi.nlm.nih.gov/17371003

DMTBRLK	DI	DMTBRLK
DMTBRLK	DN	2-morpholino-6-(quinolin-8-yl)-4H-pyran-4-one
DMTBRLK	MI	TTK3PY9
DMTBRLK	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMTBRLK	MT	DTT
DMTBRLK	MA	Inhibitor
DMTBRLK	RN	Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72.
DMTBRLK	RU	https://pubmed.ncbi.nlm.nih.gov/17371003

DMATVZB	DI	DMATVZB
DMATVZB	DN	2-morpholino-6-(thianthren-1-yl)-4H-chromen-4-one
DMATVZB	MI	TTK3PY9
DMATVZB	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMATVZB	MT	DTT
DMATVZB	MA	Inhibitor
DMATVZB	RN	Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46.
DMATVZB	RU	https://pubmed.ncbi.nlm.nih.gov/16302822

DMTWJMN	DI	DMTWJMN
DMTWJMN	DN	2-morpholino-6-(thiophen-2-yl)-4H-pyran-4-one
DMTWJMN	MI	TTK3PY9
DMTWJMN	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMTWJMN	MT	DTT
DMTWJMN	MA	Inhibitor
DMTWJMN	RN	Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72.
DMTWJMN	RU	https://pubmed.ncbi.nlm.nih.gov/17371003

DMF3NPW	DI	DMF3NPW
DMF3NPW	DN	2-morpholino-6-(thiophen-3-yl)-4H-pyran-4-one
DMF3NPW	MI	TTK3PY9
DMF3NPW	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMF3NPW	MT	DTT
DMF3NPW	MA	Inhibitor
DMF3NPW	RN	Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72.
DMF3NPW	RU	https://pubmed.ncbi.nlm.nih.gov/17371003

DMMC0ZP	DI	DMMC0ZP
DMMC0ZP	DN	2-morpholino-6-phenyl-4H-pyran-4-one
DMMC0ZP	MI	TTK3PY9
DMMC0ZP	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMMC0ZP	MT	DTT
DMMC0ZP	MA	Inhibitor
DMMC0ZP	RN	Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72.
DMMC0ZP	RU	https://pubmed.ncbi.nlm.nih.gov/17371003

DM8ZPJI	DI	DM8ZPJI
DM8ZPJI	DN	2-morpholino-6-styryl-4H-pyran-4-one
DM8ZPJI	MI	TTK3PY9
DM8ZPJI	MN	DNA-dependent protein kinase catalytic (PRKDC)
DM8ZPJI	MT	DTT
DM8ZPJI	MA	Inhibitor
DM8ZPJI	RN	Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72.
DM8ZPJI	RU	https://pubmed.ncbi.nlm.nih.gov/17371003

DM4XKYN	DI	DM4XKYN
DM4XKYN	DN	2-morpholino-7-(2-phenylethynyl)-4H-chromen-4-one
DM4XKYN	MI	TT06AWU
DM4XKYN	MN	Phosphodiesterase 3A (PDE3A)
DM4XKYN	MT	DTT
DM4XKYN	MA	Inhibitor
DM4XKYN	RN	Analysis of anti-PDE3 activity of 2-morpholinochromone derivatives reveals multiple mechanisms of anti-platelet activity. Bioorg Med Chem Lett. 2006 Feb 15;16(4):969-73.
DM4XKYN	RU	https://pubmed.ncbi.nlm.nih.gov/16290931

DMK7WON	DI	DMK7WON
DMK7WON	DN	2-morpholino-7-phenyl-4H-chromen-4-one
DMK7WON	MI	TT06AWU
DMK7WON	MN	Phosphodiesterase 3A (PDE3A)
DMK7WON	MT	DTT
DMK7WON	MA	Inhibitor
DMK7WON	RN	Analysis of anti-PDE3 activity of 2-morpholinochromone derivatives reveals multiple mechanisms of anti-platelet activity. Bioorg Med Chem Lett. 2006 Feb 15;16(4):969-73.
DMK7WON	RU	https://pubmed.ncbi.nlm.nih.gov/16290931

DMYP0UI	DI	DMYP0UI
DMYP0UI	DN	2-morpholinobenzo[h]quinolin-4(1H)-one
DMYP0UI	MI	TTK3PY9
DMYP0UI	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMYP0UI	MT	DTT
DMYP0UI	MA	Inhibitor
DMYP0UI	RN	Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46.
DMYP0UI	RU	https://pubmed.ncbi.nlm.nih.gov/16302822

DMIQYWM	DI	DMIQYWM
DMIQYWM	DN	2-morpholino-N-phenethylpyrimidin-4-amine
DMIQYWM	MI	TT1RS9F
DMIQYWM	MN	Acetylcholinesterase (AChE)
DMIQYWM	MT	DTT
DMIQYWM	MA	Inhibitor
DMIQYWM	RN	Design, synthesis and evaluation of 2,4-disubstituted pyrimidines as cholinesterase inhibitors. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3606-9.
DMIQYWM	RU	https://pubmed.ncbi.nlm.nih.gov/20472431

DMBWDXH	DI	DMBWDXH
DMBWDXH	DN	2-m-tolyl-1,8-naphthyridine
DMBWDXH	MI	TTHS256
DMBWDXH	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMBWDXH	MT	DTT
DMBWDXH	MA	Inhibitor
DMBWDXH	RN	Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8.
DMBWDXH	RU	https://pubmed.ncbi.nlm.nih.gov/17936624

DM9ZVHJ	DI	DM9ZVHJ
DM9ZVHJ	DN	2-m-Tolyl-1H-[1,8]naphthyridin-4-one
DM9ZVHJ	MI	TTML2WA
DM9ZVHJ	MN	Tubulin (TUB)
DM9ZVHJ	MT	DTT
DM9ZVHJ	MA	Inhibitor
DM9ZVHJ	RN	Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubul... J Med Chem. 1997 Sep 12;40(19):3049-56.
DM9ZVHJ	RU	https://pubmed.ncbi.nlm.nih.gov/9301667

DM9ZVHJ	DI	DM9ZVHJ
DM9ZVHJ	DN	2-m-Tolyl-1H-[1,8]naphthyridin-4-one
DM9ZVHJ	MI	TTYFKSZ
DM9ZVHJ	MN	Tubulin beta (TUBB)
DM9ZVHJ	MT	DTT
DM9ZVHJ	MA	Inhibitor
DM9ZVHJ	RN	Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubul... J Med Chem. 1997 Sep 12;40(19):3049-56.
DM9ZVHJ	RU	https://pubmed.ncbi.nlm.nih.gov/9301667

DM3AFXM	DI	DM3AFXM
DM3AFXM	DN	2-m-tolyl-2H-pyrazolo[3,4-c]quinolin-4(5H)-one
DM3AFXM	MI	TTK25J1
DM3AFXM	MN	Adenosine A1 receptor (ADORA1)
DM3AFXM	MT	DTT
DM3AFXM	MA	Inhibitor
DM3AFXM	RN	New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluati... J Med Chem. 2007 Aug 23;50(17):4061-74.
DM3AFXM	RU	https://pubmed.ncbi.nlm.nih.gov/17665891

DMIMRCH	DI	DMIMRCH
DMIMRCH	DN	2-m-tolyl-2H-pyrazolo[3,4-c]quinolin-4-amine
DMIMRCH	MI	TTK25J1
DMIMRCH	MN	Adenosine A1 receptor (ADORA1)
DMIMRCH	MT	DTT
DMIMRCH	MA	Inhibitor
DMIMRCH	RN	New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluati... J Med Chem. 2007 Aug 23;50(17):4061-74.
DMIMRCH	RU	https://pubmed.ncbi.nlm.nih.gov/17665891

DMIMRCH	DI	DMIMRCH
DMIMRCH	DN	2-m-tolyl-2H-pyrazolo[3,4-c]quinolin-4-amine
DMIMRCH	MI	TTM2AOE
DMIMRCH	MN	Adenosine A2a receptor (ADORA2A)
DMIMRCH	MT	DTT
DMIMRCH	MA	Inhibitor
DMIMRCH	RN	New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluati... J Med Chem. 2007 Aug 23;50(17):4061-74.
DMIMRCH	RU	https://pubmed.ncbi.nlm.nih.gov/17665891

DM0PT8R	DI	DM0PT8R
DM0PT8R	DN	2-N-(Isopropyl)amino-1-(4-methylthiophenyl)butane
DM0PT8R	MI	TT3ROYC
DM0PT8R	MN	Serotonin transporter (SERT)
DM0PT8R	MT	DTT
DM0PT8R	MA	Inhibitor
DM0PT8R	RN	Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88.
DM0PT8R	RU	https://pubmed.ncbi.nlm.nih.gov/19717215

DMLJ30O	DI	DMLJ30O
DMLJ30O	DN	2-N-(n-Propyl)amino-1-(4-methylthiophenyl)butane
DMLJ30O	MI	TT3ROYC
DMLJ30O	MN	Serotonin transporter (SERT)
DMLJ30O	MT	DTT
DMLJ30O	MA	Inhibitor
DMLJ30O	RN	Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88.
DMLJ30O	RU	https://pubmed.ncbi.nlm.nih.gov/19717215

DMKSUVH	DI	DMKSUVH
DMKSUVH	DN	2-N,N-Dimethylamino-1-(4-methylthiophenyl)propane
DMKSUVH	MI	TT3ROYC
DMKSUVH	MN	Serotonin transporter (SERT)
DMKSUVH	MT	DTT
DMKSUVH	MA	Inhibitor
DMKSUVH	RN	Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88.
DMKSUVH	RU	https://pubmed.ncbi.nlm.nih.gov/19717215

DM5S0BY	DI	DM5S0BY
DM5S0BY	DN	2-N-Allylamino-1-(4-methylthiophenyl)propan
DM5S0BY	MI	TT3ROYC
DM5S0BY	MN	Serotonin transporter (SERT)
DM5S0BY	MT	DTT
DM5S0BY	MA	Inhibitor
DM5S0BY	RN	Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88.
DM5S0BY	RU	https://pubmed.ncbi.nlm.nih.gov/19717215

DM2FTIC	DI	DM2FTIC
DM2FTIC	DN	2-NAP
DM2FTIC	MI	TTCG0AL
DM2FTIC	MN	Cholecystokinin receptor type A (CCKAR)
DM2FTIC	MT	DTT
DM2FTIC	MA	Antagonist
DM2FTIC	RN	Unexpected relationship between plasma protein binding and the pharmacodynamics of 2-NAP, a CCK1-receptor antagonist. Br J Clin Pharmacol. 2007 May;63(5):618-22.
DM2FTIC	RU	https://pubmed.ncbi.nlm.nih.gov/17052250

DMTSF6A	DI	DMTSF6A
DMTSF6A	DN	2-Naphthalen-1-yl-1H-[1,8]naphthyridin-4-one
DMTSF6A	MI	TTML2WA
DMTSF6A	MN	Tubulin (TUB)
DMTSF6A	MT	DTT
DMTSF6A	MA	Inhibitor
DMTSF6A	RN	Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubul... J Med Chem. 1997 Sep 12;40(19):3049-56.
DMTSF6A	RU	https://pubmed.ncbi.nlm.nih.gov/9301667

DMTSF6A	DI	DMTSF6A
DMTSF6A	DN	2-Naphthalen-1-yl-1H-[1,8]naphthyridin-4-one
DMTSF6A	MI	TTYFKSZ
DMTSF6A	MN	Tubulin beta (TUBB)
DMTSF6A	MT	DTT
DMTSF6A	MA	Inhibitor
DMTSF6A	RN	Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubul... J Med Chem. 1997 Sep 12;40(19):3049-56.
DMTSF6A	RU	https://pubmed.ncbi.nlm.nih.gov/9301667

DMBI6U9	DI	DMBI6U9
DMBI6U9	DN	2-Naphthalen-1-yl-benzooxazol-6-ol
DMBI6U9	MI	TTZAYWL
DMBI6U9	MN	Estrogen receptor (ESR)
DMBI6U9	MT	DTT
DMBI6U9	MA	Inhibitor
DMBI6U9	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMBI6U9	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMBI6U9	DI	DMBI6U9
DMBI6U9	DN	2-Naphthalen-1-yl-benzooxazol-6-ol
DMBI6U9	MI	TTOM3J0
DMBI6U9	MN	Estrogen receptor beta (ESR2)
DMBI6U9	MT	DTT
DMBI6U9	MA	Inhibitor
DMBI6U9	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMBI6U9	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMIDGNB	DI	DMIDGNB
DMIDGNB	DN	2-Naphthalen-1-ylmethyl-1,2-dihydro-indazol-3-one
DMIDGNB	MI	TT2J34L
DMIDGNB	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMIDGNB	MT	DTT
DMIDGNB	MA	Inhibitor
DMIDGNB	RN	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
DMIDGNB	RU	https://pubmed.ncbi.nlm.nih.gov/1848292

DM12YH4	DI	DM12YH4
DM12YH4	DN	2-Naphthalen-2-yl-1H-[1,8]naphthyridin-4-one
DM12YH4	MI	TTML2WA
DM12YH4	MN	Tubulin (TUB)
DM12YH4	MT	DTT
DM12YH4	MA	Inhibitor
DM12YH4	RN	Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubul... J Med Chem. 1997 Sep 12;40(19):3049-56.
DM12YH4	RU	https://pubmed.ncbi.nlm.nih.gov/9301667

DM12YH4	DI	DM12YH4
DM12YH4	DN	2-Naphthalen-2-yl-1H-[1,8]naphthyridin-4-one
DM12YH4	MI	TTYFKSZ
DM12YH4	MN	Tubulin beta (TUBB)
DM12YH4	MT	DTT
DM12YH4	MA	Inhibitor
DM12YH4	RN	Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubul... J Med Chem. 1997 Sep 12;40(19):3049-56.
DM12YH4	RU	https://pubmed.ncbi.nlm.nih.gov/9301667

DM1EJ6W	DI	DM1EJ6W
DM1EJ6W	DN	2-Naphthalen-2-ylmethyl-1,2-dihydro-indazol-3-one
DM1EJ6W	MI	TT2J34L
DM1EJ6W	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM1EJ6W	MT	DTT
DM1EJ6W	MA	Inhibitor
DM1EJ6W	RN	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
DM1EJ6W	RU	https://pubmed.ncbi.nlm.nih.gov/1848292

DM1EJ6W	DI	DM1EJ6W
DM1EJ6W	DN	2-Naphthalen-2-ylmethyl-1,2-dihydro-indazol-3-one
DM1EJ6W	MI	TT8NGED
DM1EJ6W	MN	Prostaglandin G/H synthase 1 (COX-1)
DM1EJ6W	MT	DTT
DM1EJ6W	MA	Inhibitor
DM1EJ6W	RN	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
DM1EJ6W	RU	https://pubmed.ncbi.nlm.nih.gov/1848292

DM1EJ6W	DI	DM1EJ6W
DM1EJ6W	DN	2-Naphthalen-2-ylmethyl-1,2-dihydro-indazol-3-one
DM1EJ6W	MI	TTVKILB
DM1EJ6W	MN	Prostaglandin G/H synthase 2 (COX-2)
DM1EJ6W	MT	DTT
DM1EJ6W	MA	Inhibitor
DM1EJ6W	RN	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
DM1EJ6W	RU	https://pubmed.ncbi.nlm.nih.gov/1848292

DMNMEPB	DI	DMNMEPB
DMNMEPB	DN	2-Naphthalen-2-ylmethyl-4,5-dihydro-1H-imidazole
DMNMEPB	MI	TT3ROYC
DMNMEPB	MN	Serotonin transporter (SERT)
DMNMEPB	MT	DTT
DMNMEPB	MA	Inhibitor
DMNMEPB	RN	Structure-activity studies for a novel series of N-(arylethyl)-N-(1,2,3,4-tetrahydronaphthalen-1-ylmethyl)-N-methylamine s possessing dual 5-HT upt... J Med Chem. 1997 Mar 28;40(7):1049-62.
DMNMEPB	RU	https://pubmed.ncbi.nlm.nih.gov/9089327

DMZ4LJ7	DI	DMZ4LJ7
DMZ4LJ7	DN	2-NAPHTHALENESULFONIC ACID
DMZ4LJ7	MI	TT6L509
DMZ4LJ7	MN	Coagulation factor IIa (F2)
DMZ4LJ7	MT	DTT
DMZ4LJ7	MA	Inhibitor
DMZ4LJ7	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMZ4LJ7	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMFXKN1	DI	DMFXKN1
DMFXKN1	DN	2-nas-phe(3-am)-4-(2-guanidinoethyl)piperidine
DMFXKN1	MI	TT6L509
DMFXKN1	MN	Coagulation factor IIa (F2)
DMFXKN1	MT	DTT
DMFXKN1	MA	Inhibitor
DMFXKN1	RN	Secondary amides of sulfonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase. J Med Chem. 2006 Jul 13;49(14):4116-26.
DMFXKN1	RU	https://pubmed.ncbi.nlm.nih.gov/16821772

DMFXKN1	DI	DMFXKN1
DMFXKN1	DN	2-nas-phe(3-am)-4-(2-guanidinoethyl)piperidine
DMFXKN1	MI	TTPRO7W
DMFXKN1	MN	Suppressor of tumorigenicity 14 protein (ST14)
DMFXKN1	MT	DTT
DMFXKN1	MA	Inhibitor
DMFXKN1	RN	Secondary amides of sulfonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase. J Med Chem. 2006 Jul 13;49(14):4116-26.
DMFXKN1	RU	https://pubmed.ncbi.nlm.nih.gov/16821772

DMFXKN1	DI	DMFXKN1
DMFXKN1	DN	2-nas-phe(3-am)-4-(2-guanidinoethyl)piperidine
DMFXKN1	MI	TTGY7WI
DMFXKN1	MN	Urokinase-type plasminogen activator (PLAU)
DMFXKN1	MT	DTT
DMFXKN1	MA	Inhibitor
DMFXKN1	RN	Secondary amides of sulfonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase. J Med Chem. 2006 Jul 13;49(14):4116-26.
DMFXKN1	RU	https://pubmed.ncbi.nlm.nih.gov/16821772

DMS0NW3	DI	DMS0NW3
DMS0NW3	DN	2-N-Cyclopropylamino-1-(4-methylthiophenyl)butane
DMS0NW3	MI	TT3ROYC
DMS0NW3	MN	Serotonin transporter (SERT)
DMS0NW3	MT	DTT
DMS0NW3	MA	Inhibitor
DMS0NW3	RN	Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88.
DMS0NW3	RU	https://pubmed.ncbi.nlm.nih.gov/19717215

DMCYVS0	DI	DMCYVS0
DMCYVS0	DN	2-N-Ethylamino-1-(4-ethylthiophenyl)butane
DMCYVS0	MI	TT3ROYC
DMCYVS0	MN	Serotonin transporter (SERT)
DMCYVS0	MT	DTT
DMCYVS0	MA	Inhibitor
DMCYVS0	RN	Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88.
DMCYVS0	RU	https://pubmed.ncbi.nlm.nih.gov/19717215

DM64093	DI	DM64093
DM64093	DN	2-N-Ethylamino-1-(4-ethylthiophenyl)propane
DM64093	MI	TT3ROYC
DM64093	MN	Serotonin transporter (SERT)
DM64093	MT	DTT
DM64093	MA	Inhibitor
DM64093	RN	Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88.
DM64093	RU	https://pubmed.ncbi.nlm.nih.gov/19717215

DMKA3V2	DI	DMKA3V2
DMKA3V2	DN	2-N-Ethylamino-1-(4-methylthiophenyl)butane
DMKA3V2	MI	TT3ROYC
DMKA3V2	MN	Serotonin transporter (SERT)
DMKA3V2	MT	DTT
DMKA3V2	MA	Inhibitor
DMKA3V2	RN	Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88.
DMKA3V2	RU	https://pubmed.ncbi.nlm.nih.gov/19717215

DM6O1SY	DI	DM6O1SY
DM6O1SY	DN	2-N-Ethylamino-1-(4-methylthiophenyl)propane
DM6O1SY	MI	TT3ROYC
DM6O1SY	MN	Serotonin transporter (SERT)
DM6O1SY	MT	DTT
DM6O1SY	MA	Inhibitor
DM6O1SY	RN	Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88.
DM6O1SY	RU	https://pubmed.ncbi.nlm.nih.gov/19717215

DM2MH6J	DI	DM2MH6J
DM2MH6J	DN	2-N-Hydroxyamino-1-(4-ethylthiophenyl)butane
DM2MH6J	MI	TT3ROYC
DM2MH6J	MN	Serotonin transporter (SERT)
DM2MH6J	MT	DTT
DM2MH6J	MA	Inhibitor
DM2MH6J	RN	Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88.
DM2MH6J	RU	https://pubmed.ncbi.nlm.nih.gov/19717215

DMIQGWK	DI	DMIQGWK
DMIQGWK	DN	2-N-Hydroxyamino-1-(4-ethylthiophenyl)propane
DMIQGWK	MI	TT3ROYC
DMIQGWK	MN	Serotonin transporter (SERT)
DMIQGWK	MT	DTT
DMIQGWK	MA	Inhibitor
DMIQGWK	RN	Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88.
DMIQGWK	RU	https://pubmed.ncbi.nlm.nih.gov/19717215

DME41NR	DI	DME41NR
DME41NR	DN	2-N-Hydroxyamino-1-(4-methylthiophenyl)butane
DME41NR	MI	TT3ROYC
DME41NR	MN	Serotonin transporter (SERT)
DME41NR	MT	DTT
DME41NR	MA	Inhibitor
DME41NR	RN	Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88.
DME41NR	RU	https://pubmed.ncbi.nlm.nih.gov/19717215

DMZDYCW	DI	DMZDYCW
DMZDYCW	DN	2-N-Hydroxyamino-1-(4-methylthiophenyl)propane
DMZDYCW	MI	TT3ROYC
DMZDYCW	MN	Serotonin transporter (SERT)
DMZDYCW	MT	DTT
DMZDYCW	MA	Inhibitor
DMZDYCW	RN	Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88.
DMZDYCW	RU	https://pubmed.ncbi.nlm.nih.gov/19717215

DM2NX4K	DI	DM2NX4K
DM2NX4K	DN	2'-Nitro-biphenyl-4-carboxylic acid hydroxyamide
DM2NX4K	MI	TT2J34L
DM2NX4K	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM2NX4K	MT	DTT
DM2NX4K	MA	Inhibitor
DM2NX4K	RN	Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8.
DM2NX4K	RU	https://pubmed.ncbi.nlm.nih.gov/2308149

DMRZK9A	DI	DMRZK9A
DMRZK9A	DN	2-nitro-N-(2,4,5-trichlorophenyl)benzamide
DMRZK9A	MI	TTVTX4N
DMRZK9A	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DMRZK9A	MT	DTT
DMRZK9A	MA	Inhibitor
DMRZK9A	RN	Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening. Eur J Med Chem. 2009 Sep;44(9):3718-30.
DMRZK9A	RU	https://pubmed.ncbi.nlm.nih.gov/19428156

DM4Z56O	DI	DM4Z56O
DM4Z56O	DN	2-nitro-N-(quinolin-8-yl)benzenesulfonamide
DM4Z56O	MI	TTSXVID
DM4Z56O	MN	Nuclear factor NF-kappa-B (NFKB)
DM4Z56O	MT	DTT
DM4Z56O	MA	Inhibitor
DM4Z56O	RN	Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFkappaB activity within two separate high-throughput s... Bioorg Med Chem Lett. 2008 Jan 1;18(1):329-35.
DM4Z56O	RU	https://pubmed.ncbi.nlm.nih.gov/18024113

DMHCVKJ	DI	DMHCVKJ
DMHCVKJ	DN	2-N-Methoxyamino-1-(4-methylthiophenyl)propane
DMHCVKJ	MI	TT3ROYC
DMHCVKJ	MN	Serotonin transporter (SERT)
DMHCVKJ	MT	DTT
DMHCVKJ	MA	Inhibitor
DMHCVKJ	RN	Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88.
DMHCVKJ	RU	https://pubmed.ncbi.nlm.nih.gov/19717215

DM1X5RY	DI	DM1X5RY
DM1X5RY	DN	2-N-Methylamino-1-(4-ethylthiophenyl)propane
DM1X5RY	MI	TT3ROYC
DM1X5RY	MN	Serotonin transporter (SERT)
DM1X5RY	MT	DTT
DM1X5RY	MA	Inhibitor
DM1X5RY	RN	Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88.
DM1X5RY	RU	https://pubmed.ncbi.nlm.nih.gov/19717215

DMCR49K	DI	DMCR49K
DMCR49K	DN	2-N-Methylamino-1-(4-methylthiophenyl)butane
DMCR49K	MI	TT3ROYC
DMCR49K	MN	Serotonin transporter (SERT)
DMCR49K	MT	DTT
DMCR49K	MA	Inhibitor
DMCR49K	RN	Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88.
DMCR49K	RU	https://pubmed.ncbi.nlm.nih.gov/19717215

DMVLX1T	DI	DMVLX1T
DMVLX1T	DN	2-N-Methylamino-1-(4-methylthiophenyl)propane
DMVLX1T	MI	TT3ROYC
DMVLX1T	MN	Serotonin transporter (SERT)
DMVLX1T	MT	DTT
DMVLX1T	MA	Inhibitor
DMVLX1T	RN	Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88.
DMVLX1T	RU	https://pubmed.ncbi.nlm.nih.gov/19717215

DMQWR69	DI	DMQWR69
DMQWR69	DN	2-NONYL-4-HYDROXYQUINOLINE N-OXIDE
DMQWR69	MI	TTRAMF0
DMQWR69	MN	Plasmodium Cytochrome B (Malaria MT-CYB)
DMQWR69	MT	DTT
DMQWR69	MA	Inhibitor
DMQWR69	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMQWR69	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMOGWIK	DI	DMOGWIK
DMOGWIK	DN	2-nonylamido-5-sulfonamidoindane
DMOGWIK	MI	TTHQPL7
DMOGWIK	MN	Carbonic anhydrase I (CA-I)
DMOGWIK	MT	DTT
DMOGWIK	MA	Inhibitor
DMOGWIK	RN	Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9.
DMOGWIK	RU	https://pubmed.ncbi.nlm.nih.gov/16640335

DMOGWIK	DI	DMOGWIK
DMOGWIK	DN	2-nonylamido-5-sulfonamidoindane
DMOGWIK	MI	TTANPDJ
DMOGWIK	MN	Carbonic anhydrase II (CA-II)
DMOGWIK	MT	DTT
DMOGWIK	MA	Inhibitor
DMOGWIK	RN	Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9.
DMOGWIK	RU	https://pubmed.ncbi.nlm.nih.gov/16640335

DMOGWIK	DI	DMOGWIK
DMOGWIK	DN	2-nonylamido-5-sulfonamidoindane
DMOGWIK	MI	TT2LVK8
DMOGWIK	MN	Carbonic anhydrase IX (CA-IX)
DMOGWIK	MT	DTT
DMOGWIK	MA	Inhibitor
DMOGWIK	RN	Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9.
DMOGWIK	RU	https://pubmed.ncbi.nlm.nih.gov/16640335

DMRXDS2	DI	DMRXDS2
DMRXDS2	DN	2np8
DMRXDS2	MI	TTLYXIT
DMRXDS2	MN	Aurora kinase C (AURKC)
DMRXDS2	MT	DTT
DMRXDS2	MA	Inhibitor
DMRXDS2	RN	Structural basis for the inhibition of Aurora A kinase by a novel class of high affinity disubstituted pyrimidine inhibitors. Bioorg Med Chem Lett. 2007 Feb 1;17(3):688-91.
DMRXDS2	RU	https://pubmed.ncbi.nlm.nih.gov/17157005

DMLZCOU	DI	DMLZCOU
DMLZCOU	DN	2-N-Propargylamino-1-(4-methylthiophenyl)butane
DMLZCOU	MI	TT3ROYC
DMLZCOU	MN	Serotonin transporter (SERT)
DMLZCOU	MT	DTT
DMLZCOU	MA	Inhibitor
DMLZCOU	RN	Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88.
DMLZCOU	RU	https://pubmed.ncbi.nlm.nih.gov/19717215

DM9HPG1	DI	DM9HPG1
DM9HPG1	DN	2-N-Propargylamino-1-(4-methylthiophenyl)propane
DM9HPG1	MI	TT3ROYC
DM9HPG1	MN	Serotonin transporter (SERT)
DM9HPG1	MT	DTT
DM9HPG1	MA	Inhibitor
DM9HPG1	RN	Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88.
DM9HPG1	RU	https://pubmed.ncbi.nlm.nih.gov/19717215

DMZK0JV	DI	DMZK0JV
DMZK0JV	DN	2-O-ethyl-PAF C-16
DMZK0JV	MI	TTQL5VC
DMZK0JV	MN	Platelet-activating factor receptor (PTAFR)
DMZK0JV	MT	DTT
DMZK0JV	MA	Agonist
DMZK0JV	RN	A radioreceptor binding assay for platelet-activating factor (PAF) using membranes from CHO cells expressing human PAF receptor. J Immunol Methods. 1995 Oct 26;186(2):225-31.
DMZK0JV	RU	https://pubmed.ncbi.nlm.nih.gov/7594622

DM5PXQU	DI	DM5PXQU
DM5PXQU	DN	2-oleoyl glycerol
DM5PXQU	MI	TT7QNVC
DM5PXQU	MN	Glucose-dependent insulinotropic receptor (GPR119)
DM5PXQU	MT	DTT
DM5PXQU	MA	Agonist
DM5PXQU	RN	2-Oleoyl glycerol is a GPR119 agonist and signals GLP-1 release in humans. J Clin Endocrinol Metab. 2011 Sep;96(9):E1409-17.
DM5PXQU	RU	https://pubmed.ncbi.nlm.nih.gov/21778222

DMN9OS1	DI	DMN9OS1
DMN9OS1	DN	2-oleoyl-LPA
DMN9OS1	MI	TT254XD
DMN9OS1	MN	Kynurenic acid receptor (GPR35)
DMN9OS1	MT	DTT
DMN9OS1	MA	Agonist
DMN9OS1	RN	GPR35 is a novel lysophosphatidic acid receptor. Biochem Biophys Res Commun. 2010 Apr 30;395(2):232-7.
DMN9OS1	RU	https://pubmed.ncbi.nlm.nih.gov/20361937

DMN9OS1	DI	DMN9OS1
DMN9OS1	DN	2-oleoyl-LPA
DMN9OS1	MI	TTE2YJR
DMN9OS1	MN	Lysophosphatidate-3 receptor (LPAR3)
DMN9OS1	MT	DTT
DMN9OS1	MA	Agonist
DMN9OS1	RN	Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors. FEBS Lett. 2000 Jul 28;478(1-2):159-65.
DMN9OS1	RU	https://pubmed.ncbi.nlm.nih.gov/10922489

DMN9OS1	DI	DMN9OS1
DMN9OS1	DN	2-oleoyl-LPA
DMN9OS1	MI	TTQ6S1K
DMN9OS1	MN	Lysophosphatidic acid receptor 1 (LPAR1)
DMN9OS1	MT	DTT
DMN9OS1	MA	Agonist
DMN9OS1	RN	Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors. FEBS Lett. 2000 Jul 28;478(1-2):159-65.
DMN9OS1	RU	https://pubmed.ncbi.nlm.nih.gov/10922489

DMN9OS1	DI	DMN9OS1
DMN9OS1	DN	2-oleoyl-LPA
DMN9OS1	MI	TTB7Y8I
DMN9OS1	MN	Lysophosphatidic acid receptor 2 (LPAR2)
DMN9OS1	MT	DTT
DMN9OS1	MA	Agonist
DMN9OS1	RN	Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors. FEBS Lett. 2000 Jul 28;478(1-2):159-65.
DMN9OS1	RU	https://pubmed.ncbi.nlm.nih.gov/10922489

DMO6JRW	DI	DMO6JRW
DMO6JRW	DN	2'-O-Methyl G-Clamp Containing Oligonucleotides
DMO6JRW	MI	TT8Z1FE
DMO6JRW	MN	Human immunodeficiency virus Tat-TAR RNA interaction (HIV Tat-TAR PPI)
DMO6JRW	MT	DTT
DMO6JRW	MA	Inhibitor
DMO6JRW	RN	The synthesis of 2'-O-methyl G-clamp containing oligonucleotides and their inhibition of the HIV-1 Tat-TAR interaction. Nucleosides Nucleotides Nucleic Acids. 2003 May-Aug;22(5-8):1259-62.
DMO6JRW	RU	https://pubmed.ncbi.nlm.nih.gov/14565394

DME7K64	DI	DME7K64
DME7K64	DN	2-O-methyl-PAF C-18
DME7K64	MI	TTQL5VC
DME7K64	MN	Platelet-activating factor receptor (PTAFR)
DME7K64	MT	DTT
DME7K64	MA	Agonist
DME7K64	RN	A radioreceptor binding assay for platelet-activating factor (PAF) using membranes from CHO cells expressing human PAF receptor. J Immunol Methods. 1995 Oct 26;186(2):225-31.
DME7K64	RU	https://pubmed.ncbi.nlm.nih.gov/7594622

DM2NEX4	DI	DM2NEX4
DM2NEX4	DN	2-Oxa-spiro[4.4]nonan-1-one
DM2NEX4	MI	TT1MPAY
DM2NEX4	MN	GABA(A) receptor alpha-1 (GABRA1)
DM2NEX4	MT	DTT
DM2NEX4	MA	Inhibitor
DM2NEX4	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DM2NEX4	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DM2NEX4	DI	DM2NEX4
DM2NEX4	DN	2-Oxa-spiro[4.4]nonan-1-one
DM2NEX4	MI	TTZA1NY
DM2NEX4	MN	GABA(A) receptor beta-2 (GABRB2)
DM2NEX4	MT	DTT
DM2NEX4	MA	Inhibitor
DM2NEX4	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DM2NEX4	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DM2NEX4	DI	DM2NEX4
DM2NEX4	DN	2-Oxa-spiro[4.4]nonan-1-one
DM2NEX4	MI	TT06RH5
DM2NEX4	MN	GABA(A) receptor gamma-2 (GABRG2)
DM2NEX4	MT	DTT
DM2NEX4	MA	Inhibitor
DM2NEX4	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DM2NEX4	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DM2NEX4	DI	DM2NEX4
DM2NEX4	DN	2-Oxa-spiro[4.4]nonan-1-one
DM2NEX4	MI	TTNJYV2
DM2NEX4	MN	Gamma-aminobutyric acid receptor (GAR)
DM2NEX4	MT	DTT
DM2NEX4	MA	Inhibitor
DM2NEX4	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DM2NEX4	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DMFN769	DI	DMFN769
DMFN769	DN	2-oxo-2H-chromene-3-carboxylic acid
DMFN769	MI	TTUNARX
DMFN769	MN	Carbonic anhydrase (CA)
DMFN769	MT	DTT
DMFN769	MA	Inhibitor
DMFN769	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMFN769	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMFN769	DI	DMFN769
DMFN769	DN	2-oxo-2H-chromene-3-carboxylic acid
DMFN769	MI	TTHQPL7
DMFN769	MN	Carbonic anhydrase I (CA-I)
DMFN769	MT	DTT
DMFN769	MA	Inhibitor
DMFN769	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMFN769	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMFN769	DI	DMFN769
DMFN769	DN	2-oxo-2H-chromene-3-carboxylic acid
DMFN769	MI	TTZHA0O
DMFN769	MN	Carbonic anhydrase IV (CA-IV)
DMFN769	MT	DTT
DMFN769	MA	Inhibitor
DMFN769	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMFN769	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMFN769	DI	DMFN769
DMFN769	DN	2-oxo-2H-chromene-3-carboxylic acid
DMFN769	MI	TT2LVK8
DMFN769	MN	Carbonic anhydrase IX (CA-IX)
DMFN769	MT	DTT
DMFN769	MA	Inhibitor
DMFN769	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMFN769	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMFN769	DI	DMFN769
DMFN769	DN	2-oxo-2H-chromene-3-carboxylic acid
DMFN769	MI	TTSYM0R
DMFN769	MN	Carbonic anhydrase XII (CA-XII)
DMFN769	MT	DTT
DMFN769	MA	Inhibitor
DMFN769	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMFN769	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMFN769	DI	DMFN769
DMFN769	DN	2-oxo-2H-chromene-3-carboxylic acid
DMFN769	MI	TTEYTKG
DMFN769	MN	Carbonic anhydrase XIV (CA-XIV)
DMFN769	MT	DTT
DMFN769	MA	Inhibitor
DMFN769	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMFN769	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMZTCOM	DI	DMZTCOM
DMZTCOM	DN	2-oxo-2H-thiochromene-3-carboxylic acid
DMZTCOM	MI	TTUNARX
DMZTCOM	MN	Carbonic anhydrase (CA)
DMZTCOM	MT	DTT
DMZTCOM	MA	Inhibitor
DMZTCOM	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMZTCOM	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMZTCOM	DI	DMZTCOM
DMZTCOM	DN	2-oxo-2H-thiochromene-3-carboxylic acid
DMZTCOM	MI	TTHQPL7
DMZTCOM	MN	Carbonic anhydrase I (CA-I)
DMZTCOM	MT	DTT
DMZTCOM	MA	Inhibitor
DMZTCOM	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMZTCOM	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMZTCOM	DI	DMZTCOM
DMZTCOM	DN	2-oxo-2H-thiochromene-3-carboxylic acid
DMZTCOM	MI	TTANPDJ
DMZTCOM	MN	Carbonic anhydrase II (CA-II)
DMZTCOM	MT	DTT
DMZTCOM	MA	Inhibitor
DMZTCOM	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMZTCOM	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMZTCOM	DI	DMZTCOM
DMZTCOM	DN	2-oxo-2H-thiochromene-3-carboxylic acid
DMZTCOM	MI	TT2LVK8
DMZTCOM	MN	Carbonic anhydrase IX (CA-IX)
DMZTCOM	MT	DTT
DMZTCOM	MA	Inhibitor
DMZTCOM	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMZTCOM	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMZTCOM	DI	DMZTCOM
DMZTCOM	DN	2-oxo-2H-thiochromene-3-carboxylic acid
DMZTCOM	MI	TTSYM0R
DMZTCOM	MN	Carbonic anhydrase XII (CA-XII)
DMZTCOM	MT	DTT
DMZTCOM	MA	Inhibitor
DMZTCOM	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMZTCOM	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMZTCOM	DI	DMZTCOM
DMZTCOM	DN	2-oxo-2H-thiochromene-3-carboxylic acid
DMZTCOM	MI	TTEYTKG
DMZTCOM	MN	Carbonic anhydrase XIV (CA-XIV)
DMZTCOM	MT	DTT
DMZTCOM	MA	Inhibitor
DMZTCOM	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMZTCOM	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DM3UY74	DI	DM3UY74
DM3UY74	DN	2-oxoguaia-1,4(15), 11(13)-trien-12,8beta-olide
DM3UY74	MI	TTSXVID
DM3UY74	MN	Nuclear factor NF-kappa-B (NFKB)
DM3UY74	MT	DTT
DM3UY74	MA	Inhibitor
DM3UY74	RN	Development of a structural model for NF-kappaB inhibition of sesquiterpene lactones using self-organizing neural networks. J Med Chem. 2006 Apr 6;49(7):2241-52.
DM3UY74	RU	https://pubmed.ncbi.nlm.nih.gov/16570920

DM23WOV	DI	DM23WOV
DM23WOV	DN	2-oxoguaia-1,4,11(13)-trien-12,8alpha-olide
DM23WOV	MI	TTSXVID
DM23WOV	MN	Nuclear factor NF-kappa-B (NFKB)
DM23WOV	MT	DTT
DM23WOV	MA	Inhibitor
DM23WOV	RN	Development of a structural model for NF-kappaB inhibition of sesquiterpene lactones using self-organizing neural networks. J Med Chem. 2006 Apr 6;49(7):2241-52.
DM23WOV	RU	https://pubmed.ncbi.nlm.nih.gov/16570920

DMDKSZ0	DI	DMDKSZ0
DMDKSZ0	DN	2-oxo-N-m-tolyl-2H-chromene-3-carboxamide
DMDKSZ0	MI	TT3WG5C
DMDKSZ0	MN	Monoamine oxidase type A (MAO-A)
DMDKSZ0	MT	DTT
DMDKSZ0	MA	Inhibitor
DMDKSZ0	RN	Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins. J Med Chem. 2009 Apr 9;52(7):1935-42.
DMDKSZ0	RU	https://pubmed.ncbi.nlm.nih.gov/19267475

DMDKSZ0	DI	DMDKSZ0
DMDKSZ0	DN	2-oxo-N-m-tolyl-2H-chromene-3-carboxamide
DMDKSZ0	MI	TTGP7BY
DMDKSZ0	MN	Monoamine oxidase type B (MAO-B)
DMDKSZ0	MT	DTT
DMDKSZ0	MA	Inhibitor
DMDKSZ0	RN	Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins. J Med Chem. 2009 Apr 9;52(7):1935-42.
DMDKSZ0	RU	https://pubmed.ncbi.nlm.nih.gov/19267475

DMH8QWY	DI	DMH8QWY
DMH8QWY	DN	2-oxo-N-phenyl-2H-chromene-3-carboxamide
DMH8QWY	MI	TT3WG5C
DMH8QWY	MN	Monoamine oxidase type A (MAO-A)
DMH8QWY	MT	DTT
DMH8QWY	MA	Inhibitor
DMH8QWY	RN	Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins. J Med Chem. 2009 Apr 9;52(7):1935-42.
DMH8QWY	RU	https://pubmed.ncbi.nlm.nih.gov/19267475

DMH8QWY	DI	DMH8QWY
DMH8QWY	DN	2-oxo-N-phenyl-2H-chromene-3-carboxamide
DMH8QWY	MI	TTGP7BY
DMH8QWY	MN	Monoamine oxidase type B (MAO-B)
DMH8QWY	MT	DTT
DMH8QWY	MA	Inhibitor
DMH8QWY	RN	Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins. J Med Chem. 2009 Apr 9;52(7):1935-42.
DMH8QWY	RU	https://pubmed.ncbi.nlm.nih.gov/19267475

DMWXI6C	DI	DMWXI6C
DMWXI6C	DN	2-oxo-N-p-tolyl-2H-chromene-3-carboxamide
DMWXI6C	MI	TT3WG5C
DMWXI6C	MN	Monoamine oxidase type A (MAO-A)
DMWXI6C	MT	DTT
DMWXI6C	MA	Inhibitor
DMWXI6C	RN	Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins. J Med Chem. 2009 Apr 9;52(7):1935-42.
DMWXI6C	RU	https://pubmed.ncbi.nlm.nih.gov/19267475

DMWXI6C	DI	DMWXI6C
DMWXI6C	DN	2-oxo-N-p-tolyl-2H-chromene-3-carboxamide
DMWXI6C	MI	TTGP7BY
DMWXI6C	MN	Monoamine oxidase type B (MAO-B)
DMWXI6C	MT	DTT
DMWXI6C	MA	Inhibitor
DMWXI6C	RN	Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins. J Med Chem. 2009 Apr 9;52(7):1935-42.
DMWXI6C	RU	https://pubmed.ncbi.nlm.nih.gov/19267475

DMDMK81	DI	DMDMK81
DMDMK81	DN	2-Oxoolean-12-en-28-oic acid
DMDMK81	MI	TTZHY6R
DMDMK81	MN	Glycogen phosphorylase muscle form (GP)
DMDMK81	MT	DTT
DMDMK81	MA	Inhibitor
DMDMK81	RN	Synthesis of 3-deoxypentacyclic triterpene derivatives as inhibitors of glycogen phosphorylase. J Nat Prod. 2009 Aug;72(8):1414-8.
DMDMK81	RU	https://pubmed.ncbi.nlm.nih.gov/19642687

DMZ9NCA	DI	DMZ9NCA
DMZ9NCA	DN	2-pentafluorophenylamido-5-sulfonamidoindane
DMZ9NCA	MI	TTHQPL7
DMZ9NCA	MN	Carbonic anhydrase I (CA-I)
DMZ9NCA	MT	DTT
DMZ9NCA	MA	Inhibitor
DMZ9NCA	RN	Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9.
DMZ9NCA	RU	https://pubmed.ncbi.nlm.nih.gov/16640335

DMZ9NCA	DI	DMZ9NCA
DMZ9NCA	DN	2-pentafluorophenylamido-5-sulfonamidoindane
DMZ9NCA	MI	TTANPDJ
DMZ9NCA	MN	Carbonic anhydrase II (CA-II)
DMZ9NCA	MT	DTT
DMZ9NCA	MA	Inhibitor
DMZ9NCA	RN	Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9.
DMZ9NCA	RU	https://pubmed.ncbi.nlm.nih.gov/16640335

DMZ9NCA	DI	DMZ9NCA
DMZ9NCA	DN	2-pentafluorophenylamido-5-sulfonamidoindane
DMZ9NCA	MI	TT2LVK8
DMZ9NCA	MN	Carbonic anhydrase IX (CA-IX)
DMZ9NCA	MT	DTT
DMZ9NCA	MA	Inhibitor
DMZ9NCA	RN	Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9.
DMZ9NCA	RU	https://pubmed.ncbi.nlm.nih.gov/16640335

DM032YM	DI	DM032YM
DM032YM	DN	2-pentenal
DM032YM	MI	TTELV3W
DM032YM	MN	Transformation-sensitive protein p120 (TRPA1)
DM032YM	MT	DTT
DM032YM	MA	Activator
DM032YM	RN	Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents. J Med Chem. 2010 Jul 22;53(14):5085-107.
DM032YM	RU	https://pubmed.ncbi.nlm.nih.gov/20356305

DM0WMBC	DI	DM0WMBC
DM0WMBC	DN	2-Phenethyl-1,2-dihydro-indazol-3-one
DM0WMBC	MI	TT2J34L
DM0WMBC	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM0WMBC	MT	DTT
DM0WMBC	MA	Inhibitor
DM0WMBC	RN	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
DM0WMBC	RU	https://pubmed.ncbi.nlm.nih.gov/1848292

DM0WMBC	DI	DM0WMBC
DM0WMBC	DN	2-Phenethyl-1,2-dihydro-indazol-3-one
DM0WMBC	MI	TT8NGED
DM0WMBC	MN	Prostaglandin G/H synthase 1 (COX-1)
DM0WMBC	MT	DTT
DM0WMBC	MA	Inhibitor
DM0WMBC	RN	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
DM0WMBC	RU	https://pubmed.ncbi.nlm.nih.gov/1848292

DM0WMBC	DI	DM0WMBC
DM0WMBC	DN	2-Phenethyl-1,2-dihydro-indazol-3-one
DM0WMBC	MI	TTVKILB
DM0WMBC	MN	Prostaglandin G/H synthase 2 (COX-2)
DM0WMBC	MT	DTT
DM0WMBC	MA	Inhibitor
DM0WMBC	RN	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
DM0WMBC	RU	https://pubmed.ncbi.nlm.nih.gov/1848292

DM4H6PC	DI	DM4H6PC
DM4H6PC	DN	2-Phenethyl-4,5-dihydro-1H-imidazole
DM4H6PC	MI	TT3WG5C
DM4H6PC	MN	Monoamine oxidase type A (MAO-A)
DM4H6PC	MT	DTT
DM4H6PC	MA	Inhibitor
DM4H6PC	RN	Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9.
DM4H6PC	RU	https://pubmed.ncbi.nlm.nih.gov/14698196

DM4H6PC	DI	DM4H6PC
DM4H6PC	DN	2-Phenethyl-4,5-dihydro-1H-imidazole
DM4H6PC	MI	TTGP7BY
DM4H6PC	MN	Monoamine oxidase type B (MAO-B)
DM4H6PC	MT	DTT
DM4H6PC	MA	Inhibitor
DM4H6PC	RN	Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9.
DM4H6PC	RU	https://pubmed.ncbi.nlm.nih.gov/14698196

DMPWG21	DI	DMPWG21
DMPWG21	DN	2-phenethylisoquinoline-1,3,4-trione
DMPWG21	MI	TTPF2QI
DMPWG21	MN	Caspase-3 (CASP3)
DMPWG21	MT	DTT
DMPWG21	MA	Inhibitor
DMPWG21	RN	Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors. J Med Chem. 2006 Mar 9;49(5):1613-23.
DMPWG21	RU	https://pubmed.ncbi.nlm.nih.gov/16509578

DMQX7FW	DI	DMQX7FW
DMQX7FW	DN	2-phenoxy-1-(2-p-tolylthiazolidin-3-yl)ethanone
DMQX7FW	MI	TTW0CMT
DMQX7FW	MN	Voltage-gated potassium channel Kv1.5 (KCNA5)
DMQX7FW	MT	DTT
DMQX7FW	MA	Inhibitor
DMQX7FW	RN	Evolution of thiazolidine-based blockers of human Kv1.5 for the treatment of atrial arrhythmias. Bioorg Med Chem Lett. 2007 Jan 1;17(1):282-4.
DMQX7FW	RU	https://pubmed.ncbi.nlm.nih.gov/17095219

DM6JNT5	DI	DM6JNT5
DM6JNT5	DN	2-phenoxy-3-(piperidin-4-yl)pyridine
DM6JNT5	MI	TTSQIFT
DM6JNT5	MN	5-HT 1A receptor (HTR1A)
DM6JNT5	MT	DTT
DM6JNT5	MA	Inhibitor
DM6JNT5	RN	Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7.
DM6JNT5	RU	https://pubmed.ncbi.nlm.nih.gov/20031410

DM6JNT5	DI	DM6JNT5
DM6JNT5	DN	2-phenoxy-3-(piperidin-4-yl)pyridine
DM6JNT5	MI	TTVBI8W
DM6JNT5	MN	Dopamine transporter (DAT)
DM6JNT5	MT	DTT
DM6JNT5	MA	Inhibitor
DM6JNT5	RN	Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7.
DM6JNT5	RU	https://pubmed.ncbi.nlm.nih.gov/20031410

DM6JNT5	DI	DM6JNT5
DM6JNT5	DN	2-phenoxy-3-(piperidin-4-yl)pyridine
DM6JNT5	MI	TTAWNKZ
DM6JNT5	MN	Norepinephrine transporter (NET)
DM6JNT5	MT	DTT
DM6JNT5	MA	Inhibitor
DM6JNT5	RN	Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7.
DM6JNT5	RU	https://pubmed.ncbi.nlm.nih.gov/20031410

DM6JNT5	DI	DM6JNT5
DM6JNT5	DN	2-phenoxy-3-(piperidin-4-yl)pyridine
DM6JNT5	MI	TT3ROYC
DM6JNT5	MN	Serotonin transporter (SERT)
DM6JNT5	MT	DTT
DM6JNT5	MA	Inhibitor
DM6JNT5	RN	Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7.
DM6JNT5	RU	https://pubmed.ncbi.nlm.nih.gov/20031410

DM5E74G	DI	DM5E74G
DM5E74G	DN	2-Phenoxymethyl-4,5-dihydro-1H-imidazole
DM5E74G	MI	TT3WG5C
DM5E74G	MN	Monoamine oxidase type A (MAO-A)
DM5E74G	MT	DTT
DM5E74G	MA	Inhibitor
DM5E74G	RN	Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9.
DM5E74G	RU	https://pubmed.ncbi.nlm.nih.gov/14698196

DM5E74G	DI	DM5E74G
DM5E74G	DN	2-Phenoxymethyl-4,5-dihydro-1H-imidazole
DM5E74G	MI	TTGP7BY
DM5E74G	MN	Monoamine oxidase type B (MAO-B)
DM5E74G	MT	DTT
DM5E74G	MA	Inhibitor
DM5E74G	RN	Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9.
DM5E74G	RU	https://pubmed.ncbi.nlm.nih.gov/14698196

DMERNSK	DI	DMERNSK
DMERNSK	DN	2-phenyl-1,1-di(pyridin-3-yl)ethanol
DMERNSK	MI	TTW0CMT
DMERNSK	MN	Voltage-gated potassium channel Kv1.5 (KCNA5)
DMERNSK	MT	DTT
DMERNSK	MA	Inhibitor
DMERNSK	RN	Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channel. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2493-6.
DMERNSK	RU	https://pubmed.ncbi.nlm.nih.gov/20304642

DM28CLZ	DI	DM28CLZ
DM28CLZ	DN	2-Phenyl-1,2-dihydro-indazol-3-one
DM28CLZ	MI	TT2J34L
DM28CLZ	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM28CLZ	MT	DTT
DM28CLZ	MA	Inhibitor
DM28CLZ	RN	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
DM28CLZ	RU	https://pubmed.ncbi.nlm.nih.gov/1848292

DM28CLZ	DI	DM28CLZ
DM28CLZ	DN	2-Phenyl-1,2-dihydro-indazol-3-one
DM28CLZ	MI	TT8NGED
DM28CLZ	MN	Prostaglandin G/H synthase 1 (COX-1)
DM28CLZ	MT	DTT
DM28CLZ	MA	Inhibitor
DM28CLZ	RN	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
DM28CLZ	RU	https://pubmed.ncbi.nlm.nih.gov/1848292

DM28CLZ	DI	DM28CLZ
DM28CLZ	DN	2-Phenyl-1,2-dihydro-indazol-3-one
DM28CLZ	MI	TTVKILB
DM28CLZ	MN	Prostaglandin G/H synthase 2 (COX-2)
DM28CLZ	MT	DTT
DM28CLZ	MA	Inhibitor
DM28CLZ	RN	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
DM28CLZ	RU	https://pubmed.ncbi.nlm.nih.gov/1848292

DMP8G3C	DI	DMP8G3C
DMP8G3C	DN	2-phenyl-1,2'-spirobi[1H-indene]-5'-ol
DMP8G3C	MI	TTZAYWL
DMP8G3C	MN	Estrogen receptor (ESR)
DMP8G3C	MT	DTT
DMP8G3C	MA	Inhibitor
DMP8G3C	RN	2-Phenylspiroindenes: a novel class of selective estrogen receptor modulators (SERMs). Bioorg Med Chem Lett. 2003 Feb 10;13(3):479-83.
DMP8G3C	RU	https://pubmed.ncbi.nlm.nih.gov/12565955

DMP8G3C	DI	DMP8G3C
DMP8G3C	DN	2-phenyl-1,2'-spirobi[1H-indene]-5'-ol
DMP8G3C	MI	TTOM3J0
DMP8G3C	MN	Estrogen receptor beta (ESR2)
DMP8G3C	MT	DTT
DMP8G3C	MA	Inhibitor
DMP8G3C	RN	2-Phenylspiroindenes: a novel class of selective estrogen receptor modulators (SERMs). Bioorg Med Chem Lett. 2003 Feb 10;13(3):479-83.
DMP8G3C	RU	https://pubmed.ncbi.nlm.nih.gov/12565955

DM3WOHI	DI	DM3WOHI
DM3WOHI	DN	2-phenyl-1,8-naphthyridine
DM3WOHI	MI	TTHS256
DM3WOHI	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM3WOHI	MT	DTT
DM3WOHI	MA	Inhibitor
DM3WOHI	RN	Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8.
DM3WOHI	RU	https://pubmed.ncbi.nlm.nih.gov/17936624

DMDC6XP	DI	DMDC6XP
DMDC6XP	DN	2-Phenyl-1H-imidazo[4,5-c]quinolin-4-ylamine
DMDC6XP	MI	TTK25J1
DMDC6XP	MN	Adenosine A1 receptor (ADORA1)
DMDC6XP	MT	DTT
DMDC6XP	MA	Inhibitor
DMDC6XP	RN	1H-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists. J Med Chem. 1991 Mar;34(3):1202-6.
DMDC6XP	RU	https://pubmed.ncbi.nlm.nih.gov/2002461

DMDC6XP	DI	DMDC6XP
DMDC6XP	DN	2-Phenyl-1H-imidazo[4,5-c]quinolin-4-ylamine
DMDC6XP	MI	TTM2AOE
DMDC6XP	MN	Adenosine A2a receptor (ADORA2A)
DMDC6XP	MT	DTT
DMDC6XP	MA	Inhibitor
DMDC6XP	RN	1H-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists. J Med Chem. 1991 Mar;34(3):1202-6.
DMDC6XP	RU	https://pubmed.ncbi.nlm.nih.gov/2002461

DMDC6XP	DI	DMDC6XP
DMDC6XP	DN	2-Phenyl-1H-imidazo[4,5-c]quinolin-4-ylamine
DMDC6XP	MI	TTNE7KG
DMDC6XP	MN	Adenosine A2b receptor (ADORA2B)
DMDC6XP	MT	DTT
DMDC6XP	MA	Inhibitor
DMDC6XP	RN	1H-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists. J Med Chem. 1991 Mar;34(3):1202-6.
DMDC6XP	RU	https://pubmed.ncbi.nlm.nih.gov/2002461

DMZI7O1	DI	DMZI7O1
DMZI7O1	DN	2-phenyl-1H-imidazole-4-carboxylic acid
DMZI7O1	MI	TTHI19T
DMZI7O1	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMZI7O1	MT	DTT
DMZI7O1	MA	Inhibitor
DMZI7O1	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMZI7O1	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMRNZ4X	DI	DMRNZ4X
DMRNZ4X	DN	2-phenyl-2,3-dihydrobenzo[h]chromen-4-one
DMRNZ4X	MI	TTSZLWK
DMRNZ4X	MN	Aromatase (CYP19A1)
DMRNZ4X	MT	DTT
DMRNZ4X	MA	Inhibitor
DMRNZ4X	RN	New 7,8-benzoflavanones as potent aromatase inhibitors: synthesis and biological evaluation. Bioorg Med Chem. 2008 Feb 1;16(3):1474-80.
DMRNZ4X	RU	https://pubmed.ncbi.nlm.nih.gov/18042388

DMTSBJL	DI	DMTSBJL
DMTSBJL	DN	2-phenyl-2H-benzo[d][1,2,3]triazole-4-carboxamide
DMTSBJL	MI	TTVDSZ0
DMTSBJL	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMTSBJL	MT	DTT
DMTSBJL	MA	Inhibitor
DMTSBJL	RN	Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor effica... J Med Chem. 2009 Nov 26;52(22):7170-85.
DMTSBJL	RU	https://pubmed.ncbi.nlm.nih.gov/19873981

DM8HSMU	DI	DM8HSMU
DM8HSMU	DN	2-phenyl-2H-indazole-7-carboxamide
DM8HSMU	MI	TTVDSZ0
DM8HSMU	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DM8HSMU	MT	DTT
DM8HSMU	MA	Inhibitor
DM8HSMU	RN	Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor effica... J Med Chem. 2009 Nov 26;52(22):7170-85.
DM8HSMU	RU	https://pubmed.ncbi.nlm.nih.gov/19873981

DMFE2R1	DI	DMFE2R1
DMFE2R1	DN	2-phenyl-2H-pyrazolo[3,4-c]quinolin-4(5H)-one
DMFE2R1	MI	TTK25J1
DMFE2R1	MN	Adenosine A1 receptor (ADORA1)
DMFE2R1	MT	DTT
DMFE2R1	MA	Inhibitor
DMFE2R1	RN	New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluati... J Med Chem. 2007 Aug 23;50(17):4061-74.
DMFE2R1	RU	https://pubmed.ncbi.nlm.nih.gov/17665891

DM5WOSM	DI	DM5WOSM
DM5WOSM	DN	2-phenyl-2H-pyrazolo[3,4-c]quinolin-4-amine
DM5WOSM	MI	TTK25J1
DM5WOSM	MN	Adenosine A1 receptor (ADORA1)
DM5WOSM	MT	DTT
DM5WOSM	MA	Inhibitor
DM5WOSM	RN	New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluati... J Med Chem. 2007 Aug 23;50(17):4061-74.
DM5WOSM	RU	https://pubmed.ncbi.nlm.nih.gov/17665891

DM5WOSM	DI	DM5WOSM
DM5WOSM	DN	2-phenyl-2H-pyrazolo[3,4-c]quinolin-4-amine
DM5WOSM	MI	TTM2AOE
DM5WOSM	MN	Adenosine A2a receptor (ADORA2A)
DM5WOSM	MT	DTT
DM5WOSM	MA	Inhibitor
DM5WOSM	RN	New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluati... J Med Chem. 2007 Aug 23;50(17):4061-74.
DM5WOSM	RU	https://pubmed.ncbi.nlm.nih.gov/17665891

DMAHI7G	DI	DMAHI7G
DMAHI7G	DN	2-Phenyl-2H-pyrazolo[4,3-c]quinoline
DMAHI7G	MI	TTJFY5U
DMAHI7G	MN	Adenosine A3 receptor (ADORA3)
DMAHI7G	MT	DTT
DMAHI7G	MA	Inhibitor
DMAHI7G	RN	New 2-arylpyrazolo[4,3-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. J Med Chem. 2005 Jul 28;48(15):5001-8.
DMAHI7G	RU	https://pubmed.ncbi.nlm.nih.gov/16033279

DMQXCIK	DI	DMQXCIK
DMQXCIK	DN	2-phenyl-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one
DMQXCIK	MI	TTJFY5U
DMQXCIK	MN	Adenosine A3 receptor (ADORA3)
DMQXCIK	MT	DTT
DMQXCIK	MA	Inhibitor
DMQXCIK	RN	2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into ... J Med Chem. 2009 Dec 10;52(23):7640-52.
DMQXCIK	RU	https://pubmed.ncbi.nlm.nih.gov/19743865

DMNXI6D	DI	DMNXI6D
DMNXI6D	DN	2-Phenyl-3-(1-phenyl-ethoxy)-piperidine
DMNXI6D	MI	TTZPO1L
DMNXI6D	MN	Substance-P receptor (TACR1)
DMNXI6D	MT	DTT
DMNXI6D	MA	Inhibitor
DMNXI6D	RN	3-Benzyloxy-2-phenylpiperidine NK1 antagonists: the influence of alpha methyl substitution, Bioorg. Med. Chem. Lett. 7(23):2959-2962 (1997).
DMNXI6D	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97101184

DM5YC2K	DI	DM5YC2K
DM5YC2K	DN	2-Phenyl-3-(2-piperidin-1-yl-ethyl)-1H-indole
DM5YC2K	MI	TTJQOD7
DM5YC2K	MN	5-HT 2A receptor (HTR2A)
DM5YC2K	MT	DTT
DM5YC2K	MA	Inhibitor
DM5YC2K	RN	3-(4-Piperidinyl)- and 3-(8-aza-bicyclo[3.2.1]oct-3-yl)-2-phenyl-1H-indoles as bioavailable h5-HT2A antagonists. Bioorg Med Chem Lett. 2000 Dec 18;10(24):2701-3.
DM5YC2K	RU	https://pubmed.ncbi.nlm.nih.gov/11133072

DML9DJP	DI	DML9DJP
DML9DJP	DN	2-Phenyl-3H-imidazo[4,5-c]quinoline
DML9DJP	MI	TT1MPAY
DML9DJP	MN	GABA(A) receptor alpha-1 (GABRA1)
DML9DJP	MT	DTT
DML9DJP	MA	Inhibitor
DML9DJP	RN	Synthesis and structure--activity relationships of fused imidazopyridines: a new series of benzodiazepine receptor ligands. J Med Chem. 1996 Jul 5;39(14):2844-51.
DML9DJP	RU	https://pubmed.ncbi.nlm.nih.gov/8709114

DML9DJP	DI	DML9DJP
DML9DJP	DN	2-Phenyl-3H-imidazo[4,5-c]quinoline
DML9DJP	MI	TTNJYV2
DML9DJP	MN	Gamma-aminobutyric acid receptor (GAR)
DML9DJP	MT	DTT
DML9DJP	MA	Inhibitor
DML9DJP	RN	Synthesis and structure--activity relationships of fused imidazopyridines: a new series of benzodiazepine receptor ligands. J Med Chem. 1996 Jul 5;39(14):2844-51.
DML9DJP	RU	https://pubmed.ncbi.nlm.nih.gov/8709114

DMY6NIT	DI	DMY6NIT
DMY6NIT	DN	2-Phenyl-3-piperidin-3-yl-1H-indole
DMY6NIT	MI	TTQ6VDM
DMY6NIT	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMY6NIT	MT	DTT
DMY6NIT	MA	Inhibitor
DMY6NIT	RN	3-(4-Fluoropiperidin-3-yl)-2-phenylindoles as high affinity, selective, and orally bioavailable h5-HT(2A) receptor antagonists. J Med Chem. 2001 May 10;44(10):1603-14.
DMY6NIT	RU	https://pubmed.ncbi.nlm.nih.gov/11334570

DMEXZQ5	DI	DMEXZQ5
DMEXZQ5	DN	2-Phenyl-3-piperidin-4-yl-1H-indole
DMEXZQ5	MI	TTJQOD7
DMEXZQ5	MN	5-HT 2A receptor (HTR2A)
DMEXZQ5	MT	DTT
DMEXZQ5	MA	Inhibitor
DMEXZQ5	RN	3-(4-Piperidinyl)- and 3-(8-aza-bicyclo[3.2.1]oct-3-yl)-2-phenyl-1H-indoles as bioavailable h5-HT2A antagonists. Bioorg Med Chem Lett. 2000 Dec 18;10(24):2701-3.
DMEXZQ5	RU	https://pubmed.ncbi.nlm.nih.gov/11133072

DMEXZQ5	DI	DMEXZQ5
DMEXZQ5	DN	2-Phenyl-3-piperidin-4-yl-1H-indole
DMEXZQ5	MI	TTQ6VDM
DMEXZQ5	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMEXZQ5	MT	DTT
DMEXZQ5	MA	Inhibitor
DMEXZQ5	RN	3-(4-Fluoropiperidin-3-yl)-2-phenylindoles as high affinity, selective, and orally bioavailable h5-HT(2A) receptor antagonists. J Med Chem. 2001 May 10;44(10):1603-14.
DMEXZQ5	RU	https://pubmed.ncbi.nlm.nih.gov/11334570

DMKCOS2	DI	DMKCOS2
DMKCOS2	DN	2-Phenyl-3-pyridin-4-ylmethylene-chroman-4-one
DMKCOS2	MI	TTSZLWK
DMKCOS2	MN	Aromatase (CYP19A1)
DMKCOS2	MT	DTT
DMKCOS2	MA	Inhibitor
DMKCOS2	RN	New aromatase inhibitors. Synthesis and inhibitory activity of pyridinyl-substituted flavanone derivatives. Bioorg Med Chem Lett. 2002 Apr 8;12(7):1059-61.
DMKCOS2	RU	https://pubmed.ncbi.nlm.nih.gov/11909717

DMEXYSP	DI	DMEXYSP
DMEXYSP	DN	2-Phenyl-4-[1,2,4]triazol-1-yl-chroman-7-ol
DMEXYSP	MI	TTSZLWK
DMEXYSP	MN	Aromatase (CYP19A1)
DMEXYSP	MT	DTT
DMEXYSP	MA	Inhibitor
DMEXYSP	RN	Synthesis and evaluation of 4-triazolylflavans as new aromatase inhibitors. Bioorg Med Chem Lett. 2004 Oct 18;14(20):5215-8.
DMEXYSP	RU	https://pubmed.ncbi.nlm.nih.gov/15380230

DM7A3GO	DI	DM7A3GO
DM7A3GO	DN	2-Phenyl-5-(2-methylthiazol-4ylethynyl)pyridine
DM7A3GO	MI	TTHS256
DM7A3GO	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM7A3GO	MT	DTT
DM7A3GO	MA	Inhibitor
DM7A3GO	RN	Structure-activity relationships comparing N-(6-methylpyridin-yl)-substituted aryl amides to 2-methyl-6-(substituted-arylethynyl)pyridines or 2-met... J Med Chem. 2009 Jun 11;52(11):3563-75.
DM7A3GO	RU	https://pubmed.ncbi.nlm.nih.gov/19445453

DMUIYZB	DI	DMUIYZB
DMUIYZB	DN	2-Phenyl-5,6-dihydro-pyrazolo[1,5-c]quinazoline
DMUIYZB	MI	TT1MPAY
DMUIYZB	MN	GABA(A) receptor alpha-1 (GABRA1)
DMUIYZB	MT	DTT
DMUIYZB	MA	Inhibitor
DMUIYZB	RN	Synthesis and binding activity of some pyrazolo[1,5-c]quinazolines as tools to verify an optional binding site of a benzodiazepine receptor ligand. J Med Chem. 1996 Jul 19;39(15):2915-21.
DMUIYZB	RU	https://pubmed.ncbi.nlm.nih.gov/8709126

DMUIYZB	DI	DMUIYZB
DMUIYZB	DN	2-Phenyl-5,6-dihydro-pyrazolo[1,5-c]quinazoline
DMUIYZB	MI	TTNJYV2
DMUIYZB	MN	Gamma-aminobutyric acid receptor (GAR)
DMUIYZB	MT	DTT
DMUIYZB	MA	Inhibitor
DMUIYZB	RN	Synthesis and binding activity of some pyrazolo[1,5-c]quinazolines as tools to verify an optional binding site of a benzodiazepine receptor ligand. J Med Chem. 1996 Jul 19;39(15):2915-21.
DMUIYZB	RU	https://pubmed.ncbi.nlm.nih.gov/8709126

DMMDS2T	DI	DMMDS2T
DMMDS2T	DN	2-phenyl-5H-indeno[1,2-d]pyrimidine
DMMDS2T	MI	TT3WG5C
DMMDS2T	MN	Monoamine oxidase type A (MAO-A)
DMMDS2T	MT	DTT
DMMDS2T	MA	Inhibitor
DMMDS2T	RN	Synthesis and monoamine oxidase inhibitory activity of new pyridazine-, pyrimidine- and 1,2,4-triazine-containing tricyclic derivatives. J Med Chem. 2007 Nov 1;50(22):5364-71.
DMMDS2T	RU	https://pubmed.ncbi.nlm.nih.gov/17910428

DMA1RHE	DI	DMA1RHE
DMA1RHE	DN	2-Phenyl-6H-pyrazolo[1,5-c]quinazolin-5-one
DMA1RHE	MI	TT1MPAY
DMA1RHE	MN	GABA(A) receptor alpha-1 (GABRA1)
DMA1RHE	MT	DTT
DMA1RHE	MA	Inhibitor
DMA1RHE	RN	Synthesis and binding activity of some pyrazolo[1,5-c]quinazolines as tools to verify an optional binding site of a benzodiazepine receptor ligand. J Med Chem. 1996 Jul 19;39(15):2915-21.
DMA1RHE	RU	https://pubmed.ncbi.nlm.nih.gov/8709126

DMA1RHE	DI	DMA1RHE
DMA1RHE	DN	2-Phenyl-6H-pyrazolo[1,5-c]quinazolin-5-one
DMA1RHE	MI	TTNJYV2
DMA1RHE	MN	Gamma-aminobutyric acid receptor (GAR)
DMA1RHE	MT	DTT
DMA1RHE	MA	Inhibitor
DMA1RHE	RN	Synthesis and binding activity of some pyrazolo[1,5-c]quinazolines as tools to verify an optional binding site of a benzodiazepine receptor ligand. J Med Chem. 1996 Jul 19;39(15):2915-21.
DMA1RHE	RU	https://pubmed.ncbi.nlm.nih.gov/8709126

DMY9ERA	DI	DMY9ERA
DMY9ERA	DN	2-Phenyl-6-propyl-chromen-4-one
DMY9ERA	MI	TTNJYV2
DMY9ERA	MN	Gamma-aminobutyric acid receptor (GAR)
DMY9ERA	MT	DTT
DMY9ERA	MA	Inhibitor
DMY9ERA	RN	Refinement and evaluation of a pharmacophore model for flavone derivatives binding to the benzodiazepine site of the GABA(A) receptor. J Med Chem. 2002 Sep 12;45(19):4188-201.
DMY9ERA	RU	https://pubmed.ncbi.nlm.nih.gov/12213060

DMMHSYV	DI	DMMHSYV
DMMHSYV	DN	2-phenyl-9H-indeno[2,1-d]pyrimidine
DMMHSYV	MI	TT3WG5C
DMMHSYV	MN	Monoamine oxidase type A (MAO-A)
DMMHSYV	MT	DTT
DMMHSYV	MA	Inhibitor
DMMHSYV	RN	Synthesis and monoamine oxidase inhibitory activity of new pyridazine-, pyrimidine- and 1,2,4-triazine-containing tricyclic derivatives. J Med Chem. 2007 Nov 1;50(22):5364-71.
DMMHSYV	RU	https://pubmed.ncbi.nlm.nih.gov/17910428

DMMHSYV	DI	DMMHSYV
DMMHSYV	DN	2-phenyl-9H-indeno[2,1-d]pyrimidine
DMMHSYV	MI	TTGP7BY
DMMHSYV	MN	Monoamine oxidase type B (MAO-B)
DMMHSYV	MT	DTT
DMMHSYV	MA	Inhibitor
DMMHSYV	RN	Synthesis and monoamine oxidase inhibitory activity of new pyridazine-, pyrimidine- and 1,2,4-triazine-containing tricyclic derivatives. J Med Chem. 2007 Nov 1;50(22):5364-71.
DMMHSYV	RU	https://pubmed.ncbi.nlm.nih.gov/17910428

DM60AJ2	DI	DM60AJ2
DM60AJ2	DN	2-PHENYLAMINO-4-METHYL-5-ACETYL THIAZOLE
DM60AJ2	MI	TTPH97Y
DM60AJ2	MN	Mycobacterium 3-oxoacyl-[acyl-carrier-protein] synthase 1 (MycB kasA)
DM60AJ2	MT	DTT
DM60AJ2	MA	Inhibitor
DM60AJ2	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM60AJ2	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMW0M14	DI	DMW0M14
DMW0M14	DN	2-phenylamino-9-(4-hydroxy-butyl)-6-oxopurine
DMW0M14	MI	TTP3QRF
DMW0M14	MN	Thymidine kinase 1 (TK1)
DMW0M14	MT	DTT
DMW0M14	MA	Inhibitor
DMW0M14	RN	Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate anal... Antimicrob Agents Chemother. 2007 Jun;51(6):2028-34.
DMW0M14	RU	https://pubmed.ncbi.nlm.nih.gov/17438061

DMUGH6J	DI	DMUGH6J
DMUGH6J	DN	2-Phenyl-cyclopropylamine hydrochloride
DMUGH6J	MI	TTGP7BY
DMUGH6J	MN	Monoamine oxidase type B (MAO-B)
DMUGH6J	MT	DTT
DMUGH6J	MA	Inhibitor
DMUGH6J	RN	Fluorinated phenylcyclopropylamines. 2. Effects of aromatic ring substitution and of absolute configuration on inhibition of microbial tyramine oxi... J Med Chem. 2004 Nov 18;47(24):5860-71.
DMUGH6J	RU	https://pubmed.ncbi.nlm.nih.gov/15537343

DMW3F5C	DI	DMW3F5C
DMW3F5C	DN	2-phenylethylyl-adenosine derivative
DMW3F5C	MI	TTJFY5U
DMW3F5C	MN	Adenosine A3 receptor (ADORA3)
DMW3F5C	MT	DTT
DMW3F5C	MA	Agonist
DMW3F5C	RN	Synthesis and biological evaluation of 2-alkynyl-N6-methyl-5'-N-methylcarboxamidoadenosine derivatives as potent and highly selective agonists for the human adenosine A3 receptor. J Med Chem. 2009 Dec 10;52(23):7897-900.
DMW3F5C	RU	https://pubmed.ncbi.nlm.nih.gov/19839592

DMNYOH5	DI	DMNYOH5
DMNYOH5	DN	2-phenylethynyl-5,6,7,8-tetrahydro-quinolin-5-ol
DMNYOH5	MI	TTHS256
DMNYOH5	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMNYOH5	MT	DTT
DMNYOH5	MA	Inhibitor
DMNYOH5	RN	Positive and negative modulation of group I metabotropic glutamate receptors. J Med Chem. 2008 Feb 14;51(3):634-47.
DMNYOH5	RU	https://pubmed.ncbi.nlm.nih.gov/18173231

DM4LCRS	DI	DM4LCRS
DM4LCRS	DN	2-phenylethynyl-5,6,7,8-tetrahydro-quinoline
DM4LCRS	MI	TTHS256
DM4LCRS	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM4LCRS	MT	DTT
DM4LCRS	MA	Inhibitor
DM4LCRS	RN	Positive and negative modulation of group I metabotropic glutamate receptors. J Med Chem. 2008 Feb 14;51(3):634-47.
DM4LCRS	RU	https://pubmed.ncbi.nlm.nih.gov/18173231

DMFRQJ3	DI	DMFRQJ3
DMFRQJ3	DN	2-phenylethynyl-7,8-dihydro-6H-quinolin-5-one
DMFRQJ3	MI	TTHS256
DMFRQJ3	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMFRQJ3	MT	DTT
DMFRQJ3	MA	Inhibitor
DMFRQJ3	RN	Positive and negative modulation of group I metabotropic glutamate receptors. J Med Chem. 2008 Feb 14;51(3):634-47.
DMFRQJ3	RU	https://pubmed.ncbi.nlm.nih.gov/18173231

DMPIQTE	DI	DMPIQTE
DMPIQTE	DN	2-Phenylheme
DMPIQTE	MI	TTI6V2A
DMPIQTE	MN	Heme oxygenase 1 (HMOX1)
DMPIQTE	MT	DTT
DMPIQTE	MA	Inhibitor
DMPIQTE	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMPIQTE	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMFC3B5	DI	DMFC3B5
DMFC3B5	DN	2-phenyl-N-(1,3,4-thiadiazol-2-yl)acetamide
DMFC3B5	MI	TTSJ6Q4
DMFC3B5	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DMFC3B5	MT	DTT
DMFC3B5	MA	Inhibitor
DMFC3B5	RN	Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. J Med Chem. 2007 May 31;50(11):2640-6.
DMFC3B5	RU	https://pubmed.ncbi.nlm.nih.gov/17461565

DMNOE0V	DI	DMNOE0V
DMNOE0V	DN	2-phenyl-N-(1-phenylethyl)quinoline-4-carboxamide
DMNOE0V	MI	TTBPGLU
DMNOE0V	MN	Neuromedin-K receptor (TACR3)
DMNOE0V	MT	DTT
DMNOE0V	MA	Inhibitor
DMNOE0V	RN	Virtual screening to identify novel antagonists for the G protein-coupled NK3 receptor. J Med Chem. 2010 Nov 25;53(22):8080-8.
DMNOE0V	RU	https://pubmed.ncbi.nlm.nih.gov/21047106

DMEFOV6	DI	DMEFOV6
DMEFOV6	DN	2-phenyl-N-(pyridin-4-yl)quinazolin-4-amine
DMEFOV6	MI	TTP4520
DMEFOV6	MN	TGF-beta receptor type I (TGFBR1)
DMEFOV6	MT	DTT
DMEFOV6	MA	Inhibitor
DMEFOV6	RN	Design of novel quinazoline derivatives and related analogues as potent and selective ALK5 inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2277-81.
DMEFOV6	RU	https://pubmed.ncbi.nlm.nih.gov/19285388

DMP0NW3	DI	DMP0NW3
DMP0NW3	DN	2-phenyl-N-(thiazol-2-yl)acetamide
DMP0NW3	MI	TTSJ6Q4
DMP0NW3	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DMP0NW3	MT	DTT
DMP0NW3	MA	Inhibitor
DMP0NW3	RN	Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. J Med Chem. 2007 May 31;50(11):2640-6.
DMP0NW3	RU	https://pubmed.ncbi.nlm.nih.gov/17461565

DMMJENF	DI	DMMJENF
DMMJENF	DN	2-phenyl-N,N-bis(o-tolylthiomethyl)ethanamine
DMMJENF	MI	TTX4RTB
DMMJENF	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMMJENF	MT	DTT
DMMJENF	MA	Inhibitor
DMMJENF	RN	Discovery of novel chemotypes to a G-protein-coupled receptor through ligand-steered homology modeling and structure-based virtual screening. J Med Chem. 2008 Feb 14;51(3):581-8.
DMMJENF	RU	https://pubmed.ncbi.nlm.nih.gov/18198821

DM7OHSX	DI	DM7OHSX
DM7OHSX	DN	2-phenylpiperidine hydrochloride
DM7OHSX	MI	TTVBI8W
DM7OHSX	MN	Dopamine transporter (DAT)
DM7OHSX	MT	DTT
DM7OHSX	MA	Inhibitor
DM7OHSX	RN	Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31.
DM7OHSX	RU	https://pubmed.ncbi.nlm.nih.gov/17489581

DMZQCEP	DI	DMZQCEP
DMZQCEP	DN	2-phenylpropoxyadenosine
DMZQCEP	MI	TTK25J1
DMZQCEP	MN	Adenosine A1 receptor (ADORA1)
DMZQCEP	MT	DTT
DMZQCEP	MA	Inhibitor
DMZQCEP	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DMZQCEP	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DMZQCEP	DI	DMZQCEP
DMZQCEP	DN	2-phenylpropoxyadenosine
DMZQCEP	MI	TTM2AOE
DMZQCEP	MN	Adenosine A2a receptor (ADORA2A)
DMZQCEP	MT	DTT
DMZQCEP	MA	Inhibitor
DMZQCEP	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DMZQCEP	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DMZQCEP	DI	DMZQCEP
DMZQCEP	DN	2-phenylpropoxyadenosine
DMZQCEP	MI	TTJFY5U
DMZQCEP	MN	Adenosine A3 receptor (ADORA3)
DMZQCEP	MT	DTT
DMZQCEP	MA	Inhibitor
DMZQCEP	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DMZQCEP	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DM64JE8	DI	DM64JE8
DM64JE8	DN	2-phenylpyrazolo-[1,5-a]pyridine-7-carboxamide
DM64JE8	MI	TTVDSZ0
DM64JE8	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DM64JE8	MT	DTT
DM64JE8	MA	Inhibitor
DM64JE8	RN	Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor effica... J Med Chem. 2009 Nov 26;52(22):7170-85.
DM64JE8	RU	https://pubmed.ncbi.nlm.nih.gov/19873981

DMAENRQ	DI	DMAENRQ
DMAENRQ	DN	2-phenylquinoline-8-carboxamide
DMAENRQ	MI	TTVDSZ0
DMAENRQ	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMAENRQ	MT	DTT
DMAENRQ	MA	Inhibitor
DMAENRQ	RN	Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhi... J Med Chem. 2009 Feb 12;52(3):868-77.
DMAENRQ	RU	https://pubmed.ncbi.nlm.nih.gov/19117416

DMX6GH5	DI	DMX6GH5
DMX6GH5	DN	2-Phosphoglyceric Acid
DMX6GH5	MI	TTVNA43
DMX6GH5	MN	Bacterial Deoxy-D-manno-octulosonate 8-phosphate synthase (Bact kdsA)
DMX6GH5	MT	DTT
DMX6GH5	MA	Inhibitor
DMX6GH5	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMX6GH5	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMX6GH5	DI	DMX6GH5
DMX6GH5	DN	2-Phosphoglyceric Acid
DMX6GH5	MI	TTNS6X4
DMX6GH5	MN	Bacterial Triosephosphate isomerase (Bact TPI)
DMX6GH5	MT	DTT
DMX6GH5	MA	Inhibitor
DMX6GH5	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMX6GH5	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMX6GH5	DI	DMX6GH5
DMX6GH5	DN	2-Phosphoglyceric Acid
DMX6GH5	MI	TTHJWVK
DMX6GH5	MN	Mycobacterium Bisphosphoglycerate phosphoglycerate mutase (MycB gpmI)
DMX6GH5	MT	DTT
DMX6GH5	MA	Inhibitor
DMX6GH5	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMX6GH5	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMO14NH	DI	DMO14NH
DMO14NH	DN	2-Phosphoglycolic Acid
DMO14NH	MI	TTNS6X4
DMO14NH	MN	Bacterial Triosephosphate isomerase (Bact TPI)
DMO14NH	MT	DTT
DMO14NH	MA	Inhibitor
DMO14NH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMO14NH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMM05AO	DI	DMM05AO
DMM05AO	DN	2-Phosphonooxy-pentanedioic acid
DMM05AO	MI	TT9G4N0
DMM05AO	MN	Glutamate carboxypeptidase II (GCPII)
DMM05AO	MT	DTT
DMM05AO	MA	Inhibitor
DMM05AO	RN	Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. J Med Chem. 2003 May 8;46(10):1989-96.
DMM05AO	RU	https://pubmed.ncbi.nlm.nih.gov/12723961

DM742IJ	DI	DM742IJ
DM742IJ	DN	2-Piperazin-1-yl-benzonitrile
DM742IJ	MI	TTSQIFT
DM742IJ	MN	5-HT 1A receptor (HTR1A)
DM742IJ	MT	DTT
DM742IJ	MA	Inhibitor
DM742IJ	RN	Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. J Med Chem. 1989 May;32(5):1052-6.
DM742IJ	RU	https://pubmed.ncbi.nlm.nih.gov/2565400

DM742IJ	DI	DM742IJ
DM742IJ	DN	2-Piperazin-1-yl-benzonitrile
DM742IJ	MI	TT6MSOK
DM742IJ	MN	5-HT 1D receptor (HTR1D)
DM742IJ	MT	DTT
DM742IJ	MA	Inhibitor
DM742IJ	RN	Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. J Med Chem. 1989 May;32(5):1052-6.
DM742IJ	RU	https://pubmed.ncbi.nlm.nih.gov/2565400

DMQT9OK	DI	DMQT9OK
DMQT9OK	DN	2-Piperazin-1-yl-phenol
DMQT9OK	MI	TTSQIFT
DMQT9OK	MN	5-HT 1A receptor (HTR1A)
DMQT9OK	MT	DTT
DMQT9OK	MA	Inhibitor
DMQT9OK	RN	Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents. J Med Chem. 1986 May;29(5):630-4.
DMQT9OK	RU	https://pubmed.ncbi.nlm.nih.gov/3701781

DMQT9OK	DI	DMQT9OK
DMQT9OK	DN	2-Piperazin-1-yl-phenol
DMQT9OK	MI	TT6MSOK
DMQT9OK	MN	5-HT 1D receptor (HTR1D)
DMQT9OK	MT	DTT
DMQT9OK	MA	Inhibitor
DMQT9OK	RN	Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents. J Med Chem. 1986 May;29(5):630-4.
DMQT9OK	RU	https://pubmed.ncbi.nlm.nih.gov/3701781

DMQT9OK	DI	DMQT9OK
DMQT9OK	DN	2-Piperazin-1-yl-phenol
DMQT9OK	MI	TTJQOD7
DMQT9OK	MN	5-HT 2A receptor (HTR2A)
DMQT9OK	MT	DTT
DMQT9OK	MA	Inhibitor
DMQT9OK	RN	Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents. J Med Chem. 1986 May;29(5):630-4.
DMQT9OK	RU	https://pubmed.ncbi.nlm.nih.gov/3701781

DM27GZC	DI	DM27GZC
DM27GZC	DN	2-PMPA
DM27GZC	MI	TT9G4N0
DM27GZC	MN	Glutamate carboxypeptidase II (GCPII)
DM27GZC	MT	DTT
DM27GZC	MA	Inhibitor
DM27GZC	RN	Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat Med. 1999 Dec;5(12):1396-402.
DM27GZC	RU	https://pubmed.ncbi.nlm.nih.gov/10581082

DML5O0H	DI	DML5O0H
DML5O0H	DN	2-Propanol, Isopropanol
DML5O0H	MI	TTE2KUJ
DML5O0H	MN	Adenosylhomocysteinase (AHCY)
DML5O0H	MT	DTT
DML5O0H	MA	Inhibitor
DML5O0H	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DML5O0H	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DML5O0H	DI	DML5O0H
DML5O0H	DN	2-Propanol, Isopropanol
DML5O0H	MI	TTO8QRU
DML5O0H	MN	Group IIA phospholipase A2 (GIIA sPLA2)
DML5O0H	MT	DTT
DML5O0H	MA	Inhibitor
DML5O0H	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DML5O0H	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DML5O0H	DI	DML5O0H
DML5O0H	DN	2-Propanol, Isopropanol
DML5O0H	MI	TTLSWP6
DML5O0H	MN	GTP cyclohydrolase-I (GCH1)
DML5O0H	MT	DTT
DML5O0H	MA	Inhibitor
DML5O0H	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DML5O0H	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DML5O0H	DI	DML5O0H
DML5O0H	DN	2-Propanol, Isopropanol
DML5O0H	MI	TTI6V2A
DML5O0H	MN	Heme oxygenase 1 (HMOX1)
DML5O0H	MT	DTT
DML5O0H	MA	Inhibitor
DML5O0H	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DML5O0H	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DML5O0H	DI	DML5O0H
DML5O0H	DN	2-Propanol, Isopropanol
DML5O0H	MI	TTCM4B3
DML5O0H	MN	Nitric-oxide synthase endothelial (NOS3)
DML5O0H	MT	DTT
DML5O0H	MA	Inhibitor
DML5O0H	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DML5O0H	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DML5O0H	DI	DML5O0H
DML5O0H	DN	2-Propanol, Isopropanol
DML5O0H	MI	TTXA6PH
DML5O0H	MN	Oxysterols receptor LXR-beta (NR1H2)
DML5O0H	MT	DTT
DML5O0H	MA	Inhibitor
DML5O0H	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DML5O0H	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DML5O0H	DI	DML5O0H
DML5O0H	DN	2-Propanol, Isopropanol
DML5O0H	MI	TTF8CQI
DML5O0H	MN	Tumor necrosis factor (TNF)
DML5O0H	MT	DTT
DML5O0H	MA	Inhibitor
DML5O0H	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DML5O0H	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMORG3D	DI	DMORG3D
DMORG3D	DN	2-Propionyl-1H-indole-6-carboxamidine
DMORG3D	MI	TT2WR1T
DMORG3D	MN	Cationic trypsinogen (PRSS1)
DMORG3D	MT	DTT
DMORG3D	MA	Inhibitor
DMORG3D	RN	Aromatic amidines: comparison of their ability to block respiratory syncytial virus induced cell fusion and to inhibit plasmin, urokinase, thrombin... J Med Chem. 1983 Feb;26(2):294-8.
DMORG3D	RU	https://pubmed.ncbi.nlm.nih.gov/6219223

DMP8J7E	DI	DMP8J7E
DMP8J7E	DN	2-Propionyl-cyclohexane-1,3-dione
DMP8J7E	MI	TT8DSFC
DMP8J7E	MN	Hydroxyphenylpyruvate dioxygenase (HPD)
DMP8J7E	MT	DTT
DMP8J7E	MA	Inhibitor
DMP8J7E	RN	SAR studies of 2-o-substituted-benzoyl- and 2-alkanoyl-cyclohexane-1,3-diones as inhibitors of 4-hydroxyphenylpyruvate dioxygenase. Bioorg Med Chem Lett. 2000 May 1;10(9):843-5.
DMP8J7E	RU	https://pubmed.ncbi.nlm.nih.gov/10853644

DMG0I25	DI	DMG0I25
DMG0I25	DN	2-propylamido-5-sulfonamidoindane
DMG0I25	MI	TTHQPL7
DMG0I25	MN	Carbonic anhydrase I (CA-I)
DMG0I25	MT	DTT
DMG0I25	MA	Inhibitor
DMG0I25	RN	Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9.
DMG0I25	RU	https://pubmed.ncbi.nlm.nih.gov/16640335

DMG0I25	DI	DMG0I25
DMG0I25	DN	2-propylamido-5-sulfonamidoindane
DMG0I25	MI	TTANPDJ
DMG0I25	MN	Carbonic anhydrase II (CA-II)
DMG0I25	MT	DTT
DMG0I25	MA	Inhibitor
DMG0I25	RN	Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9.
DMG0I25	RU	https://pubmed.ncbi.nlm.nih.gov/16640335

DMG0I25	DI	DMG0I25
DMG0I25	DN	2-propylamido-5-sulfonamidoindane
DMG0I25	MI	TT2LVK8
DMG0I25	MN	Carbonic anhydrase IX (CA-IX)
DMG0I25	MT	DTT
DMG0I25	MA	Inhibitor
DMG0I25	RN	Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9.
DMG0I25	RU	https://pubmed.ncbi.nlm.nih.gov/16640335

DMBW6GA	DI	DMBW6GA
DMBW6GA	DN	2-Propyl-beta-carboline-2-ium iodide
DMBW6GA	MI	TT1RS9F
DMBW6GA	MN	Acetylcholinesterase (AChE)
DMBW6GA	MT	DTT
DMBW6GA	MA	Inhibitor
DMBW6GA	RN	Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents. J Med Chem. 2010 May 13;53(9):3611-7.
DMBW6GA	RU	https://pubmed.ncbi.nlm.nih.gov/20361801

DMBW6GA	DI	DMBW6GA
DMBW6GA	DN	2-Propyl-beta-carboline-2-ium iodide
DMBW6GA	MI	TTEB0GD
DMBW6GA	MN	Cholinesterase (BCHE)
DMBW6GA	MT	DTT
DMBW6GA	MA	Inhibitor
DMBW6GA	RN	Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents. J Med Chem. 2010 May 13;53(9):3611-7.
DMBW6GA	RU	https://pubmed.ncbi.nlm.nih.gov/20361801

DM1L7PN	DI	DM1L7PN
DM1L7PN	DN	2-Propyl-pentanoic acid 4-sulfamoyl-benzyl ester
DM1L7PN	MI	TTZHA0O
DM1L7PN	MN	Carbonic anhydrase IV (CA-IV)
DM1L7PN	MT	DTT
DM1L7PN	MA	Inhibitor
DM1L7PN	RN	Carbonic anhydrase inhibitors: anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties. J Med Chem. 2002 Jan 17;45(2):312-20.
DM1L7PN	RU	https://pubmed.ncbi.nlm.nih.gov/11784136

DMVWUME	DI	DMVWUME
DMVWUME	DN	2-Propyl-pentanoic acid 4-sulfamoyl-benzylamide
DMVWUME	MI	TTZHA0O
DMVWUME	MN	Carbonic anhydrase IV (CA-IV)
DMVWUME	MT	DTT
DMVWUME	MA	Inhibitor
DMVWUME	RN	Carbonic anhydrase inhibitors: anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties. J Med Chem. 2002 Jan 17;45(2):312-20.
DMVWUME	RU	https://pubmed.ncbi.nlm.nih.gov/11784136

DM1NK2M	DI	DM1NK2M
DM1NK2M	DN	2-p-tolyl-2H-pyrazolo[3,4-c]quinolin-4(5H)-one
DM1NK2M	MI	TTK25J1
DM1NK2M	MN	Adenosine A1 receptor (ADORA1)
DM1NK2M	MT	DTT
DM1NK2M	MA	Inhibitor
DM1NK2M	RN	New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluati... J Med Chem. 2007 Aug 23;50(17):4061-74.
DM1NK2M	RU	https://pubmed.ncbi.nlm.nih.gov/17665891

DM9MIC5	DI	DM9MIC5
DM9MIC5	DN	2-p-tolyl-2H-pyrazolo[3,4-c]quinolin-4-amine
DM9MIC5	MI	TTK25J1
DM9MIC5	MN	Adenosine A1 receptor (ADORA1)
DM9MIC5	MT	DTT
DM9MIC5	MA	Inhibitor
DM9MIC5	RN	New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluati... J Med Chem. 2007 Aug 23;50(17):4061-74.
DM9MIC5	RU	https://pubmed.ncbi.nlm.nih.gov/17665891

DM9MIC5	DI	DM9MIC5
DM9MIC5	DN	2-p-tolyl-2H-pyrazolo[3,4-c]quinolin-4-amine
DM9MIC5	MI	TTM2AOE
DM9MIC5	MN	Adenosine A2a receptor (ADORA2A)
DM9MIC5	MT	DTT
DM9MIC5	MA	Inhibitor
DM9MIC5	RN	New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluati... J Med Chem. 2007 Aug 23;50(17):4061-74.
DM9MIC5	RU	https://pubmed.ncbi.nlm.nih.gov/17665891

DM37S5C	DI	DM37S5C
DM37S5C	DN	2-p-tolyl-4,5-dihydro-1H-imidazole
DM37S5C	MI	TTGP7BY
DM37S5C	MN	Monoamine oxidase type B (MAO-B)
DM37S5C	MT	DTT
DM37S5C	MA	Inhibitor
DM37S5C	RN	Ultrasound promoted synthesis of 2-imidazolines in water: a greener approach toward monoamine oxidase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):546-9.
DM37S5C	RU	https://pubmed.ncbi.nlm.nih.gov/19064321

DMFWA9Y	DI	DMFWA9Y
DMFWA9Y	DN	2-p-tolyl-4H-chromen-4-one
DMFWA9Y	MI	TTGP7BY
DMFWA9Y	MN	Monoamine oxidase type B (MAO-B)
DMFWA9Y	MT	DTT
DMFWA9Y	MA	Inhibitor
DMFWA9Y	RN	A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9.
DMFWA9Y	RU	https://pubmed.ncbi.nlm.nih.gov/20045650

DM2HKCM	DI	DM2HKCM
DM2HKCM	DN	2-p-tolyl-4H-chromene-4-thione
DM2HKCM	MI	TTGP7BY
DM2HKCM	MN	Monoamine oxidase type B (MAO-B)
DM2HKCM	MT	DTT
DM2HKCM	MA	Inhibitor
DM2HKCM	RN	A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9.
DM2HKCM	RU	https://pubmed.ncbi.nlm.nih.gov/20045650

DMJIVL3	DI	DMJIVL3
DMJIVL3	DN	2-p-Tolyl-6H-pyrazolo[1,5-c]quinazolin-5-one
DMJIVL3	MI	TT1MPAY
DMJIVL3	MN	GABA(A) receptor alpha-1 (GABRA1)
DMJIVL3	MT	DTT
DMJIVL3	MA	Inhibitor
DMJIVL3	RN	Synthesis and binding activity of some pyrazolo[1,5-c]quinazolines as tools to verify an optional binding site of a benzodiazepine receptor ligand. J Med Chem. 1996 Jul 19;39(15):2915-21.
DMJIVL3	RU	https://pubmed.ncbi.nlm.nih.gov/8709126

DMJIVL3	DI	DMJIVL3
DMJIVL3	DN	2-p-Tolyl-6H-pyrazolo[1,5-c]quinazolin-5-one
DMJIVL3	MI	TTNJYV2
DMJIVL3	MN	Gamma-aminobutyric acid receptor (GAR)
DMJIVL3	MT	DTT
DMJIVL3	MA	Inhibitor
DMJIVL3	RN	Synthesis and binding activity of some pyrazolo[1,5-c]quinazolines as tools to verify an optional binding site of a benzodiazepine receptor ligand. J Med Chem. 1996 Jul 19;39(15):2915-21.
DMJIVL3	RU	https://pubmed.ncbi.nlm.nih.gov/8709126

DMLCDZN	DI	DMLCDZN
DMLCDZN	DN	2-Pyridin-2-yl-6H-pyrazolo[1,5-c]quinazolin-5-one
DMLCDZN	MI	TT1MPAY
DMLCDZN	MN	GABA(A) receptor alpha-1 (GABRA1)
DMLCDZN	MT	DTT
DMLCDZN	MA	Inhibitor
DMLCDZN	RN	Synthesis and binding activity of some pyrazolo[1,5-c]quinazolines as tools to verify an optional binding site of a benzodiazepine receptor ligand. J Med Chem. 1996 Jul 19;39(15):2915-21.
DMLCDZN	RU	https://pubmed.ncbi.nlm.nih.gov/8709126

DMLCDZN	DI	DMLCDZN
DMLCDZN	DN	2-Pyridin-2-yl-6H-pyrazolo[1,5-c]quinazolin-5-one
DMLCDZN	MI	TTNJYV2
DMLCDZN	MN	Gamma-aminobutyric acid receptor (GAR)
DMLCDZN	MT	DTT
DMLCDZN	MA	Inhibitor
DMLCDZN	RN	Synthesis and binding activity of some pyrazolo[1,5-c]quinazolines as tools to verify an optional binding site of a benzodiazepine receptor ligand. J Med Chem. 1996 Jul 19;39(15):2915-21.
DMLCDZN	RU	https://pubmed.ncbi.nlm.nih.gov/8709126

DMAS46B	DI	DMAS46B
DMAS46B	DN	2-Pyridin-2-ylmethyl-1,2-dihydro-indazol-3-one
DMAS46B	MI	TT2J34L
DMAS46B	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMAS46B	MT	DTT
DMAS46B	MA	Inhibitor
DMAS46B	RN	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
DMAS46B	RU	https://pubmed.ncbi.nlm.nih.gov/1848292

DM7RUNT	DI	DM7RUNT
DM7RUNT	DN	2-Pyridin-3-yl-7-aza-bicyclo[2.2.1]heptane
DM7RUNT	MI	TTF4E0J
DM7RUNT	MN	Neuronal acetylcholine receptor alpha-2 (CHRNA2)
DM7RUNT	MT	DTT
DM7RUNT	MA	Inhibitor
DM7RUNT	RN	Epibatidine structure-activity relationships. Bioorg Med Chem Lett. 2004 Apr 19;14(8):1889-96.
DM7RUNT	RU	https://pubmed.ncbi.nlm.nih.gov/15050621

DMT21UX	DI	DMT21UX
DMT21UX	DN	2-Pyridin-3-yl-benzo[h]chromen-4-one
DMT21UX	MI	TTK3PY9
DMT21UX	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMT21UX	MT	DTT
DMT21UX	MA	Inhibitor
DMT21UX	RN	Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85.
DMT21UX	RU	https://pubmed.ncbi.nlm.nih.gov/15658870

DMJYI0P	DI	DMJYI0P
DMJYI0P	DN	2-Pyridin-3-ylmethyl-1,2-dihydro-indazol-3-one
DMJYI0P	MI	TT2J34L
DMJYI0P	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMJYI0P	MT	DTT
DMJYI0P	MA	Inhibitor
DMJYI0P	RN	Tumour necrosis factor production in a rat airpouch model of inflammation: role of eicosanoids. Agents Actions. 1991 Mar;32(3-4):289-94.
DMJYI0P	RU	https://pubmed.ncbi.nlm.nih.gov/1650523

DM5D09Q	DI	DM5D09Q
DM5D09Q	DN	2-Pyridin-4-yl-1,2,3,4-tetrahydro-isoquinoline
DM5D09Q	MI	TTNGILX
DM5D09Q	MN	Adrenergic receptor alpha-1A (ADRA1A)
DM5D09Q	MT	DTT
DM5D09Q	MA	Inhibitor
DM5D09Q	RN	4-(3,4-dihydro-1H-isoquinolin-2yl)-pyridines and 4-(3,4-dihydro-1H-isoquinolin-2-yl)-quinolines as potent NR1/2B subtype selective NMDA receptor an... Bioorg Med Chem Lett. 2003 May 19;13(10):1759-62.
DM5D09Q	RU	https://pubmed.ncbi.nlm.nih.gov/12729659

DM5D09Q	DI	DM5D09Q
DM5D09Q	DN	2-Pyridin-4-yl-1,2,3,4-tetrahydro-isoquinoline
DM5D09Q	MI	TTBRKXS
DM5D09Q	MN	Adrenergic receptor alpha-1B (ADRA1B)
DM5D09Q	MT	DTT
DM5D09Q	MA	Inhibitor
DM5D09Q	RN	4-(3,4-dihydro-1H-isoquinolin-2yl)-pyridines and 4-(3,4-dihydro-1H-isoquinolin-2-yl)-quinolines as potent NR1/2B subtype selective NMDA receptor an... Bioorg Med Chem Lett. 2003 May 19;13(10):1759-62.
DM5D09Q	RU	https://pubmed.ncbi.nlm.nih.gov/12729659

DM5D09Q	DI	DM5D09Q
DM5D09Q	DN	2-Pyridin-4-yl-1,2,3,4-tetrahydro-isoquinoline
DM5D09Q	MI	TT34BHT
DM5D09Q	MN	Adrenergic receptor alpha-1D (ADRA1D)
DM5D09Q	MT	DTT
DM5D09Q	MA	Inhibitor
DM5D09Q	RN	4-(3,4-dihydro-1H-isoquinolin-2yl)-pyridines and 4-(3,4-dihydro-1H-isoquinolin-2-yl)-quinolines as potent NR1/2B subtype selective NMDA receptor an... Bioorg Med Chem Lett. 2003 May 19;13(10):1759-62.
DM5D09Q	RU	https://pubmed.ncbi.nlm.nih.gov/12729659

DM5D09Q	DI	DM5D09Q
DM5D09Q	DN	2-Pyridin-4-yl-1,2,3,4-tetrahydro-isoquinoline
DM5D09Q	MI	TTLD29N
DM5D09Q	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DM5D09Q	MT	DTT
DM5D09Q	MA	Inhibitor
DM5D09Q	RN	4-(3,4-dihydro-1H-isoquinolin-2yl)-pyridines and 4-(3,4-dihydro-1H-isoquinolin-2-yl)-quinolines as potent NR1/2B subtype selective NMDA receptor an... Bioorg Med Chem Lett. 2003 May 19;13(10):1759-62.
DM5D09Q	RU	https://pubmed.ncbi.nlm.nih.gov/12729659

DM5D09Q	DI	DM5D09Q
DM5D09Q	DN	2-Pyridin-4-yl-1,2,3,4-tetrahydro-isoquinoline
DM5D09Q	MI	TTN9D8E
DM5D09Q	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DM5D09Q	MT	DTT
DM5D09Q	MA	Inhibitor
DM5D09Q	RN	4-(3,4-dihydro-1H-isoquinolin-2yl)-pyridines and 4-(3,4-dihydro-1H-isoquinolin-2-yl)-quinolines as potent NR1/2B subtype selective NMDA receptor an... Bioorg Med Chem Lett. 2003 May 19;13(10):1759-62.
DM5D09Q	RU	https://pubmed.ncbi.nlm.nih.gov/12729659

DMGB1QU	DI	DMGB1QU
DMGB1QU	DN	2-Pyridin-4-ylmethyl-1,2-dihydro-indazol-3-one
DMGB1QU	MI	TT2J34L
DMGB1QU	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMGB1QU	MT	DTT
DMGB1QU	MA	Inhibitor
DMGB1QU	RN	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
DMGB1QU	RU	https://pubmed.ncbi.nlm.nih.gov/1848292

DMVAQOZ	DI	DMVAQOZ
DMVAQOZ	DN	2-Pyridinethiol
DMVAQOZ	MI	TTF2LRI
DMVAQOZ	MN	Cathepsin B (CTSB)
DMVAQOZ	MT	DTT
DMVAQOZ	MA	Inhibitor
DMVAQOZ	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMVAQOZ	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMN516S	DI	DMN516S
DMN516S	DN	2-pyridylethylamine
DMN516S	MI	TTTIBOJ
DMN516S	MN	Histamine H1 receptor (H1R)
DMN516S	MT	DTT
DMN516S	MA	Agonist
DMN516S	RN	Large-scale overproduction, functional purification and ligand affinities of the His-tagged human histamine H1 receptor. Eur J Biochem. 2004 Jul;271(13):2636-46.
DMN516S	RU	https://pubmed.ncbi.nlm.nih.gov/15206929

DMBJXCF	DI	DMBJXCF
DMBJXCF	DN	2pyrrolidin-1-yl-1-phenylpentan-1-one
DMBJXCF	MI	TTVBI8W
DMBJXCF	MN	Dopamine transporter (DAT)
DMBJXCF	MT	DTT
DMBJXCF	MA	Inhibitor
DMBJXCF	RN	1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32.
DMBJXCF	RU	https://pubmed.ncbi.nlm.nih.gov/16480278

DMBJXCF	DI	DMBJXCF
DMBJXCF	DN	2pyrrolidin-1-yl-1-phenylpentan-1-one
DMBJXCF	MI	TTAWNKZ
DMBJXCF	MN	Norepinephrine transporter (NET)
DMBJXCF	MT	DTT
DMBJXCF	MA	Inhibitor
DMBJXCF	RN	1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32.
DMBJXCF	RU	https://pubmed.ncbi.nlm.nih.gov/16480278

DMGPI0C	DI	DMGPI0C
DMGPI0C	DN	2-Pyrrolidin-1-yl-benzo[h]chromen-4-one
DMGPI0C	MI	TTK3PY9
DMGPI0C	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMGPI0C	MT	DTT
DMGPI0C	MA	Inhibitor
DMGPI0C	RN	Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85.
DMGPI0C	RU	https://pubmed.ncbi.nlm.nih.gov/15658870

DMNU1YR	DI	DMNU1YR
DMNU1YR	DN	2S,4R-4-METHYLGLUTAMATE
DMNU1YR	MI	TT0MYE2
DMNU1YR	MN	Glutamate receptor ionotropic kainate 1 (GRIK1)
DMNU1YR	MT	DTT
DMNU1YR	MA	Inhibitor
DMNU1YR	RN	Chemo-enzymatic synthesis of a series of 2,4-syn-functionalized (S)-glutamate analogues: new insight into the structure-activity relation of ionotr... J Med Chem. 2008 Jul 24;51(14):4093-103.
DMNU1YR	RU	https://pubmed.ncbi.nlm.nih.gov/18578478

DMAO7DS	DI	DMAO7DS
DMAO7DS	DN	2-Sulfamoyl-benzoic acid methyl ester
DMAO7DS	MI	TTANPDJ
DMAO7DS	MN	Carbonic anhydrase II (CA-II)
DMAO7DS	MT	DTT
DMAO7DS	MA	Inhibitor
DMAO7DS	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamide... J Med Chem. 2005 Mar 24;48(6):2121-5.
DMAO7DS	RU	https://pubmed.ncbi.nlm.nih.gov/15771455

DMAO7DS	DI	DMAO7DS
DMAO7DS	DN	2-Sulfamoyl-benzoic acid methyl ester
DMAO7DS	MI	TT2LVK8
DMAO7DS	MN	Carbonic anhydrase IX (CA-IX)
DMAO7DS	MT	DTT
DMAO7DS	MA	Inhibitor
DMAO7DS	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamide... J Med Chem. 2005 Mar 24;48(6):2121-5.
DMAO7DS	RU	https://pubmed.ncbi.nlm.nih.gov/15771455

DMJBO3D	DI	DMJBO3D
DMJBO3D	DN	2-Sulfhydryl-Ethanol
DMJBO3D	MI	TTA7UJC
DMJBO3D	MN	Alpha-1-antitrypsin (SERPINA1)
DMJBO3D	MT	DTT
DMJBO3D	MA	Inhibitor
DMJBO3D	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMJBO3D	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMJBO3D	DI	DMJBO3D
DMJBO3D	DN	2-Sulfhydryl-Ethanol
DMJBO3D	MI	TTU6BFZ
DMJBO3D	MN	Candida Thymidylate synthase (Candi TMP1)
DMJBO3D	MT	DTT
DMJBO3D	MA	Inhibitor
DMJBO3D	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMJBO3D	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMJBO3D	DI	DMJBO3D
DMJBO3D	DN	2-Sulfhydryl-Ethanol
DMJBO3D	MI	TTUNARX
DMJBO3D	MN	Carbonic anhydrase (CA)
DMJBO3D	MT	DTT
DMJBO3D	MA	Inhibitor
DMJBO3D	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMJBO3D	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMJBO3D	DI	DMJBO3D
DMJBO3D	DN	2-Sulfhydryl-Ethanol
DMJBO3D	MI	TTANPDJ
DMJBO3D	MN	Carbonic anhydrase II (CA-II)
DMJBO3D	MT	DTT
DMJBO3D	MA	Inhibitor
DMJBO3D	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMJBO3D	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMJBO3D	DI	DMJBO3D
DMJBO3D	DN	2-Sulfhydryl-Ethanol
DMJBO3D	MI	TTJHKYD
DMJBO3D	MN	Delta-aminolevulinic acid dehydratase (ALAD)
DMJBO3D	MT	DTT
DMJBO3D	MA	Inhibitor
DMJBO3D	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMJBO3D	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMJBO3D	DI	DMJBO3D
DMJBO3D	DN	2-Sulfhydryl-Ethanol
DMJBO3D	MI	TTGKIED
DMJBO3D	MN	Fibroblast growth factor-2 (FGF2)
DMJBO3D	MT	DTT
DMJBO3D	MA	Inhibitor
DMJBO3D	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMJBO3D	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMJBO3D	DI	DMJBO3D
DMJBO3D	DN	2-Sulfhydryl-Ethanol
DMJBO3D	MI	TTWQYB7
DMJBO3D	MN	High mobility group protein B1 (HMGB1)
DMJBO3D	MT	DTT
DMJBO3D	MA	Inhibitor
DMJBO3D	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMJBO3D	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMJBO3D	DI	DMJBO3D
DMJBO3D	DN	2-Sulfhydryl-Ethanol
DMJBO3D	MI	TTZT9R2
DMJBO3D	MN	Hydroxysteroid dehydrogenase 3-beta (HSD3B)
DMJBO3D	MT	DTT
DMJBO3D	MA	Inhibitor
DMJBO3D	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMJBO3D	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMJBO3D	DI	DMJBO3D
DMJBO3D	DN	2-Sulfhydryl-Ethanol
DMJBO3D	MI	TTV9A7R
DMJBO3D	MN	Lactoylglutathione lyase (GLO1)
DMJBO3D	MT	DTT
DMJBO3D	MA	Inhibitor
DMJBO3D	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMJBO3D	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMJBO3D	DI	DMJBO3D
DMJBO3D	DN	2-Sulfhydryl-Ethanol
DMJBO3D	MI	TTR0SWN
DMJBO3D	MN	M-phase inducer phosphatase 2 (MPIP2)
DMJBO3D	MT	DTT
DMJBO3D	MA	Inhibitor
DMJBO3D	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMJBO3D	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMJBO3D	DI	DMJBO3D
DMJBO3D	DN	2-Sulfhydryl-Ethanol
DMJBO3D	MI	TTYQ4AE
DMJBO3D	MN	Plasmodium Adenylosuccinate synthetase (Malaria Adss)
DMJBO3D	MT	DTT
DMJBO3D	MA	Inhibitor
DMJBO3D	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMJBO3D	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMJBO3D	DI	DMJBO3D
DMJBO3D	DN	2-Sulfhydryl-Ethanol
DMJBO3D	MI	TT9SL3Q
DMJBO3D	MN	Polypeptide deformylase (PDF)
DMJBO3D	MT	DTT
DMJBO3D	MA	Inhibitor
DMJBO3D	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMJBO3D	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM26NKG	DI	DM26NKG
DM26NKG	DN	2-tert-butoxy-9H-carbazole
DM26NKG	MI	TTBGTCW
DM26NKG	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DM26NKG	MT	DTT
DM26NKG	MA	Inhibitor
DM26NKG	RN	Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8.
DM26NKG	RU	https://pubmed.ncbi.nlm.nih.gov/20521839

DMJBQD8	DI	DMJBQD8
DMJBQD8	DN	2-tert-butyl-7-(trifluoromethyl)-9H-carbazole
DMJBQD8	MI	TTBGTCW
DMJBQD8	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DMJBQD8	MT	DTT
DMJBQD8	MA	Inhibitor
DMJBQD8	RN	Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8.
DMJBQD8	RU	https://pubmed.ncbi.nlm.nih.gov/20521839

DM6M8Y3	DI	DM6M8Y3
DM6M8Y3	DN	2-tert-butyl-9H-carbazole
DM6M8Y3	MI	TTBGTCW
DM6M8Y3	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DM6M8Y3	MT	DTT
DM6M8Y3	MA	Inhibitor
DM6M8Y3	RN	Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8.
DM6M8Y3	RU	https://pubmed.ncbi.nlm.nih.gov/20521839

DMNXI1E	DI	DMNXI1E
DMNXI1E	DN	2-tert-butylbenzene-1,4-diol
DMNXI1E	MI	TTF4CAM
DMNXI1E	MN	Influenza Hemagglutinin (Influ HA)
DMNXI1E	MT	DTT
DMNXI1E	MA	Inhibitor
DMNXI1E	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMNXI1E	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMFAV5R	DI	DMFAV5R
DMFAV5R	DN	2-tert-Butyldimethylsilyloxylycorine
DMFAV5R	MI	TTXV4FI
DMFAV5R	MN	Albendazole monooxygenase (CYP3A4)
DMFAV5R	MT	DTT
DMFAV5R	MA	Inhibitor
DMFAV5R	RN	Selective cytochrome P450 3A4 inhibitory activity of Amaryllidaceae alkaloids. Bioorg Med Chem Lett. 2009 Jun 15;19(12):3233-7.
DMFAV5R	RU	https://pubmed.ncbi.nlm.nih.gov/19428250

DM35JQS	DI	DM35JQS
DM35JQS	DN	2-Thiazol-5-ylmethyl-1,2-dihydro-indazol-3-one
DM35JQS	MI	TT2J34L
DM35JQS	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM35JQS	MT	DTT
DM35JQS	MA	Inhibitor
DM35JQS	RN	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
DM35JQS	RU	https://pubmed.ncbi.nlm.nih.gov/1848292

DMEY9T2	DI	DMEY9T2
DMEY9T2	DN	2-Thioethenamine
DMEY9T2	MI	TT3DQUT
DMEY9T2	MN	Bacterial Lantibiotic mersacidin (Bact glmM)
DMEY9T2	MT	DTT
DMEY9T2	MA	Inhibitor
DMEY9T2	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMEY9T2	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMCEK6N	DI	DMCEK6N
DMCEK6N	DN	2-Thiomethyl-3-Phenylpropanoic Acid
DMCEK6N	MI	TT3LJ6G
DMCEK6N	MN	Carboxypeptidase A1 (CPA1)
DMCEK6N	MT	DTT
DMCEK6N	MA	Inhibitor
DMCEK6N	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1587).
DMCEK6N	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1587

DMCEK6N	DI	DMCEK6N
DMCEK6N	DN	2-Thiomethyl-3-Phenylpropanoic Acid
DMCEK6N	MI	TTGA1IV
DMCEK6N	MN	Matrix metalloproteinase-8 (MMP-8)
DMCEK6N	MT	DTT
DMCEK6N	MA	Inhibitor
DMCEK6N	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMCEK6N	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMSKNBA	DI	DMSKNBA
DMSKNBA	DN	2-Thiomorpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one
DMSKNBA	MI	TTK3PY9
DMSKNBA	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMSKNBA	MT	DTT
DMSKNBA	MA	Inhibitor
DMSKNBA	RN	Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85.
DMSKNBA	RU	https://pubmed.ncbi.nlm.nih.gov/15658870

DMFXG2E	DI	DMFXG2E
DMFXG2E	DN	2-thiomorpholino-4H-benzo[h]chromen-4-one
DMFXG2E	MI	TTK3PY9
DMFXG2E	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMFXG2E	MT	DTT
DMFXG2E	MA	Inhibitor
DMFXG2E	RN	Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46.
DMFXG2E	RU	https://pubmed.ncbi.nlm.nih.gov/16302822

DMPF598	DI	DMPF598
DMPF598	DN	2-Thiophen-2-yl-3H-imidazo[4,5-c]quinoline
DMPF598	MI	TT1MPAY
DMPF598	MN	GABA(A) receptor alpha-1 (GABRA1)
DMPF598	MT	DTT
DMPF598	MA	Inhibitor
DMPF598	RN	Synthesis and structure--activity relationships of fused imidazopyridines: a new series of benzodiazepine receptor ligands. J Med Chem. 1996 Jul 5;39(14):2844-51.
DMPF598	RU	https://pubmed.ncbi.nlm.nih.gov/8709114

DMPF598	DI	DMPF598
DMPF598	DN	2-Thiophen-2-yl-3H-imidazo[4,5-c]quinoline
DMPF598	MI	TTZA1NY
DMPF598	MN	GABA(A) receptor beta-2 (GABRB2)
DMPF598	MT	DTT
DMPF598	MA	Inhibitor
DMPF598	RN	Synthesis and structure--activity relationships of fused imidazopyridines: a new series of benzodiazepine receptor ligands. J Med Chem. 1996 Jul 5;39(14):2844-51.
DMPF598	RU	https://pubmed.ncbi.nlm.nih.gov/8709114

DMPF598	DI	DMPF598
DMPF598	DN	2-Thiophen-2-yl-3H-imidazo[4,5-c]quinoline
DMPF598	MI	TT06RH5
DMPF598	MN	GABA(A) receptor gamma-2 (GABRG2)
DMPF598	MT	DTT
DMPF598	MA	Inhibitor
DMPF598	RN	Synthesis and structure--activity relationships of fused imidazopyridines: a new series of benzodiazepine receptor ligands. J Med Chem. 1996 Jul 5;39(14):2844-51.
DMPF598	RU	https://pubmed.ncbi.nlm.nih.gov/8709114

DMPF598	DI	DMPF598
DMPF598	DN	2-Thiophen-2-yl-3H-imidazo[4,5-c]quinoline
DMPF598	MI	TTNJYV2
DMPF598	MN	Gamma-aminobutyric acid receptor (GAR)
DMPF598	MT	DTT
DMPF598	MA	Inhibitor
DMPF598	RN	Synthesis and structure--activity relationships of fused imidazopyridines: a new series of benzodiazepine receptor ligands. J Med Chem. 1996 Jul 5;39(14):2844-51.
DMPF598	RU	https://pubmed.ncbi.nlm.nih.gov/8709114

DM4J8B9	DI	DM4J8B9
DM4J8B9	DN	2-Thiophen-2-ylmethyl-1,2-dihydro-indazol-3-one
DM4J8B9	MI	TT2J34L
DM4J8B9	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM4J8B9	MT	DTT
DM4J8B9	MA	Inhibitor
DM4J8B9	RN	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
DM4J8B9	RU	https://pubmed.ncbi.nlm.nih.gov/1848292

DMIEGF4	DI	DMIEGF4
DMIEGF4	DN	2-THIOSALVINORIN B
DMIEGF4	MI	TTQW87Y
DMIEGF4	MN	Opioid receptor kappa (OPRK1)
DMIEGF4	MT	DTT
DMIEGF4	MA	Inhibitor
DMIEGF4	RN	Convenient synthesis and in vitro pharmacological activity of 2-thioanalogs of salvinorins A and B. Bioorg Med Chem Lett. 2007 Apr 15;17(8):2229-32.
DMIEGF4	RU	https://pubmed.ncbi.nlm.nih.gov/17303418

DM84R6C	DI	DM84R6C
DM84R6C	DN	2-thio-UDP
DM84R6C	MI	TT72OKI
DM84R6C	MN	P2Y purinoceptor 14 (P2RY14)
DM84R6C	MT	DTT
DM84R6C	MA	Agonist
DM84R6C	RN	Human P2Y(14) receptor agonists: truncation of the hexose moiety of uridine-5'-diphosphoglucose and its replacement with alkyl and aryl groups. J Med Chem. 2010 Jan 14;53(1):471-80.
DM84R6C	RU	https://pubmed.ncbi.nlm.nih.gov/19902968

DMJZ5V0	DI	DMJZ5V0
DMJZ5V0	DN	2-thioUTP
DMJZ5V0	MI	TTOZHQC
DMJZ5V0	MN	P2Y purinoceptor 2 (P2RY2)
DMJZ5V0	MT	DTT
DMJZ5V0	MA	Agonist
DMJZ5V0	RN	Synthesis and structure-activity relationships of uracil nucleotide derivatives and analogues as agonists at human P2Y2, P2Y4, and P2Y6 receptors. J Med Chem. 2006 Nov 30;49(24):7076-87.
DMJZ5V0	RU	https://pubmed.ncbi.nlm.nih.gov/17125260

DM1HABS	DI	DM1HABS
DM1HABS	DN	2-tolyl-6-phenyl-9H-purine
DM1HABS	MI	TTK25J1
DM1HABS	MN	Adenosine A1 receptor (ADORA1)
DM1HABS	MT	DTT
DM1HABS	MA	Inhibitor
DM1HABS	RN	2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7.
DM1HABS	RU	https://pubmed.ncbi.nlm.nih.gov/16686529

DM1HABS	DI	DM1HABS
DM1HABS	DN	2-tolyl-6-phenyl-9H-purine
DM1HABS	MI	TTM2AOE
DM1HABS	MN	Adenosine A2a receptor (ADORA2A)
DM1HABS	MT	DTT
DM1HABS	MA	Inhibitor
DM1HABS	RN	2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7.
DM1HABS	RU	https://pubmed.ncbi.nlm.nih.gov/16686529

DM1HABS	DI	DM1HABS
DM1HABS	DN	2-tolyl-6-phenyl-9H-purine
DM1HABS	MI	TTJFY5U
DM1HABS	MN	Adenosine A3 receptor (ADORA3)
DM1HABS	MT	DTT
DM1HABS	MA	Inhibitor
DM1HABS	RN	2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7.
DM1HABS	RU	https://pubmed.ncbi.nlm.nih.gov/16686529

DMOFDVE	DI	DMOFDVE
DMOFDVE	DN	2-tosylanthracene-1,4-diol
DMOFDVE	MI	TTRVTMX
DMOFDVE	MN	Bacterial Beta-ketoacyl-ACP synthase III (Bact fabH)
DMOFDVE	MT	DTT
DMOFDVE	MA	Inhibitor
DMOFDVE	RN	Synthesis and biological evaluation of novel sulfonyl-naphthalene-1,4-diols as FabH inhibitors. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6402-5.
DMOFDVE	RU	https://pubmed.ncbi.nlm.nih.gov/18996691

DM8LS6H	DI	DM8LS6H
DM8LS6H	DN	2-tosylbenzene-1,4-diol
DM8LS6H	MI	TTRVTMX
DM8LS6H	MN	Bacterial Beta-ketoacyl-ACP synthase III (Bact fabH)
DM8LS6H	MT	DTT
DM8LS6H	MA	Inhibitor
DM8LS6H	RN	Synthesis and biological evaluation of novel sulfonyl-naphthalene-1,4-diols as FabH inhibitors. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6402-5.
DM8LS6H	RU	https://pubmed.ncbi.nlm.nih.gov/18996691

DM2OUG0	DI	DM2OUG0
DM2OUG0	DN	2-tosylnaphthalene
DM2OUG0	MI	TTRVTMX
DM2OUG0	MN	Bacterial Beta-ketoacyl-ACP synthase III (Bact fabH)
DM2OUG0	MT	DTT
DM2OUG0	MA	Inhibitor
DM2OUG0	RN	Synthesis and biological evaluation of novel sulfonyl-naphthalene-1,4-diols as FabH inhibitors. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6402-5.
DM2OUG0	RU	https://pubmed.ncbi.nlm.nih.gov/18996691

DM5FHO4	DI	DM5FHO4
DM5FHO4	DN	2-Tosylnaphthalene-1,4-diol
DM5FHO4	MI	TTRVTMX
DM5FHO4	MN	Bacterial Beta-ketoacyl-ACP synthase III (Bact fabH)
DM5FHO4	MT	DTT
DM5FHO4	MA	Inhibitor
DM5FHO4	RN	Synthesis and biological evaluation of novel sulfonyl-naphthalene-1,4-diols as FabH inhibitors. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6402-5.
DM5FHO4	RU	https://pubmed.ncbi.nlm.nih.gov/18996691

DMK9OYM	DI	DMK9OYM
DMK9OYM	DN	2-tosylnaphthalene-1,4-dione
DMK9OYM	MI	TTRVTMX
DMK9OYM	MN	Bacterial Beta-ketoacyl-ACP synthase III (Bact fabH)
DMK9OYM	MT	DTT
DMK9OYM	MA	Inhibitor
DMK9OYM	RN	Synthesis and biological evaluation of novel sulfonyl-naphthalene-1,4-diols as FabH inhibitors. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6402-5.
DMK9OYM	RU	https://pubmed.ncbi.nlm.nih.gov/18996691

DMVJORE	DI	DMVJORE
DMVJORE	DN	2-trityl-4,5-dihydrooxazole
DMVJORE	MI	TTMNI76
DMVJORE	MN	Calcium-activated potassium channel (KCN)
DMVJORE	MT	DTT
DMVJORE	MA	Inhibitor
DMVJORE	RN	Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82.
DMVJORE	RU	https://pubmed.ncbi.nlm.nih.gov/18232633

DM8XSE3	DI	DM8XSE3
DM8XSE3	DN	2-valproylamido-5-sulfonamidoindane
DM8XSE3	MI	TTHQPL7
DM8XSE3	MN	Carbonic anhydrase I (CA-I)
DM8XSE3	MT	DTT
DM8XSE3	MA	Inhibitor
DM8XSE3	RN	Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9.
DM8XSE3	RU	https://pubmed.ncbi.nlm.nih.gov/16640335

DM8XSE3	DI	DM8XSE3
DM8XSE3	DN	2-valproylamido-5-sulfonamidoindane
DM8XSE3	MI	TTANPDJ
DM8XSE3	MN	Carbonic anhydrase II (CA-II)
DM8XSE3	MT	DTT
DM8XSE3	MA	Inhibitor
DM8XSE3	RN	Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9.
DM8XSE3	RU	https://pubmed.ncbi.nlm.nih.gov/16640335

DM8XSE3	DI	DM8XSE3
DM8XSE3	DN	2-valproylamido-5-sulfonamidoindane
DM8XSE3	MI	TT2LVK8
DM8XSE3	MN	Carbonic anhydrase IX (CA-IX)
DM8XSE3	MT	DTT
DM8XSE3	MA	Inhibitor
DM8XSE3	RN	Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9.
DM8XSE3	RU	https://pubmed.ncbi.nlm.nih.gov/16640335

DMOAY8R	DI	DMOAY8R
DMOAY8R	DN	3 9-DIHYDRO-N-DESMETHYL-N-ISOPROPYLERYTHROMYCIN A
DMOAY8R	MI	TTQ6VDM
DMOAY8R	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMOAY8R	MT	DTT
DMOAY8R	MA	Inhibitor
DMOAY8R	RN	9-Dihydroerythromycin ethers as motilin agonists--developing structure-activity relationships for potency and safety. Bioorg Med Chem. 2010 Nov 1;18(21):7651-8.
DMOAY8R	RU	https://pubmed.ncbi.nlm.nih.gov/20869254

DM1L5IJ	DI	DM1L5IJ
DM1L5IJ	DN	3 beta-O-acetyloleanolic acid
DM1L5IJ	MI	TT8NGED
DM1L5IJ	MN	Prostaglandin G/H synthase 1 (COX-1)
DM1L5IJ	MT	DTT
DM1L5IJ	MA	Inhibitor
DM1L5IJ	RN	Nitrogen-containing phorbol esters from Croton ciliatoglandulifer and their effects on cyclooxygenases-1 and -2. J Nat Prod. 2006 Jun;69(6):887-90.
DM1L5IJ	RU	https://pubmed.ncbi.nlm.nih.gov/16792405

DM1L5IJ	DI	DM1L5IJ
DM1L5IJ	DN	3 beta-O-acetyloleanolic acid
DM1L5IJ	MI	TTVKILB
DM1L5IJ	MN	Prostaglandin G/H synthase 2 (COX-2)
DM1L5IJ	MT	DTT
DM1L5IJ	MA	Inhibitor
DM1L5IJ	RN	Nitrogen-containing phorbol esters from Croton ciliatoglandulifer and their effects on cyclooxygenases-1 and -2. J Nat Prod. 2006 Jun;69(6):887-90.
DM1L5IJ	RU	https://pubmed.ncbi.nlm.nih.gov/16792405

DM491YV	DI	DM491YV
DM491YV	DN	3-((1H-imidazol-1-yl)methyl)-9H-xanthen-9-one
DM491YV	MI	TTSZLWK
DM491YV	MN	Aromatase (CYP19A1)
DM491YV	MT	DTT
DM491YV	MA	Inhibitor
DM491YV	RN	Novel highly potent and selective nonsteroidal aromatase inhibitors: synthesis, biological evaluation and structure-activity relationships investigation. J Med Chem. 2010 Jul 22;53(14):5347-51. 
DM491YV	RU	https://pubmed.ncbi.nlm.nih.gov/20568782

DMZ9L6Q	DI	DMZ9L6Q
DMZ9L6Q	DN	3-((1H-imidazol-1-yl)methyl)aniline
DMZ9L6Q	MI	TTIQUX7
DMZ9L6Q	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMZ9L6Q	MT	DTT
DMZ9L6Q	MA	Inhibitor
DMZ9L6Q	RN	Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25.
DMZ9L6Q	RU	https://pubmed.ncbi.nlm.nih.gov/20121113

DMJ6O43	DI	DMJ6O43
DMJ6O43	DN	3-((1H-imidazol-4-yl)methyl)pyridine
DMJ6O43	MI	TT9JNIC
DMJ6O43	MN	Histamine H3 receptor (H3R)
DMJ6O43	MT	DTT
DMJ6O43	MA	Inhibitor
DMJ6O43	RN	Investigation of the histamine H3 receptor binding site. Design and synthesis of hybrid agonists with a lipophilic side chain. J Med Chem. 2010 Sep 9;53(17):6445-56.
DMJ6O43	RU	https://pubmed.ncbi.nlm.nih.gov/20690643

DMSGX7V	DI	DMSGX7V
DMSGX7V	DN	3-((2-Pyrrolidine-1-yl)-ethyl)uracil
DMSGX7V	MI	TTMCF1Y
DMSGX7V	MN	Purine nucleoside phosphorylase (PNP)
DMSGX7V	MT	DTT
DMSGX7V	MA	Inhibitor
DMSGX7V	RN	Exploring new inhibitors of Plasmodium falciparum purine nucleoside phosphorylase. Eur J Med Chem. 2010 Nov;45(11):5140-9.
DMSGX7V	RU	https://pubmed.ncbi.nlm.nih.gov/20817362

DMJZK40	DI	DMJZK40
DMJZK40	DN	3-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol
DMJZK40	MI	TTAMQ62
DMJZK40	MN	Cyclin A2 (CCNA2)
DMJZK40	MT	DTT
DMJZK40	MA	Inhibitor
DMJZK40	RN	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
DMJZK40	RU	https://pubmed.ncbi.nlm.nih.gov/17064068

DMJZK40	DI	DMJZK40
DMJZK40	DN	3-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol
DMJZK40	MI	TT7HF4W
DMJZK40	MN	Cyclin-dependent kinase 2 (CDK2)
DMJZK40	MT	DTT
DMJZK40	MA	Inhibitor
DMJZK40	RN	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
DMJZK40	RU	https://pubmed.ncbi.nlm.nih.gov/17064068

DMJZK40	DI	DMJZK40
DMJZK40	DN	3-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol
DMJZK40	MI	TT1LVF2
DMJZK40	MN	Cyclin-dependent kinase 9 (CDK9)
DMJZK40	MT	DTT
DMJZK40	MA	Inhibitor
DMJZK40	RN	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
DMJZK40	RU	https://pubmed.ncbi.nlm.nih.gov/17064068

DMJZK40	DI	DMJZK40
DMJZK40	DN	3-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol
DMJZK40	MI	TTCEJ4F
DMJZK40	MN	G1/S-specific cyclin-E1 (CCNE1)
DMJZK40	MT	DTT
DMJZK40	MA	Inhibitor
DMJZK40	RN	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
DMJZK40	RU	https://pubmed.ncbi.nlm.nih.gov/17064068

DME3079	DI	DME3079
DME3079	DN	3-((3-bromothiophen-2-yl)methylene)indolin-2-one
DME3079	MI	TTUTJGQ
DME3079	MN	Vascular endothelial growth factor receptor 2 (KDR)
DME3079	MT	DTT
DME3079	MA	Inhibitor
DME3079	RN	Pharmacophore modeling and in silico screening for new KDR kinase inhibitors. Bioorg Med Chem Lett. 2007 Apr 15;17(8):2126-33.
DME3079	RU	https://pubmed.ncbi.nlm.nih.gov/17306530

DM37X04	DI	DM37X04
DM37X04	DN	3-((4-aminophenyl)diazenyl)benzenesulfonamide
DM37X04	MI	TTANPDJ
DM37X04	MN	Carbonic anhydrase II (CA-II)
DM37X04	MT	DTT
DM37X04	MA	Inhibitor
DM37X04	RN	Carbonic anhydrase inhibitors. Inhibition of the Rv1284 and Rv3273 beta-carbonic anhydrases from Mycobacterium tuberculosis with diazenylbenzenesul... Bioorg Med Chem Lett. 2009 Sep 1;19(17):4929-32.
DM37X04	RU	https://pubmed.ncbi.nlm.nih.gov/19651511

DM37X04	DI	DM37X04
DM37X04	DN	3-((4-aminophenyl)diazenyl)benzenesulfonamide
DM37X04	MI	TT2LVK8
DM37X04	MN	Carbonic anhydrase IX (CA-IX)
DM37X04	MT	DTT
DM37X04	MA	Inhibitor
DM37X04	RN	Carbonic anhydrase inhibitors. Diazenylbenzenesulfonamides are potent and selective inhibitors of the tumor-associated isozymes IX and XII over the... Bioorg Med Chem. 2009 Oct 15;17(20):7093-9.
DM37X04	RU	https://pubmed.ncbi.nlm.nih.gov/19773173

DM37X04	DI	DM37X04
DM37X04	DN	3-((4-aminophenyl)diazenyl)benzenesulfonamide
DM37X04	MI	TTSYM0R
DM37X04	MN	Carbonic anhydrase XII (CA-XII)
DM37X04	MT	DTT
DM37X04	MA	Inhibitor
DM37X04	RN	Carbonic anhydrase inhibitors. Diazenylbenzenesulfonamides are potent and selective inhibitors of the tumor-associated isozymes IX and XII over the... Bioorg Med Chem. 2009 Oct 15;17(20):7093-9.
DM37X04	RU	https://pubmed.ncbi.nlm.nih.gov/19773173

DMAPZQW	DI	DMAPZQW
DMAPZQW	DN	3-((4-hydroxyphenyl)diazenyl)benzenesulfonamide
DMAPZQW	MI	TTANPDJ
DMAPZQW	MN	Carbonic anhydrase II (CA-II)
DMAPZQW	MT	DTT
DMAPZQW	MA	Inhibitor
DMAPZQW	RN	Carbonic anhydrase inhibitors. Inhibition of the Rv1284 and Rv3273 beta-carbonic anhydrases from Mycobacterium tuberculosis with diazenylbenzenesul... Bioorg Med Chem Lett. 2009 Sep 1;19(17):4929-32.
DMAPZQW	RU	https://pubmed.ncbi.nlm.nih.gov/19651511

DMAPZQW	DI	DMAPZQW
DMAPZQW	DN	3-((4-hydroxyphenyl)diazenyl)benzenesulfonamide
DMAPZQW	MI	TT2LVK8
DMAPZQW	MN	Carbonic anhydrase IX (CA-IX)
DMAPZQW	MT	DTT
DMAPZQW	MA	Inhibitor
DMAPZQW	RN	Carbonic anhydrase inhibitors. Diazenylbenzenesulfonamides are potent and selective inhibitors of the tumor-associated isozymes IX and XII over the... Bioorg Med Chem. 2009 Oct 15;17(20):7093-9.
DMAPZQW	RU	https://pubmed.ncbi.nlm.nih.gov/19773173

DMAPZQW	DI	DMAPZQW
DMAPZQW	DN	3-((4-hydroxyphenyl)diazenyl)benzenesulfonamide
DMAPZQW	MI	TTSYM0R
DMAPZQW	MN	Carbonic anhydrase XII (CA-XII)
DMAPZQW	MT	DTT
DMAPZQW	MA	Inhibitor
DMAPZQW	RN	Carbonic anhydrase inhibitors. Diazenylbenzenesulfonamides are potent and selective inhibitors of the tumor-associated isozymes IX and XII over the... Bioorg Med Chem. 2009 Oct 15;17(20):7093-9.
DMAPZQW	RU	https://pubmed.ncbi.nlm.nih.gov/19773173

DMAO64J	DI	DMAO64J
DMAO64J	DN	3-((E)-Styryl)-quinoline
DMAO64J	MI	TT8FYO9
DMAO64J	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMAO64J	MT	DTT
DMAO64J	MA	Inhibitor
DMAO64J	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMAO64J	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMAO64J	DI	DMAO64J
DMAO64J	DN	3-((E)-Styryl)-quinoline
DMAO64J	MI	TTI7421
DMAO64J	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMAO64J	MT	DTT
DMAO64J	MA	Inhibitor
DMAO64J	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMAO64J	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMZU74I	DI	DMZU74I
DMZU74I	DN	3-((S)-Azetidin-2-yloxy)-5-iodo-pyridine
DMZU74I	MI	TTF4E0J
DMZU74I	MN	Neuronal acetylcholine receptor alpha-2 (CHRNA2)
DMZU74I	MT	DTT
DMZU74I	MA	Inhibitor
DMZU74I	RN	Pharmacology of the agonist binding sites of rat neuronal nicotinic receptor subtypes expressed in HEK 293 cells. Bioorg Med Chem Lett. 2004 Apr 19;14(8):1845-8.
DMZU74I	RU	https://pubmed.ncbi.nlm.nih.gov/15050613

DM57ZMJ	DI	DM57ZMJ
DM57ZMJ	DN	3-(1,1-Dimethyl-2-phenyl-ethyl)-pyridine
DM57ZMJ	MI	TTIQUX7
DM57ZMJ	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM57ZMJ	MT	DTT
DM57ZMJ	MA	Inhibitor
DM57ZMJ	RN	Structure-activity relationship study of the inhibition of adrenal cortical 11 beta-hydroxylase by new metyrapone analogues. J Med Chem. 1984 Jan;27(1):15-9.
DM57ZMJ	RU	https://pubmed.ncbi.nlm.nih.gov/6606707

DMTDB62	DI	DMTDB62
DMTDB62	DN	3-(1,2,3,6-Tetrahydro-pyridin-4-yl)-1H-indole
DMTDB62	MI	TTSQIFT
DMTDB62	MN	5-HT 1A receptor (HTR1A)
DMTDB62	MT	DTT
DMTDB62	MA	Inhibitor
DMTDB62	RN	3-(1,2,5,6-Tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one: a potent and selective serotonin (5-HT1B) agonist and rotationally restricted phenolic a... J Med Chem. 1990 Aug;33(8):2087-93.
DMTDB62	RU	https://pubmed.ncbi.nlm.nih.gov/2374139

DM5UL3F	DI	DM5UL3F
DM5UL3F	DN	3'-(1,2,3-Triazol-1-yl)-3'-deoxy-beta-D-thymidine
DM5UL3F	MI	TTP3QRF
DM5UL3F	MN	Thymidine kinase 1 (TK1)
DM5UL3F	MT	DTT
DM5UL3F	MA	Inhibitor
DM5UL3F	RN	3'-[4-Aryl-(1,2,3-triazol-1-yl)]-3'-deoxythymidine analogues as potent and selective inhibitors of human mitochondrial thymidine kinase. J Med Chem. 2010 Apr 8;53(7):2902-12.
DM5UL3F	RU	https://pubmed.ncbi.nlm.nih.gov/20218622

DMXZBQL	DI	DMXZBQL
DMXZBQL	DN	3-(1,2-dihydroacenaphthylen-3-yl)pyridine
DMXZBQL	MI	TTIQUX7
DMXZBQL	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMXZBQL	MT	DTT
DMXZBQL	MA	Inhibitor
DMXZBQL	RN	Development and evaluation of a pharmacophore model for inhibitors of aldosterone synthase (CYP11B2). Bioorg Med Chem Lett. 2006 Jan 1;16(1):25-30.
DMXZBQL	RU	https://pubmed.ncbi.nlm.nih.gov/16246562

DMHB4PA	DI	DMHB4PA
DMHB4PA	DN	3-(1,2-dihydroacenaphthylen-5-yl)pyridine
DMHB4PA	MI	TTIQUX7
DMHB4PA	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMHB4PA	MT	DTT
DMHB4PA	MA	Inhibitor
DMHB4PA	RN	Development and evaluation of a pharmacophore model for inhibitors of aldosterone synthase (CYP11B2). Bioorg Med Chem Lett. 2006 Jan 1;16(1):25-30.
DMHB4PA	RU	https://pubmed.ncbi.nlm.nih.gov/16246562

DMQC168	DI	DMQC168
DMQC168	DN	3-(1,3 dodecadiynyl)-6-oxiranebutanoic acid
DMQC168	MI	TTPADOQ
DMQC168	MN	HMG-CoA reductase (HMGCR)
DMQC168	MT	DTT
DMQC168	MA	Inhibitor
DMQC168	RN	Novel Acetylenic Acids from the Root Bark of Paramacrolobium caeruleum: Inhibitors of 3-Hydroxy-3-methyl-glutaryl Coenzyme A Reductase J. Nat. Prod. 52(1):153-161 (1989).
DMQC168	RU	http://pubs.acs.org/doi/abs/10.1021/np50061a020

DM24BG6	DI	DM24BG6
DM24BG6	DN	3-(1,5-naphthyridin-3-yl)benzonitrile
DM24BG6	MI	TTHS256
DM24BG6	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM24BG6	MT	DTT
DM24BG6	MA	Inhibitor
DM24BG6	RN	Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8.
DM24BG6	RU	https://pubmed.ncbi.nlm.nih.gov/17936624

DMSP4N5	DI	DMSP4N5
DMSP4N5	DN	3-(1,8-naphthyridin-2-yl)benzonitrile
DMSP4N5	MI	TTHS256
DMSP4N5	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMSP4N5	MT	DTT
DMSP4N5	MA	Inhibitor
DMSP4N5	RN	Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8.
DMSP4N5	RU	https://pubmed.ncbi.nlm.nih.gov/17936624

DMSZLNE	DI	DMSZLNE
DMSZLNE	DN	3'-(1-Benzothien-2-yl)biphenyl-3-ol
DMSZLNE	MI	TTIWB6L
DMSZLNE	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMSZLNE	MT	DTT
DMSZLNE	MA	Inhibitor
DMSZLNE	RN	Novel estrone mimetics with high 17beta-HSD1 inhibitory activity. Bioorg Med Chem. 2010 May 15;18(10):3494-505.
DMSZLNE	RU	https://pubmed.ncbi.nlm.nih.gov/20413314

DMGYDEK	DI	DMGYDEK
DMGYDEK	DN	3-(1-Benzyl-1H-imidazol-5-yl)-1-propanol
DMGYDEK	MI	TTIQUX7
DMGYDEK	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMGYDEK	MT	DTT
DMGYDEK	MA	Inhibitor
DMGYDEK	RN	Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25.
DMGYDEK	RU	https://pubmed.ncbi.nlm.nih.gov/20121113

DMGDN93	DI	DMGDN93
DMGDN93	DN	3-(1-Benzyl-piperidin-3-yl)-2-phenyl-1H-indole
DMGDN93	MI	TTQ6VDM
DMGDN93	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMGDN93	MT	DTT
DMGDN93	MA	Inhibitor
DMGDN93	RN	3-(4-Fluoropiperidin-3-yl)-2-phenylindoles as high affinity, selective, and orally bioavailable h5-HT(2A) receptor antagonists. J Med Chem. 2001 May 10;44(10):1603-14.
DMGDN93	RU	https://pubmed.ncbi.nlm.nih.gov/11334570

DMWP0VK	DI	DMWP0VK
DMWP0VK	DN	3-(1-Benzyl-piperidin-4-yl)-2-phenyl-1H-indole
DMWP0VK	MI	TTJQOD7
DMWP0VK	MN	5-HT 2A receptor (HTR2A)
DMWP0VK	MT	DTT
DMWP0VK	MA	Inhibitor
DMWP0VK	RN	3-(4-Piperidinyl)- and 3-(8-aza-bicyclo[3.2.1]oct-3-yl)-2-phenyl-1H-indoles as bioavailable h5-HT2A antagonists. Bioorg Med Chem Lett. 2000 Dec 18;10(24):2701-3.
DMWP0VK	RU	https://pubmed.ncbi.nlm.nih.gov/11133072

DM2YKHI	DI	DM2YKHI
DM2YKHI	DN	3-(1-benzylpiperidin-4-yl)-5-chloro-1H-indole
DM2YKHI	MI	TTNT7K8
DM2YKHI	MN	Nociceptin receptor (OPRL1)
DM2YKHI	MT	DTT
DM2YKHI	MA	Inhibitor
DM2YKHI	RN	3-(4-Piperidinyl)indoles and 3-(4-piperidinyl)pyrrolo-[2,3-b]pyridines as ligands for the ORL-1 receptor. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3524-8.
DM2YKHI	RU	https://pubmed.ncbi.nlm.nih.gov/16632355

DM2YKHI	DI	DM2YKHI
DM2YKHI	DN	3-(1-benzylpiperidin-4-yl)-5-chloro-1H-indole
DM2YKHI	MI	TTQW87Y
DM2YKHI	MN	Opioid receptor kappa (OPRK1)
DM2YKHI	MT	DTT
DM2YKHI	MA	Inhibitor
DM2YKHI	RN	3-(4-Piperidinyl)indoles and 3-(4-piperidinyl)pyrrolo-[2,3-b]pyridines as ligands for the ORL-1 receptor. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3524-8.
DM2YKHI	RU	https://pubmed.ncbi.nlm.nih.gov/16632355

DM2YKHI	DI	DM2YKHI
DM2YKHI	DN	3-(1-benzylpiperidin-4-yl)-5-chloro-1H-indole
DM2YKHI	MI	TTKWM86
DM2YKHI	MN	Opioid receptor mu (MOP)
DM2YKHI	MT	DTT
DM2YKHI	MA	Inhibitor
DM2YKHI	RN	3-(4-Piperidinyl)indoles and 3-(4-piperidinyl)pyrrolo-[2,3-b]pyridines as ligands for the ORL-1 receptor. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3524-8.
DM2YKHI	RU	https://pubmed.ncbi.nlm.nih.gov/16632355

DMG3A4Z	DI	DMG3A4Z
DMG3A4Z	DN	3-(1-benzylpiperidin-4-yloxy)benzamide
DMG3A4Z	MI	TTQW87Y
DMG3A4Z	MN	Opioid receptor kappa (OPRK1)
DMG3A4Z	MT	DTT
DMG3A4Z	MA	Inhibitor
DMG3A4Z	RN	Discovery of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as selective antagonists of the kappa opioid receptor. Part 1. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5847-52.
DMG3A4Z	RU	https://pubmed.ncbi.nlm.nih.gov/20727752

DMOMSTN	DI	DMOMSTN
DMOMSTN	DN	3-(1-carbamoyl-1,1-diphenylmethyl)-1-(4-methoxyphenylethyl)pyrrolidine (APP)
DMOMSTN	MI	TTQ13Z5
DMOMSTN	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMOMSTN	MT	DTT
DMOMSTN	MA	Antagonist
DMOMSTN	RN	Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther. 2004 Jun;309(3):1148-53.
DMOMSTN	RU	https://pubmed.ncbi.nlm.nih.gov/14769832

DMHPYWM	DI	DMHPYWM
DMHPYWM	DN	3-(1-carboxy-4-mercaptobutoxy)benzoic acid
DMHPYWM	MI	TT9G4N0
DMHPYWM	MN	Glutamate carboxypeptidase II (GCPII)
DMHPYWM	MT	DTT
DMHPYWM	MA	Inhibitor
DMHPYWM	RN	Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1' side chain. J Med Chem. 2006 May 18;49(10):2876-85.
DMHPYWM	RU	https://pubmed.ncbi.nlm.nih.gov/16686531

DMLH7YI	DI	DMLH7YI
DMLH7YI	DN	3-(1-Chloro-7-methoxy-naphthalen-2-yl)-pyridine
DMLH7YI	MI	TTIQUX7
DMLH7YI	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMLH7YI	MT	DTT
DMLH7YI	MA	Inhibitor
DMLH7YI	RN	Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42.
DMLH7YI	RU	https://pubmed.ncbi.nlm.nih.gov/16220979

DMLH7YI	DI	DMLH7YI
DMLH7YI	DN	3-(1-Chloro-7-methoxy-naphthalen-2-yl)-pyridine
DMLH7YI	MI	TTRA5BZ
DMLH7YI	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMLH7YI	MT	DTT
DMLH7YI	MA	Inhibitor
DMLH7YI	RN	Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42.
DMLH7YI	RU	https://pubmed.ncbi.nlm.nih.gov/16220979

DMR7M82	DI	DMR7M82
DMR7M82	DN	3-(1-ethyl-3,4-dihydronaphthalen-2-yl)-pyridine
DMR7M82	MI	TTSZLWK
DMR7M82	MN	Aromatase (CYP19A1)
DMR7M82	MT	DTT
DMR7M82	MA	Inhibitor
DMR7M82	RN	Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31.
DMR7M82	RU	https://pubmed.ncbi.nlm.nih.gov/16570918

DMR7M82	DI	DMR7M82
DMR7M82	DN	3-(1-ethyl-3,4-dihydronaphthalen-2-yl)-pyridine
DMR7M82	MI	TTIQUX7
DMR7M82	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMR7M82	MT	DTT
DMR7M82	MA	Inhibitor
DMR7M82	RN	Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31.
DMR7M82	RU	https://pubmed.ncbi.nlm.nih.gov/16570918

DMR7M82	DI	DMR7M82
DMR7M82	DN	3-(1-ethyl-3,4-dihydronaphthalen-2-yl)-pyridine
DMR7M82	MI	TTRA5BZ
DMR7M82	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMR7M82	MT	DTT
DMR7M82	MA	Inhibitor
DMR7M82	RN	Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31.
DMR7M82	RU	https://pubmed.ncbi.nlm.nih.gov/16570918

DMERZHK	DI	DMERZHK
DMERZHK	DN	3-(1H-Imidazol-4-yl)benzenethiol
DMERZHK	MI	TTZJYKH
DMERZHK	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMERZHK	MT	DTT
DMERZHK	MA	Inhibitor
DMERZHK	RN	Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase. J Med Chem. 2008 Aug 28;51(16):4968-77.
DMERZHK	RU	https://pubmed.ncbi.nlm.nih.gov/18665584

DM9ZDIK	DI	DM9ZDIK
DM9ZDIK	DN	3-(1H-inden-2-yl)pyridine
DM9ZDIK	MI	TTIQUX7
DM9ZDIK	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM9ZDIK	MT	DTT
DM9ZDIK	MA	Inhibitor
DM9ZDIK	RN	Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31.
DM9ZDIK	RU	https://pubmed.ncbi.nlm.nih.gov/16570918

DMLV80B	DI	DMLV80B
DMLV80B	DN	3-(1H-indol-1-yl)-N-methyl-3-phenylpropan-1-amine
DMLV80B	MI	TTAWNKZ
DMLV80B	MN	Norepinephrine transporter (NET)
DMLV80B	MT	DTT
DMLV80B	MA	Inhibitor
DMLV80B	RN	Synthesis and activity of novel 1- or 3-(3-amino-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors. Bioorg Med Chem Lett. 2008 Dec 1;18(23):6067-70.
DMLV80B	RU	https://pubmed.ncbi.nlm.nih.gov/18951020

DMLV80B	DI	DMLV80B
DMLV80B	DN	3-(1H-indol-1-yl)-N-methyl-3-phenylpropan-1-amine
DMLV80B	MI	TT3ROYC
DMLV80B	MN	Serotonin transporter (SERT)
DMLV80B	MT	DTT
DMLV80B	MA	Inhibitor
DMLV80B	RN	Synthesis and activity of novel 1- or 3-(3-amino-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors. Bioorg Med Chem Lett. 2008 Dec 1;18(23):6067-70.
DMLV80B	RU	https://pubmed.ncbi.nlm.nih.gov/18951020

DMS3JCN	DI	DMS3JCN
DMS3JCN	DN	3-(1H-Indol-2-yl)-1H-quinolin-2-one
DMS3JCN	MI	TTTU902
DMS3JCN	MN	Checkpoint kinase-1 (CHK1)
DMS3JCN	MT	DTT
DMS3JCN	MA	Inhibitor
DMS3JCN	RN	Development of 6-substituted indolylquinolinones as potent Chek1 kinase inhibitors. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5907-12.
DMS3JCN	RU	https://pubmed.ncbi.nlm.nih.gov/16990002

DMS3JCN	DI	DMS3JCN
DMS3JCN	DN	3-(1H-Indol-2-yl)-1H-quinolin-2-one
DMS3JCN	MI	TTUTJGQ
DMS3JCN	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMS3JCN	MT	DTT
DMS3JCN	MA	Inhibitor
DMS3JCN	RN	Optimization of the indolyl quinolinone class of KDR (VEGFR-2) kinase inhibitors: effects of 5-amido- and 5-sulphonamido-indolyl groups on pharmaco... Bioorg Med Chem Lett. 2004 Jan 19;14(2):351-5.
DMS3JCN	RU	https://pubmed.ncbi.nlm.nih.gov/14698157

DMP0RYB	DI	DMP0RYB
DMP0RYB	DN	3-(1H-Indol-3-yl)-4-phenylamino-pyrrole-2,5-dione
DMP0RYB	MI	TTFJ8Q1
DMP0RYB	MN	Protein kinase C alpha (PRKCA)
DMP0RYB	MT	DTT
DMP0RYB	MA	Inhibitor
DMP0RYB	RN	Synthesis of anilino-monoindolylmaleimides as potent and selective PKCbeta inhibitors. Bioorg Med Chem Lett. 2004 Oct 18;14(20):5171-4.
DMP0RYB	RU	https://pubmed.ncbi.nlm.nih.gov/15380221

DMP0RYB	DI	DMP0RYB
DMP0RYB	DN	3-(1H-Indol-3-yl)-4-phenylamino-pyrrole-2,5-dione
DMP0RYB	MI	TTYPXQF
DMP0RYB	MN	Protein kinase C beta (PRKCB)
DMP0RYB	MT	DTT
DMP0RYB	MA	Inhibitor
DMP0RYB	RN	Synthesis of anilino-monoindolylmaleimides as potent and selective PKCbeta inhibitors. Bioorg Med Chem Lett. 2004 Oct 18;14(20):5171-4.
DMP0RYB	RU	https://pubmed.ncbi.nlm.nih.gov/15380221

DMSGCKU	DI	DMSGCKU
DMSGCKU	DN	3-(1H-Indol-3-yl)-6,7-dimethoxy-quinoline
DMSGCKU	MI	TT8FYO9
DMSGCKU	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMSGCKU	MT	DTT
DMSGCKU	MA	Inhibitor
DMSGCKU	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMSGCKU	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMSGCKU	DI	DMSGCKU
DMSGCKU	DN	3-(1H-Indol-3-yl)-6,7-dimethoxy-quinoline
DMSGCKU	MI	TTI7421
DMSGCKU	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMSGCKU	MT	DTT
DMSGCKU	MA	Inhibitor
DMSGCKU	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMSGCKU	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DM6Y2XK	DI	DM6Y2XK
DM6Y2XK	DN	3-(1H-indol-3-yl)-N,N-dimethylpropan-1-amine
DM6Y2XK	MI	TT3ROYC
DM6Y2XK	MN	Serotonin transporter (SERT)
DM6Y2XK	MT	DTT
DM6Y2XK	MA	Inhibitor
DM6Y2XK	RN	Conformationally restricted homotryptamines. Part 4: Heterocyclic and naphthyl analogs of a potent selective serotonin reuptake inhibitor. Bioorg Med Chem Lett. 2007 Oct 15;17(20):5647-51.
DM6Y2XK	RU	https://pubmed.ncbi.nlm.nih.gov/17766113

DMEV6Q2	DI	DMEV6Q2
DMEV6Q2	DN	3-(1H-indol-3-yl)-N-methyl-3-phenylpropan-1-amine
DMEV6Q2	MI	TTQ6VDM
DMEV6Q2	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMEV6Q2	MT	DTT
DMEV6Q2	MA	Inhibitor
DMEV6Q2	RN	Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors. Bioorg Med Chem Lett. 2008 Dec 1;18(23):6062-6.
DMEV6Q2	RU	https://pubmed.ncbi.nlm.nih.gov/18954985

DMW7XN5	DI	DMW7XN5
DMW7XN5	DN	3-(1H-Indol-3-yl)-quinoline
DMW7XN5	MI	TT8FYO9
DMW7XN5	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMW7XN5	MT	DTT
DMW7XN5	MA	Inhibitor
DMW7XN5	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMW7XN5	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMW7XN5	DI	DMW7XN5
DMW7XN5	DN	3-(1H-Indol-3-yl)-quinoline
DMW7XN5	MI	TTI7421
DMW7XN5	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMW7XN5	MT	DTT
DMW7XN5	MA	Inhibitor
DMW7XN5	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMW7XN5	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMKFGDI	DI	DMKFGDI
DMKFGDI	DN	3-(1H-pyrazol-3-yl)benzoic acid
DMKFGDI	MI	TT6804T
DMKFGDI	MN	MIF messenger RNA (MIF mRNA)
DMKFGDI	MT	DTT
DMKFGDI	MA	Inhibitor
DMKFGDI	RN	Discovery of human macrophage migration inhibitory factor (MIF)-CD74 antagonists via virtual screening. J Med Chem. 2009 Jan 22;52(2):416-24.
DMKFGDI	RU	https://pubmed.ncbi.nlm.nih.gov/19090668

DMCKJ27	DI	DMCKJ27
DMCKJ27	DN	3-(1H-Pyrrol-3-yl)-propionamide
DMCKJ27	MI	TTG5QB7
DMCKJ27	MN	Calpain-2 (CAPN2)
DMCKJ27	MT	DTT
DMCKJ27	MA	Inhibitor
DMCKJ27	RN	Synthesis of cystamidin a (pyrrole-3-propanamide), a reported calpain inhibitor, Bioorg. Med. Chem. Lett. 6(13):1541-1542 (1996).
DMCKJ27	RU	http://www.sciencedirect.com/science/article/pii/S0960894X96002697

DMU5HMC	DI	DMU5HMC
DMU5HMC	DN	3-(1-methyl-3,4-dihydronaphthalen-2-yl)-pyridine
DMU5HMC	MI	TTSZLWK
DMU5HMC	MN	Aromatase (CYP19A1)
DMU5HMC	MT	DTT
DMU5HMC	MA	Inhibitor
DMU5HMC	RN	Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31.
DMU5HMC	RU	https://pubmed.ncbi.nlm.nih.gov/16570918

DMU5HMC	DI	DMU5HMC
DMU5HMC	DN	3-(1-methyl-3,4-dihydronaphthalen-2-yl)-pyridine
DMU5HMC	MI	TTIQUX7
DMU5HMC	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMU5HMC	MT	DTT
DMU5HMC	MA	Inhibitor
DMU5HMC	RN	Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31.
DMU5HMC	RU	https://pubmed.ncbi.nlm.nih.gov/16570918

DMU5HMC	DI	DMU5HMC
DMU5HMC	DN	3-(1-methyl-3,4-dihydronaphthalen-2-yl)-pyridine
DMU5HMC	MI	TTRA5BZ
DMU5HMC	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMU5HMC	MT	DTT
DMU5HMC	MA	Inhibitor
DMU5HMC	RN	Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31.
DMU5HMC	RU	https://pubmed.ncbi.nlm.nih.gov/16570918

DMK8LHB	DI	DMK8LHB
DMK8LHB	DN	3-(1-Methyl-piperidin-2-yl)-2-phenyl-1H-indole
DMK8LHB	MI	TTQ6VDM
DMK8LHB	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMK8LHB	MT	DTT
DMK8LHB	MA	Inhibitor
DMK8LHB	RN	3-(4-Fluoropiperidin-3-yl)-2-phenylindoles as high affinity, selective, and orally bioavailable h5-HT(2A) receptor antagonists. J Med Chem. 2001 May 10;44(10):1603-14.
DMK8LHB	RU	https://pubmed.ncbi.nlm.nih.gov/11334570

DM4UD8C	DI	DM4UD8C
DM4UD8C	DN	3-(1-Methyl-piperidin-3-yl)-2-phenyl-1H-indole
DM4UD8C	MI	TTQ6VDM
DM4UD8C	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DM4UD8C	MT	DTT
DM4UD8C	MA	Inhibitor
DM4UD8C	RN	3-(4-Fluoropiperidin-3-yl)-2-phenylindoles as high affinity, selective, and orally bioavailable h5-HT(2A) receptor antagonists. J Med Chem. 2001 May 10;44(10):1603-14.
DM4UD8C	RU	https://pubmed.ncbi.nlm.nih.gov/11334570

DM6R5HU	DI	DM6R5HU
DM6R5HU	DN	3-(1-Methyl-piperidin-4-yl)-2-phenyl-1H-indole
DM6R5HU	MI	TTJQOD7
DM6R5HU	MN	5-HT 2A receptor (HTR2A)
DM6R5HU	MT	DTT
DM6R5HU	MA	Inhibitor
DM6R5HU	RN	3-(4-Piperidinyl)- and 3-(8-aza-bicyclo[3.2.1]oct-3-yl)-2-phenyl-1H-indoles as bioavailable h5-HT2A antagonists. Bioorg Med Chem Lett. 2000 Dec 18;10(24):2701-3.
DM6R5HU	RU	https://pubmed.ncbi.nlm.nih.gov/11133072

DMXMBEF	DI	DMXMBEF
DMXMBEF	DN	3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE
DMXMBEF	MI	TTQBR95
DMXMBEF	MN	Stress-activated protein kinase 2a (p38 alpha)
DMXMBEF	MT	DTT
DMXMBEF	MA	Inhibitor
DMXMBEF	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMXMBEF	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMOQ4ER	DI	DMOQ4ER
DMOQ4ER	DN	3-(1-Phenethyl-piperidin-3-yl)-2-phenyl-1H-indole
DMOQ4ER	MI	TTQ6VDM
DMOQ4ER	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMOQ4ER	MT	DTT
DMOQ4ER	MA	Inhibitor
DMOQ4ER	RN	3-(4-Fluoropiperidin-3-yl)-2-phenylindoles as high affinity, selective, and orally bioavailable h5-HT(2A) receptor antagonists. J Med Chem. 2001 May 10;44(10):1603-14.
DMOQ4ER	RU	https://pubmed.ncbi.nlm.nih.gov/11334570

DM8TH2N	DI	DM8TH2N
DM8TH2N	DN	3-(1-Phenethyl-piperidin-4-yl)-2-phenyl-1H-indole
DM8TH2N	MI	TTJQOD7
DM8TH2N	MN	5-HT 2A receptor (HTR2A)
DM8TH2N	MT	DTT
DM8TH2N	MA	Inhibitor
DM8TH2N	RN	3-(4-Piperidinyl)- and 3-(8-aza-bicyclo[3.2.1]oct-3-yl)-2-phenyl-1H-indoles as bioavailable h5-HT2A antagonists. Bioorg Med Chem Lett. 2000 Dec 18;10(24):2701-3.
DM8TH2N	RU	https://pubmed.ncbi.nlm.nih.gov/11133072

DM8TH2N	DI	DM8TH2N
DM8TH2N	DN	3-(1-Phenethyl-piperidin-4-yl)-2-phenyl-1H-indole
DM8TH2N	MI	TTQ6VDM
DM8TH2N	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DM8TH2N	MT	DTT
DM8TH2N	MA	Inhibitor
DM8TH2N	RN	3-(4-Fluoropiperidin-3-yl)-2-phenylindoles as high affinity, selective, and orally bioavailable h5-HT(2A) receptor antagonists. J Med Chem. 2001 May 10;44(10):1603-14.
DM8TH2N	RU	https://pubmed.ncbi.nlm.nih.gov/11334570

DM4QRV9	DI	DM4QRV9
DM4QRV9	DN	3-(1-Propyl-pyrrolidin-3-yl)-phenol
DM4QRV9	MI	TTSQIFT
DM4QRV9	MN	5-HT 1A receptor (HTR1A)
DM4QRV9	MT	DTT
DM4QRV9	MA	Inhibitor
DM4QRV9	RN	Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity, Bioorg. Med. Chem. Lett. 7(3):241-246 (1997).
DM4QRV9	RU	http://www.sciencedirect.com/science/article/pii/S0960894X9600618X

DM4QRV9	DI	DM4QRV9
DM4QRV9	DN	3-(1-Propyl-pyrrolidin-3-yl)-phenol
DM4QRV9	MI	TTEX248
DM4QRV9	MN	Dopamine D2 receptor (D2R)
DM4QRV9	MT	DTT
DM4QRV9	MA	Inhibitor
DM4QRV9	RN	Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity, Bioorg. Med. Chem. Lett. 7(3):241-246 (1997).
DM4QRV9	RU	http://www.sciencedirect.com/science/article/pii/S0960894X9600618X

DM4QRV9	DI	DM4QRV9
DM4QRV9	DN	3-(1-Propyl-pyrrolidin-3-yl)-phenol
DM4QRV9	MI	TT4C8EA
DM4QRV9	MN	Dopamine D3 receptor (D3R)
DM4QRV9	MT	DTT
DM4QRV9	MA	Inhibitor
DM4QRV9	RN	Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity, Bioorg. Med. Chem. Lett. 7(3):241-246 (1997).
DM4QRV9	RU	http://www.sciencedirect.com/science/article/pii/S0960894X9600618X

DMTD7VE	DI	DMTD7VE
DMTD7VE	DN	3-(1-Pyridin-2-yl-1H-pyrazol-3-yl)-benzonitrile
DMTD7VE	MI	TTHS256
DMTD7VE	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMTD7VE	MT	DTT
DMTD7VE	MA	Inhibitor
DMTD7VE	RN	Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity. J Med Chem. 2004 Sep 9;47(19):4645-8. Letter
DMTD7VE	RU	https://pubmed.ncbi.nlm.nih.gov/15341479

DMWI37C	DI	DMWI37C
DMWI37C	DN	3-(1-Pyridin-2-yl-1H-pyrazol-4-yl)-benzonitrile
DMWI37C	MI	TTHS256
DMWI37C	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMWI37C	MT	DTT
DMWI37C	MA	Inhibitor
DMWI37C	RN	Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity. J Med Chem. 2004 Sep 9;47(19):4645-8. Letter
DMWI37C	RU	https://pubmed.ncbi.nlm.nih.gov/15341479

DMJ9LRE	DI	DMJ9LRE
DMJ9LRE	DN	3-(1-Pyridin-2-yl-1H-pyrrol-3-yl)-benzonitrile
DMJ9LRE	MI	TTHS256
DMJ9LRE	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMJ9LRE	MT	DTT
DMJ9LRE	MA	Inhibitor
DMJ9LRE	RN	Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity. J Med Chem. 2004 Sep 9;47(19):4645-8. Letter
DMJ9LRE	RU	https://pubmed.ncbi.nlm.nih.gov/15341479

DM8P26J	DI	DM8P26J
DM8P26J	DN	3-(2-((E)-3-phenylprop-1-enyl)phenyl)acrylic acid
DM8P26J	MI	TT1ZAVI
DM8P26J	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DM8P26J	MT	DTT
DM8P26J	MA	Inhibitor
DM8P26J	RN	Comparison between two classes of selective EP(3) antagonists and their biological activities. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5639-42.
DM8P26J	RU	https://pubmed.ncbi.nlm.nih.gov/16931013

DM8P26J	DI	DM8P26J
DM8P26J	DN	3-(2-((E)-3-phenylprop-1-enyl)phenyl)acrylic acid
DM8P26J	MI	TTPNGDE
DM8P26J	MN	Prostaglandin E2 receptor EP3 (PTGER3)
DM8P26J	MT	DTT
DM8P26J	MA	Inhibitor
DM8P26J	RN	Comparison between two classes of selective EP(3) antagonists and their biological activities. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5639-42.
DM8P26J	RU	https://pubmed.ncbi.nlm.nih.gov/16931013

DM8P26J	DI	DM8P26J
DM8P26J	DN	3-(2-((E)-3-phenylprop-1-enyl)phenyl)acrylic acid
DM8P26J	MI	TT79WV3
DM8P26J	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DM8P26J	MT	DTT
DM8P26J	MA	Inhibitor
DM8P26J	RN	Comparison between two classes of selective EP(3) antagonists and their biological activities. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5639-42.
DM8P26J	RU	https://pubmed.ncbi.nlm.nih.gov/16931013

DM61CHU	DI	DM61CHU
DM61CHU	DN	3-(2-(4-methoxycinnamyl)phenyl)acrylic acid
DM61CHU	MI	TT1ZAVI
DM61CHU	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DM61CHU	MT	DTT
DM61CHU	MA	Inhibitor
DM61CHU	RN	Comparison between two classes of selective EP(3) antagonists and their biological activities. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5639-42.
DM61CHU	RU	https://pubmed.ncbi.nlm.nih.gov/16931013

DM61CHU	DI	DM61CHU
DM61CHU	DN	3-(2-(4-methoxycinnamyl)phenyl)acrylic acid
DM61CHU	MI	TTPNGDE
DM61CHU	MN	Prostaglandin E2 receptor EP3 (PTGER3)
DM61CHU	MT	DTT
DM61CHU	MA	Inhibitor
DM61CHU	RN	Comparison between two classes of selective EP(3) antagonists and their biological activities. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5639-42.
DM61CHU	RU	https://pubmed.ncbi.nlm.nih.gov/16931013

DM61CHU	DI	DM61CHU
DM61CHU	DN	3-(2-(4-methoxycinnamyl)phenyl)acrylic acid
DM61CHU	MI	TT79WV3
DM61CHU	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DM61CHU	MT	DTT
DM61CHU	MA	Inhibitor
DM61CHU	RN	Comparison between two classes of selective EP(3) antagonists and their biological activities. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5639-42.
DM61CHU	RU	https://pubmed.ncbi.nlm.nih.gov/16931013

DM9O5CH	DI	DM9O5CH
DM9O5CH	DN	3-(2-(naphthalen-2-ylmethyl)phenyl)acrylic acid
DM9O5CH	MI	TT1ZAVI
DM9O5CH	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DM9O5CH	MT	DTT
DM9O5CH	MA	Inhibitor
DM9O5CH	RN	Comparison between two classes of selective EP(3) antagonists and their biological activities. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5639-42.
DM9O5CH	RU	https://pubmed.ncbi.nlm.nih.gov/16931013

DM9O5CH	DI	DM9O5CH
DM9O5CH	DN	3-(2-(naphthalen-2-ylmethyl)phenyl)acrylic acid
DM9O5CH	MI	TTPNGDE
DM9O5CH	MN	Prostaglandin E2 receptor EP3 (PTGER3)
DM9O5CH	MT	DTT
DM9O5CH	MA	Inhibitor
DM9O5CH	RN	Comparison between two classes of selective EP(3) antagonists and their biological activities. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5639-42.
DM9O5CH	RU	https://pubmed.ncbi.nlm.nih.gov/16931013

DM9O5CH	DI	DM9O5CH
DM9O5CH	DN	3-(2-(naphthalen-2-ylmethyl)phenyl)acrylic acid
DM9O5CH	MI	TT79WV3
DM9O5CH	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DM9O5CH	MT	DTT
DM9O5CH	MA	Inhibitor
DM9O5CH	RN	Comparison between two classes of selective EP(3) antagonists and their biological activities. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5639-42.
DM9O5CH	RU	https://pubmed.ncbi.nlm.nih.gov/16931013

DMSCIP2	DI	DMSCIP2
DMSCIP2	DN	3-(2,2-Dimethyl-propoxy)-9H-beta-carboline
DMSCIP2	MI	TT1MPAY
DMSCIP2	MN	GABA(A) receptor alpha-1 (GABRA1)
DMSCIP2	MT	DTT
DMSCIP2	MA	Inhibitor
DMSCIP2	RN	Predictive binding of beta-carboline inverse agonists and antagonists via the CoMFA/GOLPE approach. J Med Chem. 1992 Oct 30;35(22):4001-10.
DMSCIP2	RU	https://pubmed.ncbi.nlm.nih.gov/1331452

DMSCIP2	DI	DMSCIP2
DMSCIP2	DN	3-(2,2-Dimethyl-propoxy)-9H-beta-carboline
DMSCIP2	MI	TTNJYV2
DMSCIP2	MN	Gamma-aminobutyric acid receptor (GAR)
DMSCIP2	MT	DTT
DMSCIP2	MA	Inhibitor
DMSCIP2	RN	Predictive binding of beta-carboline inverse agonists and antagonists via the CoMFA/GOLPE approach. J Med Chem. 1992 Oct 30;35(22):4001-10.
DMSCIP2	RU	https://pubmed.ncbi.nlm.nih.gov/1331452

DMCPOQ9	DI	DMCPOQ9
DMCPOQ9	DN	3-(2,2-Diphenyl-vinyl)-pyridine
DMCPOQ9	MI	TTSZLWK
DMCPOQ9	MN	Aromatase (CYP19A1)
DMCPOQ9	MT	DTT
DMCPOQ9	MA	Inhibitor
DMCPOQ9	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMCPOQ9	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMTS4YD	DI	DMTS4YD
DMTS4YD	DN	3-(2,3-Dihydro-1,4-benzodioxin-6-yl)pyridine
DMTS4YD	MI	TTIQUX7
DMTS4YD	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMTS4YD	MT	DTT
DMTS4YD	MA	Inhibitor
DMTS4YD	RN	In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87.
DMTS4YD	RU	https://pubmed.ncbi.nlm.nih.gov/19049427

DM0ZRDV	DI	DM0ZRDV
DM0ZRDV	DN	3-(2,3-Dimethyl-phenyl)-1-propyl-piperidine
DM0ZRDV	MI	TTEX248
DM0ZRDV	MN	Dopamine D2 receptor (D2R)
DM0ZRDV	MT	DTT
DM0ZRDV	MA	Inhibitor
DM0ZRDV	RN	N-n-Propyl-substituted 3-(dimethylphenyl)piperidines display novel discriminative properties between dopamine receptor subtypes: synthesis and rece... J Med Chem. 1998 Dec 3;41(25):4933-8.
DM0ZRDV	RU	https://pubmed.ncbi.nlm.nih.gov/9836610

DMEFKJD	DI	DMEFKJD
DMEFKJD	DN	3-(2,3-Dimethyl-phenyl)-piperidine
DMEFKJD	MI	TTEX248
DMEFKJD	MN	Dopamine D2 receptor (D2R)
DMEFKJD	MT	DTT
DMEFKJD	MA	Inhibitor
DMEFKJD	RN	N-n-Propyl-substituted 3-(dimethylphenyl)piperidines display novel discriminative properties between dopamine receptor subtypes: synthesis and rece... J Med Chem. 1998 Dec 3;41(25):4933-8.
DMEFKJD	RU	https://pubmed.ncbi.nlm.nih.gov/9836610

DMXQROU	DI	DMXQROU
DMXQROU	DN	3-(2,4-dihydroxyphenyl)propionic acid
DMXQROU	MI	TTULVH8
DMXQROU	MN	Tyrosinase (TYR)
DMXQROU	MT	DTT
DMXQROU	MA	Inhibitor
DMXQROU	RN	Enhanced substituted resorcinol hydrophobicity augments tyrosinase inhibition potency. J Med Chem. 2007 May 31;50(11):2676-81.
DMXQROU	RU	https://pubmed.ncbi.nlm.nih.gov/17447749

DMB71FZ	DI	DMB71FZ
DMB71FZ	DN	3-(2,4-Dimethyl-phenyl)-1-propyl-piperidine
DMB71FZ	MI	TTEX248
DMB71FZ	MN	Dopamine D2 receptor (D2R)
DMB71FZ	MT	DTT
DMB71FZ	MA	Inhibitor
DMB71FZ	RN	N-n-Propyl-substituted 3-(dimethylphenyl)piperidines display novel discriminative properties between dopamine receptor subtypes: synthesis and rece... J Med Chem. 1998 Dec 3;41(25):4933-8.
DMB71FZ	RU	https://pubmed.ncbi.nlm.nih.gov/9836610

DMUDW1J	DI	DMUDW1J
DMUDW1J	DN	3-(2,5-dimethyl-1H-pyrrol-1-yl)benzoic acid
DMUDW1J	MI	TTIQSC1
DMUDW1J	MN	Bacterial Lethal factor (Bact lef)
DMUDW1J	MT	DTT
DMUDW1J	MA	Inhibitor
DMUDW1J	RN	Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening. J Med Chem. 2006 Aug 24;49(17):5232-44.
DMUDW1J	RU	https://pubmed.ncbi.nlm.nih.gov/16913712

DM974E5	DI	DM974E5
DM974E5	DN	3-(2,5-Dimethyl-phenyl)-1-propyl-piperidine
DM974E5	MI	TTEX248
DM974E5	MN	Dopamine D2 receptor (D2R)
DM974E5	MT	DTT
DM974E5	MA	Inhibitor
DM974E5	RN	N-n-Propyl-substituted 3-(dimethylphenyl)piperidines display novel discriminative properties between dopamine receptor subtypes: synthesis and rece... J Med Chem. 1998 Dec 3;41(25):4933-8.
DM974E5	RU	https://pubmed.ncbi.nlm.nih.gov/9836610

DM6JTNW	DI	DM6JTNW
DM6JTNW	DN	3-(2,5-Dioxo-pyrrolidin-1-yl)-benzoic acid
DM6JTNW	MI	TT1RS9F
DM6JTNW	MN	Acetylcholinesterase (AChE)
DM6JTNW	MT	DTT
DM6JTNW	MA	Inhibitor
DM6JTNW	RN	Synthesis, anticholinesterase activity and structure-activity relationships of m-Aminobenzoic acid derivatives. Bioorg Med Chem Lett. 2003 May 19;13(10):1825-7.
DM6JTNW	RU	https://pubmed.ncbi.nlm.nih.gov/12729674

DMPSAQW	DI	DMPSAQW
DMPSAQW	DN	3-(2,6-Dimethyl-phenyl)-1-propyl-piperidine
DMPSAQW	MI	TTEX248
DMPSAQW	MN	Dopamine D2 receptor (D2R)
DMPSAQW	MT	DTT
DMPSAQW	MA	Inhibitor
DMPSAQW	RN	N-n-Propyl-substituted 3-(dimethylphenyl)piperidines display novel discriminative properties between dopamine receptor subtypes: synthesis and rece... J Med Chem. 1998 Dec 3;41(25):4933-8.
DMPSAQW	RU	https://pubmed.ncbi.nlm.nih.gov/9836610

DMDYW4J	DI	DMDYW4J
DMDYW4J	DN	3-(2,6-diphenylpyridin-4-yl)phenol
DMDYW4J	MI	TT0IHXV
DMDYW4J	MN	DNA topoisomerase II (TOP2)
DMDYW4J	MT	DTT
DMDYW4J	MA	Inhibitor
DMDYW4J	RN	Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl ... Bioorg Med Chem. 2010 May 1;18(9):3066-77.
DMDYW4J	RU	https://pubmed.ncbi.nlm.nih.gov/20392646

DMS98WA	DI	DMS98WA
DMS98WA	DN	3-(2-adamantyl) pyrrolidine
DMS98WA	MI	TTXT3PU
DMS98WA	MN	Influenza M2 protein (Influ M)
DMS98WA	MT	DTT
DMS98WA	MA	Inhibitor
DMS98WA	RN	Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25.
DMS98WA	RU	https://pubmed.ncbi.nlm.nih.gov/17139286

DMQXPM3	DI	DMQXPM3
DMQXPM3	DN	3-(2-Aminoethyl)-4-(Aminomethyl)Heptanedioic Acid
DMQXPM3	MI	TTJHKYD
DMQXPM3	MN	Delta-aminolevulinic acid dehydratase (ALAD)
DMQXPM3	MT	DTT
DMQXPM3	MA	Inhibitor
DMQXPM3	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMQXPM3	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM95R6O	DI	DM95R6O
DM95R6O	DN	3-(2-Amino-ethyl)-5-imino-[1,4]oxazepane
DM95R6O	MI	TTZUFI5
DM95R6O	MN	Nitric-oxide synthase brain (NOS1)
DM95R6O	MT	DTT
DM95R6O	MA	Inhibitor
DM95R6O	RN	Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3.
DM95R6O	RU	https://pubmed.ncbi.nlm.nih.gov/11551770

DM95R6O	DI	DM95R6O
DM95R6O	DN	3-(2-Amino-ethyl)-5-imino-[1,4]oxazepane
DM95R6O	MI	TTF10I9
DM95R6O	MN	Nitric-oxide synthase inducible (NOS2)
DM95R6O	MT	DTT
DM95R6O	MA	Inhibitor
DM95R6O	RN	Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3.
DM95R6O	RU	https://pubmed.ncbi.nlm.nih.gov/11551770

DMQPNUM	DI	DMQPNUM
DMQPNUM	DN	3-(2-Amino-propyl)-1H-indol-5-ol
DMQPNUM	MI	TTSQIFT
DMQPNUM	MN	5-HT 1A receptor (HTR1A)
DMQPNUM	MT	DTT
DMQPNUM	MA	Inhibitor
DMQPNUM	RN	A novel and selective 5-HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano[3,2-e]indole. J Med Chem. 2003 Sep 11;46(19):4188-95.
DMQPNUM	RU	https://pubmed.ncbi.nlm.nih.gov/12954071

DMQPNUM	DI	DMQPNUM
DMQPNUM	DN	3-(2-Amino-propyl)-1H-indol-5-ol
DMQPNUM	MI	TTJQOD7
DMQPNUM	MN	5-HT 2A receptor (HTR2A)
DMQPNUM	MT	DTT
DMQPNUM	MA	Inhibitor
DMQPNUM	RN	1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28.
DMQPNUM	RU	https://pubmed.ncbi.nlm.nih.gov/16392816

DMQPNUM	DI	DMQPNUM
DMQPNUM	DN	3-(2-Amino-propyl)-1H-indol-5-ol
DMQPNUM	MI	TT0K1SC
DMQPNUM	MN	5-HT 2B receptor (HTR2B)
DMQPNUM	MT	DTT
DMQPNUM	MA	Inhibitor
DMQPNUM	RN	1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28.
DMQPNUM	RU	https://pubmed.ncbi.nlm.nih.gov/16392816

DMQPNUM	DI	DMQPNUM
DMQPNUM	DN	3-(2-Amino-propyl)-1H-indol-5-ol
DMQPNUM	MI	TTWJBZ5
DMQPNUM	MN	5-HT 2C receptor (HTR2C)
DMQPNUM	MT	DTT
DMQPNUM	MA	Inhibitor
DMQPNUM	RN	1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28.
DMQPNUM	RU	https://pubmed.ncbi.nlm.nih.gov/16392816

DMZCTGF	DI	DMZCTGF
DMZCTGF	DN	3-(2-Benzylamino-ethoxy)-phenol
DMZCTGF	MI	TTSQIFT
DMZCTGF	MN	5-HT 1A receptor (HTR1A)
DMZCTGF	MT	DTT
DMZCTGF	MA	Inhibitor
DMZCTGF	RN	New generation dopaminergic agents. 2. Discovery of 3-OH-phenoxyethylamine and 3-OH-N1-phenylpiperazine dopaminergic templates. Bioorg Med Chem Lett. 1998 Feb 3;8(3):295-300.
DMZCTGF	RU	https://pubmed.ncbi.nlm.nih.gov/9871673

DMZCTGF	DI	DMZCTGF
DMZCTGF	DN	3-(2-Benzylamino-ethoxy)-phenol
DMZCTGF	MI	TTEX248
DMZCTGF	MN	Dopamine D2 receptor (D2R)
DMZCTGF	MT	DTT
DMZCTGF	MA	Inhibitor
DMZCTGF	RN	New generation dopaminergic agents. 7. Heterocyclic bioisosteres that exploit the 3-OH-phenoxyethylamine D2 template. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2593-8.
DMZCTGF	RU	https://pubmed.ncbi.nlm.nih.gov/10498215

DMZCTGF	DI	DMZCTGF
DMZCTGF	DN	3-(2-Benzylamino-ethoxy)-phenol
DMZCTGF	MI	TT4C8EA
DMZCTGF	MN	Dopamine D3 receptor (D3R)
DMZCTGF	MT	DTT
DMZCTGF	MA	Inhibitor
DMZCTGF	RN	New generation dopaminergic agents. 7. Heterocyclic bioisosteres that exploit the 3-OH-phenoxyethylamine D2 template. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2593-8.
DMZCTGF	RU	https://pubmed.ncbi.nlm.nih.gov/10498215

DMZCTGF	DI	DMZCTGF
DMZCTGF	DN	3-(2-Benzylamino-ethoxy)-phenol
DMZCTGF	MI	TTE0A2F
DMZCTGF	MN	Dopamine D4 receptor (D4R)
DMZCTGF	MT	DTT
DMZCTGF	MA	Inhibitor
DMZCTGF	RN	New generation dopaminergic agents. 7. Heterocyclic bioisosteres that exploit the 3-OH-phenoxyethylamine D2 template. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2593-8.
DMZCTGF	RU	https://pubmed.ncbi.nlm.nih.gov/10498215

DMH6I4E	DI	DMH6I4E
DMH6I4E	DN	3-(2-Bromophenyl)-2-thioxo-(1H )-quinazolin-4-one
DMH6I4E	MI	TTVIAT9
DMH6I4E	MN	Phosphodiesterase 4B (PDE4B)
DMH6I4E	MT	DTT
DMH6I4E	MA	Inhibitor
DMH6I4E	RN	CODES, a novel procedure for ligand-based virtual screening: PDE7 inhibitors as an application example. Eur J Med Chem. 2008 Jul;43(7):1349-59.
DMH6I4E	RU	https://pubmed.ncbi.nlm.nih.gov/18082290

DMDM0R6	DI	DMDM0R6
DMDM0R6	DN	3-(2-Bromophenyl)-6-methylcoumarin
DMDM0R6	MI	TTGP7BY
DMDM0R6	MN	Monoamine oxidase type B (MAO-B)
DMDM0R6	MT	DTT
DMDM0R6	MA	Inhibitor
DMDM0R6	RN	New halogenated 3-phenylcoumarins as potent and selective MAO-B inhibitors. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5157-60.
DMDM0R6	RU	https://pubmed.ncbi.nlm.nih.gov/20659799

DMNOKR3	DI	DMNOKR3
DMNOKR3	DN	3-(2-carbamoyl-5-mercaptopentyl)benzoic acid
DMNOKR3	MI	TT9G4N0
DMNOKR3	MN	Glutamate carboxypeptidase II (GCPII)
DMNOKR3	MT	DTT
DMNOKR3	MA	Inhibitor
DMNOKR3	RN	Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1' side chain. J Med Chem. 2006 May 18;49(10):2876-85.
DMNOKR3	RU	https://pubmed.ncbi.nlm.nih.gov/16686531

DM67B8S	DI	DM67B8S
DM67B8S	DN	3-(2-carboxy-3-mercaptopropyl)benzoic acid
DM67B8S	MI	TT9G4N0
DM67B8S	MN	Glutamate carboxypeptidase II (GCPII)
DM67B8S	MT	DTT
DM67B8S	MA	Inhibitor
DM67B8S	RN	Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1' side chain. J Med Chem. 2006 May 18;49(10):2876-85.
DM67B8S	RU	https://pubmed.ncbi.nlm.nih.gov/16686531

DMG5R0N	DI	DMG5R0N
DMG5R0N	DN	3-(2-carboxy-3-phosphonopropyl)benzoic acid
DMG5R0N	MI	TT9G4N0
DMG5R0N	MN	Glutamate carboxypeptidase II (GCPII)
DMG5R0N	MT	DTT
DMG5R0N	MA	Inhibitor
DMG5R0N	RN	Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1' side chain. J Med Chem. 2006 May 18;49(10):2876-85.
DMG5R0N	RU	https://pubmed.ncbi.nlm.nih.gov/16686531

DM6HPYN	DI	DM6HPYN
DM6HPYN	DN	3-(2-carboxy-4-mercaptobutyl)benzoic acid
DM6HPYN	MI	TT9G4N0
DM6HPYN	MN	Glutamate carboxypeptidase II (GCPII)
DM6HPYN	MT	DTT
DM6HPYN	MA	Inhibitor
DM6HPYN	RN	Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1' side chain. J Med Chem. 2006 May 18;49(10):2876-85.
DM6HPYN	RU	https://pubmed.ncbi.nlm.nih.gov/16686531

DM6H52B	DI	DM6H52B
DM6H52B	DN	3-(2-carboxy-5-mercaptopentyl)benzoic acid
DM6H52B	MI	TT9G4N0
DM6H52B	MN	Glutamate carboxypeptidase II (GCPII)
DM6H52B	MT	DTT
DM6H52B	MA	Inhibitor
DM6H52B	RN	Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1' side chain. J Med Chem. 2006 May 18;49(10):2876-85.
DM6H52B	RU	https://pubmed.ncbi.nlm.nih.gov/16686531

DM870W1	DI	DM870W1
DM870W1	DN	3-(2-carboxy-6-mercaptohexyl)benzoic acid
DM870W1	MI	TT9G4N0
DM870W1	MN	Glutamate carboxypeptidase II (GCPII)
DM870W1	MT	DTT
DM870W1	MA	Inhibitor
DM870W1	RN	Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1' side chain. J Med Chem. 2006 May 18;49(10):2876-85.
DM870W1	RU	https://pubmed.ncbi.nlm.nih.gov/16686531

DMDS4Q0	DI	DMDS4Q0
DMDS4Q0	DN	3-(2-Chloro-1,1-dimethyl-2-phenyl-ethyl)-pyridine
DMDS4Q0	MI	TTIQUX7
DMDS4Q0	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMDS4Q0	MT	DTT
DMDS4Q0	MA	Inhibitor
DMDS4Q0	RN	Structure-activity relationship study of the inhibition of adrenal cortical 11 beta-hydroxylase by new metyrapone analogues. J Med Chem. 1984 Jan;27(1):15-9.
DMDS4Q0	RU	https://pubmed.ncbi.nlm.nih.gov/6606707

DM4XWME	DI	DM4XWME
DM4XWME	DN	3-(2-cinnamylphenyl)acrylic acid
DM4XWME	MI	TT1ZAVI
DM4XWME	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DM4XWME	MT	DTT
DM4XWME	MA	Inhibitor
DM4XWME	RN	Comparison between two classes of selective EP(3) antagonists and their biological activities. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5639-42.
DM4XWME	RU	https://pubmed.ncbi.nlm.nih.gov/16931013

DM4XWME	DI	DM4XWME
DM4XWME	DN	3-(2-cinnamylphenyl)acrylic acid
DM4XWME	MI	TTPNGDE
DM4XWME	MN	Prostaglandin E2 receptor EP3 (PTGER3)
DM4XWME	MT	DTT
DM4XWME	MA	Inhibitor
DM4XWME	RN	Comparison between two classes of selective EP(3) antagonists and their biological activities. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5639-42.
DM4XWME	RU	https://pubmed.ncbi.nlm.nih.gov/16931013

DM4XWME	DI	DM4XWME
DM4XWME	DN	3-(2-cinnamylphenyl)acrylic acid
DM4XWME	MI	TT79WV3
DM4XWME	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DM4XWME	MT	DTT
DM4XWME	MA	Inhibitor
DM4XWME	RN	Comparison between two classes of selective EP(3) antagonists and their biological activities. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5639-42.
DM4XWME	RU	https://pubmed.ncbi.nlm.nih.gov/16931013

DMVUK96	DI	DMVUK96
DMVUK96	DN	3-(2-Cyclohexyl-ethyl)-6,7-dimethoxy-quinoline
DMVUK96	MI	TT8FYO9
DMVUK96	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMVUK96	MT	DTT
DMVUK96	MA	Inhibitor
DMVUK96	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMVUK96	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMVUK96	DI	DMVUK96
DMVUK96	DN	3-(2-Cyclohexyl-ethyl)-6,7-dimethoxy-quinoline
DMVUK96	MI	TTI7421
DMVUK96	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMVUK96	MT	DTT
DMVUK96	MA	Inhibitor
DMVUK96	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMVUK96	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DM08GRF	DI	DM08GRF
DM08GRF	DN	3-(2-Diethylamino-acetamino)-rutaecarpine
DM08GRF	MI	TT1RS9F
DM08GRF	MN	Acetylcholinesterase (AChE)
DM08GRF	MT	DTT
DM08GRF	MA	Inhibitor
DM08GRF	RN	Synthesis and evaluation of novel rutaecarpine derivatives and related alkaloids derivatives as selective acetylcholinesterase inhibitors. Eur J Med Chem. 2010 Apr;45(4):1415-23.
DM08GRF	RU	https://pubmed.ncbi.nlm.nih.gov/20079560

DM08GRF	DI	DM08GRF
DM08GRF	DN	3-(2-Diethylamino-acetamino)-rutaecarpine
DM08GRF	MI	TTEB0GD
DM08GRF	MN	Cholinesterase (BCHE)
DM08GRF	MT	DTT
DM08GRF	MA	Inhibitor
DM08GRF	RN	Synthesis and evaluation of novel rutaecarpine derivatives and related alkaloids derivatives as selective acetylcholinesterase inhibitors. Eur J Med Chem. 2010 Apr;45(4):1415-23.
DM08GRF	RU	https://pubmed.ncbi.nlm.nih.gov/20079560

DM1FOIZ	DI	DM1FOIZ
DM1FOIZ	DN	3-(2-Diethylamino-propionamino)-rutaecarpine
DM1FOIZ	MI	TT1RS9F
DM1FOIZ	MN	Acetylcholinesterase (AChE)
DM1FOIZ	MT	DTT
DM1FOIZ	MA	Inhibitor
DM1FOIZ	RN	Synthesis and evaluation of novel rutaecarpine derivatives and related alkaloids derivatives as selective acetylcholinesterase inhibitors. Eur J Med Chem. 2010 Apr;45(4):1415-23.
DM1FOIZ	RU	https://pubmed.ncbi.nlm.nih.gov/20079560

DM1FOIZ	DI	DM1FOIZ
DM1FOIZ	DN	3-(2-Diethylamino-propionamino)-rutaecarpine
DM1FOIZ	MI	TTEB0GD
DM1FOIZ	MN	Cholinesterase (BCHE)
DM1FOIZ	MT	DTT
DM1FOIZ	MA	Inhibitor
DM1FOIZ	RN	Synthesis and evaluation of novel rutaecarpine derivatives and related alkaloids derivatives as selective acetylcholinesterase inhibitors. Eur J Med Chem. 2010 Apr;45(4):1415-23.
DM1FOIZ	RU	https://pubmed.ncbi.nlm.nih.gov/20079560

DM32MIE	DI	DM32MIE
DM32MIE	DN	3-(2-Dimethylamino-ethyl)-1H-indol-6-ol
DM32MIE	MI	TTJQOD7
DM32MIE	MN	5-HT 2A receptor (HTR2A)
DM32MIE	MT	DTT
DM32MIE	MA	Inhibitor
DM32MIE	RN	SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.
DM32MIE	RU	https://pubmed.ncbi.nlm.nih.gov/16061378

DM32MIE	DI	DM32MIE
DM32MIE	DN	3-(2-Dimethylamino-ethyl)-1H-indol-6-ol
DM32MIE	MI	TT0K1SC
DM32MIE	MN	5-HT 2B receptor (HTR2B)
DM32MIE	MT	DTT
DM32MIE	MA	Inhibitor
DM32MIE	RN	SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.
DM32MIE	RU	https://pubmed.ncbi.nlm.nih.gov/16061378

DM32MIE	DI	DM32MIE
DM32MIE	DN	3-(2-Dimethylamino-ethyl)-1H-indol-6-ol
DM32MIE	MI	TTWJBZ5
DM32MIE	MN	5-HT 2C receptor (HTR2C)
DM32MIE	MT	DTT
DM32MIE	MA	Inhibitor
DM32MIE	RN	SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.
DM32MIE	RU	https://pubmed.ncbi.nlm.nih.gov/16061378

DMKYZGD	DI	DMKYZGD
DMKYZGD	DN	3-(2-Dimethylamino-ethyl)-1-methyl-1H-indol-4-ol
DMKYZGD	MI	TTJQOD7
DMKYZGD	MN	5-HT 2A receptor (HTR2A)
DMKYZGD	MT	DTT
DMKYZGD	MA	Inhibitor
DMKYZGD	RN	SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.
DMKYZGD	RU	https://pubmed.ncbi.nlm.nih.gov/16061378

DMKYZGD	DI	DMKYZGD
DMKYZGD	DN	3-(2-Dimethylamino-ethyl)-1-methyl-1H-indol-4-ol
DMKYZGD	MI	TT0K1SC
DMKYZGD	MN	5-HT 2B receptor (HTR2B)
DMKYZGD	MT	DTT
DMKYZGD	MA	Inhibitor
DMKYZGD	RN	SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.
DMKYZGD	RU	https://pubmed.ncbi.nlm.nih.gov/16061378

DMKYZGD	DI	DMKYZGD
DMKYZGD	DN	3-(2-Dimethylamino-ethyl)-1-methyl-1H-indol-4-ol
DMKYZGD	MI	TTWJBZ5
DMKYZGD	MN	5-HT 2C receptor (HTR2C)
DMKYZGD	MT	DTT
DMKYZGD	MA	Inhibitor
DMKYZGD	RN	SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.
DMKYZGD	RU	https://pubmed.ncbi.nlm.nih.gov/16061378

DM9BTLC	DI	DM9BTLC
DM9BTLC	DN	3-(2-Dimethylamino-ethyl)-2-methyl-1H-indol-4-ol
DM9BTLC	MI	TTJQOD7
DM9BTLC	MN	5-HT 2A receptor (HTR2A)
DM9BTLC	MT	DTT
DM9BTLC	MA	Inhibitor
DM9BTLC	RN	SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.
DM9BTLC	RU	https://pubmed.ncbi.nlm.nih.gov/16061378

DM9BTLC	DI	DM9BTLC
DM9BTLC	DN	3-(2-Dimethylamino-ethyl)-2-methyl-1H-indol-4-ol
DM9BTLC	MI	TTWJBZ5
DM9BTLC	MN	5-HT 2C receptor (HTR2C)
DM9BTLC	MT	DTT
DM9BTLC	MA	Inhibitor
DM9BTLC	RN	SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.
DM9BTLC	RU	https://pubmed.ncbi.nlm.nih.gov/16061378

DMMJP9D	DI	DMMJP9D
DMMJP9D	DN	3-(2-Dimethylamino-propyl)-1H-indol-4-ol
DMMJP9D	MI	TTJQOD7
DMMJP9D	MN	5-HT 2A receptor (HTR2A)
DMMJP9D	MT	DTT
DMMJP9D	MA	Inhibitor
DMMJP9D	RN	SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.
DMMJP9D	RU	https://pubmed.ncbi.nlm.nih.gov/16061378

DMMJP9D	DI	DMMJP9D
DMMJP9D	DN	3-(2-Dimethylamino-propyl)-1H-indol-4-ol
DMMJP9D	MI	TT0K1SC
DMMJP9D	MN	5-HT 2B receptor (HTR2B)
DMMJP9D	MT	DTT
DMMJP9D	MA	Inhibitor
DMMJP9D	RN	SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.
DMMJP9D	RU	https://pubmed.ncbi.nlm.nih.gov/16061378

DMMJP9D	DI	DMMJP9D
DMMJP9D	DN	3-(2-Dimethylamino-propyl)-1H-indol-4-ol
DMMJP9D	MI	TTWJBZ5
DMMJP9D	MN	5-HT 2C receptor (HTR2C)
DMMJP9D	MT	DTT
DMMJP9D	MA	Inhibitor
DMMJP9D	RN	SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.
DMMJP9D	RU	https://pubmed.ncbi.nlm.nih.gov/16061378

DMD24EW	DI	DMD24EW
DMD24EW	DN	3-(2-Hydroxy-phenyl)-benzo[d]isoxazol-6-ol
DMD24EW	MI	TTZAYWL
DMD24EW	MN	Estrogen receptor (ESR)
DMD24EW	MT	DTT
DMD24EW	MA	Inhibitor
DMD24EW	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMD24EW	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMD24EW	DI	DMD24EW
DMD24EW	DN	3-(2-Hydroxy-phenyl)-benzo[d]isoxazol-6-ol
DMD24EW	MI	TTOM3J0
DMD24EW	MN	Estrogen receptor beta (ESR2)
DMD24EW	MT	DTT
DMD24EW	MA	Inhibitor
DMD24EW	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMD24EW	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DM1DQGJ	DI	DM1DQGJ
DM1DQGJ	DN	3-(2-Methyl-2-aza-bicyclo[3.3.1]non-5-yl)-phenol
DM1DQGJ	MI	TTKWM86
DM1DQGJ	MN	Opioid receptor mu (MOP)
DM1DQGJ	MT	DTT
DM1DQGJ	MA	Inhibitor
DM1DQGJ	RN	Phenylmorphans and analogues: opioid receptor subtype selectivity and effect of conformation on activity. J Med Chem. 1992 May 1;35(9):1521-5.
DM1DQGJ	RU	https://pubmed.ncbi.nlm.nih.gov/1315868

DMY782R	DI	DMY782R
DMY782R	DN	3-(2-methylbenzo[d]thiazol-5-yl)benzonitrile
DMY782R	MI	TTHS256
DMY782R	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMY782R	MT	DTT
DMY782R	MA	Inhibitor
DMY782R	RN	Discovery of heterobicyclic templates for novel metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Jun 1;17(11):2987-91.
DMY782R	RU	https://pubmed.ncbi.nlm.nih.gov/17446071

DMUPB9H	DI	DMUPB9H
DMUPB9H	DN	3-(2-methylquinolin-7-yl)benzonitrile
DMUPB9H	MI	TTHS256
DMUPB9H	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMUPB9H	MT	DTT
DMUPB9H	MA	Inhibitor
DMUPB9H	RN	Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8.
DMUPB9H	RU	https://pubmed.ncbi.nlm.nih.gov/17590335

DM41HMZ	DI	DM41HMZ
DM41HMZ	DN	3-(2-methylquinolin-7-yl)phenol
DM41HMZ	MI	TTHS256
DM41HMZ	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM41HMZ	MT	DTT
DM41HMZ	MA	Inhibitor
DM41HMZ	RN	Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8.
DM41HMZ	RU	https://pubmed.ncbi.nlm.nih.gov/17590335

DM27HSO	DI	DM27HSO
DM27HSO	DN	3-(2-naphthyl)phenol
DM27HSO	MI	TTIWB6L
DM27HSO	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DM27HSO	MT	DTT
DM27HSO	MA	Inhibitor
DM27HSO	RN	Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors... J Med Chem. 2008 Apr 10;51(7):2158-69.
DM27HSO	RU	https://pubmed.ncbi.nlm.nih.gov/18324762

DMYXQ7L	DI	DMYXQ7L
DMYXQ7L	DN	3-(2-Nitro-ethyl)-[1,4]oxazepan-(5Z)-ylideneamine
DMYXQ7L	MI	TTZUFI5
DMYXQ7L	MN	Nitric-oxide synthase brain (NOS1)
DMYXQ7L	MT	DTT
DMYXQ7L	MA	Inhibitor
DMYXQ7L	RN	Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3.
DMYXQ7L	RU	https://pubmed.ncbi.nlm.nih.gov/11551770

DMYXQ7L	DI	DMYXQ7L
DMYXQ7L	DN	3-(2-Nitro-ethyl)-[1,4]oxazepan-(5Z)-ylideneamine
DMYXQ7L	MI	TTF10I9
DMYXQ7L	MN	Nitric-oxide synthase inducible (NOS2)
DMYXQ7L	MT	DTT
DMYXQ7L	MA	Inhibitor
DMYXQ7L	RN	Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3.
DMYXQ7L	RU	https://pubmed.ncbi.nlm.nih.gov/11551770

DM3BQO0	DI	DM3BQO0
DM3BQO0	DN	3-(2-N-Piperidyl-acetamino)-rutaecarpine
DM3BQO0	MI	TT1RS9F
DM3BQO0	MN	Acetylcholinesterase (AChE)
DM3BQO0	MT	DTT
DM3BQO0	MA	Inhibitor
DM3BQO0	RN	Synthesis and evaluation of novel rutaecarpine derivatives and related alkaloids derivatives as selective acetylcholinesterase inhibitors. Eur J Med Chem. 2010 Apr;45(4):1415-23.
DM3BQO0	RU	https://pubmed.ncbi.nlm.nih.gov/20079560

DMFEHDY	DI	DMFEHDY
DMFEHDY	DN	3-(2-N-Piperidyl-propionamino)-rutaecarpine
DMFEHDY	MI	TT1RS9F
DMFEHDY	MN	Acetylcholinesterase (AChE)
DMFEHDY	MT	DTT
DMFEHDY	MA	Inhibitor
DMFEHDY	RN	Synthesis and evaluation of novel rutaecarpine derivatives and related alkaloids derivatives as selective acetylcholinesterase inhibitors. Eur J Med Chem. 2010 Apr;45(4):1415-23.
DMFEHDY	RU	https://pubmed.ncbi.nlm.nih.gov/20079560

DMFEHDY	DI	DMFEHDY
DMFEHDY	DN	3-(2-N-Piperidyl-propionamino)-rutaecarpine
DMFEHDY	MI	TTEB0GD
DMFEHDY	MN	Cholinesterase (BCHE)
DMFEHDY	MT	DTT
DMFEHDY	MA	Inhibitor
DMFEHDY	RN	Synthesis and evaluation of novel rutaecarpine derivatives and related alkaloids derivatives as selective acetylcholinesterase inhibitors. Eur J Med Chem. 2010 Apr;45(4):1415-23.
DMFEHDY	RU	https://pubmed.ncbi.nlm.nih.gov/20079560

DMQ0A8W	DI	DMQ0A8W
DMQ0A8W	DN	3-(2-N-Pyrrolyl-acetamino)-rutaecarpine
DMQ0A8W	MI	TT1RS9F
DMQ0A8W	MN	Acetylcholinesterase (AChE)
DMQ0A8W	MT	DTT
DMQ0A8W	MA	Inhibitor
DMQ0A8W	RN	Synthesis and evaluation of novel rutaecarpine derivatives and related alkaloids derivatives as selective acetylcholinesterase inhibitors. Eur J Med Chem. 2010 Apr;45(4):1415-23.
DMQ0A8W	RU	https://pubmed.ncbi.nlm.nih.gov/20079560

DMQ0A8W	DI	DMQ0A8W
DMQ0A8W	DN	3-(2-N-Pyrrolyl-acetamino)-rutaecarpine
DMQ0A8W	MI	TTEB0GD
DMQ0A8W	MN	Cholinesterase (BCHE)
DMQ0A8W	MT	DTT
DMQ0A8W	MA	Inhibitor
DMQ0A8W	RN	Synthesis and evaluation of novel rutaecarpine derivatives and related alkaloids derivatives as selective acetylcholinesterase inhibitors. Eur J Med Chem. 2010 Apr;45(4):1415-23.
DMQ0A8W	RU	https://pubmed.ncbi.nlm.nih.gov/20079560

DM9MRTW	DI	DM9MRTW
DM9MRTW	DN	3-(2-N-Pyrrolyl-propionamino)-rutaecarpine
DM9MRTW	MI	TT1RS9F
DM9MRTW	MN	Acetylcholinesterase (AChE)
DM9MRTW	MT	DTT
DM9MRTW	MA	Inhibitor
DM9MRTW	RN	Synthesis and evaluation of novel rutaecarpine derivatives and related alkaloids derivatives as selective acetylcholinesterase inhibitors. Eur J Med Chem. 2010 Apr;45(4):1415-23.
DM9MRTW	RU	https://pubmed.ncbi.nlm.nih.gov/20079560

DM9MRTW	DI	DM9MRTW
DM9MRTW	DN	3-(2-N-Pyrrolyl-propionamino)-rutaecarpine
DM9MRTW	MI	TTEB0GD
DM9MRTW	MN	Cholinesterase (BCHE)
DM9MRTW	MT	DTT
DM9MRTW	MA	Inhibitor
DM9MRTW	RN	Synthesis and evaluation of novel rutaecarpine derivatives and related alkaloids derivatives as selective acetylcholinesterase inhibitors. Eur J Med Chem. 2010 Apr;45(4):1415-23.
DM9MRTW	RU	https://pubmed.ncbi.nlm.nih.gov/20079560

DM0YEGM	DI	DM0YEGM
DM0YEGM	DN	3-(2-phenyl-2-(piperazin-1-yl)ethyl)benzamide
DM0YEGM	MI	TT3ROYC
DM0YEGM	MN	Serotonin transporter (SERT)
DM0YEGM	MT	DTT
DM0YEGM	MA	Inhibitor
DM0YEGM	RN	N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8.
DM0YEGM	RU	https://pubmed.ncbi.nlm.nih.gov/16750359

DM6YJOU	DI	DM6YJOU
DM6YJOU	DN	3-(2-phenyl-2-(piperazin-1-yl)ethyl)benzonitrile
DM6YJOU	MI	TTAWNKZ
DM6YJOU	MN	Norepinephrine transporter (NET)
DM6YJOU	MT	DTT
DM6YJOU	MA	Inhibitor
DM6YJOU	RN	N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8.
DM6YJOU	RU	https://pubmed.ncbi.nlm.nih.gov/16750359

DM6YJOU	DI	DM6YJOU
DM6YJOU	DN	3-(2-phenyl-2-(piperazin-1-yl)ethyl)benzonitrile
DM6YJOU	MI	TT3ROYC
DM6YJOU	MN	Serotonin transporter (SERT)
DM6YJOU	MT	DTT
DM6YJOU	MA	Inhibitor
DM6YJOU	RN	N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8.
DM6YJOU	RU	https://pubmed.ncbi.nlm.nih.gov/16750359

DM6QZTB	DI	DM6QZTB
DM6QZTB	DN	3-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol
DM6QZTB	MI	TTVBI8W
DM6QZTB	MN	Dopamine transporter (DAT)
DM6QZTB	MT	DTT
DM6QZTB	MA	Inhibitor
DM6QZTB	RN	N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8.
DM6QZTB	RU	https://pubmed.ncbi.nlm.nih.gov/16750359

DM6QZTB	DI	DM6QZTB
DM6QZTB	DN	3-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol
DM6QZTB	MI	TTAWNKZ
DM6QZTB	MN	Norepinephrine transporter (NET)
DM6QZTB	MT	DTT
DM6QZTB	MA	Inhibitor
DM6QZTB	RN	N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8.
DM6QZTB	RU	https://pubmed.ncbi.nlm.nih.gov/16750359

DM6QZTB	DI	DM6QZTB
DM6QZTB	DN	3-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol
DM6QZTB	MI	TT3ROYC
DM6QZTB	MN	Serotonin transporter (SERT)
DM6QZTB	MT	DTT
DM6QZTB	MA	Inhibitor
DM6QZTB	RN	N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8.
DM6QZTB	RU	https://pubmed.ncbi.nlm.nih.gov/16750359

DM63T9D	DI	DM63T9D
DM63T9D	DN	3-(2-phenyl-6-(thiophen-2-yl)pyridin-4-yl)-phenol
DM63T9D	MI	TT0IHXV
DM63T9D	MN	DNA topoisomerase II (TOP2)
DM63T9D	MT	DTT
DM63T9D	MA	Inhibitor
DM63T9D	RN	Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl ... Bioorg Med Chem. 2010 May 1;18(9):3066-77.
DM63T9D	RU	https://pubmed.ncbi.nlm.nih.gov/20392646

DMF369N	DI	DMF369N
DMF369N	DN	3-(2-phenyl-6-(thiophen-3-yl)pyridin-4-yl)-phenol
DMF369N	MI	TT0IHXV
DMF369N	MN	DNA topoisomerase II (TOP2)
DMF369N	MT	DTT
DMF369N	MA	Inhibitor
DMF369N	RN	Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl ... Bioorg Med Chem. 2010 May 1;18(9):3066-77.
DMF369N	RU	https://pubmed.ncbi.nlm.nih.gov/20392646

DMQC9WV	DI	DMQC9WV
DMQC9WV	DN	3-(2-phenylthiazol-4-yl)quinolin-2(1H)-one
DMQC9WV	MI	TTL4Q97
DMQC9WV	MN	Cyclin-dependent kinase 5 (CDK5)
DMQC9WV	MT	DTT
DMQC9WV	MA	Inhibitor
DMQC9WV	RN	Design and synthesis of quinolin-2(1H)-one derivatives as potent CDK5 inhibitors. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5384-9.
DMQC9WV	RU	https://pubmed.ncbi.nlm.nih.gov/17709247

DM2IYAP	DI	DM2IYAP
DM2IYAP	DN	3-(2-propyn-1-yl)thymidine
DM2IYAP	MI	TTP3QRF
DM2IYAP	MN	Thymidine kinase 1 (TK1)
DM2IYAP	MT	DTT
DM2IYAP	MA	Inhibitor
DM2IYAP	RN	Synthesis, in vitro, and in silico evaluation of organometallic technetium and rhenium thymidine complexes with retained substrate activity toward ... J Med Chem. 2008 Nov 13;51(21):6689-98.
DM2IYAP	RU	https://pubmed.ncbi.nlm.nih.gov/18837546

DMPWEL8	DI	DMPWEL8
DMPWEL8	DN	3-(2-Pyridin-2-yl-2H-tetrazol-5-yl)-benzonitrile
DMPWEL8	MI	TTHS256
DMPWEL8	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMPWEL8	MT	DTT
DMPWEL8	MA	Inhibitor
DMPWEL8	RN	Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity. J Med Chem. 2004 Sep 9;47(19):4645-8. Letter
DMPWEL8	RU	https://pubmed.ncbi.nlm.nih.gov/15341479

DM7VJPX	DI	DM7VJPX
DM7VJPX	DN	3-(2-Pyrrolidin-1-yl-ethyl)-1H-indol-4-ol
DM7VJPX	MI	TTJQOD7
DM7VJPX	MN	5-HT 2A receptor (HTR2A)
DM7VJPX	MT	DTT
DM7VJPX	MA	Inhibitor
DM7VJPX	RN	SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.
DM7VJPX	RU	https://pubmed.ncbi.nlm.nih.gov/16061378

DM7VJPX	DI	DM7VJPX
DM7VJPX	DN	3-(2-Pyrrolidin-1-yl-ethyl)-1H-indol-4-ol
DM7VJPX	MI	TT0K1SC
DM7VJPX	MN	5-HT 2B receptor (HTR2B)
DM7VJPX	MT	DTT
DM7VJPX	MA	Inhibitor
DM7VJPX	RN	SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.
DM7VJPX	RU	https://pubmed.ncbi.nlm.nih.gov/16061378

DM7VJPX	DI	DM7VJPX
DM7VJPX	DN	3-(2-Pyrrolidin-1-yl-ethyl)-1H-indol-4-ol
DM7VJPX	MI	TTWJBZ5
DM7VJPX	MN	5-HT 2C receptor (HTR2C)
DM7VJPX	MT	DTT
DM7VJPX	MA	Inhibitor
DM7VJPX	RN	SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.
DM7VJPX	RU	https://pubmed.ncbi.nlm.nih.gov/16061378

DMKAEUD	DI	DMKAEUD
DMKAEUD	DN	3-(3-(3-chlorobenzyloxy)-5-methylphenyl)pyridine
DMKAEUD	MI	TTHS256
DMKAEUD	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMKAEUD	MT	DTT
DMKAEUD	MA	Inhibitor
DMKAEUD	RN	Arylmethoxypyridines as novel, potent and orally active mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1892-7.
DMKAEUD	RU	https://pubmed.ncbi.nlm.nih.gov/16439120

DMY4VX2	DI	DMY4VX2
DMY4VX2	DN	3-(3-(benzamido)-5-nitrobenzamido)propanoic acid
DMY4VX2	MI	TTSJ542
DMY4VX2	MN	Integrin alpha-2 (ITGA2)
DMY4VX2	MT	DTT
DMY4VX2	MA	Inhibitor
DMY4VX2	RN	Derivatives of 7-amino-1,2,3,4-tetrahydroisoquinoline and isophthalic acids as novel fibrinogen receptor antagonists. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5294-7.
DMY4VX2	RU	https://pubmed.ncbi.nlm.nih.gov/16919941

DMY4VX2	DI	DMY4VX2
DMY4VX2	DN	3-(3-(benzamido)-5-nitrobenzamido)propanoic acid
DMY4VX2	MI	TTJA1ZO
DMY4VX2	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMY4VX2	MT	DTT
DMY4VX2	MA	Inhibitor
DMY4VX2	RN	Derivatives of 7-amino-1,2,3,4-tetrahydroisoquinoline and isophthalic acids as novel fibrinogen receptor antagonists. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5294-7.
DMY4VX2	RU	https://pubmed.ncbi.nlm.nih.gov/16919941

DM2K51S	DI	DM2K51S
DM2K51S	DN	3-(3-(carbamoyl)benzamido)-3-phenylpropanoic acid
DM2K51S	MI	TTSJ542
DM2K51S	MN	Integrin alpha-2 (ITGA2)
DM2K51S	MT	DTT
DM2K51S	MA	Inhibitor
DM2K51S	RN	Derivatives of 7-amino-1,2,3,4-tetrahydroisoquinoline and isophthalic acids as novel fibrinogen receptor antagonists. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5294-7.
DM2K51S	RU	https://pubmed.ncbi.nlm.nih.gov/16919941

DM2K51S	DI	DM2K51S
DM2K51S	DN	3-(3-(carbamoyl)benzamido)-3-phenylpropanoic acid
DM2K51S	MI	TTJA1ZO
DM2K51S	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DM2K51S	MT	DTT
DM2K51S	MA	Inhibitor
DM2K51S	RN	Derivatives of 7-amino-1,2,3,4-tetrahydroisoquinoline and isophthalic acids as novel fibrinogen receptor antagonists. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5294-7.
DM2K51S	RU	https://pubmed.ncbi.nlm.nih.gov/16919941

DM31JAZ	DI	DM31JAZ
DM31JAZ	DN	3-(3-(carbamoyl)benzamido)propanoic acid
DM31JAZ	MI	TTSJ542
DM31JAZ	MN	Integrin alpha-2 (ITGA2)
DM31JAZ	MT	DTT
DM31JAZ	MA	Inhibitor
DM31JAZ	RN	Derivatives of 7-amino-1,2,3,4-tetrahydroisoquinoline and isophthalic acids as novel fibrinogen receptor antagonists. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5294-7.
DM31JAZ	RU	https://pubmed.ncbi.nlm.nih.gov/16919941

DM31JAZ	DI	DM31JAZ
DM31JAZ	DN	3-(3-(carbamoyl)benzamido)propanoic acid
DM31JAZ	MI	TTJA1ZO
DM31JAZ	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DM31JAZ	MT	DTT
DM31JAZ	MA	Inhibitor
DM31JAZ	RN	Derivatives of 7-amino-1,2,3,4-tetrahydroisoquinoline and isophthalic acids as novel fibrinogen receptor antagonists. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5294-7.
DM31JAZ	RU	https://pubmed.ncbi.nlm.nih.gov/16919941

DMSHORK	DI	DMSHORK
DMSHORK	DN	3-(3,3-dimethyl-2-oxoindolin-5-yl)benzonitrile
DMSHORK	MI	TTUV8G9
DMSHORK	MN	Progesterone receptor (PGR)
DMSHORK	MT	DTT
DMSHORK	MA	Inhibitor
DMSHORK	RN	Design, synthesis, and SAR of new pyrrole-oxindole progesterone receptor modulators leading to 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-... J Med Chem. 2008 Mar 27;51(6):1861-73.
DMSHORK	RU	https://pubmed.ncbi.nlm.nih.gov/18318463

DMT3AW8	DI	DMT3AW8
DMT3AW8	DN	3-(3,4-dichlorophenyl)-2-nortropene
DMT3AW8	MI	TTVBI8W
DMT3AW8	MN	Dopamine transporter (DAT)
DMT3AW8	MT	DTT
DMT3AW8	MA	Inhibitor
DMT3AW8	RN	Synthesis and monoamine transporter affinity of 3alpha-arylmethoxy-3beta-arylnortropanes. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6865-8.
DMT3AW8	RU	https://pubmed.ncbi.nlm.nih.gov/19896846

DMT3AW8	DI	DMT3AW8
DMT3AW8	DN	3-(3,4-dichlorophenyl)-2-nortropene
DMT3AW8	MI	TT3ROYC
DMT3AW8	MN	Serotonin transporter (SERT)
DMT3AW8	MT	DTT
DMT3AW8	MA	Inhibitor
DMT3AW8	RN	Synthesis and monoamine transporter affinity of 3alpha-arylmethoxy-3beta-arylnortropanes. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6865-8.
DMT3AW8	RU	https://pubmed.ncbi.nlm.nih.gov/19896846

DMEJH13	DI	DMEJH13
DMEJH13	DN	3-(3,4-Dichloro-phenyl)-6,7-dimethoxy-quinoline
DMEJH13	MI	TT8FYO9
DMEJH13	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMEJH13	MT	DTT
DMEJH13	MA	Inhibitor
DMEJH13	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMEJH13	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMEJH13	DI	DMEJH13
DMEJH13	DN	3-(3,4-Dichloro-phenyl)-6,7-dimethoxy-quinoline
DMEJH13	MI	TTI7421
DMEJH13	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMEJH13	MT	DTT
DMEJH13	MA	Inhibitor
DMEJH13	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMEJH13	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMX3AMB	DI	DMX3AMB
DMX3AMB	DN	3-(3,4-Difluoro-phenyl)-6,7-dimethoxy-quinoline
DMX3AMB	MI	TT8FYO9
DMX3AMB	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMX3AMB	MT	DTT
DMX3AMB	MA	Inhibitor
DMX3AMB	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMX3AMB	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMX3AMB	DI	DMX3AMB
DMX3AMB	DN	3-(3,4-Difluoro-phenyl)-6,7-dimethoxy-quinoline
DMX3AMB	MI	TTI7421
DMX3AMB	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMX3AMB	MT	DTT
DMX3AMB	MA	Inhibitor
DMX3AMB	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMX3AMB	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DM0VL17	DI	DM0VL17
DM0VL17	DN	3-(3,4-dihydronaphthalen-2-yl)pyridine
DM0VL17	MI	TTSZLWK
DM0VL17	MN	Aromatase (CYP19A1)
DM0VL17	MT	DTT
DM0VL17	MA	Inhibitor
DM0VL17	RN	Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31.
DM0VL17	RU	https://pubmed.ncbi.nlm.nih.gov/16570918

DM0VL17	DI	DM0VL17
DM0VL17	DN	3-(3,4-dihydronaphthalen-2-yl)pyridine
DM0VL17	MI	TTIQUX7
DM0VL17	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM0VL17	MT	DTT
DM0VL17	MA	Inhibitor
DM0VL17	RN	Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31.
DM0VL17	RU	https://pubmed.ncbi.nlm.nih.gov/16570918

DMDU10A	DI	DMDU10A
DMDU10A	DN	3-(3,4-Dimethoxy-phenyl)-6,7-dimethoxy-quinoline
DMDU10A	MI	TT8FYO9
DMDU10A	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMDU10A	MT	DTT
DMDU10A	MA	Inhibitor
DMDU10A	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMDU10A	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMDU10A	DI	DMDU10A
DMDU10A	DN	3-(3,4-Dimethoxy-phenyl)-6,7-dimethoxy-quinoline
DMDU10A	MI	TTI7421
DMDU10A	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMDU10A	MT	DTT
DMDU10A	MA	Inhibitor
DMDU10A	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMDU10A	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DM9BYVL	DI	DM9BYVL
DM9BYVL	DN	3-(3,4-Dimethylbenzyl)-4-hydroxy-2H-chromen-2-one
DM9BYVL	MI	TT8XK6L
DM9BYVL	MN	Quinone reductase 1 (NQO1)
DM9BYVL	MT	DTT
DM9BYVL	MA	Inhibitor
DM9BYVL	RN	Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1). J Med Chem. 2009 Nov 26;52(22):7142-56.
DM9BYVL	RU	https://pubmed.ncbi.nlm.nih.gov/19877692

DMULX9O	DI	DMULX9O
DMULX9O	DN	3-(3,4-dimethylphenyl)-1,5-naphthyridine
DMULX9O	MI	TTHS256
DMULX9O	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMULX9O	MT	DTT
DMULX9O	MA	Inhibitor
DMULX9O	RN	Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8.
DMULX9O	RU	https://pubmed.ncbi.nlm.nih.gov/17936624

DM8W9EO	DI	DM8W9EO
DM8W9EO	DN	3-(3,4-Dimethyl-phenyl)-1-propyl-piperidine
DM8W9EO	MI	TTEX248
DM8W9EO	MN	Dopamine D2 receptor (D2R)
DM8W9EO	MT	DTT
DM8W9EO	MA	Inhibitor
DM8W9EO	RN	N-n-Propyl-substituted 3-(dimethylphenyl)piperidines display novel discriminative properties between dopamine receptor subtypes: synthesis and rece... J Med Chem. 1998 Dec 3;41(25):4933-8.
DM8W9EO	RU	https://pubmed.ncbi.nlm.nih.gov/9836610

DMOW0L9	DI	DMOW0L9
DMOW0L9	DN	3-(3,4-Dimethyl-phenyl)-piperidine
DMOW0L9	MI	TTEX248
DMOW0L9	MN	Dopamine D2 receptor (D2R)
DMOW0L9	MT	DTT
DMOW0L9	MA	Inhibitor
DMOW0L9	RN	N-n-Propyl-substituted 3-(dimethylphenyl)piperidines display novel discriminative properties between dopamine receptor subtypes: synthesis and rece... J Med Chem. 1998 Dec 3;41(25):4933-8.
DMOW0L9	RU	https://pubmed.ncbi.nlm.nih.gov/9836610

DMDFHCU	DI	DMDFHCU
DMDFHCU	DN	3-(3,5-Dibromo-4-hexyloxy-phenyl)-propionic acid
DMDFHCU	MI	TTTSEPU
DMDFHCU	MN	Thyroid hormone receptor alpha (THRA)
DMDFHCU	MT	DTT
DMDFHCU	MA	Inhibitor
DMDFHCU	RN	Thyroid receptor ligands. 3. Design and synthesis of 3,5-dihalo-4-alkoxyphenylalkanoic acids as indirect antagonists of the thyroid hormone receptor. J Med Chem. 2005 May 5;48(9):3114-7.
DMDFHCU	RU	https://pubmed.ncbi.nlm.nih.gov/15857115

DMDFHCU	DI	DMDFHCU
DMDFHCU	DN	3-(3,5-Dibromo-4-hexyloxy-phenyl)-propionic acid
DMDFHCU	MI	TTGER3L
DMDFHCU	MN	Thyroid hormone receptor beta (THRB)
DMDFHCU	MT	DTT
DMDFHCU	MA	Inhibitor
DMDFHCU	RN	Thyroid receptor ligands. 3. Design and synthesis of 3,5-dihalo-4-alkoxyphenylalkanoic acids as indirect antagonists of the thyroid hormone receptor. J Med Chem. 2005 May 5;48(9):3114-7.
DMDFHCU	RU	https://pubmed.ncbi.nlm.nih.gov/15857115

DMSI3V4	DI	DMSI3V4
DMSI3V4	DN	3-(3,5-Dimethyl-phenyl)-1-propyl-piperidine
DMSI3V4	MI	TTEX248
DMSI3V4	MN	Dopamine D2 receptor (D2R)
DMSI3V4	MT	DTT
DMSI3V4	MA	Inhibitor
DMSI3V4	RN	N-n-Propyl-substituted 3-(dimethylphenyl)piperidines display novel discriminative properties between dopamine receptor subtypes: synthesis and rece... J Med Chem. 1998 Dec 3;41(25):4933-8.
DMSI3V4	RU	https://pubmed.ncbi.nlm.nih.gov/9836610

DMUWKMN	DI	DMUWKMN
DMUWKMN	DN	3-(3,5-Dimethyl-phenyl)-piperidine
DMUWKMN	MI	TTEX248
DMUWKMN	MN	Dopamine D2 receptor (D2R)
DMUWKMN	MT	DTT
DMUWKMN	MA	Inhibitor
DMUWKMN	RN	N-n-Propyl-substituted 3-(dimethylphenyl)piperidines display novel discriminative properties between dopamine receptor subtypes: synthesis and rece... J Med Chem. 1998 Dec 3;41(25):4933-8.
DMUWKMN	RU	https://pubmed.ncbi.nlm.nih.gov/9836610

DMT0M94	DI	DMT0M94
DMT0M94	DN	3-(3-Adamantan-1-yl-ureido)-benzoic acid
DMT0M94	MI	TT7WVHI
DMT0M94	MN	Soluble epoxide hydrolase (EPHX2)
DMT0M94	MT	DTT
DMT0M94	MA	Inhibitor
DMT0M94	RN	Salicylate-urea-based soluble epoxide hydrolase inhibitors with high metabolic and chemical stabilities. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1784-9.
DMT0M94	RU	https://pubmed.ncbi.nlm.nih.gov/19216074

DMLYVPH	DI	DMLYVPH
DMLYVPH	DN	3-(3-aminobenzo[e][1,2,4]triazin-7-yl)phenol
DMLYVPH	MI	TT6PKBN
DMLYVPH	MN	Proto-oncogene c-Src (SRC)
DMLYVPH	MT	DTT
DMLYVPH	MA	Inhibitor
DMLYVPH	RN	Discovery and preliminary structure-activity relationship studies of novel benzotriazine based compounds as Src inhibitors. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5546-50.
DMLYVPH	RU	https://pubmed.ncbi.nlm.nih.gov/16931012

DMB6SP8	DI	DMB6SP8
DMB6SP8	DN	3-(3-aminocyclopentyl)-1H-indole-5-carbonitrile
DMB6SP8	MI	TT3ROYC
DMB6SP8	MN	Serotonin transporter (SERT)
DMB6SP8	MT	DTT
DMB6SP8	MA	Inhibitor
DMB6SP8	RN	Conformationally restricted homotryptamines. Part 7: 3-cis-(3-aminocyclopentyl)indoles as potent selective serotonin reuptake inhibitors. J Med Chem. 2010 Nov 11;53(21):7564-72.
DMB6SP8	RU	https://pubmed.ncbi.nlm.nih.gov/20949929

DMXKL75	DI	DMXKL75
DMXKL75	DN	3-(3-Benzoyl-1H-pyrrol-1-yl)propanoic acid
DMXKL75	MI	TTFBNVI
DMXKL75	MN	Aldose reductase (AKR1B1)
DMXKL75	MT	DTT
DMXKL75	MA	Inhibitor
DMXKL75	RN	Design and synthesis of novel series of pyrrole based chemotypes and their evaluation as selective aldose reductase inhibitors. A case of bioisoste... Bioorg Med Chem. 2010 Mar 15;18(6):2107-2114.
DMXKL75	RU	https://pubmed.ncbi.nlm.nih.gov/20189816

DM1325C	DI	DM1325C
DM1325C	DN	3-(3-Benzyl-6-methoxynaphthalen-2-yl)pyridine
DM1325C	MI	TTIQUX7
DM1325C	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM1325C	MT	DTT
DM1325C	MA	Inhibitor
DM1325C	RN	Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach. J Med Chem. 2008 Oct 9;51(19):6138-49.
DM1325C	RU	https://pubmed.ncbi.nlm.nih.gov/18763754

DMYN6Z9	DI	DMYN6Z9
DMYN6Z9	DN	3-(3-benzylamino)-piperidin-2-one
DMYN6Z9	MI	TTZ9SOR
DMYN6Z9	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMYN6Z9	MT	DTT
DMYN6Z9	MA	Inhibitor
DMYN6Z9	RN	Designing active template molecules by combining computational de novo design and human chemist's expertise. J Med Chem. 2007 Apr 19;50(8):1925-32.
DMYN6Z9	RU	https://pubmed.ncbi.nlm.nih.gov/17367122

DMYN6Z9	DI	DMYN6Z9
DMYN6Z9	DN	3-(3-benzylamino)-piperidin-2-one
DMYN6Z9	MI	TTYEG6Q
DMYN6Z9	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMYN6Z9	MT	DTT
DMYN6Z9	MA	Inhibitor
DMYN6Z9	RN	Designing active template molecules by combining computational de novo design and human chemist's expertise. J Med Chem. 2007 Apr 19;50(8):1925-32.
DMYN6Z9	RU	https://pubmed.ncbi.nlm.nih.gov/17367122

DMYN6Z9	DI	DMYN6Z9
DMYN6Z9	DN	3-(3-benzylamino)-piperidin-2-one
DMYN6Z9	MI	TTQ13Z5
DMYN6Z9	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMYN6Z9	MT	DTT
DMYN6Z9	MA	Inhibitor
DMYN6Z9	RN	Designing active template molecules by combining computational de novo design and human chemist's expertise. J Med Chem. 2007 Apr 19;50(8):1925-32.
DMYN6Z9	RU	https://pubmed.ncbi.nlm.nih.gov/17367122

DMYN6Z9	DI	DMYN6Z9
DMYN6Z9	DN	3-(3-benzylamino)-piperidin-2-one
DMYN6Z9	MI	TTQ3JTF
DMYN6Z9	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DMYN6Z9	MT	DTT
DMYN6Z9	MA	Inhibitor
DMYN6Z9	RN	Designing active template molecules by combining computational de novo design and human chemist's expertise. J Med Chem. 2007 Apr 19;50(8):1925-32.
DMYN6Z9	RU	https://pubmed.ncbi.nlm.nih.gov/17367122

DMYN6Z9	DI	DMYN6Z9
DMYN6Z9	DN	3-(3-benzylamino)-piperidin-2-one
DMYN6Z9	MI	TTH18TF
DMYN6Z9	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMYN6Z9	MT	DTT
DMYN6Z9	MA	Inhibitor
DMYN6Z9	RN	Designing active template molecules by combining computational de novo design and human chemist's expertise. J Med Chem. 2007 Apr 19;50(8):1925-32.
DMYN6Z9	RU	https://pubmed.ncbi.nlm.nih.gov/17367122

DM9S36A	DI	DM9S36A
DM9S36A	DN	3-(3-Benzylnaphthalen-2-yl)pyridine
DM9S36A	MI	TTIQUX7
DM9S36A	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM9S36A	MT	DTT
DM9S36A	MA	Inhibitor
DM9S36A	RN	Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach. J Med Chem. 2008 Oct 9;51(19):6138-49.
DM9S36A	RU	https://pubmed.ncbi.nlm.nih.gov/18763754

DMFPTXO	DI	DMFPTXO
DMFPTXO	DN	3-(3-bromophenylethynyl)-5-methyl[1,2,4]triazine
DMFPTXO	MI	TTHS256
DMFPTXO	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMFPTXO	MT	DTT
DMFPTXO	MA	Inhibitor
DMFPTXO	RN	Synthesis and pharmacological evaluation of phenylethynyl[1,2,4]methyltriazines as analogues of 3-methyl-6-(phenylethynyl)pyridine. J Med Chem. 2007 Jul 12;50(14):3388-91.
DMFPTXO	RU	https://pubmed.ncbi.nlm.nih.gov/17569516

DMSJGQE	DI	DMSJGQE
DMSJGQE	DN	3-(3-Carboxy-propionylamino)-benzoic acid
DMSJGQE	MI	TT1RS9F
DMSJGQE	MN	Acetylcholinesterase (AChE)
DMSJGQE	MT	DTT
DMSJGQE	MA	Inhibitor
DMSJGQE	RN	Synthesis, anticholinesterase activity and structure-activity relationships of m-Aminobenzoic acid derivatives. Bioorg Med Chem Lett. 2003 May 19;13(10):1825-7.
DMSJGQE	RU	https://pubmed.ncbi.nlm.nih.gov/12729674

DMI2RH1	DI	DMI2RH1
DMI2RH1	DN	3-(3-chloro-1H-pyrazol-5-yl)quinoxalin-2(1H)-one
DMI2RH1	MI	TTK25J1
DMI2RH1	MN	Adenosine A1 receptor (ADORA1)
DMI2RH1	MT	DTT
DMI2RH1	MA	Inhibitor
DMI2RH1	RN	Derivatives of 4-amino-6-hydroxy-2-mercaptopyrimidine as novel, potent, and selective A3 adenosine receptor antagonists. J Med Chem. 2008 Mar 27;51(6):1764-70.
DMI2RH1	RU	https://pubmed.ncbi.nlm.nih.gov/18269230

DMI2RH1	DI	DMI2RH1
DMI2RH1	DN	3-(3-chloro-1H-pyrazol-5-yl)quinoxalin-2(1H)-one
DMI2RH1	MI	TTJFY5U
DMI2RH1	MN	Adenosine A3 receptor (ADORA3)
DMI2RH1	MT	DTT
DMI2RH1	MA	Inhibitor
DMI2RH1	RN	Derivatives of 4-amino-6-hydroxy-2-mercaptopyrimidine as novel, potent, and selective A3 adenosine receptor antagonists. J Med Chem. 2008 Mar 27;51(6):1764-70.
DMI2RH1	RU	https://pubmed.ncbi.nlm.nih.gov/18269230

DMD4O6V	DI	DMD4O6V
DMD4O6V	DN	3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one
DMD4O6V	MI	TTGKNB4
DMD4O6V	MN	Epidermal growth factor receptor (EGFR)
DMD4O6V	MT	DTT
DMD4O6V	MA	Inhibitor
DMD4O6V	RN	Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1H)-quinolones. J Med Chem. 1999 Mar 25;42(6):1018-26.
DMD4O6V	RU	https://pubmed.ncbi.nlm.nih.gov/10090785

DMGJS9N	DI	DMGJS9N
DMGJS9N	DN	3-(3-cyano-1H-indol-6-yl)-1-methyl-1-phenylurea
DMGJS9N	MI	TTTB4UP
DMGJS9N	MN	Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2)
DMGJS9N	MT	DTT
DMGJS9N	MA	Inhibitor
DMGJS9N	RN	Novel indole inhibitors of IMPDH from fragments: synthesis and initial structure-activity relationships. Bioorg Med Chem Lett. 2006 May 1;16(9):2539-42.
DMGJS9N	RU	https://pubmed.ncbi.nlm.nih.gov/16483773

DM0O2ZB	DI	DM0O2ZB
DM0O2ZB	DN	3-(3-Dimethylamino-propyl)-1H-indol-4-ol
DM0O2ZB	MI	TTJQOD7
DM0O2ZB	MN	5-HT 2A receptor (HTR2A)
DM0O2ZB	MT	DTT
DM0O2ZB	MA	Inhibitor
DM0O2ZB	RN	SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.
DM0O2ZB	RU	https://pubmed.ncbi.nlm.nih.gov/16061378

DM0O2ZB	DI	DM0O2ZB
DM0O2ZB	DN	3-(3-Dimethylamino-propyl)-1H-indol-4-ol
DM0O2ZB	MI	TT0K1SC
DM0O2ZB	MN	5-HT 2B receptor (HTR2B)
DM0O2ZB	MT	DTT
DM0O2ZB	MA	Inhibitor
DM0O2ZB	RN	SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.
DM0O2ZB	RU	https://pubmed.ncbi.nlm.nih.gov/16061378

DM0O2ZB	DI	DM0O2ZB
DM0O2ZB	DN	3-(3-Dimethylamino-propyl)-1H-indol-4-ol
DM0O2ZB	MI	TTWJBZ5
DM0O2ZB	MN	5-HT 2C receptor (HTR2C)
DM0O2ZB	MT	DTT
DM0O2ZB	MA	Inhibitor
DM0O2ZB	RN	SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.
DM0O2ZB	RU	https://pubmed.ncbi.nlm.nih.gov/16061378

DM0ZHJQ	DI	DM0ZHJQ
DM0ZHJQ	DN	3-(3-Fluoro-phenyl)-6,7-dimethoxy-quinoline
DM0ZHJQ	MI	TT8FYO9
DM0ZHJQ	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DM0ZHJQ	MT	DTT
DM0ZHJQ	MA	Inhibitor
DM0ZHJQ	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DM0ZHJQ	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DM0ZHJQ	DI	DM0ZHJQ
DM0ZHJQ	DN	3-(3-Fluoro-phenyl)-6,7-dimethoxy-quinoline
DM0ZHJQ	MI	TTI7421
DM0ZHJQ	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM0ZHJQ	MT	DTT
DM0ZHJQ	MA	Inhibitor
DM0ZHJQ	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DM0ZHJQ	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DM7FQVC	DI	DM7FQVC
DM7FQVC	DN	3-(3'-furyl)-aniline
DM7FQVC	MI	TTAWNKZ
DM7FQVC	MN	Norepinephrine transporter (NET)
DM7FQVC	MT	DTT
DM7FQVC	MA	Inhibitor
DM7FQVC	RN	Designing active template molecules by combining computational de novo design and human chemist's expertise. J Med Chem. 2007 Apr 19;50(8):1925-32.
DM7FQVC	RU	https://pubmed.ncbi.nlm.nih.gov/17367122

DMP0DQE	DI	DMP0DQE
DMP0DQE	DN	3-(3-hydroxyphenyl)quinolin-7-ol
DMP0DQE	MI	TTIWB6L
DMP0DQE	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMP0DQE	MT	DTT
DMP0DQE	MA	Inhibitor
DMP0DQE	RN	Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors... J Med Chem. 2008 Apr 10;51(7):2158-69.
DMP0DQE	RU	https://pubmed.ncbi.nlm.nih.gov/18324762

DMRDS1U	DI	DMRDS1U
DMRDS1U	DN	3-(3-Methanesulfonyl-phenyl)-1-propyl-pyrrolidine
DMRDS1U	MI	TTSQIFT
DMRDS1U	MN	5-HT 1A receptor (HTR1A)
DMRDS1U	MT	DTT
DMRDS1U	MA	Inhibitor
DMRDS1U	RN	Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity, Bioorg. Med. Chem. Lett. 7(3):241-246 (1997).
DMRDS1U	RU	http://www.sciencedirect.com/science/article/pii/S0960894X9600618X

DMU53NZ	DI	DMU53NZ
DMU53NZ	DN	3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine
DMU53NZ	MI	TTRLW2X
DMU53NZ	MN	Fibroblast growth factor receptor 1 (FGFR1)
DMU53NZ	MT	DTT
DMU53NZ	MA	Inhibitor
DMU53NZ	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMU53NZ	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMZQ2CJ	DI	DMZQ2CJ
DMZQ2CJ	DN	3-(3-methoxyphenyl)-6-methyl-2H-chromen-2-one
DMZQ2CJ	MI	TTGP7BY
DMZQ2CJ	MN	Monoamine oxidase type B (MAO-B)
DMZQ2CJ	MT	DTT
DMZQ2CJ	MA	Inhibitor
DMZQ2CJ	RN	Synthesis and evaluation of 6-methyl-3-phenylcoumarins as potent and selective MAO-B inhibitors. Bioorg Med Chem Lett. 2009 Sep 1;19(17):5053-5.
DMZQ2CJ	RU	https://pubmed.ncbi.nlm.nih.gov/19628387

DM2YLBD	DI	DM2YLBD
DM2YLBD	DN	3-(3-methyl-3,4-dihydronaphthalen-2-yl)pyridine
DM2YLBD	MI	TTSZLWK
DM2YLBD	MN	Aromatase (CYP19A1)
DM2YLBD	MT	DTT
DM2YLBD	MA	Inhibitor
DM2YLBD	RN	Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31.
DM2YLBD	RU	https://pubmed.ncbi.nlm.nih.gov/16570918

DM2YLBD	DI	DM2YLBD
DM2YLBD	DN	3-(3-methyl-3,4-dihydronaphthalen-2-yl)pyridine
DM2YLBD	MI	TTIQUX7
DM2YLBD	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM2YLBD	MT	DTT
DM2YLBD	MA	Inhibitor
DM2YLBD	RN	Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31.
DM2YLBD	RU	https://pubmed.ncbi.nlm.nih.gov/16570918

DMTNCXP	DI	DMTNCXP
DMTNCXP	DN	3-(3-Methyl-butoxy)-9H-beta-carboline
DMTNCXP	MI	TT1MPAY
DMTNCXP	MN	GABA(A) receptor alpha-1 (GABRA1)
DMTNCXP	MT	DTT
DMTNCXP	MA	Inhibitor
DMTNCXP	RN	Predictive binding of beta-carboline inverse agonists and antagonists via the CoMFA/GOLPE approach. J Med Chem. 1992 Oct 30;35(22):4001-10.
DMTNCXP	RU	https://pubmed.ncbi.nlm.nih.gov/1331452

DMTNCXP	DI	DMTNCXP
DMTNCXP	DN	3-(3-Methyl-butoxy)-9H-beta-carboline
DMTNCXP	MI	TTBMV1G
DMTNCXP	MN	GABA(A) receptor alpha-2 (GABRA2)
DMTNCXP	MT	DTT
DMTNCXP	MA	Inhibitor
DMTNCXP	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DMTNCXP	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DMTNCXP	DI	DMTNCXP
DMTNCXP	DN	3-(3-Methyl-butoxy)-9H-beta-carboline
DMTNCXP	MI	TT37EDJ
DMTNCXP	MN	GABA(A) receptor alpha-3 (GABRA3)
DMTNCXP	MT	DTT
DMTNCXP	MA	Inhibitor
DMTNCXP	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DMTNCXP	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DMTNCXP	DI	DMTNCXP
DMTNCXP	DN	3-(3-Methyl-butoxy)-9H-beta-carboline
DMTNCXP	MI	TTNZPQ1
DMTNCXP	MN	GABA(A) receptor alpha-5 (GABRA5)
DMTNCXP	MT	DTT
DMTNCXP	MA	Inhibitor
DMTNCXP	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DMTNCXP	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DMTNCXP	DI	DMTNCXP
DMTNCXP	DN	3-(3-Methyl-butoxy)-9H-beta-carboline
DMTNCXP	MI	TT06RH5
DMTNCXP	MN	GABA(A) receptor gamma-2 (GABRG2)
DMTNCXP	MT	DTT
DMTNCXP	MA	Inhibitor
DMTNCXP	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DMTNCXP	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DMTNCXP	DI	DMTNCXP
DMTNCXP	DN	3-(3-Methyl-butoxy)-9H-beta-carboline
DMTNCXP	MI	TTNJYV2
DMTNCXP	MN	Gamma-aminobutyric acid receptor (GAR)
DMTNCXP	MT	DTT
DMTNCXP	MA	Inhibitor
DMTNCXP	RN	Predictive binding of beta-carboline inverse agonists and antagonists via the CoMFA/GOLPE approach. J Med Chem. 1992 Oct 30;35(22):4001-10.
DMTNCXP	RU	https://pubmed.ncbi.nlm.nih.gov/1331452

DMXAD0R	DI	DMXAD0R
DMXAD0R	DN	3-(3-methylphenylethynyl)-5-methyl[1,2,4]triazine
DMXAD0R	MI	TTHS256
DMXAD0R	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMXAD0R	MT	DTT
DMXAD0R	MA	Inhibitor
DMXAD0R	RN	Synthesis and pharmacological evaluation of phenylethynyl[1,2,4]methyltriazines as analogues of 3-methyl-6-(phenylethynyl)pyridine. J Med Chem. 2007 Jul 12;50(14):3388-91.
DMXAD0R	RU	https://pubmed.ncbi.nlm.nih.gov/17569516

DMHU9V5	DI	DMHU9V5
DMHU9V5	DN	3-(3-methylthiophen-2-yl)pyridine
DMHU9V5	MI	TTXV4FI
DMHU9V5	MN	Albendazole monooxygenase (CYP3A4)
DMHU9V5	MT	DTT
DMHU9V5	MA	Inhibitor
DMHU9V5	RN	Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallization. J Med Chem. 2006 Nov 30;49(24):6987-7001.
DMHU9V5	RU	https://pubmed.ncbi.nlm.nih.gov/17125252

DM314ZE	DI	DM314ZE
DM314ZE	DN	3-(3-Phenyl-ureido)-benzenesulfonamide
DM314ZE	MI	TTHQPL7
DM314ZE	MN	Carbonic anhydrase I (CA-I)
DM314ZE	MT	DTT
DM314ZE	MA	Inhibitor
DM314ZE	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DM314ZE	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DM314ZE	DI	DM314ZE
DM314ZE	DN	3-(3-Phenyl-ureido)-benzenesulfonamide
DM314ZE	MI	TTANPDJ
DM314ZE	MN	Carbonic anhydrase II (CA-II)
DM314ZE	MT	DTT
DM314ZE	MA	Inhibitor
DM314ZE	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DM314ZE	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DM314ZE	DI	DM314ZE
DM314ZE	DN	3-(3-Phenyl-ureido)-benzenesulfonamide
DM314ZE	MI	TT2LVK8
DM314ZE	MN	Carbonic anhydrase IX (CA-IX)
DM314ZE	MT	DTT
DM314ZE	MA	Inhibitor
DM314ZE	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DM314ZE	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DM314ZE	DI	DM314ZE
DM314ZE	DN	3-(3-Phenyl-ureido)-benzenesulfonamide
DM314ZE	MI	TTSYM0R
DM314ZE	MN	Carbonic anhydrase XII (CA-XII)
DM314ZE	MT	DTT
DM314ZE	MA	Inhibitor
DM314ZE	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DM314ZE	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DMU52WA	DI	DMU52WA
DMU52WA	DN	3-(3-Pyridin-2-yl-pyrazol-1-yl)-benzonitrile
DMU52WA	MI	TTHS256
DMU52WA	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMU52WA	MT	DTT
DMU52WA	MA	Inhibitor
DMU52WA	RN	Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity. J Med Chem. 2004 Sep 9;47(19):4645-8. Letter
DMU52WA	RU	https://pubmed.ncbi.nlm.nih.gov/15341479

DMZLT24	DI	DMZLT24
DMZLT24	DN	3-(3-Pyridin-2-yl-pyrrol-1-yl)-benzonitrile
DMZLT24	MI	TTHS256
DMZLT24	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMZLT24	MT	DTT
DMZLT24	MA	Inhibitor
DMZLT24	RN	Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity. J Med Chem. 2004 Sep 9;47(19):4645-8. Letter
DMZLT24	RU	https://pubmed.ncbi.nlm.nih.gov/15341479

DMQDPHT	DI	DMQDPHT
DMQDPHT	DN	3-(4-(2-phenylethynyl)benzoyl)pentanoic acid
DMQDPHT	MI	TTXZ0KQ
DMQDPHT	MN	Matrix metalloproteinase-12 (MMP-12)
DMQDPHT	MT	DTT
DMQDPHT	MA	Inhibitor
DMQDPHT	RN	Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8.
DMQDPHT	RU	https://pubmed.ncbi.nlm.nih.gov/16420030

DMQDPHT	DI	DMQDPHT
DMQDPHT	DN	3-(4-(2-phenylethynyl)benzoyl)pentanoic acid
DMQDPHT	MI	TTLM12X
DMQDPHT	MN	Matrix metalloproteinase-2 (MMP-2)
DMQDPHT	MT	DTT
DMQDPHT	MA	Inhibitor
DMQDPHT	RN	Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8.
DMQDPHT	RU	https://pubmed.ncbi.nlm.nih.gov/16420030

DMQDPHT	DI	DMQDPHT
DMQDPHT	DN	3-(4-(2-phenylethynyl)benzoyl)pentanoic acid
DMQDPHT	MI	TTYRF5E
DMQDPHT	MN	Matrix metalloproteinase-21 (MMP-21)
DMQDPHT	MT	DTT
DMQDPHT	MA	Inhibitor
DMQDPHT	RN	Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8.
DMQDPHT	RU	https://pubmed.ncbi.nlm.nih.gov/16420030

DMQDPHT	DI	DMQDPHT
DMQDPHT	DN	3-(4-(2-phenylethynyl)benzoyl)pentanoic acid
DMQDPHT	MI	TT6X50U
DMQDPHT	MN	Matrix metalloproteinase-9 (MMP-9)
DMQDPHT	MT	DTT
DMQDPHT	MA	Inhibitor
DMQDPHT	RN	Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8.
DMQDPHT	RU	https://pubmed.ncbi.nlm.nih.gov/16420030

DM1GVE8	DI	DM1GVE8
DM1GVE8	DN	3-(4-(4-hydroxyphenyl)phthalazin-1-ylamino)phenol
DM1GVE8	MI	TTXWASR
DM1GVE8	MN	Intestinal maltase-glucoamylase (MGAM)
DM1GVE8	MT	DTT
DM1GVE8	MA	Inhibitor
DM1GVE8	RN	Discovery of novel alpha-glucosidase inhibitors based on the virtual screening with the homology-modeled protein structure. Bioorg Med Chem. 2008 Jan 1;16(1):284-92.
DM1GVE8	RU	https://pubmed.ncbi.nlm.nih.gov/17920282

DM8EH07	DI	DM8EH07
DM8EH07	DN	3-(4-(4-Hydroxyphenyl)thiazol-2-ylamino)phenol
DM8EH07	MI	TTWHDVK
DM8EH07	MN	Fructose-1,6-bisphosphatase (FBP)
DM8EH07	MT	DTT
DM8EH07	MA	Inhibitor
DM8EH07	RN	A library of novel allosteric inhibitors against fructose 1,6-bisphosphatase. Bioorg Med Chem. 2009 Jun 1;17(11):3916-22.
DM8EH07	RU	https://pubmed.ncbi.nlm.nih.gov/19419876

DM36VA0	DI	DM36VA0
DM36VA0	DN	3-(4-(benzyloxy)-3,5-dibromophenyl)propanoic acid
DM36VA0	MI	TTTSEPU
DM36VA0	MN	Thyroid hormone receptor alpha (THRA)
DM36VA0	MT	DTT
DM36VA0	MA	Inhibitor
DM36VA0	RN	Thyroid receptor ligands. Part 7: Indirect antagonists of the thyroid hormone receptor with improved affinity. Bioorg Med Chem Lett. 2007 Apr 1;17(7):2018-21.
DM36VA0	RU	https://pubmed.ncbi.nlm.nih.gov/17254783

DM36VA0	DI	DM36VA0
DM36VA0	DN	3-(4-(benzyloxy)-3,5-dibromophenyl)propanoic acid
DM36VA0	MI	TTGER3L
DM36VA0	MN	Thyroid hormone receptor beta (THRB)
DM36VA0	MT	DTT
DM36VA0	MA	Inhibitor
DM36VA0	RN	Thyroid receptor ligands. Part 7: Indirect antagonists of the thyroid hormone receptor with improved affinity. Bioorg Med Chem Lett. 2007 Apr 1;17(7):2018-21.
DM36VA0	RU	https://pubmed.ncbi.nlm.nih.gov/17254783

DMX6ZHQ	DI	DMX6ZHQ
DMX6ZHQ	DN	3-(4-(o-toluidino)pyrimidin-2-ylamino)benzamide
DMX6ZHQ	MI	TT860QF
DMX6ZHQ	MN	LCK tyrosine protein kinase (LCK)
DMX6ZHQ	MT	DTT
DMX6ZHQ	MA	Inhibitor
DMX6ZHQ	RN	N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: indazoles as phenol isosteres with improved pharmacokinetics. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4363-8.
DMX6ZHQ	RU	https://pubmed.ncbi.nlm.nih.gov/17600705

DMGXPJV	DI	DMGXPJV
DMGXPJV	DN	3-(4,5-Bis-biphenyl-4-yl-1H-imidazol-2-yl)-phenol
DMGXPJV	MI	TTELIN2
DMGXPJV	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMGXPJV	MT	DTT
DMGXPJV	MA	Inhibitor
DMGXPJV	RN	Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B. J Med Chem. 2002 May 23;45(11):2213-21.
DMGXPJV	RU	https://pubmed.ncbi.nlm.nih.gov/12014959

DMONSM1	DI	DMONSM1
DMONSM1	DN	3-(4,5-Dihydrooxazol-2-yl)phenyl propylcarbamate
DMONSM1	MI	TTDP1UC
DMONSM1	MN	Fatty acid amide hydrolase (FAAH)
DMONSM1	MT	DTT
DMONSM1	MA	Inhibitor
DMONSM1	RN	Chiral 3-(4,5-dihydrooxazol-2-yl)phenyl alkylcarbamates as novel FAAH inhibitors: Insight into FAAH enantioselectivity by molecular docking and int... Eur J Med Chem. 2009 Oct;44(10):4179-91.
DMONSM1	RU	https://pubmed.ncbi.nlm.nih.gov/19539407

DMS1LDH	DI	DMS1LDH
DMS1LDH	DN	3-(4-Amino-phenyl)-1-methyl-pyrrolidine-2,5-dione
DMS1LDH	MI	TTSZLWK
DMS1LDH	MN	Aromatase (CYP19A1)
DMS1LDH	MT	DTT
DMS1LDH	MA	Inhibitor
DMS1LDH	RN	Synthesis and biochemical evaluation of analogues of aminoglutethimide based on phenylpyrrolidine-2,5-dione. J Med Chem. 1986 Apr;29(4):520-3.
DMS1LDH	RU	https://pubmed.ncbi.nlm.nih.gov/3754286

DMD5YKO	DI	DMD5YKO
DMD5YKO	DN	3-(4-Amino-phenyl)-3-butyl-piperidine-2,6-dione
DMD5YKO	MI	TTSZLWK
DMD5YKO	MN	Aromatase (CYP19A1)
DMD5YKO	MT	DTT
DMD5YKO	MA	Inhibitor
DMD5YKO	RN	Aromatase inhibitors. Synthesis and evaluation of mammary tumor inhibiting activity of 3-alkylated 3-(4-aminophenyl)piperidine-2,6-diones. J Med Chem. 1986 Aug;29(8):1362-9.
DMD5YKO	RU	https://pubmed.ncbi.nlm.nih.gov/3735304

DMD5YKO	DI	DMD5YKO
DMD5YKO	DN	3-(4-Amino-phenyl)-3-butyl-piperidine-2,6-dione
DMD5YKO	MI	TTSYVO6
DMD5YKO	MN	Cholesterol desmolase (CYP11A1)
DMD5YKO	MT	DTT
DMD5YKO	MA	Inhibitor
DMD5YKO	RN	Aromatase inhibitors. Synthesis and evaluation of mammary tumor inhibiting activity of 3-alkylated 3-(4-aminophenyl)piperidine-2,6-diones. J Med Chem. 1986 Aug;29(8):1362-9.
DMD5YKO	RU	https://pubmed.ncbi.nlm.nih.gov/3735304

DM3I15D	DI	DM3I15D
DM3I15D	DN	3-(4-Amino-phenyl)-3-ethyl-pyrrolidine-2,5-dione
DM3I15D	MI	TTSZLWK
DM3I15D	MN	Aromatase (CYP19A1)
DM3I15D	MT	DTT
DM3I15D	MA	Inhibitor
DM3I15D	RN	Synthesis and biochemical evaluation of analogues of aminoglutethimide based on phenylpyrrolidine-2,5-dione. J Med Chem. 1986 Apr;29(4):520-3.
DM3I15D	RU	https://pubmed.ncbi.nlm.nih.gov/3754286

DMZ86CS	DI	DMZ86CS
DMZ86CS	DN	3-(4-Amino-phenyl)-3-heptyl-piperidine-2,6-dione
DMZ86CS	MI	TTSZLWK
DMZ86CS	MN	Aromatase (CYP19A1)
DMZ86CS	MT	DTT
DMZ86CS	MA	Inhibitor
DMZ86CS	RN	Aromatase inhibitors. Synthesis and evaluation of mammary tumor inhibiting activity of 3-alkylated 3-(4-aminophenyl)piperidine-2,6-diones. J Med Chem. 1986 Aug;29(8):1362-9.
DMZ86CS	RU	https://pubmed.ncbi.nlm.nih.gov/3735304

DMW62U8	DI	DMW62U8
DMW62U8	DN	3-(4-Amino-phenyl)-3-hexyl-piperidine-2,6-dione
DMW62U8	MI	TTSZLWK
DMW62U8	MN	Aromatase (CYP19A1)
DMW62U8	MT	DTT
DMW62U8	MA	Inhibitor
DMW62U8	RN	Aromatase inhibitors. Synthesis and evaluation of mammary tumor inhibiting activity of 3-alkylated 3-(4-aminophenyl)piperidine-2,6-diones. J Med Chem. 1986 Aug;29(8):1362-9.
DMW62U8	RU	https://pubmed.ncbi.nlm.nih.gov/3735304

DMITHX5	DI	DMITHX5
DMITHX5	DN	3-(4-Amino-phenyl)-3-methyl-pyrrolidine-2,5-dione
DMITHX5	MI	TTSZLWK
DMITHX5	MN	Aromatase (CYP19A1)
DMITHX5	MT	DTT
DMITHX5	MA	Inhibitor
DMITHX5	RN	Synthesis and biochemical evaluation of analogues of aminoglutethimide based on phenylpyrrolidine-2,5-dione. J Med Chem. 1986 Apr;29(4):520-3.
DMITHX5	RU	https://pubmed.ncbi.nlm.nih.gov/3754286

DM20DXS	DI	DM20DXS
DM20DXS	DN	3-(4-Amino-phenyl)-3-pentyl-piperidine-2,6-dione
DM20DXS	MI	TTSZLWK
DM20DXS	MN	Aromatase (CYP19A1)
DM20DXS	MT	DTT
DM20DXS	MA	Inhibitor
DM20DXS	RN	Aromatase inhibitors. Synthesis and evaluation of mammary tumor inhibiting activity of 3-alkylated 3-(4-aminophenyl)piperidine-2,6-diones. J Med Chem. 1986 Aug;29(8):1362-9.
DM20DXS	RU	https://pubmed.ncbi.nlm.nih.gov/3735304

DM20DXS	DI	DM20DXS
DM20DXS	DN	3-(4-Amino-phenyl)-3-pentyl-piperidine-2,6-dione
DM20DXS	MI	TTSYVO6
DM20DXS	MN	Cholesterol desmolase (CYP11A1)
DM20DXS	MT	DTT
DM20DXS	MA	Inhibitor
DM20DXS	RN	Aromatase inhibitors. Synthesis and evaluation of mammary tumor inhibiting activity of 3-alkylated 3-(4-aminophenyl)piperidine-2,6-diones. J Med Chem. 1986 Aug;29(8):1362-9.
DM20DXS	RU	https://pubmed.ncbi.nlm.nih.gov/3735304

DM39XMT	DI	DM39XMT
DM39XMT	DN	3-(4-Amino-phenyl)-3-propyl-piperidine-2,6-dione
DM39XMT	MI	TTSZLWK
DM39XMT	MN	Aromatase (CYP19A1)
DM39XMT	MT	DTT
DM39XMT	MA	Inhibitor
DM39XMT	RN	Aromatase inhibitors. Synthesis and evaluation of mammary tumor inhibiting activity of 3-alkylated 3-(4-aminophenyl)piperidine-2,6-diones. J Med Chem. 1986 Aug;29(8):1362-9.
DM39XMT	RU	https://pubmed.ncbi.nlm.nih.gov/3735304

DMVN0O5	DI	DMVN0O5
DMVN0O5	DN	3-(4-Amino-phenyl)-pyrrolidine-2,5-dione
DMVN0O5	MI	TTSZLWK
DMVN0O5	MN	Aromatase (CYP19A1)
DMVN0O5	MT	DTT
DMVN0O5	MA	Inhibitor
DMVN0O5	RN	Synthesis and biochemical evaluation of analogues of aminoglutethimide based on phenylpyrrolidine-2,5-dione. J Med Chem. 1986 Apr;29(4):520-3.
DMVN0O5	RU	https://pubmed.ncbi.nlm.nih.gov/3754286

DM6XTBI	DI	DM6XTBI
DM6XTBI	DN	3-(4-aminophenyl)quinoxaline-5-carboxamide
DM6XTBI	MI	TTVDSZ0
DM6XTBI	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DM6XTBI	MT	DTT
DM6XTBI	MA	Inhibitor
DM6XTBI	RN	Design, synthesis, and cytoprotective effect of 2-aminothiazole analogues as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2009 Feb 12;52(3):718-25.
DM6XTBI	RU	https://pubmed.ncbi.nlm.nih.gov/19125579

DM30GV2	DI	DM30GV2
DM30GV2	DN	3-(4-aminophenyl)thieno[3,2-c]pyridin-4-amine
DM30GV2	MI	TTUTJGQ
DM30GV2	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM30GV2	MT	DTT
DM30GV2	MA	Inhibitor
DM30GV2	RN	Thienopyridine urea inhibitors of KDR kinase. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1246-9.
DM30GV2	RU	https://pubmed.ncbi.nlm.nih.gov/17188869

DMAT7VN	DI	DMAT7VN
DMAT7VN	DN	3-(4-Benzoylpiperazine-1-carbonyl)coumarin
DMAT7VN	MI	TT1RS9F
DMAT7VN	MN	Acetylcholinesterase (AChE)
DMAT7VN	MT	DTT
DMAT7VN	MA	Inhibitor
DMAT7VN	RN	Design, synthesis, and acetylcholinesterase inhibitory activity of novel coumarin analogues. Bioorg Med Chem. 2008 Sep 1;16(17):8011-21.
DMAT7VN	RU	https://pubmed.ncbi.nlm.nih.gov/18701305

DMWPB0G	DI	DMWPB0G
DMWPB0G	DN	3-(4-Benzyl-piperazin-1-yl)-phenol
DMWPB0G	MI	TTEX248
DMWPB0G	MN	Dopamine D2 receptor (D2R)
DMWPB0G	MT	DTT
DMWPB0G	MA	Inhibitor
DMWPB0G	RN	New generation dopaminergic agents. 5. Heterocyclic bioisosteres that exploit the 3-OH-N1-phenylpiperazine dopaminergic template. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2675-80.
DMWPB0G	RU	https://pubmed.ncbi.nlm.nih.gov/9873601

DMWPB0G	DI	DMWPB0G
DMWPB0G	DN	3-(4-Benzyl-piperazin-1-yl)-phenol
DMWPB0G	MI	TT4C8EA
DMWPB0G	MN	Dopamine D3 receptor (D3R)
DMWPB0G	MT	DTT
DMWPB0G	MA	Inhibitor
DMWPB0G	RN	New generation dopaminergic agents. 5. Heterocyclic bioisosteres that exploit the 3-OH-N1-phenylpiperazine dopaminergic template. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2675-80.
DMWPB0G	RU	https://pubmed.ncbi.nlm.nih.gov/9873601

DMFVCOP	DI	DMFVCOP
DMFVCOP	DN	3-(4-Benzyl-piperidin-1-ylmethyl)-chroman-4-one
DMFVCOP	MI	TTSQIFT
DMFVCOP	MN	5-HT 1A receptor (HTR1A)
DMFVCOP	MT	DTT
DMFVCOP	MA	Inhibitor
DMFVCOP	RN	Synthesis and structure-activity relationships of 1-aralkyl-4-benzylpiperidine and 1-aralkyl-4-benzylpiperazine derivatives as potent sigma ligands. J Med Chem. 2005 Jan 13;48(1):266-73.
DMFVCOP	RU	https://pubmed.ncbi.nlm.nih.gov/15634021

DMFVCOP	DI	DMFVCOP
DMFVCOP	DN	3-(4-Benzyl-piperidin-1-ylmethyl)-chroman-4-one
DMFVCOP	MI	TTEX248
DMFVCOP	MN	Dopamine D2 receptor (D2R)
DMFVCOP	MT	DTT
DMFVCOP	MA	Inhibitor
DMFVCOP	RN	Synthesis and structure-activity relationships of 1-aralkyl-4-benzylpiperidine and 1-aralkyl-4-benzylpiperazine derivatives as potent sigma ligands. J Med Chem. 2005 Jan 13;48(1):266-73.
DMFVCOP	RU	https://pubmed.ncbi.nlm.nih.gov/15634021

DM7LMD6	DI	DM7LMD6
DM7LMD6	DN	3-(4-Benzyl-piperidin-1-ylmethyl)-chromen-4-one
DM7LMD6	MI	TTSQIFT
DM7LMD6	MN	5-HT 1A receptor (HTR1A)
DM7LMD6	MT	DTT
DM7LMD6	MA	Inhibitor
DM7LMD6	RN	Synthesis and structure-activity relationships of 1-aralkyl-4-benzylpiperidine and 1-aralkyl-4-benzylpiperazine derivatives as potent sigma ligands. J Med Chem. 2005 Jan 13;48(1):266-73.
DM7LMD6	RU	https://pubmed.ncbi.nlm.nih.gov/15634021

DMAKMIJ	DI	DMAKMIJ
DMAKMIJ	DN	3-(4-bromobenzyl)-1,1-dimethylselenourea
DMAKMIJ	MI	TTAS2UO
DMAKMIJ	MN	Bacterial Urease (Bact ureC)
DMAKMIJ	MT	DTT
DMAKMIJ	MA	Inhibitor
DMAKMIJ	RN	Facile one-pot synthesis of thio and selenourea derivatives: a new class of potent urease inhibitors. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6387-91.
DMAKMIJ	RU	https://pubmed.ncbi.nlm.nih.gov/17889535

DMXMZRE	DI	DMXMZRE
DMXMZRE	DN	3-(4-bromophenyl)-1,1-dimethylthiourea
DMXMZRE	MI	TTAS2UO
DMXMZRE	MN	Bacterial Urease (Bact ureC)
DMXMZRE	MT	DTT
DMXMZRE	MA	Inhibitor
DMXMZRE	RN	Facile one-pot synthesis of thio and selenourea derivatives: a new class of potent urease inhibitors. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6387-91.
DMXMZRE	RU	https://pubmed.ncbi.nlm.nih.gov/17889535

DM8W3GC	DI	DM8W3GC
DM8W3GC	DN	3-(4-Butoxy-phenyl)-N-hydroxy-N-methyl-acrylamide
DM8W3GC	MI	TT2J34L
DM8W3GC	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM8W3GC	MT	DTT
DM8W3GC	MA	Inhibitor
DM8W3GC	RN	Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8.
DM8W3GC	RU	https://pubmed.ncbi.nlm.nih.gov/2308149

DMQ2D09	DI	DMQ2D09
DMQ2D09	DN	3-(4-chloro-2-cyclohexylphenoxy)propanoic acid
DMQ2D09	MI	TTQDMX5
DMQ2D09	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMQ2D09	MT	DTT
DMQ2D09	MA	Inhibitor
DMQ2D09	RN	2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4347-50.
DMQ2D09	RU	https://pubmed.ncbi.nlm.nih.gov/17531480

DM71EUO	DI	DM71EUO
DM71EUO	DN	3-(4-Chlorophenyl)-2-nortropene
DM71EUO	MI	TTVBI8W
DM71EUO	MN	Dopamine transporter (DAT)
DM71EUO	MT	DTT
DM71EUO	MA	Inhibitor
DM71EUO	RN	Synthesis and monoamine transporter affinity of 3alpha-arylmethoxy-3beta-arylnortropanes. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6865-8.
DM71EUO	RU	https://pubmed.ncbi.nlm.nih.gov/19896846

DM71EUO	DI	DM71EUO
DM71EUO	DN	3-(4-Chlorophenyl)-2-nortropene
DM71EUO	MI	TT3ROYC
DM71EUO	MN	Serotonin transporter (SERT)
DM71EUO	MT	DTT
DM71EUO	MA	Inhibitor
DM71EUO	RN	Synthesis and monoamine transporter affinity of 3alpha-arylmethoxy-3beta-arylnortropanes. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6865-8.
DM71EUO	RU	https://pubmed.ncbi.nlm.nih.gov/19896846

DM23JIY	DI	DM23JIY
DM23JIY	DN	3-(4-cyanophenyl)quinoxaline-5-carboxamide
DM23JIY	MI	TTVDSZ0
DM23JIY	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DM23JIY	MT	DTT
DM23JIY	MA	Inhibitor
DM23JIY	RN	Design, synthesis, and cytoprotective effect of 2-aminothiazole analogues as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2009 Feb 12;52(3):718-25.
DM23JIY	RU	https://pubmed.ncbi.nlm.nih.gov/19125579

DMGQE8D	DI	DMGQE8D
DMGQE8D	DN	3-(4-cyclohexylthiosemicarbazono)methyl-phenol
DMGQE8D	MI	TTHM0R1
DMGQE8D	MN	Steryl-sulfatase (STS)
DMGQE8D	MT	DTT
DMGQE8D	MA	Inhibitor
DMGQE8D	RN	Thiosemicarbazones of formyl benzoic acids as novel potent inhibitors of estrone sulfatase. J Med Chem. 2007 Jul 26;50(15):3661-6.
DMGQE8D	RU	https://pubmed.ncbi.nlm.nih.gov/17580843

DM6XC0M	DI	DM6XC0M
DM6XC0M	DN	3-(4-dimethylamino-benzylidenyl)-2-indolinone
DM6XC0M	MI	TTI7421
DM6XC0M	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM6XC0M	MT	DTT
DM6XC0M	MA	Inhibitor
DM6XC0M	RN	Synthesis and biological activity of N(4)-phenylsubstituted-6-(2,4-dichloro phenylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as vascular endo... Bioorg Med Chem. 2010 May 15;18(10):3575-87.
DM6XC0M	RU	https://pubmed.ncbi.nlm.nih.gov/20403700

DMM7BQP	DI	DMM7BQP
DMM7BQP	DN	3-(4-ethyl-3,4-dihydronaphthalen-2-yl)pyridine
DMM7BQP	MI	TTIQUX7
DMM7BQP	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMM7BQP	MT	DTT
DMM7BQP	MA	Inhibitor
DMM7BQP	RN	Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31.
DMM7BQP	RU	https://pubmed.ncbi.nlm.nih.gov/16570918

DM8CK9M	DI	DM8CK9M
DM8CK9M	DN	3-(4-Fluorophenyl)-2-nortropene
DM8CK9M	MI	TTVBI8W
DM8CK9M	MN	Dopamine transporter (DAT)
DM8CK9M	MT	DTT
DM8CK9M	MA	Inhibitor
DM8CK9M	RN	Synthesis and monoamine transporter affinity of 3alpha-arylmethoxy-3beta-arylnortropanes. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6865-8.
DM8CK9M	RU	https://pubmed.ncbi.nlm.nih.gov/19896846

DM8CK9M	DI	DM8CK9M
DM8CK9M	DN	3-(4-Fluorophenyl)-2-nortropene
DM8CK9M	MI	TT3ROYC
DM8CK9M	MN	Serotonin transporter (SERT)
DM8CK9M	MT	DTT
DM8CK9M	MA	Inhibitor
DM8CK9M	RN	Synthesis and monoamine transporter affinity of 3alpha-arylmethoxy-3beta-arylnortropanes. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6865-8.
DM8CK9M	RU	https://pubmed.ncbi.nlm.nih.gov/19896846

DM0POH2	DI	DM0POH2
DM0POH2	DN	3-(4-Fluoro-phenyl)-6,7-dimethoxy-quinoline
DM0POH2	MI	TT8FYO9
DM0POH2	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DM0POH2	MT	DTT
DM0POH2	MA	Inhibitor
DM0POH2	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DM0POH2	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DM0POH2	DI	DM0POH2
DM0POH2	DN	3-(4-Fluoro-phenyl)-6,7-dimethoxy-quinoline
DM0POH2	MI	TTI7421
DM0POH2	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM0POH2	MT	DTT
DM0POH2	MA	Inhibitor
DM0POH2	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DM0POH2	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMDYS7Q	DI	DMDYS7Q
DMDYS7Q	DN	3-(4-hexylthiosemicarbazono)methyl-benzoic acid
DMDYS7Q	MI	TTHM0R1
DMDYS7Q	MN	Steryl-sulfatase (STS)
DMDYS7Q	MT	DTT
DMDYS7Q	MA	Inhibitor
DMDYS7Q	RN	Thiosemicarbazones of formyl benzoic acids as novel potent inhibitors of estrone sulfatase. J Med Chem. 2007 Jul 26;50(15):3661-6.
DMDYS7Q	RU	https://pubmed.ncbi.nlm.nih.gov/17580843

DMPS1GW	DI	DMPS1GW
DMPS1GW	DN	3-(4H-Imidazol-4-yl)benzenethiol
DMPS1GW	MI	TTZJYKH
DMPS1GW	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMPS1GW	MT	DTT
DMPS1GW	MA	Inhibitor
DMPS1GW	RN	Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase. J Med Chem. 2008 Aug 28;51(16):4968-77.
DMPS1GW	RU	https://pubmed.ncbi.nlm.nih.gov/18665584

DME5238	DI	DME5238
DME5238	DN	3-(4-Hydroxy-phenyl)-2,3-diphenyl-acrylonitrile
DME5238	MI	TTFJ8Q1
DME5238	MN	Protein kinase C alpha (PRKCA)
DME5238	MT	DTT
DME5238	MA	Inhibitor
DME5238	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DME5238	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DME5238	DI	DME5238
DME5238	DN	3-(4-Hydroxy-phenyl)-2,3-diphenyl-acrylonitrile
DME5238	MI	TTYPXQF
DME5238	MN	Protein kinase C beta (PRKCB)
DME5238	MT	DTT
DME5238	MA	Inhibitor
DME5238	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DME5238	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DME5238	DI	DME5238
DME5238	DN	3-(4-Hydroxy-phenyl)-2,3-diphenyl-acrylonitrile
DME5238	MI	TT9WJ8U
DME5238	MN	Protein kinase C delta (PRKCD)
DME5238	MT	DTT
DME5238	MA	Inhibitor
DME5238	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DME5238	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DME5238	DI	DME5238
DME5238	DN	3-(4-Hydroxy-phenyl)-2,3-diphenyl-acrylonitrile
DME5238	MI	TTBZ7OD
DME5238	MN	Protein kinase C epsilon (PRKCE)
DME5238	MT	DTT
DME5238	MA	Inhibitor
DME5238	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DME5238	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DME5238	DI	DME5238
DME5238	DN	3-(4-Hydroxy-phenyl)-2,3-diphenyl-acrylonitrile
DME5238	MI	TTRFOXJ
DME5238	MN	Protein kinase C gamma (PRKCG)
DME5238	MT	DTT
DME5238	MA	Inhibitor
DME5238	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DME5238	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DME5238	DI	DME5238
DME5238	DN	3-(4-Hydroxy-phenyl)-2,3-diphenyl-acrylonitrile
DME5238	MI	TT8QL1J
DME5238	MN	Protein kinase C theta (PRKCQ)
DME5238	MT	DTT
DME5238	MA	Inhibitor
DME5238	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DME5238	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DME5238	DI	DME5238
DME5238	DN	3-(4-Hydroxy-phenyl)-2,3-diphenyl-acrylonitrile
DME5238	MI	TTUWGRA
DME5238	MN	Protein kinase C zeta (PRKCZ)
DME5238	MT	DTT
DME5238	MA	Inhibitor
DME5238	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DME5238	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DMN01PI	DI	DMN01PI
DMN01PI	DN	3-(4-Hydroxy-phenyl)-4H-chromen-7-ol
DMN01PI	MI	TTOM3J0
DMN01PI	MN	Estrogen receptor beta (ESR2)
DMN01PI	MT	DTT
DMN01PI	MA	Inhibitor
DMN01PI	RN	Structure-based virtual screening for plant-based ERbeta-selective ligands as potential preventative therapy against age-related neurodegenerative ... J Med Chem. 2005 May 19;48(10):3463-6.
DMN01PI	RU	https://pubmed.ncbi.nlm.nih.gov/15887952

DM3XOVL	DI	DM3XOVL
DM3XOVL	DN	3-(4-hydroxyphenyl)-6-methyl-2H-chromen-2-one
DM3XOVL	MI	TTGP7BY
DM3XOVL	MN	Monoamine oxidase type B (MAO-B)
DM3XOVL	MT	DTT
DM3XOVL	MA	Inhibitor
DM3XOVL	RN	Synthesis and evaluation of 6-methyl-3-phenylcoumarins as potent and selective MAO-B inhibitors. Bioorg Med Chem Lett. 2009 Sep 1;19(17):5053-5.
DM3XOVL	RU	https://pubmed.ncbi.nlm.nih.gov/19628387

DMS5N6Y	DI	DMS5N6Y
DMS5N6Y	DN	3-(4-Hydroxyphenyl)-7-isobutoxychromen-4-one
DMS5N6Y	MI	TTZAYWL
DMS5N6Y	MN	Estrogen receptor (ESR)
DMS5N6Y	MT	DTT
DMS5N6Y	MA	Inhibitor
DMS5N6Y	RN	Effects of 7-O substitutions on estrogenic and anti-estrogenic activities of daidzein analogues in MCF-7 breast cancer cells. J Med Chem. 2010 Aug 26;53(16):6153-63.
DMS5N6Y	RU	https://pubmed.ncbi.nlm.nih.gov/20669983

DMH75AO	DI	DMH75AO
DMH75AO	DN	3-(4-Hydroxyphenyl)-7-isopropoxychromen-4-one
DMH75AO	MI	TTZAYWL
DMH75AO	MN	Estrogen receptor (ESR)
DMH75AO	MT	DTT
DMH75AO	MA	Inhibitor
DMH75AO	RN	Effects of 7-O substitutions on estrogenic and anti-estrogenic activities of daidzein analogues in MCF-7 breast cancer cells. J Med Chem. 2010 Aug 26;53(16):6153-63.
DMH75AO	RU	https://pubmed.ncbi.nlm.nih.gov/20669983

DMXZ9T6	DI	DMXZ9T6
DMXZ9T6	DN	3-(4-Hydroxy-phenyl)-benzo[d]isoxazol-5-ol
DMXZ9T6	MI	TTZAYWL
DMXZ9T6	MN	Estrogen receptor (ESR)
DMXZ9T6	MT	DTT
DMXZ9T6	MA	Inhibitor
DMXZ9T6	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMXZ9T6	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMXZ9T6	DI	DMXZ9T6
DMXZ9T6	DN	3-(4-Hydroxy-phenyl)-benzo[d]isoxazol-5-ol
DMXZ9T6	MI	TTOM3J0
DMXZ9T6	MN	Estrogen receptor beta (ESR2)
DMXZ9T6	MT	DTT
DMXZ9T6	MA	Inhibitor
DMXZ9T6	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMXZ9T6	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMYLDFG	DI	DMYLDFG
DMYLDFG	DN	3-(4-Hydroxy-phenyl)-benzo[d]isoxazol-6-ol
DMYLDFG	MI	TTZAYWL
DMYLDFG	MN	Estrogen receptor (ESR)
DMYLDFG	MT	DTT
DMYLDFG	MA	Inhibitor
DMYLDFG	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMYLDFG	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMYLDFG	DI	DMYLDFG
DMYLDFG	DN	3-(4-Hydroxy-phenyl)-benzo[d]isoxazol-6-ol
DMYLDFG	MI	TTOM3J0
DMYLDFG	MN	Estrogen receptor beta (ESR2)
DMYLDFG	MT	DTT
DMYLDFG	MA	Inhibitor
DMYLDFG	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMYLDFG	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DM18MOH	DI	DM18MOH
DM18MOH	DN	3-(4'-Hydroxyphenyl)diazenylbenzenesulfonamide
DM18MOH	MI	TTANPDJ
DM18MOH	MN	Carbonic anhydrase II (CA-II)
DM18MOH	MT	DTT
DM18MOH	MA	Inhibitor
DM18MOH	RN	Carbonic anhydrase inhibitors. Inhibition of the Rv1284 and Rv3273 beta-carbonic anhydrases from Mycobacterium tuberculosis with diazenylbenzenesul... Bioorg Med Chem Lett. 2009 Sep 1;19(17):4929-32.
DM18MOH	RU	https://pubmed.ncbi.nlm.nih.gov/19651511

DM18MOH	DI	DM18MOH
DM18MOH	DN	3-(4'-Hydroxyphenyl)diazenylbenzenesulfonamide
DM18MOH	MI	TT2LVK8
DM18MOH	MN	Carbonic anhydrase IX (CA-IX)
DM18MOH	MT	DTT
DM18MOH	MA	Inhibitor
DM18MOH	RN	Carbonic anhydrase inhibitors. Diazenylbenzenesulfonamides are potent and selective inhibitors of the tumor-associated isozymes IX and XII over the... Bioorg Med Chem. 2009 Oct 15;17(20):7093-9.
DM18MOH	RU	https://pubmed.ncbi.nlm.nih.gov/19773173

DM18MOH	DI	DM18MOH
DM18MOH	DN	3-(4'-Hydroxyphenyl)diazenylbenzenesulfonamide
DM18MOH	MI	TTSYM0R
DM18MOH	MN	Carbonic anhydrase XII (CA-XII)
DM18MOH	MT	DTT
DM18MOH	MA	Inhibitor
DM18MOH	RN	Carbonic anhydrase inhibitors. Diazenylbenzenesulfonamides are potent and selective inhibitors of the tumor-associated isozymes IX and XII over the... Bioorg Med Chem. 2009 Oct 15;17(20):7093-9.
DM18MOH	RU	https://pubmed.ncbi.nlm.nih.gov/19773173

DMSR2O3	DI	DMSR2O3
DMSR2O3	DN	3-(4-Methanesulfonyl-phenyl)-1-phenyl-propynone
DMSR2O3	MI	TT8NGED
DMSR2O3	MN	Prostaglandin G/H synthase 1 (COX-1)
DMSR2O3	MT	DTT
DMSR2O3	MA	Inhibitor
DMSR2O3	RN	Synthesis and biological evaluation of 1,3-diphenylprop-2-yn-1-ones as dual inhibitors of cyclooxygenases and lipoxygenases. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4842-5.
DMSR2O3	RU	https://pubmed.ncbi.nlm.nih.gov/16143531

DMSR2O3	DI	DMSR2O3
DMSR2O3	DN	3-(4-Methanesulfonyl-phenyl)-1-phenyl-propynone
DMSR2O3	MI	TTVKILB
DMSR2O3	MN	Prostaglandin G/H synthase 2 (COX-2)
DMSR2O3	MT	DTT
DMSR2O3	MA	Inhibitor
DMSR2O3	RN	Synthesis and biological evaluation of 1,3-diphenylprop-2-yn-1-ones as dual inhibitors of cyclooxygenases and lipoxygenases. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4842-5.
DMSR2O3	RU	https://pubmed.ncbi.nlm.nih.gov/16143531

DM206M1	DI	DM206M1
DM206M1	DN	3-(4-Methoxy-benzenesulfonyl)-cyclohexanethiol
DM206M1	MI	TTMX39J
DM206M1	MN	Matrix metalloproteinase-1 (MMP-1)
DM206M1	MT	DTT
DM206M1	MA	Inhibitor
DM206M1	RN	Synthesis and identification of conformationally constrained selective MMP inhibitors. Bioorg Med Chem Lett. 1999 Jul 5;9(13):1757-60.
DM206M1	RU	https://pubmed.ncbi.nlm.nih.gov/10406637

DM206M1	DI	DM206M1
DM206M1	DN	3-(4-Methoxy-benzenesulfonyl)-cyclohexanethiol
DM206M1	MI	TTHY57M
DM206M1	MN	Matrix metalloproteinase-13 (MMP-13)
DM206M1	MT	DTT
DM206M1	MA	Inhibitor
DM206M1	RN	Synthesis and identification of conformationally constrained selective MMP inhibitors. Bioorg Med Chem Lett. 1999 Jul 5;9(13):1757-60.
DM206M1	RU	https://pubmed.ncbi.nlm.nih.gov/10406637

DM206M1	DI	DM206M1
DM206M1	DN	3-(4-Methoxy-benzenesulfonyl)-cyclohexanethiol
DM206M1	MI	TTGA1IV
DM206M1	MN	Matrix metalloproteinase-8 (MMP-8)
DM206M1	MT	DTT
DM206M1	MA	Inhibitor
DM206M1	RN	Synthesis and identification of conformationally constrained selective MMP inhibitors. Bioorg Med Chem Lett. 1999 Jul 5;9(13):1757-60.
DM206M1	RU	https://pubmed.ncbi.nlm.nih.gov/10406637

DMK79U1	DI	DMK79U1
DMK79U1	DN	3-(4-Methoxy-benzenesulfonyl)-cyclopentanethiol
DMK79U1	MI	TTHY57M
DMK79U1	MN	Matrix metalloproteinase-13 (MMP-13)
DMK79U1	MT	DTT
DMK79U1	MA	Inhibitor
DMK79U1	RN	Synthesis and identification of conformationally constrained selective MMP inhibitors. Bioorg Med Chem Lett. 1999 Jul 5;9(13):1757-60.
DMK79U1	RU	https://pubmed.ncbi.nlm.nih.gov/10406637

DMRLAX8	DI	DMRLAX8
DMRLAX8	DN	3-(4-Methoxy-benzenesulfonyl)-hexane-1-thiol
DMRLAX8	MI	TTMX39J
DMRLAX8	MN	Matrix metalloproteinase-1 (MMP-1)
DMRLAX8	MT	DTT
DMRLAX8	MA	Inhibitor
DMRLAX8	RN	Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols. Bioorg Med Chem Lett. 1999 Apr 5;9(7):943-8.
DMRLAX8	RU	https://pubmed.ncbi.nlm.nih.gov/10230616

DMRLAX8	DI	DMRLAX8
DMRLAX8	DN	3-(4-Methoxy-benzenesulfonyl)-hexane-1-thiol
DMRLAX8	MI	TTHY57M
DMRLAX8	MN	Matrix metalloproteinase-13 (MMP-13)
DMRLAX8	MT	DTT
DMRLAX8	MA	Inhibitor
DMRLAX8	RN	Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols. Bioorg Med Chem Lett. 1999 Apr 5;9(7):943-8.
DMRLAX8	RU	https://pubmed.ncbi.nlm.nih.gov/10230616

DM854IG	DI	DM854IG
DM854IG	DN	3-(4-Methoxy-benzenesulfonyl)-pentane-1-thiol
DM854IG	MI	TTMX39J
DM854IG	MN	Matrix metalloproteinase-1 (MMP-1)
DM854IG	MT	DTT
DM854IG	MA	Inhibitor
DM854IG	RN	Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols. Bioorg Med Chem Lett. 1999 Apr 5;9(7):943-8.
DM854IG	RU	https://pubmed.ncbi.nlm.nih.gov/10230616

DM854IG	DI	DM854IG
DM854IG	DN	3-(4-Methoxy-benzenesulfonyl)-pentane-1-thiol
DM854IG	MI	TTHY57M
DM854IG	MN	Matrix metalloproteinase-13 (MMP-13)
DM854IG	MT	DTT
DM854IG	MA	Inhibitor
DM854IG	RN	Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols. Bioorg Med Chem Lett. 1999 Apr 5;9(7):943-8.
DM854IG	RU	https://pubmed.ncbi.nlm.nih.gov/10230616

DM7B1VT	DI	DM7B1VT
DM7B1VT	DN	3-(4-Methoxy-benzenesulfonyl)-propane-1-thiol
DM7B1VT	MI	TTHY57M
DM7B1VT	MN	Matrix metalloproteinase-13 (MMP-13)
DM7B1VT	MT	DTT
DM7B1VT	MA	Inhibitor
DM7B1VT	RN	Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols. Bioorg Med Chem Lett. 1999 Apr 5;9(7):943-8.
DM7B1VT	RU	https://pubmed.ncbi.nlm.nih.gov/10230616

DM7B1VT	DI	DM7B1VT
DM7B1VT	DN	3-(4-Methoxy-benzenesulfonyl)-propane-1-thiol
DM7B1VT	MI	TTGA1IV
DM7B1VT	MN	Matrix metalloproteinase-8 (MMP-8)
DM7B1VT	MT	DTT
DM7B1VT	MA	Inhibitor
DM7B1VT	RN	Synthesis and identification of conformationally constrained selective MMP inhibitors. Bioorg Med Chem Lett. 1999 Jul 5;9(13):1757-60.
DM7B1VT	RU	https://pubmed.ncbi.nlm.nih.gov/10406637

DMFRZGS	DI	DMFRZGS
DMFRZGS	DN	3-(4-methoxybenzyloxy)-2-phenylthiazolidin-4-one
DMFRZGS	MI	TTW0CMT
DMFRZGS	MN	Voltage-gated potassium channel Kv1.5 (KCNA5)
DMFRZGS	MT	DTT
DMFRZGS	MA	Inhibitor
DMFRZGS	RN	Evolution of thiazolidine-based blockers of human Kv1.5 for the treatment of atrial arrhythmias. Bioorg Med Chem Lett. 2007 Jan 1;17(1):282-4.
DMFRZGS	RU	https://pubmed.ncbi.nlm.nih.gov/17095219

DMGC7RY	DI	DMGC7RY
DMGC7RY	DN	3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione
DMGC7RY	MI	TT9VGXW
DMGC7RY	MN	Angiopoietin 1 receptor (TEK)
DMGC7RY	MT	DTT
DMGC7RY	MA	Inhibitor
DMGC7RY	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DMGC7RY	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DMGC7RY	DI	DMGC7RY
DMGC7RY	DN	3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione
DMGC7RY	MI	TTH6V3D
DMGC7RY	MN	Cyclin-dependent kinase 1 (CDK1)
DMGC7RY	MT	DTT
DMGC7RY	MA	Inhibitor
DMGC7RY	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DMGC7RY	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DMGC7RY	DI	DMGC7RY
DMGC7RY	DN	3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione
DMGC7RY	MI	TT7HF4W
DMGC7RY	MN	Cyclin-dependent kinase 2 (CDK2)
DMGC7RY	MT	DTT
DMGC7RY	MA	Inhibitor
DMGC7RY	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DMGC7RY	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DMGC7RY	DI	DMGC7RY
DMGC7RY	DN	3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione
DMGC7RY	MI	TT0PG8F
DMGC7RY	MN	Cyclin-dependent kinase 4 (CDK4)
DMGC7RY	MT	DTT
DMGC7RY	MA	Inhibitor
DMGC7RY	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DMGC7RY	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DMGC7RY	DI	DMGC7RY
DMGC7RY	DN	3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione
DMGC7RY	MI	TTO0FDJ
DMGC7RY	MN	Cyclin-dependent kinase 6 (CDK6)
DMGC7RY	MT	DTT
DMGC7RY	MA	Inhibitor
DMGC7RY	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DMGC7RY	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DMGC7RY	DI	DMGC7RY
DMGC7RY	DN	3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione
DMGC7RY	MI	TTGKNB4
DMGC7RY	MN	Epidermal growth factor receptor (EGFR)
DMGC7RY	MT	DTT
DMGC7RY	MA	Inhibitor
DMGC7RY	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DMGC7RY	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DMGC7RY	DI	DMGC7RY
DMGC7RY	DN	3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione
DMGC7RY	MI	TTR5TV4
DMGC7RY	MN	ERBB2 messenger RNA (HER2 mRNA)
DMGC7RY	MT	DTT
DMGC7RY	MA	Inhibitor
DMGC7RY	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DMGC7RY	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DMGC7RY	DI	DMGC7RY
DMGC7RY	DN	3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione
DMGC7RY	MI	TTFCJ7S
DMGC7RY	MN	G1/S-specific cyclin-D1 (CCND1)
DMGC7RY	MT	DTT
DMGC7RY	MA	Inhibitor
DMGC7RY	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DMGC7RY	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DMGC7RY	DI	DMGC7RY
DMGC7RY	DN	3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione
DMGC7RY	MI	TTCEJ4F
DMGC7RY	MN	G1/S-specific cyclin-E1 (CCNE1)
DMGC7RY	MT	DTT
DMGC7RY	MA	Inhibitor
DMGC7RY	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DMGC7RY	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DMGC7RY	DI	DMGC7RY
DMGC7RY	DN	3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione
DMGC7RY	MI	TT9P6OW
DMGC7RY	MN	G2/mitotic-specific cyclin B1 (CCNB1)
DMGC7RY	MT	DTT
DMGC7RY	MA	Inhibitor
DMGC7RY	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DMGC7RY	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DMGC7RY	DI	DMGC7RY
DMGC7RY	DN	3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione
DMGC7RY	MI	TTFJ8Q1
DMGC7RY	MN	Protein kinase C alpha (PRKCA)
DMGC7RY	MT	DTT
DMGC7RY	MA	Inhibitor
DMGC7RY	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DMGC7RY	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DMGC7RY	DI	DMGC7RY
DMGC7RY	DN	3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione
DMGC7RY	MI	TTBZ7OD
DMGC7RY	MN	Protein kinase C epsilon (PRKCE)
DMGC7RY	MT	DTT
DMGC7RY	MA	Inhibitor
DMGC7RY	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DMGC7RY	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DMGC7RY	DI	DMGC7RY
DMGC7RY	DN	3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione
DMGC7RY	MI	TTRFOXJ
DMGC7RY	MN	Protein kinase C gamma (PRKCG)
DMGC7RY	MT	DTT
DMGC7RY	MA	Inhibitor
DMGC7RY	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DMGC7RY	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DMGC7RY	DI	DMGC7RY
DMGC7RY	DN	3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione
DMGC7RY	MI	TTUTJGQ
DMGC7RY	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMGC7RY	MT	DTT
DMGC7RY	MA	Inhibitor
DMGC7RY	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DMGC7RY	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DMXKJOC	DI	DMXKJOC
DMXKJOC	DN	3-(4-methoxyphenyl)-6-methyl-2H-chromen-2-one
DMXKJOC	MI	TTGP7BY
DMXKJOC	MN	Monoamine oxidase type B (MAO-B)
DMXKJOC	MT	DTT
DMXKJOC	MA	Inhibitor
DMXKJOC	RN	Synthesis and evaluation of 6-methyl-3-phenylcoumarins as potent and selective MAO-B inhibitors. Bioorg Med Chem Lett. 2009 Sep 1;19(17):5053-5.
DMXKJOC	RU	https://pubmed.ncbi.nlm.nih.gov/19628387

DM7WPQC	DI	DM7WPQC
DM7WPQC	DN	3-(4-methoxyphenyl)quinoxaline-5-carboxamide
DM7WPQC	MI	TTVDSZ0
DM7WPQC	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DM7WPQC	MT	DTT
DM7WPQC	MA	Inhibitor
DM7WPQC	RN	Design, synthesis, and cytoprotective effect of 2-aminothiazole analogues as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2009 Feb 12;52(3):718-25.
DM7WPQC	RU	https://pubmed.ncbi.nlm.nih.gov/19125579

DMDR20P	DI	DMDR20P
DMDR20P	DN	3-(4-methyl-3,4-dihydronaphthalen-2-yl)pyridine
DMDR20P	MI	TTSZLWK
DMDR20P	MN	Aromatase (CYP19A1)
DMDR20P	MT	DTT
DMDR20P	MA	Inhibitor
DMDR20P	RN	Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31.
DMDR20P	RU	https://pubmed.ncbi.nlm.nih.gov/16570918

DMDR20P	DI	DMDR20P
DMDR20P	DN	3-(4-methyl-3,4-dihydronaphthalen-2-yl)pyridine
DMDR20P	MI	TTIQUX7
DMDR20P	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMDR20P	MT	DTT
DMDR20P	MA	Inhibitor
DMDR20P	RN	Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31.
DMDR20P	RU	https://pubmed.ncbi.nlm.nih.gov/16570918

DM0HYDZ	DI	DM0HYDZ
DM0HYDZ	DN	3-(4-Methyl-piperidin-1-ylmethyl)-1H-indole
DM0HYDZ	MI	TTEX248
DM0HYDZ	MN	Dopamine D2 receptor (D2R)
DM0HYDZ	MT	DTT
DM0HYDZ	MA	Inhibitor
DM0HYDZ	RN	3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4... J Med Chem. 1996 May 10;39(10):1941-2.
DM0HYDZ	RU	https://pubmed.ncbi.nlm.nih.gov/8642550

DM0HYDZ	DI	DM0HYDZ
DM0HYDZ	DN	3-(4-Methyl-piperidin-1-ylmethyl)-1H-indole
DM0HYDZ	MI	TT4C8EA
DM0HYDZ	MN	Dopamine D3 receptor (D3R)
DM0HYDZ	MT	DTT
DM0HYDZ	MA	Inhibitor
DM0HYDZ	RN	3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4... J Med Chem. 1996 May 10;39(10):1941-2.
DM0HYDZ	RU	https://pubmed.ncbi.nlm.nih.gov/8642550

DM0HYDZ	DI	DM0HYDZ
DM0HYDZ	DN	3-(4-Methyl-piperidin-1-ylmethyl)-1H-indole
DM0HYDZ	MI	TTE0A2F
DM0HYDZ	MN	Dopamine D4 receptor (D4R)
DM0HYDZ	MT	DTT
DM0HYDZ	MA	Inhibitor
DM0HYDZ	RN	3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4... J Med Chem. 1996 May 10;39(10):1941-2.
DM0HYDZ	RU	https://pubmed.ncbi.nlm.nih.gov/8642550

DM54MDH	DI	DM54MDH
DM54MDH	DN	3-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenol
DM54MDH	MI	TT9H4P3
DM54MDH	MN	PI3K p110 beta messenger RNA (PIK3CB mRNA)
DM54MDH	MT	DTT
DM54MDH	MA	Inhibitor
DM54MDH	RN	Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem. 2007 Sep 1;15(17):5837-44.
DM54MDH	RU	https://pubmed.ncbi.nlm.nih.gov/17601739

DM54MDH	DI	DM54MDH
DM54MDH	DN	3-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenol
DM54MDH	MI	TTHBTOP
DM54MDH	MN	PI3-kinase gamma (PIK3CG)
DM54MDH	MT	DTT
DM54MDH	MA	Inhibitor
DM54MDH	RN	Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem. 2007 Sep 1;15(17):5837-44.
DM54MDH	RU	https://pubmed.ncbi.nlm.nih.gov/17601739

DMIBAM2	DI	DMIBAM2
DMIBAM2	DN	3-(4-o-Tolylpiperazine-1-carbonyl)coumarin
DMIBAM2	MI	TT1RS9F
DMIBAM2	MN	Acetylcholinesterase (AChE)
DMIBAM2	MT	DTT
DMIBAM2	MA	Inhibitor
DMIBAM2	RN	Design, synthesis, and acetylcholinesterase inhibitory activity of novel coumarin analogues. Bioorg Med Chem. 2008 Sep 1;16(17):8011-21.
DMIBAM2	RU	https://pubmed.ncbi.nlm.nih.gov/18701305

DMBKDZ3	DI	DMBKDZ3
DMBKDZ3	DN	3-(4-Phenoxy-benzenesulfonyl)-cyclohexanethiol
DMBKDZ3	MI	TTMX39J
DMBKDZ3	MN	Matrix metalloproteinase-1 (MMP-1)
DMBKDZ3	MT	DTT
DMBKDZ3	MA	Inhibitor
DMBKDZ3	RN	Synthesis and identification of conformationally constrained selective MMP inhibitors. Bioorg Med Chem Lett. 1999 Jul 5;9(13):1757-60.
DMBKDZ3	RU	https://pubmed.ncbi.nlm.nih.gov/10406637

DMBKDZ3	DI	DMBKDZ3
DMBKDZ3	DN	3-(4-Phenoxy-benzenesulfonyl)-cyclohexanethiol
DMBKDZ3	MI	TTHY57M
DMBKDZ3	MN	Matrix metalloproteinase-13 (MMP-13)
DMBKDZ3	MT	DTT
DMBKDZ3	MA	Inhibitor
DMBKDZ3	RN	Synthesis and identification of conformationally constrained selective MMP inhibitors. Bioorg Med Chem Lett. 1999 Jul 5;9(13):1757-60.
DMBKDZ3	RU	https://pubmed.ncbi.nlm.nih.gov/10406637

DMBKDZ3	DI	DMBKDZ3
DMBKDZ3	DN	3-(4-Phenoxy-benzenesulfonyl)-cyclohexanethiol
DMBKDZ3	MI	TTGA1IV
DMBKDZ3	MN	Matrix metalloproteinase-8 (MMP-8)
DMBKDZ3	MT	DTT
DMBKDZ3	MA	Inhibitor
DMBKDZ3	RN	Synthesis and identification of conformationally constrained selective MMP inhibitors. Bioorg Med Chem Lett. 1999 Jul 5;9(13):1757-60.
DMBKDZ3	RU	https://pubmed.ncbi.nlm.nih.gov/10406637

DM2HBGL	DI	DM2HBGL
DM2HBGL	DN	3-(4-Phenoxy-benzenesulfonyl)-propane-1-thiol
DM2HBGL	MI	TTMX39J
DM2HBGL	MN	Matrix metalloproteinase-1 (MMP-1)
DM2HBGL	MT	DTT
DM2HBGL	MA	Inhibitor
DM2HBGL	RN	Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols. Bioorg Med Chem Lett. 1999 Apr 5;9(7):943-8.
DM2HBGL	RU	https://pubmed.ncbi.nlm.nih.gov/10230616

DM2HBGL	DI	DM2HBGL
DM2HBGL	DN	3-(4-Phenoxy-benzenesulfonyl)-propane-1-thiol
DM2HBGL	MI	TTHY57M
DM2HBGL	MN	Matrix metalloproteinase-13 (MMP-13)
DM2HBGL	MT	DTT
DM2HBGL	MA	Inhibitor
DM2HBGL	RN	Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols. Bioorg Med Chem Lett. 1999 Apr 5;9(7):943-8.
DM2HBGL	RU	https://pubmed.ncbi.nlm.nih.gov/10230616

DM2HBGL	DI	DM2HBGL
DM2HBGL	DN	3-(4-Phenoxy-benzenesulfonyl)-propane-1-thiol
DM2HBGL	MI	TTGA1IV
DM2HBGL	MN	Matrix metalloproteinase-8 (MMP-8)
DM2HBGL	MT	DTT
DM2HBGL	MA	Inhibitor
DM2HBGL	RN	Synthesis and identification of conformationally constrained selective MMP inhibitors. Bioorg Med Chem Lett. 1999 Jul 5;9(13):1757-60.
DM2HBGL	RU	https://pubmed.ncbi.nlm.nih.gov/10406637

DMO6LID	DI	DMO6LID
DMO6LID	DN	3-(4-Phenoxy-phenyl)-1H-pyrazole
DMO6LID	MI	TT84DRB
DMO6LID	MN	Voltage-gated sodium channel alpha Nav1.4 (SCN4A)
DMO6LID	MT	DTT
DMO6LID	MA	Inhibitor
DMO6LID	RN	3-(4-phenoxyphenyl)pyrazoles: a novel class of sodium channel blockers. J Med Chem. 2004 Mar 11;47(6):1547-52.
DMO6LID	RU	https://pubmed.ncbi.nlm.nih.gov/14998340

DMSZ1VC	DI	DMSZ1VC
DMSZ1VC	DN	3-(4-phenyl-2,4'-bipyridin-6-yl)phenol
DMSZ1VC	MI	TTGTQHC
DMSZ1VC	MN	DNA topoisomerase I (TOP1)
DMSZ1VC	MT	DTT
DMSZ1VC	MA	Inhibitor
DMSZ1VC	RN	Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl ... Bioorg Med Chem. 2010 May 1;18(9):3066-77.
DMSZ1VC	RU	https://pubmed.ncbi.nlm.nih.gov/20392646

DM0OF64	DI	DM0OF64
DM0OF64	DN	3-(4-phenyl-6-(thiophen-2-yl)pyridin-2-yl)-phenol
DM0OF64	MI	TTGTQHC
DM0OF64	MN	DNA topoisomerase I (TOP1)
DM0OF64	MT	DTT
DM0OF64	MA	Inhibitor
DM0OF64	RN	Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl ... Bioorg Med Chem. 2010 May 1;18(9):3066-77.
DM0OF64	RU	https://pubmed.ncbi.nlm.nih.gov/20392646

DM0OF64	DI	DM0OF64
DM0OF64	DN	3-(4-phenyl-6-(thiophen-2-yl)pyridin-2-yl)-phenol
DM0OF64	MI	TT0IHXV
DM0OF64	MN	DNA topoisomerase II (TOP2)
DM0OF64	MT	DTT
DM0OF64	MA	Inhibitor
DM0OF64	RN	Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl ... Bioorg Med Chem. 2010 May 1;18(9):3066-77.
DM0OF64	RU	https://pubmed.ncbi.nlm.nih.gov/20392646

DMTR8SZ	DI	DMTR8SZ
DMTR8SZ	DN	3-(4-phenyl-6-(thiophen-3-yl)pyridin-2-yl)-phenol
DMTR8SZ	MI	TTGTQHC
DMTR8SZ	MN	DNA topoisomerase I (TOP1)
DMTR8SZ	MT	DTT
DMTR8SZ	MA	Inhibitor
DMTR8SZ	RN	Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl ... Bioorg Med Chem. 2010 May 1;18(9):3066-77.
DMTR8SZ	RU	https://pubmed.ncbi.nlm.nih.gov/20392646

DMTR8SZ	DI	DMTR8SZ
DMTR8SZ	DN	3-(4-phenyl-6-(thiophen-3-yl)pyridin-2-yl)-phenol
DMTR8SZ	MI	TT0IHXV
DMTR8SZ	MN	DNA topoisomerase II (TOP2)
DMTR8SZ	MT	DTT
DMTR8SZ	MA	Inhibitor
DMTR8SZ	RN	Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl ... Bioorg Med Chem. 2010 May 1;18(9):3066-77.
DMTR8SZ	RU	https://pubmed.ncbi.nlm.nih.gov/20392646

DMXL0J5	DI	DMXL0J5
DMXL0J5	DN	3-(4-Phenylethynylbenzoyl)nonanoic acid
DMXL0J5	MI	TTXZ0KQ
DMXL0J5	MN	Matrix metalloproteinase-12 (MMP-12)
DMXL0J5	MT	DTT
DMXL0J5	MA	Inhibitor
DMXL0J5	RN	Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8.
DMXL0J5	RU	https://pubmed.ncbi.nlm.nih.gov/16420030

DMXL0J5	DI	DMXL0J5
DMXL0J5	DN	3-(4-Phenylethynylbenzoyl)nonanoic acid
DMXL0J5	MI	TTLM12X
DMXL0J5	MN	Matrix metalloproteinase-2 (MMP-2)
DMXL0J5	MT	DTT
DMXL0J5	MA	Inhibitor
DMXL0J5	RN	Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8.
DMXL0J5	RU	https://pubmed.ncbi.nlm.nih.gov/16420030

DMXL0J5	DI	DMXL0J5
DMXL0J5	DN	3-(4-Phenylethynylbenzoyl)nonanoic acid
DMXL0J5	MI	TT6X50U
DMXL0J5	MN	Matrix metalloproteinase-9 (MMP-9)
DMXL0J5	MT	DTT
DMXL0J5	MA	Inhibitor
DMXL0J5	RN	Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8.
DMXL0J5	RU	https://pubmed.ncbi.nlm.nih.gov/16420030

DMH27E0	DI	DMH27E0
DMH27E0	DN	3-(4-Phenylpiperazin-1-carbonyl)coumarin
DMH27E0	MI	TT1RS9F
DMH27E0	MN	Acetylcholinesterase (AChE)
DMH27E0	MT	DTT
DMH27E0	MA	Inhibitor
DMH27E0	RN	Design, synthesis, and acetylcholinesterase inhibitory activity of novel coumarin analogues. Bioorg Med Chem. 2008 Sep 1;16(17):8011-21.
DMH27E0	RU	https://pubmed.ncbi.nlm.nih.gov/18701305

DM17SNR	DI	DM17SNR
DM17SNR	DN	3-(4-Phenyl-piperazin-1-ylmethyl)-1H-indole
DM17SNR	MI	TTEX248
DM17SNR	MN	Dopamine D2 receptor (D2R)
DM17SNR	MT	DTT
DM17SNR	MA	Inhibitor
DM17SNR	RN	3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4... J Med Chem. 1996 May 10;39(10):1941-2.
DM17SNR	RU	https://pubmed.ncbi.nlm.nih.gov/8642550

DM17SNR	DI	DM17SNR
DM17SNR	DN	3-(4-Phenyl-piperazin-1-ylmethyl)-1H-indole
DM17SNR	MI	TT4C8EA
DM17SNR	MN	Dopamine D3 receptor (D3R)
DM17SNR	MT	DTT
DM17SNR	MA	Inhibitor
DM17SNR	RN	3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4... J Med Chem. 1996 May 10;39(10):1941-2.
DM17SNR	RU	https://pubmed.ncbi.nlm.nih.gov/8642550

DM17SNR	DI	DM17SNR
DM17SNR	DN	3-(4-Phenyl-piperazin-1-ylmethyl)-1H-indole
DM17SNR	MI	TTE0A2F
DM17SNR	MN	Dopamine D4 receptor (D4R)
DM17SNR	MT	DTT
DM17SNR	MA	Inhibitor
DM17SNR	RN	3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4... J Med Chem. 1996 May 10;39(10):1941-2.
DM17SNR	RU	https://pubmed.ncbi.nlm.nih.gov/8642550

DMM0WGI	DI	DMM0WGI
DMM0WGI	DN	3-(4-Phenyl-piperidin-1-ylmethyl)-1H-indole
DMM0WGI	MI	TTEX248
DMM0WGI	MN	Dopamine D2 receptor (D2R)
DMM0WGI	MT	DTT
DMM0WGI	MA	Inhibitor
DMM0WGI	RN	3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4... J Med Chem. 1996 May 10;39(10):1941-2.
DMM0WGI	RU	https://pubmed.ncbi.nlm.nih.gov/8642550

DMM0WGI	DI	DMM0WGI
DMM0WGI	DN	3-(4-Phenyl-piperidin-1-ylmethyl)-1H-indole
DMM0WGI	MI	TT4C8EA
DMM0WGI	MN	Dopamine D3 receptor (D3R)
DMM0WGI	MT	DTT
DMM0WGI	MA	Inhibitor
DMM0WGI	RN	3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4... J Med Chem. 1996 May 10;39(10):1941-2.
DMM0WGI	RU	https://pubmed.ncbi.nlm.nih.gov/8642550

DMM0WGI	DI	DMM0WGI
DMM0WGI	DN	3-(4-Phenyl-piperidin-1-ylmethyl)-1H-indole
DMM0WGI	MI	TTE0A2F
DMM0WGI	MN	Dopamine D4 receptor (D4R)
DMM0WGI	MT	DTT
DMM0WGI	MA	Inhibitor
DMM0WGI	RN	3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4... J Med Chem. 1996 May 10;39(10):1941-2.
DMM0WGI	RU	https://pubmed.ncbi.nlm.nih.gov/8642550

DMDYVA7	DI	DMDYVA7
DMDYVA7	DN	3-(4-Pyridin-2-yl-imidazol-1-yl)-benzonitrile
DMDYVA7	MI	TTHS256
DMDYVA7	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMDYVA7	MT	DTT
DMDYVA7	MA	Inhibitor
DMDYVA7	RN	Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity. J Med Chem. 2004 Sep 9;47(19):4645-8. Letter
DMDYVA7	RU	https://pubmed.ncbi.nlm.nih.gov/15341479

DMTD16H	DI	DMTD16H
DMTD16H	DN	3-(4-Pyridin-2-yl-pyrazol-1-yl)-benzonitrile
DMTD16H	MI	TTHS256
DMTD16H	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMTD16H	MT	DTT
DMTD16H	MA	Inhibitor
DMTD16H	RN	Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity. J Med Chem. 2004 Sep 9;47(19):4645-8. Letter
DMTD16H	RU	https://pubmed.ncbi.nlm.nih.gov/15341479

DMBDW8P	DI	DMBDW8P
DMBDW8P	DN	3-(4-sulfamoylphenyl)propanoic acid
DMBDW8P	MI	TTUNARX
DMBDW8P	MN	Carbonic anhydrase (CA)
DMBDW8P	MT	DTT
DMBDW8P	MA	Inhibitor
DMBDW8P	RN	Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides. Bioorg Med Chem. 2009 Jul 1;17(13):4503-9.
DMBDW8P	RU	https://pubmed.ncbi.nlm.nih.gov/19450983

DMBDW8P	DI	DMBDW8P
DMBDW8P	DN	3-(4-sulfamoylphenyl)propanoic acid
DMBDW8P	MI	TTHQPL7
DMBDW8P	MN	Carbonic anhydrase I (CA-I)
DMBDW8P	MT	DTT
DMBDW8P	MA	Inhibitor
DMBDW8P	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMBDW8P	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMBDW8P	DI	DMBDW8P
DMBDW8P	DN	3-(4-sulfamoylphenyl)propanoic acid
DMBDW8P	MI	TTANPDJ
DMBDW8P	MN	Carbonic anhydrase II (CA-II)
DMBDW8P	MT	DTT
DMBDW8P	MA	Inhibitor
DMBDW8P	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMBDW8P	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMZB804	DI	DMZB804
DMZB804	DN	3-(4-Trifluoromethylphenyl)-2-nortropene
DMZB804	MI	TTVBI8W
DMZB804	MN	Dopamine transporter (DAT)
DMZB804	MT	DTT
DMZB804	MA	Inhibitor
DMZB804	RN	Synthesis and monoamine transporter affinity of 3alpha-arylmethoxy-3beta-arylnortropanes. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6865-8.
DMZB804	RU	https://pubmed.ncbi.nlm.nih.gov/19896846

DMZB804	DI	DMZB804
DMZB804	DN	3-(4-Trifluoromethylphenyl)-2-nortropene
DMZB804	MI	TT3ROYC
DMZB804	MN	Serotonin transporter (SERT)
DMZB804	MT	DTT
DMZB804	MA	Inhibitor
DMZB804	RN	Synthesis and monoamine transporter affinity of 3alpha-arylmethoxy-3beta-arylnortropanes. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6865-8.
DMZB804	RU	https://pubmed.ncbi.nlm.nih.gov/19896846

DM6S28U	DI	DM6S28U
DM6S28U	DN	3-(5-((methylthio)methyl)furan-2-yl)pyridine
DM6S28U	MI	TTXV4FI
DM6S28U	MN	Albendazole monooxygenase (CYP3A4)
DM6S28U	MT	DTT
DM6S28U	MA	Inhibitor
DM6S28U	RN	Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallization. J Med Chem. 2006 Nov 30;49(24):6987-7001.
DM6S28U	RU	https://pubmed.ncbi.nlm.nih.gov/17125252

DMTVYLM	DI	DMTVYLM
DMTVYLM	DN	3-(5,6,7,8-Tetrahydronaphthalen-2-yl)pyridine
DMTVYLM	MI	TTIQUX7
DMTVYLM	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMTVYLM	MT	DTT
DMTVYLM	MA	Inhibitor
DMTVYLM	RN	In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87.
DMTVYLM	RU	https://pubmed.ncbi.nlm.nih.gov/19049427

DMOUNPH	DI	DMOUNPH
DMOUNPH	DN	3-(5-[1,3]dithiolan-2-yl-furan-2-yl)pyridine
DMOUNPH	MI	TTXV4FI
DMOUNPH	MN	Albendazole monooxygenase (CYP3A4)
DMOUNPH	MT	DTT
DMOUNPH	MA	Inhibitor
DMOUNPH	RN	Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallization. J Med Chem. 2006 Nov 30;49(24):6987-7001.
DMOUNPH	RU	https://pubmed.ncbi.nlm.nih.gov/17125252

DMUIXNS	DI	DMUIXNS
DMUIXNS	DN	3-(5-Bromo-6-methoxy-naphthalen-2-yl)-pyridine
DMUIXNS	MI	TTSZLWK
DMUIXNS	MN	Aromatase (CYP19A1)
DMUIXNS	MT	DTT
DMUIXNS	MA	Inhibitor
DMUIXNS	RN	Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42.
DMUIXNS	RU	https://pubmed.ncbi.nlm.nih.gov/16220979

DMUIXNS	DI	DMUIXNS
DMUIXNS	DN	3-(5-Bromo-6-methoxy-naphthalen-2-yl)-pyridine
DMUIXNS	MI	TTIQUX7
DMUIXNS	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMUIXNS	MT	DTT
DMUIXNS	MA	Inhibitor
DMUIXNS	RN	Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42.
DMUIXNS	RU	https://pubmed.ncbi.nlm.nih.gov/16220979

DMM4HF8	DI	DMM4HF8
DMM4HF8	DN	3'-(5-Chloro-2-thienyl)biphenyl-3-ol
DMM4HF8	MI	TTIWB6L
DMM4HF8	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMM4HF8	MT	DTT
DMM4HF8	MA	Inhibitor
DMM4HF8	RN	Novel estrone mimetics with high 17beta-HSD1 inhibitory activity. Bioorg Med Chem. 2010 May 15;18(10):3494-505.
DMM4HF8	RU	https://pubmed.ncbi.nlm.nih.gov/20413314

DM67DVU	DI	DM67DVU
DM67DVU	DN	3-(5-Chloro-6-methoxy-naphthalen-2-yl)-pyridine
DM67DVU	MI	TTSZLWK
DM67DVU	MN	Aromatase (CYP19A1)
DM67DVU	MT	DTT
DM67DVU	MA	Inhibitor
DM67DVU	RN	Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42.
DM67DVU	RU	https://pubmed.ncbi.nlm.nih.gov/16220979

DM67DVU	DI	DM67DVU
DM67DVU	DN	3-(5-Chloro-6-methoxy-naphthalen-2-yl)-pyridine
DM67DVU	MI	TTIQUX7
DM67DVU	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM67DVU	MT	DTT
DM67DVU	MA	Inhibitor
DM67DVU	RN	Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42.
DM67DVU	RU	https://pubmed.ncbi.nlm.nih.gov/16220979

DMPRBLH	DI	DMPRBLH
DMPRBLH	DN	3-(5-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol
DMPRBLH	MI	TTZAYWL
DMPRBLH	MN	Estrogen receptor (ESR)
DMPRBLH	MT	DTT
DMPRBLH	MA	Inhibitor
DMPRBLH	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMPRBLH	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMPRBLH	DI	DMPRBLH
DMPRBLH	DN	3-(5-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol
DMPRBLH	MI	TTOM3J0
DMPRBLH	MN	Estrogen receptor beta (ESR2)
DMPRBLH	MT	DTT
DMPRBLH	MA	Inhibitor
DMPRBLH	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMPRBLH	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMTJXOU	DI	DMTJXOU
DMTJXOU	DN	3-(5-methoxy-1H-inden-2-yl)pyridine
DMTJXOU	MI	TTIQUX7
DMTJXOU	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMTJXOU	MT	DTT
DMTJXOU	MA	Inhibitor
DMTJXOU	RN	Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31.
DMTJXOU	RU	https://pubmed.ncbi.nlm.nih.gov/16570918

DMXLVG6	DI	DMXLVG6
DMXLVG6	DN	3-(5-methoxy-1H-indol-3-yl)propanoic acid
DMXLVG6	MI	TTZMAO3
DMXLVG6	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMXLVG6	MT	DTT
DMXLVG6	MA	Inhibitor
DMXLVG6	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMXLVG6	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM5NIE7	DI	DM5NIE7
DM5NIE7	DN	3-(5-phenyl-2-thienyl)phenol
DM5NIE7	MI	TTIWB6L
DM5NIE7	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DM5NIE7	MT	DTT
DM5NIE7	MA	Inhibitor
DM5NIE7	RN	New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43.
DM5NIE7	RU	https://pubmed.ncbi.nlm.nih.gov/19831396

DMPBLM2	DI	DMPBLM2
DMPBLM2	DN	3-(5-Phenyl-oxazol-2-ylamino)-benzonitrile
DMPBLM2	MI	TTUTJGQ
DMPBLM2	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMPBLM2	MT	DTT
DMPBLM2	MA	Inhibitor
DMPBLM2	RN	Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9.
DMPBLM2	RU	https://pubmed.ncbi.nlm.nih.gov/15743202

DMPBLM2	DI	DMPBLM2
DMPBLM2	DN	3-(5-Phenyl-oxazol-2-ylamino)-benzonitrile
DMPBLM2	MI	TTDCBX5
DMPBLM2	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DMPBLM2	MT	DTT
DMPBLM2	MA	Inhibitor
DMPBLM2	RN	Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9.
DMPBLM2	RU	https://pubmed.ncbi.nlm.nih.gov/15743202

DMPBLM2	DI	DMPBLM2
DMPBLM2	DN	3-(5-Phenyl-oxazol-2-ylamino)-benzonitrile
DMPBLM2	MI	TT1VAUK
DMPBLM2	MN	VEGFR1 messenger RNA (VEGFR1 mRNA)
DMPBLM2	MT	DTT
DMPBLM2	MA	Inhibitor
DMPBLM2	RN	Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9.
DMPBLM2	RU	https://pubmed.ncbi.nlm.nih.gov/15743202

DMM1CKZ	DI	DMM1CKZ
DMM1CKZ	DN	3-(5-Pyridin-2-yl-tetrazol-2-yl)-benzonitrile
DMM1CKZ	MI	TTHS256
DMM1CKZ	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMM1CKZ	MT	DTT
DMM1CKZ	MA	Inhibitor
DMM1CKZ	RN	Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity. J Med Chem. 2004 Sep 9;47(19):4645-8. Letter
DMM1CKZ	RU	https://pubmed.ncbi.nlm.nih.gov/15341479

DM9LVR5	DI	DM9LVR5
DM9LVR5	DN	3-(5-Thiophen-3-yl-pyridin-3-yl)-1H-indole
DM9LVR5	MI	TTUTJGQ
DM9LVR5	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM9LVR5	MT	DTT
DM9LVR5	MA	Inhibitor
DM9LVR5	RN	Discovery and evaluation of 3-(5-thien-3-ylpyridin-3-yl)-1H-indoles as a novel class of KDR kinase inhibitors. Bioorg Med Chem Lett. 2003 Sep 15;13(18):2973-6.
DM9LVR5	RU	https://pubmed.ncbi.nlm.nih.gov/12941314

DMADQCW	DI	DMADQCW
DMADQCW	DN	3-(6-(furan-2-yl)-4-phenylpyridin-2-yl)-phenol
DMADQCW	MI	TT0IHXV
DMADQCW	MN	DNA topoisomerase II (TOP2)
DMADQCW	MT	DTT
DMADQCW	MA	Inhibitor
DMADQCW	RN	Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl ... Bioorg Med Chem. 2010 May 1;18(9):3066-77.
DMADQCW	RU	https://pubmed.ncbi.nlm.nih.gov/20392646

DM8WL21	DI	DM8WL21
DM8WL21	DN	3-(6-(phenylamino)-9H-purin-8-yl)benzonitrile
DM8WL21	MI	TTRSMW9
DM8WL21	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DM8WL21	MT	DTT
DM8WL21	MA	Inhibitor
DM8WL21	RN	Novel 8-arylated purines as inhibitors of glycogen synthase kinase. Eur J Med Chem. 2010 Aug;45(8):3389-93.
DM8WL21	RU	https://pubmed.ncbi.nlm.nih.gov/20472330

DM4DFUS	DI	DM4DFUS
DM4DFUS	DN	3-(6,7-Dimethoxy-quinolin-4-yloxy)-phenol
DM4DFUS	MI	TTI7421
DM4DFUS	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM4DFUS	MT	DTT
DM4DFUS	MA	Inhibitor
DM4DFUS	RN	A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
DM4DFUS	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97101172

DMAWXV6	DI	DMAWXV6
DMAWXV6	DN	3-(6,7-Dimethoxy-quinolin-4-yloxy)-phenylamine
DMAWXV6	MI	TTI7421
DMAWXV6	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMAWXV6	MT	DTT
DMAWXV6	MA	Inhibitor
DMAWXV6	RN	A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
DMAWXV6	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97101172

DMISL9R	DI	DMISL9R
DMISL9R	DN	3-(6-Amino-purin-9-yl)-4-butoxy-butan-2-ol
DMISL9R	MI	TTLP57V
DMISL9R	MN	Adenosine deaminase (ADA)
DMISL9R	MT	DTT
DMISL9R	MA	Inhibitor
DMISL9R	RN	Adenosine deaminase inhibitors: synthesis and biological evaluation of unsaturated, aromatic, and oxo derivatives of (+)-erythro-9-(2'S-hydroxy-3'R... J Med Chem. 2000 Nov 30;43(24):4694-700.
DMISL9R	RU	https://pubmed.ncbi.nlm.nih.gov/11101360

DMMTU78	DI	DMMTU78
DMMTU78	DN	3-(6-Amino-purin-9-yl)-4-phenethyloxy-butan-2-ol
DMMTU78	MI	TTLP57V
DMMTU78	MN	Adenosine deaminase (ADA)
DMMTU78	MT	DTT
DMMTU78	MA	Inhibitor
DMMTU78	RN	Adenosine deaminase inhibitors: synthesis and biological evaluation of unsaturated, aromatic, and oxo derivatives of (+)-erythro-9-(2'S-hydroxy-3'R... J Med Chem. 2000 Nov 30;43(24):4694-700.
DMMTU78	RU	https://pubmed.ncbi.nlm.nih.gov/11101360

DMU08A4	DI	DMU08A4
DMU08A4	DN	3-(6-Amino-purin-9-yl)-4-p-tolyl-butan-2-ol
DMU08A4	MI	TTLP57V
DMU08A4	MN	Adenosine deaminase (ADA)
DMU08A4	MT	DTT
DMU08A4	MA	Inhibitor
DMU08A4	RN	Adenosine deaminase inhibitors: synthesis and biological evaluation of unsaturated, aromatic, and oxo derivatives of (+)-erythro-9-(2'S-hydroxy-3'R... J Med Chem. 2000 Nov 30;43(24):4694-700.
DMU08A4	RU	https://pubmed.ncbi.nlm.nih.gov/11101360

DMHXI21	DI	DMHXI21
DMHXI21	DN	3-(6-Amino-purin-9-yl)-5-m-tolyl-pentan-2-ol
DMHXI21	MI	TTLP57V
DMHXI21	MN	Adenosine deaminase (ADA)
DMHXI21	MT	DTT
DMHXI21	MA	Inhibitor
DMHXI21	RN	Adenosine deaminase inhibitors: synthesis and biological evaluation of unsaturated, aromatic, and oxo derivatives of (+)-erythro-9-(2'S-hydroxy-3'R... J Med Chem. 2000 Nov 30;43(24):4694-700.
DMHXI21	RU	https://pubmed.ncbi.nlm.nih.gov/11101360

DMYIZBK	DI	DMYIZBK
DMYIZBK	DN	3-(6-Amino-purin-9-yl)-6-o-tolyl-hexan-2-ol
DMYIZBK	MI	TTLP57V
DMYIZBK	MN	Adenosine deaminase (ADA)
DMYIZBK	MT	DTT
DMYIZBK	MA	Inhibitor
DMYIZBK	RN	Adenosine deaminase inhibitors: synthesis and biological evaluation of unsaturated, aromatic, and oxo derivatives of (+)-erythro-9-(2'S-hydroxy-3'R... J Med Chem. 2000 Nov 30;43(24):4694-700.
DMYIZBK	RU	https://pubmed.ncbi.nlm.nih.gov/11101360

DMZT8QX	DI	DMZT8QX
DMZT8QX	DN	3-(6-Amino-purin-9-yl)-6-phenyl-hexan-2-ol
DMZT8QX	MI	TTLP57V
DMZT8QX	MN	Adenosine deaminase (ADA)
DMZT8QX	MT	DTT
DMZT8QX	MA	Inhibitor
DMZT8QX	RN	Adenosine deaminase inhibitors: synthesis and biological evaluation of unsaturated, aromatic, and oxo derivatives of (+)-erythro-9-(2'S-hydroxy-3'R... J Med Chem. 2000 Nov 30;43(24):4694-700.
DMZT8QX	RU	https://pubmed.ncbi.nlm.nih.gov/11101360

DMUYELJ	DI	DMUYELJ
DMUYELJ	DN	3-(6-Amino-purin-9-yl)-7-phenyl-heptan-2-ol
DMUYELJ	MI	TTLP57V
DMUYELJ	MN	Adenosine deaminase (ADA)
DMUYELJ	MT	DTT
DMUYELJ	MA	Inhibitor
DMUYELJ	RN	Adenosine deaminase inhibitors: synthesis and biological evaluation of unsaturated, aromatic, and oxo derivatives of (+)-erythro-9-(2'S-hydroxy-3'R... J Med Chem. 2000 Nov 30;43(24):4694-700.
DMUYELJ	RU	https://pubmed.ncbi.nlm.nih.gov/11101360

DMAIS1D	DI	DMAIS1D
DMAIS1D	DN	3-(6-Amino-purin-9-yl)-8-phenyl-octan-2-ol
DMAIS1D	MI	TTLP57V
DMAIS1D	MN	Adenosine deaminase (ADA)
DMAIS1D	MT	DTT
DMAIS1D	MA	Inhibitor
DMAIS1D	RN	Adenosine deaminase inhibitors: synthesis and biological evaluation of unsaturated, aromatic, and oxo derivatives of (+)-erythro-9-(2'S-hydroxy-3'R... J Med Chem. 2000 Nov 30;43(24):4694-700.
DMAIS1D	RU	https://pubmed.ncbi.nlm.nih.gov/11101360

DM6FHWZ	DI	DM6FHWZ
DM6FHWZ	DN	3-(6-Amino-purin-9-yl)-non-5-en-2-ol
DM6FHWZ	MI	TTLP57V
DM6FHWZ	MN	Adenosine deaminase (ADA)
DM6FHWZ	MT	DTT
DM6FHWZ	MA	Inhibitor
DM6FHWZ	RN	Adenosine deaminase inhibitors: synthesis and biological evaluation of unsaturated, aromatic, and oxo derivatives of (+)-erythro-9-(2'S-hydroxy-3'R... J Med Chem. 2000 Nov 30;43(24):4694-700.
DM6FHWZ	RU	https://pubmed.ncbi.nlm.nih.gov/11101360

DM0YOZJ	DI	DM0YOZJ
DM0YOZJ	DN	3-(6-Amino-purin-9-yl)-non-5-yn-2-ol
DM0YOZJ	MI	TTLP57V
DM0YOZJ	MN	Adenosine deaminase (ADA)
DM0YOZJ	MT	DTT
DM0YOZJ	MA	Inhibitor
DM0YOZJ	RN	Adenosine deaminase inhibitors: synthesis and biological evaluation of unsaturated, aromatic, and oxo derivatives of (+)-erythro-9-(2'S-hydroxy-3'R... J Med Chem. 2000 Nov 30;43(24):4694-700.
DM0YOZJ	RU	https://pubmed.ncbi.nlm.nih.gov/11101360

DM63BI9	DI	DM63BI9
DM63BI9	DN	3-(6-Bromo-naphthalen-2-yl)-pyridine
DM63BI9	MI	TTIQUX7
DM63BI9	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM63BI9	MT	DTT
DM63BI9	MA	Inhibitor
DM63BI9	RN	Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42.
DM63BI9	RU	https://pubmed.ncbi.nlm.nih.gov/16220979

DMUQ0WI	DI	DMUQ0WI
DMUQ0WI	DN	3-(6-Ethoxy-naphthalen-2-yl)-pyridine
DMUQ0WI	MI	TTSZLWK
DMUQ0WI	MN	Aromatase (CYP19A1)
DMUQ0WI	MT	DTT
DMUQ0WI	MA	Inhibitor
DMUQ0WI	RN	Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42.
DMUQ0WI	RU	https://pubmed.ncbi.nlm.nih.gov/16220979

DMUQ0WI	DI	DMUQ0WI
DMUQ0WI	DN	3-(6-Ethoxy-naphthalen-2-yl)-pyridine
DMUQ0WI	MI	TTIQUX7
DMUQ0WI	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMUQ0WI	MT	DTT
DMUQ0WI	MA	Inhibitor
DMUQ0WI	RN	Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42.
DMUQ0WI	RU	https://pubmed.ncbi.nlm.nih.gov/16220979

DMUQ0WI	DI	DMUQ0WI
DMUQ0WI	DN	3-(6-Ethoxy-naphthalen-2-yl)-pyridine
DMUQ0WI	MI	TTRA5BZ
DMUQ0WI	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMUQ0WI	MT	DTT
DMUQ0WI	MA	Inhibitor
DMUQ0WI	RN	Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42.
DMUQ0WI	RU	https://pubmed.ncbi.nlm.nih.gov/16220979

DMHJ0SV	DI	DMHJ0SV
DMHJ0SV	DN	3-(6-fluoroquinazolin-4-ylamino)benzonitrile
DMHJ0SV	MI	TTHS256
DMHJ0SV	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMHJ0SV	MT	DTT
DMHJ0SV	MA	Inhibitor
DMHJ0SV	RN	Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6.
DMHJ0SV	RU	https://pubmed.ncbi.nlm.nih.gov/19854049

DMTIKF7	DI	DMTIKF7
DMTIKF7	DN	3-(6-hydroxy-2-naphthyl)benzoic acid
DMTIKF7	MI	TTIWB6L
DMTIKF7	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMTIKF7	MT	DTT
DMTIKF7	MA	Inhibitor
DMTIKF7	RN	Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors... J Med Chem. 2008 Apr 10;51(7):2158-69.
DMTIKF7	RU	https://pubmed.ncbi.nlm.nih.gov/18324762

DM5H9QT	DI	DM5H9QT
DM5H9QT	DN	3-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol
DM5H9QT	MI	TTZAYWL
DM5H9QT	MN	Estrogen receptor (ESR)
DM5H9QT	MT	DTT
DM5H9QT	MA	Inhibitor
DM5H9QT	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DM5H9QT	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DM5H9QT	DI	DM5H9QT
DM5H9QT	DN	3-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol
DM5H9QT	MI	TTOM3J0
DM5H9QT	MN	Estrogen receptor beta (ESR2)
DM5H9QT	MT	DTT
DM5H9QT	MA	Inhibitor
DM5H9QT	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DM5H9QT	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMAJHXO	DI	DMAJHXO
DMAJHXO	DN	3-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine
DMAJHXO	MI	TTSZLWK
DMAJHXO	MN	Aromatase (CYP19A1)
DMAJHXO	MT	DTT
DMAJHXO	MA	Inhibitor
DMAJHXO	RN	Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31.
DMAJHXO	RU	https://pubmed.ncbi.nlm.nih.gov/16570918

DMAJHXO	DI	DMAJHXO
DMAJHXO	DN	3-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine
DMAJHXO	MI	TTIQUX7
DMAJHXO	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMAJHXO	MT	DTT
DMAJHXO	MA	Inhibitor
DMAJHXO	RN	Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on pote... J Med Chem. 2008 Aug 28;51(16):5064-74.
DMAJHXO	RU	https://pubmed.ncbi.nlm.nih.gov/18672861

DMAJHXO	DI	DMAJHXO
DMAJHXO	DN	3-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine
DMAJHXO	MI	TTRA5BZ
DMAJHXO	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMAJHXO	MT	DTT
DMAJHXO	MA	Inhibitor
DMAJHXO	RN	Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31.
DMAJHXO	RU	https://pubmed.ncbi.nlm.nih.gov/16570918

DMISLV4	DI	DMISLV4
DMISLV4	DN	3-(6-Methoxy-3-methylnaphthalen-2-yl)pyridine
DMISLV4	MI	TTIQUX7
DMISLV4	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMISLV4	MT	DTT
DMISLV4	MA	Inhibitor
DMISLV4	RN	Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on pote... J Med Chem. 2008 Aug 28;51(16):5064-74.
DMISLV4	RU	https://pubmed.ncbi.nlm.nih.gov/18672861

DM0GXFB	DI	DM0GXFB
DM0GXFB	DN	3-(6-Methoxynaphthalen-2-yl)-4-methylpyridine
DM0GXFB	MI	TTIQUX7
DM0GXFB	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM0GXFB	MT	DTT
DM0GXFB	MA	Inhibitor
DM0GXFB	RN	Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on pote... J Med Chem. 2008 Aug 28;51(16):5064-74.
DM0GXFB	RU	https://pubmed.ncbi.nlm.nih.gov/18672861

DM704R5	DI	DM704R5
DM704R5	DN	3-(6-Methoxynaphthalen-2-yl)-5-phenylpyridine
DM704R5	MI	TTIQUX7
DM704R5	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM704R5	MT	DTT
DM704R5	MA	Inhibitor
DM704R5	RN	Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on pote... J Med Chem. 2008 Aug 28;51(16):5064-74.
DM704R5	RU	https://pubmed.ncbi.nlm.nih.gov/18672861

DMN75RD	DI	DMN75RD
DMN75RD	DN	3-(6-Methoxynaphthalen-2-yl)pyridin-4-amine
DMN75RD	MI	TTVG215
DMN75RD	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DMN75RD	MT	DTT
DMN75RD	MA	Inhibitor
DMN75RD	RN	Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on pote... J Med Chem. 2008 Aug 28;51(16):5064-74.
DMN75RD	RU	https://pubmed.ncbi.nlm.nih.gov/18672861

DMN75RD	DI	DMN75RD
DMN75RD	DN	3-(6-Methoxynaphthalen-2-yl)pyridin-4-amine
DMN75RD	MI	TTIQUX7
DMN75RD	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMN75RD	MT	DTT
DMN75RD	MA	Inhibitor
DMN75RD	RN	Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on pote... J Med Chem. 2008 Aug 28;51(16):5064-74.
DMN75RD	RU	https://pubmed.ncbi.nlm.nih.gov/18672861

DMYRJAB	DI	DMYRJAB
DMYRJAB	DN	3-(6-methoxynaphthalen-2-yl)pyridine
DMYRJAB	MI	TTSZLWK
DMYRJAB	MN	Aromatase (CYP19A1)
DMYRJAB	MT	DTT
DMYRJAB	MA	Inhibitor
DMYRJAB	RN	In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87.
DMYRJAB	RU	https://pubmed.ncbi.nlm.nih.gov/19049427

DMYRJAB	DI	DMYRJAB
DMYRJAB	DN	3-(6-methoxynaphthalen-2-yl)pyridine
DMYRJAB	MI	TTIQUX7
DMYRJAB	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMYRJAB	MT	DTT
DMYRJAB	MA	Inhibitor
DMYRJAB	RN	Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach. J Med Chem. 2008 Oct 9;51(19):6138-49.
DMYRJAB	RU	https://pubmed.ncbi.nlm.nih.gov/18763754

DMYRJAB	DI	DMYRJAB
DMYRJAB	DN	3-(6-methoxynaphthalen-2-yl)pyridine
DMYRJAB	MI	TTRA5BZ
DMYRJAB	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMYRJAB	MT	DTT
DMYRJAB	MA	Inhibitor
DMYRJAB	RN	In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87.
DMYRJAB	RU	https://pubmed.ncbi.nlm.nih.gov/19049427

DMS9DPO	DI	DMS9DPO
DMS9DPO	DN	3-(6-morpholino-4-oxo-4H-pyran-2-yl)benzaldehyde
DMS9DPO	MI	TTK3PY9
DMS9DPO	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMS9DPO	MT	DTT
DMS9DPO	MA	Inhibitor
DMS9DPO	RN	Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72.
DMS9DPO	RU	https://pubmed.ncbi.nlm.nih.gov/17371003

DM2VNLK	DI	DM2VNLK
DM2VNLK	DN	3-(6-morpholino-4-oxo-4H-pyran-2-yl)benzoic acid
DM2VNLK	MI	TTK3PY9
DM2VNLK	MN	DNA-dependent protein kinase catalytic (PRKDC)
DM2VNLK	MT	DTT
DM2VNLK	MA	Inhibitor
DM2VNLK	RN	Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72.
DM2VNLK	RU	https://pubmed.ncbi.nlm.nih.gov/17371003

DM2J63V	DI	DM2J63V
DM2J63V	DN	3-(6-morpholino-4-oxo-4H-pyran-2-yl)benzonitrile
DM2J63V	MI	TTK3PY9
DM2J63V	MN	DNA-dependent protein kinase catalytic (PRKDC)
DM2J63V	MT	DTT
DM2J63V	MA	Inhibitor
DM2J63V	RN	Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72.
DM2J63V	RU	https://pubmed.ncbi.nlm.nih.gov/17371003

DMS2OY9	DI	DMS2OY9
DMS2OY9	DN	3-(6-morpholino-9H-purin-2-yl)phenol
DMS2OY9	MI	TTCJG29
DMS2OY9	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMS2OY9	MT	DTT
DMS2OY9	MA	Inhibitor
DMS2OY9	RN	Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-alpha: Hit to lead studies. Bioorg Med Chem Lett. 2010 Jan 15;20(2):636-9.
DMS2OY9	RU	https://pubmed.ncbi.nlm.nih.gov/19969455

DM8ZUBY	DI	DM8ZUBY
DM8ZUBY	DN	3-(6-phenyl-2,4'-bipyridin-4-yl)phenol
DM8ZUBY	MI	TTGTQHC
DM8ZUBY	MN	DNA topoisomerase I (TOP1)
DM8ZUBY	MT	DTT
DM8ZUBY	MA	Inhibitor
DM8ZUBY	RN	Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl ... Bioorg Med Chem. 2010 May 1;18(9):3066-77.
DM8ZUBY	RU	https://pubmed.ncbi.nlm.nih.gov/20392646

DMZ53N4	DI	DMZ53N4
DMZ53N4	DN	3-(7-methyl-1,8-naphthyridin-2-yl)benzonitrile
DMZ53N4	MI	TTHS256
DMZ53N4	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMZ53N4	MT	DTT
DMZ53N4	MA	Inhibitor
DMZ53N4	RN	Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8.
DMZ53N4	RU	https://pubmed.ncbi.nlm.nih.gov/17936624

DMDIQ7H	DI	DMDIQ7H
DMDIQ7H	DN	3-(9-Acridinylamino)-5-(hydroxymethyl)aniline (AHMA)
DMDIQ7H	MI	TT2GPK3
DMDIQ7H	MN	DNA topoisomerase (TOP)
DMDIQ7H	MT	DTT
DMDIQ7H	MA	Inhibitor
DMDIQ7H	RN	Crystallization and preliminary X-ray analysis of anti-cancer agent 3-(9-acridinylamino)-5-(hydroxymethyl)aniline complexed with the DNA hexamer d(CGTACG)2. Biochim Biophys Acta. 2003 Jan 3;1625(1):27-9.
DMDIQ7H	RU	https://pubmed.ncbi.nlm.nih.gov/12527422

DM5497S	DI	DM5497S
DM5497S	DN	3-(aminomethyl)-4-(furan-2-yl)butanoic acid
DM5497S	MI	TTFK1JQ
DM5497S	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DM5497S	MT	DTT
DM5497S	MA	Inhibitor
DM5497S	RN	Heteroaromatic side-chain analogs of pregabalin. Bioorg Med Chem Lett. 2006 May 1;16(9):2329-32.
DM5497S	RU	https://pubmed.ncbi.nlm.nih.gov/16099652

DMG3FPJ	DI	DMG3FPJ
DMG3FPJ	DN	3-(aminomethyl)-4-(furan-3-yl)butanoic acid
DMG3FPJ	MI	TTFK1JQ
DMG3FPJ	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMG3FPJ	MT	DTT
DMG3FPJ	MA	Inhibitor
DMG3FPJ	RN	Heteroaromatic side-chain analogs of pregabalin. Bioorg Med Chem Lett. 2006 May 1;16(9):2329-32.
DMG3FPJ	RU	https://pubmed.ncbi.nlm.nih.gov/16099652

DMT72FB	DI	DMT72FB
DMT72FB	DN	3-(aminomethyl)-4-(thiophen-2-yl)butanoic acid
DMT72FB	MI	TTFK1JQ
DMT72FB	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMT72FB	MT	DTT
DMT72FB	MA	Inhibitor
DMT72FB	RN	Heteroaromatic side-chain analogs of pregabalin. Bioorg Med Chem Lett. 2006 May 1;16(9):2329-32.
DMT72FB	RU	https://pubmed.ncbi.nlm.nih.gov/16099652

DMWO1Z7	DI	DMWO1Z7
DMWO1Z7	DN	3-(aminomethyl)-4-(thiophen-3-yl)butanoic acid
DMWO1Z7	MI	TTFK1JQ
DMWO1Z7	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMWO1Z7	MT	DTT
DMWO1Z7	MA	Inhibitor
DMWO1Z7	RN	Heteroaromatic side-chain analogs of pregabalin. Bioorg Med Chem Lett. 2006 May 1;16(9):2329-32.
DMWO1Z7	RU	https://pubmed.ncbi.nlm.nih.gov/16099652

DMPFH15	DI	DMPFH15
DMPFH15	DN	3-(Aminooxy)propan-1-amine hydrochloride
DMPFH15	MI	TTUMGNO
DMPFH15	MN	Ornithine decarboxylase (ODC1)
DMPFH15	MT	DTT
DMPFH15	MA	Inhibitor
DMPFH15	RN	Selective delivery of 2-hydroxy APA to Trypanosoma brucei using the melamine motif. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4364-6.
DMPFH15	RU	https://pubmed.ncbi.nlm.nih.gov/20615694

DM58GRA	DI	DM58GRA
DM58GRA	DN	3-(benzo[b]thiophen-5-yl)-3-benzylpyrrolidine
DM58GRA	MI	TTQ6VDM
DM58GRA	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DM58GRA	MT	DTT
DM58GRA	MA	Inhibitor
DM58GRA	RN	Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors. Bioorg Med Chem Lett. 2008 Dec 1;18(23):6062-6.
DM58GRA	RU	https://pubmed.ncbi.nlm.nih.gov/18954985

DMPFH8U	DI	DMPFH8U
DMPFH8U	DN	3-(benzo[d]oxazol-2-yl)phenyl propylcarbamate
DMPFH8U	MI	TTDP1UC
DMPFH8U	MN	Fatty acid amide hydrolase (FAAH)
DMPFH8U	MT	DTT
DMPFH8U	MA	Inhibitor
DMPFH8U	RN	Chiral 3-(4,5-dihydrooxazol-2-yl)phenyl alkylcarbamates as novel FAAH inhibitors: Insight into FAAH enantioselectivity by molecular docking and int... Eur J Med Chem. 2009 Oct;44(10):4179-91.
DMPFH8U	RU	https://pubmed.ncbi.nlm.nih.gov/19539407

DMD4WHN	DI	DMD4WHN
DMD4WHN	DN	3-(benzyloxy)-2-(4-chlorophenyl)thiazolidin-4-one
DMD4WHN	MI	TTW0CMT
DMD4WHN	MN	Voltage-gated potassium channel Kv1.5 (KCNA5)
DMD4WHN	MT	DTT
DMD4WHN	MA	Inhibitor
DMD4WHN	RN	Evolution of thiazolidine-based blockers of human Kv1.5 for the treatment of atrial arrhythmias. Bioorg Med Chem Lett. 2007 Jan 1;17(1):282-4.
DMD4WHN	RU	https://pubmed.ncbi.nlm.nih.gov/17095219

DMDNEKR	DI	DMDNEKR
DMDNEKR	DN	3-(benzyloxy)-9H-pyrido[3,4-b]indole
DMDNEKR	MI	TT1MPAY
DMDNEKR	MN	GABA(A) receptor alpha-1 (GABRA1)
DMDNEKR	MT	DTT
DMDNEKR	MA	Inhibitor
DMDNEKR	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DMDNEKR	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DMDNEKR	DI	DMDNEKR
DMDNEKR	DN	3-(benzyloxy)-9H-pyrido[3,4-b]indole
DMDNEKR	MI	TTBMV1G
DMDNEKR	MN	GABA(A) receptor alpha-2 (GABRA2)
DMDNEKR	MT	DTT
DMDNEKR	MA	Inhibitor
DMDNEKR	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DMDNEKR	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DMDNEKR	DI	DMDNEKR
DMDNEKR	DN	3-(benzyloxy)-9H-pyrido[3,4-b]indole
DMDNEKR	MI	TT37EDJ
DMDNEKR	MN	GABA(A) receptor alpha-3 (GABRA3)
DMDNEKR	MT	DTT
DMDNEKR	MA	Inhibitor
DMDNEKR	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DMDNEKR	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DMDNEKR	DI	DMDNEKR
DMDNEKR	DN	3-(benzyloxy)-9H-pyrido[3,4-b]indole
DMDNEKR	MI	TTNZPQ1
DMDNEKR	MN	GABA(A) receptor alpha-5 (GABRA5)
DMDNEKR	MT	DTT
DMDNEKR	MA	Inhibitor
DMDNEKR	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DMDNEKR	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DMDNEKR	DI	DMDNEKR
DMDNEKR	DN	3-(benzyloxy)-9H-pyrido[3,4-b]indole
DMDNEKR	MI	TT06RH5
DMDNEKR	MN	GABA(A) receptor gamma-2 (GABRG2)
DMDNEKR	MT	DTT
DMDNEKR	MA	Inhibitor
DMDNEKR	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DMDNEKR	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DMDNEKR	DI	DMDNEKR
DMDNEKR	DN	3-(benzyloxy)-9H-pyrido[3,4-b]indole
DMDNEKR	MI	TTNJYV2
DMDNEKR	MN	Gamma-aminobutyric acid receptor (GAR)
DMDNEKR	MT	DTT
DMDNEKR	MA	Inhibitor
DMDNEKR	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DMDNEKR	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DM35VEI	DI	DM35VEI
DM35VEI	DN	3-(Benzyloxy)Pyridin-2-Amine
DM35VEI	MI	TTXZEAJ
DM35VEI	MN	Leukotriene A-4 hydrolase (LTA4H)
DM35VEI	MT	DTT
DM35VEI	MA	Inhibitor
DM35VEI	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM35VEI	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM35VEI	DI	DM35VEI
DM35VEI	DN	3-(Benzyloxy)Pyridin-2-Amine
DM35VEI	MI	TTQBR95
DM35VEI	MN	Stress-activated protein kinase 2a (p38 alpha)
DM35VEI	MT	DTT
DM35VEI	MA	Inhibitor
DM35VEI	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM35VEI	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM4GWJO	DI	DM4GWJO
DM4GWJO	DN	3-(biphenyl-4-yl)-1-(oxazol-2-yl)propan-1-one
DM4GWJO	MI	TTDP1UC
DM4GWJO	MN	Fatty acid amide hydrolase (FAAH)
DM4GWJO	MT	DTT
DM4GWJO	MA	Inhibitor
DM4GWJO	RN	Optimization of alpha-ketooxazole inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Feb 28;51(4):937-47.
DM4GWJO	RU	https://pubmed.ncbi.nlm.nih.gov/18247553

DM8PM0E	DI	DM8PM0E
DM8PM0E	DN	3-(butylsulfinyl)-1,1,1-trifluoropropan-2-one
DM8PM0E	MI	TTMF541
DM8PM0E	MN	Liver carboxylesterase (CES1)
DM8PM0E	MT	DTT
DM8PM0E	MA	Inhibitor
DM8PM0E	RN	Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30.
DM8PM0E	RU	https://pubmed.ncbi.nlm.nih.gov/18023188

DM8T2OX	DI	DM8T2OX
DM8T2OX	DN	3-(butylthio)-1,1,1-trifluoropropan-2-one
DM8T2OX	MI	TTMF541
DM8T2OX	MN	Liver carboxylesterase (CES1)
DM8T2OX	MT	DTT
DM8T2OX	MA	Inhibitor
DM8T2OX	RN	Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30.
DM8T2OX	RU	https://pubmed.ncbi.nlm.nih.gov/18023188

DMWJ6UD	DI	DMWJ6UD
DMWJ6UD	DN	3-(decylsulfinyl)-1,1,1-trifluoropropan-2-one
DMWJ6UD	MI	TTDP1UC
DMWJ6UD	MN	Fatty acid amide hydrolase (FAAH)
DMWJ6UD	MT	DTT
DMWJ6UD	MA	Inhibitor
DMWJ6UD	RN	Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30.
DMWJ6UD	RU	https://pubmed.ncbi.nlm.nih.gov/18023188

DMWJ6UD	DI	DMWJ6UD
DMWJ6UD	DN	3-(decylsulfinyl)-1,1,1-trifluoropropan-2-one
DMWJ6UD	MI	TTMF541
DMWJ6UD	MN	Liver carboxylesterase (CES1)
DMWJ6UD	MT	DTT
DMWJ6UD	MA	Inhibitor
DMWJ6UD	RN	Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30.
DMWJ6UD	RU	https://pubmed.ncbi.nlm.nih.gov/18023188

DMF27YT	DI	DMF27YT
DMF27YT	DN	3-(decylsulfonyl)-1,1,1-trifluoropropan-2-one
DMF27YT	MI	TTDP1UC
DMF27YT	MN	Fatty acid amide hydrolase (FAAH)
DMF27YT	MT	DTT
DMF27YT	MA	Inhibitor
DMF27YT	RN	Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30.
DMF27YT	RU	https://pubmed.ncbi.nlm.nih.gov/18023188

DMF27YT	DI	DMF27YT
DMF27YT	DN	3-(decylsulfonyl)-1,1,1-trifluoropropan-2-one
DMF27YT	MI	TTMF541
DMF27YT	MN	Liver carboxylesterase (CES1)
DMF27YT	MT	DTT
DMF27YT	MA	Inhibitor
DMF27YT	RN	Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30.
DMF27YT	RU	https://pubmed.ncbi.nlm.nih.gov/18023188

DM1Y6L8	DI	DM1Y6L8
DM1Y6L8	DN	3-(decylthio)-1,1,1-trifluoropropan-2-one
DM1Y6L8	MI	TTDP1UC
DM1Y6L8	MN	Fatty acid amide hydrolase (FAAH)
DM1Y6L8	MT	DTT
DM1Y6L8	MA	Inhibitor
DM1Y6L8	RN	Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30.
DM1Y6L8	RU	https://pubmed.ncbi.nlm.nih.gov/18023188

DM1Y6L8	DI	DM1Y6L8
DM1Y6L8	DN	3-(decylthio)-1,1,1-trifluoropropan-2-one
DM1Y6L8	MI	TTMF541
DM1Y6L8	MN	Liver carboxylesterase (CES1)
DM1Y6L8	MT	DTT
DM1Y6L8	MA	Inhibitor
DM1Y6L8	RN	Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30.
DM1Y6L8	RU	https://pubmed.ncbi.nlm.nih.gov/18023188

DM2JBQI	DI	DM2JBQI
DM2JBQI	DN	3-(dibutylamino)-1-(4-hexylphenyl)propan-1-one
DM2JBQI	MI	TTTSEPU
DM2JBQI	MN	Thyroid hormone receptor alpha (THRA)
DM2JBQI	MT	DTT
DM2JBQI	MA	Inhibitor
DM2JBQI	RN	Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80.
DM2JBQI	RU	https://pubmed.ncbi.nlm.nih.gov/17918822

DM2JBQI	DI	DM2JBQI
DM2JBQI	DN	3-(dibutylamino)-1-(4-hexylphenyl)propan-1-one
DM2JBQI	MI	TTGER3L
DM2JBQI	MN	Thyroid hormone receptor beta (THRB)
DM2JBQI	MT	DTT
DM2JBQI	MA	Inhibitor
DM2JBQI	RN	Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80.
DM2JBQI	RU	https://pubmed.ncbi.nlm.nih.gov/17918822

DMG5VMH	DI	DMG5VMH
DMG5VMH	DN	3-(dimethylamino)-1-(4-heptylphenyl)propan-1-one
DMG5VMH	MI	TTGER3L
DMG5VMH	MN	Thyroid hormone receptor beta (THRB)
DMG5VMH	MT	DTT
DMG5VMH	MA	Inhibitor
DMG5VMH	RN	Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors. J Med Chem. 2009 Jul 9;52(13):3892-901.
DMG5VMH	RU	https://pubmed.ncbi.nlm.nih.gov/19469546

DMG5VMH	DI	DMG5VMH
DMG5VMH	DN	3-(dimethylamino)-1-(4-heptylphenyl)propan-1-one
DMG5VMH	MI	TTQ6VDM
DMG5VMH	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMG5VMH	MT	DTT
DMG5VMH	MA	Inhibitor
DMG5VMH	RN	Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors. J Med Chem. 2009 Jul 9;52(13):3892-901.
DMG5VMH	RU	https://pubmed.ncbi.nlm.nih.gov/19469546

DMJYCHG	DI	DMJYCHG
DMJYCHG	DN	3-(dimethylamino)-1-(4-hexylphenyl)propan-1-one
DMJYCHG	MI	TTTSEPU
DMJYCHG	MN	Thyroid hormone receptor alpha (THRA)
DMJYCHG	MT	DTT
DMJYCHG	MA	Inhibitor
DMJYCHG	RN	Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80.
DMJYCHG	RU	https://pubmed.ncbi.nlm.nih.gov/17918822

DMJYCHG	DI	DMJYCHG
DMJYCHG	DN	3-(dimethylamino)-1-(4-hexylphenyl)propan-1-one
DMJYCHG	MI	TTGER3L
DMJYCHG	MN	Thyroid hormone receptor beta (THRB)
DMJYCHG	MT	DTT
DMJYCHG	MA	Inhibitor
DMJYCHG	RN	Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80.
DMJYCHG	RU	https://pubmed.ncbi.nlm.nih.gov/17918822

DMM05G2	DI	DMM05G2
DMM05G2	DN	3-(dimethylamino)phenyl phenylcarbamate
DMM05G2	MI	TT1RS9F
DMM05G2	MN	Acetylcholinesterase (AChE)
DMM05G2	MT	DTT
DMM05G2	MA	Inhibitor
DMM05G2	RN	Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. Bioorg Med Chem. 2010 Jul 1;18(13):4687-93. 
DMM05G2	RU	https://pubmed.ncbi.nlm.nih.gov/20627738

DMM05G2	DI	DMM05G2
DMM05G2	DN	3-(dimethylamino)phenyl phenylcarbamate
DMM05G2	MI	TTEB0GD
DMM05G2	MN	Cholinesterase (BCHE)
DMM05G2	MT	DTT
DMM05G2	MA	Inhibitor
DMM05G2	RN	Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. Bioorg Med Chem. 2010 Jul 1;18(13):4687-93. 
DMM05G2	RU	https://pubmed.ncbi.nlm.nih.gov/20627738

DM7AG6Y	DI	DM7AG6Y
DM7AG6Y	DN	3-(dodecylsulfinyl)-1,1,1-trifluoropropan-2-one
DM7AG6Y	MI	TTDP1UC
DM7AG6Y	MN	Fatty acid amide hydrolase (FAAH)
DM7AG6Y	MT	DTT
DM7AG6Y	MA	Inhibitor
DM7AG6Y	RN	Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30.
DM7AG6Y	RU	https://pubmed.ncbi.nlm.nih.gov/18023188

DM7AG6Y	DI	DM7AG6Y
DM7AG6Y	DN	3-(dodecylsulfinyl)-1,1,1-trifluoropropan-2-one
DM7AG6Y	MI	TTMF541
DM7AG6Y	MN	Liver carboxylesterase (CES1)
DM7AG6Y	MT	DTT
DM7AG6Y	MA	Inhibitor
DM7AG6Y	RN	Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30.
DM7AG6Y	RU	https://pubmed.ncbi.nlm.nih.gov/18023188

DMPRCS0	DI	DMPRCS0
DMPRCS0	DN	3-(dodecylsulfonyl)-1,1,1-trifluoropropan-2-one
DMPRCS0	MI	TTDP1UC
DMPRCS0	MN	Fatty acid amide hydrolase (FAAH)
DMPRCS0	MT	DTT
DMPRCS0	MA	Inhibitor
DMPRCS0	RN	Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30.
DMPRCS0	RU	https://pubmed.ncbi.nlm.nih.gov/18023188

DMPRCS0	DI	DMPRCS0
DMPRCS0	DN	3-(dodecylsulfonyl)-1,1,1-trifluoropropan-2-one
DMPRCS0	MI	TTMF541
DMPRCS0	MN	Liver carboxylesterase (CES1)
DMPRCS0	MT	DTT
DMPRCS0	MA	Inhibitor
DMPRCS0	RN	Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30.
DMPRCS0	RU	https://pubmed.ncbi.nlm.nih.gov/18023188

DM71EMN	DI	DM71EMN
DM71EMN	DN	3-(ethoxycarbonyl)phenylboronic acid
DM71EMN	MI	TTDP1UC
DM71EMN	MN	Fatty acid amide hydrolase (FAAH)
DM71EMN	MT	DTT
DM71EMN	MA	Inhibitor
DM71EMN	RN	Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Nov 27;51(22):7057-60.
DM71EMN	RU	https://pubmed.ncbi.nlm.nih.gov/18983140

DMM2AR3	DI	DMM2AR3
DMM2AR3	DN	3-(furan-3-yl)-1H-indole
DMM2AR3	MI	TTTB4UP
DMM2AR3	MN	Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2)
DMM2AR3	MT	DTT
DMM2AR3	MA	Inhibitor
DMM2AR3	RN	Low molecular weight indole fragments as IMPDH inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2535-8.
DMM2AR3	RU	https://pubmed.ncbi.nlm.nih.gov/16483769

DM6L4J8	DI	DM6L4J8
DM6L4J8	DN	3-(furan-3-yl)-1-methyl-1H-indole
DM6L4J8	MI	TTTB4UP
DM6L4J8	MN	Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2)
DM6L4J8	MT	DTT
DM6L4J8	MA	Inhibitor
DM6L4J8	RN	Low molecular weight indole fragments as IMPDH inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2535-8.
DM6L4J8	RU	https://pubmed.ncbi.nlm.nih.gov/16483769

DMQZU9G	DI	DMQZU9G
DMQZU9G	DN	3-(heptyloxy)benzoic acid
DMQZU9G	MI	TT0OFWN
DMQZU9G	MN	Pseudomonas UDP-3-O-acyl-GlcNAc deacetylase (Pseudo lpxC)
DMQZU9G	MT	DTT
DMQZU9G	MA	Inhibitor
DMQZU9G	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMQZU9G	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMKHNTY	DI	DMKHNTY
DMKHNTY	DN	3-(hexa-1,3-dienyloxy)-9H-pyrido[3,4-b]indole
DMKHNTY	MI	TT1MPAY
DMKHNTY	MN	GABA(A) receptor alpha-1 (GABRA1)
DMKHNTY	MT	DTT
DMKHNTY	MA	Inhibitor
DMKHNTY	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DMKHNTY	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DMKHNTY	DI	DMKHNTY
DMKHNTY	DN	3-(hexa-1,3-dienyloxy)-9H-pyrido[3,4-b]indole
DMKHNTY	MI	TTBMV1G
DMKHNTY	MN	GABA(A) receptor alpha-2 (GABRA2)
DMKHNTY	MT	DTT
DMKHNTY	MA	Inhibitor
DMKHNTY	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DMKHNTY	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DMKHNTY	DI	DMKHNTY
DMKHNTY	DN	3-(hexa-1,3-dienyloxy)-9H-pyrido[3,4-b]indole
DMKHNTY	MI	TT37EDJ
DMKHNTY	MN	GABA(A) receptor alpha-3 (GABRA3)
DMKHNTY	MT	DTT
DMKHNTY	MA	Inhibitor
DMKHNTY	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DMKHNTY	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DMKHNTY	DI	DMKHNTY
DMKHNTY	DN	3-(hexa-1,3-dienyloxy)-9H-pyrido[3,4-b]indole
DMKHNTY	MI	TTNZPQ1
DMKHNTY	MN	GABA(A) receptor alpha-5 (GABRA5)
DMKHNTY	MT	DTT
DMKHNTY	MA	Inhibitor
DMKHNTY	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DMKHNTY	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DMKHNTY	DI	DMKHNTY
DMKHNTY	DN	3-(hexa-1,3-dienyloxy)-9H-pyrido[3,4-b]indole
DMKHNTY	MI	TT06RH5
DMKHNTY	MN	GABA(A) receptor gamma-2 (GABRG2)
DMKHNTY	MT	DTT
DMKHNTY	MA	Inhibitor
DMKHNTY	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DMKHNTY	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DMKHNTY	DI	DMKHNTY
DMKHNTY	DN	3-(hexa-1,3-dienyloxy)-9H-pyrido[3,4-b]indole
DMKHNTY	MI	TTNJYV2
DMKHNTY	MN	Gamma-aminobutyric acid receptor (GAR)
DMKHNTY	MT	DTT
DMKHNTY	MA	Inhibitor
DMKHNTY	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DMKHNTY	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DMM52LC	DI	DMM52LC
DMM52LC	DN	3-(imidazolylmethyl)-4'-methoxyflavone
DMM52LC	MI	TTSZLWK
DMM52LC	MN	Aromatase (CYP19A1)
DMM52LC	MT	DTT
DMM52LC	MA	Inhibitor
DMM52LC	RN	Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme. J Med Chem. 2006 Jul 27;49(15):4777-80.
DMM52LC	RU	https://pubmed.ncbi.nlm.nih.gov/16854084

DMX2LT5	DI	DMX2LT5
DMX2LT5	DN	3-(imidazolylmethyl)-4'-nitroflavone
DMX2LT5	MI	TTSZLWK
DMX2LT5	MN	Aromatase (CYP19A1)
DMX2LT5	MT	DTT
DMX2LT5	MA	Inhibitor
DMX2LT5	RN	Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme. J Med Chem. 2006 Jul 27;49(15):4777-80.
DMX2LT5	RU	https://pubmed.ncbi.nlm.nih.gov/16854084

DML63MX	DI	DML63MX
DML63MX	DN	3-(imidazolylmethyl)-7-methoxy-4'-nitroflavone
DML63MX	MI	TTSZLWK
DML63MX	MN	Aromatase (CYP19A1)
DML63MX	MT	DTT
DML63MX	MA	Inhibitor
DML63MX	RN	Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme. J Med Chem. 2006 Jul 27;49(15):4777-80.
DML63MX	RU	https://pubmed.ncbi.nlm.nih.gov/16854084

DMLI7F4	DI	DMLI7F4
DMLI7F4	DN	3-(imidazolylmethyl)flavone
DMLI7F4	MI	TTSZLWK
DMLI7F4	MN	Aromatase (CYP19A1)
DMLI7F4	MT	DTT
DMLI7F4	MA	Inhibitor
DMLI7F4	RN	Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme. J Med Chem. 2006 Jul 27;49(15):4777-80.
DMLI7F4	RU	https://pubmed.ncbi.nlm.nih.gov/16854084

DM3EV9N	DI	DM3EV9N
DM3EV9N	DN	3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione
DM3EV9N	MI	TT9VGXW
DM3EV9N	MN	Angiopoietin 1 receptor (TEK)
DM3EV9N	MT	DTT
DM3EV9N	MA	Inhibitor
DM3EV9N	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DM3EV9N	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DM3EV9N	DI	DM3EV9N
DM3EV9N	DN	3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione
DM3EV9N	MI	TTH6V3D
DM3EV9N	MN	Cyclin-dependent kinase 1 (CDK1)
DM3EV9N	MT	DTT
DM3EV9N	MA	Inhibitor
DM3EV9N	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DM3EV9N	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DM3EV9N	DI	DM3EV9N
DM3EV9N	DN	3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione
DM3EV9N	MI	TT7HF4W
DM3EV9N	MN	Cyclin-dependent kinase 2 (CDK2)
DM3EV9N	MT	DTT
DM3EV9N	MA	Inhibitor
DM3EV9N	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DM3EV9N	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DM3EV9N	DI	DM3EV9N
DM3EV9N	DN	3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione
DM3EV9N	MI	TT0PG8F
DM3EV9N	MN	Cyclin-dependent kinase 4 (CDK4)
DM3EV9N	MT	DTT
DM3EV9N	MA	Inhibitor
DM3EV9N	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DM3EV9N	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DM3EV9N	DI	DM3EV9N
DM3EV9N	DN	3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione
DM3EV9N	MI	TTGKNB4
DM3EV9N	MN	Epidermal growth factor receptor (EGFR)
DM3EV9N	MT	DTT
DM3EV9N	MA	Inhibitor
DM3EV9N	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DM3EV9N	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DM3EV9N	DI	DM3EV9N
DM3EV9N	DN	3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione
DM3EV9N	MI	TTR5TV4
DM3EV9N	MN	ERBB2 messenger RNA (HER2 mRNA)
DM3EV9N	MT	DTT
DM3EV9N	MA	Inhibitor
DM3EV9N	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DM3EV9N	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DM3EV9N	DI	DM3EV9N
DM3EV9N	DN	3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione
DM3EV9N	MI	TTFCJ7S
DM3EV9N	MN	G1/S-specific cyclin-D1 (CCND1)
DM3EV9N	MT	DTT
DM3EV9N	MA	Inhibitor
DM3EV9N	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DM3EV9N	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DM3EV9N	DI	DM3EV9N
DM3EV9N	DN	3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione
DM3EV9N	MI	TTCEJ4F
DM3EV9N	MN	G1/S-specific cyclin-E1 (CCNE1)
DM3EV9N	MT	DTT
DM3EV9N	MA	Inhibitor
DM3EV9N	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DM3EV9N	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DM3EV9N	DI	DM3EV9N
DM3EV9N	DN	3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione
DM3EV9N	MI	TT9P6OW
DM3EV9N	MN	G2/mitotic-specific cyclin B1 (CCNB1)
DM3EV9N	MT	DTT
DM3EV9N	MA	Inhibitor
DM3EV9N	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DM3EV9N	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DM3EV9N	DI	DM3EV9N
DM3EV9N	DN	3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione
DM3EV9N	MI	TTFJ8Q1
DM3EV9N	MN	Protein kinase C alpha (PRKCA)
DM3EV9N	MT	DTT
DM3EV9N	MA	Inhibitor
DM3EV9N	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DM3EV9N	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DM3EV9N	DI	DM3EV9N
DM3EV9N	DN	3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione
DM3EV9N	MI	TTBZ7OD
DM3EV9N	MN	Protein kinase C epsilon (PRKCE)
DM3EV9N	MT	DTT
DM3EV9N	MA	Inhibitor
DM3EV9N	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DM3EV9N	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DM3EV9N	DI	DM3EV9N
DM3EV9N	DN	3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione
DM3EV9N	MI	TTRFOXJ
DM3EV9N	MN	Protein kinase C gamma (PRKCG)
DM3EV9N	MT	DTT
DM3EV9N	MA	Inhibitor
DM3EV9N	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DM3EV9N	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DMJDG9C	DI	DMJDG9C
DMJDG9C	DN	3-(N-alkylamino) propylphosphonic acid derivative
DMJDG9C	MI	TT9JZCK
DMJDG9C	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMJDG9C	MT	DTT
DMJDG9C	MA	Inhibitor
DMJDG9C	RN	Design and synthesis of conformationally constrained 3-(N-alkylamino)propylphosphonic acids as potent agonists of sphingosine-1-phosphate (S1P) rec... Bioorg Med Chem Lett. 2004 Oct 4;14(19):4861-6.
DMJDG9C	RU	https://pubmed.ncbi.nlm.nih.gov/15341940

DMJRBT1	DI	DMJRBT1
DMJRBT1	DN	3-(naphthalen-2-yl)pyridine
DMJRBT1	MI	TTSZLWK
DMJRBT1	MN	Aromatase (CYP19A1)
DMJRBT1	MT	DTT
DMJRBT1	MA	Inhibitor
DMJRBT1	RN	In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87.
DMJRBT1	RU	https://pubmed.ncbi.nlm.nih.gov/19049427

DMJRBT1	DI	DMJRBT1
DMJRBT1	DN	3-(naphthalen-2-yl)pyridine
DMJRBT1	MI	TTIQUX7
DMJRBT1	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMJRBT1	MT	DTT
DMJRBT1	MA	Inhibitor
DMJRBT1	RN	Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach. J Med Chem. 2008 Oct 9;51(19):6138-49.
DMJRBT1	RU	https://pubmed.ncbi.nlm.nih.gov/18763754

DM6OCU5	DI	DM6OCU5
DM6OCU5	DN	3-(N-propylpiperidin-4-yl)phenol
DM6OCU5	MI	TTEX248
DM6OCU5	MN	Dopamine D2 receptor (D2R)
DM6OCU5	MT	DTT
DM6OCU5	MA	Inhibitor
DM6OCU5	RN	Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabi... J Med Chem. 2010 Mar 25;53(6):2510-20.
DM6OCU5	RU	https://pubmed.ncbi.nlm.nih.gov/20155917

DMJRNI7	DI	DMJRNI7
DMJRNI7	DN	3-(Octahydro-indolizin-8-yl)-phenol
DMJRNI7	MI	TTEX248
DMJRNI7	MN	Dopamine D2 receptor (D2R)
DMJRNI7	MT	DTT
DMJRNI7	MA	Inhibitor
DMJRNI7	RN	Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP). ... J Med Chem. 1990 Mar;33(3):1015-22.
DMJRNI7	RU	https://pubmed.ncbi.nlm.nih.gov/1968512

DMU1SGX	DI	DMU1SGX
DMU1SGX	DN	3-(Octahydro-quinolizin-1-yl)-phenol
DMU1SGX	MI	TTEX248
DMU1SGX	MN	Dopamine D2 receptor (D2R)
DMU1SGX	MT	DTT
DMU1SGX	MA	Inhibitor
DMU1SGX	RN	Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP). ... J Med Chem. 1990 Mar;33(3):1015-22.
DMU1SGX	RU	https://pubmed.ncbi.nlm.nih.gov/1968512

DM01BKR	DI	DM01BKR
DM01BKR	DN	3-(Octahydro-quinolizin-3-yl)-phenol
DM01BKR	MI	TTEX248
DM01BKR	MN	Dopamine D2 receptor (D2R)
DM01BKR	MT	DTT
DM01BKR	MA	Inhibitor
DM01BKR	RN	Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP). ... J Med Chem. 1990 Mar;33(3):1015-22.
DM01BKR	RU	https://pubmed.ncbi.nlm.nih.gov/1968512

DMMRV1N	DI	DMMRV1N
DMMRV1N	DN	3-(Oxalyl-Amino)-Naphthalene-2-Carboxylic Acid
DMMRV1N	MI	TTELIN2
DMMRV1N	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMMRV1N	MT	DTT
DMMRV1N	MA	Inhibitor
DMMRV1N	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMMRV1N	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM2UPQG	DI	DM2UPQG
DM2UPQG	DN	3-(phenoxymethyl)-5H-indeno[1,2-c]pyridazin-5-one
DM2UPQG	MI	TTGP7BY
DM2UPQG	MN	Monoamine oxidase type B (MAO-B)
DM2UPQG	MT	DTT
DM2UPQG	MA	Inhibitor
DM2UPQG	RN	Synthesis and monoamine oxidase inhibitory activity of new pyridazine-, pyrimidine- and 1,2,4-triazine-containing tricyclic derivatives. J Med Chem. 2007 Nov 1;50(22):5364-71.
DM2UPQG	RU	https://pubmed.ncbi.nlm.nih.gov/17910428

DMSRHLC	DI	DMSRHLC
DMSRHLC	DN	3-(phenylsulfonyl)-1-(piperidin-3-yl)-1H-indole
DMSRHLC	MI	TTJS8PY
DMSRHLC	MN	5-HT 6 receptor (HTR6)
DMSRHLC	MT	DTT
DMSRHLC	MA	Inhibitor
DMSRHLC	RN	3-(Arylsulfonyl)-1-(azacyclyl)-1H-indoles are 5-HT(6) receptor modulators. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1657-60.
DMSRHLC	RU	https://pubmed.ncbi.nlm.nih.gov/20138763

DM9QB0X	DI	DM9QB0X
DM9QB0X	DN	3-(phenylsulfonyl)-1-(piperidin-4-yl)-1H-indole
DM9QB0X	MI	TTJS8PY
DM9QB0X	MN	5-HT 6 receptor (HTR6)
DM9QB0X	MT	DTT
DM9QB0X	MA	Inhibitor
DM9QB0X	RN	3-(Arylsulfonyl)-1-(azacyclyl)-1H-indoles are 5-HT(6) receptor modulators. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1657-60.
DM9QB0X	RU	https://pubmed.ncbi.nlm.nih.gov/20138763

DMVKO5N	DI	DMVKO5N
DMVKO5N	DN	3-(phenylsulfonyl)-1-(pyrrolidin-3-yl)-1H-indole
DMVKO5N	MI	TTJS8PY
DMVKO5N	MN	5-HT 6 receptor (HTR6)
DMVKO5N	MT	DTT
DMVKO5N	MA	Inhibitor
DMVKO5N	RN	3-(Arylsulfonyl)-1-(azacyclyl)-1H-indoles are 5-HT(6) receptor modulators. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1657-60.
DMVKO5N	RU	https://pubmed.ncbi.nlm.nih.gov/20138763

DMN1DWF	DI	DMN1DWF
DMN1DWF	DN	3-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine
DMN1DWF	MI	TTNDSF4
DMN1DWF	MN	Proto-oncogene c-Met (MET)
DMN1DWF	MT	DTT
DMN1DWF	MA	Inhibitor
DMN1DWF	RN	Discovery of 4-azaindoles as novel inhibitors of c-Met kinase. Bioorg Med Chem Lett. 2009 May 15;19(10):2780-4.
DMN1DWF	RU	https://pubmed.ncbi.nlm.nih.gov/19369077

DM2ETXB	DI	DM2ETXB
DM2ETXB	DN	3-(piperidin-4-yl)-2-(o-tolyloxy)pyridine
DM2ETXB	MI	TTSQIFT
DM2ETXB	MN	5-HT 1A receptor (HTR1A)
DM2ETXB	MT	DTT
DM2ETXB	MA	Inhibitor
DM2ETXB	RN	Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7.
DM2ETXB	RU	https://pubmed.ncbi.nlm.nih.gov/20031410

DM2ETXB	DI	DM2ETXB
DM2ETXB	DN	3-(piperidin-4-yl)-2-(o-tolyloxy)pyridine
DM2ETXB	MI	TTAWNKZ
DM2ETXB	MN	Norepinephrine transporter (NET)
DM2ETXB	MT	DTT
DM2ETXB	MA	Inhibitor
DM2ETXB	RN	Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7.
DM2ETXB	RU	https://pubmed.ncbi.nlm.nih.gov/20031410

DM2ETXB	DI	DM2ETXB
DM2ETXB	DN	3-(piperidin-4-yl)-2-(o-tolyloxy)pyridine
DM2ETXB	MI	TT3ROYC
DM2ETXB	MN	Serotonin transporter (SERT)
DM2ETXB	MT	DTT
DM2ETXB	MA	Inhibitor
DM2ETXB	RN	Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7.
DM2ETXB	RU	https://pubmed.ncbi.nlm.nih.gov/20031410

DMMOE40	DI	DMMOE40
DMMOE40	DN	3-(Prop-2-Ene-1-Sulfinyl)-Propene-1-Thiol
DMMOE40	MI	TTEP6RV
DMMOE40	MN	Glutathione reductase (GR)
DMMOE40	MT	DTT
DMMOE40	MA	Inhibitor
DMMOE40	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMMOE40	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM3EDQ1	DI	DM3EDQ1
DM3EDQ1	DN	3-(pyridin-3-yl)prop-2-yn-1-amine
DM3EDQ1	MI	TTXV4FI
DM3EDQ1	MN	Albendazole monooxygenase (CYP3A4)
DM3EDQ1	MT	DTT
DM3EDQ1	MA	Inhibitor
DM3EDQ1	RN	Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallization. J Med Chem. 2006 Nov 30;49(24):6987-7001.
DM3EDQ1	RU	https://pubmed.ncbi.nlm.nih.gov/17125252

DMZARSD	DI	DMZARSD
DMZARSD	DN	3-(pyridin-4-yl)-1H-indol-6-amine
DMZARSD	MI	TTTB4UP
DMZARSD	MN	Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2)
DMZARSD	MT	DTT
DMZARSD	MA	Inhibitor
DMZARSD	RN	Low molecular weight indole fragments as IMPDH inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2535-8.
DMZARSD	RU	https://pubmed.ncbi.nlm.nih.gov/16483769

DMRFPNE	DI	DMRFPNE
DMRFPNE	DN	3-(pyridin-4-yl)-1H-indol-7-amine
DMRFPNE	MI	TTTB4UP
DMRFPNE	MN	Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2)
DMRFPNE	MT	DTT
DMRFPNE	MA	Inhibitor
DMRFPNE	RN	Low molecular weight indole fragments as IMPDH inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2535-8.
DMRFPNE	RU	https://pubmed.ncbi.nlm.nih.gov/16483769

DMNA6LF	DI	DMNA6LF
DMNA6LF	DN	3-(tetradecylamino)propylphosphonic acid
DMNA6LF	MI	TT9JZCK
DMNA6LF	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMNA6LF	MT	DTT
DMNA6LF	MA	Inhibitor
DMNA6LF	RN	A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 re... J Med Chem. 2004 Dec 30;47(27):6662-5.
DMNA6LF	RU	https://pubmed.ncbi.nlm.nih.gov/15615513

DMMI0UC	DI	DMMI0UC
DMMI0UC	DN	3-(thiophen-3-yl)-1H-indol-6-amine
DMMI0UC	MI	TTTB4UP
DMMI0UC	MN	Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2)
DMMI0UC	MT	DTT
DMMI0UC	MA	Inhibitor
DMMI0UC	RN	Low molecular weight indole fragments as IMPDH inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2535-8.
DMMI0UC	RU	https://pubmed.ncbi.nlm.nih.gov/16483769

DMWX4L5	DI	DMWX4L5
DMWX4L5	DN	3-(trifluoromethyl)-9H-carbazole
DMWX4L5	MI	TTBGTCW
DMWX4L5	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DMWX4L5	MT	DTT
DMWX4L5	MA	Inhibitor
DMWX4L5	RN	Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8.
DMWX4L5	RU	https://pubmed.ncbi.nlm.nih.gov/20521839

DM2YVA1	DI	DM2YVA1
DM2YVA1	DN	3-(trifluoromethyl)benzaldehyde thiosemicarbazone
DM2YVA1	MI	TTEAID7
DM2YVA1	MN	Trypanosoma Cruzipain (Trypano CYSP)
DM2YVA1	MT	DTT
DM2YVA1	MA	Inhibitor
DM2YVA1	RN	Synthesis and structure-activity relationship study of potent trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine protease cruz... J Med Chem. 2002 Jun 20;45(13):2695-707.
DM2YVA1	RU	https://pubmed.ncbi.nlm.nih.gov/12061873

DMH7K0N	DI	DMH7K0N
DMH7K0N	DN	3-(trifluoromethyl)phenyl 4-butoxybenzylcarbamate
DMH7K0N	MI	TTDP1UC
DMH7K0N	MN	Fatty acid amide hydrolase (FAAH)
DMH7K0N	MT	DTT
DMH7K0N	MA	Inhibitor
DMH7K0N	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DMH7K0N	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DM4B5JY	DI	DM4B5JY
DM4B5JY	DN	3-(trifluoromethyl)phenylboronic acid
DM4B5JY	MI	TTDP1UC
DM4B5JY	MN	Fatty acid amide hydrolase (FAAH)
DM4B5JY	MT	DTT
DM4B5JY	MA	Inhibitor
DM4B5JY	RN	Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Nov 27;51(22):7057-60.
DM4B5JY	RU	https://pubmed.ncbi.nlm.nih.gov/18983140

DMR9WF7	DI	DMR9WF7
DMR9WF7	DN	3,14-DIDEHYDROGINKGOLIDE A
DMR9WF7	MI	TTZ8EM9
DMR9WF7	MN	Glycine receptor (GlyR)
DMR9WF7	MT	DTT
DMR9WF7	MA	Inhibitor
DMR9WF7	RN	Probing the pharmacophore of ginkgolides as glycine receptor antagonists. J Med Chem. 2007 Apr 5;50(7):1610-7.
DMR9WF7	RU	https://pubmed.ncbi.nlm.nih.gov/17352465

DMR9WF7	DI	DMR9WF7
DMR9WF7	DN	3,14-DIDEHYDROGINKGOLIDE A
DMR9WF7	MI	TTF45NW
DMR9WF7	MN	Strychnine-binding glycine receptor (GLRA1)
DMR9WF7	MT	DTT
DMR9WF7	MA	Inhibitor
DMR9WF7	RN	Probing the pharmacophore of ginkgolides as glycine receptor antagonists. J Med Chem. 2007 Apr 5;50(7):1610-7.
DMR9WF7	RU	https://pubmed.ncbi.nlm.nih.gov/17352465

DMD0Z3U	DI	DMD0Z3U
DMD0Z3U	DN	3,2'-bis-trifluoromethyl-biphenyl-4-carbonitrile
DMD0Z3U	MI	TTKPW01
DMD0Z3U	MN	Androgen receptor messenger RNA (AR mRNA)
DMD0Z3U	MT	DTT
DMD0Z3U	MA	Inhibitor
DMD0Z3U	RN	Preparation of 4-aryl-2-trifluoromethylbenzonitrile derivatives as androgen receptor antagonists for topical suppression of sebum production. Bioorg Med Chem Lett. 2007 Oct 15;17(20):5529-32.
DMD0Z3U	RU	https://pubmed.ncbi.nlm.nih.gov/17764935

DM9GO8Y	DI	DM9GO8Y
DM9GO8Y	DN	3,3'-(1,2,4,5-tetrazine-3,6-diyl)diphenol
DM9GO8Y	MI	TTIWB6L
DM9GO8Y	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DM9GO8Y	MT	DTT
DM9GO8Y	MA	Inhibitor
DM9GO8Y	RN	Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as p... J Med Chem. 2008 Nov 13;51(21):6725-39.
DM9GO8Y	RU	https://pubmed.ncbi.nlm.nih.gov/18855374

DM4O2VC	DI	DM4O2VC
DM4O2VC	DN	3,3'-(1,2,4-Thiadiazol-2,5-diyl)diphenol
DM4O2VC	MI	TTIWB6L
DM4O2VC	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DM4O2VC	MT	DTT
DM4O2VC	MA	Inhibitor
DM4O2VC	RN	Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as p... J Med Chem. 2008 Nov 13;51(21):6725-39.
DM4O2VC	RU	https://pubmed.ncbi.nlm.nih.gov/18855374

DMC34UW	DI	DMC34UW
DMC34UW	DN	3,3'-(1,2,4-thiadiazole-3,5-diyl)diphenol
DMC34UW	MI	TTIWB6L
DMC34UW	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMC34UW	MT	DTT
DMC34UW	MA	Inhibitor
DMC34UW	RN	Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as p... J Med Chem. 2008 Nov 13;51(21):6725-39.
DMC34UW	RU	https://pubmed.ncbi.nlm.nih.gov/18855374

DM9AJNW	DI	DM9AJNW
DM9AJNW	DN	3,3'-(1,3-Thiazol-2,4-diyl)diphenol
DM9AJNW	MI	TTIWB6L
DM9AJNW	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DM9AJNW	MT	DTT
DM9AJNW	MA	Inhibitor
DM9AJNW	RN	Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as p... J Med Chem. 2008 Nov 13;51(21):6725-39.
DM9AJNW	RU	https://pubmed.ncbi.nlm.nih.gov/18855374

DMQY50A	DI	DMQY50A
DMQY50A	DN	3,3-(1,3-Thiazole-2,5-diyl)diphenol
DMQY50A	MI	TTXV4FI
DMQY50A	MN	Albendazole monooxygenase (CYP3A4)
DMQY50A	MT	DTT
DMQY50A	MA	Inhibitor
DMQY50A	RN	Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as p... J Med Chem. 2008 Nov 13;51(21):6725-39.
DMQY50A	RU	https://pubmed.ncbi.nlm.nih.gov/18855374

DMQY50A	DI	DMQY50A
DMQY50A	DN	3,3-(1,3-Thiazole-2,5-diyl)diphenol
DMQY50A	MI	TTIWB6L
DMQY50A	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMQY50A	MT	DTT
DMQY50A	MA	Inhibitor
DMQY50A	RN	Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as p... J Med Chem. 2008 Nov 13;51(21):6725-39.
DMQY50A	RU	https://pubmed.ncbi.nlm.nih.gov/18855374

DM40SNY	DI	DM40SNY
DM40SNY	DN	3,3'-(3-Methylthiene-2,5-diyl]diphenol
DM40SNY	MI	TTIWB6L
DM40SNY	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DM40SNY	MT	DTT
DM40SNY	MA	Inhibitor
DM40SNY	RN	New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43.
DM40SNY	RU	https://pubmed.ncbi.nlm.nih.gov/19831396

DMUK1VX	DI	DMUK1VX
DMUK1VX	DN	3,3'-(3-Phenylthiene-2,5-diyl)diphenol
DMUK1VX	MI	TTIWB6L
DMUK1VX	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMUK1VX	MT	DTT
DMUK1VX	MA	Inhibitor
DMUK1VX	RN	New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43.
DMUK1VX	RU	https://pubmed.ncbi.nlm.nih.gov/19831396

DMJVKMO	DI	DMJVKMO
DMJVKMO	DN	3,3'-(4-phenylpyridine-2,6-diyl)diphenol
DMJVKMO	MI	TTGTQHC
DMJVKMO	MN	DNA topoisomerase I (TOP1)
DMJVKMO	MT	DTT
DMJVKMO	MA	Inhibitor
DMJVKMO	RN	Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl ... Bioorg Med Chem. 2010 May 1;18(9):3066-77.
DMJVKMO	RU	https://pubmed.ncbi.nlm.nih.gov/20392646

DMJVKMO	DI	DMJVKMO
DMJVKMO	DN	3,3'-(4-phenylpyridine-2,6-diyl)diphenol
DMJVKMO	MI	TT0IHXV
DMJVKMO	MN	DNA topoisomerase II (TOP2)
DMJVKMO	MT	DTT
DMJVKMO	MA	Inhibitor
DMJVKMO	RN	Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl ... Bioorg Med Chem. 2010 May 1;18(9):3066-77.
DMJVKMO	RU	https://pubmed.ncbi.nlm.nih.gov/20392646

DMH7A32	DI	DMH7A32
DMH7A32	DN	3,3',3''-Thiene-2,3,5-triyltriphenol
DMH7A32	MI	TTIWB6L
DMH7A32	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMH7A32	MT	DTT
DMH7A32	MA	Inhibitor
DMH7A32	RN	New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43.
DMH7A32	RU	https://pubmed.ncbi.nlm.nih.gov/19831396

DMBFY4H	DI	DMBFY4H
DMBFY4H	DN	3,3,3-tris(4-chlorophenyl)propanoic acid
DMBFY4H	MI	TT6804T
DMBFY4H	MN	MIF messenger RNA (MIF mRNA)
DMBFY4H	MT	DTT
DMBFY4H	MA	Inhibitor
DMBFY4H	RN	Classification of chemical compounds by protein-compound docking for use in designing a focused library. J Med Chem. 2006 Jan 26;49(2):523-33.
DMBFY4H	RU	https://pubmed.ncbi.nlm.nih.gov/16420039

DMO51QG	DI	DMO51QG
DMO51QG	DN	3,3-Bis-(4-hydroxy-phenyl)-2-phenyl-acrylonitrile
DMO51QG	MI	TTFJ8Q1
DMO51QG	MN	Protein kinase C alpha (PRKCA)
DMO51QG	MT	DTT
DMO51QG	MA	Inhibitor
DMO51QG	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DMO51QG	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DMO51QG	DI	DMO51QG
DMO51QG	DN	3,3-Bis-(4-hydroxy-phenyl)-2-phenyl-acrylonitrile
DMO51QG	MI	TTYPXQF
DMO51QG	MN	Protein kinase C beta (PRKCB)
DMO51QG	MT	DTT
DMO51QG	MA	Inhibitor
DMO51QG	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DMO51QG	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DMO51QG	DI	DMO51QG
DMO51QG	DN	3,3-Bis-(4-hydroxy-phenyl)-2-phenyl-acrylonitrile
DMO51QG	MI	TT9WJ8U
DMO51QG	MN	Protein kinase C delta (PRKCD)
DMO51QG	MT	DTT
DMO51QG	MA	Inhibitor
DMO51QG	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DMO51QG	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DMO51QG	DI	DMO51QG
DMO51QG	DN	3,3-Bis-(4-hydroxy-phenyl)-2-phenyl-acrylonitrile
DMO51QG	MI	TTBZ7OD
DMO51QG	MN	Protein kinase C epsilon (PRKCE)
DMO51QG	MT	DTT
DMO51QG	MA	Inhibitor
DMO51QG	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DMO51QG	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DMO51QG	DI	DMO51QG
DMO51QG	DN	3,3-Bis-(4-hydroxy-phenyl)-2-phenyl-acrylonitrile
DMO51QG	MI	TTRFOXJ
DMO51QG	MN	Protein kinase C gamma (PRKCG)
DMO51QG	MT	DTT
DMO51QG	MA	Inhibitor
DMO51QG	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DMO51QG	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DMO51QG	DI	DMO51QG
DMO51QG	DN	3,3-Bis-(4-hydroxy-phenyl)-2-phenyl-acrylonitrile
DMO51QG	MI	TT8QL1J
DMO51QG	MN	Protein kinase C theta (PRKCQ)
DMO51QG	MT	DTT
DMO51QG	MA	Inhibitor
DMO51QG	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DMO51QG	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DMO51QG	DI	DMO51QG
DMO51QG	DN	3,3-Bis-(4-hydroxy-phenyl)-2-phenyl-acrylonitrile
DMO51QG	MI	TTUWGRA
DMO51QG	MN	Protein kinase C zeta (PRKCZ)
DMO51QG	MT	DTT
DMO51QG	MA	Inhibitor
DMO51QG	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DMO51QG	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DMZPYN2	DI	DMZPYN2
DMZPYN2	DN	3,3-Bis-(4-methoxy-phenyl)-2-phenyl-acrylonitrile
DMZPYN2	MI	TTFJ8Q1
DMZPYN2	MN	Protein kinase C alpha (PRKCA)
DMZPYN2	MT	DTT
DMZPYN2	MA	Inhibitor
DMZPYN2	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DMZPYN2	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DMZPYN2	DI	DMZPYN2
DMZPYN2	DN	3,3-Bis-(4-methoxy-phenyl)-2-phenyl-acrylonitrile
DMZPYN2	MI	TTYPXQF
DMZPYN2	MN	Protein kinase C beta (PRKCB)
DMZPYN2	MT	DTT
DMZPYN2	MA	Inhibitor
DMZPYN2	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DMZPYN2	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DMZPYN2	DI	DMZPYN2
DMZPYN2	DN	3,3-Bis-(4-methoxy-phenyl)-2-phenyl-acrylonitrile
DMZPYN2	MI	TT9WJ8U
DMZPYN2	MN	Protein kinase C delta (PRKCD)
DMZPYN2	MT	DTT
DMZPYN2	MA	Inhibitor
DMZPYN2	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DMZPYN2	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DMZPYN2	DI	DMZPYN2
DMZPYN2	DN	3,3-Bis-(4-methoxy-phenyl)-2-phenyl-acrylonitrile
DMZPYN2	MI	TTBZ7OD
DMZPYN2	MN	Protein kinase C epsilon (PRKCE)
DMZPYN2	MT	DTT
DMZPYN2	MA	Inhibitor
DMZPYN2	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DMZPYN2	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DMZPYN2	DI	DMZPYN2
DMZPYN2	DN	3,3-Bis-(4-methoxy-phenyl)-2-phenyl-acrylonitrile
DMZPYN2	MI	TTRFOXJ
DMZPYN2	MN	Protein kinase C gamma (PRKCG)
DMZPYN2	MT	DTT
DMZPYN2	MA	Inhibitor
DMZPYN2	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DMZPYN2	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DMZPYN2	DI	DMZPYN2
DMZPYN2	DN	3,3-Bis-(4-methoxy-phenyl)-2-phenyl-acrylonitrile
DMZPYN2	MI	TT8QL1J
DMZPYN2	MN	Protein kinase C theta (PRKCQ)
DMZPYN2	MT	DTT
DMZPYN2	MA	Inhibitor
DMZPYN2	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DMZPYN2	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DMZPYN2	DI	DMZPYN2
DMZPYN2	DN	3,3-Bis-(4-methoxy-phenyl)-2-phenyl-acrylonitrile
DMZPYN2	MI	TTUWGRA
DMZPYN2	MN	Protein kinase C zeta (PRKCZ)
DMZPYN2	MT	DTT
DMZPYN2	MA	Inhibitor
DMZPYN2	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DMZPYN2	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DMK9BN0	DI	DMK9BN0
DMK9BN0	DN	3,3-di(pent-4-enyl)azetidin-2-one
DMK9BN0	MI	TTDP1UC
DMK9BN0	MN	Fatty acid amide hydrolase (FAAH)
DMK9BN0	MT	DTT
DMK9BN0	MA	Inhibitor
DMK9BN0	RN	3-Alkenyl-2-azetidinones as fatty acid amide hydrolase inhibitors. Bioorg Med Chem Lett. 2008 Jul 15;18(14):4163-7.
DMK9BN0	RU	https://pubmed.ncbi.nlm.nih.gov/18547805

DMWFD5C	DI	DMWFD5C
DMWFD5C	DN	3,3-Diethyl-1-(pyridin-3-yl)azetidine-2,4-dione
DMWFD5C	MI	TTPLTSQ
DMWFD5C	MN	Neutrophil elastase (NE)
DMWFD5C	MT	DTT
DMWFD5C	MA	Inhibitor
DMWFD5C	RN	4-Oxo-beta-lactams (azetidine-2,4-diones) are potent and selective inhibitors of human leukocyte elastase. J Med Chem. 2010 Jan 14;53(1):241-53.
DMWFD5C	RU	https://pubmed.ncbi.nlm.nih.gov/19904934

DMY8S94	DI	DMY8S94
DMY8S94	DN	3,3-Diethyl-1-o-tolylazetidine-2,4-dione
DMY8S94	MI	TTPLTSQ
DMY8S94	MN	Neutrophil elastase (NE)
DMY8S94	MT	DTT
DMY8S94	MA	Inhibitor
DMY8S94	RN	4-Oxo-beta-lactams (azetidine-2,4-diones) are potent and selective inhibitors of human leukocyte elastase. J Med Chem. 2010 Jan 14;53(1):241-53.
DMY8S94	RU	https://pubmed.ncbi.nlm.nih.gov/19904934

DMCFJIP	DI	DMCFJIP
DMCFJIP	DN	3,3-diethyl-1-phenylazetidine-2,4-dione
DMCFJIP	MI	TTPLTSQ
DMCFJIP	MN	Neutrophil elastase (NE)
DMCFJIP	MT	DTT
DMCFJIP	MA	Inhibitor
DMCFJIP	RN	4-Oxo-beta-lactams (azetidine-2,4-diones) are potent and selective inhibitors of human leukocyte elastase. J Med Chem. 2010 Jan 14;53(1):241-53.
DMCFJIP	RU	https://pubmed.ncbi.nlm.nih.gov/19904934

DMFJ9N0	DI	DMFJ9N0
DMFJ9N0	DN	3,3-Diethyl-dihydro-furan-2-one
DMFJ9N0	MI	TT1MPAY
DMFJ9N0	MN	GABA(A) receptor alpha-1 (GABRA1)
DMFJ9N0	MT	DTT
DMFJ9N0	MA	Inhibitor
DMFJ9N0	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DMFJ9N0	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DMFJ9N0	DI	DMFJ9N0
DMFJ9N0	DN	3,3-Diethyl-dihydro-furan-2-one
DMFJ9N0	MI	TTZA1NY
DMFJ9N0	MN	GABA(A) receptor beta-2 (GABRB2)
DMFJ9N0	MT	DTT
DMFJ9N0	MA	Inhibitor
DMFJ9N0	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DMFJ9N0	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DMFJ9N0	DI	DMFJ9N0
DMFJ9N0	DN	3,3-Diethyl-dihydro-furan-2-one
DMFJ9N0	MI	TT06RH5
DMFJ9N0	MN	GABA(A) receptor gamma-2 (GABRG2)
DMFJ9N0	MT	DTT
DMFJ9N0	MA	Inhibitor
DMFJ9N0	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DMFJ9N0	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DMFJ9N0	DI	DMFJ9N0
DMFJ9N0	DN	3,3-Diethyl-dihydro-furan-2-one
DMFJ9N0	MI	TTNJYV2
DMFJ9N0	MN	Gamma-aminobutyric acid receptor (GAR)
DMFJ9N0	MT	DTT
DMFJ9N0	MA	Inhibitor
DMFJ9N0	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DMFJ9N0	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DMGMJWL	DI	DMGMJWL
DMGMJWL	DN	3,3'-difluorobenzaldazine
DMGMJWL	MI	TTHS256
DMGMJWL	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMGMJWL	MT	DTT
DMGMJWL	MA	Modulator (allosteric modulator)
DMGMJWL	RN	A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5. Mol Pharmacol. 2003 Sep;64(3):731-40.
DMGMJWL	RU	https://pubmed.ncbi.nlm.nih.gov/12920211

DMIFUDG	DI	DMIFUDG
DMIFUDG	DN	3,3-Diisopropyl-dihydro-furan-2-one
DMIFUDG	MI	TT1MPAY
DMIFUDG	MN	GABA(A) receptor alpha-1 (GABRA1)
DMIFUDG	MT	DTT
DMIFUDG	MA	Inhibitor
DMIFUDG	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DMIFUDG	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DMIFUDG	DI	DMIFUDG
DMIFUDG	DN	3,3-Diisopropyl-dihydro-furan-2-one
DMIFUDG	MI	TTZA1NY
DMIFUDG	MN	GABA(A) receptor beta-2 (GABRB2)
DMIFUDG	MT	DTT
DMIFUDG	MA	Inhibitor
DMIFUDG	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DMIFUDG	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DMIFUDG	DI	DMIFUDG
DMIFUDG	DN	3,3-Diisopropyl-dihydro-furan-2-one
DMIFUDG	MI	TT06RH5
DMIFUDG	MN	GABA(A) receptor gamma-2 (GABRG2)
DMIFUDG	MT	DTT
DMIFUDG	MA	Inhibitor
DMIFUDG	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DMIFUDG	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DMIFUDG	DI	DMIFUDG
DMIFUDG	DN	3,3-Diisopropyl-dihydro-furan-2-one
DMIFUDG	MI	TTNJYV2
DMIFUDG	MN	Gamma-aminobutyric acid receptor (GAR)
DMIFUDG	MT	DTT
DMIFUDG	MA	Inhibitor
DMIFUDG	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DMIFUDG	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DMUS0A4	DI	DMUS0A4
DMUS0A4	DN	3,3-dimethyl-5-m-tolyl-2,3-dihydro-1H-inden-1-one
DMUS0A4	MI	TTUV8G9
DMUS0A4	MN	Progesterone receptor (PGR)
DMUS0A4	MT	DTT
DMUS0A4	MA	Inhibitor
DMUS0A4	RN	5-Aryl indanones and derivatives as non-steroidal progesterone receptor modulators. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6666-9.
DMUS0A4	RU	https://pubmed.ncbi.nlm.nih.gov/19864132

DM09LY4	DI	DM09LY4
DM09LY4	DN	3,3-Dimethyl-dihydro-furan-2-one
DM09LY4	MI	TTNJYV2
DM09LY4	MN	Gamma-aminobutyric acid receptor (GAR)
DM09LY4	MT	DTT
DM09LY4	MA	Inhibitor
DM09LY4	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DM09LY4	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DMNOUSV	DI	DMNOUSV
DMNOUSV	DN	3,3-diphenylpropan-1-amine
DMNOUSV	MI	TTTIBOJ
DMNOUSV	MN	Histamine H1 receptor (H1R)
DMNOUSV	MT	DTT
DMNOUSV	MA	Inhibitor
DMNOUSV	RN	Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504.
DMNOUSV	RU	https://pubmed.ncbi.nlm.nih.gov/19700330

DMZTIPJ	DI	DMZTIPJ
DMZTIPJ	DN	3,3'-pyrazine-2,5-diyldiphenol
DMZTIPJ	MI	TTIWB6L
DMZTIPJ	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMZTIPJ	MT	DTT
DMZTIPJ	MA	Inhibitor
DMZTIPJ	RN	Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as p... J Med Chem. 2008 Nov 13;51(21):6725-39.
DMZTIPJ	RU	https://pubmed.ncbi.nlm.nih.gov/18855374

DMZILNC	DI	DMZILNC
DMZILNC	DN	3,3'-Pyridine-2,5-diyldiphenol
DMZILNC	MI	TTIWB6L
DMZILNC	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMZILNC	MT	DTT
DMZILNC	MA	Inhibitor
DMZILNC	RN	Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as p... J Med Chem. 2008 Nov 13;51(21):6725-39.
DMZILNC	RU	https://pubmed.ncbi.nlm.nih.gov/18855374

DMW7XFQ	DI	DMW7XFQ
DMW7XFQ	DN	3,3'-Thiene-2,4-diyldiphenol
DMW7XFQ	MI	TTIWB6L
DMW7XFQ	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMW7XFQ	MT	DTT
DMW7XFQ	MA	Inhibitor
DMW7XFQ	RN	Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as p... J Med Chem. 2008 Nov 13;51(21):6725-39.
DMW7XFQ	RU	https://pubmed.ncbi.nlm.nih.gov/18855374

DMWH0ER	DI	DMWH0ER
DMWH0ER	DN	3,3'-thiene-2,5-diyldiphenol
DMWH0ER	MI	TTIWB6L
DMWH0ER	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMWH0ER	MT	DTT
DMWH0ER	MA	Inhibitor
DMWH0ER	RN	New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43.
DMWH0ER	RU	https://pubmed.ncbi.nlm.nih.gov/19831396

DMQDKYI	DI	DMQDKYI
DMQDKYI	DN	3,4'-(1H-1,2,4-triazole-3,5-diyl)dipyridine
DMQDKYI	MI	TT7RJY8
DMQDKYI	MN	Xanthine dehydrogenase/oxidase (XDH)
DMQDKYI	MT	DTT
DMQDKYI	MA	Inhibitor
DMQDKYI	RN	Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051 - a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia [... Bioorg Med Chem Lett. 2009 Nov 1;19(21):6225-9.
DMQDKYI	RU	https://pubmed.ncbi.nlm.nih.gov/19783139

DMFM60H	DI	DMFM60H
DMFM60H	DN	3,4'-(Ethane-1,2-diyl)dibenzenamine
DMFM60H	MI	TTSZLWK
DMFM60H	MN	Aromatase (CYP19A1)
DMFM60H	MT	DTT
DMFM60H	MA	Inhibitor
DMFM60H	RN	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
DMFM60H	RU	https://pubmed.ncbi.nlm.nih.gov/20558073

DMEN9T4	DI	DMEN9T4
DMEN9T4	DN	3,4'-(thiophene-2,4-diyl)diphenol
DMEN9T4	MI	TTIWB6L
DMEN9T4	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMEN9T4	MT	DTT
DMEN9T4	MA	Inhibitor
DMEN9T4	RN	New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43.
DMEN9T4	RU	https://pubmed.ncbi.nlm.nih.gov/19831396

DMSN814	DI	DMSN814
DMSN814	DN	3,4,4',5-tetramethoxy-(Z)-stilbene
DMSN814	MI	TTYFKSZ
DMSN814	MN	Tubulin beta (TUBB)
DMSN814	MT	DTT
DMSN814	MA	Inhibitor
DMSN814	RN	2-amino and 2'-aminocombretastatin derivatives as potent antimitotic agents. J Med Chem. 2006 Oct 19;49(21):6412-5.
DMSN814	RU	https://pubmed.ncbi.nlm.nih.gov/17034147

DMSN814	DI	DMSN814
DMSN814	DN	3,4,4',5-tetramethoxy-(Z)-stilbene
DMSN814	MI	TTJ2PTI
DMSN814	MN	Tubulin beta-2 chain (TUBB2)
DMSN814	MT	DTT
DMSN814	MA	Inhibitor
DMSN814	RN	2-amino and 2'-aminocombretastatin derivatives as potent antimitotic agents. J Med Chem. 2006 Oct 19;49(21):6412-5.
DMSN814	RU	https://pubmed.ncbi.nlm.nih.gov/17034147

DMSV6K5	DI	DMSV6K5
DMSV6K5	DN	3,4,5,6-Tetrachloro-[1,2]benzoquinone
DMSV6K5	MI	TT1RS9F
DMSV6K5	MN	Acetylcholinesterase (AChE)
DMSV6K5	MT	DTT
DMSV6K5	MA	Inhibitor
DMSV6K5	RN	Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15.
DMSV6K5	RU	https://pubmed.ncbi.nlm.nih.gov/15828829

DMSV6K5	DI	DMSV6K5
DMSV6K5	DN	3,4,5,6-Tetrachloro-[1,2]benzoquinone
DMSV6K5	MI	TTEB0GD
DMSV6K5	MN	Cholinesterase (BCHE)
DMSV6K5	MT	DTT
DMSV6K5	MA	Inhibitor
DMSV6K5	RN	Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15.
DMSV6K5	RU	https://pubmed.ncbi.nlm.nih.gov/15828829

DMSV6K5	DI	DMSV6K5
DMSV6K5	DN	3,4,5,6-Tetrachloro-[1,2]benzoquinone
DMSV6K5	MI	TTMF541
DMSV6K5	MN	Liver carboxylesterase (CES1)
DMSV6K5	MT	DTT
DMSV6K5	MA	Inhibitor
DMSV6K5	RN	Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15.
DMSV6K5	RU	https://pubmed.ncbi.nlm.nih.gov/15828829

DMKOE9I	DI	DMKOE9I
DMKOE9I	DN	3,4,5,6-Tetrahydrobenzo[c]quinolizin-3-(4aH)-one
DMKOE9I	MI	TTTU72V
DMKOE9I	MN	Steroid 5-alpha-reductase 1 (SRD5A1)
DMKOE9I	MT	DTT
DMKOE9I	MA	Inhibitor
DMKOE9I	RN	Benzo[c]quinolizin-3-ones: a novel class of potent and selective nonsteroidal inhibitors of human steroid 5alpha-reductase 1. J Med Chem. 2000 Oct 5;43(20):3718-35.
DMKOE9I	RU	https://pubmed.ncbi.nlm.nih.gov/11020287

DMS42CA	DI	DMS42CA
DMS42CA	DN	3,4,5-tribromo-2-(2', 4'-dibromo-phenoxy)phenol
DMS42CA	MI	TTCFP0V
DMS42CA	MN	Glutamine amidotransferase (GMPS)
DMS42CA	MT	DTT
DMS42CA	MA	Inhibitor
DMS42CA	RN	Enzyme inhibitors: new and known polybrominated phenols and diphenyl ethers from four Indo-Pacific Dysidea sponges. J Nat Prod. 1995 Sep;58(9):1384-91.
DMS42CA	RU	https://pubmed.ncbi.nlm.nih.gov/7494145

DMYHC3S	DI	DMYHC3S
DMYHC3S	DN	3,4',5-trimethoxy-(Z)-stilbene
DMYHC3S	MI	TTYFKSZ
DMYHC3S	MN	Tubulin beta (TUBB)
DMYHC3S	MT	DTT
DMYHC3S	MA	Inhibitor
DMYHC3S	RN	2-amino and 2'-aminocombretastatin derivatives as potent antimitotic agents. J Med Chem. 2006 Oct 19;49(21):6412-5.
DMYHC3S	RU	https://pubmed.ncbi.nlm.nih.gov/17034147

DMYHC3S	DI	DMYHC3S
DMYHC3S	DN	3,4',5-trimethoxy-(Z)-stilbene
DMYHC3S	MI	TTJ2PTI
DMYHC3S	MN	Tubulin beta-2 chain (TUBB2)
DMYHC3S	MT	DTT
DMYHC3S	MA	Inhibitor
DMYHC3S	RN	2-amino and 2'-aminocombretastatin derivatives as potent antimitotic agents. J Med Chem. 2006 Oct 19;49(21):6412-5.
DMYHC3S	RU	https://pubmed.ncbi.nlm.nih.gov/17034147

DMCA7XU	DI	DMCA7XU
DMCA7XU	DN	3,4,5-Trimethoxy-3'-amino-trans-stilbene
DMCA7XU	MI	TTSZLWK
DMCA7XU	MN	Aromatase (CYP19A1)
DMCA7XU	MT	DTT
DMCA7XU	MA	Inhibitor
DMCA7XU	RN	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
DMCA7XU	RU	https://pubmed.ncbi.nlm.nih.gov/20558073

DMDBOJ5	DI	DMDBOJ5
DMDBOJ5	DN	3,4,5-Trimethoxy-4'-amino-trans-stilbene
DMDBOJ5	MI	TTSZLWK
DMDBOJ5	MN	Aromatase (CYP19A1)
DMDBOJ5	MT	DTT
DMDBOJ5	MA	Inhibitor
DMDBOJ5	RN	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
DMDBOJ5	RU	https://pubmed.ncbi.nlm.nih.gov/20558073

DMDBOJ5	DI	DMDBOJ5
DMDBOJ5	DN	3,4,5-Trimethoxy-4'-amino-trans-stilbene
DMDBOJ5	MI	TTJLP0R
DMDBOJ5	MN	Quinone reductase 2 (NQO2)
DMDBOJ5	MT	DTT
DMDBOJ5	MA	Inhibitor
DMDBOJ5	RN	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
DMDBOJ5	RU	https://pubmed.ncbi.nlm.nih.gov/20558073

DMU5NRA	DI	DMU5NRA
DMU5NRA	DN	3,4,5-trimethoxy-N-(thiazol-2-yl)benzamide
DMU5NRA	MI	TTSJ6Q4
DMU5NRA	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DMU5NRA	MT	DTT
DMU5NRA	MA	Inhibitor
DMU5NRA	RN	Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. J Med Chem. 2007 May 31;50(11):2640-6.
DMU5NRA	RU	https://pubmed.ncbi.nlm.nih.gov/17461565

DMO34LJ	DI	DMO34LJ
DMO34LJ	DN	3,4,6-Tribromo-2-(2,4-dibromo-phenoxy)-phenol
DMO34LJ	MI	TT12ABZ
DMO34LJ	MN	Arachidonate 12-lipoxygenase (12-LOX)
DMO34LJ	MT	DTT
DMO34LJ	MA	Inhibitor
DMO34LJ	RN	Probing the activity differences of simple and complex brominated aryl compounds against 15-soybean, 15-human, and 12-human lipoxygenase. J Med Chem. 2004 Jul 29;47(16):4060-5.
DMO34LJ	RU	https://pubmed.ncbi.nlm.nih.gov/15267244

DMO34LJ	DI	DMO34LJ
DMO34LJ	DN	3,4,6-Tribromo-2-(2,4-dibromo-phenoxy)-phenol
DMO34LJ	MI	TTN9T81
DMO34LJ	MN	Arachidonate 15-lipoxygenase (15-LOX)
DMO34LJ	MT	DTT
DMO34LJ	MA	Inhibitor
DMO34LJ	RN	Probing the activity differences of simple and complex brominated aryl compounds against 15-soybean, 15-human, and 12-human lipoxygenase. J Med Chem. 2004 Jul 29;47(16):4060-5.
DMO34LJ	RU	https://pubmed.ncbi.nlm.nih.gov/15267244

DM3MAEQ	DI	DM3MAEQ
DM3MAEQ	DN	3,4,6-Trihydroxy-2-(4-hydroxy-phenyl)-inden-1-one
DM3MAEQ	MI	TTOM3J0
DM3MAEQ	MN	Estrogen receptor beta (ESR2)
DM3MAEQ	MT	DTT
DM3MAEQ	MA	Inhibitor
DM3MAEQ	RN	Estrogen receptor ligands: design and synthesis of new 2-arylindene-1-ones. Bioorg Med Chem Lett. 2005 Jun 15;15(12):3137-42.
DM3MAEQ	RU	https://pubmed.ncbi.nlm.nih.gov/15876535

DMN4Z27	DI	DMN4Z27
DMN4Z27	DN	3,4-Benzo-7-(beta-bromoallyloxy)-8-methylcoumarin
DMN4Z27	MI	TT3WG5C
DMN4Z27	MN	Monoamine oxidase type A (MAO-A)
DMN4Z27	MT	DTT
DMN4Z27	MA	Inhibitor
DMN4Z27	RN	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J Med Chem. 2008 Nov 13;51(21):6740-51.
DMN4Z27	RU	https://pubmed.ncbi.nlm.nih.gov/18834112

DMN4Z27	DI	DMN4Z27
DMN4Z27	DN	3,4-Benzo-7-(beta-bromoallyloxy)-8-methylcoumarin
DMN4Z27	MI	TTGP7BY
DMN4Z27	MN	Monoamine oxidase type B (MAO-B)
DMN4Z27	MT	DTT
DMN4Z27	MA	Inhibitor
DMN4Z27	RN	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J Med Chem. 2008 Nov 13;51(21):6740-51.
DMN4Z27	RU	https://pubmed.ncbi.nlm.nih.gov/18834112

DM1MC06	DI	DM1MC06
DM1MC06	DN	3,4-Benzo-7-acetonyloxy-8-methoxycoumarin
DM1MC06	MI	TT3WG5C
DM1MC06	MN	Monoamine oxidase type A (MAO-A)
DM1MC06	MT	DTT
DM1MC06	MA	Inhibitor
DM1MC06	RN	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J Med Chem. 2008 Nov 13;51(21):6740-51.
DM1MC06	RU	https://pubmed.ncbi.nlm.nih.gov/18834112

DM1MC06	DI	DM1MC06
DM1MC06	DN	3,4-Benzo-7-acetonyloxy-8-methoxycoumarin
DM1MC06	MI	TTGP7BY
DM1MC06	MN	Monoamine oxidase type B (MAO-B)
DM1MC06	MT	DTT
DM1MC06	MA	Inhibitor
DM1MC06	RN	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J Med Chem. 2008 Nov 13;51(21):6740-51.
DM1MC06	RU	https://pubmed.ncbi.nlm.nih.gov/18834112

DMKC6L8	DI	DMKC6L8
DMKC6L8	DN	3,4-Benzo-7-acetonyloxy-8-methylcoumarin
DMKC6L8	MI	TT3WG5C
DMKC6L8	MN	Monoamine oxidase type A (MAO-A)
DMKC6L8	MT	DTT
DMKC6L8	MA	Inhibitor
DMKC6L8	RN	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J Med Chem. 2008 Nov 13;51(21):6740-51.
DMKC6L8	RU	https://pubmed.ncbi.nlm.nih.gov/18834112

DM91W2K	DI	DM91W2K
DM91W2K	DN	3,4-bis(3,4-dimethoxyphenyl)furan-2(5H)-one
DM91W2K	MI	TTSZLWK
DM91W2K	MN	Aromatase (CYP19A1)
DM91W2K	MT	DTT
DM91W2K	MA	Inhibitor
DM91W2K	RN	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
DM91W2K	RU	https://pubmed.ncbi.nlm.nih.gov/20413308

DMEQ1HC	DI	DMEQ1HC
DMEQ1HC	DN	3,4-bis(indol-3-yl)maleimide derivative
DMEQ1HC	MI	TTH6V3D
DMEQ1HC	MN	Cyclin-dependent kinase 1 (CDK1)
DMEQ1HC	MT	DTT
DMEQ1HC	MA	Inhibitor
DMEQ1HC	RN	Design of new inhibitors for cdc2 kinase based on a multiple pseudosubstrate structure. Bioorg Med Chem Lett. 1998 May 5;8(9):1019-22.
DMEQ1HC	RU	https://pubmed.ncbi.nlm.nih.gov/9871700

DMEQ1HC	DI	DMEQ1HC
DMEQ1HC	DN	3,4-bis(indol-3-yl)maleimide derivative
DMEQ1HC	MI	TT9P6OW
DMEQ1HC	MN	G2/mitotic-specific cyclin B1 (CCNB1)
DMEQ1HC	MT	DTT
DMEQ1HC	MA	Inhibitor
DMEQ1HC	RN	Design of new inhibitors for cdc2 kinase based on a multiple pseudosubstrate structure. Bioorg Med Chem Lett. 1998 May 5;8(9):1019-22.
DMEQ1HC	RU	https://pubmed.ncbi.nlm.nih.gov/9871700

DMDO175	DI	DMDO175
DMDO175	DN	3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione
DMDO175	MI	TT9VGXW
DMDO175	MN	Angiopoietin 1 receptor (TEK)
DMDO175	MT	DTT
DMDO175	MA	Inhibitor
DMDO175	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DMDO175	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DMDO175	DI	DMDO175
DMDO175	DN	3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione
DMDO175	MI	TTH6V3D
DMDO175	MN	Cyclin-dependent kinase 1 (CDK1)
DMDO175	MT	DTT
DMDO175	MA	Inhibitor
DMDO175	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DMDO175	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DMDO175	DI	DMDO175
DMDO175	DN	3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione
DMDO175	MI	TT7HF4W
DMDO175	MN	Cyclin-dependent kinase 2 (CDK2)
DMDO175	MT	DTT
DMDO175	MA	Inhibitor
DMDO175	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DMDO175	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DMDO175	DI	DMDO175
DMDO175	DN	3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione
DMDO175	MI	TT0PG8F
DMDO175	MN	Cyclin-dependent kinase 4 (CDK4)
DMDO175	MT	DTT
DMDO175	MA	Inhibitor
DMDO175	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DMDO175	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DMDO175	DI	DMDO175
DMDO175	DN	3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione
DMDO175	MI	TTO0FDJ
DMDO175	MN	Cyclin-dependent kinase 6 (CDK6)
DMDO175	MT	DTT
DMDO175	MA	Inhibitor
DMDO175	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DMDO175	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DMDO175	DI	DMDO175
DMDO175	DN	3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione
DMDO175	MI	TTGKNB4
DMDO175	MN	Epidermal growth factor receptor (EGFR)
DMDO175	MT	DTT
DMDO175	MA	Inhibitor
DMDO175	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DMDO175	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DMDO175	DI	DMDO175
DMDO175	DN	3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione
DMDO175	MI	TTR5TV4
DMDO175	MN	ERBB2 messenger RNA (HER2 mRNA)
DMDO175	MT	DTT
DMDO175	MA	Inhibitor
DMDO175	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DMDO175	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DMDO175	DI	DMDO175
DMDO175	DN	3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione
DMDO175	MI	TTFCJ7S
DMDO175	MN	G1/S-specific cyclin-D1 (CCND1)
DMDO175	MT	DTT
DMDO175	MA	Inhibitor
DMDO175	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DMDO175	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DMDO175	DI	DMDO175
DMDO175	DN	3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione
DMDO175	MI	TTCEJ4F
DMDO175	MN	G1/S-specific cyclin-E1 (CCNE1)
DMDO175	MT	DTT
DMDO175	MA	Inhibitor
DMDO175	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DMDO175	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DMDO175	DI	DMDO175
DMDO175	DN	3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione
DMDO175	MI	TT9P6OW
DMDO175	MN	G2/mitotic-specific cyclin B1 (CCNB1)
DMDO175	MT	DTT
DMDO175	MA	Inhibitor
DMDO175	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DMDO175	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DMDO175	DI	DMDO175
DMDO175	DN	3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione
DMDO175	MI	TTFJ8Q1
DMDO175	MN	Protein kinase C alpha (PRKCA)
DMDO175	MT	DTT
DMDO175	MA	Inhibitor
DMDO175	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DMDO175	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DMDO175	DI	DMDO175
DMDO175	DN	3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione
DMDO175	MI	TTBZ7OD
DMDO175	MN	Protein kinase C epsilon (PRKCE)
DMDO175	MT	DTT
DMDO175	MA	Inhibitor
DMDO175	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DMDO175	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DMDO175	DI	DMDO175
DMDO175	DN	3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione
DMDO175	MI	TTRFOXJ
DMDO175	MN	Protein kinase C gamma (PRKCG)
DMDO175	MT	DTT
DMDO175	MA	Inhibitor
DMDO175	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DMDO175	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DMDO175	DI	DMDO175
DMDO175	DN	3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione
DMDO175	MI	TTUTJGQ
DMDO175	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMDO175	MT	DTT
DMDO175	MA	Inhibitor
DMDO175	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DMDO175	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DM8R03D	DI	DM8R03D
DM8R03D	DN	3,4-diarylpyrazoline derivative
DM8R03D	MI	TT6OEDT
DM8R03D	MN	Cannabinoid receptor 1 (CB1)
DM8R03D	MT	DTT
DM8R03D	MA	Inhibitor
DM8R03D	RN	Novel 3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicity. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4794-8.
DM8R03D	RU	https://pubmed.ncbi.nlm.nih.gov/16140010

DM8R03D	DI	DM8R03D
DM8R03D	DN	3,4-diarylpyrazoline derivative
DM8R03D	MI	TTMSFAW
DM8R03D	MN	Cannabinoid receptor 2 (CB2)
DM8R03D	MT	DTT
DM8R03D	MA	Inhibitor
DM8R03D	RN	Novel 3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicity. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4794-8.
DM8R03D	RU	https://pubmed.ncbi.nlm.nih.gov/16140010

DMBUT8A	DI	DMBUT8A
DMBUT8A	DN	3,4-dibenzyloxy-2'-hydroxychalcone
DMBUT8A	MI	TTVKILB
DMBUT8A	MN	Prostaglandin G/H synthase 2 (COX-2)
DMBUT8A	MT	DTT
DMBUT8A	MA	Inhibitor
DMBUT8A	RN	Inhibitory activity of prostaglandin E2 production by the synthetic 2'-hydroxychalcone analogues: Synthesis and SAR study. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1650-3.
DMBUT8A	RU	https://pubmed.ncbi.nlm.nih.gov/19233646

DMXQVRD	DI	DMXQVRD
DMXQVRD	DN	3,4-Dibromo-2-(5-bromo-2-hydroxy-phenoxy)-phenol
DMXQVRD	MI	TTN9T81
DMXQVRD	MN	Arachidonate 15-lipoxygenase (15-LOX)
DMXQVRD	MT	DTT
DMXQVRD	MA	Inhibitor
DMXQVRD	RN	Probing the activity differences of simple and complex brominated aryl compounds against 15-soybean, 15-human, and 12-human lipoxygenase. J Med Chem. 2004 Jul 29;47(16):4060-5.
DMXQVRD	RU	https://pubmed.ncbi.nlm.nih.gov/15267244

DMS1QIJ	DI	DMS1QIJ
DMS1QIJ	DN	3',4'-dichloroacetophenonethiosemicarbazone
DMS1QIJ	MI	TTEAID7
DMS1QIJ	MN	Trypanosoma Cruzipain (Trypano CYSP)
DMS1QIJ	MT	DTT
DMS1QIJ	MA	Inhibitor
DMS1QIJ	RN	Studies toward the structural optimization of novel thiazolylhydrazone-based potent antitrypanosomal agents. Bioorg Med Chem. 2010 Nov 15;18(22):7826-35.
DMS1QIJ	RU	https://pubmed.ncbi.nlm.nih.gov/20961766

DMUSPIC	DI	DMUSPIC
DMUSPIC	DN	3,4-dichlorobenzaldehyde thiosemicarbazone
DMUSPIC	MI	TTEAID7
DMUSPIC	MN	Trypanosoma Cruzipain (Trypano CYSP)
DMUSPIC	MT	DTT
DMUSPIC	MA	Inhibitor
DMUSPIC	RN	Synthesis and structure-activity relationship study of potent trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine protease cruz... J Med Chem. 2002 Jun 20;45(13):2695-707.
DMUSPIC	RU	https://pubmed.ncbi.nlm.nih.gov/12061873

DMN61Q5	DI	DMN61Q5
DMN61Q5	DN	3,4-Dichlorobenzenemethanethiol
DMN61Q5	MI	TTZJYKH
DMN61Q5	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMN61Q5	MT	DTT
DMN61Q5	MA	Inhibitor
DMN61Q5	RN	S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9.
DMN61Q5	RU	https://pubmed.ncbi.nlm.nih.gov/20688518

DMOZCDK	DI	DMOZCDK
DMOZCDK	DN	3,4-dichloroisocoumarin
DMOZCDK	MI	TTPLTSQ
DMOZCDK	MN	Neutrophil elastase (NE)
DMOZCDK	MT	DTT
DMOZCDK	MA	Inhibitor
DMOZCDK	RN	Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and G... Antimicrob Agents Chemother. 2007 Feb;51(2):543-50.
DMOZCDK	RU	https://pubmed.ncbi.nlm.nih.gov/17145787

DMMZURL	DI	DMMZURL
DMMZURL	DN	3,4-Dichloro-N-(2-methyl-1H-indol-5-yl)benzamide
DMMZURL	MI	TT3WG5C
DMMZURL	MN	Monoamine oxidase type A (MAO-A)
DMMZURL	MT	DTT
DMMZURL	MA	Inhibitor
DMMZURL	RN	Inhibition of monoamine oxidase by indole and benzofuran derivatives. Eur J Med Chem. 2010 Oct;45(10):4458-66.
DMMZURL	RU	https://pubmed.ncbi.nlm.nih.gov/20674099

DMMZURL	DI	DMMZURL
DMMZURL	DN	3,4-Dichloro-N-(2-methyl-1H-indol-5-yl)benzamide
DMMZURL	MI	TTGP7BY
DMMZURL	MN	Monoamine oxidase type B (MAO-B)
DMMZURL	MT	DTT
DMMZURL	MA	Inhibitor
DMMZURL	RN	Inhibition of monoamine oxidase by indole and benzofuran derivatives. Eur J Med Chem. 2010 Oct;45(10):4458-66.
DMMZURL	RU	https://pubmed.ncbi.nlm.nih.gov/20674099

DMWOMVF	DI	DMWOMVF
DMWOMVF	DN	3,4-Dichloro-N-(3,3-diphenyl-allyl)-benzamide
DMWOMVF	MI	TTCG0AL
DMWOMVF	MN	Cholecystokinin receptor type A (CCKAR)
DMWOMVF	MT	DTT
DMWOMVF	MA	Inhibitor
DMWOMVF	RN	Hybrid cholecystokinin-A antagonists based on molecular modeling of lorglumide and L-364,718. J Med Chem. 1992 Mar 20;35(6):1042-9.
DMWOMVF	RU	https://pubmed.ncbi.nlm.nih.gov/1552499

DM4RNOE	DI	DM4RNOE
DM4RNOE	DN	3,4-Dichloro-N-(4-phenyl-thiazol-2-yl)-benzamide
DM4RNOE	MI	TTK25J1
DM4RNOE	MN	Adenosine A1 receptor (ADORA1)
DM4RNOE	MT	DTT
DM4RNOE	MA	Inhibitor
DM4RNOE	RN	Substituted 4-phenyl-2-(phenylcarboxamido)-1,3-thiazole derivatives as antagonists for the adenosine A(1) receptor. Bioorg Med Chem Lett. 2001 Aug 6;11(15):2017-9.
DM4RNOE	RU	https://pubmed.ncbi.nlm.nih.gov/11454470

DMFV3Y9	DI	DMFV3Y9
DMFV3Y9	DN	3,4-difluorobenzaldehyde O-benzoyloxime
DMFV3Y9	MI	TTDNFMT
DMFV3Y9	MN	Platelet-activating factor acetylhydrolase (PLA2G7)
DMFV3Y9	MT	DTT
DMFV3Y9	MA	Inhibitor
DMFV3Y9	RN	Potent inhibitors of lipoprotein-associated phospholipase A(2): benzaldehyde O-heterocycle-4-carbonyloxime. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5576-9.
DMFV3Y9	RU	https://pubmed.ncbi.nlm.nih.gov/16919943

DM0I6UT	DI	DM0I6UT
DM0I6UT	DN	3,4-Dihydro-1H-quinolin-(2E)-ylideneamine
DM0I6UT	MI	TTZUFI5
DM0I6UT	MN	Nitric-oxide synthase brain (NOS1)
DM0I6UT	MT	DTT
DM0I6UT	MA	Inhibitor
DM0I6UT	RN	Bicyclic amidine inhibitors of nitric oxide synthase: discovery of perhydro-iminopyrindine and perhydro-iminoquinoline as potent, orally active inh... Bioorg Med Chem Lett. 2005 Apr 15;15(8):1997-2001.
DM0I6UT	RU	https://pubmed.ncbi.nlm.nih.gov/15808455

DM0I6UT	DI	DM0I6UT
DM0I6UT	DN	3,4-Dihydro-1H-quinolin-(2E)-ylideneamine
DM0I6UT	MI	TTF10I9
DM0I6UT	MN	Nitric-oxide synthase inducible (NOS2)
DM0I6UT	MT	DTT
DM0I6UT	MA	Inhibitor
DM0I6UT	RN	Bicyclic amidine inhibitors of nitric oxide synthase: discovery of perhydro-iminopyrindine and perhydro-iminoquinoline as potent, orally active inh... Bioorg Med Chem Lett. 2005 Apr 15;15(8):1997-2001.
DM0I6UT	RU	https://pubmed.ncbi.nlm.nih.gov/15808455

DMUOXHP	DI	DMUOXHP
DMUOXHP	DN	3,4-dihydroquinazolin-2-amine hydrobromide
DMUOXHP	MI	TTRUFDT
DMUOXHP	MN	5-HT 5A receptor (HTR5A)
DMUOXHP	MT	DTT
DMUOXHP	MA	Inhibitor
DMUOXHP	RN	Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61.
DMUOXHP	RU	https://pubmed.ncbi.nlm.nih.gov/17998160

DMG4NR3	DI	DMG4NR3
DMG4NR3	DN	3,4-Dihydroxy-10H-anthracen-9-one
DMG4NR3	MI	TT2J34L
DMG4NR3	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMG4NR3	MT	DTT
DMG4NR3	MA	Inhibitor
DMG4NR3	RN	Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80.
DMG4NR3	RU	https://pubmed.ncbi.nlm.nih.gov/9371243

DMZJ4VL	DI	DMZJ4VL
DMZJ4VL	DN	3,4-dihydroxybenzaldehyde-O-ethyloxime
DMZJ4VL	MI	TTULVH8
DMZJ4VL	MN	Tyrosinase (TYR)
DMZJ4VL	MT	DTT
DMZJ4VL	MA	Inhibitor
DMZJ4VL	RN	Discovery of 4-functionalized phenyl-O-beta-D-glycosides as a new class of mushroom tyrosinase inhibitors. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6157-60.
DMZJ4VL	RU	https://pubmed.ncbi.nlm.nih.gov/19800229

DM7N3MX	DI	DM7N3MX
DM7N3MX	DN	3,4-dihydroxyphenylacetaldehyde
DM7N3MX	MI	DEXI4UQ
DM7N3MX	MN	Aldehyde dehydrogenase 5 (ALDHX)
DM7N3MX	MT	DME
DM7N3MX	MA	Metabolism
DM7N3MX	RN	Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase. Pharmacol Rev. 2007 Jun;59(2):125-50.
DM7N3MX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17379813

DM7N3MX	DI	DM7N3MX
DM7N3MX	DN	3,4-dihydroxyphenylacetaldehyde
DM7N3MX	MI	DE2ZWSM
DM7N3MX	MN	Aldehyde dehydrogenase 7 (ALDH7)
DM7N3MX	MT	DME
DM7N3MX	MA	Metabolism
DM7N3MX	RN	Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase. Pharmacol Rev. 2007 Jun;59(2):125-50.
DM7N3MX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17379813

DM7N3MX	DI	DM7N3MX
DM7N3MX	DN	3,4-dihydroxyphenylacetaldehyde
DM7N3MX	MI	DE870HF
DM7N3MX	MN	Aminomuconic semialdehyde dehydrogenase (ALDH12)
DM7N3MX	MT	DME
DM7N3MX	MA	Metabolism
DM7N3MX	RN	Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase. Pharmacol Rev. 2007 Jun;59(2):125-50.
DM7N3MX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17379813

DMTQX92	DI	DMTQX92
DMTQX92	DN	3,4-dihydroxyxanthone
DMTQX92	MI	TTVKILB
DMTQX92	MN	Prostaglandin G/H synthase 2 (COX-2)
DMTQX92	MT	DTT
DMTQX92	MA	Inhibitor
DMTQX92	RN	Selective cyclooxygenase-2 inhibitors from Calophyllum membranaceum. J Nat Prod. 2005 Oct;68(10):1514-8.
DMTQX92	RU	https://pubmed.ncbi.nlm.nih.gov/16252917

DMVDZCE	DI	DMVDZCE
DMVDZCE	DN	3,4-Dimethoxy-4'-amino-trans-stilbene
DMVDZCE	MI	TTSZLWK
DMVDZCE	MN	Aromatase (CYP19A1)
DMVDZCE	MT	DTT
DMVDZCE	MA	Inhibitor
DMVDZCE	RN	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
DMVDZCE	RU	https://pubmed.ncbi.nlm.nih.gov/20558073

DMMO6QI	DI	DMMO6QI
DMMO6QI	DN	3,4-Dimethyl-pyrrolidin-(2Z)-ylideneamine
DMMO6QI	MI	TTZUFI5
DMMO6QI	MN	Nitric-oxide synthase brain (NOS1)
DMMO6QI	MT	DTT
DMMO6QI	MA	Inhibitor
DMMO6QI	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DMMO6QI	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DMMO6QI	DI	DMMO6QI
DMMO6QI	DN	3,4-Dimethyl-pyrrolidin-(2Z)-ylideneamine
DMMO6QI	MI	TTCM4B3
DMMO6QI	MN	Nitric-oxide synthase endothelial (NOS3)
DMMO6QI	MT	DTT
DMMO6QI	MA	Inhibitor
DMMO6QI	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DMMO6QI	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DMMO6QI	DI	DMMO6QI
DMMO6QI	DN	3,4-Dimethyl-pyrrolidin-(2Z)-ylideneamine
DMMO6QI	MI	TTF10I9
DMMO6QI	MN	Nitric-oxide synthase inducible (NOS2)
DMMO6QI	MT	DTT
DMMO6QI	MA	Inhibitor
DMMO6QI	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DMMO6QI	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DMPK6YT	DI	DMPK6YT
DMPK6YT	DN	3,4-diphenyl-1H-pyrrole-2,5-dione
DMPK6YT	MI	TT9VGXW
DMPK6YT	MN	Angiopoietin 1 receptor (TEK)
DMPK6YT	MT	DTT
DMPK6YT	MA	Inhibitor
DMPK6YT	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DMPK6YT	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DMPK6YT	DI	DMPK6YT
DMPK6YT	DN	3,4-diphenyl-1H-pyrrole-2,5-dione
DMPK6YT	MI	TTH6V3D
DMPK6YT	MN	Cyclin-dependent kinase 1 (CDK1)
DMPK6YT	MT	DTT
DMPK6YT	MA	Inhibitor
DMPK6YT	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DMPK6YT	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DMPK6YT	DI	DMPK6YT
DMPK6YT	DN	3,4-diphenyl-1H-pyrrole-2,5-dione
DMPK6YT	MI	TT7HF4W
DMPK6YT	MN	Cyclin-dependent kinase 2 (CDK2)
DMPK6YT	MT	DTT
DMPK6YT	MA	Inhibitor
DMPK6YT	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DMPK6YT	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DMPK6YT	DI	DMPK6YT
DMPK6YT	DN	3,4-diphenyl-1H-pyrrole-2,5-dione
DMPK6YT	MI	TT0PG8F
DMPK6YT	MN	Cyclin-dependent kinase 4 (CDK4)
DMPK6YT	MT	DTT
DMPK6YT	MA	Inhibitor
DMPK6YT	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DMPK6YT	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DMPK6YT	DI	DMPK6YT
DMPK6YT	DN	3,4-diphenyl-1H-pyrrole-2,5-dione
DMPK6YT	MI	TTO0FDJ
DMPK6YT	MN	Cyclin-dependent kinase 6 (CDK6)
DMPK6YT	MT	DTT
DMPK6YT	MA	Inhibitor
DMPK6YT	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DMPK6YT	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DMPK6YT	DI	DMPK6YT
DMPK6YT	DN	3,4-diphenyl-1H-pyrrole-2,5-dione
DMPK6YT	MI	TTGKNB4
DMPK6YT	MN	Epidermal growth factor receptor (EGFR)
DMPK6YT	MT	DTT
DMPK6YT	MA	Inhibitor
DMPK6YT	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DMPK6YT	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DMPK6YT	DI	DMPK6YT
DMPK6YT	DN	3,4-diphenyl-1H-pyrrole-2,5-dione
DMPK6YT	MI	TTR5TV4
DMPK6YT	MN	ERBB2 messenger RNA (HER2 mRNA)
DMPK6YT	MT	DTT
DMPK6YT	MA	Inhibitor
DMPK6YT	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DMPK6YT	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DMPK6YT	DI	DMPK6YT
DMPK6YT	DN	3,4-diphenyl-1H-pyrrole-2,5-dione
DMPK6YT	MI	TTFCJ7S
DMPK6YT	MN	G1/S-specific cyclin-D1 (CCND1)
DMPK6YT	MT	DTT
DMPK6YT	MA	Inhibitor
DMPK6YT	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DMPK6YT	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DMPK6YT	DI	DMPK6YT
DMPK6YT	DN	3,4-diphenyl-1H-pyrrole-2,5-dione
DMPK6YT	MI	TTCEJ4F
DMPK6YT	MN	G1/S-specific cyclin-E1 (CCNE1)
DMPK6YT	MT	DTT
DMPK6YT	MA	Inhibitor
DMPK6YT	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DMPK6YT	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DMPK6YT	DI	DMPK6YT
DMPK6YT	DN	3,4-diphenyl-1H-pyrrole-2,5-dione
DMPK6YT	MI	TT9P6OW
DMPK6YT	MN	G2/mitotic-specific cyclin B1 (CCNB1)
DMPK6YT	MT	DTT
DMPK6YT	MA	Inhibitor
DMPK6YT	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DMPK6YT	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DMPK6YT	DI	DMPK6YT
DMPK6YT	DN	3,4-diphenyl-1H-pyrrole-2,5-dione
DMPK6YT	MI	TTFJ8Q1
DMPK6YT	MN	Protein kinase C alpha (PRKCA)
DMPK6YT	MT	DTT
DMPK6YT	MA	Inhibitor
DMPK6YT	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DMPK6YT	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DMPK6YT	DI	DMPK6YT
DMPK6YT	DN	3,4-diphenyl-1H-pyrrole-2,5-dione
DMPK6YT	MI	TTBZ7OD
DMPK6YT	MN	Protein kinase C epsilon (PRKCE)
DMPK6YT	MT	DTT
DMPK6YT	MA	Inhibitor
DMPK6YT	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DMPK6YT	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DMPK6YT	DI	DMPK6YT
DMPK6YT	DN	3,4-diphenyl-1H-pyrrole-2,5-dione
DMPK6YT	MI	TTRFOXJ
DMPK6YT	MN	Protein kinase C gamma (PRKCG)
DMPK6YT	MT	DTT
DMPK6YT	MA	Inhibitor
DMPK6YT	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DMPK6YT	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DMPK6YT	DI	DMPK6YT
DMPK6YT	DN	3,4-diphenyl-1H-pyrrole-2,5-dione
DMPK6YT	MI	TTUTJGQ
DMPK6YT	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMPK6YT	MT	DTT
DMPK6YT	MA	Inhibitor
DMPK6YT	RN	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
DMPK6YT	RU	https://pubmed.ncbi.nlm.nih.gov/16480264

DM8BJPU	DI	DM8BJPU
DM8BJPU	DN	3,4-epoxydehydroleucodin
DM8BJPU	MI	TTSXVID
DM8BJPU	MN	Nuclear factor NF-kappa-B (NFKB)
DM8BJPU	MT	DTT
DM8BJPU	MA	Inhibitor
DM8BJPU	RN	Development of a structural model for NF-kappaB inhibition of sesquiterpene lactones using self-organizing neural networks. J Med Chem. 2006 Apr 6;49(7):2241-52.
DM8BJPU	RU	https://pubmed.ncbi.nlm.nih.gov/16570920

DMLIG3X	DI	DMLIG3X
DMLIG3X	DN	3,5 DIBROMOTYROSINE
DMLIG3X	MI	TTAUX24
DMLIG3X	MN	Erythropoietin Receptor (EPOR)
DMLIG3X	MT	DTT
DMLIG3X	MA	Inhibitor
DMLIG3X	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMLIG3X	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMAU80W	DI	DMAU80W
DMAU80W	DN	3,5,6,8-Tetramethyl-N-Methyl Phenanthrolinium
DMAU80W	MI	TTZL0OI
DMAU80W	MN	Methionine aminopeptidase 2 (METAP2)
DMAU80W	MT	DTT
DMAU80W	MA	Inhibitor
DMAU80W	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMAU80W	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMV859W	DI	DMV859W
DMV859W	DN	3,5-bis(2-methylpyridin-4-yl)-1H-1,2,4-triazole
DMV859W	MI	TT7RJY8
DMV859W	MN	Xanthine dehydrogenase/oxidase (XDH)
DMV859W	MT	DTT
DMV859W	MA	Inhibitor
DMV859W	RN	Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051 - a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia [... Bioorg Med Chem Lett. 2009 Nov 1;19(21):6225-9.
DMV859W	RU	https://pubmed.ncbi.nlm.nih.gov/19783139

DMFEQ6S	DI	DMFEQ6S
DMFEQ6S	DN	3,5-DHPG
DMFEQ6S	MI	TTVBPDM
DMFEQ6S	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMFEQ6S	MT	DTT
DMFEQ6S	MA	Agonist
DMFEQ6S	RN	[3H]R214127: a novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists. Mol Pharmacol. 2003 May;63(5):1082-93.
DMFEQ6S	RU	https://pubmed.ncbi.nlm.nih.gov/12695537

DMFEQ6S	DI	DMFEQ6S
DMFEQ6S	DN	3,5-DHPG
DMFEQ6S	MI	TTHS256
DMFEQ6S	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMFEQ6S	MT	DTT
DMFEQ6S	MA	Agonist
DMFEQ6S	RN	Characterization of [(3)H]Quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections. J Neurochem. 2000 Dec;75(6):2590-601.
DMFEQ6S	RU	https://pubmed.ncbi.nlm.nih.gov/11080213

DM6CBTE	DI	DM6CBTE
DM6CBTE	DN	3,5-di(pyridin-4-yl)-1H-1,2,4-triazole
DM6CBTE	MI	TT7RJY8
DM6CBTE	MN	Xanthine dehydrogenase/oxidase (XDH)
DM6CBTE	MT	DTT
DM6CBTE	MA	Inhibitor
DM6CBTE	RN	Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051 - a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia [... Bioorg Med Chem Lett. 2009 Nov 1;19(21):6225-9.
DM6CBTE	RU	https://pubmed.ncbi.nlm.nih.gov/19783139

DMEXPIJ	DI	DMEXPIJ
DMEXPIJ	DN	3,5-Diacetoxy-4'-amino-trans-stilbene
DMEXPIJ	MI	TTSZLWK
DMEXPIJ	MN	Aromatase (CYP19A1)
DMEXPIJ	MT	DTT
DMEXPIJ	MA	Inhibitor
DMEXPIJ	RN	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
DMEXPIJ	RU	https://pubmed.ncbi.nlm.nih.gov/20558073

DMK9JCA	DI	DMK9JCA
DMK9JCA	DN	3,5-Diamino-4'-amino-trans-stilbene
DMK9JCA	MI	TTSZLWK
DMK9JCA	MN	Aromatase (CYP19A1)
DMK9JCA	MT	DTT
DMK9JCA	MA	Inhibitor
DMK9JCA	RN	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
DMK9JCA	RU	https://pubmed.ncbi.nlm.nih.gov/20558073

DMCEY6O	DI	DMCEY6O
DMCEY6O	DN	3,5-dibromo-2-(2,4-dibromophenoxy)phenol
DMCEY6O	MI	TTCFP0V
DMCEY6O	MN	Glutamine amidotransferase (GMPS)
DMCEY6O	MT	DTT
DMCEY6O	MA	Inhibitor
DMCEY6O	RN	Enzyme inhibitors: new and known polybrominated phenols and diphenyl ethers from four Indo-Pacific Dysidea sponges. J Nat Prod. 1995 Sep;58(9):1384-91.
DMCEY6O	RU	https://pubmed.ncbi.nlm.nih.gov/7494145

DMPVI9W	DI	DMPVI9W
DMPVI9W	DN	3,5-dichlorobenzaldehyde thiosemicarbazone
DMPVI9W	MI	TTEAID7
DMPVI9W	MN	Trypanosoma Cruzipain (Trypano CYSP)
DMPVI9W	MT	DTT
DMPVI9W	MA	Inhibitor
DMPVI9W	RN	Synthesis and structure-activity relationship study of potent trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine protease cruz... J Med Chem. 2002 Jun 20;45(13):2695-707.
DMPVI9W	RU	https://pubmed.ncbi.nlm.nih.gov/12061873

DMQ45WH	DI	DMQ45WH
DMQ45WH	DN	3,5-dichlorosalicylic acid
DMQ45WH	MI	TTFBNVI
DMQ45WH	MN	Aldose reductase (AKR1B1)
DMQ45WH	MT	DTT
DMQ45WH	MA	Inhibitor
DMQ45WH	RN	Correlation of binding constants and molecular modelling of inhibitors in the active sites of aldose reductase and aldehyde reductase. Bioorg Med Chem. 2009 Feb 1;17(3):1244-50.
DMQ45WH	RU	https://pubmed.ncbi.nlm.nih.gov/19121944

DMQ45WH	DI	DMQ45WH
DMQ45WH	DN	3,5-dichlorosalicylic acid
DMQ45WH	MI	TTJS7O4
DMQ45WH	MN	Entamoeba Alcohol dehydrogenase 2 (Entamo ADH2)
DMQ45WH	MT	DTT
DMQ45WH	MA	Inhibitor
DMQ45WH	RN	Correlation of binding constants and molecular modelling of inhibitors in the active sites of aldose reductase and aldehyde reductase. Bioorg Med Chem. 2009 Feb 1;17(3):1244-50.
DMQ45WH	RU	https://pubmed.ncbi.nlm.nih.gov/19121944

DMET46F	DI	DMET46F
DMET46F	DN	3,5-Difluorobenzenesulfonamide
DMET46F	MI	TTANPDJ
DMET46F	MN	Carbonic anhydrase II (CA-II)
DMET46F	MT	DTT
DMET46F	MA	Inhibitor
DMET46F	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMET46F	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM4VT0Q	DI	DM4VT0Q
DM4VT0Q	DN	3,5-difluorophenol
DM4VT0Q	MI	TTUNARX
DM4VT0Q	MN	Carbonic anhydrase (CA)
DM4VT0Q	MT	DTT
DM4VT0Q	MA	Inhibitor
DM4VT0Q	RN	Carbonic anhydrase inhibitors: Inhibition of the new membrane-associated isoform XV with phenols. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3593-6.
DM4VT0Q	RU	https://pubmed.ncbi.nlm.nih.gov/18501600

DM04N7I	DI	DM04N7I
DM04N7I	DN	3,5-dihydroxybenzoic acid
DM04N7I	MI	TTVK4ZO
DM04N7I	MN	G protein coupled receptor 81 (HCAR1)
DM04N7I	MT	DTT
DM04N7I	MA	Agonist
DM04N7I	RN	3,5-Dihydroxybenzoic acid, a specific agonist for hydroxycarboxylic acid 1, inhibits lipolysis in adipocytes. J Pharmacol Exp Ther. 2012 Jun;341(3):794-801.
DM04N7I	RU	https://pubmed.ncbi.nlm.nih.gov/22434674

DMQ9TNB	DI	DMQ9TNB
DMQ9TNB	DN	3,5-Dihydroxyl-4'-amino-trans-stilbene
DMQ9TNB	MI	TTSZLWK
DMQ9TNB	MN	Aromatase (CYP19A1)
DMQ9TNB	MT	DTT
DMQ9TNB	MA	Inhibitor
DMQ9TNB	RN	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
DMQ9TNB	RU	https://pubmed.ncbi.nlm.nih.gov/20558073

DMRY2ZC	DI	DMRY2ZC
DMRY2ZC	DN	3'',5''-dimethoxy-[1,1':2',1'']-terphenyl-4-ol
DMRY2ZC	MI	TTS7G69
DMRY2ZC	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMRY2ZC	MT	DTT
DMRY2ZC	MA	Inhibitor
DMRY2ZC	RN	Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells. J Med Chem. 2006 May 18;49(10):3012-8.
DMRY2ZC	RU	https://pubmed.ncbi.nlm.nih.gov/16686543

DMXCZAK	DI	DMXCZAK
DMXCZAK	DN	3'',5''-dimethoxy-[1,1':3',1'']-terphenyl-4-ol
DMXCZAK	MI	TTS7G69
DMXCZAK	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMXCZAK	MT	DTT
DMXCZAK	MA	Inhibitor
DMXCZAK	RN	Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells. J Med Chem. 2006 May 18;49(10):3012-8.
DMXCZAK	RU	https://pubmed.ncbi.nlm.nih.gov/16686543

DMC3917	DI	DMC3917
DMC3917	DN	3,5-Dimethoxy-4'-amino-trans-stilbene
DMC3917	MI	TTSZLWK
DMC3917	MN	Aromatase (CYP19A1)
DMC3917	MT	DTT
DMC3917	MA	Inhibitor
DMC3917	RN	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
DMC3917	RU	https://pubmed.ncbi.nlm.nih.gov/20558073

DMC3917	DI	DMC3917
DMC3917	DN	3,5-Dimethoxy-4'-amino-trans-stilbene
DMC3917	MI	TTJLP0R
DMC3917	MN	Quinone reductase 2 (NQO2)
DMC3917	MT	DTT
DMC3917	MA	Inhibitor
DMC3917	RN	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
DMC3917	RU	https://pubmed.ncbi.nlm.nih.gov/20558073

DM3E98I	DI	DM3E98I
DM3E98I	DN	3,5-dimethyl PPP
DM3E98I	MI	TTVBPDM
DM3E98I	MN	Metabotropic glutamate receptor 1 (mGluR1)
DM3E98I	MT	DTT
DM3E98I	MA	Modulator (allosteric modulator)
DM3E98I	RN	Synthesis and pharmacological characterisation of 2,4-dicarboxy-pyrroles as selective non-competitive mGluR1 antagonists. Bioorg Med Chem. 2003 Jan 17;11(2):171-83.
DM3E98I	RU	https://pubmed.ncbi.nlm.nih.gov/12470711

DMAQ6OM	DI	DMAQ6OM
DMAQ6OM	DN	3,5-dimethyl-2-(phenylsulfonamido)benzoic acid
DMAQ6OM	MI	TTZL0OI
DMAQ6OM	MN	Methionine aminopeptidase 2 (METAP2)
DMAQ6OM	MT	DTT
DMAQ6OM	MA	Inhibitor
DMAQ6OM	RN	Development of sulfonamide compounds as potent methionine aminopeptidase type II inhibitors with antiproliferative properties. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3574-7.
DMAQ6OM	RU	https://pubmed.ncbi.nlm.nih.gov/16632353

DMBGSHD	DI	DMBGSHD
DMBGSHD	DN	3,5-Dinitrocatechol
DMBGSHD	MI	TTKWFB8
DMBGSHD	MN	Catechol-O-methyl-transferase (COMT)
DMBGSHD	MT	DTT
DMBGSHD	MA	Inhibitor
DMBGSHD	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMBGSHD	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMWOB7Q	DI	DMWOB7Q
DMWOB7Q	DN	3,5-Di-tert-butyl-[1,2]benzoquinone
DMWOB7Q	MI	TTMF541
DMWOB7Q	MN	Liver carboxylesterase (CES1)
DMWOB7Q	MT	DTT
DMWOB7Q	MA	Inhibitor
DMWOB7Q	RN	Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15.
DMWOB7Q	RU	https://pubmed.ncbi.nlm.nih.gov/15828829

DMM632N	DI	DMM632N
DMM632N	DN	3,6,8-Tribromo-dibenzo[1,4]dioxin-1-ol
DMM632N	MI	TTN9T81
DMM632N	MN	Arachidonate 15-lipoxygenase (15-LOX)
DMM632N	MT	DTT
DMM632N	MA	Inhibitor
DMM632N	RN	Probing the activity differences of simple and complex brominated aryl compounds against 15-soybean, 15-human, and 12-human lipoxygenase. J Med Chem. 2004 Jul 29;47(16):4060-5.
DMM632N	RU	https://pubmed.ncbi.nlm.nih.gov/15267244

DMY26JI	DI	DMY26JI
DMY26JI	DN	3,6,9,12,15,18-HEXAOXAICOSANE
DMY26JI	MI	TTJNTSI
DMY26JI	MN	Rotamase Pin1 (PIN1)
DMY26JI	MT	DTT
DMY26JI	MA	Inhibitor
DMY26JI	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMY26JI	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMY8IOP	DI	DMY8IOP
DMY8IOP	DN	3,6,9,12,15-Pentaoxaheptadecane
DMY8IOP	MI	TT1RS9F
DMY8IOP	MN	Acetylcholinesterase (AChE)
DMY8IOP	MT	DTT
DMY8IOP	MA	Inhibitor
DMY8IOP	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMY8IOP	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMY8IOP	DI	DMY8IOP
DMY8IOP	DN	3,6,9,12,15-Pentaoxaheptadecane
DMY8IOP	MI	TTWQM3J
DMY8IOP	MN	Kynureninase (KYNU)
DMY8IOP	MT	DTT
DMY8IOP	MA	Inhibitor
DMY8IOP	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMY8IOP	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMMVL5P	DI	DMMVL5P
DMMVL5P	DN	3,6,9,12,15-PENTAOXATRICOSAN-1-OL
DMMVL5P	MI	TT3PQ2Y
DMMVL5P	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DMMVL5P	MT	DTT
DMMVL5P	MA	Inhibitor
DMMVL5P	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMMVL5P	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMWTP7Y	DI	DMWTP7Y
DMWTP7Y	DN	3,6-bis(Dmt-Tic-NH-butyl)-2(1H)-pyrazinone
DMWTP7Y	MI	TT27RFC
DMWTP7Y	MN	Opioid receptor delta (OPRD1)
DMWTP7Y	MT	DTT
DMWTP7Y	MA	Inhibitor
DMWTP7Y	RN	Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists. J Med Chem. 2005 Dec 15;48(25):8035-44.
DMWTP7Y	RU	https://pubmed.ncbi.nlm.nih.gov/16335927

DMWTP7Y	DI	DMWTP7Y
DMWTP7Y	DN	3,6-bis(Dmt-Tic-NH-butyl)-2(1H)-pyrazinone
DMWTP7Y	MI	TTKWM86
DMWTP7Y	MN	Opioid receptor mu (MOP)
DMWTP7Y	MT	DTT
DMWTP7Y	MA	Inhibitor
DMWTP7Y	RN	Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists. J Med Chem. 2005 Dec 15;48(25):8035-44.
DMWTP7Y	RU	https://pubmed.ncbi.nlm.nih.gov/16335927

DM2Y4A6	DI	DM2Y4A6
DM2Y4A6	DN	3,6-bis(Dmt-Tic-NH-ethyl)-2(1H)-pyrazinone
DM2Y4A6	MI	TT27RFC
DM2Y4A6	MN	Opioid receptor delta (OPRD1)
DM2Y4A6	MT	DTT
DM2Y4A6	MA	Inhibitor
DM2Y4A6	RN	Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists. J Med Chem. 2005 Dec 15;48(25):8035-44.
DM2Y4A6	RU	https://pubmed.ncbi.nlm.nih.gov/16335927

DM2Y4A6	DI	DM2Y4A6
DM2Y4A6	DN	3,6-bis(Dmt-Tic-NH-ethyl)-2(1H)-pyrazinone
DM2Y4A6	MI	TTKWM86
DM2Y4A6	MN	Opioid receptor mu (MOP)
DM2Y4A6	MT	DTT
DM2Y4A6	MA	Inhibitor
DM2Y4A6	RN	Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists. J Med Chem. 2005 Dec 15;48(25):8035-44.
DM2Y4A6	RU	https://pubmed.ncbi.nlm.nih.gov/16335927

DMJR983	DI	DMJR983
DMJR983	DN	3,6-bis(Dmt-Tic-NH-methyl)-2(1H)-pyrazinone
DMJR983	MI	TT27RFC
DMJR983	MN	Opioid receptor delta (OPRD1)
DMJR983	MT	DTT
DMJR983	MA	Inhibitor
DMJR983	RN	Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists. J Med Chem. 2005 Dec 15;48(25):8035-44.
DMJR983	RU	https://pubmed.ncbi.nlm.nih.gov/16335927

DMJR983	DI	DMJR983
DMJR983	DN	3,6-bis(Dmt-Tic-NH-methyl)-2(1H)-pyrazinone
DMJR983	MI	TTKWM86
DMJR983	MN	Opioid receptor mu (MOP)
DMJR983	MT	DTT
DMJR983	MA	Inhibitor
DMJR983	RN	Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists. J Med Chem. 2005 Dec 15;48(25):8035-44.
DMJR983	RU	https://pubmed.ncbi.nlm.nih.gov/16335927

DMEQBS3	DI	DMEQBS3
DMEQBS3	DN	3,6-bis(Dmt-Tic-NH-propyl)-2(1H)-pyrazinone
DMEQBS3	MI	TT27RFC
DMEQBS3	MN	Opioid receptor delta (OPRD1)
DMEQBS3	MT	DTT
DMEQBS3	MA	Inhibitor
DMEQBS3	RN	Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists. J Med Chem. 2005 Dec 15;48(25):8035-44.
DMEQBS3	RU	https://pubmed.ncbi.nlm.nih.gov/16335927

DMEQBS3	DI	DMEQBS3
DMEQBS3	DN	3,6-bis(Dmt-Tic-NH-propyl)-2(1H)-pyrazinone
DMEQBS3	MI	TTKWM86
DMEQBS3	MN	Opioid receptor mu (MOP)
DMEQBS3	MT	DTT
DMEQBS3	MA	Inhibitor
DMEQBS3	RN	Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists. J Med Chem. 2005 Dec 15;48(25):8035-44.
DMEQBS3	RU	https://pubmed.ncbi.nlm.nih.gov/16335927

DMUH4OV	DI	DMUH4OV
DMUH4OV	DN	3,6-Dihydroxy-2-(4-hydroxy-phenyl)-inden-1-one
DMUH4OV	MI	TTOM3J0
DMUH4OV	MN	Estrogen receptor beta (ESR2)
DMUH4OV	MT	DTT
DMUH4OV	MA	Inhibitor
DMUH4OV	RN	Estrogen receptor ligands: design and synthesis of new 2-arylindene-1-ones. Bioorg Med Chem Lett. 2005 Jun 15;15(12):3137-42.
DMUH4OV	RU	https://pubmed.ncbi.nlm.nih.gov/15876535

DM7AORH	DI	DM7AORH
DM7AORH	DN	3,6-Dihydroxy-Xanthene-9-Propionic Acid
DM7AORH	MI	TTEP6RV
DM7AORH	MN	Glutathione reductase (GR)
DM7AORH	MT	DTT
DM7AORH	MA	Inhibitor
DM7AORH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM7AORH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMEOBNJ	DI	DMEOBNJ
DMEOBNJ	DN	3,6-Diphenyl-1-oxa-7-aza-spiro[4.5]decane
DMEOBNJ	MI	TTZPO1L
DMEOBNJ	MN	Substance-P receptor (TACR1)
DMEOBNJ	MT	DTT
DMEOBNJ	MA	Inhibitor
DMEOBNJ	RN	Spirocyclic NK(1) antagonists II: [4.5]-spiroethers. Bioorg Med Chem Lett. 2002 Oct 7;12(19):2719-22.
DMEOBNJ	RU	https://pubmed.ncbi.nlm.nih.gov/12217362

DMNV0EZ	DI	DMNV0EZ
DMNV0EZ	DN	3,6-Di-pyridin-4-yl-pyrazolo[1,5-a]pyrimidine
DMNV0EZ	MI	TTUTJGQ
DMNV0EZ	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMNV0EZ	MT	DTT
DMNV0EZ	MA	Inhibitor
DMNV0EZ	RN	Optimization of a pyrazolo[1,5-a]pyrimidine class of KDR kinase inhibitors: improvements in physical properties enhance cellular activity and pharm... Bioorg Med Chem Lett. 2002 Dec 16;12(24):3537-41.
DMNV0EZ	RU	https://pubmed.ncbi.nlm.nih.gov/12443771

DMNV0EZ	DI	DMNV0EZ
DMNV0EZ	DN	3,6-Di-pyridin-4-yl-pyrazolo[1,5-a]pyrimidine
DMNV0EZ	MI	TTDCBX5
DMNV0EZ	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DMNV0EZ	MT	DTT
DMNV0EZ	MA	Inhibitor
DMNV0EZ	RN	Synthesis and initial SAR studies of 3,6-disubstituted pyrazolo[1,5-a]pyrimidines: a new class of KDR kinase inhibitors. Bioorg Med Chem Lett. 2002 Oct 7;12(19):2767-70.
DMNV0EZ	RU	https://pubmed.ncbi.nlm.nih.gov/12217372

DMNV0EZ	DI	DMNV0EZ
DMNV0EZ	DN	3,6-Di-pyridin-4-yl-pyrazolo[1,5-a]pyrimidine
DMNV0EZ	MI	TT1VAUK
DMNV0EZ	MN	VEGFR1 messenger RNA (VEGFR1 mRNA)
DMNV0EZ	MT	DTT
DMNV0EZ	MA	Inhibitor
DMNV0EZ	RN	Synthesis and initial SAR studies of 3,6-disubstituted pyrazolo[1,5-a]pyrimidines: a new class of KDR kinase inhibitors. Bioorg Med Chem Lett. 2002 Oct 7;12(19):2767-70.
DMNV0EZ	RU	https://pubmed.ncbi.nlm.nih.gov/12217372

DMES906	DI	DMES906
DMES906	DN	3,7,3',4'-TETRAHYDROXYFLAVONE
DMES906	MI	TTO0FDJ
DMES906	MN	Cyclin-dependent kinase 6 (CDK6)
DMES906	MT	DTT
DMES906	MA	Inhibitor
DMES906	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMES906	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMES906	DI	DMES906
DMES906	DN	3,7,3',4'-TETRAHYDROXYFLAVONE
DMES906	MI	TT7AOUD
DMES906	MN	Fatty acid synthase (FASN)
DMES906	MT	DTT
DMES906	MA	Inhibitor
DMES906	RN	Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
DMES906	RU	https://pubmed.ncbi.nlm.nih.gov/16722653

DMES906	DI	DMES906
DMES906	DN	3,7,3',4'-TETRAHYDROXYFLAVONE
DMES906	MI	TTHPFTS
DMES906	MN	Plasmodium Beta-hydroxyacyl-ACP dehydratase (Malaria FabZ)
DMES906	MT	DTT
DMES906	MA	Inhibitor
DMES906	RN	Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
DMES906	RU	https://pubmed.ncbi.nlm.nih.gov/16722653

DMES906	DI	DMES906
DMES906	DN	3,7,3',4'-TETRAHYDROXYFLAVONE
DMES906	MI	TTNX2CS
DMES906	MN	Plasmodium Enoyl-ACP reductase (Malaria fabI)
DMES906	MT	DTT
DMES906	MA	Inhibitor
DMES906	RN	Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
DMES906	RU	https://pubmed.ncbi.nlm.nih.gov/16722653

DMES906	DI	DMES906
DMES906	DN	3,7,3',4'-TETRAHYDROXYFLAVONE
DMES906	MI	TTBE4IR
DMES906	MN	Plasmodium Oxoacyl-[acyl-carrier protein] reductase (Malaria fabG)
DMES906	MT	DTT
DMES906	MA	Inhibitor
DMES906	RN	Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
DMES906	RU	https://pubmed.ncbi.nlm.nih.gov/16722653

DMQADXL	DI	DMQADXL
DMQADXL	DN	3,7-Bis(2-hydroxyethyl)icaritin
DMQADXL	MI	TTJ0IQB
DMQADXL	MN	Phosphodiesterase 5A (PDE5A)
DMQADXL	MT	DTT
DMQADXL	MA	Inhibitor
DMQADXL	RN	Potent inhibition of human phosphodiesterase-5 by icariin derivatives. J Nat Prod. 2008 Sep;71(9):1513-7.
DMQADXL	RU	https://pubmed.ncbi.nlm.nih.gov/18778098

DMBIRC6	DI	DMBIRC6
DMBIRC6	DN	3,7-BIS(DIMETHYLAMINO)PHENOTHIAZIN-5-IUM
DMBIRC6	MI	TT1RS9F
DMBIRC6	MN	Acetylcholinesterase (AChE)
DMBIRC6	MT	DTT
DMBIRC6	MA	Inhibitor
DMBIRC6	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMBIRC6	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMH04P7	DI	DMH04P7
DMH04P7	DN	3,7-dihydroxy-flavone
DMH04P7	MI	TTNX2CS
DMH04P7	MN	Plasmodium Enoyl-ACP reductase (Malaria fabI)
DMH04P7	MT	DTT
DMH04P7	MA	Inhibitor
DMH04P7	RN	Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
DMH04P7	RU	https://pubmed.ncbi.nlm.nih.gov/16722653

DMJ0654	DI	DMJ0654
DMJ0654	DN	3,7-DIHYDROXYNAPHTHALENE-2-CARBOXYLIC ACID
DMJ0654	MI	TTAZHU0
DMJ0654	MN	L-lactate dehydrogenase (LDH)
DMJ0654	MT	DTT
DMJ0654	MA	Inhibitor
DMJ0654	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMJ0654	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DM23CEI	DI	DM23CEI
DM23CEI	DN	3,8-dibromoboldine
DM23CEI	MI	TTZFYLI
DM23CEI	MN	Dopamine D1 receptor (D1R)
DM23CEI	MT	DTT
DM23CEI	MA	Inhibitor
DM23CEI	RN	Halogenated boldine derivatives with enhanced monoamine receptor selectivity. J Nat Prod. 2000 Apr;63(4):480-4.
DM23CEI	RU	https://pubmed.ncbi.nlm.nih.gov/10785418

DM23CEI	DI	DM23CEI
DM23CEI	DN	3,8-dibromoboldine
DM23CEI	MI	TTEX248
DM23CEI	MN	Dopamine D2 receptor (D2R)
DM23CEI	MT	DTT
DM23CEI	MA	Inhibitor
DM23CEI	RN	Halogenated boldine derivatives with enhanced monoamine receptor selectivity. J Nat Prod. 2000 Apr;63(4):480-4.
DM23CEI	RU	https://pubmed.ncbi.nlm.nih.gov/10785418

DM23CEI	DI	DM23CEI
DM23CEI	DN	3,8-dibromoboldine
DM23CEI	MI	TTLA931
DM23CEI	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DM23CEI	MT	DTT
DM23CEI	MA	Inhibitor
DM23CEI	RN	Aporphine metho salts as neuronal nicotinic acetylcholine receptor blockers. Bioorg Med Chem. 2007 May 15;15(10):3368-72.
DM23CEI	RU	https://pubmed.ncbi.nlm.nih.gov/17391965

DMIFJRS	DI	DMIFJRS
DMIFJRS	DN	3,8-dihydroxy-4-methyl-6H-benzo[c]chromen-6-one
DMIFJRS	MI	TTZAYWL
DMIFJRS	MN	Estrogen receptor (ESR)
DMIFJRS	MT	DTT
DMIFJRS	MA	Inhibitor
DMIFJRS	RN	6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72.
DMIFJRS	RU	https://pubmed.ncbi.nlm.nih.gov/16412638

DMIFJRS	DI	DMIFJRS
DMIFJRS	DN	3,8-dihydroxy-4-methyl-6H-benzo[c]chromen-6-one
DMIFJRS	MI	TTOM3J0
DMIFJRS	MN	Estrogen receptor beta (ESR2)
DMIFJRS	MT	DTT
DMIFJRS	MA	Inhibitor
DMIFJRS	RN	6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72.
DMIFJRS	RU	https://pubmed.ncbi.nlm.nih.gov/16412638

DMW0B4H	DI	DMW0B4H
DMW0B4H	DN	3,8-dihydroxy-7-methyl-6H-benzo[c]chromen-6-one
DMW0B4H	MI	TTZAYWL
DMW0B4H	MN	Estrogen receptor (ESR)
DMW0B4H	MT	DTT
DMW0B4H	MA	Inhibitor
DMW0B4H	RN	6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72.
DMW0B4H	RU	https://pubmed.ncbi.nlm.nih.gov/16412638

DMW0B4H	DI	DMW0B4H
DMW0B4H	DN	3,8-dihydroxy-7-methyl-6H-benzo[c]chromen-6-one
DMW0B4H	MI	TTOM3J0
DMW0B4H	MN	Estrogen receptor beta (ESR2)
DMW0B4H	MT	DTT
DMW0B4H	MA	Inhibitor
DMW0B4H	RN	6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72.
DMW0B4H	RU	https://pubmed.ncbi.nlm.nih.gov/16412638

DMXZ8RJ	DI	DMXZ8RJ
DMXZ8RJ	DN	3,9-dihydroxy-2,10-diprenylpterocap-6a-ene
DMXZ8RJ	MI	TT9V5JH
DMXZ8RJ	MN	Phospholipase A2 (PLA2G1B)
DMXZ8RJ	MT	DTT
DMXZ8RJ	MA	Inhibitor
DMXZ8RJ	RN	Phospholipase A2 Inhibitors from an Erythrina Species from Samoa J. Nat. Prod. 60(6):537-539 (1997).
DMXZ8RJ	RU	http://pubs.acs.org/doi/abs/10.1021/np960533e

DMK53AT	DI	DMK53AT
DMK53AT	DN	3,9-Dihydroxy-4-prenyl-[6aR,11aR]pterocarpan
DMK53AT	MI	TTELIN2
DMK53AT	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMK53AT	MT	DTT
DMK53AT	MA	Inhibitor
DMK53AT	RN	Cytotoxic and PTP1B inhibitory activities from Erythrina abyssinica. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6745-9.
DMK53AT	RU	https://pubmed.ncbi.nlm.nih.gov/19836230

DMLSET4	DI	DMLSET4
DMLSET4	DN	3-[(1-carboxy-4-mercaptobutyl)thio]benzoic acid
DMLSET4	MI	TT9G4N0
DMLSET4	MN	Glutamate carboxypeptidase II (GCPII)
DMLSET4	MT	DTT
DMLSET4	MA	Inhibitor
DMLSET4	RN	Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1' side chain. J Med Chem. 2006 May 18;49(10):2876-85.
DMLSET4	RU	https://pubmed.ncbi.nlm.nih.gov/16686531

DM2KXFS	DI	DM2KXFS
DM2KXFS	DN	3-[(1s)-1-(Dimethylamino)Ethyl]Phenol
DM2KXFS	MI	TT1RS9F
DM2KXFS	MN	Acetylcholinesterase (AChE)
DM2KXFS	MT	DTT
DM2KXFS	MA	Inhibitor
DM2KXFS	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM2KXFS	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMBAHRJ	DI	DMBAHRJ
DMBAHRJ	DN	3-[(2,5-dimethyl-4-thiazolyl)ethynyl]pyridine
DMBAHRJ	MI	TTHS256
DMBAHRJ	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMBAHRJ	MT	DTT
DMBAHRJ	MA	Inhibitor
DMBAHRJ	RN	Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100.
DMBAHRJ	RU	https://pubmed.ncbi.nlm.nih.gov/16451073

DMZ78WB	DI	DMZ78WB
DMZ78WB	DN	3-[(2-methyl-4-thiazolyl)ethynyl]-5-vinylpyridine
DMZ78WB	MI	TTHS256
DMZ78WB	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMZ78WB	MT	DTT
DMZ78WB	MA	Inhibitor
DMZ78WB	RN	Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100.
DMZ78WB	RU	https://pubmed.ncbi.nlm.nih.gov/16451073

DMMLDOZ	DI	DMMLDOZ
DMMLDOZ	DN	3-[(2-methyl-4-thiazolyl)ethynyl]benzamide
DMMLDOZ	MI	TTHS256
DMMLDOZ	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMMLDOZ	MT	DTT
DMMLDOZ	MA	Inhibitor
DMMLDOZ	RN	Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100.
DMMLDOZ	RU	https://pubmed.ncbi.nlm.nih.gov/16451073

DMQUDR1	DI	DMQUDR1
DMQUDR1	DN	3-[(2-methyl-4-thiazolyl)ethynyl]benzonitrile
DMQUDR1	MI	TTHS256
DMQUDR1	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMQUDR1	MT	DTT
DMQUDR1	MA	Inhibitor
DMQUDR1	RN	Discovery of novel modulators of metabotropic glutamate receptor subtype-5. Bioorg Med Chem. 2004 Jan 2;12(1):17-21.
DMQUDR1	RU	https://pubmed.ncbi.nlm.nih.gov/14697765

DMF0QM2	DI	DMF0QM2
DMF0QM2	DN	3-[(2-methyl-4-thiazolyl)ethynyl]phenol
DMF0QM2	MI	TTHS256
DMF0QM2	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMF0QM2	MT	DTT
DMF0QM2	MA	Inhibitor
DMF0QM2	RN	Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100.
DMF0QM2	RU	https://pubmed.ncbi.nlm.nih.gov/16451073

DMHISM2	DI	DMHISM2
DMHISM2	DN	3-[(4'-Hydroxybiphenyl-4-yl)methyl]pyridine
DMHISM2	MI	TTRA5BZ
DMHISM2	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMHISM2	MT	DTT
DMHISM2	MA	Inhibitor
DMHISM2	RN	Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
DMHISM2	RU	https://pubmed.ncbi.nlm.nih.gov/20684610

DM9OI2R	DI	DM9OI2R
DM9OI2R	DN	3-[(5-ethyl-2-methyl-4-thiazolyl)ethynyl]pyridine
DM9OI2R	MI	TTHS256
DM9OI2R	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM9OI2R	MT	DTT
DM9OI2R	MA	Inhibitor
DM9OI2R	RN	Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100.
DM9OI2R	RU	https://pubmed.ncbi.nlm.nih.gov/16451073

DMH5329	DI	DMH5329
DMH5329	DN	3-[(6-Methylpyridin-2-yl)ethynyl]benzonitrile
DMH5329	MI	TTHS256
DMH5329	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMH5329	MT	DTT
DMH5329	MA	Inhibitor
DMH5329	RN	Structure-activity relationships comparing N-(6-methylpyridin-yl)-substituted aryl amides to 2-methyl-6-(substituted-arylethynyl)pyridines or 2-met... J Med Chem. 2009 Jun 11;52(11):3563-75.
DMH5329	RU	https://pubmed.ncbi.nlm.nih.gov/19445453

DMNPKZ6	DI	DMNPKZ6
DMNPKZ6	DN	3-[(Z)-2-phenylvinyl]pyridine
DMNPKZ6	MI	TTIQUX7
DMNPKZ6	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMNPKZ6	MT	DTT
DMNPKZ6	MA	Inhibitor
DMNPKZ6	RN	Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31.
DMNPKZ6	RU	https://pubmed.ncbi.nlm.nih.gov/16570918

DM7URMW	DI	DM7URMW
DM7URMW	DN	3-[1-(4-Bromobenzyl)-1H-imidazol-5-yl]-1-propanol
DM7URMW	MI	TTIQUX7
DM7URMW	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM7URMW	MT	DTT
DM7URMW	MA	Inhibitor
DM7URMW	RN	Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25.
DM7URMW	RU	https://pubmed.ncbi.nlm.nih.gov/20121113

DM63IKF	DI	DM63IKF
DM63IKF	DN	3-[1-(4-Cyanobenzyl)-1H-imidazol-5-yl]-1-propanol
DM63IKF	MI	TTIQUX7
DM63IKF	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM63IKF	MT	DTT
DM63IKF	MA	Inhibitor
DM63IKF	RN	Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25.
DM63IKF	RU	https://pubmed.ncbi.nlm.nih.gov/20121113

DMIHWAJ	DI	DMIHWAJ
DMIHWAJ	DN	3-[1'-{4'-(Benzyloxy)-phenyl}]-quinuclidine-2-ene
DMIHWAJ	MI	TTFQEO5
DMIHWAJ	MN	Squalene synthetase (FDFT1)
DMIHWAJ	MT	DTT
DMIHWAJ	MA	Inhibitor
DMIHWAJ	RN	Quinuclidine derivatives as potential antiparasitics. Antimicrob Agents Chemother. 2007 Nov;51(11):4049-61.
DMIHWAJ	RU	https://pubmed.ncbi.nlm.nih.gov/17709461

DMBHUP3	DI	DMBHUP3
DMBHUP3	DN	3-[10-(benzylmethylamino)decyloxy]xanthen-9-one
DMBHUP3	MI	TTEB0GD
DMBHUP3	MN	Cholinesterase (BCHE)
DMBHUP3	MT	DTT
DMBHUP3	MA	Inhibitor
DMBHUP3	RN	Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[omega-(benzylmethylamino)alkoxy]xanthen-9-ones. Bioorg Med Chem. 2007 Jan 1;15(1):575-85.
DMBHUP3	RU	https://pubmed.ncbi.nlm.nih.gov/17008100

DM287UO	DI	DM287UO
DM287UO	DN	3-[11-(benzylmethylamino)undecyloxy]xanthen-9-one
DM287UO	MI	TTEB0GD
DM287UO	MN	Cholinesterase (BCHE)
DM287UO	MT	DTT
DM287UO	MA	Inhibitor
DM287UO	RN	Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[omega-(benzylmethylamino)alkoxy]xanthen-9-ones. Bioorg Med Chem. 2007 Jan 1;15(1):575-85.
DM287UO	RU	https://pubmed.ncbi.nlm.nih.gov/17008100

DM9KVHQ	DI	DM9KVHQ
DM9KVHQ	DN	3-[12-(benzylmethylamino)dodecyloxy]xanthen-9-one
DM9KVHQ	MI	TTEB0GD
DM9KVHQ	MN	Cholinesterase (BCHE)
DM9KVHQ	MT	DTT
DM9KVHQ	MA	Inhibitor
DM9KVHQ	RN	Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[omega-(benzylmethylamino)alkoxy]xanthen-9-ones. Bioorg Med Chem. 2007 Jan 1;15(1):575-85.
DM9KVHQ	RU	https://pubmed.ncbi.nlm.nih.gov/17008100

DMPTI1Z	DI	DMPTI1Z
DMPTI1Z	DN	3-[1-ethyl-2-(3-hydroxyphenyl)butyl]phenol
DMPTI1Z	MI	TTZAYWL
DMPTI1Z	MN	Estrogen receptor (ESR)
DMPTI1Z	MT	DTT
DMPTI1Z	MA	Inhibitor
DMPTI1Z	RN	Influence of alkyl chain ramification on estradiol receptor binding affinity and intrinsic activity of 1,2-dialkylated 1,2-bis(4- or 3-hydroxypheny... J Med Chem. 1986 Sep;29(9):1668-74.
DMPTI1Z	RU	https://pubmed.ncbi.nlm.nih.gov/3018243

DMPTI1Z	DI	DMPTI1Z
DMPTI1Z	DN	3-[1-ethyl-2-(3-hydroxyphenyl)butyl]phenol
DMPTI1Z	MI	TTOM3J0
DMPTI1Z	MN	Estrogen receptor beta (ESR2)
DMPTI1Z	MT	DTT
DMPTI1Z	MA	Inhibitor
DMPTI1Z	RN	Influence of alkyl chain ramification on estradiol receptor binding affinity and intrinsic activity of 1,2-dialkylated 1,2-bis(4- or 3-hydroxypheny... J Med Chem. 1986 Sep;29(9):1668-74.
DMPTI1Z	RU	https://pubmed.ncbi.nlm.nih.gov/3018243

DME1UNY	DI	DME1UNY
DME1UNY	DN	3-[2-(1-Benzyl-piperidin-4-yl)-ethyl]-1H-indazole
DME1UNY	MI	TT1RS9F
DME1UNY	MN	Acetylcholinesterase (AChE)
DME1UNY	MT	DTT
DME1UNY	MA	Inhibitor
DME1UNY	RN	A docking score function for estimating ligand-protein interactions: application to acetylcholinesterase inhibition. J Med Chem. 2004 Oct 21;47(22):5492-500.
DME1UNY	RU	https://pubmed.ncbi.nlm.nih.gov/15481986

DMXE1LC	DI	DMXE1LC
DMXE1LC	DN	3-[2-(3,5-Dimethoxy-phenyl)-vinyl]-furan
DMXE1LC	MI	TTI84H7
DMXE1LC	MN	Cytochrome P450 1B1 (CYP1B1)
DMXE1LC	MT	DTT
DMXE1LC	MA	Inhibitor
DMXE1LC	RN	Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors. J Med Chem. 2002 Jan 3;45(1):160-4.
DMXE1LC	RU	https://pubmed.ncbi.nlm.nih.gov/11754588

DM5EJLD	DI	DM5EJLD
DM5EJLD	DN	3-[2-(5-Chloro-2-thienyl)pyridin-4-yl]phenol
DM5EJLD	MI	TTIWB6L
DM5EJLD	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DM5EJLD	MT	DTT
DM5EJLD	MA	Inhibitor
DM5EJLD	RN	Novel estrone mimetics with high 17beta-HSD1 inhibitory activity. Bioorg Med Chem. 2010 May 15;18(10):3494-505.
DM5EJLD	RU	https://pubmed.ncbi.nlm.nih.gov/20413314

DMJB1KL	DI	DMJB1KL
DMJB1KL	DN	3-[2-(N,N,N-trimethylammonium)ethoxy]pyridine
DMJB1KL	MI	TT4H1MQ
DMJB1KL	MN	Neuronal acetylcholine receptor alpha-4 (CHRNA4)
DMJB1KL	MT	DTT
DMJB1KL	MA	Inhibitor
DMJB1KL	RN	Aryloxyethylamines: binding at alpha7 nicotinic acetylcholine receptors. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4283-6.
DMJB1KL	RU	https://pubmed.ncbi.nlm.nih.gov/16765047

DMJB1KL	DI	DMJB1KL
DMJB1KL	DN	3-[2-(N,N,N-trimethylammonium)ethoxy]pyridine
DMJB1KL	MI	TT5KPZR
DMJB1KL	MN	Neuronal acetylcholine receptor beta-2 (CHRNB2)
DMJB1KL	MT	DTT
DMJB1KL	MA	Inhibitor
DMJB1KL	RN	Aryloxyethylamines: binding at alpha7 nicotinic acetylcholine receptors. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4283-6.
DMJB1KL	RU	https://pubmed.ncbi.nlm.nih.gov/16765047

DMLX9SI	DI	DMLX9SI
DMLX9SI	DN	3-[3-(2-Hydroxy-ethoxy)-phenyl]-1H-quinolin-2-one
DMLX9SI	MI	TTSFWA7
DMLX9SI	MN	Plasmodium CDK Pfmrk (Malaria Pfmrk)
DMLX9SI	MT	DTT
DMLX9SI	MA	Inhibitor
DMLX9SI	RN	A three-dimensional in silico pharmacophore model for inhibition of Plasmodium falciparum cyclin-dependent kinases and discovery of different class... J Med Chem. 2004 Oct 21;47(22):5418-26.
DMLX9SI	RU	https://pubmed.ncbi.nlm.nih.gov/15481979

DM60YGF	DI	DM60YGF
DM60YGF	DN	3-[3-(3-benzyloxy-pyridin-2-yl)-ureido]-benzamide
DM60YGF	MI	TTL2ADK
DM60YGF	MN	Rotamase A (PPIA)
DM60YGF	MT	DTT
DM60YGF	MA	Inhibitor
DM60YGF	RN	Structure-based design, synthesis, and biological evaluation of novel inhibitors of human cyclophilin A. J Med Chem. 2006 Feb 9;49(3):900-10.
DM60YGF	RU	https://pubmed.ncbi.nlm.nih.gov/16451056

DMNC6W9	DI	DMNC6W9
DMNC6W9	DN	3-[3-(4-hydroxyphenyl)isoxazol-5-yl]phenol
DMNC6W9	MI	TTIWB6L
DMNC6W9	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMNC6W9	MT	DTT
DMNC6W9	MA	Inhibitor
DMNC6W9	RN	Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid ... Bioorg Med Chem. 2008 Jun 15;16(12):6423-35.
DMNC6W9	RU	https://pubmed.ncbi.nlm.nih.gov/18514529

DMTLJMF	DI	DMTLJMF
DMTLJMF	DN	3-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine
DMTLJMF	MI	TTXV4FI
DMTLJMF	MN	Albendazole monooxygenase (CYP3A4)
DMTLJMF	MT	DTT
DMTLJMF	MA	Inhibitor
DMTLJMF	RN	Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):333-6.
DMTLJMF	RU	https://pubmed.ncbi.nlm.nih.gov/14698153

DMTLJMF	DI	DMTLJMF
DMTLJMF	DN	3-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine
DMTLJMF	MI	TTVG215
DMTLJMF	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DMTLJMF	MT	DTT
DMTLJMF	MA	Inhibitor
DMTLJMF	RN	Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):333-6.
DMTLJMF	RU	https://pubmed.ncbi.nlm.nih.gov/14698153

DM8NRJQ	DI	DM8NRJQ
DM8NRJQ	DN	3-[3-(4-Methoxybenzyl)naphthalen-2-yl]pyridine
DM8NRJQ	MI	TTXV4FI
DM8NRJQ	MN	Albendazole monooxygenase (CYP3A4)
DM8NRJQ	MT	DTT
DM8NRJQ	MA	Inhibitor
DM8NRJQ	RN	Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach. J Med Chem. 2008 Oct 9;51(19):6138-49.
DM8NRJQ	RU	https://pubmed.ncbi.nlm.nih.gov/18763754

DM8NRJQ	DI	DM8NRJQ
DM8NRJQ	DN	3-[3-(4-Methoxybenzyl)naphthalen-2-yl]pyridine
DM8NRJQ	MI	TTIQUX7
DM8NRJQ	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM8NRJQ	MT	DTT
DM8NRJQ	MA	Inhibitor
DM8NRJQ	RN	Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach. J Med Chem. 2008 Oct 9;51(19):6138-49.
DM8NRJQ	RU	https://pubmed.ncbi.nlm.nih.gov/18763754

DMPVXTB	DI	DMPVXTB
DMPVXTB	DN	3-[3-(benzylmethylamino)propoxy]xanthen-9-one
DMPVXTB	MI	TT1RS9F
DMPVXTB	MN	Acetylcholinesterase (AChE)
DMPVXTB	MT	DTT
DMPVXTB	MA	Inhibitor
DMPVXTB	RN	Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[omega-(benzylmethylamino)alkoxy]xanthen-9-ones. Bioorg Med Chem. 2007 Jan 1;15(1):575-85.
DMPVXTB	RU	https://pubmed.ncbi.nlm.nih.gov/17008100

DMPVXTB	DI	DMPVXTB
DMPVXTB	DN	3-[3-(benzylmethylamino)propoxy]xanthen-9-one
DMPVXTB	MI	TTEB0GD
DMPVXTB	MN	Cholinesterase (BCHE)
DMPVXTB	MT	DTT
DMPVXTB	MA	Inhibitor
DMPVXTB	RN	Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[omega-(benzylmethylamino)alkoxy]xanthen-9-ones. Bioorg Med Chem. 2007 Jan 1;15(1):575-85.
DMPVXTB	RU	https://pubmed.ncbi.nlm.nih.gov/17008100

DMDS8UJ	DI	DMDS8UJ
DMDS8UJ	DN	3-[3-Methyl-indan-(1E)-ylidenemethyl]-pyridine
DMDS8UJ	MI	TTSZLWK
DMDS8UJ	MN	Aromatase (CYP19A1)
DMDS8UJ	MT	DTT
DMDS8UJ	MA	Inhibitor
DMDS8UJ	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMDS8UJ	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMTF520	DI	DMTF520
DMTF520	DN	3-[3-Methyl-indan-(1Z)-ylidenemethyl]-pyridine
DMTF520	MI	TTSZLWK
DMTF520	MN	Aromatase (CYP19A1)
DMTF520	MT	DTT
DMTF520	MA	Inhibitor
DMTF520	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMTF520	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMYEWA4	DI	DMYEWA4
DMYEWA4	DN	3-[3-Phenyl-indan-(1E)-ylidenemethyl]-pyridine
DMYEWA4	MI	TTSZLWK
DMYEWA4	MN	Aromatase (CYP19A1)
DMYEWA4	MT	DTT
DMYEWA4	MA	Inhibitor
DMYEWA4	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMYEWA4	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DME86OK	DI	DME86OK
DME86OK	DN	3-[4-(4-Fluoro-phenoxy)-phenyl]-1H-pyrazole
DME86OK	MI	TT84DRB
DME86OK	MN	Voltage-gated sodium channel alpha Nav1.4 (SCN4A)
DME86OK	MT	DTT
DME86OK	MA	Inhibitor
DME86OK	RN	3-(4-phenoxyphenyl)pyrazoles: a novel class of sodium channel blockers. J Med Chem. 2004 Mar 11;47(6):1547-52.
DME86OK	RU	https://pubmed.ncbi.nlm.nih.gov/14998340

DMIM5WE	DI	DMIM5WE
DMIM5WE	DN	3-[4-(4-Hydroxyphenyl)-1,3-oxazol-2-yl]phenol
DMIM5WE	MI	TTIWB6L
DMIM5WE	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMIM5WE	MT	DTT
DMIM5WE	MA	Inhibitor
DMIM5WE	RN	Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid ... Bioorg Med Chem. 2008 Jun 15;16(12):6423-35.
DMIM5WE	RU	https://pubmed.ncbi.nlm.nih.gov/18514529

DM75F1Q	DI	DM75F1Q
DM75F1Q	DN	3-[4-(4-phenoxybenzoyl)phenyl]propanoic acid
DM75F1Q	MI	TTT02K8
DM75F1Q	MN	Steroid 5-alpha-reductase 2 (SRD5A2)
DM75F1Q	MT	DTT
DM75F1Q	MA	Inhibitor
DM75F1Q	RN	Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J Med Chem. 2006 Jan 26;49(2):748-59.
DM75F1Q	RU	https://pubmed.ncbi.nlm.nih.gov/16420060

DMZCO83	DI	DMZCO83
DMZCO83	DN	3-[4-(5-Chloro-2-thienyl)pyridin-2-yl]phenol
DMZCO83	MI	TTIWB6L
DMZCO83	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMZCO83	MT	DTT
DMZCO83	MA	Inhibitor
DMZCO83	RN	Novel estrone mimetics with high 17beta-HSD1 inhibitory activity. Bioorg Med Chem. 2010 May 15;18(10):3494-505.
DMZCO83	RU	https://pubmed.ncbi.nlm.nih.gov/20413314

DMZPULH	DI	DMZPULH
DMZPULH	DN	3-[4-(benzylmethylamino)butoxy]xanthen-9-one
DMZPULH	MI	TT1RS9F
DMZPULH	MN	Acetylcholinesterase (AChE)
DMZPULH	MT	DTT
DMZPULH	MA	Inhibitor
DMZPULH	RN	Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[omega-(benzylmethylamino)alkoxy]xanthen-9-ones. Bioorg Med Chem. 2007 Jan 1;15(1):575-85.
DMZPULH	RU	https://pubmed.ncbi.nlm.nih.gov/17008100

DMZPULH	DI	DMZPULH
DMZPULH	DN	3-[4-(benzylmethylamino)butoxy]xanthen-9-one
DMZPULH	MI	TTEB0GD
DMZPULH	MN	Cholinesterase (BCHE)
DMZPULH	MT	DTT
DMZPULH	MA	Inhibitor
DMZPULH	RN	Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[omega-(benzylmethylamino)alkoxy]xanthen-9-ones. Bioorg Med Chem. 2007 Jan 1;15(1):575-85.
DMZPULH	RU	https://pubmed.ncbi.nlm.nih.gov/17008100

DM0XD6T	DI	DM0XD6T
DM0XD6T	DN	3-[4-Chloro-indan-(1E)-ylidenemethyl]-pyridine
DM0XD6T	MI	TTSZLWK
DM0XD6T	MN	Aromatase (CYP19A1)
DM0XD6T	MT	DTT
DM0XD6T	MA	Inhibitor
DM0XD6T	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DM0XD6T	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DM0XD6T	DI	DM0XD6T
DM0XD6T	DN	3-[4-Chloro-indan-(1E)-ylidenemethyl]-pyridine
DM0XD6T	MI	TTIQUX7
DM0XD6T	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM0XD6T	MT	DTT
DM0XD6T	MA	Inhibitor
DM0XD6T	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DM0XD6T	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMMDIB9	DI	DMMDIB9
DMMDIB9	DN	3-[4-Chloro-indan-(1Z)-ylidenemethyl]-pyridine
DMMDIB9	MI	TTSZLWK
DMMDIB9	MN	Aromatase (CYP19A1)
DMMDIB9	MT	DTT
DMMDIB9	MA	Inhibitor
DMMDIB9	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMMDIB9	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMMDIB9	DI	DMMDIB9
DMMDIB9	DN	3-[4-Chloro-indan-(1Z)-ylidenemethyl]-pyridine
DMMDIB9	MI	TTIQUX7
DMMDIB9	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMMDIB9	MT	DTT
DMMDIB9	MA	Inhibitor
DMMDIB9	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMMDIB9	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMZS20Y	DI	DMZS20Y
DMZS20Y	DN	3-[4-Fluoro-indan-(1E)-ylidenemethyl]-pyridine
DMZS20Y	MI	TTSZLWK
DMZS20Y	MN	Aromatase (CYP19A1)
DMZS20Y	MT	DTT
DMZS20Y	MA	Inhibitor
DMZS20Y	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMZS20Y	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMZS20Y	DI	DMZS20Y
DMZS20Y	DN	3-[4-Fluoro-indan-(1E)-ylidenemethyl]-pyridine
DMZS20Y	MI	TTIQUX7
DMZS20Y	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMZS20Y	MT	DTT
DMZS20Y	MA	Inhibitor
DMZS20Y	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMZS20Y	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMPS340	DI	DMPS340
DMPS340	DN	3-[4-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine
DMPS340	MI	TTSZLWK
DMPS340	MN	Aromatase (CYP19A1)
DMPS340	MT	DTT
DMPS340	MA	Inhibitor
DMPS340	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMPS340	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMPS340	DI	DMPS340
DMPS340	DN	3-[4-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine
DMPS340	MI	TTRA5BZ
DMPS340	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMPS340	MT	DTT
DMPS340	MA	Inhibitor
DMPS340	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMPS340	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMJN93U	DI	DMJN93U
DMJN93U	DN	3-[4-Methyl-indan-(1E)-ylidenemethyl]-pyridine
DMJN93U	MI	TTSZLWK
DMJN93U	MN	Aromatase (CYP19A1)
DMJN93U	MT	DTT
DMJN93U	MA	Inhibitor
DMJN93U	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMJN93U	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMJN93U	DI	DMJN93U
DMJN93U	DN	3-[4-Methyl-indan-(1E)-ylidenemethyl]-pyridine
DMJN93U	MI	TTIQUX7
DMJN93U	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMJN93U	MT	DTT
DMJN93U	MA	Inhibitor
DMJN93U	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMJN93U	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMNILXG	DI	DMNILXG
DMNILXG	DN	3-[4-Methyl-indan-(1Z)-ylidenemethyl]-pyridine
DMNILXG	MI	TTSZLWK
DMNILXG	MN	Aromatase (CYP19A1)
DMNILXG	MT	DTT
DMNILXG	MA	Inhibitor
DMNILXG	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMNILXG	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMYZIG3	DI	DMYZIG3
DMYZIG3	DN	3-[5-(3,4-Difluorophenyl)-2-thienyl]phenol
DMYZIG3	MI	TTIWB6L
DMYZIG3	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMYZIG3	MT	DTT
DMYZIG3	MA	Inhibitor
DMYZIG3	RN	New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43.
DMYZIG3	RU	https://pubmed.ncbi.nlm.nih.gov/19831396

DMD5QOW	DI	DMD5QOW
DMD5QOW	DN	3-[5-(3-Fluorophenyl)-2-thienyl]phenol
DMD5QOW	MI	TTIWB6L
DMD5QOW	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMD5QOW	MT	DTT
DMD5QOW	MA	Inhibitor
DMD5QOW	RN	New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43.
DMD5QOW	RU	https://pubmed.ncbi.nlm.nih.gov/19831396

DM1QKNU	DI	DM1QKNU
DM1QKNU	DN	3-[5-(3-nitrophenyl)thiophen-2-yl]propanoic acid
DM1QKNU	MI	TTFBNVI
DM1QKNU	MN	Aldose reductase (AKR1B1)
DM1QKNU	MT	DTT
DM1QKNU	MA	Inhibitor
DM1QKNU	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM1QKNU	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMYZ2U0	DI	DMYZ2U0
DMYZ2U0	DN	3-[5-(4-Fluorophenyl)-2-thienyl]phenol
DMYZ2U0	MI	TTIWB6L
DMYZ2U0	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMYZ2U0	MT	DTT
DMYZ2U0	MA	Inhibitor
DMYZ2U0	RN	New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43.
DMYZ2U0	RU	https://pubmed.ncbi.nlm.nih.gov/19831396

DM4TFMA	DI	DM4TFMA
DM4TFMA	DN	3-[5-(4-hydroxyphenyl)-1,3-oxazol-2-yl]phenol
DM4TFMA	MI	TTIWB6L
DM4TFMA	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DM4TFMA	MT	DTT
DM4TFMA	MA	Inhibitor
DM4TFMA	RN	Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as p... J Med Chem. 2008 Nov 13;51(21):6725-39.
DM4TFMA	RU	https://pubmed.ncbi.nlm.nih.gov/18855374

DM2IXO0	DI	DM2IXO0
DM2IXO0	DN	3-[5-(4-hydroxyphenyl)-1,3-thiazol-2-yl]phenol
DM2IXO0	MI	TTIWB6L
DM2IXO0	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DM2IXO0	MT	DTT
DM2IXO0	MA	Inhibitor
DM2IXO0	RN	New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43.
DM2IXO0	RU	https://pubmed.ncbi.nlm.nih.gov/19831396

DMAMOJE	DI	DMAMOJE
DMAMOJE	DN	3-[5-(4-Hydroxyphenyl)-2-thienyl]-5-methylphenol
DMAMOJE	MI	TTIWB6L
DMAMOJE	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMAMOJE	MT	DTT
DMAMOJE	MA	Inhibitor
DMAMOJE	RN	New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43.
DMAMOJE	RU	https://pubmed.ncbi.nlm.nih.gov/19831396

DMSFW9T	DI	DMSFW9T
DMSFW9T	DN	3-[5-(4-hydroxyphenyl)-2-thienyl]phenol
DMSFW9T	MI	TTIWB6L
DMSFW9T	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMSFW9T	MT	DTT
DMSFW9T	MA	Inhibitor
DMSFW9T	RN	New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43.
DMSFW9T	RU	https://pubmed.ncbi.nlm.nih.gov/19831396

DM40GJ8	DI	DM40GJ8
DM40GJ8	DN	3-[5-(4-Hydroxyphenyl)-3-thienyl]phenol
DM40GJ8	MI	TTXV4FI
DM40GJ8	MN	Albendazole monooxygenase (CYP3A4)
DM40GJ8	MT	DTT
DM40GJ8	MA	Inhibitor
DM40GJ8	RN	Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as p... J Med Chem. 2008 Nov 13;51(21):6725-39.
DM40GJ8	RU	https://pubmed.ncbi.nlm.nih.gov/18855374

DM40GJ8	DI	DM40GJ8
DM40GJ8	DN	3-[5-(4-Hydroxyphenyl)-3-thienyl]phenol
DM40GJ8	MI	TTIWB6L
DM40GJ8	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DM40GJ8	MT	DTT
DM40GJ8	MA	Inhibitor
DM40GJ8	RN	Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as p... J Med Chem. 2008 Nov 13;51(21):6725-39.
DM40GJ8	RU	https://pubmed.ncbi.nlm.nih.gov/18855374

DMQZ0A7	DI	DMQZ0A7
DMQZ0A7	DN	3-[5-(benzylmethylamino)pentyloxy]xanthen-9-one
DMQZ0A7	MI	TT1RS9F
DMQZ0A7	MN	Acetylcholinesterase (AChE)
DMQZ0A7	MT	DTT
DMQZ0A7	MA	Inhibitor
DMQZ0A7	RN	Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[omega-(benzylmethylamino)alkoxy]xanthen-9-ones. Bioorg Med Chem. 2007 Jan 1;15(1):575-85.
DMQZ0A7	RU	https://pubmed.ncbi.nlm.nih.gov/17008100

DMQZ0A7	DI	DMQZ0A7
DMQZ0A7	DN	3-[5-(benzylmethylamino)pentyloxy]xanthen-9-one
DMQZ0A7	MI	TTEB0GD
DMQZ0A7	MN	Cholinesterase (BCHE)
DMQZ0A7	MT	DTT
DMQZ0A7	MA	Inhibitor
DMQZ0A7	RN	Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[omega-(benzylmethylamino)alkoxy]xanthen-9-ones. Bioorg Med Chem. 2007 Jan 1;15(1):575-85.
DMQZ0A7	RU	https://pubmed.ncbi.nlm.nih.gov/17008100

DMUEVAQ	DI	DMUEVAQ
DMUEVAQ	DN	3-[5-Bromo-indan-(1E)-ylidenemethyl]-pyridine
DMUEVAQ	MI	TTSZLWK
DMUEVAQ	MN	Aromatase (CYP19A1)
DMUEVAQ	MT	DTT
DMUEVAQ	MA	Inhibitor
DMUEVAQ	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMUEVAQ	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMUEVAQ	DI	DMUEVAQ
DMUEVAQ	DN	3-[5-Bromo-indan-(1E)-ylidenemethyl]-pyridine
DMUEVAQ	MI	TTIQUX7
DMUEVAQ	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMUEVAQ	MT	DTT
DMUEVAQ	MA	Inhibitor
DMUEVAQ	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMUEVAQ	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMCXSIH	DI	DMCXSIH
DMCXSIH	DN	3-[5-Bromo-indan-(1Z)-ylidenemethyl]-pyridine
DMCXSIH	MI	TTSZLWK
DMCXSIH	MN	Aromatase (CYP19A1)
DMCXSIH	MT	DTT
DMCXSIH	MA	Inhibitor
DMCXSIH	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMCXSIH	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMCXSIH	DI	DMCXSIH
DMCXSIH	DN	3-[5-Bromo-indan-(1Z)-ylidenemethyl]-pyridine
DMCXSIH	MI	TTIQUX7
DMCXSIH	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMCXSIH	MT	DTT
DMCXSIH	MA	Inhibitor
DMCXSIH	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMCXSIH	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DM8TWLO	DI	DM8TWLO
DM8TWLO	DN	3-[5-Chloro-indan-(1E)-ylidenemethyl]-pyridine
DM8TWLO	MI	TTSZLWK
DM8TWLO	MN	Aromatase (CYP19A1)
DM8TWLO	MT	DTT
DM8TWLO	MA	Inhibitor
DM8TWLO	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DM8TWLO	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DM8TWLO	DI	DM8TWLO
DM8TWLO	DN	3-[5-Chloro-indan-(1E)-ylidenemethyl]-pyridine
DM8TWLO	MI	TTIQUX7
DM8TWLO	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM8TWLO	MT	DTT
DM8TWLO	MA	Inhibitor
DM8TWLO	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DM8TWLO	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMN60YG	DI	DMN60YG
DMN60YG	DN	3-[5-Chloro-indan-(1Z)-ylidenemethyl]-pyridine
DMN60YG	MI	TTSZLWK
DMN60YG	MN	Aromatase (CYP19A1)
DMN60YG	MT	DTT
DMN60YG	MA	Inhibitor
DMN60YG	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMN60YG	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMN60YG	DI	DMN60YG
DMN60YG	DN	3-[5-Chloro-indan-(1Z)-ylidenemethyl]-pyridine
DMN60YG	MI	TTIQUX7
DMN60YG	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMN60YG	MT	DTT
DMN60YG	MA	Inhibitor
DMN60YG	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMN60YG	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMLJQZS	DI	DMLJQZS
DMLJQZS	DN	3-[5-Ethoxy-indan-(1E)-ylidenemethyl]-pyridine
DMLJQZS	MI	TTSZLWK
DMLJQZS	MN	Aromatase (CYP19A1)
DMLJQZS	MT	DTT
DMLJQZS	MA	Inhibitor
DMLJQZS	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMLJQZS	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMLJQZS	DI	DMLJQZS
DMLJQZS	DN	3-[5-Ethoxy-indan-(1E)-ylidenemethyl]-pyridine
DMLJQZS	MI	TTIQUX7
DMLJQZS	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMLJQZS	MT	DTT
DMLJQZS	MA	Inhibitor
DMLJQZS	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMLJQZS	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMMTUON	DI	DMMTUON
DMMTUON	DN	3-[5-Ethoxy-indan-(1Z)-ylidenemethyl]-pyridine
DMMTUON	MI	TTSZLWK
DMMTUON	MN	Aromatase (CYP19A1)
DMMTUON	MT	DTT
DMMTUON	MA	Inhibitor
DMMTUON	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMMTUON	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMMTUON	DI	DMMTUON
DMMTUON	DN	3-[5-Ethoxy-indan-(1Z)-ylidenemethyl]-pyridine
DMMTUON	MI	TTIQUX7
DMMTUON	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMMTUON	MT	DTT
DMMTUON	MA	Inhibitor
DMMTUON	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMMTUON	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMWSFIR	DI	DMWSFIR
DMWSFIR	DN	3-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyridine
DMWSFIR	MI	TTSZLWK
DMWSFIR	MN	Aromatase (CYP19A1)
DMWSFIR	MT	DTT
DMWSFIR	MA	Inhibitor
DMWSFIR	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMWSFIR	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMWSFIR	DI	DMWSFIR
DMWSFIR	DN	3-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyridine
DMWSFIR	MI	TTIQUX7
DMWSFIR	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMWSFIR	MT	DTT
DMWSFIR	MA	Inhibitor
DMWSFIR	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMWSFIR	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMN42I5	DI	DMN42I5
DMN42I5	DN	3-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine
DMN42I5	MI	TTSZLWK
DMN42I5	MN	Aromatase (CYP19A1)
DMN42I5	MT	DTT
DMN42I5	MA	Inhibitor
DMN42I5	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMN42I5	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMN42I5	DI	DMN42I5
DMN42I5	DN	3-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine
DMN42I5	MI	TTIQUX7
DMN42I5	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMN42I5	MT	DTT
DMN42I5	MA	Inhibitor
DMN42I5	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMN42I5	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DM9AW5U	DI	DM9AW5U
DM9AW5U	DN	3-[5-Methoxy-indan-(1E)-ylidenemethyl]-pyridine
DM9AW5U	MI	TTSZLWK
DM9AW5U	MN	Aromatase (CYP19A1)
DM9AW5U	MT	DTT
DM9AW5U	MA	Inhibitor
DM9AW5U	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DM9AW5U	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DM9AW5U	DI	DM9AW5U
DM9AW5U	DN	3-[5-Methoxy-indan-(1E)-ylidenemethyl]-pyridine
DM9AW5U	MI	TTIQUX7
DM9AW5U	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM9AW5U	MT	DTT
DM9AW5U	MA	Inhibitor
DM9AW5U	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DM9AW5U	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMB3XYE	DI	DMB3XYE
DMB3XYE	DN	3-[5-Methoxy-indan-(1Z)-ylidenemethyl]-pyridine
DMB3XYE	MI	TTSZLWK
DMB3XYE	MN	Aromatase (CYP19A1)
DMB3XYE	MT	DTT
DMB3XYE	MA	Inhibitor
DMB3XYE	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMB3XYE	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMB3XYE	DI	DMB3XYE
DMB3XYE	DN	3-[5-Methoxy-indan-(1Z)-ylidenemethyl]-pyridine
DMB3XYE	MI	TTIQUX7
DMB3XYE	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMB3XYE	MT	DTT
DMB3XYE	MA	Inhibitor
DMB3XYE	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMB3XYE	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMLTZ5F	DI	DMLTZ5F
DMLTZ5F	DN	3-[6-(5-Chloro-2-thienyl)pyridin-2-yl]phenol
DMLTZ5F	MI	TTIWB6L
DMLTZ5F	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMLTZ5F	MT	DTT
DMLTZ5F	MA	Inhibitor
DMLTZ5F	RN	Novel estrone mimetics with high 17beta-HSD1 inhibitory activity. Bioorg Med Chem. 2010 May 15;18(10):3494-505.
DMLTZ5F	RU	https://pubmed.ncbi.nlm.nih.gov/20413314

DM89RN3	DI	DM89RN3
DM89RN3	DN	3-[6-(benzylmethylamino)hexyloxy]xanthen-9-one
DM89RN3	MI	TT1RS9F
DM89RN3	MN	Acetylcholinesterase (AChE)
DM89RN3	MT	DTT
DM89RN3	MA	Inhibitor
DM89RN3	RN	Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[omega-(benzylmethylamino)alkoxy]xanthen-9-ones. Bioorg Med Chem. 2007 Jan 1;15(1):575-85.
DM89RN3	RU	https://pubmed.ncbi.nlm.nih.gov/17008100

DM89RN3	DI	DM89RN3
DM89RN3	DN	3-[6-(benzylmethylamino)hexyloxy]xanthen-9-one
DM89RN3	MI	TTEB0GD
DM89RN3	MN	Cholinesterase (BCHE)
DM89RN3	MT	DTT
DM89RN3	MA	Inhibitor
DM89RN3	RN	Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[omega-(benzylmethylamino)alkoxy]xanthen-9-ones. Bioorg Med Chem. 2007 Jan 1;15(1):575-85.
DM89RN3	RU	https://pubmed.ncbi.nlm.nih.gov/17008100

DMHT6FX	DI	DMHT6FX
DMHT6FX	DN	3-[6-Methoxy-indan-(1E)-ylidenemethyl]-pyridine
DMHT6FX	MI	TTSZLWK
DMHT6FX	MN	Aromatase (CYP19A1)
DMHT6FX	MT	DTT
DMHT6FX	MA	Inhibitor
DMHT6FX	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMHT6FX	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMG76LS	DI	DMG76LS
DMG76LS	DN	3-[6-Methyl-indan-(1E)-ylidenemethyl]-pyridine
DMG76LS	MI	TTSZLWK
DMG76LS	MN	Aromatase (CYP19A1)
DMG76LS	MT	DTT
DMG76LS	MA	Inhibitor
DMG76LS	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMG76LS	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMKOB2T	DI	DMKOB2T
DMKOB2T	DN	3-[6-Methyl-indan-(1Z)-ylidenemethyl]-pyridine
DMKOB2T	MI	TTSZLWK
DMKOB2T	MN	Aromatase (CYP19A1)
DMKOB2T	MT	DTT
DMKOB2T	MA	Inhibitor
DMKOB2T	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMKOB2T	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMMD3G6	DI	DMMD3G6
DMMD3G6	DN	3-[7-(benzylmethylamino)-heptyloxy]xanthen-9-one
DMMD3G6	MI	TT1RS9F
DMMD3G6	MN	Acetylcholinesterase (AChE)
DMMD3G6	MT	DTT
DMMD3G6	MA	Inhibitor
DMMD3G6	RN	Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[omega-(benzylmethylamino)alkoxy]xanthen-9-ones. Bioorg Med Chem. 2007 Jan 1;15(1):575-85.
DMMD3G6	RU	https://pubmed.ncbi.nlm.nih.gov/17008100

DMMD3G6	DI	DMMD3G6
DMMD3G6	DN	3-[7-(benzylmethylamino)-heptyloxy]xanthen-9-one
DMMD3G6	MI	TTEB0GD
DMMD3G6	MN	Cholinesterase (BCHE)
DMMD3G6	MT	DTT
DMMD3G6	MA	Inhibitor
DMMD3G6	RN	Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[omega-(benzylmethylamino)alkoxy]xanthen-9-ones. Bioorg Med Chem. 2007 Jan 1;15(1):575-85.
DMMD3G6	RU	https://pubmed.ncbi.nlm.nih.gov/17008100

DM7IHUK	DI	DM7IHUK
DM7IHUK	DN	3-[7'-(Methoxy)-napht-2'-yl]-quinuclidine-2-ene
DM7IHUK	MI	TTFQEO5
DM7IHUK	MN	Squalene synthetase (FDFT1)
DM7IHUK	MT	DTT
DM7IHUK	MA	Inhibitor
DM7IHUK	RN	Quinuclidine derivatives as potential antiparasitics. Antimicrob Agents Chemother. 2007 Nov;51(11):4049-61.
DM7IHUK	RU	https://pubmed.ncbi.nlm.nih.gov/17709461

DMVWIQ2	DI	DMVWIQ2
DMVWIQ2	DN	3-[7-Methoxy-indan-(1E)-ylidenemethyl]-pyridine
DMVWIQ2	MI	TTSZLWK
DMVWIQ2	MN	Aromatase (CYP19A1)
DMVWIQ2	MT	DTT
DMVWIQ2	MA	Inhibitor
DMVWIQ2	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMVWIQ2	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMVWIQ2	DI	DMVWIQ2
DMVWIQ2	DN	3-[7-Methoxy-indan-(1E)-ylidenemethyl]-pyridine
DMVWIQ2	MI	TTIQUX7
DMVWIQ2	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMVWIQ2	MT	DTT
DMVWIQ2	MA	Inhibitor
DMVWIQ2	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMVWIQ2	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DM31WYF	DI	DM31WYF
DM31WYF	DN	3-[8-(benzylmethylamino)octyloxy]xanthen-9-one
DM31WYF	MI	TT1RS9F
DM31WYF	MN	Acetylcholinesterase (AChE)
DM31WYF	MT	DTT
DM31WYF	MA	Inhibitor
DM31WYF	RN	Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[omega-(benzylmethylamino)alkoxy]xanthen-9-ones. Bioorg Med Chem. 2007 Jan 1;15(1):575-85.
DM31WYF	RU	https://pubmed.ncbi.nlm.nih.gov/17008100

DM31WYF	DI	DM31WYF
DM31WYF	DN	3-[8-(benzylmethylamino)octyloxy]xanthen-9-one
DM31WYF	MI	TTEB0GD
DM31WYF	MN	Cholinesterase (BCHE)
DM31WYF	MT	DTT
DM31WYF	MA	Inhibitor
DM31WYF	RN	Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[omega-(benzylmethylamino)alkoxy]xanthen-9-ones. Bioorg Med Chem. 2007 Jan 1;15(1):575-85.
DM31WYF	RU	https://pubmed.ncbi.nlm.nih.gov/17008100

DMZSBU5	DI	DMZSBU5
DMZSBU5	DN	3-[9-(benzylmethylamino)nonyloxy]xanthen-9-one
DMZSBU5	MI	TTEB0GD
DMZSBU5	MN	Cholinesterase (BCHE)
DMZSBU5	MT	DTT
DMZSBU5	MA	Inhibitor
DMZSBU5	RN	Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[omega-(benzylmethylamino)alkoxy]xanthen-9-ones. Bioorg Med Chem. 2007 Jan 1;15(1):575-85.
DMZSBU5	RU	https://pubmed.ncbi.nlm.nih.gov/17008100

DMLZ5F1	DI	DMLZ5F1
DMLZ5F1	DN	3-{[2-(2-phenylethyl)phenoxy]methyl}pyridine
DMLZ5F1	MI	TTSQIFT
DMLZ5F1	MN	5-HT 1A receptor (HTR1A)
DMLZ5F1	MT	DTT
DMLZ5F1	MA	Inhibitor
DMLZ5F1	RN	Arylmethyloxyphenyl derivatives: small molecules displaying P-glycoprotein inhibition. J Med Chem. 2006 Nov 2;49(22):6607-13.
DMLZ5F1	RU	https://pubmed.ncbi.nlm.nih.gov/17064079

DMLZ5F1	DI	DMLZ5F1
DMLZ5F1	DN	3-{[2-(2-phenylethyl)phenoxy]methyl}pyridine
DMLZ5F1	MI	TTEX248
DMLZ5F1	MN	Dopamine D2 receptor (D2R)
DMLZ5F1	MT	DTT
DMLZ5F1	MA	Inhibitor
DMLZ5F1	RN	Arylmethyloxyphenyl derivatives: small molecules displaying P-glycoprotein inhibition. J Med Chem. 2006 Nov 2;49(22):6607-13.
DMLZ5F1	RU	https://pubmed.ncbi.nlm.nih.gov/17064079

DMUH9PF	DI	DMUH9PF
DMUH9PF	DN	3-{3-[(aminosulfonyl)oxy]benzoyl}phenyl sulfamate
DMUH9PF	MI	TTHM0R1
DMUH9PF	MN	Steryl-sulfatase (STS)
DMUH9PF	MT	DTT
DMUH9PF	MA	Inhibitor
DMUH9PF	RN	4,4'-Benzophenone-O,O'-disulfamate: a potent inhibitor of steroid sulfatase. Bioorg Med Chem Lett. 2002 Aug 19;12(16):2093-5.
DMUH9PF	RU	https://pubmed.ncbi.nlm.nih.gov/12127511

DMGS2X7	DI	DMGS2X7
DMGS2X7	DN	3-{4-[(aminosulfonyl)oxy]benzoyl}phenyl sulfamate
DMGS2X7	MI	TTHM0R1
DMGS2X7	MN	Steryl-sulfatase (STS)
DMGS2X7	MT	DTT
DMGS2X7	MA	Inhibitor
DMGS2X7	RN	4,4'-Benzophenone-O,O'-disulfamate: a potent inhibitor of steroid sulfatase. Bioorg Med Chem Lett. 2002 Aug 19;12(16):2093-5.
DMGS2X7	RU	https://pubmed.ncbi.nlm.nih.gov/12127511

DMT80IF	DI	DMT80IF
DMT80IF	DN	3570-0208
DMT80IF	MI	TT5Y4EM
DMT80IF	MN	N-formyl peptide receptor (FPR1)
DMT80IF	MT	DTT
DMT80IF	MA	Antagonist
DMT80IF	RN	Discovery of selective probes and antagonists for G-protein-coupled receptors FPR/FPRL1 and GPR30. Curr Top Med Chem. 2009;9(13):1227-36.
DMT80IF	RU	https://pubmed.ncbi.nlm.nih.gov/19807662

DMGO2D7	DI	DMGO2D7
DMGO2D7	DN	3-acetyl-11-keto-beta-boswellic acid
DMGO2D7	MI	TTN7BL9
DMGO2D7	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMGO2D7	MT	DTT
DMGO2D7	MA	Inhibitor
DMGO2D7	RN	11beta-Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational a... Bioorg Med Chem. 2010 Feb 15;18(4):1507-15.
DMGO2D7	RU	https://pubmed.ncbi.nlm.nih.gov/20100662

DMGO2D7	DI	DMGO2D7
DMGO2D7	DN	3-acetyl-11-keto-beta-boswellic acid
DMGO2D7	MI	TT9H85R
DMGO2D7	MN	Corticosteroid 11-beta-dehydrogenase 2 (HSD11B2)
DMGO2D7	MT	DTT
DMGO2D7	MA	Inhibitor
DMGO2D7	RN	11beta-Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational a... Bioorg Med Chem. 2010 Feb 15;18(4):1507-15.
DMGO2D7	RU	https://pubmed.ncbi.nlm.nih.gov/20100662

DMHRZ2V	DI	DMHRZ2V
DMHRZ2V	DN	3-acetyl-11-keto-ursolic acid
DMHRZ2V	MI	TTN7BL9
DMHRZ2V	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMHRZ2V	MT	DTT
DMHRZ2V	MA	Inhibitor
DMHRZ2V	RN	11beta-Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational a... Bioorg Med Chem. 2010 Feb 15;18(4):1507-15.
DMHRZ2V	RU	https://pubmed.ncbi.nlm.nih.gov/20100662

DM01WBD	DI	DM01WBD
DM01WBD	DN	3-acetyl-7-hydroxy-2H-chromen-2-one
DM01WBD	MI	TT6804T
DM01WBD	MN	MIF messenger RNA (MIF mRNA)
DM01WBD	MT	DTT
DM01WBD	MA	Inhibitor
DM01WBD	RN	Discovery of human macrophage migration inhibitory factor (MIF)-CD74 antagonists via virtual screening. J Med Chem. 2009 Jan 22;52(2):416-24.
DM01WBD	RU	https://pubmed.ncbi.nlm.nih.gov/19090668

DMCNX34	DI	DMCNX34
DMCNX34	DN	3alpha-(1'-Methyl-2'-Indolecarbonyloxy)-tropane
DMCNX34	MI	TTPC4TU
DMCNX34	MN	5-HT 3A receptor (HTR3A)
DMCNX34	MT	DTT
DMCNX34	MA	Inhibitor
DMCNX34	RN	Synthesis of heteroaromatic tropeines and heterogeneous binding to glycine receptors. Bioorg Med Chem. 2009 Oct 1;17(19):6872-8.
DMCNX34	RU	https://pubmed.ncbi.nlm.nih.gov/19726200

DM3BRYJ	DI	DM3BRYJ
DM3BRYJ	DN	3alpha-(2'-Indolecarbonyloxy)-nortropane
DM3BRYJ	MI	TTPC4TU
DM3BRYJ	MN	5-HT 3A receptor (HTR3A)
DM3BRYJ	MT	DTT
DM3BRYJ	MA	Inhibitor
DM3BRYJ	RN	Synthesis of heteroaromatic tropeines and heterogeneous binding to glycine receptors. Bioorg Med Chem. 2009 Oct 1;17(19):6872-8.
DM3BRYJ	RU	https://pubmed.ncbi.nlm.nih.gov/19726200

DMBUZWQ	DI	DMBUZWQ
DMBUZWQ	DN	3alpha-(bis-chloro-phenylmethoxy)tropane
DMBUZWQ	MI	TTVBI8W
DMBUZWQ	MN	Dopamine transporter (DAT)
DMBUZWQ	MT	DTT
DMBUZWQ	MA	Inhibitor
DMBUZWQ	RN	Structure-activity relationship studies on a novel series of (S)-2beta-substituted 3alpha-[bis(4-fluoro- or 4-chlorophenyl)methoxy]tropane analogue... J Med Chem. 2006 Oct 19;49(21):6391-9.
DMBUZWQ	RU	https://pubmed.ncbi.nlm.nih.gov/17034144

DMBUZWQ	DI	DMBUZWQ
DMBUZWQ	DN	3alpha-(bis-chloro-phenylmethoxy)tropane
DMBUZWQ	MI	TTZ9SOR
DMBUZWQ	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMBUZWQ	MT	DTT
DMBUZWQ	MA	Inhibitor
DMBUZWQ	RN	Structure-activity relationship studies on a novel series of (S)-2beta-substituted 3alpha-[bis(4-fluoro- or 4-chlorophenyl)methoxy]tropane analogue... J Med Chem. 2006 Oct 19;49(21):6391-9.
DMBUZWQ	RU	https://pubmed.ncbi.nlm.nih.gov/17034144

DMBUZWQ	DI	DMBUZWQ
DMBUZWQ	DN	3alpha-(bis-chloro-phenylmethoxy)tropane
DMBUZWQ	MI	TTAWNKZ
DMBUZWQ	MN	Norepinephrine transporter (NET)
DMBUZWQ	MT	DTT
DMBUZWQ	MA	Inhibitor
DMBUZWQ	RN	Structure-activity relationship studies on a novel series of (S)-2beta-substituted 3alpha-[bis(4-fluoro- or 4-chlorophenyl)methoxy]tropane analogue... J Med Chem. 2006 Oct 19;49(21):6391-9.
DMBUZWQ	RU	https://pubmed.ncbi.nlm.nih.gov/17034144

DMBUZWQ	DI	DMBUZWQ
DMBUZWQ	DN	3alpha-(bis-chloro-phenylmethoxy)tropane
DMBUZWQ	MI	TT3ROYC
DMBUZWQ	MN	Serotonin transporter (SERT)
DMBUZWQ	MT	DTT
DMBUZWQ	MA	Inhibitor
DMBUZWQ	RN	Structure-activity relationship studies on a novel series of (S)-2beta-substituted 3alpha-[bis(4-fluoro- or 4-chlorophenyl)methoxy]tropane analogue... J Med Chem. 2006 Oct 19;49(21):6391-9.
DMBUZWQ	RU	https://pubmed.ncbi.nlm.nih.gov/17034144

DM3ZR7A	DI	DM3ZR7A
DM3ZR7A	DN	3alpha,24-dihydroxyolean-12-en-27-oic acid
DM3ZR7A	MI	TTELIN2
DM3ZR7A	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DM3ZR7A	MT	DTT
DM3ZR7A	MA	Inhibitor
DM3ZR7A	RN	Protein tyrosine phosphatase 1B inhibitory activity of triterpenes isolated from Astilbe koreana. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3273-6.
DM3ZR7A	RU	https://pubmed.ncbi.nlm.nih.gov/16580200

DMV6OPB	DI	DMV6OPB
DMV6OPB	DN	3alpha-Hydroxyurs-12-en-28-oic Acid
DMV6OPB	MI	TTZHY6R
DMV6OPB	MN	Glycogen phosphorylase muscle form (GP)
DMV6OPB	MT	DTT
DMV6OPB	MA	Inhibitor
DMV6OPB	RN	Naturally occurring pentacyclic triterpenes as inhibitors of glycogen phosphorylase: synthesis, structure-activity relationships, and X-ray crystal... J Med Chem. 2008 Jun 26;51(12):3540-54.
DMV6OPB	RU	https://pubmed.ncbi.nlm.nih.gov/18517260

DM4M6LR	DI	DM4M6LR
DM4M6LR	DN	3alpha-O-trans-p-coumaroyl-7-labden-15-oic acid
DM4M6LR	MI	TTIU7X1
DM4M6LR	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DM4M6LR	MT	DTT
DM4M6LR	MA	Inhibitor
DM4M6LR	RN	Harbinatic acid, a novel and potent DNA polymerase beta inhibitor from Hardwickia binata. J Nat Prod. 1999 Jul;62(7):1000-2.
DM4M6LR	RU	https://pubmed.ncbi.nlm.nih.gov/10425125

DMO5IJA	DI	DMO5IJA
DMO5IJA	DN	3-alpha-Phenylmethoxy-3-beta-phenyl-nortropane
DMO5IJA	MI	TTVBI8W
DMO5IJA	MN	Dopamine transporter (DAT)
DMO5IJA	MT	DTT
DMO5IJA	MA	Inhibitor
DMO5IJA	RN	Synthesis and monoamine transporter affinity of 3alpha-arylmethoxy-3beta-arylnortropanes. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6865-8.
DMO5IJA	RU	https://pubmed.ncbi.nlm.nih.gov/19896846

DMO5IJA	DI	DMO5IJA
DMO5IJA	DN	3-alpha-Phenylmethoxy-3-beta-phenyl-nortropane
DMO5IJA	MI	TT3ROYC
DMO5IJA	MN	Serotonin transporter (SERT)
DMO5IJA	MT	DTT
DMO5IJA	MA	Inhibitor
DMO5IJA	RN	Synthesis and monoamine transporter affinity of 3alpha-arylmethoxy-3beta-arylnortropanes. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6865-8.
DMO5IJA	RU	https://pubmed.ncbi.nlm.nih.gov/19896846

DMKGIQ1	DI	DMKGIQ1
DMKGIQ1	DN	3-Amino-1-(2-amino-5-methoxy-phenyl)-propan-1-one
DMKGIQ1	MI	TTSQIFT
DMKGIQ1	MN	5-HT 1A receptor (HTR1A)
DMKGIQ1	MT	DTT
DMKGIQ1	MA	Inhibitor
DMKGIQ1	RN	Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents. J Med Chem. 1986 May;29(5):630-4.
DMKGIQ1	RU	https://pubmed.ncbi.nlm.nih.gov/3701781

DMKGIQ1	DI	DMKGIQ1
DMKGIQ1	DN	3-Amino-1-(2-amino-5-methoxy-phenyl)-propan-1-one
DMKGIQ1	MI	TT6MSOK
DMKGIQ1	MN	5-HT 1D receptor (HTR1D)
DMKGIQ1	MT	DTT
DMKGIQ1	MA	Inhibitor
DMKGIQ1	RN	Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents. J Med Chem. 1986 May;29(5):630-4.
DMKGIQ1	RU	https://pubmed.ncbi.nlm.nih.gov/3701781

DMKGIQ1	DI	DMKGIQ1
DMKGIQ1	DN	3-Amino-1-(2-amino-5-methoxy-phenyl)-propan-1-one
DMKGIQ1	MI	TTJQOD7
DMKGIQ1	MN	5-HT 2A receptor (HTR2A)
DMKGIQ1	MT	DTT
DMKGIQ1	MA	Inhibitor
DMKGIQ1	RN	Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents. J Med Chem. 1986 May;29(5):630-4.
DMKGIQ1	RU	https://pubmed.ncbi.nlm.nih.gov/3701781

DMF3DBE	DI	DMF3DBE
DMF3DBE	DN	3-amino-2-(benzylideneamino)-5-mercaptophenol
DMF3DBE	MI	TTGX0HR
DMF3DBE	MN	Bacterial DNA ligase (Bact ligA)
DMF3DBE	MT	DTT
DMF3DBE	MA	Inhibitor
DMF3DBE	RN	Identification and validation of human DNA ligase inhibitors using computer-aided drug design. J Med Chem. 2008 Aug 14;51(15):4553-62.
DMF3DBE	RU	https://pubmed.ncbi.nlm.nih.gov/18630893

DMV4XGT	DI	DMV4XGT
DMV4XGT	DN	3-Amino-3-(methoxycarbonyl)-1,5-pentandioic acid
DMV4XGT	MI	TTHI19T
DMV4XGT	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMV4XGT	MT	DTT
DMV4XGT	MA	Inhibitor
DMV4XGT	RN	Discovery of novel lipophilic inhibitors of OXA-10 enzyme (class D beta-lactamase) by screening amino analogs and homologs of citrate and isocitrate. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3593-7.
DMV4XGT	RU	https://pubmed.ncbi.nlm.nih.gov/19467869

DM60K7H	DI	DM60K7H
DM60K7H	DN	3-amino-3-demethoxythiocolchicine
DM60K7H	MI	TT1MPAY
DM60K7H	MN	GABA(A) receptor alpha-1 (GABRA1)
DM60K7H	MT	DTT
DM60K7H	MA	Inhibitor
DM60K7H	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DM60K7H	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DM60K7H	DI	DM60K7H
DM60K7H	DN	3-amino-3-demethoxythiocolchicine
DM60K7H	MI	TTZA1NY
DM60K7H	MN	GABA(A) receptor beta-2 (GABRB2)
DM60K7H	MT	DTT
DM60K7H	MA	Inhibitor
DM60K7H	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DM60K7H	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DM60K7H	DI	DM60K7H
DM60K7H	DN	3-amino-3-demethoxythiocolchicine
DM60K7H	MI	TT06RH5
DM60K7H	MN	GABA(A) receptor gamma-2 (GABRG2)
DM60K7H	MT	DTT
DM60K7H	MA	Inhibitor
DM60K7H	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DM60K7H	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DM60K7H	DI	DM60K7H
DM60K7H	DN	3-amino-3-demethoxythiocolchicine
DM60K7H	MI	TTNJYV2
DM60K7H	MN	Gamma-aminobutyric acid receptor (GAR)
DM60K7H	MT	DTT
DM60K7H	MA	Inhibitor
DM60K7H	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DM60K7H	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DMJ7Y3H	DI	DMJ7Y3H
DMJ7Y3H	DN	3'-amino-4-(1,1-dimethyl-heptyl)-biphenyl-2-ol
DMJ7Y3H	MI	TT6OEDT
DMJ7Y3H	MN	Cannabinoid receptor 1 (CB1)
DMJ7Y3H	MT	DTT
DMJ7Y3H	MA	Inhibitor
DMJ7Y3H	RN	Biaryl cannabinoid mimetics--synthesis and structure-activity relationship. Bioorg Med Chem Lett. 2007 Jul 1;17(13):3652-6.
DMJ7Y3H	RU	https://pubmed.ncbi.nlm.nih.gov/17507224

DMJ7Y3H	DI	DMJ7Y3H
DMJ7Y3H	DN	3'-amino-4-(1,1-dimethyl-heptyl)-biphenyl-2-ol
DMJ7Y3H	MI	TTMSFAW
DMJ7Y3H	MN	Cannabinoid receptor 2 (CB2)
DMJ7Y3H	MT	DTT
DMJ7Y3H	MA	Inhibitor
DMJ7Y3H	RN	Biaryl cannabinoid mimetics--synthesis and structure-activity relationship. Bioorg Med Chem Lett. 2007 Jul 1;17(13):3652-6.
DMJ7Y3H	RU	https://pubmed.ncbi.nlm.nih.gov/17507224

DMIS3LN	DI	DMIS3LN
DMIS3LN	DN	3-Amino-4'-amino-trans-stilbene
DMIS3LN	MI	TTSZLWK
DMIS3LN	MN	Aromatase (CYP19A1)
DMIS3LN	MT	DTT
DMIS3LN	MA	Inhibitor
DMIS3LN	RN	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
DMIS3LN	RU	https://pubmed.ncbi.nlm.nih.gov/20558073

DM5Z0O6	DI	DM5Z0O6
DM5Z0O6	DN	3-Amino-4-Oxybenzyl-2-Butanone
DM5Z0O6	MI	TTF2LRI
DM5Z0O6	MN	Cathepsin B (CTSB)
DM5Z0O6	MT	DTT
DM5Z0O6	MA	Inhibitor
DM5Z0O6	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM5Z0O6	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM2U9RY	DI	DM2U9RY
DM2U9RY	DN	3-amino-5-(4-chlorophenyl)thiophene-2-carboxamide
DM2U9RY	MI	TTJ3E9X
DM2U9RY	MN	Inhibitor of nuclear factor kappa-B kinase beta (IKKB)
DM2U9RY	MT	DTT
DM2U9RY	MA	Inhibitor
DM2U9RY	RN	Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies. J Med Chem. 2006 May 18;49(10):2898-908.
DM2U9RY	RU	https://pubmed.ncbi.nlm.nih.gov/16686533

DMONHFR	DI	DMONHFR
DMONHFR	DN	3-amino-5-(4-octylphenyl)pentanoic acid
DMONHFR	MI	TT9JZCK
DMONHFR	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMONHFR	MT	DTT
DMONHFR	MA	Inhibitor
DMONHFR	RN	S1P receptor mediated activity of FTY720 phosphate mimics. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1485-7.
DMONHFR	RU	https://pubmed.ncbi.nlm.nih.gov/20153186

DM6Y2KW	DI	DM6Y2KW
DM6Y2KW	DN	3-amino-5-(furan-2-yl)biphenyl-2,4-dicarbonitrile
DM6Y2KW	MI	TTEAID7
DM6Y2KW	MN	Trypanosoma Cruzipain (Trypano CYSP)
DM6Y2KW	MT	DTT
DM6Y2KW	MA	Inhibitor
DM6Y2KW	RN	Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease. J Med Chem. 2010 Jan 14;53(1):37-51.
DM6Y2KW	RU	https://pubmed.ncbi.nlm.nih.gov/19908840

DMP2K1A	DI	DMP2K1A
DMP2K1A	DN	3-Amino-5,6-dihydro-2H-benzo[f]quinazolin-1-one
DMP2K1A	MI	TTU6BFZ
DMP2K1A	MN	Candida Thymidylate synthase (Candi TMP1)
DMP2K1A	MT	DTT
DMP2K1A	MA	Inhibitor
DMP2K1A	RN	Benzoquinazoline inhibitors of thymidylate synthase: enzyme inhibitory activity and cytotoxicity of some sulfonamidobenzoylglutamate and related de... J Med Chem. 1993 Oct 29;36(22):3464-71.
DMP2K1A	RU	https://pubmed.ncbi.nlm.nih.gov/8230138

DMHDFZE	DI	DMHDFZE
DMHDFZE	DN	3-Amino-5-Phenylpentane
DMHDFZE	MI	TTDZN01
DMHDFZE	MN	Cathepsin K (CTSK)
DMHDFZE	MT	DTT
DMHDFZE	MA	Inhibitor
DMHDFZE	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMHDFZE	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM0GJZM	DI	DM0GJZM
DM0GJZM	DN	3-aminoacetamido-4'-methylfuro[3,2-g]coumarin
DM0GJZM	MI	TT3WG5C
DM0GJZM	MN	Monoamine oxidase type A (MAO-A)
DM0GJZM	MT	DTT
DM0GJZM	MA	Inhibitor
DM0GJZM	RN	A QSAR model for in silico screening of MAO-A inhibitors. Prediction, synthesis, and biological assay of novel coumarins. J Med Chem. 2006 Feb 9;49(3):1149-56.
DM0GJZM	RU	https://pubmed.ncbi.nlm.nih.gov/16451079

DM5073T	DI	DM5073T
DM5073T	DN	3-AMINO-AZACYCLOTRIDECAN-2-ONE
DM5073T	MI	TTGA1IV
DM5073T	MN	Matrix metalloproteinase-8 (MMP-8)
DM5073T	MT	DTT
DM5073T	MA	Inhibitor
DM5073T	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM5073T	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM7P3IZ	DI	DM7P3IZ
DM7P3IZ	DN	3-aminobenzamide
DM7P3IZ	MI	TTVDSZ0
DM7P3IZ	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DM7P3IZ	MT	DTT
DM7P3IZ	MA	Inhibitor
DM7P3IZ	RN	Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med. 2001 Jan;7(1):108-13.
DM7P3IZ	RU	https://pubmed.ncbi.nlm.nih.gov/11135624

DME0TNA	DI	DME0TNA
DME0TNA	DN	3-Amino-benzenesulfonamide
DME0TNA	MI	TTUNARX
DME0TNA	MN	Carbonic anhydrase (CA)
DME0TNA	MT	DTT
DME0TNA	MA	Inhibitor
DME0TNA	RN	Carbonic anhydrase inhibitors. Inhibition of the prokariotic beta and gamma-class enzymes from Archaea with sulfonamides. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6001-6.
DME0TNA	RU	https://pubmed.ncbi.nlm.nih.gov/15546717

DME0TNA	DI	DME0TNA
DME0TNA	DN	3-Amino-benzenesulfonamide
DME0TNA	MI	TTANPDJ
DME0TNA	MN	Carbonic anhydrase II (CA-II)
DME0TNA	MT	DTT
DME0TNA	MA	Inhibitor
DME0TNA	RN	Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1149-54.
DME0TNA	RU	https://pubmed.ncbi.nlm.nih.gov/15686931

DME0TNA	DI	DME0TNA
DME0TNA	DN	3-Amino-benzenesulfonamide
DME0TNA	MI	TTZHA0O
DME0TNA	MN	Carbonic anhydrase IV (CA-IV)
DME0TNA	MT	DTT
DME0TNA	MA	Inhibitor
DME0TNA	RN	Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1149-54.
DME0TNA	RU	https://pubmed.ncbi.nlm.nih.gov/15686931

DME0TNA	DI	DME0TNA
DME0TNA	DN	3-Amino-benzenesulfonamide
DME0TNA	MI	TT2LVK8
DME0TNA	MN	Carbonic anhydrase IX (CA-IX)
DME0TNA	MT	DTT
DME0TNA	MA	Inhibitor
DME0TNA	RN	Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33.
DME0TNA	RU	https://pubmed.ncbi.nlm.nih.gov/16039848

DME0TNA	DI	DME0TNA
DME0TNA	DN	3-Amino-benzenesulfonamide
DME0TNA	MI	TTSYM0R
DME0TNA	MN	Carbonic anhydrase XII (CA-XII)
DME0TNA	MT	DTT
DME0TNA	MA	Inhibitor
DME0TNA	RN	Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33.
DME0TNA	RU	https://pubmed.ncbi.nlm.nih.gov/16039848

DME0TNA	DI	DME0TNA
DME0TNA	DN	3-Amino-benzenesulfonamide
DME0TNA	MI	TTEYTKG
DME0TNA	MN	Carbonic anhydrase XIV (CA-XIV)
DME0TNA	MT	DTT
DME0TNA	MA	Inhibitor
DME0TNA	RN	Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33.
DME0TNA	RU	https://pubmed.ncbi.nlm.nih.gov/16039848

DMWOTD3	DI	DMWOTD3
DMWOTD3	DN	3-amino-benzo[b]thiophene-2-carboxylic acid amide
DMWOTD3	MI	TTJ3E9X
DMWOTD3	MN	Inhibitor of nuclear factor kappa-B kinase beta (IKKB)
DMWOTD3	MT	DTT
DMWOTD3	MA	Inhibitor
DMWOTD3	RN	Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies. J Med Chem. 2006 May 18;49(10):2898-908.
DMWOTD3	RU	https://pubmed.ncbi.nlm.nih.gov/16686533

DML2UCP	DI	DML2UCP
DML2UCP	DN	3-aminobenzo[c][1,5]naphthyridin-6(5H)-one
DML2UCP	MI	TTVDSZ0
DML2UCP	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DML2UCP	MT	DTT
DML2UCP	MA	Inhibitor
DML2UCP	RN	Design, synthesis, and cytoprotective effect of 2-aminothiazole analogues as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2009 Feb 12;52(3):718-25.
DML2UCP	RU	https://pubmed.ncbi.nlm.nih.gov/19125579

DMTYXH1	DI	DMTYXH1
DMTYXH1	DN	3-Aminomethyl-5-methyl-hexanoic acid
DMTYXH1	MI	TTFK1JQ
DMTYXH1	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMTYXH1	MT	DTT
DMTYXH1	MA	Inhibitor
DMTYXH1	RN	Enantioselective synthesis of PD144723: a potent stereospecific anticonvulsant, Bioorg. Med. Chem. Lett. 4(6):823-826 (1994).
DMTYXH1	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01808556

DMTYXH1	DI	DMTYXH1
DMTYXH1	DN	3-Aminomethyl-5-methyl-hexanoic acid
DMTYXH1	MI	TTU8P3M
DMTYXH1	MN	Voltage-gated calcium channel alpha-2/delta-2 (CACNA2D2)
DMTYXH1	MT	DTT
DMTYXH1	MA	Inhibitor
DMTYXH1	RN	Enantioselective synthesis of PD144723: a potent stereospecific anticonvulsant, Bioorg. Med. Chem. Lett. 4(6):823-826 (1994).
DMTYXH1	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01808556

DMTYXH1	DI	DMTYXH1
DMTYXH1	DN	3-Aminomethyl-5-methyl-hexanoic acid
DMTYXH1	MI	TTN7T29
DMTYXH1	MN	Voltage-gated calcium channel alpha-2/delta-3 (CACNA2D3)
DMTYXH1	MT	DTT
DMTYXH1	MA	Inhibitor
DMTYXH1	RN	Enantioselective synthesis of PD144723: a potent stereospecific anticonvulsant, Bioorg. Med. Chem. Lett. 4(6):823-826 (1994).
DMTYXH1	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01808556

DM5SQVC	DI	DM5SQVC
DM5SQVC	DN	3-ammoniopropane-1-sulfinate
DM5SQVC	MI	TTDCVZW
DM5SQVC	MN	Gamma-aminobutyric acid B receptor (GABBR)
DM5SQVC	MT	DTT
DM5SQVC	MA	Inhibitor
DM5SQVC	RN	A study of 3-amino-N-hydroxypropanesulfonamide derivatives as potential GABAB agonists and their fragmentation to 3-aminopropanesulfinic acid, Bioorg. Med. Chem. Lett. 6(14):1709-1714 (1996).
DM5SQVC	RU	http://www.sciencedirect.com/science/article/pii/0960894X96003071

DM5SQVC	DI	DM5SQVC
DM5SQVC	DN	3-ammoniopropane-1-sulfinate
DM5SQVC	MI	TTNJYV2
DM5SQVC	MN	Gamma-aminobutyric acid receptor (GAR)
DM5SQVC	MT	DTT
DM5SQVC	MA	Inhibitor
DM5SQVC	RN	A study of 3-amino-N-hydroxypropanesulfonamide derivatives as potential GABAB agonists and their fragmentation to 3-aminopropanesulfinic acid, Bioorg. Med. Chem. Lett. 6(14):1709-1714 (1996).
DM5SQVC	RU	http://www.sciencedirect.com/science/article/pii/0960894X96003071

DM3VYNJ	DI	DM3VYNJ
DM3VYNJ	DN	3-anilino-5-benzylthio-1,2,4-triazole
DM3VYNJ	MI	TTZL0OI
DM3VYNJ	MN	Methionine aminopeptidase 2 (METAP2)
DM3VYNJ	MT	DTT
DM3VYNJ	MA	Inhibitor
DM3VYNJ	RN	Highly potent inhibitors of methionine aminopeptidase-2 based on a 1,2,4-triazole pharmacophore. J Med Chem. 2007 Aug 9;50(16):3777-85.
DM3VYNJ	RU	https://pubmed.ncbi.nlm.nih.gov/17636946

DM6KNMB	DI	DM6KNMB
DM6KNMB	DN	3-azageranylgeranyl diphosphate
DM6KNMB	MI	TTIKWV4
DM6KNMB	MN	Geranyltranstransferase (FDPS)
DM6KNMB	MT	DTT
DM6KNMB	MA	Inhibitor
DM6KNMB	RN	Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents. J Med Chem. 2002 May 23;45(11):2185-96.
DM6KNMB	RU	https://pubmed.ncbi.nlm.nih.gov/12014956

DMU08MN	DI	DMU08MN
DMU08MN	DN	3'-Azido-3'-Deoxythymidine-5'-Monophosphate
DMU08MN	MI	TT5B8AX
DMU08MN	MN	Mycobacterium Thymidine monophosphate kinase (MycB tmk)
DMU08MN	MT	DTT
DMU08MN	MA	Inhibitor
DMU08MN	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMU08MN	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMU08MN	DI	DMU08MN
DMU08MN	DN	3'-Azido-3'-Deoxythymidine-5'-Monophosphate
DMU08MN	MI	DEOTVYU
DMU08MN	MN	Thymidylate kinase (DTYMK)
DMU08MN	MT	DME
DMU08MN	MA	Metabolism
DMU08MN	RN	Azidothymidine-triphosphate impairs mitochondrial dynamics by disrupting the quality control system. Redox Biol. 2017 Oct;13:407-417.
DMU08MN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28683400

DMQXD0N	DI	DMQXD0N
DMQXD0N	DN	3-Benzenesulfinyl-heptanoic acid hydroxyamide
DMQXD0N	MI	TTMX39J
DMQXD0N	MN	Matrix metalloproteinase-1 (MMP-1)
DMQXD0N	MT	DTT
DMQXD0N	MA	Inhibitor
DMQXD0N	RN	Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents. J Med Chem. 2000 Jun 15;43(12):2324-31.
DMQXD0N	RU	https://pubmed.ncbi.nlm.nih.gov/10882358

DM7XDCF	DI	DM7XDCF
DM7XDCF	DN	3-Benzenesulfonyl-heptanoic acid hydroxyamide
DM7XDCF	MI	TTMX39J
DM7XDCF	MN	Matrix metalloproteinase-1 (MMP-1)
DM7XDCF	MT	DTT
DM7XDCF	MA	Inhibitor
DM7XDCF	RN	Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents. J Med Chem. 2000 Jun 15;43(12):2324-31.
DM7XDCF	RU	https://pubmed.ncbi.nlm.nih.gov/10882358

DM7XDCF	DI	DM7XDCF
DM7XDCF	DN	3-Benzenesulfonyl-heptanoic acid hydroxyamide
DM7XDCF	MI	TTXZ0KQ
DM7XDCF	MN	Matrix metalloproteinase-12 (MMP-12)
DM7XDCF	MT	DTT
DM7XDCF	MA	Inhibitor
DM7XDCF	RN	Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents. J Med Chem. 2000 Jun 15;43(12):2324-31.
DM7XDCF	RU	https://pubmed.ncbi.nlm.nih.gov/10882358

DM7XDCF	DI	DM7XDCF
DM7XDCF	DN	3-Benzenesulfonyl-heptanoic acid hydroxyamide
DM7XDCF	MI	TTHY57M
DM7XDCF	MN	Matrix metalloproteinase-13 (MMP-13)
DM7XDCF	MT	DTT
DM7XDCF	MA	Inhibitor
DM7XDCF	RN	Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents. J Med Chem. 2000 Jun 15;43(12):2324-31.
DM7XDCF	RU	https://pubmed.ncbi.nlm.nih.gov/10882358

DM7XDCF	DI	DM7XDCF
DM7XDCF	DN	3-Benzenesulfonyl-heptanoic acid hydroxyamide
DM7XDCF	MI	TTMTWOS
DM7XDCF	MN	Matrix metalloproteinase-7 (MMP-7)
DM7XDCF	MT	DTT
DM7XDCF	MA	Inhibitor
DM7XDCF	RN	Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents. J Med Chem. 2000 Jun 15;43(12):2324-31.
DM7XDCF	RU	https://pubmed.ncbi.nlm.nih.gov/10882358

DMQXJA1	DI	DMQXJA1
DMQXJA1	DN	3-Benzimidazol-2-ylhydroquinolin-2-one
DMQXJA1	MI	TTRLW2X
DMQXJA1	MN	Fibroblast growth factor receptor 1 (FGFR1)
DMQXJA1	MT	DTT
DMQXJA1	MA	Inhibitor
DMQXJA1	RN	Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor... J Med Chem. 2009 Jan 22;52(2):278-92.
DMQXJA1	RU	https://pubmed.ncbi.nlm.nih.gov/19113866

DMQXJA1	DI	DMQXJA1
DMQXJA1	DN	3-Benzimidazol-2-ylhydroquinolin-2-one
DMQXJA1	MI	TTI7421
DMQXJA1	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMQXJA1	MT	DTT
DMQXJA1	MA	Inhibitor
DMQXJA1	RN	Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor... J Med Chem. 2009 Jan 22;52(2):278-92.
DMQXJA1	RU	https://pubmed.ncbi.nlm.nih.gov/19113866

DMQXJA1	DI	DMQXJA1
DMQXJA1	DN	3-Benzimidazol-2-ylhydroquinolin-2-one
DMQXJA1	MI	TTUTJGQ
DMQXJA1	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMQXJA1	MT	DTT
DMQXJA1	MA	Inhibitor
DMQXJA1	RN	Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor... J Med Chem. 2009 Jan 22;52(2):278-92.
DMQXJA1	RU	https://pubmed.ncbi.nlm.nih.gov/19113866

DMWLIK1	DI	DMWLIK1
DMWLIK1	DN	3-benzofuran-2-yl-2-benzothiazol-2-yl-3-oxo-propanenitrile
DMWLIK1	MI	TTHGL48
DMWLIK1	MN	AP endonuclease 1 (APEX1)
DMWLIK1	MT	DTT
DMWLIK1	MA	Inhibitor
DMWLIK1	RN	Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines. Br J Cancer. 2011 Feb 15;104(4):653-63.
DMWLIK1	RU	https://pubmed.ncbi.nlm.nih.gov/21266972

DMHXRQL	DI	DMHXRQL
DMHXRQL	DN	3-benzoyl-1-pentyl-1,4-dihydroquinolin-4-one
DMHXRQL	MI	TTMSFAW
DMHXRQL	MN	Cannabinoid receptor 2 (CB2)
DMHXRQL	MT	DTT
DMHXRQL	MA	Inhibitor
DMHXRQL	RN	Pharmacomodulations around the 4-oxo-1,4-dihydroquinoline-3-carboxamides, a class of potent CB2-selective cannabinoid receptor ligands: consequence... J Med Chem. 2007 Nov 1;50(22):5471-84.
DMHXRQL	RU	https://pubmed.ncbi.nlm.nih.gov/17915849

DMAH4DG	DI	DMAH4DG
DMAH4DG	DN	3-Benzoyl-7-chloro-4-hydroxy-1H-quinolin-2-one
DMAH4DG	MI	TTLD29N
DMAH4DG	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMAH4DG	MT	DTT
DMAH4DG	MA	Inhibitor
DMAH4DG	RN	Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993).
DMAH4DG	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01808970

DMAH4DG	DI	DMAH4DG
DMAH4DG	DN	3-Benzoyl-7-chloro-4-hydroxy-1H-quinolin-2-one
DMAH4DG	MI	TTKJEMQ
DMAH4DG	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMAH4DG	MT	DTT
DMAH4DG	MA	Inhibitor
DMAH4DG	RN	Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993).
DMAH4DG	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01808970

DMAH4DG	DI	DMAH4DG
DMAH4DG	DN	3-Benzoyl-7-chloro-4-hydroxy-1H-quinolin-2-one
DMAH4DG	MI	TTN9D8E
DMAH4DG	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMAH4DG	MT	DTT
DMAH4DG	MA	Inhibitor
DMAH4DG	RN	Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993).
DMAH4DG	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01808970

DM25K86	DI	DM25K86
DM25K86	DN	3-Benzoyl-N-hydroxy-benzamide
DM25K86	MI	TT2J34L
DM25K86	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM25K86	MT	DTT
DM25K86	MA	Inhibitor
DM25K86	RN	Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8.
DM25K86	RU	https://pubmed.ncbi.nlm.nih.gov/2308149

DMNG0TY	DI	DMNG0TY
DMNG0TY	DN	3-benzyl-1-cyclohexylpyrrolidin-2-one
DMNG0TY	MI	TTN7BL9
DMNG0TY	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMNG0TY	MT	DTT
DMNG0TY	MA	Inhibitor
DMNG0TY	RN	Discovery of orally active butyrolactam 11beta-HSD1 inhibitors. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5555-60.
DMNG0TY	RU	https://pubmed.ncbi.nlm.nih.gov/16931002

DMQ13Z8	DI	DMQ13Z8
DMQ13Z8	DN	3-Benzyl-2-ethylthio-6-nitro-quinazolin-4(3H)-one
DMQ13Z8	MI	TT9SL3Q
DMQ13Z8	MN	Polypeptide deformylase (PDF)
DMQ13Z8	MT	DTT
DMQ13Z8	MA	Inhibitor
DMQ13Z8	RN	Non-classical antifolates. Part 2: synthesis, biological evaluation, and molecular modeling study of some new 2,6-substituted-quinazolin-4-ones. Bioorg Med Chem. 2010 Apr 15;18(8):2849-63.
DMQ13Z8	RU	https://pubmed.ncbi.nlm.nih.gov/20350811

DM4GWAH	DI	DM4GWAH
DM4GWAH	DN	3-benzyl-2-mercapto-6-nitroquinazolin-4(3H)-one
DM4GWAH	MI	TT9SL3Q
DM4GWAH	MN	Polypeptide deformylase (PDF)
DM4GWAH	MT	DTT
DM4GWAH	MA	Inhibitor
DM4GWAH	RN	Non-classical antifolates. Part 2: synthesis, biological evaluation, and molecular modeling study of some new 2,6-substituted-quinazolin-4-ones. Bioorg Med Chem. 2010 Apr 15;18(8):2849-63.
DM4GWAH	RU	https://pubmed.ncbi.nlm.nih.gov/20350811

DMDAO28	DI	DMDAO28
DMDAO28	DN	3-Benzyl-3-ethyl-1-phenylazetidine-2,4-dione
DMDAO28	MI	TTPLTSQ
DMDAO28	MN	Neutrophil elastase (NE)
DMDAO28	MT	DTT
DMDAO28	MA	Inhibitor
DMDAO28	RN	4-Oxo-beta-lactams (azetidine-2,4-diones) are potent and selective inhibitors of human leukocyte elastase. J Med Chem. 2010 Jan 14;53(1):241-53.
DMDAO28	RU	https://pubmed.ncbi.nlm.nih.gov/19904934

DMHINWF	DI	DMHINWF
DMHINWF	DN	3-Benzyl-3-methyl-1-phenylazetidine-2,4-dione
DMHINWF	MI	TTPLTSQ
DMHINWF	MN	Neutrophil elastase (NE)
DMHINWF	MT	DTT
DMHINWF	MA	Inhibitor
DMHINWF	RN	4-Oxo-beta-lactams (azetidine-2,4-diones) are potent and selective inhibitors of human leukocyte elastase. J Med Chem. 2010 Jan 14;53(1):241-53.
DMHINWF	RU	https://pubmed.ncbi.nlm.nih.gov/19904934

DMA5EHC	DI	DMA5EHC
DMA5EHC	DN	3-Benzyl-4-hydroxy-2H-benzo[h]chromen-2-one
DMA5EHC	MI	TT8XK6L
DMA5EHC	MN	Quinone reductase 1 (NQO1)
DMA5EHC	MT	DTT
DMA5EHC	MA	Inhibitor
DMA5EHC	RN	Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1). J Med Chem. 2009 Nov 26;52(22):7142-56.
DMA5EHC	RU	https://pubmed.ncbi.nlm.nih.gov/19877692

DM3BFX0	DI	DM3BFX0
DM3BFX0	DN	3-Benzyl-4-hydroxy-2H-chromen-2-one
DM3BFX0	MI	TT8XK6L
DM3BFX0	MN	Quinone reductase 1 (NQO1)
DM3BFX0	MT	DTT
DM3BFX0	MA	Inhibitor
DM3BFX0	RN	Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1). J Med Chem. 2009 Nov 26;52(22):7142-56.
DM3BFX0	RU	https://pubmed.ncbi.nlm.nih.gov/19877692

DML0ME9	DI	DML0ME9
DML0ME9	DN	3-Benzyl-4-hydroxy-6,7-dimethyl-2H-chromen-2-one
DML0ME9	MI	TT8XK6L
DML0ME9	MN	Quinone reductase 1 (NQO1)
DML0ME9	MT	DTT
DML0ME9	MA	Inhibitor
DML0ME9	RN	Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1). J Med Chem. 2009 Nov 26;52(22):7142-56.
DML0ME9	RU	https://pubmed.ncbi.nlm.nih.gov/19877692

DMZ85NC	DI	DMZ85NC
DMZ85NC	DN	3-benzyl-5-fluorobenzo[d]oxazol-2(3H)-one
DMZ85NC	MI	TT6804T
DMZ85NC	MN	MIF messenger RNA (MIF mRNA)
DMZ85NC	MT	DTT
DMZ85NC	MA	Inhibitor
DMZ85NC	RN	Optimization of N-benzyl-benzoxazol-2-ones as receptor antagonists of macrophage migration inhibitory factor (MIF). Bioorg Med Chem Lett. 2010 Oct 1;20(19):5811-4.
DMZ85NC	RU	https://pubmed.ncbi.nlm.nih.gov/20728358

DMKZDYP	DI	DMKZDYP
DMKZDYP	DN	3-Benzyl-5-isopropyl-8-methylchromen-2-one
DMKZDYP	MI	TT6OEDT
DMKZDYP	MN	Cannabinoid receptor 1 (CB1)
DMKZDYP	MT	DTT
DMKZDYP	MA	Inhibitor
DMKZDYP	RN	Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists. Bioorg Med Chem. 2009 Apr 1;17(7):2842-51.
DMKZDYP	RU	https://pubmed.ncbi.nlm.nih.gov/19278853

DMKZDYP	DI	DMKZDYP
DMKZDYP	DN	3-Benzyl-5-isopropyl-8-methylchromen-2-one
DMKZDYP	MI	TTMSFAW
DMKZDYP	MN	Cannabinoid receptor 2 (CB2)
DMKZDYP	MT	DTT
DMKZDYP	MA	Inhibitor
DMKZDYP	RN	Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists. Bioorg Med Chem. 2009 Apr 1;17(7):2842-51.
DMKZDYP	RU	https://pubmed.ncbi.nlm.nih.gov/19278853

DMF04YH	DI	DMF04YH
DMF04YH	DN	3-Benzyl-5-methoxy-7-methylchromen-2-one
DMF04YH	MI	TT6OEDT
DMF04YH	MN	Cannabinoid receptor 1 (CB1)
DMF04YH	MT	DTT
DMF04YH	MA	Inhibitor
DMF04YH	RN	Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists. Bioorg Med Chem. 2009 Apr 1;17(7):2842-51.
DMF04YH	RU	https://pubmed.ncbi.nlm.nih.gov/19278853

DMSIAMN	DI	DMSIAMN
DMSIAMN	DN	3-Benzyl-5-methoxychromen-2-one
DMSIAMN	MI	TT6OEDT
DMSIAMN	MN	Cannabinoid receptor 1 (CB1)
DMSIAMN	MT	DTT
DMSIAMN	MA	Inhibitor
DMSIAMN	RN	Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists. Bioorg Med Chem. 2009 Apr 1;17(7):2842-51.
DMSIAMN	RU	https://pubmed.ncbi.nlm.nih.gov/19278853

DMHYQ3Z	DI	DMHYQ3Z
DMHYQ3Z	DN	3-benzyl-5-methylbenzo[d]oxazol-2(3H)-one
DMHYQ3Z	MI	TT6804T
DMHYQ3Z	MN	MIF messenger RNA (MIF mRNA)
DMHYQ3Z	MT	DTT
DMHYQ3Z	MA	Inhibitor
DMHYQ3Z	RN	Optimization of N-benzyl-benzoxazol-2-ones as receptor antagonists of macrophage migration inhibitory factor (MIF). Bioorg Med Chem Lett. 2010 Oct 1;20(19):5811-4.
DMHYQ3Z	RU	https://pubmed.ncbi.nlm.nih.gov/20728358

DMGPKIY	DI	DMGPKIY
DMGPKIY	DN	3-benzyl-6-methylbenzo[d]oxazol-2(3H)-one
DMGPKIY	MI	TT6804T
DMGPKIY	MN	MIF messenger RNA (MIF mRNA)
DMGPKIY	MT	DTT
DMGPKIY	MA	Inhibitor
DMGPKIY	RN	Optimization of N-benzyl-benzoxazol-2-ones as receptor antagonists of macrophage migration inhibitory factor (MIF). Bioorg Med Chem Lett. 2010 Oct 1;20(19):5811-4.
DMGPKIY	RU	https://pubmed.ncbi.nlm.nih.gov/20728358

DMHQ467	DI	DMHQ467
DMHQ467	DN	3-Benzyl-7-methyl-[1,8]naphthyridin-4-ol
DMHQ467	MI	TTK25J1
DMHQ467	MN	Adenosine A1 receptor (ADORA1)
DMHQ467	MT	DTT
DMHQ467	MA	Inhibitor
DMHQ467	RN	1,8-Naphthyridin-4-one derivatives as new ligands of A2A adenosine receptors. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4604-10.
DMHQ467	RU	https://pubmed.ncbi.nlm.nih.gov/16099648

DMHQ467	DI	DMHQ467
DMHQ467	DN	3-Benzyl-7-methyl-[1,8]naphthyridin-4-ol
DMHQ467	MI	TTM2AOE
DMHQ467	MN	Adenosine A2a receptor (ADORA2A)
DMHQ467	MT	DTT
DMHQ467	MA	Inhibitor
DMHQ467	RN	1,8-Naphthyridin-4-one derivatives as new ligands of A2A adenosine receptors. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4604-10.
DMHQ467	RU	https://pubmed.ncbi.nlm.nih.gov/16099648

DM12RH3	DI	DM12RH3
DM12RH3	DN	3-Benzyl-7-methyl-[1,8]naphthyridine-4-thiol
DM12RH3	MI	TTK25J1
DM12RH3	MN	Adenosine A1 receptor (ADORA1)
DM12RH3	MT	DTT
DM12RH3	MA	Inhibitor
DM12RH3	RN	1,8-Naphthyridin-4-one derivatives as new ligands of A2A adenosine receptors. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4604-10.
DM12RH3	RU	https://pubmed.ncbi.nlm.nih.gov/16099648

DM12RH3	DI	DM12RH3
DM12RH3	DN	3-Benzyl-7-methyl-[1,8]naphthyridine-4-thiol
DM12RH3	MI	TTM2AOE
DM12RH3	MN	Adenosine A2a receptor (ADORA2A)
DM12RH3	MT	DTT
DM12RH3	MA	Inhibitor
DM12RH3	RN	1,8-Naphthyridin-4-one derivatives as new ligands of A2A adenosine receptors. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4604-10.
DM12RH3	RU	https://pubmed.ncbi.nlm.nih.gov/16099648

DMB4WP5	DI	DMB4WP5
DMB4WP5	DN	3-Benzylamino-5-ethyl-6-methyl-1H-pyridin-2-one
DMB4WP5	MI	TT84ETX
DMB4WP5	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMB4WP5	MT	DTT
DMB4WP5	MA	Inhibitor
DMB4WP5	RN	Synthesis and evaluation of 2-pyridinone derivatives as HIV-1-specific reverse transcriptase inhibitors. 2. Analogues of 3-aminopyridin-2(1H)-one. J Med Chem. 1992 Oct 16;35(21):3792-802.
DMB4WP5	RU	https://pubmed.ncbi.nlm.nih.gov/1279173

DMZIOJS	DI	DMZIOJS
DMZIOJS	DN	3-benzyl-N-(2-morpholinoethyl)quinoxalin-2-amine
DMZIOJS	MI	TT3WG5C
DMZIOJS	MN	Monoamine oxidase type A (MAO-A)
DMZIOJS	MT	DTT
DMZIOJS	MA	Inhibitor
DMZIOJS	RN	Synthesis of 3-benzyl-2-substituted quinoxalines as novel monoamine oxidase A inhibitors. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1753-6.
DMZIOJS	RU	https://pubmed.ncbi.nlm.nih.gov/16356714

DM94K83	DI	DM94K83
DM94K83	DN	3-Benzyloxy-2-phenyl-piperidine
DM94K83	MI	TTZPO1L
DM94K83	MN	Substance-P receptor (TACR1)
DM94K83	MT	DTT
DM94K83	MA	Inhibitor
DM94K83	RN	3-Benzyloxy-2-phenylpiperidine NK1 antagonists: the influence of alpha methyl substitution, Bioorg. Med. Chem. Lett. 7(23):2959-2962 (1997).
DM94K83	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97101184

DMKD874	DI	DMKD874
DMKD874	DN	3-benzyloxy-4-methoxy-2'-hydroxychalcone
DMKD874	MI	TTVKILB
DMKD874	MN	Prostaglandin G/H synthase 2 (COX-2)
DMKD874	MT	DTT
DMKD874	MA	Inhibitor
DMKD874	RN	Inhibitory activity of prostaglandin E2 production by the synthetic 2'-hydroxychalcone analogues: Synthesis and SAR study. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1650-3.
DMKD874	RU	https://pubmed.ncbi.nlm.nih.gov/19233646

DMPG315	DI	DMPG315
DMPG315	DN	3-Benzyloxy-6,7-dimethoxy-quinoline
DMPG315	MI	TT8FYO9
DMPG315	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMPG315	MT	DTT
DMPG315	MA	Inhibitor
DMPG315	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMPG315	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMPG315	DI	DMPG315
DMPG315	DN	3-Benzyloxy-6,7-dimethoxy-quinoline
DMPG315	MI	TTI7421
DMPG315	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMPG315	MT	DTT
DMPG315	MA	Inhibitor
DMPG315	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMPG315	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMLEXWC	DI	DMLEXWC
DMLEXWC	DN	3beta,6beta-dihydroxyolean-12-en-27-oic acid
DMLEXWC	MI	TTELIN2
DMLEXWC	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMLEXWC	MT	DTT
DMLEXWC	MA	Inhibitor
DMLEXWC	RN	Protein tyrosine phosphatase 1B inhibitory activity of triterpenes isolated from Astilbe koreana. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3273-6.
DMLEXWC	RU	https://pubmed.ncbi.nlm.nih.gov/16580200

DMOZAHB	DI	DMOZAHB
DMOZAHB	DN	3beta-acetoxyolean-12-en-27-oic acid
DMOZAHB	MI	TTELIN2
DMOZAHB	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMOZAHB	MT	DTT
DMOZAHB	MA	Inhibitor
DMOZAHB	RN	Protein tyrosine phosphatase 1B inhibitory activity of triterpenes isolated from Astilbe koreana. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3273-6.
DMOZAHB	RU	https://pubmed.ncbi.nlm.nih.gov/16580200

DMF6VGK	DI	DMF6VGK
DMF6VGK	DN	3beta-hydroxyolean-12-en-27-oic acid
DMF6VGK	MI	TTELIN2
DMF6VGK	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMF6VGK	MT	DTT
DMF6VGK	MA	Inhibitor
DMF6VGK	RN	Protein tyrosine phosphatase 1B inhibitory activity of triterpenes isolated from Astilbe koreana. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3273-6.
DMF6VGK	RU	https://pubmed.ncbi.nlm.nih.gov/16580200

DML8NY0	DI	DML8NY0
DML8NY0	DN	3beta-hydroxyrus-12,19(29)-dien-28-oic acid
DML8NY0	MI	TTIU7X1
DML8NY0	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DML8NY0	MT	DTT
DML8NY0	MA	Inhibitor
DML8NY0	RN	DNA polymerase beta inhibitors from Baeckea gunniana. J Nat Prod. 1999 Dec;62(12):1624-6.
DML8NY0	RU	https://pubmed.ncbi.nlm.nih.gov/10654412

DMKL59W	DI	DMKL59W
DMKL59W	DN	3beta-hydroxyrus-18,20(30)-dien-28-oic acid
DMKL59W	MI	TTIU7X1
DMKL59W	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMKL59W	MT	DTT
DMKL59W	MA	Inhibitor
DMKL59W	RN	DNA polymerase beta inhibitors from Baeckea gunniana. J Nat Prod. 1999 Dec;62(12):1624-6.
DMKL59W	RU	https://pubmed.ncbi.nlm.nih.gov/10654412

DM6NFO0	DI	DM6NFO0
DM6NFO0	DN	3beta-hydroxyurs-12-en-27-oic acid
DM6NFO0	MI	TTELIN2
DM6NFO0	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DM6NFO0	MT	DTT
DM6NFO0	MA	Inhibitor
DM6NFO0	RN	Protein tyrosine phosphatase 1B inhibitory activity of triterpenes isolated from Astilbe koreana. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3273-6.
DM6NFO0	RU	https://pubmed.ncbi.nlm.nih.gov/16580200

DMZ8WMA	DI	DMZ8WMA
DMZ8WMA	DN	3-bicyclo[2.2.1]hept-2-yl-benzene-1,2-diol
DMZ8WMA	MI	TT5OEKU
DMZ8WMA	MN	Voltage-gated potassium channel Kv2.1 (KCNB1)
DMZ8WMA	MT	DTT
DMZ8WMA	MA	Blocker (channel blocker)
DMZ8WMA	RN	Novel neuroprotective K+ channel inhibitor identified by high-throughput screening in yeast. Mol Pharmacol. 2004 Jan;65(1):214-9.
DMZ8WMA	RU	https://pubmed.ncbi.nlm.nih.gov/14722253

DMHSAOQ	DI	DMHSAOQ
DMHSAOQ	DN	3-Biphenyl-3-yl-N-hydroxy-N-methyl-acrylamide
DMHSAOQ	MI	TT2J34L
DMHSAOQ	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMHSAOQ	MT	DTT
DMHSAOQ	MA	Inhibitor
DMHSAOQ	RN	Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8.
DMHSAOQ	RU	https://pubmed.ncbi.nlm.nih.gov/2308149

DMMC2Q9	DI	DMMC2Q9
DMMC2Q9	DN	3-biphenyl-4-ylethynyl-5-methyl-[1,2,4]triazine
DMMC2Q9	MI	TTHS256
DMMC2Q9	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMMC2Q9	MT	DTT
DMMC2Q9	MA	Inhibitor
DMMC2Q9	RN	Synthesis and pharmacological evaluation of phenylethynyl[1,2,4]methyltriazines as analogues of 3-methyl-6-(phenylethynyl)pyridine. J Med Chem. 2007 Jul 12;50(14):3388-91.
DMMC2Q9	RU	https://pubmed.ncbi.nlm.nih.gov/17569516

DMKBRIM	DI	DMKBRIM
DMKBRIM	DN	3-Biphenyl-4-yl-N-hydroxy-N-methyl-acrylamide
DMKBRIM	MI	TT2J34L
DMKBRIM	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMKBRIM	MT	DTT
DMKBRIM	MA	Inhibitor
DMKBRIM	RN	Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8.
DMKBRIM	RU	https://pubmed.ncbi.nlm.nih.gov/2308149

DMRCJW0	DI	DMRCJW0
DMRCJW0	DN	3-boronobenzoic acid
DMRCJW0	MI	TTLP6GN
DMRCJW0	MN	Bacterial DD-carboxypeptidase (Bact vanYB)
DMRCJW0	MT	DTT
DMRCJW0	MA	Inhibitor
DMRCJW0	RN	Synthesis and evaluation of 3-(dihydroxyboryl)benzoic acids as D,D-carboxypeptidase R39 inhibitors. J Med Chem. 2009 Oct 8;52(19):6097-106.
DMRCJW0	RU	https://pubmed.ncbi.nlm.nih.gov/19731939

DM03ROH	DI	DM03ROH
DM03ROH	DN	3-bromo-1-(4-hexylphenyl)propan-1-one
DM03ROH	MI	TTTSEPU
DM03ROH	MN	Thyroid hormone receptor alpha (THRA)
DM03ROH	MT	DTT
DM03ROH	MA	Inhibitor
DM03ROH	RN	Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80.
DM03ROH	RU	https://pubmed.ncbi.nlm.nih.gov/17918822

DM03ROH	DI	DM03ROH
DM03ROH	DN	3-bromo-1-(4-hexylphenyl)propan-1-one
DM03ROH	MI	TTGER3L
DM03ROH	MN	Thyroid hormone receptor beta (THRB)
DM03ROH	MT	DTT
DM03ROH	MA	Inhibitor
DM03ROH	RN	Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80.
DM03ROH	RU	https://pubmed.ncbi.nlm.nih.gov/17918822

DMZGWL2	DI	DMZGWL2
DMZGWL2	DN	3-Bromo-1H-indazole-7-carbonitrile
DMZGWL2	MI	TTZUFI5
DMZGWL2	MN	Nitric-oxide synthase brain (NOS1)
DMZGWL2	MT	DTT
DMZGWL2	MA	Inhibitor
DMZGWL2	RN	Inhibitory effects of a series of 7-substituted-indazoles toward nitric oxide synthases: particular potency of 1H-indazole-7-carbonitrile. Bioorg Med Chem. 2008 Jun 1;16(11):5962-73.
DMZGWL2	RU	https://pubmed.ncbi.nlm.nih.gov/18502134

DMZGWL2	DI	DMZGWL2
DMZGWL2	DN	3-Bromo-1H-indazole-7-carbonitrile
DMZGWL2	MI	TTCM4B3
DMZGWL2	MN	Nitric-oxide synthase endothelial (NOS3)
DMZGWL2	MT	DTT
DMZGWL2	MA	Inhibitor
DMZGWL2	RN	Inhibitory effects of a series of 7-substituted-indazoles toward nitric oxide synthases: particular potency of 1H-indazole-7-carbonitrile. Bioorg Med Chem. 2008 Jun 1;16(11):5962-73.
DMZGWL2	RU	https://pubmed.ncbi.nlm.nih.gov/18502134

DMZGWL2	DI	DMZGWL2
DMZGWL2	DN	3-Bromo-1H-indazole-7-carbonitrile
DMZGWL2	MI	TTF10I9
DMZGWL2	MN	Nitric-oxide synthase inducible (NOS2)
DMZGWL2	MT	DTT
DMZGWL2	MA	Inhibitor
DMZGWL2	RN	Inhibitory effects of a series of 7-substituted-indazoles toward nitric oxide synthases: particular potency of 1H-indazole-7-carbonitrile. Bioorg Med Chem. 2008 Jun 1;16(11):5962-73.
DMZGWL2	RU	https://pubmed.ncbi.nlm.nih.gov/18502134

DM1BALV	DI	DM1BALV
DM1BALV	DN	3-Bromo-2'-hydroxy-4-methoxychalcone
DM1BALV	MI	TTVKILB
DM1BALV	MN	Prostaglandin G/H synthase 2 (COX-2)
DM1BALV	MT	DTT
DM1BALV	MA	Inhibitor
DM1BALV	RN	Inhibitory activity of prostaglandin E2 production by the synthetic 2'-hydroxychalcone analogues: Synthesis and SAR study. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1650-3.
DM1BALV	RU	https://pubmed.ncbi.nlm.nih.gov/19233646

DMPZ4M8	DI	DMPZ4M8
DMPZ4M8	DN	3-bromo-4,4',5-trimethoxy-(Z)-stilbene
DMPZ4M8	MI	TTYFKSZ
DMPZ4M8	MN	Tubulin beta (TUBB)
DMPZ4M8	MT	DTT
DMPZ4M8	MA	Inhibitor
DMPZ4M8	RN	2-amino and 2'-aminocombretastatin derivatives as potent antimitotic agents. J Med Chem. 2006 Oct 19;49(21):6412-5.
DMPZ4M8	RU	https://pubmed.ncbi.nlm.nih.gov/17034147

DMPZ4M8	DI	DMPZ4M8
DMPZ4M8	DN	3-bromo-4,4',5-trimethoxy-(Z)-stilbene
DMPZ4M8	MI	TTJ2PTI
DMPZ4M8	MN	Tubulin beta-2 chain (TUBB2)
DMPZ4M8	MT	DTT
DMPZ4M8	MA	Inhibitor
DMPZ4M8	RN	2-amino and 2'-aminocombretastatin derivatives as potent antimitotic agents. J Med Chem. 2006 Oct 19;49(21):6412-5.
DMPZ4M8	RU	https://pubmed.ncbi.nlm.nih.gov/17034147

DMPQOS2	DI	DMPQOS2
DMPQOS2	DN	3-bromo-5-(2-methylquinolin-7-yl)benzonitrile
DMPQOS2	MI	TTHS256
DMPQOS2	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMPQOS2	MT	DTT
DMPQOS2	MA	Inhibitor
DMPQOS2	RN	Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8.
DMPQOS2	RU	https://pubmed.ncbi.nlm.nih.gov/17590335

DMOXY78	DI	DMOXY78
DMOXY78	DN	3-bromo-5-[(2-methyl-4-thiazolyl)ethynyl]pyridine
DMOXY78	MI	TTHS256
DMOXY78	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMOXY78	MT	DTT
DMOXY78	MA	Inhibitor
DMOXY78	RN	Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100.
DMOXY78	RU	https://pubmed.ncbi.nlm.nih.gov/16451073

DMZTDCL	DI	DMZTDCL
DMZTDCL	DN	3-Bromo-5-phenylsalicylc acid
DMZTDCL	MI	TT5ZWB6
DMZTDCL	MN	Dihydrodiol dehydrogenase type I (AKR1C3)
DMZTDCL	MT	DTT
DMZTDCL	MA	Inhibitor
DMZTDCL	RN	Structure-guided design, synthesis, and evaluation of salicylic acid-based inhibitors targeting a selectivity pocket in the active site of human 20... J Med Chem. 2009 May 28;52(10):3259-64.
DMZTDCL	RU	https://pubmed.ncbi.nlm.nih.gov/19397269

DMXZB5C	DI	DMXZB5C
DMXZB5C	DN	3-Bromo-6-nitro-2-piperazin-1-yl-quinoline
DMXZB5C	MI	TT3ROYC
DMXZB5C	MN	Serotonin transporter (SERT)
DMXZB5C	MT	DTT
DMXZB5C	MA	Inhibitor
DMXZB5C	RN	Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 1. Bioorg Med Chem Lett. 2000 Jul 17;10(14):1559-62.
DMXZB5C	RU	https://pubmed.ncbi.nlm.nih.gov/10915050

DMM7DHB	DI	DMM7DHB
DMM7DHB	DN	3-bromo-7-nitro-1H-indazole
DMM7DHB	MI	TTZUFI5
DMM7DHB	MN	Nitric-oxide synthase brain (NOS1)
DMM7DHB	MT	DTT
DMM7DHB	MA	Inhibitor
DMM7DHB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMM7DHB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMM7DHB	DI	DMM7DHB
DMM7DHB	DN	3-bromo-7-nitro-1H-indazole
DMM7DHB	MI	TTCM4B3
DMM7DHB	MN	Nitric-oxide synthase endothelial (NOS3)
DMM7DHB	MT	DTT
DMM7DHB	MA	Inhibitor
DMM7DHB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMM7DHB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMM7DHB	DI	DMM7DHB
DMM7DHB	DN	3-bromo-7-nitro-1H-indazole
DMM7DHB	MI	TTF10I9
DMM7DHB	MN	Nitric-oxide synthase inducible (NOS2)
DMM7DHB	MT	DTT
DMM7DHB	MA	Inhibitor
DMM7DHB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMM7DHB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMPF7O2	DI	DMPF7O2
DMPF7O2	DN	3-bromoboldine
DMPF7O2	MI	TTZFYLI
DMPF7O2	MN	Dopamine D1 receptor (D1R)
DMPF7O2	MT	DTT
DMPF7O2	MA	Inhibitor
DMPF7O2	RN	Halogenated boldine derivatives with enhanced monoamine receptor selectivity. J Nat Prod. 2000 Apr;63(4):480-4.
DMPF7O2	RU	https://pubmed.ncbi.nlm.nih.gov/10785418

DMPF7O2	DI	DMPF7O2
DMPF7O2	DN	3-bromoboldine
DMPF7O2	MI	TTEX248
DMPF7O2	MN	Dopamine D2 receptor (D2R)
DMPF7O2	MT	DTT
DMPF7O2	MA	Inhibitor
DMPF7O2	RN	Halogenated boldine derivatives with enhanced monoamine receptor selectivity. J Nat Prod. 2000 Apr;63(4):480-4.
DMPF7O2	RU	https://pubmed.ncbi.nlm.nih.gov/10785418

DMPF7O2	DI	DMPF7O2
DMPF7O2	DN	3-bromoboldine
DMPF7O2	MI	TTLA931
DMPF7O2	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMPF7O2	MT	DTT
DMPF7O2	MA	Inhibitor
DMPF7O2	RN	Aporphine metho salts as neuronal nicotinic acetylcholine receptor blockers. Bioorg Med Chem. 2007 May 15;15(10):3368-72.
DMPF7O2	RU	https://pubmed.ncbi.nlm.nih.gov/17391965

DM62Y1S	DI	DM62Y1S
DM62Y1S	DN	3-bromo-N-(6-methylpyridin-2-yl)benzamide
DM62Y1S	MI	TTHS256
DM62Y1S	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM62Y1S	MT	DTT
DM62Y1S	MA	Inhibitor
DM62Y1S	RN	Design and synthesis of noncompetitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3371-5.
DM62Y1S	RU	https://pubmed.ncbi.nlm.nih.gov/16678408

DMXZW3R	DI	DMXZW3R
DMXZW3R	DN	3-bromophenyl-difluoromethanesulfonamide
DMXZW3R	MI	TTUNARX
DMXZW3R	MN	Carbonic anhydrase (CA)
DMXZW3R	MT	DTT
DMXZW3R	MA	Inhibitor
DMXZW3R	RN	Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6.
DMXZW3R	RU	https://pubmed.ncbi.nlm.nih.gov/16203142

DMXZW3R	DI	DMXZW3R
DMXZW3R	DN	3-bromophenyl-difluoromethanesulfonamide
DMXZW3R	MI	TTHQPL7
DMXZW3R	MN	Carbonic anhydrase I (CA-I)
DMXZW3R	MT	DTT
DMXZW3R	MA	Inhibitor
DMXZW3R	RN	Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6.
DMXZW3R	RU	https://pubmed.ncbi.nlm.nih.gov/16203142

DMXZW3R	DI	DMXZW3R
DMXZW3R	DN	3-bromophenyl-difluoromethanesulfonamide
DMXZW3R	MI	TTANPDJ
DMXZW3R	MN	Carbonic anhydrase II (CA-II)
DMXZW3R	MT	DTT
DMXZW3R	MA	Inhibitor
DMXZW3R	RN	Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6.
DMXZW3R	RU	https://pubmed.ncbi.nlm.nih.gov/16203142

DMXZW3R	DI	DMXZW3R
DMXZW3R	DN	3-bromophenyl-difluoromethanesulfonamide
DMXZW3R	MI	TT2LVK8
DMXZW3R	MN	Carbonic anhydrase IX (CA-IX)
DMXZW3R	MT	DTT
DMXZW3R	MA	Inhibitor
DMXZW3R	RN	Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6.
DMXZW3R	RU	https://pubmed.ncbi.nlm.nih.gov/16203142

DMK7D8N	DI	DMK7D8N
DMK7D8N	DN	3'-bromopropiophenonethiosemicarbazone
DMK7D8N	MI	TTEAID7
DMK7D8N	MN	Trypanosoma Cruzipain (Trypano CYSP)
DMK7D8N	MT	DTT
DMK7D8N	MA	Inhibitor
DMK7D8N	RN	Studies toward the structural optimization of novel thiazolylhydrazone-based potent antitrypanosomal agents. Bioorg Med Chem. 2010 Nov 15;18(22):7826-35.
DMK7D8N	RU	https://pubmed.ncbi.nlm.nih.gov/20961766

DMYL3ST	DI	DMYL3ST
DMYL3ST	DN	3-bromopyruvate
DMYL3ST	MI	TT58ZYW
DMYL3ST	MN	Mycobacterium Isocitrate lyase (MycB icl)
DMYL3ST	MT	DTT
DMYL3ST	MA	Inhibitor
DMYL3ST	RN	Structure of isocitrate lyase, a persistence factor of Mycobacterium tuberculosis. Nat Struct Biol. 2000 Aug;7(8):663-8.
DMYL3ST	RU	https://pubmed.ncbi.nlm.nih.gov/10932251

DMQ8H74	DI	DMQ8H74
DMQ8H74	DN	3-Butoxy-9H-beta-carboline
DMQ8H74	MI	TT1MPAY
DMQ8H74	MN	GABA(A) receptor alpha-1 (GABRA1)
DMQ8H74	MT	DTT
DMQ8H74	MA	Inhibitor
DMQ8H74	RN	Predictive binding of beta-carboline inverse agonists and antagonists via the CoMFA/GOLPE approach. J Med Chem. 1992 Oct 30;35(22):4001-10.
DMQ8H74	RU	https://pubmed.ncbi.nlm.nih.gov/1331452

DMQ8H74	DI	DMQ8H74
DMQ8H74	DN	3-Butoxy-9H-beta-carboline
DMQ8H74	MI	TTBMV1G
DMQ8H74	MN	GABA(A) receptor alpha-2 (GABRA2)
DMQ8H74	MT	DTT
DMQ8H74	MA	Inhibitor
DMQ8H74	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DMQ8H74	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DMQ8H74	DI	DMQ8H74
DMQ8H74	DN	3-Butoxy-9H-beta-carboline
DMQ8H74	MI	TT37EDJ
DMQ8H74	MN	GABA(A) receptor alpha-3 (GABRA3)
DMQ8H74	MT	DTT
DMQ8H74	MA	Inhibitor
DMQ8H74	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DMQ8H74	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DMQ8H74	DI	DMQ8H74
DMQ8H74	DN	3-Butoxy-9H-beta-carboline
DMQ8H74	MI	TTNZPQ1
DMQ8H74	MN	GABA(A) receptor alpha-5 (GABRA5)
DMQ8H74	MT	DTT
DMQ8H74	MA	Inhibitor
DMQ8H74	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DMQ8H74	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DMQ8H74	DI	DMQ8H74
DMQ8H74	DN	3-Butoxy-9H-beta-carboline
DMQ8H74	MI	TT06RH5
DMQ8H74	MN	GABA(A) receptor gamma-2 (GABRG2)
DMQ8H74	MT	DTT
DMQ8H74	MA	Inhibitor
DMQ8H74	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DMQ8H74	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DMQ8H74	DI	DMQ8H74
DMQ8H74	DN	3-Butoxy-9H-beta-carboline
DMQ8H74	MI	TTNJYV2
DMQ8H74	MN	Gamma-aminobutyric acid receptor (GAR)
DMQ8H74	MT	DTT
DMQ8H74	MA	Inhibitor
DMQ8H74	RN	Predictive binding of beta-carboline inverse agonists and antagonists via the CoMFA/GOLPE approach. J Med Chem. 1992 Oct 30;35(22):4001-10.
DMQ8H74	RU	https://pubmed.ncbi.nlm.nih.gov/1331452

DMRF2Q8	DI	DMRF2Q8
DMRF2Q8	DN	3-butoxycarbonyl-4-quinolone
DMRF2Q8	MI	TT1MPAY
DMRF2Q8	MN	GABA(A) receptor alpha-1 (GABRA1)
DMRF2Q8	MT	DTT
DMRF2Q8	MA	Inhibitor
DMRF2Q8	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMRF2Q8	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMRF2Q8	DI	DMRF2Q8
DMRF2Q8	DN	3-butoxycarbonyl-4-quinolone
DMRF2Q8	MI	TTZA1NY
DMRF2Q8	MN	GABA(A) receptor beta-2 (GABRB2)
DMRF2Q8	MT	DTT
DMRF2Q8	MA	Inhibitor
DMRF2Q8	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMRF2Q8	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMRF2Q8	DI	DMRF2Q8
DMRF2Q8	DN	3-butoxycarbonyl-4-quinolone
DMRF2Q8	MI	TT06RH5
DMRF2Q8	MN	GABA(A) receptor gamma-2 (GABRG2)
DMRF2Q8	MT	DTT
DMRF2Q8	MA	Inhibitor
DMRF2Q8	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMRF2Q8	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMRF2Q8	DI	DMRF2Q8
DMRF2Q8	DN	3-butoxycarbonyl-4-quinolone
DMRF2Q8	MI	TTNJYV2
DMRF2Q8	MN	Gamma-aminobutyric acid receptor (GAR)
DMRF2Q8	MT	DTT
DMRF2Q8	MA	Inhibitor
DMRF2Q8	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMRF2Q8	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMD6PMZ	DI	DMD6PMZ
DMD6PMZ	DN	3-butoxycarbonyl-6-ethyl-4-quinolone
DMD6PMZ	MI	TT1MPAY
DMD6PMZ	MN	GABA(A) receptor alpha-1 (GABRA1)
DMD6PMZ	MT	DTT
DMD6PMZ	MA	Inhibitor
DMD6PMZ	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMD6PMZ	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMD6PMZ	DI	DMD6PMZ
DMD6PMZ	DN	3-butoxycarbonyl-6-ethyl-4-quinolone
DMD6PMZ	MI	TTZA1NY
DMD6PMZ	MN	GABA(A) receptor beta-2 (GABRB2)
DMD6PMZ	MT	DTT
DMD6PMZ	MA	Inhibitor
DMD6PMZ	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMD6PMZ	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMD6PMZ	DI	DMD6PMZ
DMD6PMZ	DN	3-butoxycarbonyl-6-ethyl-4-quinolone
DMD6PMZ	MI	TT06RH5
DMD6PMZ	MN	GABA(A) receptor gamma-2 (GABRG2)
DMD6PMZ	MT	DTT
DMD6PMZ	MA	Inhibitor
DMD6PMZ	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMD6PMZ	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMD6PMZ	DI	DMD6PMZ
DMD6PMZ	DN	3-butoxycarbonyl-6-ethyl-4-quinolone
DMD6PMZ	MI	TTNJYV2
DMD6PMZ	MN	Gamma-aminobutyric acid receptor (GAR)
DMD6PMZ	MT	DTT
DMD6PMZ	MA	Inhibitor
DMD6PMZ	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMD6PMZ	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMRI503	DI	DMRI503
DMRI503	DN	3-Butyl-[1,4]oxazepan-(5Z)-ylideneamine
DMRI503	MI	TTF10I9
DMRI503	MN	Nitric-oxide synthase inducible (NOS2)
DMRI503	MT	DTT
DMRI503	MA	Inhibitor
DMRI503	RN	Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3.
DMRI503	RU	https://pubmed.ncbi.nlm.nih.gov/11551770

DM6A80U	DI	DM6A80U
DM6A80U	DN	3-Butyl-[1,4]thiazepan-(5E)-ylideneamine
DM6A80U	MI	TTZUFI5
DM6A80U	MN	Nitric-oxide synthase brain (NOS1)
DM6A80U	MT	DTT
DM6A80U	MA	Inhibitor
DM6A80U	RN	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
DM6A80U	RU	https://pubmed.ncbi.nlm.nih.gov/15501067

DM6A80U	DI	DM6A80U
DM6A80U	DN	3-Butyl-[1,4]thiazepan-(5E)-ylideneamine
DM6A80U	MI	TTF10I9
DM6A80U	MN	Nitric-oxide synthase inducible (NOS2)
DM6A80U	MT	DTT
DM6A80U	MA	Inhibitor
DM6A80U	RN	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
DM6A80U	RU	https://pubmed.ncbi.nlm.nih.gov/15501067

DMXF8M0	DI	DMXF8M0
DMXF8M0	DN	3-butyl-1-(naphthalen-1-yl)piperidin-4-amine
DMXF8M0	MI	TTDIGC1
DMXF8M0	MN	Dipeptidyl peptidase 4 (DPP-4)
DMXF8M0	MT	DTT
DMXF8M0	MA	Inhibitor
DMXF8M0	RN	1,3-disubstituted 4-aminopiperidines as useful tools in the optimization of the 2-aminobenzo[a]quinolizine dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett. 2007 Jun 1;17(11):2966-70.
DMXF8M0	RU	https://pubmed.ncbi.nlm.nih.gov/17418568

DMDOPVM	DI	DMDOPVM
DMDOPVM	DN	3-Butyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-6-ol
DMDOPVM	MI	TTSQIFT
DMDOPVM	MN	5-HT 1A receptor (HTR1A)
DMDOPVM	MT	DTT
DMDOPVM	MA	Inhibitor
DMDOPVM	RN	6-Hydroxy-3-n-propyl-2,3,4,5-tetrahydro-1H-3-benzazepine and analogs: new centrally acting 5-HT1A receptor agonists. J Med Chem. 1992 Oct 30;35(22):3984-90.
DMDOPVM	RU	https://pubmed.ncbi.nlm.nih.gov/1433207

DMDOPVM	DI	DMDOPVM
DMDOPVM	DN	3-Butyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-6-ol
DMDOPVM	MI	TTEX248
DMDOPVM	MN	Dopamine D2 receptor (D2R)
DMDOPVM	MT	DTT
DMDOPVM	MA	Inhibitor
DMDOPVM	RN	6-Hydroxy-3-n-propyl-2,3,4,5-tetrahydro-1H-3-benzazepine and analogs: new centrally acting 5-HT1A receptor agonists. J Med Chem. 1992 Oct 30;35(22):3984-90.
DMDOPVM	RU	https://pubmed.ncbi.nlm.nih.gov/1433207

DMOGZUK	DI	DMOGZUK
DMOGZUK	DN	3-butyl-3-ethyl-1-phenylazetidine-2,4-dione
DMOGZUK	MI	TTPLTSQ
DMOGZUK	MN	Neutrophil elastase (NE)
DMOGZUK	MT	DTT
DMOGZUK	MA	Inhibitor
DMOGZUK	RN	4-Oxo-beta-lactams (azetidine-2,4-diones) are potent and selective inhibitors of human leukocyte elastase. J Med Chem. 2010 Jan 14;53(1):241-53.
DMOGZUK	RU	https://pubmed.ncbi.nlm.nih.gov/19904934

DM95XWR	DI	DM95XWR
DM95XWR	DN	3-butylaminocarbonyl-6-ethyl-4-quinolone
DM95XWR	MI	TT1MPAY
DM95XWR	MN	GABA(A) receptor alpha-1 (GABRA1)
DM95XWR	MT	DTT
DM95XWR	MA	Inhibitor
DM95XWR	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DM95XWR	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DM95XWR	DI	DM95XWR
DM95XWR	DN	3-butylaminocarbonyl-6-ethyl-4-quinolone
DM95XWR	MI	TTZA1NY
DM95XWR	MN	GABA(A) receptor beta-2 (GABRB2)
DM95XWR	MT	DTT
DM95XWR	MA	Inhibitor
DM95XWR	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DM95XWR	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DM95XWR	DI	DM95XWR
DM95XWR	DN	3-butylaminocarbonyl-6-ethyl-4-quinolone
DM95XWR	MI	TT06RH5
DM95XWR	MN	GABA(A) receptor gamma-2 (GABRG2)
DM95XWR	MT	DTT
DM95XWR	MA	Inhibitor
DM95XWR	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DM95XWR	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DM95XWR	DI	DM95XWR
DM95XWR	DN	3-butylaminocarbonyl-6-ethyl-4-quinolone
DM95XWR	MI	TTNJYV2
DM95XWR	MN	Gamma-aminobutyric acid receptor (GAR)
DM95XWR	MT	DTT
DM95XWR	MA	Inhibitor
DM95XWR	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DM95XWR	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMP6TLY	DI	DMP6TLY
DMP6TLY	DN	3-Carbamoyl-6-chloro-1H-indole-2-carboxylic acid
DMP6TLY	MI	TTLD29N
DMP6TLY	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMP6TLY	MT	DTT
DMP6TLY	MA	Inhibitor
DMP6TLY	RN	2-carboxy indolines and indoles as potential glycine/NMDA antagonists: effect of five-membered ring conformation on affinity. Bioorg. Med. Chem. Lett. 2(12):1627-1630 (1992).
DMP6TLY	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00804448

DM530OW	DI	DM530OW
DM530OW	DN	3'-carbamoylbiphenyl-3-yl 6-phenylhexylcarbamate
DM530OW	MI	TTDP1UC
DM530OW	MN	Fatty acid amide hydrolase (FAAH)
DM530OW	MT	DTT
DM530OW	MA	Inhibitor
DM530OW	RN	Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors. J Med Chem. 2008 Dec 11;51(23):7327-43.
DM530OW	RU	https://pubmed.ncbi.nlm.nih.gov/18983142

DMHUBT5	DI	DMHUBT5
DMHUBT5	DN	3-Carbazol-9-yl-propionic acid
DMHUBT5	MI	TTHWMFZ
DMHUBT5	MN	Fatty acid-binding protein 4 (FABP4)
DMHUBT5	MT	DTT
DMHUBT5	MA	Inhibitor
DMHUBT5	RN	Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4445-8.
DMHUBT5	RU	https://pubmed.ncbi.nlm.nih.gov/15357969

DMRUX93	DI	DMRUX93
DMRUX93	DN	3-carboxy-6-ethyl-4-quinolone
DMRUX93	MI	TT1MPAY
DMRUX93	MN	GABA(A) receptor alpha-1 (GABRA1)
DMRUX93	MT	DTT
DMRUX93	MA	Inhibitor
DMRUX93	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMRUX93	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMRUX93	DI	DMRUX93
DMRUX93	DN	3-carboxy-6-ethyl-4-quinolone
DMRUX93	MI	TTZA1NY
DMRUX93	MN	GABA(A) receptor beta-2 (GABRB2)
DMRUX93	MT	DTT
DMRUX93	MA	Inhibitor
DMRUX93	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMRUX93	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMRUX93	DI	DMRUX93
DMRUX93	DN	3-carboxy-6-ethyl-4-quinolone
DMRUX93	MI	TT06RH5
DMRUX93	MN	GABA(A) receptor gamma-2 (GABRG2)
DMRUX93	MT	DTT
DMRUX93	MA	Inhibitor
DMRUX93	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMRUX93	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMRUX93	DI	DMRUX93
DMRUX93	DN	3-carboxy-6-ethyl-4-quinolone
DMRUX93	MI	TTNJYV2
DMRUX93	MN	Gamma-aminobutyric acid receptor (GAR)
DMRUX93	MT	DTT
DMRUX93	MA	Inhibitor
DMRUX93	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMRUX93	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DM9OGNE	DI	DM9OGNE
DM9OGNE	DN	3-chloro-1-(4-hydroxyphenyl)propan-1-one
DM9OGNE	MI	TTT2LD9
DM9OGNE	MN	GABA transaminase (ABAT)
DM9OGNE	MT	DTT
DM9OGNE	MA	Inhibitor
DM9OGNE	RN	Inactivation of GABA transaminase by 3-chloro-1-(4-hydroxyphenyl)propan-1-one. Bioorg Med Chem Lett. 2009 Feb 1;19(3):731-4.
DM9OGNE	RU	https://pubmed.ncbi.nlm.nih.gov/19138517

DM3R8OM	DI	DM3R8OM
DM3R8OM	DN	3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
DM3R8OM	MI	TTZAYWL
DM3R8OM	MN	Estrogen receptor (ESR)
DM3R8OM	MT	DTT
DM3R8OM	MA	Inhibitor
DM3R8OM	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM3R8OM	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMZ5JFG	DI	DMZ5JFG
DMZ5JFG	DN	3-chloro-4-(4-chloro-2-hydroxyphenoxy)benzamide
DMZ5JFG	MI	TTNX2CS
DMZ5JFG	MN	Plasmodium Enoyl-ACP reductase (Malaria fabI)
DMZ5JFG	MT	DTT
DMZ5JFG	MA	Inhibitor
DMZ5JFG	RN	Synthesis, biological activity, and X-ray crystal structural analysis of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. ... Bioorg Med Chem Lett. 2005 Dec 1;15(23):5247-52.
DMZ5JFG	RU	https://pubmed.ncbi.nlm.nih.gov/16198563

DMER4U1	DI	DMER4U1
DMER4U1	DN	3-chloro-4-(4-hydroxyphenyl)salicylaldoxime
DMER4U1	MI	TTZAYWL
DMER4U1	MN	Estrogen receptor (ESR)
DMER4U1	MT	DTT
DMER4U1	MA	Inhibitor
DMER4U1	RN	Monoaryl-substituted salicylaldoximes as ligands for estrogen receptor beta. J Med Chem. 2008 Mar 13;51(5):1344-51.
DMER4U1	RU	https://pubmed.ncbi.nlm.nih.gov/18269232

DMER4U1	DI	DMER4U1
DMER4U1	DN	3-chloro-4-(4-hydroxyphenyl)salicylaldoxime
DMER4U1	MI	TTOM3J0
DMER4U1	MN	Estrogen receptor beta (ESR2)
DMER4U1	MT	DTT
DMER4U1	MA	Inhibitor
DMER4U1	RN	Monoaryl-substituted salicylaldoximes as ligands for estrogen receptor beta. J Med Chem. 2008 Mar 13;51(5):1344-51.
DMER4U1	RU	https://pubmed.ncbi.nlm.nih.gov/18269232

DMNQF03	DI	DMNQF03
DMNQF03	DN	3-chloro-4-(o-tolyloxy)benzonitrile
DMNQF03	MI	TTKPW01
DMNQF03	MN	Androgen receptor messenger RNA (AR mRNA)
DMNQF03	MT	DTT
DMNQF03	MA	Inhibitor
DMNQF03	RN	Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2176-8.
DMNQF03	RU	https://pubmed.ncbi.nlm.nih.gov/19286380

DM6Z3I8	DI	DM6Z3I8
DM6Z3I8	DN	3-chloro-4-(o-tolylthio)benzonitrile
DM6Z3I8	MI	TTKPW01
DM6Z3I8	MN	Androgen receptor messenger RNA (AR mRNA)
DM6Z3I8	MT	DTT
DM6Z3I8	MA	Inhibitor
DM6Z3I8	RN	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
DM6Z3I8	RU	https://pubmed.ncbi.nlm.nih.gov/19201190

DMSB5IQ	DI	DMSB5IQ
DMSB5IQ	DN	3-Chloro-4-hydrazino-benzenesulfonamide
DMSB5IQ	MI	TTHQPL7
DMSB5IQ	MN	Carbonic anhydrase I (CA-I)
DMSB5IQ	MT	DTT
DMSB5IQ	MA	Inhibitor
DMSB5IQ	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamide... J Med Chem. 2005 Mar 24;48(6):2121-5.
DMSB5IQ	RU	https://pubmed.ncbi.nlm.nih.gov/15771455

DMSB5IQ	DI	DMSB5IQ
DMSB5IQ	DN	3-Chloro-4-hydrazino-benzenesulfonamide
DMSB5IQ	MI	TTANPDJ
DMSB5IQ	MN	Carbonic anhydrase II (CA-II)
DMSB5IQ	MT	DTT
DMSB5IQ	MA	Inhibitor
DMSB5IQ	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamide... J Med Chem. 2005 Mar 24;48(6):2121-5.
DMSB5IQ	RU	https://pubmed.ncbi.nlm.nih.gov/15771455

DMSB5IQ	DI	DMSB5IQ
DMSB5IQ	DN	3-Chloro-4-hydrazino-benzenesulfonamide
DMSB5IQ	MI	TT2LVK8
DMSB5IQ	MN	Carbonic anhydrase IX (CA-IX)
DMSB5IQ	MT	DTT
DMSB5IQ	MA	Inhibitor
DMSB5IQ	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamide... J Med Chem. 2005 Mar 24;48(6):2121-5.
DMSB5IQ	RU	https://pubmed.ncbi.nlm.nih.gov/15771455

DMBMH96	DI	DMBMH96
DMBMH96	DN	3-chloro-5-(2-methylquinolin-7-yl)benzonitrile
DMBMH96	MI	TTHS256
DMBMH96	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMBMH96	MT	DTT
DMBMH96	MA	Inhibitor
DMBMH96	RN	Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8.
DMBMH96	RU	https://pubmed.ncbi.nlm.nih.gov/17590335

DMCD901	DI	DMCD901
DMCD901	DN	3-Chloro-9H-beta-carboline
DMCD901	MI	TT1MPAY
DMCD901	MN	GABA(A) receptor alpha-1 (GABRA1)
DMCD901	MT	DTT
DMCD901	MA	Inhibitor
DMCD901	RN	Synthesis of novel 3-substituted beta-carbolines as benzodiazepine receptor ligands: probing the benzodiazepine receptor pharmacophore. J Med Chem. 1988 Sep;31(9):1854-61.
DMCD901	RU	https://pubmed.ncbi.nlm.nih.gov/2842507

DMCD901	DI	DMCD901
DMCD901	DN	3-Chloro-9H-beta-carboline
DMCD901	MI	TTNJYV2
DMCD901	MN	Gamma-aminobutyric acid receptor (GAR)
DMCD901	MT	DTT
DMCD901	MA	Inhibitor
DMCD901	RN	Synthesis of novel 3-substituted beta-carbolines as benzodiazepine receptor ligands: probing the benzodiazepine receptor pharmacophore. J Med Chem. 1988 Sep;31(9):1854-61.
DMCD901	RU	https://pubmed.ncbi.nlm.nih.gov/2842507

DM5J1TX	DI	DM5J1TX
DM5J1TX	DN	3-Chloroboldine
DM5J1TX	MI	TTZFYLI
DM5J1TX	MN	Dopamine D1 receptor (D1R)
DM5J1TX	MT	DTT
DM5J1TX	MA	Inhibitor
DM5J1TX	RN	Halogenated boldine derivatives with enhanced monoamine receptor selectivity. J Nat Prod. 2000 Apr;63(4):480-4.
DM5J1TX	RU	https://pubmed.ncbi.nlm.nih.gov/10785418

DM5J1TX	DI	DM5J1TX
DM5J1TX	DN	3-Chloroboldine
DM5J1TX	MI	TTEX248
DM5J1TX	MN	Dopamine D2 receptor (D2R)
DM5J1TX	MT	DTT
DM5J1TX	MA	Inhibitor
DM5J1TX	RN	Halogenated boldine derivatives with enhanced monoamine receptor selectivity. J Nat Prod. 2000 Apr;63(4):480-4.
DM5J1TX	RU	https://pubmed.ncbi.nlm.nih.gov/10785418

DMIEZGD	DI	DMIEZGD
DMIEZGD	DN	3-Chloro-N-(2-methyl-1H-indol-5-yl)benzamide
DMIEZGD	MI	TT3WG5C
DMIEZGD	MN	Monoamine oxidase type A (MAO-A)
DMIEZGD	MT	DTT
DMIEZGD	MA	Inhibitor
DMIEZGD	RN	Inhibition of monoamine oxidase by indole and benzofuran derivatives. Eur J Med Chem. 2010 Oct;45(10):4458-66.
DMIEZGD	RU	https://pubmed.ncbi.nlm.nih.gov/20674099

DMIEZGD	DI	DMIEZGD
DMIEZGD	DN	3-Chloro-N-(2-methyl-1H-indol-5-yl)benzamide
DMIEZGD	MI	TTGP7BY
DMIEZGD	MN	Monoamine oxidase type B (MAO-B)
DMIEZGD	MT	DTT
DMIEZGD	MA	Inhibitor
DMIEZGD	RN	Inhibition of monoamine oxidase by indole and benzofuran derivatives. Eur J Med Chem. 2010 Oct;45(10):4458-66.
DMIEZGD	RU	https://pubmed.ncbi.nlm.nih.gov/20674099

DMV8TNO	DI	DMV8TNO
DMV8TNO	DN	3-chloro-N-(3-isobutyramidophenyl)benzamide
DMV8TNO	MI	TTHS256
DMV8TNO	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMV8TNO	MT	DTT
DMV8TNO	MA	Inhibitor
DMV8TNO	RN	Synthesis and SAR of novel, non-MPEP chemotype mGluR5 NAMs identified by functional HTS. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6502-6.
DMV8TNO	RU	https://pubmed.ncbi.nlm.nih.gov/19875287

DMBVCLY	DI	DMBVCLY
DMBVCLY	DN	3-chloro-N-(4-(phenyldiazenyl)phenyl)benzamide
DMBVCLY	MI	TTEAID7
DMBVCLY	MN	Trypanosoma Cruzipain (Trypano CYSP)
DMBVCLY	MT	DTT
DMBVCLY	MA	Inhibitor
DMBVCLY	RN	Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease. J Med Chem. 2010 Jan 14;53(1):37-51.
DMBVCLY	RU	https://pubmed.ncbi.nlm.nih.gov/19908840

DM4EL6M	DI	DM4EL6M
DM4EL6M	DN	3-chloro-N-(4-methylthiazol-2-yl)benzamide
DM4EL6M	MI	TTHS256
DM4EL6M	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM4EL6M	MT	DTT
DM4EL6M	MA	Inhibitor
DM4EL6M	RN	Design and synthesis of noncompetitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3371-5.
DM4EL6M	RU	https://pubmed.ncbi.nlm.nih.gov/16678408

DMAWC7S	DI	DMAWC7S
DMAWC7S	DN	3-Chloro-N-(4-phenyl-thiazol-2-yl)-benzamide
DMAWC7S	MI	TTK25J1
DMAWC7S	MN	Adenosine A1 receptor (ADORA1)
DMAWC7S	MT	DTT
DMAWC7S	MA	Inhibitor
DMAWC7S	RN	Substituted 4-phenyl-2-(phenylcarboxamido)-1,3-thiazole derivatives as antagonists for the adenosine A(1) receptor. Bioorg Med Chem Lett. 2001 Aug 6;11(15):2017-9.
DMAWC7S	RU	https://pubmed.ncbi.nlm.nih.gov/11454470

DMLC2I6	DI	DMLC2I6
DMLC2I6	DN	3-chloro-N-(6-chloropyridin-2-yl)benzamide
DMLC2I6	MI	TTHS256
DMLC2I6	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMLC2I6	MT	DTT
DMLC2I6	MA	Inhibitor
DMLC2I6	RN	Design and synthesis of noncompetitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3371-5.
DMLC2I6	RU	https://pubmed.ncbi.nlm.nih.gov/16678408

DMLJGF1	DI	DMLJGF1
DMLJGF1	DN	3-chloro-N-(6-methylpyridin-2-yl)benzamide
DMLJGF1	MI	TTHS256
DMLJGF1	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMLJGF1	MT	DTT
DMLJGF1	MA	Inhibitor
DMLJGF1	RN	Structure-activity relationships comparing N-(6-methylpyridin-yl)-substituted aryl amides to 2-methyl-6-(substituted-arylethynyl)pyridines or 2-met... J Med Chem. 2009 Jun 11;52(11):3563-75.
DMLJGF1	RU	https://pubmed.ncbi.nlm.nih.gov/19445453

DMQCVKO	DI	DMQCVKO
DMQCVKO	DN	3-chlorophenyl 10H-phenothiazine-10-carboxylate
DMQCVKO	MI	TTEB0GD
DMQCVKO	MN	Cholinesterase (BCHE)
DMQCVKO	MT	DTT
DMQCVKO	MA	Inhibitor
DMQCVKO	RN	Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. J Med Chem. 2008 Jul 24;51(14):4200-12.
DMQCVKO	RU	https://pubmed.ncbi.nlm.nih.gov/18570368

DMZ0F7E	DI	DMZ0F7E
DMZ0F7E	DN	3-chlorophenyl 2-oxo-2H-chromene-3-carboxylate
DMZ0F7E	MI	TT6L509
DMZ0F7E	MN	Coagulation factor IIa (F2)
DMZ0F7E	MT	DTT
DMZ0F7E	MA	Inhibitor
DMZ0F7E	RN	3,6-disubstituted coumarins as mechanism-based inhibitors of thrombin and factor Xa. J Med Chem. 2005 Dec 1;48(24):7592-603.
DMZ0F7E	RU	https://pubmed.ncbi.nlm.nih.gov/16302799

DMZ0F7E	DI	DMZ0F7E
DMZ0F7E	DN	3-chlorophenyl 2-oxo-2H-chromene-3-carboxylate
DMZ0F7E	MI	TTCIHJA
DMZ0F7E	MN	Coagulation factor Xa (F10)
DMZ0F7E	MT	DTT
DMZ0F7E	MA	Inhibitor
DMZ0F7E	RN	3,6-disubstituted coumarins as mechanism-based inhibitors of thrombin and factor Xa. J Med Chem. 2005 Dec 1;48(24):7592-603.
DMZ0F7E	RU	https://pubmed.ncbi.nlm.nih.gov/16302799

DMJ2SZ1	DI	DMJ2SZ1
DMJ2SZ1	DN	3-chlorophenyl 4-butoxybenzylcarbamate
DMJ2SZ1	MI	TTDP1UC
DMJ2SZ1	MN	Fatty acid amide hydrolase (FAAH)
DMJ2SZ1	MT	DTT
DMJ2SZ1	MA	Inhibitor
DMJ2SZ1	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DMJ2SZ1	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DMJ4SDM	DI	DMJ4SDM
DMJ4SDM	DN	3-chlorotyrosine
DMJ4SDM	MI	TTUHP71
DMJ4SDM	MN	Tyrosine 3-monooxygenase (TH)
DMJ4SDM	MT	DTT
DMJ4SDM	MA	Inhibitor
DMJ4SDM	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1243).
DMJ4SDM	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1243

DM78FWG	DI	DM78FWG
DM78FWG	DN	3-cis-p-coumaroyl maslinic acid
DM78FWG	MI	TTIU7X1
DM78FWG	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DM78FWG	MT	DTT
DM78FWG	MA	Inhibitor
DM78FWG	RN	DNA polymerase beta inhibitors from Tetracera boiviniana. J Nat Prod. 1999 Dec;62(12):1660-3.
DM78FWG	RU	https://pubmed.ncbi.nlm.nih.gov/10654414

DMF1PIW	DI	DMF1PIW
DMF1PIW	DN	3-cyano-5-fluoro-N-(3-fluorophenyl)benzamide
DMF1PIW	MI	TTHS256
DMF1PIW	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMF1PIW	MT	DTT
DMF1PIW	MA	Inhibitor
DMF1PIW	RN	3-Cyano-5-fluoro-N-arylbenzamides as negative allosteric modulators of mGlu(5): Identification of easily prepared tool compounds with CNS exposure ... Bioorg Med Chem Lett. 2010 Aug 1;20(15):4390-4.
DMF1PIW	RU	https://pubmed.ncbi.nlm.nih.gov/20598884

DMBA4XN	DI	DMBA4XN
DMBA4XN	DN	3-cyano-5-fluoro-N-(pyridin-2-yl)benzamide
DMBA4XN	MI	TTHS256
DMBA4XN	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMBA4XN	MT	DTT
DMBA4XN	MA	Inhibitor
DMBA4XN	RN	3-Cyano-5-fluoro-N-arylbenzamides as negative allosteric modulators of mGlu(5): Identification of easily prepared tool compounds with CNS exposure ... Bioorg Med Chem Lett. 2010 Aug 1;20(15):4390-4.
DMBA4XN	RU	https://pubmed.ncbi.nlm.nih.gov/20598884

DMF097H	DI	DMF097H
DMF097H	DN	3-cyano-5-fluoro-N-m-tolylbenzamide
DMF097H	MI	TTHS256
DMF097H	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMF097H	MT	DTT
DMF097H	MA	Inhibitor
DMF097H	RN	3-Cyano-5-fluoro-N-arylbenzamides as negative allosteric modulators of mGlu(5): Identification of easily prepared tool compounds with CNS exposure ... Bioorg Med Chem Lett. 2010 Aug 1;20(15):4390-4.
DMF097H	RU	https://pubmed.ncbi.nlm.nih.gov/20598884

DMIZ8RC	DI	DMIZ8RC
DMIZ8RC	DN	3-cyano-5-fluoro-N-phenylbenzamide
DMIZ8RC	MI	TTHS256
DMIZ8RC	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMIZ8RC	MT	DTT
DMIZ8RC	MA	Inhibitor
DMIZ8RC	RN	3-Cyano-5-fluoro-N-arylbenzamides as negative allosteric modulators of mGlu(5): Identification of easily prepared tool compounds with CNS exposure ... Bioorg Med Chem Lett. 2010 Aug 1;20(15):4390-4.
DMIZ8RC	RU	https://pubmed.ncbi.nlm.nih.gov/20598884

DMH7FC9	DI	DMH7FC9
DMH7FC9	DN	3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide
DMH7FC9	MI	TTHS256
DMH7FC9	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMH7FC9	MT	DTT
DMH7FC9	MA	Inhibitor
DMH7FC9	RN	Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H- pyrazol-5-yl)benzamides that potentiate receptor function in vivo. JMed Chem. 2004 Nov 18;47(24):5825-8.
DMH7FC9	RU	https://pubmed.ncbi.nlm.nih.gov/15537338

DM3EIWC	DI	DM3EIWC
DM3EIWC	DN	3-cyano-N-(1,4-diphenyl-1H-pyrazol-5-yl)benzamide
DM3EIWC	MI	TTHS256
DM3EIWC	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM3EIWC	MT	DTT
DM3EIWC	MA	Inhibitor
DM3EIWC	RN	Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat... J Med Chem. 2006 Jun 1;49(11):3332-44.
DM3EIWC	RU	https://pubmed.ncbi.nlm.nih.gov/16722652

DMRD8VM	DI	DMRD8VM
DMRD8VM	DN	3-cyano-N-(3-cyanophenyl)-5-fluorobenzamide
DMRD8VM	MI	TTHS256
DMRD8VM	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMRD8VM	MT	DTT
DMRD8VM	MA	Inhibitor
DMRD8VM	RN	3-Cyano-5-fluoro-N-arylbenzamides as negative allosteric modulators of mGlu(5): Identification of easily prepared tool compounds with CNS exposure ... Bioorg Med Chem Lett. 2010 Aug 1;20(15):4390-4.
DMRD8VM	RU	https://pubmed.ncbi.nlm.nih.gov/20598884

DMFUT57	DI	DMFUT57
DMFUT57	DN	3-cyano-N-(3-ethylphenyl)-5-fluorobenzamide
DMFUT57	MI	TTHS256
DMFUT57	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMFUT57	MT	DTT
DMFUT57	MA	Inhibitor
DMFUT57	RN	3-Cyano-5-fluoro-N-arylbenzamides as negative allosteric modulators of mGlu(5): Identification of easily prepared tool compounds with CNS exposure ... Bioorg Med Chem Lett. 2010 Aug 1;20(15):4390-4.
DMFUT57	RU	https://pubmed.ncbi.nlm.nih.gov/20598884

DM9FEMV	DI	DM9FEMV
DM9FEMV	DN	3-cyano-N-(3-ethynylphenyl)-5-fluorobenzamide
DM9FEMV	MI	TTHS256
DM9FEMV	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM9FEMV	MT	DTT
DM9FEMV	MA	Inhibitor
DM9FEMV	RN	3-Cyano-5-fluoro-N-arylbenzamides as negative allosteric modulators of mGlu(5): Identification of easily prepared tool compounds with CNS exposure ... Bioorg Med Chem Lett. 2010 Aug 1;20(15):4390-4.
DM9FEMV	RU	https://pubmed.ncbi.nlm.nih.gov/20598884

DMUB9XW	DI	DMUB9XW
DMUB9XW	DN	3-cyano-N-(6-ethylpyridin-2-yl)-5-fluorobenzamide
DMUB9XW	MI	TTHS256
DMUB9XW	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMUB9XW	MT	DTT
DMUB9XW	MA	Inhibitor
DMUB9XW	RN	3-Cyano-5-fluoro-N-arylbenzamides as negative allosteric modulators of mGlu(5): Identification of easily prepared tool compounds with CNS exposure ... Bioorg Med Chem Lett. 2010 Aug 1;20(15):4390-4.
DMUB9XW	RU	https://pubmed.ncbi.nlm.nih.gov/20598884

DMTDEYL	DI	DMTDEYL
DMTDEYL	DN	3-cyano-N-(6-methylpyridin-2-yl)benzamide
DMTDEYL	MI	TTHS256
DMTDEYL	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMTDEYL	MT	DTT
DMTDEYL	MA	Inhibitor
DMTDEYL	RN	Structure-activity relationships comparing N-(6-methylpyridin-yl)-substituted aryl amides to 2-methyl-6-(substituted-arylethynyl)pyridines or 2-met... J Med Chem. 2009 Jun 11;52(11):3563-75.
DMTDEYL	RU	https://pubmed.ncbi.nlm.nih.gov/19445453

DMPWR90	DI	DMPWR90
DMPWR90	DN	3-cyanophenylboronic acid
DMPWR90	MI	TTDP1UC
DMPWR90	MN	Fatty acid amide hydrolase (FAAH)
DMPWR90	MT	DTT
DMPWR90	MA	Inhibitor
DMPWR90	RN	Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Nov 27;51(22):7057-60.
DMPWR90	RU	https://pubmed.ncbi.nlm.nih.gov/18983140

DMJSOTE	DI	DMJSOTE
DMJSOTE	DN	3-Cyclohexanesulfonyl-heptanoic acid hydroxyamide
DMJSOTE	MI	TTMX39J
DMJSOTE	MN	Matrix metalloproteinase-1 (MMP-1)
DMJSOTE	MT	DTT
DMJSOTE	MA	Inhibitor
DMJSOTE	RN	Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents. J Med Chem. 2000 Jun 15;43(12):2324-31.
DMJSOTE	RU	https://pubmed.ncbi.nlm.nih.gov/10882358

DMJSOTE	DI	DMJSOTE
DMJSOTE	DN	3-Cyclohexanesulfonyl-heptanoic acid hydroxyamide
DMJSOTE	MI	TTXZ0KQ
DMJSOTE	MN	Matrix metalloproteinase-12 (MMP-12)
DMJSOTE	MT	DTT
DMJSOTE	MA	Inhibitor
DMJSOTE	RN	Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents. J Med Chem. 2000 Jun 15;43(12):2324-31.
DMJSOTE	RU	https://pubmed.ncbi.nlm.nih.gov/10882358

DMJSOTE	DI	DMJSOTE
DMJSOTE	DN	3-Cyclohexanesulfonyl-heptanoic acid hydroxyamide
DMJSOTE	MI	TTHY57M
DMJSOTE	MN	Matrix metalloproteinase-13 (MMP-13)
DMJSOTE	MT	DTT
DMJSOTE	MA	Inhibitor
DMJSOTE	RN	Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents. J Med Chem. 2000 Jun 15;43(12):2324-31.
DMJSOTE	RU	https://pubmed.ncbi.nlm.nih.gov/10882358

DMJSOTE	DI	DMJSOTE
DMJSOTE	DN	3-Cyclohexanesulfonyl-heptanoic acid hydroxyamide
DMJSOTE	MI	TTMTWOS
DMJSOTE	MN	Matrix metalloproteinase-7 (MMP-7)
DMJSOTE	MT	DTT
DMJSOTE	MA	Inhibitor
DMJSOTE	RN	Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents. J Med Chem. 2000 Jun 15;43(12):2324-31.
DMJSOTE	RU	https://pubmed.ncbi.nlm.nih.gov/10882358

DMWMFZ3	DI	DMWMFZ3
DMWMFZ3	DN	3-Cyclohexyl-1-propyl-piperidine hydrochloride
DMWMFZ3	MI	TTEX248
DMWMFZ3	MN	Dopamine D2 receptor (D2R)
DMWMFZ3	MT	DTT
DMWMFZ3	MA	Inhibitor
DMWMFZ3	RN	New N-n-propyl-substituted 3-aryl- and 3-cyclohexylpiperidines as partial agonists at the D4 dopamine receptor. J Med Chem. 2003 Jan 2;46(1):161-8.
DMWMFZ3	RU	https://pubmed.ncbi.nlm.nih.gov/12502370

DMCQ6J8	DI	DMCQ6J8
DMCQ6J8	DN	3-Cyclohexylethynyl-6,7-dimethoxy-quinoline
DMCQ6J8	MI	TT8FYO9
DMCQ6J8	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMCQ6J8	MT	DTT
DMCQ6J8	MA	Inhibitor
DMCQ6J8	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMCQ6J8	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMCQ6J8	DI	DMCQ6J8
DMCQ6J8	DN	3-Cyclohexylethynyl-6,7-dimethoxy-quinoline
DMCQ6J8	MI	TTI7421
DMCQ6J8	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMCQ6J8	MT	DTT
DMCQ6J8	MA	Inhibitor
DMCQ6J8	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMCQ6J8	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DM1FSZM	DI	DM1FSZM
DM1FSZM	DN	3-Cyclopent-1-enyl-6,7-dimethoxy-quinoline
DM1FSZM	MI	TT8FYO9
DM1FSZM	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DM1FSZM	MT	DTT
DM1FSZM	MA	Inhibitor
DM1FSZM	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DM1FSZM	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DM1FSZM	DI	DM1FSZM
DM1FSZM	DN	3-Cyclopent-1-enyl-6,7-dimethoxy-quinoline
DM1FSZM	MI	TTI7421
DM1FSZM	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM1FSZM	MT	DTT
DM1FSZM	MA	Inhibitor
DM1FSZM	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DM1FSZM	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMEL8S5	DI	DMEL8S5
DMEL8S5	DN	3-cyclopentoxycarbonyl-6-ethyl-4-quinolone
DMEL8S5	MI	TT1MPAY
DMEL8S5	MN	GABA(A) receptor alpha-1 (GABRA1)
DMEL8S5	MT	DTT
DMEL8S5	MA	Inhibitor
DMEL8S5	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMEL8S5	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMEL8S5	DI	DMEL8S5
DMEL8S5	DN	3-cyclopentoxycarbonyl-6-ethyl-4-quinolone
DMEL8S5	MI	TTZA1NY
DMEL8S5	MN	GABA(A) receptor beta-2 (GABRB2)
DMEL8S5	MT	DTT
DMEL8S5	MA	Inhibitor
DMEL8S5	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMEL8S5	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMEL8S5	DI	DMEL8S5
DMEL8S5	DN	3-cyclopentoxycarbonyl-6-ethyl-4-quinolone
DMEL8S5	MI	TT06RH5
DMEL8S5	MN	GABA(A) receptor gamma-2 (GABRG2)
DMEL8S5	MT	DTT
DMEL8S5	MA	Inhibitor
DMEL8S5	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMEL8S5	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMEL8S5	DI	DMEL8S5
DMEL8S5	DN	3-cyclopentoxycarbonyl-6-ethyl-4-quinolone
DMEL8S5	MI	TTNJYV2
DMEL8S5	MN	Gamma-aminobutyric acid receptor (GAR)
DMEL8S5	MT	DTT
DMEL8S5	MA	Inhibitor
DMEL8S5	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMEL8S5	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMS7B6T	DI	DMS7B6T
DMS7B6T	DN	3-Cyclopentyl-6,7-dimethoxy-quinoline
DMS7B6T	MI	TT8FYO9
DMS7B6T	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMS7B6T	MT	DTT
DMS7B6T	MA	Inhibitor
DMS7B6T	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMS7B6T	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMS7B6T	DI	DMS7B6T
DMS7B6T	DN	3-Cyclopentyl-6,7-dimethoxy-quinoline
DMS7B6T	MI	TTI7421
DMS7B6T	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMS7B6T	MT	DTT
DMS7B6T	MA	Inhibitor
DMS7B6T	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMS7B6T	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMLQJ64	DI	DMLQJ64
DMLQJ64	DN	3-Decanoyl-4-hydroxy-6-nonyl-pyran-2-one
DMLQJ64	MI	TTPLTSQ
DMLQJ64	MN	Neutrophil elastase (NE)
DMLQJ64	MT	DTT
DMLQJ64	MA	Inhibitor
DMLQJ64	RN	Inhibition of human sputum elastase by substituted 2-pyrones. J Med Chem. 1987 Jun;30(6):1017-23.
DMLQJ64	RU	https://pubmed.ncbi.nlm.nih.gov/3647139

DMID7TC	DI	DMID7TC
DMID7TC	DN	3-demethoxy-3D-glucopyranosylaminothiocolchicine
DMID7TC	MI	TT1MPAY
DMID7TC	MN	GABA(A) receptor alpha-1 (GABRA1)
DMID7TC	MT	DTT
DMID7TC	MA	Inhibitor
DMID7TC	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DMID7TC	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DMID7TC	DI	DMID7TC
DMID7TC	DN	3-demethoxy-3D-glucopyranosylaminothiocolchicine
DMID7TC	MI	TTZA1NY
DMID7TC	MN	GABA(A) receptor beta-2 (GABRB2)
DMID7TC	MT	DTT
DMID7TC	MA	Inhibitor
DMID7TC	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DMID7TC	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DMID7TC	DI	DMID7TC
DMID7TC	DN	3-demethoxy-3D-glucopyranosylaminothiocolchicine
DMID7TC	MI	TT06RH5
DMID7TC	MN	GABA(A) receptor gamma-2 (GABRG2)
DMID7TC	MT	DTT
DMID7TC	MA	Inhibitor
DMID7TC	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DMID7TC	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DMID7TC	DI	DMID7TC
DMID7TC	DN	3-demethoxy-3D-glucopyranosylaminothiocolchicine
DMID7TC	MI	TTNJYV2
DMID7TC	MN	Gamma-aminobutyric acid receptor (GAR)
DMID7TC	MT	DTT
DMID7TC	MA	Inhibitor
DMID7TC	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DMID7TC	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DMID7TC	DI	DMID7TC
DMID7TC	DN	3-demethoxy-3D-glucopyranosylaminothiocolchicine
DMID7TC	MI	TTZ8EM9
DMID7TC	MN	Glycine receptor (GlyR)
DMID7TC	MT	DTT
DMID7TC	MA	Inhibitor
DMID7TC	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DMID7TC	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DMID7TC	DI	DMID7TC
DMID7TC	DN	3-demethoxy-3D-glucopyranosylaminothiocolchicine
DMID7TC	MI	TTF45NW
DMID7TC	MN	Strychnine-binding glycine receptor (GLRA1)
DMID7TC	MT	DTT
DMID7TC	MA	Inhibitor
DMID7TC	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DMID7TC	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DME8VPC	DI	DME8VPC
DME8VPC	DN	3-demethoxy-3-D-lyxopyranosylaminothiocolchicine
DME8VPC	MI	TT1MPAY
DME8VPC	MN	GABA(A) receptor alpha-1 (GABRA1)
DME8VPC	MT	DTT
DME8VPC	MA	Inhibitor
DME8VPC	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DME8VPC	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DME8VPC	DI	DME8VPC
DME8VPC	DN	3-demethoxy-3-D-lyxopyranosylaminothiocolchicine
DME8VPC	MI	TTZA1NY
DME8VPC	MN	GABA(A) receptor beta-2 (GABRB2)
DME8VPC	MT	DTT
DME8VPC	MA	Inhibitor
DME8VPC	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DME8VPC	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DME8VPC	DI	DME8VPC
DME8VPC	DN	3-demethoxy-3-D-lyxopyranosylaminothiocolchicine
DME8VPC	MI	TT06RH5
DME8VPC	MN	GABA(A) receptor gamma-2 (GABRG2)
DME8VPC	MT	DTT
DME8VPC	MA	Inhibitor
DME8VPC	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DME8VPC	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DME8VPC	DI	DME8VPC
DME8VPC	DN	3-demethoxy-3-D-lyxopyranosylaminothiocolchicine
DME8VPC	MI	TTNJYV2
DME8VPC	MN	Gamma-aminobutyric acid receptor (GAR)
DME8VPC	MT	DTT
DME8VPC	MA	Inhibitor
DME8VPC	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DME8VPC	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DME8VPC	DI	DME8VPC
DME8VPC	DN	3-demethoxy-3-D-lyxopyranosylaminothiocolchicine
DME8VPC	MI	TTZ8EM9
DME8VPC	MN	Glycine receptor (GlyR)
DME8VPC	MT	DTT
DME8VPC	MA	Inhibitor
DME8VPC	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DME8VPC	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DME8VPC	DI	DME8VPC
DME8VPC	DN	3-demethoxy-3-D-lyxopyranosylaminothiocolchicine
DME8VPC	MI	TTF45NW
DME8VPC	MN	Strychnine-binding glycine receptor (GLRA1)
DME8VPC	MT	DTT
DME8VPC	MA	Inhibitor
DME8VPC	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DME8VPC	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DMALMGH	DI	DMALMGH
DMALMGH	DN	3-demethoxy-3-D-mannopyranosylaminothiocolchicine
DMALMGH	MI	TT1MPAY
DMALMGH	MN	GABA(A) receptor alpha-1 (GABRA1)
DMALMGH	MT	DTT
DMALMGH	MA	Inhibitor
DMALMGH	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DMALMGH	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DMALMGH	DI	DMALMGH
DMALMGH	DN	3-demethoxy-3-D-mannopyranosylaminothiocolchicine
DMALMGH	MI	TTZA1NY
DMALMGH	MN	GABA(A) receptor beta-2 (GABRB2)
DMALMGH	MT	DTT
DMALMGH	MA	Inhibitor
DMALMGH	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DMALMGH	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DMALMGH	DI	DMALMGH
DMALMGH	DN	3-demethoxy-3-D-mannopyranosylaminothiocolchicine
DMALMGH	MI	TT06RH5
DMALMGH	MN	GABA(A) receptor gamma-2 (GABRG2)
DMALMGH	MT	DTT
DMALMGH	MA	Inhibitor
DMALMGH	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DMALMGH	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DMALMGH	DI	DMALMGH
DMALMGH	DN	3-demethoxy-3-D-mannopyranosylaminothiocolchicine
DMALMGH	MI	TTNJYV2
DMALMGH	MN	Gamma-aminobutyric acid receptor (GAR)
DMALMGH	MT	DTT
DMALMGH	MA	Inhibitor
DMALMGH	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DMALMGH	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DMALMGH	DI	DMALMGH
DMALMGH	DN	3-demethoxy-3-D-mannopyranosylaminothiocolchicine
DMALMGH	MI	TTZ8EM9
DMALMGH	MN	Glycine receptor (GlyR)
DMALMGH	MT	DTT
DMALMGH	MA	Inhibitor
DMALMGH	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DMALMGH	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DMALMGH	DI	DMALMGH
DMALMGH	DN	3-demethoxy-3-D-mannopyranosylaminothiocolchicine
DMALMGH	MI	TTF45NW
DMALMGH	MN	Strychnine-binding glycine receptor (GLRA1)
DMALMGH	MT	DTT
DMALMGH	MA	Inhibitor
DMALMGH	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DMALMGH	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DMXFVD1	DI	DMXFVD1
DMXFVD1	DN	3-demethoxy-3-D-xylopyranosylaminothiocolchicine
DMXFVD1	MI	TT1MPAY
DMXFVD1	MN	GABA(A) receptor alpha-1 (GABRA1)
DMXFVD1	MT	DTT
DMXFVD1	MA	Inhibitor
DMXFVD1	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DMXFVD1	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DMXFVD1	DI	DMXFVD1
DMXFVD1	DN	3-demethoxy-3-D-xylopyranosylaminothiocolchicine
DMXFVD1	MI	TTZA1NY
DMXFVD1	MN	GABA(A) receptor beta-2 (GABRB2)
DMXFVD1	MT	DTT
DMXFVD1	MA	Inhibitor
DMXFVD1	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DMXFVD1	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DMXFVD1	DI	DMXFVD1
DMXFVD1	DN	3-demethoxy-3-D-xylopyranosylaminothiocolchicine
DMXFVD1	MI	TT06RH5
DMXFVD1	MN	GABA(A) receptor gamma-2 (GABRG2)
DMXFVD1	MT	DTT
DMXFVD1	MA	Inhibitor
DMXFVD1	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DMXFVD1	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DMXFVD1	DI	DMXFVD1
DMXFVD1	DN	3-demethoxy-3-D-xylopyranosylaminothiocolchicine
DMXFVD1	MI	TTNJYV2
DMXFVD1	MN	Gamma-aminobutyric acid receptor (GAR)
DMXFVD1	MT	DTT
DMXFVD1	MA	Inhibitor
DMXFVD1	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DMXFVD1	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DMXFVD1	DI	DMXFVD1
DMXFVD1	DN	3-demethoxy-3-D-xylopyranosylaminothiocolchicine
DMXFVD1	MI	TTZ8EM9
DMXFVD1	MN	Glycine receptor (GlyR)
DMXFVD1	MT	DTT
DMXFVD1	MA	Inhibitor
DMXFVD1	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DMXFVD1	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DMXFVD1	DI	DMXFVD1
DMXFVD1	DN	3-demethoxy-3-D-xylopyranosylaminothiocolchicine
DMXFVD1	MI	TTF45NW
DMXFVD1	MN	Strychnine-binding glycine receptor (GLRA1)
DMXFVD1	MT	DTT
DMXFVD1	MA	Inhibitor
DMXFVD1	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DMXFVD1	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DM4ERYF	DI	DM4ERYF
DM4ERYF	DN	3-demethoxy-3-L-fucopyranosylaminothiocolchicine
DM4ERYF	MI	TT1MPAY
DM4ERYF	MN	GABA(A) receptor alpha-1 (GABRA1)
DM4ERYF	MT	DTT
DM4ERYF	MA	Inhibitor
DM4ERYF	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DM4ERYF	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DM4ERYF	DI	DM4ERYF
DM4ERYF	DN	3-demethoxy-3-L-fucopyranosylaminothiocolchicine
DM4ERYF	MI	TTZA1NY
DM4ERYF	MN	GABA(A) receptor beta-2 (GABRB2)
DM4ERYF	MT	DTT
DM4ERYF	MA	Inhibitor
DM4ERYF	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DM4ERYF	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DM4ERYF	DI	DM4ERYF
DM4ERYF	DN	3-demethoxy-3-L-fucopyranosylaminothiocolchicine
DM4ERYF	MI	TT06RH5
DM4ERYF	MN	GABA(A) receptor gamma-2 (GABRG2)
DM4ERYF	MT	DTT
DM4ERYF	MA	Inhibitor
DM4ERYF	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DM4ERYF	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DM4ERYF	DI	DM4ERYF
DM4ERYF	DN	3-demethoxy-3-L-fucopyranosylaminothiocolchicine
DM4ERYF	MI	TTNJYV2
DM4ERYF	MN	Gamma-aminobutyric acid receptor (GAR)
DM4ERYF	MT	DTT
DM4ERYF	MA	Inhibitor
DM4ERYF	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DM4ERYF	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DM4ERYF	DI	DM4ERYF
DM4ERYF	DN	3-demethoxy-3-L-fucopyranosylaminothiocolchicine
DM4ERYF	MI	TTZ8EM9
DM4ERYF	MN	Glycine receptor (GlyR)
DM4ERYF	MT	DTT
DM4ERYF	MA	Inhibitor
DM4ERYF	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DM4ERYF	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DM4ERYF	DI	DM4ERYF
DM4ERYF	DN	3-demethoxy-3-L-fucopyranosylaminothiocolchicine
DM4ERYF	MI	TTF45NW
DM4ERYF	MN	Strychnine-binding glycine receptor (GLRA1)
DM4ERYF	MT	DTT
DM4ERYF	MA	Inhibitor
DM4ERYF	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DM4ERYF	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DMFQUGE	DI	DMFQUGE
DMFQUGE	DN	3-Deoxyguanosine
DMFQUGE	MI	TTMCF1Y
DMFQUGE	MN	Purine nucleoside phosphorylase (PNP)
DMFQUGE	MT	DTT
DMFQUGE	MA	Inhibitor
DMFQUGE	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMFQUGE	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMBNA0V	DI	DMBNA0V
DMBNA0V	DN	3-desoxy-3-carboxamidonaltrexone
DMBNA0V	MI	TT27RFC
DMBNA0V	MN	Opioid receptor delta (OPRD1)
DMBNA0V	MT	DTT
DMBNA0V	MA	Inhibitor
DMBNA0V	RN	Syntheses of novel high affinity ligands for opioid receptors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2289-94.
DMBNA0V	RU	https://pubmed.ncbi.nlm.nih.gov/19282177

DMBNA0V	DI	DMBNA0V
DMBNA0V	DN	3-desoxy-3-carboxamidonaltrexone
DMBNA0V	MI	TTQW87Y
DMBNA0V	MN	Opioid receptor kappa (OPRK1)
DMBNA0V	MT	DTT
DMBNA0V	MA	Inhibitor
DMBNA0V	RN	Syntheses of novel high affinity ligands for opioid receptors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2289-94.
DMBNA0V	RU	https://pubmed.ncbi.nlm.nih.gov/19282177

DMBNA0V	DI	DMBNA0V
DMBNA0V	DN	3-desoxy-3-carboxamidonaltrexone
DMBNA0V	MI	TTKWM86
DMBNA0V	MN	Opioid receptor mu (MOP)
DMBNA0V	MT	DTT
DMBNA0V	MA	Inhibitor
DMBNA0V	RN	Syntheses of novel high affinity ligands for opioid receptors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2289-94.
DMBNA0V	RU	https://pubmed.ncbi.nlm.nih.gov/19282177

DMSJUOH	DI	DMSJUOH
DMSJUOH	DN	3-Dimethylaminomethyl-1H-indol-4-ol
DMSJUOH	MI	TTJQOD7
DMSJUOH	MN	5-HT 2A receptor (HTR2A)
DMSJUOH	MT	DTT
DMSJUOH	MA	Inhibitor
DMSJUOH	RN	SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.
DMSJUOH	RU	https://pubmed.ncbi.nlm.nih.gov/16061378

DMSJUOH	DI	DMSJUOH
DMSJUOH	DN	3-Dimethylaminomethyl-1H-indol-4-ol
DMSJUOH	MI	TT0K1SC
DMSJUOH	MN	5-HT 2B receptor (HTR2B)
DMSJUOH	MT	DTT
DMSJUOH	MA	Inhibitor
DMSJUOH	RN	SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.
DMSJUOH	RU	https://pubmed.ncbi.nlm.nih.gov/16061378

DMSJUOH	DI	DMSJUOH
DMSJUOH	DN	3-Dimethylaminomethyl-1H-indol-4-ol
DMSJUOH	MI	TTWJBZ5
DMSJUOH	MN	5-HT 2C receptor (HTR2C)
DMSJUOH	MT	DTT
DMSJUOH	MA	Inhibitor
DMSJUOH	RN	SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.
DMSJUOH	RU	https://pubmed.ncbi.nlm.nih.gov/16061378

DMDOIJM	DI	DMDOIJM
DMDOIJM	DN	3-Dimethylaminomethyl-1-methyl-1H-indol-4-ol
DMDOIJM	MI	TTJQOD7
DMDOIJM	MN	5-HT 2A receptor (HTR2A)
DMDOIJM	MT	DTT
DMDOIJM	MA	Inhibitor
DMDOIJM	RN	SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.
DMDOIJM	RU	https://pubmed.ncbi.nlm.nih.gov/16061378

DMDOIJM	DI	DMDOIJM
DMDOIJM	DN	3-Dimethylaminomethyl-1-methyl-1H-indol-4-ol
DMDOIJM	MI	TT0K1SC
DMDOIJM	MN	5-HT 2B receptor (HTR2B)
DMDOIJM	MT	DTT
DMDOIJM	MA	Inhibitor
DMDOIJM	RN	SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.
DMDOIJM	RU	https://pubmed.ncbi.nlm.nih.gov/16061378

DMDOIJM	DI	DMDOIJM
DMDOIJM	DN	3-Dimethylaminomethyl-1-methyl-1H-indol-4-ol
DMDOIJM	MI	TTWJBZ5
DMDOIJM	MN	5-HT 2C receptor (HTR2C)
DMDOIJM	MT	DTT
DMDOIJM	MA	Inhibitor
DMDOIJM	RN	SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.
DMDOIJM	RU	https://pubmed.ncbi.nlm.nih.gov/16061378

DMVHQB8	DI	DMVHQB8
DMVHQB8	DN	3-DIPHENOL-6-NITRO-3H-BENZO[DE]ISOCHROMEN-1-ONE
DMVHQB8	MI	TTU6BFZ
DMVHQB8	MN	Candida Thymidylate synthase (Candi TMP1)
DMVHQB8	MT	DTT
DMVHQB8	MA	Inhibitor
DMVHQB8	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMVHQB8	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMO5EBI	DI	DMO5EBI
DMO5EBI	DN	3-dodecyl-1,1-dimethylthiourea
DMO5EBI	MI	TTAS2UO
DMO5EBI	MN	Bacterial Urease (Bact ureC)
DMO5EBI	MT	DTT
DMO5EBI	MA	Inhibitor
DMO5EBI	RN	Facile one-pot synthesis of thio and selenourea derivatives: a new class of potent urease inhibitors. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6387-91.
DMO5EBI	RU	https://pubmed.ncbi.nlm.nih.gov/17889535

DMQ8VIU	DI	DMQ8VIU
DMQ8VIU	DN	3-epicorosolic acid methyl ester
DMQ8VIU	MI	TTN7BL9
DMQ8VIU	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMQ8VIU	MT	DTT
DMQ8VIU	MA	Inhibitor
DMQ8VIU	RN	11beta-Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational a... Bioorg Med Chem. 2010 Feb 15;18(4):1507-15.
DMQ8VIU	RU	https://pubmed.ncbi.nlm.nih.gov/20100662

DM1UOWB	DI	DM1UOWB
DM1UOWB	DN	3-epi-masilinic acid
DM1UOWB	MI	TTELIN2
DM1UOWB	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DM1UOWB	MT	DTT
DM1UOWB	MA	Inhibitor
DM1UOWB	RN	Synthesis and biological evaluation of heterocyclic ring-substituted maslinic acid derivatives as novel inhibitors of protein tyrosine phosphatase 1B. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6618-22.
DM1UOWB	RU	https://pubmed.ncbi.nlm.nih.gov/19846303

DMTKQNU	DI	DMTKQNU
DMTKQNU	DN	3-Ethenylquinoline-8-carboxamide
DMTKQNU	MI	TTVDSZ0
DMTKQNU	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMTKQNU	MT	DTT
DMTKQNU	MA	Inhibitor
DMTKQNU	RN	Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhi... J Med Chem. 2009 Feb 12;52(3):868-77.
DMTKQNU	RU	https://pubmed.ncbi.nlm.nih.gov/19117416

DMSK6EM	DI	DMSK6EM
DMSK6EM	DN	3-ethoxy-5-(2-methylquinolin-7-yl)benzonitrile
DMSK6EM	MI	TTHS256
DMSK6EM	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMSK6EM	MT	DTT
DMSK6EM	MA	Inhibitor
DMSK6EM	RN	Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8.
DMSK6EM	RU	https://pubmed.ncbi.nlm.nih.gov/17590335

DMWZDA1	DI	DMWZDA1
DMWZDA1	DN	3-Ethoxy-5-(6-methoxynaphthalen-2-yl)pyridine
DMWZDA1	MI	TTIQUX7
DMWZDA1	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMWZDA1	MT	DTT
DMWZDA1	MA	Inhibitor
DMWZDA1	RN	Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on pote... J Med Chem. 2008 Aug 28;51(16):5064-74.
DMWZDA1	RU	https://pubmed.ncbi.nlm.nih.gov/18672861

DM6K7BI	DI	DM6K7BI
DM6K7BI	DN	3-Ethoxy-9H-beta-carboline
DM6K7BI	MI	TT1MPAY
DM6K7BI	MN	GABA(A) receptor alpha-1 (GABRA1)
DM6K7BI	MT	DTT
DM6K7BI	MA	Inhibitor
DM6K7BI	RN	Synthesis of novel 3-substituted beta-carbolines as benzodiazepine receptor ligands: probing the benzodiazepine receptor pharmacophore. J Med Chem. 1988 Sep;31(9):1854-61.
DM6K7BI	RU	https://pubmed.ncbi.nlm.nih.gov/2842507

DM6K7BI	DI	DM6K7BI
DM6K7BI	DN	3-Ethoxy-9H-beta-carboline
DM6K7BI	MI	TTBMV1G
DM6K7BI	MN	GABA(A) receptor alpha-2 (GABRA2)
DM6K7BI	MT	DTT
DM6K7BI	MA	Inhibitor
DM6K7BI	RN	Synthesis and evaluation of analogues of the partial agonist 6-(propyloxy)-4-(methoxymethyl)-beta-carboline-3-carboxylic acid ethyl ester (6-PBC) a... J Med Chem. 1998 Jul 2;41(14):2537-52.
DM6K7BI	RU	https://pubmed.ncbi.nlm.nih.gov/9651158

DM6K7BI	DI	DM6K7BI
DM6K7BI	DN	3-Ethoxy-9H-beta-carboline
DM6K7BI	MI	TT37EDJ
DM6K7BI	MN	GABA(A) receptor alpha-3 (GABRA3)
DM6K7BI	MT	DTT
DM6K7BI	MA	Inhibitor
DM6K7BI	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DM6K7BI	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DM6K7BI	DI	DM6K7BI
DM6K7BI	DN	3-Ethoxy-9H-beta-carboline
DM6K7BI	MI	TTNZPQ1
DM6K7BI	MN	GABA(A) receptor alpha-5 (GABRA5)
DM6K7BI	MT	DTT
DM6K7BI	MA	Inhibitor
DM6K7BI	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DM6K7BI	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DM6K7BI	DI	DM6K7BI
DM6K7BI	DN	3-Ethoxy-9H-beta-carboline
DM6K7BI	MI	TT06RH5
DM6K7BI	MN	GABA(A) receptor gamma-2 (GABRG2)
DM6K7BI	MT	DTT
DM6K7BI	MA	Inhibitor
DM6K7BI	RN	Synthesis and evaluation of analogues of the partial agonist 6-(propyloxy)-4-(methoxymethyl)-beta-carboline-3-carboxylic acid ethyl ester (6-PBC) a... J Med Chem. 1998 Jul 2;41(14):2537-52.
DM6K7BI	RU	https://pubmed.ncbi.nlm.nih.gov/9651158

DM6K7BI	DI	DM6K7BI
DM6K7BI	DN	3-Ethoxy-9H-beta-carboline
DM6K7BI	MI	TTNJYV2
DM6K7BI	MN	Gamma-aminobutyric acid receptor (GAR)
DM6K7BI	MT	DTT
DM6K7BI	MA	Inhibitor
DM6K7BI	RN	Synthesis and evaluation of analogues of the partial agonist 6-(propyloxy)-4-(methoxymethyl)-beta-carboline-3-carboxylic acid ethyl ester (6-PBC) a... J Med Chem. 1998 Jul 2;41(14):2537-52.
DM6K7BI	RU	https://pubmed.ncbi.nlm.nih.gov/9651158

DMY4VOI	DI	DMY4VOI
DMY4VOI	DN	3-ethoxycarbonyl-4-quinolone
DMY4VOI	MI	TT1MPAY
DMY4VOI	MN	GABA(A) receptor alpha-1 (GABRA1)
DMY4VOI	MT	DTT
DMY4VOI	MA	Inhibitor
DMY4VOI	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMY4VOI	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMY4VOI	DI	DMY4VOI
DMY4VOI	DN	3-ethoxycarbonyl-4-quinolone
DMY4VOI	MI	TTZA1NY
DMY4VOI	MN	GABA(A) receptor beta-2 (GABRB2)
DMY4VOI	MT	DTT
DMY4VOI	MA	Inhibitor
DMY4VOI	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMY4VOI	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMY4VOI	DI	DMY4VOI
DMY4VOI	DN	3-ethoxycarbonyl-4-quinolone
DMY4VOI	MI	TT06RH5
DMY4VOI	MN	GABA(A) receptor gamma-2 (GABRG2)
DMY4VOI	MT	DTT
DMY4VOI	MA	Inhibitor
DMY4VOI	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMY4VOI	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMY4VOI	DI	DMY4VOI
DMY4VOI	DN	3-ethoxycarbonyl-4-quinolone
DMY4VOI	MI	TTNJYV2
DMY4VOI	MN	Gamma-aminobutyric acid receptor (GAR)
DMY4VOI	MT	DTT
DMY4VOI	MA	Inhibitor
DMY4VOI	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMY4VOI	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMMDOI4	DI	DMMDOI4
DMMDOI4	DN	3-ethoxycarbonyl-6-ethyl-2-methyl-4-quinolone
DMMDOI4	MI	TT1MPAY
DMMDOI4	MN	GABA(A) receptor alpha-1 (GABRA1)
DMMDOI4	MT	DTT
DMMDOI4	MA	Inhibitor
DMMDOI4	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMMDOI4	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMMDOI4	DI	DMMDOI4
DMMDOI4	DN	3-ethoxycarbonyl-6-ethyl-2-methyl-4-quinolone
DMMDOI4	MI	TTZA1NY
DMMDOI4	MN	GABA(A) receptor beta-2 (GABRB2)
DMMDOI4	MT	DTT
DMMDOI4	MA	Inhibitor
DMMDOI4	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMMDOI4	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMMDOI4	DI	DMMDOI4
DMMDOI4	DN	3-ethoxycarbonyl-6-ethyl-2-methyl-4-quinolone
DMMDOI4	MI	TT06RH5
DMMDOI4	MN	GABA(A) receptor gamma-2 (GABRG2)
DMMDOI4	MT	DTT
DMMDOI4	MA	Inhibitor
DMMDOI4	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMMDOI4	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMMDOI4	DI	DMMDOI4
DMMDOI4	DN	3-ethoxycarbonyl-6-ethyl-2-methyl-4-quinolone
DMMDOI4	MI	TTNJYV2
DMMDOI4	MN	Gamma-aminobutyric acid receptor (GAR)
DMMDOI4	MT	DTT
DMMDOI4	MA	Inhibitor
DMMDOI4	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMMDOI4	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DM1E5QZ	DI	DM1E5QZ
DM1E5QZ	DN	3-ethoxycarbonyl-6-propyl-4-quinolone
DM1E5QZ	MI	TT1MPAY
DM1E5QZ	MN	GABA(A) receptor alpha-1 (GABRA1)
DM1E5QZ	MT	DTT
DM1E5QZ	MA	Inhibitor
DM1E5QZ	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DM1E5QZ	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DM1E5QZ	DI	DM1E5QZ
DM1E5QZ	DN	3-ethoxycarbonyl-6-propyl-4-quinolone
DM1E5QZ	MI	TTZA1NY
DM1E5QZ	MN	GABA(A) receptor beta-2 (GABRB2)
DM1E5QZ	MT	DTT
DM1E5QZ	MA	Inhibitor
DM1E5QZ	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DM1E5QZ	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DM1E5QZ	DI	DM1E5QZ
DM1E5QZ	DN	3-ethoxycarbonyl-6-propyl-4-quinolone
DM1E5QZ	MI	TT06RH5
DM1E5QZ	MN	GABA(A) receptor gamma-2 (GABRG2)
DM1E5QZ	MT	DTT
DM1E5QZ	MA	Inhibitor
DM1E5QZ	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DM1E5QZ	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DM1E5QZ	DI	DM1E5QZ
DM1E5QZ	DN	3-ethoxycarbonyl-6-propyl-4-quinolone
DM1E5QZ	MI	TTNJYV2
DM1E5QZ	MN	Gamma-aminobutyric acid receptor (GAR)
DM1E5QZ	MT	DTT
DM1E5QZ	MA	Inhibitor
DM1E5QZ	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DM1E5QZ	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DM4YL5Q	DI	DM4YL5Q
DM4YL5Q	DN	3-ethoxycarbonylpyroglutamate
DM4YL5Q	MI	TTHI19T
DM4YL5Q	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DM4YL5Q	MT	DTT
DM4YL5Q	MA	Inhibitor
DM4YL5Q	RN	Discovery of novel lipophilic inhibitors of OXA-10 enzyme (class D beta-lactamase) by screening amino analogs and homologs of citrate and isocitrate. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3593-7.
DM4YL5Q	RU	https://pubmed.ncbi.nlm.nih.gov/19467869

DMX2JKQ	DI	DMX2JKQ
DMX2JKQ	DN	3-Ethyl-[1,4]thiazepan-(5E)-ylideneamine
DMX2JKQ	MI	TTZUFI5
DMX2JKQ	MN	Nitric-oxide synthase brain (NOS1)
DMX2JKQ	MT	DTT
DMX2JKQ	MA	Inhibitor
DMX2JKQ	RN	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
DMX2JKQ	RU	https://pubmed.ncbi.nlm.nih.gov/15501067

DMX2JKQ	DI	DMX2JKQ
DMX2JKQ	DN	3-Ethyl-[1,4]thiazepan-(5E)-ylideneamine
DMX2JKQ	MI	TTCM4B3
DMX2JKQ	MN	Nitric-oxide synthase endothelial (NOS3)
DMX2JKQ	MT	DTT
DMX2JKQ	MA	Inhibitor
DMX2JKQ	RN	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
DMX2JKQ	RU	https://pubmed.ncbi.nlm.nih.gov/15501067

DMX2JKQ	DI	DMX2JKQ
DMX2JKQ	DN	3-Ethyl-[1,4]thiazepan-(5E)-ylideneamine
DMX2JKQ	MI	TTF10I9
DMX2JKQ	MN	Nitric-oxide synthase inducible (NOS2)
DMX2JKQ	MT	DTT
DMX2JKQ	MA	Inhibitor
DMX2JKQ	RN	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
DMX2JKQ	RU	https://pubmed.ncbi.nlm.nih.gov/15501067

DMEWAVM	DI	DMEWAVM
DMEWAVM	DN	3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
DMEWAVM	MI	TTZAYWL
DMEWAVM	MN	Estrogen receptor (ESR)
DMEWAVM	MT	DTT
DMEWAVM	MA	Inhibitor
DMEWAVM	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMEWAVM	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMN8C93	DI	DMN8C93
DMN8C93	DN	3-Ethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-6-ol
DMN8C93	MI	TTSQIFT
DMN8C93	MN	5-HT 1A receptor (HTR1A)
DMN8C93	MT	DTT
DMN8C93	MA	Inhibitor
DMN8C93	RN	6-Hydroxy-3-n-propyl-2,3,4,5-tetrahydro-1H-3-benzazepine and analogs: new centrally acting 5-HT1A receptor agonists. J Med Chem. 1992 Oct 30;35(22):3984-90.
DMN8C93	RU	https://pubmed.ncbi.nlm.nih.gov/1433207

DMN8C93	DI	DMN8C93
DMN8C93	DN	3-Ethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-6-ol
DMN8C93	MI	TTEX248
DMN8C93	MN	Dopamine D2 receptor (D2R)
DMN8C93	MT	DTT
DMN8C93	MA	Inhibitor
DMN8C93	RN	6-Hydroxy-3-n-propyl-2,3,4,5-tetrahydro-1H-3-benzazepine and analogs: new centrally acting 5-HT1A receptor agonists. J Med Chem. 1992 Oct 30;35(22):3984-90.
DMN8C93	RU	https://pubmed.ncbi.nlm.nih.gov/1433207

DMB8Q7T	DI	DMB8Q7T
DMB8Q7T	DN	3-Ethyl-3-isobutyl-1-phenylazetidine-2,4-dione
DMB8Q7T	MI	TTPLTSQ
DMB8Q7T	MN	Neutrophil elastase (NE)
DMB8Q7T	MT	DTT
DMB8Q7T	MA	Inhibitor
DMB8Q7T	RN	4-Oxo-beta-lactams (azetidine-2,4-diones) are potent and selective inhibitors of human leukocyte elastase. J Med Chem. 2010 Jan 14;53(1):241-53.
DMB8Q7T	RU	https://pubmed.ncbi.nlm.nih.gov/19904934

DMZK13I	DI	DMZK13I
DMZK13I	DN	3-Ethyl-3-isopropyl-dihydro-furan-2-one
DMZK13I	MI	TT1MPAY
DMZK13I	MN	GABA(A) receptor alpha-1 (GABRA1)
DMZK13I	MT	DTT
DMZK13I	MA	Inhibitor
DMZK13I	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DMZK13I	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DMZK13I	DI	DMZK13I
DMZK13I	DN	3-Ethyl-3-isopropyl-dihydro-furan-2-one
DMZK13I	MI	TTZA1NY
DMZK13I	MN	GABA(A) receptor beta-2 (GABRB2)
DMZK13I	MT	DTT
DMZK13I	MA	Inhibitor
DMZK13I	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DMZK13I	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DMZK13I	DI	DMZK13I
DMZK13I	DN	3-Ethyl-3-isopropyl-dihydro-furan-2-one
DMZK13I	MI	TT06RH5
DMZK13I	MN	GABA(A) receptor gamma-2 (GABRG2)
DMZK13I	MT	DTT
DMZK13I	MA	Inhibitor
DMZK13I	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DMZK13I	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DMZK13I	DI	DMZK13I
DMZK13I	DN	3-Ethyl-3-isopropyl-dihydro-furan-2-one
DMZK13I	MI	TTNJYV2
DMZK13I	MN	Gamma-aminobutyric acid receptor (GAR)
DMZK13I	MT	DTT
DMZK13I	MA	Inhibitor
DMZK13I	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DMZK13I	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DM1VTFU	DI	DM1VTFU
DM1VTFU	DN	3-Ethyl-3-methyl-dihydro-furan-2-one
DM1VTFU	MI	TT1MPAY
DM1VTFU	MN	GABA(A) receptor alpha-1 (GABRA1)
DM1VTFU	MT	DTT
DM1VTFU	MA	Inhibitor
DM1VTFU	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DM1VTFU	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DM1VTFU	DI	DM1VTFU
DM1VTFU	DN	3-Ethyl-3-methyl-dihydro-furan-2-one
DM1VTFU	MI	TTZA1NY
DM1VTFU	MN	GABA(A) receptor beta-2 (GABRB2)
DM1VTFU	MT	DTT
DM1VTFU	MA	Inhibitor
DM1VTFU	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DM1VTFU	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DM1VTFU	DI	DM1VTFU
DM1VTFU	DN	3-Ethyl-3-methyl-dihydro-furan-2-one
DM1VTFU	MI	TT06RH5
DM1VTFU	MN	GABA(A) receptor gamma-2 (GABRG2)
DM1VTFU	MT	DTT
DM1VTFU	MA	Inhibitor
DM1VTFU	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DM1VTFU	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DM1VTFU	DI	DM1VTFU
DM1VTFU	DN	3-Ethyl-3-methyl-dihydro-furan-2-one
DM1VTFU	MI	TTNJYV2
DM1VTFU	MN	Gamma-aminobutyric acid receptor (GAR)
DM1VTFU	MT	DTT
DM1VTFU	MA	Inhibitor
DM1VTFU	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DM1VTFU	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DMGPRBE	DI	DMGPRBE
DMGPRBE	DN	3-Ethylquinoline-8-carboxamide
DMGPRBE	MI	TTVDSZ0
DMGPRBE	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMGPRBE	MT	DTT
DMGPRBE	MA	Inhibitor
DMGPRBE	RN	Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhi... J Med Chem. 2009 Feb 12;52(3):868-77.
DMGPRBE	RU	https://pubmed.ncbi.nlm.nih.gov/19117416

DMS4JGT	DI	DMS4JGT
DMS4JGT	DN	3-Ethynylquinoline-8-carboxamide
DMS4JGT	MI	TTVDSZ0
DMS4JGT	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMS4JGT	MT	DTT
DMS4JGT	MA	Inhibitor
DMS4JGT	RN	Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhi... J Med Chem. 2009 Feb 12;52(3):868-77.
DMS4JGT	RU	https://pubmed.ncbi.nlm.nih.gov/19117416

DMR29IQ	DI	DMR29IQ
DMR29IQ	DN	3-Fluoren-9-ylidenemethyl-pyridine
DMR29IQ	MI	TTSZLWK
DMR29IQ	MN	Aromatase (CYP19A1)
DMR29IQ	MT	DTT
DMR29IQ	MA	Inhibitor
DMR29IQ	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMR29IQ	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMTY92S	DI	DMTY92S
DMTY92S	DN	3-Fluoro-2-(Phosphonooxy)Propanoic Acid
DMTY92S	MI	TTVNA43
DMTY92S	MN	Bacterial Deoxy-D-manno-octulosonate 8-phosphate synthase (Bact kdsA)
DMTY92S	MT	DTT
DMTY92S	MA	Inhibitor
DMTY92S	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMTY92S	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM4PLSU	DI	DM4PLSU
DM4PLSU	DN	3-fluoro-4'-(1-(pyridin-4-yl)propyl)biphenyl-4-ol
DM4PLSU	MI	TTRA5BZ
DM4PLSU	MN	Steroid 17-alpha-monooxygenase (S17AH)
DM4PLSU	MT	DTT
DM4PLSU	MA	Inhibitor
DM4PLSU	RN	Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors. J Med Chem. 2010 Jul 8;53(13):5049-53.
DM4PLSU	RU	https://pubmed.ncbi.nlm.nih.gov/20550118

DMJ3WNP	DI	DMJ3WNP
DMJ3WNP	DN	3-Fluoro-4'-(pyridin-4-ylmethyl)biphenyl-4-ol
DMJ3WNP	MI	TTSZLWK
DMJ3WNP	MN	Aromatase (CYP19A1)
DMJ3WNP	MT	DTT
DMJ3WNP	MA	Inhibitor
DMJ3WNP	RN	Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
DMJ3WNP	RU	https://pubmed.ncbi.nlm.nih.gov/20684610

DMJ3WNP	DI	DMJ3WNP
DMJ3WNP	DN	3-Fluoro-4'-(pyridin-4-ylmethyl)biphenyl-4-ol
DMJ3WNP	MI	TTIQUX7
DMJ3WNP	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMJ3WNP	MT	DTT
DMJ3WNP	MA	Inhibitor
DMJ3WNP	RN	Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
DMJ3WNP	RU	https://pubmed.ncbi.nlm.nih.gov/20684610

DMJ3WNP	DI	DMJ3WNP
DMJ3WNP	DN	3-Fluoro-4'-(pyridin-4-ylmethyl)biphenyl-4-ol
DMJ3WNP	MI	TTRA5BZ
DMJ3WNP	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMJ3WNP	MT	DTT
DMJ3WNP	MA	Inhibitor
DMJ3WNP	RN	Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
DMJ3WNP	RU	https://pubmed.ncbi.nlm.nih.gov/20684610

DMLG69R	DI	DMLG69R
DMLG69R	DN	3-Fluoro-4-hydrazino-benzenesulfonamide
DMLG69R	MI	TTHQPL7
DMLG69R	MN	Carbonic anhydrase I (CA-I)
DMLG69R	MT	DTT
DMLG69R	MA	Inhibitor
DMLG69R	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamide... J Med Chem. 2005 Mar 24;48(6):2121-5.
DMLG69R	RU	https://pubmed.ncbi.nlm.nih.gov/15771455

DMLG69R	DI	DMLG69R
DMLG69R	DN	3-Fluoro-4-hydrazino-benzenesulfonamide
DMLG69R	MI	TTANPDJ
DMLG69R	MN	Carbonic anhydrase II (CA-II)
DMLG69R	MT	DTT
DMLG69R	MA	Inhibitor
DMLG69R	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamide... J Med Chem. 2005 Mar 24;48(6):2121-5.
DMLG69R	RU	https://pubmed.ncbi.nlm.nih.gov/15771455

DMLG69R	DI	DMLG69R
DMLG69R	DN	3-Fluoro-4-hydrazino-benzenesulfonamide
DMLG69R	MI	TT2LVK8
DMLG69R	MN	Carbonic anhydrase IX (CA-IX)
DMLG69R	MT	DTT
DMLG69R	MA	Inhibitor
DMLG69R	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamide... J Med Chem. 2005 Mar 24;48(6):2121-5.
DMLG69R	RU	https://pubmed.ncbi.nlm.nih.gov/15771455

DMH9VLF	DI	DMH9VLF
DMH9VLF	DN	3-fluoro-5-(1,6-naphthyridin-7-yl)benzonitrile
DMH9VLF	MI	TTHS256
DMH9VLF	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMH9VLF	MT	DTT
DMH9VLF	MA	Inhibitor
DMH9VLF	RN	Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8.
DMH9VLF	RU	https://pubmed.ncbi.nlm.nih.gov/17936624

DM2V45Z	DI	DM2V45Z
DM2V45Z	DN	3-fluoro-5-(2-methylquinolin-7-yl)benzonitrile
DM2V45Z	MI	TTHS256
DM2V45Z	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM2V45Z	MT	DTT
DM2V45Z	MA	Inhibitor
DM2V45Z	RN	Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8.
DM2V45Z	RU	https://pubmed.ncbi.nlm.nih.gov/17590335

DMDPY9N	DI	DMDPY9N
DMDPY9N	DN	3-Fluoro-5-[5-(4-hydroxyphenyl)-2-thienyl]phenol
DMDPY9N	MI	TTIWB6L
DMDPY9N	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMDPY9N	MT	DTT
DMDPY9N	MA	Inhibitor
DMDPY9N	RN	New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43.
DMDPY9N	RU	https://pubmed.ncbi.nlm.nih.gov/19831396

DMDPUC7	DI	DMDPUC7
DMDPUC7	DN	3-Fluoromethyl-1,2,3,4-tetrahydro-isoquinoline
DMDPUC7	MI	TTWG9A4
DMDPUC7	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMDPUC7	MT	DTT
DMDPUC7	MA	Inhibitor
DMDPUC7	RN	3-hydroxymethyl-7-(N-substituted aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline inhibitors of phenylethanolamine N-methyltransferase that display re... J Med Chem. 2005 Jan 13;48(1):134-40.
DMDPUC7	RU	https://pubmed.ncbi.nlm.nih.gov/15634007

DMDPUC7	DI	DMDPUC7
DMDPUC7	DN	3-Fluoromethyl-1,2,3,4-tetrahydro-isoquinoline
DMDPUC7	MI	TTWM4TY
DMDPUC7	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMDPUC7	MT	DTT
DMDPUC7	MA	Inhibitor
DMDPUC7	RN	3-hydroxymethyl-7-(N-substituted aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline inhibitors of phenylethanolamine N-methyltransferase that display re... J Med Chem. 2005 Jan 13;48(1):134-40.
DMDPUC7	RU	https://pubmed.ncbi.nlm.nih.gov/15634007

DMDPUC7	DI	DMDPUC7
DMDPUC7	DN	3-Fluoromethyl-1,2,3,4-tetrahydro-isoquinoline
DMDPUC7	MI	TT2NUT5
DMDPUC7	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMDPUC7	MT	DTT
DMDPUC7	MA	Inhibitor
DMDPUC7	RN	3-hydroxymethyl-7-(N-substituted aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline inhibitors of phenylethanolamine N-methyltransferase that display re... J Med Chem. 2005 Jan 13;48(1):134-40.
DMDPUC7	RU	https://pubmed.ncbi.nlm.nih.gov/15634007

DMECBLA	DI	DMECBLA
DMECBLA	DN	3-fluorovinylglycine
DMECBLA	MI	TT6TMZU
DMECBLA	MN	Mycobacterium Biosynthetic alanine racemase (MycB alr)
DMECBLA	MT	DTT
DMECBLA	MA	Inhibitor
DMECBLA	RN	Mechanism-based inactivation of alanine racemase by 3-halovinylglycines. J Biol Chem. 1991 Nov 15;266(32):21657-65.
DMECBLA	RU	https://pubmed.ncbi.nlm.nih.gov/1939194

DM8RY7G	DI	DM8RY7G
DM8RY7G	DN	3-formyl-4-phenyl-1,2,5-oxadiazole 2-oxide
DM8RY7G	MI	TTR7UJ3
DM8RY7G	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DM8RY7G	MT	DTT
DM8RY7G	MA	Inhibitor
DM8RY7G	RN	Structure mechanism insights and the role of nitric oxide donation guide the development of oxadiazole-2-oxides as therapeutic agents against schis... J Med Chem. 2009 Oct 22;52(20):6474-83.
DM8RY7G	RU	https://pubmed.ncbi.nlm.nih.gov/19761212

DMBFCTZ	DI	DMBFCTZ
DMBFCTZ	DN	3h-Indole-5,6-Diol
DMBFCTZ	MI	TTSZDQU
DMBFCTZ	MN	Lactotransferrin (LTF)
DMBFCTZ	MT	DTT
DMBFCTZ	MA	Inhibitor
DMBFCTZ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMBFCTZ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMLB2W5	DI	DMLB2W5
DMLB2W5	DN	3h-Pyrazolo[4,3-D]Pyrimidin-7-Ol
DMLB2W5	MI	TTBL49X
DMLB2W5	MN	Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ)
DMLB2W5	MT	DTT
DMLB2W5	MA	Inhibitor
DMLB2W5	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMLB2W5	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMC70P1	DI	DMC70P1
DMC70P1	DN	3-hydroxy capric acid
DMC70P1	MI	TTG0MQD
DMC70P1	MN	Inflammation-related GPCR EX33 (GPR84)
DMC70P1	MT	DTT
DMC70P1	MA	Agonist
DMC70P1	RN	Medium-chain fatty acid-sensing receptor, GPR84, is a proinflammatory receptor. J Biol Chem. 2013 Apr 12;288(15):10684-91.
DMC70P1	RU	https://pubmed.ncbi.nlm.nih.gov/23449982

DMZSOPU	DI	DMZSOPU
DMZSOPU	DN	3-Hydroxy-1H-benzo[b]azepine-2,5-dione
DMZSOPU	MI	TTLD29N
DMZSOPU	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMZSOPU	MT	DTT
DMZSOPU	MA	Inhibitor
DMZSOPU	RN	Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53.
DMZSOPU	RU	https://pubmed.ncbi.nlm.nih.gov/8917653

DMZSOPU	DI	DMZSOPU
DMZSOPU	DN	3-Hydroxy-1H-benzo[b]azepine-2,5-dione
DMZSOPU	MI	TTKJEMQ
DMZSOPU	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMZSOPU	MT	DTT
DMZSOPU	MA	Inhibitor
DMZSOPU	RN	Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53.
DMZSOPU	RU	https://pubmed.ncbi.nlm.nih.gov/8917653

DMZSOPU	DI	DMZSOPU
DMZSOPU	DN	3-Hydroxy-1H-benzo[b]azepine-2,5-dione
DMZSOPU	MI	TTN9D8E
DMZSOPU	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMZSOPU	MT	DTT
DMZSOPU	MA	Inhibitor
DMZSOPU	RN	Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53.
DMZSOPU	RU	https://pubmed.ncbi.nlm.nih.gov/8917653

DM4758S	DI	DM4758S
DM4758S	DN	3hydroxy-1-methyl-1-phenylurea
DM4758S	MI	TTULVH8
DM4758S	MN	Tyrosinase (TYR)
DM4758S	MT	DTT
DM4758S	MA	Inhibitor
DM4758S	RN	Analogues of N-hydroxy-N'-phenylthiourea and N-hydroxy-N'-phenylurea as inhibitors of tyrosinase and melanin formation. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3607-10.
DM4758S	RU	https://pubmed.ncbi.nlm.nih.gov/18501598

DMI785L	DI	DMI785L
DMI785L	DN	3-hydroxy-2-methoxybenzaldehyde
DMI785L	MI	TTANPDJ
DMI785L	MN	Carbonic anhydrase II (CA-II)
DMI785L	MT	DTT
DMI785L	MA	Inhibitor
DMI785L	RN	Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols. Bioorg Med Chem. 2009 Apr 15;17(8):3207-11.
DMI785L	RU	https://pubmed.ncbi.nlm.nih.gov/19231207

DMIVDFW	DI	DMIVDFW
DMIVDFW	DN	3-hydroxy-2-phenylquinoline-4-carboxylic acid
DMIVDFW	MI	TT3PQ2Y
DMIVDFW	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DMIVDFW	MT	DTT
DMIVDFW	MA	Inhibitor
DMIVDFW	RN	Synthesis and biological evaluation of quinoline salicylic acids as P-selectin antagonists. J Med Chem. 2007 Jan 11;50(1):21-39.
DMIVDFW	RU	https://pubmed.ncbi.nlm.nih.gov/17201408

DMEK9DH	DI	DMEK9DH
DMEK9DH	DN	3-hydroxy-2-propionylcyclohex-2-enone
DMEK9DH	MI	TT8DSFC
DMEK9DH	MN	Hydroxyphenylpyruvate dioxygenase (HPD)
DMEK9DH	MT	DTT
DMEK9DH	MA	Inhibitor
DMEK9DH	RN	Enzyme inhibition potency enhancement by active site metal chelating and hydrogen bonding induced conformation-restricted cyclopropanecarbonyl deri... Bioorg Med Chem Lett. 2006 Dec 1;16(23):6024-7.
DMEK9DH	RU	https://pubmed.ncbi.nlm.nih.gov/16979340

DM3YO72	DI	DM3YO72
DM3YO72	DN	3-hydroxy-3-methyl-6-phosphohexanoic acid
DM3YO72	MI	TTXMI0C
DM3YO72	MN	Phosphomevalonate kinase (PMVK)
DM3YO72	MT	DTT
DM3YO72	MA	Inhibitor
DM3YO72	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 641).
DM3YO72	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=641

DMJD0UV	DI	DMJD0UV
DMJD0UV	DN	3-Hydroxy-3-Methyl-Glutaric Acid
DMJD0UV	MI	TTPADOQ
DMJD0UV	MN	HMG-CoA reductase (HMGCR)
DMJD0UV	MT	DTT
DMJD0UV	MA	Inhibitor
DMJD0UV	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMJD0UV	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMEJQTA	DI	DMEJQTA
DMEJQTA	DN	3-hydroxy-4,10-dimethyl-6H-benzo[c]chromen-6-one
DMEJQTA	MI	TTOM3J0
DMEJQTA	MN	Estrogen receptor beta (ESR2)
DMEJQTA	MT	DTT
DMEJQTA	MA	Inhibitor
DMEJQTA	RN	6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72.
DMEJQTA	RU	https://pubmed.ncbi.nlm.nih.gov/16412638

DMUME74	DI	DMUME74
DMUME74	DN	3-hydroxy-4,7-dimethyl-6H-benzo[c]chromen-6-one
DMUME74	MI	TTOM3J0
DMUME74	MN	Estrogen receptor beta (ESR2)
DMUME74	MT	DTT
DMUME74	MA	Inhibitor
DMUME74	RN	6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72.
DMUME74	RU	https://pubmed.ncbi.nlm.nih.gov/16412638

DMDBJCY	DI	DMDBJCY
DMDBJCY	DN	3-hydroxy-4-methyl-6H-benzo[c]chromen-6-one
DMDBJCY	MI	TTOM3J0
DMDBJCY	MN	Estrogen receptor beta (ESR2)
DMDBJCY	MT	DTT
DMDBJCY	MA	Inhibitor
DMDBJCY	RN	6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72.
DMDBJCY	RU	https://pubmed.ncbi.nlm.nih.gov/16412638

DM5QZDL	DI	DM5QZDL
DM5QZDL	DN	3-Hydroxy-4-phenyl-5H-furan-2-one
DM5QZDL	MI	TT8DSFC
DM5QZDL	MN	Hydroxyphenylpyruvate dioxygenase (HPD)
DM5QZDL	MT	DTT
DM5QZDL	MA	Inhibitor
DM5QZDL	RN	Design, synthesis, and evaluation of postulated transient intermediate and substrate analogues as inhibitors of 4-hydroxyphenylpyruvate dioxygenase. Bioorg Med Chem Lett. 2002 Jul 8;12(13):1709-13.
DM5QZDL	RU	https://pubmed.ncbi.nlm.nih.gov/12067543

DMZS4P7	DI	DMZS4P7
DMZS4P7	DN	3-hydroxy-5-(2-methylquinolin-7-yl)benzonitrile
DMZS4P7	MI	TTHS256
DMZS4P7	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMZS4P7	MT	DTT
DMZS4P7	MA	Inhibitor
DMZS4P7	RN	Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8.
DMZS4P7	RU	https://pubmed.ncbi.nlm.nih.gov/17590335

DMYR350	DI	DMYR350
DMYR350	DN	3-Hydroxy-6-methyl-1H-benzo[b]azepine-2,5-dione
DMYR350	MI	TTLD29N
DMYR350	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMYR350	MT	DTT
DMYR350	MA	Inhibitor
DMYR350	RN	Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53.
DMYR350	RU	https://pubmed.ncbi.nlm.nih.gov/8917653

DMYR350	DI	DMYR350
DMYR350	DN	3-Hydroxy-6-methyl-1H-benzo[b]azepine-2,5-dione
DMYR350	MI	TTKJEMQ
DMYR350	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMYR350	MT	DTT
DMYR350	MA	Inhibitor
DMYR350	RN	Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53.
DMYR350	RU	https://pubmed.ncbi.nlm.nih.gov/8917653

DMYR350	DI	DMYR350
DMYR350	DN	3-Hydroxy-6-methyl-1H-benzo[b]azepine-2,5-dione
DMYR350	MI	TTN9D8E
DMYR350	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMYR350	MT	DTT
DMYR350	MA	Inhibitor
DMYR350	RN	Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53.
DMYR350	RU	https://pubmed.ncbi.nlm.nih.gov/8917653

DM3SOFX	DI	DM3SOFX
DM3SOFX	DN	3-Hydroxy-7-(3-hydroxyphenyl)-1-naphthonitrile
DM3SOFX	MI	TTIWB6L
DM3SOFX	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DM3SOFX	MT	DTT
DM3SOFX	MA	Inhibitor
DM3SOFX	RN	Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design,... J Med Chem. 2008 Aug 14;51(15):4685-98.
DM3SOFX	RU	https://pubmed.ncbi.nlm.nih.gov/18630892

DMTEJOY	DI	DMTEJOY
DMTEJOY	DN	3-Hydroxy-7-nitro-1H-benzo[b]azepine-2,5-dione
DMTEJOY	MI	TTLD29N
DMTEJOY	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMTEJOY	MT	DTT
DMTEJOY	MA	Inhibitor
DMTEJOY	RN	Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53.
DMTEJOY	RU	https://pubmed.ncbi.nlm.nih.gov/8917653

DMTEJOY	DI	DMTEJOY
DMTEJOY	DN	3-Hydroxy-7-nitro-1H-benzo[b]azepine-2,5-dione
DMTEJOY	MI	TTKJEMQ
DMTEJOY	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMTEJOY	MT	DTT
DMTEJOY	MA	Inhibitor
DMTEJOY	RN	Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53.
DMTEJOY	RU	https://pubmed.ncbi.nlm.nih.gov/8917653

DMTEJOY	DI	DMTEJOY
DMTEJOY	DN	3-Hydroxy-7-nitro-1H-benzo[b]azepine-2,5-dione
DMTEJOY	MI	TTN9D8E
DMTEJOY	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMTEJOY	MT	DTT
DMTEJOY	MA	Inhibitor
DMTEJOY	RN	Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53.
DMTEJOY	RU	https://pubmed.ncbi.nlm.nih.gov/8917653

DM3H56L	DI	DM3H56L
DM3H56L	DN	3-hydroxy-8,10-dimethyl-6H-benzo[c]chromen-6-one
DM3H56L	MI	TTZAYWL
DM3H56L	MN	Estrogen receptor (ESR)
DM3H56L	MT	DTT
DM3H56L	MA	Inhibitor
DM3H56L	RN	6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72.
DM3H56L	RU	https://pubmed.ncbi.nlm.nih.gov/16412638

DM3H56L	DI	DM3H56L
DM3H56L	DN	3-hydroxy-8,10-dimethyl-6H-benzo[c]chromen-6-one
DM3H56L	MI	TTOM3J0
DM3H56L	MN	Estrogen receptor beta (ESR2)
DM3H56L	MT	DTT
DM3H56L	MA	Inhibitor
DM3H56L	RN	6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72.
DM3H56L	RU	https://pubmed.ncbi.nlm.nih.gov/16412638

DM7HKIF	DI	DM7HKIF
DM7HKIF	DN	3-Hydroxy-8-methyl-1H-benzo[b]azepine-2,5-dione
DM7HKIF	MI	TTLD29N
DM7HKIF	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DM7HKIF	MT	DTT
DM7HKIF	MA	Inhibitor
DM7HKIF	RN	Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53.
DM7HKIF	RU	https://pubmed.ncbi.nlm.nih.gov/8917653

DM7HKIF	DI	DM7HKIF
DM7HKIF	DN	3-Hydroxy-8-methyl-1H-benzo[b]azepine-2,5-dione
DM7HKIF	MI	TTKJEMQ
DM7HKIF	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DM7HKIF	MT	DTT
DM7HKIF	MA	Inhibitor
DM7HKIF	RN	Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53.
DM7HKIF	RU	https://pubmed.ncbi.nlm.nih.gov/8917653

DM7HKIF	DI	DM7HKIF
DM7HKIF	DN	3-Hydroxy-8-methyl-1H-benzo[b]azepine-2,5-dione
DM7HKIF	MI	TTN9D8E
DM7HKIF	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DM7HKIF	MT	DTT
DM7HKIF	MA	Inhibitor
DM7HKIF	RN	Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53.
DM7HKIF	RU	https://pubmed.ncbi.nlm.nih.gov/8917653

DMNV1P3	DI	DMNV1P3
DMNV1P3	DN	3-Hydroxy-benzamide
DMNV1P3	MI	TTVDSZ0
DMNV1P3	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMNV1P3	MT	DTT
DMNV1P3	MA	Inhibitor
DMNV1P3	RN	Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56.
DMNV1P3	RU	https://pubmed.ncbi.nlm.nih.gov/9857092

DMNUM4K	DI	DMNUM4K
DMNUM4K	DN	3-hydroxybenzylhydrazine
DMNUM4K	MI	TTN451K
DMNUM4K	MN	Aromatic-L-amino-acid decarboxylase (DDC)
DMNUM4K	MT	DTT
DMNUM4K	MA	Inhibitor
DMNUM4K	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1271).
DMNUM4K	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1271

DM5T6AM	DI	DM5T6AM
DM5T6AM	DN	3-hydroxydesaminokynurenine
DM5T6AM	MI	TTWQM3J
DM5T6AM	MN	Kynureninase (KYNU)
DM5T6AM	MT	DTT
DM5T6AM	MA	Inhibitor
DM5T6AM	RN	Comparative inhibition by substrate analogues 3-methoxy- and 3-hydroxydesaminokynurenine and an improved 3 step purification of recombinant human kynureninase. BMC Biochem. 2003 Sep 24;4:13.
DM5T6AM	RU	https://pubmed.ncbi.nlm.nih.gov/14505498

DM2LBFW	DI	DM2LBFW
DM2LBFW	DN	3-Hydroxyhippuric acid
DM2LBFW	MI	TTWQM3J
DM2LBFW	MN	Kynureninase (KYNU)
DM2LBFW	MT	DTT
DM2LBFW	MA	Inhibitor
DM2LBFW	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM2LBFW	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMKLZXV	DI	DMKLZXV
DMKLZXV	DN	3-Hydroxyisoxazole-4-Carboxylic Acid
DMKLZXV	MI	TTAZHU0
DMKLZXV	MN	L-lactate dehydrogenase (LDH)
DMKLZXV	MT	DTT
DMKLZXV	MA	Inhibitor
DMKLZXV	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMKLZXV	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMNMB6V	DI	DMNMB6V
DMNMB6V	DN	3-hydroxylauric acid
DMNMB6V	MI	TTG0MQD
DMNMB6V	MN	Inflammation-related GPCR EX33 (GPR84)
DMNMB6V	MT	DTT
DMNMB6V	MA	Agonist
DMNMB6V	RN	Medium-chain fatty acid-sensing receptor, GPR84, is a proinflammatory receptor. J Biol Chem. 2013 Apr 12;288(15):10684-91.
DMNMB6V	RU	https://pubmed.ncbi.nlm.nih.gov/23449982

DMFJLWO	DI	DMFJLWO
DMFJLWO	DN	3-Hydroxy-Myristic Acid
DMFJLWO	MI	TT8S9AV
DMFJLWO	MN	Lymphocyte antigen 96 (LY96)
DMFJLWO	MT	DTT
DMFJLWO	MA	Inhibitor
DMFJLWO	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMFJLWO	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMFJLWO	DI	DMFJLWO
DMFJLWO	DN	3-Hydroxy-Myristic Acid
DMFJLWO	MI	TTISGCA
DMFJLWO	MN	Toll-like receptor 4 (TLR4)
DMFJLWO	MT	DTT
DMFJLWO	MA	Inhibitor
DMFJLWO	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMFJLWO	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMXO98C	DI	DMXO98C
DMXO98C	DN	3-hydroxy-N,N,N-trimethylbenzenaminium iodide
DMXO98C	MI	TT1RS9F
DMXO98C	MN	Acetylcholinesterase (AChE)
DMXO98C	MT	DTT
DMXO98C	MA	Inhibitor
DMXO98C	RN	Homo- and hetero-bivalent edrophonium-like ammonium salts as highly potent, dual binding site AChE inhibitors. Bioorg Med Chem. 2008 Aug 1;16(15):7450-6.
DMXO98C	RU	https://pubmed.ncbi.nlm.nih.gov/18585045

DMS658R	DI	DMS658R
DMS658R	DN	3-hydroxyoctanoic acid
DMS658R	MI	TT8WFXV
DMS658R	MN	Hydroxycarboxylic acid receptor 3 (HCAR3)
DMS658R	MT	DTT
DMS658R	MA	Agonist
DMS658R	RN	Deorphanization of GPR109B as a receptor for the beta-oxidation intermediate 3-OH-octanoic acid and its role in the regulation of lipolysis. J Biol Chem. 2009 Aug 14;284(33):21928-33.
DMS658R	RU	https://pubmed.ncbi.nlm.nih.gov/19561068

DMMAK83	DI	DMMAK83
DMMAK83	DN	3-hydroxyphenethyl 3,4,5-trihydroxybenzoate
DMMAK83	MI	TTULVH8
DMMAK83	MN	Tyrosinase (TYR)
DMMAK83	MT	DTT
DMMAK83	MA	Inhibitor
DMMAK83	RN	Synthetic tyrosyl gallate derivatives as potent melanin formation inhibitors. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5462-4.
DMMAK83	RU	https://pubmed.ncbi.nlm.nih.gov/17693086

DM5OR96	DI	DM5OR96
DM5OR96	DN	3-Hydroxy-piperidine-4-carboxylic acid
DM5OR96	MI	TTNJYV2
DM5OR96	MN	Gamma-aminobutyric acid receptor (GAR)
DM5OR96	MT	DTT
DM5OR96	MA	Inhibitor
DM5OR96	RN	Hydroxy- and amino-substituted piperidinecarboxylic acids as gamma-aminobutyric acid agonists and uptake inhibitors. J Med Chem. 1982 Oct;25(10):1157-62.
DM5OR96	RU	https://pubmed.ncbi.nlm.nih.gov/6292417

DM67QDT	DI	DM67QDT
DM67QDT	DN	3-Hydroxypyruvic Acid
DM67QDT	MI	TTNS6X4
DM67QDT	MN	Bacterial Triosephosphate isomerase (Bact TPI)
DM67QDT	MT	DTT
DM67QDT	MA	Inhibitor
DM67QDT	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM67QDT	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMCXZ9L	DI	DMCXZ9L
DMCXZ9L	DN	3-hydroxyquinazoline-2,4(1H,3H)-dione
DMCXZ9L	MI	TT37KAF
DMCXZ9L	MN	Human immunodeficiency virus Ribonuclease H (HIV RNH)
DMCXZ9L	MT	DTT
DMCXZ9L	MA	Inhibitor
DMCXZ9L	RN	RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: design, biochemical activity, and structural information. J Med Chem. 2009 Oct 8;52(19):5781-4.
DMCXZ9L	RU	https://pubmed.ncbi.nlm.nih.gov/19791799

DMBZ60O	DI	DMBZ60O
DMBZ60O	DN	3-Imidazol-1-ylmethyl-1H-indole
DMBZ60O	MI	TTIQUX7
DMBZ60O	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMBZ60O	MT	DTT
DMBZ60O	MA	Inhibitor
DMBZ60O	RN	Selective thromboxane synthetase inhibitors. 2. 3-(1H-imidazol-1-ylmethyl)-2-methyl-1H-indole-1-propanoic acid and analogues. J Med Chem. 1986 Mar;29(3):342-6.
DMBZ60O	RU	https://pubmed.ncbi.nlm.nih.gov/3081722

DMAQOL0	DI	DMAQOL0
DMAQOL0	DN	3-Imidazol-1-ylmethyl-2-isopropyl-1H-indole
DMAQOL0	MI	TTIQUX7
DMAQOL0	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMAQOL0	MT	DTT
DMAQOL0	MA	Inhibitor
DMAQOL0	RN	Selective thromboxane synthetase inhibitors. 2. 3-(1H-imidazol-1-ylmethyl)-2-methyl-1H-indole-1-propanoic acid and analogues. J Med Chem. 1986 Mar;29(3):342-6.
DMAQOL0	RU	https://pubmed.ncbi.nlm.nih.gov/3081722

DMVF6OQ	DI	DMVF6OQ
DMVF6OQ	DN	3-Imidazol-1-yl-quinoline
DMVF6OQ	MI	TTIQUX7
DMVF6OQ	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMVF6OQ	MT	DTT
DMVF6OQ	MA	Inhibitor
DMVF6OQ	RN	Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42.
DMVF6OQ	RU	https://pubmed.ncbi.nlm.nih.gov/16220979

DMYH6A2	DI	DMYH6A2
DMYH6A2	DN	3-Indan-(1E)-ylidenemethyl-pyridine
DMYH6A2	MI	TTSZLWK
DMYH6A2	MN	Aromatase (CYP19A1)
DMYH6A2	MT	DTT
DMYH6A2	MA	Inhibitor
DMYH6A2	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMYH6A2	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMYH6A2	DI	DMYH6A2
DMYH6A2	DN	3-Indan-(1E)-ylidenemethyl-pyridine
DMYH6A2	MI	TTIQUX7
DMYH6A2	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMYH6A2	MT	DTT
DMYH6A2	MA	Inhibitor
DMYH6A2	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMYH6A2	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMTQERW	DI	DMTQERW
DMTQERW	DN	3-Indan-(1Z)-ylidenemethyl-pyridine
DMTQERW	MI	TTSZLWK
DMTQERW	MN	Aromatase (CYP19A1)
DMTQERW	MT	DTT
DMTQERW	MA	Inhibitor
DMTQERW	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMTQERW	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMTQERW	DI	DMTQERW
DMTQERW	DN	3-Indan-(1Z)-ylidenemethyl-pyridine
DMTQERW	MI	TTIQUX7
DMTQERW	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMTQERW	MT	DTT
DMTQERW	MA	Inhibitor
DMTQERW	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMTQERW	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DM890WJ	DI	DM890WJ
DM890WJ	DN	3-Iodoboldine
DM890WJ	MI	TTZFYLI
DM890WJ	MN	Dopamine D1 receptor (D1R)
DM890WJ	MT	DTT
DM890WJ	MA	Inhibitor
DM890WJ	RN	Halogenated boldine derivatives with enhanced monoamine receptor selectivity. J Nat Prod. 2000 Apr;63(4):480-4.
DM890WJ	RU	https://pubmed.ncbi.nlm.nih.gov/10785418

DM890WJ	DI	DM890WJ
DM890WJ	DN	3-Iodoboldine
DM890WJ	MI	TTEX248
DM890WJ	MN	Dopamine D2 receptor (D2R)
DM890WJ	MT	DTT
DM890WJ	MA	Inhibitor
DM890WJ	RN	Halogenated boldine derivatives with enhanced monoamine receptor selectivity. J Nat Prod. 2000 Apr;63(4):480-4.
DM890WJ	RU	https://pubmed.ncbi.nlm.nih.gov/10785418

DMDSJ0O	DI	DMDSJ0O
DMDSJ0O	DN	3-iodo-N-(6-methylpyridin-2-yl)benzamide
DMDSJ0O	MI	TTHS256
DMDSJ0O	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMDSJ0O	MT	DTT
DMDSJ0O	MA	Inhibitor
DMDSJ0O	RN	Design and synthesis of noncompetitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3371-5.
DMDSJ0O	RU	https://pubmed.ncbi.nlm.nih.gov/16678408

DM3L0F8	DI	DM3L0F8
DM3L0F8	DN	3-iodothyronamine
DM3L0F8	MI	TTIU98M
DM3L0F8	MN	Trace amine-associated receptor-1 (TAAR1)
DM3L0F8	MT	DTT
DM3L0F8	MA	Agonist
DM3L0F8	RN	Exploring the structure-activity relationship of the ethylamine portion of 3-iodothyronamine for rat and mouse trace amine-associated receptor 1. J Med Chem. 2007 Jun 14;50(12):2787-98.
DM3L0F8	RU	https://pubmed.ncbi.nlm.nih.gov/17497842

DMNZMH6	DI	DMNZMH6
DMNZMH6	DN	3-iodotyrosine
DMNZMH6	MI	TTUHP71
DMNZMH6	MN	Tyrosine 3-monooxygenase (TH)
DMNZMH6	MT	DTT
DMNZMH6	MA	Inhibitor
DMNZMH6	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1243).
DMNZMH6	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1243

DMJSLVT	DI	DMJSLVT
DMJSLVT	DN	3-Iodyl-benzoic acid
DMJSLVT	MI	TTELIN2
DMJSLVT	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMJSLVT	MT	DTT
DMJSLVT	MA	Inhibitor
DMJSLVT	RN	Periodinates: a new class of protein tyrosine phosphatase inhibitors. Bioorg Med Chem Lett. 1999 Feb 8;9(3):353-6.
DMJSLVT	RU	https://pubmed.ncbi.nlm.nih.gov/10091683

DMWP0LZ	DI	DMWP0LZ
DMWP0LZ	DN	3-isobutoxy-5-(2-methylquinolin-7-yl)benzonitrile
DMWP0LZ	MI	TTHS256
DMWP0LZ	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMWP0LZ	MT	DTT
DMWP0LZ	MA	Inhibitor
DMWP0LZ	RN	Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8.
DMWP0LZ	RU	https://pubmed.ncbi.nlm.nih.gov/17590335

DM6X5TZ	DI	DM6X5TZ
DM6X5TZ	DN	3-Isobutoxy-9H-beta-carboline
DM6X5TZ	MI	TT1MPAY
DM6X5TZ	MN	GABA(A) receptor alpha-1 (GABRA1)
DM6X5TZ	MT	DTT
DM6X5TZ	MA	Inhibitor
DM6X5TZ	RN	Predictive binding of beta-carboline inverse agonists and antagonists via the CoMFA/GOLPE approach. J Med Chem. 1992 Oct 30;35(22):4001-10.
DM6X5TZ	RU	https://pubmed.ncbi.nlm.nih.gov/1331452

DM6X5TZ	DI	DM6X5TZ
DM6X5TZ	DN	3-Isobutoxy-9H-beta-carboline
DM6X5TZ	MI	TTBMV1G
DM6X5TZ	MN	GABA(A) receptor alpha-2 (GABRA2)
DM6X5TZ	MT	DTT
DM6X5TZ	MA	Inhibitor
DM6X5TZ	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DM6X5TZ	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DM6X5TZ	DI	DM6X5TZ
DM6X5TZ	DN	3-Isobutoxy-9H-beta-carboline
DM6X5TZ	MI	TT37EDJ
DM6X5TZ	MN	GABA(A) receptor alpha-3 (GABRA3)
DM6X5TZ	MT	DTT
DM6X5TZ	MA	Inhibitor
DM6X5TZ	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DM6X5TZ	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DM6X5TZ	DI	DM6X5TZ
DM6X5TZ	DN	3-Isobutoxy-9H-beta-carboline
DM6X5TZ	MI	TTNZPQ1
DM6X5TZ	MN	GABA(A) receptor alpha-5 (GABRA5)
DM6X5TZ	MT	DTT
DM6X5TZ	MA	Inhibitor
DM6X5TZ	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DM6X5TZ	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DM6X5TZ	DI	DM6X5TZ
DM6X5TZ	DN	3-Isobutoxy-9H-beta-carboline
DM6X5TZ	MI	TT06RH5
DM6X5TZ	MN	GABA(A) receptor gamma-2 (GABRG2)
DM6X5TZ	MT	DTT
DM6X5TZ	MA	Inhibitor
DM6X5TZ	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DM6X5TZ	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DM6X5TZ	DI	DM6X5TZ
DM6X5TZ	DN	3-Isobutoxy-9H-beta-carboline
DM6X5TZ	MI	TTNJYV2
DM6X5TZ	MN	Gamma-aminobutyric acid receptor (GAR)
DM6X5TZ	MT	DTT
DM6X5TZ	MA	Inhibitor
DM6X5TZ	RN	Predictive binding of beta-carboline inverse agonists and antagonists via the CoMFA/GOLPE approach. J Med Chem. 1992 Oct 30;35(22):4001-10.
DM6X5TZ	RU	https://pubmed.ncbi.nlm.nih.gov/1331452

DMQXP7C	DI	DMQXP7C
DMQXP7C	DN	3-Isobutyl-[1,4]thiazepan-(5E)-ylideneamine
DMQXP7C	MI	TTZUFI5
DMQXP7C	MN	Nitric-oxide synthase brain (NOS1)
DMQXP7C	MT	DTT
DMQXP7C	MA	Inhibitor
DMQXP7C	RN	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
DMQXP7C	RU	https://pubmed.ncbi.nlm.nih.gov/15501067

DMQXP7C	DI	DMQXP7C
DMQXP7C	DN	3-Isobutyl-[1,4]thiazepan-(5E)-ylideneamine
DMQXP7C	MI	TTF10I9
DMQXP7C	MN	Nitric-oxide synthase inducible (NOS2)
DMQXP7C	MT	DTT
DMQXP7C	MA	Inhibitor
DMQXP7C	RN	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
DMQXP7C	RU	https://pubmed.ncbi.nlm.nih.gov/15501067

DM9GM1H	DI	DM9GM1H
DM9GM1H	DN	3-isobutyl-8-pyrrolidinoxanthine
DM9GM1H	MI	TTNE7KG
DM9GM1H	MN	Adenosine A2b receptor (ADORA2B)
DM9GM1H	MT	DTT
DM9GM1H	MA	Antagonist
DM9GM1H	RN	Inhibition of human mast cell activation with the novel selective adenosine A(2B) receptor antagonist 3-isobutyl-8-pyrrolidinoxanthine (IPDX)(2). Biochem Pharmacol. 2001 Nov 1;62(9):1163-73.
DM9GM1H	RU	https://pubmed.ncbi.nlm.nih.gov/11705449

DM7PHO4	DI	DM7PHO4
DM7PHO4	DN	3-Isopropoxy-9H-beta-carboline
DM7PHO4	MI	TT1MPAY
DM7PHO4	MN	GABA(A) receptor alpha-1 (GABRA1)
DM7PHO4	MT	DTT
DM7PHO4	MA	Inhibitor
DM7PHO4	RN	Predictive binding of beta-carboline inverse agonists and antagonists via the CoMFA/GOLPE approach. J Med Chem. 1992 Oct 30;35(22):4001-10.
DM7PHO4	RU	https://pubmed.ncbi.nlm.nih.gov/1331452

DM7PHO4	DI	DM7PHO4
DM7PHO4	DN	3-Isopropoxy-9H-beta-carboline
DM7PHO4	MI	TTNJYV2
DM7PHO4	MN	Gamma-aminobutyric acid receptor (GAR)
DM7PHO4	MT	DTT
DM7PHO4	MA	Inhibitor
DM7PHO4	RN	Predictive binding of beta-carboline inverse agonists and antagonists via the CoMFA/GOLPE approach. J Med Chem. 1992 Oct 30;35(22):4001-10.
DM7PHO4	RU	https://pubmed.ncbi.nlm.nih.gov/1331452

DMYKVRF	DI	DMYKVRF
DMYKVRF	DN	3-Isopropyl-1-methyl-3,7-dihydro-purine-2,6-dione
DMYKVRF	MI	TTM2AOE
DMYKVRF	MN	Adenosine A2a receptor (ADORA2A)
DMYKVRF	MT	DTT
DMYKVRF	MA	Inhibitor
DMYKVRF	RN	Analogues of caffeine and theophylline: effect of structural alterations on affinity at adenosine receptors. J Med Chem. 1986 Jul;29(7):1305-8.
DMYKVRF	RU	https://pubmed.ncbi.nlm.nih.gov/3806581

DMSLPGZ	DI	DMSLPGZ
DMSLPGZ	DN	3-Isopropyl-3-methyl-dihydro-furan-2-one
DMSLPGZ	MI	TT1MPAY
DMSLPGZ	MN	GABA(A) receptor alpha-1 (GABRA1)
DMSLPGZ	MT	DTT
DMSLPGZ	MA	Inhibitor
DMSLPGZ	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DMSLPGZ	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DMSLPGZ	DI	DMSLPGZ
DMSLPGZ	DN	3-Isopropyl-3-methyl-dihydro-furan-2-one
DMSLPGZ	MI	TTZA1NY
DMSLPGZ	MN	GABA(A) receptor beta-2 (GABRB2)
DMSLPGZ	MT	DTT
DMSLPGZ	MA	Inhibitor
DMSLPGZ	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DMSLPGZ	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DMSLPGZ	DI	DMSLPGZ
DMSLPGZ	DN	3-Isopropyl-3-methyl-dihydro-furan-2-one
DMSLPGZ	MI	TT06RH5
DMSLPGZ	MN	GABA(A) receptor gamma-2 (GABRG2)
DMSLPGZ	MT	DTT
DMSLPGZ	MA	Inhibitor
DMSLPGZ	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DMSLPGZ	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DMSLPGZ	DI	DMSLPGZ
DMSLPGZ	DN	3-Isopropyl-3-methyl-dihydro-furan-2-one
DMSLPGZ	MI	TTNJYV2
DMSLPGZ	MN	Gamma-aminobutyric acid receptor (GAR)
DMSLPGZ	MT	DTT
DMSLPGZ	MA	Inhibitor
DMSLPGZ	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DMSLPGZ	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DMHAJ6W	DI	DMHAJ6W
DMHAJ6W	DN	3-isopropyl-4-(phenylamino)naphthalene-1,2-dione
DMHAJ6W	MI	TTLZS4Q
DMHAJ6W	MN	M-phase inducer phosphatase 1 (MPIP1)
DMHAJ6W	MT	DTT
DMHAJ6W	MA	Inhibitor
DMHAJ6W	RN	Synthesis of miltirone analogues as inhibitors of Cdc25 phosphatases. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1905-8.
DMHAJ6W	RU	https://pubmed.ncbi.nlm.nih.gov/16434190

DMHAJ6W	DI	DMHAJ6W
DMHAJ6W	DN	3-isopropyl-4-(phenylamino)naphthalene-1,2-dione
DMHAJ6W	MI	TTR0SWN
DMHAJ6W	MN	M-phase inducer phosphatase 2 (MPIP2)
DMHAJ6W	MT	DTT
DMHAJ6W	MA	Inhibitor
DMHAJ6W	RN	Synthesis of miltirone analogues as inhibitors of Cdc25 phosphatases. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1905-8.
DMHAJ6W	RU	https://pubmed.ncbi.nlm.nih.gov/16434190

DMJZEMB	DI	DMJZEMB
DMJZEMB	DN	3-isopropyl-4-(phenylthio)naphthalene-1,2-dione
DMJZEMB	MI	TTLZS4Q
DMJZEMB	MN	M-phase inducer phosphatase 1 (MPIP1)
DMJZEMB	MT	DTT
DMJZEMB	MA	Inhibitor
DMJZEMB	RN	Synthesis of miltirone analogues as inhibitors of Cdc25 phosphatases. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1905-8.
DMJZEMB	RU	https://pubmed.ncbi.nlm.nih.gov/16434190

DMJZEMB	DI	DMJZEMB
DMJZEMB	DN	3-isopropyl-4-(phenylthio)naphthalene-1,2-dione
DMJZEMB	MI	TTR0SWN
DMJZEMB	MN	M-phase inducer phosphatase 2 (MPIP2)
DMJZEMB	MT	DTT
DMJZEMB	MA	Inhibitor
DMJZEMB	RN	Synthesis of miltirone analogues as inhibitors of Cdc25 phosphatases. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1905-8.
DMJZEMB	RU	https://pubmed.ncbi.nlm.nih.gov/16434190

DMJZEMB	DI	DMJZEMB
DMJZEMB	DN	3-isopropyl-4-(phenylthio)naphthalene-1,2-dione
DMJZEMB	MI	TTELIN2
DMJZEMB	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMJZEMB	MT	DTT
DMJZEMB	MA	Inhibitor
DMJZEMB	RN	Synthesis of miltirone analogues as inhibitors of Cdc25 phosphatases. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1905-8.
DMJZEMB	RU	https://pubmed.ncbi.nlm.nih.gov/16434190

DMYZCWX	DI	DMYZCWX
DMYZCWX	DN	3-isopropyl-4-phenylnaphthalene-1,2-dione
DMYZCWX	MI	TTLZS4Q
DMYZCWX	MN	M-phase inducer phosphatase 1 (MPIP1)
DMYZCWX	MT	DTT
DMYZCWX	MA	Inhibitor
DMYZCWX	RN	Synthesis of miltirone analogues as inhibitors of Cdc25 phosphatases. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1905-8.
DMYZCWX	RU	https://pubmed.ncbi.nlm.nih.gov/16434190

DMYZCWX	DI	DMYZCWX
DMYZCWX	DN	3-isopropyl-4-phenylnaphthalene-1,2-dione
DMYZCWX	MI	TTR0SWN
DMYZCWX	MN	M-phase inducer phosphatase 2 (MPIP2)
DMYZCWX	MT	DTT
DMYZCWX	MA	Inhibitor
DMYZCWX	RN	Synthesis of miltirone analogues as inhibitors of Cdc25 phosphatases. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1905-8.
DMYZCWX	RU	https://pubmed.ncbi.nlm.nih.gov/16434190

DM46ID2	DI	DM46ID2
DM46ID2	DN	3-isopropylnaphthalene-1,2-dione
DM46ID2	MI	TTLZS4Q
DM46ID2	MN	M-phase inducer phosphatase 1 (MPIP1)
DM46ID2	MT	DTT
DM46ID2	MA	Inhibitor
DM46ID2	RN	Synthesis of miltirone analogues as inhibitors of Cdc25 phosphatases. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1905-8.
DM46ID2	RU	https://pubmed.ncbi.nlm.nih.gov/16434190

DMZPGBT	DI	DMZPGBT
DMZPGBT	DN	3-isopr-sal-cyclosal-d4TMP
DMZPGBT	MI	TTEB0GD
DMZPGBT	MN	Cholinesterase (BCHE)
DMZPGBT	MT	DTT
DMZPGBT	MA	Inhibitor
DMZPGBT	RN	Bis-cycloSal-d4T-monophosphates: drugs that deliver two molecules of bioactive nucleotides. J Med Chem. 2007 Mar 22;50(6):1335-46.
DMZPGBT	RU	https://pubmed.ncbi.nlm.nih.gov/17328534

DM9LEWH	DI	DM9LEWH
DM9LEWH	DN	3-Isothiocyanato-9H-beta-carboline
DM9LEWH	MI	TT1MPAY
DM9LEWH	MN	GABA(A) receptor alpha-1 (GABRA1)
DM9LEWH	MT	DTT
DM9LEWH	MA	Inhibitor
DM9LEWH	RN	Synthetic and computer-assisted analyses of the pharmacophore for the benzodiazepine receptor inverse agonist site. J Med Chem. 1990 Sep;33(9):2343-57.
DM9LEWH	RU	https://pubmed.ncbi.nlm.nih.gov/2167977

DM9LEWH	DI	DM9LEWH
DM9LEWH	DN	3-Isothiocyanato-9H-beta-carboline
DM9LEWH	MI	TTZA1NY
DM9LEWH	MN	GABA(A) receptor beta-2 (GABRB2)
DM9LEWH	MT	DTT
DM9LEWH	MA	Inhibitor
DM9LEWH	RN	Synthetic and computer-assisted analyses of the pharmacophore for the benzodiazepine receptor inverse agonist site. J Med Chem. 1990 Sep;33(9):2343-57.
DM9LEWH	RU	https://pubmed.ncbi.nlm.nih.gov/2167977

DM9LEWH	DI	DM9LEWH
DM9LEWH	DN	3-Isothiocyanato-9H-beta-carboline
DM9LEWH	MI	TT06RH5
DM9LEWH	MN	GABA(A) receptor gamma-2 (GABRG2)
DM9LEWH	MT	DTT
DM9LEWH	MA	Inhibitor
DM9LEWH	RN	Synthetic and computer-assisted analyses of the pharmacophore for the benzodiazepine receptor inverse agonist site. J Med Chem. 1990 Sep;33(9):2343-57.
DM9LEWH	RU	https://pubmed.ncbi.nlm.nih.gov/2167977

DM9LEWH	DI	DM9LEWH
DM9LEWH	DN	3-Isothiocyanato-9H-beta-carboline
DM9LEWH	MI	TTNJYV2
DM9LEWH	MN	Gamma-aminobutyric acid receptor (GAR)
DM9LEWH	MT	DTT
DM9LEWH	MA	Inhibitor
DM9LEWH	RN	Synthetic and computer-assisted analyses of the pharmacophore for the benzodiazepine receptor inverse agonist site. J Med Chem. 1990 Sep;33(9):2343-57.
DM9LEWH	RU	https://pubmed.ncbi.nlm.nih.gov/2167977

DM5LUED	DI	DM5LUED
DM5LUED	DN	3-keto-lithocholic acid
DM5LUED	MI	TT7LCTF
DM5LUED	MN	Pregnane X receptor (NR1I2)
DM5LUED	MT	DTT
DM5LUED	MA	Agonist
DM5LUED	RN	The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3369-74.
DM5LUED	RU	https://pubmed.ncbi.nlm.nih.gov/11248085

DM5LUED	DI	DM5LUED
DM5LUED	DN	3-keto-lithocholic acid
DM5LUED	MI	TTK59TV
DM5LUED	MN	Vitamin D3 receptor (VDR)
DM5LUED	MT	DTT
DM5LUED	MA	Agonist
DM5LUED	RN	Vitamin D receptor as an intestinal bile acid sensor. Science. 2002 May 17;296(5571):1313-6.
DM5LUED	RU	https://pubmed.ncbi.nlm.nih.gov/12016314

DMRMF13	DI	DMRMF13
DMRMF13	DN	3-MATIDA
DMRMF13	MI	TTVBPDM
DMRMF13	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMRMF13	MT	DTT
DMRMF13	MA	Antagonist
DMRMF13	RN	The novel and systemically active metabotropic glutamate 1 (mGlu1) receptor antagonist 3-MATIDA reduces post-ischemic neuronal death. Neuropharmacology. 2002 May;42(6):741-51.
DMRMF13	RU	https://pubmed.ncbi.nlm.nih.gov/12015200

DMPJBNC	DI	DMPJBNC
DMPJBNC	DN	3-mercapto-2-(piperidin-3-yl)propanoic acid
DMPJBNC	MI	TTP18AY
DMPJBNC	MN	Carboxypeptidase B2 (CPB2)
DMPJBNC	MT	DTT
DMPJBNC	MA	Inhibitor
DMPJBNC	RN	3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa). Bioorg Med Chem Lett. 2007 Mar 1;17(5):1349-54.
DMPJBNC	RU	https://pubmed.ncbi.nlm.nih.gov/17189688

DMYQG7A	DI	DMYQG7A
DMYQG7A	DN	3-mercapto-2-(piperidin-4-yl)propanoic acid
DMYQG7A	MI	TTP18AY
DMYQG7A	MN	Carboxypeptidase B2 (CPB2)
DMYQG7A	MT	DTT
DMYQG7A	MA	Inhibitor
DMYQG7A	RN	3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa). Bioorg Med Chem Lett. 2007 Mar 1;17(5):1349-54.
DMYQG7A	RU	https://pubmed.ncbi.nlm.nih.gov/17189688

DMQ09J8	DI	DMQ09J8
DMQ09J8	DN	3-mercapto-N-(4-sulfamoyl-phenyl)-propionamide
DMQ09J8	MI	TTHQPL7
DMQ09J8	MN	Carbonic anhydrase I (CA-I)
DMQ09J8	MT	DTT
DMQ09J8	MA	Inhibitor
DMQ09J8	RN	Carbonic anhydrase inhibitors: Hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX. J Med Chem. 2006 Sep 7;49(18):5544-51.
DMQ09J8	RU	https://pubmed.ncbi.nlm.nih.gov/16942027

DMQ09J8	DI	DMQ09J8
DMQ09J8	DN	3-mercapto-N-(4-sulfamoyl-phenyl)-propionamide
DMQ09J8	MI	TTANPDJ
DMQ09J8	MN	Carbonic anhydrase II (CA-II)
DMQ09J8	MT	DTT
DMQ09J8	MA	Inhibitor
DMQ09J8	RN	Carbonic anhydrase inhibitors: Hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX. J Med Chem. 2006 Sep 7;49(18):5544-51.
DMQ09J8	RU	https://pubmed.ncbi.nlm.nih.gov/16942027

DMQ09J8	DI	DMQ09J8
DMQ09J8	DN	3-mercapto-N-(4-sulfamoyl-phenyl)-propionamide
DMQ09J8	MI	TT2LVK8
DMQ09J8	MN	Carbonic anhydrase IX (CA-IX)
DMQ09J8	MT	DTT
DMQ09J8	MA	Inhibitor
DMQ09J8	RN	Carbonic anhydrase inhibitors: Hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX. J Med Chem. 2006 Sep 7;49(18):5544-51.
DMQ09J8	RU	https://pubmed.ncbi.nlm.nih.gov/16942027

DMX3ANZ	DI	DMX3ANZ
DMX3ANZ	DN	3-Mercuri-4-Aminobenzenesulfonamide
DMX3ANZ	MI	TTANPDJ
DMX3ANZ	MN	Carbonic anhydrase II (CA-II)
DMX3ANZ	MT	DTT
DMX3ANZ	MA	Inhibitor
DMX3ANZ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMX3ANZ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMAWEQH	DI	DMAWEQH
DMAWEQH	DN	3-MeSO2-DDE
DMAWEQH	MI	TTIQUX7
DMAWEQH	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMAWEQH	MT	DTT
DMAWEQH	MA	Inhibitor
DMAWEQH	RN	Effects of 3-MeSO2-DDE and some CYP inhibitors on glucocorticoid steroidogenesis in the H295R human adrenocortical carcinoma cell line. Toxicol In Vitro. 2002 Apr;16(2):113-21.
DMAWEQH	RU	https://pubmed.ncbi.nlm.nih.gov/11869873

DM2QD45	DI	DM2QD45
DM2QD45	DN	3-methoxy-4-(m-tolyloxy)benzonitrile
DM2QD45	MI	TTKPW01
DM2QD45	MN	Androgen receptor messenger RNA (AR mRNA)
DM2QD45	MT	DTT
DM2QD45	MA	Inhibitor
DM2QD45	RN	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
DM2QD45	RU	https://pubmed.ncbi.nlm.nih.gov/19201190

DMEGF58	DI	DMEGF58
DMEGF58	DN	3-methoxy-4-(o-tolyloxy)benzonitrile
DMEGF58	MI	TTKPW01
DMEGF58	MN	Androgen receptor messenger RNA (AR mRNA)
DMEGF58	MT	DTT
DMEGF58	MA	Inhibitor
DMEGF58	RN	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
DMEGF58	RU	https://pubmed.ncbi.nlm.nih.gov/19201190

DMKUM4L	DI	DMKUM4L
DMKUM4L	DN	3-methoxy-4-(oxazol-5-yl)aniline
DMKUM4L	MI	TTTB4UP
DMKUM4L	MN	Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2)
DMKUM4L	MT	DTT
DMKUM4L	MA	Inhibitor
DMKUM4L	RN	Low molecular weight indole fragments as IMPDH inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2535-8.
DMKUM4L	RU	https://pubmed.ncbi.nlm.nih.gov/16483769

DM37QE8	DI	DM37QE8
DM37QE8	DN	3-methoxy-4-(p-tolyloxy)benzonitrile
DM37QE8	MI	TTKPW01
DM37QE8	MN	Androgen receptor messenger RNA (AR mRNA)
DM37QE8	MT	DTT
DM37QE8	MA	Inhibitor
DM37QE8	RN	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
DM37QE8	RU	https://pubmed.ncbi.nlm.nih.gov/19201190

DMG1T6H	DI	DMG1T6H
DMG1T6H	DN	3'-Methoxy-4'Hydroxyclomiphene
DMG1T6H	MI	TTZAYWL
DMG1T6H	MN	Estrogen receptor (ESR)
DMG1T6H	MT	DTT
DMG1T6H	MA	Inhibitor
DMG1T6H	RN	Phenolic metabolites of clomiphene: [(E,Z)-2-[4-(1,2-diphenyl-2-chlorovinyl)phenoxy]ethyl]diethylamine. Preparation, electrophilicity, and effects ... J Med Chem. 1989 Jan;32(1):192-7.
DMG1T6H	RU	https://pubmed.ncbi.nlm.nih.gov/2909731

DMG1T6H	DI	DMG1T6H
DMG1T6H	DN	3'-Methoxy-4'Hydroxyclomiphene
DMG1T6H	MI	TTOM3J0
DMG1T6H	MN	Estrogen receptor beta (ESR2)
DMG1T6H	MT	DTT
DMG1T6H	MA	Inhibitor
DMG1T6H	RN	Phenolic metabolites of clomiphene: [(E,Z)-2-[4-(1,2-diphenyl-2-chlorovinyl)phenoxy]ethyl]diethylamine. Preparation, electrophilicity, and effects ... J Med Chem. 1989 Jan;32(1):192-7.
DMG1T6H	RU	https://pubmed.ncbi.nlm.nih.gov/2909731

DMAL1CP	DI	DMAL1CP
DMAL1CP	DN	3-methoxy-4-hydroxylonchocarpin
DMAL1CP	MI	TTUMGNO
DMAL1CP	MN	Ornithine decarboxylase (ODC1)
DMAL1CP	MT	DTT
DMAL1CP	MA	Inhibitor
DMAL1CP	RN	New bioactive flavonoids and stilbenes in cub resin insecticide. J Nat Prod. 1999 Feb;62(2):205-10.
DMAL1CP	RU	https://pubmed.ncbi.nlm.nih.gov/10075742

DMHYRES	DI	DMHYRES
DMHYRES	DN	3-methoxy-5-(1,5-naphthyridin-3-yl)benzonitrile
DMHYRES	MI	TTHS256
DMHYRES	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMHYRES	MT	DTT
DMHYRES	MA	Inhibitor
DMHYRES	RN	Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8.
DMHYRES	RU	https://pubmed.ncbi.nlm.nih.gov/17936624

DMKHJ8G	DI	DMKHJ8G
DMKHJ8G	DN	3-methoxy-5-(1,6-naphthyridin-7-yl)benzonitrile
DMKHJ8G	MI	TTHS256
DMKHJ8G	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMKHJ8G	MT	DTT
DMKHJ8G	MA	Inhibitor
DMKHJ8G	RN	Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8.
DMKHJ8G	RU	https://pubmed.ncbi.nlm.nih.gov/17936624

DMRMZLV	DI	DMRMZLV
DMRMZLV	DN	3-methoxy-5-(2-methylquinolin-7-yl)benzonitrile
DMRMZLV	MI	TTHS256
DMRMZLV	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMRMZLV	MT	DTT
DMRMZLV	MA	Inhibitor
DMRMZLV	RN	Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8.
DMRMZLV	RU	https://pubmed.ncbi.nlm.nih.gov/17590335

DMF2IW8	DI	DMF2IW8
DMF2IW8	DN	3-methoxy-5-(6-methoxynaphthalen-2-yl)pyridine
DMF2IW8	MI	TTXV4FI
DMF2IW8	MN	Albendazole monooxygenase (CYP3A4)
DMF2IW8	MT	DTT
DMF2IW8	MA	Inhibitor
DMF2IW8	RN	Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on pote... J Med Chem. 2008 Aug 28;51(16):5064-74.
DMF2IW8	RU	https://pubmed.ncbi.nlm.nih.gov/18672861

DMF2IW8	DI	DMF2IW8
DMF2IW8	DN	3-methoxy-5-(6-methoxynaphthalen-2-yl)pyridine
DMF2IW8	MI	TTIQUX7
DMF2IW8	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMF2IW8	MT	DTT
DMF2IW8	MA	Inhibitor
DMF2IW8	RN	Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on pote... J Med Chem. 2008 Aug 28;51(16):5064-74.
DMF2IW8	RU	https://pubmed.ncbi.nlm.nih.gov/18672861

DMO2N56	DI	DMO2N56
DMO2N56	DN	3-methoxy-9-aminomethyl-9,10-dihydroanthracene
DMO2N56	MI	TTJQOD7
DMO2N56	MN	5-HT 2A receptor (HTR2A)
DMO2N56	MT	DTT
DMO2N56	MA	Inhibitor
DMO2N56	RN	Methoxy-substituted 9-aminomethyl-9,10-dihydroanthracene (AMDA) derivatives exhibit differential binding affinities at the 5-HT(2A) receptor. Bioorg Med Chem Lett. 2008 Oct 1;18(19):5268-71.
DMO2N56	RU	https://pubmed.ncbi.nlm.nih.gov/18774714

DMTBX0D	DI	DMTBX0D
DMTBX0D	DN	3-Methoxy-9H-beta-carboline
DMTBX0D	MI	TT1MPAY
DMTBX0D	MN	GABA(A) receptor alpha-1 (GABRA1)
DMTBX0D	MT	DTT
DMTBX0D	MA	Inhibitor
DMTBX0D	RN	Synthesis of novel 3-substituted beta-carbolines as benzodiazepine receptor ligands: probing the benzodiazepine receptor pharmacophore. J Med Chem. 1988 Sep;31(9):1854-61.
DMTBX0D	RU	https://pubmed.ncbi.nlm.nih.gov/2842507

DMTBX0D	DI	DMTBX0D
DMTBX0D	DN	3-Methoxy-9H-beta-carboline
DMTBX0D	MI	TTNJYV2
DMTBX0D	MN	Gamma-aminobutyric acid receptor (GAR)
DMTBX0D	MT	DTT
DMTBX0D	MA	Inhibitor
DMTBX0D	RN	Synthesis of novel 3-substituted beta-carbolines as benzodiazepine receptor ligands: probing the benzodiazepine receptor pharmacophore. J Med Chem. 1988 Sep;31(9):1854-61.
DMTBX0D	RU	https://pubmed.ncbi.nlm.nih.gov/2842507

DM245AB	DI	DM245AB
DM245AB	DN	3-Methoxybenzamide
DM245AB	MI	TTVDSZ0
DM245AB	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DM245AB	MT	DTT
DM245AB	MA	Inhibitor
DM245AB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM245AB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMQMT1A	DI	DMQMT1A
DMQMT1A	DN	3-Methoxycarbonyl-2-methyl-9H-beta-carbolin-2-ium
DMQMT1A	MI	TT1MPAY
DMQMT1A	MN	GABA(A) receptor alpha-1 (GABRA1)
DMQMT1A	MT	DTT
DMQMT1A	MA	Inhibitor
DMQMT1A	RN	N-2 methylated quaternary derivatives of beta-carboline-3-carboxylates inhibit acetylcholinesterase in vitroO, Bioorg. Med. Chem. Lett. 3(12):2831-2836 (1993).
DMQMT1A	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01807745

DMQMT1A	DI	DMQMT1A
DMQMT1A	DN	3-Methoxycarbonyl-2-methyl-9H-beta-carbolin-2-ium
DMQMT1A	MI	TTNJYV2
DMQMT1A	MN	Gamma-aminobutyric acid receptor (GAR)
DMQMT1A	MT	DTT
DMQMT1A	MA	Inhibitor
DMQMT1A	RN	N-2 methylated quaternary derivatives of beta-carboline-3-carboxylates inhibit acetylcholinesterase in vitroO, Bioorg. Med. Chem. Lett. 3(12):2831-2836 (1993).
DMQMT1A	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01807745

DMHVIK3	DI	DMHVIK3
DMHVIK3	DN	3-methoxydesaminokynurenine
DMHVIK3	MI	TTWQM3J
DMHVIK3	MN	Kynureninase (KYNU)
DMHVIK3	MT	DTT
DMHVIK3	MA	Inhibitor
DMHVIK3	RN	Comparative inhibition by substrate analogues 3-methoxy- and 3-hydroxydesaminokynurenine and an improved 3 step purification of recombinant human kynureninase. BMC Biochem. 2003 Sep 24;4:13.
DMHVIK3	RU	https://pubmed.ncbi.nlm.nih.gov/14505498

DMWNO4D	DI	DMWNO4D
DMWNO4D	DN	3-Methoxyl-4'-amino-trans-stilbene
DMWNO4D	MI	TTSZLWK
DMWNO4D	MN	Aromatase (CYP19A1)
DMWNO4D	MT	DTT
DMWNO4D	MA	Inhibitor
DMWNO4D	RN	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
DMWNO4D	RU	https://pubmed.ncbi.nlm.nih.gov/20558073

DMH1RX6	DI	DMH1RX6
DMH1RX6	DN	3-Methoxymethyl-1,2,3,4-tetrahydro-isoquinoline
DMH1RX6	MI	TTWG9A4
DMH1RX6	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMH1RX6	MT	DTT
DMH1RX6	MA	Inhibitor
DMH1RX6	RN	3,7-Disubstituted-1,2,3,4-tetrahydroisoquinolines display remarkable potency and selectivity as inhibitors of phenylethanolamine N-methyltransferas... J Med Chem. 1999 Jun 3;42(11):1982-90.
DMH1RX6	RU	https://pubmed.ncbi.nlm.nih.gov/10354406

DMH1RX6	DI	DMH1RX6
DMH1RX6	DN	3-Methoxymethyl-1,2,3,4-tetrahydro-isoquinoline
DMH1RX6	MI	TTWM4TY
DMH1RX6	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMH1RX6	MT	DTT
DMH1RX6	MA	Inhibitor
DMH1RX6	RN	3,7-Disubstituted-1,2,3,4-tetrahydroisoquinolines display remarkable potency and selectivity as inhibitors of phenylethanolamine N-methyltransferas... J Med Chem. 1999 Jun 3;42(11):1982-90.
DMH1RX6	RU	https://pubmed.ncbi.nlm.nih.gov/10354406

DMH1RX6	DI	DMH1RX6
DMH1RX6	DN	3-Methoxymethyl-1,2,3,4-tetrahydro-isoquinoline
DMH1RX6	MI	TT2NUT5
DMH1RX6	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMH1RX6	MT	DTT
DMH1RX6	MA	Inhibitor
DMH1RX6	RN	3,7-Disubstituted-1,2,3,4-tetrahydroisoquinolines display remarkable potency and selectivity as inhibitors of phenylethanolamine N-methyltransferas... J Med Chem. 1999 Jun 3;42(11):1982-90.
DMH1RX6	RU	https://pubmed.ncbi.nlm.nih.gov/10354406

DMFEL39	DI	DMFEL39
DMFEL39	DN	3-methoxy-N-(1,3,4-thiadiazol-2-yl)benzamide
DMFEL39	MI	TTSJ6Q4
DMFEL39	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DMFEL39	MT	DTT
DMFEL39	MA	Inhibitor
DMFEL39	RN	Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. J Med Chem. 2007 May 31;50(11):2640-6.
DMFEL39	RU	https://pubmed.ncbi.nlm.nih.gov/17461565

DM4WJX3	DI	DM4WJX3
DM4WJX3	DN	3-methoxy-N-(4-methylthiazol-2-yl)benzamide
DM4WJX3	MI	TTSJ6Q4
DM4WJX3	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DM4WJX3	MT	DTT
DM4WJX3	MA	Inhibitor
DM4WJX3	RN	Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. J Med Chem. 2007 May 31;50(11):2640-6.
DM4WJX3	RU	https://pubmed.ncbi.nlm.nih.gov/17461565

DM4WJX3	DI	DM4WJX3
DM4WJX3	DN	3-methoxy-N-(4-methylthiazol-2-yl)benzamide
DM4WJX3	MI	TTHS256
DM4WJX3	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM4WJX3	MT	DTT
DM4WJX3	MA	Inhibitor
DM4WJX3	RN	Design and synthesis of noncompetitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3371-5.
DM4WJX3	RU	https://pubmed.ncbi.nlm.nih.gov/16678408

DMSFJNE	DI	DMSFJNE
DMSFJNE	DN	3-methoxy-N-(6-methylpyridin-2-yl)benzamide
DMSFJNE	MI	TTHS256
DMSFJNE	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMSFJNE	MT	DTT
DMSFJNE	MA	Inhibitor
DMSFJNE	RN	Design and synthesis of noncompetitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3371-5.
DMSFJNE	RU	https://pubmed.ncbi.nlm.nih.gov/16678408

DMZ9MQ5	DI	DMZ9MQ5
DMZ9MQ5	DN	3-methoxy-N',2-diphenylquinoline-4-carbohydrazide
DMZ9MQ5	MI	TTBPGLU
DMZ9MQ5	MN	Neuromedin-K receptor (TACR3)
DMZ9MQ5	MT	DTT
DMZ9MQ5	MA	Inhibitor
DMZ9MQ5	RN	N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5748-51.
DMZ9MQ5	RU	https://pubmed.ncbi.nlm.nih.gov/16950620

DMKHVGJ	DI	DMKHVGJ
DMKHVGJ	DN	3-methoxyphenyl 10H-phenothiazine-10-carboxylate
DMKHVGJ	MI	TTEB0GD
DMKHVGJ	MN	Cholinesterase (BCHE)
DMKHVGJ	MT	DTT
DMKHVGJ	MA	Inhibitor
DMKHVGJ	RN	Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. J Med Chem. 2008 Jul 24;51(14):4200-12.
DMKHVGJ	RU	https://pubmed.ncbi.nlm.nih.gov/18570368

DMHJTLW	DI	DMHJTLW
DMHJTLW	DN	3-methoxyphenylboronic acid
DMHJTLW	MI	TTDP1UC
DMHJTLW	MN	Fatty acid amide hydrolase (FAAH)
DMHJTLW	MT	DTT
DMHJTLW	MA	Inhibitor
DMHJTLW	RN	Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Nov 27;51(22):7057-60.
DMHJTLW	RU	https://pubmed.ncbi.nlm.nih.gov/18983140

DMCOH46	DI	DMCOH46
DMCOH46	DN	3-Methyl-[1,4]thiazepan-(5E)-ylideneamine
DMCOH46	MI	TTZUFI5
DMCOH46	MN	Nitric-oxide synthase brain (NOS1)
DMCOH46	MT	DTT
DMCOH46	MA	Inhibitor
DMCOH46	RN	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
DMCOH46	RU	https://pubmed.ncbi.nlm.nih.gov/15501067

DMCOH46	DI	DMCOH46
DMCOH46	DN	3-Methyl-[1,4]thiazepan-(5E)-ylideneamine
DMCOH46	MI	TTCM4B3
DMCOH46	MN	Nitric-oxide synthase endothelial (NOS3)
DMCOH46	MT	DTT
DMCOH46	MA	Inhibitor
DMCOH46	RN	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
DMCOH46	RU	https://pubmed.ncbi.nlm.nih.gov/15501067

DMCOH46	DI	DMCOH46
DMCOH46	DN	3-Methyl-[1,4]thiazepan-(5E)-ylideneamine
DMCOH46	MI	TTF10I9
DMCOH46	MN	Nitric-oxide synthase inducible (NOS2)
DMCOH46	MT	DTT
DMCOH46	MA	Inhibitor
DMCOH46	RN	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
DMCOH46	RU	https://pubmed.ncbi.nlm.nih.gov/15501067

DMIWQ7G	DI	DMIWQ7G
DMIWQ7G	DN	3-Methyl-1,2,3,4-tetrahydro-isoquinoline
DMIWQ7G	MI	TTWG9A4
DMIWQ7G	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMIWQ7G	MT	DTT
DMIWQ7G	MA	Inhibitor
DMIWQ7G	RN	Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46.
DMIWQ7G	RU	https://pubmed.ncbi.nlm.nih.gov/8784452

DMIWQ7G	DI	DMIWQ7G
DMIWQ7G	DN	3-Methyl-1,2,3,4-tetrahydro-isoquinoline
DMIWQ7G	MI	TTWM4TY
DMIWQ7G	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMIWQ7G	MT	DTT
DMIWQ7G	MA	Inhibitor
DMIWQ7G	RN	Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46.
DMIWQ7G	RU	https://pubmed.ncbi.nlm.nih.gov/8784452

DMIWQ7G	DI	DMIWQ7G
DMIWQ7G	DN	3-Methyl-1,2,3,4-tetrahydro-isoquinoline
DMIWQ7G	MI	TT2NUT5
DMIWQ7G	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMIWQ7G	MT	DTT
DMIWQ7G	MA	Inhibitor
DMIWQ7G	RN	Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46.
DMIWQ7G	RU	https://pubmed.ncbi.nlm.nih.gov/8784452

DMKOX0N	DI	DMKOX0N
DMKOX0N	DN	3-methyl-1H-thieno[2,3-c]pyrazole-5-carboxamide
DMKOX0N	MI	TTUTJGQ
DMKOX0N	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMKOX0N	MT	DTT
DMKOX0N	MA	Inhibitor
DMKOX0N	RN	Scaffold oriented synthesis. Part 1: Design, preparation, and biological evaluation of thienopyrazoles as kinase inhibitors. Bioorg Med Chem Lett. 2006 Jan 1;16(1):96-9.
DMKOX0N	RU	https://pubmed.ncbi.nlm.nih.gov/16216502

DMKYPUW	DI	DMKYPUW
DMKYPUW	DN	3-Methyl-1-phenethyl-3,7-dihydro-purine-2,6-dione
DMKYPUW	MI	TTNE7KG
DMKYPUW	MN	Adenosine A2b receptor (ADORA2B)
DMKYPUW	MT	DTT
DMKYPUW	MA	Inhibitor
DMKYPUW	RN	Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. J Med Chem. 2002 May 23;45(11):2131-8.
DMKYPUW	RU	https://pubmed.ncbi.nlm.nih.gov/12014951

DMKYPUW	DI	DMKYPUW
DMKYPUW	DN	3-Methyl-1-phenethyl-3,7-dihydro-purine-2,6-dione
DMKYPUW	MI	TTJFY5U
DMKYPUW	MN	Adenosine A3 receptor (ADORA3)
DMKYPUW	MT	DTT
DMKYPUW	MA	Inhibitor
DMKYPUW	RN	Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. J Med Chem. 2002 May 23;45(11):2131-8.
DMKYPUW	RU	https://pubmed.ncbi.nlm.nih.gov/12014951

DMTM6B0	DI	DMTM6B0
DMTM6B0	DN	3-Methyl-1-phenyl-1H-chromeno[4,3-c]pyrazol-4-one
DMTM6B0	MI	TT1MPAY
DMTM6B0	MN	GABA(A) receptor alpha-1 (GABRA1)
DMTM6B0	MT	DTT
DMTM6B0	MA	Inhibitor
DMTM6B0	RN	Synthesis, binding studies, and structure-activity relationships of 1-aryl-and 2-aryl[1]benzopyranopyrazol-4-ones, central benzodiazepine receptor ... J Med Chem. 1988 Jan;31(1):1-3.
DMTM6B0	RU	https://pubmed.ncbi.nlm.nih.gov/2826782

DMTM6B0	DI	DMTM6B0
DMTM6B0	DN	3-Methyl-1-phenyl-1H-chromeno[4,3-c]pyrazol-4-one
DMTM6B0	MI	TT06RH5
DMTM6B0	MN	GABA(A) receptor gamma-2 (GABRG2)
DMTM6B0	MT	DTT
DMTM6B0	MA	Inhibitor
DMTM6B0	RN	Synthesis, binding studies, and structure-activity relationships of 1-aryl-and 2-aryl[1]benzopyranopyrazol-4-ones, central benzodiazepine receptor ... J Med Chem. 1988 Jan;31(1):1-3.
DMTM6B0	RU	https://pubmed.ncbi.nlm.nih.gov/2826782

DMTM6B0	DI	DMTM6B0
DMTM6B0	DN	3-Methyl-1-phenyl-1H-chromeno[4,3-c]pyrazol-4-one
DMTM6B0	MI	TTNJYV2
DMTM6B0	MN	Gamma-aminobutyric acid receptor (GAR)
DMTM6B0	MT	DTT
DMTM6B0	MA	Inhibitor
DMTM6B0	RN	Synthesis, binding studies, and structure-activity relationships of 1-aryl-and 2-aryl[1]benzopyranopyrazol-4-ones, central benzodiazepine receptor ... J Med Chem. 1988 Jan;31(1):1-3.
DMTM6B0	RU	https://pubmed.ncbi.nlm.nih.gov/2826782

DMHVNQM	DI	DMHVNQM
DMHVNQM	DN	3-methyl-2(1H)-thioxo-4(3H)-quinazolinone
DMHVNQM	MI	TT3WG5C
DMHVNQM	MN	Monoamine oxidase type A (MAO-A)
DMHVNQM	MT	DTT
DMHVNQM	MA	Inhibitor
DMHVNQM	RN	New pyrazoline bearing 4(3H)-quinazolinone inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A ... Bioorg Med Chem. 2009 Jan 15;17(2):675-89.
DMHVNQM	RU	https://pubmed.ncbi.nlm.nih.gov/19091581

DMFC0H5	DI	DMFC0H5
DMFC0H5	DN	3-Methyl-2H-benzo[f]quinazolin-1-one
DMFC0H5	MI	TTU6BFZ
DMFC0H5	MN	Candida Thymidylate synthase (Candi TMP1)
DMFC0H5	MT	DTT
DMFC0H5	MA	Inhibitor
DMFC0H5	RN	Benzoquinazoline inhibitors of thymidylate synthase: enzyme inhibitory activity and cytotoxicity of some sulfonamidobenzoylglutamate and related de... J Med Chem. 1993 Oct 29;36(22):3464-71.
DMFC0H5	RU	https://pubmed.ncbi.nlm.nih.gov/8230138

DMKWAV6	DI	DMKWAV6
DMKWAV6	DN	3-methyl-2-morpholino-1,1-diphenylbutan-1-ol
DMKWAV6	MI	TTW0CMT
DMKWAV6	MN	Voltage-gated potassium channel Kv1.5 (KCNA5)
DMKWAV6	MT	DTT
DMKWAV6	MA	Inhibitor
DMKWAV6	RN	Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channel. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2493-6.
DMKWAV6	RU	https://pubmed.ncbi.nlm.nih.gov/20304642

DM870UV	DI	DM870UV
DM870UV	DN	3-Methyl-2-phenyl-2H-chromeno[4,3-c]pyrazol-4-one
DM870UV	MI	TT1MPAY
DM870UV	MN	GABA(A) receptor alpha-1 (GABRA1)
DM870UV	MT	DTT
DM870UV	MA	Inhibitor
DM870UV	RN	Synthesis, binding studies, and structure-activity relationships of 1-aryl-and 2-aryl[1]benzopyranopyrazol-4-ones, central benzodiazepine receptor ... J Med Chem. 1988 Jan;31(1):1-3.
DM870UV	RU	https://pubmed.ncbi.nlm.nih.gov/2826782

DM870UV	DI	DM870UV
DM870UV	DN	3-Methyl-2-phenyl-2H-chromeno[4,3-c]pyrazol-4-one
DM870UV	MI	TT06RH5
DM870UV	MN	GABA(A) receptor gamma-2 (GABRG2)
DM870UV	MT	DTT
DM870UV	MA	Inhibitor
DM870UV	RN	Synthesis, binding studies, and structure-activity relationships of 1-aryl-and 2-aryl[1]benzopyranopyrazol-4-ones, central benzodiazepine receptor ... J Med Chem. 1988 Jan;31(1):1-3.
DM870UV	RU	https://pubmed.ncbi.nlm.nih.gov/2826782

DM870UV	DI	DM870UV
DM870UV	DN	3-Methyl-2-phenyl-2H-chromeno[4,3-c]pyrazol-4-one
DM870UV	MI	TTNJYV2
DM870UV	MN	Gamma-aminobutyric acid receptor (GAR)
DM870UV	MT	DTT
DM870UV	MA	Inhibitor
DM870UV	RN	Synthesis, binding studies, and structure-activity relationships of 1-aryl-and 2-aryl[1]benzopyranopyrazol-4-ones, central benzodiazepine receptor ... J Med Chem. 1988 Jan;31(1):1-3.
DM870UV	RU	https://pubmed.ncbi.nlm.nih.gov/2826782

DM0WVTF	DI	DM0WVTF
DM0WVTF	DN	3-Methyl-4-phenylbut-3-en-2-one oxime
DM0WVTF	MI	TTELV3W
DM0WVTF	MN	Transformation-sensitive protein p120 (TRPA1)
DM0WVTF	MT	DTT
DM0WVTF	MA	Inhibitor
DM0WVTF	RN	Oxime derivatives related to AP18: Agonists and antagonists of the TRPA1 receptor. Bioorg Med Chem Lett. 2010 Jan 1;20(1):276-9.
DM0WVTF	RU	https://pubmed.ncbi.nlm.nih.gov/19945872

DMM3RNV	DI	DMM3RNV
DMM3RNV	DN	3-methyl-5-(2-methylquinolin-7-yl)benzonitrile
DMM3RNV	MI	TTHS256
DMM3RNV	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMM3RNV	MT	DTT
DMM3RNV	MA	Inhibitor
DMM3RNV	RN	Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8.
DMM3RNV	RU	https://pubmed.ncbi.nlm.nih.gov/17590335

DM3BL45	DI	DM3BL45
DM3BL45	DN	3-methyl-6-(trifluoromethyl)-9H-carbazole
DM3BL45	MI	TTBGTCW
DM3BL45	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DM3BL45	MT	DTT
DM3BL45	MA	Inhibitor
DM3BL45	RN	Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8.
DM3BL45	RU	https://pubmed.ncbi.nlm.nih.gov/20521839

DMZY6VX	DI	DMZY6VX
DMZY6VX	DN	3-Methyl-7-nitro-1,2,3,4-tetrahydro-isoquinoline
DMZY6VX	MI	TTWG9A4
DMZY6VX	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMZY6VX	MT	DTT
DMZY6VX	MA	Inhibitor
DMZY6VX	RN	Exploring the active site of phenylethanolamine N-methyltransferase with 3-hydroxyethyl- and 3-hydroxypropyl-7-substituted-1,2,3,4-tetrahydroisoqui... Bioorg Med Chem Lett. 2005 Feb 15;15(4):1143-7.
DMZY6VX	RU	https://pubmed.ncbi.nlm.nih.gov/15686930

DME81U3	DI	DME81U3
DME81U3	DN	3-Methyl-7-pyrrolidin-1-yl-hept-5-yn-2-one
DME81U3	MI	TTZ9SOR
DME81U3	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DME81U3	MT	DTT
DME81U3	MA	Inhibitor
DME81U3	RN	Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992).
DME81U3	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805351

DME81U3	DI	DME81U3
DME81U3	DN	3-Methyl-7-pyrrolidin-1-yl-hept-5-yn-2-one
DME81U3	MI	TTYEG6Q
DME81U3	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DME81U3	MT	DTT
DME81U3	MA	Inhibitor
DME81U3	RN	Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992).
DME81U3	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805351

DME81U3	DI	DME81U3
DME81U3	DN	3-Methyl-7-pyrrolidin-1-yl-hept-5-yn-2-one
DME81U3	MI	TTQ13Z5
DME81U3	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DME81U3	MT	DTT
DME81U3	MA	Inhibitor
DME81U3	RN	Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992).
DME81U3	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805351

DME81U3	DI	DME81U3
DME81U3	DN	3-Methyl-7-pyrrolidin-1-yl-hept-5-yn-2-one
DME81U3	MI	TTQ3JTF
DME81U3	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DME81U3	MT	DTT
DME81U3	MA	Inhibitor
DME81U3	RN	Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992).
DME81U3	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805351

DME81U3	DI	DME81U3
DME81U3	DN	3-Methyl-7-pyrrolidin-1-yl-hept-5-yn-2-one
DME81U3	MI	TTH18TF
DME81U3	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DME81U3	MT	DTT
DME81U3	MA	Inhibitor
DME81U3	RN	Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992).
DME81U3	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805351

DMEJKZN	DI	DMEJKZN
DMEJKZN	DN	3-Methyl-9H-beta-carboline
DMEJKZN	MI	TT1MPAY
DMEJKZN	MN	GABA(A) receptor alpha-1 (GABRA1)
DMEJKZN	MT	DTT
DMEJKZN	MA	Inhibitor
DMEJKZN	RN	Four amino acid exchanges convert a diazepam-insensitive, inverse agonist-preferring GABAA receptor into a diazepam-preferring GABAA receptor. J Med Chem. 1994 Dec 23;37(26):4576-80.
DMEJKZN	RU	https://pubmed.ncbi.nlm.nih.gov/7799410

DMEJKZN	DI	DMEJKZN
DMEJKZN	DN	3-Methyl-9H-beta-carboline
DMEJKZN	MI	TTZA1NY
DMEJKZN	MN	GABA(A) receptor beta-2 (GABRB2)
DMEJKZN	MT	DTT
DMEJKZN	MA	Inhibitor
DMEJKZN	RN	Four amino acid exchanges convert a diazepam-insensitive, inverse agonist-preferring GABAA receptor into a diazepam-preferring GABAA receptor. J Med Chem. 1994 Dec 23;37(26):4576-80.
DMEJKZN	RU	https://pubmed.ncbi.nlm.nih.gov/7799410

DMEJKZN	DI	DMEJKZN
DMEJKZN	DN	3-Methyl-9H-beta-carboline
DMEJKZN	MI	TT06RH5
DMEJKZN	MN	GABA(A) receptor gamma-2 (GABRG2)
DMEJKZN	MT	DTT
DMEJKZN	MA	Inhibitor
DMEJKZN	RN	Four amino acid exchanges convert a diazepam-insensitive, inverse agonist-preferring GABAA receptor into a diazepam-preferring GABAA receptor. J Med Chem. 1994 Dec 23;37(26):4576-80.
DMEJKZN	RU	https://pubmed.ncbi.nlm.nih.gov/7799410

DMEJKZN	DI	DMEJKZN
DMEJKZN	DN	3-Methyl-9H-beta-carboline
DMEJKZN	MI	TTNJYV2
DMEJKZN	MN	Gamma-aminobutyric acid receptor (GAR)
DMEJKZN	MT	DTT
DMEJKZN	MA	Inhibitor
DMEJKZN	RN	Four amino acid exchanges convert a diazepam-insensitive, inverse agonist-preferring GABAA receptor into a diazepam-preferring GABAA receptor. J Med Chem. 1994 Dec 23;37(26):4576-80.
DMEJKZN	RU	https://pubmed.ncbi.nlm.nih.gov/7799410

DMX71N9	DI	DMX71N9
DMX71N9	DN	3-Methylfentanyl
DMX71N9	MI	TT27RFC
DMX71N9	MN	Opioid receptor delta (OPRD1)
DMX71N9	MT	DTT
DMX71N9	MA	Agonist
DMX71N9	RN	Subramanian G, Paterlini MG, Portoghese PS, Ferguson DM: Molecular docking reveals a novel binding site model for fentanyl at the mu-opioid receptor. J Med Chem. 2000 Feb 10;43(3):381-91.
DMX71N9	RU	https://pubmed.ncbi.nlm.nih.gov/10669565

DMX71N9	DI	DMX71N9
DMX71N9	DN	3-Methylfentanyl
DMX71N9	MI	TTQW87Y
DMX71N9	MN	Opioid receptor kappa (OPRK1)
DMX71N9	MT	DTT
DMX71N9	MA	Agonist
DMX71N9	RN	Subramanian G, Paterlini MG, Portoghese PS, Ferguson DM: Molecular docking reveals a novel binding site model for fentanyl at the mu-opioid receptor. J Med Chem. 2000 Feb 10;43(3):381-91.
DMX71N9	RU	https://pubmed.ncbi.nlm.nih.gov/10669565

DMX71N9	DI	DMX71N9
DMX71N9	DN	3-Methylfentanyl
DMX71N9	MI	TTKWM86
DMX71N9	MN	Opioid receptor mu (MOP)
DMX71N9	MT	DTT
DMX71N9	MA	Agonist
DMX71N9	RN	Subramanian G, Paterlini MG, Portoghese PS, Ferguson DM: Molecular docking reveals a novel binding site model for fentanyl at the mu-opioid receptor. J Med Chem. 2000 Feb 10;43(3):381-91.
DMX71N9	RU	https://pubmed.ncbi.nlm.nih.gov/10669565

DMRNMKG	DI	DMRNMKG
DMRNMKG	DN	3-methyl-N-(6-methylpyridin-2-yl)benzamide
DMRNMKG	MI	TTHS256
DMRNMKG	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMRNMKG	MT	DTT
DMRNMKG	MA	Inhibitor
DMRNMKG	RN	Design and synthesis of noncompetitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3371-5.
DMRNMKG	RU	https://pubmed.ncbi.nlm.nih.gov/16678408

DMQOI5X	DI	DMQOI5X
DMQOI5X	DN	3-Methylphenylalanine
DMQOI5X	MI	TTF2LRI
DMQOI5X	MN	Cathepsin B (CTSB)
DMQOI5X	MT	DTT
DMQOI5X	MA	Inhibitor
DMQOI5X	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMQOI5X	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMF3JHM	DI	DMF3JHM
DMF3JHM	DN	3-Methylpyridine
DMF3JHM	MI	TTHY57M
DMF3JHM	MN	Matrix metalloproteinase-13 (MMP-13)
DMF3JHM	MT	DTT
DMF3JHM	MA	Inhibitor
DMF3JHM	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMF3JHM	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMF3JHM	DI	DMF3JHM
DMF3JHM	DN	3-Methylpyridine
DMF3JHM	MI	TTUZ2L5
DMF3JHM	MN	Matrix metalloproteinase-3 (MMP-3)
DMF3JHM	MT	DTT
DMF3JHM	MA	Inhibitor
DMF3JHM	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMF3JHM	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMHVUF8	DI	DMHVUF8
DMHVUF8	DN	3-Methyl-pyrrolidin-(2Z)-ylideneamine
DMHVUF8	MI	TTZUFI5
DMHVUF8	MN	Nitric-oxide synthase brain (NOS1)
DMHVUF8	MT	DTT
DMHVUF8	MA	Inhibitor
DMHVUF8	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DMHVUF8	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DMHVUF8	DI	DMHVUF8
DMHVUF8	DN	3-Methyl-pyrrolidin-(2Z)-ylideneamine
DMHVUF8	MI	TTCM4B3
DMHVUF8	MN	Nitric-oxide synthase endothelial (NOS3)
DMHVUF8	MT	DTT
DMHVUF8	MA	Inhibitor
DMHVUF8	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DMHVUF8	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DMHVUF8	DI	DMHVUF8
DMHVUF8	DN	3-Methyl-pyrrolidin-(2Z)-ylideneamine
DMHVUF8	MI	TTF10I9
DMHVUF8	MN	Nitric-oxide synthase inducible (NOS2)
DMHVUF8	MT	DTT
DMHVUF8	MA	Inhibitor
DMHVUF8	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DMHVUF8	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DMQZULR	DI	DMQZULR
DMQZULR	DN	3-Methylquinoline-8-carboxamide
DMQZULR	MI	TTVDSZ0
DMQZULR	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMQZULR	MT	DTT
DMQZULR	MA	Inhibitor
DMQZULR	RN	Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhi... J Med Chem. 2009 Feb 12;52(3):868-77.
DMQZULR	RU	https://pubmed.ncbi.nlm.nih.gov/19117416

DMC153X	DI	DMC153X
DMC153X	DN	3-Methylthiofentanyl
DMC153X	MI	TT27RFC
DMC153X	MN	Opioid receptor delta (OPRD1)
DMC153X	MT	DTT
DMC153X	MA	Agonist
DMC153X	RN	You HJ, Colpaert FC, Arendt-Nielsen L: The novel analgesic and high-efficacy 5-HT1A receptor agonist F 13640 inhibits nociceptive responses, wind-up, and after-discharges in spinal neurons and withdrawal reflexes. Exp Neurol. 2005 Jan;191(1):174-83.
DMC153X	RU	https://pubmed.ncbi.nlm.nih.gov/15589524

DMC153X	DI	DMC153X
DMC153X	DN	3-Methylthiofentanyl
DMC153X	MI	TTQW87Y
DMC153X	MN	Opioid receptor kappa (OPRK1)
DMC153X	MT	DTT
DMC153X	MA	Agonist
DMC153X	RN	You HJ, Colpaert FC, Arendt-Nielsen L: The novel analgesic and high-efficacy 5-HT1A receptor agonist F 13640 inhibits nociceptive responses, wind-up, and after-discharges in spinal neurons and withdrawal reflexes. Exp Neurol. 2005 Jan;191(1):174-83.
DMC153X	RU	https://pubmed.ncbi.nlm.nih.gov/15589524

DMC153X	DI	DMC153X
DMC153X	DN	3-Methylthiofentanyl
DMC153X	MI	TTKWM86
DMC153X	MN	Opioid receptor mu (MOP)
DMC153X	MT	DTT
DMC153X	MA	Agonist
DMC153X	RN	You HJ, Colpaert FC, Arendt-Nielsen L: The novel analgesic and high-efficacy 5-HT1A receptor agonist F 13640 inhibits nociceptive responses, wind-up, and after-discharges in spinal neurons and withdrawal reflexes. Exp Neurol. 2005 Jan;191(1):174-83.
DMC153X	RU	https://pubmed.ncbi.nlm.nih.gov/15589524

DM0YS25	DI	DM0YS25
DM0YS25	DN	3-Morpholin-4-ylmethyl-5H-phenanthridin-6-one
DM0YS25	MI	TTVDSZ0
DM0YS25	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DM0YS25	MT	DTT
DM0YS25	MA	Inhibitor
DM0YS25	RN	4-Phenyl-1,2,3,6-tetrahydropyridine, an excellent fragment to improve the potency of PARP-1 inhibitors. Bioorg Med Chem Lett. 2005 Oct 1;15(19):4221-5.
DM0YS25	RU	https://pubmed.ncbi.nlm.nih.gov/16098744

DMGWH0E	DI	DMGWH0E
DMGWH0E	DN	3-morpholino-1H-benzo[f]chromen-1-one
DMGWH0E	MI	TTK3PY9
DMGWH0E	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMGWH0E	MT	DTT
DMGWH0E	MA	Inhibitor
DMGWH0E	RN	Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72.
DMGWH0E	RU	https://pubmed.ncbi.nlm.nih.gov/17371003

DMCDLG4	DI	DMCDLG4
DMCDLG4	DN	3-MPPTS
DMCDLG4	MI	TTXJ47W
DMCDLG4	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMCDLG4	MT	DTT
DMCDLG4	MA	Modulator (allosteric modulator)
DMCDLG4	RN	Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and... Psychopharmacology (Berl). 2005 Apr;179(1):271-83.
DMCDLG4	RU	https://pubmed.ncbi.nlm.nih.gov/15717213

DMMFA4N	DI	DMMFA4N
DMMFA4N	DN	3-m-tolyl-1,5-naphthyridine
DMMFA4N	MI	TTHS256
DMMFA4N	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMMFA4N	MT	DTT
DMMFA4N	MA	Inhibitor
DMMFA4N	RN	Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8.
DMMFA4N	RU	https://pubmed.ncbi.nlm.nih.gov/17936624

DMNZI9R	DI	DMNZI9R
DMNZI9R	DN	3-Naphthalen-1-yl-1-propyl-pyrrolidine
DMNZI9R	MI	TTSQIFT
DMNZI9R	MN	5-HT 1A receptor (HTR1A)
DMNZI9R	MT	DTT
DMNZI9R	MA	Inhibitor
DMNZI9R	RN	Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity, Bioorg. Med. Chem. Lett. 7(3):241-246 (1997).
DMNZI9R	RU	http://www.sciencedirect.com/science/article/pii/S0960894X9600618X

DMNZI9R	DI	DMNZI9R
DMNZI9R	DN	3-Naphthalen-1-yl-1-propyl-pyrrolidine
DMNZI9R	MI	TTJQOD7
DMNZI9R	MN	5-HT 2A receptor (HTR2A)
DMNZI9R	MT	DTT
DMNZI9R	MA	Inhibitor
DMNZI9R	RN	Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity, Bioorg. Med. Chem. Lett. 7(3):241-246 (1997).
DMNZI9R	RU	http://www.sciencedirect.com/science/article/pii/S0960894X9600618X

DMNZI9R	DI	DMNZI9R
DMNZI9R	DN	3-Naphthalen-1-yl-1-propyl-pyrrolidine
DMNZI9R	MI	TTEX248
DMNZI9R	MN	Dopamine D2 receptor (D2R)
DMNZI9R	MT	DTT
DMNZI9R	MA	Inhibitor
DMNZI9R	RN	Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity, Bioorg. Med. Chem. Lett. 7(3):241-246 (1997).
DMNZI9R	RU	http://www.sciencedirect.com/science/article/pii/S0960894X9600618X

DMCW7F5	DI	DMCW7F5
DMCW7F5	DN	3-Naphthalen-1-yl-pyrrolidine
DMCW7F5	MI	TTSQIFT
DMCW7F5	MN	5-HT 1A receptor (HTR1A)
DMCW7F5	MT	DTT
DMCW7F5	MA	Inhibitor
DMCW7F5	RN	Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity, Bioorg. Med. Chem. Lett. 7(3):241-246 (1997).
DMCW7F5	RU	http://www.sciencedirect.com/science/article/pii/S0960894X9600618X

DMCW7F5	DI	DMCW7F5
DMCW7F5	DN	3-Naphthalen-1-yl-pyrrolidine
DMCW7F5	MI	TTJQOD7
DMCW7F5	MN	5-HT 2A receptor (HTR2A)
DMCW7F5	MT	DTT
DMCW7F5	MA	Inhibitor
DMCW7F5	RN	Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity, Bioorg. Med. Chem. Lett. 7(3):241-246 (1997).
DMCW7F5	RU	http://www.sciencedirect.com/science/article/pii/S0960894X9600618X

DMCW7F5	DI	DMCW7F5
DMCW7F5	DN	3-Naphthalen-1-yl-pyrrolidine
DMCW7F5	MI	TTEX248
DMCW7F5	MN	Dopamine D2 receptor (D2R)
DMCW7F5	MT	DTT
DMCW7F5	MA	Inhibitor
DMCW7F5	RN	Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity, Bioorg. Med. Chem. Lett. 7(3):241-246 (1997).
DMCW7F5	RU	http://www.sciencedirect.com/science/article/pii/S0960894X9600618X

DMZRNOT	DI	DMZRNOT
DMZRNOT	DN	3-Nitro-4'-nitro-trans-stilbene
DMZRNOT	MI	TTSZLWK
DMZRNOT	MN	Aromatase (CYP19A1)
DMZRNOT	MT	DTT
DMZRNOT	MA	Inhibitor
DMZRNOT	RN	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
DMZRNOT	RU	https://pubmed.ncbi.nlm.nih.gov/20558073

DM08V9W	DI	DM08V9W
DM08V9W	DN	3-Nitro-9H-beta-carboline
DM08V9W	MI	TT1MPAY
DM08V9W	MN	GABA(A) receptor alpha-1 (GABRA1)
DM08V9W	MT	DTT
DM08V9W	MA	Inhibitor
DM08V9W	RN	Synthesis of novel 3-substituted beta-carbolines as benzodiazepine receptor ligands: probing the benzodiazepine receptor pharmacophore. J Med Chem. 1988 Sep;31(9):1854-61.
DM08V9W	RU	https://pubmed.ncbi.nlm.nih.gov/2842507

DM08V9W	DI	DM08V9W
DM08V9W	DN	3-Nitro-9H-beta-carboline
DM08V9W	MI	TTNJYV2
DM08V9W	MN	Gamma-aminobutyric acid receptor (GAR)
DM08V9W	MT	DTT
DM08V9W	MA	Inhibitor
DM08V9W	RN	Synthesis of novel 3-substituted beta-carbolines as benzodiazepine receptor ligands: probing the benzodiazepine receptor pharmacophore. J Med Chem. 1988 Sep;31(9):1854-61.
DM08V9W	RU	https://pubmed.ncbi.nlm.nih.gov/2842507

DMAY4OZ	DI	DMAY4OZ
DMAY4OZ	DN	3-Nitro-benzenesulfonamide
DMAY4OZ	MI	TTUNARX
DMAY4OZ	MN	Carbonic anhydrase (CA)
DMAY4OZ	MT	DTT
DMAY4OZ	MA	Inhibitor
DMAY4OZ	RN	Carbonic anhydrase inhibitors: inhibition of human cytosolic isozyme II and mitochondrial isozyme V with a series of benzene sulfonamide derivatives. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5703-7.
DMAY4OZ	RU	https://pubmed.ncbi.nlm.nih.gov/15482952

DMAY4OZ	DI	DMAY4OZ
DMAY4OZ	DN	3-Nitro-benzenesulfonamide
DMAY4OZ	MI	TTANPDJ
DMAY4OZ	MN	Carbonic anhydrase II (CA-II)
DMAY4OZ	MT	DTT
DMAY4OZ	MA	Inhibitor
DMAY4OZ	RN	Carbonic anhydrase inhibitors: inhibition of human cytosolic isozyme II and mitochondrial isozyme V with a series of benzene sulfonamide derivatives. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5703-7.
DMAY4OZ	RU	https://pubmed.ncbi.nlm.nih.gov/15482952

DMIZJ9G	DI	DMIZJ9G
DMIZJ9G	DN	3-nitro-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide
DMIZJ9G	MI	TTHS256
DMIZJ9G	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMIZJ9G	MT	DTT
DMIZJ9G	MA	Inhibitor
DMIZJ9G	RN	Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat... J Med Chem. 2006 Jun 1;49(11):3332-44.
DMIZJ9G	RU	https://pubmed.ncbi.nlm.nih.gov/16722652

DMPMX8R	DI	DMPMX8R
DMPMX8R	DN	3-Nitrophenylboronic Acid
DMPMX8R	MI	TTHI19T
DMPMX8R	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMPMX8R	MT	DTT
DMPMX8R	MA	Inhibitor
DMPMX8R	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMPMX8R	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMH798G	DI	DMH798G
DMH798G	DN	3-nitropropionate
DMH798G	MI	TT58ZYW
DMH798G	MN	Mycobacterium Isocitrate lyase (MycB icl)
DMH798G	MT	DTT
DMH798G	MA	Inhibitor
DMH798G	RN	Structure of isocitrate lyase, a persistence factor of Mycobacterium tuberculosis. Nat Struct Biol. 2000 Aug;7(8):663-8.
DMH798G	RU	https://pubmed.ncbi.nlm.nih.gov/10932251

DMFHYAE	DI	DMFHYAE
DMFHYAE	DN	3-noradamantyl-1,3-dipropylxanthine
DMFHYAE	MI	TTK25J1
DMFHYAE	MN	Adenosine A1 receptor (ADORA1)
DMFHYAE	MT	DTT
DMFHYAE	MA	Inhibitor
DMFHYAE	RN	Potent and orally bioavailable 8-bicyclo[2.2.2]octylxanthines as adenosine A1 receptor antagonists. J Med Chem. 2006 Nov 30;49(24):7119-31.
DMFHYAE	RU	https://pubmed.ncbi.nlm.nih.gov/17125264

DMFHYAE	DI	DMFHYAE
DMFHYAE	DN	3-noradamantyl-1,3-dipropylxanthine
DMFHYAE	MI	TTM2AOE
DMFHYAE	MN	Adenosine A2a receptor (ADORA2A)
DMFHYAE	MT	DTT
DMFHYAE	MA	Inhibitor
DMFHYAE	RN	Potent and orally bioavailable 8-bicyclo[2.2.2]octylxanthines as adenosine A1 receptor antagonists. J Med Chem. 2006 Nov 30;49(24):7119-31.
DMFHYAE	RU	https://pubmed.ncbi.nlm.nih.gov/17125264

DMFHYAE	DI	DMFHYAE
DMFHYAE	DN	3-noradamantyl-1,3-dipropylxanthine
DMFHYAE	MI	TTNE7KG
DMFHYAE	MN	Adenosine A2b receptor (ADORA2B)
DMFHYAE	MT	DTT
DMFHYAE	MA	Inhibitor
DMFHYAE	RN	Potent and orally bioavailable 8-bicyclo[2.2.2]octylxanthines as adenosine A1 receptor antagonists. J Med Chem. 2006 Nov 30;49(24):7119-31.
DMFHYAE	RU	https://pubmed.ncbi.nlm.nih.gov/17125264

DMFHYAE	DI	DMFHYAE
DMFHYAE	DN	3-noradamantyl-1,3-dipropylxanthine
DMFHYAE	MI	TTJFY5U
DMFHYAE	MN	Adenosine A3 receptor (ADORA3)
DMFHYAE	MT	DTT
DMFHYAE	MA	Inhibitor
DMFHYAE	RN	Potent and orally bioavailable 8-bicyclo[2.2.2]octylxanthines as adenosine A1 receptor antagonists. J Med Chem. 2006 Nov 30;49(24):7119-31.
DMFHYAE	RU	https://pubmed.ncbi.nlm.nih.gov/17125264

DMVIZ1S	DI	DMVIZ1S
DMVIZ1S	DN	3-O-METHYLQUERCETIN
DMVIZ1S	MI	TT7RJY8
DMVIZ1S	MN	Xanthine dehydrogenase/oxidase (XDH)
DMVIZ1S	MT	DTT
DMVIZ1S	MA	Inhibitor
DMVIZ1S	RN	Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod. 1988 Mar-Apr;51(2):345-8.
DMVIZ1S	RU	https://pubmed.ncbi.nlm.nih.gov/3379415

DMVIRLX	DI	DMVIRLX
DMVIRLX	DN	3-Oximo-olean-12-en-29-oic acid
DMVIRLX	MI	TTIU7X1
DMVIRLX	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMVIRLX	MT	DTT
DMVIRLX	MA	Inhibitor
DMVIRLX	RN	DNA polymerase beta inhibitors from Sandoricum koetjape. J Nat Prod. 1999 Aug;62(8):1110-3.
DMVIRLX	RU	https://pubmed.ncbi.nlm.nih.gov/10479314

DM47ZWK	DI	DM47ZWK
DM47ZWK	DN	3'-Oxo-Adenosine
DM47ZWK	MI	TTE2KUJ
DM47ZWK	MN	Adenosylhomocysteinase (AHCY)
DM47ZWK	MT	DTT
DM47ZWK	MA	Inhibitor
DM47ZWK	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DM47ZWK	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DM6JYWQ	DI	DM6JYWQ
DM6JYWQ	DN	3-oxoolean-12-en-27-oic acid
DM6JYWQ	MI	TTELIN2
DM6JYWQ	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DM6JYWQ	MT	DTT
DM6JYWQ	MA	Inhibitor
DM6JYWQ	RN	Protein tyrosine phosphatase 1B inhibitory activity of triterpenes isolated from Astilbe koreana. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3273-6.
DM6JYWQ	RU	https://pubmed.ncbi.nlm.nih.gov/16580200

DMOLZ65	DI	DMOLZ65
DMOLZ65	DN	3-phenacyl-UDP
DMOLZ65	MI	TTNVSKA
DMOLZ65	MN	P2Y purinoceptor 6 (P2RY6)
DMOLZ65	MT	DTT
DMOLZ65	MA	Agonist
DMOLZ65	RN	Synthesis and structure-activity relationships of uracil nucleotide derivatives and analogues as agonists at human P2Y2, P2Y4, and P2Y6 receptors. J Med Chem. 2006 Nov 30;49(24):7076-87.
DMOLZ65	RU	https://pubmed.ncbi.nlm.nih.gov/17125260

DM7RWQT	DI	DM7RWQT
DM7RWQT	DN	3-Phenanthren-9-yl-pyridine
DM7RWQT	MI	TTIQUX7
DM7RWQT	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM7RWQT	MT	DTT
DM7RWQT	MA	Inhibitor
DM7RWQT	RN	Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42.
DM7RWQT	RU	https://pubmed.ncbi.nlm.nih.gov/16220979

DMVSQFI	DI	DMVSQFI
DMVSQFI	DN	3-Phenethyl-2-phenyl-3H-quinazolin-4-one
DMVSQFI	MI	TTBUYHA
DMVSQFI	MN	Extracellular calcium-sensing receptor (CASR)
DMVSQFI	MT	DTT
DMVSQFI	MA	Inhibitor
DMVSQFI	RN	3H-Quinazolin-4-ones as a new calcilytic template for the potential treatment of osteoporosis. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1557-60.
DMVSQFI	RU	https://pubmed.ncbi.nlm.nih.gov/15745796

DMGPOZE	DI	DMGPOZE
DMGPOZE	DN	3-Phenyl-1-(2-methylthiazol-4-ylethynyl)benzene
DMGPOZE	MI	TTHS256
DMGPOZE	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMGPOZE	MT	DTT
DMGPOZE	MA	Inhibitor
DMGPOZE	RN	Structure-activity relationships comparing N-(6-methylpyridin-yl)-substituted aryl amides to 2-methyl-6-(substituted-arylethynyl)pyridines or 2-met... J Med Chem. 2009 Jun 11;52(11):3563-75.
DMGPOZE	RU	https://pubmed.ncbi.nlm.nih.gov/19445453

DMU9WGT	DI	DMU9WGT
DMU9WGT	DN	3-Phenyl-1,2-Propandiol
DMU9WGT	MI	TTB2MXP
DMU9WGT	MN	Angiotensinogenase renin (REN)
DMU9WGT	MT	DTT
DMU9WGT	MA	Inhibitor
DMU9WGT	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMU9WGT	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD0OZ8	DI	DMD0OZ8
DMD0OZ8	DN	3-phenyl-1,4-dihydroindeno[1,2-c]pyrazole
DMD0OZ8	MI	TTUTJGQ
DMD0OZ8	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMD0OZ8	MT	DTT
DMD0OZ8	MA	Inhibitor
DMD0OZ8	RN	Hit-to-lead optimization of 1,4-dihydroindeno[1,2-c]pyrazoles as a novel class of KDR kinase inhibitors. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4371-5.
DMD0OZ8	RU	https://pubmed.ncbi.nlm.nih.gov/16750628

DM568CK	DI	DM568CK
DM568CK	DN	3-Phenyl-1-propyl-piperidine hydrochloride
DM568CK	MI	TTEX248
DM568CK	MN	Dopamine D2 receptor (D2R)
DM568CK	MT	DTT
DM568CK	MA	Inhibitor
DM568CK	RN	New N-n-propyl-substituted 3-aryl- and 3-cyclohexylpiperidines as partial agonists at the D4 dopamine receptor. J Med Chem. 2003 Jan 2;46(1):161-8.
DM568CK	RU	https://pubmed.ncbi.nlm.nih.gov/12502370

DMJ0SVB	DI	DMJ0SVB
DMJ0SVB	DN	3-Phenyl-1-propyl-pyrrolidine
DMJ0SVB	MI	TTSQIFT
DMJ0SVB	MN	5-HT 1A receptor (HTR1A)
DMJ0SVB	MT	DTT
DMJ0SVB	MA	Inhibitor
DMJ0SVB	RN	Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity, Bioorg. Med. Chem. Lett. 7(3):241-246 (1997).
DMJ0SVB	RU	http://www.sciencedirect.com/science/article/pii/S0960894X9600618X

DMJ0SVB	DI	DMJ0SVB
DMJ0SVB	DN	3-Phenyl-1-propyl-pyrrolidine
DMJ0SVB	MI	TTEX248
DMJ0SVB	MN	Dopamine D2 receptor (D2R)
DMJ0SVB	MT	DTT
DMJ0SVB	MA	Inhibitor
DMJ0SVB	RN	Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity, Bioorg. Med. Chem. Lett. 7(3):241-246 (1997).
DMJ0SVB	RU	http://www.sciencedirect.com/science/article/pii/S0960894X9600618X

DMEG3YX	DI	DMEG3YX
DMEG3YX	DN	3-Phenyl-1-propylquinazoline-2,4(1H,3H)-dione
DMEG3YX	MI	TTUV8G9
DMEG3YX	MN	Progesterone receptor (PGR)
DMEG3YX	MT	DTT
DMEG3YX	MA	Inhibitor
DMEG3YX	RN	Progesterone receptor antagonists with a 3-phenylquinazoline-2,4-dione/2-phenylisoquinoline-1,3-dione skeleton. Bioorg Med Chem. 2008 Jul 15;16(14):7046-54.
DMEG3YX	RU	https://pubmed.ncbi.nlm.nih.gov/18586498

DMAJMU6	DI	DMAJMU6
DMAJMU6	DN	3-Phenyl-2-nortropene
DMAJMU6	MI	TTVBI8W
DMAJMU6	MN	Dopamine transporter (DAT)
DMAJMU6	MT	DTT
DMAJMU6	MA	Inhibitor
DMAJMU6	RN	Synthesis and monoamine transporter affinity of 3alpha-arylmethoxy-3beta-arylnortropanes. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6865-8.
DMAJMU6	RU	https://pubmed.ncbi.nlm.nih.gov/19896846

DMAJMU6	DI	DMAJMU6
DMAJMU6	DN	3-Phenyl-2-nortropene
DMAJMU6	MI	TT3ROYC
DMAJMU6	MN	Serotonin transporter (SERT)
DMAJMU6	MT	DTT
DMAJMU6	MA	Inhibitor
DMAJMU6	RN	Synthesis and monoamine transporter affinity of 3alpha-arylmethoxy-3beta-arylnortropanes. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6865-8.
DMAJMU6	RU	https://pubmed.ncbi.nlm.nih.gov/19896846

DM6T5K4	DI	DM6T5K4
DM6T5K4	DN	3-phenyl-4-(phenylamino)-1H-pyrrole-2,5-dione
DM6T5K4	MI	TTRSMW9
DM6T5K4	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DM6T5K4	MT	DTT
DM6T5K4	MA	Inhibitor
DM6T5K4	RN	Novel GSK-3beta inhibitors from sequential virtual screening. Bioorg Med Chem. 2008 Jan 15;16(2):636-43.
DM6T5K4	RU	https://pubmed.ncbi.nlm.nih.gov/18006321

DM2C9X8	DI	DM2C9X8
DM2C9X8	DN	3-phenyl-4-hydroxyquinolin-2(1H)-one
DM2C9X8	MI	TTLD29N
DM2C9X8	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DM2C9X8	MT	DTT
DM2C9X8	MA	Inhibitor
DM2C9X8	RN	Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor. J Med Chem. 2006 Feb 9;49(3):864-71.
DM2C9X8	RU	https://pubmed.ncbi.nlm.nih.gov/16451052

DM2C9X8	DI	DM2C9X8
DM2C9X8	DN	3-phenyl-4-hydroxyquinolin-2(1H)-one
DM2C9X8	MI	TTKJEMQ
DM2C9X8	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DM2C9X8	MT	DTT
DM2C9X8	MA	Inhibitor
DM2C9X8	RN	Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor. J Med Chem. 2006 Feb 9;49(3):864-71.
DM2C9X8	RU	https://pubmed.ncbi.nlm.nih.gov/16451052

DM2C9X8	DI	DM2C9X8
DM2C9X8	DN	3-phenyl-4-hydroxyquinolin-2(1H)-one
DM2C9X8	MI	TTN9D8E
DM2C9X8	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DM2C9X8	MT	DTT
DM2C9X8	MA	Inhibitor
DM2C9X8	RN	Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor. J Med Chem. 2006 Feb 9;49(3):864-71.
DM2C9X8	RU	https://pubmed.ncbi.nlm.nih.gov/16451052

DM43CIK	DI	DM43CIK
DM43CIK	DN	3-phenyl-5-sulfamoyl-1H-indole-2-carboxamide
DM43CIK	MI	TTHQPL7
DM43CIK	MN	Carbonic anhydrase I (CA-I)
DM43CIK	MT	DTT
DM43CIK	MA	Inhibitor
DM43CIK	RN	Discovery of low nanomolar and subnanomolar inhibitors of the mycobacterial beta-carbonic anhydrases Rv1284 and Rv3273. J Med Chem. 2009 Jul 9;52(13):4063-7.
DM43CIK	RU	https://pubmed.ncbi.nlm.nih.gov/19438226

DM43CIK	DI	DM43CIK
DM43CIK	DN	3-phenyl-5-sulfamoyl-1H-indole-2-carboxamide
DM43CIK	MI	TTANPDJ
DM43CIK	MN	Carbonic anhydrase II (CA-II)
DM43CIK	MT	DTT
DM43CIK	MA	Inhibitor
DM43CIK	RN	Discovery of low nanomolar and subnanomolar inhibitors of the mycobacterial beta-carbonic anhydrases Rv1284 and Rv3273. J Med Chem. 2009 Jul 9;52(13):4063-7.
DM43CIK	RU	https://pubmed.ncbi.nlm.nih.gov/19438226

DM830FW	DI	DM830FW
DM830FW	DN	3-phenyl-9H-indeno[1,2-e][1,2,4]triazin-9-one
DM830FW	MI	TTGP7BY
DM830FW	MN	Monoamine oxidase type B (MAO-B)
DM830FW	MT	DTT
DM830FW	MA	Inhibitor
DM830FW	RN	Synthesis and monoamine oxidase inhibitory activity of new pyridazine-, pyrimidine- and 1,2,4-triazine-containing tricyclic derivatives. J Med Chem. 2007 Nov 1;50(22):5364-71.
DM830FW	RU	https://pubmed.ncbi.nlm.nih.gov/17910428

DMQZJYS	DI	DMQZJYS
DMQZJYS	DN	3-phenyl-CPP
DMQZJYS	MI	TT823N1
DMQZJYS	MN	Chloride channel protein ClC-Ka (ClC-K1)
DMQZJYS	MT	DTT
DMQZJYS	MA	Blocker (channel blocker)
DMQZJYS	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 700).
DMQZJYS	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=700

DMQZJYS	DI	DMQZJYS
DMQZJYS	DN	3-phenyl-CPP
DMQZJYS	MI	TTR68GQ
DMQZJYS	MN	Chloride channel protein ClC-Kb (ClC-K2)
DMQZJYS	MT	DTT
DMQZJYS	MA	Blocker (channel blocker)
DMQZJYS	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 701).
DMQZJYS	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=701

DMJOD1T	DI	DMJOD1T
DMJOD1T	DN	3-Phenylcyclopentanecarboxylic acid
DMJOD1T	MI	TT5ZWB6
DMJOD1T	MN	Dihydrodiol dehydrogenase type I (AKR1C3)
DMJOD1T	MT	DTT
DMJOD1T	MA	Inhibitor
DMJOD1T	RN	New cyclopentane derivatives as inhibitors of steroid metabolizing enzymes AKR1C1 and AKR1C3. Eur J Med Chem. 2009 Jun;44(6):2563-71.
DMJOD1T	RU	https://pubmed.ncbi.nlm.nih.gov/19237229

DM3LM6B	DI	DM3LM6B
DM3LM6B	DN	3-phenyl-cyclosal-d4TMP
DM3LM6B	MI	TTEB0GD
DM3LM6B	MN	Cholinesterase (BCHE)
DM3LM6B	MT	DTT
DM3LM6B	MA	Inhibitor
DM3LM6B	RN	Bis-cycloSal-d4T-monophosphates: drugs that deliver two molecules of bioactive nucleotides. J Med Chem. 2007 Mar 22;50(6):1335-46.
DM3LM6B	RU	https://pubmed.ncbi.nlm.nih.gov/17328534

DMIJN9E	DI	DMIJN9E
DMIJN9E	DN	3-phenylprop-1-enylboronic acid
DMIJN9E	MI	TTHQPL7
DMIJN9E	MN	Carbonic anhydrase I (CA-I)
DMIJN9E	MT	DTT
DMIJN9E	MA	Inhibitor
DMIJN9E	RN	Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5.
DMIJN9E	RU	https://pubmed.ncbi.nlm.nih.gov/19375309

DMIJN9E	DI	DMIJN9E
DMIJN9E	DN	3-phenylprop-1-enylboronic acid
DMIJN9E	MI	TTANPDJ
DMIJN9E	MN	Carbonic anhydrase II (CA-II)
DMIJN9E	MT	DTT
DMIJN9E	MA	Inhibitor
DMIJN9E	RN	Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5.
DMIJN9E	RU	https://pubmed.ncbi.nlm.nih.gov/19375309

DMBTDZL	DI	DMBTDZL
DMBTDZL	DN	3-Phenyl-pyrrolidine
DMBTDZL	MI	TTEX248
DMBTDZL	MN	Dopamine D2 receptor (D2R)
DMBTDZL	MT	DTT
DMBTDZL	MA	Inhibitor
DMBTDZL	RN	Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity, Bioorg. Med. Chem. Lett. 7(3):241-246 (1997).
DMBTDZL	RU	http://www.sciencedirect.com/science/article/pii/S0960894X9600618X

DM12SKU	DI	DM12SKU
DM12SKU	DN	3-Phenylquinoline-8-carboxamide
DM12SKU	MI	TTVDSZ0
DM12SKU	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DM12SKU	MT	DTT
DM12SKU	MA	Inhibitor
DM12SKU	RN	Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhi... J Med Chem. 2009 Feb 12;52(3):868-77.
DM12SKU	RU	https://pubmed.ncbi.nlm.nih.gov/19117416

DMRNHXE	DI	DMRNHXE
DMRNHXE	DN	3-Phenylsulfanylmethyl-quinoxaline-5,7-diamine
DMRNHXE	MI	TT9SL3Q
DMRNHXE	MN	Polypeptide deformylase (PDF)
DMRNHXE	MT	DTT
DMRNHXE	MA	Inhibitor
DMRNHXE	RN	New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii. J Med Chem. 1995 Nov 24;38(24):4739-59.
DMRNHXE	RU	https://pubmed.ncbi.nlm.nih.gov/7490723

DMIK9VO	DI	DMIK9VO
DMIK9VO	DN	3-Phosphoglyceric Acid
DMIK9VO	MI	TTNS6X4
DMIK9VO	MN	Bacterial Triosephosphate isomerase (Bact TPI)
DMIK9VO	MT	DTT
DMIK9VO	MA	Inhibitor
DMIK9VO	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMIK9VO	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMIK9VO	DI	DMIK9VO
DMIK9VO	DN	3-Phosphoglyceric Acid
DMIK9VO	MI	TTHJWVK
DMIK9VO	MN	Mycobacterium Bisphosphoglycerate phosphoglycerate mutase (MycB gpmI)
DMIK9VO	MT	DTT
DMIK9VO	MA	Inhibitor
DMIK9VO	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMIK9VO	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9BDV2	DI	DM9BDV2
DM9BDV2	DN	3-Phosphoglycerol
DM9BDV2	MI	TTHB48R
DM9BDV2	MN	Bacterial Pyridoxal phosphate biosynthetic pdxJ (Bact pdxJ)
DM9BDV2	MT	DTT
DM9BDV2	MA	Inhibitor
DM9BDV2	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9BDV2	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9BDV2	DI	DM9BDV2
DM9BDV2	DN	3-Phosphoglycerol
DM9BDV2	MI	TTNS6X4
DM9BDV2	MN	Bacterial Triosephosphate isomerase (Bact TPI)
DM9BDV2	MT	DTT
DM9BDV2	MA	Inhibitor
DM9BDV2	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9BDV2	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMPF5OX	DI	DMPF5OX
DMPF5OX	DN	3PO
DMPF5OX	MI	TTTHMQJ
DMPF5OX	MN	Renal carcinoma antigen NY-REN-56 (PFKFB3)
DMPF5OX	MT	DTT
DMPF5OX	MA	Antagonist
DMPF5OX	RN	CPEB4 Increases Expression of PFKFB3 to Induce Glycolysis and Activate Mouse and Human Hepatic Stellate Cells, Promoting Liver Fibrosis. Gastroenterology. 2020 Jul;159(1):273-288.
DMPF5OX	RU	https://pubmed.ncbi.nlm.nih.gov/32169429

DM23I8E	DI	DM23I8E
DM23I8E	DN	3-Prop-1-ynylquinoline-8-carboxamide
DM23I8E	MI	TTVDSZ0
DM23I8E	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DM23I8E	MT	DTT
DM23I8E	MA	Inhibitor
DM23I8E	RN	Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhi... J Med Chem. 2009 Feb 12;52(3):868-77.
DM23I8E	RU	https://pubmed.ncbi.nlm.nih.gov/19117416

DMDEV64	DI	DMDEV64
DMDEV64	DN	3-Propoxy-9H-beta-carboline
DMDEV64	MI	TT1MPAY
DMDEV64	MN	GABA(A) receptor alpha-1 (GABRA1)
DMDEV64	MT	DTT
DMDEV64	MA	Inhibitor
DMDEV64	RN	Synthesis of novel 3-substituted beta-carbolines as benzodiazepine receptor ligands: probing the benzodiazepine receptor pharmacophore. J Med Chem. 1988 Sep;31(9):1854-61.
DMDEV64	RU	https://pubmed.ncbi.nlm.nih.gov/2842507

DMDEV64	DI	DMDEV64
DMDEV64	DN	3-Propoxy-9H-beta-carboline
DMDEV64	MI	TTBMV1G
DMDEV64	MN	GABA(A) receptor alpha-2 (GABRA2)
DMDEV64	MT	DTT
DMDEV64	MA	Inhibitor
DMDEV64	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DMDEV64	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DMDEV64	DI	DMDEV64
DMDEV64	DN	3-Propoxy-9H-beta-carboline
DMDEV64	MI	TT37EDJ
DMDEV64	MN	GABA(A) receptor alpha-3 (GABRA3)
DMDEV64	MT	DTT
DMDEV64	MA	Inhibitor
DMDEV64	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DMDEV64	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DMDEV64	DI	DMDEV64
DMDEV64	DN	3-Propoxy-9H-beta-carboline
DMDEV64	MI	TTNZPQ1
DMDEV64	MN	GABA(A) receptor alpha-5 (GABRA5)
DMDEV64	MT	DTT
DMDEV64	MA	Inhibitor
DMDEV64	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DMDEV64	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DMDEV64	DI	DMDEV64
DMDEV64	DN	3-Propoxy-9H-beta-carboline
DMDEV64	MI	TT06RH5
DMDEV64	MN	GABA(A) receptor gamma-2 (GABRG2)
DMDEV64	MT	DTT
DMDEV64	MA	Inhibitor
DMDEV64	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DMDEV64	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DMDEV64	DI	DMDEV64
DMDEV64	DN	3-Propoxy-9H-beta-carboline
DMDEV64	MI	TTNJYV2
DMDEV64	MN	Gamma-aminobutyric acid receptor (GAR)
DMDEV64	MT	DTT
DMDEV64	MA	Inhibitor
DMDEV64	RN	Synthesis of novel 3-substituted beta-carbolines as benzodiazepine receptor ligands: probing the benzodiazepine receptor pharmacophore. J Med Chem. 1988 Sep;31(9):1854-61.
DMDEV64	RU	https://pubmed.ncbi.nlm.nih.gov/2842507

DMYACO7	DI	DMYACO7
DMYACO7	DN	3-Propyl-[1,4]thiazepan-(5E)-ylideneamine
DMYACO7	MI	TTZUFI5
DMYACO7	MN	Nitric-oxide synthase brain (NOS1)
DMYACO7	MT	DTT
DMYACO7	MA	Inhibitor
DMYACO7	RN	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
DMYACO7	RU	https://pubmed.ncbi.nlm.nih.gov/15501067

DMYACO7	DI	DMYACO7
DMYACO7	DN	3-Propyl-[1,4]thiazepan-(5E)-ylideneamine
DMYACO7	MI	TTF10I9
DMYACO7	MN	Nitric-oxide synthase inducible (NOS2)
DMYACO7	MT	DTT
DMYACO7	MA	Inhibitor
DMYACO7	RN	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
DMYACO7	RU	https://pubmed.ncbi.nlm.nih.gov/15501067

DM0872E	DI	DM0872E
DM0872E	DN	3-p-Tolyl-8-aza-bicyclo[3.2.1]octane
DM0872E	MI	TTVBI8W
DM0872E	MN	Dopamine transporter (DAT)
DM0872E	MT	DTT
DM0872E	MA	Inhibitor
DM0872E	RN	3alpha-(4-Substituted phenyl)nortropane-2beta-carboxylic acid methyl esters show selective binding at the norepinephrine transporter. Bioorg Med Chem Lett. 2000 Nov 6;10(21):2445-7.
DM0872E	RU	https://pubmed.ncbi.nlm.nih.gov/11078197

DM0872E	DI	DM0872E
DM0872E	DN	3-p-Tolyl-8-aza-bicyclo[3.2.1]octane
DM0872E	MI	TTAWNKZ
DM0872E	MN	Norepinephrine transporter (NET)
DM0872E	MT	DTT
DM0872E	MA	Inhibitor
DM0872E	RN	3alpha-(4-Substituted phenyl)nortropane-2beta-carboxylic acid methyl esters show selective binding at the norepinephrine transporter. Bioorg Med Chem Lett. 2000 Nov 6;10(21):2445-7.
DM0872E	RU	https://pubmed.ncbi.nlm.nih.gov/11078197

DM0872E	DI	DM0872E
DM0872E	DN	3-p-Tolyl-8-aza-bicyclo[3.2.1]octane
DM0872E	MI	TT3ROYC
DM0872E	MN	Serotonin transporter (SERT)
DM0872E	MT	DTT
DM0872E	MA	Inhibitor
DM0872E	RN	3alpha-(4-Substituted phenyl)nortropane-2beta-carboxylic acid methyl esters show selective binding at the norepinephrine transporter. Bioorg Med Chem Lett. 2000 Nov 6;10(21):2445-7.
DM0872E	RU	https://pubmed.ncbi.nlm.nih.gov/11078197

DM60Q1B	DI	DM60Q1B
DM60Q1B	DN	3-Pyridin-3-yl-quinoline-6,7-diol
DM60Q1B	MI	TT8FYO9
DM60Q1B	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DM60Q1B	MT	DTT
DM60Q1B	MA	Inhibitor
DM60Q1B	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DM60Q1B	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DM60Q1B	DI	DM60Q1B
DM60Q1B	DN	3-Pyridin-3-yl-quinoline-6,7-diol
DM60Q1B	MI	TTI7421
DM60Q1B	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM60Q1B	MT	DTT
DM60Q1B	MA	Inhibitor
DM60Q1B	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DM60Q1B	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DM0SEL5	DI	DM0SEL5
DM0SEL5	DN	3-Pyridin-4-yl-quinolin-7-ol
DM0SEL5	MI	TT8FYO9
DM0SEL5	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DM0SEL5	MT	DTT
DM0SEL5	MA	Inhibitor
DM0SEL5	RN	5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.
DM0SEL5	RU	https://pubmed.ncbi.nlm.nih.gov/8064792

DM0SEL5	DI	DM0SEL5
DM0SEL5	DN	3-Pyridin-4-yl-quinolin-7-ol
DM0SEL5	MI	TTI7421
DM0SEL5	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM0SEL5	MT	DTT
DM0SEL5	MA	Inhibitor
DM0SEL5	RN	5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.
DM0SEL5	RU	https://pubmed.ncbi.nlm.nih.gov/8064792

DM6U074	DI	DM6U074
DM6U074	DN	3-Pyridin-4-yl-quinoline
DM6U074	MI	TT8FYO9
DM6U074	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DM6U074	MT	DTT
DM6U074	MA	Inhibitor
DM6U074	RN	5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.
DM6U074	RU	https://pubmed.ncbi.nlm.nih.gov/8064792

DM6U074	DI	DM6U074
DM6U074	DN	3-Pyridin-4-yl-quinoline
DM6U074	MI	TTI7421
DM6U074	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM6U074	MT	DTT
DM6U074	MA	Inhibitor
DM6U074	RN	5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.
DM6U074	RU	https://pubmed.ncbi.nlm.nih.gov/8064792

DMPCT0A	DI	DMPCT0A
DMPCT0A	DN	3-Pyridin-4-yl-quinoline-5,7-diol
DMPCT0A	MI	TT8FYO9
DMPCT0A	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMPCT0A	MT	DTT
DMPCT0A	MA	Inhibitor
DMPCT0A	RN	5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.
DMPCT0A	RU	https://pubmed.ncbi.nlm.nih.gov/8064792

DMPCT0A	DI	DMPCT0A
DMPCT0A	DN	3-Pyridin-4-yl-quinoline-5,7-diol
DMPCT0A	MI	TTI7421
DMPCT0A	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMPCT0A	MT	DTT
DMPCT0A	MA	Inhibitor
DMPCT0A	RN	5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.
DMPCT0A	RU	https://pubmed.ncbi.nlm.nih.gov/8064792

DME1TUK	DI	DME1TUK
DME1TUK	DN	3-Pyridin-4-yl-quinoline-6,7-diol
DME1TUK	MI	TTGKNB4
DME1TUK	MN	Epidermal growth factor receptor (EGFR)
DME1TUK	MT	DTT
DME1TUK	MA	Inhibitor
DME1TUK	RN	5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.
DME1TUK	RU	https://pubmed.ncbi.nlm.nih.gov/8064792

DMAGXMJ	DI	DMAGXMJ
DMAGXMJ	DN	3-pyridine-acetic acid
DMAGXMJ	MI	TTWNV8U
DMAGXMJ	MN	Nicotinic acid receptor (HCAR2)
DMAGXMJ	MT	DTT
DMAGXMJ	MA	Agonist
DMAGXMJ	RN	Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem. 2003 Mar 14;278(11):9869-74.
DMAGXMJ	RU	https://pubmed.ncbi.nlm.nih.gov/12522134

DM2KEW6	DI	DM2KEW6
DM2KEW6	DN	3R14S-OCHRATOXIN A
DM2KEW6	MI	DT9NXMV
DM2KEW6	MN	ATP-binding cassette sub-family A member 8 (ABCA8)
DM2KEW6	MT	DTP
DM2KEW6	MA	Substrate
DM2KEW6	RN	Functional analysis of ABCA8, a new drug transporter. Biochem Biophys Res Commun. 2002 Oct 18;298(1):41-5.
DM2KEW6	RU	http://www.ncbi.nlm.nih.gov/pubmed/12379217

DM2KEW6	DI	DM2KEW6
DM2KEW6	DN	3R14S-OCHRATOXIN A
DM2KEW6	MI	DTQ23VB
DM2KEW6	MN	Organic anion transporter 1 (SLC22A6)
DM2KEW6	MT	DTP
DM2KEW6	MA	Substrate
DM2KEW6	RN	Characterization of ochratoxin A transport by human organic anion transporters. Life Sci. 2001 Sep 21;69(18):2123-35.
DM2KEW6	RU	http://www.ncbi.nlm.nih.gov/pubmed/11669456

DM2KEW6	DI	DM2KEW6
DM2KEW6	DN	3R14S-OCHRATOXIN A
DM2KEW6	MI	DTVP67E
DM2KEW6	MN	Organic anion transporter 3 (SLC22A8)
DM2KEW6	MT	DTP
DM2KEW6	MA	Substrate
DM2KEW6	RN	Characterization of ochratoxin A transport by human organic anion transporters. Life Sci. 2001 Sep 21;69(18):2123-35.
DM2KEW6	RU	http://www.ncbi.nlm.nih.gov/pubmed/11669456

DM2KEW6	DI	DM2KEW6
DM2KEW6	DN	3R14S-OCHRATOXIN A
DM2KEW6	MI	DT06JWZ
DM2KEW6	MN	Organic anion transporter 4 (SLC22A11)
DM2KEW6	MT	DTP
DM2KEW6	MA	Substrate
DM2KEW6	RN	Role of human organic anion transporter 4 in the transport of ochratoxin A. Biochim Biophys Acta. 2002 Jun 12;1590(1-3):64-75.
DM2KEW6	RU	http://www.ncbi.nlm.nih.gov/pubmed/12063169

DM2KEW6	DI	DM2KEW6
DM2KEW6	DN	3R14S-OCHRATOXIN A
DM2KEW6	MI	TTTQR47
DM2KEW6	MN	Solute carrier family 22 member 8 (SLC22A8)
DM2KEW6	MT	DTT
DM2KEW6	MA	Inhibitor
DM2KEW6	RN	Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members. J Biol Chem. 2007 Aug 17;282(33):23841-53.
DM2KEW6	RU	https://pubmed.ncbi.nlm.nih.gov/17553798

DMV1HMX	DI	DMV1HMX
DMV1HMX	DN	3r-Hydroxydecanoyl-Coa
DMV1HMX	MI	TTL1WGS
DMV1HMX	MN	Estradiol 17 beta-dehydrogenase 4 (HSD17B4)
DMV1HMX	MT	DTT
DMV1HMX	MA	Inhibitor
DMV1HMX	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMV1HMX	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMVGDSM	DI	DMVGDSM
DMVGDSM	DN	3S,4R-293B
DMVGDSM	MI	TT846HF
DMVGDSM	MN	Voltage-gated potassium channel Kv7.1 (KCNQ1)
DMVGDSM	MT	DTT
DMVGDSM	MA	Blocker (channel blocker)
DMVGDSM	RN	A kinetic study on the stereospecific inhibition of KCNQ1 and I(Ks) by the chromanol 293B. Br J Pharmacol. 2001 Dec;134(8):1647-54.
DMVGDSM	RU	https://pubmed.ncbi.nlm.nih.gov/11739240

DMCD4GR	DI	DMCD4GR
DMCD4GR	DN	3-sal-cyclosal-d4TMP
DMCD4GR	MI	TTEB0GD
DMCD4GR	MN	Cholinesterase (BCHE)
DMCD4GR	MT	DTT
DMCD4GR	MA	Inhibitor
DMCD4GR	RN	Bis-cycloSal-d4T-monophosphates: drugs that deliver two molecules of bioactive nucleotides. J Med Chem. 2007 Mar 22;50(6):1335-46.
DMCD4GR	RU	https://pubmed.ncbi.nlm.nih.gov/17328534

DMNP8DQ	DI	DMNP8DQ
DMNP8DQ	DN	3-sec-Butoxy-9H-beta-carboline
DMNP8DQ	MI	TT1MPAY
DMNP8DQ	MN	GABA(A) receptor alpha-1 (GABRA1)
DMNP8DQ	MT	DTT
DMNP8DQ	MA	Inhibitor
DMNP8DQ	RN	Predictive binding of beta-carboline inverse agonists and antagonists via the CoMFA/GOLPE approach. J Med Chem. 1992 Oct 30;35(22):4001-10.
DMNP8DQ	RU	https://pubmed.ncbi.nlm.nih.gov/1331452

DMNP8DQ	DI	DMNP8DQ
DMNP8DQ	DN	3-sec-Butoxy-9H-beta-carboline
DMNP8DQ	MI	TTNJYV2
DMNP8DQ	MN	Gamma-aminobutyric acid receptor (GAR)
DMNP8DQ	MT	DTT
DMNP8DQ	MA	Inhibitor
DMNP8DQ	RN	Predictive binding of beta-carboline inverse agonists and antagonists via the CoMFA/GOLPE approach. J Med Chem. 1992 Oct 30;35(22):4001-10.
DMNP8DQ	RU	https://pubmed.ncbi.nlm.nih.gov/1331452

DMILTRN	DI	DMILTRN
DMILTRN	DN	3-Sulfinoalanine
DMILTRN	MI	TTEP6RV
DMILTRN	MN	Glutathione reductase (GR)
DMILTRN	MT	DTT
DMILTRN	MA	Inhibitor
DMILTRN	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMILTRN	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMILTRN	DI	DMILTRN
DMILTRN	DN	3-Sulfinoalanine
DMILTRN	MI	TTS0EZJ
DMILTRN	MN	Hydroxymethylglutaryl-CoA synthase 2 (HMGCS2)
DMILTRN	MT	DTT
DMILTRN	MA	Inhibitor
DMILTRN	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMILTRN	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMILTRN	DI	DMILTRN
DMILTRN	DN	3-Sulfinoalanine
DMILTRN	MI	TTICO5G
DMILTRN	MN	Staphylococcus Peptide deformylase (Stap-coc def)
DMILTRN	MT	DTT
DMILTRN	MA	Inhibitor
DMILTRN	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMILTRN	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMKSUV9	DI	DMKSUV9
DMKSUV9	DN	3-tapap
DMKSUV9	MI	TTPRO7W
DMKSUV9	MN	Suppressor of tumorigenicity 14 protein (ST14)
DMKSUV9	MT	DTT
DMKSUV9	MA	Inhibitor
DMKSUV9	RN	Secondary amides of sulfonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase. J Med Chem. 2006 Jul 13;49(14):4116-26.
DMKSUV9	RU	https://pubmed.ncbi.nlm.nih.gov/16821772

DMGDT8V	DI	DMGDT8V
DMGDT8V	DN	3-tert-Butyl-3-ethyl-dihydro-furan-2-one
DMGDT8V	MI	TT1MPAY
DMGDT8V	MN	GABA(A) receptor alpha-1 (GABRA1)
DMGDT8V	MT	DTT
DMGDT8V	MA	Inhibitor
DMGDT8V	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DMGDT8V	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DMGDT8V	DI	DMGDT8V
DMGDT8V	DN	3-tert-Butyl-3-ethyl-dihydro-furan-2-one
DMGDT8V	MI	TTZA1NY
DMGDT8V	MN	GABA(A) receptor beta-2 (GABRB2)
DMGDT8V	MT	DTT
DMGDT8V	MA	Inhibitor
DMGDT8V	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DMGDT8V	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DMGDT8V	DI	DMGDT8V
DMGDT8V	DN	3-tert-Butyl-3-ethyl-dihydro-furan-2-one
DMGDT8V	MI	TT06RH5
DMGDT8V	MN	GABA(A) receptor gamma-2 (GABRG2)
DMGDT8V	MT	DTT
DMGDT8V	MA	Inhibitor
DMGDT8V	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DMGDT8V	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DMGDT8V	DI	DMGDT8V
DMGDT8V	DN	3-tert-Butyl-3-ethyl-dihydro-furan-2-one
DMGDT8V	MI	TTNJYV2
DMGDT8V	MN	Gamma-aminobutyric acid receptor (GAR)
DMGDT8V	MT	DTT
DMGDT8V	MA	Inhibitor
DMGDT8V	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DMGDT8V	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DMY57CV	DI	DMY57CV
DMY57CV	DN	3-tert-butyl-9H-carbazole
DMY57CV	MI	TTBGTCW
DMY57CV	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DMY57CV	MT	DTT
DMY57CV	MA	Inhibitor
DMY57CV	RN	Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8.
DMY57CV	RU	https://pubmed.ncbi.nlm.nih.gov/20521839

DMIH6JU	DI	DMIH6JU
DMIH6JU	DN	3-Tetrazol-2-yl-1-aza-bicyclo[2.2.2]octane
DMIH6JU	MI	TTZ9SOR
DMIH6JU	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMIH6JU	MT	DTT
DMIH6JU	MA	Inhibitor
DMIH6JU	RN	Synthesis and muscarinic activities of quinuclidin-3-yltriazole and -tetrazole derivatives. J Med Chem. 1992 Apr 3;35(7):1280-90.
DMIH6JU	RU	https://pubmed.ncbi.nlm.nih.gov/1560440

DMIH6JU	DI	DMIH6JU
DMIH6JU	DN	3-Tetrazol-2-yl-1-aza-bicyclo[2.2.2]octane
DMIH6JU	MI	TTYEG6Q
DMIH6JU	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMIH6JU	MT	DTT
DMIH6JU	MA	Inhibitor
DMIH6JU	RN	Synthesis and muscarinic activities of quinuclidin-3-yltriazole and -tetrazole derivatives. J Med Chem. 1992 Apr 3;35(7):1280-90.
DMIH6JU	RU	https://pubmed.ncbi.nlm.nih.gov/1560440

DMIH6JU	DI	DMIH6JU
DMIH6JU	DN	3-Tetrazol-2-yl-1-aza-bicyclo[2.2.2]octane
DMIH6JU	MI	TTQ13Z5
DMIH6JU	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMIH6JU	MT	DTT
DMIH6JU	MA	Inhibitor
DMIH6JU	RN	Synthesis and muscarinic activities of quinuclidin-3-yltriazole and -tetrazole derivatives. J Med Chem. 1992 Apr 3;35(7):1280-90.
DMIH6JU	RU	https://pubmed.ncbi.nlm.nih.gov/1560440

DMIH6JU	DI	DMIH6JU
DMIH6JU	DN	3-Tetrazol-2-yl-1-aza-bicyclo[2.2.2]octane
DMIH6JU	MI	TTQ3JTF
DMIH6JU	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DMIH6JU	MT	DTT
DMIH6JU	MA	Inhibitor
DMIH6JU	RN	Synthesis and muscarinic activities of quinuclidin-3-yltriazole and -tetrazole derivatives. J Med Chem. 1992 Apr 3;35(7):1280-90.
DMIH6JU	RU	https://pubmed.ncbi.nlm.nih.gov/1560440

DMIH6JU	DI	DMIH6JU
DMIH6JU	DN	3-Tetrazol-2-yl-1-aza-bicyclo[2.2.2]octane
DMIH6JU	MI	TTH18TF
DMIH6JU	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMIH6JU	MT	DTT
DMIH6JU	MA	Inhibitor
DMIH6JU	RN	Synthesis and muscarinic activities of quinuclidin-3-yltriazole and -tetrazole derivatives. J Med Chem. 1992 Apr 3;35(7):1280-90.
DMIH6JU	RU	https://pubmed.ncbi.nlm.nih.gov/1560440

DM2K59V	DI	DM2K59V
DM2K59V	DN	3'thiacytidine
DM2K59V	MI	TT84ETX
DM2K59V	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM2K59V	MT	DTT
DM2K59V	MA	Inhibitor
DM2K59V	RN	Current use of anti-HIV drugs in AIDS. J Antimicrob Chemother. 1993 Jul;32 Suppl A:133-8.
DM2K59V	RU	https://pubmed.ncbi.nlm.nih.gov/8407695

DM9MFZ1	DI	DM9MFZ1
DM9MFZ1	DN	3-Thiophen-3-yl-quinoline
DM9MFZ1	MI	TT8FYO9
DM9MFZ1	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DM9MFZ1	MT	DTT
DM9MFZ1	MA	Inhibitor
DM9MFZ1	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DM9MFZ1	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DM9MFZ1	DI	DM9MFZ1
DM9MFZ1	DN	3-Thiophen-3-yl-quinoline
DM9MFZ1	MI	TTI7421
DM9MFZ1	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM9MFZ1	MT	DTT
DM9MFZ1	MA	Inhibitor
DM9MFZ1	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DM9MFZ1	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DM5SM8X	DI	DM5SM8X
DM5SM8X	DN	3'-THIO-THYMIDINE-5'-PHOSPHATE
DM5SM8X	MI	TT4NVEM
DM5SM8X	MN	DNA topoisomerase II beta (TOP2B)
DM5SM8X	MT	DTT
DM5SM8X	MA	Inhibitor
DM5SM8X	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM5SM8X	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMOQWDS	DI	DMOQWDS
DMOQWDS	DN	3-trans-p-coumaroyl maslinic acid
DMOQWDS	MI	TTIU7X1
DMOQWDS	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMOQWDS	MT	DTT
DMOQWDS	MA	Inhibitor
DMOQWDS	RN	DNA polymerase beta inhibitors from Tetracera boiviniana. J Nat Prod. 1999 Dec;62(12):1660-3.
DMOQWDS	RU	https://pubmed.ncbi.nlm.nih.gov/10654414

DMI15VQ	DI	DMI15VQ
DMI15VQ	DN	4-((+/-)-(1H-imidazol-1-yl)-(E)-methylretinoate
DMI15VQ	MI	TTD7Q0R
DMI15VQ	MN	Cytochrome P450 26 (CYP26A1)
DMI15VQ	MT	DTT
DMI15VQ	MA	Inhibitor
DMI15VQ	RN	Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and pros... J Med Chem. 2004 Dec 30;47(27):6716-29.
DMI15VQ	RU	https://pubmed.ncbi.nlm.nih.gov/15615521

DMKYB4D	DI	DMKYB4D
DMKYB4D	DN	4-((+/-)-(1H-imidazol-1-yl)-(E)-retinoic acid
DMKYB4D	MI	TTD7Q0R
DMKYB4D	MN	Cytochrome P450 26 (CYP26A1)
DMKYB4D	MT	DTT
DMKYB4D	MA	Inhibitor
DMKYB4D	RN	Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and pros... J Med Chem. 2004 Dec 30;47(27):6716-29.
DMKYB4D	RU	https://pubmed.ncbi.nlm.nih.gov/15615521

DMDHV0N	DI	DMDHV0N
DMDHV0N	DN	4-((1H-imidazol-1-yl)methyl)-2H-chromen-2-one
DMDHV0N	MI	TTSZLWK
DMDHV0N	MN	Aromatase (CYP19A1)
DMDHV0N	MT	DTT
DMDHV0N	MA	Inhibitor
DMDHV0N	RN	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
DMDHV0N	RU	https://pubmed.ncbi.nlm.nih.gov/19072235

DMFUBRC	DI	DMFUBRC
DMFUBRC	DN	4-((1H-imidazol-1-yl)methyl)benzonitrile
DMFUBRC	MI	TTSZLWK
DMFUBRC	MN	Aromatase (CYP19A1)
DMFUBRC	MT	DTT
DMFUBRC	MA	Inhibitor
DMFUBRC	RN	Fadrozole hydrochloride: a potent, selective, nonsteroidal inhibitor of aromatase for the treatment of estrogen-dependent disease. J Med Chem. 1991 Feb;34(2):725-36.
DMFUBRC	RU	https://pubmed.ncbi.nlm.nih.gov/1825337

DMFUBRC	DI	DMFUBRC
DMFUBRC	DN	4-((1H-imidazol-1-yl)methyl)benzonitrile
DMFUBRC	MI	TTIQUX7
DMFUBRC	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMFUBRC	MT	DTT
DMFUBRC	MA	Inhibitor
DMFUBRC	RN	Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25.
DMFUBRC	RU	https://pubmed.ncbi.nlm.nih.gov/20121113

DMFUBRC	DI	DMFUBRC
DMFUBRC	DN	4-((1H-imidazol-1-yl)methyl)benzonitrile
DMFUBRC	MI	TTRA5BZ
DMFUBRC	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMFUBRC	MT	DTT
DMFUBRC	MA	Inhibitor
DMFUBRC	RN	Synthesis and biochemical evaluation of a range of potent benzyl imidazole-based compounds as potential inhibitors of the enzyme complex 17alpha-hy... Bioorg Med Chem Lett. 2006 Aug 1;16(15):4011-5.
DMFUBRC	RU	https://pubmed.ncbi.nlm.nih.gov/16750362

DMYDGH4	DI	DMYDGH4
DMYDGH4	DN	4-((1H-imidazol-1-yl)methyl)phenol
DMYDGH4	MI	TTRA5BZ
DMYDGH4	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMYDGH4	MT	DTT
DMYDGH4	MA	Inhibitor
DMYDGH4	RN	Synthesis and biochemical evaluation of a range of (4-substituted phenyl)sulfonate derivatives of 4-hydroxybenzyl imidazole-based compounds as pote... Bioorg Med Chem Lett. 2010 Sep 1;20(17):5345-8.
DMYDGH4	RU	https://pubmed.ncbi.nlm.nih.gov/20675132

DMX2QD5	DI	DMX2QD5
DMX2QD5	DN	4-((1H-imidazol-4-yl)methyl)-1-heptylpiperidine
DMX2QD5	MI	TT9JNIC
DMX2QD5	MN	Histamine H3 receptor (H3R)
DMX2QD5	MT	DTT
DMX2QD5	MA	Inhibitor
DMX2QD5	RN	Novel histamine H3 receptor antagonists based on the 4-[(1H-imidazol-4-yl)methyl]piperidine scaffold. Bioorg Med Chem Lett. 2006 Jan 15;16(2):395-9.
DMX2QD5	RU	https://pubmed.ncbi.nlm.nih.gov/16246552

DMRYWSN	DI	DMRYWSN
DMRYWSN	DN	4-((1H-Imidazol-4-yl)methyl)-1-phenylpiperidine
DMRYWSN	MI	TT9JNIC
DMRYWSN	MN	Histamine H3 receptor (H3R)
DMRYWSN	MT	DTT
DMRYWSN	MA	Inhibitor
DMRYWSN	RN	Synthesis and structure-activity relationships of N-aryl-piperidine derivatives as potent (partial) agonists for human histamine H3 receptor. Bioorg Med Chem. 2010 Jul 15;18(14):5441-8. 
DMRYWSN	RU	https://pubmed.ncbi.nlm.nih.gov/20541426

DMLV59R	DI	DMLV59R
DMLV59R	DN	4-((1H-indazol-6-ylamino)methyl)benzene-1,2-diol
DMLV59R	MI	TTCBFJO
DMLV59R	MN	Insulin receptor (INSR)
DMLV59R	MT	DTT
DMLV59R	MA	Inhibitor
DMLV59R	RN	ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents. Eur J Pharmacol. 2007 May 7;562(1-2):1-11.
DMLV59R	RU	https://pubmed.ncbi.nlm.nih.gov/17376430

DMLV59R	DI	DMLV59R
DMLV59R	DN	4-((1H-indazol-6-ylamino)methyl)benzene-1,2-diol
DMLV59R	MI	TTHRID2
DMLV59R	MN	Insulin-like growth factor I receptor (IGF1R)
DMLV59R	MT	DTT
DMLV59R	MA	Inhibitor
DMLV59R	RN	ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents. Eur J Pharmacol. 2007 May 7;562(1-2):1-11.
DMLV59R	RU	https://pubmed.ncbi.nlm.nih.gov/17376430

DMRWZ6T	DI	DMRWZ6T
DMRWZ6T	DN	4-((1H-indol-1-yl)methyl)benzenamine
DMRWZ6T	MI	TTJS8PY
DMRWZ6T	MN	5-HT 6 receptor (HTR6)
DMRWZ6T	MT	DTT
DMRWZ6T	MA	Inhibitor
DMRWZ6T	RN	Further studies on the binding of N1-substituted tryptamines at h5-HT6 receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1691-4.
DMRWZ6T	RU	https://pubmed.ncbi.nlm.nih.gov/17239595

DMCRWTH	DI	DMCRWTH
DMCRWTH	DN	4'-((2-butylbenzofuran-3-yl)methyl)biphenyl-4-ol
DMCRWTH	MI	TTELIN2
DMCRWTH	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMCRWTH	MT	DTT
DMCRWTH	MA	Inhibitor
DMCRWTH	RN	Synthesis, activity and molecular modeling of a new series of chromones as low molecular weight protein tyrosine phosphatase inhibitors. Bioorg Med Chem. 2009 Apr 1;17(7):2658-72.
DMCRWTH	RU	https://pubmed.ncbi.nlm.nih.gov/19297174

DMJN2OW	DI	DMJN2OW
DMJN2OW	DN	4-((2R,3S)-2-Methyl-pyrrolidin-3-yl)-1H-imidazole
DMJN2OW	MI	TT9JNIC
DMJN2OW	MN	Histamine H3 receptor (H3R)
DMJN2OW	MT	DTT
DMJN2OW	MA	Inhibitor
DMJN2OW	RN	A novel pyrrolidine analog of histamine as a potent, highly selective histamine H3 receptor agonist. J Med Chem. 1995 May 12;38(10):1593-9.
DMJN2OW	RU	https://pubmed.ncbi.nlm.nih.gov/7752184

DM8WCJK	DI	DM8WCJK
DM8WCJK	DN	4-((2S,3R)-2-Methyl-pyrrolidin-3-yl)-1H-imidazole
DM8WCJK	MI	TT9JNIC
DM8WCJK	MN	Histamine H3 receptor (H3R)
DM8WCJK	MT	DTT
DM8WCJK	MA	Inhibitor
DM8WCJK	RN	A novel pyrrolidine analog of histamine as a potent, highly selective histamine H3 receptor agonist. J Med Chem. 1995 May 12;38(10):1593-9.
DM8WCJK	RU	https://pubmed.ncbi.nlm.nih.gov/7752184

DMHN5OL	DI	DMHN5OL
DMHN5OL	DN	4-((3',4'-Difluorobiphenyl-4-yl)methyl)pyridine
DMHN5OL	MI	TTIQUX7
DMHN5OL	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMHN5OL	MT	DTT
DMHN5OL	MA	Inhibitor
DMHN5OL	RN	Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
DMHN5OL	RU	https://pubmed.ncbi.nlm.nih.gov/20684610

DMHN5OL	DI	DMHN5OL
DMHN5OL	DN	4-((3',4'-Difluorobiphenyl-4-yl)methyl)pyridine
DMHN5OL	MI	TTRA5BZ
DMHN5OL	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMHN5OL	MT	DTT
DMHN5OL	MA	Inhibitor
DMHN5OL	RN	Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
DMHN5OL	RU	https://pubmed.ncbi.nlm.nih.gov/20684610

DM5EP3V	DI	DM5EP3V
DM5EP3V	DN	4-((4-hydroxyphenyl)diazenyl)benzenesulfonamide
DM5EP3V	MI	TTANPDJ
DM5EP3V	MN	Carbonic anhydrase II (CA-II)
DM5EP3V	MT	DTT
DM5EP3V	MA	Inhibitor
DM5EP3V	RN	Carbonic anhydrase inhibitors. Inhibition of the Rv1284 and Rv3273 beta-carbonic anhydrases from Mycobacterium tuberculosis with diazenylbenzenesul... Bioorg Med Chem Lett. 2009 Sep 1;19(17):4929-32.
DM5EP3V	RU	https://pubmed.ncbi.nlm.nih.gov/19651511

DM5EP3V	DI	DM5EP3V
DM5EP3V	DN	4-((4-hydroxyphenyl)diazenyl)benzenesulfonamide
DM5EP3V	MI	TT2LVK8
DM5EP3V	MN	Carbonic anhydrase IX (CA-IX)
DM5EP3V	MT	DTT
DM5EP3V	MA	Inhibitor
DM5EP3V	RN	Carbonic anhydrase inhibitors. Diazenylbenzenesulfonamides are potent and selective inhibitors of the tumor-associated isozymes IX and XII over the... Bioorg Med Chem. 2009 Oct 15;17(20):7093-9.
DM5EP3V	RU	https://pubmed.ncbi.nlm.nih.gov/19773173

DM5EP3V	DI	DM5EP3V
DM5EP3V	DN	4-((4-hydroxyphenyl)diazenyl)benzenesulfonamide
DM5EP3V	MI	TTSYM0R
DM5EP3V	MN	Carbonic anhydrase XII (CA-XII)
DM5EP3V	MT	DTT
DM5EP3V	MA	Inhibitor
DM5EP3V	RN	Carbonic anhydrase inhibitors. Diazenylbenzenesulfonamides are potent and selective inhibitors of the tumor-associated isozymes IX and XII over the... Bioorg Med Chem. 2009 Oct 15;17(20):7093-9.
DM5EP3V	RU	https://pubmed.ncbi.nlm.nih.gov/19773173

DMNAT1D	DI	DMNAT1D
DMNAT1D	DN	4-((4-methoxyphenyl)diazenyl)benzenesulfonamide
DMNAT1D	MI	TTVKILB
DMNAT1D	MN	Prostaglandin G/H synthase 2 (COX-2)
DMNAT1D	MT	DTT
DMNAT1D	MA	Inhibitor
DMNAT1D	RN	Selective COX-2 inhibitors. Part 1: synthesis and biological evaluation of phenylazobenzenesulfonamides. Bioorg Med Chem Lett. 2006 Sep 1;16(17):4440-3.
DMNAT1D	RU	https://pubmed.ncbi.nlm.nih.gov/16814546

DM6R43J	DI	DM6R43J
DM6R43J	DN	4-((benzylideneamino)methyl)benzenesulfonamide
DM6R43J	MI	TTANPDJ
DM6R43J	MN	Carbonic anhydrase II (CA-II)
DM6R43J	MT	DTT
DM6R43J	MA	Inhibitor
DM6R43J	RN	Carbonic anhydrase II-induced selection of inhibitors from a dynamic combinatorial library of Schiff's bases. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6014-7.
DM6R43J	RU	https://pubmed.ncbi.nlm.nih.gov/19796939

DMDOJ4E	DI	DMDOJ4E
DMDOJ4E	DN	4-((E)-1-Naphthalen-1-yl-propenyl)-1H-imidazole
DMDOJ4E	MI	TTNGILX
DMDOJ4E	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMDOJ4E	MT	DTT
DMDOJ4E	MA	Inhibitor
DMDOJ4E	RN	Medetomidine analogs as alpha 2-adrenergic ligands. 2. Design, synthesis, and biological activity of conformationally restricted naphthalene deriva... J Med Chem. 1996 Jul 19;39(15):3001-13.
DMDOJ4E	RU	https://pubmed.ncbi.nlm.nih.gov/8709134

DMDOJ4E	DI	DMDOJ4E
DMDOJ4E	DN	4-((E)-1-Naphthalen-1-yl-propenyl)-1H-imidazole
DMDOJ4E	MI	TTBRKXS
DMDOJ4E	MN	Adrenergic receptor alpha-1B (ADRA1B)
DMDOJ4E	MT	DTT
DMDOJ4E	MA	Inhibitor
DMDOJ4E	RN	Medetomidine analogs as alpha 2-adrenergic ligands. 2. Design, synthesis, and biological activity of conformationally restricted naphthalene deriva... J Med Chem. 1996 Jul 19;39(15):3001-13.
DMDOJ4E	RU	https://pubmed.ncbi.nlm.nih.gov/8709134

DMDOJ4E	DI	DMDOJ4E
DMDOJ4E	DN	4-((E)-1-Naphthalen-1-yl-propenyl)-1H-imidazole
DMDOJ4E	MI	TT34BHT
DMDOJ4E	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMDOJ4E	MT	DTT
DMDOJ4E	MA	Inhibitor
DMDOJ4E	RN	Medetomidine analogs as alpha 2-adrenergic ligands. 2. Design, synthesis, and biological activity of conformationally restricted naphthalene deriva... J Med Chem. 1996 Jul 19;39(15):3001-13.
DMDOJ4E	RU	https://pubmed.ncbi.nlm.nih.gov/8709134

DM52Y3Q	DI	DM52Y3Q
DM52Y3Q	DN	4-((naphthalen-2-ylamino)methyl)benzene-1,2-diol
DM52Y3Q	MI	TTCBFJO
DM52Y3Q	MN	Insulin receptor (INSR)
DM52Y3Q	MT	DTT
DM52Y3Q	MA	Inhibitor
DM52Y3Q	RN	ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents. Eur J Pharmacol. 2007 May 7;562(1-2):1-11.
DM52Y3Q	RU	https://pubmed.ncbi.nlm.nih.gov/17376430

DM52Y3Q	DI	DM52Y3Q
DM52Y3Q	DN	4-((naphthalen-2-ylamino)methyl)benzene-1,2-diol
DM52Y3Q	MI	TTHRID2
DM52Y3Q	MN	Insulin-like growth factor I receptor (IGF1R)
DM52Y3Q	MT	DTT
DM52Y3Q	MA	Inhibitor
DM52Y3Q	RN	ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents. Eur J Pharmacol. 2007 May 7;562(1-2):1-11.
DM52Y3Q	RU	https://pubmed.ncbi.nlm.nih.gov/17376430

DMIQHYZ	DI	DMIQHYZ
DMIQHYZ	DN	4-((naphthalen-2-yloxy)methyl)piperidine
DMIQHYZ	MI	TTPC4TU
DMIQHYZ	MN	5-HT 3A receptor (HTR3A)
DMIQHYZ	MT	DTT
DMIQHYZ	MA	Inhibitor
DMIQHYZ	RN	Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32.
DMIQHYZ	RU	https://pubmed.ncbi.nlm.nih.gov/19282174

DMIQHYZ	DI	DMIQHYZ
DMIQHYZ	DN	4-((naphthalen-2-yloxy)methyl)piperidine
DMIQHYZ	MI	TTAWNKZ
DMIQHYZ	MN	Norepinephrine transporter (NET)
DMIQHYZ	MT	DTT
DMIQHYZ	MA	Inhibitor
DMIQHYZ	RN	Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32.
DMIQHYZ	RU	https://pubmed.ncbi.nlm.nih.gov/19282174

DMIQHYZ	DI	DMIQHYZ
DMIQHYZ	DN	4-((naphthalen-2-yloxy)methyl)piperidine
DMIQHYZ	MI	TT3ROYC
DMIQHYZ	MN	Serotonin transporter (SERT)
DMIQHYZ	MT	DTT
DMIQHYZ	MA	Inhibitor
DMIQHYZ	RN	Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32.
DMIQHYZ	RU	https://pubmed.ncbi.nlm.nih.gov/19282174

DMIQHYZ	DI	DMIQHYZ
DMIQHYZ	DN	4-((naphthalen-2-yloxy)methyl)piperidine
DMIQHYZ	MI	TTQ6VDM
DMIQHYZ	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMIQHYZ	MT	DTT
DMIQHYZ	MA	Inhibitor
DMIQHYZ	RN	Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32.
DMIQHYZ	RU	https://pubmed.ncbi.nlm.nih.gov/19282174

DM7X2AY	DI	DM7X2AY
DM7X2AY	DN	4-((pyridin-4-ylthio)methyl)benzene-1,2-diol
DM7X2AY	MI	TT6804T
DM7X2AY	MN	MIF messenger RNA (MIF mRNA)
DM7X2AY	MT	DTT
DM7X2AY	MA	Inhibitor
DM7X2AY	RN	Classification of chemical compounds by protein-compound docking for use in designing a focused library. J Med Chem. 2006 Jan 26;49(2):523-33.
DM7X2AY	RU	https://pubmed.ncbi.nlm.nih.gov/16420039

DM1UK3G	DI	DM1UK3G
DM1UK3G	DN	4-((Z)-1-Naphthalen-1-yl-propenyl)-1H-imidazole
DM1UK3G	MI	TTNGILX
DM1UK3G	MN	Adrenergic receptor alpha-1A (ADRA1A)
DM1UK3G	MT	DTT
DM1UK3G	MA	Inhibitor
DM1UK3G	RN	Medetomidine analogs as alpha 2-adrenergic ligands. 2. Design, synthesis, and biological activity of conformationally restricted naphthalene deriva... J Med Chem. 1996 Jul 19;39(15):3001-13.
DM1UK3G	RU	https://pubmed.ncbi.nlm.nih.gov/8709134

DM1UK3G	DI	DM1UK3G
DM1UK3G	DN	4-((Z)-1-Naphthalen-1-yl-propenyl)-1H-imidazole
DM1UK3G	MI	TTBRKXS
DM1UK3G	MN	Adrenergic receptor alpha-1B (ADRA1B)
DM1UK3G	MT	DTT
DM1UK3G	MA	Inhibitor
DM1UK3G	RN	Medetomidine analogs as alpha 2-adrenergic ligands. 2. Design, synthesis, and biological activity of conformationally restricted naphthalene deriva... J Med Chem. 1996 Jul 19;39(15):3001-13.
DM1UK3G	RU	https://pubmed.ncbi.nlm.nih.gov/8709134

DM1UK3G	DI	DM1UK3G
DM1UK3G	DN	4-((Z)-1-Naphthalen-1-yl-propenyl)-1H-imidazole
DM1UK3G	MI	TT34BHT
DM1UK3G	MN	Adrenergic receptor alpha-1D (ADRA1D)
DM1UK3G	MT	DTT
DM1UK3G	MA	Inhibitor
DM1UK3G	RN	Medetomidine analogs as alpha 2-adrenergic ligands. 2. Design, synthesis, and biological activity of conformationally restricted naphthalene deriva... J Med Chem. 1996 Jul 19;39(15):3001-13.
DM1UK3G	RU	https://pubmed.ncbi.nlm.nih.gov/8709134

DMEW1CP	DI	DMEW1CP
DMEW1CP	DN	4'-(1-(pyridin-4-yl)propyl)biphenyl-3-ol
DMEW1CP	MI	TTRA5BZ
DMEW1CP	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMEW1CP	MT	DTT
DMEW1CP	MA	Inhibitor
DMEW1CP	RN	Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors. J Med Chem. 2010 Jul 8;53(13):5049-53.
DMEW1CP	RU	https://pubmed.ncbi.nlm.nih.gov/20550118

DMV4QRF	DI	DMV4QRF
DMV4QRF	DN	4-(1,1-dimethyl-heptyl)-2'-methoxy-biphenyl-2-ol
DMV4QRF	MI	TT6OEDT
DMV4QRF	MN	Cannabinoid receptor 1 (CB1)
DMV4QRF	MT	DTT
DMV4QRF	MA	Inhibitor
DMV4QRF	RN	Biaryl cannabinoid mimetics--synthesis and structure-activity relationship. Bioorg Med Chem Lett. 2007 Jul 1;17(13):3652-6.
DMV4QRF	RU	https://pubmed.ncbi.nlm.nih.gov/17507224

DMV4QRF	DI	DMV4QRF
DMV4QRF	DN	4-(1,1-dimethyl-heptyl)-2'-methoxy-biphenyl-2-ol
DMV4QRF	MI	TTMSFAW
DMV4QRF	MN	Cannabinoid receptor 2 (CB2)
DMV4QRF	MT	DTT
DMV4QRF	MA	Inhibitor
DMV4QRF	RN	Biaryl cannabinoid mimetics--synthesis and structure-activity relationship. Bioorg Med Chem Lett. 2007 Jul 1;17(13):3652-6.
DMV4QRF	RU	https://pubmed.ncbi.nlm.nih.gov/17507224

DMUMD8L	DI	DMUMD8L
DMUMD8L	DN	4'-(1,1-dimethyl-heptyl)-3,5-dimethyl-biphenyl
DMUMD8L	MI	TTMSFAW
DMUMD8L	MN	Cannabinoid receptor 2 (CB2)
DMUMD8L	MT	DTT
DMUMD8L	MA	Inhibitor
DMUMD8L	RN	Biaryl cannabinoid mimetics--synthesis and structure-activity relationship. Bioorg Med Chem Lett. 2007 Jul 1;17(13):3652-6.
DMUMD8L	RU	https://pubmed.ncbi.nlm.nih.gov/17507224

DM5BN41	DI	DM5BN41
DM5BN41	DN	4-(1,1-dimethyl-heptyl)-3'-methoxy-biphenyl-2-ol
DM5BN41	MI	TT6OEDT
DM5BN41	MN	Cannabinoid receptor 1 (CB1)
DM5BN41	MT	DTT
DM5BN41	MA	Inhibitor
DM5BN41	RN	Biaryl cannabinoid mimetics--synthesis and structure-activity relationship. Bioorg Med Chem Lett. 2007 Jul 1;17(13):3652-6.
DM5BN41	RU	https://pubmed.ncbi.nlm.nih.gov/17507224

DM5BN41	DI	DM5BN41
DM5BN41	DN	4-(1,1-dimethyl-heptyl)-3'-methoxy-biphenyl-2-ol
DM5BN41	MI	TTMSFAW
DM5BN41	MN	Cannabinoid receptor 2 (CB2)
DM5BN41	MT	DTT
DM5BN41	MA	Inhibitor
DM5BN41	RN	Biaryl cannabinoid mimetics--synthesis and structure-activity relationship. Bioorg Med Chem Lett. 2007 Jul 1;17(13):3652-6.
DM5BN41	RU	https://pubmed.ncbi.nlm.nih.gov/17507224

DMG4HO3	DI	DMG4HO3
DMG4HO3	DN	4-(1,2,3-thiadiazol-4-yl)phenyl butylcarbamate
DMG4HO3	MI	TTDP1UC
DMG4HO3	MN	Fatty acid amide hydrolase (FAAH)
DMG4HO3	MT	DTT
DMG4HO3	MA	Inhibitor
DMG4HO3	RN	The synthesis and biological evaluation of para-substituted phenolic N-alkyl carbamates as endocannabinoid hydrolyzing enzyme inhibitors. Eur J Med Chem. 2009 Jul;44(7):2994-3008.
DMG4HO3	RU	https://pubmed.ncbi.nlm.nih.gov/19232787

DMSFGRI	DI	DMSFGRI
DMSFGRI	DN	4-(1,2,3-thiadiazol-4-yl)phenyl hexylcarbamate
DMSFGRI	MI	TTDP1UC
DMSFGRI	MN	Fatty acid amide hydrolase (FAAH)
DMSFGRI	MT	DTT
DMSFGRI	MA	Inhibitor
DMSFGRI	RN	The synthesis and biological evaluation of para-substituted phenolic N-alkyl carbamates as endocannabinoid hydrolyzing enzyme inhibitors. Eur J Med Chem. 2009 Jul;44(7):2994-3008.
DMSFGRI	RU	https://pubmed.ncbi.nlm.nih.gov/19232787

DMJDW50	DI	DMJDW50
DMJDW50	DN	4-(1,2-Diphenyl-but-1-enyl)-phenol
DMJDW50	MI	TTZAYWL
DMJDW50	MN	Estrogen receptor (ESR)
DMJDW50	MT	DTT
DMJDW50	MA	Inhibitor
DMJDW50	RN	Investigations on estrogen receptor binding. The estrogenic, antiestrogenic, and cytotoxic properties of C2-alkyl-substituted 1,1-bis(4-hydroxyphen... J Med Chem. 2002 Nov 21;45(24):5358-64.
DMJDW50	RU	https://pubmed.ncbi.nlm.nih.gov/12431063

DM1SP36	DI	DM1SP36
DM1SP36	DN	4-(10H-Anthracen-9-ylidene)-1-methyl-piperidine
DM1SP36	MI	TTJQOD7
DM1SP36	MN	5-HT 2A receptor (HTR2A)
DM1SP36	MT	DTT
DM1SP36	MA	Inhibitor
DM1SP36	RN	Exploring the relationship between binding modes of 9-(aminomethyl)-9,10-dihydroanthracene and cyproheptadine analogues at the 5-HT2A serotonin rec... Bioorg Med Chem Lett. 2001 Feb 26;11(4):563-6.
DM1SP36	RU	https://pubmed.ncbi.nlm.nih.gov/11229772

DMNV9H5	DI	DMNV9H5
DMNV9H5	DN	4-(1-benzyl-7-chloro-1H-indazol-3-yl)phenol
DMNV9H5	MI	TTZAYWL
DMNV9H5	MN	Estrogen receptor (ESR)
DMNV9H5	MT	DTT
DMNV9H5	MA	Inhibitor
DMNV9H5	RN	Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid ... J Med Chem. 2004 Dec 16;47(26):6435-8.
DMNV9H5	RU	https://pubmed.ncbi.nlm.nih.gov/15588074

DMS1OYA	DI	DMS1OYA
DMS1OYA	DN	4-(1-butyl-7-chloro-1H-indazol-3-yl)phenol
DMS1OYA	MI	TTZAYWL
DMS1OYA	MN	Estrogen receptor (ESR)
DMS1OYA	MT	DTT
DMS1OYA	MA	Inhibitor
DMS1OYA	RN	Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid ... J Med Chem. 2004 Dec 16;47(26):6435-8.
DMS1OYA	RU	https://pubmed.ncbi.nlm.nih.gov/15588074

DM3NEYB	DI	DM3NEYB
DM3NEYB	DN	4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenol
DM3NEYB	MI	TTZAYWL
DM3NEYB	MN	Estrogen receptor (ESR)
DM3NEYB	MT	DTT
DM3NEYB	MA	Inhibitor
DM3NEYB	RN	Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid ... J Med Chem. 2004 Dec 16;47(26):6435-8.
DM3NEYB	RU	https://pubmed.ncbi.nlm.nih.gov/15588074

DMFWVJI	DI	DMFWVJI
DMFWVJI	DN	4-(1H-1,2,3-triazol-5-yl)pyridine
DMFWVJI	MI	TTZJYKH
DMFWVJI	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMFWVJI	MT	DTT
DMFWVJI	MA	Inhibitor
DMFWVJI	RN	Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2010 Feb 11;53(3):1172-89.
DMFWVJI	RU	https://pubmed.ncbi.nlm.nih.gov/20055453

DM5JDYO	DI	DM5JDYO
DM5JDYO	DN	4-(1H-IMIDAZOL-1-YL)PHENOL
DM5JDYO	MI	TTF10I9
DM5JDYO	MN	Nitric-oxide synthase inducible (NOS2)
DM5JDYO	MT	DTT
DM5JDYO	MA	Inhibitor
DM5JDYO	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM5JDYO	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMMJI4R	DI	DMMJI4R
DMMJI4R	DN	4-(1H-Inden-1-ylmethyl)-phenylamine
DMMJI4R	MI	TTJS8PY
DMMJI4R	MN	5-HT 6 receptor (HTR6)
DMMJI4R	MT	DTT
DMMJI4R	MA	Inhibitor
DMMJI4R	RN	Binding of isotryptamines and indenes at h5-HT6 serotonin receptors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1987-91.
DMMJI4R	RU	https://pubmed.ncbi.nlm.nih.gov/15808453

DMY5QBF	DI	DMY5QBF
DMY5QBF	DN	4-(1H-indol-1-ylsulfonyl)benzenamine
DMY5QBF	MI	TTJS8PY
DMY5QBF	MN	5-HT 6 receptor (HTR6)
DMY5QBF	MT	DTT
DMY5QBF	MA	Inhibitor
DMY5QBF	RN	Binding of amine-substituted N1-benzenesulfonylindoles at human 5-HT6 serotonin receptors. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5298-302.
DMY5QBF	RU	https://pubmed.ncbi.nlm.nih.gov/16183286

DM9FKSM	DI	DM9FKSM
DM9FKSM	DN	4-(1H-indol-3-yl)-1-morpholinobutan-1-one
DM9FKSM	MI	TT2J34L
DM9FKSM	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM9FKSM	MT	DTT
DM9FKSM	MA	Inhibitor
DM9FKSM	RN	Indole derivatives as potent inhibitors of 5-lipoxygenase: design, synthesis, biological evaluation, and molecular modeling. Bioorg Med Chem Lett. 2007 May 1;17(9):2414-20.
DM9FKSM	RU	https://pubmed.ncbi.nlm.nih.gov/17336065

DM7Y1ZD	DI	DM7Y1ZD
DM7Y1ZD	DN	4-(1H-indol-3-yl)-N,N-dimethylcyclohex-3-enamine
DM7Y1ZD	MI	TTVBI8W
DM7Y1ZD	MN	Dopamine transporter (DAT)
DM7Y1ZD	MT	DTT
DM7Y1ZD	MA	Inhibitor
DM7Y1ZD	RN	Conformationally restricted homotryptamines 3. Indole tetrahydropyridines and cyclohexenylamines as selective serotonin reuptake inhibitors. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3099-104.
DM7Y1ZD	RU	https://pubmed.ncbi.nlm.nih.gov/17391962

DM7Y1ZD	DI	DM7Y1ZD
DM7Y1ZD	DN	4-(1H-indol-3-yl)-N,N-dimethylcyclohex-3-enamine
DM7Y1ZD	MI	TTAWNKZ
DM7Y1ZD	MN	Norepinephrine transporter (NET)
DM7Y1ZD	MT	DTT
DM7Y1ZD	MA	Inhibitor
DM7Y1ZD	RN	Conformationally restricted homotryptamines 3. Indole tetrahydropyridines and cyclohexenylamines as selective serotonin reuptake inhibitors. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3099-104.
DM7Y1ZD	RU	https://pubmed.ncbi.nlm.nih.gov/17391962

DM7Y1ZD	DI	DM7Y1ZD
DM7Y1ZD	DN	4-(1H-indol-3-yl)-N,N-dimethylcyclohex-3-enamine
DM7Y1ZD	MI	TT3ROYC
DM7Y1ZD	MN	Serotonin transporter (SERT)
DM7Y1ZD	MT	DTT
DM7Y1ZD	MA	Inhibitor
DM7Y1ZD	RN	Conformationally restricted homotryptamines 3. Indole tetrahydropyridines and cyclohexenylamines as selective serotonin reuptake inhibitors. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3099-104.
DM7Y1ZD	RU	https://pubmed.ncbi.nlm.nih.gov/17391962

DMK5CJO	DI	DMK5CJO
DMK5CJO	DN	4-(1H-Indol-3-ylmethyl)-phenylamine
DMK5CJO	MI	TTJS8PY
DMK5CJO	MN	5-HT 6 receptor (HTR6)
DMK5CJO	MT	DTT
DMK5CJO	MA	Inhibitor
DMK5CJO	RN	Binding of isotryptamines and indenes at h5-HT6 serotonin receptors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1987-91.
DMK5CJO	RU	https://pubmed.ncbi.nlm.nih.gov/15808453

DMQVOSU	DI	DMQVOSU
DMQVOSU	DN	4-(1H-indol-4-yloxy)-1-(isopropylamino)butan-2-ol
DMQVOSU	MI	TTSQIFT
DMQVOSU	MN	5-HT 1A receptor (HTR1A)
DMQVOSU	MT	DTT
DMQVOSU	MA	Inhibitor
DMQVOSU	RN	Indoloxypropanolamine analogues as 5-HT(1A) receptor antagonists. Bioorg Med Chem Lett. 2007 Oct 15;17(20):5600-4.
DMQVOSU	RU	https://pubmed.ncbi.nlm.nih.gov/17804228

DMAU0SF	DI	DMAU0SF
DMAU0SF	DN	4-(1H-indol-5-ylamino)-5-styrylnicotinonitrile
DMAU0SF	MI	TT1MS7X
DMAU0SF	MN	PKC-theta messenger RNA (PRKCQ mRNA)
DMAU0SF	MT	DTT
DMAU0SF	MA	Inhibitor
DMAU0SF	RN	First generation 5-vinyl-3-pyridinecarbonitrile PKCtheta inhibitors. Bioorg Med Chem Lett. 2009 Oct 15;19(20):5829-32.
DMAU0SF	RU	https://pubmed.ncbi.nlm.nih.gov/19762237

DMH360U	DI	DMH360U
DMH360U	DN	4-(1H-indol-5-yloxy)-5-styrylnicotinonitrile
DMH360U	MI	TT1MS7X
DMH360U	MN	PKC-theta messenger RNA (PRKCQ mRNA)
DMH360U	MT	DTT
DMH360U	MA	Inhibitor
DMH360U	RN	First generation 5-vinyl-3-pyridinecarbonitrile PKCtheta inhibitors. Bioorg Med Chem Lett. 2009 Oct 15;19(20):5829-32.
DMH360U	RU	https://pubmed.ncbi.nlm.nih.gov/19762237

DMB07TU	DI	DMB07TU
DMB07TU	DN	4-(1H-indol-6-ylamino)-5-styrylnicotinonitrile
DMB07TU	MI	TT1MS7X
DMB07TU	MN	PKC-theta messenger RNA (PRKCQ mRNA)
DMB07TU	MT	DTT
DMB07TU	MA	Inhibitor
DMB07TU	RN	First generation 5-vinyl-3-pyridinecarbonitrile PKCtheta inhibitors. Bioorg Med Chem Lett. 2009 Oct 15;19(20):5829-32.
DMB07TU	RU	https://pubmed.ncbi.nlm.nih.gov/19762237

DM9MPHF	DI	DM9MPHF
DM9MPHF	DN	4-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine
DM9MPHF	MI	TT9RTBL
DM9MPHF	MN	Aurora B messenger RNA (AURKB mRNA)
DM9MPHF	MT	DTT
DM9MPHF	MA	Inhibitor
DM9MPHF	RN	Discovery of a new series of Aurora inhibitors through truncation of GSK1070916. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2552-5.
DM9MPHF	RU	https://pubmed.ncbi.nlm.nih.gov/20335034

DM9MPHF	DI	DM9MPHF
DM9MPHF	DN	4-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine
DM9MPHF	MI	TTPS3C0
DM9MPHF	MN	Aurora kinase A (AURKA)
DM9MPHF	MT	DTT
DM9MPHF	MA	Inhibitor
DM9MPHF	RN	Discovery of a new series of Aurora inhibitors through truncation of GSK1070916. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2552-5.
DM9MPHF	RU	https://pubmed.ncbi.nlm.nih.gov/20335034

DM08963	DI	DM08963
DM08963	DN	4-(1-Imidazol-1-yl-vinyl)-benzonitrile
DM08963	MI	TTSZLWK
DM08963	MN	Aromatase (CYP19A1)
DM08963	MT	DTT
DM08963	MA	Inhibitor
DM08963	RN	Aromatase inhibitors: synthesis, biological activity, and binding mode of azole-type compounds. J Med Chem. 1993 May 14;36(10):1393-400.
DM08963	RU	https://pubmed.ncbi.nlm.nih.gov/8496907

DMFYBLH	DI	DMFYBLH
DMFYBLH	DN	4-(1-Naphthalen-1-yl-ethyl)-1H-imidazole
DMFYBLH	MI	TTNGILX
DMFYBLH	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMFYBLH	MT	DTT
DMFYBLH	MA	Inhibitor
DMFYBLH	RN	A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
DMFYBLH	RU	https://pubmed.ncbi.nlm.nih.gov/7914537

DMFYBLH	DI	DMFYBLH
DMFYBLH	DN	4-(1-Naphthalen-1-yl-ethyl)-1H-imidazole
DMFYBLH	MI	TTBRKXS
DMFYBLH	MN	Adrenergic receptor alpha-1B (ADRA1B)
DMFYBLH	MT	DTT
DMFYBLH	MA	Inhibitor
DMFYBLH	RN	A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
DMFYBLH	RU	https://pubmed.ncbi.nlm.nih.gov/7914537

DMFYBLH	DI	DMFYBLH
DMFYBLH	DN	4-(1-Naphthalen-1-yl-ethyl)-1H-imidazole
DMFYBLH	MI	TT34BHT
DMFYBLH	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMFYBLH	MT	DTT
DMFYBLH	MA	Inhibitor
DMFYBLH	RN	A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
DMFYBLH	RU	https://pubmed.ncbi.nlm.nih.gov/7914537

DMFYBLH	DI	DMFYBLH
DMFYBLH	DN	4-(1-Naphthalen-1-yl-ethyl)-1H-imidazole
DMFYBLH	MI	TTWG9A4
DMFYBLH	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMFYBLH	MT	DTT
DMFYBLH	MA	Inhibitor
DMFYBLH	RN	A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
DMFYBLH	RU	https://pubmed.ncbi.nlm.nih.gov/7914537

DMFYBLH	DI	DMFYBLH
DMFYBLH	DN	4-(1-Naphthalen-1-yl-ethyl)-1H-imidazole
DMFYBLH	MI	TTWM4TY
DMFYBLH	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMFYBLH	MT	DTT
DMFYBLH	MA	Inhibitor
DMFYBLH	RN	A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
DMFYBLH	RU	https://pubmed.ncbi.nlm.nih.gov/7914537

DMFYBLH	DI	DMFYBLH
DMFYBLH	DN	4-(1-Naphthalen-1-yl-ethyl)-1H-imidazole
DMFYBLH	MI	TT2NUT5
DMFYBLH	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMFYBLH	MT	DTT
DMFYBLH	MA	Inhibitor
DMFYBLH	RN	A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
DMFYBLH	RU	https://pubmed.ncbi.nlm.nih.gov/7914537

DM64THP	DI	DM64THP
DM64THP	DN	4-(1-Naphthalen-1-yl-propyl)-1H-imidazole
DM64THP	MI	TTNGILX
DM64THP	MN	Adrenergic receptor alpha-1A (ADRA1A)
DM64THP	MT	DTT
DM64THP	MA	Inhibitor
DM64THP	RN	Medetomidine analogs as alpha 2-adrenergic ligands. 2. Design, synthesis, and biological activity of conformationally restricted naphthalene deriva... J Med Chem. 1996 Jul 19;39(15):3001-13.
DM64THP	RU	https://pubmed.ncbi.nlm.nih.gov/8709134

DM64THP	DI	DM64THP
DM64THP	DN	4-(1-Naphthalen-1-yl-propyl)-1H-imidazole
DM64THP	MI	TTBRKXS
DM64THP	MN	Adrenergic receptor alpha-1B (ADRA1B)
DM64THP	MT	DTT
DM64THP	MA	Inhibitor
DM64THP	RN	Medetomidine analogs as alpha 2-adrenergic ligands. 2. Design, synthesis, and biological activity of conformationally restricted naphthalene deriva... J Med Chem. 1996 Jul 19;39(15):3001-13.
DM64THP	RU	https://pubmed.ncbi.nlm.nih.gov/8709134

DM64THP	DI	DM64THP
DM64THP	DN	4-(1-Naphthalen-1-yl-propyl)-1H-imidazole
DM64THP	MI	TT34BHT
DM64THP	MN	Adrenergic receptor alpha-1D (ADRA1D)
DM64THP	MT	DTT
DM64THP	MA	Inhibitor
DM64THP	RN	Medetomidine analogs as alpha 2-adrenergic ligands. 2. Design, synthesis, and biological activity of conformationally restricted naphthalene deriva... J Med Chem. 1996 Jul 19;39(15):3001-13.
DM64THP	RU	https://pubmed.ncbi.nlm.nih.gov/8709134

DM49PR1	DI	DM49PR1
DM49PR1	DN	4-(1-Naphthalen-1-yl-vinyl)-1H-imidazole
DM49PR1	MI	TTNGILX
DM49PR1	MN	Adrenergic receptor alpha-1A (ADRA1A)
DM49PR1	MT	DTT
DM49PR1	MA	Inhibitor
DM49PR1	RN	Medetomidine analogs as alpha 2-adrenergic ligands. 2. Design, synthesis, and biological activity of conformationally restricted naphthalene deriva... J Med Chem. 1996 Jul 19;39(15):3001-13.
DM49PR1	RU	https://pubmed.ncbi.nlm.nih.gov/8709134

DM49PR1	DI	DM49PR1
DM49PR1	DN	4-(1-Naphthalen-1-yl-vinyl)-1H-imidazole
DM49PR1	MI	TTBRKXS
DM49PR1	MN	Adrenergic receptor alpha-1B (ADRA1B)
DM49PR1	MT	DTT
DM49PR1	MA	Inhibitor
DM49PR1	RN	Medetomidine analogs as alpha 2-adrenergic ligands. 2. Design, synthesis, and biological activity of conformationally restricted naphthalene deriva... J Med Chem. 1996 Jul 19;39(15):3001-13.
DM49PR1	RU	https://pubmed.ncbi.nlm.nih.gov/8709134

DM49PR1	DI	DM49PR1
DM49PR1	DN	4-(1-Naphthalen-1-yl-vinyl)-1H-imidazole
DM49PR1	MI	TT34BHT
DM49PR1	MN	Adrenergic receptor alpha-1D (ADRA1D)
DM49PR1	MT	DTT
DM49PR1	MA	Inhibitor
DM49PR1	RN	Medetomidine analogs as alpha 2-adrenergic ligands. 2. Design, synthesis, and biological activity of conformationally restricted naphthalene deriva... J Med Chem. 1996 Jul 19;39(15):3001-13.
DM49PR1	RU	https://pubmed.ncbi.nlm.nih.gov/8709134

DMJ9CNA	DI	DMJ9CNA
DMJ9CNA	DN	4-(2-((3-fluorophenoxy)methyl)phenyl)piperidine
DMJ9CNA	MI	TTVBI8W
DMJ9CNA	MN	Dopamine transporter (DAT)
DMJ9CNA	MT	DTT
DMJ9CNA	MA	Inhibitor
DMJ9CNA	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMJ9CNA	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMJ9CNA	DI	DMJ9CNA
DMJ9CNA	DN	4-(2-((3-fluorophenoxy)methyl)phenyl)piperidine
DMJ9CNA	MI	TTAWNKZ
DMJ9CNA	MN	Norepinephrine transporter (NET)
DMJ9CNA	MT	DTT
DMJ9CNA	MA	Inhibitor
DMJ9CNA	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMJ9CNA	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMJ9CNA	DI	DMJ9CNA
DMJ9CNA	DN	4-(2-((3-fluorophenoxy)methyl)phenyl)piperidine
DMJ9CNA	MI	TT3ROYC
DMJ9CNA	MN	Serotonin transporter (SERT)
DMJ9CNA	MT	DTT
DMJ9CNA	MA	Inhibitor
DMJ9CNA	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMJ9CNA	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DM0MWVU	DI	DM0MWVU
DM0MWVU	DN	4-(2-((dimethylamino)methyl)phenoxy)benzonitrile
DM0MWVU	MI	TT3ROYC
DM0MWVU	MN	Serotonin transporter (SERT)
DM0MWVU	MT	DTT
DM0MWVU	MA	Inhibitor
DM0MWVU	RN	Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines. Bioorg Med Chem Lett. 2008 Jul 15;18(14):4018-21.
DM0MWVU	RU	https://pubmed.ncbi.nlm.nih.gov/18571404

DM1043B	DI	DM1043B
DM1043B	DN	4-(2-(1H-imidazol-1-yl)ethoxy)-2H-chromen-2-one
DM1043B	MI	TTSZLWK
DM1043B	MN	Aromatase (CYP19A1)
DM1043B	MT	DTT
DM1043B	MA	Inhibitor
DM1043B	RN	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
DM1043B	RU	https://pubmed.ncbi.nlm.nih.gov/19072235

DMTJGBL	DI	DMTJGBL
DMTJGBL	DN	4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine
DMTJGBL	MI	TTCJG29
DMTJGBL	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMTJGBL	MT	DTT
DMTJGBL	MA	Inhibitor
DMTJGBL	RN	Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-alpha: Hit to lead studies. Bioorg Med Chem Lett. 2010 Jan 15;20(2):636-9.
DMTJGBL	RU	https://pubmed.ncbi.nlm.nih.gov/19969455

DM9UA0N	DI	DM9UA0N
DM9UA0N	DN	4-(2-(2-fluoro-5-methylphenoxy)phenyl)piperidine
DM9UA0N	MI	TTSQIFT
DM9UA0N	MN	5-HT 1A receptor (HTR1A)
DM9UA0N	MT	DTT
DM9UA0N	MA	Inhibitor
DM9UA0N	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DM9UA0N	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DM9UA0N	DI	DM9UA0N
DM9UA0N	DN	4-(2-(2-fluoro-5-methylphenoxy)phenyl)piperidine
DM9UA0N	MI	TTVBI8W
DM9UA0N	MN	Dopamine transporter (DAT)
DM9UA0N	MT	DTT
DM9UA0N	MA	Inhibitor
DM9UA0N	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DM9UA0N	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DM9UA0N	DI	DM9UA0N
DM9UA0N	DN	4-(2-(2-fluoro-5-methylphenoxy)phenyl)piperidine
DM9UA0N	MI	TTAWNKZ
DM9UA0N	MN	Norepinephrine transporter (NET)
DM9UA0N	MT	DTT
DM9UA0N	MA	Inhibitor
DM9UA0N	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DM9UA0N	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DM9UA0N	DI	DM9UA0N
DM9UA0N	DN	4-(2-(2-fluoro-5-methylphenoxy)phenyl)piperidine
DM9UA0N	MI	TT3ROYC
DM9UA0N	MN	Serotonin transporter (SERT)
DM9UA0N	MT	DTT
DM9UA0N	MA	Inhibitor
DM9UA0N	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DM9UA0N	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMCR3VM	DI	DMCR3VM
DMCR3VM	DN	4-(2-(2-fluorobenzyloxy)phenyl)piperidine
DMCR3VM	MI	TTSQIFT
DMCR3VM	MN	5-HT 1A receptor (HTR1A)
DMCR3VM	MT	DTT
DMCR3VM	MA	Inhibitor
DMCR3VM	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMCR3VM	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMCR3VM	DI	DMCR3VM
DMCR3VM	DN	4-(2-(2-fluorobenzyloxy)phenyl)piperidine
DMCR3VM	MI	TTVBI8W
DMCR3VM	MN	Dopamine transporter (DAT)
DMCR3VM	MT	DTT
DMCR3VM	MA	Inhibitor
DMCR3VM	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMCR3VM	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMCR3VM	DI	DMCR3VM
DMCR3VM	DN	4-(2-(2-fluorobenzyloxy)phenyl)piperidine
DMCR3VM	MI	TTAWNKZ
DMCR3VM	MN	Norepinephrine transporter (NET)
DMCR3VM	MT	DTT
DMCR3VM	MA	Inhibitor
DMCR3VM	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMCR3VM	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMCR3VM	DI	DMCR3VM
DMCR3VM	DN	4-(2-(2-fluorobenzyloxy)phenyl)piperidine
DMCR3VM	MI	TT3ROYC
DMCR3VM	MN	Serotonin transporter (SERT)
DMCR3VM	MT	DTT
DMCR3VM	MA	Inhibitor
DMCR3VM	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMCR3VM	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMKZ6JW	DI	DMKZ6JW
DMKZ6JW	DN	4-(2-(3,4-Dimethylphenylamino)ethyl)-1H-imidazole
DMKZ6JW	MI	TT9JNIC
DMKZ6JW	MN	Histamine H3 receptor (H3R)
DMKZ6JW	MT	DTT
DMKZ6JW	MA	Inhibitor
DMKZ6JW	RN	Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active hi... J Med Chem. 2010 May 13;53(9):3840-4.
DMKZ6JW	RU	https://pubmed.ncbi.nlm.nih.gov/20384344

DM0IT5E	DI	DM0IT5E
DM0IT5E	DN	4-(2-(3-chlorophenoxy)phenyl)piperidine
DM0IT5E	MI	TTSQIFT
DM0IT5E	MN	5-HT 1A receptor (HTR1A)
DM0IT5E	MT	DTT
DM0IT5E	MA	Inhibitor
DM0IT5E	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DM0IT5E	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DM0IT5E	DI	DM0IT5E
DM0IT5E	DN	4-(2-(3-chlorophenoxy)phenyl)piperidine
DM0IT5E	MI	TTVBI8W
DM0IT5E	MN	Dopamine transporter (DAT)
DM0IT5E	MT	DTT
DM0IT5E	MA	Inhibitor
DM0IT5E	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DM0IT5E	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DM0IT5E	DI	DM0IT5E
DM0IT5E	DN	4-(2-(3-chlorophenoxy)phenyl)piperidine
DM0IT5E	MI	TTAWNKZ
DM0IT5E	MN	Norepinephrine transporter (NET)
DM0IT5E	MT	DTT
DM0IT5E	MA	Inhibitor
DM0IT5E	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DM0IT5E	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DM0IT5E	DI	DM0IT5E
DM0IT5E	DN	4-(2-(3-chlorophenoxy)phenyl)piperidine
DM0IT5E	MI	TT3ROYC
DM0IT5E	MN	Serotonin transporter (SERT)
DM0IT5E	MT	DTT
DM0IT5E	MA	Inhibitor
DM0IT5E	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DM0IT5E	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMEPB9L	DI	DMEPB9L
DMEPB9L	DN	4-(2-(3-fluorophenoxy)-4-methylphenyl)piperidine
DMEPB9L	MI	TTVBI8W
DMEPB9L	MN	Dopamine transporter (DAT)
DMEPB9L	MT	DTT
DMEPB9L	MA	Inhibitor
DMEPB9L	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMEPB9L	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMEPB9L	DI	DMEPB9L
DMEPB9L	DN	4-(2-(3-fluorophenoxy)-4-methylphenyl)piperidine
DMEPB9L	MI	TTAWNKZ
DMEPB9L	MN	Norepinephrine transporter (NET)
DMEPB9L	MT	DTT
DMEPB9L	MA	Inhibitor
DMEPB9L	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMEPB9L	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMEPB9L	DI	DMEPB9L
DMEPB9L	DN	4-(2-(3-fluorophenoxy)-4-methylphenyl)piperidine
DMEPB9L	MI	TT3ROYC
DMEPB9L	MN	Serotonin transporter (SERT)
DMEPB9L	MT	DTT
DMEPB9L	MA	Inhibitor
DMEPB9L	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMEPB9L	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMZMEOG	DI	DMZMEOG
DMZMEOG	DN	4-(2-(3-fluorophenoxy)phenyl)piperidine
DMZMEOG	MI	TTSQIFT
DMZMEOG	MN	5-HT 1A receptor (HTR1A)
DMZMEOG	MT	DTT
DMZMEOG	MA	Inhibitor
DMZMEOG	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMZMEOG	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMZMEOG	DI	DMZMEOG
DMZMEOG	DN	4-(2-(3-fluorophenoxy)phenyl)piperidine
DMZMEOG	MI	TTVBI8W
DMZMEOG	MN	Dopamine transporter (DAT)
DMZMEOG	MT	DTT
DMZMEOG	MA	Inhibitor
DMZMEOG	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMZMEOG	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMZMEOG	DI	DMZMEOG
DMZMEOG	DN	4-(2-(3-fluorophenoxy)phenyl)piperidine
DMZMEOG	MI	TTAWNKZ
DMZMEOG	MN	Norepinephrine transporter (NET)
DMZMEOG	MT	DTT
DMZMEOG	MA	Inhibitor
DMZMEOG	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMZMEOG	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMZMEOG	DI	DMZMEOG
DMZMEOG	DN	4-(2-(3-fluorophenoxy)phenyl)piperidine
DMZMEOG	MI	TT3ROYC
DMZMEOG	MN	Serotonin transporter (SERT)
DMZMEOG	MT	DTT
DMZMEOG	MA	Inhibitor
DMZMEOG	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMZMEOG	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMRDWUT	DI	DMRDWUT
DMRDWUT	DN	4-(2-(3-fluorophenyl)ethynyl)-2-methylthiazole
DMRDWUT	MI	TTHS256
DMRDWUT	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMRDWUT	MT	DTT
DMRDWUT	MA	Inhibitor
DMRDWUT	RN	Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100.
DMRDWUT	RU	https://pubmed.ncbi.nlm.nih.gov/16451073

DMP1LY4	DI	DMP1LY4
DMP1LY4	DN	4-(2-(3-tert-Butylphenylamino)ethyl)-1H-imidazole
DMP1LY4	MI	TT9JNIC
DMP1LY4	MN	Histamine H3 receptor (H3R)
DMP1LY4	MT	DTT
DMP1LY4	MA	Inhibitor
DMP1LY4	RN	Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active hi... J Med Chem. 2010 May 13;53(9):3840-4.
DMP1LY4	RU	https://pubmed.ncbi.nlm.nih.gov/20384344

DMN97TC	DI	DMN97TC
DMN97TC	DN	4-(2-(4-chlorobenzyloxy)-5-bromobenzyl)morpholine
DMN97TC	MI	TT2CEJG
DMN97TC	MN	C-C chemokine receptor type 5 (CCR5)
DMN97TC	MT	DTT
DMN97TC	MA	Inhibitor
DMN97TC	RN	CCR5 receptor antagonists: discovery and SAR study of guanylhydrazone derivatives. Bioorg Med Chem Lett. 2007 Jan 1;17(1):231-4.
DMN97TC	RU	https://pubmed.ncbi.nlm.nih.gov/17081751

DMM8CU2	DI	DMM8CU2
DMM8CU2	DN	4-(2-(4-Cyclohexylphenylamino)ethyl)-1H-imidazole
DMM8CU2	MI	TT9JNIC
DMM8CU2	MN	Histamine H3 receptor (H3R)
DMM8CU2	MT	DTT
DMM8CU2	MA	Inhibitor
DMM8CU2	RN	Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active hi... J Med Chem. 2010 May 13;53(9):3840-4.
DMM8CU2	RU	https://pubmed.ncbi.nlm.nih.gov/20384344

DM29QLG	DI	DM29QLG
DM29QLG	DN	4-(2-(4-fluorobenzyloxy)phenyl)piperidine
DM29QLG	MI	TTSQIFT
DM29QLG	MN	5-HT 1A receptor (HTR1A)
DM29QLG	MT	DTT
DM29QLG	MA	Inhibitor
DM29QLG	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DM29QLG	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DM29QLG	DI	DM29QLG
DM29QLG	DN	4-(2-(4-fluorobenzyloxy)phenyl)piperidine
DM29QLG	MI	TTVBI8W
DM29QLG	MN	Dopamine transporter (DAT)
DM29QLG	MT	DTT
DM29QLG	MA	Inhibitor
DM29QLG	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DM29QLG	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DM29QLG	DI	DM29QLG
DM29QLG	DN	4-(2-(4-fluorobenzyloxy)phenyl)piperidine
DM29QLG	MI	TTAWNKZ
DM29QLG	MN	Norepinephrine transporter (NET)
DM29QLG	MT	DTT
DM29QLG	MA	Inhibitor
DM29QLG	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DM29QLG	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DM29QLG	DI	DM29QLG
DM29QLG	DN	4-(2-(4-fluorobenzyloxy)phenyl)piperidine
DM29QLG	MI	TT3ROYC
DM29QLG	MN	Serotonin transporter (SERT)
DM29QLG	MT	DTT
DM29QLG	MA	Inhibitor
DM29QLG	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DM29QLG	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMJNB8C	DI	DMJNB8C
DMJNB8C	DN	4-(2-(4-fluorophenoxy)-4-methylphenyl)piperidine
DMJNB8C	MI	TTVBI8W
DMJNB8C	MN	Dopamine transporter (DAT)
DMJNB8C	MT	DTT
DMJNB8C	MA	Inhibitor
DMJNB8C	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMJNB8C	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMJNB8C	DI	DMJNB8C
DMJNB8C	DN	4-(2-(4-fluorophenoxy)-4-methylphenyl)piperidine
DMJNB8C	MI	TTAWNKZ
DMJNB8C	MN	Norepinephrine transporter (NET)
DMJNB8C	MT	DTT
DMJNB8C	MA	Inhibitor
DMJNB8C	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMJNB8C	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMJNB8C	DI	DMJNB8C
DMJNB8C	DN	4-(2-(4-fluorophenoxy)-4-methylphenyl)piperidine
DMJNB8C	MI	TT3ROYC
DMJNB8C	MN	Serotonin transporter (SERT)
DMJNB8C	MT	DTT
DMJNB8C	MA	Inhibitor
DMJNB8C	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMJNB8C	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMFQT9O	DI	DMFQT9O
DMFQT9O	DN	4-(2-(4-fluorophenoxy)phenyl)piperidine
DMFQT9O	MI	TTSQIFT
DMFQT9O	MN	5-HT 1A receptor (HTR1A)
DMFQT9O	MT	DTT
DMFQT9O	MA	Inhibitor
DMFQT9O	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMFQT9O	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMFQT9O	DI	DMFQT9O
DMFQT9O	DN	4-(2-(4-fluorophenoxy)phenyl)piperidine
DMFQT9O	MI	TTVBI8W
DMFQT9O	MN	Dopamine transporter (DAT)
DMFQT9O	MT	DTT
DMFQT9O	MA	Inhibitor
DMFQT9O	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMFQT9O	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMFQT9O	DI	DMFQT9O
DMFQT9O	DN	4-(2-(4-fluorophenoxy)phenyl)piperidine
DMFQT9O	MI	TTAWNKZ
DMFQT9O	MN	Norepinephrine transporter (NET)
DMFQT9O	MT	DTT
DMFQT9O	MA	Inhibitor
DMFQT9O	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMFQT9O	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMFQT9O	DI	DMFQT9O
DMFQT9O	DN	4-(2-(4-fluorophenoxy)phenyl)piperidine
DMFQT9O	MI	TT3ROYC
DMFQT9O	MN	Serotonin transporter (SERT)
DMFQT9O	MT	DTT
DMFQT9O	MA	Inhibitor
DMFQT9O	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMFQT9O	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMOX40J	DI	DMOX40J
DMOX40J	DN	4-(2-(4-fluorophenyl)ethynyl)-2-methylthiazole
DMOX40J	MI	TTHS256
DMOX40J	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMOX40J	MT	DTT
DMOX40J	MA	Inhibitor
DMOX40J	RN	Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100.
DMOX40J	RU	https://pubmed.ncbi.nlm.nih.gov/16451073

DMFCS8G	DI	DMFCS8G
DMFCS8G	DN	4-(2-(4-Methoxyphenylamino)ethyl)-1H-imidazole
DMFCS8G	MI	TT9JNIC
DMFCS8G	MN	Histamine H3 receptor (H3R)
DMFCS8G	MT	DTT
DMFCS8G	MA	Inhibitor
DMFCS8G	RN	Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active hi... J Med Chem. 2010 May 13;53(9):3840-4.
DMFCS8G	RU	https://pubmed.ncbi.nlm.nih.gov/20384344

DMYM72T	DI	DMYM72T
DMYM72T	DN	4-(2-(4-Methylphenylamino)ethyl)-1H-imidazole
DMYM72T	MI	TT9JNIC
DMYM72T	MN	Histamine H3 receptor (H3R)
DMYM72T	MT	DTT
DMYM72T	MA	Inhibitor
DMYM72T	RN	Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active hi... J Med Chem. 2010 May 13;53(9):3840-4.
DMYM72T	RU	https://pubmed.ncbi.nlm.nih.gov/20384344

DMK8ROX	DI	DMK8ROX
DMK8ROX	DN	4-(2-(4-tert-Butylphenylamino)ethyl)-1H-imidazole
DMK8ROX	MI	TT9JNIC
DMK8ROX	MN	Histamine H3 receptor (H3R)
DMK8ROX	MT	DTT
DMK8ROX	MA	Inhibitor
DMK8ROX	RN	Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active hi... J Med Chem. 2010 May 13;53(9):3840-4.
DMK8ROX	RU	https://pubmed.ncbi.nlm.nih.gov/20384344

DMUYPMO	DI	DMUYPMO
DMUYPMO	DN	4-(2-(aminomethyl)phenyl)-1-benzylpiperidin-4-ol
DMUYPMO	MI	TTNT7K8
DMUYPMO	MN	Nociceptin receptor (OPRL1)
DMUYPMO	MT	DTT
DMUYPMO	MA	Inhibitor
DMUYPMO	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
DMUYPMO	RU	https://pubmed.ncbi.nlm.nih.gov/17420123

DMM2NHZ	DI	DMM2NHZ
DMM2NHZ	DN	4-(2-(benzyloxy)-3-fluorophenyl)piperidine
DMM2NHZ	MI	TTSQIFT
DMM2NHZ	MN	5-HT 1A receptor (HTR1A)
DMM2NHZ	MT	DTT
DMM2NHZ	MA	Inhibitor
DMM2NHZ	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMM2NHZ	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMM2NHZ	DI	DMM2NHZ
DMM2NHZ	DN	4-(2-(benzyloxy)-3-fluorophenyl)piperidine
DMM2NHZ	MI	TTVBI8W
DMM2NHZ	MN	Dopamine transporter (DAT)
DMM2NHZ	MT	DTT
DMM2NHZ	MA	Inhibitor
DMM2NHZ	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMM2NHZ	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMM2NHZ	DI	DMM2NHZ
DMM2NHZ	DN	4-(2-(benzyloxy)-3-fluorophenyl)piperidine
DMM2NHZ	MI	TTAWNKZ
DMM2NHZ	MN	Norepinephrine transporter (NET)
DMM2NHZ	MT	DTT
DMM2NHZ	MA	Inhibitor
DMM2NHZ	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMM2NHZ	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMM2NHZ	DI	DMM2NHZ
DMM2NHZ	DN	4-(2-(benzyloxy)-3-fluorophenyl)piperidine
DMM2NHZ	MI	TT3ROYC
DMM2NHZ	MN	Serotonin transporter (SERT)
DMM2NHZ	MT	DTT
DMM2NHZ	MA	Inhibitor
DMM2NHZ	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMM2NHZ	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMF3S50	DI	DMF3S50
DMF3S50	DN	4-(2-(benzyloxy)-6-fluorophenyl)piperidine
DMF3S50	MI	TTSQIFT
DMF3S50	MN	5-HT 1A receptor (HTR1A)
DMF3S50	MT	DTT
DMF3S50	MA	Inhibitor
DMF3S50	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMF3S50	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMF3S50	DI	DMF3S50
DMF3S50	DN	4-(2-(benzyloxy)-6-fluorophenyl)piperidine
DMF3S50	MI	TTVBI8W
DMF3S50	MN	Dopamine transporter (DAT)
DMF3S50	MT	DTT
DMF3S50	MA	Inhibitor
DMF3S50	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMF3S50	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMF3S50	DI	DMF3S50
DMF3S50	DN	4-(2-(benzyloxy)-6-fluorophenyl)piperidine
DMF3S50	MI	TTAWNKZ
DMF3S50	MN	Norepinephrine transporter (NET)
DMF3S50	MT	DTT
DMF3S50	MA	Inhibitor
DMF3S50	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMF3S50	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMF3S50	DI	DMF3S50
DMF3S50	DN	4-(2-(benzyloxy)-6-fluorophenyl)piperidine
DMF3S50	MI	TT3ROYC
DMF3S50	MN	Serotonin transporter (SERT)
DMF3S50	MT	DTT
DMF3S50	MA	Inhibitor
DMF3S50	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMF3S50	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMOC7PY	DI	DMOC7PY
DMOC7PY	DN	4-(2-(benzyloxy)phenyl)piperidine
DMOC7PY	MI	TTSQIFT
DMOC7PY	MN	5-HT 1A receptor (HTR1A)
DMOC7PY	MT	DTT
DMOC7PY	MA	Inhibitor
DMOC7PY	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMOC7PY	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMOC7PY	DI	DMOC7PY
DMOC7PY	DN	4-(2-(benzyloxy)phenyl)piperidine
DMOC7PY	MI	TTVBI8W
DMOC7PY	MN	Dopamine transporter (DAT)
DMOC7PY	MT	DTT
DMOC7PY	MA	Inhibitor
DMOC7PY	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMOC7PY	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMOC7PY	DI	DMOC7PY
DMOC7PY	DN	4-(2-(benzyloxy)phenyl)piperidine
DMOC7PY	MI	TTAWNKZ
DMOC7PY	MN	Norepinephrine transporter (NET)
DMOC7PY	MT	DTT
DMOC7PY	MA	Inhibitor
DMOC7PY	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMOC7PY	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMOC7PY	DI	DMOC7PY
DMOC7PY	DN	4-(2-(benzyloxy)phenyl)piperidine
DMOC7PY	MI	TT3ROYC
DMOC7PY	MN	Serotonin transporter (SERT)
DMOC7PY	MT	DTT
DMOC7PY	MA	Inhibitor
DMOC7PY	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMOC7PY	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DM1MP96	DI	DM1MP96
DM1MP96	DN	4-(2-(Cyclohexylamino)ethyl)-1H-imidazole
DM1MP96	MI	TT9JNIC
DM1MP96	MN	Histamine H3 receptor (H3R)
DM1MP96	MT	DTT
DM1MP96	MA	Inhibitor
DM1MP96	RN	Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active hi... J Med Chem. 2010 May 13;53(9):3840-4.
DM1MP96	RU	https://pubmed.ncbi.nlm.nih.gov/20384344

DMRQ8T9	DI	DMRQ8T9
DMRQ8T9	DN	4-(2-(diethylamino)ethylamino)-1-naphthol
DMRQ8T9	MI	TTZJYKH
DMRQ8T9	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMRQ8T9	MT	DTT
DMRQ8T9	MA	Inhibitor
DMRQ8T9	RN	Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2010 Feb 11;53(3):1172-89.
DMRQ8T9	RU	https://pubmed.ncbi.nlm.nih.gov/20055453

DM0OFRQ	DI	DM0OFRQ
DM0OFRQ	DN	4-(2-(phenoxymethyl)phenyl)piperidine
DM0OFRQ	MI	TTVBI8W
DM0OFRQ	MN	Dopamine transporter (DAT)
DM0OFRQ	MT	DTT
DM0OFRQ	MA	Inhibitor
DM0OFRQ	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DM0OFRQ	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DM0OFRQ	DI	DM0OFRQ
DM0OFRQ	DN	4-(2-(phenoxymethyl)phenyl)piperidine
DM0OFRQ	MI	TTAWNKZ
DM0OFRQ	MN	Norepinephrine transporter (NET)
DM0OFRQ	MT	DTT
DM0OFRQ	MA	Inhibitor
DM0OFRQ	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DM0OFRQ	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DM0OFRQ	DI	DM0OFRQ
DM0OFRQ	DN	4-(2-(phenoxymethyl)phenyl)piperidine
DM0OFRQ	MI	TT3ROYC
DM0OFRQ	MN	Serotonin transporter (SERT)
DM0OFRQ	MT	DTT
DM0OFRQ	MA	Inhibitor
DM0OFRQ	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DM0OFRQ	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMX1HKU	DI	DMX1HKU
DMX1HKU	DN	4-(2-(Phenylamino)ethyl)-1H-imidazole
DMX1HKU	MI	TT9JNIC
DMX1HKU	MN	Histamine H3 receptor (H3R)
DMX1HKU	MT	DTT
DMX1HKU	MA	Inhibitor
DMX1HKU	RN	Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active hi... J Med Chem. 2010 May 13;53(9):3840-4.
DMX1HKU	RU	https://pubmed.ncbi.nlm.nih.gov/20384344

DMHWD2C	DI	DMHWD2C
DMHWD2C	DN	4-(2-(pyrrolidin-1-yl)ethyl)pyridine
DMHWD2C	MI	TT9JNIC
DMHWD2C	MN	Histamine H3 receptor (H3R)
DMHWD2C	MT	DTT
DMHWD2C	MA	Inhibitor
DMHWD2C	RN	In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9.
DMHWD2C	RU	https://pubmed.ncbi.nlm.nih.gov/18077160

DMWN1CM	DI	DMWN1CM
DMWN1CM	DN	4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine
DMWN1CM	MI	TTCJG29
DMWN1CM	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMWN1CM	MT	DTT
DMWN1CM	MA	Inhibitor
DMWN1CM	RN	Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-alpha: Hit to lead studies. Bioorg Med Chem Lett. 2010 Jan 15;20(2):636-9.
DMWN1CM	RU	https://pubmed.ncbi.nlm.nih.gov/19969455

DMAO6X9	DI	DMAO6X9
DMAO6X9	DN	4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine
DMAO6X9	MI	TTCJG29
DMAO6X9	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMAO6X9	MT	DTT
DMAO6X9	MA	Inhibitor
DMAO6X9	RN	Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-alpha: Hit to lead studies. Bioorg Med Chem Lett. 2010 Jan 15;20(2):636-9.
DMAO6X9	RU	https://pubmed.ncbi.nlm.nih.gov/19969455

DMIL45X	DI	DMIL45X
DMIL45X	DN	4-(2'-(trifluoromethoxy)biphenyl-3-yl)oxazole
DMIL45X	MI	TT4G2JS
DMIL45X	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DMIL45X	MT	DTT
DMIL45X	MA	Inhibitor
DMIL45X	RN	Substituted biaryl oxazoles, imidazoles, and thiazoles as sodium channel blockers. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5536-40.
DMIL45X	RU	https://pubmed.ncbi.nlm.nih.gov/20709552

DM3R2D1	DI	DM3R2D1
DM3R2D1	DN	4-(2'-(trifluoromethoxy)biphenyl-3-yl)thiazole
DM3R2D1	MI	TT4G2JS
DM3R2D1	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DM3R2D1	MT	DTT
DM3R2D1	MA	Inhibitor
DM3R2D1	RN	Substituted biaryl oxazoles, imidazoles, and thiazoles as sodium channel blockers. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5536-40.
DM3R2D1	RU	https://pubmed.ncbi.nlm.nih.gov/20709552

DMXC5S0	DI	DMXC5S0
DMXC5S0	DN	4-(2'-(trifluoromethyl)biphenyl-3-yl)oxazole
DMXC5S0	MI	TT4G2JS
DMXC5S0	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DMXC5S0	MT	DTT
DMXC5S0	MA	Inhibitor
DMXC5S0	RN	Substituted biaryl oxazoles, imidazoles, and thiazoles as sodium channel blockers. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5536-40.
DMXC5S0	RU	https://pubmed.ncbi.nlm.nih.gov/20709552

DMRZY0B	DI	DMRZY0B
DMRZY0B	DN	4-(2,2'-bithiophen-5-ylmethyleneamino)phenol
DMRZY0B	MI	TTHY57M
DMRZY0B	MN	Matrix metalloproteinase-13 (MMP-13)
DMRZY0B	MT	DTT
DMRZY0B	MA	Inhibitor
DMRZY0B	RN	High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg Med Chem. 2009 Feb 1;17(3):990-1005.
DMRZY0B	RU	https://pubmed.ncbi.nlm.nih.gov/18358729

DMI638K	DI	DMI638K
DMI638K	DN	4-(2,2-Diphenyl-vinyl)-pyridine
DMI638K	MI	TTSZLWK
DMI638K	MN	Aromatase (CYP19A1)
DMI638K	MT	DTT
DMI638K	MA	Inhibitor
DMI638K	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMI638K	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMGOHSF	DI	DMGOHSF
DMGOHSF	DN	4-(2,3-dichlorobenzylthio)-2-aminobutanoic acid
DMGOHSF	MI	TTFK1JQ
DMGOHSF	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMGOHSF	MT	DTT
DMGOHSF	MA	Inhibitor
DMGOHSF	RN	Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41.
DMGOHSF	RU	https://pubmed.ncbi.nlm.nih.gov/16380257

DMVIQ7F	DI	DMVIQ7F
DMVIQ7F	DN	4-(2,3-Dihydro-1H-phenalen-1-yl)-1H-imidazole
DMVIQ7F	MI	TTNGILX
DMVIQ7F	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMVIQ7F	MT	DTT
DMVIQ7F	MA	Inhibitor
DMVIQ7F	RN	Medetomidine analogs as alpha 2-adrenergic ligands. 2. Design, synthesis, and biological activity of conformationally restricted naphthalene deriva... J Med Chem. 1996 Jul 19;39(15):3001-13.
DMVIQ7F	RU	https://pubmed.ncbi.nlm.nih.gov/8709134

DMVIQ7F	DI	DMVIQ7F
DMVIQ7F	DN	4-(2,3-Dihydro-1H-phenalen-1-yl)-1H-imidazole
DMVIQ7F	MI	TTBRKXS
DMVIQ7F	MN	Adrenergic receptor alpha-1B (ADRA1B)
DMVIQ7F	MT	DTT
DMVIQ7F	MA	Inhibitor
DMVIQ7F	RN	Medetomidine analogs as alpha 2-adrenergic ligands. 2. Design, synthesis, and biological activity of conformationally restricted naphthalene deriva... J Med Chem. 1996 Jul 19;39(15):3001-13.
DMVIQ7F	RU	https://pubmed.ncbi.nlm.nih.gov/8709134

DMVIQ7F	DI	DMVIQ7F
DMVIQ7F	DN	4-(2,3-Dihydro-1H-phenalen-1-yl)-1H-imidazole
DMVIQ7F	MI	TT34BHT
DMVIQ7F	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMVIQ7F	MT	DTT
DMVIQ7F	MA	Inhibitor
DMVIQ7F	RN	Medetomidine analogs as alpha 2-adrenergic ligands. 2. Design, synthesis, and biological activity of conformationally restricted naphthalene deriva... J Med Chem. 1996 Jul 19;39(15):3001-13.
DMVIQ7F	RU	https://pubmed.ncbi.nlm.nih.gov/8709134

DM6PMFJ	DI	DM6PMFJ
DM6PMFJ	DN	4-(2,3-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline
DM6PMFJ	MI	TTI7421
DM6PMFJ	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM6PMFJ	MT	DTT
DM6PMFJ	MA	Inhibitor
DM6PMFJ	RN	A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
DM6PMFJ	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97101172

DMPKE6G	DI	DMPKE6G
DMPKE6G	DN	4-(2,4-dichloro-phenoxy)-2'-methyl-biphenyl-3-ol
DMPKE6G	MI	TTNX2CS
DMPKE6G	MN	Plasmodium Enoyl-ACP reductase (Malaria fabI)
DMPKE6G	MT	DTT
DMPKE6G	MA	Inhibitor
DMPKE6G	RN	X-ray structural analysis of Plasmodium falciparum enoyl acyl carrier protein reductase as a pathway toward the optimization of triclosan antimalar... J Biol Chem. 2007 Aug 31;282(35):25436-44.
DMPKE6G	RU	https://pubmed.ncbi.nlm.nih.gov/17567585

DMS7POY	DI	DMS7POY
DMS7POY	DN	4-(2,4-dichlorophenoxy)-3-hydroxybenzonitrile
DMS7POY	MI	TTNX2CS
DMS7POY	MN	Plasmodium Enoyl-ACP reductase (Malaria fabI)
DMS7POY	MT	DTT
DMS7POY	MA	Inhibitor
DMS7POY	RN	X-ray structural analysis of Plasmodium falciparum enoyl acyl carrier protein reductase as a pathway toward the optimization of triclosan antimalar... J Biol Chem. 2007 Aug 31;282(35):25436-44.
DMS7POY	RU	https://pubmed.ncbi.nlm.nih.gov/17567585

DMY6GWF	DI	DMY6GWF
DMY6GWF	DN	4-(2,4-dichlorophenoxy)-3'-methylbiphenyl-3-ol
DMY6GWF	MI	TTNX2CS
DMY6GWF	MN	Plasmodium Enoyl-ACP reductase (Malaria fabI)
DMY6GWF	MT	DTT
DMY6GWF	MA	Inhibitor
DMY6GWF	RN	Design and in silico screening of combinatorial library of antimalarial analogs of triclosan inhibiting Plasmodium falciparum enoyl-acyl carrier pr... Eur J Med Chem. 2009 Jul;44(7):3009-19.
DMY6GWF	RU	https://pubmed.ncbi.nlm.nih.gov/19217192

DMAK789	DI	DMAK789
DMAK789	DN	4-(2,4-dichloro-phenoxy)-4'-fluoro-biphenyl-3-ol
DMAK789	MI	TTNX2CS
DMAK789	MN	Plasmodium Enoyl-ACP reductase (Malaria fabI)
DMAK789	MT	DTT
DMAK789	MA	Inhibitor
DMAK789	RN	X-ray structural analysis of Plasmodium falciparum enoyl acyl carrier protein reductase as a pathway toward the optimization of triclosan antimalar... J Biol Chem. 2007 Aug 31;282(35):25436-44.
DMAK789	RU	https://pubmed.ncbi.nlm.nih.gov/17567585

DMRPVO3	DI	DMRPVO3
DMRPVO3	DN	4-(2,4-dichlorophenoxy)-4'-methylbiphenyl-3-ol
DMRPVO3	MI	TTNX2CS
DMRPVO3	MN	Plasmodium Enoyl-ACP reductase (Malaria fabI)
DMRPVO3	MT	DTT
DMRPVO3	MA	Inhibitor
DMRPVO3	RN	Design and in silico screening of combinatorial library of antimalarial analogs of triclosan inhibiting Plasmodium falciparum enoyl-acyl carrier pr... Eur J Med Chem. 2009 Jul;44(7):3009-19.
DMRPVO3	RU	https://pubmed.ncbi.nlm.nih.gov/19217192

DMB96SY	DI	DMB96SY
DMB96SY	DN	4-(2,4-dichloro-phenoxy)-biphenyl-3-ol
DMB96SY	MI	TTNX2CS
DMB96SY	MN	Plasmodium Enoyl-ACP reductase (Malaria fabI)
DMB96SY	MT	DTT
DMB96SY	MA	Inhibitor
DMB96SY	RN	X-ray structural analysis of Plasmodium falciparum enoyl acyl carrier protein reductase as a pathway toward the optimization of triclosan antimalar... J Biol Chem. 2007 Aug 31;282(35):25436-44.
DMB96SY	RU	https://pubmed.ncbi.nlm.nih.gov/17567585

DMCGOPQ	DI	DMCGOPQ
DMCGOPQ	DN	4-(2,4-dichlorophenyl)-1-phenylpyrrolidin-3-amine
DMCGOPQ	MI	TTDIGC1
DMCGOPQ	MN	Dipeptidyl peptidase 4 (DPP-4)
DMCGOPQ	MT	DTT
DMCGOPQ	MA	Inhibitor
DMCGOPQ	RN	Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibito... Bioorg Med Chem Lett. 2007 Apr 1;17(7):2005-12.
DMCGOPQ	RU	https://pubmed.ncbi.nlm.nih.gov/17276063

DMRMAOI	DI	DMRMAOI
DMRMAOI	DN	4-(2,4-dichlorophenyl)-1-tosylpyrrolidin-3-amine
DMRMAOI	MI	TTDIGC1
DMRMAOI	MN	Dipeptidyl peptidase 4 (DPP-4)
DMRMAOI	MT	DTT
DMRMAOI	MA	Inhibitor
DMRMAOI	RN	Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibito... Bioorg Med Chem Lett. 2007 Apr 1;17(7):2005-12.
DMRMAOI	RU	https://pubmed.ncbi.nlm.nih.gov/17276063

DMBLAI1	DI	DMBLAI1
DMBLAI1	DN	4-(2,4-diethyl-1H-pyrrol-3-yloxy)benzonitrile
DMBLAI1	MI	TTUV8G9
DMBLAI1	MN	Progesterone receptor (PGR)
DMBLAI1	MT	DTT
DMBLAI1	MA	Inhibitor
DMBLAI1	RN	Optimisation of a pyrazole series of progesterone antagonists; Part 1. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3384-6.
DMBLAI1	RU	https://pubmed.ncbi.nlm.nih.gov/20430618

DME8BLW	DI	DME8BLW
DME8BLW	DN	4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine
DME8BLW	MI	TT7HF4W
DME8BLW	MN	Cyclin-dependent kinase 2 (CDK2)
DME8BLW	MT	DTT
DME8BLW	MA	Inhibitor
DME8BLW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DME8BLW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM3D8OK	DI	DM3D8OK
DM3D8OK	DN	4-(2,5-DIAMINO-5-HYDROXY-PENTYL)-PHENOL
DM3D8OK	MI	TT6L509
DM3D8OK	MN	Coagulation factor IIa (F2)
DM3D8OK	MT	DTT
DM3D8OK	MA	Inhibitor
DM3D8OK	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM3D8OK	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMKVH90	DI	DMKVH90
DMKVH90	DN	4-(2,5-dichlorobenzylthio)-2-aminobutanoic acid
DMKVH90	MI	TTFK1JQ
DMKVH90	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMKVH90	MT	DTT
DMKVH90	MA	Inhibitor
DMKVH90	RN	Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41.
DMKVH90	RU	https://pubmed.ncbi.nlm.nih.gov/16380257

DMVYALJ	DI	DMVYALJ
DMVYALJ	DN	4-(2,5-Diphenyl-furan-3-yl)-morpholine
DMVYALJ	MI	TTZ97H5
DMVYALJ	MN	Phosphodiesterase 4A (PDE4A)
DMVYALJ	MT	DTT
DMVYALJ	MA	Inhibitor
DMVYALJ	RN	Substituted furans as inhibitors of the PDE4 enzyme. Bioorg Med Chem Lett. 1999 Feb 8;9(3):323-6.
DMVYALJ	RU	https://pubmed.ncbi.nlm.nih.gov/10091677

DMH3TBQ	DI	DMH3TBQ
DMH3TBQ	DN	4-(2,6-diamino-9H-purin-8-yl)-2,6-dimethoxyphenol
DMH3TBQ	MI	TT9SL3Q
DMH3TBQ	MN	Polypeptide deformylase (PDF)
DMH3TBQ	MT	DTT
DMH3TBQ	MA	Inhibitor
DMH3TBQ	RN	CoMFA analysis of tgDHFR and rlDHFR based on antifolates with 6-5 fused ring system using the all-orientation search (AOS) routine and a modified c... Bioorg Med Chem. 2010 Feb 15;18(4):1684-701.
DMH3TBQ	RU	https://pubmed.ncbi.nlm.nih.gov/20117005

DMPLG9Q	DI	DMPLG9Q
DMPLG9Q	DN	4-(2,6-dimethylphenylthio)-2-methoxybenzonitrile
DMPLG9Q	MI	TTKPW01
DMPLG9Q	MN	Androgen receptor messenger RNA (AR mRNA)
DMPLG9Q	MT	DTT
DMPLG9Q	MA	Inhibitor
DMPLG9Q	RN	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
DMPLG9Q	RU	https://pubmed.ncbi.nlm.nih.gov/19201190

DMH5CAQ	DI	DMH5CAQ
DMH5CAQ	DN	4-(2-amino-1,3-thiazol-4-yl)phenol
DMH5CAQ	MI	TTWHDVK
DMH5CAQ	MN	Fructose-1,6-bisphosphatase (FBP)
DMH5CAQ	MT	DTT
DMH5CAQ	MA	Inhibitor
DMH5CAQ	RN	A library of novel allosteric inhibitors against fructose 1,6-bisphosphatase. Bioorg Med Chem. 2009 Jun 1;17(11):3916-22.
DMH5CAQ	RU	https://pubmed.ncbi.nlm.nih.gov/19419876

DMH5CAQ	DI	DMH5CAQ
DMH5CAQ	DN	4-(2-amino-1,3-thiazol-4-yl)phenol
DMH5CAQ	MI	TTXZEAJ
DMH5CAQ	MN	Leukotriene A-4 hydrolase (LTA4H)
DMH5CAQ	MT	DTT
DMH5CAQ	MA	Inhibitor
DMH5CAQ	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMH5CAQ	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMWHDRI	DI	DMWHDRI
DMWHDRI	DN	4-(2-Aminoethyl) benzenesulfonyl fluoride
DMWHDRI	MI	DTCSGPB
DMWHDRI	MN	Multidrug resistance-associated protein 4 (ABCC4)
DMWHDRI	MT	DTP
DMWHDRI	MA	Substrate
DMWHDRI	RN	Fluo-cAMP is transported by multidrug resistance-associated protein isoform 4 in rat choroid plexus. J Neurochem. 2010 Oct;115(1):200-8.
DMWHDRI	RU	http://www.ncbi.nlm.nih.gov/pubmed/20649844

DMCS538	DI	DMCS538
DMCS538	DN	4-(2-aminoethyl)-1,2,5-oxadiazol-3-ol
DMCS538	MI	TT1MPAY
DMCS538	MN	GABA(A) receptor alpha-1 (GABRA1)
DMCS538	MT	DTT
DMCS538	MA	Inhibitor
DMCS538	RN	Hydroxy-1,2,5-oxadiazolyl moiety as bioisoster of the carboxy function. Synthesis, ionization constants, and pharmacological characterization of ga... J Med Chem. 2006 Jul 13;49(14):4442-6.
DMCS538	RU	https://pubmed.ncbi.nlm.nih.gov/16821803

DMCS538	DI	DMCS538
DMCS538	DN	4-(2-aminoethyl)-1,2,5-oxadiazol-3-ol
DMCS538	MI	TTZA1NY
DMCS538	MN	GABA(A) receptor beta-2 (GABRB2)
DMCS538	MT	DTT
DMCS538	MA	Inhibitor
DMCS538	RN	Hydroxy-1,2,5-oxadiazolyl moiety as bioisoster of the carboxy function. Synthesis, ionization constants, and pharmacological characterization of ga... J Med Chem. 2006 Jul 13;49(14):4442-6.
DMCS538	RU	https://pubmed.ncbi.nlm.nih.gov/16821803

DMCS538	DI	DMCS538
DMCS538	DN	4-(2-aminoethyl)-1,2,5-oxadiazol-3-ol
DMCS538	MI	TT06RH5
DMCS538	MN	GABA(A) receptor gamma-2 (GABRG2)
DMCS538	MT	DTT
DMCS538	MA	Inhibitor
DMCS538	RN	Hydroxy-1,2,5-oxadiazolyl moiety as bioisoster of the carboxy function. Synthesis, ionization constants, and pharmacological characterization of ga... J Med Chem. 2006 Jul 13;49(14):4442-6.
DMCS538	RU	https://pubmed.ncbi.nlm.nih.gov/16821803

DMCS538	DI	DMCS538
DMCS538	DN	4-(2-aminoethyl)-1,2,5-oxadiazol-3-ol
DMCS538	MI	TTNJYV2
DMCS538	MN	Gamma-aminobutyric acid receptor (GAR)
DMCS538	MT	DTT
DMCS538	MA	Inhibitor
DMCS538	RN	Hydroxy-1,2,5-oxadiazolyl moiety as bioisoster of the carboxy function. Synthesis, ionization constants, and pharmacological characterization of ga... J Med Chem. 2006 Jul 13;49(14):4442-6.
DMCS538	RU	https://pubmed.ncbi.nlm.nih.gov/16821803

DMZSN1Y	DI	DMZSN1Y
DMZSN1Y	DN	4-(2-aminoethyl)-2-cyclohexylphenol
DMZSN1Y	MI	TT8JRS7
DMZSN1Y	MN	Beta-secretase (BACE)
DMZSN1Y	MT	DTT
DMZSN1Y	MA	Inhibitor
DMZSN1Y	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMZSN1Y	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMF8D5S	DI	DMF8D5S
DMF8D5S	DN	4-(2-aminoethyl)-2-ethylphenol
DMF8D5S	MI	TT8JRS7
DMF8D5S	MN	Beta-secretase (BACE)
DMF8D5S	MT	DTT
DMF8D5S	MA	Inhibitor
DMF8D5S	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMF8D5S	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMEK6WX	DI	DMEK6WX
DMEK6WX	DN	4-(2-AMINOETHYL)BENZENESULFONAMIDE
DMEK6WX	MI	TTUNARX
DMEK6WX	MN	Carbonic anhydrase (CA)
DMEK6WX	MT	DTT
DMEK6WX	MA	Inhibitor
DMEK6WX	RN	Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides. Bioorg Med Chem Lett. 2005 Feb 15;15(4):971-6.
DMEK6WX	RU	https://pubmed.ncbi.nlm.nih.gov/15686895

DMEK6WX	DI	DMEK6WX
DMEK6WX	DN	4-(2-AMINOETHYL)BENZENESULFONAMIDE
DMEK6WX	MI	TTHQPL7
DMEK6WX	MN	Carbonic anhydrase I (CA-I)
DMEK6WX	MT	DTT
DMEK6WX	MA	Inhibitor
DMEK6WX	RN	Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-media... J Med Chem. 2005 Jul 28;48(15):4834-41.
DMEK6WX	RU	https://pubmed.ncbi.nlm.nih.gov/16033263

DMEK6WX	DI	DMEK6WX
DMEK6WX	DN	4-(2-AMINOETHYL)BENZENESULFONAMIDE
DMEK6WX	MI	TTANPDJ
DMEK6WX	MN	Carbonic anhydrase II (CA-II)
DMEK6WX	MT	DTT
DMEK6WX	MA	Inhibitor
DMEK6WX	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMEK6WX	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMEK6WX	DI	DMEK6WX
DMEK6WX	DN	4-(2-AMINOETHYL)BENZENESULFONAMIDE
DMEK6WX	MI	TTZHA0O
DMEK6WX	MN	Carbonic anhydrase IV (CA-IV)
DMEK6WX	MT	DTT
DMEK6WX	MA	Inhibitor
DMEK6WX	RN	Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1149-54.
DMEK6WX	RU	https://pubmed.ncbi.nlm.nih.gov/15686931

DMEK6WX	DI	DMEK6WX
DMEK6WX	DN	4-(2-AMINOETHYL)BENZENESULFONAMIDE
DMEK6WX	MI	TT2LVK8
DMEK6WX	MN	Carbonic anhydrase IX (CA-IX)
DMEK6WX	MT	DTT
DMEK6WX	MA	Inhibitor
DMEK6WX	RN	Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-media... J Med Chem. 2005 Jul 28;48(15):4834-41.
DMEK6WX	RU	https://pubmed.ncbi.nlm.nih.gov/16033263

DMEK6WX	DI	DMEK6WX
DMEK6WX	DN	4-(2-AMINOETHYL)BENZENESULFONAMIDE
DMEK6WX	MI	TTSYM0R
DMEK6WX	MN	Carbonic anhydrase XII (CA-XII)
DMEK6WX	MT	DTT
DMEK6WX	MA	Inhibitor
DMEK6WX	RN	Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglauc... Bioorg Med Chem Lett. 2005 Feb 15;15(4):963-9.
DMEK6WX	RU	https://pubmed.ncbi.nlm.nih.gov/15686894

DMEK6WX	DI	DMEK6WX
DMEK6WX	DN	4-(2-AMINOETHYL)BENZENESULFONAMIDE
DMEK6WX	MI	TTEYTKG
DMEK6WX	MN	Carbonic anhydrase XIV (CA-XIV)
DMEK6WX	MT	DTT
DMEK6WX	MA	Inhibitor
DMEK6WX	RN	Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33.
DMEK6WX	RU	https://pubmed.ncbi.nlm.nih.gov/16039848

DMWG706	DI	DMWG706
DMWG706	DN	4-(2-aminopyrimidin-4-ylamino)benzenesulfonamide
DMWG706	MI	TTUNARX
DMWG706	MN	Carbonic anhydrase (CA)
DMWG706	MT	DTT
DMWG706	MA	Inhibitor
DMWG706	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DMWG706	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DMWG706	DI	DMWG706
DMWG706	DN	4-(2-aminopyrimidin-4-ylamino)benzenesulfonamide
DMWG706	MI	TTHQPL7
DMWG706	MN	Carbonic anhydrase I (CA-I)
DMWG706	MT	DTT
DMWG706	MA	Inhibitor
DMWG706	RN	Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorg Med Chem. 2009 Jul 15;17(14):5054-8.
DMWG706	RU	https://pubmed.ncbi.nlm.nih.gov/19520577

DMWG706	DI	DMWG706
DMWG706	DN	4-(2-aminopyrimidin-4-ylamino)benzenesulfonamide
DMWG706	MI	TTANPDJ
DMWG706	MN	Carbonic anhydrase II (CA-II)
DMWG706	MT	DTT
DMWG706	MA	Inhibitor
DMWG706	RN	Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, ... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6649-54.
DMWG706	RU	https://pubmed.ncbi.nlm.nih.gov/19846301

DMWG706	DI	DMWG706
DMWG706	DN	4-(2-aminopyrimidin-4-ylamino)benzenesulfonamide
DMWG706	MI	TT2LVK8
DMWG706	MN	Carbonic anhydrase IX (CA-IX)
DMWG706	MT	DTT
DMWG706	MA	Inhibitor
DMWG706	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DMWG706	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DMWG706	DI	DMWG706
DMWG706	DN	4-(2-aminopyrimidin-4-ylamino)benzenesulfonamide
DMWG706	MI	TTCFSPE
DMWG706	MN	Carbonic anhydrase VI (CA-VI)
DMWG706	MT	DTT
DMWG706	MA	Inhibitor
DMWG706	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DMWG706	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DMAZ0LV	DI	DMAZ0LV
DMAZ0LV	DN	4-(2-benzenesulfonylphenyl)piperazine
DMAZ0LV	MI	TTJS8PY
DMAZ0LV	MN	5-HT 6 receptor (HTR6)
DMAZ0LV	MT	DTT
DMAZ0LV	MA	Inhibitor
DMAZ0LV	RN	Binding of sulfonyl-containing arylalkylamines at human 5-HT6 serotonin receptors. J Med Chem. 2006 Aug 24;49(17):5217-25.
DMAZ0LV	RU	https://pubmed.ncbi.nlm.nih.gov/16913710

DMYVD2E	DI	DMYVD2E
DMYVD2E	DN	4-(2-Benzylamino-ethoxy)-1,3-dihydro-indol-2-one
DMYVD2E	MI	TTEX248
DMYVD2E	MN	Dopamine D2 receptor (D2R)
DMYVD2E	MT	DTT
DMYVD2E	MA	Inhibitor
DMYVD2E	RN	New generation dopaminergic agents. 7. Heterocyclic bioisosteres that exploit the 3-OH-phenoxyethylamine D2 template. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2593-8.
DMYVD2E	RU	https://pubmed.ncbi.nlm.nih.gov/10498215

DMYVD2E	DI	DMYVD2E
DMYVD2E	DN	4-(2-Benzylamino-ethoxy)-1,3-dihydro-indol-2-one
DMYVD2E	MI	TT4C8EA
DMYVD2E	MN	Dopamine D3 receptor (D3R)
DMYVD2E	MT	DTT
DMYVD2E	MA	Inhibitor
DMYVD2E	RN	New generation dopaminergic agents. 7. Heterocyclic bioisosteres that exploit the 3-OH-phenoxyethylamine D2 template. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2593-8.
DMYVD2E	RU	https://pubmed.ncbi.nlm.nih.gov/10498215

DMYVD2E	DI	DMYVD2E
DMYVD2E	DN	4-(2-Benzylamino-ethoxy)-1,3-dihydro-indol-2-one
DMYVD2E	MI	TTE0A2F
DMYVD2E	MN	Dopamine D4 receptor (D4R)
DMYVD2E	MT	DTT
DMYVD2E	MA	Inhibitor
DMYVD2E	RN	New generation dopaminergic agents. 7. Heterocyclic bioisosteres that exploit the 3-OH-phenoxyethylamine D2 template. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2593-8.
DMYVD2E	RU	https://pubmed.ncbi.nlm.nih.gov/10498215

DMZ9TSR	DI	DMZ9TSR
DMZ9TSR	DN	4-(2-bromobenzylthio)-2-aminobutanoic acid
DMZ9TSR	MI	TTFK1JQ
DMZ9TSR	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMZ9TSR	MT	DTT
DMZ9TSR	MA	Inhibitor
DMZ9TSR	RN	Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41.
DMZ9TSR	RU	https://pubmed.ncbi.nlm.nih.gov/16380257

DM2MSEF	DI	DM2MSEF
DM2MSEF	DN	4'-(2-butylbenzofuran-3-yl)biphenyl-4-ol
DM2MSEF	MI	TTELIN2
DM2MSEF	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DM2MSEF	MT	DTT
DM2MSEF	MA	Inhibitor
DM2MSEF	RN	Synthesis, activity and molecular modeling of a new series of chromones as low molecular weight protein tyrosine phosphatase inhibitors. Bioorg Med Chem. 2009 Apr 1;17(7):2658-72.
DM2MSEF	RU	https://pubmed.ncbi.nlm.nih.gov/19297174

DM8HLEP	DI	DM8HLEP
DM8HLEP	DN	4-(2-Butyl-benzoimidazol-1-ylmethyl)-phenol
DM8HLEP	MI	TT8DBY3
DM8HLEP	MN	Angiotensin II receptor type-1 (AGTR1)
DM8HLEP	MT	DTT
DM8HLEP	MA	Inhibitor
DM8HLEP	RN	Discovery and development of aryl-fused imidazole-based angiotensin II antagonists, Bioorg. Med. Chem. Lett. 4(1):213-218 (1994).
DM8HLEP	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01811495

DM5L4WP	DI	DM5L4WP
DM5L4WP	DN	4-(2-carboxy-5-mercaptopentyl)benzoic acid
DM5L4WP	MI	TT9G4N0
DM5L4WP	MN	Glutamate carboxypeptidase II (GCPII)
DM5L4WP	MT	DTT
DM5L4WP	MA	Inhibitor
DM5L4WP	RN	Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1' side chain. J Med Chem. 2006 May 18;49(10):2876-85.
DM5L4WP	RU	https://pubmed.ncbi.nlm.nih.gov/16686531

DM82D9N	DI	DM82D9N
DM82D9N	DN	4-(2-cyanobenzylthio)-2-aminobutanoic acid
DM82D9N	MI	TTFK1JQ
DM82D9N	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DM82D9N	MT	DTT
DM82D9N	MA	Inhibitor
DM82D9N	RN	Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41.
DM82D9N	RU	https://pubmed.ncbi.nlm.nih.gov/16380257

DMFJW2E	DI	DMFJW2E
DMFJW2E	DN	4-(2-Ethyl-4-m-tolyl-thiazol-5-yl)-pyridine
DMFJW2E	MI	TTQBR95
DMFJW2E	MN	Stress-activated protein kinase 2a (p38 alpha)
DMFJW2E	MT	DTT
DMFJW2E	MA	Inhibitor
DMFJW2E	RN	Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (T... J Med Chem. 2005 Sep 22;48(19):5966-79.
DMFJW2E	RU	https://pubmed.ncbi.nlm.nih.gov/16162000

DMQUAP2	DI	DMQUAP2
DMQUAP2	DN	4-(2-fluoro-6-(2-fluorophenoxy)phenyl)piperidine
DMQUAP2	MI	TTSQIFT
DMQUAP2	MN	5-HT 1A receptor (HTR1A)
DMQUAP2	MT	DTT
DMQUAP2	MA	Inhibitor
DMQUAP2	RN	Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7.
DMQUAP2	RU	https://pubmed.ncbi.nlm.nih.gov/20031410

DMQUAP2	DI	DMQUAP2
DMQUAP2	DN	4-(2-fluoro-6-(2-fluorophenoxy)phenyl)piperidine
DMQUAP2	MI	TTVBI8W
DMQUAP2	MN	Dopamine transporter (DAT)
DMQUAP2	MT	DTT
DMQUAP2	MA	Inhibitor
DMQUAP2	RN	Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7.
DMQUAP2	RU	https://pubmed.ncbi.nlm.nih.gov/20031410

DMQUAP2	DI	DMQUAP2
DMQUAP2	DN	4-(2-fluoro-6-(2-fluorophenoxy)phenyl)piperidine
DMQUAP2	MI	TTAWNKZ
DMQUAP2	MN	Norepinephrine transporter (NET)
DMQUAP2	MT	DTT
DMQUAP2	MA	Inhibitor
DMQUAP2	RN	Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7.
DMQUAP2	RU	https://pubmed.ncbi.nlm.nih.gov/20031410

DMQUAP2	DI	DMQUAP2
DMQUAP2	DN	4-(2-fluoro-6-(2-fluorophenoxy)phenyl)piperidine
DMQUAP2	MI	TT3ROYC
DMQUAP2	MN	Serotonin transporter (SERT)
DMQUAP2	MT	DTT
DMQUAP2	MA	Inhibitor
DMQUAP2	RN	Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7.
DMQUAP2	RU	https://pubmed.ncbi.nlm.nih.gov/20031410

DMUBHRF	DI	DMUBHRF
DMUBHRF	DN	4-(2-fluoro-6-(3-fluorophenoxy)phenyl)piperidine
DMUBHRF	MI	TTSQIFT
DMUBHRF	MN	5-HT 1A receptor (HTR1A)
DMUBHRF	MT	DTT
DMUBHRF	MA	Inhibitor
DMUBHRF	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMUBHRF	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMUBHRF	DI	DMUBHRF
DMUBHRF	DN	4-(2-fluoro-6-(3-fluorophenoxy)phenyl)piperidine
DMUBHRF	MI	TTVBI8W
DMUBHRF	MN	Dopamine transporter (DAT)
DMUBHRF	MT	DTT
DMUBHRF	MA	Inhibitor
DMUBHRF	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMUBHRF	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMUBHRF	DI	DMUBHRF
DMUBHRF	DN	4-(2-fluoro-6-(3-fluorophenoxy)phenyl)piperidine
DMUBHRF	MI	TTAWNKZ
DMUBHRF	MN	Norepinephrine transporter (NET)
DMUBHRF	MT	DTT
DMUBHRF	MA	Inhibitor
DMUBHRF	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMUBHRF	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMUBHRF	DI	DMUBHRF
DMUBHRF	DN	4-(2-fluoro-6-(3-fluorophenoxy)phenyl)piperidine
DMUBHRF	MI	TT3ROYC
DMUBHRF	MN	Serotonin transporter (SERT)
DMUBHRF	MT	DTT
DMUBHRF	MA	Inhibitor
DMUBHRF	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMUBHRF	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMJ2GW0	DI	DMJ2GW0
DMJ2GW0	DN	4-(2-fluoro-6-(4-fluorophenoxy)phenyl)piperidine
DMJ2GW0	MI	TTSQIFT
DMJ2GW0	MN	5-HT 1A receptor (HTR1A)
DMJ2GW0	MT	DTT
DMJ2GW0	MA	Inhibitor
DMJ2GW0	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMJ2GW0	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMJ2GW0	DI	DMJ2GW0
DMJ2GW0	DN	4-(2-fluoro-6-(4-fluorophenoxy)phenyl)piperidine
DMJ2GW0	MI	TTVBI8W
DMJ2GW0	MN	Dopamine transporter (DAT)
DMJ2GW0	MT	DTT
DMJ2GW0	MA	Inhibitor
DMJ2GW0	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMJ2GW0	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMJ2GW0	DI	DMJ2GW0
DMJ2GW0	DN	4-(2-fluoro-6-(4-fluorophenoxy)phenyl)piperidine
DMJ2GW0	MI	TTAWNKZ
DMJ2GW0	MN	Norepinephrine transporter (NET)
DMJ2GW0	MT	DTT
DMJ2GW0	MA	Inhibitor
DMJ2GW0	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMJ2GW0	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMJ2GW0	DI	DMJ2GW0
DMJ2GW0	DN	4-(2-fluoro-6-(4-fluorophenoxy)phenyl)piperidine
DMJ2GW0	MI	TT3ROYC
DMJ2GW0	MN	Serotonin transporter (SERT)
DMJ2GW0	MT	DTT
DMJ2GW0	MA	Inhibitor
DMJ2GW0	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMJ2GW0	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMXIGWC	DI	DMXIGWC
DMXIGWC	DN	4-(2-fluoro-6-phenoxyphenyl)piperidine
DMXIGWC	MI	TTSQIFT
DMXIGWC	MN	5-HT 1A receptor (HTR1A)
DMXIGWC	MT	DTT
DMXIGWC	MA	Inhibitor
DMXIGWC	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMXIGWC	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMXIGWC	DI	DMXIGWC
DMXIGWC	DN	4-(2-fluoro-6-phenoxyphenyl)piperidine
DMXIGWC	MI	TTVBI8W
DMXIGWC	MN	Dopamine transporter (DAT)
DMXIGWC	MT	DTT
DMXIGWC	MA	Inhibitor
DMXIGWC	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMXIGWC	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMXIGWC	DI	DMXIGWC
DMXIGWC	DN	4-(2-fluoro-6-phenoxyphenyl)piperidine
DMXIGWC	MI	TTAWNKZ
DMXIGWC	MN	Norepinephrine transporter (NET)
DMXIGWC	MT	DTT
DMXIGWC	MA	Inhibitor
DMXIGWC	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMXIGWC	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMXIGWC	DI	DMXIGWC
DMXIGWC	DN	4-(2-fluoro-6-phenoxyphenyl)piperidine
DMXIGWC	MI	TT3ROYC
DMXIGWC	MN	Serotonin transporter (SERT)
DMXIGWC	MT	DTT
DMXIGWC	MA	Inhibitor
DMXIGWC	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMXIGWC	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMCWZF6	DI	DMCWZF6
DMCWZF6	DN	4-(2-fluorophenylethynyl)-2-methylthiazole
DMCWZF6	MI	TTHS256
DMCWZF6	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMCWZF6	MT	DTT
DMCWZF6	MA	Inhibitor
DMCWZF6	RN	Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100.
DMCWZF6	RU	https://pubmed.ncbi.nlm.nih.gov/16451073

DM17QG8	DI	DM17QG8
DM17QG8	DN	4-(2-Hydroxyethoxy)-1-naphthol
DM17QG8	MI	TTZJYKH
DM17QG8	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DM17QG8	MT	DTT
DM17QG8	MA	Inhibitor
DM17QG8	RN	Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2010 Feb 11;53(3):1172-89.
DM17QG8	RU	https://pubmed.ncbi.nlm.nih.gov/20055453

DM1C5U6	DI	DM1C5U6
DM1C5U6	DN	4-(2-Hydroxy-ethyl)-benzenesulfonamide
DM1C5U6	MI	TTUNARX
DM1C5U6	MN	Carbonic anhydrase (CA)
DM1C5U6	MT	DTT
DM1C5U6	MA	Inhibitor
DM1C5U6	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DM1C5U6	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DM1C5U6	DI	DM1C5U6
DM1C5U6	DN	4-(2-Hydroxy-ethyl)-benzenesulfonamide
DM1C5U6	MI	TTANPDJ
DM1C5U6	MN	Carbonic anhydrase II (CA-II)
DM1C5U6	MT	DTT
DM1C5U6	MA	Inhibitor
DM1C5U6	RN	Mutation of Phe91 to Asn in human carbonic anhydrase I unexpectedly enhanced both catalytic activity and affinity for sulfonamide inhibitors. Bioorg Med Chem. 2010 Aug 1;18(15):5498-503.
DM1C5U6	RU	https://pubmed.ncbi.nlm.nih.gov/20624682

DM1C5U6	DI	DM1C5U6
DM1C5U6	DN	4-(2-Hydroxy-ethyl)-benzenesulfonamide
DM1C5U6	MI	TT2LVK8
DM1C5U6	MN	Carbonic anhydrase IX (CA-IX)
DM1C5U6	MT	DTT
DM1C5U6	MA	Inhibitor
DM1C5U6	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DM1C5U6	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DM1C5U6	DI	DM1C5U6
DM1C5U6	DN	4-(2-Hydroxy-ethyl)-benzenesulfonamide
DM1C5U6	MI	TTCFSPE
DM1C5U6	MN	Carbonic anhydrase VI (CA-VI)
DM1C5U6	MT	DTT
DM1C5U6	MA	Inhibitor
DM1C5U6	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DM1C5U6	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DM1C5U6	DI	DM1C5U6
DM1C5U6	DN	4-(2-Hydroxy-ethyl)-benzenesulfonamide
DM1C5U6	MI	TTSYM0R
DM1C5U6	MN	Carbonic anhydrase XII (CA-XII)
DM1C5U6	MT	DTT
DM1C5U6	MA	Inhibitor
DM1C5U6	RN	Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglauc... Bioorg Med Chem Lett. 2005 Feb 15;15(4):963-9.
DM1C5U6	RU	https://pubmed.ncbi.nlm.nih.gov/15686894

DM1C5U6	DI	DM1C5U6
DM1C5U6	DN	4-(2-Hydroxy-ethyl)-benzenesulfonamide
DM1C5U6	MI	TTEYTKG
DM1C5U6	MN	Carbonic anhydrase XIV (CA-XIV)
DM1C5U6	MT	DTT
DM1C5U6	MA	Inhibitor
DM1C5U6	RN	Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33.
DM1C5U6	RU	https://pubmed.ncbi.nlm.nih.gov/16039848

DMB6SNE	DI	DMB6SNE
DMB6SNE	DN	4-(2-Imidazol-1-yl-ethoxy)-benzamide
DMB6SNE	MI	TTIQUX7
DMB6SNE	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMB6SNE	MT	DTT
DMB6SNE	MA	Inhibitor
DMB6SNE	RN	Selective thromboxane synthetase inhibitors. 1. 1-[(Aryloxy)alkyl]-1H-imidazoles. J Med Chem. 1985 Oct;28(10):1427-32.
DMB6SNE	RU	https://pubmed.ncbi.nlm.nih.gov/3930740

DMNSKXR	DI	DMNSKXR
DMNSKXR	DN	4-(2-methoxybenzylthio)-2-aminobutanoic acid
DMNSKXR	MI	TTFK1JQ
DMNSKXR	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMNSKXR	MT	DTT
DMNSKXR	MA	Inhibitor
DMNSKXR	RN	Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41.
DMNSKXR	RU	https://pubmed.ncbi.nlm.nih.gov/16380257

DM9WQOJ	DI	DM9WQOJ
DM9WQOJ	DN	4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine
DM9WQOJ	MI	TT78R5H
DM9WQOJ	MN	Heat shock protein 90 alpha (HSP90A)
DM9WQOJ	MT	DTT
DM9WQOJ	MA	Inhibitor
DM9WQOJ	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM9WQOJ	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMFVYHI	DI	DMFVYHI
DMFVYHI	DN	4-(2-methoxyphenylethynyl)-2-methylthiazole
DMFVYHI	MI	TTHS256
DMFVYHI	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMFVYHI	MT	DTT
DMFVYHI	MA	Inhibitor
DMFVYHI	RN	Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100.
DMFVYHI	RU	https://pubmed.ncbi.nlm.nih.gov/16451073

DM6DSNI	DI	DM6DSNI
DM6DSNI	DN	4'-(2-methyl-1-(pyridin-4-yl)propyl)biphenyl-3-ol
DM6DSNI	MI	TTRA5BZ
DM6DSNI	MN	Steroid 17-alpha-monooxygenase (S17AH)
DM6DSNI	MT	DTT
DM6DSNI	MA	Inhibitor
DM6DSNI	RN	Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors. J Med Chem. 2010 Jul 8;53(13):5049-53.
DM6DSNI	RU	https://pubmed.ncbi.nlm.nih.gov/20550118

DME6DHX	DI	DME6DHX
DME6DHX	DN	4-(2-Methyl-8-quinolinoxy)-3-pyridinesulfonamide
DME6DHX	MI	TTHQPL7
DME6DHX	MN	Carbonic anhydrase I (CA-I)
DME6DHX	MT	DTT
DME6DHX	MA	Inhibitor
DME6DHX	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DME6DHX	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DME6DHX	DI	DME6DHX
DME6DHX	DN	4-(2-Methyl-8-quinolinoxy)-3-pyridinesulfonamide
DME6DHX	MI	TTANPDJ
DME6DHX	MN	Carbonic anhydrase II (CA-II)
DME6DHX	MT	DTT
DME6DHX	MA	Inhibitor
DME6DHX	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DME6DHX	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DME6DHX	DI	DME6DHX
DME6DHX	DN	4-(2-Methyl-8-quinolinoxy)-3-pyridinesulfonamide
DME6DHX	MI	TT2LVK8
DME6DHX	MN	Carbonic anhydrase IX (CA-IX)
DME6DHX	MT	DTT
DME6DHX	MA	Inhibitor
DME6DHX	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DME6DHX	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DME6DHX	DI	DME6DHX
DME6DHX	DN	4-(2-Methyl-8-quinolinoxy)-3-pyridinesulfonamide
DME6DHX	MI	TTSYM0R
DME6DHX	MN	Carbonic anhydrase XII (CA-XII)
DME6DHX	MT	DTT
DME6DHX	MA	Inhibitor
DME6DHX	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DME6DHX	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DME6DHX	DI	DME6DHX
DME6DHX	DN	4-(2-Methyl-8-quinolinoxy)-3-pyridinesulfonamide
DME6DHX	MI	TTEYTKG
DME6DHX	MN	Carbonic anhydrase XIV (CA-XIV)
DME6DHX	MT	DTT
DME6DHX	MA	Inhibitor
DME6DHX	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DME6DHX	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMEAV9Q	DI	DMEAV9Q
DMEAV9Q	DN	4-(2-Methyl-thiazol-4-ylethynyl)-pyridine
DMEAV9Q	MI	TTHS256
DMEAV9Q	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMEAV9Q	MT	DTT
DMEAV9Q	MA	Inhibitor
DMEAV9Q	RN	5-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-2,3'-bipyridine: a highly potent, orally active metabotropic glutamate subtype 5 (mGlu5) receptor antagonist... Bioorg Med Chem Lett. 2004 Aug 2;14(15):3993-6.
DMEAV9Q	RU	https://pubmed.ncbi.nlm.nih.gov/15225713

DMC1KEG	DI	DMC1KEG
DMC1KEG	DN	4-(2-nitrobenzylthio)-2-aminobutanoic acid
DMC1KEG	MI	TTFK1JQ
DMC1KEG	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMC1KEG	MT	DTT
DMC1KEG	MA	Inhibitor
DMC1KEG	RN	Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41.
DMC1KEG	RU	https://pubmed.ncbi.nlm.nih.gov/16380257

DMCHTI0	DI	DMCHTI0
DMCHTI0	DN	4-(2-nitroprop-1-enyl)benzene-1,2-diol
DMCHTI0	MI	TTGKNB4
DMCHTI0	MN	Epidermal growth factor receptor (EGFR)
DMCHTI0	MT	DTT
DMCHTI0	MA	Inhibitor
DMCHTI0	RN	Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J Nat Prod. 1992 Nov;55(11):1529-60.
DMCHTI0	RU	https://pubmed.ncbi.nlm.nih.gov/1479375

DM62ZRE	DI	DM62ZRE
DM62ZRE	DN	4-(2-nitrovinyl)benzene-1,2-diol
DM62ZRE	MI	TTGKNB4
DM62ZRE	MN	Epidermal growth factor receptor (EGFR)
DM62ZRE	MT	DTT
DM62ZRE	MA	Inhibitor
DM62ZRE	RN	Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J Nat Prod. 1992 Nov;55(11):1529-60.
DM62ZRE	RU	https://pubmed.ncbi.nlm.nih.gov/1479375

DMPTVR2	DI	DMPTVR2
DMPTVR2	DN	4-(2-nitrovinyl)phenol
DMPTVR2	MI	TTGKNB4
DMPTVR2	MN	Epidermal growth factor receptor (EGFR)
DMPTVR2	MT	DTT
DMPTVR2	MA	Inhibitor
DMPTVR2	RN	Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J Nat Prod. 1992 Nov;55(11):1529-60.
DMPTVR2	RU	https://pubmed.ncbi.nlm.nih.gov/1479375

DMWIALU	DI	DMWIALU
DMWIALU	DN	4-(2-oxo-2H-chromene-3-carboxamido)benzoic acid
DMWIALU	MI	TT3WG5C
DMWIALU	MN	Monoamine oxidase type A (MAO-A)
DMWIALU	MT	DTT
DMWIALU	MA	Inhibitor
DMWIALU	RN	Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins. J Med Chem. 2009 Apr 9;52(7):1935-42.
DMWIALU	RU	https://pubmed.ncbi.nlm.nih.gov/19267475

DMWIALU	DI	DMWIALU
DMWIALU	DN	4-(2-oxo-2H-chromene-3-carboxamido)benzoic acid
DMWIALU	MI	TTGP7BY
DMWIALU	MN	Monoamine oxidase type B (MAO-B)
DMWIALU	MT	DTT
DMWIALU	MA	Inhibitor
DMWIALU	RN	Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins. J Med Chem. 2009 Apr 9;52(7):1935-42.
DMWIALU	RU	https://pubmed.ncbi.nlm.nih.gov/19267475

DMFPNQ9	DI	DMFPNQ9
DMFPNQ9	DN	4-(2-Oxo-2-phenyl-acetyl)-benzoic acid
DMFPNQ9	MI	TTMF541
DMFPNQ9	MN	Liver carboxylesterase (CES1)
DMFPNQ9	MT	DTT
DMFPNQ9	MA	Inhibitor
DMFPNQ9	RN	Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15.
DMFPNQ9	RU	https://pubmed.ncbi.nlm.nih.gov/15828829

DMBMJC5	DI	DMBMJC5
DMBMJC5	DN	4-(2-oxohexadecanamido)butanoic acid
DMBMJC5	MI	TTT1JVS
DMBMJC5	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DMBMJC5	MT	DTT
DMBMJC5	MA	Inhibitor
DMBMJC5	RN	Discovery of Ecopladib, an indole inhibitor of cytosolic phospholipase A2alpha. J Med Chem. 2007 Mar 22;50(6):1380-400.
DMBMJC5	RU	https://pubmed.ncbi.nlm.nih.gov/17305324

DMB5IFA	DI	DMB5IFA
DMB5IFA	DN	4-(2-phenoxyphenyl)piperidine
DMB5IFA	MI	TTSQIFT
DMB5IFA	MN	5-HT 1A receptor (HTR1A)
DMB5IFA	MT	DTT
DMB5IFA	MA	Inhibitor
DMB5IFA	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMB5IFA	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMB5IFA	DI	DMB5IFA
DMB5IFA	DN	4-(2-phenoxyphenyl)piperidine
DMB5IFA	MI	TTVBI8W
DMB5IFA	MN	Dopamine transporter (DAT)
DMB5IFA	MT	DTT
DMB5IFA	MA	Inhibitor
DMB5IFA	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMB5IFA	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMB5IFA	DI	DMB5IFA
DMB5IFA	DN	4-(2-phenoxyphenyl)piperidine
DMB5IFA	MI	TTAWNKZ
DMB5IFA	MN	Norepinephrine transporter (NET)
DMB5IFA	MT	DTT
DMB5IFA	MA	Inhibitor
DMB5IFA	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMB5IFA	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMB5IFA	DI	DMB5IFA
DMB5IFA	DN	4-(2-phenoxyphenyl)piperidine
DMB5IFA	MI	TT3ROYC
DMB5IFA	MN	Serotonin transporter (SERT)
DMB5IFA	MT	DTT
DMB5IFA	MA	Inhibitor
DMB5IFA	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DMB5IFA	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMFQZOI	DI	DMFQZOI
DMFQZOI	DN	4-(2-phenyl-1H-benzo[d]imidazol-1-yl)phenol
DMFQZOI	MI	TTZAYWL
DMFQZOI	MN	Estrogen receptor (ESR)
DMFQZOI	MT	DTT
DMFQZOI	MA	Inhibitor
DMFQZOI	RN	Estrogen receptor beta selective ligands: discovery and SAR of novel heterocyclic ligands. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5562-6.
DMFQZOI	RU	https://pubmed.ncbi.nlm.nih.gov/16219463

DMFQZOI	DI	DMFQZOI
DMFQZOI	DN	4-(2-phenyl-1H-benzo[d]imidazol-1-yl)phenol
DMFQZOI	MI	TTOM3J0
DMFQZOI	MN	Estrogen receptor beta (ESR2)
DMFQZOI	MT	DTT
DMFQZOI	MA	Inhibitor
DMFQZOI	RN	Estrogen receptor beta selective ligands: discovery and SAR of novel heterocyclic ligands. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5562-6.
DMFQZOI	RU	https://pubmed.ncbi.nlm.nih.gov/16219463

DMCPSE9	DI	DMCPSE9
DMCPSE9	DN	4-(2-phenyl-1H-indol-3-yl)phenol
DMCPSE9	MI	TTZAYWL
DMCPSE9	MN	Estrogen receptor (ESR)
DMCPSE9	MT	DTT
DMCPSE9	MA	Inhibitor
DMCPSE9	RN	Estrogen receptor beta selective ligands: discovery and SAR of novel heterocyclic ligands. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5562-6.
DMCPSE9	RU	https://pubmed.ncbi.nlm.nih.gov/16219463

DMCPSE9	DI	DMCPSE9
DMCPSE9	DN	4-(2-phenyl-1H-indol-3-yl)phenol
DMCPSE9	MI	TTOM3J0
DMCPSE9	MN	Estrogen receptor beta (ESR2)
DMCPSE9	MT	DTT
DMCPSE9	MA	Inhibitor
DMCPSE9	RN	Estrogen receptor beta selective ligands: discovery and SAR of novel heterocyclic ligands. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5562-6.
DMCPSE9	RU	https://pubmed.ncbi.nlm.nih.gov/16219463

DMZ62L3	DI	DMZ62L3
DMZ62L3	DN	4-(2-Phenylacetamido)-3-bromobenzenesulfonamide
DMZ62L3	MI	TTUNARX
DMZ62L3	MN	Carbonic anhydrase (CA)
DMZ62L3	MT	DTT
DMZ62L3	MA	Inhibitor
DMZ62L3	RN	Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9.
DMZ62L3	RU	https://pubmed.ncbi.nlm.nih.gov/19539481

DMZ62L3	DI	DMZ62L3
DMZ62L3	DN	4-(2-Phenylacetamido)-3-bromobenzenesulfonamide
DMZ62L3	MI	TTHQPL7
DMZ62L3	MN	Carbonic anhydrase I (CA-I)
DMZ62L3	MT	DTT
DMZ62L3	MA	Inhibitor
DMZ62L3	RN	Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9.
DMZ62L3	RU	https://pubmed.ncbi.nlm.nih.gov/19539481

DMZ62L3	DI	DMZ62L3
DMZ62L3	DN	4-(2-Phenylacetamido)-3-bromobenzenesulfonamide
DMZ62L3	MI	TTANPDJ
DMZ62L3	MN	Carbonic anhydrase II (CA-II)
DMZ62L3	MT	DTT
DMZ62L3	MA	Inhibitor
DMZ62L3	RN	Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9.
DMZ62L3	RU	https://pubmed.ncbi.nlm.nih.gov/19539481

DM9GOTA	DI	DM9GOTA
DM9GOTA	DN	4-(2-Phenylacetamido)-3-chlorobenzenesulfonamide
DM9GOTA	MI	TTUNARX
DM9GOTA	MN	Carbonic anhydrase (CA)
DM9GOTA	MT	DTT
DM9GOTA	MA	Inhibitor
DM9GOTA	RN	Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9.
DM9GOTA	RU	https://pubmed.ncbi.nlm.nih.gov/19539481

DM9GOTA	DI	DM9GOTA
DM9GOTA	DN	4-(2-Phenylacetamido)-3-chlorobenzenesulfonamide
DM9GOTA	MI	TTHQPL7
DM9GOTA	MN	Carbonic anhydrase I (CA-I)
DM9GOTA	MT	DTT
DM9GOTA	MA	Inhibitor
DM9GOTA	RN	Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9.
DM9GOTA	RU	https://pubmed.ncbi.nlm.nih.gov/19539481

DM9GOTA	DI	DM9GOTA
DM9GOTA	DN	4-(2-Phenylacetamido)-3-chlorobenzenesulfonamide
DM9GOTA	MI	TTANPDJ
DM9GOTA	MN	Carbonic anhydrase II (CA-II)
DM9GOTA	MT	DTT
DM9GOTA	MA	Inhibitor
DM9GOTA	RN	Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9.
DM9GOTA	RU	https://pubmed.ncbi.nlm.nih.gov/19539481

DMCOD4N	DI	DMCOD4N
DMCOD4N	DN	4-(2-Phenylacetamido)-3-fluorobenzenesulfonamide
DMCOD4N	MI	TTUNARX
DMCOD4N	MN	Carbonic anhydrase (CA)
DMCOD4N	MT	DTT
DMCOD4N	MA	Inhibitor
DMCOD4N	RN	Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9.
DMCOD4N	RU	https://pubmed.ncbi.nlm.nih.gov/19539481

DMCOD4N	DI	DMCOD4N
DMCOD4N	DN	4-(2-Phenylacetamido)-3-fluorobenzenesulfonamide
DMCOD4N	MI	TTHQPL7
DMCOD4N	MN	Carbonic anhydrase I (CA-I)
DMCOD4N	MT	DTT
DMCOD4N	MA	Inhibitor
DMCOD4N	RN	Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9.
DMCOD4N	RU	https://pubmed.ncbi.nlm.nih.gov/19539481

DMCOD4N	DI	DMCOD4N
DMCOD4N	DN	4-(2-Phenylacetamido)-3-fluorobenzenesulfonamide
DMCOD4N	MI	TTANPDJ
DMCOD4N	MN	Carbonic anhydrase II (CA-II)
DMCOD4N	MT	DTT
DMCOD4N	MA	Inhibitor
DMCOD4N	RN	Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9.
DMCOD4N	RU	https://pubmed.ncbi.nlm.nih.gov/19539481

DMFYR6H	DI	DMFYR6H
DMFYR6H	DN	4-(2-Phenylacetamido)benzenesulfonamide
DMFYR6H	MI	TTUNARX
DMFYR6H	MN	Carbonic anhydrase (CA)
DMFYR6H	MT	DTT
DMFYR6H	MA	Inhibitor
DMFYR6H	RN	Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9.
DMFYR6H	RU	https://pubmed.ncbi.nlm.nih.gov/19539481

DMFYR6H	DI	DMFYR6H
DMFYR6H	DN	4-(2-Phenylacetamido)benzenesulfonamide
DMFYR6H	MI	TTHQPL7
DMFYR6H	MN	Carbonic anhydrase I (CA-I)
DMFYR6H	MT	DTT
DMFYR6H	MA	Inhibitor
DMFYR6H	RN	Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9.
DMFYR6H	RU	https://pubmed.ncbi.nlm.nih.gov/19539481

DMFYR6H	DI	DMFYR6H
DMFYR6H	DN	4-(2-Phenylacetamido)benzenesulfonamide
DMFYR6H	MI	TTANPDJ
DMFYR6H	MN	Carbonic anhydrase II (CA-II)
DMFYR6H	MT	DTT
DMFYR6H	MA	Inhibitor
DMFYR6H	RN	Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9.
DMFYR6H	RU	https://pubmed.ncbi.nlm.nih.gov/19539481

DM1JL03	DI	DM1JL03
DM1JL03	DN	4-(2-Phenylacetamidoethyl)benzenesulfonamide
DM1JL03	MI	TTUNARX
DM1JL03	MN	Carbonic anhydrase (CA)
DM1JL03	MT	DTT
DM1JL03	MA	Inhibitor
DM1JL03	RN	Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9.
DM1JL03	RU	https://pubmed.ncbi.nlm.nih.gov/19539481

DM1JL03	DI	DM1JL03
DM1JL03	DN	4-(2-Phenylacetamidoethyl)benzenesulfonamide
DM1JL03	MI	TTHQPL7
DM1JL03	MN	Carbonic anhydrase I (CA-I)
DM1JL03	MT	DTT
DM1JL03	MA	Inhibitor
DM1JL03	RN	Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9.
DM1JL03	RU	https://pubmed.ncbi.nlm.nih.gov/19539481

DM1JL03	DI	DM1JL03
DM1JL03	DN	4-(2-Phenylacetamidoethyl)benzenesulfonamide
DM1JL03	MI	TTANPDJ
DM1JL03	MN	Carbonic anhydrase II (CA-II)
DM1JL03	MT	DTT
DM1JL03	MA	Inhibitor
DM1JL03	RN	Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9.
DM1JL03	RU	https://pubmed.ncbi.nlm.nih.gov/19539481

DMDYHXE	DI	DMDYHXE
DMDYHXE	DN	4-(2-Phenylacetamidomethyl)benzenesulfonamide
DMDYHXE	MI	TTUNARX
DMDYHXE	MN	Carbonic anhydrase (CA)
DMDYHXE	MT	DTT
DMDYHXE	MA	Inhibitor
DMDYHXE	RN	Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9.
DMDYHXE	RU	https://pubmed.ncbi.nlm.nih.gov/19539481

DMDYHXE	DI	DMDYHXE
DMDYHXE	DN	4-(2-Phenylacetamidomethyl)benzenesulfonamide
DMDYHXE	MI	TTHQPL7
DMDYHXE	MN	Carbonic anhydrase I (CA-I)
DMDYHXE	MT	DTT
DMDYHXE	MA	Inhibitor
DMDYHXE	RN	Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9.
DMDYHXE	RU	https://pubmed.ncbi.nlm.nih.gov/19539481

DMDYHXE	DI	DMDYHXE
DMDYHXE	DN	4-(2-Phenylacetamidomethyl)benzenesulfonamide
DMDYHXE	MI	TTANPDJ
DMDYHXE	MN	Carbonic anhydrase II (CA-II)
DMDYHXE	MT	DTT
DMDYHXE	MA	Inhibitor
DMDYHXE	RN	Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9.
DMDYHXE	RU	https://pubmed.ncbi.nlm.nih.gov/19539481

DMT9RAC	DI	DMT9RAC
DMT9RAC	DN	4-(2-Propynylthio)pyridine-3-sulfonamide
DMT9RAC	MI	TTHQPL7
DMT9RAC	MN	Carbonic anhydrase I (CA-I)
DMT9RAC	MT	DTT
DMT9RAC	MA	Inhibitor
DMT9RAC	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMT9RAC	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMT9RAC	DI	DMT9RAC
DMT9RAC	DN	4-(2-Propynylthio)pyridine-3-sulfonamide
DMT9RAC	MI	TTANPDJ
DMT9RAC	MN	Carbonic anhydrase II (CA-II)
DMT9RAC	MT	DTT
DMT9RAC	MA	Inhibitor
DMT9RAC	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMT9RAC	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMT9RAC	DI	DMT9RAC
DMT9RAC	DN	4-(2-Propynylthio)pyridine-3-sulfonamide
DMT9RAC	MI	TT2LVK8
DMT9RAC	MN	Carbonic anhydrase IX (CA-IX)
DMT9RAC	MT	DTT
DMT9RAC	MA	Inhibitor
DMT9RAC	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMT9RAC	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMT9RAC	DI	DMT9RAC
DMT9RAC	DN	4-(2-Propynylthio)pyridine-3-sulfonamide
DMT9RAC	MI	TTSYM0R
DMT9RAC	MN	Carbonic anhydrase XII (CA-XII)
DMT9RAC	MT	DTT
DMT9RAC	MA	Inhibitor
DMT9RAC	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMT9RAC	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMT9RAC	DI	DMT9RAC
DMT9RAC	DN	4-(2-Propynylthio)pyridine-3-sulfonamide
DMT9RAC	MI	TTEYTKG
DMT9RAC	MN	Carbonic anhydrase XIV (CA-XIV)
DMT9RAC	MT	DTT
DMT9RAC	MA	Inhibitor
DMT9RAC	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMT9RAC	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DM9LKMP	DI	DM9LKMP
DM9LKMP	DN	4-(2-Pyridin-2-ylacetamido)benzenesulfonamide
DM9LKMP	MI	TTUNARX
DM9LKMP	MN	Carbonic anhydrase (CA)
DM9LKMP	MT	DTT
DM9LKMP	MA	Inhibitor
DM9LKMP	RN	Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9.
DM9LKMP	RU	https://pubmed.ncbi.nlm.nih.gov/19539481

DM9LKMP	DI	DM9LKMP
DM9LKMP	DN	4-(2-Pyridin-2-ylacetamido)benzenesulfonamide
DM9LKMP	MI	TTHQPL7
DM9LKMP	MN	Carbonic anhydrase I (CA-I)
DM9LKMP	MT	DTT
DM9LKMP	MA	Inhibitor
DM9LKMP	RN	Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9.
DM9LKMP	RU	https://pubmed.ncbi.nlm.nih.gov/19539481

DM9LKMP	DI	DM9LKMP
DM9LKMP	DN	4-(2-Pyridin-2-ylacetamido)benzenesulfonamide
DM9LKMP	MI	TTANPDJ
DM9LKMP	MN	Carbonic anhydrase II (CA-II)
DM9LKMP	MT	DTT
DM9LKMP	MA	Inhibitor
DM9LKMP	RN	Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9.
DM9LKMP	RU	https://pubmed.ncbi.nlm.nih.gov/19539481

DMD6AYQ	DI	DMD6AYQ
DMD6AYQ	DN	4-(2-Pyridin-4-ylacetamido)benzenesulfonamide
DMD6AYQ	MI	TTUNARX
DMD6AYQ	MN	Carbonic anhydrase (CA)
DMD6AYQ	MT	DTT
DMD6AYQ	MA	Inhibitor
DMD6AYQ	RN	Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9.
DMD6AYQ	RU	https://pubmed.ncbi.nlm.nih.gov/19539481

DMD6AYQ	DI	DMD6AYQ
DMD6AYQ	DN	4-(2-Pyridin-4-ylacetamido)benzenesulfonamide
DMD6AYQ	MI	TTHQPL7
DMD6AYQ	MN	Carbonic anhydrase I (CA-I)
DMD6AYQ	MT	DTT
DMD6AYQ	MA	Inhibitor
DMD6AYQ	RN	Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9.
DMD6AYQ	RU	https://pubmed.ncbi.nlm.nih.gov/19539481

DMD6AYQ	DI	DMD6AYQ
DMD6AYQ	DN	4-(2-Pyridin-4-ylacetamido)benzenesulfonamide
DMD6AYQ	MI	TTANPDJ
DMD6AYQ	MN	Carbonic anhydrase II (CA-II)
DMD6AYQ	MT	DTT
DMD6AYQ	MA	Inhibitor
DMD6AYQ	RN	Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9.
DMD6AYQ	RU	https://pubmed.ncbi.nlm.nih.gov/19539481

DMOSDAN	DI	DMOSDAN
DMOSDAN	DN	4-(2-pyrrolidin-1-yl-pentanoyl)benzonitrile
DMOSDAN	MI	TTVBI8W
DMOSDAN	MN	Dopamine transporter (DAT)
DMOSDAN	MT	DTT
DMOSDAN	MA	Inhibitor
DMOSDAN	RN	1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32.
DMOSDAN	RU	https://pubmed.ncbi.nlm.nih.gov/16480278

DMX681M	DI	DMX681M
DMX681M	DN	4-(2-Thienyl)-1-(4-Methylbenzyl)-1h-Imidazole
DMX681M	MI	TTVTX4N
DMX681M	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DMX681M	MT	DTT
DMX681M	MA	Inhibitor
DMX681M	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMX681M	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMX681M	DI	DMX681M
DMX681M	DN	4-(2-Thienyl)-1-(4-Methylbenzyl)-1h-Imidazole
DMX681M	MI	TTNX2CS
DMX681M	MN	Plasmodium Enoyl-ACP reductase (Malaria fabI)
DMX681M	MT	DTT
DMX681M	MA	Inhibitor
DMX681M	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMX681M	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM4YWQN	DI	DM4YWQN
DM4YWQN	DN	4-(2-thienyl)benzene-1,2-diamine
DM4YWQN	MI	TTQ6VDM
DM4YWQN	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DM4YWQN	MT	DTT
DM4YWQN	MA	Inhibitor
DM4YWQN	RN	Parallel medicinal chemistry approaches to selective HDAC1/HDAC2 inhibitor (SHI-1:2) optimization. Bioorg Med Chem Lett. 2009 Feb 15;19(4):1168-72.
DM4YWQN	RU	https://pubmed.ncbi.nlm.nih.gov/19138845

DMR3T2D	DI	DMR3T2D
DMR3T2D	DN	4-(3-(4-hydroxyphenyl)-1H-indol-2-yl)phenol
DMR3T2D	MI	TTZAYWL
DMR3T2D	MN	Estrogen receptor (ESR)
DMR3T2D	MT	DTT
DMR3T2D	MA	Inhibitor
DMR3T2D	RN	Estrogen receptor beta selective ligands: discovery and SAR of novel heterocyclic ligands. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5562-6.
DMR3T2D	RU	https://pubmed.ncbi.nlm.nih.gov/16219463

DMR3T2D	DI	DMR3T2D
DMR3T2D	DN	4-(3-(4-hydroxyphenyl)-1H-indol-2-yl)phenol
DMR3T2D	MI	TTOM3J0
DMR3T2D	MN	Estrogen receptor beta (ESR2)
DMR3T2D	MT	DTT
DMR3T2D	MA	Inhibitor
DMR3T2D	RN	Estrogen receptor beta selective ligands: discovery and SAR of novel heterocyclic ligands. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5562-6.
DMR3T2D	RU	https://pubmed.ncbi.nlm.nih.gov/16219463

DMX5V9T	DI	DMX5V9T
DMX5V9T	DN	4-(3-(Dimethylamino)propanoyl)-N-hexylbenzamide
DMX5V9T	MI	TTGER3L
DMX5V9T	MN	Thyroid hormone receptor beta (THRB)
DMX5V9T	MT	DTT
DMX5V9T	MA	Inhibitor
DMX5V9T	RN	Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors. J Med Chem. 2009 Jul 9;52(13):3892-901.
DMX5V9T	RU	https://pubmed.ncbi.nlm.nih.gov/19469546

DMNUWK2	DI	DMNUWK2
DMNUWK2	DN	4-(3,4,5-Trimethoxyphenethyl)aniline
DMNUWK2	MI	TTSZLWK
DMNUWK2	MN	Aromatase (CYP19A1)
DMNUWK2	MT	DTT
DMNUWK2	MA	Inhibitor
DMNUWK2	RN	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
DMNUWK2	RU	https://pubmed.ncbi.nlm.nih.gov/20558073

DMBEA23	DI	DMBEA23
DMBEA23	DN	4-(3,4-dichlorobenzylthio)-2-aminobutanoic acid
DMBEA23	MI	TTFK1JQ
DMBEA23	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMBEA23	MT	DTT
DMBEA23	MA	Inhibitor
DMBEA23	RN	Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41.
DMBEA23	RU	https://pubmed.ncbi.nlm.nih.gov/16380257

DMIZXYM	DI	DMIZXYM
DMIZXYM	DN	4-(3,4-Diethoxy-benzylamino)-benzamidine
DMIZXYM	MI	TT2WR1T
DMIZXYM	MN	Cationic trypsinogen (PRSS1)
DMIZXYM	MT	DTT
DMIZXYM	MA	Inhibitor
DMIZXYM	RN	Design of selective phenylglycine amide tissue factor/factor VIIa inhibitors. Bioorg Med Chem Lett. 2005 Feb 1;15(3):817-22.
DMIZXYM	RU	https://pubmed.ncbi.nlm.nih.gov/15664864

DMIZXYM	DI	DMIZXYM
DMIZXYM	DN	4-(3,4-Diethoxy-benzylamino)-benzamidine
DMIZXYM	MI	TT6L509
DMIZXYM	MN	Coagulation factor IIa (F2)
DMIZXYM	MT	DTT
DMIZXYM	MA	Inhibitor
DMIZXYM	RN	Design of selective phenylglycine amide tissue factor/factor VIIa inhibitors. Bioorg Med Chem Lett. 2005 Feb 1;15(3):817-22.
DMIZXYM	RU	https://pubmed.ncbi.nlm.nih.gov/15664864

DMIZXYM	DI	DMIZXYM
DMIZXYM	DN	4-(3,4-Diethoxy-benzylamino)-benzamidine
DMIZXYM	MI	TTF0EGX
DMIZXYM	MN	Coagulation factor VII (F7)
DMIZXYM	MT	DTT
DMIZXYM	MA	Inhibitor
DMIZXYM	RN	Design of selective phenylglycine amide tissue factor/factor VIIa inhibitors. Bioorg Med Chem Lett. 2005 Feb 1;15(3):817-22.
DMIZXYM	RU	https://pubmed.ncbi.nlm.nih.gov/15664864

DMCOJIL	DI	DMCOJIL
DMCOJIL	DN	4-(3,4-Dihydro-1H-isoquinolin-2-yl)-quinoline
DMCOJIL	MI	TTNGILX
DMCOJIL	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMCOJIL	MT	DTT
DMCOJIL	MA	Inhibitor
DMCOJIL	RN	4-(3,4-dihydro-1H-isoquinolin-2yl)-pyridines and 4-(3,4-dihydro-1H-isoquinolin-2-yl)-quinolines as potent NR1/2B subtype selective NMDA receptor an... Bioorg Med Chem Lett. 2003 May 19;13(10):1759-62.
DMCOJIL	RU	https://pubmed.ncbi.nlm.nih.gov/12729659

DMCOJIL	DI	DMCOJIL
DMCOJIL	DN	4-(3,4-Dihydro-1H-isoquinolin-2-yl)-quinoline
DMCOJIL	MI	TTBRKXS
DMCOJIL	MN	Adrenergic receptor alpha-1B (ADRA1B)
DMCOJIL	MT	DTT
DMCOJIL	MA	Inhibitor
DMCOJIL	RN	4-(3,4-dihydro-1H-isoquinolin-2yl)-pyridines and 4-(3,4-dihydro-1H-isoquinolin-2-yl)-quinolines as potent NR1/2B subtype selective NMDA receptor an... Bioorg Med Chem Lett. 2003 May 19;13(10):1759-62.
DMCOJIL	RU	https://pubmed.ncbi.nlm.nih.gov/12729659

DMCOJIL	DI	DMCOJIL
DMCOJIL	DN	4-(3,4-Dihydro-1H-isoquinolin-2-yl)-quinoline
DMCOJIL	MI	TT34BHT
DMCOJIL	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMCOJIL	MT	DTT
DMCOJIL	MA	Inhibitor
DMCOJIL	RN	4-(3,4-dihydro-1H-isoquinolin-2yl)-pyridines and 4-(3,4-dihydro-1H-isoquinolin-2-yl)-quinolines as potent NR1/2B subtype selective NMDA receptor an... Bioorg Med Chem Lett. 2003 May 19;13(10):1759-62.
DMCOJIL	RU	https://pubmed.ncbi.nlm.nih.gov/12729659

DMCOJIL	DI	DMCOJIL
DMCOJIL	DN	4-(3,4-Dihydro-1H-isoquinolin-2-yl)-quinoline
DMCOJIL	MI	TTLD29N
DMCOJIL	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMCOJIL	MT	DTT
DMCOJIL	MA	Inhibitor
DMCOJIL	RN	4-(3,4-dihydro-1H-isoquinolin-2yl)-pyridines and 4-(3,4-dihydro-1H-isoquinolin-2-yl)-quinolines as potent NR1/2B subtype selective NMDA receptor an... Bioorg Med Chem Lett. 2003 May 19;13(10):1759-62.
DMCOJIL	RU	https://pubmed.ncbi.nlm.nih.gov/12729659

DMCOJIL	DI	DMCOJIL
DMCOJIL	DN	4-(3,4-Dihydro-1H-isoquinolin-2-yl)-quinoline
DMCOJIL	MI	TTN9D8E
DMCOJIL	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMCOJIL	MT	DTT
DMCOJIL	MA	Inhibitor
DMCOJIL	RN	4-(3,4-dihydro-1H-isoquinolin-2yl)-pyridines and 4-(3,4-dihydro-1H-isoquinolin-2-yl)-quinolines as potent NR1/2B subtype selective NMDA receptor an... Bioorg Med Chem Lett. 2003 May 19;13(10):1759-62.
DMCOJIL	RU	https://pubmed.ncbi.nlm.nih.gov/12729659

DMBI7MS	DI	DMBI7MS
DMBI7MS	DN	4-(3,4-Dimethoxyphenethyl)aniline
DMBI7MS	MI	TTSZLWK
DMBI7MS	MN	Aromatase (CYP19A1)
DMBI7MS	MT	DTT
DMBI7MS	MA	Inhibitor
DMBI7MS	RN	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
DMBI7MS	RU	https://pubmed.ncbi.nlm.nih.gov/20558073

DMW1H6C	DI	DMW1H6C
DMW1H6C	DN	4-(3,4-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline
DMW1H6C	MI	TT8FYO9
DMW1H6C	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMW1H6C	MT	DTT
DMW1H6C	MA	Inhibitor
DMW1H6C	RN	A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
DMW1H6C	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97101172

DMW1H6C	DI	DMW1H6C
DMW1H6C	DN	4-(3,4-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline
DMW1H6C	MI	TTI7421
DMW1H6C	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMW1H6C	MT	DTT
DMW1H6C	MA	Inhibitor
DMW1H6C	RN	A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
DMW1H6C	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97101172

DM5ZTXO	DI	DM5ZTXO
DM5ZTXO	DN	4-(3,4-dimethylbenzylthio)-2-aminobutanoic acid
DM5ZTXO	MI	TTFK1JQ
DM5ZTXO	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DM5ZTXO	MT	DTT
DM5ZTXO	MA	Inhibitor
DM5ZTXO	RN	Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41.
DM5ZTXO	RU	https://pubmed.ncbi.nlm.nih.gov/16380257

DMM3F9K	DI	DMM3F9K
DMM3F9K	DN	4-(3,5-dichlorobenzylthio)-2-aminobutanoic acid
DMM3F9K	MI	TTFK1JQ
DMM3F9K	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMM3F9K	MT	DTT
DMM3F9K	MA	Inhibitor
DMM3F9K	RN	Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41.
DMM3F9K	RU	https://pubmed.ncbi.nlm.nih.gov/16380257

DM48Z5Y	DI	DM48Z5Y
DM48Z5Y	DN	4-(3,5-difluorophenylethynyl)-2-methylthiazole
DM48Z5Y	MI	TTHS256
DM48Z5Y	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM48Z5Y	MT	DTT
DM48Z5Y	MA	Inhibitor
DM48Z5Y	RN	Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100.
DM48Z5Y	RU	https://pubmed.ncbi.nlm.nih.gov/16451073

DM4FC9O	DI	DM4FC9O
DM4FC9O	DN	4-(3,5-Dimethoxyphenethyl)benzenamine
DM4FC9O	MI	TTSZLWK
DM4FC9O	MN	Aromatase (CYP19A1)
DM4FC9O	MT	DTT
DM4FC9O	MA	Inhibitor
DM4FC9O	RN	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
DM4FC9O	RU	https://pubmed.ncbi.nlm.nih.gov/20558073

DM5279R	DI	DM5279R
DM5279R	DN	4-(3,5-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline
DM5279R	MI	TTI7421
DM5279R	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM5279R	MT	DTT
DM5279R	MA	Inhibitor
DM5279R	RN	A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
DM5279R	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97101172

DM9MIQB	DI	DM9MIQB
DM9MIQB	DN	4-(3,5-dimethylbenzylthio)-2-aminobutanoic acid
DM9MIQB	MI	TTFK1JQ
DM9MIQB	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DM9MIQB	MT	DTT
DM9MIQB	MA	Inhibitor
DM9MIQB	RN	Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41.
DM9MIQB	RU	https://pubmed.ncbi.nlm.nih.gov/16380257

DMKUAEY	DI	DMKUAEY
DMKUAEY	DN	4-(3-Adamantan-1-yl-ureido)-benzoic acid
DMKUAEY	MI	TT7WVHI
DMKUAEY	MN	Soluble epoxide hydrolase (EPHX2)
DMKUAEY	MT	DTT
DMKUAEY	MA	Inhibitor
DMKUAEY	RN	Salicylate-urea-based soluble epoxide hydrolase inhibitors with high metabolic and chemical stabilities. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1784-9.
DMKUAEY	RU	https://pubmed.ncbi.nlm.nih.gov/19216074

DMLVZ6O	DI	DMLVZ6O
DMLVZ6O	DN	4-(3-benzenesulfonamidophenyl)piperazine
DMLVZ6O	MI	TTJS8PY
DMLVZ6O	MN	5-HT 6 receptor (HTR6)
DMLVZ6O	MT	DTT
DMLVZ6O	MA	Inhibitor
DMLVZ6O	RN	Binding of sulfonyl-containing arylalkylamines at human 5-HT6 serotonin receptors. J Med Chem. 2006 Aug 24;49(17):5217-25.
DMLVZ6O	RU	https://pubmed.ncbi.nlm.nih.gov/16913710

DMG4X13	DI	DMG4X13
DMG4X13	DN	4-(3-benzenesulfonylphenyl)piperazine
DMG4X13	MI	TTJS8PY
DMG4X13	MN	5-HT 6 receptor (HTR6)
DMG4X13	MT	DTT
DMG4X13	MA	Inhibitor
DMG4X13	RN	Binding of sulfonyl-containing arylalkylamines at human 5-HT6 serotonin receptors. J Med Chem. 2006 Aug 24;49(17):5217-25.
DMG4X13	RU	https://pubmed.ncbi.nlm.nih.gov/16913710

DMT0EK8	DI	DMT0EK8
DMT0EK8	DN	4-(3-Benzoyl-1H-pyrrol-1-yl)butanoic acid
DMT0EK8	MI	TTFBNVI
DMT0EK8	MN	Aldose reductase (AKR1B1)
DMT0EK8	MT	DTT
DMT0EK8	MA	Inhibitor
DMT0EK8	RN	Design and synthesis of novel series of pyrrole based chemotypes and their evaluation as selective aldose reductase inhibitors. A case of bioisoste... Bioorg Med Chem. 2010 Mar 15;18(6):2107-2114.
DMT0EK8	RU	https://pubmed.ncbi.nlm.nih.gov/20189816

DML3VB7	DI	DML3VB7
DML3VB7	DN	4-(3-bromobenzylthio)-2-aminobutanoic acid
DML3VB7	MI	TTFK1JQ
DML3VB7	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DML3VB7	MT	DTT
DML3VB7	MA	Inhibitor
DML3VB7	RN	Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41.
DML3VB7	RU	https://pubmed.ncbi.nlm.nih.gov/16380257

DMNBLQ8	DI	DMNBLQ8
DMNBLQ8	DN	4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline
DMNBLQ8	MI	TTGKNB4
DMNBLQ8	MN	Epidermal growth factor receptor (EGFR)
DMNBLQ8	MT	DTT
DMNBLQ8	MA	Inhibitor
DMNBLQ8	RN	A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
DMNBLQ8	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97101172

DMNBLQ8	DI	DMNBLQ8
DMNBLQ8	DN	4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline
DMNBLQ8	MI	TTI7421
DMNBLQ8	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMNBLQ8	MT	DTT
DMNBLQ8	MA	Inhibitor
DMNBLQ8	RN	A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
DMNBLQ8	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97101172

DMK6JV7	DI	DMK6JV7
DMK6JV7	DN	4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline
DMK6JV7	MI	TTGKNB4
DMK6JV7	MN	Epidermal growth factor receptor (EGFR)
DMK6JV7	MT	DTT
DMK6JV7	MA	Inhibitor
DMK6JV7	RN	A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
DMK6JV7	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97101172

DMK6JV7	DI	DMK6JV7
DMK6JV7	DN	4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline
DMK6JV7	MI	TTI7421
DMK6JV7	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMK6JV7	MT	DTT
DMK6JV7	MA	Inhibitor
DMK6JV7	RN	A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
DMK6JV7	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97101172

DM3LGOT	DI	DM3LGOT
DM3LGOT	DN	4-(3-bromophenoxy)-6-chloroquinazoline
DM3LGOT	MI	TTHS256
DM3LGOT	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM3LGOT	MT	DTT
DM3LGOT	MA	Inhibitor
DM3LGOT	RN	Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6.
DM3LGOT	RU	https://pubmed.ncbi.nlm.nih.gov/19854049

DM1Q5KV	DI	DM1Q5KV
DM1Q5KV	DN	4-(3-Bromo-phenylamino)-quinazoline-6,7-diol
DM1Q5KV	MI	TTGKNB4
DM1Q5KV	MN	Epidermal growth factor receptor (EGFR)
DM1Q5KV	MT	DTT
DM1Q5KV	MA	Inhibitor
DM1Q5KV	RN	Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase acti... J Med Chem. 1996 Feb 16;39(4):918-28.
DM1Q5KV	RU	https://pubmed.ncbi.nlm.nih.gov/8632415

DMQBHF2	DI	DMQBHF2
DMQBHF2	DN	4-(3-bromophenylthio)-2-(pyridin-2-yl)pyrimidine
DMQBHF2	MI	TTHS256
DMQBHF2	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMQBHF2	MT	DTT
DMQBHF2	MA	Inhibitor
DMQBHF2	RN	Structure-activity relationship of thiopyrimidines as mGluR5 antagonists. Bioorg Med Chem Lett. 2006 May 1;16(9):2467-9.
DMQBHF2	RU	https://pubmed.ncbi.nlm.nih.gov/16481165

DML5NF6	DI	DML5NF6
DML5NF6	DN	4-(3-bromopyrazolo[1,5-a]pyrimidin-6-yl)phenol
DML5NF6	MI	TTLAFZV
DML5NF6	MN	AMP-activated protein kinase (AMPK)
DML5NF6	MT	DTT
DML5NF6	MA	Inhibitor
DML5NF6	RN	The rational design of a novel potent analogue of the 5'-AMP-activated protein kinase inhibitor compound C with improved selectivity and cellular a... Bioorg Med Chem Lett. 2010 Nov 15;20(22):6394-9.
DML5NF6	RU	https://pubmed.ncbi.nlm.nih.gov/20932747

DMQVXMZ	DI	DMQVXMZ
DMQVXMZ	DN	4-(3-chlorobenzylthio)-2-aminobutanoic acid
DMQVXMZ	MI	TTFK1JQ
DMQVXMZ	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMQVXMZ	MT	DTT
DMQVXMZ	MA	Inhibitor
DMQVXMZ	RN	Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41.
DMQVXMZ	RU	https://pubmed.ncbi.nlm.nih.gov/16380257

DMDS2LZ	DI	DMDS2LZ
DMDS2LZ	DN	4-(3-Chloro-phenoxy)-6,7-dimethoxy-quinazoline
DMDS2LZ	MI	TT860QF
DMDS2LZ	MN	LCK tyrosine protein kinase (LCK)
DMDS2LZ	MT	DTT
DMDS2LZ	MA	Inhibitor
DMDS2LZ	RN	he preparation and sar of 4-(anilino), 4-(phenoxy), and 4-(thiophenoxy)-quinazolines: Inhibitors of p56lck and EGF-R tyrosine kinase activity, Bioorg. Med. Chem. Lett. 7(4):417-420 (1997).
DMDS2LZ	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97000346

DMDTFKL	DI	DMDTFKL
DMDTFKL	DN	4-(3-chlorophenylethynyl)-2-methylthiazole
DMDTFKL	MI	TTHS256
DMDTFKL	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMDTFKL	MT	DTT
DMDTFKL	MA	Inhibitor
DMDTFKL	RN	Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100.
DMDTFKL	RU	https://pubmed.ncbi.nlm.nih.gov/16451073

DMJH2OE	DI	DMJH2OE
DMJH2OE	DN	4-(3-chlorophenylthio)-2-(pyridin-2-yl)pyrimidine
DMJH2OE	MI	TTHS256
DMJH2OE	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMJH2OE	MT	DTT
DMJH2OE	MA	Inhibitor
DMJH2OE	RN	Structure-activity relationship of thiopyrimidines as mGluR5 antagonists. Bioorg Med Chem Lett. 2006 May 1;16(9):2467-9.
DMJH2OE	RU	https://pubmed.ncbi.nlm.nih.gov/16481165

DMSUB8D	DI	DMSUB8D
DMSUB8D	DN	4-(3-cyanobenzylthio)-2-aminobutanoic acid
DMSUB8D	MI	TTFK1JQ
DMSUB8D	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMSUB8D	MT	DTT
DMSUB8D	MA	Inhibitor
DMSUB8D	RN	Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41.
DMSUB8D	RU	https://pubmed.ncbi.nlm.nih.gov/16380257

DMXFLMK	DI	DMXFLMK
DMXFLMK	DN	4-(3-cyclohexylureido)butanoic acid
DMXFLMK	MI	TT7WVHI
DMXFLMK	MN	Soluble epoxide hydrolase (EPHX2)
DMXFLMK	MT	DTT
DMXFLMK	MA	Inhibitor
DMXFLMK	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMXFLMK	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMOQE5W	DI	DMOQE5W
DMOQE5W	DN	4-(3-Ethoxy-phenoxy)-6,7-dimethoxy-quinoline
DMOQE5W	MI	TTI7421
DMOQE5W	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMOQE5W	MT	DTT
DMOQE5W	MA	Inhibitor
DMOQE5W	RN	A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
DMOQE5W	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97101172

DMFM9SH	DI	DMFM9SH
DMFM9SH	DN	4-(3-Ethyl-phenoxy)-6,7-dimethoxy-quinoline
DMFM9SH	MI	TTI7421
DMFM9SH	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMFM9SH	MT	DTT
DMFM9SH	MA	Inhibitor
DMFM9SH	RN	A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
DMFM9SH	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97101172

DM1C3NZ	DI	DM1C3NZ
DM1C3NZ	DN	4-(3-fluoro-2-phenoxyphenyl)piperidine
DM1C3NZ	MI	TTSQIFT
DM1C3NZ	MN	5-HT 1A receptor (HTR1A)
DM1C3NZ	MT	DTT
DM1C3NZ	MA	Inhibitor
DM1C3NZ	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DM1C3NZ	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DM1C3NZ	DI	DM1C3NZ
DM1C3NZ	DN	4-(3-fluoro-2-phenoxyphenyl)piperidine
DM1C3NZ	MI	TTVBI8W
DM1C3NZ	MN	Dopamine transporter (DAT)
DM1C3NZ	MT	DTT
DM1C3NZ	MA	Inhibitor
DM1C3NZ	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DM1C3NZ	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DM1C3NZ	DI	DM1C3NZ
DM1C3NZ	DN	4-(3-fluoro-2-phenoxyphenyl)piperidine
DM1C3NZ	MI	TTAWNKZ
DM1C3NZ	MN	Norepinephrine transporter (NET)
DM1C3NZ	MT	DTT
DM1C3NZ	MA	Inhibitor
DM1C3NZ	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DM1C3NZ	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DM1C3NZ	DI	DM1C3NZ
DM1C3NZ	DN	4-(3-fluoro-2-phenoxyphenyl)piperidine
DM1C3NZ	MI	TT3ROYC
DM1C3NZ	MN	Serotonin transporter (SERT)
DM1C3NZ	MT	DTT
DM1C3NZ	MA	Inhibitor
DM1C3NZ	RN	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
DM1C3NZ	RU	https://pubmed.ncbi.nlm.nih.gov/19854053

DMXLC94	DI	DMXLC94
DMXLC94	DN	4-(3-fluorobenzylthio)-2-aminobutanoic acid
DMXLC94	MI	TTFK1JQ
DMXLC94	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMXLC94	MT	DTT
DMXLC94	MA	Inhibitor
DMXLC94	RN	Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41.
DMXLC94	RU	https://pubmed.ncbi.nlm.nih.gov/16380257

DMER3D9	DI	DMER3D9
DMER3D9	DN	4-(3-Fluoro-phenoxy)-6,7-dimethoxy-quinoline
DMER3D9	MI	TTI7421
DMER3D9	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMER3D9	MT	DTT
DMER3D9	MA	Inhibitor
DMER3D9	RN	A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
DMER3D9	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97101172

DM6RV9L	DI	DM6RV9L
DM6RV9L	DN	4-(3-fluorophenylethynyl)-2-thiazolylamine
DM6RV9L	MI	TTHS256
DM6RV9L	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM6RV9L	MT	DTT
DM6RV9L	MA	Inhibitor
DM6RV9L	RN	Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100.
DM6RV9L	RU	https://pubmed.ncbi.nlm.nih.gov/16451073

DMZ1TNM	DI	DMZ1TNM
DMZ1TNM	DN	4-(3'-furyl)-aniline
DMZ1TNM	MI	TTAWNKZ
DMZ1TNM	MN	Norepinephrine transporter (NET)
DMZ1TNM	MT	DTT
DMZ1TNM	MA	Inhibitor
DMZ1TNM	RN	Designing active template molecules by combining computational de novo design and human chemist's expertise. J Med Chem. 2007 Apr 19;50(8):1925-32.
DMZ1TNM	RU	https://pubmed.ncbi.nlm.nih.gov/17367122

DMC5GAW	DI	DMC5GAW
DMC5GAW	DN	4-(3-hexylureido)-N-phenylbenzenesulfonamide
DMC5GAW	MI	TTWDC17
DMC5GAW	MN	Growth hormone secretagogue receptor 1 (GHSR)
DMC5GAW	MT	DTT
DMC5GAW	MA	Inhibitor
DMC5GAW	RN	Discovery and optimization of novel 4-[(aminocarbonyl)amino]-N-[4-(2-aminoethyl)phenyl]benzenesulfonamide ghrelin receptor antagonists. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6237-40.
DMC5GAW	RU	https://pubmed.ncbi.nlm.nih.gov/19767208

DM3QJVT	DI	DM3QJVT
DM3QJVT	DN	4-(3H-Inden-1-ylmethyl)-phenylamine
DM3QJVT	MI	TTJS8PY
DM3QJVT	MN	5-HT 6 receptor (HTR6)
DM3QJVT	MT	DTT
DM3QJVT	MA	Inhibitor
DM3QJVT	RN	Binding of isotryptamines and indenes at h5-HT6 serotonin receptors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1987-91.
DM3QJVT	RU	https://pubmed.ncbi.nlm.nih.gov/15808453

DMM8AY5	DI	DMM8AY5
DMM8AY5	DN	4-(3H-indol-4-ylamino)-5-styrylnicotinonitrile
DMM8AY5	MI	TT1MS7X
DMM8AY5	MN	PKC-theta messenger RNA (PRKCQ mRNA)
DMM8AY5	MT	DTT
DMM8AY5	MA	Inhibitor
DMM8AY5	RN	First generation 5-vinyl-3-pyridinecarbonitrile PKCtheta inhibitors. Bioorg Med Chem Lett. 2009 Oct 15;19(20):5829-32.
DMM8AY5	RU	https://pubmed.ncbi.nlm.nih.gov/19762237

DMY2OVL	DI	DMY2OVL
DMY2OVL	DN	4-(3-hydroxy-benzylideneamino)-benzenesulfonamide
DMY2OVL	MI	TTVKILB
DMY2OVL	MN	Prostaglandin G/H synthase 2 (COX-2)
DMY2OVL	MT	DTT
DMY2OVL	MA	Inhibitor
DMY2OVL	RN	Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides. Bioorg Med Chem. 2008 Mar 1;16(5):2697-706.
DMY2OVL	RU	https://pubmed.ncbi.nlm.nih.gov/18063374

DMUQWJZ	DI	DMUQWJZ
DMUQWJZ	DN	4-(3-Hydroxy-piperidin-3-yl)-benzene-1,2-diol
DMUQWJZ	MI	TTNGILX
DMUQWJZ	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMUQWJZ	MT	DTT
DMUQWJZ	MA	Inhibitor
DMUQWJZ	RN	Conformational effects on the activity of drugs. 13. A revision of previously proposed models for the activation of alpha- and beta-adrenergic rece... J Med Chem. 1992 Mar 20;35(6):1009-18.
DMUQWJZ	RU	https://pubmed.ncbi.nlm.nih.gov/1313109

DMUQWJZ	DI	DMUQWJZ
DMUQWJZ	DN	4-(3-Hydroxy-piperidin-3-yl)-benzene-1,2-diol
DMUQWJZ	MI	TTBRKXS
DMUQWJZ	MN	Adrenergic receptor alpha-1B (ADRA1B)
DMUQWJZ	MT	DTT
DMUQWJZ	MA	Inhibitor
DMUQWJZ	RN	Conformational effects on the activity of drugs. 13. A revision of previously proposed models for the activation of alpha- and beta-adrenergic rece... J Med Chem. 1992 Mar 20;35(6):1009-18.
DMUQWJZ	RU	https://pubmed.ncbi.nlm.nih.gov/1313109

DMUQWJZ	DI	DMUQWJZ
DMUQWJZ	DN	4-(3-Hydroxy-piperidin-3-yl)-benzene-1,2-diol
DMUQWJZ	MI	TT34BHT
DMUQWJZ	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMUQWJZ	MT	DTT
DMUQWJZ	MA	Inhibitor
DMUQWJZ	RN	Conformational effects on the activity of drugs. 13. A revision of previously proposed models for the activation of alpha- and beta-adrenergic rece... J Med Chem. 1992 Mar 20;35(6):1009-18.
DMUQWJZ	RU	https://pubmed.ncbi.nlm.nih.gov/1313109

DMO8SQA	DI	DMO8SQA
DMO8SQA	DN	4-(3-methoxy-benzylideneamino)-benzenesulfonamide
DMO8SQA	MI	TTVKILB
DMO8SQA	MN	Prostaglandin G/H synthase 2 (COX-2)
DMO8SQA	MT	DTT
DMO8SQA	MA	Inhibitor
DMO8SQA	RN	Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides. Bioorg Med Chem. 2008 Mar 1;16(5):2697-706.
DMO8SQA	RU	https://pubmed.ncbi.nlm.nih.gov/18063374

DMTPL0C	DI	DMTPL0C
DMTPL0C	DN	4-(3-methoxybenzylthio)-2-aminobutanoic acid
DMTPL0C	MI	TTFK1JQ
DMTPL0C	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMTPL0C	MT	DTT
DMTPL0C	MA	Inhibitor
DMTPL0C	RN	Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41.
DMTPL0C	RU	https://pubmed.ncbi.nlm.nih.gov/16380257

DMSUFJZ	DI	DMSUFJZ
DMSUFJZ	DN	4-(3-Methoxy-phenyl)-isoxazolidine-3,5-dione
DMSUFJZ	MI	TTFBNVI
DMSUFJZ	MN	Aldose reductase (AKR1B1)
DMSUFJZ	MT	DTT
DMSUFJZ	MA	Inhibitor
DMSUFJZ	RN	Isoxazolidine-3,5-diones as lens aldose reductase inhibitors. J Med Chem. 1982 Jun;25(6):745-7.
DMSUFJZ	RU	https://pubmed.ncbi.nlm.nih.gov/6808134

DMGCPKU	DI	DMGCPKU
DMGCPKU	DN	4-(3-methoxyphenylethynyl)-2-methylthiazole
DMGCPKU	MI	TTHS256
DMGCPKU	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMGCPKU	MT	DTT
DMGCPKU	MA	Inhibitor
DMGCPKU	RN	Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100.
DMGCPKU	RU	https://pubmed.ncbi.nlm.nih.gov/16451073

DM67A4U	DI	DM67A4U
DM67A4U	DN	4-(3-Methyl-indole-1-sulfonyl)-phenylamine
DM67A4U	MI	TTJS8PY
DM67A4U	MN	5-HT 6 receptor (HTR6)
DM67A4U	MT	DTT
DM67A4U	MA	Inhibitor
DM67A4U	RN	1-(1-Naphthyl)piperazine as a novel template for 5-HT6 serotonin receptor ligands. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1707-11.
DM67A4U	RU	https://pubmed.ncbi.nlm.nih.gov/15745826

DM5I6O2	DI	DM5I6O2
DM5I6O2	DN	4-(3-methylpyridin-2-yl)-N-p-tolylbenzamide
DM5I6O2	MI	TTMI6F5
DM5I6O2	MN	Transient receptor potential cation channel V1 (TRPV1)
DM5I6O2	MT	DTT
DM5I6O2	MA	Inhibitor
DM5I6O2	RN	From arylureas to biarylamides to aminoquinazolines: discovery of a novel, potent TRPV1 antagonist. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5217-21.
DM5I6O2	RU	https://pubmed.ncbi.nlm.nih.gov/16870426

DMD94OB	DI	DMD94OB
DMD94OB	DN	4-(3-nitro-benzylideneamino)-benzenesulfonamide
DMD94OB	MI	TTVKILB
DMD94OB	MN	Prostaglandin G/H synthase 2 (COX-2)
DMD94OB	MT	DTT
DMD94OB	MA	Inhibitor
DMD94OB	RN	Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides. Bioorg Med Chem. 2008 Mar 1;16(5):2697-706.
DMD94OB	RU	https://pubmed.ncbi.nlm.nih.gov/18063374

DM4WI0Y	DI	DM4WI0Y
DM4WI0Y	DN	4-(3-nitrobenzylthio)-2-aminobutanoic acid
DM4WI0Y	MI	TTFK1JQ
DM4WI0Y	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DM4WI0Y	MT	DTT
DM4WI0Y	MA	Inhibitor
DM4WI0Y	RN	Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41.
DM4WI0Y	RU	https://pubmed.ncbi.nlm.nih.gov/16380257

DMEYV1B	DI	DMEYV1B
DMEYV1B	DN	4-(3-Pent-1-ynyl-benzyl)-1H-imidazole
DMEYV1B	MI	TTVG215
DMEYV1B	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DMEYV1B	MT	DTT
DMEYV1B	MA	Inhibitor
DMEYV1B	RN	4-benzyl-1H-imidazoles with oxazoline termini as histamine H3 receptor agonists. J Med Chem. 2008 May 22;51(10):2944-53.
DMEYV1B	RU	https://pubmed.ncbi.nlm.nih.gov/18433114

DMSXG23	DI	DMSXG23
DMSXG23	DN	4-(3-phenoxylphenyl)-5-cyano-2H-1,2,3-triazole
DMSXG23	MI	TTR5TV4
DMSXG23	MN	ERBB2 messenger RNA (HER2 mRNA)
DMSXG23	MT	DTT
DMSXG23	MA	Inhibitor
DMSXG23	RN	Synthesis and biological evaluation of 4-aryl-5-cyano-2H-1,2,3-triazoles as inhibitor of HER2 tyrosine kinase. Bioorg Med Chem. 2007 Feb 1;15(3):1533-8.
DMSXG23	RU	https://pubmed.ncbi.nlm.nih.gov/17174554

DM5F13I	DI	DM5F13I
DM5F13I	DN	4-(3-Phenoxy-propyl)-1H-imidazole
DM5F13I	MI	TT9JNIC
DM5F13I	MN	Histamine H3 receptor (H3R)
DM5F13I	MT	DTT
DM5F13I	MA	Inhibitor
DM5F13I	RN	Different antagonist binding properties of human and rat histamine H3 receptors. Bioorg Med Chem Lett. 2001 Apr 9;11(7):951-4.
DM5F13I	RU	https://pubmed.ncbi.nlm.nih.gov/11294398

DMEJF6V	DI	DMEJF6V
DMEJF6V	DN	4-(3-phenyl-1H-indol-2-yl)phenol
DMEJF6V	MI	TTZAYWL
DMEJF6V	MN	Estrogen receptor (ESR)
DMEJF6V	MT	DTT
DMEJF6V	MA	Inhibitor
DMEJF6V	RN	Estrogen receptor beta selective ligands: discovery and SAR of novel heterocyclic ligands. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5562-6.
DMEJF6V	RU	https://pubmed.ncbi.nlm.nih.gov/16219463

DMEJF6V	DI	DMEJF6V
DMEJF6V	DN	4-(3-phenyl-1H-indol-2-yl)phenol
DMEJF6V	MI	TTOM3J0
DMEJF6V	MN	Estrogen receptor beta (ESR2)
DMEJF6V	MT	DTT
DMEJF6V	MA	Inhibitor
DMEJF6V	RN	Estrogen receptor beta selective ligands: discovery and SAR of novel heterocyclic ligands. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5562-6.
DMEJF6V	RU	https://pubmed.ncbi.nlm.nih.gov/16219463

DMS4JVT	DI	DMS4JVT
DMS4JVT	DN	4-(3-Phenylethynyl-benzyl)-1H-imidazole
DMS4JVT	MI	TTVG215
DMS4JVT	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DMS4JVT	MT	DTT
DMS4JVT	MA	Inhibitor
DMS4JVT	RN	4-benzyl-1H-imidazoles with oxazoline termini as histamine H3 receptor agonists. J Med Chem. 2008 May 22;51(10):2944-53.
DMS4JVT	RU	https://pubmed.ncbi.nlm.nih.gov/18433114

DMRXKMP	DI	DMRXKMP
DMRXKMP	DN	4-(3-pyridylethynyl)-2-thiazolylamine
DMRXKMP	MI	TTHS256
DMRXKMP	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMRXKMP	MT	DTT
DMRXKMP	MA	Inhibitor
DMRXKMP	RN	Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100.
DMRXKMP	RU	https://pubmed.ncbi.nlm.nih.gov/16451073

DML4NJU	DI	DML4NJU
DML4NJU	DN	4-(3-thienyl)benzene-1,2-diamine)
DML4NJU	MI	TTQ6VDM
DML4NJU	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DML4NJU	MT	DTT
DML4NJU	MA	Inhibitor
DML4NJU	RN	Parallel medicinal chemistry approaches to selective HDAC1/HDAC2 inhibitor (SHI-1:2) optimization. Bioorg Med Chem Lett. 2009 Feb 15;19(4):1168-72.
DML4NJU	RU	https://pubmed.ncbi.nlm.nih.gov/19138845

DM0QRJ3	DI	DM0QRJ3
DM0QRJ3	DN	4-(4-((phenethylamino)methyl)phenoxy)benzamide
DM0QRJ3	MI	TT27RFC
DM0QRJ3	MN	Opioid receptor delta (OPRD1)
DM0QRJ3	MT	DTT
DM0QRJ3	MA	Inhibitor
DM0QRJ3	RN	Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5349-52.
DM0QRJ3	RU	https://pubmed.ncbi.nlm.nih.gov/17720493

DM0QRJ3	DI	DM0QRJ3
DM0QRJ3	DN	4-(4-((phenethylamino)methyl)phenoxy)benzamide
DM0QRJ3	MI	TTQW87Y
DM0QRJ3	MN	Opioid receptor kappa (OPRK1)
DM0QRJ3	MT	DTT
DM0QRJ3	MA	Inhibitor
DM0QRJ3	RN	Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5349-52.
DM0QRJ3	RU	https://pubmed.ncbi.nlm.nih.gov/17720493

DM0QRJ3	DI	DM0QRJ3
DM0QRJ3	DN	4-(4-((phenethylamino)methyl)phenoxy)benzamide
DM0QRJ3	MI	TTKWM86
DM0QRJ3	MN	Opioid receptor mu (MOP)
DM0QRJ3	MT	DTT
DM0QRJ3	MA	Inhibitor
DM0QRJ3	RN	Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5349-52.
DM0QRJ3	RU	https://pubmed.ncbi.nlm.nih.gov/17720493

DMWBVMH	DI	DMWBVMH
DMWBVMH	DN	4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid
DMWBVMH	MI	TTGKNB4
DMWBVMH	MN	Epidermal growth factor receptor (EGFR)
DMWBVMH	MT	DTT
DMWBVMH	MA	Inhibitor
DMWBVMH	RN	Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J Nat Prod. 1992 Nov;55(11):1529-60.
DMWBVMH	RU	https://pubmed.ncbi.nlm.nih.gov/1479375

DMA9TCD	DI	DMA9TCD
DMA9TCD	DN	4-(4-(4-Nitrophenyl)thiazol-2-ylamino)phenol
DMA9TCD	MI	TTWHDVK
DMA9TCD	MN	Fructose-1,6-bisphosphatase (FBP)
DMA9TCD	MT	DTT
DMA9TCD	MA	Inhibitor
DMA9TCD	RN	A library of novel allosteric inhibitors against fructose 1,6-bisphosphatase. Bioorg Med Chem. 2009 Jun 1;17(11):3916-22.
DMA9TCD	RU	https://pubmed.ncbi.nlm.nih.gov/19419876

DM6KIG0	DI	DM6KIG0
DM6KIG0	DN	4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid
DM6KIG0	MI	TTXZ0KQ
DM6KIG0	MN	Matrix metalloproteinase-12 (MMP-12)
DM6KIG0	MT	DTT
DM6KIG0	MA	Inhibitor
DM6KIG0	RN	Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8.
DM6KIG0	RU	https://pubmed.ncbi.nlm.nih.gov/16420030

DM6KIG0	DI	DM6KIG0
DM6KIG0	DN	4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid
DM6KIG0	MI	TTLM12X
DM6KIG0	MN	Matrix metalloproteinase-2 (MMP-2)
DM6KIG0	MT	DTT
DM6KIG0	MA	Inhibitor
DM6KIG0	RN	Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8.
DM6KIG0	RU	https://pubmed.ncbi.nlm.nih.gov/16420030

DMYXHUO	DI	DMYXHUO
DMYXHUO	DN	4-(4-(pentyloxy)phenoxy)phenol
DMYXHUO	MI	TTXZEAJ
DMYXHUO	MN	Leukotriene A-4 hydrolase (LTA4H)
DMYXHUO	MT	DTT
DMYXHUO	MA	Inhibitor
DMYXHUO	RN	Activation and inhibition of leukotriene A4 hydrolase aminopeptidase activity by diphenyl ether and derivatives. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6549-52.
DMYXHUO	RU	https://pubmed.ncbi.nlm.nih.gov/18952425

DMVXJU6	DI	DMVXJU6
DMVXJU6	DN	4-(4-(thiophen-2-yl)benzyl)pyridine
DMVXJU6	MI	TTIQUX7
DMVXJU6	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMVXJU6	MT	DTT
DMVXJU6	MA	Inhibitor
DMVXJU6	RN	Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
DMVXJU6	RU	https://pubmed.ncbi.nlm.nih.gov/20684610

DMVXJU6	DI	DMVXJU6
DMVXJU6	DN	4-(4-(thiophen-2-yl)benzyl)pyridine
DMVXJU6	MI	TTRA5BZ
DMVXJU6	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMVXJU6	MT	DTT
DMVXJU6	MA	Inhibitor
DMVXJU6	RN	Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
DMVXJU6	RU	https://pubmed.ncbi.nlm.nih.gov/20684610

DM7I21V	DI	DM7I21V
DM7I21V	DN	4-(4-(thiophen-3-yl)benzyl)pyridine
DM7I21V	MI	TTIQUX7
DM7I21V	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM7I21V	MT	DTT
DM7I21V	MA	Inhibitor
DM7I21V	RN	Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
DM7I21V	RU	https://pubmed.ncbi.nlm.nih.gov/20684610

DM7I21V	DI	DM7I21V
DM7I21V	DN	4-(4-(thiophen-3-yl)benzyl)pyridine
DM7I21V	MI	TTRA5BZ
DM7I21V	MN	Steroid 17-alpha-monooxygenase (S17AH)
DM7I21V	MT	DTT
DM7I21V	MA	Inhibitor
DM7I21V	RN	Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
DM7I21V	RU	https://pubmed.ncbi.nlm.nih.gov/20684610

DMOF0J1	DI	DMOF0J1
DMOF0J1	DN	4-(4,5-dihydrothiazol-2-yl)phenyl butylcarbamate
DMOF0J1	MI	TTDP1UC
DMOF0J1	MN	Fatty acid amide hydrolase (FAAH)
DMOF0J1	MT	DTT
DMOF0J1	MA	Inhibitor
DMOF0J1	RN	The synthesis and biological evaluation of para-substituted phenolic N-alkyl carbamates as endocannabinoid hydrolyzing enzyme inhibitors. Eur J Med Chem. 2009 Jul;44(7):2994-3008.
DMOF0J1	RU	https://pubmed.ncbi.nlm.nih.gov/19232787

DMI1598	DI	DMI1598
DMI1598	DN	4-(4,6-dinitro-1H-indol-1-ylsulfonyl)benzenamine
DMI1598	MI	TTJS8PY
DMI1598	MN	5-HT 6 receptor (HTR6)
DMI1598	MT	DTT
DMI1598	MA	Inhibitor
DMI1598	RN	Binding of amine-substituted N1-benzenesulfonylindoles at human 5-HT6 serotonin receptors. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5298-302.
DMI1598	RU	https://pubmed.ncbi.nlm.nih.gov/16183286

DMETK18	DI	DMETK18
DMETK18	DN	4-(4,6-diphenylpyridin-2-yl)phenol
DMETK18	MI	TTGTQHC
DMETK18	MN	DNA topoisomerase I (TOP1)
DMETK18	MT	DTT
DMETK18	MA	Inhibitor
DMETK18	RN	Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl ... Bioorg Med Chem. 2010 May 1;18(9):3066-77.
DMETK18	RU	https://pubmed.ncbi.nlm.nih.gov/20392646

DMGOTYC	DI	DMGOTYC
DMGOTYC	DN	4'-(4-Aminobenzensulfonamide)-4-hydroxychalcone
DMGOTYC	MI	TTULVH8
DMGOTYC	MN	Tyrosinase (TYR)
DMGOTYC	MT	DTT
DMGOTYC	MA	Inhibitor
DMGOTYC	RN	Evaluation of anti-pigmentary effect of synthetic sulfonylamino chalcone. Eur J Med Chem. 2010 May;45(5):2010-7.
DMGOTYC	RU	https://pubmed.ncbi.nlm.nih.gov/20149498

DMK1IWD	DI	DMK1IWD
DMK1IWD	DN	4-(4-aminophenyl)-1H-indazol-3yl-amine
DMK1IWD	MI	TTGJCWZ
DMK1IWD	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMK1IWD	MT	DTT
DMK1IWD	MA	Inhibitor
DMK1IWD	RN	Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted ... J Med Chem. 2007 Apr 5;50(7):1584-97.
DMK1IWD	RU	https://pubmed.ncbi.nlm.nih.gov/17343372

DMK1IWD	DI	DMK1IWD
DMK1IWD	DN	4-(4-aminophenyl)-1H-indazol-3yl-amine
DMK1IWD	MI	TTX41N9
DMK1IWD	MN	Tyrosine-protein kinase Kit (KIT)
DMK1IWD	MT	DTT
DMK1IWD	MA	Inhibitor
DMK1IWD	RN	Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted ... J Med Chem. 2007 Apr 5;50(7):1584-97.
DMK1IWD	RU	https://pubmed.ncbi.nlm.nih.gov/17343372

DMK1IWD	DI	DMK1IWD
DMK1IWD	DN	4-(4-aminophenyl)-1H-indazol-3yl-amine
DMK1IWD	MI	TTUTJGQ
DMK1IWD	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMK1IWD	MT	DTT
DMK1IWD	MA	Inhibitor
DMK1IWD	RN	Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted ... J Med Chem. 2007 Apr 5;50(7):1584-97.
DMK1IWD	RU	https://pubmed.ncbi.nlm.nih.gov/17343372

DMP0G1W	DI	DMP0G1W
DMP0G1W	DN	4-(4-benzenesulfonamidophenyl)piperazine
DMP0G1W	MI	TTJS8PY
DMP0G1W	MN	5-HT 6 receptor (HTR6)
DMP0G1W	MT	DTT
DMP0G1W	MA	Inhibitor
DMP0G1W	RN	Binding of sulfonyl-containing arylalkylamines at human 5-HT6 serotonin receptors. J Med Chem. 2006 Aug 24;49(17):5217-25.
DMP0G1W	RU	https://pubmed.ncbi.nlm.nih.gov/16913710

DM0DZFX	DI	DM0DZFX
DM0DZFX	DN	4-(4-benzenesulfonylphenyl)piperazine
DM0DZFX	MI	TTJS8PY
DM0DZFX	MN	5-HT 6 receptor (HTR6)
DM0DZFX	MT	DTT
DM0DZFX	MA	Inhibitor
DM0DZFX	RN	Binding of sulfonyl-containing arylalkylamines at human 5-HT6 serotonin receptors. J Med Chem. 2006 Aug 24;49(17):5217-25.
DM0DZFX	RU	https://pubmed.ncbi.nlm.nih.gov/16913710

DMT2S9U	DI	DMT2S9U
DMT2S9U	DN	4-(4-benzyl-1H-1,2,3-triazol-1-yl)phenol
DMT2S9U	MI	TT6804T
DMT2S9U	MN	MIF messenger RNA (MIF mRNA)
DMT2S9U	MT	DTT
DMT2S9U	MA	Inhibitor
DMT2S9U	RN	Receptor agonists of macrophage migration inhibitory factor. Bioorg Med Chem Lett. 2010 Dec 1;20(23):7033-6.
DMT2S9U	RU	https://pubmed.ncbi.nlm.nih.gov/20971005

DME3PUT	DI	DME3PUT
DME3PUT	DN	4-(4-Benzyloxy-3-methoxy-benzylamino)-benzamidine
DME3PUT	MI	TT2WR1T
DME3PUT	MN	Cationic trypsinogen (PRSS1)
DME3PUT	MT	DTT
DME3PUT	MA	Inhibitor
DME3PUT	RN	Design of selective phenylglycine amide tissue factor/factor VIIa inhibitors. Bioorg Med Chem Lett. 2005 Feb 1;15(3):817-22.
DME3PUT	RU	https://pubmed.ncbi.nlm.nih.gov/15664864

DME3PUT	DI	DME3PUT
DME3PUT	DN	4-(4-Benzyloxy-3-methoxy-benzylamino)-benzamidine
DME3PUT	MI	TT6L509
DME3PUT	MN	Coagulation factor IIa (F2)
DME3PUT	MT	DTT
DME3PUT	MA	Inhibitor
DME3PUT	RN	Design of selective phenylglycine amide tissue factor/factor VIIa inhibitors. Bioorg Med Chem Lett. 2005 Feb 1;15(3):817-22.
DME3PUT	RU	https://pubmed.ncbi.nlm.nih.gov/15664864

DME3PUT	DI	DME3PUT
DME3PUT	DN	4-(4-Benzyloxy-3-methoxy-benzylamino)-benzamidine
DME3PUT	MI	TTF0EGX
DME3PUT	MN	Coagulation factor VII (F7)
DME3PUT	MT	DTT
DME3PUT	MA	Inhibitor
DME3PUT	RN	Design of selective phenylglycine amide tissue factor/factor VIIa inhibitors. Bioorg Med Chem Lett. 2005 Feb 1;15(3):817-22.
DME3PUT	RU	https://pubmed.ncbi.nlm.nih.gov/15664864

DME3PUT	DI	DME3PUT
DME3PUT	DN	4-(4-Benzyloxy-3-methoxy-benzylamino)-benzamidine
DME3PUT	MI	TTCIHJA
DME3PUT	MN	Coagulation factor Xa (F10)
DME3PUT	MT	DTT
DME3PUT	MA	Inhibitor
DME3PUT	RN	Design of selective phenylglycine amide tissue factor/factor VIIa inhibitors. Bioorg Med Chem Lett. 2005 Feb 1;15(3):817-22.
DME3PUT	RU	https://pubmed.ncbi.nlm.nih.gov/15664864

DMXAEW9	DI	DMXAEW9
DMXAEW9	DN	4-(4-Benzyl-piperazin-1-yl)-1H-benzoimidazole
DMXAEW9	MI	TTEX248
DMXAEW9	MN	Dopamine D2 receptor (D2R)
DMXAEW9	MT	DTT
DMXAEW9	MA	Inhibitor
DMXAEW9	RN	New generation dopaminergic agents. 5. Heterocyclic bioisosteres that exploit the 3-OH-N1-phenylpiperazine dopaminergic template. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2675-80.
DMXAEW9	RU	https://pubmed.ncbi.nlm.nih.gov/9873601

DMXAEW9	DI	DMXAEW9
DMXAEW9	DN	4-(4-Benzyl-piperazin-1-yl)-1H-benzoimidazole
DMXAEW9	MI	TT4C8EA
DMXAEW9	MN	Dopamine D3 receptor (D3R)
DMXAEW9	MT	DTT
DMXAEW9	MA	Inhibitor
DMXAEW9	RN	New generation dopaminergic agents. 5. Heterocyclic bioisosteres that exploit the 3-OH-N1-phenylpiperazine dopaminergic template. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2675-80.
DMXAEW9	RU	https://pubmed.ncbi.nlm.nih.gov/9873601

DMXAEW9	DI	DMXAEW9
DMXAEW9	DN	4-(4-Benzyl-piperazin-1-yl)-1H-benzoimidazole
DMXAEW9	MI	TTE0A2F
DMXAEW9	MN	Dopamine D4 receptor (D4R)
DMXAEW9	MT	DTT
DMXAEW9	MA	Inhibitor
DMXAEW9	RN	New generation dopaminergic agents. 5. Heterocyclic bioisosteres that exploit the 3-OH-N1-phenylpiperazine dopaminergic template. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2675-80.
DMXAEW9	RU	https://pubmed.ncbi.nlm.nih.gov/9873601

DMWR0AS	DI	DMWR0AS
DMWR0AS	DN	4-(4-Benzyl-piperazin-1-yl)-1H-indole
DMWR0AS	MI	TTEX248
DMWR0AS	MN	Dopamine D2 receptor (D2R)
DMWR0AS	MT	DTT
DMWR0AS	MA	Inhibitor
DMWR0AS	RN	New generation dopaminergic agents. 5. Heterocyclic bioisosteres that exploit the 3-OH-N1-phenylpiperazine dopaminergic template. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2675-80.
DMWR0AS	RU	https://pubmed.ncbi.nlm.nih.gov/9873601

DMWR0AS	DI	DMWR0AS
DMWR0AS	DN	4-(4-Benzyl-piperazin-1-yl)-1H-indole
DMWR0AS	MI	TT4C8EA
DMWR0AS	MN	Dopamine D3 receptor (D3R)
DMWR0AS	MT	DTT
DMWR0AS	MA	Inhibitor
DMWR0AS	RN	New generation dopaminergic agents. 5. Heterocyclic bioisosteres that exploit the 3-OH-N1-phenylpiperazine dopaminergic template. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2675-80.
DMWR0AS	RU	https://pubmed.ncbi.nlm.nih.gov/9873601

DMWR0AS	DI	DMWR0AS
DMWR0AS	DN	4-(4-Benzyl-piperazin-1-yl)-1H-indole
DMWR0AS	MI	TTE0A2F
DMWR0AS	MN	Dopamine D4 receptor (D4R)
DMWR0AS	MT	DTT
DMWR0AS	MA	Inhibitor
DMWR0AS	RN	New generation dopaminergic agents. 5. Heterocyclic bioisosteres that exploit the 3-OH-N1-phenylpiperazine dopaminergic template. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2675-80.
DMWR0AS	RU	https://pubmed.ncbi.nlm.nih.gov/9873601

DMZ4237	DI	DMZ4237
DMZ4237	DN	4-(4-Benzyl-piperazin-1-yl)-5-chloro-1H-indole
DMZ4237	MI	TTEX248
DMZ4237	MN	Dopamine D2 receptor (D2R)
DMZ4237	MT	DTT
DMZ4237	MA	Inhibitor
DMZ4237	RN	New generation dopaminergic agents. 5. Heterocyclic bioisosteres that exploit the 3-OH-N1-phenylpiperazine dopaminergic template. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2675-80.
DMZ4237	RU	https://pubmed.ncbi.nlm.nih.gov/9873601

DMZ4237	DI	DMZ4237
DMZ4237	DN	4-(4-Benzyl-piperazin-1-yl)-5-chloro-1H-indole
DMZ4237	MI	TT4C8EA
DMZ4237	MN	Dopamine D3 receptor (D3R)
DMZ4237	MT	DTT
DMZ4237	MA	Inhibitor
DMZ4237	RN	New generation dopaminergic agents. 5. Heterocyclic bioisosteres that exploit the 3-OH-N1-phenylpiperazine dopaminergic template. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2675-80.
DMZ4237	RU	https://pubmed.ncbi.nlm.nih.gov/9873601

DMZ4237	DI	DMZ4237
DMZ4237	DN	4-(4-Benzyl-piperazin-1-yl)-5-chloro-1H-indole
DMZ4237	MI	TTE0A2F
DMZ4237	MN	Dopamine D4 receptor (D4R)
DMZ4237	MT	DTT
DMZ4237	MA	Inhibitor
DMZ4237	RN	New generation dopaminergic agents. 5. Heterocyclic bioisosteres that exploit the 3-OH-N1-phenylpiperazine dopaminergic template. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2675-80.
DMZ4237	RU	https://pubmed.ncbi.nlm.nih.gov/9873601

DMVAB7U	DI	DMVAB7U
DMVAB7U	DN	4-(4-Benzyl-piperazin-1-yl)-7-bromo-1H-indole
DMVAB7U	MI	TTEX248
DMVAB7U	MN	Dopamine D2 receptor (D2R)
DMVAB7U	MT	DTT
DMVAB7U	MA	Inhibitor
DMVAB7U	RN	New generation dopaminergic agents. 5. Heterocyclic bioisosteres that exploit the 3-OH-N1-phenylpiperazine dopaminergic template. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2675-80.
DMVAB7U	RU	https://pubmed.ncbi.nlm.nih.gov/9873601

DMVAB7U	DI	DMVAB7U
DMVAB7U	DN	4-(4-Benzyl-piperazin-1-yl)-7-bromo-1H-indole
DMVAB7U	MI	TT4C8EA
DMVAB7U	MN	Dopamine D3 receptor (D3R)
DMVAB7U	MT	DTT
DMVAB7U	MA	Inhibitor
DMVAB7U	RN	New generation dopaminergic agents. 5. Heterocyclic bioisosteres that exploit the 3-OH-N1-phenylpiperazine dopaminergic template. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2675-80.
DMVAB7U	RU	https://pubmed.ncbi.nlm.nih.gov/9873601

DMVAB7U	DI	DMVAB7U
DMVAB7U	DN	4-(4-Benzyl-piperazin-1-yl)-7-bromo-1H-indole
DMVAB7U	MI	TTE0A2F
DMVAB7U	MN	Dopamine D4 receptor (D4R)
DMVAB7U	MT	DTT
DMVAB7U	MA	Inhibitor
DMVAB7U	RN	New generation dopaminergic agents. 5. Heterocyclic bioisosteres that exploit the 3-OH-N1-phenylpiperazine dopaminergic template. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2675-80.
DMVAB7U	RU	https://pubmed.ncbi.nlm.nih.gov/9873601

DMHWIMO	DI	DMHWIMO
DMHWIMO	DN	4-(4-bromobenzylthio)-2-aminobutanoic acid
DMHWIMO	MI	TTFK1JQ
DMHWIMO	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMHWIMO	MT	DTT
DMHWIMO	MA	Inhibitor
DMHWIMO	RN	Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41.
DMHWIMO	RU	https://pubmed.ncbi.nlm.nih.gov/16380257

DMFEBCO	DI	DMFEBCO
DMFEBCO	DN	4-(4-bromophenyl)-5-cyano-2H-1,2,3-triazole
DMFEBCO	MI	TTR5TV4
DMFEBCO	MN	ERBB2 messenger RNA (HER2 mRNA)
DMFEBCO	MT	DTT
DMFEBCO	MA	Inhibitor
DMFEBCO	RN	Synthesis and biological evaluation of 4-aryl-5-cyano-2H-1,2,3-triazoles as inhibitor of HER2 tyrosine kinase. Bioorg Med Chem. 2007 Feb 1;15(3):1533-8.
DMFEBCO	RU	https://pubmed.ncbi.nlm.nih.gov/17174554

DMI2EM5	DI	DMI2EM5
DMI2EM5	DN	4-(4-butoxyphenoxy)phenol
DMI2EM5	MI	TTXZEAJ
DMI2EM5	MN	Leukotriene A-4 hydrolase (LTA4H)
DMI2EM5	MT	DTT
DMI2EM5	MA	Inhibitor
DMI2EM5	RN	Activation and inhibition of leukotriene A4 hydrolase aminopeptidase activity by diphenyl ether and derivatives. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6549-52.
DMI2EM5	RU	https://pubmed.ncbi.nlm.nih.gov/18952425

DMNGDOM	DI	DMNGDOM
DMNGDOM	DN	4-(4-Butoxy-phenyl)-N-hydroxy-4-oxo-butyramide
DMNGDOM	MI	TTMX39J
DMNGDOM	MN	Matrix metalloproteinase-1 (MMP-1)
DMNGDOM	MT	DTT
DMNGDOM	MA	Inhibitor
DMNGDOM	RN	Receptor flexibility in de novo ligand design and docking. J Med Chem. 2005 Oct 20;48(21):6585-96.
DMNGDOM	RU	https://pubmed.ncbi.nlm.nih.gov/16220975

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TTSQIFT
DMM9X0G	MN	5-HT 1A receptor (HTR1A)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/20684563

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TTJQOD7
DMM9X0G	MN	5-HT 2A receptor (HTR2A)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/20684563

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TT0K1SC
DMM9X0G	MN	5-HT 2B receptor (HTR2B)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/20684563

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TTWJBZ5
DMM9X0G	MN	5-HT 2C receptor (HTR2C)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/20684563

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TTPC4TU
DMM9X0G	MN	5-HT 3A receptor (HTR3A)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/20684563

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TT07C3Y
DMM9X0G	MN	5-HT 4 receptor (HTR4)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/20684563

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TTO9X1H
DMM9X0G	MN	5-HT 7 receptor (HTR7)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/20684563

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TT1RS9F
DMM9X0G	MN	Acetylcholinesterase (AChE)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/20684563

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TTK25J1
DMM9X0G	MN	Adenosine A1 receptor (ADORA1)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/20684563

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TTM2AOE
DMM9X0G	MN	Adenosine A2a receptor (ADORA2A)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/20684563

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TTJFY5U
DMM9X0G	MN	Adenosine A3 receptor (ADORA3)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/20684563

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TTNGILX
DMM9X0G	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/20684563

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TTBRKXS
DMM9X0G	MN	Adrenergic receptor alpha-1B (ADRA1B)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/20684563

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TT34BHT
DMM9X0G	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/20684563

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TTWG9A4
DMM9X0G	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/20684563

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TTR6W5O
DMM9X0G	MN	Adrenergic receptor beta-1 (ADRB1)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/20684563

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TT6OEDT
DMM9X0G	MN	Cannabinoid receptor 1 (CB1)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/20684563

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TTZFYLI
DMM9X0G	MN	Dopamine D1 receptor (D1R)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/20684563

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TTEX248
DMM9X0G	MN	Dopamine D2 receptor (D2R)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/20684563

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TT4C8EA
DMM9X0G	MN	Dopamine D3 receptor (D3R)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/20684563

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TTVBI8W
DMM9X0G	MN	Dopamine transporter (DAT)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/20684563

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TTKRD0G
DMM9X0G	MN	Endothelin A receptor (EDNRA)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/20684563

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TTVFO0U
DMM9X0G	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/20684563

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TTOZRK6
DMM9X0G	MN	Glucocorticoid receptor messenger RNA (GCR mRNA)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/20684563

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TTTIBOJ
DMM9X0G	MN	Histamine H1 receptor (H1R)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/20684563

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TTQHJ1K
DMM9X0G	MN	Histamine H2 receptor (H2R)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/20684563

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TT9JNIC
DMM9X0G	MN	Histamine H3 receptor (H3R)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/20684563

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TTD0CIQ
DMM9X0G	MN	Melanocortin receptor 4 (MC4R)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/20684563

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TT0WAIE
DMM9X0G	MN	Melatonin receptor type 1A (MTNR1A)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/20684563

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TTZ9SOR
DMM9X0G	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur J Pharmacol. 2009 Mar 1;605(1-3):53-6.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/19168056

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TTYEG6Q
DMM9X0G	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/20684563

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TTQ13Z5
DMM9X0G	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/20684563

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TTQ3JTF
DMM9X0G	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/20684563

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TTH18TF
DMM9X0G	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/20684563

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TT4H1MQ
DMM9X0G	MN	Neuronal acetylcholine receptor alpha-4 (CHRNA4)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/20684563

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TT5KPZR
DMM9X0G	MN	Neuronal acetylcholine receptor beta-2 (CHRNB2)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/20684563

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TTRK9JT
DMM9X0G	MN	Neuropeptide Y receptor type 1 (NPY1R)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/20684563

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TTTUMEP
DMM9X0G	MN	Neurotensin receptor type 1 (NTSR1)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/20684563

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TTAWNKZ
DMM9X0G	MN	Norepinephrine transporter (NET)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/20684563

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TTKWM86
DMM9X0G	MN	Opioid receptor mu (MOP)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/20684563

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TT3ROYC
DMM9X0G	MN	Serotonin transporter (SERT)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/20684563

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TTYO0A3
DMM9X0G	MN	Substance-K receptor (TACR2)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/20684563

DMM9X0G	DI	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	MI	TTZPO1L
DMM9X0G	MN	Substance-P receptor (TACR1)
DMM9X0G	MT	DTT
DMM9X0G	MA	Inhibitor
DMM9X0G	RN	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
DMM9X0G	RU	https://pubmed.ncbi.nlm.nih.gov/20684563

DM14I6C	DI	DM14I6C
DM14I6C	DN	4-(4-chloro-2-cyclohexylphenoxy)butanoic acid
DM14I6C	MI	TTQDMX5
DM14I6C	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DM14I6C	MT	DTT
DM14I6C	MA	Inhibitor
DM14I6C	RN	2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4347-50.
DM14I6C	RU	https://pubmed.ncbi.nlm.nih.gov/17531480

DMRBEZD	DI	DMRBEZD
DMRBEZD	DN	4-(4-chlorobenzyl)-2-allylphthalazin-1(2H)-one
DMRBEZD	MI	TTNGILX
DMRBEZD	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMRBEZD	MT	DTT
DMRBEZD	MA	Inhibitor
DMRBEZD	RN	Vasorelaxant activity of phthalazinones and related compounds. Bioorg Med Chem Lett. 2006 May 15;16(10):2786-90.
DMRBEZD	RU	https://pubmed.ncbi.nlm.nih.gov/16513345

DMRBEZD	DI	DMRBEZD
DMRBEZD	DN	4-(4-chlorobenzyl)-2-allylphthalazin-1(2H)-one
DMRBEZD	MI	TT34BHT
DMRBEZD	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMRBEZD	MT	DTT
DMRBEZD	MA	Inhibitor
DMRBEZD	RN	Vasorelaxant activity of phthalazinones and related compounds. Bioorg Med Chem Lett. 2006 May 15;16(10):2786-90.
DMRBEZD	RU	https://pubmed.ncbi.nlm.nih.gov/16513345

DMNYQGV	DI	DMNYQGV
DMNYQGV	DN	4-(4-chlorobenzyl)-2-methylphthalazin-1(2H)-one
DMNYQGV	MI	TTNGILX
DMNYQGV	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMNYQGV	MT	DTT
DMNYQGV	MA	Inhibitor
DMNYQGV	RN	Vasorelaxant activity of phthalazinones and related compounds. Bioorg Med Chem Lett. 2006 May 15;16(10):2786-90.
DMNYQGV	RU	https://pubmed.ncbi.nlm.nih.gov/16513345

DMNYQGV	DI	DMNYQGV
DMNYQGV	DN	4-(4-chlorobenzyl)-2-methylphthalazin-1(2H)-one
DMNYQGV	MI	TT34BHT
DMNYQGV	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMNYQGV	MT	DTT
DMNYQGV	MA	Inhibitor
DMNYQGV	RN	Vasorelaxant activity of phthalazinones and related compounds. Bioorg Med Chem Lett. 2006 May 15;16(10):2786-90.
DMNYQGV	RU	https://pubmed.ncbi.nlm.nih.gov/16513345

DM9AEF0	DI	DM9AEF0
DM9AEF0	DN	4-(4-chlorobenzyl)phthalazin-1(2H)-one
DM9AEF0	MI	TTNGILX
DM9AEF0	MN	Adrenergic receptor alpha-1A (ADRA1A)
DM9AEF0	MT	DTT
DM9AEF0	MA	Inhibitor
DM9AEF0	RN	Vasorelaxant activity of phthalazinones and related compounds. Bioorg Med Chem Lett. 2006 May 15;16(10):2786-90.
DM9AEF0	RU	https://pubmed.ncbi.nlm.nih.gov/16513345

DM9AEF0	DI	DM9AEF0
DM9AEF0	DN	4-(4-chlorobenzyl)phthalazin-1(2H)-one
DM9AEF0	MI	TT34BHT
DM9AEF0	MN	Adrenergic receptor alpha-1D (ADRA1D)
DM9AEF0	MT	DTT
DM9AEF0	MA	Inhibitor
DM9AEF0	RN	Vasorelaxant activity of phthalazinones and related compounds. Bioorg Med Chem Lett. 2006 May 15;16(10):2786-90.
DM9AEF0	RU	https://pubmed.ncbi.nlm.nih.gov/16513345

DMENLUP	DI	DMENLUP
DMENLUP	DN	4-(4-chlorobenzylthio)-2-aminobutanoic acid
DMENLUP	MI	TTFK1JQ
DMENLUP	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMENLUP	MT	DTT
DMENLUP	MA	Inhibitor
DMENLUP	RN	Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41.
DMENLUP	RU	https://pubmed.ncbi.nlm.nih.gov/16380257

DMJI6QH	DI	DMJI6QH
DMJI6QH	DN	4-(4-chlorophenyl)-1-pyrid-2-yl-pyrazole
DMJI6QH	MI	TT1MPAY
DMJI6QH	MN	GABA(A) receptor alpha-1 (GABRA1)
DMJI6QH	MT	DTT
DMJI6QH	MA	Inhibitor
DMJI6QH	RN	Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors. J Med Chem. 2006 Mar 23;49(6):1855-66.
DMJI6QH	RU	https://pubmed.ncbi.nlm.nih.gov/16539371

DMJI6QH	DI	DMJI6QH
DMJI6QH	DN	4-(4-chlorophenyl)-1-pyrid-2-yl-pyrazole
DMJI6QH	MI	TTZA1NY
DMJI6QH	MN	GABA(A) receptor beta-2 (GABRB2)
DMJI6QH	MT	DTT
DMJI6QH	MA	Inhibitor
DMJI6QH	RN	Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors. J Med Chem. 2006 Mar 23;49(6):1855-66.
DMJI6QH	RU	https://pubmed.ncbi.nlm.nih.gov/16539371

DMJI6QH	DI	DMJI6QH
DMJI6QH	DN	4-(4-chlorophenyl)-1-pyrid-2-yl-pyrazole
DMJI6QH	MI	TT06RH5
DMJI6QH	MN	GABA(A) receptor gamma-2 (GABRG2)
DMJI6QH	MT	DTT
DMJI6QH	MA	Inhibitor
DMJI6QH	RN	Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors. J Med Chem. 2006 Mar 23;49(6):1855-66.
DMJI6QH	RU	https://pubmed.ncbi.nlm.nih.gov/16539371

DMJI6QH	DI	DMJI6QH
DMJI6QH	DN	4-(4-chlorophenyl)-1-pyrid-2-yl-pyrazole
DMJI6QH	MI	TTNJYV2
DMJI6QH	MN	Gamma-aminobutyric acid receptor (GAR)
DMJI6QH	MT	DTT
DMJI6QH	MA	Inhibitor
DMJI6QH	RN	Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors. J Med Chem. 2006 Mar 23;49(6):1855-66.
DMJI6QH	RU	https://pubmed.ncbi.nlm.nih.gov/16539371

DMODVGN	DI	DMODVGN
DMODVGN	DN	4-(4-Chlorophenyl)-5-(4-methoxyphenyl)isothiazole
DMODVGN	MI	TT8NGED
DMODVGN	MN	Prostaglandin G/H synthase 1 (COX-1)
DMODVGN	MT	DTT
DMODVGN	MA	Inhibitor
DMODVGN	RN	Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities. Bioorg Med Chem. 2009 Jan 15;17(2):558-68.
DMODVGN	RU	https://pubmed.ncbi.nlm.nih.gov/19097798

DMVN7GC	DI	DMVN7GC
DMVN7GC	DN	4-(4-chlorophenyl)-5-cyano-2H-1,2,3-triazole
DMVN7GC	MI	TTR5TV4
DMVN7GC	MN	ERBB2 messenger RNA (HER2 mRNA)
DMVN7GC	MT	DTT
DMVN7GC	MA	Inhibitor
DMVN7GC	RN	Synthesis and biological evaluation of 4-aryl-5-cyano-2H-1,2,3-triazoles as inhibitor of HER2 tyrosine kinase. Bioorg Med Chem. 2007 Feb 1;15(3):1533-8.
DMVN7GC	RU	https://pubmed.ncbi.nlm.nih.gov/17174554

DMZBEYO	DI	DMZBEYO
DMZBEYO	DN	4-(4-Chlorophenyl)-5-p-tolyl-1,2-selenazole
DMZBEYO	MI	TT8NGED
DMZBEYO	MN	Prostaglandin G/H synthase 1 (COX-1)
DMZBEYO	MT	DTT
DMZBEYO	MA	Inhibitor
DMZBEYO	RN	Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles. Eur J Med Chem. 2008 Jun;43(6):1152-9.
DMZBEYO	RU	https://pubmed.ncbi.nlm.nih.gov/17976864

DMZBEYO	DI	DMZBEYO
DMZBEYO	DN	4-(4-Chlorophenyl)-5-p-tolyl-1,2-selenazole
DMZBEYO	MI	TTVKILB
DMZBEYO	MN	Prostaglandin G/H synthase 2 (COX-2)
DMZBEYO	MT	DTT
DMZBEYO	MA	Inhibitor
DMZBEYO	RN	Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles. Eur J Med Chem. 2008 Jun;43(6):1152-9.
DMZBEYO	RU	https://pubmed.ncbi.nlm.nih.gov/17976864

DMVDF9Q	DI	DMVDF9Q
DMVDF9Q	DN	4-(4-Chlorophenyl)-5-p-tolyl-3H-1,2-dithiol-3-one
DMVDF9Q	MI	TT8NGED
DMVDF9Q	MN	Prostaglandin G/H synthase 1 (COX-1)
DMVDF9Q	MT	DTT
DMVDF9Q	MA	Inhibitor
DMVDF9Q	RN	Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities. Bioorg Med Chem. 2009 Jan 15;17(2):558-68.
DMVDF9Q	RU	https://pubmed.ncbi.nlm.nih.gov/19097798

DMMK9RC	DI	DMMK9RC
DMMK9RC	DN	4-(4-Chlorophenyl)-5-p-tolylisothiazole
DMMK9RC	MI	TT8NGED
DMMK9RC	MN	Prostaglandin G/H synthase 1 (COX-1)
DMMK9RC	MT	DTT
DMMK9RC	MA	Inhibitor
DMMK9RC	RN	Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities. Bioorg Med Chem. 2009 Jan 15;17(2):558-68.
DMMK9RC	RU	https://pubmed.ncbi.nlm.nih.gov/19097798

DM9YRHW	DI	DM9YRHW
DM9YRHW	DN	4-(4-chlorophenylthio)-2-(pyridin-2-yl)pyrimidine
DM9YRHW	MI	TTHS256
DM9YRHW	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM9YRHW	MT	DTT
DM9YRHW	MA	Inhibitor
DM9YRHW	RN	Structure-activity relationship of thiopyrimidines as mGluR5 antagonists. Bioorg Med Chem Lett. 2006 May 1;16(9):2467-9.
DM9YRHW	RU	https://pubmed.ncbi.nlm.nih.gov/16481165

DMNEAJH	DI	DMNEAJH
DMNEAJH	DN	4-(4-Cyanophenoxy)-3-pyridinesulfonamide
DMNEAJH	MI	TTHQPL7
DMNEAJH	MN	Carbonic anhydrase I (CA-I)
DMNEAJH	MT	DTT
DMNEAJH	MA	Inhibitor
DMNEAJH	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMNEAJH	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMNEAJH	DI	DMNEAJH
DMNEAJH	DN	4-(4-Cyanophenoxy)-3-pyridinesulfonamide
DMNEAJH	MI	TTANPDJ
DMNEAJH	MN	Carbonic anhydrase II (CA-II)
DMNEAJH	MT	DTT
DMNEAJH	MA	Inhibitor
DMNEAJH	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMNEAJH	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMNEAJH	DI	DMNEAJH
DMNEAJH	DN	4-(4-Cyanophenoxy)-3-pyridinesulfonamide
DMNEAJH	MI	TT2LVK8
DMNEAJH	MN	Carbonic anhydrase IX (CA-IX)
DMNEAJH	MT	DTT
DMNEAJH	MA	Inhibitor
DMNEAJH	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMNEAJH	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMNEAJH	DI	DMNEAJH
DMNEAJH	DN	4-(4-Cyanophenoxy)-3-pyridinesulfonamide
DMNEAJH	MI	TTSYM0R
DMNEAJH	MN	Carbonic anhydrase XII (CA-XII)
DMNEAJH	MT	DTT
DMNEAJH	MA	Inhibitor
DMNEAJH	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMNEAJH	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMSYH8R	DI	DMSYH8R
DMSYH8R	DN	4-(4-cyclohexylthiosemicarbazono)methyl-phenol
DMSYH8R	MI	TTHM0R1
DMSYH8R	MN	Steryl-sulfatase (STS)
DMSYH8R	MT	DTT
DMSYH8R	MA	Inhibitor
DMSYH8R	RN	Thiosemicarbazones of formyl benzoic acids as novel potent inhibitors of estrone sulfatase. J Med Chem. 2007 Jul 26;50(15):3661-6.
DMSYH8R	RU	https://pubmed.ncbi.nlm.nih.gov/17580843

DMCDKHJ	DI	DMCDKHJ
DMCDKHJ	DN	4-(4-Decyloxy-phenyl)-1,1,1-trifluoro-butan-2-one
DMCDKHJ	MI	TTT1JVS
DMCDKHJ	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DMCDKHJ	MT	DTT
DMCDKHJ	MA	Inhibitor
DMCDKHJ	RN	Synthesis of polyfluoro ketones for selective inhibition of human phospholipase A2 enzymes. J Med Chem. 2008 Dec 25;51(24):8027-37.
DMCDKHJ	RU	https://pubmed.ncbi.nlm.nih.gov/19053783

DMA6E28	DI	DMA6E28
DMA6E28	DN	4'-(4-Fluorobenzensulfonamide)-4-hydroxychalcone
DMA6E28	MI	TTULVH8
DMA6E28	MN	Tyrosinase (TYR)
DMA6E28	MT	DTT
DMA6E28	MA	Inhibitor
DMA6E28	RN	Evaluation of anti-pigmentary effect of synthetic sulfonylamino chalcone. Eur J Med Chem. 2010 May;45(5):2010-7.
DMA6E28	RU	https://pubmed.ncbi.nlm.nih.gov/20149498

DMW8IN3	DI	DMW8IN3
DMW8IN3	DN	4-(4-FLUOROBENZYL)PIPERIDINE
DMW8IN3	MI	TT8JRS7
DMW8IN3	MN	Beta-secretase (BACE)
DMW8IN3	MT	DTT
DMW8IN3	MA	Inhibitor
DMW8IN3	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMW8IN3	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM4NEOU	DI	DM4NEOU
DM4NEOU	DN	4-(4-Fluoro-benzyl)-piperidine hydrochloride
DM4NEOU	MI	TTJQOD7
DM4NEOU	MN	5-HT 2A receptor (HTR2A)
DM4NEOU	MT	DTT
DM4NEOU	MA	Inhibitor
DM4NEOU	RN	Ketanserin analogues: structure-affinity relationships for 5-HT2 and 5-HT1C serotonin receptor binding. J Med Chem. 1992 Dec 25;35(26):4903-10.
DM4NEOU	RU	https://pubmed.ncbi.nlm.nih.gov/1479590

DMRJD75	DI	DMRJD75
DMRJD75	DN	4-(4-fluoro-benzylideneamino)-benzenesulfonamide
DMRJD75	MI	TTVKILB
DMRJD75	MN	Prostaglandin G/H synthase 2 (COX-2)
DMRJD75	MT	DTT
DMRJD75	MA	Inhibitor
DMRJD75	RN	Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides. Bioorg Med Chem. 2008 Mar 1;16(5):2697-706.
DMRJD75	RU	https://pubmed.ncbi.nlm.nih.gov/18063374

DM52NMU	DI	DM52NMU
DM52NMU	DN	4-(4'-Fluoro-biphenyl-4-ylmethyl)pyridine
DM52NMU	MI	TTIQUX7
DM52NMU	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM52NMU	MT	DTT
DM52NMU	MA	Inhibitor
DM52NMU	RN	Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
DM52NMU	RU	https://pubmed.ncbi.nlm.nih.gov/20684610

DM52NMU	DI	DM52NMU
DM52NMU	DN	4-(4'-Fluoro-biphenyl-4-ylmethyl)pyridine
DM52NMU	MI	TTRA5BZ
DM52NMU	MN	Steroid 17-alpha-monooxygenase (S17AH)
DM52NMU	MT	DTT
DM52NMU	MA	Inhibitor
DM52NMU	RN	Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
DM52NMU	RU	https://pubmed.ncbi.nlm.nih.gov/20684610

DMRJLAP	DI	DMRJLAP
DMRJLAP	DN	4-(4-Fluorophenoxy)-3-pyridinesulfonamide
DMRJLAP	MI	TTHQPL7
DMRJLAP	MN	Carbonic anhydrase I (CA-I)
DMRJLAP	MT	DTT
DMRJLAP	MA	Inhibitor
DMRJLAP	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMRJLAP	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMRJLAP	DI	DMRJLAP
DMRJLAP	DN	4-(4-Fluorophenoxy)-3-pyridinesulfonamide
DMRJLAP	MI	TTANPDJ
DMRJLAP	MN	Carbonic anhydrase II (CA-II)
DMRJLAP	MT	DTT
DMRJLAP	MA	Inhibitor
DMRJLAP	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMRJLAP	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMRJLAP	DI	DMRJLAP
DMRJLAP	DN	4-(4-Fluorophenoxy)-3-pyridinesulfonamide
DMRJLAP	MI	TT2LVK8
DMRJLAP	MN	Carbonic anhydrase IX (CA-IX)
DMRJLAP	MT	DTT
DMRJLAP	MA	Inhibitor
DMRJLAP	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMRJLAP	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMRJLAP	DI	DMRJLAP
DMRJLAP	DN	4-(4-Fluorophenoxy)-3-pyridinesulfonamide
DMRJLAP	MI	TTSYM0R
DMRJLAP	MN	Carbonic anhydrase XII (CA-XII)
DMRJLAP	MT	DTT
DMRJLAP	MA	Inhibitor
DMRJLAP	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMRJLAP	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMK8DCF	DI	DMK8DCF
DMK8DCF	DN	4-(4-fluoro-phenyliminomethyl)-benzenesulfonamide
DMK8DCF	MI	TTVKILB
DMK8DCF	MN	Prostaglandin G/H synthase 2 (COX-2)
DMK8DCF	MT	DTT
DMK8DCF	MA	Inhibitor
DMK8DCF	RN	Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides. Bioorg Med Chem. 2008 Mar 1;16(5):2697-706.
DMK8DCF	RU	https://pubmed.ncbi.nlm.nih.gov/18063374

DMR9TBW	DI	DMR9TBW
DMR9TBW	DN	4-(4-hexylphenyl)-4-oxobut-2-enoic acid
DMR9TBW	MI	TTTSEPU
DMR9TBW	MN	Thyroid hormone receptor alpha (THRA)
DMR9TBW	MT	DTT
DMR9TBW	MA	Inhibitor
DMR9TBW	RN	Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80.
DMR9TBW	RU	https://pubmed.ncbi.nlm.nih.gov/17918822

DMR9TBW	DI	DMR9TBW
DMR9TBW	DN	4-(4-hexylphenyl)-4-oxobut-2-enoic acid
DMR9TBW	MI	TTGER3L
DMR9TBW	MN	Thyroid hormone receptor beta (THRB)
DMR9TBW	MT	DTT
DMR9TBW	MA	Inhibitor
DMR9TBW	RN	Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80.
DMR9TBW	RU	https://pubmed.ncbi.nlm.nih.gov/17918822

DMNY0I5	DI	DMNY0I5
DMNY0I5	DN	4-(4-hydroxy-benzylideneamino)-benzenesulfonamide
DMNY0I5	MI	TTANPDJ
DMNY0I5	MN	Carbonic anhydrase II (CA-II)
DMNY0I5	MT	DTT
DMNY0I5	MA	Inhibitor
DMNY0I5	RN	Carbonic anhydrase II-induced selection of inhibitors from a dynamic combinatorial library of Schiff's bases. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6014-7.
DMNY0I5	RU	https://pubmed.ncbi.nlm.nih.gov/19796939

DMNY0I5	DI	DMNY0I5
DMNY0I5	DN	4-(4-hydroxy-benzylideneamino)-benzenesulfonamide
DMNY0I5	MI	TTVKILB
DMNY0I5	MN	Prostaglandin G/H synthase 2 (COX-2)
DMNY0I5	MT	DTT
DMNY0I5	MA	Inhibitor
DMNY0I5	RN	Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides. Bioorg Med Chem. 2008 Mar 1;16(5):2697-706.
DMNY0I5	RU	https://pubmed.ncbi.nlm.nih.gov/18063374

DML357W	DI	DML357W
DML357W	DN	4-(4-hydroxybenzylideneamino)benzoic acid
DML357W	MI	TTANPDJ
DML357W	MN	Carbonic anhydrase II (CA-II)
DML357W	MT	DTT
DML357W	MA	Inhibitor
DML357W	RN	Carbonic anhydrase II-induced selection of inhibitors from a dynamic combinatorial library of Schiff's bases. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6014-7.
DML357W	RU	https://pubmed.ncbi.nlm.nih.gov/19796939

DMZT6HL	DI	DMZT6HL
DMZT6HL	DN	4-(4-HYDROXYPHENYL)-1-NAPHTHALDEHYDE OXIME
DMZT6HL	MI	TTOM3J0
DMZT6HL	MN	Estrogen receptor beta (ESR2)
DMZT6HL	MT	DTT
DMZT6HL	MA	Inhibitor
DMZT6HL	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMZT6HL	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMC9Z45	DI	DMC9Z45
DMC9Z45	DN	4-(4-Isopropyl-morpholin-2-yl)-benzene-1,2-diol
DMC9Z45	MI	TTNGILX
DMC9Z45	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMC9Z45	MT	DTT
DMC9Z45	MA	Inhibitor
DMC9Z45	RN	Conformational effects on the activity of drugs. 13. A revision of previously proposed models for the activation of alpha- and beta-adrenergic rece... J Med Chem. 1992 Mar 20;35(6):1009-18.
DMC9Z45	RU	https://pubmed.ncbi.nlm.nih.gov/1313109

DMC9Z45	DI	DMC9Z45
DMC9Z45	DN	4-(4-Isopropyl-morpholin-2-yl)-benzene-1,2-diol
DMC9Z45	MI	TTBRKXS
DMC9Z45	MN	Adrenergic receptor alpha-1B (ADRA1B)
DMC9Z45	MT	DTT
DMC9Z45	MA	Inhibitor
DMC9Z45	RN	Conformational effects on the activity of drugs. 13. A revision of previously proposed models for the activation of alpha- and beta-adrenergic rece... J Med Chem. 1992 Mar 20;35(6):1009-18.
DMC9Z45	RU	https://pubmed.ncbi.nlm.nih.gov/1313109

DMC9Z45	DI	DMC9Z45
DMC9Z45	DN	4-(4-Isopropyl-morpholin-2-yl)-benzene-1,2-diol
DMC9Z45	MI	TT34BHT
DMC9Z45	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMC9Z45	MT	DTT
DMC9Z45	MA	Inhibitor
DMC9Z45	RN	Conformational effects on the activity of drugs. 13. A revision of previously proposed models for the activation of alpha- and beta-adrenergic rece... J Med Chem. 1992 Mar 20;35(6):1009-18.
DMC9Z45	RU	https://pubmed.ncbi.nlm.nih.gov/1313109

DMRGM21	DI	DMRGM21
DMRGM21	DN	4-(4-isopropylphenyl)-5-cyano-2H-1,2,3-triazole
DMRGM21	MI	TTR5TV4
DMRGM21	MN	ERBB2 messenger RNA (HER2 mRNA)
DMRGM21	MT	DTT
DMRGM21	MA	Inhibitor
DMRGM21	RN	Synthesis and biological evaluation of 4-aryl-5-cyano-2H-1,2,3-triazoles as inhibitor of HER2 tyrosine kinase. Bioorg Med Chem. 2007 Feb 1;15(3):1533-8.
DMRGM21	RU	https://pubmed.ncbi.nlm.nih.gov/17174554

DMA7LEO	DI	DMA7LEO
DMA7LEO	DN	4-(4-methoxy-1H-indol-1-ylsulfonyl)benzenamine
DMA7LEO	MI	TTJS8PY
DMA7LEO	MN	5-HT 6 receptor (HTR6)
DMA7LEO	MT	DTT
DMA7LEO	MA	Inhibitor
DMA7LEO	RN	Binding of methoxy-substituted N1-benzenesulfonylindole analogs at human 5-HT6 serotonin receptors. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3793-6.
DMA7LEO	RU	https://pubmed.ncbi.nlm.nih.gov/16709453

DM5PTB9	DI	DM5PTB9
DM5PTB9	DN	4-(4-Methoxy-benzenesulfonyl)-butane-2-thiol
DM5PTB9	MI	TTMX39J
DM5PTB9	MN	Matrix metalloproteinase-1 (MMP-1)
DM5PTB9	MT	DTT
DM5PTB9	MA	Inhibitor
DM5PTB9	RN	Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols. Bioorg Med Chem Lett. 1999 Apr 5;9(7):943-8.
DM5PTB9	RU	https://pubmed.ncbi.nlm.nih.gov/10230616

DM5PTB9	DI	DM5PTB9
DM5PTB9	DN	4-(4-Methoxy-benzenesulfonyl)-butane-2-thiol
DM5PTB9	MI	TTHY57M
DM5PTB9	MN	Matrix metalloproteinase-13 (MMP-13)
DM5PTB9	MT	DTT
DM5PTB9	MA	Inhibitor
DM5PTB9	RN	Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols. Bioorg Med Chem Lett. 1999 Apr 5;9(7):943-8.
DM5PTB9	RU	https://pubmed.ncbi.nlm.nih.gov/10230616

DM2OR8E	DI	DM2OR8E
DM2OR8E	DN	4-(4-methoxy-benzylideneamino)-benzenesulfonamide
DM2OR8E	MI	TTVKILB
DM2OR8E	MN	Prostaglandin G/H synthase 2 (COX-2)
DM2OR8E	MT	DTT
DM2OR8E	MA	Inhibitor
DM2OR8E	RN	Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides. Bioorg Med Chem. 2008 Mar 1;16(5):2697-706.
DM2OR8E	RU	https://pubmed.ncbi.nlm.nih.gov/18063374

DMZSQ04	DI	DMZSQ04
DMZSQ04	DN	4-(4-methyl-benzylideneamino)-benzenesulfonamide
DMZSQ04	MI	TTVKILB
DMZSQ04	MN	Prostaglandin G/H synthase 2 (COX-2)
DMZSQ04	MT	DTT
DMZSQ04	MA	Inhibitor
DMZSQ04	RN	Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides. Bioorg Med Chem. 2008 Mar 1;16(5):2697-706.
DMZSQ04	RU	https://pubmed.ncbi.nlm.nih.gov/18063374

DMYZHXR	DI	DMYZHXR
DMYZHXR	DN	4-(4-Methyl-indan-1-yl)-1H-imidazole
DMYZHXR	MI	TTNGILX
DMYZHXR	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMYZHXR	MT	DTT
DMYZHXR	MA	Inhibitor
DMYZHXR	RN	Medetomidine analogs as alpha 2-adrenergic ligands. 3. Synthesis and biological evaluation of a new series of medetomidine analogs and their potent... J Med Chem. 1997 Sep 12;40(19):3014-24.
DMYZHXR	RU	https://pubmed.ncbi.nlm.nih.gov/9301663

DMYZHXR	DI	DMYZHXR
DMYZHXR	DN	4-(4-Methyl-indan-1-yl)-1H-imidazole
DMYZHXR	MI	TTBRKXS
DMYZHXR	MN	Adrenergic receptor alpha-1B (ADRA1B)
DMYZHXR	MT	DTT
DMYZHXR	MA	Inhibitor
DMYZHXR	RN	Medetomidine analogs as alpha 2-adrenergic ligands. 3. Synthesis and biological evaluation of a new series of medetomidine analogs and their potent... J Med Chem. 1997 Sep 12;40(19):3014-24.
DMYZHXR	RU	https://pubmed.ncbi.nlm.nih.gov/9301663

DMYZHXR	DI	DMYZHXR
DMYZHXR	DN	4-(4-Methyl-indan-1-yl)-1H-imidazole
DMYZHXR	MI	TT34BHT
DMYZHXR	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMYZHXR	MT	DTT
DMYZHXR	MA	Inhibitor
DMYZHXR	RN	Medetomidine analogs as alpha 2-adrenergic ligands. 3. Synthesis and biological evaluation of a new series of medetomidine analogs and their potent... J Med Chem. 1997 Sep 12;40(19):3014-24.
DMYZHXR	RU	https://pubmed.ncbi.nlm.nih.gov/9301663

DMYZHXR	DI	DMYZHXR
DMYZHXR	DN	4-(4-Methyl-indan-1-yl)-1H-imidazole
DMYZHXR	MI	TTWG9A4
DMYZHXR	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMYZHXR	MT	DTT
DMYZHXR	MA	Inhibitor
DMYZHXR	RN	Medetomidine analogs as alpha 2-adrenergic ligands. 3. Synthesis and biological evaluation of a new series of medetomidine analogs and their potent... J Med Chem. 1997 Sep 12;40(19):3014-24.
DMYZHXR	RU	https://pubmed.ncbi.nlm.nih.gov/9301663

DMYZHXR	DI	DMYZHXR
DMYZHXR	DN	4-(4-Methyl-indan-1-yl)-1H-imidazole
DMYZHXR	MI	TTWM4TY
DMYZHXR	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMYZHXR	MT	DTT
DMYZHXR	MA	Inhibitor
DMYZHXR	RN	Medetomidine analogs as alpha 2-adrenergic ligands. 3. Synthesis and biological evaluation of a new series of medetomidine analogs and their potent... J Med Chem. 1997 Sep 12;40(19):3014-24.
DMYZHXR	RU	https://pubmed.ncbi.nlm.nih.gov/9301663

DMYZHXR	DI	DMYZHXR
DMYZHXR	DN	4-(4-Methyl-indan-1-yl)-1H-imidazole
DMYZHXR	MI	TT2NUT5
DMYZHXR	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMYZHXR	MT	DTT
DMYZHXR	MA	Inhibitor
DMYZHXR	RN	Medetomidine analogs as alpha 2-adrenergic ligands. 3. Synthesis and biological evaluation of a new series of medetomidine analogs and their potent... J Med Chem. 1997 Sep 12;40(19):3014-24.
DMYZHXR	RU	https://pubmed.ncbi.nlm.nih.gov/9301663

DMV0S4U	DI	DMV0S4U
DMV0S4U	DN	4-(4-methyl-phenyliminomethyl)-benzenesulfonamide
DMV0S4U	MI	TTVKILB
DMV0S4U	MN	Prostaglandin G/H synthase 2 (COX-2)
DMV0S4U	MT	DTT
DMV0S4U	MA	Inhibitor
DMV0S4U	RN	Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides. Bioorg Med Chem. 2008 Mar 1;16(5):2697-706.
DMV0S4U	RU	https://pubmed.ncbi.nlm.nih.gov/18063374

DMS74F2	DI	DMS74F2
DMS74F2	DN	4-(4-Morpholin-4-yl-butyl)-2H-phthalazin-1-one
DMS74F2	MI	TTVDSZ0
DMS74F2	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMS74F2	MT	DTT
DMS74F2	MA	Inhibitor
DMS74F2	RN	4-Phenyl-1,2,3,6-tetrahydropyridine, an excellent fragment to improve the potency of PARP-1 inhibitors. Bioorg Med Chem Lett. 2005 Oct 1;15(19):4221-5.
DMS74F2	RU	https://pubmed.ncbi.nlm.nih.gov/16098744

DM3KCL1	DI	DM3KCL1
DM3KCL1	DN	4-(4-m-Tolylamino-phthalazin-1-yl)-benzamide
DM3KCL1	MI	TTUTJGQ
DM3KCL1	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM3KCL1	MT	DTT
DM3KCL1	MA	Inhibitor
DM3KCL1	RN	Arylphthalazines: identification of a new phthalazine chemotype as inhibitors of VEGFR kinase. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4696-8.
DM3KCL1	RU	https://pubmed.ncbi.nlm.nih.gov/16143524

DMHB1N6	DI	DMHB1N6
DMHB1N6	DN	4'-(4-Nitrobenzensulfonamide)-4-hydroxychalcone
DMHB1N6	MI	TTULVH8
DMHB1N6	MN	Tyrosinase (TYR)
DMHB1N6	MT	DTT
DMHB1N6	MA	Inhibitor
DMHB1N6	RN	Evaluation of anti-pigmentary effect of synthetic sulfonylamino chalcone. Eur J Med Chem. 2010 May;45(5):2010-7.
DMHB1N6	RU	https://pubmed.ncbi.nlm.nih.gov/20149498

DMM86YK	DI	DMM86YK
DMM86YK	DN	4-(4-nitro-benzylideneamino)-benzenesulfonamide
DMM86YK	MI	TTVKILB
DMM86YK	MN	Prostaglandin G/H synthase 2 (COX-2)
DMM86YK	MT	DTT
DMM86YK	MA	Inhibitor
DMM86YK	RN	Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides. Bioorg Med Chem. 2008 Mar 1;16(5):2697-706.
DMM86YK	RU	https://pubmed.ncbi.nlm.nih.gov/18063374

DMGVNE3	DI	DMGVNE3
DMGVNE3	DN	4-(4'-N-Methylphenyl)diazenylbenzenesulfonamide
DMGVNE3	MI	TT2LVK8
DMGVNE3	MN	Carbonic anhydrase IX (CA-IX)
DMGVNE3	MT	DTT
DMGVNE3	MA	Inhibitor
DMGVNE3	RN	Carbonic anhydrase inhibitors. Diazenylbenzenesulfonamides are potent and selective inhibitors of the tumor-associated isozymes IX and XII over the... Bioorg Med Chem. 2009 Oct 15;17(20):7093-9.
DMGVNE3	RU	https://pubmed.ncbi.nlm.nih.gov/19773173

DMGVNE3	DI	DMGVNE3
DMGVNE3	DN	4-(4'-N-Methylphenyl)diazenylbenzenesulfonamide
DMGVNE3	MI	TTSYM0R
DMGVNE3	MN	Carbonic anhydrase XII (CA-XII)
DMGVNE3	MT	DTT
DMGVNE3	MA	Inhibitor
DMGVNE3	RN	Carbonic anhydrase inhibitors. Diazenylbenzenesulfonamides are potent and selective inhibitors of the tumor-associated isozymes IX and XII over the... Bioorg Med Chem. 2009 Oct 15;17(20):7093-9.
DMGVNE3	RU	https://pubmed.ncbi.nlm.nih.gov/19773173

DMOHB6U	DI	DMOHB6U
DMOHB6U	DN	4-(4-phenoxybenzoyl)benzoic acid
DMOHB6U	MI	TTTU72V
DMOHB6U	MN	Steroid 5-alpha-reductase 1 (SRD5A1)
DMOHB6U	MT	DTT
DMOHB6U	MA	Inhibitor
DMOHB6U	RN	Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J Med Chem. 2006 Jan 26;49(2):748-59.
DMOHB6U	RU	https://pubmed.ncbi.nlm.nih.gov/16420060

DMOHB6U	DI	DMOHB6U
DMOHB6U	DN	4-(4-phenoxybenzoyl)benzoic acid
DMOHB6U	MI	TTT02K8
DMOHB6U	MN	Steroid 5-alpha-reductase 2 (SRD5A2)
DMOHB6U	MT	DTT
DMOHB6U	MA	Inhibitor
DMOHB6U	RN	Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J Med Chem. 2006 Jan 26;49(2):748-59.
DMOHB6U	RU	https://pubmed.ncbi.nlm.nih.gov/16420060

DMQ0JWZ	DI	DMQ0JWZ
DMQ0JWZ	DN	4-(4-phenoxybenzoyl)phenylacetic acid
DMQ0JWZ	MI	TTT02K8
DMQ0JWZ	MN	Steroid 5-alpha-reductase 2 (SRD5A2)
DMQ0JWZ	MT	DTT
DMQ0JWZ	MA	Inhibitor
DMQ0JWZ	RN	Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J Med Chem. 2006 Jan 26;49(2):748-59.
DMQ0JWZ	RU	https://pubmed.ncbi.nlm.nih.gov/16420060

DMKMH5L	DI	DMKMH5L
DMKMH5L	DN	4-(4-phenoxybutoxy)-7H-furo[3,2-g]chromen-7-one
DMKMH5L	MI	TTMNI76
DMKMH5L	MN	Calcium-activated potassium channel (KCN)
DMKMH5L	MT	DTT
DMKMH5L	MA	Inhibitor
DMKMH5L	RN	Inhibitors of potassium channels KV1.3 and IK-1 as immunosuppressants. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2299-304.
DMKMH5L	RU	https://pubmed.ncbi.nlm.nih.gov/19282171

DMKMH5L	DI	DMKMH5L
DMKMH5L	DN	4-(4-phenoxybutoxy)-7H-furo[3,2-g]chromen-7-one
DMKMH5L	MI	TTY3UE6
DMKMH5L	MN	Voltage-gated potassium channel Kv1.3 (KCNA3)
DMKMH5L	MT	DTT
DMKMH5L	MA	Inhibitor
DMKMH5L	RN	Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol Pharmacol. 2005 Nov;68(5):1254-70.
DMKMH5L	RU	https://pubmed.ncbi.nlm.nih.gov/16099841

DMKMH5L	DI	DMKMH5L
DMKMH5L	DN	4-(4-phenoxybutoxy)-7H-furo[3,2-g]chromen-7-one
DMKMH5L	MI	TTW0CMT
DMKMH5L	MN	Voltage-gated potassium channel Kv1.5 (KCNA5)
DMKMH5L	MT	DTT
DMKMH5L	MA	Inhibitor
DMKMH5L	RN	Substituted N-{3-[(1,1-dioxido-1,2-benzothiazol-3-yl)(phenyl)amino]propyl}benzamide analogs as potent Kv1.3 ion channel blockers. Part 2. Bioorg Med Chem Lett. 2010 Dec 1;20(23):6989-92.
DMKMH5L	RU	https://pubmed.ncbi.nlm.nih.gov/20974533

DMBZHUA	DI	DMBZHUA
DMBZHUA	DN	4-(4-propoxyphenoxy)phenol
DMBZHUA	MI	TTXZEAJ
DMBZHUA	MN	Leukotriene A-4 hydrolase (LTA4H)
DMBZHUA	MT	DTT
DMBZHUA	MA	Inhibitor
DMBZHUA	RN	Activation and inhibition of leukotriene A4 hydrolase aminopeptidase activity by diphenyl ether and derivatives. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6549-52.
DMBZHUA	RU	https://pubmed.ncbi.nlm.nih.gov/18952425

DM6ESXB	DI	DM6ESXB
DM6ESXB	DN	4-(4-p-Tolylamino-phthalazin-1-yl)-benzamide
DM6ESXB	MI	TTUTJGQ
DM6ESXB	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM6ESXB	MT	DTT
DM6ESXB	MA	Inhibitor
DM6ESXB	RN	Arylphthalazines: identification of a new phthalazine chemotype as inhibitors of VEGFR kinase. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4696-8.
DM6ESXB	RU	https://pubmed.ncbi.nlm.nih.gov/16143524

DMFLH2G	DI	DMFLH2G
DMFLH2G	DN	4-(4-tert-butylbenzylideneamino)benzoic acid
DMFLH2G	MI	TTANPDJ
DMFLH2G	MN	Carbonic anhydrase II (CA-II)
DMFLH2G	MT	DTT
DMFLH2G	MA	Inhibitor
DMFLH2G	RN	Carbonic anhydrase II-induced selection of inhibitors from a dynamic combinatorial library of Schiff's bases. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6014-7.
DMFLH2G	RU	https://pubmed.ncbi.nlm.nih.gov/19796939

DMG6DV9	DI	DMG6DV9
DMG6DV9	DN	4-(4-tert-butylbenzylthio)-2-aminobutanoic acid
DMG6DV9	MI	TTFK1JQ
DMG6DV9	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMG6DV9	MT	DTT
DMG6DV9	MA	Inhibitor
DMG6DV9	RN	Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41.
DMG6DV9	RU	https://pubmed.ncbi.nlm.nih.gov/16380257

DMGHVW7	DI	DMGHVW7
DMGHVW7	DN	4-(5-(4-(methylamino)phenyl)thiophen-2-yl)phenol
DMGHVW7	MI	TTE4KHA
DMGHVW7	MN	Amyloid beta A4 protein (APP)
DMGHVW7	MT	DTT
DMGHVW7	MA	Inhibitor
DMGHVW7	RN	Design, synthesis, and structure-activity relationship of novel thiophene derivatives for beta-amyloid plaque imaging. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1350-2.
DMGHVW7	RU	https://pubmed.ncbi.nlm.nih.gov/16325402

DMOGMJ9	DI	DMOGMJ9
DMOGMJ9	DN	4-(5-(4-aminophenyl)thiophen-2-yl)benzenamine
DMOGMJ9	MI	TTE4KHA
DMOGMJ9	MN	Amyloid beta A4 protein (APP)
DMOGMJ9	MT	DTT
DMOGMJ9	MA	Inhibitor
DMOGMJ9	RN	Design, synthesis, and structure-activity relationship of novel thiophene derivatives for beta-amyloid plaque imaging. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1350-2.
DMOGMJ9	RU	https://pubmed.ncbi.nlm.nih.gov/16325402

DM1UX89	DI	DM1UX89
DM1UX89	DN	4-(5-(4-aminophenyl)thiophen-2-yl)phenol
DM1UX89	MI	TTE4KHA
DM1UX89	MN	Amyloid beta A4 protein (APP)
DM1UX89	MT	DTT
DM1UX89	MA	Inhibitor
DM1UX89	RN	Design, synthesis, and structure-activity relationship of novel thiophene derivatives for beta-amyloid plaque imaging. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1350-2.
DM1UX89	RU	https://pubmed.ncbi.nlm.nih.gov/16325402

DMK1ZF2	DI	DMK1ZF2
DMK1ZF2	DN	4-(5-(4-Hydroxyphenyl)isothiazol-4-yl)phenol
DMK1ZF2	MI	TT8NGED
DMK1ZF2	MN	Prostaglandin G/H synthase 1 (COX-1)
DMK1ZF2	MT	DTT
DMK1ZF2	MA	Inhibitor
DMK1ZF2	RN	Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities. Bioorg Med Chem. 2009 Jan 15;17(2):558-68.
DMK1ZF2	RU	https://pubmed.ncbi.nlm.nih.gov/19097798

DMO9YH0	DI	DMO9YH0
DMO9YH0	DN	4-(5-(4-methoxyphenyl)thiophen-2-yl)benzenamine
DMO9YH0	MI	TTE4KHA
DMO9YH0	MN	Amyloid beta A4 protein (APP)
DMO9YH0	MT	DTT
DMO9YH0	MA	Inhibitor
DMO9YH0	RN	Design, synthesis, and structure-activity relationship of novel thiophene derivatives for beta-amyloid plaque imaging. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1350-2.
DMO9YH0	RU	https://pubmed.ncbi.nlm.nih.gov/16325402

DMCNLBZ	DI	DMCNLBZ
DMCNLBZ	DN	4-(5-(4-methoxyphenyl)thiophen-2-yl)phenol
DMCNLBZ	MI	TTE4KHA
DMCNLBZ	MN	Amyloid beta A4 protein (APP)
DMCNLBZ	MT	DTT
DMCNLBZ	MA	Inhibitor
DMCNLBZ	RN	Design, synthesis, and structure-activity relationship of novel thiophene derivatives for beta-amyloid plaque imaging. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1350-2.
DMCNLBZ	RU	https://pubmed.ncbi.nlm.nih.gov/16325402

DMJKUQI	DI	DMJKUQI
DMJKUQI	DN	4-(5-bromo-1H-indol-3-yl)pyrimidin-2-amine
DMJKUQI	MI	TTRSMW9
DMJKUQI	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMJKUQI	MT	DTT
DMJKUQI	MA	Inhibitor
DMJKUQI	RN	Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models. Eur J Med Chem. 2009 Jun;44(6):2361-71.
DMJKUQI	RU	https://pubmed.ncbi.nlm.nih.gov/18929433

DMLSGU1	DI	DMLSGU1
DMLSGU1	DN	4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline
DMLSGU1	MI	TTGKNB4
DMLSGU1	MN	Epidermal growth factor receptor (EGFR)
DMLSGU1	MT	DTT
DMLSGU1	MA	Inhibitor
DMLSGU1	RN	Syntheses of 4-(indole-3-yl)quinazolines: a new class of epidermal growth factor receptor tyrosine kinase inhibitors. Eur J Med Chem. 2008 Jul;43(7):1478-88.
DMLSGU1	RU	https://pubmed.ncbi.nlm.nih.gov/17981366

DMDYBIC	DI	DMDYBIC
DMDYBIC	DN	4'-(5-Chloro-2-thienyl)biphenyl-3-ol
DMDYBIC	MI	TTIWB6L
DMDYBIC	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMDYBIC	MT	DTT
DMDYBIC	MA	Inhibitor
DMDYBIC	RN	Novel estrone mimetics with high 17beta-HSD1 inhibitory activity. Bioorg Med Chem. 2010 May 15;18(10):3494-505.
DMDYBIC	RU	https://pubmed.ncbi.nlm.nih.gov/20413314

DM1EANV	DI	DM1EANV
DM1EANV	DN	4-(5-Hydroxy-benzooxazol-2-yl)-benzene-1,3-diol
DM1EANV	MI	TTZAYWL
DM1EANV	MN	Estrogen receptor (ESR)
DM1EANV	MT	DTT
DM1EANV	MA	Inhibitor
DM1EANV	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DM1EANV	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DM1EANV	DI	DM1EANV
DM1EANV	DN	4-(5-Hydroxy-benzooxazol-2-yl)-benzene-1,3-diol
DM1EANV	MI	TTOM3J0
DM1EANV	MN	Estrogen receptor beta (ESR2)
DM1EANV	MT	DTT
DM1EANV	MA	Inhibitor
DM1EANV	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DM1EANV	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMIWT60	DI	DMIWT60
DMIWT60	DN	4-(5-Methoxy-benzoimidazol-1-yl)-phenylamine
DMIWT60	MI	TT8FYO9
DMIWT60	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMIWT60	MT	DTT
DMIWT60	MA	Inhibitor
DMIWT60	RN	Structure-activity relationships for 5-substituted 1-phenylbenzimidazoles as selective inhibitors of the platelet-derived growth factor receptor. J Med Chem. 1999 Jul 1;42(13):2373-82.
DMIWT60	RU	https://pubmed.ncbi.nlm.nih.gov/10395478

DMIWT60	DI	DMIWT60
DMIWT60	DN	4-(5-Methoxy-benzoimidazol-1-yl)-phenylamine
DMIWT60	MI	TTI7421
DMIWT60	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMIWT60	MT	DTT
DMIWT60	MA	Inhibitor
DMIWT60	RN	Structure-activity relationships for 5-substituted 1-phenylbenzimidazoles as selective inhibitors of the platelet-derived growth factor receptor. J Med Chem. 1999 Jul 1;42(13):2373-82.
DMIWT60	RU	https://pubmed.ncbi.nlm.nih.gov/10395478

DMKT20Q	DI	DMKT20Q
DMKT20Q	DN	4-(5-Methyl-2-pirazolino)-3-pyridinesulfonamide
DMKT20Q	MI	TTHQPL7
DMKT20Q	MN	Carbonic anhydrase I (CA-I)
DMKT20Q	MT	DTT
DMKT20Q	MA	Inhibitor
DMKT20Q	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMKT20Q	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMKT20Q	DI	DMKT20Q
DMKT20Q	DN	4-(5-Methyl-2-pirazolino)-3-pyridinesulfonamide
DMKT20Q	MI	TTANPDJ
DMKT20Q	MN	Carbonic anhydrase II (CA-II)
DMKT20Q	MT	DTT
DMKT20Q	MA	Inhibitor
DMKT20Q	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMKT20Q	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMKT20Q	DI	DMKT20Q
DMKT20Q	DN	4-(5-Methyl-2-pirazolino)-3-pyridinesulfonamide
DMKT20Q	MI	TT2LVK8
DMKT20Q	MN	Carbonic anhydrase IX (CA-IX)
DMKT20Q	MT	DTT
DMKT20Q	MA	Inhibitor
DMKT20Q	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMKT20Q	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMKT20Q	DI	DMKT20Q
DMKT20Q	DN	4-(5-Methyl-2-pirazolino)-3-pyridinesulfonamide
DMKT20Q	MI	TTSYM0R
DMKT20Q	MN	Carbonic anhydrase XII (CA-XII)
DMKT20Q	MT	DTT
DMKT20Q	MA	Inhibitor
DMKT20Q	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMKT20Q	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMKT20Q	DI	DMKT20Q
DMKT20Q	DN	4-(5-Methyl-2-pirazolino)-3-pyridinesulfonamide
DMKT20Q	MI	TTEYTKG
DMKT20Q	MN	Carbonic anhydrase XIV (CA-XIV)
DMKT20Q	MT	DTT
DMKT20Q	MA	Inhibitor
DMKT20Q	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMKT20Q	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMXHIK5	DI	DMXHIK5
DMXHIK5	DN	4-(5-Morpholin-4-yl-pentyl)-2H-phthalazin-1-one
DMXHIK5	MI	TTVDSZ0
DMXHIK5	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMXHIK5	MT	DTT
DMXHIK5	MA	Inhibitor
DMXHIK5	RN	4-Phenyl-1,2,3,6-tetrahydropyridine, an excellent fragment to improve the potency of PARP-1 inhibitors. Bioorg Med Chem Lett. 2005 Oct 1;15(19):4221-5.
DMXHIK5	RU	https://pubmed.ncbi.nlm.nih.gov/16098744

DMUHQ0J	DI	DMUHQ0J
DMUHQ0J	DN	4-(5-Nitro-indol-1-ylmethyl)-benzamidine
DMUHQ0J	MI	TT2WR1T
DMUHQ0J	MN	Cationic trypsinogen (PRSS1)
DMUHQ0J	MT	DTT
DMUHQ0J	MA	Inhibitor
DMUHQ0J	RN	Aromatic amidines: comparison of their ability to block respiratory syncytial virus induced cell fusion and to inhibit plasmin, urokinase, thrombin... J Med Chem. 1983 Feb;26(2):294-8.
DMUHQ0J	RU	https://pubmed.ncbi.nlm.nih.gov/6219223

DM3N9O5	DI	DM3N9O5
DM3N9O5	DN	4-(5-Phenyl-oxazol-2-ylamino)-benzenesulfonamide
DM3N9O5	MI	TTUTJGQ
DM3N9O5	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM3N9O5	MT	DTT
DM3N9O5	MA	Inhibitor
DM3N9O5	RN	Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9.
DM3N9O5	RU	https://pubmed.ncbi.nlm.nih.gov/15743202

DM3N9O5	DI	DM3N9O5
DM3N9O5	DN	4-(5-Phenyl-oxazol-2-ylamino)-benzenesulfonamide
DM3N9O5	MI	TTDCBX5
DM3N9O5	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DM3N9O5	MT	DTT
DM3N9O5	MA	Inhibitor
DM3N9O5	RN	Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9.
DM3N9O5	RU	https://pubmed.ncbi.nlm.nih.gov/15743202

DM3N9O5	DI	DM3N9O5
DM3N9O5	DN	4-(5-Phenyl-oxazol-2-ylamino)-benzenesulfonamide
DM3N9O5	MI	TT1VAUK
DM3N9O5	MN	VEGFR1 messenger RNA (VEGFR1 mRNA)
DM3N9O5	MT	DTT
DM3N9O5	MA	Inhibitor
DM3N9O5	RN	Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9.
DM3N9O5	RU	https://pubmed.ncbi.nlm.nih.gov/15743202

DMZ1DW0	DI	DMZ1DW0
DMZ1DW0	DN	4-(5-tert-Butyl-[1,3]dithian-2-yl)-benzonitrile
DMZ1DW0	MI	TTNJYV2
DMZ1DW0	MN	Gamma-aminobutyric acid receptor (GAR)
DMZ1DW0	MT	DTT
DMZ1DW0	MA	Inhibitor
DMZ1DW0	RN	Synthesis of carbon-11-, fluorine-18-, and iodine-125-labeled GABAA-gated chloride ion channel blockers: substituted 5-tert-butyl-2-phenyl-1,3-dith... J Med Chem. 1995 Jul 7;38(14):2663-71.
DMZ1DW0	RU	https://pubmed.ncbi.nlm.nih.gov/7629805

DM8A6UH	DI	DM8A6UH
DM8A6UH	DN	4-(6,7-Dimethoxy-quinolin-3-yl)-benzoic acid
DM8A6UH	MI	TT8FYO9
DM8A6UH	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DM8A6UH	MT	DTT
DM8A6UH	MA	Inhibitor
DM8A6UH	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DM8A6UH	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DM8A6UH	DI	DM8A6UH
DM8A6UH	DN	4-(6,7-Dimethoxy-quinolin-3-yl)-benzoic acid
DM8A6UH	MI	TTI7421
DM8A6UH	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM8A6UH	MT	DTT
DM8A6UH	MA	Inhibitor
DM8A6UH	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DM8A6UH	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DM9RNUX	DI	DM9RNUX
DM9RNUX	DN	4-(6,7-Dimethoxy-quinolin-3-yl)-phenol
DM9RNUX	MI	TT8FYO9
DM9RNUX	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DM9RNUX	MT	DTT
DM9RNUX	MA	Inhibitor
DM9RNUX	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DM9RNUX	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DM9RNUX	DI	DM9RNUX
DM9RNUX	DN	4-(6,7-Dimethoxy-quinolin-3-yl)-phenol
DM9RNUX	MI	TTI7421
DM9RNUX	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM9RNUX	MT	DTT
DM9RNUX	MA	Inhibitor
DM9RNUX	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DM9RNUX	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMPD9GE	DI	DMPD9GE
DMPD9GE	DN	4-(6-Cyclohexyl-hex-3-ynyl)-1H-imidazole
DMPD9GE	MI	TT9JNIC
DMPD9GE	MN	Histamine H3 receptor (H3R)
DMPD9GE	MT	DTT
DMPD9GE	MA	Inhibitor
DMPD9GE	RN	New acetylene based histamine H3 receptor antagonists derived from the marine natural product verongamine. Bioorg Med Chem Lett. 1998 May 19;8(10):1133-8.
DMPD9GE	RU	https://pubmed.ncbi.nlm.nih.gov/9871722

DM4EC0J	DI	DM4EC0J
DM4EC0J	DN	4-(6-Cyclopentyl-hex-3-ynyl)-1H-imidazole
DM4EC0J	MI	TT9JNIC
DM4EC0J	MN	Histamine H3 receptor (H3R)
DM4EC0J	MT	DTT
DM4EC0J	MA	Inhibitor
DM4EC0J	RN	New acetylene based histamine H3 receptor antagonists derived from the marine natural product verongamine. Bioorg Med Chem Lett. 1998 May 19;8(10):1133-8.
DM4EC0J	RU	https://pubmed.ncbi.nlm.nih.gov/9871722

DMHGRPB	DI	DMHGRPB
DMHGRPB	DN	4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL
DMHGRPB	MI	TTZAYWL
DMHGRPB	MN	Estrogen receptor (ESR)
DMHGRPB	MT	DTT
DMHGRPB	MA	Inhibitor
DMHGRPB	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMHGRPB	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM38YZ4	DI	DM38YZ4
DM38YZ4	DN	4-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol
DM38YZ4	MI	TTZAYWL
DM38YZ4	MN	Estrogen receptor (ESR)
DM38YZ4	MT	DTT
DM38YZ4	MA	Inhibitor
DM38YZ4	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DM38YZ4	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DM38YZ4	DI	DM38YZ4
DM38YZ4	DN	4-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol
DM38YZ4	MI	TTOM3J0
DM38YZ4	MN	Estrogen receptor beta (ESR2)
DM38YZ4	MT	DTT
DM38YZ4	MA	Inhibitor
DM38YZ4	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DM38YZ4	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DM07NT9	DI	DM07NT9
DM07NT9	DN	4-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,3-diol
DM07NT9	MI	TTZAYWL
DM07NT9	MN	Estrogen receptor (ESR)
DM07NT9	MT	DTT
DM07NT9	MA	Inhibitor
DM07NT9	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DM07NT9	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DM07NT9	DI	DM07NT9
DM07NT9	DN	4-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,3-diol
DM07NT9	MI	TTOM3J0
DM07NT9	MN	Estrogen receptor beta (ESR2)
DM07NT9	MT	DTT
DM07NT9	MA	Inhibitor
DM07NT9	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DM07NT9	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DM4SPV7	DI	DM4SPV7
DM4SPV7	DN	4-(6-hydroxynaphthalen-2-yl)benzene-1,3-diol
DM4SPV7	MI	TTULVH8
DM4SPV7	MN	Tyrosinase (TYR)
DM4SPV7	MT	DTT
DM4SPV7	MA	Inhibitor
DM4SPV7	RN	Syntheses of hydroxy substituted 2-phenyl-naphthalenes as inhibitors of tyrosinase. Bioorg Med Chem Lett. 2007 Jan 15;17(2):461-4.
DM4SPV7	RU	https://pubmed.ncbi.nlm.nih.gov/17064896

DM3L5I6	DI	DM3L5I6
DM3L5I6	DN	4-(6-methoxy-1H-indol-1-ylsulfonyl)benzenamine
DM3L5I6	MI	TTJS8PY
DM3L5I6	MN	5-HT 6 receptor (HTR6)
DM3L5I6	MT	DTT
DM3L5I6	MA	Inhibitor
DM3L5I6	RN	Binding of methoxy-substituted N1-benzenesulfonylindole analogs at human 5-HT6 serotonin receptors. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3793-6.
DM3L5I6	RU	https://pubmed.ncbi.nlm.nih.gov/16709453

DM3ACVD	DI	DM3ACVD
DM3ACVD	DN	4-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine
DM3ACVD	MI	TTIQUX7
DM3ACVD	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM3ACVD	MT	DTT
DM3ACVD	MA	Inhibitor
DM3ACVD	RN	Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31.
DM3ACVD	RU	https://pubmed.ncbi.nlm.nih.gov/16570918

DMRPU0V	DI	DMRPU0V
DMRPU0V	DN	4-(6-Methoxy-3-methylnaphthalen-2-yl)isoquinoline
DMRPU0V	MI	TTIQUX7
DMRPU0V	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMRPU0V	MT	DTT
DMRPU0V	MA	Inhibitor
DMRPU0V	RN	Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on pote... J Med Chem. 2008 Aug 28;51(16):5064-74.
DMRPU0V	RU	https://pubmed.ncbi.nlm.nih.gov/18672861

DM51XDA	DI	DM51XDA
DM51XDA	DN	4-(6-Methoxynaphthalen-2-yl)isoquinoline
DM51XDA	MI	TTXV4FI
DM51XDA	MN	Albendazole monooxygenase (CYP3A4)
DM51XDA	MT	DTT
DM51XDA	MA	Inhibitor
DM51XDA	RN	Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on pote... J Med Chem. 2008 Aug 28;51(16):5064-74.
DM51XDA	RU	https://pubmed.ncbi.nlm.nih.gov/18672861

DM51XDA	DI	DM51XDA
DM51XDA	DN	4-(6-Methoxynaphthalen-2-yl)isoquinoline
DM51XDA	MI	TTIQUX7
DM51XDA	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM51XDA	MT	DTT
DM51XDA	MA	Inhibitor
DM51XDA	RN	Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on pote... J Med Chem. 2008 Aug 28;51(16):5064-74.
DM51XDA	RU	https://pubmed.ncbi.nlm.nih.gov/18672861

DM4B73F	DI	DM4B73F
DM4B73F	DN	4'-(6-Methoxypyridin-3-yl)biphenyl-3-ol
DM4B73F	MI	TTIWB6L
DM4B73F	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DM4B73F	MT	DTT
DM4B73F	MA	Inhibitor
DM4B73F	RN	Novel estrone mimetics with high 17beta-HSD1 inhibitory activity. Bioorg Med Chem. 2010 May 15;18(10):3494-505.
DM4B73F	RU	https://pubmed.ncbi.nlm.nih.gov/20413314

DM9O8VY	DI	DM9O8VY
DM9O8VY	DN	4-(6-morpholino-4-oxo-4H-pyran-2-yl)benzonitrile
DM9O8VY	MI	TTK3PY9
DM9O8VY	MN	DNA-dependent protein kinase catalytic (PRKDC)
DM9O8VY	MT	DTT
DM9O8VY	MA	Inhibitor
DM9O8VY	RN	Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72.
DM9O8VY	RU	https://pubmed.ncbi.nlm.nih.gov/17371003

DM1Z3N6	DI	DM1Z3N6
DM1Z3N6	DN	4-(6-morpholino-9H-purin-2-yl)phenol
DM1Z3N6	MI	TTCJG29
DM1Z3N6	MN	Serine/threonine-protein kinase mTOR (mTOR)
DM1Z3N6	MT	DTT
DM1Z3N6	MA	Inhibitor
DM1Z3N6	RN	Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-alpha: Hit to lead studies. Bioorg Med Chem Lett. 2010 Jan 15;20(2):636-9.
DM1Z3N6	RU	https://pubmed.ncbi.nlm.nih.gov/19969455

DMJ81IL	DI	DMJ81IL
DMJ81IL	DN	4-(6-phenyl-2,4'-bipyridin-4-yl)phenol
DMJ81IL	MI	TTGTQHC
DMJ81IL	MN	DNA topoisomerase I (TOP1)
DMJ81IL	MT	DTT
DMJ81IL	MA	Inhibitor
DMJ81IL	RN	Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl ... Bioorg Med Chem. 2010 May 1;18(9):3066-77.
DMJ81IL	RU	https://pubmed.ncbi.nlm.nih.gov/20392646

DMIY5QU	DI	DMIY5QU
DMIY5QU	DN	4-(7,7-Dimethyl-oct-3-ynyl)-1H-imidazole
DMIY5QU	MI	TT9JNIC
DMIY5QU	MN	Histamine H3 receptor (H3R)
DMIY5QU	MT	DTT
DMIY5QU	MA	Inhibitor
DMIY5QU	RN	New acetylene based histamine H3 receptor antagonists derived from the marine natural product verongamine. Bioorg Med Chem Lett. 1998 May 19;8(10):1133-8.
DMIY5QU	RU	https://pubmed.ncbi.nlm.nih.gov/9871722

DMUXZOM	DI	DMUXZOM
DMUXZOM	DN	4-(7-chloro-1-cyclohexyl-1H-indazol-3-yl)phenol
DMUXZOM	MI	TTZAYWL
DMUXZOM	MN	Estrogen receptor (ESR)
DMUXZOM	MT	DTT
DMUXZOM	MA	Inhibitor
DMUXZOM	RN	Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid ... J Med Chem. 2004 Dec 16;47(26):6435-8.
DMUXZOM	RU	https://pubmed.ncbi.nlm.nih.gov/15588074

DM0X5SY	DI	DM0X5SY
DM0X5SY	DN	4-(7-chloro-1-cyclopentyl-1H-indazol-3-yl)phenol
DM0X5SY	MI	TTZAYWL
DM0X5SY	MN	Estrogen receptor (ESR)
DM0X5SY	MT	DTT
DM0X5SY	MA	Inhibitor
DM0X5SY	RN	Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid ... J Med Chem. 2004 Dec 16;47(26):6435-8.
DM0X5SY	RU	https://pubmed.ncbi.nlm.nih.gov/15588074

DMEYUH0	DI	DMEYUH0
DMEYUH0	DN	4-(7-chloro-1-propyl-1H-indazol-3-yl)phenol
DMEYUH0	MI	TTZAYWL
DMEYUH0	MN	Estrogen receptor (ESR)
DMEYUH0	MT	DTT
DMEYUH0	MA	Inhibitor
DMEYUH0	RN	Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid ... J Med Chem. 2004 Dec 16;47(26):6435-8.
DMEYUH0	RU	https://pubmed.ncbi.nlm.nih.gov/15588074

DMX2K8R	DI	DMX2K8R
DMX2K8R	DN	4-(7-methyl-1-propyl-1H-indazol-3-yl)phenol
DMX2K8R	MI	TTZAYWL
DMX2K8R	MN	Estrogen receptor (ESR)
DMX2K8R	MT	DTT
DMX2K8R	MA	Inhibitor
DMX2K8R	RN	Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid ... J Med Chem. 2004 Dec 16;47(26):6435-8.
DMX2K8R	RU	https://pubmed.ncbi.nlm.nih.gov/15588074

DMJ86OS	DI	DMJ86OS
DMJ86OS	DN	4-(7-Methyl-oct-3-ynyl)-1H-imidazole
DMJ86OS	MI	TT9JNIC
DMJ86OS	MN	Histamine H3 receptor (H3R)
DMJ86OS	MT	DTT
DMJ86OS	MA	Inhibitor
DMJ86OS	RN	New acetylene based histamine H3 receptor antagonists derived from the marine natural product verongamine. Bioorg Med Chem Lett. 1998 May 19;8(10):1133-8.
DMJ86OS	RU	https://pubmed.ncbi.nlm.nih.gov/9871722

DM27OGL	DI	DM27OGL
DM27OGL	DN	4-(8-Phenyl-oct-3-ynyl)-1H-imidazole
DM27OGL	MI	TT9JNIC
DM27OGL	MN	Histamine H3 receptor (H3R)
DM27OGL	MT	DTT
DM27OGL	MA	Inhibitor
DM27OGL	RN	New acetylene based histamine H3 receptor antagonists derived from the marine natural product verongamine. Bioorg Med Chem Lett. 1998 May 19;8(10):1133-8.
DM27OGL	RU	https://pubmed.ncbi.nlm.nih.gov/9871722

DMR37FN	DI	DMR37FN
DMR37FN	DN	4-(Acetylamino)-3-Amino Benzoic Acid
DMR37FN	MI	TT50QJ3
DMR37FN	MN	Influenza Neuraminidase (Influ NA)
DMR37FN	MT	DTT
DMR37FN	MA	Inhibitor
DMR37FN	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMR37FN	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM8F0N5	DI	DM8F0N5
DM8F0N5	DN	4-(ACETYLAMINO)-3-HYDROXY-5-NITROBENZOIC ACID
DM8F0N5	MI	TT50QJ3
DM8F0N5	MN	Influenza Neuraminidase (Influ NA)
DM8F0N5	MT	DTT
DM8F0N5	MA	Inhibitor
DM8F0N5	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM8F0N5	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM1DKSV	DI	DM1DKSV
DM1DKSV	DN	4-(ACETYLAMINO)-5-AMINO-3-HYDROXYBENZOIC ACID
DM1DKSV	MI	TT50QJ3
DM1DKSV	MN	Influenza Neuraminidase (Influ NA)
DM1DKSV	MT	DTT
DM1DKSV	MA	Inhibitor
DM1DKSV	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM1DKSV	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM6MQCI	DI	DM6MQCI
DM6MQCI	DN	4-(Allylamino)-3-pyridinesulfonamide
DM6MQCI	MI	TTHQPL7
DM6MQCI	MN	Carbonic anhydrase I (CA-I)
DM6MQCI	MT	DTT
DM6MQCI	MA	Inhibitor
DM6MQCI	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DM6MQCI	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DM6MQCI	DI	DM6MQCI
DM6MQCI	DN	4-(Allylamino)-3-pyridinesulfonamide
DM6MQCI	MI	TTANPDJ
DM6MQCI	MN	Carbonic anhydrase II (CA-II)
DM6MQCI	MT	DTT
DM6MQCI	MA	Inhibitor
DM6MQCI	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DM6MQCI	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DM6MQCI	DI	DM6MQCI
DM6MQCI	DN	4-(Allylamino)-3-pyridinesulfonamide
DM6MQCI	MI	TT2LVK8
DM6MQCI	MN	Carbonic anhydrase IX (CA-IX)
DM6MQCI	MT	DTT
DM6MQCI	MA	Inhibitor
DM6MQCI	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DM6MQCI	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DM6MQCI	DI	DM6MQCI
DM6MQCI	DN	4-(Allylamino)-3-pyridinesulfonamide
DM6MQCI	MI	TTSYM0R
DM6MQCI	MN	Carbonic anhydrase XII (CA-XII)
DM6MQCI	MT	DTT
DM6MQCI	MA	Inhibitor
DM6MQCI	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DM6MQCI	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DM6MQCI	DI	DM6MQCI
DM6MQCI	DN	4-(Allylamino)-3-pyridinesulfonamide
DM6MQCI	MI	TTEYTKG
DM6MQCI	MN	Carbonic anhydrase XIV (CA-XIV)
DM6MQCI	MT	DTT
DM6MQCI	MA	Inhibitor
DM6MQCI	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DM6MQCI	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMTB80W	DI	DMTB80W
DMTB80W	DN	4-(Aminomethyl)-7-(benzyloxy)-2H-chromen-2-one
DMTB80W	MI	TT3WG5C
DMTB80W	MN	Monoamine oxidase type A (MAO-A)
DMTB80W	MT	DTT
DMTB80W	MA	Inhibitor
DMTB80W	RN	Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: development and biopharmacological profiling of 7-[(3-chlorobenzyl)ox... J Med Chem. 2009 Nov 12;52(21):6685-706.
DMTB80W	RU	https://pubmed.ncbi.nlm.nih.gov/19810674

DMTB80W	DI	DMTB80W
DMTB80W	DN	4-(Aminomethyl)-7-(benzyloxy)-2H-chromen-2-one
DMTB80W	MI	TTGP7BY
DMTB80W	MN	Monoamine oxidase type B (MAO-B)
DMTB80W	MT	DTT
DMTB80W	MA	Inhibitor
DMTB80W	RN	Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: development and biopharmacological profiling of 7-[(3-chlorobenzyl)ox... J Med Chem. 2009 Nov 12;52(21):6685-706.
DMTB80W	RU	https://pubmed.ncbi.nlm.nih.gov/19810674

DML2EF4	DI	DML2EF4
DML2EF4	DN	4'-(Benzensulfonamide)-4-hydroxychalcone
DML2EF4	MI	TTULVH8
DML2EF4	MN	Tyrosinase (TYR)
DML2EF4	MT	DTT
DML2EF4	MA	Inhibitor
DML2EF4	RN	Evaluation of anti-pigmentary effect of synthetic sulfonylamino chalcone. Eur J Med Chem. 2010 May;45(5):2010-7.
DML2EF4	RU	https://pubmed.ncbi.nlm.nih.gov/20149498

DMF6S3X	DI	DMF6S3X
DMF6S3X	DN	4-(Benzylamino)-1-naphthol
DMF6S3X	MI	TTZJYKH
DMF6S3X	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMF6S3X	MT	DTT
DMF6S3X	MA	Inhibitor
DMF6S3X	RN	Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2010 Feb 11;53(3):1172-89.
DMF6S3X	RU	https://pubmed.ncbi.nlm.nih.gov/20055453

DM03BQD	DI	DM03BQD
DM03BQD	DN	4-(benzylideneamino)benzenesulfonamide
DM03BQD	MI	TTANPDJ
DM03BQD	MN	Carbonic anhydrase II (CA-II)
DM03BQD	MT	DTT
DM03BQD	MA	Inhibitor
DM03BQD	RN	Carbonic anhydrase II-induced selection of inhibitors from a dynamic combinatorial library of Schiff's bases. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6014-7.
DM03BQD	RU	https://pubmed.ncbi.nlm.nih.gov/19796939

DM03BQD	DI	DM03BQD
DM03BQD	DN	4-(benzylideneamino)benzenesulfonamide
DM03BQD	MI	TTVKILB
DM03BQD	MN	Prostaglandin G/H synthase 2 (COX-2)
DM03BQD	MT	DTT
DM03BQD	MA	Inhibitor
DM03BQD	RN	Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides. Bioorg Med Chem. 2008 Mar 1;16(5):2697-706.
DM03BQD	RU	https://pubmed.ncbi.nlm.nih.gov/18063374

DMJM2H1	DI	DMJM2H1
DMJM2H1	DN	4-(benzylideneamino)benzoic acid
DMJM2H1	MI	TTANPDJ
DMJM2H1	MN	Carbonic anhydrase II (CA-II)
DMJM2H1	MT	DTT
DMJM2H1	MA	Inhibitor
DMJM2H1	RN	Carbonic anhydrase II-induced selection of inhibitors from a dynamic combinatorial library of Schiff's bases. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6014-7.
DMJM2H1	RU	https://pubmed.ncbi.nlm.nih.gov/19796939

DM1T95Y	DI	DM1T95Y
DM1T95Y	DN	4-(biphenyl-3-yl)-5-(piperidin-4-yl)isoxazol-3-ol
DM1T95Y	MI	TT1MPAY
DM1T95Y	MN	GABA(A) receptor alpha-1 (GABRA1)
DM1T95Y	MT	DTT
DM1T95Y	MA	Inhibitor
DM1T95Y	RN	Novel 4-(piperidin-4-yl)-1-hydroxypyrazoles as gamma-aminobutyric acid(A) receptor ligands: synthesis, pharmacology, and structure-activity relatio... J Med Chem. 2010 Apr 22;53(8):3417-21.
DM1T95Y	RU	https://pubmed.ncbi.nlm.nih.gov/20355712

DM1T95Y	DI	DM1T95Y
DM1T95Y	DN	4-(biphenyl-3-yl)-5-(piperidin-4-yl)isoxazol-3-ol
DM1T95Y	MI	TTZA1NY
DM1T95Y	MN	GABA(A) receptor beta-2 (GABRB2)
DM1T95Y	MT	DTT
DM1T95Y	MA	Inhibitor
DM1T95Y	RN	Novel 4-(piperidin-4-yl)-1-hydroxypyrazoles as gamma-aminobutyric acid(A) receptor ligands: synthesis, pharmacology, and structure-activity relatio... J Med Chem. 2010 Apr 22;53(8):3417-21.
DM1T95Y	RU	https://pubmed.ncbi.nlm.nih.gov/20355712

DM1T95Y	DI	DM1T95Y
DM1T95Y	DN	4-(biphenyl-3-yl)-5-(piperidin-4-yl)isoxazol-3-ol
DM1T95Y	MI	TT06RH5
DM1T95Y	MN	GABA(A) receptor gamma-2 (GABRG2)
DM1T95Y	MT	DTT
DM1T95Y	MA	Inhibitor
DM1T95Y	RN	Novel 4-(piperidin-4-yl)-1-hydroxypyrazoles as gamma-aminobutyric acid(A) receptor ligands: synthesis, pharmacology, and structure-activity relatio... J Med Chem. 2010 Apr 22;53(8):3417-21.
DM1T95Y	RU	https://pubmed.ncbi.nlm.nih.gov/20355712

DMNE5H7	DI	DMNE5H7
DMNE5H7	DN	4-(Bis(2-chloroethyl)amino)-N-p-tolylbenzamide
DMNE5H7	MI	TTR5TV4
DMNE5H7	MN	ERBB2 messenger RNA (HER2 mRNA)
DMNE5H7	MT	DTT
DMNE5H7	MA	Inhibitor
DMNE5H7	RN	Synthesis, biological evaluation and molecular docking studies of amide-coupled benzoic nitrogen mustard derivatives as potential antitumor agents. Bioorg Med Chem. 2010 Jan 15;18(2):880-6.
DMNE5H7	RU	https://pubmed.ncbi.nlm.nih.gov/20005116

DM3GUFI	DI	DM3GUFI
DM3GUFI	DN	4-(butyl(methyl)amino)-N-(quinolin-3-yl)benzamide
DM3GUFI	MI	TTMI6F5
DM3GUFI	MN	Transient receptor potential cation channel V1 (TRPV1)
DM3GUFI	MT	DTT
DM3GUFI	MA	Inhibitor
DM3GUFI	RN	N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4.
DM3GUFI	RU	https://pubmed.ncbi.nlm.nih.gov/18359227

DM6SIA4	DI	DM6SIA4
DM6SIA4	DN	4-(butylthio)-2-(trifluoromethyl)benzonitrile
DM6SIA4	MI	TTKPW01
DM6SIA4	MN	Androgen receptor messenger RNA (AR mRNA)
DM6SIA4	MT	DTT
DM6SIA4	MA	Inhibitor
DM6SIA4	RN	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
DM6SIA4	RU	https://pubmed.ncbi.nlm.nih.gov/19201190

DMH1AZV	DI	DMH1AZV
DMH1AZV	DN	4-(butylthio)-2-methoxybenzonitrile
DMH1AZV	MI	TTKPW01
DMH1AZV	MN	Androgen receptor messenger RNA (AR mRNA)
DMH1AZV	MT	DTT
DMH1AZV	MA	Inhibitor
DMH1AZV	RN	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
DMH1AZV	RU	https://pubmed.ncbi.nlm.nih.gov/19201190

DM12R4M	DI	DM12R4M
DM12R4M	DN	4-(Carbamolymethylthio)pyridine-3-sulfonamide
DM12R4M	MI	TTHQPL7
DM12R4M	MN	Carbonic anhydrase I (CA-I)
DM12R4M	MT	DTT
DM12R4M	MA	Inhibitor
DM12R4M	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DM12R4M	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DM12R4M	DI	DM12R4M
DM12R4M	DN	4-(Carbamolymethylthio)pyridine-3-sulfonamide
DM12R4M	MI	TTANPDJ
DM12R4M	MN	Carbonic anhydrase II (CA-II)
DM12R4M	MT	DTT
DM12R4M	MA	Inhibitor
DM12R4M	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DM12R4M	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DM12R4M	DI	DM12R4M
DM12R4M	DN	4-(Carbamolymethylthio)pyridine-3-sulfonamide
DM12R4M	MI	TT2LVK8
DM12R4M	MN	Carbonic anhydrase IX (CA-IX)
DM12R4M	MT	DTT
DM12R4M	MA	Inhibitor
DM12R4M	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DM12R4M	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DM12R4M	DI	DM12R4M
DM12R4M	DN	4-(Carbamolymethylthio)pyridine-3-sulfonamide
DM12R4M	MI	TTSYM0R
DM12R4M	MN	Carbonic anhydrase XII (CA-XII)
DM12R4M	MT	DTT
DM12R4M	MA	Inhibitor
DM12R4M	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DM12R4M	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DM12R4M	DI	DM12R4M
DM12R4M	DN	4-(Carbamolymethylthio)pyridine-3-sulfonamide
DM12R4M	MI	TTEYTKG
DM12R4M	MN	Carbonic anhydrase XIV (CA-XIV)
DM12R4M	MT	DTT
DM12R4M	MA	Inhibitor
DM12R4M	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DM12R4M	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMSG9LV	DI	DMSG9LV
DMSG9LV	DN	4-(Carboxyvin-2-Yl)Phenylboronic Acid
DMSG9LV	MI	TTHI19T
DMSG9LV	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMSG9LV	MT	DTT
DMSG9LV	MA	Inhibitor
DMSG9LV	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMSG9LV	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMZP20H	DI	DMZP20H
DMZP20H	DN	4-(Cyanomethylthio)pyridine-3-sulfonamide
DMZP20H	MI	TTHQPL7
DMZP20H	MN	Carbonic anhydrase I (CA-I)
DMZP20H	MT	DTT
DMZP20H	MA	Inhibitor
DMZP20H	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMZP20H	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMZP20H	DI	DMZP20H
DMZP20H	DN	4-(Cyanomethylthio)pyridine-3-sulfonamide
DMZP20H	MI	TTANPDJ
DMZP20H	MN	Carbonic anhydrase II (CA-II)
DMZP20H	MT	DTT
DMZP20H	MA	Inhibitor
DMZP20H	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMZP20H	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMZP20H	DI	DMZP20H
DMZP20H	DN	4-(Cyanomethylthio)pyridine-3-sulfonamide
DMZP20H	MI	TT2LVK8
DMZP20H	MN	Carbonic anhydrase IX (CA-IX)
DMZP20H	MT	DTT
DMZP20H	MA	Inhibitor
DMZP20H	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMZP20H	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMZP20H	DI	DMZP20H
DMZP20H	DN	4-(Cyanomethylthio)pyridine-3-sulfonamide
DMZP20H	MI	TTSYM0R
DMZP20H	MN	Carbonic anhydrase XII (CA-XII)
DMZP20H	MT	DTT
DMZP20H	MA	Inhibitor
DMZP20H	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMZP20H	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMZP20H	DI	DMZP20H
DMZP20H	DN	4-(Cyanomethylthio)pyridine-3-sulfonamide
DMZP20H	MI	TTEYTKG
DMZP20H	MN	Carbonic anhydrase XIV (CA-XIV)
DMZP20H	MT	DTT
DMZP20H	MA	Inhibitor
DMZP20H	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMZP20H	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMR69K2	DI	DMR69K2
DMR69K2	DN	4-(cyclobutylmethylthio)-2-methoxybenzonitrile
DMR69K2	MI	TTKPW01
DMR69K2	MN	Androgen receptor messenger RNA (AR mRNA)
DMR69K2	MT	DTT
DMR69K2	MA	Inhibitor
DMR69K2	RN	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
DMR69K2	RU	https://pubmed.ncbi.nlm.nih.gov/19201190

DMUOQN7	DI	DMUOQN7
DMUOQN7	DN	4-(Cyclohexylamino)-1-naphthol
DMUOQN7	MI	TTZJYKH
DMUOQN7	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMUOQN7	MT	DTT
DMUOQN7	MA	Inhibitor
DMUOQN7	RN	Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2010 Feb 11;53(3):1172-89.
DMUOQN7	RU	https://pubmed.ncbi.nlm.nih.gov/20055453

DMWELVK	DI	DMWELVK
DMWELVK	DN	4-(cyclohexylamino)-N-(quinolin-3-yl)benzamide
DMWELVK	MI	TTMI6F5
DMWELVK	MN	Transient receptor potential cation channel V1 (TRPV1)
DMWELVK	MT	DTT
DMWELVK	MA	Inhibitor
DMWELVK	RN	N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4.
DMWELVK	RU	https://pubmed.ncbi.nlm.nih.gov/18359227

DMWYESB	DI	DMWYESB
DMWYESB	DN	4-(cyclohexylmethylcarbamoyloxy)benzoic acid
DMWYESB	MI	TTDP1UC
DMWYESB	MN	Fatty acid amide hydrolase (FAAH)
DMWYESB	MT	DTT
DMWYESB	MA	Inhibitor
DMWYESB	RN	Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors. J Med Chem. 2008 Dec 11;51(23):7327-43.
DMWYESB	RU	https://pubmed.ncbi.nlm.nih.gov/18983142

DMCDZ7E	DI	DMCDZ7E
DMCDZ7E	DN	4-(cyclohexyloxy)quinazoline
DMCDZ7E	MI	TTVBPDM
DMCDZ7E	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMCDZ7E	MT	DTT
DMCDZ7E	MA	Inhibitor
DMCDZ7E	RN	In vitro and in vivo SAR of pyrido[3,4-d]pyramid-4-ylamine based mGluR1 antagonists. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2190-4.
DMCDZ7E	RU	https://pubmed.ncbi.nlm.nih.gov/19289283

DM43Z2J	DI	DM43Z2J
DM43Z2J	DN	4-(cyclopropylmethylthio)-2-methoxybenzonitrile
DM43Z2J	MI	TTKPW01
DM43Z2J	MN	Androgen receptor messenger RNA (AR mRNA)
DM43Z2J	MT	DTT
DM43Z2J	MA	Inhibitor
DM43Z2J	RN	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
DM43Z2J	RU	https://pubmed.ncbi.nlm.nih.gov/19201190

DM68S9F	DI	DM68S9F
DM68S9F	DN	4-(DIMETHYLAMINO)BUTYL IMIDOTHIOCARBAMATE
DM68S9F	MI	TT2B6EV
DM68S9F	MN	Histamine N-methyltransferase (HNMT)
DM68S9F	MT	DTT
DM68S9F	MA	Inhibitor
DM68S9F	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM68S9F	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMJP5YH	DI	DMJP5YH
DMJP5YH	DN	4-(dimethylamino)-N-(thiazol-2-yl)benzamide
DMJP5YH	MI	TTSJ6Q4
DMJP5YH	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DMJP5YH	MT	DTT
DMJP5YH	MA	Inhibitor
DMJP5YH	RN	Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. J Med Chem. 2007 May 31;50(11):2640-6.
DMJP5YH	RU	https://pubmed.ncbi.nlm.nih.gov/17461565

DM14C9V	DI	DM14C9V
DM14C9V	DN	4-(ethylamino)naphthalen-1-ol
DM14C9V	MI	TTZJYKH
DM14C9V	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DM14C9V	MT	DTT
DM14C9V	MA	Inhibitor
DM14C9V	RN	Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2010 Feb 11;53(3):1172-89.
DM14C9V	RU	https://pubmed.ncbi.nlm.nih.gov/20055453

DM0GCEK	DI	DM0GCEK
DM0GCEK	DN	4-(ethylthio)-6-phenyl-1,3,5-triazin-2-amine
DM0GCEK	MI	TTK25J1
DM0GCEK	MN	Adenosine A1 receptor (ADORA1)
DM0GCEK	MT	DTT
DM0GCEK	MA	Inhibitor
DM0GCEK	RN	Identification of non-furan containing A2A antagonists using database mining and molecular similarity approaches. Bioorg Med Chem Lett. 2006 Dec 1;16(23):5993-7.
DM0GCEK	RU	https://pubmed.ncbi.nlm.nih.gov/16971117

DM0GCEK	DI	DM0GCEK
DM0GCEK	DN	4-(ethylthio)-6-phenyl-1,3,5-triazin-2-amine
DM0GCEK	MI	TTM2AOE
DM0GCEK	MN	Adenosine A2a receptor (ADORA2A)
DM0GCEK	MT	DTT
DM0GCEK	MA	Inhibitor
DM0GCEK	RN	Identification of non-furan containing A2A antagonists using database mining and molecular similarity approaches. Bioorg Med Chem Lett. 2006 Dec 1;16(23):5993-7.
DM0GCEK	RU	https://pubmed.ncbi.nlm.nih.gov/16971117

DMY7035	DI	DMY7035
DMY7035	DN	4-(furan-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine
DMY7035	MI	TTK25J1
DMY7035	MN	Adenosine A1 receptor (ADORA1)
DMY7035	MT	DTT
DMY7035	MA	Inhibitor
DMY7035	RN	Antagonists of the human A(2A) adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines. J Med Chem. 2009 Jan 8;52(1):33-47.
DMY7035	RU	https://pubmed.ncbi.nlm.nih.gov/19072055

DMY7035	DI	DMY7035
DMY7035	DN	4-(furan-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine
DMY7035	MI	TTM2AOE
DMY7035	MN	Adenosine A2a receptor (ADORA2A)
DMY7035	MT	DTT
DMY7035	MA	Inhibitor
DMY7035	RN	Antagonists of the human A(2A) adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines. J Med Chem. 2009 Jan 8;52(1):33-47.
DMY7035	RU	https://pubmed.ncbi.nlm.nih.gov/19072055

DM7LVKP	DI	DM7LVKP
DM7LVKP	DN	4-(furan-2-yl)thieno[3,2-d]pyrimidin-2-amine
DM7LVKP	MI	TTK25J1
DM7LVKP	MN	Adenosine A1 receptor (ADORA1)
DM7LVKP	MT	DTT
DM7LVKP	MA	Inhibitor
DM7LVKP	RN	Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpu... Bioorg Med Chem Lett. 2008 May 1;18(9):2924-9.
DM7LVKP	RU	https://pubmed.ncbi.nlm.nih.gov/18411049

DM7LVKP	DI	DM7LVKP
DM7LVKP	DN	4-(furan-2-yl)thieno[3,2-d]pyrimidin-2-amine
DM7LVKP	MI	TTM2AOE
DM7LVKP	MN	Adenosine A2a receptor (ADORA2A)
DM7LVKP	MT	DTT
DM7LVKP	MA	Inhibitor
DM7LVKP	RN	Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpu... Bioorg Med Chem Lett. 2008 May 1;18(9):2924-9.
DM7LVKP	RU	https://pubmed.ncbi.nlm.nih.gov/18411049

DMW4O31	DI	DMW4O31
DMW4O31	DN	4-(furan-3-yl)-2,6-di(thiophen-2-yl)pyridine
DMW4O31	MI	TT0IHXV
DMW4O31	MN	DNA topoisomerase II (TOP2)
DMW4O31	MT	DTT
DMW4O31	MA	Inhibitor
DMW4O31	RN	2,6-Dithienyl-4-furyl pyridines: Synthesis, topoisomerase I and II inhibition, cytotoxicity, structure-activity relationship, and docking study. Bioorg Med Chem Lett. 2010 Jan 1;20(1):42-7.
DMW4O31	RU	https://pubmed.ncbi.nlm.nih.gov/19954977

DM70MRZ	DI	DM70MRZ
DM70MRZ	DN	4-(hexyl(methyl)amino)-N-(quinolin-3-yl)benzamide
DM70MRZ	MI	TTMI6F5
DM70MRZ	MN	Transient receptor potential cation channel V1 (TRPV1)
DM70MRZ	MT	DTT
DM70MRZ	MA	Inhibitor
DM70MRZ	RN	N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4.
DM70MRZ	RU	https://pubmed.ncbi.nlm.nih.gov/18359227

DMWJN73	DI	DMWJN73
DMWJN73	DN	4-(Hydroxymercury)Benzoic Acid
DMWJN73	MI	TTANPDJ
DMWJN73	MN	Carbonic anhydrase II (CA-II)
DMWJN73	MT	DTT
DMWJN73	MA	Inhibitor
DMWJN73	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMWJN73	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMR6VWL	DI	DMR6VWL
DMR6VWL	DN	4-(hydroxymethyl)benzenesulfonamide
DMR6VWL	MI	TTUNARX
DMR6VWL	MN	Carbonic anhydrase (CA)
DMR6VWL	MT	DTT
DMR6VWL	MA	Inhibitor
DMR6VWL	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DMR6VWL	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DMR6VWL	DI	DMR6VWL
DMR6VWL	DN	4-(hydroxymethyl)benzenesulfonamide
DMR6VWL	MI	TTHQPL7
DMR6VWL	MN	Carbonic anhydrase I (CA-I)
DMR6VWL	MT	DTT
DMR6VWL	MA	Inhibitor
DMR6VWL	RN	Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorg Med Chem. 2009 Jul 15;17(14):5054-8.
DMR6VWL	RU	https://pubmed.ncbi.nlm.nih.gov/19520577

DMR6VWL	DI	DMR6VWL
DMR6VWL	DN	4-(hydroxymethyl)benzenesulfonamide
DMR6VWL	MI	TTANPDJ
DMR6VWL	MN	Carbonic anhydrase II (CA-II)
DMR6VWL	MT	DTT
DMR6VWL	MA	Inhibitor
DMR6VWL	RN	Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, ... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6649-54.
DMR6VWL	RU	https://pubmed.ncbi.nlm.nih.gov/19846301

DMR6VWL	DI	DMR6VWL
DMR6VWL	DN	4-(hydroxymethyl)benzenesulfonamide
DMR6VWL	MI	TT2LVK8
DMR6VWL	MN	Carbonic anhydrase IX (CA-IX)
DMR6VWL	MT	DTT
DMR6VWL	MA	Inhibitor
DMR6VWL	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DMR6VWL	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DMR6VWL	DI	DMR6VWL
DMR6VWL	DN	4-(hydroxymethyl)benzenesulfonamide
DMR6VWL	MI	TTCFSPE
DMR6VWL	MN	Carbonic anhydrase VI (CA-VI)
DMR6VWL	MT	DTT
DMR6VWL	MA	Inhibitor
DMR6VWL	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DMR6VWL	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DMR6VWL	DI	DMR6VWL
DMR6VWL	DN	4-(hydroxymethyl)benzenesulfonamide
DMR6VWL	MI	TTSYM0R
DMR6VWL	MN	Carbonic anhydrase XII (CA-XII)
DMR6VWL	MT	DTT
DMR6VWL	MA	Inhibitor
DMR6VWL	RN	Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglauc... Bioorg Med Chem Lett. 2005 Feb 15;15(4):963-9.
DMR6VWL	RU	https://pubmed.ncbi.nlm.nih.gov/15686894

DMR6VWL	DI	DMR6VWL
DMR6VWL	DN	4-(hydroxymethyl)benzenesulfonamide
DMR6VWL	MI	TTEYTKG
DMR6VWL	MN	Carbonic anhydrase XIV (CA-XIV)
DMR6VWL	MT	DTT
DMR6VWL	MA	Inhibitor
DMR6VWL	RN	Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33.
DMR6VWL	RU	https://pubmed.ncbi.nlm.nih.gov/16039848

DMHI50W	DI	DMHI50W
DMHI50W	DN	4-(Indan-1-ylsulfanyl)-phenylamine
DMHI50W	MI	TTJS8PY
DMHI50W	MN	5-HT 6 receptor (HTR6)
DMHI50W	MT	DTT
DMHI50W	MA	Inhibitor
DMHI50W	RN	Binding of isotryptamines and indenes at h5-HT6 serotonin receptors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1987-91.
DMHI50W	RU	https://pubmed.ncbi.nlm.nih.gov/15808453

DM201UM	DI	DM201UM
DM201UM	DN	4-(Indane-1-sulfonyl)-phenylamine
DM201UM	MI	TTJS8PY
DM201UM	MN	5-HT 6 receptor (HTR6)
DM201UM	MT	DTT
DM201UM	MA	Inhibitor
DM201UM	RN	Binding of isotryptamines and indenes at h5-HT6 serotonin receptors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1987-91.
DM201UM	RU	https://pubmed.ncbi.nlm.nih.gov/15808453

DMGSZB2	DI	DMGSZB2
DMGSZB2	DN	4-(isopentylthio)-2-(trifluoromethyl)benzonitrile
DMGSZB2	MI	TTKPW01
DMGSZB2	MN	Androgen receptor messenger RNA (AR mRNA)
DMGSZB2	MT	DTT
DMGSZB2	MA	Inhibitor
DMGSZB2	RN	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
DMGSZB2	RU	https://pubmed.ncbi.nlm.nih.gov/19201190

DML1G9S	DI	DML1G9S
DML1G9S	DN	4-(isopentylthio)-2-methoxybenzonitrile
DML1G9S	MI	TTKPW01
DML1G9S	MN	Androgen receptor messenger RNA (AR mRNA)
DML1G9S	MT	DTT
DML1G9S	MA	Inhibitor
DML1G9S	RN	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
DML1G9S	RU	https://pubmed.ncbi.nlm.nih.gov/19201190

DMJFSTX	DI	DMJFSTX
DMJFSTX	DN	4-(Isopropylamino)-1-naphthol
DMJFSTX	MI	TTZJYKH
DMJFSTX	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMJFSTX	MT	DTT
DMJFSTX	MA	Inhibitor
DMJFSTX	RN	Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2010 Feb 11;53(3):1172-89.
DMJFSTX	RU	https://pubmed.ncbi.nlm.nih.gov/20055453

DMVDHX1	DI	DMVDHX1
DMVDHX1	DN	4-(isopropylthio)-2-(trifluoromethyl)benzonitrile
DMVDHX1	MI	TTKPW01
DMVDHX1	MN	Androgen receptor messenger RNA (AR mRNA)
DMVDHX1	MT	DTT
DMVDHX1	MA	Inhibitor
DMVDHX1	RN	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
DMVDHX1	RU	https://pubmed.ncbi.nlm.nih.gov/19201190

DMR5HNI	DI	DMR5HNI
DMR5HNI	DN	4-(isopropylthio)-2-methoxybenzonitrile
DMR5HNI	MI	TTKPW01
DMR5HNI	MN	Androgen receptor messenger RNA (AR mRNA)
DMR5HNI	MT	DTT
DMR5HNI	MA	Inhibitor
DMR5HNI	RN	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
DMR5HNI	RU	https://pubmed.ncbi.nlm.nih.gov/19201190

DM8LODU	DI	DM8LODU
DM8LODU	DN	4-(isoquinolin-5-yl)-N-m-tolylphthalazin-1-amine
DM8LODU	MI	TTUTJGQ
DM8LODU	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM8LODU	MT	DTT
DM8LODU	MA	Inhibitor
DM8LODU	RN	Arylphthalazines. Part 2: 1-(Isoquinolin-5-yl)-4-arylamino phthalazines as potent inhibitors of VEGF receptors I and II. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1579-81.
DM8LODU	RU	https://pubmed.ncbi.nlm.nih.gov/16386418

DM8LODU	DI	DM8LODU
DM8LODU	DN	4-(isoquinolin-5-yl)-N-m-tolylphthalazin-1-amine
DM8LODU	MI	TT1VAUK
DM8LODU	MN	VEGFR1 messenger RNA (VEGFR1 mRNA)
DM8LODU	MT	DTT
DM8LODU	MA	Inhibitor
DM8LODU	RN	Arylphthalazines. Part 2: 1-(Isoquinolin-5-yl)-4-arylamino phthalazines as potent inhibitors of VEGF receptors I and II. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1579-81.
DM8LODU	RU	https://pubmed.ncbi.nlm.nih.gov/16386418

DMS30HQ	DI	DMS30HQ
DMS30HQ	DN	4-(isoquinolin-5-yl)-N-o-tolylphthalazin-1-amine
DMS30HQ	MI	TTUTJGQ
DMS30HQ	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMS30HQ	MT	DTT
DMS30HQ	MA	Inhibitor
DMS30HQ	RN	Arylphthalazines. Part 2: 1-(Isoquinolin-5-yl)-4-arylamino phthalazines as potent inhibitors of VEGF receptors I and II. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1579-81.
DMS30HQ	RU	https://pubmed.ncbi.nlm.nih.gov/16386418

DMS30HQ	DI	DMS30HQ
DMS30HQ	DN	4-(isoquinolin-5-yl)-N-o-tolylphthalazin-1-amine
DMS30HQ	MI	TT1VAUK
DMS30HQ	MN	VEGFR1 messenger RNA (VEGFR1 mRNA)
DMS30HQ	MT	DTT
DMS30HQ	MA	Inhibitor
DMS30HQ	RN	Arylphthalazines. Part 2: 1-(Isoquinolin-5-yl)-4-arylamino phthalazines as potent inhibitors of VEGF receptors I and II. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1579-81.
DMS30HQ	RU	https://pubmed.ncbi.nlm.nih.gov/16386418

DMQG57D	DI	DMQG57D
DMQG57D	DN	4-(mesityloxy)-2-(trifluoromethyl)benzonitrile
DMQG57D	MI	TTKPW01
DMQG57D	MN	Androgen receptor messenger RNA (AR mRNA)
DMQG57D	MT	DTT
DMQG57D	MA	Inhibitor
DMQG57D	RN	Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2176-8.
DMQG57D	RU	https://pubmed.ncbi.nlm.nih.gov/19286380

DMAI3NZ	DI	DMAI3NZ
DMAI3NZ	DN	4-(mesitylthio)-2-(trifluoromethyl)benzonitrile
DMAI3NZ	MI	TTKPW01
DMAI3NZ	MN	Androgen receptor messenger RNA (AR mRNA)
DMAI3NZ	MT	DTT
DMAI3NZ	MA	Inhibitor
DMAI3NZ	RN	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
DMAI3NZ	RU	https://pubmed.ncbi.nlm.nih.gov/19201190

DM1XK68	DI	DM1XK68
DM1XK68	DN	4-(mesitylthio)-2-methoxybenzonitrile
DM1XK68	MI	TTKPW01
DM1XK68	MN	Androgen receptor messenger RNA (AR mRNA)
DM1XK68	MT	DTT
DM1XK68	MA	Inhibitor
DM1XK68	RN	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
DM1XK68	RU	https://pubmed.ncbi.nlm.nih.gov/19201190

DMQCMFU	DI	DMQCMFU
DMQCMFU	DN	4-(methyl(4-phenylthiazol-2-yl)amino)phenol
DMQCMFU	MI	TTHY57M
DMQCMFU	MN	Matrix metalloproteinase-13 (MMP-13)
DMQCMFU	MT	DTT
DMQCMFU	MA	Inhibitor
DMQCMFU	RN	High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg Med Chem. 2009 Feb 1;17(3):990-1005.
DMQCMFU	RU	https://pubmed.ncbi.nlm.nih.gov/18358729

DM3TF9Y	DI	DM3TF9Y
DM3TF9Y	DN	4-(methyl(nonyl)amino)-N-(quinolin-3-yl)benzamide
DM3TF9Y	MI	TTMI6F5
DM3TF9Y	MN	Transient receptor potential cation channel V1 (TRPV1)
DM3TF9Y	MT	DTT
DM3TF9Y	MA	Inhibitor
DM3TF9Y	RN	N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4.
DM3TF9Y	RU	https://pubmed.ncbi.nlm.nih.gov/18359227

DM1I0TA	DI	DM1I0TA
DM1I0TA	DN	4-(methyl(octyl)amino)-N-(quinolin-3-yl)benzamide
DM1I0TA	MI	TTMI6F5
DM1I0TA	MN	Transient receptor potential cation channel V1 (TRPV1)
DM1I0TA	MT	DTT
DM1I0TA	MA	Inhibitor
DM1I0TA	RN	N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4.
DM1I0TA	RU	https://pubmed.ncbi.nlm.nih.gov/18359227

DMF3O10	DI	DMF3O10
DMF3O10	DN	4-(methylamino)naphthalen-1-ol
DMF3O10	MI	TTZJYKH
DMF3O10	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMF3O10	MT	DTT
DMF3O10	MA	Inhibitor
DMF3O10	RN	Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2010 Feb 11;53(3):1172-89.
DMF3O10	RU	https://pubmed.ncbi.nlm.nih.gov/20055453

DM4BPL1	DI	DM4BPL1
DM4BPL1	DN	4-(Methylhydrazino)-3-pyridinesulfonamide
DM4BPL1	MI	TTHQPL7
DM4BPL1	MN	Carbonic anhydrase I (CA-I)
DM4BPL1	MT	DTT
DM4BPL1	MA	Inhibitor
DM4BPL1	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DM4BPL1	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DM4BPL1	DI	DM4BPL1
DM4BPL1	DN	4-(Methylhydrazino)-3-pyridinesulfonamide
DM4BPL1	MI	TTANPDJ
DM4BPL1	MN	Carbonic anhydrase II (CA-II)
DM4BPL1	MT	DTT
DM4BPL1	MA	Inhibitor
DM4BPL1	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DM4BPL1	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DM4BPL1	DI	DM4BPL1
DM4BPL1	DN	4-(Methylhydrazino)-3-pyridinesulfonamide
DM4BPL1	MI	TT2LVK8
DM4BPL1	MN	Carbonic anhydrase IX (CA-IX)
DM4BPL1	MT	DTT
DM4BPL1	MA	Inhibitor
DM4BPL1	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DM4BPL1	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DM4BPL1	DI	DM4BPL1
DM4BPL1	DN	4-(Methylhydrazino)-3-pyridinesulfonamide
DM4BPL1	MI	TTSYM0R
DM4BPL1	MN	Carbonic anhydrase XII (CA-XII)
DM4BPL1	MT	DTT
DM4BPL1	MA	Inhibitor
DM4BPL1	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DM4BPL1	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DM4BPL1	DI	DM4BPL1
DM4BPL1	DN	4-(Methylhydrazino)-3-pyridinesulfonamide
DM4BPL1	MI	TTEYTKG
DM4BPL1	MN	Carbonic anhydrase XIV (CA-XIV)
DM4BPL1	MT	DTT
DM4BPL1	MA	Inhibitor
DM4BPL1	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DM4BPL1	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DM8BWZO	DI	DM8BWZO
DM8BWZO	DN	4-(m-tolyloxy)-2-(trifluoromethyl)benzonitrile
DM8BWZO	MI	TTKPW01
DM8BWZO	MN	Androgen receptor messenger RNA (AR mRNA)
DM8BWZO	MT	DTT
DM8BWZO	MA	Inhibitor
DM8BWZO	RN	Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2176-8.
DM8BWZO	RU	https://pubmed.ncbi.nlm.nih.gov/19286380

DMI5XB1	DI	DMI5XB1
DMI5XB1	DN	4-(Naphthalene-1-sulfonyl)-phenylamine
DMI5XB1	MI	TTJS8PY
DMI5XB1	MN	5-HT 6 receptor (HTR6)
DMI5XB1	MT	DTT
DMI5XB1	MA	Inhibitor
DMI5XB1	RN	1-(1-Naphthyl)piperazine as a novel template for 5-HT6 serotonin receptor ligands. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1707-11.
DMI5XB1	RU	https://pubmed.ncbi.nlm.nih.gov/15745826

DMADWTI	DI	DMADWTI
DMADWTI	DN	4-(N-Methyl-hydrazino)-benzenesulfonamide
DMADWTI	MI	TTANPDJ
DMADWTI	MN	Carbonic anhydrase II (CA-II)
DMADWTI	MT	DTT
DMADWTI	MA	Inhibitor
DMADWTI	RN	Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglauc... Bioorg Med Chem Lett. 2005 Feb 15;15(4):963-9.
DMADWTI	RU	https://pubmed.ncbi.nlm.nih.gov/15686894

DMADWTI	DI	DMADWTI
DMADWTI	DN	4-(N-Methyl-hydrazino)-benzenesulfonamide
DMADWTI	MI	TTSYM0R
DMADWTI	MN	Carbonic anhydrase XII (CA-XII)
DMADWTI	MT	DTT
DMADWTI	MA	Inhibitor
DMADWTI	RN	Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglauc... Bioorg Med Chem Lett. 2005 Feb 15;15(4):963-9.
DMADWTI	RU	https://pubmed.ncbi.nlm.nih.gov/15686894

DMYCV8E	DI	DMYCV8E
DMYCV8E	DN	4-(N-Oxide-2-pyridylthio)pyridine-3-sulfonamide
DMYCV8E	MI	TTHQPL7
DMYCV8E	MN	Carbonic anhydrase I (CA-I)
DMYCV8E	MT	DTT
DMYCV8E	MA	Inhibitor
DMYCV8E	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMYCV8E	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMYCV8E	DI	DMYCV8E
DMYCV8E	DN	4-(N-Oxide-2-pyridylthio)pyridine-3-sulfonamide
DMYCV8E	MI	TTANPDJ
DMYCV8E	MN	Carbonic anhydrase II (CA-II)
DMYCV8E	MT	DTT
DMYCV8E	MA	Inhibitor
DMYCV8E	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMYCV8E	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMYCV8E	DI	DMYCV8E
DMYCV8E	DN	4-(N-Oxide-2-pyridylthio)pyridine-3-sulfonamide
DMYCV8E	MI	TT2LVK8
DMYCV8E	MN	Carbonic anhydrase IX (CA-IX)
DMYCV8E	MT	DTT
DMYCV8E	MA	Inhibitor
DMYCV8E	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMYCV8E	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMYCV8E	DI	DMYCV8E
DMYCV8E	DN	4-(N-Oxide-2-pyridylthio)pyridine-3-sulfonamide
DMYCV8E	MI	TTSYM0R
DMYCV8E	MN	Carbonic anhydrase XII (CA-XII)
DMYCV8E	MT	DTT
DMYCV8E	MA	Inhibitor
DMYCV8E	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMYCV8E	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMP43HI	DI	DMP43HI
DMP43HI	DN	4-(n-propyl)amino-3-nitrobenzoic acid
DMP43HI	MI	TT8WFXV
DMP43HI	MN	Hydroxycarboxylic acid receptor 3 (HCAR3)
DMP43HI	MT	DTT
DMP43HI	MA	Agonist
DMP43HI	RN	3-Nitro-4-amino benzoic acids and 6-amino nicotinic acids are highly selective agonists of GPR109b. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6619-22.
DMP43HI	RU	https://pubmed.ncbi.nlm.nih.gov/17931863

DM8I4B9	DI	DM8I4B9
DM8I4B9	DN	4-(o-tolyloxy)-2-(trifluoromethyl)benzonitrile
DM8I4B9	MI	TTKPW01
DM8I4B9	MN	Androgen receptor messenger RNA (AR mRNA)
DM8I4B9	MT	DTT
DM8I4B9	MA	Inhibitor
DM8I4B9	RN	Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2176-8.
DM8I4B9	RU	https://pubmed.ncbi.nlm.nih.gov/19286380

DM85XP6	DI	DM85XP6
DM85XP6	DN	4-(o-tolylthio)-2-(trifluoromethyl)benzonitrile
DM85XP6	MI	TTKPW01
DM85XP6	MN	Androgen receptor messenger RNA (AR mRNA)
DM85XP6	MT	DTT
DM85XP6	MA	Inhibitor
DM85XP6	RN	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
DM85XP6	RU	https://pubmed.ncbi.nlm.nih.gov/19201190

DMHIDY6	DI	DMHIDY6
DMHIDY6	DN	4-(Pent-3-ylamino)-1-naphthol
DMHIDY6	MI	TTZJYKH
DMHIDY6	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMHIDY6	MT	DTT
DMHIDY6	MA	Inhibitor
DMHIDY6	RN	Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2010 Feb 11;53(3):1172-89.
DMHIDY6	RU	https://pubmed.ncbi.nlm.nih.gov/20055453

DM54MOP	DI	DM54MOP
DM54MOP	DN	4-(phenyldiazenyl)-1H-pyrazole-3,5-diamine
DM54MOP	MI	TTAMQ62
DM54MOP	MN	Cyclin A2 (CCNA2)
DM54MOP	MT	DTT
DM54MOP	MA	Inhibitor
DM54MOP	RN	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
DM54MOP	RU	https://pubmed.ncbi.nlm.nih.gov/17064068

DM54MOP	DI	DM54MOP
DM54MOP	DN	4-(phenyldiazenyl)-1H-pyrazole-3,5-diamine
DM54MOP	MI	TT1LVF2
DM54MOP	MN	Cyclin-dependent kinase 9 (CDK9)
DM54MOP	MT	DTT
DM54MOP	MA	Inhibitor
DM54MOP	RN	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
DM54MOP	RU	https://pubmed.ncbi.nlm.nih.gov/17064068

DMM1RCS	DI	DMM1RCS
DMM1RCS	DN	4-(piperazin-1-yl)-1H-indole
DMM1RCS	MI	TTJS8PY
DMM1RCS	MN	5-HT 6 receptor (HTR6)
DMM1RCS	MT	DTT
DMM1RCS	MA	Inhibitor
DMM1RCS	RN	Binding of amine-substituted N1-benzenesulfonylindoles at human 5-HT6 serotonin receptors. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5298-302.
DMM1RCS	RU	https://pubmed.ncbi.nlm.nih.gov/16183286

DM1HM3F	DI	DM1HM3F
DM1HM3F	DN	4-(piperazin-1-yl)-3-tosyl-1H-indazole
DM1HM3F	MI	TTJS8PY
DM1HM3F	MN	5-HT 6 receptor (HTR6)
DM1HM3F	MT	DTT
DM1HM3F	MA	Inhibitor
DM1HM3F	RN	5-Piperazinyl-3-sulfonylindazoles as potent and selective 5-hydroxytryptamine-6 antagonists. J Med Chem. 2010 Nov 11;53(21):7639-46.
DM1HM3F	RU	https://pubmed.ncbi.nlm.nih.gov/20932009

DMTNVFZ	DI	DMTNVFZ
DMTNVFZ	DN	4-(piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine
DMTNVFZ	MI	TTWJBZ5
DMTNVFZ	MN	5-HT 2C receptor (HTR2C)
DMTNVFZ	MT	DTT
DMTNVFZ	MA	Inhibitor
DMTNVFZ	RN	Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity. Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71.
DMTNVFZ	RU	https://pubmed.ncbi.nlm.nih.gov/19914063

DMNM8VY	DI	DMNM8VY
DMNM8VY	DN	4-(piperazin-1-yl)furo[3,2-c]pyridine
DMNM8VY	MI	TTWJBZ5
DMNM8VY	MN	5-HT 2C receptor (HTR2C)
DMNM8VY	MT	DTT
DMNM8VY	MA	Inhibitor
DMNM8VY	RN	Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity. Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71.
DMNM8VY	RU	https://pubmed.ncbi.nlm.nih.gov/19914063

DMNU2RM	DI	DMNU2RM
DMNU2RM	DN	4-(piperazin-1-yl)thieno[2,3-d]pyrimidine
DMNU2RM	MI	TTWJBZ5
DMNU2RM	MN	5-HT 2C receptor (HTR2C)
DMNU2RM	MT	DTT
DMNU2RM	MA	Inhibitor
DMNU2RM	RN	Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity. Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71.
DMNU2RM	RU	https://pubmed.ncbi.nlm.nih.gov/19914063

DMJGTS7	DI	DMJGTS7
DMJGTS7	DN	4-(piperazin-1-yl)thieno[3,2-c]pyridine
DMJGTS7	MI	TTWJBZ5
DMJGTS7	MN	5-HT 2C receptor (HTR2C)
DMJGTS7	MT	DTT
DMJGTS7	MA	Inhibitor
DMJGTS7	RN	Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity. Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71.
DMJGTS7	RU	https://pubmed.ncbi.nlm.nih.gov/19914063

DM2KAG5	DI	DM2KAG5
DM2KAG5	DN	4-(piperazin-1-yl)thieno[3,2-d]pyrimidine
DM2KAG5	MI	TTWJBZ5
DM2KAG5	MN	5-HT 2C receptor (HTR2C)
DM2KAG5	MT	DTT
DM2KAG5	MA	Inhibitor
DM2KAG5	RN	Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity. Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71.
DM2KAG5	RU	https://pubmed.ncbi.nlm.nih.gov/19914063

DMEAZFJ	DI	DMEAZFJ
DMEAZFJ	DN	4-(propylamino)naphthalen-1-ol
DMEAZFJ	MI	TTZJYKH
DMEAZFJ	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMEAZFJ	MT	DTT
DMEAZFJ	MA	Inhibitor
DMEAZFJ	RN	Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2010 Feb 11;53(3):1172-89.
DMEAZFJ	RU	https://pubmed.ncbi.nlm.nih.gov/20055453

DM8BZQ3	DI	DM8BZQ3
DM8BZQ3	DN	4-(propylthio)-2-(trifluoromethyl)benzonitrile
DM8BZQ3	MI	TTKPW01
DM8BZQ3	MN	Androgen receptor messenger RNA (AR mRNA)
DM8BZQ3	MT	DTT
DM8BZQ3	MA	Inhibitor
DM8BZQ3	RN	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
DM8BZQ3	RU	https://pubmed.ncbi.nlm.nih.gov/19201190

DM8M0N9	DI	DM8M0N9
DM8M0N9	DN	4'-(p-toluenesulfonamide)-3,4-dihydroxy chalcone
DM8M0N9	MI	TTXWASR
DM8M0N9	MN	Intestinal maltase-glucoamylase (MGAM)
DM8M0N9	MT	DTT
DM8M0N9	MA	Inhibitor
DM8M0N9	RN	Sulfonamide chalcone as a new class of alpha-glucosidase inhibitors. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5514-6.
DM8M0N9	RU	https://pubmed.ncbi.nlm.nih.gov/16202584

DMRFWE1	DI	DMRFWE1
DMRFWE1	DN	4'-(p-Toluenesulfonamide)-4-hydroxychalcone
DMRFWE1	MI	TTULVH8
DMRFWE1	MN	Tyrosinase (TYR)
DMRFWE1	MT	DTT
DMRFWE1	MA	Inhibitor
DMRFWE1	RN	Evaluation of anti-pigmentary effect of synthetic sulfonylamino chalcone. Eur J Med Chem. 2010 May;45(5):2010-7.
DMRFWE1	RU	https://pubmed.ncbi.nlm.nih.gov/20149498

DMQA0EJ	DI	DMQA0EJ
DMQA0EJ	DN	4-(p-toluidino)-3-isopropylnaphthalene-1,2-dione
DMQA0EJ	MI	TTLZS4Q
DMQA0EJ	MN	M-phase inducer phosphatase 1 (MPIP1)
DMQA0EJ	MT	DTT
DMQA0EJ	MA	Inhibitor
DMQA0EJ	RN	Synthesis of miltirone analogues as inhibitors of Cdc25 phosphatases. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1905-8.
DMQA0EJ	RU	https://pubmed.ncbi.nlm.nih.gov/16434190

DMQA0EJ	DI	DMQA0EJ
DMQA0EJ	DN	4-(p-toluidino)-3-isopropylnaphthalene-1,2-dione
DMQA0EJ	MI	TTR0SWN
DMQA0EJ	MN	M-phase inducer phosphatase 2 (MPIP2)
DMQA0EJ	MT	DTT
DMQA0EJ	MA	Inhibitor
DMQA0EJ	RN	Synthesis of miltirone analogues as inhibitors of Cdc25 phosphatases. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1905-8.
DMQA0EJ	RU	https://pubmed.ncbi.nlm.nih.gov/16434190

DMQA0EJ	DI	DMQA0EJ
DMQA0EJ	DN	4-(p-toluidino)-3-isopropylnaphthalene-1,2-dione
DMQA0EJ	MI	TTELIN2
DMQA0EJ	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMQA0EJ	MT	DTT
DMQA0EJ	MA	Inhibitor
DMQA0EJ	RN	Synthesis of miltirone analogues as inhibitors of Cdc25 phosphatases. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1905-8.
DMQA0EJ	RU	https://pubmed.ncbi.nlm.nih.gov/16434190

DMIOQJD	DI	DMIOQJD
DMIOQJD	DN	4-(p-Tolyl)spiro[chromene-2,4'-piperidine]
DMIOQJD	MI	TT27RFC
DMIOQJD	MN	Opioid receptor delta (OPRD1)
DMIOQJD	MT	DTT
DMIOQJD	MA	Inhibitor
DMIOQJD	RN	Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-pipe... J Med Chem. 2008 Oct 9;51(19):5893-6.
DMIOQJD	RU	https://pubmed.ncbi.nlm.nih.gov/18788723

DMIOQJD	DI	DMIOQJD
DMIOQJD	DN	4-(p-Tolyl)spiro[chromene-2,4'-piperidine]
DMIOQJD	MI	TTQW87Y
DMIOQJD	MN	Opioid receptor kappa (OPRK1)
DMIOQJD	MT	DTT
DMIOQJD	MA	Inhibitor
DMIOQJD	RN	Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-pipe... J Med Chem. 2008 Oct 9;51(19):5893-6.
DMIOQJD	RU	https://pubmed.ncbi.nlm.nih.gov/18788723

DMIOQJD	DI	DMIOQJD
DMIOQJD	DN	4-(p-Tolyl)spiro[chromene-2,4'-piperidine]
DMIOQJD	MI	TTQ6VDM
DMIOQJD	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMIOQJD	MT	DTT
DMIOQJD	MA	Inhibitor
DMIOQJD	RN	Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-pipe... J Med Chem. 2008 Oct 9;51(19):5893-6.
DMIOQJD	RU	https://pubmed.ncbi.nlm.nih.gov/18788723

DMXK56P	DI	DMXK56P
DMXK56P	DN	4-(p-tolyloxy)-2-(trifluoromethyl)benzonitrile
DMXK56P	MI	TTKPW01
DMXK56P	MN	Androgen receptor messenger RNA (AR mRNA)
DMXK56P	MT	DTT
DMXK56P	MA	Inhibitor
DMXK56P	RN	Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2176-8.
DMXK56P	RU	https://pubmed.ncbi.nlm.nih.gov/19286380

DMZ0H5X	DI	DMZ0H5X
DMZ0H5X	DN	4'-(Pyridin-4-ylmethyl)biphenyl-3,4-diamine
DMZ0H5X	MI	TTIQUX7
DMZ0H5X	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMZ0H5X	MT	DTT
DMZ0H5X	MA	Inhibitor
DMZ0H5X	RN	Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
DMZ0H5X	RU	https://pubmed.ncbi.nlm.nih.gov/20684610

DMZ0H5X	DI	DMZ0H5X
DMZ0H5X	DN	4'-(Pyridin-4-ylmethyl)biphenyl-3,4-diamine
DMZ0H5X	MI	TTRA5BZ
DMZ0H5X	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMZ0H5X	MT	DTT
DMZ0H5X	MA	Inhibitor
DMZ0H5X	RN	Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
DMZ0H5X	RU	https://pubmed.ncbi.nlm.nih.gov/20684610

DM6Z5EK	DI	DM6Z5EK
DM6Z5EK	DN	4'-(Pyridin-4-ylmethyl)biphenyl-3,4-diol
DM6Z5EK	MI	TTSZLWK
DM6Z5EK	MN	Aromatase (CYP19A1)
DM6Z5EK	MT	DTT
DM6Z5EK	MA	Inhibitor
DM6Z5EK	RN	Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
DM6Z5EK	RU	https://pubmed.ncbi.nlm.nih.gov/20684610

DM6Z5EK	DI	DM6Z5EK
DM6Z5EK	DN	4'-(Pyridin-4-ylmethyl)biphenyl-3,4-diol
DM6Z5EK	MI	TTIQUX7
DM6Z5EK	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM6Z5EK	MT	DTT
DM6Z5EK	MA	Inhibitor
DM6Z5EK	RN	Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
DM6Z5EK	RU	https://pubmed.ncbi.nlm.nih.gov/20684610

DM6Z5EK	DI	DM6Z5EK
DM6Z5EK	DN	4'-(Pyridin-4-ylmethyl)biphenyl-3,4-diol
DM6Z5EK	MI	TTRA5BZ
DM6Z5EK	MN	Steroid 17-alpha-monooxygenase (S17AH)
DM6Z5EK	MT	DTT
DM6Z5EK	MA	Inhibitor
DM6Z5EK	RN	Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
DM6Z5EK	RU	https://pubmed.ncbi.nlm.nih.gov/20684610

DMR8O1B	DI	DMR8O1B
DMR8O1B	DN	4'-(Pyridin-4-ylmethyl)biphenyl-3-amine
DMR8O1B	MI	TTSZLWK
DMR8O1B	MN	Aromatase (CYP19A1)
DMR8O1B	MT	DTT
DMR8O1B	MA	Inhibitor
DMR8O1B	RN	Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
DMR8O1B	RU	https://pubmed.ncbi.nlm.nih.gov/20684610

DMR8O1B	DI	DMR8O1B
DMR8O1B	DN	4'-(Pyridin-4-ylmethyl)biphenyl-3-amine
DMR8O1B	MI	TTIQUX7
DMR8O1B	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMR8O1B	MT	DTT
DMR8O1B	MA	Inhibitor
DMR8O1B	RN	Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
DMR8O1B	RU	https://pubmed.ncbi.nlm.nih.gov/20684610

DMR8O1B	DI	DMR8O1B
DMR8O1B	DN	4'-(Pyridin-4-ylmethyl)biphenyl-3-amine
DMR8O1B	MI	TTRA5BZ
DMR8O1B	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMR8O1B	MT	DTT
DMR8O1B	MA	Inhibitor
DMR8O1B	RN	Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
DMR8O1B	RU	https://pubmed.ncbi.nlm.nih.gov/20684610

DM8HXYS	DI	DM8HXYS
DM8HXYS	DN	4'-(Pyridin-4-ylmethyl)biphenyl-4-amine
DM8HXYS	MI	TTIQUX7
DM8HXYS	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM8HXYS	MT	DTT
DM8HXYS	MA	Inhibitor
DM8HXYS	RN	Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
DM8HXYS	RU	https://pubmed.ncbi.nlm.nih.gov/20684610

DM8HXYS	DI	DM8HXYS
DM8HXYS	DN	4'-(Pyridin-4-ylmethyl)biphenyl-4-amine
DM8HXYS	MI	TTRA5BZ
DM8HXYS	MN	Steroid 17-alpha-monooxygenase (S17AH)
DM8HXYS	MT	DTT
DM8HXYS	MA	Inhibitor
DM8HXYS	RN	Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
DM8HXYS	RU	https://pubmed.ncbi.nlm.nih.gov/20684610

DMYXMT6	DI	DMYXMT6
DMYXMT6	DN	4'-(Pyridin-4-ylmethyl)biphenyl-4-carboxamide
DMYXMT6	MI	TTRA5BZ
DMYXMT6	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMYXMT6	MT	DTT
DMYXMT6	MA	Inhibitor
DMYXMT6	RN	Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
DMYXMT6	RU	https://pubmed.ncbi.nlm.nih.gov/20684610

DM4YFU5	DI	DM4YFU5
DM4YFU5	DN	4-(Quinolin-3-yl)-N-p-tolylpyrimidin-2-amine
DM4YFU5	MI	TTH6V3D
DM4YFU5	MN	Cyclin-dependent kinase 1 (CDK1)
DM4YFU5	MT	DTT
DM4YFU5	MA	Inhibitor
DM4YFU5	RN	Synthesis and cytotoxic activity of 2-methylimidazo[1,2-a]pyridine- and quinoline-substituted 2-aminopyrimidine derivatives. Eur J Med Chem. 2010 Jan;45(1):379-86.
DM4YFU5	RU	https://pubmed.ncbi.nlm.nih.gov/19879023

DM4YFU5	DI	DM4YFU5
DM4YFU5	DN	4-(Quinolin-3-yl)-N-p-tolylpyrimidin-2-amine
DM4YFU5	MI	TT9P6OW
DM4YFU5	MN	G2/mitotic-specific cyclin B1 (CCNB1)
DM4YFU5	MT	DTT
DM4YFU5	MA	Inhibitor
DM4YFU5	RN	Synthesis and cytotoxic activity of 2-methylimidazo[1,2-a]pyridine- and quinoline-substituted 2-aminopyrimidine derivatives. Eur J Med Chem. 2010 Jan;45(1):379-86.
DM4YFU5	RU	https://pubmed.ncbi.nlm.nih.gov/19879023

DMDW3SX	DI	DMDW3SX
DMDW3SX	DN	4-(Quinolin-4-yl)-N-p-tolylpyrimidin-2-amine
DMDW3SX	MI	TTH6V3D
DMDW3SX	MN	Cyclin-dependent kinase 1 (CDK1)
DMDW3SX	MT	DTT
DMDW3SX	MA	Inhibitor
DMDW3SX	RN	Synthesis and cytotoxic activity of 2-methylimidazo[1,2-a]pyridine- and quinoline-substituted 2-aminopyrimidine derivatives. Eur J Med Chem. 2010 Jan;45(1):379-86.
DMDW3SX	RU	https://pubmed.ncbi.nlm.nih.gov/19879023

DMDW3SX	DI	DMDW3SX
DMDW3SX	DN	4-(Quinolin-4-yl)-N-p-tolylpyrimidin-2-amine
DMDW3SX	MI	TT9P6OW
DMDW3SX	MN	G2/mitotic-specific cyclin B1 (CCNB1)
DMDW3SX	MT	DTT
DMDW3SX	MA	Inhibitor
DMDW3SX	RN	Synthesis and cytotoxic activity of 2-methylimidazo[1,2-a]pyridine- and quinoline-substituted 2-aminopyrimidine derivatives. Eur J Med Chem. 2010 Jan;45(1):379-86.
DMDW3SX	RU	https://pubmed.ncbi.nlm.nih.gov/19879023

DMPNXFA	DI	DMPNXFA
DMPNXFA	DN	4-(Quinolinoxy)-3-pyridinesulfonamide
DMPNXFA	MI	TTHQPL7
DMPNXFA	MN	Carbonic anhydrase I (CA-I)
DMPNXFA	MT	DTT
DMPNXFA	MA	Inhibitor
DMPNXFA	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMPNXFA	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMPNXFA	DI	DMPNXFA
DMPNXFA	DN	4-(Quinolinoxy)-3-pyridinesulfonamide
DMPNXFA	MI	TTANPDJ
DMPNXFA	MN	Carbonic anhydrase II (CA-II)
DMPNXFA	MT	DTT
DMPNXFA	MA	Inhibitor
DMPNXFA	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMPNXFA	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMPNXFA	DI	DMPNXFA
DMPNXFA	DN	4-(Quinolinoxy)-3-pyridinesulfonamide
DMPNXFA	MI	TT2LVK8
DMPNXFA	MN	Carbonic anhydrase IX (CA-IX)
DMPNXFA	MT	DTT
DMPNXFA	MA	Inhibitor
DMPNXFA	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMPNXFA	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMPNXFA	DI	DMPNXFA
DMPNXFA	DN	4-(Quinolinoxy)-3-pyridinesulfonamide
DMPNXFA	MI	TTSYM0R
DMPNXFA	MN	Carbonic anhydrase XII (CA-XII)
DMPNXFA	MT	DTT
DMPNXFA	MA	Inhibitor
DMPNXFA	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMPNXFA	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMPNXFA	DI	DMPNXFA
DMPNXFA	DN	4-(Quinolinoxy)-3-pyridinesulfonamide
DMPNXFA	MI	TTEYTKG
DMPNXFA	MN	Carbonic anhydrase XIV (CA-XIV)
DMPNXFA	MT	DTT
DMPNXFA	MA	Inhibitor
DMPNXFA	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMPNXFA	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DM0XDG6	DI	DM0XDG6
DM0XDG6	DN	4-(Spiro[chromene-2,4'-piperidine]-4-yl)benzamide
DM0XDG6	MI	TTVG215
DM0XDG6	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DM0XDG6	MT	DTT
DM0XDG6	MA	Inhibitor
DM0XDG6	RN	Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) b... J Med Chem. 2009 Sep 24;52(18):5685-702.
DM0XDG6	RU	https://pubmed.ncbi.nlm.nih.gov/19694468

DM0XDG6	DI	DM0XDG6
DM0XDG6	DN	4-(Spiro[chromene-2,4'-piperidine]-4-yl)benzamide
DM0XDG6	MI	TT27RFC
DM0XDG6	MN	Opioid receptor delta (OPRD1)
DM0XDG6	MT	DTT
DM0XDG6	MA	Inhibitor
DM0XDG6	RN	Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) b... J Med Chem. 2009 Sep 24;52(18):5685-702.
DM0XDG6	RU	https://pubmed.ncbi.nlm.nih.gov/19694468

DM0XDG6	DI	DM0XDG6
DM0XDG6	DN	4-(Spiro[chromene-2,4'-piperidine]-4-yl)benzamide
DM0XDG6	MI	TTQW87Y
DM0XDG6	MN	Opioid receptor kappa (OPRK1)
DM0XDG6	MT	DTT
DM0XDG6	MA	Inhibitor
DM0XDG6	RN	Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) b... J Med Chem. 2009 Sep 24;52(18):5685-702.
DM0XDG6	RU	https://pubmed.ncbi.nlm.nih.gov/19694468

DM0XDG6	DI	DM0XDG6
DM0XDG6	DN	4-(Spiro[chromene-2,4'-piperidine]-4-yl)benzamide
DM0XDG6	MI	TTKWM86
DM0XDG6	MN	Opioid receptor mu (MOP)
DM0XDG6	MT	DTT
DM0XDG6	MA	Inhibitor
DM0XDG6	RN	Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) b... J Med Chem. 2009 Sep 24;52(18):5685-702.
DM0XDG6	RU	https://pubmed.ncbi.nlm.nih.gov/19694468

DM0XDG6	DI	DM0XDG6
DM0XDG6	DN	4-(Spiro[chromene-2,4'-piperidine]-4-yl)benzamide
DM0XDG6	MI	TTQ6VDM
DM0XDG6	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DM0XDG6	MT	DTT
DM0XDG6	MA	Inhibitor
DM0XDG6	RN	Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) b... J Med Chem. 2009 Sep 24;52(18):5685-702.
DM0XDG6	RU	https://pubmed.ncbi.nlm.nih.gov/19694468

DM8ZRAE	DI	DM8ZRAE
DM8ZRAE	DN	4-(Spiro[chromene-2,4'-piperidine]-4-yl)phenol
DM8ZRAE	MI	TT27RFC
DM8ZRAE	MN	Opioid receptor delta (OPRD1)
DM8ZRAE	MT	DTT
DM8ZRAE	MA	Inhibitor
DM8ZRAE	RN	Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-pipe... J Med Chem. 2008 Oct 9;51(19):5893-6.
DM8ZRAE	RU	https://pubmed.ncbi.nlm.nih.gov/18788723

DM8ZRAE	DI	DM8ZRAE
DM8ZRAE	DN	4-(Spiro[chromene-2,4'-piperidine]-4-yl)phenol
DM8ZRAE	MI	TTQW87Y
DM8ZRAE	MN	Opioid receptor kappa (OPRK1)
DM8ZRAE	MT	DTT
DM8ZRAE	MA	Inhibitor
DM8ZRAE	RN	Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-pipe... J Med Chem. 2008 Oct 9;51(19):5893-6.
DM8ZRAE	RU	https://pubmed.ncbi.nlm.nih.gov/18788723

DM8ZRAE	DI	DM8ZRAE
DM8ZRAE	DN	4-(Spiro[chromene-2,4'-piperidine]-4-yl)phenol
DM8ZRAE	MI	TTKWM86
DM8ZRAE	MN	Opioid receptor mu (MOP)
DM8ZRAE	MT	DTT
DM8ZRAE	MA	Inhibitor
DM8ZRAE	RN	Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-pipe... J Med Chem. 2008 Oct 9;51(19):5893-6.
DM8ZRAE	RU	https://pubmed.ncbi.nlm.nih.gov/18788723

DM8ZRAE	DI	DM8ZRAE
DM8ZRAE	DN	4-(Spiro[chromene-2,4'-piperidine]-4-yl)phenol
DM8ZRAE	MI	TTQ6VDM
DM8ZRAE	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DM8ZRAE	MT	DTT
DM8ZRAE	MA	Inhibitor
DM8ZRAE	RN	Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-pipe... J Med Chem. 2008 Oct 9;51(19):5893-6.
DM8ZRAE	RU	https://pubmed.ncbi.nlm.nih.gov/18788723

DMU5A2B	DI	DMU5A2B
DMU5A2B	DN	4-(tert-butylamino)naphthalen-1-ol
DMU5A2B	MI	TTZJYKH
DMU5A2B	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMU5A2B	MT	DTT
DMU5A2B	MA	Inhibitor
DMU5A2B	RN	Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2010 Feb 11;53(3):1172-89.
DMU5A2B	RU	https://pubmed.ncbi.nlm.nih.gov/20055453

DMSUM3C	DI	DMSUM3C
DMSUM3C	DN	4-(thiazol-2-yl)phenyl butylcarbamate
DMSUM3C	MI	TTDP1UC
DMSUM3C	MN	Fatty acid amide hydrolase (FAAH)
DMSUM3C	MT	DTT
DMSUM3C	MA	Inhibitor
DMSUM3C	RN	Fatty acid amide hydrolase inhibitors from virtual screening of the endocannabinoid system. J Med Chem. 2006 Jul 27;49(15):4650-6.
DMSUM3C	RU	https://pubmed.ncbi.nlm.nih.gov/16854070

DMK3J8Q	DI	DMK3J8Q
DMK3J8Q	DN	4-(thiazol-2-yl)thieno[3,2-d]pyrimidin-2-amine
DMK3J8Q	MI	TTK25J1
DMK3J8Q	MN	Adenosine A1 receptor (ADORA1)
DMK3J8Q	MT	DTT
DMK3J8Q	MA	Inhibitor
DMK3J8Q	RN	Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2920-3.
DMK3J8Q	RU	https://pubmed.ncbi.nlm.nih.gov/18407496

DMK3J8Q	DI	DMK3J8Q
DMK3J8Q	DN	4-(thiazol-2-yl)thieno[3,2-d]pyrimidin-2-amine
DMK3J8Q	MI	TTM2AOE
DMK3J8Q	MN	Adenosine A2a receptor (ADORA2A)
DMK3J8Q	MT	DTT
DMK3J8Q	MA	Inhibitor
DMK3J8Q	RN	Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2920-3.
DMK3J8Q	RU	https://pubmed.ncbi.nlm.nih.gov/18407496

DMMWZLC	DI	DMMWZLC
DMMWZLC	DN	4'-(trifluoromethyl)-4-biphenylol
DMMWZLC	MI	TTBGTCW
DMMWZLC	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DMMWZLC	MT	DTT
DMMWZLC	MA	Inhibitor
DMMWZLC	RN	Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52.
DMMWZLC	RU	https://pubmed.ncbi.nlm.nih.gov/17725339

DMLP67R	DI	DMLP67R
DMLP67R	DN	4'-(trifluoromethyl)-4-biphenylsulfonamide
DMLP67R	MI	TTBGTCW
DMLP67R	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DMLP67R	MT	DTT
DMLP67R	MA	Inhibitor
DMLP67R	RN	Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52.
DMLP67R	RU	https://pubmed.ncbi.nlm.nih.gov/17725339

DMT3BX9	DI	DMT3BX9
DMT3BX9	DN	4'-(trifluoromethyl)-4-biphenylyl carbamate
DMT3BX9	MI	TTBGTCW
DMT3BX9	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DMT3BX9	MT	DTT
DMT3BX9	MA	Inhibitor
DMT3BX9	RN	Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52.
DMT3BX9	RU	https://pubmed.ncbi.nlm.nih.gov/17725339

DM8PTNR	DI	DM8PTNR
DM8PTNR	DN	4'-(trifluoromethyl)-4-biphenylyl sulfamate
DM8PTNR	MI	TTBGTCW
DM8PTNR	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DM8PTNR	MT	DTT
DM8PTNR	MA	Inhibitor
DM8PTNR	RN	Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52.
DM8PTNR	RU	https://pubmed.ncbi.nlm.nih.gov/17725339

DMZ0AKP	DI	DMZ0AKP
DMZ0AKP	DN	4-(trifluoromethyl)biphenyl
DMZ0AKP	MI	TTBGTCW
DMZ0AKP	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DMZ0AKP	MT	DTT
DMZ0AKP	MA	Inhibitor
DMZ0AKP	RN	Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52.
DMZ0AKP	RU	https://pubmed.ncbi.nlm.nih.gov/17725339

DMADZQ9	DI	DMADZQ9
DMADZQ9	DN	4-(trifluoromethyl)phenylboronic acid
DMADZQ9	MI	TTDP1UC
DMADZQ9	MN	Fatty acid amide hydrolase (FAAH)
DMADZQ9	MT	DTT
DMADZQ9	MA	Inhibitor
DMADZQ9	RN	Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Nov 27;51(22):7057-60.
DMADZQ9	RU	https://pubmed.ncbi.nlm.nih.gov/18983140

DM2YAUX	DI	DM2YAUX
DM2YAUX	DN	4(Z)-(5'-Deoxyadenosin-5'-ylidene)butanoic acid
DM2YAUX	MI	TTE2KUJ
DM2YAUX	MN	Adenosylhomocysteinase (AHCY)
DM2YAUX	MT	DTT
DM2YAUX	MA	Inhibitor
DM2YAUX	RN	Synthesis of 5'-functionalized nucleosides: S-Adenosylhomocysteine analogues with the carbon-5' and sulfur atoms replaced by a vinyl or halovinyl u... Bioorg Med Chem. 2008 May 15;16(10):5424-33.
DM2YAUX	RU	https://pubmed.ncbi.nlm.nih.gov/18457953

DMB5RJK	DI	DMB5RJK
DMB5RJK	DN	4,10-dimethyl-6H-benzo[c]chromene-3,8-diol
DMB5RJK	MI	TTZAYWL
DMB5RJK	MN	Estrogen receptor (ESR)
DMB5RJK	MT	DTT
DMB5RJK	MA	Inhibitor
DMB5RJK	RN	6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72.
DMB5RJK	RU	https://pubmed.ncbi.nlm.nih.gov/16412638

DMB5RJK	DI	DMB5RJK
DMB5RJK	DN	4,10-dimethyl-6H-benzo[c]chromene-3,8-diol
DMB5RJK	MI	TTOM3J0
DMB5RJK	MN	Estrogen receptor beta (ESR2)
DMB5RJK	MT	DTT
DMB5RJK	MA	Inhibitor
DMB5RJK	RN	6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72.
DMB5RJK	RU	https://pubmed.ncbi.nlm.nih.gov/16412638

DM1XTJC	DI	DM1XTJC
DM1XTJC	DN	4,12,17-dehydroxyriccardin C
DM1XTJC	MI	TTECBXN
DM1XTJC	MN	Oxysterols receptor LXR-alpha (NR1H3)
DM1XTJC	MT	DTT
DM1XTJC	MA	Inhibitor
DM1XTJC	RN	Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85.
DM1XTJC	RU	https://pubmed.ncbi.nlm.nih.gov/18343126

DMIZ0GO	DI	DMIZ0GO
DMIZ0GO	DN	4,17-dehydroxyriccardin C
DMIZ0GO	MI	TTECBXN
DMIZ0GO	MN	Oxysterols receptor LXR-alpha (NR1H3)
DMIZ0GO	MT	DTT
DMIZ0GO	MA	Inhibitor
DMIZ0GO	RN	Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85.
DMIZ0GO	RU	https://pubmed.ncbi.nlm.nih.gov/18343126

DMIZ0GO	DI	DMIZ0GO
DMIZ0GO	DN	4,17-dehydroxyriccardin C
DMIZ0GO	MI	TTXA6PH
DMIZ0GO	MN	Oxysterols receptor LXR-beta (NR1H2)
DMIZ0GO	MT	DTT
DMIZ0GO	MA	Inhibitor
DMIZ0GO	RN	Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85.
DMIZ0GO	RU	https://pubmed.ncbi.nlm.nih.gov/18343126

DMBN4G6	DI	DMBN4G6
DMBN4G6	DN	4,3'',5''-trimethoxy-[1,1':2',1'']-terphenyl
DMBN4G6	MI	TTS7G69
DMBN4G6	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMBN4G6	MT	DTT
DMBN4G6	MA	Inhibitor
DMBN4G6	RN	Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells. J Med Chem. 2006 May 18;49(10):3012-8.
DMBN4G6	RU	https://pubmed.ncbi.nlm.nih.gov/16686543

DMBN4G6	DI	DMBN4G6
DMBN4G6	DN	4,3'',5''-trimethoxy-[1,1':2',1'']-terphenyl
DMBN4G6	MI	TT3OT40
DMBN4G6	MN	Multidrug resistance protein 1 (ABCB1)
DMBN4G6	MT	DTT
DMBN4G6	MA	Inhibitor
DMBN4G6	RN	Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells. J Med Chem. 2006 May 18;49(10):3012-8.
DMBN4G6	RU	https://pubmed.ncbi.nlm.nih.gov/16686543

DM40E1T	DI	DM40E1T
DM40E1T	DN	4,3'',5''-trimethoxy-[1,1':3',1'']-terphenyl
DM40E1T	MI	TTS7G69
DM40E1T	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DM40E1T	MT	DTT
DM40E1T	MA	Inhibitor
DM40E1T	RN	Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells. J Med Chem. 2006 May 18;49(10):3012-8.
DM40E1T	RU	https://pubmed.ncbi.nlm.nih.gov/16686543

DMJKWFI	DI	DMJKWFI
DMJKWFI	DN	4,4'-(4-phenylpyridine-2,6-diyl)diphenol
DMJKWFI	MI	TT0IHXV
DMJKWFI	MN	DNA topoisomerase II (TOP2)
DMJKWFI	MT	DTT
DMJKWFI	MA	Inhibitor
DMJKWFI	RN	Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl ... Bioorg Med Chem. 2010 May 1;18(9):3066-77.
DMJKWFI	RU	https://pubmed.ncbi.nlm.nih.gov/20392646

DM1NVEI	DI	DM1NVEI
DM1NVEI	DN	4,4'-(ethane-1,2-diyl)dibenzene-1,3-diol
DM1NVEI	MI	TTULVH8
DM1NVEI	MN	Tyrosinase (TYR)
DM1NVEI	MT	DTT
DM1NVEI	MA	Inhibitor
DM1NVEI	RN	Molecular design of potent tyrosinase inhibitors having the bibenzyl skeleton. Bioorg Med Chem Lett. 2008 Oct 1;18(19):5252-4.
DM1NVEI	RU	https://pubmed.ncbi.nlm.nih.gov/18782667

DMFGQ02	DI	DMFGQ02
DMFGQ02	DN	4,4'-Biphenyldiboronic Acid
DMFGQ02	MI	TTHI19T
DMFGQ02	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMFGQ02	MT	DTT
DMFGQ02	MA	Inhibitor
DMFGQ02	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMFGQ02	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMFPO16	DI	DMFPO16
DMFPO16	DN	4',4-Dihydroxychalcone
DMFPO16	MI	TTULVH8
DMFPO16	MN	Tyrosinase (TYR)
DMFPO16	MT	DTT
DMFPO16	MA	Inhibitor
DMFPO16	RN	Evaluation of anti-pigmentary effect of synthetic sulfonylamino chalcone. Eur J Med Chem. 2010 May;45(5):2010-7.
DMFPO16	RU	https://pubmed.ncbi.nlm.nih.gov/20149498

DM1ONBT	DI	DM1ONBT
DM1ONBT	DN	4,4'-dihydroxyoctafluoroazobenzene
DM1ONBT	MI	TTTU72V
DM1ONBT	MN	Steroid 5-alpha-reductase 1 (SRD5A1)
DM1ONBT	MT	DTT
DM1ONBT	MA	Inhibitor
DM1ONBT	RN	Hydroxyperfluoroazobenzenes: novel inhibitors of enzymes of androgen biosynthesis. J Med Chem. 1990 Sep;33(9):2452-5.
DM1ONBT	RU	https://pubmed.ncbi.nlm.nih.gov/2391687

DM1ONBT	DI	DM1ONBT
DM1ONBT	DN	4,4'-dihydroxyoctafluoroazobenzene
DM1ONBT	MI	TTT02K8
DM1ONBT	MN	Steroid 5-alpha-reductase 2 (SRD5A2)
DM1ONBT	MT	DTT
DM1ONBT	MA	Inhibitor
DM1ONBT	RN	Hydroxyperfluoroazobenzenes: novel inhibitors of enzymes of androgen biosynthesis. J Med Chem. 1990 Sep;33(9):2452-5.
DM1ONBT	RU	https://pubmed.ncbi.nlm.nih.gov/2391687

DMQ0TBX	DI	DMQ0TBX
DMQ0TBX	DN	4,4-Diphenylbutan-1-amine
DMQ0TBX	MI	TTJQOD7
DMQ0TBX	MN	5-HT 2A receptor (HTR2A)
DMQ0TBX	MT	DTT
DMQ0TBX	MA	Inhibitor
DMQ0TBX	RN	Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504.
DMQ0TBX	RU	https://pubmed.ncbi.nlm.nih.gov/19700330

DMQ0TBX	DI	DMQ0TBX
DMQ0TBX	DN	4,4-Diphenylbutan-1-amine
DMQ0TBX	MI	TTTIBOJ
DMQ0TBX	MN	Histamine H1 receptor (H1R)
DMQ0TBX	MT	DTT
DMQ0TBX	MA	Inhibitor
DMQ0TBX	RN	Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504.
DMQ0TBX	RU	https://pubmed.ncbi.nlm.nih.gov/19700330

DMM0H9Y	DI	DMM0H9Y
DMM0H9Y	DN	4,4-Diphenyl-N-(pyridin-3-yl)-butyramide
DMM0H9Y	MI	TT7WVHI
DMM0H9Y	MN	Soluble epoxide hydrolase (EPHX2)
DMM0H9Y	MT	DTT
DMM0H9Y	MA	Inhibitor
DMM0H9Y	RN	Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase. J Med Chem. 2009 Oct 8;52(19):5880-95.
DMM0H9Y	RU	https://pubmed.ncbi.nlm.nih.gov/19746975

DM0K5JM	DI	DM0K5JM
DM0K5JM	DN	4,4'-thiodipyridine-3-sulfonamide
DM0K5JM	MI	TTHQPL7
DM0K5JM	MN	Carbonic anhydrase I (CA-I)
DM0K5JM	MT	DTT
DM0K5JM	MA	Inhibitor
DM0K5JM	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DM0K5JM	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DM0K5JM	DI	DM0K5JM
DM0K5JM	DN	4,4'-thiodipyridine-3-sulfonamide
DM0K5JM	MI	TTANPDJ
DM0K5JM	MN	Carbonic anhydrase II (CA-II)
DM0K5JM	MT	DTT
DM0K5JM	MA	Inhibitor
DM0K5JM	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DM0K5JM	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DM0K5JM	DI	DM0K5JM
DM0K5JM	DN	4,4'-thiodipyridine-3-sulfonamide
DM0K5JM	MI	TT2LVK8
DM0K5JM	MN	Carbonic anhydrase IX (CA-IX)
DM0K5JM	MT	DTT
DM0K5JM	MA	Inhibitor
DM0K5JM	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DM0K5JM	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DM0K5JM	DI	DM0K5JM
DM0K5JM	DN	4,4'-thiodipyridine-3-sulfonamide
DM0K5JM	MI	TTSYM0R
DM0K5JM	MN	Carbonic anhydrase XII (CA-XII)
DM0K5JM	MT	DTT
DM0K5JM	MA	Inhibitor
DM0K5JM	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DM0K5JM	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DM0K5JM	DI	DM0K5JM
DM0K5JM	DN	4,4'-thiodipyridine-3-sulfonamide
DM0K5JM	MI	TTEYTKG
DM0K5JM	MN	Carbonic anhydrase XIV (CA-XIV)
DM0K5JM	MT	DTT
DM0K5JM	MA	Inhibitor
DM0K5JM	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DM0K5JM	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMUE4K3	DI	DMUE4K3
DMUE4K3	DN	4,5,6,7-tetrabromo-1H-benzimidazole
DMUE4K3	MI	TTER6YH
DMUE4K3	MN	Casein kinase II alpha (CSNK2A1)
DMUE4K3	MT	DTT
DMUE4K3	MA	Inhibitor
DMUE4K3	RN	Synthesis of new analogs of benzotriazole, benzimidazole and phthalimide--potential inhibitors of human protein kinase CK2. Bioorg Med Chem. 2009 Feb 15;17(4):1573-8.
DMUE4K3	RU	https://pubmed.ncbi.nlm.nih.gov/19168362

DMN9YOB	DI	DMN9YOB
DMN9YOB	DN	4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole
DMN9YOB	MI	TTLAFZV
DMN9YOB	MN	AMP-activated protein kinase (AMPK)
DMN9YOB	MT	DTT
DMN9YOB	MA	Inhibitor
DMN9YOB	RN	Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
DMN9YOB	RU	https://pubmed.ncbi.nlm.nih.gov/15566294

DMN9YOB	DI	DMN9YOB
DMN9YOB	DN	4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole
DMN9YOB	MI	TTER6YH
DMN9YOB	MN	Casein kinase II alpha (CSNK2A1)
DMN9YOB	MT	DTT
DMN9YOB	MA	Inhibitor
DMN9YOB	RN	Structural insight into human CK2alpha in complex with the potent inhibitor ellagic acid. Bioorg Med Chem Lett. 2009 Jun 1;19(11):2920-3.
DMN9YOB	RU	https://pubmed.ncbi.nlm.nih.gov/19414254

DMN9YOB	DI	DMN9YOB
DMN9YOB	DN	4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole
DMN9YOB	MI	TTTU902
DMN9YOB	MN	Checkpoint kinase-1 (CHK1)
DMN9YOB	MT	DTT
DMN9YOB	MA	Inhibitor
DMN9YOB	RN	Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
DMN9YOB	RU	https://pubmed.ncbi.nlm.nih.gov/15566294

DMN9YOB	DI	DMN9YOB
DMN9YOB	DN	4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole
DMN9YOB	MI	TTIDAPM
DMN9YOB	MN	ERK activator kinase 1 (MEK1)
DMN9YOB	MT	DTT
DMN9YOB	MA	Inhibitor
DMN9YOB	RN	Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
DMN9YOB	RU	https://pubmed.ncbi.nlm.nih.gov/15566294

DMN9YOB	DI	DMN9YOB
DMN9YOB	DN	4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole
DMN9YOB	MI	TT4TQBX
DMN9YOB	MN	Extracellular signal-regulated kinase 2 (ERK2)
DMN9YOB	MT	DTT
DMN9YOB	MA	Inhibitor
DMN9YOB	RN	Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
DMN9YOB	RU	https://pubmed.ncbi.nlm.nih.gov/15566294

DMN9YOB	DI	DMN9YOB
DMN9YOB	DN	4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole
DMN9YOB	MI	TTRSMW9
DMN9YOB	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMN9YOB	MT	DTT
DMN9YOB	MA	Inhibitor
DMN9YOB	RN	Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
DMN9YOB	RU	https://pubmed.ncbi.nlm.nih.gov/15566294

DMN9YOB	DI	DMN9YOB
DMN9YOB	DN	4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole
DMN9YOB	MI	TT860QF
DMN9YOB	MN	LCK tyrosine protein kinase (LCK)
DMN9YOB	MT	DTT
DMN9YOB	MA	Inhibitor
DMN9YOB	RN	Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
DMN9YOB	RU	https://pubmed.ncbi.nlm.nih.gov/15566294

DMN9YOB	DI	DMN9YOB
DMN9YOB	DN	4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole
DMN9YOB	MI	TTYT93M
DMN9YOB	MN	MAP kinase p38 (MAPK12)
DMN9YOB	MT	DTT
DMN9YOB	MA	Inhibitor
DMN9YOB	RN	Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
DMN9YOB	RU	https://pubmed.ncbi.nlm.nih.gov/15566294

DMN9YOB	DI	DMN9YOB
DMN9YOB	DN	4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole
DMN9YOB	MI	TTFJ8Q1
DMN9YOB	MN	Protein kinase C alpha (PRKCA)
DMN9YOB	MT	DTT
DMN9YOB	MA	Inhibitor
DMN9YOB	RN	Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
DMN9YOB	RU	https://pubmed.ncbi.nlm.nih.gov/15566294

DMN9YOB	DI	DMN9YOB
DMN9YOB	DN	4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole
DMN9YOB	MI	TTWTSCV
DMN9YOB	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DMN9YOB	MT	DTT
DMN9YOB	MA	Inhibitor
DMN9YOB	RN	Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
DMN9YOB	RU	https://pubmed.ncbi.nlm.nih.gov/15566294

DMN9YOB	DI	DMN9YOB
DMN9YOB	DN	4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole
DMN9YOB	MI	TTZN7RP
DMN9YOB	MN	Rho-associated protein kinase 1 (ROCK1)
DMN9YOB	MT	DTT
DMN9YOB	MA	Inhibitor
DMN9YOB	RN	Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
DMN9YOB	RU	https://pubmed.ncbi.nlm.nih.gov/15566294

DMN9YOB	DI	DMN9YOB
DMN9YOB	DN	4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole
DMN9YOB	MI	TTG0U4H
DMN9YOB	MN	Ribosomal protein S6 kinase beta-1 (S6K1)
DMN9YOB	MT	DTT
DMN9YOB	MA	Inhibitor
DMN9YOB	RN	Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
DMN9YOB	RU	https://pubmed.ncbi.nlm.nih.gov/15566294

DMN9YOB	DI	DMN9YOB
DMN9YOB	DN	4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole
DMN9YOB	MI	TTTV8EJ
DMN9YOB	MN	Serine/threonine-protein kinase Sgk1 (SGK1)
DMN9YOB	MT	DTT
DMN9YOB	MA	Inhibitor
DMN9YOB	RN	Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
DMN9YOB	RU	https://pubmed.ncbi.nlm.nih.gov/15566294

DMN9YOB	DI	DMN9YOB
DMN9YOB	DN	4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole
DMN9YOB	MI	TTQBR95
DMN9YOB	MN	Stress-activated protein kinase 2a (p38 alpha)
DMN9YOB	MT	DTT
DMN9YOB	MA	Inhibitor
DMN9YOB	RN	Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
DMN9YOB	RU	https://pubmed.ncbi.nlm.nih.gov/15566294

DMN9YOB	DI	DMN9YOB
DMN9YOB	DN	4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole
DMN9YOB	MI	TT73U6C
DMN9YOB	MN	Stress-activated protein kinase 2b (p38 beta)
DMN9YOB	MT	DTT
DMN9YOB	MA	Inhibitor
DMN9YOB	RN	Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
DMN9YOB	RU	https://pubmed.ncbi.nlm.nih.gov/15566294

DMN9YOB	DI	DMN9YOB
DMN9YOB	DN	4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole
DMN9YOB	MI	TT0K6EO
DMN9YOB	MN	Stress-activated protein kinase JNK1 (JNK1)
DMN9YOB	MT	DTT
DMN9YOB	MA	Inhibitor
DMN9YOB	RN	Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
DMN9YOB	RU	https://pubmed.ncbi.nlm.nih.gov/15566294

DMTC7J2	DI	DMTC7J2
DMTC7J2	DN	4,5,6,7-tetrafluoro-3-methyl-1H-indazole
DMTC7J2	MI	TTZUFI5
DMTC7J2	MN	Nitric-oxide synthase brain (NOS1)
DMTC7J2	MT	DTT
DMTC7J2	MA	Inhibitor
DMTC7J2	RN	Fluorinated indazoles as novel selective inhibitors of nitric oxide synthase (NOS): synthesis and biological evaluation. Bioorg Med Chem. 2009 Sep 1;17(17):6180-7.
DMTC7J2	RU	https://pubmed.ncbi.nlm.nih.gov/19679481

DMTC7J2	DI	DMTC7J2
DMTC7J2	DN	4,5,6,7-tetrafluoro-3-methyl-1H-indazole
DMTC7J2	MI	TTF10I9
DMTC7J2	MN	Nitric-oxide synthase inducible (NOS2)
DMTC7J2	MT	DTT
DMTC7J2	MA	Inhibitor
DMTC7J2	RN	Fluorinated indazoles as novel selective inhibitors of nitric oxide synthase (NOS): synthesis and biological evaluation. Bioorg Med Chem. 2009 Sep 1;17(17):6180-7.
DMTC7J2	RU	https://pubmed.ncbi.nlm.nih.gov/19679481

DMZEY31	DI	DMZEY31
DMZEY31	DN	4,5,6,7-tetrafluoro-3-perfluorophenyl-1H-indazole
DMZEY31	MI	TTF10I9
DMZEY31	MN	Nitric-oxide synthase inducible (NOS2)
DMZEY31	MT	DTT
DMZEY31	MA	Inhibitor
DMZEY31	RN	Fluorinated indazoles as novel selective inhibitors of nitric oxide synthase (NOS): synthesis and biological evaluation. Bioorg Med Chem. 2009 Sep 1;17(17):6180-7.
DMZEY31	RU	https://pubmed.ncbi.nlm.nih.gov/19679481

DMDQL24	DI	DMDQL24
DMDQL24	DN	4,5,6,7-Tetrahydro-1H-indazole-3-carboxylic acid
DMDQL24	MI	TTWNV8U
DMDQL24	MN	Nicotinic acid receptor (HCAR2)
DMDQL24	MT	DTT
DMDQL24	MA	Inhibitor
DMDQL24	RN	Pyrazole derivatives as partial agonists for the nicotinic acid receptor. J Med Chem. 2003 Aug 28;46(18):3945-51.
DMDQL24	RU	https://pubmed.ncbi.nlm.nih.gov/12930155

DMO91EH	DI	DMO91EH
DMO91EH	DN	4,5,6,7-tetrahydroisoxazolo-[5,4-c]-pyridin-3-ol
DMO91EH	MI	TTAN6JD
DMO91EH	MN	Glutamate receptor AMPA (GRIA)
DMO91EH	MT	DTT
DMO91EH	MA	Agonist
DMO91EH	RN	Reduction in potency of selective gamma-aminobutyric acidA agonists and diazepam in CA1 region of in vitro hippocampal slices from chronic flurazepam-treated rats. J Pharmacol Exp Ther. 1992 Jul;262(1):204-11.
DMO91EH	RU	https://pubmed.ncbi.nlm.nih.gov/1320683

DMQFTJ7	DI	DMQFTJ7
DMQFTJ7	DN	4,5,6-trihydroxy-3-methylphthalide
DMQFTJ7	MI	TTWTSCV
DMQFTJ7	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DMQFTJ7	MT	DTT
DMQFTJ7	MA	Inhibitor
DMQFTJ7	RN	A phthalide with in vitro growth inhibitory activity from an oidiodendron strain. J Nat Prod. 2004 Dec;67(12):2086-9.
DMQFTJ7	RU	https://pubmed.ncbi.nlm.nih.gov/15620258

DMXZ9PI	DI	DMXZ9PI
DMXZ9PI	DN	4,5,7-Trichloro-3-hydroxy-1H-quinolin-2-one
DMXZ9PI	MI	TTLD29N
DMXZ9PI	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMXZ9PI	MT	DTT
DMXZ9PI	MA	Inhibitor
DMXZ9PI	RN	3-Hydroxy-quinolin-2-ones: Inhibitors of [3H]-glycine binding to the site associated with the NMDA receptor, Bioorg. Med. Chem. Lett. 6(5):499-504 (1996).
DMXZ9PI	RU	http://www.sciencedirect.com/science/article/pii/0960894X96000315

DMXZ9PI	DI	DMXZ9PI
DMXZ9PI	DN	4,5,7-Trichloro-3-hydroxy-1H-quinolin-2-one
DMXZ9PI	MI	TTKJEMQ
DMXZ9PI	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMXZ9PI	MT	DTT
DMXZ9PI	MA	Inhibitor
DMXZ9PI	RN	3-Hydroxy-quinolin-2-ones: Inhibitors of [3H]-glycine binding to the site associated with the NMDA receptor, Bioorg. Med. Chem. Lett. 6(5):499-504 (1996).
DMXZ9PI	RU	http://www.sciencedirect.com/science/article/pii/0960894X96000315

DMXZ9PI	DI	DMXZ9PI
DMXZ9PI	DN	4,5,7-Trichloro-3-hydroxy-1H-quinolin-2-one
DMXZ9PI	MI	TTN9D8E
DMXZ9PI	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMXZ9PI	MT	DTT
DMXZ9PI	MA	Inhibitor
DMXZ9PI	RN	3-Hydroxy-quinolin-2-ones: Inhibitors of [3H]-glycine binding to the site associated with the NMDA receptor, Bioorg. Med. Chem. Lett. 6(5):499-504 (1996).
DMXZ9PI	RU	http://www.sciencedirect.com/science/article/pii/0960894X96000315

DM1RM3H	DI	DM1RM3H
DM1RM3H	DN	4',5,7-trihydroxy-6,8-dimethylisoflavone
DM1RM3H	MI	TTZAYWL
DM1RM3H	MN	Estrogen receptor (ESR)
DM1RM3H	MT	DTT
DM1RM3H	MA	Inhibitor
DM1RM3H	RN	Isolation and structure elucidation of an isoflavone and a sesterterpenoic acid from Henriettella fascicularis. J Nat Prod. 2002 Dec;65(12):1749-53.
DM1RM3H	RU	https://pubmed.ncbi.nlm.nih.gov/12502307

DM1RM3H	DI	DM1RM3H
DM1RM3H	DN	4',5,7-trihydroxy-6,8-dimethylisoflavone
DM1RM3H	MI	TTOM3J0
DM1RM3H	MN	Estrogen receptor beta (ESR2)
DM1RM3H	MT	DTT
DM1RM3H	MA	Inhibitor
DM1RM3H	RN	Isolation and structure elucidation of an isoflavone and a sesterterpenoic acid from Henriettella fascicularis. J Nat Prod. 2002 Dec;65(12):1749-53.
DM1RM3H	RU	https://pubmed.ncbi.nlm.nih.gov/12502307

DMIO254	DI	DMIO254
DMIO254	DN	4,5-Bis(4-chlorophenyl)-1,2-selenazole
DMIO254	MI	TT8NGED
DMIO254	MN	Prostaglandin G/H synthase 1 (COX-1)
DMIO254	MT	DTT
DMIO254	MA	Inhibitor
DMIO254	RN	Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles. Eur J Med Chem. 2008 Jun;43(6):1152-9.
DMIO254	RU	https://pubmed.ncbi.nlm.nih.gov/17976864

DMIO254	DI	DMIO254
DMIO254	DN	4,5-Bis(4-chlorophenyl)-1,2-selenazole
DMIO254	MI	TTVKILB
DMIO254	MN	Prostaglandin G/H synthase 2 (COX-2)
DMIO254	MT	DTT
DMIO254	MA	Inhibitor
DMIO254	RN	Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles. Eur J Med Chem. 2008 Jun;43(6):1152-9.
DMIO254	RU	https://pubmed.ncbi.nlm.nih.gov/17976864

DMENLFY	DI	DMENLFY
DMENLFY	DN	4,5-Bis(4-chlorophenyl)isothiazole
DMENLFY	MI	TT8NGED
DMENLFY	MN	Prostaglandin G/H synthase 1 (COX-1)
DMENLFY	MT	DTT
DMENLFY	MA	Inhibitor
DMENLFY	RN	Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities. Bioorg Med Chem. 2009 Jan 15;17(2):558-68.
DMENLFY	RU	https://pubmed.ncbi.nlm.nih.gov/19097798

DMENLFY	DI	DMENLFY
DMENLFY	DN	4,5-Bis(4-chlorophenyl)isothiazole
DMENLFY	MI	TTVKILB
DMENLFY	MN	Prostaglandin G/H synthase 2 (COX-2)
DMENLFY	MT	DTT
DMENLFY	MA	Inhibitor
DMENLFY	RN	Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities. Bioorg Med Chem. 2009 Jan 15;17(2):558-68.
DMENLFY	RU	https://pubmed.ncbi.nlm.nih.gov/19097798

DMKHD1M	DI	DMKHD1M
DMKHD1M	DN	4,5-Bis(4-methoxyphenyl)-1,2-selenazole
DMKHD1M	MI	TT8NGED
DMKHD1M	MN	Prostaglandin G/H synthase 1 (COX-1)
DMKHD1M	MT	DTT
DMKHD1M	MA	Inhibitor
DMKHD1M	RN	Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles. Eur J Med Chem. 2008 Jun;43(6):1152-9.
DMKHD1M	RU	https://pubmed.ncbi.nlm.nih.gov/17976864

DMKHD1M	DI	DMKHD1M
DMKHD1M	DN	4,5-Bis(4-methoxyphenyl)-1,2-selenazole
DMKHD1M	MI	TTVKILB
DMKHD1M	MN	Prostaglandin G/H synthase 2 (COX-2)
DMKHD1M	MT	DTT
DMKHD1M	MA	Inhibitor
DMKHD1M	RN	Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles. Eur J Med Chem. 2008 Jun;43(6):1152-9.
DMKHD1M	RU	https://pubmed.ncbi.nlm.nih.gov/17976864

DMI39QT	DI	DMI39QT
DMI39QT	DN	4,5-Bis(4-methoxyphenyl)-3H-1,2-dithiol-3-one
DMI39QT	MI	TT8NGED
DMI39QT	MN	Prostaglandin G/H synthase 1 (COX-1)
DMI39QT	MT	DTT
DMI39QT	MA	Inhibitor
DMI39QT	RN	Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities. Bioorg Med Chem. 2009 Jan 15;17(2):558-68.
DMI39QT	RU	https://pubmed.ncbi.nlm.nih.gov/19097798

DMI39QT	DI	DMI39QT
DMI39QT	DN	4,5-Bis(4-methoxyphenyl)-3H-1,2-dithiol-3-one
DMI39QT	MI	TTVKILB
DMI39QT	MN	Prostaglandin G/H synthase 2 (COX-2)
DMI39QT	MT	DTT
DMI39QT	MA	Inhibitor
DMI39QT	RN	Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities. Bioorg Med Chem. 2009 Jan 15;17(2):558-68.
DMI39QT	RU	https://pubmed.ncbi.nlm.nih.gov/19097798

DMPW145	DI	DMPW145
DMPW145	DN	4,5-Bis(4-methoxyphenyl)-3H-1,2-dithiole-3-thione
DMPW145	MI	TT8NGED
DMPW145	MN	Prostaglandin G/H synthase 1 (COX-1)
DMPW145	MT	DTT
DMPW145	MA	Inhibitor
DMPW145	RN	Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities. Bioorg Med Chem. 2009 Jan 15;17(2):558-68.
DMPW145	RU	https://pubmed.ncbi.nlm.nih.gov/19097798

DM90DV6	DI	DM90DV6
DM90DV6	DN	4,5-Bis(4-methoxyphenyl)isothiazole
DM90DV6	MI	TT8NGED
DM90DV6	MN	Prostaglandin G/H synthase 1 (COX-1)
DM90DV6	MT	DTT
DM90DV6	MA	Inhibitor
DM90DV6	RN	Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities. Bioorg Med Chem. 2009 Jan 15;17(2):558-68.
DM90DV6	RU	https://pubmed.ncbi.nlm.nih.gov/19097798

DM90DV6	DI	DM90DV6
DM90DV6	DN	4,5-Bis(4-methoxyphenyl)isothiazole
DM90DV6	MI	TTVKILB
DM90DV6	MN	Prostaglandin G/H synthase 2 (COX-2)
DM90DV6	MT	DTT
DM90DV6	MA	Inhibitor
DM90DV6	RN	Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities. Bioorg Med Chem. 2009 Jan 15;17(2):558-68.
DM90DV6	RU	https://pubmed.ncbi.nlm.nih.gov/19097798

DMHURXY	DI	DMHURXY
DMHURXY	DN	4,5-dibenzylbenzene-1,2-diol
DMHURXY	MI	TTJGNVC
DMHURXY	MN	Apoptosis regulator Bcl-2 (BCL-2)
DMHURXY	MT	DTT
DMHURXY	MA	Inhibitor
DMHURXY	RN	Vaccinia virus virulence factor N1L is a novel promising target for antiviral therapeutic intervention. J Med Chem. 2010 May 27;53(10):3899-906.
DMHURXY	RU	https://pubmed.ncbi.nlm.nih.gov/20441222

DMHURXY	DI	DMHURXY
DMHURXY	DN	4,5-dibenzylbenzene-1,2-diol
DMHURXY	MI	TTRE6AX
DMHURXY	MN	Bcl-x messenger RNA (BCL2L1 mRNA)
DMHURXY	MT	DTT
DMHURXY	MA	Inhibitor
DMHURXY	RN	Vaccinia virus virulence factor N1L is a novel promising target for antiviral therapeutic intervention. J Med Chem. 2010 May 27;53(10):3899-906.
DMHURXY	RU	https://pubmed.ncbi.nlm.nih.gov/20441222

DMDM9UV	DI	DMDM9UV
DMDM9UV	DN	4,5-Dibromo-1H-pyrrole-2-carboxylic acid amide
DMDM9UV	MI	TTIDAPM
DMDM9UV	MN	ERK activator kinase 1 (MEK1)
DMDM9UV	MT	DTT
DMDM9UV	MA	Inhibitor
DMDM9UV	RN	Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1). J Med Chem. 2002 Jan 17;45(2):529-32.
DMDM9UV	RU	https://pubmed.ncbi.nlm.nih.gov/11784156

DMX94EK	DI	DMX94EK
DMX94EK	DN	4,5-dichloro-1H-indole-2,3-dione
DMX94EK	MI	TTMF541
DMX94EK	MN	Liver carboxylesterase (CES1)
DMX94EK	MT	DTT
DMX94EK	MA	Inhibitor
DMX94EK	RN	Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85.
DMX94EK	RU	https://pubmed.ncbi.nlm.nih.gov/17378546

DMG8KRN	DI	DMG8KRN
DMG8KRN	DN	4,5-Dihydroxy-10H-anthracen-9-one
DMG8KRN	MI	TT2J34L
DMG8KRN	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMG8KRN	MT	DTT
DMG8KRN	MA	Inhibitor
DMG8KRN	RN	Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80.
DMG8KRN	RU	https://pubmed.ncbi.nlm.nih.gov/9371243

DM34L89	DI	DM34L89
DM34L89	DN	4,5-Dimethoxy-10H-anthracen-9-one
DM34L89	MI	TT2J34L
DM34L89	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM34L89	MT	DTT
DM34L89	MA	Inhibitor
DM34L89	RN	Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80.
DM34L89	RU	https://pubmed.ncbi.nlm.nih.gov/9371243

DMB9CJM	DI	DMB9CJM
DMB9CJM	DN	4,5-Dimethyl-pyrrolidin-(2Z)-ylideneamine
DMB9CJM	MI	TTZUFI5
DMB9CJM	MN	Nitric-oxide synthase brain (NOS1)
DMB9CJM	MT	DTT
DMB9CJM	MA	Inhibitor
DMB9CJM	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DMB9CJM	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DMB9CJM	DI	DMB9CJM
DMB9CJM	DN	4,5-Dimethyl-pyrrolidin-(2Z)-ylideneamine
DMB9CJM	MI	TTCM4B3
DMB9CJM	MN	Nitric-oxide synthase endothelial (NOS3)
DMB9CJM	MT	DTT
DMB9CJM	MA	Inhibitor
DMB9CJM	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DMB9CJM	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DMB9CJM	DI	DMB9CJM
DMB9CJM	DN	4,5-Dimethyl-pyrrolidin-(2Z)-ylideneamine
DMB9CJM	MI	TTF10I9
DMB9CJM	MN	Nitric-oxide synthase inducible (NOS2)
DMB9CJM	MT	DTT
DMB9CJM	MA	Inhibitor
DMB9CJM	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DMB9CJM	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DMXNP2W	DI	DMXNP2W
DMXNP2W	DN	4,5-ISOBUDLEIN A
DMXNP2W	MI	TTSXVID
DMXNP2W	MN	Nuclear factor NF-kappa-B (NFKB)
DMXNP2W	MT	DTT
DMXNP2W	MA	Inhibitor
DMXNP2W	RN	Development of a structural model for NF-kappaB inhibition of sesquiterpene lactones using self-organizing neural networks. J Med Chem. 2006 Apr 6;49(7):2241-52.
DMXNP2W	RU	https://pubmed.ncbi.nlm.nih.gov/16570920

DM6N98E	DI	DM6N98E
DM6N98E	DN	4,6,10-trimethyl-6H-benzo[c]chromene-3,8-diol
DM6N98E	MI	TTZAYWL
DM6N98E	MN	Estrogen receptor (ESR)
DM6N98E	MT	DTT
DM6N98E	MA	Inhibitor
DM6N98E	RN	6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72.
DM6N98E	RU	https://pubmed.ncbi.nlm.nih.gov/16412638

DM6N98E	DI	DM6N98E
DM6N98E	DN	4,6,10-trimethyl-6H-benzo[c]chromene-3,8-diol
DM6N98E	MI	TTOM3J0
DM6N98E	MN	Estrogen receptor beta (ESR2)
DM6N98E	MT	DTT
DM6N98E	MA	Inhibitor
DM6N98E	RN	6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72.
DM6N98E	RU	https://pubmed.ncbi.nlm.nih.gov/16412638

DM14VI3	DI	DM14VI3
DM14VI3	DN	4,6,6,7-tetramethyl-6H-benzo[c]chromene-3,8-diol
DM14VI3	MI	TTZAYWL
DM14VI3	MN	Estrogen receptor (ESR)
DM14VI3	MT	DTT
DM14VI3	MA	Inhibitor
DM14VI3	RN	6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72.
DM14VI3	RU	https://pubmed.ncbi.nlm.nih.gov/16412638

DM14VI3	DI	DM14VI3
DM14VI3	DN	4,6,6,7-tetramethyl-6H-benzo[c]chromene-3,8-diol
DM14VI3	MI	TTOM3J0
DM14VI3	MN	Estrogen receptor beta (ESR2)
DM14VI3	MT	DTT
DM14VI3	MA	Inhibitor
DM14VI3	RN	6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72.
DM14VI3	RU	https://pubmed.ncbi.nlm.nih.gov/16412638

DMYN25U	DI	DMYN25U
DMYN25U	DN	4,6,7,10-tetramethyl-6H-benzo[c]chromene-3,8-diol
DMYN25U	MI	TTZAYWL
DMYN25U	MN	Estrogen receptor (ESR)
DMYN25U	MT	DTT
DMYN25U	MA	Inhibitor
DMYN25U	RN	6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72.
DMYN25U	RU	https://pubmed.ncbi.nlm.nih.gov/16412638

DMYN25U	DI	DMYN25U
DMYN25U	DN	4,6,7,10-tetramethyl-6H-benzo[c]chromene-3,8-diol
DMYN25U	MI	TTOM3J0
DMYN25U	MN	Estrogen receptor beta (ESR2)
DMYN25U	MT	DTT
DMYN25U	MA	Inhibitor
DMYN25U	RN	6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72.
DMYN25U	RU	https://pubmed.ncbi.nlm.nih.gov/16412638

DMFECXI	DI	DMFECXI
DMFECXI	DN	4,6,7-trimethyl-6H-benzo[c]chromene-3,8-diol
DMFECXI	MI	TTZAYWL
DMFECXI	MN	Estrogen receptor (ESR)
DMFECXI	MT	DTT
DMFECXI	MA	Inhibitor
DMFECXI	RN	6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72.
DMFECXI	RU	https://pubmed.ncbi.nlm.nih.gov/16412638

DMFECXI	DI	DMFECXI
DMFECXI	DN	4,6,7-trimethyl-6H-benzo[c]chromene-3,8-diol
DMFECXI	MI	TTOM3J0
DMFECXI	MN	Estrogen receptor beta (ESR2)
DMFECXI	MT	DTT
DMFECXI	MA	Inhibitor
DMFECXI	RN	6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72.
DMFECXI	RU	https://pubmed.ncbi.nlm.nih.gov/16412638

DMHBO17	DI	DMHBO17
DMHBO17	DN	4,6-dichloro-1H-indole-2,3-dione
DMHBO17	MI	TTMF541
DMHBO17	MN	Liver carboxylesterase (CES1)
DMHBO17	MT	DTT
DMHBO17	MA	Inhibitor
DMHBO17	RN	Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85.
DMHBO17	RU	https://pubmed.ncbi.nlm.nih.gov/17378546

DM62XC3	DI	DM62XC3
DM62XC3	DN	4,6-Dichloro-1H-indole-2-carboxylic acid
DM62XC3	MI	TTWHDVK
DM62XC3	MN	Fructose-1,6-bisphosphatase (FBP)
DM62XC3	MT	DTT
DM62XC3	MA	Inhibitor
DM62XC3	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM62XC3	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM62XC3	DI	DM62XC3
DM62XC3	DN	4,6-Dichloro-1H-indole-2-carboxylic acid
DM62XC3	MI	TTLD29N
DM62XC3	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DM62XC3	MT	DTT
DM62XC3	MA	Inhibitor
DM62XC3	RN	3-(2-carboxyindol-3-yl)propionic acid derivatives: antagonists of the strychnine-insensitive glycine receptor associated with the N-methyl-D-aspart... J Med Chem. 1990 Nov;33(11):2944-6.
DM62XC3	RU	https://pubmed.ncbi.nlm.nih.gov/2146391

DM62XC3	DI	DM62XC3
DM62XC3	DN	4,6-Dichloro-1H-indole-2-carboxylic acid
DM62XC3	MI	TTKJEMQ
DM62XC3	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DM62XC3	MT	DTT
DM62XC3	MA	Inhibitor
DM62XC3	RN	3-(2-carboxyindol-3-yl)propionic acid derivatives: antagonists of the strychnine-insensitive glycine receptor associated with the N-methyl-D-aspart... J Med Chem. 1990 Nov;33(11):2944-6.
DM62XC3	RU	https://pubmed.ncbi.nlm.nih.gov/2146391

DM62XC3	DI	DM62XC3
DM62XC3	DN	4,6-Dichloro-1H-indole-2-carboxylic acid
DM62XC3	MI	TTN9D8E
DM62XC3	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DM62XC3	MT	DTT
DM62XC3	MA	Inhibitor
DM62XC3	RN	3-(2-carboxyindol-3-yl)propionic acid derivatives: antagonists of the strychnine-insensitive glycine receptor associated with the N-methyl-D-aspart... J Med Chem. 1990 Nov;33(11):2944-6.
DM62XC3	RU	https://pubmed.ncbi.nlm.nih.gov/2146391

DMBZIG7	DI	DMBZIG7
DMBZIG7	DN	4,6-Dideoxy-4-Amino-Alpha-D-Glucose
DMBZIG7	MI	TTCGSZ4
DMBZIG7	MN	Pancreatic alpha-amylase (AMY2A)
DMBZIG7	MT	DTT
DMBZIG7	MA	Inhibitor
DMBZIG7	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMBZIG7	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMP5M9E	DI	DMP5M9E
DMP5M9E	DN	4,6-Dideoxyglucose
DMP5M9E	MI	TTHCF4J
DMP5M9E	MN	Alpha-glucosidase (GLA)
DMP5M9E	MT	DTT
DMP5M9E	MA	Inhibitor
DMP5M9E	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMP5M9E	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMIJ4VZ	DI	DMIJ4VZ
DMIJ4VZ	DN	4,6-Dinitro salicylic acid
DMIJ4VZ	MI	TTHQPL7
DMIJ4VZ	MN	Carbonic anhydrase I (CA-I)
DMIJ4VZ	MT	DTT
DMIJ4VZ	MA	Inhibitor
DMIJ4VZ	RN	In vitro inhibition of salicylic acid derivatives on human cytosolic carbonic anhydrase isozymes I and II. Bioorg Med Chem. 2008 Oct 15;16(20):9101-5.
DMIJ4VZ	RU	https://pubmed.ncbi.nlm.nih.gov/18819808

DMIJ4VZ	DI	DMIJ4VZ
DMIJ4VZ	DN	4,6-Dinitro salicylic acid
DMIJ4VZ	MI	TTANPDJ
DMIJ4VZ	MN	Carbonic anhydrase II (CA-II)
DMIJ4VZ	MT	DTT
DMIJ4VZ	MA	Inhibitor
DMIJ4VZ	RN	In vitro inhibition of salicylic acid derivatives on human cytosolic carbonic anhydrase isozymes I and II. Bioorg Med Chem. 2008 Oct 15;16(20):9101-5.
DMIJ4VZ	RU	https://pubmed.ncbi.nlm.nih.gov/18819808

DMWDYLR	DI	DMWDYLR
DMWDYLR	DN	4,6-dinitrobenzo[c][1,2,5]thiadiazole
DMWDYLR	MI	TTR7UJ3
DMWDYLR	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMWDYLR	MT	DTT
DMWDYLR	MA	Inhibitor
DMWDYLR	RN	Specific inhibitors of Plasmodium falciparum thioredoxin reductase as potential antimalarial agents. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2283-92.
DMWDYLR	RU	https://pubmed.ncbi.nlm.nih.gov/16458512

DMEVK5F	DI	DMEVK5F
DMEVK5F	DN	4,7-dichloro-1H-indole-2,3-dione
DMEVK5F	MI	TTMF541
DMEVK5F	MN	Liver carboxylesterase (CES1)
DMEVK5F	MT	DTT
DMEVK5F	MA	Inhibitor
DMEVK5F	RN	Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85.
DMEVK5F	RU	https://pubmed.ncbi.nlm.nih.gov/17378546

DM67Z81	DI	DM67Z81
DM67Z81	DN	4,7-dimethyl-6H-benzo[c]chromene-3,8-diol
DM67Z81	MI	TTZAYWL
DM67Z81	MN	Estrogen receptor (ESR)
DM67Z81	MT	DTT
DM67Z81	MA	Inhibitor
DM67Z81	RN	6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72.
DM67Z81	RU	https://pubmed.ncbi.nlm.nih.gov/16412638

DM67Z81	DI	DM67Z81
DM67Z81	DN	4,7-dimethyl-6H-benzo[c]chromene-3,8-diol
DM67Z81	MI	TTOM3J0
DM67Z81	MN	Estrogen receptor beta (ESR2)
DM67Z81	MT	DTT
DM67Z81	MA	Inhibitor
DM67Z81	RN	6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72.
DM67Z81	RU	https://pubmed.ncbi.nlm.nih.gov/16412638

DML5302	DI	DML5302
DML5302	DN	4,7-Dioxosebacic Acid
DML5302	MI	TTJHKYD
DML5302	MN	Delta-aminolevulinic acid dehydratase (ALAD)
DML5302	MT	DTT
DML5302	MA	Inhibitor
DML5302	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DML5302	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMQNXL1	DI	DMQNXL1
DMQNXL1	DN	4,8-Dimethyl-7-(2'-oxocyclohexyloxy)coumarin
DMQNXL1	MI	TT3WG5C
DMQNXL1	MN	Monoamine oxidase type A (MAO-A)
DMQNXL1	MT	DTT
DMQNXL1	MA	Inhibitor
DMQNXL1	RN	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J Med Chem. 2008 Nov 13;51(21):6740-51.
DMQNXL1	RU	https://pubmed.ncbi.nlm.nih.gov/18834112

DMQNXL1	DI	DMQNXL1
DMQNXL1	DN	4,8-Dimethyl-7-(2'-oxocyclohexyloxy)coumarin
DMQNXL1	MI	TTGP7BY
DMQNXL1	MN	Monoamine oxidase type B (MAO-B)
DMQNXL1	MT	DTT
DMQNXL1	MA	Inhibitor
DMQNXL1	RN	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J Med Chem. 2008 Nov 13;51(21):6740-51.
DMQNXL1	RU	https://pubmed.ncbi.nlm.nih.gov/18834112

DMEKI1B	DI	DMEKI1B
DMEKI1B	DN	4,9-anhydro-tetrodotoxin
DMEKI1B	MI	TT54ERL
DMEKI1B	MN	Voltage-gated sodium channel alpha Nav1.6 (SCN8A)
DMEKI1B	MT	DTT
DMEKI1B	MA	Blocker (channel blocker)
DMEKI1B	RN	The TTX metabolite 4,9-anhydro-TTX is a highly specific blocker of the Na(v1.6) voltage-dependent sodium channel. Am J Physiol Cell Physiol. 2007 Aug;293(2):C783-9.
DMEKI1B	RU	https://pubmed.ncbi.nlm.nih.gov/17522141

DM27HMT	DI	DM27HMT
DM27HMT	DN	4,9-Dihydro-3H-beta-carboline
DM27HMT	MI	TT3WG5C
DM27HMT	MN	Monoamine oxidase type A (MAO-A)
DM27HMT	MT	DTT
DM27HMT	MA	Inhibitor
DM27HMT	RN	Pyrazino[1,2-a]indoles as novel high-affinity and selective imidazoline I(2) receptor ligands. Bioorg Med Chem Lett. 2004 Feb 23;14(4):1003-5.
DM27HMT	RU	https://pubmed.ncbi.nlm.nih.gov/15013010

DM27HMT	DI	DM27HMT
DM27HMT	DN	4,9-Dihydro-3H-beta-carboline
DM27HMT	MI	TTGP7BY
DM27HMT	MN	Monoamine oxidase type B (MAO-B)
DM27HMT	MT	DTT
DM27HMT	MA	Inhibitor
DM27HMT	RN	Pyrazino[1,2-a]indoles as novel high-affinity and selective imidazoline I(2) receptor ligands. Bioorg Med Chem Lett. 2004 Feb 23;14(4):1003-5.
DM27HMT	RU	https://pubmed.ncbi.nlm.nih.gov/15013010

DM8BPTQ	DI	DM8BPTQ
DM8BPTQ	DN	4-[(2-Methyl-1H-imidazol-1-yl)methyl]pyridine
DM8BPTQ	MI	TTZUFI5
DM8BPTQ	MN	Nitric-oxide synthase brain (NOS1)
DM8BPTQ	MT	DTT
DM8BPTQ	MA	Inhibitor
DM8BPTQ	RN	N-Substituted acetamidines and 2-methylimidazole derivatives as selective inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6495-9.
DM8BPTQ	RU	https://pubmed.ncbi.nlm.nih.gov/20933416

DM8BPTQ	DI	DM8BPTQ
DM8BPTQ	DN	4-[(2-Methyl-1H-imidazol-1-yl)methyl]pyridine
DM8BPTQ	MI	TTF10I9
DM8BPTQ	MN	Nitric-oxide synthase inducible (NOS2)
DM8BPTQ	MT	DTT
DM8BPTQ	MA	Inhibitor
DM8BPTQ	RN	N-Substituted acetamidines and 2-methylimidazole derivatives as selective inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6495-9.
DM8BPTQ	RU	https://pubmed.ncbi.nlm.nih.gov/20933416

DMSKJ1X	DI	DMSKJ1X
DMSKJ1X	DN	4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol
DMSKJ1X	MI	TTW4Y2M
DMSKJ1X	MN	cAMP protein kinase type II-beta (PRKAR2B)
DMSKJ1X	MT	DTT
DMSKJ1X	MA	Inhibitor
DMSKJ1X	RN	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
DMSKJ1X	RU	https://pubmed.ncbi.nlm.nih.gov/17064068

DMSKJ1X	DI	DMSKJ1X
DMSKJ1X	DN	4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol
DMSKJ1X	MI	TTER6YH
DMSKJ1X	MN	Casein kinase II alpha (CSNK2A1)
DMSKJ1X	MT	DTT
DMSKJ1X	MA	Inhibitor
DMSKJ1X	RN	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
DMSKJ1X	RU	https://pubmed.ncbi.nlm.nih.gov/17064068

DMSKJ1X	DI	DMSKJ1X
DMSKJ1X	DN	4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol
DMSKJ1X	MI	TTTU902
DMSKJ1X	MN	Checkpoint kinase-1 (CHK1)
DMSKJ1X	MT	DTT
DMSKJ1X	MA	Inhibitor
DMSKJ1X	RN	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
DMSKJ1X	RU	https://pubmed.ncbi.nlm.nih.gov/17064068

DMSKJ1X	DI	DMSKJ1X
DMSKJ1X	DN	4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol
DMSKJ1X	MI	TTAMQ62
DMSKJ1X	MN	Cyclin A2 (CCNA2)
DMSKJ1X	MT	DTT
DMSKJ1X	MA	Inhibitor
DMSKJ1X	RN	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
DMSKJ1X	RU	https://pubmed.ncbi.nlm.nih.gov/17064068

DMSKJ1X	DI	DMSKJ1X
DMSKJ1X	DN	4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol
DMSKJ1X	MI	TT7HF4W
DMSKJ1X	MN	Cyclin-dependent kinase 2 (CDK2)
DMSKJ1X	MT	DTT
DMSKJ1X	MA	Inhibitor
DMSKJ1X	RN	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
DMSKJ1X	RU	https://pubmed.ncbi.nlm.nih.gov/17064068

DMSKJ1X	DI	DMSKJ1X
DMSKJ1X	DN	4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol
DMSKJ1X	MI	TT0PG8F
DMSKJ1X	MN	Cyclin-dependent kinase 4 (CDK4)
DMSKJ1X	MT	DTT
DMSKJ1X	MA	Inhibitor
DMSKJ1X	RN	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
DMSKJ1X	RU	https://pubmed.ncbi.nlm.nih.gov/17064068

DMSKJ1X	DI	DMSKJ1X
DMSKJ1X	DN	4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol
DMSKJ1X	MI	TT1LVF2
DMSKJ1X	MN	Cyclin-dependent kinase 9 (CDK9)
DMSKJ1X	MT	DTT
DMSKJ1X	MA	Inhibitor
DMSKJ1X	RN	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
DMSKJ1X	RU	https://pubmed.ncbi.nlm.nih.gov/17064068

DMSKJ1X	DI	DMSKJ1X
DMSKJ1X	DN	4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol
DMSKJ1X	MI	TT4TQBX
DMSKJ1X	MN	Extracellular signal-regulated kinase 2 (ERK2)
DMSKJ1X	MT	DTT
DMSKJ1X	MA	Inhibitor
DMSKJ1X	RN	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
DMSKJ1X	RU	https://pubmed.ncbi.nlm.nih.gov/17064068

DMSKJ1X	DI	DMSKJ1X
DMSKJ1X	DN	4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol
DMSKJ1X	MI	TTYVI76
DMSKJ1X	MN	Fungal Protein kinase A (Fung ypkA)
DMSKJ1X	MT	DTT
DMSKJ1X	MA	Inhibitor
DMSKJ1X	RN	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
DMSKJ1X	RU	https://pubmed.ncbi.nlm.nih.gov/17064068

DMSKJ1X	DI	DMSKJ1X
DMSKJ1X	DN	4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol
DMSKJ1X	MI	TTFCJ7S
DMSKJ1X	MN	G1/S-specific cyclin-D1 (CCND1)
DMSKJ1X	MT	DTT
DMSKJ1X	MA	Inhibitor
DMSKJ1X	RN	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
DMSKJ1X	RU	https://pubmed.ncbi.nlm.nih.gov/17064068

DMSKJ1X	DI	DMSKJ1X
DMSKJ1X	DN	4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol
DMSKJ1X	MI	TTCEJ4F
DMSKJ1X	MN	G1/S-specific cyclin-E1 (CCNE1)
DMSKJ1X	MT	DTT
DMSKJ1X	MA	Inhibitor
DMSKJ1X	RN	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
DMSKJ1X	RU	https://pubmed.ncbi.nlm.nih.gov/17064068

DMSKJ1X	DI	DMSKJ1X
DMSKJ1X	DN	4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol
DMSKJ1X	MI	TTRSMW9
DMSKJ1X	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMSKJ1X	MT	DTT
DMSKJ1X	MA	Inhibitor
DMSKJ1X	RN	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
DMSKJ1X	RU	https://pubmed.ncbi.nlm.nih.gov/17064068

DMSKJ1X	DI	DMSKJ1X
DMSKJ1X	DN	4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol
DMSKJ1X	MI	TT5U49F
DMSKJ1X	MN	PRKACA messenger RNA (PRKACA mRNA)
DMSKJ1X	MT	DTT
DMSKJ1X	MA	Inhibitor
DMSKJ1X	RN	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
DMSKJ1X	RU	https://pubmed.ncbi.nlm.nih.gov/17064068

DMSKJ1X	DI	DMSKJ1X
DMSKJ1X	DN	4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol
DMSKJ1X	MI	TTWTSCV
DMSKJ1X	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DMSKJ1X	MT	DTT
DMSKJ1X	MA	Inhibitor
DMSKJ1X	RN	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
DMSKJ1X	RU	https://pubmed.ncbi.nlm.nih.gov/17064068

DMSKJ1X	DI	DMSKJ1X
DMSKJ1X	DN	4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol
DMSKJ1X	MI	TTG0U4H
DMSKJ1X	MN	Ribosomal protein S6 kinase beta-1 (S6K1)
DMSKJ1X	MT	DTT
DMSKJ1X	MA	Inhibitor
DMSKJ1X	RN	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
DMSKJ1X	RU	https://pubmed.ncbi.nlm.nih.gov/17064068

DMSKJ1X	DI	DMSKJ1X
DMSKJ1X	DN	4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol
DMSKJ1X	MI	TTQBR95
DMSKJ1X	MN	Stress-activated protein kinase 2a (p38 alpha)
DMSKJ1X	MT	DTT
DMSKJ1X	MA	Inhibitor
DMSKJ1X	RN	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
DMSKJ1X	RU	https://pubmed.ncbi.nlm.nih.gov/17064068

DMSKJ1X	DI	DMSKJ1X
DMSKJ1X	DN	4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol
DMSKJ1X	MI	TT3PJMV
DMSKJ1X	MN	Tyrosine-protein kinase ABL1 (ABL)
DMSKJ1X	MT	DTT
DMSKJ1X	MA	Inhibitor
DMSKJ1X	RN	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
DMSKJ1X	RU	https://pubmed.ncbi.nlm.nih.gov/17064068

DM04MK7	DI	DM04MK7
DM04MK7	DN	4-[(3'-Hydroxybiphenyl-4-yl)methyl]pyridine
DM04MK7	MI	TTSZLWK
DM04MK7	MN	Aromatase (CYP19A1)
DM04MK7	MT	DTT
DM04MK7	MA	Inhibitor
DM04MK7	RN	Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
DM04MK7	RU	https://pubmed.ncbi.nlm.nih.gov/20684610

DM04MK7	DI	DM04MK7
DM04MK7	DN	4-[(3'-Hydroxybiphenyl-4-yl)methyl]pyridine
DM04MK7	MI	TTIQUX7
DM04MK7	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM04MK7	MT	DTT
DM04MK7	MA	Inhibitor
DM04MK7	RN	Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
DM04MK7	RU	https://pubmed.ncbi.nlm.nih.gov/20684610

DM04MK7	DI	DM04MK7
DM04MK7	DN	4-[(3'-Hydroxybiphenyl-4-yl)methyl]pyridine
DM04MK7	MI	TTRA5BZ
DM04MK7	MN	Steroid 17-alpha-monooxygenase (S17AH)
DM04MK7	MT	DTT
DM04MK7	MA	Inhibitor
DM04MK7	RN	Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
DM04MK7	RU	https://pubmed.ncbi.nlm.nih.gov/20684610

DMIEMWA	DI	DMIEMWA
DMIEMWA	DN	4-[(4'-Hydroxybiphenyl-4-yl)methyl]pyridine
DMIEMWA	MI	TTSZLWK
DMIEMWA	MN	Aromatase (CYP19A1)
DMIEMWA	MT	DTT
DMIEMWA	MA	Inhibitor
DMIEMWA	RN	Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
DMIEMWA	RU	https://pubmed.ncbi.nlm.nih.gov/20684610

DMIEMWA	DI	DMIEMWA
DMIEMWA	DN	4-[(4'-Hydroxybiphenyl-4-yl)methyl]pyridine
DMIEMWA	MI	TTIQUX7
DMIEMWA	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMIEMWA	MT	DTT
DMIEMWA	MA	Inhibitor
DMIEMWA	RN	Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
DMIEMWA	RU	https://pubmed.ncbi.nlm.nih.gov/20684610

DMIEMWA	DI	DMIEMWA
DMIEMWA	DN	4-[(4'-Hydroxybiphenyl-4-yl)methyl]pyridine
DMIEMWA	MI	TTRA5BZ
DMIEMWA	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMIEMWA	MT	DTT
DMIEMWA	MA	Inhibitor
DMIEMWA	RN	Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
DMIEMWA	RU	https://pubmed.ncbi.nlm.nih.gov/20684610

DMNMC9O	DI	DMNMC9O
DMNMC9O	DN	4-[(5-methoxy-2-methylphenoxy)methyl]pyridine
DMNMC9O	MI	TTQO71U
DMNMC9O	MN	Hemoglobin (HB)
DMNMC9O	MT	DTT
DMNMC9O	MA	Inhibitor
DMNMC9O	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMNMC9O	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMGRWEU	DI	DMGRWEU
DMGRWEU	DN	4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide
DMGRWEU	MI	TT7HF4W
DMGRWEU	MN	Cyclin-dependent kinase 2 (CDK2)
DMGRWEU	MT	DTT
DMGRWEU	MA	Inhibitor
DMGRWEU	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMGRWEU	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMT1PM4	DI	DMT1PM4
DMT1PM4	DN	4-[(diphenylmethyl)amino]-2-phenylquinazoline
DMT1PM4	MI	TT8DBY3
DMT1PM4	MN	Angiotensin II receptor type-1 (AGTR1)
DMT1PM4	MT	DTT
DMT1PM4	MA	Antagonist
DMT1PM4	RN	Identification of a novel partial inhibitor of dopamine transporter among 4-substituted 2-phenylquinazolines. Bioorg Med Chem Lett. 2002 Aug 19;12(16):2225-8.
DMT1PM4	RU	https://pubmed.ncbi.nlm.nih.gov/12127543

DMT1PM4	DI	DMT1PM4
DMT1PM4	DN	4-[(diphenylmethyl)amino]-2-phenylquinazoline
DMT1PM4	MI	TTVBI8W
DMT1PM4	MN	Dopamine transporter (DAT)
DMT1PM4	MT	DTT
DMT1PM4	MA	Inhibitor
DMT1PM4	RN	Identification of a novel partial inhibitor of dopamine transporter among 4-substituted 2-phenylquinazolines. Bioorg Med Chem Lett. 2002 Aug 19;12(16):2225-8.
DMT1PM4	RU	https://pubmed.ncbi.nlm.nih.gov/12127543

DMXKT6M	DI	DMXKT6M
DMXKT6M	DN	4-[(METHYLSULFONYL)AMINO]BENZOIC ACID
DMXKT6M	MI	TTHI19T
DMXKT6M	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMXKT6M	MT	DTT
DMXKT6M	MA	Inhibitor
DMXKT6M	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMXKT6M	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMTMLXU	DI	DMTMLXU
DMTMLXU	DN	4-[1-(4-hydroxyphenyl)-2-phenylbut-1-enyl]phenol
DMTMLXU	MI	TTZAYWL
DMTMLXU	MN	Estrogen receptor (ESR)
DMTMLXU	MT	DTT
DMTMLXU	MA	Inhibitor
DMTMLXU	RN	Investigations on estrogen receptor binding. The estrogenic, antiestrogenic, and cytotoxic properties of C2-alkyl-substituted 1,1-bis(4-hydroxyphen... J Med Chem. 2002 Nov 21;45(24):5358-64.
DMTMLXU	RU	https://pubmed.ncbi.nlm.nih.gov/12431063

DM30421	DI	DM30421
DM30421	DN	4-[1-(4-hydroxyphenyl)-2-phenylhex-1-enyl]phenol
DM30421	MI	TTZAYWL
DM30421	MN	Estrogen receptor (ESR)
DM30421	MT	DTT
DM30421	MA	Inhibitor
DM30421	RN	Investigations on estrogen receptor binding. The estrogenic, antiestrogenic, and cytotoxic properties of C2-alkyl-substituted 1,1-bis(4-hydroxyphen... J Med Chem. 2002 Nov 21;45(24):5358-64.
DM30421	RU	https://pubmed.ncbi.nlm.nih.gov/12431063

DMWHKLA	DI	DMWHKLA
DMWHKLA	DN	4-[1-(4-hydroxyphenyl)-2-phenylpent-1-enyl]phenol
DMWHKLA	MI	TTZAYWL
DMWHKLA	MN	Estrogen receptor (ESR)
DMWHKLA	MT	DTT
DMWHKLA	MA	Inhibitor
DMWHKLA	RN	Investigations on estrogen receptor binding. The estrogenic, antiestrogenic, and cytotoxic properties of C2-alkyl-substituted 1,1-bis(4-hydroxyphen... J Med Chem. 2002 Nov 21;45(24):5358-64.
DMWHKLA	RU	https://pubmed.ncbi.nlm.nih.gov/12431063

DMH1I32	DI	DMH1I32
DMH1I32	DN	4-[1-(4-hydroxyphenyl)-2-phenylprop-1-enyl]phenol
DMH1I32	MI	TTZAYWL
DMH1I32	MN	Estrogen receptor (ESR)
DMH1I32	MT	DTT
DMH1I32	MA	Inhibitor
DMH1I32	RN	Investigations on estrogen receptor binding. The estrogenic, antiestrogenic, and cytotoxic properties of C2-alkyl-substituted 1,1-bis(4-hydroxyphen... J Med Chem. 2002 Nov 21;45(24):5358-64.
DMH1I32	RU	https://pubmed.ncbi.nlm.nih.gov/12431063

DM4BFPE	DI	DM4BFPE
DM4BFPE	DN	4-[1-(4-hydroxyphenyl)-2-phenylvinyl]phenol
DM4BFPE	MI	TTZAYWL
DM4BFPE	MN	Estrogen receptor (ESR)
DM4BFPE	MT	DTT
DM4BFPE	MA	Inhibitor
DM4BFPE	RN	Investigations on estrogen receptor binding. The estrogenic, antiestrogenic, and cytotoxic properties of C2-alkyl-substituted 1,1-bis(4-hydroxyphen... J Med Chem. 2002 Nov 21;45(24):5358-64.
DM4BFPE	RU	https://pubmed.ncbi.nlm.nih.gov/12431063

DM8IYG1	DI	DM8IYG1
DM8IYG1	DN	4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol
DM8IYG1	MI	TTFJ8Q1
DM8IYG1	MN	Protein kinase C alpha (PRKCA)
DM8IYG1	MT	DTT
DM8IYG1	MA	Inhibitor
DM8IYG1	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DM8IYG1	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DM8IYG1	DI	DM8IYG1
DM8IYG1	DN	4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol
DM8IYG1	MI	TTYPXQF
DM8IYG1	MN	Protein kinase C beta (PRKCB)
DM8IYG1	MT	DTT
DM8IYG1	MA	Inhibitor
DM8IYG1	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DM8IYG1	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DM8IYG1	DI	DM8IYG1
DM8IYG1	DN	4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol
DM8IYG1	MI	TT9WJ8U
DM8IYG1	MN	Protein kinase C delta (PRKCD)
DM8IYG1	MT	DTT
DM8IYG1	MA	Inhibitor
DM8IYG1	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DM8IYG1	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DM8IYG1	DI	DM8IYG1
DM8IYG1	DN	4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol
DM8IYG1	MI	TTBZ7OD
DM8IYG1	MN	Protein kinase C epsilon (PRKCE)
DM8IYG1	MT	DTT
DM8IYG1	MA	Inhibitor
DM8IYG1	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DM8IYG1	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DM8IYG1	DI	DM8IYG1
DM8IYG1	DN	4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol
DM8IYG1	MI	TTRFOXJ
DM8IYG1	MN	Protein kinase C gamma (PRKCG)
DM8IYG1	MT	DTT
DM8IYG1	MA	Inhibitor
DM8IYG1	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DM8IYG1	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DM8IYG1	DI	DM8IYG1
DM8IYG1	DN	4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol
DM8IYG1	MI	TT8QL1J
DM8IYG1	MN	Protein kinase C theta (PRKCQ)
DM8IYG1	MT	DTT
DM8IYG1	MA	Inhibitor
DM8IYG1	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DM8IYG1	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DM8IYG1	DI	DM8IYG1
DM8IYG1	DN	4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol
DM8IYG1	MI	TTUWGRA
DM8IYG1	MN	Protein kinase C zeta (PRKCZ)
DM8IYG1	MT	DTT
DM8IYG1	MA	Inhibitor
DM8IYG1	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DM8IYG1	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DMCEABJ	DI	DMCEABJ
DMCEABJ	DN	4-[1-(4'-Methoxybiphenyl-4-yl)propyl]pyridine
DMCEABJ	MI	TTRA5BZ
DMCEABJ	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMCEABJ	MT	DTT
DMCEABJ	MA	Inhibitor
DMCEABJ	RN	Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
DMCEABJ	RU	https://pubmed.ncbi.nlm.nih.gov/20684610

DMW1IXY	DI	DMW1IXY
DMW1IXY	DN	4-[1,2-bis(4-hydroxyphenyl)but-1-enyl]phenol
DMW1IXY	MI	TTZAYWL
DMW1IXY	MN	Estrogen receptor (ESR)
DMW1IXY	MT	DTT
DMW1IXY	MA	Inhibitor
DMW1IXY	RN	Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity. J Med Chem. 2003 Apr 10;46(8):1484-91.
DMW1IXY	RU	https://pubmed.ncbi.nlm.nih.gov/12672249

DMW1IXY	DI	DMW1IXY
DMW1IXY	DN	4-[1,2-bis(4-hydroxyphenyl)but-1-enyl]phenol
DMW1IXY	MI	TTOM3J0
DMW1IXY	MN	Estrogen receptor beta (ESR2)
DMW1IXY	MT	DTT
DMW1IXY	MA	Inhibitor
DMW1IXY	RN	Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity. J Med Chem. 2003 Apr 10;46(8):1484-91.
DMW1IXY	RU	https://pubmed.ncbi.nlm.nih.gov/12672249

DMTL6ES	DI	DMTL6ES
DMTL6ES	DN	4-[1,2-bis(4-hydroxyphenyl)hex-1-enyl]phenol
DMTL6ES	MI	TTZAYWL
DMTL6ES	MN	Estrogen receptor (ESR)
DMTL6ES	MT	DTT
DMTL6ES	MA	Inhibitor
DMTL6ES	RN	Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity. J Med Chem. 2003 Apr 10;46(8):1484-91.
DMTL6ES	RU	https://pubmed.ncbi.nlm.nih.gov/12672249

DMTL6ES	DI	DMTL6ES
DMTL6ES	DN	4-[1,2-bis(4-hydroxyphenyl)hex-1-enyl]phenol
DMTL6ES	MI	TTOM3J0
DMTL6ES	MN	Estrogen receptor beta (ESR2)
DMTL6ES	MT	DTT
DMTL6ES	MA	Inhibitor
DMTL6ES	RN	Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity. J Med Chem. 2003 Apr 10;46(8):1484-91.
DMTL6ES	RU	https://pubmed.ncbi.nlm.nih.gov/12672249

DMTHG0Y	DI	DMTHG0Y
DMTHG0Y	DN	4-[1,2-bis(4-hydroxyphenyl)pent-1-enyl]phenol
DMTHG0Y	MI	TTZAYWL
DMTHG0Y	MN	Estrogen receptor (ESR)
DMTHG0Y	MT	DTT
DMTHG0Y	MA	Inhibitor
DMTHG0Y	RN	Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity. J Med Chem. 2003 Apr 10;46(8):1484-91.
DMTHG0Y	RU	https://pubmed.ncbi.nlm.nih.gov/12672249

DMTHG0Y	DI	DMTHG0Y
DMTHG0Y	DN	4-[1,2-bis(4-hydroxyphenyl)pent-1-enyl]phenol
DMTHG0Y	MI	TTOM3J0
DMTHG0Y	MN	Estrogen receptor beta (ESR2)
DMTHG0Y	MT	DTT
DMTHG0Y	MA	Inhibitor
DMTHG0Y	RN	Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity. J Med Chem. 2003 Apr 10;46(8):1484-91.
DMTHG0Y	RU	https://pubmed.ncbi.nlm.nih.gov/12672249

DMR7GP6	DI	DMR7GP6
DMR7GP6	DN	4-[1,2-bis(4-hydroxyphenyl)vinyl]phenol
DMR7GP6	MI	TTZAYWL
DMR7GP6	MN	Estrogen receptor (ESR)
DMR7GP6	MT	DTT
DMR7GP6	MA	Inhibitor
DMR7GP6	RN	Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity. J Med Chem. 2003 Apr 10;46(8):1484-91.
DMR7GP6	RU	https://pubmed.ncbi.nlm.nih.gov/12672249

DMR7GP6	DI	DMR7GP6
DMR7GP6	DN	4-[1,2-bis(4-hydroxyphenyl)vinyl]phenol
DMR7GP6	MI	TTOM3J0
DMR7GP6	MN	Estrogen receptor beta (ESR2)
DMR7GP6	MT	DTT
DMR7GP6	MA	Inhibitor
DMR7GP6	RN	Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity. J Med Chem. 2003 Apr 10;46(8):1484-91.
DMR7GP6	RU	https://pubmed.ncbi.nlm.nih.gov/12672249

DM08CG7	DI	DM08CG7
DM08CG7	DN	4-[2-(2-Benzyl-phenoxy)-ethyl]-morpholine
DM08CG7	MI	TTZFYLI
DM08CG7	MN	Dopamine D1 receptor (D1R)
DM08CG7	MT	DTT
DM08CG7	MA	Inhibitor
DM08CG7	RN	Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
DM08CG7	RU	https://pubmed.ncbi.nlm.nih.gov/15293986

DM08CG7	DI	DM08CG7
DM08CG7	DN	4-[2-(2-Benzyl-phenoxy)-ethyl]-morpholine
DM08CG7	MI	TTE0A2F
DM08CG7	MN	Dopamine D4 receptor (D4R)
DM08CG7	MT	DTT
DM08CG7	MA	Inhibitor
DM08CG7	RN	Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
DM08CG7	RU	https://pubmed.ncbi.nlm.nih.gov/15293986

DM08CG7	DI	DM08CG7
DM08CG7	DN	4-[2-(2-Benzyl-phenoxy)-ethyl]-morpholine
DM08CG7	MI	TTS2PH3
DM08CG7	MN	Dopamine D5 receptor (D5R)
DM08CG7	MT	DTT
DM08CG7	MA	Inhibitor
DM08CG7	RN	Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
DM08CG7	RU	https://pubmed.ncbi.nlm.nih.gov/15293986

DMYESXB	DI	DMYESXB
DMYESXB	DN	4-[2-(2-Thienyl)acetamido]benzenesulfonamide
DMYESXB	MI	TTUNARX
DMYESXB	MN	Carbonic anhydrase (CA)
DMYESXB	MT	DTT
DMYESXB	MA	Inhibitor
DMYESXB	RN	Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9.
DMYESXB	RU	https://pubmed.ncbi.nlm.nih.gov/19539481

DMYESXB	DI	DMYESXB
DMYESXB	DN	4-[2-(2-Thienyl)acetamido]benzenesulfonamide
DMYESXB	MI	TTHQPL7
DMYESXB	MN	Carbonic anhydrase I (CA-I)
DMYESXB	MT	DTT
DMYESXB	MA	Inhibitor
DMYESXB	RN	Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9.
DMYESXB	RU	https://pubmed.ncbi.nlm.nih.gov/19539481

DMYESXB	DI	DMYESXB
DMYESXB	DN	4-[2-(2-Thienyl)acetamido]benzenesulfonamide
DMYESXB	MI	TTANPDJ
DMYESXB	MN	Carbonic anhydrase II (CA-II)
DMYESXB	MT	DTT
DMYESXB	MA	Inhibitor
DMYESXB	RN	Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9.
DMYESXB	RU	https://pubmed.ncbi.nlm.nih.gov/19539481

DMH3UPO	DI	DMH3UPO
DMH3UPO	DN	4-[2-(2-Thienyl)acetamidoethyl]benzenesulfonamide
DMH3UPO	MI	TTUNARX
DMH3UPO	MN	Carbonic anhydrase (CA)
DMH3UPO	MT	DTT
DMH3UPO	MA	Inhibitor
DMH3UPO	RN	Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9.
DMH3UPO	RU	https://pubmed.ncbi.nlm.nih.gov/19539481

DMH3UPO	DI	DMH3UPO
DMH3UPO	DN	4-[2-(2-Thienyl)acetamidoethyl]benzenesulfonamide
DMH3UPO	MI	TTHQPL7
DMH3UPO	MN	Carbonic anhydrase I (CA-I)
DMH3UPO	MT	DTT
DMH3UPO	MA	Inhibitor
DMH3UPO	RN	Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9.
DMH3UPO	RU	https://pubmed.ncbi.nlm.nih.gov/19539481

DMH3UPO	DI	DMH3UPO
DMH3UPO	DN	4-[2-(2-Thienyl)acetamidoethyl]benzenesulfonamide
DMH3UPO	MI	TTANPDJ
DMH3UPO	MN	Carbonic anhydrase II (CA-II)
DMH3UPO	MT	DTT
DMH3UPO	MA	Inhibitor
DMH3UPO	RN	Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9.
DMH3UPO	RU	https://pubmed.ncbi.nlm.nih.gov/19539481

DM4ENGI	DI	DM4ENGI
DM4ENGI	DN	4-[2-(3,5-Dimethoxy-phenyl)-vinyl]-pyridine
DM4ENGI	MI	TTI84H7
DM4ENGI	MN	Cytochrome P450 1B1 (CYP1B1)
DM4ENGI	MT	DTT
DM4ENGI	MA	Inhibitor
DM4ENGI	RN	Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors. J Med Chem. 2002 Jan 3;45(1):160-4.
DM4ENGI	RU	https://pubmed.ncbi.nlm.nih.gov/11754588

DM64WSV	DI	DM64WSV
DM64WSV	DN	4-[2-(3-Phenyl-propylamino)-ethyl]-phenol
DM64WSV	MI	TTLD29N
DM64WSV	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DM64WSV	MT	DTT
DM64WSV	MA	Inhibitor
DM64WSV	RN	Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506.
DM64WSV	RU	https://pubmed.ncbi.nlm.nih.gov/9719603

DM64WSV	DI	DM64WSV
DM64WSV	DN	4-[2-(3-Phenyl-propylamino)-ethyl]-phenol
DM64WSV	MI	TTN9D8E
DM64WSV	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DM64WSV	MT	DTT
DM64WSV	MA	Inhibitor
DM64WSV	RN	Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506.
DM64WSV	RU	https://pubmed.ncbi.nlm.nih.gov/9719603

DMGXM9C	DI	DMGXM9C
DMGXM9C	DN	4-[2-(3-Phenyl-ureido)-ethyl]-benzenesulfonamide
DMGXM9C	MI	TTHQPL7
DMGXM9C	MN	Carbonic anhydrase I (CA-I)
DMGXM9C	MT	DTT
DMGXM9C	MA	Inhibitor
DMGXM9C	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DMGXM9C	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DMGXM9C	DI	DMGXM9C
DMGXM9C	DN	4-[2-(3-Phenyl-ureido)-ethyl]-benzenesulfonamide
DMGXM9C	MI	TTANPDJ
DMGXM9C	MN	Carbonic anhydrase II (CA-II)
DMGXM9C	MT	DTT
DMGXM9C	MA	Inhibitor
DMGXM9C	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DMGXM9C	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DMGXM9C	DI	DMGXM9C
DMGXM9C	DN	4-[2-(3-Phenyl-ureido)-ethyl]-benzenesulfonamide
DMGXM9C	MI	TT2LVK8
DMGXM9C	MN	Carbonic anhydrase IX (CA-IX)
DMGXM9C	MT	DTT
DMGXM9C	MA	Inhibitor
DMGXM9C	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DMGXM9C	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DMGXM9C	DI	DMGXM9C
DMGXM9C	DN	4-[2-(3-Phenyl-ureido)-ethyl]-benzenesulfonamide
DMGXM9C	MI	TTSYM0R
DMGXM9C	MN	Carbonic anhydrase XII (CA-XII)
DMGXM9C	MT	DTT
DMGXM9C	MA	Inhibitor
DMGXM9C	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DMGXM9C	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DMDI32S	DI	DMDI32S
DMDI32S	DN	4-[2-(4-Benzylphenoxy)ethyl]pyridine
DMDI32S	MI	TTXZEAJ
DMDI32S	MN	Leukotriene A-4 hydrolase (LTA4H)
DMDI32S	MT	DTT
DMDI32S	MA	Inhibitor
DMDI32S	RN	Discovery of 4-[(2S)-2-{[4-(4-chlorophenoxy)phenoxy]methyl}-1-pyrrolidinyl]butanoic acid (DG-051) as a novel leukotriene A4 hydrolase inhibitor of ... J Med Chem. 2010 Jan 28;53(2):573-85.
DMDI32S	RU	https://pubmed.ncbi.nlm.nih.gov/19950900

DM74G6Q	DI	DM74G6Q
DM74G6Q	DN	4-[2-(4-Benzyl-piperidin-1-yl)-ethoxy]-phenol
DM74G6Q	MI	TTLD29N
DM74G6Q	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DM74G6Q	MT	DTT
DM74G6Q	MA	Inhibitor
DM74G6Q	RN	4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist. J Med Chem. 1999 Jul 29;42(15):2993-3000.
DM74G6Q	RU	https://pubmed.ncbi.nlm.nih.gov/10425109

DM74G6Q	DI	DM74G6Q
DM74G6Q	DN	4-[2-(4-Benzyl-piperidin-1-yl)-ethoxy]-phenol
DM74G6Q	MI	TTN9D8E
DM74G6Q	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DM74G6Q	MT	DTT
DM74G6Q	MA	Inhibitor
DM74G6Q	RN	4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist. J Med Chem. 1999 Jul 29;42(15):2993-3000.
DM74G6Q	RU	https://pubmed.ncbi.nlm.nih.gov/10425109

DM9UGO0	DI	DM9UGO0
DM9UGO0	DN	4-[2-(4-Imidazol-1-yl-phenoxy)-ethyl]-morpholine
DM9UGO0	MI	TTXV4FI
DM9UGO0	MN	Albendazole monooxygenase (CYP3A4)
DM9UGO0	MT	DTT
DM9UGO0	MA	Inhibitor
DM9UGO0	RN	Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):333-6.
DM9UGO0	RU	https://pubmed.ncbi.nlm.nih.gov/14698153

DM9UGO0	DI	DM9UGO0
DM9UGO0	DN	4-[2-(4-Imidazol-1-yl-phenoxy)-ethyl]-morpholine
DM9UGO0	MI	TTVG215
DM9UGO0	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DM9UGO0	MT	DTT
DM9UGO0	MA	Inhibitor
DM9UGO0	RN	Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):333-6.
DM9UGO0	RU	https://pubmed.ncbi.nlm.nih.gov/14698153

DML8B3T	DI	DML8B3T
DML8B3T	DN	4-[2-(4-Phenyl-butoxy)-ethyl]-phenol
DML8B3T	MI	TTLD29N
DML8B3T	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DML8B3T	MT	DTT
DML8B3T	MA	Inhibitor
DML8B3T	RN	Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506.
DML8B3T	RU	https://pubmed.ncbi.nlm.nih.gov/9719603

DML8B3T	DI	DML8B3T
DML8B3T	DN	4-[2-(4-Phenyl-butoxy)-ethyl]-phenol
DML8B3T	MI	TTN9D8E
DML8B3T	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DML8B3T	MT	DTT
DML8B3T	MA	Inhibitor
DML8B3T	RN	Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506.
DML8B3T	RU	https://pubmed.ncbi.nlm.nih.gov/9719603

DMXLVJW	DI	DMXLVJW
DMXLVJW	DN	4-[2-(4-Phenyl-butylamino)-ethyl]-phenol
DMXLVJW	MI	TTLD29N
DMXLVJW	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMXLVJW	MT	DTT
DMXLVJW	MA	Inhibitor
DMXLVJW	RN	Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506.
DMXLVJW	RU	https://pubmed.ncbi.nlm.nih.gov/9719603

DMXLVJW	DI	DMXLVJW
DMXLVJW	DN	4-[2-(4-Phenyl-butylamino)-ethyl]-phenol
DMXLVJW	MI	TTKJEMQ
DMXLVJW	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMXLVJW	MT	DTT
DMXLVJW	MA	Inhibitor
DMXLVJW	RN	Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506.
DMXLVJW	RU	https://pubmed.ncbi.nlm.nih.gov/9719603

DMXLVJW	DI	DMXLVJW
DMXLVJW	DN	4-[2-(4-Phenyl-butylamino)-ethyl]-phenol
DMXLVJW	MI	TTN9D8E
DMXLVJW	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMXLVJW	MT	DTT
DMXLVJW	MA	Inhibitor
DMXLVJW	RN	Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506.
DMXLVJW	RU	https://pubmed.ncbi.nlm.nih.gov/9719603

DM8JM4Q	DI	DM8JM4Q
DM8JM4Q	DN	4-[2-(4-Phenyl-piperidin-1-yl)-ethoxy]-phenol
DM8JM4Q	MI	TTLD29N
DM8JM4Q	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DM8JM4Q	MT	DTT
DM8JM4Q	MA	Inhibitor
DM8JM4Q	RN	4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist. J Med Chem. 1999 Jul 29;42(15):2993-3000.
DM8JM4Q	RU	https://pubmed.ncbi.nlm.nih.gov/10425109

DM8JM4Q	DI	DM8JM4Q
DM8JM4Q	DN	4-[2-(4-Phenyl-piperidin-1-yl)-ethoxy]-phenol
DM8JM4Q	MI	TTN9D8E
DM8JM4Q	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DM8JM4Q	MT	DTT
DM8JM4Q	MA	Inhibitor
DM8JM4Q	RN	4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist. J Med Chem. 1999 Jul 29;42(15):2993-3000.
DM8JM4Q	RU	https://pubmed.ncbi.nlm.nih.gov/10425109

DM5J7O8	DI	DM5J7O8
DM5J7O8	DN	4-[2-(5-Phenyl-pentylamino)-ethyl]-phenol
DM5J7O8	MI	TTLD29N
DM5J7O8	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DM5J7O8	MT	DTT
DM5J7O8	MA	Inhibitor
DM5J7O8	RN	Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506.
DM5J7O8	RU	https://pubmed.ncbi.nlm.nih.gov/9719603

DM5J7O8	DI	DM5J7O8
DM5J7O8	DN	4-[2-(5-Phenyl-pentylamino)-ethyl]-phenol
DM5J7O8	MI	TTKJEMQ
DM5J7O8	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DM5J7O8	MT	DTT
DM5J7O8	MA	Inhibitor
DM5J7O8	RN	Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506.
DM5J7O8	RU	https://pubmed.ncbi.nlm.nih.gov/9719603

DM5J7O8	DI	DM5J7O8
DM5J7O8	DN	4-[2-(5-Phenyl-pentylamino)-ethyl]-phenol
DM5J7O8	MI	TTN9D8E
DM5J7O8	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DM5J7O8	MT	DTT
DM5J7O8	MA	Inhibitor
DM5J7O8	RN	Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506.
DM5J7O8	RU	https://pubmed.ncbi.nlm.nih.gov/9719603

DMLCIJX	DI	DMLCIJX
DMLCIJX	DN	4-[2-(6-Phenyl-hexylamino)-ethyl]-phenol
DMLCIJX	MI	TTLD29N
DMLCIJX	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMLCIJX	MT	DTT
DMLCIJX	MA	Inhibitor
DMLCIJX	RN	Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506.
DMLCIJX	RU	https://pubmed.ncbi.nlm.nih.gov/9719603

DMLCIJX	DI	DMLCIJX
DMLCIJX	DN	4-[2-(6-Phenyl-hexylamino)-ethyl]-phenol
DMLCIJX	MI	TTKJEMQ
DMLCIJX	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMLCIJX	MT	DTT
DMLCIJX	MA	Inhibitor
DMLCIJX	RN	Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506.
DMLCIJX	RU	https://pubmed.ncbi.nlm.nih.gov/9719603

DMLCIJX	DI	DMLCIJX
DMLCIJX	DN	4-[2-(6-Phenyl-hexylamino)-ethyl]-phenol
DMLCIJX	MI	TTN9D8E
DMLCIJX	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMLCIJX	MT	DTT
DMLCIJX	MA	Inhibitor
DMLCIJX	RN	Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506.
DMLCIJX	RU	https://pubmed.ncbi.nlm.nih.gov/9719603

DMS0HV6	DI	DMS0HV6
DMS0HV6	DN	4-[2,2-bis(4-hydroxyphenyl)-1-methylvinyl]phenol
DMS0HV6	MI	TTZAYWL
DMS0HV6	MN	Estrogen receptor (ESR)
DMS0HV6	MT	DTT
DMS0HV6	MA	Inhibitor
DMS0HV6	RN	Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity. J Med Chem. 2003 Apr 10;46(8):1484-91.
DMS0HV6	RU	https://pubmed.ncbi.nlm.nih.gov/12672249

DMS0HV6	DI	DMS0HV6
DMS0HV6	DN	4-[2,2-bis(4-hydroxyphenyl)-1-methylvinyl]phenol
DMS0HV6	MI	TTOM3J0
DMS0HV6	MN	Estrogen receptor beta (ESR2)
DMS0HV6	MT	DTT
DMS0HV6	MA	Inhibitor
DMS0HV6	RN	Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity. J Med Chem. 2003 Apr 10;46(8):1484-91.
DMS0HV6	RU	https://pubmed.ncbi.nlm.nih.gov/12672249

DMOPRQ7	DI	DMOPRQ7
DMOPRQ7	DN	4-[3-(3-benzyloxy-pyridin-2-yl)-ureido]-benzamide
DMOPRQ7	MI	TTL2ADK
DMOPRQ7	MN	Rotamase A (PPIA)
DMOPRQ7	MT	DTT
DMOPRQ7	MA	Inhibitor
DMOPRQ7	RN	Structure-based design, synthesis, and biological evaluation of novel inhibitors of human cyclophilin A. J Med Chem. 2006 Feb 9;49(3):900-10.
DMOPRQ7	RU	https://pubmed.ncbi.nlm.nih.gov/16451056

DMFKRMG	DI	DMFKRMG
DMFKRMG	DN	4-[3-(4-Butyl-phenoxy)-propyl]-1H-imidazole
DMFKRMG	MI	TT9JNIC
DMFKRMG	MN	Histamine H3 receptor (H3R)
DMFKRMG	MT	DTT
DMFKRMG	MA	Inhibitor
DMFKRMG	RN	Analogues and derivatives of ciproxifan, a novel prototype for generating potent histamine H3-receptor antagonists. Bioorg Med Chem Lett. 2000 Oct 16;10(20):2379-82.
DMFKRMG	RU	https://pubmed.ncbi.nlm.nih.gov/11055360

DMJI6AM	DI	DMJI6AM
DMJI6AM	DN	4-[3-(4-CHLOROPHENYL)-1H-PYRAZOL-5-YL]PIPERIDINE
DMJI6AM	MI	TT6L509
DMJI6AM	MN	Coagulation factor IIa (F2)
DMJI6AM	MT	DTT
DMJI6AM	MA	Inhibitor
DMJI6AM	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMJI6AM	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMXBEYQ	DI	DMXBEYQ
DMXBEYQ	DN	4-[3-(4-Ethynyl-phenoxy)-propyl]-1H-imidazole
DMXBEYQ	MI	TT9JNIC
DMXBEYQ	MN	Histamine H3 receptor (H3R)
DMXBEYQ	MT	DTT
DMXBEYQ	MA	Inhibitor
DMXBEYQ	RN	Analogues and derivatives of ciproxifan, a novel prototype for generating potent histamine H3-receptor antagonists. Bioorg Med Chem Lett. 2000 Oct 16;10(20):2379-82.
DMXBEYQ	RU	https://pubmed.ncbi.nlm.nih.gov/11055360

DM7LV5A	DI	DM7LV5A
DM7LV5A	DN	4-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine
DM7LV5A	MI	TTXV4FI
DM7LV5A	MN	Albendazole monooxygenase (CYP3A4)
DM7LV5A	MT	DTT
DM7LV5A	MA	Inhibitor
DM7LV5A	RN	Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):333-6.
DM7LV5A	RU	https://pubmed.ncbi.nlm.nih.gov/14698153

DM7LV5A	DI	DM7LV5A
DM7LV5A	DN	4-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine
DM7LV5A	MI	TTVG215
DM7LV5A	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DM7LV5A	MT	DTT
DM7LV5A	MA	Inhibitor
DM7LV5A	RN	Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):333-6.
DM7LV5A	RU	https://pubmed.ncbi.nlm.nih.gov/14698153

DM4GU29	DI	DM4GU29
DM4GU29	DN	4-[3-(4-Methoxy-phenoxy)-propyl]-1H-imidazole
DM4GU29	MI	TT9JNIC
DM4GU29	MN	Histamine H3 receptor (H3R)
DM4GU29	MT	DTT
DM4GU29	MA	Inhibitor
DM4GU29	RN	Different antagonist binding properties of human and rat histamine H3 receptors. Bioorg Med Chem Lett. 2001 Apr 9;11(7):951-4.
DM4GU29	RU	https://pubmed.ncbi.nlm.nih.gov/11294398

DMOF9YN	DI	DMOF9YN
DMOF9YN	DN	4-[3-(4-Phenyl-butylamino)-propyl]-phenol
DMOF9YN	MI	TTLD29N
DMOF9YN	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMOF9YN	MT	DTT
DMOF9YN	MA	Inhibitor
DMOF9YN	RN	Structure-activity relationship for a series of 2-substituted 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indoles: potent subtype-selective inhibitors of N-... Bioorg Med Chem Lett. 1999 Jun 7;9(11):1619-24.
DMOF9YN	RU	https://pubmed.ncbi.nlm.nih.gov/10386947

DMOF9YN	DI	DMOF9YN
DMOF9YN	DN	4-[3-(4-Phenyl-butylamino)-propyl]-phenol
DMOF9YN	MI	TTKJEMQ
DMOF9YN	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMOF9YN	MT	DTT
DMOF9YN	MA	Inhibitor
DMOF9YN	RN	Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506.
DMOF9YN	RU	https://pubmed.ncbi.nlm.nih.gov/9719603

DMOF9YN	DI	DMOF9YN
DMOF9YN	DN	4-[3-(4-Phenyl-butylamino)-propyl]-phenol
DMOF9YN	MI	TTN9D8E
DMOF9YN	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMOF9YN	MT	DTT
DMOF9YN	MA	Inhibitor
DMOF9YN	RN	Structure-activity relationship for a series of 2-substituted 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indoles: potent subtype-selective inhibitors of N-... Bioorg Med Chem Lett. 1999 Jun 7;9(11):1619-24.
DMOF9YN	RU	https://pubmed.ncbi.nlm.nih.gov/10386947

DMKDBHN	DI	DMKDBHN
DMKDBHN	DN	4-[3-(5-Phenyl-pentylamino)-propyl]-phenol
DMKDBHN	MI	TTLD29N
DMKDBHN	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMKDBHN	MT	DTT
DMKDBHN	MA	Inhibitor
DMKDBHN	RN	Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506.
DMKDBHN	RU	https://pubmed.ncbi.nlm.nih.gov/9719603

DMKDBHN	DI	DMKDBHN
DMKDBHN	DN	4-[3-(5-Phenyl-pentylamino)-propyl]-phenol
DMKDBHN	MI	TTKJEMQ
DMKDBHN	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMKDBHN	MT	DTT
DMKDBHN	MA	Inhibitor
DMKDBHN	RN	Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506.
DMKDBHN	RU	https://pubmed.ncbi.nlm.nih.gov/9719603

DMKDBHN	DI	DMKDBHN
DMKDBHN	DN	4-[3-(5-Phenyl-pentylamino)-propyl]-phenol
DMKDBHN	MI	TTN9D8E
DMKDBHN	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMKDBHN	MT	DTT
DMKDBHN	MA	Inhibitor
DMKDBHN	RN	Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506.
DMKDBHN	RU	https://pubmed.ncbi.nlm.nih.gov/9719603

DMZU23D	DI	DMZU23D
DMZU23D	DN	4-[3-(benzyloxy)benzoyl]benzoic acid
DMZU23D	MI	TTT02K8
DMZU23D	MN	Steroid 5-alpha-reductase 2 (SRD5A2)
DMZU23D	MT	DTT
DMZU23D	MA	Inhibitor
DMZU23D	RN	Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J Med Chem. 2006 Jan 26;49(2):748-59.
DMZU23D	RU	https://pubmed.ncbi.nlm.nih.gov/16420060

DMTIA27	DI	DMTIA27
DMTIA27	DN	4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline
DMTIA27	MI	TT7HF4W
DMTIA27	MN	Cyclin-dependent kinase 2 (CDK2)
DMTIA27	MT	DTT
DMTIA27	MA	Inhibitor
DMTIA27	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMTIA27	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMTIA27	DI	DMTIA27
DMTIA27	DN	4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline
DMTIA27	MI	TTUTJGQ
DMTIA27	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMTIA27	MT	DTT
DMTIA27	MA	Inhibitor
DMTIA27	RN	Pharmacophore modeling and in silico screening for new KDR kinase inhibitors. Bioorg Med Chem Lett. 2007 Apr 15;17(8):2126-33.
DMTIA27	RU	https://pubmed.ncbi.nlm.nih.gov/17306530

DM62351	DI	DM62351
DM62351	DN	4-[4-(6-methoxynaphthalen-2-yl)benzyl]pyridine
DM62351	MI	TTRA5BZ
DM62351	MN	Steroid 17-alpha-monooxygenase (S17AH)
DM62351	MT	DTT
DM62351	MA	Inhibitor
DM62351	RN	Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
DM62351	RU	https://pubmed.ncbi.nlm.nih.gov/20684610

DM8MVE9	DI	DM8MVE9
DM8MVE9	DN	4-[4-(benzhydryloxy)benzoyl]benzoic acid
DM8MVE9	MI	TTTU72V
DM8MVE9	MN	Steroid 5-alpha-reductase 1 (SRD5A1)
DM8MVE9	MT	DTT
DM8MVE9	MA	Inhibitor
DM8MVE9	RN	Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J Med Chem. 2006 Jan 26;49(2):748-59.
DM8MVE9	RU	https://pubmed.ncbi.nlm.nih.gov/16420060

DM8MVE9	DI	DM8MVE9
DM8MVE9	DN	4-[4-(benzhydryloxy)benzoyl]benzoic acid
DM8MVE9	MI	TTT02K8
DM8MVE9	MN	Steroid 5-alpha-reductase 2 (SRD5A2)
DM8MVE9	MT	DTT
DM8MVE9	MA	Inhibitor
DM8MVE9	RN	Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J Med Chem. 2006 Jan 26;49(2):748-59.
DM8MVE9	RU	https://pubmed.ncbi.nlm.nih.gov/16420060

DM5Z64L	DI	DM5Z64L
DM5Z64L	DN	4-[4-(benzhydryloxy)piperidino]butyl benzoate
DM5Z64L	MI	TT1RS9F
DM5Z64L	MN	Acetylcholinesterase (AChE)
DM5Z64L	MT	DTT
DM5Z64L	MA	Inhibitor
DM5Z64L	RN	Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abe... Bioorg Med Chem. 2007 Oct 15;15(20):6596-607.
DM5Z64L	RU	https://pubmed.ncbi.nlm.nih.gov/17681794

DM9VPFL	DI	DM9VPFL
DM9VPFL	DN	4-[4-(benzoylamino)benzoyl]benzoic acid
DM9VPFL	MI	TTT02K8
DM9VPFL	MN	Steroid 5-alpha-reductase 2 (SRD5A2)
DM9VPFL	MT	DTT
DM9VPFL	MA	Inhibitor
DM9VPFL	RN	Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J Med Chem. 2006 Jan 26;49(2):748-59.
DM9VPFL	RU	https://pubmed.ncbi.nlm.nih.gov/16420060

DMQC5EH	DI	DMQC5EH
DMQC5EH	DN	4-[4-(benzylamino)benzoyl]benzoic acid
DMQC5EH	MI	TTT02K8
DMQC5EH	MN	Steroid 5-alpha-reductase 2 (SRD5A2)
DMQC5EH	MT	DTT
DMQC5EH	MA	Inhibitor
DMQC5EH	RN	Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J Med Chem. 2006 Jan 26;49(2):748-59.
DMQC5EH	RU	https://pubmed.ncbi.nlm.nih.gov/16420060

DMTDYHE	DI	DMTDYHE
DMTDYHE	DN	4-[4-(benzyloxy)piperidino]butyl benzoate
DMTDYHE	MI	TTEB0GD
DMTDYHE	MN	Cholinesterase (BCHE)
DMTDYHE	MT	DTT
DMTDYHE	MA	Inhibitor
DMTDYHE	RN	Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abe... Bioorg Med Chem. 2007 Oct 15;15(20):6596-607.
DMTDYHE	RU	https://pubmed.ncbi.nlm.nih.gov/17681794

DMIXRCS	DI	DMIXRCS
DMIXRCS	DN	4-[4-(benzyloxy)piperidino]butyl-3-chlorobenzoate
DMIXRCS	MI	TTEB0GD
DMIXRCS	MN	Cholinesterase (BCHE)
DMIXRCS	MT	DTT
DMIXRCS	MA	Inhibitor
DMIXRCS	RN	Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abe... Bioorg Med Chem. 2007 Oct 15;15(20):6596-607.
DMIXRCS	RU	https://pubmed.ncbi.nlm.nih.gov/17681794

DM87AYP	DI	DM87AYP
DM87AYP	DN	4-[4-(benzyloxy)piperidino]butyl-3-fluorobenzoate
DM87AYP	MI	TTEB0GD
DM87AYP	MN	Cholinesterase (BCHE)
DM87AYP	MT	DTT
DM87AYP	MA	Inhibitor
DM87AYP	RN	Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abe... Bioorg Med Chem. 2007 Oct 15;15(20):6596-607.
DM87AYP	RU	https://pubmed.ncbi.nlm.nih.gov/17681794

DM0V8MA	DI	DM0V8MA
DM0V8MA	DN	4-[4-(benzyloxy)piperidino]butyl-4-chlorobenzoate
DM0V8MA	MI	TTEB0GD
DM0V8MA	MN	Cholinesterase (BCHE)
DM0V8MA	MT	DTT
DM0V8MA	MA	Inhibitor
DM0V8MA	RN	Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abe... Bioorg Med Chem. 2007 Oct 15;15(20):6596-607.
DM0V8MA	RU	https://pubmed.ncbi.nlm.nih.gov/17681794

DML7UQ1	DI	DML7UQ1
DML7UQ1	DN	4-[4-(benzyloxy)piperidino]butyl-4-fluorobenzoate
DML7UQ1	MI	TTEB0GD
DML7UQ1	MN	Cholinesterase (BCHE)
DML7UQ1	MT	DTT
DML7UQ1	MA	Inhibitor
DML7UQ1	RN	Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abe... Bioorg Med Chem. 2007 Oct 15;15(20):6596-607.
DML7UQ1	RU	https://pubmed.ncbi.nlm.nih.gov/17681794

DMNOD2Q	DI	DMNOD2Q
DMNOD2Q	DN	4-[4-(benzyloxy)piperidino]butyl-4-nitrobenzoate
DMNOD2Q	MI	TTEB0GD
DMNOD2Q	MN	Cholinesterase (BCHE)
DMNOD2Q	MT	DTT
DMNOD2Q	MA	Inhibitor
DMNOD2Q	RN	Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abe... Bioorg Med Chem. 2007 Oct 15;15(20):6596-607.
DMNOD2Q	RU	https://pubmed.ncbi.nlm.nih.gov/17681794

DMQ9IN4	DI	DMQ9IN4
DMQ9IN4	DN	4-[4-benzyloxy)benzoyl]benzoic acid
DMQ9IN4	MI	TTTU72V
DMQ9IN4	MN	Steroid 5-alpha-reductase 1 (SRD5A1)
DMQ9IN4	MT	DTT
DMQ9IN4	MA	Inhibitor
DMQ9IN4	RN	Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J Med Chem. 2006 Jan 26;49(2):748-59.
DMQ9IN4	RU	https://pubmed.ncbi.nlm.nih.gov/16420060

DMQ9IN4	DI	DMQ9IN4
DMQ9IN4	DN	4-[4-benzyloxy)benzoyl]benzoic acid
DMQ9IN4	MI	TTT02K8
DMQ9IN4	MN	Steroid 5-alpha-reductase 2 (SRD5A2)
DMQ9IN4	MT	DTT
DMQ9IN4	MA	Inhibitor
DMQ9IN4	RN	Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J Med Chem. 2006 Jan 26;49(2):748-59.
DMQ9IN4	RU	https://pubmed.ncbi.nlm.nih.gov/16420060

DMK4ICB	DI	DMK4ICB
DMK4ICB	DN	4-[5-(3-Hydroxyphenyl)-2-thienyl)-2-methyl]phenol
DMK4ICB	MI	TTXV4FI
DMK4ICB	MN	Albendazole monooxygenase (CYP3A4)
DMK4ICB	MT	DTT
DMK4ICB	MA	Inhibitor
DMK4ICB	RN	New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43.
DMK4ICB	RU	https://pubmed.ncbi.nlm.nih.gov/19831396

DMK4ICB	DI	DMK4ICB
DMK4ICB	DN	4-[5-(3-Hydroxyphenyl)-2-thienyl)-2-methyl]phenol
DMK4ICB	MI	TTVG215
DMK4ICB	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DMK4ICB	MT	DTT
DMK4ICB	MA	Inhibitor
DMK4ICB	RN	New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43.
DMK4ICB	RU	https://pubmed.ncbi.nlm.nih.gov/19831396

DMK4ICB	DI	DMK4ICB
DMK4ICB	DN	4-[5-(3-Hydroxyphenyl)-2-thienyl)-2-methyl]phenol
DMK4ICB	MI	TTIWB6L
DMK4ICB	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMK4ICB	MT	DTT
DMK4ICB	MA	Inhibitor
DMK4ICB	RN	New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43.
DMK4ICB	RU	https://pubmed.ncbi.nlm.nih.gov/19831396

DMZHVFO	DI	DMZHVFO
DMZHVFO	DN	4-[5-(3-Hydroxyphenyl)-2-thienyl]benzene-1,2-diol
DMZHVFO	MI	TTIWB6L
DMZHVFO	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMZHVFO	MT	DTT
DMZHVFO	MA	Inhibitor
DMZHVFO	RN	New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43.
DMZHVFO	RU	https://pubmed.ncbi.nlm.nih.gov/19831396

DM7ERYJ	DI	DM7ERYJ
DM7ERYJ	DN	4-[5-(3-Hydroxyphenyl)-3-thienyl]-2-methylphenol
DM7ERYJ	MI	TTXV4FI
DM7ERYJ	MN	Albendazole monooxygenase (CYP3A4)
DM7ERYJ	MT	DTT
DM7ERYJ	MA	Inhibitor
DM7ERYJ	RN	New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43.
DM7ERYJ	RU	https://pubmed.ncbi.nlm.nih.gov/19831396

DM7ERYJ	DI	DM7ERYJ
DM7ERYJ	DN	4-[5-(3-Hydroxyphenyl)-3-thienyl]-2-methylphenol
DM7ERYJ	MI	TTVG215
DM7ERYJ	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DM7ERYJ	MT	DTT
DM7ERYJ	MA	Inhibitor
DM7ERYJ	RN	New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43.
DM7ERYJ	RU	https://pubmed.ncbi.nlm.nih.gov/19831396

DM7ERYJ	DI	DM7ERYJ
DM7ERYJ	DN	4-[5-(3-Hydroxyphenyl)-3-thienyl]-2-methylphenol
DM7ERYJ	MI	TTIWB6L
DM7ERYJ	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DM7ERYJ	MT	DTT
DM7ERYJ	MA	Inhibitor
DM7ERYJ	RN	New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43.
DM7ERYJ	RU	https://pubmed.ncbi.nlm.nih.gov/19831396

DMI7YAQ	DI	DMI7YAQ
DMI7YAQ	DN	4-[5-Bromo-indan-(1E)-ylidenemethyl]-pyridine
DMI7YAQ	MI	TTIQUX7
DMI7YAQ	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMI7YAQ	MT	DTT
DMI7YAQ	MA	Inhibitor
DMI7YAQ	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMI7YAQ	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMI7YAQ	DI	DMI7YAQ
DMI7YAQ	DN	4-[5-Bromo-indan-(1E)-ylidenemethyl]-pyridine
DMI7YAQ	MI	TTRA5BZ
DMI7YAQ	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMI7YAQ	MT	DTT
DMI7YAQ	MA	Inhibitor
DMI7YAQ	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMI7YAQ	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMQKHXN	DI	DMQKHXN
DMQKHXN	DN	4-[5-Bromo-indan-(1Z)-ylidenemethyl]-pyridine
DMQKHXN	MI	TTSZLWK
DMQKHXN	MN	Aromatase (CYP19A1)
DMQKHXN	MT	DTT
DMQKHXN	MA	Inhibitor
DMQKHXN	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMQKHXN	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMQKHXN	DI	DMQKHXN
DMQKHXN	DN	4-[5-Bromo-indan-(1Z)-ylidenemethyl]-pyridine
DMQKHXN	MI	TTIQUX7
DMQKHXN	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMQKHXN	MT	DTT
DMQKHXN	MA	Inhibitor
DMQKHXN	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMQKHXN	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMQKHXN	DI	DMQKHXN
DMQKHXN	DN	4-[5-Bromo-indan-(1Z)-ylidenemethyl]-pyridine
DMQKHXN	MI	TTRA5BZ
DMQKHXN	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMQKHXN	MT	DTT
DMQKHXN	MA	Inhibitor
DMQKHXN	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMQKHXN	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMZL8KN	DI	DMZL8KN
DMZL8KN	DN	4-[5-Chloro-indan-(1E)-ylidenemethyl]-pyridine
DMZL8KN	MI	TTSZLWK
DMZL8KN	MN	Aromatase (CYP19A1)
DMZL8KN	MT	DTT
DMZL8KN	MA	Inhibitor
DMZL8KN	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMZL8KN	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMZL8KN	DI	DMZL8KN
DMZL8KN	DN	4-[5-Chloro-indan-(1E)-ylidenemethyl]-pyridine
DMZL8KN	MI	TTIQUX7
DMZL8KN	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMZL8KN	MT	DTT
DMZL8KN	MA	Inhibitor
DMZL8KN	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMZL8KN	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMZL8KN	DI	DMZL8KN
DMZL8KN	DN	4-[5-Chloro-indan-(1E)-ylidenemethyl]-pyridine
DMZL8KN	MI	TTRA5BZ
DMZL8KN	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMZL8KN	MT	DTT
DMZL8KN	MA	Inhibitor
DMZL8KN	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMZL8KN	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DM1Z3DG	DI	DM1Z3DG
DM1Z3DG	DN	4-[5-Chloro-indan-(1Z)-ylidenemethyl]-pyridine
DM1Z3DG	MI	TTSZLWK
DM1Z3DG	MN	Aromatase (CYP19A1)
DM1Z3DG	MT	DTT
DM1Z3DG	MA	Inhibitor
DM1Z3DG	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DM1Z3DG	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DM1Z3DG	DI	DM1Z3DG
DM1Z3DG	DN	4-[5-Chloro-indan-(1Z)-ylidenemethyl]-pyridine
DM1Z3DG	MI	TTIQUX7
DM1Z3DG	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM1Z3DG	MT	DTT
DM1Z3DG	MA	Inhibitor
DM1Z3DG	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DM1Z3DG	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DM1Z3DG	DI	DM1Z3DG
DM1Z3DG	DN	4-[5-Chloro-indan-(1Z)-ylidenemethyl]-pyridine
DM1Z3DG	MI	TTRA5BZ
DM1Z3DG	MN	Steroid 17-alpha-monooxygenase (S17AH)
DM1Z3DG	MT	DTT
DM1Z3DG	MA	Inhibitor
DM1Z3DG	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DM1Z3DG	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMY08FE	DI	DMY08FE
DMY08FE	DN	4-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyridine
DMY08FE	MI	TTSZLWK
DMY08FE	MN	Aromatase (CYP19A1)
DMY08FE	MT	DTT
DMY08FE	MA	Inhibitor
DMY08FE	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMY08FE	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMY08FE	DI	DMY08FE
DMY08FE	DN	4-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyridine
DMY08FE	MI	TTIQUX7
DMY08FE	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMY08FE	MT	DTT
DMY08FE	MA	Inhibitor
DMY08FE	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMY08FE	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMY08FE	DI	DMY08FE
DMY08FE	DN	4-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyridine
DMY08FE	MI	TTRA5BZ
DMY08FE	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMY08FE	MT	DTT
DMY08FE	MA	Inhibitor
DMY08FE	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMY08FE	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMHDZUO	DI	DMHDZUO
DMHDZUO	DN	4-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine
DMHDZUO	MI	TTSZLWK
DMHDZUO	MN	Aromatase (CYP19A1)
DMHDZUO	MT	DTT
DMHDZUO	MA	Inhibitor
DMHDZUO	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMHDZUO	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMHDZUO	DI	DMHDZUO
DMHDZUO	DN	4-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine
DMHDZUO	MI	TTIQUX7
DMHDZUO	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMHDZUO	MT	DTT
DMHDZUO	MA	Inhibitor
DMHDZUO	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMHDZUO	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMHDZUO	DI	DMHDZUO
DMHDZUO	DN	4-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine
DMHDZUO	MI	TTRA5BZ
DMHDZUO	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMHDZUO	MT	DTT
DMHDZUO	MA	Inhibitor
DMHDZUO	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMHDZUO	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DM25GS6	DI	DM25GS6
DM25GS6	DN	4-[5-Methoxy-indan-(1E)-ylidenemethyl]-pyridine
DM25GS6	MI	TTSZLWK
DM25GS6	MN	Aromatase (CYP19A1)
DM25GS6	MT	DTT
DM25GS6	MA	Inhibitor
DM25GS6	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DM25GS6	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMLBX4Q	DI	DMLBX4Q
DMLBX4Q	DN	4-[5-Methoxy-indan-(1Z)-ylidenemethyl]-pyridine
DMLBX4Q	MI	TTSZLWK
DMLBX4Q	MN	Aromatase (CYP19A1)
DMLBX4Q	MT	DTT
DMLBX4Q	MA	Inhibitor
DMLBX4Q	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMLBX4Q	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DM3IR8Y	DI	DM3IR8Y
DM3IR8Y	DN	4-[6-Methoxy-indan-(1E)-ylidenemethyl]-pyridine
DM3IR8Y	MI	TTSZLWK
DM3IR8Y	MN	Aromatase (CYP19A1)
DM3IR8Y	MT	DTT
DM3IR8Y	MA	Inhibitor
DM3IR8Y	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DM3IR8Y	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMIBZJC	DI	DMIBZJC
DMIBZJC	DN	4-[6-Methoxy-indan-(1Z)-ylidenemethyl]-pyridine
DMIBZJC	MI	TTSZLWK
DMIBZJC	MN	Aromatase (CYP19A1)
DMIBZJC	MT	DTT
DMIBZJC	MA	Inhibitor
DMIBZJC	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMIBZJC	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMYGN1K	DI	DMYGN1K
DMYGN1K	DN	4-[6-Methyl-indan-(1E)-ylidenemethyl]-pyridine
DMYGN1K	MI	TTSZLWK
DMYGN1K	MN	Aromatase (CYP19A1)
DMYGN1K	MT	DTT
DMYGN1K	MA	Inhibitor
DMYGN1K	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMYGN1K	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DM5VN3D	DI	DM5VN3D
DM5VN3D	DN	4-[6-Methyl-indan-(1Z)-ylidenemethyl]-pyridine
DM5VN3D	MI	TTSZLWK
DM5VN3D	MN	Aromatase (CYP19A1)
DM5VN3D	MT	DTT
DM5VN3D	MA	Inhibitor
DM5VN3D	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DM5VN3D	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMMGHNA	DI	DMMGHNA
DMMGHNA	DN	4-{2-[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid
DMMGHNA	MI	TTZHY6R
DMMGHNA	MN	Glycogen phosphorylase muscle form (GP)
DMMGHNA	MT	DTT
DMMGHNA	MA	Inhibitor
DMMGHNA	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMMGHNA	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMA21GM	DI	DMA21GM
DMA21GM	DN	4-{2-[Ethyl-(4-phenyl-butyl)-amino]-ethyl}-phenol
DMA21GM	MI	TTLD29N
DMA21GM	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMA21GM	MT	DTT
DMA21GM	MA	Inhibitor
DMA21GM	RN	Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506.
DMA21GM	RU	https://pubmed.ncbi.nlm.nih.gov/9719603

DMA21GM	DI	DMA21GM
DMA21GM	DN	4-{2-[Ethyl-(4-phenyl-butyl)-amino]-ethyl}-phenol
DMA21GM	MI	TTN9D8E
DMA21GM	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMA21GM	MT	DTT
DMA21GM	MA	Inhibitor
DMA21GM	RN	Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506.
DMA21GM	RU	https://pubmed.ncbi.nlm.nih.gov/9719603

DMZUM95	DI	DMZUM95
DMZUM95	DN	4-{4-[(aminosulfonyl)oxy]benzoyl}phenyl sulfamate
DMZUM95	MI	TTHM0R1
DMZUM95	MN	Steryl-sulfatase (STS)
DMZUM95	MT	DTT
DMZUM95	MA	Inhibitor
DMZUM95	RN	Chiral aromatase and dual aromatase-steroid sulfatase inhibitors from the letrozole template: synthesis, absolute configuration, and in vitro activ... J Med Chem. 2008 Jul 24;51(14):4226-38.
DMZUM95	RU	https://pubmed.ncbi.nlm.nih.gov/18590272

DMLE0I7	DI	DMLE0I7
DMLE0I7	DN	4557W
DMLE0I7	MI	TTGKNB4
DMLE0I7	MN	Epidermal growth factor receptor (EGFR)
DMLE0I7	MT	DTT
DMLE0I7	MA	Inhibitor
DMLE0I7	RN	Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2. Bioorg Med Chem Lett. 2001 Jun 4;11(11):1401-5.
DMLE0I7	RU	https://pubmed.ncbi.nlm.nih.gov/11378364

DMLE0I7	DI	DMLE0I7
DMLE0I7	DN	4557W
DMLE0I7	MI	TTR5TV4
DMLE0I7	MN	ERBB2 messenger RNA (HER2 mRNA)
DMLE0I7	MT	DTT
DMLE0I7	MA	Inhibitor
DMLE0I7	RN	Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2. Bioorg Med Chem Lett. 2001 Jun 4;11(11):1401-5.
DMLE0I7	RU	https://pubmed.ncbi.nlm.nih.gov/11378364

DMN2TMS	DI	DMN2TMS
DMN2TMS	DN	4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide
DMN2TMS	MI	TTGKNB4
DMN2TMS	MN	Epidermal growth factor receptor (EGFR)
DMN2TMS	MT	DTT
DMN2TMS	MA	Inhibitor
DMN2TMS	RN	Acryloylamino-salicylanilides as EGFR PTK inhibitors. Bioorg Med Chem Lett. 2006 Jan 15;16(2):469-72.
DMN2TMS	RU	https://pubmed.ncbi.nlm.nih.gov/16275081

DME24LV	DI	DME24LV
DME24LV	DN	4-adamantyl resorcinol
DME24LV	MI	TTULVH8
DME24LV	MN	Tyrosinase (TYR)
DME24LV	MT	DTT
DME24LV	MA	Inhibitor
DME24LV	RN	Studies on depigmenting activities of dihydroxyl benzamide derivatives containing adamantane moiety. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1532-3.
DME24LV	RU	https://pubmed.ncbi.nlm.nih.gov/19181523

DM9WT8M	DI	DM9WT8M
DM9WT8M	DN	4-Allyl-6-nitro-2-piperazin-1-yl-quinoline
DM9WT8M	MI	TT3ROYC
DM9WT8M	MN	Serotonin transporter (SERT)
DM9WT8M	MT	DTT
DM9WT8M	MA	Inhibitor
DM9WT8M	RN	Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 2: 4-substituted 6-nitroquipazines. Bioorg Med Chem Lett. 2002 Mar 11;12(5):811-5.
DM9WT8M	RU	https://pubmed.ncbi.nlm.nih.gov/11859009

DMGYK25	DI	DMGYK25
DMGYK25	DN	4ALPHA-(HYDROXYMETHYL)-4ALPHA-DEMETHYLTERRITREM B
DMGYK25	MI	TT1RS9F
DMGYK25	MN	Acetylcholinesterase (AChE)
DMGYK25	MT	DTT
DMGYK25	MA	Inhibitor
DMGYK25	RN	Structure and anti-acetylcholinesterase activity of 4 alpha-(hydroxymethyl)-4 alpha-demethylterritrem B. J Nat Prod. 1997 Aug;60(8):842-3.
DMGYK25	RU	https://pubmed.ncbi.nlm.nih.gov/9287420

DMTSPLX	DI	DMTSPLX
DMTSPLX	DN	4alpha-PDD
DMTSPLX	MI	TTKP2SU
DMTSPLX	MN	Transient receptor potential cation channel V4 (TRPV4)
DMTSPLX	MT	DTT
DMTSPLX	MA	Activator
DMTSPLX	RN	Activation of TRPV4 channels (hVRL-2/mTRP12) by phorbol derivatives. J Biol Chem. 2002 Apr 19;277(16):13569-77.
DMTSPLX	RU	https://pubmed.ncbi.nlm.nih.gov/11827975

DMUOLES	DI	DMUOLES
DMUOLES	DN	4alpha-PDH
DMUOLES	MI	TTKP2SU
DMUOLES	MN	Transient receptor potential cation channel V4 (TRPV4)
DMUOLES	MT	DTT
DMUOLES	MA	Activator
DMUOLES	RN	Modulation of the transient receptor potential vanilloid channel TRPV4 by 4alpha-phorbol esters: a structure-activity study. J Med Chem. 2009 May 14;52(9):2933-9.
DMUOLES	RU	https://pubmed.ncbi.nlm.nih.gov/19361196

DMYNASR	DI	DMYNASR
DMYNASR	DN	4-AMBA
DMYNASR	MI	TT5LF3C
DMYNASR	MN	Solute carrier family 15 member 1 (SLC15A1)
DMYNASR	MT	DTT
DMYNASR	MA	Inhibitor
DMYNASR	RN	Activation of vagal afferents in the rat duodenum by protein digests requires PepT1. J Nutr. 2005 Jun;135(6):1491-5.
DMYNASR	RU	https://pubmed.ncbi.nlm.nih.gov/15930458

DMYX34S	DI	DMYX34S
DMYX34S	DN	4-Amino Hexanoic Acid
DMYX34S	MI	TTT2LD9
DMYX34S	MN	GABA transaminase (ABAT)
DMYX34S	MT	DTT
DMYX34S	MA	Inhibitor
DMYX34S	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMYX34S	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMNXSM2	DI	DMNXSM2
DMNXSM2	DN	4-amino-1,2,5-oxadiazole-3-carboximidamide
DMNXSM2	MI	TTZJYKH
DMNXSM2	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMNXSM2	MT	DTT
DMNXSM2	MA	Inhibitor
DMNXSM2	RN	Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma mo... J Med Chem. 2009 Dec 10;52(23):7364-7.
DMNXSM2	RU	https://pubmed.ncbi.nlm.nih.gov/19507862

DMU49H6	DI	DMU49H6
DMU49H6	DN	4-amino-1,8-naphthalimide
DMU49H6	MI	TTVDSZ0
DMU49H6	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMU49H6	MT	DTT
DMU49H6	MA	Inhibitor
DMU49H6	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMU49H6	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM7X59V	DI	DM7X59V
DM7X59V	DN	4-Amino-2,6-diphenyl-pyrimidine-5-carbonitrile
DM7X59V	MI	TTK25J1
DM7X59V	MN	Adenosine A1 receptor (ADORA1)
DM7X59V	MT	DTT
DM7X59V	MA	Inhibitor
DM7X59V	RN	A new generation of adenosine receptor antagonists: from di- to trisubstituted aminopyrimidines. Bioorg Med Chem. 2008 Mar 15;16(6):2741-52.
DM7X59V	RU	https://pubmed.ncbi.nlm.nih.gov/18258439

DM7X59V	DI	DM7X59V
DM7X59V	DN	4-Amino-2,6-diphenyl-pyrimidine-5-carbonitrile
DM7X59V	MI	TTM2AOE
DM7X59V	MN	Adenosine A2a receptor (ADORA2A)
DM7X59V	MT	DTT
DM7X59V	MA	Inhibitor
DM7X59V	RN	A new generation of adenosine receptor antagonists: from di- to trisubstituted aminopyrimidines. Bioorg Med Chem. 2008 Mar 15;16(6):2741-52.
DM7X59V	RU	https://pubmed.ncbi.nlm.nih.gov/18258439

DMINUHD	DI	DMINUHD
DMINUHD	DN	4-Amino-2-Deoxy-2,3-Dehydro-N-Neuraminic Acid
DMINUHD	MI	TT50QJ3
DMINUHD	MN	Influenza Neuraminidase (Influ NA)
DMINUHD	MT	DTT
DMINUHD	MA	Inhibitor
DMINUHD	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMINUHD	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DM3MUF1	DI	DM3MUF1
DM3MUF1	DN	4-amino-2H-chromen-2-one
DM3MUF1	MI	TT8XK6L
DM3MUF1	MN	Quinone reductase 1 (NQO1)
DM3MUF1	MT	DTT
DM3MUF1	MA	Inhibitor
DM3MUF1	RN	Coumarin-based inhibitors of human NAD(P)H:quinone oxidoreductase-1. Identification, structure-activity, off-target effects and in vitro human panc... J Med Chem. 2007 Dec 13;50(25):6316-25.
DM3MUF1	RU	https://pubmed.ncbi.nlm.nih.gov/17999461

DMOJTZD	DI	DMOJTZD
DMOJTZD	DN	4-amino-2-p-tolylisoindoline-1,3-dione
DMOJTZD	MI	TTM2AOE
DMOJTZD	MN	Adenosine A2a receptor (ADORA2A)
DMOJTZD	MT	DTT
DMOJTZD	MA	Inhibitor
DMOJTZD	RN	Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. J Med Chem. 2010 Feb 25;53(4):1799-809.
DMOJTZD	RU	https://pubmed.ncbi.nlm.nih.gov/20095623

DMIX81A	DI	DMIX81A
DMIX81A	DN	4-Amino-3-(2-chloro-phenyl)-butyric acid
DMIX81A	MI	TTDCVZW
DMIX81A	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMIX81A	MT	DTT
DMIX81A	MA	Inhibitor
DMIX81A	RN	3-Thienyl- and 3-furylaminobutyric acids. Synthesis and binding GABAB receptor studies. J Med Chem. 1991 Aug;34(8):2557-60.
DMIX81A	RU	https://pubmed.ncbi.nlm.nih.gov/1652022

DMGI0YV	DI	DMGI0YV
DMGI0YV	DN	4-amino-3-(4-(hexyloxy)phenyl)-4-oxobutanoic acid
DMGI0YV	MI	TTHY57M
DMGI0YV	MN	Matrix metalloproteinase-13 (MMP-13)
DMGI0YV	MT	DTT
DMGI0YV	MA	Inhibitor
DMGI0YV	RN	Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study. Bioorg Med Chem. 2009 Feb 1;17(3):1101-8.
DMGI0YV	RU	https://pubmed.ncbi.nlm.nih.gov/18364257

DMGI0YV	DI	DMGI0YV
DMGI0YV	DN	4-amino-3-(4-(hexyloxy)phenyl)-4-oxobutanoic acid
DMGI0YV	MI	TTGA1IV
DMGI0YV	MN	Matrix metalloproteinase-8 (MMP-8)
DMGI0YV	MT	DTT
DMGI0YV	MA	Inhibitor
DMGI0YV	RN	Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study. Bioorg Med Chem. 2009 Feb 1;17(3):1101-8.
DMGI0YV	RU	https://pubmed.ncbi.nlm.nih.gov/18364257

DMGI0YV	DI	DMGI0YV
DMGI0YV	DN	4-amino-3-(4-(hexyloxy)phenyl)-4-oxobutanoic acid
DMGI0YV	MI	TT6X50U
DMGI0YV	MN	Matrix metalloproteinase-9 (MMP-9)
DMGI0YV	MT	DTT
DMGI0YV	MA	Inhibitor
DMGI0YV	RN	Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study. Bioorg Med Chem. 2009 Feb 1;17(3):1101-8.
DMGI0YV	RU	https://pubmed.ncbi.nlm.nih.gov/18364257

DMVKPF1	DI	DMVKPF1
DMVKPF1	DN	4-Amino-3-(4-fluoro-phenyl)-butyric acid
DMVKPF1	MI	TTDCVZW
DMVKPF1	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMVKPF1	MT	DTT
DMVKPF1	MA	Inhibitor
DMVKPF1	RN	3-Thienyl- and 3-furylaminobutyric acids. Synthesis and binding GABAB receptor studies. J Med Chem. 1991 Aug;34(8):2557-60.
DMVKPF1	RU	https://pubmed.ncbi.nlm.nih.gov/1652022

DMTO8NV	DI	DMTO8NV
DMTO8NV	DN	4-Amino-3-(5-bromo-thiophen-2-yl)-butyric acid
DMTO8NV	MI	TTDCVZW
DMTO8NV	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMTO8NV	MT	DTT
DMTO8NV	MA	Inhibitor
DMTO8NV	RN	3-Thienyl- and 3-furylaminobutyric acids. Synthesis and binding GABAB receptor studies. J Med Chem. 1991 Aug;34(8):2557-60.
DMTO8NV	RU	https://pubmed.ncbi.nlm.nih.gov/1652022

DM415DB	DI	DM415DB
DM415DB	DN	4-Amino-3-(5-chloro-thiophen-2-yl)-butyric acid
DM415DB	MI	TTDCVZW
DM415DB	MN	Gamma-aminobutyric acid B receptor (GABBR)
DM415DB	MT	DTT
DM415DB	MA	Inhibitor
DM415DB	RN	3-Thienyl- and 3-furylaminobutyric acids. Synthesis and binding GABAB receptor studies. J Med Chem. 1991 Aug;34(8):2557-60.
DM415DB	RU	https://pubmed.ncbi.nlm.nih.gov/1652022

DMEDRAX	DI	DMEDRAX
DMEDRAX	DN	4-Amino-3-(5-methyl-thiophen-2-yl)-butyric acid
DMEDRAX	MI	TTDCVZW
DMEDRAX	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMEDRAX	MT	DTT
DMEDRAX	MA	Inhibitor
DMEDRAX	RN	3-Thienyl- and 3-furylaminobutyric acids. Synthesis and binding GABAB receptor studies. J Med Chem. 1991 Aug;34(8):2557-60.
DMEDRAX	RU	https://pubmed.ncbi.nlm.nih.gov/1652022

DMDCQAX	DI	DMDCQAX
DMDCQAX	DN	4-amino-3,5-dibromobenzenesulfonamide
DMDCQAX	MI	TTUNARX
DMDCQAX	MN	Carbonic anhydrase (CA)
DMDCQAX	MT	DTT
DMDCQAX	MA	Inhibitor
DMDCQAX	RN	Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. Bioorg Med Chem. 2007 Dec 1;15(23):7229-36.
DMDCQAX	RU	https://pubmed.ncbi.nlm.nih.gov/17826101

DM1IHCV	DI	DM1IHCV
DM1IHCV	DN	4-Amino-3-benzofuran-2-yl-butyric acid
DM1IHCV	MI	TTDCVZW
DM1IHCV	MN	Gamma-aminobutyric acid B receptor (GABBR)
DM1IHCV	MT	DTT
DM1IHCV	MA	Inhibitor
DM1IHCV	RN	Synthesis and pharmacological evaluation of gamma-aminobutyric acid analogues. New ligand for GABAB sites. J Med Chem. 1987 Apr;30(4):743-6.
DM1IHCV	RU	https://pubmed.ncbi.nlm.nih.gov/3031294

DMVUCZK	DI	DMVUCZK
DMVUCZK	DN	4-Amino-3-bromo-benzenesulfonamide
DMVUCZK	MI	TTUNARX
DMVUCZK	MN	Carbonic anhydrase (CA)
DMVUCZK	MT	DTT
DMVUCZK	MA	Inhibitor
DMVUCZK	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DMVUCZK	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DMVUCZK	DI	DMVUCZK
DMVUCZK	DN	4-Amino-3-bromo-benzenesulfonamide
DMVUCZK	MI	TTHQPL7
DMVUCZK	MN	Carbonic anhydrase I (CA-I)
DMVUCZK	MT	DTT
DMVUCZK	MA	Inhibitor
DMVUCZK	RN	Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorg Med Chem. 2009 Jul 15;17(14):5054-8.
DMVUCZK	RU	https://pubmed.ncbi.nlm.nih.gov/19520577

DMVUCZK	DI	DMVUCZK
DMVUCZK	DN	4-Amino-3-bromo-benzenesulfonamide
DMVUCZK	MI	TTANPDJ
DMVUCZK	MN	Carbonic anhydrase II (CA-II)
DMVUCZK	MT	DTT
DMVUCZK	MA	Inhibitor
DMVUCZK	RN	Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, ... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6649-54.
DMVUCZK	RU	https://pubmed.ncbi.nlm.nih.gov/19846301

DMVUCZK	DI	DMVUCZK
DMVUCZK	DN	4-Amino-3-bromo-benzenesulfonamide
DMVUCZK	MI	TTZHA0O
DMVUCZK	MN	Carbonic anhydrase IV (CA-IV)
DMVUCZK	MT	DTT
DMVUCZK	MA	Inhibitor
DMVUCZK	RN	Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1149-54.
DMVUCZK	RU	https://pubmed.ncbi.nlm.nih.gov/15686931

DMVUCZK	DI	DMVUCZK
DMVUCZK	DN	4-Amino-3-bromo-benzenesulfonamide
DMVUCZK	MI	TT2LVK8
DMVUCZK	MN	Carbonic anhydrase IX (CA-IX)
DMVUCZK	MT	DTT
DMVUCZK	MA	Inhibitor
DMVUCZK	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DMVUCZK	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DMVUCZK	DI	DMVUCZK
DMVUCZK	DN	4-Amino-3-bromo-benzenesulfonamide
DMVUCZK	MI	TTCFSPE
DMVUCZK	MN	Carbonic anhydrase VI (CA-VI)
DMVUCZK	MT	DTT
DMVUCZK	MA	Inhibitor
DMVUCZK	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DMVUCZK	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DMVUCZK	DI	DMVUCZK
DMVUCZK	DN	4-Amino-3-bromo-benzenesulfonamide
DMVUCZK	MI	TTSYM0R
DMVUCZK	MN	Carbonic anhydrase XII (CA-XII)
DMVUCZK	MT	DTT
DMVUCZK	MA	Inhibitor
DMVUCZK	RN	Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglauc... Bioorg Med Chem Lett. 2005 Feb 15;15(4):963-9.
DMVUCZK	RU	https://pubmed.ncbi.nlm.nih.gov/15686894

DMVUCZK	DI	DMVUCZK
DMVUCZK	DN	4-Amino-3-bromo-benzenesulfonamide
DMVUCZK	MI	TTEYTKG
DMVUCZK	MN	Carbonic anhydrase XIV (CA-XIV)
DMVUCZK	MT	DTT
DMVUCZK	MA	Inhibitor
DMVUCZK	RN	Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33.
DMVUCZK	RU	https://pubmed.ncbi.nlm.nih.gov/16039848

DMERTQ4	DI	DMERTQ4
DMERTQ4	DN	4-Amino-3-chloro-benzenesulfonamide
DMERTQ4	MI	TTUNARX
DMERTQ4	MN	Carbonic anhydrase (CA)
DMERTQ4	MT	DTT
DMERTQ4	MA	Inhibitor
DMERTQ4	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DMERTQ4	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DMERTQ4	DI	DMERTQ4
DMERTQ4	DN	4-Amino-3-chloro-benzenesulfonamide
DMERTQ4	MI	TTHQPL7
DMERTQ4	MN	Carbonic anhydrase I (CA-I)
DMERTQ4	MT	DTT
DMERTQ4	MA	Inhibitor
DMERTQ4	RN	Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorg Med Chem. 2009 Jul 15;17(14):5054-8.
DMERTQ4	RU	https://pubmed.ncbi.nlm.nih.gov/19520577

DMERTQ4	DI	DMERTQ4
DMERTQ4	DN	4-Amino-3-chloro-benzenesulfonamide
DMERTQ4	MI	TTANPDJ
DMERTQ4	MN	Carbonic anhydrase II (CA-II)
DMERTQ4	MT	DTT
DMERTQ4	MA	Inhibitor
DMERTQ4	RN	Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, ... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6649-54.
DMERTQ4	RU	https://pubmed.ncbi.nlm.nih.gov/19846301

DMERTQ4	DI	DMERTQ4
DMERTQ4	DN	4-Amino-3-chloro-benzenesulfonamide
DMERTQ4	MI	TTZHA0O
DMERTQ4	MN	Carbonic anhydrase IV (CA-IV)
DMERTQ4	MT	DTT
DMERTQ4	MA	Inhibitor
DMERTQ4	RN	Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1149-54.
DMERTQ4	RU	https://pubmed.ncbi.nlm.nih.gov/15686931

DMERTQ4	DI	DMERTQ4
DMERTQ4	DN	4-Amino-3-chloro-benzenesulfonamide
DMERTQ4	MI	TT2LVK8
DMERTQ4	MN	Carbonic anhydrase IX (CA-IX)
DMERTQ4	MT	DTT
DMERTQ4	MA	Inhibitor
DMERTQ4	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DMERTQ4	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DMERTQ4	DI	DMERTQ4
DMERTQ4	DN	4-Amino-3-chloro-benzenesulfonamide
DMERTQ4	MI	TTCFSPE
DMERTQ4	MN	Carbonic anhydrase VI (CA-VI)
DMERTQ4	MT	DTT
DMERTQ4	MA	Inhibitor
DMERTQ4	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DMERTQ4	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DMERTQ4	DI	DMERTQ4
DMERTQ4	DN	4-Amino-3-chloro-benzenesulfonamide
DMERTQ4	MI	TTSYM0R
DMERTQ4	MN	Carbonic anhydrase XII (CA-XII)
DMERTQ4	MT	DTT
DMERTQ4	MA	Inhibitor
DMERTQ4	RN	Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglauc... Bioorg Med Chem Lett. 2005 Feb 15;15(4):963-9.
DMERTQ4	RU	https://pubmed.ncbi.nlm.nih.gov/15686894

DMERTQ4	DI	DMERTQ4
DMERTQ4	DN	4-Amino-3-chloro-benzenesulfonamide
DMERTQ4	MI	TTEYTKG
DMERTQ4	MN	Carbonic anhydrase XIV (CA-XIV)
DMERTQ4	MT	DTT
DMERTQ4	MA	Inhibitor
DMERTQ4	RN	Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33.
DMERTQ4	RU	https://pubmed.ncbi.nlm.nih.gov/16039848

DMR9M6H	DI	DMR9M6H
DMR9M6H	DN	4-amino-3-fluoro-5-iodobenzenesulfonamide
DMR9M6H	MI	TTUNARX
DMR9M6H	MN	Carbonic anhydrase (CA)
DMR9M6H	MT	DTT
DMR9M6H	MA	Inhibitor
DMR9M6H	RN	Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. Bioorg Med Chem. 2007 Dec 1;15(23):7229-36.
DMR9M6H	RU	https://pubmed.ncbi.nlm.nih.gov/17826101

DMIQ3VR	DI	DMIQ3VR
DMIQ3VR	DN	4-Amino-3-fluoro-benzenesulfonamide
DMIQ3VR	MI	TTUNARX
DMIQ3VR	MN	Carbonic anhydrase (CA)
DMIQ3VR	MT	DTT
DMIQ3VR	MA	Inhibitor
DMIQ3VR	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DMIQ3VR	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DMIQ3VR	DI	DMIQ3VR
DMIQ3VR	DN	4-Amino-3-fluoro-benzenesulfonamide
DMIQ3VR	MI	TTHQPL7
DMIQ3VR	MN	Carbonic anhydrase I (CA-I)
DMIQ3VR	MT	DTT
DMIQ3VR	MA	Inhibitor
DMIQ3VR	RN	Mutation of Phe91 to Asn in human carbonic anhydrase I unexpectedly enhanced both catalytic activity and affinity for sulfonamide inhibitors. Bioorg Med Chem. 2010 Aug 1;18(15):5498-503.
DMIQ3VR	RU	https://pubmed.ncbi.nlm.nih.gov/20624682

DMIQ3VR	DI	DMIQ3VR
DMIQ3VR	DN	4-Amino-3-fluoro-benzenesulfonamide
DMIQ3VR	MI	TTANPDJ
DMIQ3VR	MN	Carbonic anhydrase II (CA-II)
DMIQ3VR	MT	DTT
DMIQ3VR	MA	Inhibitor
DMIQ3VR	RN	Mutation of Phe91 to Asn in human carbonic anhydrase I unexpectedly enhanced both catalytic activity and affinity for sulfonamide inhibitors. Bioorg Med Chem. 2010 Aug 1;18(15):5498-503.
DMIQ3VR	RU	https://pubmed.ncbi.nlm.nih.gov/20624682

DMIQ3VR	DI	DMIQ3VR
DMIQ3VR	DN	4-Amino-3-fluoro-benzenesulfonamide
DMIQ3VR	MI	TTZHA0O
DMIQ3VR	MN	Carbonic anhydrase IV (CA-IV)
DMIQ3VR	MT	DTT
DMIQ3VR	MA	Inhibitor
DMIQ3VR	RN	Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1149-54.
DMIQ3VR	RU	https://pubmed.ncbi.nlm.nih.gov/15686931

DMIQ3VR	DI	DMIQ3VR
DMIQ3VR	DN	4-Amino-3-fluoro-benzenesulfonamide
DMIQ3VR	MI	TT2LVK8
DMIQ3VR	MN	Carbonic anhydrase IX (CA-IX)
DMIQ3VR	MT	DTT
DMIQ3VR	MA	Inhibitor
DMIQ3VR	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DMIQ3VR	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DMIQ3VR	DI	DMIQ3VR
DMIQ3VR	DN	4-Amino-3-fluoro-benzenesulfonamide
DMIQ3VR	MI	TTCFSPE
DMIQ3VR	MN	Carbonic anhydrase VI (CA-VI)
DMIQ3VR	MT	DTT
DMIQ3VR	MA	Inhibitor
DMIQ3VR	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DMIQ3VR	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DMIQ3VR	DI	DMIQ3VR
DMIQ3VR	DN	4-Amino-3-fluoro-benzenesulfonamide
DMIQ3VR	MI	TTSYM0R
DMIQ3VR	MN	Carbonic anhydrase XII (CA-XII)
DMIQ3VR	MT	DTT
DMIQ3VR	MA	Inhibitor
DMIQ3VR	RN	Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglauc... Bioorg Med Chem Lett. 2005 Feb 15;15(4):963-9.
DMIQ3VR	RU	https://pubmed.ncbi.nlm.nih.gov/15686894

DMIQ3VR	DI	DMIQ3VR
DMIQ3VR	DN	4-Amino-3-fluoro-benzenesulfonamide
DMIQ3VR	MI	TTEYTKG
DMIQ3VR	MN	Carbonic anhydrase XIV (CA-XIV)
DMIQ3VR	MT	DTT
DMIQ3VR	MA	Inhibitor
DMIQ3VR	RN	Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33.
DMIQ3VR	RU	https://pubmed.ncbi.nlm.nih.gov/16039848

DMPY8D3	DI	DMPY8D3
DMPY8D3	DN	4-Amino-3-hydroxy-butyric acid
DMPY8D3	MI	TTNJYV2
DMPY8D3	MN	Gamma-aminobutyric acid receptor (GAR)
DMPY8D3	MT	DTT
DMPY8D3	MA	Inhibitor
DMPY8D3	RN	GABA agonists. Resolution, absolute stereochemistry, and enantioselectivity of (S)-(+)- and (R)-(-)-dihydromuscimol. J Med Chem. 1985 Nov;28(11):1612-7.
DMPY8D3	RU	https://pubmed.ncbi.nlm.nih.gov/2999396

DMCOYHR	DI	DMCOYHR
DMCOYHR	DN	4-Amino-3-iodo-benzenesulfonamide
DMCOYHR	MI	TTUNARX
DMCOYHR	MN	Carbonic anhydrase (CA)
DMCOYHR	MT	DTT
DMCOYHR	MA	Inhibitor
DMCOYHR	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DMCOYHR	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DMCOYHR	DI	DMCOYHR
DMCOYHR	DN	4-Amino-3-iodo-benzenesulfonamide
DMCOYHR	MI	TTHQPL7
DMCOYHR	MN	Carbonic anhydrase I (CA-I)
DMCOYHR	MT	DTT
DMCOYHR	MA	Inhibitor
DMCOYHR	RN	Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorg Med Chem. 2009 Jul 15;17(14):5054-8.
DMCOYHR	RU	https://pubmed.ncbi.nlm.nih.gov/19520577

DMCOYHR	DI	DMCOYHR
DMCOYHR	DN	4-Amino-3-iodo-benzenesulfonamide
DMCOYHR	MI	TTANPDJ
DMCOYHR	MN	Carbonic anhydrase II (CA-II)
DMCOYHR	MT	DTT
DMCOYHR	MA	Inhibitor
DMCOYHR	RN	Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, ... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6649-54.
DMCOYHR	RU	https://pubmed.ncbi.nlm.nih.gov/19846301

DMCOYHR	DI	DMCOYHR
DMCOYHR	DN	4-Amino-3-iodo-benzenesulfonamide
DMCOYHR	MI	TTZHA0O
DMCOYHR	MN	Carbonic anhydrase IV (CA-IV)
DMCOYHR	MT	DTT
DMCOYHR	MA	Inhibitor
DMCOYHR	RN	Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1149-54.
DMCOYHR	RU	https://pubmed.ncbi.nlm.nih.gov/15686931

DMCOYHR	DI	DMCOYHR
DMCOYHR	DN	4-Amino-3-iodo-benzenesulfonamide
DMCOYHR	MI	TT2LVK8
DMCOYHR	MN	Carbonic anhydrase IX (CA-IX)
DMCOYHR	MT	DTT
DMCOYHR	MA	Inhibitor
DMCOYHR	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DMCOYHR	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DMCOYHR	DI	DMCOYHR
DMCOYHR	DN	4-Amino-3-iodo-benzenesulfonamide
DMCOYHR	MI	TTCFSPE
DMCOYHR	MN	Carbonic anhydrase VI (CA-VI)
DMCOYHR	MT	DTT
DMCOYHR	MA	Inhibitor
DMCOYHR	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DMCOYHR	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DMCOYHR	DI	DMCOYHR
DMCOYHR	DN	4-Amino-3-iodo-benzenesulfonamide
DMCOYHR	MI	TTSYM0R
DMCOYHR	MN	Carbonic anhydrase XII (CA-XII)
DMCOYHR	MT	DTT
DMCOYHR	MA	Inhibitor
DMCOYHR	RN	Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglauc... Bioorg Med Chem Lett. 2005 Feb 15;15(4):963-9.
DMCOYHR	RU	https://pubmed.ncbi.nlm.nih.gov/15686894

DMCOYHR	DI	DMCOYHR
DMCOYHR	DN	4-Amino-3-iodo-benzenesulfonamide
DMCOYHR	MI	TTEYTKG
DMCOYHR	MN	Carbonic anhydrase XIV (CA-XIV)
DMCOYHR	MT	DTT
DMCOYHR	MA	Inhibitor
DMCOYHR	RN	Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33.
DMCOYHR	RU	https://pubmed.ncbi.nlm.nih.gov/16039848

DMZJS2E	DI	DMZJS2E
DMZJS2E	DN	4-Amino-3-thiophen-2-yl-butyric acid
DMZJS2E	MI	TTDCVZW
DMZJS2E	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMZJS2E	MT	DTT
DMZJS2E	MA	Inhibitor
DMZJS2E	RN	3-Thienyl- and 3-furylaminobutyric acids. Synthesis and binding GABAB receptor studies. J Med Chem. 1991 Aug;34(8):2557-60.
DMZJS2E	RU	https://pubmed.ncbi.nlm.nih.gov/1652022

DMQ6EBR	DI	DMQ6EBR
DMQ6EBR	DN	4'-amino-4-(1,1-dimethyl-heptyl)-biphenyl-2-ol
DMQ6EBR	MI	TT6OEDT
DMQ6EBR	MN	Cannabinoid receptor 1 (CB1)
DMQ6EBR	MT	DTT
DMQ6EBR	MA	Inhibitor
DMQ6EBR	RN	Biaryl cannabinoid mimetics--synthesis and structure-activity relationship. Bioorg Med Chem Lett. 2007 Jul 1;17(13):3652-6.
DMQ6EBR	RU	https://pubmed.ncbi.nlm.nih.gov/17507224

DMQ6EBR	DI	DMQ6EBR
DMQ6EBR	DN	4'-amino-4-(1,1-dimethyl-heptyl)-biphenyl-2-ol
DMQ6EBR	MI	TTMSFAW
DMQ6EBR	MN	Cannabinoid receptor 2 (CB2)
DMQ6EBR	MT	DTT
DMQ6EBR	MA	Inhibitor
DMQ6EBR	RN	Biaryl cannabinoid mimetics--synthesis and structure-activity relationship. Bioorg Med Chem Lett. 2007 Jul 1;17(13):3652-6.
DMQ6EBR	RU	https://pubmed.ncbi.nlm.nih.gov/17507224

DM9S5V0	DI	DM9S5V0
DM9S5V0	DN	4'-Amino-4-hydroxychalcone
DM9S5V0	MI	TTULVH8
DM9S5V0	MN	Tyrosinase (TYR)
DM9S5V0	MT	DTT
DM9S5V0	MA	Inhibitor
DM9S5V0	RN	Evaluation of anti-pigmentary effect of synthetic sulfonylamino chalcone. Eur J Med Chem. 2010 May;45(5):2010-7.
DM9S5V0	RU	https://pubmed.ncbi.nlm.nih.gov/20149498

DMZRM0Q	DI	DMZRM0Q
DMZRM0Q	DN	4-amino-6-(4-octylphenyl)hexanoic acid
DMZRM0Q	MI	TT9JZCK
DMZRM0Q	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMZRM0Q	MT	DTT
DMZRM0Q	MA	Inhibitor
DMZRM0Q	RN	S1P receptor mediated activity of FTY720 phosphate mimics. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1485-7.
DMZRM0Q	RU	https://pubmed.ncbi.nlm.nih.gov/20153186

DMIWGZS	DI	DMIWGZS
DMIWGZS	DN	4-amino-6-chlorobenzene-1,3-disulfonamide
DMIWGZS	MI	TTUNARX
DMIWGZS	MN	Carbonic anhydrase (CA)
DMIWGZS	MT	DTT
DMIWGZS	MA	Inhibitor
DMIWGZS	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DMIWGZS	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DMIWGZS	DI	DMIWGZS
DMIWGZS	DN	4-amino-6-chlorobenzene-1,3-disulfonamide
DMIWGZS	MI	TTHQPL7
DMIWGZS	MN	Carbonic anhydrase I (CA-I)
DMIWGZS	MT	DTT
DMIWGZS	MA	Inhibitor
DMIWGZS	RN	Mutation of Phe91 to Asn in human carbonic anhydrase I unexpectedly enhanced both catalytic activity and affinity for sulfonamide inhibitors. Bioorg Med Chem. 2010 Aug 1;18(15):5498-503.
DMIWGZS	RU	https://pubmed.ncbi.nlm.nih.gov/20624682

DMIWGZS	DI	DMIWGZS
DMIWGZS	DN	4-amino-6-chlorobenzene-1,3-disulfonamide
DMIWGZS	MI	TTANPDJ
DMIWGZS	MN	Carbonic anhydrase II (CA-II)
DMIWGZS	MT	DTT
DMIWGZS	MA	Inhibitor
DMIWGZS	RN	Mutation of Phe91 to Asn in human carbonic anhydrase I unexpectedly enhanced both catalytic activity and affinity for sulfonamide inhibitors. Bioorg Med Chem. 2010 Aug 1;18(15):5498-503.
DMIWGZS	RU	https://pubmed.ncbi.nlm.nih.gov/20624682

DMIWGZS	DI	DMIWGZS
DMIWGZS	DN	4-amino-6-chlorobenzene-1,3-disulfonamide
DMIWGZS	MI	TT2LVK8
DMIWGZS	MN	Carbonic anhydrase IX (CA-IX)
DMIWGZS	MT	DTT
DMIWGZS	MA	Inhibitor
DMIWGZS	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DMIWGZS	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DMIWGZS	DI	DMIWGZS
DMIWGZS	DN	4-amino-6-chlorobenzene-1,3-disulfonamide
DMIWGZS	MI	TTCFSPE
DMIWGZS	MN	Carbonic anhydrase VI (CA-VI)
DMIWGZS	MT	DTT
DMIWGZS	MA	Inhibitor
DMIWGZS	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DMIWGZS	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DMP2GN7	DI	DMP2GN7
DMP2GN7	DN	4-aminobenzoic acid hydrazide
DMP2GN7	MI	TTVCZPI
DMP2GN7	MN	Myeloperoxidase (MPO)
DMP2GN7	MT	DTT
DMP2GN7	MA	Inhibitor
DMP2GN7	RN	Myeloperoxidase expression as a potential determinant of parthenolide-induced apoptosis in leukemia bulk and leukemia stem cells. J Pharmacol Exp Ther. 2010 Nov;335(2):389-400.
DMP2GN7	RU	https://pubmed.ncbi.nlm.nih.gov/20699435

DMHDB70	DI	DMHDB70
DMHDB70	DN	4-amino-biphenyl-3-carboxylic acid amide
DMHDB70	MI	TTJ3E9X
DMHDB70	MN	Inhibitor of nuclear factor kappa-B kinase beta (IKKB)
DMHDB70	MT	DTT
DMHDB70	MA	Inhibitor
DMHDB70	RN	Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies. J Med Chem. 2006 May 18;49(10):2898-908.
DMHDB70	RU	https://pubmed.ncbi.nlm.nih.gov/16686533

DM6PQ5V	DI	DM6PQ5V
DM6PQ5V	DN	4-amino-N-(2-chlorophenyl)benzenesulfonamide
DM6PQ5V	MI	TT8NGED
DM6PQ5V	MN	Prostaglandin G/H synthase 1 (COX-1)
DM6PQ5V	MT	DTT
DM6PQ5V	MA	Inhibitor
DM6PQ5V	RN	Analgesic agents without gastric damage: design and synthesis of structurally simple benzenesulfonanilide-type cyclooxygenase-1-selective inhibitors. Bioorg Med Chem. 2007 Jan 15;15(2):1014-21.
DM6PQ5V	RU	https://pubmed.ncbi.nlm.nih.gov/17079150

DMCUSD4	DI	DMCUSD4
DMCUSD4	DN	4-amino-N-(4-chlorophenyl)benzenesulfonamide
DMCUSD4	MI	TT8NGED
DMCUSD4	MN	Prostaglandin G/H synthase 1 (COX-1)
DMCUSD4	MT	DTT
DMCUSD4	MA	Inhibitor
DMCUSD4	RN	Analgesic agents without gastric damage: design and synthesis of structurally simple benzenesulfonanilide-type cyclooxygenase-1-selective inhibitors. Bioorg Med Chem. 2007 Jan 15;15(2):1014-21.
DMCUSD4	RU	https://pubmed.ncbi.nlm.nih.gov/17079150

DMCUSD4	DI	DMCUSD4
DMCUSD4	DN	4-amino-N-(4-chlorophenyl)benzenesulfonamide
DMCUSD4	MI	TTVKILB
DMCUSD4	MN	Prostaglandin G/H synthase 2 (COX-2)
DMCUSD4	MT	DTT
DMCUSD4	MA	Inhibitor
DMCUSD4	RN	Analgesic agents without gastric damage: design and synthesis of structurally simple benzenesulfonanilide-type cyclooxygenase-1-selective inhibitors. Bioorg Med Chem. 2007 Jan 15;15(2):1014-21.
DMCUSD4	RU	https://pubmed.ncbi.nlm.nih.gov/17079150

DMN19QP	DI	DMN19QP
DMN19QP	DN	4-amino-N-(4-iodophenyl)benzenesulfonamide
DMN19QP	MI	TTVKILB
DMN19QP	MN	Prostaglandin G/H synthase 2 (COX-2)
DMN19QP	MT	DTT
DMN19QP	MA	Inhibitor
DMN19QP	RN	Analgesic agents without gastric damage: design and synthesis of structurally simple benzenesulfonanilide-type cyclooxygenase-1-selective inhibitors. Bioorg Med Chem. 2007 Jan 15;15(2):1014-21.
DMN19QP	RU	https://pubmed.ncbi.nlm.nih.gov/17079150

DMJZNX6	DI	DMJZNX6
DMJZNX6	DN	4-amino-N-(4-sulfamoylbenzyl)benzenesulfonamide
DMJZNX6	MI	TTUNARX
DMJZNX6	MN	Carbonic anhydrase (CA)
DMJZNX6	MT	DTT
DMJZNX6	MA	Inhibitor
DMJZNX6	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DMJZNX6	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DMJZNX6	DI	DMJZNX6
DMJZNX6	DN	4-amino-N-(4-sulfamoylbenzyl)benzenesulfonamide
DMJZNX6	MI	TTHQPL7
DMJZNX6	MN	Carbonic anhydrase I (CA-I)
DMJZNX6	MT	DTT
DMJZNX6	MA	Inhibitor
DMJZNX6	RN	Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorg Med Chem. 2009 Jul 15;17(14):5054-8.
DMJZNX6	RU	https://pubmed.ncbi.nlm.nih.gov/19520577

DMJZNX6	DI	DMJZNX6
DMJZNX6	DN	4-amino-N-(4-sulfamoylbenzyl)benzenesulfonamide
DMJZNX6	MI	TTANPDJ
DMJZNX6	MN	Carbonic anhydrase II (CA-II)
DMJZNX6	MT	DTT
DMJZNX6	MA	Inhibitor
DMJZNX6	RN	Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, ... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6649-54.
DMJZNX6	RU	https://pubmed.ncbi.nlm.nih.gov/19846301

DMJZNX6	DI	DMJZNX6
DMJZNX6	DN	4-amino-N-(4-sulfamoylbenzyl)benzenesulfonamide
DMJZNX6	MI	TT2LVK8
DMJZNX6	MN	Carbonic anhydrase IX (CA-IX)
DMJZNX6	MT	DTT
DMJZNX6	MA	Inhibitor
DMJZNX6	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DMJZNX6	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DMJZNX6	DI	DMJZNX6
DMJZNX6	DN	4-amino-N-(4-sulfamoylbenzyl)benzenesulfonamide
DMJZNX6	MI	TTCFSPE
DMJZNX6	MN	Carbonic anhydrase VI (CA-VI)
DMJZNX6	MT	DTT
DMJZNX6	MA	Inhibitor
DMJZNX6	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DMJZNX6	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DMDX0VP	DI	DMDX0VP
DMDX0VP	DN	4-amino-N-[4-(benzyloxy)phenyl]butanamide
DMDX0VP	MI	TTXZEAJ
DMDX0VP	MN	Leukotriene A-4 hydrolase (LTA4H)
DMDX0VP	MT	DTT
DMDX0VP	MA	Inhibitor
DMDX0VP	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMDX0VP	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMIG82P	DI	DMIG82P
DMIG82P	DN	4-aminonaphthalen-1-ol
DMIG82P	MI	TTZJYKH
DMIG82P	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMIG82P	MT	DTT
DMIG82P	MA	Inhibitor
DMIG82P	RN	Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2010 Feb 11;53(3):1172-89.
DMIG82P	RU	https://pubmed.ncbi.nlm.nih.gov/20055453

DMLW651	DI	DMLW651
DMLW651	DN	4-amino-N-p-tolylbenzenesulfonamide
DMLW651	MI	TT8NGED
DMLW651	MN	Prostaglandin G/H synthase 1 (COX-1)
DMLW651	MT	DTT
DMLW651	MA	Inhibitor
DMLW651	RN	Analgesic agents without gastric damage: design and synthesis of structurally simple benzenesulfonanilide-type cyclooxygenase-1-selective inhibitors. Bioorg Med Chem. 2007 Jan 15;15(2):1014-21.
DMLW651	RU	https://pubmed.ncbi.nlm.nih.gov/17079150

DMYC1T6	DI	DMYC1T6
DMYC1T6	DN	4-AMINOPHENOL
DMYC1T6	MI	TTUNARX
DMYC1T6	MN	Carbonic anhydrase (CA)
DMYC1T6	MT	DTT
DMYC1T6	MA	Inhibitor
DMYC1T6	RN	Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8.
DMYC1T6	RU	https://pubmed.ncbi.nlm.nih.gov/18579385

DMYC1T6	DI	DMYC1T6
DMYC1T6	DN	4-AMINOPHENOL
DMYC1T6	MI	TTEYTKG
DMYC1T6	MN	Carbonic anhydrase XIV (CA-XIV)
DMYC1T6	MT	DTT
DMYC1T6	MA	Inhibitor
DMYC1T6	RN	Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8.
DMYC1T6	RU	https://pubmed.ncbi.nlm.nih.gov/18579385

DMSE8NU	DI	DMSE8NU
DMSE8NU	DN	4-ANDROSTENE-3-17-DIONE
DMSE8NU	MI	TTSZLWK
DMSE8NU	MN	Aromatase (CYP19A1)
DMSE8NU	MT	DTT
DMSE8NU	MA	Inhibitor
DMSE8NU	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMSE8NU	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMSE8NU	DI	DMSE8NU
DMSE8NU	DN	4-ANDROSTENE-3-17-DIONE
DMSE8NU	MI	TT5ZWB6
DMSE8NU	MN	Dihydrodiol dehydrogenase type I (AKR1C3)
DMSE8NU	MT	DTT
DMSE8NU	MA	Inhibitor
DMSE8NU	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMSE8NU	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMSE8NU	DI	DMSE8NU
DMSE8NU	DN	4-ANDROSTENE-3-17-DIONE
DMSE8NU	MI	TTIWB6L
DMSE8NU	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMSE8NU	MT	DTT
DMSE8NU	MA	Inhibitor
DMSE8NU	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMSE8NU	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMSE8NU	DI	DMSE8NU
DMSE8NU	DN	4-ANDROSTENE-3-17-DIONE
DMSE8NU	MI	TTZT9R2
DMSE8NU	MN	Hydroxysteroid dehydrogenase 3-beta (HSD3B)
DMSE8NU	MT	DTT
DMSE8NU	MA	Agonist
DMSE8NU	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMSE8NU	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMSE8NU	DI	DMSE8NU
DMSE8NU	DN	4-ANDROSTENE-3-17-DIONE
DMSE8NU	MI	DEX8J7E
DMSE8NU	MN	Testicular 17-beta-hydroxysteroid dehydrogenase (HSD17B3)
DMSE8NU	MT	DME
DMSE8NU	MA	Metabolism
DMSE8NU	RN	17beta-hydroxysteroid dehydrogenase-3 deficiency: a rare endocrine cause of male-to-female sex reversal. Gynecol Endocrinol. 2006 Sep;22(9):488-94.
DMSE8NU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17071532

DM1UXHE	DI	DM1UXHE
DM1UXHE	DN	4-APPES
DM1UXHE	MI	TTXJ47W
DM1UXHE	MN	Metabotropic glutamate receptor 2 (mGluR2)
DM1UXHE	MT	DTT
DM1UXHE	MA	Modulator (allosteric modulator)
DM1UXHE	RN	Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and... Psychopharmacology (Berl). 2005 Apr;179(1):271-83.
DM1UXHE	RU	https://pubmed.ncbi.nlm.nih.gov/15717213

DM3UE42	DI	DM3UE42
DM3UE42	DN	4-arylphthalazin-1(2H)-3,4-Di-F
DM3UE42	MI	TTX4RTB
DM3UE42	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DM3UE42	MT	DTT
DM3UE42	MA	Antagonist
DM3UE42	RN	4-arylphthalazin-1(2H)-one derivatives as potent antagonists of the melanin concentrating hormone receptor 1 (MCH-R1). Bioorg Med Chem Lett. 2012 Jan 1;22(1):427-30.
DM3UE42	RU	https://pubmed.ncbi.nlm.nih.gov/22137790

DM7EQ06	DI	DM7EQ06
DM7EQ06	DN	4-azidobenzenesulfonamide
DM7EQ06	MI	TTUNARX
DM7EQ06	MN	Carbonic anhydrase (CA)
DM7EQ06	MT	DTT
DM7EQ06	MA	Inhibitor
DM7EQ06	RN	Inhibition of human mitochondrial carbonic anhydrases VA and VB with para-(4-phenyltriazole-1-yl)-benzenesulfonamide derivatives. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4624-7.
DM7EQ06	RU	https://pubmed.ncbi.nlm.nih.gov/18644716

DM7EQ06	DI	DM7EQ06
DM7EQ06	DN	4-azidobenzenesulfonamide
DM7EQ06	MI	TTHQPL7
DM7EQ06	MN	Carbonic anhydrase I (CA-I)
DM7EQ06	MT	DTT
DM7EQ06	MA	Inhibitor
DM7EQ06	RN	Inhibition of human mitochondrial carbonic anhydrases VA and VB with para-(4-phenyltriazole-1-yl)-benzenesulfonamide derivatives. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4624-7.
DM7EQ06	RU	https://pubmed.ncbi.nlm.nih.gov/18644716

DM7EQ06	DI	DM7EQ06
DM7EQ06	DN	4-azidobenzenesulfonamide
DM7EQ06	MI	TTANPDJ
DM7EQ06	MN	Carbonic anhydrase II (CA-II)
DM7EQ06	MT	DTT
DM7EQ06	MA	Inhibitor
DM7EQ06	RN	Inhibition of human mitochondrial carbonic anhydrases VA and VB with para-(4-phenyltriazole-1-yl)-benzenesulfonamide derivatives. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4624-7.
DM7EQ06	RU	https://pubmed.ncbi.nlm.nih.gov/18644716

DM7EQ06	DI	DM7EQ06
DM7EQ06	DN	4-azidobenzenesulfonamide
DM7EQ06	MI	TT2LVK8
DM7EQ06	MN	Carbonic anhydrase IX (CA-IX)
DM7EQ06	MT	DTT
DM7EQ06	MA	Inhibitor
DM7EQ06	RN	Inhibition of carbonic anhydrase isozymes with benzene sulfonamides incorporating thio, sulfinyl and sulfonyl glycoside moieties. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2273-6.
DM7EQ06	RU	https://pubmed.ncbi.nlm.nih.gov/19286378

DMACRHS	DI	DMACRHS
DMACRHS	DN	4-Benzenesulfonyl-1-(3-phenyl-propyl)-piperidine
DMACRHS	MI	TTQ6VDM
DMACRHS	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMACRHS	MT	DTT
DMACRHS	MA	Inhibitor
DMACRHS	RN	4-(Phenylsulfonyl)piperidines: novel, selective, and bioavailable 5-HT(2A) receptor antagonists. J Med Chem. 2002 Jan 17;45(2):492-503.
DMACRHS	RU	https://pubmed.ncbi.nlm.nih.gov/11784153

DMCKT3Q	DI	DMCKT3Q
DMCKT3Q	DN	4-Benzenesulfonyl-1-phenethyl-piperidine
DMCKT3Q	MI	TTQ6VDM
DMCKT3Q	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMCKT3Q	MT	DTT
DMCKT3Q	MA	Inhibitor
DMCKT3Q	RN	4-(Phenylsulfonyl)piperidines: novel, selective, and bioavailable 5-HT(2A) receptor antagonists. J Med Chem. 2002 Jan 17;45(2):492-503.
DMCKT3Q	RU	https://pubmed.ncbi.nlm.nih.gov/11784153

DMC7HKA	DI	DMC7HKA
DMC7HKA	DN	4-Benzenesulfonylamino-benzenesulfonamide
DMC7HKA	MI	TTHQPL7
DMC7HKA	MN	Carbonic anhydrase I (CA-I)
DMC7HKA	MT	DTT
DMC7HKA	MA	Inhibitor
DMC7HKA	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DMC7HKA	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DMC7HKA	DI	DMC7HKA
DMC7HKA	DN	4-Benzenesulfonylamino-benzenesulfonamide
DMC7HKA	MI	TTANPDJ
DMC7HKA	MN	Carbonic anhydrase II (CA-II)
DMC7HKA	MT	DTT
DMC7HKA	MA	Inhibitor
DMC7HKA	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DMC7HKA	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DMC7HKA	DI	DMC7HKA
DMC7HKA	DN	4-Benzenesulfonylamino-benzenesulfonamide
DMC7HKA	MI	TT2LVK8
DMC7HKA	MN	Carbonic anhydrase IX (CA-IX)
DMC7HKA	MT	DTT
DMC7HKA	MA	Inhibitor
DMC7HKA	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DMC7HKA	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DMC7HKA	DI	DMC7HKA
DMC7HKA	DN	4-Benzenesulfonylamino-benzenesulfonamide
DMC7HKA	MI	TTSYM0R
DMC7HKA	MN	Carbonic anhydrase XII (CA-XII)
DMC7HKA	MT	DTT
DMC7HKA	MA	Inhibitor
DMC7HKA	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DMC7HKA	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DMM6UPD	DI	DMM6UPD
DMM6UPD	DN	4-Benzenesulfonylamino-N-hydroxy-benzamide
DMM6UPD	MI	TT6R7JZ
DMM6UPD	MN	Histone deacetylase 1 (HDAC1)
DMM6UPD	MT	DTT
DMM6UPD	MA	Inhibitor
DMM6UPD	RN	Design and synthesis of a novel class of histone deacetylase inhibitors. Bioorg Med Chem Lett. 2001 Nov 5;11(21):2847-50.
DMM6UPD	RU	https://pubmed.ncbi.nlm.nih.gov/11597413

DMVSNPB	DI	DMVSNPB
DMVSNPB	DN	4-benzhydryl-N-butylpiperazine-1-carboxamide
DMVSNPB	MI	TT6OEDT
DMVSNPB	MN	Cannabinoid receptor 1 (CB1)
DMVSNPB	MT	DTT
DMVSNPB	MA	Inhibitor
DMVSNPB	RN	Discovery of benzhydrylpiperazine derivatives as CB1 receptor inverse agonists via privileged structure-based approach. Eur J Med Chem. 2010 Mar;45(3):1133-9.
DMVSNPB	RU	https://pubmed.ncbi.nlm.nih.gov/20047779

DMVSNPB	DI	DMVSNPB
DMVSNPB	DN	4-benzhydryl-N-butylpiperazine-1-carboxamide
DMVSNPB	MI	TTMSFAW
DMVSNPB	MN	Cannabinoid receptor 2 (CB2)
DMVSNPB	MT	DTT
DMVSNPB	MA	Inhibitor
DMVSNPB	RN	Discovery of benzhydrylpiperazine derivatives as CB1 receptor inverse agonists via privileged structure-based approach. Eur J Med Chem. 2010 Mar;45(3):1133-9.
DMVSNPB	RU	https://pubmed.ncbi.nlm.nih.gov/20047779

DMASO86	DI	DMASO86
DMASO86	DN	4-benzhydryl-N-cyclohexylpiperazine-1-carboxamide
DMASO86	MI	TT6OEDT
DMASO86	MN	Cannabinoid receptor 1 (CB1)
DMASO86	MT	DTT
DMASO86	MA	Inhibitor
DMASO86	RN	Discovery of benzhydrylpiperazine derivatives as CB1 receptor inverse agonists via privileged structure-based approach. Eur J Med Chem. 2010 Mar;45(3):1133-9.
DMASO86	RU	https://pubmed.ncbi.nlm.nih.gov/20047779

DMASO86	DI	DMASO86
DMASO86	DN	4-benzhydryl-N-cyclohexylpiperazine-1-carboxamide
DMASO86	MI	TTMSFAW
DMASO86	MN	Cannabinoid receptor 2 (CB2)
DMASO86	MT	DTT
DMASO86	MA	Inhibitor
DMASO86	RN	Discovery of benzhydrylpiperazine derivatives as CB1 receptor inverse agonists via privileged structure-based approach. Eur J Med Chem. 2010 Mar;45(3):1133-9.
DMASO86	RU	https://pubmed.ncbi.nlm.nih.gov/20047779

DM02Q8N	DI	DM02Q8N
DM02Q8N	DN	4-Benzo[b]thiophen-4-yl-1H-imidazole
DM02Q8N	MI	TTNGILX
DM02Q8N	MN	Adrenergic receptor alpha-1A (ADRA1A)
DM02Q8N	MT	DTT
DM02Q8N	MA	Inhibitor
DM02Q8N	RN	alpha(2) Adrenoceptor agonists as potential analgesic agents. 2. Discovery of 4-(4-Imidazo)-1,3-dimethyl-6,7-dihydrothianaphthene [corrected] as a ... J Med Chem. 2000 Mar 9;43(5):765-8.
DM02Q8N	RU	https://pubmed.ncbi.nlm.nih.gov/10715142

DM02Q8N	DI	DM02Q8N
DM02Q8N	DN	4-Benzo[b]thiophen-4-yl-1H-imidazole
DM02Q8N	MI	TTBRKXS
DM02Q8N	MN	Adrenergic receptor alpha-1B (ADRA1B)
DM02Q8N	MT	DTT
DM02Q8N	MA	Inhibitor
DM02Q8N	RN	alpha(2) Adrenoceptor agonists as potential analgesic agents. 2. Discovery of 4-(4-Imidazo)-1,3-dimethyl-6,7-dihydrothianaphthene [corrected] as a ... J Med Chem. 2000 Mar 9;43(5):765-8.
DM02Q8N	RU	https://pubmed.ncbi.nlm.nih.gov/10715142

DM02Q8N	DI	DM02Q8N
DM02Q8N	DN	4-Benzo[b]thiophen-4-yl-1H-imidazole
DM02Q8N	MI	TT34BHT
DM02Q8N	MN	Adrenergic receptor alpha-1D (ADRA1D)
DM02Q8N	MT	DTT
DM02Q8N	MA	Inhibitor
DM02Q8N	RN	alpha(2) Adrenoceptor agonists as potential analgesic agents. 2. Discovery of 4-(4-Imidazo)-1,3-dimethyl-6,7-dihydrothianaphthene [corrected] as a ... J Med Chem. 2000 Mar 9;43(5):765-8.
DM02Q8N	RU	https://pubmed.ncbi.nlm.nih.gov/10715142

DM02Q8N	DI	DM02Q8N
DM02Q8N	DN	4-Benzo[b]thiophen-4-yl-1H-imidazole
DM02Q8N	MI	TTWG9A4
DM02Q8N	MN	Adrenergic receptor alpha-2A (ADRA2A)
DM02Q8N	MT	DTT
DM02Q8N	MA	Inhibitor
DM02Q8N	RN	Alpha(2) adrenoceptor agonists as potential analgesic agents. 2. Discovery of 4-(4-imidazo)-1,3-dimethyl-6,7-dihydro-thianaphthene as a high-affini... J Med Chem. 2000 Apr 6;43(7):1423-6.
DM02Q8N	RU	https://pubmed.ncbi.nlm.nih.gov/10753480

DM02Q8N	DI	DM02Q8N
DM02Q8N	DN	4-Benzo[b]thiophen-4-yl-1H-imidazole
DM02Q8N	MI	TTWM4TY
DM02Q8N	MN	Adrenergic receptor alpha-2B (ADRA2B)
DM02Q8N	MT	DTT
DM02Q8N	MA	Inhibitor
DM02Q8N	RN	alpha(2) Adrenoceptor agonists as potential analgesic agents. 2. Discovery of 4-(4-Imidazo)-1,3-dimethyl-6,7-dihydrothianaphthene [corrected] as a ... J Med Chem. 2000 Mar 9;43(5):765-8.
DM02Q8N	RU	https://pubmed.ncbi.nlm.nih.gov/10715142

DM1UG2A	DI	DM1UG2A
DM1UG2A	DN	4-Benzo[d]isoxazol-3-yl-benzene-1,3-diol
DM1UG2A	MI	TTZAYWL
DM1UG2A	MN	Estrogen receptor (ESR)
DM1UG2A	MT	DTT
DM1UG2A	MA	Inhibitor
DM1UG2A	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DM1UG2A	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DM1UG2A	DI	DM1UG2A
DM1UG2A	DN	4-Benzo[d]isoxazol-3-yl-benzene-1,3-diol
DM1UG2A	MI	TTOM3J0
DM1UG2A	MN	Estrogen receptor beta (ESR2)
DM1UG2A	MT	DTT
DM1UG2A	MA	Inhibitor
DM1UG2A	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DM1UG2A	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DM7AOGD	DI	DM7AOGD
DM7AOGD	DN	4-Benzoimidazol-1-yl-phenylamine
DM7AOGD	MI	TT8FYO9
DM7AOGD	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DM7AOGD	MT	DTT
DM7AOGD	MA	Inhibitor
DM7AOGD	RN	Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor. J Med Chem. 1998 Dec 31;41(27):5457-65.
DM7AOGD	RU	https://pubmed.ncbi.nlm.nih.gov/9876115

DM7AOGD	DI	DM7AOGD
DM7AOGD	DN	4-Benzoimidazol-1-yl-phenylamine
DM7AOGD	MI	TTI7421
DM7AOGD	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM7AOGD	MT	DTT
DM7AOGD	MA	Inhibitor
DM7AOGD	RN	Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor. J Med Chem. 1998 Dec 31;41(27):5457-65.
DM7AOGD	RU	https://pubmed.ncbi.nlm.nih.gov/9876115

DMA9DHE	DI	DMA9DHE
DMA9DHE	DN	4-Benzoxazo-2-yl-1,4-diazabicyclo[3.2.2]nonane
DMA9DHE	MI	TTPC4TU
DMA9DHE	MN	5-HT 3A receptor (HTR3A)
DMA9DHE	MT	DTT
DMA9DHE	MA	Inhibitor
DMA9DHE	RN	Discovery of 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a novel alpha 7 nicotinic acetylcholine receptor ag... J Med Chem. 2010 Feb 11;53(3):1222-37.
DMA9DHE	RU	https://pubmed.ncbi.nlm.nih.gov/20043678

DMYBPFS	DI	DMYBPFS
DMYBPFS	DN	4-Benzoylamino-N-hydroxy-benzamide
DMYBPFS	MI	TTBH0VX
DMYBPFS	MN	Histone deacetylase (HDAC)
DMYBPFS	MT	DTT
DMYBPFS	MA	Inhibitor
DMYBPFS	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMYBPFS	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMYBPFS	DI	DMYBPFS
DMYBPFS	DN	4-Benzoylamino-N-hydroxy-benzamide
DMYBPFS	MI	TT6R7JZ
DMYBPFS	MN	Histone deacetylase 1 (HDAC1)
DMYBPFS	MT	DTT
DMYBPFS	MA	Inhibitor
DMYBPFS	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMYBPFS	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMYBPFS	DI	DMYBPFS
DMYBPFS	DN	4-Benzoylamino-N-hydroxy-benzamide
DMYBPFS	MI	TTYHPU6
DMYBPFS	MN	Histone deacetylase 10 (HDAC10)
DMYBPFS	MT	DTT
DMYBPFS	MA	Inhibitor
DMYBPFS	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMYBPFS	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMYBPFS	DI	DMYBPFS
DMYBPFS	DN	4-Benzoylamino-N-hydroxy-benzamide
DMYBPFS	MI	TTSHTOI
DMYBPFS	MN	Histone deacetylase 2 (HDAC2)
DMYBPFS	MT	DTT
DMYBPFS	MA	Inhibitor
DMYBPFS	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMYBPFS	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMYBPFS	DI	DMYBPFS
DMYBPFS	DN	4-Benzoylamino-N-hydroxy-benzamide
DMYBPFS	MI	TTTQGH8
DMYBPFS	MN	Histone deacetylase 4 (HDAC4)
DMYBPFS	MT	DTT
DMYBPFS	MA	Inhibitor
DMYBPFS	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMYBPFS	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMYBPFS	DI	DMYBPFS
DMYBPFS	DN	4-Benzoylamino-N-hydroxy-benzamide
DMYBPFS	MI	TT5ZKDI
DMYBPFS	MN	Histone deacetylase 6 (HDAC6)
DMYBPFS	MT	DTT
DMYBPFS	MA	Inhibitor
DMYBPFS	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMYBPFS	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMYBPFS	DI	DMYBPFS
DMYBPFS	DN	4-Benzoylamino-N-hydroxy-benzamide
DMYBPFS	MI	TTT6LFV
DMYBPFS	MN	Histone deacetylase 8 (HDAC8)
DMYBPFS	MT	DTT
DMYBPFS	MA	Inhibitor
DMYBPFS	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMYBPFS	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMQZ0D6	DI	DMQZ0D6
DMQZ0D6	DN	4-Benzyl-1-(2-phenoxy-ethyl)-piperidine
DMQZ0D6	MI	TTLD29N
DMQZ0D6	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMQZ0D6	MT	DTT
DMQZ0D6	MA	Inhibitor
DMQZ0D6	RN	4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist. J Med Chem. 1999 Jul 29;42(15):2993-3000.
DMQZ0D6	RU	https://pubmed.ncbi.nlm.nih.gov/10425109

DMQZ0D6	DI	DMQZ0D6
DMQZ0D6	DN	4-Benzyl-1-(2-phenoxy-ethyl)-piperidine
DMQZ0D6	MI	TTN9D8E
DMQZ0D6	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMQZ0D6	MT	DTT
DMQZ0D6	MA	Inhibitor
DMQZ0D6	RN	4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist. J Med Chem. 1999 Jul 29;42(15):2993-3000.
DMQZ0D6	RU	https://pubmed.ncbi.nlm.nih.gov/10425109

DMIX6RG	DI	DMIX6RG
DMIX6RG	DN	4-Benzyl-1-[3-phenylpropoxy)propyl]piperidine
DMIX6RG	MI	TT9JNIC
DMIX6RG	MN	Histamine H3 receptor (H3R)
DMIX6RG	MT	DTT
DMIX6RG	MA	Inhibitor
DMIX6RG	RN	Piperidine variations in search for non-imidazole histamine H(3) receptor ligands. Bioorg Med Chem. 2008 Sep 15;16(18):8729-36.
DMIX6RG	RU	https://pubmed.ncbi.nlm.nih.gov/18774720

DM6XLZ0	DI	DM6XLZ0
DM6XLZ0	DN	4-Benzyl-1-chroman-2-ylmethyl-piperidine
DM6XLZ0	MI	TTSQIFT
DM6XLZ0	MN	5-HT 1A receptor (HTR1A)
DM6XLZ0	MT	DTT
DM6XLZ0	MA	Inhibitor
DM6XLZ0	RN	Synthesis and structure-activity relationships of 1-aralkyl-4-benzylpiperidine and 1-aralkyl-4-benzylpiperazine derivatives as potent sigma ligands. J Med Chem. 2005 Jan 13;48(1):266-73.
DM6XLZ0	RU	https://pubmed.ncbi.nlm.nih.gov/15634021

DM6XLZ0	DI	DM6XLZ0
DM6XLZ0	DN	4-Benzyl-1-chroman-2-ylmethyl-piperidine
DM6XLZ0	MI	TTEX248
DM6XLZ0	MN	Dopamine D2 receptor (D2R)
DM6XLZ0	MT	DTT
DM6XLZ0	MA	Inhibitor
DM6XLZ0	RN	Synthesis and structure-activity relationships of 1-aralkyl-4-benzylpiperidine and 1-aralkyl-4-benzylpiperazine derivatives as potent sigma ligands. J Med Chem. 2005 Jan 13;48(1):266-73.
DM6XLZ0	RU	https://pubmed.ncbi.nlm.nih.gov/15634021

DMAZMPF	DI	DMAZMPF
DMAZMPF	DN	4-Benzyl-1-chroman-3-ylmethyl-piperidine
DMAZMPF	MI	TTSQIFT
DMAZMPF	MN	5-HT 1A receptor (HTR1A)
DMAZMPF	MT	DTT
DMAZMPF	MA	Inhibitor
DMAZMPF	RN	Synthesis and structure-activity relationships of 1-aralkyl-4-benzylpiperidine and 1-aralkyl-4-benzylpiperazine derivatives as potent sigma ligands. J Med Chem. 2005 Jan 13;48(1):266-73.
DMAZMPF	RU	https://pubmed.ncbi.nlm.nih.gov/15634021

DMAZMPF	DI	DMAZMPF
DMAZMPF	DN	4-Benzyl-1-chroman-3-ylmethyl-piperidine
DMAZMPF	MI	TTEX248
DMAZMPF	MN	Dopamine D2 receptor (D2R)
DMAZMPF	MT	DTT
DMAZMPF	MA	Inhibitor
DMAZMPF	RN	Synthesis and structure-activity relationships of 1-aralkyl-4-benzylpiperidine and 1-aralkyl-4-benzylpiperazine derivatives as potent sigma ligands. J Med Chem. 2005 Jan 13;48(1):266-73.
DMAZMPF	RU	https://pubmed.ncbi.nlm.nih.gov/15634021

DMES9AJ	DI	DMES9AJ
DMES9AJ	DN	4-Benzyl-1-indan-2-ylmethyl-piperidine
DMES9AJ	MI	TTEX248
DMES9AJ	MN	Dopamine D2 receptor (D2R)
DMES9AJ	MT	DTT
DMES9AJ	MA	Inhibitor
DMES9AJ	RN	Synthesis and structure-activity relationships of 1-aralkyl-4-benzylpiperidine and 1-aralkyl-4-benzylpiperazine derivatives as potent sigma ligands. J Med Chem. 2005 Jan 13;48(1):266-73.
DMES9AJ	RU	https://pubmed.ncbi.nlm.nih.gov/15634021

DMQKCGI	DI	DMQKCGI
DMQKCGI	DN	4-Benzyl-1-methyl-piperidine hydrochloride
DMQKCGI	MI	TTJQOD7
DMQKCGI	MN	5-HT 2A receptor (HTR2A)
DMQKCGI	MT	DTT
DMQKCGI	MA	Inhibitor
DMQKCGI	RN	Ketanserin analogues: structure-affinity relationships for 5-HT2 and 5-HT1C serotonin receptor binding. J Med Chem. 1992 Dec 25;35(26):4903-10.
DMQKCGI	RU	https://pubmed.ncbi.nlm.nih.gov/1479590

DMAI6X2	DI	DMAI6X2
DMAI6X2	DN	4-Benzyl-1-phenethyl-piperidine hydrochloride
DMAI6X2	MI	TTLD29N
DMAI6X2	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMAI6X2	MT	DTT
DMAI6X2	MA	Inhibitor
DMAI6X2	RN	Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506.
DMAI6X2	RU	https://pubmed.ncbi.nlm.nih.gov/9719603

DMAI6X2	DI	DMAI6X2
DMAI6X2	DN	4-Benzyl-1-phenethyl-piperidine hydrochloride
DMAI6X2	MI	TTN9D8E
DMAI6X2	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMAI6X2	MT	DTT
DMAI6X2	MA	Inhibitor
DMAI6X2	RN	Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506.
DMAI6X2	RU	https://pubmed.ncbi.nlm.nih.gov/9719603

DM2Q0VB	DI	DM2Q0VB
DM2Q0VB	DN	4-benzyl-2,6-diisobutylamino-pyrimidine
DM2Q0VB	MI	TTZAYWL
DM2Q0VB	MN	Estrogen receptor (ESR)
DM2Q0VB	MT	DTT
DM2Q0VB	MA	Inhibitor
DM2Q0VB	RN	Blocking estrogen signaling after the hormone: pyrimidine-core inhibitors of estrogen receptor-coactivator binding. J Med Chem. 2008 Oct 23;51(20):6512-30.
DM2Q0VB	RU	https://pubmed.ncbi.nlm.nih.gov/18785725

DM8MVU4	DI	DM8MVU4
DM8MVU4	DN	4-benzyl-2-methylphthalazin-1(2H)-one
DM8MVU4	MI	TTNGILX
DM8MVU4	MN	Adrenergic receptor alpha-1A (ADRA1A)
DM8MVU4	MT	DTT
DM8MVU4	MA	Inhibitor
DM8MVU4	RN	Vasorelaxant activity of phthalazinones and related compounds. Bioorg Med Chem Lett. 2006 May 15;16(10):2786-90.
DM8MVU4	RU	https://pubmed.ncbi.nlm.nih.gov/16513345

DM8MVU4	DI	DM8MVU4
DM8MVU4	DN	4-benzyl-2-methylphthalazin-1(2H)-one
DM8MVU4	MI	TT34BHT
DM8MVU4	MN	Adrenergic receptor alpha-1D (ADRA1D)
DM8MVU4	MT	DTT
DM8MVU4	MA	Inhibitor
DM8MVU4	RN	Vasorelaxant activity of phthalazinones and related compounds. Bioorg Med Chem Lett. 2006 May 15;16(10):2786-90.
DM8MVU4	RU	https://pubmed.ncbi.nlm.nih.gov/16513345

DMZ18OJ	DI	DMZ18OJ
DMZ18OJ	DN	4-benzyl-5-(4-piperidyl)isothiazol-3-ol
DMZ18OJ	MI	TT1MPAY
DMZ18OJ	MN	GABA(A) receptor alpha-1 (GABRA1)
DMZ18OJ	MT	DTT
DMZ18OJ	MA	Inhibitor
DMZ18OJ	RN	Potent 4-arylalkyl-substituted 3-isothiazolol GABA(A) competitive/noncompetitive antagonists: synthesis and pharmacology. J Med Chem. 2006 Feb 23;49(4):1388-96.
DMZ18OJ	RU	https://pubmed.ncbi.nlm.nih.gov/16480274

DMZ18OJ	DI	DMZ18OJ
DMZ18OJ	DN	4-benzyl-5-(4-piperidyl)isothiazol-3-ol
DMZ18OJ	MI	TT06RH5
DMZ18OJ	MN	GABA(A) receptor gamma-2 (GABRG2)
DMZ18OJ	MT	DTT
DMZ18OJ	MA	Inhibitor
DMZ18OJ	RN	Potent 4-arylalkyl-substituted 3-isothiazolol GABA(A) competitive/noncompetitive antagonists: synthesis and pharmacology. J Med Chem. 2006 Feb 23;49(4):1388-96.
DMZ18OJ	RU	https://pubmed.ncbi.nlm.nih.gov/16480274

DMZ18OJ	DI	DMZ18OJ
DMZ18OJ	DN	4-benzyl-5-(4-piperidyl)isothiazol-3-ol
DMZ18OJ	MI	TTNJYV2
DMZ18OJ	MN	Gamma-aminobutyric acid receptor (GAR)
DMZ18OJ	MT	DTT
DMZ18OJ	MA	Inhibitor
DMZ18OJ	RN	Potent 4-arylalkyl-substituted 3-isothiazolol GABA(A) competitive/noncompetitive antagonists: synthesis and pharmacology. J Med Chem. 2006 Feb 23;49(4):1388-96.
DMZ18OJ	RU	https://pubmed.ncbi.nlm.nih.gov/16480274

DMA4CZK	DI	DMA4CZK
DMA4CZK	DN	4-Benzyl-5-piperidin-4-yl-isoxazol-3-ol
DMA4CZK	MI	TT1MPAY
DMA4CZK	MN	GABA(A) receptor alpha-1 (GABRA1)
DMA4CZK	MT	DTT
DMA4CZK	MA	Inhibitor
DMA4CZK	RN	Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling. J Med Chem. 2005 Jan 27;48(2):427-39.
DMA4CZK	RU	https://pubmed.ncbi.nlm.nih.gov/15658856

DMA4CZK	DI	DMA4CZK
DMA4CZK	DN	4-Benzyl-5-piperidin-4-yl-isoxazol-3-ol
DMA4CZK	MI	TTZA1NY
DMA4CZK	MN	GABA(A) receptor beta-2 (GABRB2)
DMA4CZK	MT	DTT
DMA4CZK	MA	Inhibitor
DMA4CZK	RN	Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling. J Med Chem. 2005 Jan 27;48(2):427-39.
DMA4CZK	RU	https://pubmed.ncbi.nlm.nih.gov/15658856

DMA4CZK	DI	DMA4CZK
DMA4CZK	DN	4-Benzyl-5-piperidin-4-yl-isoxazol-3-ol
DMA4CZK	MI	TT06RH5
DMA4CZK	MN	GABA(A) receptor gamma-2 (GABRG2)
DMA4CZK	MT	DTT
DMA4CZK	MA	Inhibitor
DMA4CZK	RN	Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling. J Med Chem. 2005 Jan 27;48(2):427-39.
DMA4CZK	RU	https://pubmed.ncbi.nlm.nih.gov/15658856

DMA4CZK	DI	DMA4CZK
DMA4CZK	DN	4-Benzyl-5-piperidin-4-yl-isoxazol-3-ol
DMA4CZK	MI	TTNJYV2
DMA4CZK	MN	Gamma-aminobutyric acid receptor (GAR)
DMA4CZK	MT	DTT
DMA4CZK	MA	Inhibitor
DMA4CZK	RN	Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling. J Med Chem. 2005 Jan 27;48(2):427-39.
DMA4CZK	RU	https://pubmed.ncbi.nlm.nih.gov/15658856

DMOBC0F	DI	DMOBC0F
DMOBC0F	DN	4-Benzyl-6-nitro-2-piperazin-1-yl-quinoline
DMOBC0F	MI	TT3ROYC
DMOBC0F	MN	Serotonin transporter (SERT)
DMOBC0F	MT	DTT
DMOBC0F	MA	Inhibitor
DMOBC0F	RN	Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 2: 4-substituted 6-nitroquipazines. Bioorg Med Chem Lett. 2002 Mar 11;12(5):811-5.
DMOBC0F	RU	https://pubmed.ncbi.nlm.nih.gov/11859009

DMDC7TL	DI	DMDC7TL
DMDC7TL	DN	4-benzyloxy-2'-hydroxychalcone
DMDC7TL	MI	TTVKILB
DMDC7TL	MN	Prostaglandin G/H synthase 2 (COX-2)
DMDC7TL	MT	DTT
DMDC7TL	MA	Inhibitor
DMDC7TL	RN	Inhibitory activity of prostaglandin E2 production by the synthetic 2'-hydroxychalcone analogues: Synthesis and SAR study. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1650-3.
DMDC7TL	RU	https://pubmed.ncbi.nlm.nih.gov/19233646

DM0T1NZ	DI	DM0T1NZ
DM0T1NZ	DN	4-Benzyloxybenzo[b]thiophene-2-carboxamidine
DM0T1NZ	MI	TTFEZ5Q
DM0T1NZ	MN	Coagulation factor IX (F9)
DM0T1NZ	MT	DTT
DM0T1NZ	MA	Inhibitor
DM0T1NZ	RN	Studies of benzothiophene template as potent factor IXa (FIXa) inhibitors in thrombosis. J Med Chem. 2010 Feb 25;53(4):1465-72.
DM0T1NZ	RU	https://pubmed.ncbi.nlm.nih.gov/20121198

DMA5FEM	DI	DMA5FEM
DMA5FEM	DN	4-benzylphthalazin-1(2H)-one
DMA5FEM	MI	TTVDSZ0
DMA5FEM	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMA5FEM	MT	DTT
DMA5FEM	MA	Inhibitor
DMA5FEM	RN	Design, synthesis, and cytoprotective effect of 2-aminothiazole analogues as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2009 Feb 12;52(3):718-25.
DMA5FEM	RU	https://pubmed.ncbi.nlm.nih.gov/19125579

DMI1EFY	DI	DMI1EFY
DMI1EFY	DN	4-Benzythiopyridine-3-sulfonamide
DMI1EFY	MI	TTHQPL7
DMI1EFY	MN	Carbonic anhydrase I (CA-I)
DMI1EFY	MT	DTT
DMI1EFY	MA	Inhibitor
DMI1EFY	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMI1EFY	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMI1EFY	DI	DMI1EFY
DMI1EFY	DN	4-Benzythiopyridine-3-sulfonamide
DMI1EFY	MI	TTANPDJ
DMI1EFY	MN	Carbonic anhydrase II (CA-II)
DMI1EFY	MT	DTT
DMI1EFY	MA	Inhibitor
DMI1EFY	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMI1EFY	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMI1EFY	DI	DMI1EFY
DMI1EFY	DN	4-Benzythiopyridine-3-sulfonamide
DMI1EFY	MI	TT2LVK8
DMI1EFY	MN	Carbonic anhydrase IX (CA-IX)
DMI1EFY	MT	DTT
DMI1EFY	MA	Inhibitor
DMI1EFY	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMI1EFY	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMI1EFY	DI	DMI1EFY
DMI1EFY	DN	4-Benzythiopyridine-3-sulfonamide
DMI1EFY	MI	TTSYM0R
DMI1EFY	MN	Carbonic anhydrase XII (CA-XII)
DMI1EFY	MT	DTT
DMI1EFY	MA	Inhibitor
DMI1EFY	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMI1EFY	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMI1EFY	DI	DMI1EFY
DMI1EFY	DN	4-Benzythiopyridine-3-sulfonamide
DMI1EFY	MI	TTEYTKG
DMI1EFY	MN	Carbonic anhydrase XIV (CA-XIV)
DMI1EFY	MT	DTT
DMI1EFY	MA	Inhibitor
DMI1EFY	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMI1EFY	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMDF3KJ	DI	DMDF3KJ
DMDF3KJ	DN	4beta,15-epoxy-miller-9E-enolide
DMDF3KJ	MI	TTSXVID
DMDF3KJ	MN	Nuclear factor NF-kappa-B (NFKB)
DMDF3KJ	MT	DTT
DMDF3KJ	MA	Inhibitor
DMDF3KJ	RN	Development of a structural model for NF-kappaB inhibition of sesquiterpene lactones using self-organizing neural networks. J Med Chem. 2006 Apr 6;49(7):2241-52.
DMDF3KJ	RU	https://pubmed.ncbi.nlm.nih.gov/16570920

DMZ01SV	DI	DMZ01SV
DMZ01SV	DN	4beta,15-epoxy-miller-9Z-enolide
DMZ01SV	MI	TTSXVID
DMZ01SV	MN	Nuclear factor NF-kappa-B (NFKB)
DMZ01SV	MT	DTT
DMZ01SV	MA	Inhibitor
DMZ01SV	RN	Development of a structural model for NF-kappaB inhibition of sesquiterpene lactones using self-organizing neural networks. J Med Chem. 2006 Apr 6;49(7):2241-52.
DMZ01SV	RU	https://pubmed.ncbi.nlm.nih.gov/16570920

DM3B2TG	DI	DM3B2TG
DM3B2TG	DN	4-Biphenyl-2-ylethynyl-2-methyl-thiazole
DM3B2TG	MI	TTHS256
DM3B2TG	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM3B2TG	MT	DTT
DM3B2TG	MA	Inhibitor
DM3B2TG	RN	5-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-2,3'-bipyridine: a highly potent, orally active metabotropic glutamate subtype 5 (mGlu5) receptor antagonist... Bioorg Med Chem Lett. 2004 Aug 2;14(15):3993-6.
DM3B2TG	RU	https://pubmed.ncbi.nlm.nih.gov/15225713

DMYUL9J	DI	DMYUL9J
DMYUL9J	DN	4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline
DMYUL9J	MI	TTGKNB4
DMYUL9J	MN	Epidermal growth factor receptor (EGFR)
DMYUL9J	MT	DTT
DMYUL9J	MA	Inhibitor
DMYUL9J	RN	Synthesis and inhibitory activity of 4-alkynyl and 4-alkenylquinazolines: identification of new scaffolds for potent EGFR tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5863-7.
DMYUL9J	RU	https://pubmed.ncbi.nlm.nih.gov/17869510

DML6PTX	DI	DML6PTX
DML6PTX	DN	4-Biphenyl-4-yl-2-(1-pentyl-hexyl)-1H-imidazole
DML6PTX	MI	TTRK8B9
DML6PTX	MN	Sodium channel unspecific (NaC)
DML6PTX	MT	DTT
DML6PTX	MA	Inhibitor
DML6PTX	RN	2-Alkyl-4-arylimidazoles: structurally novel sodium channel modulators. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3521-3.
DML6PTX	RU	https://pubmed.ncbi.nlm.nih.gov/15177465

DML6PTX	DI	DML6PTX
DML6PTX	DN	4-Biphenyl-4-yl-2-(1-pentyl-hexyl)-1H-imidazole
DML6PTX	MI	TTAXZ0K
DML6PTX	MN	Voltage-gated sodium channel alpha Nav1.3 (SCN3A)
DML6PTX	MT	DTT
DML6PTX	MA	Inhibitor
DML6PTX	RN	2-Alkyl-4-arylimidazoles: structurally novel sodium channel modulators. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3521-3.
DML6PTX	RU	https://pubmed.ncbi.nlm.nih.gov/15177465

DM2I13S	DI	DM2I13S
DM2I13S	DN	4-Biphenyl-4-yl-2-(1-propyl-butyl)-1H-imidazole
DM2I13S	MI	TTRK8B9
DM2I13S	MN	Sodium channel unspecific (NaC)
DM2I13S	MT	DTT
DM2I13S	MA	Inhibitor
DM2I13S	RN	2-Alkyl-4-arylimidazoles: structurally novel sodium channel modulators. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3521-3.
DM2I13S	RU	https://pubmed.ncbi.nlm.nih.gov/15177465

DM2I13S	DI	DM2I13S
DM2I13S	DN	4-Biphenyl-4-yl-2-(1-propyl-butyl)-1H-imidazole
DM2I13S	MI	TTAXZ0K
DM2I13S	MN	Voltage-gated sodium channel alpha Nav1.3 (SCN3A)
DM2I13S	MT	DTT
DM2I13S	MA	Inhibitor
DM2I13S	RN	2-Alkyl-4-arylimidazoles: structurally novel sodium channel modulators. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3521-3.
DM2I13S	RU	https://pubmed.ncbi.nlm.nih.gov/15177465

DMLSUXD	DI	DMLSUXD
DMLSUXD	DN	4-Biphenyl-4-yl-2-cyclohexylmethyl-1H-imidazole
DMLSUXD	MI	TTRK8B9
DMLSUXD	MN	Sodium channel unspecific (NaC)
DMLSUXD	MT	DTT
DMLSUXD	MA	Inhibitor
DMLSUXD	RN	2-Alkyl-4-arylimidazoles: structurally novel sodium channel modulators. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3521-3.
DMLSUXD	RU	https://pubmed.ncbi.nlm.nih.gov/15177465

DMLSUXD	DI	DMLSUXD
DMLSUXD	DN	4-Biphenyl-4-yl-2-cyclohexylmethyl-1H-imidazole
DMLSUXD	MI	TTAXZ0K
DMLSUXD	MN	Voltage-gated sodium channel alpha Nav1.3 (SCN3A)
DMLSUXD	MT	DTT
DMLSUXD	MA	Inhibitor
DMLSUXD	RN	2-Alkyl-4-arylimidazoles: structurally novel sodium channel modulators. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3521-3.
DMLSUXD	RU	https://pubmed.ncbi.nlm.nih.gov/15177465

DMPIH4L	DI	DMPIH4L
DMPIH4L	DN	4-Biphenyl-4-yl-2-hexyl-1H-imidazole
DMPIH4L	MI	TTRK8B9
DMPIH4L	MN	Sodium channel unspecific (NaC)
DMPIH4L	MT	DTT
DMPIH4L	MA	Inhibitor
DMPIH4L	RN	2-Alkyl-4-arylimidazoles: structurally novel sodium channel modulators. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3521-3.
DMPIH4L	RU	https://pubmed.ncbi.nlm.nih.gov/15177465

DMPIH4L	DI	DMPIH4L
DMPIH4L	DN	4-Biphenyl-4-yl-2-hexyl-1H-imidazole
DMPIH4L	MI	TTAXZ0K
DMPIH4L	MN	Voltage-gated sodium channel alpha Nav1.3 (SCN3A)
DMPIH4L	MT	DTT
DMPIH4L	MA	Inhibitor
DMPIH4L	RN	2-Alkyl-4-arylimidazoles: structurally novel sodium channel modulators. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3521-3.
DMPIH4L	RU	https://pubmed.ncbi.nlm.nih.gov/15177465

DMNLC2Y	DI	DMNLC2Y
DMNLC2Y	DN	4-Biphenyl-4-yl-2-methyl-1H-imidazole
DMNLC2Y	MI	TTRK8B9
DMNLC2Y	MN	Sodium channel unspecific (NaC)
DMNLC2Y	MT	DTT
DMNLC2Y	MA	Inhibitor
DMNLC2Y	RN	2-Alkyl-4-arylimidazoles: structurally novel sodium channel modulators. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3521-3.
DMNLC2Y	RU	https://pubmed.ncbi.nlm.nih.gov/15177465

DMNLC2Y	DI	DMNLC2Y
DMNLC2Y	DN	4-Biphenyl-4-yl-2-methyl-1H-imidazole
DMNLC2Y	MI	TTAXZ0K
DMNLC2Y	MN	Voltage-gated sodium channel alpha Nav1.3 (SCN3A)
DMNLC2Y	MT	DTT
DMNLC2Y	MA	Inhibitor
DMNLC2Y	RN	2-Alkyl-4-arylimidazoles: structurally novel sodium channel modulators. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3521-3.
DMNLC2Y	RU	https://pubmed.ncbi.nlm.nih.gov/15177465

DMCQYKO	DI	DMCQYKO
DMCQYKO	DN	4-Biphenyl-4-ylethynyl-2-methyl-thiazole
DMCQYKO	MI	TTHS256
DMCQYKO	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMCQYKO	MT	DTT
DMCQYKO	MA	Inhibitor
DMCQYKO	RN	5-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-2,3'-bipyridine: a highly potent, orally active metabotropic glutamate subtype 5 (mGlu5) receptor antagonist... Bioorg Med Chem Lett. 2004 Aug 2;14(15):3993-6.
DMCQYKO	RU	https://pubmed.ncbi.nlm.nih.gov/15225713

DMS0JVE	DI	DMS0JVE
DMS0JVE	DN	4BP-TQS
DMS0JVE	MI	TTLA931
DMS0JVE	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMS0JVE	MT	DTT
DMS0JVE	MA	Agonist
DMS0JVE	RN	Agonist activation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site. Proc Natl Acad Sci U S A. 2011 Apr 5;108(14):5867-72.
DMS0JVE	RU	https://pubmed.ncbi.nlm.nih.gov/21436053

DM81D90	DI	DM81D90
DM81D90	DN	4-bromo-1H-indazole
DM81D90	MI	TTZUFI5
DM81D90	MN	Nitric-oxide synthase brain (NOS1)
DM81D90	MT	DTT
DM81D90	MA	Inhibitor
DM81D90	RN	4-substituted indazoles as new inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3177-80.
DM81D90	RU	https://pubmed.ncbi.nlm.nih.gov/17395463

DMMVASI	DI	DMMVASI
DMMVASI	DN	4-Bromo-1-imidazol-1-ylmethyl-xanthen-9-one
DMMVASI	MI	TTSZLWK
DMMVASI	MN	Aromatase (CYP19A1)
DMMVASI	MT	DTT
DMMVASI	MA	Inhibitor
DMMVASI	RN	A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase. J Med Chem. 2001 Mar 1;44(5):672-80.
DMMVASI	RU	https://pubmed.ncbi.nlm.nih.gov/11262078

DMMVASI	DI	DMMVASI
DMMVASI	DN	4-Bromo-1-imidazol-1-ylmethyl-xanthen-9-one
DMMVASI	MI	TTRA5BZ
DMMVASI	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMMVASI	MT	DTT
DMMVASI	MA	Inhibitor
DMMVASI	RN	A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase. J Med Chem. 2001 Mar 1;44(5):672-80.
DMMVASI	RU	https://pubmed.ncbi.nlm.nih.gov/11262078

DMPSRAC	DI	DMPSRAC
DMPSRAC	DN	4-Bromo-2-(4-hydroxy-phenyl)-quinolin-6-ol
DMPSRAC	MI	TTZAYWL
DMPSRAC	MN	Estrogen receptor (ESR)
DMPSRAC	MT	DTT
DMPSRAC	MA	Inhibitor
DMPSRAC	RN	ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5.
DMPSRAC	RU	https://pubmed.ncbi.nlm.nih.gov/16098741

DMPSRAC	DI	DMPSRAC
DMPSRAC	DN	4-Bromo-2-(4-hydroxy-phenyl)-quinolin-6-ol
DMPSRAC	MI	TTOM3J0
DMPSRAC	MN	Estrogen receptor beta (ESR2)
DMPSRAC	MT	DTT
DMPSRAC	MA	Inhibitor
DMPSRAC	RN	ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5.
DMPSRAC	RU	https://pubmed.ncbi.nlm.nih.gov/16098741

DMPSRAC	DI	DMPSRAC
DMPSRAC	DN	4-Bromo-2-(4-hydroxy-phenyl)-quinolin-6-ol
DMPSRAC	MI	TTPNQAC
DMPSRAC	MN	Estrogen-related receptor-alpha (ESRRA)
DMPSRAC	MT	DTT
DMPSRAC	MA	Inhibitor
DMPSRAC	RN	ERbeta ligands. Part 6: 6H-Chromeno[4,3-b]quinolines as a new series of estrogen receptor beta-selective ligands. Bioorg Med Chem Lett. 2007 Jul 15;17(14):4053-6.
DMPSRAC	RU	https://pubmed.ncbi.nlm.nih.gov/17482813

DMY8TLO	DI	DMY8TLO
DMY8TLO	DN	4-Bromo-2,6-diisopropyl-phenol
DMY8TLO	MI	TTNJYV2
DMY8TLO	MN	Gamma-aminobutyric acid receptor (GAR)
DMY8TLO	MT	DTT
DMY8TLO	MA	Inhibitor
DMY8TLO	RN	Propofol analogues. Synthesis, relationships between structure and affinity at GABAA receptor in rat brain, and differential electrophysiological p... J Med Chem. 1998 May 21;41(11):1846-54.
DMY8TLO	RU	https://pubmed.ncbi.nlm.nih.gov/9599235

DMK2PBJ	DI	DMK2PBJ
DMK2PBJ	DN	4'-bromo-3-(imidazolylmethyl)-7-methoxyflavone
DMK2PBJ	MI	TTSZLWK
DMK2PBJ	MN	Aromatase (CYP19A1)
DMK2PBJ	MT	DTT
DMK2PBJ	MA	Inhibitor
DMK2PBJ	RN	Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme. J Med Chem. 2006 Jul 27;49(15):4777-80.
DMK2PBJ	RU	https://pubmed.ncbi.nlm.nih.gov/16854084

DM2V3S8	DI	DM2V3S8
DM2V3S8	DN	4'-bromo-3-(imidazolylmethyl)flavone
DM2V3S8	MI	TTSZLWK
DM2V3S8	MN	Aromatase (CYP19A1)
DM2V3S8	MT	DTT
DM2V3S8	MA	Inhibitor
DM2V3S8	RN	Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme. J Med Chem. 2006 Jul 27;49(15):4777-80.
DM2V3S8	RU	https://pubmed.ncbi.nlm.nih.gov/16854084

DMYOCFX	DI	DMYOCFX
DMYOCFX	DN	4-Bromo-3-hydroxy-1H-quinolin-2-one
DMYOCFX	MI	TTLD29N
DMYOCFX	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMYOCFX	MT	DTT
DMYOCFX	MA	Inhibitor
DMYOCFX	RN	3-Hydroxy-quinolin-2-ones: Inhibitors of [3H]-glycine binding to the site associated with the NMDA receptor, Bioorg. Med. Chem. Lett. 6(5):499-504 (1996).
DMYOCFX	RU	http://www.sciencedirect.com/science/article/pii/0960894X96000315

DMYOCFX	DI	DMYOCFX
DMYOCFX	DN	4-Bromo-3-hydroxy-1H-quinolin-2-one
DMYOCFX	MI	TTKJEMQ
DMYOCFX	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMYOCFX	MT	DTT
DMYOCFX	MA	Inhibitor
DMYOCFX	RN	3-Hydroxy-quinolin-2-ones: Inhibitors of [3H]-glycine binding to the site associated with the NMDA receptor, Bioorg. Med. Chem. Lett. 6(5):499-504 (1996).
DMYOCFX	RU	http://www.sciencedirect.com/science/article/pii/0960894X96000315

DMYOCFX	DI	DMYOCFX
DMYOCFX	DN	4-Bromo-3-hydroxy-1H-quinolin-2-one
DMYOCFX	MI	TTN9D8E
DMYOCFX	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMYOCFX	MT	DTT
DMYOCFX	MA	Inhibitor
DMYOCFX	RN	3-Hydroxy-quinolin-2-ones: Inhibitors of [3H]-glycine binding to the site associated with the NMDA receptor, Bioorg. Med. Chem. Lett. 6(5):499-504 (1996).
DMYOCFX	RU	http://www.sciencedirect.com/science/article/pii/0960894X96000315

DM2QJ5A	DI	DM2QJ5A
DM2QJ5A	DN	4-Bromo-5,7-dichloro-3-hydroxy-1H-quinolin-2-one
DM2QJ5A	MI	TTLD29N
DM2QJ5A	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DM2QJ5A	MT	DTT
DM2QJ5A	MA	Inhibitor
DM2QJ5A	RN	3-Hydroxy-quinolin-2-ones: Inhibitors of [3H]-glycine binding to the site associated with the NMDA receptor, Bioorg. Med. Chem. Lett. 6(5):499-504 (1996).
DM2QJ5A	RU	http://www.sciencedirect.com/science/article/pii/0960894X96000315

DM2QJ5A	DI	DM2QJ5A
DM2QJ5A	DN	4-Bromo-5,7-dichloro-3-hydroxy-1H-quinolin-2-one
DM2QJ5A	MI	TTKJEMQ
DM2QJ5A	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DM2QJ5A	MT	DTT
DM2QJ5A	MA	Inhibitor
DM2QJ5A	RN	3-Hydroxy-quinolin-2-ones: Inhibitors of [3H]-glycine binding to the site associated with the NMDA receptor, Bioorg. Med. Chem. Lett. 6(5):499-504 (1996).
DM2QJ5A	RU	http://www.sciencedirect.com/science/article/pii/0960894X96000315

DM2QJ5A	DI	DM2QJ5A
DM2QJ5A	DN	4-Bromo-5,7-dichloro-3-hydroxy-1H-quinolin-2-one
DM2QJ5A	MI	TTN9D8E
DM2QJ5A	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DM2QJ5A	MT	DTT
DM2QJ5A	MA	Inhibitor
DM2QJ5A	RN	3-Hydroxy-quinolin-2-ones: Inhibitors of [3H]-glycine binding to the site associated with the NMDA receptor, Bioorg. Med. Chem. Lett. 6(5):499-504 (1996).
DM2QJ5A	RU	http://www.sciencedirect.com/science/article/pii/0960894X96000315

DMH6OPI	DI	DMH6OPI
DMH6OPI	DN	4-Bromo-6-nitro-2-piperazin-1-yl-quinoline
DMH6OPI	MI	TT3ROYC
DMH6OPI	MN	Serotonin transporter (SERT)
DMH6OPI	MT	DTT
DMH6OPI	MA	Inhibitor
DMH6OPI	RN	Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 2: 4-substituted 6-nitroquipazines. Bioorg Med Chem Lett. 2002 Mar 11;12(5):811-5.
DMH6OPI	RU	https://pubmed.ncbi.nlm.nih.gov/11859009

DMJFY9Z	DI	DMJFY9Z
DMJFY9Z	DN	4-Bromo-N-(4-phenyl-thiazol-2-yl)-benzamide
DMJFY9Z	MI	TTK25J1
DMJFY9Z	MN	Adenosine A1 receptor (ADORA1)
DMJFY9Z	MT	DTT
DMJFY9Z	MA	Inhibitor
DMJFY9Z	RN	Substituted 4-phenyl-2-(phenylcarboxamido)-1,3-thiazole derivatives as antagonists for the adenosine A(1) receptor. Bioorg Med Chem Lett. 2001 Aug 6;11(15):2017-9.
DMJFY9Z	RU	https://pubmed.ncbi.nlm.nih.gov/11454470

DMF38M5	DI	DMF38M5
DMF38M5	DN	4-Bromo-N-hydroxy-benzamide
DMF38M5	MI	TT2J34L
DMF38M5	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMF38M5	MT	DTT
DMF38M5	MA	Inhibitor
DMF38M5	RN	Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8.
DMF38M5	RU	https://pubmed.ncbi.nlm.nih.gov/2308149

DM2YN37	DI	DM2YN37
DM2YN37	DN	4-bromophenylboronic acid
DM2YN37	MI	TTUNARX
DM2YN37	MN	Carbonic anhydrase (CA)
DM2YN37	MT	DTT
DM2YN37	MA	Inhibitor
DM2YN37	RN	Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5.
DM2YN37	RU	https://pubmed.ncbi.nlm.nih.gov/19375309

DM2YN37	DI	DM2YN37
DM2YN37	DN	4-bromophenylboronic acid
DM2YN37	MI	TTHQPL7
DM2YN37	MN	Carbonic anhydrase I (CA-I)
DM2YN37	MT	DTT
DM2YN37	MA	Inhibitor
DM2YN37	RN	Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5.
DM2YN37	RU	https://pubmed.ncbi.nlm.nih.gov/19375309

DM2YN37	DI	DM2YN37
DM2YN37	DN	4-bromophenylboronic acid
DM2YN37	MI	TTANPDJ
DM2YN37	MN	Carbonic anhydrase II (CA-II)
DM2YN37	MT	DTT
DM2YN37	MA	Inhibitor
DM2YN37	RN	Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5.
DM2YN37	RU	https://pubmed.ncbi.nlm.nih.gov/19375309

DMMGK2B	DI	DMMGK2B
DMMGK2B	DN	4-Butoxy-N-hydroxycarbamoylmethyl-benzamide
DMMGK2B	MI	TTMX39J
DMMGK2B	MN	Matrix metalloproteinase-1 (MMP-1)
DMMGK2B	MT	DTT
DMMGK2B	MA	Inhibitor
DMMGK2B	RN	Receptor flexibility in de novo ligand design and docking. J Med Chem. 2005 Oct 20;48(21):6585-96.
DMMGK2B	RU	https://pubmed.ncbi.nlm.nih.gov/16220975

DMFCB7L	DI	DMFCB7L
DMFCB7L	DN	4-Butoxy-N-hydroxy-N-methyl-benzamide
DMFCB7L	MI	TT2J34L
DMFCB7L	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMFCB7L	MT	DTT
DMFCB7L	MA	Inhibitor
DMFCB7L	RN	Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8.
DMFCB7L	RU	https://pubmed.ncbi.nlm.nih.gov/2308149

DM6ADJM	DI	DM6ADJM
DM6ADJM	DN	4-Butyl-1-[3-(phenylpropoxy)propyl]piperidine
DM6ADJM	MI	TT9JNIC
DM6ADJM	MN	Histamine H3 receptor (H3R)
DM6ADJM	MT	DTT
DM6ADJM	MA	Inhibitor
DM6ADJM	RN	Piperidine variations in search for non-imidazole histamine H(3) receptor ligands. Bioorg Med Chem. 2008 Sep 15;16(18):8729-36.
DM6ADJM	RU	https://pubmed.ncbi.nlm.nih.gov/18774720

DMZHGP6	DI	DMZHGP6
DMZHGP6	DN	4-butyl-N-(7-hydroxynaphthalen-1-yl)benzamide
DMZHGP6	MI	TTMI6F5
DMZHGP6	MN	Transient receptor potential cation channel V1 (TRPV1)
DMZHGP6	MT	DTT
DMZHGP6	MA	Inhibitor
DMZHGP6	RN	N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4.
DMZHGP6	RU	https://pubmed.ncbi.nlm.nih.gov/18359227

DMHLQSE	DI	DMHLQSE
DMHLQSE	DN	4-butyl-N-(isoquinolin-5-yl)benzamide
DMHLQSE	MI	TTMI6F5
DMHLQSE	MN	Transient receptor potential cation channel V1 (TRPV1)
DMHLQSE	MT	DTT
DMHLQSE	MA	Inhibitor
DMHLQSE	RN	N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4.
DMHLQSE	RU	https://pubmed.ncbi.nlm.nih.gov/18359227

DMGW9XJ	DI	DMGW9XJ
DMGW9XJ	DN	4-butyl-N-(pyridin-3-yl)benzamide
DMGW9XJ	MI	TTMI6F5
DMGW9XJ	MN	Transient receptor potential cation channel V1 (TRPV1)
DMGW9XJ	MT	DTT
DMGW9XJ	MA	Inhibitor
DMGW9XJ	RN	N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4.
DMGW9XJ	RU	https://pubmed.ncbi.nlm.nih.gov/18359227

DMRMGWF	DI	DMRMGWF
DMRMGWF	DN	4-butyl-N-(quinolin-3-yl)benzamide
DMRMGWF	MI	TTMI6F5
DMRMGWF	MN	Transient receptor potential cation channel V1 (TRPV1)
DMRMGWF	MT	DTT
DMRMGWF	MA	Inhibitor
DMRMGWF	RN	N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4.
DMRMGWF	RU	https://pubmed.ncbi.nlm.nih.gov/18359227

DMIMW1E	DI	DMIMW1E
DMIMW1E	DN	4-butyl-N-phenylbenzamide
DMIMW1E	MI	TTMI6F5
DMIMW1E	MN	Transient receptor potential cation channel V1 (TRPV1)
DMIMW1E	MT	DTT
DMIMW1E	MA	Inhibitor
DMIMW1E	RN	N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4.
DMIMW1E	RU	https://pubmed.ncbi.nlm.nih.gov/18359227

DMD9FZW	DI	DMD9FZW
DMD9FZW	DN	4-butylphenylboronic acid
DMD9FZW	MI	TTUNARX
DMD9FZW	MN	Carbonic anhydrase (CA)
DMD9FZW	MT	DTT
DMD9FZW	MA	Inhibitor
DMD9FZW	RN	Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5.
DMD9FZW	RU	https://pubmed.ncbi.nlm.nih.gov/19375309

DMD9FZW	DI	DMD9FZW
DMD9FZW	DN	4-butylphenylboronic acid
DMD9FZW	MI	TTHQPL7
DMD9FZW	MN	Carbonic anhydrase I (CA-I)
DMD9FZW	MT	DTT
DMD9FZW	MA	Inhibitor
DMD9FZW	RN	Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5.
DMD9FZW	RU	https://pubmed.ncbi.nlm.nih.gov/19375309

DMD9FZW	DI	DMD9FZW
DMD9FZW	DN	4-butylphenylboronic acid
DMD9FZW	MI	TTANPDJ
DMD9FZW	MN	Carbonic anhydrase II (CA-II)
DMD9FZW	MT	DTT
DMD9FZW	MA	Inhibitor
DMD9FZW	RN	Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5.
DMD9FZW	RU	https://pubmed.ncbi.nlm.nih.gov/19375309

DMKU4TR	DI	DMKU4TR
DMKU4TR	DN	4-Butyl-thiazolidin-(2E)-ylideneamine
DMKU4TR	MI	TTZUFI5
DMKU4TR	MN	Nitric-oxide synthase brain (NOS1)
DMKU4TR	MT	DTT
DMKU4TR	MA	Inhibitor
DMKU4TR	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DMKU4TR	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DMKU4TR	DI	DMKU4TR
DMKU4TR	DN	4-Butyl-thiazolidin-(2E)-ylideneamine
DMKU4TR	MI	TTF10I9
DMKU4TR	MN	Nitric-oxide synthase inducible (NOS2)
DMKU4TR	MT	DTT
DMKU4TR	MA	Inhibitor
DMKU4TR	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DMKU4TR	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DMRY6B4	DI	DMRY6B4
DMRY6B4	DN	4-Butyrylamino-N-hydroxy-benzamide
DMRY6B4	MI	TTBH0VX
DMRY6B4	MN	Histone deacetylase (HDAC)
DMRY6B4	MT	DTT
DMRY6B4	MA	Inhibitor
DMRY6B4	RN	Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74.
DMRY6B4	RU	https://pubmed.ncbi.nlm.nih.gov/14711316

DMRY6B4	DI	DMRY6B4
DMRY6B4	DN	4-Butyrylamino-N-hydroxy-benzamide
DMRY6B4	MI	TT6R7JZ
DMRY6B4	MN	Histone deacetylase 1 (HDAC1)
DMRY6B4	MT	DTT
DMRY6B4	MA	Inhibitor
DMRY6B4	RN	Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74.
DMRY6B4	RU	https://pubmed.ncbi.nlm.nih.gov/14711316

DMRY6B4	DI	DMRY6B4
DMRY6B4	DN	4-Butyrylamino-N-hydroxy-benzamide
DMRY6B4	MI	TTYHPU6
DMRY6B4	MN	Histone deacetylase 10 (HDAC10)
DMRY6B4	MT	DTT
DMRY6B4	MA	Inhibitor
DMRY6B4	RN	Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74.
DMRY6B4	RU	https://pubmed.ncbi.nlm.nih.gov/14711316

DMRY6B4	DI	DMRY6B4
DMRY6B4	DN	4-Butyrylamino-N-hydroxy-benzamide
DMRY6B4	MI	TTSHTOI
DMRY6B4	MN	Histone deacetylase 2 (HDAC2)
DMRY6B4	MT	DTT
DMRY6B4	MA	Inhibitor
DMRY6B4	RN	Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74.
DMRY6B4	RU	https://pubmed.ncbi.nlm.nih.gov/14711316

DMRY6B4	DI	DMRY6B4
DMRY6B4	DN	4-Butyrylamino-N-hydroxy-benzamide
DMRY6B4	MI	TTTQGH8
DMRY6B4	MN	Histone deacetylase 4 (HDAC4)
DMRY6B4	MT	DTT
DMRY6B4	MA	Inhibitor
DMRY6B4	RN	Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74.
DMRY6B4	RU	https://pubmed.ncbi.nlm.nih.gov/14711316

DMRY6B4	DI	DMRY6B4
DMRY6B4	DN	4-Butyrylamino-N-hydroxy-benzamide
DMRY6B4	MI	TT5ZKDI
DMRY6B4	MN	Histone deacetylase 6 (HDAC6)
DMRY6B4	MT	DTT
DMRY6B4	MA	Inhibitor
DMRY6B4	RN	Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74.
DMRY6B4	RU	https://pubmed.ncbi.nlm.nih.gov/14711316

DMRY6B4	DI	DMRY6B4
DMRY6B4	DN	4-Butyrylamino-N-hydroxy-benzamide
DMRY6B4	MI	TTT6LFV
DMRY6B4	MN	Histone deacetylase 8 (HDAC8)
DMRY6B4	MT	DTT
DMRY6B4	MA	Inhibitor
DMRY6B4	RN	Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74.
DMRY6B4	RU	https://pubmed.ncbi.nlm.nih.gov/14711316

DM74GWO	DI	DM74GWO
DM74GWO	DN	4-Carbazol-9-yl-butyric acid
DM74GWO	MI	TTHWMFZ
DM74GWO	MN	Fatty acid-binding protein 4 (FABP4)
DM74GWO	MT	DTT
DM74GWO	MA	Inhibitor
DM74GWO	RN	Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4445-8.
DM74GWO	RU	https://pubmed.ncbi.nlm.nih.gov/15357969

DM74GWO	DI	DM74GWO
DM74GWO	DN	4-Carbazol-9-yl-butyric acid
DM74GWO	MI	TTNT2S6
DM74GWO	MN	Fatty acid-binding protein 5 (FABP5)
DM74GWO	MT	DTT
DM74GWO	MA	Inhibitor
DM74GWO	RN	Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4445-8.
DM74GWO	RU	https://pubmed.ncbi.nlm.nih.gov/15357969

DMBIQV3	DI	DMBIQV3
DMBIQV3	DN	4-Carboxycinnamic Acid
DMBIQV3	MI	TTQO71U
DMBIQV3	MN	Hemoglobin (HB)
DMBIQV3	MT	DTT
DMBIQV3	MA	Inhibitor
DMBIQV3	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMBIQV3	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM8A2QO	DI	DM8A2QO
DM8A2QO	DN	4-Carboxyphenylboronic Acid
DM8A2QO	MI	TTHI19T
DM8A2QO	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DM8A2QO	MT	DTT
DM8A2QO	MA	Inhibitor
DM8A2QO	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM8A2QO	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMMIA36	DI	DMMIA36
DMMIA36	DN	4-chloro-1-guanidino-7-isoquinolinesulphonamide
DMMIA36	MI	TTGY7WI
DMMIA36	MN	Urokinase-type plasminogen activator (PLAU)
DMMIA36	MT	DTT
DMMIA36	MA	Inhibitor
DMMIA36	RN	Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-sulfonamidoisoquinolinyl)guanidines. J Med Chem. 2007 May 17;50(10):2341-51.
DMMIA36	RU	https://pubmed.ncbi.nlm.nih.gov/17447747

DMHNSXP	DI	DMHNSXP
DMHNSXP	DN	4-chloro-1H-indazole
DMHNSXP	MI	TTZUFI5
DMHNSXP	MN	Nitric-oxide synthase brain (NOS1)
DMHNSXP	MT	DTT
DMHNSXP	MA	Inhibitor
DMHNSXP	RN	4-substituted indazoles as new inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3177-80.
DMHNSXP	RU	https://pubmed.ncbi.nlm.nih.gov/17395463

DM9HXPR	DI	DM9HXPR
DM9HXPR	DN	4-chloro-1H-indole-2,3-dione
DM9HXPR	MI	TTMF541
DM9HXPR	MN	Liver carboxylesterase (CES1)
DM9HXPR	MT	DTT
DM9HXPR	MA	Inhibitor
DM9HXPR	RN	Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85.
DM9HXPR	RU	https://pubmed.ncbi.nlm.nih.gov/17378546

DMKJ18X	DI	DMKJ18X
DMKJ18X	DN	4-Chloro-2-(4-hydroxy-phenyl)-quinolin-6-ol
DMKJ18X	MI	TTZAYWL
DMKJ18X	MN	Estrogen receptor (ESR)
DMKJ18X	MT	DTT
DMKJ18X	MA	Inhibitor
DMKJ18X	RN	ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5.
DMKJ18X	RU	https://pubmed.ncbi.nlm.nih.gov/16098741

DMKJ18X	DI	DMKJ18X
DMKJ18X	DN	4-Chloro-2-(4-hydroxy-phenyl)-quinolin-6-ol
DMKJ18X	MI	TTOM3J0
DMKJ18X	MN	Estrogen receptor beta (ESR2)
DMKJ18X	MT	DTT
DMKJ18X	MA	Inhibitor
DMKJ18X	RN	ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5.
DMKJ18X	RU	https://pubmed.ncbi.nlm.nih.gov/16098741

DMKJ18X	DI	DMKJ18X
DMKJ18X	DN	4-Chloro-2-(4-hydroxy-phenyl)-quinolin-6-ol
DMKJ18X	MI	TTPNQAC
DMKJ18X	MN	Estrogen-related receptor-alpha (ESRRA)
DMKJ18X	MT	DTT
DMKJ18X	MA	Inhibitor
DMKJ18X	RN	ERbeta ligands. Part 6: 6H-Chromeno[4,3-b]quinolines as a new series of estrogen receptor beta-selective ligands. Bioorg Med Chem Lett. 2007 Jul 15;17(14):4053-6.
DMKJ18X	RU	https://pubmed.ncbi.nlm.nih.gov/17482813

DM9VN21	DI	DM9VN21
DM9VN21	DN	4-Chloro-2,6-diisopropyl-phenol
DM9VN21	MI	TTNJYV2
DM9VN21	MN	Gamma-aminobutyric acid receptor (GAR)
DM9VN21	MT	DTT
DM9VN21	MA	Inhibitor
DM9VN21	RN	Propofol analogues. Synthesis, relationships between structure and affinity at GABAA receptor in rat brain, and differential electrophysiological p... J Med Chem. 1998 May 21;41(11):1846-54.
DM9VN21	RU	https://pubmed.ncbi.nlm.nih.gov/9599235

DMIYVJX	DI	DMIYVJX
DMIYVJX	DN	4-CHLORO-3',3''-DIBROMOPHENOL-1,8-NAPHTHALEIN
DMIYVJX	MI	TTU6BFZ
DMIYVJX	MN	Candida Thymidylate synthase (Candi TMP1)
DMIYVJX	MT	DTT
DMIYVJX	MA	Inhibitor
DMIYVJX	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMIYVJX	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMMALY3	DI	DMMALY3
DMMALY3	DN	4-Chloro-3-hydroxy-1H-quinolin-2-one
DMMALY3	MI	TTLD29N
DMMALY3	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMMALY3	MT	DTT
DMMALY3	MA	Inhibitor
DMMALY3	RN	3-Hydroxy-quinolin-2-ones: Inhibitors of [3H]-glycine binding to the site associated with the NMDA receptor, Bioorg. Med. Chem. Lett. 6(5):499-504 (1996).
DMMALY3	RU	http://www.sciencedirect.com/science/article/pii/0960894X96000315

DMMALY3	DI	DMMALY3
DMMALY3	DN	4-Chloro-3-hydroxy-1H-quinolin-2-one
DMMALY3	MI	TTKJEMQ
DMMALY3	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMMALY3	MT	DTT
DMMALY3	MA	Inhibitor
DMMALY3	RN	3-Hydroxy-quinolin-2-ones: Inhibitors of [3H]-glycine binding to the site associated with the NMDA receptor, Bioorg. Med. Chem. Lett. 6(5):499-504 (1996).
DMMALY3	RU	http://www.sciencedirect.com/science/article/pii/0960894X96000315

DMMALY3	DI	DMMALY3
DMMALY3	DN	4-Chloro-3-hydroxy-1H-quinolin-2-one
DMMALY3	MI	TTN9D8E
DMMALY3	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMMALY3	MT	DTT
DMMALY3	MA	Inhibitor
DMMALY3	RN	3-Hydroxy-quinolin-2-ones: Inhibitors of [3H]-glycine binding to the site associated with the NMDA receptor, Bioorg. Med. Chem. Lett. 6(5):499-504 (1996).
DMMALY3	RU	http://www.sciencedirect.com/science/article/pii/0960894X96000315

DMI580M	DI	DMI580M
DMI580M	DN	4-Chloro-5,7-diphenyl-7H-pyrrolo[2,3-d]pyrimidine
DMI580M	MI	TT6PKBN
DMI580M	MN	Proto-oncogene c-Src (SRC)
DMI580M	MT	DTT
DMI580M	MA	Inhibitor
DMI580M	RN	Substituted 5,7-diphenyl-pyrrolo[2,3d]pyrimidines: potent inhibitors of the tyrosine kinase c-Src. Bioorg Med Chem Lett. 2000 May 1;10(9):945-9.
DMI580M	RU	https://pubmed.ncbi.nlm.nih.gov/10853665

DM04OFE	DI	DM04OFE
DM04OFE	DN	4-Chloro-6-nitro-2-piperazin-1-yl-quinoline
DM04OFE	MI	TT3ROYC
DM04OFE	MN	Serotonin transporter (SERT)
DM04OFE	MT	DTT
DM04OFE	MA	Inhibitor
DM04OFE	RN	Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 2: 4-substituted 6-nitroquipazines. Bioorg Med Chem Lett. 2002 Mar 11;12(5):811-5.
DM04OFE	RU	https://pubmed.ncbi.nlm.nih.gov/11859009

DM16P3N	DI	DM16P3N
DM16P3N	DN	4-chloro-7-methyl-1H-indole-2,3-dione
DM16P3N	MI	TTMF541
DM16P3N	MN	Liver carboxylesterase (CES1)
DM16P3N	MT	DTT
DM16P3N	MA	Inhibitor
DM16P3N	RN	Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85.
DM16P3N	RU	https://pubmed.ncbi.nlm.nih.gov/17378546

DM9SVEB	DI	DM9SVEB
DM9SVEB	DN	4-Chloro-7-methyl-2-phenyl-[1,8]naphthyridine
DM9SVEB	MI	TTK25J1
DM9SVEB	MN	Adenosine A1 receptor (ADORA1)
DM9SVEB	MT	DTT
DM9SVEB	MA	Inhibitor
DM9SVEB	RN	A novel class of highly potent and selective A1 adenosine antagonists: structure-affinity profile of a series of 1,8-naphthyridine derivatives. J Med Chem. 2000 Jul 27;43(15):2814-23.
DM9SVEB	RU	https://pubmed.ncbi.nlm.nih.gov/10956189

DMKTSPM	DI	DMKTSPM
DMKTSPM	DN	4-Chlorobenzenemethanethiol
DMKTSPM	MI	TTZJYKH
DMKTSPM	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMKTSPM	MT	DTT
DMKTSPM	MA	Inhibitor
DMKTSPM	RN	S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9.
DMKTSPM	RU	https://pubmed.ncbi.nlm.nih.gov/20688518

DMHL9V3	DI	DMHL9V3
DMHL9V3	DN	4-chloro-N-(2,5-dichlorophenyl)-3-nitrobenzamide
DMHL9V3	MI	TTVTX4N
DMHL9V3	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DMHL9V3	MT	DTT
DMHL9V3	MA	Inhibitor
DMHL9V3	RN	Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening. Eur J Med Chem. 2009 Sep;44(9):3718-30.
DMHL9V3	RU	https://pubmed.ncbi.nlm.nih.gov/19428156

DMVJ61A	DI	DMVJ61A
DMVJ61A	DN	4-Chloro-N-(2-chloro-benzoyl)-benzenesulfonamide
DMVJ61A	MI	TTUTJGQ
DMVJ61A	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMVJ61A	MT	DTT
DMVJ61A	MA	Inhibitor
DMVJ61A	RN	Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80.
DMVJ61A	RU	https://pubmed.ncbi.nlm.nih.gov/15481975

DMVJ61A	DI	DMVJ61A
DMVJ61A	DN	4-Chloro-N-(2-chloro-benzoyl)-benzenesulfonamide
DMVJ61A	MI	TTDCBX5
DMVJ61A	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DMVJ61A	MT	DTT
DMVJ61A	MA	Inhibitor
DMVJ61A	RN	Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80.
DMVJ61A	RU	https://pubmed.ncbi.nlm.nih.gov/15481975

DMVJ61A	DI	DMVJ61A
DMVJ61A	DN	4-Chloro-N-(2-chloro-benzoyl)-benzenesulfonamide
DMVJ61A	MI	TT1VAUK
DMVJ61A	MN	VEGFR1 messenger RNA (VEGFR1 mRNA)
DMVJ61A	MT	DTT
DMVJ61A	MA	Inhibitor
DMVJ61A	RN	Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80.
DMVJ61A	RU	https://pubmed.ncbi.nlm.nih.gov/15481975

DM6SI78	DI	DM6SI78
DM6SI78	DN	4-Chloro-N-(2-methyl-benzoyl)-benzenesulfonamide
DM6SI78	MI	TTUTJGQ
DM6SI78	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM6SI78	MT	DTT
DM6SI78	MA	Inhibitor
DM6SI78	RN	Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80.
DM6SI78	RU	https://pubmed.ncbi.nlm.nih.gov/15481975

DM6SI78	DI	DM6SI78
DM6SI78	DN	4-Chloro-N-(2-methyl-benzoyl)-benzenesulfonamide
DM6SI78	MI	TTDCBX5
DM6SI78	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DM6SI78	MT	DTT
DM6SI78	MA	Inhibitor
DM6SI78	RN	Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80.
DM6SI78	RU	https://pubmed.ncbi.nlm.nih.gov/15481975

DM6SI78	DI	DM6SI78
DM6SI78	DN	4-Chloro-N-(2-methyl-benzoyl)-benzenesulfonamide
DM6SI78	MI	TT1VAUK
DM6SI78	MN	VEGFR1 messenger RNA (VEGFR1 mRNA)
DM6SI78	MT	DTT
DM6SI78	MA	Inhibitor
DM6SI78	RN	Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80.
DM6SI78	RU	https://pubmed.ncbi.nlm.nih.gov/15481975

DMVCLP8	DI	DMVCLP8
DMVCLP8	DN	4-Chloro-N-(2-morpholinoethyl)nicotinamide
DMVCLP8	MI	TT3WG5C
DMVCLP8	MN	Monoamine oxidase type A (MAO-A)
DMVCLP8	MT	DTT
DMVCLP8	MA	Inhibitor
DMVCLP8	RN	Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1659-64.
DMVCLP8	RU	https://pubmed.ncbi.nlm.nih.gov/20117937

DMI3OR9	DI	DMI3OR9
DMI3OR9	DN	4-Chloro-N-(3-chloro-benzoyl)-benzenesulfonamide
DMI3OR9	MI	TTUTJGQ
DMI3OR9	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMI3OR9	MT	DTT
DMI3OR9	MA	Inhibitor
DMI3OR9	RN	Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80.
DMI3OR9	RU	https://pubmed.ncbi.nlm.nih.gov/15481975

DMI3OR9	DI	DMI3OR9
DMI3OR9	DN	4-Chloro-N-(3-chloro-benzoyl)-benzenesulfonamide
DMI3OR9	MI	TTDCBX5
DMI3OR9	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DMI3OR9	MT	DTT
DMI3OR9	MA	Inhibitor
DMI3OR9	RN	Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80.
DMI3OR9	RU	https://pubmed.ncbi.nlm.nih.gov/15481975

DMI3OR9	DI	DMI3OR9
DMI3OR9	DN	4-Chloro-N-(3-chloro-benzoyl)-benzenesulfonamide
DMI3OR9	MI	TT1VAUK
DMI3OR9	MN	VEGFR1 messenger RNA (VEGFR1 mRNA)
DMI3OR9	MT	DTT
DMI3OR9	MA	Inhibitor
DMI3OR9	RN	Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80.
DMI3OR9	RU	https://pubmed.ncbi.nlm.nih.gov/15481975

DMM8G6H	DI	DMM8G6H
DMM8G6H	DN	4-Chloro-N-(3-morpholinopropyl)nicotinamide
DMM8G6H	MI	TT3WG5C
DMM8G6H	MN	Monoamine oxidase type A (MAO-A)
DMM8G6H	MT	DTT
DMM8G6H	MA	Inhibitor
DMM8G6H	RN	Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1659-64.
DMM8G6H	RU	https://pubmed.ncbi.nlm.nih.gov/20117937

DMTDX2S	DI	DMTDX2S
DMTDX2S	DN	4-Chloro-N-(4-chloro-benzoyl)-benzenesulfonamide
DMTDX2S	MI	TTUTJGQ
DMTDX2S	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMTDX2S	MT	DTT
DMTDX2S	MA	Inhibitor
DMTDX2S	RN	Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80.
DMTDX2S	RU	https://pubmed.ncbi.nlm.nih.gov/15481975

DMTDX2S	DI	DMTDX2S
DMTDX2S	DN	4-Chloro-N-(4-chloro-benzoyl)-benzenesulfonamide
DMTDX2S	MI	TTDCBX5
DMTDX2S	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DMTDX2S	MT	DTT
DMTDX2S	MA	Inhibitor
DMTDX2S	RN	Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80.
DMTDX2S	RU	https://pubmed.ncbi.nlm.nih.gov/15481975

DMTDX2S	DI	DMTDX2S
DMTDX2S	DN	4-Chloro-N-(4-chloro-benzoyl)-benzenesulfonamide
DMTDX2S	MI	TT1VAUK
DMTDX2S	MN	VEGFR1 messenger RNA (VEGFR1 mRNA)
DMTDX2S	MT	DTT
DMTDX2S	MA	Inhibitor
DMTDX2S	RN	Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80.
DMTDX2S	RU	https://pubmed.ncbi.nlm.nih.gov/15481975

DMM0TL6	DI	DMM0TL6
DMM0TL6	DN	4-Chloro-N-(4-nitro-benzoyl)-benzenesulfonamide
DMM0TL6	MI	TTUTJGQ
DMM0TL6	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMM0TL6	MT	DTT
DMM0TL6	MA	Inhibitor
DMM0TL6	RN	Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80.
DMM0TL6	RU	https://pubmed.ncbi.nlm.nih.gov/15481975

DMM0TL6	DI	DMM0TL6
DMM0TL6	DN	4-Chloro-N-(4-nitro-benzoyl)-benzenesulfonamide
DMM0TL6	MI	TTDCBX5
DMM0TL6	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DMM0TL6	MT	DTT
DMM0TL6	MA	Inhibitor
DMM0TL6	RN	Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80.
DMM0TL6	RU	https://pubmed.ncbi.nlm.nih.gov/15481975

DMM0TL6	DI	DMM0TL6
DMM0TL6	DN	4-Chloro-N-(4-nitro-benzoyl)-benzenesulfonamide
DMM0TL6	MI	TT1VAUK
DMM0TL6	MN	VEGFR1 messenger RNA (VEGFR1 mRNA)
DMM0TL6	MT	DTT
DMM0TL6	MA	Inhibitor
DMM0TL6	RN	Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80.
DMM0TL6	RU	https://pubmed.ncbi.nlm.nih.gov/15481975

DMVKU4L	DI	DMVKU4L
DMVKU4L	DN	4-Chloro-N-(4-phenyl-thiazol-2-yl)-benzamide
DMVKU4L	MI	TTK25J1
DMVKU4L	MN	Adenosine A1 receptor (ADORA1)
DMVKU4L	MT	DTT
DMVKU4L	MA	Inhibitor
DMVKU4L	RN	Substituted 4-phenyl-2-(phenylcarboxamido)-1,3-thiazole derivatives as antagonists for the adenosine A(1) receptor. Bioorg Med Chem Lett. 2001 Aug 6;11(15):2017-9.
DMVKU4L	RU	https://pubmed.ncbi.nlm.nih.gov/11454470

DM5AVG3	DI	DM5AVG3
DM5AVG3	DN	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide
DM5AVG3	MI	TTBH0VX
DM5AVG3	MN	Histone deacetylase (HDAC)
DM5AVG3	MT	DTT
DM5AVG3	MA	Inhibitor
DM5AVG3	RN	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
DM5AVG3	RU	https://pubmed.ncbi.nlm.nih.gov/11831887

DM5AVG3	DI	DM5AVG3
DM5AVG3	DN	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide
DM5AVG3	MI	TT6R7JZ
DM5AVG3	MN	Histone deacetylase 1 (HDAC1)
DM5AVG3	MT	DTT
DM5AVG3	MA	Inhibitor
DM5AVG3	RN	Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
DM5AVG3	RU	https://pubmed.ncbi.nlm.nih.gov/14613312

DM5AVG3	DI	DM5AVG3
DM5AVG3	DN	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide
DM5AVG3	MI	TTYHPU6
DM5AVG3	MN	Histone deacetylase 10 (HDAC10)
DM5AVG3	MT	DTT
DM5AVG3	MA	Inhibitor
DM5AVG3	RN	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
DM5AVG3	RU	https://pubmed.ncbi.nlm.nih.gov/11831887

DM5AVG3	DI	DM5AVG3
DM5AVG3	DN	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide
DM5AVG3	MI	TTSHTOI
DM5AVG3	MN	Histone deacetylase 2 (HDAC2)
DM5AVG3	MT	DTT
DM5AVG3	MA	Inhibitor
DM5AVG3	RN	Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
DM5AVG3	RU	https://pubmed.ncbi.nlm.nih.gov/14613312

DM5AVG3	DI	DM5AVG3
DM5AVG3	DN	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide
DM5AVG3	MI	TTTQGH8
DM5AVG3	MN	Histone deacetylase 4 (HDAC4)
DM5AVG3	MT	DTT
DM5AVG3	MA	Inhibitor
DM5AVG3	RN	Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
DM5AVG3	RU	https://pubmed.ncbi.nlm.nih.gov/14613312

DM5AVG3	DI	DM5AVG3
DM5AVG3	DN	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide
DM5AVG3	MI	TT5ZKDI
DM5AVG3	MN	Histone deacetylase 6 (HDAC6)
DM5AVG3	MT	DTT
DM5AVG3	MA	Inhibitor
DM5AVG3	RN	Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
DM5AVG3	RU	https://pubmed.ncbi.nlm.nih.gov/14613312

DM5AVG3	DI	DM5AVG3
DM5AVG3	DN	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide
DM5AVG3	MI	TTT6LFV
DM5AVG3	MN	Histone deacetylase 8 (HDAC8)
DM5AVG3	MT	DTT
DM5AVG3	MA	Inhibitor
DM5AVG3	RN	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
DM5AVG3	RU	https://pubmed.ncbi.nlm.nih.gov/11831887

DM2UYCS	DI	DM2UYCS
DM2UYCS	DN	4-Chloro-N-(5-sulfamoyl-indan-2-yl)-benzamide
DM2UYCS	MI	TTHQPL7
DM2UYCS	MN	Carbonic anhydrase I (CA-I)
DM2UYCS	MT	DTT
DM2UYCS	MA	Inhibitor
DM2UYCS	RN	Carbonic anhydrase inhibitors. Design of anticonvulsant sulfonamides incorporating indane moieties. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5781-6.
DM2UYCS	RU	https://pubmed.ncbi.nlm.nih.gov/15501040

DM2UYCS	DI	DM2UYCS
DM2UYCS	DN	4-Chloro-N-(5-sulfamoyl-indan-2-yl)-benzamide
DM2UYCS	MI	TTANPDJ
DM2UYCS	MN	Carbonic anhydrase II (CA-II)
DM2UYCS	MT	DTT
DM2UYCS	MA	Inhibitor
DM2UYCS	RN	Carbonic anhydrase inhibitors. Design of anticonvulsant sulfonamides incorporating indane moieties. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5781-6.
DM2UYCS	RU	https://pubmed.ncbi.nlm.nih.gov/15501040

DMPINBR	DI	DMPINBR
DMPINBR	DN	4-chlorophenyl 10H-phenothiazine-10-carboxylate
DMPINBR	MI	TTEB0GD
DMPINBR	MN	Cholinesterase (BCHE)
DMPINBR	MT	DTT
DMPINBR	MA	Inhibitor
DMPINBR	RN	Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. J Med Chem. 2008 Jul 24;51(14):4200-12.
DMPINBR	RU	https://pubmed.ncbi.nlm.nih.gov/18570368

DMWGF9R	DI	DMWGF9R
DMWGF9R	DN	4'-cyano-3-(imidazolylmethyl)-7-methoxyflavone
DMWGF9R	MI	TTSZLWK
DMWGF9R	MN	Aromatase (CYP19A1)
DMWGF9R	MT	DTT
DMWGF9R	MA	Inhibitor
DMWGF9R	RN	Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme. J Med Chem. 2006 Jul 27;49(15):4777-80.
DMWGF9R	RU	https://pubmed.ncbi.nlm.nih.gov/16854084

DMUJS4R	DI	DMUJS4R
DMUJS4R	DN	4'-cyano-3-(imidazolylmethyl)flavone
DMUJS4R	MI	TTSZLWK
DMUJS4R	MN	Aromatase (CYP19A1)
DMUJS4R	MT	DTT
DMUJS4R	MA	Inhibitor
DMUJS4R	RN	Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme. J Med Chem. 2006 Jul 27;49(15):4777-80.
DMUJS4R	RU	https://pubmed.ncbi.nlm.nih.gov/16854084

DMJ610E	DI	DMJ610E
DMJ610E	DN	4-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide
DMJ610E	MI	TTHS256
DMJ610E	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMJ610E	MT	DTT
DMJ610E	MA	Inhibitor
DMJ610E	RN	Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat... J Med Chem. 2006 Jun 1;49(11):3332-44.
DMJ610E	RU	https://pubmed.ncbi.nlm.nih.gov/16722652

DMN12EX	DI	DMN12EX
DMN12EX	DN	4-CYANOPHENOL
DMN12EX	MI	TTUNARX
DMN12EX	MN	Carbonic anhydrase (CA)
DMN12EX	MT	DTT
DMN12EX	MA	Inhibitor
DMN12EX	RN	Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8.
DMN12EX	RU	https://pubmed.ncbi.nlm.nih.gov/18579385

DMN12EX	DI	DMN12EX
DMN12EX	DN	4-CYANOPHENOL
DMN12EX	MI	TTANPDJ
DMN12EX	MN	Carbonic anhydrase II (CA-II)
DMN12EX	MT	DTT
DMN12EX	MA	Inhibitor
DMN12EX	RN	Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8.
DMN12EX	RU	https://pubmed.ncbi.nlm.nih.gov/18579385

DMN12EX	DI	DMN12EX
DMN12EX	DN	4-CYANOPHENOL
DMN12EX	MI	TTCFSPE
DMN12EX	MN	Carbonic anhydrase VI (CA-VI)
DMN12EX	MT	DTT
DMN12EX	MA	Inhibitor
DMN12EX	RN	Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8.
DMN12EX	RU	https://pubmed.ncbi.nlm.nih.gov/18579385

DMN12EX	DI	DMN12EX
DMN12EX	DN	4-CYANOPHENOL
DMN12EX	MI	TTSYM0R
DMN12EX	MN	Carbonic anhydrase XII (CA-XII)
DMN12EX	MT	DTT
DMN12EX	MA	Inhibitor
DMN12EX	RN	Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8.
DMN12EX	RU	https://pubmed.ncbi.nlm.nih.gov/18579385

DMEP80Q	DI	DMEP80Q
DMEP80Q	DN	4-cyanophenyl ethyl dodecylphosphonate
DMEP80Q	MI	TT6OEDT
DMEP80Q	MN	Cannabinoid receptor 1 (CB1)
DMEP80Q	MT	DTT
DMEP80Q	MA	Inhibitor
DMEP80Q	RN	Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5875-8.
DMEP80Q	RU	https://pubmed.ncbi.nlm.nih.gov/18752948

DMEP80Q	DI	DMEP80Q
DMEP80Q	DN	4-cyanophenyl ethyl dodecylphosphonate
DMEP80Q	MI	TTDP1UC
DMEP80Q	MN	Fatty acid amide hydrolase (FAAH)
DMEP80Q	MT	DTT
DMEP80Q	MA	Inhibitor
DMEP80Q	RN	Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5875-8.
DMEP80Q	RU	https://pubmed.ncbi.nlm.nih.gov/18752948

DMOLFHZ	DI	DMOLFHZ
DMOLFHZ	DN	4-cyanophenylboronic acid
DMOLFHZ	MI	TTDP1UC
DMOLFHZ	MN	Fatty acid amide hydrolase (FAAH)
DMOLFHZ	MT	DTT
DMOLFHZ	MA	Inhibitor
DMOLFHZ	RN	Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Nov 27;51(22):7057-60.
DMOLFHZ	RU	https://pubmed.ncbi.nlm.nih.gov/18983140

DMNT5BF	DI	DMNT5BF
DMNT5BF	DN	4-cycloheptyl-6-propylpyrimidine-2-carbonitrile
DMNT5BF	MI	TTDZN01
DMNT5BF	MN	Cathepsin K (CTSK)
DMNT5BF	MT	DTT
DMNT5BF	MA	Inhibitor
DMNT5BF	RN	Design and optimization of a series of novel 2-cyano-pyrimidines as cathepsin K inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1524-7.
DMNT5BF	RU	https://pubmed.ncbi.nlm.nih.gov/20149657

DMNT5BF	DI	DMNT5BF
DMNT5BF	DN	4-cycloheptyl-6-propylpyrimidine-2-carbonitrile
DMNT5BF	MI	TTUMQVO
DMNT5BF	MN	Cathepsin S (CTSS)
DMNT5BF	MT	DTT
DMNT5BF	MA	Inhibitor
DMNT5BF	RN	Design and optimization of a series of novel 2-cyano-pyrimidines as cathepsin K inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1524-7.
DMNT5BF	RU	https://pubmed.ncbi.nlm.nih.gov/20149657

DM4LIUC	DI	DM4LIUC
DM4LIUC	DN	4-cycloheptyliden(4-hydroxyphenyl)methylphenol
DM4LIUC	MI	TTFJ8Q1
DM4LIUC	MN	Protein kinase C alpha (PRKCA)
DM4LIUC	MT	DTT
DM4LIUC	MA	Inhibitor
DM4LIUC	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DM4LIUC	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DM4LIUC	DI	DM4LIUC
DM4LIUC	DN	4-cycloheptyliden(4-hydroxyphenyl)methylphenol
DM4LIUC	MI	TTYPXQF
DM4LIUC	MN	Protein kinase C beta (PRKCB)
DM4LIUC	MT	DTT
DM4LIUC	MA	Inhibitor
DM4LIUC	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DM4LIUC	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DM4LIUC	DI	DM4LIUC
DM4LIUC	DN	4-cycloheptyliden(4-hydroxyphenyl)methylphenol
DM4LIUC	MI	TT9WJ8U
DM4LIUC	MN	Protein kinase C delta (PRKCD)
DM4LIUC	MT	DTT
DM4LIUC	MA	Inhibitor
DM4LIUC	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DM4LIUC	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DM4LIUC	DI	DM4LIUC
DM4LIUC	DN	4-cycloheptyliden(4-hydroxyphenyl)methylphenol
DM4LIUC	MI	TTBZ7OD
DM4LIUC	MN	Protein kinase C epsilon (PRKCE)
DM4LIUC	MT	DTT
DM4LIUC	MA	Inhibitor
DM4LIUC	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DM4LIUC	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DM4LIUC	DI	DM4LIUC
DM4LIUC	DN	4-cycloheptyliden(4-hydroxyphenyl)methylphenol
DM4LIUC	MI	TTRFOXJ
DM4LIUC	MN	Protein kinase C gamma (PRKCG)
DM4LIUC	MT	DTT
DM4LIUC	MA	Inhibitor
DM4LIUC	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DM4LIUC	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DM4LIUC	DI	DM4LIUC
DM4LIUC	DN	4-cycloheptyliden(4-hydroxyphenyl)methylphenol
DM4LIUC	MI	TT8QL1J
DM4LIUC	MN	Protein kinase C theta (PRKCQ)
DM4LIUC	MT	DTT
DM4LIUC	MA	Inhibitor
DM4LIUC	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DM4LIUC	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DM4LIUC	DI	DM4LIUC
DM4LIUC	DN	4-cycloheptyliden(4-hydroxyphenyl)methylphenol
DM4LIUC	MI	TTUWGRA
DM4LIUC	MN	Protein kinase C zeta (PRKCZ)
DM4LIUC	MT	DTT
DM4LIUC	MA	Inhibitor
DM4LIUC	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DM4LIUC	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DMTFL5J	DI	DMTFL5J
DMTFL5J	DN	4-Cyclohexyl-4-hydroxy-but-2-enoic acid
DMTFL5J	MI	TT6TKEN
DMTFL5J	MN	Gamma-hydroxybutyrate receptor (SLC52A2)
DMTFL5J	MT	DTT
DMTFL5J	MA	Inhibitor
DMTFL5J	RN	Analogues of gamma-hydroxybutyric acid. Synthesis and binding studies. J Med Chem. 1988 May;31(5):893-7.
DMTFL5J	RU	https://pubmed.ncbi.nlm.nih.gov/3361576

DM10U6S	DI	DM10U6S
DM10U6S	DN	4-cyclohexyl-6-propylpyrimidine-2-carbonitrile
DM10U6S	MI	TTDZN01
DM10U6S	MN	Cathepsin K (CTSK)
DM10U6S	MT	DTT
DM10U6S	MA	Inhibitor
DM10U6S	RN	Design and optimization of a series of novel 2-cyano-pyrimidines as cathepsin K inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1524-7.
DM10U6S	RU	https://pubmed.ncbi.nlm.nih.gov/20149657

DMGVIXW	DI	DMGVIXW
DMGVIXW	DN	4-cyclohexylamino-pyrimidine-2-carbonitrile
DMGVIXW	MI	TTDZN01
DMGVIXW	MN	Cathepsin K (CTSK)
DMGVIXW	MT	DTT
DMGVIXW	MA	Inhibitor
DMGVIXW	RN	2-Cyano-pyrimidines: a new chemotype for inhibitors of the cysteine protease cathepsin K. J Med Chem. 2007 Feb 22;50(4):591-4.
DMGVIXW	RU	https://pubmed.ncbi.nlm.nih.gov/17256925

DM8BLK2	DI	DM8BLK2
DM8BLK2	DN	4-cyclohexyliden(4-hydroxyphenyl)methylphenol
DM8BLK2	MI	TTFJ8Q1
DM8BLK2	MN	Protein kinase C alpha (PRKCA)
DM8BLK2	MT	DTT
DM8BLK2	MA	Inhibitor
DM8BLK2	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DM8BLK2	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DM8BLK2	DI	DM8BLK2
DM8BLK2	DN	4-cyclohexyliden(4-hydroxyphenyl)methylphenol
DM8BLK2	MI	TTYPXQF
DM8BLK2	MN	Protein kinase C beta (PRKCB)
DM8BLK2	MT	DTT
DM8BLK2	MA	Inhibitor
DM8BLK2	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DM8BLK2	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DM8BLK2	DI	DM8BLK2
DM8BLK2	DN	4-cyclohexyliden(4-hydroxyphenyl)methylphenol
DM8BLK2	MI	TT9WJ8U
DM8BLK2	MN	Protein kinase C delta (PRKCD)
DM8BLK2	MT	DTT
DM8BLK2	MA	Inhibitor
DM8BLK2	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DM8BLK2	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DM8BLK2	DI	DM8BLK2
DM8BLK2	DN	4-cyclohexyliden(4-hydroxyphenyl)methylphenol
DM8BLK2	MI	TTBZ7OD
DM8BLK2	MN	Protein kinase C epsilon (PRKCE)
DM8BLK2	MT	DTT
DM8BLK2	MA	Inhibitor
DM8BLK2	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DM8BLK2	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DM8BLK2	DI	DM8BLK2
DM8BLK2	DN	4-cyclohexyliden(4-hydroxyphenyl)methylphenol
DM8BLK2	MI	TTRFOXJ
DM8BLK2	MN	Protein kinase C gamma (PRKCG)
DM8BLK2	MT	DTT
DM8BLK2	MA	Inhibitor
DM8BLK2	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DM8BLK2	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DM8BLK2	DI	DM8BLK2
DM8BLK2	DN	4-cyclohexyliden(4-hydroxyphenyl)methylphenol
DM8BLK2	MI	TT8QL1J
DM8BLK2	MN	Protein kinase C theta (PRKCQ)
DM8BLK2	MT	DTT
DM8BLK2	MA	Inhibitor
DM8BLK2	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DM8BLK2	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DM8BLK2	DI	DM8BLK2
DM8BLK2	DN	4-cyclohexyliden(4-hydroxyphenyl)methylphenol
DM8BLK2	MI	TTUWGRA
DM8BLK2	MN	Protein kinase C zeta (PRKCZ)
DM8BLK2	MT	DTT
DM8BLK2	MA	Inhibitor
DM8BLK2	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DM8BLK2	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DMS42TN	DI	DMS42TN
DMS42TN	DN	4-cyclooctyl-6-propylpyrimidine-2-carbonitrile
DMS42TN	MI	TTDZN01
DMS42TN	MN	Cathepsin K (CTSK)
DMS42TN	MT	DTT
DMS42TN	MA	Inhibitor
DMS42TN	RN	Design and optimization of a series of novel 2-cyano-pyrimidines as cathepsin K inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1524-7.
DMS42TN	RU	https://pubmed.ncbi.nlm.nih.gov/20149657

DMS42TN	DI	DMS42TN
DMS42TN	DN	4-cyclooctyl-6-propylpyrimidine-2-carbonitrile
DMS42TN	MI	TTUMQVO
DMS42TN	MN	Cathepsin S (CTSS)
DMS42TN	MT	DTT
DMS42TN	MA	Inhibitor
DMS42TN	RN	Design and optimization of a series of novel 2-cyano-pyrimidines as cathepsin K inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1524-7.
DMS42TN	RU	https://pubmed.ncbi.nlm.nih.gov/20149657

DM7LN53	DI	DM7LN53
DM7LN53	DN	4-cyclopentyliden(4-hydroxyphenyl)methylphenol
DM7LN53	MI	TTFJ8Q1
DM7LN53	MN	Protein kinase C alpha (PRKCA)
DM7LN53	MT	DTT
DM7LN53	MA	Inhibitor
DM7LN53	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DM7LN53	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DM7LN53	DI	DM7LN53
DM7LN53	DN	4-cyclopentyliden(4-hydroxyphenyl)methylphenol
DM7LN53	MI	TTYPXQF
DM7LN53	MN	Protein kinase C beta (PRKCB)
DM7LN53	MT	DTT
DM7LN53	MA	Inhibitor
DM7LN53	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DM7LN53	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DM7LN53	DI	DM7LN53
DM7LN53	DN	4-cyclopentyliden(4-hydroxyphenyl)methylphenol
DM7LN53	MI	TTRFOXJ
DM7LN53	MN	Protein kinase C gamma (PRKCG)
DM7LN53	MT	DTT
DM7LN53	MA	Inhibitor
DM7LN53	RN	Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
DM7LN53	RU	https://pubmed.ncbi.nlm.nih.gov/1738150

DMZIUQ2	DI	DMZIUQ2
DMZIUQ2	DN	4-DAMP
DMZIUQ2	MI	TTQ13Z5
DMZIUQ2	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMZIUQ2	MT	DTT
DMZIUQ2	MA	Antagonist
DMZIUQ2	RN	An increase in intracelluar free calcium ions modulated by cholinergic receptors in rat facial nucleus. Chin Med J (Engl). 2009 May 5;122(9):1049-55.
DMZIUQ2	RU	https://pubmed.ncbi.nlm.nih.gov/19493439

DMGQTF9	DI	DMGQTF9
DMGQTF9	DN	4-decyl-N-(pyridin-3-yl)benzamide
DMGQTF9	MI	TTMI6F5
DMGQTF9	MN	Transient receptor potential cation channel V1 (TRPV1)
DMGQTF9	MT	DTT
DMGQTF9	MA	Inhibitor
DMGQTF9	RN	N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4.
DMGQTF9	RU	https://pubmed.ncbi.nlm.nih.gov/18359227

DM93DQG	DI	DM93DQG
DM93DQG	DN	4-dehydroxyriccardin C
DM93DQG	MI	TTECBXN
DM93DQG	MN	Oxysterols receptor LXR-alpha (NR1H3)
DM93DQG	MT	DTT
DM93DQG	MA	Inhibitor
DM93DQG	RN	Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85.
DM93DQG	RU	https://pubmed.ncbi.nlm.nih.gov/18343126

DM93DQG	DI	DM93DQG
DM93DQG	DN	4-dehydroxyriccardin C
DM93DQG	MI	TTXA6PH
DM93DQG	MN	Oxysterols receptor LXR-beta (NR1H2)
DM93DQG	MT	DTT
DM93DQG	MA	Inhibitor
DM93DQG	RN	Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85.
DM93DQG	RU	https://pubmed.ncbi.nlm.nih.gov/18343126

DMQWHLM	DI	DMQWHLM
DMQWHLM	DN	4'-Demethyl-4beta-amino-4-desoxypodophyllotoxin
DMQWHLM	MI	TT0IHXV
DMQWHLM	MN	DNA topoisomerase II (TOP2)
DMQWHLM	MT	DTT
DMQWHLM	MA	Inhibitor
DMQWHLM	RN	Antitumor agents, 107. New cytotoxic 4-alkylamino analogues of 4'-demethyl-epipodophyllotoxin as inhibitors of human DNA topoisomerase II. J Nat Prod. 1989 May-Jun;52(3):606-13.
DMQWHLM	RU	https://pubmed.ncbi.nlm.nih.gov/2550587

DMIWX3B	DI	DMIWX3B
DMIWX3B	DN	4'-Demethyl-epipodophyllotoxin
DMIWX3B	MI	TT0IHXV
DMIWX3B	MN	DNA topoisomerase II (TOP2)
DMIWX3B	MT	DTT
DMIWX3B	MA	Inhibitor
DMIWX3B	RN	Antitumor agents, 107. New cytotoxic 4-alkylamino analogues of 4'-demethyl-epipodophyllotoxin as inhibitors of human DNA topoisomerase II. J Nat Prod. 1989 May-Jun;52(3):606-13.
DMIWX3B	RU	https://pubmed.ncbi.nlm.nih.gov/2550587

DMEC1PS	DI	DMEC1PS
DMEC1PS	DN	4-Dimethylamino-2,6-diisopropyl-phenol
DMEC1PS	MI	TTNJYV2
DMEC1PS	MN	Gamma-aminobutyric acid receptor (GAR)
DMEC1PS	MT	DTT
DMEC1PS	MA	Inhibitor
DMEC1PS	RN	Propofol analogues. Synthesis, relationships between structure and affinity at GABAA receptor in rat brain, and differential electrophysiological p... J Med Chem. 1998 May 21;41(11):1846-54.
DMEC1PS	RU	https://pubmed.ncbi.nlm.nih.gov/9599235

DM0M8G5	DI	DM0M8G5
DM0M8G5	DN	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide
DM0M8G5	MI	TTBH0VX
DM0M8G5	MN	Histone deacetylase (HDAC)
DM0M8G5	MT	DTT
DM0M8G5	MA	Inhibitor
DM0M8G5	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DM0M8G5	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DM0M8G5	DI	DM0M8G5
DM0M8G5	DN	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide
DM0M8G5	MI	TT6R7JZ
DM0M8G5	MN	Histone deacetylase 1 (HDAC1)
DM0M8G5	MT	DTT
DM0M8G5	MA	Inhibitor
DM0M8G5	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DM0M8G5	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DM0M8G5	DI	DM0M8G5
DM0M8G5	DN	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide
DM0M8G5	MI	TTYHPU6
DM0M8G5	MN	Histone deacetylase 10 (HDAC10)
DM0M8G5	MT	DTT
DM0M8G5	MA	Inhibitor
DM0M8G5	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DM0M8G5	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DM0M8G5	DI	DM0M8G5
DM0M8G5	DN	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide
DM0M8G5	MI	TTSHTOI
DM0M8G5	MN	Histone deacetylase 2 (HDAC2)
DM0M8G5	MT	DTT
DM0M8G5	MA	Inhibitor
DM0M8G5	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DM0M8G5	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DM0M8G5	DI	DM0M8G5
DM0M8G5	DN	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide
DM0M8G5	MI	TTTQGH8
DM0M8G5	MN	Histone deacetylase 4 (HDAC4)
DM0M8G5	MT	DTT
DM0M8G5	MA	Inhibitor
DM0M8G5	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DM0M8G5	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DM0M8G5	DI	DM0M8G5
DM0M8G5	DN	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide
DM0M8G5	MI	TT5ZKDI
DM0M8G5	MN	Histone deacetylase 6 (HDAC6)
DM0M8G5	MT	DTT
DM0M8G5	MA	Inhibitor
DM0M8G5	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DM0M8G5	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DM0M8G5	DI	DM0M8G5
DM0M8G5	DN	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide
DM0M8G5	MI	TTT6LFV
DM0M8G5	MN	Histone deacetylase 8 (HDAC8)
DM0M8G5	MT	DTT
DM0M8G5	MA	Inhibitor
DM0M8G5	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DM0M8G5	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMKEHLD	DI	DMKEHLD
DMKEHLD	DN	4-Dipropylamino-cyclohex-1-enecarbonitrile
DMKEHLD	MI	TT4C8EA
DMKEHLD	MN	Dopamine D3 receptor (D3R)
DMKEHLD	MT	DTT
DMKEHLD	MA	Inhibitor
DMKEHLD	RN	Conjugated enynes as nonaromatic catechol bioisosteres: synthesis, binding experiments, and computational studies of novel dopamine receptor agonis... J Med Chem. 2000 Feb 24;43(4):756-62.
DMKEHLD	RU	https://pubmed.ncbi.nlm.nih.gov/10691700

DMD6ROZ	DI	DMD6ROZ
DMD6ROZ	DN	4E2Rcat
DMD6ROZ	MI	TTXQ1JS
DMD6ROZ	MN	HUAMN eIF4E-eIF4G interaction (eIF4E-eIF4G)
DMD6ROZ	MT	DTT
DMD6ROZ	MA	Inhibitor
DMD6ROZ	RN	Blocking eIF4E-eIF4G interaction as a strategy to impair coronavirus replication. J Virol. 2011 Jul;85(13):6381-9.
DMD6ROZ	RU	https://pubmed.ncbi.nlm.nih.gov/21507972

DM8WAOR	DI	DM8WAOR
DM8WAOR	DN	4-Ethoxy-3-pyridinesulfonamide
DM8WAOR	MI	TTHQPL7
DM8WAOR	MN	Carbonic anhydrase I (CA-I)
DM8WAOR	MT	DTT
DM8WAOR	MA	Inhibitor
DM8WAOR	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DM8WAOR	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DM8WAOR	DI	DM8WAOR
DM8WAOR	DN	4-Ethoxy-3-pyridinesulfonamide
DM8WAOR	MI	TTANPDJ
DM8WAOR	MN	Carbonic anhydrase II (CA-II)
DM8WAOR	MT	DTT
DM8WAOR	MA	Inhibitor
DM8WAOR	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DM8WAOR	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DM8WAOR	DI	DM8WAOR
DM8WAOR	DN	4-Ethoxy-3-pyridinesulfonamide
DM8WAOR	MI	TT2LVK8
DM8WAOR	MN	Carbonic anhydrase IX (CA-IX)
DM8WAOR	MT	DTT
DM8WAOR	MA	Inhibitor
DM8WAOR	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DM8WAOR	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DM8WAOR	DI	DM8WAOR
DM8WAOR	DN	4-Ethoxy-3-pyridinesulfonamide
DM8WAOR	MI	TTSYM0R
DM8WAOR	MN	Carbonic anhydrase XII (CA-XII)
DM8WAOR	MT	DTT
DM8WAOR	MA	Inhibitor
DM8WAOR	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DM8WAOR	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DM8WAOR	DI	DM8WAOR
DM8WAOR	DN	4-Ethoxy-3-pyridinesulfonamide
DM8WAOR	MI	TTEYTKG
DM8WAOR	MN	Carbonic anhydrase XIV (CA-XIV)
DM8WAOR	MT	DTT
DM8WAOR	MA	Inhibitor
DM8WAOR	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DM8WAOR	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DM8642Z	DI	DM8642Z
DM8642Z	DN	4-Ethoxy-7-((E)-styryl)-furo[3,2-g]chromen-5-one
DM8642Z	MI	TTK25J1
DM8642Z	MN	Adenosine A1 receptor (ADORA1)
DM8642Z	MT	DTT
DM8642Z	MA	Antagonist
DM8642Z	RN	Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301.
DM8642Z	RU	https://pubmed.ncbi.nlm.nih.gov/8691424

DM8642Z	DI	DM8642Z
DM8642Z	DN	4-Ethoxy-7-((E)-styryl)-furo[3,2-g]chromen-5-one
DM8642Z	MI	TTNE7KG
DM8642Z	MN	Adenosine A2b receptor (ADORA2B)
DM8642Z	MT	DTT
DM8642Z	MA	Antagonist
DM8642Z	RN	Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301.
DM8642Z	RU	https://pubmed.ncbi.nlm.nih.gov/8691424

DM8642Z	DI	DM8642Z
DM8642Z	DN	4-Ethoxy-7-((E)-styryl)-furo[3,2-g]chromen-5-one
DM8642Z	MI	TTJFY5U
DM8642Z	MN	Adenosine A3 receptor (ADORA3)
DM8642Z	MT	DTT
DM8642Z	MA	Inhibitor
DM8642Z	RN	Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301.
DM8642Z	RU	https://pubmed.ncbi.nlm.nih.gov/8691424

DMUN7KC	DI	DMUN7KC
DMUN7KC	DN	4-ethoxynaphthalene-1,2-dione
DMUN7KC	MI	TTG8HIM
DMUN7KC	MN	Dual specificity protein phosphatase 1 (DUSP1)
DMUN7KC	MT	DTT
DMUN7KC	MA	Inhibitor
DMUN7KC	RN	Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases. Bioorg Med Chem. 2009 Mar 15;17(6):2276-81.
DMUN7KC	RU	https://pubmed.ncbi.nlm.nih.gov/19028102

DMUN7KC	DI	DMUN7KC
DMUN7KC	DN	4-ethoxynaphthalene-1,2-dione
DMUN7KC	MI	TTR0SWN
DMUN7KC	MN	M-phase inducer phosphatase 2 (MPIP2)
DMUN7KC	MT	DTT
DMUN7KC	MA	Inhibitor
DMUN7KC	RN	Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases. Bioorg Med Chem. 2009 Mar 15;17(6):2276-81.
DMUN7KC	RU	https://pubmed.ncbi.nlm.nih.gov/19028102

DMTIY89	DI	DMTIY89
DMTIY89	DN	4-Ethyl-2-(4-hydroxy-phenyl)-quinolin-6-ol
DMTIY89	MI	TTZAYWL
DMTIY89	MN	Estrogen receptor (ESR)
DMTIY89	MT	DTT
DMTIY89	MA	Inhibitor
DMTIY89	RN	ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5.
DMTIY89	RU	https://pubmed.ncbi.nlm.nih.gov/16098741

DMTIY89	DI	DMTIY89
DMTIY89	DN	4-Ethyl-2-(4-hydroxy-phenyl)-quinolin-6-ol
DMTIY89	MI	TTOM3J0
DMTIY89	MN	Estrogen receptor beta (ESR2)
DMTIY89	MT	DTT
DMTIY89	MA	Inhibitor
DMTIY89	RN	ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5.
DMTIY89	RU	https://pubmed.ncbi.nlm.nih.gov/16098741

DMTIY89	DI	DMTIY89
DMTIY89	DN	4-Ethyl-2-(4-hydroxy-phenyl)-quinolin-6-ol
DMTIY89	MI	TTPNQAC
DMTIY89	MN	Estrogen-related receptor-alpha (ESRRA)
DMTIY89	MT	DTT
DMTIY89	MA	Inhibitor
DMTIY89	RN	ERbeta ligands. Part 6: 6H-Chromeno[4,3-b]quinolines as a new series of estrogen receptor beta-selective ligands. Bioorg Med Chem Lett. 2007 Jul 15;17(14):4053-6.
DMTIY89	RU	https://pubmed.ncbi.nlm.nih.gov/17482813

DMHDN25	DI	DMHDN25
DMHDN25	DN	4-ethyl-3,4-dihydroquinazolin-2-amine
DMHDN25	MI	TTRUFDT
DMHDN25	MN	5-HT 5A receptor (HTR5A)
DMHDN25	MT	DTT
DMHDN25	MA	Inhibitor
DMHDN25	RN	Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61.
DMHDN25	RU	https://pubmed.ncbi.nlm.nih.gov/17998160

DM5G3NU	DI	DM5G3NU
DM5G3NU	DN	4-Ethyl-3-methyl-pyrrolidin-(2Z)-ylideneamine
DM5G3NU	MI	TTZUFI5
DM5G3NU	MN	Nitric-oxide synthase brain (NOS1)
DM5G3NU	MT	DTT
DM5G3NU	MA	Inhibitor
DM5G3NU	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DM5G3NU	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DM5G3NU	DI	DM5G3NU
DM5G3NU	DN	4-Ethyl-3-methyl-pyrrolidin-(2Z)-ylideneamine
DM5G3NU	MI	TTF10I9
DM5G3NU	MN	Nitric-oxide synthase inducible (NOS2)
DM5G3NU	MT	DTT
DM5G3NU	MA	Inhibitor
DM5G3NU	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DM5G3NU	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DMTM1VD	DI	DMTM1VD
DMTM1VD	DN	4-Ethyl-5,6-dihydro-1H-pyridin-(2Z)-ylideneamine
DMTM1VD	MI	TTCM4B3
DMTM1VD	MN	Nitric-oxide synthase endothelial (NOS3)
DMTM1VD	MT	DTT
DMTM1VD	MA	Inhibitor
DMTM1VD	RN	Design and synthesis of orally bioavailable inhibitors of inducible nitric oxide synthase. Part 1: synthesis and biological evaluation of dihydropy... Bioorg Med Chem Lett. 2002 Sep 2;12(17):2291-4.
DMTM1VD	RU	https://pubmed.ncbi.nlm.nih.gov/12161118

DMOAQ1E	DI	DMOAQ1E
DMOAQ1E	DN	4-Ethyl-5-methyl-pyrrolidin-(2Z)-ylideneamine
DMOAQ1E	MI	TTZUFI5
DMOAQ1E	MN	Nitric-oxide synthase brain (NOS1)
DMOAQ1E	MT	DTT
DMOAQ1E	MA	Inhibitor
DMOAQ1E	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DMOAQ1E	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DMOAQ1E	DI	DMOAQ1E
DMOAQ1E	DN	4-Ethyl-5-methyl-pyrrolidin-(2Z)-ylideneamine
DMOAQ1E	MI	TTCM4B3
DMOAQ1E	MN	Nitric-oxide synthase endothelial (NOS3)
DMOAQ1E	MT	DTT
DMOAQ1E	MA	Inhibitor
DMOAQ1E	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DMOAQ1E	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DMOAQ1E	DI	DMOAQ1E
DMOAQ1E	DN	4-Ethyl-5-methyl-pyrrolidin-(2Z)-ylideneamine
DMOAQ1E	MI	TTF10I9
DMOAQ1E	MN	Nitric-oxide synthase inducible (NOS2)
DMOAQ1E	MT	DTT
DMOAQ1E	MA	Inhibitor
DMOAQ1E	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DMOAQ1E	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DMYO2GP	DI	DMYO2GP
DMYO2GP	DN	4-Ethyl-5-piperidin-4-yl-isoxazol-3-ol
DMYO2GP	MI	TTNJYV2
DMYO2GP	MN	Gamma-aminobutyric acid receptor (GAR)
DMYO2GP	MT	DTT
DMYO2GP	MA	Inhibitor
DMYO2GP	RN	A novel class of potent 3-isoxazolol GABA(A) antagonists: design, synthesis, and pharmacology. J Med Chem. 2000 Dec 28;43(26):4930-3.
DMYO2GP	RU	https://pubmed.ncbi.nlm.nih.gov/11150163

DMG0Y3W	DI	DMG0Y3W
DMG0Y3W	DN	4-Ethyl-oxazolidin-(2Z)-ylideneamine
DMG0Y3W	MI	TTZUFI5
DMG0Y3W	MN	Nitric-oxide synthase brain (NOS1)
DMG0Y3W	MT	DTT
DMG0Y3W	MA	Inhibitor
DMG0Y3W	RN	4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor. Bioorg Med Chem Lett. 2004 Jan 19;14(2):313-6.
DMG0Y3W	RU	https://pubmed.ncbi.nlm.nih.gov/14698148

DMG0Y3W	DI	DMG0Y3W
DMG0Y3W	DN	4-Ethyl-oxazolidin-(2Z)-ylideneamine
DMG0Y3W	MI	TTF10I9
DMG0Y3W	MN	Nitric-oxide synthase inducible (NOS2)
DMG0Y3W	MT	DTT
DMG0Y3W	MA	Inhibitor
DMG0Y3W	RN	4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor. Bioorg Med Chem Lett. 2004 Jan 19;14(2):313-6.
DMG0Y3W	RU	https://pubmed.ncbi.nlm.nih.gov/14698148

DMYIWAH	DI	DMYIWAH
DMYIWAH	DN	4-Ethyl-pyrrolidin-(2Z)-ylideneamine
DMYIWAH	MI	TTZUFI5
DMYIWAH	MN	Nitric-oxide synthase brain (NOS1)
DMYIWAH	MT	DTT
DMYIWAH	MA	Inhibitor
DMYIWAH	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DMYIWAH	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DMYIWAH	DI	DMYIWAH
DMYIWAH	DN	4-Ethyl-pyrrolidin-(2Z)-ylideneamine
DMYIWAH	MI	TTCM4B3
DMYIWAH	MN	Nitric-oxide synthase endothelial (NOS3)
DMYIWAH	MT	DTT
DMYIWAH	MA	Inhibitor
DMYIWAH	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DMYIWAH	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DMYIWAH	DI	DMYIWAH
DMYIWAH	DN	4-Ethyl-pyrrolidin-(2Z)-ylideneamine
DMYIWAH	MI	TTF10I9
DMYIWAH	MN	Nitric-oxide synthase inducible (NOS2)
DMYIWAH	MT	DTT
DMYIWAH	MA	Inhibitor
DMYIWAH	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DMYIWAH	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DMIF1D6	DI	DMIF1D6
DMIF1D6	DN	4-ethynyl benzene sulfonamide
DMIF1D6	MI	TTHQPL7
DMIF1D6	MN	Carbonic anhydrase I (CA-I)
DMIF1D6	MT	DTT
DMIF1D6	MA	Inhibitor
DMIF1D6	RN	Inhibition of carbonic anhydrases with glycosyltriazole benzene sulfonamides. J Med Chem. 2008 Mar 27;51(6):1945-53.
DMIF1D6	RU	https://pubmed.ncbi.nlm.nih.gov/18307288

DMIF1D6	DI	DMIF1D6
DMIF1D6	DN	4-ethynyl benzene sulfonamide
DMIF1D6	MI	TTANPDJ
DMIF1D6	MN	Carbonic anhydrase II (CA-II)
DMIF1D6	MT	DTT
DMIF1D6	MA	Inhibitor
DMIF1D6	RN	Inhibition of carbonic anhydrases with glycosyltriazole benzene sulfonamides. J Med Chem. 2008 Mar 27;51(6):1945-53.
DMIF1D6	RU	https://pubmed.ncbi.nlm.nih.gov/18307288

DMIF1D6	DI	DMIF1D6
DMIF1D6	DN	4-ethynyl benzene sulfonamide
DMIF1D6	MI	TT2LVK8
DMIF1D6	MN	Carbonic anhydrase IX (CA-IX)
DMIF1D6	MT	DTT
DMIF1D6	MA	Inhibitor
DMIF1D6	RN	Inhibition of carbonic anhydrases with glycosyltriazole benzene sulfonamides. J Med Chem. 2008 Mar 27;51(6):1945-53.
DMIF1D6	RU	https://pubmed.ncbi.nlm.nih.gov/18307288

DMXLZAT	DI	DMXLZAT
DMXLZAT	DN	4-Ethynyl-2-(4-hydroxy-phenyl)-quinolin-6-ol
DMXLZAT	MI	TTZAYWL
DMXLZAT	MN	Estrogen receptor (ESR)
DMXLZAT	MT	DTT
DMXLZAT	MA	Inhibitor
DMXLZAT	RN	ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5.
DMXLZAT	RU	https://pubmed.ncbi.nlm.nih.gov/16098741

DMXLZAT	DI	DMXLZAT
DMXLZAT	DN	4-Ethynyl-2-(4-hydroxy-phenyl)-quinolin-6-ol
DMXLZAT	MI	TTOM3J0
DMXLZAT	MN	Estrogen receptor beta (ESR2)
DMXLZAT	MT	DTT
DMXLZAT	MA	Inhibitor
DMXLZAT	RN	ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5.
DMXLZAT	RU	https://pubmed.ncbi.nlm.nih.gov/16098741

DMXLZAT	DI	DMXLZAT
DMXLZAT	DN	4-Ethynyl-2-(4-hydroxy-phenyl)-quinolin-6-ol
DMXLZAT	MI	TTPNQAC
DMXLZAT	MN	Estrogen-related receptor-alpha (ESRRA)
DMXLZAT	MT	DTT
DMXLZAT	MA	Inhibitor
DMXLZAT	RN	ERbeta ligands. Part 6: 6H-Chromeno[4,3-b]quinolines as a new series of estrogen receptor beta-selective ligands. Bioorg Med Chem Lett. 2007 Jul 15;17(14):4053-6.
DMXLZAT	RU	https://pubmed.ncbi.nlm.nih.gov/17482813

DMNDS19	DI	DMNDS19
DMNDS19	DN	4-Flourobenzenesulfonamide
DMNDS19	MI	TTANPDJ
DMNDS19	MN	Carbonic anhydrase II (CA-II)
DMNDS19	MT	DTT
DMNDS19	MA	Inhibitor
DMNDS19	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMNDS19	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMW9I1X	DI	DMW9I1X
DMW9I1X	DN	4-Fluoren-9-ylidenemethyl-pyridine
DMW9I1X	MI	TTSZLWK
DMW9I1X	MN	Aromatase (CYP19A1)
DMW9I1X	MT	DTT
DMW9I1X	MA	Inhibitor
DMW9I1X	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMW9I1X	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DM0INZX	DI	DM0INZX
DM0INZX	DN	4-Fluoro-1,1':4',1''-terphenyl-3,3''-diol
DM0INZX	MI	TTIWB6L
DM0INZX	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DM0INZX	MT	DTT
DM0INZX	MA	Inhibitor
DM0INZX	RN	New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43.
DM0INZX	RU	https://pubmed.ncbi.nlm.nih.gov/19831396

DMQ1D9A	DI	DMQ1D9A
DMQ1D9A	DN	4'-FLUORO-1,1'-BIPHENYL-4-CARBOXYLIC ACID
DMQ1D9A	MI	TTU1E82
DMQ1D9A	MN	Apoptosis regulator Bcl-xL (BCL-xL)
DMQ1D9A	MT	DTT
DMQ1D9A	MA	Inhibitor
DMQ1D9A	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMQ1D9A	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM2N4BJ	DI	DM2N4BJ
DM2N4BJ	DN	4-fluorobenzaldehyde O-benzoyloxime
DM2N4BJ	MI	TTDNFMT
DM2N4BJ	MN	Platelet-activating factor acetylhydrolase (PLA2G7)
DM2N4BJ	MT	DTT
DM2N4BJ	MA	Inhibitor
DM2N4BJ	RN	Potent inhibitors of lipoprotein-associated phospholipase A(2): benzaldehyde O-heterocycle-4-carbonyloxime. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5576-9.
DM2N4BJ	RU	https://pubmed.ncbi.nlm.nih.gov/16919943

DMS6RHD	DI	DMS6RHD
DMS6RHD	DN	4-Fluorobenzenemethanethiol
DMS6RHD	MI	TTZJYKH
DMS6RHD	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMS6RHD	MT	DTT
DMS6RHD	MA	Inhibitor
DMS6RHD	RN	S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9.
DMS6RHD	RU	https://pubmed.ncbi.nlm.nih.gov/20688518

DMWD42N	DI	DMWD42N
DMWD42N	DN	4-fluorobenzoyl-Phe-Gly-Leu-Arg-Trp-NH2
DMWD42N	MI	TT3KBZY
DMWD42N	MN	G-protein coupled receptor 54 (KISS1R)
DMWD42N	MT	DTT
DMWD42N	MA	Inhibitor
DMWD42N	RN	Development of novel G-protein-coupled receptor 54 agonists with resistance to degradation by matrix metalloproteinase. J Med Chem. 2008 Dec 11;51(23):7645-9.
DMWD42N	RU	https://pubmed.ncbi.nlm.nih.gov/19007202

DMV6M5U	DI	DMV6M5U
DMV6M5U	DN	4-fluoro-N-(4-(methylsulfonyl)phenyl)aniline
DMV6M5U	MI	TTVKILB
DMV6M5U	MN	Prostaglandin G/H synthase 2 (COX-2)
DMV6M5U	MT	DTT
DMV6M5U	MA	Inhibitor
DMV6M5U	RN	Synthesis, anti-inflammatory activity, and in vitro antitumor effect of a novel class of cyclooxygenase inhibitors: 4-(aryloyl)phenyl methyl sulfones. J Med Chem. 2010 Sep 23;53(18):6560-71.
DMV6M5U	RU	https://pubmed.ncbi.nlm.nih.gov/20804197

DMGBKN7	DI	DMGBKN7
DMGBKN7	DN	4-fluoro-N-(4-sulfamoylbenzyl)benzenesulfonamide
DMGBKN7	MI	TTHQPL7
DMGBKN7	MN	Carbonic anhydrase I (CA-I)
DMGBKN7	MT	DTT
DMGBKN7	MA	Inhibitor
DMGBKN7	RN	Ligand-based and structure-based virtual screening to identify carbonic anhydrase IX inhibitors. Bioorg Med Chem. 2009 Jan 15;17(2):553-7.
DMGBKN7	RU	https://pubmed.ncbi.nlm.nih.gov/19097911

DMGBKN7	DI	DMGBKN7
DMGBKN7	DN	4-fluoro-N-(4-sulfamoylbenzyl)benzenesulfonamide
DMGBKN7	MI	TTANPDJ
DMGBKN7	MN	Carbonic anhydrase II (CA-II)
DMGBKN7	MT	DTT
DMGBKN7	MA	Inhibitor
DMGBKN7	RN	Ligand-based and structure-based virtual screening to identify carbonic anhydrase IX inhibitors. Bioorg Med Chem. 2009 Jan 15;17(2):553-7.
DMGBKN7	RU	https://pubmed.ncbi.nlm.nih.gov/19097911

DMGBKN7	DI	DMGBKN7
DMGBKN7	DN	4-fluoro-N-(4-sulfamoylbenzyl)benzenesulfonamide
DMGBKN7	MI	TT2LVK8
DMGBKN7	MN	Carbonic anhydrase IX (CA-IX)
DMGBKN7	MT	DTT
DMGBKN7	MA	Inhibitor
DMGBKN7	RN	Ligand-based and structure-based virtual screening to identify carbonic anhydrase IX inhibitors. Bioorg Med Chem. 2009 Jan 15;17(2):553-7.
DMGBKN7	RU	https://pubmed.ncbi.nlm.nih.gov/19097911

DMZV3MD	DI	DMZV3MD
DMZV3MD	DN	4-fluorophenyl 1-(4-butoxyphenyl)propylcarbamate
DMZV3MD	MI	TTDP1UC
DMZV3MD	MN	Fatty acid amide hydrolase (FAAH)
DMZV3MD	MT	DTT
DMZV3MD	MA	Inhibitor
DMZV3MD	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DMZV3MD	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DMCRJ54	DI	DMCRJ54
DMCRJ54	DN	4-fluorophenyl 4-butoxybenzylcarbamate
DMCRJ54	MI	TTDP1UC
DMCRJ54	MN	Fatty acid amide hydrolase (FAAH)
DMCRJ54	MT	DTT
DMCRJ54	MA	Inhibitor
DMCRJ54	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DMCRJ54	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DMI03KV	DI	DMI03KV
DMI03KV	DN	4-fluorophenyl-2,2-diphenylacetamide
DMI03KV	MI	TTMNI76
DMI03KV	MN	Calcium-activated potassium channel (KCN)
DMI03KV	MT	DTT
DMI03KV	MA	Inhibitor
DMI03KV	RN	Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82.
DMI03KV	RU	https://pubmed.ncbi.nlm.nih.gov/18232633

DMD5LXQ	DI	DMD5LXQ
DMD5LXQ	DN	4-fluorophenylboronic acid
DMD5LXQ	MI	TTDP1UC
DMD5LXQ	MN	Fatty acid amide hydrolase (FAAH)
DMD5LXQ	MT	DTT
DMD5LXQ	MA	Inhibitor
DMD5LXQ	RN	Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Nov 27;51(22):7057-60.
DMD5LXQ	RU	https://pubmed.ncbi.nlm.nih.gov/18983140

DMRC49E	DI	DMRC49E
DMRC49E	DN	4-fluoroselegiline
DMRC49E	MI	TTGP7BY
DMRC49E	MN	Monoamine oxidase type B (MAO-B)
DMRC49E	MT	DTT
DMRC49E	MA	Modulator
DMRC49E	RN	Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition. Arch Int Pharmacodyn Ther. 1994 Jul-Aug;328(1):1-15.
DMRC49E	RU	https://pubmed.ncbi.nlm.nih.gov/7893186

DM1VNEF	DI	DM1VNEF
DM1VNEF	DN	4-formylphenyl-O-beta-Dglucopyranoside
DM1VNEF	MI	TT1RS9F
DM1VNEF	MN	Acetylcholinesterase (AChE)
DM1VNEF	MT	DTT
DM1VNEF	MA	Inhibitor
DM1VNEF	RN	Synthesis and biological evaluation of helicid analogues as novel acetylcholinesterase inhibitors. Eur J Med Chem. 2008 Jan;43(1):166-73.
DM1VNEF	RU	https://pubmed.ncbi.nlm.nih.gov/17574306

DM7DW0G	DI	DM7DW0G
DM7DW0G	DN	4-formylphenyl-O-beta-D-ribopyranoside
DM7DW0G	MI	TT1RS9F
DM7DW0G	MN	Acetylcholinesterase (AChE)
DM7DW0G	MT	DTT
DM7DW0G	MA	Inhibitor
DM7DW0G	RN	Synthesis and biological evaluation of helicid analogues as novel acetylcholinesterase inhibitors. Eur J Med Chem. 2008 Jan;43(1):166-73.
DM7DW0G	RU	https://pubmed.ncbi.nlm.nih.gov/17574306

DMKT915	DI	DMKT915
DMKT915	DN	4-Furan-2-yl-6-nitro-2-piperazin-1-yl-quinoline
DMKT915	MI	TT3ROYC
DMKT915	MN	Serotonin transporter (SERT)
DMKT915	MT	DTT
DMKT915	MA	Inhibitor
DMKT915	RN	Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 2: 4-substituted 6-nitroquipazines. Bioorg Med Chem Lett. 2002 Mar 11;12(5):811-5.
DMKT915	RU	https://pubmed.ncbi.nlm.nih.gov/11859009

DMRF9NH	DI	DMRF9NH
DMRF9NH	DN	4'-GALACTOSYLLACTOSE
DMRF9NH	MI	DELUCK5
DMRF9NH	MN	Oligosaccharyltransferase (pglB)
DMRF9NH	MT	DME
DMRF9NH	MA	Metabolism
DMRF9NH	RN	Characterization of N-linked protein glycosylation in Helicobacter pullorum. J Bacteriol. 2010 Oct;192(19):5228-36.
DMRF9NH	RU	https://pubmed.ncbi.nlm.nih.gov/20581208

DMRF9NH	DI	DMRF9NH
DMRF9NH	DN	4'-GALACTOSYLLACTOSE
DMRF9NH	MI	DETD1FG
DMRF9NH	MN	Oligosaccharyltransferase (pglB)
DMRF9NH	MT	DME
DMRF9NH	MA	Metabolism
DMRF9NH	RN	Characterization of N-linked protein glycosylation in Helicobacter pullorum. J Bacteriol. 2010 Oct;192(19):5228-36.
DMRF9NH	RU	https://pubmed.ncbi.nlm.nih.gov/20581208

DMRF9NH	DI	DMRF9NH
DMRF9NH	DN	4'-GALACTOSYLLACTOSE
DMRF9NH	MI	DEZKVM5
DMRF9NH	MN	Oligosaccharyltransferase (pglB)
DMRF9NH	MT	DME
DMRF9NH	MA	Metabolism
DMRF9NH	RN	Characterization of N-linked protein glycosylation in Helicobacter pullorum. J Bacteriol. 2010 Oct;192(19):5228-36.
DMRF9NH	RU	https://pubmed.ncbi.nlm.nih.gov/20581208

DM5MHO6	DI	DM5MHO6
DM5MHO6	DN	4-Hept-3-ynyl-1H-imidazole
DM5MHO6	MI	TT9JNIC
DM5MHO6	MN	Histamine H3 receptor (H3R)
DM5MHO6	MT	DTT
DM5MHO6	MA	Inhibitor
DM5MHO6	RN	New acetylene based histamine H3 receptor antagonists derived from the marine natural product verongamine. Bioorg Med Chem Lett. 1998 May 19;8(10):1133-8.
DM5MHO6	RU	https://pubmed.ncbi.nlm.nih.gov/9871722

DMA3MX5	DI	DMA3MX5
DMA3MX5	DN	4-heptyl-N-(pyridin-3-yl)benzamide
DMA3MX5	MI	TTMI6F5
DMA3MX5	MN	Transient receptor potential cation channel V1 (TRPV1)
DMA3MX5	MT	DTT
DMA3MX5	MA	Inhibitor
DMA3MX5	RN	N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4.
DMA3MX5	RU	https://pubmed.ncbi.nlm.nih.gov/18359227

DMAHLF6	DI	DMAHLF6
DMAHLF6	DN	4-heptyl-N-(quinolin-3-yl)benzamide
DMAHLF6	MI	TTMI6F5
DMAHLF6	MN	Transient receptor potential cation channel V1 (TRPV1)
DMAHLF6	MT	DTT
DMAHLF6	MA	Inhibitor
DMAHLF6	RN	N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4.
DMAHLF6	RU	https://pubmed.ncbi.nlm.nih.gov/18359227

DMYNTJ0	DI	DMYNTJ0
DMYNTJ0	DN	4-Hex-3-ynyl-1H-imidazole
DMYNTJ0	MI	TT9JNIC
DMYNTJ0	MN	Histamine H3 receptor (H3R)
DMYNTJ0	MT	DTT
DMYNTJ0	MA	Inhibitor
DMYNTJ0	RN	New acetylene based histamine H3 receptor antagonists derived from the marine natural product verongamine. Bioorg Med Chem Lett. 1998 May 19;8(10):1133-8.
DMYNTJ0	RU	https://pubmed.ncbi.nlm.nih.gov/9871722

DM36JUD	DI	DM36JUD
DM36JUD	DN	4-hexyl resorcinol
DM36JUD	MI	TTULVH8
DM36JUD	MN	Tyrosinase (TYR)
DM36JUD	MT	DTT
DM36JUD	MA	Inhibitor
DM36JUD	RN	PEG-immobilization of cardol and soluble polymer-supported synthesis of some cardol-coumarin derivatives: preliminary evaluation of their inhibitor... Bioorg Med Chem Lett. 2009 Jan 1;19(1):36-9.
DM36JUD	RU	https://pubmed.ncbi.nlm.nih.gov/19054671

DM5E03C	DI	DM5E03C
DM5E03C	DN	4-hexyl-N-(quinolin-3-yl)benzamide
DM5E03C	MI	TTMI6F5
DM5E03C	MN	Transient receptor potential cation channel V1 (TRPV1)
DM5E03C	MT	DTT
DM5E03C	MA	Inhibitor
DM5E03C	RN	N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4.
DM5E03C	RU	https://pubmed.ncbi.nlm.nih.gov/18359227

DMONZ0Y	DI	DMONZ0Y
DMONZ0Y	DN	4-hexylphenyl propiolate
DMONZ0Y	MI	TTTSEPU
DMONZ0Y	MN	Thyroid hormone receptor alpha (THRA)
DMONZ0Y	MT	DTT
DMONZ0Y	MA	Inhibitor
DMONZ0Y	RN	Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80.
DMONZ0Y	RU	https://pubmed.ncbi.nlm.nih.gov/17918822

DMONZ0Y	DI	DMONZ0Y
DMONZ0Y	DN	4-hexylphenyl propiolate
DMONZ0Y	MI	TTGER3L
DMONZ0Y	MN	Thyroid hormone receptor beta (THRB)
DMONZ0Y	MT	DTT
DMONZ0Y	MA	Inhibitor
DMONZ0Y	RN	Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80.
DMONZ0Y	RU	https://pubmed.ncbi.nlm.nih.gov/17918822

DMSZMQU	DI	DMSZMQU
DMSZMQU	DN	4-Hydrazino-3-pyridinesulfonamide
DMSZMQU	MI	TTHQPL7
DMSZMQU	MN	Carbonic anhydrase I (CA-I)
DMSZMQU	MT	DTT
DMSZMQU	MA	Inhibitor
DMSZMQU	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMSZMQU	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMSZMQU	DI	DMSZMQU
DMSZMQU	DN	4-Hydrazino-3-pyridinesulfonamide
DMSZMQU	MI	TTANPDJ
DMSZMQU	MN	Carbonic anhydrase II (CA-II)
DMSZMQU	MT	DTT
DMSZMQU	MA	Inhibitor
DMSZMQU	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMSZMQU	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMSZMQU	DI	DMSZMQU
DMSZMQU	DN	4-Hydrazino-3-pyridinesulfonamide
DMSZMQU	MI	TT2LVK8
DMSZMQU	MN	Carbonic anhydrase IX (CA-IX)
DMSZMQU	MT	DTT
DMSZMQU	MA	Inhibitor
DMSZMQU	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMSZMQU	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMSZMQU	DI	DMSZMQU
DMSZMQU	DN	4-Hydrazino-3-pyridinesulfonamide
DMSZMQU	MI	TTSYM0R
DMSZMQU	MN	Carbonic anhydrase XII (CA-XII)
DMSZMQU	MT	DTT
DMSZMQU	MA	Inhibitor
DMSZMQU	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMSZMQU	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMSZMQU	DI	DMSZMQU
DMSZMQU	DN	4-Hydrazino-3-pyridinesulfonamide
DMSZMQU	MI	TTEYTKG
DMSZMQU	MN	Carbonic anhydrase XIV (CA-XIV)
DMSZMQU	MT	DTT
DMSZMQU	MA	Inhibitor
DMSZMQU	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMSZMQU	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DM49B18	DI	DM49B18
DM49B18	DN	4-Hydrazino-benzenesulfonamide
DM49B18	MI	TTUNARX
DM49B18	MN	Carbonic anhydrase (CA)
DM49B18	MT	DTT
DM49B18	MA	Inhibitor
DM49B18	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DM49B18	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DM49B18	DI	DM49B18
DM49B18	DN	4-Hydrazino-benzenesulfonamide
DM49B18	MI	TTHQPL7
DM49B18	MN	Carbonic anhydrase I (CA-I)
DM49B18	MT	DTT
DM49B18	MA	Inhibitor
DM49B18	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamide... J Med Chem. 2005 Mar 24;48(6):2121-5.
DM49B18	RU	https://pubmed.ncbi.nlm.nih.gov/15771455

DM49B18	DI	DM49B18
DM49B18	DN	4-Hydrazino-benzenesulfonamide
DM49B18	MI	TTANPDJ
DM49B18	MN	Carbonic anhydrase II (CA-II)
DM49B18	MT	DTT
DM49B18	MA	Inhibitor
DM49B18	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DM49B18	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DM49B18	DI	DM49B18
DM49B18	DN	4-Hydrazino-benzenesulfonamide
DM49B18	MI	TTZHA0O
DM49B18	MN	Carbonic anhydrase IV (CA-IV)
DM49B18	MT	DTT
DM49B18	MA	Inhibitor
DM49B18	RN	Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1149-54.
DM49B18	RU	https://pubmed.ncbi.nlm.nih.gov/15686931

DM49B18	DI	DM49B18
DM49B18	DN	4-Hydrazino-benzenesulfonamide
DM49B18	MI	TT2LVK8
DM49B18	MN	Carbonic anhydrase IX (CA-IX)
DM49B18	MT	DTT
DM49B18	MA	Inhibitor
DM49B18	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DM49B18	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DM49B18	DI	DM49B18
DM49B18	DN	4-Hydrazino-benzenesulfonamide
DM49B18	MI	TTCFSPE
DM49B18	MN	Carbonic anhydrase VI (CA-VI)
DM49B18	MT	DTT
DM49B18	MA	Inhibitor
DM49B18	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DM49B18	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DM49B18	DI	DM49B18
DM49B18	DN	4-Hydrazino-benzenesulfonamide
DM49B18	MI	TTSYM0R
DM49B18	MN	Carbonic anhydrase XII (CA-XII)
DM49B18	MT	DTT
DM49B18	MA	Inhibitor
DM49B18	RN	Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33.
DM49B18	RU	https://pubmed.ncbi.nlm.nih.gov/16039848

DM49B18	DI	DM49B18
DM49B18	DN	4-Hydrazino-benzenesulfonamide
DM49B18	MI	TTEYTKG
DM49B18	MN	Carbonic anhydrase XIV (CA-XIV)
DM49B18	MT	DTT
DM49B18	MA	Inhibitor
DM49B18	RN	Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33.
DM49B18	RU	https://pubmed.ncbi.nlm.nih.gov/16039848

DM8PBEJ	DI	DM8PBEJ
DM8PBEJ	DN	4-Hydrazinocarbonyl-benzenesulfonamide
DM8PBEJ	MI	TTHQPL7
DM8PBEJ	MN	Carbonic anhydrase I (CA-I)
DM8PBEJ	MT	DTT
DM8PBEJ	MA	Inhibitor
DM8PBEJ	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamide... J Med Chem. 2005 Mar 24;48(6):2121-5.
DM8PBEJ	RU	https://pubmed.ncbi.nlm.nih.gov/15771455

DM8PBEJ	DI	DM8PBEJ
DM8PBEJ	DN	4-Hydrazinocarbonyl-benzenesulfonamide
DM8PBEJ	MI	TTANPDJ
DM8PBEJ	MN	Carbonic anhydrase II (CA-II)
DM8PBEJ	MT	DTT
DM8PBEJ	MA	Inhibitor
DM8PBEJ	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamide... J Med Chem. 2005 Mar 24;48(6):2121-5.
DM8PBEJ	RU	https://pubmed.ncbi.nlm.nih.gov/15771455

DM8PBEJ	DI	DM8PBEJ
DM8PBEJ	DN	4-Hydrazinocarbonyl-benzenesulfonamide
DM8PBEJ	MI	TT2LVK8
DM8PBEJ	MN	Carbonic anhydrase IX (CA-IX)
DM8PBEJ	MT	DTT
DM8PBEJ	MA	Inhibitor
DM8PBEJ	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamide... J Med Chem. 2005 Mar 24;48(6):2121-5.
DM8PBEJ	RU	https://pubmed.ncbi.nlm.nih.gov/15771455

DM6WJ4K	DI	DM6WJ4K
DM6WJ4K	DN	4-Hydroxy-1,2,5-Oxadiazole-3-Carboxylic Acid
DM6WJ4K	MI	TTAZHU0
DM6WJ4K	MN	L-lactate dehydrogenase (LDH)
DM6WJ4K	MT	DTT
DM6WJ4K	MA	Inhibitor
DM6WJ4K	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM6WJ4K	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DME29PX	DI	DME29PX
DME29PX	DN	4-Hydroxy-1,2,5-Thiadiazole-3-Carboxylic Acid
DME29PX	MI	TTAZHU0
DME29PX	MN	L-lactate dehydrogenase (LDH)
DME29PX	MT	DTT
DME29PX	MA	Inhibitor
DME29PX	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DME29PX	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMTZ9G3	DI	DMTZ9G3
DMTZ9G3	DN	4-hydroxy-1-methyl-4-(4-methylphenyl)-3-piperidyl 4-methylphenyl ketone
DMTZ9G3	MI	TT8DBY3
DMTZ9G3	MN	Angiotensin II receptor type-1 (AGTR1)
DMTZ9G3	MT	DTT
DMTZ9G3	MA	Antagonist
DMTZ9G3	RN	Discovery of a novel dopamine transporter inhibitor, 4-hydroxy-1-methyl-4-(4-methylphenyl)-3-piperidyl 4-methylphenyl ketone, as a potential cocaine antagonist through 3D-database pharmacophore searching. Molecular modeling, structure-activity relationships, and behavioral pharmacological studies. J Med Chem. 2000 Feb 10;43(3):351-60.
DMTZ9G3	RU	https://pubmed.ncbi.nlm.nih.gov/10669562

DM7BQ65	DI	DM7BQ65
DM7BQ65	DN	4-Hydroxy-2-Butanone
DM7BQ65	MI	TTMW94E
DM7BQ65	MN	FK506-binding protein 1A (FKBP1A)
DM7BQ65	MT	DTT
DM7BQ65	MA	Inhibitor
DM7BQ65	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM7BQ65	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM2LJFZ	DI	DM2LJFZ
DM2LJFZ	DN	4-hydroxy-2-nonenal
DM2LJFZ	MI	TTRPDBG
DM2LJFZ	MN	Inhibitor of nuclear factor kappa-B kinase (IKK)
DM2LJFZ	MT	DTT
DM2LJFZ	MA	Inhibitor
DM2LJFZ	RN	IkappaB kinase, a molecular target for inhibition by 4-hydroxy-2-nonenal. J Biol Chem. 2001 May 25;276(21):18223-8.
DM2LJFZ	RU	https://pubmed.ncbi.nlm.nih.gov/11359792

DM2LJFZ	DI	DM2LJFZ
DM2LJFZ	DN	4-hydroxy-2-nonenal
DM2LJFZ	MI	DE8RYV5
DM2LJFZ	MN	NADPH:quinone reductase (CRYZ)
DM2LJFZ	MT	DME
DM2LJFZ	MA	Metabolism
DM2LJFZ	RN	Kinetic and structural evidence of the alkenal/one reductase specificity of human crystallin. Cell Mol Life Sci. 2011 Mar;68(6):1065-77.
DM2LJFZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20835842

DMY3OHK	DI	DMY3OHK
DMY3OHK	DN	4-Hydroxy-3-(1-naphthylmethyl)-2H-chromen-2-one
DMY3OHK	MI	TT8XK6L
DMY3OHK	MN	Quinone reductase 1 (NQO1)
DMY3OHK	MT	DTT
DMY3OHK	MA	Inhibitor
DMY3OHK	RN	Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1). J Med Chem. 2009 Nov 26;52(22):7142-56.
DMY3OHK	RU	https://pubmed.ncbi.nlm.nih.gov/19877692

DMM3QPL	DI	DMM3QPL
DMM3QPL	DN	4-Hydroxy-3-(2-naphthylmethyl)-2H-chromen-2-one
DMM3QPL	MI	TT8XK6L
DMM3QPL	MN	Quinone reductase 1 (NQO1)
DMM3QPL	MT	DTT
DMM3QPL	MA	Inhibitor
DMM3QPL	RN	Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1). J Med Chem. 2009 Nov 26;52(22):7142-56.
DMM3QPL	RU	https://pubmed.ncbi.nlm.nih.gov/19877692

DM2PS89	DI	DM2PS89
DM2PS89	DN	4-Hydroxy-3,5-diisopropyl-benzaldehyde
DM2PS89	MI	TTNJYV2
DM2PS89	MN	Gamma-aminobutyric acid receptor (GAR)
DM2PS89	MT	DTT
DM2PS89	MA	Inhibitor
DM2PS89	RN	Propofol analogues. Synthesis, relationships between structure and affinity at GABAA receptor in rat brain, and differential electrophysiological p... J Med Chem. 1998 May 21;41(11):1846-54.
DM2PS89	RU	https://pubmed.ncbi.nlm.nih.gov/9599235

DMWDBHC	DI	DMWDBHC
DMWDBHC	DN	4-Hydroxy-3-methyl-but-2-enoic acid
DMWDBHC	MI	TT6TKEN
DMWDBHC	MN	Gamma-hydroxybutyrate receptor (SLC52A2)
DMWDBHC	MT	DTT
DMWDBHC	MA	Inhibitor
DMWDBHC	RN	Analogues of gamma-hydroxybutyric acid. Synthesis and binding studies. J Med Chem. 1988 May;31(5):893-7.
DMWDBHC	RU	https://pubmed.ncbi.nlm.nih.gov/3361576

DM6AHO4	DI	DM6AHO4
DM6AHO4	DN	4-Hydroxy-3-methyl-butyric acid
DM6AHO4	MI	TT6TKEN
DM6AHO4	MN	Gamma-hydroxybutyrate receptor (SLC52A2)
DM6AHO4	MT	DTT
DM6AHO4	MA	Inhibitor
DM6AHO4	RN	Analogues of gamma-hydroxybutyric acid. Synthesis and binding studies. J Med Chem. 1988 May;31(5):893-7.
DM6AHO4	RU	https://pubmed.ncbi.nlm.nih.gov/3361576

DMR0S8X	DI	DMR0S8X
DMR0S8X	DN	4-hydroxy-3-nitrobenzaldehyde
DMR0S8X	MI	TTT2LD9
DMR0S8X	MN	GABA transaminase (ABAT)
DMR0S8X	MT	DTT
DMR0S8X	MA	Inhibitor
DMR0S8X	RN	Inhibition of GABA shunt enzymes' activity by 4-hydroxybenzaldehyde derivatives. Bioorg Med Chem Lett. 2006 Feb;16(3):592-5.
DMR0S8X	RU	https://pubmed.ncbi.nlm.nih.gov/16290145

DMDEMV8	DI	DMDEMV8
DMDEMV8	DN	4-Hydroxy-3-nonanoyl-6-octyl-pyran-2-one
DMDEMV8	MI	TTPLTSQ
DMDEMV8	MN	Neutrophil elastase (NE)
DMDEMV8	MT	DTT
DMDEMV8	MA	Inhibitor
DMDEMV8	RN	Inhibition of human sputum elastase by substituted 2-pyrones. J Med Chem. 1987 Jun;30(6):1017-23.
DMDEMV8	RU	https://pubmed.ncbi.nlm.nih.gov/3647139

DMIVQGW	DI	DMIVQGW
DMIVQGW	DN	4-Hydroxy-4-phenyl-but-2-enoic acid
DMIVQGW	MI	TT6TKEN
DMIVQGW	MN	Gamma-hydroxybutyrate receptor (SLC52A2)
DMIVQGW	MT	DTT
DMIVQGW	MA	Inhibitor
DMIVQGW	RN	Analogues of gamma-hydroxybutyric acid. Synthesis and binding studies. J Med Chem. 1988 May;31(5):893-7.
DMIVQGW	RU	https://pubmed.ncbi.nlm.nih.gov/3361576

DMDWGS9	DI	DMDWGS9
DMDWGS9	DN	4-Hydroxy-4-phenyl-butyric acid
DMDWGS9	MI	TT6TKEN
DMDWGS9	MN	Gamma-hydroxybutyrate receptor (SLC52A2)
DMDWGS9	MT	DTT
DMDWGS9	MA	Inhibitor
DMDWGS9	RN	Analogues of gamma-hydroxybutyric acid. Synthesis and binding studies. J Med Chem. 1988 May;31(5):893-7.
DMDWGS9	RU	https://pubmed.ncbi.nlm.nih.gov/3361576

DMVFKSX	DI	DMVFKSX
DMVFKSX	DN	4-Hydroxy-5-methoxy-10H-anthracen-9-one
DMVFKSX	MI	TT2J34L
DMVFKSX	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMVFKSX	MT	DTT
DMVFKSX	MA	Inhibitor
DMVFKSX	RN	Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80.
DMVFKSX	RU	https://pubmed.ncbi.nlm.nih.gov/9371243

DMT3H2X	DI	DMT3H2X
DMT3H2X	DN	4-hydroxy-5-phenylthieno[2,3-b]pyridin-6(7H)-one
DMT3H2X	MI	TTLD29N
DMT3H2X	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMT3H2X	MT	DTT
DMT3H2X	MA	Inhibitor
DMT3H2X	RN	Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor. J Med Chem. 2006 Feb 9;49(3):864-71.
DMT3H2X	RU	https://pubmed.ncbi.nlm.nih.gov/16451052

DMT3H2X	DI	DMT3H2X
DMT3H2X	DN	4-hydroxy-5-phenylthieno[2,3-b]pyridin-6(7H)-one
DMT3H2X	MI	TTKJEMQ
DMT3H2X	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMT3H2X	MT	DTT
DMT3H2X	MA	Inhibitor
DMT3H2X	RN	Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor. J Med Chem. 2006 Feb 9;49(3):864-71.
DMT3H2X	RU	https://pubmed.ncbi.nlm.nih.gov/16451052

DMT3H2X	DI	DMT3H2X
DMT3H2X	DN	4-hydroxy-5-phenylthieno[2,3-b]pyridin-6(7H)-one
DMT3H2X	MI	TTN9D8E
DMT3H2X	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMT3H2X	MT	DTT
DMT3H2X	MA	Inhibitor
DMT3H2X	RN	Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor. J Med Chem. 2006 Feb 9;49(3):864-71.
DMT3H2X	RU	https://pubmed.ncbi.nlm.nih.gov/16451052

DM7PWOL	DI	DM7PWOL
DM7PWOL	DN	4'-hydroxy-6,3',5'-triprenylisoflavonone
DM7PWOL	MI	TT9V5JH
DM7PWOL	MN	Phospholipase A2 (PLA2G1B)
DM7PWOL	MT	DTT
DM7PWOL	MA	Inhibitor
DM7PWOL	RN	Phospholipase A2 Inhibitors from an Erythrina Species from Samoa J. Nat. Prod. 60(6):537-539 (1997).
DM7PWOL	RU	http://pubs.acs.org/doi/abs/10.1021/np960533e

DMH78QU	DI	DMH78QU
DMH78QU	DN	4-hydroxy-6-nitro-3-phenylquinolin-2(1H)-one
DMH78QU	MI	TT7AOUD
DMH78QU	MN	Fatty acid synthase (FASN)
DMH78QU	MT	DTT
DMH78QU	MA	Inhibitor
DMH78QU	RN	3-Aryl-4-hydroxyquinolin-2(1H)-one derivatives as type I fatty acid synthase inhibitors. Bioorg Med Chem Lett. 2006 Sep 1;16(17):4620-3.
DMH78QU	RU	https://pubmed.ncbi.nlm.nih.gov/16784844

DMD3OV8	DI	DMD3OV8
DMD3OV8	DN	4-hydroxy-8-nitro-3-phenylquinolin-2(1H)-one
DMD3OV8	MI	TT7AOUD
DMD3OV8	MN	Fatty acid synthase (FASN)
DMD3OV8	MT	DTT
DMD3OV8	MA	Inhibitor
DMD3OV8	RN	3-Aryl-4-hydroxyquinolin-2(1H)-one derivatives as type I fatty acid synthase inhibitors. Bioorg Med Chem Lett. 2006 Sep 1;16(17):4620-3.
DMD3OV8	RU	https://pubmed.ncbi.nlm.nih.gov/16784844

DMT8L5R	DI	DMT8L5R
DMT8L5R	DN	4-Hydroxy-Aconitate Ion
DMT8L5R	MI	TTMTF2P
DMT8L5R	MN	Citrate hydro-lyase (ACO2)
DMT8L5R	MT	DTT
DMT8L5R	MA	Inhibitor
DMT8L5R	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMT8L5R	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM7WPGN	DI	DM7WPGN
DM7WPGN	DN	4-HYDROXYBENZALDEHYDE O-(CYCLOHEXYLCARBONYL)OXIME
DM7WPGN	MI	TT2AST1
DM7WPGN	MN	Macrophage migration inhibitory factor (MIF)
DM7WPGN	MT	DTT
DM7WPGN	MA	Inhibitor
DM7WPGN	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM7WPGN	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMJVPF0	DI	DMJVPF0
DMJVPF0	DN	4-hydroxybenzylamine
DMJVPF0	MI	TTT2LD9
DMJVPF0	MN	GABA transaminase (ABAT)
DMJVPF0	MT	DTT
DMJVPF0	MA	Inhibitor
DMJVPF0	RN	Inhibition of GABA shunt enzymes' activity by 4-hydroxybenzaldehyde derivatives. Bioorg Med Chem Lett. 2006 Feb;16(3):592-5.
DMJVPF0	RU	https://pubmed.ncbi.nlm.nih.gov/16290145

DMCA2XQ	DI	DMCA2XQ
DMCA2XQ	DN	4-hydroxy-but-2-enoate
DMCA2XQ	MI	TT6TKEN
DMCA2XQ	MN	Gamma-hydroxybutyrate receptor (SLC52A2)
DMCA2XQ	MT	DTT
DMCA2XQ	MA	Inhibitor
DMCA2XQ	RN	Analogues of gamma-hydroxybutyric acid. Synthesis and binding studies. J Med Chem. 1988 May;31(5):893-7.
DMCA2XQ	RU	https://pubmed.ncbi.nlm.nih.gov/3361576

DM36PHM	DI	DM36PHM
DM36PHM	DN	4-hydroxylonchocarpin
DM36PHM	MI	TTUMGNO
DM36PHM	MN	Ornithine decarboxylase (ODC1)
DM36PHM	MT	DTT
DM36PHM	MA	Inhibitor
DM36PHM	RN	New bioactive flavonoids and stilbenes in cub resin insecticide. J Nat Prod. 1999 Feb;62(2):205-10.
DM36PHM	RU	https://pubmed.ncbi.nlm.nih.gov/10075742

DMULOHZ	DI	DMULOHZ
DMULOHZ	DN	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide
DMULOHZ	MI	TTBH0VX
DMULOHZ	MN	Histone deacetylase (HDAC)
DMULOHZ	MT	DTT
DMULOHZ	MA	Inhibitor
DMULOHZ	RN	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
DMULOHZ	RU	https://pubmed.ncbi.nlm.nih.gov/11831887

DMULOHZ	DI	DMULOHZ
DMULOHZ	DN	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide
DMULOHZ	MI	TT6R7JZ
DMULOHZ	MN	Histone deacetylase 1 (HDAC1)
DMULOHZ	MT	DTT
DMULOHZ	MA	Inhibitor
DMULOHZ	RN	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
DMULOHZ	RU	https://pubmed.ncbi.nlm.nih.gov/11831887

DMULOHZ	DI	DMULOHZ
DMULOHZ	DN	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide
DMULOHZ	MI	TTYHPU6
DMULOHZ	MN	Histone deacetylase 10 (HDAC10)
DMULOHZ	MT	DTT
DMULOHZ	MA	Inhibitor
DMULOHZ	RN	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
DMULOHZ	RU	https://pubmed.ncbi.nlm.nih.gov/11831887

DMULOHZ	DI	DMULOHZ
DMULOHZ	DN	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide
DMULOHZ	MI	TTSHTOI
DMULOHZ	MN	Histone deacetylase 2 (HDAC2)
DMULOHZ	MT	DTT
DMULOHZ	MA	Inhibitor
DMULOHZ	RN	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
DMULOHZ	RU	https://pubmed.ncbi.nlm.nih.gov/11831887

DMULOHZ	DI	DMULOHZ
DMULOHZ	DN	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide
DMULOHZ	MI	TTTQGH8
DMULOHZ	MN	Histone deacetylase 4 (HDAC4)
DMULOHZ	MT	DTT
DMULOHZ	MA	Inhibitor
DMULOHZ	RN	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
DMULOHZ	RU	https://pubmed.ncbi.nlm.nih.gov/11831887

DMULOHZ	DI	DMULOHZ
DMULOHZ	DN	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide
DMULOHZ	MI	TT5ZKDI
DMULOHZ	MN	Histone deacetylase 6 (HDAC6)
DMULOHZ	MT	DTT
DMULOHZ	MA	Inhibitor
DMULOHZ	RN	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
DMULOHZ	RU	https://pubmed.ncbi.nlm.nih.gov/11831887

DMULOHZ	DI	DMULOHZ
DMULOHZ	DN	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide
DMULOHZ	MI	TTT6LFV
DMULOHZ	MN	Histone deacetylase 8 (HDAC8)
DMULOHZ	MT	DTT
DMULOHZ	MA	Inhibitor
DMULOHZ	RN	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
DMULOHZ	RU	https://pubmed.ncbi.nlm.nih.gov/11831887

DMXPQ5H	DI	DMXPQ5H
DMXPQ5H	DN	4-hydroxy-N,N-diphenylbenzenesulfonamide
DMXPQ5H	MI	TTZAYWL
DMXPQ5H	MN	Estrogen receptor (ESR)
DMXPQ5H	MT	DTT
DMXPQ5H	MA	Inhibitor
DMXPQ5H	RN	Substituted 4-hydroxyphenyl sulfonamides as pathway-selective estrogen receptor ligands. Bioorg Med Chem Lett. 2006 Feb 15;16(4):854-8.
DMXPQ5H	RU	https://pubmed.ncbi.nlm.nih.gov/16300947

DMVAP9U	DI	DMVAP9U
DMVAP9U	DN	4-hydroxy-N-isopropyl-N-phenylbenzenesulfonamide
DMVAP9U	MI	TTZAYWL
DMVAP9U	MN	Estrogen receptor (ESR)
DMVAP9U	MT	DTT
DMVAP9U	MA	Inhibitor
DMVAP9U	RN	Substituted 4-hydroxyphenyl sulfonamides as pathway-selective estrogen receptor ligands. Bioorg Med Chem Lett. 2006 Feb 15;16(4):854-8.
DMVAP9U	RU	https://pubmed.ncbi.nlm.nih.gov/16300947

DM8XOJC	DI	DM8XOJC
DM8XOJC	DN	4-hydroxy-N-neopentyl-N-phenylbenzenesulfonamide
DM8XOJC	MI	TTZAYWL
DM8XOJC	MN	Estrogen receptor (ESR)
DM8XOJC	MT	DTT
DM8XOJC	MA	Inhibitor
DM8XOJC	RN	Substituted 4-hydroxyphenyl sulfonamides as pathway-selective estrogen receptor ligands. Bioorg Med Chem Lett. 2006 Feb 15;16(4):854-8.
DM8XOJC	RU	https://pubmed.ncbi.nlm.nih.gov/16300947

DM5TU98	DI	DM5TU98
DM5TU98	DN	4-hydroxy-N-phenyl-N-propylbenzenesulfonamide
DM5TU98	MI	TTZAYWL
DM5TU98	MN	Estrogen receptor (ESR)
DM5TU98	MT	DTT
DM5TU98	MA	Inhibitor
DM5TU98	RN	Substituted 4-hydroxyphenyl sulfonamides as pathway-selective estrogen receptor ligands. Bioorg Med Chem Lett. 2006 Feb 15;16(4):854-8.
DM5TU98	RU	https://pubmed.ncbi.nlm.nih.gov/16300947

DMNMJDL	DI	DMNMJDL
DMNMJDL	DN	4-HYDROXY-N-PROPARGYL-1(R)-AMINOINDAN
DMNMJDL	MI	TTGP7BY
DMNMJDL	MN	Monoamine oxidase type B (MAO-B)
DMNMJDL	MT	DTT
DMNMJDL	MA	Inhibitor
DMNMJDL	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMNMJDL	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM5ZQK1	DI	DM5ZQK1
DM5ZQK1	DN	4-Hydroxy-pent-2-enoic acid
DM5ZQK1	MI	TT6TKEN
DM5ZQK1	MN	Gamma-hydroxybutyrate receptor (SLC52A2)
DM5ZQK1	MT	DTT
DM5ZQK1	MA	Inhibitor
DM5ZQK1	RN	Analogues of gamma-hydroxybutyric acid. Synthesis and binding studies. J Med Chem. 1988 May;31(5):893-7.
DM5ZQK1	RU	https://pubmed.ncbi.nlm.nih.gov/3361576

DMDGKFV	DI	DMDGKFV
DMDGKFV	DN	4-Hydroxy-pentanoic acid
DMDGKFV	MI	TT6TKEN
DMDGKFV	MN	Gamma-hydroxybutyrate receptor (SLC52A2)
DMDGKFV	MT	DTT
DMDGKFV	MA	Inhibitor
DMDGKFV	RN	Analogues of gamma-hydroxybutyric acid. Synthesis and binding studies. J Med Chem. 1988 May;31(5):893-7.
DMDGKFV	RU	https://pubmed.ncbi.nlm.nih.gov/3361576

DMJ7G0E	DI	DMJ7G0E
DMJ7G0E	DN	4-hydroxyphenethyl 3,4,5-trihydroxybenzoate
DMJ7G0E	MI	TTULVH8
DMJ7G0E	MN	Tyrosinase (TYR)
DMJ7G0E	MT	DTT
DMJ7G0E	MA	Inhibitor
DMJ7G0E	RN	Synthetic tyrosyl gallate derivatives as potent melanin formation inhibitors. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5462-4.
DMJ7G0E	RU	https://pubmed.ncbi.nlm.nih.gov/17693086

DM0564K	DI	DM0564K
DM0564K	DN	4-hydroxyphenylpyruvic acid
DM0564K	MI	TT6L509
DM0564K	MN	Coagulation factor IIa (F2)
DM0564K	MT	DTT
DM0564K	MA	Inhibitor
DM0564K	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM0564K	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM0564K	DI	DM0564K
DM0564K	DN	4-hydroxyphenylpyruvic acid
DM0564K	MI	TT2AST1
DM0564K	MN	Macrophage migration inhibitory factor (MIF)
DM0564K	MT	DTT
DM0564K	MA	Inhibitor
DM0564K	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM0564K	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM9VQ0T	DI	DM9VQ0T
DM9VQ0T	DN	4-Hydroxy-piperidine-3-carboxylic acid
DM9VQ0T	MI	TTPRKM0
DM9VQ0T	MN	GABA transporter GAT-1 (SLC6A1)
DM9VQ0T	MT	DTT
DM9VQ0T	MA	Inhibitor
DM9VQ0T	RN	Hydroxy- and amino-substituted piperidinecarboxylic acids as gamma-aminobutyric acid agonists and uptake inhibitors. J Med Chem. 1982 Oct;25(10):1157-62.
DM9VQ0T	RU	https://pubmed.ncbi.nlm.nih.gov/6292417

DM9VQ0T	DI	DM9VQ0T
DM9VQ0T	DN	4-Hydroxy-piperidine-3-carboxylic acid
DM9VQ0T	MI	TT8RXO5
DM9VQ0T	MN	GABA transporter-3 (SLC6A11)
DM9VQ0T	MT	DTT
DM9VQ0T	MA	Inhibitor
DM9VQ0T	RN	Hydroxy- and amino-substituted piperidinecarboxylic acids as gamma-aminobutyric acid agonists and uptake inhibitors. J Med Chem. 1982 Oct;25(10):1157-62.
DM9VQ0T	RU	https://pubmed.ncbi.nlm.nih.gov/6292417

DMPIV6J	DI	DMPIV6J
DMPIV6J	DN	4-hydroxysaprothoquinone
DMPIV6J	MI	TTGTQHC
DMPIV6J	MN	DNA topoisomerase I (TOP1)
DMPIV6J	MT	DTT
DMPIV6J	MA	Inhibitor
DMPIV6J	RN	Bioactive abietane and seco-abietane diterpenoids from Salvia prionitis. J Nat Prod. 2002 Jul;65(7):1016-20.
DMPIV6J	RU	https://pubmed.ncbi.nlm.nih.gov/12141863

DMJKF17	DI	DMJKF17
DMJKF17	DN	4-Imidazol-1-yl-2-phenyl-chroman-7-ol
DMJKF17	MI	TTSZLWK
DMJKF17	MN	Aromatase (CYP19A1)
DMJKF17	MT	DTT
DMJKF17	MA	Inhibitor
DMJKF17	RN	Synthesis and evaluation of 4-triazolylflavans as new aromatase inhibitors. Bioorg Med Chem Lett. 2004 Oct 18;14(20):5215-8.
DMJKF17	RU	https://pubmed.ncbi.nlm.nih.gov/15380230

DM28DEU	DI	DM28DEU
DM28DEU	DN	4-Imidazol-1-ylmethyl-1-nitrothioxanthen-9-one
DM28DEU	MI	TTSZLWK
DM28DEU	MN	Aromatase (CYP19A1)
DM28DEU	MT	DTT
DM28DEU	MA	Inhibitor
DM28DEU	RN	Novel highly potent and selective nonsteroidal aromatase inhibitors: synthesis, biological evaluation and structure-activity relationships investigation. J Med Chem. 2010 Jul 22;53(14):5347-51. 
DM28DEU	RU	https://pubmed.ncbi.nlm.nih.gov/20568782

DMZLVIF	DI	DMZLVIF
DMZLVIF	DN	4-Imidazol-1-ylmethyl-1-nitro-xanthen-9-one
DMZLVIF	MI	TTSZLWK
DMZLVIF	MN	Aromatase (CYP19A1)
DMZLVIF	MT	DTT
DMZLVIF	MA	Inhibitor
DMZLVIF	RN	A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase. J Med Chem. 2001 Mar 1;44(5):672-80.
DMZLVIF	RU	https://pubmed.ncbi.nlm.nih.gov/11262078

DM6FMO1	DI	DM6FMO1
DM6FMO1	DN	4-Imidazol-1-ylmethyl-2-nitroxanthen-9-one
DM6FMO1	MI	TTSZLWK
DM6FMO1	MN	Aromatase (CYP19A1)
DM6FMO1	MT	DTT
DM6FMO1	MA	Inhibitor
DM6FMO1	RN	Novel highly potent and selective nonsteroidal aromatase inhibitors: synthesis, biological evaluation and structure-activity relationships investigation. J Med Chem. 2010 Jul 22;53(14):5347-51. 
DM6FMO1	RU	https://pubmed.ncbi.nlm.nih.gov/20568782

DM8KZQN	DI	DM8KZQN
DM8KZQN	DN	4-Imidazol-1-ylmethyl-3-nitroxanthen-9-one
DM8KZQN	MI	TTSZLWK
DM8KZQN	MN	Aromatase (CYP19A1)
DM8KZQN	MT	DTT
DM8KZQN	MA	Inhibitor
DM8KZQN	RN	Novel highly potent and selective nonsteroidal aromatase inhibitors: synthesis, biological evaluation and structure-activity relationships investigation. J Med Chem. 2010 Jul 22;53(14):5347-51. 
DM8KZQN	RU	https://pubmed.ncbi.nlm.nih.gov/20568782

DMVUSMP	DI	DMVUSMP
DMVUSMP	DN	4-Imidazol-1-ylmethylthioxanthen-9-one
DMVUSMP	MI	TTSZLWK
DMVUSMP	MN	Aromatase (CYP19A1)
DMVUSMP	MT	DTT
DMVUSMP	MA	Inhibitor
DMVUSMP	RN	Novel highly potent and selective nonsteroidal aromatase inhibitors: synthesis, biological evaluation and structure-activity relationships investigation. J Med Chem. 2010 Jul 22;53(14):5347-51. 
DMVUSMP	RU	https://pubmed.ncbi.nlm.nih.gov/20568782

DMM8HK0	DI	DMM8HK0
DMM8HK0	DN	4-Imidazol-1-ylmethylxanthen-9-one
DMM8HK0	MI	TTSZLWK
DMM8HK0	MN	Aromatase (CYP19A1)
DMM8HK0	MT	DTT
DMM8HK0	MA	Inhibitor
DMM8HK0	RN	Novel highly potent and selective nonsteroidal aromatase inhibitors: synthesis, biological evaluation and structure-activity relationships investigation. J Med Chem. 2010 Jul 22;53(14):5347-51. 
DMM8HK0	RU	https://pubmed.ncbi.nlm.nih.gov/20568782

DMFRCQS	DI	DMFRCQS
DMFRCQS	DN	4-Indan-(1E)-ylidenemethyl-pyridine
DMFRCQS	MI	TTSZLWK
DMFRCQS	MN	Aromatase (CYP19A1)
DMFRCQS	MT	DTT
DMFRCQS	MA	Inhibitor
DMFRCQS	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMFRCQS	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DM25DR7	DI	DM25DR7
DM25DR7	DN	4-Indan-(1Z)-ylidenemethyl-pyridine
DM25DR7	MI	TTSZLWK
DM25DR7	MN	Aromatase (CYP19A1)
DM25DR7	MT	DTT
DM25DR7	MA	Inhibitor
DM25DR7	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DM25DR7	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DM25DR7	DI	DM25DR7
DM25DR7	DN	4-Indan-(1Z)-ylidenemethyl-pyridine
DM25DR7	MI	TTIQUX7
DM25DR7	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM25DR7	MT	DTT
DM25DR7	MA	Inhibitor
DM25DR7	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DM25DR7	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DM25DR7	DI	DM25DR7
DM25DR7	DN	4-Indan-(1Z)-ylidenemethyl-pyridine
DM25DR7	MI	TTRA5BZ
DM25DR7	MN	Steroid 17-alpha-monooxygenase (S17AH)
DM25DR7	MT	DTT
DM25DR7	MA	Inhibitor
DM25DR7	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DM25DR7	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DM6YON7	DI	DM6YON7
DM6YON7	DN	4-Indan-1-ylmethyl-phenylamine
DM6YON7	MI	TTJS8PY
DM6YON7	MN	5-HT 6 receptor (HTR6)
DM6YON7	MT	DTT
DM6YON7	MA	Inhibitor
DM6YON7	RN	Binding of isotryptamines and indenes at h5-HT6 serotonin receptors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1987-91.
DM6YON7	RU	https://pubmed.ncbi.nlm.nih.gov/15808453

DM23E0R	DI	DM23E0R
DM23E0R	DN	4-Inden-(1E)-ylidenemethyl-phenylamine
DM23E0R	MI	TTJS8PY
DM23E0R	MN	5-HT 6 receptor (HTR6)
DM23E0R	MT	DTT
DM23E0R	MA	Inhibitor
DM23E0R	RN	Binding of isotryptamines and indenes at h5-HT6 serotonin receptors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1987-91.
DM23E0R	RU	https://pubmed.ncbi.nlm.nih.gov/15808453

DMG9JSK	DI	DMG9JSK
DMG9JSK	DN	4-Indol-1-ylmethyl-benzamidine
DMG9JSK	MI	TT2WR1T
DMG9JSK	MN	Cationic trypsinogen (PRSS1)
DMG9JSK	MT	DTT
DMG9JSK	MA	Inhibitor
DMG9JSK	RN	Aromatic amidines: comparison of their ability to block respiratory syncytial virus induced cell fusion and to inhibit plasmin, urokinase, thrombin... J Med Chem. 1983 Feb;26(2):294-8.
DMG9JSK	RU	https://pubmed.ncbi.nlm.nih.gov/6219223

DMKZQ3I	DI	DMKZQ3I
DMKZQ3I	DN	4-iodo-1H-indazole
DMKZQ3I	MI	TTZUFI5
DMKZQ3I	MN	Nitric-oxide synthase brain (NOS1)
DMKZQ3I	MT	DTT
DMKZQ3I	MA	Inhibitor
DMKZQ3I	RN	4-substituted indazoles as new inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3177-80.
DMKZQ3I	RU	https://pubmed.ncbi.nlm.nih.gov/17395463

DMIPENJ	DI	DMIPENJ
DMIPENJ	DN	4-Iodo-2,6-diisopropyl-phenol
DMIPENJ	MI	TTNJYV2
DMIPENJ	MN	Gamma-aminobutyric acid receptor (GAR)
DMIPENJ	MT	DTT
DMIPENJ	MA	Inhibitor
DMIPENJ	RN	Propofol analogues. Synthesis, relationships between structure and affinity at GABAA receptor in rat brain, and differential electrophysiological p... J Med Chem. 1998 May 21;41(11):1846-54.
DMIPENJ	RU	https://pubmed.ncbi.nlm.nih.gov/9599235

DMC8D4R	DI	DMC8D4R
DMC8D4R	DN	4-Iodo-6-nitro-2-piperazin-1-yl-quinoline
DMC8D4R	MI	TT3ROYC
DMC8D4R	MN	Serotonin transporter (SERT)
DMC8D4R	MT	DTT
DMC8D4R	MA	Inhibitor
DMC8D4R	RN	Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 2: 4-substituted 6-nitroquipazines. Bioorg Med Chem Lett. 2002 Mar 11;12(5):811-5.
DMC8D4R	RU	https://pubmed.ncbi.nlm.nih.gov/11859009

DMYNVLZ	DI	DMYNVLZ
DMYNVLZ	DN	4-iodo-6-phenylpyrimidine
DMYNVLZ	MI	TT6804T
DMYNVLZ	MN	MIF messenger RNA (MIF mRNA)
DMYNVLZ	MT	DTT
DMYNVLZ	MA	Inhibitor
DMYNVLZ	RN	Optimization of N-benzyl-benzoxazol-2-ones as receptor antagonists of macrophage migration inhibitory factor (MIF). Bioorg Med Chem Lett. 2010 Oct 1;20(19):5811-4.
DMYNVLZ	RU	https://pubmed.ncbi.nlm.nih.gov/20728358

DMFSH2I	DI	DMFSH2I
DMFSH2I	DN	4-iodo-acetamido phenylboronic acid
DMFSH2I	MI	TTHI19T
DMFSH2I	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMFSH2I	MT	DTT
DMFSH2I	MA	Inhibitor
DMFSH2I	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMFSH2I	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMXAEGF	DI	DMXAEGF
DMXAEGF	DN	4-iodobenzo[b]thiophene 2-carboxamidine
DMXAEGF	MI	TT6L509
DMXAEGF	MN	Coagulation factor IIa (F2)
DMXAEGF	MT	DTT
DMXAEGF	MA	Inhibitor
DMXAEGF	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMXAEGF	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMXAEGF	DI	DMXAEGF
DMXAEGF	DN	4-iodobenzo[b]thiophene 2-carboxamidine
DMXAEGF	MI	TTFEZ5Q
DMXAEGF	MN	Coagulation factor IX (F9)
DMXAEGF	MT	DTT
DMXAEGF	MA	Inhibitor
DMXAEGF	RN	Studies of benzothiophene template as potent factor IXa (FIXa) inhibitors in thrombosis. J Med Chem. 2010 Feb 25;53(4):1465-72.
DMXAEGF	RU	https://pubmed.ncbi.nlm.nih.gov/20121198

DMXAEGF	DI	DMXAEGF
DMXAEGF	DN	4-iodobenzo[b]thiophene 2-carboxamidine
DMXAEGF	MI	TTGY7WI
DMXAEGF	MN	Urokinase-type plasminogen activator (PLAU)
DMXAEGF	MT	DTT
DMXAEGF	MA	Inhibitor
DMXAEGF	RN	Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator. Chem Biol. 2000 Apr;7(4):299-312.
DMXAEGF	RU	https://pubmed.ncbi.nlm.nih.gov/10779411

DMJMOAI	DI	DMJMOAI
DMJMOAI	DN	4-iodophenyl-alaninyl-(S)-2-cyano-pyrrolidine
DMJMOAI	MI	TTDIGC1
DMJMOAI	MN	Dipeptidyl peptidase 4 (DPP-4)
DMJMOAI	MT	DTT
DMJMOAI	MA	Inhibitor
DMJMOAI	RN	Discovery, SAR, and X-ray structure of novel biaryl-based dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett. 2006 Jan 1;16(1):123-8.
DMJMOAI	RU	https://pubmed.ncbi.nlm.nih.gov/16236500

DMF3CLX	DI	DMF3CLX
DMF3CLX	DN	4-Iodopyrazole
DMF3CLX	MI	TTBK0PU
DMF3CLX	MN	Mycobacterium Cytochrome p450 121 (MycB cyp121)
DMF3CLX	MT	DTT
DMF3CLX	MA	Inhibitor
DMF3CLX	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMF3CLX	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMQ95EG	DI	DMQ95EG
DMQ95EG	DN	4-Iodyl-benzoic acid
DMQ95EG	MI	TTELIN2
DMQ95EG	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMQ95EG	MT	DTT
DMQ95EG	MA	Inhibitor
DMQ95EG	RN	Periodinates: a new class of protein tyrosine phosphatase inhibitors. Bioorg Med Chem Lett. 1999 Feb 8;9(3):353-6.
DMQ95EG	RU	https://pubmed.ncbi.nlm.nih.gov/10091683

DM7F38J	DI	DM7F38J
DM7F38J	DN	4-isopropyl-2-(phenoxymethyl)morpholine
DM7F38J	MI	TT9JNIC
DM7F38J	MN	Histamine H3 receptor (H3R)
DM7F38J	MT	DTT
DM7F38J	MA	Inhibitor
DM7F38J	RN	2-Aryloxymethylmorpholine histamine H(3) antagonists. Bioorg Med Chem Lett. 2008 Nov 1;18(21):5796-9.
DM7F38J	RU	https://pubmed.ncbi.nlm.nih.gov/18922693

DMW1T93	DI	DMW1T93
DMW1T93	DN	4-isopropyl-N-(naphthalen-1-yl)thiazol-2-amine
DMW1T93	MI	TT7HQD0
DMW1T93	MN	C-C chemokine receptor type 4 (CCR4)
DMW1T93	MT	DTT
DMW1T93	MA	Inhibitor
DMW1T93	RN	Optimization of 2-aminothiazole derivatives as CCR4 antagonists. Bioorg Med Chem Lett. 2006 May 15;16(10):2800-3.
DMW1T93	RU	https://pubmed.ncbi.nlm.nih.gov/16497499

DMMDGR2	DI	DMMDGR2
DMMDGR2	DN	4-ISOPROPYLPHENSERINE
DMMDGR2	MI	TT1RS9F
DMMDGR2	MN	Acetylcholinesterase (AChE)
DMMDGR2	MT	DTT
DMMDGR2	MA	Inhibitor
DMMDGR2	RN	Design, synthesis, evaluation and QSAR analysis of N(1)-substituted norcymserine derivatives as selective butyrylcholinesterase inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1718-20.
DMMDGR2	RU	https://pubmed.ncbi.nlm.nih.gov/20137934

DMMDGR2	DI	DMMDGR2
DMMDGR2	DN	4-ISOPROPYLPHENSERINE
DMMDGR2	MI	TTEB0GD
DMMDGR2	MN	Cholinesterase (BCHE)
DMMDGR2	MT	DTT
DMMDGR2	MA	Inhibitor
DMMDGR2	RN	A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase. Curr Med Res Opin. 2001;17(3):159-65.
DMMDGR2	RU	https://pubmed.ncbi.nlm.nih.gov/11900310

DMVTEOQ	DI	DMVTEOQ
DMVTEOQ	DN	4-Isopropyl-pyrrolidin-(2Z)-ylideneamine
DMVTEOQ	MI	TTZUFI5
DMVTEOQ	MN	Nitric-oxide synthase brain (NOS1)
DMVTEOQ	MT	DTT
DMVTEOQ	MA	Inhibitor
DMVTEOQ	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DMVTEOQ	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DMVTEOQ	DI	DMVTEOQ
DMVTEOQ	DN	4-Isopropyl-pyrrolidin-(2Z)-ylideneamine
DMVTEOQ	MI	TTF10I9
DMVTEOQ	MN	Nitric-oxide synthase inducible (NOS2)
DMVTEOQ	MT	DTT
DMVTEOQ	MA	Inhibitor
DMVTEOQ	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DMVTEOQ	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DMBK67H	DI	DMBK67H
DMBK67H	DN	4-isothiocyanatobenzenesulfonamide
DMBK67H	MI	TTHQPL7
DMBK67H	MN	Carbonic anhydrase I (CA-I)
DMBK67H	MT	DTT
DMBK67H	MA	Inhibitor
DMBK67H	RN	Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library. J Med Chem. 2004 Oct 7;47(21):5224-9.
DMBK67H	RU	https://pubmed.ncbi.nlm.nih.gov/15456265

DMBK67H	DI	DMBK67H
DMBK67H	DN	4-isothiocyanatobenzenesulfonamide
DMBK67H	MI	TTANPDJ
DMBK67H	MN	Carbonic anhydrase II (CA-II)
DMBK67H	MT	DTT
DMBK67H	MA	Inhibitor
DMBK67H	RN	Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library. J Med Chem. 2004 Oct 7;47(21):5224-9.
DMBK67H	RU	https://pubmed.ncbi.nlm.nih.gov/15456265

DMNCVIP	DI	DMNCVIP
DMNCVIP	DN	4-MA
DMNCVIP	MI	TTZT9R2
DMNCVIP	MN	Hydroxysteroid dehydrogenase 3-beta (HSD3B)
DMNCVIP	MT	DTT
DMNCVIP	MA	Inhibitor
DMNCVIP	RN	Activity and inhibition of 3-beta-hydroxysteroid dehydrogenase/delta-5-4-isomerase in human skin. Skin Pharmacol. 1997;10(3):160-8.
DMNCVIP	RU	https://pubmed.ncbi.nlm.nih.gov/9287397

DMPH4C8	DI	DMPH4C8
DMPH4C8	DN	4-Methanesulfonylamino-benzenesulfonamide
DMPH4C8	MI	TTHQPL7
DMPH4C8	MN	Carbonic anhydrase I (CA-I)
DMPH4C8	MT	DTT
DMPH4C8	MA	Inhibitor
DMPH4C8	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DMPH4C8	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DMPH4C8	DI	DMPH4C8
DMPH4C8	DN	4-Methanesulfonylamino-benzenesulfonamide
DMPH4C8	MI	TTANPDJ
DMPH4C8	MN	Carbonic anhydrase II (CA-II)
DMPH4C8	MT	DTT
DMPH4C8	MA	Inhibitor
DMPH4C8	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DMPH4C8	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DMPH4C8	DI	DMPH4C8
DMPH4C8	DN	4-Methanesulfonylamino-benzenesulfonamide
DMPH4C8	MI	TT2LVK8
DMPH4C8	MN	Carbonic anhydrase IX (CA-IX)
DMPH4C8	MT	DTT
DMPH4C8	MA	Inhibitor
DMPH4C8	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DMPH4C8	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DMPH4C8	DI	DMPH4C8
DMPH4C8	DN	4-Methanesulfonylamino-benzenesulfonamide
DMPH4C8	MI	TTSYM0R
DMPH4C8	MN	Carbonic anhydrase XII (CA-XII)
DMPH4C8	MT	DTT
DMPH4C8	MA	Inhibitor
DMPH4C8	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DMPH4C8	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DM97B2G	DI	DM97B2G
DM97B2G	DN	4-Methoxy-2-phenyl-2H-pyrazolo[4,3-c]quinoline
DM97B2G	MI	TTJFY5U
DM97B2G	MN	Adenosine A3 receptor (ADORA3)
DM97B2G	MT	DTT
DM97B2G	MA	Inhibitor
DM97B2G	RN	New 2-arylpyrazolo[4,3-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. J Med Chem. 2005 Jul 28;48(15):5001-8.
DM97B2G	RU	https://pubmed.ncbi.nlm.nih.gov/16033279

DMJIX7H	DI	DMJIX7H
DMJIX7H	DN	4-Methoxy-3-pyridinesulfonamide
DMJIX7H	MI	TTHQPL7
DMJIX7H	MN	Carbonic anhydrase I (CA-I)
DMJIX7H	MT	DTT
DMJIX7H	MA	Inhibitor
DMJIX7H	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMJIX7H	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMJIX7H	DI	DMJIX7H
DMJIX7H	DN	4-Methoxy-3-pyridinesulfonamide
DMJIX7H	MI	TTANPDJ
DMJIX7H	MN	Carbonic anhydrase II (CA-II)
DMJIX7H	MT	DTT
DMJIX7H	MA	Inhibitor
DMJIX7H	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMJIX7H	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMJIX7H	DI	DMJIX7H
DMJIX7H	DN	4-Methoxy-3-pyridinesulfonamide
DMJIX7H	MI	TT2LVK8
DMJIX7H	MN	Carbonic anhydrase IX (CA-IX)
DMJIX7H	MT	DTT
DMJIX7H	MA	Inhibitor
DMJIX7H	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMJIX7H	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMJIX7H	DI	DMJIX7H
DMJIX7H	DN	4-Methoxy-3-pyridinesulfonamide
DMJIX7H	MI	TTSYM0R
DMJIX7H	MN	Carbonic anhydrase XII (CA-XII)
DMJIX7H	MT	DTT
DMJIX7H	MA	Inhibitor
DMJIX7H	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMJIX7H	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DM5FRV2	DI	DM5FRV2
DM5FRV2	DN	4'-Methoxy-5,3'-dipropyl-biphenyl-2ol
DM5FRV2	MI	TTSJ6Q4
DM5FRV2	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DM5FRV2	MT	DTT
DM5FRV2	MA	Inhibitor
DM5FRV2	RN	Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxyge... Bioorg Med Chem. 2009 Jul 1;17(13):4459-65.
DM5FRV2	RU	https://pubmed.ncbi.nlm.nih.gov/19481465

DM5FRV2	DI	DM5FRV2
DM5FRV2	DN	4'-Methoxy-5,3'-dipropyl-biphenyl-2ol
DM5FRV2	MI	TT8NGED
DM5FRV2	MN	Prostaglandin G/H synthase 1 (COX-1)
DM5FRV2	MT	DTT
DM5FRV2	MA	Inhibitor
DM5FRV2	RN	Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxyge... Bioorg Med Chem. 2009 Jul 1;17(13):4459-65.
DM5FRV2	RU	https://pubmed.ncbi.nlm.nih.gov/19481465

DMID40H	DI	DMID40H
DMID40H	DN	4-Methoxy-5-phenyl-6-thia-10b-aza-benzo[e]azulene
DMID40H	MI	TTPTXIN
DMID40H	MN	Translocator protein (TSPO)
DMID40H	MT	DTT
DMID40H	MA	Inhibitor
DMID40H	RN	A concerted study using binding measurements, X-ray structural data, and molecular modeling on the stereochemical features responsible for the affi... J Med Chem. 1995 Nov 10;38(23):4730-8.
DMID40H	RU	https://pubmed.ncbi.nlm.nih.gov/7473601

DM54A3W	DI	DM54A3W
DM54A3W	DN	4-methoxy-9-aminomethyl-9,10-dihydroanthracene
DM54A3W	MI	TTJQOD7
DM54A3W	MN	5-HT 2A receptor (HTR2A)
DM54A3W	MT	DTT
DM54A3W	MA	Inhibitor
DM54A3W	RN	Methoxy-substituted 9-aminomethyl-9,10-dihydroanthracene (AMDA) derivatives exhibit differential binding affinities at the 5-HT(2A) receptor. Bioorg Med Chem Lett. 2008 Oct 1;18(19):5268-71.
DM54A3W	RU	https://pubmed.ncbi.nlm.nih.gov/18774714

DMVFLCM	DI	DMVFLCM
DMVFLCM	DN	4-Methoxybenzenemethanethiol
DMVFLCM	MI	TTZJYKH
DMVFLCM	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMVFLCM	MT	DTT
DMVFLCM	MA	Inhibitor
DMVFLCM	RN	S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9.
DMVFLCM	RU	https://pubmed.ncbi.nlm.nih.gov/20688518

DMCS83F	DI	DMCS83F
DMCS83F	DN	4-Methoxymethyl-3,6-dipropoxy-9H-beta-carboline
DMCS83F	MI	TT1MPAY
DMCS83F	MN	GABA(A) receptor alpha-1 (GABRA1)
DMCS83F	MT	DTT
DMCS83F	MA	Inhibitor
DMCS83F	RN	Synthesis and evaluation of analogues of the partial agonist 6-(propyloxy)-4-(methoxymethyl)-beta-carboline-3-carboxylic acid ethyl ester (6-PBC) a... J Med Chem. 1998 Jul 2;41(14):2537-52.
DMCS83F	RU	https://pubmed.ncbi.nlm.nih.gov/9651158

DMCS83F	DI	DMCS83F
DMCS83F	DN	4-Methoxymethyl-3,6-dipropoxy-9H-beta-carboline
DMCS83F	MI	TTNJYV2
DMCS83F	MN	Gamma-aminobutyric acid receptor (GAR)
DMCS83F	MT	DTT
DMCS83F	MA	Inhibitor
DMCS83F	RN	Synthesis and evaluation of analogues of the partial agonist 6-(propyloxy)-4-(methoxymethyl)-beta-carboline-3-carboxylic acid ethyl ester (6-PBC) a... J Med Chem. 1998 Jul 2;41(14):2537-52.
DMCS83F	RU	https://pubmed.ncbi.nlm.nih.gov/9651158

DMF079L	DI	DMF079L
DMF079L	DN	4-methoxy-N'-(2-phenylacetyl)benzohydrazide
DMF079L	MI	TTPLTSQ
DMF079L	MN	Neutrophil elastase (NE)
DMF079L	MT	DTT
DMF079L	MA	Inhibitor
DMF079L	RN	N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
DMF079L	RU	https://pubmed.ncbi.nlm.nih.gov/17850059

DMF079L	DI	DMF079L
DMF079L	DN	4-methoxy-N'-(2-phenylacetyl)benzohydrazide
DMF079L	MI	TTGY7WI
DMF079L	MN	Urokinase-type plasminogen activator (PLAU)
DMF079L	MT	DTT
DMF079L	MA	Inhibitor
DMF079L	RN	N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
DMF079L	RU	https://pubmed.ncbi.nlm.nih.gov/17850059

DMFKN1M	DI	DMFKN1M
DMFKN1M	DN	4-Methoxy-N-(3-phenyl-isoquinolin-1-yl)-benzamide
DMFKN1M	MI	TTK25J1
DMFKN1M	MN	Adenosine A1 receptor (ADORA1)
DMFKN1M	MT	DTT
DMFKN1M	MA	Inhibitor
DMFKN1M	RN	Substituted 4-phenyl-2-(phenylcarboxamido)-1,3-thiazole derivatives as antagonists for the adenosine A(1) receptor. Bioorg Med Chem Lett. 2001 Aug 6;11(15):2017-9.
DMFKN1M	RU	https://pubmed.ncbi.nlm.nih.gov/11454470

DMFKN1M	DI	DMFKN1M
DMFKN1M	DN	4-Methoxy-N-(3-phenyl-isoquinolin-1-yl)-benzamide
DMFKN1M	MI	TTJFY5U
DMFKN1M	MN	Adenosine A3 receptor (ADORA3)
DMFKN1M	MT	DTT
DMFKN1M	MA	Inhibitor
DMFKN1M	RN	Substituted 4-phenyl-2-(phenylcarboxamido)-1,3-thiazole derivatives as antagonists for the adenosine A(1) receptor. Bioorg Med Chem Lett. 2001 Aug 6;11(15):2017-9.
DMFKN1M	RU	https://pubmed.ncbi.nlm.nih.gov/11454470

DMPQKGY	DI	DMPQKGY
DMPQKGY	DN	4-methoxy-N-(thiazol-2-yl)benzamide
DMPQKGY	MI	TTSJ6Q4
DMPQKGY	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DMPQKGY	MT	DTT
DMPQKGY	MA	Inhibitor
DMPQKGY	RN	Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. J Med Chem. 2007 May 31;50(11):2640-6.
DMPQKGY	RU	https://pubmed.ncbi.nlm.nih.gov/17461565

DMBS61O	DI	DMBS61O
DMBS61O	DN	4-methoxynaphthalen-1-amine
DMBS61O	MI	TTZJYKH
DMBS61O	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMBS61O	MT	DTT
DMBS61O	MA	Inhibitor
DMBS61O	RN	Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2010 Feb 11;53(3):1172-89.
DMBS61O	RU	https://pubmed.ncbi.nlm.nih.gov/20055453

DM739SQ	DI	DM739SQ
DM739SQ	DN	4-methoxyphenyl 1-(4-butoxyphenyl)propylcarbamate
DM739SQ	MI	TTDP1UC
DM739SQ	MN	Fatty acid amide hydrolase (FAAH)
DM739SQ	MT	DTT
DM739SQ	MA	Inhibitor
DM739SQ	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DM739SQ	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DM3L76R	DI	DM3L76R
DM3L76R	DN	4-methoxyphenyl 10H-phenothiazine-10-carboxylate
DM3L76R	MI	TTEB0GD
DM3L76R	MN	Cholinesterase (BCHE)
DM3L76R	MT	DTT
DM3L76R	MA	Inhibitor
DM3L76R	RN	Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. J Med Chem. 2008 Jul 24;51(14):4200-12.
DM3L76R	RU	https://pubmed.ncbi.nlm.nih.gov/18570368

DMP5YFQ	DI	DMP5YFQ
DMP5YFQ	DN	4-methoxyphenylboronic acid
DMP5YFQ	MI	TTUNARX
DMP5YFQ	MN	Carbonic anhydrase (CA)
DMP5YFQ	MT	DTT
DMP5YFQ	MA	Inhibitor
DMP5YFQ	RN	Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5.
DMP5YFQ	RU	https://pubmed.ncbi.nlm.nih.gov/19375309

DMP5YFQ	DI	DMP5YFQ
DMP5YFQ	DN	4-methoxyphenylboronic acid
DMP5YFQ	MI	TTHQPL7
DMP5YFQ	MN	Carbonic anhydrase I (CA-I)
DMP5YFQ	MT	DTT
DMP5YFQ	MA	Inhibitor
DMP5YFQ	RN	Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5.
DMP5YFQ	RU	https://pubmed.ncbi.nlm.nih.gov/19375309

DMP5YFQ	DI	DMP5YFQ
DMP5YFQ	DN	4-methoxyphenylboronic acid
DMP5YFQ	MI	TTANPDJ
DMP5YFQ	MN	Carbonic anhydrase II (CA-II)
DMP5YFQ	MT	DTT
DMP5YFQ	MA	Inhibitor
DMP5YFQ	RN	Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5.
DMP5YFQ	RU	https://pubmed.ncbi.nlm.nih.gov/19375309

DMP5YFQ	DI	DMP5YFQ
DMP5YFQ	DN	4-methoxyphenylboronic acid
DMP5YFQ	MI	TTDP1UC
DMP5YFQ	MN	Fatty acid amide hydrolase (FAAH)
DMP5YFQ	MT	DTT
DMP5YFQ	MA	Inhibitor
DMP5YFQ	RN	Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Nov 27;51(22):7057-60.
DMP5YFQ	RU	https://pubmed.ncbi.nlm.nih.gov/18983140

DMVW8KN	DI	DMVW8KN
DMVW8KN	DN	4-methoxyphenylsulfamide
DMVW8KN	MI	TTANPDJ
DMVW8KN	MN	Carbonic anhydrase II (CA-II)
DMVW8KN	MT	DTT
DMVW8KN	MA	Inhibitor
DMVW8KN	RN	Inhibition of carbonic anhydrase-II by sulfamate and sulfamide groups: an investigation involving direct thermodynamic binding measurements. J Med Chem. 2006 Jun 15;49(12):3496-500.
DMVW8KN	RU	https://pubmed.ncbi.nlm.nih.gov/16759092

DM2IZA3	DI	DM2IZA3
DM2IZA3	DN	4-Methyl-1,1':4',1''-terphenyl-3,4''-diol
DM2IZA3	MI	TTIWB6L
DM2IZA3	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DM2IZA3	MT	DTT
DM2IZA3	MA	Inhibitor
DM2IZA3	RN	New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43.
DM2IZA3	RU	https://pubmed.ncbi.nlm.nih.gov/19831396

DMKRHQ3	DI	DMKRHQ3
DMKRHQ3	DN	4-methyl-2H-benzofuro[3,2-g]chromen-2-one
DMKRHQ3	MI	TT3WG5C
DMKRHQ3	MN	Monoamine oxidase type A (MAO-A)
DMKRHQ3	MT	DTT
DMKRHQ3	MA	Inhibitor
DMKRHQ3	RN	A QSAR model for in silico screening of MAO-A inhibitors. Prediction, synthesis, and biological assay of novel coumarins. J Med Chem. 2006 Feb 9;49(3):1149-56.
DMKRHQ3	RU	https://pubmed.ncbi.nlm.nih.gov/16451079

DMH6QZO	DI	DMH6QZO
DMH6QZO	DN	4-Methyl-3-(2-oxo-azetidin-1-yl)-benzoic acid
DMH6QZO	MI	TTHI19T
DMH6QZO	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMH6QZO	MT	DTT
DMH6QZO	MA	Inhibitor
DMH6QZO	RN	N-aryl 3-halogenated azetidin-2-ones and benzocarbacephems, inhibitors of beta-lactamases. J Med Chem. 1988 Feb;31(2):370-4.
DMH6QZO	RU	https://pubmed.ncbi.nlm.nih.gov/3257523

DM5FWYG	DI	DM5FWYG
DM5FWYG	DN	4-Methyl-3,6-dihydro-1H-pyridin-(2Z)-ylideneamine
DM5FWYG	MI	TTCM4B3
DM5FWYG	MN	Nitric-oxide synthase endothelial (NOS3)
DM5FWYG	MT	DTT
DM5FWYG	MA	Inhibitor
DM5FWYG	RN	Design and synthesis of orally bioavailable inhibitors of inducible nitric oxide synthase. Part 1: synthesis and biological evaluation of dihydropy... Bioorg Med Chem Lett. 2002 Sep 2;12(17):2291-4.
DM5FWYG	RU	https://pubmed.ncbi.nlm.nih.gov/12161118

DMV19HC	DI	DMV19HC
DMV19HC	DN	4-Methyl-5-(4-piperidyl)isothiazol-3-ol
DMV19HC	MI	TT1MPAY
DMV19HC	MN	GABA(A) receptor alpha-1 (GABRA1)
DMV19HC	MT	DTT
DMV19HC	MA	Inhibitor
DMV19HC	RN	Potent 4-arylalkyl-substituted 3-isothiazolol GABA(A) competitive/noncompetitive antagonists: synthesis and pharmacology. J Med Chem. 2006 Feb 23;49(4):1388-96.
DMV19HC	RU	https://pubmed.ncbi.nlm.nih.gov/16480274

DMV19HC	DI	DMV19HC
DMV19HC	DN	4-Methyl-5-(4-piperidyl)isothiazol-3-ol
DMV19HC	MI	TT06RH5
DMV19HC	MN	GABA(A) receptor gamma-2 (GABRG2)
DMV19HC	MT	DTT
DMV19HC	MA	Inhibitor
DMV19HC	RN	Potent 4-arylalkyl-substituted 3-isothiazolol GABA(A) competitive/noncompetitive antagonists: synthesis and pharmacology. J Med Chem. 2006 Feb 23;49(4):1388-96.
DMV19HC	RU	https://pubmed.ncbi.nlm.nih.gov/16480274

DMV19HC	DI	DMV19HC
DMV19HC	DN	4-Methyl-5-(4-piperidyl)isothiazol-3-ol
DMV19HC	MI	TTNJYV2
DMV19HC	MN	Gamma-aminobutyric acid receptor (GAR)
DMV19HC	MT	DTT
DMV19HC	MA	Inhibitor
DMV19HC	RN	Potent 4-arylalkyl-substituted 3-isothiazolol GABA(A) competitive/noncompetitive antagonists: synthesis and pharmacology. J Med Chem. 2006 Feb 23;49(4):1388-96.
DMV19HC	RU	https://pubmed.ncbi.nlm.nih.gov/16480274

DMUP8NS	DI	DMUP8NS
DMUP8NS	DN	4-Methyl-5,6-dihydro-1H-pyridin-(2Z)-ylideneamine
DMUP8NS	MI	TTCM4B3
DMUP8NS	MN	Nitric-oxide synthase endothelial (NOS3)
DMUP8NS	MT	DTT
DMUP8NS	MA	Inhibitor
DMUP8NS	RN	Design and synthesis of orally bioavailable inhibitors of inducible nitric oxide synthase. Part 1: synthesis and biological evaluation of dihydropy... Bioorg Med Chem Lett. 2002 Sep 2;12(17):2291-4.
DMUP8NS	RU	https://pubmed.ncbi.nlm.nih.gov/12161118

DM7LPON	DI	DM7LPON
DM7LPON	DN	4-Methyl-5,6-dihydro-pyrido[1,2-a]quinolin-3-one
DM7LPON	MI	TTTU72V
DM7LPON	MN	Steroid 5-alpha-reductase 1 (SRD5A1)
DM7LPON	MT	DTT
DM7LPON	MA	Inhibitor
DM7LPON	RN	Benzo[c]quinolizin-3-ones: a novel class of potent and selective nonsteroidal inhibitors of human steroid 5alpha-reductase 1. J Med Chem. 2000 Oct 5;43(20):3718-35.
DM7LPON	RU	https://pubmed.ncbi.nlm.nih.gov/11020287

DM0ZA7T	DI	DM0ZA7T
DM0ZA7T	DN	4-Methyl-5-piperidin-4-yl-isoxazol-3-ol
DM0ZA7T	MI	TTNJYV2
DM0ZA7T	MN	Gamma-aminobutyric acid receptor (GAR)
DM0ZA7T	MT	DTT
DM0ZA7T	MA	Inhibitor
DM0ZA7T	RN	A novel class of potent 3-isoxazolol GABA(A) antagonists: design, synthesis, and pharmacology. J Med Chem. 2000 Dec 28;43(26):4930-3.
DM0ZA7T	RU	https://pubmed.ncbi.nlm.nih.gov/11150163

DMN8Z3C	DI	DMN8Z3C
DMN8Z3C	DN	4-Methyl-5-propyl-pyrrolidin-(2Z)-ylideneamine
DMN8Z3C	MI	TTZUFI5
DMN8Z3C	MN	Nitric-oxide synthase brain (NOS1)
DMN8Z3C	MT	DTT
DMN8Z3C	MA	Inhibitor
DMN8Z3C	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DMN8Z3C	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DMN8Z3C	DI	DMN8Z3C
DMN8Z3C	DN	4-Methyl-5-propyl-pyrrolidin-(2Z)-ylideneamine
DMN8Z3C	MI	TTF10I9
DMN8Z3C	MN	Nitric-oxide synthase inducible (NOS2)
DMN8Z3C	MT	DTT
DMN8Z3C	MA	Inhibitor
DMN8Z3C	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DMN8Z3C	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DMW7YHS	DI	DMW7YHS
DMW7YHS	DN	4-Methyl-6-(2-methylprop-1-enyl)pyridin-2-amine
DMW7YHS	MI	TTF10I9
DMW7YHS	MN	Nitric-oxide synthase inducible (NOS2)
DMW7YHS	MT	DTT
DMW7YHS	MA	Inhibitor
DMW7YHS	RN	Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [18F]6-(2-fl... J Med Chem. 2009 Apr 23;52(8):2443-53.
DMW7YHS	RU	https://pubmed.ncbi.nlm.nih.gov/19323559

DMY04D1	DI	DMY04D1
DMY04D1	DN	4-methyl-6-propylpyridin-2-amine
DMY04D1	MI	TTZUFI5
DMY04D1	MN	Nitric-oxide synthase brain (NOS1)
DMY04D1	MT	DTT
DMY04D1	MA	Inhibitor
DMY04D1	RN	Anchored plasticity opens doors for selective inhibitor design in nitric oxide synthase. Nat Chem Biol. 2008 Nov;4(11):700-7.
DMY04D1	RU	https://pubmed.ncbi.nlm.nih.gov/18849972

DMY04D1	DI	DMY04D1
DMY04D1	DN	4-methyl-6-propylpyridin-2-amine
DMY04D1	MI	TTCM4B3
DMY04D1	MN	Nitric-oxide synthase endothelial (NOS3)
DMY04D1	MT	DTT
DMY04D1	MA	Inhibitor
DMY04D1	RN	Anchored plasticity opens doors for selective inhibitor design in nitric oxide synthase. Nat Chem Biol. 2008 Nov;4(11):700-7.
DMY04D1	RU	https://pubmed.ncbi.nlm.nih.gov/18849972

DMY04D1	DI	DMY04D1
DMY04D1	DN	4-methyl-6-propylpyridin-2-amine
DMY04D1	MI	TTF10I9
DMY04D1	MN	Nitric-oxide synthase inducible (NOS2)
DMY04D1	MT	DTT
DMY04D1	MA	Inhibitor
DMY04D1	RN	Anchored plasticity opens doors for selective inhibitor design in nitric oxide synthase. Nat Chem Biol. 2008 Nov;4(11):700-7.
DMY04D1	RU	https://pubmed.ncbi.nlm.nih.gov/18849972

DM9K7CQ	DI	DM9K7CQ
DM9K7CQ	DN	4-methyl-7-(2-oxocyclopentyloxy)-2H-chromen-2-one
DM9K7CQ	MI	TT3WG5C
DM9K7CQ	MN	Monoamine oxidase type A (MAO-A)
DM9K7CQ	MT	DTT
DM9K7CQ	MA	Inhibitor
DM9K7CQ	RN	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J Med Chem. 2008 Nov 13;51(21):6740-51.
DM9K7CQ	RU	https://pubmed.ncbi.nlm.nih.gov/18834112

DM9K7CQ	DI	DM9K7CQ
DM9K7CQ	DN	4-methyl-7-(2-oxocyclopentyloxy)-2H-chromen-2-one
DM9K7CQ	MI	TTGP7BY
DM9K7CQ	MN	Monoamine oxidase type B (MAO-B)
DM9K7CQ	MT	DTT
DM9K7CQ	MA	Inhibitor
DM9K7CQ	RN	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J Med Chem. 2008 Nov 13;51(21):6740-51.
DM9K7CQ	RU	https://pubmed.ncbi.nlm.nih.gov/18834112

DM5XMI9	DI	DM5XMI9
DM5XMI9	DN	4-Methylamino-benzenesulfonamide
DM5XMI9	MI	TTANPDJ
DM5XMI9	MN	Carbonic anhydrase II (CA-II)
DM5XMI9	MT	DTT
DM5XMI9	MA	Inhibitor
DM5XMI9	RN	Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglauc... Bioorg Med Chem Lett. 2005 Feb 15;15(4):963-9.
DM5XMI9	RU	https://pubmed.ncbi.nlm.nih.gov/15686894

DM5XMI9	DI	DM5XMI9
DM5XMI9	DN	4-Methylamino-benzenesulfonamide
DM5XMI9	MI	TTSYM0R
DM5XMI9	MN	Carbonic anhydrase XII (CA-XII)
DM5XMI9	MT	DTT
DM5XMI9	MA	Inhibitor
DM5XMI9	RN	Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglauc... Bioorg Med Chem Lett. 2005 Feb 15;15(4):963-9.
DM5XMI9	RU	https://pubmed.ncbi.nlm.nih.gov/15686894

DMI1L6Q	DI	DMI1L6Q
DMI1L6Q	DN	4-methylaminomethyl-7-methoxycoumarin
DMI1L6Q	MI	TTVG215
DMI1L6Q	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DMI1L6Q	MT	DTT
DMI1L6Q	MA	Inhibitor
DMI1L6Q	RN	Exploration of the amine terminus in a novel series of 1,2,4-triazolo-3-yl-azabicyclo[3.1.0]hexanes as selective dopamine D3 receptor antagonists. J Med Chem. 2010 Oct 14;53(19):7129-39.
DMI1L6Q	RU	https://pubmed.ncbi.nlm.nih.gov/20839775

DM3S2P8	DI	DM3S2P8
DM3S2P8	DN	4-Methylbenzenemethanethiol
DM3S2P8	MI	TTZJYKH
DM3S2P8	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DM3S2P8	MT	DTT
DM3S2P8	MA	Inhibitor
DM3S2P8	RN	S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9.
DM3S2P8	RU	https://pubmed.ncbi.nlm.nih.gov/20688518

DMABMPQ	DI	DMABMPQ
DMABMPQ	DN	4-methylhistamine
DMABMPQ	MI	TTXJ178
DMABMPQ	MN	Histamine H4 receptor (H4R)
DMABMPQ	MT	DTT
DMABMPQ	MA	Agonist
DMABMPQ	RN	Compared pharmacology of human histamine H3 and H4 receptors: structure-activity relationships of histamine derivatives. Br J Pharmacol. 2006 Apr;147(7):744-54.
DMABMPQ	RU	https://pubmed.ncbi.nlm.nih.gov/16432504

DM45N6U	DI	DM45N6U
DM45N6U	DN	4-Methylimidazole
DM45N6U	MI	TTANPDJ
DM45N6U	MN	Carbonic anhydrase II (CA-II)
DM45N6U	MT	DTT
DM45N6U	MA	Inhibitor
DM45N6U	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DM45N6U	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMSF5DR	DI	DMSF5DR
DMSF5DR	DN	4-Methyl-N-(4-phenyl-thiazol-2-yl)-benzamide
DMSF5DR	MI	TTK25J1
DMSF5DR	MN	Adenosine A1 receptor (ADORA1)
DMSF5DR	MT	DTT
DMSF5DR	MA	Inhibitor
DMSF5DR	RN	Substituted 4-phenyl-2-(phenylcarboxamido)-1,3-thiazole derivatives as antagonists for the adenosine A(1) receptor. Bioorg Med Chem Lett. 2001 Aug 6;11(15):2017-9.
DMSF5DR	RU	https://pubmed.ncbi.nlm.nih.gov/11454470

DMFRASQ	DI	DMFRASQ
DMFRASQ	DN	4-methyl-N-(naphthalen-1-yl)thiazol-2-amine
DMFRASQ	MI	TT7HQD0
DMFRASQ	MN	C-C chemokine receptor type 4 (CCR4)
DMFRASQ	MT	DTT
DMFRASQ	MA	Inhibitor
DMFRASQ	RN	Optimization of 2-aminothiazole derivatives as CCR4 antagonists. Bioorg Med Chem Lett. 2006 May 15;16(10):2800-3.
DMFRASQ	RU	https://pubmed.ncbi.nlm.nih.gov/16497499

DMN45EH	DI	DMN45EH
DMN45EH	DN	4-methyl-N-propyl-3,4-dihydroquinazolin-2-amine
DMN45EH	MI	TTRUFDT
DMN45EH	MN	5-HT 5A receptor (HTR5A)
DMN45EH	MT	DTT
DMN45EH	MA	Inhibitor
DMN45EH	RN	Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: optimising brain penetration. Bioorg Med Chem Lett. 2008 Jan 1;18(1):262-6.
DMN45EH	RU	https://pubmed.ncbi.nlm.nih.gov/18023344

DME7W0Q	DI	DME7W0Q
DME7W0Q	DN	4-Methyl-oxazolidin-(2Z)-ylideneamine
DME7W0Q	MI	TTZUFI5
DME7W0Q	MN	Nitric-oxide synthase brain (NOS1)
DME7W0Q	MT	DTT
DME7W0Q	MA	Inhibitor
DME7W0Q	RN	4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor. Bioorg Med Chem Lett. 2004 Jan 19;14(2):313-6.
DME7W0Q	RU	https://pubmed.ncbi.nlm.nih.gov/14698148

DME7W0Q	DI	DME7W0Q
DME7W0Q	DN	4-Methyl-oxazolidin-(2Z)-ylideneamine
DME7W0Q	MI	TTF10I9
DME7W0Q	MN	Nitric-oxide synthase inducible (NOS2)
DME7W0Q	MT	DTT
DME7W0Q	MA	Inhibitor
DME7W0Q	RN	4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor. Bioorg Med Chem Lett. 2004 Jan 19;14(2):313-6.
DME7W0Q	RU	https://pubmed.ncbi.nlm.nih.gov/14698148

DMR5NLM	DI	DMR5NLM
DMR5NLM	DN	4-methylphenyl-difluoromethanesulfonamide
DMR5NLM	MI	TTUNARX
DMR5NLM	MN	Carbonic anhydrase (CA)
DMR5NLM	MT	DTT
DMR5NLM	MA	Inhibitor
DMR5NLM	RN	Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6.
DMR5NLM	RU	https://pubmed.ncbi.nlm.nih.gov/16203142

DMR5NLM	DI	DMR5NLM
DMR5NLM	DN	4-methylphenyl-difluoromethanesulfonamide
DMR5NLM	MI	TTHQPL7
DMR5NLM	MN	Carbonic anhydrase I (CA-I)
DMR5NLM	MT	DTT
DMR5NLM	MA	Inhibitor
DMR5NLM	RN	Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6.
DMR5NLM	RU	https://pubmed.ncbi.nlm.nih.gov/16203142

DMR5NLM	DI	DMR5NLM
DMR5NLM	DN	4-methylphenyl-difluoromethanesulfonamide
DMR5NLM	MI	TTANPDJ
DMR5NLM	MN	Carbonic anhydrase II (CA-II)
DMR5NLM	MT	DTT
DMR5NLM	MA	Inhibitor
DMR5NLM	RN	Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6.
DMR5NLM	RU	https://pubmed.ncbi.nlm.nih.gov/16203142

DMR5NLM	DI	DMR5NLM
DMR5NLM	DN	4-methylphenyl-difluoromethanesulfonamide
DMR5NLM	MI	TT2LVK8
DMR5NLM	MN	Carbonic anhydrase IX (CA-IX)
DMR5NLM	MT	DTT
DMR5NLM	MA	Inhibitor
DMR5NLM	RN	Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6.
DMR5NLM	RU	https://pubmed.ncbi.nlm.nih.gov/16203142

DMNMXCE	DI	DMNMXCE
DMNMXCE	DN	4-Methyl-piperidin-(2E)-ylideneamine
DMNMXCE	MI	TTZUFI5
DMNMXCE	MN	Nitric-oxide synthase brain (NOS1)
DMNMXCE	MT	DTT
DMNMXCE	MA	Inhibitor
DMNMXCE	RN	Bicyclic amidine inhibitors of nitric oxide synthase: discovery of perhydro-iminopyrindine and perhydro-iminoquinoline as potent, orally active inh... Bioorg Med Chem Lett. 2005 Apr 15;15(8):1997-2001.
DMNMXCE	RU	https://pubmed.ncbi.nlm.nih.gov/15808455

DMNMXCE	DI	DMNMXCE
DMNMXCE	DN	4-Methyl-piperidin-(2E)-ylideneamine
DMNMXCE	MI	TTCM4B3
DMNMXCE	MN	Nitric-oxide synthase endothelial (NOS3)
DMNMXCE	MT	DTT
DMNMXCE	MA	Inhibitor
DMNMXCE	RN	Bicyclic amidine inhibitors of nitric oxide synthase: discovery of perhydro-iminopyrindine and perhydro-iminoquinoline as potent, orally active inh... Bioorg Med Chem Lett. 2005 Apr 15;15(8):1997-2001.
DMNMXCE	RU	https://pubmed.ncbi.nlm.nih.gov/15808455

DMNMXCE	DI	DMNMXCE
DMNMXCE	DN	4-Methyl-piperidin-(2E)-ylideneamine
DMNMXCE	MI	TTF10I9
DMNMXCE	MN	Nitric-oxide synthase inducible (NOS2)
DMNMXCE	MT	DTT
DMNMXCE	MA	Inhibitor
DMNMXCE	RN	Bicyclic amidine inhibitors of nitric oxide synthase: discovery of perhydro-iminopyrindine and perhydro-iminoquinoline as potent, orally active inh... Bioorg Med Chem Lett. 2005 Apr 15;15(8):1997-2001.
DMNMXCE	RU	https://pubmed.ncbi.nlm.nih.gov/15808455

DME6UOM	DI	DME6UOM
DME6UOM	DN	4-Methyl-pyridine
DME6UOM	MI	TTKNWZ4
DME6UOM	MN	Thromboxane-A synthase (TBXAS1)
DME6UOM	MT	DTT
DME6UOM	MA	Inhibitor
DME6UOM	RN	Highly selective inhibitors of thromboxane synthetase. 2. Pyridine derivatives. J Med Chem. 1981 Oct;24(10):1149-55.
DME6UOM	RU	https://pubmed.ncbi.nlm.nih.gov/7199089

DM0YS36	DI	DM0YS36
DM0YS36	DN	4-Methyl-pyrrolidin-(2Z)-ylideneamine
DM0YS36	MI	TTZUFI5
DM0YS36	MN	Nitric-oxide synthase brain (NOS1)
DM0YS36	MT	DTT
DM0YS36	MA	Inhibitor
DM0YS36	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DM0YS36	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DM0YS36	DI	DM0YS36
DM0YS36	DN	4-Methyl-pyrrolidin-(2Z)-ylideneamine
DM0YS36	MI	TTCM4B3
DM0YS36	MN	Nitric-oxide synthase endothelial (NOS3)
DM0YS36	MT	DTT
DM0YS36	MA	Inhibitor
DM0YS36	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DM0YS36	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DM0YS36	DI	DM0YS36
DM0YS36	DN	4-Methyl-pyrrolidin-(2Z)-ylideneamine
DM0YS36	MI	TTF10I9
DM0YS36	MN	Nitric-oxide synthase inducible (NOS2)
DM0YS36	MT	DTT
DM0YS36	MA	Inhibitor
DM0YS36	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DM0YS36	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DMVMHBL	DI	DMVMHBL
DMVMHBL	DN	4-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione
DMVMHBL	MI	TTVDSZ0
DMVMHBL	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMVMHBL	MT	DTT
DMVMHBL	MA	Inhibitor
DMVMHBL	RN	Synthesis and structure-activity relationships of novel poly(ADP-ribose) polymerase-1 inhibitors. Bioorg Med Chem Lett. 2006 Feb 15;16(4):938-42.
DMVMHBL	RU	https://pubmed.ncbi.nlm.nih.gov/16290935

DMW0Y29	DI	DMW0Y29
DMW0Y29	DN	4-methylstyrylboronic acid
DMW0Y29	MI	TTHQPL7
DMW0Y29	MN	Carbonic anhydrase I (CA-I)
DMW0Y29	MT	DTT
DMW0Y29	MA	Inhibitor
DMW0Y29	RN	Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5.
DMW0Y29	RU	https://pubmed.ncbi.nlm.nih.gov/19375309

DMEB5XP	DI	DMEB5XP
DMEB5XP	DN	4-Methylthiopyridine-3-sulfonamide
DMEB5XP	MI	TTHQPL7
DMEB5XP	MN	Carbonic anhydrase I (CA-I)
DMEB5XP	MT	DTT
DMEB5XP	MA	Inhibitor
DMEB5XP	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMEB5XP	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMEB5XP	DI	DMEB5XP
DMEB5XP	DN	4-Methylthiopyridine-3-sulfonamide
DMEB5XP	MI	TTANPDJ
DMEB5XP	MN	Carbonic anhydrase II (CA-II)
DMEB5XP	MT	DTT
DMEB5XP	MA	Inhibitor
DMEB5XP	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMEB5XP	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMEB5XP	DI	DMEB5XP
DMEB5XP	DN	4-Methylthiopyridine-3-sulfonamide
DMEB5XP	MI	TT2LVK8
DMEB5XP	MN	Carbonic anhydrase IX (CA-IX)
DMEB5XP	MT	DTT
DMEB5XP	MA	Inhibitor
DMEB5XP	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMEB5XP	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMEB5XP	DI	DMEB5XP
DMEB5XP	DN	4-Methylthiopyridine-3-sulfonamide
DMEB5XP	MI	TTSYM0R
DMEB5XP	MN	Carbonic anhydrase XII (CA-XII)
DMEB5XP	MT	DTT
DMEB5XP	MA	Inhibitor
DMEB5XP	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMEB5XP	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DMEB5XP	DI	DMEB5XP
DMEB5XP	DN	4-Methylthiopyridine-3-sulfonamide
DMEB5XP	MI	TTEYTKG
DMEB5XP	MN	Carbonic anhydrase XIV (CA-XIV)
DMEB5XP	MT	DTT
DMEB5XP	MA	Inhibitor
DMEB5XP	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404.
DMEB5XP	RU	https://pubmed.ncbi.nlm.nih.gov/20202722

DM049QO	DI	DM049QO
DM049QO	DN	4-Morpholin-2-yl-benzene-1,2-diol
DM049QO	MI	TTNGILX
DM049QO	MN	Adrenergic receptor alpha-1A (ADRA1A)
DM049QO	MT	DTT
DM049QO	MA	Inhibitor
DM049QO	RN	Conformational effects on the activity of drugs. 13. A revision of previously proposed models for the activation of alpha- and beta-adrenergic rece... J Med Chem. 1992 Mar 20;35(6):1009-18.
DM049QO	RU	https://pubmed.ncbi.nlm.nih.gov/1313109

DM049QO	DI	DM049QO
DM049QO	DN	4-Morpholin-2-yl-benzene-1,2-diol
DM049QO	MI	TTBRKXS
DM049QO	MN	Adrenergic receptor alpha-1B (ADRA1B)
DM049QO	MT	DTT
DM049QO	MA	Inhibitor
DM049QO	RN	Conformational effects on the activity of drugs. 13. A revision of previously proposed models for the activation of alpha- and beta-adrenergic rece... J Med Chem. 1992 Mar 20;35(6):1009-18.
DM049QO	RU	https://pubmed.ncbi.nlm.nih.gov/1313109

DM049QO	DI	DM049QO
DM049QO	DN	4-Morpholin-2-yl-benzene-1,2-diol
DM049QO	MI	TT34BHT
DM049QO	MN	Adrenergic receptor alpha-1D (ADRA1D)
DM049QO	MT	DTT
DM049QO	MA	Inhibitor
DM049QO	RN	Conformational effects on the activity of drugs. 13. A revision of previously proposed models for the activation of alpha- and beta-adrenergic rece... J Med Chem. 1992 Mar 20;35(6):1009-18.
DM049QO	RU	https://pubmed.ncbi.nlm.nih.gov/1313109

DMEJ6G9	DI	DMEJ6G9
DMEJ6G9	DN	4-Morpholin-4-yl-benzo[g]chromen-2-one
DMEJ6G9	MI	TTK3PY9
DMEJ6G9	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMEJ6G9	MT	DTT
DMEJ6G9	MA	Inhibitor
DMEJ6G9	RN	Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85.
DMEJ6G9	RU	https://pubmed.ncbi.nlm.nih.gov/15658870

DMW2MRP	DI	DMW2MRP
DMW2MRP	DN	4-Morpholin-4-yl-benzo[h]chromen-2-one
DMW2MRP	MI	TTK3PY9
DMW2MRP	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMW2MRP	MT	DTT
DMW2MRP	MA	Inhibitor
DMW2MRP	RN	Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85.
DMW2MRP	RU	https://pubmed.ncbi.nlm.nih.gov/15658870

DM7T3CU	DI	DM7T3CU
DM7T3CU	DN	4-Morpholin-4-yl-chromen-2-one
DM7T3CU	MI	TTK3PY9
DM7T3CU	MN	DNA-dependent protein kinase catalytic (PRKDC)
DM7T3CU	MT	DTT
DM7T3CU	MA	Inhibitor
DM7T3CU	RN	Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85.
DM7T3CU	RU	https://pubmed.ncbi.nlm.nih.gov/15658870

DM8QPTJ	DI	DM8QPTJ
DM8QPTJ	DN	4-morpholino-6-phenyl-2H-pyran-2-one
DM8QPTJ	MI	TTK3PY9
DM8QPTJ	MN	DNA-dependent protein kinase catalytic (PRKDC)
DM8QPTJ	MT	DTT
DM8QPTJ	MA	Inhibitor
DM8QPTJ	RN	Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72.
DM8QPTJ	RU	https://pubmed.ncbi.nlm.nih.gov/17371003

DM4E6HW	DI	DM4E6HW
DM4E6HW	DN	4-MPPTS
DM4E6HW	MI	TTXJ47W
DM4E6HW	MN	Metabotropic glutamate receptor 2 (mGluR2)
DM4E6HW	MT	DTT
DM4E6HW	MA	Modulator (allosteric modulator)
DM4E6HW	RN	SAR study of a subtype selective allosteric potentiator of metabotropic glutamate 2 receptor, N-(4-phenoxyphenyl)-N-(3-pyridinylmethyl)ethanesulfonamide. Bioorg Med Chem Lett. 2004 Jun 21;14(12):3099-102.
DM4E6HW	RU	https://pubmed.ncbi.nlm.nih.gov/15149652

DMEIA3L	DI	DMEIA3L
DMEIA3L	DN	4-Naphthalen-1-yl-5-piperidin-4-yl-isoxazol-3-ol
DMEIA3L	MI	TT1MPAY
DMEIA3L	MN	GABA(A) receptor alpha-1 (GABRA1)
DMEIA3L	MT	DTT
DMEIA3L	MA	Inhibitor
DMEIA3L	RN	Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling. J Med Chem. 2005 Jan 27;48(2):427-39.
DMEIA3L	RU	https://pubmed.ncbi.nlm.nih.gov/15658856

DMEIA3L	DI	DMEIA3L
DMEIA3L	DN	4-Naphthalen-1-yl-5-piperidin-4-yl-isoxazol-3-ol
DMEIA3L	MI	TTZA1NY
DMEIA3L	MN	GABA(A) receptor beta-2 (GABRB2)
DMEIA3L	MT	DTT
DMEIA3L	MA	Inhibitor
DMEIA3L	RN	Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling. J Med Chem. 2005 Jan 27;48(2):427-39.
DMEIA3L	RU	https://pubmed.ncbi.nlm.nih.gov/15658856

DMEIA3L	DI	DMEIA3L
DMEIA3L	DN	4-Naphthalen-1-yl-5-piperidin-4-yl-isoxazol-3-ol
DMEIA3L	MI	TT06RH5
DMEIA3L	MN	GABA(A) receptor gamma-2 (GABRG2)
DMEIA3L	MT	DTT
DMEIA3L	MA	Inhibitor
DMEIA3L	RN	Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling. J Med Chem. 2005 Jan 27;48(2):427-39.
DMEIA3L	RU	https://pubmed.ncbi.nlm.nih.gov/15658856

DMEIA3L	DI	DMEIA3L
DMEIA3L	DN	4-Naphthalen-1-yl-5-piperidin-4-yl-isoxazol-3-ol
DMEIA3L	MI	TTNJYV2
DMEIA3L	MN	Gamma-aminobutyric acid receptor (GAR)
DMEIA3L	MT	DTT
DMEIA3L	MA	Inhibitor
DMEIA3L	RN	Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling. J Med Chem. 2005 Jan 27;48(2):427-39.
DMEIA3L	RU	https://pubmed.ncbi.nlm.nih.gov/15658856

DM9O8UM	DI	DM9O8UM
DM9O8UM	DN	4-Naphthalen-2-yl-5-piperidin-4-yl-isoxazol-3-ol
DM9O8UM	MI	TT1MPAY
DM9O8UM	MN	GABA(A) receptor alpha-1 (GABRA1)
DM9O8UM	MT	DTT
DM9O8UM	MA	Inhibitor
DM9O8UM	RN	Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling. J Med Chem. 2005 Jan 27;48(2):427-39.
DM9O8UM	RU	https://pubmed.ncbi.nlm.nih.gov/15658856

DM9O8UM	DI	DM9O8UM
DM9O8UM	DN	4-Naphthalen-2-yl-5-piperidin-4-yl-isoxazol-3-ol
DM9O8UM	MI	TTZA1NY
DM9O8UM	MN	GABA(A) receptor beta-2 (GABRB2)
DM9O8UM	MT	DTT
DM9O8UM	MA	Inhibitor
DM9O8UM	RN	Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling. J Med Chem. 2005 Jan 27;48(2):427-39.
DM9O8UM	RU	https://pubmed.ncbi.nlm.nih.gov/15658856

DM9O8UM	DI	DM9O8UM
DM9O8UM	DN	4-Naphthalen-2-yl-5-piperidin-4-yl-isoxazol-3-ol
DM9O8UM	MI	TT06RH5
DM9O8UM	MN	GABA(A) receptor gamma-2 (GABRG2)
DM9O8UM	MT	DTT
DM9O8UM	MA	Inhibitor
DM9O8UM	RN	Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling. J Med Chem. 2005 Jan 27;48(2):427-39.
DM9O8UM	RU	https://pubmed.ncbi.nlm.nih.gov/15658856

DM9O8UM	DI	DM9O8UM
DM9O8UM	DN	4-Naphthalen-2-yl-5-piperidin-4-yl-isoxazol-3-ol
DM9O8UM	MI	TTNJYV2
DM9O8UM	MN	Gamma-aminobutyric acid receptor (GAR)
DM9O8UM	MT	DTT
DM9O8UM	MA	Inhibitor
DM9O8UM	RN	Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling. J Med Chem. 2005 Jan 27;48(2):427-39.
DM9O8UM	RU	https://pubmed.ncbi.nlm.nih.gov/15658856

DMKPNSH	DI	DMKPNSH
DMKPNSH	DN	4-Naphthalen-2-yl-phenol
DMKPNSH	MI	TTZAYWL
DMKPNSH	MN	Estrogen receptor (ESR)
DMKPNSH	MT	DTT
DMKPNSH	MA	Inhibitor
DMKPNSH	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DMKPNSH	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMKPNSH	DI	DMKPNSH
DMKPNSH	DN	4-Naphthalen-2-yl-phenol
DMKPNSH	MI	TTOM3J0
DMKPNSH	MN	Estrogen receptor beta (ESR2)
DMKPNSH	MT	DTT
DMKPNSH	MA	Inhibitor
DMKPNSH	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DMKPNSH	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMZY8UW	DI	DMZY8UW
DMZY8UW	DN	4-Nitro-benzenesulfonamide
DMZY8UW	MI	TTUNARX
DMZY8UW	MN	Carbonic anhydrase (CA)
DMZY8UW	MT	DTT
DMZY8UW	MA	Inhibitor
DMZY8UW	RN	Carbonic anhydrase inhibitors: inhibition of human cytosolic isozyme II and mitochondrial isozyme V with a series of benzene sulfonamide derivatives. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5703-7.
DMZY8UW	RU	https://pubmed.ncbi.nlm.nih.gov/15482952

DMZY8UW	DI	DMZY8UW
DMZY8UW	DN	4-Nitro-benzenesulfonamide
DMZY8UW	MI	TTANPDJ
DMZY8UW	MN	Carbonic anhydrase II (CA-II)
DMZY8UW	MT	DTT
DMZY8UW	MA	Inhibitor
DMZY8UW	RN	Carbonic anhydrase inhibitors: inhibition of human cytosolic isozyme II and mitochondrial isozyme V with a series of benzene sulfonamide derivatives. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5703-7.
DMZY8UW	RU	https://pubmed.ncbi.nlm.nih.gov/15482952

DMKZJ1V	DI	DMKZJ1V
DMKZJ1V	DN	4-nitrobenzo[c][1,2,5]thiadiazole
DMKZJ1V	MI	TTEP6RV
DMKZJ1V	MN	Glutathione reductase (GR)
DMKZJ1V	MT	DTT
DMKZJ1V	MA	Inhibitor
DMKZJ1V	RN	Specific inhibitors of Plasmodium falciparum thioredoxin reductase as potential antimalarial agents. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2283-92.
DMKZJ1V	RU	https://pubmed.ncbi.nlm.nih.gov/16458512

DMKZUWY	DI	DMKZUWY
DMKZUWY	DN	4-Nitro-N-(4-phenyl-thiazol-2-yl)-benzamide
DMKZUWY	MI	TTK25J1
DMKZUWY	MN	Adenosine A1 receptor (ADORA1)
DMKZUWY	MT	DTT
DMKZUWY	MA	Inhibitor
DMKZUWY	RN	Substituted 4-phenyl-2-(phenylcarboxamido)-1,3-thiazole derivatives as antagonists for the adenosine A(1) receptor. Bioorg Med Chem Lett. 2001 Aug 6;11(15):2017-9.
DMKZUWY	RU	https://pubmed.ncbi.nlm.nih.gov/11454470

DMLJDU5	DI	DMLJDU5
DMLJDU5	DN	4-nitro-N-(quinolin-8-yl)benzenesulfonamide
DMLJDU5	MI	TTSXVID
DMLJDU5	MN	Nuclear factor NF-kappa-B (NFKB)
DMLJDU5	MT	DTT
DMLJDU5	MA	Inhibitor
DMLJDU5	RN	Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFkappaB activity within two separate high-throughput s... Bioorg Med Chem Lett. 2008 Jan 1;18(1):329-35.
DMLJDU5	RU	https://pubmed.ncbi.nlm.nih.gov/18024113

DMTJ3F9	DI	DMTJ3F9
DMTJ3F9	DN	4-Nitrophenyl 4-Benzylpiperazine-1-carboxylate
DMTJ3F9	MI	TTDP1UC
DMTJ3F9	MN	Fatty acid amide hydrolase (FAAH)
DMTJ3F9	MT	DTT
DMTJ3F9	MA	Inhibitor
DMTJ3F9	RN	Characterization of tunable piperidine and piperazine carbamates as inhibitors of endocannabinoid hydrolases. J Med Chem. 2010 Feb 25;53(4):1830-42.
DMTJ3F9	RU	https://pubmed.ncbi.nlm.nih.gov/20099888

DMBX4UJ	DI	DMBX4UJ
DMBX4UJ	DN	4-nitrophenyl phosphate
DMBX4UJ	MI	TTUNARX
DMBX4UJ	MN	Carbonic anhydrase (CA)
DMBX4UJ	MT	DTT
DMBX4UJ	MA	Inhibitor
DMBX4UJ	RN	Paraoxon, 4-nitrophenyl phosphate and acetate are substrates of - but not of -, - and -carbonic anhydrases. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6208-12.
DMBX4UJ	RU	https://pubmed.ncbi.nlm.nih.gov/20833546

DMBX4UJ	DI	DMBX4UJ
DMBX4UJ	DN	4-nitrophenyl phosphate
DMBX4UJ	MI	TTHQPL7
DMBX4UJ	MN	Carbonic anhydrase I (CA-I)
DMBX4UJ	MT	DTT
DMBX4UJ	MA	Inhibitor
DMBX4UJ	RN	Paraoxon, 4-nitrophenyl phosphate and acetate are substrates of - but not of -, - and -carbonic anhydrases. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6208-12.
DMBX4UJ	RU	https://pubmed.ncbi.nlm.nih.gov/20833546

DMBX4UJ	DI	DMBX4UJ
DMBX4UJ	DN	4-nitrophenyl phosphate
DMBX4UJ	MI	TTANPDJ
DMBX4UJ	MN	Carbonic anhydrase II (CA-II)
DMBX4UJ	MT	DTT
DMBX4UJ	MA	Inhibitor
DMBX4UJ	RN	Paraoxon, 4-nitrophenyl phosphate and acetate are substrates of - but not of -, - and -carbonic anhydrases. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6208-12.
DMBX4UJ	RU	https://pubmed.ncbi.nlm.nih.gov/20833546

DMBX4UJ	DI	DMBX4UJ
DMBX4UJ	DN	4-nitrophenyl phosphate
DMBX4UJ	MI	DE6TFXV
DMBX4UJ	MN	Tyrosine-protein phosphatase non-receptor 1 (PTP1B)
DMBX4UJ	MT	DME
DMBX4UJ	MA	Metabolism
DMBX4UJ	RN	Residues distant from the active site influence protein-tyrosine phosphatase 1B inhibitor binding. J Biol Chem. 2006 Feb 24;281(8):5258-66.
DMBX4UJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16332678

DMO6XK2	DI	DMO6XK2
DMO6XK2	DN	4-nitrophenylboronic acid
DMO6XK2	MI	TTDP1UC
DMO6XK2	MN	Fatty acid amide hydrolase (FAAH)
DMO6XK2	MT	DTT
DMO6XK2	MA	Inhibitor
DMO6XK2	RN	Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Nov 27;51(22):7057-60.
DMO6XK2	RU	https://pubmed.ncbi.nlm.nih.gov/18983140

DM9ETMD	DI	DM9ETMD
DM9ETMD	DN	4-nitrophenyl-difluoromethanesulfonamide
DM9ETMD	MI	TTUNARX
DM9ETMD	MN	Carbonic anhydrase (CA)
DM9ETMD	MT	DTT
DM9ETMD	MA	Inhibitor
DM9ETMD	RN	Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6.
DM9ETMD	RU	https://pubmed.ncbi.nlm.nih.gov/16203142

DM9ETMD	DI	DM9ETMD
DM9ETMD	DN	4-nitrophenyl-difluoromethanesulfonamide
DM9ETMD	MI	TTHQPL7
DM9ETMD	MN	Carbonic anhydrase I (CA-I)
DM9ETMD	MT	DTT
DM9ETMD	MA	Inhibitor
DM9ETMD	RN	Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6.
DM9ETMD	RU	https://pubmed.ncbi.nlm.nih.gov/16203142

DM9ETMD	DI	DM9ETMD
DM9ETMD	DN	4-nitrophenyl-difluoromethanesulfonamide
DM9ETMD	MI	TTANPDJ
DM9ETMD	MN	Carbonic anhydrase II (CA-II)
DM9ETMD	MT	DTT
DM9ETMD	MA	Inhibitor
DM9ETMD	RN	Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6.
DM9ETMD	RU	https://pubmed.ncbi.nlm.nih.gov/16203142

DM9ETMD	DI	DM9ETMD
DM9ETMD	DN	4-nitrophenyl-difluoromethanesulfonamide
DM9ETMD	MI	TT2LVK8
DM9ETMD	MN	Carbonic anhydrase IX (CA-IX)
DM9ETMD	MT	DTT
DM9ETMD	MA	Inhibitor
DM9ETMD	RN	Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6.
DM9ETMD	RU	https://pubmed.ncbi.nlm.nih.gov/16203142

DM47IFL	DI	DM47IFL
DM47IFL	DN	4-nitrophenylsulfamide
DM47IFL	MI	TTANPDJ
DM47IFL	MN	Carbonic anhydrase II (CA-II)
DM47IFL	MT	DTT
DM47IFL	MA	Inhibitor
DM47IFL	RN	Inhibition of carbonic anhydrase-II by sulfamate and sulfamide groups: an investigation involving direct thermodynamic binding measurements. J Med Chem. 2006 Jun 15;49(12):3496-500.
DM47IFL	RU	https://pubmed.ncbi.nlm.nih.gov/16759092

DMOW8TM	DI	DMOW8TM
DMOW8TM	DN	4-nonyl-N-(quinolin-3-yl)benzamide
DMOW8TM	MI	TTMI6F5
DMOW8TM	MN	Transient receptor potential cation channel V1 (TRPV1)
DMOW8TM	MT	DTT
DMOW8TM	MA	Inhibitor
DMOW8TM	RN	N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4.
DMOW8TM	RU	https://pubmed.ncbi.nlm.nih.gov/18359227

DMBF5KW	DI	DMBF5KW
DMBF5KW	DN	4-nonylphenylboronic acid
DMBF5KW	MI	TTDP1UC
DMBF5KW	MN	Fatty acid amide hydrolase (FAAH)
DMBF5KW	MT	DTT
DMBF5KW	MA	Inhibitor
DMBF5KW	RN	Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Nov 27;51(22):7057-60.
DMBF5KW	RU	https://pubmed.ncbi.nlm.nih.gov/18983140

DMNSU1H	DI	DMNSU1H
DMNSU1H	DN	4-octyl-N-(pyridin-3-yl)benzamide
DMNSU1H	MI	TTMI6F5
DMNSU1H	MN	Transient receptor potential cation channel V1 (TRPV1)
DMNSU1H	MT	DTT
DMNSU1H	MA	Inhibitor
DMNSU1H	RN	N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4.
DMNSU1H	RU	https://pubmed.ncbi.nlm.nih.gov/18359227

DMOGM3H	DI	DMOGM3H
DMOGM3H	DN	4-octyl-N-(quinolin-3-yl)benzamide
DMOGM3H	MI	TTMI6F5
DMOGM3H	MN	Transient receptor potential cation channel V1 (TRPV1)
DMOGM3H	MT	DTT
DMOGM3H	MA	Inhibitor
DMOGM3H	RN	N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4.
DMOGM3H	RU	https://pubmed.ncbi.nlm.nih.gov/18359227

DM7GW4P	DI	DM7GW4P
DM7GW4P	DN	4-oxo-4H-chromene-3-carboxylic acid
DM7GW4P	MI	TTGP7BY
DM7GW4P	MN	Monoamine oxidase type B (MAO-B)
DM7GW4P	MT	DTT
DM7GW4P	MA	Inhibitor
DM7GW4P	RN	Chromone-2- and -3-carboxylic acids inhibit differently monoamine oxidases A and B. Bioorg Med Chem Lett. 2010 May 1;20(9):2709-12.
DM7GW4P	RU	https://pubmed.ncbi.nlm.nih.gov/20382016

DMPX1J9	DI	DMPX1J9
DMPX1J9	DN	4-oxo-nonenal
DMPX1J9	MI	DEGQTXO
DMPX1J9	MN	Aldo-keto reductase 1C3 (AKR1C3)
DMPX1J9	MT	DME
DMPX1J9	MA	Metabolism
DMPX1J9	RN	Instability of C154Y variant of aldo-keto reductase 1C3. Chem Biol Interact. 2017 Oct 1;276:194-202.
DMPX1J9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28025170

DMPX1J9	DI	DMPX1J9
DMPX1J9	DN	4-oxo-nonenal
DMPX1J9	MI	TTELV3W
DMPX1J9	MN	Transformation-sensitive protein p120 (TRPA1)
DMPX1J9	MT	DTT
DMPX1J9	MA	Activator
DMPX1J9	RN	Transient receptor potential A1 is a sensory receptor for multiple products of oxidative stress. J Neurosci. 2008 Mar 5;28(10):2485-94.
DMPX1J9	RU	https://pubmed.ncbi.nlm.nih.gov/18322093

DMADSUY	DI	DMADSUY
DMADSUY	DN	4-Oxosebacic Acid
DMADSUY	MI	TTJHKYD
DMADSUY	MN	Delta-aminolevulinic acid dehydratase (ALAD)
DMADSUY	MT	DTT
DMADSUY	MA	Inhibitor
DMADSUY	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMADSUY	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMN1XMK	DI	DMN1XMK
DMN1XMK	DN	4-Pentadeca-1,3,6-trienylsulfanyl-butyric acid
DMN1XMK	MI	TT2J34L
DMN1XMK	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMN1XMK	MT	DTT
DMN1XMK	MA	Inhibitor
DMN1XMK	RN	Design, synthesis, and 5-lipoxygenase-inhibiting properties of 1-thio-substituted butadienes. J Med Chem. 1990 Apr;33(4):1163-70.
DMN1XMK	RU	https://pubmed.ncbi.nlm.nih.gov/2319562

DMW198G	DI	DMW198G
DMW198G	DN	4-pentyl-N-pyridin-3-yl benzamide
DMW198G	MI	TTMI6F5
DMW198G	MN	Transient receptor potential cation channel V1 (TRPV1)
DMW198G	MT	DTT
DMW198G	MA	Inhibitor
DMW198G	RN	N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4.
DMW198G	RU	https://pubmed.ncbi.nlm.nih.gov/18359227

DMIPQTW	DI	DMIPQTW
DMIPQTW	DN	4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE
DMIPQTW	MI	TTQBR95
DMIPQTW	MN	Stress-activated protein kinase 2a (p38 alpha)
DMIPQTW	MT	DTT
DMIPQTW	MA	Inhibitor
DMIPQTW	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMIPQTW	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMMWYI9	DI	DMMWYI9
DMMWYI9	DN	4-phenoxyphenylboronic acid
DMMWYI9	MI	TTUNARX
DMMWYI9	MN	Carbonic anhydrase (CA)
DMMWYI9	MT	DTT
DMMWYI9	MA	Inhibitor
DMMWYI9	RN	Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5.
DMMWYI9	RU	https://pubmed.ncbi.nlm.nih.gov/19375309

DMMWYI9	DI	DMMWYI9
DMMWYI9	DN	4-phenoxyphenylboronic acid
DMMWYI9	MI	TTHQPL7
DMMWYI9	MN	Carbonic anhydrase I (CA-I)
DMMWYI9	MT	DTT
DMMWYI9	MA	Inhibitor
DMMWYI9	RN	Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5.
DMMWYI9	RU	https://pubmed.ncbi.nlm.nih.gov/19375309

DMMWYI9	DI	DMMWYI9
DMMWYI9	DN	4-phenoxyphenylboronic acid
DMMWYI9	MI	TTANPDJ
DMMWYI9	MN	Carbonic anhydrase II (CA-II)
DMMWYI9	MT	DTT
DMMWYI9	MA	Inhibitor
DMMWYI9	RN	Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5.
DMMWYI9	RU	https://pubmed.ncbi.nlm.nih.gov/19375309

DMVCIJB	DI	DMVCIJB
DMVCIJB	DN	4-phenyl-1-(1-phenylbutyl)piperidin-4-ol
DMVCIJB	MI	TTNT7K8
DMVCIJB	MN	Nociceptin receptor (OPRL1)
DMVCIJB	MT	DTT
DMVCIJB	MA	Inhibitor
DMVCIJB	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMVCIJB	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMVCIJB	DI	DMVCIJB
DMVCIJB	DN	4-phenyl-1-(1-phenylbutyl)piperidin-4-ol
DMVCIJB	MI	TT27RFC
DMVCIJB	MN	Opioid receptor delta (OPRD1)
DMVCIJB	MT	DTT
DMVCIJB	MA	Inhibitor
DMVCIJB	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMVCIJB	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMVCIJB	DI	DMVCIJB
DMVCIJB	DN	4-phenyl-1-(1-phenylbutyl)piperidin-4-ol
DMVCIJB	MI	TTQW87Y
DMVCIJB	MN	Opioid receptor kappa (OPRK1)
DMVCIJB	MT	DTT
DMVCIJB	MA	Inhibitor
DMVCIJB	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMVCIJB	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMVCIJB	DI	DMVCIJB
DMVCIJB	DN	4-phenyl-1-(1-phenylbutyl)piperidin-4-ol
DMVCIJB	MI	TTKWM86
DMVCIJB	MN	Opioid receptor mu (MOP)
DMVCIJB	MT	DTT
DMVCIJB	MA	Inhibitor
DMVCIJB	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMVCIJB	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DM6EFLV	DI	DM6EFLV
DM6EFLV	DN	4-phenyl-1-(1-phenylethyl)piperidin-4-ol
DM6EFLV	MI	TTNT7K8
DM6EFLV	MN	Nociceptin receptor (OPRL1)
DM6EFLV	MT	DTT
DM6EFLV	MA	Inhibitor
DM6EFLV	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DM6EFLV	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DM6EFLV	DI	DM6EFLV
DM6EFLV	DN	4-phenyl-1-(1-phenylethyl)piperidin-4-ol
DM6EFLV	MI	TTQW87Y
DM6EFLV	MN	Opioid receptor kappa (OPRK1)
DM6EFLV	MT	DTT
DM6EFLV	MA	Inhibitor
DM6EFLV	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DM6EFLV	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DM6EFLV	DI	DM6EFLV
DM6EFLV	DN	4-phenyl-1-(1-phenylethyl)piperidin-4-ol
DM6EFLV	MI	TTKWM86
DM6EFLV	MN	Opioid receptor mu (MOP)
DM6EFLV	MT	DTT
DM6EFLV	MA	Inhibitor
DM6EFLV	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DM6EFLV	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMISTXQ	DI	DMISTXQ
DMISTXQ	DN	4-phenyl-1-(1-phenylheptyl)piperidin-4-ol
DMISTXQ	MI	TTNT7K8
DMISTXQ	MN	Nociceptin receptor (OPRL1)
DMISTXQ	MT	DTT
DMISTXQ	MA	Inhibitor
DMISTXQ	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMISTXQ	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMISTXQ	DI	DMISTXQ
DMISTXQ	DN	4-phenyl-1-(1-phenylheptyl)piperidin-4-ol
DMISTXQ	MI	TT27RFC
DMISTXQ	MN	Opioid receptor delta (OPRD1)
DMISTXQ	MT	DTT
DMISTXQ	MA	Inhibitor
DMISTXQ	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMISTXQ	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMISTXQ	DI	DMISTXQ
DMISTXQ	DN	4-phenyl-1-(1-phenylheptyl)piperidin-4-ol
DMISTXQ	MI	TTQW87Y
DMISTXQ	MN	Opioid receptor kappa (OPRK1)
DMISTXQ	MT	DTT
DMISTXQ	MA	Inhibitor
DMISTXQ	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMISTXQ	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMISTXQ	DI	DMISTXQ
DMISTXQ	DN	4-phenyl-1-(1-phenylheptyl)piperidin-4-ol
DMISTXQ	MI	TTKWM86
DMISTXQ	MN	Opioid receptor mu (MOP)
DMISTXQ	MT	DTT
DMISTXQ	MA	Inhibitor
DMISTXQ	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMISTXQ	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DM1GRWY	DI	DM1GRWY
DM1GRWY	DN	4-phenyl-1-(1-phenylhexyl)piperidin-4-ol
DM1GRWY	MI	TTNT7K8
DM1GRWY	MN	Nociceptin receptor (OPRL1)
DM1GRWY	MT	DTT
DM1GRWY	MA	Inhibitor
DM1GRWY	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DM1GRWY	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DM1GRWY	DI	DM1GRWY
DM1GRWY	DN	4-phenyl-1-(1-phenylhexyl)piperidin-4-ol
DM1GRWY	MI	TT27RFC
DM1GRWY	MN	Opioid receptor delta (OPRD1)
DM1GRWY	MT	DTT
DM1GRWY	MA	Inhibitor
DM1GRWY	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DM1GRWY	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DM1GRWY	DI	DM1GRWY
DM1GRWY	DN	4-phenyl-1-(1-phenylhexyl)piperidin-4-ol
DM1GRWY	MI	TTQW87Y
DM1GRWY	MN	Opioid receptor kappa (OPRK1)
DM1GRWY	MT	DTT
DM1GRWY	MA	Inhibitor
DM1GRWY	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DM1GRWY	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DM1GRWY	DI	DM1GRWY
DM1GRWY	DN	4-phenyl-1-(1-phenylhexyl)piperidin-4-ol
DM1GRWY	MI	TTKWM86
DM1GRWY	MN	Opioid receptor mu (MOP)
DM1GRWY	MT	DTT
DM1GRWY	MA	Inhibitor
DM1GRWY	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DM1GRWY	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMZQ7DP	DI	DMZQ7DP
DMZQ7DP	DN	4-phenyl-1-(1-phenylpentyl)piperidin-4-ol
DMZQ7DP	MI	TTNT7K8
DMZQ7DP	MN	Nociceptin receptor (OPRL1)
DMZQ7DP	MT	DTT
DMZQ7DP	MA	Inhibitor
DMZQ7DP	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMZQ7DP	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMZQ7DP	DI	DMZQ7DP
DMZQ7DP	DN	4-phenyl-1-(1-phenylpentyl)piperidin-4-ol
DMZQ7DP	MI	TT27RFC
DMZQ7DP	MN	Opioid receptor delta (OPRD1)
DMZQ7DP	MT	DTT
DMZQ7DP	MA	Inhibitor
DMZQ7DP	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMZQ7DP	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMZQ7DP	DI	DMZQ7DP
DMZQ7DP	DN	4-phenyl-1-(1-phenylpentyl)piperidin-4-ol
DMZQ7DP	MI	TTQW87Y
DMZQ7DP	MN	Opioid receptor kappa (OPRK1)
DMZQ7DP	MT	DTT
DMZQ7DP	MA	Inhibitor
DMZQ7DP	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMZQ7DP	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMZQ7DP	DI	DMZQ7DP
DMZQ7DP	DN	4-phenyl-1-(1-phenylpentyl)piperidin-4-ol
DMZQ7DP	MI	TTKWM86
DMZQ7DP	MN	Opioid receptor mu (MOP)
DMZQ7DP	MT	DTT
DMZQ7DP	MA	Inhibitor
DMZQ7DP	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMZQ7DP	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DM491FJ	DI	DM491FJ
DM491FJ	DN	4-phenyl-1-(1-phenylpropan-2-yl)piperidin-4-ol
DM491FJ	MI	TTNT7K8
DM491FJ	MN	Nociceptin receptor (OPRL1)
DM491FJ	MT	DTT
DM491FJ	MA	Inhibitor
DM491FJ	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DM491FJ	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMALIQ8	DI	DMALIQ8
DMALIQ8	DN	4-phenyl-1-(1-phenylpropyl)piperidin-4-ol
DMALIQ8	MI	TTNT7K8
DMALIQ8	MN	Nociceptin receptor (OPRL1)
DMALIQ8	MT	DTT
DMALIQ8	MA	Inhibitor
DMALIQ8	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMALIQ8	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMALIQ8	DI	DMALIQ8
DMALIQ8	DN	4-phenyl-1-(1-phenylpropyl)piperidin-4-ol
DMALIQ8	MI	TTQW87Y
DMALIQ8	MN	Opioid receptor kappa (OPRK1)
DMALIQ8	MT	DTT
DMALIQ8	MA	Inhibitor
DMALIQ8	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMALIQ8	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMALIQ8	DI	DMALIQ8
DMALIQ8	DN	4-phenyl-1-(1-phenylpropyl)piperidin-4-ol
DMALIQ8	MI	TTKWM86
DMALIQ8	MN	Opioid receptor mu (MOP)
DMALIQ8	MT	DTT
DMALIQ8	MA	Inhibitor
DMALIQ8	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMALIQ8	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMM8O1X	DI	DMM8O1X
DMM8O1X	DN	4-phenyl-1-(3-phenylpropyl)piperidin-4-ol
DMM8O1X	MI	TTNT7K8
DMM8O1X	MN	Nociceptin receptor (OPRL1)
DMM8O1X	MT	DTT
DMM8O1X	MA	Inhibitor
DMM8O1X	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMM8O1X	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMFV0JC	DI	DMFV0JC
DMFV0JC	DN	4-phenyl-1-(phenyl(m-tolyl)methyl)piperidin-4-ol
DMFV0JC	MI	TTNT7K8
DMFV0JC	MN	Nociceptin receptor (OPRL1)
DMFV0JC	MT	DTT
DMFV0JC	MA	Inhibitor
DMFV0JC	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMFV0JC	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMFV0JC	DI	DMFV0JC
DMFV0JC	DN	4-phenyl-1-(phenyl(m-tolyl)methyl)piperidin-4-ol
DMFV0JC	MI	TT27RFC
DMFV0JC	MN	Opioid receptor delta (OPRD1)
DMFV0JC	MT	DTT
DMFV0JC	MA	Inhibitor
DMFV0JC	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMFV0JC	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMFV0JC	DI	DMFV0JC
DMFV0JC	DN	4-phenyl-1-(phenyl(m-tolyl)methyl)piperidin-4-ol
DMFV0JC	MI	TTQW87Y
DMFV0JC	MN	Opioid receptor kappa (OPRK1)
DMFV0JC	MT	DTT
DMFV0JC	MA	Inhibitor
DMFV0JC	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMFV0JC	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMFV0JC	DI	DMFV0JC
DMFV0JC	DN	4-phenyl-1-(phenyl(m-tolyl)methyl)piperidin-4-ol
DMFV0JC	MI	TTKWM86
DMFV0JC	MN	Opioid receptor mu (MOP)
DMFV0JC	MT	DTT
DMFV0JC	MA	Inhibitor
DMFV0JC	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DMFV0JC	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DM2MPWC	DI	DM2MPWC
DM2MPWC	DN	4-phenyl-1-(phenyl(o-tolyl)methyl)piperidin-4-ol
DM2MPWC	MI	TTNT7K8
DM2MPWC	MN	Nociceptin receptor (OPRL1)
DM2MPWC	MT	DTT
DM2MPWC	MA	Inhibitor
DM2MPWC	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DM2MPWC	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DM2MPWC	DI	DM2MPWC
DM2MPWC	DN	4-phenyl-1-(phenyl(o-tolyl)methyl)piperidin-4-ol
DM2MPWC	MI	TT27RFC
DM2MPWC	MN	Opioid receptor delta (OPRD1)
DM2MPWC	MT	DTT
DM2MPWC	MA	Inhibitor
DM2MPWC	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DM2MPWC	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DM2MPWC	DI	DM2MPWC
DM2MPWC	DN	4-phenyl-1-(phenyl(o-tolyl)methyl)piperidin-4-ol
DM2MPWC	MI	TTQW87Y
DM2MPWC	MN	Opioid receptor kappa (OPRK1)
DM2MPWC	MT	DTT
DM2MPWC	MA	Inhibitor
DM2MPWC	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DM2MPWC	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DM2MPWC	DI	DM2MPWC
DM2MPWC	DN	4-phenyl-1-(phenyl(o-tolyl)methyl)piperidin-4-ol
DM2MPWC	MI	TTKWM86
DM2MPWC	MN	Opioid receptor mu (MOP)
DM2MPWC	MT	DTT
DM2MPWC	MA	Inhibitor
DM2MPWC	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DM2MPWC	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DM5R6T4	DI	DM5R6T4
DM5R6T4	DN	4-phenyl-1-(phenyl(p-tolyl)methyl)piperidin-4-ol
DM5R6T4	MI	TTNT7K8
DM5R6T4	MN	Nociceptin receptor (OPRL1)
DM5R6T4	MT	DTT
DM5R6T4	MA	Inhibitor
DM5R6T4	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DM5R6T4	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DM5R6T4	DI	DM5R6T4
DM5R6T4	DN	4-phenyl-1-(phenyl(p-tolyl)methyl)piperidin-4-ol
DM5R6T4	MI	TT27RFC
DM5R6T4	MN	Opioid receptor delta (OPRD1)
DM5R6T4	MT	DTT
DM5R6T4	MA	Inhibitor
DM5R6T4	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DM5R6T4	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DM5R6T4	DI	DM5R6T4
DM5R6T4	DN	4-phenyl-1-(phenyl(p-tolyl)methyl)piperidin-4-ol
DM5R6T4	MI	TTQW87Y
DM5R6T4	MN	Opioid receptor kappa (OPRK1)
DM5R6T4	MT	DTT
DM5R6T4	MA	Inhibitor
DM5R6T4	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DM5R6T4	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DM5R6T4	DI	DM5R6T4
DM5R6T4	DN	4-phenyl-1-(phenyl(p-tolyl)methyl)piperidin-4-ol
DM5R6T4	MI	TTKWM86
DM5R6T4	MN	Opioid receptor mu (MOP)
DM5R6T4	MT	DTT
DM5R6T4	MA	Inhibitor
DM5R6T4	RN	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
DM5R6T4	RU	https://pubmed.ncbi.nlm.nih.gov/17428659

DMV6WC4	DI	DMV6WC4
DMV6WC4	DN	4-phenyl-1,2,3,6-tetrahydropyridine
DMV6WC4	MI	TTGP7BY
DMV6WC4	MN	Monoamine oxidase type B (MAO-B)
DMV6WC4	MT	DTT
DMV6WC4	MA	Inhibitor
DMV6WC4	RN	Further explorations of unnatural alkaloids. J Nat Prod. 1985 Nov-Dec;48(6):878-93.
DMV6WC4	RU	https://pubmed.ncbi.nlm.nih.gov/3879267

DMONKDQ	DI	DMONKDQ
DMONKDQ	DN	4-phenyl-2-(phenylamino)pyrimidine-5-carbonitrile
DMONKDQ	MI	TTH6V3D
DMONKDQ	MN	Cyclin-dependent kinase 1 (CDK1)
DMONKDQ	MT	DTT
DMONKDQ	MA	Inhibitor
DMONKDQ	RN	4-Aryl-5-cyano-2-aminopyrimidines as VEGF-R2 inhibitors: synthesis and biological evaluation. Bioorg Med Chem Lett. 2007 Jun 15;17(12):3266-70.
DMONKDQ	RU	https://pubmed.ncbi.nlm.nih.gov/17481894

DMONKDQ	DI	DMONKDQ
DMONKDQ	DN	4-phenyl-2-(phenylamino)pyrimidine-5-carbonitrile
DMONKDQ	MI	TTUTJGQ
DMONKDQ	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMONKDQ	MT	DTT
DMONKDQ	MA	Inhibitor
DMONKDQ	RN	4-Aryl-5-cyano-2-aminopyrimidines as VEGF-R2 inhibitors: synthesis and biological evaluation. Bioorg Med Chem Lett. 2007 Jun 15;17(12):3266-70.
DMONKDQ	RU	https://pubmed.ncbi.nlm.nih.gov/17481894

DMPY4G1	DI	DMPY4G1
DMPY4G1	DN	4-phenyl-4-[1H-imidazol-2-yl]-piperidine
DMPY4G1	MI	TT27RFC
DMPY4G1	MN	Opioid receptor delta (OPRD1)
DMPY4G1	MT	DTT
DMPY4G1	MA	Inhibitor
DMPY4G1	RN	4-Phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives, a novel class of selective delta-opioid agonists. Bioorg Med Chem Lett. 2006 Jan 1;16(1):146-9.
DMPY4G1	RU	https://pubmed.ncbi.nlm.nih.gov/16236510

DMPY4G1	DI	DMPY4G1
DMPY4G1	DN	4-phenyl-4-[1H-imidazol-2-yl]-piperidine
DMPY4G1	MI	TTQW87Y
DMPY4G1	MN	Opioid receptor kappa (OPRK1)
DMPY4G1	MT	DTT
DMPY4G1	MA	Inhibitor
DMPY4G1	RN	4-Phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives, a novel class of selective delta-opioid agonists. Bioorg Med Chem Lett. 2006 Jan 1;16(1):146-9.
DMPY4G1	RU	https://pubmed.ncbi.nlm.nih.gov/16236510

DM7E4JU	DI	DM7E4JU
DM7E4JU	DN	4-Phenyl-5-piperidin-4-yl-isoxazol-3-ol
DM7E4JU	MI	TT1MPAY
DM7E4JU	MN	GABA(A) receptor alpha-1 (GABRA1)
DM7E4JU	MT	DTT
DM7E4JU	MA	Inhibitor
DM7E4JU	RN	Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling. J Med Chem. 2005 Jan 27;48(2):427-39.
DM7E4JU	RU	https://pubmed.ncbi.nlm.nih.gov/15658856

DM7E4JU	DI	DM7E4JU
DM7E4JU	DN	4-Phenyl-5-piperidin-4-yl-isoxazol-3-ol
DM7E4JU	MI	TTZA1NY
DM7E4JU	MN	GABA(A) receptor beta-2 (GABRB2)
DM7E4JU	MT	DTT
DM7E4JU	MA	Inhibitor
DM7E4JU	RN	Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling. J Med Chem. 2005 Jan 27;48(2):427-39.
DM7E4JU	RU	https://pubmed.ncbi.nlm.nih.gov/15658856

DM7E4JU	DI	DM7E4JU
DM7E4JU	DN	4-Phenyl-5-piperidin-4-yl-isoxazol-3-ol
DM7E4JU	MI	TT06RH5
DM7E4JU	MN	GABA(A) receptor gamma-2 (GABRG2)
DM7E4JU	MT	DTT
DM7E4JU	MA	Inhibitor
DM7E4JU	RN	Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling. J Med Chem. 2005 Jan 27;48(2):427-39.
DM7E4JU	RU	https://pubmed.ncbi.nlm.nih.gov/15658856

DM7E4JU	DI	DM7E4JU
DM7E4JU	DN	4-Phenyl-5-piperidin-4-yl-isoxazol-3-ol
DM7E4JU	MI	TTNJYV2
DM7E4JU	MN	Gamma-aminobutyric acid receptor (GAR)
DM7E4JU	MT	DTT
DM7E4JU	MA	Inhibitor
DM7E4JU	RN	4-aryl-5-(4-piperidyl)-3-isoxazolol GABAA antagonists: synthesis, pharmacology, and structure-activity relationships. J Med Chem. 2007 Apr 19;50(8):1988-92.
DM7E4JU	RU	https://pubmed.ncbi.nlm.nih.gov/17375905

DMMIB0R	DI	DMMIB0R
DMMIB0R	DN	4-phenyl-6-propylpyrimidine-2-carbonitrile
DMMIB0R	MI	TTDZN01
DMMIB0R	MN	Cathepsin K (CTSK)
DMMIB0R	MT	DTT
DMMIB0R	MA	Inhibitor
DMMIB0R	RN	2-Phenyl-9H-purine-6-carbonitrile derivatives as selective cathepsin S inhibitors. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4447-50.
DMMIB0R	RU	https://pubmed.ncbi.nlm.nih.gov/20594841

DMLZSH1	DI	DMLZSH1
DMLZSH1	DN	4-Phenyl-benzo[b]thiophene-2-carboxamidine
DMLZSH1	MI	TTFEZ5Q
DMLZSH1	MN	Coagulation factor IX (F9)
DMLZSH1	MT	DTT
DMLZSH1	MA	Inhibitor
DMLZSH1	RN	Studies of benzothiophene template as potent factor IXa (FIXa) inhibitors in thrombosis. J Med Chem. 2010 Feb 25;53(4):1465-72.
DMLZSH1	RU	https://pubmed.ncbi.nlm.nih.gov/20121198

DM871ZE	DI	DM871ZE
DM871ZE	DN	4-Phenylbutylcarbamic Acid Biphenyl-3-yl Ester
DM871ZE	MI	TTDP1UC
DM871ZE	MN	Fatty acid amide hydrolase (FAAH)
DM871ZE	MT	DTT
DM871ZE	MA	Inhibitor
DM871ZE	RN	Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl a... J Med Chem. 2008 Jun 26;51(12):3487-98.
DM871ZE	RU	https://pubmed.ncbi.nlm.nih.gov/18507372

DMCZKN7	DI	DMCZKN7
DMCZKN7	DN	4-Phenylbutyrohydroxamic acid
DMCZKN7	MI	TTBH0VX
DMCZKN7	MN	Histone deacetylase (HDAC)
DMCZKN7	MT	DTT
DMCZKN7	MA	Inhibitor
DMCZKN7	RN	Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010 Mar;6(3):238-243.
DMCZKN7	RU	https://pubmed.ncbi.nlm.nih.gov/20139990

DMCZKN7	DI	DMCZKN7
DMCZKN7	DN	4-Phenylbutyrohydroxamic acid
DMCZKN7	MI	TT6R7JZ
DMCZKN7	MN	Histone deacetylase 1 (HDAC1)
DMCZKN7	MT	DTT
DMCZKN7	MA	Inhibitor
DMCZKN7	RN	Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010 Mar;6(3):238-243.
DMCZKN7	RU	https://pubmed.ncbi.nlm.nih.gov/20139990

DMCZKN7	DI	DMCZKN7
DMCZKN7	DN	4-Phenylbutyrohydroxamic acid
DMCZKN7	MI	TTSHTOI
DMCZKN7	MN	Histone deacetylase 2 (HDAC2)
DMCZKN7	MT	DTT
DMCZKN7	MA	Inhibitor
DMCZKN7	RN	Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010 Mar;6(3):238-243.
DMCZKN7	RU	https://pubmed.ncbi.nlm.nih.gov/20139990

DMCZKN7	DI	DMCZKN7
DMCZKN7	DN	4-Phenylbutyrohydroxamic acid
DMCZKN7	MI	TT5ZKDI
DMCZKN7	MN	Histone deacetylase 6 (HDAC6)
DMCZKN7	MT	DTT
DMCZKN7	MA	Inhibitor
DMCZKN7	RN	Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010 Mar;6(3):238-243.
DMCZKN7	RU	https://pubmed.ncbi.nlm.nih.gov/20139990

DMCZKN7	DI	DMCZKN7
DMCZKN7	DN	4-Phenylbutyrohydroxamic acid
DMCZKN7	MI	TTT6LFV
DMCZKN7	MN	Histone deacetylase 8 (HDAC8)
DMCZKN7	MT	DTT
DMCZKN7	MA	Inhibitor
DMCZKN7	RN	Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010 Mar;6(3):238-243.
DMCZKN7	RU	https://pubmed.ncbi.nlm.nih.gov/20139990

DM5UNBW	DI	DM5UNBW
DM5UNBW	DN	4-Phenylimidazole
DM5UNBW	MI	TTZJYKH
DM5UNBW	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DM5UNBW	MT	DTT
DM5UNBW	MA	Inhibitor
DM5UNBW	RN	Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase. J Med Chem. 2008 Aug 28;51(16):4968-77.
DM5UNBW	RU	https://pubmed.ncbi.nlm.nih.gov/18665584

DM9J5TZ	DI	DM9J5TZ
DM9J5TZ	DN	4-phenyliminomethyl-benzenesulfonamide
DM9J5TZ	MI	TTVKILB
DM9J5TZ	MN	Prostaglandin G/H synthase 2 (COX-2)
DM9J5TZ	MT	DTT
DM9J5TZ	MA	Inhibitor
DM9J5TZ	RN	Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides. Bioorg Med Chem. 2008 Mar 1;16(5):2697-706.
DM9J5TZ	RU	https://pubmed.ncbi.nlm.nih.gov/18063374

DMW46K7	DI	DMW46K7
DMW46K7	DN	4-Phenylspiro[chromene-2,4'-piperidine]
DMW46K7	MI	TT27RFC
DMW46K7	MN	Opioid receptor delta (OPRD1)
DMW46K7	MT	DTT
DMW46K7	MA	Inhibitor
DMW46K7	RN	Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-pipe... J Med Chem. 2008 Oct 9;51(19):5893-6.
DMW46K7	RU	https://pubmed.ncbi.nlm.nih.gov/18788723

DMW46K7	DI	DMW46K7
DMW46K7	DN	4-Phenylspiro[chromene-2,4'-piperidine]
DMW46K7	MI	TTQW87Y
DMW46K7	MN	Opioid receptor kappa (OPRK1)
DMW46K7	MT	DTT
DMW46K7	MA	Inhibitor
DMW46K7	RN	Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-pipe... J Med Chem. 2008 Oct 9;51(19):5893-6.
DMW46K7	RU	https://pubmed.ncbi.nlm.nih.gov/18788723

DMW46K7	DI	DMW46K7
DMW46K7	DN	4-Phenylspiro[chromene-2,4'-piperidine]
DMW46K7	MI	TTQ6VDM
DMW46K7	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMW46K7	MT	DTT
DMW46K7	MA	Inhibitor
DMW46K7	RN	Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-pipe... J Med Chem. 2008 Oct 9;51(19):5893-6.
DMW46K7	RU	https://pubmed.ncbi.nlm.nih.gov/18788723

DMHANXD	DI	DMHANXD
DMHANXD	DN	4-Phenylsulfanyl-7H-pyrrolo[2,3-d]pyrimidine
DMHANXD	MI	TT860QF
DMHANXD	MN	LCK tyrosine protein kinase (LCK)
DMHANXD	MT	DTT
DMHANXD	MA	Inhibitor
DMHANXD	RN	Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22.
DMHANXD	RU	https://pubmed.ncbi.nlm.nih.gov/15689155

DMHANXD	DI	DMHANXD
DMHANXD	DN	4-Phenylsulfanyl-7H-pyrrolo[2,3-d]pyrimidine
DMHANXD	MI	TTQBR95
DMHANXD	MN	Stress-activated protein kinase 2a (p38 alpha)
DMHANXD	MT	DTT
DMHANXD	MA	Inhibitor
DMHANXD	RN	Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22.
DMHANXD	RU	https://pubmed.ncbi.nlm.nih.gov/15689155

DM3B1CE	DI	DM3B1CE
DM3B1CE	DN	4-phenylthiazole-2-thiol
DM3B1CE	MI	TTZJYKH
DM3B1CE	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DM3B1CE	MT	DTT
DM3B1CE	MA	Inhibitor
DM3B1CE	RN	Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2010 Feb 11;53(3):1172-89.
DM3B1CE	RU	https://pubmed.ncbi.nlm.nih.gov/20055453

DMW4KXQ	DI	DMW4KXQ
DMW4KXQ	DN	4-phospho-D-erythronate
DMW4KXQ	MI	TTZ3IFB
DMW4KXQ	MN	Phosphogluconate dehydrogenase (PGD)
DMW4KXQ	MT	DTT
DMW4KXQ	MA	Inhibitor
DMW4KXQ	RN	Virtual fragment screening for novel inhibitors of 6-phosphogluconate dehydrogenase. Bioorg Med Chem. 2010 Jul 15;18(14):5056-62. 
DMW4KXQ	RU	https://pubmed.ncbi.nlm.nih.gov/20598892

DMJ0A4Z	DI	DMJ0A4Z
DMJ0A4Z	DN	4'-Phosphopantetheine
DMJ0A4Z	MI	TT4YO0Z
DMJ0A4Z	MN	Phosphopantetheine adenylyltransferase (PPAT)
DMJ0A4Z	MT	DTT
DMJ0A4Z	MA	Inhibitor
DMJ0A4Z	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMJ0A4Z	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMOHDRS	DI	DMOHDRS
DMOHDRS	DN	4-Piperidin-1-yl-chromen-2-one
DMOHDRS	MI	TTK3PY9
DMOHDRS	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMOHDRS	MT	DTT
DMOHDRS	MA	Inhibitor
DMOHDRS	RN	Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85.
DMOHDRS	RU	https://pubmed.ncbi.nlm.nih.gov/15658870

DMONGDX	DI	DMONGDX
DMONGDX	DN	4-Piperidino-Piperidine
DMONGDX	MI	TTMF541
DMONGDX	MN	Liver carboxylesterase (CES1)
DMONGDX	MT	DTT
DMONGDX	MA	Inhibitor
DMONGDX	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMONGDX	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMEMN0W	DI	DMEMN0W
DMEMN0W	DN	4P-PDOT
DMEMN0W	MI	TT0WAIE
DMEMN0W	MN	Melatonin receptor type 1A (MTNR1A)
DMEMN0W	MT	DTT
DMEMN0W	MA	Antagonist
DMEMN0W	RN	Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms. FASEB J. 1998 Sep;12(12):1211-20.
DMEMN0W	RU	https://pubmed.ncbi.nlm.nih.gov/9737724

DMDBC1K	DI	DMDBC1K
DMDBC1K	DN	4-Propyl-1-[3-(phenylpropoxy)propyl]piperidine
DMDBC1K	MI	TT9JNIC
DMDBC1K	MN	Histamine H3 receptor (H3R)
DMDBC1K	MT	DTT
DMDBC1K	MA	Inhibitor
DMDBC1K	RN	Piperidine variations in search for non-imidazole histamine H(3) receptor ligands. Bioorg Med Chem. 2008 Sep 15;16(18):8729-36.
DMDBC1K	RU	https://pubmed.ncbi.nlm.nih.gov/18774720

DMRYCL6	DI	DMRYCL6
DMRYCL6	DN	4-propyl-3,4-dihydroquinazolin-2-amine
DMRYCL6	MI	TTRUFDT
DMRYCL6	MN	5-HT 5A receptor (HTR5A)
DMRYCL6	MT	DTT
DMRYCL6	MA	Inhibitor
DMRYCL6	RN	Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61.
DMRYCL6	RU	https://pubmed.ncbi.nlm.nih.gov/17998160

DMNM4GE	DI	DMNM4GE
DMNM4GE	DN	4-propyl-6-m-tolylpyrimidine-2-carbonitrile
DMNM4GE	MI	TTDZN01
DMNM4GE	MN	Cathepsin K (CTSK)
DMNM4GE	MT	DTT
DMNM4GE	MA	Inhibitor
DMNM4GE	RN	2-Phenyl-9H-purine-6-carbonitrile derivatives as selective cathepsin S inhibitors. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4447-50.
DMNM4GE	RU	https://pubmed.ncbi.nlm.nih.gov/20594841

DMNM4GE	DI	DMNM4GE
DMNM4GE	DN	4-propyl-6-m-tolylpyrimidine-2-carbonitrile
DMNM4GE	MI	TTUMQVO
DMNM4GE	MN	Cathepsin S (CTSS)
DMNM4GE	MT	DTT
DMNM4GE	MA	Inhibitor
DMNM4GE	RN	2-Phenyl-9H-purine-6-carbonitrile derivatives as selective cathepsin S inhibitors. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4447-50.
DMNM4GE	RU	https://pubmed.ncbi.nlm.nih.gov/20594841

DM4FLK6	DI	DM4FLK6
DM4FLK6	DN	4-propyl-N-(quinolin-3-yl)benzamide
DM4FLK6	MI	TTMI6F5
DM4FLK6	MN	Transient receptor potential cation channel V1 (TRPV1)
DM4FLK6	MT	DTT
DM4FLK6	MA	Inhibitor
DM4FLK6	RN	N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4.
DM4FLK6	RU	https://pubmed.ncbi.nlm.nih.gov/18359227

DMY8ZLM	DI	DMY8ZLM
DMY8ZLM	DN	4-Pyridin-2-yl-5-quinolin-2-yl-thiazol-2-ylamine
DMY8ZLM	MI	TTP4520
DMY8ZLM	MN	TGF-beta receptor type I (TGFBR1)
DMY8ZLM	MT	DTT
DMY8ZLM	MA	Inhibitor
DMY8ZLM	RN	Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors. J Med Chem. 2004 Aug 26;47(18):4494-506.
DMY8ZLM	RU	https://pubmed.ncbi.nlm.nih.gov/15317461

DM6RVB3	DI	DM6RVB3
DM6RVB3	DN	4-Pyridin-2-yl-5-quinolin-4-yl-thiazol-2-ylamine
DM6RVB3	MI	TTP4520
DM6RVB3	MN	TGF-beta receptor type I (TGFBR1)
DM6RVB3	MT	DTT
DM6RVB3	MA	Inhibitor
DM6RVB3	RN	Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors. J Med Chem. 2004 Aug 26;47(18):4494-506.
DM6RVB3	RU	https://pubmed.ncbi.nlm.nih.gov/15317461

DMFC8Q4	DI	DMFC8Q4
DMFC8Q4	DN	4-Pyridin-2-yl-piperazine-1-carboxylic acid amide
DMFC8Q4	MI	TTMI6F5
DMFC8Q4	MN	Transient receptor potential cation channel V1 (TRPV1)
DMFC8Q4	MT	DTT
DMFC8Q4	MA	Inhibitor
DMFC8Q4	RN	N-4-methansulfonamidobenzyl-N'-2-substituted-4-tert-butyl-benzyl thioureas as potent vanilloid receptor antagonistic ligands. Bioorg Med Chem Lett. 2004 Apr 5;14(7):1693-6.
DMFC8Q4	RU	https://pubmed.ncbi.nlm.nih.gov/15026052

DMFC8Q4	DI	DMFC8Q4
DMFC8Q4	DN	4-Pyridin-2-yl-piperazine-1-carboxylic acid amide
DMFC8Q4	MI	TTKP2SU
DMFC8Q4	MN	Transient receptor potential cation channel V4 (TRPV4)
DMFC8Q4	MT	DTT
DMFC8Q4	MA	Inhibitor
DMFC8Q4	RN	N-4-methansulfonamidobenzyl-N'-2-substituted-4-tert-butyl-benzyl thioureas as potent vanilloid receptor antagonistic ligands. Bioorg Med Chem Lett. 2004 Apr 5;14(7):1693-6.
DMFC8Q4	RU	https://pubmed.ncbi.nlm.nih.gov/15026052

DM06AV8	DI	DM06AV8
DM06AV8	DN	4-Pyridin-3-yl-5-quinolin-4-yl-thiazol-2-ylamine
DM06AV8	MI	TTP4520
DM06AV8	MN	TGF-beta receptor type I (TGFBR1)
DM06AV8	MT	DTT
DM06AV8	MA	Inhibitor
DM06AV8	RN	Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors. J Med Chem. 2004 Aug 26;47(18):4494-506.
DM06AV8	RU	https://pubmed.ncbi.nlm.nih.gov/15317461

DMUGFS3	DI	DMUGFS3
DMUGFS3	DN	4r-Fluoro-N6-Ethanimidoyl-L-Lysine
DMUGFS3	MI	TTF10I9
DMUGFS3	MN	Nitric-oxide synthase inducible (NOS2)
DMUGFS3	MT	DTT
DMUGFS3	MA	Inhibitor
DMUGFS3	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMUGFS3	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMQNT8D	DI	DMQNT8D
DMQNT8D	DN	4S-4,5-Diamino-N-(4-phenoxyphenyl)pentanamide
DMQNT8D	MI	TTXZEAJ
DMQNT8D	MN	Leukotriene A-4 hydrolase (LTA4H)
DMQNT8D	MT	DTT
DMQNT8D	MA	Inhibitor
DMQNT8D	RN	Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83.
DMQNT8D	RU	https://pubmed.ncbi.nlm.nih.gov/18394906

DMELGKY	DI	DMELGKY
DMELGKY	DN	4-substituted 2,4-dioxobutanoic acids
DMELGKY	MI	TTTG60L
DMELGKY	MN	CAP-dependent endonuclease (CDE)
DMELGKY	MT	DTT
DMELGKY	MA	Inhibitor
DMELGKY	RN	Anti-influenza virus activities of 4-substituted 2,4-dioxobutanoic acid inhibitors. Antimicrob Agents Chemother. 1996 May;40(5):1304-7.
DMELGKY	RU	https://pubmed.ncbi.nlm.nih.gov/8723491

DMELGKY	DI	DMELGKY
DMELGKY	DN	4-substituted 2,4-dioxobutanoic acids
DMELGKY	MI	TTV9MQG
DMELGKY	MN	Gamma-aminobutyric acid uptake (GABAU)
DMELGKY	MT	DTT
DMELGKY	MA	Inhibitor
DMELGKY	RN	GABA uptake inhibitors. Design, molecular pharmacology and therapeutic aspects. Curr Pharm Des. 2000 Aug;6(12):1193-209.
DMELGKY	RU	https://pubmed.ncbi.nlm.nih.gov/10903390

DMWH2NT	DI	DMWH2NT
DMWH2NT	DN	4-Sulfamoyloxy-benzoic acid butyl ester
DMWH2NT	MI	TTHM0R1
DMWH2NT	MN	Steryl-sulfatase (STS)
DMWH2NT	MT	DTT
DMWH2NT	MA	Inhibitor
DMWH2NT	RN	Inhibition of estrone sulfatase (ES) by alkyl and cycloalkyl ester derivatives of 4-[(aminosulfonyl)oxy] benzoic acid. Bioorg Med Chem Lett. 2004 Feb 9;14(3):605-9.
DMWH2NT	RU	https://pubmed.ncbi.nlm.nih.gov/14741252

DMDNRCU	DI	DMDNRCU
DMDNRCU	DN	4-Sulfamoyloxy-benzoic acid cycloheptyl ester
DMDNRCU	MI	TTHM0R1
DMDNRCU	MN	Steryl-sulfatase (STS)
DMDNRCU	MT	DTT
DMDNRCU	MA	Inhibitor
DMDNRCU	RN	Inhibition of estrone sulfatase (ES) by alkyl and cycloalkyl ester derivatives of 4-[(aminosulfonyl)oxy] benzoic acid. Bioorg Med Chem Lett. 2004 Feb 9;14(3):605-9.
DMDNRCU	RU	https://pubmed.ncbi.nlm.nih.gov/14741252

DMIX0UN	DI	DMIX0UN
DMIX0UN	DN	4-Sulfamoyloxy-benzoic acid cyclohexyl ester
DMIX0UN	MI	TTHM0R1
DMIX0UN	MN	Steryl-sulfatase (STS)
DMIX0UN	MT	DTT
DMIX0UN	MA	Inhibitor
DMIX0UN	RN	Inhibition of estrone sulfatase (ES) by alkyl and cycloalkyl ester derivatives of 4-[(aminosulfonyl)oxy] benzoic acid. Bioorg Med Chem Lett. 2004 Feb 9;14(3):605-9.
DMIX0UN	RU	https://pubmed.ncbi.nlm.nih.gov/14741252

DMG4LD9	DI	DMG4LD9
DMG4LD9	DN	4-Sulfamoyloxy-benzoic acid cyclooctyl ester
DMG4LD9	MI	TTHM0R1
DMG4LD9	MN	Steryl-sulfatase (STS)
DMG4LD9	MT	DTT
DMG4LD9	MA	Inhibitor
DMG4LD9	RN	Inhibition of estrone sulfatase (ES) by alkyl and cycloalkyl ester derivatives of 4-[(aminosulfonyl)oxy] benzoic acid. Bioorg Med Chem Lett. 2004 Feb 9;14(3):605-9.
DMG4LD9	RU	https://pubmed.ncbi.nlm.nih.gov/14741252

DMF3C71	DI	DMF3C71
DMF3C71	DN	4-Sulfamoyloxy-benzoic acid cyclopentyl ester
DMF3C71	MI	TTHM0R1
DMF3C71	MN	Steryl-sulfatase (STS)
DMF3C71	MT	DTT
DMF3C71	MA	Inhibitor
DMF3C71	RN	Inhibition of estrone sulfatase (ES) by alkyl and cycloalkyl ester derivatives of 4-[(aminosulfonyl)oxy] benzoic acid. Bioorg Med Chem Lett. 2004 Feb 9;14(3):605-9.
DMF3C71	RU	https://pubmed.ncbi.nlm.nih.gov/14741252

DMTC25W	DI	DMTC25W
DMTC25W	DN	4-Sulfamoyloxy-benzoic acid heptyl ester
DMTC25W	MI	TTHM0R1
DMTC25W	MN	Steryl-sulfatase (STS)
DMTC25W	MT	DTT
DMTC25W	MA	Inhibitor
DMTC25W	RN	Inhibition of estrone sulfatase (ES) by alkyl and cycloalkyl ester derivatives of 4-[(aminosulfonyl)oxy] benzoic acid. Bioorg Med Chem Lett. 2004 Feb 9;14(3):605-9.
DMTC25W	RU	https://pubmed.ncbi.nlm.nih.gov/14741252

DMU784M	DI	DMU784M
DMU784M	DN	4-Sulfamoyloxy-benzoic acid hexyl ester
DMU784M	MI	TTHM0R1
DMU784M	MN	Steryl-sulfatase (STS)
DMU784M	MT	DTT
DMU784M	MA	Inhibitor
DMU784M	RN	Inhibition of estrone sulfatase (ES) by alkyl and cycloalkyl ester derivatives of 4-[(aminosulfonyl)oxy] benzoic acid. Bioorg Med Chem Lett. 2004 Feb 9;14(3):605-9.
DMU784M	RU	https://pubmed.ncbi.nlm.nih.gov/14741252

DM4Z7TU	DI	DM4Z7TU
DM4Z7TU	DN	4-Sulfamoyloxy-benzoic acid nonyl ester
DM4Z7TU	MI	TTHM0R1
DM4Z7TU	MN	Steryl-sulfatase (STS)
DM4Z7TU	MT	DTT
DM4Z7TU	MA	Inhibitor
DM4Z7TU	RN	Inhibition of estrone sulfatase (ES) by alkyl and cycloalkyl ester derivatives of 4-[(aminosulfonyl)oxy] benzoic acid. Bioorg Med Chem Lett. 2004 Feb 9;14(3):605-9.
DM4Z7TU	RU	https://pubmed.ncbi.nlm.nih.gov/14741252

DMQMSW3	DI	DMQMSW3
DMQMSW3	DN	4-Sulfamoyloxy-benzoic acid octyl ester
DMQMSW3	MI	TTHM0R1
DMQMSW3	MN	Steryl-sulfatase (STS)
DMQMSW3	MT	DTT
DMQMSW3	MA	Inhibitor
DMQMSW3	RN	Inhibition of estrone sulfatase (ES) by alkyl and cycloalkyl ester derivatives of 4-[(aminosulfonyl)oxy] benzoic acid. Bioorg Med Chem Lett. 2004 Feb 9;14(3):605-9.
DMQMSW3	RU	https://pubmed.ncbi.nlm.nih.gov/14741252

DMZIFW7	DI	DMZIFW7
DMZIFW7	DN	4-Sulfamoyloxy-benzoic acid pentyl ester
DMZIFW7	MI	TTHM0R1
DMZIFW7	MN	Steryl-sulfatase (STS)
DMZIFW7	MT	DTT
DMZIFW7	MA	Inhibitor
DMZIFW7	RN	Inhibition of estrone sulfatase (ES) by alkyl and cycloalkyl ester derivatives of 4-[(aminosulfonyl)oxy] benzoic acid. Bioorg Med Chem Lett. 2004 Feb 9;14(3):605-9.
DMZIFW7	RU	https://pubmed.ncbi.nlm.nih.gov/14741252

DMRILJC	DI	DMRILJC
DMRILJC	DN	4-Sulfamoyloxy-benzoic acid propyl ester
DMRILJC	MI	TTHM0R1
DMRILJC	MN	Steryl-sulfatase (STS)
DMRILJC	MT	DTT
DMRILJC	MA	Inhibitor
DMRILJC	RN	Inhibition of estrone sulfatase (ES) by alkyl and cycloalkyl ester derivatives of 4-[(aminosulfonyl)oxy] benzoic acid. Bioorg Med Chem Lett. 2004 Feb 9;14(3):605-9.
DMRILJC	RU	https://pubmed.ncbi.nlm.nih.gov/14741252

DM61CJK	DI	DM61CJK
DM61CJK	DN	4-Sulfonamide-[1-(4-Aminobutane)]Benzamide
DM61CJK	MI	TTANPDJ
DM61CJK	MN	Carbonic anhydrase II (CA-II)
DM61CJK	MT	DTT
DM61CJK	MA	Inhibitor
DM61CJK	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM61CJK	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMGCYS1	DI	DMGCYS1
DMGCYS1	DN	4-TERT-BUTYLBENZENESULFONIC ACID
DMGCYS1	MI	TT6L509
DMGCYS1	MN	Coagulation factor IIa (F2)
DMGCYS1	MT	DTT
DMGCYS1	MA	Inhibitor
DMGCYS1	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMGCYS1	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMDWRE5	DI	DMDWRE5
DMDWRE5	DN	4-tert-butyl-N-(2-isopropylphenyl)thiazol-2-amine
DMDWRE5	MI	TT7HQD0
DMDWRE5	MN	C-C chemokine receptor type 4 (CCR4)
DMDWRE5	MT	DTT
DMDWRE5	MA	Inhibitor
DMDWRE5	RN	Optimization of 2-aminothiazole derivatives as CCR4 antagonists. Bioorg Med Chem Lett. 2006 May 15;16(10):2800-3.
DMDWRE5	RU	https://pubmed.ncbi.nlm.nih.gov/16497499

DMLFZ6Q	DI	DMLFZ6Q
DMLFZ6Q	DN	4-tert-Butyl-N-(4-phenyl-thiazol-2-yl)-benzamide
DMLFZ6Q	MI	TTK25J1
DMLFZ6Q	MN	Adenosine A1 receptor (ADORA1)
DMLFZ6Q	MT	DTT
DMLFZ6Q	MA	Inhibitor
DMLFZ6Q	RN	Substituted 4-phenyl-2-(phenylcarboxamido)-1,3-thiazole derivatives as antagonists for the adenosine A(1) receptor. Bioorg Med Chem Lett. 2001 Aug 6;11(15):2017-9.
DMLFZ6Q	RU	https://pubmed.ncbi.nlm.nih.gov/11454470

DM5U6ZW	DI	DM5U6ZW
DM5U6ZW	DN	4-tert-butyl-N-(naphthalen-1-yl)oxazol-2-amine
DM5U6ZW	MI	TT7HQD0
DM5U6ZW	MN	C-C chemokine receptor type 4 (CCR4)
DM5U6ZW	MT	DTT
DM5U6ZW	MA	Inhibitor
DM5U6ZW	RN	Optimization of 2-aminothiazole derivatives as CCR4 antagonists. Bioorg Med Chem Lett. 2006 May 15;16(10):2800-3.
DM5U6ZW	RU	https://pubmed.ncbi.nlm.nih.gov/16497499

DMBUZ75	DI	DMBUZ75
DMBUZ75	DN	4-tert-butyl-N-(naphthalen-1-yl)thiazol-2-amine
DMBUZ75	MI	TT7HQD0
DMBUZ75	MN	C-C chemokine receptor type 4 (CCR4)
DMBUZ75	MT	DTT
DMBUZ75	MA	Inhibitor
DMBUZ75	RN	Optimization of 2-aminothiazole derivatives as CCR4 antagonists. Bioorg Med Chem Lett. 2006 May 15;16(10):2800-3.
DMBUZ75	RU	https://pubmed.ncbi.nlm.nih.gov/16497499

DM1OBHQ	DI	DM1OBHQ
DM1OBHQ	DN	4-tert-butyl-N-(quinolin-3-yl)benzamide
DM1OBHQ	MI	TTMI6F5
DM1OBHQ	MN	Transient receptor potential cation channel V1 (TRPV1)
DM1OBHQ	MT	DTT
DM1OBHQ	MA	Inhibitor
DM1OBHQ	RN	N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4.
DM1OBHQ	RU	https://pubmed.ncbi.nlm.nih.gov/18359227

DMUWTPX	DI	DMUWTPX
DMUWTPX	DN	4-tert-butyl-N-hydroxybenzamide
DMUWTPX	MI	TT6R7JZ
DMUWTPX	MN	Histone deacetylase 1 (HDAC1)
DMUWTPX	MT	DTT
DMUWTPX	MA	Inhibitor
DMUWTPX	RN	Design of novel histone deacetylase inhibitors. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4619-24.
DMUWTPX	RU	https://pubmed.ncbi.nlm.nih.gov/17555962

DM9K27Q	DI	DM9K27Q
DM9K27Q	DN	4-tert-butyl-N-m-tolylthiazol-2-amine
DM9K27Q	MI	TT7HQD0
DM9K27Q	MN	C-C chemokine receptor type 4 (CCR4)
DM9K27Q	MT	DTT
DM9K27Q	MA	Inhibitor
DM9K27Q	RN	Optimization of 2-aminothiazole derivatives as CCR4 antagonists. Bioorg Med Chem Lett. 2006 May 15;16(10):2800-3.
DM9K27Q	RU	https://pubmed.ncbi.nlm.nih.gov/16497499

DMJQFD5	DI	DMJQFD5
DMJQFD5	DN	4-tert-butyl-N-o-tolylthiazol-2-amine
DMJQFD5	MI	TT7HQD0
DMJQFD5	MN	C-C chemokine receptor type 4 (CCR4)
DMJQFD5	MT	DTT
DMJQFD5	MA	Inhibitor
DMJQFD5	RN	Optimization of 2-aminothiazole derivatives as CCR4 antagonists. Bioorg Med Chem Lett. 2006 May 15;16(10):2800-3.
DMJQFD5	RU	https://pubmed.ncbi.nlm.nih.gov/16497499

DM5CPBK	DI	DM5CPBK
DM5CPBK	DN	4-tert-butyl-N-phenylthiazol-2-amine
DM5CPBK	MI	TT7HQD0
DM5CPBK	MN	C-C chemokine receptor type 4 (CCR4)
DM5CPBK	MT	DTT
DM5CPBK	MA	Inhibitor
DM5CPBK	RN	Optimization of 2-aminothiazole derivatives as CCR4 antagonists. Bioorg Med Chem Lett. 2006 May 15;16(10):2800-3.
DM5CPBK	RU	https://pubmed.ncbi.nlm.nih.gov/16497499

DMUGMVI	DI	DMUGMVI
DMUGMVI	DN	4-Thiocyanato-benzenesulfonamide
DMUGMVI	MI	TTUNARX
DMUGMVI	MN	Carbonic anhydrase (CA)
DMUGMVI	MT	DTT
DMUGMVI	MA	Inhibitor
DMUGMVI	RN	Carbonic anhydrase inhibitors: inhibition of human cytosolic isozyme II and mitochondrial isozyme V with a series of benzene sulfonamide derivatives. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5703-7.
DMUGMVI	RU	https://pubmed.ncbi.nlm.nih.gov/15482952

DMUGMVI	DI	DMUGMVI
DMUGMVI	DN	4-Thiocyanato-benzenesulfonamide
DMUGMVI	MI	TTANPDJ
DMUGMVI	MN	Carbonic anhydrase II (CA-II)
DMUGMVI	MT	DTT
DMUGMVI	MA	Inhibitor
DMUGMVI	RN	Carbonic anhydrase inhibitors: inhibition of human cytosolic isozyme II and mitochondrial isozyme V with a series of benzene sulfonamide derivatives. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5703-7.
DMUGMVI	RU	https://pubmed.ncbi.nlm.nih.gov/15482952

DMA8SHN	DI	DMA8SHN
DMA8SHN	DN	4-Thiomorpholin-4-yl-benzo[g]chromen-2-one
DMA8SHN	MI	TTK3PY9
DMA8SHN	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMA8SHN	MT	DTT
DMA8SHN	MA	Inhibitor
DMA8SHN	RN	Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85.
DMA8SHN	RU	https://pubmed.ncbi.nlm.nih.gov/15658870

DM7YOXW	DI	DM7YOXW
DM7YOXW	DN	4-thio-UTP
DM7YOXW	MI	TTOZHQC
DM7YOXW	MN	P2Y purinoceptor 2 (P2RY2)
DM7YOXW	MT	DTT
DM7YOXW	MA	Agonist
DM7YOXW	RN	P2 receptors activated by uracil nucleotides--an update. Curr Med Chem. 2006;13(3):289-312.
DM7YOXW	RU	https://pubmed.ncbi.nlm.nih.gov/16475938

DMT81SD	DI	DMT81SD
DMT81SD	DN	4'-trifluoromethyl-biphenyl-4-ylamine
DMT81SD	MI	TTBGTCW
DMT81SD	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DMT81SD	MT	DTT
DMT81SD	MA	Inhibitor
DMT81SD	RN	Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52.
DMT81SD	RU	https://pubmed.ncbi.nlm.nih.gov/17725339

DML4DSG	DI	DML4DSG
DML4DSG	DN	5-((1H-imidazol-1-yl)methyl)-7,8-dihydroquinoline
DML4DSG	MI	TTSZLWK
DML4DSG	MN	Aromatase (CYP19A1)
DML4DSG	MT	DTT
DML4DSG	MA	Inhibitor
DML4DSG	RN	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
DML4DSG	RU	https://pubmed.ncbi.nlm.nih.gov/19072235

DMBSFLW	DI	DMBSFLW
DMBSFLW	DN	5-((6-Methylpyridin-2-yl)ethynyl)nicotinonitrile
DMBSFLW	MI	TTHS256
DMBSFLW	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMBSFLW	MT	DTT
DMBSFLW	MA	Inhibitor
DMBSFLW	RN	Structure-activity relationships in a novel series of 7-substituted-aryl quinolines and 5-substituted-aryl benzothiazoles at the metabotropic gluta... Bioorg Med Chem. 2010 May 1;18(9):3026-35.
DMBSFLW	RU	https://pubmed.ncbi.nlm.nih.gov/20382541

DMH0QA7	DI	DMH0QA7
DMH0QA7	DN	5-((E)-Styryl)-quinazoline-2,4-diamine
DMH0QA7	MI	TT9SL3Q
DMH0QA7	MN	Polypeptide deformylase (PDF)
DMH0QA7	MT	DTT
DMH0QA7	MA	Inhibitor
DMH0QA7	RN	2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dih... J Med Chem. 1995 Mar 3;38(5):745-52.
DMH0QA7	RU	https://pubmed.ncbi.nlm.nih.gov/7877140

DMT6D5V	DI	DMT6D5V
DMT6D5V	DN	5'-([(Z)-4-amino-2-butenyl]methylamino)-5'-deoxyadenosine
DMT6D5V	MI	TTBFROQ
DMT6D5V	MN	S-adenosylmethionine decarboxylase proenzyme (AMD1)
DMT6D5V	MT	DTT
DMT6D5V	MA	Inhibitor
DMT6D5V	RN	S-adenosylmethionine decarboxylase as an enzyme target for therapy. Pharmacol Ther. 1992 Dec;56(3):359-77.
DMT6D5V	RU	https://pubmed.ncbi.nlm.nih.gov/1301596

DMS31H9	DI	DMS31H9
DMS31H9	DN	5-(1,1-dimethyl-heptyl)-2-pyridin-3-yl-phenol
DMS31H9	MI	TT6OEDT
DMS31H9	MN	Cannabinoid receptor 1 (CB1)
DMS31H9	MT	DTT
DMS31H9	MA	Inhibitor
DMS31H9	RN	Biaryl cannabinoid mimetics--synthesis and structure-activity relationship. Bioorg Med Chem Lett. 2007 Jul 1;17(13):3652-6.
DMS31H9	RU	https://pubmed.ncbi.nlm.nih.gov/17507224

DMS31H9	DI	DMS31H9
DMS31H9	DN	5-(1,1-dimethyl-heptyl)-2-pyridin-3-yl-phenol
DMS31H9	MI	TTMSFAW
DMS31H9	MN	Cannabinoid receptor 2 (CB2)
DMS31H9	MT	DTT
DMS31H9	MA	Inhibitor
DMS31H9	RN	Biaryl cannabinoid mimetics--synthesis and structure-activity relationship. Bioorg Med Chem Lett. 2007 Jul 1;17(13):3652-6.
DMS31H9	RU	https://pubmed.ncbi.nlm.nih.gov/17507224

DMMSK9W	DI	DMMSK9W
DMMSK9W	DN	5-(1-Methyl-pyrrolidin-2-yl)-2-phenethyl-pyridine
DMMSK9W	MI	TTF4E0J
DMMSK9W	MN	Neuronal acetylcholine receptor alpha-2 (CHRNA2)
DMMSK9W	MT	DTT
DMMSK9W	MA	Inhibitor
DMMSK9W	RN	6-(2-Phenylethyl)nicotine: a novel nicotinic cholinergic receptor ligand. Bioorg Med Chem Lett. 2005 Jul 1;15(13):3237-40.
DMMSK9W	RU	https://pubmed.ncbi.nlm.nih.gov/15925512

DMA2GIE	DI	DMA2GIE
DMA2GIE	DN	5-(2-(1H-imidazol-1-yl)ethyl)quinoline
DMA2GIE	MI	TTSZLWK
DMA2GIE	MN	Aromatase (CYP19A1)
DMA2GIE	MT	DTT
DMA2GIE	MA	Inhibitor
DMA2GIE	RN	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
DMA2GIE	RU	https://pubmed.ncbi.nlm.nih.gov/19072235

DMCFKGW	DI	DMCFKGW
DMCFKGW	DN	5-(2-(2,5-dimethylphenyl)ethynyl)pyrimidine
DMCFKGW	MI	TTHS256
DMCFKGW	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMCFKGW	MT	DTT
DMCFKGW	MA	Inhibitor
DMCFKGW	RN	Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: unexpected modulation of pharmacology with slight structural modifications to a 5... Bioorg Med Chem Lett. 2008 Jul 15;18(14):4098-101.
DMCFKGW	RU	https://pubmed.ncbi.nlm.nih.gov/18550372

DM3XMKJ	DI	DM3XMKJ
DM3XMKJ	DN	5-(2-(3,5-difluorophenyl)ethynyl)pyrimidine
DM3XMKJ	MI	TTHS256
DM3XMKJ	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM3XMKJ	MT	DTT
DM3XMKJ	MA	Inhibitor
DM3XMKJ	RN	Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: unexpected modulation of pharmacology with slight structural modifications to a 5... Bioorg Med Chem Lett. 2008 Jul 15;18(14):4098-101.
DM3XMKJ	RU	https://pubmed.ncbi.nlm.nih.gov/18550372

DM37KG6	DI	DM37KG6
DM37KG6	DN	5-(2-(3-chlorophenyl)ethynyl)pyrimidine
DM37KG6	MI	TTHS256
DM37KG6	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM37KG6	MT	DTT
DM37KG6	MA	Inhibitor
DM37KG6	RN	Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: unexpected modulation of pharmacology with slight structural modifications to a 5... Bioorg Med Chem Lett. 2008 Jul 15;18(14):4098-101.
DM37KG6	RU	https://pubmed.ncbi.nlm.nih.gov/18550372

DMRS1Q5	DI	DMRS1Q5
DMRS1Q5	DN	5-(2-(4-fluoro-3-methylphenyl)ethynyl)pyrimidine
DMRS1Q5	MI	TTHS256
DMRS1Q5	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMRS1Q5	MT	DTT
DMRS1Q5	MA	Inhibitor
DMRS1Q5	RN	Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: unexpected modulation of pharmacology with slight structural modifications to a 5... Bioorg Med Chem Lett. 2008 Jul 15;18(14):4098-101.
DMRS1Q5	RU	https://pubmed.ncbi.nlm.nih.gov/18550372

DMXAF7Y	DI	DMXAF7Y
DMXAF7Y	DN	5-(2-(pyrrolidin-1-yl)ethyl)isothiazole
DMXAF7Y	MI	TT9JNIC
DMXAF7Y	MN	Histamine H3 receptor (H3R)
DMXAF7Y	MT	DTT
DMXAF7Y	MA	Inhibitor
DMXAF7Y	RN	In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9.
DMXAF7Y	RU	https://pubmed.ncbi.nlm.nih.gov/18077160

DM149IX	DI	DM149IX
DM149IX	DN	5-(2-1H-indenyl)-1,3-benzodioxole
DM149IX	MI	TT8NGED
DM149IX	MN	Prostaglandin G/H synthase 1 (COX-1)
DM149IX	MT	DTT
DM149IX	MA	Inhibitor
DM149IX	RN	'Bridged' stilbene derivatives as selective cyclooxygenase-1 inhibitors. Bioorg Med Chem. 2007 Sep 15;15(18):6109-18.
DM149IX	RU	https://pubmed.ncbi.nlm.nih.gov/17604631

DMJXI65	DI	DMJXI65
DMJXI65	DN	5-(2-Amino-ethyl)-2-chloro-phenol hydrobromide
DMJXI65	MI	TTZFYLI
DMJXI65	MN	Dopamine D1 receptor (D1R)
DMJXI65	MT	DTT
DMJXI65	MA	Inhibitor
DMJXI65	RN	Synthesis and pharmacological characterization of 2-(4-chloro-3-hydroxyphenyl)ethylamine and N,N-dialkyl derivatives as dopamine receptor ligands. J Med Chem. 1992 Nov 13;35(23):4408-14.
DMJXI65	RU	https://pubmed.ncbi.nlm.nih.gov/1360027

DMQCYEK	DI	DMQCYEK
DMQCYEK	DN	5-(2-fluorobenzyloxy)quinazoline-2,4-diamine
DMQCYEK	MI	TT9SL3Q
DMQCYEK	MN	Polypeptide deformylase (PDF)
DMQCYEK	MT	DTT
DMQCYEK	MA	Inhibitor
DMQCYEK	RN	Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal m... J Med Chem. 2008 Feb 14;51(3):449-69.
DMQCYEK	RU	https://pubmed.ncbi.nlm.nih.gov/18205293

DMHBD1T	DI	DMHBD1T
DMHBD1T	DN	5-(2-hydroxyethyl)nonane-1,9-diol
DMHBD1T	MI	TTQ9RYT
DMHBD1T	MN	Endothelin-converting enzyme 1 (ECE1)
DMHBD1T	MT	DTT
DMHBD1T	MA	Inhibitor
DMHBD1T	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMHBD1T	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMCP5U8	DI	DMCP5U8
DMCP5U8	DN	5-(2-Imidazol-1-yl-ethyl)-7,8-dihydro-quinoline
DMCP5U8	MI	TT8NGED
DMCP5U8	MN	Prostaglandin G/H synthase 1 (COX-1)
DMCP5U8	MT	DTT
DMCP5U8	MA	Inhibitor
DMCP5U8	RN	1-imidazolyl(alkyl)-substituted di- and tetrahydroquinolines and analogues: syntheses and evaluation of dual inhibitors of thromboxane A(2) synthas... J Med Chem. 2000 May 4;43(9):1841-51.
DMCP5U8	RU	https://pubmed.ncbi.nlm.nih.gov/10794700

DMCP5U8	DI	DMCP5U8
DMCP5U8	DN	5-(2-Imidazol-1-yl-ethyl)-7,8-dihydro-quinoline
DMCP5U8	MI	TTVKILB
DMCP5U8	MN	Prostaglandin G/H synthase 2 (COX-2)
DMCP5U8	MT	DTT
DMCP5U8	MA	Inhibitor
DMCP5U8	RN	1-imidazolyl(alkyl)-substituted di- and tetrahydroquinolines and analogues: syntheses and evaluation of dual inhibitors of thromboxane A(2) synthas... J Med Chem. 2000 May 4;43(9):1841-51.
DMCP5U8	RU	https://pubmed.ncbi.nlm.nih.gov/10794700

DMCP5U8	DI	DMCP5U8
DMCP5U8	DN	5-(2-Imidazol-1-yl-ethyl)-7,8-dihydro-quinoline
DMCP5U8	MI	TTKNWZ4
DMCP5U8	MN	Thromboxane-A synthase (TBXAS1)
DMCP5U8	MT	DTT
DMCP5U8	MA	Inhibitor
DMCP5U8	RN	1-imidazolyl(alkyl)-substituted di- and tetrahydroquinolines and analogues: syntheses and evaluation of dual inhibitors of thromboxane A(2) synthas... J Med Chem. 2000 May 4;43(9):1841-51.
DMCP5U8	RU	https://pubmed.ncbi.nlm.nih.gov/10794700

DMV3KBE	DI	DMV3KBE
DMV3KBE	DN	5-(2-methylpiperazin-1-ylsulfonyl)isoquinoline
DMV3KBE	MI	TTNAHEX
DMV3KBE	MN	cAMP-dependent protein kinase A type I (PRKAR1A)
DMV3KBE	MT	DTT
DMV3KBE	MA	Inhibitor
DMV3KBE	RN	Crystal structures of catalytic subunit of cAMP-dependent protein kinase in complex with isoquinolinesulfonyl protein kinase inhibitors H7, H8, and... J Biol Chem. 1996 Oct 18;271(42):26157-64.
DMV3KBE	RU	https://pubmed.ncbi.nlm.nih.gov/8824261

DMIQJM4	DI	DMIQJM4
DMIQJM4	DN	5-(2-Methylquinolin-7-yl)-2-phenylbenzonitrile
DMIQJM4	MI	TTHS256
DMIQJM4	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMIQJM4	MT	DTT
DMIQJM4	MA	Inhibitor
DMIQJM4	RN	Structure-activity relationships in a novel series of 7-substituted-aryl quinolines and 5-substituted-aryl benzothiazoles at the metabotropic gluta... Bioorg Med Chem. 2010 May 1;18(9):3026-35.
DMIQJM4	RU	https://pubmed.ncbi.nlm.nih.gov/20382541

DMO74HX	DI	DMO74HX
DMO74HX	DN	5-(2-Methylquinolin-7-yl)-2-phenylnicotinonitrile
DMO74HX	MI	TTHS256
DMO74HX	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMO74HX	MT	DTT
DMO74HX	MA	Inhibitor
DMO74HX	RN	Structure-activity relationships in a novel series of 7-substituted-aryl quinolines and 5-substituted-aryl benzothiazoles at the metabotropic gluta... Bioorg Med Chem. 2010 May 1;18(9):3026-35.
DMO74HX	RU	https://pubmed.ncbi.nlm.nih.gov/20382541

DMMX69H	DI	DMMX69H
DMMX69H	DN	5-(2-methylquinolin-7-yl)isophthalonitrile
DMMX69H	MI	TTHS256
DMMX69H	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMMX69H	MT	DTT
DMMX69H	MA	Inhibitor
DMMX69H	RN	Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8.
DMMX69H	RU	https://pubmed.ncbi.nlm.nih.gov/17590335

DM8LN2X	DI	DM8LN2X
DM8LN2X	DN	5-(2-methylquinolin-7-yl)nicotinonitrile
DM8LN2X	MI	TTHS256
DM8LN2X	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM8LN2X	MT	DTT
DM8LN2X	MA	Inhibitor
DM8LN2X	RN	Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8.
DM8LN2X	RU	https://pubmed.ncbi.nlm.nih.gov/17590335

DMO5WG8	DI	DMO5WG8
DMO5WG8	DN	5-(2-m-tolylethynyl)pyrimidine
DMO5WG8	MI	TTHS256
DMO5WG8	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMO5WG8	MT	DTT
DMO5WG8	MA	Inhibitor
DMO5WG8	RN	Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: unexpected modulation of pharmacology with slight structural modifications to a 5... Bioorg Med Chem Lett. 2008 Jul 15;18(14):4098-101.
DMO5WG8	RU	https://pubmed.ncbi.nlm.nih.gov/18550372

DMR7OHB	DI	DMR7OHB
DMR7OHB	DN	5-(2-oxoindolin-5-yl)-1H-pyrrole-2-carbonitrile
DMR7OHB	MI	TTUV8G9
DMR7OHB	MN	Progesterone receptor (PGR)
DMR7OHB	MT	DTT
DMR7OHB	MA	Inhibitor
DMR7OHB	RN	Design, synthesis, and SAR of new pyrrole-oxindole progesterone receptor modulators leading to 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-... J Med Chem. 2008 Mar 27;51(6):1861-73.
DMR7OHB	RU	https://pubmed.ncbi.nlm.nih.gov/18318463

DM07P5E	DI	DM07P5E
DM07P5E	DN	5-(2-phenethylpiperazin-1-yl)-1H-indazole
DM07P5E	MI	TTXV4FI
DM07P5E	MN	Albendazole monooxygenase (CYP3A4)
DM07P5E	MT	DTT
DM07P5E	MA	Inhibitor
DM07P5E	RN	2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression, Bioorg. Med. Chem. Lett. 20(13):3941-3945 (2010).
DM07P5E	RU	http://www.sciencedirect.com/science/article/pii/S0960894X10006372

DMR35OM	DI	DMR35OM
DMR35OM	DN	5-(3-(4-fluorobenzyl)pyrrolidin-3-yl)-1H-indole
DMR35OM	MI	TTQ6VDM
DMR35OM	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMR35OM	MT	DTT
DMR35OM	MA	Inhibitor
DMR35OM	RN	Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors. Bioorg Med Chem Lett. 2008 Dec 1;18(23):6062-6.
DMR35OM	RU	https://pubmed.ncbi.nlm.nih.gov/18954985

DMRF0PS	DI	DMRF0PS
DMRF0PS	DN	5-(3,4-dichlorophenyl)-1H-pyrazol-3-ol
DMRF0PS	MI	TTEAID7
DMRF0PS	MN	Trypanosoma Cruzipain (Trypano CYSP)
DMRF0PS	MT	DTT
DMRF0PS	MA	Inhibitor
DMRF0PS	RN	Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease. J Med Chem. 2010 Jan 14;53(1):37-51.
DMRF0PS	RU	https://pubmed.ncbi.nlm.nih.gov/19908840

DMZK4AH	DI	DMZK4AH
DMZK4AH	DN	5-(3-benzylpyrrolidin-3-yl)-1h-indole (structural mix)
DMZK4AH	MI	TTQ6VDM
DMZK4AH	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMZK4AH	MT	DTT
DMZK4AH	MA	Inhibitor
DMZK4AH	RN	Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors. Bioorg Med Chem Lett. 2008 Dec 1;18(23):6062-6.
DMZK4AH	RU	https://pubmed.ncbi.nlm.nih.gov/18954985

DM2ZUFO	DI	DM2ZUFO
DM2ZUFO	DN	5-(3-benzylpyrrolidin-3-yl)-1-methyl-1H-indole
DM2ZUFO	MI	TTQ6VDM
DM2ZUFO	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DM2ZUFO	MT	DTT
DM2ZUFO	MA	Inhibitor
DM2ZUFO	RN	Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors. Bioorg Med Chem Lett. 2008 Dec 1;18(23):6062-6.
DM2ZUFO	RU	https://pubmed.ncbi.nlm.nih.gov/18954985

DMPKGJC	DI	DMPKGJC
DMPKGJC	DN	5-(3-butylpyrrolidin-3-yl)-1H-indole
DMPKGJC	MI	TTQ6VDM
DMPKGJC	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMPKGJC	MT	DTT
DMPKGJC	MA	Inhibitor
DMPKGJC	RN	Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors. Bioorg Med Chem Lett. 2008 Dec 1;18(23):6062-6.
DMPKGJC	RU	https://pubmed.ncbi.nlm.nih.gov/18954985

DMCR9KX	DI	DMCR9KX
DMCR9KX	DN	5-(3-Chloro-benzyl)-1H-pyrazole-3-carboxylic acid
DMCR9KX	MI	TTWNV8U
DMCR9KX	MN	Nicotinic acid receptor (HCAR2)
DMCR9KX	MT	DTT
DMCR9KX	MA	Inhibitor
DMCR9KX	RN	Pyrazole derivatives as partial agonists for the nicotinic acid receptor. J Med Chem. 2003 Aug 28;46(18):3945-51.
DMCR9KX	RU	https://pubmed.ncbi.nlm.nih.gov/12930155

DMABSOC	DI	DMABSOC
DMABSOC	DN	5-(3-chlorophenylethynyl)-5-methyl[1,2,4]triazine
DMABSOC	MI	TTHS256
DMABSOC	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMABSOC	MT	DTT
DMABSOC	MA	Inhibitor
DMABSOC	RN	Synthesis and pharmacological evaluation of phenylethynyl[1,2,4]methyltriazines as analogues of 3-methyl-6-(phenylethynyl)pyridine. J Med Chem. 2007 Jul 12;50(14):3388-91.
DMABSOC	RU	https://pubmed.ncbi.nlm.nih.gov/17569516

DMPC9DV	DI	DMPC9DV
DMPC9DV	DN	5-(3'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid
DMPC9DV	MI	TTXZ0KQ
DMPC9DV	MN	Matrix metalloproteinase-12 (MMP-12)
DMPC9DV	MT	DTT
DMPC9DV	MA	Inhibitor
DMPC9DV	RN	The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3.
DMPC9DV	RU	https://pubmed.ncbi.nlm.nih.gov/19703773

DM2H9ND	DI	DM2H9ND
DM2H9ND	DN	5-(3-hydroxyphenyl)-1,3,4-oxadiazole-2(3H)-thione
DM2H9ND	MI	TTULVH8
DM2H9ND	MN	Tyrosinase (TYR)
DM2H9ND	MT	DTT
DM2H9ND	MA	Inhibitor
DM2H9ND	RN	New potent inhibitors of tyrosinase: novel clues to binding of 1,3,4-thiadiazole-2(3H)-thiones, 1,3,4-oxadiazole-2(3H)-thiones, 4-amino-1,2,4-triaz... Bioorg Med Chem. 2010 Jun 1;18(11):4042-8.
DM2H9ND	RU	https://pubmed.ncbi.nlm.nih.gov/20452224

DMPCFA6	DI	DMPCFA6
DMPCFA6	DN	5-(3-Phenyl-propyl)-1H-pyrazole-3-carboxylic acid
DMPCFA6	MI	TTWNV8U
DMPCFA6	MN	Nicotinic acid receptor (HCAR2)
DMPCFA6	MT	DTT
DMPCFA6	MA	Inhibitor
DMPCFA6	RN	Pyrazole derivatives as partial agonists for the nicotinic acid receptor. J Med Chem. 2003 Aug 28;46(18):3945-51.
DMPCFA6	RU	https://pubmed.ncbi.nlm.nih.gov/12930155

DMZYE8W	DI	DMZYE8W
DMZYE8W	DN	5-(4-((phenethylamino)methyl)phenoxy)picolinamide
DMZYE8W	MI	TT27RFC
DMZYE8W	MN	Opioid receptor delta (OPRD1)
DMZYE8W	MT	DTT
DMZYE8W	MA	Inhibitor
DMZYE8W	RN	Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5349-52.
DMZYE8W	RU	https://pubmed.ncbi.nlm.nih.gov/17720493

DMZYE8W	DI	DMZYE8W
DMZYE8W	DN	5-(4-((phenethylamino)methyl)phenoxy)picolinamide
DMZYE8W	MI	TTQW87Y
DMZYE8W	MN	Opioid receptor kappa (OPRK1)
DMZYE8W	MT	DTT
DMZYE8W	MA	Inhibitor
DMZYE8W	RN	Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5349-52.
DMZYE8W	RU	https://pubmed.ncbi.nlm.nih.gov/17720493

DMZYE8W	DI	DMZYE8W
DMZYE8W	DN	5-(4-((phenethylamino)methyl)phenoxy)picolinamide
DMZYE8W	MI	TTKWM86
DMZYE8W	MN	Opioid receptor mu (MOP)
DMZYE8W	MT	DTT
DMZYE8W	MA	Inhibitor
DMZYE8W	RN	Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5349-52.
DMZYE8W	RU	https://pubmed.ncbi.nlm.nih.gov/17720493

DM6KSN9	DI	DM6KSN9
DM6KSN9	DN	5-(4'-benzoylbiphenyl-4-yl)-2-furoic acid
DM6KSN9	MI	TT9INHD
DM6KSN9	MN	Creatine kinase (CK)
DM6KSN9	MT	DTT
DM6KSN9	MA	Inhibitor
DM6KSN9	RN	NMR screening applied to the fragment-based generation of inhibitors of creatine kinase exploiting a new interaction proximate to the ATP binding s... J Med Chem. 2007 Apr 19;50(8):1865-75.
DM6KSN9	RU	https://pubmed.ncbi.nlm.nih.gov/17375903

DMT4856	DI	DMT4856
DMT4856	DN	5-(4-bromophenyl)-2-furaldehyde thiosemicarbazone
DMT4856	MI	TTEAID7
DMT4856	MN	Trypanosoma Cruzipain (Trypano CYSP)
DMT4856	MT	DTT
DMT4856	MA	Inhibitor
DMT4856	RN	Synthesis and structure-activity relationship study of potent trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine protease cruz... J Med Chem. 2002 Jun 20;45(13):2695-707.
DMT4856	RU	https://pubmed.ncbi.nlm.nih.gov/12061873

DMDCNZE	DI	DMDCNZE
DMDCNZE	DN	5-(4-Chloro-benzyl)-1H-pyrazole-3-carboxylic acid
DMDCNZE	MI	TTWNV8U
DMDCNZE	MN	Nicotinic acid receptor (HCAR2)
DMDCNZE	MT	DTT
DMDCNZE	MA	Inhibitor
DMDCNZE	RN	Pyrazole derivatives as partial agonists for the nicotinic acid receptor. J Med Chem. 2003 Aug 28;46(18):3945-51.
DMDCNZE	RU	https://pubmed.ncbi.nlm.nih.gov/12930155

DMJKAF0	DI	DMJKAF0
DMJKAF0	DN	5-(4-Chloro-phenyl)-1-methyl-piperidin-2-one
DMJKAF0	MI	TTTU72V
DMJKAF0	MN	Steroid 5-alpha-reductase 1 (SRD5A1)
DMJKAF0	MT	DTT
DMJKAF0	MA	Inhibitor
DMJKAF0	RN	Simple bi- and tricyclic inhibitors of human steroid 5alpha-reductase. Bioorg Med Chem Lett. 2000 Sep 4;10(17):1909-11.
DMJKAF0	RU	https://pubmed.ncbi.nlm.nih.gov/10987415

DMQB1UI	DI	DMQB1UI
DMQB1UI	DN	5-(4-Chloro-phenyl)-1-methyl-piperidine-2-thione
DMQB1UI	MI	TTTU72V
DMQB1UI	MN	Steroid 5-alpha-reductase 1 (SRD5A1)
DMQB1UI	MT	DTT
DMQB1UI	MA	Inhibitor
DMQB1UI	RN	Simple bi- and tricyclic inhibitors of human steroid 5alpha-reductase. Bioorg Med Chem Lett. 2000 Sep 4;10(17):1909-11.
DMQB1UI	RU	https://pubmed.ncbi.nlm.nih.gov/10987415

DMSTG03	DI	DMSTG03
DMSTG03	DN	5-(4-Chlorophenyl)-4-(4-methoxyphenyl)isothiazole
DMSTG03	MI	TT8NGED
DMSTG03	MN	Prostaglandin G/H synthase 1 (COX-1)
DMSTG03	MT	DTT
DMSTG03	MA	Inhibitor
DMSTG03	RN	Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities. Bioorg Med Chem. 2009 Jan 15;17(2):558-68.
DMSTG03	RU	https://pubmed.ncbi.nlm.nih.gov/19097798

DMY0P86	DI	DMY0P86
DMY0P86	DN	5-(4-Chlorophenyl)-4-p-tolyl-1,2-selenazole
DMY0P86	MI	TT8NGED
DMY0P86	MN	Prostaglandin G/H synthase 1 (COX-1)
DMY0P86	MT	DTT
DMY0P86	MA	Inhibitor
DMY0P86	RN	Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles. Eur J Med Chem. 2008 Jun;43(6):1152-9.
DMY0P86	RU	https://pubmed.ncbi.nlm.nih.gov/17976864

DMY0P86	DI	DMY0P86
DMY0P86	DN	5-(4-Chlorophenyl)-4-p-tolyl-1,2-selenazole
DMY0P86	MI	TTVKILB
DMY0P86	MN	Prostaglandin G/H synthase 2 (COX-2)
DMY0P86	MT	DTT
DMY0P86	MA	Inhibitor
DMY0P86	RN	Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles. Eur J Med Chem. 2008 Jun;43(6):1152-9.
DMY0P86	RU	https://pubmed.ncbi.nlm.nih.gov/17976864

DMFYEL8	DI	DMFYEL8
DMFYEL8	DN	5-(4-Chlorophenyl)-4-p-tolyl-3H-1,2-dithiol-3-one
DMFYEL8	MI	TT8NGED
DMFYEL8	MN	Prostaglandin G/H synthase 1 (COX-1)
DMFYEL8	MT	DTT
DMFYEL8	MA	Inhibitor
DMFYEL8	RN	Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities. Bioorg Med Chem. 2009 Jan 15;17(2):558-68.
DMFYEL8	RU	https://pubmed.ncbi.nlm.nih.gov/19097798

DMA1N75	DI	DMA1N75
DMA1N75	DN	5-(4-Chlorophenyl)-4-p-tolylisothiazole
DMA1N75	MI	TT8NGED
DMA1N75	MN	Prostaglandin G/H synthase 1 (COX-1)
DMA1N75	MT	DTT
DMA1N75	MA	Inhibitor
DMA1N75	RN	Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities. Bioorg Med Chem. 2009 Jan 15;17(2):558-68.
DMA1N75	RU	https://pubmed.ncbi.nlm.nih.gov/19097798

DMV7HA1	DI	DMV7HA1
DMV7HA1	DN	5-(4-chlorophenyl)-N-(2-methylbenzyl)nicotinamide
DMV7HA1	MI	TT90XZ8
DMV7HA1	MN	Voltage-gated sodium channel alpha Nav1.8 (SCN10A)
DMV7HA1	MT	DTT
DMV7HA1	MA	Inhibitor
DMV7HA1	RN	Subtype-selective Na(v)1.8 sodium channel blockers: identification of potent, orally active nicotinamide derivatives. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6812-5.
DMV7HA1	RU	https://pubmed.ncbi.nlm.nih.gov/20855211

DM6CRVS	DI	DM6CRVS
DM6CRVS	DN	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide
DM6CRVS	MI	TTBH0VX
DM6CRVS	MN	Histone deacetylase (HDAC)
DM6CRVS	MT	DTT
DM6CRVS	MA	Inhibitor
DM6CRVS	RN	Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides. Bioorg Med Chem Lett. 2004 May 17;14(10):2477-81.
DM6CRVS	RU	https://pubmed.ncbi.nlm.nih.gov/15109636

DM6CRVS	DI	DM6CRVS
DM6CRVS	DN	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide
DM6CRVS	MI	TT6R7JZ
DM6CRVS	MN	Histone deacetylase 1 (HDAC1)
DM6CRVS	MT	DTT
DM6CRVS	MA	Inhibitor
DM6CRVS	RN	Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides. Bioorg Med Chem Lett. 2004 May 17;14(10):2477-81.
DM6CRVS	RU	https://pubmed.ncbi.nlm.nih.gov/15109636

DM6CRVS	DI	DM6CRVS
DM6CRVS	DN	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide
DM6CRVS	MI	TTYHPU6
DM6CRVS	MN	Histone deacetylase 10 (HDAC10)
DM6CRVS	MT	DTT
DM6CRVS	MA	Inhibitor
DM6CRVS	RN	Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides. Bioorg Med Chem Lett. 2004 May 17;14(10):2477-81.
DM6CRVS	RU	https://pubmed.ncbi.nlm.nih.gov/15109636

DM6CRVS	DI	DM6CRVS
DM6CRVS	DN	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide
DM6CRVS	MI	TTSHTOI
DM6CRVS	MN	Histone deacetylase 2 (HDAC2)
DM6CRVS	MT	DTT
DM6CRVS	MA	Inhibitor
DM6CRVS	RN	Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides. Bioorg Med Chem Lett. 2004 May 17;14(10):2477-81.
DM6CRVS	RU	https://pubmed.ncbi.nlm.nih.gov/15109636

DM6CRVS	DI	DM6CRVS
DM6CRVS	DN	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide
DM6CRVS	MI	TTTQGH8
DM6CRVS	MN	Histone deacetylase 4 (HDAC4)
DM6CRVS	MT	DTT
DM6CRVS	MA	Inhibitor
DM6CRVS	RN	Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides. Bioorg Med Chem Lett. 2004 May 17;14(10):2477-81.
DM6CRVS	RU	https://pubmed.ncbi.nlm.nih.gov/15109636

DM6CRVS	DI	DM6CRVS
DM6CRVS	DN	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide
DM6CRVS	MI	TT5ZKDI
DM6CRVS	MN	Histone deacetylase 6 (HDAC6)
DM6CRVS	MT	DTT
DM6CRVS	MA	Inhibitor
DM6CRVS	RN	Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides. Bioorg Med Chem Lett. 2004 May 17;14(10):2477-81.
DM6CRVS	RU	https://pubmed.ncbi.nlm.nih.gov/15109636

DM6CRVS	DI	DM6CRVS
DM6CRVS	DN	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide
DM6CRVS	MI	TTT6LFV
DM6CRVS	MN	Histone deacetylase 8 (HDAC8)
DM6CRVS	MT	DTT
DM6CRVS	MA	Inhibitor
DM6CRVS	RN	Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides. Bioorg Med Chem Lett. 2004 May 17;14(10):2477-81.
DM6CRVS	RU	https://pubmed.ncbi.nlm.nih.gov/15109636

DMTDNX3	DI	DMTDNX3
DMTDNX3	DN	5-(4'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid
DMTDNX3	MI	TTXZ0KQ
DMTDNX3	MN	Matrix metalloproteinase-12 (MMP-12)
DMTDNX3	MT	DTT
DMTDNX3	MA	Inhibitor
DMTDNX3	RN	The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3.
DMTDNX3	RU	https://pubmed.ncbi.nlm.nih.gov/19703773

DMTDNX3	DI	DMTDNX3
DMTDNX3	DN	5-(4'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid
DMTDNX3	MI	TTHY57M
DMTDNX3	MN	Matrix metalloproteinase-13 (MMP-13)
DMTDNX3	MT	DTT
DMTDNX3	MA	Inhibitor
DMTDNX3	RN	The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3.
DMTDNX3	RU	https://pubmed.ncbi.nlm.nih.gov/19703773

DMISOLU	DI	DMISOLU
DMISOLU	DN	5-(4-hydroxy-2,6-dimethylstyryl)nicotinic acid
DMISOLU	MI	TTAN5W2
DMISOLU	MN	Raf messenger RNA (Raf mRNA)
DMISOLU	MT	DTT
DMISOLU	MA	Inhibitor
DMISOLU	RN	Aza-stilbenes as potent and selective c-RAF inhibitors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5378-83.
DMISOLU	RU	https://pubmed.ncbi.nlm.nih.gov/16890436

DMB2GLE	DI	DMB2GLE
DMB2GLE	DN	5-(4-hydroxyphenyl)-1,3,4-oxadiazole-2(3H)-thione
DMB2GLE	MI	TTULVH8
DMB2GLE	MN	Tyrosinase (TYR)
DMB2GLE	MT	DTT
DMB2GLE	MA	Inhibitor
DMB2GLE	RN	New potent inhibitors of tyrosinase: novel clues to binding of 1,3,4-thiadiazole-2(3H)-thiones, 1,3,4-oxadiazole-2(3H)-thiones, 4-amino-1,2,4-triaz... Bioorg Med Chem. 2010 Jun 1;18(11):4042-8.
DMB2GLE	RU	https://pubmed.ncbi.nlm.nih.gov/20452224

DM7KQXL	DI	DM7KQXL
DM7KQXL	DN	5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione
DM7KQXL	MI	TTBH0VX
DM7KQXL	MN	Histone deacetylase (HDAC)
DM7KQXL	MT	DTT
DM7KQXL	MA	Inhibitor
DM7KQXL	RN	New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7.
DM7KQXL	RU	https://pubmed.ncbi.nlm.nih.gov/18294844

DM7KQXL	DI	DM7KQXL
DM7KQXL	DN	5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione
DM7KQXL	MI	TT6R7JZ
DM7KQXL	MN	Histone deacetylase 1 (HDAC1)
DM7KQXL	MT	DTT
DM7KQXL	MA	Inhibitor
DM7KQXL	RN	New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7.
DM7KQXL	RU	https://pubmed.ncbi.nlm.nih.gov/18294844

DM7KQXL	DI	DM7KQXL
DM7KQXL	DN	5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione
DM7KQXL	MI	TTYHPU6
DM7KQXL	MN	Histone deacetylase 10 (HDAC10)
DM7KQXL	MT	DTT
DM7KQXL	MA	Inhibitor
DM7KQXL	RN	New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7.
DM7KQXL	RU	https://pubmed.ncbi.nlm.nih.gov/18294844

DM7KQXL	DI	DM7KQXL
DM7KQXL	DN	5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione
DM7KQXL	MI	TTSHTOI
DM7KQXL	MN	Histone deacetylase 2 (HDAC2)
DM7KQXL	MT	DTT
DM7KQXL	MA	Inhibitor
DM7KQXL	RN	New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7.
DM7KQXL	RU	https://pubmed.ncbi.nlm.nih.gov/18294844

DM7KQXL	DI	DM7KQXL
DM7KQXL	DN	5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione
DM7KQXL	MI	TTTQGH8
DM7KQXL	MN	Histone deacetylase 4 (HDAC4)
DM7KQXL	MT	DTT
DM7KQXL	MA	Inhibitor
DM7KQXL	RN	New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7.
DM7KQXL	RU	https://pubmed.ncbi.nlm.nih.gov/18294844

DM7KQXL	DI	DM7KQXL
DM7KQXL	DN	5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione
DM7KQXL	MI	TT5ZKDI
DM7KQXL	MN	Histone deacetylase 6 (HDAC6)
DM7KQXL	MT	DTT
DM7KQXL	MA	Inhibitor
DM7KQXL	RN	New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7.
DM7KQXL	RU	https://pubmed.ncbi.nlm.nih.gov/18294844

DM7KQXL	DI	DM7KQXL
DM7KQXL	DN	5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione
DM7KQXL	MI	TTT6LFV
DM7KQXL	MN	Histone deacetylase 8 (HDAC8)
DM7KQXL	MT	DTT
DM7KQXL	MA	Inhibitor
DM7KQXL	RN	New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7.
DM7KQXL	RU	https://pubmed.ncbi.nlm.nih.gov/18294844

DM3SQEY	DI	DM3SQEY
DM3SQEY	DN	5-(4-Methoxyphenoxy)-2,4-Quinazolinediamine
DM3SQEY	MI	TT9SL3Q
DM3SQEY	MN	Polypeptide deformylase (PDF)
DM3SQEY	MT	DTT
DM3SQEY	MA	Inhibitor
DM3SQEY	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM3SQEY	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMCMNKA	DI	DMCMNKA
DMCMNKA	DN	5-(4-Methoxy-phenyl)-1-phenyl-1H-benzoimidazole
DMCMNKA	MI	TTUTJGQ
DMCMNKA	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMCMNKA	MT	DTT
DMCMNKA	MA	Inhibitor
DMCMNKA	RN	Design and synthesis of 1,5-diarylbenzimidazoles as inhibitors of the VEGF-receptor KDR. Bioorg Med Chem Lett. 2003 Aug 4;13(15):2485-8.
DMCMNKA	RU	https://pubmed.ncbi.nlm.nih.gov/12852948

DMEV8WS	DI	DMEV8WS
DMEV8WS	DN	5-(4-Methoxyphenyl)-4-p-tolyl-1,2-selenazole
DMEV8WS	MI	TT8NGED
DMEV8WS	MN	Prostaglandin G/H synthase 1 (COX-1)
DMEV8WS	MT	DTT
DMEV8WS	MA	Inhibitor
DMEV8WS	RN	Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles. Eur J Med Chem. 2008 Jun;43(6):1152-9.
DMEV8WS	RU	https://pubmed.ncbi.nlm.nih.gov/17976864

DMEV8WS	DI	DMEV8WS
DMEV8WS	DN	5-(4-Methoxyphenyl)-4-p-tolyl-1,2-selenazole
DMEV8WS	MI	TTVKILB
DMEV8WS	MN	Prostaglandin G/H synthase 2 (COX-2)
DMEV8WS	MT	DTT
DMEV8WS	MA	Inhibitor
DMEV8WS	RN	Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles. Eur J Med Chem. 2008 Jun;43(6):1152-9.
DMEV8WS	RU	https://pubmed.ncbi.nlm.nih.gov/17976864

DMJSTCK	DI	DMJSTCK
DMJSTCK	DN	5-(4-Methoxyphenyl)-4-p-tolylisothiazole
DMJSTCK	MI	TT8NGED
DMJSTCK	MN	Prostaglandin G/H synthase 1 (COX-1)
DMJSTCK	MT	DTT
DMJSTCK	MA	Inhibitor
DMJSTCK	RN	Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities. Bioorg Med Chem. 2009 Jan 15;17(2):558-68.
DMJSTCK	RU	https://pubmed.ncbi.nlm.nih.gov/19097798

DMNSIF2	DI	DMNSIF2
DMNSIF2	DN	5-(4-Methylpiperazin-1-yl)-3-tosyl-1H-indazole
DMNSIF2	MI	TTJS8PY
DMNSIF2	MN	5-HT 6 receptor (HTR6)
DMNSIF2	MT	DTT
DMNSIF2	MA	Inhibitor
DMNSIF2	RN	5-Piperazinyl-3-sulfonylindazoles as potent and selective 5-hydroxytryptamine-6 antagonists. J Med Chem. 2010 Nov 11;53(21):7639-46.
DMNSIF2	RU	https://pubmed.ncbi.nlm.nih.gov/20932009

DM05OMF	DI	DM05OMF
DM05OMF	DN	5-(4-Phenoxy-phenyl)-pyrimidine-2,4,6-trione
DM05OMF	MI	TTLM12X
DM05OMF	MN	Matrix metalloproteinase-2 (MMP-2)
DM05OMF	MT	DTT
DM05OMF	MA	Inhibitor
DM05OMF	RN	Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. Bioorg Med Chem Lett. 2001 Apr 23;11(8):969-72.
DM05OMF	RU	https://pubmed.ncbi.nlm.nih.gov/11327602

DM05OMF	DI	DM05OMF
DM05OMF	DN	5-(4-Phenoxy-phenyl)-pyrimidine-2,4,6-trione
DM05OMF	MI	TT6X50U
DM05OMF	MN	Matrix metalloproteinase-9 (MMP-9)
DM05OMF	MT	DTT
DM05OMF	MA	Inhibitor
DM05OMF	RN	Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. Bioorg Med Chem Lett. 2001 Apr 23;11(8):969-72.
DM05OMF	RU	https://pubmed.ncbi.nlm.nih.gov/11327602

DM3QFCV	DI	DM3QFCV
DM3QFCV	DN	5-(4-Phenylbutoxy)psoralen
DM3QFCV	MI	TTY3UE6
DM3QFCV	MN	Voltage-gated potassium channel Kv1.3 (KCNA3)
DM3QFCV	MT	DTT
DM3QFCV	MA	Inhibitor
DM3QFCV	RN	Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators. Mol Pharmacol. 2004 Jun;65(6):1364-74.
DM3QFCV	RU	https://pubmed.ncbi.nlm.nih.gov/15155830

DMZ7K5G	DI	DMZ7K5G
DMZ7K5G	DN	5-(4-piperidyl)-4-propylisothiazol-3-ol
DMZ7K5G	MI	TT1MPAY
DMZ7K5G	MN	GABA(A) receptor alpha-1 (GABRA1)
DMZ7K5G	MT	DTT
DMZ7K5G	MA	Inhibitor
DMZ7K5G	RN	Potent 4-arylalkyl-substituted 3-isothiazolol GABA(A) competitive/noncompetitive antagonists: synthesis and pharmacology. J Med Chem. 2006 Feb 23;49(4):1388-96.
DMZ7K5G	RU	https://pubmed.ncbi.nlm.nih.gov/16480274

DMZ7K5G	DI	DMZ7K5G
DMZ7K5G	DN	5-(4-piperidyl)-4-propylisothiazol-3-ol
DMZ7K5G	MI	TT06RH5
DMZ7K5G	MN	GABA(A) receptor gamma-2 (GABRG2)
DMZ7K5G	MT	DTT
DMZ7K5G	MA	Inhibitor
DMZ7K5G	RN	Potent 4-arylalkyl-substituted 3-isothiazolol GABA(A) competitive/noncompetitive antagonists: synthesis and pharmacology. J Med Chem. 2006 Feb 23;49(4):1388-96.
DMZ7K5G	RU	https://pubmed.ncbi.nlm.nih.gov/16480274

DMZ7K5G	DI	DMZ7K5G
DMZ7K5G	DN	5-(4-piperidyl)-4-propylisothiazol-3-ol
DMZ7K5G	MI	TTNJYV2
DMZ7K5G	MN	Gamma-aminobutyric acid receptor (GAR)
DMZ7K5G	MT	DTT
DMZ7K5G	MA	Inhibitor
DMZ7K5G	RN	Potent 4-arylalkyl-substituted 3-isothiazolol GABA(A) competitive/noncompetitive antagonists: synthesis and pharmacology. J Med Chem. 2006 Feb 23;49(4):1388-96.
DMZ7K5G	RU	https://pubmed.ncbi.nlm.nih.gov/16480274

DMVMBG0	DI	DMVMBG0
DMVMBG0	DN	5-(6,7-Dimethoxy-quinolin-3-yl)-1H-pyridin-2-one
DMVMBG0	MI	TT8FYO9
DMVMBG0	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMVMBG0	MT	DTT
DMVMBG0	MA	Inhibitor
DMVMBG0	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMVMBG0	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMVMBG0	DI	DMVMBG0
DMVMBG0	DN	5-(6,7-Dimethoxy-quinolin-3-yl)-1H-pyridin-2-one
DMVMBG0	MI	TTI7421
DMVMBG0	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMVMBG0	MT	DTT
DMVMBG0	MA	Inhibitor
DMVMBG0	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMVMBG0	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DM0K7U5	DI	DM0K7U5
DM0K7U5	DN	5-(6-chloro-2-hexyl-1H-indol-1-yl)-5-oxo-valeric acid
DM0K7U5	MI	TT7WBSV
DM0K7U5	MN	Oxoeicosanoid receptor 1 (OXER1)
DM0K7U5	MT	DTT
DM0K7U5	MA	Antagonist
DM0K7U5	RN	5-Oxo-ETE receptor antagonists. J Med Chem. 2013 May 9;56(9):3725-32.
DM0K7U5	RU	https://pubmed.ncbi.nlm.nih.gov/23581530

DMIB9AX	DI	DMIB9AX
DMIB9AX	DN	5-(6-hydroxy-2-naphthyl)-1,2,3-benzenetriol
DMIB9AX	MI	TTULVH8
DMIB9AX	MN	Tyrosinase (TYR)
DMIB9AX	MT	DTT
DMIB9AX	MA	Inhibitor
DMIB9AX	RN	A newly synthesized, potent tyrosinase inhibitor: 5-(6-hydroxy-2-naphthyl)-1,2,3-benzenetriol. Bioorg Med Chem Lett. 2010 Aug 15;20(16):4882-4.
DMIB9AX	RU	https://pubmed.ncbi.nlm.nih.gov/20619644

DMJWIPS	DI	DMJWIPS
DMJWIPS	DN	5-(6-hydroxy-2-naphthyl)pyridin-3-ol
DMJWIPS	MI	TTIWB6L
DMJWIPS	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMJWIPS	MT	DTT
DMJWIPS	MA	Inhibitor
DMJWIPS	RN	Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors... J Med Chem. 2008 Apr 10;51(7):2158-69.
DMJWIPS	RU	https://pubmed.ncbi.nlm.nih.gov/18324762

DMJRBKO	DI	DMJRBKO
DMJRBKO	DN	5-(6-hydroxynaphthalen-2-yl)benzene-1,3-diol
DMJRBKO	MI	TTULVH8
DMJRBKO	MN	Tyrosinase (TYR)
DMJRBKO	MT	DTT
DMJRBKO	MA	Inhibitor
DMJRBKO	RN	Syntheses of hydroxy substituted 2-phenyl-naphthalenes as inhibitors of tyrosinase. Bioorg Med Chem Lett. 2007 Jan 15;17(2):461-4.
DMJRBKO	RU	https://pubmed.ncbi.nlm.nih.gov/17064896

DMMPAWD	DI	DMMPAWD
DMMPAWD	DN	5-(6-Methoxynaphthalen-2-yl)pyridin-3-ol
DMMPAWD	MI	TTIQUX7
DMMPAWD	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMMPAWD	MT	DTT
DMMPAWD	MA	Inhibitor
DMMPAWD	RN	Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on pote... J Med Chem. 2008 Aug 28;51(16):5064-74.
DMMPAWD	RU	https://pubmed.ncbi.nlm.nih.gov/18672861

DMGIO3R	DI	DMGIO3R
DMGIO3R	DN	5-(azepan-1-ylsulfonyl)indoline-2,3-dione
DMGIO3R	MI	TTPF2QI
DMGIO3R	MN	Caspase-3 (CASP3)
DMGIO3R	MT	DTT
DMGIO3R	MA	Inhibitor
DMGIO3R	RN	Design, synthesis, and discovery of novel non-peptide inhibitor of Caspase-3 using ligand based and structure based virtual screening approach. Bioorg Med Chem. 2009 Aug 15;17(16):6040-7.
DMGIO3R	RU	https://pubmed.ncbi.nlm.nih.gov/19631549

DMJIVLY	DI	DMJIVLY
DMJIVLY	DN	5-(azetidin-1-ylsulfonyl)indoline-2,3-dione
DMJIVLY	MI	TTPF2QI
DMJIVLY	MN	Caspase-3 (CASP3)
DMJIVLY	MT	DTT
DMJIVLY	MA	Inhibitor
DMJIVLY	RN	Design, synthesis, and discovery of novel non-peptide inhibitor of Caspase-3 using ligand based and structure based virtual screening approach. Bioorg Med Chem. 2009 Aug 15;17(16):6040-7.
DMJIVLY	RU	https://pubmed.ncbi.nlm.nih.gov/19631549

DMJAG7M	DI	DMJAG7M
DMJAG7M	DN	5-(biphenyl-4-yl)-3-methoxypentanoic acid
DMJAG7M	MI	TTXZ0KQ
DMJAG7M	MN	Matrix metalloproteinase-12 (MMP-12)
DMJAG7M	MT	DTT
DMJAG7M	MA	Inhibitor
DMJAG7M	RN	The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3.
DMJAG7M	RU	https://pubmed.ncbi.nlm.nih.gov/19703773

DMQKU9H	DI	DMQKU9H
DMQKU9H	DN	5-(biphenyl-4-yl)-3-oxopentanoic acid
DMQKU9H	MI	TTXZ0KQ
DMQKU9H	MN	Matrix metalloproteinase-12 (MMP-12)
DMQKU9H	MT	DTT
DMQKU9H	MA	Inhibitor
DMQKU9H	RN	The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3.
DMQKU9H	RU	https://pubmed.ncbi.nlm.nih.gov/19703773

DMPQSZN	DI	DMPQSZN
DMPQSZN	DN	5-(Biphenyl-4-yl)-pentanoic acid N-hydroxyamide
DMPQSZN	MI	TTSHTOI
DMPQSZN	MN	Histone deacetylase 2 (HDAC2)
DMPQSZN	MT	DTT
DMPQSZN	MA	Inhibitor
DMPQSZN	RN	Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. Eur J Med Chem. 2009 May;44(5):1900-12.
DMPQSZN	RU	https://pubmed.ncbi.nlm.nih.gov/19084294

DMPFX0S	DI	DMPFX0S
DMPFX0S	DN	5-(DIMETHYLAMINO)-2-NAPHTHALENESULFONIC ACID
DMPFX0S	MI	TTXAGYU
DMPFX0S	MN	Tissue-type plasminogen activator (PLAT)
DMPFX0S	MT	DTT
DMPFX0S	MA	Inhibitor
DMPFX0S	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMPFX0S	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM1IGOD	DI	DM1IGOD
DM1IGOD	DN	5(E)-(5'-Deoxyadenosin-5'-ylidene)pentanoic acid
DM1IGOD	MI	TTE2KUJ
DM1IGOD	MN	Adenosylhomocysteinase (AHCY)
DM1IGOD	MT	DTT
DM1IGOD	MA	Inhibitor
DM1IGOD	RN	Synthesis of 5'-functionalized nucleosides: S-Adenosylhomocysteine analogues with the carbon-5' and sulfur atoms replaced by a vinyl or halovinyl u... Bioorg Med Chem. 2008 May 15;16(10):5424-33.
DM1IGOD	RU	https://pubmed.ncbi.nlm.nih.gov/18457953

DM45VRX	DI	DM45VRX
DM45VRX	DN	5-(isopropylamino)quinolin-8-ol
DM45VRX	MI	TTZJYKH
DM45VRX	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DM45VRX	MT	DTT
DM45VRX	MA	Inhibitor
DM45VRX	RN	Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2010 Feb 11;53(3):1172-89.
DM45VRX	RU	https://pubmed.ncbi.nlm.nih.gov/20055453

DMYLIX9	DI	DMYLIX9
DMYLIX9	DN	5-(methylthio)thiophene-2-carboxylic acid
DMYLIX9	MI	TTGX0HR
DMYLIX9	MN	Bacterial DNA ligase (Bact ligA)
DMYLIX9	MT	DTT
DMYLIX9	MA	Inhibitor
DMYLIX9	RN	Identification and validation of human DNA ligase inhibitors using computer-aided drug design. J Med Chem. 2008 Aug 14;51(15):4553-62.
DMYLIX9	RU	https://pubmed.ncbi.nlm.nih.gov/18630893

DM3TPMO	DI	DM3TPMO
DM3TPMO	DN	5'-(N-ethyl-N-isopropyl)amiloride
DM3TPMO	MI	TTGSEFH
DM3TPMO	MN	Sodium/hydrogen exchanger 1 (SLC9A1)
DM3TPMO	MT	DTT
DM3TPMO	MA	Inhibitor
DM3TPMO	RN	NHE1 inhibition by amiloride- and benzoylguanidine-type compounds. Inhibitor binding loci deduced from chimeras of NHE1 homologues with endogenous ... J Biol Chem. 2007 Jul 6;282(27):19716-27.
DM3TPMO	RU	https://pubmed.ncbi.nlm.nih.gov/17493937

DMG2VQB	DI	DMG2VQB
DMG2VQB	DN	5-(pentylthio)thiazolo[4,5-d]pyrimidin-7-ol
DMG2VQB	MI	TT30C9G
DMG2VQB	MN	C-X-C chemokine receptor type 2 (CXCR2)
DMG2VQB	MT	DTT
DMG2VQB	MA	Inhibitor
DMG2VQB	RN	Hit-to-Lead studies: the discovery of potent, orally bioavailable thiazolopyrimidine CXCR2 receptor antagonists. Bioorg Med Chem Lett. 2006 Feb 15;16(4):960-3.
DMG2VQB	RU	https://pubmed.ncbi.nlm.nih.gov/16297626

DMP4RO3	DI	DMP4RO3
DMP4RO3	DN	5-(phenylethynyl)pyrimidine
DMP4RO3	MI	TTHS256
DMP4RO3	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMP4RO3	MT	DTT
DMP4RO3	MA	Inhibitor
DMP4RO3	RN	Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: unexpected modulation of pharmacology with slight structural modifications to a 5... Bioorg Med Chem Lett. 2008 Jul 15;18(14):4098-101.
DMP4RO3	RU	https://pubmed.ncbi.nlm.nih.gov/18550372

DMT60AM	DI	DMT60AM
DMT60AM	DN	5-(piperidin-1-ylsulfonyl)indoline-2,3-dione
DMT60AM	MI	TTPF2QI
DMT60AM	MN	Caspase-3 (CASP3)
DMT60AM	MT	DTT
DMT60AM	MA	Inhibitor
DMT60AM	RN	Design, synthesis, and discovery of novel non-peptide inhibitor of Caspase-3 using ligand based and structure based virtual screening approach. Bioorg Med Chem. 2009 Aug 15;17(16):6040-7.
DMT60AM	RU	https://pubmed.ncbi.nlm.nih.gov/19631549

DM4XGFW	DI	DM4XGFW
DM4XGFW	DN	5-(piperidin-4-yl)isothiazol-3-ol
DM4XGFW	MI	TT1MPAY
DM4XGFW	MN	GABA(A) receptor alpha-1 (GABRA1)
DM4XGFW	MT	DTT
DM4XGFW	MA	Inhibitor
DM4XGFW	RN	Potent 4-arylalkyl-substituted 3-isothiazolol GABA(A) competitive/noncompetitive antagonists: synthesis and pharmacology. J Med Chem. 2006 Feb 23;49(4):1388-96.
DM4XGFW	RU	https://pubmed.ncbi.nlm.nih.gov/16480274

DM4XGFW	DI	DM4XGFW
DM4XGFW	DN	5-(piperidin-4-yl)isothiazol-3-ol
DM4XGFW	MI	TT06RH5
DM4XGFW	MN	GABA(A) receptor gamma-2 (GABRG2)
DM4XGFW	MT	DTT
DM4XGFW	MA	Inhibitor
DM4XGFW	RN	Potent 4-arylalkyl-substituted 3-isothiazolol GABA(A) competitive/noncompetitive antagonists: synthesis and pharmacology. J Med Chem. 2006 Feb 23;49(4):1388-96.
DM4XGFW	RU	https://pubmed.ncbi.nlm.nih.gov/16480274

DM4XGFW	DI	DM4XGFW
DM4XGFW	DN	5-(piperidin-4-yl)isothiazol-3-ol
DM4XGFW	MI	TTNJYV2
DM4XGFW	MN	Gamma-aminobutyric acid receptor (GAR)
DM4XGFW	MT	DTT
DM4XGFW	MA	Inhibitor
DM4XGFW	RN	Potent 4-arylalkyl-substituted 3-isothiazolol GABA(A) competitive/noncompetitive antagonists: synthesis and pharmacology. J Med Chem. 2006 Feb 23;49(4):1388-96.
DM4XGFW	RU	https://pubmed.ncbi.nlm.nih.gov/16480274

DM6GO2I	DI	DM6GO2I
DM6GO2I	DN	5-(piperidin-4-yl)isoxazol-3-ol
DM6GO2I	MI	TT1MPAY
DM6GO2I	MN	GABA(A) receptor alpha-1 (GABRA1)
DM6GO2I	MT	DTT
DM6GO2I	MA	Inhibitor
DM6GO2I	RN	Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling. J Med Chem. 2005 Jan 27;48(2):427-39.
DM6GO2I	RU	https://pubmed.ncbi.nlm.nih.gov/15658856

DM6GO2I	DI	DM6GO2I
DM6GO2I	DN	5-(piperidin-4-yl)isoxazol-3-ol
DM6GO2I	MI	TTZA1NY
DM6GO2I	MN	GABA(A) receptor beta-2 (GABRB2)
DM6GO2I	MT	DTT
DM6GO2I	MA	Inhibitor
DM6GO2I	RN	Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling. J Med Chem. 2005 Jan 27;48(2):427-39.
DM6GO2I	RU	https://pubmed.ncbi.nlm.nih.gov/15658856

DM6GO2I	DI	DM6GO2I
DM6GO2I	DN	5-(piperidin-4-yl)isoxazol-3-ol
DM6GO2I	MI	TT06RH5
DM6GO2I	MN	GABA(A) receptor gamma-2 (GABRG2)
DM6GO2I	MT	DTT
DM6GO2I	MA	Inhibitor
DM6GO2I	RN	Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling. J Med Chem. 2005 Jan 27;48(2):427-39.
DM6GO2I	RU	https://pubmed.ncbi.nlm.nih.gov/15658856

DM6GO2I	DI	DM6GO2I
DM6GO2I	DN	5-(piperidin-4-yl)isoxazol-3-ol
DM6GO2I	MI	TTNJYV2
DM6GO2I	MN	Gamma-aminobutyric acid receptor (GAR)
DM6GO2I	MT	DTT
DM6GO2I	MA	Inhibitor
DM6GO2I	RN	4-aryl-5-(4-piperidyl)-3-isoxazolol GABAA antagonists: synthesis, pharmacology, and structure-activity relationships. J Med Chem. 2007 Apr 19;50(8):1988-92.
DM6GO2I	RU	https://pubmed.ncbi.nlm.nih.gov/17375905

DM93MAX	DI	DM93MAX
DM93MAX	DN	5-(pyridin-4-yl)-1,3,4-oxadiazole-2(3H)-thione
DM93MAX	MI	TTULVH8
DM93MAX	MN	Tyrosinase (TYR)
DM93MAX	MT	DTT
DM93MAX	MA	Inhibitor
DM93MAX	RN	New potent inhibitors of tyrosinase: novel clues to binding of 1,3,4-thiadiazole-2(3H)-thiones, 1,3,4-oxadiazole-2(3H)-thiones, 4-amino-1,2,4-triaz... Bioorg Med Chem. 2010 Jun 1;18(11):4042-8.
DM93MAX	RU	https://pubmed.ncbi.nlm.nih.gov/20452224

DMEL8XU	DI	DMEL8XU
DMEL8XU	DN	5-(pyridin-4-yl)-1,3,4-thiadiazole-2(3H)-thione
DMEL8XU	MI	TTULVH8
DMEL8XU	MN	Tyrosinase (TYR)
DMEL8XU	MT	DTT
DMEL8XU	MA	Inhibitor
DMEL8XU	RN	New potent inhibitors of tyrosinase: novel clues to binding of 1,3,4-thiadiazole-2(3H)-thiones, 1,3,4-oxadiazole-2(3H)-thiones, 4-amino-1,2,4-triaz... Bioorg Med Chem. 2010 Jun 1;18(11):4042-8.
DMEL8XU	RU	https://pubmed.ncbi.nlm.nih.gov/20452224

DMJBK7F	DI	DMJBK7F
DMJBK7F	DN	5-(pyrrolidin-1-ylsulfonyl)indoline-2,3-dione
DMJBK7F	MI	TTPF2QI
DMJBK7F	MN	Caspase-3 (CASP3)
DMJBK7F	MT	DTT
DMJBK7F	MA	Inhibitor
DMJBK7F	RN	Design, synthesis, and discovery of novel non-peptide inhibitor of Caspase-3 using ligand based and structure based virtual screening approach. Bioorg Med Chem. 2009 Aug 15;17(16):6040-7.
DMJBK7F	RU	https://pubmed.ncbi.nlm.nih.gov/19631549

DMK3TEV	DI	DMK3TEV
DMK3TEV	DN	5-(trifluoromethoxy)-1H-indole-2,3-dione
DMK3TEV	MI	TTMF541
DMK3TEV	MN	Liver carboxylesterase (CES1)
DMK3TEV	MT	DTT
DMK3TEV	MA	Inhibitor
DMK3TEV	RN	Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85.
DMK3TEV	RU	https://pubmed.ncbi.nlm.nih.gov/17378546

DMM7N6K	DI	DMM7N6K
DMM7N6K	DN	5,10-Dioxy-2-phenyl-benzo[g]pteridin-4-ylamine
DMM7N6K	MI	TTJGNVC
DMM7N6K	MN	Apoptosis regulator Bcl-2 (BCL-2)
DMM7N6K	MT	DTT
DMM7N6K	MA	Inhibitor
DMM7N6K	RN	Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J Med Chem. 2001 Dec 6;44(25):4313-24.
DMM7N6K	RU	https://pubmed.ncbi.nlm.nih.gov/11728179

DMAQDK9	DI	DMAQDK9
DMAQDK9	DN	5,10-Methylene-6-Hydrofolic Acid
DMAQDK9	MI	TTU6BFZ
DMAQDK9	MN	Candida Thymidylate synthase (Candi TMP1)
DMAQDK9	MT	DTT
DMAQDK9	MA	Inhibitor
DMAQDK9	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMAQDK9	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMWSLTB	DI	DMWSLTB
DMWSLTB	DN	5,11-Dimethyl-6H-pyrido[4,3-b]carbazol-9-ol
DMWSLTB	MI	TTST7KB
DMWSLTB	MN	Fibroblast growth factor receptor 3 (FGFR3)
DMWSLTB	MT	DTT
DMWSLTB	MA	Inhibitor
DMWSLTB	RN	Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases. J Med Chem. 2005 Oct 6;48(20):6194-201.
DMWSLTB	RU	https://pubmed.ncbi.nlm.nih.gov/16190746

DMWSLTB	DI	DMWSLTB
DMWSLTB	DN	5,11-Dimethyl-6H-pyrido[4,3-b]carbazol-9-ol
DMWSLTB	MI	TT8FYO9
DMWSLTB	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMWSLTB	MT	DTT
DMWSLTB	MA	Inhibitor
DMWSLTB	RN	Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases. J Med Chem. 2005 Oct 6;48(20):6194-201.
DMWSLTB	RU	https://pubmed.ncbi.nlm.nih.gov/16190746

DMWSLTB	DI	DMWSLTB
DMWSLTB	DN	5,11-Dimethyl-6H-pyrido[4,3-b]carbazol-9-ol
DMWSLTB	MI	TTX41N9
DMWSLTB	MN	Tyrosine-protein kinase Kit (KIT)
DMWSLTB	MT	DTT
DMWSLTB	MA	Inhibitor
DMWSLTB	RN	Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases. J Med Chem. 2005 Oct 6;48(20):6194-201.
DMWSLTB	RU	https://pubmed.ncbi.nlm.nih.gov/16190746

DMJRXLD	DI	DMJRXLD
DMJRXLD	DN	5,3'-Dipropyl-biphenyl-2,4'-diol
DMJRXLD	MI	TTSJ6Q4
DMJRXLD	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DMJRXLD	MT	DTT
DMJRXLD	MA	Inhibitor
DMJRXLD	RN	Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxyge... Bioorg Med Chem. 2009 Jul 1;17(13):4459-65.
DMJRXLD	RU	https://pubmed.ncbi.nlm.nih.gov/19481465

DMJRXLD	DI	DMJRXLD
DMJRXLD	DN	5,3'-Dipropyl-biphenyl-2,4'-diol
DMJRXLD	MI	TT8NGED
DMJRXLD	MN	Prostaglandin G/H synthase 1 (COX-1)
DMJRXLD	MT	DTT
DMJRXLD	MA	Inhibitor
DMJRXLD	RN	Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxyge... Bioorg Med Chem. 2009 Jul 1;17(13):4459-65.
DMJRXLD	RU	https://pubmed.ncbi.nlm.nih.gov/19481465

DMJRXLD	DI	DMJRXLD
DMJRXLD	DN	5,3'-Dipropyl-biphenyl-2,4'-diol
DMJRXLD	MI	TTVKILB
DMJRXLD	MN	Prostaglandin G/H synthase 2 (COX-2)
DMJRXLD	MT	DTT
DMJRXLD	MA	Inhibitor
DMJRXLD	RN	Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxyge... Bioorg Med Chem. 2009 Jul 1;17(13):4459-65.
DMJRXLD	RU	https://pubmed.ncbi.nlm.nih.gov/19481465

DMWL1UY	DI	DMWL1UY
DMWL1UY	DN	5,5-diethyl-2-(phenethylamino)oxazol-4(5H)-one
DMWL1UY	MI	TTN7BL9
DMWL1UY	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMWL1UY	MT	DTT
DMWL1UY	MA	Inhibitor
DMWL1UY	RN	Oxazolones as potent inhibitors of 11beta-hydroxysteroid dehydrogenase type 1. Bioorg Med Chem Lett. 2007 Sep 1;17(17):4837-40.
DMWL1UY	RU	https://pubmed.ncbi.nlm.nih.gov/17600707

DM28LNV	DI	DM28LNV
DM28LNV	DN	5,5-Diphenyl-2-iminohydantoin
DM28LNV	MI	TT8JRS7
DM28LNV	MN	Beta-secretase (BACE)
DM28LNV	MT	DTT
DM28LNV	MA	Inhibitor
DM28LNV	RN	Discovery of cyclic acylguanidines as highly potent and selective beta-site amyloid cleaving enzyme (BACE) inhibitors: Part I--inhibitor design and... J Med Chem. 2010 Feb 11;53(3):951-65.
DM28LNV	RU	https://pubmed.ncbi.nlm.nih.gov/20043696

DMPVBC2	DI	DMPVBC2
DMPVBC2	DN	5,5'-methylenebis(1,3,4-oxadiazole-2(3H)-thione)
DMPVBC2	MI	TTULVH8
DMPVBC2	MN	Tyrosinase (TYR)
DMPVBC2	MT	DTT
DMPVBC2	MA	Inhibitor
DMPVBC2	RN	New potent inhibitors of tyrosinase: novel clues to binding of 1,3,4-thiadiazole-2(3H)-thiones, 1,3,4-oxadiazole-2(3H)-thiones, 4-amino-1,2,4-triaz... Bioorg Med Chem. 2010 Jun 1;18(11):4042-8.
DMPVBC2	RU	https://pubmed.ncbi.nlm.nih.gov/20452224

DMW13SO	DI	DMW13SO
DMW13SO	DN	5,5'-methylenebis(1,3,4-thiadiazole-2(3H)-thione)
DMW13SO	MI	TTULVH8
DMW13SO	MN	Tyrosinase (TYR)
DMW13SO	MT	DTT
DMW13SO	MA	Inhibitor
DMW13SO	RN	New potent inhibitors of tyrosinase: novel clues to binding of 1,3,4-thiadiazole-2(3H)-thiones, 1,3,4-oxadiazole-2(3H)-thiones, 4-amino-1,2,4-triaz... Bioorg Med Chem. 2010 Jun 1;18(11):4042-8.
DMW13SO	RU	https://pubmed.ncbi.nlm.nih.gov/20452224

DMZ693W	DI	DMZ693W
DMZ693W	DN	5,5'-methylenebis(3,4-dibromobenzene-1,2-diol)
DMZ693W	MI	TT58ZYW
DMZ693W	MN	Mycobacterium Isocitrate lyase (MycB icl)
DMZ693W	MT	DTT
DMZ693W	MA	Inhibitor
DMZ693W	RN	Bromophenols as Candida albicans isocitrate lyase inhibitors. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6644-8.
DMZ693W	RU	https://pubmed.ncbi.nlm.nih.gov/20888765

DMIQAO9	DI	DMIQAO9
DMIQAO9	DN	5,6,7,8-tetrahydroanthracene-1,4-dione
DMIQAO9	MI	TTR0SWN
DMIQAO9	MN	M-phase inducer phosphatase 2 (MPIP2)
DMIQAO9	MT	DTT
DMIQAO9	MA	Inhibitor
DMIQAO9	RN	Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases. Bioorg Med Chem. 2009 Mar 15;17(6):2276-81.
DMIQAO9	RU	https://pubmed.ncbi.nlm.nih.gov/19028102

DMTL4S9	DI	DMTL4S9
DMTL4S9	DN	5,6,7-Trichloro-1,4-dihydro-quinoxaline-2,3-dione
DMTL4S9	MI	TTLD29N
DMTL4S9	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMTL4S9	MT	DTT
DMTL4S9	MA	Inhibitor
DMTL4S9	RN	1-Hydroxy-1,4-dihydroquinoxaline-2,3-diones: Novel antagonists at NMDA receptor glycine sites, Bioorg. Med. Chem. Lett. 6(4):439-440 (1996).
DMTL4S9	RU	http://www.sciencedirect.com/science/article/pii/0960894X96000364

DM53CLY	DI	DM53CLY
DM53CLY	DN	5,6,7-Trimethoxy-3-pyridin-4-yl-quinoline
DM53CLY	MI	TT8FYO9
DM53CLY	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DM53CLY	MT	DTT
DM53CLY	MA	Inhibitor
DM53CLY	RN	5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.
DM53CLY	RU	https://pubmed.ncbi.nlm.nih.gov/8064792

DM53CLY	DI	DM53CLY
DM53CLY	DN	5,6,7-Trimethoxy-3-pyridin-4-yl-quinoline
DM53CLY	MI	TTI7421
DM53CLY	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM53CLY	MT	DTT
DM53CLY	MA	Inhibitor
DM53CLY	RN	5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.
DM53CLY	RU	https://pubmed.ncbi.nlm.nih.gov/8064792

DM6VPF4	DI	DM6VPF4
DM6VPF4	DN	5,6,7-Trimethyl-2-p-tolyl-chromen-4-one
DM6VPF4	MI	TTJFY5U
DM6VPF4	MN	Adenosine A3 receptor (ADORA3)
DM6VPF4	MT	DTT
DM6VPF4	MA	Inhibitor
DM6VPF4	RN	Interactions of flavonoids and other phytochemicals with adenosine receptors. J Med Chem. 1996 Feb 2;39(3):781-8.
DM6VPF4	RU	https://pubmed.ncbi.nlm.nih.gov/8576921

DMDCE1M	DI	DMDCE1M
DMDCE1M	DN	5,6,8-trichloroquinoline-4-one-3-carboxylic acid
DMDCE1M	MI	TTER6YH
DMDCE1M	MN	Casein kinase II alpha (CSNK2A1)
DMDCE1M	MT	DTT
DMDCE1M	MA	Inhibitor
DMDCE1M	RN	Evaluation of 3-carboxy-4(1H)-quinolones as inhibitors of human protein kinase CK2. J Med Chem. 2006 Nov 2;49(22):6443-50.
DMDCE1M	RU	https://pubmed.ncbi.nlm.nih.gov/17064064

DMNHT7Q	DI	DMNHT7Q
DMNHT7Q	DN	5,6,8-Trimethoxy-1,4-dimethylquinolin-2(1H)-one
DMNHT7Q	MI	TTJLP0R
DMNHT7Q	MN	Quinone reductase 2 (NQO2)
DMNHT7Q	MT	DTT
DMNHT7Q	MA	Inhibitor
DMNHT7Q	RN	Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities. J Med Chem. 2009 Apr 9;52(7):1873-84.
DMNHT7Q	RU	https://pubmed.ncbi.nlm.nih.gov/19265439

DM97XZ1	DI	DM97XZ1
DM97XZ1	DN	5,6,8-Trimethoxy-4-methylquinolin-2(1H)-one
DM97XZ1	MI	TTJLP0R
DM97XZ1	MN	Quinone reductase 2 (NQO2)
DM97XZ1	MT	DTT
DM97XZ1	MA	Inhibitor
DM97XZ1	RN	Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities. J Med Chem. 2009 Apr 9;52(7):1873-84.
DM97XZ1	RU	https://pubmed.ncbi.nlm.nih.gov/19265439

DM6A4LM	DI	DM6A4LM
DM6A4LM	DN	5,6-Bis-p-tolylamino-isoindole-1,3-dione
DM6A4LM	MI	TTGKNB4
DM6A4LM	MN	Epidermal growth factor receptor (EGFR)
DM6A4LM	MT	DTT
DM6A4LM	MA	Inhibitor
DM6A4LM	RN	Dianilinophthalimides: potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase. J Med Chem. 1994 Apr 1;37(7):1015-27.
DM6A4LM	RU	https://pubmed.ncbi.nlm.nih.gov/8151612

DMDE7XJ	DI	DMDE7XJ
DMDE7XJ	DN	5,6-Cyclic-Tetrahydropteridine
DMDE7XJ	MI	TTCM4B3
DMDE7XJ	MN	Nitric-oxide synthase endothelial (NOS3)
DMDE7XJ	MT	DTT
DMDE7XJ	MA	Inhibitor
DMDE7XJ	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMDE7XJ	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DM3JB6S	DI	DM3JB6S
DM3JB6S	DN	5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole
DM3JB6S	MI	TTER6YH
DM3JB6S	MN	Casein kinase II alpha (CSNK2A1)
DM3JB6S	MT	DTT
DM3JB6S	MA	Inhibitor
DM3JB6S	RN	Structural insight into human CK2alpha in complex with the potent inhibitor ellagic acid. Bioorg Med Chem Lett. 2009 Jun 1;19(11):2920-3.
DM3JB6S	RU	https://pubmed.ncbi.nlm.nih.gov/19414254

DMN1S35	DI	DMN1S35
DMN1S35	DN	5,6-dichloro-3,4-dihydroquinazolin-2-amine
DMN1S35	MI	TTSQIFT
DMN1S35	MN	5-HT 1A receptor (HTR1A)
DMN1S35	MT	DTT
DMN1S35	MA	Inhibitor
DMN1S35	RN	Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61.
DMN1S35	RU	https://pubmed.ncbi.nlm.nih.gov/17998160

DMN1S35	DI	DMN1S35
DMN1S35	DN	5,6-dichloro-3,4-dihydroquinazolin-2-amine
DMN1S35	MI	TT6MSOK
DMN1S35	MN	5-HT 1D receptor (HTR1D)
DMN1S35	MT	DTT
DMN1S35	MA	Inhibitor
DMN1S35	RN	Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61.
DMN1S35	RU	https://pubmed.ncbi.nlm.nih.gov/17998160

DMN1S35	DI	DMN1S35
DMN1S35	DN	5,6-dichloro-3,4-dihydroquinazolin-2-amine
DMN1S35	MI	TTJQOD7
DMN1S35	MN	5-HT 2A receptor (HTR2A)
DMN1S35	MT	DTT
DMN1S35	MA	Inhibitor
DMN1S35	RN	Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61.
DMN1S35	RU	https://pubmed.ncbi.nlm.nih.gov/17998160

DMN1S35	DI	DMN1S35
DMN1S35	DN	5,6-dichloro-3,4-dihydroquinazolin-2-amine
DMN1S35	MI	TTWJBZ5
DMN1S35	MN	5-HT 2C receptor (HTR2C)
DMN1S35	MT	DTT
DMN1S35	MA	Inhibitor
DMN1S35	RN	Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61.
DMN1S35	RU	https://pubmed.ncbi.nlm.nih.gov/17998160

DMN1S35	DI	DMN1S35
DMN1S35	DN	5,6-dichloro-3,4-dihydroquinazolin-2-amine
DMN1S35	MI	TTPC4TU
DMN1S35	MN	5-HT 3A receptor (HTR3A)
DMN1S35	MT	DTT
DMN1S35	MA	Inhibitor
DMN1S35	RN	Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61.
DMN1S35	RU	https://pubmed.ncbi.nlm.nih.gov/17998160

DMN1S35	DI	DMN1S35
DMN1S35	DN	5,6-dichloro-3,4-dihydroquinazolin-2-amine
DMN1S35	MI	TTRUFDT
DMN1S35	MN	5-HT 5A receptor (HTR5A)
DMN1S35	MT	DTT
DMN1S35	MA	Inhibitor
DMN1S35	RN	Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61.
DMN1S35	RU	https://pubmed.ncbi.nlm.nih.gov/17998160

DMN1S35	DI	DMN1S35
DMN1S35	DN	5,6-dichloro-3,4-dihydroquinazolin-2-amine
DMN1S35	MI	TTJS8PY
DMN1S35	MN	5-HT 6 receptor (HTR6)
DMN1S35	MT	DTT
DMN1S35	MA	Inhibitor
DMN1S35	RN	Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61.
DMN1S35	RU	https://pubmed.ncbi.nlm.nih.gov/17998160

DMN1S35	DI	DMN1S35
DMN1S35	DN	5,6-dichloro-3,4-dihydroquinazolin-2-amine
DMN1S35	MI	TTO9X1H
DMN1S35	MN	5-HT 7 receptor (HTR7)
DMN1S35	MT	DTT
DMN1S35	MA	Inhibitor
DMN1S35	RN	Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61.
DMN1S35	RU	https://pubmed.ncbi.nlm.nih.gov/17998160

DMR2OMU	DI	DMR2OMU
DMR2OMU	DN	5,6-Dichloro-N-(2-morpholinoethyl)nicotinamide
DMR2OMU	MI	TT3WG5C
DMR2OMU	MN	Monoamine oxidase type A (MAO-A)
DMR2OMU	MT	DTT
DMR2OMU	MA	Inhibitor
DMR2OMU	RN	Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1659-64.
DMR2OMU	RU	https://pubmed.ncbi.nlm.nih.gov/20117937

DMZL87A	DI	DMZL87A
DMZL87A	DN	5,6-Dichloro-N-(3-morpholinopropyl)nicotinamide
DMZL87A	MI	TT3WG5C
DMZL87A	MN	Monoamine oxidase type A (MAO-A)
DMZL87A	MT	DTT
DMZL87A	MA	Inhibitor
DMZL87A	RN	Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1659-64.
DMZL87A	RU	https://pubmed.ncbi.nlm.nih.gov/20117937

DM94V8D	DI	DM94V8D
DM94V8D	DN	5,6-dihydroxy-7-nitro-2,3-dihydroinden-1-one
DM94V8D	MI	TTKWFB8
DM94V8D	MN	Catechol-O-methyl-transferase (COMT)
DM94V8D	MT	DTT
DM94V8D	MA	Inhibitor
DM94V8D	RN	Synthesis and biological evaluation of a novel series of "ortho-nitrated" inhibitors of catechol-O-methyltransferase. J Med Chem. 2005 Dec 15;48(25):8070-8.
DM94V8D	RU	https://pubmed.ncbi.nlm.nih.gov/16335931

DM07HYA	DI	DM07HYA
DM07HYA	DN	5,6-dinitroacenaphthoquinone
DM07HYA	MI	TT1RS9F
DM07HYA	MN	Acetylcholinesterase (AChE)
DM07HYA	MT	DTT
DM07HYA	MA	Inhibitor
DM07HYA	RN	Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34.
DM07HYA	RU	https://pubmed.ncbi.nlm.nih.gov/17941623

DM07HYA	DI	DM07HYA
DM07HYA	DN	5,6-dinitroacenaphthoquinone
DM07HYA	MI	TTEB0GD
DM07HYA	MN	Cholinesterase (BCHE)
DM07HYA	MT	DTT
DM07HYA	MA	Inhibitor
DM07HYA	RN	Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34.
DM07HYA	RU	https://pubmed.ncbi.nlm.nih.gov/17941623

DM07HYA	DI	DM07HYA
DM07HYA	DN	5,6-dinitroacenaphthoquinone
DM07HYA	MI	TTMF541
DM07HYA	MN	Liver carboxylesterase (CES1)
DM07HYA	MT	DTT
DM07HYA	MA	Inhibitor
DM07HYA	RN	Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34.
DM07HYA	RU	https://pubmed.ncbi.nlm.nih.gov/17941623

DMXTYCU	DI	DMXTYCU
DMXTYCU	DN	5,6-epoxyeicosatrienoic acid
DMXTYCU	MI	TTKP2SU
DMXTYCU	MN	Transient receptor potential cation channel V4 (TRPV4)
DMXTYCU	MT	DTT
DMXTYCU	MA	Activator
DMXTYCU	RN	Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels. Nature. 2003 Jul 24;424(6947):434-8.
DMXTYCU	RU	https://pubmed.ncbi.nlm.nih.gov/12879072

DMA50BQ	DI	DMA50BQ
DMA50BQ	DN	5,7-Dibromo-1,4-dihydro-quinoxaline-2,3-dione
DMA50BQ	MI	TTLD29N
DMA50BQ	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMA50BQ	MT	DTT
DMA50BQ	MA	Inhibitor
DMA50BQ	RN	1-Hydroxy-1,4-dihydroquinoxaline-2,3-diones: Novel antagonists at NMDA receptor glycine sites, Bioorg. Med. Chem. Lett. 6(4):439-440 (1996).
DMA50BQ	RU	http://www.sciencedirect.com/science/article/pii/0960894X96000364

DMZLOVB	DI	DMZLOVB
DMZLOVB	DN	5,7-dibromo-9H-pyrido[3,4-b]indol-6-ol
DMZLOVB	MI	TTK25J1
DMZLOVB	MN	Adenosine A1 receptor (ADORA1)
DMZLOVB	MT	DTT
DMZLOVB	MA	Inhibitor
DMZLOVB	RN	Synthesis of eudistomin D analogues and its effects on adenosine receptors. Bioorg Med Chem. 2008 Apr 1;16(7):3825-30.
DMZLOVB	RU	https://pubmed.ncbi.nlm.nih.gov/18262425

DMZLOVB	DI	DMZLOVB
DMZLOVB	DN	5,7-dibromo-9H-pyrido[3,4-b]indol-6-ol
DMZLOVB	MI	TTM2AOE
DMZLOVB	MN	Adenosine A2a receptor (ADORA2A)
DMZLOVB	MT	DTT
DMZLOVB	MA	Inhibitor
DMZLOVB	RN	Synthesis of eudistomin D analogues and its effects on adenosine receptors. Bioorg Med Chem. 2008 Apr 1;16(7):3825-30.
DMZLOVB	RU	https://pubmed.ncbi.nlm.nih.gov/18262425

DMZLOVB	DI	DMZLOVB
DMZLOVB	DN	5,7-dibromo-9H-pyrido[3,4-b]indol-6-ol
DMZLOVB	MI	TTJFY5U
DMZLOVB	MN	Adenosine A3 receptor (ADORA3)
DMZLOVB	MT	DTT
DMZLOVB	MA	Inhibitor
DMZLOVB	RN	Synthesis of eudistomin D analogues and its effects on adenosine receptors. Bioorg Med Chem. 2008 Apr 1;16(7):3825-30.
DMZLOVB	RU	https://pubmed.ncbi.nlm.nih.gov/18262425

DMOJ5LM	DI	DMOJ5LM
DMOJ5LM	DN	5,7-Dichloro-1,4-dihydro-quinoxaline-2,3-dione
DMOJ5LM	MI	TTLD29N
DMOJ5LM	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMOJ5LM	MT	DTT
DMOJ5LM	MA	Inhibitor
DMOJ5LM	RN	1-Hydroxy-1,4-dihydroquinoxaline-2,3-diones: Novel antagonists at NMDA receptor glycine sites, Bioorg. Med. Chem. Lett. 6(4):439-440 (1996).
DMOJ5LM	RU	http://www.sciencedirect.com/science/article/pii/0960894X96000364

DMFHDWG	DI	DMFHDWG
DMFHDWG	DN	5,7-dichloro-1H-indole-2,3-dione
DMFHDWG	MI	TTMF541
DMFHDWG	MN	Liver carboxylesterase (CES1)
DMFHDWG	MT	DTT
DMFHDWG	MA	Inhibitor
DMFHDWG	RN	Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85.
DMFHDWG	RU	https://pubmed.ncbi.nlm.nih.gov/17378546

DMUADN4	DI	DMUADN4
DMUADN4	DN	5,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione
DMUADN4	MI	TTLD29N
DMUADN4	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMUADN4	MT	DTT
DMUADN4	MA	Inhibitor
DMUADN4	RN	3-hydroxy-quinazoline-2,4-dione as a useful scaffold to obtain selective Gly/NMDA and AMPA receptor antagonists. Bioorg Med Chem Lett. 2004 May 3;14(9):2345-9.
DMUADN4	RU	https://pubmed.ncbi.nlm.nih.gov/15081038

DMUADN4	DI	DMUADN4
DMUADN4	DN	5,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione
DMUADN4	MI	TTKJEMQ
DMUADN4	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMUADN4	MT	DTT
DMUADN4	MA	Inhibitor
DMUADN4	RN	3-hydroxy-quinazoline-2,4-dione as a useful scaffold to obtain selective Gly/NMDA and AMPA receptor antagonists. Bioorg Med Chem Lett. 2004 May 3;14(9):2345-9.
DMUADN4	RU	https://pubmed.ncbi.nlm.nih.gov/15081038

DMUADN4	DI	DMUADN4
DMUADN4	DN	5,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione
DMUADN4	MI	TTN9D8E
DMUADN4	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMUADN4	MT	DTT
DMUADN4	MA	Inhibitor
DMUADN4	RN	3-hydroxy-quinazoline-2,4-dione as a useful scaffold to obtain selective Gly/NMDA and AMPA receptor antagonists. Bioorg Med Chem Lett. 2004 May 3;14(9):2345-9.
DMUADN4	RU	https://pubmed.ncbi.nlm.nih.gov/15081038

DMZJKIU	DI	DMZJKIU
DMZJKIU	DN	5,7-Dichloro-4-hydroxy-3-phenyl-1H-quinolin-2-one
DMZJKIU	MI	TTLD29N
DMZJKIU	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMZJKIU	MT	DTT
DMZJKIU	MA	Inhibitor
DMZJKIU	RN	Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993).
DMZJKIU	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01808970

DMZJKIU	DI	DMZJKIU
DMZJKIU	DN	5,7-Dichloro-4-hydroxy-3-phenyl-1H-quinolin-2-one
DMZJKIU	MI	TTKJEMQ
DMZJKIU	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMZJKIU	MT	DTT
DMZJKIU	MA	Inhibitor
DMZJKIU	RN	Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993).
DMZJKIU	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01808970

DMZJKIU	DI	DMZJKIU
DMZJKIU	DN	5,7-Dichloro-4-hydroxy-3-phenyl-1H-quinolin-2-one
DMZJKIU	MI	TTN9D8E
DMZJKIU	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMZJKIU	MT	DTT
DMZJKIU	MA	Inhibitor
DMZJKIU	RN	Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993).
DMZJKIU	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01808970

DMHKQ1L	DI	DMHKQ1L
DMHKQ1L	DN	5,7-Dichlorokynurenic Acid
DMHKQ1L	MI	TTLD29N
DMHKQ1L	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMHKQ1L	MT	DTT
DMHKQ1L	MA	Inhibitor
DMHKQ1L	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMHKQ1L	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMA61I2	DI	DMA61I2
DMA61I2	DN	5,7-dihydroxy-3-phenyl-3H-quinazolin-4-one
DMA61I2	MI	TTOM3J0
DMA61I2	MN	Estrogen receptor beta (ESR2)
DMA61I2	MT	DTT
DMA61I2	MA	Inhibitor
DMA61I2	RN	Synthesis and characterization of 3-arylquinazolinone and 3-arylquinazolinethione derivatives as selective estrogen receptor beta modulators. J Med Chem. 2006 Apr 20;49(8):2440-55.
DMA61I2	RU	https://pubmed.ncbi.nlm.nih.gov/16610787

DM724JF	DI	DM724JF
DM724JF	DN	5,7-Dimethoxy-3-pyridin-4-yl-quinoline
DM724JF	MI	TT8FYO9
DM724JF	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DM724JF	MT	DTT
DM724JF	MA	Inhibitor
DM724JF	RN	5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.
DM724JF	RU	https://pubmed.ncbi.nlm.nih.gov/8064792

DM724JF	DI	DM724JF
DM724JF	DN	5,7-Dimethoxy-3-pyridin-4-yl-quinoline
DM724JF	MI	TTI7421
DM724JF	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM724JF	MT	DTT
DM724JF	MA	Inhibitor
DM724JF	RN	5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.
DM724JF	RU	https://pubmed.ncbi.nlm.nih.gov/8064792

DMJAQ41	DI	DMJAQ41
DMJAQ41	DN	5,7-Dimethoxy-3-thiophen-3-yl-quinoline
DMJAQ41	MI	TT8FYO9
DMJAQ41	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMJAQ41	MT	DTT
DMJAQ41	MA	Inhibitor
DMJAQ41	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMJAQ41	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMJAQ41	DI	DMJAQ41
DMJAQ41	DN	5,7-Dimethoxy-3-thiophen-3-yl-quinoline
DMJAQ41	MI	TTI7421
DMJAQ41	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMJAQ41	MT	DTT
DMJAQ41	MA	Inhibitor
DMJAQ41	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMJAQ41	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMU618S	DI	DMU618S
DMU618S	DN	5,7-Dimethyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one
DMU618S	MI	TTML2WA
DMU618S	MN	Tubulin (TUB)
DMU618S	MT	DTT
DMU618S	MA	Inhibitor
DMU618S	RN	Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubul... J Med Chem. 1997 Sep 12;40(19):3049-56.
DMU618S	RU	https://pubmed.ncbi.nlm.nih.gov/9301667

DMU618S	DI	DMU618S
DMU618S	DN	5,7-Dimethyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one
DMU618S	MI	TTYFKSZ
DMU618S	MN	Tubulin beta (TUBB)
DMU618S	MT	DTT
DMU618S	MA	Inhibitor
DMU618S	RN	Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubul... J Med Chem. 1997 Sep 12;40(19):3049-56.
DMU618S	RU	https://pubmed.ncbi.nlm.nih.gov/9301667

DM3P79O	DI	DM3P79O
DM3P79O	DN	5,7-Dimethyl-3-thiophen-3-yl-quinoline
DM3P79O	MI	TT8FYO9
DM3P79O	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DM3P79O	MT	DTT
DM3P79O	MA	Inhibitor
DM3P79O	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DM3P79O	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DM3P79O	DI	DM3P79O
DM3P79O	DN	5,7-Dimethyl-3-thiophen-3-yl-quinoline
DM3P79O	MI	TTI7421
DM3P79O	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM3P79O	MT	DTT
DM3P79O	MA	Inhibitor
DM3P79O	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DM3P79O	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMG4UCX	DI	DMG4UCX
DMG4UCX	DN	5,7-Dinitro-1,4-dihydro-quinoxaline-2,3-dione
DMG4UCX	MI	TTLD29N
DMG4UCX	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMG4UCX	MT	DTT
DMG4UCX	MA	Inhibitor
DMG4UCX	RN	Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993).
DMG4UCX	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01808970

DMG4UCX	DI	DMG4UCX
DMG4UCX	DN	5,7-Dinitro-1,4-dihydro-quinoxaline-2,3-dione
DMG4UCX	MI	TTKJEMQ
DMG4UCX	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMG4UCX	MT	DTT
DMG4UCX	MA	Inhibitor
DMG4UCX	RN	Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993).
DMG4UCX	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01808970

DMG4UCX	DI	DMG4UCX
DMG4UCX	DN	5,7-Dinitro-1,4-dihydro-quinoxaline-2,3-dione
DMG4UCX	MI	TTN9D8E
DMG4UCX	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMG4UCX	MT	DTT
DMG4UCX	MA	Inhibitor
DMG4UCX	RN	Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993).
DMG4UCX	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01808970

DM4TIXY	DI	DM4TIXY
DM4TIXY	DN	5,7-diphenyl-3H-imidazo[4,5-b]pyridin-2-ol
DM4TIXY	MI	TTK25J1
DM4TIXY	MN	Adenosine A1 receptor (ADORA1)
DM4TIXY	MT	DTT
DM4TIXY	MA	Inhibitor
DM4TIXY	RN	2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34.
DM4TIXY	RU	https://pubmed.ncbi.nlm.nih.gov/17300165

DM4TIXY	DI	DM4TIXY
DM4TIXY	DN	5,7-diphenyl-3H-imidazo[4,5-b]pyridin-2-ol
DM4TIXY	MI	TTM2AOE
DM4TIXY	MN	Adenosine A2a receptor (ADORA2A)
DM4TIXY	MT	DTT
DM4TIXY	MA	Inhibitor
DM4TIXY	RN	2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34.
DM4TIXY	RU	https://pubmed.ncbi.nlm.nih.gov/17300165

DM4TIXY	DI	DM4TIXY
DM4TIXY	DN	5,7-diphenyl-3H-imidazo[4,5-b]pyridin-2-ol
DM4TIXY	MI	TTJFY5U
DM4TIXY	MN	Adenosine A3 receptor (ADORA3)
DM4TIXY	MT	DTT
DM4TIXY	MA	Inhibitor
DM4TIXY	RN	2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34.
DM4TIXY	RU	https://pubmed.ncbi.nlm.nih.gov/17300165

DMKXIWQ	DI	DMKXIWQ
DMKXIWQ	DN	5,7-Diphenyl-7H-pyrrolo[2,3-d]pyrimidin-4-ol
DMKXIWQ	MI	TT6PKBN
DMKXIWQ	MN	Proto-oncogene c-Src (SRC)
DMKXIWQ	MT	DTT
DMKXIWQ	MA	Inhibitor
DMKXIWQ	RN	Substituted 5,7-diphenyl-pyrrolo[2,3d]pyrimidines: potent inhibitors of the tyrosine kinase c-Src. Bioorg Med Chem Lett. 2000 May 1;10(9):945-9.
DMKXIWQ	RU	https://pubmed.ncbi.nlm.nih.gov/10853665

DMOCEPA	DI	DMOCEPA
DMOCEPA	DN	5,8-Dihydroxy-1,4-naphthoquinone
DMOCEPA	MI	TT2J34L
DMOCEPA	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMOCEPA	MT	DTT
DMOCEPA	MA	Inhibitor
DMOCEPA	RN	Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80.
DMOCEPA	RU	https://pubmed.ncbi.nlm.nih.gov/9371243

DMOCEPA	DI	DMOCEPA
DMOCEPA	DN	5,8-Dihydroxy-1,4-naphthoquinone
DMOCEPA	MI	TTR7UJ3
DMOCEPA	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMOCEPA	MT	DTT
DMOCEPA	MA	Inhibitor
DMOCEPA	RN	Novel molecular targets for antimalarial chemotherapy. Int J Antimicrob Agents. 2007 Jul;30(1):4-10.
DMOCEPA	RU	https://pubmed.ncbi.nlm.nih.gov/17339102

DMJ1IRO	DI	DMJ1IRO
DMJ1IRO	DN	5,8-dimethoxy-1,4-dimethylquinolin-2(1H)-one
DMJ1IRO	MI	TTJLP0R
DMJ1IRO	MN	Quinone reductase 2 (NQO2)
DMJ1IRO	MT	DTT
DMJ1IRO	MA	Inhibitor
DMJ1IRO	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMJ1IRO	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMEMBKW	DI	DMEMBKW
DMEMBKW	DN	5,8-Dimethoxy-4-methylquinolin-2(1H)-one
DMEMBKW	MI	TTJLP0R
DMEMBKW	MN	Quinone reductase 2 (NQO2)
DMEMBKW	MT	DTT
DMEMBKW	MA	Inhibitor
DMEMBKW	RN	Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities. J Med Chem. 2009 Apr 9;52(7):1873-84.
DMEMBKW	RU	https://pubmed.ncbi.nlm.nih.gov/19265439

DM1SO62	DI	DM1SO62
DM1SO62	DN	5,8-hydroxy-naphthoquinone
DM1SO62	MI	TT3PQ2Y
DM1SO62	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DM1SO62	MT	DTT
DM1SO62	MA	Inhibitor
DM1SO62	RN	Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Chem Biol Interact. 2000 Jan 3;124(1):61-76.
DM1SO62	RU	https://pubmed.ncbi.nlm.nih.gov/10658902

DM3MSZN	DI	DM3MSZN
DM3MSZN	DN	5,N-Dihydroxythalidomide
DM3MSZN	MI	TTUV8G9
DM3MSZN	MN	Progesterone receptor (PGR)
DM3MSZN	MT	DTT
DM3MSZN	MA	Inhibitor
DM3MSZN	RN	Progesterone receptor antagonists with a 3-phenylquinazoline-2,4-dione/2-phenylisoquinoline-1,3-dione skeleton. Bioorg Med Chem. 2008 Jul 15;16(14):7046-54.
DM3MSZN	RU	https://pubmed.ncbi.nlm.nih.gov/18586498

DM23PL4	DI	DM23PL4
DM23PL4	DN	5-[(1R)-1-ammonioethyl]isoxazol-3-olate
DM23PL4	MI	TT1MPAY
DM23PL4	MN	GABA(A) receptor alpha-1 (GABRA1)
DM23PL4	MT	DTT
DM23PL4	MA	Inhibitor
DM23PL4	RN	gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83.
DM23PL4	RU	https://pubmed.ncbi.nlm.nih.gov/6118436

DM23PL4	DI	DM23PL4
DM23PL4	DN	5-[(1R)-1-ammonioethyl]isoxazol-3-olate
DM23PL4	MI	TTBMV1G
DM23PL4	MN	GABA(A) receptor alpha-2 (GABRA2)
DM23PL4	MT	DTT
DM23PL4	MA	Inhibitor
DM23PL4	RN	gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83.
DM23PL4	RU	https://pubmed.ncbi.nlm.nih.gov/6118436

DM23PL4	DI	DM23PL4
DM23PL4	DN	5-[(1R)-1-ammonioethyl]isoxazol-3-olate
DM23PL4	MI	TT37EDJ
DM23PL4	MN	GABA(A) receptor alpha-3 (GABRA3)
DM23PL4	MT	DTT
DM23PL4	MA	Inhibitor
DM23PL4	RN	gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83.
DM23PL4	RU	https://pubmed.ncbi.nlm.nih.gov/6118436

DM23PL4	DI	DM23PL4
DM23PL4	DN	5-[(1R)-1-ammonioethyl]isoxazol-3-olate
DM23PL4	MI	TTNZPQ1
DM23PL4	MN	GABA(A) receptor alpha-5 (GABRA5)
DM23PL4	MT	DTT
DM23PL4	MA	Inhibitor
DM23PL4	RN	gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83.
DM23PL4	RU	https://pubmed.ncbi.nlm.nih.gov/6118436

DM23PL4	DI	DM23PL4
DM23PL4	DN	5-[(1R)-1-ammonioethyl]isoxazol-3-olate
DM23PL4	MI	TTZA1NY
DM23PL4	MN	GABA(A) receptor beta-2 (GABRB2)
DM23PL4	MT	DTT
DM23PL4	MA	Inhibitor
DM23PL4	RN	gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83.
DM23PL4	RU	https://pubmed.ncbi.nlm.nih.gov/6118436

DM23PL4	DI	DM23PL4
DM23PL4	DN	5-[(1R)-1-ammonioethyl]isoxazol-3-olate
DM23PL4	MI	TT06RH5
DM23PL4	MN	GABA(A) receptor gamma-2 (GABRG2)
DM23PL4	MT	DTT
DM23PL4	MA	Inhibitor
DM23PL4	RN	gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83.
DM23PL4	RU	https://pubmed.ncbi.nlm.nih.gov/6118436

DM23PL4	DI	DM23PL4
DM23PL4	DN	5-[(1R)-1-ammonioethyl]isoxazol-3-olate
DM23PL4	MI	TTNJYV2
DM23PL4	MN	Gamma-aminobutyric acid receptor (GAR)
DM23PL4	MT	DTT
DM23PL4	MA	Inhibitor
DM23PL4	RN	gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83.
DM23PL4	RU	https://pubmed.ncbi.nlm.nih.gov/6118436

DMYAPLT	DI	DMYAPLT
DMYAPLT	DN	5-[(1S)-1-ammonioethyl]isoxazol-3-olate
DMYAPLT	MI	TT1MPAY
DMYAPLT	MN	GABA(A) receptor alpha-1 (GABRA1)
DMYAPLT	MT	DTT
DMYAPLT	MA	Inhibitor
DMYAPLT	RN	gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83.
DMYAPLT	RU	https://pubmed.ncbi.nlm.nih.gov/6118436

DMYAPLT	DI	DMYAPLT
DMYAPLT	DN	5-[(1S)-1-ammonioethyl]isoxazol-3-olate
DMYAPLT	MI	TTBMV1G
DMYAPLT	MN	GABA(A) receptor alpha-2 (GABRA2)
DMYAPLT	MT	DTT
DMYAPLT	MA	Inhibitor
DMYAPLT	RN	gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83.
DMYAPLT	RU	https://pubmed.ncbi.nlm.nih.gov/6118436

DMYAPLT	DI	DMYAPLT
DMYAPLT	DN	5-[(1S)-1-ammonioethyl]isoxazol-3-olate
DMYAPLT	MI	TT37EDJ
DMYAPLT	MN	GABA(A) receptor alpha-3 (GABRA3)
DMYAPLT	MT	DTT
DMYAPLT	MA	Inhibitor
DMYAPLT	RN	gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83.
DMYAPLT	RU	https://pubmed.ncbi.nlm.nih.gov/6118436

DMYAPLT	DI	DMYAPLT
DMYAPLT	DN	5-[(1S)-1-ammonioethyl]isoxazol-3-olate
DMYAPLT	MI	TTNZPQ1
DMYAPLT	MN	GABA(A) receptor alpha-5 (GABRA5)
DMYAPLT	MT	DTT
DMYAPLT	MA	Inhibitor
DMYAPLT	RN	gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83.
DMYAPLT	RU	https://pubmed.ncbi.nlm.nih.gov/6118436

DMYAPLT	DI	DMYAPLT
DMYAPLT	DN	5-[(1S)-1-ammonioethyl]isoxazol-3-olate
DMYAPLT	MI	TTZA1NY
DMYAPLT	MN	GABA(A) receptor beta-2 (GABRB2)
DMYAPLT	MT	DTT
DMYAPLT	MA	Inhibitor
DMYAPLT	RN	gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83.
DMYAPLT	RU	https://pubmed.ncbi.nlm.nih.gov/6118436

DMYAPLT	DI	DMYAPLT
DMYAPLT	DN	5-[(1S)-1-ammonioethyl]isoxazol-3-olate
DMYAPLT	MI	TT06RH5
DMYAPLT	MN	GABA(A) receptor gamma-2 (GABRG2)
DMYAPLT	MT	DTT
DMYAPLT	MA	Inhibitor
DMYAPLT	RN	gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83.
DMYAPLT	RU	https://pubmed.ncbi.nlm.nih.gov/6118436

DMYAPLT	DI	DMYAPLT
DMYAPLT	DN	5-[(1S)-1-ammonioethyl]isoxazol-3-olate
DMYAPLT	MI	TTNJYV2
DMYAPLT	MN	Gamma-aminobutyric acid receptor (GAR)
DMYAPLT	MT	DTT
DMYAPLT	MA	Inhibitor
DMYAPLT	RN	gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83.
DMYAPLT	RU	https://pubmed.ncbi.nlm.nih.gov/6118436

DMM9GCA	DI	DMM9GCA
DMM9GCA	DN	5-[(2-methyl-4-thiazolyl)ethynyl]pyrimidine
DMM9GCA	MI	TTHS256
DMM9GCA	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMM9GCA	MT	DTT
DMM9GCA	MA	Inhibitor
DMM9GCA	RN	Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100.
DMM9GCA	RU	https://pubmed.ncbi.nlm.nih.gov/16451073

DMLFY2T	DI	DMLFY2T
DMLFY2T	DN	5-[2-(1H-pyrrol-1-yl)ethoxy]-1H-indole
DMLFY2T	MI	TTXZEAJ
DMLFY2T	MN	Leukotriene A-4 hydrolase (LTA4H)
DMLFY2T	MT	DTT
DMLFY2T	MA	Inhibitor
DMLFY2T	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMLFY2T	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM1KO7U	DI	DM1KO7U
DM1KO7U	DN	5-[2-(4-hydroxyphenyl)ethyl]benzene-1,3-diol
DM1KO7U	MI	TTXZEAJ
DM1KO7U	MN	Leukotriene A-4 hydrolase (LTA4H)
DM1KO7U	MT	DTT
DM1KO7U	MA	Inhibitor
DM1KO7U	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM1KO7U	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMW8RLN	DI	DMW8RLN
DMW8RLN	DN	5-[4-(Pyridin-4-ylmethyl)phenyl]-1H-indole
DMW8RLN	MI	TTIQUX7
DMW8RLN	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMW8RLN	MT	DTT
DMW8RLN	MA	Inhibitor
DMW8RLN	RN	Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
DMW8RLN	RU	https://pubmed.ncbi.nlm.nih.gov/20684610

DMW8RLN	DI	DMW8RLN
DMW8RLN	DN	5-[4-(Pyridin-4-ylmethyl)phenyl]-1H-indole
DMW8RLN	MI	TTRA5BZ
DMW8RLN	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMW8RLN	MT	DTT
DMW8RLN	MA	Inhibitor
DMW8RLN	RN	Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
DMW8RLN	RU	https://pubmed.ncbi.nlm.nih.gov/20684610

DMV7QU3	DI	DMV7QU3
DMV7QU3	DN	5-[5-Bromo-indan-(1E)-ylidenemethyl]-1H-imidazole
DMV7QU3	MI	TTSZLWK
DMV7QU3	MN	Aromatase (CYP19A1)
DMV7QU3	MT	DTT
DMV7QU3	MA	Inhibitor
DMV7QU3	RN	Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase. J Med Chem. 2005 Mar 24;48(6):1796-805.
DMV7QU3	RU	https://pubmed.ncbi.nlm.nih.gov/15771425

DMV7QU3	DI	DMV7QU3
DMV7QU3	DN	5-[5-Bromo-indan-(1E)-ylidenemethyl]-1H-imidazole
DMV7QU3	MI	TTIQUX7
DMV7QU3	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMV7QU3	MT	DTT
DMV7QU3	MA	Inhibitor
DMV7QU3	RN	Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase. J Med Chem. 2005 Mar 24;48(6):1796-805.
DMV7QU3	RU	https://pubmed.ncbi.nlm.nih.gov/15771425

DMZICL8	DI	DMZICL8
DMZICL8	DN	5-[5-Bromo-indan-(1Z)-ylidenemethyl]-1H-imidazole
DMZICL8	MI	TTSZLWK
DMZICL8	MN	Aromatase (CYP19A1)
DMZICL8	MT	DTT
DMZICL8	MA	Inhibitor
DMZICL8	RN	Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase. J Med Chem. 2005 Mar 24;48(6):1796-805.
DMZICL8	RU	https://pubmed.ncbi.nlm.nih.gov/15771425

DMZICL8	DI	DMZICL8
DMZICL8	DN	5-[5-Bromo-indan-(1Z)-ylidenemethyl]-1H-imidazole
DMZICL8	MI	TTIQUX7
DMZICL8	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMZICL8	MT	DTT
DMZICL8	MA	Inhibitor
DMZICL8	RN	Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase. J Med Chem. 2005 Mar 24;48(6):1796-805.
DMZICL8	RU	https://pubmed.ncbi.nlm.nih.gov/15771425

DM2RIHT	DI	DM2RIHT
DM2RIHT	DN	5-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyrimidine
DM2RIHT	MI	TTSZLWK
DM2RIHT	MN	Aromatase (CYP19A1)
DM2RIHT	MT	DTT
DM2RIHT	MA	Inhibitor
DM2RIHT	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DM2RIHT	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DM2RIHT	DI	DM2RIHT
DM2RIHT	DN	5-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyrimidine
DM2RIHT	MI	TTIQUX7
DM2RIHT	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM2RIHT	MT	DTT
DM2RIHT	MA	Inhibitor
DM2RIHT	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DM2RIHT	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DM2RIHT	DI	DM2RIHT
DM2RIHT	DN	5-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyrimidine
DM2RIHT	MI	TTRA5BZ
DM2RIHT	MN	Steroid 17-alpha-monooxygenase (S17AH)
DM2RIHT	MT	DTT
DM2RIHT	MA	Inhibitor
DM2RIHT	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DM2RIHT	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMQGX2Z	DI	DMQGX2Z
DMQGX2Z	DN	5-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyrimidine
DMQGX2Z	MI	TTSZLWK
DMQGX2Z	MN	Aromatase (CYP19A1)
DMQGX2Z	MT	DTT
DMQGX2Z	MA	Inhibitor
DMQGX2Z	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMQGX2Z	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DM5FA74	DI	DM5FA74
DM5FA74	DN	5-[5-Methoxy-indan-(1E)-ylidenemethyl]-thiazole
DM5FA74	MI	TTSZLWK
DM5FA74	MN	Aromatase (CYP19A1)
DM5FA74	MT	DTT
DM5FA74	MA	Inhibitor
DM5FA74	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DM5FA74	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMPDN63	DI	DMPDN63
DMPDN63	DN	5-[5-Methoxy-indan-(1Z)-ylidenemethyl]-thiazole
DMPDN63	MI	TTSZLWK
DMPDN63	MN	Aromatase (CYP19A1)
DMPDN63	MT	DTT
DMPDN63	MA	Inhibitor
DMPDN63	RN	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
DMPDN63	RU	https://pubmed.ncbi.nlm.nih.gov/15743198

DMSZ3T6	DI	DMSZ3T6
DMSZ3T6	DN	5-{8(Z),11(Z),14-pentadecatrienyl}resorcinol
DMSZ3T6	MI	TTULVH8
DMSZ3T6	MN	Tyrosinase (TYR)
DMSZ3T6	MT	DTT
DMSZ3T6	MA	Inhibitor
DMSZ3T6	RN	Tyrosinase inhibitors from Anacardium occidentale fruits. J Nat Prod. 1994 Apr;57(4):545-51.
DMSZ3T6	RU	https://pubmed.ncbi.nlm.nih.gov/8021657

DM0EBWR	DI	DM0EBWR
DM0EBWR	DN	5-{8(Z),11(Z)-pentadecadienyl}resorcinol
DM0EBWR	MI	TTULVH8
DM0EBWR	MN	Tyrosinase (TYR)
DM0EBWR	MT	DTT
DM0EBWR	MA	Inhibitor
DM0EBWR	RN	Tyrosinase inhibitors from Anacardium occidentale fruits. J Nat Prod. 1994 Apr;57(4):545-51.
DM0EBWR	RU	https://pubmed.ncbi.nlm.nih.gov/8021657

DMNRWEV	DI	DMNRWEV
DMNRWEV	DN	5-{8(Z),-pentadecenyl}resorcinol
DMNRWEV	MI	TTULVH8
DMNRWEV	MN	Tyrosinase (TYR)
DMNRWEV	MT	DTT
DMNRWEV	MA	Inhibitor
DMNRWEV	RN	Tyrosinase inhibitors from Anacardium occidentale fruits. J Nat Prod. 1994 Apr;57(4):545-51.
DMNRWEV	RU	https://pubmed.ncbi.nlm.nih.gov/8021657

DMB7R95	DI	DMB7R95
DMB7R95	DN	5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide
DMB7R95	MI	TTGKNB4
DMB7R95	MN	Epidermal growth factor receptor (EGFR)
DMB7R95	MT	DTT
DMB7R95	MA	Inhibitor
DMB7R95	RN	Acryloylamino-salicylanilides as EGFR PTK inhibitors. Bioorg Med Chem Lett. 2006 Jan 15;16(2):469-72.
DMB7R95	RU	https://pubmed.ncbi.nlm.nih.gov/16275081

DMHI7Y2	DI	DMHI7Y2
DMHI7Y2	DN	5alpha-Androstan-3,17-Dione
DMHI7Y2	MI	TTIWB6L
DMHI7Y2	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMHI7Y2	MT	DTT
DMHI7Y2	MA	Inhibitor
DMHI7Y2	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMHI7Y2	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMHI7Y2	DI	DMHI7Y2
DMHI7Y2	DN	5alpha-Androstan-3,17-Dione
DMHI7Y2	MI	TTZT9R2
DMHI7Y2	MN	Hydroxysteroid dehydrogenase 3-beta (HSD3B)
DMHI7Y2	MT	DTT
DMHI7Y2	MA	Inhibitor
DMHI7Y2	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMHI7Y2	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMGA47N	DI	DMGA47N
DMGA47N	DN	5-Amino-[1,3,4]thiadiazole-2-thiol
DMGA47N	MI	TTHQPL7
DMGA47N	MN	Carbonic anhydrase I (CA-I)
DMGA47N	MT	DTT
DMGA47N	MA	Inhibitor
DMGA47N	RN	Carbonic anhydrase inhibitors. Inhibition of the cytosolic and tumor-associated carbonic anhydrase isozymes I, II, and IX with a series of 1,3,4-th... Bioorg Med Chem Lett. 2005 May 2;15(9):2347-52.
DMGA47N	RU	https://pubmed.ncbi.nlm.nih.gov/15837323

DMGA47N	DI	DMGA47N
DMGA47N	DN	5-Amino-[1,3,4]thiadiazole-2-thiol
DMGA47N	MI	TTANPDJ
DMGA47N	MN	Carbonic anhydrase II (CA-II)
DMGA47N	MT	DTT
DMGA47N	MA	Inhibitor
DMGA47N	RN	Carbonic anhydrase inhibitors. Inhibition of the cytosolic and tumor-associated carbonic anhydrase isozymes I, II, and IX with a series of 1,3,4-th... Bioorg Med Chem Lett. 2005 May 2;15(9):2347-52.
DMGA47N	RU	https://pubmed.ncbi.nlm.nih.gov/15837323

DMGA47N	DI	DMGA47N
DMGA47N	DN	5-Amino-[1,3,4]thiadiazole-2-thiol
DMGA47N	MI	TT2LVK8
DMGA47N	MN	Carbonic anhydrase IX (CA-IX)
DMGA47N	MT	DTT
DMGA47N	MA	Inhibitor
DMGA47N	RN	Carbonic anhydrase inhibitors. Inhibition of the cytosolic and tumor-associated carbonic anhydrase isozymes I, II, and IX with a series of 1,3,4-th... Bioorg Med Chem Lett. 2005 May 2;15(9):2347-52.
DMGA47N	RU	https://pubmed.ncbi.nlm.nih.gov/15837323

DMX37ZC	DI	DMX37ZC
DMX37ZC	DN	5-amino-2-phenyl-oxazole-4-carboxylic acid amide
DMX37ZC	MI	TTJ3E9X
DMX37ZC	MN	Inhibitor of nuclear factor kappa-B kinase beta (IKKB)
DMX37ZC	MT	DTT
DMX37ZC	MA	Inhibitor
DMX37ZC	RN	Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies. J Med Chem. 2006 May 18;49(10):2898-908.
DMX37ZC	RU	https://pubmed.ncbi.nlm.nih.gov/16686533

DM4SWJ7	DI	DM4SWJ7
DM4SWJ7	DN	5-amino-2-p-tolyl-oxazole-4-carboxylic acid amide
DM4SWJ7	MI	TTJ3E9X
DM4SWJ7	MN	Inhibitor of nuclear factor kappa-B kinase beta (IKKB)
DM4SWJ7	MT	DTT
DM4SWJ7	MA	Inhibitor
DM4SWJ7	RN	Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies. J Med Chem. 2006 May 18;49(10):2898-908.
DM4SWJ7	RU	https://pubmed.ncbi.nlm.nih.gov/16686533

DMJKQ5I	DI	DMJKQ5I
DMJKQ5I	DN	5-amino-3-(N-methylpiperidin-4-yl)-1H-indole
DMJKQ5I	MI	TTK8CXU
DMJKQ5I	MN	5-HT 1B receptor (HTR1B)
DMJKQ5I	MT	DTT
DMJKQ5I	MA	Inhibitor
DMJKQ5I	RN	Designing selective, high affinity ligands of 5-HT1D receptor by covalent dimerization of 5-HT1F ligands derived from 4-fluoro-N-[3-(1-methyl-4-pip... J Med Chem. 2008 Jun 26;51(12):3609-16.
DMJKQ5I	RU	https://pubmed.ncbi.nlm.nih.gov/18507369

DMJKQ5I	DI	DMJKQ5I
DMJKQ5I	DN	5-amino-3-(N-methylpiperidin-4-yl)-1H-indole
DMJKQ5I	MI	TT6MSOK
DMJKQ5I	MN	5-HT 1D receptor (HTR1D)
DMJKQ5I	MT	DTT
DMJKQ5I	MA	Inhibitor
DMJKQ5I	RN	Designing selective, high affinity ligands of 5-HT1D receptor by covalent dimerization of 5-HT1F ligands derived from 4-fluoro-N-[3-(1-methyl-4-pip... J Med Chem. 2008 Jun 26;51(12):3609-16.
DMJKQ5I	RU	https://pubmed.ncbi.nlm.nih.gov/18507369

DMR853M	DI	DMR853M
DMR853M	DN	5-amino-3,4-dihydroisoquinolin-1(2H)-one
DMR853M	MI	TTVDSZ0
DMR853M	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMR853M	MT	DTT
DMR853M	MA	Inhibitor
DMR853M	RN	Discovery and SAR of novel, potent and selective hexahydrobenzonaphthyridinone inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1). Bioorg Med Chem Lett. 2010 Jan 15;20(2):448-52.
DMR853M	RU	https://pubmed.ncbi.nlm.nih.gov/20015648

DMBF42W	DI	DMBF42W
DMBF42W	DN	5'-amino-5'-deoxy-alpha-D-thymidine
DMBF42W	MI	TT5B8AX
DMBF42W	MN	Mycobacterium Thymidine monophosphate kinase (MycB tmk)
DMBF42W	MT	DTT
DMBF42W	MA	Inhibitor
DMBF42W	RN	Rational design of 5'-thiourea-substituted alpha-thymidine analogues as thymidine monophosphate kinase inhibitors capable of inhibiting mycobacteri... J Med Chem. 2007 Nov 1;50(22):5281-92.
DMBF42W	RU	https://pubmed.ncbi.nlm.nih.gov/17910427

DMVPSXW	DI	DMVPSXW
DMVPSXW	DN	5-aminoisoquinolin-1(2H)-one
DMVPSXW	MI	TTVDSZ0
DMVPSXW	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMVPSXW	MT	DTT
DMVPSXW	MA	Inhibitor
DMVPSXW	RN	Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhi... J Med Chem. 2009 Feb 12;52(3):868-77.
DMVPSXW	RU	https://pubmed.ncbi.nlm.nih.gov/19117416

DMWDUVC	DI	DMWDUVC
DMWDUVC	DN	5-Aminomethyl-3-pyrrol-1-yl-oxazolidin-2-one
DMWDUVC	MI	TTGP7BY
DMWDUVC	MN	Monoamine oxidase type B (MAO-B)
DMWDUVC	MT	DTT
DMWDUVC	MA	Inhibitor
DMWDUVC	RN	3-(1H-Pyrrol-1-yl)-2-oxazolidinones as reversible, highly potent, and selective inhibitors of monoamine oxidase type A. J Med Chem. 2002 Mar 14;45(6):1180-3.
DMWDUVC	RU	https://pubmed.ncbi.nlm.nih.gov/11881986

DMZK8V5	DI	DMZK8V5
DMZK8V5	DN	5-Aminomethyl-4,5-dihydro-isoxazol-3-ol
DMZK8V5	MI	TTNJYV2
DMZK8V5	MN	Gamma-aminobutyric acid receptor (GAR)
DMZK8V5	MT	DTT
DMZK8V5	MA	Inhibitor
DMZK8V5	RN	GABA agonists. Resolution, absolute stereochemistry, and enantioselectivity of (S)-(+)- and (R)-(-)-dihydromuscimol. J Med Chem. 1985 Nov;28(11):1612-7.
DMZK8V5	RU	https://pubmed.ncbi.nlm.nih.gov/2999396

DMTP9DB	DI	DMTP9DB
DMTP9DB	DN	5-Aminomethyl-naphthalen-2-ol
DMTP9DB	MI	TTWG9A4
DMTP9DB	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMTP9DB	MT	DTT
DMTP9DB	MA	Inhibitor
DMTP9DB	RN	Examination of the role of the acidic hydrogen in imparting selectivity of 7-(aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline (SK&amp;F 29661) toward inh... J Med Chem. 1997 Dec 5;40(25):3997-4005.
DMTP9DB	RU	https://pubmed.ncbi.nlm.nih.gov/9406590

DMTP9DB	DI	DMTP9DB
DMTP9DB	DN	5-Aminomethyl-naphthalen-2-ol
DMTP9DB	MI	TTWM4TY
DMTP9DB	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMTP9DB	MT	DTT
DMTP9DB	MA	Inhibitor
DMTP9DB	RN	Examination of the role of the acidic hydrogen in imparting selectivity of 7-(aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline (SK&amp;F 29661) toward inh... J Med Chem. 1997 Dec 5;40(25):3997-4005.
DMTP9DB	RU	https://pubmed.ncbi.nlm.nih.gov/9406590

DMTP9DB	DI	DMTP9DB
DMTP9DB	DN	5-Aminomethyl-naphthalen-2-ol
DMTP9DB	MI	TT2NUT5
DMTP9DB	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMTP9DB	MT	DTT
DMTP9DB	MA	Inhibitor
DMTP9DB	RN	Examination of the role of the acidic hydrogen in imparting selectivity of 7-(aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline (SK&amp;F 29661) toward inh... J Med Chem. 1997 Dec 5;40(25):3997-4005.
DMTP9DB	RU	https://pubmed.ncbi.nlm.nih.gov/9406590

DMYTUNE	DI	DMYTUNE
DMYTUNE	DN	5-AMINO-NAPHTALENE-2-MONOSULFONATE
DMYTUNE	MI	TTMY81X
DMYTUNE	MN	Heparin-binding growth factor 1 (FGF1)
DMYTUNE	MT	DTT
DMYTUNE	MA	Inhibitor
DMYTUNE	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMYTUNE	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMIBHP5	DI	DMIBHP5
DMIBHP5	DN	5-aminoquinolin-8-ol
DMIBHP5	MI	TTZJYKH
DMIBHP5	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMIBHP5	MT	DTT
DMIBHP5	MA	Inhibitor
DMIBHP5	RN	Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2010 Feb 11;53(3):1172-89.
DMIBHP5	RU	https://pubmed.ncbi.nlm.nih.gov/20055453

DMURTHE	DI	DMURTHE
DMURTHE	DN	5-Azido-6-benzyl-2-methyl-[1,8]naphthyridine
DMURTHE	MI	TTM2AOE
DMURTHE	MN	Adenosine A2a receptor (ADORA2A)
DMURTHE	MT	DTT
DMURTHE	MA	Inhibitor
DMURTHE	RN	1,8-Naphthyridin-4-one derivatives as new ligands of A2A adenosine receptors. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4604-10.
DMURTHE	RU	https://pubmed.ncbi.nlm.nih.gov/16099648

DM0HO6C	DI	DM0HO6C
DM0HO6C	DN	5-Azidomethyl-3-pyrrol-1-yl-oxazolidin-2-one
DM0HO6C	MI	TT3WG5C
DM0HO6C	MN	Monoamine oxidase type A (MAO-A)
DM0HO6C	MT	DTT
DM0HO6C	MA	Inhibitor
DM0HO6C	RN	3-(1H-Pyrrol-1-yl)-2-oxazolidinones as reversible, highly potent, and selective inhibitors of monoamine oxidase type A. J Med Chem. 2002 Mar 14;45(6):1180-3.
DM0HO6C	RU	https://pubmed.ncbi.nlm.nih.gov/11881986

DM65WZ7	DI	DM65WZ7
DM65WZ7	DN	5-benzhydryl-1,3,4-oxadiazole-2(3H)-thione
DM65WZ7	MI	TTULVH8
DM65WZ7	MN	Tyrosinase (TYR)
DM65WZ7	MT	DTT
DM65WZ7	MA	Inhibitor
DM65WZ7	RN	New potent inhibitors of tyrosinase: novel clues to binding of 1,3,4-thiadiazole-2(3H)-thiones, 1,3,4-oxadiazole-2(3H)-thiones, 4-amino-1,2,4-triaz... Bioorg Med Chem. 2010 Jun 1;18(11):4042-8.
DM65WZ7	RU	https://pubmed.ncbi.nlm.nih.gov/20452224

DMBQ5HV	DI	DMBQ5HV
DMBQ5HV	DN	5-benzhydryl-1,3,4-thiadiazole-2(3H)-thione
DMBQ5HV	MI	TTULVH8
DMBQ5HV	MN	Tyrosinase (TYR)
DMBQ5HV	MT	DTT
DMBQ5HV	MA	Inhibitor
DMBQ5HV	RN	New potent inhibitors of tyrosinase: novel clues to binding of 1,3,4-thiadiazole-2(3H)-thiones, 1,3,4-oxadiazole-2(3H)-thiones, 4-amino-1,2,4-triaz... Bioorg Med Chem. 2010 Jun 1;18(11):4042-8.
DMBQ5HV	RU	https://pubmed.ncbi.nlm.nih.gov/20452224

DM8QK2O	DI	DM8QK2O
DM8QK2O	DN	5-benzyl-1,3,4-oxadiazole-2(3H)-thione
DM8QK2O	MI	TTULVH8
DM8QK2O	MN	Tyrosinase (TYR)
DM8QK2O	MT	DTT
DM8QK2O	MA	Inhibitor
DM8QK2O	RN	New potent inhibitors of tyrosinase: novel clues to binding of 1,3,4-thiadiazole-2(3H)-thiones, 1,3,4-oxadiazole-2(3H)-thiones, 4-amino-1,2,4-triaz... Bioorg Med Chem. 2010 Jun 1;18(11):4042-8.
DM8QK2O	RU	https://pubmed.ncbi.nlm.nih.gov/20452224

DMJVGUZ	DI	DMJVGUZ
DMJVGUZ	DN	5-Benzyl-1H-pyrazole-3-carboxylic acid
DMJVGUZ	MI	TTWNV8U
DMJVGUZ	MN	Nicotinic acid receptor (HCAR2)
DMJVGUZ	MT	DTT
DMJVGUZ	MA	Inhibitor
DMJVGUZ	RN	Pyrazole derivatives as partial agonists for the nicotinic acid receptor. J Med Chem. 2003 Aug 28;46(18):3945-51.
DMJVGUZ	RU	https://pubmed.ncbi.nlm.nih.gov/12930155

DM5MJ3I	DI	DM5MJ3I
DM5MJ3I	DN	5-benzyl-2-(2,4-dichlorophenoxy)phenol
DM5MJ3I	MI	TTNX2CS
DM5MJ3I	MN	Plasmodium Enoyl-ACP reductase (Malaria fabI)
DM5MJ3I	MT	DTT
DM5MJ3I	MA	Inhibitor
DM5MJ3I	RN	Design and in silico screening of combinatorial library of antimalarial analogs of triclosan inhibiting Plasmodium falciparum enoyl-acyl carrier pr... Eur J Med Chem. 2009 Jul;44(7):3009-19.
DM5MJ3I	RU	https://pubmed.ncbi.nlm.nih.gov/19217192

DMCKODQ	DI	DMCKODQ
DMCKODQ	DN	5-benzyl-6-chloropyrimidine-2,4(1H,3H)-dione
DMCKODQ	MI	TTO0IB8
DMCKODQ	MN	Thymidine phosphorylase (TYMP)
DMCKODQ	MT	DTT
DMCKODQ	MA	Inhibitor
DMCKODQ	RN	Discovery of 5-substituted-6-chlorouracils as efficient inhibitors of human thymidine phosphorylase. J Med Chem. 2007 Nov 29;50(24):6016-23.
DMCKODQ	RU	https://pubmed.ncbi.nlm.nih.gov/17963370

DM8WB96	DI	DM8WB96
DM8WB96	DN	5-Benzyloxy-benzo[b]thiophene-2-carboxamidine
DM8WB96	MI	TTFEZ5Q
DM8WB96	MN	Coagulation factor IX (F9)
DM8WB96	MT	DTT
DM8WB96	MA	Inhibitor
DM8WB96	RN	Studies of benzothiophene template as potent factor IXa (FIXa) inhibitors in thrombosis. J Med Chem. 2010 Feb 25;53(4):1465-72.
DM8WB96	RU	https://pubmed.ncbi.nlm.nih.gov/20121198

DMOM35G	DI	DMOM35G
DMOM35G	DN	5-Benzyloxytryptamine
DMOM35G	MI	TTXDKTO
DMOM35G	MN	Long transient receptor potential channel 8 (TRPM8)
DMOM35G	MT	DTT
DMOM35G	MA	Inhibitor
DMOM35G	RN	5-benzyloxytryptamine as an antagonist of TRPM8. Bioorg Med Chem Lett. 2010 Dec 1;20(23):7076-9.
DMOM35G	RU	https://pubmed.ncbi.nlm.nih.gov/20965726

DMFAITE	DI	DMFAITE
DMFAITE	DN	5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione
DMFAITE	MI	TTLM12X
DMFAITE	MN	Matrix metalloproteinase-2 (MMP-2)
DMFAITE	MT	DTT
DMFAITE	MA	Inhibitor
DMFAITE	RN	Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. Bioorg Med Chem Lett. 2001 Apr 23;11(8):969-72.
DMFAITE	RU	https://pubmed.ncbi.nlm.nih.gov/11327602

DMFAITE	DI	DMFAITE
DMFAITE	DN	5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione
DMFAITE	MI	TTUZ2L5
DMFAITE	MN	Matrix metalloproteinase-3 (MMP-3)
DMFAITE	MT	DTT
DMFAITE	MA	Inhibitor
DMFAITE	RN	Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. Bioorg Med Chem Lett. 2001 Apr 23;11(8):969-72.
DMFAITE	RU	https://pubmed.ncbi.nlm.nih.gov/11327602

DMFAITE	DI	DMFAITE
DMFAITE	DN	5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione
DMFAITE	MI	TT6X50U
DMFAITE	MN	Matrix metalloproteinase-9 (MMP-9)
DMFAITE	MT	DTT
DMFAITE	MA	Inhibitor
DMFAITE	RN	Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. Bioorg Med Chem Lett. 2001 Apr 23;11(8):969-72.
DMFAITE	RU	https://pubmed.ncbi.nlm.nih.gov/11327602

DMI2PXO	DI	DMI2PXO
DMI2PXO	DN	5-Biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione
DMI2PXO	MI	TTLM12X
DMI2PXO	MN	Matrix metalloproteinase-2 (MMP-2)
DMI2PXO	MT	DTT
DMI2PXO	MA	Inhibitor
DMI2PXO	RN	Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. Bioorg Med Chem Lett. 2001 Apr 23;11(8):969-72.
DMI2PXO	RU	https://pubmed.ncbi.nlm.nih.gov/11327602

DMI2PXO	DI	DMI2PXO
DMI2PXO	DN	5-Biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione
DMI2PXO	MI	TT6X50U
DMI2PXO	MN	Matrix metalloproteinase-9 (MMP-9)
DMI2PXO	MT	DTT
DMI2PXO	MA	Inhibitor
DMI2PXO	RN	Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. Bioorg Med Chem Lett. 2001 Apr 23;11(8):969-72.
DMI2PXO	RU	https://pubmed.ncbi.nlm.nih.gov/11327602

DMMG9PV	DI	DMMG9PV
DMMG9PV	DN	5-Biphenyl-4-ylethynyl-pyrimidine
DMMG9PV	MI	TTHS256
DMMG9PV	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMMG9PV	MT	DTT
DMMG9PV	MA	Inhibitor
DMMG9PV	RN	Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: unexpected modulation of pharmacology with slight structural modifications to a 5... Bioorg Med Chem Lett. 2008 Jul 15;18(14):4098-101.
DMMG9PV	RU	https://pubmed.ncbi.nlm.nih.gov/18550372

DM6W0QI	DI	DM6W0QI
DM6W0QI	DN	5-Biphenyl-4-ylmethyl-1-isobutyl-1H-tetrazole
DM6W0QI	MI	TTMSFAW
DM6W0QI	MN	Cannabinoid receptor 2 (CB2)
DM6W0QI	MT	DTT
DM6W0QI	MA	Inhibitor
DM6W0QI	RN	New tetrazole-based selective anandamide uptake inhibitors. Bioorg Med Chem Lett. 2008 May 1;18(9):2820-4.
DM6W0QI	RU	https://pubmed.ncbi.nlm.nih.gov/18424134

DMCPIK5	DI	DMCPIK5
DMCPIK5	DN	5-Biphenyl-4-ylmethyl-2-isobutyl-2H-tetrazole
DMCPIK5	MI	TT6OEDT
DMCPIK5	MN	Cannabinoid receptor 1 (CB1)
DMCPIK5	MT	DTT
DMCPIK5	MA	Inhibitor
DMCPIK5	RN	New tetrazole-based selective anandamide uptake inhibitors. Bioorg Med Chem Lett. 2008 May 1;18(9):2820-4.
DMCPIK5	RU	https://pubmed.ncbi.nlm.nih.gov/18424134

DMCPIK5	DI	DMCPIK5
DMCPIK5	DN	5-Biphenyl-4-ylmethyl-2-isobutyl-2H-tetrazole
DMCPIK5	MI	TTMSFAW
DMCPIK5	MN	Cannabinoid receptor 2 (CB2)
DMCPIK5	MT	DTT
DMCPIK5	MA	Inhibitor
DMCPIK5	RN	New tetrazole-based selective anandamide uptake inhibitors. Bioorg Med Chem Lett. 2008 May 1;18(9):2820-4.
DMCPIK5	RU	https://pubmed.ncbi.nlm.nih.gov/18424134

DM7BWG5	DI	DM7BWG5
DM7BWG5	DN	5-BODMT
DM7BWG5	MI	TTCPG9S
DM7BWG5	MN	5-HT 1E receptor (HTR1E)
DM7BWG5	MT	DTT
DM7BWG5	MA	Agonist
DM7BWG5	RN	Toward selective drug development for the human 5-hydroxytryptamine 1E receptor: a comparison of 5-hydroxytryptamine 1E and 1F receptor structure-affinity relationships. J Pharmacol Exp Ther. 2011 Jun;337(3):860-7.
DM7BWG5	RU	https://pubmed.ncbi.nlm.nih.gov/21422162

DM7BWG5	DI	DM7BWG5
DM7BWG5	DN	5-BODMT
DM7BWG5	MI	TT0MI3F
DM7BWG5	MN	5-HT 1F receptor (HTR1F)
DM7BWG5	MT	DTT
DM7BWG5	MA	Agonist
DM7BWG5	RN	Toward selective drug development for the human 5-hydroxytryptamine 1E receptor: a comparison of 5-hydroxytryptamine 1E and 1F receptor structure-affinity relationships. J Pharmacol Exp Ther. 2011 Jun;337(3):860-7.
DM7BWG5	RU	https://pubmed.ncbi.nlm.nih.gov/21422162

DMPITR9	DI	DMPITR9
DMPITR9	DN	5-boronothiophene-2-carboxylic acid
DMPITR9	MI	TTLP6GN
DMPITR9	MN	Bacterial DD-carboxypeptidase (Bact vanYB)
DMPITR9	MT	DTT
DMPITR9	MA	Inhibitor
DMPITR9	RN	Synthesis and evaluation of 3-(dihydroxyboryl)benzoic acids as D,D-carboxypeptidase R39 inhibitors. J Med Chem. 2009 Oct 8;52(19):6097-106.
DMPITR9	RU	https://pubmed.ncbi.nlm.nih.gov/19731939

DM0HCG6	DI	DM0HCG6
DM0HCG6	DN	5-bromo orotate
DM0HCG6	MI	TT09NOX
DM0HCG6	MN	Plasmodium Dihydroorotase (Malaria dho)
DM0HCG6	MT	DTT
DM0HCG6	MA	Inhibitor
DM0HCG6	RN	Antimalarial activity of orotate analogs that inhibit dihydroorotase and dihydroorotate dehydrogenase. Biochem Pharmacol. 1992 Mar 17;43(6):1295-301.
DM0HCG6	RU	https://pubmed.ncbi.nlm.nih.gov/1348618

DM2QPHE	DI	DM2QPHE
DM2QPHE	DN	5-bromo-1H-indazole
DM2QPHE	MI	TTZUFI5
DM2QPHE	MN	Nitric-oxide synthase brain (NOS1)
DM2QPHE	MT	DTT
DM2QPHE	MA	Inhibitor
DM2QPHE	RN	4-substituted indazoles as new inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3177-80.
DM2QPHE	RU	https://pubmed.ncbi.nlm.nih.gov/17395463

DM4WVSB	DI	DM4WVSB
DM4WVSB	DN	5-bromo-2-(4-chlorophenylsulfonamido)benzoic acid
DM4WVSB	MI	TTZL0OI
DM4WVSB	MN	Methionine aminopeptidase 2 (METAP2)
DM4WVSB	MT	DTT
DM4WVSB	MA	Inhibitor
DM4WVSB	RN	Development of sulfonamide compounds as potent methionine aminopeptidase type II inhibitors with antiproliferative properties. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3574-7.
DM4WVSB	RU	https://pubmed.ncbi.nlm.nih.gov/16632353

DM2YL0T	DI	DM2YL0T
DM2YL0T	DN	5-Bromo-2-(4-hydroxy-phenyl)-quinolin-6-ol
DM2YL0T	MI	TTZAYWL
DM2YL0T	MN	Estrogen receptor (ESR)
DM2YL0T	MT	DTT
DM2YL0T	MA	Inhibitor
DM2YL0T	RN	ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5.
DM2YL0T	RU	https://pubmed.ncbi.nlm.nih.gov/16098741

DM2YL0T	DI	DM2YL0T
DM2YL0T	DN	5-Bromo-2-(4-hydroxy-phenyl)-quinolin-6-ol
DM2YL0T	MI	TTOM3J0
DM2YL0T	MN	Estrogen receptor beta (ESR2)
DM2YL0T	MT	DTT
DM2YL0T	MA	Inhibitor
DM2YL0T	RN	ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5.
DM2YL0T	RU	https://pubmed.ncbi.nlm.nih.gov/16098741

DMMI4H3	DI	DMMI4H3
DMMI4H3	DN	5-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline
DMMI4H3	MI	TTJQOD7
DMMI4H3	MN	5-HT 2A receptor (HTR2A)
DMMI4H3	MT	DTT
DMMI4H3	MA	Inhibitor
DMMI4H3	RN	Binding of beta-carbolines at 5-HT(2) serotonin receptors. Bioorg Med Chem Lett. 2003 Dec 15;13(24):4421-5.
DMMI4H3	RU	https://pubmed.ncbi.nlm.nih.gov/14643338

DMMI4H3	DI	DMMI4H3
DMMI4H3	DN	5-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline
DMMI4H3	MI	TT3WG5C
DMMI4H3	MN	Monoamine oxidase type A (MAO-A)
DMMI4H3	MT	DTT
DMMI4H3	MA	Inhibitor
DMMI4H3	RN	Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
DMMI4H3	RU	https://pubmed.ncbi.nlm.nih.gov/15013009

DMMI4H3	DI	DMMI4H3
DMMI4H3	DN	5-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline
DMMI4H3	MI	TTGP7BY
DMMI4H3	MN	Monoamine oxidase type B (MAO-B)
DMMI4H3	MT	DTT
DMMI4H3	MA	Inhibitor
DMMI4H3	RN	Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
DMMI4H3	RU	https://pubmed.ncbi.nlm.nih.gov/15013009

DM2SEFR	DI	DM2SEFR
DM2SEFR	DN	5-Bromo-4,9-dihydro-3H-beta-carboline
DM2SEFR	MI	TT3WG5C
DM2SEFR	MN	Monoamine oxidase type A (MAO-A)
DM2SEFR	MT	DTT
DM2SEFR	MA	Inhibitor
DM2SEFR	RN	Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
DM2SEFR	RU	https://pubmed.ncbi.nlm.nih.gov/15013009

DM2SEFR	DI	DM2SEFR
DM2SEFR	DN	5-Bromo-4,9-dihydro-3H-beta-carboline
DM2SEFR	MI	TTGP7BY
DM2SEFR	MN	Monoamine oxidase type B (MAO-B)
DM2SEFR	MT	DTT
DM2SEFR	MA	Inhibitor
DM2SEFR	RN	Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
DM2SEFR	RU	https://pubmed.ncbi.nlm.nih.gov/15013009

DMRY0OL	DI	DMRY0OL
DMRY0OL	DN	5-bromo-6-(cyclopropylamino)uracil hydrochloride
DMRY0OL	MI	TTO0IB8
DMRY0OL	MN	Thymidine phosphorylase (TYMP)
DMRY0OL	MT	DTT
DMRY0OL	MA	Inhibitor
DMRY0OL	RN	Design and synthesis of novel 5,6-disubstituted uracil derivatives as potent inhibitors of thymidine phosphorylase. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1335-7.
DMRY0OL	RU	https://pubmed.ncbi.nlm.nih.gov/16337119

DMZJE6M	DI	DMZJE6M
DMZJE6M	DN	5-bromo-6-hydrazinouracil hydrochloride
DMZJE6M	MI	TTO0IB8
DMZJE6M	MN	Thymidine phosphorylase (TYMP)
DMZJE6M	MT	DTT
DMZJE6M	MA	Inhibitor
DMZJE6M	RN	Design and synthesis of novel 5,6-disubstituted uracil derivatives as potent inhibitors of thymidine phosphorylase. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1335-7.
DMZJE6M	RU	https://pubmed.ncbi.nlm.nih.gov/16337119

DM157OQ	DI	DM157OQ
DM157OQ	DN	5-Bromo-6-methoxy-9H-beta-carboline
DM157OQ	MI	TT1F8OQ
DM157OQ	MN	IKKA messenger RNA (IKKA mRNA)
DM157OQ	MT	DTT
DM157OQ	MA	Inhibitor
DM157OQ	RN	Novel IKK inhibitors: beta-carbolines. Bioorg Med Chem Lett. 2003 Jul 21;13(14):2419-22.
DM157OQ	RU	https://pubmed.ncbi.nlm.nih.gov/12824047

DM157OQ	DI	DM157OQ
DM157OQ	DN	5-Bromo-6-methoxy-9H-beta-carboline
DM157OQ	MI	TTRPDBG
DM157OQ	MN	Inhibitor of nuclear factor kappa-B kinase (IKK)
DM157OQ	MT	DTT
DM157OQ	MA	Inhibitor
DM157OQ	RN	Novel IKK inhibitors: beta-carbolines. Bioorg Med Chem Lett. 2003 Jul 21;13(14):2419-22.
DM157OQ	RU	https://pubmed.ncbi.nlm.nih.gov/12824047

DM157OQ	DI	DM157OQ
DM157OQ	DN	5-Bromo-6-methoxy-9H-beta-carboline
DM157OQ	MI	TTJ3E9X
DM157OQ	MN	Inhibitor of nuclear factor kappa-B kinase beta (IKKB)
DM157OQ	MT	DTT
DM157OQ	MA	Inhibitor
DM157OQ	RN	Novel IKK inhibitors: beta-carbolines. Bioorg Med Chem Lett. 2003 Jul 21;13(14):2419-22.
DM157OQ	RU	https://pubmed.ncbi.nlm.nih.gov/12824047

DMTPRIW	DI	DMTPRIW
DMTPRIW	DN	5-Bromo-6-p-tolylamino-1H-pyrimidine-2,4-dione
DMTPRIW	MI	TT2GPK3
DMTPRIW	MN	DNA topoisomerase (TOP)
DMTPRIW	MT	DTT
DMTPRIW	MA	Inhibitor
DMTPRIW	RN	Inhibitors of Bacillus subtilis DNA polymerase III. Influence of modifications in the pyrimidine ring of anilino- and (benzylamino)pyrimidines. J Med Chem. 1986 May;29(5):676-81.
DMTPRIW	RU	https://pubmed.ncbi.nlm.nih.gov/3084785

DM09Y72	DI	DM09Y72
DM09Y72	DN	5-Bromo-8-imidazol-1-ylmethyl-chromen-4-one
DM09Y72	MI	TTSZLWK
DM09Y72	MN	Aromatase (CYP19A1)
DM09Y72	MT	DTT
DM09Y72	MA	Inhibitor
DM09Y72	RN	A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase. J Med Chem. 2001 Mar 1;44(5):672-80.
DM09Y72	RU	https://pubmed.ncbi.nlm.nih.gov/11262078

DMSVCJM	DI	DMSVCJM
DMSVCJM	DN	5-Bromo-8-piperazin-1-yl-imidazo[1,2-a]pyrazine
DMSVCJM	MI	TTNGILX
DMSVCJM	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMSVCJM	MT	DTT
DMSVCJM	MA	Inhibitor
DMSVCJM	RN	Synthesis and hypoglycemic activity of substituted 8-(1-piperazinyl)imidazo[1,2-a]pyrazines. J Med Chem. 1992 Oct 16;35(21):3845-57.
DMSVCJM	RU	https://pubmed.ncbi.nlm.nih.gov/1359141

DMSVCJM	DI	DMSVCJM
DMSVCJM	DN	5-Bromo-8-piperazin-1-yl-imidazo[1,2-a]pyrazine
DMSVCJM	MI	TT34BHT
DMSVCJM	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMSVCJM	MT	DTT
DMSVCJM	MA	Inhibitor
DMSVCJM	RN	Synthesis and hypoglycemic activity of substituted 8-(1-piperazinyl)imidazo[1,2-a]pyrazines. J Med Chem. 1992 Oct 16;35(21):3845-57.
DMSVCJM	RU	https://pubmed.ncbi.nlm.nih.gov/1359141

DMH908V	DI	DMH908V
DMH908V	DN	5-Bromomethyl-oxazolidin-(2Z)-ylideneamine
DMH908V	MI	TTZUFI5
DMH908V	MN	Nitric-oxide synthase brain (NOS1)
DMH908V	MT	DTT
DMH908V	MA	Inhibitor
DMH908V	RN	4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor. Bioorg Med Chem Lett. 2004 Jan 19;14(2):313-6.
DMH908V	RU	https://pubmed.ncbi.nlm.nih.gov/14698148

DMH908V	DI	DMH908V
DMH908V	DN	5-Bromomethyl-oxazolidin-(2Z)-ylideneamine
DMH908V	MI	TTF10I9
DMH908V	MN	Nitric-oxide synthase inducible (NOS2)
DMH908V	MT	DTT
DMH908V	MA	Inhibitor
DMH908V	RN	4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor. Bioorg Med Chem Lett. 2004 Jan 19;14(2):313-6.
DMH908V	RU	https://pubmed.ncbi.nlm.nih.gov/14698148

DM37T5L	DI	DM37T5L
DM37T5L	DN	5-bromo-N-(quinolin-8-yl)thiophene-2-sulfonamide
DM37T5L	MI	TTSXVID
DM37T5L	MN	Nuclear factor NF-kappa-B (NFKB)
DM37T5L	MT	DTT
DM37T5L	MA	Inhibitor
DM37T5L	RN	Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFkappaB activity within two separate high-throughput s... Bioorg Med Chem Lett. 2008 Jan 1;18(1):329-35.
DM37T5L	RU	https://pubmed.ncbi.nlm.nih.gov/18024113

DMZ8X3H	DI	DMZ8X3H
DMZ8X3H	DN	5-Bromothienyldeoxyuridine
DMZ8X3H	MI	TTP3QRF
DMZ8X3H	MN	Thymidine kinase 1 (TK1)
DMZ8X3H	MT	DTT
DMZ8X3H	MA	Inhibitor
DMZ8X3H	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMZ8X3H	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMEVRH4	DI	DMEVRH4
DMEVRH4	DN	5BrUTP
DMEVRH4	MI	TTOZHQC
DMEVRH4	MN	P2Y purinoceptor 2 (P2RY2)
DMEVRH4	MT	DTT
DMEVRH4	MA	Agonist
DMEVRH4	RN	Pharmacological selectivity of the cloned human P2U-purinoceptor: potent activation by diadenosine tetraphosphate. Br J Pharmacol. 1995 Sep;116(1):1619-27.
DMEVRH4	RU	https://pubmed.ncbi.nlm.nih.gov/8564228

DMEVRH4	DI	DMEVRH4
DMEVRH4	DN	5BrUTP
DMEVRH4	MI	TTNVSKA
DMEVRH4	MN	P2Y purinoceptor 6 (P2RY6)
DMEVRH4	MT	DTT
DMEVRH4	MA	Agonist
DMEVRH4	RN	Cloning, functional expression and tissue distribution of the human P2Y6 receptor. Biochem Biophys Res Commun. 1996 May 15;222(2):303-8.
DMEVRH4	RU	https://pubmed.ncbi.nlm.nih.gov/8670200

DMXKQFM	DI	DMXKQFM
DMXKQFM	DN	5-Butyl-1H-pyrazole-3-carboxylic acid
DMXKQFM	MI	TTWNV8U
DMXKQFM	MN	Nicotinic acid receptor (HCAR2)
DMXKQFM	MT	DTT
DMXKQFM	MA	Inhibitor
DMXKQFM	RN	Pyrazole derivatives as partial agonists for the nicotinic acid receptor. J Med Chem. 2003 Aug 28;46(18):3945-51.
DMXKQFM	RU	https://pubmed.ncbi.nlm.nih.gov/12930155

DMCNU6I	DI	DMCNU6I
DMCNU6I	DN	5-butyl-2-(2,4-dichlorophenoxy)phenol
DMCNU6I	MI	TTNX2CS
DMCNU6I	MN	Plasmodium Enoyl-ACP reductase (Malaria fabI)
DMCNU6I	MT	DTT
DMCNU6I	MA	Inhibitor
DMCNU6I	RN	Design and in silico screening of combinatorial library of antimalarial analogs of triclosan inhibiting Plasmodium falciparum enoyl-acyl carrier pr... Eur J Med Chem. 2009 Jul;44(7):3009-19.
DMCNU6I	RU	https://pubmed.ncbi.nlm.nih.gov/19217192

DMI7DSM	DI	DMI7DSM
DMI7DSM	DN	5-butyl-2-(phenylsulfonamido)benzoic acid
DMI7DSM	MI	TTZL0OI
DMI7DSM	MN	Methionine aminopeptidase 2 (METAP2)
DMI7DSM	MT	DTT
DMI7DSM	MA	Inhibitor
DMI7DSM	RN	Development of sulfonamide compounds as potent methionine aminopeptidase type II inhibitors with antiproliferative properties. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3574-7.
DMI7DSM	RU	https://pubmed.ncbi.nlm.nih.gov/16632353

DMFKMYV	DI	DMFKMYV
DMFKMYV	DN	5-butyl-6-chloropyrimidine-2,4(1H,3H)-dione
DMFKMYV	MI	TTO0IB8
DMFKMYV	MN	Thymidine phosphorylase (TYMP)
DMFKMYV	MT	DTT
DMFKMYV	MA	Inhibitor
DMFKMYV	RN	Discovery of 5-substituted-6-chlorouracils as efficient inhibitors of human thymidine phosphorylase. J Med Chem. 2007 Nov 29;50(24):6016-23.
DMFKMYV	RU	https://pubmed.ncbi.nlm.nih.gov/17963370

DM2EPFZ	DI	DM2EPFZ
DM2EPFZ	DN	5-Butyl-8-phenyl-3H-[1,2,4]triazolo[5,1-i]purine
DM2EPFZ	MI	TTM2AOE
DM2EPFZ	MN	Adenosine A2a receptor (ADORA2A)
DM2EPFZ	MT	DTT
DM2EPFZ	MA	Inhibitor
DM2EPFZ	RN	Facile synthesis of fused 1,2,4-triazolo[1,5-c]pyrimidine derivatives as human adenosine A3 receptor ligands. Bioorg Med Chem Lett. 2004 May 17;14(10):2443-6.
DM2EPFZ	RU	https://pubmed.ncbi.nlm.nih.gov/15109629

DM2EPFZ	DI	DM2EPFZ
DM2EPFZ	DN	5-Butyl-8-phenyl-3H-[1,2,4]triazolo[5,1-i]purine
DM2EPFZ	MI	TTJFY5U
DM2EPFZ	MN	Adenosine A3 receptor (ADORA3)
DM2EPFZ	MT	DTT
DM2EPFZ	MA	Inhibitor
DM2EPFZ	RN	Facile synthesis of fused 1,2,4-triazolo[1,5-c]pyrimidine derivatives as human adenosine A3 receptor ligands. Bioorg Med Chem Lett. 2004 May 17;14(10):2443-6.
DM2EPFZ	RU	https://pubmed.ncbi.nlm.nih.gov/15109629

DM0VGCX	DI	DM0VGCX
DM0VGCX	DN	5-butyl-methyl immidazole carboxylate 30
DM0VGCX	MI	TT8DBY3
DM0VGCX	MN	Angiotensin II receptor type-1 (AGTR1)
DM0VGCX	MT	DTT
DM0VGCX	MA	Antagonist
DM0VGCX	RN	The discovery of new potent non-peptide Angiotensin II AT1 receptor blockers: a concise synthesis, molecular docking studies and biological evaluation of N-substituted 5-butylimidazole derivatives. Eur J Med Chem. 2012 Sep;55:358-74.
DM0VGCX	RU	https://pubmed.ncbi.nlm.nih.gov/22889560

DM04WVH	DI	DM04WVH
DM04WVH	DN	5-Carbazol-9-yl-pentanoic acid
DM04WVH	MI	TTHWMFZ
DM04WVH	MN	Fatty acid-binding protein 4 (FABP4)
DM04WVH	MT	DTT
DM04WVH	MA	Inhibitor
DM04WVH	RN	Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4445-8.
DM04WVH	RU	https://pubmed.ncbi.nlm.nih.gov/15357969

DM04WVH	DI	DM04WVH
DM04WVH	DN	5-Carbazol-9-yl-pentanoic acid
DM04WVH	MI	TTNT2S6
DM04WVH	MN	Fatty acid-binding protein 5 (FABP5)
DM04WVH	MT	DTT
DM04WVH	MA	Inhibitor
DM04WVH	RN	Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4445-8.
DM04WVH	RU	https://pubmed.ncbi.nlm.nih.gov/15357969

DMIH7W1	DI	DMIH7W1
DMIH7W1	DN	5-Chloro-1-(4-chloro-benzyl)-1H-indole-2,3-dione
DMIH7W1	MI	TTEAID7
DMIH7W1	MN	Trypanosoma Cruzipain (Trypano CYSP)
DMIH7W1	MT	DTT
DMIH7W1	MA	Inhibitor
DMIH7W1	RN	Synthesis and evaluation of isatins and thiosemicarbazone derivatives against cruzain, falcipain-2 and rhodesain. Bioorg Med Chem Lett. 2003 Oct 20;13(20):3527-30.
DMIH7W1	RU	https://pubmed.ncbi.nlm.nih.gov/14505663

DMTJNY0	DI	DMTJNY0
DMTJNY0	DN	5-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamine
DMTJNY0	MI	TT1RS9F
DMTJNY0	MN	Acetylcholinesterase (AChE)
DMTJNY0	MT	DTT
DMTJNY0	MA	Inhibitor
DMTJNY0	RN	The synthesis and in vitro acetylcholinesterase and butyrylcholinesterase inhibitory activity of tacrine (Cognex ) derivaties, Bioorg. Med. Chem. Lett. 2(8):861-864 (1992).
DMTJNY0	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805454

DMOCYDU	DI	DMOCYDU
DMOCYDU	DN	5-chloro-1H-indazole
DMOCYDU	MI	TTZUFI5
DMOCYDU	MN	Nitric-oxide synthase brain (NOS1)
DMOCYDU	MT	DTT
DMOCYDU	MA	Inhibitor
DMOCYDU	RN	4-substituted indazoles as new inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3177-80.
DMOCYDU	RU	https://pubmed.ncbi.nlm.nih.gov/17395463

DMQ350F	DI	DMQ350F
DMQ350F	DN	5-chloro-1H-indole-2,3-dione
DMQ350F	MI	TTMF541
DMQ350F	MN	Liver carboxylesterase (CES1)
DMQ350F	MT	DTT
DMQ350F	MA	Inhibitor
DMQ350F	RN	Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85.
DMQ350F	RU	https://pubmed.ncbi.nlm.nih.gov/17378546

DMDZ8NA	DI	DMDZ8NA
DMDZ8NA	DN	5-chloro-2-(2-chloro-4-hydroxyphenoxy)phenol
DMDZ8NA	MI	TTNX2CS
DMDZ8NA	MN	Plasmodium Enoyl-ACP reductase (Malaria fabI)
DMDZ8NA	MT	DTT
DMDZ8NA	MA	Inhibitor
DMDZ8NA	RN	Synthesis, biological activity, and X-ray crystal structural analysis of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. ... Bioorg Med Chem Lett. 2005 Dec 1;15(23):5247-52.
DMDZ8NA	RU	https://pubmed.ncbi.nlm.nih.gov/16198563

DMAJ8BS	DI	DMAJ8BS
DMAJ8BS	DN	5-chloro-2-(2-chloro-4-nitrophenoxy)phenol
DMAJ8BS	MI	TTNX2CS
DMAJ8BS	MN	Plasmodium Enoyl-ACP reductase (Malaria fabI)
DMAJ8BS	MT	DTT
DMAJ8BS	MA	Inhibitor
DMAJ8BS	RN	Synthesis, biological activity, and X-ray crystal structural analysis of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. ... Bioorg Med Chem Lett. 2005 Dec 1;15(23):5247-52.
DMAJ8BS	RU	https://pubmed.ncbi.nlm.nih.gov/16198563

DMH4SLZ	DI	DMH4SLZ
DMH4SLZ	DN	5-Chloro-2-(2-methylquinolin-7-yl)benzonitrile
DMH4SLZ	MI	TTHS256
DMH4SLZ	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMH4SLZ	MT	DTT
DMH4SLZ	MA	Inhibitor
DMH4SLZ	RN	Structure-activity relationships in a novel series of 7-substituted-aryl quinolines and 5-substituted-aryl benzothiazoles at the metabotropic gluta... Bioorg Med Chem. 2010 May 1;18(9):3026-35.
DMH4SLZ	RU	https://pubmed.ncbi.nlm.nih.gov/20382541

DMCFIZN	DI	DMCFIZN
DMCFIZN	DN	5-Chloro-2-(4-hydroxy-phenyl)-benzooxazol-6-ol
DMCFIZN	MI	TTZAYWL
DMCFIZN	MN	Estrogen receptor (ESR)
DMCFIZN	MT	DTT
DMCFIZN	MA	Inhibitor
DMCFIZN	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMCFIZN	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMCFIZN	DI	DMCFIZN
DMCFIZN	DN	5-Chloro-2-(4-hydroxy-phenyl)-benzooxazol-6-ol
DMCFIZN	MI	TTOM3J0
DMCFIZN	MN	Estrogen receptor beta (ESR2)
DMCFIZN	MT	DTT
DMCFIZN	MA	Inhibitor
DMCFIZN	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMCFIZN	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMXNPSB	DI	DMXNPSB
DMXNPSB	DN	5-Chloro-2-(4-hydroxy-phenyl)-quinolin-6-ol
DMXNPSB	MI	TTZAYWL
DMXNPSB	MN	Estrogen receptor (ESR)
DMXNPSB	MT	DTT
DMXNPSB	MA	Inhibitor
DMXNPSB	RN	ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5.
DMXNPSB	RU	https://pubmed.ncbi.nlm.nih.gov/16098741

DMXNPSB	DI	DMXNPSB
DMXNPSB	DN	5-Chloro-2-(4-hydroxy-phenyl)-quinolin-6-ol
DMXNPSB	MI	TTOM3J0
DMXNPSB	MN	Estrogen receptor beta (ESR2)
DMXNPSB	MT	DTT
DMXNPSB	MA	Inhibitor
DMXNPSB	RN	ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5.
DMXNPSB	RU	https://pubmed.ncbi.nlm.nih.gov/16098741

DM9QBAZ	DI	DM9QBAZ
DM9QBAZ	DN	5-chloro-2-(4-phenylbutyl)isoindoline-1,3-dione
DM9QBAZ	MI	TTECBXN
DM9QBAZ	MN	Oxysterols receptor LXR-alpha (NR1H3)
DM9QBAZ	MT	DTT
DM9QBAZ	MA	Inhibitor
DM9QBAZ	RN	Liver X receptor antagonists with a phthalimide skeleton derived from thalidomide-related glucosidase inhibitors. Bioorg Med Chem Lett. 2007 Jul 15;17(14):3957-61.
DM9QBAZ	RU	https://pubmed.ncbi.nlm.nih.gov/17498949

DMJBHR9	DI	DMJBHR9
DMJBHR9	DN	5-chloro-2-(pyridin-2-yl)-1H-benzo[d]imidazole
DMJBHR9	MI	TTZL0OI
DMJBHR9	MN	Methionine aminopeptidase 2 (METAP2)
DMJBHR9	MT	DTT
DMJBHR9	MA	Inhibitor
DMJBHR9	RN	Subtype-selectivity of metal-dependent methionine aminopeptidase inhibitors, Bioorg. Med. Chem. Lett. 20(14):4038-4044 (2010).
DMJBHR9	RU	http://www.sciencedirect.com/science/article/pii/S0960894X10007468

DM6YBZR	DI	DM6YBZR
DM6YBZR	DN	5-Chloro-2-methyl-3H-quinazolin-4-one
DM6YBZR	MI	TTVDSZ0
DM6YBZR	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DM6YBZR	MT	DTT
DM6YBZR	MA	Inhibitor
DM6YBZR	RN	Rational approaches to discovery of orally active and brain-penetrable quinazolinone inhibitors of poly(ADP-ribose)polymerase. J Med Chem. 2004 Aug 12;47(17):4151-4.
DM6YBZR	RU	https://pubmed.ncbi.nlm.nih.gov/15293985

DMKEFJ0	DI	DMKEFJ0
DMKEFJ0	DN	5-chloro-3,4-dihydroquinazolin-2-amine
DMKEFJ0	MI	TTSQIFT
DMKEFJ0	MN	5-HT 1A receptor (HTR1A)
DMKEFJ0	MT	DTT
DMKEFJ0	MA	Inhibitor
DMKEFJ0	RN	Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61.
DMKEFJ0	RU	https://pubmed.ncbi.nlm.nih.gov/17998160

DMKEFJ0	DI	DMKEFJ0
DMKEFJ0	DN	5-chloro-3,4-dihydroquinazolin-2-amine
DMKEFJ0	MI	TT6MSOK
DMKEFJ0	MN	5-HT 1D receptor (HTR1D)
DMKEFJ0	MT	DTT
DMKEFJ0	MA	Inhibitor
DMKEFJ0	RN	Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61.
DMKEFJ0	RU	https://pubmed.ncbi.nlm.nih.gov/17998160

DMKEFJ0	DI	DMKEFJ0
DMKEFJ0	DN	5-chloro-3,4-dihydroquinazolin-2-amine
DMKEFJ0	MI	TTJQOD7
DMKEFJ0	MN	5-HT 2A receptor (HTR2A)
DMKEFJ0	MT	DTT
DMKEFJ0	MA	Inhibitor
DMKEFJ0	RN	Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61.
DMKEFJ0	RU	https://pubmed.ncbi.nlm.nih.gov/17998160

DMKEFJ0	DI	DMKEFJ0
DMKEFJ0	DN	5-chloro-3,4-dihydroquinazolin-2-amine
DMKEFJ0	MI	TTWJBZ5
DMKEFJ0	MN	5-HT 2C receptor (HTR2C)
DMKEFJ0	MT	DTT
DMKEFJ0	MA	Inhibitor
DMKEFJ0	RN	Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61.
DMKEFJ0	RU	https://pubmed.ncbi.nlm.nih.gov/17998160

DMKEFJ0	DI	DMKEFJ0
DMKEFJ0	DN	5-chloro-3,4-dihydroquinazolin-2-amine
DMKEFJ0	MI	TTPC4TU
DMKEFJ0	MN	5-HT 3A receptor (HTR3A)
DMKEFJ0	MT	DTT
DMKEFJ0	MA	Inhibitor
DMKEFJ0	RN	Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61.
DMKEFJ0	RU	https://pubmed.ncbi.nlm.nih.gov/17998160

DMKEFJ0	DI	DMKEFJ0
DMKEFJ0	DN	5-chloro-3,4-dihydroquinazolin-2-amine
DMKEFJ0	MI	TTRUFDT
DMKEFJ0	MN	5-HT 5A receptor (HTR5A)
DMKEFJ0	MT	DTT
DMKEFJ0	MA	Inhibitor
DMKEFJ0	RN	Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61.
DMKEFJ0	RU	https://pubmed.ncbi.nlm.nih.gov/17998160

DMKEFJ0	DI	DMKEFJ0
DMKEFJ0	DN	5-chloro-3,4-dihydroquinazolin-2-amine
DMKEFJ0	MI	TTO9X1H
DMKEFJ0	MN	5-HT 7 receptor (HTR7)
DMKEFJ0	MT	DTT
DMKEFJ0	MA	Inhibitor
DMKEFJ0	RN	Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61.
DMKEFJ0	RU	https://pubmed.ncbi.nlm.nih.gov/17998160

DM207CQ	DI	DM207CQ
DM207CQ	DN	5-Chloro-3-ethyl-1-(4-fluoro-phenyl)-1H-indole
DM207CQ	MI	TTQ6VDM
DM207CQ	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DM207CQ	MT	DTT
DM207CQ	MA	Inhibitor
DM207CQ	RN	Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. Bioorg Med Chem Lett. 2003 May 19;13(10):1829-35.
DM207CQ	RU	https://pubmed.ncbi.nlm.nih.gov/12729675

DMGDTNI	DI	DMGDTNI
DMGDTNI	DN	5-chloro-4-ethyl-3,4-dihydroquinazolin-2-amine
DMGDTNI	MI	TTSQIFT
DMGDTNI	MN	5-HT 1A receptor (HTR1A)
DMGDTNI	MT	DTT
DMGDTNI	MA	Inhibitor
DMGDTNI	RN	Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61.
DMGDTNI	RU	https://pubmed.ncbi.nlm.nih.gov/17998160

DMGDTNI	DI	DMGDTNI
DMGDTNI	DN	5-chloro-4-ethyl-3,4-dihydroquinazolin-2-amine
DMGDTNI	MI	TTWJBZ5
DMGDTNI	MN	5-HT 2C receptor (HTR2C)
DMGDTNI	MT	DTT
DMGDTNI	MA	Inhibitor
DMGDTNI	RN	Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61.
DMGDTNI	RU	https://pubmed.ncbi.nlm.nih.gov/17998160

DMGDTNI	DI	DMGDTNI
DMGDTNI	DN	5-chloro-4-ethyl-3,4-dihydroquinazolin-2-amine
DMGDTNI	MI	TTRUFDT
DMGDTNI	MN	5-HT 5A receptor (HTR5A)
DMGDTNI	MT	DTT
DMGDTNI	MA	Inhibitor
DMGDTNI	RN	Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61.
DMGDTNI	RU	https://pubmed.ncbi.nlm.nih.gov/17998160

DMGDTNI	DI	DMGDTNI
DMGDTNI	DN	5-chloro-4-ethyl-3,4-dihydroquinazolin-2-amine
DMGDTNI	MI	TTO9X1H
DMGDTNI	MN	5-HT 7 receptor (HTR7)
DMGDTNI	MT	DTT
DMGDTNI	MA	Inhibitor
DMGDTNI	RN	Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61.
DMGDTNI	RU	https://pubmed.ncbi.nlm.nih.gov/17998160

DM7FZU2	DI	DM7FZU2
DM7FZU2	DN	5-chloro-4-methyl-3,4-dihydroquinazolin-2-amine
DM7FZU2	MI	TTSQIFT
DM7FZU2	MN	5-HT 1A receptor (HTR1A)
DM7FZU2	MT	DTT
DM7FZU2	MA	Inhibitor
DM7FZU2	RN	Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61.
DM7FZU2	RU	https://pubmed.ncbi.nlm.nih.gov/17998160

DM7FZU2	DI	DM7FZU2
DM7FZU2	DN	5-chloro-4-methyl-3,4-dihydroquinazolin-2-amine
DM7FZU2	MI	TT6MSOK
DM7FZU2	MN	5-HT 1D receptor (HTR1D)
DM7FZU2	MT	DTT
DM7FZU2	MA	Inhibitor
DM7FZU2	RN	Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61.
DM7FZU2	RU	https://pubmed.ncbi.nlm.nih.gov/17998160

DM7FZU2	DI	DM7FZU2
DM7FZU2	DN	5-chloro-4-methyl-3,4-dihydroquinazolin-2-amine
DM7FZU2	MI	TTWJBZ5
DM7FZU2	MN	5-HT 2C receptor (HTR2C)
DM7FZU2	MT	DTT
DM7FZU2	MA	Inhibitor
DM7FZU2	RN	Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61.
DM7FZU2	RU	https://pubmed.ncbi.nlm.nih.gov/17998160

DM7FZU2	DI	DM7FZU2
DM7FZU2	DN	5-chloro-4-methyl-3,4-dihydroquinazolin-2-amine
DM7FZU2	MI	TTRUFDT
DM7FZU2	MN	5-HT 5A receptor (HTR5A)
DM7FZU2	MT	DTT
DM7FZU2	MA	Inhibitor
DM7FZU2	RN	Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61.
DM7FZU2	RU	https://pubmed.ncbi.nlm.nih.gov/17998160

DM7FZU2	DI	DM7FZU2
DM7FZU2	DN	5-chloro-4-methyl-3,4-dihydroquinazolin-2-amine
DM7FZU2	MI	TTO9X1H
DM7FZU2	MN	5-HT 7 receptor (HTR7)
DM7FZU2	MT	DTT
DM7FZU2	MA	Inhibitor
DM7FZU2	RN	Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61.
DM7FZU2	RU	https://pubmed.ncbi.nlm.nih.gov/17998160

DMRS82Q	DI	DMRS82Q
DMRS82Q	DN	5-chloro-4-nitrothiophene-2-sulfonamide
DMRS82Q	MI	TTSFWA7
DMRS82Q	MN	Plasmodium CDK Pfmrk (Malaria Pfmrk)
DMRS82Q	MT	DTT
DMRS82Q	MA	Inhibitor
DMRS82Q	RN	Activity of substituted thiophene sulfonamides against malarial and mammalian cyclin dependent protein kinases, Bioorg. Med. Chem. Lett. 20(13):3863-3867 (2010).
DMRS82Q	RU	http://www.sciencedirect.com/science/article/pii/S0960894X10006803

DMMT7WO	DI	DMMT7WO
DMMT7WO	DN	5-chloro-6-hydrazinouracil hydrochloride
DMMT7WO	MI	TTO0IB8
DMMT7WO	MN	Thymidine phosphorylase (TYMP)
DMMT7WO	MT	DTT
DMMT7WO	MA	Inhibitor
DMMT7WO	RN	Design and synthesis of novel 5,6-disubstituted uracil derivatives as potent inhibitors of thymidine phosphorylase. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1335-7.
DMMT7WO	RU	https://pubmed.ncbi.nlm.nih.gov/16337119

DM2SKP7	DI	DM2SKP7
DM2SKP7	DN	5-Chloro-N-(4-ethylphenyl)benzo[d]oxazol-2-amine
DM2SKP7	MI	TT2J34L
DM2SKP7	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM2SKP7	MT	DTT
DM2SKP7	MA	Inhibitor
DM2SKP7	RN	Synthesis and evaluation of benzoxazole derivatives as 5-lipoxygenase inhibitors. Bioorg Med Chem. 2010 Nov 1;18(21):7580-5.
DM2SKP7	RU	https://pubmed.ncbi.nlm.nih.gov/20870413

DMZ5MDY	DI	DMZ5MDY
DMZ5MDY	DN	5-chloro-N-(pyridin-3-yl)indoline-1-carboxamide
DMZ5MDY	MI	TTJQOD7
DMZ5MDY	MN	5-HT 2A receptor (HTR2A)
DMZ5MDY	MT	DTT
DMZ5MDY	MA	Inhibitor
DMZ5MDY	RN	Synthesis and structure-affinity relationships of novel small molecule natural product derivatives capable of discriminating between serotonin 5-HT1A, 5-HT2A, 5-HT2C receptor subtypes. Bioorg Med Chem. 2010 Jul 1;18(13):4783-92. 
DMZ5MDY	RU	https://pubmed.ncbi.nlm.nih.gov/20570529

DMZ5MDY	DI	DMZ5MDY
DMZ5MDY	DN	5-chloro-N-(pyridin-3-yl)indoline-1-carboxamide
DMZ5MDY	MI	TTWJBZ5
DMZ5MDY	MN	5-HT 2C receptor (HTR2C)
DMZ5MDY	MT	DTT
DMZ5MDY	MA	Inhibitor
DMZ5MDY	RN	Synthesis and structure-affinity relationships of novel small molecule natural product derivatives capable of discriminating between serotonin 5-HT1A, 5-HT2A, 5-HT2C receptor subtypes. Bioorg Med Chem. 2010 Jul 1;18(13):4783-92. 
DMZ5MDY	RU	https://pubmed.ncbi.nlm.nih.gov/20570529

DMMV931	DI	DMMV931
DMMV931	DN	5-chloro-N-(quinolin-8-yl)thiophene-2-sulfonamide
DMMV931	MI	TTSXVID
DMMV931	MN	Nuclear factor NF-kappa-B (NFKB)
DMMV931	MT	DTT
DMMV931	MA	Inhibitor
DMMV931	RN	Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFkappaB activity within two separate high-throughput s... Bioorg Med Chem Lett. 2008 Jan 1;18(1):329-35.
DMMV931	RU	https://pubmed.ncbi.nlm.nih.gov/18024113

DMVQLFB	DI	DMVQLFB
DMVQLFB	DN	5-Chloro-N-phenylbenzo[d]oxazol-2-amine
DMVQLFB	MI	TT2J34L
DMVQLFB	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMVQLFB	MT	DTT
DMVQLFB	MA	Inhibitor
DMVQLFB	RN	Synthesis and evaluation of benzoxazole derivatives as 5-lipoxygenase inhibitors. Bioorg Med Chem. 2010 Nov 1;18(21):7580-5.
DMVQLFB	RU	https://pubmed.ncbi.nlm.nih.gov/20870413

DMH397E	DI	DMH397E
DMH397E	DN	5-Chlorosalicylic Acid
DMH397E	MI	TTHQPL7
DMH397E	MN	Carbonic anhydrase I (CA-I)
DMH397E	MT	DTT
DMH397E	MA	Inhibitor
DMH397E	RN	In vitro inhibition of salicylic acid derivatives on human cytosolic carbonic anhydrase isozymes I and II. Bioorg Med Chem. 2008 Oct 15;16(20):9101-5.
DMH397E	RU	https://pubmed.ncbi.nlm.nih.gov/18819808

DMH397E	DI	DMH397E
DMH397E	DN	5-Chlorosalicylic Acid
DMH397E	MI	TTANPDJ
DMH397E	MN	Carbonic anhydrase II (CA-II)
DMH397E	MT	DTT
DMH397E	MA	Inhibitor
DMH397E	RN	In vitro inhibition of salicylic acid derivatives on human cytosolic carbonic anhydrase isozymes I and II. Bioorg Med Chem. 2008 Oct 15;16(20):9101-5.
DMH397E	RU	https://pubmed.ncbi.nlm.nih.gov/18819808

DMWS3D6	DI	DMWS3D6
DMWS3D6	DN	5-Chloryl-2,4,6-Quinazolinetriamine
DMWS3D6	MI	TT9SL3Q
DMWS3D6	MN	Polypeptide deformylase (PDF)
DMWS3D6	MT	DTT
DMWS3D6	MA	Inhibitor
DMWS3D6	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMWS3D6	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM109IL	DI	DM109IL
DM109IL	DN	5-Cl-5-deoxy-(+/-)-ENBA
DM109IL	MI	TTK25J1
DM109IL	MN	Adenosine A1 receptor (ADORA1)
DM109IL	MT	DTT
DM109IL	MA	Agonist
DM109IL	RN	N6-Cycloalkyl- and N6-bicycloalkyl-C5'(C2')-modified adenosine derivatives as high-affinity and selective agonists at the human A1 adenosine recept... J Med Chem. 2009 Apr 23;52(8):2393-406.
DM109IL	RU	https://pubmed.ncbi.nlm.nih.gov/19317449

DM260KD	DI	DM260KD
DM260KD	DN	5-CT
DM260KD	MI	TTSQIFT
DM260KD	MN	5-HT 1A receptor (HTR1A)
DM260KD	MT	DTT
DM260KD	MA	Agonist
DM260KD	RN	Agonist activity of antimigraine drugs at recombinant human 5-HT1A receptors: potential implications for prophylactic and acute therapy. Naunyn Schmiedebergs Arch Pharmacol. 1997 Jun;355(6):682-8.
DM260KD	RU	https://pubmed.ncbi.nlm.nih.gov/9205951

DM260KD	DI	DM260KD
DM260KD	DN	5-CT
DM260KD	MI	TTK8CXU
DM260KD	MN	5-HT 1B receptor (HTR1B)
DM260KD	MT	DTT
DM260KD	MA	Agonist
DM260KD	RN	Mouse 5HT1B serotonin receptor: cloning, functional expression, and localization in motor control centers. Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):3020-4.
DM260KD	RU	https://pubmed.ncbi.nlm.nih.gov/1557407

DM260KD	DI	DM260KD
DM260KD	DN	5-CT
DM260KD	MI	TT6MSOK
DM260KD	MN	5-HT 1D receptor (HTR1D)
DM260KD	MT	DTT
DM260KD	MA	Agonist
DM260KD	RN	Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143-8.
DM260KD	RU	https://pubmed.ncbi.nlm.nih.gov/1652050

DM260KD	DI	DM260KD
DM260KD	DN	5-CT
DM260KD	MI	TTCPG9S
DM260KD	MN	5-HT 1E receptor (HTR1E)
DM260KD	MT	DTT
DM260KD	MA	Agonist
DM260KD	RN	Molecular cloning and pharmacological characterization of the guinea pig 5-HT1E receptor. Eur J Pharmacol. 2004 Jan 26;484(2-3):127-39.
DM260KD	RU	https://pubmed.ncbi.nlm.nih.gov/14744596

DM260KD	DI	DM260KD
DM260KD	DN	5-CT
DM260KD	MI	TT0MI3F
DM260KD	MN	5-HT 1F receptor (HTR1F)
DM260KD	MT	DTT
DM260KD	MA	Agonist
DM260KD	RN	Cloning and characterization of the guinea pig 5-HT1F receptor subtype: a comparison of the pharmacological profile to the human species homolog. Neuropharmacology. 1997 Apr-May;36(4-5):569-76.
DM260KD	RU	https://pubmed.ncbi.nlm.nih.gov/9225282

DM260KD	DI	DM260KD
DM260KD	DN	5-CT
DM260KD	MI	TTJQOD7
DM260KD	MN	5-HT 2A receptor (HTR2A)
DM260KD	MT	DTT
DM260KD	MA	Agonist
DM260KD	RN	Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
DM260KD	RU	https://pubmed.ncbi.nlm.nih.gov/15322733

DM260KD	DI	DM260KD
DM260KD	DN	5-CT
DM260KD	MI	TT0K1SC
DM260KD	MN	5-HT 2B receptor (HTR2B)
DM260KD	MT	DTT
DM260KD	MA	Agonist
DM260KD	RN	Pharmacological characteristics of the newly cloned rat 5-hydroxytryptamine2F receptor. Mol Pharmacol. 1993 Mar;43(3):419-26.
DM260KD	RU	https://pubmed.ncbi.nlm.nih.gov/8450835

DM260KD	DI	DM260KD
DM260KD	DN	5-CT
DM260KD	MI	TTWJBZ5
DM260KD	MN	5-HT 2C receptor (HTR2C)
DM260KD	MT	DTT
DM260KD	MA	Agonist
DM260KD	RN	Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors. Synapse. 2000 Feb;35(2):144-50.
DM260KD	RU	https://pubmed.ncbi.nlm.nih.gov/10611640

DM260KD	DI	DM260KD
DM260KD	DN	5-CT
DM260KD	MI	TTRUFDT
DM260KD	MN	5-HT 5A receptor (HTR5A)
DM260KD	MT	DTT
DM260KD	MA	Agonist
DM260KD	RN	Expression of functional mouse 5-HT5A serotonin receptor in the methylotrophic yeast Pichia pastoris: pharmacological characterization and localization. FEBS Lett. 1995 Dec 27;377(3):451-6.
DM260KD	RU	https://pubmed.ncbi.nlm.nih.gov/8549774

DM260KD	DI	DM260KD
DM260KD	DN	5-CT
DM260KD	MI	TTJS8PY
DM260KD	MN	5-HT 6 receptor (HTR6)
DM260KD	MT	DTT
DM260KD	MA	Agonist
DM260KD	RN	Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor. J Neurochem. 1996 Jan;66(1):47-56.
DM260KD	RU	https://pubmed.ncbi.nlm.nih.gov/8522988

DM260KD	DI	DM260KD
DM260KD	DN	5-CT
DM260KD	MI	TTO9X1H
DM260KD	MN	5-HT 7 receptor (HTR7)
DM260KD	MT	DTT
DM260KD	MA	Agonist
DM260KD	RN	Molecular cloning of a mammalian serotonin receptor that activates adenylate cyclase. Mol Pharmacol. 1993 Aug;44(2):229-36.
DM260KD	RU	https://pubmed.ncbi.nlm.nih.gov/8394987

DMMYENH	DI	DMMYENH
DMMYENH	DN	5-cyclohexyl-1,3,4-oxadiazole-2(3H)-thione
DMMYENH	MI	TTULVH8
DMMYENH	MN	Tyrosinase (TYR)
DMMYENH	MT	DTT
DMMYENH	MA	Inhibitor
DMMYENH	RN	New potent inhibitors of tyrosinase: novel clues to binding of 1,3,4-thiadiazole-2(3H)-thiones, 1,3,4-oxadiazole-2(3H)-thiones, 4-amino-1,2,4-triaz... Bioorg Med Chem. 2010 Jun 1;18(11):4042-8.
DMMYENH	RU	https://pubmed.ncbi.nlm.nih.gov/20452224

DMRFH9U	DI	DMRFH9U
DMRFH9U	DN	5'-deoxy-4'-hydroxy-5'-methylthio-DADMe-ImmH
DMRFH9U	MI	TTMCF1Y
DMRFH9U	MN	Purine nucleoside phosphorylase (PNP)
DMRFH9U	MT	DTT
DMRFH9U	MA	Inhibitor
DMRFH9U	RN	Immucillins in custom catalytic-site cavities. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5900-3.
DMRFH9U	RU	https://pubmed.ncbi.nlm.nih.gov/18778937

DMR28HG	DI	DMR28HG
DMR28HG	DN	5'-Deoxy-5'-(Methylthio)-Tubercidin
DMR28HG	MI	TTFSX6G
DMR28HG	MN	Bacterial MTA/SAH nucleosidase (Bact mtnN)
DMR28HG	MT	DTT
DMR28HG	MA	Inhibitor
DMR28HG	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMR28HG	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMR28HG	DI	DMR28HG
DMR28HG	DN	5'-Deoxy-5'-(Methylthio)-Tubercidin
DMR28HG	MI	TTDBX7N
DMR28HG	MN	S-methyl-5'-thioadenosine phosphorylase (MTAP)
DMR28HG	MT	DTT
DMR28HG	MA	Inhibitor
DMR28HG	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMR28HG	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMOHSY0	DI	DMOHSY0
DMOHSY0	DN	5'-Deoxy-5'-(N,N-dimethylamino)-8-methyladenosine
DMOHSY0	MI	TTBFROQ
DMOHSY0	MN	S-adenosylmethionine decarboxylase proenzyme (AMD1)
DMOHSY0	MT	DTT
DMOHSY0	MA	Inhibitor
DMOHSY0	RN	New insights into the design of inhibitors of human S-adenosylmethionine decarboxylase: studies of adenine C8 substitution in structural analogues ... J Med Chem. 2009 Mar 12;52(5):1388-407.
DMOHSY0	RU	https://pubmed.ncbi.nlm.nih.gov/19209891

DMF7JPO	DI	DMF7JPO
DMF7JPO	DN	5'-Deoxy-5'-(N,N-dimethylamino)adenosine
DMF7JPO	MI	TTBFROQ
DMF7JPO	MN	S-adenosylmethionine decarboxylase proenzyme (AMD1)
DMF7JPO	MT	DTT
DMF7JPO	MA	Inhibitor
DMF7JPO	RN	New insights into the design of inhibitors of human S-adenosylmethionine decarboxylase: studies of adenine C8 substitution in structural analogues ... J Med Chem. 2009 Mar 12;52(5):1388-407.
DMF7JPO	RU	https://pubmed.ncbi.nlm.nih.gov/19209891

DM6HGUL	DI	DM6HGUL
DM6HGUL	DN	5'-deoxy-5'-[(3-hydrazinopropyl)methylamino]adenosine
DM6HGUL	MI	TTVF2BJ
DM6HGUL	MN	Lactosylceramide alpha-2,3-sialyltransferase (ST3GAL5)
DM6HGUL	MT	DTT
DM6HGUL	MA	Inhibitor
DM6HGUL	RN	S-adenosylmethionine decarboxylase as an enzyme target for therapy. Pharmacol Ther. 1992 Dec;56(3):359-77.
DM6HGUL	RU	https://pubmed.ncbi.nlm.nih.gov/1301596

DM6HGUL	DI	DM6HGUL
DM6HGUL	DN	5'-deoxy-5'-[(3-hydrazinopropyl)methylamino]adenosine
DM6HGUL	MI	TTBFROQ
DM6HGUL	MN	S-adenosylmethionine decarboxylase proenzyme (AMD1)
DM6HGUL	MT	DTT
DM6HGUL	MA	Inhibitor
DM6HGUL	RN	S-adenosylmethionine decarboxylase as an enzyme target for therapy. Pharmacol Ther. 1992 Dec;56(3):359-77.
DM6HGUL	RU	https://pubmed.ncbi.nlm.nih.gov/1301596

DM1NAMK	DI	DM1NAMK
DM1NAMK	DN	5'-Deoxy-5'-dimethylsulfonioadenosine chloride
DM1NAMK	MI	TTBFROQ
DM1NAMK	MN	S-adenosylmethionine decarboxylase proenzyme (AMD1)
DM1NAMK	MT	DTT
DM1NAMK	MA	Inhibitor
DM1NAMK	RN	New insights into the design of inhibitors of human S-adenosylmethionine decarboxylase: studies of adenine C8 substitution in structural analogues ... J Med Chem. 2009 Mar 12;52(5):1388-407.
DM1NAMK	RU	https://pubmed.ncbi.nlm.nih.gov/19209891

DMU4MCK	DI	DMU4MCK
DMU4MCK	DN	5'-Deoxy-5'-phenyladenophostin A
DMU4MCK	MI	TTC9IZL
DMU4MCK	MN	Inositol 1,4,5-trisphosphate receptor (ITPR)
DMU4MCK	MT	DTT
DMU4MCK	MA	Inhibitor
DMU4MCK	RN	Synthesis of adenophostin A analogues conjugating an aromatic group at the 5'-position as potent IP3 receptor ligands. J Med Chem. 2006 Sep 21;49(19):5750-8.
DMU4MCK	RU	https://pubmed.ncbi.nlm.nih.gov/16970399

DM65XZJ	DI	DM65XZJ
DM65XZJ	DN	5-deoxy-5-phosphono-D-arabinonate
DM65XZJ	MI	TTZ3IFB
DM65XZJ	MN	Phosphogluconate dehydrogenase (PGD)
DM65XZJ	MT	DTT
DM65XZJ	MA	Inhibitor
DM65XZJ	RN	Sugar derivatives as new 6-phosphogluconate dehydrogenase inhibitors selective for the parasite Trypanosoma brucei. Bioorg Med Chem. 2003 Apr 3;11(7):1207-14.
DM65XZJ	RU	https://pubmed.ncbi.nlm.nih.gov/12628648

DM8IQX4	DI	DM8IQX4
DM8IQX4	DN	5'-deoxy-5'-ureidoadenosine
DM8IQX4	MI	TTE2KUJ
DM8IQX4	MN	Adenosylhomocysteinase (AHCY)
DM8IQX4	MT	DTT
DM8IQX4	MA	Inhibitor
DM8IQX4	RN	Design, synthesis, and molecular modeling studies of 5'-deoxy-5'-ureidoadenosine: 5'-ureido group as multiple hydrogen bonding donor in the active ... Bioorg Med Chem Lett. 2007 Aug 15;17(16):4456-9.
DM8IQX4	RU	https://pubmed.ncbi.nlm.nih.gov/17582766

DM1Q0BF	DI	DM1Q0BF
DM1Q0BF	DN	5-deoxyabyssinin II
DM1Q0BF	MI	TTELIN2
DM1Q0BF	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DM1Q0BF	MT	DTT
DM1Q0BF	MA	Inhibitor
DM1Q0BF	RN	Isoprenylated flavonoids from the stem bark of Erythrina abyssinica. J Nat Prod. 2007 Jun;70(6):1039-42.
DM1Q0BF	RU	https://pubmed.ncbi.nlm.nih.gov/17489632

DMR48NG	DI	DMR48NG
DMR48NG	DN	5'-deoxythymidine
DMR48NG	MI	TT5B8AX
DMR48NG	MN	Mycobacterium Thymidine monophosphate kinase (MycB tmk)
DMR48NG	MT	DTT
DMR48NG	MA	Inhibitor
DMR48NG	RN	Thymidylate kinase as target enzyme for 5'-deoxythymidine and various 5'-deoxy-5'-halogeno pyrimidine nucleosides. Acta Biol Med Ger. 1969;23(6):Suppl:K 19+.
DMR48NG	RU	https://pubmed.ncbi.nlm.nih.gov/5375492

DM6TM1L	DI	DM6TM1L
DM6TM1L	DN	5-desgalloylstachyurin
DM6TM1L	MI	TT6L509
DM6TM1L	MN	Coagulation factor IIa (F2)
DM6TM1L	MT	DTT
DM6TM1L	MA	Inhibitor
DM6TM1L	RN	Effects of tannins from Geum japonicum on the catalytic activity of thrombin and factor Xa of blood coagulation cascade. J Nat Prod. 1998 Nov;61(11):1356-60.
DM6TM1L	RU	https://pubmed.ncbi.nlm.nih.gov/9834152

DM6TM1L	DI	DM6TM1L
DM6TM1L	DN	5-desgalloylstachyurin
DM6TM1L	MI	TTCIHJA
DM6TM1L	MN	Coagulation factor Xa (F10)
DM6TM1L	MT	DTT
DM6TM1L	MA	Inhibitor
DM6TM1L	RN	Effects of tannins from Geum japonicum on the catalytic activity of thrombin and factor Xa of blood coagulation cascade. J Nat Prod. 1998 Nov;61(11):1356-60.
DM6TM1L	RU	https://pubmed.ncbi.nlm.nih.gov/9834152

DMX64E3	DI	DMX64E3
DMX64E3	DN	5-ethyl-2-(2-(pyrrolidin-1-yl)ethyl)pyridine
DMX64E3	MI	TT9JNIC
DMX64E3	MN	Histamine H3 receptor (H3R)
DMX64E3	MT	DTT
DMX64E3	MA	Inhibitor
DMX64E3	RN	In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9.
DMX64E3	RU	https://pubmed.ncbi.nlm.nih.gov/18077160

DM0E9O1	DI	DM0E9O1
DM0E9O1	DN	5-ethyl-2-(phenylsulfonamido)benzoic acid
DM0E9O1	MI	TTZL0OI
DM0E9O1	MN	Methionine aminopeptidase 2 (METAP2)
DM0E9O1	MT	DTT
DM0E9O1	MA	Inhibitor
DM0E9O1	RN	Development of sulfonamide compounds as potent methionine aminopeptidase type II inhibitors with antiproliferative properties. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3574-7.
DM0E9O1	RU	https://pubmed.ncbi.nlm.nih.gov/16632353

DMK57W2	DI	DMK57W2
DMK57W2	DN	5-Ethyl-3-(2-pyrrolidin-1-yl-ethyl)-1H-indole
DMK57W2	MI	TTK8CXU
DMK57W2	MN	5-HT 1B receptor (HTR1B)
DMK57W2	MT	DTT
DMK57W2	MA	Inhibitor
DMK57W2	RN	5-Alkyltryptamine derivatives as highly selective and potent 5-HT1D receptor agonists. Bioorg Med Chem Lett. 2000 Aug 7;10(15):1707-9.
DMK57W2	RU	https://pubmed.ncbi.nlm.nih.gov/10937729

DMK57W2	DI	DMK57W2
DMK57W2	DN	5-Ethyl-3-(2-pyrrolidin-1-yl-ethyl)-1H-indole
DMK57W2	MI	TT6MSOK
DMK57W2	MN	5-HT 1D receptor (HTR1D)
DMK57W2	MT	DTT
DMK57W2	MA	Inhibitor
DMK57W2	RN	5-Alkyltryptamine derivatives as highly selective and potent 5-HT1D receptor agonists. Bioorg Med Chem Lett. 2000 Aug 7;10(15):1707-9.
DMK57W2	RU	https://pubmed.ncbi.nlm.nih.gov/10937729

DMRIGXA	DI	DMRIGXA
DMRIGXA	DN	5-Ethyl-3,4-diphenyl-isoxazole
DMRIGXA	MI	TT8NGED
DMRIGXA	MN	Prostaglandin G/H synthase 1 (COX-1)
DMRIGXA	MT	DTT
DMRIGXA	MA	Inhibitor
DMRIGXA	RN	Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: reversal cyclooxygenase-2 selectivity by sulfonamide group removal. J Med Chem. 2004 Sep 23;47(20):4881-90.
DMRIGXA	RU	https://pubmed.ncbi.nlm.nih.gov/15369392

DMRIGXA	DI	DMRIGXA
DMRIGXA	DN	5-Ethyl-3,4-diphenyl-isoxazole
DMRIGXA	MI	TTVKILB
DMRIGXA	MN	Prostaglandin G/H synthase 2 (COX-2)
DMRIGXA	MT	DTT
DMRIGXA	MA	Inhibitor
DMRIGXA	RN	Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: reversal cyclooxygenase-2 selectivity by sulfonamide group removal. J Med Chem. 2004 Sep 23;47(20):4881-90.
DMRIGXA	RU	https://pubmed.ncbi.nlm.nih.gov/15369392

DMYD8GP	DI	DMYD8GP
DMYD8GP	DN	5-Ethyl-3-methyl-5-phenyl-oxazolidine-2,4-dione
DMYD8GP	MI	TTRK8B9
DMYD8GP	MN	Sodium channel unspecific (NaC)
DMYD8GP	MT	DTT
DMYD8GP	MA	Inhibitor
DMYD8GP	RN	Sodium channel binding and anticonvulsant activities for the enantiomers of a bicyclic 2,4-oxazolidinedione and monocyclic models. J Med Chem. 1989 Jul;32(7):1577-80.
DMYD8GP	RU	https://pubmed.ncbi.nlm.nih.gov/2544727

DMYD8GP	DI	DMYD8GP
DMYD8GP	DN	5-Ethyl-3-methyl-5-phenyl-oxazolidine-2,4-dione
DMYD8GP	MI	TTAXZ0K
DMYD8GP	MN	Voltage-gated sodium channel alpha Nav1.3 (SCN3A)
DMYD8GP	MT	DTT
DMYD8GP	MA	Inhibitor
DMYD8GP	RN	Sodium channel binding and anticonvulsant activities for the enantiomers of a bicyclic 2,4-oxazolidinedione and monocyclic models. J Med Chem. 1989 Jul;32(7):1577-80.
DMYD8GP	RU	https://pubmed.ncbi.nlm.nih.gov/2544727

DMS9TFC	DI	DMS9TFC
DMS9TFC	DN	5-Ethyl-3-methyl-pyrrolidin-(2Z)-ylideneamine
DMS9TFC	MI	TTZUFI5
DMS9TFC	MN	Nitric-oxide synthase brain (NOS1)
DMS9TFC	MT	DTT
DMS9TFC	MA	Inhibitor
DMS9TFC	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DMS9TFC	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DMS9TFC	DI	DMS9TFC
DMS9TFC	DN	5-Ethyl-3-methyl-pyrrolidin-(2Z)-ylideneamine
DMS9TFC	MI	TTCM4B3
DMS9TFC	MN	Nitric-oxide synthase endothelial (NOS3)
DMS9TFC	MT	DTT
DMS9TFC	MA	Inhibitor
DMS9TFC	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DMS9TFC	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DMQWOIG	DI	DMQWOIG
DMQWOIG	DN	5-Ethyl-4-methyl-pyrrolidin-(2Z)-ylideneamine
DMQWOIG	MI	TTZUFI5
DMQWOIG	MN	Nitric-oxide synthase brain (NOS1)
DMQWOIG	MT	DTT
DMQWOIG	MA	Inhibitor
DMQWOIG	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DMQWOIG	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DMQWOIG	DI	DMQWOIG
DMQWOIG	DN	5-Ethyl-4-methyl-pyrrolidin-(2Z)-ylideneamine
DMQWOIG	MI	TTCM4B3
DMQWOIG	MN	Nitric-oxide synthase endothelial (NOS3)
DMQWOIG	MT	DTT
DMQWOIG	MA	Inhibitor
DMQWOIG	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DMQWOIG	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DMQWOIG	DI	DMQWOIG
DMQWOIG	DN	5-Ethyl-4-methyl-pyrrolidin-(2Z)-ylideneamine
DMQWOIG	MI	TTF10I9
DMQWOIG	MN	Nitric-oxide synthase inducible (NOS2)
DMQWOIG	MT	DTT
DMQWOIG	MA	Inhibitor
DMQWOIG	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DMQWOIG	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DMSA8X2	DI	DMSA8X2
DMSA8X2	DN	5-Ethyl-4-propyl-pyrrolidin-(2Z)-ylideneamine
DMSA8X2	MI	TTZUFI5
DMSA8X2	MN	Nitric-oxide synthase brain (NOS1)
DMSA8X2	MT	DTT
DMSA8X2	MA	Inhibitor
DMSA8X2	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DMSA8X2	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DMSA8X2	DI	DMSA8X2
DMSA8X2	DN	5-Ethyl-4-propyl-pyrrolidin-(2Z)-ylideneamine
DMSA8X2	MI	TTF10I9
DMSA8X2	MN	Nitric-oxide synthase inducible (NOS2)
DMSA8X2	MT	DTT
DMSA8X2	MA	Inhibitor
DMSA8X2	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DMSA8X2	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DM8Y4G5	DI	DM8Y4G5
DM8Y4G5	DN	5-Ethyl-oxazolidin-(2Z)-ylideneamine
DM8Y4G5	MI	TTZUFI5
DM8Y4G5	MN	Nitric-oxide synthase brain (NOS1)
DM8Y4G5	MT	DTT
DM8Y4G5	MA	Inhibitor
DM8Y4G5	RN	4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor. Bioorg Med Chem Lett. 2004 Jan 19;14(2):313-6.
DM8Y4G5	RU	https://pubmed.ncbi.nlm.nih.gov/14698148

DM8Y4G5	DI	DM8Y4G5
DM8Y4G5	DN	5-Ethyl-oxazolidin-(2Z)-ylideneamine
DM8Y4G5	MI	TTF10I9
DM8Y4G5	MN	Nitric-oxide synthase inducible (NOS2)
DM8Y4G5	MT	DTT
DM8Y4G5	MA	Inhibitor
DM8Y4G5	RN	4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor. Bioorg Med Chem Lett. 2004 Jan 19;14(2):313-6.
DM8Y4G5	RU	https://pubmed.ncbi.nlm.nih.gov/14698148

DMLSC10	DI	DMLSC10
DMLSC10	DN	5-Fluoro orotate
DMLSC10	MI	TT09NOX
DMLSC10	MN	Plasmodium Dihydroorotase (Malaria dho)
DMLSC10	MT	DTT
DMLSC10	MA	Inhibitor
DMLSC10	RN	Antimalarial activity of orotate analogs that inhibit dihydroorotase and dihydroorotate dehydrogenase. Biochem Pharmacol. 1992 Mar 17;43(6):1295-301.
DMLSC10	RU	https://pubmed.ncbi.nlm.nih.gov/1348618

DMLSC10	DI	DMLSC10
DMLSC10	DN	5-Fluoro orotate
DMLSC10	MI	TT3PQ2Y
DMLSC10	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DMLSC10	MT	DTT
DMLSC10	MA	Inhibitor
DMLSC10	RN	Antimalarial activity of orotate analogs that inhibit dihydroorotase and dihydroorotate dehydrogenase. Biochem Pharmacol. 1992 Mar 17;43(6):1295-301.
DMLSC10	RU	https://pubmed.ncbi.nlm.nih.gov/1348618

DM9U1HV	DI	DM9U1HV
DM9U1HV	DN	5-fluoro-1H-indole-2-carboxylic acid
DM9U1HV	MI	TTHGL48
DM9U1HV	MN	AP endonuclease 1 (APEX1)
DM9U1HV	MT	DTT
DM9U1HV	MA	Inhibitor
DM9U1HV	RN	Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines. Br J Cancer. 2011 Feb 15;104(4):653-63.
DM9U1HV	RU	https://pubmed.ncbi.nlm.nih.gov/21266972

DMEA8WP	DI	DMEA8WP
DMEA8WP	DN	5-fluoro-2-(pyridin-2-yl)-1H-benzo[d]imidazole
DMEA8WP	MI	TTZL0OI
DMEA8WP	MN	Methionine aminopeptidase 2 (METAP2)
DMEA8WP	MT	DTT
DMEA8WP	MA	Inhibitor
DMEA8WP	RN	Subtype-selectivity of metal-dependent methionine aminopeptidase inhibitors, Bioorg. Med. Chem. Lett. 20(14):4038-4044 (2010).
DMEA8WP	RU	http://www.sciencedirect.com/science/article/pii/S0960894X10007468

DME1AGO	DI	DME1AGO
DME1AGO	DN	5-Fluoro-2'-Deoxyuridine-5'-Monophosphate
DME1AGO	MI	TTU6BFZ
DME1AGO	MN	Candida Thymidylate synthase (Candi TMP1)
DME1AGO	MT	DTT
DME1AGO	MA	Inhibitor
DME1AGO	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DME1AGO	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMOI7ME	DI	DMOI7ME
DMOI7ME	DN	5-Fluoro-2-hydroxy-N-isopropyl-benzamide
DMOI7ME	MI	TT64EPS
DMOI7ME	MN	Fungal Scytalone dehydratase (Fung SDH1)
DMOI7ME	MT	DTT
DMOI7ME	MA	Inhibitor
DMOI7ME	RN	Binding dynamics of two water molecules constrained within the scytalone dehydratase binding pocket. Bioorg Med Chem Lett. 2000 Jan 3;10(1):23-6.
DMOI7ME	RU	https://pubmed.ncbi.nlm.nih.gov/10636235

DMUCLAV	DI	DMUCLAV
DMUCLAV	DN	5-Fluoro-2-sulfanyl-phenylphosphonic acid
DMUCLAV	MI	TTHI19T
DMUCLAV	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMUCLAV	MT	DTT
DMUCLAV	MA	Inhibitor
DMUCLAV	RN	Mercaptophosphonate compounds as broad-spectrum inhibitors of the metallo-beta-lactamases. J Med Chem. 2010 Jul 8;53(13):4862-76.
DMUCLAV	RU	https://pubmed.ncbi.nlm.nih.gov/20527888

DM0OQTJ	DI	DM0OQTJ
DM0OQTJ	DN	5-Fluoro-3-thiophen-3-yl-quinoline
DM0OQTJ	MI	TT8FYO9
DM0OQTJ	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DM0OQTJ	MT	DTT
DM0OQTJ	MA	Inhibitor
DM0OQTJ	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DM0OQTJ	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMEV0GO	DI	DMEV0GO
DMEV0GO	DN	5-fluoro-6-[(2-aminoimidazol-1-yl)methyl]uracil
DMEV0GO	MI	TTO0IB8
DMEV0GO	MN	Thymidine phosphorylase (TYMP)
DMEV0GO	MT	DTT
DMEV0GO	MA	Inhibitor
DMEV0GO	RN	The role of phosphate in the action of thymidine phosphorylase inhibitors: Implications for the catalytic mechanism. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1648-51.
DMEV0GO	RU	https://pubmed.ncbi.nlm.nih.gov/20138520

DM6QHIA	DI	DM6QHIA
DM6QHIA	DN	5-fluoro-6-amino-UMP
DM6QHIA	MI	TTAFJUD
DM6QHIA	MN	Orotidine 5'-monophosphate decarboxylase (UMPS)
DM6QHIA	MT	DTT
DM6QHIA	MA	Inhibitor
DM6QHIA	RN	Structure-activity relationships of orotidine-5'-monophosphate decarboxylase inhibitors as anticancer agents. J Med Chem. 2009 Mar 26;52(6):1648-58.
DM6QHIA	RU	https://pubmed.ncbi.nlm.nih.gov/19260677

DMZLJRS	DI	DMZLJRS
DMZLJRS	DN	5-fluoro-6-azido-UMP
DMZLJRS	MI	TTAFJUD
DMZLJRS	MN	Orotidine 5'-monophosphate decarboxylase (UMPS)
DMZLJRS	MT	DTT
DMZLJRS	MA	Inhibitor
DMZLJRS	RN	Structure-activity relationships of orotidine-5'-monophosphate decarboxylase inhibitors as anticancer agents. J Med Chem. 2009 Mar 26;52(6):1648-58.
DMZLJRS	RU	https://pubmed.ncbi.nlm.nih.gov/19260677

DMTAZ71	DI	DMTAZ71
DMTAZ71	DN	5-Fluoro-6-ethyluridine-5'-O-monophosphate
DMTAZ71	MI	TTAFJUD
DMTAZ71	MN	Orotidine 5'-monophosphate decarboxylase (UMPS)
DMTAZ71	MT	DTT
DMTAZ71	MA	Inhibitor
DMTAZ71	RN	Structure-activity relationships of orotidine-5'-monophosphate decarboxylase inhibitors as anticancer agents. J Med Chem. 2009 Mar 26;52(6):1648-58.
DMTAZ71	RU	https://pubmed.ncbi.nlm.nih.gov/19260677

DM3LMIS	DI	DM3LMIS
DM3LMIS	DN	5-fluoro-6-iodo-UMP
DM3LMIS	MI	TTAFJUD
DM3LMIS	MN	Orotidine 5'-monophosphate decarboxylase (UMPS)
DM3LMIS	MT	DTT
DM3LMIS	MA	Inhibitor
DM3LMIS	RN	Structure-activity relationships of orotidine-5'-monophosphate decarboxylase inhibitors as anticancer agents. J Med Chem. 2009 Mar 26;52(6):1648-58.
DM3LMIS	RU	https://pubmed.ncbi.nlm.nih.gov/19260677

DMDV48S	DI	DMDV48S
DMDV48S	DN	5-Fluorolevulinic Acid
DMDV48S	MI	TTJHKYD
DMDV48S	MN	Delta-aminolevulinic acid dehydratase (ALAD)
DMDV48S	MT	DTT
DMDV48S	MA	Inhibitor
DMDV48S	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMDV48S	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM371WE	DI	DM371WE
DM371WE	DN	5-Formyl-6-Hydrofolic Acid
DM371WE	MI	TT9SL3Q
DM371WE	MN	Polypeptide deformylase (PDF)
DM371WE	MT	DTT
DM371WE	MA	Inhibitor
DM371WE	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM371WE	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMIARG7	DI	DMIARG7
DMIARG7	DN	5'-Guanosine-Diphosphate-Monothiophosphate
DMIARG7	MI	TT4W1VJ
DMIARG7	MN	Bacterial Celldivision protein FtsZ (Bact ftsZ)
DMIARG7	MT	DTT
DMIARG7	MA	Inhibitor
DMIARG7	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMIARG7	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM1SON5	DI	DM1SON5
DM1SON5	DN	5H-6-thia-4,5-diaza-chrysene 6,6-dioxide
DM1SON5	MI	TTSXVID
DM1SON5	MN	Nuclear factor NF-kappa-B (NFKB)
DM1SON5	MT	DTT
DM1SON5	MA	Inhibitor
DM1SON5	RN	Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFkappaB activity within two separate high-throughput s... Bioorg Med Chem Lett. 2008 Jan 1;18(1):329-35.
DM1SON5	RU	https://pubmed.ncbi.nlm.nih.gov/18024113

DMKUT6A	DI	DMKUT6A
DMKUT6A	DN	5-HEAT
DMKUT6A	MI	TT0WAIE
DMKUT6A	MN	Melatonin receptor type 1A (MTNR1A)
DMKUT6A	MT	DTT
DMKUT6A	MA	Agonist
DMKUT6A	RN	A new melatonin receptor ligand with mt1-agonist and MT2-antagonist properties. J Pineal Res. 2000 Nov;29(4):234-40.
DMKUT6A	RU	https://pubmed.ncbi.nlm.nih.gov/11068946

DMICKOU	DI	DMICKOU
DMICKOU	DN	5-Heptyl-5-phenyl-imidazolidine-2,4-dione
DMICKOU	MI	TTRK8B9
DMICKOU	MN	Sodium channel unspecific (NaC)
DMICKOU	MT	DTT
DMICKOU	MA	Inhibitor
DMICKOU	RN	Comparative molecular field analysis of hydantoin binding to the neuronal voltage-dependent sodium channel. J Med Chem. 1999 May 6;42(9):1537-45.
DMICKOU	RU	https://pubmed.ncbi.nlm.nih.gov/10229624

DMICKOU	DI	DMICKOU
DMICKOU	DN	5-Heptyl-5-phenyl-imidazolidine-2,4-dione
DMICKOU	MI	TTAXZ0K
DMICKOU	MN	Voltage-gated sodium channel alpha Nav1.3 (SCN3A)
DMICKOU	MT	DTT
DMICKOU	MA	Inhibitor
DMICKOU	RN	Comparative molecular field analysis of hydantoin binding to the neuronal voltage-dependent sodium channel. J Med Chem. 1999 May 6;42(9):1537-45.
DMICKOU	RU	https://pubmed.ncbi.nlm.nih.gov/10229624

DM49F6Z	DI	DM49F6Z
DM49F6Z	DN	5-heptyl-6-hydroxy-1,3-benzothiazole-4,7-dione
DM49F6Z	MI	TTRAMF0
DM49F6Z	MN	Plasmodium Cytochrome B (Malaria MT-CYB)
DM49F6Z	MT	DTT
DM49F6Z	MA	Inhibitor
DM49F6Z	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM49F6Z	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMHGQRF	DI	DMHGQRF
DMHGQRF	DN	5-Hex-5-enyl-2-nonyl-3,4-dihydro-2H-pyrrole
DMHGQRF	MI	TT1RS9F
DMHGQRF	MN	Acetylcholinesterase (AChE)
DMHGQRF	MT	DTT
DMHGQRF	MA	Inhibitor
DMHGQRF	RN	Acetylcholinesterase inhibition by alkaloids of the ant's venom Monomorium minutum, Bioorg. Med. Chem. Lett. 5(11):1131-1132 (1995).
DMHGQRF	RU	http://www.sciencedirect.com/science/article/pii/0960894X9500179W

DM0OJZF	DI	DM0OJZF
DM0OJZF	DN	5-hexyl-2-(2-nitrophenoxy)phenol
DM0OJZF	MI	TTVTX4N
DM0OJZF	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DM0OJZF	MT	DTT
DM0OJZF	MA	Inhibitor
DM0OJZF	RN	Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33.
DM0OJZF	RU	https://pubmed.ncbi.nlm.nih.gov/18457948

DM7EBQL	DI	DM7EBQL
DM7EBQL	DN	5-hexyl-2-(3-nitrophenoxy)phenol
DM7EBQL	MI	TTVTX4N
DM7EBQL	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DM7EBQL	MT	DTT
DM7EBQL	MA	Inhibitor
DM7EBQL	RN	Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33.
DM7EBQL	RU	https://pubmed.ncbi.nlm.nih.gov/18457948

DMNBLPA	DI	DMNBLPA
DMNBLPA	DN	5-hexyl-2-(4-nitrophenoxy)phenol
DMNBLPA	MI	TTVTX4N
DMNBLPA	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DMNBLPA	MT	DTT
DMNBLPA	MA	Inhibitor
DMNBLPA	RN	Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33.
DMNBLPA	RU	https://pubmed.ncbi.nlm.nih.gov/18457948

DM9263J	DI	DM9263J
DM9263J	DN	5-hexyl-2-(pyrazin-2-yloxy)phenol
DM9263J	MI	TTVTX4N
DM9263J	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DM9263J	MT	DTT
DM9263J	MA	Inhibitor
DM9263J	RN	Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33.
DM9263J	RU	https://pubmed.ncbi.nlm.nih.gov/18457948

DMLIMOP	DI	DMLIMOP
DMLIMOP	DN	5-hexyl-2-(pyridin-2-yloxy)phenol
DMLIMOP	MI	TTVTX4N
DMLIMOP	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DMLIMOP	MT	DTT
DMLIMOP	MA	Inhibitor
DMLIMOP	RN	Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33.
DMLIMOP	RU	https://pubmed.ncbi.nlm.nih.gov/18457948

DMHZT1S	DI	DMHZT1S
DMHZT1S	DN	5-hexyl-2-(pyridin-3-yloxy)phenol
DMHZT1S	MI	TTVTX4N
DMHZT1S	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DMHZT1S	MT	DTT
DMHZT1S	MA	Inhibitor
DMHZT1S	RN	Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33.
DMHZT1S	RU	https://pubmed.ncbi.nlm.nih.gov/18457948

DMP6U3L	DI	DMP6U3L
DMP6U3L	DN	5-hexyl-2-(pyridin-4-yloxy)phenol
DMP6U3L	MI	TTVTX4N
DMP6U3L	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DMP6U3L	MT	DTT
DMP6U3L	MA	Inhibitor
DMP6U3L	RN	Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33.
DMP6U3L	RU	https://pubmed.ncbi.nlm.nih.gov/18457948

DMNYOV3	DI	DMNYOV3
DMNYOV3	DN	5-hexyl-2-(pyrimidin-2-yloxy)phenol
DMNYOV3	MI	TTVTX4N
DMNYOV3	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DMNYOV3	MT	DTT
DMNYOV3	MA	Inhibitor
DMNYOV3	RN	Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33.
DMNYOV3	RU	https://pubmed.ncbi.nlm.nih.gov/18457948

DMHNRXT	DI	DMHNRXT
DMHNRXT	DN	5-hexyl-2-phenoxyphenol
DMHNRXT	MI	TTVTX4N
DMHNRXT	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DMHNRXT	MT	DTT
DMHNRXT	MA	Inhibitor
DMHNRXT	RN	Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33.
DMHNRXT	RU	https://pubmed.ncbi.nlm.nih.gov/18457948

DMCDUO1	DI	DMCDUO1
DMCDUO1	DN	5-Hexyl-5-phenyl-imidazolidine-2,4-dione
DMCDUO1	MI	TTRK8B9
DMCDUO1	MN	Sodium channel unspecific (NaC)
DMCDUO1	MT	DTT
DMCDUO1	MA	Inhibitor
DMCDUO1	RN	Comparative molecular field analysis of hydantoin binding to the neuronal voltage-dependent sodium channel. J Med Chem. 1999 May 6;42(9):1537-45.
DMCDUO1	RU	https://pubmed.ncbi.nlm.nih.gov/10229624

DMCDUO1	DI	DMCDUO1
DMCDUO1	DN	5-Hexyl-5-phenyl-imidazolidine-2,4-dione
DMCDUO1	MI	TTAXZ0K
DMCDUO1	MN	Voltage-gated sodium channel alpha Nav1.3 (SCN3A)
DMCDUO1	MT	DTT
DMCDUO1	MA	Inhibitor
DMCDUO1	RN	Comparative molecular field analysis of hydantoin binding to the neuronal voltage-dependent sodium channel. J Med Chem. 1999 May 6;42(9):1537-45.
DMCDUO1	RU	https://pubmed.ncbi.nlm.nih.gov/10229624

DM4S86L	DI	DM4S86L
DM4S86L	DN	5-Hexyl-5-phenyl-pyrimidine-2,4,6-trione
DM4S86L	MI	TTLM12X
DM4S86L	MN	Matrix metalloproteinase-2 (MMP-2)
DM4S86L	MT	DTT
DM4S86L	MA	Inhibitor
DM4S86L	RN	Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. Bioorg Med Chem Lett. 2001 Apr 23;11(8):969-72.
DM4S86L	RU	https://pubmed.ncbi.nlm.nih.gov/11327602

DM4S86L	DI	DM4S86L
DM4S86L	DN	5-Hexyl-5-phenyl-pyrimidine-2,4,6-trione
DM4S86L	MI	TT6X50U
DM4S86L	MN	Matrix metalloproteinase-9 (MMP-9)
DM4S86L	MT	DTT
DM4S86L	MA	Inhibitor
DM4S86L	RN	Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. Bioorg Med Chem Lett. 2001 Apr 23;11(8):969-72.
DM4S86L	RU	https://pubmed.ncbi.nlm.nih.gov/11327602

DM98OEQ	DI	DM98OEQ
DM98OEQ	DN	5-hydroxy-1H-indole-3-acetic acid
DM98OEQ	MI	TTGTQHC
DM98OEQ	MN	DNA topoisomerase I (TOP1)
DM98OEQ	MT	DTT
DM98OEQ	MA	Binder
DM98OEQ	RN	Comparison of responses of DNA topoisomerase I from Candida albicans and human cells to four new agents which stimulate topoisomerase-dependent DNA nicking. FEMS Microbiol Lett. 1996 May 1;138(2-3):105-11.
DM98OEQ	RU	https://pubmed.ncbi.nlm.nih.gov/9026436

DM5RI4H	DI	DM5RI4H
DM5RI4H	DN	5-hydroxy-1-tosyl-1H-pyrrol-2(5H)-one
DM5RI4H	MI	TTHQPL7
DM5RI4H	MN	Carbonic anhydrase I (CA-I)
DM5RI4H	MT	DTT
DM5RI4H	MA	Inhibitor
DM5RI4H	RN	A novel and one-pot synthesis of new 1-tosyl pyrrol-2-one derivatives and analysis of carbonic anhydrase inhibitory potencies. Bioorg Med Chem. 2010 Jun 15;18(12):4468-74.
DM5RI4H	RU	https://pubmed.ncbi.nlm.nih.gov/20554206

DM5RI4H	DI	DM5RI4H
DM5RI4H	DN	5-hydroxy-1-tosyl-1H-pyrrol-2(5H)-one
DM5RI4H	MI	TTANPDJ
DM5RI4H	MN	Carbonic anhydrase II (CA-II)
DM5RI4H	MT	DTT
DM5RI4H	MA	Inhibitor
DM5RI4H	RN	A novel and one-pot synthesis of new 1-tosyl pyrrol-2-one derivatives and analysis of carbonic anhydrase inhibitory potencies. Bioorg Med Chem. 2010 Jun 15;18(12):4468-74.
DM5RI4H	RU	https://pubmed.ncbi.nlm.nih.gov/20554206

DM8KON3	DI	DM8KON3
DM8KON3	DN	5-hydroxy-2-(4-aminophenyl)benzofuran
DM8KON3	MI	TTE4KHA
DM8KON3	MN	Amyloid beta A4 protein (APP)
DM8KON3	MT	DTT
DM8KON3	MA	Inhibitor
DM8KON3	RN	Novel benzofuran derivatives for PET imaging of beta-amyloid plaques in Alzheimer's disease brains. J Med Chem. 2006 May 4;49(9):2725-30.
DM8KON3	RU	https://pubmed.ncbi.nlm.nih.gov/16640332

DMYL0ZF	DI	DMYL0ZF
DMYL0ZF	DN	5-hydroxy-2-(4-dimethylaminophenyl)benzofuran
DMYL0ZF	MI	TTE4KHA
DMYL0ZF	MN	Amyloid beta A4 protein (APP)
DMYL0ZF	MT	DTT
DMYL0ZF	MA	Inhibitor
DMYL0ZF	RN	Novel benzofuran derivatives for PET imaging of beta-amyloid plaques in Alzheimer's disease brains. J Med Chem. 2006 May 4;49(9):2725-30.
DMYL0ZF	RU	https://pubmed.ncbi.nlm.nih.gov/16640332

DM4QC0R	DI	DM4QC0R
DM4QC0R	DN	5-hydroxy-2-(4-methylaminophenyl)benzofuran
DM4QC0R	MI	TTE4KHA
DM4QC0R	MN	Amyloid beta A4 protein (APP)
DM4QC0R	MT	DTT
DM4QC0R	MA	Inhibitor
DM4QC0R	RN	Novel benzofuran derivatives for PET imaging of beta-amyloid plaques in Alzheimer's disease brains. J Med Chem. 2006 May 4;49(9):2725-30.
DM4QC0R	RU	https://pubmed.ncbi.nlm.nih.gov/16640332

DMTO2L3	DI	DMTO2L3
DMTO2L3	DN	5-hydroxy-2-(pentylthiomethyl)-4H-pyran-4-one
DMTO2L3	MI	TTULVH8
DMTO2L3	MN	Tyrosinase (TYR)
DMTO2L3	MT	DTT
DMTO2L3	MA	Inhibitor
DMTO2L3	RN	Kojyl thioether derivatives having both tyrosinase inhibitory and anti-inflammatory properties. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6569-71.
DMTO2L3	RU	https://pubmed.ncbi.nlm.nih.gov/20934336

DM7M1RZ	DI	DM7M1RZ
DM7M1RZ	DN	5-hydroxy-2-(propylthiomethyl)-4H-pyran-4-one
DM7M1RZ	MI	TTULVH8
DM7M1RZ	MN	Tyrosinase (TYR)
DM7M1RZ	MT	DTT
DM7M1RZ	MA	Inhibitor
DM7M1RZ	RN	Kojyl thioether derivatives having both tyrosinase inhibitory and anti-inflammatory properties. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6569-71.
DM7M1RZ	RU	https://pubmed.ncbi.nlm.nih.gov/20934336

DMLZKNF	DI	DMLZKNF
DMLZKNF	DN	5-hydroxy-2-phenylisoindoline-1,3-dione
DMLZKNF	MI	TTZAYWL
DMLZKNF	MN	Estrogen receptor (ESR)
DMLZKNF	MT	DTT
DMLZKNF	MA	Inhibitor
DMLZKNF	RN	Estrogen receptor beta ligands: design and synthesis of new 2-phenyl-isoindole-1,3-diones. Bioorg Med Chem Lett. 2007 Jan 1;17(1):118-22.
DMLZKNF	RU	https://pubmed.ncbi.nlm.nih.gov/17049855

DMI0GMB	DI	DMI0GMB
DMI0GMB	DN	5-hydroxyindole
DMI0GMB	MI	TTPC4TU
DMI0GMB	MN	5-HT 3A receptor (HTR3A)
DMI0GMB	MT	DTT
DMI0GMB	MA	Modulator (allosteric modulator)
DMI0GMB	RN	The 5-HT3B subunit confers spontaneous channel opening and altered ligand properties of the 5-HT3 receptor. J Biol Chem. 2008 Mar 14;283(11):6826-31.
DMI0GMB	RU	https://pubmed.ncbi.nlm.nih.gov/18187416

DMDWZGJ	DI	DMDWZGJ
DMDWZGJ	DN	5-hydroxy-L-tryptophan
DMDWZGJ	MI	TTUYIZW
DMDWZGJ	MN	Solute carrier family 36 member 1 (SLC36A1)
DMDWZGJ	MT	DTT
DMDWZGJ	MA	Inhibitor
DMDWZGJ	RN	Serotonin, L-tryptophan, and tryptamine are effective inhibitors of the amino acid transport system PAT1. FASEB J. 2005 Sep;19(11):1468-73.
DMDWZGJ	RU	https://pubmed.ncbi.nlm.nih.gov/16126914

DMDWZGJ	DI	DMDWZGJ
DMDWZGJ	DN	5-hydroxy-L-tryptophan
DMDWZGJ	MI	TT5U0XA
DMDWZGJ	MN	Solute carrier family 36 member 2 (SLC36A2)
DMDWZGJ	MT	DTT
DMDWZGJ	MA	Inhibitor
DMDWZGJ	RN	Amino acid derivatives are substrates or non-transported inhibitors of the amino acid transporter PAT2 (slc36a2). Biochim Biophys Acta. 2011 Jan;1808(1):260-70.
DMDWZGJ	RU	https://pubmed.ncbi.nlm.nih.gov/20691150

DMT9FQN	DI	DMT9FQN
DMT9FQN	DN	5-Hydroxymethyl-3-pyrrol-1-yl-oxazolidin-2-one
DMT9FQN	MI	TT3WG5C
DMT9FQN	MN	Monoamine oxidase type A (MAO-A)
DMT9FQN	MT	DTT
DMT9FQN	MA	Inhibitor
DMT9FQN	RN	3-(1H-Pyrrol-1-yl)-2-oxazolidinones as reversible, highly potent, and selective inhibitors of monoamine oxidase type A. J Med Chem. 2002 Mar 14;45(6):1180-3.
DMT9FQN	RU	https://pubmed.ncbi.nlm.nih.gov/11881986

DMT9FQN	DI	DMT9FQN
DMT9FQN	DN	5-Hydroxymethyl-3-pyrrol-1-yl-oxazolidin-2-one
DMT9FQN	MI	TTGP7BY
DMT9FQN	MN	Monoamine oxidase type B (MAO-B)
DMT9FQN	MT	DTT
DMT9FQN	MA	Inhibitor
DMT9FQN	RN	3-(1H-Pyrrol-1-yl)-2-oxazolidinones as reversible, highly potent, and selective inhibitors of monoamine oxidase type A. J Med Chem. 2002 Mar 14;45(6):1180-3.
DMT9FQN	RU	https://pubmed.ncbi.nlm.nih.gov/11881986

DMN9FPV	DI	DMN9FPV
DMN9FPV	DN	5-hydroxymethylbenzo[b]thiophen-2-ylboronic acid
DMN9FPV	MI	TTHI19T
DMN9FPV	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMN9FPV	MT	DTT
DMN9FPV	MA	Inhibitor
DMN9FPV	RN	Optimizing cell permeation of an antibiotic resistance inhibitor for improved efficacy. J Med Chem. 2007 Nov 15;50(23):5644-54.
DMN9FPV	RU	https://pubmed.ncbi.nlm.nih.gov/17956081

DMZHVRW	DI	DMZHVRW
DMZHVRW	DN	5-Hydroxymethyl-Chonduritol
DMZHVRW	MI	TTCGSZ4
DMZHVRW	MN	Pancreatic alpha-amylase (AMY2A)
DMZHVRW	MT	DTT
DMZHVRW	MA	Inhibitor
DMZHVRW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMZHVRW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMWVCJ1	DI	DMWVCJ1
DMWVCJ1	DN	5-Hydroxymethyluridine-2'-Deoxy-5'-Monophosphate
DMWVCJ1	MI	TT5B8AX
DMWVCJ1	MN	Mycobacterium Thymidine monophosphate kinase (MycB tmk)
DMWVCJ1	MT	DTT
DMWVCJ1	MA	Inhibitor
DMWVCJ1	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMWVCJ1	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMMF57V	DI	DMMF57V
DMMF57V	DN	5-hydroxynaphthalene-1-sulfonamide
DMMF57V	MI	TT7HF4W
DMMF57V	MN	Cyclin-dependent kinase 2 (CDK2)
DMMF57V	MT	DTT
DMMF57V	MA	Inhibitor
DMMF57V	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMMF57V	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMJQFZH	DI	DMJQFZH
DMJQFZH	DN	5-hydroxy-pentanoate
DMJQFZH	MI	TT6TKEN
DMJQFZH	MN	Gamma-hydroxybutyrate receptor (SLC52A2)
DMJQFZH	MT	DTT
DMJQFZH	MA	Inhibitor
DMJQFZH	RN	Analogues of gamma-hydroxybutyric acid. Synthesis and binding studies. J Med Chem. 1988 May;31(5):893-7.
DMJQFZH	RU	https://pubmed.ncbi.nlm.nih.gov/3361576

DMIXQG6	DI	DMIXQG6
DMIXQG6	DN	5-hydroxyvaleric acid
DMIXQG6	MI	TTJHKYD
DMIXQG6	MN	Delta-aminolevulinic acid dehydratase (ALAD)
DMIXQG6	MT	DTT
DMIXQG6	MA	Inhibitor
DMIXQG6	RN	Structure of yeast 5-aminolaevulinic acid dehydratase complexed with the inhibitor 5-hydroxylaevulinic acid. Acta Crystallogr D Biol Crystallogr. 2005 Sep;61(Pt 9):1222-6.
DMIXQG6	RU	https://pubmed.ncbi.nlm.nih.gov/16131755

DMVSBHU	DI	DMVSBHU
DMVSBHU	DN	5-Imidazol-1-yl-5,6,7,8-tetrahydro-quinoline
DMVSBHU	MI	TTKNWZ4
DMVSBHU	MN	Thromboxane-A synthase (TBXAS1)
DMVSBHU	MT	DTT
DMVSBHU	MA	Inhibitor
DMVSBHU	RN	1-imidazolyl(alkyl)-substituted di- and tetrahydroquinolines and analogues: syntheses and evaluation of dual inhibitors of thromboxane A(2) synthas... J Med Chem. 2000 May 4;43(9):1841-51.
DMVSBHU	RU	https://pubmed.ncbi.nlm.nih.gov/10794700

DMW8AOM	DI	DMW8AOM
DMW8AOM	DN	5-Indan-(1E)-ylidenemethyl-1H-imidazole
DMW8AOM	MI	TTSZLWK
DMW8AOM	MN	Aromatase (CYP19A1)
DMW8AOM	MT	DTT
DMW8AOM	MA	Inhibitor
DMW8AOM	RN	Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase. J Med Chem. 2005 Mar 24;48(6):1796-805.
DMW8AOM	RU	https://pubmed.ncbi.nlm.nih.gov/15771425

DMW8AOM	DI	DMW8AOM
DMW8AOM	DN	5-Indan-(1E)-ylidenemethyl-1H-imidazole
DMW8AOM	MI	TTIQUX7
DMW8AOM	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMW8AOM	MT	DTT
DMW8AOM	MA	Inhibitor
DMW8AOM	RN	Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase. J Med Chem. 2005 Mar 24;48(6):1796-805.
DMW8AOM	RU	https://pubmed.ncbi.nlm.nih.gov/15771425

DMKLY20	DI	DMKLY20
DMKLY20	DN	5-Indan-(1Z)-ylidenemethyl-1H-imidazole
DMKLY20	MI	TTSZLWK
DMKLY20	MN	Aromatase (CYP19A1)
DMKLY20	MT	DTT
DMKLY20	MA	Inhibitor
DMKLY20	RN	Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase. J Med Chem. 2005 Mar 24;48(6):1796-805.
DMKLY20	RU	https://pubmed.ncbi.nlm.nih.gov/15771425

DMKLY20	DI	DMKLY20
DMKLY20	DN	5-Indan-(1Z)-ylidenemethyl-1H-imidazole
DMKLY20	MI	TTIQUX7
DMKLY20	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMKLY20	MT	DTT
DMKLY20	MA	Inhibitor
DMKLY20	RN	Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase. J Med Chem. 2005 Mar 24;48(6):1796-805.
DMKLY20	RU	https://pubmed.ncbi.nlm.nih.gov/15771425

DMDKFIO	DI	DMDKFIO
DMDKFIO	DN	5-iodo orotate
DMDKFIO	MI	TT09NOX
DMDKFIO	MN	Plasmodium Dihydroorotase (Malaria dho)
DMDKFIO	MT	DTT
DMDKFIO	MA	Inhibitor
DMDKFIO	RN	Antimalarial activity of orotate analogs that inhibit dihydroorotase and dihydroorotate dehydrogenase. Biochem Pharmacol. 1992 Mar 17;43(6):1295-301.
DMDKFIO	RU	https://pubmed.ncbi.nlm.nih.gov/1348618

DMVT2LW	DI	DMVT2LW
DMVT2LW	DN	5-iodo,5'-deoxytubercidin
DMVT2LW	MI	TTL732K
DMVT2LW	MN	Adenosine kinase (ADK)
DMVT2LW	MT	DTT
DMVT2LW	MA	Inhibitor
DMVT2LW	RN	Crystal structures of human adenosine kinase inhibitor complexes reveal two distinct binding modes. J Med Chem. 2006 Nov 16;49(23):6726-31.
DMVT2LW	RU	https://pubmed.ncbi.nlm.nih.gov/17154503

DM4NQY6	DI	DM4NQY6
DM4NQY6	DN	5-iodo-1H-indazole
DM4NQY6	MI	TTZUFI5
DM4NQY6	MN	Nitric-oxide synthase brain (NOS1)
DM4NQY6	MT	DTT
DM4NQY6	MA	Inhibitor
DM4NQY6	RN	4-substituted indazoles as new inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3177-80.
DM4NQY6	RU	https://pubmed.ncbi.nlm.nih.gov/17395463

DMZACXG	DI	DMZACXG
DMZACXG	DN	5-Iodo-2'-Deoxyuridine-5'-Monophosphate
DMZACXG	MI	TTP3QRF
DMZACXG	MN	Thymidine kinase 1 (TK1)
DMZACXG	MT	DTT
DMZACXG	MA	Inhibitor
DMZACXG	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMZACXG	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMQINY5	DI	DMQINY5
DMQINY5	DN	5'-iodoresiniferatoxin
DMQINY5	MI	TTKP2SU
DMQINY5	MN	Transient receptor potential cation channel V4 (TRPV4)
DMQINY5	MT	DTT
DMQINY5	MA	Inhibitor
DMQINY5	RN	N-4-methansulfonamidobenzyl-N'-2-substituted-4-tert-butyl-benzyl thioureas as potent vanilloid receptor antagonistic ligands. Bioorg Med Chem Lett. 2004 Apr 5;14(7):1693-6.
DMQINY5	RU	https://pubmed.ncbi.nlm.nih.gov/15026052

DML5ZEJ	DI	DML5ZEJ
DML5ZEJ	DN	5'-iodotubercidin
DML5ZEJ	MI	TTL732K
DML5ZEJ	MN	Adenosine kinase (ADK)
DML5ZEJ	MT	DTT
DML5ZEJ	MA	Inhibitor
DML5ZEJ	RN	Inhibition of adenosine kinase attenuates interleukin-1- and lipopolysaccharide-induced alterations in articular cartilage metabolism. Osteoarthritis Cartilage. 2005 Mar;13(3):250-7.
DML5ZEJ	RU	https://pubmed.ncbi.nlm.nih.gov/15727892

DM4O6I5	DI	DM4O6I5
DM4O6I5	DN	5-Iodouracil
DM4O6I5	MI	TTZPS91
DM4O6I5	MN	Dihydrothymine dehydrogenase (DPYD)
DM4O6I5	MT	DTT
DM4O6I5	MA	Inhibitor
DM4O6I5	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM4O6I5	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DME6BX5	DI	DME6BX5
DME6BX5	DN	5-Isopropyl-1H-pyrazole-3-carboxylic acid
DME6BX5	MI	TTWNV8U
DME6BX5	MN	Nicotinic acid receptor (HCAR2)
DME6BX5	MT	DTT
DME6BX5	MA	Inhibitor
DME6BX5	RN	Pyrazole derivatives as partial agonists for the nicotinic acid receptor. J Med Chem. 2003 Aug 28;46(18):3945-51.
DME6BX5	RU	https://pubmed.ncbi.nlm.nih.gov/12930155

DM2TNWO	DI	DM2TNWO
DM2TNWO	DN	5-isopropyl-2-(phenylamino)thiazol-4(5H)-one
DM2TNWO	MI	TTN7BL9
DM2TNWO	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DM2TNWO	MT	DTT
DM2TNWO	MA	Inhibitor
DM2TNWO	RN	The discovery of 2-anilinothiazolones as 11beta-HSD1 inhibitors. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6056-61.
DM2TNWO	RU	https://pubmed.ncbi.nlm.nih.gov/17919905

DMXGRMB	DI	DMXGRMB
DMXGRMB	DN	5-Isopropyl-3-(2-pyrrolidin-1-yl-ethyl)-1H-indole
DMXGRMB	MI	TTK8CXU
DMXGRMB	MN	5-HT 1B receptor (HTR1B)
DMXGRMB	MT	DTT
DMXGRMB	MA	Inhibitor
DMXGRMB	RN	5-Alkyltryptamine derivatives as highly selective and potent 5-HT1D receptor agonists. Bioorg Med Chem Lett. 2000 Aug 7;10(15):1707-9.
DMXGRMB	RU	https://pubmed.ncbi.nlm.nih.gov/10937729

DMXGRMB	DI	DMXGRMB
DMXGRMB	DN	5-Isopropyl-3-(2-pyrrolidin-1-yl-ethyl)-1H-indole
DMXGRMB	MI	TT6MSOK
DMXGRMB	MN	5-HT 1D receptor (HTR1D)
DMXGRMB	MT	DTT
DMXGRMB	MA	Inhibitor
DMXGRMB	RN	5-Alkyltryptamine derivatives as highly selective and potent 5-HT1D receptor agonists. Bioorg Med Chem Lett. 2000 Aug 7;10(15):1707-9.
DMXGRMB	RU	https://pubmed.ncbi.nlm.nih.gov/10937729

DMXVPL1	DI	DMXVPL1
DMXVPL1	DN	5-ketodihydromevinolin
DMXVPL1	MI	TTPADOQ
DMXVPL1	MN	HMG-CoA reductase (HMGCR)
DMXVPL1	MT	DTT
DMXVPL1	MA	Inhibitor
DMXVPL1	RN	Total synthesis and biological evaluation of structural analogues of compactin and dihydromevinolin. J Med Chem. 1987 Oct;30(10):1858-73.
DMXVPL1	RU	https://pubmed.ncbi.nlm.nih.gov/3656359

DMFZN7J	DI	DMFZN7J
DMFZN7J	DN	5-Me-IAA
DMFZN7J	MI	TT6XFEU
DMFZN7J	MN	GABA(A) receptor rho1 (GABRR1)
DMFZN7J	MT	DTT
DMFZN7J	MA	Agonist
DMFZN7J	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 420).
DMFZN7J	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=420

DMFZN7J	DI	DMFZN7J
DMFZN7J	DN	5-Me-IAA
DMFZN7J	MI	TTQMXLS
DMFZN7J	MN	GABA(A) receptor rho2 (GABRR2)
DMFZN7J	MT	DTT
DMFZN7J	MA	Agonist
DMFZN7J	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 421).
DMFZN7J	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=421

DMFZN7J	DI	DMFZN7J
DMFZN7J	DN	5-Me-IAA
DMFZN7J	MI	TT4N6D8
DMFZN7J	MN	GABA(A) receptor rho3 (GABRR3)
DMFZN7J	MT	DTT
DMFZN7J	MA	Agonist
DMFZN7J	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 422).
DMFZN7J	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=422

DMG0EL7	DI	DMG0EL7
DMG0EL7	DN	5-MEO-DMT
DMG0EL7	MI	TTJQOD7
DMG0EL7	MN	5-HT 2A receptor (HTR2A)
DMG0EL7	MT	DTT
DMG0EL7	MA	Inhibitor
DMG0EL7	RN	1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28.
DMG0EL7	RU	https://pubmed.ncbi.nlm.nih.gov/16392816

DMG0EL7	DI	DMG0EL7
DMG0EL7	DN	5-MEO-DMT
DMG0EL7	MI	TT0K1SC
DMG0EL7	MN	5-HT 2B receptor (HTR2B)
DMG0EL7	MT	DTT
DMG0EL7	MA	Inhibitor
DMG0EL7	RN	1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28.
DMG0EL7	RU	https://pubmed.ncbi.nlm.nih.gov/16392816

DMG0EL7	DI	DMG0EL7
DMG0EL7	DN	5-MEO-DMT
DMG0EL7	MI	TTWJBZ5
DMG0EL7	MN	5-HT 2C receptor (HTR2C)
DMG0EL7	MT	DTT
DMG0EL7	MA	Inhibitor
DMG0EL7	RN	1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28.
DMG0EL7	RU	https://pubmed.ncbi.nlm.nih.gov/16392816

DMG0EL7	DI	DMG0EL7
DMG0EL7	DN	5-MEO-DMT
DMG0EL7	MI	TTJS8PY
DMG0EL7	MN	5-HT 6 receptor (HTR6)
DMG0EL7	MT	DTT
DMG0EL7	MA	Inhibitor
DMG0EL7	RN	Interaction of N1-unsubstituted and N1-benzenesulfonyltryptamines at h5-HT6 receptors. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5832-5.
DMG0EL7	RU	https://pubmed.ncbi.nlm.nih.gov/16945532

DMG0EL7	DI	DMG0EL7
DMG0EL7	DN	5-MEO-DMT
DMG0EL7	MI	DECB0K3
DMG0EL7	MN	Cytochrome P450 2D6 (CYP2D6)
DMG0EL7	MT	DME
DMG0EL7	MA	Metabolism
DMG0EL7	RN	Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions. Curr Drug Metab. 2010 Oct;11(8):659-66.
DMG0EL7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20942780

DM7YGJO	DI	DM7YGJO
DM7YGJO	DN	5-Mercapto-pentanoic acid
DM7YGJO	MI	TT9G4N0
DM7YGJO	MN	Glutamate carboxypeptidase II (GCPII)
DM7YGJO	MT	DTT
DM7YGJO	MA	Inhibitor
DM7YGJO	RN	Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. J Med Chem. 2003 May 8;46(10):1989-96.
DM7YGJO	RU	https://pubmed.ncbi.nlm.nih.gov/12723961

DMET3OJ	DI	DMET3OJ
DMET3OJ	DN	5-Mercapto-pentanoic acid phenylamide
DMET3OJ	MI	TTBH0VX
DMET3OJ	MN	Histone deacetylase (HDAC)
DMET3OJ	MT	DTT
DMET3OJ	MA	Inhibitor
DMET3OJ	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMET3OJ	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMET3OJ	DI	DMET3OJ
DMET3OJ	DN	5-Mercapto-pentanoic acid phenylamide
DMET3OJ	MI	TT6R7JZ
DMET3OJ	MN	Histone deacetylase 1 (HDAC1)
DMET3OJ	MT	DTT
DMET3OJ	MA	Inhibitor
DMET3OJ	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMET3OJ	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMET3OJ	DI	DMET3OJ
DMET3OJ	DN	5-Mercapto-pentanoic acid phenylamide
DMET3OJ	MI	TTYHPU6
DMET3OJ	MN	Histone deacetylase 10 (HDAC10)
DMET3OJ	MT	DTT
DMET3OJ	MA	Inhibitor
DMET3OJ	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMET3OJ	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMET3OJ	DI	DMET3OJ
DMET3OJ	DN	5-Mercapto-pentanoic acid phenylamide
DMET3OJ	MI	TTSHTOI
DMET3OJ	MN	Histone deacetylase 2 (HDAC2)
DMET3OJ	MT	DTT
DMET3OJ	MA	Inhibitor
DMET3OJ	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMET3OJ	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMET3OJ	DI	DMET3OJ
DMET3OJ	DN	5-Mercapto-pentanoic acid phenylamide
DMET3OJ	MI	TTTQGH8
DMET3OJ	MN	Histone deacetylase 4 (HDAC4)
DMET3OJ	MT	DTT
DMET3OJ	MA	Inhibitor
DMET3OJ	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMET3OJ	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMET3OJ	DI	DMET3OJ
DMET3OJ	DN	5-Mercapto-pentanoic acid phenylamide
DMET3OJ	MI	TT5ZKDI
DMET3OJ	MN	Histone deacetylase 6 (HDAC6)
DMET3OJ	MT	DTT
DMET3OJ	MA	Inhibitor
DMET3OJ	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMET3OJ	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMET3OJ	DI	DMET3OJ
DMET3OJ	DN	5-Mercapto-pentanoic acid phenylamide
DMET3OJ	MI	TTT6LFV
DMET3OJ	MN	Histone deacetylase 8 (HDAC8)
DMET3OJ	MT	DTT
DMET3OJ	MA	Inhibitor
DMET3OJ	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMET3OJ	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMPEKWD	DI	DMPEKWD
DMPEKWD	DN	5-Methoxy-1-phenyl-1H-benzoimidazole
DMPEKWD	MI	TT8FYO9
DMPEKWD	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMPEKWD	MT	DTT
DMPEKWD	MA	Inhibitor
DMPEKWD	RN	Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor. J Med Chem. 1998 Dec 31;41(27):5457-65.
DMPEKWD	RU	https://pubmed.ncbi.nlm.nih.gov/9876115

DMPEKWD	DI	DMPEKWD
DMPEKWD	DN	5-Methoxy-1-phenyl-1H-benzoimidazole
DMPEKWD	MI	TTI7421
DMPEKWD	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMPEKWD	MT	DTT
DMPEKWD	MA	Inhibitor
DMPEKWD	RN	Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor. J Med Chem. 1998 Dec 31;41(27):5457-65.
DMPEKWD	RU	https://pubmed.ncbi.nlm.nih.gov/9876115

DMX1LY3	DI	DMX1LY3
DMX1LY3	DN	5-methoxy-2-(2-(pyrrolidin-1-yl)ethyl)-1H-indole
DMX1LY3	MI	TT9JNIC
DMX1LY3	MN	Histamine H3 receptor (H3R)
DMX1LY3	MT	DTT
DMX1LY3	MA	Inhibitor
DMX1LY3	RN	In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9.
DMX1LY3	RU	https://pubmed.ncbi.nlm.nih.gov/18077160

DMG2HSU	DI	DMG2HSU
DMG2HSU	DN	5-methoxy-2-(4-(methylsulfonyl)phenyl)-1H-indole
DMG2HSU	MI	TTVKILB
DMG2HSU	MN	Prostaglandin G/H synthase 2 (COX-2)
DMG2HSU	MT	DTT
DMG2HSU	MA	Inhibitor
DMG2HSU	RN	Synthesis and biological evaluation of new 4-carboxyl quinoline derivatives as cyclooxygenase-2 inhibitors. Bioorg Med Chem. 2009 Jul 15;17(14):5312-7.
DMG2HSU	RU	https://pubmed.ncbi.nlm.nih.gov/19560931

DMW7IXL	DI	DMW7IXL
DMW7IXL	DN	5-methoxy-2-(4-aminophenyl)benzofuran
DMW7IXL	MI	TTE4KHA
DMW7IXL	MN	Amyloid beta A4 protein (APP)
DMW7IXL	MT	DTT
DMW7IXL	MA	Inhibitor
DMW7IXL	RN	Novel benzofuran derivatives for PET imaging of beta-amyloid plaques in Alzheimer's disease brains. J Med Chem. 2006 May 4;49(9):2725-30.
DMW7IXL	RU	https://pubmed.ncbi.nlm.nih.gov/16640332

DM3NUMG	DI	DM3NUMG
DM3NUMG	DN	5-methoxy-2-(4-dimethylaminophenyl)benzofuran
DM3NUMG	MI	TTE4KHA
DM3NUMG	MN	Amyloid beta A4 protein (APP)
DM3NUMG	MT	DTT
DM3NUMG	MA	Inhibitor
DM3NUMG	RN	Novel benzofuran derivatives for PET imaging of beta-amyloid plaques in Alzheimer's disease brains. J Med Chem. 2006 May 4;49(9):2725-30.
DM3NUMG	RU	https://pubmed.ncbi.nlm.nih.gov/16640332

DM5N1JX	DI	DM5N1JX
DM5N1JX	DN	5-methoxy-2-(4-methylaminophenyl)benzofuran
DM5N1JX	MI	TTE4KHA
DM5N1JX	MN	Amyloid beta A4 protein (APP)
DM5N1JX	MT	DTT
DM5N1JX	MA	Inhibitor
DM5N1JX	RN	Novel benzofuran derivatives for PET imaging of beta-amyloid plaques in Alzheimer's disease brains. J Med Chem. 2006 May 4;49(9):2725-30.
DM5N1JX	RU	https://pubmed.ncbi.nlm.nih.gov/16640332

DMNRSYA	DI	DMNRSYA
DMNRSYA	DN	5-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline
DMNRSYA	MI	TTJQOD7
DMNRSYA	MN	5-HT 2A receptor (HTR2A)
DMNRSYA	MT	DTT
DMNRSYA	MA	Inhibitor
DMNRSYA	RN	Binding of beta-carbolines at 5-HT(2) serotonin receptors. Bioorg Med Chem Lett. 2003 Dec 15;13(24):4421-5.
DMNRSYA	RU	https://pubmed.ncbi.nlm.nih.gov/14643338

DMNRSYA	DI	DMNRSYA
DMNRSYA	DN	5-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline
DMNRSYA	MI	TT3WG5C
DMNRSYA	MN	Monoamine oxidase type A (MAO-A)
DMNRSYA	MT	DTT
DMNRSYA	MA	Inhibitor
DMNRSYA	RN	Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
DMNRSYA	RU	https://pubmed.ncbi.nlm.nih.gov/15013009

DMNRSYA	DI	DMNRSYA
DMNRSYA	DN	5-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline
DMNRSYA	MI	TTGP7BY
DMNRSYA	MN	Monoamine oxidase type B (MAO-B)
DMNRSYA	MT	DTT
DMNRSYA	MA	Inhibitor
DMNRSYA	RN	Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
DMNRSYA	RU	https://pubmed.ncbi.nlm.nih.gov/15013009

DMW9D30	DI	DMW9D30
DMW9D30	DN	5-Methoxy-3-(2-methoxybenzyl)-2H-chromen-2-one
DMW9D30	MI	TT6OEDT
DMW9D30	MN	Cannabinoid receptor 1 (CB1)
DMW9D30	MT	DTT
DMW9D30	MA	Inhibitor
DMW9D30	RN	Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists. Bioorg Med Chem. 2009 Apr 1;17(7):2842-51.
DMW9D30	RU	https://pubmed.ncbi.nlm.nih.gov/19278853

DMW9D30	DI	DMW9D30
DMW9D30	DN	5-Methoxy-3-(2-methoxybenzyl)-2H-chromen-2-one
DMW9D30	MI	TTMSFAW
DMW9D30	MN	Cannabinoid receptor 2 (CB2)
DMW9D30	MT	DTT
DMW9D30	MA	Inhibitor
DMW9D30	RN	Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists. Bioorg Med Chem. 2009 Apr 1;17(7):2842-51.
DMW9D30	RU	https://pubmed.ncbi.nlm.nih.gov/19278853

DMBOMZE	DI	DMBOMZE
DMBOMZE	DN	5-Methoxy-4,9-dihydro-3H-beta-carboline
DMBOMZE	MI	TTJQOD7
DMBOMZE	MN	5-HT 2A receptor (HTR2A)
DMBOMZE	MT	DTT
DMBOMZE	MA	Inhibitor
DMBOMZE	RN	Binding of beta-carbolines at 5-HT(2) serotonin receptors. Bioorg Med Chem Lett. 2003 Dec 15;13(24):4421-5.
DMBOMZE	RU	https://pubmed.ncbi.nlm.nih.gov/14643338

DMBOMZE	DI	DMBOMZE
DMBOMZE	DN	5-Methoxy-4,9-dihydro-3H-beta-carboline
DMBOMZE	MI	TT3WG5C
DMBOMZE	MN	Monoamine oxidase type A (MAO-A)
DMBOMZE	MT	DTT
DMBOMZE	MA	Inhibitor
DMBOMZE	RN	Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
DMBOMZE	RU	https://pubmed.ncbi.nlm.nih.gov/15013009

DMBOMZE	DI	DMBOMZE
DMBOMZE	DN	5-Methoxy-4,9-dihydro-3H-beta-carboline
DMBOMZE	MI	TTGP7BY
DMBOMZE	MN	Monoamine oxidase type B (MAO-B)
DMBOMZE	MT	DTT
DMBOMZE	MA	Inhibitor
DMBOMZE	RN	Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
DMBOMZE	RU	https://pubmed.ncbi.nlm.nih.gov/15013009

DMCZSP3	DI	DMCZSP3
DMCZSP3	DN	5-methoxycarbonylamino-N-acetyltryptamine
DMCZSP3	MI	TT0WAIE
DMCZSP3	MN	Melatonin receptor type 1A (MTNR1A)
DMCZSP3	MT	DTT
DMCZSP3	MA	Inhibitor
DMCZSP3	RN	Design and synthesis of benzofuranic derivatives as new ligands at the melatonin-binding site MT3. Bioorg Med Chem. 2008 May 1;16(9):4954-62.
DMCZSP3	RU	https://pubmed.ncbi.nlm.nih.gov/18372181

DMCZSP3	DI	DMCZSP3
DMCZSP3	DN	5-methoxycarbonylamino-N-acetyltryptamine
DMCZSP3	MI	TT32JK8
DMCZSP3	MN	Melatonin receptor type 1B (MTNR1B)
DMCZSP3	MT	DTT
DMCZSP3	MA	Inhibitor
DMCZSP3	RN	Design and synthesis of benzofuranic derivatives as new ligands at the melatonin-binding site MT3. Bioorg Med Chem. 2008 May 1;16(9):4954-62.
DMCZSP3	RU	https://pubmed.ncbi.nlm.nih.gov/18372181

DMQX3V9	DI	DMQX3V9
DMQX3V9	DN	5-Methoxyflavone
DMQX3V9	MI	TTKPW01
DMQX3V9	MN	Androgen receptor messenger RNA (AR mRNA)
DMQX3V9	MT	DTT
DMQX3V9	MA	Inhibitor
DMQX3V9	RN	Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4706-10.
DMQX3V9	RU	https://pubmed.ncbi.nlm.nih.gov/19592245

DMUXTWC	DI	DMUXTWC
DMUXTWC	DN	5-methoxy-luzindole
DMUXTWC	MI	TT0WAIE
DMUXTWC	MN	Melatonin receptor type 1A (MTNR1A)
DMUXTWC	MT	DTT
DMUXTWC	MA	Agonist
DMUXTWC	RN	Melatonin receptor antagonists that differentiate between the human Mel1a and Mel1b recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML1 presynaptic heteroreceptor. Naunyn Schmiedebergs Arch Pharmacol. 1997 Mar;355(3):365-75.
DMUXTWC	RU	https://pubmed.ncbi.nlm.nih.gov/9089668

DMJ1HX2	DI	DMJ1HX2
DMJ1HX2	DN	5-Methoxymethyl-3-pyrrol-1-yl-oxazolidin-2-one
DMJ1HX2	MI	TT3WG5C
DMJ1HX2	MN	Monoamine oxidase type A (MAO-A)
DMJ1HX2	MT	DTT
DMJ1HX2	MA	Inhibitor
DMJ1HX2	RN	3-(1H-Pyrrol-1-yl)-2-oxazolidinones as reversible, highly potent, and selective inhibitors of monoamine oxidase type A. J Med Chem. 2002 Mar 14;45(6):1180-3.
DMJ1HX2	RU	https://pubmed.ncbi.nlm.nih.gov/11881986

DM98EQX	DI	DM98EQX
DM98EQX	DN	5-Methoxy-N-phenylbenzo[d]oxazol-2-amine
DM98EQX	MI	TT2J34L
DM98EQX	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM98EQX	MT	DTT
DM98EQX	MA	Inhibitor
DM98EQX	RN	Synthesis and evaluation of benzoxazole derivatives as 5-lipoxygenase inhibitors. Bioorg Med Chem. 2010 Nov 1;18(21):7580-5.
DM98EQX	RU	https://pubmed.ncbi.nlm.nih.gov/20870413

DMARCKD	DI	DMARCKD
DMARCKD	DN	5-METHOXYTRYPTAMINE
DMARCKD	MI	TTJQOD7
DMARCKD	MN	5-HT 2A receptor (HTR2A)
DMARCKD	MT	DTT
DMARCKD	MA	Inhibitor
DMARCKD	RN	Central serotonin receptors as targets for drug research. J Med Chem. 1987 Jan;30(1):1-12.
DMARCKD	RU	https://pubmed.ncbi.nlm.nih.gov/3543362

DMARCKD	DI	DMARCKD
DMARCKD	DN	5-METHOXYTRYPTAMINE
DMARCKD	MI	TTJS8PY
DMARCKD	MN	5-HT 6 receptor (HTR6)
DMARCKD	MT	DTT
DMARCKD	MA	Inhibitor
DMARCKD	RN	Medicinal chemistry driven approaches toward novel and selective serotonin 5-HT6 receptor ligands. J Med Chem. 2005 Mar 24;48(6):1781-95.
DMARCKD	RU	https://pubmed.ncbi.nlm.nih.gov/15771424

DMARCKD	DI	DMARCKD
DMARCKD	DN	5-METHOXYTRYPTAMINE
DMARCKD	MI	TTXDKTO
DMARCKD	MN	Long transient receptor potential channel 8 (TRPM8)
DMARCKD	MT	DTT
DMARCKD	MA	Inhibitor
DMARCKD	RN	5-benzyloxytryptamine as an antagonist of TRPM8. Bioorg Med Chem Lett. 2010 Dec 1;20(23):7076-9.
DMARCKD	RU	https://pubmed.ncbi.nlm.nih.gov/20965726

DM0AIOW	DI	DM0AIOW
DM0AIOW	DN	5-methyl nicotinic acid
DM0AIOW	MI	TTWNV8U
DM0AIOW	MN	Nicotinic acid receptor (HCAR2)
DM0AIOW	MT	DTT
DM0AIOW	MA	Agonist
DM0AIOW	RN	Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem. 2003 Mar 14;278(11):9869-74.
DM0AIOW	RU	https://pubmed.ncbi.nlm.nih.gov/12522134

DMYNFIP	DI	DMYNFIP
DMYNFIP	DN	5-methyl orotate
DMYNFIP	MI	TT09NOX
DMYNFIP	MN	Plasmodium Dihydroorotase (Malaria dho)
DMYNFIP	MT	DTT
DMYNFIP	MA	Inhibitor
DMYNFIP	RN	Antimalarial activity of orotate analogs that inhibit dihydroorotase and dihydroorotate dehydrogenase. Biochem Pharmacol. 1992 Mar 17;43(6):1295-301.
DMYNFIP	RU	https://pubmed.ncbi.nlm.nih.gov/1348618

DM0E1Y9	DI	DM0E1Y9
DM0E1Y9	DN	5-Methyl-1,3-dihydro-imidazo[4,5-b]quinolin-2-one
DM0E1Y9	MI	TT06AWU
DM0E1Y9	MN	Phosphodiesterase 3A (PDE3A)
DM0E1Y9	MT	DTT
DM0E1Y9	MA	Inhibitor
DM0E1Y9	RN	1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-ones--inhibitors of blood platelet cAMP phosphodiesterase and induced aggregation. J Med Chem. 1991 Sep;34(9):2906-16.
DM0E1Y9	RU	https://pubmed.ncbi.nlm.nih.gov/1654430

DMC10HG	DI	DMC10HG
DMC10HG	DN	5-methyl-2-(phenylsulfonamido)benzoic acid
DMC10HG	MI	TTZL0OI
DMC10HG	MN	Methionine aminopeptidase 2 (METAP2)
DMC10HG	MT	DTT
DMC10HG	MA	Inhibitor
DMC10HG	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMC10HG	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMAR4ZF	DI	DMAR4ZF
DMAR4ZF	DN	5-methyl-2-(pyridin-2-yl)-1H-benzo[d]imidazole
DMAR4ZF	MI	TTZL0OI
DMAR4ZF	MN	Methionine aminopeptidase 2 (METAP2)
DMAR4ZF	MT	DTT
DMAR4ZF	MA	Inhibitor
DMAR4ZF	RN	Subtype-selectivity of metal-dependent methionine aminopeptidase inhibitors, Bioorg. Med. Chem. Lett. 20(14):4038-4044 (2010).
DMAR4ZF	RU	http://www.sciencedirect.com/science/article/pii/S0960894X10007468

DMH1IVN	DI	DMH1IVN
DMH1IVN	DN	5-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one
DMH1IVN	MI	TTML2WA
DMH1IVN	MN	Tubulin (TUB)
DMH1IVN	MT	DTT
DMH1IVN	MA	Inhibitor
DMH1IVN	RN	Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubul... J Med Chem. 1997 Sep 12;40(19):3049-56.
DMH1IVN	RU	https://pubmed.ncbi.nlm.nih.gov/9301667

DMH1IVN	DI	DMH1IVN
DMH1IVN	DN	5-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one
DMH1IVN	MI	TTYFKSZ
DMH1IVN	MN	Tubulin beta (TUBB)
DMH1IVN	MT	DTT
DMH1IVN	MA	Inhibitor
DMH1IVN	RN	Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubul... J Med Chem. 1997 Sep 12;40(19):3049-56.
DMH1IVN	RU	https://pubmed.ncbi.nlm.nih.gov/9301667

DMIE9BG	DI	DMIE9BG
DMIE9BG	DN	5-Methyl-2-p-tolyl-thiazol-4-ol
DMIE9BG	MI	TT2J34L
DMIE9BG	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMIE9BG	MT	DTT
DMIE9BG	MA	Inhibitor
DMIE9BG	RN	4-hydroxythiazole inhibitors of 5-lipoxygenase. J Med Chem. 1991 Jul;34(7):2158-65.
DMIE9BG	RU	https://pubmed.ncbi.nlm.nih.gov/2066989

DM0G2N5	DI	DM0G2N5
DM0G2N5	DN	5-Methyl-3,4-diphenyl-isoxazole
DM0G2N5	MI	TT8NGED
DM0G2N5	MN	Prostaglandin G/H synthase 1 (COX-1)
DM0G2N5	MT	DTT
DM0G2N5	MA	Inhibitor
DM0G2N5	RN	Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: reversal cyclooxygenase-2 selectivity by sulfonamide group removal. J Med Chem. 2004 Sep 23;47(20):4881-90.
DM0G2N5	RU	https://pubmed.ncbi.nlm.nih.gov/15369392

DM0G2N5	DI	DM0G2N5
DM0G2N5	DN	5-Methyl-3,4-diphenyl-isoxazole
DM0G2N5	MI	TTVKILB
DM0G2N5	MN	Prostaglandin G/H synthase 2 (COX-2)
DM0G2N5	MT	DTT
DM0G2N5	MA	Inhibitor
DM0G2N5	RN	Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: reversal cyclooxygenase-2 selectivity by sulfonamide group removal. J Med Chem. 2004 Sep 23;47(20):4881-90.
DM0G2N5	RU	https://pubmed.ncbi.nlm.nih.gov/15369392

DMF0IJ2	DI	DMF0IJ2
DMF0IJ2	DN	5-methyl-3-phenylethynyl[1,2,4]triazine
DMF0IJ2	MI	TTHS256
DMF0IJ2	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMF0IJ2	MT	DTT
DMF0IJ2	MA	Inhibitor
DMF0IJ2	RN	Synthesis and pharmacological evaluation of phenylethynyl[1,2,4]methyltriazines as analogues of 3-methyl-6-(phenylethynyl)pyridine. J Med Chem. 2007 Jul 12;50(14):3388-91.
DMF0IJ2	RU	https://pubmed.ncbi.nlm.nih.gov/17569516

DM6DEOC	DI	DM6DEOC
DM6DEOC	DN	5-Methyl-4-propyl-pyrrolidin-(2Z)-ylideneamine
DM6DEOC	MI	TTF10I9
DM6DEOC	MN	Nitric-oxide synthase inducible (NOS2)
DM6DEOC	MT	DTT
DM6DEOC	MA	Inhibitor
DM6DEOC	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DM6DEOC	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DMO37W4	DI	DMO37W4
DMO37W4	DN	5-methyl-5-(5-methylthiophen-3-yl)-4-oxo-4,5-dihydrofuran-2-carboxylic acid
DMO37W4	MI	TT8WFXV
DMO37W4	MN	Hydroxycarboxylic acid receptor 3 (HCAR3)
DMO37W4	MT	DTT
DMO37W4	MA	Agonist
DMO37W4	RN	Analogues of acifran: agonists of the high and low affinity niacin receptors, GPR109a and GPR109b. J Med Chem. 2007 Apr 5;50(7):1445-8.
DMO37W4	RU	https://pubmed.ncbi.nlm.nih.gov/17358052

DMRMKXD	DI	DMRMKXD
DMRMKXD	DN	5-Methyl-5-phenyl-pyrimidine-2,4,6-trione
DMRMKXD	MI	TT6X50U
DMRMKXD	MN	Matrix metalloproteinase-9 (MMP-9)
DMRMKXD	MT	DTT
DMRMKXD	MA	Inhibitor
DMRMKXD	RN	Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. Bioorg Med Chem Lett. 2001 Apr 23;11(8):969-72.
DMRMKXD	RU	https://pubmed.ncbi.nlm.nih.gov/11327602

DMLJVB7	DI	DMLJVB7
DMLJVB7	DN	5-methyl-benzo[b]thiophen-2-ylboronic acid
DMLJVB7	MI	TTHI19T
DMLJVB7	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMLJVB7	MT	DTT
DMLJVB7	MA	Inhibitor
DMLJVB7	RN	Optimizing cell permeation of an antibiotic resistance inhibitor for improved efficacy. J Med Chem. 2007 Nov 15;50(23):5644-54.
DMLJVB7	RU	https://pubmed.ncbi.nlm.nih.gov/17956081

DMRC8SO	DI	DMRC8SO
DMRC8SO	DN	5-methyl-cyclosal-d4TMP
DMRC8SO	MI	TTEB0GD
DMRC8SO	MN	Cholinesterase (BCHE)
DMRC8SO	MT	DTT
DMRC8SO	MA	Inhibitor
DMRC8SO	RN	Bis-cycloSal-d4T-monophosphates: drugs that deliver two molecules of bioactive nucleotides. J Med Chem. 2007 Mar 22;50(6):1335-46.
DMRC8SO	RU	https://pubmed.ncbi.nlm.nih.gov/17328534

DMIQ1X3	DI	DMIQ1X3
DMIQ1X3	DN	5-methylenearisteromycin
DMIQ1X3	MI	TTE2KUJ
DMIQ1X3	MN	Adenosylhomocysteinase (AHCY)
DMIQ1X3	MT	DTT
DMIQ1X3	MA	Inhibitor
DMIQ1X3	RN	Synthesis of 2-modified aristeromycins and their analogs as potent inhibitors against Plasmodium falciparum S-adenosyl-L-homocysteine hydrolase. Bioorg Med Chem. 2008 Apr 1;16(7):3809-15.
DMIQ1X3	RU	https://pubmed.ncbi.nlm.nih.gov/18295495

DMNJ0XZ	DI	DMNJ0XZ
DMNJ0XZ	DN	5-Methyl-N-phenylbenzo[d]oxazol-2-amine
DMNJ0XZ	MI	TT2J34L
DMNJ0XZ	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMNJ0XZ	MT	DTT
DMNJ0XZ	MA	Inhibitor
DMNJ0XZ	RN	Synthesis and evaluation of benzoxazole derivatives as 5-lipoxygenase inhibitors. Bioorg Med Chem. 2010 Nov 1;18(21):7580-5.
DMNJ0XZ	RU	https://pubmed.ncbi.nlm.nih.gov/20870413

DMBQS31	DI	DMBQS31
DMBQS31	DN	5-Methyl-oxazolidin-(2Z)-ylideneamine
DMBQS31	MI	TTZUFI5
DMBQS31	MN	Nitric-oxide synthase brain (NOS1)
DMBQS31	MT	DTT
DMBQS31	MA	Inhibitor
DMBQS31	RN	4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor. Bioorg Med Chem Lett. 2004 Jan 19;14(2):313-6.
DMBQS31	RU	https://pubmed.ncbi.nlm.nih.gov/14698148

DMBQS31	DI	DMBQS31
DMBQS31	DN	5-Methyl-oxazolidin-(2Z)-ylideneamine
DMBQS31	MI	TTF10I9
DMBQS31	MN	Nitric-oxide synthase inducible (NOS2)
DMBQS31	MT	DTT
DMBQS31	MA	Inhibitor
DMBQS31	RN	4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor. Bioorg Med Chem Lett. 2004 Jan 19;14(2):313-6.
DMBQS31	RU	https://pubmed.ncbi.nlm.nih.gov/14698148

DM4QB3G	DI	DM4QB3G
DM4QB3G	DN	5-Methyl-pyrrolidin-(2Z)-ylideneamine
DM4QB3G	MI	TTZUFI5
DM4QB3G	MN	Nitric-oxide synthase brain (NOS1)
DM4QB3G	MT	DTT
DM4QB3G	MA	Inhibitor
DM4QB3G	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DM4QB3G	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DM4QB3G	DI	DM4QB3G
DM4QB3G	DN	5-Methyl-pyrrolidin-(2Z)-ylideneamine
DM4QB3G	MI	TTCM4B3
DM4QB3G	MN	Nitric-oxide synthase endothelial (NOS3)
DM4QB3G	MT	DTT
DM4QB3G	MA	Inhibitor
DM4QB3G	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DM4QB3G	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DM4QB3G	DI	DM4QB3G
DM4QB3G	DN	5-Methyl-pyrrolidin-(2Z)-ylideneamine
DM4QB3G	MI	TTF10I9
DM4QB3G	MN	Nitric-oxide synthase inducible (NOS2)
DM4QB3G	MT	DTT
DM4QB3G	MA	Inhibitor
DM4QB3G	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DM4QB3G	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DMYERNM	DI	DMYERNM
DMYERNM	DN	5-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione
DMYERNM	MI	TTVDSZ0
DMYERNM	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMYERNM	MT	DTT
DMYERNM	MA	Inhibitor
DMYERNM	RN	Synthesis and structure-activity relationships of novel poly(ADP-ribose) polymerase-1 inhibitors. Bioorg Med Chem Lett. 2006 Feb 15;16(4):938-42.
DMYERNM	RU	https://pubmed.ncbi.nlm.nih.gov/16290935

DM3MVSD	DI	DM3MVSD
DM3MVSD	DN	5-Methylsulfanyl-thiophene-2-carboxamidine
DM3MVSD	MI	TTGY7WI
DM3MVSD	MN	Urokinase-type plasminogen activator (PLAU)
DM3MVSD	MT	DTT
DM3MVSD	MA	Inhibitor
DM3MVSD	RN	Design and synthesis of 4,5-disubstituted-thiophene-2-amidines as potent urokinase inhibitors. Bioorg Med Chem Lett. 2002 Feb 11;12(3):491-5.
DM3MVSD	RU	https://pubmed.ncbi.nlm.nih.gov/11814826

DM3LY0Q	DI	DM3LY0Q
DM3LY0Q	DN	5'-Methylthio-ImmH
DM3LY0Q	MI	TTMCF1Y
DM3LY0Q	MN	Purine nucleoside phosphorylase (PNP)
DM3LY0Q	MT	DTT
DM3LY0Q	MA	Inhibitor
DM3LY0Q	RN	Immucillins in custom catalytic-site cavities. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5900-3.
DM3LY0Q	RU	https://pubmed.ncbi.nlm.nih.gov/18778937

DMK52UH	DI	DMK52UH
DMK52UH	DN	5'-methylthio-immucillin-H
DMK52UH	MI	TTMCF1Y
DMK52UH	MN	Purine nucleoside phosphorylase (PNP)
DMK52UH	MT	DTT
DMK52UH	MA	Inhibitor
DMK52UH	RN	Exploring new inhibitors of Plasmodium falciparum purine nucleoside phosphorylase. Eur J Med Chem. 2010 Nov;45(11):5140-9.
DMK52UH	RU	https://pubmed.ncbi.nlm.nih.gov/20817362

DMCX9WN	DI	DMCX9WN
DMCX9WN	DN	5-methylurapidil
DMCX9WN	MI	TTBRKXS
DMCX9WN	MN	Adrenergic receptor alpha-1B (ADRA1B)
DMCX9WN	MT	DTT
DMCX9WN	MA	Antagonist
DMCX9WN	RN	Affinity of serotonin receptor antagonists and agonists to recombinant and native alpha1-adrenoceptor subtypes. Jpn J Pharmacol. 2001 Jun;86(2):189-95.
DMCX9WN	RU	https://pubmed.ncbi.nlm.nih.gov/11459121

DMCX9WN	DI	DMCX9WN
DMCX9WN	DN	5-methylurapidil
DMCX9WN	MI	TT2NUT5
DMCX9WN	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMCX9WN	MT	DTT
DMCX9WN	MA	Antagonist
DMCX9WN	RN	Phe-308 and Phe-312 in transmembrane domain 7 are major sites of alpha 1-adrenergic receptor antagonist binding. Imidazoline agonists bind like ant... J Biol Chem. 2001 Jul 6;276(27):25366-71.
DMCX9WN	RU	https://pubmed.ncbi.nlm.nih.gov/11331292

DMX0EAK	DI	DMX0EAK
DMX0EAK	DN	5--Monophosphate-9-Beta-D-Ribofuranosyl Xanthine
DMX0EAK	MI	TTBL49X
DMX0EAK	MN	Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ)
DMX0EAK	MT	DTT
DMX0EAK	MA	Inhibitor
DMX0EAK	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMX0EAK	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMSRGTI	DI	DMSRGTI
DMSRGTI	DN	5-MPEP
DMSRGTI	MI	TTHS256
DMSRGTI	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMSRGTI	MT	DTT
DMSRGTI	MA	Modulator (allosteric modulator)
DMSRGTI	RN	A close structural analog of 2-methyl-6-(phenylethynyl)-pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtyp... Mol Pharmacol. 2005 Dec;68(6):1793-802.
DMSRGTI	RU	https://pubmed.ncbi.nlm.nih.gov/16155210

DMOSKJ8	DI	DMOSKJ8
DMOSKJ8	DN	5-N-Allyl-Arginine
DMOSKJ8	MI	TTZUFI5
DMOSKJ8	MN	Nitric-oxide synthase brain (NOS1)
DMOSKJ8	MT	DTT
DMOSKJ8	MA	Inhibitor
DMOSKJ8	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMOSKJ8	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMK0PAL	DI	DMK0PAL
DMK0PAL	DN	5-Naphthalen-2-yl-1H-imidazole
DMK0PAL	MI	TTIQUX7
DMK0PAL	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMK0PAL	MT	DTT
DMK0PAL	MA	Inhibitor
DMK0PAL	RN	Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42.
DMK0PAL	RU	https://pubmed.ncbi.nlm.nih.gov/16220979

DMTH3BW	DI	DMTH3BW
DMTH3BW	DN	5-Naphthalen-2-yl-oxazole
DMTH3BW	MI	TTIQUX7
DMTH3BW	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMTH3BW	MT	DTT
DMTH3BW	MA	Inhibitor
DMTH3BW	RN	Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42.
DMTH3BW	RU	https://pubmed.ncbi.nlm.nih.gov/16220979

DMTS06Z	DI	DMTS06Z
DMTS06Z	DN	5-Nitro-1H-indole-2,3-dione
DMTS06Z	MI	TTSFWA7
DMTS06Z	MN	Plasmodium CDK Pfmrk (Malaria Pfmrk)
DMTS06Z	MT	DTT
DMTS06Z	MA	Inhibitor
DMTS06Z	RN	A three-dimensional in silico pharmacophore model for inhibition of Plasmodium falciparum cyclin-dependent kinases and discovery of different class... J Med Chem. 2004 Oct 21;47(22):5418-26.
DMTS06Z	RU	https://pubmed.ncbi.nlm.nih.gov/15481979

DM26MIC	DI	DM26MIC
DM26MIC	DN	5-Nitro-2-(4-phenoxy-phenyl)-1H-benzoimidazole
DM26MIC	MI	TT9ABMF
DM26MIC	MN	Serine/threonine-protein kinase Chk2 (RAD53)
DM26MIC	MT	DTT
DM26MIC	MA	Inhibitor
DM26MIC	RN	Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. J Med Chem. 2005 Mar 24;48(6):1873-85.
DM26MIC	RU	https://pubmed.ncbi.nlm.nih.gov/15771432

DMH7SIX	DI	DMH7SIX
DMH7SIX	DN	5-Nitroindazole
DMH7SIX	MI	TTCM4B3
DMH7SIX	MN	Nitric-oxide synthase endothelial (NOS3)
DMH7SIX	MT	DTT
DMH7SIX	MA	Inhibitor
DMH7SIX	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMH7SIX	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMH7SIX	DI	DMH7SIX
DMH7SIX	DN	5-Nitroindazole
DMH7SIX	MI	TTF10I9
DMH7SIX	MN	Nitric-oxide synthase inducible (NOS2)
DMH7SIX	MT	DTT
DMH7SIX	MA	Inhibitor
DMH7SIX	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMH7SIX	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM4K8N2	DI	DM4K8N2
DM4K8N2	DN	5-nitroindirubin-3'-oxime
DM4K8N2	MI	TT7HF4W
DM4K8N2	MN	Cyclin-dependent kinase 2 (CDK2)
DM4K8N2	MT	DTT
DM4K8N2	MA	Inhibitor
DM4K8N2	RN	5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706.
DM4K8N2	RU	https://pubmed.ncbi.nlm.nih.gov/20361800

DM4K8N2	DI	DM4K8N2
DM4K8N2	DN	5-nitroindirubin-3'-oxime
DM4K8N2	MI	TTCEJ4F
DM4K8N2	MN	G1/S-specific cyclin-E1 (CCNE1)
DM4K8N2	MT	DTT
DM4K8N2	MA	Inhibitor
DM4K8N2	RN	5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706.
DM4K8N2	RU	https://pubmed.ncbi.nlm.nih.gov/20361800

DM2DWUQ	DI	DM2DWUQ
DM2DWUQ	DN	5-Nonyl-5-phenyl-imidazolidine-2,4-dione
DM2DWUQ	MI	TTRK8B9
DM2DWUQ	MN	Sodium channel unspecific (NaC)
DM2DWUQ	MT	DTT
DM2DWUQ	MA	Inhibitor
DM2DWUQ	RN	Comparative molecular field analysis of hydantoin binding to the neuronal voltage-dependent sodium channel. J Med Chem. 1999 May 6;42(9):1537-45.
DM2DWUQ	RU	https://pubmed.ncbi.nlm.nih.gov/10229624

DM2DWUQ	DI	DM2DWUQ
DM2DWUQ	DN	5-Nonyl-5-phenyl-imidazolidine-2,4-dione
DM2DWUQ	MI	TTAXZ0K
DM2DWUQ	MN	Voltage-gated sodium channel alpha Nav1.3 (SCN3A)
DM2DWUQ	MT	DTT
DM2DWUQ	MA	Inhibitor
DM2DWUQ	RN	Comparative molecular field analysis of hydantoin binding to the neuronal voltage-dependent sodium channel. J Med Chem. 1999 May 6;42(9):1537-45.
DM2DWUQ	RU	https://pubmed.ncbi.nlm.nih.gov/10229624

DM74JL8	DI	DM74JL8
DM74JL8	DN	5-n-undecyl-6-hydroxy-4,7-dioxobenzothiazole
DM74JL8	MI	TTRAMF0
DM74JL8	MN	Plasmodium Cytochrome B (Malaria MT-CYB)
DM74JL8	MT	DTT
DM74JL8	MA	Inhibitor
DM74JL8	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM74JL8	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM20X8C	DI	DM20X8C
DM20X8C	DN	5'-O-[(L-Methionyl)-Sulphamoyl]Adenosine
DM20X8C	MI	TTOJ46K
DM20X8C	MN	Streptococcus Methionyl-tRNA synthetase (Stre-coc metG)
DM20X8C	MT	DTT
DM20X8C	MA	Inhibitor
DM20X8C	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM20X8C	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMAXHEU	DI	DMAXHEU
DMAXHEU	DN	5-octyl-2-phenoxyphenol
DMAXHEU	MI	TTVTX4N
DMAXHEU	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DMAXHEU	MT	DTT
DMAXHEU	MA	Inhibitor
DMAXHEU	RN	Natural products, small molecules, and genetics in tuberculosis drug development. J Med Chem. 2008 May 8;51(9):2606-12.
DMAXHEU	RU	https://pubmed.ncbi.nlm.nih.gov/18393405

DMZT6JR	DI	DMZT6JR
DMZT6JR	DN	5-OH-DPAT
DMZT6JR	MI	TTK8CXU
DMZT6JR	MN	5-HT 1B receptor (HTR1B)
DMZT6JR	MT	DTT
DMZT6JR	MA	Antagonist
DMZT6JR	RN	Mouse 5HT1B serotonin receptor: cloning, functional expression, and localization in motor control centers. Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):3020-4.
DMZT6JR	RU	https://pubmed.ncbi.nlm.nih.gov/1557407

DMZT6JR	DI	DMZT6JR
DMZT6JR	DN	5-OH-DPAT
DMZT6JR	MI	TTEX248
DMZT6JR	MN	Dopamine D2 receptor (D2R)
DMZT6JR	MT	DTT
DMZT6JR	MA	Inhibitor
DMZT6JR	RN	Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a... J Med Chem. 2010 Feb 11;53(3):1023-37.
DMZT6JR	RU	https://pubmed.ncbi.nlm.nih.gov/20038106

DMZT6JR	DI	DMZT6JR
DMZT6JR	DN	5-OH-DPAT
DMZT6JR	MI	TT4C8EA
DMZT6JR	MN	Dopamine D3 receptor (D3R)
DMZT6JR	MT	DTT
DMZT6JR	MA	Inhibitor
DMZT6JR	RN	Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a... J Med Chem. 2010 Feb 11;53(3):1023-37.
DMZT6JR	RU	https://pubmed.ncbi.nlm.nih.gov/20038106

DME62OQ	DI	DME62OQ
DME62OQ	DN	5-oxo-1-2-4-oxadiazol biphenyl
DME62OQ	MI	TT8DBY3
DME62OQ	MN	Angiotensin II receptor type-1 (AGTR1)
DME62OQ	MT	DTT
DME62OQ	MA	Antagonist
DME62OQ	RN	Synthesis and biological evaluation of novel potent angiotensin II receptor antagonists with anti-hypertension effect. Bioorg Med Chem. 2012 Apr 15;20(8):2747-61.
DME62OQ	RU	https://pubmed.ncbi.nlm.nih.gov/22410249

DMLABR9	DI	DMLABR9
DMLABR9	DN	5-oxo-12-HETE
DMLABR9	MI	TT7WBSV
DMLABR9	MN	Oxoeicosanoid receptor 1 (OXER1)
DMLABR9	MT	DTT
DMLABR9	MA	Antagonist
DMLABR9	RN	Biological inactivation of 5-oxo-6,8,11,14-eicosatetraenoic acid by human platelets. Blood. 1999 Feb 1;93(3):1086-96.
DMLABR9	RU	https://pubmed.ncbi.nlm.nih.gov/9920859

DM9ZC7B	DI	DM9ZC7B
DM9ZC7B	DN	5-oxo-15-HETE
DM9ZC7B	MI	TT7WBSV
DM9ZC7B	MN	Oxoeicosanoid receptor 1 (OXER1)
DM9ZC7B	MT	DTT
DM9ZC7B	MA	Agonist
DM9ZC7B	RN	Metabolism and biologic effects of 5-oxoeicosanoids on human neutrophils. J Immunol. 1996 Jan 1;156(1):336-42.
DM9ZC7B	RU	https://pubmed.ncbi.nlm.nih.gov/8598482

DMQ94BX	DI	DMQ94BX
DMQ94BX	DN	5-oxo-1-tosyl-2,5-dihydro-1Hpyrrol-2-yl acetate
DMQ94BX	MI	TTHQPL7
DMQ94BX	MN	Carbonic anhydrase I (CA-I)
DMQ94BX	MT	DTT
DMQ94BX	MA	Inhibitor
DMQ94BX	RN	A novel and one-pot synthesis of new 1-tosyl pyrrol-2-one derivatives and analysis of carbonic anhydrase inhibitory potencies. Bioorg Med Chem. 2010 Jun 15;18(12):4468-74.
DMQ94BX	RU	https://pubmed.ncbi.nlm.nih.gov/20554206

DM493GU	DI	DM493GU
DM493GU	DN	5-oxo-20-HETE
DM493GU	MI	TT7WBSV
DM493GU	MN	Oxoeicosanoid receptor 1 (OXER1)
DM493GU	MT	DTT
DM493GU	MA	Agonist
DM493GU	RN	Metabolism and biologic effects of 5-oxoeicosanoids on human neutrophils. J Immunol. 1996 Jan 1;156(1):336-42.
DM493GU	RU	https://pubmed.ncbi.nlm.nih.gov/8598482

DM6FSUW	DI	DM6FSUW
DM6FSUW	DN	5-oxo-C20:3
DM6FSUW	MI	TT7WBSV
DM6FSUW	MN	Oxoeicosanoid receptor 1 (OXER1)
DM6FSUW	MT	DTT
DM6FSUW	MA	Agonist
DM6FSUW	RN	Structural requirements for activation of the 5-oxo-6E,8Z, 11Z,14Z-eicosatetraenoic acid (5-oxo-ETE) receptor: identification of a mead acid metabolite with potent agonist activity. J Pharmacol Exp Ther. 2008 May;325(2):698-707.
DM6FSUW	RU	https://pubmed.ncbi.nlm.nih.gov/18292294

DM56TVA	DI	DM56TVA
DM56TVA	DN	5-oxo-ODE
DM56TVA	MI	TT7WBSV
DM56TVA	MN	Oxoeicosanoid receptor 1 (OXER1)
DM56TVA	MT	DTT
DM56TVA	MA	Agonist
DM56TVA	RN	Human neutrophils convert the sebum-derived polyunsaturated fatty acid Sebaleic acid to a potent granulocyte chemoattractant. J Biol Chem. 2008 Apr 25;283(17):11234-43.
DM56TVA	RU	https://pubmed.ncbi.nlm.nih.gov/18287092

DMPLB3S	DI	DMPLB3S
DMPLB3S	DN	5PAM523
DMPLB3S	MI	TTHS256
DMPLB3S	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMPLB3S	MT	DTT
DMPLB3S	MA	Modulator (allosteric modulator)
DMPLB3S	RN	Mechanism based neurotoxicity of mGlu5 positive allosteric modulators--development challenges for a promising novel antipsychotic target. Neuropharmacology. 2014 Jul;82:161-73.
DMPLB3S	RU	https://pubmed.ncbi.nlm.nih.gov/23291536

DMKHFV4	DI	DMKHFV4
DMKHFV4	DN	5-PENTYL-2-PHENOXYPHENOL
DMKHFV4	MI	TTVTX4N
DMKHFV4	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DMKHFV4	MT	DTT
DMKHFV4	MA	Inhibitor
DMKHFV4	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMKHFV4	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMZKJF8	DI	DMZKJF8
DMZKJF8	DN	5-Phenethyl-1H-pyrazole-3-carboxylic acid
DMZKJF8	MI	TTWNV8U
DMZKJF8	MN	Nicotinic acid receptor (HCAR2)
DMZKJF8	MT	DTT
DMZKJF8	MA	Inhibitor
DMZKJF8	RN	Pyrazole derivatives as partial agonists for the nicotinic acid receptor. J Med Chem. 2003 Aug 28;46(18):3945-51.
DMZKJF8	RU	https://pubmed.ncbi.nlm.nih.gov/12930155

DMWI7XJ	DI	DMWI7XJ
DMWI7XJ	DN	5-Phenethyl-quinazoline-2,4-diamine
DMWI7XJ	MI	TT9SL3Q
DMWI7XJ	MN	Polypeptide deformylase (PDF)
DMWI7XJ	MT	DTT
DMWI7XJ	MA	Inhibitor
DMWI7XJ	RN	2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dih... J Med Chem. 1995 Mar 3;38(5):745-52.
DMWI7XJ	RU	https://pubmed.ncbi.nlm.nih.gov/7877140

DMZ6TRV	DI	DMZ6TRV
DMZ6TRV	DN	5-phenyl-1,3,4-oxadiazole-2(3H)-thione
DMZ6TRV	MI	TTULVH8
DMZ6TRV	MN	Tyrosinase (TYR)
DMZ6TRV	MT	DTT
DMZ6TRV	MA	Inhibitor
DMZ6TRV	RN	New potent inhibitors of tyrosinase: novel clues to binding of 1,3,4-thiadiazole-2(3H)-thiones, 1,3,4-oxadiazole-2(3H)-thiones, 4-amino-1,2,4-triaz... Bioorg Med Chem. 2010 Jun 1;18(11):4042-8.
DMZ6TRV	RU	https://pubmed.ncbi.nlm.nih.gov/20452224

DMCKBQY	DI	DMCKBQY
DMCKBQY	DN	5-phenyl-1,3,4-thiadiazole-2(3H)-thione
DMCKBQY	MI	TTULVH8
DMCKBQY	MN	Tyrosinase (TYR)
DMCKBQY	MT	DTT
DMCKBQY	MA	Inhibitor
DMCKBQY	RN	New potent inhibitors of tyrosinase: novel clues to binding of 1,3,4-thiadiazole-2(3H)-thiones, 1,3,4-oxadiazole-2(3H)-thiones, 4-amino-1,2,4-triaz... Bioorg Med Chem. 2010 Jun 1;18(11):4042-8.
DMCKBQY	RU	https://pubmed.ncbi.nlm.nih.gov/20452224

DMWF4HX	DI	DMWF4HX
DMWF4HX	DN	5-phenyl-1H-1,2,3-triazole
DMWF4HX	MI	TTZJYKH
DMWF4HX	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMWF4HX	MT	DTT
DMWF4HX	MA	Inhibitor
DMWF4HX	RN	Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2010 Feb 11;53(3):1172-89.
DMWF4HX	RU	https://pubmed.ncbi.nlm.nih.gov/20055453

DMJBEIF	DI	DMJBEIF
DMJBEIF	DN	5-phenyl-1H-indazol-3-amine
DMJBEIF	MI	TTRMX3V
DMJBEIF	MN	Janus kinase 2 (JAK-2)
DMJBEIF	MT	DTT
DMJBEIF	MA	Inhibitor
DMJBEIF	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMJBEIF	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMQHU0J	DI	DMQHU0J
DMQHU0J	DN	5-phenyl-2-(4-(piperidin-1-yl)butyl)oxazole
DMQHU0J	MI	TT9JNIC
DMQHU0J	MN	Histamine H3 receptor (H3R)
DMQHU0J	MT	DTT
DMQHU0J	MA	Inhibitor
DMQHU0J	RN	Azole derivatives as histamine H3 receptor antagonists, part 2: C-C and C-S coupled heterocycles. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5883-6.
DMQHU0J	RU	https://pubmed.ncbi.nlm.nih.gov/20727744

DMLK2VT	DI	DMLK2VT
DMLK2VT	DN	5-Phenyl-6-thia-10b-aza-benzo[e]azulen-4-one
DMLK2VT	MI	TTPTXIN
DMLK2VT	MN	Translocator protein (TSPO)
DMLK2VT	MT	DTT
DMLK2VT	MA	Inhibitor
DMLK2VT	RN	Novel ligands specific for mitochondrial benzodiazepine receptors: 6-arylpyrrolo[2,1-d][1,5]benzothiazepine derivatives. Synthesis, structure-activ... J Med Chem. 1994 May 13;37(10):1427-38.
DMLK2VT	RU	https://pubmed.ncbi.nlm.nih.gov/8182701

DMUBCVL	DI	DMUBCVL
DMUBCVL	DN	5-Phenyl-6-thia-10b-aza-benzo[e]azulene
DMUBCVL	MI	TTPTXIN
DMUBCVL	MN	Translocator protein (TSPO)
DMUBCVL	MT	DTT
DMUBCVL	MA	Inhibitor
DMUBCVL	RN	A concerted study using binding measurements, X-ray structural data, and molecular modeling on the stereochemical features responsible for the affi... J Med Chem. 1995 Nov 10;38(23):4730-8.
DMUBCVL	RU	https://pubmed.ncbi.nlm.nih.gov/7473601

DMX6R0H	DI	DMX6R0H
DMX6R0H	DN	5-phenylamino-4-cyano-3-hydroxy-isothiazole
DMX6R0H	MI	TTIDAPM
DMX6R0H	MN	ERK activator kinase 1 (MEK1)
DMX6R0H	MT	DTT
DMX6R0H	MA	Inhibitor
DMX6R0H	RN	Discovery of 3-hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles as potent MEK1 inhibitors. Bioorg Med Chem Lett. 2006 Aug 1;16(15):3975-80.
DMX6R0H	RU	https://pubmed.ncbi.nlm.nih.gov/16725322

DM3B6A8	DI	DM3B6A8
DM3B6A8	DN	5-Phenyl-pentanoic acid benzyl-hydroxy-amide
DM3B6A8	MI	TT8NGED
DM3B6A8	MN	Prostaglandin G/H synthase 1 (COX-1)
DM3B6A8	MT	DTT
DM3B6A8	MA	Inhibitor
DM3B6A8	RN	Differential effects of a series of hydroxamic acid derivatives on 5-lipoxygenase and cyclooxygenase from neutrophils and 12-lipoxygenase from plat... J Med Chem. 1989 Aug;32(8):1836-42.
DM3B6A8	RU	https://pubmed.ncbi.nlm.nih.gov/2502629

DM3B6A8	DI	DM3B6A8
DM3B6A8	DN	5-Phenyl-pentanoic acid benzyl-hydroxy-amide
DM3B6A8	MI	TTVKILB
DM3B6A8	MN	Prostaglandin G/H synthase 2 (COX-2)
DM3B6A8	MT	DTT
DM3B6A8	MA	Inhibitor
DM3B6A8	RN	Differential effects of a series of hydroxamic acid derivatives on 5-lipoxygenase and cyclooxygenase from neutrophils and 12-lipoxygenase from plat... J Med Chem. 1989 Aug;32(8):1836-42.
DM3B6A8	RU	https://pubmed.ncbi.nlm.nih.gov/2502629

DMMWYFR	DI	DMMWYFR
DMMWYFR	DN	5-Phenylsulfanyl-2,4-Quinazolinediamine
DMMWYFR	MI	TT9SL3Q
DMMWYFR	MN	Polypeptide deformylase (PDF)
DMMWYFR	MT	DTT
DMMWYFR	MA	Inhibitor
DMMWYFR	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMMWYFR	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMQMZ0Y	DI	DMQMZ0Y
DMQMZ0Y	DN	5'-phenylthio-ImmH
DMQMZ0Y	MI	TTMCF1Y
DMQMZ0Y	MN	Purine nucleoside phosphorylase (PNP)
DMQMZ0Y	MT	DTT
DMQMZ0Y	MA	Inhibitor
DMQMZ0Y	RN	Immucillins in custom catalytic-site cavities. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5900-3.
DMQMZ0Y	RU	https://pubmed.ncbi.nlm.nih.gov/18778937

DMGK05W	DI	DMGK05W
DMGK05W	DN	5-Phosphoribosyl-1-(Beta-Methylene) Pyrophosphate
DMGK05W	MI	TTH29K0
DMGK05W	MN	Mycobacterium Nicotinate-nucleotide pyrophosphorylase (MycB nadC)
DMGK05W	MT	DTT
DMGK05W	MA	Inhibitor
DMGK05W	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMGK05W	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM6A902	DI	DM6A902
DM6A902	DN	5-propenyl-2'-deoxyuridine triphosphate
DM6A902	MI	TTIU7X1
DM6A902	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DM6A902	MT	DTT
DM6A902	MA	Inhibitor
DM6A902	RN	Inhibition of human hepatitis B virus DNA polymerase and duck hepatitis B virus DNA polymerase by triphosphates of thymidine analogs and pharmacokinetic properties of the corresponding nucleosides. JMed Virol. 1988 Dec;26(4):353-62.
DM6A902	RU	https://pubmed.ncbi.nlm.nih.gov/3145322

DM762FY	DI	DM762FY
DM762FY	DN	5-propenyl-arabinofuranosyluracil 5'-triphosphate
DM762FY	MI	TTIU7X1
DM762FY	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DM762FY	MT	DTT
DM762FY	MA	Inhibitor
DM762FY	RN	Inhibition of human hepatitis B virus DNA polymerase and duck hepatitis B virus DNA polymerase by triphosphates of thymidine analogs and pharmacokinetic properties of the corresponding nucleosides. JMed Virol. 1988 Dec;26(4):353-62.
DM762FY	RU	https://pubmed.ncbi.nlm.nih.gov/3145322

DMSPVXM	DI	DMSPVXM
DMSPVXM	DN	5-Propyl-1H-pyrazole-3-carboxylic acid
DMSPVXM	MI	TTWNV8U
DMSPVXM	MN	Nicotinic acid receptor (HCAR2)
DMSPVXM	MT	DTT
DMSPVXM	MA	Inhibitor
DMSPVXM	RN	Pyrazole derivatives as partial agonists for the nicotinic acid receptor. J Med Chem. 2003 Aug 28;46(18):3945-51.
DMSPVXM	RU	https://pubmed.ncbi.nlm.nih.gov/12930155

DM9IHV6	DI	DM9IHV6
DM9IHV6	DN	5-propyl-2'-deoxyuridine
DM9IHV6	MI	TTP3QRF
DM9IHV6	MN	Thymidine kinase 1 (TK1)
DM9IHV6	MT	DTT
DM9IHV6	MA	Inhibitor
DM9IHV6	RN	Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate anal... Antimicrob Agents Chemother. 2007 Jun;51(6):2028-34.
DM9IHV6	RU	https://pubmed.ncbi.nlm.nih.gov/17438061

DM2W0AD	DI	DM2W0AD
DM2W0AD	DN	5-p-Tolyl-1H-[1,2,3]triazole
DM2W0AD	MI	TTZL0OI
DM2W0AD	MN	Methionine aminopeptidase 2 (METAP2)
DM2W0AD	MT	DTT
DM2W0AD	MA	Inhibitor
DM2W0AD	RN	4-Aryl-1,2,3-triazole: a novel template for a reversible methionine aminopeptidase 2 inhibitor, optimized to inhibit angiogenesis in vivo. J Med Chem. 2005 Sep 8;48(18):5644-7.
DM2W0AD	RU	https://pubmed.ncbi.nlm.nih.gov/16134930

DMV4ICS	DI	DMV4ICS
DMV4ICS	DN	5-p-Tolylsulfanyl-quinazoline-2,4-diamine
DMV4ICS	MI	TT9SL3Q
DMV4ICS	MN	Polypeptide deformylase (PDF)
DMV4ICS	MT	DTT
DMV4ICS	MA	Inhibitor
DMV4ICS	RN	X-Ray crystal structures of Candida albicans dihydrofolate reductase: high resolution ternary complexes in which the dihydronicotinamide moiety of ... J Med Chem. 2001 Aug 30;44(18):2928-32.
DMV4ICS	RU	https://pubmed.ncbi.nlm.nih.gov/11520201

DMLRM9Z	DI	DMLRM9Z
DMLRM9Z	DN	5-Pyridin-3-yl-1,3-dihydro-2H-indol-2-one
DMLRM9Z	MI	TTSZLWK
DMLRM9Z	MN	Aromatase (CYP19A1)
DMLRM9Z	MT	DTT
DMLRM9Z	MA	Inhibitor
DMLRM9Z	RN	In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87.
DMLRM9Z	RU	https://pubmed.ncbi.nlm.nih.gov/19049427

DMLRM9Z	DI	DMLRM9Z
DMLRM9Z	DN	5-Pyridin-3-yl-1,3-dihydro-2H-indol-2-one
DMLRM9Z	MI	TTIQUX7
DMLRM9Z	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMLRM9Z	MT	DTT
DMLRM9Z	MA	Inhibitor
DMLRM9Z	RN	In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87.
DMLRM9Z	RU	https://pubmed.ncbi.nlm.nih.gov/19049427

DMQYIBC	DI	DMQYIBC
DMQYIBC	DN	5-Pyridin-3-yl-2,3-dihydro-1H-inden-1-one
DMQYIBC	MI	TTSZLWK
DMQYIBC	MN	Aromatase (CYP19A1)
DMQYIBC	MT	DTT
DMQYIBC	MA	Inhibitor
DMQYIBC	RN	In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87.
DMQYIBC	RU	https://pubmed.ncbi.nlm.nih.gov/19049427

DMQYIBC	DI	DMQYIBC
DMQYIBC	DN	5-Pyridin-3-yl-2,3-dihydro-1H-inden-1-one
DMQYIBC	MI	TTIQUX7
DMQYIBC	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMQYIBC	MT	DTT
DMQYIBC	MA	Inhibitor
DMQYIBC	RN	In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87.
DMQYIBC	RU	https://pubmed.ncbi.nlm.nih.gov/19049427

DMZQPTU	DI	DMZQPTU
DMZQPTU	DN	5-Pyridin-3-yl-thiophene-2-carbaldehyde oxime
DMZQPTU	MI	TTXV4FI
DMZQPTU	MN	Albendazole monooxygenase (CYP3A4)
DMZQPTU	MT	DTT
DMZQPTU	MA	Inhibitor
DMZQPTU	RN	5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6. J Med Chem. 2005 Jan 13;48(1):224-39.
DMZQPTU	RU	https://pubmed.ncbi.nlm.nih.gov/15634016

DMNYQGS	DI	DMNYQGS
DMNYQGS	DN	5''-Quinolin-4-yl-[2,4'']bithiazolyl-2''-ylamine
DMNYQGS	MI	TTP4520
DMNYQGS	MN	TGF-beta receptor type I (TGFBR1)
DMNYQGS	MT	DTT
DMNYQGS	MA	Inhibitor
DMNYQGS	RN	Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors. J Med Chem. 2004 Aug 26;47(18):4494-506.
DMNYQGS	RU	https://pubmed.ncbi.nlm.nih.gov/15317461

DMVX063	DI	DMVX063
DMVX063	DN	5-QUINOXALIN-6-YLMETHYLENE-THIAZOLIDINE-2,4-DIONE
DMVX063	MI	TTGP7BY
DMVX063	MN	Monoamine oxidase type B (MAO-B)
DMVX063	MT	DTT
DMVX063	MA	Inhibitor
DMVX063	RN	Identification of novel monoamine oxidase B inhibitors by structure-based virtual screening. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5295-8.
DMVX063	RU	https://pubmed.ncbi.nlm.nih.gov/20650633

DMVX063	DI	DMVX063
DMVX063	DN	5-QUINOXALIN-6-YLMETHYLENE-THIAZOLIDINE-2,4-DIONE
DMVX063	MI	TTHBTOP
DMVX063	MN	PI3-kinase gamma (PIK3CG)
DMVX063	MT	DTT
DMVX063	MA	Inhibitor
DMVX063	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMVX063	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM0PQH1	DI	DM0PQH1
DM0PQH1	DN	5'-S-ethyl-5'-thioadenosine
DM0PQH1	MI	TTE2KUJ
DM0PQH1	MN	Adenosylhomocysteinase (AHCY)
DM0PQH1	MT	DTT
DM0PQH1	MA	Inhibitor
DM0PQH1	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM0PQH1	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM3Z6G4	DI	DM3Z6G4
DM3Z6G4	DN	5S-HETE
DM3Z6G4	MI	TT2J34L
DM3Z6G4	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM3Z6G4	MT	DTT
DM3Z6G4	MA	Inhibitor
DM3Z6G4	RN	Preview of potential therapeutic applications of leukotriene B4 inhibitors in dermatology. Skin Pharmacol Appl Skin Physiol. 2000 Sep-Oct;13(5):235-45.
DM3Z6G4	RU	https://pubmed.ncbi.nlm.nih.gov/10940813

DM3Z6G4	DI	DM3Z6G4
DM3Z6G4	DN	5S-HETE
DM3Z6G4	MI	TT7WBSV
DM3Z6G4	MN	Oxoeicosanoid receptor 1 (OXER1)
DM3Z6G4	MT	DTT
DM3Z6G4	MA	Agonist
DM3Z6G4	RN	TG1019/OXE, a Galpha(i/o)-protein-coupled receptor, mediates 5-oxo-eicosatetraenoic acid-induced chemotaxis. Biochem Biophys Res Commun. 2005 Sep 9;334(4):987-95.
DM3Z6G4	RU	https://pubmed.ncbi.nlm.nih.gov/16039985

DM3Z6G4	DI	DM3Z6G4
DM3Z6G4	DN	5S-HETE
DM3Z6G4	MI	TTMI6F5
DM3Z6G4	MN	Transient receptor potential cation channel V1 (TRPV1)
DM3Z6G4	MT	DTT
DM3Z6G4	MA	Activator
DM3Z6G4	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 507).
DM3Z6G4	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=507

DME1304	DI	DME1304
DME1304	DN	5S-HPETE
DME1304	MI	TT7WBSV
DME1304	MN	Oxoeicosanoid receptor 1 (OXER1)
DME1304	MT	DTT
DME1304	MA	Agonist
DME1304	RN	TG1019/OXE, a Galpha(i/o)-protein-coupled receptor, mediates 5-oxo-eicosatetraenoic acid-induced chemotaxis. Biochem Biophys Res Commun. 2005 Sep 9;334(4):987-95.
DME1304	RU	https://pubmed.ncbi.nlm.nih.gov/16039985

DME1304	DI	DME1304
DME1304	DN	5S-HPETE
DME1304	MI	TTMI6F5
DME1304	MN	Transient receptor potential cation channel V1 (TRPV1)
DME1304	MT	DTT
DME1304	MA	Activator
DME1304	RN	Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc Natl Acad Sci U S A. 2000 May 23;97(11):6155-60.
DME1304	RU	https://pubmed.ncbi.nlm.nih.gov/10823958

DMCG6EK	DI	DMCG6EK
DMCG6EK	DN	5-tert-Butyl-2-(4-ethynyl-phenyl)-[1,3]dithiane
DMCG6EK	MI	TTNJYV2
DMCG6EK	MN	Gamma-aminobutyric acid receptor (GAR)
DMCG6EK	MT	DTT
DMCG6EK	MA	Inhibitor
DMCG6EK	RN	Synthesis of carbon-11-, fluorine-18-, and iodine-125-labeled GABAA-gated chloride ion channel blockers: substituted 5-tert-butyl-2-phenyl-1,3-dith... J Med Chem. 1995 Jul 7;38(14):2663-71.
DMCG6EK	RU	https://pubmed.ncbi.nlm.nih.gov/7629805

DMQK32F	DI	DMQK32F
DMQK32F	DN	5-tert-Butyl-2-(4-fluoro-phenyl)-[1,3]dithiane
DMQK32F	MI	TTNJYV2
DMQK32F	MN	Gamma-aminobutyric acid receptor (GAR)
DMQK32F	MT	DTT
DMQK32F	MA	Inhibitor
DMQK32F	RN	Synthesis of carbon-11-, fluorine-18-, and iodine-125-labeled GABAA-gated chloride ion channel blockers: substituted 5-tert-butyl-2-phenyl-1,3-dith... J Med Chem. 1995 Jul 7;38(14):2663-71.
DMQK32F	RU	https://pubmed.ncbi.nlm.nih.gov/7629805

DMF4RGW	DI	DMF4RGW
DMF4RGW	DN	5-thia-8,11,14,17-eicosatetraenoic acid
DMF4RGW	MI	TTVKILB
DMF4RGW	MN	Prostaglandin G/H synthase 2 (COX-2)
DMF4RGW	MT	DTT
DMF4RGW	MA	Inhibitor
DMF4RGW	RN	Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
DMF4RGW	RU	https://pubmed.ncbi.nlm.nih.gov/11421736

DMTB91D	DI	DMTB91D
DMTB91D	DN	5-tosyl-5H-dibenzo[b,d]azepin-7(6H)-one
DMTB91D	MI	TTMNI76
DMTB91D	MN	Calcium-activated potassium channel (KCN)
DMTB91D	MT	DTT
DMTB91D	MA	Inhibitor
DMTB91D	RN	Inhibitors of potassium channels KV1.3 and IK-1 as immunosuppressants. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2299-304.
DMTB91D	RU	https://pubmed.ncbi.nlm.nih.gov/19282171

DMOR04W	DI	DMOR04W
DMOR04W	DN	6-((1H-imidazol-1-yl)methyl)-2H-chromene-2-thione
DMOR04W	MI	TTSZLWK
DMOR04W	MN	Aromatase (CYP19A1)
DMOR04W	MT	DTT
DMOR04W	MA	Inhibitor
DMOR04W	RN	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
DMOR04W	RU	https://pubmed.ncbi.nlm.nih.gov/19072235

DM5RX0K	DI	DM5RX0K
DM5RX0K	DN	6-(1H-Benzoimidazol-2-yl)-benzocyclohepten-7-one
DM5RX0K	MI	TTUTJGQ
DM5RX0K	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM5RX0K	MT	DTT
DM5RX0K	MA	Inhibitor
DM5RX0K	RN	Optimization of the indolyl quinolinone class of KDR (VEGFR-2) kinase inhibitors: effects of 5-amido- and 5-sulphonamido-indolyl groups on pharmaco... Bioorg Med Chem Lett. 2004 Jan 19;14(2):351-5.
DM5RX0K	RU	https://pubmed.ncbi.nlm.nih.gov/14698157

DM1TOFD	DI	DM1TOFD
DM1TOFD	DN	6-(1H-Indole-2-sulfonyl)-2H-pyridazin-3-one
DM1TOFD	MI	TTFBNVI
DM1TOFD	MN	Aldose reductase (AKR1B1)
DM1TOFD	MT	DTT
DM1TOFD	MA	Inhibitor
DM1TOFD	RN	A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3... J Med Chem. 2005 Oct 6;48(20):6326-39.
DM1TOFD	RU	https://pubmed.ncbi.nlm.nih.gov/16190759

DMRU963	DI	DMRU963
DMRU963	DN	6-(2,5-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol
DMRU963	MI	TTZAYWL
DMRU963	MN	Estrogen receptor (ESR)
DMRU963	MT	DTT
DMRU963	MA	Inhibitor
DMRU963	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DMRU963	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMRU963	DI	DMRU963
DMRU963	DN	6-(2,5-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol
DMRU963	MI	TTOM3J0
DMRU963	MN	Estrogen receptor beta (ESR2)
DMRU963	MT	DTT
DMRU963	MA	Inhibitor
DMRU963	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DMRU963	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMFALTY	DI	DMFALTY
DMFALTY	DN	6-(2,6-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol
DMFALTY	MI	TTZAYWL
DMFALTY	MN	Estrogen receptor (ESR)
DMFALTY	MT	DTT
DMFALTY	MA	Inhibitor
DMFALTY	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DMFALTY	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMFALTY	DI	DMFALTY
DMFALTY	DN	6-(2,6-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol
DMFALTY	MI	TTOM3J0
DMFALTY	MN	Estrogen receptor beta (ESR2)
DMFALTY	MT	DTT
DMFALTY	MA	Inhibitor
DMFALTY	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DMFALTY	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMA9LFR	DI	DMA9LFR
DMA9LFR	DN	6-(2-acetylphenyl)-2-morpholin-4-ylchromen-4-one
DMA9LFR	MI	TTK3PY9
DMA9LFR	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMA9LFR	MT	DTT
DMA9LFR	MA	Inhibitor
DMA9LFR	RN	Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46.
DMA9LFR	RU	https://pubmed.ncbi.nlm.nih.gov/16302822

DMO724D	DI	DMO724D
DMO724D	DN	6-(2-Amino-ethyl)-biphenyl-2,3,4'-triol
DMO724D	MI	TTZFYLI
DMO724D	MN	Dopamine D1 receptor (D1R)
DMO724D	MT	DTT
DMO724D	MA	Inhibitor
DMO724D	RN	Synthesis and dopaminergic binding of 2-aryldopamine analogues: phenethylamines, 3-benzazepines, and 9-(aminomethyl)fluorenes. J Med Chem. 1986 Oct;29(10):1904-12.
DMO724D	RU	https://pubmed.ncbi.nlm.nih.gov/3761310

DMI8KOF	DI	DMI8KOF
DMI8KOF	DN	6-(2-Amino-ethyl)-biphenyl-2,3-diol
DMI8KOF	MI	TTZFYLI
DMI8KOF	MN	Dopamine D1 receptor (D1R)
DMI8KOF	MT	DTT
DMI8KOF	MA	Inhibitor
DMI8KOF	RN	Synthesis and dopaminergic binding of 2-aryldopamine analogues: phenethylamines, 3-benzazepines, and 9-(aminomethyl)fluorenes. J Med Chem. 1986 Oct;29(10):1904-12.
DMI8KOF	RU	https://pubmed.ncbi.nlm.nih.gov/3761310

DMXFRW9	DI	DMXFRW9
DMXFRW9	DN	6-(2-aminophenoxy)benzo[d]isothiazol-3-amine
DMXFRW9	MI	TTISGCA
DMXFRW9	MN	Toll-like receptor 4 (TLR4)
DMXFRW9	MT	DTT
DMXFRW9	MA	Inhibitor
DMXFRW9	RN	Small molecule modulators of toll-like receptors. J Med Chem. 2008 Nov 13;51(21):6621-6.
DMXFRW9	RU	https://pubmed.ncbi.nlm.nih.gov/18828583

DMUD2R9	DI	DMUD2R9
DMUD2R9	DN	6-(2-benzylisoindolin-5-yloxy)nicotinamide
DMUD2R9	MI	TTKWM86
DMUD2R9	MN	Opioid receptor mu (MOP)
DMUD2R9	MT	DTT
DMUD2R9	MA	Inhibitor
DMUD2R9	RN	Structure activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 2. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6841-6.
DMUD2R9	RU	https://pubmed.ncbi.nlm.nih.gov/17980586

DM9LKXD	DI	DM9LKXD
DM9LKXD	DN	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide
DM9LKXD	MI	TTBH0VX
DM9LKXD	MN	Histone deacetylase (HDAC)
DM9LKXD	MT	DTT
DM9LKXD	MA	Inhibitor
DM9LKXD	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DM9LKXD	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DM9LKXD	DI	DM9LKXD
DM9LKXD	DN	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide
DM9LKXD	MI	TT6R7JZ
DM9LKXD	MN	Histone deacetylase 1 (HDAC1)
DM9LKXD	MT	DTT
DM9LKXD	MA	Inhibitor
DM9LKXD	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DM9LKXD	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DM9LKXD	DI	DM9LKXD
DM9LKXD	DN	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide
DM9LKXD	MI	TTYHPU6
DM9LKXD	MN	Histone deacetylase 10 (HDAC10)
DM9LKXD	MT	DTT
DM9LKXD	MA	Inhibitor
DM9LKXD	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DM9LKXD	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DM9LKXD	DI	DM9LKXD
DM9LKXD	DN	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide
DM9LKXD	MI	TTSHTOI
DM9LKXD	MN	Histone deacetylase 2 (HDAC2)
DM9LKXD	MT	DTT
DM9LKXD	MA	Inhibitor
DM9LKXD	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DM9LKXD	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DM9LKXD	DI	DM9LKXD
DM9LKXD	DN	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide
DM9LKXD	MI	TTTQGH8
DM9LKXD	MN	Histone deacetylase 4 (HDAC4)
DM9LKXD	MT	DTT
DM9LKXD	MA	Inhibitor
DM9LKXD	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DM9LKXD	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DM9LKXD	DI	DM9LKXD
DM9LKXD	DN	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide
DM9LKXD	MI	TT5ZKDI
DM9LKXD	MN	Histone deacetylase 6 (HDAC6)
DM9LKXD	MT	DTT
DM9LKXD	MA	Inhibitor
DM9LKXD	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DM9LKXD	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DM9LKXD	DI	DM9LKXD
DM9LKXD	DN	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide
DM9LKXD	MI	TTT6LFV
DM9LKXD	MN	Histone deacetylase 8 (HDAC8)
DM9LKXD	MT	DTT
DM9LKXD	MA	Inhibitor
DM9LKXD	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DM9LKXD	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMYDHLN	DI	DMYDHLN
DMYDHLN	DN	6-(2-Bromo-benzenesulfonyl)-2H-pyridazin-3-one
DMYDHLN	MI	TTFBNVI
DMYDHLN	MN	Aldose reductase (AKR1B1)
DMYDHLN	MT	DTT
DMYDHLN	MA	Inhibitor
DMYDHLN	RN	A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3... J Med Chem. 2005 Oct 6;48(20):6326-39.
DMYDHLN	RU	https://pubmed.ncbi.nlm.nih.gov/16190759

DMTPAMS	DI	DMTPAMS
DMTPAMS	DN	6-(2-Chloro-4-hydroxy-phenyl)-naphthalen-2-ol
DMTPAMS	MI	TTZAYWL
DMTPAMS	MN	Estrogen receptor (ESR)
DMTPAMS	MT	DTT
DMTPAMS	MA	Inhibitor
DMTPAMS	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DMTPAMS	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMTPAMS	DI	DMTPAMS
DMTPAMS	DN	6-(2-Chloro-4-hydroxy-phenyl)-naphthalen-2-ol
DMTPAMS	MI	TTOM3J0
DMTPAMS	MN	Estrogen receptor beta (ESR2)
DMTPAMS	MT	DTT
DMTPAMS	MA	Inhibitor
DMTPAMS	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DMTPAMS	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DM2Y9O4	DI	DM2Y9O4
DM2Y9O4	DN	6-(2-Chloro-benzenesulfonyl)-2H-pyridazin-3-one
DM2Y9O4	MI	TTFBNVI
DM2Y9O4	MN	Aldose reductase (AKR1B1)
DM2Y9O4	MT	DTT
DM2Y9O4	MA	Inhibitor
DM2Y9O4	RN	A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3... J Med Chem. 2005 Oct 6;48(20):6326-39.
DM2Y9O4	RU	https://pubmed.ncbi.nlm.nih.gov/16190759

DM3VME7	DI	DM3VME7
DM3VME7	DN	6-(2-Dipropylamino-ethyl)-biphenyl-2,3,4'-triol
DM3VME7	MI	TTZFYLI
DM3VME7	MN	Dopamine D1 receptor (D1R)
DM3VME7	MT	DTT
DM3VME7	MA	Inhibitor
DM3VME7	RN	Synthesis and dopaminergic binding of 2-aryldopamine analogues: phenethylamines, 3-benzazepines, and 9-(aminomethyl)fluorenes. J Med Chem. 1986 Oct;29(10):1904-12.
DM3VME7	RU	https://pubmed.ncbi.nlm.nih.gov/3761310

DMNQWZO	DI	DMNQWZO
DMNQWZO	DN	6-(2-Dipropylamino-ethyl)-biphenyl-2,3-diol
DMNQWZO	MI	TTZFYLI
DMNQWZO	MN	Dopamine D1 receptor (D1R)
DMNQWZO	MT	DTT
DMNQWZO	MA	Inhibitor
DMNQWZO	RN	Synthesis and dopaminergic binding of 2-aryldopamine analogues: phenethylamines, 3-benzazepines, and 9-(aminomethyl)fluorenes. J Med Chem. 1986 Oct;29(10):1904-12.
DMNQWZO	RU	https://pubmed.ncbi.nlm.nih.gov/3761310

DM6Q3M7	DI	DM6Q3M7
DM6Q3M7	DN	6-(2-Fluoro-4-hydroxy-phenyl)-naphthalen-2-ol
DM6Q3M7	MI	TTZAYWL
DM6Q3M7	MN	Estrogen receptor (ESR)
DM6Q3M7	MT	DTT
DM6Q3M7	MA	Inhibitor
DM6Q3M7	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DM6Q3M7	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DM6Q3M7	DI	DM6Q3M7
DM6Q3M7	DN	6-(2-Fluoro-4-hydroxy-phenyl)-naphthalen-2-ol
DM6Q3M7	MI	TTOM3J0
DM6Q3M7	MN	Estrogen receptor beta (ESR2)
DM6Q3M7	MT	DTT
DM6Q3M7	MA	Inhibitor
DM6Q3M7	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DM6Q3M7	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMQKR2W	DI	DMQKR2W
DMQKR2W	DN	6-(2-Fluoro-benzenesulfonyl)-2H-pyridazin-3-one
DMQKR2W	MI	TTFBNVI
DMQKR2W	MN	Aldose reductase (AKR1B1)
DMQKR2W	MT	DTT
DMQKR2W	MA	Inhibitor
DMQKR2W	RN	A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3... J Med Chem. 2005 Oct 6;48(20):6326-39.
DMQKR2W	RU	https://pubmed.ncbi.nlm.nih.gov/16190759

DME1JLM	DI	DME1JLM
DME1JLM	DN	6-(2-Fluoropropyl)-4-methylpyridin-2-amine
DME1JLM	MI	TTZUFI5
DME1JLM	MN	Nitric-oxide synthase brain (NOS1)
DME1JLM	MT	DTT
DME1JLM	MA	Inhibitor
DME1JLM	RN	Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [18F]6-(2-fl... J Med Chem. 2009 Apr 23;52(8):2443-53.
DME1JLM	RU	https://pubmed.ncbi.nlm.nih.gov/19323559

DME1JLM	DI	DME1JLM
DME1JLM	DN	6-(2-Fluoropropyl)-4-methylpyridin-2-amine
DME1JLM	MI	TTCM4B3
DME1JLM	MN	Nitric-oxide synthase endothelial (NOS3)
DME1JLM	MT	DTT
DME1JLM	MA	Inhibitor
DME1JLM	RN	Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [18F]6-(2-fl... J Med Chem. 2009 Apr 23;52(8):2443-53.
DME1JLM	RU	https://pubmed.ncbi.nlm.nih.gov/19323559

DME1JLM	DI	DME1JLM
DME1JLM	DN	6-(2-Fluoropropyl)-4-methylpyridin-2-amine
DME1JLM	MI	TTF10I9
DME1JLM	MN	Nitric-oxide synthase inducible (NOS2)
DME1JLM	MT	DTT
DME1JLM	MA	Inhibitor
DME1JLM	RN	Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [18F]6-(2-fl... J Med Chem. 2009 Apr 23;52(8):2443-53.
DME1JLM	RU	https://pubmed.ncbi.nlm.nih.gov/19323559

DMA2CPG	DI	DMA2CPG
DMA2CPG	DN	6-(2-HYDROXY-CYCLOPENTYL)-7-OXO-HEPTANAMIDINE
DMA2CPG	MI	TT6L509
DMA2CPG	MN	Coagulation factor IIa (F2)
DMA2CPG	MT	DTT
DMA2CPG	MA	Inhibitor
DMA2CPG	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMA2CPG	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMM3798	DI	DMM3798
DMM3798	DN	6-(2-Hydroxy-phenyl)-naphthalen-2-ol
DMM3798	MI	TTOM3J0
DMM3798	MN	Estrogen receptor beta (ESR2)
DMM3798	MT	DTT
DMM3798	MA	Inhibitor
DMM3798	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DMM3798	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMXZWOA	DI	DMXZWOA
DMXZWOA	DN	6-(2-Imidazol-1-yl-vinyl)-1H-quinolin-2-one
DMXZWOA	MI	TT06AWU
DMXZWOA	MN	Phosphodiesterase 3A (PDE3A)
DMXZWOA	MT	DTT
DMXZWOA	MA	Inhibitor
DMXZWOA	RN	3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase. J Med Chem. 1992 Feb 21;35(4):620-8.
DMXZWOA	RU	https://pubmed.ncbi.nlm.nih.gov/1311763

DM9P4LB	DI	DM9P4LB
DM9P4LB	DN	6-(2-mercaptoacetamido)-N-phenylhexanamide
DM9P4LB	MI	TTT6LFV
DM9P4LB	MN	Histone deacetylase 8 (HDAC8)
DM9P4LB	MT	DTT
DM9P4LB	MA	Inhibitor
DM9P4LB	RN	Histone deacetylase inhibitors: from bench to clinic. J Med Chem. 2008 Mar 27;51(6):1505-29.
DM9P4LB	RU	https://pubmed.ncbi.nlm.nih.gov/18247554

DMQOJBN	DI	DMQOJBN
DMQOJBN	DN	6-(2-phenethylisoindolin-5-yloxy)nicotinamide
DMQOJBN	MI	TT27RFC
DMQOJBN	MN	Opioid receptor delta (OPRD1)
DMQOJBN	MT	DTT
DMQOJBN	MA	Inhibitor
DMQOJBN	RN	Structure activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 2. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6841-6.
DMQOJBN	RU	https://pubmed.ncbi.nlm.nih.gov/17980586

DMQOJBN	DI	DMQOJBN
DMQOJBN	DN	6-(2-phenethylisoindolin-5-yloxy)nicotinamide
DMQOJBN	MI	TTKWM86
DMQOJBN	MN	Opioid receptor mu (MOP)
DMQOJBN	MT	DTT
DMQOJBN	MA	Inhibitor
DMQOJBN	RN	Structure activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 2. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6841-6.
DMQOJBN	RU	https://pubmed.ncbi.nlm.nih.gov/17980586

DMKXNP0	DI	DMKXNP0
DMKXNP0	DN	6-(2-Phenylsulfanyl-ethyl)-pteridine-2,4-diamine
DMKXNP0	MI	TT9SL3Q
DMKXNP0	MN	Polypeptide deformylase (PDF)
DMKXNP0	MT	DTT
DMKXNP0	MA	Inhibitor
DMKXNP0	RN	Further studies on 2,4-diamino-5-(2',5'-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three ... J Med Chem. 2003 Apr 24;46(9):1726-36.
DMKXNP0	RU	https://pubmed.ncbi.nlm.nih.gov/12699390

DMA8TWC	DI	DMA8TWC
DMA8TWC	DN	6-(3-(pyridin-4-yl)phenyl)naphthalen-2-ol
DMA8TWC	MI	TTRA5BZ
DMA8TWC	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMA8TWC	MT	DTT
DMA8TWC	MA	Inhibitor
DMA8TWC	RN	Synthesis, biological evaluation and molecular modelling studies of novel ACD- and ABD-ring steroidomimetics as inhibitors of CYP17. Bioorg Med Chem Lett. 2008 Jan 1;18(1):267-73.
DMA8TWC	RU	https://pubmed.ncbi.nlm.nih.gov/18024111

DMDYQE2	DI	DMDYQE2
DMDYQE2	DN	6-(3-(trifluoromethyl)phenyl)picolinonitrile
DMDYQE2	MI	TTUMQVO
DMDYQE2	MN	Cathepsin S (CTSS)
DMDYQE2	MT	DTT
DMDYQE2	MA	Inhibitor
DMDYQE2	RN	4-(3-Trifluoromethylphenyl)-pyrimidine-2-carbonitrile as cathepsin S inhibitors: N3, not N1 is critically important. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4507-10.
DMDYQE2	RU	https://pubmed.ncbi.nlm.nih.gov/20580231

DMZHFWX	DI	DMZHFWX
DMZHFWX	DN	6-(3,4-DICHLOROPHENYL)-1-[1-(METHYLOXY)-3-BUTEN-1-YL]-3-AZABICYCLO[4.1.0]HEPTANE (DIASTEREOMERIC MIX)
DMZHFWX	MI	TTXV4FI
DMZHFWX	MN	Albendazole monooxygenase (CYP3A4)
DMZHFWX	MT	DTT
DMZHFWX	MA	Inhibitor
DMZHFWX	RN	6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor. J Med Chem. 2010 Jul 8;53(13):4989-5001.
DMZHFWX	RU	https://pubmed.ncbi.nlm.nih.gov/20527970

DMZHFWX	DI	DMZHFWX
DMZHFWX	DN	6-(3,4-DICHLOROPHENYL)-1-[1-(METHYLOXY)-3-BUTEN-1-YL]-3-AZABICYCLO[4.1.0]HEPTANE (DIASTEREOMERIC MIX)
DMZHFWX	MI	TTVG215
DMZHFWX	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DMZHFWX	MT	DTT
DMZHFWX	MA	Inhibitor
DMZHFWX	RN	6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor. J Med Chem. 2010 Jul 8;53(13):4989-5001.
DMZHFWX	RU	https://pubmed.ncbi.nlm.nih.gov/20527970

DMKJOL6	DI	DMKJOL6
DMKJOL6	DN	6-(3,5-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol
DMKJOL6	MI	TTZAYWL
DMKJOL6	MN	Estrogen receptor (ESR)
DMKJOL6	MT	DTT
DMKJOL6	MA	Inhibitor
DMKJOL6	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DMKJOL6	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMKJOL6	DI	DMKJOL6
DMKJOL6	DN	6-(3,5-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol
DMKJOL6	MI	TTOM3J0
DMKJOL6	MN	Estrogen receptor beta (ESR2)
DMKJOL6	MT	DTT
DMKJOL6	MA	Inhibitor
DMKJOL6	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DMKJOL6	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMIXT2L	DI	DMIXT2L
DMIXT2L	DN	6-(3,5-dimethoxy-phenyl)-naphthalen-2-ol
DMIXT2L	MI	TT3OT40
DMIXT2L	MN	Multidrug resistance protein 1 (ABCB1)
DMIXT2L	MT	DTT
DMIXT2L	MA	Inhibitor
DMIXT2L	RN	Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells. J Med Chem. 2006 May 18;49(10):3012-8.
DMIXT2L	RU	https://pubmed.ncbi.nlm.nih.gov/16686543

DMJ92W0	DI	DMJ92W0
DMJ92W0	DN	6-(3-Amino-benzyloxy)-9H-purin-2-ylamine
DMJ92W0	MI	TTAMQ62
DMJ92W0	MN	Cyclin A2 (CCNA2)
DMJ92W0	MT	DTT
DMJ92W0	MA	Inhibitor
DMJ92W0	RN	Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives. J Med Chem. 2002 Aug 1;45(16):3381-93.
DMJ92W0	RU	https://pubmed.ncbi.nlm.nih.gov/12139449

DMJ92W0	DI	DMJ92W0
DMJ92W0	DN	6-(3-Amino-benzyloxy)-9H-purin-2-ylamine
DMJ92W0	MI	TT7HF4W
DMJ92W0	MN	Cyclin-dependent kinase 2 (CDK2)
DMJ92W0	MT	DTT
DMJ92W0	MA	Inhibitor
DMJ92W0	RN	Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives. J Med Chem. 2002 Aug 1;45(16):3381-93.
DMJ92W0	RU	https://pubmed.ncbi.nlm.nih.gov/12139449

DMYA4D2	DI	DMYA4D2
DMYA4D2	DN	6-(3-aminopropyl)benzo[h]isoquinolin-1(2H)-one
DMYA4D2	MI	TTTU902
DMYA4D2	MN	Checkpoint kinase-1 (CHK1)
DMYA4D2	MT	DTT
DMYA4D2	MA	Inhibitor
DMYA4D2	RN	Synthesis and evaluation of substituted benzoisoquinolinones as potent inhibitors of Chk1 kinase. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6280-5.
DMYA4D2	RU	https://pubmed.ncbi.nlm.nih.gov/17900896

DMKFDQ7	DI	DMKFDQ7
DMKFDQ7	DN	6-(3-aza-bicyclo[3.1.0]hexan-1-yl)quinoline
DMKFDQ7	MI	TTVBI8W
DMKFDQ7	MN	Dopamine transporter (DAT)
DMKFDQ7	MT	DTT
DMKFDQ7	MA	Inhibitor
DMKFDQ7	RN	Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3682-6.
DMKFDQ7	RU	https://pubmed.ncbi.nlm.nih.gov/18539031

DMKFDQ7	DI	DMKFDQ7
DMKFDQ7	DN	6-(3-aza-bicyclo[3.1.0]hexan-1-yl)quinoline
DMKFDQ7	MI	TT3ROYC
DMKFDQ7	MN	Serotonin transporter (SERT)
DMKFDQ7	MT	DTT
DMKFDQ7	MA	Inhibitor
DMKFDQ7	RN	Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3682-6.
DMKFDQ7	RU	https://pubmed.ncbi.nlm.nih.gov/18539031

DMQZTS3	DI	DMQZTS3
DMQZTS3	DN	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide
DMQZTS3	MI	TT6R7JZ
DMQZTS3	MN	Histone deacetylase 1 (HDAC1)
DMQZTS3	MT	DTT
DMQZTS3	MA	Inhibitor
DMQZTS3	RN	Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3314-21.
DMQZTS3	RU	https://pubmed.ncbi.nlm.nih.gov/20451378

DM89LF5	DI	DM89LF5
DM89LF5	DN	6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE
DM89LF5	MI	TT78R5H
DM89LF5	MN	Heat shock protein 90 alpha (HSP90A)
DM89LF5	MT	DTT
DM89LF5	MA	Inhibitor
DM89LF5	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM89LF5	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMMFWYX	DI	DMMFWYX
DMMFWYX	DN	6-(3-Bromo-phenylamino)-1H-pyrimidine-2,4-dione
DMMFWYX	MI	TT2GPK3
DMMFWYX	MN	DNA topoisomerase (TOP)
DMMFWYX	MT	DTT
DMMFWYX	MA	Inhibitor
DMMFWYX	RN	Inhibitors of Bacillus subtilis DNA polymerase III. 6-Anilinouracils and 6-(alkylamino)uracils. J Med Chem. 1980 Jan;23(1):34-8.
DMMFWYX	RU	https://pubmed.ncbi.nlm.nih.gov/6767030

DM4YP3Q	DI	DM4YP3Q
DM4YP3Q	DN	6-(3-Chloro-4-hydroxy-phenyl)-naphthalen-2-ol
DM4YP3Q	MI	TTZAYWL
DM4YP3Q	MN	Estrogen receptor (ESR)
DM4YP3Q	MT	DTT
DM4YP3Q	MA	Inhibitor
DM4YP3Q	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DM4YP3Q	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DM4YP3Q	DI	DM4YP3Q
DM4YP3Q	DN	6-(3-Chloro-4-hydroxy-phenyl)-naphthalen-2-ol
DM4YP3Q	MI	TTOM3J0
DM4YP3Q	MN	Estrogen receptor beta (ESR2)
DM4YP3Q	MT	DTT
DM4YP3Q	MA	Inhibitor
DM4YP3Q	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DM4YP3Q	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMJO4I7	DI	DMJO4I7
DMJO4I7	DN	6-(3-Chloro-benzenesulfonyl)-2H-pyridazin-3-one
DMJO4I7	MI	TTFBNVI
DMJO4I7	MN	Aldose reductase (AKR1B1)
DMJO4I7	MT	DTT
DMJO4I7	MA	Inhibitor
DMJO4I7	RN	A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3... J Med Chem. 2005 Oct 6;48(20):6326-39.
DMJO4I7	RU	https://pubmed.ncbi.nlm.nih.gov/16190759

DMKUHN9	DI	DMKUHN9
DMKUHN9	DN	6-(3-Ethyl-phenylamino)-1H-pyrimidine-2,4-dione
DMKUHN9	MI	TT2GPK3
DMKUHN9	MN	DNA topoisomerase (TOP)
DMKUHN9	MT	DTT
DMKUHN9	MA	Inhibitor
DMKUHN9	RN	Inhibitors of Bacillus subtilis DNA polymerase III. 6-Anilinouracils and 6-(alkylamino)uracils. J Med Chem. 1980 Jan;23(1):34-8.
DMKUHN9	RU	https://pubmed.ncbi.nlm.nih.gov/6767030

DMKUHN9	DI	DMKUHN9
DMKUHN9	DN	6-(3-Ethyl-phenylamino)-1H-pyrimidine-2,4-dione
DMKUHN9	MI	TTIU7X1
DMKUHN9	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMKUHN9	MT	DTT
DMKUHN9	MA	Inhibitor
DMKUHN9	RN	Inhibitors of Bacillus subtilis DNA polymerase III. 6-Anilinouracils and 6-(alkylamino)uracils. J Med Chem. 1980 Jan;23(1):34-8.
DMKUHN9	RU	https://pubmed.ncbi.nlm.nih.gov/6767030

DMAJEDG	DI	DMAJEDG
DMAJEDG	DN	6-(3-Fluoro-4-hydroxy-phenyl)-naphthalen-2-ol
DMAJEDG	MI	TTZAYWL
DMAJEDG	MN	Estrogen receptor (ESR)
DMAJEDG	MT	DTT
DMAJEDG	MA	Inhibitor
DMAJEDG	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DMAJEDG	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMAJEDG	DI	DMAJEDG
DMAJEDG	DN	6-(3-Fluoro-4-hydroxy-phenyl)-naphthalen-2-ol
DMAJEDG	MI	TTOM3J0
DMAJEDG	MN	Estrogen receptor beta (ESR2)
DMAJEDG	MT	DTT
DMAJEDG	MA	Inhibitor
DMAJEDG	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DMAJEDG	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMTJPZU	DI	DMTJPZU
DMTJPZU	DN	6-(3-Fluoropropyl)-4-methylpyridin-2-amine
DMTJPZU	MI	TTZUFI5
DMTJPZU	MN	Nitric-oxide synthase brain (NOS1)
DMTJPZU	MT	DTT
DMTJPZU	MA	Inhibitor
DMTJPZU	RN	Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [18F]6-(2-fl... J Med Chem. 2009 Apr 23;52(8):2443-53.
DMTJPZU	RU	https://pubmed.ncbi.nlm.nih.gov/19323559

DMTJPZU	DI	DMTJPZU
DMTJPZU	DN	6-(3-Fluoropropyl)-4-methylpyridin-2-amine
DMTJPZU	MI	TTCM4B3
DMTJPZU	MN	Nitric-oxide synthase endothelial (NOS3)
DMTJPZU	MT	DTT
DMTJPZU	MA	Inhibitor
DMTJPZU	RN	Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [18F]6-(2-fl... J Med Chem. 2009 Apr 23;52(8):2443-53.
DMTJPZU	RU	https://pubmed.ncbi.nlm.nih.gov/19323559

DMTJPZU	DI	DMTJPZU
DMTJPZU	DN	6-(3-Fluoropropyl)-4-methylpyridin-2-amine
DMTJPZU	MI	TTF10I9
DMTJPZU	MN	Nitric-oxide synthase inducible (NOS2)
DMTJPZU	MT	DTT
DMTJPZU	MA	Inhibitor
DMTJPZU	RN	Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [18F]6-(2-fl... J Med Chem. 2009 Apr 23;52(8):2443-53.
DMTJPZU	RU	https://pubmed.ncbi.nlm.nih.gov/19323559

DMMZENV	DI	DMMZENV
DMMZENV	DN	6-(3-Hydroxyphenyl)-1-phenyl-2-naphthol
DMMZENV	MI	TTIWB6L
DMMZENV	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMMZENV	MT	DTT
DMMZENV	MA	Inhibitor
DMMZENV	RN	Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design,... J Med Chem. 2008 Aug 14;51(15):4685-98.
DMMZENV	RU	https://pubmed.ncbi.nlm.nih.gov/18630892

DM28DPY	DI	DM28DPY
DM28DPY	DN	6-(3-hydroxyphenyl)-2-morpholino-4H-chromen-4-one
DM28DPY	MI	TTK3PY9
DM28DPY	MN	DNA-dependent protein kinase catalytic (PRKDC)
DM28DPY	MT	DTT
DM28DPY	MA	Inhibitor
DM28DPY	RN	Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46.
DM28DPY	RU	https://pubmed.ncbi.nlm.nih.gov/16302822

DMMHRVO	DI	DMMHRVO
DMMHRVO	DN	6-(3-Hydroxy-phenyl)-naphthalen-1-ol
DMMHRVO	MI	TTZAYWL
DMMHRVO	MN	Estrogen receptor (ESR)
DMMHRVO	MT	DTT
DMMHRVO	MA	Inhibitor
DMMHRVO	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DMMHRVO	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMMHRVO	DI	DMMHRVO
DMMHRVO	DN	6-(3-Hydroxy-phenyl)-naphthalen-1-ol
DMMHRVO	MI	TTOM3J0
DMMHRVO	MN	Estrogen receptor beta (ESR2)
DMMHRVO	MT	DTT
DMMHRVO	MA	Inhibitor
DMMHRVO	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DMMHRVO	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMH8WA2	DI	DMH8WA2
DMH8WA2	DN	6-(3-Hydroxy-phenyl)-naphthalen-2-ol
DMH8WA2	MI	TTXV4FI
DMH8WA2	MN	Albendazole monooxygenase (CYP3A4)
DMH8WA2	MT	DTT
DMH8WA2	MA	Inhibitor
DMH8WA2	RN	Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors... J Med Chem. 2008 Apr 10;51(7):2158-69.
DMH8WA2	RU	https://pubmed.ncbi.nlm.nih.gov/18324762

DMH8WA2	DI	DMH8WA2
DMH8WA2	DN	6-(3-Hydroxy-phenyl)-naphthalen-2-ol
DMH8WA2	MI	TTIWB6L
DMH8WA2	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMH8WA2	MT	DTT
DMH8WA2	MA	Inhibitor
DMH8WA2	RN	Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design,... J Med Chem. 2008 Aug 14;51(15):4685-98.
DMH8WA2	RU	https://pubmed.ncbi.nlm.nih.gov/18630892

DMH8WA2	DI	DMH8WA2
DMH8WA2	DN	6-(3-Hydroxy-phenyl)-naphthalen-2-ol
DMH8WA2	MI	TTZAYWL
DMH8WA2	MN	Estrogen receptor (ESR)
DMH8WA2	MT	DTT
DMH8WA2	MA	Inhibitor
DMH8WA2	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DMH8WA2	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMH8WA2	DI	DMH8WA2
DMH8WA2	DN	6-(3-Hydroxy-phenyl)-naphthalen-2-ol
DMH8WA2	MI	TTOM3J0
DMH8WA2	MN	Estrogen receptor beta (ESR2)
DMH8WA2	MT	DTT
DMH8WA2	MA	Inhibitor
DMH8WA2	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DMH8WA2	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMH8WA2	DI	DMH8WA2
DMH8WA2	DN	6-(3-Hydroxy-phenyl)-naphthalen-2-ol
DMH8WA2	MI	TTULVH8
DMH8WA2	MN	Tyrosinase (TYR)
DMH8WA2	MT	DTT
DMH8WA2	MA	Inhibitor
DMH8WA2	RN	Syntheses of hydroxy substituted 2-phenyl-naphthalenes as inhibitors of tyrosinase. Bioorg Med Chem Lett. 2007 Jan 15;17(2):461-4.
DMH8WA2	RU	https://pubmed.ncbi.nlm.nih.gov/17064896

DMISV5A	DI	DMISV5A
DMISV5A	DN	6-(3-Iodo-phenylamino)-1H-pyrimidine-2,4-dione
DMISV5A	MI	TT2GPK3
DMISV5A	MN	DNA topoisomerase (TOP)
DMISV5A	MT	DTT
DMISV5A	MA	Inhibitor
DMISV5A	RN	Inhibitors of Bacillus subtilis DNA polymerase III. 6-Anilinouracils and 6-(alkylamino)uracils. J Med Chem. 1980 Jan;23(1):34-8.
DMISV5A	RU	https://pubmed.ncbi.nlm.nih.gov/6767030

DMSW3KN	DI	DMSW3KN
DMSW3KN	DN	6-(3-Methyl-benzyloxy)-9H-purin-2-ylamine
DMSW3KN	MI	TTAMQ62
DMSW3KN	MN	Cyclin A2 (CCNA2)
DMSW3KN	MT	DTT
DMSW3KN	MA	Inhibitor
DMSW3KN	RN	Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives. J Med Chem. 2002 Aug 1;45(16):3381-93.
DMSW3KN	RU	https://pubmed.ncbi.nlm.nih.gov/12139449

DMSW3KN	DI	DMSW3KN
DMSW3KN	DN	6-(3-Methyl-benzyloxy)-9H-purin-2-ylamine
DMSW3KN	MI	TT7HF4W
DMSW3KN	MN	Cyclin-dependent kinase 2 (CDK2)
DMSW3KN	MT	DTT
DMSW3KN	MA	Inhibitor
DMSW3KN	RN	Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives. J Med Chem. 2002 Aug 1;45(16):3381-93.
DMSW3KN	RU	https://pubmed.ncbi.nlm.nih.gov/12139449

DM83VN6	DI	DM83VN6
DM83VN6	DN	6-(3-Nitro-phenyl)-3H-benzothiazol-2-one
DM83VN6	MI	TTUV8G9
DM83VN6	MN	Progesterone receptor (PGR)
DM83VN6	MT	DTT
DM83VN6	MA	Inhibitor
DM83VN6	RN	Synthesis and structure-activity relationship of novel 6-aryl-1,4-dihydrobenzo[d][1,3]oxazine-2-thiones as progesterone receptor modulators leading... J Med Chem. 2005 Aug 11;48(16):5092-5.
DM83VN6	RU	https://pubmed.ncbi.nlm.nih.gov/16078826

DMEM1BA	DI	DMEM1BA
DMEM1BA	DN	6-(4-((benzylamino)methyl)phenoxy)nicotinamide
DMEM1BA	MI	TT27RFC
DMEM1BA	MN	Opioid receptor delta (OPRD1)
DMEM1BA	MT	DTT
DMEM1BA	MA	Inhibitor
DMEM1BA	RN	Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5349-52.
DMEM1BA	RU	https://pubmed.ncbi.nlm.nih.gov/17720493

DMEM1BA	DI	DMEM1BA
DMEM1BA	DN	6-(4-((benzylamino)methyl)phenoxy)nicotinamide
DMEM1BA	MI	TTQW87Y
DMEM1BA	MN	Opioid receptor kappa (OPRK1)
DMEM1BA	MT	DTT
DMEM1BA	MA	Inhibitor
DMEM1BA	RN	Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5349-52.
DMEM1BA	RU	https://pubmed.ncbi.nlm.nih.gov/17720493

DMEM1BA	DI	DMEM1BA
DMEM1BA	DN	6-(4-((benzylamino)methyl)phenoxy)nicotinamide
DMEM1BA	MI	TTKWM86
DMEM1BA	MN	Opioid receptor mu (MOP)
DMEM1BA	MT	DTT
DMEM1BA	MA	Inhibitor
DMEM1BA	RN	Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5349-52.
DMEM1BA	RU	https://pubmed.ncbi.nlm.nih.gov/17720493

DM9VD4W	DI	DM9VD4W
DM9VD4W	DN	6-(4-((phenethylamino)methyl)phenoxy)nicotinamide
DM9VD4W	MI	TT27RFC
DM9VD4W	MN	Opioid receptor delta (OPRD1)
DM9VD4W	MT	DTT
DM9VD4W	MA	Inhibitor
DM9VD4W	RN	Structure activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 2. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6841-6.
DM9VD4W	RU	https://pubmed.ncbi.nlm.nih.gov/17980586

DM9VD4W	DI	DM9VD4W
DM9VD4W	DN	6-(4-((phenethylamino)methyl)phenoxy)nicotinamide
DM9VD4W	MI	TTQW87Y
DM9VD4W	MN	Opioid receptor kappa (OPRK1)
DM9VD4W	MT	DTT
DM9VD4W	MA	Inhibitor
DM9VD4W	RN	Structure activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 2. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6841-6.
DM9VD4W	RU	https://pubmed.ncbi.nlm.nih.gov/17980586

DM9VD4W	DI	DM9VD4W
DM9VD4W	DN	6-(4-((phenethylamino)methyl)phenoxy)nicotinamide
DM9VD4W	MI	TTKWM86
DM9VD4W	MN	Opioid receptor mu (MOP)
DM9VD4W	MT	DTT
DM9VD4W	MA	Inhibitor
DM9VD4W	RN	Structure activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 2. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6841-6.
DM9VD4W	RU	https://pubmed.ncbi.nlm.nih.gov/17980586

DMDKOWP	DI	DMDKOWP
DMDKOWP	DN	6-(4-(2-(benzylamino)ethyl)phenoxy)nicotinamide
DMDKOWP	MI	TT27RFC
DMDKOWP	MN	Opioid receptor delta (OPRD1)
DMDKOWP	MT	DTT
DMDKOWP	MA	Inhibitor
DMDKOWP	RN	Structure activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 2. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6841-6.
DMDKOWP	RU	https://pubmed.ncbi.nlm.nih.gov/17980586

DMDKOWP	DI	DMDKOWP
DMDKOWP	DN	6-(4-(2-(benzylamino)ethyl)phenoxy)nicotinamide
DMDKOWP	MI	TTQW87Y
DMDKOWP	MN	Opioid receptor kappa (OPRK1)
DMDKOWP	MT	DTT
DMDKOWP	MA	Inhibitor
DMDKOWP	RN	Structure activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 2. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6841-6.
DMDKOWP	RU	https://pubmed.ncbi.nlm.nih.gov/17980586

DMDKOWP	DI	DMDKOWP
DMDKOWP	DN	6-(4-(2-(benzylamino)ethyl)phenoxy)nicotinamide
DMDKOWP	MI	TTKWM86
DMDKOWP	MN	Opioid receptor mu (MOP)
DMDKOWP	MT	DTT
DMDKOWP	MA	Inhibitor
DMDKOWP	RN	Structure activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 2. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6841-6.
DMDKOWP	RU	https://pubmed.ncbi.nlm.nih.gov/17980586

DMOSDM2	DI	DMOSDM2
DMOSDM2	DN	6-(4-(2-(benzylamino)ethyl)phenoxy)picolinamide
DMOSDM2	MI	TTKWM86
DMOSDM2	MN	Opioid receptor mu (MOP)
DMOSDM2	MT	DTT
DMOSDM2	MA	Inhibitor
DMOSDM2	RN	Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5349-52.
DMOSDM2	RU	https://pubmed.ncbi.nlm.nih.gov/17720493

DMDTMB7	DI	DMDTMB7
DMDTMB7	DN	6-(4-(3-(benzylamino)propyl)phenoxy)nicotinamide
DMDTMB7	MI	TT27RFC
DMDTMB7	MN	Opioid receptor delta (OPRD1)
DMDTMB7	MT	DTT
DMDTMB7	MA	Inhibitor
DMDTMB7	RN	Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5349-52.
DMDTMB7	RU	https://pubmed.ncbi.nlm.nih.gov/17720493

DMDTMB7	DI	DMDTMB7
DMDTMB7	DN	6-(4-(3-(benzylamino)propyl)phenoxy)nicotinamide
DMDTMB7	MI	TTQW87Y
DMDTMB7	MN	Opioid receptor kappa (OPRK1)
DMDTMB7	MT	DTT
DMDTMB7	MA	Inhibitor
DMDTMB7	RN	Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5349-52.
DMDTMB7	RU	https://pubmed.ncbi.nlm.nih.gov/17720493

DMDTMB7	DI	DMDTMB7
DMDTMB7	DN	6-(4-(3-(benzylamino)propyl)phenoxy)nicotinamide
DMDTMB7	MI	TTKWM86
DMDTMB7	MN	Opioid receptor mu (MOP)
DMDTMB7	MT	DTT
DMDTMB7	MA	Inhibitor
DMDTMB7	RN	Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5349-52.
DMDTMB7	RU	https://pubmed.ncbi.nlm.nih.gov/17720493

DM9K8DY	DI	DM9K8DY
DM9K8DY	DN	6-(4-Bromo-benzenesulfonyl)-2H-pyridazin-3-one
DM9K8DY	MI	TTFBNVI
DM9K8DY	MN	Aldose reductase (AKR1B1)
DM9K8DY	MT	DTT
DM9K8DY	MA	Inhibitor
DM9K8DY	RN	A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3... J Med Chem. 2005 Oct 6;48(20):6326-39.
DM9K8DY	RU	https://pubmed.ncbi.nlm.nih.gov/16190759

DMCYQDU	DI	DMCYQDU
DMCYQDU	DN	6-(4-Bromo-phenylamino)-1H-pyrimidine-2,4-dione
DMCYQDU	MI	TTIU7X1
DMCYQDU	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMCYQDU	MT	DTT
DMCYQDU	MA	Inhibitor
DMCYQDU	RN	Inhibitors of Bacillus subtilis DNA polymerase III. 6-Anilinouracils and 6-(alkylamino)uracils. J Med Chem. 1980 Jan;23(1):34-8.
DMCYQDU	RU	https://pubmed.ncbi.nlm.nih.gov/6767030

DMNAHVB	DI	DMNAHVB
DMNAHVB	DN	6-(4-Chloro-benzenesulfonyl)-2H-pyridazin-3-one
DMNAHVB	MI	TTFBNVI
DMNAHVB	MN	Aldose reductase (AKR1B1)
DMNAHVB	MT	DTT
DMNAHVB	MA	Inhibitor
DMNAHVB	RN	A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3... J Med Chem. 2005 Oct 6;48(20):6326-39.
DMNAHVB	RU	https://pubmed.ncbi.nlm.nih.gov/16190759

DMSO2JW	DI	DMSO2JW
DMSO2JW	DN	6-(4-chlorophenyl)-2-morpholin-4-ylpyridin-4-ol
DMSO2JW	MI	TTK3PY9
DMSO2JW	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMSO2JW	MT	DTT
DMSO2JW	MA	Inhibitor
DMSO2JW	RN	Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72.
DMSO2JW	RU	https://pubmed.ncbi.nlm.nih.gov/17371003

DMMTG7L	DI	DMMTG7L
DMMTG7L	DN	6-(4-chlorophenyl)-4-morpholino-2H-pyran-2-one
DMMTG7L	MI	TTK3PY9
DMMTG7L	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMMTG7L	MT	DTT
DMMTG7L	MA	Inhibitor
DMMTG7L	RN	Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72.
DMMTG7L	RU	https://pubmed.ncbi.nlm.nih.gov/17371003

DM0C1FX	DI	DM0C1FX
DM0C1FX	DN	6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)
DM0C1FX	MI	TT6OEDT
DM0C1FX	MN	Cannabinoid receptor 1 (CB1)
DM0C1FX	MT	DTT
DM0C1FX	MA	Inhibitor
DM0C1FX	RN	Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4.
DM0C1FX	RU	https://pubmed.ncbi.nlm.nih.gov/20483606

DM0C1FX	DI	DM0C1FX
DM0C1FX	DN	6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)
DM0C1FX	MI	TTMSFAW
DM0C1FX	MN	Cannabinoid receptor 2 (CB2)
DM0C1FX	MT	DTT
DM0C1FX	MA	Inhibitor
DM0C1FX	RN	Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4.
DM0C1FX	RU	https://pubmed.ncbi.nlm.nih.gov/20483606

DM1N46J	DI	DM1N46J
DM1N46J	DN	6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-((R)-1-HYDROXYETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)
DM1N46J	MI	TT6OEDT
DM1N46J	MN	Cannabinoid receptor 1 (CB1)
DM1N46J	MT	DTT
DM1N46J	MA	Inhibitor
DM1N46J	RN	Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4.
DM1N46J	RU	https://pubmed.ncbi.nlm.nih.gov/20483606

DM1N46J	DI	DM1N46J
DM1N46J	DN	6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-((R)-1-HYDROXYETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)
DM1N46J	MI	TTMSFAW
DM1N46J	MN	Cannabinoid receptor 2 (CB2)
DM1N46J	MT	DTT
DM1N46J	MA	Inhibitor
DM1N46J	RN	Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4.
DM1N46J	RU	https://pubmed.ncbi.nlm.nih.gov/20483606

DM5H4KE	DI	DM5H4KE
DM5H4KE	DN	6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(1-HYDROXY-2-METHYLPROPAN-2-YL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)
DM5H4KE	MI	TT6OEDT
DM5H4KE	MN	Cannabinoid receptor 1 (CB1)
DM5H4KE	MT	DTT
DM5H4KE	MA	Inhibitor
DM5H4KE	RN	Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4.
DM5H4KE	RU	https://pubmed.ncbi.nlm.nih.gov/20483606

DM5H4KE	DI	DM5H4KE
DM5H4KE	DN	6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(1-HYDROXY-2-METHYLPROPAN-2-YL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)
DM5H4KE	MI	TTMSFAW
DM5H4KE	MN	Cannabinoid receptor 2 (CB2)
DM5H4KE	MT	DTT
DM5H4KE	MA	Inhibitor
DM5H4KE	RN	Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4.
DM5H4KE	RU	https://pubmed.ncbi.nlm.nih.gov/20483606

DMEJ83H	DI	DMEJ83H
DMEJ83H	DN	6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)
DMEJ83H	MI	TT6OEDT
DMEJ83H	MN	Cannabinoid receptor 1 (CB1)
DMEJ83H	MT	DTT
DMEJ83H	MA	Inhibitor
DMEJ83H	RN	Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4.
DMEJ83H	RU	https://pubmed.ncbi.nlm.nih.gov/20483606

DMEJ83H	DI	DMEJ83H
DMEJ83H	DN	6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)
DMEJ83H	MI	TTMSFAW
DMEJ83H	MN	Cannabinoid receptor 2 (CB2)
DMEJ83H	MT	DTT
DMEJ83H	MA	Inhibitor
DMEJ83H	RN	Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4.
DMEJ83H	RU	https://pubmed.ncbi.nlm.nih.gov/20483606

DMEJ83H	DI	DMEJ83H
DMEJ83H	DN	6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)
DMEJ83H	MI	TTQ6VDM
DMEJ83H	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMEJ83H	MT	DTT
DMEJ83H	MA	Inhibitor
DMEJ83H	RN	Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4.
DMEJ83H	RU	https://pubmed.ncbi.nlm.nih.gov/20483606

DM5LUF4	DI	DM5LUF4
DM5LUF4	DN	6-(4-Chloro-phenylamino)-1H-pyrimidine-2,4-dione
DM5LUF4	MI	TTIU7X1
DM5LUF4	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DM5LUF4	MT	DTT
DM5LUF4	MA	Inhibitor
DM5LUF4	RN	Inhibitors of Bacillus subtilis DNA polymerase III. 6-Anilinouracils and 6-(alkylamino)uracils. J Med Chem. 1980 Jan;23(1):34-8.
DM5LUF4	RU	https://pubmed.ncbi.nlm.nih.gov/6767030

DMOZFU5	DI	DMOZFU5
DMOZFU5	DN	6-(4-chlorophenylamino)-N,N-diethylnicotinamide
DMOZFU5	MI	TTHS256
DMOZFU5	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMOZFU5	MT	DTT
DMOZFU5	MA	Inhibitor
DMOZFU5	RN	Piperidyl amides as novel, potent and orally active mGlu5 receptor antagonists with anxiolytic-like activity. Bioorg Med Chem Lett. 2010 Jan 1;20(1):184-8.
DMOZFU5	RU	https://pubmed.ncbi.nlm.nih.gov/19931453

DMYQB5R	DI	DMYQB5R
DMYQB5R	DN	6-(4-Decyloxy-phenyl)-1,1,1-trifluoro-hexan-2-one
DMYQB5R	MI	TTT1JVS
DMYQB5R	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DMYQB5R	MT	DTT
DMYQB5R	MA	Inhibitor
DMYQB5R	RN	Synthesis of polyfluoro ketones for selective inhibition of human phospholipase A2 enzymes. J Med Chem. 2008 Dec 25;51(24):8027-37.
DMYQB5R	RU	https://pubmed.ncbi.nlm.nih.gov/19053783

DM7WYNT	DI	DM7WYNT
DM7WYNT	DN	6-(4-Fluoro-benzenesulfonyl)-2H-pyridazin-3-one
DM7WYNT	MI	TTFBNVI
DM7WYNT	MN	Aldose reductase (AKR1B1)
DM7WYNT	MT	DTT
DM7WYNT	MA	Inhibitor
DM7WYNT	RN	A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3... J Med Chem. 2005 Oct 6;48(20):6326-39.
DM7WYNT	RU	https://pubmed.ncbi.nlm.nih.gov/16190759

DM3EDBO	DI	DM3EDBO
DM3EDBO	DN	6-(4-Fluorobutyl)-4-methylpyridin-2-amine
DM3EDBO	MI	TTF10I9
DM3EDBO	MN	Nitric-oxide synthase inducible (NOS2)
DM3EDBO	MT	DTT
DM3EDBO	MA	Inhibitor
DM3EDBO	RN	Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [18F]6-(2-fl... J Med Chem. 2009 Apr 23;52(8):2443-53.
DM3EDBO	RU	https://pubmed.ncbi.nlm.nih.gov/19323559

DM5JWEY	DI	DM5JWEY
DM5JWEY	DN	6-(4-Fluoro-phenylsulfanyl)-9H-purine
DM5JWEY	MI	TTQBR95
DM5JWEY	MN	Stress-activated protein kinase 2a (p38 alpha)
DM5JWEY	MT	DTT
DM5JWEY	MA	Inhibitor
DM5JWEY	RN	Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22.
DM5JWEY	RU	https://pubmed.ncbi.nlm.nih.gov/15689155

DMKGTRF	DI	DMKGTRF
DMKGTRF	DN	6-(4-fluorostyryl)-2-morpholino-4H-chromen-4-one
DMKGTRF	MI	TTK3PY9
DMKGTRF	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMKGTRF	MT	DTT
DMKGTRF	MA	Inhibitor
DMKGTRF	RN	Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46.
DMKGTRF	RU	https://pubmed.ncbi.nlm.nih.gov/16302822

DMYM3EW	DI	DMYM3EW
DMYM3EW	DN	6-(4-Hydroxy-2-methoxy-phenyl)-naphthalen-2-ol
DMYM3EW	MI	TTZAYWL
DMYM3EW	MN	Estrogen receptor (ESR)
DMYM3EW	MT	DTT
DMYM3EW	MA	Inhibitor
DMYM3EW	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DMYM3EW	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMYM3EW	DI	DMYM3EW
DMYM3EW	DN	6-(4-Hydroxy-2-methoxy-phenyl)-naphthalen-2-ol
DMYM3EW	MI	TTOM3J0
DMYM3EW	MN	Estrogen receptor beta (ESR2)
DMYM3EW	MT	DTT
DMYM3EW	MA	Inhibitor
DMYM3EW	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DMYM3EW	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMYEIRH	DI	DMYEIRH
DMYEIRH	DN	6-(4-Hydroxy-2-methyl-phenyl)-naphthalen-2-ol
DMYEIRH	MI	TTZAYWL
DMYEIRH	MN	Estrogen receptor (ESR)
DMYEIRH	MT	DTT
DMYEIRH	MA	Inhibitor
DMYEIRH	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DMYEIRH	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMYEIRH	DI	DMYEIRH
DMYEIRH	DN	6-(4-Hydroxy-2-methyl-phenyl)-naphthalen-2-ol
DMYEIRH	MI	TTOM3J0
DMYEIRH	MN	Estrogen receptor beta (ESR2)
DMYEIRH	MT	DTT
DMYEIRH	MA	Inhibitor
DMYEIRH	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DMYEIRH	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMBG5Y8	DI	DMBG5Y8
DMBG5Y8	DN	6-(4-Hydroxy-phenyl)-1-methoxy-naphthalen-2-ol
DMBG5Y8	MI	TTZAYWL
DMBG5Y8	MN	Estrogen receptor (ESR)
DMBG5Y8	MT	DTT
DMBG5Y8	MA	Inhibitor
DMBG5Y8	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DMBG5Y8	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMBG5Y8	DI	DMBG5Y8
DMBG5Y8	DN	6-(4-Hydroxy-phenyl)-1-methoxy-naphthalen-2-ol
DMBG5Y8	MI	TTOM3J0
DMBG5Y8	MN	Estrogen receptor beta (ESR2)
DMBG5Y8	MT	DTT
DMBG5Y8	MA	Inhibitor
DMBG5Y8	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DMBG5Y8	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMGLT0N	DI	DMGLT0N
DMGLT0N	DN	6-(4-Hydroxy-phenyl)-1-methyl-naphthalen-2-ol
DMGLT0N	MI	TTZAYWL
DMGLT0N	MN	Estrogen receptor (ESR)
DMGLT0N	MT	DTT
DMGLT0N	MA	Inhibitor
DMGLT0N	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DMGLT0N	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMGLT0N	DI	DMGLT0N
DMGLT0N	DN	6-(4-Hydroxy-phenyl)-1-methyl-naphthalen-2-ol
DMGLT0N	MI	TTOM3J0
DMGLT0N	MN	Estrogen receptor beta (ESR2)
DMGLT0N	MT	DTT
DMGLT0N	MA	Inhibitor
DMGLT0N	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DMGLT0N	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMGC84U	DI	DMGC84U
DMGC84U	DN	6-(4-Hydroxy-phenyl)-1-nitro-naphthalen-2-ol
DMGC84U	MI	TTZAYWL
DMGC84U	MN	Estrogen receptor (ESR)
DMGC84U	MT	DTT
DMGC84U	MA	Inhibitor
DMGC84U	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DMGC84U	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMGC84U	DI	DMGC84U
DMGC84U	DN	6-(4-Hydroxy-phenyl)-1-nitro-naphthalen-2-ol
DMGC84U	MI	TTOM3J0
DMGC84U	MN	Estrogen receptor beta (ESR2)
DMGC84U	MT	DTT
DMGC84U	MA	Inhibitor
DMGC84U	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DMGC84U	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMI6UVN	DI	DMI6UVN
DMI6UVN	DN	6-(4-Hydroxy-phenyl)-1-phenyl-naphthalen-2-ol
DMI6UVN	MI	TTZAYWL
DMI6UVN	MN	Estrogen receptor (ESR)
DMI6UVN	MT	DTT
DMI6UVN	MA	Inhibitor
DMI6UVN	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DMI6UVN	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMI6UVN	DI	DMI6UVN
DMI6UVN	DN	6-(4-Hydroxy-phenyl)-1-phenyl-naphthalen-2-ol
DMI6UVN	MI	TTOM3J0
DMI6UVN	MN	Estrogen receptor beta (ESR2)
DMI6UVN	MT	DTT
DMI6UVN	MA	Inhibitor
DMI6UVN	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DMI6UVN	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMTYWCS	DI	DMTYWCS
DMTYWCS	DN	6-(4-hydroxyphenyl)-2-morpholino-4H-chromen-4-one
DMTYWCS	MI	TTK3PY9
DMTYWCS	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMTYWCS	MT	DTT
DMTYWCS	MA	Inhibitor
DMTYWCS	RN	Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46.
DMTYWCS	RU	https://pubmed.ncbi.nlm.nih.gov/16302822

DM2V9XI	DI	DM2V9XI
DM2V9XI	DN	6-(4-Hydroxy-phenyl)-naphthalen-1-ol
DM2V9XI	MI	TTIWB6L
DM2V9XI	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DM2V9XI	MT	DTT
DM2V9XI	MA	Inhibitor
DM2V9XI	RN	Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors... J Med Chem. 2008 Apr 10;51(7):2158-69.
DM2V9XI	RU	https://pubmed.ncbi.nlm.nih.gov/18324762

DM2V9XI	DI	DM2V9XI
DM2V9XI	DN	6-(4-Hydroxy-phenyl)-naphthalen-1-ol
DM2V9XI	MI	TTZAYWL
DM2V9XI	MN	Estrogen receptor (ESR)
DM2V9XI	MT	DTT
DM2V9XI	MA	Inhibitor
DM2V9XI	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DM2V9XI	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DM2V9XI	DI	DM2V9XI
DM2V9XI	DN	6-(4-Hydroxy-phenyl)-naphthalen-1-ol
DM2V9XI	MI	TTOM3J0
DM2V9XI	MN	Estrogen receptor beta (ESR2)
DM2V9XI	MT	DTT
DM2V9XI	MA	Inhibitor
DM2V9XI	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DM2V9XI	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DM3L2OI	DI	DM3L2OI
DM3L2OI	DN	6-(4-Hydroxy-phenyl)-naphthalen-2-ol
DM3L2OI	MI	TTZAYWL
DM3L2OI	MN	Estrogen receptor (ESR)
DM3L2OI	MT	DTT
DM3L2OI	MA	Inhibitor
DM3L2OI	RN	ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5.
DM3L2OI	RU	https://pubmed.ncbi.nlm.nih.gov/16098741

DM3L2OI	DI	DM3L2OI
DM3L2OI	DN	6-(4-Hydroxy-phenyl)-naphthalen-2-ol
DM3L2OI	MI	TTOM3J0
DM3L2OI	MN	Estrogen receptor beta (ESR2)
DM3L2OI	MT	DTT
DM3L2OI	MA	Inhibitor
DM3L2OI	RN	ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5.
DM3L2OI	RU	https://pubmed.ncbi.nlm.nih.gov/16098741

DM5LBCH	DI	DM5LBCH
DM5LBCH	DN	6-(4-Methoxy-benzenesulfonyl)-2H-pyridazin-3-one
DM5LBCH	MI	TTFBNVI
DM5LBCH	MN	Aldose reductase (AKR1B1)
DM5LBCH	MT	DTT
DM5LBCH	MA	Inhibitor
DM5LBCH	RN	A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3... J Med Chem. 2005 Oct 6;48(20):6326-39.
DM5LBCH	RU	https://pubmed.ncbi.nlm.nih.gov/16190759

DMUHCO8	DI	DMUHCO8
DMUHCO8	DN	6-(4-methoxyphenyl)-4-morpholino-2H-pyran-2-one
DMUHCO8	MI	TTK3PY9
DMUHCO8	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMUHCO8	MT	DTT
DMUHCO8	MA	Inhibitor
DMUHCO8	RN	Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72.
DMUHCO8	RU	https://pubmed.ncbi.nlm.nih.gov/17371003

DMWITYU	DI	DMWITYU
DMWITYU	DN	6-(4-Methylpiperazin-1-yl)-9H-purin-2-amine
DMWITYU	MI	TTXJ178
DMWITYU	MN	Histamine H4 receptor (H4R)
DMWITYU	MT	DTT
DMWITYU	MA	Inhibitor
DMWITYU	RN	2,4-Diaminopyrimidines as histamine H4 receptor ligands--Scaffold optimization and pharmacological characterization. Bioorg Med Chem. 2009 Oct 15;17(20):7186-96.
DMWITYU	RU	https://pubmed.ncbi.nlm.nih.gov/19773175

DMA3FQP	DI	DMA3FQP
DMA3FQP	DN	6-(4-methylpiperazin-1-yl)-9Hpurine
DMA3FQP	MI	TTXJ178
DMA3FQP	MN	Histamine H4 receptor (H4R)
DMA3FQP	MT	DTT
DMA3FQP	MA	Inhibitor
DMA3FQP	RN	2,4-Diaminopyrimidines as histamine H4 receptor ligands--Scaffold optimization and pharmacological characterization. Bioorg Med Chem. 2009 Oct 15;17(20):7186-96.
DMA3FQP	RU	https://pubmed.ncbi.nlm.nih.gov/19773175

DM1HAWR	DI	DM1HAWR
DM1HAWR	DN	6-(4-Methyl-piperazin-1-yl)-phenanthridine
DM1HAWR	MI	TTPC4TU
DM1HAWR	MN	5-HT 3A receptor (HTR3A)
DM1HAWR	MT	DTT
DM1HAWR	MA	Inhibitor
DM1HAWR	RN	Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy ... J Med Chem. 1999 May 6;42(9):1556-75.
DM1HAWR	RU	https://pubmed.ncbi.nlm.nih.gov/10229626

DM1HAWR	DI	DM1HAWR
DM1HAWR	DN	6-(4-Methyl-piperazin-1-yl)-phenanthridine
DM1HAWR	MI	TTR6K75
DM1HAWR	MN	5-HT 3B receptor (HTR3B)
DM1HAWR	MT	DTT
DM1HAWR	MA	Inhibitor
DM1HAWR	RN	Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy ... J Med Chem. 1999 May 6;42(9):1556-75.
DM1HAWR	RU	https://pubmed.ncbi.nlm.nih.gov/10229626

DMYAS2V	DI	DMYAS2V
DMYAS2V	DN	6-(4-Methylpiperazin-1-yl)pyrimidine-2,4-diamine
DMYAS2V	MI	TTXJ178
DMYAS2V	MN	Histamine H4 receptor (H4R)
DMYAS2V	MT	DTT
DMYAS2V	MA	Inhibitor
DMYAS2V	RN	2,4-Diaminopyrimidines as histamine H4 receptor ligands--Scaffold optimization and pharmacological characterization. Bioorg Med Chem. 2009 Oct 15;17(20):7186-96.
DMYAS2V	RU	https://pubmed.ncbi.nlm.nih.gov/19773175

DMTV753	DI	DMTV753
DMTV753	DN	6-(4-Methylpyridin-3-yl)-2-naphthonitrile
DMTV753	MI	TTIQUX7
DMTV753	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMTV753	MT	DTT
DMTV753	MA	Inhibitor
DMTV753	RN	Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on pote... J Med Chem. 2008 Aug 28;51(16):5064-74.
DMTV753	RU	https://pubmed.ncbi.nlm.nih.gov/18672861

DMPL5XV	DI	DMPL5XV
DMPL5XV	DN	6-(4-Nitro-benzylsulfanyl)-9-phenethyl-9H-purine
DMPL5XV	MI	TTLXAKE
DMPL5XV	MN	Solute carrier family 29 member 1 (SLC29A1)
DMPL5XV	MT	DTT
DMPL5XV	MA	Inhibitor
DMPL5XV	RN	Inhibition of nucleoside transport by new analogues of 4-nitrobenzylthioinosine: replacement of the ribose moiety by substituted benzyl groups. J Med Chem. 2004 Oct 21;47(22):5441-50.
DMPL5XV	RU	https://pubmed.ncbi.nlm.nih.gov/15481982

DMVMDJ3	DI	DMVMDJ3
DMVMDJ3	DN	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide
DMVMDJ3	MI	TT6R7JZ
DMVMDJ3	MN	Histone deacetylase 1 (HDAC1)
DMVMDJ3	MT	DTT
DMVMDJ3	MA	Inhibitor
DMVMDJ3	RN	Inhibitors selective for HDAC6 in enzymes and cells. Bioorg Med Chem Lett. 2010 Dec 1;20(23):7067-70.
DMVMDJ3	RU	https://pubmed.ncbi.nlm.nih.gov/20947351

DMVMDJ3	DI	DMVMDJ3
DMVMDJ3	DN	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide
DMVMDJ3	MI	TT5ZKDI
DMVMDJ3	MN	Histone deacetylase 6 (HDAC6)
DMVMDJ3	MT	DTT
DMVMDJ3	MA	Inhibitor
DMVMDJ3	RN	Inhibitors selective for HDAC6 in enzymes and cells. Bioorg Med Chem Lett. 2010 Dec 1;20(23):7067-70.
DMVMDJ3	RU	https://pubmed.ncbi.nlm.nih.gov/20947351

DMYMJHF	DI	DMYMJHF
DMYMJHF	DN	6-(Allyl-methyl-amino)-4,4-diphenyl-heptan-3-ol
DMYMJHF	MI	TT27RFC
DMYMJHF	MN	Opioid receptor delta (OPRD1)
DMYMJHF	MT	DTT
DMYMJHF	MA	Inhibitor
DMYMJHF	RN	Synthesis of analogues of acetylmethadol and methadol as potential narcotic antagonists. J Med Chem. 1981 Jul;24(7):903-6.
DMYMJHF	RU	https://pubmed.ncbi.nlm.nih.gov/6268789

DMYMJHF	DI	DMYMJHF
DMYMJHF	DN	6-(Allyl-methyl-amino)-4,4-diphenyl-heptan-3-ol
DMYMJHF	MI	TTQW87Y
DMYMJHF	MN	Opioid receptor kappa (OPRK1)
DMYMJHF	MT	DTT
DMYMJHF	MA	Inhibitor
DMYMJHF	RN	Synthesis of analogues of acetylmethadol and methadol as potential narcotic antagonists. J Med Chem. 1981 Jul;24(7):903-6.
DMYMJHF	RU	https://pubmed.ncbi.nlm.nih.gov/6268789

DMYMJHF	DI	DMYMJHF
DMYMJHF	DN	6-(Allyl-methyl-amino)-4,4-diphenyl-heptan-3-ol
DMYMJHF	MI	TTKWM86
DMYMJHF	MN	Opioid receptor mu (MOP)
DMYMJHF	MT	DTT
DMYMJHF	MA	Inhibitor
DMYMJHF	RN	Synthesis of analogues of acetylmethadol and methadol as potential narcotic antagonists. J Med Chem. 1981 Jul;24(7):903-6.
DMYMJHF	RU	https://pubmed.ncbi.nlm.nih.gov/6268789

DMJU9TG	DI	DMJU9TG
DMJU9TG	DN	6-(aminomethyl)-2H-chromen-2-one
DMJU9TG	MI	TTUNARX
DMJU9TG	MN	Carbonic anhydrase (CA)
DMJU9TG	MT	DTT
DMJU9TG	MA	Inhibitor
DMJU9TG	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMJU9TG	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMJU9TG	DI	DMJU9TG
DMJU9TG	DN	6-(aminomethyl)-2H-chromen-2-one
DMJU9TG	MI	TTHQPL7
DMJU9TG	MN	Carbonic anhydrase I (CA-I)
DMJU9TG	MT	DTT
DMJU9TG	MA	Inhibitor
DMJU9TG	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMJU9TG	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMJU9TG	DI	DMJU9TG
DMJU9TG	DN	6-(aminomethyl)-2H-chromen-2-one
DMJU9TG	MI	TTANPDJ
DMJU9TG	MN	Carbonic anhydrase II (CA-II)
DMJU9TG	MT	DTT
DMJU9TG	MA	Inhibitor
DMJU9TG	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMJU9TG	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMJU9TG	DI	DMJU9TG
DMJU9TG	DN	6-(aminomethyl)-2H-chromen-2-one
DMJU9TG	MI	TTZHA0O
DMJU9TG	MN	Carbonic anhydrase IV (CA-IV)
DMJU9TG	MT	DTT
DMJU9TG	MA	Inhibitor
DMJU9TG	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMJU9TG	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMJU9TG	DI	DMJU9TG
DMJU9TG	DN	6-(aminomethyl)-2H-chromen-2-one
DMJU9TG	MI	TT2LVK8
DMJU9TG	MN	Carbonic anhydrase IX (CA-IX)
DMJU9TG	MT	DTT
DMJU9TG	MA	Inhibitor
DMJU9TG	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMJU9TG	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMJU9TG	DI	DMJU9TG
DMJU9TG	DN	6-(aminomethyl)-2H-chromen-2-one
DMJU9TG	MI	TTCFSPE
DMJU9TG	MN	Carbonic anhydrase VI (CA-VI)
DMJU9TG	MT	DTT
DMJU9TG	MA	Inhibitor
DMJU9TG	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMJU9TG	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMJU9TG	DI	DMJU9TG
DMJU9TG	DN	6-(aminomethyl)-2H-chromen-2-one
DMJU9TG	MI	TTSYM0R
DMJU9TG	MN	Carbonic anhydrase XII (CA-XII)
DMJU9TG	MT	DTT
DMJU9TG	MA	Inhibitor
DMJU9TG	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMJU9TG	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMJU9TG	DI	DMJU9TG
DMJU9TG	DN	6-(aminomethyl)-2H-chromen-2-one
DMJU9TG	MI	TTEYTKG
DMJU9TG	MN	Carbonic anhydrase XIV (CA-XIV)
DMJU9TG	MT	DTT
DMJU9TG	MA	Inhibitor
DMJU9TG	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMJU9TG	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DM2GFI3	DI	DM2GFI3
DM2GFI3	DN	6-(Benzofuran-2-sulfonyl)-2H-pyridazin-3-one
DM2GFI3	MI	TTFBNVI
DM2GFI3	MN	Aldose reductase (AKR1B1)
DM2GFI3	MT	DTT
DM2GFI3	MA	Inhibitor
DM2GFI3	RN	A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3... J Med Chem. 2005 Oct 6;48(20):6326-39.
DM2GFI3	RU	https://pubmed.ncbi.nlm.nih.gov/16190759

DMXLDHR	DI	DMXLDHR
DMXLDHR	DN	6-(Benzothiazole-2-sulfonyl)-2H-pyridazin-3-one
DMXLDHR	MI	TTFBNVI
DMXLDHR	MN	Aldose reductase (AKR1B1)
DMXLDHR	MT	DTT
DMXLDHR	MA	Inhibitor
DMXLDHR	RN	A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3... J Med Chem. 2005 Oct 6;48(20):6326-39.
DMXLDHR	RU	https://pubmed.ncbi.nlm.nih.gov/16190759

DM7BIJH	DI	DM7BIJH
DM7BIJH	DN	6-(benzylamino)-9-butyl-9H-purine-2-carbonitrile
DM7BIJH	MI	TT36ETB
DM7BIJH	MN	Cathepsin L (CTSL)
DM7BIJH	MT	DTT
DM7BIJH	MA	Inhibitor
DM7BIJH	RN	Development of potent purine-derived nitrile inhibitors of the trypanosomal protease TbcatB. J Med Chem. 2008 Feb 14;51(3):545-52.
DM7BIJH	RU	https://pubmed.ncbi.nlm.nih.gov/18173229

DM4KMDB	DI	DM4KMDB
DM4KMDB	DN	6-(Biphenyl-2-sulfonyl)-2H-pyridazin-3-one
DM4KMDB	MI	TTFBNVI
DM4KMDB	MN	Aldose reductase (AKR1B1)
DM4KMDB	MT	DTT
DM4KMDB	MA	Inhibitor
DM4KMDB	RN	A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3... J Med Chem. 2005 Oct 6;48(20):6326-39.
DM4KMDB	RU	https://pubmed.ncbi.nlm.nih.gov/16190759

DMAYWIN	DI	DMAYWIN
DMAYWIN	DN	6-(Cyclohex-3-enylmethoxy)-9H-purin-2-ylamine
DMAYWIN	MI	TTAMQ62
DMAYWIN	MN	Cyclin A2 (CCNA2)
DMAYWIN	MT	DTT
DMAYWIN	MA	Inhibitor
DMAYWIN	RN	Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives. J Med Chem. 2002 Aug 1;45(16):3381-93.
DMAYWIN	RU	https://pubmed.ncbi.nlm.nih.gov/12139449

DMAYWIN	DI	DMAYWIN
DMAYWIN	DN	6-(Cyclohex-3-enylmethoxy)-9H-purin-2-ylamine
DMAYWIN	MI	TT7HF4W
DMAYWIN	MN	Cyclin-dependent kinase 2 (CDK2)
DMAYWIN	MT	DTT
DMAYWIN	MA	Inhibitor
DMAYWIN	RN	Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives. J Med Chem. 2002 Aug 1;45(16):3381-93.
DMAYWIN	RU	https://pubmed.ncbi.nlm.nih.gov/12139449

DMQPTL5	DI	DMQPTL5
DMQPTL5	DN	6-(Dihydroxy-Isobutyl)-Thymine
DMQPTL5	MI	TTP3QRF
DMQPTL5	MN	Thymidine kinase 1 (TK1)
DMQPTL5	MT	DTT
DMQPTL5	MA	Inhibitor
DMQPTL5	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMQPTL5	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMOYCBH	DI	DMOYCBH
DMOYCBH	DN	6-(furan-2-yl)-9H-purin-2-amine
DMOYCBH	MI	TTK25J1
DMOYCBH	MN	Adenosine A1 receptor (ADORA1)
DMOYCBH	MT	DTT
DMOYCBH	MA	Inhibitor
DMOYCBH	RN	Antagonists of the human A(2A) adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines. J Med Chem. 2009 Jan 8;52(1):33-47.
DMOYCBH	RU	https://pubmed.ncbi.nlm.nih.gov/19072055

DMOYCBH	DI	DMOYCBH
DMOYCBH	DN	6-(furan-2-yl)-9H-purin-2-amine
DMOYCBH	MI	TTM2AOE
DMOYCBH	MN	Adenosine A2a receptor (ADORA2A)
DMOYCBH	MT	DTT
DMOYCBH	MA	Inhibitor
DMOYCBH	RN	Antagonists of the human A(2A) adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines. J Med Chem. 2009 Jan 8;52(1):33-47.
DMOYCBH	RU	https://pubmed.ncbi.nlm.nih.gov/19072055

DM5TOX2	DI	DM5TOX2
DM5TOX2	DN	6-(hydroxymethyl)-2H-chromen-2-one
DM5TOX2	MI	TTUNARX
DM5TOX2	MN	Carbonic anhydrase (CA)
DM5TOX2	MT	DTT
DM5TOX2	MA	Inhibitor
DM5TOX2	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DM5TOX2	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DM5TOX2	DI	DM5TOX2
DM5TOX2	DN	6-(hydroxymethyl)-2H-chromen-2-one
DM5TOX2	MI	TTANPDJ
DM5TOX2	MN	Carbonic anhydrase II (CA-II)
DM5TOX2	MT	DTT
DM5TOX2	MA	Inhibitor
DM5TOX2	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DM5TOX2	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DM5TOX2	DI	DM5TOX2
DM5TOX2	DN	6-(hydroxymethyl)-2H-chromen-2-one
DM5TOX2	MI	TTZHA0O
DM5TOX2	MN	Carbonic anhydrase IV (CA-IV)
DM5TOX2	MT	DTT
DM5TOX2	MA	Inhibitor
DM5TOX2	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DM5TOX2	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DM5TOX2	DI	DM5TOX2
DM5TOX2	DN	6-(hydroxymethyl)-2H-chromen-2-one
DM5TOX2	MI	TT2LVK8
DM5TOX2	MN	Carbonic anhydrase IX (CA-IX)
DM5TOX2	MT	DTT
DM5TOX2	MA	Inhibitor
DM5TOX2	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DM5TOX2	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DM5TOX2	DI	DM5TOX2
DM5TOX2	DN	6-(hydroxymethyl)-2H-chromen-2-one
DM5TOX2	MI	TTCFSPE
DM5TOX2	MN	Carbonic anhydrase VI (CA-VI)
DM5TOX2	MT	DTT
DM5TOX2	MA	Inhibitor
DM5TOX2	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DM5TOX2	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DM5TOX2	DI	DM5TOX2
DM5TOX2	DN	6-(hydroxymethyl)-2H-chromen-2-one
DM5TOX2	MI	TTSYM0R
DM5TOX2	MN	Carbonic anhydrase XII (CA-XII)
DM5TOX2	MT	DTT
DM5TOX2	MA	Inhibitor
DM5TOX2	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DM5TOX2	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DM5TOX2	DI	DM5TOX2
DM5TOX2	DN	6-(hydroxymethyl)-2H-chromen-2-one
DM5TOX2	MI	TTEYTKG
DM5TOX2	MN	Carbonic anhydrase XIV (CA-XIV)
DM5TOX2	MT	DTT
DM5TOX2	MA	Inhibitor
DM5TOX2	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DM5TOX2	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMSH107	DI	DMSH107
DMSH107	DN	6-(Indan-5-ylamino)-1H-pyrimidine-2,4-dione
DMSH107	MI	TT2GPK3
DMSH107	MN	DNA topoisomerase (TOP)
DMSH107	MT	DTT
DMSH107	MA	Inhibitor
DMSH107	RN	Inhibitors of Bacillus subtilis DNA polymerase III. 6-Anilinouracils and 6-(alkylamino)uracils. J Med Chem. 1980 Jan;23(1):34-8.
DMSH107	RU	https://pubmed.ncbi.nlm.nih.gov/6767030

DMM2TFX	DI	DMM2TFX
DMM2TFX	DN	6-(Naphthalen-2-ylamino)-1H-pyrimidine-2,4-dione
DMM2TFX	MI	TT2GPK3
DMM2TFX	MN	DNA topoisomerase (TOP)
DMM2TFX	MT	DTT
DMM2TFX	MA	Inhibitor
DMM2TFX	RN	Inhibitors of Bacillus subtilis DNA polymerase III. 6-Anilinouracils and 6-(alkylamino)uracils. J Med Chem. 1980 Jan;23(1):34-8.
DMM2TFX	RU	https://pubmed.ncbi.nlm.nih.gov/6767030

DMXSCQE	DI	DMXSCQE
DMXSCQE	DN	6-(Naphthalene-1-sulfonyl)-2H-pyridazin-3-one
DMXSCQE	MI	TTFBNVI
DMXSCQE	MN	Aldose reductase (AKR1B1)
DMXSCQE	MT	DTT
DMXSCQE	MA	Inhibitor
DMXSCQE	RN	A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3... J Med Chem. 2005 Oct 6;48(20):6326-39.
DMXSCQE	RU	https://pubmed.ncbi.nlm.nih.gov/16190759

DMCIA63	DI	DMCIA63
DMCIA63	DN	6-(Naphthalene-2-sulfonyl)-2H-pyridazin-3-one
DMCIA63	MI	TTFBNVI
DMCIA63	MN	Aldose reductase (AKR1B1)
DMCIA63	MT	DTT
DMCIA63	MA	Inhibitor
DMCIA63	RN	A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3... J Med Chem. 2005 Oct 6;48(20):6326-39.
DMCIA63	RU	https://pubmed.ncbi.nlm.nih.gov/16190759

DMHM0RW	DI	DMHM0RW
DMHM0RW	DN	6-(N-Phenylcarbamyl)-2-Naphthalenecarboxamidine
DMHM0RW	MI	TTGY7WI
DMHM0RW	MN	Urokinase-type plasminogen activator (PLAU)
DMHM0RW	MT	DTT
DMHM0RW	MA	Inhibitor
DMHM0RW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMHM0RW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM1LY0S	DI	DM1LY0S
DM1LY0S	DN	6-(Oxalyl-Amino)-1h-Indole-5-Carboxylic Acid
DM1LY0S	MI	TTELIN2
DM1LY0S	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DM1LY0S	MT	DTT
DM1LY0S	MA	Inhibitor
DM1LY0S	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM1LY0S	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMM9G0J	DI	DMM9G0J
DMM9G0J	DN	6-(piperazin-1-yl)-3-tosyl-1H-indazole
DMM9G0J	MI	TTJS8PY
DMM9G0J	MN	5-HT 6 receptor (HTR6)
DMM9G0J	MT	DTT
DMM9G0J	MA	Inhibitor
DMM9G0J	RN	5-Piperazinyl-3-sulfonylindazoles as potent and selective 5-hydroxytryptamine-6 antagonists. J Med Chem. 2010 Nov 11;53(21):7639-46.
DMM9G0J	RU	https://pubmed.ncbi.nlm.nih.gov/20932009

DMUNWJR	DI	DMUNWJR
DMUNWJR	DN	6-(piperazin-1-yl)-9-propyl-9H-purine
DMUNWJR	MI	TTWJBZ5
DMUNWJR	MN	5-HT 2C receptor (HTR2C)
DMUNWJR	MT	DTT
DMUNWJR	MA	Inhibitor
DMUNWJR	RN	Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity. Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71.
DMUNWJR	RU	https://pubmed.ncbi.nlm.nih.gov/19914063

DMBQKGY	DI	DMBQKGY
DMBQKGY	DN	6-(piperidin-4-ylmethoxy)-2-naphthonitrile
DMBQKGY	MI	TTVBI8W
DMBQKGY	MN	Dopamine transporter (DAT)
DMBQKGY	MT	DTT
DMBQKGY	MA	Inhibitor
DMBQKGY	RN	Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32.
DMBQKGY	RU	https://pubmed.ncbi.nlm.nih.gov/19282174

DMBQKGY	DI	DMBQKGY
DMBQKGY	DN	6-(piperidin-4-ylmethoxy)-2-naphthonitrile
DMBQKGY	MI	TTAWNKZ
DMBQKGY	MN	Norepinephrine transporter (NET)
DMBQKGY	MT	DTT
DMBQKGY	MA	Inhibitor
DMBQKGY	RN	Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32.
DMBQKGY	RU	https://pubmed.ncbi.nlm.nih.gov/19282174

DMBQKGY	DI	DMBQKGY
DMBQKGY	DN	6-(piperidin-4-ylmethoxy)-2-naphthonitrile
DMBQKGY	MI	TT3ROYC
DMBQKGY	MN	Serotonin transporter (SERT)
DMBQKGY	MT	DTT
DMBQKGY	MA	Inhibitor
DMBQKGY	RN	Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32.
DMBQKGY	RU	https://pubmed.ncbi.nlm.nih.gov/19282174

DMC3SJI	DI	DMC3SJI
DMC3SJI	DN	6-(pyridin-3-yl)-2-naphthonitrile
DMC3SJI	MI	TTIQUX7
DMC3SJI	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMC3SJI	MT	DTT
DMC3SJI	MA	Inhibitor
DMC3SJI	RN	Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on pote... J Med Chem. 2008 Aug 28;51(16):5064-74.
DMC3SJI	RU	https://pubmed.ncbi.nlm.nih.gov/18672861

DMC3SJI	DI	DMC3SJI
DMC3SJI	DN	6-(pyridin-3-yl)-2-naphthonitrile
DMC3SJI	MI	TTRA5BZ
DMC3SJI	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMC3SJI	MT	DTT
DMC3SJI	MA	Inhibitor
DMC3SJI	RN	In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87.
DMC3SJI	RU	https://pubmed.ncbi.nlm.nih.gov/19049427

DMV3MF4	DI	DMV3MF4
DMV3MF4	DN	6-(Toluene-4-sulfonyl)-2H-pyridazin-3-one
DMV3MF4	MI	TTFBNVI
DMV3MF4	MN	Aldose reductase (AKR1B1)
DMV3MF4	MT	DTT
DMV3MF4	MA	Inhibitor
DMV3MF4	RN	A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3... J Med Chem. 2005 Oct 6;48(20):6326-39.
DMV3MF4	RU	https://pubmed.ncbi.nlm.nih.gov/16190759

DMSB8WQ	DI	DMSB8WQ
DMSB8WQ	DN	6,11-dihydro-5H-benzo[a]carbazole
DMSB8WQ	MI	TT3WG5C
DMSB8WQ	MN	Monoamine oxidase type A (MAO-A)
DMSB8WQ	MT	DTT
DMSB8WQ	MA	Inhibitor
DMSB8WQ	RN	Synthesis and monoamine oxidase inhibitory activity of new pyridazine-, pyrimidine- and 1,2,4-triazine-containing tricyclic derivatives. J Med Chem. 2007 Nov 1;50(22):5364-71.
DMSB8WQ	RU	https://pubmed.ncbi.nlm.nih.gov/17910428

DM0RB53	DI	DM0RB53
DM0RB53	DN	6,11-dihydrothiochromeno[4,3-b]indol-8-ol
DM0RB53	MI	TTS64P2
DM0RB53	MN	Androgen receptor (AR)
DM0RB53	MT	DTT
DM0RB53	MA	Inhibitor
DM0RB53	RN	Discovery of indole-containing tetracycles as a new scaffold for androgen receptor ligands. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3233-7.
DM0RB53	RU	https://pubmed.ncbi.nlm.nih.gov/16603353

DMMZTE3	DI	DMMZTE3
DMMZTE3	DN	6,6-dimethyl-1-phenyl-3-aza-bicyclo[3.1.0]hexane
DMMZTE3	MI	TT3ROYC
DMMZTE3	MN	Serotonin transporter (SERT)
DMMZTE3	MT	DTT
DMMZTE3	MA	Inhibitor
DMMZTE3	RN	Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3682-6.
DMMZTE3	RU	https://pubmed.ncbi.nlm.nih.gov/18539031

DMOIFAP	DI	DMOIFAP
DMOIFAP	DN	6,6-Dimethyl-2-oxa-spiro[4.4]nonan-1-one
DMOIFAP	MI	TT1MPAY
DMOIFAP	MN	GABA(A) receptor alpha-1 (GABRA1)
DMOIFAP	MT	DTT
DMOIFAP	MA	Inhibitor
DMOIFAP	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DMOIFAP	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DMOIFAP	DI	DMOIFAP
DMOIFAP	DN	6,6-Dimethyl-2-oxa-spiro[4.4]nonan-1-one
DMOIFAP	MI	TTZA1NY
DMOIFAP	MN	GABA(A) receptor beta-2 (GABRB2)
DMOIFAP	MT	DTT
DMOIFAP	MA	Inhibitor
DMOIFAP	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DMOIFAP	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DMOIFAP	DI	DMOIFAP
DMOIFAP	DN	6,6-Dimethyl-2-oxa-spiro[4.4]nonan-1-one
DMOIFAP	MI	TT06RH5
DMOIFAP	MN	GABA(A) receptor gamma-2 (GABRG2)
DMOIFAP	MT	DTT
DMOIFAP	MA	Inhibitor
DMOIFAP	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DMOIFAP	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DMOIFAP	DI	DMOIFAP
DMOIFAP	DN	6,6-Dimethyl-2-oxa-spiro[4.4]nonan-1-one
DMOIFAP	MI	TTNJYV2
DMOIFAP	MN	Gamma-aminobutyric acid receptor (GAR)
DMOIFAP	MT	DTT
DMOIFAP	MA	Inhibitor
DMOIFAP	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DMOIFAP	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DMNOI7B	DI	DMNOI7B
DMNOI7B	DN	6,7,8,9-Tetrahydro-5-thia-8-aza-benzocycloheptene
DMNOI7B	MI	TTWG9A4
DMNOI7B	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMNOI7B	MT	DTT
DMNOI7B	MA	Inhibitor
DMNOI7B	RN	Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46.
DMNOI7B	RU	https://pubmed.ncbi.nlm.nih.gov/8784452

DMNOI7B	DI	DMNOI7B
DMNOI7B	DN	6,7,8,9-Tetrahydro-5-thia-8-aza-benzocycloheptene
DMNOI7B	MI	TTWM4TY
DMNOI7B	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMNOI7B	MT	DTT
DMNOI7B	MA	Inhibitor
DMNOI7B	RN	Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46.
DMNOI7B	RU	https://pubmed.ncbi.nlm.nih.gov/8784452

DMNOI7B	DI	DMNOI7B
DMNOI7B	DN	6,7,8,9-Tetrahydro-5-thia-8-aza-benzocycloheptene
DMNOI7B	MI	TT2NUT5
DMNOI7B	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMNOI7B	MT	DTT
DMNOI7B	MA	Inhibitor
DMNOI7B	RN	Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46.
DMNOI7B	RU	https://pubmed.ncbi.nlm.nih.gov/8784452

DMAMD87	DI	DMAMD87
DMAMD87	DN	6,7,8-Trimethoxy-1,4-dimethylquinolin-2(1H)-one
DMAMD87	MI	TTJLP0R
DMAMD87	MN	Quinone reductase 2 (NQO2)
DMAMD87	MT	DTT
DMAMD87	MA	Inhibitor
DMAMD87	RN	Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities. J Med Chem. 2009 Apr 9;52(7):1873-84.
DMAMD87	RU	https://pubmed.ncbi.nlm.nih.gov/19265439

DMJX9NQ	DI	DMJX9NQ
DMJX9NQ	DN	6,7,8-Trimethoxy-4-methylquinolin-2(1H)-one
DMJX9NQ	MI	TTJLP0R
DMJX9NQ	MN	Quinone reductase 2 (NQO2)
DMJX9NQ	MT	DTT
DMJX9NQ	MA	Inhibitor
DMJX9NQ	RN	Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities. J Med Chem. 2009 Apr 9;52(7):1873-84.
DMJX9NQ	RU	https://pubmed.ncbi.nlm.nih.gov/19265439

DMDO083	DI	DMDO083
DMDO083	DN	6,7-dibromoquinoline-5,8-dione
DMDO083	MI	TTR0SWN
DMDO083	MN	M-phase inducer phosphatase 2 (MPIP2)
DMDO083	MT	DTT
DMDO083	MA	Inhibitor
DMDO083	RN	Novel naphthoquinone and quinolinedione inhibitors of CDC25 phosphatase activity with antiproliferative properties. Bioorg Med Chem. 2008 Oct 1;16(19):9040-9.
DMDO083	RU	https://pubmed.ncbi.nlm.nih.gov/18789703

DMMX1QJ	DI	DMMX1QJ
DMMX1QJ	DN	6,7-Dichloro-1,4-dihydro-quinoxaline-2,3-dione
DMMX1QJ	MI	TTLD29N
DMMX1QJ	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMMX1QJ	MT	DTT
DMMX1QJ	MA	Inhibitor
DMMX1QJ	RN	1-Hydroxy-1,4-dihydroquinoxaline-2,3-diones: Novel antagonists at NMDA receptor glycine sites, Bioorg. Med. Chem. Lett. 6(4):439-440 (1996).
DMMX1QJ	RU	http://www.sciencedirect.com/science/article/pii/0960894X96000364

DMZHDFM	DI	DMZHDFM
DMZHDFM	DN	6,7-dichloro-1H-indole-2,3-dione
DMZHDFM	MI	TTMF541
DMZHDFM	MN	Liver carboxylesterase (CES1)
DMZHDFM	MT	DTT
DMZHDFM	MA	Inhibitor
DMZHDFM	RN	Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85.
DMZHDFM	RU	https://pubmed.ncbi.nlm.nih.gov/17378546

DM592FB	DI	DM592FB
DM592FB	DN	6,7-dichloro-2,3,4,5-tetrahydro-1H-3-benzazepine
DM592FB	MI	TTJQOD7
DM592FB	MN	5-HT 2A receptor (HTR2A)
DM592FB	MT	DTT
DM592FB	MA	Inhibitor
DM592FB	RN	Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists. Bioorg Med Chem. 2008 Mar 15;16(6):3309-20.
DM592FB	RU	https://pubmed.ncbi.nlm.nih.gov/18083579

DM592FB	DI	DM592FB
DM592FB	DN	6,7-dichloro-2,3,4,5-tetrahydro-1H-3-benzazepine
DM592FB	MI	TT0K1SC
DM592FB	MN	5-HT 2B receptor (HTR2B)
DM592FB	MT	DTT
DM592FB	MA	Inhibitor
DM592FB	RN	Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists. Bioorg Med Chem. 2008 Mar 15;16(6):3309-20.
DM592FB	RU	https://pubmed.ncbi.nlm.nih.gov/18083579

DM592FB	DI	DM592FB
DM592FB	DN	6,7-dichloro-2,3,4,5-tetrahydro-1H-3-benzazepine
DM592FB	MI	TTWJBZ5
DM592FB	MN	5-HT 2C receptor (HTR2C)
DM592FB	MT	DTT
DM592FB	MA	Inhibitor
DM592FB	RN	Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists. Bioorg Med Chem. 2008 Mar 15;16(6):3309-20.
DM592FB	RU	https://pubmed.ncbi.nlm.nih.gov/18083579

DMNEJ8W	DI	DMNEJ8W
DMNEJ8W	DN	6,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione
DMNEJ8W	MI	TTLD29N
DMNEJ8W	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMNEJ8W	MT	DTT
DMNEJ8W	MA	Inhibitor
DMNEJ8W	RN	3-hydroxy-quinazoline-2,4-dione as a useful scaffold to obtain selective Gly/NMDA and AMPA receptor antagonists. Bioorg Med Chem Lett. 2004 May 3;14(9):2345-9.
DMNEJ8W	RU	https://pubmed.ncbi.nlm.nih.gov/15081038

DMNEJ8W	DI	DMNEJ8W
DMNEJ8W	DN	6,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione
DMNEJ8W	MI	TTKJEMQ
DMNEJ8W	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMNEJ8W	MT	DTT
DMNEJ8W	MA	Inhibitor
DMNEJ8W	RN	3-hydroxy-quinazoline-2,4-dione as a useful scaffold to obtain selective Gly/NMDA and AMPA receptor antagonists. Bioorg Med Chem Lett. 2004 May 3;14(9):2345-9.
DMNEJ8W	RU	https://pubmed.ncbi.nlm.nih.gov/15081038

DMNEJ8W	DI	DMNEJ8W
DMNEJ8W	DN	6,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione
DMNEJ8W	MI	TTN9D8E
DMNEJ8W	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMNEJ8W	MT	DTT
DMNEJ8W	MA	Inhibitor
DMNEJ8W	RN	3-hydroxy-quinazoline-2,4-dione as a useful scaffold to obtain selective Gly/NMDA and AMPA receptor antagonists. Bioorg Med Chem Lett. 2004 May 3;14(9):2345-9.
DMNEJ8W	RU	https://pubmed.ncbi.nlm.nih.gov/15081038

DMJNHSL	DI	DMJNHSL
DMJNHSL	DN	6,7-Dichloro-3-thiophen-3-yl-quinoline
DMJNHSL	MI	TT8FYO9
DMJNHSL	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMJNHSL	MT	DTT
DMJNHSL	MA	Inhibitor
DMJNHSL	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMJNHSL	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMJNHSL	DI	DMJNHSL
DMJNHSL	DN	6,7-Dichloro-3-thiophen-3-yl-quinoline
DMJNHSL	MI	TTI7421
DMJNHSL	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMJNHSL	MT	DTT
DMJNHSL	MA	Inhibitor
DMJNHSL	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMJNHSL	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMI7FVJ	DI	DMI7FVJ
DMI7FVJ	DN	6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline
DMI7FVJ	MI	TTGKNB4
DMI7FVJ	MN	Epidermal growth factor receptor (EGFR)
DMI7FVJ	MT	DTT
DMI7FVJ	MA	Inhibitor
DMI7FVJ	RN	Synthesis and inhibitory activity of 4-alkynyl and 4-alkenylquinazolines: identification of new scaffolds for potent EGFR tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5863-7.
DMI7FVJ	RU	https://pubmed.ncbi.nlm.nih.gov/17869510

DMFVT8A	DI	DMFVT8A
DMFVT8A	DN	6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline
DMFVT8A	MI	TTGKNB4
DMFVT8A	MN	Epidermal growth factor receptor (EGFR)
DMFVT8A	MT	DTT
DMFVT8A	MA	Inhibitor
DMFVT8A	RN	Synthesis and inhibitory activity of 4-alkynyl and 4-alkenylquinazolines: identification of new scaffolds for potent EGFR tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5863-7.
DMFVT8A	RU	https://pubmed.ncbi.nlm.nih.gov/17869510

DMVR4OW	DI	DMVR4OW
DMVR4OW	DN	6,7-diethoxy-4-styrylquinazoline
DMVR4OW	MI	TTGKNB4
DMVR4OW	MN	Epidermal growth factor receptor (EGFR)
DMVR4OW	MT	DTT
DMVR4OW	MA	Inhibitor
DMVR4OW	RN	Synthesis and inhibitory activity of 4-alkynyl and 4-alkenylquinazolines: identification of new scaffolds for potent EGFR tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5863-7.
DMVR4OW	RU	https://pubmed.ncbi.nlm.nih.gov/17869510

DMUZYXQ	DI	DMUZYXQ
DMUZYXQ	DN	6,7-Difluoro-3-thiophen-3-yl-quinoline
DMUZYXQ	MI	TT8FYO9
DMUZYXQ	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMUZYXQ	MT	DTT
DMUZYXQ	MA	Inhibitor
DMUZYXQ	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMUZYXQ	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMUZYXQ	DI	DMUZYXQ
DMUZYXQ	DN	6,7-Difluoro-3-thiophen-3-yl-quinoline
DMUZYXQ	MI	TTI7421
DMUZYXQ	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMUZYXQ	MT	DTT
DMUZYXQ	MA	Inhibitor
DMUZYXQ	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMUZYXQ	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMF08UT	DI	DMF08UT
DMF08UT	DN	6,7-Dihydroxy-2-phenyl-chromen-4-one
DMF08UT	MI	TTFBNVI
DMF08UT	MN	Aldose reductase (AKR1B1)
DMF08UT	MT	DTT
DMF08UT	MA	Inhibitor
DMF08UT	RN	1-Benzopyran-4-one antioxidants as aldose reductase inhibitors. J Med Chem. 1999 Jun 3;42(11):1881-93.
DMF08UT	RU	https://pubmed.ncbi.nlm.nih.gov/10354396

DM9JLUS	DI	DM9JLUS
DM9JLUS	DN	6,7-dihydroxy-8-nitro-1-tetralone
DM9JLUS	MI	TTKWFB8
DM9JLUS	MN	Catechol-O-methyl-transferase (COMT)
DM9JLUS	MT	DTT
DM9JLUS	MA	Inhibitor
DM9JLUS	RN	Synthesis and biological evaluation of a novel series of "ortho-nitrated" inhibitors of catechol-O-methyltransferase. J Med Chem. 2005 Dec 15;48(25):8070-8.
DM9JLUS	RU	https://pubmed.ncbi.nlm.nih.gov/16335931

DMSM0QV	DI	DMSM0QV
DMSM0QV	DN	6,7-Dimethoxy-3-((E)-styryl)-quinoline
DMSM0QV	MI	TT8FYO9
DMSM0QV	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMSM0QV	MT	DTT
DMSM0QV	MA	Inhibitor
DMSM0QV	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMSM0QV	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMSM0QV	DI	DMSM0QV
DMSM0QV	DN	6,7-Dimethoxy-3-((E)-styryl)-quinoline
DMSM0QV	MI	TTI7421
DMSM0QV	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMSM0QV	MT	DTT
DMSM0QV	MA	Inhibitor
DMSM0QV	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMSM0QV	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMPYGK9	DI	DMPYGK9
DMPYGK9	DN	6,7-Dimethoxy-3-(2-methoxy-phenyl)-quinoline
DMPYGK9	MI	TT8FYO9
DMPYGK9	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMPYGK9	MT	DTT
DMPYGK9	MA	Inhibitor
DMPYGK9	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMPYGK9	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMDENVF	DI	DMDENVF
DMDENVF	DN	6,7-Dimethoxy-3-(3-methoxy-phenyl)-quinoline
DMDENVF	MI	TT8FYO9
DMDENVF	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMDENVF	MT	DTT
DMDENVF	MA	Inhibitor
DMDENVF	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMDENVF	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMDENVF	DI	DMDENVF
DMDENVF	DN	6,7-Dimethoxy-3-(3-methoxy-phenyl)-quinoline
DMDENVF	MI	TTI7421
DMDENVF	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMDENVF	MT	DTT
DMDENVF	MA	Inhibitor
DMDENVF	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMDENVF	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DM12DVT	DI	DM12DVT
DM12DVT	DN	6,7-Dimethoxy-3-(4-methoxy-phenyl)-quinoline
DM12DVT	MI	TT8FYO9
DM12DVT	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DM12DVT	MT	DTT
DM12DVT	MA	Inhibitor
DM12DVT	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DM12DVT	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DM12DVT	DI	DM12DVT
DM12DVT	DN	6,7-Dimethoxy-3-(4-methoxy-phenyl)-quinoline
DM12DVT	MI	TTI7421
DM12DVT	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM12DVT	MT	DTT
DM12DVT	MA	Inhibitor
DM12DVT	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DM12DVT	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMM7NHI	DI	DMM7NHI
DMM7NHI	DN	6,7-Dimethoxy-3-(4-nitro-phenyl)-quinoline
DMM7NHI	MI	TT8FYO9
DMM7NHI	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMM7NHI	MT	DTT
DMM7NHI	MA	Inhibitor
DMM7NHI	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMM7NHI	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMM7NHI	DI	DMM7NHI
DMM7NHI	DN	6,7-Dimethoxy-3-(4-nitro-phenyl)-quinoline
DMM7NHI	MI	TTI7421
DMM7NHI	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMM7NHI	MT	DTT
DMM7NHI	MA	Inhibitor
DMM7NHI	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMM7NHI	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMFRXDT	DI	DMFRXDT
DMFRXDT	DN	6,7-Dimethoxy-3-phenylethynyl-quinoline
DMFRXDT	MI	TT8FYO9
DMFRXDT	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMFRXDT	MT	DTT
DMFRXDT	MA	Inhibitor
DMFRXDT	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMFRXDT	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMFRXDT	DI	DMFRXDT
DMFRXDT	DN	6,7-Dimethoxy-3-phenylethynyl-quinoline
DMFRXDT	MI	TTI7421
DMFRXDT	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMFRXDT	MT	DTT
DMFRXDT	MA	Inhibitor
DMFRXDT	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMFRXDT	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DM516B4	DI	DM516B4
DM516B4	DN	6,7-Dimethoxy-3-phenyl-quinoline
DM516B4	MI	TT8FYO9
DM516B4	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DM516B4	MT	DTT
DM516B4	MA	Inhibitor
DM516B4	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DM516B4	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DM516B4	DI	DM516B4
DM516B4	DN	6,7-Dimethoxy-3-phenyl-quinoline
DM516B4	MI	TTI7421
DM516B4	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM516B4	MT	DTT
DM516B4	MA	Inhibitor
DM516B4	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DM516B4	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMM7IAK	DI	DMM7IAK
DMM7IAK	DN	6,7-Dimethoxy-3-p-tolyl-quinoline
DMM7IAK	MI	TT8FYO9
DMM7IAK	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMM7IAK	MT	DTT
DMM7IAK	MA	Inhibitor
DMM7IAK	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMM7IAK	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMM7IAK	DI	DMM7IAK
DMM7IAK	DN	6,7-Dimethoxy-3-p-tolyl-quinoline
DMM7IAK	MI	TTI7421
DMM7IAK	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMM7IAK	MT	DTT
DMM7IAK	MA	Inhibitor
DMM7IAK	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMM7IAK	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMSG1AY	DI	DMSG1AY
DMSG1AY	DN	6,7-Dimethoxy-3-pyridin-3-yl-quinoline
DMSG1AY	MI	TT8FYO9
DMSG1AY	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMSG1AY	MT	DTT
DMSG1AY	MA	Inhibitor
DMSG1AY	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMSG1AY	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMSG1AY	DI	DMSG1AY
DMSG1AY	DN	6,7-Dimethoxy-3-pyridin-3-yl-quinoline
DMSG1AY	MI	TTI7421
DMSG1AY	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMSG1AY	MT	DTT
DMSG1AY	MA	Inhibitor
DMSG1AY	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMSG1AY	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMW7K5P	DI	DMW7K5P
DMW7K5P	DN	6,7-Dimethoxy-3-pyridin-4-yl-quinoline
DMW7K5P	MI	TT8FYO9
DMW7K5P	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMW7K5P	MT	DTT
DMW7K5P	MA	Inhibitor
DMW7K5P	RN	5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.
DMW7K5P	RU	https://pubmed.ncbi.nlm.nih.gov/8064792

DMW7K5P	DI	DMW7K5P
DMW7K5P	DN	6,7-Dimethoxy-3-pyridin-4-yl-quinoline
DMW7K5P	MI	TTI7421
DMW7K5P	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMW7K5P	MT	DTT
DMW7K5P	MA	Inhibitor
DMW7K5P	RN	5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.
DMW7K5P	RU	https://pubmed.ncbi.nlm.nih.gov/8064792

DM6WD8T	DI	DM6WD8T
DM6WD8T	DN	6,7-Dimethoxy-3-thiophen-2-yl-quinoline
DM6WD8T	MI	TT8FYO9
DM6WD8T	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DM6WD8T	MT	DTT
DM6WD8T	MA	Inhibitor
DM6WD8T	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DM6WD8T	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DM6WD8T	DI	DM6WD8T
DM6WD8T	DN	6,7-Dimethoxy-3-thiophen-2-yl-quinoline
DM6WD8T	MI	TTI7421
DM6WD8T	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM6WD8T	MT	DTT
DM6WD8T	MA	Inhibitor
DM6WD8T	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DM6WD8T	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMU15YV	DI	DMU15YV
DMU15YV	DN	6,7-Dimethoxy-4-(2-methoxy-phenoxy)-quinoline
DMU15YV	MI	TTI7421
DMU15YV	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMU15YV	MT	DTT
DMU15YV	MA	Inhibitor
DMU15YV	RN	A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
DMU15YV	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97101172

DMQTHV7	DI	DMQTHV7
DMQTHV7	DN	6,7-dimethoxy-4-(2-phenylethynyl)quinazoline
DMQTHV7	MI	TTGKNB4
DMQTHV7	MN	Epidermal growth factor receptor (EGFR)
DMQTHV7	MT	DTT
DMQTHV7	MA	Inhibitor
DMQTHV7	RN	Synthesis and inhibitory activity of 4-alkynyl and 4-alkenylquinazolines: identification of new scaffolds for potent EGFR tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5863-7.
DMQTHV7	RU	https://pubmed.ncbi.nlm.nih.gov/17869510

DMPS2GX	DI	DMPS2GX
DMPS2GX	DN	6,7-Dimethoxy-4-(3-methoxy-phenoxy)-quinoline
DMPS2GX	MI	TTI7421
DMPS2GX	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMPS2GX	MT	DTT
DMPS2GX	MA	Inhibitor
DMPS2GX	RN	A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
DMPS2GX	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97101172

DM3YSNX	DI	DM3YSNX
DM3YSNX	DN	6,7-Dimethoxy-4-(3-nitro-phenoxy)-quinoline
DM3YSNX	MI	TTI7421
DM3YSNX	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM3YSNX	MT	DTT
DM3YSNX	MA	Inhibitor
DM3YSNX	RN	A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
DM3YSNX	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97101172

DMKO8QT	DI	DMKO8QT
DMKO8QT	DN	6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline
DMKO8QT	MI	TTGKNB4
DMKO8QT	MN	Epidermal growth factor receptor (EGFR)
DMKO8QT	MT	DTT
DMKO8QT	MA	Inhibitor
DMKO8QT	RN	Synthesis and inhibitory activity of 4-alkynyl and 4-alkenylquinazolines: identification of new scaffolds for potent EGFR tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5863-7.
DMKO8QT	RU	https://pubmed.ncbi.nlm.nih.gov/17869510

DMX2VFP	DI	DMX2VFP
DMX2VFP	DN	6,7-Dimethoxy-4-(4-methoxy-phenoxy)-quinoline
DMX2VFP	MI	TTI7421
DMX2VFP	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMX2VFP	MT	DTT
DMX2VFP	MA	Inhibitor
DMX2VFP	RN	A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
DMX2VFP	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97101172

DMBI40Y	DI	DMBI40Y
DMBI40Y	DN	6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline
DMBI40Y	MI	TTGKNB4
DMBI40Y	MN	Epidermal growth factor receptor (EGFR)
DMBI40Y	MT	DTT
DMBI40Y	MA	Inhibitor
DMBI40Y	RN	Synthesis and inhibitory activity of 4-alkynyl and 4-alkenylquinazolines: identification of new scaffolds for potent EGFR tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5863-7.
DMBI40Y	RU	https://pubmed.ncbi.nlm.nih.gov/17869510

DMEMGPU	DI	DMEMGPU
DMEMGPU	DN	6,7-Dimethoxy-4-m-tolyloxy-quinoline
DMEMGPU	MI	TTI7421
DMEMGPU	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMEMGPU	MT	DTT
DMEMGPU	MA	Inhibitor
DMEMGPU	RN	A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
DMEMGPU	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97101172

DMBZP3I	DI	DMBZP3I
DMBZP3I	DN	6,7-Dimethoxy-4-phenoxy-quinoline
DMBZP3I	MI	TTI7421
DMBZP3I	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMBZP3I	MT	DTT
DMBZP3I	MA	Inhibitor
DMBZP3I	RN	A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
DMBZP3I	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97101172

DMP8LXB	DI	DMP8LXB
DMP8LXB	DN	6,7-dimethoxy-N-m-tolylquinazolin-4-amine
DMP8LXB	MI	TTGKNB4
DMP8LXB	MN	Epidermal growth factor receptor (EGFR)
DMP8LXB	MT	DTT
DMP8LXB	MA	Inhibitor
DMP8LXB	RN	Computational studies of epidermal growth factor receptor: docking reliability, three-dimensional quantitative structure-activity relationship anal... J Med Chem. 2009 Feb 26;52(4):964-75.
DMP8LXB	RU	https://pubmed.ncbi.nlm.nih.gov/19170633

DM7U8ID	DI	DM7U8ID
DM7U8ID	DN	6,7-Diphenyl-pteridine-2,4-diamine
DM7U8ID	MI	TT9SL3Q
DM7U8ID	MN	Polypeptide deformylase (PDF)
DM7U8ID	MT	DTT
DM7U8ID	MA	Inhibitor
DM7U8ID	RN	Further studies on 2,4-diamino-5-(2',5'-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three ... J Med Chem. 2003 Apr 24;46(9):1726-36.
DM7U8ID	RU	https://pubmed.ncbi.nlm.nih.gov/12699390

DMT09YC	DI	DMT09YC
DMT09YC	DN	6,7'-oxybis(2-phenyl-4H-chromen-4-one)
DMT09YC	MI	TTVKILB
DMT09YC	MN	Prostaglandin G/H synthase 2 (COX-2)
DMT09YC	MT	DTT
DMT09YC	MA	Inhibitor
DMT09YC	RN	Synthesis of biflavones having a 6-O-7'' linkage and effects on cyclooxygenase-2 and inducible nitric oxide synthase. Bioorg Med Chem Lett. 2009 Jan 1;19(1):74-6.
DMT09YC	RU	https://pubmed.ncbi.nlm.nih.gov/19041241

DMUEFDM	DI	DMUEFDM
DMUEFDM	DN	6,8-Dichloro-1,2,3,4-tetrahydro-acridin-9-ylamine
DMUEFDM	MI	TT1RS9F
DMUEFDM	MN	Acetylcholinesterase (AChE)
DMUEFDM	MT	DTT
DMUEFDM	MA	Inhibitor
DMUEFDM	RN	Novel and potent tacrine-related hetero- and homobivalent ligands for acetylcholinesterase and butyrylcholinesterase. Bioorg Med Chem Lett. 2001 Jul 9;11(13):1779-82.
DMUEFDM	RU	https://pubmed.ncbi.nlm.nih.gov/11425559

DMAFP18	DI	DMAFP18
DMAFP18	DN	6,8-Dimethoxy-1,4-dimethylquinolin-2(1H)-one
DMAFP18	MI	TTJLP0R
DMAFP18	MN	Quinone reductase 2 (NQO2)
DMAFP18	MT	DTT
DMAFP18	MA	Inhibitor
DMAFP18	RN	Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities. J Med Chem. 2009 Apr 9;52(7):1873-84.
DMAFP18	RU	https://pubmed.ncbi.nlm.nih.gov/19265439

DMYKSTZ	DI	DMYKSTZ
DMYKSTZ	DN	6,8-Dimethoxy-4-methylquinolin-2(1H)-one
DMYKSTZ	MI	TTJLP0R
DMYKSTZ	MN	Quinone reductase 2 (NQO2)
DMYKSTZ	MT	DTT
DMYKSTZ	MA	Inhibitor
DMYKSTZ	RN	Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities. J Med Chem. 2009 Apr 9;52(7):1873-84.
DMYKSTZ	RU	https://pubmed.ncbi.nlm.nih.gov/19265439

DME4193	DI	DME4193
DME4193	DN	6,8-Dinitro-2-piperazin-1-yl-quinoline
DME4193	MI	TT3ROYC
DME4193	MN	Serotonin transporter (SERT)
DME4193	MT	DTT
DME4193	MA	Inhibitor
DME4193	RN	Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 1. Bioorg Med Chem Lett. 2000 Jul 17;10(14):1559-62.
DME4193	RU	https://pubmed.ncbi.nlm.nih.gov/10915050

DM7FMWS	DI	DM7FMWS
DM7FMWS	DN	6,9-Dimethyl-2-oxa-spiro[4.4]nonan-1-one
DM7FMWS	MI	TT1MPAY
DM7FMWS	MN	GABA(A) receptor alpha-1 (GABRA1)
DM7FMWS	MT	DTT
DM7FMWS	MA	Inhibitor
DM7FMWS	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DM7FMWS	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DM7FMWS	DI	DM7FMWS
DM7FMWS	DN	6,9-Dimethyl-2-oxa-spiro[4.4]nonan-1-one
DM7FMWS	MI	TTZA1NY
DM7FMWS	MN	GABA(A) receptor beta-2 (GABRB2)
DM7FMWS	MT	DTT
DM7FMWS	MA	Inhibitor
DM7FMWS	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DM7FMWS	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DM7FMWS	DI	DM7FMWS
DM7FMWS	DN	6,9-Dimethyl-2-oxa-spiro[4.4]nonan-1-one
DM7FMWS	MI	TT06RH5
DM7FMWS	MN	GABA(A) receptor gamma-2 (GABRG2)
DM7FMWS	MT	DTT
DM7FMWS	MA	Inhibitor
DM7FMWS	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DM7FMWS	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DM7FMWS	DI	DM7FMWS
DM7FMWS	DN	6,9-Dimethyl-2-oxa-spiro[4.4]nonan-1-one
DM7FMWS	MI	TTNJYV2
DM7FMWS	MN	Gamma-aminobutyric acid receptor (GAR)
DM7FMWS	MT	DTT
DM7FMWS	MA	Inhibitor
DM7FMWS	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DM7FMWS	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DMDNG8F	DI	DMDNG8F
DMDNG8F	DN	6-[(E)-2-(4-Fluoro-phenyl)-vinyl]-9H-purine
DMDNG8F	MI	TT1MG9E
DMDNG8F	MN	Extracellular signal-regulated kinase 1 (ERK1)
DMDNG8F	MT	DTT
DMDNG8F	MA	Inhibitor
DMDNG8F	RN	Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22.
DMDNG8F	RU	https://pubmed.ncbi.nlm.nih.gov/15689155

DMDNG8F	DI	DMDNG8F
DMDNG8F	DN	6-[(E)-2-(4-Fluoro-phenyl)-vinyl]-9H-purine
DMDNG8F	MI	TTAN5W2
DMDNG8F	MN	Raf messenger RNA (Raf mRNA)
DMDNG8F	MT	DTT
DMDNG8F	MA	Inhibitor
DMDNG8F	RN	Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22.
DMDNG8F	RU	https://pubmed.ncbi.nlm.nih.gov/15689155

DMNJPCD	DI	DMNJPCD
DMNJPCD	DN	6-[2-(1H-INDOL-6-YL)ETHYL]PYRIDIN-2-AMINE
DMNJPCD	MI	TT8JRS7
DMNJPCD	MN	Beta-secretase (BACE)
DMNJPCD	MT	DTT
DMNJPCD	MA	Inhibitor
DMNJPCD	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMNJPCD	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM40LQ9	DI	DM40LQ9
DM40LQ9	DN	6-[4-(Pyridin-4-ylmethyl)phenyl]naphthalen-2-ol
DM40LQ9	MI	TTIQUX7
DM40LQ9	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM40LQ9	MT	DTT
DM40LQ9	MA	Inhibitor
DM40LQ9	RN	Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
DM40LQ9	RU	https://pubmed.ncbi.nlm.nih.gov/20684610

DM40LQ9	DI	DM40LQ9
DM40LQ9	DN	6-[4-(Pyridin-4-ylmethyl)phenyl]naphthalen-2-ol
DM40LQ9	MI	TTRA5BZ
DM40LQ9	MN	Steroid 17-alpha-monooxygenase (S17AH)
DM40LQ9	MT	DTT
DM40LQ9	MA	Inhibitor
DM40LQ9	RN	Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
DM40LQ9	RU	https://pubmed.ncbi.nlm.nih.gov/20684610

DM1G7P9	DI	DM1G7P9
DM1G7P9	DN	6-{[(CYCLOHEXYLAMINO)CARBONYL]AMINO}HEXANOIC ACID
DM1G7P9	MI	TT7WVHI
DM1G7P9	MN	Soluble epoxide hydrolase (EPHX2)
DM1G7P9	MT	DTT
DM1G7P9	MA	Inhibitor
DM1G7P9	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM1G7P9	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM7D52Z	DI	DM7D52Z
DM7D52Z	DN	677T
DM7D52Z	MI	TTQWOU1
DM7D52Z	MN	MTHFR messenger RNA (MTHFR mRNA)
DM7D52Z	MT	DTT
DM7D52Z	RN	Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36.
DM7D52Z	RU	https://pubmed.ncbi.nlm.nih.gov/21948793

DMERKGH	DI	DMERKGH
DMERKGH	DN	6-Acetyl-7-ethoxy-2H-chromen-2-one
DMERKGH	MI	TT2LVK8
DMERKGH	MN	Carbonic anhydrase IX (CA-IX)
DMERKGH	MT	DTT
DMERKGH	MA	Inhibitor
DMERKGH	RN	7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and X... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7255-8.
DMERKGH	RU	https://pubmed.ncbi.nlm.nih.gov/21067924

DM1K0E2	DI	DM1K0E2
DM1K0E2	DN	6-Acetyl-7-hydroxy-2H-chromen-2-one
DM1K0E2	MI	TT2LVK8
DM1K0E2	MN	Carbonic anhydrase IX (CA-IX)
DM1K0E2	MT	DTT
DM1K0E2	MA	Inhibitor
DM1K0E2	RN	7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and X... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7255-8.
DM1K0E2	RU	https://pubmed.ncbi.nlm.nih.gov/21067924

DMXOB2K	DI	DMXOB2K
DMXOB2K	DN	6-acetyl-7-methoxy-2H-chromen-2-one
DMXOB2K	MI	TT2LVK8
DMXOB2K	MN	Carbonic anhydrase IX (CA-IX)
DMXOB2K	MT	DTT
DMXOB2K	MA	Inhibitor
DMXOB2K	RN	7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and X... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7255-8.
DMXOB2K	RU	https://pubmed.ncbi.nlm.nih.gov/21067924

DMCG8BJ	DI	DMCG8BJ
DMCG8BJ	DN	6-acetyl-7-propoxy-2H-chromen-2-one
DMCG8BJ	MI	TT2LVK8
DMCG8BJ	MN	Carbonic anhydrase IX (CA-IX)
DMCG8BJ	MT	DTT
DMCG8BJ	MA	Inhibitor
DMCG8BJ	RN	7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and X... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7255-8.
DMCG8BJ	RU	https://pubmed.ncbi.nlm.nih.gov/21067924

DMI2XUQ	DI	DMI2XUQ
DMI2XUQ	DN	6-Allyloxy-9H-purin-2-ylamine
DMI2XUQ	MI	TTJ8DV7
DMI2XUQ	MN	O-6-methylguanine-DNA-alkyltransferase (MGMT)
DMI2XUQ	MT	DTT
DMI2XUQ	MA	Inhibitor
DMI2XUQ	RN	Resistance-modifying agents. 8. Inhibition of O(6)-alkylguanine-DNA alkyltransferase by O(6)-alkenyl-, O(6)-cycloalkenyl-, and O(6)-(2-oxoalkyl)gua... J Med Chem. 2000 Nov 2;43(22):4071-83.
DMI2XUQ	RU	https://pubmed.ncbi.nlm.nih.gov/11063604

DMMUE05	DI	DMMUE05
DMMUE05	DN	6-Amino-2-(1H-imidazol-4-yl)-hexanoic acid
DMMUE05	MI	TTP18AY
DMMUE05	MN	Carboxypeptidase B2 (CPB2)
DMMUE05	MT	DTT
DMMUE05	MA	Inhibitor
DMMUE05	RN	Imidazole acetic acid TAFIa inhibitors: SAR studies centered around the basic P(1)(') group. Bioorg Med Chem Lett. 2004 May 3;14(9):2141-5.
DMMUE05	RU	https://pubmed.ncbi.nlm.nih.gov/15080996

DMC5M76	DI	DMC5M76
DMC5M76	DN	6-amino-4-trifluoromethylquinolin-2(1H)-one
DMC5M76	MI	TTKPW01
DMC5M76	MN	Androgen receptor messenger RNA (AR mRNA)
DMC5M76	MT	DTT
DMC5M76	MA	Inhibitor
DMC5M76	RN	Discovery of 6-N,N-bis(2,2,2-trifluoroethyl)amino- 4-trifluoromethylquinolin-2(1H)-one as a novel selective androgen receptor modulator. J Med Chem. 2006 Oct 19;49(21):6143-6.
DMC5M76	RU	https://pubmed.ncbi.nlm.nih.gov/17034117

DM5SZHR	DI	DM5SZHR
DM5SZHR	DN	6-amino-5-bromouracil
DM5SZHR	MI	TTO0IB8
DM5SZHR	MN	Thymidine phosphorylase (TYMP)
DM5SZHR	MT	DTT
DM5SZHR	MA	Inhibitor
DM5SZHR	RN	Xanthine oxidase-activated prodrugs of thymidine phosphorylase inhibitors. Eur J Med Chem. 2008 Jun;43(6):1248-60.
DM5SZHR	RU	https://pubmed.ncbi.nlm.nih.gov/17870212

DMFPCSJ	DI	DMFPCSJ
DMFPCSJ	DN	6-amino-5-chlorouracil hydrochloride
DMFPCSJ	MI	TTO0IB8
DMFPCSJ	MN	Thymidine phosphorylase (TYMP)
DMFPCSJ	MT	DTT
DMFPCSJ	MA	Inhibitor
DMFPCSJ	RN	Design and synthesis of novel 5,6-disubstituted uracil derivatives as potent inhibitors of thymidine phosphorylase. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1335-7.
DMFPCSJ	RU	https://pubmed.ncbi.nlm.nih.gov/16337119

DMU1CV4	DI	DMU1CV4
DMU1CV4	DN	6-amino-9-methoxy-7H-furo[3,2-g]chromen-7-one
DMU1CV4	MI	TT3WG5C
DMU1CV4	MN	Monoamine oxidase type A (MAO-A)
DMU1CV4	MT	DTT
DMU1CV4	MA	Inhibitor
DMU1CV4	RN	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J Med Chem. 2008 Nov 13;51(21):6740-51.
DMU1CV4	RU	https://pubmed.ncbi.nlm.nih.gov/18834112

DMU1CV4	DI	DMU1CV4
DMU1CV4	DN	6-amino-9-methoxy-7H-furo[3,2-g]chromen-7-one
DMU1CV4	MI	TTGP7BY
DMU1CV4	MN	Monoamine oxidase type B (MAO-B)
DMU1CV4	MT	DTT
DMU1CV4	MA	Inhibitor
DMU1CV4	RN	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J Med Chem. 2008 Nov 13;51(21):6740-51.
DMU1CV4	RU	https://pubmed.ncbi.nlm.nih.gov/18834112

DMWPELS	DI	DMWPELS
DMWPELS	DN	6-Amino-benzothiazole-2-sulfonic acid amide
DMWPELS	MI	TTHQPL7
DMWPELS	MN	Carbonic anhydrase I (CA-I)
DMWPELS	MT	DTT
DMWPELS	MA	Inhibitor
DMWPELS	RN	Carbonic anhydrase inhibitors. Synthesis of water-soluble, topically effective, intraocular pressure-lowering aromatic/heterocyclic sulfonamides co... J Med Chem. 1999 Jul 15;42(14):2641-50.
DMWPELS	RU	https://pubmed.ncbi.nlm.nih.gov/10411484

DMWPELS	DI	DMWPELS
DMWPELS	DN	6-Amino-benzothiazole-2-sulfonic acid amide
DMWPELS	MI	TTANPDJ
DMWPELS	MN	Carbonic anhydrase II (CA-II)
DMWPELS	MT	DTT
DMWPELS	MA	Inhibitor
DMWPELS	RN	Carbonic anhydrase inhibitors. Synthesis of water-soluble, topically effective, intraocular pressure-lowering aromatic/heterocyclic sulfonamides co... J Med Chem. 1999 Jul 15;42(14):2641-50.
DMWPELS	RU	https://pubmed.ncbi.nlm.nih.gov/10411484

DMEHG2F	DI	DMEHG2F
DMEHG2F	DN	6-amino-N-(2,4-dichlorobenzyl)nicotinamide
DMEHG2F	MI	TT7WVHI
DMEHG2F	MN	Soluble epoxide hydrolase (EPHX2)
DMEHG2F	MT	DTT
DMEHG2F	MA	Inhibitor
DMEHG2F	RN	Design and synthesis of substituted nicotinamides as inhibitors of soluble epoxide hydrolase. Bioorg Med Chem Lett. 2009 Oct 15;19(20):5864-8.
DMEHG2F	RU	https://pubmed.ncbi.nlm.nih.gov/19758802

DMYI5GU	DI	DMYI5GU
DMYI5GU	DN	6-amino-N-(3,3-diphenylpropyl)nicotinamide
DMYI5GU	MI	TT7WVHI
DMYI5GU	MN	Soluble epoxide hydrolase (EPHX2)
DMYI5GU	MT	DTT
DMYI5GU	MA	Inhibitor
DMYI5GU	RN	Design and synthesis of substituted nicotinamides as inhibitors of soluble epoxide hydrolase. Bioorg Med Chem Lett. 2009 Oct 15;19(20):5864-8.
DMYI5GU	RU	https://pubmed.ncbi.nlm.nih.gov/19758802

DMUZOYN	DI	DMUZOYN
DMUZOYN	DN	6-amino-uridine monophosphate
DMUZOYN	MI	TTV7Y40
DMUZOYN	MN	Mycobacterium Orotidine phosphate decarboxylase (MycB pyrF)
DMUZOYN	MT	DTT
DMUZOYN	MA	Inhibitor
DMUZOYN	RN	Design of inhibitors of orotidine monophosphate decarboxylase using bioisosteric replacement and determination of inhibition kinetics. J Med Chem. 2006 Aug 10;49(16):4937-45.
DMUZOYN	RU	https://pubmed.ncbi.nlm.nih.gov/16884305

DM7WYCM	DI	DM7WYCM
DM7WYCM	DN	6-aza-uridine monophosphate
DM7WYCM	MI	TTV7Y40
DM7WYCM	MN	Mycobacterium Orotidine phosphate decarboxylase (MycB pyrF)
DM7WYCM	MT	DTT
DM7WYCM	MA	Inhibitor
DM7WYCM	RN	Design of inhibitors of orotidine monophosphate decarboxylase using bioisosteric replacement and determination of inhibition kinetics. J Med Chem. 2006 Aug 10;49(16):4937-45.
DM7WYCM	RU	https://pubmed.ncbi.nlm.nih.gov/16884305

DM8BNWH	DI	DM8BNWH
DM8BNWH	DN	6-Azido-8-(3-iodo-phenyl)-quinoline
DM8BNWH	MI	TTZ97H5
DM8BNWH	MN	Phosphodiesterase 4A (PDE4A)
DM8BNWH	MT	DTT
DM8BNWH	MA	Inhibitor
DM8BNWH	RN	Hunting the emesis and efficacy targets of PDE4 inhibitors: identification of the photoaffinity probe 8-(3-azidophenyl)-6- [(4-iodo-1H-1-imidazolyl... J Med Chem. 2000 Oct 19;43(21):3820-3.
DM8BNWH	RU	https://pubmed.ncbi.nlm.nih.gov/11052785

DM2I95Z	DI	DM2I95Z
DM2I95Z	DN	6-benzenesulfinylhexanoic acid hydroxamide
DM2I95Z	MI	TTBH0VX
DM2I95Z	MN	Histone deacetylase (HDAC)
DM2I95Z	MT	DTT
DM2I95Z	MA	Inhibitor
DM2I95Z	RN	Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5.
DM2I95Z	RU	https://pubmed.ncbi.nlm.nih.gov/16420064

DM2I95Z	DI	DM2I95Z
DM2I95Z	DN	6-benzenesulfinylhexanoic acid hydroxamide
DM2I95Z	MI	TT6R7JZ
DM2I95Z	MN	Histone deacetylase 1 (HDAC1)
DM2I95Z	MT	DTT
DM2I95Z	MA	Inhibitor
DM2I95Z	RN	Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5.
DM2I95Z	RU	https://pubmed.ncbi.nlm.nih.gov/16420064

DM2I95Z	DI	DM2I95Z
DM2I95Z	DN	6-benzenesulfinylhexanoic acid hydroxamide
DM2I95Z	MI	TTYHPU6
DM2I95Z	MN	Histone deacetylase 10 (HDAC10)
DM2I95Z	MT	DTT
DM2I95Z	MA	Inhibitor
DM2I95Z	RN	Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5.
DM2I95Z	RU	https://pubmed.ncbi.nlm.nih.gov/16420064

DM2I95Z	DI	DM2I95Z
DM2I95Z	DN	6-benzenesulfinylhexanoic acid hydroxamide
DM2I95Z	MI	TTSHTOI
DM2I95Z	MN	Histone deacetylase 2 (HDAC2)
DM2I95Z	MT	DTT
DM2I95Z	MA	Inhibitor
DM2I95Z	RN	Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5.
DM2I95Z	RU	https://pubmed.ncbi.nlm.nih.gov/16420064

DM2I95Z	DI	DM2I95Z
DM2I95Z	DN	6-benzenesulfinylhexanoic acid hydroxamide
DM2I95Z	MI	TTTQGH8
DM2I95Z	MN	Histone deacetylase 4 (HDAC4)
DM2I95Z	MT	DTT
DM2I95Z	MA	Inhibitor
DM2I95Z	RN	Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5.
DM2I95Z	RU	https://pubmed.ncbi.nlm.nih.gov/16420064

DM2I95Z	DI	DM2I95Z
DM2I95Z	DN	6-benzenesulfinylhexanoic acid hydroxamide
DM2I95Z	MI	TT5ZKDI
DM2I95Z	MN	Histone deacetylase 6 (HDAC6)
DM2I95Z	MT	DTT
DM2I95Z	MA	Inhibitor
DM2I95Z	RN	Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5.
DM2I95Z	RU	https://pubmed.ncbi.nlm.nih.gov/16420064

DM2I95Z	DI	DM2I95Z
DM2I95Z	DN	6-benzenesulfinylhexanoic acid hydroxamide
DM2I95Z	MI	TTT6LFV
DM2I95Z	MN	Histone deacetylase 8 (HDAC8)
DM2I95Z	MT	DTT
DM2I95Z	MA	Inhibitor
DM2I95Z	RN	Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5.
DM2I95Z	RU	https://pubmed.ncbi.nlm.nih.gov/16420064

DM81DTC	DI	DM81DTC
DM81DTC	DN	6-Benzenesulfonyl-2H-pyridazin-3-one
DM81DTC	MI	TTFBNVI
DM81DTC	MN	Aldose reductase (AKR1B1)
DM81DTC	MT	DTT
DM81DTC	MA	Inhibitor
DM81DTC	RN	A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3... J Med Chem. 2005 Oct 6;48(20):6326-39.
DM81DTC	RU	https://pubmed.ncbi.nlm.nih.gov/16190759

DMY9IK8	DI	DMY9IK8
DMY9IK8	DN	6-benzenesulfonylhexanoic acid hydroxamide
DMY9IK8	MI	TTBH0VX
DMY9IK8	MN	Histone deacetylase (HDAC)
DMY9IK8	MT	DTT
DMY9IK8	MA	Inhibitor
DMY9IK8	RN	Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5.
DMY9IK8	RU	https://pubmed.ncbi.nlm.nih.gov/16420064

DMY9IK8	DI	DMY9IK8
DMY9IK8	DN	6-benzenesulfonylhexanoic acid hydroxamide
DMY9IK8	MI	TT6R7JZ
DMY9IK8	MN	Histone deacetylase 1 (HDAC1)
DMY9IK8	MT	DTT
DMY9IK8	MA	Inhibitor
DMY9IK8	RN	Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5.
DMY9IK8	RU	https://pubmed.ncbi.nlm.nih.gov/16420064

DMY9IK8	DI	DMY9IK8
DMY9IK8	DN	6-benzenesulfonylhexanoic acid hydroxamide
DMY9IK8	MI	TTYHPU6
DMY9IK8	MN	Histone deacetylase 10 (HDAC10)
DMY9IK8	MT	DTT
DMY9IK8	MA	Inhibitor
DMY9IK8	RN	Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5.
DMY9IK8	RU	https://pubmed.ncbi.nlm.nih.gov/16420064

DMY9IK8	DI	DMY9IK8
DMY9IK8	DN	6-benzenesulfonylhexanoic acid hydroxamide
DMY9IK8	MI	TTSHTOI
DMY9IK8	MN	Histone deacetylase 2 (HDAC2)
DMY9IK8	MT	DTT
DMY9IK8	MA	Inhibitor
DMY9IK8	RN	Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5.
DMY9IK8	RU	https://pubmed.ncbi.nlm.nih.gov/16420064

DMY9IK8	DI	DMY9IK8
DMY9IK8	DN	6-benzenesulfonylhexanoic acid hydroxamide
DMY9IK8	MI	TTTQGH8
DMY9IK8	MN	Histone deacetylase 4 (HDAC4)
DMY9IK8	MT	DTT
DMY9IK8	MA	Inhibitor
DMY9IK8	RN	Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5.
DMY9IK8	RU	https://pubmed.ncbi.nlm.nih.gov/16420064

DMY9IK8	DI	DMY9IK8
DMY9IK8	DN	6-benzenesulfonylhexanoic acid hydroxamide
DMY9IK8	MI	TT5ZKDI
DMY9IK8	MN	Histone deacetylase 6 (HDAC6)
DMY9IK8	MT	DTT
DMY9IK8	MA	Inhibitor
DMY9IK8	RN	Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5.
DMY9IK8	RU	https://pubmed.ncbi.nlm.nih.gov/16420064

DMY9IK8	DI	DMY9IK8
DMY9IK8	DN	6-benzenesulfonylhexanoic acid hydroxamide
DMY9IK8	MI	TTT6LFV
DMY9IK8	MN	Histone deacetylase 8 (HDAC8)
DMY9IK8	MT	DTT
DMY9IK8	MA	Inhibitor
DMY9IK8	RN	Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5.
DMY9IK8	RU	https://pubmed.ncbi.nlm.nih.gov/16420064

DM0CZ1F	DI	DM0CZ1F
DM0CZ1F	DN	6-Benzyl-2-cyclohexylsulfanyl-3H-pyrimidin-4-one
DM0CZ1F	MI	TT84ETX
DM0CZ1F	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM0CZ1F	MT	DTT
DM0CZ1F	MA	Inhibitor
DM0CZ1F	RN	Synthesis and anti-HIV-1 activity of thio analogues of dihydroalkoxybenzyloxopyrimidines. J Med Chem. 1995 Aug 18;38(17):3258-63.
DM0CZ1F	RU	https://pubmed.ncbi.nlm.nih.gov/7650679

DMZRQEF	DI	DMZRQEF
DMZRQEF	DN	6-Benzyl-2-cyclopentylsulfanyl-3H-pyrimidin-4-one
DMZRQEF	MI	TT84ETX
DMZRQEF	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMZRQEF	MT	DTT
DMZRQEF	MA	Inhibitor
DMZRQEF	RN	5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3, 4-dihydropyrimidin-4(3H)-ones: novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine d... J Med Chem. 1999 Feb 25;42(4):619-27.
DMZRQEF	RU	https://pubmed.ncbi.nlm.nih.gov/10052969

DMI5RNJ	DI	DMI5RNJ
DMI5RNJ	DN	6-Benzyl-2-isobutylsulfanyl-3H-pyrimidin-4-one
DMI5RNJ	MI	TT84ETX
DMI5RNJ	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMI5RNJ	MT	DTT
DMI5RNJ	MA	Inhibitor
DMI5RNJ	RN	Synthesis and anti-HIV-1 activity of thio analogues of dihydroalkoxybenzyloxopyrimidines. J Med Chem. 1995 Aug 18;38(17):3258-63.
DMI5RNJ	RU	https://pubmed.ncbi.nlm.nih.gov/7650679

DM7ANE3	DI	DM7ANE3
DM7ANE3	DN	6-Benzyl-2-sec-butylsulfanyl-3H-pyrimidin-4-one
DM7ANE3	MI	TT84ETX
DM7ANE3	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM7ANE3	MT	DTT
DM7ANE3	MA	Inhibitor
DM7ANE3	RN	5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3, 4-dihydropyrimidin-4(3H)-ones: novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine d... J Med Chem. 1999 Feb 25;42(4):619-27.
DM7ANE3	RU	https://pubmed.ncbi.nlm.nih.gov/10052969

DMICRFQ	DI	DMICRFQ
DMICRFQ	DN	6-benzyl-3-ethoxycarbonyl-4-quinolone
DMICRFQ	MI	TT1MPAY
DMICRFQ	MN	GABA(A) receptor alpha-1 (GABRA1)
DMICRFQ	MT	DTT
DMICRFQ	MA	Inhibitor
DMICRFQ	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMICRFQ	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMICRFQ	DI	DMICRFQ
DMICRFQ	DN	6-benzyl-3-ethoxycarbonyl-4-quinolone
DMICRFQ	MI	TT37EDJ
DMICRFQ	MN	GABA(A) receptor alpha-3 (GABRA3)
DMICRFQ	MT	DTT
DMICRFQ	MA	Inhibitor
DMICRFQ	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMICRFQ	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMICRFQ	DI	DMICRFQ
DMICRFQ	DN	6-benzyl-3-ethoxycarbonyl-4-quinolone
DMICRFQ	MI	TTZA1NY
DMICRFQ	MN	GABA(A) receptor beta-2 (GABRB2)
DMICRFQ	MT	DTT
DMICRFQ	MA	Inhibitor
DMICRFQ	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMICRFQ	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMICRFQ	DI	DMICRFQ
DMICRFQ	DN	6-benzyl-3-ethoxycarbonyl-4-quinolone
DMICRFQ	MI	TT06RH5
DMICRFQ	MN	GABA(A) receptor gamma-2 (GABRG2)
DMICRFQ	MT	DTT
DMICRFQ	MA	Inhibitor
DMICRFQ	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMICRFQ	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMICRFQ	DI	DMICRFQ
DMICRFQ	DN	6-benzyl-3-ethoxycarbonyl-4-quinolone
DMICRFQ	MI	TTNJYV2
DMICRFQ	MN	Gamma-aminobutyric acid receptor (GAR)
DMICRFQ	MT	DTT
DMICRFQ	MA	Inhibitor
DMICRFQ	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMICRFQ	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMXMI5E	DI	DMXMI5E
DMXMI5E	DN	6-benzyl-3-propoxycarbonyl-4-quinolone
DMXMI5E	MI	TT1MPAY
DMXMI5E	MN	GABA(A) receptor alpha-1 (GABRA1)
DMXMI5E	MT	DTT
DMXMI5E	MA	Inhibitor
DMXMI5E	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMXMI5E	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMXMI5E	DI	DMXMI5E
DMXMI5E	DN	6-benzyl-3-propoxycarbonyl-4-quinolone
DMXMI5E	MI	TTZA1NY
DMXMI5E	MN	GABA(A) receptor beta-2 (GABRB2)
DMXMI5E	MT	DTT
DMXMI5E	MA	Inhibitor
DMXMI5E	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMXMI5E	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMXMI5E	DI	DMXMI5E
DMXMI5E	DN	6-benzyl-3-propoxycarbonyl-4-quinolone
DMXMI5E	MI	TT06RH5
DMXMI5E	MN	GABA(A) receptor gamma-2 (GABRG2)
DMXMI5E	MT	DTT
DMXMI5E	MA	Inhibitor
DMXMI5E	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMXMI5E	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMXMI5E	DI	DMXMI5E
DMXMI5E	DN	6-benzyl-3-propoxycarbonyl-4-quinolone
DMXMI5E	MI	TTNJYV2
DMXMI5E	MN	Gamma-aminobutyric acid receptor (GAR)
DMXMI5E	MT	DTT
DMXMI5E	MA	Inhibitor
DMXMI5E	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMXMI5E	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DM7HNPJ	DI	DM7HNPJ
DM7HNPJ	DN	6-benzyl-3-propylaminocarbonyl-4-quinolone
DM7HNPJ	MI	TT1MPAY
DM7HNPJ	MN	GABA(A) receptor alpha-1 (GABRA1)
DM7HNPJ	MT	DTT
DM7HNPJ	MA	Inhibitor
DM7HNPJ	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DM7HNPJ	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DM7HNPJ	DI	DM7HNPJ
DM7HNPJ	DN	6-benzyl-3-propylaminocarbonyl-4-quinolone
DM7HNPJ	MI	TTZA1NY
DM7HNPJ	MN	GABA(A) receptor beta-2 (GABRB2)
DM7HNPJ	MT	DTT
DM7HNPJ	MA	Inhibitor
DM7HNPJ	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DM7HNPJ	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DM7HNPJ	DI	DM7HNPJ
DM7HNPJ	DN	6-benzyl-3-propylaminocarbonyl-4-quinolone
DM7HNPJ	MI	TT06RH5
DM7HNPJ	MN	GABA(A) receptor gamma-2 (GABRG2)
DM7HNPJ	MT	DTT
DM7HNPJ	MA	Inhibitor
DM7HNPJ	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DM7HNPJ	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DM7HNPJ	DI	DM7HNPJ
DM7HNPJ	DN	6-benzyl-3-propylaminocarbonyl-4-quinolone
DM7HNPJ	MI	TTNJYV2
DM7HNPJ	MN	Gamma-aminobutyric acid receptor (GAR)
DM7HNPJ	MT	DTT
DM7HNPJ	MA	Inhibitor
DM7HNPJ	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DM7HNPJ	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DM8FUZL	DI	DM8FUZL
DM8FUZL	DN	6-Benzylamino-1H-pyrimidine-2,4-dione
DM8FUZL	MI	TT2GPK3
DM8FUZL	MN	DNA topoisomerase (TOP)
DM8FUZL	MT	DTT
DM8FUZL	MA	Inhibitor
DM8FUZL	RN	Inhibitors of Bacillus subtilis DNA polymerase III. Influence of modifications in the pyrimidine ring of anilino- and (benzylamino)pyrimidines. J Med Chem. 1986 May;29(5):676-81.
DM8FUZL	RU	https://pubmed.ncbi.nlm.nih.gov/3084785

DMGJYWF	DI	DMGJYWF
DMGJYWF	DN	6-Benzylamino-5-bromo-1H-pyrimidine-2,4-dione
DMGJYWF	MI	TT2GPK3
DMGJYWF	MN	DNA topoisomerase (TOP)
DMGJYWF	MT	DTT
DMGJYWF	MA	Inhibitor
DMGJYWF	RN	Inhibitors of Bacillus subtilis DNA polymerase III. Influence of modifications in the pyrimidine ring of anilino- and (benzylamino)pyrimidines. J Med Chem. 1986 May;29(5):676-81.
DMGJYWF	RU	https://pubmed.ncbi.nlm.nih.gov/3084785

DM8FTNC	DI	DM8FTNC
DM8FTNC	DN	6-Benzylamino-5-iodo-1H-pyrimidine-2,4-dione
DM8FTNC	MI	TT2GPK3
DM8FTNC	MN	DNA topoisomerase (TOP)
DM8FTNC	MT	DTT
DM8FTNC	MA	Inhibitor
DM8FTNC	RN	Inhibitors of Bacillus subtilis DNA polymerase III. Influence of modifications in the pyrimidine ring of anilino- and (benzylamino)pyrimidines. J Med Chem. 1986 May;29(5):676-81.
DM8FTNC	RU	https://pubmed.ncbi.nlm.nih.gov/3084785

DMK8XIO	DI	DMK8XIO
DMK8XIO	DN	6-Benzyloxy-5-nitro-pyrimidine-2,4-diamine
DMK8XIO	MI	TTJ8DV7
DMK8XIO	MN	O-6-methylguanine-DNA-alkyltransferase (MGMT)
DMK8XIO	MT	DTT
DMK8XIO	MA	Inhibitor
DMK8XIO	RN	Inhibition of human O6-alkylguanine-DNA alkyltransferase and potentiation of the cytotoxicity of chloroethylnitrosourea by 4(6)-(benzyloxy)-2,6(4)-... J Med Chem. 1998 Feb 12;41(4):503-8.
DMK8XIO	RU	https://pubmed.ncbi.nlm.nih.gov/9484500

DMUFSE2	DI	DMUFSE2
DMUFSE2	DN	6-Benzyloxy-5-nitroso-pyrimidine-2,4-diamine
DMUFSE2	MI	TTJ8DV7
DMUFSE2	MN	O-6-methylguanine-DNA-alkyltransferase (MGMT)
DMUFSE2	MT	DTT
DMUFSE2	MA	Inhibitor
DMUFSE2	RN	Inhibition of human O6-alkylguanine-DNA alkyltransferase and potentiation of the cytotoxicity of chloroethylnitrosourea by 4(6)-(benzyloxy)-2,6(4)-... J Med Chem. 1998 Feb 12;41(4):503-8.
DMUFSE2	RU	https://pubmed.ncbi.nlm.nih.gov/9484500

DMFI7A8	DI	DMFI7A8
DMFI7A8	DN	6-Benzyloxy-9H-purin-2-ylamine
DMFI7A8	MI	DEJGDUW
DMFI7A8	MN	Cytochrome P450 1A2 (CYP1A2)
DMFI7A8	MT	DME
DMFI7A8	MA	Metabolism
DMFI7A8	RN	Human liver oxidative metabolism of O6-benzylguanine. Biochem Pharmacol. 1995 Oct 26;50(9):1385-9.
DMFI7A8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7503788

DMFI7A8	DI	DMFI7A8
DMFI7A8	DN	6-Benzyloxy-9H-purin-2-ylamine
DMFI7A8	MI	DE4LYSA
DMFI7A8	MN	Cytochrome P450 3A4 (CYP3A4)
DMFI7A8	MT	DME
DMFI7A8	MA	Metabolism
DMFI7A8	RN	Human liver oxidative metabolism of O6-benzylguanine. Biochem Pharmacol. 1995 Oct 26;50(9):1385-9.
DMFI7A8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7503788

DMFI7A8	DI	DMFI7A8
DMFI7A8	DN	6-Benzyloxy-9H-purin-2-ylamine
DMFI7A8	MI	TTJ8DV7
DMFI7A8	MN	O-6-methylguanine-DNA-alkyltransferase (MGMT)
DMFI7A8	MT	DTT
DMFI7A8	MA	Inhibitor
DMFI7A8	RN	Inhibition of human O6-alkylguanine-DNA alkyltransferase and potentiation of the cytotoxicity of chloroethylnitrosourea by 4(6)-(benzyloxy)-2,6(4)-... J Med Chem. 1998 Feb 12;41(4):503-8.
DMFI7A8	RU	https://pubmed.ncbi.nlm.nih.gov/9484500

DMARP3M	DI	DMARP3M
DMARP3M	DN	6-Benzyloxybenzo[b]thiophene-2-carboxamidine
DMARP3M	MI	TTFEZ5Q
DMARP3M	MN	Coagulation factor IX (F9)
DMARP3M	MT	DTT
DMARP3M	MA	Inhibitor
DMARP3M	RN	Studies of benzothiophene template as potent factor IXa (FIXa) inhibitors in thrombosis. J Med Chem. 2010 Feb 25;53(4):1465-72.
DMARP3M	RU	https://pubmed.ncbi.nlm.nih.gov/20121198

DMI7FNZ	DI	DMI7FNZ
DMI7FNZ	DN	6-Benzylsulfanyl-9H-purine
DMI7FNZ	MI	TTAN5W2
DMI7FNZ	MN	Raf messenger RNA (Raf mRNA)
DMI7FNZ	MT	DTT
DMI7FNZ	MA	Inhibitor
DMI7FNZ	RN	Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22.
DMI7FNZ	RU	https://pubmed.ncbi.nlm.nih.gov/15689155

DMI7FNZ	DI	DMI7FNZ
DMI7FNZ	DN	6-Benzylsulfanyl-9H-purine
DMI7FNZ	MI	TTQBR95
DMI7FNZ	MN	Stress-activated protein kinase 2a (p38 alpha)
DMI7FNZ	MT	DTT
DMI7FNZ	MA	Inhibitor
DMI7FNZ	RN	Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22.
DMI7FNZ	RU	https://pubmed.ncbi.nlm.nih.gov/15689155

DMNXGZP	DI	DMNXGZP
DMNXGZP	DN	6-Benzylthioinosine
DMNXGZP	MI	TTL732K
DMNXGZP	MN	Adenosine kinase (ADK)
DMNXGZP	MT	DTT
DMNXGZP	MA	Inhibitor
DMNXGZP	RN	Structure-activity relationships of carbocyclic 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase. Bioorg Med Chem. 2010 May 15;18(10):3403-12.
DMNXGZP	RU	https://pubmed.ncbi.nlm.nih.gov/20456959

DMZ8PBE	DI	DMZ8PBE
DMZ8PBE	DN	6beta-naltrexol HCl
DMZ8PBE	MI	TT27RFC
DMZ8PBE	MN	Opioid receptor delta (OPRD1)
DMZ8PBE	MT	DTT
DMZ8PBE	MA	Inhibitor
DMZ8PBE	RN	Design, synthesis, and characterization of 6beta-naltrexol analogs, and their selectivity for in vitro opioid receptor subtypes. Bioorg Med Chem Lett. 2009 May 15;19(10):2811-4.
DMZ8PBE	RU	https://pubmed.ncbi.nlm.nih.gov/19364645

DMZ8PBE	DI	DMZ8PBE
DMZ8PBE	DN	6beta-naltrexol HCl
DMZ8PBE	MI	TTQW87Y
DMZ8PBE	MN	Opioid receptor kappa (OPRK1)
DMZ8PBE	MT	DTT
DMZ8PBE	MA	Inhibitor
DMZ8PBE	RN	Design, synthesis, and characterization of 6beta-naltrexol analogs, and their selectivity for in vitro opioid receptor subtypes. Bioorg Med Chem Lett. 2009 May 15;19(10):2811-4.
DMZ8PBE	RU	https://pubmed.ncbi.nlm.nih.gov/19364645

DMZ8PBE	DI	DMZ8PBE
DMZ8PBE	DN	6beta-naltrexol HCl
DMZ8PBE	MI	TTKWM86
DMZ8PBE	MN	Opioid receptor mu (MOP)
DMZ8PBE	MT	DTT
DMZ8PBE	MA	Inhibitor
DMZ8PBE	RN	Design, synthesis, and characterization of 6beta-naltrexol analogs, and their selectivity for in vitro opioid receptor subtypes. Bioorg Med Chem Lett. 2009 May 15;19(10):2811-4.
DMZ8PBE	RU	https://pubmed.ncbi.nlm.nih.gov/19364645

DMZPY69	DI	DMZPY69
DMZPY69	DN	6-biphenyl-2-yl-2-morpholin-4-yl-chromen-4-one
DMZPY69	MI	TTK3PY9
DMZPY69	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMZPY69	MT	DTT
DMZPY69	MA	Inhibitor
DMZPY69	RN	Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46.
DMZPY69	RU	https://pubmed.ncbi.nlm.nih.gov/16302822

DMU9WG0	DI	DMU9WG0
DMU9WG0	DN	6-bromo-1H-indazole
DMU9WG0	MI	TTZUFI5
DMU9WG0	MN	Nitric-oxide synthase brain (NOS1)
DMU9WG0	MT	DTT
DMU9WG0	MA	Inhibitor
DMU9WG0	RN	4-substituted indazoles as new inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3177-80.
DMU9WG0	RU	https://pubmed.ncbi.nlm.nih.gov/17395463

DMM9GOR	DI	DMM9GOR
DMM9GOR	DN	6-bromo-1-methyl-3-(pyridin-4-yl)-1H-indole
DMM9GOR	MI	TTTB4UP
DMM9GOR	MN	Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2)
DMM9GOR	MT	DTT
DMM9GOR	MA	Inhibitor
DMM9GOR	RN	Low molecular weight indole fragments as IMPDH inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2535-8.
DMM9GOR	RU	https://pubmed.ncbi.nlm.nih.gov/16483769

DM7U58O	DI	DM7U58O
DM7U58O	DN	6-Bromo-2-(2-nitro-phenyl)-chromen-4-one
DM7U58O	MI	TT1MPAY
DM7U58O	MN	GABA(A) receptor alpha-1 (GABRA1)
DM7U58O	MT	DTT
DM7U58O	MA	Inhibitor
DM7U58O	RN	6-Bromo-3 nitroflavone, a new high affinity benzodiazepine receptor agonist recognizes two populations of cerebral cortical binding sites, Bioorg. Med. Chem. Lett. 7(3):373-378 (1997).
DM7U58O	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97000206

DM7U58O	DI	DM7U58O
DM7U58O	DN	6-Bromo-2-(2-nitro-phenyl)-chromen-4-one
DM7U58O	MI	TTNJYV2
DM7U58O	MN	Gamma-aminobutyric acid receptor (GAR)
DM7U58O	MT	DTT
DM7U58O	MA	Inhibitor
DM7U58O	RN	6-Bromo-3 nitroflavone, a new high affinity benzodiazepine receptor agonist recognizes two populations of cerebral cortical binding sites, Bioorg. Med. Chem. Lett. 7(3):373-378 (1997).
DM7U58O	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97000206

DMTJRF3	DI	DMTJRF3
DMTJRF3	DN	6-Bromo-2-(3-bromo-phenyl)-chromen-4-one
DMTJRF3	MI	TT1MPAY
DMTJRF3	MN	GABA(A) receptor alpha-1 (GABRA1)
DMTJRF3	MT	DTT
DMTJRF3	MA	Inhibitor
DMTJRF3	RN	Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997).
DMTJRF3	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97003430

DMTJRF3	DI	DMTJRF3
DMTJRF3	DN	6-Bromo-2-(3-bromo-phenyl)-chromen-4-one
DMTJRF3	MI	TTNJYV2
DMTJRF3	MN	Gamma-aminobutyric acid receptor (GAR)
DMTJRF3	MT	DTT
DMTJRF3	MA	Inhibitor
DMTJRF3	RN	Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997).
DMTJRF3	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97003430

DMP8ZVS	DI	DMP8ZVS
DMP8ZVS	DN	6-Bromo-2-(3-nitro-phenyl)-chromen-4-one
DMP8ZVS	MI	TT1MPAY
DMP8ZVS	MN	GABA(A) receptor alpha-1 (GABRA1)
DMP8ZVS	MT	DTT
DMP8ZVS	MA	Inhibitor
DMP8ZVS	RN	6-Bromo-3 nitroflavone, a new high affinity benzodiazepine receptor agonist recognizes two populations of cerebral cortical binding sites, Bioorg. Med. Chem. Lett. 7(3):373-378 (1997).
DMP8ZVS	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97000206

DMP8ZVS	DI	DMP8ZVS
DMP8ZVS	DN	6-Bromo-2-(3-nitro-phenyl)-chromen-4-one
DMP8ZVS	MI	TTNJYV2
DMP8ZVS	MN	Gamma-aminobutyric acid receptor (GAR)
DMP8ZVS	MT	DTT
DMP8ZVS	MA	Inhibitor
DMP8ZVS	RN	6-Bromo-3 nitroflavone, a new high affinity benzodiazepine receptor agonist recognizes two populations of cerebral cortical binding sites, Bioorg. Med. Chem. Lett. 7(3):373-378 (1997).
DMP8ZVS	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97000206

DMCX3TM	DI	DMCX3TM
DMCX3TM	DN	6-Bromo-2-(4-nitro-phenyl)-chromen-4-one
DMCX3TM	MI	TT1MPAY
DMCX3TM	MN	GABA(A) receptor alpha-1 (GABRA1)
DMCX3TM	MT	DTT
DMCX3TM	MA	Inhibitor
DMCX3TM	RN	6-Bromo-3 nitroflavone, a new high affinity benzodiazepine receptor agonist recognizes two populations of cerebral cortical binding sites, Bioorg. Med. Chem. Lett. 7(3):373-378 (1997).
DMCX3TM	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97000206

DMCX3TM	DI	DMCX3TM
DMCX3TM	DN	6-Bromo-2-(4-nitro-phenyl)-chromen-4-one
DMCX3TM	MI	TTNJYV2
DMCX3TM	MN	Gamma-aminobutyric acid receptor (GAR)
DMCX3TM	MT	DTT
DMCX3TM	MA	Inhibitor
DMCX3TM	RN	6-Bromo-3 nitroflavone, a new high affinity benzodiazepine receptor agonist recognizes two populations of cerebral cortical binding sites, Bioorg. Med. Chem. Lett. 7(3):373-378 (1997).
DMCX3TM	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97000206

DMXQ8K1	DI	DMXQ8K1
DMXQ8K1	DN	6-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline
DMXQ8K1	MI	TT3WG5C
DMXQ8K1	MN	Monoamine oxidase type A (MAO-A)
DMXQ8K1	MT	DTT
DMXQ8K1	MA	Inhibitor
DMXQ8K1	RN	Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
DMXQ8K1	RU	https://pubmed.ncbi.nlm.nih.gov/15013009

DMXQ8K1	DI	DMXQ8K1
DMXQ8K1	DN	6-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline
DMXQ8K1	MI	TTGP7BY
DMXQ8K1	MN	Monoamine oxidase type B (MAO-B)
DMXQ8K1	MT	DTT
DMXQ8K1	MA	Inhibitor
DMXQ8K1	RN	Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
DMXQ8K1	RU	https://pubmed.ncbi.nlm.nih.gov/15013009

DM39VT6	DI	DM39VT6
DM39VT6	DN	6-bromo-2'-de-N-methylaplysinopsin
DM39VT6	MI	TTWJBZ5
DM39VT6	MN	5-HT 2C receptor (HTR2C)
DM39VT6	MT	DTT
DM39VT6	MA	Inhibitor
DM39VT6	RN	New antiinfective and human 5-HT2 receptor binding natural and semisynthetic compounds from the Jamaican sponge Smenospongia aurea. J Nat Prod. 2002 Apr;65(4):476-80.
DM39VT6	RU	https://pubmed.ncbi.nlm.nih.gov/11975483

DMMCNQI	DI	DMMCNQI
DMMCNQI	DN	6-Bromo-2-phenyl-chromen-4-one
DMMCNQI	MI	TT1MPAY
DMMCNQI	MN	GABA(A) receptor alpha-1 (GABRA1)
DMMCNQI	MT	DTT
DMMCNQI	MA	Inhibitor
DMMCNQI	RN	Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997).
DMMCNQI	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97003430

DMMCNQI	DI	DMMCNQI
DMMCNQI	DN	6-Bromo-2-phenyl-chromen-4-one
DMMCNQI	MI	TTNJYV2
DMMCNQI	MN	Gamma-aminobutyric acid receptor (GAR)
DMMCNQI	MT	DTT
DMMCNQI	MA	Inhibitor
DMMCNQI	RN	Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997).
DMMCNQI	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97003430

DMLT01H	DI	DMLT01H
DMLT01H	DN	6-Bromo-2-piperazin-1-yl-quinoline
DMLT01H	MI	TT3ROYC
DMLT01H	MN	Serotonin transporter (SERT)
DMLT01H	MT	DTT
DMLT01H	MA	Inhibitor
DMLT01H	RN	Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 1. Bioorg Med Chem Lett. 2000 Jul 17;10(14):1559-62.
DMLT01H	RU	https://pubmed.ncbi.nlm.nih.gov/10915050

DMVWX62	DI	DMVWX62
DMVWX62	DN	6-bromo-3-(pyridin-4-yl)-1H-indole
DMVWX62	MI	TTTB4UP
DMVWX62	MN	Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2)
DMVWX62	MT	DTT
DMVWX62	MA	Inhibitor
DMVWX62	RN	Low molecular weight indole fragments as IMPDH inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2535-8.
DMVWX62	RU	https://pubmed.ncbi.nlm.nih.gov/16483769

DM4HRIX	DI	DM4HRIX
DM4HRIX	DN	6-bromo-3-ethoxycarbonyl-2-methyl-4-quinolone
DM4HRIX	MI	TT1MPAY
DM4HRIX	MN	GABA(A) receptor alpha-1 (GABRA1)
DM4HRIX	MT	DTT
DM4HRIX	MA	Inhibitor
DM4HRIX	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DM4HRIX	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DM4HRIX	DI	DM4HRIX
DM4HRIX	DN	6-bromo-3-ethoxycarbonyl-2-methyl-4-quinolone
DM4HRIX	MI	TTZA1NY
DM4HRIX	MN	GABA(A) receptor beta-2 (GABRB2)
DM4HRIX	MT	DTT
DM4HRIX	MA	Inhibitor
DM4HRIX	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DM4HRIX	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DM4HRIX	DI	DM4HRIX
DM4HRIX	DN	6-bromo-3-ethoxycarbonyl-2-methyl-4-quinolone
DM4HRIX	MI	TT06RH5
DM4HRIX	MN	GABA(A) receptor gamma-2 (GABRG2)
DM4HRIX	MT	DTT
DM4HRIX	MA	Inhibitor
DM4HRIX	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DM4HRIX	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DM4HRIX	DI	DM4HRIX
DM4HRIX	DN	6-bromo-3-ethoxycarbonyl-2-methyl-4-quinolone
DM4HRIX	MI	TTNJYV2
DM4HRIX	MN	Gamma-aminobutyric acid receptor (GAR)
DM4HRIX	MT	DTT
DM4HRIX	MA	Inhibitor
DM4HRIX	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DM4HRIX	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DM0MQHP	DI	DM0MQHP
DM0MQHP	DN	6-bromo-3-ethoxycarbonyl-4-quinolone
DM0MQHP	MI	TT1MPAY
DM0MQHP	MN	GABA(A) receptor alpha-1 (GABRA1)
DM0MQHP	MT	DTT
DM0MQHP	MA	Inhibitor
DM0MQHP	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DM0MQHP	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DM0MQHP	DI	DM0MQHP
DM0MQHP	DN	6-bromo-3-ethoxycarbonyl-4-quinolone
DM0MQHP	MI	TT37EDJ
DM0MQHP	MN	GABA(A) receptor alpha-3 (GABRA3)
DM0MQHP	MT	DTT
DM0MQHP	MA	Inhibitor
DM0MQHP	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DM0MQHP	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DM0MQHP	DI	DM0MQHP
DM0MQHP	DN	6-bromo-3-ethoxycarbonyl-4-quinolone
DM0MQHP	MI	TTZA1NY
DM0MQHP	MN	GABA(A) receptor beta-2 (GABRB2)
DM0MQHP	MT	DTT
DM0MQHP	MA	Inhibitor
DM0MQHP	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DM0MQHP	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DM0MQHP	DI	DM0MQHP
DM0MQHP	DN	6-bromo-3-ethoxycarbonyl-4-quinolone
DM0MQHP	MI	TT06RH5
DM0MQHP	MN	GABA(A) receptor gamma-2 (GABRG2)
DM0MQHP	MT	DTT
DM0MQHP	MA	Inhibitor
DM0MQHP	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DM0MQHP	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DM0MQHP	DI	DM0MQHP
DM0MQHP	DN	6-bromo-3-ethoxycarbonyl-4-quinolone
DM0MQHP	MI	TTNJYV2
DM0MQHP	MN	Gamma-aminobutyric acid receptor (GAR)
DM0MQHP	MT	DTT
DM0MQHP	MA	Inhibitor
DM0MQHP	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DM0MQHP	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DM64KOZ	DI	DM64KOZ
DM64KOZ	DN	6-Bromo-4,9-dihydro-3H-beta-carboline
DM64KOZ	MI	TT3WG5C
DM64KOZ	MN	Monoamine oxidase type A (MAO-A)
DM64KOZ	MT	DTT
DM64KOZ	MA	Inhibitor
DM64KOZ	RN	Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
DM64KOZ	RU	https://pubmed.ncbi.nlm.nih.gov/15013009

DM64KOZ	DI	DM64KOZ
DM64KOZ	DN	6-Bromo-4,9-dihydro-3H-beta-carboline
DM64KOZ	MI	TTGP7BY
DM64KOZ	MN	Monoamine oxidase type B (MAO-B)
DM64KOZ	MT	DTT
DM64KOZ	MA	Inhibitor
DM64KOZ	RN	Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
DM64KOZ	RU	https://pubmed.ncbi.nlm.nih.gov/15013009

DMFZ2PI	DI	DMFZ2PI
DMFZ2PI	DN	6-bromo-5-methyl-1H-indole-2,3-dione
DMFZ2PI	MI	TTMF541
DMFZ2PI	MN	Liver carboxylesterase (CES1)
DMFZ2PI	MT	DTT
DMFZ2PI	MA	Inhibitor
DMFZ2PI	RN	Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85.
DMFZ2PI	RU	https://pubmed.ncbi.nlm.nih.gov/17378546

DM8A1ZU	DI	DM8A1ZU
DM8A1ZU	DN	6-bromo-5-phenylpyrimidine-2,4(1H,3H)-dione
DM8A1ZU	MI	TTO0IB8
DM8A1ZU	MN	Thymidine phosphorylase (TYMP)
DM8A1ZU	MT	DTT
DM8A1ZU	MA	Inhibitor
DM8A1ZU	RN	Discovery of 5-substituted-6-chlorouracils as efficient inhibitors of human thymidine phosphorylase. J Med Chem. 2007 Nov 29;50(24):6016-23.
DM8A1ZU	RU	https://pubmed.ncbi.nlm.nih.gov/17963370

DMZJ6M8	DI	DMZJ6M8
DMZJ6M8	DN	6-bromo-8-(piperazin-1-yl)imidazo[1,2-a]pyrazine
DMZJ6M8	MI	TTWJBZ5
DMZJ6M8	MN	5-HT 2C receptor (HTR2C)
DMZJ6M8	MT	DTT
DMZJ6M8	MA	Inhibitor
DMZJ6M8	RN	Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity. Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71.
DMZJ6M8	RU	https://pubmed.ncbi.nlm.nih.gov/19914063

DMQGB70	DI	DMQGB70
DMQGB70	DN	6-bromoaplysinopsin
DMQGB70	MI	TTJQOD7
DMQGB70	MN	5-HT 2A receptor (HTR2A)
DMQGB70	MT	DTT
DMQGB70	MA	Inhibitor
DMQGB70	RN	New antiinfective and human 5-HT2 receptor binding natural and semisynthetic compounds from the Jamaican sponge Smenospongia aurea. J Nat Prod. 2002 Apr;65(4):476-80.
DMQGB70	RU	https://pubmed.ncbi.nlm.nih.gov/11975483

DMQGB70	DI	DMQGB70
DMQGB70	DN	6-bromoaplysinopsin
DMQGB70	MI	TTWJBZ5
DMQGB70	MN	5-HT 2C receptor (HTR2C)
DMQGB70	MT	DTT
DMQGB70	MA	Inhibitor
DMQGB70	RN	New antiinfective and human 5-HT2 receptor binding natural and semisynthetic compounds from the Jamaican sponge Smenospongia aurea. J Nat Prod. 2002 Apr;65(4):476-80.
DMQGB70	RU	https://pubmed.ncbi.nlm.nih.gov/11975483

DM12WYV	DI	DM12WYV
DM12WYV	DN	6-bromoindirubin-3-oxime
DM12WYV	MI	TT9RTBL
DM12WYV	MN	Aurora B messenger RNA (AURKB mRNA)
DM12WYV	MT	DTT
DM12WYV	MA	Inhibitor
DM12WYV	RN	An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37.
DM12WYV	RU	https://pubmed.ncbi.nlm.nih.gov/17665890

DM12WYV	DI	DM12WYV
DM12WYV	DN	6-bromoindirubin-3-oxime
DM12WYV	MI	TTPS3C0
DM12WYV	MN	Aurora kinase A (AURKA)
DM12WYV	MT	DTT
DM12WYV	MA	Inhibitor
DM12WYV	RN	An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37.
DM12WYV	RU	https://pubmed.ncbi.nlm.nih.gov/17665890

DM12WYV	DI	DM12WYV
DM12WYV	DN	6-bromoindirubin-3-oxime
DM12WYV	MI	TTLYXIT
DM12WYV	MN	Aurora kinase C (AURKC)
DM12WYV	MT	DTT
DM12WYV	MA	Inhibitor
DM12WYV	RN	An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37.
DM12WYV	RU	https://pubmed.ncbi.nlm.nih.gov/17665890

DM12WYV	DI	DM12WYV
DM12WYV	DN	6-bromoindirubin-3-oxime
DM12WYV	MI	TTRZQE3
DM12WYV	MN	Glycogen synthase kinase-3 alpha (GSK-3A)
DM12WYV	MT	DTT
DM12WYV	MA	Inhibitor
DM12WYV	RN	Stable generation of serum- and feeder-free embryonic stem cell-derived mice with full germline-competency by using a GSK3 specific inhibitor. Genesis. 2009 Jun;47(6):414-22.
DM12WYV	RU	https://pubmed.ncbi.nlm.nih.gov/19391115

DMP9O7G	DI	DMP9O7G
DMP9O7G	DN	6-bromo-N-(3-bromophenyl)quinazolin-4-amine
DMP9O7G	MI	TTHS256
DMP9O7G	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMP9O7G	MT	DTT
DMP9O7G	MA	Inhibitor
DMP9O7G	RN	Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6.
DMP9O7G	RU	https://pubmed.ncbi.nlm.nih.gov/19854049

DM0A3DB	DI	DM0A3DB
DM0A3DB	DN	6-bromo-N-(3-chlorophenyl)quinazolin-4-amine
DM0A3DB	MI	TTVBPDM
DM0A3DB	MN	Metabotropic glutamate receptor 1 (mGluR1)
DM0A3DB	MT	DTT
DM0A3DB	MA	Inhibitor
DM0A3DB	RN	Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6.
DM0A3DB	RU	https://pubmed.ncbi.nlm.nih.gov/19854049

DM0A3DB	DI	DM0A3DB
DM0A3DB	DN	6-bromo-N-(3-chlorophenyl)quinazolin-4-amine
DM0A3DB	MI	TTHS256
DM0A3DB	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM0A3DB	MT	DTT
DM0A3DB	MA	Inhibitor
DM0A3DB	RN	Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6.
DM0A3DB	RU	https://pubmed.ncbi.nlm.nih.gov/19854049

DM2IP5F	DI	DM2IP5F
DM2IP5F	DN	6-bromo-N-(3-fluorophenyl)quinazolin-4-amine
DM2IP5F	MI	TTHS256
DM2IP5F	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM2IP5F	MT	DTT
DM2IP5F	MA	Inhibitor
DM2IP5F	RN	Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6.
DM2IP5F	RU	https://pubmed.ncbi.nlm.nih.gov/19854049

DM2MJ9F	DI	DM2MJ9F
DM2MJ9F	DN	6-bromo-N-m-tolylquinazolin-4-amine
DM2MJ9F	MI	TTHS256
DM2MJ9F	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM2MJ9F	MT	DTT
DM2MJ9F	MA	Inhibitor
DM2MJ9F	RN	Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6.
DM2MJ9F	RU	https://pubmed.ncbi.nlm.nih.gov/19854049

DM46GLQ	DI	DM46GLQ
DM46GLQ	DN	6-butyl-2,4-dipropylaminopyrimidine
DM46GLQ	MI	TTZAYWL
DM46GLQ	MN	Estrogen receptor (ESR)
DM46GLQ	MT	DTT
DM46GLQ	MA	Inhibitor
DM46GLQ	RN	Blocking estrogen signaling after the hormone: pyrimidine-core inhibitors of estrogen receptor-coactivator binding. J Med Chem. 2008 Oct 23;51(20):6512-30.
DM46GLQ	RU	https://pubmed.ncbi.nlm.nih.gov/18785725

DMWTMDH	DI	DMWTMDH
DMWTMDH	DN	6-Carboxyfluorescein
DMWTMDH	MI	DTQ23VB
DMWTMDH	MN	Organic anion transporter 1 (SLC22A6)
DMWTMDH	MT	DTP
DMWTMDH	MA	Substrate
DMWTMDH	RN	Fluorescence-based assay for the interaction of small molecules with the human renal organic anion transporter 1. Anal Biochem. 2000 Jul 15;283(1):49-55.
DMWTMDH	RU	http://www.ncbi.nlm.nih.gov/pubmed/10929807

DM9MPDK	DI	DM9MPDK
DM9MPDK	DN	6-Carboxymethyluracil
DM9MPDK	MI	TTZPS91
DM9MPDK	MN	Dihydrothymine dehydrogenase (DPYD)
DM9MPDK	MT	DTT
DM9MPDK	MA	Inhibitor
DM9MPDK	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9MPDK	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMW6320	DI	DMW6320
DMW6320	DN	6-Chloro-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole
DMW6320	MI	TTJQOD7
DMW6320	MN	5-HT 2A receptor (HTR2A)
DMW6320	MT	DTT
DMW6320	MA	Inhibitor
DMW6320	RN	Evaluation of isotryptamine derivatives at 5-HT(2) serotonin receptors. Bioorg Med Chem Lett. 2002 Jan 21;12(2):155-8.
DMW6320	RU	https://pubmed.ncbi.nlm.nih.gov/11755343

DMURJ34	DI	DMURJ34
DMURJ34	DN	6-Chloro-1,4-dihydro-quinoxaline-2,3-dione
DMURJ34	MI	TTLD29N
DMURJ34	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMURJ34	MT	DTT
DMURJ34	MA	Inhibitor
DMURJ34	RN	5-(N-oxyaza)-7-substituted-1,4-dihydroquinoxaline-2,3-diones: novel, systemically active and broad spectrum antagonists for NMDA/glycine, AMPA, and... J Med Chem. 1997 Oct 24;40(22):3679-86.
DMURJ34	RU	https://pubmed.ncbi.nlm.nih.gov/9357535

DMURJ34	DI	DMURJ34
DMURJ34	DN	6-Chloro-1,4-dihydro-quinoxaline-2,3-dione
DMURJ34	MI	TTKJEMQ
DMURJ34	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMURJ34	MT	DTT
DMURJ34	MA	Inhibitor
DMURJ34	RN	5-(N-oxyaza)-7-substituted-1,4-dihydroquinoxaline-2,3-diones: novel, systemically active and broad spectrum antagonists for NMDA/glycine, AMPA, and... J Med Chem. 1997 Oct 24;40(22):3679-86.
DMURJ34	RU	https://pubmed.ncbi.nlm.nih.gov/9357535

DMURJ34	DI	DMURJ34
DMURJ34	DN	6-Chloro-1,4-dihydro-quinoxaline-2,3-dione
DMURJ34	MI	TTN9D8E
DMURJ34	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMURJ34	MT	DTT
DMURJ34	MA	Inhibitor
DMURJ34	RN	5-(N-oxyaza)-7-substituted-1,4-dihydroquinoxaline-2,3-diones: novel, systemically active and broad spectrum antagonists for NMDA/glycine, AMPA, and... J Med Chem. 1997 Oct 24;40(22):3679-86.
DMURJ34	RU	https://pubmed.ncbi.nlm.nih.gov/9357535

DMKCBIL	DI	DMKCBIL
DMKCBIL	DN	6-chloro-1H-indazole
DMKCBIL	MI	TTZUFI5
DMKCBIL	MN	Nitric-oxide synthase brain (NOS1)
DMKCBIL	MT	DTT
DMKCBIL	MA	Inhibitor
DMKCBIL	RN	4-substituted indazoles as new inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3177-80.
DMKCBIL	RU	https://pubmed.ncbi.nlm.nih.gov/17395463

DMTWBOV	DI	DMTWBOV
DMTWBOV	DN	6-Chloro-2-(3-nitro-phenyl)-chromen-4-one
DMTWBOV	MI	TT1MPAY
DMTWBOV	MN	GABA(A) receptor alpha-1 (GABRA1)
DMTWBOV	MT	DTT
DMTWBOV	MA	Inhibitor
DMTWBOV	RN	Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997).
DMTWBOV	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97003430

DMTWBOV	DI	DMTWBOV
DMTWBOV	DN	6-Chloro-2-(3-nitro-phenyl)-chromen-4-one
DMTWBOV	MI	TTNJYV2
DMTWBOV	MN	Gamma-aminobutyric acid receptor (GAR)
DMTWBOV	MT	DTT
DMTWBOV	MA	Inhibitor
DMTWBOV	RN	Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997).
DMTWBOV	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97003430

DMLMOC0	DI	DMLMOC0
DMLMOC0	DN	6-Chloro-2-(4-hydroxy-phenyl)-benzooxazol-5-ol
DMLMOC0	MI	TTZAYWL
DMLMOC0	MN	Estrogen receptor (ESR)
DMLMOC0	MT	DTT
DMLMOC0	MA	Inhibitor
DMLMOC0	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMLMOC0	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMLMOC0	DI	DMLMOC0
DMLMOC0	DN	6-Chloro-2-(4-hydroxy-phenyl)-benzooxazol-5-ol
DMLMOC0	MI	TTOM3J0
DMLMOC0	MN	Estrogen receptor beta (ESR2)
DMLMOC0	MT	DTT
DMLMOC0	MA	Inhibitor
DMLMOC0	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMLMOC0	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DM5FZDI	DI	DM5FZDI
DM5FZDI	DN	6-Chloro-2-phenyl-chromen-4-one
DM5FZDI	MI	TT1MPAY
DM5FZDI	MN	GABA(A) receptor alpha-1 (GABRA1)
DM5FZDI	MT	DTT
DM5FZDI	MA	Inhibitor
DM5FZDI	RN	Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997).
DM5FZDI	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97003430

DM5FZDI	DI	DM5FZDI
DM5FZDI	DN	6-Chloro-2-phenyl-chromen-4-one
DM5FZDI	MI	TTNJYV2
DM5FZDI	MN	Gamma-aminobutyric acid receptor (GAR)
DM5FZDI	MT	DTT
DM5FZDI	MA	Inhibitor
DM5FZDI	RN	Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997).
DM5FZDI	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97003430

DMM41AQ	DI	DMM41AQ
DMM41AQ	DN	6-Chloro-2-piperazin-1-yl-quinoline
DMM41AQ	MI	TT3ROYC
DMM41AQ	MN	Serotonin transporter (SERT)
DMM41AQ	MT	DTT
DMM41AQ	MA	Inhibitor
DMM41AQ	RN	Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 1. Bioorg Med Chem Lett. 2000 Jul 17;10(14):1559-62.
DMM41AQ	RU	https://pubmed.ncbi.nlm.nih.gov/10915050

DMHJIN0	DI	DMHJIN0
DMHJIN0	DN	6-Chloro-4-morpholin-4-yl-chromen-2-one
DMHJIN0	MI	TTK3PY9
DMHJIN0	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMHJIN0	MT	DTT
DMHJIN0	MA	Inhibitor
DMHJIN0	RN	Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85.
DMHJIN0	RU	https://pubmed.ncbi.nlm.nih.gov/15658870

DMSZML2	DI	DMSZML2
DMSZML2	DN	6-chloro-5-(2-thienyl)pyrimidine-2,4(1H,3H)-dione
DMSZML2	MI	TTO0IB8
DMSZML2	MN	Thymidine phosphorylase (TYMP)
DMSZML2	MT	DTT
DMSZML2	MA	Inhibitor
DMSZML2	RN	Discovery of 5-substituted-6-chlorouracils as efficient inhibitors of human thymidine phosphorylase. J Med Chem. 2007 Nov 29;50(24):6016-23.
DMSZML2	RU	https://pubmed.ncbi.nlm.nih.gov/17963370

DMASFR6	DI	DMASFR6
DMASFR6	DN	6-chloro-5-heptylpyrimidine-2,4(1H,3H)-dione
DMASFR6	MI	TTO0IB8
DMASFR6	MN	Thymidine phosphorylase (TYMP)
DMASFR6	MT	DTT
DMASFR6	MA	Inhibitor
DMASFR6	RN	Discovery of 5-substituted-6-chlorouracils as efficient inhibitors of human thymidine phosphorylase. J Med Chem. 2007 Nov 29;50(24):6016-23.
DMASFR6	RU	https://pubmed.ncbi.nlm.nih.gov/17963370

DMP4V8Y	DI	DMP4V8Y
DMP4V8Y	DN	6-chloro-5-hexylpyrimidine-2,4(1H,3H)-dione
DMP4V8Y	MI	TTO0IB8
DMP4V8Y	MN	Thymidine phosphorylase (TYMP)
DMP4V8Y	MT	DTT
DMP4V8Y	MA	Inhibitor
DMP4V8Y	RN	Discovery of 5-substituted-6-chlorouracils as efficient inhibitors of human thymidine phosphorylase. J Med Chem. 2007 Nov 29;50(24):6016-23.
DMP4V8Y	RU	https://pubmed.ncbi.nlm.nih.gov/17963370

DMUJSP7	DI	DMUJSP7
DMUJSP7	DN	6-chloro-5-pentylpyrimidine-2,4(1H,3H)-dione
DMUJSP7	MI	TTO0IB8
DMUJSP7	MN	Thymidine phosphorylase (TYMP)
DMUJSP7	MT	DTT
DMUJSP7	MA	Inhibitor
DMUJSP7	RN	Discovery of 5-substituted-6-chlorouracils as efficient inhibitors of human thymidine phosphorylase. J Med Chem. 2007 Nov 29;50(24):6016-23.
DMUJSP7	RU	https://pubmed.ncbi.nlm.nih.gov/17963370

DM90JMN	DI	DM90JMN
DM90JMN	DN	6-chloro-5-phenylpyrimidine-2,4(1H,3H)-dione
DM90JMN	MI	TTO0IB8
DM90JMN	MN	Thymidine phosphorylase (TYMP)
DM90JMN	MT	DTT
DM90JMN	MA	Inhibitor
DM90JMN	RN	Discovery of 5-substituted-6-chlorouracils as efficient inhibitors of human thymidine phosphorylase. J Med Chem. 2007 Nov 29;50(24):6016-23.
DM90JMN	RU	https://pubmed.ncbi.nlm.nih.gov/17963370

DMB24LJ	DI	DMB24LJ
DMB24LJ	DN	6-chloro-5-propylpyrimidine-2,4(1H,3H)-dione
DMB24LJ	MI	TTO0IB8
DMB24LJ	MN	Thymidine phosphorylase (TYMP)
DMB24LJ	MT	DTT
DMB24LJ	MA	Inhibitor
DMB24LJ	RN	Discovery of 5-substituted-6-chlorouracils as efficient inhibitors of human thymidine phosphorylase. J Med Chem. 2007 Nov 29;50(24):6016-23.
DMB24LJ	RU	https://pubmed.ncbi.nlm.nih.gov/17963370

DM10A9S	DI	DM10A9S
DM10A9S	DN	6-Chloro-N-(2-morpholinoethyl)nicotinamide
DM10A9S	MI	TT3WG5C
DM10A9S	MN	Monoamine oxidase type A (MAO-A)
DM10A9S	MT	DTT
DM10A9S	MA	Inhibitor
DM10A9S	RN	Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1659-64.
DM10A9S	RU	https://pubmed.ncbi.nlm.nih.gov/20117937

DMPIFLA	DI	DMPIFLA
DMPIFLA	DN	6-chloro-N-(3-chlorophenyl)quinazolin-4-amine
DMPIFLA	MI	TTGKNB4
DMPIFLA	MN	Epidermal growth factor receptor (EGFR)
DMPIFLA	MT	DTT
DMPIFLA	MA	Inhibitor
DMPIFLA	RN	Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6.
DMPIFLA	RU	https://pubmed.ncbi.nlm.nih.gov/19854049

DMPIFLA	DI	DMPIFLA
DMPIFLA	DN	6-chloro-N-(3-chlorophenyl)quinazolin-4-amine
DMPIFLA	MI	TTHS256
DMPIFLA	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMPIFLA	MT	DTT
DMPIFLA	MA	Inhibitor
DMPIFLA	RN	Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6.
DMPIFLA	RU	https://pubmed.ncbi.nlm.nih.gov/19854049

DM78I4P	DI	DM78I4P
DM78I4P	DN	6-Chloro-N-(3-morpholinopropyl)nicotinamide
DM78I4P	MI	TT3WG5C
DM78I4P	MN	Monoamine oxidase type A (MAO-A)
DM78I4P	MT	DTT
DM78I4P	MA	Inhibitor
DM78I4P	RN	Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1659-64.
DM78I4P	RU	https://pubmed.ncbi.nlm.nih.gov/20117937

DMUY9TF	DI	DMUY9TF
DMUY9TF	DN	6-chloro-N-(pyridin-3-yl)indoline-1-carboxamide
DMUY9TF	MI	TTJQOD7
DMUY9TF	MN	5-HT 2A receptor (HTR2A)
DMUY9TF	MT	DTT
DMUY9TF	MA	Inhibitor
DMUY9TF	RN	Synthesis and structure-affinity relationships of novel small molecule natural product derivatives capable of discriminating between serotonin 5-HT1A, 5-HT2A, 5-HT2C receptor subtypes. Bioorg Med Chem. 2010 Jul 1;18(13):4783-92. 
DMUY9TF	RU	https://pubmed.ncbi.nlm.nih.gov/20570529

DMUY9TF	DI	DMUY9TF
DMUY9TF	DN	6-chloro-N-(pyridin-3-yl)indoline-1-carboxamide
DMUY9TF	MI	TTWJBZ5
DMUY9TF	MN	5-HT 2C receptor (HTR2C)
DMUY9TF	MT	DTT
DMUY9TF	MA	Inhibitor
DMUY9TF	RN	Synthesis and structure-affinity relationships of novel small molecule natural product derivatives capable of discriminating between serotonin 5-HT1A, 5-HT2A, 5-HT2C receptor subtypes. Bioorg Med Chem. 2010 Jul 1;18(13):4783-92. 
DMUY9TF	RU	https://pubmed.ncbi.nlm.nih.gov/20570529

DMWB43U	DI	DMWB43U
DMWB43U	DN	6-Chloropurine Riboside, 5'-Monophosphate
DMWB43U	MI	TTZFTY4
DMWB43U	MN	Amidophosphoribosyltransferase (PPAT)
DMWB43U	MT	DTT
DMWB43U	MA	Inhibitor
DMWB43U	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMWB43U	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMWB43U	DI	DMWB43U
DMWB43U	DN	6-Chloropurine Riboside, 5'-Monophosphate
DMWB43U	MI	TTTB4UP
DMWB43U	MN	Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2)
DMWB43U	MT	DTT
DMWB43U	MA	Inhibitor
DMWB43U	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMWB43U	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMV0C69	DI	DMV0C69
DMV0C69	DN	6-chlorotacrine hydrochloride
DMV0C69	MI	TT1RS9F
DMV0C69	MN	Acetylcholinesterase (AChE)
DMV0C69	MT	DTT
DMV0C69	MA	Inhibitor
DMV0C69	RN	Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds. J Med Chem. 2009 Sep 10;52(17):5365-79.
DMV0C69	RU	https://pubmed.ncbi.nlm.nih.gov/19663388

DMV0C69	DI	DMV0C69
DMV0C69	DN	6-chlorotacrine hydrochloride
DMV0C69	MI	TTEB0GD
DMV0C69	MN	Cholinesterase (BCHE)
DMV0C69	MT	DTT
DMV0C69	MA	Inhibitor
DMV0C69	RN	Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds. J Med Chem. 2009 Sep 10;52(17):5365-79.
DMV0C69	RU	https://pubmed.ncbi.nlm.nih.gov/19663388

DMPULH3	DI	DMPULH3
DMPULH3	DN	6-cinnamoylhernandine
DMPULH3	MI	TT27RFC
DMPULH3	MN	Opioid receptor delta (OPRD1)
DMPULH3	MT	DTT
DMPULH3	MA	Inhibitor
DMPULH3	RN	Hasubanan alkaloids with delta-opioid binding affinity from the aerial parts of Stephania japonica. J Nat Prod. 2010 May 28;73(5):988-91.
DMPULH3	RU	https://pubmed.ncbi.nlm.nih.gov/20426456

DMPXS9F	DI	DMPXS9F
DMPXS9F	DN	6-cinnamoyl-N-methylstephasunoline
DMPXS9F	MI	TT27RFC
DMPXS9F	MN	Opioid receptor delta (OPRD1)
DMPXS9F	MT	DTT
DMPXS9F	MA	Inhibitor
DMPXS9F	RN	Hasubanan alkaloids with delta-opioid binding affinity from the aerial parts of Stephania japonica. J Nat Prod. 2010 May 28;73(5):988-91.
DMPXS9F	RU	https://pubmed.ncbi.nlm.nih.gov/20426456

DMNTDFV	DI	DMNTDFV
DMNTDFV	DN	6-Cl-IMP
DMNTDFV	MI	TTL7C8Q
DMNTDFV	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMNTDFV	MT	DTT
DMNTDFV	MA	Inhibitor
DMNTDFV	RN	Identification of the IMP binding site in the IMP dehydrogenase from Tritrichomonas foetus. Biochemistry. 1995 Oct 24;34(42):13889-94.
DMNTDFV	RU	https://pubmed.ncbi.nlm.nih.gov/7577983

DMNTDFV	DI	DMNTDFV
DMNTDFV	DN	6-Cl-IMP
DMNTDFV	MI	TTYQ4AE
DMNTDFV	MN	Plasmodium Adenylosuccinate synthetase (Malaria Adss)
DMNTDFV	MT	DTT
DMNTDFV	MA	Inhibitor
DMNTDFV	RN	High performance liquid chromatography analysis of hypoxanthine metabolism in mouse oocyte-cumulus cell complexes: effects of purine metabolic perturbants. Biol Reprod. 1994 Jun;50(6):1403-12.
DMNTDFV	RU	https://pubmed.ncbi.nlm.nih.gov/8080928

DMKNOLV	DI	DMKNOLV
DMKNOLV	DN	6-Cl-MLT
DMKNOLV	MI	TT0WAIE
DMKNOLV	MN	Melatonin receptor type 1A (MTNR1A)
DMKNOLV	MT	DTT
DMKNOLV	MA	Agonist
DMKNOLV	RN	Characterization of a retinal melatonin receptor. J Pharmacol Exp Ther. 1985 Aug;234(2):395-401.
DMKNOLV	RU	https://pubmed.ncbi.nlm.nih.gov/2991499

DMACTDZ	DI	DMACTDZ
DMACTDZ	DN	6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE
DMACTDZ	MI	TT7HF4W
DMACTDZ	MN	Cyclin-dependent kinase 2 (CDK2)
DMACTDZ	MT	DTT
DMACTDZ	MA	Inhibitor
DMACTDZ	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMACTDZ	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM9IHYS	DI	DM9IHYS
DM9IHYS	DN	6-Cyclohexylmethoxy-pyrimidine-2,4,5-triamine
DM9IHYS	MI	TTAMQ62
DM9IHYS	MN	Cyclin A2 (CCNA2)
DM9IHYS	MT	DTT
DM9IHYS	MA	Inhibitor
DM9IHYS	RN	4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2. Bioorg Med Chem Lett. 2003 Jan 20;13(2):217-22.
DM9IHYS	RU	https://pubmed.ncbi.nlm.nih.gov/12482427

DM9IHYS	DI	DM9IHYS
DM9IHYS	DN	6-Cyclohexylmethoxy-pyrimidine-2,4,5-triamine
DM9IHYS	MI	TT7HF4W
DM9IHYS	MN	Cyclin-dependent kinase 2 (CDK2)
DM9IHYS	MT	DTT
DM9IHYS	MA	Inhibitor
DM9IHYS	RN	4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2. Bioorg Med Chem Lett. 2003 Jan 20;13(2):217-22.
DM9IHYS	RU	https://pubmed.ncbi.nlm.nih.gov/12482427

DM6UP25	DI	DM6UP25
DM6UP25	DN	6-cyclohexylmethyloxy-2-(4'-hydroxyanilino)purine
DM6UP25	MI	TT7HF4W
DM6UP25	MN	Cyclin-dependent kinase 2 (CDK2)
DM6UP25	MT	DTT
DM6UP25	MA	Inhibitor
DM6UP25	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM6UP25	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM9HBY5	DI	DM9HBY5
DM9HBY5	DN	6-Deoxy-Alpha-D-Glucose
DM9HBY5	MI	TTHCF4J
DM9HBY5	MN	Alpha-glucosidase (GLA)
DM9HBY5	MT	DTT
DM9HBY5	MA	Inhibitor
DM9HBY5	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9HBY5	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9HBY5	DI	DM9HBY5
DM9HBY5	DN	6-Deoxy-Alpha-D-Glucose
DM9HBY5	MI	TTCGSZ4
DM9HBY5	MN	Pancreatic alpha-amylase (AMY2A)
DM9HBY5	MT	DTT
DM9HBY5	MA	Inhibitor
DM9HBY5	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9HBY5	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMKPWN0	DI	DMKPWN0
DMKPWN0	DN	6-deoxymanzamine X
DMKPWN0	MI	TTRSMW9
DMKPWN0	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMKPWN0	MT	DTT
DMKPWN0	MA	Inhibitor
DMKPWN0	RN	Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for ... J Nat Prod. 2007 Sep;70(9):1397-405.
DMKPWN0	RU	https://pubmed.ncbi.nlm.nih.gov/17708655

DMGZQNS	DI	DMGZQNS
DMGZQNS	DN	6-desoxonaltrexone
DMGZQNS	MI	TT27RFC
DMGZQNS	MN	Opioid receptor delta (OPRD1)
DMGZQNS	MT	DTT
DMGZQNS	MA	Inhibitor
DMGZQNS	RN	Syntheses of novel high affinity ligands for opioid receptors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2289-94.
DMGZQNS	RU	https://pubmed.ncbi.nlm.nih.gov/19282177

DMGZQNS	DI	DMGZQNS
DMGZQNS	DN	6-desoxonaltrexone
DMGZQNS	MI	TTQW87Y
DMGZQNS	MN	Opioid receptor kappa (OPRK1)
DMGZQNS	MT	DTT
DMGZQNS	MA	Inhibitor
DMGZQNS	RN	Syntheses of novel high affinity ligands for opioid receptors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2289-94.
DMGZQNS	RU	https://pubmed.ncbi.nlm.nih.gov/19282177

DMGZQNS	DI	DMGZQNS
DMGZQNS	DN	6-desoxonaltrexone
DMGZQNS	MI	TTKWM86
DMGZQNS	MN	Opioid receptor mu (MOP)
DMGZQNS	MT	DTT
DMGZQNS	MA	Inhibitor
DMGZQNS	RN	Syntheses of novel high affinity ligands for opioid receptors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2289-94.
DMGZQNS	RU	https://pubmed.ncbi.nlm.nih.gov/19282177

DML2AC1	DI	DML2AC1
DML2AC1	DN	6-Dimethylamino-2-methyl-hex-4-ynal oxime
DML2AC1	MI	TTZ9SOR
DML2AC1	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DML2AC1	MT	DTT
DML2AC1	MA	Inhibitor
DML2AC1	RN	Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992).
DML2AC1	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805351

DML2AC1	DI	DML2AC1
DML2AC1	DN	6-Dimethylamino-2-methyl-hex-4-ynal oxime
DML2AC1	MI	TTYEG6Q
DML2AC1	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DML2AC1	MT	DTT
DML2AC1	MA	Inhibitor
DML2AC1	RN	Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992).
DML2AC1	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805351

DML2AC1	DI	DML2AC1
DML2AC1	DN	6-Dimethylamino-2-methyl-hex-4-ynal oxime
DML2AC1	MI	TTQ13Z5
DML2AC1	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DML2AC1	MT	DTT
DML2AC1	MA	Inhibitor
DML2AC1	RN	Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992).
DML2AC1	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805351

DML2AC1	DI	DML2AC1
DML2AC1	DN	6-Dimethylamino-2-methyl-hex-4-ynal oxime
DML2AC1	MI	TTQ3JTF
DML2AC1	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DML2AC1	MT	DTT
DML2AC1	MA	Inhibitor
DML2AC1	RN	Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992).
DML2AC1	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805351

DML2AC1	DI	DML2AC1
DML2AC1	DN	6-Dimethylamino-2-methyl-hex-4-ynal oxime
DML2AC1	MI	TTH18TF
DML2AC1	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DML2AC1	MT	DTT
DML2AC1	MA	Inhibitor
DML2AC1	RN	Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992).
DML2AC1	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805351

DMBMRUI	DI	DMBMRUI
DMBMRUI	DN	6-ethyl-2,4-diisobutylaminopyrimidine
DMBMRUI	MI	TTZAYWL
DMBMRUI	MN	Estrogen receptor (ESR)
DMBMRUI	MT	DTT
DMBMRUI	MA	Inhibitor
DMBMRUI	RN	Blocking estrogen signaling after the hormone: pyrimidine-core inhibitors of estrogen receptor-coactivator binding. J Med Chem. 2008 Oct 23;51(20):6512-30.
DMBMRUI	RU	https://pubmed.ncbi.nlm.nih.gov/18785725

DMUHOF4	DI	DMUHOF4
DMUHOF4	DN	6-Ethyl-2-phenyl-chromen-4-one
DMUHOF4	MI	TTNJYV2
DMUHOF4	MN	Gamma-aminobutyric acid receptor (GAR)
DMUHOF4	MT	DTT
DMUHOF4	MA	Inhibitor
DMUHOF4	RN	Refinement and evaluation of a pharmacophore model for flavone derivatives binding to the benzodiazepine site of the GABA(A) receptor. J Med Chem. 2002 Sep 12;45(19):4188-201.
DMUHOF4	RU	https://pubmed.ncbi.nlm.nih.gov/12213060

DMLEUP2	DI	DMLEUP2
DMLEUP2	DN	6-ethyl-3-(2-ethylbutoxycarbonyl)-4-quinolone
DMLEUP2	MI	TT1MPAY
DMLEUP2	MN	GABA(A) receptor alpha-1 (GABRA1)
DMLEUP2	MT	DTT
DMLEUP2	MA	Inhibitor
DMLEUP2	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMLEUP2	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMLEUP2	DI	DMLEUP2
DMLEUP2	DN	6-ethyl-3-(2-ethylbutoxycarbonyl)-4-quinolone
DMLEUP2	MI	TTZA1NY
DMLEUP2	MN	GABA(A) receptor beta-2 (GABRB2)
DMLEUP2	MT	DTT
DMLEUP2	MA	Inhibitor
DMLEUP2	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMLEUP2	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMLEUP2	DI	DMLEUP2
DMLEUP2	DN	6-ethyl-3-(2-ethylbutoxycarbonyl)-4-quinolone
DMLEUP2	MI	TT06RH5
DMLEUP2	MN	GABA(A) receptor gamma-2 (GABRG2)
DMLEUP2	MT	DTT
DMLEUP2	MA	Inhibitor
DMLEUP2	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMLEUP2	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMLEUP2	DI	DMLEUP2
DMLEUP2	DN	6-ethyl-3-(2-ethylbutoxycarbonyl)-4-quinolone
DMLEUP2	MI	TTNJYV2
DMLEUP2	MN	Gamma-aminobutyric acid receptor (GAR)
DMLEUP2	MT	DTT
DMLEUP2	MA	Inhibitor
DMLEUP2	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMLEUP2	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMESU53	DI	DMESU53
DMESU53	DN	6-ethyl-3-(2-methylbutoxycarbonyl)-4-quinolone
DMESU53	MI	TT1MPAY
DMESU53	MN	GABA(A) receptor alpha-1 (GABRA1)
DMESU53	MT	DTT
DMESU53	MA	Inhibitor
DMESU53	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMESU53	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMESU53	DI	DMESU53
DMESU53	DN	6-ethyl-3-(2-methylbutoxycarbonyl)-4-quinolone
DMESU53	MI	TTZA1NY
DMESU53	MN	GABA(A) receptor beta-2 (GABRB2)
DMESU53	MT	DTT
DMESU53	MA	Inhibitor
DMESU53	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMESU53	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMESU53	DI	DMESU53
DMESU53	DN	6-ethyl-3-(2-methylbutoxycarbonyl)-4-quinolone
DMESU53	MI	TT06RH5
DMESU53	MN	GABA(A) receptor gamma-2 (GABRG2)
DMESU53	MT	DTT
DMESU53	MA	Inhibitor
DMESU53	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMESU53	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMESU53	DI	DMESU53
DMESU53	DN	6-ethyl-3-(2-methylbutoxycarbonyl)-4-quinolone
DMESU53	MI	TTNJYV2
DMESU53	MN	Gamma-aminobutyric acid receptor (GAR)
DMESU53	MT	DTT
DMESU53	MA	Inhibitor
DMESU53	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMESU53	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DM1POEA	DI	DM1POEA
DM1POEA	DN	6-ethyl-3-(3-methylbutoxycarbonyl)-4-quinolone
DM1POEA	MI	TT1MPAY
DM1POEA	MN	GABA(A) receptor alpha-1 (GABRA1)
DM1POEA	MT	DTT
DM1POEA	MA	Inhibitor
DM1POEA	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DM1POEA	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DM1POEA	DI	DM1POEA
DM1POEA	DN	6-ethyl-3-(3-methylbutoxycarbonyl)-4-quinolone
DM1POEA	MI	TT37EDJ
DM1POEA	MN	GABA(A) receptor alpha-3 (GABRA3)
DM1POEA	MT	DTT
DM1POEA	MA	Inhibitor
DM1POEA	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DM1POEA	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DM1POEA	DI	DM1POEA
DM1POEA	DN	6-ethyl-3-(3-methylbutoxycarbonyl)-4-quinolone
DM1POEA	MI	TTZA1NY
DM1POEA	MN	GABA(A) receptor beta-2 (GABRB2)
DM1POEA	MT	DTT
DM1POEA	MA	Inhibitor
DM1POEA	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DM1POEA	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DM1POEA	DI	DM1POEA
DM1POEA	DN	6-ethyl-3-(3-methylbutoxycarbonyl)-4-quinolone
DM1POEA	MI	TT06RH5
DM1POEA	MN	GABA(A) receptor gamma-2 (GABRG2)
DM1POEA	MT	DTT
DM1POEA	MA	Inhibitor
DM1POEA	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DM1POEA	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DM1POEA	DI	DM1POEA
DM1POEA	DN	6-ethyl-3-(3-methylbutoxycarbonyl)-4-quinolone
DM1POEA	MI	TTNJYV2
DM1POEA	MN	Gamma-aminobutyric acid receptor (GAR)
DM1POEA	MT	DTT
DM1POEA	MA	Inhibitor
DM1POEA	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DM1POEA	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMG05V1	DI	DMG05V1
DMG05V1	DN	6-ethyl-3-(3-pentoxycarbonyl)-4-quinolone
DMG05V1	MI	TT1MPAY
DMG05V1	MN	GABA(A) receptor alpha-1 (GABRA1)
DMG05V1	MT	DTT
DMG05V1	MA	Inhibitor
DMG05V1	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMG05V1	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMG05V1	DI	DMG05V1
DMG05V1	DN	6-ethyl-3-(3-pentoxycarbonyl)-4-quinolone
DMG05V1	MI	TTZA1NY
DMG05V1	MN	GABA(A) receptor beta-2 (GABRB2)
DMG05V1	MT	DTT
DMG05V1	MA	Inhibitor
DMG05V1	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMG05V1	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMG05V1	DI	DMG05V1
DMG05V1	DN	6-ethyl-3-(3-pentoxycarbonyl)-4-quinolone
DMG05V1	MI	TT06RH5
DMG05V1	MN	GABA(A) receptor gamma-2 (GABRG2)
DMG05V1	MT	DTT
DMG05V1	MA	Inhibitor
DMG05V1	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMG05V1	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMG05V1	DI	DMG05V1
DMG05V1	DN	6-ethyl-3-(3-pentoxycarbonyl)-4-quinolone
DMG05V1	MI	TTNJYV2
DMG05V1	MN	Gamma-aminobutyric acid receptor (GAR)
DMG05V1	MT	DTT
DMG05V1	MA	Inhibitor
DMG05V1	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMG05V1	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DML9EU7	DI	DML9EU7
DML9EU7	DN	6-ethyl-3-i-propoxycarbonyl-4-quinolone
DML9EU7	MI	TT1MPAY
DML9EU7	MN	GABA(A) receptor alpha-1 (GABRA1)
DML9EU7	MT	DTT
DML9EU7	MA	Inhibitor
DML9EU7	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DML9EU7	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DML9EU7	DI	DML9EU7
DML9EU7	DN	6-ethyl-3-i-propoxycarbonyl-4-quinolone
DML9EU7	MI	TTZA1NY
DML9EU7	MN	GABA(A) receptor beta-2 (GABRB2)
DML9EU7	MT	DTT
DML9EU7	MA	Inhibitor
DML9EU7	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DML9EU7	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DML9EU7	DI	DML9EU7
DML9EU7	DN	6-ethyl-3-i-propoxycarbonyl-4-quinolone
DML9EU7	MI	TT06RH5
DML9EU7	MN	GABA(A) receptor gamma-2 (GABRG2)
DML9EU7	MT	DTT
DML9EU7	MA	Inhibitor
DML9EU7	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DML9EU7	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DML9EU7	DI	DML9EU7
DML9EU7	DN	6-ethyl-3-i-propoxycarbonyl-4-quinolone
DML9EU7	MI	TTNJYV2
DML9EU7	MN	Gamma-aminobutyric acid receptor (GAR)
DML9EU7	MT	DTT
DML9EU7	MA	Inhibitor
DML9EU7	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DML9EU7	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMSGJM6	DI	DMSGJM6
DMSGJM6	DN	6-ethyl-3-pentoxycarbonyl-4-quinolone
DMSGJM6	MI	TT1MPAY
DMSGJM6	MN	GABA(A) receptor alpha-1 (GABRA1)
DMSGJM6	MT	DTT
DMSGJM6	MA	Inhibitor
DMSGJM6	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMSGJM6	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMSGJM6	DI	DMSGJM6
DMSGJM6	DN	6-ethyl-3-pentoxycarbonyl-4-quinolone
DMSGJM6	MI	TTZA1NY
DMSGJM6	MN	GABA(A) receptor beta-2 (GABRB2)
DMSGJM6	MT	DTT
DMSGJM6	MA	Inhibitor
DMSGJM6	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMSGJM6	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMSGJM6	DI	DMSGJM6
DMSGJM6	DN	6-ethyl-3-pentoxycarbonyl-4-quinolone
DMSGJM6	MI	TT06RH5
DMSGJM6	MN	GABA(A) receptor gamma-2 (GABRG2)
DMSGJM6	MT	DTT
DMSGJM6	MA	Inhibitor
DMSGJM6	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMSGJM6	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMSGJM6	DI	DMSGJM6
DMSGJM6	DN	6-ethyl-3-pentoxycarbonyl-4-quinolone
DMSGJM6	MI	TTNJYV2
DMSGJM6	MN	Gamma-aminobutyric acid receptor (GAR)
DMSGJM6	MT	DTT
DMSGJM6	MA	Inhibitor
DMSGJM6	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMSGJM6	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMGVI08	DI	DMGVI08
DMGVI08	DN	6-ethyl-3-propoxycarbonyl-4-quinolone
DMGVI08	MI	TT1MPAY
DMGVI08	MN	GABA(A) receptor alpha-1 (GABRA1)
DMGVI08	MT	DTT
DMGVI08	MA	Inhibitor
DMGVI08	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMGVI08	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMGVI08	DI	DMGVI08
DMGVI08	DN	6-ethyl-3-propoxycarbonyl-4-quinolone
DMGVI08	MI	TTZA1NY
DMGVI08	MN	GABA(A) receptor beta-2 (GABRB2)
DMGVI08	MT	DTT
DMGVI08	MA	Inhibitor
DMGVI08	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMGVI08	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMGVI08	DI	DMGVI08
DMGVI08	DN	6-ethyl-3-propoxycarbonyl-4-quinolone
DMGVI08	MI	TT06RH5
DMGVI08	MN	GABA(A) receptor gamma-2 (GABRG2)
DMGVI08	MT	DTT
DMGVI08	MA	Inhibitor
DMGVI08	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMGVI08	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMGVI08	DI	DMGVI08
DMGVI08	DN	6-ethyl-3-propoxycarbonyl-4-quinolone
DMGVI08	MI	TTNJYV2
DMGVI08	MN	Gamma-aminobutyric acid receptor (GAR)
DMGVI08	MT	DTT
DMGVI08	MA	Inhibitor
DMGVI08	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMGVI08	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMC1F2E	DI	DMC1F2E
DMC1F2E	DN	6-ethyl-3-propylaminocarbonyl-4-quinolone
DMC1F2E	MI	TT1MPAY
DMC1F2E	MN	GABA(A) receptor alpha-1 (GABRA1)
DMC1F2E	MT	DTT
DMC1F2E	MA	Inhibitor
DMC1F2E	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMC1F2E	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMC1F2E	DI	DMC1F2E
DMC1F2E	DN	6-ethyl-3-propylaminocarbonyl-4-quinolone
DMC1F2E	MI	TTZA1NY
DMC1F2E	MN	GABA(A) receptor beta-2 (GABRB2)
DMC1F2E	MT	DTT
DMC1F2E	MA	Inhibitor
DMC1F2E	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMC1F2E	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMC1F2E	DI	DMC1F2E
DMC1F2E	DN	6-ethyl-3-propylaminocarbonyl-4-quinolone
DMC1F2E	MI	TT06RH5
DMC1F2E	MN	GABA(A) receptor gamma-2 (GABRG2)
DMC1F2E	MT	DTT
DMC1F2E	MA	Inhibitor
DMC1F2E	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMC1F2E	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMC1F2E	DI	DMC1F2E
DMC1F2E	DN	6-ethyl-3-propylaminocarbonyl-4-quinolone
DMC1F2E	MI	TTNJYV2
DMC1F2E	MN	Gamma-aminobutyric acid receptor (GAR)
DMC1F2E	MT	DTT
DMC1F2E	MA	Inhibitor
DMC1F2E	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMC1F2E	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMOGETD	DI	DMOGETD
DMOGETD	DN	6-ethyl-4,7-dimethyl-6H-benzo[c]chromene-3,8-diol
DMOGETD	MI	TTZAYWL
DMOGETD	MN	Estrogen receptor (ESR)
DMOGETD	MT	DTT
DMOGETD	MA	Inhibitor
DMOGETD	RN	6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72.
DMOGETD	RU	https://pubmed.ncbi.nlm.nih.gov/16412638

DMOGETD	DI	DMOGETD
DMOGETD	DN	6-ethyl-4,7-dimethyl-6H-benzo[c]chromene-3,8-diol
DMOGETD	MI	TTOM3J0
DMOGETD	MN	Estrogen receptor beta (ESR2)
DMOGETD	MT	DTT
DMOGETD	MA	Inhibitor
DMOGETD	RN	6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72.
DMOGETD	RU	https://pubmed.ncbi.nlm.nih.gov/16412638

DM9OD7U	DI	DM9OD7U
DM9OD7U	DN	6-ETHYL-5-PHENYLPYRIMIDINE-2,4-DIAMINE
DM9OD7U	MI	TTU6BFZ
DM9OD7U	MN	Candida Thymidylate synthase (Candi TMP1)
DM9OD7U	MT	DTT
DM9OD7U	MA	Inhibitor
DM9OD7U	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM9OD7U	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DME4GBS	DI	DME4GBS
DME4GBS	DN	6-ethylamino-2-(3''-indolyl)ethyloxy)adenosine
DME4GBS	MI	TTK25J1
DME4GBS	MN	Adenosine A1 receptor (ADORA1)
DME4GBS	MT	DTT
DME4GBS	MA	Inhibitor
DME4GBS	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DME4GBS	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DME4GBS	DI	DME4GBS
DME4GBS	DN	6-ethylamino-2-(3''-indolyl)ethyloxy)adenosine
DME4GBS	MI	TTJFY5U
DME4GBS	MN	Adenosine A3 receptor (ADORA3)
DME4GBS	MT	DTT
DME4GBS	MA	Inhibitor
DME4GBS	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DME4GBS	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DMPZIV0	DI	DMPZIV0
DMPZIV0	DN	6-Fluoro-2-(3-nitro-phenyl)-chromen-4-one
DMPZIV0	MI	TT1MPAY
DMPZIV0	MN	GABA(A) receptor alpha-1 (GABRA1)
DMPZIV0	MT	DTT
DMPZIV0	MA	Inhibitor
DMPZIV0	RN	Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997).
DMPZIV0	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97003430

DMPZIV0	DI	DMPZIV0
DMPZIV0	DN	6-Fluoro-2-(3-nitro-phenyl)-chromen-4-one
DMPZIV0	MI	TTNJYV2
DMPZIV0	MN	Gamma-aminobutyric acid receptor (GAR)
DMPZIV0	MT	DTT
DMPZIV0	MA	Inhibitor
DMPZIV0	RN	Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997).
DMPZIV0	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97003430

DM2DTHV	DI	DM2DTHV
DM2DTHV	DN	6-fluoro-2-methyl-9H-carbazole
DM2DTHV	MI	TTBGTCW
DM2DTHV	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DM2DTHV	MT	DTT
DM2DTHV	MA	Inhibitor
DM2DTHV	RN	Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8.
DM2DTHV	RU	https://pubmed.ncbi.nlm.nih.gov/20521839

DM4Q5TX	DI	DM4Q5TX
DM4Q5TX	DN	6-fluoro-5-phenylpyrimidine-2,4(1H,3H)-dione
DM4Q5TX	MI	TTO0IB8
DM4Q5TX	MN	Thymidine phosphorylase (TYMP)
DM4Q5TX	MT	DTT
DM4Q5TX	MA	Inhibitor
DM4Q5TX	RN	Discovery of 5-substituted-6-chlorouracils as efficient inhibitors of human thymidine phosphorylase. J Med Chem. 2007 Nov 29;50(24):6016-23.
DM4Q5TX	RU	https://pubmed.ncbi.nlm.nih.gov/17963370

DMKFUO0	DI	DMKFUO0
DMKFUO0	DN	6-Fluoromelatonin
DMKFUO0	MI	TT0K1SC
DMKFUO0	MN	5-HT 2B receptor (HTR2B)
DMKFUO0	MT	DTT
DMKFUO0	MA	Inhibitor
DMKFUO0	RN	Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify no... J Med Chem. 2010 Nov 11;53(21):7573-86.
DMKFUO0	RU	https://pubmed.ncbi.nlm.nih.gov/20958049

DMPZ92X	DI	DMPZ92X
DMPZ92X	DN	6-fluoromevalonate 5-diphosphate
DMPZ92X	MI	TTE5J6X
DMPZ92X	MN	Diphosphomevalonate decarboxylase (MVD)
DMPZ92X	MT	DTT
DMPZ92X	MA	Inhibitor
DMPZ92X	RN	Human mevalonate diphosphate decarboxylase: characterization, investigation of the mevalonate diphosphate binding site, and crystal structure. Arch Biochem Biophys. 2008 Dec 1;480(1):58-67.
DMPZ92X	RU	https://pubmed.ncbi.nlm.nih.gov/18823933

DMZ26LS	DI	DMZ26LS
DMZ26LS	DN	6-fluoromevalonate pyrophosphate
DMZ26LS	MI	TTE5J6X
DMZ26LS	MN	Diphosphomevalonate decarboxylase (MVD)
DMZ26LS	MT	DTT
DMZ26LS	MA	Inhibitor
DMZ26LS	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 642).
DMZ26LS	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=642

DMA1QH0	DI	DMA1QH0
DMA1QH0	DN	6-Fluoro-N-(2-morpholinoethyl)nicotinamide
DMA1QH0	MI	TT3WG5C
DMA1QH0	MN	Monoamine oxidase type A (MAO-A)
DMA1QH0	MT	DTT
DMA1QH0	MA	Inhibitor
DMA1QH0	RN	Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1659-64.
DMA1QH0	RU	https://pubmed.ncbi.nlm.nih.gov/20117937

DMVADTP	DI	DMVADTP
DMVADTP	DN	6-fluoro-N-m-tolylquinazolin-4-amine
DMVADTP	MI	TTHS256
DMVADTP	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMVADTP	MT	DTT
DMVADTP	MA	Inhibitor
DMVADTP	RN	Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6.
DMVADTP	RU	https://pubmed.ncbi.nlm.nih.gov/19854049

DMF2RGY	DI	DMF2RGY
DMF2RGY	DN	6-fluoro-noradrenaline
DMF2RGY	MI	TT2NUT5
DMF2RGY	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMF2RGY	MT	DTT
DMF2RGY	MA	Agonist
DMF2RGY	RN	Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes. Mol Pharmacol. 1994 Nov;46(5):929-36.
DMF2RGY	RU	https://pubmed.ncbi.nlm.nih.gov/7969082

DMPWXI8	DI	DMPWXI8
DMPWXI8	DN	6-fluoronorepinehprine
DMPWXI8	MI	TTBRKXS
DMPWXI8	MN	Adrenergic receptor alpha-1B (ADRA1B)
DMPWXI8	MT	DTT
DMPWXI8	MA	Inhibitor
DMPWXI8	RN	Structural basis of the selectivity of the beta(2)-adrenergic receptor for fluorinated catecholamines. Bioorg Med Chem. 2009 Dec 1;17(23):7987-92.
DMPWXI8	RU	https://pubmed.ncbi.nlm.nih.gov/19857969

DMS325C	DI	DMS325C
DMS325C	DN	6-fluoropyridin-3-ylboronic acid
DMS325C	MI	TTDP1UC
DMS325C	MN	Fatty acid amide hydrolase (FAAH)
DMS325C	MT	DTT
DMS325C	MA	Inhibitor
DMS325C	RN	Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Nov 27;51(22):7057-60.
DMS325C	RU	https://pubmed.ncbi.nlm.nih.gov/18983140

DM6YD3U	DI	DM6YD3U
DM6YD3U	DN	6-fluorotryptophan
DM6YD3U	MI	TT3KLDP
DM6YD3U	MN	L-Tryptophan hydroxylase 2 (TPH2)
DM6YD3U	MT	DTT
DM6YD3U	MA	Inhibitor
DM6YD3U	RN	(+)-6-fluorotryptophan, an inhibitor of tryptophan hydroxylase: sleep and wakefulness in the rat. Neuropharmacology. 1981 Apr;20(4):335-9.
DM6YD3U	RU	https://pubmed.ncbi.nlm.nih.gov/6457252

DM6YD3U	DI	DM6YD3U
DM6YD3U	DN	6-fluorotryptophan
DM6YD3U	MI	TTZSJHV
DM6YD3U	MN	Tryptophan 5-hydroxylase 1 (TPH1)
DM6YD3U	MT	DTT
DM6YD3U	MA	Inhibitor
DM6YD3U	RN	(+)-6-fluorotryptophan, an inhibitor of tryptophan hydroxylase: sleep and wakefulness in the rat. Neuropharmacology. 1981 Apr;20(4):335-9.
DM6YD3U	RU	https://pubmed.ncbi.nlm.nih.gov/6457252

DMN84RM	DI	DMN84RM
DMN84RM	DN	6-Formylindolo[3,2-b]carbazole
DMN84RM	MI	TT037IE
DMN84RM	MN	Aryl hydrocarbon receptor (AHR)
DMN84RM	MT	DTT
DMN84RM	MA	Agonist
DMN84RM	RN	6-Formylindolo(3,2-b)carbazole induced aryl hydrocarbon receptor activation prevents intestinal barrier dysfunction through regulation of claudin-2 expression. Chem Biol Interact. 2018 May 25;288:83-90.
DMN84RM	RU	https://pubmed.ncbi.nlm.nih.gov/29680209

DMOLIW4	DI	DMOLIW4
DMOLIW4	DN	6-Furan-2-yl-9-phenethyl-9H-purin-2-ylamine
DMOLIW4	MI	TTM2AOE
DMOLIW4	MN	Adenosine A2a receptor (ADORA2A)
DMOLIW4	MT	DTT
DMOLIW4	MA	Inhibitor
DMOLIW4	RN	6-(2-Furanyl)-9H-purin-2-amine derivatives as A2A adenosine antagonists. Bioorg Med Chem Lett. 2005 Apr 15;15(8):2119-22.
DMOLIW4	RU	https://pubmed.ncbi.nlm.nih.gov/15808481

DMSJP6T	DI	DMSJP6T
DMSJP6T	DN	6-Furan-2-yl-9-phenyl-9H-purin-2-ylamine
DMSJP6T	MI	TTM2AOE
DMSJP6T	MN	Adenosine A2a receptor (ADORA2A)
DMSJP6T	MT	DTT
DMSJP6T	MA	Inhibitor
DMSJP6T	RN	6-(2-Furanyl)-9H-purin-2-amine derivatives as A2A adenosine antagonists. Bioorg Med Chem Lett. 2005 Apr 15;15(8):2119-22.
DMSJP6T	RU	https://pubmed.ncbi.nlm.nih.gov/15808481

DMM86PK	DI	DMM86PK
DMM86PK	DN	6-guanidino-2-(3''-indolylethyloxy)adenosine
DMM86PK	MI	TTK25J1
DMM86PK	MN	Adenosine A1 receptor (ADORA1)
DMM86PK	MT	DTT
DMM86PK	MA	Inhibitor
DMM86PK	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DMM86PK	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DMM86PK	DI	DMM86PK
DMM86PK	DN	6-guanidino-2-(3''-indolylethyloxy)adenosine
DMM86PK	MI	TTM2AOE
DMM86PK	MN	Adenosine A2a receptor (ADORA2A)
DMM86PK	MT	DTT
DMM86PK	MA	Inhibitor
DMM86PK	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DMM86PK	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DMM86PK	DI	DMM86PK
DMM86PK	DN	6-guanidino-2-(3''-indolylethyloxy)adenosine
DMM86PK	MI	TTJFY5U
DMM86PK	MN	Adenosine A3 receptor (ADORA3)
DMM86PK	MT	DTT
DMM86PK	MA	Inhibitor
DMM86PK	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DMM86PK	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DMF3W15	DI	DMF3W15
DMF3W15	DN	6-Heptyl-4-hydroxy-3-octanoyl-pyran-2-one
DMF3W15	MI	TTPLTSQ
DMF3W15	MN	Neutrophil elastase (NE)
DMF3W15	MT	DTT
DMF3W15	MA	Inhibitor
DMF3W15	RN	Inhibition of human sputum elastase by substituted 2-pyrones. J Med Chem. 1987 Jun;30(6):1017-23.
DMF3W15	RU	https://pubmed.ncbi.nlm.nih.gov/3647139

DMWLN2Y	DI	DMWLN2Y
DMWLN2Y	DN	6-hydroxy-1,2,9-trimethyl-9H-beta-carbolin-2-ium
DMWLN2Y	MI	TT1RS9F
DMWLN2Y	MN	Acetylcholinesterase (AChE)
DMWLN2Y	MT	DTT
DMWLN2Y	MA	Inhibitor
DMWLN2Y	RN	6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5840-3.
DMWLN2Y	RU	https://pubmed.ncbi.nlm.nih.gov/16945529

DMWLN2Y	DI	DMWLN2Y
DMWLN2Y	DN	6-hydroxy-1,2,9-trimethyl-9H-beta-carbolin-2-ium
DMWLN2Y	MI	TTEB0GD
DMWLN2Y	MN	Cholinesterase (BCHE)
DMWLN2Y	MT	DTT
DMWLN2Y	MA	Inhibitor
DMWLN2Y	RN	6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5840-3.
DMWLN2Y	RU	https://pubmed.ncbi.nlm.nih.gov/16945529

DM20DAG	DI	DM20DAG
DM20DAG	DN	6-hydroxy-1,2-dimethyl-9H-beta-carbolin-2-ium
DM20DAG	MI	TT1RS9F
DM20DAG	MN	Acetylcholinesterase (AChE)
DM20DAG	MT	DTT
DM20DAG	MA	Inhibitor
DM20DAG	RN	6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5840-3.
DM20DAG	RU	https://pubmed.ncbi.nlm.nih.gov/16945529

DM20DAG	DI	DM20DAG
DM20DAG	DN	6-hydroxy-1,2-dimethyl-9H-beta-carbolin-2-ium
DM20DAG	MI	TTEB0GD
DM20DAG	MN	Cholinesterase (BCHE)
DM20DAG	MT	DTT
DM20DAG	MA	Inhibitor
DM20DAG	RN	6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5840-3.
DM20DAG	RU	https://pubmed.ncbi.nlm.nih.gov/16945529

DMPSOIF	DI	DMPSOIF
DMPSOIF	DN	6-HYDROXY-1,3-BENZOTHIAZOLE-2-SULFONAMIDE
DMPSOIF	MI	TTANPDJ
DMPSOIF	MN	Carbonic anhydrase II (CA-II)
DMPSOIF	MT	DTT
DMPSOIF	MA	Inhibitor
DMPSOIF	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMPSOIF	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMPSOIF	DI	DMPSOIF
DMPSOIF	DN	6-HYDROXY-1,3-BENZOTHIAZOLE-2-SULFONAMIDE
DMPSOIF	MI	TT2AST1
DMPSOIF	MN	Macrophage migration inhibitory factor (MIF)
DMPSOIF	MT	DTT
DMPSOIF	MA	Inhibitor
DMPSOIF	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMPSOIF	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMUD1CG	DI	DMUD1CG
DMUD1CG	DN	6-Hydroxy-1,6-Dihydro Purine Nucleoside
DMUD1CG	MI	TTLP57V
DMUD1CG	MN	Adenosine deaminase (ADA)
DMUD1CG	MT	DTT
DMUD1CG	MA	Inhibitor
DMUD1CG	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMUD1CG	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMU1CGD	DI	DMU1CGD
DMU1CGD	DN	6-Hydroxy-2-(4-hydroxy-benzyl)-chromen-4-one
DMU1CGD	MI	TTFBNVI
DMU1CGD	MN	Aldose reductase (AKR1B1)
DMU1CGD	MT	DTT
DMU1CGD	MA	Inhibitor
DMU1CGD	RN	1-Benzopyran-4-one antioxidants as aldose reductase inhibitors. J Med Chem. 1999 Jun 3;42(11):1881-93.
DMU1CGD	RU	https://pubmed.ncbi.nlm.nih.gov/10354396

DMNA2M6	DI	DMNA2M6
DMNA2M6	DN	6-hydroxy-2,9-dimethyl-9H-beta-carbolin-2-ium
DMNA2M6	MI	TT1RS9F
DMNA2M6	MN	Acetylcholinesterase (AChE)
DMNA2M6	MT	DTT
DMNA2M6	MA	Inhibitor
DMNA2M6	RN	6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5840-3.
DMNA2M6	RU	https://pubmed.ncbi.nlm.nih.gov/16945529

DMAK35M	DI	DMAK35M
DMAK35M	DN	6-hydroxy-2-methyl-9H-beta-carbolin-2-ium
DMAK35M	MI	TT1RS9F
DMAK35M	MN	Acetylcholinesterase (AChE)
DMAK35M	MT	DTT
DMAK35M	MA	Inhibitor
DMAK35M	RN	6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5840-3.
DMAK35M	RU	https://pubmed.ncbi.nlm.nih.gov/16945529

DMAK35M	DI	DMAK35M
DMAK35M	DN	6-hydroxy-2-methyl-9H-beta-carbolin-2-ium
DMAK35M	MI	TTEB0GD
DMAK35M	MN	Cholinesterase (BCHE)
DMAK35M	MT	DTT
DMAK35M	MA	Inhibitor
DMAK35M	RN	6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5840-3.
DMAK35M	RU	https://pubmed.ncbi.nlm.nih.gov/16945529

DM4F5OG	DI	DM4F5OG
DM4F5OG	DN	6-hydroxy-3-(3',5'-dihydroxyphenyl)coumarin
DM4F5OG	MI	TT34BHT
DM4F5OG	MN	Adrenergic receptor alpha-1D (ADRA1D)
DM4F5OG	MT	DTT
DM4F5OG	MA	Inhibitor
DM4F5OG	RN	Design, synthesis, and vasorelaxant and platelet antiaggregatory activities of coumarin-resveratrol hybrids. Bioorg Med Chem Lett. 2006 Jan 15;16(2):257-61.
DM4F5OG	RU	https://pubmed.ncbi.nlm.nih.gov/16275073

DM0CVTI	DI	DM0CVTI
DM0CVTI	DN	6-Hydroxy-5,7-dimethyl-beta-carboline
DM0CVTI	MI	TTJFY5U
DM0CVTI	MN	Adenosine A3 receptor (ADORA3)
DM0CVTI	MT	DTT
DM0CVTI	MA	Inhibitor
DM0CVTI	RN	Synthesis of eudistomin D analogues and its effects on adenosine receptors. Bioorg Med Chem. 2008 Apr 1;16(7):3825-30.
DM0CVTI	RU	https://pubmed.ncbi.nlm.nih.gov/18262425

DMNM1EZ	DI	DMNM1EZ
DMNM1EZ	DN	6-Hydroxy-7,8-Dihydro Purine Nucleoside
DMNM1EZ	MI	TTLP57V
DMNM1EZ	MN	Adenosine deaminase (ADA)
DMNM1EZ	MT	DTT
DMNM1EZ	MA	Inhibitor
DMNM1EZ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMNM1EZ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMPQTNK	DI	DMPQTNK
DMPQTNK	DN	6-hydroxy-7,9-octadecadiynoic acid
DMPQTNK	MI	TTPADOQ
DMPQTNK	MN	HMG-CoA reductase (HMGCR)
DMPQTNK	MT	DTT
DMPQTNK	MA	Inhibitor
DMPQTNK	RN	Novel Acetylenic Acids from the Root Bark of Paramacrolobium caeruleum: Inhibitors of 3-Hydroxy-3-methyl-glutaryl Coenzyme A Reductase J. Nat. Prod. 52(1):153-161 (1989).
DMPQTNK	RU	http://pubs.acs.org/doi/abs/10.1021/np50061a020

DMDRSNH	DI	DMDRSNH
DMDRSNH	DN	6-hydroxybenzo[d][1,3]oxathiol-2-one
DMDRSNH	MI	TTANPDJ
DMDRSNH	MN	Carbonic anhydrase II (CA-II)
DMDRSNH	MT	DTT
DMDRSNH	MA	Inhibitor
DMDRSNH	RN	Carbonic anhydrase inhibitors: thioxolone versus sulfonamides for obtaining isozyme-selective inhibitors Bioorg Med Chem Lett. 2008 Jul 15;18(14):3938-41.
DMDRSNH	RU	https://pubmed.ncbi.nlm.nih.gov/18572406

DM2B4S5	DI	DM2B4S5
DM2B4S5	DN	6-Hydroxy-benzothiazole-2-sulfonic acid amide
DM2B4S5	MI	TTUNARX
DM2B4S5	MN	Carbonic anhydrase (CA)
DM2B4S5	MT	DTT
DM2B4S5	MA	Inhibitor
DM2B4S5	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DM2B4S5	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DM2B4S5	DI	DM2B4S5
DM2B4S5	DN	6-Hydroxy-benzothiazole-2-sulfonic acid amide
DM2B4S5	MI	TTHQPL7
DM2B4S5	MN	Carbonic anhydrase I (CA-I)
DM2B4S5	MT	DTT
DM2B4S5	MA	Inhibitor
DM2B4S5	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DM2B4S5	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DM2B4S5	DI	DM2B4S5
DM2B4S5	DN	6-Hydroxy-benzothiazole-2-sulfonic acid amide
DM2B4S5	MI	TTANPDJ
DM2B4S5	MN	Carbonic anhydrase II (CA-II)
DM2B4S5	MT	DTT
DM2B4S5	MA	Inhibitor
DM2B4S5	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DM2B4S5	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DM2B4S5	DI	DM2B4S5
DM2B4S5	DN	6-Hydroxy-benzothiazole-2-sulfonic acid amide
DM2B4S5	MI	TT2LVK8
DM2B4S5	MN	Carbonic anhydrase IX (CA-IX)
DM2B4S5	MT	DTT
DM2B4S5	MA	Inhibitor
DM2B4S5	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DM2B4S5	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DM2B4S5	DI	DM2B4S5
DM2B4S5	DN	6-Hydroxy-benzothiazole-2-sulfonic acid amide
DM2B4S5	MI	TTCFSPE
DM2B4S5	MN	Carbonic anhydrase VI (CA-VI)
DM2B4S5	MT	DTT
DM2B4S5	MA	Inhibitor
DM2B4S5	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DM2B4S5	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DM2B4S5	DI	DM2B4S5
DM2B4S5	DN	6-Hydroxy-benzothiazole-2-sulfonic acid amide
DM2B4S5	MI	TTSYM0R
DM2B4S5	MN	Carbonic anhydrase XII (CA-XII)
DM2B4S5	MT	DTT
DM2B4S5	MA	Inhibitor
DM2B4S5	RN	Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglauc... Bioorg Med Chem Lett. 2005 Feb 15;15(4):963-9.
DM2B4S5	RU	https://pubmed.ncbi.nlm.nih.gov/15686894

DM2B4S5	DI	DM2B4S5
DM2B4S5	DN	6-Hydroxy-benzothiazole-2-sulfonic acid amide
DM2B4S5	MI	TTEYTKG
DM2B4S5	MN	Carbonic anhydrase XIV (CA-XIV)
DM2B4S5	MT	DTT
DM2B4S5	MA	Inhibitor
DM2B4S5	RN	Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33.
DM2B4S5	RU	https://pubmed.ncbi.nlm.nih.gov/16039848

DM7M58P	DI	DM7M58P
DM7M58P	DN	6-hydroxydopa quinone
DM7M58P	MI	TT7HC21
DM7M58P	MN	Membrane copper amine oxidase (AOC3)
DM7M58P	MT	DTT
DM7M58P	MA	Inhibitor
DM7M58P	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM7M58P	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM6FNVC	DI	DM6FNVC
DM6FNVC	DN	6-Hydroxyflavanone
DM6FNVC	MI	TTKPW01
DM6FNVC	MN	Androgen receptor messenger RNA (AR mRNA)
DM6FNVC	MT	DTT
DM6FNVC	MA	Inhibitor
DM6FNVC	RN	Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4706-10.
DM6FNVC	RU	https://pubmed.ncbi.nlm.nih.gov/19592245

DM89YV7	DI	DM89YV7
DM89YV7	DN	6-hydroxymelatonin
DM89YV7	MI	TT0WAIE
DM89YV7	MN	Melatonin receptor type 1A (MTNR1A)
DM89YV7	MT	DTT
DM89YV7	MA	Agonist
DM89YV7	RN	Characterization of a retinal melatonin receptor. J Pharmacol Exp Ther. 1985 Aug;234(2):395-401.
DM89YV7	RU	https://pubmed.ncbi.nlm.nih.gov/2991499

DMYF60K	DI	DMYF60K
DMYF60K	DN	6-Hydroxymethyl-7,8-Dihydropterin
DMYF60K	MI	TTG9CFY
DMYF60K	MN	Bacterial Dihydroneopterinaldolase (Bact folB)
DMYF60K	MT	DTT
DMYF60K	MA	Inhibitor
DMYF60K	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMYF60K	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMYF60K	DI	DMYF60K
DMYF60K	DN	6-Hydroxymethyl-7,8-Dihydropterin
DMYF60K	MI	TT38ECI
DMYF60K	MN	Bacterial Hydroxymethyl-dihydropterin pyrophosphokinase (Bact folK)
DMYF60K	MT	DTT
DMYF60K	MA	Inhibitor
DMYF60K	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMYF60K	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM7EWDN	DI	DM7EWDN
DM7EWDN	DN	6-Hydroxymethylpterin
DM7EWDN	MI	TT38ECI
DM7EWDN	MN	Bacterial Hydroxymethyl-dihydropterin pyrophosphokinase (Bact folK)
DM7EWDN	MT	DTT
DM7EWDN	MA	Inhibitor
DM7EWDN	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DM7EWDN	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DM6KVO0	DI	DM6KVO0
DM6KVO0	DN	6-Hydroxy-N-(2-morpholinoethyl)nicotinamide
DM6KVO0	MI	TT3WG5C
DM6KVO0	MN	Monoamine oxidase type A (MAO-A)
DM6KVO0	MT	DTT
DM6KVO0	MA	Inhibitor
DM6KVO0	RN	Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1659-64.
DM6KVO0	RU	https://pubmed.ncbi.nlm.nih.gov/20117937

DMVRFU5	DI	DMVRFU5
DMVRFU5	DN	6-Hydroxypropylthymine
DMVRFU5	MI	TTP3QRF
DMVRFU5	MN	Thymidine kinase 1 (TK1)
DMVRFU5	MT	DTT
DMVRFU5	MA	Inhibitor
DMVRFU5	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMVRFU5	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMDMNQV	DI	DMDMNQV
DMDMNQV	DN	6-Hydroxyuridine-5'-Phosphate
DMDMNQV	MI	TTV7Y40
DMDMNQV	MN	Mycobacterium Orotidine phosphate decarboxylase (MycB pyrF)
DMDMNQV	MT	DTT
DMDMNQV	MA	Inhibitor
DMDMNQV	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMDMNQV	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMDMNQV	DI	DMDMNQV
DMDMNQV	DN	6-Hydroxyuridine-5'-Phosphate
DMDMNQV	MI	TTAFJUD
DMDMNQV	MN	Orotidine 5'-monophosphate decarboxylase (UMPS)
DMDMNQV	MT	DTT
DMDMNQV	MA	Inhibitor
DMDMNQV	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMDMNQV	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMQF8JG	DI	DMQF8JG
DMQF8JG	DN	6-ile-ustiloxin
DMQF8JG	MI	TTYFKSZ
DMQF8JG	MN	Tubulin beta (TUBB)
DMQF8JG	MT	DTT
DMQF8JG	MA	Inhibitor
DMQF8JG	RN	Total synthesis and biological evaluation of ustiloxin natural products and two analogs. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4804-7.
DMQF8JG	RU	https://pubmed.ncbi.nlm.nih.gov/16837194

DMQF8JG	DI	DMQF8JG
DMQF8JG	DN	6-ile-ustiloxin
DMQF8JG	MI	TTJ2PTI
DMQF8JG	MN	Tubulin beta-2 chain (TUBB2)
DMQF8JG	MT	DTT
DMQF8JG	MA	Inhibitor
DMQF8JG	RN	Total synthesis and biological evaluation of ustiloxin natural products and two analogs. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4804-7.
DMQF8JG	RU	https://pubmed.ncbi.nlm.nih.gov/16837194

DMRMSU5	DI	DMRMSU5
DMRMSU5	DN	6-Imidazol-1-yl-3,4-dihydro-1H-quinolin-2-one
DMRMSU5	MI	TT06AWU
DMRMSU5	MN	Phosphodiesterase 3A (PDE3A)
DMRMSU5	MT	DTT
DMRMSU5	MA	Inhibitor
DMRMSU5	RN	3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase. J Med Chem. 1992 Feb 21;35(4):620-8.
DMRMSU5	RU	https://pubmed.ncbi.nlm.nih.gov/1311763

DMQXL1Y	DI	DMQXL1Y
DMQXL1Y	DN	6-Imidazol-1-yl-isoquinoline
DMQXL1Y	MI	TTSZLWK
DMQXL1Y	MN	Aromatase (CYP19A1)
DMQXL1Y	MT	DTT
DMQXL1Y	MA	Inhibitor
DMQXL1Y	RN	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
DMQXL1Y	RU	https://pubmed.ncbi.nlm.nih.gov/19072235

DMQXL1Y	DI	DMQXL1Y
DMQXL1Y	DN	6-Imidazol-1-yl-isoquinoline
DMQXL1Y	MI	TTKNWZ4
DMQXL1Y	MN	Thromboxane-A synthase (TBXAS1)
DMQXL1Y	MT	DTT
DMQXL1Y	MA	Inhibitor
DMQXL1Y	RN	1-imidazolyl(alkyl)-substituted di- and tetrahydroquinolines and analogues: syntheses and evaluation of dual inhibitors of thromboxane A(2) synthas... J Med Chem. 2000 May 4;43(9):1841-51.
DMQXL1Y	RU	https://pubmed.ncbi.nlm.nih.gov/10794700

DMBQ3HV	DI	DMBQ3HV
DMBQ3HV	DN	6-Imidazol-1-ylmethyl-8-phenyl-quinoline
DMBQ3HV	MI	TTZ97H5
DMBQ3HV	MN	Phosphodiesterase 4A (PDE4A)
DMBQ3HV	MT	DTT
DMBQ3HV	MA	Inhibitor
DMBQ3HV	RN	Hunting the emesis and efficacy targets of PDE4 inhibitors: identification of the photoaffinity probe 8-(3-azidophenyl)-6- [(4-iodo-1H-1-imidazolyl... J Med Chem. 2000 Oct 19;43(21):3820-3.
DMBQ3HV	RU	https://pubmed.ncbi.nlm.nih.gov/11052785

DM31VLA	DI	DM31VLA
DM31VLA	DN	6-Iodo-2-piperazin-1-yl-quinoline
DM31VLA	MI	TT3ROYC
DM31VLA	MN	Serotonin transporter (SERT)
DM31VLA	MT	DTT
DM31VLA	MA	Inhibitor
DM31VLA	RN	Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 1. Bioorg Med Chem Lett. 2000 Jul 17;10(14):1559-62.
DM31VLA	RU	https://pubmed.ncbi.nlm.nih.gov/10915050

DMAL1UH	DI	DMAL1UH
DMAL1UH	DN	6-iodo-4'-dimethyaminoflavone
DMAL1UH	MI	TTE4KHA
DMAL1UH	MN	Amyloid beta A4 protein (APP)
DMAL1UH	MT	DTT
DMAL1UH	MA	Inhibitor
DMAL1UH	RN	Radioiodinated flavones for in vivo imaging of beta-amyloid plaques in the brain. J Med Chem. 2005 Nov 17;48(23):7253-60.
DMAL1UH	RU	https://pubmed.ncbi.nlm.nih.gov/16279784

DM5FZBI	DI	DM5FZBI
DM5FZBI	DN	6-iodo-4'-hydroxyflavone
DM5FZBI	MI	TTE4KHA
DM5FZBI	MN	Amyloid beta A4 protein (APP)
DM5FZBI	MT	DTT
DM5FZBI	MA	Inhibitor
DM5FZBI	RN	Radioiodinated flavones for in vivo imaging of beta-amyloid plaques in the brain. J Med Chem. 2005 Nov 17;48(23):7253-60.
DM5FZBI	RU	https://pubmed.ncbi.nlm.nih.gov/16279784

DM6U9CY	DI	DM6U9CY
DM6U9CY	DN	6-iodo-4'-methoxyflavone
DM6U9CY	MI	TTE4KHA
DM6U9CY	MN	Amyloid beta A4 protein (APP)
DM6U9CY	MT	DTT
DM6U9CY	MA	Inhibitor
DM6U9CY	RN	Radioiodinated flavones for in vivo imaging of beta-amyloid plaques in the brain. J Med Chem. 2005 Nov 17;48(23):7253-60.
DM6U9CY	RU	https://pubmed.ncbi.nlm.nih.gov/16279784

DM9GJAY	DI	DM9GJAY
DM9GJAY	DN	6-iodo-4'-methylaminoflavone
DM9GJAY	MI	TTE4KHA
DM9GJAY	MN	Amyloid beta A4 protein (APP)
DM9GJAY	MT	DTT
DM9GJAY	MA	Inhibitor
DM9GJAY	RN	Radioiodinated flavones for in vivo imaging of beta-amyloid plaques in the brain. J Med Chem. 2005 Nov 17;48(23):7253-60.
DM9GJAY	RU	https://pubmed.ncbi.nlm.nih.gov/16279784

DM0GSRL	DI	DM0GSRL
DM0GSRL	DN	6'-Iodononivamide
DM0GSRL	MI	TTMI6F5
DM0GSRL	MN	Transient receptor potential cation channel V1 (TRPV1)
DM0GSRL	MT	DTT
DM0GSRL	MA	Inhibitor
DM0GSRL	RN	Halogenation of 4-hydroxy/amino-3-methoxyphenyl acetamide TRPV1 agonists showed enhanced antagonism to capsaicin. Bioorg Med Chem. 2010 Nov 15;18(22):8092-105.
DM0GSRL	RU	https://pubmed.ncbi.nlm.nih.gov/20937561

DM1S9DB	DI	DM1S9DB
DM1S9DB	DN	6-iodo-nordihydrocapsaicin
DM1S9DB	MI	TTMI6F5
DM1S9DB	MN	Transient receptor potential cation channel V1 (TRPV1)
DM1S9DB	MT	DTT
DM1S9DB	MA	Blocker (channel blocker)
DM1S9DB	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 507).
DM1S9DB	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=507

DM2XB68	DI	DM2XB68
DM2XB68	DN	6-isobutyl-4-methylpyridin-2-amine
DM2XB68	MI	TTZUFI5
DM2XB68	MN	Nitric-oxide synthase brain (NOS1)
DM2XB68	MT	DTT
DM2XB68	MA	Inhibitor
DM2XB68	RN	Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [18F]6-(2-fl... J Med Chem. 2009 Apr 23;52(8):2443-53.
DM2XB68	RU	https://pubmed.ncbi.nlm.nih.gov/19323559

DM2XB68	DI	DM2XB68
DM2XB68	DN	6-isobutyl-4-methylpyridin-2-amine
DM2XB68	MI	TTCM4B3
DM2XB68	MN	Nitric-oxide synthase endothelial (NOS3)
DM2XB68	MT	DTT
DM2XB68	MA	Inhibitor
DM2XB68	RN	Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [18F]6-(2-fl... J Med Chem. 2009 Apr 23;52(8):2443-53.
DM2XB68	RU	https://pubmed.ncbi.nlm.nih.gov/19323559

DM2XB68	DI	DM2XB68
DM2XB68	DN	6-isobutyl-4-methylpyridin-2-amine
DM2XB68	MI	TTF10I9
DM2XB68	MN	Nitric-oxide synthase inducible (NOS2)
DM2XB68	MT	DTT
DM2XB68	MA	Inhibitor
DM2XB68	RN	Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [18F]6-(2-fl... J Med Chem. 2009 Apr 23;52(8):2443-53.
DM2XB68	RU	https://pubmed.ncbi.nlm.nih.gov/19323559

DMGXMZL	DI	DMGXMZL
DMGXMZL	DN	6-isopropyl-2-morpholin-4-yl-4H-thiopyran-4-one
DMGXMZL	MI	TTK3PY9
DMGXMZL	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMGXMZL	MT	DTT
DMGXMZL	MA	Inhibitor
DMGXMZL	RN	Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72.
DMGXMZL	RU	https://pubmed.ncbi.nlm.nih.gov/17371003

DMO2F8L	DI	DMO2F8L
DMO2F8L	DN	6-Isopropyl-2-phenyl-chromen-4-one
DMO2F8L	MI	TTNJYV2
DMO2F8L	MN	Gamma-aminobutyric acid receptor (GAR)
DMO2F8L	MT	DTT
DMO2F8L	MA	Inhibitor
DMO2F8L	RN	Refinement and evaluation of a pharmacophore model for flavone derivatives binding to the benzodiazepine site of the GABA(A) receptor. J Med Chem. 2002 Sep 12;45(19):4188-201.
DMO2F8L	RU	https://pubmed.ncbi.nlm.nih.gov/12213060

DM2WUZP	DI	DM2WUZP
DM2WUZP	DN	6-Isoquinolin-4-yl-3,4-dihydroquinolin-2(1H)-one
DM2WUZP	MI	TTIQUX7
DM2WUZP	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM2WUZP	MT	DTT
DM2WUZP	MA	Inhibitor
DM2WUZP	RN	In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87.
DM2WUZP	RU	https://pubmed.ncbi.nlm.nih.gov/19049427

DMD2FW9	DI	DMD2FW9
DMD2FW9	DN	6-Mercapto-hexanoic acid phenylamide
DMD2FW9	MI	TTBH0VX
DMD2FW9	MN	Histone deacetylase (HDAC)
DMD2FW9	MT	DTT
DMD2FW9	MA	Inhibitor
DMD2FW9	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMD2FW9	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMD2FW9	DI	DMD2FW9
DMD2FW9	DN	6-Mercapto-hexanoic acid phenylamide
DMD2FW9	MI	TT6R7JZ
DMD2FW9	MN	Histone deacetylase 1 (HDAC1)
DMD2FW9	MT	DTT
DMD2FW9	MA	Inhibitor
DMD2FW9	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMD2FW9	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMD2FW9	DI	DMD2FW9
DMD2FW9	DN	6-Mercapto-hexanoic acid phenylamide
DMD2FW9	MI	TTYHPU6
DMD2FW9	MN	Histone deacetylase 10 (HDAC10)
DMD2FW9	MT	DTT
DMD2FW9	MA	Inhibitor
DMD2FW9	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMD2FW9	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMD2FW9	DI	DMD2FW9
DMD2FW9	DN	6-Mercapto-hexanoic acid phenylamide
DMD2FW9	MI	TTSHTOI
DMD2FW9	MN	Histone deacetylase 2 (HDAC2)
DMD2FW9	MT	DTT
DMD2FW9	MA	Inhibitor
DMD2FW9	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMD2FW9	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMD2FW9	DI	DMD2FW9
DMD2FW9	DN	6-Mercapto-hexanoic acid phenylamide
DMD2FW9	MI	TTTQGH8
DMD2FW9	MN	Histone deacetylase 4 (HDAC4)
DMD2FW9	MT	DTT
DMD2FW9	MA	Inhibitor
DMD2FW9	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMD2FW9	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMD2FW9	DI	DMD2FW9
DMD2FW9	DN	6-Mercapto-hexanoic acid phenylamide
DMD2FW9	MI	TT5ZKDI
DMD2FW9	MN	Histone deacetylase 6 (HDAC6)
DMD2FW9	MT	DTT
DMD2FW9	MA	Inhibitor
DMD2FW9	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMD2FW9	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMD2FW9	DI	DMD2FW9
DMD2FW9	DN	6-Mercapto-hexanoic acid phenylamide
DMD2FW9	MI	TTT6LFV
DMD2FW9	MN	Histone deacetylase 8 (HDAC8)
DMD2FW9	MT	DTT
DMD2FW9	MA	Inhibitor
DMD2FW9	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMD2FW9	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMJUT70	DI	DMJUT70
DMJUT70	DN	6-methoxy-1,2-dimethyl-9H-beta-carbolin-2-ium
DMJUT70	MI	TT1RS9F
DMJUT70	MN	Acetylcholinesterase (AChE)
DMJUT70	MT	DTT
DMJUT70	MA	Inhibitor
DMJUT70	RN	6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5840-3.
DMJUT70	RU	https://pubmed.ncbi.nlm.nih.gov/16945529

DMJUT70	DI	DMJUT70
DMJUT70	DN	6-methoxy-1,2-dimethyl-9H-beta-carbolin-2-ium
DMJUT70	MI	TTEB0GD
DMJUT70	MN	Cholinesterase (BCHE)
DMJUT70	MT	DTT
DMJUT70	MA	Inhibitor
DMJUT70	RN	6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5840-3.
DMJUT70	RU	https://pubmed.ncbi.nlm.nih.gov/16945529

DMOHWPD	DI	DMOHWPD
DMOHWPD	DN	6-methoxy-1,9-dimethyl-9H-pyrido[3,4-b]indole
DMOHWPD	MI	TT1RS9F
DMOHWPD	MN	Acetylcholinesterase (AChE)
DMOHWPD	MT	DTT
DMOHWPD	MA	Inhibitor
DMOHWPD	RN	6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5840-3.
DMOHWPD	RU	https://pubmed.ncbi.nlm.nih.gov/16945529

DMOHWPD	DI	DMOHWPD
DMOHWPD	DN	6-methoxy-1,9-dimethyl-9H-pyrido[3,4-b]indole
DMOHWPD	MI	TTEB0GD
DMOHWPD	MN	Cholinesterase (BCHE)
DMOHWPD	MT	DTT
DMOHWPD	MA	Inhibitor
DMOHWPD	RN	6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5840-3.
DMOHWPD	RU	https://pubmed.ncbi.nlm.nih.gov/16945529

DMZP3XJ	DI	DMZP3XJ
DMZP3XJ	DN	6-Methoxy-2-(4-phenoxy-benzyl)-1H-benzoimidazole
DMZP3XJ	MI	TTLD29N
DMZP3XJ	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMZP3XJ	MT	DTT
DMZP3XJ	MA	Inhibitor
DMZP3XJ	RN	NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J Med Chem. 2004 Apr 8;47(8):2089-96.
DMZP3XJ	RU	https://pubmed.ncbi.nlm.nih.gov/15056006

DMZP3XJ	DI	DMZP3XJ
DMZP3XJ	DN	6-Methoxy-2-(4-phenoxy-benzyl)-1H-benzoimidazole
DMZP3XJ	MI	TTN9D8E
DMZP3XJ	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMZP3XJ	MT	DTT
DMZP3XJ	MA	Inhibitor
DMZP3XJ	RN	NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J Med Chem. 2004 Apr 8;47(8):2089-96.
DMZP3XJ	RU	https://pubmed.ncbi.nlm.nih.gov/15056006

DMSA367	DI	DMSA367
DMSA367	DN	6-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline
DMSA367	MI	TTJQOD7
DMSA367	MN	5-HT 2A receptor (HTR2A)
DMSA367	MT	DTT
DMSA367	MA	Inhibitor
DMSA367	RN	Binding of beta-carbolines at 5-HT(2) serotonin receptors. Bioorg Med Chem Lett. 2003 Dec 15;13(24):4421-5.
DMSA367	RU	https://pubmed.ncbi.nlm.nih.gov/14643338

DMSA367	DI	DMSA367
DMSA367	DN	6-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline
DMSA367	MI	TT3WG5C
DMSA367	MN	Monoamine oxidase type A (MAO-A)
DMSA367	MT	DTT
DMSA367	MA	Inhibitor
DMSA367	RN	Pyrazino[1,2-a]indoles as novel high-affinity and selective imidazoline I(2) receptor ligands. Bioorg Med Chem Lett. 2004 Feb 23;14(4):1003-5.
DMSA367	RU	https://pubmed.ncbi.nlm.nih.gov/15013010

DMSA367	DI	DMSA367
DMSA367	DN	6-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline
DMSA367	MI	TTGP7BY
DMSA367	MN	Monoamine oxidase type B (MAO-B)
DMSA367	MT	DTT
DMSA367	MA	Inhibitor
DMSA367	RN	Pyrazino[1,2-a]indoles as novel high-affinity and selective imidazoline I(2) receptor ligands. Bioorg Med Chem Lett. 2004 Feb 23;14(4):1003-5.
DMSA367	RU	https://pubmed.ncbi.nlm.nih.gov/15013010

DMG3F7D	DI	DMG3F7D
DMG3F7D	DN	6-methoxy-2,9-dimethyl-9H-beta-carbolin-2-ium
DMG3F7D	MI	TT1RS9F
DMG3F7D	MN	Acetylcholinesterase (AChE)
DMG3F7D	MT	DTT
DMG3F7D	MA	Inhibitor
DMG3F7D	RN	6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5840-3.
DMG3F7D	RU	https://pubmed.ncbi.nlm.nih.gov/16945529

DMHITF8	DI	DMHITF8
DMHITF8	DN	6-methoxy-2-methyl-9H-beta-carbolin-2-ium
DMHITF8	MI	TT1RS9F
DMHITF8	MN	Acetylcholinesterase (AChE)
DMHITF8	MT	DTT
DMHITF8	MA	Inhibitor
DMHITF8	RN	6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5840-3.
DMHITF8	RU	https://pubmed.ncbi.nlm.nih.gov/16945529

DMHITF8	DI	DMHITF8
DMHITF8	DN	6-methoxy-2-methyl-9H-beta-carbolin-2-ium
DMHITF8	MI	TTEB0GD
DMHITF8	MN	Cholinesterase (BCHE)
DMHITF8	MT	DTT
DMHITF8	MA	Inhibitor
DMHITF8	RN	6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5840-3.
DMHITF8	RU	https://pubmed.ncbi.nlm.nih.gov/16945529

DM7WH82	DI	DM7WH82
DM7WH82	DN	6-methoxy-2-oxo-2H-chromene-3-carboxylic acid
DM7WH82	MI	TTUNARX
DM7WH82	MN	Carbonic anhydrase (CA)
DM7WH82	MT	DTT
DM7WH82	MA	Inhibitor
DM7WH82	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DM7WH82	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DM7WH82	DI	DM7WH82
DM7WH82	DN	6-methoxy-2-oxo-2H-chromene-3-carboxylic acid
DM7WH82	MI	TTHQPL7
DM7WH82	MN	Carbonic anhydrase I (CA-I)
DM7WH82	MT	DTT
DM7WH82	MA	Inhibitor
DM7WH82	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DM7WH82	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DM7WH82	DI	DM7WH82
DM7WH82	DN	6-methoxy-2-oxo-2H-chromene-3-carboxylic acid
DM7WH82	MI	TTANPDJ
DM7WH82	MN	Carbonic anhydrase II (CA-II)
DM7WH82	MT	DTT
DM7WH82	MA	Inhibitor
DM7WH82	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DM7WH82	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DM7WH82	DI	DM7WH82
DM7WH82	DN	6-methoxy-2-oxo-2H-chromene-3-carboxylic acid
DM7WH82	MI	TT2LVK8
DM7WH82	MN	Carbonic anhydrase IX (CA-IX)
DM7WH82	MT	DTT
DM7WH82	MA	Inhibitor
DM7WH82	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DM7WH82	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DM7WH82	DI	DM7WH82
DM7WH82	DN	6-methoxy-2-oxo-2H-chromene-3-carboxylic acid
DM7WH82	MI	TTSYM0R
DM7WH82	MN	Carbonic anhydrase XII (CA-XII)
DM7WH82	MT	DTT
DM7WH82	MA	Inhibitor
DM7WH82	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DM7WH82	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DM7WH82	DI	DM7WH82
DM7WH82	DN	6-methoxy-2-oxo-2H-chromene-3-carboxylic acid
DM7WH82	MI	TTEYTKG
DM7WH82	MN	Carbonic anhydrase XIV (CA-XIV)
DM7WH82	MT	DTT
DM7WH82	MA	Inhibitor
DM7WH82	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DM7WH82	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DM52SDO	DI	DM52SDO
DM52SDO	DN	6-Methoxy-3-pyridin-4-yl-quinoline
DM52SDO	MI	TT8FYO9
DM52SDO	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DM52SDO	MT	DTT
DM52SDO	MA	Inhibitor
DM52SDO	RN	5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.
DM52SDO	RU	https://pubmed.ncbi.nlm.nih.gov/8064792

DM52SDO	DI	DM52SDO
DM52SDO	DN	6-Methoxy-3-pyridin-4-yl-quinoline
DM52SDO	MI	TTI7421
DM52SDO	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM52SDO	MT	DTT
DM52SDO	MA	Inhibitor
DM52SDO	RN	5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.
DM52SDO	RU	https://pubmed.ncbi.nlm.nih.gov/8064792

DMOYL71	DI	DMOYL71
DMOYL71	DN	6-Methoxy-3-thiophen-3-yl-quinoline
DMOYL71	MI	TT8FYO9
DMOYL71	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMOYL71	MT	DTT
DMOYL71	MA	Inhibitor
DMOYL71	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMOYL71	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMOYL71	DI	DMOYL71
DMOYL71	DN	6-Methoxy-3-thiophen-3-yl-quinoline
DMOYL71	MI	TTI7421
DMOYL71	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMOYL71	MT	DTT
DMOYL71	MA	Inhibitor
DMOYL71	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMOYL71	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DM98FQO	DI	DM98FQO
DM98FQO	DN	6-Methoxy-4,9-dihydro-3H-beta-carboline
DM98FQO	MI	TT3WG5C
DM98FQO	MN	Monoamine oxidase type A (MAO-A)
DM98FQO	MT	DTT
DM98FQO	MA	Inhibitor
DM98FQO	RN	Pyrazino[1,2-a]indoles as novel high-affinity and selective imidazoline I(2) receptor ligands. Bioorg Med Chem Lett. 2004 Feb 23;14(4):1003-5.
DM98FQO	RU	https://pubmed.ncbi.nlm.nih.gov/15013010

DM98FQO	DI	DM98FQO
DM98FQO	DN	6-Methoxy-4,9-dihydro-3H-beta-carboline
DM98FQO	MI	TTGP7BY
DM98FQO	MN	Monoamine oxidase type B (MAO-B)
DM98FQO	MT	DTT
DM98FQO	MA	Inhibitor
DM98FQO	RN	Pyrazino[1,2-a]indoles as novel high-affinity and selective imidazoline I(2) receptor ligands. Bioorg Med Chem Lett. 2004 Feb 23;14(4):1003-5.
DM98FQO	RU	https://pubmed.ncbi.nlm.nih.gov/15013010

DMPB9MY	DI	DMPB9MY
DMPB9MY	DN	6-Methoxy-4-morpholin-4-yl-chromen-2-one
DMPB9MY	MI	TTK3PY9
DMPB9MY	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMPB9MY	MT	DTT
DMPB9MY	MA	Inhibitor
DMPB9MY	RN	Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85.
DMPB9MY	RU	https://pubmed.ncbi.nlm.nih.gov/15658870

DMHO7TZ	DI	DMHO7TZ
DMHO7TZ	DN	6-Methoxy-5-oxazol-5-yl-2-phenyl-1H-indole
DMHO7TZ	MI	TTTB4UP
DMHO7TZ	MN	Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2)
DMHO7TZ	MT	DTT
DMHO7TZ	MA	Inhibitor
DMHO7TZ	RN	Novel indole-based inhibitors of IMPDH: introduction of hydrogen bond acceptors at indole C-3. Bioorg Med Chem Lett. 2003 Apr 7;13(7):1273-6.
DMHO7TZ	RU	https://pubmed.ncbi.nlm.nih.gov/12657262

DM5JB9D	DI	DM5JB9D
DM5JB9D	DN	6-methoxykaempferol 3-O-beta-D-robinobioside
DM5JB9D	MI	TTFBNVI
DM5JB9D	MN	Aldose reductase (AKR1B1)
DM5JB9D	MT	DTT
DM5JB9D	MA	Inhibitor
DM5JB9D	RN	Flavonoids with anti-cataract activity from Brickellia arguta. J Nat Prod. 1984 Mar-Apr;47(2):316-9.
DM5JB9D	RU	https://pubmed.ncbi.nlm.nih.gov/6429283

DMOIC64	DI	DMOIC64
DMOIC64	DN	6-Methyl-[1,3]dioxolo[4,5-h]quinolin-8(9H)-one
DMOIC64	MI	TTJLP0R
DMOIC64	MN	Quinone reductase 2 (NQO2)
DMOIC64	MT	DTT
DMOIC64	MA	Inhibitor
DMOIC64	RN	Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities. J Med Chem. 2009 Apr 9;52(7):1873-84.
DMOIC64	RU	https://pubmed.ncbi.nlm.nih.gov/19265439

DMAQGZR	DI	DMAQGZR
DMAQGZR	DN	6-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one
DMAQGZR	MI	TTML2WA
DMAQGZR	MN	Tubulin (TUB)
DMAQGZR	MT	DTT
DMAQGZR	MA	Inhibitor
DMAQGZR	RN	Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubul... J Med Chem. 1997 Sep 12;40(19):3049-56.
DMAQGZR	RU	https://pubmed.ncbi.nlm.nih.gov/9301667

DMAQGZR	DI	DMAQGZR
DMAQGZR	DN	6-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one
DMAQGZR	MI	TTYFKSZ
DMAQGZR	MN	Tubulin beta (TUBB)
DMAQGZR	MT	DTT
DMAQGZR	MA	Inhibitor
DMAQGZR	RN	Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubul... J Med Chem. 1997 Sep 12;40(19):3049-56.
DMAQGZR	RU	https://pubmed.ncbi.nlm.nih.gov/9301667

DMNJRFP	DI	DMNJRFP
DMNJRFP	DN	6-Methyl-2-oxa-spiro[4.4]nonan-1-one
DMNJRFP	MI	TT1MPAY
DMNJRFP	MN	GABA(A) receptor alpha-1 (GABRA1)
DMNJRFP	MT	DTT
DMNJRFP	MA	Inhibitor
DMNJRFP	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DMNJRFP	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DMNJRFP	DI	DMNJRFP
DMNJRFP	DN	6-Methyl-2-oxa-spiro[4.4]nonan-1-one
DMNJRFP	MI	TTZA1NY
DMNJRFP	MN	GABA(A) receptor beta-2 (GABRB2)
DMNJRFP	MT	DTT
DMNJRFP	MA	Inhibitor
DMNJRFP	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DMNJRFP	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DMNJRFP	DI	DMNJRFP
DMNJRFP	DN	6-Methyl-2-oxa-spiro[4.4]nonan-1-one
DMNJRFP	MI	TT06RH5
DMNJRFP	MN	GABA(A) receptor gamma-2 (GABRG2)
DMNJRFP	MT	DTT
DMNJRFP	MA	Inhibitor
DMNJRFP	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DMNJRFP	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DMNJRFP	DI	DMNJRFP
DMNJRFP	DN	6-Methyl-2-oxa-spiro[4.4]nonan-1-one
DMNJRFP	MI	TTNJYV2
DMNJRFP	MN	Gamma-aminobutyric acid receptor (GAR)
DMNJRFP	MT	DTT
DMNJRFP	MA	Inhibitor
DMNJRFP	RN	Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86.
DMNJRFP	RU	https://pubmed.ncbi.nlm.nih.gov/8295215

DMZ6HQL	DI	DMZ6HQL
DMZ6HQL	DN	6-methyl-2-oxo-2H-chromene-3-carboxylic acid
DMZ6HQL	MI	TTUNARX
DMZ6HQL	MN	Carbonic anhydrase (CA)
DMZ6HQL	MT	DTT
DMZ6HQL	MA	Inhibitor
DMZ6HQL	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMZ6HQL	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMZ6HQL	DI	DMZ6HQL
DMZ6HQL	DN	6-methyl-2-oxo-2H-chromene-3-carboxylic acid
DMZ6HQL	MI	TTHQPL7
DMZ6HQL	MN	Carbonic anhydrase I (CA-I)
DMZ6HQL	MT	DTT
DMZ6HQL	MA	Inhibitor
DMZ6HQL	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMZ6HQL	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMZ6HQL	DI	DMZ6HQL
DMZ6HQL	DN	6-methyl-2-oxo-2H-chromene-3-carboxylic acid
DMZ6HQL	MI	TTANPDJ
DMZ6HQL	MN	Carbonic anhydrase II (CA-II)
DMZ6HQL	MT	DTT
DMZ6HQL	MA	Inhibitor
DMZ6HQL	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMZ6HQL	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMZ6HQL	DI	DMZ6HQL
DMZ6HQL	DN	6-methyl-2-oxo-2H-chromene-3-carboxylic acid
DMZ6HQL	MI	TTZHA0O
DMZ6HQL	MN	Carbonic anhydrase IV (CA-IV)
DMZ6HQL	MT	DTT
DMZ6HQL	MA	Inhibitor
DMZ6HQL	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMZ6HQL	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMZ6HQL	DI	DMZ6HQL
DMZ6HQL	DN	6-methyl-2-oxo-2H-chromene-3-carboxylic acid
DMZ6HQL	MI	TT2LVK8
DMZ6HQL	MN	Carbonic anhydrase IX (CA-IX)
DMZ6HQL	MT	DTT
DMZ6HQL	MA	Inhibitor
DMZ6HQL	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMZ6HQL	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMZ6HQL	DI	DMZ6HQL
DMZ6HQL	DN	6-methyl-2-oxo-2H-chromene-3-carboxylic acid
DMZ6HQL	MI	TTSYM0R
DMZ6HQL	MN	Carbonic anhydrase XII (CA-XII)
DMZ6HQL	MT	DTT
DMZ6HQL	MA	Inhibitor
DMZ6HQL	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMZ6HQL	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMZ6HQL	DI	DMZ6HQL
DMZ6HQL	DN	6-methyl-2-oxo-2H-chromene-3-carboxylic acid
DMZ6HQL	MI	TTEYTKG
DMZ6HQL	MN	Carbonic anhydrase XIV (CA-XIV)
DMZ6HQL	MT	DTT
DMZ6HQL	MA	Inhibitor
DMZ6HQL	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMZ6HQL	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMAXBOU	DI	DMAXBOU
DMAXBOU	DN	6-Methyl-2-phenyl-chromen-4-one
DMAXBOU	MI	TTNJYV2
DMAXBOU	MN	Gamma-aminobutyric acid receptor (GAR)
DMAXBOU	MT	DTT
DMAXBOU	MA	Inhibitor
DMAXBOU	RN	Refinement and evaluation of a pharmacophore model for flavone derivatives binding to the benzodiazepine site of the GABA(A) receptor. J Med Chem. 2002 Sep 12;45(19):4188-201.
DMAXBOU	RU	https://pubmed.ncbi.nlm.nih.gov/12213060

DM8KMEG	DI	DM8KMEG
DM8KMEG	DN	6-Methyl-2-p-tolyl-chromen-4-one
DM8KMEG	MI	TTNJYV2
DM8KMEG	MN	Gamma-aminobutyric acid receptor (GAR)
DM8KMEG	MT	DTT
DM8KMEG	MA	Inhibitor
DM8KMEG	RN	Refinement and evaluation of a pharmacophore model for flavone derivatives binding to the benzodiazepine site of the GABA(A) receptor. J Med Chem. 2002 Sep 12;45(19):4188-201.
DM8KMEG	RU	https://pubmed.ncbi.nlm.nih.gov/12213060

DMFMK6Y	DI	DMFMK6Y
DMFMK6Y	DN	6-Methyl-2-pyridin-3-yl-chromen-4-one
DMFMK6Y	MI	TTNJYV2
DMFMK6Y	MN	Gamma-aminobutyric acid receptor (GAR)
DMFMK6Y	MT	DTT
DMFMK6Y	MA	Inhibitor
DMFMK6Y	RN	Refinement and evaluation of a pharmacophore model for flavone derivatives binding to the benzodiazepine site of the GABA(A) receptor. J Med Chem. 2002 Sep 12;45(19):4188-201.
DMFMK6Y	RU	https://pubmed.ncbi.nlm.nih.gov/12213060

DMOVUP2	DI	DMOVUP2
DMOVUP2	DN	6-Methyl-4-(4-benzoylpiperazin-1-yl)coumarin
DMOVUP2	MI	TT1RS9F
DMOVUP2	MN	Acetylcholinesterase (AChE)
DMOVUP2	MT	DTT
DMOVUP2	MA	Inhibitor
DMOVUP2	RN	Design, synthesis, and acetylcholinesterase inhibitory activity of novel coumarin analogues. Bioorg Med Chem. 2008 Sep 1;16(17):8011-21.
DMOVUP2	RU	https://pubmed.ncbi.nlm.nih.gov/18701305

DMN0SYW	DI	DMN0SYW
DMN0SYW	DN	6-Methyl-4-(4-o-tolylpiperazin-1-yl)coumarin
DMN0SYW	MI	TT1RS9F
DMN0SYW	MN	Acetylcholinesterase (AChE)
DMN0SYW	MT	DTT
DMN0SYW	MA	Inhibitor
DMN0SYW	RN	Design, synthesis, and acetylcholinesterase inhibitory activity of novel coumarin analogues. Bioorg Med Chem. 2008 Sep 1;16(17):8011-21.
DMN0SYW	RU	https://pubmed.ncbi.nlm.nih.gov/18701305

DMU7E3O	DI	DMU7E3O
DMU7E3O	DN	6-Methyl-4-(4-phenylpiperazin-1-yl)coumarin
DMU7E3O	MI	TT1RS9F
DMU7E3O	MN	Acetylcholinesterase (AChE)
DMU7E3O	MT	DTT
DMU7E3O	MA	Inhibitor
DMU7E3O	RN	Design, synthesis, and acetylcholinesterase inhibitory activity of novel coumarin analogues. Bioorg Med Chem. 2008 Sep 1;16(17):8011-21.
DMU7E3O	RU	https://pubmed.ncbi.nlm.nih.gov/18701305

DM1LW62	DI	DM1LW62
DM1LW62	DN	6-methyl-4-(piperazin-1-yl)furo[2,3-d]pyrimidine
DM1LW62	MI	TTWJBZ5
DM1LW62	MN	5-HT 2C receptor (HTR2C)
DM1LW62	MT	DTT
DM1LW62	MA	Inhibitor
DM1LW62	RN	Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity. Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71.
DM1LW62	RU	https://pubmed.ncbi.nlm.nih.gov/19914063

DMO7RPW	DI	DMO7RPW
DMO7RPW	DN	6-Methyl-4-morpholin-4-yl-chromen-2-one
DMO7RPW	MI	TTK3PY9
DMO7RPW	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMO7RPW	MT	DTT
DMO7RPW	MA	Inhibitor
DMO7RPW	RN	Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85.
DMO7RPW	RU	https://pubmed.ncbi.nlm.nih.gov/15658870

DMSLT3I	DI	DMSLT3I
DMSLT3I	DN	6-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine
DMSLT3I	MI	TTF10I9
DMSLT3I	MN	Nitric-oxide synthase inducible (NOS2)
DMSLT3I	MT	DTT
DMSLT3I	MA	Inhibitor
DMSLT3I	RN	Synthesis of biflavones having a 6-O-7'' linkage and effects on cyclooxygenase-2 and inducible nitric oxide synthase. Bioorg Med Chem Lett. 2009 Jan 1;19(1):74-6.
DMSLT3I	RU	https://pubmed.ncbi.nlm.nih.gov/19041241

DMN6IDK	DI	DMN6IDK
DMN6IDK	DN	6-Methylamino-5-Nitroisocytosine
DMN6IDK	MI	TT4ILYC
DMN6IDK	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMN6IDK	MT	DTT
DMN6IDK	MA	Inhibitor
DMN6IDK	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMN6IDK	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMTG8D0	DI	DMTG8D0
DMTG8D0	DN	6'-methylepibatidine
DMTG8D0	MI	TT4H1MQ
DMTG8D0	MN	Neuronal acetylcholine receptor alpha-4 (CHRNA4)
DMTG8D0	MT	DTT
DMTG8D0	MA	Inhibitor
DMTG8D0	RN	Synthesis and nicotinic acetylcholine receptor binding properties of bridged and fused ring analogues of epibatidine. J Med Chem. 2007 Dec 13;50(25):6383-91.
DMTG8D0	RU	https://pubmed.ncbi.nlm.nih.gov/17994682

DMTG8D0	DI	DMTG8D0
DMTG8D0	DN	6'-methylepibatidine
DMTG8D0	MI	TT5KPZR
DMTG8D0	MN	Neuronal acetylcholine receptor beta-2 (CHRNB2)
DMTG8D0	MT	DTT
DMTG8D0	MA	Inhibitor
DMTG8D0	RN	Synthesis and nicotinic acetylcholine receptor binding properties of bridged and fused ring analogues of epibatidine. J Med Chem. 2007 Dec 13;50(25):6383-91.
DMTG8D0	RU	https://pubmed.ncbi.nlm.nih.gov/17994682

DMTNZKU	DI	DMTNZKU
DMTNZKU	DN	6-MORPHOLIN-4-YL-9H-PURINE
DMTNZKU	MI	TTTU902
DMTNZKU	MN	Checkpoint kinase-1 (CHK1)
DMTNZKU	MT	DTT
DMTNZKU	MA	Inhibitor
DMTNZKU	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMTNZKU	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMHU78R	DI	DMHU78R
DMHU78R	DN	6-m-Tolyl-pteridine-2,4,7-triamine
DMHU78R	MI	TT9SL3Q
DMHU78R	MN	Polypeptide deformylase (PDF)
DMHU78R	MT	DTT
DMHU78R	MA	Inhibitor
DMHU78R	RN	Further studies on 2,4-diamino-5-(2',5'-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three ... J Med Chem. 2003 Apr 24;46(9):1726-36.
DMHU78R	RU	https://pubmed.ncbi.nlm.nih.gov/12699390

DM84CTA	DI	DM84CTA
DM84CTA	DN	6-Nitro-1,4-dihydro-quinoxaline-2,3-dione
DM84CTA	MI	TTLD29N
DM84CTA	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DM84CTA	MT	DTT
DM84CTA	MA	Inhibitor
DM84CTA	RN	5-(N-oxyaza)-7-substituted-1,4-dihydroquinoxaline-2,3-diones: novel, systemically active and broad spectrum antagonists for NMDA/glycine, AMPA, and... J Med Chem. 1997 Oct 24;40(22):3679-86.
DM84CTA	RU	https://pubmed.ncbi.nlm.nih.gov/9357535

DM84CTA	DI	DM84CTA
DM84CTA	DN	6-Nitro-1,4-dihydro-quinoxaline-2,3-dione
DM84CTA	MI	TTKJEMQ
DM84CTA	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DM84CTA	MT	DTT
DM84CTA	MA	Inhibitor
DM84CTA	RN	5-(N-oxyaza)-7-substituted-1,4-dihydroquinoxaline-2,3-diones: novel, systemically active and broad spectrum antagonists for NMDA/glycine, AMPA, and... J Med Chem. 1997 Oct 24;40(22):3679-86.
DM84CTA	RU	https://pubmed.ncbi.nlm.nih.gov/9357535

DM84CTA	DI	DM84CTA
DM84CTA	DN	6-Nitro-1,4-dihydro-quinoxaline-2,3-dione
DM84CTA	MI	TTN9D8E
DM84CTA	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DM84CTA	MT	DTT
DM84CTA	MA	Inhibitor
DM84CTA	RN	5-(N-oxyaza)-7-substituted-1,4-dihydroquinoxaline-2,3-diones: novel, systemically active and broad spectrum antagonists for NMDA/glycine, AMPA, and... J Med Chem. 1997 Oct 24;40(22):3679-86.
DM84CTA	RU	https://pubmed.ncbi.nlm.nih.gov/9357535

DMRCTBA	DI	DMRCTBA
DMRCTBA	DN	6-Nitro-2-(3-nitro-phenyl)-chromen-4-one
DMRCTBA	MI	TT1MPAY
DMRCTBA	MN	GABA(A) receptor alpha-1 (GABRA1)
DMRCTBA	MT	DTT
DMRCTBA	MA	Inhibitor
DMRCTBA	RN	6,3'-Dinitroflavone, a novel high affinity ligand for the benzodiazepine receptor with potent anxiolytic properties, Bioorg. Med. Chem. Lett. 5(22):2717-2720 (1995).
DMRCTBA	RU	http://www.sciencedirect.com/science/article/pii/0960894X95004645

DMRCTBA	DI	DMRCTBA
DMRCTBA	DN	6-Nitro-2-(3-nitro-phenyl)-chromen-4-one
DMRCTBA	MI	TT06RH5
DMRCTBA	MN	GABA(A) receptor gamma-2 (GABRG2)
DMRCTBA	MT	DTT
DMRCTBA	MA	Inhibitor
DMRCTBA	RN	6,3'-Dinitroflavone, a novel high affinity ligand for the benzodiazepine receptor with potent anxiolytic properties, Bioorg. Med. Chem. Lett. 5(22):2717-2720 (1995).
DMRCTBA	RU	http://www.sciencedirect.com/science/article/pii/0960894X95004645

DMRCTBA	DI	DMRCTBA
DMRCTBA	DN	6-Nitro-2-(3-nitro-phenyl)-chromen-4-one
DMRCTBA	MI	TTNJYV2
DMRCTBA	MN	Gamma-aminobutyric acid receptor (GAR)
DMRCTBA	MT	DTT
DMRCTBA	MA	Inhibitor
DMRCTBA	RN	6,3'-Dinitroflavone, a novel high affinity ligand for the benzodiazepine receptor with potent anxiolytic properties, Bioorg. Med. Chem. Lett. 5(22):2717-2720 (1995).
DMRCTBA	RU	http://www.sciencedirect.com/science/article/pii/0960894X95004645

DMM635K	DI	DMM635K
DMM635K	DN	6-Nitro-2-(4-nitro-phenyl)-chromen-4-one
DMM635K	MI	TT1MPAY
DMM635K	MN	GABA(A) receptor alpha-1 (GABRA1)
DMM635K	MT	DTT
DMM635K	MA	Inhibitor
DMM635K	RN	6,3'-Dinitroflavone, a novel high affinity ligand for the benzodiazepine receptor with potent anxiolytic properties, Bioorg. Med. Chem. Lett. 5(22):2717-2720 (1995).
DMM635K	RU	http://www.sciencedirect.com/science/article/pii/0960894X95004645

DMM635K	DI	DMM635K
DMM635K	DN	6-Nitro-2-(4-nitro-phenyl)-chromen-4-one
DMM635K	MI	TT06RH5
DMM635K	MN	GABA(A) receptor gamma-2 (GABRG2)
DMM635K	MT	DTT
DMM635K	MA	Inhibitor
DMM635K	RN	6,3'-Dinitroflavone, a novel high affinity ligand for the benzodiazepine receptor with potent anxiolytic properties, Bioorg. Med. Chem. Lett. 5(22):2717-2720 (1995).
DMM635K	RU	http://www.sciencedirect.com/science/article/pii/0960894X95004645

DMM635K	DI	DMM635K
DMM635K	DN	6-Nitro-2-(4-nitro-phenyl)-chromen-4-one
DMM635K	MI	TTNJYV2
DMM635K	MN	Gamma-aminobutyric acid receptor (GAR)
DMM635K	MT	DTT
DMM635K	MA	Inhibitor
DMM635K	RN	6,3'-Dinitroflavone, a novel high affinity ligand for the benzodiazepine receptor with potent anxiolytic properties, Bioorg. Med. Chem. Lett. 5(22):2717-2720 (1995).
DMM635K	RU	http://www.sciencedirect.com/science/article/pii/0960894X95004645

DMZTXDV	DI	DMZTXDV
DMZTXDV	DN	6-Nitro-2-(4-phenoxy-benzyl)-1H-benzoimidazole
DMZTXDV	MI	TTLD29N
DMZTXDV	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMZTXDV	MT	DTT
DMZTXDV	MA	Inhibitor
DMZTXDV	RN	NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J Med Chem. 2004 Apr 8;47(8):2089-96.
DMZTXDV	RU	https://pubmed.ncbi.nlm.nih.gov/15056006

DMZTXDV	DI	DMZTXDV
DMZTXDV	DN	6-Nitro-2-(4-phenoxy-benzyl)-1H-benzoimidazole
DMZTXDV	MI	TTN9D8E
DMZTXDV	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMZTXDV	MT	DTT
DMZTXDV	MA	Inhibitor
DMZTXDV	RN	NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J Med Chem. 2004 Apr 8;47(8):2089-96.
DMZTXDV	RU	https://pubmed.ncbi.nlm.nih.gov/15056006

DMVLID9	DI	DMVLID9
DMVLID9	DN	6-Nitro-2-phenyl-chromen-4-one
DMVLID9	MI	TT1MPAY
DMVLID9	MN	GABA(A) receptor alpha-1 (GABRA1)
DMVLID9	MT	DTT
DMVLID9	MA	Inhibitor
DMVLID9	RN	Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997).
DMVLID9	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97003430

DMVLID9	DI	DMVLID9
DMVLID9	DN	6-Nitro-2-phenyl-chromen-4-one
DMVLID9	MI	TTNJYV2
DMVLID9	MN	Gamma-aminobutyric acid receptor (GAR)
DMVLID9	MT	DTT
DMVLID9	MA	Inhibitor
DMVLID9	RN	Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997).
DMVLID9	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97003430

DMAOUQI	DI	DMAOUQI
DMAOUQI	DN	6-Nitro-2-piperazin-1-yl-4-vinyl-quinoline
DMAOUQI	MI	TT3ROYC
DMAOUQI	MN	Serotonin transporter (SERT)
DMAOUQI	MT	DTT
DMAOUQI	MA	Inhibitor
DMAOUQI	RN	Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 2: 4-substituted 6-nitroquipazines. Bioorg Med Chem Lett. 2002 Mar 11;12(5):811-5.
DMAOUQI	RU	https://pubmed.ncbi.nlm.nih.gov/11859009

DMCEG6V	DI	DMCEG6V
DMCEG6V	DN	6-Nitro-4-phenyl-2-piperazin-1-yl-quinoline
DMCEG6V	MI	TT3ROYC
DMCEG6V	MN	Serotonin transporter (SERT)
DMCEG6V	MT	DTT
DMCEG6V	MA	Inhibitor
DMCEG6V	RN	Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 2: 4-substituted 6-nitroquipazines. Bioorg Med Chem Lett. 2002 Mar 11;12(5):811-5.
DMCEG6V	RU	https://pubmed.ncbi.nlm.nih.gov/11859009

DMYP7UG	DI	DMYP7UG
DMYP7UG	DN	6-Nitro-benzothiazole-2-sulfonic acid amide
DMYP7UG	MI	TTANPDJ
DMYP7UG	MN	Carbonic anhydrase II (CA-II)
DMYP7UG	MT	DTT
DMYP7UG	MA	Inhibitor
DMYP7UG	RN	Carbonic anhydrase inhibitors: inhibition of human cytosolic isozyme II and mitochondrial isozyme V with a series of benzene sulfonamide derivatives. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5703-7.
DMYP7UG	RU	https://pubmed.ncbi.nlm.nih.gov/15482952

DM2WZCX	DI	DM2WZCX
DM2WZCX	DN	6-Nitroindazole
DM2WZCX	MI	TTCM4B3
DM2WZCX	MN	Nitric-oxide synthase endothelial (NOS3)
DM2WZCX	MT	DTT
DM2WZCX	MA	Inhibitor
DM2WZCX	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM2WZCX	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM2WZCX	DI	DM2WZCX
DM2WZCX	DN	6-Nitroindazole
DM2WZCX	MI	TTF10I9
DM2WZCX	MN	Nitric-oxide synthase inducible (NOS2)
DM2WZCX	MT	DTT
DM2WZCX	MA	Inhibitor
DM2WZCX	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM2WZCX	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMXJFCQ	DI	DMXJFCQ
DMXJFCQ	DN	6-n-octylaminouracil
DMXJFCQ	MI	TTG0MQD
DMXJFCQ	MN	Inflammation-related GPCR EX33 (GPR84)
DMXJFCQ	MT	DTT
DMXJFCQ	MA	Agonist
DMXJFCQ	RN	Medium-chain fatty acid-sensing receptor, GPR84, is a proinflammatory receptor. J Biol Chem. 2013 Apr 12;288(15):10684-91.
DMXJFCQ	RU	https://pubmed.ncbi.nlm.nih.gov/23449982

DMDPA2T	DI	DMDPA2T
DMDPA2T	DN	6-N-propyl -4-trifluoromethylquinolin-2(1H)-one
DMDPA2T	MI	TTKPW01
DMDPA2T	MN	Androgen receptor messenger RNA (AR mRNA)
DMDPA2T	MT	DTT
DMDPA2T	MA	Inhibitor
DMDPA2T	RN	Discovery of 6-N,N-bis(2,2,2-trifluoroethyl)amino- 4-trifluoromethylquinolin-2(1H)-one as a novel selective androgen receptor modulator. J Med Chem. 2006 Oct 19;49(21):6143-6.
DMDPA2T	RU	https://pubmed.ncbi.nlm.nih.gov/17034117

DMDIW08	DI	DMDIW08
DMDIW08	DN	6-O-Cyclohexylmethyl Guanine
DMDIW08	MI	TTAMQ62
DMDIW08	MN	Cyclin A2 (CCNA2)
DMDIW08	MT	DTT
DMDIW08	MA	Inhibitor
DMDIW08	RN	N2-substituted O6-cyclohexylmethylguanine derivatives: potent inhibitors of cyclin-dependent kinases 1 and 2. J Med Chem. 2004 Jul 15;47(15):3710-22.
DMDIW08	RU	https://pubmed.ncbi.nlm.nih.gov/15239650

DMDIW08	DI	DMDIW08
DMDIW08	DN	6-O-Cyclohexylmethyl Guanine
DMDIW08	MI	TT7HF4W
DMDIW08	MN	Cyclin-dependent kinase 2 (CDK2)
DMDIW08	MT	DTT
DMDIW08	MA	Inhibitor
DMDIW08	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMDIW08	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM6YHBR	DI	DM6YHBR
DM6YHBR	DN	6-O-Phosphoryl Inosine Monophosphate
DM6YHBR	MI	TTYQ4AE
DM6YHBR	MN	Plasmodium Adenylosuccinate synthetase (Malaria Adss)
DM6YHBR	MT	DTT
DM6YHBR	MA	Inhibitor
DM6YHBR	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM6YHBR	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM4TX9O	DI	DM4TX9O
DM4TX9O	DN	6-o-tolylquinazolin-2-amine
DM4TX9O	MI	TTT7PJU
DM4TX9O	MN	Janus kinase 3 (JAK-3)
DM4TX9O	MT	DTT
DM4TX9O	MA	Inhibitor
DM4TX9O	RN	Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity. J Med Chem. 2006 Sep 21;49(19):5671-86.
DM4TX9O	RU	https://pubmed.ncbi.nlm.nih.gov/16970394

DM4TX9O	DI	DM4TX9O
DM4TX9O	DN	6-o-tolylquinazolin-2-amine
DM4TX9O	MI	TT860QF
DM4TX9O	MN	LCK tyrosine protein kinase (LCK)
DM4TX9O	MT	DTT
DM4TX9O	MA	Inhibitor
DM4TX9O	RN	Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity. J Med Chem. 2006 Sep 21;49(19):5671-86.
DM4TX9O	RU	https://pubmed.ncbi.nlm.nih.gov/16970394

DM4TX9O	DI	DM4TX9O
DM4TX9O	DN	6-o-tolylquinazolin-2-amine
DM4TX9O	MI	TTQBR95
DM4TX9O	MN	Stress-activated protein kinase 2a (p38 alpha)
DM4TX9O	MT	DTT
DM4TX9O	MA	Inhibitor
DM4TX9O	RN	Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity. J Med Chem. 2006 Sep 21;49(19):5671-86.
DM4TX9O	RU	https://pubmed.ncbi.nlm.nih.gov/16970394

DM4TX9O	DI	DM4TX9O
DM4TX9O	DN	6-o-tolylquinazolin-2-amine
DM4TX9O	MI	TTUTJGQ
DM4TX9O	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM4TX9O	MT	DTT
DM4TX9O	MA	Inhibitor
DM4TX9O	RN	Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity. J Med Chem. 2006 Sep 21;49(19):5671-86.
DM4TX9O	RU	https://pubmed.ncbi.nlm.nih.gov/16970394

DMPBE5H	DI	DMPBE5H
DMPBE5H	DN	6-oxo-16-formyl-estrone
DMPBE5H	MI	TTIWB6L
DMPBE5H	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMPBE5H	MT	DTT
DMPBE5H	MA	Inhibitor
DMPBE5H	RN	Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45.
DMPBE5H	RU	https://pubmed.ncbi.nlm.nih.gov/16480268

DMKMYAJ	DI	DMKMYAJ
DMKMYAJ	DN	6-oxo-estrone
DMKMYAJ	MI	TTIWB6L
DMKMYAJ	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMKMYAJ	MT	DTT
DMKMYAJ	MA	Inhibitor
DMKMYAJ	RN	Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45.
DMKMYAJ	RU	https://pubmed.ncbi.nlm.nih.gov/16480268

DMVYIN2	DI	DMVYIN2
DMVYIN2	DN	6-Phenoxy-hexane-1-thiol
DMVYIN2	MI	TTBH0VX
DMVYIN2	MN	Histone deacetylase (HDAC)
DMVYIN2	MT	DTT
DMVYIN2	MA	Inhibitor
DMVYIN2	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMVYIN2	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMVYIN2	DI	DMVYIN2
DMVYIN2	DN	6-Phenoxy-hexane-1-thiol
DMVYIN2	MI	TT6R7JZ
DMVYIN2	MN	Histone deacetylase 1 (HDAC1)
DMVYIN2	MT	DTT
DMVYIN2	MA	Inhibitor
DMVYIN2	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMVYIN2	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMVYIN2	DI	DMVYIN2
DMVYIN2	DN	6-Phenoxy-hexane-1-thiol
DMVYIN2	MI	TTYHPU6
DMVYIN2	MN	Histone deacetylase 10 (HDAC10)
DMVYIN2	MT	DTT
DMVYIN2	MA	Inhibitor
DMVYIN2	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMVYIN2	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMVYIN2	DI	DMVYIN2
DMVYIN2	DN	6-Phenoxy-hexane-1-thiol
DMVYIN2	MI	TTSHTOI
DMVYIN2	MN	Histone deacetylase 2 (HDAC2)
DMVYIN2	MT	DTT
DMVYIN2	MA	Inhibitor
DMVYIN2	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMVYIN2	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMVYIN2	DI	DMVYIN2
DMVYIN2	DN	6-Phenoxy-hexane-1-thiol
DMVYIN2	MI	TTTQGH8
DMVYIN2	MN	Histone deacetylase 4 (HDAC4)
DMVYIN2	MT	DTT
DMVYIN2	MA	Inhibitor
DMVYIN2	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMVYIN2	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMVYIN2	DI	DMVYIN2
DMVYIN2	DN	6-Phenoxy-hexane-1-thiol
DMVYIN2	MI	TT5ZKDI
DMVYIN2	MN	Histone deacetylase 6 (HDAC6)
DMVYIN2	MT	DTT
DMVYIN2	MA	Inhibitor
DMVYIN2	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMVYIN2	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMVYIN2	DI	DMVYIN2
DMVYIN2	DN	6-Phenoxy-hexane-1-thiol
DMVYIN2	MI	TTT6LFV
DMVYIN2	MN	Histone deacetylase 8 (HDAC8)
DMVYIN2	MT	DTT
DMVYIN2	MA	Inhibitor
DMVYIN2	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMVYIN2	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DM3UBR5	DI	DM3UBR5
DM3UBR5	DN	6-phenyl-3-(pyridin-4-yl)-1H-indole
DM3UBR5	MI	TTTB4UP
DM3UBR5	MN	Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2)
DM3UBR5	MT	DTT
DM3UBR5	MA	Inhibitor
DM3UBR5	RN	Novel indole inhibitors of IMPDH from fragments: synthesis and initial structure-activity relationships. Bioorg Med Chem Lett. 2006 May 1;16(9):2539-42.
DM3UBR5	RU	https://pubmed.ncbi.nlm.nih.gov/16483773

DMG6PZT	DI	DMG6PZT
DMG6PZT	DN	6-Phenylaminomethyl-quinazoline-2,4-diamine
DMG6PZT	MI	TT9SL3Q
DMG6PZT	MN	Polypeptide deformylase (PDF)
DMG6PZT	MT	DTT
DMG6PZT	MA	Inhibitor
DMG6PZT	RN	Design and synthesis of dihydrofolate reductase inhibitors encompassing a bridging ester group. Evaluation in a mouse colitis model. J Med Chem. 2003 Jul 31;46(16):3455-62.
DMG6PZT	RU	https://pubmed.ncbi.nlm.nih.gov/12877583

DMIKRP6	DI	DMIKRP6
DMIKRP6	DN	6-phenylethynyl-nicotinic acid methyl ester
DMIKRP6	MI	TTHS256
DMIKRP6	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMIKRP6	MT	DTT
DMIKRP6	MA	Inhibitor
DMIKRP6	RN	Positive and negative modulation of group I metabotropic glutamate receptors. J Med Chem. 2008 Feb 14;51(3):634-47.
DMIKRP6	RU	https://pubmed.ncbi.nlm.nih.gov/18173231

DMLJN8Z	DI	DMLJN8Z
DMLJN8Z	DN	6-Phenylhexylcarbamic Acid Biphenyl-3-yl Ester
DMLJN8Z	MI	TTDP1UC
DMLJN8Z	MN	Fatty acid amide hydrolase (FAAH)
DMLJN8Z	MT	DTT
DMLJN8Z	MA	Inhibitor
DMLJN8Z	RN	Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl a... J Med Chem. 2008 Jun 26;51(12):3487-98.
DMLJN8Z	RU	https://pubmed.ncbi.nlm.nih.gov/18507372

DMPA534	DI	DMPA534
DMPA534	DN	6-Phenylmethanesulfonyl-2H-pyridazin-3-one
DMPA534	MI	TTFBNVI
DMPA534	MN	Aldose reductase (AKR1B1)
DMPA534	MT	DTT
DMPA534	MA	Inhibitor
DMPA534	RN	A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3... J Med Chem. 2005 Oct 6;48(20):6326-39.
DMPA534	RU	https://pubmed.ncbi.nlm.nih.gov/16190759

DMEYOF7	DI	DMEYOF7
DMEYOF7	DN	6-Phenyl-naphthalen-2-ol
DMEYOF7	MI	TTZAYWL
DMEYOF7	MN	Estrogen receptor (ESR)
DMEYOF7	MT	DTT
DMEYOF7	MA	Inhibitor
DMEYOF7	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DMEYOF7	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMEYOF7	DI	DMEYOF7
DMEYOF7	DN	6-Phenyl-naphthalen-2-ol
DMEYOF7	MI	TTOM3J0
DMEYOF7	MN	Estrogen receptor beta (ESR2)
DMEYOF7	MT	DTT
DMEYOF7	MA	Inhibitor
DMEYOF7	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DMEYOF7	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMXTV1B	DI	DMXTV1B
DMXTV1B	DN	6-phenylpyridazin-3-yl thiophene-2-carboxylate
DMXTV1B	MI	TT6804T
DMXTV1B	MN	MIF messenger RNA (MIF mRNA)
DMXTV1B	MT	DTT
DMXTV1B	MA	Inhibitor
DMXTV1B	RN	An integrative in silico methodology for the identification of modulators of macrophage migration inhibitory factor (MIF) tautomerase activity. Bioorg Med Chem. 2010 Jul 15;18(14):5425-40. 
DMXTV1B	RU	https://pubmed.ncbi.nlm.nih.gov/20639113

DMZ76NQ	DI	DMZ76NQ
DMZ76NQ	DN	6-Phenylsulfanyl-9H-purine
DMZ76NQ	MI	TTQBR95
DMZ76NQ	MN	Stress-activated protein kinase 2a (p38 alpha)
DMZ76NQ	MT	DTT
DMZ76NQ	MA	Inhibitor
DMZ76NQ	RN	Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22.
DMZ76NQ	RU	https://pubmed.ncbi.nlm.nih.gov/15689155

DM3OLM6	DI	DM3OLM6
DM3OLM6	DN	6-phenylsulfanylhexanoic acid hydroxamide
DM3OLM6	MI	TTBH0VX
DM3OLM6	MN	Histone deacetylase (HDAC)
DM3OLM6	MT	DTT
DM3OLM6	MA	Inhibitor
DM3OLM6	RN	Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5.
DM3OLM6	RU	https://pubmed.ncbi.nlm.nih.gov/16420064

DM3OLM6	DI	DM3OLM6
DM3OLM6	DN	6-phenylsulfanylhexanoic acid hydroxamide
DM3OLM6	MI	TT6R7JZ
DM3OLM6	MN	Histone deacetylase 1 (HDAC1)
DM3OLM6	MT	DTT
DM3OLM6	MA	Inhibitor
DM3OLM6	RN	Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5.
DM3OLM6	RU	https://pubmed.ncbi.nlm.nih.gov/16420064

DM3OLM6	DI	DM3OLM6
DM3OLM6	DN	6-phenylsulfanylhexanoic acid hydroxamide
DM3OLM6	MI	TTYHPU6
DM3OLM6	MN	Histone deacetylase 10 (HDAC10)
DM3OLM6	MT	DTT
DM3OLM6	MA	Inhibitor
DM3OLM6	RN	Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5.
DM3OLM6	RU	https://pubmed.ncbi.nlm.nih.gov/16420064

DM3OLM6	DI	DM3OLM6
DM3OLM6	DN	6-phenylsulfanylhexanoic acid hydroxamide
DM3OLM6	MI	TTSHTOI
DM3OLM6	MN	Histone deacetylase 2 (HDAC2)
DM3OLM6	MT	DTT
DM3OLM6	MA	Inhibitor
DM3OLM6	RN	Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5.
DM3OLM6	RU	https://pubmed.ncbi.nlm.nih.gov/16420064

DM3OLM6	DI	DM3OLM6
DM3OLM6	DN	6-phenylsulfanylhexanoic acid hydroxamide
DM3OLM6	MI	TTTQGH8
DM3OLM6	MN	Histone deacetylase 4 (HDAC4)
DM3OLM6	MT	DTT
DM3OLM6	MA	Inhibitor
DM3OLM6	RN	Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5.
DM3OLM6	RU	https://pubmed.ncbi.nlm.nih.gov/16420064

DM3OLM6	DI	DM3OLM6
DM3OLM6	DN	6-phenylsulfanylhexanoic acid hydroxamide
DM3OLM6	MI	TT5ZKDI
DM3OLM6	MN	Histone deacetylase 6 (HDAC6)
DM3OLM6	MT	DTT
DM3OLM6	MA	Inhibitor
DM3OLM6	RN	Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5.
DM3OLM6	RU	https://pubmed.ncbi.nlm.nih.gov/16420064

DM3OLM6	DI	DM3OLM6
DM3OLM6	DN	6-phenylsulfanylhexanoic acid hydroxamide
DM3OLM6	MI	TTT6LFV
DM3OLM6	MN	Histone deacetylase 8 (HDAC8)
DM3OLM6	MT	DTT
DM3OLM6	MA	Inhibitor
DM3OLM6	RN	Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5.
DM3OLM6	RU	https://pubmed.ncbi.nlm.nih.gov/16420064

DM6GWRB	DI	DM6GWRB
DM6GWRB	DN	6-Phenylsulfanylmethyl-pteridine-2,4-diamine
DM6GWRB	MI	TT9SL3Q
DM6GWRB	MN	Polypeptide deformylase (PDF)
DM6GWRB	MT	DTT
DM6GWRB	MA	Inhibitor
DM6GWRB	RN	Nonclassical 2,4-diamino-8-deazafolate analogues as inhibitors of dihydrofolate reductases from rat liver, Pneumocystis carinii, and Toxoplasma gon... J Med Chem. 1996 Apr 26;39(9):1836-45.
DM6GWRB	RU	https://pubmed.ncbi.nlm.nih.gov/8627607

DME230I	DI	DME230I
DME230I	DN	6-phenyl-thieno[3,2-d]pyrimidin-4-ylamine
DME230I	MI	TTJ3E9X
DME230I	MN	Inhibitor of nuclear factor kappa-B kinase beta (IKKB)
DME230I	MT	DTT
DME230I	MA	Inhibitor
DME230I	RN	Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies. J Med Chem. 2006 May 18;49(10):2898-908.
DME230I	RU	https://pubmed.ncbi.nlm.nih.gov/16686533

DMB1QCY	DI	DMB1QCY
DMB1QCY	DN	6-Phosphogluconic Acid
DMB1QCY	MI	TTZ3IFB
DMB1QCY	MN	Phosphogluconate dehydrogenase (PGD)
DMB1QCY	MT	DTT
DMB1QCY	MA	Inhibitor
DMB1QCY	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMB1QCY	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMIAQUC	DI	DMIAQUC
DMIAQUC	DN	6-p-Tolylamino-1H-pyrimidine-2,4-dione
DMIAQUC	MI	TT2GPK3
DMIAQUC	MN	DNA topoisomerase (TOP)
DMIAQUC	MT	DTT
DMIAQUC	MA	Inhibitor
DMIAQUC	RN	Inhibitors of Bacillus subtilis DNA polymerase III. 6-Anilinouracils and 6-(alkylamino)uracils. J Med Chem. 1980 Jan;23(1):34-8.
DMIAQUC	RU	https://pubmed.ncbi.nlm.nih.gov/6767030

DM86XG5	DI	DM86XG5
DM86XG5	DN	6-Pyridin-3-yl-1,2,3,4-tetrahydronaphthalen-2-ol
DM86XG5	MI	TTIQUX7
DM86XG5	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM86XG5	MT	DTT
DM86XG5	MA	Inhibitor
DM86XG5	RN	In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87.
DM86XG5	RU	https://pubmed.ncbi.nlm.nih.gov/19049427

DMG5ABT	DI	DMG5ABT
DMG5ABT	DN	6-Pyridin-3-yl-3,4-dihydro-1H-quinolin-2-one
DMG5ABT	MI	TT06AWU
DMG5ABT	MN	Phosphodiesterase 3A (PDE3A)
DMG5ABT	MT	DTT
DMG5ABT	MA	Inhibitor
DMG5ABT	RN	3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase. J Med Chem. 1992 Feb 21;35(4):620-8.
DMG5ABT	RU	https://pubmed.ncbi.nlm.nih.gov/1311763

DMG5ABT	DI	DMG5ABT
DMG5ABT	DN	6-Pyridin-3-yl-3,4-dihydro-1H-quinolin-2-one
DMG5ABT	MI	TTIQUX7
DMG5ABT	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMG5ABT	MT	DTT
DMG5ABT	MA	Inhibitor
DMG5ABT	RN	In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87.
DMG5ABT	RU	https://pubmed.ncbi.nlm.nih.gov/19049427

DMIM5DL	DI	DMIM5DL
DMIM5DL	DN	6-Pyridin-3-yl-3,4-dihydronaphthalen-2(1H)-one
DMIM5DL	MI	TTXV4FI
DMIM5DL	MN	Albendazole monooxygenase (CYP3A4)
DMIM5DL	MT	DTT
DMIM5DL	MA	Inhibitor
DMIM5DL	RN	In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87.
DMIM5DL	RU	https://pubmed.ncbi.nlm.nih.gov/19049427

DMIM5DL	DI	DMIM5DL
DMIM5DL	DN	6-Pyridin-3-yl-3,4-dihydronaphthalen-2(1H)-one
DMIM5DL	MI	TTIQUX7
DMIM5DL	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMIM5DL	MT	DTT
DMIM5DL	MA	Inhibitor
DMIM5DL	RN	In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87.
DMIM5DL	RU	https://pubmed.ncbi.nlm.nih.gov/19049427

DMHAS2B	DI	DMHAS2B
DMHAS2B	DN	6-Pyridin-3-yl-3,4-dihydroquinoline-2(1H)-thione
DMHAS2B	MI	TTIQUX7
DMHAS2B	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMHAS2B	MT	DTT
DMHAS2B	MA	Inhibitor
DMHAS2B	RN	In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87.
DMHAS2B	RU	https://pubmed.ncbi.nlm.nih.gov/19049427

DMHAS2B	DI	DMHAS2B
DMHAS2B	DN	6-Pyridin-3-yl-3,4-dihydroquinoline-2(1H)-thione
DMHAS2B	MI	TTRA5BZ
DMHAS2B	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMHAS2B	MT	DTT
DMHAS2B	MA	Inhibitor
DMHAS2B	RN	In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87.
DMHAS2B	RU	https://pubmed.ncbi.nlm.nih.gov/19049427

DMGWNDB	DI	DMGWNDB
DMGWNDB	DN	6-Pyridin-3-yl-naphthalen-2-ol
DMGWNDB	MI	TTIQUX7
DMGWNDB	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMGWNDB	MT	DTT
DMGWNDB	MA	Inhibitor
DMGWNDB	RN	Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42.
DMGWNDB	RU	https://pubmed.ncbi.nlm.nih.gov/16220979

DMGWNDB	DI	DMGWNDB
DMGWNDB	DN	6-Pyridin-3-yl-naphthalen-2-ol
DMGWNDB	MI	TTRA5BZ
DMGWNDB	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMGWNDB	MT	DTT
DMGWNDB	MA	Inhibitor
DMGWNDB	RN	Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42.
DMGWNDB	RU	https://pubmed.ncbi.nlm.nih.gov/16220979

DMIA7ND	DI	DMIA7ND
DMIA7ND	DN	6s-5,6,7,8-Tetrahydrobiopterin
DMIA7ND	MI	TTCM4B3
DMIA7ND	MN	Nitric-oxide synthase endothelial (NOS3)
DMIA7ND	MT	DTT
DMIA7ND	MA	Inhibitor
DMIA7ND	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMIA7ND	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMDO13Y	DI	DMDO13Y
DMDO13Y	DN	6-Styryl-naphthalene-2-carboxamidine
DMDO13Y	MI	TT2WR1T
DMDO13Y	MN	Cationic trypsinogen (PRSS1)
DMDO13Y	MT	DTT
DMDO13Y	MA	Inhibitor
DMDO13Y	RN	Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties. Bioorg Med Chem Lett. 2005 Jan 3;15(1):93-8.
DMDO13Y	RU	https://pubmed.ncbi.nlm.nih.gov/15582418

DMQAG1B	DI	DMQAG1B
DMQAG1B	DN	6-tert-Butyl-2-morpholin-4-yl-4H-thiopyran-4-one
DMQAG1B	MI	TTK3PY9
DMQAG1B	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMQAG1B	MT	DTT
DMQAG1B	MA	Inhibitor
DMQAG1B	RN	Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72.
DMQAG1B	RU	https://pubmed.ncbi.nlm.nih.gov/17371003

DM9EA3C	DI	DM9EA3C
DM9EA3C	DN	6-tert-butyl-m-cresol
DM9EA3C	MI	TT946IA
DM9EA3C	MN	Transient receptor potential cation channel V3 (TRPV3)
DM9EA3C	MT	DTT
DM9EA3C	MA	Activator
DM9EA3C	RN	Monoterpenoid agonists of TRPV3. Br J Pharmacol. 2007 Jun;151(4):530-40.
DM9EA3C	RU	https://pubmed.ncbi.nlm.nih.gov/17420775

DMVGC7H	DI	DMVGC7H
DMVGC7H	DN	6-Thia-10b-aza-benzo[e]azulen-4-one
DMVGC7H	MI	TTPTXIN
DMVGC7H	MN	Translocator protein (TSPO)
DMVGC7H	MT	DTT
DMVGC7H	MA	Inhibitor
DMVGC7H	RN	Novel ligands specific for mitochondrial benzodiazepine receptors: 6-arylpyrrolo[2,1-d][1,5]benzothiazepine derivatives. Synthesis, structure-activ... J Med Chem. 1994 May 13;37(10):1427-38.
DMVGC7H	RU	https://pubmed.ncbi.nlm.nih.gov/8182701

DMC013U	DI	DMC013U
DMC013U	DN	6-Thiophen-2-yl-imidazo[2,1-b]thiazole
DMC013U	MI	TTTJF7V
DMC013U	MN	NADH dehydrogenase (MT-ND3)
DMC013U	MT	DTT
DMC013U	MA	Inhibitor
DMC013U	RN	Thienylimidazo[2,1-b]thiazoles as inhibitors of mitochondrial NADH dehydrogenase. J Med Chem. 1995 Mar 31;38(7):1090-7.
DMC013U	RU	https://pubmed.ncbi.nlm.nih.gov/7707312

DM90VJ6	DI	DM90VJ6
DM90VJ6	DN	6-Thiophen-3-yl-imidazo[2,1-b]thiazole
DM90VJ6	MI	TTTJF7V
DM90VJ6	MN	NADH dehydrogenase (MT-ND3)
DM90VJ6	MT	DTT
DM90VJ6	MA	Inhibitor
DM90VJ6	RN	Thienylimidazo[2,1-b]thiazoles as inhibitors of mitochondrial NADH dehydrogenase. J Med Chem. 1995 Mar 31;38(7):1090-7.
DM90VJ6	RU	https://pubmed.ncbi.nlm.nih.gov/7707312

DMVL218	DI	DMVL218
DMVL218	DN	6-tosyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole
DMVL218	MI	TTJS8PY
DMVL218	MN	5-HT 6 receptor (HTR6)
DMVL218	MT	DTT
DMVL218	MA	Inhibitor
DMVL218	RN	A regiospecific synthesis of a series of 1-sulfonyl azepinoindoles as potent 5-HT6 ligands. Bioorg Med Chem Lett. 2008 Jul 15;18(14):3929-31.
DMVL218	RU	https://pubmed.ncbi.nlm.nih.gov/18583130

DM2UTEA	DI	DM2UTEA
DM2UTEA	DN	7-((1H-imidazol-1-yl)methyl)-2H-chromen-2-one
DM2UTEA	MI	TTSZLWK
DM2UTEA	MN	Aromatase (CYP19A1)
DM2UTEA	MT	DTT
DM2UTEA	MA	Inhibitor
DM2UTEA	RN	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
DM2UTEA	RU	https://pubmed.ncbi.nlm.nih.gov/19072235

DMOS4ZQ	DI	DMOS4ZQ
DMOS4ZQ	DN	7-((1H-imidazol-1-yl)methyl)-4H-chromen-4-one
DMOS4ZQ	MI	TTSZLWK
DMOS4ZQ	MN	Aromatase (CYP19A1)
DMOS4ZQ	MT	DTT
DMOS4ZQ	MA	Inhibitor
DMOS4ZQ	RN	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
DMOS4ZQ	RU	https://pubmed.ncbi.nlm.nih.gov/19072235

DM9ID4T	DI	DM9ID4T
DM9ID4T	DN	7-((1H-imidazol-1-yl)methyl)isoquinoline
DM9ID4T	MI	TTSZLWK
DM9ID4T	MN	Aromatase (CYP19A1)
DM9ID4T	MT	DTT
DM9ID4T	MA	Inhibitor
DM9ID4T	RN	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
DM9ID4T	RU	https://pubmed.ncbi.nlm.nih.gov/19072235

DMRPFNU	DI	DMRPFNU
DMRPFNU	DN	7-(1-(1H-imidazol-1-yl)ethyl)-9H-fluoren-2-ol
DMRPFNU	MI	TTIQUX7
DMRPFNU	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMRPFNU	MT	DTT
DMRPFNU	MA	Inhibitor
DMRPFNU	RN	Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxyl... Bioorg Med Chem. 2008 Aug 15;16(16):7715-27.
DMRPFNU	RU	https://pubmed.ncbi.nlm.nih.gov/18674917

DMRPFNU	DI	DMRPFNU
DMRPFNU	DN	7-(1-(1H-imidazol-1-yl)ethyl)-9H-fluoren-2-ol
DMRPFNU	MI	TTRA5BZ
DMRPFNU	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMRPFNU	MT	DTT
DMRPFNU	MA	Inhibitor
DMRPFNU	RN	Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxyl... Bioorg Med Chem. 2008 Aug 15;16(16):7715-27.
DMRPFNU	RU	https://pubmed.ncbi.nlm.nih.gov/18674917

DMOZV9W	DI	DMOZV9W
DMOZV9W	DN	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide
DMOZV9W	MI	TT6R7JZ
DMOZV9W	MN	Histone deacetylase 1 (HDAC1)
DMOZV9W	MT	DTT
DMOZV9W	MA	Inhibitor
DMOZV9W	RN	Structure-activity relationships of aryloxyalkanoic acid hydroxyamides as potent inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2007 Jan 1;17(1):136-41.
DMOZV9W	RU	https://pubmed.ncbi.nlm.nih.gov/17046252

DM4HUO1	DI	DM4HUO1
DM4HUO1	DN	7-(2-(1H-imidazol-1-yl)ethoxy)-2H-chromen-2-one
DM4HUO1	MI	TTSZLWK
DM4HUO1	MN	Aromatase (CYP19A1)
DM4HUO1	MT	DTT
DM4HUO1	MA	Inhibitor
DM4HUO1	RN	Design, synthesis, and 3D QSAR of novel potent and selective aromatase inhibitors. J Med Chem. 2004 Dec 30;47(27):6792-803.
DM4HUO1	RU	https://pubmed.ncbi.nlm.nih.gov/15615528

DMPV674	DI	DMPV674
DMPV674	DN	7-(2-Amino-ethyl)-4-hydroxy-3H-benzothiazol-2-one
DMPV674	MI	TTEX248
DMPV674	MN	Dopamine D2 receptor (D2R)
DMPV674	MT	DTT
DMPV674	MA	Inhibitor
DMPV674	RN	Synthesis and evaluation of non-catechol D-1 and D-2 dopamine receptor agonists: benzimidazol-2-one, benzoxazol-2-one, and the highly potent benzot... J Med Chem. 1987 Jul;30(7):1166-76.
DMPV674	RU	https://pubmed.ncbi.nlm.nih.gov/2955118

DMWXGLE	DI	DMWXGLE
DMWXGLE	DN	7-(2-Dipropylamino-ethyl)-3H-benzothiazol-2-one
DMWXGLE	MI	TTEX248
DMWXGLE	MN	Dopamine D2 receptor (D2R)
DMWXGLE	MT	DTT
DMWXGLE	MA	Inhibitor
DMWXGLE	RN	Synthesis and evaluation of non-catechol D-1 and D-2 dopamine receptor agonists: benzimidazol-2-one, benzoxazol-2-one, and the highly potent benzot... J Med Chem. 1987 Jul;30(7):1166-76.
DMWXGLE	RU	https://pubmed.ncbi.nlm.nih.gov/2955118

DMBIY98	DI	DMBIY98
DMBIY98	DN	7-(2-Hydroxyethyl)-3-O-rhamnosylicariin
DMBIY98	MI	TTJ0IQB
DMBIY98	MN	Phosphodiesterase 5A (PDE5A)
DMBIY98	MT	DTT
DMBIY98	MA	Inhibitor
DMBIY98	RN	Potent inhibition of human phosphodiesterase-5 by icariin derivatives. J Nat Prod. 2008 Sep;71(9):1513-7.
DMBIY98	RU	https://pubmed.ncbi.nlm.nih.gov/18778098

DMO8DYW	DI	DMO8DYW
DMO8DYW	DN	7-(2-methoxyphenyl)-2-methylquinoline
DMO8DYW	MI	TTHS256
DMO8DYW	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMO8DYW	MT	DTT
DMO8DYW	MA	Inhibitor
DMO8DYW	RN	Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8.
DMO8DYW	RU	https://pubmed.ncbi.nlm.nih.gov/17590335

DMK28IS	DI	DMK28IS
DMK28IS	DN	7-(2-Nitro-ethyl)-azepan-(2Z)-ylideneamine
DMK28IS	MI	TTZUFI5
DMK28IS	MN	Nitric-oxide synthase brain (NOS1)
DMK28IS	MT	DTT
DMK28IS	MA	Inhibitor
DMK28IS	RN	Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3.
DMK28IS	RU	https://pubmed.ncbi.nlm.nih.gov/11551770

DMK28IS	DI	DMK28IS
DMK28IS	DN	7-(2-Nitro-ethyl)-azepan-(2Z)-ylideneamine
DMK28IS	MI	TTCM4B3
DMK28IS	MN	Nitric-oxide synthase endothelial (NOS3)
DMK28IS	MT	DTT
DMK28IS	MA	Inhibitor
DMK28IS	RN	Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3.
DMK28IS	RU	https://pubmed.ncbi.nlm.nih.gov/11551770

DMK28IS	DI	DMK28IS
DMK28IS	DN	7-(2-Nitro-ethyl)-azepan-(2Z)-ylideneamine
DMK28IS	MI	TTF10I9
DMK28IS	MN	Nitric-oxide synthase inducible (NOS2)
DMK28IS	MT	DTT
DMK28IS	MA	Inhibitor
DMK28IS	RN	Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3.
DMK28IS	RU	https://pubmed.ncbi.nlm.nih.gov/11551770

DMYNLOI	DI	DMYNLOI
DMYNLOI	DN	7-(3-(methoxymethyl)phenyl)-2-methylquinoline
DMYNLOI	MI	TTHS256
DMYNLOI	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMYNLOI	MT	DTT
DMYNLOI	MA	Inhibitor
DMYNLOI	RN	Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8.
DMYNLOI	RU	https://pubmed.ncbi.nlm.nih.gov/17590335

DM9BS5L	DI	DM9BS5L
DM9BS5L	DN	7-(3,5-dihydroxyphenyl)naphthalene-1,3-diol
DM9BS5L	MI	TTULVH8
DM9BS5L	MN	Tyrosinase (TYR)
DM9BS5L	MT	DTT
DM9BS5L	MA	Inhibitor
DM9BS5L	RN	Syntheses of hydroxy substituted 2-phenyl-naphthalenes as inhibitors of tyrosinase. Bioorg Med Chem Lett. 2007 Jan 15;17(2):461-4.
DM9BS5L	RU	https://pubmed.ncbi.nlm.nih.gov/17064896

DM2RFOB	DI	DM2RFOB
DM2RFOB	DN	7-(3,5-dimethoxyphenyl)-1,6-naphthyridine
DM2RFOB	MI	TTHS256
DM2RFOB	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM2RFOB	MT	DTT
DM2RFOB	MA	Inhibitor
DM2RFOB	RN	Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8.
DM2RFOB	RU	https://pubmed.ncbi.nlm.nih.gov/17936624

DMNQW2B	DI	DMNQW2B
DMNQW2B	DN	7-(3,6,9,12-tetraoxatricos-22-enyl)theophylline
DMNQW2B	MI	TTK25J1
DMNQW2B	MN	Adenosine A1 receptor (ADORA1)
DMNQW2B	MT	DTT
DMNQW2B	MA	Inhibitor
DMNQW2B	RN	Synthesis of theophylline derivatives and study of their activity as antagonists at adenosine receptors. Bioorg Med Chem. 2010 Mar 15;18(6):2081-2088.
DMNQW2B	RU	https://pubmed.ncbi.nlm.nih.gov/20202853

DMCFV0X	DI	DMCFV0X
DMCFV0X	DN	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide
DMCFV0X	MI	TT6R7JZ
DMCFV0X	MN	Histone deacetylase 1 (HDAC1)
DMCFV0X	MT	DTT
DMCFV0X	MA	Inhibitor
DMCFV0X	RN	Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3314-21.
DMCFV0X	RU	https://pubmed.ncbi.nlm.nih.gov/20451378

DM762G3	DI	DM762G3
DM762G3	DN	7-(3-chlorobenzyloxy)-4-carboxaldehyde-coumarin
DM762G3	MI	TT3WG5C
DM762G3	MN	Monoamine oxidase type A (MAO-A)
DM762G3	MT	DTT
DM762G3	MA	Inhibitor
DM762G3	RN	Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J Med Chem. 2007 Nov 15;50(23):5848-52.
DM762G3	RU	https://pubmed.ncbi.nlm.nih.gov/17915852

DM762G3	DI	DM762G3
DM762G3	DN	7-(3-chlorobenzyloxy)-4-carboxaldehyde-coumarin
DM762G3	MI	TTGP7BY
DM762G3	MN	Monoamine oxidase type B (MAO-B)
DM762G3	MT	DTT
DM762G3	MA	Inhibitor
DM762G3	RN	Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J Med Chem. 2007 Nov 15;50(23):5848-52.
DM762G3	RU	https://pubmed.ncbi.nlm.nih.gov/17915852

DM0Q56N	DI	DM0Q56N
DM0Q56N	DN	7-(3-chlorophenyl)-2-methylquinoline
DM0Q56N	MI	TTHS256
DM0Q56N	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM0Q56N	MT	DTT
DM0Q56N	MA	Inhibitor
DM0Q56N	RN	Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8.
DM0Q56N	RU	https://pubmed.ncbi.nlm.nih.gov/17590335

DME2VD7	DI	DME2VD7
DME2VD7	DN	7-(3-fluoro-5-methylphenyl)-1,6-naphthyridine
DME2VD7	MI	TTHS256
DME2VD7	MN	Metabotropic glutamate receptor 5 (mGluR5)
DME2VD7	MT	DTT
DME2VD7	MA	Inhibitor
DME2VD7	RN	Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8.
DME2VD7	RU	https://pubmed.ncbi.nlm.nih.gov/17936624

DMDXOBH	DI	DMDXOBH
DMDXOBH	DN	7-(3-fluorophenyl)-2-methylquinoline
DMDXOBH	MI	TTHS256
DMDXOBH	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMDXOBH	MT	DTT
DMDXOBH	MA	Inhibitor
DMDXOBH	RN	Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8.
DMDXOBH	RU	https://pubmed.ncbi.nlm.nih.gov/17590335

DM2I91C	DI	DM2I91C
DM2I91C	DN	7-(3-Hydroxy-phenyl)-naphthalen-2-ol
DM2I91C	MI	TTIWB6L
DM2I91C	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DM2I91C	MT	DTT
DM2I91C	MA	Inhibitor
DM2I91C	RN	Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors... J Med Chem. 2008 Apr 10;51(7):2158-69.
DM2I91C	RU	https://pubmed.ncbi.nlm.nih.gov/18324762

DM2I91C	DI	DM2I91C
DM2I91C	DN	7-(3-Hydroxy-phenyl)-naphthalen-2-ol
DM2I91C	MI	TTZAYWL
DM2I91C	MN	Estrogen receptor (ESR)
DM2I91C	MT	DTT
DM2I91C	MA	Inhibitor
DM2I91C	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DM2I91C	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DM2I91C	DI	DM2I91C
DM2I91C	DN	7-(3-Hydroxy-phenyl)-naphthalen-2-ol
DM2I91C	MI	TTOM3J0
DM2I91C	MN	Estrogen receptor beta (ESR2)
DM2I91C	MT	DTT
DM2I91C	MA	Inhibitor
DM2I91C	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DM2I91C	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMEC9YK	DI	DMEC9YK
DMEC9YK	DN	7-(3-methoxyphenyl)-2-methyl-1,6-naphthyridine
DMEC9YK	MI	TTHS256
DMEC9YK	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMEC9YK	MT	DTT
DMEC9YK	MA	Inhibitor
DMEC9YK	RN	Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8.
DMEC9YK	RU	https://pubmed.ncbi.nlm.nih.gov/17936624

DMW6LCH	DI	DMW6LCH
DMW6LCH	DN	7-(3-methoxyphenyl)-2-methylquinoline
DMW6LCH	MI	TTHS256
DMW6LCH	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMW6LCH	MT	DTT
DMW6LCH	MA	Inhibitor
DMW6LCH	RN	Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8.
DMW6LCH	RU	https://pubmed.ncbi.nlm.nih.gov/17590335

DM2TNCK	DI	DM2TNCK
DM2TNCK	DN	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide
DM2TNCK	MI	TT6R7JZ
DM2TNCK	MN	Histone deacetylase 1 (HDAC1)
DM2TNCK	MT	DTT
DM2TNCK	MA	Inhibitor
DM2TNCK	RN	Structure-activity relationships of aryloxyalkanoic acid hydroxyamides as potent inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2007 Jan 1;17(1):136-41.
DM2TNCK	RU	https://pubmed.ncbi.nlm.nih.gov/17046252

DMHXMY5	DI	DMHXMY5
DMHXMY5	DN	7-(4,6-dimethoxypyrimidin-2-yl)-2-methylquinoline
DMHXMY5	MI	TTHS256
DMHXMY5	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMHXMY5	MT	DTT
DMHXMY5	MA	Inhibitor
DMHXMY5	RN	Discovery of heterobicyclic templates for novel metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Jun 1;17(11):2987-91.
DMHXMY5	RU	https://pubmed.ncbi.nlm.nih.gov/17446071

DMQFBTW	DI	DMQFBTW
DMQFBTW	DN	7-(4,6-dimethylpyrimidin-2-yl)-2-methylquinoline
DMQFBTW	MI	TTHS256
DMQFBTW	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMQFBTW	MT	DTT
DMQFBTW	MA	Inhibitor
DMQFBTW	RN	Discovery of heterobicyclic templates for novel metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Jun 1;17(11):2987-91.
DMQFBTW	RU	https://pubmed.ncbi.nlm.nih.gov/17446071

DMM9IXB	DI	DMM9IXB
DMM9IXB	DN	7-(4-Hydroxy-phenyl)-naphthalen-2-ol
DMM9IXB	MI	TTZAYWL
DMM9IXB	MN	Estrogen receptor (ESR)
DMM9IXB	MT	DTT
DMM9IXB	MA	Inhibitor
DMM9IXB	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DMM9IXB	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMM9IXB	DI	DMM9IXB
DMM9IXB	DN	7-(4-Hydroxy-phenyl)-naphthalen-2-ol
DMM9IXB	MI	TTOM3J0
DMM9IXB	MN	Estrogen receptor beta (ESR2)
DMM9IXB	MT	DTT
DMM9IXB	MA	Inhibitor
DMM9IXB	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DMM9IXB	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMBT1KS	DI	DMBT1KS
DMBT1KS	DN	7-(4-methoxyphenyl)-2-methylquinoline
DMBT1KS	MI	TTHS256
DMBT1KS	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMBT1KS	MT	DTT
DMBT1KS	MA	Inhibitor
DMBT1KS	RN	Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8.
DMBT1KS	RU	https://pubmed.ncbi.nlm.nih.gov/17590335

DMLIYUJ	DI	DMLIYUJ
DMLIYUJ	DN	7-(4-methoxyphenyl)pteridine-2,4-diol
DMLIYUJ	MI	TTGX0HR
DMLIYUJ	MN	Bacterial DNA ligase (Bact ligA)
DMLIYUJ	MT	DTT
DMLIYUJ	MA	Inhibitor
DMLIYUJ	RN	Identification and validation of human DNA ligase inhibitors using computer-aided drug design. J Med Chem. 2008 Aug 14;51(15):4553-62.
DMLIYUJ	RU	https://pubmed.ncbi.nlm.nih.gov/18630893

DMSRKF0	DI	DMSRKF0
DMSRKF0	DN	7-(4-methoxypyrimidin-2-yl)-2-methylquinoline
DMSRKF0	MI	TTHS256
DMSRKF0	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMSRKF0	MT	DTT
DMSRKF0	MA	Inhibitor
DMSRKF0	RN	Discovery of heterobicyclic templates for novel metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Jun 1;17(11):2987-91.
DMSRKF0	RU	https://pubmed.ncbi.nlm.nih.gov/17446071

DMTKFPW	DI	DMTKFPW
DMTKFPW	DN	7-(benzyloxy)-2H-chromen-2-one
DMTKFPW	MI	TTUNARX
DMTKFPW	MN	Carbonic anhydrase (CA)
DMTKFPW	MT	DTT
DMTKFPW	MA	Inhibitor
DMTKFPW	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMTKFPW	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMTKFPW	DI	DMTKFPW
DMTKFPW	DN	7-(benzyloxy)-2H-chromen-2-one
DMTKFPW	MI	TTZHA0O
DMTKFPW	MN	Carbonic anhydrase IV (CA-IV)
DMTKFPW	MT	DTT
DMTKFPW	MA	Inhibitor
DMTKFPW	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMTKFPW	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMTKFPW	DI	DMTKFPW
DMTKFPW	DN	7-(benzyloxy)-2H-chromen-2-one
DMTKFPW	MI	TT2LVK8
DMTKFPW	MN	Carbonic anhydrase IX (CA-IX)
DMTKFPW	MT	DTT
DMTKFPW	MA	Inhibitor
DMTKFPW	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMTKFPW	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMTKFPW	DI	DMTKFPW
DMTKFPW	DN	7-(benzyloxy)-2H-chromen-2-one
DMTKFPW	MI	TTSYM0R
DMTKFPW	MN	Carbonic anhydrase XII (CA-XII)
DMTKFPW	MT	DTT
DMTKFPW	MA	Inhibitor
DMTKFPW	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMTKFPW	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMTKFPW	DI	DMTKFPW
DMTKFPW	DN	7-(benzyloxy)-2H-chromen-2-one
DMTKFPW	MI	TTEYTKG
DMTKFPW	MN	Carbonic anhydrase XIV (CA-XIV)
DMTKFPW	MT	DTT
DMTKFPW	MA	Inhibitor
DMTKFPW	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMTKFPW	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMLCGSY	DI	DMLCGSY
DMLCGSY	DN	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one
DMLCGSY	MI	TTBH0VX
DMLCGSY	MN	Histone deacetylase (HDAC)
DMLCGSY	MT	DTT
DMLCGSY	MA	Inhibitor
DMLCGSY	RN	Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.
DMLCGSY	RU	https://pubmed.ncbi.nlm.nih.gov/14592473

DMLCGSY	DI	DMLCGSY
DMLCGSY	DN	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one
DMLCGSY	MI	TT6R7JZ
DMLCGSY	MN	Histone deacetylase 1 (HDAC1)
DMLCGSY	MT	DTT
DMLCGSY	MA	Inhibitor
DMLCGSY	RN	Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.
DMLCGSY	RU	https://pubmed.ncbi.nlm.nih.gov/14592473

DMLCGSY	DI	DMLCGSY
DMLCGSY	DN	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one
DMLCGSY	MI	TTYHPU6
DMLCGSY	MN	Histone deacetylase 10 (HDAC10)
DMLCGSY	MT	DTT
DMLCGSY	MA	Inhibitor
DMLCGSY	RN	Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.
DMLCGSY	RU	https://pubmed.ncbi.nlm.nih.gov/14592473

DMLCGSY	DI	DMLCGSY
DMLCGSY	DN	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one
DMLCGSY	MI	TTSHTOI
DMLCGSY	MN	Histone deacetylase 2 (HDAC2)
DMLCGSY	MT	DTT
DMLCGSY	MA	Inhibitor
DMLCGSY	RN	Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.
DMLCGSY	RU	https://pubmed.ncbi.nlm.nih.gov/14592473

DMLCGSY	DI	DMLCGSY
DMLCGSY	DN	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one
DMLCGSY	MI	TTTQGH8
DMLCGSY	MN	Histone deacetylase 4 (HDAC4)
DMLCGSY	MT	DTT
DMLCGSY	MA	Inhibitor
DMLCGSY	RN	Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.
DMLCGSY	RU	https://pubmed.ncbi.nlm.nih.gov/14592473

DMLCGSY	DI	DMLCGSY
DMLCGSY	DN	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one
DMLCGSY	MI	TT5ZKDI
DMLCGSY	MN	Histone deacetylase 6 (HDAC6)
DMLCGSY	MT	DTT
DMLCGSY	MA	Inhibitor
DMLCGSY	RN	Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.
DMLCGSY	RU	https://pubmed.ncbi.nlm.nih.gov/14592473

DMLCGSY	DI	DMLCGSY
DMLCGSY	DN	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one
DMLCGSY	MI	TTT6LFV
DMLCGSY	MN	Histone deacetylase 8 (HDAC8)
DMLCGSY	MT	DTT
DMLCGSY	MA	Inhibitor
DMLCGSY	RN	Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.
DMLCGSY	RU	https://pubmed.ncbi.nlm.nih.gov/14592473

DM28GZ7	DI	DM28GZ7
DM28GZ7	DN	7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one
DM28GZ7	MI	TTBH0VX
DM28GZ7	MN	Histone deacetylase (HDAC)
DM28GZ7	MT	DTT
DM28GZ7	MA	Inhibitor
DM28GZ7	RN	Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
DM28GZ7	RU	https://pubmed.ncbi.nlm.nih.gov/14613312

DM28GZ7	DI	DM28GZ7
DM28GZ7	DN	7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one
DM28GZ7	MI	TT6R7JZ
DM28GZ7	MN	Histone deacetylase 1 (HDAC1)
DM28GZ7	MT	DTT
DM28GZ7	MA	Inhibitor
DM28GZ7	RN	Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3443-7.
DM28GZ7	RU	https://pubmed.ncbi.nlm.nih.gov/12419380

DM28GZ7	DI	DM28GZ7
DM28GZ7	DN	7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one
DM28GZ7	MI	TTYHPU6
DM28GZ7	MN	Histone deacetylase 10 (HDAC10)
DM28GZ7	MT	DTT
DM28GZ7	MA	Inhibitor
DM28GZ7	RN	Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
DM28GZ7	RU	https://pubmed.ncbi.nlm.nih.gov/14613312

DM28GZ7	DI	DM28GZ7
DM28GZ7	DN	7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one
DM28GZ7	MI	TTSHTOI
DM28GZ7	MN	Histone deacetylase 2 (HDAC2)
DM28GZ7	MT	DTT
DM28GZ7	MA	Inhibitor
DM28GZ7	RN	Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3443-7.
DM28GZ7	RU	https://pubmed.ncbi.nlm.nih.gov/12419380

DM28GZ7	DI	DM28GZ7
DM28GZ7	DN	7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one
DM28GZ7	MI	TTTQGH8
DM28GZ7	MN	Histone deacetylase 4 (HDAC4)
DM28GZ7	MT	DTT
DM28GZ7	MA	Inhibitor
DM28GZ7	RN	Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
DM28GZ7	RU	https://pubmed.ncbi.nlm.nih.gov/14613312

DM28GZ7	DI	DM28GZ7
DM28GZ7	DN	7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one
DM28GZ7	MI	TT5ZKDI
DM28GZ7	MN	Histone deacetylase 6 (HDAC6)
DM28GZ7	MT	DTT
DM28GZ7	MA	Inhibitor
DM28GZ7	RN	Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
DM28GZ7	RU	https://pubmed.ncbi.nlm.nih.gov/14613312

DM28GZ7	DI	DM28GZ7
DM28GZ7	DN	7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one
DM28GZ7	MI	TTT6LFV
DM28GZ7	MN	Histone deacetylase 8 (HDAC8)
DM28GZ7	MT	DTT
DM28GZ7	MA	Inhibitor
DM28GZ7	RN	Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
DM28GZ7	RU	https://pubmed.ncbi.nlm.nih.gov/14613312

DMY027P	DI	DMY027P
DMY027P	DN	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one
DMY027P	MI	TTBH0VX
DMY027P	MN	Histone deacetylase (HDAC)
DMY027P	MT	DTT
DMY027P	MA	Inhibitor
DMY027P	RN	Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.
DMY027P	RU	https://pubmed.ncbi.nlm.nih.gov/14592473

DMY027P	DI	DMY027P
DMY027P	DN	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one
DMY027P	MI	TT6R7JZ
DMY027P	MN	Histone deacetylase 1 (HDAC1)
DMY027P	MT	DTT
DMY027P	MA	Inhibitor
DMY027P	RN	Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.
DMY027P	RU	https://pubmed.ncbi.nlm.nih.gov/14592473

DMY027P	DI	DMY027P
DMY027P	DN	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one
DMY027P	MI	TTYHPU6
DMY027P	MN	Histone deacetylase 10 (HDAC10)
DMY027P	MT	DTT
DMY027P	MA	Inhibitor
DMY027P	RN	Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.
DMY027P	RU	https://pubmed.ncbi.nlm.nih.gov/14592473

DMY027P	DI	DMY027P
DMY027P	DN	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one
DMY027P	MI	TTSHTOI
DMY027P	MN	Histone deacetylase 2 (HDAC2)
DMY027P	MT	DTT
DMY027P	MA	Inhibitor
DMY027P	RN	Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.
DMY027P	RU	https://pubmed.ncbi.nlm.nih.gov/14592473

DMY027P	DI	DMY027P
DMY027P	DN	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one
DMY027P	MI	TTTQGH8
DMY027P	MN	Histone deacetylase 4 (HDAC4)
DMY027P	MT	DTT
DMY027P	MA	Inhibitor
DMY027P	RN	Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.
DMY027P	RU	https://pubmed.ncbi.nlm.nih.gov/14592473

DMY027P	DI	DMY027P
DMY027P	DN	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one
DMY027P	MI	TT5ZKDI
DMY027P	MN	Histone deacetylase 6 (HDAC6)
DMY027P	MT	DTT
DMY027P	MA	Inhibitor
DMY027P	RN	Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.
DMY027P	RU	https://pubmed.ncbi.nlm.nih.gov/14592473

DMY027P	DI	DMY027P
DMY027P	DN	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one
DMY027P	MI	TTT6LFV
DMY027P	MN	Histone deacetylase 8 (HDAC8)
DMY027P	MT	DTT
DMY027P	MA	Inhibitor
DMY027P	RN	Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.
DMY027P	RU	https://pubmed.ncbi.nlm.nih.gov/14592473

DMO4YLA	DI	DMO4YLA
DMO4YLA	DN	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide
DMO4YLA	MI	TT6R7JZ
DMO4YLA	MN	Histone deacetylase 1 (HDAC1)
DMO4YLA	MT	DTT
DMO4YLA	MA	Inhibitor
DMO4YLA	RN	Alpha-keto amides as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Oct 6;13(19):3331-5.
DMO4YLA	RU	https://pubmed.ncbi.nlm.nih.gov/12951120

DMO4YLA	DI	DMO4YLA
DMO4YLA	DN	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide
DMO4YLA	MI	TTSHTOI
DMO4YLA	MN	Histone deacetylase 2 (HDAC2)
DMO4YLA	MT	DTT
DMO4YLA	MA	Inhibitor
DMO4YLA	RN	Alpha-keto amides as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Oct 6;13(19):3331-5.
DMO4YLA	RU	https://pubmed.ncbi.nlm.nih.gov/12951120

DMU74R8	DI	DMU74R8
DMU74R8	DN	7-(naphthalen-2-yl)benzo[e][1,2,4]triazin-3-amine
DMU74R8	MI	TT6PKBN
DMU74R8	MN	Proto-oncogene c-Src (SRC)
DMU74R8	MT	DTT
DMU74R8	MA	Inhibitor
DMU74R8	RN	Discovery and preliminary structure-activity relationship studies of novel benzotriazine based compounds as Src inhibitors. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5546-50.
DMU74R8	RU	https://pubmed.ncbi.nlm.nih.gov/16931012

DM4VQN8	DI	DM4VQN8
DM4VQN8	DN	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one
DM4VQN8	MI	TTBH0VX
DM4VQN8	MN	Histone deacetylase (HDAC)
DM4VQN8	MT	DTT
DM4VQN8	MA	Inhibitor
DM4VQN8	RN	Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.
DM4VQN8	RU	https://pubmed.ncbi.nlm.nih.gov/14592473

DM4VQN8	DI	DM4VQN8
DM4VQN8	DN	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one
DM4VQN8	MI	TT6R7JZ
DM4VQN8	MN	Histone deacetylase 1 (HDAC1)
DM4VQN8	MT	DTT
DM4VQN8	MA	Inhibitor
DM4VQN8	RN	Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.
DM4VQN8	RU	https://pubmed.ncbi.nlm.nih.gov/14592473

DM4VQN8	DI	DM4VQN8
DM4VQN8	DN	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one
DM4VQN8	MI	TTYHPU6
DM4VQN8	MN	Histone deacetylase 10 (HDAC10)
DM4VQN8	MT	DTT
DM4VQN8	MA	Inhibitor
DM4VQN8	RN	Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.
DM4VQN8	RU	https://pubmed.ncbi.nlm.nih.gov/14592473

DM4VQN8	DI	DM4VQN8
DM4VQN8	DN	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one
DM4VQN8	MI	TTSHTOI
DM4VQN8	MN	Histone deacetylase 2 (HDAC2)
DM4VQN8	MT	DTT
DM4VQN8	MA	Inhibitor
DM4VQN8	RN	Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.
DM4VQN8	RU	https://pubmed.ncbi.nlm.nih.gov/14592473

DM4VQN8	DI	DM4VQN8
DM4VQN8	DN	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one
DM4VQN8	MI	TTTQGH8
DM4VQN8	MN	Histone deacetylase 4 (HDAC4)
DM4VQN8	MT	DTT
DM4VQN8	MA	Inhibitor
DM4VQN8	RN	Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.
DM4VQN8	RU	https://pubmed.ncbi.nlm.nih.gov/14592473

DM4VQN8	DI	DM4VQN8
DM4VQN8	DN	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one
DM4VQN8	MI	TT5ZKDI
DM4VQN8	MN	Histone deacetylase 6 (HDAC6)
DM4VQN8	MT	DTT
DM4VQN8	MA	Inhibitor
DM4VQN8	RN	Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.
DM4VQN8	RU	https://pubmed.ncbi.nlm.nih.gov/14592473

DM4VQN8	DI	DM4VQN8
DM4VQN8	DN	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one
DM4VQN8	MI	TTT6LFV
DM4VQN8	MN	Histone deacetylase 8 (HDAC8)
DM4VQN8	MT	DTT
DM4VQN8	MA	Inhibitor
DM4VQN8	RN	Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.
DM4VQN8	RU	https://pubmed.ncbi.nlm.nih.gov/14592473

DM6I5K1	DI	DM6I5K1
DM6I5K1	DN	7-(piperidin-4-ylmethoxy)-2-naphthonitrile
DM6I5K1	MI	TTPC4TU
DM6I5K1	MN	5-HT 3A receptor (HTR3A)
DM6I5K1	MT	DTT
DM6I5K1	MA	Inhibitor
DM6I5K1	RN	Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32.
DM6I5K1	RU	https://pubmed.ncbi.nlm.nih.gov/19282174

DM6I5K1	DI	DM6I5K1
DM6I5K1	DN	7-(piperidin-4-ylmethoxy)-2-naphthonitrile
DM6I5K1	MI	TTVBI8W
DM6I5K1	MN	Dopamine transporter (DAT)
DM6I5K1	MT	DTT
DM6I5K1	MA	Inhibitor
DM6I5K1	RN	Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32.
DM6I5K1	RU	https://pubmed.ncbi.nlm.nih.gov/19282174

DM6I5K1	DI	DM6I5K1
DM6I5K1	DN	7-(piperidin-4-ylmethoxy)-2-naphthonitrile
DM6I5K1	MI	TTAWNKZ
DM6I5K1	MN	Norepinephrine transporter (NET)
DM6I5K1	MT	DTT
DM6I5K1	MA	Inhibitor
DM6I5K1	RN	Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32.
DM6I5K1	RU	https://pubmed.ncbi.nlm.nih.gov/19282174

DM6I5K1	DI	DM6I5K1
DM6I5K1	DN	7-(piperidin-4-ylmethoxy)-2-naphthonitrile
DM6I5K1	MI	TT3ROYC
DM6I5K1	MN	Serotonin transporter (SERT)
DM6I5K1	MT	DTT
DM6I5K1	MA	Inhibitor
DM6I5K1	RN	Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32.
DM6I5K1	RU	https://pubmed.ncbi.nlm.nih.gov/19282174

DM6I5K1	DI	DM6I5K1
DM6I5K1	DN	7-(piperidin-4-ylmethoxy)-2-naphthonitrile
DM6I5K1	MI	TTQ6VDM
DM6I5K1	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DM6I5K1	MT	DTT
DM6I5K1	MA	Inhibitor
DM6I5K1	RN	Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32.
DM6I5K1	RU	https://pubmed.ncbi.nlm.nih.gov/19282174

DM46VT2	DI	DM46VT2
DM46VT2	DN	7-(trifluoromethyl)-1H-indole-2,3-dione
DM46VT2	MI	TTMF541
DM46VT2	MN	Liver carboxylesterase (CES1)
DM46VT2	MT	DTT
DM46VT2	MA	Inhibitor
DM46VT2	RN	Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85.
DM46VT2	RU	https://pubmed.ncbi.nlm.nih.gov/17378546

DM3FXRC	DI	DM3FXRC
DM3FXRC	DN	7,12-Dihydro-5,7,12-triaza-indeno[1,2-a]fluorene
DM3FXRC	MI	TT1MPAY
DM3FXRC	MN	GABA(A) receptor alpha-1 (GABRA1)
DM3FXRC	MT	DTT
DM3FXRC	MA	Inhibitor
DM3FXRC	RN	Synthesis of 7,12-dihydropyrido[3,4-b:5,4-b']diindoles. A novel class of rigid, planar benzodiazepine receptor ligands. J Med Chem. 1987 Mar;30(3):456-8.
DM3FXRC	RU	https://pubmed.ncbi.nlm.nih.gov/3029372

DM3FXRC	DI	DM3FXRC
DM3FXRC	DN	7,12-Dihydro-5,7,12-triaza-indeno[1,2-a]fluorene
DM3FXRC	MI	TTNJYV2
DM3FXRC	MN	Gamma-aminobutyric acid receptor (GAR)
DM3FXRC	MT	DTT
DM3FXRC	MA	Inhibitor
DM3FXRC	RN	Synthesis of 7,12-dihydropyrido[3,4-b:5,4-b']diindoles. A novel class of rigid, planar benzodiazepine receptor ligands. J Med Chem. 1987 Mar;30(3):456-8.
DM3FXRC	RU	https://pubmed.ncbi.nlm.nih.gov/3029372

DMTZ943	DI	DMTZ943
DMTZ943	DN	7,12-Dihydro-7,12-diaza-indeno[1,2-a]fluorene
DMTZ943	MI	TT1MPAY
DMTZ943	MN	GABA(A) receptor alpha-1 (GABRA1)
DMTZ943	MT	DTT
DMTZ943	MA	Inhibitor
DMTZ943	RN	Synthesis of novel 3-substituted beta-carbolines as benzodiazepine receptor ligands: probing the benzodiazepine receptor pharmacophore. J Med Chem. 1988 Sep;31(9):1854-61.
DMTZ943	RU	https://pubmed.ncbi.nlm.nih.gov/2842507

DMTZ943	DI	DMTZ943
DMTZ943	DN	7,12-Dihydro-7,12-diaza-indeno[1,2-a]fluorene
DMTZ943	MI	TTNJYV2
DMTZ943	MN	Gamma-aminobutyric acid receptor (GAR)
DMTZ943	MT	DTT
DMTZ943	MA	Inhibitor
DMTZ943	RN	Synthesis of novel 3-substituted beta-carbolines as benzodiazepine receptor ligands: probing the benzodiazepine receptor pharmacophore. J Med Chem. 1988 Sep;31(9):1854-61.
DMTZ943	RU	https://pubmed.ncbi.nlm.nih.gov/2842507

DM5JV8G	DI	DM5JV8G
DM5JV8G	DN	7,3',4'-trihydroxyisoflavone
DM5JV8G	MI	TTULVH8
DM5JV8G	MN	Tyrosinase (TYR)
DM5JV8G	MT	DTT
DM5JV8G	MA	Inhibitor
DM5JV8G	RN	Natural ortho-dihydroxyisoflavone derivatives from aged Korean fermented soybean paste as potent tyrosinase and melanin formation inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1162-4.
DM5JV8G	RU	https://pubmed.ncbi.nlm.nih.gov/20022495

DMXQ1K0	DI	DMXQ1K0
DMXQ1K0	DN	7,4'-Dihydroxyflavone
DMXQ1K0	MI	TTSZLWK
DMXQ1K0	MN	Aromatase (CYP19A1)
DMXQ1K0	MT	DTT
DMXQ1K0	MA	Inhibitor
DMXQ1K0	RN	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
DMXQ1K0	RU	https://pubmed.ncbi.nlm.nih.gov/20413308

DMOBEL9	DI	DMOBEL9
DMOBEL9	DN	7,8,3',4'-tetrahydroxyflavone
DMOBEL9	MI	TTQY2EJ
DMOBEL9	MN	TERT messenger RNA (TERT mRNA)
DMOBEL9	MT	DTT
DMOBEL9	MA	Inhibitor
DMOBEL9	RN	Catecholic flavonoids acting as telomerase inhibitors. J Med Chem. 2004 Dec 16;47(26):6466-75.
DMOBEL9	RU	https://pubmed.ncbi.nlm.nih.gov/15588081

DM80GFL	DI	DM80GFL
DM80GFL	DN	7,8,4'-trihydroxyisoflavone
DM80GFL	MI	DEEZYQV
DM80GFL	MN	Amylosucrase (AMS)
DM80GFL	MT	DME
DM80GFL	MA	Metabolism
DM80GFL	RN	Potential industrial production of a well-soluble, alkaline-stable, and anti-inflammatory isoflavone glucoside from 8-hydroxydaidzein glucosylated by recombinant amylosucrase of Deinococcus geothermalis. Molecules. 2019 Jun 15;24(12). pii: E2236.
DM80GFL	RU	https://pubmed.ncbi.nlm.nih.gov/31208027

DM80GFL	DI	DM80GFL
DM80GFL	DN	7,8,4'-trihydroxyisoflavone
DM80GFL	MI	TTULVH8
DM80GFL	MN	Tyrosinase (TYR)
DM80GFL	MT	DTT
DM80GFL	MA	Inhibitor
DM80GFL	RN	Natural ortho-dihydroxyisoflavone derivatives from aged Korean fermented soybean paste as potent tyrosinase and melanin formation inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1162-4.
DM80GFL	RU	https://pubmed.ncbi.nlm.nih.gov/20022495

DMIMLUO	DI	DMIMLUO
DMIMLUO	DN	7,8,9,10-tetrahydro-6H-furo-[2,3-g][3]benzazepine
DMIMLUO	MI	TTJQOD7
DMIMLUO	MN	5-HT 2A receptor (HTR2A)
DMIMLUO	MT	DTT
DMIMLUO	MA	Inhibitor
DMIMLUO	RN	Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists. Bioorg Med Chem. 2008 Mar 15;16(6):3309-20.
DMIMLUO	RU	https://pubmed.ncbi.nlm.nih.gov/18083579

DMIMLUO	DI	DMIMLUO
DMIMLUO	DN	7,8,9,10-tetrahydro-6H-furo-[2,3-g][3]benzazepine
DMIMLUO	MI	TT0K1SC
DMIMLUO	MN	5-HT 2B receptor (HTR2B)
DMIMLUO	MT	DTT
DMIMLUO	MA	Inhibitor
DMIMLUO	RN	Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists. Bioorg Med Chem. 2008 Mar 15;16(6):3309-20.
DMIMLUO	RU	https://pubmed.ncbi.nlm.nih.gov/18083579

DMIMLUO	DI	DMIMLUO
DMIMLUO	DN	7,8,9,10-tetrahydro-6H-furo-[2,3-g][3]benzazepine
DMIMLUO	MI	TTWJBZ5
DMIMLUO	MN	5-HT 2C receptor (HTR2C)
DMIMLUO	MT	DTT
DMIMLUO	MA	Inhibitor
DMIMLUO	RN	Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists. Bioorg Med Chem. 2008 Mar 15;16(6):3309-20.
DMIMLUO	RU	https://pubmed.ncbi.nlm.nih.gov/18083579

DMVZA27	DI	DMVZA27
DMVZA27	DN	7,8,9,10-tetrahydro-6H-furo-[3,2-g][3]benzazepine
DMVZA27	MI	TTJQOD7
DMVZA27	MN	5-HT 2A receptor (HTR2A)
DMVZA27	MT	DTT
DMVZA27	MA	Inhibitor
DMVZA27	RN	Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists. Bioorg Med Chem. 2008 Mar 15;16(6):3309-20.
DMVZA27	RU	https://pubmed.ncbi.nlm.nih.gov/18083579

DMVZA27	DI	DMVZA27
DMVZA27	DN	7,8,9,10-tetrahydro-6H-furo-[3,2-g][3]benzazepine
DMVZA27	MI	TT0K1SC
DMVZA27	MN	5-HT 2B receptor (HTR2B)
DMVZA27	MT	DTT
DMVZA27	MA	Inhibitor
DMVZA27	RN	Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists. Bioorg Med Chem. 2008 Mar 15;16(6):3309-20.
DMVZA27	RU	https://pubmed.ncbi.nlm.nih.gov/18083579

DMVZA27	DI	DMVZA27
DMVZA27	DN	7,8,9,10-tetrahydro-6H-furo-[3,2-g][3]benzazepine
DMVZA27	MI	TTWJBZ5
DMVZA27	MN	5-HT 2C receptor (HTR2C)
DMVZA27	MT	DTT
DMVZA27	MA	Inhibitor
DMVZA27	RN	Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists. Bioorg Med Chem. 2008 Mar 15;16(6):3309-20.
DMVZA27	RU	https://pubmed.ncbi.nlm.nih.gov/18083579

DMKNQW4	DI	DMKNQW4
DMKNQW4	DN	7,8-dichloroquinoline-4-one-3-carboxylic acid
DMKNQW4	MI	TTER6YH
DMKNQW4	MN	Casein kinase II alpha (CSNK2A1)
DMKNQW4	MT	DTT
DMKNQW4	MA	Inhibitor
DMKNQW4	RN	Evaluation of 3-carboxy-4(1H)-quinolones as inhibitors of human protein kinase CK2. J Med Chem. 2006 Nov 2;49(22):6443-50.
DMKNQW4	RU	https://pubmed.ncbi.nlm.nih.gov/17064064

DMQU4XM	DI	DMQU4XM
DMQU4XM	DN	7,8-dihydrobiopterin
DMQU4XM	MI	TTG9CFY
DMQU4XM	MN	Bacterial Dihydroneopterinaldolase (Bact folB)
DMQU4XM	MT	DTT
DMQU4XM	MA	Inhibitor
DMQU4XM	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMQU4XM	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMQU4XM	DI	DMQU4XM
DMQU4XM	DN	7,8-dihydrobiopterin
DMQU4XM	MI	TTF10I9
DMQU4XM	MN	Nitric-oxide synthase inducible (NOS2)
DMQU4XM	MT	DTT
DMQU4XM	MA	Inhibitor
DMQU4XM	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMQU4XM	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMQU4XM	DI	DMQU4XM
DMQU4XM	DN	7,8-dihydrobiopterin
DMQU4XM	MI	TTUHP71
DMQU4XM	MN	Tyrosine 3-monooxygenase (TH)
DMQU4XM	MT	DTT
DMQU4XM	MA	Inhibitor
DMQU4XM	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMQU4XM	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM5TXY1	DI	DM5TXY1
DM5TXY1	DN	7,8-Dihydroneopterin
DM5TXY1	MI	TTG9CFY
DM5TXY1	MN	Bacterial Dihydroneopterinaldolase (Bact folB)
DM5TXY1	MT	DTT
DM5TXY1	MA	Inhibitor
DM5TXY1	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM5TXY1	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMUB5E8	DI	DMUB5E8
DMUB5E8	DN	7,8-dihydroxy-4-phenyl-2H-chromen-2-one
DMUB5E8	MI	TTKWFB8
DMUB5E8	MN	Catechol-O-methyl-transferase (COMT)
DMUB5E8	MT	DTT
DMUB5E8	MA	Inhibitor
DMUB5E8	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMUB5E8	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMPF6MD	DI	DMPF6MD
DMPF6MD	DN	7,8-Dimethoxy-1,4-dimethylquinolin-2(1H)-one
DMPF6MD	MI	TTJLP0R
DMPF6MD	MN	Quinone reductase 2 (NQO2)
DMPF6MD	MT	DTT
DMPF6MD	MA	Inhibitor
DMPF6MD	RN	Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities. J Med Chem. 2009 Apr 9;52(7):1873-84.
DMPF6MD	RU	https://pubmed.ncbi.nlm.nih.gov/19265439

DMO8GEI	DI	DMO8GEI
DMO8GEI	DN	7,9-octadecadiynoic acid
DMO8GEI	MI	TTPADOQ
DMO8GEI	MN	HMG-CoA reductase (HMGCR)
DMO8GEI	MT	DTT
DMO8GEI	MA	Inhibitor
DMO8GEI	RN	Novel Acetylenic Acids from the Root Bark of Paramacrolobium caeruleum: Inhibitors of 3-Hydroxy-3-methyl-glutaryl Coenzyme A Reductase J. Nat. Prod. 52(1):153-161 (1989).
DMO8GEI	RU	http://pubs.acs.org/doi/abs/10.1021/np50061a020

DMPEXTB	DI	DMPEXTB
DMPEXTB	DN	7,9-tetradecadiynoic acid
DMPEXTB	MI	TTPADOQ
DMPEXTB	MN	HMG-CoA reductase (HMGCR)
DMPEXTB	MT	DTT
DMPEXTB	MA	Inhibitor
DMPEXTB	RN	Novel Acetylenic Acids from the Root Bark of Paramacrolobium caeruleum: Inhibitors of 3-Hydroxy-3-methyl-glutaryl Coenzyme A Reductase J. Nat. Prod. 52(1):153-161 (1989).
DMPEXTB	RU	http://pubs.acs.org/doi/abs/10.1021/np50061a020

DMNGLM1	DI	DMNGLM1
DMNGLM1	DN	7-[1,2,4]Triazol-4-ylmethyl-chromen-4-one
DMNGLM1	MI	TTSZLWK
DMNGLM1	MN	Aromatase (CYP19A1)
DMNGLM1	MT	DTT
DMNGLM1	MA	Inhibitor
DMNGLM1	RN	A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase. J Med Chem. 2001 Mar 1;44(5):672-80.
DMNGLM1	RU	https://pubmed.ncbi.nlm.nih.gov/11262078

DMQCDT1	DI	DMQCDT1
DMQCDT1	DN	7-Acetonyloxy-3,4-cyclohexene-8-methylcoumarin
DMQCDT1	MI	TT3WG5C
DMQCDT1	MN	Monoamine oxidase type A (MAO-A)
DMQCDT1	MT	DTT
DMQCDT1	MA	Inhibitor
DMQCDT1	RN	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J Med Chem. 2008 Nov 13;51(21):6740-51.
DMQCDT1	RU	https://pubmed.ncbi.nlm.nih.gov/18834112

DMQCDT1	DI	DMQCDT1
DMQCDT1	DN	7-Acetonyloxy-3,4-cyclohexene-8-methylcoumarin
DMQCDT1	MI	TTGP7BY
DMQCDT1	MN	Monoamine oxidase type B (MAO-B)
DMQCDT1	MT	DTT
DMQCDT1	MA	Inhibitor
DMQCDT1	RN	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J Med Chem. 2008 Nov 13;51(21):6740-51.
DMQCDT1	RU	https://pubmed.ncbi.nlm.nih.gov/18834112

DMQMTSX	DI	DMQMTSX
DMQMTSX	DN	7-Acetonyloxy-3,4-cyclopentene-8-methylcoumarin
DMQMTSX	MI	TT3WG5C
DMQMTSX	MN	Monoamine oxidase type A (MAO-A)
DMQMTSX	MT	DTT
DMQMTSX	MA	Inhibitor
DMQMTSX	RN	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J Med Chem. 2008 Nov 13;51(21):6740-51.
DMQMTSX	RU	https://pubmed.ncbi.nlm.nih.gov/18834112

DMQMTSX	DI	DMQMTSX
DMQMTSX	DN	7-Acetonyloxy-3,4-cyclopentene-8-methylcoumarin
DMQMTSX	MI	TTGP7BY
DMQMTSX	MN	Monoamine oxidase type B (MAO-B)
DMQMTSX	MT	DTT
DMQMTSX	MA	Inhibitor
DMQMTSX	RN	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J Med Chem. 2008 Nov 13;51(21):6740-51.
DMQMTSX	RU	https://pubmed.ncbi.nlm.nih.gov/18834112

DMYSNQO	DI	DMYSNQO
DMYSNQO	DN	7-acetonyloxy-3-acetylamino-8-methoxycoumarin
DMYSNQO	MI	TT3WG5C
DMYSNQO	MN	Monoamine oxidase type A (MAO-A)
DMYSNQO	MT	DTT
DMYSNQO	MA	Inhibitor
DMYSNQO	RN	A QSAR model for in silico screening of MAO-A inhibitors. Prediction, synthesis, and biological assay of novel coumarins. J Med Chem. 2006 Feb 9;49(3):1149-56.
DMYSNQO	RU	https://pubmed.ncbi.nlm.nih.gov/16451079

DMPRBO1	DI	DMPRBO1
DMPRBO1	DN	7-Allyl-1,3-dimethyl-3,7-dihydro-purine-2,6-dione
DMPRBO1	MI	TTM2AOE
DMPRBO1	MN	Adenosine A2a receptor (ADORA2A)
DMPRBO1	MT	DTT
DMPRBO1	MA	Inhibitor
DMPRBO1	RN	Analogues of caffeine and theophylline: effect of structural alterations on affinity at adenosine receptors. J Med Chem. 1986 Jul;29(7):1305-8.
DMPRBO1	RU	https://pubmed.ncbi.nlm.nih.gov/3806581

DMHJ6TU	DI	DMHJ6TU
DMHJ6TU	DN	7-Allyl-1,3-dipropyl-3,7-dihydro-purine-2,6-dione
DMHJ6TU	MI	TTM2AOE
DMHJ6TU	MN	Adenosine A2a receptor (ADORA2A)
DMHJ6TU	MT	DTT
DMHJ6TU	MA	Inhibitor
DMHJ6TU	RN	Analogues of caffeine and theophylline: effect of structural alterations on affinity at adenosine receptors. J Med Chem. 1986 Jul;29(7):1305-8.
DMHJ6TU	RU	https://pubmed.ncbi.nlm.nih.gov/3806581

DMSRQ1L	DI	DMSRQ1L
DMSRQ1L	DN	7-Allyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol
DMSRQ1L	MI	TTZAYWL
DMSRQ1L	MN	Estrogen receptor (ESR)
DMSRQ1L	MT	DTT
DMSRQ1L	MA	Inhibitor
DMSRQ1L	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMSRQ1L	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMSRQ1L	DI	DMSRQ1L
DMSRQ1L	DN	7-Allyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol
DMSRQ1L	MI	TTOM3J0
DMSRQ1L	MN	Estrogen receptor beta (ESR2)
DMSRQ1L	MT	DTT
DMSRQ1L	MA	Inhibitor
DMSRQ1L	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMSRQ1L	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DM2N8TW	DI	DM2N8TW
DM2N8TW	DN	7alpha,25-dihydroxycholesterol
DM2N8TW	MI	TTME5YJ
DM2N8TW	MN	EBV-induced G-protein coupled receptor 2 (GPR183)
DM2N8TW	MT	DTT
DM2N8TW	MA	Agonist
DM2N8TW	RN	Oxysterols direct immune cell migration via EBI2. Nature. 2011 Jul 27;475(7357):524-7.
DM2N8TW	RU	https://pubmed.ncbi.nlm.nih.gov/21796212

DM52UOM	DI	DM52UOM
DM52UOM	DN	7alpha,27-dihydroxycholesterol
DM52UOM	MI	TTME5YJ
DM52UOM	MN	EBV-induced G-protein coupled receptor 2 (GPR183)
DM52UOM	MT	DTT
DM52UOM	MA	Agonist
DM52UOM	RN	Oxysterols direct B-cell migration through EBI2. Nature. 2011 Jul 27;475(7357):519-23.
DM52UOM	RU	https://pubmed.ncbi.nlm.nih.gov/21796211

DMD6UC9	DI	DMD6UC9
DMD6UC9	DN	7alpha-Cl-ginkgolide B
DMD6UC9	MI	TTQL5VC
DMD6UC9	MN	Platelet-activating factor receptor (PTAFR)
DMD6UC9	MT	DTT
DMD6UC9	MA	Antagonist
DMD6UC9	RN	Preparation of 7-substituted ginkgolide derivatives: potent platelet activating factor (PAF) receptor antagonists. J Med Chem. 2003 Feb 13;46(4):601-8.
DMD6UC9	RU	https://pubmed.ncbi.nlm.nih.gov/12570381

DMRQ24A	DI	DMRQ24A
DMRQ24A	DN	7alpha-F-ginkgolide B
DMRQ24A	MI	TTQL5VC
DMRQ24A	MN	Platelet-activating factor receptor (PTAFR)
DMRQ24A	MT	DTT
DMRQ24A	MA	Antagonist
DMRQ24A	RN	Preparation of 7-substituted ginkgolide derivatives: potent platelet activating factor (PAF) receptor antagonists. J Med Chem. 2003 Feb 13;46(4):601-8.
DMRQ24A	RU	https://pubmed.ncbi.nlm.nih.gov/12570381

DMH6LD0	DI	DMH6LD0
DMH6LD0	DN	7alpha-hydroxycholesterol
DMH6LD0	MI	TTME5YJ
DMH6LD0	MN	EBV-induced G-protein coupled receptor 2 (GPR183)
DMH6LD0	MT	DTT
DMH6LD0	MA	Agonist
DMH6LD0	RN	Oxysterols direct B-cell migration through EBI2. Nature. 2011 Jul 27;475(7357):519-23.
DMH6LD0	RU	https://pubmed.ncbi.nlm.nih.gov/21796211

DMGNWBV	DI	DMGNWBV
DMGNWBV	DN	7alpha-N3-ginkgolide B
DMGNWBV	MI	TTQL5VC
DMGNWBV	MN	Platelet-activating factor receptor (PTAFR)
DMGNWBV	MT	DTT
DMGNWBV	MA	Antagonist
DMGNWBV	RN	Preparation of 7-substituted ginkgolide derivatives: potent platelet activating factor (PAF) receptor antagonists. J Med Chem. 2003 Feb 13;46(4):601-8.
DMGNWBV	RU	https://pubmed.ncbi.nlm.nih.gov/12570381

DMZUYX1	DI	DMZUYX1
DMZUYX1	DN	7alpha-NH2-ginkgolide B
DMZUYX1	MI	TTQL5VC
DMZUYX1	MN	Platelet-activating factor receptor (PTAFR)
DMZUYX1	MT	DTT
DMZUYX1	MA	Antagonist
DMZUYX1	RN	Preparation of 7-substituted ginkgolide derivatives: potent platelet activating factor (PAF) receptor antagonists. J Med Chem. 2003 Feb 13;46(4):601-8.
DMZUYX1	RU	https://pubmed.ncbi.nlm.nih.gov/12570381

DMWAB7F	DI	DMWAB7F
DMWAB7F	DN	7alpha-NHEt-ginkgolide B
DMWAB7F	MI	TTQL5VC
DMWAB7F	MN	Platelet-activating factor receptor (PTAFR)
DMWAB7F	MT	DTT
DMWAB7F	MA	Antagonist
DMWAB7F	RN	Preparation of 7-substituted ginkgolide derivatives: potent platelet activating factor (PAF) receptor antagonists. J Med Chem. 2003 Feb 13;46(4):601-8.
DMWAB7F	RU	https://pubmed.ncbi.nlm.nih.gov/12570381

DMSPLYF	DI	DMSPLYF
DMSPLYF	DN	7alpha-NHMe-ginkgolide B
DMSPLYF	MI	TTQL5VC
DMSPLYF	MN	Platelet-activating factor receptor (PTAFR)
DMSPLYF	MT	DTT
DMSPLYF	MA	Antagonist
DMSPLYF	RN	Preparation of 7-substituted ginkgolide derivatives: potent platelet activating factor (PAF) receptor antagonists. J Med Chem. 2003 Feb 13;46(4):601-8.
DMSPLYF	RU	https://pubmed.ncbi.nlm.nih.gov/12570381

DMN1U56	DI	DMN1U56
DMN1U56	DN	7alpha-OAc-ginkgolide B
DMN1U56	MI	TTQL5VC
DMN1U56	MN	Platelet-activating factor receptor (PTAFR)
DMN1U56	MT	DTT
DMN1U56	MA	Antagonist
DMN1U56	RN	Preparation of 7-substituted ginkgolide derivatives: potent platelet activating factor (PAF) receptor antagonists. J Med Chem. 2003 Feb 13;46(4):601-8.
DMN1U56	RU	https://pubmed.ncbi.nlm.nih.gov/12570381

DMGAPCD	DI	DMGAPCD
DMGAPCD	DN	7alpha-OCOCH2Ph-ginkgolide B
DMGAPCD	MI	TTQL5VC
DMGAPCD	MN	Platelet-activating factor receptor (PTAFR)
DMGAPCD	MT	DTT
DMGAPCD	MA	Antagonist
DMGAPCD	RN	Preparation of 7-substituted ginkgolide derivatives: potent platelet activating factor (PAF) receptor antagonists. J Med Chem. 2003 Feb 13;46(4):601-8.
DMGAPCD	RU	https://pubmed.ncbi.nlm.nih.gov/12570381

DMDUB63	DI	DMDUB63
DMDUB63	DN	7-amino-4-hydroxy-2-naphthalenesulfonic acid
DMDUB63	MI	TTGTQHC
DMDUB63	MN	DNA topoisomerase I (TOP1)
DMDUB63	MT	DTT
DMDUB63	MA	Binder
DMDUB63	RN	Comparison of responses of DNA topoisomerase I from Candida albicans and human cells to four new agents which stimulate topoisomerase-dependent DNA nicking. FEMS Microbiol Lett. 1996 May 1;138(2-3):105-11.
DMDUB63	RU	https://pubmed.ncbi.nlm.nih.gov/9026436

DMC8O3Z	DI	DMC8O3Z
DMC8O3Z	DN	7-AMINO-4-METHYL-CHROMEN-2-ONE
DMC8O3Z	MI	TTL2ADK
DMC8O3Z	MN	Rotamase A (PPIA)
DMC8O3Z	MT	DTT
DMC8O3Z	MA	Inhibitor
DMC8O3Z	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMC8O3Z	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMZDP5S	DI	DMZDP5S
DMZDP5S	DN	7-benzoyloxy-2-(morpholin-4-yl)-chromen-4-one
DMZDP5S	MI	TTK3PY9
DMZDP5S	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMZDP5S	MT	DTT
DMZDP5S	MA	Inhibitor
DMZDP5S	RN	Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46.
DMZDP5S	RU	https://pubmed.ncbi.nlm.nih.gov/16302822

DMCJED6	DI	DMCJED6
DMCJED6	DN	7-benzylidenenaltrexone
DMCJED6	MI	TT27RFC
DMCJED6	MN	Opioid receptor delta (OPRD1)
DMCJED6	MT	DTT
DMCJED6	MA	Antagonist
DMCJED6	RN	Delta-opioid receptor antagonists as a new concept for central acting antitussive drugs. Pulm Pharmacol Ther. 2002;15(3):235-40.
DMCJED6	RU	https://pubmed.ncbi.nlm.nih.gov/12099770

DMMXAEN	DI	DMMXAEN
DMMXAEN	DN	7-benzyloxy-2-(morpholin-4-yl)-chromen-4-one
DMMXAEN	MI	TTK3PY9
DMMXAEN	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMMXAEN	MT	DTT
DMMXAEN	MA	Inhibitor
DMMXAEN	RN	Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46.
DMMXAEN	RU	https://pubmed.ncbi.nlm.nih.gov/16302822

DMYKXWE	DI	DMYKXWE
DMYKXWE	DN	7beta, 25-dihydroxycholesterol
DMYKXWE	MI	TTME5YJ
DMYKXWE	MN	EBV-induced G-protein coupled receptor 2 (GPR183)
DMYKXWE	MT	DTT
DMYKXWE	MA	Agonist
DMYKXWE	RN	Oxysterols direct B-cell migration through EBI2. Nature. 2011 Jul 27;475(7357):519-23.
DMYKXWE	RU	https://pubmed.ncbi.nlm.nih.gov/21796211

DMSDINR	DI	DMSDINR
DMSDINR	DN	7beta, 27-dihydroxycholesterol
DMSDINR	MI	TTME5YJ
DMSDINR	MN	EBV-induced G-protein coupled receptor 2 (GPR183)
DMSDINR	MT	DTT
DMSDINR	MA	Agonist
DMSDINR	RN	Oxysterols direct B-cell migration through EBI2. Nature. 2011 Jul 27;475(7357):519-23.
DMSDINR	RU	https://pubmed.ncbi.nlm.nih.gov/21796211

DMPHJZU	DI	DMPHJZU
DMPHJZU	DN	7beta-hydroxycholesterol
DMPHJZU	MI	TTME5YJ
DMPHJZU	MN	EBV-induced G-protein coupled receptor 2 (GPR183)
DMPHJZU	MT	DTT
DMPHJZU	MA	Agonist
DMPHJZU	RN	Oxysterols direct B-cell migration through EBI2. Nature. 2011 Jul 27;475(7357):519-23.
DMPHJZU	RU	https://pubmed.ncbi.nlm.nih.gov/21796211

DMV54MT	DI	DMV54MT
DMV54MT	DN	7-Biphenyl-4-yl-heptanoic acid hydroxyamide
DMV54MT	MI	TT6R7JZ
DMV54MT	MN	Histone deacetylase 1 (HDAC1)
DMV54MT	MT	DTT
DMV54MT	MA	Inhibitor
DMV54MT	RN	A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units. Bioorg Med Chem Lett. 2003 Nov 3;13(21):3817-20.
DMV54MT	RU	https://pubmed.ncbi.nlm.nih.gov/14552787

DMV54MT	DI	DMV54MT
DMV54MT	DN	7-Biphenyl-4-yl-heptanoic acid hydroxyamide
DMV54MT	MI	TTSHTOI
DMV54MT	MN	Histone deacetylase 2 (HDAC2)
DMV54MT	MT	DTT
DMV54MT	MA	Inhibitor
DMV54MT	RN	A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units. Bioorg Med Chem Lett. 2003 Nov 3;13(21):3817-20.
DMV54MT	RU	https://pubmed.ncbi.nlm.nih.gov/14552787

DMYBNCO	DI	DMYBNCO
DMYBNCO	DN	7-bromo-1H-indazole
DMYBNCO	MI	TTZUFI5
DMYBNCO	MN	Nitric-oxide synthase brain (NOS1)
DMYBNCO	MT	DTT
DMYBNCO	MA	Inhibitor
DMYBNCO	RN	4-substituted indazoles as new inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3177-80.
DMYBNCO	RU	https://pubmed.ncbi.nlm.nih.gov/17395463

DMA8DXG	DI	DMA8DXG
DMA8DXG	DN	7-Bromo-2-(4-hydroxy-phenyl)-benzofuran-5-ol
DMA8DXG	MI	TTZAYWL
DMA8DXG	MN	Estrogen receptor (ESR)
DMA8DXG	MT	DTT
DMA8DXG	MA	Inhibitor
DMA8DXG	RN	7-Substituted 2-phenyl-benzofurans as ER beta selective ligands. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4925-9.
DMA8DXG	RU	https://pubmed.ncbi.nlm.nih.gov/15341953

DMA8DXG	DI	DMA8DXG
DMA8DXG	DN	7-Bromo-2-(4-hydroxy-phenyl)-benzofuran-5-ol
DMA8DXG	MI	TTOM3J0
DMA8DXG	MN	Estrogen receptor beta (ESR2)
DMA8DXG	MT	DTT
DMA8DXG	MA	Inhibitor
DMA8DXG	RN	7-Substituted 2-phenyl-benzofurans as ER beta selective ligands. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4925-9.
DMA8DXG	RU	https://pubmed.ncbi.nlm.nih.gov/15341953

DMVTH0Q	DI	DMVTH0Q
DMVTH0Q	DN	7-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline
DMVTH0Q	MI	TT3WG5C
DMVTH0Q	MN	Monoamine oxidase type A (MAO-A)
DMVTH0Q	MT	DTT
DMVTH0Q	MA	Inhibitor
DMVTH0Q	RN	Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
DMVTH0Q	RU	https://pubmed.ncbi.nlm.nih.gov/15013009

DMVTH0Q	DI	DMVTH0Q
DMVTH0Q	DN	7-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline
DMVTH0Q	MI	TTGP7BY
DMVTH0Q	MN	Monoamine oxidase type B (MAO-B)
DMVTH0Q	MT	DTT
DMVTH0Q	MA	Inhibitor
DMVTH0Q	RN	Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
DMVTH0Q	RU	https://pubmed.ncbi.nlm.nih.gov/15013009

DMG8ZJA	DI	DMG8ZJA
DMG8ZJA	DN	7-Bromo-2-phenyl-[1,8]naphthyridin-4-ol
DMG8ZJA	MI	TTK25J1
DMG8ZJA	MN	Adenosine A1 receptor (ADORA1)
DMG8ZJA	MT	DTT
DMG8ZJA	MA	Inhibitor
DMG8ZJA	RN	Study on affinity profile toward native human and bovine adenosine receptors of a series of 1,8-naphthyridine derivatives. J Med Chem. 2004 Jun 3;47(12):3019-31.
DMG8ZJA	RU	https://pubmed.ncbi.nlm.nih.gov/15163184

DMCWYT7	DI	DMCWYT7
DMCWYT7	DN	7-Bromo-4,9-dihydro-3H-beta-carboline
DMCWYT7	MI	TT3WG5C
DMCWYT7	MN	Monoamine oxidase type A (MAO-A)
DMCWYT7	MT	DTT
DMCWYT7	MA	Inhibitor
DMCWYT7	RN	Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
DMCWYT7	RU	https://pubmed.ncbi.nlm.nih.gov/15013009

DMCWYT7	DI	DMCWYT7
DMCWYT7	DN	7-Bromo-4,9-dihydro-3H-beta-carboline
DMCWYT7	MI	TTGP7BY
DMCWYT7	MN	Monoamine oxidase type B (MAO-B)
DMCWYT7	MT	DTT
DMCWYT7	MA	Inhibitor
DMCWYT7	RN	Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
DMCWYT7	RU	https://pubmed.ncbi.nlm.nih.gov/15013009

DMX85IF	DI	DMX85IF
DMX85IF	DN	7-bromo-6H-chromeno[4,3-b]quinoline-3,9-diol
DMX85IF	MI	TTPNQAC
DMX85IF	MN	Estrogen-related receptor-alpha (ESRRA)
DMX85IF	MT	DTT
DMX85IF	MA	Inhibitor
DMX85IF	RN	ERbeta ligands. Part 6: 6H-Chromeno[4,3-b]quinolines as a new series of estrogen receptor beta-selective ligands. Bioorg Med Chem Lett. 2007 Jul 15;17(14):4053-6.
DMX85IF	RU	https://pubmed.ncbi.nlm.nih.gov/17482813

DM3G8I7	DI	DM3G8I7
DM3G8I7	DN	7-bromoindirubin-3-acetoxime
DM3G8I7	MI	TTLYXIT
DM3G8I7	MN	Aurora kinase C (AURKC)
DM3G8I7	MT	DTT
DM3G8I7	MA	Inhibitor
DM3G8I7	RN	An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37.
DM3G8I7	RU	https://pubmed.ncbi.nlm.nih.gov/17665890

DM07QD3	DI	DM07QD3
DM07QD3	DN	7-bromoindirubin-3-oxime
DM07QD3	MI	TT9RTBL
DM07QD3	MN	Aurora B messenger RNA (AURKB mRNA)
DM07QD3	MT	DTT
DM07QD3	MA	Inhibitor
DM07QD3	RN	An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37.
DM07QD3	RU	https://pubmed.ncbi.nlm.nih.gov/17665890

DM07QD3	DI	DM07QD3
DM07QD3	DN	7-bromoindirubin-3-oxime
DM07QD3	MI	TTLYXIT
DM07QD3	MN	Aurora kinase C (AURKC)
DM07QD3	MT	DTT
DM07QD3	MA	Inhibitor
DM07QD3	RN	An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37.
DM07QD3	RU	https://pubmed.ncbi.nlm.nih.gov/17665890

DML8PH7	DI	DML8PH7
DML8PH7	DN	7-bromo-N-(3-bromophenyl)isoquinolin-1-amine
DML8PH7	MI	TTHS256
DML8PH7	MN	Metabotropic glutamate receptor 5 (mGluR5)
DML8PH7	MT	DTT
DML8PH7	MA	Inhibitor
DML8PH7	RN	Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6.
DML8PH7	RU	https://pubmed.ncbi.nlm.nih.gov/19854049

DM78C5A	DI	DM78C5A
DM78C5A	DN	7-butoxy-2H-chromen-2-one
DM78C5A	MI	TTUNARX
DM78C5A	MN	Carbonic anhydrase (CA)
DM78C5A	MT	DTT
DM78C5A	MA	Inhibitor
DM78C5A	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DM78C5A	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DM78C5A	DI	DM78C5A
DM78C5A	DN	7-butoxy-2H-chromen-2-one
DM78C5A	MI	TT2LVK8
DM78C5A	MN	Carbonic anhydrase IX (CA-IX)
DM78C5A	MT	DTT
DM78C5A	MA	Inhibitor
DM78C5A	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DM78C5A	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DM78C5A	DI	DM78C5A
DM78C5A	DN	7-butoxy-2H-chromen-2-one
DM78C5A	MI	TTCFSPE
DM78C5A	MN	Carbonic anhydrase VI (CA-VI)
DM78C5A	MT	DTT
DM78C5A	MA	Inhibitor
DM78C5A	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DM78C5A	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DM78C5A	DI	DM78C5A
DM78C5A	DN	7-butoxy-2H-chromen-2-one
DM78C5A	MI	TTSYM0R
DM78C5A	MN	Carbonic anhydrase XII (CA-XII)
DM78C5A	MT	DTT
DM78C5A	MA	Inhibitor
DM78C5A	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DM78C5A	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DM78C5A	DI	DM78C5A
DM78C5A	DN	7-butoxy-2H-chromen-2-one
DM78C5A	MI	TTEYTKG
DM78C5A	MN	Carbonic anhydrase XIV (CA-XIV)
DM78C5A	MT	DTT
DM78C5A	MA	Inhibitor
DM78C5A	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DM78C5A	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMQ8BIX	DI	DMQ8BIX
DMQ8BIX	DN	7-Butyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol
DMQ8BIX	MI	TTZAYWL
DMQ8BIX	MN	Estrogen receptor (ESR)
DMQ8BIX	MT	DTT
DMQ8BIX	MA	Inhibitor
DMQ8BIX	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMQ8BIX	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMQ8BIX	DI	DMQ8BIX
DMQ8BIX	DN	7-Butyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol
DMQ8BIX	MI	TTOM3J0
DMQ8BIX	MN	Estrogen receptor beta (ESR2)
DMQ8BIX	MT	DTT
DMQ8BIX	MA	Inhibitor
DMQ8BIX	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMQ8BIX	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMVTK0A	DI	DMVTK0A
DMVTK0A	DN	7-Butyl-azepan-(2Z)-ylideneamine
DMVTK0A	MI	TTZUFI5
DMVTK0A	MN	Nitric-oxide synthase brain (NOS1)
DMVTK0A	MT	DTT
DMVTK0A	MA	Inhibitor
DMVTK0A	RN	Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3.
DMVTK0A	RU	https://pubmed.ncbi.nlm.nih.gov/11551770

DMVTK0A	DI	DMVTK0A
DMVTK0A	DN	7-Butyl-azepan-(2Z)-ylideneamine
DMVTK0A	MI	TTF10I9
DMVTK0A	MN	Nitric-oxide synthase inducible (NOS2)
DMVTK0A	MT	DTT
DMVTK0A	MA	Inhibitor
DMVTK0A	RN	Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3.
DMVTK0A	RU	https://pubmed.ncbi.nlm.nih.gov/11551770

DM1SEXA	DI	DM1SEXA
DM1SEXA	DN	7-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamine
DM1SEXA	MI	TT1RS9F
DM1SEXA	MN	Acetylcholinesterase (AChE)
DM1SEXA	MT	DTT
DM1SEXA	MA	Inhibitor
DM1SEXA	RN	The synthesis and in vitro acetylcholinesterase and butyrylcholinesterase inhibitory activity of tacrine (Cognex ) derivaties, Bioorg. Med. Chem. Lett. 2(8):861-864 (1992).
DM1SEXA	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805454

DMP5JF8	DI	DMP5JF8
DMP5JF8	DN	7-Chloro-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole
DMP5JF8	MI	TTJQOD7
DMP5JF8	MN	5-HT 2A receptor (HTR2A)
DMP5JF8	MT	DTT
DMP5JF8	MA	Inhibitor
DMP5JF8	RN	Evaluation of isotryptamine derivatives at 5-HT(2) serotonin receptors. Bioorg Med Chem Lett. 2002 Jan 21;12(2):155-8.
DMP5JF8	RU	https://pubmed.ncbi.nlm.nih.gov/11755343

DMWUS5Q	DI	DMWUS5Q
DMWUS5Q	DN	7-Chloro-1,3-dihydro-imidazo[4,5-b]quinolin-2-one
DMWUS5Q	MI	TT06AWU
DMWUS5Q	MN	Phosphodiesterase 3A (PDE3A)
DMWUS5Q	MT	DTT
DMWUS5Q	MA	Inhibitor
DMWUS5Q	RN	1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-ones--inhibitors of blood platelet cAMP phosphodiesterase and induced aggregation. J Med Chem. 1991 Sep;34(9):2906-16.
DMWUS5Q	RU	https://pubmed.ncbi.nlm.nih.gov/1654430

DMPJWIB	DI	DMPJWIB
DMPJWIB	DN	7-chloro-1,3-dihydroxyacridone
DMPJWIB	MI	TT0IHXV
DMPJWIB	MN	DNA topoisomerase II (TOP2)
DMPJWIB	MT	DTT
DMPJWIB	MA	Inhibitor
DMPJWIB	RN	1,3-Dihydroxyacridone derivatives as inhibitors of herpes virus replication. Antiviral Res. 2000 Feb;45(2):123-34.
DMPJWIB	RU	https://pubmed.ncbi.nlm.nih.gov/10809021

DMX8DZM	DI	DMX8DZM
DMX8DZM	DN	7-chloro-1H-indazole
DMX8DZM	MI	TTZUFI5
DMX8DZM	MN	Nitric-oxide synthase brain (NOS1)
DMX8DZM	MT	DTT
DMX8DZM	MA	Inhibitor
DMX8DZM	RN	4-substituted indazoles as new inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3177-80.
DMX8DZM	RU	https://pubmed.ncbi.nlm.nih.gov/17395463

DMCZLKA	DI	DMCZLKA
DMCZLKA	DN	7-chloro-1H-indole-2,3-dione
DMCZLKA	MI	TTMF541
DMCZLKA	MN	Liver carboxylesterase (CES1)
DMCZLKA	MT	DTT
DMCZLKA	MA	Inhibitor
DMCZLKA	RN	Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85.
DMCZLKA	RU	https://pubmed.ncbi.nlm.nih.gov/17378546

DM38HKE	DI	DM38HKE
DM38HKE	DN	7-Chloro-2-(4-hydroxy-phenyl)-benzofuran-5-ol
DM38HKE	MI	TTZAYWL
DM38HKE	MN	Estrogen receptor (ESR)
DM38HKE	MT	DTT
DM38HKE	MA	Inhibitor
DM38HKE	RN	7-Substituted 2-phenyl-benzofurans as ER beta selective ligands. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4925-9.
DM38HKE	RU	https://pubmed.ncbi.nlm.nih.gov/15341953

DM38HKE	DI	DM38HKE
DM38HKE	DN	7-Chloro-2-(4-hydroxy-phenyl)-benzofuran-5-ol
DM38HKE	MI	TTOM3J0
DM38HKE	MN	Estrogen receptor beta (ESR2)
DM38HKE	MT	DTT
DM38HKE	MA	Inhibitor
DM38HKE	RN	7-Substituted 2-phenyl-benzofurans as ER beta selective ligands. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4925-9.
DM38HKE	RU	https://pubmed.ncbi.nlm.nih.gov/15341953

DM9TZH4	DI	DM9TZH4
DM9TZH4	DN	7-Chloro-2-phenyl-[1,8]naphthyridin-4-ol
DM9TZH4	MI	TTK25J1
DM9TZH4	MN	Adenosine A1 receptor (ADORA1)
DM9TZH4	MT	DTT
DM9TZH4	MA	Inhibitor
DM9TZH4	RN	Study on affinity profile toward native human and bovine adenosine receptors of a series of 1,8-naphthyridine derivatives. J Med Chem. 2004 Jun 3;47(12):3019-31.
DM9TZH4	RU	https://pubmed.ncbi.nlm.nih.gov/15163184

DM3OMLU	DI	DM3OMLU
DM3OMLU	DN	7-chloro-3-hydroxyquinazoline-2,4-dione
DM3OMLU	MI	TTAN6JD
DM3OMLU	MN	Glutamate receptor AMPA (GRIA)
DM3OMLU	MT	DTT
DM3OMLU	MA	Inhibitor
DM3OMLU	RN	Structural investigation of the 7-chloro-3-hydroxy-1H-quinazoline-2,4-dione scaffold to obtain AMPA and kainate receptor selective antagonists. Syn... J Med Chem. 2006 Oct 5;49(20):6015-26.
DM3OMLU	RU	https://pubmed.ncbi.nlm.nih.gov/17004715

DM3OMLU	DI	DM3OMLU
DM3OMLU	DN	7-chloro-3-hydroxyquinazoline-2,4-dione
DM3OMLU	MI	TTVPQTF
DM3OMLU	MN	Glutamate receptor AMPA 1 (GRIA1)
DM3OMLU	MT	DTT
DM3OMLU	MA	Inhibitor
DM3OMLU	RN	Structural investigation of the 7-chloro-3-hydroxy-1H-quinazoline-2,4-dione scaffold to obtain AMPA and kainate receptor selective antagonists. Syn... J Med Chem. 2006 Oct 5;49(20):6015-26.
DM3OMLU	RU	https://pubmed.ncbi.nlm.nih.gov/17004715

DM3OMLU	DI	DM3OMLU
DM3OMLU	DN	7-chloro-3-hydroxyquinazoline-2,4-dione
DM3OMLU	MI	TTLD29N
DM3OMLU	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DM3OMLU	MT	DTT
DM3OMLU	MA	Inhibitor
DM3OMLU	RN	Structural investigation of the 7-chloro-3-hydroxy-1H-quinazoline-2,4-dione scaffold to obtain AMPA and kainate receptor selective antagonists. Syn... J Med Chem. 2006 Oct 5;49(20):6015-26.
DM3OMLU	RU	https://pubmed.ncbi.nlm.nih.gov/17004715

DM3OMLU	DI	DM3OMLU
DM3OMLU	DN	7-chloro-3-hydroxyquinazoline-2,4-dione
DM3OMLU	MI	TTKJEMQ
DM3OMLU	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DM3OMLU	MT	DTT
DM3OMLU	MA	Inhibitor
DM3OMLU	RN	Structural investigation of the 7-chloro-3-hydroxy-1H-quinazoline-2,4-dione scaffold to obtain AMPA and kainate receptor selective antagonists. Syn... J Med Chem. 2006 Oct 5;49(20):6015-26.
DM3OMLU	RU	https://pubmed.ncbi.nlm.nih.gov/17004715

DM3OMLU	DI	DM3OMLU
DM3OMLU	DN	7-chloro-3-hydroxyquinazoline-2,4-dione
DM3OMLU	MI	TTN9D8E
DM3OMLU	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DM3OMLU	MT	DTT
DM3OMLU	MA	Inhibitor
DM3OMLU	RN	Structural investigation of the 7-chloro-3-hydroxy-1H-quinazoline-2,4-dione scaffold to obtain AMPA and kainate receptor selective antagonists. Syn... J Med Chem. 2006 Oct 5;49(20):6015-26.
DM3OMLU	RU	https://pubmed.ncbi.nlm.nih.gov/17004715

DM53A1R	DI	DM53A1R
DM53A1R	DN	7-Chloro-3-pyridin-4-yl-quinoline
DM53A1R	MI	TT8FYO9
DM53A1R	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DM53A1R	MT	DTT
DM53A1R	MA	Inhibitor
DM53A1R	RN	5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.
DM53A1R	RU	https://pubmed.ncbi.nlm.nih.gov/8064792

DM53A1R	DI	DM53A1R
DM53A1R	DN	7-Chloro-3-pyridin-4-yl-quinoline
DM53A1R	MI	TTI7421
DM53A1R	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM53A1R	MT	DTT
DM53A1R	MA	Inhibitor
DM53A1R	RN	5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.
DM53A1R	RU	https://pubmed.ncbi.nlm.nih.gov/8064792

DMRNZYQ	DI	DMRNZYQ
DMRNZYQ	DN	7-chloro-6H-chromeno[4,3-b]quinoline-3,9-diol
DMRNZYQ	MI	TTPNQAC
DMRNZYQ	MN	Estrogen-related receptor-alpha (ESRRA)
DMRNZYQ	MT	DTT
DMRNZYQ	MA	Inhibitor
DMRNZYQ	RN	ERbeta ligands. Part 6: 6H-Chromeno[4,3-b]quinolines as a new series of estrogen receptor beta-selective ligands. Bioorg Med Chem Lett. 2007 Jul 15;17(14):4053-6.
DMRNZYQ	RU	https://pubmed.ncbi.nlm.nih.gov/17482813

DM28NAB	DI	DM28NAB
DM28NAB	DN	7-chloroindirubin-3-oxime
DM28NAB	MI	TT9RTBL
DM28NAB	MN	Aurora B messenger RNA (AURKB mRNA)
DM28NAB	MT	DTT
DM28NAB	MA	Inhibitor
DM28NAB	RN	An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37.
DM28NAB	RU	https://pubmed.ncbi.nlm.nih.gov/17665890

DM28NAB	DI	DM28NAB
DM28NAB	DN	7-chloroindirubin-3-oxime
DM28NAB	MI	TTLYXIT
DM28NAB	MN	Aurora kinase C (AURKC)
DM28NAB	MT	DTT
DM28NAB	MA	Inhibitor
DM28NAB	RN	An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37.
DM28NAB	RU	https://pubmed.ncbi.nlm.nih.gov/17665890

DM2MIJY	DI	DM2MIJY
DM2MIJY	DN	7-Cyclopentyloxy-3-(4-hydroxyphenyl)chromen-4-one
DM2MIJY	MI	TTZAYWL
DM2MIJY	MN	Estrogen receptor (ESR)
DM2MIJY	MT	DTT
DM2MIJY	MA	Inhibitor
DM2MIJY	RN	Effects of 7-O substitutions on estrogenic and anti-estrogenic activities of daidzein analogues in MCF-7 breast cancer cells. J Med Chem. 2010 Aug 26;53(16):6153-63.
DM2MIJY	RU	https://pubmed.ncbi.nlm.nih.gov/20669983

DMANYSO	DI	DMANYSO
DMANYSO	DN	7-Diazonium-naphthalene-1-sulfonic acid anion
DMANYSO	MI	TTNJYV2
DMANYSO	MN	Gamma-aminobutyric acid receptor (GAR)
DMANYSO	MT	DTT
DMANYSO	MA	Inhibitor
DMANYSO	RN	Aryl diazo compounds and diazonium salts as potential irreversible probes of the gamma-aminobutyric acid receptor. J Med Chem. 1987 Dec;30(12):2222-7.
DMANYSO	RU	https://pubmed.ncbi.nlm.nih.gov/2824775

DMNEAU0	DI	DMNEAU0
DMNEAU0	DN	7-Dimethylamino-2-phenyl-[1,8]naphthyridin-4-ol
DMNEAU0	MI	TTK25J1
DMNEAU0	MN	Adenosine A1 receptor (ADORA1)
DMNEAU0	MT	DTT
DMNEAU0	MA	Inhibitor
DMNEAU0	RN	Study on affinity profile toward native human and bovine adenosine receptors of a series of 1,8-naphthyridine derivatives. J Med Chem. 2004 Jun 3;47(12):3019-31.
DMNEAU0	RU	https://pubmed.ncbi.nlm.nih.gov/15163184

DMDY2PQ	DI	DMDY2PQ
DMDY2PQ	DN	7-Dimethylamino-3-methyl-hept-5-yn-2-one
DMDY2PQ	MI	TTZ9SOR
DMDY2PQ	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMDY2PQ	MT	DTT
DMDY2PQ	MA	Inhibitor
DMDY2PQ	RN	Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992).
DMDY2PQ	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805351

DMDY2PQ	DI	DMDY2PQ
DMDY2PQ	DN	7-Dimethylamino-3-methyl-hept-5-yn-2-one
DMDY2PQ	MI	TTYEG6Q
DMDY2PQ	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMDY2PQ	MT	DTT
DMDY2PQ	MA	Inhibitor
DMDY2PQ	RN	Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992).
DMDY2PQ	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805351

DMDY2PQ	DI	DMDY2PQ
DMDY2PQ	DN	7-Dimethylamino-3-methyl-hept-5-yn-2-one
DMDY2PQ	MI	TTQ13Z5
DMDY2PQ	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMDY2PQ	MT	DTT
DMDY2PQ	MA	Inhibitor
DMDY2PQ	RN	Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992).
DMDY2PQ	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805351

DMDY2PQ	DI	DMDY2PQ
DMDY2PQ	DN	7-Dimethylamino-3-methyl-hept-5-yn-2-one
DMDY2PQ	MI	TTQ3JTF
DMDY2PQ	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DMDY2PQ	MT	DTT
DMDY2PQ	MA	Inhibitor
DMDY2PQ	RN	Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992).
DMDY2PQ	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805351

DMDY2PQ	DI	DMDY2PQ
DMDY2PQ	DN	7-Dimethylamino-3-methyl-hept-5-yn-2-one
DMDY2PQ	MI	TTH18TF
DMDY2PQ	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMDY2PQ	MT	DTT
DMDY2PQ	MA	Inhibitor
DMDY2PQ	RN	Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992).
DMDY2PQ	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805351

DMH782V	DI	DMH782V
DMH782V	DN	7-Dimethylamino-hept-5-yn-2-one
DMH782V	MI	TTZ9SOR
DMH782V	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMH782V	MT	DTT
DMH782V	MA	Inhibitor
DMH782V	RN	Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992).
DMH782V	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805351

DMH782V	DI	DMH782V
DMH782V	DN	7-Dimethylamino-hept-5-yn-2-one
DMH782V	MI	TTYEG6Q
DMH782V	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMH782V	MT	DTT
DMH782V	MA	Inhibitor
DMH782V	RN	Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992).
DMH782V	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805351

DMH782V	DI	DMH782V
DMH782V	DN	7-Dimethylamino-hept-5-yn-2-one
DMH782V	MI	TTQ13Z5
DMH782V	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMH782V	MT	DTT
DMH782V	MA	Inhibitor
DMH782V	RN	Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992).
DMH782V	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805351

DMH782V	DI	DMH782V
DMH782V	DN	7-Dimethylamino-hept-5-yn-2-one
DMH782V	MI	TTQ3JTF
DMH782V	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DMH782V	MT	DTT
DMH782V	MA	Inhibitor
DMH782V	RN	Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992).
DMH782V	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805351

DMH782V	DI	DMH782V
DMH782V	DN	7-Dimethylamino-hept-5-yn-2-one
DMH782V	MI	TTH18TF
DMH782V	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMH782V	MT	DTT
DMH782V	MA	Inhibitor
DMH782V	RN	Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992).
DMH782V	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805351

DMRAZDW	DI	DMRAZDW
DMRAZDW	DN	7-epi-ginkgolide C
DMRAZDW	MI	TTQL5VC
DMRAZDW	MN	Platelet-activating factor receptor (PTAFR)
DMRAZDW	MT	DTT
DMRAZDW	MA	Antagonist
DMRAZDW	RN	Preparation of 7-substituted ginkgolide derivatives: potent platelet activating factor (PAF) receptor antagonists. J Med Chem. 2003 Feb 13;46(4):601-8.
DMRAZDW	RU	https://pubmed.ncbi.nlm.nih.gov/12570381

DMI16MD	DI	DMI16MD
DMI16MD	DN	7-Ethoxy-1,3-dihydro-imidazo[4,5-b]quinolin-2-one
DMI16MD	MI	TT06AWU
DMI16MD	MN	Phosphodiesterase 3A (PDE3A)
DMI16MD	MT	DTT
DMI16MD	MA	Inhibitor
DMI16MD	RN	1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-ones--inhibitors of blood platelet cAMP phosphodiesterase and induced aggregation. J Med Chem. 1991 Sep;34(9):2906-16.
DMI16MD	RU	https://pubmed.ncbi.nlm.nih.gov/1654430

DMYJBPI	DI	DMYJBPI
DMYJBPI	DN	7-ethoxy-8-propionyl-2H-chromen-2-one
DMYJBPI	MI	TT2LVK8
DMYJBPI	MN	Carbonic anhydrase IX (CA-IX)
DMYJBPI	MT	DTT
DMYJBPI	MA	Inhibitor
DMYJBPI	RN	7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and X... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7255-8.
DMYJBPI	RU	https://pubmed.ncbi.nlm.nih.gov/21067924

DMUMN4B	DI	DMUMN4B
DMUMN4B	DN	7-Ethyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol
DMUMN4B	MI	TTZAYWL
DMUMN4B	MN	Estrogen receptor (ESR)
DMUMN4B	MT	DTT
DMUMN4B	MA	Inhibitor
DMUMN4B	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMUMN4B	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMUMN4B	DI	DMUMN4B
DMUMN4B	DN	7-Ethyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol
DMUMN4B	MI	TTOM3J0
DMUMN4B	MN	Estrogen receptor beta (ESR2)
DMUMN4B	MT	DTT
DMUMN4B	MA	Inhibitor
DMUMN4B	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMUMN4B	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMSFODU	DI	DMSFODU
DMSFODU	DN	7-ethyl-6H-chromeno[4,3-b]quinoline-3,9-diol
DMSFODU	MI	TTPNQAC
DMSFODU	MN	Estrogen-related receptor-alpha (ESRRA)
DMSFODU	MT	DTT
DMSFODU	MA	Inhibitor
DMSFODU	RN	ERbeta ligands. Part 6: 6H-Chromeno[4,3-b]quinolines as a new series of estrogen receptor beta-selective ligands. Bioorg Med Chem Lett. 2007 Jul 15;17(14):4053-6.
DMSFODU	RU	https://pubmed.ncbi.nlm.nih.gov/17482813

DMXM2G7	DI	DMXM2G7
DMXM2G7	DN	7-ethyloxyethoxy-2-morpholin-4-yl-chromen-4-one
DMXM2G7	MI	TTK3PY9
DMXM2G7	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMXM2G7	MT	DTT
DMXM2G7	MA	Inhibitor
DMXM2G7	RN	Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46.
DMXM2G7	RU	https://pubmed.ncbi.nlm.nih.gov/16302822

DM92EG5	DI	DM92EG5
DM92EG5	DN	7-Ethynyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol
DM92EG5	MI	TTZAYWL
DM92EG5	MN	Estrogen receptor (ESR)
DM92EG5	MT	DTT
DM92EG5	MA	Inhibitor
DM92EG5	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DM92EG5	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DM92EG5	DI	DM92EG5
DM92EG5	DN	7-Ethynyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol
DM92EG5	MI	TTOM3J0
DM92EG5	MN	Estrogen receptor beta (ESR2)
DM92EG5	MT	DTT
DM92EG5	MA	Inhibitor
DM92EG5	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DM92EG5	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMJWCAH	DI	DMJWCAH
DMJWCAH	DN	7-ethynyl-6H-chromeno[4,3-b]quinoline-3,9-diol
DMJWCAH	MI	TTPNQAC
DMJWCAH	MN	Estrogen-related receptor-alpha (ESRRA)
DMJWCAH	MT	DTT
DMJWCAH	MA	Inhibitor
DMJWCAH	RN	ERbeta ligands. Part 6: 6H-Chromeno[4,3-b]quinolines as a new series of estrogen receptor beta-selective ligands. Bioorg Med Chem Lett. 2007 Jul 15;17(14):4053-6.
DMJWCAH	RU	https://pubmed.ncbi.nlm.nih.gov/17482813

DMNRCDI	DI	DMNRCDI
DMNRCDI	DN	7-Fluoro-1,3-dihydro-imidazo[4,5-b]quinolin-2-one
DMNRCDI	MI	TT06AWU
DMNRCDI	MN	Phosphodiesterase 3A (PDE3A)
DMNRCDI	MT	DTT
DMNRCDI	MA	Inhibitor
DMNRCDI	RN	1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-ones--inhibitors of blood platelet cAMP phosphodiesterase and induced aggregation. J Med Chem. 1991 Sep;34(9):2906-16.
DMNRCDI	RU	https://pubmed.ncbi.nlm.nih.gov/1654430

DM4HJZI	DI	DM4HJZI
DM4HJZI	DN	7-fluoro-2-(4-fluorophenyl)-4H-chromene-4-thione
DM4HJZI	MI	TTGP7BY
DM4HJZI	MN	Monoamine oxidase type B (MAO-B)
DM4HJZI	MT	DTT
DM4HJZI	MA	Inhibitor
DM4HJZI	RN	A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9.
DM4HJZI	RU	https://pubmed.ncbi.nlm.nih.gov/20045650

DMUPXBJ	DI	DMUPXBJ
DMUPXBJ	DN	7-fluoro-2-(4-methoxyphenyl)-4H-chromen-4-one
DMUPXBJ	MI	TTGP7BY
DMUPXBJ	MN	Monoamine oxidase type B (MAO-B)
DMUPXBJ	MT	DTT
DMUPXBJ	MA	Inhibitor
DMUPXBJ	RN	A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9.
DMUPXBJ	RU	https://pubmed.ncbi.nlm.nih.gov/20045650

DMFOU8G	DI	DMFOU8G
DMFOU8G	DN	7-fluoro-2-p-tolyl-4H-chromen-4-one
DMFOU8G	MI	TTGP7BY
DMFOU8G	MN	Monoamine oxidase type B (MAO-B)
DMFOU8G	MT	DTT
DMFOU8G	MA	Inhibitor
DMFOU8G	RN	A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9.
DMFOU8G	RU	https://pubmed.ncbi.nlm.nih.gov/20045650

DMJFXKA	DI	DMJFXKA
DMJFXKA	DN	7-fluoro-2-p-tolyl-4H-chromene-4-thione
DMJFXKA	MI	TTGP7BY
DMJFXKA	MN	Monoamine oxidase type B (MAO-B)
DMJFXKA	MT	DTT
DMJFXKA	MA	Inhibitor
DMJFXKA	RN	A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9.
DMJFXKA	RU	https://pubmed.ncbi.nlm.nih.gov/20045650

DM0QI8V	DI	DM0QI8V
DM0QI8V	DN	7-Fluoro-3-thiophen-3-yl-quinoline
DM0QI8V	MI	TT8FYO9
DM0QI8V	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DM0QI8V	MT	DTT
DM0QI8V	MA	Inhibitor
DM0QI8V	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DM0QI8V	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DM0QI8V	DI	DM0QI8V
DM0QI8V	DN	7-Fluoro-3-thiophen-3-yl-quinoline
DM0QI8V	MI	TTI7421
DM0QI8V	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM0QI8V	MT	DTT
DM0QI8V	MA	Inhibitor
DM0QI8V	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DM0QI8V	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMQ2ZTJ	DI	DMQ2ZTJ
DMQ2ZTJ	DN	7-fluorochromone-2-carboxamide
DMQ2ZTJ	MI	TTX4RTB
DMQ2ZTJ	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMQ2ZTJ	MT	DTT
DMQ2ZTJ	MA	Antagonist
DMQ2ZTJ	RN	Optimization of chromone-2-carboxamide melanin concentrating hormone receptor 1 antagonists: assessment of potency, efficacy, and cardiovascular safety. J Med Chem. 2006 Nov 2;49(22):6569-84.
DMQ2ZTJ	RU	https://pubmed.ncbi.nlm.nih.gov/17064075

DM70I3V	DI	DM70I3V
DM70I3V	DN	7-fluoroindirubin-3-acetoxime
DM70I3V	MI	TT9RTBL
DM70I3V	MN	Aurora B messenger RNA (AURKB mRNA)
DM70I3V	MT	DTT
DM70I3V	MA	Inhibitor
DM70I3V	RN	An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37.
DM70I3V	RU	https://pubmed.ncbi.nlm.nih.gov/17665890

DM70I3V	DI	DM70I3V
DM70I3V	DN	7-fluoroindirubin-3-acetoxime
DM70I3V	MI	TTLYXIT
DM70I3V	MN	Aurora kinase C (AURKC)
DM70I3V	MT	DTT
DM70I3V	MA	Inhibitor
DM70I3V	RN	An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37.
DM70I3V	RU	https://pubmed.ncbi.nlm.nih.gov/17665890

DMQD34N	DI	DMQD34N
DMQD34N	DN	7-fluoroindirubin-3-oxime
DMQD34N	MI	TT9RTBL
DMQD34N	MN	Aurora B messenger RNA (AURKB mRNA)
DMQD34N	MT	DTT
DMQD34N	MA	Inhibitor
DMQD34N	RN	An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37.
DMQD34N	RU	https://pubmed.ncbi.nlm.nih.gov/17665890

DMQD34N	DI	DMQD34N
DMQD34N	DN	7-fluoroindirubin-3-oxime
DMQD34N	MI	TTPS3C0
DMQD34N	MN	Aurora kinase A (AURKA)
DMQD34N	MT	DTT
DMQD34N	MA	Inhibitor
DMQD34N	RN	An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37.
DMQD34N	RU	https://pubmed.ncbi.nlm.nih.gov/17665890

DMQD34N	DI	DMQD34N
DMQD34N	DN	7-fluoroindirubin-3-oxime
DMQD34N	MI	TTLYXIT
DMQD34N	MN	Aurora kinase C (AURKC)
DMQD34N	MT	DTT
DMQD34N	MA	Inhibitor
DMQD34N	RN	An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37.
DMQD34N	RU	https://pubmed.ncbi.nlm.nih.gov/17665890

DMEGSZD	DI	DMEGSZD
DMEGSZD	DN	7H-Pyrrolo[3,2-f]quinazoline-1,3-diamine
DMEGSZD	MI	TT9SL3Q
DMEGSZD	MN	Polypeptide deformylase (PDF)
DMEGSZD	MT	DTT
DMEGSZD	MA	Inhibitor
DMEGSZD	RN	High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines w... J Med Chem. 1996 Feb 16;39(4):892-903.
DMEGSZD	RU	https://pubmed.ncbi.nlm.nih.gov/8632413

DMKSJE3	DI	DMKSJE3
DMKSJE3	DN	7-hydroxy-1,2,9,9a-tetrahydrofluoren-3-one
DMKSJE3	MI	TTOM3J0
DMKSJE3	MN	Estrogen receptor beta (ESR2)
DMKSJE3	MT	DTT
DMKSJE3	MA	Inhibitor
DMKSJE3	RN	The discovery of tetrahydrofluorenones as a new class of estrogen receptor beta-subtype selective ligands. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3489-94.
DMKSJE3	RU	https://pubmed.ncbi.nlm.nih.gov/16632357

DMXBUNV	DI	DMXBUNV
DMXBUNV	DN	7-hydroxy-2-(3-hydroxyphenyl)chroman-4-one
DMXBUNV	MI	TTSZLWK
DMXBUNV	MN	Aromatase (CYP19A1)
DMXBUNV	MT	DTT
DMXBUNV	MA	Inhibitor
DMXBUNV	RN	New 7,8-benzoflavanones as potent aromatase inhibitors: synthesis and biological evaluation. Bioorg Med Chem. 2008 Feb 1;16(3):1474-80.
DMXBUNV	RU	https://pubmed.ncbi.nlm.nih.gov/18042388

DMCB2IM	DI	DMCB2IM
DMCB2IM	DN	7-Hydroxy-2-(4-hydroxy-benzyl)-chromen-4-one
DMCB2IM	MI	TTFBNVI
DMCB2IM	MN	Aldose reductase (AKR1B1)
DMCB2IM	MT	DTT
DMCB2IM	MA	Inhibitor
DMCB2IM	RN	1-Benzopyran-4-one antioxidants as aldose reductase inhibitors. J Med Chem. 1999 Jun 3;42(11):1881-93.
DMCB2IM	RU	https://pubmed.ncbi.nlm.nih.gov/10354396

DM2BV6P	DI	DM2BV6P
DM2BV6P	DN	7-Hydroxy-2-(4-methoxy-benzyl)-chromen-4-one
DM2BV6P	MI	TTFBNVI
DM2BV6P	MN	Aldose reductase (AKR1B1)
DM2BV6P	MT	DTT
DM2BV6P	MA	Inhibitor
DM2BV6P	RN	1-Benzopyran-4-one antioxidants as aldose reductase inhibitors. J Med Chem. 1999 Jun 3;42(11):1881-93.
DM2BV6P	RU	https://pubmed.ncbi.nlm.nih.gov/10354396

DMIKSTL	DI	DMIKSTL
DMIKSTL	DN	7-hydroxy-2-(morpholin-4-yl)chromen-4-one
DMIKSTL	MI	TTK3PY9
DMIKSTL	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMIKSTL	MT	DTT
DMIKSTL	MA	Inhibitor
DMIKSTL	RN	Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46.
DMIKSTL	RU	https://pubmed.ncbi.nlm.nih.gov/16302822

DM4UW65	DI	DM4UW65
DM4UW65	DN	7-hydroxy-2-phenylchroman-4-one
DM4UW65	MI	TTSZLWK
DM4UW65	MN	Aromatase (CYP19A1)
DM4UW65	MT	DTT
DM4UW65	MA	Inhibitor
DM4UW65	RN	New 7,8-benzoflavanones as potent aromatase inhibitors: synthesis and biological evaluation. Bioorg Med Chem. 2008 Feb 1;16(3):1474-80.
DM4UW65	RU	https://pubmed.ncbi.nlm.nih.gov/18042388

DMS2NZA	DI	DMS2NZA
DMS2NZA	DN	7-Hydroxy-3-(3-hydroxyphenyl)-1-naphthonitrile
DMS2NZA	MI	TTIWB6L
DMS2NZA	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMS2NZA	MT	DTT
DMS2NZA	MA	Inhibitor
DMS2NZA	RN	Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design,... J Med Chem. 2008 Aug 14;51(15):4685-98.
DMS2NZA	RU	https://pubmed.ncbi.nlm.nih.gov/18630892

DM46J2H	DI	DM46J2H
DM46J2H	DN	7-hydroxy-3-(4-hydroxyphenyl)-3H-quinazolin-4-one
DM46J2H	MI	TTOM3J0
DM46J2H	MN	Estrogen receptor beta (ESR2)
DM46J2H	MT	DTT
DM46J2H	MA	Inhibitor
DM46J2H	RN	Synthesis and characterization of 3-arylquinazolinone and 3-arylquinazolinethione derivatives as selective estrogen receptor beta modulators. J Med Chem. 2006 Apr 20;49(8):2440-55.
DM46J2H	RU	https://pubmed.ncbi.nlm.nih.gov/16610787

DM2ZE8U	DI	DM2ZE8U
DM2ZE8U	DN	7-hydroxy-3-phenyl-2H-chromen-2-one
DM2ZE8U	MI	TT6804T
DM2ZE8U	MN	MIF messenger RNA (MIF mRNA)
DM2ZE8U	MT	DTT
DM2ZE8U	MA	Inhibitor
DM2ZE8U	RN	Discovery of human macrophage migration inhibitory factor (MIF)-CD74 antagonists via virtual screening. J Med Chem. 2009 Jan 22;52(2):416-24.
DM2ZE8U	RU	https://pubmed.ncbi.nlm.nih.gov/19090668

DM3T612	DI	DM3T612
DM3T612	DN	7-Hydroxy-4-phenylcoumarin
DM3T612	MI	TTFBNVI
DM3T612	MN	Aldose reductase (AKR1B1)
DM3T612	MT	DTT
DM3T612	MA	Inhibitor
DM3T612	RN	6,7-Dihydroxy-4-phenylcoumarin as inhibitor of aldose reductase 2. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5630-3.
DM3T612	RU	https://pubmed.ncbi.nlm.nih.gov/20805028

DM49RWY	DI	DM49RWY
DM49RWY	DN	7-Hydroxy-6-nitro-2-phenyl-chromen-4-one
DM49RWY	MI	TTFBNVI
DM49RWY	MN	Aldose reductase (AKR1B1)
DM49RWY	MT	DTT
DM49RWY	MA	Inhibitor
DM49RWY	RN	1-Benzopyran-4-one antioxidants as aldose reductase inhibitors. J Med Chem. 1999 Jun 3;42(11):1881-93.
DM49RWY	RU	https://pubmed.ncbi.nlm.nih.gov/10354396

DMQ3RVK	DI	DMQ3RVK
DMQ3RVK	DN	7-hydroxy-6-propionyl-2H-chromen-2-one
DMQ3RVK	MI	TT2LVK8
DMQ3RVK	MN	Carbonic anhydrase IX (CA-IX)
DMQ3RVK	MT	DTT
DMQ3RVK	MA	Inhibitor
DMQ3RVK	RN	7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and X... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7255-8.
DMQ3RVK	RU	https://pubmed.ncbi.nlm.nih.gov/21067924

DMFKSMW	DI	DMFKSMW
DMFKSMW	DN	7-hydroxy-8-propionyl-2H-chromen-2-one
DMFKSMW	MI	TT2LVK8
DMFKSMW	MN	Carbonic anhydrase IX (CA-IX)
DMFKSMW	MT	DTT
DMFKSMW	MA	Inhibitor
DMFKSMW	RN	7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and X... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7255-8.
DMFKSMW	RU	https://pubmed.ncbi.nlm.nih.gov/21067924

DMZXMB7	DI	DMZXMB7
DMZXMB7	DN	7-hydroxycholesterol
DMZXMB7	MI	TT1TYN7
DMZXMB7	MN	Nuclear receptor ROR-alpha (RORA)
DMZXMB7	MT	DTT
DMZXMB7	MA	Agonist
DMZXMB7	RN	Identification of natural ligands of retinoic acid receptor-related orphan receptor alpha ligand-binding domain expressed in Sf9 cells--a mass spectrometry approach. Anal Biochem. 2003 Dec 1;323(1):139-49.
DMZXMB7	RU	https://pubmed.ncbi.nlm.nih.gov/14622968

DMV0PT8	DI	DMV0PT8
DMV0PT8	DN	7-hydroxycostunolide
DMV0PT8	MI	TTSXVID
DMV0PT8	MN	Nuclear factor NF-kappa-B (NFKB)
DMV0PT8	MT	DTT
DMV0PT8	MA	Inhibitor
DMV0PT8	RN	Development of a structural model for NF-kappaB inhibition of sesquiterpene lactones using self-organizing neural networks. J Med Chem. 2006 Apr 6;49(7):2241-52.
DMV0PT8	RU	https://pubmed.ncbi.nlm.nih.gov/16570920

DMTMNO7	DI	DMTMNO7
DMTMNO7	DN	7-hydroxycoumarin
DMTMNO7	MI	TT2LVK8
DMTMNO7	MN	Carbonic anhydrase IX (CA-IX)
DMTMNO7	MT	DTT
DMTMNO7	MA	Inhibitor
DMTMNO7	RN	7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and X... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7255-8.
DMTMNO7	RU	https://pubmed.ncbi.nlm.nih.gov/21067924

DMTMNO7	DI	DMTMNO7
DMTMNO7	DN	7-hydroxycoumarin
DMTMNO7	MI	TTFCJ7S
DMTMNO7	MN	G1/S-specific cyclin-D1 (CCND1)
DMTMNO7	MT	DTT
DMTMNO7	MA	Inhibitor
DMTMNO7	RN	Decrease of cyclin D1 in the human lung adenocarcinoma cell line A-427 by 7-hydroxycoumarin. Lung Cancer. 2001 Nov;34(2):185-94.
DMTMNO7	RU	https://pubmed.ncbi.nlm.nih.gov/11679177

DMV39XT	DI	DMV39XT
DMV39XT	DN	7-Hydroxy-Pyrazolo[4,3-D]Pyrimidine
DMV39XT	MI	TTBL49X
DMV39XT	MN	Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ)
DMV39XT	MT	DTT
DMV39XT	MA	Inhibitor
DMV39XT	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMV39XT	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DM6K5NF	DI	DM6K5NF
DM6K5NF	DN	7-Iodo-1,5-dihydro-imidazo[2,1-b]quinazolin-2-one
DM6K5NF	MI	TT06AWU
DM6K5NF	MN	Phosphodiesterase 3A (PDE3A)
DM6K5NF	MT	DTT
DM6K5NF	MA	Inhibitor
DM6K5NF	RN	Inhibitors of cyclic AMP phosphodiesterase. 3. Synthesis and biological evaluation of pyrido and imidazolyl analogues of 1,2,3,5-tetrahydro-2-oxoim... J Med Chem. 1988 Nov;31(11):2136-45.
DM6K5NF	RU	https://pubmed.ncbi.nlm.nih.gov/2846839

DMNFI02	DI	DMNFI02
DMNFI02	DN	7-iodoindirubin-3-oxime
DMNFI02	MI	TT9RTBL
DMNFI02	MN	Aurora B messenger RNA (AURKB mRNA)
DMNFI02	MT	DTT
DMNFI02	MA	Inhibitor
DMNFI02	RN	An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37.
DMNFI02	RU	https://pubmed.ncbi.nlm.nih.gov/17665890

DMNFI02	DI	DMNFI02
DMNFI02	DN	7-iodoindirubin-3-oxime
DMNFI02	MI	TTLYXIT
DMNFI02	MN	Aurora kinase C (AURKC)
DMNFI02	MT	DTT
DMNFI02	MA	Inhibitor
DMNFI02	RN	An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37.
DMNFI02	RU	https://pubmed.ncbi.nlm.nih.gov/17665890

DMVSF0O	DI	DMVSF0O
DMVSF0O	DN	7-Isopropyl-7H-adenine
DMVSF0O	MI	TTM2AOE
DMVSF0O	MN	Adenosine A2a receptor (ADORA2A)
DMVSF0O	MT	DTT
DMVSF0O	MA	Inhibitor
DMVSF0O	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMVSF0O	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMPYTHV	DI	DMPYTHV
DMPYTHV	DN	7-Mercapto-heptanoic acid benzothiazol-2-ylamide
DMPYTHV	MI	TTBH0VX
DMPYTHV	MN	Histone deacetylase (HDAC)
DMPYTHV	MT	DTT
DMPYTHV	MA	Inhibitor
DMPYTHV	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMPYTHV	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMPYTHV	DI	DMPYTHV
DMPYTHV	DN	7-Mercapto-heptanoic acid benzothiazol-2-ylamide
DMPYTHV	MI	TT6R7JZ
DMPYTHV	MN	Histone deacetylase 1 (HDAC1)
DMPYTHV	MT	DTT
DMPYTHV	MA	Inhibitor
DMPYTHV	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMPYTHV	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMPYTHV	DI	DMPYTHV
DMPYTHV	DN	7-Mercapto-heptanoic acid benzothiazol-2-ylamide
DMPYTHV	MI	TTYHPU6
DMPYTHV	MN	Histone deacetylase 10 (HDAC10)
DMPYTHV	MT	DTT
DMPYTHV	MA	Inhibitor
DMPYTHV	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMPYTHV	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMPYTHV	DI	DMPYTHV
DMPYTHV	DN	7-Mercapto-heptanoic acid benzothiazol-2-ylamide
DMPYTHV	MI	TTSHTOI
DMPYTHV	MN	Histone deacetylase 2 (HDAC2)
DMPYTHV	MT	DTT
DMPYTHV	MA	Inhibitor
DMPYTHV	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMPYTHV	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMPYTHV	DI	DMPYTHV
DMPYTHV	DN	7-Mercapto-heptanoic acid benzothiazol-2-ylamide
DMPYTHV	MI	TTTQGH8
DMPYTHV	MN	Histone deacetylase 4 (HDAC4)
DMPYTHV	MT	DTT
DMPYTHV	MA	Inhibitor
DMPYTHV	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMPYTHV	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMPYTHV	DI	DMPYTHV
DMPYTHV	DN	7-Mercapto-heptanoic acid benzothiazol-2-ylamide
DMPYTHV	MI	TT5ZKDI
DMPYTHV	MN	Histone deacetylase 6 (HDAC6)
DMPYTHV	MT	DTT
DMPYTHV	MA	Inhibitor
DMPYTHV	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMPYTHV	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMPYTHV	DI	DMPYTHV
DMPYTHV	DN	7-Mercapto-heptanoic acid benzothiazol-2-ylamide
DMPYTHV	MI	TTT6LFV
DMPYTHV	MN	Histone deacetylase 8 (HDAC8)
DMPYTHV	MT	DTT
DMPYTHV	MA	Inhibitor
DMPYTHV	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMPYTHV	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMEQKPO	DI	DMEQKPO
DMEQKPO	DN	7-Mercapto-heptanoic acid biphenyl-3-ylamide
DMEQKPO	MI	TTBH0VX
DMEQKPO	MN	Histone deacetylase (HDAC)
DMEQKPO	MT	DTT
DMEQKPO	MA	Inhibitor
DMEQKPO	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMEQKPO	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMEQKPO	DI	DMEQKPO
DMEQKPO	DN	7-Mercapto-heptanoic acid biphenyl-3-ylamide
DMEQKPO	MI	TT6R7JZ
DMEQKPO	MN	Histone deacetylase 1 (HDAC1)
DMEQKPO	MT	DTT
DMEQKPO	MA	Inhibitor
DMEQKPO	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMEQKPO	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMEQKPO	DI	DMEQKPO
DMEQKPO	DN	7-Mercapto-heptanoic acid biphenyl-3-ylamide
DMEQKPO	MI	TTYHPU6
DMEQKPO	MN	Histone deacetylase 10 (HDAC10)
DMEQKPO	MT	DTT
DMEQKPO	MA	Inhibitor
DMEQKPO	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMEQKPO	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMEQKPO	DI	DMEQKPO
DMEQKPO	DN	7-Mercapto-heptanoic acid biphenyl-3-ylamide
DMEQKPO	MI	TTSHTOI
DMEQKPO	MN	Histone deacetylase 2 (HDAC2)
DMEQKPO	MT	DTT
DMEQKPO	MA	Inhibitor
DMEQKPO	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMEQKPO	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMEQKPO	DI	DMEQKPO
DMEQKPO	DN	7-Mercapto-heptanoic acid biphenyl-3-ylamide
DMEQKPO	MI	TTTQGH8
DMEQKPO	MN	Histone deacetylase 4 (HDAC4)
DMEQKPO	MT	DTT
DMEQKPO	MA	Inhibitor
DMEQKPO	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMEQKPO	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMEQKPO	DI	DMEQKPO
DMEQKPO	DN	7-Mercapto-heptanoic acid biphenyl-3-ylamide
DMEQKPO	MI	TT5ZKDI
DMEQKPO	MN	Histone deacetylase 6 (HDAC6)
DMEQKPO	MT	DTT
DMEQKPO	MA	Inhibitor
DMEQKPO	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMEQKPO	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMEQKPO	DI	DMEQKPO
DMEQKPO	DN	7-Mercapto-heptanoic acid biphenyl-3-ylamide
DMEQKPO	MI	TTT6LFV
DMEQKPO	MN	Histone deacetylase 8 (HDAC8)
DMEQKPO	MT	DTT
DMEQKPO	MA	Inhibitor
DMEQKPO	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMEQKPO	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMJMOUK	DI	DMJMOUK
DMJMOUK	DN	7-Mercapto-heptanoic acid biphenyl-4-ylamide
DMJMOUK	MI	TTBH0VX
DMJMOUK	MN	Histone deacetylase (HDAC)
DMJMOUK	MT	DTT
DMJMOUK	MA	Inhibitor
DMJMOUK	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMJMOUK	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMJMOUK	DI	DMJMOUK
DMJMOUK	DN	7-Mercapto-heptanoic acid biphenyl-4-ylamide
DMJMOUK	MI	TT6R7JZ
DMJMOUK	MN	Histone deacetylase 1 (HDAC1)
DMJMOUK	MT	DTT
DMJMOUK	MA	Inhibitor
DMJMOUK	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMJMOUK	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMJMOUK	DI	DMJMOUK
DMJMOUK	DN	7-Mercapto-heptanoic acid biphenyl-4-ylamide
DMJMOUK	MI	TTYHPU6
DMJMOUK	MN	Histone deacetylase 10 (HDAC10)
DMJMOUK	MT	DTT
DMJMOUK	MA	Inhibitor
DMJMOUK	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMJMOUK	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMJMOUK	DI	DMJMOUK
DMJMOUK	DN	7-Mercapto-heptanoic acid biphenyl-4-ylamide
DMJMOUK	MI	TTSHTOI
DMJMOUK	MN	Histone deacetylase 2 (HDAC2)
DMJMOUK	MT	DTT
DMJMOUK	MA	Inhibitor
DMJMOUK	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMJMOUK	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMJMOUK	DI	DMJMOUK
DMJMOUK	DN	7-Mercapto-heptanoic acid biphenyl-4-ylamide
DMJMOUK	MI	TTTQGH8
DMJMOUK	MN	Histone deacetylase 4 (HDAC4)
DMJMOUK	MT	DTT
DMJMOUK	MA	Inhibitor
DMJMOUK	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMJMOUK	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMJMOUK	DI	DMJMOUK
DMJMOUK	DN	7-Mercapto-heptanoic acid biphenyl-4-ylamide
DMJMOUK	MI	TT5ZKDI
DMJMOUK	MN	Histone deacetylase 6 (HDAC6)
DMJMOUK	MT	DTT
DMJMOUK	MA	Inhibitor
DMJMOUK	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMJMOUK	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMJMOUK	DI	DMJMOUK
DMJMOUK	DN	7-Mercapto-heptanoic acid biphenyl-4-ylamide
DMJMOUK	MI	TTT6LFV
DMJMOUK	MN	Histone deacetylase 8 (HDAC8)
DMJMOUK	MT	DTT
DMJMOUK	MA	Inhibitor
DMJMOUK	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMJMOUK	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DM4912P	DI	DM4912P
DM4912P	DN	7-Mercapto-heptanoic acid phenylamide
DM4912P	MI	TTBH0VX
DM4912P	MN	Histone deacetylase (HDAC)
DM4912P	MT	DTT
DM4912P	MA	Inhibitor
DM4912P	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DM4912P	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DM4912P	DI	DM4912P
DM4912P	DN	7-Mercapto-heptanoic acid phenylamide
DM4912P	MI	TT6R7JZ
DM4912P	MN	Histone deacetylase 1 (HDAC1)
DM4912P	MT	DTT
DM4912P	MA	Inhibitor
DM4912P	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DM4912P	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DM4912P	DI	DM4912P
DM4912P	DN	7-Mercapto-heptanoic acid phenylamide
DM4912P	MI	TTYHPU6
DM4912P	MN	Histone deacetylase 10 (HDAC10)
DM4912P	MT	DTT
DM4912P	MA	Inhibitor
DM4912P	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DM4912P	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DM4912P	DI	DM4912P
DM4912P	DN	7-Mercapto-heptanoic acid phenylamide
DM4912P	MI	TTSHTOI
DM4912P	MN	Histone deacetylase 2 (HDAC2)
DM4912P	MT	DTT
DM4912P	MA	Inhibitor
DM4912P	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DM4912P	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DM4912P	DI	DM4912P
DM4912P	DN	7-Mercapto-heptanoic acid phenylamide
DM4912P	MI	TTTQGH8
DM4912P	MN	Histone deacetylase 4 (HDAC4)
DM4912P	MT	DTT
DM4912P	MA	Inhibitor
DM4912P	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DM4912P	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DM4912P	DI	DM4912P
DM4912P	DN	7-Mercapto-heptanoic acid phenylamide
DM4912P	MI	TT5ZKDI
DM4912P	MN	Histone deacetylase 6 (HDAC6)
DM4912P	MT	DTT
DM4912P	MA	Inhibitor
DM4912P	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DM4912P	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DM4912P	DI	DM4912P
DM4912P	DN	7-Mercapto-heptanoic acid phenylamide
DM4912P	MI	TTT6LFV
DM4912P	MN	Histone deacetylase 8 (HDAC8)
DM4912P	MT	DTT
DM4912P	MA	Inhibitor
DM4912P	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DM4912P	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMQ9PLA	DI	DMQ9PLA
DMQ9PLA	DN	7-Mercapto-heptanoic acid pyridin-3-ylamide
DMQ9PLA	MI	TTBH0VX
DMQ9PLA	MN	Histone deacetylase (HDAC)
DMQ9PLA	MT	DTT
DMQ9PLA	MA	Inhibitor
DMQ9PLA	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMQ9PLA	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMQ9PLA	DI	DMQ9PLA
DMQ9PLA	DN	7-Mercapto-heptanoic acid pyridin-3-ylamide
DMQ9PLA	MI	TT6R7JZ
DMQ9PLA	MN	Histone deacetylase 1 (HDAC1)
DMQ9PLA	MT	DTT
DMQ9PLA	MA	Inhibitor
DMQ9PLA	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMQ9PLA	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMQ9PLA	DI	DMQ9PLA
DMQ9PLA	DN	7-Mercapto-heptanoic acid pyridin-3-ylamide
DMQ9PLA	MI	TTYHPU6
DMQ9PLA	MN	Histone deacetylase 10 (HDAC10)
DMQ9PLA	MT	DTT
DMQ9PLA	MA	Inhibitor
DMQ9PLA	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMQ9PLA	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMQ9PLA	DI	DMQ9PLA
DMQ9PLA	DN	7-Mercapto-heptanoic acid pyridin-3-ylamide
DMQ9PLA	MI	TTSHTOI
DMQ9PLA	MN	Histone deacetylase 2 (HDAC2)
DMQ9PLA	MT	DTT
DMQ9PLA	MA	Inhibitor
DMQ9PLA	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMQ9PLA	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMQ9PLA	DI	DMQ9PLA
DMQ9PLA	DN	7-Mercapto-heptanoic acid pyridin-3-ylamide
DMQ9PLA	MI	TTTQGH8
DMQ9PLA	MN	Histone deacetylase 4 (HDAC4)
DMQ9PLA	MT	DTT
DMQ9PLA	MA	Inhibitor
DMQ9PLA	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMQ9PLA	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMQ9PLA	DI	DMQ9PLA
DMQ9PLA	DN	7-Mercapto-heptanoic acid pyridin-3-ylamide
DMQ9PLA	MI	TT5ZKDI
DMQ9PLA	MN	Histone deacetylase 6 (HDAC6)
DMQ9PLA	MT	DTT
DMQ9PLA	MA	Inhibitor
DMQ9PLA	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMQ9PLA	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMQ9PLA	DI	DMQ9PLA
DMQ9PLA	DN	7-Mercapto-heptanoic acid pyridin-3-ylamide
DMQ9PLA	MI	TTT6LFV
DMQ9PLA	MN	Histone deacetylase 8 (HDAC8)
DMQ9PLA	MT	DTT
DMQ9PLA	MA	Inhibitor
DMQ9PLA	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMQ9PLA	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMTAGJ1	DI	DMTAGJ1
DMTAGJ1	DN	7-Mercapto-heptanoic acid quinolin-3-ylamide
DMTAGJ1	MI	TTBH0VX
DMTAGJ1	MN	Histone deacetylase (HDAC)
DMTAGJ1	MT	DTT
DMTAGJ1	MA	Inhibitor
DMTAGJ1	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMTAGJ1	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMTAGJ1	DI	DMTAGJ1
DMTAGJ1	DN	7-Mercapto-heptanoic acid quinolin-3-ylamide
DMTAGJ1	MI	TT6R7JZ
DMTAGJ1	MN	Histone deacetylase 1 (HDAC1)
DMTAGJ1	MT	DTT
DMTAGJ1	MA	Inhibitor
DMTAGJ1	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMTAGJ1	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMTAGJ1	DI	DMTAGJ1
DMTAGJ1	DN	7-Mercapto-heptanoic acid quinolin-3-ylamide
DMTAGJ1	MI	TTYHPU6
DMTAGJ1	MN	Histone deacetylase 10 (HDAC10)
DMTAGJ1	MT	DTT
DMTAGJ1	MA	Inhibitor
DMTAGJ1	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMTAGJ1	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMTAGJ1	DI	DMTAGJ1
DMTAGJ1	DN	7-Mercapto-heptanoic acid quinolin-3-ylamide
DMTAGJ1	MI	TTSHTOI
DMTAGJ1	MN	Histone deacetylase 2 (HDAC2)
DMTAGJ1	MT	DTT
DMTAGJ1	MA	Inhibitor
DMTAGJ1	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMTAGJ1	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMTAGJ1	DI	DMTAGJ1
DMTAGJ1	DN	7-Mercapto-heptanoic acid quinolin-3-ylamide
DMTAGJ1	MI	TTTQGH8
DMTAGJ1	MN	Histone deacetylase 4 (HDAC4)
DMTAGJ1	MT	DTT
DMTAGJ1	MA	Inhibitor
DMTAGJ1	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMTAGJ1	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMTAGJ1	DI	DMTAGJ1
DMTAGJ1	DN	7-Mercapto-heptanoic acid quinolin-3-ylamide
DMTAGJ1	MI	TT5ZKDI
DMTAGJ1	MN	Histone deacetylase 6 (HDAC6)
DMTAGJ1	MT	DTT
DMTAGJ1	MA	Inhibitor
DMTAGJ1	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMTAGJ1	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMTAGJ1	DI	DMTAGJ1
DMTAGJ1	DN	7-Mercapto-heptanoic acid quinolin-3-ylamide
DMTAGJ1	MI	TTT6LFV
DMTAGJ1	MN	Histone deacetylase 8 (HDAC8)
DMTAGJ1	MT	DTT
DMTAGJ1	MA	Inhibitor
DMTAGJ1	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMTAGJ1	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DM03XYF	DI	DM03XYF
DM03XYF	DN	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide
DM03XYF	MI	TT6R7JZ
DM03XYF	MN	Histone deacetylase 1 (HDAC1)
DM03XYF	MT	DTT
DM03XYF	MA	Inhibitor
DM03XYF	RN	Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhib... J Med Chem. 2007 Nov 1;50(22):5425-38.
DM03XYF	RU	https://pubmed.ncbi.nlm.nih.gov/17929798

DM03XYF	DI	DM03XYF
DM03XYF	DN	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide
DM03XYF	MI	TTTQGH8
DM03XYF	MN	Histone deacetylase 4 (HDAC4)
DM03XYF	MT	DTT
DM03XYF	MA	Inhibitor
DM03XYF	RN	Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhib... J Med Chem. 2007 Nov 1;50(22):5425-38.
DM03XYF	RU	https://pubmed.ncbi.nlm.nih.gov/17929798

DM03XYF	DI	DM03XYF
DM03XYF	DN	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide
DM03XYF	MI	TT5ZKDI
DM03XYF	MN	Histone deacetylase 6 (HDAC6)
DM03XYF	MT	DTT
DM03XYF	MA	Inhibitor
DM03XYF	RN	Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhib... J Med Chem. 2007 Nov 1;50(22):5425-38.
DM03XYF	RU	https://pubmed.ncbi.nlm.nih.gov/17929798

DMTFBCU	DI	DMTFBCU
DMTFBCU	DN	7-Methoxy-1H-indazole
DMTFBCU	MI	TTZUFI5
DMTFBCU	MN	Nitric-oxide synthase brain (NOS1)
DMTFBCU	MT	DTT
DMTFBCU	MA	Inhibitor
DMTFBCU	RN	Inhibition of neuronal nitric oxide synthase by 7-methoxyindazole and related substituted indazoles. Bioorg Med Chem Lett. 2001 May 7;11(9):1153-6.
DMTFBCU	RU	https://pubmed.ncbi.nlm.nih.gov/11354365

DM3MXI5	DI	DM3MXI5
DM3MXI5	DN	7-methoxy-1-naphthylpiperazine
DM3MXI5	MI	TTSQIFT
DM3MXI5	MN	5-HT 1A receptor (HTR1A)
DM3MXI5	MT	DTT
DM3MXI5	MA	Agonist
DM3MXI5	RN	5-HT1B receptor antagonist properties of novel arylpiperazide derivatives of 1-naphthylpiperazine. J Med Chem. 1997 Nov 21;40(24):3974-8.
DM3MXI5	RU	https://pubmed.ncbi.nlm.nih.gov/9397179

DM3MXI5	DI	DM3MXI5
DM3MXI5	DN	7-methoxy-1-naphthylpiperazine
DM3MXI5	MI	TTK8CXU
DM3MXI5	MN	5-HT 1B receptor (HTR1B)
DM3MXI5	MT	DTT
DM3MXI5	MA	Agonist
DM3MXI5	RN	5-HT1B receptor antagonist properties of novel arylpiperazide derivatives of 1-naphthylpiperazine. J Med Chem. 1997 Nov 21;40(24):3974-8.
DM3MXI5	RU	https://pubmed.ncbi.nlm.nih.gov/9397179

DM3MXI5	DI	DM3MXI5
DM3MXI5	DN	7-methoxy-1-naphthylpiperazine
DM3MXI5	MI	TT6MSOK
DM3MXI5	MN	5-HT 1D receptor (HTR1D)
DM3MXI5	MT	DTT
DM3MXI5	MA	Agonist
DM3MXI5	RN	5-HT1B receptor antagonist properties of novel arylpiperazide derivatives of 1-naphthylpiperazine. J Med Chem. 1997 Nov 21;40(24):3974-8.
DM3MXI5	RU	https://pubmed.ncbi.nlm.nih.gov/9397179

DMQ1BE8	DI	DMQ1BE8
DMQ1BE8	DN	7-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline
DMQ1BE8	MI	TTJQOD7
DMQ1BE8	MN	5-HT 2A receptor (HTR2A)
DMQ1BE8	MT	DTT
DMQ1BE8	MA	Inhibitor
DMQ1BE8	RN	Binding of beta-carbolines at 5-HT(2) serotonin receptors. Bioorg Med Chem Lett. 2003 Dec 15;13(24):4421-5.
DMQ1BE8	RU	https://pubmed.ncbi.nlm.nih.gov/14643338

DMQ1BE8	DI	DMQ1BE8
DMQ1BE8	DN	7-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline
DMQ1BE8	MI	TTWG9A4
DMQ1BE8	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMQ1BE8	MT	DTT
DMQ1BE8	MA	Inhibitor
DMQ1BE8	RN	Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9.
DMQ1BE8	RU	https://pubmed.ncbi.nlm.nih.gov/14698196

DMQ1BE8	DI	DMQ1BE8
DMQ1BE8	DN	7-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline
DMQ1BE8	MI	TTWM4TY
DMQ1BE8	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMQ1BE8	MT	DTT
DMQ1BE8	MA	Inhibitor
DMQ1BE8	RN	Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9.
DMQ1BE8	RU	https://pubmed.ncbi.nlm.nih.gov/14698196

DMQ1BE8	DI	DMQ1BE8
DMQ1BE8	DN	7-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline
DMQ1BE8	MI	TT2NUT5
DMQ1BE8	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMQ1BE8	MT	DTT
DMQ1BE8	MA	Inhibitor
DMQ1BE8	RN	Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9.
DMQ1BE8	RU	https://pubmed.ncbi.nlm.nih.gov/14698196

DMQ1BE8	DI	DMQ1BE8
DMQ1BE8	DN	7-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline
DMQ1BE8	MI	TT3WG5C
DMQ1BE8	MN	Monoamine oxidase type A (MAO-A)
DMQ1BE8	MT	DTT
DMQ1BE8	MA	Inhibitor
DMQ1BE8	RN	Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9.
DMQ1BE8	RU	https://pubmed.ncbi.nlm.nih.gov/14698196

DMQ1BE8	DI	DMQ1BE8
DMQ1BE8	DN	7-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline
DMQ1BE8	MI	TTGP7BY
DMQ1BE8	MN	Monoamine oxidase type B (MAO-B)
DMQ1BE8	MT	DTT
DMQ1BE8	MA	Inhibitor
DMQ1BE8	RN	Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9.
DMQ1BE8	RU	https://pubmed.ncbi.nlm.nih.gov/14698196

DMR713M	DI	DMR713M
DMR713M	DN	7-Methoxy-2-morpholin-4-yl-chromen-4-one
DMR713M	MI	TTK3PY9
DMR713M	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMR713M	MT	DTT
DMR713M	MA	Inhibitor
DMR713M	RN	Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85.
DMR713M	RU	https://pubmed.ncbi.nlm.nih.gov/15658870

DMJITU0	DI	DMJITU0
DMJITU0	DN	7-methoxy-2-oxo-2H-chromene-4-carboxylic acid
DMJITU0	MI	TTUNARX
DMJITU0	MN	Carbonic anhydrase (CA)
DMJITU0	MT	DTT
DMJITU0	MA	Inhibitor
DMJITU0	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMJITU0	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMJITU0	DI	DMJITU0
DMJITU0	DN	7-methoxy-2-oxo-2H-chromene-4-carboxylic acid
DMJITU0	MI	TTHQPL7
DMJITU0	MN	Carbonic anhydrase I (CA-I)
DMJITU0	MT	DTT
DMJITU0	MA	Inhibitor
DMJITU0	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMJITU0	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMJITU0	DI	DMJITU0
DMJITU0	DN	7-methoxy-2-oxo-2H-chromene-4-carboxylic acid
DMJITU0	MI	TT2LVK8
DMJITU0	MN	Carbonic anhydrase IX (CA-IX)
DMJITU0	MT	DTT
DMJITU0	MA	Inhibitor
DMJITU0	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMJITU0	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMJITU0	DI	DMJITU0
DMJITU0	DN	7-methoxy-2-oxo-2H-chromene-4-carboxylic acid
DMJITU0	MI	TTSYM0R
DMJITU0	MN	Carbonic anhydrase XII (CA-XII)
DMJITU0	MT	DTT
DMJITU0	MA	Inhibitor
DMJITU0	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMJITU0	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMJITU0	DI	DMJITU0
DMJITU0	DN	7-methoxy-2-oxo-2H-chromene-4-carboxylic acid
DMJITU0	MI	TTEYTKG
DMJITU0	MN	Carbonic anhydrase XIV (CA-XIV)
DMJITU0	MT	DTT
DMJITU0	MA	Inhibitor
DMJITU0	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMJITU0	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DME5WZQ	DI	DME5WZQ
DME5WZQ	DN	7-methoxy-2-p-tolyl-4H-chromen-4-one
DME5WZQ	MI	TTGP7BY
DME5WZQ	MN	Monoamine oxidase type B (MAO-B)
DME5WZQ	MT	DTT
DME5WZQ	MA	Inhibitor
DME5WZQ	RN	A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9.
DME5WZQ	RU	https://pubmed.ncbi.nlm.nih.gov/20045650

DM4WMGK	DI	DM4WMGK
DM4WMGK	DN	7-methoxy-2-p-tolyl-4H-chromene-4-thione
DM4WMGK	MI	TTGP7BY
DM4WMGK	MN	Monoamine oxidase type B (MAO-B)
DM4WMGK	MT	DTT
DM4WMGK	MA	Inhibitor
DM4WMGK	RN	A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9.
DM4WMGK	RU	https://pubmed.ncbi.nlm.nih.gov/20045650

DMUZIDT	DI	DMUZIDT
DMUZIDT	DN	7-Methoxy-3-pyridin-4-yl-quinoline
DMUZIDT	MI	TT8FYO9
DMUZIDT	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMUZIDT	MT	DTT
DMUZIDT	MA	Inhibitor
DMUZIDT	RN	5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.
DMUZIDT	RU	https://pubmed.ncbi.nlm.nih.gov/8064792

DMUZIDT	DI	DMUZIDT
DMUZIDT	DN	7-Methoxy-3-pyridin-4-yl-quinoline
DMUZIDT	MI	TTI7421
DMUZIDT	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMUZIDT	MT	DTT
DMUZIDT	MA	Inhibitor
DMUZIDT	RN	5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.
DMUZIDT	RU	https://pubmed.ncbi.nlm.nih.gov/8064792

DM9QKLC	DI	DM9QKLC
DM9QKLC	DN	7-Methoxy-3-thiophen-3-yl-quinoline
DM9QKLC	MI	TT8FYO9
DM9QKLC	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DM9QKLC	MT	DTT
DM9QKLC	MA	Inhibitor
DM9QKLC	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DM9QKLC	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DM9QKLC	DI	DM9QKLC
DM9QKLC	DN	7-Methoxy-3-thiophen-3-yl-quinoline
DM9QKLC	MI	TTI7421
DM9QKLC	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM9QKLC	MT	DTT
DM9QKLC	MA	Inhibitor
DM9QKLC	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DM9QKLC	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMNFIZD	DI	DMNFIZD
DMNFIZD	DN	7-Methoxy-4-morpholin-4-yl-chromen-2-one
DMNFIZD	MI	TTK3PY9
DMNFIZD	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMNFIZD	MT	DTT
DMNFIZD	MA	Inhibitor
DMNFIZD	RN	Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85.
DMNFIZD	RU	https://pubmed.ncbi.nlm.nih.gov/15658870

DMH0UVE	DI	DMH0UVE
DMH0UVE	DN	7-methoxy-8-propionyl-2H-chromen-2-one
DMH0UVE	MI	TT2LVK8
DMH0UVE	MN	Carbonic anhydrase IX (CA-IX)
DMH0UVE	MT	DTT
DMH0UVE	MA	Inhibitor
DMH0UVE	RN	7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and X... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7255-8.
DMH0UVE	RU	https://pubmed.ncbi.nlm.nih.gov/21067924

DMHKMU1	DI	DMHKMU1
DMHKMU1	DN	7-Methoxy-9H-beta-carboline
DMHKMU1	MI	TT3WG5C
DMHKMU1	MN	Monoamine oxidase type A (MAO-A)
DMHKMU1	MT	DTT
DMHKMU1	MA	Inhibitor
DMHKMU1	RN	Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
DMHKMU1	RU	https://pubmed.ncbi.nlm.nih.gov/15013009

DMHKMU1	DI	DMHKMU1
DMHKMU1	DN	7-Methoxy-9H-beta-carboline
DMHKMU1	MI	TTGP7BY
DMHKMU1	MN	Monoamine oxidase type B (MAO-B)
DMHKMU1	MT	DTT
DMHKMU1	MA	Inhibitor
DMHKMU1	RN	Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
DMHKMU1	RU	https://pubmed.ncbi.nlm.nih.gov/15013009

DMUCJA6	DI	DMUCJA6
DMUCJA6	DN	7-Methyl-[1,4]thiazepan-(5E)-ylideneamine
DMUCJA6	MI	TTZUFI5
DMUCJA6	MN	Nitric-oxide synthase brain (NOS1)
DMUCJA6	MT	DTT
DMUCJA6	MA	Inhibitor
DMUCJA6	RN	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
DMUCJA6	RU	https://pubmed.ncbi.nlm.nih.gov/15501067

DMUCJA6	DI	DMUCJA6
DMUCJA6	DN	7-Methyl-[1,4]thiazepan-(5E)-ylideneamine
DMUCJA6	MI	TTCM4B3
DMUCJA6	MN	Nitric-oxide synthase endothelial (NOS3)
DMUCJA6	MT	DTT
DMUCJA6	MA	Inhibitor
DMUCJA6	RN	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
DMUCJA6	RU	https://pubmed.ncbi.nlm.nih.gov/15501067

DMUCJA6	DI	DMUCJA6
DMUCJA6	DN	7-Methyl-[1,4]thiazepan-(5E)-ylideneamine
DMUCJA6	MI	TTF10I9
DMUCJA6	MN	Nitric-oxide synthase inducible (NOS2)
DMUCJA6	MT	DTT
DMUCJA6	MA	Inhibitor
DMUCJA6	RN	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
DMUCJA6	RU	https://pubmed.ncbi.nlm.nih.gov/15501067

DM5EQJU	DI	DM5EQJU
DM5EQJU	DN	7-Methyl-1,3-dihydro-imidazo[4,5-b]quinolin-2-one
DM5EQJU	MI	TT06AWU
DM5EQJU	MN	Phosphodiesterase 3A (PDE3A)
DM5EQJU	MT	DTT
DM5EQJU	MA	Inhibitor
DM5EQJU	RN	1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-ones--inhibitors of blood platelet cAMP phosphodiesterase and induced aggregation. J Med Chem. 1991 Sep;34(9):2906-16.
DM5EQJU	RU	https://pubmed.ncbi.nlm.nih.gov/1654430

DM7LGDC	DI	DM7LGDC
DM7LGDC	DN	7-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one
DM7LGDC	MI	TTML2WA
DM7LGDC	MN	Tubulin (TUB)
DM7LGDC	MT	DTT
DM7LGDC	MA	Inhibitor
DM7LGDC	RN	Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubul... J Med Chem. 1997 Sep 12;40(19):3049-56.
DM7LGDC	RU	https://pubmed.ncbi.nlm.nih.gov/9301667

DM7LGDC	DI	DM7LGDC
DM7LGDC	DN	7-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one
DM7LGDC	MI	TTYFKSZ
DM7LGDC	MN	Tubulin beta (TUBB)
DM7LGDC	MT	DTT
DM7LGDC	MA	Inhibitor
DM7LGDC	RN	Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubul... J Med Chem. 1997 Sep 12;40(19):3049-56.
DM7LGDC	RU	https://pubmed.ncbi.nlm.nih.gov/9301667

DMCV891	DI	DMCV891
DMCV891	DN	7-methyl-2-m-tolylpyrido[2,3-d]pyrimidine
DMCV891	MI	TTHS256
DMCV891	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMCV891	MT	DTT
DMCV891	MA	Inhibitor
DMCV891	RN	Synthesis and SAR of 2-aryl pyrido[2,3-d]pyrimidines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5396-9.
DMCV891	RU	https://pubmed.ncbi.nlm.nih.gov/17723296

DMJ4G27	DI	DMJ4G27
DMJ4G27	DN	7-methyl-2-phenylpyrido[2,3-d]pyrimidine
DMJ4G27	MI	TTHS256
DMJ4G27	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMJ4G27	MT	DTT
DMJ4G27	MA	Inhibitor
DMJ4G27	RN	Synthesis and SAR of 2-aryl pyrido[2,3-d]pyrimidines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5396-9.
DMJ4G27	RU	https://pubmed.ncbi.nlm.nih.gov/17723296

DMGB9IE	DI	DMGB9IE
DMGB9IE	DN	7-Methyl-2-propyl-[1,8]naphthyridin-4-ol
DMGB9IE	MI	TTK25J1
DMGB9IE	MN	Adenosine A1 receptor (ADORA1)
DMGB9IE	MT	DTT
DMGB9IE	MA	Inhibitor
DMGB9IE	RN	Study on affinity profile toward native human and bovine adenosine receptors of a series of 1,8-naphthyridine derivatives. J Med Chem. 2004 Jun 3;47(12):3019-31.
DMGB9IE	RU	https://pubmed.ncbi.nlm.nih.gov/15163184

DMB9YA8	DI	DMB9YA8
DMB9YA8	DN	7-methyl-2-p-tolyl-4H-chromene-4-thione
DMB9YA8	MI	TTGP7BY
DMB9YA8	MN	Monoamine oxidase type B (MAO-B)
DMB9YA8	MT	DTT
DMB9YA8	MA	Inhibitor
DMB9YA8	RN	A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9.
DMB9YA8	RU	https://pubmed.ncbi.nlm.nih.gov/20045650

DMZKO14	DI	DMZKO14
DMZKO14	DN	7-Methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine
DMZKO14	MI	TT9SL3Q
DMZKO14	MN	Polypeptide deformylase (PDF)
DMZKO14	MT	DTT
DMZKO14	MA	Inhibitor
DMZKO14	RN	High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines w... J Med Chem. 1996 Feb 16;39(4):892-903.
DMZKO14	RU	https://pubmed.ncbi.nlm.nih.gov/8632413

DMMENDC	DI	DMMENDC
DMMENDC	DN	7-METHYL-8-OXO-5-P-TOLYL-7,8-DIHYDRO-[1,7]NAPHTHYRIDINE-6-CARBOXYLIC ACID (3,5-BIS-TRIFLUOROMETHYL-BENZYL)-METHYL-AMIDE (STRUCTURAL MIX)
DMMENDC	MI	TTZPO1L
DMMENDC	MN	Substance-P receptor (TACR1)
DMMENDC	MT	DTT
DMMENDC	MA	Inhibitor
DMMENDC	RN	Axially chiral N-benzyl-N,7-dimethyl-5-phenyl-1, 7-naphthyridine-6-carboxamide derivatives as tachykinin NK1 receptor antagonists: determination of... J Med Chem. 1998 Oct 22;41(22):4232-9.
DMMENDC	RU	https://pubmed.ncbi.nlm.nih.gov/9784098

DMO0RGL	DI	DMO0RGL
DMO0RGL	DN	7-METHYL-8-OXO-5-P-TOLYL-7,8-DIHYDRO-[1,7]NAPHTHYRIDINE-6-CARBOXYLIC ACID (S)-[(R)-1-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-ETHYL]-METHYL-AMIDE (ENANTIOMERIC MIX)
DMO0RGL	MI	TTZPO1L
DMO0RGL	MN	Substance-P receptor (TACR1)
DMO0RGL	MT	DTT
DMO0RGL	MA	Inhibitor
DMO0RGL	RN	Axially chiral N-benzyl-N,7-dimethyl-5-phenyl-1, 7-naphthyridine-6-carboxamide derivatives as tachykinin NK1 receptor antagonists: determination of... J Med Chem. 1998 Oct 22;41(22):4232-9.
DMO0RGL	RU	https://pubmed.ncbi.nlm.nih.gov/9784098

DMOAJ0E	DI	DMOAJ0E
DMOAJ0E	DN	7-METHYL-8-OXO-5-P-TOLYL-7,8-DIHYDRO-[1,7]NAPHTHYRIDINE-6-CARBOXYLIC ACID (S)-[(S)-1-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-ETHYL]-METHYL-AMIDE (ENANTIOMERIC MIX)
DMOAJ0E	MI	TTZPO1L
DMOAJ0E	MN	Substance-P receptor (TACR1)
DMOAJ0E	MT	DTT
DMOAJ0E	MA	Inhibitor
DMOAJ0E	RN	Axially chiral N-benzyl-N,7-dimethyl-5-phenyl-1, 7-naphthyridine-6-carboxamide derivatives as tachykinin NK1 receptor antagonists: determination of... J Med Chem. 1998 Oct 22;41(22):4232-9.
DMOAJ0E	RU	https://pubmed.ncbi.nlm.nih.gov/9784098

DME39U2	DI	DME39U2
DME39U2	DN	7-Methyl-Gpppa
DME39U2	MI	TTZGCP6
DME39U2	MN	EIF4E messenger RNA (EIF4E mRNA)
DME39U2	MT	DTT
DME39U2	MA	Inhibitor
DME39U2	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DME39U2	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMCGNUO	DI	DMCGNUO
DMCGNUO	DN	7-Methyl-Guanosine-5'-Triphosphate
DMCGNUO	MI	TTZGCP6
DMCGNUO	MN	EIF4E messenger RNA (EIF4E mRNA)
DMCGNUO	MT	DTT
DMCGNUO	MA	Inhibitor
DMCGNUO	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMCGNUO	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMBDFP2	DI	DMBDFP2
DMBDFP2	DN	7-m-tolyl-1,6-naphthyridine
DMBDFP2	MI	TTHS256
DMBDFP2	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMBDFP2	MT	DTT
DMBDFP2	MA	Inhibitor
DMBDFP2	RN	Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8.
DMBDFP2	RU	https://pubmed.ncbi.nlm.nih.gov/17936624

DMX3UV1	DI	DMX3UV1
DMX3UV1	DN	7-Nitro-1,2,3,4-tetrahydro-isoquinoline
DMX3UV1	MI	TTWG9A4
DMX3UV1	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMX3UV1	MT	DTT
DMX3UV1	MA	Inhibitor
DMX3UV1	RN	Exploring the active site of phenylethanolamine N-methyltransferase with 3-hydroxyethyl- and 3-hydroxypropyl-7-substituted-1,2,3,4-tetrahydroisoqui... Bioorg Med Chem Lett. 2005 Feb 15;15(4):1143-7.
DMX3UV1	RU	https://pubmed.ncbi.nlm.nih.gov/15686930

DMW4XKQ	DI	DMW4XKQ
DMW4XKQ	DN	7-nitro-1H-indazole
DMW4XKQ	MI	TTZUFI5
DMW4XKQ	MN	Nitric-oxide synthase brain (NOS1)
DMW4XKQ	MT	DTT
DMW4XKQ	MA	Inhibitor
DMW4XKQ	RN	Fluorinated indazoles as novel selective inhibitors of nitric oxide synthase (NOS): synthesis and biological evaluation. Bioorg Med Chem. 2009 Sep 1;17(17):6180-7.
DMW4XKQ	RU	https://pubmed.ncbi.nlm.nih.gov/19679481

DMW4XKQ	DI	DMW4XKQ
DMW4XKQ	DN	7-nitro-1H-indazole
DMW4XKQ	MI	TTCM4B3
DMW4XKQ	MN	Nitric-oxide synthase endothelial (NOS3)
DMW4XKQ	MT	DTT
DMW4XKQ	MA	Inhibitor
DMW4XKQ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMW4XKQ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMW4XKQ	DI	DMW4XKQ
DMW4XKQ	DN	7-nitro-1H-indazole
DMW4XKQ	MI	TTF10I9
DMW4XKQ	MN	Nitric-oxide synthase inducible (NOS2)
DMW4XKQ	MT	DTT
DMW4XKQ	MA	Inhibitor
DMW4XKQ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMW4XKQ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMGLWOM	DI	DMGLWOM
DMGLWOM	DN	7-Nitroindazole-2-Carboxamidine
DMGLWOM	MI	TTCM4B3
DMGLWOM	MN	Nitric-oxide synthase endothelial (NOS3)
DMGLWOM	MT	DTT
DMGLWOM	MA	Inhibitor
DMGLWOM	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMGLWOM	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM2403T	DI	DM2403T
DM2403T	DN	7n-Methyl-8-Hydroguanosine-5'-Diphosphate
DM2403T	MI	TTZGCP6
DM2403T	MN	EIF4E messenger RNA (EIF4E mRNA)
DM2403T	MT	DTT
DM2403T	MA	Inhibitor
DM2403T	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM2403T	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM8IY3D	DI	DM8IY3D
DM8IY3D	DN	7-O-b-D-Glucopyranosyl-a-homonojirimycin
DM8IY3D	MI	TTLPC70
DM8IY3D	MN	Lysosomal alpha-glucosidase (GAA)
DM8IY3D	MT	DTT
DM8IY3D	MA	Inhibitor
DM8IY3D	RN	In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures. Bioorg Med Chem. 2008 Aug 1;16(15):7330-6.
DM8IY3D	RU	https://pubmed.ncbi.nlm.nih.gov/18595718

DMJZR0A	DI	DMJZR0A
DMJZR0A	DN	7-Oxo-7H-dibenzo[de,g]quinoline
DMJZR0A	MI	TT1RS9F
DMJZR0A	MN	Acetylcholinesterase (AChE)
DMJZR0A	MT	DTT
DMJZR0A	MA	Inhibitor
DMJZR0A	RN	Synthesis, biological evaluation and molecular modeling of oxoisoaporphine and oxoaporphine derivatives as new dual inhibitors of acetylcholinester... Eur J Med Chem. 2009 Jun;44(6):2523-32.
DMJZR0A	RU	https://pubmed.ncbi.nlm.nih.gov/19243862

DMJZR0A	DI	DMJZR0A
DMJZR0A	DN	7-Oxo-7H-dibenzo[de,g]quinoline
DMJZR0A	MI	TTEB0GD
DMJZR0A	MN	Cholinesterase (BCHE)
DMJZR0A	MT	DTT
DMJZR0A	MA	Inhibitor
DMJZR0A	RN	Synthesis, biological evaluation and molecular modeling of oxoisoaporphine and oxoaporphine derivatives as new dual inhibitors of acetylcholinester... Eur J Med Chem. 2009 Jun;44(6):2523-32.
DMJZR0A	RU	https://pubmed.ncbi.nlm.nih.gov/19243862

DM8Q267	DI	DM8Q267
DM8Q267	DN	7-phenethoxy-2H-chromen-2-one
DM8Q267	MI	TTUNARX
DM8Q267	MN	Carbonic anhydrase (CA)
DM8Q267	MT	DTT
DM8Q267	MA	Inhibitor
DM8Q267	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DM8Q267	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DM8Q267	DI	DM8Q267
DM8Q267	DN	7-phenethoxy-2H-chromen-2-one
DM8Q267	MI	TT2LVK8
DM8Q267	MN	Carbonic anhydrase IX (CA-IX)
DM8Q267	MT	DTT
DM8Q267	MA	Inhibitor
DM8Q267	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DM8Q267	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DM8Q267	DI	DM8Q267
DM8Q267	DN	7-phenethoxy-2H-chromen-2-one
DM8Q267	MI	TTSYM0R
DM8Q267	MN	Carbonic anhydrase XII (CA-XII)
DM8Q267	MT	DTT
DM8Q267	MA	Inhibitor
DM8Q267	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DM8Q267	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DM8Q267	DI	DM8Q267
DM8Q267	DN	7-phenethoxy-2H-chromen-2-one
DM8Q267	MI	TTEYTKG
DM8Q267	MN	Carbonic anhydrase XIV (CA-XIV)
DM8Q267	MT	DTT
DM8Q267	MA	Inhibitor
DM8Q267	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DM8Q267	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DM1FL5G	DI	DM1FL5G
DM1FL5G	DN	7-Phenoxy-heptanoic acid hydroxyamide
DM1FL5G	MI	TT6R7JZ
DM1FL5G	MN	Histone deacetylase 1 (HDAC1)
DM1FL5G	MT	DTT
DM1FL5G	MA	Inhibitor
DM1FL5G	RN	A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units. Bioorg Med Chem Lett. 2003 Nov 3;13(21):3817-20.
DM1FL5G	RU	https://pubmed.ncbi.nlm.nih.gov/14552787

DM1FL5G	DI	DM1FL5G
DM1FL5G	DN	7-Phenoxy-heptanoic acid hydroxyamide
DM1FL5G	MI	TTSHTOI
DM1FL5G	MN	Histone deacetylase 2 (HDAC2)
DM1FL5G	MT	DTT
DM1FL5G	MA	Inhibitor
DM1FL5G	RN	A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units. Bioorg Med Chem Lett. 2003 Nov 3;13(21):3817-20.
DM1FL5G	RU	https://pubmed.ncbi.nlm.nih.gov/14552787

DMQMRGD	DI	DMQMRGD
DMQMRGD	DN	7-Phenyl-1-(1,3,4-thiadiazol-2-yl)-heptan-1-one
DMQMRGD	MI	TTDP1UC
DMQMRGD	MN	Fatty acid amide hydrolase (FAAH)
DMQMRGD	MT	DTT
DMQMRGD	MA	Inhibitor
DMQMRGD	RN	Optimization of the central heterocycle of alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Aug 14;51(15):4392-403.
DMQMRGD	RU	https://pubmed.ncbi.nlm.nih.gov/18630870

DMEABGI	DI	DMEABGI
DMEABGI	DN	7-Phenyl-1-(2H-tetrazol-5-yl)-heptan-1-one
DMEABGI	MI	TTDP1UC
DMEABGI	MN	Fatty acid amide hydrolase (FAAH)
DMEABGI	MT	DTT
DMEABGI	MA	Inhibitor
DMEABGI	RN	Optimization of the central heterocycle of alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Aug 14;51(15):4392-403.
DMEABGI	RU	https://pubmed.ncbi.nlm.nih.gov/18630870

DM62PAU	DI	DM62PAU
DM62PAU	DN	7-phenyl-1-(4-phenyloxazol-2-yl)heptan-1-one
DM62PAU	MI	TTDP1UC
DM62PAU	MN	Fatty acid amide hydrolase (FAAH)
DM62PAU	MT	DTT
DM62PAU	MA	Inhibitor
DM62PAU	RN	Exploration of a fundamental substituent effect of alpha-ketoheterocycle enzyme inhibitors: Potent and selective inhibitors of fatty acid amide hyd... Bioorg Med Chem Lett. 2008 Nov 15;18(22):5842-6.
DM62PAU	RU	https://pubmed.ncbi.nlm.nih.gov/18639454

DM9SGBW	DI	DM9SGBW
DM9SGBW	DN	7-phenyl-1-(5-phenyloxazol-2-yl)heptan-1-one
DM9SGBW	MI	TTDP1UC
DM9SGBW	MN	Fatty acid amide hydrolase (FAAH)
DM9SGBW	MT	DTT
DM9SGBW	MA	Inhibitor
DM9SGBW	RN	Optimization of the central heterocycle of alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Aug 14;51(15):4392-403.
DM9SGBW	RU	https://pubmed.ncbi.nlm.nih.gov/18630870

DMG1PNX	DI	DMG1PNX
DMG1PNX	DN	7-Phenyl-1-(pyridazin-3-yl)-heptan-1-one
DMG1PNX	MI	TTDP1UC
DMG1PNX	MN	Fatty acid amide hydrolase (FAAH)
DMG1PNX	MT	DTT
DMG1PNX	MA	Inhibitor
DMG1PNX	RN	Optimization of the central heterocycle of alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Aug 14;51(15):4392-403.
DMG1PNX	RU	https://pubmed.ncbi.nlm.nih.gov/18630870

DMLHI5T	DI	DMLHI5T
DMLHI5T	DN	7-Phenyl-1-(thiazol-2-yl)-heptan-1-one
DMLHI5T	MI	TTDP1UC
DMLHI5T	MN	Fatty acid amide hydrolase (FAAH)
DMLHI5T	MT	DTT
DMLHI5T	MA	Inhibitor
DMLHI5T	RN	Optimization of the central heterocycle of alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Aug 14;51(15):4392-403.
DMLHI5T	RU	https://pubmed.ncbi.nlm.nih.gov/18630870

DMEDOFB	DI	DMEDOFB
DMEDOFB	DN	7-phenylethoxy-2-morpholin-4-yl-chromen-4-one
DMEDOFB	MI	TTK3PY9
DMEDOFB	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMEDOFB	MT	DTT
DMEDOFB	MA	Inhibitor
DMEDOFB	RN	Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46.
DMEDOFB	RU	https://pubmed.ncbi.nlm.nih.gov/16302822

DM1WJFR	DI	DM1WJFR
DM1WJFR	DN	7-Phenyl-naphthalen-2-ol
DM1WJFR	MI	TTZAYWL
DM1WJFR	MN	Estrogen receptor (ESR)
DM1WJFR	MT	DTT
DM1WJFR	MA	Inhibitor
DM1WJFR	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DM1WJFR	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DM1WJFR	DI	DM1WJFR
DM1WJFR	DN	7-Phenyl-naphthalen-2-ol
DM1WJFR	MI	TTOM3J0
DM1WJFR	MN	Estrogen receptor beta (ESR2)
DM1WJFR	MT	DTT
DM1WJFR	MA	Inhibitor
DM1WJFR	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DM1WJFR	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMSBJ4M	DI	DMSBJ4M
DMSBJ4M	DN	7-phenyloxyethoxy-2-morpholin-4-yl-chromen-4-one
DMSBJ4M	MI	TTK3PY9
DMSBJ4M	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMSBJ4M	MT	DTT
DMSBJ4M	MA	Inhibitor
DMSBJ4M	RN	Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46.
DMSBJ4M	RU	https://pubmed.ncbi.nlm.nih.gov/16302822

DM19I62	DI	DM19I62
DM19I62	DN	7-Phloroethol
DM19I62	MI	TT8JRS7
DM19I62	MN	Beta-secretase (BACE)
DM19I62	MT	DTT
DM19I62	MA	Inhibitor
DM19I62	RN	Molecular docking studies of phlorotannins from Eisenia bicyclis with BACE1 inhibitory activity. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3211-5.
DM19I62	RU	https://pubmed.ncbi.nlm.nih.gov/20462757

DMO8WB2	DI	DMO8WB2
DMO8WB2	DN	7-propoxy-2-(morpholin-4-yl)-chromen-4-one
DMO8WB2	MI	TTK3PY9
DMO8WB2	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMO8WB2	MT	DTT
DMO8WB2	MA	Inhibitor
DMO8WB2	RN	Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46.
DMO8WB2	RU	https://pubmed.ncbi.nlm.nih.gov/16302822

DMD5CB6	DI	DMD5CB6
DMD5CB6	DN	7-propoxy-2H-chromen-2-one
DMD5CB6	MI	TTUNARX
DMD5CB6	MN	Carbonic anhydrase (CA)
DMD5CB6	MT	DTT
DMD5CB6	MA	Inhibitor
DMD5CB6	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMD5CB6	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMD5CB6	DI	DMD5CB6
DMD5CB6	DN	7-propoxy-2H-chromen-2-one
DMD5CB6	MI	TT2LVK8
DMD5CB6	MN	Carbonic anhydrase IX (CA-IX)
DMD5CB6	MT	DTT
DMD5CB6	MA	Inhibitor
DMD5CB6	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMD5CB6	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMD5CB6	DI	DMD5CB6
DMD5CB6	DN	7-propoxy-2H-chromen-2-one
DMD5CB6	MI	TTCFSPE
DMD5CB6	MN	Carbonic anhydrase VI (CA-VI)
DMD5CB6	MT	DTT
DMD5CB6	MA	Inhibitor
DMD5CB6	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMD5CB6	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMD5CB6	DI	DMD5CB6
DMD5CB6	DN	7-propoxy-2H-chromen-2-one
DMD5CB6	MI	TTSYM0R
DMD5CB6	MN	Carbonic anhydrase XII (CA-XII)
DMD5CB6	MT	DTT
DMD5CB6	MA	Inhibitor
DMD5CB6	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMD5CB6	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMD5CB6	DI	DMD5CB6
DMD5CB6	DN	7-propoxy-2H-chromen-2-one
DMD5CB6	MI	TTEYTKG
DMD5CB6	MN	Carbonic anhydrase XIV (CA-XIV)
DMD5CB6	MT	DTT
DMD5CB6	MA	Inhibitor
DMD5CB6	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMD5CB6	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DM4I0B1	DI	DM4I0B1
DM4I0B1	DN	7-Propyl-7H-adenine
DM4I0B1	MI	TTM2AOE
DM4I0B1	MN	Adenosine A2a receptor (ADORA2A)
DM4I0B1	MT	DTT
DM4I0B1	MA	Inhibitor
DM4I0B1	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DM4I0B1	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMW8XME	DI	DMW8XME
DMW8XME	DN	7-Pyridin-3-yl-2H-1,4-benzothiazin-3(4H)-one
DMW8XME	MI	TTIQUX7
DMW8XME	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMW8XME	MT	DTT
DMW8XME	MA	Inhibitor
DMW8XME	RN	In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87.
DMW8XME	RU	https://pubmed.ncbi.nlm.nih.gov/19049427

DMQJ26K	DI	DMQJ26K
DMQJ26K	DN	7-Pyrrolidin-1-yl-hept-5-yn-2-one
DMQJ26K	MI	TTZ9SOR
DMQJ26K	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMQJ26K	MT	DTT
DMQJ26K	MA	Inhibitor
DMQJ26K	RN	Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992).
DMQJ26K	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805351

DMQJ26K	DI	DMQJ26K
DMQJ26K	DN	7-Pyrrolidin-1-yl-hept-5-yn-2-one
DMQJ26K	MI	TTYEG6Q
DMQJ26K	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMQJ26K	MT	DTT
DMQJ26K	MA	Inhibitor
DMQJ26K	RN	Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992).
DMQJ26K	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805351

DMQJ26K	DI	DMQJ26K
DMQJ26K	DN	7-Pyrrolidin-1-yl-hept-5-yn-2-one
DMQJ26K	MI	TTQ13Z5
DMQJ26K	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMQJ26K	MT	DTT
DMQJ26K	MA	Inhibitor
DMQJ26K	RN	Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992).
DMQJ26K	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805351

DMQJ26K	DI	DMQJ26K
DMQJ26K	DN	7-Pyrrolidin-1-yl-hept-5-yn-2-one
DMQJ26K	MI	TTQ3JTF
DMQJ26K	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DMQJ26K	MT	DTT
DMQJ26K	MA	Inhibitor
DMQJ26K	RN	Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992).
DMQJ26K	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805351

DMQJ26K	DI	DMQJ26K
DMQJ26K	DN	7-Pyrrolidin-1-yl-hept-5-yn-2-one
DMQJ26K	MI	TTH18TF
DMQJ26K	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMQJ26K	MT	DTT
DMQJ26K	MA	Inhibitor
DMQJ26K	RN	Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992).
DMQJ26K	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805351

DMSU06X	DI	DMSU06X
DMSU06X	DN	7-tert-butyl-2, 3-dihydro-3, 3-dimethyl substituted dihydrofuran 30 (DHDMBF30)
DMSU06X	MI	TT2J34L
DMSU06X	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMSU06X	MT	DTT
DMSU06X	MA	Inhibitor
DMSU06X	RN	Effect of 5-LOX/COX-2 common inhibitor DHDMBF30 on pancreatic cancer cell Capan2. World J Gastroenterol. 2008 Apr 28;14(16):2494-500.
DMSU06X	RU	https://pubmed.ncbi.nlm.nih.gov/18442195

DMSU06X	DI	DMSU06X
DMSU06X	DN	7-tert-butyl-2, 3-dihydro-3, 3-dimethyl substituted dihydrofuran 30 (DHDMBF30)
DMSU06X	MI	TTT1MCF
DMSU06X	MN	Permeability pathway (NP pathway)
DMSU06X	MT	DTT
DMSU06X	MA	Inhibitor
DMSU06X	RN	Novel molecular targets for antimalarial drug development. Chem Biol Drug Des. 2008 Apr;71(4):287-97.
DMSU06X	RU	https://pubmed.ncbi.nlm.nih.gov/18298458

DMSU06X	DI	DMSU06X
DMSU06X	DN	7-tert-butyl-2, 3-dihydro-3, 3-dimethyl substituted dihydrofuran 30 (DHDMBF30)
DMSU06X	MI	TTMCF1Y
DMSU06X	MN	Purine nucleoside phosphorylase (PNP)
DMSU06X	MT	DTT
DMSU06X	MA	Inhibitor
DMSU06X	RN	Expression of human malaria parasite purine nucleoside phosphorylase in host enzyme-deficient erythrocyte culture. Enzyme characterization and identification of novel inhibitors. J Biol Chem. 1986 Sep 5;261(25):11667-73.
DMSU06X	RU	https://pubmed.ncbi.nlm.nih.gov/3091593

DMD7Q1R	DI	DMD7Q1R
DMD7Q1R	DN	7-tert-butyl-9H-carbazole-3-carboxylic acid
DMD7Q1R	MI	TTBGTCW
DMD7Q1R	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DMD7Q1R	MT	DTT
DMD7Q1R	MA	Inhibitor
DMD7Q1R	RN	Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8.
DMD7Q1R	RU	https://pubmed.ncbi.nlm.nih.gov/20521839

DMMU5SO	DI	DMMU5SO
DMMU5SO	DN	7-Thiophen-3-yl-[1,3]dioxolo[4,5-g]quinoline
DMMU5SO	MI	TT8FYO9
DMMU5SO	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMMU5SO	MT	DTT
DMMU5SO	MA	Inhibitor
DMMU5SO	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMMU5SO	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMMU5SO	DI	DMMU5SO
DMMU5SO	DN	7-Thiophen-3-yl-[1,3]dioxolo[4,5-g]quinoline
DMMU5SO	MI	TTI7421
DMMU5SO	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMMU5SO	MT	DTT
DMMU5SO	MA	Inhibitor
DMMU5SO	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMMU5SO	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMOQMA0	DI	DMOQMA0
DMOQMA0	DN	7-trans-OH-PIPAT
DMOQMA0	MI	TTEX248
DMOQMA0	MN	Dopamine D2 receptor (D2R)
DMOQMA0	MT	DTT
DMOQMA0	MA	Agonist
DMOQMA0	RN	Iodinated 2-aminotetralins and 3-amino-1-benzopyrans: ligands for dopamine D2 and D3 receptors. J Med Chem. 1994 Nov 25;37(24):4245-50.
DMOQMA0	RU	https://pubmed.ncbi.nlm.nih.gov/7990123

DMOQMA0	DI	DMOQMA0
DMOQMA0	DN	7-trans-OH-PIPAT
DMOQMA0	MI	TT4C8EA
DMOQMA0	MN	Dopamine D3 receptor (D3R)
DMOQMA0	MT	DTT
DMOQMA0	MA	Agonist
DMOQMA0	RN	Iodinated 2-aminotetralins and 3-amino-1-benzopyrans: ligands for dopamine D2 and D3 receptors. J Med Chem. 1994 Nov 25;37(24):4245-50.
DMOQMA0	RU	https://pubmed.ncbi.nlm.nih.gov/7990123

DM14OHR	DI	DM14OHR
DM14OHR	DN	7-vinyl-6H-chromeno[4,3-b]quinoline-3,9-diol
DM14OHR	MI	TTPNQAC
DM14OHR	MN	Estrogen-related receptor-alpha (ESRRA)
DM14OHR	MT	DTT
DM14OHR	MA	Inhibitor
DM14OHR	RN	ERbeta ligands. Part 6: 6H-Chromeno[4,3-b]quinolines as a new series of estrogen receptor beta-selective ligands. Bioorg Med Chem Lett. 2007 Jul 15;17(14):4053-6.
DM14OHR	RU	https://pubmed.ncbi.nlm.nih.gov/17482813

DMUE15B	DI	DMUE15B
DMUE15B	DN	8-(1,2-Dimethyl-propoxy)-quinolin-2-ylamine
DMUE15B	MI	TTX4RTB
DMUE15B	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMUE15B	MT	DTT
DMUE15B	MA	Inhibitor
DMUE15B	RN	Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7.
DMUE15B	RU	https://pubmed.ncbi.nlm.nih.gov/15341942

DMGS7CE	DI	DMGS7CE
DMGS7CE	DN	8-(1,3,3-Trimethyl-butoxy)-quinolin-2-ylamine
DMGS7CE	MI	TTX4RTB
DMGS7CE	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMGS7CE	MT	DTT
DMGS7CE	MA	Inhibitor
DMGS7CE	RN	Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 2. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4879-82.
DMGS7CE	RU	https://pubmed.ncbi.nlm.nih.gov/15341943

DMYERNW	DI	DMYERNW
DMYERNW	DN	8-(1-Ethyl-propoxy)-quinolin-2-ylamine
DMYERNW	MI	TTX4RTB
DMYERNW	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMYERNW	MT	DTT
DMYERNW	MA	Inhibitor
DMYERNW	RN	Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7.
DMYERNW	RU	https://pubmed.ncbi.nlm.nih.gov/15341942

DMMBH9N	DI	DMMBH9N
DMMBH9N	DN	8-(1H-indol-5-yl)-2-morpholin-4-ylchromen-4-one
DMMBH9N	MI	TTK3PY9
DMMBH9N	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMMBH9N	MT	DTT
DMMBH9N	MA	Inhibitor
DMMBH9N	RN	Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46.
DMMBH9N	RU	https://pubmed.ncbi.nlm.nih.gov/16302822

DM7VT3P	DI	DM7VT3P
DM7VT3P	DN	8-(1-Methyl-butoxy)-quinolin-2-ylamine
DM7VT3P	MI	TTX4RTB
DM7VT3P	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DM7VT3P	MT	DTT
DM7VT3P	MA	Inhibitor
DM7VT3P	RN	Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7.
DM7VT3P	RU	https://pubmed.ncbi.nlm.nih.gov/15341942

DMV5FZO	DI	DMV5FZO
DMV5FZO	DN	8-(2,2-dimethylpropyl)naringenin
DMV5FZO	MI	TTZAYWL
DMV5FZO	MN	Estrogen receptor (ESR)
DMV5FZO	MT	DTT
DMV5FZO	MA	Inhibitor
DMV5FZO	RN	Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65.
DMV5FZO	RU	https://pubmed.ncbi.nlm.nih.gov/17149865

DMV5FZO	DI	DMV5FZO
DMV5FZO	DN	8-(2,2-dimethylpropyl)naringenin
DMV5FZO	MI	TTOM3J0
DMV5FZO	MN	Estrogen receptor beta (ESR2)
DMV5FZO	MT	DTT
DMV5FZO	MA	Inhibitor
DMV5FZO	RN	Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65.
DMV5FZO	RU	https://pubmed.ncbi.nlm.nih.gov/17149865

DM3QV95	DI	DM3QV95
DM3QV95	DN	8-(2,3,4-trimethoxyphenyl)-9H-purine-2,6-diamine
DM3QV95	MI	TT9SL3Q
DM3QV95	MN	Polypeptide deformylase (PDF)
DM3QV95	MT	DTT
DM3QV95	MA	Inhibitor
DM3QV95	RN	CoMFA analysis of tgDHFR and rlDHFR based on antifolates with 6-5 fused ring system using the all-orientation search (AOS) routine and a modified c... Bioorg Med Chem. 2010 Feb 15;18(4):1684-701.
DM3QV95	RU	https://pubmed.ncbi.nlm.nih.gov/20117005

DM4KP5M	DI	DM4KP5M
DM4KP5M	DN	8-(2,4,5-trimethoxyphenyl)-9H-purine-2,6-diamine
DM4KP5M	MI	TT9SL3Q
DM4KP5M	MN	Polypeptide deformylase (PDF)
DM4KP5M	MT	DTT
DM4KP5M	MA	Inhibitor
DM4KP5M	RN	CoMFA analysis of tgDHFR and rlDHFR based on antifolates with 6-5 fused ring system using the all-orientation search (AOS) routine and a modified c... Bioorg Med Chem. 2010 Feb 15;18(4):1684-701.
DM4KP5M	RU	https://pubmed.ncbi.nlm.nih.gov/20117005

DM5TSJF	DI	DM5TSJF
DM5TSJF	DN	8-(2,4,6-trimethoxyphenyl)-9H-purine-2,6-diamine
DM5TSJF	MI	TT9SL3Q
DM5TSJF	MN	Polypeptide deformylase (PDF)
DM5TSJF	MT	DTT
DM5TSJF	MA	Inhibitor
DM5TSJF	RN	CoMFA analysis of tgDHFR and rlDHFR based on antifolates with 6-5 fused ring system using the all-orientation search (AOS) routine and a modified c... Bioorg Med Chem. 2010 Feb 15;18(4):1684-701.
DM5TSJF	RU	https://pubmed.ncbi.nlm.nih.gov/20117005

DMJPYIZ	DI	DMJPYIZ
DMJPYIZ	DN	8-(2,4-dimethoxyphenyl)-9H-purine-2,6-diamine
DMJPYIZ	MI	TT9SL3Q
DMJPYIZ	MN	Polypeptide deformylase (PDF)
DMJPYIZ	MT	DTT
DMJPYIZ	MA	Inhibitor
DMJPYIZ	RN	CoMFA analysis of tgDHFR and rlDHFR based on antifolates with 6-5 fused ring system using the all-orientation search (AOS) routine and a modified c... Bioorg Med Chem. 2010 Feb 15;18(4):1684-701.
DMJPYIZ	RU	https://pubmed.ncbi.nlm.nih.gov/20117005

DM0MIGU	DI	DM0MIGU
DM0MIGU	DN	8-(2,5-dimethoxyphenyl)-9H-purine-2,6-diamine
DM0MIGU	MI	TT9SL3Q
DM0MIGU	MN	Polypeptide deformylase (PDF)
DM0MIGU	MT	DTT
DM0MIGU	MA	Inhibitor
DM0MIGU	RN	CoMFA analysis of tgDHFR and rlDHFR based on antifolates with 6-5 fused ring system using the all-orientation search (AOS) routine and a modified c... Bioorg Med Chem. 2010 Feb 15;18(4):1684-701.
DM0MIGU	RU	https://pubmed.ncbi.nlm.nih.gov/20117005

DMECWL1	DI	DMECWL1
DMECWL1	DN	8-(2,6-Dichloro-phenyl)-9H-purine-2,6-diamine
DMECWL1	MI	TT9SL3Q
DMECWL1	MN	Polypeptide deformylase (PDF)
DMECWL1	MT	DTT
DMECWL1	MA	Inhibitor
DMECWL1	RN	Conformationally restricted analogues of trimethoprim: 2,6-diamino-8-substituted purines as potential dihydrofolate reductase inhibitors from Pneum... J Med Chem. 1997 Sep 12;40(19):3032-9.
DMECWL1	RU	https://pubmed.ncbi.nlm.nih.gov/9301665

DM8SRM0	DI	DM8SRM0
DM8SRM0	DN	8-(2-acetylphenyl)-2-morpholin-4-ylchromen-4-one
DM8SRM0	MI	TTK3PY9
DM8SRM0	MN	DNA-dependent protein kinase catalytic (PRKDC)
DM8SRM0	MT	DTT
DM8SRM0	MA	Inhibitor
DM8SRM0	RN	Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46.
DM8SRM0	RU	https://pubmed.ncbi.nlm.nih.gov/16302822

DMJKL3Z	DI	DMJKL3Z
DMJKL3Z	DN	8-(2-Cyclopropyl-ethoxy)-quinolin-2-ylamine
DMJKL3Z	MI	TTX4RTB
DMJKL3Z	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMJKL3Z	MT	DTT
DMJKL3Z	MA	Inhibitor
DMJKL3Z	RN	Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7.
DMJKL3Z	RU	https://pubmed.ncbi.nlm.nih.gov/15341942

DMOB8XT	DI	DMOB8XT
DMOB8XT	DN	8-(2-Ethoxy-1-methyl-ethoxy)-quinolin-2-ylamine
DMOB8XT	MI	TTX4RTB
DMOB8XT	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMOB8XT	MT	DTT
DMOB8XT	MA	Inhibitor
DMOB8XT	RN	Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7.
DMOB8XT	RU	https://pubmed.ncbi.nlm.nih.gov/15341942

DMSKTVW	DI	DMSKTVW
DMSKTVW	DN	8-(2-Ethyl-1-methyl-butoxy)-quinolin-2-ylamine
DMSKTVW	MI	TTX4RTB
DMSKTVW	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMSKTVW	MT	DTT
DMSKTVW	MA	Inhibitor
DMSKTVW	RN	Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7.
DMSKTVW	RU	https://pubmed.ncbi.nlm.nih.gov/15341942

DMA5K04	DI	DMA5K04
DMA5K04	DN	8-(2-Methoxy-1-methyl-ethoxy)-quinolin-2-ylamine
DMA5K04	MI	TTX4RTB
DMA5K04	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMA5K04	MT	DTT
DMA5K04	MA	Inhibitor
DMA5K04	RN	Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7.
DMA5K04	RU	https://pubmed.ncbi.nlm.nih.gov/15341942

DMVBRMF	DI	DMVBRMF
DMVBRMF	DN	8-(2-Methyl-butoxy)-quinolin-2-ylamine
DMVBRMF	MI	TTX4RTB
DMVBRMF	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMVBRMF	MT	DTT
DMVBRMF	MA	Inhibitor
DMVBRMF	RN	Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7.
DMVBRMF	RU	https://pubmed.ncbi.nlm.nih.gov/15341942

DMUIFJY	DI	DMUIFJY
DMUIFJY	DN	8-(2-Methyl-cyclohexyloxy)-quinolin-2-ylamine
DMUIFJY	MI	TTX4RTB
DMUIFJY	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMUIFJY	MT	DTT
DMUIFJY	MA	Inhibitor
DMUIFJY	RN	Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7.
DMUIFJY	RU	https://pubmed.ncbi.nlm.nih.gov/15341942

DMQUZSJ	DI	DMQUZSJ
DMQUZSJ	DN	8-(2-methylpropyl)naringenin
DMQUZSJ	MI	TTZAYWL
DMQUZSJ	MN	Estrogen receptor (ESR)
DMQUZSJ	MT	DTT
DMQUZSJ	MA	Inhibitor
DMQUZSJ	RN	Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65.
DMQUZSJ	RU	https://pubmed.ncbi.nlm.nih.gov/17149865

DMQUZSJ	DI	DMQUZSJ
DMQUZSJ	DN	8-(2-methylpropyl)naringenin
DMQUZSJ	MI	TTOM3J0
DMQUZSJ	MN	Estrogen receptor beta (ESR2)
DMQUZSJ	MT	DTT
DMQUZSJ	MA	Inhibitor
DMQUZSJ	RN	Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65.
DMQUZSJ	RU	https://pubmed.ncbi.nlm.nih.gov/17149865

DMRUP0A	DI	DMRUP0A
DMRUP0A	DN	8-(3,3,3-trifluoropropoxy)quinolin-2-amine
DMRUP0A	MI	TTX4RTB
DMRUP0A	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMRUP0A	MT	DTT
DMRUP0A	MA	Inhibitor
DMRUP0A	RN	Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7.
DMRUP0A	RU	https://pubmed.ncbi.nlm.nih.gov/15341942

DM72EM9	DI	DM72EM9
DM72EM9	DN	8-(3,3-Dimethyl-butoxy)-quinolin-2-ylamine
DM72EM9	MI	TTX4RTB
DM72EM9	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DM72EM9	MT	DTT
DM72EM9	MA	Inhibitor
DM72EM9	RN	Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7.
DM72EM9	RU	https://pubmed.ncbi.nlm.nih.gov/15341942

DMV63G1	DI	DMV63G1
DMV63G1	DN	8-(3,4,5-trimethoxyphenyl)-9H-purine-2,6-diamine
DMV63G1	MI	TT9SL3Q
DMV63G1	MN	Polypeptide deformylase (PDF)
DMV63G1	MT	DTT
DMV63G1	MA	Inhibitor
DMV63G1	RN	CoMFA analysis of tgDHFR and rlDHFR based on antifolates with 6-5 fused ring system using the all-orientation search (AOS) routine and a modified c... Bioorg Med Chem. 2010 Feb 15;18(4):1684-701.
DMV63G1	RU	https://pubmed.ncbi.nlm.nih.gov/20117005

DMZU0YF	DI	DMZU0YF
DMZU0YF	DN	8-(3,4-dichlorophenyl)-9H-purine-2,6-diamine
DMZU0YF	MI	TT9SL3Q
DMZU0YF	MN	Polypeptide deformylase (PDF)
DMZU0YF	MT	DTT
DMZU0YF	MA	Inhibitor
DMZU0YF	RN	CoMFA analysis of tgDHFR and rlDHFR based on antifolates with 6-5 fused ring system using the all-orientation search (AOS) routine and a modified c... Bioorg Med Chem. 2010 Feb 15;18(4):1684-701.
DMZU0YF	RU	https://pubmed.ncbi.nlm.nih.gov/20117005

DMYZC3I	DI	DMYZC3I
DMYZC3I	DN	8-(3,4-dimethoxyphenyl)-9H-purine-2,6-diamine
DMYZC3I	MI	TT9SL3Q
DMYZC3I	MN	Polypeptide deformylase (PDF)
DMYZC3I	MT	DTT
DMYZC3I	MA	Inhibitor
DMYZC3I	RN	CoMFA analysis of tgDHFR and rlDHFR based on antifolates with 6-5 fused ring system using the all-orientation search (AOS) routine and a modified c... Bioorg Med Chem. 2010 Feb 15;18(4):1684-701.
DMYZC3I	RU	https://pubmed.ncbi.nlm.nih.gov/20117005

DM920XR	DI	DM920XR
DM920XR	DN	8-(3,5-dimethoxyphenyl)-9H-purine-2,6-diamine
DM920XR	MI	TT9SL3Q
DM920XR	MN	Polypeptide deformylase (PDF)
DM920XR	MT	DTT
DM920XR	MA	Inhibitor
DM920XR	RN	CoMFA analysis of tgDHFR and rlDHFR based on antifolates with 6-5 fused ring system using the all-orientation search (AOS) routine and a modified c... Bioorg Med Chem. 2010 Feb 15;18(4):1684-701.
DM920XR	RU	https://pubmed.ncbi.nlm.nih.gov/20117005

DM9J2LT	DI	DM9J2LT
DM9J2LT	DN	8-(3-Azido-phenyl)-6-iodo-quinoline
DM9J2LT	MI	TTZ97H5
DM9J2LT	MN	Phosphodiesterase 4A (PDE4A)
DM9J2LT	MT	DTT
DM9J2LT	MA	Inhibitor
DM9J2LT	RN	Hunting the emesis and efficacy targets of PDE4 inhibitors: identification of the photoaffinity probe 8-(3-azidophenyl)-6- [(4-iodo-1H-1-imidazolyl... J Med Chem. 2000 Oct 19;43(21):3820-3.
DM9J2LT	RU	https://pubmed.ncbi.nlm.nih.gov/11052785

DMON7RZ	DI	DMON7RZ
DMON7RZ	DN	8-(3-Azido-phenyl)-6-pyridin-4-ylmethyl-quinoline
DMON7RZ	MI	TTZ97H5
DMON7RZ	MN	Phosphodiesterase 4A (PDE4A)
DMON7RZ	MT	DTT
DMON7RZ	MA	Inhibitor
DMON7RZ	RN	Hunting the emesis and efficacy targets of PDE4 inhibitors: identification of the photoaffinity probe 8-(3-azidophenyl)-6- [(4-iodo-1H-1-imidazolyl... J Med Chem. 2000 Oct 19;43(21):3820-3.
DMON7RZ	RU	https://pubmed.ncbi.nlm.nih.gov/11052785

DMW2NJR	DI	DMW2NJR
DMW2NJR	DN	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide
DMW2NJR	MI	TT6R7JZ
DMW2NJR	MN	Histone deacetylase 1 (HDAC1)
DMW2NJR	MT	DTT
DMW2NJR	MA	Inhibitor
DMW2NJR	RN	Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3314-21.
DMW2NJR	RU	https://pubmed.ncbi.nlm.nih.gov/20451378

DM2RA4N	DI	DM2RA4N
DM2RA4N	DN	8-(3-Bromobenzyloxy)caffeine
DM2RA4N	MI	TT3WG5C
DM2RA4N	MN	Monoamine oxidase type A (MAO-A)
DM2RA4N	MT	DTT
DM2RA4N	MA	Inhibitor
DM2RA4N	RN	Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues. Bioorg Med Chem. 2010 Feb;18(3):1018-28.
DM2RA4N	RU	https://pubmed.ncbi.nlm.nih.gov/20093036

DM2RA4N	DI	DM2RA4N
DM2RA4N	DN	8-(3-Bromobenzyloxy)caffeine
DM2RA4N	MI	TTGP7BY
DM2RA4N	MN	Monoamine oxidase type B (MAO-B)
DM2RA4N	MT	DTT
DM2RA4N	MA	Inhibitor
DM2RA4N	RN	Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues. Bioorg Med Chem. 2010 Feb;18(3):1018-28.
DM2RA4N	RU	https://pubmed.ncbi.nlm.nih.gov/20093036

DM7HMNP	DI	DM7HMNP
DM7HMNP	DN	8-(3-Chlorobenzyloxy)caffeine
DM7HMNP	MI	TT3WG5C
DM7HMNP	MN	Monoamine oxidase type A (MAO-A)
DM7HMNP	MT	DTT
DM7HMNP	MA	Inhibitor
DM7HMNP	RN	Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues. Bioorg Med Chem. 2010 Feb;18(3):1018-28.
DM7HMNP	RU	https://pubmed.ncbi.nlm.nih.gov/20093036

DM7HMNP	DI	DM7HMNP
DM7HMNP	DN	8-(3-Chlorobenzyloxy)caffeine
DM7HMNP	MI	TTGP7BY
DM7HMNP	MN	Monoamine oxidase type B (MAO-B)
DM7HMNP	MT	DTT
DM7HMNP	MA	Inhibitor
DM7HMNP	RN	Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues. Bioorg Med Chem. 2010 Feb;18(3):1018-28.
DM7HMNP	RU	https://pubmed.ncbi.nlm.nih.gov/20093036

DME85GS	DI	DME85GS
DME85GS	DN	8-(3-Fluorobenzyloxy)caffeine
DME85GS	MI	TT3WG5C
DME85GS	MN	Monoamine oxidase type A (MAO-A)
DME85GS	MT	DTT
DME85GS	MA	Inhibitor
DME85GS	RN	Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues. Bioorg Med Chem. 2010 Feb;18(3):1018-28.
DME85GS	RU	https://pubmed.ncbi.nlm.nih.gov/20093036

DME85GS	DI	DME85GS
DME85GS	DN	8-(3-Fluorobenzyloxy)caffeine
DME85GS	MI	TTGP7BY
DME85GS	MN	Monoamine oxidase type B (MAO-B)
DME85GS	MT	DTT
DME85GS	MA	Inhibitor
DME85GS	RN	Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues. Bioorg Med Chem. 2010 Feb;18(3):1018-28.
DME85GS	RU	https://pubmed.ncbi.nlm.nih.gov/20093036

DMLQPVH	DI	DMLQPVH
DMLQPVH	DN	8-(3-Fluoro-phenyl)-9-methyl-9H-purin-6-ylamine
DMLQPVH	MI	TTNE7KG
DMLQPVH	MN	Adenosine A2b receptor (ADORA2B)
DMLQPVH	MT	DTT
DMLQPVH	MA	Inhibitor
DMLQPVH	RN	2-Alkynyl-8-aryl-9-methyladenines as novel adenosine receptor antagonists: their synthesis and structure-activity relationships toward hepatic gluc... J Med Chem. 2001 Jan 18;44(2):170-9.
DMLQPVH	RU	https://pubmed.ncbi.nlm.nih.gov/11170626

DM15LVG	DI	DM15LVG
DM15LVG	DN	8-(3-hydroxyphenyl)-2-morpholin-4-ylchromen-4-one
DM15LVG	MI	TTK3PY9
DM15LVG	MN	DNA-dependent protein kinase catalytic (PRKDC)
DM15LVG	MT	DTT
DM15LVG	MA	Inhibitor
DM15LVG	RN	Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46.
DM15LVG	RU	https://pubmed.ncbi.nlm.nih.gov/16302822

DM3WEQA	DI	DM3WEQA
DM3WEQA	DN	8-(3-Methoxy-3-methyl-butoxy)-quinolin-2-ylamine
DM3WEQA	MI	TTX4RTB
DM3WEQA	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DM3WEQA	MT	DTT
DM3WEQA	MA	Inhibitor
DM3WEQA	RN	Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7.
DM3WEQA	RU	https://pubmed.ncbi.nlm.nih.gov/15341942

DMLY46X	DI	DMLY46X
DMLY46X	DN	8-(3-Methoxybenzyloxy)caffeine
DMLY46X	MI	TT3WG5C
DMLY46X	MN	Monoamine oxidase type A (MAO-A)
DMLY46X	MT	DTT
DMLY46X	MA	Inhibitor
DMLY46X	RN	Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues. Bioorg Med Chem. 2010 Feb;18(3):1018-28.
DMLY46X	RU	https://pubmed.ncbi.nlm.nih.gov/20093036

DMLY46X	DI	DMLY46X
DMLY46X	DN	8-(3-Methoxybenzyloxy)caffeine
DMLY46X	MI	TTGP7BY
DMLY46X	MN	Monoamine oxidase type B (MAO-B)
DMLY46X	MT	DTT
DMLY46X	MA	Inhibitor
DMLY46X	RN	Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues. Bioorg Med Chem. 2010 Feb;18(3):1018-28.
DMLY46X	RU	https://pubmed.ncbi.nlm.nih.gov/20093036

DMB9645	DI	DMB9645
DMB9645	DN	8-(3-Methylbenzyloxy)caffeine
DMB9645	MI	TT3WG5C
DMB9645	MN	Monoamine oxidase type A (MAO-A)
DMB9645	MT	DTT
DMB9645	MA	Inhibitor
DMB9645	RN	Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues. Bioorg Med Chem. 2010 Feb;18(3):1018-28.
DMB9645	RU	https://pubmed.ncbi.nlm.nih.gov/20093036

DMB9645	DI	DMB9645
DMB9645	DN	8-(3-Methylbenzyloxy)caffeine
DMB9645	MI	TTGP7BY
DMB9645	MN	Monoamine oxidase type B (MAO-B)
DMB9645	MT	DTT
DMB9645	MA	Inhibitor
DMB9645	RN	Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues. Bioorg Med Chem. 2010 Feb;18(3):1018-28.
DMB9645	RU	https://pubmed.ncbi.nlm.nih.gov/20093036

DMNYPCQ	DI	DMNYPCQ
DMNYPCQ	DN	8-(3-Methyl-butoxy)-quinolin-2-ylamine
DMNYPCQ	MI	TTX4RTB
DMNYPCQ	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMNYPCQ	MT	DTT
DMNYPCQ	MA	Inhibitor
DMNYPCQ	RN	Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7.
DMNYPCQ	RU	https://pubmed.ncbi.nlm.nih.gov/15341942

DM2VAJE	DI	DM2VAJE
DM2VAJE	DN	8-(3-methylbutyl)naringenin
DM2VAJE	MI	TTZAYWL
DM2VAJE	MN	Estrogen receptor (ESR)
DM2VAJE	MT	DTT
DM2VAJE	MA	Inhibitor
DM2VAJE	RN	Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65.
DM2VAJE	RU	https://pubmed.ncbi.nlm.nih.gov/17149865

DM2VAJE	DI	DM2VAJE
DM2VAJE	DN	8-(3-methylbutyl)naringenin
DM2VAJE	MI	TTOM3J0
DM2VAJE	MN	Estrogen receptor beta (ESR2)
DM2VAJE	MT	DTT
DM2VAJE	MA	Inhibitor
DM2VAJE	RN	Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65.
DM2VAJE	RU	https://pubmed.ncbi.nlm.nih.gov/17149865

DMPMJHV	DI	DMPMJHV
DMPMJHV	DN	8-(3-Methyl-cyclohexyloxy)-quinolin-2-ylamine
DMPMJHV	MI	TTX4RTB
DMPMJHV	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMPMJHV	MT	DTT
DMPMJHV	MA	Inhibitor
DMPMJHV	RN	Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7.
DMPMJHV	RU	https://pubmed.ncbi.nlm.nih.gov/15341942

DM8N314	DI	DM8N314
DM8N314	DN	8-(3-Methyl-cyclopentyloxy)-quinolin-2-ylamine
DM8N314	MI	TTX4RTB
DM8N314	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DM8N314	MT	DTT
DM8N314	MA	Inhibitor
DM8N314	RN	Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7.
DM8N314	RU	https://pubmed.ncbi.nlm.nih.gov/15341942

DMP6Z3R	DI	DMP6Z3R
DMP6Z3R	DN	8-(3-Nitro-phenyl)-6-phenyl-[1,7]naphthyridine
DMP6Z3R	MI	TTZ97H5
DMP6Z3R	MN	Phosphodiesterase 4A (PDE4A)
DMP6Z3R	MT	DTT
DMP6Z3R	MA	Inhibitor
DMP6Z3R	RN	Palladium-catalyzed cross-coupling reactions for the synthesis of 6, 8-disubstituted 1,7-naphthyridines: a novel class of potent and selective phos... J Med Chem. 2000 Feb 24;43(4):675-82.
DMP6Z3R	RU	https://pubmed.ncbi.nlm.nih.gov/10691693

DMP6Z3R	DI	DMP6Z3R
DMP6Z3R	DN	8-(3-Nitro-phenyl)-6-phenyl-[1,7]naphthyridine
DMP6Z3R	MI	TTVIAT9
DMP6Z3R	MN	Phosphodiesterase 4B (PDE4B)
DMP6Z3R	MT	DTT
DMP6Z3R	MA	Inhibitor
DMP6Z3R	RN	Palladium-catalyzed cross-coupling reactions for the synthesis of 6, 8-disubstituted 1,7-naphthyridines: a novel class of potent and selective phos... J Med Chem. 2000 Feb 24;43(4):675-82.
DMP6Z3R	RU	https://pubmed.ncbi.nlm.nih.gov/10691693

DM0N68L	DI	DM0N68L
DM0N68L	DN	8-(3-Nitro-phenyl)-6-pyridin-4-ylmethyl-quinoline
DM0N68L	MI	TTZ97H5
DM0N68L	MN	Phosphodiesterase 4A (PDE4A)
DM0N68L	MT	DTT
DM0N68L	MA	Inhibitor
DM0N68L	RN	Hunting the emesis and efficacy targets of PDE4 inhibitors: identification of the photoaffinity probe 8-(3-azidophenyl)-6- [(4-iodo-1H-1-imidazolyl... J Med Chem. 2000 Oct 19;43(21):3820-3.
DM0N68L	RU	https://pubmed.ncbi.nlm.nih.gov/11052785

DMAK0P3	DI	DMAK0P3
DMAK0P3	DN	8-(4-acetylphenyl)-2-morpholin-4-ylchromen-4-one
DMAK0P3	MI	TTK3PY9
DMAK0P3	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMAK0P3	MT	DTT
DMAK0P3	MA	Inhibitor
DMAK0P3	RN	Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46.
DMAK0P3	RU	https://pubmed.ncbi.nlm.nih.gov/16302822

DMVOCWY	DI	DMVOCWY
DMVOCWY	DN	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide
DMVOCWY	MI	TT6R7JZ
DMVOCWY	MN	Histone deacetylase 1 (HDAC1)
DMVOCWY	MT	DTT
DMVOCWY	MA	Inhibitor
DMVOCWY	RN	3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. Eur J Med Chem. 2009 Jul;44(7):2868-76.
DMVOCWY	RU	https://pubmed.ncbi.nlm.nih.gov/19136179

DM4186A	DI	DM4186A
DM4186A	DN	8-(4-chlorophenyl)-2-morpholin-4-ylchromen-4-one
DM4186A	MI	TTK3PY9
DM4186A	MN	DNA-dependent protein kinase catalytic (PRKDC)
DM4186A	MT	DTT
DM4186A	MA	Inhibitor
DM4186A	RN	Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46.
DM4186A	RU	https://pubmed.ncbi.nlm.nih.gov/16302822

DMLANGY	DI	DMLANGY
DMLANGY	DN	8-(4-hydroxyphenyl)-2-morpholin-4-ylchromen-4-one
DMLANGY	MI	TTK3PY9
DMLANGY	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMLANGY	MT	DTT
DMLANGY	MA	Inhibitor
DMLANGY	RN	Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46.
DMLANGY	RU	https://pubmed.ncbi.nlm.nih.gov/16302822

DMPVQN3	DI	DMPVQN3
DMPVQN3	DN	8-(4-Methyl-cyclohexyloxy)-quinolin-2-ylamine
DMPVQN3	MI	TTX4RTB
DMPVQN3	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMPVQN3	MT	DTT
DMPVQN3	MA	Inhibitor
DMPVQN3	RN	Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7.
DMPVQN3	RU	https://pubmed.ncbi.nlm.nih.gov/15341942

DMH3SDO	DI	DMH3SDO
DMH3SDO	DN	8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one
DMH3SDO	MI	TT6R7JZ
DMH3SDO	MN	Histone deacetylase 1 (HDAC1)
DMH3SDO	MT	DTT
DMH3SDO	MA	Inhibitor
DMH3SDO	RN	Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3443-7.
DMH3SDO	RU	https://pubmed.ncbi.nlm.nih.gov/12419380

DMH3SDO	DI	DMH3SDO
DMH3SDO	DN	8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one
DMH3SDO	MI	TTSHTOI
DMH3SDO	MN	Histone deacetylase 2 (HDAC2)
DMH3SDO	MT	DTT
DMH3SDO	MA	Inhibitor
DMH3SDO	RN	Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3443-7.
DMH3SDO	RU	https://pubmed.ncbi.nlm.nih.gov/12419380

DMD6VSY	DI	DMD6VSY
DMD6VSY	DN	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide
DMD6VSY	MI	TT6R7JZ
DMD6VSY	MN	Histone deacetylase 1 (HDAC1)
DMD6VSY	MT	DTT
DMD6VSY	MA	Inhibitor
DMD6VSY	RN	3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. Eur J Med Chem. 2009 Jul;44(7):2868-76.
DMD6VSY	RU	https://pubmed.ncbi.nlm.nih.gov/19136179

DM23XGW	DI	DM23XGW
DM23XGW	DN	8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one
DM23XGW	MI	TTBH0VX
DM23XGW	MN	Histone deacetylase (HDAC)
DM23XGW	MT	DTT
DM23XGW	MA	Inhibitor
DM23XGW	RN	Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.
DM23XGW	RU	https://pubmed.ncbi.nlm.nih.gov/14592473

DM23XGW	DI	DM23XGW
DM23XGW	DN	8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one
DM23XGW	MI	TT6R7JZ
DM23XGW	MN	Histone deacetylase 1 (HDAC1)
DM23XGW	MT	DTT
DM23XGW	MA	Inhibitor
DM23XGW	RN	Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3443-7.
DM23XGW	RU	https://pubmed.ncbi.nlm.nih.gov/12419380

DM23XGW	DI	DM23XGW
DM23XGW	DN	8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one
DM23XGW	MI	TTYHPU6
DM23XGW	MN	Histone deacetylase 10 (HDAC10)
DM23XGW	MT	DTT
DM23XGW	MA	Inhibitor
DM23XGW	RN	Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.
DM23XGW	RU	https://pubmed.ncbi.nlm.nih.gov/14592473

DM23XGW	DI	DM23XGW
DM23XGW	DN	8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one
DM23XGW	MI	TTSHTOI
DM23XGW	MN	Histone deacetylase 2 (HDAC2)
DM23XGW	MT	DTT
DM23XGW	MA	Inhibitor
DM23XGW	RN	Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3443-7.
DM23XGW	RU	https://pubmed.ncbi.nlm.nih.gov/12419380

DM23XGW	DI	DM23XGW
DM23XGW	DN	8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one
DM23XGW	MI	TTTQGH8
DM23XGW	MN	Histone deacetylase 4 (HDAC4)
DM23XGW	MT	DTT
DM23XGW	MA	Inhibitor
DM23XGW	RN	Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.
DM23XGW	RU	https://pubmed.ncbi.nlm.nih.gov/14592473

DM23XGW	DI	DM23XGW
DM23XGW	DN	8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one
DM23XGW	MI	TT5ZKDI
DM23XGW	MN	Histone deacetylase 6 (HDAC6)
DM23XGW	MT	DTT
DM23XGW	MA	Inhibitor
DM23XGW	RN	Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.
DM23XGW	RU	https://pubmed.ncbi.nlm.nih.gov/14592473

DM23XGW	DI	DM23XGW
DM23XGW	DN	8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one
DM23XGW	MI	TTT6LFV
DM23XGW	MN	Histone deacetylase 8 (HDAC8)
DM23XGW	MT	DTT
DM23XGW	MA	Inhibitor
DM23XGW	RN	Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.
DM23XGW	RU	https://pubmed.ncbi.nlm.nih.gov/14592473

DMDIGPW	DI	DMDIGPW
DMDIGPW	DN	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid
DMDIGPW	MI	TT6R7JZ
DMDIGPW	MN	Histone deacetylase 1 (HDAC1)
DMDIGPW	MT	DTT
DMDIGPW	MA	Inhibitor
DMDIGPW	RN	Alpha-keto amides as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Oct 6;13(19):3331-5.
DMDIGPW	RU	https://pubmed.ncbi.nlm.nih.gov/12951120

DMDIGPW	DI	DMDIGPW
DMDIGPW	DN	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid
DMDIGPW	MI	TTSHTOI
DMDIGPW	MN	Histone deacetylase 2 (HDAC2)
DMDIGPW	MT	DTT
DMDIGPW	MA	Inhibitor
DMDIGPW	RN	Alpha-keto amides as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Oct 6;13(19):3331-5.
DMDIGPW	RU	https://pubmed.ncbi.nlm.nih.gov/12951120

DMT1NW2	DI	DMT1NW2
DMT1NW2	DN	8(S)-amino-2(R)-methyl-7-oxononanoic acid
DMT1NW2	MI	TTXZEAJ
DMT1NW2	MN	Leukotriene A-4 hydrolase (LTA4H)
DMT1NW2	MT	DTT
DMT1NW2	MA	Inhibitor
DMT1NW2	RN	Isolation and structure of leukotriene-A4 hydrolase inhibitor: 8(S)-amino-2(R)-methyl-7-oxononanoic acid produced by Streptomyces diastaticus. J Nat Prod. 1996 Oct;59(10):962-4.
DMT1NW2	RU	https://pubmed.ncbi.nlm.nih.gov/8904845

DMT3IOB	DI	DMT3IOB
DMT3IOB	DN	8-[(3-Trifluoromethyl)benzyloxy]caffeine
DMT3IOB	MI	TT3WG5C
DMT3IOB	MN	Monoamine oxidase type A (MAO-A)
DMT3IOB	MT	DTT
DMT3IOB	MA	Inhibitor
DMT3IOB	RN	Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues. Bioorg Med Chem. 2010 Feb;18(3):1018-28.
DMT3IOB	RU	https://pubmed.ncbi.nlm.nih.gov/20093036

DMT3IOB	DI	DMT3IOB
DMT3IOB	DN	8-[(3-Trifluoromethyl)benzyloxy]caffeine
DMT3IOB	MI	TTGP7BY
DMT3IOB	MN	Monoamine oxidase type B (MAO-B)
DMT3IOB	MT	DTT
DMT3IOB	MA	Inhibitor
DMT3IOB	RN	Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues. Bioorg Med Chem. 2010 Feb;18(3):1018-28.
DMT3IOB	RU	https://pubmed.ncbi.nlm.nih.gov/20093036

DM4R2EX	DI	DM4R2EX
DM4R2EX	DN	8-acetyl-7-(benzyloxy)-2H-chromen-2-one
DM4R2EX	MI	TT2LVK8
DM4R2EX	MN	Carbonic anhydrase IX (CA-IX)
DM4R2EX	MT	DTT
DM4R2EX	MA	Inhibitor
DM4R2EX	RN	7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and X... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7255-8.
DM4R2EX	RU	https://pubmed.ncbi.nlm.nih.gov/21067924

DMCTWBL	DI	DMCTWBL
DMCTWBL	DN	8-acetyl-7-butoxy-2H-chromen-2-one
DMCTWBL	MI	TT2LVK8
DMCTWBL	MN	Carbonic anhydrase IX (CA-IX)
DMCTWBL	MT	DTT
DMCTWBL	MA	Inhibitor
DMCTWBL	RN	7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and X... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7255-8.
DMCTWBL	RU	https://pubmed.ncbi.nlm.nih.gov/21067924

DMDV8UT	DI	DMDV8UT
DMDV8UT	DN	8-acetyl-7-ethoxy-2H-chromen-2-one
DMDV8UT	MI	TT2LVK8
DMDV8UT	MN	Carbonic anhydrase IX (CA-IX)
DMDV8UT	MT	DTT
DMDV8UT	MA	Inhibitor
DMDV8UT	RN	7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and X... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7255-8.
DMDV8UT	RU	https://pubmed.ncbi.nlm.nih.gov/21067924

DMAMJW2	DI	DMAMJW2
DMAMJW2	DN	8-Acetyl-7-hydroxy-2H-chromen-2-one
DMAMJW2	MI	TT2LVK8
DMAMJW2	MN	Carbonic anhydrase IX (CA-IX)
DMAMJW2	MT	DTT
DMAMJW2	MA	Inhibitor
DMAMJW2	RN	7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and X... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7255-8.
DMAMJW2	RU	https://pubmed.ncbi.nlm.nih.gov/21067924

DMZSJRC	DI	DMZSJRC
DMZSJRC	DN	8-acetyl-7-methoxy-2H-chromen-2-one
DMZSJRC	MI	TT2LVK8
DMZSJRC	MN	Carbonic anhydrase IX (CA-IX)
DMZSJRC	MT	DTT
DMZSJRC	MA	Inhibitor
DMZSJRC	RN	7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and X... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7255-8.
DMZSJRC	RU	https://pubmed.ncbi.nlm.nih.gov/21067924

DMGRK3V	DI	DMGRK3V
DMGRK3V	DN	8-acetyl-7-propoxy-2H-chromen-2-one
DMGRK3V	MI	TT2LVK8
DMGRK3V	MN	Carbonic anhydrase IX (CA-IX)
DMGRK3V	MT	DTT
DMGRK3V	MA	Inhibitor
DMGRK3V	RN	7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and X... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7255-8.
DMGRK3V	RU	https://pubmed.ncbi.nlm.nih.gov/21067924

DM7K2DN	DI	DM7K2DN
DM7K2DN	DN	8alpha,19-dihydroxylabd-13 E-en-15-oic acid
DM7K2DN	MI	TTVKILB
DM7K2DN	MN	Prostaglandin G/H synthase 2 (COX-2)
DM7K2DN	MT	DTT
DM7K2DN	MA	Inhibitor
DM7K2DN	RN	Cyclooxygenase (COX)-1 and -2 inhibitory labdane diterpenes from Crassocephalum mannii. J Nat Prod. 2008 Jun;71(6):1070-3.
DM7K2DN	RU	https://pubmed.ncbi.nlm.nih.gov/18473477

DM84D9W	DI	DM84D9W
DM84D9W	DN	8-Amino-1,3-Dimethyl-3,7-Dihydropurine-2,6-Dione
DM84D9W	MI	TTG9CFY
DM84D9W	MN	Bacterial Dihydroneopterinaldolase (Bact folB)
DM84D9W	MT	DTT
DM84D9W	MA	Inhibitor
DM84D9W	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM84D9W	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMTRBDP	DI	DMTRBDP
DMTRBDP	DN	8-Amino-6H,11H-indeno[1,2-c]isoquinolin-5-one
DMTRBDP	MI	TTVDSZ0
DMTRBDP	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMTRBDP	MT	DTT
DMTRBDP	MA	Inhibitor
DMTRBDP	RN	Discovery of potent poly(ADP-ribose) polymerase-1 inhibitors from the modification of indeno[1,2-c]isoquinolinone. J Med Chem. 2005 Aug 11;48(16):5100-3.
DMTRBDP	RU	https://pubmed.ncbi.nlm.nih.gov/16078828

DMSNG7M	DI	DMSNG7M
DMSNG7M	DN	8-amino-9-benzylguanine
DMSNG7M	MI	TTMCF1Y
DMSNG7M	MN	Purine nucleoside phosphorylase (PNP)
DMSNG7M	MT	DTT
DMSNG7M	MA	Inhibitor
DMSNG7M	RN	Expression of human malaria parasite purine nucleoside phosphorylase in host enzyme-deficient erythrocyte culture. Enzyme characterization and identification of novel inhibitors. J Biol Chem. 1986 Sep 5;261(25):11667-73.
DMSNG7M	RU	https://pubmed.ncbi.nlm.nih.gov/3091593

DMYXJG7	DI	DMYXJG7
DMYXJG7	DN	8-AMINOGUANINE
DMYXJG7	MI	TTMCF1Y
DMYXJG7	MN	Purine nucleoside phosphorylase (PNP)
DMYXJG7	MT	DTT
DMYXJG7	MA	Inhibitor
DMYXJG7	RN	Nucleosides. 5. Synthesis of guanine and formycin B derivatives as potential inhibitors of purine nucleoside phosphorylase. J Med Chem. 1993 Apr 16;36(8):1024-31.
DMYXJG7	RU	https://pubmed.ncbi.nlm.nih.gov/8478902

DM0JEA6	DI	DM0JEA6
DM0JEA6	DN	8-aminoguanosine
DM0JEA6	MI	TTMCF1Y
DM0JEA6	MN	Purine nucleoside phosphorylase (PNP)
DM0JEA6	MT	DTT
DM0JEA6	MA	Inhibitor
DM0JEA6	RN	Differential metabolism of guanine nucleosides by human lymphoid cell lines. Proc Soc Exp Biol Med. 1985 Sep;179(4):427-31.
DM0JEA6	RU	https://pubmed.ncbi.nlm.nih.gov/3875100

DMN8QAF	DI	DMN8QAF
DMN8QAF	DN	8-aminoquinolines
DMN8QAF	MI	TTJSZTB
DMN8QAF	MN	Nicotinic acetylcholine receptor (nAChR)
DMN8QAF	MT	DTT
DMN8QAF	MA	Antagonist
DMN8QAF	RN	Opioids induce while nicotine suppresses apoptosis in human lung cancer cells. Cell Growth Differ. 1994 Oct;5(10):1033-40.
DMN8QAF	RU	https://pubmed.ncbi.nlm.nih.gov/7848904

DMN8QAF	DI	DMN8QAF
DMN8QAF	DN	8-aminoquinolines
DMN8QAF	MI	TT3PQ2Y
DMN8QAF	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DMN8QAF	MT	DTT
DMN8QAF	MA	Inhibitor
DMN8QAF	RN	The effects of antimalarials on the Plasmodium falciparum dihydroorotate dehydrogenase. Exp Parasitol. 1994 Aug;79(1):50-6.
DMN8QAF	RU	https://pubmed.ncbi.nlm.nih.gov/8050525

DMYBPGA	DI	DMYBPGA
DMYBPGA	DN	8-aza-11-deoxyprostaglandin E1
DMYBPGA	MI	TT79WV3
DMYBPGA	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DMYBPGA	MT	DTT
DMYBPGA	MA	Inhibitor
DMYBPGA	RN	Lactams as EP4 prostanoid receptor agonists. 3. Discovery of N-ethylbenzoic acid 2-pyrrolidinones as subtype selective agents. J Med Chem. 2004 Dec 2;47(25):6124-7.
DMYBPGA	RU	https://pubmed.ncbi.nlm.nih.gov/15566283

DMQMSZR	DI	DMQMSZR
DMQMSZR	DN	8-azabicyclo[3.2.1]octan-3-yloxy-benzamide
DMQMSZR	MI	TT27RFC
DMQMSZR	MN	Opioid receptor delta (OPRD1)
DMQMSZR	MT	DTT
DMQMSZR	MA	Inhibitor
DMQMSZR	RN	SAR development of a series of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as kappa opioid receptor antagonists. Part 2. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5405-10.
DMQMSZR	RU	https://pubmed.ncbi.nlm.nih.gov/20719509

DMQMSZR	DI	DMQMSZR
DMQMSZR	DN	8-azabicyclo[3.2.1]octan-3-yloxy-benzamide
DMQMSZR	MI	TTQW87Y
DMQMSZR	MN	Opioid receptor kappa (OPRK1)
DMQMSZR	MT	DTT
DMQMSZR	MA	Inhibitor
DMQMSZR	RN	SAR development of a series of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as kappa opioid receptor antagonists. Part 2. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5405-10.
DMQMSZR	RU	https://pubmed.ncbi.nlm.nih.gov/20719509

DMQMSZR	DI	DMQMSZR
DMQMSZR	DN	8-azabicyclo[3.2.1]octan-3-yloxy-benzamide
DMQMSZR	MI	TTKWM86
DMQMSZR	MN	Opioid receptor mu (MOP)
DMQMSZR	MT	DTT
DMQMSZR	MA	Inhibitor
DMQMSZR	RN	SAR development of a series of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as kappa opioid receptor antagonists. Part 2. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5405-10.
DMQMSZR	RU	https://pubmed.ncbi.nlm.nih.gov/20719509

DMQMSZR	DI	DMQMSZR
DMQMSZR	DN	8-azabicyclo[3.2.1]octan-3-yloxy-benzamide
DMQMSZR	MI	TTQ6VDM
DMQMSZR	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMQMSZR	MT	DTT
DMQMSZR	MA	Inhibitor
DMQMSZR	RN	SAR development of a series of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as kappa opioid receptor antagonists. Part 2. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5405-10.
DMQMSZR	RU	https://pubmed.ncbi.nlm.nih.gov/20719509

DMBVFKR	DI	DMBVFKR
DMBVFKR	DN	8-aza-DADMe-ImmH
DMBVFKR	MI	TTMCF1Y
DMBVFKR	MN	Purine nucleoside phosphorylase (PNP)
DMBVFKR	MT	DTT
DMBVFKR	MA	Inhibitor
DMBVFKR	RN	Achieving the ultimate physiological goal in transition state analogue inhibitors for purine nucleoside phosphorylase. J Biol Chem. 2003 Aug 22;278(34):31465-8.
DMBVFKR	RU	https://pubmed.ncbi.nlm.nih.gov/12842889

DM7VP90	DI	DM7VP90
DM7VP90	DN	8-Azaguanine
DM7VP90	MI	TTMCF1Y
DM7VP90	MN	Purine nucleoside phosphorylase (PNP)
DM7VP90	MT	DTT
DM7VP90	MA	Inhibitor
DM7VP90	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM7VP90	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMT8QAP	DI	DMT8QAP
DMT8QAP	DN	8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-
DMT8QAP	MI	TT78R5H
DMT8QAP	MN	Heat shock protein 90 alpha (HSP90A)
DMT8QAP	MT	DTT
DMT8QAP	MA	Inhibitor
DMT8QAP	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMT8QAP	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM32OQB	DI	DM32OQB
DM32OQB	DN	8-benzyl-9H-purine-2,6-diamine
DM32OQB	MI	TT9SL3Q
DM32OQB	MN	Polypeptide deformylase (PDF)
DM32OQB	MT	DTT
DM32OQB	MA	Inhibitor
DM32OQB	RN	CoMFA analysis of tgDHFR and rlDHFR based on antifolates with 6-5 fused ring system using the all-orientation search (AOS) routine and a modified c... Bioorg Med Chem. 2010 Feb 15;18(4):1684-701.
DM32OQB	RU	https://pubmed.ncbi.nlm.nih.gov/20117005

DMKHF87	DI	DMKHF87
DMKHF87	DN	8-benzylnaringenin
DMKHF87	MI	TTZAYWL
DMKHF87	MN	Estrogen receptor (ESR)
DMKHF87	MT	DTT
DMKHF87	MA	Inhibitor
DMKHF87	RN	Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65.
DMKHF87	RU	https://pubmed.ncbi.nlm.nih.gov/17149865

DMKHF87	DI	DMKHF87
DMKHF87	DN	8-benzylnaringenin
DMKHF87	MI	TTOM3J0
DMKHF87	MN	Estrogen receptor beta (ESR2)
DMKHF87	MT	DTT
DMKHF87	MA	Inhibitor
DMKHF87	RN	Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65.
DMKHF87	RU	https://pubmed.ncbi.nlm.nih.gov/17149865

DMJQ8AP	DI	DMJQ8AP
DMJQ8AP	DN	8-Benzyloxycaffeine
DMJQ8AP	MI	TT3WG5C
DMJQ8AP	MN	Monoamine oxidase type A (MAO-A)
DMJQ8AP	MT	DTT
DMJQ8AP	MA	Inhibitor
DMJQ8AP	RN	Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues. Bioorg Med Chem. 2010 Feb;18(3):1018-28.
DMJQ8AP	RU	https://pubmed.ncbi.nlm.nih.gov/20093036

DMJQ8AP	DI	DMJQ8AP
DMJQ8AP	DN	8-Benzyloxycaffeine
DMJQ8AP	MI	TTGP7BY
DMJQ8AP	MN	Monoamine oxidase type B (MAO-B)
DMJQ8AP	MT	DTT
DMJQ8AP	MA	Inhibitor
DMJQ8AP	RN	Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues. Bioorg Med Chem. 2010 Feb;18(3):1018-28.
DMJQ8AP	RU	https://pubmed.ncbi.nlm.nih.gov/20093036

DMMCAZG	DI	DMMCAZG
DMMCAZG	DN	8-biphenyl-2-yl-2-morpholin-4-ylchromen-4-one
DMMCAZG	MI	TTK3PY9
DMMCAZG	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMMCAZG	MT	DTT
DMMCAZG	MA	Inhibitor
DMMCAZG	RN	Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46.
DMMCAZG	RU	https://pubmed.ncbi.nlm.nih.gov/16302822

DMVPIYG	DI	DMVPIYG
DMVPIYG	DN	8-Br-adenine
DMVPIYG	MI	TTM2AOE
DMVPIYG	MN	Adenosine A2a receptor (ADORA2A)
DMVPIYG	MT	DTT
DMVPIYG	MA	Inhibitor
DMVPIYG	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMVPIYG	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMALRU4	DI	DMALRU4
DMALRU4	DN	8-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline
DMALRU4	MI	TTJQOD7
DMALRU4	MN	5-HT 2A receptor (HTR2A)
DMALRU4	MT	DTT
DMALRU4	MA	Inhibitor
DMALRU4	RN	Binding of beta-carbolines at 5-HT(2) serotonin receptors. Bioorg Med Chem Lett. 2003 Dec 15;13(24):4421-5.
DMALRU4	RU	https://pubmed.ncbi.nlm.nih.gov/14643338

DMALRU4	DI	DMALRU4
DMALRU4	DN	8-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline
DMALRU4	MI	TT3WG5C
DMALRU4	MN	Monoamine oxidase type A (MAO-A)
DMALRU4	MT	DTT
DMALRU4	MA	Inhibitor
DMALRU4	RN	Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
DMALRU4	RU	https://pubmed.ncbi.nlm.nih.gov/15013009

DMALRU4	DI	DMALRU4
DMALRU4	DN	8-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline
DMALRU4	MI	TTGP7BY
DMALRU4	MN	Monoamine oxidase type B (MAO-B)
DMALRU4	MT	DTT
DMALRU4	MA	Inhibitor
DMALRU4	RN	Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
DMALRU4	RU	https://pubmed.ncbi.nlm.nih.gov/15013009

DMPVU7H	DI	DMPVU7H
DMPVU7H	DN	8-Bromo-3-hydroxy-1H-benzo[b]azepine-2,5-dione
DMPVU7H	MI	TTLD29N
DMPVU7H	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMPVU7H	MT	DTT
DMPVU7H	MA	Inhibitor
DMPVU7H	RN	Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53.
DMPVU7H	RU	https://pubmed.ncbi.nlm.nih.gov/8917653

DMPVU7H	DI	DMPVU7H
DMPVU7H	DN	8-Bromo-3-hydroxy-1H-benzo[b]azepine-2,5-dione
DMPVU7H	MI	TTKJEMQ
DMPVU7H	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMPVU7H	MT	DTT
DMPVU7H	MA	Inhibitor
DMPVU7H	RN	Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53.
DMPVU7H	RU	https://pubmed.ncbi.nlm.nih.gov/8917653

DMPVU7H	DI	DMPVU7H
DMPVU7H	DN	8-Bromo-3-hydroxy-1H-benzo[b]azepine-2,5-dione
DMPVU7H	MI	TTN9D8E
DMPVU7H	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMPVU7H	MT	DTT
DMPVU7H	MA	Inhibitor
DMPVU7H	RN	Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53.
DMPVU7H	RU	https://pubmed.ncbi.nlm.nih.gov/8917653

DM4V5RU	DI	DM4V5RU
DM4V5RU	DN	8-Bromo-4,9-dihydro-3H-beta-carboline
DM4V5RU	MI	TTJQOD7
DM4V5RU	MN	5-HT 2A receptor (HTR2A)
DM4V5RU	MT	DTT
DM4V5RU	MA	Inhibitor
DM4V5RU	RN	Binding of beta-carbolines at 5-HT(2) serotonin receptors. Bioorg Med Chem Lett. 2003 Dec 15;13(24):4421-5.
DM4V5RU	RU	https://pubmed.ncbi.nlm.nih.gov/14643338

DM4V5RU	DI	DM4V5RU
DM4V5RU	DN	8-Bromo-4,9-dihydro-3H-beta-carboline
DM4V5RU	MI	TT3WG5C
DM4V5RU	MN	Monoamine oxidase type A (MAO-A)
DM4V5RU	MT	DTT
DM4V5RU	MA	Inhibitor
DM4V5RU	RN	Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
DM4V5RU	RU	https://pubmed.ncbi.nlm.nih.gov/15013009

DM4V5RU	DI	DM4V5RU
DM4V5RU	DN	8-Bromo-4,9-dihydro-3H-beta-carboline
DM4V5RU	MI	TTGP7BY
DM4V5RU	MN	Monoamine oxidase type B (MAO-B)
DM4V5RU	MT	DTT
DM4V5RU	MA	Inhibitor
DM4V5RU	RN	Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
DM4V5RU	RU	https://pubmed.ncbi.nlm.nih.gov/15013009

DM51FL9	DI	DM51FL9
DM51FL9	DN	8-Bromo-6-methyl-3-(4'-methoxyphenyl)coumarin
DM51FL9	MI	TTGP7BY
DM51FL9	MN	Monoamine oxidase type B (MAO-B)
DM51FL9	MT	DTT
DM51FL9	MA	Inhibitor
DM51FL9	RN	New halogenated 3-phenylcoumarins as potent and selective MAO-B inhibitors. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5157-60.
DM51FL9	RU	https://pubmed.ncbi.nlm.nih.gov/20659799

DMD1LM8	DI	DMD1LM8
DMD1LM8	DN	8-Bromo-6-methyl-3-phenylcoumarin
DMD1LM8	MI	TTGP7BY
DMD1LM8	MN	Monoamine oxidase type B (MAO-B)
DMD1LM8	MT	DTT
DMD1LM8	MA	Inhibitor
DMD1LM8	RN	New halogenated 3-phenylcoumarins as potent and selective MAO-B inhibitors. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5157-60.
DMD1LM8	RU	https://pubmed.ncbi.nlm.nih.gov/20659799

DMKU06T	DI	DMKU06T
DMKU06T	DN	8-Bromo-6-styryl-naphthalene-2-carboxamidine
DMKU06T	MI	TT2WR1T
DMKU06T	MN	Cationic trypsinogen (PRSS1)
DMKU06T	MT	DTT
DMKU06T	MA	Inhibitor
DMKU06T	RN	Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties. Bioorg Med Chem Lett. 2005 Jan 3;15(1):93-8.
DMKU06T	RU	https://pubmed.ncbi.nlm.nih.gov/15582418

DMMQ79W	DI	DMMQ79W
DMMQ79W	DN	8-Bromo-9-(2,3-dihydroxypropyl)-9H-adenine
DMMQ79W	MI	TTK25J1
DMMQ79W	MN	Adenosine A1 receptor (ADORA1)
DMMQ79W	MT	DTT
DMMQ79W	MA	Inhibitor
DMMQ79W	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMMQ79W	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMMQ79W	DI	DMMQ79W
DMMQ79W	DN	8-Bromo-9-(2,3-dihydroxypropyl)-9H-adenine
DMMQ79W	MI	TTM2AOE
DMMQ79W	MN	Adenosine A2a receptor (ADORA2A)
DMMQ79W	MT	DTT
DMMQ79W	MA	Inhibitor
DMMQ79W	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMMQ79W	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMMQ79W	DI	DMMQ79W
DMMQ79W	DN	8-Bromo-9-(2,3-dihydroxypropyl)-9H-adenine
DMMQ79W	MI	TTNE7KG
DMMQ79W	MN	Adenosine A2b receptor (ADORA2B)
DMMQ79W	MT	DTT
DMMQ79W	MA	Inhibitor
DMMQ79W	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMMQ79W	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DM5DCPF	DI	DM5DCPF
DM5DCPF	DN	8-Bromo-9-(2-butyl)-9H-adenine
DM5DCPF	MI	TTK25J1
DM5DCPF	MN	Adenosine A1 receptor (ADORA1)
DM5DCPF	MT	DTT
DM5DCPF	MA	Inhibitor
DM5DCPF	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DM5DCPF	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DM5DCPF	DI	DM5DCPF
DM5DCPF	DN	8-Bromo-9-(2-butyl)-9H-adenine
DM5DCPF	MI	TTM2AOE
DM5DCPF	MN	Adenosine A2a receptor (ADORA2A)
DM5DCPF	MT	DTT
DM5DCPF	MA	Inhibitor
DM5DCPF	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DM5DCPF	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DM5DCPF	DI	DM5DCPF
DM5DCPF	DN	8-Bromo-9-(2-butyl)-9H-adenine
DM5DCPF	MI	TTNE7KG
DM5DCPF	MN	Adenosine A2b receptor (ADORA2B)
DM5DCPF	MT	DTT
DM5DCPF	MA	Inhibitor
DM5DCPF	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DM5DCPF	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMKW2PE	DI	DMKW2PE
DMKW2PE	DN	8-Bromo-9-(2-hydroxypropyl)-9H-adenine
DMKW2PE	MI	TTK25J1
DMKW2PE	MN	Adenosine A1 receptor (ADORA1)
DMKW2PE	MT	DTT
DMKW2PE	MA	Inhibitor
DMKW2PE	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMKW2PE	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMKW2PE	DI	DMKW2PE
DMKW2PE	DN	8-Bromo-9-(2-hydroxypropyl)-9H-adenine
DMKW2PE	MI	TTM2AOE
DMKW2PE	MN	Adenosine A2a receptor (ADORA2A)
DMKW2PE	MT	DTT
DMKW2PE	MA	Inhibitor
DMKW2PE	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMKW2PE	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMKW2PE	DI	DMKW2PE
DMKW2PE	DN	8-Bromo-9-(2-hydroxypropyl)-9H-adenine
DMKW2PE	MI	TTNE7KG
DMKW2PE	MN	Adenosine A2b receptor (ADORA2B)
DMKW2PE	MT	DTT
DMKW2PE	MA	Inhibitor
DMKW2PE	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMKW2PE	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMA258T	DI	DMA258T
DMA258T	DN	8-Bromo-9-(3-hydroxypropyl)-9H-adenine
DMA258T	MI	TTK25J1
DMA258T	MN	Adenosine A1 receptor (ADORA1)
DMA258T	MT	DTT
DMA258T	MA	Inhibitor
DMA258T	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMA258T	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMA258T	DI	DMA258T
DMA258T	DN	8-Bromo-9-(3-hydroxypropyl)-9H-adenine
DMA258T	MI	TTM2AOE
DMA258T	MN	Adenosine A2a receptor (ADORA2A)
DMA258T	MT	DTT
DMA258T	MA	Inhibitor
DMA258T	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMA258T	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMA258T	DI	DMA258T
DMA258T	DN	8-Bromo-9-(3-hydroxypropyl)-9H-adenine
DMA258T	MI	TTNE7KG
DMA258T	MN	Adenosine A2b receptor (ADORA2B)
DMA258T	MT	DTT
DMA258T	MA	Inhibitor
DMA258T	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMA258T	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMA258T	DI	DMA258T
DMA258T	DN	8-Bromo-9-(3-hydroxypropyl)-9H-adenine
DMA258T	MI	TTJFY5U
DMA258T	MN	Adenosine A3 receptor (ADORA3)
DMA258T	MT	DTT
DMA258T	MA	Inhibitor
DMA258T	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMA258T	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMXNF3V	DI	DMXNF3V
DMXNF3V	DN	8-Bromo-9-(but-3-enyl)-9H-adenine
DMXNF3V	MI	TTK25J1
DMXNF3V	MN	Adenosine A1 receptor (ADORA1)
DMXNF3V	MT	DTT
DMXNF3V	MA	Inhibitor
DMXNF3V	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMXNF3V	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMXNF3V	DI	DMXNF3V
DMXNF3V	DN	8-Bromo-9-(but-3-enyl)-9H-adenine
DMXNF3V	MI	TTM2AOE
DMXNF3V	MN	Adenosine A2a receptor (ADORA2A)
DMXNF3V	MT	DTT
DMXNF3V	MA	Inhibitor
DMXNF3V	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMXNF3V	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMSQPFM	DI	DMSQPFM
DMSQPFM	DN	8-Bromo-9-(sec-butyl)-9H-adenine
DMSQPFM	MI	TTK25J1
DMSQPFM	MN	Adenosine A1 receptor (ADORA1)
DMSQPFM	MT	DTT
DMSQPFM	MA	Inhibitor
DMSQPFM	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMSQPFM	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMSQPFM	DI	DMSQPFM
DMSQPFM	DN	8-Bromo-9-(sec-butyl)-9H-adenine
DMSQPFM	MI	TTM2AOE
DMSQPFM	MN	Adenosine A2a receptor (ADORA2A)
DMSQPFM	MT	DTT
DMSQPFM	MA	Inhibitor
DMSQPFM	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMSQPFM	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMSQPFM	DI	DMSQPFM
DMSQPFM	DN	8-Bromo-9-(sec-butyl)-9H-adenine
DMSQPFM	MI	TTNE7KG
DMSQPFM	MN	Adenosine A2b receptor (ADORA2B)
DMSQPFM	MT	DTT
DMSQPFM	MA	Inhibitor
DMSQPFM	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMSQPFM	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMSQPFM	DI	DMSQPFM
DMSQPFM	DN	8-Bromo-9-(sec-butyl)-9H-adenine
DMSQPFM	MI	TTJFY5U
DMSQPFM	MN	Adenosine A3 receptor (ADORA3)
DMSQPFM	MT	DTT
DMSQPFM	MA	Inhibitor
DMSQPFM	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMSQPFM	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMUTV76	DI	DMUTV76
DMUTV76	DN	8-Bromo-9-cyclobutyl-9H-adenine
DMUTV76	MI	TTK25J1
DMUTV76	MN	Adenosine A1 receptor (ADORA1)
DMUTV76	MT	DTT
DMUTV76	MA	Inhibitor
DMUTV76	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMUTV76	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMUTV76	DI	DMUTV76
DMUTV76	DN	8-Bromo-9-cyclobutyl-9H-adenine
DMUTV76	MI	TTM2AOE
DMUTV76	MN	Adenosine A2a receptor (ADORA2A)
DMUTV76	MT	DTT
DMUTV76	MA	Inhibitor
DMUTV76	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMUTV76	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMUTV76	DI	DMUTV76
DMUTV76	DN	8-Bromo-9-cyclobutyl-9H-adenine
DMUTV76	MI	TTNE7KG
DMUTV76	MN	Adenosine A2b receptor (ADORA2B)
DMUTV76	MT	DTT
DMUTV76	MA	Inhibitor
DMUTV76	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMUTV76	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMUTV76	DI	DMUTV76
DMUTV76	DN	8-Bromo-9-cyclobutyl-9H-adenine
DMUTV76	MI	TTJFY5U
DMUTV76	MN	Adenosine A3 receptor (ADORA3)
DMUTV76	MT	DTT
DMUTV76	MA	Inhibitor
DMUTV76	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMUTV76	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMLVCON	DI	DMLVCON
DMLVCON	DN	8-Bromo-9-cyclohexyl-9H-adenine
DMLVCON	MI	TTK25J1
DMLVCON	MN	Adenosine A1 receptor (ADORA1)
DMLVCON	MT	DTT
DMLVCON	MA	Inhibitor
DMLVCON	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMLVCON	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMLVCON	DI	DMLVCON
DMLVCON	DN	8-Bromo-9-cyclohexyl-9H-adenine
DMLVCON	MI	TTM2AOE
DMLVCON	MN	Adenosine A2a receptor (ADORA2A)
DMLVCON	MT	DTT
DMLVCON	MA	Inhibitor
DMLVCON	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMLVCON	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMLVCON	DI	DMLVCON
DMLVCON	DN	8-Bromo-9-cyclohexyl-9H-adenine
DMLVCON	MI	TTJFY5U
DMLVCON	MN	Adenosine A3 receptor (ADORA3)
DMLVCON	MT	DTT
DMLVCON	MA	Inhibitor
DMLVCON	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMLVCON	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMCK0O1	DI	DMCK0O1
DMCK0O1	DN	8-Bromo-9-cyclopentyl-9H-adenine
DMCK0O1	MI	TTK25J1
DMCK0O1	MN	Adenosine A1 receptor (ADORA1)
DMCK0O1	MT	DTT
DMCK0O1	MA	Inhibitor
DMCK0O1	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMCK0O1	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMCK0O1	DI	DMCK0O1
DMCK0O1	DN	8-Bromo-9-cyclopentyl-9H-adenine
DMCK0O1	MI	TTM2AOE
DMCK0O1	MN	Adenosine A2a receptor (ADORA2A)
DMCK0O1	MT	DTT
DMCK0O1	MA	Inhibitor
DMCK0O1	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMCK0O1	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMCK0O1	DI	DMCK0O1
DMCK0O1	DN	8-Bromo-9-cyclopentyl-9H-adenine
DMCK0O1	MI	TTNE7KG
DMCK0O1	MN	Adenosine A2b receptor (ADORA2B)
DMCK0O1	MT	DTT
DMCK0O1	MA	Inhibitor
DMCK0O1	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMCK0O1	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMCK0O1	DI	DMCK0O1
DMCK0O1	DN	8-Bromo-9-cyclopentyl-9H-adenine
DMCK0O1	MI	TTJFY5U
DMCK0O1	MN	Adenosine A3 receptor (ADORA3)
DMCK0O1	MT	DTT
DMCK0O1	MA	Inhibitor
DMCK0O1	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMCK0O1	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DM4YAD6	DI	DM4YAD6
DM4YAD6	DN	8-Bromo-9-ethyl-9H-adenine
DM4YAD6	MI	TTK25J1
DM4YAD6	MN	Adenosine A1 receptor (ADORA1)
DM4YAD6	MT	DTT
DM4YAD6	MA	Inhibitor
DM4YAD6	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DM4YAD6	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DM4YAD6	DI	DM4YAD6
DM4YAD6	DN	8-Bromo-9-ethyl-9H-adenine
DM4YAD6	MI	TTM2AOE
DM4YAD6	MN	Adenosine A2a receptor (ADORA2A)
DM4YAD6	MT	DTT
DM4YAD6	MA	Inhibitor
DM4YAD6	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DM4YAD6	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DM4YAD6	DI	DM4YAD6
DM4YAD6	DN	8-Bromo-9-ethyl-9H-adenine
DM4YAD6	MI	TTNE7KG
DM4YAD6	MN	Adenosine A2b receptor (ADORA2B)
DM4YAD6	MT	DTT
DM4YAD6	MA	Inhibitor
DM4YAD6	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DM4YAD6	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMZF3UN	DI	DMZF3UN
DMZF3UN	DN	8-bromo-9-isobutyl-9H-purin-6-amine
DMZF3UN	MI	TTK25J1
DMZF3UN	MN	Adenosine A1 receptor (ADORA1)
DMZF3UN	MT	DTT
DMZF3UN	MA	Inhibitor
DMZF3UN	RN	Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods. Eur J Med Chem. 2010 Aug;45(8):3459-71.
DMZF3UN	RU	https://pubmed.ncbi.nlm.nih.gov/20537438

DMZF3UN	DI	DMZF3UN
DMZF3UN	DN	8-bromo-9-isobutyl-9H-purin-6-amine
DMZF3UN	MI	TTM2AOE
DMZF3UN	MN	Adenosine A2a receptor (ADORA2A)
DMZF3UN	MT	DTT
DMZF3UN	MA	Inhibitor
DMZF3UN	RN	Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods. Eur J Med Chem. 2010 Aug;45(8):3459-71.
DMZF3UN	RU	https://pubmed.ncbi.nlm.nih.gov/20537438

DMZF3UN	DI	DMZF3UN
DMZF3UN	DN	8-bromo-9-isobutyl-9H-purin-6-amine
DMZF3UN	MI	TTNE7KG
DMZF3UN	MN	Adenosine A2b receptor (ADORA2B)
DMZF3UN	MT	DTT
DMZF3UN	MA	Inhibitor
DMZF3UN	RN	Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods. Eur J Med Chem. 2010 Aug;45(8):3459-71.
DMZF3UN	RU	https://pubmed.ncbi.nlm.nih.gov/20537438

DMZF3UN	DI	DMZF3UN
DMZF3UN	DN	8-bromo-9-isobutyl-9H-purin-6-amine
DMZF3UN	MI	TTJFY5U
DMZF3UN	MN	Adenosine A3 receptor (ADORA3)
DMZF3UN	MT	DTT
DMZF3UN	MA	Inhibitor
DMZF3UN	RN	Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods. Eur J Med Chem. 2010 Aug;45(8):3459-71.
DMZF3UN	RU	https://pubmed.ncbi.nlm.nih.gov/20537438

DMIN9HC	DI	DMIN9HC
DMIN9HC	DN	8-Bromo-9-isopropyl-9H-adenine
DMIN9HC	MI	TTK25J1
DMIN9HC	MN	Adenosine A1 receptor (ADORA1)
DMIN9HC	MT	DTT
DMIN9HC	MA	Inhibitor
DMIN9HC	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMIN9HC	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMIN9HC	DI	DMIN9HC
DMIN9HC	DN	8-Bromo-9-isopropyl-9H-adenine
DMIN9HC	MI	TTM2AOE
DMIN9HC	MN	Adenosine A2a receptor (ADORA2A)
DMIN9HC	MT	DTT
DMIN9HC	MA	Inhibitor
DMIN9HC	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMIN9HC	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMIN9HC	DI	DMIN9HC
DMIN9HC	DN	8-Bromo-9-isopropyl-9H-adenine
DMIN9HC	MI	TTNE7KG
DMIN9HC	MN	Adenosine A2b receptor (ADORA2B)
DMIN9HC	MT	DTT
DMIN9HC	MA	Inhibitor
DMIN9HC	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMIN9HC	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMIN9HC	DI	DMIN9HC
DMIN9HC	DN	8-Bromo-9-isopropyl-9H-adenine
DMIN9HC	MI	TTJFY5U
DMIN9HC	MN	Adenosine A3 receptor (ADORA3)
DMIN9HC	MT	DTT
DMIN9HC	MA	Inhibitor
DMIN9HC	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMIN9HC	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DM1DS3B	DI	DM1DS3B
DM1DS3B	DN	8-Bromo-9-methyl-9H-adenine
DM1DS3B	MI	TTK25J1
DM1DS3B	MN	Adenosine A1 receptor (ADORA1)
DM1DS3B	MT	DTT
DM1DS3B	MA	Inhibitor
DM1DS3B	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DM1DS3B	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DM1DS3B	DI	DM1DS3B
DM1DS3B	DN	8-Bromo-9-methyl-9H-adenine
DM1DS3B	MI	TTM2AOE
DM1DS3B	MN	Adenosine A2a receptor (ADORA2A)
DM1DS3B	MT	DTT
DM1DS3B	MA	Inhibitor
DM1DS3B	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DM1DS3B	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DM1DS3B	DI	DM1DS3B
DM1DS3B	DN	8-Bromo-9-methyl-9H-adenine
DM1DS3B	MI	TTNE7KG
DM1DS3B	MN	Adenosine A2b receptor (ADORA2B)
DM1DS3B	MT	DTT
DM1DS3B	MA	Inhibitor
DM1DS3B	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DM1DS3B	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMB7EWZ	DI	DMB7EWZ
DMB7EWZ	DN	8-Bromo-9-phenylethyl-9H-adenine
DMB7EWZ	MI	TTK25J1
DMB7EWZ	MN	Adenosine A1 receptor (ADORA1)
DMB7EWZ	MT	DTT
DMB7EWZ	MA	Inhibitor
DMB7EWZ	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMB7EWZ	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMB7EWZ	DI	DMB7EWZ
DMB7EWZ	DN	8-Bromo-9-phenylethyl-9H-adenine
DMB7EWZ	MI	TTM2AOE
DMB7EWZ	MN	Adenosine A2a receptor (ADORA2A)
DMB7EWZ	MT	DTT
DMB7EWZ	MA	Inhibitor
DMB7EWZ	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMB7EWZ	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMRIPU5	DI	DMRIPU5
DMRIPU5	DN	8-Bromo-9-propyl-9H-adenine
DMRIPU5	MI	TTK25J1
DMRIPU5	MN	Adenosine A1 receptor (ADORA1)
DMRIPU5	MT	DTT
DMRIPU5	MA	Inhibitor
DMRIPU5	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMRIPU5	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMRIPU5	DI	DMRIPU5
DMRIPU5	DN	8-Bromo-9-propyl-9H-adenine
DMRIPU5	MI	TTM2AOE
DMRIPU5	MN	Adenosine A2a receptor (ADORA2A)
DMRIPU5	MT	DTT
DMRIPU5	MA	Inhibitor
DMRIPU5	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMRIPU5	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMRIPU5	DI	DMRIPU5
DMRIPU5	DN	8-Bromo-9-propyl-9H-adenine
DMRIPU5	MI	TTNE7KG
DMRIPU5	MN	Adenosine A2b receptor (ADORA2B)
DMRIPU5	MT	DTT
DMRIPU5	MA	Inhibitor
DMRIPU5	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMRIPU5	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DM4CV1E	DI	DM4CV1E
DM4CV1E	DN	8-Bromo-Adenosine-5'-Monophosphate
DM4CV1E	MI	TTVIAT9
DM4CV1E	MN	Phosphodiesterase 4B (PDE4B)
DM4CV1E	MT	DTT
DM4CV1E	MA	Inhibitor
DM4CV1E	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DM4CV1E	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DM5RFCN	DI	DM5RFCN
DM5RFCN	DN	8-Butoxy-quinolin-2-ylamine
DM5RFCN	MI	TTX4RTB
DM5RFCN	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DM5RFCN	MT	DTT
DM5RFCN	MA	Inhibitor
DM5RFCN	RN	Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7.
DM5RFCN	RU	https://pubmed.ncbi.nlm.nih.gov/15341942

DMD18V5	DI	DMD18V5
DMD18V5	DN	8-carboxamidocyclazocine
DMD18V5	MI	TT27RFC
DMD18V5	MN	Opioid receptor delta (OPRD1)
DMD18V5	MT	DTT
DMD18V5	MA	Inhibitor
DMD18V5	RN	Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 6: Opioid receptor binding properties of cyclic variants of 8-c... Bioorg Med Chem. 2008 May 15;16(10):5653-64.
DMD18V5	RU	https://pubmed.ncbi.nlm.nih.gov/18417347

DMD18V5	DI	DMD18V5
DMD18V5	DN	8-carboxamidocyclazocine
DMD18V5	MI	TTQW87Y
DMD18V5	MN	Opioid receptor kappa (OPRK1)
DMD18V5	MT	DTT
DMD18V5	MA	Inhibitor
DMD18V5	RN	Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 6: Opioid receptor binding properties of cyclic variants of 8-c... Bioorg Med Chem. 2008 May 15;16(10):5653-64.
DMD18V5	RU	https://pubmed.ncbi.nlm.nih.gov/18417347

DMD18V5	DI	DMD18V5
DMD18V5	DN	8-carboxamidocyclazocine
DMD18V5	MI	TTKWM86
DMD18V5	MN	Opioid receptor mu (MOP)
DMD18V5	MT	DTT
DMD18V5	MA	Inhibitor
DMD18V5	RN	Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 6: Opioid receptor binding properties of cyclic variants of 8-c... Bioorg Med Chem. 2008 May 15;16(10):5653-64.
DMD18V5	RU	https://pubmed.ncbi.nlm.nih.gov/18417347

DMS7DA3	DI	DMS7DA3
DMS7DA3	DN	8-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamine
DMS7DA3	MI	TT1RS9F
DMS7DA3	MN	Acetylcholinesterase (AChE)
DMS7DA3	MT	DTT
DMS7DA3	MA	Inhibitor
DMS7DA3	RN	The synthesis and in vitro acetylcholinesterase and butyrylcholinesterase inhibitory activity of tacrine (Cognex ) derivaties, Bioorg. Med. Chem. Lett. 2(8):861-864 (1992).
DMS7DA3	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805454

DMFW6Q0	DI	DMFW6Q0
DMFW6Q0	DN	8-Chloro-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole
DMFW6Q0	MI	TTJQOD7
DMFW6Q0	MN	5-HT 2A receptor (HTR2A)
DMFW6Q0	MT	DTT
DMFW6Q0	MA	Inhibitor
DMFW6Q0	RN	Evaluation of isotryptamine derivatives at 5-HT(2) serotonin receptors. Bioorg Med Chem Lett. 2002 Jan 21;12(2):155-8.
DMFW6Q0	RU	https://pubmed.ncbi.nlm.nih.gov/11755343

DM5IGOL	DI	DM5IGOL
DM5IGOL	DN	8-Chloro-1,3-dihydro-imidazo[4,5-b]quinolin-2-one
DM5IGOL	MI	TT06AWU
DM5IGOL	MN	Phosphodiesterase 3A (PDE3A)
DM5IGOL	MT	DTT
DM5IGOL	MA	Inhibitor
DM5IGOL	RN	1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-ones--inhibitors of blood platelet cAMP phosphodiesterase and induced aggregation. J Med Chem. 1991 Sep;34(9):2906-16.
DM5IGOL	RU	https://pubmed.ncbi.nlm.nih.gov/1654430

DM61VJO	DI	DM61VJO
DM61VJO	DN	8-chloro-3,4-dihydroquinazolin-2-amine
DM61VJO	MI	TTRUFDT
DM61VJO	MN	5-HT 5A receptor (HTR5A)
DM61VJO	MT	DTT
DM61VJO	MA	Inhibitor
DM61VJO	RN	Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61.
DM61VJO	RU	https://pubmed.ncbi.nlm.nih.gov/17998160

DM842L6	DI	DM842L6
DM842L6	DN	8-Chloro-3-hydroxy-1H-benzo[b]azepine-2,5-dione
DM842L6	MI	TTLD29N
DM842L6	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DM842L6	MT	DTT
DM842L6	MA	Inhibitor
DM842L6	RN	Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53.
DM842L6	RU	https://pubmed.ncbi.nlm.nih.gov/8917653

DM842L6	DI	DM842L6
DM842L6	DN	8-Chloro-3-hydroxy-1H-benzo[b]azepine-2,5-dione
DM842L6	MI	TTKJEMQ
DM842L6	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DM842L6	MT	DTT
DM842L6	MA	Inhibitor
DM842L6	RN	Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53.
DM842L6	RU	https://pubmed.ncbi.nlm.nih.gov/8917653

DM842L6	DI	DM842L6
DM842L6	DN	8-Chloro-3-hydroxy-1H-benzo[b]azepine-2,5-dione
DM842L6	MI	TTN9D8E
DM842L6	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DM842L6	MT	DTT
DM842L6	MA	Inhibitor
DM842L6	RN	Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53.
DM842L6	RU	https://pubmed.ncbi.nlm.nih.gov/8917653

DMB76ZN	DI	DMB76ZN
DMB76ZN	DN	8-Chloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol
DMB76ZN	MI	TTZAYWL
DMB76ZN	MN	Estrogen receptor (ESR)
DMB76ZN	MT	DTT
DMB76ZN	MA	Inhibitor
DMB76ZN	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DMB76ZN	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMB76ZN	DI	DMB76ZN
DMB76ZN	DN	8-Chloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol
DMB76ZN	MI	TTOM3J0
DMB76ZN	MN	Estrogen receptor beta (ESR2)
DMB76ZN	MT	DTT
DMB76ZN	MA	Inhibitor
DMB76ZN	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DMB76ZN	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMFNUHQ	DI	DMFNUHQ
DMFNUHQ	DN	8-chloro-quinoline-3-carbonitrile
DMFNUHQ	MI	TTGECUM
DMFNUHQ	MN	Cot oncogene messenger RNA (MAP3K8 mRNA)
DMFNUHQ	MT	DTT
DMFNUHQ	MA	Inhibitor
DMFNUHQ	RN	Pharmacologic inhibition of tpl2 blocks inflammatory responses in primary human monocytes, synoviocytes, and blood. J Biol Chem. 2007 Nov 16;282(46):33295-304.
DMFNUHQ	RU	https://pubmed.ncbi.nlm.nih.gov/17848581

DMFNUHQ	DI	DMFNUHQ
DMFNUHQ	DN	8-chloro-quinoline-3-carbonitrile
DMFNUHQ	MI	TTUZ2L5
DMFNUHQ	MN	Matrix metalloproteinase-3 (MMP-3)
DMFNUHQ	MT	DTT
DMFNUHQ	MA	Inhibitor
DMFNUHQ	RN	Pharmacologic inhibition of tpl2 blocks inflammatory responses in primary human monocytes, synoviocytes, and blood. J Biol Chem. 2007 Nov 16;282(46):33295-304.
DMFNUHQ	RU	https://pubmed.ncbi.nlm.nih.gov/17848581

DM4VTM2	DI	DM4VTM2
DM4VTM2	DN	8-Cyclobutylmethoxy-quinolin-2-ylamine
DM4VTM2	MI	TTX4RTB
DM4VTM2	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DM4VTM2	MT	DTT
DM4VTM2	MA	Inhibitor
DM4VTM2	RN	Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7.
DM4VTM2	RU	https://pubmed.ncbi.nlm.nih.gov/15341942

DMEBYRW	DI	DMEBYRW
DMEBYRW	DN	8-Cycloheptyloxy-quinolin-2-ylamine
DMEBYRW	MI	TTX4RTB
DMEBYRW	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMEBYRW	MT	DTT
DMEBYRW	MA	Inhibitor
DMEBYRW	RN	Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7.
DMEBYRW	RU	https://pubmed.ncbi.nlm.nih.gov/15341942

DM79VQM	DI	DM79VQM
DM79VQM	DN	8-cyclohexyl-6-(4-tolyl)-2-phenyl-9H-purine
DM79VQM	MI	TTK25J1
DM79VQM	MN	Adenosine A1 receptor (ADORA1)
DM79VQM	MT	DTT
DM79VQM	MA	Inhibitor
DM79VQM	RN	2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7.
DM79VQM	RU	https://pubmed.ncbi.nlm.nih.gov/16686529

DMKT0YQ	DI	DMKT0YQ
DMKT0YQ	DN	8-Cyclohexyloxy-quinolin-2-ylamine
DMKT0YQ	MI	TTX4RTB
DMKT0YQ	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMKT0YQ	MT	DTT
DMKT0YQ	MA	Inhibitor
DMKT0YQ	RN	Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7.
DMKT0YQ	RU	https://pubmed.ncbi.nlm.nih.gov/15341942

DM16KZS	DI	DM16KZS
DM16KZS	DN	8-Cyclopentylmethoxy-quinolin-2-ylamine
DM16KZS	MI	TTX4RTB
DM16KZS	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DM16KZS	MT	DTT
DM16KZS	MA	Inhibitor
DM16KZS	RN	Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7.
DM16KZS	RU	https://pubmed.ncbi.nlm.nih.gov/15341942

DMMITAJ	DI	DMMITAJ
DMMITAJ	DN	8-cyclopentyltheophylline
DMMITAJ	MI	TTK25J1
DMMITAJ	MN	Adenosine A1 receptor (ADORA1)
DMMITAJ	MT	DTT
DMMITAJ	MA	Antagonist
DMMITAJ	RN	Thermodynamics of full agonist, partial agonist, and antagonist binding to wild-type and mutant adenosine A1 receptors. Biochem Pharmacol. 1998 Dec 1;56(11):1437-45.
DMMITAJ	RU	https://pubmed.ncbi.nlm.nih.gov/9827575

DMEOP4J	DI	DMEOP4J
DMEOP4J	DN	8-DEOXYGARTANIN
DMEOP4J	MI	TT50QJ3
DMEOP4J	MN	Influenza Neuraminidase (Influ NA)
DMEOP4J	MT	DTT
DMEOP4J	MA	Inhibitor
DMEOP4J	RN	Xanthones with neuraminidase inhibitory activity from the seedcases of Garcinia mangostana. Bioorg Med Chem. 2010 Sep 1;18(17):6258-64.
DMEOP4J	RU	https://pubmed.ncbi.nlm.nih.gov/20696581

DM7YW3B	DI	DM7YW3B
DM7YW3B	DN	8-deoxy-neodysiherbaine
DM7YW3B	MI	TT0MYE2
DM7YW3B	MN	Glutamate receptor ionotropic kainate 1 (GRIK1)
DM7YW3B	MT	DTT
DM7YW3B	MA	Agonist
DM7YW3B	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 450).
DM7YW3B	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=450

DMQJA4F	DI	DMQJA4F
DMQJA4F	DN	8-Diazonium-naphthalene-1-sulfonic acid anion
DMQJA4F	MI	TTNJYV2
DMQJA4F	MN	Gamma-aminobutyric acid receptor (GAR)
DMQJA4F	MT	DTT
DMQJA4F	MA	Inhibitor
DMQJA4F	RN	Aryl diazo compounds and diazonium salts as potential irreversible probes of the gamma-aminobutyric acid receptor. J Med Chem. 1987 Dec;30(12):2222-7.
DMQJA4F	RU	https://pubmed.ncbi.nlm.nih.gov/2824775

DMUR97N	DI	DMUR97N
DMUR97N	DN	8-dibenzofuran-4-yl-2-morpholin-4-ylchromen-4-one
DMUR97N	MI	TTK3PY9
DMUR97N	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMUR97N	MT	DTT
DMUR97N	MA	Inhibitor
DMUR97N	RN	Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46.
DMUR97N	RU	https://pubmed.ncbi.nlm.nih.gov/16302822

DMY8W0K	DI	DMY8W0K
DMY8W0K	DN	8-Ethyl-3-hydroxy-1H-benzo[b]azepine-2,5-dione
DMY8W0K	MI	TTLD29N
DMY8W0K	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMY8W0K	MT	DTT
DMY8W0K	MA	Inhibitor
DMY8W0K	RN	Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53.
DMY8W0K	RU	https://pubmed.ncbi.nlm.nih.gov/8917653

DMY8W0K	DI	DMY8W0K
DMY8W0K	DN	8-Ethyl-3-hydroxy-1H-benzo[b]azepine-2,5-dione
DMY8W0K	MI	TTKJEMQ
DMY8W0K	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMY8W0K	MT	DTT
DMY8W0K	MA	Inhibitor
DMY8W0K	RN	Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53.
DMY8W0K	RU	https://pubmed.ncbi.nlm.nih.gov/8917653

DMY8W0K	DI	DMY8W0K
DMY8W0K	DN	8-Ethyl-3-hydroxy-1H-benzo[b]azepine-2,5-dione
DMY8W0K	MI	TTN9D8E
DMY8W0K	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMY8W0K	MT	DTT
DMY8W0K	MA	Inhibitor
DMY8W0K	RN	Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53.
DMY8W0K	RU	https://pubmed.ncbi.nlm.nih.gov/8917653

DMBZSAO	DI	DMBZSAO
DMBZSAO	DN	8-Fluoro-3-hydroxy-1H-benzo[b]azepine-2,5-dione
DMBZSAO	MI	TTLD29N
DMBZSAO	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMBZSAO	MT	DTT
DMBZSAO	MA	Inhibitor
DMBZSAO	RN	Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53.
DMBZSAO	RU	https://pubmed.ncbi.nlm.nih.gov/8917653

DMBZSAO	DI	DMBZSAO
DMBZSAO	DN	8-Fluoro-3-hydroxy-1H-benzo[b]azepine-2,5-dione
DMBZSAO	MI	TTKJEMQ
DMBZSAO	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMBZSAO	MT	DTT
DMBZSAO	MA	Inhibitor
DMBZSAO	RN	Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53.
DMBZSAO	RU	https://pubmed.ncbi.nlm.nih.gov/8917653

DMBZSAO	DI	DMBZSAO
DMBZSAO	DN	8-Fluoro-3-hydroxy-1H-benzo[b]azepine-2,5-dione
DMBZSAO	MI	TTN9D8E
DMBZSAO	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMBZSAO	MT	DTT
DMBZSAO	MA	Inhibitor
DMBZSAO	RN	Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53.
DMBZSAO	RU	https://pubmed.ncbi.nlm.nih.gov/8917653

DMGJ3L6	DI	DMGJ3L6
DMGJ3L6	DN	8-Fluoro-6-(4-hydroxy-phenyl)-naphthalen-2-ol
DMGJ3L6	MI	TTZAYWL
DMGJ3L6	MN	Estrogen receptor (ESR)
DMGJ3L6	MT	DTT
DMGJ3L6	MA	Inhibitor
DMGJ3L6	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DMGJ3L6	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMGJ3L6	DI	DMGJ3L6
DMGJ3L6	DN	8-Fluoro-6-(4-hydroxy-phenyl)-naphthalen-2-ol
DMGJ3L6	MI	TTOM3J0
DMGJ3L6	MN	Estrogen receptor beta (ESR2)
DMGJ3L6	MT	DTT
DMGJ3L6	MA	Inhibitor
DMGJ3L6	RN	ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
DMGJ3L6	RU	https://pubmed.ncbi.nlm.nih.gov/15943471

DMKPMFJ	DI	DMKPMFJ
DMKPMFJ	DN	8-Fluoro-6H,11H-indeno[1,2-c]isoquinolin-5-one
DMKPMFJ	MI	TTVDSZ0
DMKPMFJ	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMKPMFJ	MT	DTT
DMKPMFJ	MA	Inhibitor
DMKPMFJ	RN	Discovery of potent poly(ADP-ribose) polymerase-1 inhibitors from the modification of indeno[1,2-c]isoquinolinone. J Med Chem. 2005 Aug 11;48(16):5100-3.
DMKPMFJ	RU	https://pubmed.ncbi.nlm.nih.gov/16078828

DMPY9OI	DI	DMPY9OI
DMPY9OI	DN	8-furan-2-yl-2-morpholin-4-ylchromen-4-one
DMPY9OI	MI	TTK3PY9
DMPY9OI	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMPY9OI	MT	DTT
DMPY9OI	MA	Inhibitor
DMPY9OI	RN	Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46.
DMPY9OI	RU	https://pubmed.ncbi.nlm.nih.gov/16302822

DMFNCG8	DI	DMFNCG8
DMFNCG8	DN	8-Furan-3-yl-6-styryl-naphthalene-2-carboxamidine
DMFNCG8	MI	TT2WR1T
DMFNCG8	MN	Cationic trypsinogen (PRSS1)
DMFNCG8	MT	DTT
DMFNCG8	MA	Inhibitor
DMFNCG8	RN	Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties. Bioorg Med Chem Lett. 2005 Jan 3;15(1):93-8.
DMFNCG8	RU	https://pubmed.ncbi.nlm.nih.gov/15582418

DM7PJN9	DI	DM7PJN9
DM7PJN9	DN	8-Hexyloxy-quinolin-2-ylamine
DM7PJN9	MI	TTX4RTB
DM7PJN9	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DM7PJN9	MT	DTT
DM7PJN9	MA	Inhibitor
DM7PJN9	RN	Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7.
DM7PJN9	RU	https://pubmed.ncbi.nlm.nih.gov/15341942

DMNE52B	DI	DMNE52B
DMNE52B	DN	8-Hydroxy-2-(4-nitro-phenyl)-3H-quinazolin-4-one
DMNE52B	MI	TTVDSZ0
DMNE52B	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMNE52B	MT	DTT
DMNE52B	MA	Inhibitor
DMNE52B	RN	Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56.
DMNE52B	RU	https://pubmed.ncbi.nlm.nih.gov/9857092

DMKD2Q4	DI	DMKD2Q4
DMKD2Q4	DN	8-Hydroxy-2-phenyl-3H-quinazolin-4-one
DMKD2Q4	MI	TTVDSZ0
DMKD2Q4	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMKD2Q4	MT	DTT
DMKD2Q4	MA	Inhibitor
DMKD2Q4	RN	Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56.
DMKD2Q4	RU	https://pubmed.ncbi.nlm.nih.gov/9857092

DMG4W2C	DI	DMG4W2C
DMG4W2C	DN	8-Hydroxy-5,7,9-trimethyl-delta-carboline
DMG4W2C	MI	TTJFY5U
DMG4W2C	MN	Adenosine A3 receptor (ADORA3)
DMG4W2C	MT	DTT
DMG4W2C	MA	Inhibitor
DMG4W2C	RN	Synthesis of eudistomin D analogues and its effects on adenosine receptors. Bioorg Med Chem. 2008 Apr 1;16(7):3825-30.
DMG4W2C	RU	https://pubmed.ncbi.nlm.nih.gov/18262425

DMFL46R	DI	DMFL46R
DMFL46R	DN	8-Hydroxy-7,9-dimethyl-delta-carboline
DMFL46R	MI	TTJFY5U
DMFL46R	MN	Adenosine A3 receptor (ADORA3)
DMFL46R	MT	DTT
DMFL46R	MA	Inhibitor
DMFL46R	RN	Synthesis of eudistomin D analogues and its effects on adenosine receptors. Bioorg Med Chem. 2008 Apr 1;16(7):3825-30.
DMFL46R	RU	https://pubmed.ncbi.nlm.nih.gov/18262425

DMT9BPN	DI	DMT9BPN
DMT9BPN	DN	8-hydroxyguanine
DMT9BPN	MI	TTLSWP6
DMT9BPN	MN	GTP cyclohydrolase-I (GCH1)
DMT9BPN	MT	DTT
DMT9BPN	MA	Inhibitor
DMT9BPN	RN	GTP cyclohydrolase I feedback regulatory protein-dependent and -independent inhibitors of GTP cyclohydrolase I. Arch Biochem Biophys. 2001 Apr 1;388(1):67-73.
DMT9BPN	RU	https://pubmed.ncbi.nlm.nih.gov/11361142

DMA26L4	DI	DMA26L4
DMA26L4	DN	8-Imidazol-1-ylmethyl-5-nitro-chromen-4-one
DMA26L4	MI	TTSZLWK
DMA26L4	MN	Aromatase (CYP19A1)
DMA26L4	MT	DTT
DMA26L4	MA	Inhibitor
DMA26L4	RN	A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase. J Med Chem. 2001 Mar 1;44(5):672-80.
DMA26L4	RU	https://pubmed.ncbi.nlm.nih.gov/11262078

DM3K1EO	DI	DM3K1EO
DM3K1EO	DN	8-Iodo-Guanine
DM3K1EO	MI	TTMCF1Y
DM3K1EO	MN	Purine nucleoside phosphorylase (PNP)
DM3K1EO	MT	DTT
DM3K1EO	MA	Inhibitor
DM3K1EO	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM3K1EO	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMBIAGJ	DI	DMBIAGJ
DMBIAGJ	DN	8-Isopropoxy-quinolin-2-ylamine
DMBIAGJ	MI	TTX4RTB
DMBIAGJ	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMBIAGJ	MT	DTT
DMBIAGJ	MA	Inhibitor
DMBIAGJ	RN	Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7.
DMBIAGJ	RU	https://pubmed.ncbi.nlm.nih.gov/15341942

DMD3FWU	DI	DMD3FWU
DMD3FWU	DN	8-Mercapto-octanoic acid phenylamide
DMD3FWU	MI	TTBH0VX
DMD3FWU	MN	Histone deacetylase (HDAC)
DMD3FWU	MT	DTT
DMD3FWU	MA	Inhibitor
DMD3FWU	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMD3FWU	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMD3FWU	DI	DMD3FWU
DMD3FWU	DN	8-Mercapto-octanoic acid phenylamide
DMD3FWU	MI	TT6R7JZ
DMD3FWU	MN	Histone deacetylase 1 (HDAC1)
DMD3FWU	MT	DTT
DMD3FWU	MA	Inhibitor
DMD3FWU	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMD3FWU	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMD3FWU	DI	DMD3FWU
DMD3FWU	DN	8-Mercapto-octanoic acid phenylamide
DMD3FWU	MI	TTYHPU6
DMD3FWU	MN	Histone deacetylase 10 (HDAC10)
DMD3FWU	MT	DTT
DMD3FWU	MA	Inhibitor
DMD3FWU	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMD3FWU	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMD3FWU	DI	DMD3FWU
DMD3FWU	DN	8-Mercapto-octanoic acid phenylamide
DMD3FWU	MI	TTSHTOI
DMD3FWU	MN	Histone deacetylase 2 (HDAC2)
DMD3FWU	MT	DTT
DMD3FWU	MA	Inhibitor
DMD3FWU	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMD3FWU	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMD3FWU	DI	DMD3FWU
DMD3FWU	DN	8-Mercapto-octanoic acid phenylamide
DMD3FWU	MI	TTTQGH8
DMD3FWU	MN	Histone deacetylase 4 (HDAC4)
DMD3FWU	MT	DTT
DMD3FWU	MA	Inhibitor
DMD3FWU	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMD3FWU	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMD3FWU	DI	DMD3FWU
DMD3FWU	DN	8-Mercapto-octanoic acid phenylamide
DMD3FWU	MI	TT5ZKDI
DMD3FWU	MN	Histone deacetylase 6 (HDAC6)
DMD3FWU	MT	DTT
DMD3FWU	MA	Inhibitor
DMD3FWU	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMD3FWU	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMD3FWU	DI	DMD3FWU
DMD3FWU	DN	8-Mercapto-octanoic acid phenylamide
DMD3FWU	MI	TTT6LFV
DMD3FWU	MN	Histone deacetylase 8 (HDAC8)
DMD3FWU	MT	DTT
DMD3FWU	MA	Inhibitor
DMD3FWU	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMD3FWU	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMY50UR	DI	DMY50UR
DMY50UR	DN	8-Methoxy-1,2,3,4-tetrahydro-benzo[h]isoquinoline
DMY50UR	MI	TTWG9A4
DMY50UR	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMY50UR	MT	DTT
DMY50UR	MA	Inhibitor
DMY50UR	RN	Examination of the role of the acidic hydrogen in imparting selectivity of 7-(aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline (SK&amp;F 29661) toward inh... J Med Chem. 1997 Dec 5;40(25):3997-4005.
DMY50UR	RU	https://pubmed.ncbi.nlm.nih.gov/9406590

DMY50UR	DI	DMY50UR
DMY50UR	DN	8-Methoxy-1,2,3,4-tetrahydro-benzo[h]isoquinoline
DMY50UR	MI	TTWM4TY
DMY50UR	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMY50UR	MT	DTT
DMY50UR	MA	Inhibitor
DMY50UR	RN	Examination of the role of the acidic hydrogen in imparting selectivity of 7-(aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline (SK&amp;F 29661) toward inh... J Med Chem. 1997 Dec 5;40(25):3997-4005.
DMY50UR	RU	https://pubmed.ncbi.nlm.nih.gov/9406590

DMY50UR	DI	DMY50UR
DMY50UR	DN	8-Methoxy-1,2,3,4-tetrahydro-benzo[h]isoquinoline
DMY50UR	MI	TT2NUT5
DMY50UR	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMY50UR	MT	DTT
DMY50UR	MA	Inhibitor
DMY50UR	RN	Examination of the role of the acidic hydrogen in imparting selectivity of 7-(aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline (SK&amp;F 29661) toward inh... J Med Chem. 1997 Dec 5;40(25):3997-4005.
DMY50UR	RU	https://pubmed.ncbi.nlm.nih.gov/9406590

DMFOM10	DI	DMFOM10
DMFOM10	DN	8-Methoxy-1,2,3,4-tetrahydro-naphthalen-2-ylamine
DMFOM10	MI	TTSQIFT
DMFOM10	MN	5-HT 1A receptor (HTR1A)
DMFOM10	MT	DTT
DMFOM10	MA	Inhibitor
DMFOM10	RN	Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993).
DMFOM10	RU	http://www.sciencedirect.com/science/article/pii/S0960894X0181009X

DM0Y52J	DI	DM0Y52J
DM0Y52J	DN	8-Methoxy-1,4-dimethylquinolin-2(1H)-one
DM0Y52J	MI	TTJLP0R
DM0Y52J	MN	Quinone reductase 2 (NQO2)
DM0Y52J	MT	DTT
DM0Y52J	MA	Inhibitor
DM0Y52J	RN	Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities. J Med Chem. 2009 Apr 9;52(7):1873-84.
DM0Y52J	RU	https://pubmed.ncbi.nlm.nih.gov/19265439

DMQIFZC	DI	DMQIFZC
DMQIFZC	DN	8-Methoxy-2-(4-methyl-piperazin-1-yl)-quinoline
DMQIFZC	MI	TTSQIFT
DMQIFZC	MN	5-HT 1A receptor (HTR1A)
DMQIFZC	MT	DTT
DMQIFZC	MA	Inhibitor
DMQIFZC	RN	5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80.
DMQIFZC	RU	https://pubmed.ncbi.nlm.nih.gov/3783595

DMQIFZC	DI	DMQIFZC
DMQIFZC	DN	8-Methoxy-2-(4-methyl-piperazin-1-yl)-quinoline
DMQIFZC	MI	TT6MSOK
DMQIFZC	MN	5-HT 1D receptor (HTR1D)
DMQIFZC	MT	DTT
DMQIFZC	MA	Inhibitor
DMQIFZC	RN	5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80.
DMQIFZC	RU	https://pubmed.ncbi.nlm.nih.gov/3783595

DMQIFZC	DI	DMQIFZC
DMQIFZC	DN	8-Methoxy-2-(4-methyl-piperazin-1-yl)-quinoline
DMQIFZC	MI	TTJQOD7
DMQIFZC	MN	5-HT 2A receptor (HTR2A)
DMQIFZC	MT	DTT
DMQIFZC	MA	Inhibitor
DMQIFZC	RN	5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80.
DMQIFZC	RU	https://pubmed.ncbi.nlm.nih.gov/3783595

DMSN0ZE	DI	DMSN0ZE
DMSN0ZE	DN	8-Methoxy-2-(4-nitro-phenyl)-3H-quinazolin-4-one
DMSN0ZE	MI	TTVDSZ0
DMSN0ZE	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMSN0ZE	MT	DTT
DMSN0ZE	MA	Inhibitor
DMSN0ZE	RN	Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56.
DMSN0ZE	RU	https://pubmed.ncbi.nlm.nih.gov/9857092

DMHE7J5	DI	DMHE7J5
DMHE7J5	DN	8-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline
DMHE7J5	MI	TTJQOD7
DMHE7J5	MN	5-HT 2A receptor (HTR2A)
DMHE7J5	MT	DTT
DMHE7J5	MA	Inhibitor
DMHE7J5	RN	Binding of beta-carbolines at 5-HT(2) serotonin receptors. Bioorg Med Chem Lett. 2003 Dec 15;13(24):4421-5.
DMHE7J5	RU	https://pubmed.ncbi.nlm.nih.gov/14643338

DMHE7J5	DI	DMHE7J5
DMHE7J5	DN	8-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline
DMHE7J5	MI	TT3WG5C
DMHE7J5	MN	Monoamine oxidase type A (MAO-A)
DMHE7J5	MT	DTT
DMHE7J5	MA	Inhibitor
DMHE7J5	RN	Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
DMHE7J5	RU	https://pubmed.ncbi.nlm.nih.gov/15013009

DMHE7J5	DI	DMHE7J5
DMHE7J5	DN	8-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline
DMHE7J5	MI	TTGP7BY
DMHE7J5	MN	Monoamine oxidase type B (MAO-B)
DMHE7J5	MT	DTT
DMHE7J5	MA	Inhibitor
DMHE7J5	RN	Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
DMHE7J5	RU	https://pubmed.ncbi.nlm.nih.gov/15013009

DMOPN4K	DI	DMOPN4K
DMOPN4K	DN	8-Methoxy-2-methyl-3H-quinazolin-4-one
DMOPN4K	MI	TTVDSZ0
DMOPN4K	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMOPN4K	MT	DTT
DMOPN4K	MA	Inhibitor
DMOPN4K	RN	Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56.
DMOPN4K	RU	https://pubmed.ncbi.nlm.nih.gov/9857092

DMYE1X2	DI	DMYE1X2
DMYE1X2	DN	8-Methoxy-2-morpholin-4-yl-chromen-4-one
DMYE1X2	MI	TTK3PY9
DMYE1X2	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMYE1X2	MT	DTT
DMYE1X2	MA	Inhibitor
DMYE1X2	RN	Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85.
DMYE1X2	RU	https://pubmed.ncbi.nlm.nih.gov/15658870

DMHCWY8	DI	DMHCWY8
DMHCWY8	DN	8-methoxy-2-oxo-2H-chromene-3-carboxylic acid
DMHCWY8	MI	TTUNARX
DMHCWY8	MN	Carbonic anhydrase (CA)
DMHCWY8	MT	DTT
DMHCWY8	MA	Inhibitor
DMHCWY8	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMHCWY8	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMHCWY8	DI	DMHCWY8
DMHCWY8	DN	8-methoxy-2-oxo-2H-chromene-3-carboxylic acid
DMHCWY8	MI	TTHQPL7
DMHCWY8	MN	Carbonic anhydrase I (CA-I)
DMHCWY8	MT	DTT
DMHCWY8	MA	Inhibitor
DMHCWY8	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMHCWY8	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMHCWY8	DI	DMHCWY8
DMHCWY8	DN	8-methoxy-2-oxo-2H-chromene-3-carboxylic acid
DMHCWY8	MI	TT2LVK8
DMHCWY8	MN	Carbonic anhydrase IX (CA-IX)
DMHCWY8	MT	DTT
DMHCWY8	MA	Inhibitor
DMHCWY8	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMHCWY8	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMHCWY8	DI	DMHCWY8
DMHCWY8	DN	8-methoxy-2-oxo-2H-chromene-3-carboxylic acid
DMHCWY8	MI	TTSYM0R
DMHCWY8	MN	Carbonic anhydrase XII (CA-XII)
DMHCWY8	MT	DTT
DMHCWY8	MA	Inhibitor
DMHCWY8	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMHCWY8	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMHCWY8	DI	DMHCWY8
DMHCWY8	DN	8-methoxy-2-oxo-2H-chromene-3-carboxylic acid
DMHCWY8	MI	TTEYTKG
DMHCWY8	MN	Carbonic anhydrase XIV (CA-XIV)
DMHCWY8	MT	DTT
DMHCWY8	MA	Inhibitor
DMHCWY8	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMHCWY8	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DM56EW7	DI	DM56EW7
DM56EW7	DN	8-Methoxy-2-phenyl-3H-quinazolin-4-one
DM56EW7	MI	TTVDSZ0
DM56EW7	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DM56EW7	MT	DTT
DM56EW7	MA	Inhibitor
DM56EW7	RN	Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56.
DM56EW7	RU	https://pubmed.ncbi.nlm.nih.gov/9857092

DMNWC29	DI	DMNWC29
DMNWC29	DN	8-Methoxy-2-piperazin-1-yl-quinoline
DMNWC29	MI	TTSQIFT
DMNWC29	MN	5-HT 1A receptor (HTR1A)
DMNWC29	MT	DTT
DMNWC29	MA	Inhibitor
DMNWC29	RN	5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80.
DMNWC29	RU	https://pubmed.ncbi.nlm.nih.gov/3783595

DMNWC29	DI	DMNWC29
DMNWC29	DN	8-Methoxy-2-piperazin-1-yl-quinoline
DMNWC29	MI	TT6MSOK
DMNWC29	MN	5-HT 1D receptor (HTR1D)
DMNWC29	MT	DTT
DMNWC29	MA	Inhibitor
DMNWC29	RN	5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80.
DMNWC29	RU	https://pubmed.ncbi.nlm.nih.gov/3783595

DMNWC29	DI	DMNWC29
DMNWC29	DN	8-Methoxy-2-piperazin-1-yl-quinoline
DMNWC29	MI	TTJQOD7
DMNWC29	MN	5-HT 2A receptor (HTR2A)
DMNWC29	MT	DTT
DMNWC29	MA	Inhibitor
DMNWC29	RN	5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80.
DMNWC29	RU	https://pubmed.ncbi.nlm.nih.gov/3783595

DM8MBSN	DI	DM8MBSN
DM8MBSN	DN	8-Methoxy-4,9-dihydro-3H-beta-carboline
DM8MBSN	MI	TTJQOD7
DM8MBSN	MN	5-HT 2A receptor (HTR2A)
DM8MBSN	MT	DTT
DM8MBSN	MA	Inhibitor
DM8MBSN	RN	Binding of beta-carbolines at 5-HT(2) serotonin receptors. Bioorg Med Chem Lett. 2003 Dec 15;13(24):4421-5.
DM8MBSN	RU	https://pubmed.ncbi.nlm.nih.gov/14643338

DM8MBSN	DI	DM8MBSN
DM8MBSN	DN	8-Methoxy-4,9-dihydro-3H-beta-carboline
DM8MBSN	MI	TT3WG5C
DM8MBSN	MN	Monoamine oxidase type A (MAO-A)
DM8MBSN	MT	DTT
DM8MBSN	MA	Inhibitor
DM8MBSN	RN	Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
DM8MBSN	RU	https://pubmed.ncbi.nlm.nih.gov/15013009

DM8MBSN	DI	DM8MBSN
DM8MBSN	DN	8-Methoxy-4,9-dihydro-3H-beta-carboline
DM8MBSN	MI	TTGP7BY
DM8MBSN	MN	Monoamine oxidase type B (MAO-B)
DM8MBSN	MT	DTT
DM8MBSN	MA	Inhibitor
DM8MBSN	RN	Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
DM8MBSN	RU	https://pubmed.ncbi.nlm.nih.gov/15013009

DMK6U2V	DI	DMK6U2V
DMK6U2V	DN	8-methoxy-4-methyl-3,4-dihydroquinazolin-2-amine
DMK6U2V	MI	TTSQIFT
DMK6U2V	MN	5-HT 1A receptor (HTR1A)
DMK6U2V	MT	DTT
DMK6U2V	MA	Inhibitor
DMK6U2V	RN	Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61.
DMK6U2V	RU	https://pubmed.ncbi.nlm.nih.gov/17998160

DMK6U2V	DI	DMK6U2V
DMK6U2V	DN	8-methoxy-4-methyl-3,4-dihydroquinazolin-2-amine
DMK6U2V	MI	TT6MSOK
DMK6U2V	MN	5-HT 1D receptor (HTR1D)
DMK6U2V	MT	DTT
DMK6U2V	MA	Inhibitor
DMK6U2V	RN	Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61.
DMK6U2V	RU	https://pubmed.ncbi.nlm.nih.gov/17998160

DMK6U2V	DI	DMK6U2V
DMK6U2V	DN	8-methoxy-4-methyl-3,4-dihydroquinazolin-2-amine
DMK6U2V	MI	TTWJBZ5
DMK6U2V	MN	5-HT 2C receptor (HTR2C)
DMK6U2V	MT	DTT
DMK6U2V	MA	Inhibitor
DMK6U2V	RN	Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61.
DMK6U2V	RU	https://pubmed.ncbi.nlm.nih.gov/17998160

DMK6U2V	DI	DMK6U2V
DMK6U2V	DN	8-methoxy-4-methyl-3,4-dihydroquinazolin-2-amine
DMK6U2V	MI	TTRUFDT
DMK6U2V	MN	5-HT 5A receptor (HTR5A)
DMK6U2V	MT	DTT
DMK6U2V	MA	Inhibitor
DMK6U2V	RN	Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61.
DMK6U2V	RU	https://pubmed.ncbi.nlm.nih.gov/17998160

DMK6U2V	DI	DMK6U2V
DMK6U2V	DN	8-methoxy-4-methyl-3,4-dihydroquinazolin-2-amine
DMK6U2V	MI	TTO9X1H
DMK6U2V	MN	5-HT 7 receptor (HTR7)
DMK6U2V	MT	DTT
DMK6U2V	MA	Inhibitor
DMK6U2V	RN	Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61.
DMK6U2V	RU	https://pubmed.ncbi.nlm.nih.gov/17998160

DMHLKAE	DI	DMHLKAE
DMHLKAE	DN	8-Methoxy-4-morpholin-4-yl-chromen-2-one
DMHLKAE	MI	TTK3PY9
DMHLKAE	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMHLKAE	MT	DTT
DMHLKAE	MA	Inhibitor
DMHLKAE	RN	Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85.
DMHLKAE	RU	https://pubmed.ncbi.nlm.nih.gov/15658870

DMHZ5SB	DI	DMHZ5SB
DMHZ5SB	DN	8-Methoxy-quinolin-2-ylamine
DMHZ5SB	MI	TTSQIFT
DMHZ5SB	MN	5-HT 1A receptor (HTR1A)
DMHZ5SB	MT	DTT
DMHZ5SB	MA	Inhibitor
DMHZ5SB	RN	5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80.
DMHZ5SB	RU	https://pubmed.ncbi.nlm.nih.gov/3783595

DMHZ5SB	DI	DMHZ5SB
DMHZ5SB	DN	8-Methoxy-quinolin-2-ylamine
DMHZ5SB	MI	TT6MSOK
DMHZ5SB	MN	5-HT 1D receptor (HTR1D)
DMHZ5SB	MT	DTT
DMHZ5SB	MA	Inhibitor
DMHZ5SB	RN	5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80.
DMHZ5SB	RU	https://pubmed.ncbi.nlm.nih.gov/3783595

DMHZ5SB	DI	DMHZ5SB
DMHZ5SB	DN	8-Methoxy-quinolin-2-ylamine
DMHZ5SB	MI	TTX4RTB
DMHZ5SB	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMHZ5SB	MT	DTT
DMHZ5SB	MA	Inhibitor
DMHZ5SB	RN	Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7.
DMHZ5SB	RU	https://pubmed.ncbi.nlm.nih.gov/15341942

DM92XPO	DI	DM92XPO
DM92XPO	DN	8-Methyl-1,3-dihydro-imidazo[4,5-b]quinolin-2-one
DM92XPO	MI	TT06AWU
DM92XPO	MN	Phosphodiesterase 3A (PDE3A)
DM92XPO	MT	DTT
DM92XPO	MA	Inhibitor
DM92XPO	RN	1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-ones--inhibitors of blood platelet cAMP phosphodiesterase and induced aggregation. J Med Chem. 1991 Sep;34(9):2906-16.
DM92XPO	RU	https://pubmed.ncbi.nlm.nih.gov/1654430

DM7FSZM	DI	DM7FSZM
DM7FSZM	DN	8-Methyl-2-(4-nitro-phenyl)-3H-quinazolin-4-one
DM7FSZM	MI	TTVDSZ0
DM7FSZM	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DM7FSZM	MT	DTT
DM7FSZM	MA	Inhibitor
DM7FSZM	RN	Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56.
DM7FSZM	RU	https://pubmed.ncbi.nlm.nih.gov/9857092

DMLQ90D	DI	DMLQ90D
DMLQ90D	DN	8-Methyl-2-morpholin-4-yl-chromen-4-one
DMLQ90D	MI	TTK3PY9
DMLQ90D	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMLQ90D	MT	DTT
DMLQ90D	MA	Inhibitor
DMLQ90D	RN	Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85.
DMLQ90D	RU	https://pubmed.ncbi.nlm.nih.gov/15658870

DMWZ27A	DI	DMWZ27A
DMWZ27A	DN	8-methyl-2-morpholino-7-phenoxy-4H-chromen-4-one
DMWZ27A	MI	TT06AWU
DMWZ27A	MN	Phosphodiesterase 3A (PDE3A)
DMWZ27A	MT	DTT
DMWZ27A	MA	Inhibitor
DMWZ27A	RN	Analysis of anti-PDE3 activity of 2-morpholinochromone derivatives reveals multiple mechanisms of anti-platelet activity. Bioorg Med Chem Lett. 2006 Feb 15;16(4):969-73.
DMWZ27A	RU	https://pubmed.ncbi.nlm.nih.gov/16290931

DMUI1YZ	DI	DMUI1YZ
DMUI1YZ	DN	8-methyl-2-morpholino-7-phenyl-4H-chromen-4-one
DMUI1YZ	MI	TT06AWU
DMUI1YZ	MN	Phosphodiesterase 3A (PDE3A)
DMUI1YZ	MT	DTT
DMUI1YZ	MA	Inhibitor
DMUI1YZ	RN	Analysis of anti-PDE3 activity of 2-morpholinochromone derivatives reveals multiple mechanisms of anti-platelet activity. Bioorg Med Chem Lett. 2006 Feb 15;16(4):969-73.
DMUI1YZ	RU	https://pubmed.ncbi.nlm.nih.gov/16290931

DMEM6Q0	DI	DMEM6Q0
DMEM6Q0	DN	8-Methyl-2-phenyl-3H-quinazolin-4-one
DMEM6Q0	MI	TTVDSZ0
DMEM6Q0	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMEM6Q0	MT	DTT
DMEM6Q0	MA	Inhibitor
DMEM6Q0	RN	Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56.
DMEM6Q0	RU	https://pubmed.ncbi.nlm.nih.gov/9857092

DMOM4VS	DI	DMOM4VS
DMOM4VS	DN	8-Methyl-3-p-tolyl-8-aza-bicyclo[3.2.1]octane
DMOM4VS	MI	TTVBI8W
DMOM4VS	MN	Dopamine transporter (DAT)
DMOM4VS	MT	DTT
DMOM4VS	MA	Inhibitor
DMOM4VS	RN	3alpha-(4-Substituted phenyl)nortropane-2beta-carboxylic acid methyl esters show selective binding at the norepinephrine transporter. Bioorg Med Chem Lett. 2000 Nov 6;10(21):2445-7.
DMOM4VS	RU	https://pubmed.ncbi.nlm.nih.gov/11078197

DMOM4VS	DI	DMOM4VS
DMOM4VS	DN	8-Methyl-3-p-tolyl-8-aza-bicyclo[3.2.1]octane
DMOM4VS	MI	TTAWNKZ
DMOM4VS	MN	Norepinephrine transporter (NET)
DMOM4VS	MT	DTT
DMOM4VS	MA	Inhibitor
DMOM4VS	RN	3alpha-(4-Substituted phenyl)nortropane-2beta-carboxylic acid methyl esters show selective binding at the norepinephrine transporter. Bioorg Med Chem Lett. 2000 Nov 6;10(21):2445-7.
DMOM4VS	RU	https://pubmed.ncbi.nlm.nih.gov/11078197

DMOM4VS	DI	DMOM4VS
DMOM4VS	DN	8-Methyl-3-p-tolyl-8-aza-bicyclo[3.2.1]octane
DMOM4VS	MI	TT3ROYC
DMOM4VS	MN	Serotonin transporter (SERT)
DMOM4VS	MT	DTT
DMOM4VS	MA	Inhibitor
DMOM4VS	RN	3alpha-(4-Substituted phenyl)nortropane-2beta-carboxylic acid methyl esters show selective binding at the norepinephrine transporter. Bioorg Med Chem Lett. 2000 Nov 6;10(21):2445-7.
DMOM4VS	RU	https://pubmed.ncbi.nlm.nih.gov/11078197

DMA28OL	DI	DMA28OL
DMA28OL	DN	8-methyl-4H,7H-indolo[6,5,4-cd]indol-5-one
DMA28OL	MI	TTUTJGQ
DMA28OL	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMA28OL	MT	DTT
DMA28OL	MA	Inhibitor
DMA28OL	RN	Pharmacophore modeling and in silico screening for new KDR kinase inhibitors. Bioorg Med Chem Lett. 2007 Apr 15;17(8):2126-33.
DMA28OL	RU	https://pubmed.ncbi.nlm.nih.gov/17306530

DMVAOIG	DI	DMVAOIG
DMVAOIG	DN	8-Methyl-4-morpholin-4-yl-chromen-2-one
DMVAOIG	MI	TTK3PY9
DMVAOIG	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMVAOIG	MT	DTT
DMVAOIG	MA	Inhibitor
DMVAOIG	RN	Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85.
DMVAOIG	RU	https://pubmed.ncbi.nlm.nih.gov/15658870

DMK63P2	DI	DMK63P2
DMK63P2	DN	8-methylnaringenin
DMK63P2	MI	TTZAYWL
DMK63P2	MN	Estrogen receptor (ESR)
DMK63P2	MT	DTT
DMK63P2	MA	Inhibitor
DMK63P2	RN	Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65.
DMK63P2	RU	https://pubmed.ncbi.nlm.nih.gov/17149865

DMK63P2	DI	DMK63P2
DMK63P2	DN	8-methylnaringenin
DMK63P2	MI	TTOM3J0
DMK63P2	MN	Estrogen receptor beta (ESR2)
DMK63P2	MT	DTT
DMK63P2	MA	Inhibitor
DMK63P2	RN	Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65.
DMK63P2	RU	https://pubmed.ncbi.nlm.nih.gov/17149865

DMWMVI3	DI	DMWMVI3
DMWMVI3	DN	8-n-heptylnaringenin
DMWMVI3	MI	TTZAYWL
DMWMVI3	MN	Estrogen receptor (ESR)
DMWMVI3	MT	DTT
DMWMVI3	MA	Inhibitor
DMWMVI3	RN	Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65.
DMWMVI3	RU	https://pubmed.ncbi.nlm.nih.gov/17149865

DMWMVI3	DI	DMWMVI3
DMWMVI3	DN	8-n-heptylnaringenin
DMWMVI3	MI	TTOM3J0
DMWMVI3	MN	Estrogen receptor beta (ESR2)
DMWMVI3	MT	DTT
DMWMVI3	MA	Inhibitor
DMWMVI3	RN	Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65.
DMWMVI3	RU	https://pubmed.ncbi.nlm.nih.gov/17149865

DM5L40C	DI	DM5L40C
DM5L40C	DN	8-Nitro-6H,11H-indeno[1,2-c]isoquinolin-5-one
DM5L40C	MI	TTVDSZ0
DM5L40C	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DM5L40C	MT	DTT
DM5L40C	MA	Inhibitor
DM5L40C	RN	Discovery of potent poly(ADP-ribose) polymerase-1 inhibitors from the modification of indeno[1,2-c]isoquinolinone. J Med Chem. 2005 Aug 11;48(16):5100-3.
DM5L40C	RU	https://pubmed.ncbi.nlm.nih.gov/16078828

DMC2JLQ	DI	DMC2JLQ
DMC2JLQ	DN	8-n-nonylnaringenin
DMC2JLQ	MI	TTZAYWL
DMC2JLQ	MN	Estrogen receptor (ESR)
DMC2JLQ	MT	DTT
DMC2JLQ	MA	Inhibitor
DMC2JLQ	RN	Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65.
DMC2JLQ	RU	https://pubmed.ncbi.nlm.nih.gov/17149865

DMC2JLQ	DI	DMC2JLQ
DMC2JLQ	DN	8-n-nonylnaringenin
DMC2JLQ	MI	TTOM3J0
DMC2JLQ	MN	Estrogen receptor beta (ESR2)
DMC2JLQ	MT	DTT
DMC2JLQ	MA	Inhibitor
DMC2JLQ	RN	Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65.
DMC2JLQ	RU	https://pubmed.ncbi.nlm.nih.gov/17149865

DMRDOP0	DI	DMRDOP0
DMRDOP0	DN	8-n-pentylnaringenin
DMRDOP0	MI	TTZAYWL
DMRDOP0	MN	Estrogen receptor (ESR)
DMRDOP0	MT	DTT
DMRDOP0	MA	Inhibitor
DMRDOP0	RN	Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65.
DMRDOP0	RU	https://pubmed.ncbi.nlm.nih.gov/17149865

DMRDOP0	DI	DMRDOP0
DMRDOP0	DN	8-n-pentylnaringenin
DMRDOP0	MI	TTOM3J0
DMRDOP0	MN	Estrogen receptor beta (ESR2)
DMRDOP0	MT	DTT
DMRDOP0	MA	Inhibitor
DMRDOP0	RN	Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65.
DMRDOP0	RU	https://pubmed.ncbi.nlm.nih.gov/17149865

DMDOW5S	DI	DMDOW5S
DMDOW5S	DN	8-n-propylnaringenin
DMDOW5S	MI	TTZAYWL
DMDOW5S	MN	Estrogen receptor (ESR)
DMDOW5S	MT	DTT
DMDOW5S	MA	Inhibitor
DMDOW5S	RN	Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65.
DMDOW5S	RU	https://pubmed.ncbi.nlm.nih.gov/17149865

DMDOW5S	DI	DMDOW5S
DMDOW5S	DN	8-n-propylnaringenin
DMDOW5S	MI	TTOM3J0
DMDOW5S	MN	Estrogen receptor beta (ESR2)
DMDOW5S	MT	DTT
DMDOW5S	MA	Inhibitor
DMDOW5S	RN	Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65.
DMDOW5S	RU	https://pubmed.ncbi.nlm.nih.gov/17149865

DMXURM8	DI	DMXURM8
DMXURM8	DN	8-n-undecylnaringenin
DMXURM8	MI	TTZAYWL
DMXURM8	MN	Estrogen receptor (ESR)
DMXURM8	MT	DTT
DMXURM8	MA	Inhibitor
DMXURM8	RN	Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65.
DMXURM8	RU	https://pubmed.ncbi.nlm.nih.gov/17149865

DMXURM8	DI	DMXURM8
DMXURM8	DN	8-n-undecylnaringenin
DMXURM8	MI	TTOM3J0
DMXURM8	MN	Estrogen receptor beta (ESR2)
DMXURM8	MT	DTT
DMXURM8	MA	Inhibitor
DMXURM8	RN	Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65.
DMXURM8	RU	https://pubmed.ncbi.nlm.nih.gov/17149865

DMDRPLA	DI	DMDRPLA
DMDRPLA	DN	8-O-(4-bromobenzenesulfonyl)manzamine F
DMDRPLA	MI	TTRSMW9
DMDRPLA	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMDRPLA	MT	DTT
DMDRPLA	MA	Inhibitor
DMDRPLA	RN	Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for ... J Nat Prod. 2007 Sep;70(9):1397-405.
DMDRPLA	RU	https://pubmed.ncbi.nlm.nih.gov/17708655

DM48JMC	DI	DM48JMC
DM48JMC	DN	8-O-(4-chlorobenzenesulfonyl)manzamine F
DM48JMC	MI	TTRSMW9
DM48JMC	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DM48JMC	MT	DTT
DM48JMC	MA	Inhibitor
DM48JMC	RN	Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for ... J Nat Prod. 2007 Sep;70(9):1397-405.
DM48JMC	RU	https://pubmed.ncbi.nlm.nih.gov/17708655

DM249GI	DI	DM249GI
DM249GI	DN	8-O-(4-toluenesulfonyl)manzamine A
DM249GI	MI	TTRSMW9
DM249GI	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DM249GI	MT	DTT
DM249GI	MA	Inhibitor
DM249GI	RN	Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for ... J Nat Prod. 2007 Sep;70(9):1397-405.
DM249GI	RU	https://pubmed.ncbi.nlm.nih.gov/17708655

DM4Z15M	DI	DM4Z15M
DM4Z15M	DN	8-Octyl-benzolactam-V9
DM4Z15M	MI	TT7A1BO
DM4Z15M	MN	PKC-delta messenger RNA (PRKCD mRNA)
DM4Z15M	MT	DTT
DM4Z15M	MA	Inhibitor
DM4Z15M	RN	Design and synthesis of 8-octyl-benzolactam-V9, a selective activator for protein kinase C epsilon and eta. J Med Chem. 2006 May 4;49(9):2681-8.
DM4Z15M	RU	https://pubmed.ncbi.nlm.nih.gov/16640328

DM4Z15M	DI	DM4Z15M
DM4Z15M	DN	8-Octyl-benzolactam-V9
DM4Z15M	MI	TT57MT2
DM4Z15M	MN	PKC-epsilon messenger RNA (PRKCE mRNA)
DM4Z15M	MT	DTT
DM4Z15M	MA	Inhibitor
DM4Z15M	RN	Design and synthesis of 8-octyl-benzolactam-V9, a selective activator for protein kinase C epsilon and eta. J Med Chem. 2006 May 4;49(9):2681-8.
DM4Z15M	RU	https://pubmed.ncbi.nlm.nih.gov/16640328

DM4Z15M	DI	DM4Z15M
DM4Z15M	DN	8-Octyl-benzolactam-V9
DM4Z15M	MI	TTONI0R
DM4Z15M	MN	PKC-eta messenger RNA (PRKCH mRNA)
DM4Z15M	MT	DTT
DM4Z15M	MA	Inhibitor
DM4Z15M	RN	Design and synthesis of 8-octyl-benzolactam-V9, a selective activator for protein kinase C epsilon and eta. J Med Chem. 2006 May 4;49(9):2681-8.
DM4Z15M	RU	https://pubmed.ncbi.nlm.nih.gov/16640328

DM4Z15M	DI	DM4Z15M
DM4Z15M	DN	8-Octyl-benzolactam-V9
DM4Z15M	MI	TT1MS7X
DM4Z15M	MN	PKC-theta messenger RNA (PRKCQ mRNA)
DM4Z15M	MT	DTT
DM4Z15M	MA	Inhibitor
DM4Z15M	RN	Design and synthesis of 8-octyl-benzolactam-V9, a selective activator for protein kinase C epsilon and eta. J Med Chem. 2006 May 4;49(9):2681-8.
DM4Z15M	RU	https://pubmed.ncbi.nlm.nih.gov/16640328

DM4Z15M	DI	DM4Z15M
DM4Z15M	DN	8-Octyl-benzolactam-V9
DM4Z15M	MI	TTRFOXJ
DM4Z15M	MN	Protein kinase C gamma (PRKCG)
DM4Z15M	MT	DTT
DM4Z15M	MA	Inhibitor
DM4Z15M	RN	Design and synthesis of 8-octyl-benzolactam-V9, a selective activator for protein kinase C epsilon and eta. J Med Chem. 2006 May 4;49(9):2681-8.
DM4Z15M	RU	https://pubmed.ncbi.nlm.nih.gov/16640328

DM4QYEF	DI	DM4QYEF
DM4QYEF	DN	8-OH-MANZAMINE A
DM4QYEF	MI	TTRSMW9
DM4QYEF	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DM4QYEF	MT	DTT
DM4QYEF	MA	Inhibitor
DM4QYEF	RN	Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical p... J Nat Prod. 2006 Jul;69(7):1034-40.
DM4QYEF	RU	https://pubmed.ncbi.nlm.nih.gov/16872140

DMXDQ25	DI	DMXDQ25
DMXDQ25	DN	8-Oxo-8-phenyl-octanoic acid
DMXDQ25	MI	TTBH0VX
DMXDQ25	MN	Histone deacetylase (HDAC)
DMXDQ25	MT	DTT
DMXDQ25	MA	Inhibitor
DMXDQ25	RN	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
DMXDQ25	RU	https://pubmed.ncbi.nlm.nih.gov/11831887

DMXDQ25	DI	DMXDQ25
DMXDQ25	DN	8-Oxo-8-phenyl-octanoic acid
DMXDQ25	MI	TT6R7JZ
DMXDQ25	MN	Histone deacetylase 1 (HDAC1)
DMXDQ25	MT	DTT
DMXDQ25	MA	Inhibitor
DMXDQ25	RN	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
DMXDQ25	RU	https://pubmed.ncbi.nlm.nih.gov/11831887

DMXDQ25	DI	DMXDQ25
DMXDQ25	DN	8-Oxo-8-phenyl-octanoic acid
DMXDQ25	MI	TTYHPU6
DMXDQ25	MN	Histone deacetylase 10 (HDAC10)
DMXDQ25	MT	DTT
DMXDQ25	MA	Inhibitor
DMXDQ25	RN	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
DMXDQ25	RU	https://pubmed.ncbi.nlm.nih.gov/11831887

DMXDQ25	DI	DMXDQ25
DMXDQ25	DN	8-Oxo-8-phenyl-octanoic acid
DMXDQ25	MI	TTSHTOI
DMXDQ25	MN	Histone deacetylase 2 (HDAC2)
DMXDQ25	MT	DTT
DMXDQ25	MA	Inhibitor
DMXDQ25	RN	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
DMXDQ25	RU	https://pubmed.ncbi.nlm.nih.gov/11831887

DMXDQ25	DI	DMXDQ25
DMXDQ25	DN	8-Oxo-8-phenyl-octanoic acid
DMXDQ25	MI	TTTQGH8
DMXDQ25	MN	Histone deacetylase 4 (HDAC4)
DMXDQ25	MT	DTT
DMXDQ25	MA	Inhibitor
DMXDQ25	RN	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
DMXDQ25	RU	https://pubmed.ncbi.nlm.nih.gov/11831887

DMXDQ25	DI	DMXDQ25
DMXDQ25	DN	8-Oxo-8-phenyl-octanoic acid
DMXDQ25	MI	TT5ZKDI
DMXDQ25	MN	Histone deacetylase 6 (HDAC6)
DMXDQ25	MT	DTT
DMXDQ25	MA	Inhibitor
DMXDQ25	RN	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
DMXDQ25	RU	https://pubmed.ncbi.nlm.nih.gov/11831887

DMXDQ25	DI	DMXDQ25
DMXDQ25	DN	8-Oxo-8-phenyl-octanoic acid
DMXDQ25	MI	TTT6LFV
DMXDQ25	MN	Histone deacetylase 8 (HDAC8)
DMXDQ25	MT	DTT
DMXDQ25	MA	Inhibitor
DMXDQ25	RN	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
DMXDQ25	RU	https://pubmed.ncbi.nlm.nih.gov/11831887

DMWM1UL	DI	DMWM1UL
DMWM1UL	DN	8-Oxo-8-phenyl-octanoic acid hydroxyamide
DMWM1UL	MI	TTBH0VX
DMWM1UL	MN	Histone deacetylase (HDAC)
DMWM1UL	MT	DTT
DMWM1UL	MA	Inhibitor
DMWM1UL	RN	Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
DMWM1UL	RU	https://pubmed.ncbi.nlm.nih.gov/14613312

DMWM1UL	DI	DMWM1UL
DMWM1UL	DN	8-Oxo-8-phenyl-octanoic acid hydroxyamide
DMWM1UL	MI	TT6R7JZ
DMWM1UL	MN	Histone deacetylase 1 (HDAC1)
DMWM1UL	MT	DTT
DMWM1UL	MA	Inhibitor
DMWM1UL	RN	Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
DMWM1UL	RU	https://pubmed.ncbi.nlm.nih.gov/14613312

DMWM1UL	DI	DMWM1UL
DMWM1UL	DN	8-Oxo-8-phenyl-octanoic acid hydroxyamide
DMWM1UL	MI	TTSHTOI
DMWM1UL	MN	Histone deacetylase 2 (HDAC2)
DMWM1UL	MT	DTT
DMWM1UL	MA	Inhibitor
DMWM1UL	RN	Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
DMWM1UL	RU	https://pubmed.ncbi.nlm.nih.gov/14613312

DMWM1UL	DI	DMWM1UL
DMWM1UL	DN	8-Oxo-8-phenyl-octanoic acid hydroxyamide
DMWM1UL	MI	TTTQGH8
DMWM1UL	MN	Histone deacetylase 4 (HDAC4)
DMWM1UL	MT	DTT
DMWM1UL	MA	Inhibitor
DMWM1UL	RN	Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
DMWM1UL	RU	https://pubmed.ncbi.nlm.nih.gov/14613312

DMWM1UL	DI	DMWM1UL
DMWM1UL	DN	8-Oxo-8-phenyl-octanoic acid hydroxyamide
DMWM1UL	MI	TT5ZKDI
DMWM1UL	MN	Histone deacetylase 6 (HDAC6)
DMWM1UL	MT	DTT
DMWM1UL	MA	Inhibitor
DMWM1UL	RN	Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
DMWM1UL	RU	https://pubmed.ncbi.nlm.nih.gov/14613312

DME8S0R	DI	DME8S0R
DME8S0R	DN	8-Pentyloxy-quinolin-2-ylamine
DME8S0R	MI	TTX4RTB
DME8S0R	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DME8S0R	MT	DTT
DME8S0R	MA	Inhibitor
DME8S0R	RN	Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7.
DME8S0R	RU	https://pubmed.ncbi.nlm.nih.gov/15341942

DMFGUCY	DI	DMFGUCY
DMFGUCY	DN	8-PHENYL THEOPHYLLINE
DMFGUCY	MI	TTK25J1
DMFGUCY	MN	Adenosine A1 receptor (ADORA1)
DMFGUCY	MT	DTT
DMFGUCY	MA	Inhibitor
DMFGUCY	RN	1H-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists. J Med Chem. 1991 Mar;34(3):1202-6.
DMFGUCY	RU	https://pubmed.ncbi.nlm.nih.gov/2002461

DMFGUCY	DI	DMFGUCY
DMFGUCY	DN	8-PHENYL THEOPHYLLINE
DMFGUCY	MI	TTM2AOE
DMFGUCY	MN	Adenosine A2a receptor (ADORA2A)
DMFGUCY	MT	DTT
DMFGUCY	MA	Inhibitor
DMFGUCY	RN	1H-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists. J Med Chem. 1991 Mar;34(3):1202-6.
DMFGUCY	RU	https://pubmed.ncbi.nlm.nih.gov/2002461

DMFGUCY	DI	DMFGUCY
DMFGUCY	DN	8-PHENYL THEOPHYLLINE
DMFGUCY	MI	TTNE7KG
DMFGUCY	MN	Adenosine A2b receptor (ADORA2B)
DMFGUCY	MT	DTT
DMFGUCY	MA	Inhibitor
DMFGUCY	RN	2-Alkynyl-8-aryl-9-methyladenines as novel adenosine receptor antagonists: their synthesis and structure-activity relationships toward hepatic gluc... J Med Chem. 2001 Jan 18;44(2):170-9.
DMFGUCY	RU	https://pubmed.ncbi.nlm.nih.gov/11170626

DMFGUCY	DI	DMFGUCY
DMFGUCY	DN	8-PHENYL THEOPHYLLINE
DMFGUCY	MI	TTJFY5U
DMFGUCY	MN	Adenosine A3 receptor (ADORA3)
DMFGUCY	MT	DTT
DMFGUCY	MA	Inhibitor
DMFGUCY	RN	Adenosine receptors: targets for future drugs. J Med Chem. 1982 Mar;25(3):197-207.
DMFGUCY	RU	https://pubmed.ncbi.nlm.nih.gov/6279840

DMHQGOC	DI	DMHQGOC
DMHQGOC	DN	8-Phenyl-1-propyl-3,7-dihydro-purine-2,6-dione
DMHQGOC	MI	TTK25J1
DMHQGOC	MN	Adenosine A1 receptor (ADORA1)
DMHQGOC	MT	DTT
DMHQGOC	MA	Inhibitor
DMHQGOC	RN	Synthesis of paraxanthine analogs (1,7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: structure-activity relationshi... J Med Chem. 1993 Oct 29;36(22):3341-9.
DMHQGOC	RU	https://pubmed.ncbi.nlm.nih.gov/8230124

DMHQGOC	DI	DMHQGOC
DMHQGOC	DN	8-Phenyl-1-propyl-3,7-dihydro-purine-2,6-dione
DMHQGOC	MI	TTM2AOE
DMHQGOC	MN	Adenosine A2a receptor (ADORA2A)
DMHQGOC	MT	DTT
DMHQGOC	MA	Inhibitor
DMHQGOC	RN	Preparation, properties, reactions, and adenosine receptor affinities of sulfophenylxanthine nitrophenyl esters: toward the development of sulfonic... J Med Chem. 2004 Feb 12;47(4):1031-43.
DMHQGOC	RU	https://pubmed.ncbi.nlm.nih.gov/14761205

DMHQGOC	DI	DMHQGOC
DMHQGOC	DN	8-Phenyl-1-propyl-3,7-dihydro-purine-2,6-dione
DMHQGOC	MI	TTNE7KG
DMHQGOC	MN	Adenosine A2b receptor (ADORA2B)
DMHQGOC	MT	DTT
DMHQGOC	MA	Inhibitor
DMHQGOC	RN	Preparation, properties, reactions, and adenosine receptor affinities of sulfophenylxanthine nitrophenyl esters: toward the development of sulfonic... J Med Chem. 2004 Feb 12;47(4):1031-43.
DMHQGOC	RU	https://pubmed.ncbi.nlm.nih.gov/14761205

DM29L4D	DI	DM29L4D
DM29L4D	DN	8-Phenyl-2-piperidin-1-yl-chromen-4-one
DM29L4D	MI	TTK3PY9
DM29L4D	MN	DNA-dependent protein kinase catalytic (PRKDC)
DM29L4D	MT	DTT
DM29L4D	MA	Inhibitor
DM29L4D	RN	Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85.
DM29L4D	RU	https://pubmed.ncbi.nlm.nih.gov/15658870

DMJMWOE	DI	DMJMWOE
DMJMWOE	DN	8-Phenyl-2-thiomorpholin-4-yl-chromen-4-one
DMJMWOE	MI	TTK3PY9
DMJMWOE	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMJMWOE	MT	DTT
DMJMWOE	MA	Inhibitor
DMJMWOE	RN	Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85.
DMJMWOE	RU	https://pubmed.ncbi.nlm.nih.gov/15658870

DMJB1NI	DI	DMJB1NI
DMJB1NI	DN	8-Phenyl-3,7-dihydro-purine-2,6-dione
DMJB1NI	MI	TTK25J1
DMJB1NI	MN	Adenosine A1 receptor (ADORA1)
DMJB1NI	MT	DTT
DMJB1NI	MA	Inhibitor
DMJB1NI	RN	Synthesis of paraxanthine analogs (1,7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: structure-activity relationshi... J Med Chem. 1993 Oct 29;36(22):3341-9.
DMJB1NI	RU	https://pubmed.ncbi.nlm.nih.gov/8230124

DM516NE	DI	DM516NE
DM516NE	DN	8-Phenyl-octanoic acid hydroxyamide
DM516NE	MI	TT6R7JZ
DM516NE	MN	Histone deacetylase 1 (HDAC1)
DM516NE	MT	DTT
DM516NE	MA	Inhibitor
DM516NE	RN	A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units. Bioorg Med Chem Lett. 2003 Nov 3;13(21):3817-20.
DM516NE	RU	https://pubmed.ncbi.nlm.nih.gov/14552787

DM516NE	DI	DM516NE
DM516NE	DN	8-Phenyl-octanoic acid hydroxyamide
DM516NE	MI	TTSHTOI
DM516NE	MN	Histone deacetylase 2 (HDAC2)
DM516NE	MT	DTT
DM516NE	MA	Inhibitor
DM516NE	RN	A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units. Bioorg Med Chem Lett. 2003 Nov 3;13(21):3817-20.
DM516NE	RU	https://pubmed.ncbi.nlm.nih.gov/14552787

DM4TWRJ	DI	DM4TWRJ
DM4TWRJ	DN	8-Phenyloctylcarbamic Acid Biphenyl-3-yl Ester
DM4TWRJ	MI	TTDP1UC
DM4TWRJ	MN	Fatty acid amide hydrolase (FAAH)
DM4TWRJ	MT	DTT
DM4TWRJ	MA	Inhibitor
DM4TWRJ	RN	Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl a... J Med Chem. 2008 Jun 26;51(12):3487-98.
DM4TWRJ	RU	https://pubmed.ncbi.nlm.nih.gov/18507372

DM958EN	DI	DM958EN
DM958EN	DN	8-Piperazin-1-yl-imidazo[1,2-a]pyrazine
DM958EN	MI	TTNGILX
DM958EN	MN	Adrenergic receptor alpha-1A (ADRA1A)
DM958EN	MT	DTT
DM958EN	MA	Inhibitor
DM958EN	RN	Synthesis and hypoglycemic activity of substituted 8-(1-piperazinyl)imidazo[1,2-a]pyrazines. J Med Chem. 1992 Oct 16;35(21):3845-57.
DM958EN	RU	https://pubmed.ncbi.nlm.nih.gov/1359141

DM958EN	DI	DM958EN
DM958EN	DN	8-Piperazin-1-yl-imidazo[1,2-a]pyrazine
DM958EN	MI	TT34BHT
DM958EN	MN	Adrenergic receptor alpha-1D (ADRA1D)
DM958EN	MT	DTT
DM958EN	MA	Inhibitor
DM958EN	RN	Synthesis and hypoglycemic activity of substituted 8-(1-piperazinyl)imidazo[1,2-a]pyrazines. J Med Chem. 1992 Oct 16;35(21):3845-57.
DM958EN	RU	https://pubmed.ncbi.nlm.nih.gov/1359141

DM2VC0E	DI	DM2VC0E
DM2VC0E	DN	8-prenylapigenin
DM2VC0E	MI	TTJ0IQB
DM2VC0E	MN	Phosphodiesterase 5A (PDE5A)
DM2VC0E	MT	DTT
DM2VC0E	MA	Inhibitor
DM2VC0E	RN	Potent inhibition of human phosphodiesterase-5 by icariin derivatives. J Nat Prod. 2008 Sep;71(9):1513-7.
DM2VC0E	RU	https://pubmed.ncbi.nlm.nih.gov/18778098

DMZC1SV	DI	DMZC1SV
DMZC1SV	DN	8-prenylquercetin
DMZC1SV	MI	TTJ0IQB
DMZC1SV	MN	Phosphodiesterase 5A (PDE5A)
DMZC1SV	MT	DTT
DMZC1SV	MA	Inhibitor
DMZC1SV	RN	Potent inhibition of human phosphodiesterase-5 by icariin derivatives. J Nat Prod. 2008 Sep;71(9):1513-7.
DMZC1SV	RU	https://pubmed.ncbi.nlm.nih.gov/18778098

DMKWYJX	DI	DMKWYJX
DMKWYJX	DN	8-Propionyl-7-propoxy-2H-chromen-2-one
DMKWYJX	MI	TT2LVK8
DMKWYJX	MN	Carbonic anhydrase IX (CA-IX)
DMKWYJX	MT	DTT
DMKWYJX	MA	Inhibitor
DMKWYJX	RN	7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and X... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7255-8.
DMKWYJX	RU	https://pubmed.ncbi.nlm.nih.gov/21067924

DM0TVL5	DI	DM0TVL5
DM0TVL5	DN	8-Propoxy-quinolin-2-ylamine
DM0TVL5	MI	TTX4RTB
DM0TVL5	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DM0TVL5	MT	DTT
DM0TVL5	MA	Inhibitor
DM0TVL5	RN	Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7.
DM0TVL5	RU	https://pubmed.ncbi.nlm.nih.gov/15341942

DMT6YUF	DI	DMT6YUF
DMT6YUF	DN	8-propyl-2,6-diphenyl-9H-purine
DMT6YUF	MI	TTK25J1
DMT6YUF	MN	Adenosine A1 receptor (ADORA1)
DMT6YUF	MT	DTT
DMT6YUF	MA	Inhibitor
DMT6YUF	RN	2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7.
DMT6YUF	RU	https://pubmed.ncbi.nlm.nih.gov/16686529

DMT6YUF	DI	DMT6YUF
DMT6YUF	DN	8-propyl-2,6-diphenyl-9H-purine
DMT6YUF	MI	TTM2AOE
DMT6YUF	MN	Adenosine A2a receptor (ADORA2A)
DMT6YUF	MT	DTT
DMT6YUF	MA	Inhibitor
DMT6YUF	RN	2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7.
DMT6YUF	RU	https://pubmed.ncbi.nlm.nih.gov/16686529

DMT6YUF	DI	DMT6YUF
DMT6YUF	DN	8-propyl-2,6-diphenyl-9H-purine
DMT6YUF	MI	TTJFY5U
DMT6YUF	MN	Adenosine A3 receptor (ADORA3)
DMT6YUF	MT	DTT
DMT6YUF	MA	Inhibitor
DMT6YUF	RN	2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7.
DMT6YUF	RU	https://pubmed.ncbi.nlm.nih.gov/16686529

DM1I25F	DI	DM1I25F
DM1I25F	DN	8-Pyridin-4-yl-9H-purine-2,6-diamine
DM1I25F	MI	TT9SL3Q
DM1I25F	MN	Polypeptide deformylase (PDF)
DM1I25F	MT	DTT
DM1I25F	MA	Inhibitor
DM1I25F	RN	Conformationally restricted analogues of trimethoprim: 2,6-diamino-8-substituted purines as potential dihydrofolate reductase inhibitors from Pneum... J Med Chem. 1997 Sep 12;40(19):3032-9.
DM1I25F	RU	https://pubmed.ncbi.nlm.nih.gov/9301665

DML9HDA	DI	DML9HDA
DML9HDA	DN	8R-hydroxylobel-9-ene
DML9HDA	MI	TTVBI8W
DML9HDA	MN	Dopamine transporter (DAT)
DML9HDA	MT	DTT
DML9HDA	MA	Inhibitor
DML9HDA	RN	Lobeline esters as novel ligands for neuronal nicotinic acetylcholine receptors and neurotransmitter transporters. Bioorg Med Chem. 2010 Jan 15;18(2):640-9.
DML9HDA	RU	https://pubmed.ncbi.nlm.nih.gov/20036131

DML9HDA	DI	DML9HDA
DML9HDA	DN	8R-hydroxylobel-9-ene
DML9HDA	MI	TT3ROYC
DML9HDA	MN	Serotonin transporter (SERT)
DML9HDA	MT	DTT
DML9HDA	MA	Inhibitor
DML9HDA	RN	Lobeline esters as novel ligands for neuronal nicotinic acetylcholine receptors and neurotransmitter transporters. Bioorg Med Chem. 2010 Jan 15;18(2):640-9.
DML9HDA	RU	https://pubmed.ncbi.nlm.nih.gov/20036131

DMJ82TO	DI	DMJ82TO
DMJ82TO	DN	8R-hydroxylobelane
DMJ82TO	MI	TTVBI8W
DMJ82TO	MN	Dopamine transporter (DAT)
DMJ82TO	MT	DTT
DMJ82TO	MA	Inhibitor
DMJ82TO	RN	Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5018-21.
DMJ82TO	RU	https://pubmed.ncbi.nlm.nih.gov/16905316

DMJ82TO	DI	DMJ82TO
DMJ82TO	DN	8R-hydroxylobelane
DMJ82TO	MI	TT3ROYC
DMJ82TO	MN	Serotonin transporter (SERT)
DMJ82TO	MT	DTT
DMJ82TO	MA	Inhibitor
DMJ82TO	RN	Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5018-21.
DMJ82TO	RU	https://pubmed.ncbi.nlm.nih.gov/16905316

DMLK4WO	DI	DMLK4WO
DMLK4WO	DN	8R-Lisuride
DMLK4WO	MI	TTTIBOJ
DMLK4WO	MN	Histamine H1 receptor (H1R)
DMLK4WO	MT	DTT
DMLK4WO	MA	Agonist
DMLK4WO	RN	8R-lisuride is a potent stereospecific histamine H1-receptor partial agonist. Mol Pharmacol. 2004 Mar;65(3):538-49.
DMLK4WO	RU	https://pubmed.ncbi.nlm.nih.gov/14978232

DMFPWJL	DI	DMFPWJL
DMFPWJL	DN	8-sec-Butoxy-quinolin-2-ylamine
DMFPWJL	MI	TTX4RTB
DMFPWJL	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMFPWJL	MT	DTT
DMFPWJL	MA	Inhibitor
DMFPWJL	RN	Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7.
DMFPWJL	RU	https://pubmed.ncbi.nlm.nih.gov/15341942

DMT9SAC	DI	DMT9SAC
DMT9SAC	DN	8S-HETE
DMT9SAC	MI	TTJ584C
DMT9SAC	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMT9SAC	MT	DTT
DMT9SAC	MA	Agonist
DMT9SAC	RN	Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem. 1995 Oct 13;270(41):23975-83.
DMT9SAC	RU	https://pubmed.ncbi.nlm.nih.gov/7592593

DMRL3BK	DI	DMRL3BK
DMRL3BK	DN	8S-hydroxylobel-9-ene
DMRL3BK	MI	TTVBI8W
DMRL3BK	MN	Dopamine transporter (DAT)
DMRL3BK	MT	DTT
DMRL3BK	MA	Inhibitor
DMRL3BK	RN	Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5018-21.
DMRL3BK	RU	https://pubmed.ncbi.nlm.nih.gov/16905316

DMRL3BK	DI	DMRL3BK
DMRL3BK	DN	8S-hydroxylobel-9-ene
DMRL3BK	MI	TT3ROYC
DMRL3BK	MN	Serotonin transporter (SERT)
DMRL3BK	MT	DTT
DMRL3BK	MA	Inhibitor
DMRL3BK	RN	Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5018-21.
DMRL3BK	RU	https://pubmed.ncbi.nlm.nih.gov/16905316

DMLONTS	DI	DMLONTS
DMLONTS	DN	8S-hydroxylobelane
DMLONTS	MI	TTVBI8W
DMLONTS	MN	Dopamine transporter (DAT)
DMLONTS	MT	DTT
DMLONTS	MA	Inhibitor
DMLONTS	RN	Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5018-21.
DMLONTS	RU	https://pubmed.ncbi.nlm.nih.gov/16905316

DMLONTS	DI	DMLONTS
DMLONTS	DN	8S-hydroxylobelane
DMLONTS	MI	TT3ROYC
DMLONTS	MN	Serotonin transporter (SERT)
DMLONTS	MT	DTT
DMLONTS	MA	Inhibitor
DMLONTS	RN	Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5018-21.
DMLONTS	RU	https://pubmed.ncbi.nlm.nih.gov/16905316

DMOHB3Z	DI	DMOHB3Z
DMOHB3Z	DN	8-sulfophenyl theophylline
DMOHB3Z	MI	TTSLI08
DMOHB3Z	MN	Adenosine receptor (ADOR)
DMOHB3Z	MT	DTT
DMOHB3Z	MA	Antagonist
DMOHB3Z	RN	Minoxidil-induced hair growth is mediated by adenosine in cultured dermal papilla cells: possible involvement of sulfonylurea receptor 2B as a target of minoxidil. J Invest Dermatol. 2001 Dec;117(6):1594-600.
DMOHB3Z	RU	https://pubmed.ncbi.nlm.nih.gov/11886528

DM4Y9U3	DI	DM4Y9U3
DM4Y9U3	DN	9-(2-aminoethyl)-9,10-dihydroanthracene
DM4Y9U3	MI	TTJQOD7
DM4Y9U3	MN	5-HT 2A receptor (HTR2A)
DM4Y9U3	MT	DTT
DM4Y9U3	MA	Inhibitor
DM4Y9U3	RN	Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504.
DM4Y9U3	RU	https://pubmed.ncbi.nlm.nih.gov/19700330

DM4Y9U3	DI	DM4Y9U3
DM4Y9U3	DN	9-(2-aminoethyl)-9,10-dihydroanthracene
DM4Y9U3	MI	TTTIBOJ
DM4Y9U3	MN	Histamine H1 receptor (H1R)
DM4Y9U3	MT	DTT
DM4Y9U3	MA	Inhibitor
DM4Y9U3	RN	Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504.
DM4Y9U3	RU	https://pubmed.ncbi.nlm.nih.gov/19700330

DMND39P	DI	DMND39P
DMND39P	DN	9-(2-aminopropyl)-9,10-dihydroanthracene
DMND39P	MI	TTJQOD7
DMND39P	MN	5-HT 2A receptor (HTR2A)
DMND39P	MT	DTT
DMND39P	MA	Inhibitor
DMND39P	RN	Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504.
DMND39P	RU	https://pubmed.ncbi.nlm.nih.gov/19700330

DMND39P	DI	DMND39P
DMND39P	DN	9-(2-aminopropyl)-9,10-dihydroanthracene
DMND39P	MI	TTTIBOJ
DMND39P	MN	Histamine H1 receptor (H1R)
DMND39P	MT	DTT
DMND39P	MA	Inhibitor
DMND39P	RN	Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504.
DMND39P	RU	https://pubmed.ncbi.nlm.nih.gov/19700330

DMYUMHG	DI	DMYUMHG
DMYUMHG	DN	9-(2-Hydroxyethyl)-9H-adenine
DMYUMHG	MI	TTM2AOE
DMYUMHG	MN	Adenosine A2a receptor (ADORA2A)
DMYUMHG	MT	DTT
DMYUMHG	MA	Inhibitor
DMYUMHG	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMYUMHG	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DM2UQ0R	DI	DM2UQ0R
DM2UQ0R	DN	9-(2-Hydroxypropyl)-9H-adenine
DM2UQ0R	MI	TTM2AOE
DM2UQ0R	MN	Adenosine A2a receptor (ADORA2A)
DM2UQ0R	MT	DTT
DM2UQ0R	MA	Inhibitor
DM2UQ0R	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DM2UQ0R	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMDYZCH	DI	DMDYZCH
DMDYZCH	DN	9-(3-aminobenzyl)-6-(furan-2-yl)-9H-purin-2-amine
DMDYZCH	MI	TTK25J1
DMDYZCH	MN	Adenosine A1 receptor (ADORA1)
DMDYZCH	MT	DTT
DMDYZCH	MA	Inhibitor
DMDYZCH	RN	Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpu... Bioorg Med Chem Lett. 2008 May 1;18(9):2924-9.
DMDYZCH	RU	https://pubmed.ncbi.nlm.nih.gov/18411049

DMDYZCH	DI	DMDYZCH
DMDYZCH	DN	9-(3-aminobenzyl)-6-(furan-2-yl)-9H-purin-2-amine
DMDYZCH	MI	TTM2AOE
DMDYZCH	MN	Adenosine A2a receptor (ADORA2A)
DMDYZCH	MT	DTT
DMDYZCH	MA	Inhibitor
DMDYZCH	RN	Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpu... Bioorg Med Chem Lett. 2008 May 1;18(9):2924-9.
DMDYZCH	RU	https://pubmed.ncbi.nlm.nih.gov/18411049

DM51MRV	DI	DM51MRV
DM51MRV	DN	9-(3-aminopropoxy)-7H-furo[3,2-g]chromen-7-one
DM51MRV	MI	TT3WG5C
DM51MRV	MN	Monoamine oxidase type A (MAO-A)
DM51MRV	MT	DTT
DM51MRV	MA	Inhibitor
DM51MRV	RN	A QSAR model for in silico screening of MAO-A inhibitors. Prediction, synthesis, and biological assay of novel coumarins. J Med Chem. 2006 Feb 9;49(3):1149-56.
DM51MRV	RU	https://pubmed.ncbi.nlm.nih.gov/16451079

DM80MTI	DI	DM80MTI
DM80MTI	DN	9-(3-Hydroxypropyl)-9H-adenine
DM80MTI	MI	TTM2AOE
DM80MTI	MN	Adenosine A2a receptor (ADORA2A)
DM80MTI	MT	DTT
DM80MTI	MA	Inhibitor
DM80MTI	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DM80MTI	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMOP5AJ	DI	DMOP5AJ
DMOP5AJ	DN	9-(3-IODOBENZYLAMINO)-1,2,3,4-TETRAHYDROACRIDINE
DMOP5AJ	MI	TTEB0GD
DMOP5AJ	MN	Cholinesterase (BCHE)
DMOP5AJ	MT	DTT
DMOP5AJ	MA	Inhibitor
DMOP5AJ	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMOP5AJ	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM4X18V	DI	DM4X18V
DM4X18V	DN	9-(3-nitrobenzyl)-6-(furan-2-yl)-9H-purin-2-amine
DM4X18V	MI	TTK25J1
DM4X18V	MN	Adenosine A1 receptor (ADORA1)
DM4X18V	MT	DTT
DM4X18V	MA	Inhibitor
DM4X18V	RN	Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpu... Bioorg Med Chem Lett. 2008 May 1;18(9):2924-9.
DM4X18V	RU	https://pubmed.ncbi.nlm.nih.gov/18411049

DM4X18V	DI	DM4X18V
DM4X18V	DN	9-(3-nitrobenzyl)-6-(furan-2-yl)-9H-purin-2-amine
DM4X18V	MI	TTM2AOE
DM4X18V	MN	Adenosine A2a receptor (ADORA2A)
DM4X18V	MT	DTT
DM4X18V	MA	Inhibitor
DM4X18V	RN	Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpu... Bioorg Med Chem Lett. 2008 May 1;18(9):2924-9.
DM4X18V	RU	https://pubmed.ncbi.nlm.nih.gov/18411049

DMUIRS1	DI	DMUIRS1
DMUIRS1	DN	9-(3-n-Pentylureido)non-4(Z)-enoic acid
DMUIRS1	MI	TT7WVHI
DMUIRS1	MN	Soluble epoxide hydrolase (EPHX2)
DMUIRS1	MT	DTT
DMUIRS1	MA	Inhibitor
DMUIRS1	RN	14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxi... J Med Chem. 2009 Aug 27;52(16):5069-75.
DMUIRS1	RU	https://pubmed.ncbi.nlm.nih.gov/19653681

DMJYMFE	DI	DMJYMFE
DMJYMFE	DN	9-(3-n-Pentylureido)non-4-ynoic acid
DMJYMFE	MI	TT7WVHI
DMJYMFE	MN	Soluble epoxide hydrolase (EPHX2)
DMJYMFE	MT	DTT
DMJYMFE	MA	Inhibitor
DMJYMFE	RN	14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxi... J Med Chem. 2009 Aug 27;52(16):5069-75.
DMJYMFE	RU	https://pubmed.ncbi.nlm.nih.gov/19653681

DMW2NY9	DI	DMW2NY9
DMW2NY9	DN	9-(4-Fluoro-benzyl)-6-phenylsulfanyl-9H-purine
DMW2NY9	MI	TTQBR95
DMW2NY9	MN	Stress-activated protein kinase 2a (p38 alpha)
DMW2NY9	MT	DTT
DMW2NY9	MA	Inhibitor
DMW2NY9	RN	Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22.
DMW2NY9	RU	https://pubmed.ncbi.nlm.nih.gov/15689155

DMLKJD9	DI	DMLKJD9
DMLKJD9	DN	9-(4-Hydroxybutyl)-N2-Phenylguanine
DMLKJD9	MI	TTP3QRF
DMLKJD9	MN	Thymidine kinase 1 (TK1)
DMLKJD9	MT	DTT
DMLKJD9	MA	Inhibitor
DMLKJD9	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMLKJD9	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMOL01E	DI	DMOL01E
DMOL01E	DN	9-(4-Hydroxyphenyl)-2,7-Phenanthroline
DMOL01E	MI	TT056SO
DMOL01E	MN	Stress-activated protein kinase JNK3 (JNK3)
DMOL01E	MT	DTT
DMOL01E	MA	Inhibitor
DMOL01E	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMOL01E	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMURKL9	DI	DMURKL9
DMURKL9	DN	9-(4-nitrobenzyl)-6-(furan-2-yl)-9H-purin-2-amine
DMURKL9	MI	TTK25J1
DMURKL9	MN	Adenosine A1 receptor (ADORA1)
DMURKL9	MT	DTT
DMURKL9	MA	Inhibitor
DMURKL9	RN	Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpu... Bioorg Med Chem Lett. 2008 May 1;18(9):2924-9.
DMURKL9	RU	https://pubmed.ncbi.nlm.nih.gov/18411049

DMURKL9	DI	DMURKL9
DMURKL9	DN	9-(4-nitrobenzyl)-6-(furan-2-yl)-9H-purin-2-amine
DMURKL9	MI	TTM2AOE
DMURKL9	MN	Adenosine A2a receptor (ADORA2A)
DMURKL9	MT	DTT
DMURKL9	MA	Inhibitor
DMURKL9	RN	Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpu... Bioorg Med Chem Lett. 2008 May 1;18(9):2924-9.
DMURKL9	RU	https://pubmed.ncbi.nlm.nih.gov/18411049

DMGFQLE	DI	DMGFQLE
DMGFQLE	DN	9-(5,5-Difluoro-5-Phosphonopentyl)Guanine
DMGFQLE	MI	TTMCF1Y
DMGFQLE	MN	Purine nucleoside phosphorylase (PNP)
DMGFQLE	MT	DTT
DMGFQLE	MA	Inhibitor
DMGFQLE	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMGFQLE	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM6QDNH	DI	DM6QDNH
DM6QDNH	DN	9-(Aminomethyl)-9,10-dihydroanthracene
DM6QDNH	MI	TTJQOD7
DM6QDNH	MN	5-HT 2A receptor (HTR2A)
DM6QDNH	MT	DTT
DM6QDNH	MA	Inhibitor
DM6QDNH	RN	Exploring the relationship between binding modes of 9-(aminomethyl)-9,10-dihydroanthracene and cyproheptadine analogues at the 5-HT2A serotonin rec... Bioorg Med Chem Lett. 2001 Feb 26;11(4):563-6.
DM6QDNH	RU	https://pubmed.ncbi.nlm.nih.gov/11229772

DM6QDNH	DI	DM6QDNH
DM6QDNH	DN	9-(Aminomethyl)-9,10-dihydroanthracene
DM6QDNH	MI	TTTIBOJ
DM6QDNH	MN	Histamine H1 receptor (H1R)
DM6QDNH	MT	DTT
DM6QDNH	MA	Inhibitor
DM6QDNH	RN	Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504.
DM6QDNH	RU	https://pubmed.ncbi.nlm.nih.gov/19700330

DMIY3D6	DI	DMIY3D6
DMIY3D6	DN	9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one
DMIY3D6	MI	TTBH0VX
DMIY3D6	MN	Histone deacetylase (HDAC)
DMIY3D6	MT	DTT
DMIY3D6	MA	Inhibitor
DMIY3D6	RN	Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
DMIY3D6	RU	https://pubmed.ncbi.nlm.nih.gov/14613312

DMIY3D6	DI	DMIY3D6
DMIY3D6	DN	9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one
DMIY3D6	MI	TT6R7JZ
DMIY3D6	MN	Histone deacetylase 1 (HDAC1)
DMIY3D6	MT	DTT
DMIY3D6	MA	Inhibitor
DMIY3D6	RN	Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3443-7.
DMIY3D6	RU	https://pubmed.ncbi.nlm.nih.gov/12419380

DMIY3D6	DI	DMIY3D6
DMIY3D6	DN	9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one
DMIY3D6	MI	TTYHPU6
DMIY3D6	MN	Histone deacetylase 10 (HDAC10)
DMIY3D6	MT	DTT
DMIY3D6	MA	Inhibitor
DMIY3D6	RN	Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
DMIY3D6	RU	https://pubmed.ncbi.nlm.nih.gov/14613312

DMIY3D6	DI	DMIY3D6
DMIY3D6	DN	9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one
DMIY3D6	MI	TTSHTOI
DMIY3D6	MN	Histone deacetylase 2 (HDAC2)
DMIY3D6	MT	DTT
DMIY3D6	MA	Inhibitor
DMIY3D6	RN	Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3443-7.
DMIY3D6	RU	https://pubmed.ncbi.nlm.nih.gov/12419380

DMIY3D6	DI	DMIY3D6
DMIY3D6	DN	9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one
DMIY3D6	MI	TTTQGH8
DMIY3D6	MN	Histone deacetylase 4 (HDAC4)
DMIY3D6	MT	DTT
DMIY3D6	MA	Inhibitor
DMIY3D6	RN	Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
DMIY3D6	RU	https://pubmed.ncbi.nlm.nih.gov/14613312

DMIY3D6	DI	DMIY3D6
DMIY3D6	DN	9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one
DMIY3D6	MI	TT5ZKDI
DMIY3D6	MN	Histone deacetylase 6 (HDAC6)
DMIY3D6	MT	DTT
DMIY3D6	MA	Inhibitor
DMIY3D6	RN	Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
DMIY3D6	RU	https://pubmed.ncbi.nlm.nih.gov/14613312

DMIY3D6	DI	DMIY3D6
DMIY3D6	DN	9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one
DMIY3D6	MI	TTT6LFV
DMIY3D6	MN	Histone deacetylase 8 (HDAC8)
DMIY3D6	MT	DTT
DMIY3D6	MA	Inhibitor
DMIY3D6	RN	Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
DMIY3D6	RU	https://pubmed.ncbi.nlm.nih.gov/14613312

DMA2RCD	DI	DMA2RCD
DMA2RCD	DN	9-(N-benzylaminomethyl)-9,10-dihydroanthracene
DMA2RCD	MI	TTJQOD7
DMA2RCD	MN	5-HT 2A receptor (HTR2A)
DMA2RCD	MT	DTT
DMA2RCD	MA	Inhibitor
DMA2RCD	RN	9-Aminomethyl-9,10-dihydroanthracene (AMDA) analogs as structural probes for steric tolerance in 5-HT2A and H1 receptor binding sites. Bioorg Med Chem Lett. 2010 Feb 1;20(3):935-8.
DMA2RCD	RU	https://pubmed.ncbi.nlm.nih.gov/20045641

DMFKVPA	DI	DMFKVPA
DMFKVPA	DN	9-(sec-Butyl)-9H-adenine
DMFKVPA	MI	TTM2AOE
DMFKVPA	MN	Adenosine A2a receptor (ADORA2A)
DMFKVPA	MT	DTT
DMFKVPA	MA	Inhibitor
DMFKVPA	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMFKVPA	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMFKVPA	DI	DMFKVPA
DMFKVPA	DN	9-(sec-Butyl)-9H-adenine
DMFKVPA	MI	TTNE7KG
DMFKVPA	MN	Adenosine A2b receptor (ADORA2B)
DMFKVPA	MT	DTT
DMFKVPA	MA	Inhibitor
DMFKVPA	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMFKVPA	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMVBCID	DI	DMVBCID
DMVBCID	DN	9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide
DMVBCID	MI	TTBH0VX
DMVBCID	MN	Histone deacetylase (HDAC)
DMVBCID	MT	DTT
DMVBCID	MA	Inhibitor
DMVBCID	RN	Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
DMVBCID	RU	https://pubmed.ncbi.nlm.nih.gov/14613312

DMVBCID	DI	DMVBCID
DMVBCID	DN	9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide
DMVBCID	MI	TT6R7JZ
DMVBCID	MN	Histone deacetylase 1 (HDAC1)
DMVBCID	MT	DTT
DMVBCID	MA	Inhibitor
DMVBCID	RN	Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3443-7.
DMVBCID	RU	https://pubmed.ncbi.nlm.nih.gov/12419380

DMVBCID	DI	DMVBCID
DMVBCID	DN	9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide
DMVBCID	MI	TTYHPU6
DMVBCID	MN	Histone deacetylase 10 (HDAC10)
DMVBCID	MT	DTT
DMVBCID	MA	Inhibitor
DMVBCID	RN	Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
DMVBCID	RU	https://pubmed.ncbi.nlm.nih.gov/14613312

DMVBCID	DI	DMVBCID
DMVBCID	DN	9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide
DMVBCID	MI	TTSHTOI
DMVBCID	MN	Histone deacetylase 2 (HDAC2)
DMVBCID	MT	DTT
DMVBCID	MA	Inhibitor
DMVBCID	RN	Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3443-7.
DMVBCID	RU	https://pubmed.ncbi.nlm.nih.gov/12419380

DMVBCID	DI	DMVBCID
DMVBCID	DN	9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide
DMVBCID	MI	TTTQGH8
DMVBCID	MN	Histone deacetylase 4 (HDAC4)
DMVBCID	MT	DTT
DMVBCID	MA	Inhibitor
DMVBCID	RN	Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
DMVBCID	RU	https://pubmed.ncbi.nlm.nih.gov/14613312

DMVBCID	DI	DMVBCID
DMVBCID	DN	9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide
DMVBCID	MI	TT5ZKDI
DMVBCID	MN	Histone deacetylase 6 (HDAC6)
DMVBCID	MT	DTT
DMVBCID	MA	Inhibitor
DMVBCID	RN	Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
DMVBCID	RU	https://pubmed.ncbi.nlm.nih.gov/14613312

DMVBCID	DI	DMVBCID
DMVBCID	DN	9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide
DMVBCID	MI	TTT6LFV
DMVBCID	MN	Histone deacetylase 8 (HDAC8)
DMVBCID	MT	DTT
DMVBCID	MA	Inhibitor
DMVBCID	RN	Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
DMVBCID	RU	https://pubmed.ncbi.nlm.nih.gov/14613312

DMOGD42	DI	DMOGD42
DMOGD42	DN	9-[2-(1-Phosphonobutan-2-yloxy)ethyl]guanine
DMOGD42	MI	TTBL49X
DMOGD42	MN	Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ)
DMOGD42	MT	DTT
DMOGD42	MA	Inhibitor
DMOGD42	RN	Synthesis of branched 9-[2-(2-phosphonoethoxy)ethyl]purines as a new class of acyclic nucleoside phosphonates which inhibit Plasmodium falciparum h... Bioorg Med Chem. 2009 Sep 1;17(17):6218-32.
DMOGD42	RU	https://pubmed.ncbi.nlm.nih.gov/19666228

DMKHXT9	DI	DMKHXT9
DMKHXT9	DN	9-[2-(1-Phosphonobutan-2-yloxy)ethyl]hypoxanthine
DMKHXT9	MI	TTBL49X
DMKHXT9	MN	Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ)
DMKHXT9	MT	DTT
DMKHXT9	MA	Inhibitor
DMKHXT9	RN	Synthesis of branched 9-[2-(2-phosphonoethoxy)ethyl]purines as a new class of acyclic nucleoside phosphonates which inhibit Plasmodium falciparum h... Bioorg Med Chem. 2009 Sep 1;17(17):6218-32.
DMKHXT9	RU	https://pubmed.ncbi.nlm.nih.gov/19666228

DMCXN6R	DI	DMCXN6R
DMCXN6R	DN	9-[2-(1-Phosphonopropan-2-yloxy)ethyl]guanine
DMCXN6R	MI	TTBL49X
DMCXN6R	MN	Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ)
DMCXN6R	MT	DTT
DMCXN6R	MA	Inhibitor
DMCXN6R	RN	Synthesis of branched 9-[2-(2-phosphonoethoxy)ethyl]purines as a new class of acyclic nucleoside phosphonates which inhibit Plasmodium falciparum h... Bioorg Med Chem. 2009 Sep 1;17(17):6218-32.
DMCXN6R	RU	https://pubmed.ncbi.nlm.nih.gov/19666228

DMFR3SD	DI	DMFR3SD
DMFR3SD	DN	9-[5-(beta-Carboline-9-yl)pentyl]-beta-carboline
DMFR3SD	MI	TTEB0GD
DMFR3SD	MN	Cholinesterase (BCHE)
DMFR3SD	MT	DTT
DMFR3SD	MA	Inhibitor
DMFR3SD	RN	Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents. J Med Chem. 2010 May 13;53(9):3611-7.
DMFR3SD	RU	https://pubmed.ncbi.nlm.nih.gov/20361801

DM6M5A4	DI	DM6M5A4
DM6M5A4	DN	9-[9-(beta-Carboline-9-yl)nonyl]-beta-carboline
DM6M5A4	MI	TTEB0GD
DM6M5A4	MN	Cholinesterase (BCHE)
DM6M5A4	MT	DTT
DM6M5A4	MA	Inhibitor
DM6M5A4	RN	Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents. J Med Chem. 2010 May 13;53(9):3611-7.
DM6M5A4	RU	https://pubmed.ncbi.nlm.nih.gov/20361801

DMJ1VAE	DI	DMJ1VAE
DMJ1VAE	DN	98mTc-CIM-ANT
DMJ1VAE	MI	TTZ6T9E
DMJ1VAE	MN	Somatostatin receptor type 2 (SSTR2)
DMJ1VAE	MT	DTT
DMJ1VAE	MA	Antagonist
DMJ1VAE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 356).
DMJ1VAE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=356

DMAGTL1	DI	DMAGTL1
DMAGTL1	DN	99mTc-EC-0652
DMAGTL1	MI	TT9G4N0
DMAGTL1	MN	Glutamate carboxypeptidase II (GCPII)
DMAGTL1	MT	DTT
DMAGTL1	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1606).
DMAGTL1	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1606

DMQOFX2	DI	DMQOFX2
DMQOFX2	DN	99mTc-MIP-1340
DMQOFX2	MI	TT9G4N0
DMQOFX2	MN	Glutamate carboxypeptidase II (GCPII)
DMQOFX2	MT	DTT
DMQOFX2	MA	Modulator
DMQOFX2	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1606).
DMQOFX2	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1606

DMYPD5L	DI	DMYPD5L
DMYPD5L	DN	99mTc-MIP-1407
DMYPD5L	MI	TTIND6G
DMYPD5L	MN	Somatostatin receptor type 1 (SSTR1)
DMYPD5L	MT	DTT
DMYPD5L	MA	Modulator
DMYPD5L	RN	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
DMYPD5L	RU	https://pubmed.ncbi.nlm.nih.gov/23370234

DMYPD5L	DI	DMYPD5L
DMYPD5L	DN	99mTc-MIP-1407
DMYPD5L	MI	TTZ6T9E
DMYPD5L	MN	Somatostatin receptor type 2 (SSTR2)
DMYPD5L	MT	DTT
DMYPD5L	MA	Modulator
DMYPD5L	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 356).
DMYPD5L	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=356

DMYPD5L	DI	DMYPD5L
DMYPD5L	DN	99mTc-MIP-1407
DMYPD5L	MI	TTJX3UE
DMYPD5L	MN	Somatostatin receptor type 3 (SSTR3)
DMYPD5L	MT	DTT
DMYPD5L	MA	Modulator
DMYPD5L	RN	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
DMYPD5L	RU	https://pubmed.ncbi.nlm.nih.gov/23370234

DMYPD5L	DI	DMYPD5L
DMYPD5L	DN	99mTc-MIP-1407
DMYPD5L	MI	TTAE1BR
DMYPD5L	MN	Somatostatin receptor type 4 (SSTR4)
DMYPD5L	MT	DTT
DMYPD5L	MA	Modulator
DMYPD5L	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 358).
DMYPD5L	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=358

DMYPD5L	DI	DMYPD5L
DMYPD5L	DN	99mTc-MIP-1407
DMYPD5L	MI	TT2BC4G
DMYPD5L	MN	Somatostatin receptor type 5 (SSTR5)
DMYPD5L	MT	DTT
DMYPD5L	MA	Modulator
DMYPD5L	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 359).
DMYPD5L	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=359

DM8VZIY	DI	DM8VZIY
DM8VZIY	DN	9-Allyl-8-bromo-9H-adenine
DM8VZIY	MI	TTK25J1
DM8VZIY	MN	Adenosine A1 receptor (ADORA1)
DM8VZIY	MT	DTT
DM8VZIY	MA	Inhibitor
DM8VZIY	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DM8VZIY	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DM8VZIY	DI	DM8VZIY
DM8VZIY	DN	9-Allyl-8-bromo-9H-adenine
DM8VZIY	MI	TTM2AOE
DM8VZIY	MN	Adenosine A2a receptor (ADORA2A)
DM8VZIY	MT	DTT
DM8VZIY	MA	Inhibitor
DM8VZIY	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DM8VZIY	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DM8VZIY	DI	DM8VZIY
DM8VZIY	DN	9-Allyl-8-bromo-9H-adenine
DM8VZIY	MI	TTNE7KG
DM8VZIY	MN	Adenosine A2b receptor (ADORA2B)
DM8VZIY	MT	DTT
DM8VZIY	MA	Inhibitor
DM8VZIY	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DM8VZIY	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMO9R6T	DI	DMO9R6T
DMO9R6T	DN	9alpha-acetoxy-miller-1(10)Z-enolide
DMO9R6T	MI	TTSXVID
DMO9R6T	MN	Nuclear factor NF-kappa-B (NFKB)
DMO9R6T	MT	DTT
DMO9R6T	MA	Inhibitor
DMO9R6T	RN	Development of a structural model for NF-kappaB inhibition of sesquiterpene lactones using self-organizing neural networks. J Med Chem. 2006 Apr 6;49(7):2241-52.
DMO9R6T	RU	https://pubmed.ncbi.nlm.nih.gov/16570920

DMNHZFG	DI	DMNHZFG
DMNHZFG	DN	9-Amino-1,2,3,4-tetrahydro-acridine-1,7-diol
DMNHZFG	MI	TT1RS9F
DMNHZFG	MN	Acetylcholinesterase (AChE)
DMNHZFG	MT	DTT
DMNHZFG	MA	Inhibitor
DMNHZFG	RN	Synthesis and biological activity of putative mono-hydroxylated metabolites of velnacrine, Bioorg. Med. Chem. Lett. 2(8):865-870 (1992).
DMNHZFG	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805466

DMUL6QR	DI	DMUL6QR
DMUL6QR	DN	9-Amino-6H,11H-indeno[1,2-c]isoquinolin-5-one
DMUL6QR	MI	TTVDSZ0
DMUL6QR	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMUL6QR	MT	DTT
DMUL6QR	MA	Inhibitor
DMUL6QR	RN	Discovery of potent poly(ADP-ribose) polymerase-1 inhibitors from the modification of indeno[1,2-c]isoquinolinone. J Med Chem. 2005 Aug 11;48(16):5100-3.
DMUL6QR	RU	https://pubmed.ncbi.nlm.nih.gov/16078828

DMNMVCZ	DI	DMNMVCZ
DMNMVCZ	DN	9-amino-7H-dibenzo[de,h]quinolin-7-one
DMNMVCZ	MI	TT1RS9F
DMNMVCZ	MN	Acetylcholinesterase (AChE)
DMNMVCZ	MT	DTT
DMNMVCZ	MA	Inhibitor
DMNMVCZ	RN	Synthesis, biological evaluation and molecular modeling of oxoisoaporphine and oxoaporphine derivatives as new dual inhibitors of acetylcholinester... Eur J Med Chem. 2009 Jun;44(6):2523-32.
DMNMVCZ	RU	https://pubmed.ncbi.nlm.nih.gov/19243862

DM9123M	DI	DM9123M
DM9123M	DN	9-Aminomethyl-9H-fluorene-2,5,6-triol
DM9123M	MI	TTZFYLI
DM9123M	MN	Dopamine D1 receptor (D1R)
DM9123M	MT	DTT
DM9123M	MA	Inhibitor
DM9123M	RN	Synthesis and dopaminergic binding of 2-aryldopamine analogues: phenethylamines, 3-benzazepines, and 9-(aminomethyl)fluorenes. J Med Chem. 1986 Oct;29(10):1904-12.
DM9123M	RU	https://pubmed.ncbi.nlm.nih.gov/3761310

DMNG6O7	DI	DMNG6O7
DMNG6O7	DN	9-Aminomethyl-9H-fluorene-3,4-diol
DMNG6O7	MI	TTZFYLI
DMNG6O7	MN	Dopamine D1 receptor (D1R)
DMNG6O7	MT	DTT
DMNG6O7	MA	Inhibitor
DMNG6O7	RN	Synthesis and dopaminergic binding of 2-aryldopamine analogues: phenethylamines, 3-benzazepines, and 9-(aminomethyl)fluorenes. J Med Chem. 1986 Oct;29(10):1904-12.
DMNG6O7	RU	https://pubmed.ncbi.nlm.nih.gov/3761310

DMGCVT2	DI	DMGCVT2
DMGCVT2	DN	9-anthroic acid
DMGCVT2	MI	TTOJI4S
DMGCVT2	MN	Calcium-dependent chloride channel anoctamin (ANO)
DMGCVT2	MT	DTT
DMGCVT2	MA	Blocker (channel blocker)
DMGCVT2	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 708).
DMGCVT2	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=708

DMGCVT2	DI	DMGCVT2
DMGCVT2	DN	9-anthroic acid
DMGCVT2	MI	TTUYAF3
DMGCVT2	MN	Chloride channel protein 1 (ClC-1)
DMGCVT2	MT	DTT
DMGCVT2	MA	Blocker (channel blocker)
DMGCVT2	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 698).
DMGCVT2	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=698

DMGCVT2	DI	DMGCVT2
DMGCVT2	DN	9-anthroic acid
DMGCVT2	MI	TT0FC1V
DMGCVT2	MN	Volume regulated chloride channel (VRAC)
DMGCVT2	MT	DTT
DMGCVT2	MA	Blocker (channel blocker)
DMGCVT2	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 710).
DMGCVT2	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=710

DM8Q0D9	DI	DM8Q0D9
DM8Q0D9	DN	9-Benzyl-6-(4-fluoro-phenylsulfanyl)-9H-purine
DM8Q0D9	MI	TTQBR95
DM8Q0D9	MN	Stress-activated protein kinase 2a (p38 alpha)
DM8Q0D9	MT	DTT
DM8Q0D9	MA	Inhibitor
DM8Q0D9	RN	Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22.
DM8Q0D9	RU	https://pubmed.ncbi.nlm.nih.gov/15689155

DM4JG60	DI	DM4JG60
DM4JG60	DN	9-benzyl-6-(4-methylpiperazin-1-yl)-9H-purine
DM4JG60	MI	TTXJ178
DM4JG60	MN	Histamine H4 receptor (H4R)
DM4JG60	MT	DTT
DM4JG60	MA	Inhibitor
DM4JG60	RN	2,4-Diaminopyrimidines as histamine H4 receptor ligands--Scaffold optimization and pharmacological characterization. Bioorg Med Chem. 2009 Oct 15;17(20):7186-96.
DM4JG60	RU	https://pubmed.ncbi.nlm.nih.gov/19773175

DMNY5P1	DI	DMNY5P1
DMNY5P1	DN	9-Benzyl-6-(4-nitro-benzylsulfanyl)-9H-purine
DMNY5P1	MI	TTLXAKE
DMNY5P1	MN	Solute carrier family 29 member 1 (SLC29A1)
DMNY5P1	MT	DTT
DMNY5P1	MA	Inhibitor
DMNY5P1	RN	Inhibition of nucleoside transport by new analogues of 4-nitrobenzylthioinosine: replacement of the ribose moiety by substituted benzyl groups. J Med Chem. 2004 Oct 21;47(22):5441-50.
DMNY5P1	RU	https://pubmed.ncbi.nlm.nih.gov/15481982

DMUMOE2	DI	DMUMOE2
DMUMOE2	DN	9-benzyl-6-(benzylamino)-9H-purine-2-carbonitrile
DMUMOE2	MI	TT36ETB
DMUMOE2	MN	Cathepsin L (CTSL)
DMUMOE2	MT	DTT
DMUMOE2	MA	Inhibitor
DMUMOE2	RN	Development of potent purine-derived nitrile inhibitors of the trypanosomal protease TbcatB. J Med Chem. 2008 Feb 14;51(3):545-52.
DMUMOE2	RU	https://pubmed.ncbi.nlm.nih.gov/18173229

DMO6CB7	DI	DMO6CB7
DMO6CB7	DN	9-benzyl-6-(furan-2-yl)-9H-purin-2-amine
DMO6CB7	MI	TTK25J1
DMO6CB7	MN	Adenosine A1 receptor (ADORA1)
DMO6CB7	MT	DTT
DMO6CB7	MA	Inhibitor
DMO6CB7	RN	Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpu... Bioorg Med Chem Lett. 2008 May 1;18(9):2924-9.
DMO6CB7	RU	https://pubmed.ncbi.nlm.nih.gov/18411049

DMO6CB7	DI	DMO6CB7
DMO6CB7	DN	9-benzyl-6-(furan-2-yl)-9H-purin-2-amine
DMO6CB7	MI	TTM2AOE
DMO6CB7	MN	Adenosine A2a receptor (ADORA2A)
DMO6CB7	MT	DTT
DMO6CB7	MA	Inhibitor
DMO6CB7	RN	Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpu... Bioorg Med Chem Lett. 2008 May 1;18(9):2924-9.
DMO6CB7	RU	https://pubmed.ncbi.nlm.nih.gov/18411049

DMNCL5G	DI	DMNCL5G
DMNCL5G	DN	9-Benzyl-6-phenylsulfanyl-9H-purine
DMNCL5G	MI	TTQBR95
DMNCL5G	MN	Stress-activated protein kinase 2a (p38 alpha)
DMNCL5G	MT	DTT
DMNCL5G	MA	Inhibitor
DMNCL5G	RN	Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22.
DMNCL5G	RU	https://pubmed.ncbi.nlm.nih.gov/15689155

DMMWGVI	DI	DMMWGVI
DMMWGVI	DN	9-Benzyl-8-bromo-9H-adenine
DMMWGVI	MI	TTK25J1
DMMWGVI	MN	Adenosine A1 receptor (ADORA1)
DMMWGVI	MT	DTT
DMMWGVI	MA	Inhibitor
DMMWGVI	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMMWGVI	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMMWGVI	DI	DMMWGVI
DMMWGVI	DN	9-Benzyl-8-bromo-9H-adenine
DMMWGVI	MI	TTM2AOE
DMMWGVI	MN	Adenosine A2a receptor (ADORA2A)
DMMWGVI	MT	DTT
DMMWGVI	MA	Inhibitor
DMMWGVI	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMMWGVI	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMONCUL	DI	DMONCUL
DMONCUL	DN	9-BENZYL-9H-ADENINE
DMONCUL	MI	TTM2AOE
DMONCUL	MN	Adenosine A2a receptor (ADORA2A)
DMONCUL	MT	DTT
DMONCUL	MA	Inhibitor
DMONCUL	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMONCUL	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMQEO7F	DI	DMQEO7F
DMQEO7F	DN	9-Bromo-5,11-dimethyl-6H-pyrido[4,3-b]carbazole
DMQEO7F	MI	TTX41N9
DMQEO7F	MN	Tyrosine-protein kinase Kit (KIT)
DMQEO7F	MT	DTT
DMQEO7F	MA	Inhibitor
DMQEO7F	RN	Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases. J Med Chem. 2005 Oct 6;48(20):6194-201.
DMQEO7F	RU	https://pubmed.ncbi.nlm.nih.gov/16190746

DMSWQY7	DI	DMSWQY7
DMSWQY7	DN	9-But-3-enyl-9H-adenine
DMSWQY7	MI	TTM2AOE
DMSWQY7	MN	Adenosine A2a receptor (ADORA2A)
DMSWQY7	MT	DTT
DMSWQY7	MA	Inhibitor
DMSWQY7	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMSWQY7	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMXU90T	DI	DMXU90T
DMXU90T	DN	9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine
DMXU90T	MI	TT78R5H
DMXU90T	MN	Heat shock protein 90 alpha (HSP90A)
DMXU90T	MT	DTT
DMXU90T	MA	Inhibitor
DMXU90T	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMXU90T	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMKHPAE	DI	DMKHPAE
DMKHPAE	DN	9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine
DMKHPAE	MI	TT78R5H
DMKHPAE	MN	Heat shock protein 90 alpha (HSP90A)
DMKHPAE	MT	DTT
DMKHPAE	MA	Inhibitor
DMKHPAE	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMKHPAE	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMZQLBD	DI	DMZQLBD
DMZQLBD	DN	9-Butyl-9H-adenine
DMZQLBD	MI	TTM2AOE
DMZQLBD	MN	Adenosine A2a receptor (ADORA2A)
DMZQLBD	MT	DTT
DMZQLBD	MA	Inhibitor
DMZQLBD	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMZQLBD	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMK5DUA	DI	DMK5DUA
DMK5DUA	DN	9-chloro-5H-6-thia-4,5-diaza-chrysene 6,6-dioxide
DMK5DUA	MI	TTSXVID
DMK5DUA	MN	Nuclear factor NF-kappa-B (NFKB)
DMK5DUA	MT	DTT
DMK5DUA	MA	Inhibitor
DMK5DUA	RN	Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFkappaB activity within two separate high-throughput s... Bioorg Med Chem Lett. 2008 Jan 1;18(1):329-35.
DMK5DUA	RU	https://pubmed.ncbi.nlm.nih.gov/18024113

DM6EFN2	DI	DM6EFN2
DM6EFN2	DN	9-chlorobenzo[h]isoquinolin-1(2H)-one
DM6EFN2	MI	TTTU902
DM6EFN2	MN	Checkpoint kinase-1 (CHK1)
DM6EFN2	MT	DTT
DM6EFN2	MA	Inhibitor
DM6EFN2	RN	Synthesis and evaluation of substituted benzoisoquinolinones as potent inhibitors of Chk1 kinase. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6280-5.
DM6EFN2	RU	https://pubmed.ncbi.nlm.nih.gov/17900896

DM04QWX	DI	DM04QWX
DM04QWX	DN	9-Cyclobutyl-9H-adenine
DM04QWX	MI	TTK25J1
DM04QWX	MN	Adenosine A1 receptor (ADORA1)
DM04QWX	MT	DTT
DM04QWX	MA	Inhibitor
DM04QWX	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DM04QWX	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DM04QWX	DI	DM04QWX
DM04QWX	DN	9-Cyclobutyl-9H-adenine
DM04QWX	MI	TTM2AOE
DM04QWX	MN	Adenosine A2a receptor (ADORA2A)
DM04QWX	MT	DTT
DM04QWX	MA	Inhibitor
DM04QWX	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DM04QWX	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DM04QWX	DI	DM04QWX
DM04QWX	DN	9-Cyclobutyl-9H-adenine
DM04QWX	MI	TTNE7KG
DM04QWX	MN	Adenosine A2b receptor (ADORA2B)
DM04QWX	MT	DTT
DM04QWX	MA	Inhibitor
DM04QWX	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DM04QWX	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMP8VM2	DI	DMP8VM2
DMP8VM2	DN	9-Cycloheptyl-9H-adenine
DMP8VM2	MI	TTM2AOE
DMP8VM2	MN	Adenosine A2a receptor (ADORA2A)
DMP8VM2	MT	DTT
DMP8VM2	MA	Inhibitor
DMP8VM2	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMP8VM2	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMSGU2L	DI	DMSGU2L
DMSGU2L	DN	9-Cyclopentyl-9H-adenine
DMSGU2L	MI	TTK25J1
DMSGU2L	MN	Adenosine A1 receptor (ADORA1)
DMSGU2L	MT	DTT
DMSGU2L	MA	Inhibitor
DMSGU2L	RN	N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor. J Med Chem. 1991 Sep;34(9):2877-82.
DMSGU2L	RU	https://pubmed.ncbi.nlm.nih.gov/1895305

DMSGU2L	DI	DMSGU2L
DMSGU2L	DN	9-Cyclopentyl-9H-adenine
DMSGU2L	MI	TTM2AOE
DMSGU2L	MN	Adenosine A2a receptor (ADORA2A)
DMSGU2L	MT	DTT
DMSGU2L	MA	Inhibitor
DMSGU2L	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMSGU2L	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMSGU2L	DI	DMSGU2L
DMSGU2L	DN	9-Cyclopentyl-9H-adenine
DMSGU2L	MI	TTJFY5U
DMSGU2L	MN	Adenosine A3 receptor (ADORA3)
DMSGU2L	MT	DTT
DMSGU2L	MA	Inhibitor
DMSGU2L	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMSGU2L	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMAFCZL	DI	DMAFCZL
DMAFCZL	DN	9-Cyclopropyl-9H-adenine
DMAFCZL	MI	TTM2AOE
DMAFCZL	MN	Adenosine A2a receptor (ADORA2A)
DMAFCZL	MT	DTT
DMAFCZL	MA	Inhibitor
DMAFCZL	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMAFCZL	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DM68IPZ	DI	DM68IPZ
DM68IPZ	DN	9-Deazaguanine
DM68IPZ	MI	TTBL49X
DM68IPZ	MN	Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ)
DM68IPZ	MT	DTT
DM68IPZ	MA	Inhibitor
DM68IPZ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM68IPZ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM3G6LY	DI	DM3G6LY
DM3G6LY	DN	9-Deazahypoxanthine
DM3G6LY	MI	TTMCF1Y
DM3G6LY	MN	Purine nucleoside phosphorylase (PNP)
DM3G6LY	MT	DTT
DM3G6LY	MA	Inhibitor
DM3G6LY	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM3G6LY	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DME7ONQ	DI	DME7ONQ
DME7ONQ	DN	9-Deazainosine
DME7ONQ	MI	TTMCF1Y
DME7ONQ	MN	Purine nucleoside phosphorylase (PNP)
DME7ONQ	MT	DTT
DME7ONQ	MA	Inhibitor
DME7ONQ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DME7ONQ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9BCDT	DI	DM9BCDT
DM9BCDT	DN	9-DEAZAINOSINE-2',3'-O-ETHYLIDENEPHOSPHONATE
DM9BCDT	MI	TTMCF1Y
DM9BCDT	MN	Purine nucleoside phosphorylase (PNP)
DM9BCDT	MT	DTT
DM9BCDT	MA	Inhibitor
DM9BCDT	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM9BCDT	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM70MPJ	DI	DM70MPJ
DM70MPJ	DN	9-Ethyl-2-methyl-beta-carboline-2-ium iodide
DM70MPJ	MI	TT1RS9F
DM70MPJ	MN	Acetylcholinesterase (AChE)
DM70MPJ	MT	DTT
DM70MPJ	MA	Inhibitor
DM70MPJ	RN	Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents. J Med Chem. 2010 May 13;53(9):3611-7.
DM70MPJ	RU	https://pubmed.ncbi.nlm.nih.gov/20361801

DM70MPJ	DI	DM70MPJ
DM70MPJ	DN	9-Ethyl-2-methyl-beta-carboline-2-ium iodide
DM70MPJ	MI	TTEB0GD
DM70MPJ	MN	Cholinesterase (BCHE)
DM70MPJ	MT	DTT
DM70MPJ	MA	Inhibitor
DM70MPJ	RN	Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents. J Med Chem. 2010 May 13;53(9):3611-7.
DM70MPJ	RU	https://pubmed.ncbi.nlm.nih.gov/20361801

DMRVS2D	DI	DMRVS2D
DMRVS2D	DN	9-Ethyl-8-phenylethynyl-9H-purin-6-ylamine
DMRVS2D	MI	TTK25J1
DMRVS2D	MN	Adenosine A1 receptor (ADORA1)
DMRVS2D	MT	DTT
DMRVS2D	MA	Inhibitor
DMRVS2D	RN	Introduction of alkynyl chains on C-8 of adenosine led to very selective antagonists of the A(3) adenosine receptor. Bioorg Med Chem Lett. 2001 Jul 23;11(14):1931-4.
DMRVS2D	RU	https://pubmed.ncbi.nlm.nih.gov/11459663

DMRVS2D	DI	DMRVS2D
DMRVS2D	DN	9-Ethyl-8-phenylethynyl-9H-purin-6-ylamine
DMRVS2D	MI	TTM2AOE
DMRVS2D	MN	Adenosine A2a receptor (ADORA2A)
DMRVS2D	MT	DTT
DMRVS2D	MA	Inhibitor
DMRVS2D	RN	Introduction of alkynyl chains on C-8 of adenosine led to very selective antagonists of the A(3) adenosine receptor. Bioorg Med Chem Lett. 2001 Jul 23;11(14):1931-4.
DMRVS2D	RU	https://pubmed.ncbi.nlm.nih.gov/11459663

DMRVS2D	DI	DMRVS2D
DMRVS2D	DN	9-Ethyl-8-phenylethynyl-9H-purin-6-ylamine
DMRVS2D	MI	TTJFY5U
DMRVS2D	MN	Adenosine A3 receptor (ADORA3)
DMRVS2D	MT	DTT
DMRVS2D	MA	Inhibitor
DMRVS2D	RN	Introduction of alkynyl chains on C-8 of adenosine led to very selective antagonists of the A(3) adenosine receptor. Bioorg Med Chem Lett. 2001 Jul 23;11(14):1931-4.
DMRVS2D	RU	https://pubmed.ncbi.nlm.nih.gov/11459663

DMWV8YX	DI	DMWV8YX
DMWV8YX	DN	9-Ethyl-9H-adenine
DMWV8YX	MI	TTK25J1
DMWV8YX	MN	Adenosine A1 receptor (ADORA1)
DMWV8YX	MT	DTT
DMWV8YX	MA	Inhibitor
DMWV8YX	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMWV8YX	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMWV8YX	DI	DMWV8YX
DMWV8YX	DN	9-Ethyl-9H-adenine
DMWV8YX	MI	TTM2AOE
DMWV8YX	MN	Adenosine A2a receptor (ADORA2A)
DMWV8YX	MT	DTT
DMWV8YX	MA	Inhibitor
DMWV8YX	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMWV8YX	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMHKUO9	DI	DMHKUO9
DMHKUO9	DN	9-Ethyl-beta-carboline
DMHKUO9	MI	TT1RS9F
DMHKUO9	MN	Acetylcholinesterase (AChE)
DMHKUO9	MT	DTT
DMHKUO9	MA	Inhibitor
DMHKUO9	RN	Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents. J Med Chem. 2010 May 13;53(9):3611-7.
DMHKUO9	RU	https://pubmed.ncbi.nlm.nih.gov/20361801

DMLK0TX	DI	DMLK0TX
DMLK0TX	DN	9-fluoro-5H-6-thia-4,5-diaza-chrysene 6,6-dioxide
DMLK0TX	MI	TTSXVID
DMLK0TX	MN	Nuclear factor NF-kappa-B (NFKB)
DMLK0TX	MT	DTT
DMLK0TX	MA	Inhibitor
DMLK0TX	RN	Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFkappaB activity within two separate high-throughput s... Bioorg Med Chem Lett. 2008 Jan 1;18(1):329-35.
DMLK0TX	RU	https://pubmed.ncbi.nlm.nih.gov/18024113

DMGAE9Z	DI	DMGAE9Z
DMGAE9Z	DN	9-Fluoro-6H,11H-indeno[1,2-c]isoquinolin-5-one
DMGAE9Z	MI	TTVDSZ0
DMGAE9Z	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMGAE9Z	MT	DTT
DMGAE9Z	MA	Inhibitor
DMGAE9Z	RN	Discovery of potent poly(ADP-ribose) polymerase-1 inhibitors from the modification of indeno[1,2-c]isoquinolinone. J Med Chem. 2005 Aug 11;48(16):5100-3.
DMGAE9Z	RU	https://pubmed.ncbi.nlm.nih.gov/16078828

DMBWAMR	DI	DMBWAMR
DMBWAMR	DN	9H-beta-Carbolin-3-ol
DMBWAMR	MI	TT1MPAY
DMBWAMR	MN	GABA(A) receptor alpha-1 (GABRA1)
DMBWAMR	MT	DTT
DMBWAMR	MA	Inhibitor
DMBWAMR	RN	Synthesis of novel 3-substituted beta-carbolines as benzodiazepine receptor ligands: probing the benzodiazepine receptor pharmacophore. J Med Chem. 1988 Sep;31(9):1854-61.
DMBWAMR	RU	https://pubmed.ncbi.nlm.nih.gov/2842507

DMBWAMR	DI	DMBWAMR
DMBWAMR	DN	9H-beta-Carbolin-3-ol
DMBWAMR	MI	TTNJYV2
DMBWAMR	MN	Gamma-aminobutyric acid receptor (GAR)
DMBWAMR	MT	DTT
DMBWAMR	MA	Inhibitor
DMBWAMR	RN	Synthesis of novel 3-substituted beta-carbolines as benzodiazepine receptor ligands: probing the benzodiazepine receptor pharmacophore. J Med Chem. 1988 Sep;31(9):1854-61.
DMBWAMR	RU	https://pubmed.ncbi.nlm.nih.gov/2842507

DMBLEI7	DI	DMBLEI7
DMBLEI7	DN	9H-beta-Carbolin-6-ylamine
DMBLEI7	MI	TT1MPAY
DMBLEI7	MN	GABA(A) receptor alpha-1 (GABRA1)
DMBLEI7	MT	DTT
DMBLEI7	MA	Inhibitor
DMBLEI7	RN	Synthesis of 6-substituted beta-carbolines that behave as benzodiazepine receptor antagonists or inverse agonists. J Med Chem. 1987 Apr;30(4):750-3.
DMBLEI7	RU	https://pubmed.ncbi.nlm.nih.gov/3031296

DMBLEI7	DI	DMBLEI7
DMBLEI7	DN	9H-beta-Carbolin-6-ylamine
DMBLEI7	MI	TTNJYV2
DMBLEI7	MN	Gamma-aminobutyric acid receptor (GAR)
DMBLEI7	MT	DTT
DMBLEI7	MA	Inhibitor
DMBLEI7	RN	Synthesis of 6-substituted beta-carbolines that behave as benzodiazepine receptor antagonists or inverse agonists. J Med Chem. 1987 Apr;30(4):750-3.
DMBLEI7	RU	https://pubmed.ncbi.nlm.nih.gov/3031296

DMK459I	DI	DMK459I
DMK459I	DN	9H-beta-Carboline-3-carboxylic acid ethyl ester
DMK459I	MI	TT1MPAY
DMK459I	MN	GABA(A) receptor alpha-1 (GABRA1)
DMK459I	MT	DTT
DMK459I	MA	Inhibitor
DMK459I	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DMK459I	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DMK459I	DI	DMK459I
DMK459I	DN	9H-beta-Carboline-3-carboxylic acid ethyl ester
DMK459I	MI	TTBMV1G
DMK459I	MN	GABA(A) receptor alpha-2 (GABRA2)
DMK459I	MT	DTT
DMK459I	MA	Inhibitor
DMK459I	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DMK459I	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DMK459I	DI	DMK459I
DMK459I	DN	9H-beta-Carboline-3-carboxylic acid ethyl ester
DMK459I	MI	TT37EDJ
DMK459I	MN	GABA(A) receptor alpha-3 (GABRA3)
DMK459I	MT	DTT
DMK459I	MA	Inhibitor
DMK459I	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DMK459I	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DMK459I	DI	DMK459I
DMK459I	DN	9H-beta-Carboline-3-carboxylic acid ethyl ester
DMK459I	MI	TTNZPQ1
DMK459I	MN	GABA(A) receptor alpha-5 (GABRA5)
DMK459I	MT	DTT
DMK459I	MA	Inhibitor
DMK459I	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DMK459I	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DMK459I	DI	DMK459I
DMK459I	DN	9H-beta-Carboline-3-carboxylic acid ethyl ester
DMK459I	MI	TT06RH5
DMK459I	MN	GABA(A) receptor gamma-2 (GABRG2)
DMK459I	MT	DTT
DMK459I	MA	Inhibitor
DMK459I	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DMK459I	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DMK459I	DI	DMK459I
DMK459I	DN	9H-beta-Carboline-3-carboxylic acid ethyl ester
DMK459I	MI	TTNJYV2
DMK459I	MN	Gamma-aminobutyric acid receptor (GAR)
DMK459I	MT	DTT
DMK459I	MA	Inhibitor
DMK459I	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DMK459I	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DMMUH98	DI	DMMUH98
DMMUH98	DN	9H-beta-Carboline-3-carboxylic acid propyl ester
DMMUH98	MI	TT1MPAY
DMMUH98	MN	GABA(A) receptor alpha-1 (GABRA1)
DMMUH98	MT	DTT
DMMUH98	MA	Inhibitor
DMMUH98	RN	beta-Carbolines as benzodiazepine receptor ligands. 1. Synthesis and benzodiazepine receptor interaction of esters of beta-carboline-3-carboxylic a... J Med Chem. 1983 Apr;26(4):499-503.
DMMUH98	RU	https://pubmed.ncbi.nlm.nih.gov/6300400

DMMUH98	DI	DMMUH98
DMMUH98	DN	9H-beta-Carboline-3-carboxylic acid propyl ester
DMMUH98	MI	TT06RH5
DMMUH98	MN	GABA(A) receptor gamma-2 (GABRG2)
DMMUH98	MT	DTT
DMMUH98	MA	Inhibitor
DMMUH98	RN	beta-Carbolines as benzodiazepine receptor ligands. 1. Synthesis and benzodiazepine receptor interaction of esters of beta-carboline-3-carboxylic a... J Med Chem. 1983 Apr;26(4):499-503.
DMMUH98	RU	https://pubmed.ncbi.nlm.nih.gov/6300400

DMMUH98	DI	DMMUH98
DMMUH98	DN	9H-beta-Carboline-3-carboxylic acid propyl ester
DMMUH98	MI	TTNJYV2
DMMUH98	MN	Gamma-aminobutyric acid receptor (GAR)
DMMUH98	MT	DTT
DMMUH98	MA	Inhibitor
DMMUH98	RN	beta-Carbolines as benzodiazepine receptor ligands. 1. Synthesis and benzodiazepine receptor interaction of esters of beta-carboline-3-carboxylic a... J Med Chem. 1983 Apr;26(4):499-503.
DMMUH98	RU	https://pubmed.ncbi.nlm.nih.gov/6300400

DM6WHIA	DI	DM6WHIA
DM6WHIA	DN	9H-carbazole-2-carbaldehyde
DM6WHIA	MI	TTBGTCW
DM6WHIA	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DM6WHIA	MT	DTT
DM6WHIA	MA	Inhibitor
DM6WHIA	RN	Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8.
DM6WHIA	RU	https://pubmed.ncbi.nlm.nih.gov/20521839

DM0HNU3	DI	DM0HNU3
DM0HNU3	DN	9H-carbazole-3-carbaldehyde
DM0HNU3	MI	TTBGTCW
DM0HNU3	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DM0HNU3	MT	DTT
DM0HNU3	MA	Inhibitor
DM0HNU3	RN	Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8.
DM0HNU3	RU	https://pubmed.ncbi.nlm.nih.gov/20521839

DMF1XLZ	DI	DMF1XLZ
DMF1XLZ	DN	9H-purine derivative
DMF1XLZ	MI	TTJFY5U
DMF1XLZ	MN	Adenosine A3 receptor (ADORA3)
DMF1XLZ	MT	DTT
DMF1XLZ	MA	Inhibitor
DMF1XLZ	RN	2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96.
DMF1XLZ	RU	https://pubmed.ncbi.nlm.nih.gov/16250647

DMOX21P	DI	DMOX21P
DMOX21P	DN	9-hydrazino-1,2,3,4-tetrahydroacridine
DMOX21P	MI	TT1RS9F
DMOX21P	MN	Acetylcholinesterase (AChE)
DMOX21P	MT	DTT
DMOX21P	MA	Inhibitor
DMOX21P	RN	Novel heterobivalent tacrine derivatives as cholinesterase inhibitors with notable selectivity toward butyrylcholinesterase. J Med Chem. 2006 Dec 14;49(25):7540-4.
DMOX21P	RU	https://pubmed.ncbi.nlm.nih.gov/17149883

DMH72MU	DI	DMH72MU
DMH72MU	DN	9-Hydroxy-7,8-benzoflavone
DMH72MU	MI	TTSZLWK
DMH72MU	MN	Aromatase (CYP19A1)
DMH72MU	MT	DTT
DMH72MU	MA	Inhibitor
DMH72MU	RN	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
DMH72MU	RU	https://pubmed.ncbi.nlm.nih.gov/20413308

DM0FWNJ	DI	DM0FWNJ
DM0FWNJ	DN	9-hydroxyoctadecadienoic acid
DM0FWNJ	MI	TTNBW4F
DM0FWNJ	MN	G2 accumulation protein (GPR132)
DM0FWNJ	MT	DTT
DM0FWNJ	MA	Agonist
DM0FWNJ	RN	Identification of 9-hydroxyoctadecadienoic acid and other oxidized free fatty acids as ligands of the G protein-coupled receptor G2A. J Biol Chem. 2005 Dec 9;280(49):40676-83.
DM0FWNJ	RU	https://pubmed.ncbi.nlm.nih.gov/16236715

DM0FWNJ	DI	DM0FWNJ
DM0FWNJ	DN	9-hydroxyoctadecadienoic acid
DM0FWNJ	MI	TTZMAO3
DM0FWNJ	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DM0FWNJ	MT	DTT
DM0FWNJ	MA	Inhibitor
DM0FWNJ	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM0FWNJ	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMB9FCK	DI	DMB9FCK
DMB9FCK	DN	9-Hydroxypropyladenine, R-Isomer
DMB9FCK	MI	TTP3QRF
DMB9FCK	MN	Thymidine kinase 1 (TK1)
DMB9FCK	MT	DTT
DMB9FCK	MA	Inhibitor
DMB9FCK	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMB9FCK	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM8QJUH	DI	DM8QJUH
DM8QJUH	DN	9-Hydroxypropyladenine, S-Isomer
DM8QJUH	MI	TTP3QRF
DM8QJUH	MN	Thymidine kinase 1 (TK1)
DM8QJUH	MT	DTT
DM8QJUH	MA	Inhibitor
DM8QJUH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM8QJUH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMGCX7E	DI	DMGCX7E
DMGCX7E	DN	9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione
DMGCX7E	MI	TTTU902
DMGCX7E	MN	Checkpoint kinase-1 (CHK1)
DMGCX7E	MT	DTT
DMGCX7E	MA	Inhibitor
DMGCX7E	RN	4-Phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione inhibitors of the checkpoint kinase Wee1. Structure-activity relationships for chromophore modific... J Med Chem. 2006 Aug 10;49(16):4896-911.
DMGCX7E	RU	https://pubmed.ncbi.nlm.nih.gov/16884302

DMGCX7E	DI	DMGCX7E
DMGCX7E	DN	9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione
DMGCX7E	MI	TTJFOAL
DMGCX7E	MN	Wee1-like protein kinase (WEE1)
DMGCX7E	MT	DTT
DMGCX7E	MA	Inhibitor
DMGCX7E	RN	Receptor-based 3D-QSAR studies of checkpoint Wee1 kinase inhibitors. Eur J Med Chem. 2009 Apr;44(4):1383-95.
DMGCX7E	RU	https://pubmed.ncbi.nlm.nih.gov/18976834

DMBQLAI	DI	DMBQLAI
DMBQLAI	DN	9-Isopropyl-9H-adenine
DMBQLAI	MI	TTK25J1
DMBQLAI	MN	Adenosine A1 receptor (ADORA1)
DMBQLAI	MT	DTT
DMBQLAI	MA	Inhibitor
DMBQLAI	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMBQLAI	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMBQLAI	DI	DMBQLAI
DMBQLAI	DN	9-Isopropyl-9H-adenine
DMBQLAI	MI	TTM2AOE
DMBQLAI	MN	Adenosine A2a receptor (ADORA2A)
DMBQLAI	MT	DTT
DMBQLAI	MA	Inhibitor
DMBQLAI	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMBQLAI	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMBQLAI	DI	DMBQLAI
DMBQLAI	DN	9-Isopropyl-9H-adenine
DMBQLAI	MI	TTNE7KG
DMBQLAI	MN	Adenosine A2b receptor (ADORA2B)
DMBQLAI	MT	DTT
DMBQLAI	MA	Inhibitor
DMBQLAI	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMBQLAI	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMW905K	DI	DMW905K
DMW905K	DN	9-mercapto-8-oxo-N-phenylnonanamide
DMW905K	MI	TTT6LFV
DMW905K	MN	Histone deacetylase 8 (HDAC8)
DMW905K	MT	DTT
DMW905K	MA	Inhibitor
DMW905K	RN	Histone deacetylase inhibitors: from bench to clinic. J Med Chem. 2008 Mar 27;51(6):1505-29.
DMW905K	RU	https://pubmed.ncbi.nlm.nih.gov/18247554

DMM2GQC	DI	DMM2GQC
DMM2GQC	DN	9-Mercaptomethyl-10-oxo-azecane-2-carboxylic acid
DMM2GQC	MI	TT5TKPM
DMM2GQC	MN	Neutral endopeptidase (MME)
DMM2GQC	MT	DTT
DMM2GQC	MA	Inhibitor
DMM2GQC	RN	Design and synthesis of an orally active macrocyclic neutral endopeptidase 24.11 inhibitor. J Med Chem. 1993 Nov 26;36(24):3821-8.
DMM2GQC	RU	https://pubmed.ncbi.nlm.nih.gov/8254611

DM1YK42	DI	DM1YK42
DM1YK42	DN	9-Methoxy-1,2,3,4-tetrahydro-anthracen-2-ylamine
DM1YK42	MI	TTSQIFT
DM1YK42	MN	5-HT 1A receptor (HTR1A)
DM1YK42	MT	DTT
DM1YK42	MA	Inhibitor
DM1YK42	RN	Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993).
DM1YK42	RU	http://www.sciencedirect.com/science/article/pii/S0960894X0181009X

DMDW267	DI	DMDW267
DMDW267	DN	9-Methoxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazole
DMDW267	MI	TTX41N9
DMDW267	MN	Tyrosine-protein kinase Kit (KIT)
DMDW267	MT	DTT
DMDW267	MA	Inhibitor
DMDW267	RN	Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases. J Med Chem. 2005 Oct 6;48(20):6194-201.
DMDW267	RU	https://pubmed.ncbi.nlm.nih.gov/16190746

DMKLTD5	DI	DMKLTD5
DMKLTD5	DN	9-methyl-2-(trifluoromethyl)-9H-carbazole
DMKLTD5	MI	TTBGTCW
DMKLTD5	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DMKLTD5	MT	DTT
DMKLTD5	MA	Inhibitor
DMKLTD5	RN	Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8.
DMKLTD5	RU	https://pubmed.ncbi.nlm.nih.gov/20521839

DMF7QS5	DI	DMF7QS5
DMF7QS5	DN	9-Methyl-2,3,4,9-tetrahydro-1H-beta-carboline
DMF7QS5	MI	TT3WG5C
DMF7QS5	MN	Monoamine oxidase type A (MAO-A)
DMF7QS5	MT	DTT
DMF7QS5	MA	Inhibitor
DMF7QS5	RN	Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
DMF7QS5	RU	https://pubmed.ncbi.nlm.nih.gov/15013009

DMF7QS5	DI	DMF7QS5
DMF7QS5	DN	9-Methyl-2,3,4,9-tetrahydro-1H-beta-carboline
DMF7QS5	MI	TTGP7BY
DMF7QS5	MN	Monoamine oxidase type B (MAO-B)
DMF7QS5	MT	DTT
DMF7QS5	MA	Inhibitor
DMF7QS5	RN	Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
DMF7QS5	RU	https://pubmed.ncbi.nlm.nih.gov/15013009

DMKD0ZP	DI	DMKD0ZP
DMKD0ZP	DN	9-methyl-5H-6-thia-4,5-diaza-chrysene 6,6-dioxide
DMKD0ZP	MI	TTSXVID
DMKD0ZP	MN	Nuclear factor NF-kappa-B (NFKB)
DMKD0ZP	MT	DTT
DMKD0ZP	MA	Inhibitor
DMKD0ZP	RN	Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFkappaB activity within two separate high-throughput s... Bioorg Med Chem Lett. 2008 Jan 1;18(1):329-35.
DMKD0ZP	RU	https://pubmed.ncbi.nlm.nih.gov/18024113

DMO4CSP	DI	DMO4CSP
DMO4CSP	DN	9-Methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine
DMO4CSP	MI	TTK25J1
DMO4CSP	MN	Adenosine A1 receptor (ADORA1)
DMO4CSP	MT	DTT
DMO4CSP	MA	Inhibitor
DMO4CSP	RN	2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96.
DMO4CSP	RU	https://pubmed.ncbi.nlm.nih.gov/16250647

DMO4CSP	DI	DMO4CSP
DMO4CSP	DN	9-Methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine
DMO4CSP	MI	TTM2AOE
DMO4CSP	MN	Adenosine A2a receptor (ADORA2A)
DMO4CSP	MT	DTT
DMO4CSP	MA	Inhibitor
DMO4CSP	RN	2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96.
DMO4CSP	RU	https://pubmed.ncbi.nlm.nih.gov/16250647

DM6DOVL	DI	DM6DOVL
DM6DOVL	DN	9-Methyl-9H-adenine
DM6DOVL	MI	TTK25J1
DM6DOVL	MN	Adenosine A1 receptor (ADORA1)
DM6DOVL	MT	DTT
DM6DOVL	MA	Inhibitor
DM6DOVL	RN	Novel amino acid derived natural products from the ascidian Atriolum robustum: identification and pharmacological characterization of a unique aden... J Med Chem. 2004 Apr 22;47(9):2243-55.
DM6DOVL	RU	https://pubmed.ncbi.nlm.nih.gov/15084123

DM6DOVL	DI	DM6DOVL
DM6DOVL	DN	9-Methyl-9H-adenine
DM6DOVL	MI	TTM2AOE
DM6DOVL	MN	Adenosine A2a receptor (ADORA2A)
DM6DOVL	MT	DTT
DM6DOVL	MA	Inhibitor
DM6DOVL	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DM6DOVL	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DM54FRI	DI	DM54FRI
DM54FRI	DN	9-Methylguanine
DM54FRI	MI	TTG9CFY
DM54FRI	MN	Bacterial Dihydroneopterinaldolase (Bact folB)
DM54FRI	MT	DTT
DM54FRI	MA	Inhibitor
DM54FRI	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM54FRI	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMPXLEU	DI	DMPXLEU
DMPXLEU	DN	9-N-ETHYL-8-ETHOXY-MANZAMINE A
DMPXLEU	MI	TTRSMW9
DMPXLEU	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMPXLEU	MT	DTT
DMPXLEU	MA	Inhibitor
DMPXLEU	RN	Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for ... J Nat Prod. 2007 Sep;70(9):1397-405.
DMPXLEU	RU	https://pubmed.ncbi.nlm.nih.gov/17708655

DM8LUYM	DI	DM8LUYM
DM8LUYM	DN	9-Nitropaullone
DM8LUYM	MI	TTH6V3D
DM8LUYM	MN	Cyclin-dependent kinase 1 (CDK1)
DM8LUYM	MT	DTT
DM8LUYM	MA	Inhibitor
DM8LUYM	RN	Down-regulation of survivin in nitric oxide-induced cell growth inhibition and apoptosis of the human lung carcinoma cells. J Biol Chem. 2004 May 7;279(19):20267-76.
DM8LUYM	RU	https://pubmed.ncbi.nlm.nih.gov/14988404

DM8LUYM	DI	DM8LUYM
DM8LUYM	DN	9-Nitropaullone
DM8LUYM	MI	TT7HF4W
DM8LUYM	MN	Cyclin-dependent kinase 2 (CDK2)
DM8LUYM	MT	DTT
DM8LUYM	MA	Inhibitor
DM8LUYM	RN	Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
DM8LUYM	RU	https://pubmed.ncbi.nlm.nih.gov/12237154

DM8LUYM	DI	DM8LUYM
DM8LUYM	DN	9-Nitropaullone
DM8LUYM	MI	TTL4Q97
DM8LUYM	MN	Cyclin-dependent kinase 5 (CDK5)
DM8LUYM	MT	DTT
DM8LUYM	MA	Inhibitor
DM8LUYM	RN	Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
DM8LUYM	RU	https://pubmed.ncbi.nlm.nih.gov/12237154

DM1YUBX	DI	DM1YUBX
DM1YUBX	DN	9-N-METHYL-8-METHOXY-MANZAMINE A
DM1YUBX	MI	TTRSMW9
DM1YUBX	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DM1YUBX	MT	DTT
DM1YUBX	MA	Inhibitor
DM1YUBX	RN	Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for ... J Nat Prod. 2007 Sep;70(9):1397-405.
DM1YUBX	RU	https://pubmed.ncbi.nlm.nih.gov/17708655

DMGMD1K	DI	DMGMD1K
DMGMD1K	DN	9-N-Phenylmethylamino-Tacrine
DMGMD1K	MI	TTEB0GD
DMGMD1K	MN	Cholinesterase (BCHE)
DMGMD1K	MT	DTT
DMGMD1K	MA	Inhibitor
DMGMD1K	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMGMD1K	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMYXEJ8	DI	DMYXEJ8
DMYXEJ8	DN	9-O-[2-(Phenylol-1-yloxy)ethyl]berberine bromide
DMYXEJ8	MI	TT1RS9F
DMYXEJ8	MN	Acetylcholinesterase (AChE)
DMYXEJ8	MT	DTT
DMYXEJ8	MA	Inhibitor
DMYXEJ8	RN	Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1244-51.
DMYXEJ8	RU	https://pubmed.ncbi.nlm.nih.gov/20056426

DMYXEJ8	DI	DMYXEJ8
DMYXEJ8	DN	9-O-[2-(Phenylol-1-yloxy)ethyl]berberine bromide
DMYXEJ8	MI	TTEB0GD
DMYXEJ8	MN	Cholinesterase (BCHE)
DMYXEJ8	MT	DTT
DMYXEJ8	MA	Inhibitor
DMYXEJ8	RN	Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1244-51.
DMYXEJ8	RU	https://pubmed.ncbi.nlm.nih.gov/20056426

DM081G2	DI	DM081G2
DM081G2	DN	9-O-[2-(Phenylol-1-yloxy)hexyl]berberine bromide
DM081G2	MI	TT1RS9F
DM081G2	MN	Acetylcholinesterase (AChE)
DM081G2	MT	DTT
DM081G2	MA	Inhibitor
DM081G2	RN	Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1244-51.
DM081G2	RU	https://pubmed.ncbi.nlm.nih.gov/20056426

DM081G2	DI	DM081G2
DM081G2	DN	9-O-[2-(Phenylol-1-yloxy)hexyl]berberine bromide
DM081G2	MI	TTEB0GD
DM081G2	MN	Cholinesterase (BCHE)
DM081G2	MT	DTT
DM081G2	MA	Inhibitor
DM081G2	RN	Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1244-51.
DM081G2	RU	https://pubmed.ncbi.nlm.nih.gov/20056426

DMHRV2A	DI	DMHRV2A
DMHRV2A	DN	9-O-[3-(2-Pyridinoxyl)butyl]-berberine bromide
DMHRV2A	MI	TT1RS9F
DMHRV2A	MN	Acetylcholinesterase (AChE)
DMHRV2A	MT	DTT
DMHRV2A	MA	Inhibitor
DMHRV2A	RN	Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase. Bioorg Med Chem. 2010 Jun 15;18(12):4475-84.
DMHRV2A	RU	https://pubmed.ncbi.nlm.nih.gov/20471843

DMHRV2A	DI	DMHRV2A
DMHRV2A	DN	9-O-[3-(2-Pyridinoxyl)butyl]-berberine bromide
DMHRV2A	MI	TTEB0GD
DMHRV2A	MN	Cholinesterase (BCHE)
DMHRV2A	MT	DTT
DMHRV2A	MA	Inhibitor
DMHRV2A	RN	Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase. Bioorg Med Chem. 2010 Jun 15;18(12):4475-84.
DMHRV2A	RU	https://pubmed.ncbi.nlm.nih.gov/20471843

DM4JG9S	DI	DM4JG9S
DM4JG9S	DN	9-O-[3-(4-Bromo-phenoxyl)butyl]-berberine bromide
DM4JG9S	MI	TT1RS9F
DM4JG9S	MN	Acetylcholinesterase (AChE)
DM4JG9S	MT	DTT
DM4JG9S	MA	Inhibitor
DM4JG9S	RN	Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase. Bioorg Med Chem. 2010 Jun 15;18(12):4475-84.
DM4JG9S	RU	https://pubmed.ncbi.nlm.nih.gov/20471843

DM4JG9S	DI	DM4JG9S
DM4JG9S	DN	9-O-[3-(4-Bromo-phenoxyl)butyl]-berberine bromide
DM4JG9S	MI	TTEB0GD
DM4JG9S	MN	Cholinesterase (BCHE)
DM4JG9S	MT	DTT
DM4JG9S	MA	Inhibitor
DM4JG9S	RN	Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase. Bioorg Med Chem. 2010 Jun 15;18(12):4475-84.
DM4JG9S	RU	https://pubmed.ncbi.nlm.nih.gov/20471843

DMWVSPH	DI	DMWVSPH
DMWVSPH	DN	9-O-[3-(4-Nitro-phenoxyl)butyl]-berberine bromide
DMWVSPH	MI	TT1RS9F
DMWVSPH	MN	Acetylcholinesterase (AChE)
DMWVSPH	MT	DTT
DMWVSPH	MA	Inhibitor
DMWVSPH	RN	Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase. Bioorg Med Chem. 2010 Jun 15;18(12):4475-84.
DMWVSPH	RU	https://pubmed.ncbi.nlm.nih.gov/20471843

DMWVSPH	DI	DMWVSPH
DMWVSPH	DN	9-O-[3-(4-Nitro-phenoxyl)butyl]-berberine bromide
DMWVSPH	MI	TTEB0GD
DMWVSPH	MN	Cholinesterase (BCHE)
DMWVSPH	MT	DTT
DMWVSPH	MA	Inhibitor
DMWVSPH	RN	Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase. Bioorg Med Chem. 2010 Jun 15;18(12):4475-84.
DMWVSPH	RU	https://pubmed.ncbi.nlm.nih.gov/20471843

DMKPUWX	DI	DMKPUWX
DMKPUWX	DN	9-O-[3-(Phenylamino)propyl]-berberine bromide
DMKPUWX	MI	TT1RS9F
DMKPUWX	MN	Acetylcholinesterase (AChE)
DMKPUWX	MT	DTT
DMKPUWX	MA	Inhibitor
DMKPUWX	RN	Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase. Bioorg Med Chem. 2010 Jun 15;18(12):4475-84.
DMKPUWX	RU	https://pubmed.ncbi.nlm.nih.gov/20471843

DMKPUWX	DI	DMKPUWX
DMKPUWX	DN	9-O-[3-(Phenylamino)propyl]-berberine bromide
DMKPUWX	MI	TTEB0GD
DMKPUWX	MN	Cholinesterase (BCHE)
DMKPUWX	MT	DTT
DMKPUWX	MA	Inhibitor
DMKPUWX	RN	Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase. Bioorg Med Chem. 2010 Jun 15;18(12):4475-84.
DMKPUWX	RU	https://pubmed.ncbi.nlm.nih.gov/20471843

DM0FNUX	DI	DM0FNUX
DM0FNUX	DN	9-O-[3-(Phenylol-1-yloxy)propyl]berberine bromide
DM0FNUX	MI	TT1RS9F
DM0FNUX	MN	Acetylcholinesterase (AChE)
DM0FNUX	MT	DTT
DM0FNUX	MA	Inhibitor
DM0FNUX	RN	Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1244-51.
DM0FNUX	RU	https://pubmed.ncbi.nlm.nih.gov/20056426

DM0FNUX	DI	DM0FNUX
DM0FNUX	DN	9-O-[3-(Phenylol-1-yloxy)propyl]berberine bromide
DM0FNUX	MI	TTEB0GD
DM0FNUX	MN	Cholinesterase (BCHE)
DM0FNUX	MT	DTT
DM0FNUX	MA	Inhibitor
DM0FNUX	RN	Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1244-51.
DM0FNUX	RU	https://pubmed.ncbi.nlm.nih.gov/20056426

DM58XF6	DI	DM58XF6
DM58XF6	DN	9-O-[4-(Phenylol-1-yloxy)butyl]berberine bromide
DM58XF6	MI	TT1RS9F
DM58XF6	MN	Acetylcholinesterase (AChE)
DM58XF6	MT	DTT
DM58XF6	MA	Inhibitor
DM58XF6	RN	Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1244-51.
DM58XF6	RU	https://pubmed.ncbi.nlm.nih.gov/20056426

DM58XF6	DI	DM58XF6
DM58XF6	DN	9-O-[4-(Phenylol-1-yloxy)butyl]berberine bromide
DM58XF6	MI	TTEB0GD
DM58XF6	MN	Cholinesterase (BCHE)
DM58XF6	MT	DTT
DM58XF6	MA	Inhibitor
DM58XF6	RN	Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1244-51.
DM58XF6	RU	https://pubmed.ncbi.nlm.nih.gov/20056426

DMPZTG9	DI	DMPZTG9
DMPZTG9	DN	9-O-[5-(Phenylol-1-yloxy)pentyl]berberine bromide
DMPZTG9	MI	TT1RS9F
DMPZTG9	MN	Acetylcholinesterase (AChE)
DMPZTG9	MT	DTT
DMPZTG9	MA	Inhibitor
DMPZTG9	RN	Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1244-51.
DMPZTG9	RU	https://pubmed.ncbi.nlm.nih.gov/20056426

DMPZTG9	DI	DMPZTG9
DMPZTG9	DN	9-O-[5-(Phenylol-1-yloxy)pentyl]berberine bromide
DMPZTG9	MI	TTEB0GD
DMPZTG9	MN	Cholinesterase (BCHE)
DMPZTG9	MT	DTT
DMPZTG9	MA	Inhibitor
DMPZTG9	RN	Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1244-51.
DMPZTG9	RU	https://pubmed.ncbi.nlm.nih.gov/20056426

DM1DYU4	DI	DM1DYU4
DM1DYU4	DN	9-octadecynoic acid
DM1DYU4	MI	TTPADOQ
DM1DYU4	MN	HMG-CoA reductase (HMGCR)
DM1DYU4	MT	DTT
DM1DYU4	MA	Inhibitor
DM1DYU4	RN	Novel Acetylenic Acids from the Root Bark of Paramacrolobium caeruleum: Inhibitors of 3-Hydroxy-3-methyl-glutaryl Coenzyme A Reductase J. Nat. Prod. 52(1):153-161 (1989).
DM1DYU4	RU	http://pubs.acs.org/doi/abs/10.1021/np50061a020

DMGORXQ	DI	DMGORXQ
DMGORXQ	DN	9-OH-risperidone
DMGORXQ	MI	TTSQIFT
DMGORXQ	MN	5-HT 1A receptor (HTR1A)
DMGORXQ	MT	DTT
DMGORXQ	MA	Antagonist
DMGORXQ	RN	Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73.
DMGORXQ	RU	https://pubmed.ncbi.nlm.nih.gov/8935801

DMGORXQ	DI	DMGORXQ
DMGORXQ	DN	9-OH-risperidone
DMGORXQ	MI	TTK8CXU
DMGORXQ	MN	5-HT 1B receptor (HTR1B)
DMGORXQ	MT	DTT
DMGORXQ	MA	Antagonist
DMGORXQ	RN	Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73.
DMGORXQ	RU	https://pubmed.ncbi.nlm.nih.gov/8935801

DMGORXQ	DI	DMGORXQ
DMGORXQ	DN	9-OH-risperidone
DMGORXQ	MI	TT6MSOK
DMGORXQ	MN	5-HT 1D receptor (HTR1D)
DMGORXQ	MT	DTT
DMGORXQ	MA	Antagonist
DMGORXQ	RN	Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73.
DMGORXQ	RU	https://pubmed.ncbi.nlm.nih.gov/8935801

DMGORXQ	DI	DMGORXQ
DMGORXQ	DN	9-OH-risperidone
DMGORXQ	MI	TTCPG9S
DMGORXQ	MN	5-HT 1E receptor (HTR1E)
DMGORXQ	MT	DTT
DMGORXQ	MA	Antagonist
DMGORXQ	RN	Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73.
DMGORXQ	RU	https://pubmed.ncbi.nlm.nih.gov/8935801

DMGORXQ	DI	DMGORXQ
DMGORXQ	DN	9-OH-risperidone
DMGORXQ	MI	TTJQOD7
DMGORXQ	MN	5-HT 2A receptor (HTR2A)
DMGORXQ	MT	DTT
DMGORXQ	MA	Antagonist
DMGORXQ	RN	Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73.
DMGORXQ	RU	https://pubmed.ncbi.nlm.nih.gov/8935801

DMGORXQ	DI	DMGORXQ
DMGORXQ	DN	9-OH-risperidone
DMGORXQ	MI	TTTIBOJ
DMGORXQ	MN	Histamine H1 receptor (H1R)
DMGORXQ	MT	DTT
DMGORXQ	MA	Antagonist
DMGORXQ	RN	Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73.
DMGORXQ	RU	https://pubmed.ncbi.nlm.nih.gov/8935801

DMJFBQ1	DI	DMJFBQ1
DMJFBQ1	DN	9-phenanthrol
DMJFBQ1	MI	TTJ2HKA
DMJFBQ1	MN	Long transient receptor potential channel 4 (TRPM4)
DMJFBQ1	MT	DTT
DMJFBQ1	MA	Blocker (channel blocker)
DMJFBQ1	RN	9-phenanthrol inhibits human TRPM4 but not TRPM5 cationic channels. Br J Pharmacol. 2008 Apr;153(8):1697-705.
DMJFBQ1	RU	https://pubmed.ncbi.nlm.nih.gov/18297105

DMRCM7Q	DI	DMRCM7Q
DMRCM7Q	DN	9-Phenyl-2,3-dihydro-1H-indeno[2,1-c]pyridine
DMRCM7Q	MI	TTTIBOJ
DMRCM7Q	MN	Histamine H1 receptor (H1R)
DMRCM7Q	MT	DTT
DMRCM7Q	MA	Inhibitor
DMRCM7Q	RN	Conformationally-restricted ligands for the histamine H1 receptor. Bioorg Med Chem Lett. 2000 Jun 5;10(11):1277-9.
DMRCM7Q	RU	https://pubmed.ncbi.nlm.nih.gov/10866399

DM73O2A	DI	DM73O2A
DM73O2A	DN	9-Phenyl-9H-purin-6-ylamine
DM73O2A	MI	TTK25J1
DM73O2A	MN	Adenosine A1 receptor (ADORA1)
DM73O2A	MT	DTT
DM73O2A	MA	Inhibitor
DM73O2A	RN	N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor. J Med Chem. 1991 Sep;34(9):2877-82.
DM73O2A	RU	https://pubmed.ncbi.nlm.nih.gov/1895305

DMO17J0	DI	DMO17J0
DMO17J0	DN	9-Phenylethyl-9H-adenine
DMO17J0	MI	TTM2AOE
DMO17J0	MN	Adenosine A2a receptor (ADORA2A)
DMO17J0	MT	DTT
DMO17J0	MA	Inhibitor
DMO17J0	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMO17J0	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMQTEPY	DI	DMQTEPY
DMQTEPY	DN	9-Propyl-9H-adenine
DMQTEPY	MI	TTK25J1
DMQTEPY	MN	Adenosine A1 receptor (ADORA1)
DMQTEPY	MT	DTT
DMQTEPY	MA	Inhibitor
DMQTEPY	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMQTEPY	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMQTEPY	DI	DMQTEPY
DMQTEPY	DN	9-Propyl-9H-adenine
DMQTEPY	MI	TTM2AOE
DMQTEPY	MN	Adenosine A2a receptor (ADORA2A)
DMQTEPY	MT	DTT
DMQTEPY	MA	Inhibitor
DMQTEPY	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMQTEPY	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DMQTEPY	DI	DMQTEPY
DMQTEPY	DN	9-Propyl-9H-adenine
DMQTEPY	MI	TTNE7KG
DMQTEPY	MN	Adenosine A2b receptor (ADORA2B)
DMQTEPY	MT	DTT
DMQTEPY	MA	Inhibitor
DMQTEPY	RN	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
DMQTEPY	RU	https://pubmed.ncbi.nlm.nih.gov/19282184

DM1H3FJ	DI	DM1H3FJ
DM1H3FJ	DN	A 137491
DM1H3FJ	MI	TTQL5VC
DM1H3FJ	MN	Platelet-activating factor receptor (PTAFR)
DM1H3FJ	MT	DTT
DM1H3FJ	MA	Modulator
DM1H3FJ	RN	The role of platelet-activating factor (PAF) and the efficacy of ABT-491, a highly potent and selective PAF antagonist, in experimental allergic rhinitis. J Pharmacol Exp Ther. 1998 Jan;284(1):83-8.
DM1H3FJ	RU	https://pubmed.ncbi.nlm.nih.gov/9435164

DMHSPRE	DI	DMHSPRE
DMHSPRE	DN	A-058
DMHSPRE	MI	TTMVBWH
DMHSPRE	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMHSPRE	MT	DTT
DMHSPRE	MA	Modulator
DMHSPRE	RN	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
DMHSPRE	RU	https://www.ncbi.nlm.nih.gov/pubmed/27899562

DM1DWRN	DI	DM1DWRN
DM1DWRN	DN	A-119637
DM1DWRN	MI	TTNGILX
DM1DWRN	MN	Adrenergic receptor alpha-1A (ADRA1A)
DM1DWRN	MT	DTT
DM1DWRN	MA	Inhibitor
DM1DWRN	RN	Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
DM1DWRN	RU	https://pubmed.ncbi.nlm.nih.gov/15664832

DM1DWRN	DI	DM1DWRN
DM1DWRN	DN	A-119637
DM1DWRN	MI	TTBRKXS
DM1DWRN	MN	Adrenergic receptor alpha-1B (ADRA1B)
DM1DWRN	MT	DTT
DM1DWRN	MA	Inhibitor
DM1DWRN	RN	Two novel and potent 3-[(o-methoxyphenyl)piperazinylethyl]-5-phenylthien. Bioorg Med Chem Lett. 2001 May 7;11(9):1119-21.
DM1DWRN	RU	https://pubmed.ncbi.nlm.nih.gov/11354357

DMZ51UJ	DI	DMZ51UJ
DMZ51UJ	DN	A-123189
DMZ51UJ	MI	TTNGILX
DMZ51UJ	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMZ51UJ	MT	DTT
DMZ51UJ	MA	Inhibitor
DMZ51UJ	RN	Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
DMZ51UJ	RU	https://pubmed.ncbi.nlm.nih.gov/15664832

DMZ51UJ	DI	DMZ51UJ
DMZ51UJ	DN	A-123189
DMZ51UJ	MI	TTBRKXS
DMZ51UJ	MN	Adrenergic receptor alpha-1B (ADRA1B)
DMZ51UJ	MT	DTT
DMZ51UJ	MA	Inhibitor
DMZ51UJ	RN	Two novel and potent 3-[(o-methoxyphenyl)piperazinylethyl]-5-phenylthien. Bioorg Med Chem Lett. 2001 May 7;11(9):1119-21.
DMZ51UJ	RU	https://pubmed.ncbi.nlm.nih.gov/11354357

DMV03NS	DI	DMV03NS
DMV03NS	DN	A-192558
DMV03NS	MI	TT50QJ3
DMV03NS	MN	Influenza Neuraminidase (Influ NA)
DMV03NS	MT	DTT
DMV03NS	MA	Inhibitor
DMV03NS	RN	Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25.
DMV03NS	RU	https://pubmed.ncbi.nlm.nih.gov/17139286

DMV8AH6	DI	DMV8AH6
DMV8AH6	DN	A192621
DMV8AH6	MI	TT3ZTGU
DMV8AH6	MN	Endothelin B receptor (EDNRB)
DMV8AH6	MT	DTT
DMV8AH6	MA	Antagonist
DMV8AH6	RN	Pyrrolidine-3-carboxylic acids as endothelin antagonists. 4. Side chain conformational restriction leads to ET(B) selectivity. J Med Chem. 1999 Sep 9;42(18):3668-78.
DMV8AH6	RU	https://pubmed.ncbi.nlm.nih.gov/10479298

DM5VQ8E	DI	DM5VQ8E
DM5VQ8E	DN	A-224940
DM5VQ8E	MI	TTX4RTB
DM5VQ8E	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DM5VQ8E	MT	DTT
DM5VQ8E	MA	Inhibitor
DM5VQ8E	RN	Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 3. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4883-6.
DM5VQ8E	RU	https://pubmed.ncbi.nlm.nih.gov/15341944

DM98VFW	DI	DM98VFW
DM98VFW	DN	A-286982
DM98VFW	MI	TTA1L39
DM98VFW	MN	ICAM1 messenger RNA (ICAM1 mRNA)
DM98VFW	MT	DTT
DM98VFW	MA	Inhibitor
DM98VFW	RN	Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonists. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5269-73.
DM98VFW	RU	https://pubmed.ncbi.nlm.nih.gov/20655213

DM98VFW	DI	DM98VFW
DM98VFW	DN	A-286982
DM98VFW	MI	TT48WR6
DM98VFW	MN	Integrin alpha-L (ITGAL)
DM98VFW	MT	DTT
DM98VFW	MA	Inhibitor
DM98VFW	RN	Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonists. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5269-73.
DM98VFW	RU	https://pubmed.ncbi.nlm.nih.gov/20655213

DM98VFW	DI	DM98VFW
DM98VFW	DN	A-286982
DM98VFW	MI	TTIJWR7
DM98VFW	MN	Integrin beta-2 (ITGB2)
DM98VFW	MT	DTT
DM98VFW	MA	Inhibitor
DM98VFW	RN	Novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intracellular adhesion molecule-1 interaction. 2. Mechanism o... J Med Chem. 2001 Apr 12;44(8):1202-10.
DM98VFW	RU	https://pubmed.ncbi.nlm.nih.gov/11312920

DMK4OD7	DI	DMK4OD7
DMK4OD7	DN	A2P5P
DMK4OD7	MI	TTA93TL
DMK4OD7	MN	P2Y purinoceptor 1 (P2RY1)
DMK4OD7	MT	DTT
DMK4OD7	MA	Antagonist
DMK4OD7	RN	Identification of competitive antagonists of the P2Y1 receptor. Mol Pharmacol. 1996 Nov;50(5):1323-9.
DMK4OD7	RU	https://pubmed.ncbi.nlm.nih.gov/8913364

DMPI0YX	DI	DMPI0YX
DMPI0YX	DN	A-304121
DMPI0YX	MI	TT9JNIC
DMPI0YX	MN	Histamine H3 receptor (H3R)
DMPI0YX	MT	DTT
DMPI0YX	MA	Antagonist
DMPI0YX	RN	Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist. Biochem Pharmacol. 2004 Sep 1;68(5):933-45.
DMPI0YX	RU	https://pubmed.ncbi.nlm.nih.gov/15294456

DML4P6O	DI	DML4P6O
DML4P6O	DN	A-313326
DML4P6O	MI	TT7WZIJ
DML4P6O	MN	CAAX farnesyltransferase beta (FNTB)
DML4P6O	MT	DTT
DML4P6O	MA	Inhibitor
DML4P6O	RN	Design and synthesis of o-trifluoromethylbiphenyl substituted 2-amino-nicotinonitriles as inhibitors of farnesyltransferase. Bioorg Med Chem Lett. 2005 Jan 3;15(1):153-8.
DML4P6O	RU	https://pubmed.ncbi.nlm.nih.gov/15582430

DML4P6O	DI	DML4P6O
DML4P6O	DN	A-313326
DML4P6O	MI	TTX20QP
DML4P6O	MN	Geranylgeranyl transferase I (GGTase-I)
DML4P6O	MT	DTT
DML4P6O	MA	Inhibitor
DML4P6O	RN	Design and synthesis of o-trifluoromethylbiphenyl substituted 2-amino-nicotinonitriles as inhibitors of farnesyltransferase. Bioorg Med Chem Lett. 2005 Jan 3;15(1):153-8.
DML4P6O	RU	https://pubmed.ncbi.nlm.nih.gov/15582430

DMV8MKP	DI	DMV8MKP
DMV8MKP	DN	A-315456
DMV8MKP	MI	TTNGILX
DMV8MKP	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMV8MKP	MT	DTT
DMV8MKP	MA	Inhibitor
DMV8MKP	RN	Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
DMV8MKP	RU	https://pubmed.ncbi.nlm.nih.gov/15664832

DMSQLZF	DI	DMSQLZF
DMSQLZF	DN	A-315675
DMSQLZF	MI	TT50QJ3
DMSQLZF	MN	Influenza Neuraminidase (Influ NA)
DMSQLZF	MT	DTT
DMSQLZF	MA	Inhibitor
DMSQLZF	RN	Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25.
DMSQLZF	RU	https://pubmed.ncbi.nlm.nih.gov/17139286

DMGWO9J	DI	DMGWO9J
DMGWO9J	DN	A-317567
DMGWO9J	MI	TTVMWLP
DMGWO9J	MN	Acid-sensing ion channel 2 (ASIC2)
DMGWO9J	MT	DTT
DMGWO9J	MA	Blocker (channel blocker)
DMGWO9J	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 685).
DMGWO9J	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=685

DMGWO9J	DI	DMGWO9J
DMGWO9J	DN	A-317567
DMGWO9J	MI	TTLGDIS
DMGWO9J	MN	Acid-sensing ion channel 3 (ASIC3)
DMGWO9J	MT	DTT
DMGWO9J	MA	Blocker (channel blocker)
DMGWO9J	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 686).
DMGWO9J	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=686

DM124K5	DI	DM124K5
DM124K5	DN	A-317920
DM124K5	MI	TT9JNIC
DM124K5	MN	Histamine H3 receptor (H3R)
DM124K5	MT	DTT
DM124K5	MA	Antagonist
DM124K5	RN	The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20.
DM124K5	RU	https://pubmed.ncbi.nlm.nih.gov/15665857

DMPU3QR	DI	DMPU3QR
DMPU3QR	DN	A-331440
DMPU3QR	MI	TT9JNIC
DMPU3QR	MN	Histamine H3 receptor (H3R)
DMPU3QR	MT	DTT
DMPU3QR	MA	Antagonist
DMPU3QR	RN	The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20.
DMPU3QR	RU	https://pubmed.ncbi.nlm.nih.gov/15665857

DMFNR3Y	DI	DMFNR3Y
DMFNR3Y	DN	A35566-A
DMFNR3Y	MI	TTGTQHC
DMFNR3Y	MN	DNA topoisomerase I (TOP1)
DMFNR3Y	MT	DTT
DMFNR3Y	MA	Inhibitor
DMFNR3Y	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2636).
DMFNR3Y	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2636

DMZHDWN	DI	DMZHDWN
DMZHDWN	DN	A-357300
DMZHDWN	MI	TTZL0OI
DMZHDWN	MN	Methionine aminopeptidase 2 (METAP2)
DMZHDWN	MT	DTT
DMZHDWN	MA	Inhibitor
DMZHDWN	RN	Tumor suppression by a rationally designed reversible inhibitor of methionine aminopeptidase-2. Cancer Res. 2003 Nov 15;63(22):7861-9.
DMZHDWN	RU	https://pubmed.ncbi.nlm.nih.gov/14633714

DMI4TVB	DI	DMI4TVB
DMI4TVB	DN	A-381393
DMI4TVB	MI	TTE0A2F
DMI4TVB	MN	Dopamine D4 receptor (D4R)
DMI4TVB	MT	DTT
DMI4TVB	MA	Antagonist
DMI4TVB	RN	Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI. Psychopharmacology (Berl). 2009 Apr;203(2):265-77.
DMI4TVB	RU	https://pubmed.ncbi.nlm.nih.gov/18604600

DMSTZ14	DI	DMSTZ14
DMSTZ14	DN	A-395
DMSTZ14	MI	TTFNJ4R
DMSTZ14	MN	Embryonic ectoderm development protein (EED)
DMSTZ14	MT	DTT
DMSTZ14	MA	Inhibitor
DMSTZ14	RN	The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex. Nat Chem Biol. 2017 Apr;13(4):389-395.
DMSTZ14	RU	https://pubmed.ncbi.nlm.nih.gov/28135237

DMKY9G5	DI	DMKY9G5
DMKY9G5	DN	A412997
DMKY9G5	MI	TTE0A2F
DMKY9G5	MN	Dopamine D4 receptor (D4R)
DMKY9G5	MT	DTT
DMKY9G5	MA	Agonist
DMKY9G5	RN	A-412997 is a selective dopamine D4 receptor agonist in rats. Pharmacol Biochem Behav. 2005 Sep;82(1):140-7.
DMKY9G5	RU	https://pubmed.ncbi.nlm.nih.gov/16153699

DM7HSCI	DI	DM7HSCI
DM7HSCI	DN	A-420983
DM7HSCI	MI	TT9VGXW
DM7HSCI	MN	Angiopoietin 1 receptor (TEK)
DM7HSCI	MT	DTT
DM7HSCI	MA	Inhibitor
DM7HSCI	RN	A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection. Bioorg Med Chem Lett. 2004 May 17;14(10):2613-6.
DM7HSCI	RU	https://pubmed.ncbi.nlm.nih.gov/15109663

DM7HSCI	DI	DM7HSCI
DM7HSCI	DN	A-420983
DM7HSCI	MI	TT860QF
DM7HSCI	MN	LCK tyrosine protein kinase (LCK)
DM7HSCI	MT	DTT
DM7HSCI	MA	Inhibitor
DM7HSCI	RN	A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection. Bioorg Med Chem Lett. 2004 May 17;14(10):2613-6.
DM7HSCI	RU	https://pubmed.ncbi.nlm.nih.gov/15109663

DM7HSCI	DI	DM7HSCI
DM7HSCI	DN	A-420983
DM7HSCI	MI	TT6PKBN
DM7HSCI	MN	Proto-oncogene c-Src (SRC)
DM7HSCI	MT	DTT
DM7HSCI	MA	Inhibitor
DM7HSCI	RN	A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection. Bioorg Med Chem Lett. 2004 May 17;14(10):2613-6.
DM7HSCI	RU	https://pubmed.ncbi.nlm.nih.gov/15109663

DMM5XD6	DI	DMM5XD6
DMM5XD6	DN	A-425444
DMM5XD6	MI	TTE0A2F
DMM5XD6	MN	Dopamine D4 receptor (D4R)
DMM5XD6	MT	DTT
DMM5XD6	MA	Inhibitor
DMM5XD6	RN	Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 ago... J Med Chem. 2006 Dec 14;49(25):7450-65.
DMM5XD6	RU	https://pubmed.ncbi.nlm.nih.gov/17149874

DMQHKIA	DI	DMQHKIA
DMQHKIA	DN	A-432411
DMQHKIA	MI	TTTU902
DMQHKIA	MN	Checkpoint kinase-1 (CHK1)
DMQHKIA	MT	DTT
DMQHKIA	MA	Inhibitor
DMQHKIA	RN	Synthesis of selenophene derivatives as novel CHK1 inhibitors. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5065-8.
DMQHKIA	RU	https://pubmed.ncbi.nlm.nih.gov/20674356

DMUBM8X	DI	DMUBM8X
DMUBM8X	DN	A438079
DMUBM8X	MI	TT473XN
DMUBM8X	MN	P2X purinoceptor 7 (P2RX7)
DMUBM8X	MT	DTT
DMUBM8X	MA	Antagonist
DMUBM8X	RN	Discovery of P2X7 receptor-selective antagonists offers new insights into P2X7 receptor function and indicates a role in chronic pain states. Br J Pharmacol. 2007 Jul;151(5):571-9.
DMUBM8X	RU	https://pubmed.ncbi.nlm.nih.gov/17471177

DMLMU63	DI	DMLMU63
DMLMU63	DN	A-443654
DMLMU63	MI	TTWTSCV
DMLMU63	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DMLMU63	MT	DTT
DMLMU63	MA	Inhibitor
DMLMU63	RN	Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension. J Med Chem. 2007 Jun 28;50(13):2990-3003.
DMLMU63	RU	https://pubmed.ncbi.nlm.nih.gov/17523610

DMN320E	DI	DMN320E
DMN320E	DN	A-558693
DMN320E	MI	TTG5QB7
DMN320E	MN	Calpain-2 (CAPN2)
DMN320E	MT	DTT
DMN320E	MA	Inhibitor
DMN320E	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2336).
DMN320E	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2336

DM7R8DJ	DI	DM7R8DJ
DM7R8DJ	DN	A-582941
DM7R8DJ	MI	TTLA931
DM7R8DJ	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DM7R8DJ	MT	DTT
DM7R8DJ	MA	Agonist
DM7R8DJ	RN	Broad-spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways. J Neurosci. 2007 Sep 26;27(39):10578-87.
DM7R8DJ	RU	https://pubmed.ncbi.nlm.nih.gov/17898229

DM7W2ME	DI	DM7W2ME
DM7W2ME	DN	A61603
DM7W2ME	MI	TT2NUT5
DM7W2ME	MN	Adrenergic receptor alpha-2C (ADRA2C)
DM7W2ME	MT	DTT
DM7W2ME	MA	Agonist
DM7W2ME	RN	A-61603, a potent alpha 1-adrenergic receptor agonist, selective for the alpha 1A receptor subtype. J Pharmacol Exp Ther. 1995 Jul;274(1):97-103.
DM7W2ME	RU	https://pubmed.ncbi.nlm.nih.gov/7616455

DM9SXDI	DI	DM9SXDI
DM9SXDI	DN	A-620223
DM9SXDI	MI	TTVDSZ0
DM9SXDI	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DM9SXDI	MT	DTT
DM9SXDI	MA	Inhibitor
DM9SXDI	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2771).
DM9SXDI	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2771

DMJ6IMZ	DI	DMJ6IMZ
DMJ6IMZ	DN	A-62824
DMJ6IMZ	MI	TTFK8YB
DMJ6IMZ	MN	Bacterial DNA topoisomerase 4A (Bact parC)
DMJ6IMZ	MT	DTT
DMJ6IMZ	MA	Inhibitor
DMJ6IMZ	RN	Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent anti... Bioorg Med Chem Lett. 2006 Mar 1;16(5):1272-6.
DMJ6IMZ	RU	https://pubmed.ncbi.nlm.nih.gov/16337791

DM5JSXI	DI	DM5JSXI
DM5JSXI	DN	A-641359
DM5JSXI	MI	TT860QF
DM5JSXI	MN	LCK tyrosine protein kinase (LCK)
DM5JSXI	MT	DTT
DM5JSXI	MA	Inhibitor
DM5JSXI	RN	Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection. Bioorg Med Chem Lett. 2006 Jan 1;16(1):118-22.
DM5JSXI	RU	https://pubmed.ncbi.nlm.nih.gov/16216497

DMJ83LK	DI	DMJ83LK
DMJ83LK	DN	A-674563
DMJ83LK	MI	TTWTSCV
DMJ83LK	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DMJ83LK	MT	DTT
DMJ83LK	MA	Inhibitor
DMJ83LK	RN	Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011 Oct 30;29(11):1046-51.
DMJ83LK	RU	https://pubmed.ncbi.nlm.nih.gov/22037378

DMT6A7G	DI	DMT6A7G
DMT6A7G	DN	A-690344
DMT6A7G	MI	TTEX248
DMT6A7G	MN	Dopamine D2 receptor (D2R)
DMT6A7G	MT	DTT
DMT6A7G	MA	Inhibitor
DMT6A7G	RN	Synthesis and SAR of highly potent and selective dopamine D(3)-receptor antagonists: 1H-pyrimidin-2-one derivatives. Bioorg Med Chem Lett. 2006 Feb;16(3):490-4.
DMT6A7G	RU	https://pubmed.ncbi.nlm.nih.gov/16290141

DMT6A7G	DI	DMT6A7G
DMT6A7G	DN	A-690344
DMT6A7G	MI	TT4C8EA
DMT6A7G	MN	Dopamine D3 receptor (D3R)
DMT6A7G	MT	DTT
DMT6A7G	MA	Inhibitor
DMT6A7G	RN	Synthesis and SAR of highly potent and selective dopamine D(3)-receptor antagonists: 1H-pyrimidin-2-one derivatives. Bioorg Med Chem Lett. 2006 Feb;16(3):490-4.
DMT6A7G	RU	https://pubmed.ncbi.nlm.nih.gov/16290141

DMXOPFU	DI	DMXOPFU
DMXOPFU	DN	A-706149
DMXOPFU	MI	TTEX248
DMXOPFU	MN	Dopamine D2 receptor (D2R)
DMXOPFU	MT	DTT
DMXOPFU	MA	Inhibitor
DMXOPFU	RN	Synthesis and SAR of highly potent and selective dopamine D(3)-receptor antagonists: Quinolin(di)one and benzazepin(di)one derivatives. herve.genes... Bioorg Med Chem Lett. 2006 Feb;16(3):658-62.
DMXOPFU	RU	https://pubmed.ncbi.nlm.nih.gov/16271293

DMXOPFU	DI	DMXOPFU
DMXOPFU	DN	A-706149
DMXOPFU	MI	TT4C8EA
DMXOPFU	MN	Dopamine D3 receptor (D3R)
DMXOPFU	MT	DTT
DMXOPFU	MA	Inhibitor
DMXOPFU	RN	Synthesis and SAR of highly potent and selective dopamine D(3)-receptor antagonists: Quinolin(di)one and benzazepin(di)one derivatives. herve.genes... Bioorg Med Chem Lett. 2006 Feb;16(3):658-62.
DMXOPFU	RU	https://pubmed.ncbi.nlm.nih.gov/16271293

DMI7J1L	DI	DMI7J1L
DMI7J1L	DN	A-740003
DMI7J1L	MI	TT473XN
DMI7J1L	MN	P2X purinoceptor 7 (P2RX7)
DMI7J1L	MT	DTT
DMI7J1L	MA	Inhibitor
DMI7J1L	RN	Purinergic P2X(7) receptor antagonists: Chemistry and fundamentals of biological screening. Bioorg Med Chem. 2009 Jul 15;17(14):4861-5.
DMI7J1L	RU	https://pubmed.ncbi.nlm.nih.gov/19540765

DMT9N1I	DI	DMT9N1I
DMT9N1I	DN	A-76341
DMT9N1I	MI	TT3C1VN
DMT9N1I	MN	Enzyme unspecific (Enz)
DMT9N1I	MT	DTT
DMT9N1I	MA	Modulator
DMT9N1I	RN	WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.
DMT9N1I	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20131212&CC=WO&NR=2013185032A1&KC=A1

DMP78JY	DI	DMP78JY
DMP78JY	DN	A-770041
DMP78JY	MI	TT860QF
DMP78JY	MN	LCK tyrosine protein kinase (LCK)
DMP78JY	MT	DTT
DMP78JY	MA	Inhibitor
DMP78JY	RN	Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection. Bioorg Med Chem Lett. 2006 Jan 1;16(1):118-22.
DMP78JY	RU	https://pubmed.ncbi.nlm.nih.gov/16216497

DMP78JY	DI	DMP78JY
DMP78JY	DN	A-770041
DMP78JY	MI	TT6PKBN
DMP78JY	MN	Proto-oncogene c-Src (SRC)
DMP78JY	MT	DTT
DMP78JY	MA	Inhibitor
DMP78JY	RN	Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection. Bioorg Med Chem Lett. 2006 Jan 1;16(1):118-22.
DMP78JY	RU	https://pubmed.ncbi.nlm.nih.gov/16216497

DMG6ZHO	DI	DMG6ZHO
DMG6ZHO	DN	A778317
DMG6ZHO	MI	TTMI6F5
DMG6ZHO	MN	Transient receptor potential cation channel V1 (TRPV1)
DMG6ZHO	MT	DTT
DMG6ZHO	MA	Blocker (channel blocker)
DMG6ZHO	RN	[3H]A-778317 [1-((R)-5-tert-butyl-indan-1-yl)-3-isoquinolin-5-yl-urea]: a novel, stereoselective, high-affinity antagonist is a useful radioligand ... J Pharmacol Exp Ther. 2007 Oct;323(1):285-93.
DMG6ZHO	RU	https://pubmed.ncbi.nlm.nih.gov/17660385

DM6BRTF	DI	DM6BRTF
DM6BRTF	DN	A-794278
DM6BRTF	MI	TTVBPDM
DM6BRTF	MN	Metabotropic glutamate receptor 1 (mGluR1)
DM6BRTF	MT	DTT
DM6BRTF	MA	Modulator (allosteric modulator)
DM6BRTF	RN	Structure-activity relationship of triazafluorenone derivatives as potent and selective mGluR1 antagonists. J Med Chem. 2005 Nov 17;48(23):7374-88.
DM6BRTF	RU	https://pubmed.ncbi.nlm.nih.gov/16279797

DMU965M	DI	DMU965M
DMU965M	DN	A-794282
DMU965M	MI	TTVBPDM
DMU965M	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMU965M	MT	DTT
DMU965M	MA	Modulator (allosteric modulator)
DMU965M	RN	Structure-activity relationship of triazafluorenone derivatives as potent and selective mGluR1 antagonists. J Med Chem. 2005 Nov 17;48(23):7374-88.
DMU965M	RU	https://pubmed.ncbi.nlm.nih.gov/16279797

DM2W4IQ	DI	DM2W4IQ
DM2W4IQ	DN	A-795614
DM2W4IQ	MI	TTMI6F5
DM2W4IQ	MN	Transient receptor potential cation channel V1 (TRPV1)
DM2W4IQ	MT	DTT
DM2W4IQ	MA	Inhibitor
DM2W4IQ	RN	Tetrahydropyridine-4-carboxamides as novel, potent transient receptor potential vanilloid 1 (TRPV1) antagonists. Bioorg Med Chem. 2008 Sep 15;16(18):8516-25.
DM2W4IQ	RU	https://pubmed.ncbi.nlm.nih.gov/18722778

DMHFPRJ	DI	DMHFPRJ
DMHFPRJ	DN	A-796260
DMHFPRJ	MI	TT6OEDT
DMHFPRJ	MN	Cannabinoid receptor 1 (CB1)
DMHFPRJ	MT	DTT
DMHFPRJ	MA	Inhibitor
DMHFPRJ	RN	Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity. J Med Chem. 2010 Jan 14;53(1):295-315.
DMHFPRJ	RU	https://pubmed.ncbi.nlm.nih.gov/19921781

DMHFPRJ	DI	DMHFPRJ
DMHFPRJ	DN	A-796260
DMHFPRJ	MI	TTMSFAW
DMHFPRJ	MN	Cannabinoid receptor 2 (CB2)
DMHFPRJ	MT	DTT
DMHFPRJ	MA	Inhibitor
DMHFPRJ	RN	Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity. J Med Chem. 2010 Jan 14;53(1):295-315.
DMHFPRJ	RU	https://pubmed.ncbi.nlm.nih.gov/19921781

DML20N9	DI	DML20N9
DML20N9	DN	A-80040
DML20N9	MI	TTY84UG
DML20N9	MN	Acetyl-CoA carboxylase 2 (ACACB)
DML20N9	MT	DTT
DML20N9	MA	Inhibitor
DML20N9	RN	Synthesis and structure-activity relationships of N-{3-[2-(4-alkoxyphenoxy)thiazol-5-yl]-1- methylprop-2-ynyl}carboxy derivatives as selective acet... J Med Chem. 2006 Jun 29;49(13):3770-3.
DML20N9	RU	https://pubmed.ncbi.nlm.nih.gov/16789734

DML20N9	DI	DML20N9
DML20N9	DN	A-80040
DML20N9	MI	TTYAWV0
DML20N9	MN	Plasmodium Acetyl-CoA carboxylase 1 (Malaria ACC1)
DML20N9	MT	DTT
DML20N9	MA	Inhibitor
DML20N9	RN	Synthesis and structure-activity relationships of N-{3-[2-(4-alkoxyphenoxy)thiazol-5-yl]-1- methylprop-2-ynyl}carboxy derivatives as selective acet... J Med Chem. 2006 Jun 29;49(13):3770-3.
DML20N9	RU	https://pubmed.ncbi.nlm.nih.gov/16789734

DMWGRL8	DI	DMWGRL8
DMWGRL8	DN	A-803467
DMWGRL8	MI	TT90XZ8
DMWGRL8	MN	Voltage-gated sodium channel alpha Nav1.8 (SCN10A)
DMWGRL8	MT	DTT
DMWGRL8	MA	Inhibitor
DMWGRL8	RN	Sensory neuron voltage-gated sodium channels as analgesic drug targets. Curr Opin Neurobiol. 2008 Aug;18(4):383-8.
DMWGRL8	RU	https://pubmed.ncbi.nlm.nih.gov/18824099

DMLC7HE	DI	DMLC7HE
DMLC7HE	DN	A804598
DMLC7HE	MI	TT473XN
DMLC7HE	MN	P2X purinoceptor 7 (P2RX7)
DMLC7HE	MT	DTT
DMLC7HE	MA	Antagonist
DMLC7HE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 484).
DMLC7HE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=484

DMQ5AJW	DI	DMQ5AJW
DMQ5AJW	DN	A-82186
DMQ5AJW	MI	TTGN1ZA
DMQ5AJW	MN	Angiotensin II receptor (AGTR)
DMQ5AJW	MT	DTT
DMQ5AJW	MA	Modulator
DMQ5AJW	RN	WO patent application no. 2011,0583,31, Pemirolast for the treatment of systemic low grade inflammation.
DMQ5AJW	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20110519&CC=WO&NR=2011058331A1&KC=A1

DMPXKOE	DI	DMPXKOE
DMPXKOE	DN	A839977
DMPXKOE	MI	TT473XN
DMPXKOE	MN	P2X purinoceptor 7 (P2RX7)
DMPXKOE	MT	DTT
DMPXKOE	MA	Antagonist
DMPXKOE	RN	The antihyperalgesic activity of a selective P2X7 receptor antagonist, A-839977, is lost in IL-1alphabeta knockout mice. Behav Brain Res. 2009 Dec 1;204(1):77-81.
DMPXKOE	RU	https://pubmed.ncbi.nlm.nih.gov/19464323

DM5TDEW	DI	DM5TDEW
DM5TDEW	DN	A-846714
DM5TDEW	MI	TTXJ178
DM5TDEW	MN	Histamine H4 receptor (H4R)
DM5TDEW	MT	DTT
DM5TDEW	MA	Inhibitor
DM5TDEW	RN	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and... J Med Chem. 2008 Oct 23;51(20):6547-57.
DM5TDEW	RU	https://pubmed.ncbi.nlm.nih.gov/18817367

DMJBPR3	DI	DMJBPR3
DMJBPR3	DN	A-849531
DMJBPR3	MI	TTN7BL9
DMJBPR3	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMJBPR3	MT	DTT
DMJBPR3	MA	Inhibitor
DMJBPR3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2763).
DMJBPR3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2763

DMJCPSD	DI	DMJCPSD
DMJCPSD	DN	A-850002
DMJCPSD	MI	TTVBPDM
DMJCPSD	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMJCPSD	MT	DTT
DMJCPSD	MA	Modulator (allosteric modulator)
DMJCPSD	RN	Structure-activity relationship of triazafluorenone derivatives as potent and selective mGluR1 antagonists. J Med Chem. 2005 Nov 17;48(23):7374-88.
DMJCPSD	RU	https://pubmed.ncbi.nlm.nih.gov/16279797

DM96F8U	DI	DM96F8U
DM96F8U	DN	A-867744
DM96F8U	MI	TTH18TF
DM96F8U	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DM96F8U	MT	DTT
DM96F8U	MA	Blocker (channel blocker)
DM96F8U	RN	In vitro pharmacological characterization of a novel allosteric modulator of alpha 7 neuronal acetylcholine receptor, 4-(5-(4-chlorophenyl)-2-methy... J Pharmacol Exp Ther. 2009 Jul;330(1):257-67.
DM96F8U	RU	https://pubmed.ncbi.nlm.nih.gov/19389923

DM96F8U	DI	DM96F8U
DM96F8U	DN	A-867744
DM96F8U	MI	TTLA931
DM96F8U	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DM96F8U	MT	DTT
DM96F8U	MA	Modulator (allosteric modulator)
DM96F8U	RN	In vitro pharmacological characterization of a novel allosteric modulator of alpha 7 neuronal acetylcholine receptor, 4-(5-(4-chlorophenyl)-2-methy... J Pharmacol Exp Ther. 2009 Jul;330(1):257-67.
DM96F8U	RU	https://pubmed.ncbi.nlm.nih.gov/19389923

DM96F8U	DI	DM96F8U
DM96F8U	DN	A-867744
DM96F8U	MI	TT5KPZR
DM96F8U	MN	Neuronal acetylcholine receptor beta-2 (CHRNB2)
DM96F8U	MT	DTT
DM96F8U	MA	Blocker (channel blocker)
DM96F8U	RN	In vitro pharmacological characterization of a novel allosteric modulator of alpha 7 neuronal acetylcholine receptor, 4-(5-(4-chlorophenyl)-2-methy... J Pharmacol Exp Ther. 2009 Jul;330(1):257-67.
DM96F8U	RU	https://pubmed.ncbi.nlm.nih.gov/19389923

DM8IWUE	DI	DM8IWUE
DM8IWUE	DN	A-887755
DM8IWUE	MI	TTE4KHA
DM8IWUE	MN	Amyloid beta A4 protein (APP)
DM8IWUE	MT	DTT
DM8IWUE	MA	Inhibitor
DM8IWUE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
DM8IWUE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402

DMBF1OY	DI	DMBF1OY
DMBF1OY	DN	A-935142
DMBF1OY	MI	TTQ6VDM
DMBF1OY	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMBF1OY	MT	DTT
DMBF1OY	MA	Activator
DMBF1OY	RN	Electrophysiologic characterization of a novel hERG channel activator. Biochem Pharmacol. 2009 Apr 15;77(8):1383-90.
DMBF1OY	RU	https://pubmed.ncbi.nlm.nih.gov/19426677

DMROD7Q	DI	DMROD7Q
DMROD7Q	DN	A-943931
DMROD7Q	MI	TTXJ178
DMROD7Q	MN	Histamine H4 receptor (H4R)
DMROD7Q	MT	DTT
DMROD7Q	MA	Inhibitor
DMROD7Q	RN	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and... J Med Chem. 2008 Oct 23;51(20):6547-57.
DMROD7Q	RU	https://pubmed.ncbi.nlm.nih.gov/18817367

DMOY7TF	DI	DMOY7TF
DMOY7TF	DN	A-967079
DMOY7TF	MI	TTELV3W
DMOY7TF	MN	Transformation-sensitive protein p120 (TRPA1)
DMOY7TF	MT	DTT
DMOY7TF	MA	Antagonist
DMOY7TF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 485).
DMOY7TF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=485

DMU34BK	DI	DMU34BK
DMU34BK	DN	A-987306
DMU34BK	MI	TTSQIFT
DMU34BK	MN	5-HT 1A receptor (HTR1A)
DMU34BK	MT	DTT
DMU34BK	MA	Inhibitor
DMU34BK	RN	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
DMU34BK	RU	https://pubmed.ncbi.nlm.nih.gov/18983139

DMU34BK	DI	DMU34BK
DMU34BK	DN	A-987306
DMU34BK	MI	TTK8CXU
DMU34BK	MN	5-HT 1B receptor (HTR1B)
DMU34BK	MT	DTT
DMU34BK	MA	Inhibitor
DMU34BK	RN	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
DMU34BK	RU	https://pubmed.ncbi.nlm.nih.gov/18983139

DMU34BK	DI	DMU34BK
DMU34BK	DN	A-987306
DMU34BK	MI	TTJQOD7
DMU34BK	MN	5-HT 2A receptor (HTR2A)
DMU34BK	MT	DTT
DMU34BK	MA	Inhibitor
DMU34BK	RN	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
DMU34BK	RU	https://pubmed.ncbi.nlm.nih.gov/18983139

DMU34BK	DI	DMU34BK
DMU34BK	DN	A-987306
DMU34BK	MI	TT0K1SC
DMU34BK	MN	5-HT 2B receptor (HTR2B)
DMU34BK	MT	DTT
DMU34BK	MA	Inhibitor
DMU34BK	RN	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
DMU34BK	RU	https://pubmed.ncbi.nlm.nih.gov/18983139

DMU34BK	DI	DMU34BK
DMU34BK	DN	A-987306
DMU34BK	MI	TTPC4TU
DMU34BK	MN	5-HT 3A receptor (HTR3A)
DMU34BK	MT	DTT
DMU34BK	MA	Inhibitor
DMU34BK	RN	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
DMU34BK	RU	https://pubmed.ncbi.nlm.nih.gov/18983139

DMU34BK	DI	DMU34BK
DMU34BK	DN	A-987306
DMU34BK	MI	TTK25J1
DMU34BK	MN	Adenosine A1 receptor (ADORA1)
DMU34BK	MT	DTT
DMU34BK	MA	Inhibitor
DMU34BK	RN	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
DMU34BK	RU	https://pubmed.ncbi.nlm.nih.gov/18983139

DMU34BK	DI	DMU34BK
DMU34BK	DN	A-987306
DMU34BK	MI	TTC24WT
DMU34BK	MN	C-C chemokine receptor type 1 (CCR1)
DMU34BK	MT	DTT
DMU34BK	MA	Inhibitor
DMU34BK	RN	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
DMU34BK	RU	https://pubmed.ncbi.nlm.nih.gov/18983139

DMU34BK	DI	DMU34BK
DMU34BK	DN	A-987306
DMU34BK	MI	TT4C8EA
DMU34BK	MN	Dopamine D3 receptor (D3R)
DMU34BK	MT	DTT
DMU34BK	MA	Inhibitor
DMU34BK	RN	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
DMU34BK	RU	https://pubmed.ncbi.nlm.nih.gov/18983139

DMU34BK	DI	DMU34BK
DMU34BK	DN	A-987306
DMU34BK	MI	TTZ9SOR
DMU34BK	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMU34BK	MT	DTT
DMU34BK	MA	Inhibitor
DMU34BK	RN	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
DMU34BK	RU	https://pubmed.ncbi.nlm.nih.gov/18983139

DMU34BK	DI	DMU34BK
DMU34BK	DN	A-987306
DMU34BK	MI	TTYEG6Q
DMU34BK	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMU34BK	MT	DTT
DMU34BK	MA	Inhibitor
DMU34BK	RN	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
DMU34BK	RU	https://pubmed.ncbi.nlm.nih.gov/18983139

DMU34BK	DI	DMU34BK
DMU34BK	DN	A-987306
DMU34BK	MI	TTQ13Z5
DMU34BK	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMU34BK	MT	DTT
DMU34BK	MA	Inhibitor
DMU34BK	RN	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
DMU34BK	RU	https://pubmed.ncbi.nlm.nih.gov/18983139

DMU34BK	DI	DMU34BK
DMU34BK	DN	A-987306
DMU34BK	MI	TTQ3JTF
DMU34BK	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DMU34BK	MT	DTT
DMU34BK	MA	Inhibitor
DMU34BK	RN	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
DMU34BK	RU	https://pubmed.ncbi.nlm.nih.gov/18983139

DMU34BK	DI	DMU34BK
DMU34BK	DN	A-987306
DMU34BK	MI	TTYO0A3
DMU34BK	MN	Substance-K receptor (TACR2)
DMU34BK	MT	DTT
DMU34BK	MA	Inhibitor
DMU34BK	RN	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
DMU34BK	RU	https://pubmed.ncbi.nlm.nih.gov/18983139

DMU34BK	DI	DMU34BK
DMU34BK	DN	A-987306
DMU34BK	MI	TT4TFGN
DMU34BK	MN	Vasopressin V1a receptor (V1AR)
DMU34BK	MT	DTT
DMU34BK	MA	Inhibitor
DMU34BK	RN	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
DMU34BK	RU	https://pubmed.ncbi.nlm.nih.gov/18983139

DME4ULA	DI	DME4ULA
DME4ULA	DN	A-993610
DME4ULA	MI	TTMI6F5
DME4ULA	MN	Transient receptor potential cation channel V1 (TRPV1)
DME4ULA	MT	DTT
DME4ULA	MA	Blocker
DME4ULA	RN	Analgesic potential of TRPV1 antagonists. Biochem Pharmacol. 2009 Aug 1;78(3):211-6.
DME4ULA	RU	https://pubmed.ncbi.nlm.nih.gov/19481638

DMW73A8	DI	DMW73A8
DMW73A8	DN	AA-123
DMW73A8	MI	TTGKF90
DMW73A8	MN	Bone morphogenetic protein receptor (BMPR2)
DMW73A8	MT	DTT
DMW73A8	MA	Agonist
DMW73A8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1794).
DMW73A8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1794

DM2BMAZ	DI	DM2BMAZ
DM2BMAZ	DN	AA-166
DM2BMAZ	MI	TTGKF90
DM2BMAZ	MN	Bone morphogenetic protein receptor (BMPR2)
DM2BMAZ	MT	DTT
DM2BMAZ	MA	Agonist
DM2BMAZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1794).
DM2BMAZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1794

DMCN4ZD	DI	DMCN4ZD
DMCN4ZD	DN	AA-184
DMCN4ZD	MI	TTGKF90
DMCN4ZD	MN	Bone morphogenetic protein receptor (BMPR2)
DMCN4ZD	MT	DTT
DMCN4ZD	MA	Agonist
DMCN4ZD	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1794).
DMCN4ZD	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1794

DMBGTX9	DI	DMBGTX9
DMBGTX9	DN	AA-204
DMBGTX9	MI	TTGKF90
DMBGTX9	MN	Bone morphogenetic protein receptor (BMPR2)
DMBGTX9	MT	DTT
DMBGTX9	MA	Agonist
DMBGTX9	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1794).
DMBGTX9	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1794

DMI59T7	DI	DMI59T7
DMI59T7	DN	AA-29504
DMI59T7	MI	TTEX6LM
DMI59T7	MN	GABA(A) receptor gamma-3 (GABRG3)
DMI59T7	MT	DTT
DMI59T7	MA	Modulator
DMI59T7	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415).
DMI59T7	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415

DMNO51B	DI	DMNO51B
DMNO51B	DN	AAE-M-PBP-amine
DMNO51B	MI	TT0WAIE
DMNO51B	MN	Melatonin receptor type 1A (MTNR1A)
DMNO51B	MT	DTT
DMNO51B	MA	Agonist
DMNO51B	RN	MT1-selective melatonin receptor ligands: synthesis, pharmacological evaluation, and molecular dynamics investigation of N-{[(3-O-substituted)anilino]alkyl}amides. ChemMedChem. 2012 Nov;7(11):1954-64.
DMNO51B	RU	https://pubmed.ncbi.nlm.nih.gov/22927210

DM35RFH	DI	DM35RFH
DM35RFH	DN	AAL-993
DM35RFH	MI	TTRLW2X
DM35RFH	MN	Fibroblast growth factor receptor 1 (FGFR1)
DM35RFH	MT	DTT
DM35RFH	MA	Inhibitor
DM35RFH	RN	Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93.
DM35RFH	RU	https://pubmed.ncbi.nlm.nih.gov/12477352

DM35RFH	DI	DM35RFH
DM35RFH	DN	AAL-993
DM35RFH	MI	TT2Q6G1
DM35RFH	MN	Vascular endothelial growth factor receptor 1 (FLT-1)
DM35RFH	MT	DTT
DM35RFH	MA	Inhibitor
DM35RFH	RN	Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93.
DM35RFH	RU	https://pubmed.ncbi.nlm.nih.gov/12477352

DM35RFH	DI	DM35RFH
DM35RFH	DN	AAL-993
DM35RFH	MI	TTUTJGQ
DM35RFH	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM35RFH	MT	DTT
DM35RFH	MA	Inhibitor
DM35RFH	RN	Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93.
DM35RFH	RU	https://pubmed.ncbi.nlm.nih.gov/12477352

DM35RFH	DI	DM35RFH
DM35RFH	DN	AAL-993
DM35RFH	MI	TT1VAUK
DM35RFH	MN	VEGFR1 messenger RNA (VEGFR1 mRNA)
DM35RFH	MT	DTT
DM35RFH	MA	Inhibitor
DM35RFH	RN	Inhibitors of VEGF receptors-1 and -2 based on the 2-((pyridin-4-yl)ethyl)pyridine template. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1913-9.
DM35RFH	RU	https://pubmed.ncbi.nlm.nih.gov/16460936

DMDBWT6	DI	DMDBWT6
DMDBWT6	DN	Abbott 14c
DMDBWT6	MI	TTWDC17
DMDBWT6	MN	Growth hormone secretagogue receptor 1 (GHSR)
DMDBWT6	MT	DTT
DMDBWT6	MA	Antagonist
DMDBWT6	RN	Discovery and pharmacological evaluation of growth hormone secretagogue receptor antagonists. J Med Chem. 2006 Jul 27;49(15):4459-69.
DMDBWT6	RU	https://pubmed.ncbi.nlm.nih.gov/16854051

DMHRPAM	DI	DMHRPAM
DMHRPAM	DN	ABBV-744
DMHRPAM	MI	TTNISW6
DMHRPAM	MN	HUMAN bromodomain-containing protein 2 (BRD2)
DMHRPAM	MT	DTT
DMHRPAM	MA	Inhibitor
DMHRPAM	RN	Uncovering the Role of BRD2 in COVID-19. 2020-03-19
DMHRPAM	RU	https://www.caymanchem.com/news/uncovering-the-role-of-brd2-in-covid-19

DMA01OF	DI	DMA01OF
DMA01OF	DN	ABC-4
DMA01OF	MI	TT5BR7T
DMA01OF	MN	Fibroblast growth factor receptor 4 (FGFR4)
DMA01OF	MT	DTT
DMA01OF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1811).
DMA01OF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1811

DM2AIE9	DI	DM2AIE9
DM2AIE9	DN	ABC-7
DM2AIE9	MI	TTBQ3OC
DM2AIE9	MN	Macrophage-stimulating protein receptor (RON)
DM2AIE9	MT	DTT
DM2AIE9	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1816).
DM2AIE9	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1816

DMW1Y2G	DI	DMW1Y2G
DMW1Y2G	DN	Abietic acid
DMW1Y2G	MI	TTN7BL9
DMW1Y2G	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMW1Y2G	MT	DTT
DMW1Y2G	MA	Inhibitor
DMW1Y2G	RN	A rapid screening assay for inhibitors of 11beta-hydroxysteroid dehydrogenases (11beta-HSD): flavanone selectively inhibits 11beta-HSD1 reductase activity. Mol Cell Endocrinol. 2003 Dec 30;212(1-2):41-9.
DMW1Y2G	RU	https://pubmed.ncbi.nlm.nih.gov/14654249

DM0LUOM	DI	DM0LUOM
DM0LUOM	DN	ABIO 09-01
DM0LUOM	MI	TTFYL58
DM0LUOM	MN	CaM-kinase II (CAMK2)
DM0LUOM	MT	DTT
DM0LUOM	MA	Inhibitor
DM0LUOM	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1558).
DM0LUOM	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1558

DMRC3A5	DI	DMRC3A5
DMRC3A5	DN	ABL127
DMRC3A5	MI	TTXQ54R
DMRC3A5	MN	Protein phosphatase methylesterase 1 (PME-1)
DMRC3A5	MT	DTT
DMRC3A5	MA	Inhibitor
DMRC3A5	RN	A high-throughput, multiplexed assay for superfamily-wide profiling of enzyme activity. Nat Chem Biol. 2014 Aug;10(8):656-63.
DMRC3A5	RU	https://pubmed.ncbi.nlm.nih.gov/24997602

DMKN10X	DI	DMKN10X
DMKN10X	DN	Abloid
DMKN10X	MI	TTE4KHA
DMKN10X	MN	Amyloid beta A4 protein (APP)
DMKN10X	MT	DTT
DMKN10X	MA	Inhibitor
DMKN10X	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
DMKN10X	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402

DMQPHFU	DI	DMQPHFU
DMQPHFU	DN	AB-MECA
DMQPHFU	MI	TTNE7KG
DMQPHFU	MN	Adenosine A2b receptor (ADORA2B)
DMQPHFU	MT	DTT
DMQPHFU	MA	Agonist
DMQPHFU	RN	Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 1998 Jan;357(1):1-9.
DMQPHFU	RU	https://pubmed.ncbi.nlm.nih.gov/9459566

DMQPHFU	DI	DMQPHFU
DMQPHFU	DN	AB-MECA
DMQPHFU	MI	TTJFY5U
DMQPHFU	MN	Adenosine A3 receptor (ADORA3)
DMQPHFU	MT	DTT
DMQPHFU	MA	Agonist
DMQPHFU	RN	[(3)H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors. Mol Pharmacol. 2000 May;57(5):968-75.
DMQPHFU	RU	https://pubmed.ncbi.nlm.nih.gov/10779381

DME8G7F	DI	DME8G7F
DME8G7F	DN	AB-NECA
DME8G7F	MI	TTNE7KG
DME8G7F	MN	Adenosine A2b receptor (ADORA2B)
DME8G7F	MT	DTT
DME8G7F	MA	Agonist
DME8G7F	RN	Characterization of human A(2B) adenosine receptors: radioligand binding, western blotting, and coupling to G(q) in human embryonic kidney 293 cells and HMC-1 mast cells. Mol Pharmacol. 1999 Oct;56(4):705-13.
DME8G7F	RU	https://pubmed.ncbi.nlm.nih.gov/10496952

DMV6DAO	DI	DMV6DAO
DMV6DAO	DN	abnormal cannabidiol
DMV6DAO	MI	TTNET8J
DMV6DAO	MN	G-protein coupled receptor 55 (GPR55)
DMV6DAO	MT	DTT
DMV6DAO	MA	Agonist
DMV6DAO	RN	The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007 Dec;152(7):1092-101.
DMV6DAO	RU	https://pubmed.ncbi.nlm.nih.gov/17876302

DMV6DAO	DI	DMV6DAO
DMV6DAO	DN	abnormal cannabidiol
DMV6DAO	MI	TTSLJAR
DMV6DAO	MN	N-arachidonyl glycine receptor (GPR18)
DMV6DAO	MT	DTT
DMV6DAO	MA	Agonist
DMV6DAO	RN	Delta(9) -Tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells. Br J Pharmacol. 2012 Apr;165(8):2414-24.
DMV6DAO	RU	https://pubmed.ncbi.nlm.nih.gov/21595653

DMJ6MUE	DI	DMJ6MUE
DMJ6MUE	DN	ABT-116
DMJ6MUE	MI	TTMI6F5
DMJ6MUE	MN	Transient receptor potential cation channel V1 (TRPV1)
DMJ6MUE	MT	DTT
DMJ6MUE	MA	Antagonist
DMJ6MUE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 507).
DMJ6MUE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=507

DMZ3YTO	DI	DMZ3YTO
DMZ3YTO	DN	ABT-341
DMZ3YTO	MI	TTDIGC1
DMZ3YTO	MN	Dipeptidyl peptidase 4 (DPP-4)
DMZ3YTO	MT	DTT
DMZ3YTO	MA	Inhibitor
DMZ3YTO	RN	Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)... J Med Chem. 2006 Nov 2;49(22):6439-42.
DMZ3YTO	RU	https://pubmed.ncbi.nlm.nih.gov/17064063

DM6J57N	DI	DM6J57N
DM6J57N	DN	ABT-670
DM6J57N	MI	TTE0A2F
DM6J57N	MN	Dopamine D4 receptor (D4R)
DM6J57N	MT	DTT
DM6J57N	MA	Inhibitor
DM6J57N	RN	Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 ago... J Med Chem. 2006 Dec 14;49(25):7450-65.
DM6J57N	RU	https://pubmed.ncbi.nlm.nih.gov/17149874

DM79DSN	DI	DM79DSN
DM79DSN	DN	ABTAA
DM79DSN	MI	TT9VGXW
DM79DSN	MN	Angiopoietin 1 receptor (TEK)
DM79DSN	MT	DTT
DM79DSN	MA	Activator
DM79DSN	RN	Amelioration of sepsis by TIE2 activation-induced vascular protection. Sci Transl Med. 2016 Apr 20;8(335):335ra55.
DM79DSN	RU	https://pubmed.ncbi.nlm.nih.gov/27099174

DM79DSN	DI	DM79DSN
DM79DSN	DN	ABTAA
DM79DSN	MI	TTKLQTJ
DM79DSN	MN	Angiopoietin-2 (ANGPT2)
DM79DSN	MT	DTT
DM79DSN	MA	Binder
DM79DSN	RN	Amelioration of sepsis by TIE2 activation-induced vascular protection. Sci Transl Med. 2016 Apr 20;8(335):335ra55.
DM79DSN	RU	https://pubmed.ncbi.nlm.nih.gov/27099174

DMC02FP	DI	DMC02FP
DMC02FP	DN	Abyssinin I
DMC02FP	MI	TTELIN2
DMC02FP	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMC02FP	MT	DTT
DMC02FP	MA	Inhibitor
DMC02FP	RN	Isoprenylated flavonoids from the stem bark of Erythrina abyssinica. J Nat Prod. 2007 Jun;70(6):1039-42.
DMC02FP	RU	https://pubmed.ncbi.nlm.nih.gov/17489632

DMR7IGZ	DI	DMR7IGZ
DMR7IGZ	DN	Abyssinin II
DMR7IGZ	MI	TTELIN2
DMR7IGZ	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMR7IGZ	MT	DTT
DMR7IGZ	MA	Inhibitor
DMR7IGZ	RN	Isoprenylated flavonoids from the stem bark of Erythrina abyssinica. J Nat Prod. 2007 Jun;70(6):1039-42.
DMR7IGZ	RU	https://pubmed.ncbi.nlm.nih.gov/17489632

DMEYQF9	DI	DMEYQF9
DMEYQF9	DN	Abyssinoflavanone VI
DMEYQF9	MI	TTELIN2
DMEYQF9	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMEYQF9	MT	DTT
DMEYQF9	MA	Inhibitor
DMEYQF9	RN	Isoprenylated flavonoids from the stem bark of Erythrina abyssinica. J Nat Prod. 2007 Jun;70(6):1039-42.
DMEYQF9	RU	https://pubmed.ncbi.nlm.nih.gov/17489632

DMTVQSL	DI	DMTVQSL
DMTVQSL	DN	Abyssinoflavanone VII
DMTVQSL	MI	TTELIN2
DMTVQSL	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMTVQSL	MT	DTT
DMTVQSL	MA	Inhibitor
DMTVQSL	RN	Isoprenylated flavonoids from the stem bark of Erythrina abyssinica. J Nat Prod. 2007 Jun;70(6):1039-42.
DMTVQSL	RU	https://pubmed.ncbi.nlm.nih.gov/17489632

DMH3CK2	DI	DMH3CK2
DMH3CK2	DN	ABYSSINONE V
DMH3CK2	MI	TT9V5JH
DMH3CK2	MN	Phospholipase A2 (PLA2G1B)
DMH3CK2	MT	DTT
DMH3CK2	MA	Inhibitor
DMH3CK2	RN	Phospholipase A2 Inhibitors from an Erythrina Species from Samoa J. Nat. Prod. 60(6):537-539 (1997).
DMH3CK2	RU	http://pubs.acs.org/doi/abs/10.1021/np960533e

DM9YAVX	DI	DM9YAVX
DM9YAVX	DN	Abyssinone-IV
DM9YAVX	MI	TTELIN2
DM9YAVX	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DM9YAVX	MT	DTT
DM9YAVX	MA	Inhibitor
DM9YAVX	RN	Protein tyrosine phosphatase-1B inhibitory activity of isoprenylated flavonoids isolated from Erythrina mildbraedii. J Nat Prod. 2006 Nov;69(11):1572-6.
DM9YAVX	RU	https://pubmed.ncbi.nlm.nih.gov/17125223

DMZUY93	DI	DMZUY93
DMZUY93	DN	Abyssinone-VI-4-O-methyl ether
DMZUY93	MI	TTELIN2
DMZUY93	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMZUY93	MT	DTT
DMZUY93	MA	Inhibitor
DMZUY93	RN	Protein tyrosine phosphatase-1B inhibitory activity of isoprenylated flavonoids isolated from Erythrina mildbraedii. J Nat Prod. 2006 Nov;69(11):1572-6.
DMZUY93	RU	https://pubmed.ncbi.nlm.nih.gov/17125223

DMZ0RP5	DI	DMZ0RP5
DMZ0RP5	DN	AC-(D)PHE-PRO-BOROHOMOLYS-OH
DMZ0RP5	MI	TT6L509
DMZ0RP5	MN	Coagulation factor IIa (F2)
DMZ0RP5	MT	DTT
DMZ0RP5	MA	Inhibitor
DMZ0RP5	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMZ0RP5	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMPHV7K	DI	DMPHV7K
DMPHV7K	DN	AC-(D)PHE-PRO-BOROHOMOORNITHINE-OH
DMPHV7K	MI	TT6L509
DMPHV7K	MN	Coagulation factor IIa (F2)
DMPHV7K	MT	DTT
DMPHV7K	MA	Inhibitor
DMPHV7K	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMPHV7K	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM2YWRL	DI	DM2YWRL
DM2YWRL	DN	AC-(D)PHE-PRO-BOROLYS-OH
DM2YWRL	MI	TT6L509
DM2YWRL	MN	Coagulation factor IIa (F2)
DM2YWRL	MT	DTT
DM2YWRL	MA	Inhibitor
DM2YWRL	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM2YWRL	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMRLOGP	DI	DMRLOGP
DMRLOGP	DN	Ac-[CEHdFRWC]-NH2
DMRLOGP	MI	TT0MV2T
DMRLOGP	MN	Melanocortin receptor 1 (MC1R)
DMRLOGP	MT	DTT
DMRLOGP	MA	Inhibitor
DMRLOGP	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMRLOGP	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMRLOGP	DI	DMRLOGP
DMRLOGP	DN	Ac-[CEHdFRWC]-NH2
DMRLOGP	MI	TTNI91K
DMRLOGP	MN	Melanocortin receptor 3 (MC3R)
DMRLOGP	MT	DTT
DMRLOGP	MA	Inhibitor
DMRLOGP	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMRLOGP	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMRLOGP	DI	DMRLOGP
DMRLOGP	DN	Ac-[CEHdFRWC]-NH2
DMRLOGP	MI	TTD0CIQ
DMRLOGP	MN	Melanocortin receptor 4 (MC4R)
DMRLOGP	MT	DTT
DMRLOGP	MA	Inhibitor
DMRLOGP	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMRLOGP	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DM9IN4T	DI	DM9IN4T
DM9IN4T	DN	Ac-[CFWKFC]-NH2
DM9IN4T	MI	TTW5UDX
DM9IN4T	MN	Urotensin II receptor (UTS2R)
DM9IN4T	MT	DTT
DM9IN4T	MA	Inhibitor
DM9IN4T	RN	Urotensin-II receptor modulators as potential drugs. J Med Chem. 2010 Apr 8;53(7):2695-708.
DM9IN4T	RU	https://pubmed.ncbi.nlm.nih.gov/20043680

DMW24UH	DI	DMW24UH
DMW24UH	DN	Ac-[CFWkYC]-NH2
DMW24UH	MI	TTW5UDX
DMW24UH	MN	Urotensin II receptor (UTS2R)
DMW24UH	MT	DTT
DMW24UH	MA	Inhibitor
DMW24UH	RN	Urotensin-II receptor modulators as potential drugs. J Med Chem. 2010 Apr 8;53(7):2695-708.
DMW24UH	RU	https://pubmed.ncbi.nlm.nih.gov/20043680

DMFKV97	DI	DMFKV97
DMFKV97	DN	AC1LG8KT
DMFKV97	MI	TT3IVG2
DMFKV97	MN	JNK2 messenger RNA (JNK2 mRNA)
DMFKV97	MT	DTT
DMFKV97	MA	Inhibitor
DMFKV97	RN	N-(3-Cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amides as potent, selective, inhibitors of JNK2 and JNK3. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1296-301.
DMFKV97	RU	https://pubmed.ncbi.nlm.nih.gov/17194588

DMFKV97	DI	DMFKV97
DMFKV97	DN	AC1LG8KT
DMFKV97	MI	TT056SO
DMFKV97	MN	Stress-activated protein kinase JNK3 (JNK3)
DMFKV97	MT	DTT
DMFKV97	MA	Inhibitor
DMFKV97	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1498).
DMFKV97	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1498

DMSKE1I	DI	DMSKE1I
DMSKE1I	DN	AC261066
DMSKE1I	MI	TTISP28
DMSKE1I	MN	Retinoic acid receptor beta (RARB)
DMSKE1I	MT	DTT
DMSKE1I	MA	Agonist
DMSKE1I	RN	Discovery of a potent, orally available, and isoform-selective retinoic acid beta2 receptor agonist. J Med Chem. 2005 Dec 1;48(24):7517-9.
DMSKE1I	RU	https://pubmed.ncbi.nlm.nih.gov/16302793

DM4G60V	DI	DM4G60V
DM4G60V	DN	AC265347
DM4G60V	MI	TTBUYHA
DM4G60V	MN	Extracellular calcium-sensing receptor (CASR)
DM4G60V	MT	DTT
DM4G60V	MA	Modulator (allosteric modulator)
DM4G60V	RN	Characterization of highly efficacious allosteric agonists of the human calcium-sensing receptor. J Pharmacol Exp Ther. 2011 Apr;337(1):275-84.
DM4G60V	RU	https://pubmed.ncbi.nlm.nih.gov/21239511

DMNUE4H	DI	DMNUE4H
DMNUE4H	DN	AC-3174
DMNUE4H	MI	TTVIMDE
DMNUE4H	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMNUE4H	MT	DTT
DMNUE4H	MA	Agonist
DMNUE4H	RN	2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006).
DMNUE4H	RU	http://www.nature.com/nrd/journal/v11/n1/full/nrd3645.html

DM4JNY9	DI	DM4JNY9
DM4JNY9	DN	AC55649
DM4JNY9	MI	TTISP28
DM4JNY9	MN	Retinoic acid receptor beta (RARB)
DM4JNY9	MT	DTT
DM4JNY9	MA	Agonist
DM4JNY9	RN	Discovery of a potent, orally available, and isoform-selective retinoic acid beta2 receptor agonist. J Med Chem. 2005 Dec 1;48(24):7517-9.
DM4JNY9	RU	https://pubmed.ncbi.nlm.nih.gov/16302793

DMXS72J	DI	DMXS72J
DMXS72J	DN	AC-710
DMXS72J	MI	TTC70AJ
DMXS72J	MN	Granulocyte colony-stimulating factor receptor (G-CSF-R)
DMXS72J	MT	DTT
DMXS72J	MA	Inhibitor
DMXS72J	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1719).
DMXS72J	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1719

DM367MF	DI	DM367MF
DM367MF	DN	AC-7954
DM367MF	MI	TTW5UDX
DM367MF	MN	Urotensin II receptor (UTS2R)
DM367MF	MT	DTT
DM367MF	MA	Agonist
DM367MF	RN	Isochromanone-based urotensin-II receptor agonists. Bioorg Med Chem. 2005 Apr 15;13(8):3057-68.
DM367MF	RU	https://pubmed.ncbi.nlm.nih.gov/15781415

DM09BJ4	DI	DM09BJ4
DM09BJ4	DN	AC-8632
DM09BJ4	MI	TTY84UG
DM09BJ4	MN	Acetyl-CoA carboxylase 2 (ACACB)
DM09BJ4	MT	DTT
DM09BJ4	MA	Inhibitor
DM09BJ4	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1264).
DM09BJ4	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1264

DM09BJ4	DI	DM09BJ4
DM09BJ4	DN	AC-8632
DM09BJ4	MI	TTYAWV0
DM09BJ4	MN	Plasmodium Acetyl-CoA carboxylase 1 (Malaria ACC1)
DM09BJ4	MT	DTT
DM09BJ4	MA	Inhibitor
DM09BJ4	RN	Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science. 2000 Jun 30;288(5475):2379-81.
DM09BJ4	RU	https://pubmed.ncbi.nlm.nih.gov/10875926

DMACYPW	DI	DMACYPW
DMACYPW	DN	ACAA
DMACYPW	MI	TTEBMN7
DMACYPW	MN	Long transient receptor potential channel 2 (TRPM2)
DMACYPW	MT	DTT
DMACYPW	MA	Blocker (channel blocker)
DMACYPW	RN	Inhibition of TRPM2 cation channels by N-(p-amylcinnamoyl)anthranilic acid. Br J Pharmacol. 2006 Jun;148(3):264-73.
DMACYPW	RU	https://pubmed.ncbi.nlm.nih.gov/16604090

DMACYPW	DI	DMACYPW
DMACYPW	DN	ACAA
DMACYPW	MI	TTXDKTO
DMACYPW	MN	Long transient receptor potential channel 8 (TRPM8)
DMACYPW	MT	DTT
DMACYPW	MA	Blocker (channel blocker)
DMACYPW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 500).
DMACYPW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=500

DMACYPW	DI	DMACYPW
DMACYPW	DN	ACAA
DMACYPW	MI	TTNVC34
DMACYPW	MN	Short transient receptor potential channel 3 (TRPC3)
DMACYPW	MT	DTT
DMACYPW	MA	Blocker (channel blocker)
DMACYPW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 488).
DMACYPW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=488

DMACYPW	DI	DMACYPW
DMACYPW	DN	ACAA
DMACYPW	MI	TTRBT3W
DMACYPW	MN	Short transient receptor potential channel 6 (TRPC6)
DMACYPW	MT	DTT
DMACYPW	MA	Blocker (channel blocker)
DMACYPW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 491).
DMACYPW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=491

DMQOB0X	DI	DMQOB0X
DMQOB0X	DN	Acacetin
DMQOB0X	MI	TT2J34L
DMQOB0X	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMQOB0X	MT	DTT
DMQOB0X	MA	Inhibitor
DMQOB0X	RN	Novel and known constituents from Buddleja species and their activity against leukocyte eicosanoid generation. J Nat Prod. 1999 Sep;62(9):1241-5.
DMQOB0X	RU	https://pubmed.ncbi.nlm.nih.gov/10514305

DMQOB0X	DI	DMQOB0X
DMQOB0X	DN	Acacetin
DMQOB0X	MI	TTI84H7
DMQOB0X	MN	Cytochrome P450 1B1 (CYP1B1)
DMQOB0X	MT	DTT
DMQOB0X	MA	Inhibitor
DMQOB0X	RN	Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5.
DMQOB0X	RU	https://pubmed.ncbi.nlm.nih.gov/20696580

DMQOB0X	DI	DMQOB0X
DMQOB0X	DN	Acacetin
DMQOB0X	MI	TT7RJY8
DMQOB0X	MN	Xanthine dehydrogenase/oxidase (XDH)
DMQOB0X	MT	DTT
DMQOB0X	MA	Inhibitor
DMQOB0X	RN	Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod. 1988 Mar-Apr;51(2):345-8.
DMQOB0X	RU	https://pubmed.ncbi.nlm.nih.gov/3379415

DMJ3C20	DI	DMJ3C20
DMJ3C20	DN	Ac-Ala-Pro-Val-(2-benzoxazole)
DMJ3C20	MI	TTPLTSQ
DMJ3C20	MN	Neutrophil elastase (NE)
DMJ3C20	MT	DTT
DMJ3C20	MA	Inhibitor
DMJ3C20	RN	Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. Bioorg Med Chem. 2008 Feb 15;16(4):1562-95.
DMJ3C20	RU	https://pubmed.ncbi.nlm.nih.gov/18053726

DMZDFRI	DI	DMZDFRI
DMZDFRI	DN	Acanthus ilicifolius Linn
DMZDFRI	MI	TT2J34L
DMZDFRI	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMZDFRI	MT	DTT
DMZDFRI	MA	Inhibitor
DMZDFRI	RN	Anti-inflammatory activity of Acanthus ilicifolius. J Ethnopharmacol. 2008 Oct 30;120(1):7-12.
DMZDFRI	RU	https://pubmed.ncbi.nlm.nih.gov/18703126

DMZDFRI	DI	DMZDFRI
DMZDFRI	DN	Acanthus ilicifolius Linn
DMZDFRI	MI	TTCGSZ4
DMZDFRI	MN	Pancreatic alpha-amylase (AMY2A)
DMZDFRI	MT	DTT
DMZDFRI	MA	Inhibitor
DMZDFRI	RN	Four acarviosin-containing oligosaccharides identified from Streptomyces coelicoflavus ZG0656 are potent inhibitors of alpha-amylase. Carbohydr Res. 2008 Apr 7;343(5):882-92.
DMZDFRI	RU	https://pubmed.ncbi.nlm.nih.gov/18294624

DMS9COH	DI	DMS9COH
DMS9COH	DN	Acarbose Derived Hexasaccharide
DMS9COH	MI	TTCGSZ4
DMS9COH	MN	Pancreatic alpha-amylase (AMY2A)
DMS9COH	MT	DTT
DMS9COH	MA	Inhibitor
DMS9COH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMS9COH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMYHADT	DI	DMYHADT
DMYHADT	DN	Ac-Asp-Arg-Leu-Asp-Ser-OH
DMYHADT	MI	TTT1R2L
DMYHADT	MN	Integrin alpha-V (ITGAV)
DMYHADT	MT	DTT
DMYHADT	MA	Inhibitor
DMYHADT	RN	Synthesis and biological evaluation of non-peptide alpha(v)beta(3)/alpha(5)beta(1) integrin dual antagonists containing 5,6-dihydropyridin-2-one sc... Bioorg Med Chem. 2007 Dec 1;15(23):7380-90.
DMYHADT	RU	https://pubmed.ncbi.nlm.nih.gov/17869121

DMYHADT	DI	DMYHADT
DMYHADT	DN	Ac-Asp-Arg-Leu-Asp-Ser-OH
DMYHADT	MI	TTJA1ZO
DMYHADT	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMYHADT	MT	DTT
DMYHADT	MA	Inhibitor
DMYHADT	RN	Synthesis and biological evaluation of non-peptide alpha(v)beta(3)/alpha(5)beta(1) integrin dual antagonists containing 5,6-dihydropyridin-2-one sc... Bioorg Med Chem. 2007 Dec 1;15(23):7380-90.
DMYHADT	RU	https://pubmed.ncbi.nlm.nih.gov/17869121

DMT74F5	DI	DMT74F5
DMT74F5	DN	AcAsp-D-Gla-Leu-Ile-Cha-Cys
DMT74F5	MI	TTWXB3E
DMT74F5	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DMT74F5	MT	DTT
DMT74F5	MA	Inhibitor
DMT74F5	RN	Control of hepatitis C: a medicinal chemistry perspective. J Med Chem. 2005 Jan 13;48(1):1-20.
DMT74F5	RU	https://pubmed.ncbi.nlm.nih.gov/15633995

DMDC71B	DI	DMDC71B
DMDC71B	DN	AcAsp-D-Glu-Leu-Glu-Cha-Cys
DMDC71B	MI	TTWXB3E
DMDC71B	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DMDC71B	MT	DTT
DMDC71B	MA	Inhibitor
DMDC71B	RN	Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain. Bioorg Med Chem Lett. 2001 Jan 22;11(2):203-6.
DMDC71B	RU	https://pubmed.ncbi.nlm.nih.gov/11206459

DMXQATR	DI	DMXQATR
DMXQATR	DN	AcAsp-Gla-Leu-Ile-Cha-Cys
DMXQATR	MI	TTWXB3E
DMXQATR	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DMXQATR	MT	DTT
DMXQATR	MA	Inhibitor
DMXQATR	RN	Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain. Bioorg Med Chem Lett. 2001 Jan 22;11(2):203-6.
DMXQATR	RU	https://pubmed.ncbi.nlm.nih.gov/11206459

DMHZ5W3	DI	DMHZ5W3
DMHZ5W3	DN	AcAsp-Glu-Cha-Val-Prb-Cpg
DMHZ5W3	MI	TTWXB3E
DMHZ5W3	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DMHZ5W3	MT	DTT
DMHZ5W3	MA	Inhibitor
DMHZ5W3	RN	Control of hepatitis C: a medicinal chemistry perspective. J Med Chem. 2005 Jan 13;48(1):1-20.
DMHZ5W3	RU	https://pubmed.ncbi.nlm.nih.gov/15633995

DMDH5EJ	DI	DMDH5EJ
DMDH5EJ	DN	AcAsp-Glu-Cha-Val-Prb-Cys
DMDH5EJ	MI	TTWXB3E
DMDH5EJ	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DMDH5EJ	MT	DTT
DMDH5EJ	MA	Inhibitor
DMDH5EJ	RN	Control of hepatitis C: a medicinal chemistry perspective. J Med Chem. 2005 Jan 13;48(1):1-20.
DMDH5EJ	RU	https://pubmed.ncbi.nlm.nih.gov/15633995

DMEB8UA	DI	DMEB8UA
DMEB8UA	DN	AcAsp-Glu-Dif-Glu-Cha-Cys
DMEB8UA	MI	TTWXB3E
DMEB8UA	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DMEB8UA	MT	DTT
DMEB8UA	MA	Inhibitor
DMEB8UA	RN	Control of hepatitis C: a medicinal chemistry perspective. J Med Chem. 2005 Jan 13;48(1):1-20.
DMEB8UA	RU	https://pubmed.ncbi.nlm.nih.gov/15633995

DMPQ8Z9	DI	DMPQ8Z9
DMPQ8Z9	DN	AcAsp-Glu-Dif-Glu-Cha-Fab
DMPQ8Z9	MI	TTWXB3E
DMPQ8Z9	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DMPQ8Z9	MT	DTT
DMPQ8Z9	MA	Inhibitor
DMPQ8Z9	RN	Control of hepatitis C: a medicinal chemistry perspective. J Med Chem. 2005 Jan 13;48(1):1-20.
DMPQ8Z9	RU	https://pubmed.ncbi.nlm.nih.gov/15633995

DM6IP17	DI	DM6IP17
DM6IP17	DN	AcAsp-Glu-Dif-Ile-Cha-Cys
DM6IP17	MI	TTWXB3E
DM6IP17	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DM6IP17	MT	DTT
DM6IP17	MA	Inhibitor
DM6IP17	RN	Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain. Bioorg Med Chem Lett. 2001 Jan 22;11(2):203-6.
DM6IP17	RU	https://pubmed.ncbi.nlm.nih.gov/11206459

DM3W68X	DI	DM3W68X
DM3W68X	DN	AcAsp-Glu-Dif-Ile-Cha-Cys-Iqc-Nle-Thr-TyrNH2
DM3W68X	MI	TTWXB3E
DM3W68X	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DM3W68X	MT	DTT
DM3W68X	MA	Inhibitor
DM3W68X	RN	Control of hepatitis C: a medicinal chemistry perspective. J Med Chem. 2005 Jan 13;48(1):1-20.
DM3W68X	RU	https://pubmed.ncbi.nlm.nih.gov/15633995

DMCIJ6Q	DI	DMCIJ6Q
DMCIJ6Q	DN	AcAsp-Glu-Dif-Ile-Cha-Cys-Pro-Cha-Asp-ValNH2
DMCIJ6Q	MI	TTWXB3E
DMCIJ6Q	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DMCIJ6Q	MT	DTT
DMCIJ6Q	MA	Inhibitor
DMCIJ6Q	RN	Control of hepatitis C: a medicinal chemistry perspective. J Med Chem. 2005 Jan 13;48(1):1-20.
DMCIJ6Q	RU	https://pubmed.ncbi.nlm.nih.gov/15633995

DMA7ZSY	DI	DMA7ZSY
DMA7ZSY	DN	AcAsp-Glu-Dif-Ile-Cha-Cys-Pro-Nle-Asp-ValNH2
DMA7ZSY	MI	TTWXB3E
DMA7ZSY	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DMA7ZSY	MT	DTT
DMA7ZSY	MA	Inhibitor
DMA7ZSY	RN	Control of hepatitis C: a medicinal chemistry perspective. J Med Chem. 2005 Jan 13;48(1):1-20.
DMA7ZSY	RU	https://pubmed.ncbi.nlm.nih.gov/15633995

DM6PZ45	DI	DM6PZ45
DM6PZ45	DN	AcAsp-Glu-Dif-Lys-Cha-Cys
DM6PZ45	MI	TTWXB3E
DM6PZ45	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DM6PZ45	MT	DTT
DM6PZ45	MA	Inhibitor
DM6PZ45	RN	Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain. Bioorg Med Chem Lett. 2001 Jan 22;11(2):203-6.
DM6PZ45	RU	https://pubmed.ncbi.nlm.nih.gov/11206459

DMKDZH4	DI	DMKDZH4
DMKDZH4	DN	AcAsp-Glu-Leu-Glu-Cha-Cys
DMKDZH4	MI	TTWXB3E
DMKDZH4	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DMKDZH4	MT	DTT
DMKDZH4	MA	Inhibitor
DMKDZH4	RN	Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain. Bioorg Med Chem Lett. 2001 Jan 22;11(2):203-6.
DMKDZH4	RU	https://pubmed.ncbi.nlm.nih.gov/11206459

DMOMI91	DI	DMOMI91
DMOMI91	DN	AcAsp-Glu-Met-Glu-Cha-Cys
DMOMI91	MI	TTWXB3E
DMOMI91	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DMOMI91	MT	DTT
DMOMI91	MA	Inhibitor
DMOMI91	RN	Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain. Bioorg Med Chem Lett. 2001 Jan 22;11(2):203-6.
DMOMI91	RU	https://pubmed.ncbi.nlm.nih.gov/11206459

DMIVFZE	DI	DMIVFZE
DMIVFZE	DN	AcAsp-Glu-Met-Glu-Glu-Cys
DMIVFZE	MI	TTWXB3E
DMIVFZE	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DMIVFZE	MT	DTT
DMIVFZE	MA	Inhibitor
DMIVFZE	RN	Control of hepatitis C: a medicinal chemistry perspective. J Med Chem. 2005 Jan 13;48(1):1-20.
DMIVFZE	RU	https://pubmed.ncbi.nlm.nih.gov/15633995

DMBGHX7	DI	DMBGHX7
DMBGHX7	DN	AcAsp-Glu-Met-Glu-Nal-Cyse
DMBGHX7	MI	TTWXB3E
DMBGHX7	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DMBGHX7	MT	DTT
DMBGHX7	MA	Inhibitor
DMBGHX7	RN	Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain. Bioorg Med Chem Lett. 2001 Jan 22;11(2):203-6.
DMBGHX7	RU	https://pubmed.ncbi.nlm.nih.gov/11206459

DM4KQUS	DI	DM4KQUS
DM4KQUS	DN	Ac-Asp-Glu-Val-Asp-CHO
DM4KQUS	MI	TTPF2QI
DM4KQUS	MN	Caspase-3 (CASP3)
DM4KQUS	MT	DTT
DM4KQUS	MA	Inhibitor
DM4KQUS	RN	Design and synthesis of a potent and selective peptidomimetic inhibitor of caspase-3. J Med Chem. 2004 Dec 16;47(26):6455-8.
DM4KQUS	RU	https://pubmed.ncbi.nlm.nih.gov/15588079

DM1KDJV	DI	DM1KDJV
DM1KDJV	DN	Ac-bhg-F-N-Y-Y-W
DM1KDJV	MI	TTKRD0G
DM1KDJV	MN	Endothelin A receptor (EDNRA)
DM1KDJV	MT	DTT
DM1KDJV	MA	Inhibitor
DM1KDJV	RN	Res-701-1, synthesis and a reevaluation of its effects on the endothelin receptors, Bioorg. Med. Chem. Lett. 5(6):621-626 (1995).
DM1KDJV	RU	http://www.sciencedirect.com/science/article/pii/0960894X95000847

DM1KDJV	DI	DM1KDJV
DM1KDJV	DN	Ac-bhg-F-N-Y-Y-W
DM1KDJV	MI	TT3ZTGU
DM1KDJV	MN	Endothelin B receptor (EDNRB)
DM1KDJV	MT	DTT
DM1KDJV	MA	Inhibitor
DM1KDJV	RN	Res-701-1, synthesis and a reevaluation of its effects on the endothelin receptors, Bioorg. Med. Chem. Lett. 5(6):621-626 (1995).
DM1KDJV	RU	http://www.sciencedirect.com/science/article/pii/0960894X95000847

DMSE29N	DI	DMSE29N
DMSE29N	DN	Ac-Bth-Thr(PO3H2)-Pip-Nal-Gln-NH2
DMSE29N	MI	TTJNTSI
DMSE29N	MN	Rotamase Pin1 (PIN1)
DMSE29N	MT	DTT
DMSE29N	MA	Inhibitor
DMSE29N	RN	Nanomolar inhibitors of the peptidyl prolyl cis/trans isomerase Pin1 from combinatorial peptide libraries. J Med Chem. 2006 Apr 6;49(7):2147-50.
DMSE29N	RU	https://pubmed.ncbi.nlm.nih.gov/16570909

DMH0SQC	DI	DMH0SQC
DMH0SQC	DN	Ac-Cys-Ile-cyclo[Phe-Lys]-Tyr-Tyr
DMH0SQC	MI	TT6PKBN
DMH0SQC	MN	Proto-oncogene c-Src (SRC)
DMH0SQC	MT	DTT
DMH0SQC	MA	Inhibitor
DMH0SQC	RN	Synthesis and structure-activity relationships of linear and conformationally constrained peptide analogues of CIYKYY as Src tyrosine kinase inhibi... J Med Chem. 2006 Jun 1;49(11):3395-401.
DMH0SQC	RU	https://pubmed.ncbi.nlm.nih.gov/16722659

DMG19LW	DI	DMG19LW
DMG19LW	DN	Ac-Cys-Ile-Phe(4-NO2)-Lys-Phe(4-NO2)-Tyr
DMG19LW	MI	TT6PKBN
DMG19LW	MN	Proto-oncogene c-Src (SRC)
DMG19LW	MT	DTT
DMG19LW	MA	Inhibitor
DMG19LW	RN	Synthesis and structure-activity relationships of linear and conformationally constrained peptide analogues of CIYKYY as Src tyrosine kinase inhibi... J Med Chem. 2006 Jun 1;49(11):3395-401.
DMG19LW	RU	https://pubmed.ncbi.nlm.nih.gov/16722659

DMORPDV	DI	DMORPDV
DMORPDV	DN	Ac-Cys-Ile-Phe(4-NO2)-Lys-Tyr-Phe(4-NO2)
DMORPDV	MI	TT6PKBN
DMORPDV	MN	Proto-oncogene c-Src (SRC)
DMORPDV	MT	DTT
DMORPDV	MA	Inhibitor
DMORPDV	RN	Synthesis and structure-activity relationships of linear and conformationally constrained peptide analogues of CIYKYY as Src tyrosine kinase inhibi... J Med Chem. 2006 Jun 1;49(11):3395-401.
DMORPDV	RU	https://pubmed.ncbi.nlm.nih.gov/16722659

DMK7YIG	DI	DMK7YIG
DMK7YIG	DN	Ac-Cys-Ile-Phe(4-NO2)-Lys-Tyr-Tyr
DMK7YIG	MI	TT6PKBN
DMK7YIG	MN	Proto-oncogene c-Src (SRC)
DMK7YIG	MT	DTT
DMK7YIG	MA	Inhibitor
DMK7YIG	RN	Synthesis and structure-activity relationships of linear and conformationally constrained peptide analogues of CIYKYY as Src tyrosine kinase inhibi... J Med Chem. 2006 Jun 1;49(11):3395-401.
DMK7YIG	RU	https://pubmed.ncbi.nlm.nih.gov/16722659

DMUWI2F	DI	DMUWI2F
DMUWI2F	DN	Ac-Cys-Ile-Tyr-Lys-Phe(4-Cl)-Tyr
DMUWI2F	MI	TT6PKBN
DMUWI2F	MN	Proto-oncogene c-Src (SRC)
DMUWI2F	MT	DTT
DMUWI2F	MA	Inhibitor
DMUWI2F	RN	Synthesis and structure-activity relationships of linear and conformationally constrained peptide analogues of CIYKYY as Src tyrosine kinase inhibi... J Med Chem. 2006 Jun 1;49(11):3395-401.
DMUWI2F	RU	https://pubmed.ncbi.nlm.nih.gov/16722659

DMNW7GR	DI	DMNW7GR
DMNW7GR	DN	Ac-Cys-Ile-Tyr-Lys-Phe(4-CN)-Tyr
DMNW7GR	MI	TT6PKBN
DMNW7GR	MN	Proto-oncogene c-Src (SRC)
DMNW7GR	MT	DTT
DMNW7GR	MA	Inhibitor
DMNW7GR	RN	Synthesis and structure-activity relationships of linear and conformationally constrained peptide analogues of CIYKYY as Src tyrosine kinase inhibi... J Med Chem. 2006 Jun 1;49(11):3395-401.
DMNW7GR	RU	https://pubmed.ncbi.nlm.nih.gov/16722659

DMO4MYI	DI	DMO4MYI
DMO4MYI	DN	Ac-Cys-Ile-Tyr-Lys-Phe(4-I)-Tyr
DMO4MYI	MI	TT6PKBN
DMO4MYI	MN	Proto-oncogene c-Src (SRC)
DMO4MYI	MT	DTT
DMO4MYI	MA	Inhibitor
DMO4MYI	RN	Synthesis and structure-activity relationships of linear and conformationally constrained peptide analogues of CIYKYY as Src tyrosine kinase inhibi... J Med Chem. 2006 Jun 1;49(11):3395-401.
DMO4MYI	RU	https://pubmed.ncbi.nlm.nih.gov/16722659

DME4FZD	DI	DME4FZD
DME4FZD	DN	Ac-Cys-Ile-Tyr-Lys-Phe(4-N3)-Tyr
DME4FZD	MI	TT6PKBN
DME4FZD	MN	Proto-oncogene c-Src (SRC)
DME4FZD	MT	DTT
DME4FZD	MA	Inhibitor
DME4FZD	RN	Synthesis and structure-activity relationships of linear and conformationally constrained peptide analogues of CIYKYY as Src tyrosine kinase inhibi... J Med Chem. 2006 Jun 1;49(11):3395-401.
DME4FZD	RU	https://pubmed.ncbi.nlm.nih.gov/16722659

DM856JM	DI	DM856JM
DM856JM	DN	Ac-Cys-Ile-Tyr-Lys-Phe(4-NO2)-Phe(4-NO2)
DM856JM	MI	TT6PKBN
DM856JM	MN	Proto-oncogene c-Src (SRC)
DM856JM	MT	DTT
DM856JM	MA	Inhibitor
DM856JM	RN	Synthesis and structure-activity relationships of linear and conformationally constrained peptide analogues of CIYKYY as Src tyrosine kinase inhibi... J Med Chem. 2006 Jun 1;49(11):3395-401.
DM856JM	RU	https://pubmed.ncbi.nlm.nih.gov/16722659

DMU2PT1	DI	DMU2PT1
DMU2PT1	DN	Ac-Cys-Ile-Tyr-Lys-Phe(4-NO2)-Tyr-Phe
DMU2PT1	MI	TT6PKBN
DMU2PT1	MN	Proto-oncogene c-Src (SRC)
DMU2PT1	MT	DTT
DMU2PT1	MA	Inhibitor
DMU2PT1	RN	Synthesis and structure-activity relationships of linear and conformationally constrained peptide analogues of CIYKYY as Src tyrosine kinase inhibi... J Med Chem. 2006 Jun 1;49(11):3395-401.
DMU2PT1	RU	https://pubmed.ncbi.nlm.nih.gov/16722659

DM4MP69	DI	DM4MP69
DM4MP69	DN	Ac-Cys-Ile-Tyr-Lys-Tyr-Phe(4-NO2)
DM4MP69	MI	TT6PKBN
DM4MP69	MN	Proto-oncogene c-Src (SRC)
DM4MP69	MT	DTT
DM4MP69	MA	Inhibitor
DM4MP69	RN	Synthesis and structure-activity relationships of linear and conformationally constrained peptide analogues of CIYKYY as Src tyrosine kinase inhibi... J Med Chem. 2006 Jun 1;49(11):3395-401.
DM4MP69	RU	https://pubmed.ncbi.nlm.nih.gov/16722659

DMW02H7	DI	DMW02H7
DMW02H7	DN	Ac-DEVD-CHO
DMW02H7	MI	TTZY5KP
DMW02H7	MN	Caspase (CASP)
DMW02H7	MT	DTT
DMW02H7	MA	Inhibitor
DMW02H7	RN	Synthesis and evaluation of vinyl sulfones as caspase-3 inhibitors. A structure-activity study. Eur J Med Chem. 2010 Sep;45(9):3858-63.
DMW02H7	RU	https://pubmed.ncbi.nlm.nih.gov/20541849

DMW02H7	DI	DMW02H7
DMW02H7	DN	Ac-DEVD-CHO
DMW02H7	MI	TTPF2QI
DMW02H7	MN	Caspase-3 (CASP3)
DMW02H7	MT	DTT
DMW02H7	MA	Inhibitor
DMW02H7	RN	Synthesis and evaluation of vinyl sulfones as caspase-3 inhibitors. A structure-activity study. Eur J Med Chem. 2010 Sep;45(9):3858-63.
DMW02H7	RU	https://pubmed.ncbi.nlm.nih.gov/20541849

DMKDEWH	DI	DMKDEWH
DMKDEWH	DN	AcDif-Glu-Cha-Cys
DMKDEWH	MI	TTWXB3E
DMKDEWH	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DMKDEWH	MT	DTT
DMKDEWH	MA	Inhibitor
DMKDEWH	RN	Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain. Bioorg Med Chem Lett. 2001 Jan 22;11(2):203-6.
DMKDEWH	RU	https://pubmed.ncbi.nlm.nih.gov/11206459

DM1DWCP	DI	DM1DWCP
DM1DWCP	DN	AcDif-Ile-Cha-Cys
DM1DWCP	MI	TTWXB3E
DM1DWCP	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DM1DWCP	MT	DTT
DM1DWCP	MA	Inhibitor
DM1DWCP	RN	Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain. Bioorg Med Chem Lett. 2001 Jan 22;11(2):203-6.
DM1DWCP	RU	https://pubmed.ncbi.nlm.nih.gov/11206459

DMPMH7Z	DI	DMPMH7Z
DMPMH7Z	DN	ACDPP
DMPMH7Z	MI	TTHS256
DMPMH7Z	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMPMH7Z	MT	DTT
DMPMH7Z	MA	Antagonist
DMPMH7Z	RN	Dipyridyl amides: potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1197-200.
DMPMH7Z	RU	https://pubmed.ncbi.nlm.nih.gov/15686941

DMVDH4I	DI	DMVDH4I
DMVDH4I	DN	Ac-D-pro-L-Phe-D-trp-L-Phe-NH2
DMVDH4I	MI	TTKWM86
DMVDH4I	MN	Opioid receptor mu (MOP)
DMVDH4I	MT	DTT
DMVDH4I	MA	Inhibitor
DMVDH4I	RN	Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50.
DMVDH4I	RU	https://pubmed.ncbi.nlm.nih.gov/19464172

DM7XY41	DI	DM7XY41
DM7XY41	DN	Ac-dR[CEHdFRWC]-NH2
DM7XY41	MI	TT0MV2T
DM7XY41	MN	Melanocortin receptor 1 (MC1R)
DM7XY41	MT	DTT
DM7XY41	MA	Inhibitor
DM7XY41	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DM7XY41	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DM7XY41	DI	DM7XY41
DM7XY41	DN	Ac-dR[CEHdFRWC]-NH2
DM7XY41	MI	TTNI91K
DM7XY41	MN	Melanocortin receptor 3 (MC3R)
DM7XY41	MT	DTT
DM7XY41	MA	Inhibitor
DM7XY41	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DM7XY41	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DM7XY41	DI	DM7XY41
DM7XY41	DN	Ac-dR[CEHdFRWC]-NH2
DM7XY41	MI	TTD0CIQ
DM7XY41	MN	Melanocortin receptor 4 (MC4R)
DM7XY41	MT	DTT
DM7XY41	MA	Inhibitor
DM7XY41	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DM7XY41	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DM9MDBO	DI	DM9MDBO
DM9MDBO	DN	AcDRGDS
DM9MDBO	MI	TTT1R2L
DM9MDBO	MN	Integrin alpha-V (ITGAV)
DM9MDBO	MT	DTT
DM9MDBO	MA	Inhibitor
DM9MDBO	RN	Inhibition of cancer cell adhesion by heterochiral Pro-containing RGD mimetics. Bioorg Med Chem Lett. 2007 Apr 15;17(8):2329-33.
DM9MDBO	RU	https://pubmed.ncbi.nlm.nih.gov/17289386

DM9MDBO	DI	DM9MDBO
DM9MDBO	DN	AcDRGDS
DM9MDBO	MI	TTJA1ZO
DM9MDBO	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DM9MDBO	MT	DTT
DM9MDBO	MA	Inhibitor
DM9MDBO	RN	Inhibition of cancer cell adhesion by heterochiral Pro-containing RGD mimetics. Bioorg Med Chem Lett. 2007 Apr 15;17(8):2329-33.
DM9MDBO	RU	https://pubmed.ncbi.nlm.nih.gov/17289386

DMOJGF3	DI	DMOJGF3
DMOJGF3	DN	ACE-435
DMOJGF3	MI	TTP4520
DMOJGF3	MN	TGF-beta receptor type I (TGFBR1)
DMOJGF3	MT	DTT
DMOJGF3	MA	Inhibitor
DMOJGF3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1788).
DMOJGF3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1788

DMWX3HT	DI	DMWX3HT
DMWX3HT	DN	ACEA
DMWX3HT	MI	TT6OEDT
DMWX3HT	MN	Cannabinoid receptor 1 (CB1)
DMWX3HT	MT	DTT
DMWX3HT	MA	Agonist
DMWX3HT	RN	Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J Pharmacol Exp Ther. 1999 Jun;289(3):1427-33.
DMWX3HT	RU	https://pubmed.ncbi.nlm.nih.gov/10336536

DMVTSM8	DI	DMVTSM8
DMVTSM8	DN	Acefylline
DMVTSM8	MI	DEJGDUW
DMVTSM8	MN	Cytochrome P450 1A2 (CYP1A2)
DMVTSM8	MT	DME
DMVTSM8	MA	Metabolism
DMVTSM8	RN	PharmGKB summary: caffeine pathway. Pharmacogenet Genomics. 2012 May;22(5):389-95.
DMVTSM8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22293536

DMU9O7K	DI	DMU9O7K
DMU9O7K	DN	Acenanthrene-9,10-dione
DMU9O7K	MI	TTMF541
DMU9O7K	MN	Liver carboxylesterase (CES1)
DMU9O7K	MT	DTT
DMU9O7K	MA	Inhibitor
DMU9O7K	RN	Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34.
DMU9O7K	RU	https://pubmed.ncbi.nlm.nih.gov/17941623

DMT3QYZ	DI	DMT3QYZ
DMT3QYZ	DN	Acenaphthenol
DMT3QYZ	MI	DEGQTXO
DMT3QYZ	MN	Aldo-keto reductase 1C3 (AKR1C3)
DMT3QYZ	MT	DME
DMT3QYZ	MA	Metabolism
DMT3QYZ	RN	Expression and characterization of four recombinant human dihydrodiol dehydrogenase isoforms: oxidation of trans-7, 8-dihydroxy-7,8-dihydrobenzo[a]pyrene to the activated o-quinone metabolite benzo[a]pyrene-7,8-dione. Biochemistry. 1998 May 12;37(19):6781-90.
DMT3QYZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9578563

DMU3DMH	DI	DMU3DMH
DMU3DMH	DN	ACENAPHTHOQUINONE
DMU3DMH	MI	TTEB0GD
DMU3DMH	MN	Cholinesterase (BCHE)
DMU3DMH	MT	DTT
DMU3DMH	MA	Inhibitor
DMU3DMH	RN	Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34.
DMU3DMH	RU	https://pubmed.ncbi.nlm.nih.gov/17941623

DMU3DMH	DI	DMU3DMH
DMU3DMH	DN	ACENAPHTHOQUINONE
DMU3DMH	MI	TTMF541
DMU3DMH	MN	Liver carboxylesterase (CES1)
DMU3DMH	MT	DTT
DMU3DMH	MA	Inhibitor
DMU3DMH	RN	Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34.
DMU3DMH	RU	https://pubmed.ncbi.nlm.nih.gov/17941623

DM4BWMO	DI	DM4BWMO
DM4BWMO	DN	Acerogenin A
DM4BWMO	MI	TT2UE56
DM4BWMO	MN	Sodium/glucose cotransporter 1 (SGLT1)
DM4BWMO	MT	DTT
DM4BWMO	MA	Inhibitor
DM4BWMO	RN	Cyclic diarylheptanoids as Na+-glucose cotransporter (SGLT) inhibitors from Acer nikoense. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1070-4.
DM4BWMO	RU	https://pubmed.ncbi.nlm.nih.gov/20036535

DMVQ30P	DI	DMVQ30P
DMVQ30P	DN	Acerogenin B
DMVQ30P	MI	TTF8JAT
DMVQ30P	MN	SLC5A2 messenger RNA (SLC5A2 mRNA)
DMVQ30P	MT	DTT
DMVQ30P	MA	Inhibitor
DMVQ30P	RN	Cyclic diarylheptanoids as Na+-glucose cotransporter (SGLT) inhibitors from Acer nikoense. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1070-4.
DMVQ30P	RU	https://pubmed.ncbi.nlm.nih.gov/20036535

DMVQ30P	DI	DMVQ30P
DMVQ30P	DN	Acerogenin B
DMVQ30P	MI	TT2UE56
DMVQ30P	MN	Sodium/glucose cotransporter 1 (SGLT1)
DMVQ30P	MT	DTT
DMVQ30P	MA	Inhibitor
DMVQ30P	RN	Cyclic diarylheptanoids as Na+-glucose cotransporter (SGLT) inhibitors from Acer nikoense. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1070-4.
DMVQ30P	RU	https://pubmed.ncbi.nlm.nih.gov/20036535

DMNETSX	DI	DMNETSX
DMNETSX	DN	Acerogenin C
DMNETSX	MI	TTF8JAT
DMNETSX	MN	SLC5A2 messenger RNA (SLC5A2 mRNA)
DMNETSX	MT	DTT
DMNETSX	MA	Inhibitor
DMNETSX	RN	Cyclic diarylheptanoids as Na+-glucose cotransporter (SGLT) inhibitors from Acer nikoense. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1070-4.
DMNETSX	RU	https://pubmed.ncbi.nlm.nih.gov/20036535

DMB2463	DI	DMB2463
DMB2463	DN	ACET
DMB2463	MI	TT0MYE2
DMB2463	MN	Glutamate receptor ionotropic kainate 1 (GRIK1)
DMB2463	MT	DTT
DMB2463	MA	Antagonist
DMB2463	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 450).
DMB2463	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=450

DMJFKG4	DI	DMJFKG4
DMJFKG4	DN	Acetaldehyde
DMJFKG4	MI	DEM1HNL
DMJFKG4	MN	Alcohol dehydrogenase class-I gamma (ADH1C)
DMJFKG4	MT	DME
DMJFKG4	MA	Metabolism
DMJFKG4	RN	Oxidation of alcohols and reduction of aldehydes derived from methyl- and dimethylpyrenes by cDNA-expressed human alcohol dehydrogenases. Toxicology. 2008 Mar 12;245(1-2):65-75.
DMJFKG4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18242813

DMJFKG4	DI	DMJFKG4
DMJFKG4	DN	Acetaldehyde
DMJFKG4	MI	DEOCWU3
DMJFKG4	MN	Alcohol dehydrogenase class-II (ADH4)
DMJFKG4	MT	DME
DMJFKG4	MA	Metabolism
DMJFKG4	RN	Oxidation of alcohols and reduction of aldehydes derived from methyl- and dimethylpyrenes by cDNA-expressed human alcohol dehydrogenases. Toxicology. 2008 Mar 12;245(1-2):65-75.
DMJFKG4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18242813

DMJFKG4	DI	DMJFKG4
DMJFKG4	DN	Acetaldehyde
DMJFKG4	MI	TTELV3W
DMJFKG4	MN	Transformation-sensitive protein p120 (TRPA1)
DMJFKG4	MT	DTT
DMJFKG4	MA	Activator
DMJFKG4	RN	Transient receptor potential A1 mediates acetaldehyde-evoked pain sensation. Eur J Neurosci. 2007 Nov;26(9):2516-23.
DMJFKG4	RU	https://pubmed.ncbi.nlm.nih.gov/17970723

DMD08RH	DI	DMD08RH
DMD08RH	DN	Acetate Ion
DMD08RH	MI	TTL69WB
DMD08RH	MN	Angiotensin-converting enzyme (ACE)
DMD08RH	MT	DTT
DMD08RH	MA	Inhibitor
DMD08RH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD08RH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD08RH	DI	DMD08RH
DMD08RH	DN	Acetate Ion
DMD08RH	MI	TTY8KJS
DMD08RH	MN	Bacterial Deoxyuridine triphosphate nucleotidohydrolase (Bact dut)
DMD08RH	MT	DTT
DMD08RH	MA	Inhibitor
DMD08RH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD08RH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD08RH	DI	DMD08RH
DMD08RH	DN	Acetate Ion
DMD08RH	MI	TTC67I0
DMD08RH	MN	Bacterial Glucosamine-6-phosphate synthase (Bact glmS)
DMD08RH	MT	DTT
DMD08RH	MA	Inhibitor
DMD08RH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD08RH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD08RH	DI	DMD08RH
DMD08RH	DN	Acetate Ion
DMD08RH	MI	TT38ECI
DMD08RH	MN	Bacterial Hydroxymethyl-dihydropterin pyrophosphokinase (Bact folK)
DMD08RH	MT	DTT
DMD08RH	MA	Inhibitor
DMD08RH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD08RH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD08RH	DI	DMD08RH
DMD08RH	DN	Acetate Ion
DMD08RH	MI	TTV3NH6
DMD08RH	MN	Calmodulin (CALM)
DMD08RH	MT	DTT
DMD08RH	MA	Inhibitor
DMD08RH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD08RH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD08RH	DI	DMD08RH
DMD08RH	DN	Acetate Ion
DMD08RH	MI	TT915ZD
DMD08RH	MN	Candida Mannose-6-phosphate isomerase (Candi PMI1)
DMD08RH	MT	DTT
DMD08RH	MA	Inhibitor
DMD08RH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD08RH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD08RH	DI	DMD08RH
DMD08RH	DN	Acetate Ion
DMD08RH	MI	TTANPDJ
DMD08RH	MN	Carbonic anhydrase II (CA-II)
DMD08RH	MT	DTT
DMD08RH	MA	Inhibitor
DMD08RH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD08RH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD08RH	DI	DMD08RH
DMD08RH	DN	Acetate Ion
DMD08RH	MI	TT5ZWB6
DMD08RH	MN	Dihydrodiol dehydrogenase type I (AKR1C3)
DMD08RH	MT	DTT
DMD08RH	MA	Inhibitor
DMD08RH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD08RH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD08RH	DI	DMD08RH
DMD08RH	DN	Acetate Ion
DMD08RH	MI	TTOM3J0
DMD08RH	MN	Estrogen receptor beta (ESR2)
DMD08RH	MT	DTT
DMD08RH	MA	Inhibitor
DMD08RH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD08RH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD08RH	DI	DMD08RH
DMD08RH	DN	Acetate Ion
DMD08RH	MI	TTT2LD9
DMD08RH	MN	GABA transaminase (ABAT)
DMD08RH	MT	DTT
DMD08RH	MA	Inhibitor
DMD08RH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD08RH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD08RH	DI	DMD08RH
DMD08RH	DN	Acetate Ion
DMD08RH	MI	TT8DSFC
DMD08RH	MN	Hydroxyphenylpyruvate dioxygenase (HPD)
DMD08RH	MT	DTT
DMD08RH	MA	Inhibitor
DMD08RH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD08RH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD08RH	DI	DMD08RH
DMD08RH	DN	Acetate Ion
DMD08RH	MI	TTXZEAJ
DMD08RH	MN	Leukotriene A-4 hydrolase (LTA4H)
DMD08RH	MT	DTT
DMD08RH	MA	Inhibitor
DMD08RH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD08RH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD08RH	DI	DMD08RH
DMD08RH	DN	Acetate Ion
DMD08RH	MI	TTXZ0KQ
DMD08RH	MN	Matrix metalloproteinase-12 (MMP-12)
DMD08RH	MT	DTT
DMD08RH	MA	Inhibitor
DMD08RH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD08RH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD08RH	DI	DMD08RH
DMD08RH	DN	Acetate Ion
DMD08RH	MI	TT6TMZU
DMD08RH	MN	Mycobacterium Biosynthetic alanine racemase (MycB alr)
DMD08RH	MT	DTT
DMD08RH	MA	Inhibitor
DMD08RH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD08RH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD08RH	DI	DMD08RH
DMD08RH	DN	Acetate Ion
DMD08RH	MI	TT5B8AX
DMD08RH	MN	Mycobacterium Thymidine monophosphate kinase (MycB tmk)
DMD08RH	MT	DTT
DMD08RH	MA	Inhibitor
DMD08RH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD08RH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD08RH	DI	DMD08RH
DMD08RH	DN	Acetate Ion
DMD08RH	MI	TTZUFI5
DMD08RH	MN	Nitric-oxide synthase brain (NOS1)
DMD08RH	MT	DTT
DMD08RH	MA	Inhibitor
DMD08RH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD08RH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD08RH	DI	DMD08RH
DMD08RH	DN	Acetate Ion
DMD08RH	MI	TTCM4B3
DMD08RH	MN	Nitric-oxide synthase endothelial (NOS3)
DMD08RH	MT	DTT
DMD08RH	MA	Inhibitor
DMD08RH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD08RH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD08RH	DI	DMD08RH
DMD08RH	DN	Acetate Ion
DMD08RH	MI	TT3NKIB
DMD08RH	MN	Pancreatic elastase 1 (CELA1)
DMD08RH	MT	DTT
DMD08RH	MA	Inhibitor
DMD08RH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD08RH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD08RH	DI	DMD08RH
DMD08RH	DN	Acetate Ion
DMD08RH	MI	TT9V5JH
DMD08RH	MN	Phospholipase A2 (PLA2G1B)
DMD08RH	MT	DTT
DMD08RH	MA	Inhibitor
DMD08RH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD08RH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD08RH	DI	DMD08RH
DMD08RH	DN	Acetate Ion
DMD08RH	MI	TT3PQ2Y
DMD08RH	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DMD08RH	MT	DTT
DMD08RH	MA	Inhibitor
DMD08RH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD08RH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD08RH	DI	DMD08RH
DMD08RH	DN	Acetate Ion
DMD08RH	MI	TTBL49X
DMD08RH	MN	Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ)
DMD08RH	MT	DTT
DMD08RH	MA	Inhibitor
DMD08RH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD08RH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD08RH	DI	DMD08RH
DMD08RH	DN	Acetate Ion
DMD08RH	MI	TTELIN2
DMD08RH	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMD08RH	MT	DTT
DMD08RH	MA	Inhibitor
DMD08RH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD08RH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD08RH	DI	DMD08RH
DMD08RH	DN	Acetate Ion
DMD08RH	MI	TTHI19T
DMD08RH	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMD08RH	MT	DTT
DMD08RH	MA	Inhibitor
DMD08RH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD08RH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD08RH	DI	DMD08RH
DMD08RH	DN	Acetate Ion
DMD08RH	MI	TTN6GE9
DMD08RH	MN	Staphylococcus D-amino acid aminotransferase (Stap-coc dat)
DMD08RH	MT	DTT
DMD08RH	MA	Inhibitor
DMD08RH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD08RH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD08RH	DI	DMD08RH
DMD08RH	DN	Acetate Ion
DMD08RH	MI	TT6RVLG
DMD08RH	MN	Superoxide dismutase Cu-Zn (SOD Cu-Zn)
DMD08RH	MT	DTT
DMD08RH	MA	Inhibitor
DMD08RH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD08RH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD08RH	DI	DMD08RH
DMD08RH	DN	Acetate Ion
DMD08RH	MI	TTZJ5U9
DMD08RH	MN	Thioredoxin (TXN)
DMD08RH	MT	DTT
DMD08RH	MA	Inhibitor
DMD08RH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD08RH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMBP5L4	DI	DMBP5L4
DMBP5L4	DN	Acetic acid 2,6-diisopropyl-phenyl ester
DMBP5L4	MI	TTNJYV2
DMBP5L4	MN	Gamma-aminobutyric acid receptor (GAR)
DMBP5L4	MT	DTT
DMBP5L4	MA	Inhibitor
DMBP5L4	RN	Propofol analogues. Synthesis, relationships between structure and affinity at GABAA receptor in rat brain, and differential electrophysiological p... J Med Chem. 1998 May 21;41(11):1846-54.
DMBP5L4	RU	https://pubmed.ncbi.nlm.nih.gov/9599235

DM97DJL	DI	DM97DJL
DM97DJL	DN	Acetic acid 2-hept-2-ynylsulfanyl-phenyl ester
DM97DJL	MI	TT8NGED
DM97DJL	MN	Prostaglandin G/H synthase 1 (COX-1)
DM97DJL	MT	DTT
DM97DJL	MA	Inhibitor
DM97DJL	RN	Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators. J Med Chem. 1998 Nov 19;41(24):4800-18.
DM97DJL	RU	https://pubmed.ncbi.nlm.nih.gov/9822550

DMD89A1	DI	DMD89A1
DMD89A1	DN	Acetic acid 2-hept-3-ynylsulfanyl-phenyl ester
DMD89A1	MI	TT8NGED
DMD89A1	MN	Prostaglandin G/H synthase 1 (COX-1)
DMD89A1	MT	DTT
DMD89A1	MA	Inhibitor
DMD89A1	RN	Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators. J Med Chem. 1998 Nov 19;41(24):4800-18.
DMD89A1	RU	https://pubmed.ncbi.nlm.nih.gov/9822550

DM50BTA	DI	DM50BTA
DM50BTA	DN	Acetic acid 2-heptylselanyl-phenyl ester
DM50BTA	MI	TT8NGED
DM50BTA	MN	Prostaglandin G/H synthase 1 (COX-1)
DM50BTA	MT	DTT
DM50BTA	MA	Inhibitor
DM50BTA	RN	Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators. J Med Chem. 1998 Nov 19;41(24):4800-18.
DM50BTA	RU	https://pubmed.ncbi.nlm.nih.gov/9822550

DMLPRIG	DI	DMLPRIG
DMLPRIG	DN	Acetic acid 2-heptylsulfanyl-phenyl ester
DMLPRIG	MI	TT8NGED
DMLPRIG	MN	Prostaglandin G/H synthase 1 (COX-1)
DMLPRIG	MT	DTT
DMLPRIG	MA	Inhibitor
DMLPRIG	RN	Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators. J Med Chem. 1998 Nov 19;41(24):4800-18.
DMLPRIG	RU	https://pubmed.ncbi.nlm.nih.gov/9822550

DMFQE1C	DI	DMFQE1C
DMFQE1C	DN	Acetic acid 2-hex-2-ynylsulfanyl-phenyl ester
DMFQE1C	MI	TT8NGED
DMFQE1C	MN	Prostaglandin G/H synthase 1 (COX-1)
DMFQE1C	MT	DTT
DMFQE1C	MA	Inhibitor
DMFQE1C	RN	Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators. J Med Chem. 1998 Nov 19;41(24):4800-18.
DMFQE1C	RU	https://pubmed.ncbi.nlm.nih.gov/9822550

DMAKNUH	DI	DMAKNUH
DMAKNUH	DN	Acetic acid 2-hexylsulfanyl-phenyl ester
DMAKNUH	MI	TT8NGED
DMAKNUH	MN	Prostaglandin G/H synthase 1 (COX-1)
DMAKNUH	MT	DTT
DMAKNUH	MA	Inhibitor
DMAKNUH	RN	Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators. J Med Chem. 1998 Nov 19;41(24):4800-18.
DMAKNUH	RU	https://pubmed.ncbi.nlm.nih.gov/9822550

DMFKRIH	DI	DMFKRIH
DMFKRIH	DN	Acetic acid 2-pentylsulfanyl-phenyl ester
DMFKRIH	MI	TT8NGED
DMFKRIH	MN	Prostaglandin G/H synthase 1 (COX-1)
DMFKRIH	MT	DTT
DMFKRIH	MA	Inhibitor
DMFKRIH	RN	Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators. J Med Chem. 1998 Nov 19;41(24):4800-18.
DMFKRIH	RU	https://pubmed.ncbi.nlm.nih.gov/9822550

DMUYKIE	DI	DMUYKIE
DMUYKIE	DN	Acetic acid 2-phenyl-5-propyl-thiazol-4-yl ester
DMUYKIE	MI	TT2J34L
DMUYKIE	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMUYKIE	MT	DTT
DMUYKIE	MA	Inhibitor
DMUYKIE	RN	4-hydroxythiazole inhibitors of 5-lipoxygenase. J Med Chem. 1991 Jul;34(7):2158-65.
DMUYKIE	RU	https://pubmed.ncbi.nlm.nih.gov/2066989

DM95QEA	DI	DM95QEA
DM95QEA	DN	Acetic acid 5-butyl-2-phenyl-thiazol-4-yl ester
DM95QEA	MI	TT2J34L
DM95QEA	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM95QEA	MT	DTT
DM95QEA	MA	Inhibitor
DM95QEA	RN	4-hydroxythiazole inhibitors of 5-lipoxygenase. J Med Chem. 1991 Jul;34(7):2158-65.
DM95QEA	RU	https://pubmed.ncbi.nlm.nih.gov/2066989

DMVEH40	DI	DMVEH40
DMVEH40	DN	Acetic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester
DMVEH40	MI	TTZ9SOR
DMVEH40	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMVEH40	MT	DTT
DMVEH40	MA	Inhibitor
DMVEH40	RN	6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors. J Med Chem. 1998 Jun 4;41(12):2047-55.
DMVEH40	RU	https://pubmed.ncbi.nlm.nih.gov/9622546

DMVEH40	DI	DMVEH40
DMVEH40	DN	Acetic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester
DMVEH40	MI	TTYEG6Q
DMVEH40	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMVEH40	MT	DTT
DMVEH40	MA	Inhibitor
DMVEH40	RN	6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors. J Med Chem. 1998 Jun 4;41(12):2047-55.
DMVEH40	RU	https://pubmed.ncbi.nlm.nih.gov/9622546

DMVEH40	DI	DMVEH40
DMVEH40	DN	Acetic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester
DMVEH40	MI	TTQ13Z5
DMVEH40	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMVEH40	MT	DTT
DMVEH40	MA	Inhibitor
DMVEH40	RN	6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors. J Med Chem. 1998 Jun 4;41(12):2047-55.
DMVEH40	RU	https://pubmed.ncbi.nlm.nih.gov/9622546

DMVEH40	DI	DMVEH40
DMVEH40	DN	Acetic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester
DMVEH40	MI	TTQ3JTF
DMVEH40	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DMVEH40	MT	DTT
DMVEH40	MA	Inhibitor
DMVEH40	RN	6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors. J Med Chem. 1998 Jun 4;41(12):2047-55.
DMVEH40	RU	https://pubmed.ncbi.nlm.nih.gov/9622546

DMVEH40	DI	DMVEH40
DMVEH40	DN	Acetic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester
DMVEH40	MI	TTH18TF
DMVEH40	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMVEH40	MT	DTT
DMVEH40	MA	Inhibitor
DMVEH40	RN	6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors. J Med Chem. 2000 Jun 29;43(13):2514-22.
DMVEH40	RU	https://pubmed.ncbi.nlm.nih.gov/10891110

DMLTNHY	DI	DMLTNHY
DMLTNHY	DN	Acetic Acid Salicyloyl-Amino-Ester
DMLTNHY	MI	TT8NGED
DMLTNHY	MN	Prostaglandin G/H synthase 1 (COX-1)
DMLTNHY	MT	DTT
DMLTNHY	MA	Inhibitor
DMLTNHY	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMLTNHY	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM3HYU8	DI	DM3HYU8
DM3HYU8	DN	Acetoacetyl-Coenzyme A
DM3HYU8	MI	TTS0EZJ
DM3HYU8	MN	Hydroxymethylglutaryl-CoA synthase 2 (HMGCS2)
DM3HYU8	MT	DTT
DM3HYU8	MA	Inhibitor
DM3HYU8	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM3HYU8	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM3HYU8	DI	DM3HYU8
DM3HYU8	DN	Acetoacetyl-Coenzyme A
DM3HYU8	MI	TT8HWCD
DM3HYU8	MN	Staphylococcus DHNA-CoA synthase (Stap-coc menB)
DM3HYU8	MT	DTT
DM3HYU8	MA	Inhibitor
DM3HYU8	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM3HYU8	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMH65Q8	DI	DMH65Q8
DMH65Q8	DN	Acetyl Coa
DMH65Q8	MI	DEA742Z
DMH65Q8	MN	Cysteinyl-conjugate N-acetyltransferase (NAT8)
DMH65Q8	MT	DME
DMH65Q8	MA	Metabolism
DMH65Q8	RN	Molecular identification of NAT8 as the enzyme that acetylates cysteine S-conjugates to mercapturic acids. J Biol Chem. 2010 Jun 11;285(24):18888-98.
DMH65Q8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20392701

DMUH4N7	DI	DMUH4N7
DMUH4N7	DN	Acetyl ethylene
DMUH4N7	MI	DE8RYV5
DMUH4N7	MN	NADPH:quinone reductase (CRYZ)
DMUH4N7	MT	DME
DMUH4N7	MA	Metabolism
DMUH4N7	RN	Kinetic and structural evidence of the alkenal/one reductase specificity of human crystallin. Cell Mol Life Sci. 2011 Mar;68(6):1065-77.
DMUH4N7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20835842

DMFZJRN	DI	DMFZJRN
DMFZJRN	DN	Acetyl-Ala-Ala-Pro-Ala-trifluromethane
DMFZJRN	MI	TT3NKIB
DMFZJRN	MN	Pancreatic elastase 1 (CELA1)
DMFZJRN	MT	DTT
DMFZJRN	MA	Inhibitor
DMFZJRN	RN	Synthesis of peptidyl fluoromethyl ketones and peptidyl alpha-keto esters as inhibitors of porcine pancreatic elastase, human neutrophil elastase, ... J Med Chem. 1990 Jan;33(1):394-407.
DMFZJRN	RU	https://pubmed.ncbi.nlm.nih.gov/2296031

DM1VE6S	DI	DM1VE6S
DM1VE6S	DN	Acetyl-Ile-Glu-Thr-Asp-aldehyde
DM1VE6S	MI	TT6SZNG
DM1VE6S	MN	Caspase 8 messenger RNA (CASP8 mRNA)
DM1VE6S	MT	DTT
DM1VE6S	MA	Inhibitor
DM1VE6S	RN	Synthesis and in vitro evaluation of sulfonamide isatin Michael acceptors as small molecule inhibitors of caspase-6. J Med Chem. 2009 Apr 23;52(8):2188-91.
DM1VE6S	RU	https://pubmed.ncbi.nlm.nih.gov/19326941

DM1VE6S	DI	DM1VE6S
DM1VE6S	DN	Acetyl-Ile-Glu-Thr-Asp-aldehyde
DM1VE6S	MI	TTEVCT0
DM1VE6S	MN	Caspase-8 (CASP8)
DM1VE6S	MT	DTT
DM1VE6S	MA	Inhibitor
DM1VE6S	RN	The atomic-resolution structure of human caspase-8, a key activator of apoptosis. Structure. 1999 Sep 15;7(9):1135-43.
DM1VE6S	RU	https://pubmed.ncbi.nlm.nih.gov/10508785

DM74HGJ	DI	DM74HGJ
DM74HGJ	DN	Acetyl-L-carnitine
DM74HGJ	MI	DT3HUVD
DM74HGJ	MN	Organic cation/carnitine transporter 2 (SLC22A5)
DM74HGJ	MT	DTP
DM74HGJ	MA	Substrate
DM74HGJ	RN	Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84.
DM74HGJ	RU	http://www.ncbi.nlm.nih.gov/pubmed/10525100

DMGTPFY	DI	DMGTPFY
DMGTPFY	DN	acetyl-podocarpic dimer
DMGTPFY	MI	TTECBXN
DMGTPFY	MN	Oxysterols receptor LXR-alpha (NR1H3)
DMGTPFY	MT	DTT
DMGTPFY	MA	Agonist
DMGTPFY	RN	A potent synthetic LXR agonist is more effective than cholesterol loading at inducing ABCA1 mRNA and stimulating cholesterol efflux. J Biol Chem. 2002 Mar 22;277(12):10021-7.
DMGTPFY	RU	https://pubmed.ncbi.nlm.nih.gov/11790770

DMGTPFY	DI	DMGTPFY
DMGTPFY	DN	acetyl-podocarpic dimer
DMGTPFY	MI	TTXA6PH
DMGTPFY	MN	Oxysterols receptor LXR-beta (NR1H2)
DMGTPFY	MT	DTT
DMGTPFY	MA	Agonist
DMGTPFY	RN	A potent synthetic LXR agonist is more effective than cholesterol loading at inducing ABCA1 mRNA and stimulating cholesterol efflux. J Biol Chem. 2002 Mar 22;277(12):10021-7.
DMGTPFY	RU	https://pubmed.ncbi.nlm.nih.gov/11790770

DMN5Z0F	DI	DMN5Z0F
DMN5Z0F	DN	Acetyl-Pro-Ala-Pro-Ala-trifluoro methane
DMN5Z0F	MI	TT3NKIB
DMN5Z0F	MN	Pancreatic elastase 1 (CELA1)
DMN5Z0F	MT	DTT
DMN5Z0F	MA	Inhibitor
DMN5Z0F	RN	Synthesis of peptidyl fluoromethyl ketones and peptidyl alpha-keto esters as inhibitors of porcine pancreatic elastase, human neutrophil elastase, ... J Med Chem. 1990 Jan;33(1):394-407.
DMN5Z0F	RU	https://pubmed.ncbi.nlm.nih.gov/2296031

DMG8P24	DI	DMG8P24
DMG8P24	DN	ACETYLSULFANILAMIDE
DMG8P24	MI	TTANPDJ
DMG8P24	MN	Carbonic anhydrase II (CA-II)
DMG8P24	MT	DTT
DMG8P24	MA	Inhibitor
DMG8P24	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DMG8P24	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DMG8P24	DI	DMG8P24
DMG8P24	DN	ACETYLSULFANILAMIDE
DMG8P24	MI	TT2LVK8
DMG8P24	MN	Carbonic anhydrase IX (CA-IX)
DMG8P24	MT	DTT
DMG8P24	MA	Inhibitor
DMG8P24	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DMG8P24	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DMG8P24	DI	DMG8P24
DMG8P24	DN	ACETYLSULFANILAMIDE
DMG8P24	MI	TTSYM0R
DMG8P24	MN	Carbonic anhydrase XII (CA-XII)
DMG8P24	MT	DTT
DMG8P24	MA	Inhibitor
DMG8P24	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DMG8P24	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DM3XHIY	DI	DM3XHIY
DM3XHIY	DN	Ac-FWKY-NH2
DM3XHIY	MI	TTW5UDX
DM3XHIY	MN	Urotensin II receptor (UTS2R)
DM3XHIY	MT	DTT
DM3XHIY	MA	Inhibitor
DM3XHIY	RN	Urotensin-II receptor modulators as potential drugs. J Med Chem. 2010 Apr 8;53(7):2695-708.
DM3XHIY	RU	https://pubmed.ncbi.nlm.nih.gov/20043680

DMAI43O	DI	DMAI43O
DMAI43O	DN	AcGlu-Asp-Val-Val-Leu-Cys-Iqc-Nle-Thr-TyrNH2
DMAI43O	MI	TTWXB3E
DMAI43O	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DMAI43O	MT	DTT
DMAI43O	MA	Inhibitor
DMAI43O	RN	Control of hepatitis C: a medicinal chemistry perspective. J Med Chem. 2005 Jan 13;48(1):1-20.
DMAI43O	RU	https://pubmed.ncbi.nlm.nih.gov/15633995

DM6T09B	DI	DM6T09B
DM6T09B	DN	Ac-Glu-Cha-Cys
DM6T09B	MI	TTWXB3E
DM6T09B	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DM6T09B	MT	DTT
DM6T09B	MA	Inhibitor
DM6T09B	RN	Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain. Bioorg Med Chem Lett. 2001 Jan 22;11(2):203-6.
DM6T09B	RU	https://pubmed.ncbi.nlm.nih.gov/11206459

DM0BV9I	DI	DM0BV9I
DM0BV9I	DN	AcGlu-Dif-Glu-Cha-Cys
DM0BV9I	MI	TTWXB3E
DM0BV9I	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DM0BV9I	MT	DTT
DM0BV9I	MA	Inhibitor
DM0BV9I	RN	Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain. Bioorg Med Chem Lett. 2001 Jan 22;11(2):203-6.
DM0BV9I	RU	https://pubmed.ncbi.nlm.nih.gov/11206459

DMK6HGI	DI	DMK6HGI
DMK6HGI	DN	AcGlu-Dif-Ile-Cha-Cys
DMK6HGI	MI	TTWXB3E
DMK6HGI	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DMK6HGI	MT	DTT
DMK6HGI	MA	Inhibitor
DMK6HGI	RN	Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain. Bioorg Med Chem Lett. 2001 Jan 22;11(2):203-6.
DMK6HGI	RU	https://pubmed.ncbi.nlm.nih.gov/11206459

DMMNQE3	DI	DMMNQE3
DMMNQE3	DN	ACH-702
DMMNQE3	MI	TTE72ID
DMMNQE3	MN	Haemophilus influenzae DNA gyrase A (Hae-influ gyrA)
DMMNQE3	MT	DTT
DMMNQE3	MA	Inhibitor
DMMNQE3	RN	In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates. Antimicrob Agents Chemother. 2010 Aug;54(8):3478-80.
DMMNQE3	RU	https://pubmed.ncbi.nlm.nih.gov/20516287

DMUEBRN	DI	DMUEBRN
DMUEBRN	DN	Ac-His-DNal(2)-Arg-Trp-NH2
DMUEBRN	MI	TTEOSZT
DMUEBRN	MN	Melanocortin receptor (MCR)
DMUEBRN	MT	DTT
DMUEBRN	MA	Inhibitor
DMUEBRN	RN	Melanocortin tetrapeptide Ac-His-DPhe-Arg-Trp-NH2 modified at the para position of the benzyl side chain (DPhe): importance for mouse melanocortin-... J Med Chem. 2008 Sep 25;51(18):5585-93.
DMUEBRN	RU	https://pubmed.ncbi.nlm.nih.gov/18800761

DMR31Z9	DI	DMR31Z9
DMR31Z9	DN	Ac-His-DPhe(3,4-diCl)-Arg-Trp-NH2
DMR31Z9	MI	TTEOSZT
DMR31Z9	MN	Melanocortin receptor (MCR)
DMR31Z9	MT	DTT
DMR31Z9	MA	Inhibitor
DMR31Z9	RN	Melanocortin tetrapeptide Ac-His-DPhe-Arg-Trp-NH2 modified at the para position of the benzyl side chain (DPhe): importance for mouse melanocortin-... J Med Chem. 2008 Sep 25;51(18):5585-93.
DMR31Z9	RU	https://pubmed.ncbi.nlm.nih.gov/18800761

DMXU5ZP	DI	DMXU5ZP
DMXU5ZP	DN	Ac-His-DPhe(pBr)-Arg-Trp-NH2
DMXU5ZP	MI	TTEOSZT
DMXU5ZP	MN	Melanocortin receptor (MCR)
DMXU5ZP	MT	DTT
DMXU5ZP	MA	Inhibitor
DMXU5ZP	RN	Melanocortin tetrapeptide Ac-His-DPhe-Arg-Trp-NH2 modified at the para position of the benzyl side chain (DPhe): importance for mouse melanocortin-... J Med Chem. 2008 Sep 25;51(18):5585-93.
DMXU5ZP	RU	https://pubmed.ncbi.nlm.nih.gov/18800761

DMTA6I5	DI	DMTA6I5
DMTA6I5	DN	Ac-His-DPhe(pCF3)-Arg-Trp-NH2
DMTA6I5	MI	TTEOSZT
DMTA6I5	MN	Melanocortin receptor (MCR)
DMTA6I5	MT	DTT
DMTA6I5	MA	Inhibitor
DMTA6I5	RN	Melanocortin tetrapeptide Ac-His-DPhe-Arg-Trp-NH2 modified at the para position of the benzyl side chain (DPhe): importance for mouse melanocortin-... J Med Chem. 2008 Sep 25;51(18):5585-93.
DMTA6I5	RU	https://pubmed.ncbi.nlm.nih.gov/18800761

DM3GSPX	DI	DM3GSPX
DM3GSPX	DN	Ac-His-DPhe(pI)-Arg-Trp-NH2
DM3GSPX	MI	TTEOSZT
DM3GSPX	MN	Melanocortin receptor (MCR)
DM3GSPX	MT	DTT
DM3GSPX	MA	Inhibitor
DM3GSPX	RN	Melanocortin tetrapeptide Ac-His-DPhe-Arg-Trp-NH2 modified at the para position of the benzyl side chain (DPhe): importance for mouse melanocortin-... J Med Chem. 2008 Sep 25;51(18):5585-93.
DM3GSPX	RU	https://pubmed.ncbi.nlm.nih.gov/18800761

DMAQR29	DI	DMAQR29
DMAQR29	DN	Ac-His-D-Phe-Arg-2-Nal-NHCH3
DMAQR29	MI	TT0MV2T
DMAQR29	MN	Melanocortin receptor 1 (MC1R)
DMAQR29	MT	DTT
DMAQR29	MA	Inhibitor
DMAQR29	RN	Design and synthesis of potent and selective 1,3,4-trisubstituted-2-oxopiperazine based melanocortin-4 receptor agonists. Bioorg Med Chem Lett. 2006 Sep 1;16(17):4668-73.
DMAQR29	RU	https://pubmed.ncbi.nlm.nih.gov/16766182

DMAQR29	DI	DMAQR29
DMAQR29	DN	Ac-His-D-Phe-Arg-2-Nal-NHCH3
DMAQR29	MI	TTNI91K
DMAQR29	MN	Melanocortin receptor 3 (MC3R)
DMAQR29	MT	DTT
DMAQR29	MA	Inhibitor
DMAQR29	RN	Design and synthesis of potent and selective 1,3,4-trisubstituted-2-oxopiperazine based melanocortin-4 receptor agonists. Bioorg Med Chem Lett. 2006 Sep 1;16(17):4668-73.
DMAQR29	RU	https://pubmed.ncbi.nlm.nih.gov/16766182

DMAQR29	DI	DMAQR29
DMAQR29	DN	Ac-His-D-Phe-Arg-2-Nal-NHCH3
DMAQR29	MI	TTD0CIQ
DMAQR29	MN	Melanocortin receptor 4 (MC4R)
DMAQR29	MT	DTT
DMAQR29	MA	Inhibitor
DMAQR29	RN	Design and synthesis of potent and selective 1,3,4-trisubstituted-2-oxopiperazine based melanocortin-4 receptor agonists. Bioorg Med Chem Lett. 2006 Sep 1;16(17):4668-73.
DMAQR29	RU	https://pubmed.ncbi.nlm.nih.gov/16766182

DMMP0D8	DI	DMMP0D8
DMMP0D8	DN	Ac-His-DPhe-Arg-Trp-NH2
DMMP0D8	MI	TT0MV2T
DMMP0D8	MN	Melanocortin receptor 1 (MC1R)
DMMP0D8	MT	DTT
DMMP0D8	MA	Inhibitor
DMMP0D8	RN	Discovery of prototype peptidomimetic agonists at the human melanocortin receptors MC1R and MC4R. J Med Chem. 1997 Jul 4;40(14):2133-9.
DMMP0D8	RU	https://pubmed.ncbi.nlm.nih.gov/9216831

DMMP0D8	DI	DMMP0D8
DMMP0D8	DN	Ac-His-DPhe-Arg-Trp-NH2
DMMP0D8	MI	TTD0CIQ
DMMP0D8	MN	Melanocortin receptor 4 (MC4R)
DMMP0D8	MT	DTT
DMMP0D8	MA	Inhibitor
DMMP0D8	RN	Discovery of prototype peptidomimetic agonists at the human melanocortin receptors MC1R and MC4R. J Med Chem. 1997 Jul 4;40(14):2133-9.
DMMP0D8	RU	https://pubmed.ncbi.nlm.nih.gov/9216831

DMCA4QR	DI	DMCA4QR
DMCA4QR	DN	Ac-His-Trp-Ala-Val-Ala-His-Leu-Met-NH2
DMCA4QR	MI	TTC1MVT
DMCA4QR	MN	Gastrin-releasing peptide receptor (GRPR)
DMCA4QR	MT	DTT
DMCA4QR	MA	Inhibitor
DMCA4QR	RN	Gastrin releasing peptide antagonists with improved potency and stability. J Med Chem. 1991 Jul;34(7):2102-7.
DMCA4QR	RU	https://pubmed.ncbi.nlm.nih.gov/2066982

DMUINVT	DI	DMUINVT
DMUINVT	DN	Ac-His-Trp-Ala-Val-D-Ala-His-Leu-Met-NH2
DMUINVT	MI	TTC1MVT
DMUINVT	MN	Gastrin-releasing peptide receptor (GRPR)
DMUINVT	MT	DTT
DMUINVT	MA	Inhibitor
DMUINVT	RN	Gastrin releasing peptide antagonists with improved potency and stability. J Med Chem. 1991 Jul;34(7):2102-7.
DMUINVT	RU	https://pubmed.ncbi.nlm.nih.gov/2066982

DMUGO9M	DI	DMUGO9M
DMUGO9M	DN	Ac-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2
DMUGO9M	MI	TTC1MVT
DMUGO9M	MN	Gastrin-releasing peptide receptor (GRPR)
DMUGO9M	MT	DTT
DMUGO9M	MA	Inhibitor
DMUGO9M	RN	Gastrin releasing peptide antagonists with improved potency and stability. J Med Chem. 1991 Jul;34(7):2102-7.
DMUGO9M	RU	https://pubmed.ncbi.nlm.nih.gov/2066982

DMZO5Y7	DI	DMZO5Y7
DMZO5Y7	DN	ACHP
DMZO5Y7	MI	TTSXVID
DMZO5Y7	MN	Nuclear factor NF-kappa-B (NFKB)
DMZO5Y7	MT	DTT
DMZO5Y7	MA	Inhibitor
DMZO5Y7	RN	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
DMZO5Y7	RU	https://pubmed.ncbi.nlm.nih.gov/19249983

DMU7SBD	DI	DMU7SBD
DMU7SBD	DN	Ac-hPhe-Leu-Ala-LeuVSMe
DMU7SBD	MI	TTF2LRI
DMU7SBD	MN	Cathepsin B (CTSB)
DMU7SBD	MT	DTT
DMU7SBD	MA	Inhibitor
DMU7SBD	RN	Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and c... J Med Chem. 2006 May 18;49(10):2953-68.
DMU7SBD	RU	https://pubmed.ncbi.nlm.nih.gov/16686537

DMU7SBD	DI	DMU7SBD
DMU7SBD	DN	Ac-hPhe-Leu-Ala-LeuVSMe
DMU7SBD	MI	TTUMQVO
DMU7SBD	MN	Cathepsin S (CTSS)
DMU7SBD	MT	DTT
DMU7SBD	MA	Inhibitor
DMU7SBD	RN	Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and c... J Med Chem. 2006 May 18;49(10):2953-68.
DMU7SBD	RU	https://pubmed.ncbi.nlm.nih.gov/16686537

DMH2SU4	DI	DMH2SU4
DMH2SU4	DN	Ac-hPhe-Leu-Gly-LeuVSMe
DMH2SU4	MI	TTUMQVO
DMH2SU4	MN	Cathepsin S (CTSS)
DMH2SU4	MT	DTT
DMH2SU4	MA	Inhibitor
DMH2SU4	RN	Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and c... J Med Chem. 2006 May 18;49(10):2953-68.
DMH2SU4	RU	https://pubmed.ncbi.nlm.nih.gov/16686537

DMMDJPC	DI	DMMDJPC
DMMDJPC	DN	Ac-hPhe-Leu-Phe-LeuVSMe
DMMDJPC	MI	TTF2LRI
DMMDJPC	MN	Cathepsin B (CTSB)
DMMDJPC	MT	DTT
DMMDJPC	MA	Inhibitor
DMMDJPC	RN	Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and c... J Med Chem. 2006 May 18;49(10):2953-68.
DMMDJPC	RU	https://pubmed.ncbi.nlm.nih.gov/16686537

DMMDJPC	DI	DMMDJPC
DMMDJPC	DN	Ac-hPhe-Leu-Phe-LeuVSMe
DMMDJPC	MI	TTUMQVO
DMMDJPC	MN	Cathepsin S (CTSS)
DMMDJPC	MT	DTT
DMMDJPC	MA	Inhibitor
DMMDJPC	RN	Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and c... J Med Chem. 2006 May 18;49(10):2953-68.
DMMDJPC	RU	https://pubmed.ncbi.nlm.nih.gov/16686537

DMV58GQ	DI	DMV58GQ
DMV58GQ	DN	Ac-HSDAVFTDQYTRLRKQVAAKKYLQSIKQKRYC
DMV58GQ	MI	TTZC9FV
DMV58GQ	MN	Vasoactive intestinal polypeptide receptor (VIPR)
DMV58GQ	MT	DTT
DMV58GQ	MA	Inhibitor
DMV58GQ	RN	Engineering of a VPAC2 receptor peptide agonist to impart dipeptidyl peptidase IV stability and enhance in vivo glucose disposal. J Med Chem. 2006 Dec 14;49(25):7545-8.
DMV58GQ	RU	https://pubmed.ncbi.nlm.nih.gov/17149884

DMJVRPD	DI	DMJVRPD
DMJVRPD	DN	Ac-I[CV(1Nal)QDWGAHRC]T
DMJVRPD	MI	TTJGY7A
DMJVRPD	MN	Complement C3 (CO3)
DMJVRPD	MT	DTT
DMJVRPD	MA	Inhibitor
DMJVRPD	RN	Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86.
DMJVRPD	RU	https://pubmed.ncbi.nlm.nih.gov/15634022

DM14DEL	DI	DM14DEL
DM14DEL	DN	Ac-I[CV(2Igl)QDWGAHRC]T
DM14DEL	MI	TTJGY7A
DM14DEL	MN	Complement C3 (CO3)
DM14DEL	MT	DTT
DM14DEL	MA	Inhibitor
DM14DEL	RN	Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86.
DM14DEL	RU	https://pubmed.ncbi.nlm.nih.gov/15634022

DMQISG6	DI	DMQISG6
DMQISG6	DN	Ac-I[CV(2Igl)QDWGAHRC]T-NH2
DMQISG6	MI	TTJGY7A
DMQISG6	MN	Complement C3 (CO3)
DMQISG6	MT	DTT
DMQISG6	MA	Inhibitor
DMQISG6	RN	Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86.
DMQISG6	RU	https://pubmed.ncbi.nlm.nih.gov/15634022

DM20PEO	DI	DM20PEO
DM20PEO	DN	Ac-I[CV(2Nal)QDWGAHRC]T
DM20PEO	MI	TTJGY7A
DM20PEO	MN	Complement C3 (CO3)
DM20PEO	MT	DTT
DM20PEO	MA	Inhibitor
DM20PEO	RN	Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86.
DM20PEO	RU	https://pubmed.ncbi.nlm.nih.gov/15634022

DMX2IRY	DI	DMX2IRY
DMX2IRY	DN	Ac-I[CV(2Nal)QDWGAHRC]T-NH2
DMX2IRY	MI	TTJGY7A
DMX2IRY	MN	Complement C3 (CO3)
DMX2IRY	MT	DTT
DMX2IRY	MA	Inhibitor
DMX2IRY	RN	Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86.
DMX2IRY	RU	https://pubmed.ncbi.nlm.nih.gov/15634022

DMDFKU3	DI	DMDFKU3
DMDFKU3	DN	Ac-I[CV(Bpa)QDWGAHRC]T
DMDFKU3	MI	TTJGY7A
DMDFKU3	MN	Complement C3 (CO3)
DMDFKU3	MT	DTT
DMDFKU3	MA	Inhibitor
DMDFKU3	RN	Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86.
DMDFKU3	RU	https://pubmed.ncbi.nlm.nih.gov/15634022

DMZG46O	DI	DMZG46O
DMZG46O	DN	Ac-I[CV(Bpa)QDWGAHRC]T-NH2
DMZG46O	MI	TTJGY7A
DMZG46O	MN	Complement C3 (CO3)
DMZG46O	MT	DTT
DMZG46O	MA	Inhibitor
DMZG46O	RN	Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86.
DMZG46O	RU	https://pubmed.ncbi.nlm.nih.gov/15634022

DM5NMVP	DI	DM5NMVP
DM5NMVP	DN	Ac-I[CV(Bta)QDWGAHRC]T
DM5NMVP	MI	TTJGY7A
DM5NMVP	MN	Complement C3 (CO3)
DM5NMVP	MT	DTT
DM5NMVP	MA	Inhibitor
DM5NMVP	RN	Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86.
DM5NMVP	RU	https://pubmed.ncbi.nlm.nih.gov/15634022

DMFLA5T	DI	DMFLA5T
DMFLA5T	DN	Ac-I[CV(Bta)QDWGAHRC]T-NH2
DMFLA5T	MI	TTJGY7A
DMFLA5T	MN	Complement C3 (CO3)
DMFLA5T	MT	DTT
DMFLA5T	MA	Inhibitor
DMFLA5T	RN	Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86.
DMFLA5T	RU	https://pubmed.ncbi.nlm.nih.gov/15634022

DMO9VWH	DI	DMO9VWH
DMO9VWH	DN	Ac-I[CV(Dht)QDWGAHRC]T
DMO9VWH	MI	TTJGY7A
DMO9VWH	MN	Complement C3 (CO3)
DMO9VWH	MT	DTT
DMO9VWH	MA	Inhibitor
DMO9VWH	RN	Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86.
DMO9VWH	RU	https://pubmed.ncbi.nlm.nih.gov/15634022

DMY18ET	DI	DMY18ET
DMY18ET	DN	Ac-I[CV(Yphs)QDWGAHRC]I-NH2
DMY18ET	MI	TTJGY7A
DMY18ET	MN	Complement C3 (CO3)
DMY18ET	MT	DTT
DMY18ET	MA	Inhibitor
DMY18ET	RN	Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86.
DMY18ET	RU	https://pubmed.ncbi.nlm.nih.gov/15634022

DMFOTYQ	DI	DMFOTYQ
DMFOTYQ	DN	Ac-I[CVFQDWGHHRC]T-NH2
DMFOTYQ	MI	TTJGY7A
DMFOTYQ	MN	Complement C3 (CO3)
DMFOTYQ	MT	DTT
DMFOTYQ	MA	Inhibitor
DMFOTYQ	RN	Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86.
DMFOTYQ	RU	https://pubmed.ncbi.nlm.nih.gov/15634022

DMLU3PZ	DI	DMLU3PZ
DMLU3PZ	DN	Ac-I[CVHQDWGHHRC]T-NH2
DMLU3PZ	MI	TTJGY7A
DMLU3PZ	MN	Complement C3 (CO3)
DMLU3PZ	MT	DTT
DMLU3PZ	MA	Inhibitor
DMLU3PZ	RN	Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86.
DMLU3PZ	RU	https://pubmed.ncbi.nlm.nih.gov/15634022

DMDPSBQ	DI	DMDPSBQ
DMDPSBQ	DN	Ac-I[CVSQDWGHHRC]T-NH2
DMDPSBQ	MI	TTJGY7A
DMDPSBQ	MN	Complement C3 (CO3)
DMDPSBQ	MT	DTT
DMDPSBQ	MA	Inhibitor
DMDPSBQ	RN	Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86.
DMDPSBQ	RU	https://pubmed.ncbi.nlm.nih.gov/15634022

DMNVMB5	DI	DMNVMB5
DMNVMB5	DN	Ac-I[CVTQDWGHHRC]T-NH2
DMNVMB5	MI	TTJGY7A
DMNVMB5	MN	Complement C3 (CO3)
DMNVMB5	MT	DTT
DMNVMB5	MA	Inhibitor
DMNVMB5	RN	Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86.
DMNVMB5	RU	https://pubmed.ncbi.nlm.nih.gov/15634022

DMRSKIY	DI	DMRSKIY
DMRSKIY	DN	Ac-I[CVVQDWGAHRC]T-NH2
DMRSKIY	MI	TTJGY7A
DMRSKIY	MN	Complement C3 (CO3)
DMRSKIY	MT	DTT
DMRSKIY	MA	Inhibitor
DMRSKIY	RN	Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86.
DMRSKIY	RU	https://pubmed.ncbi.nlm.nih.gov/15634022

DMUW3T4	DI	DMUW3T4
DMUW3T4	DN	Ac-I[CVWQDWG(Abu)HRC]T-NH2
DMUW3T4	MI	TTJGY7A
DMUW3T4	MN	Complement C3 (CO3)
DMUW3T4	MT	DTT
DMUW3T4	MA	Inhibitor
DMUW3T4	RN	Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86.
DMUW3T4	RU	https://pubmed.ncbi.nlm.nih.gov/15634022

DML5ZSJ	DI	DML5ZSJ
DML5ZSJ	DN	Ac-I[CVWQDWGAHRC]dT
DML5ZSJ	MI	TTJGY7A
DML5ZSJ	MN	Complement C3 (CO3)
DML5ZSJ	MT	DTT
DML5ZSJ	MA	Inhibitor
DML5ZSJ	RN	Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86.
DML5ZSJ	RU	https://pubmed.ncbi.nlm.nih.gov/15634022

DMV3PC7	DI	DMV3PC7
DMV3PC7	DN	Ac-I[CVWQDWGAHRC]T
DMV3PC7	MI	TTJGY7A
DMV3PC7	MN	Complement C3 (CO3)
DMV3PC7	MT	DTT
DMV3PC7	MA	Inhibitor
DMV3PC7	RN	Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86.
DMV3PC7	RU	https://pubmed.ncbi.nlm.nih.gov/15634022

DMBA1LS	DI	DMBA1LS
DMBA1LS	DN	Ac-I[CVWQDWGHHRC]T-NH2
DMBA1LS	MI	TTJGY7A
DMBA1LS	MN	Complement C3 (CO3)
DMBA1LS	MT	DTT
DMBA1LS	MA	Inhibitor
DMBA1LS	RN	Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86.
DMBA1LS	RU	https://pubmed.ncbi.nlm.nih.gov/15634022

DMDIUK6	DI	DMDIUK6
DMDIUK6	DN	Ac-I[CVWQDWGWHRC]T-NH2
DMDIUK6	MI	TTJGY7A
DMDIUK6	MN	Complement C3 (CO3)
DMDIUK6	MT	DTT
DMDIUK6	MA	Inhibitor
DMDIUK6	RN	Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86.
DMDIUK6	RU	https://pubmed.ncbi.nlm.nih.gov/15634022

DM3Q5SU	DI	DM3Q5SU
DM3Q5SU	DN	Ac-I[CVYQDWGAHRC]T-NH2
DM3Q5SU	MI	TTJGY7A
DM3Q5SU	MN	Complement C3 (CO3)
DM3Q5SU	MT	DTT
DM3Q5SU	MA	Inhibitor
DM3Q5SU	RN	Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86.
DM3Q5SU	RU	https://pubmed.ncbi.nlm.nih.gov/15634022

DMPLNTM	DI	DMPLNTM
DMPLNTM	DN	ACI-636
DMPLNTM	MI	TTE4KHA
DMPLNTM	MN	Amyloid beta A4 protein (APP)
DMPLNTM	MT	DTT
DMPLNTM	MA	Inhibitor
DMPLNTM	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
DMPLNTM	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402

DM351NL	DI	DM351NL
DM351NL	DN	Ac-ICV(1MeW)QDWGAHRCT-NH2
DM351NL	MI	TTJGY7A
DM351NL	MN	Complement C3 (CO3)
DM351NL	MT	DTT
DM351NL	MA	Inhibitor
DM351NL	RN	Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin. J Med Chem. 2006 Jul 27;49(15):4616-22.
DM351NL	RU	https://pubmed.ncbi.nlm.nih.gov/16854067

DMQLPGA	DI	DMQLPGA
DMQLPGA	DN	Ac-ICV(5fW)QDWGAHRCT-NH2
DMQLPGA	MI	TTJGY7A
DMQLPGA	MN	Complement C3 (CO3)
DMQLPGA	MT	DTT
DMQLPGA	MA	Inhibitor
DMQLPGA	RN	Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin. J Med Chem. 2006 Jul 27;49(15):4616-22.
DMQLPGA	RU	https://pubmed.ncbi.nlm.nih.gov/16854067

DM52T90	DI	DM52T90
DM52T90	DN	Ac-ICV(5MeW)QDWGAHRCT-NH2
DM52T90	MI	TTJGY7A
DM52T90	MN	Complement C3 (CO3)
DM52T90	MT	DTT
DM52T90	MA	Inhibitor
DM52T90	RN	Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin. J Med Chem. 2006 Jul 27;49(15):4616-22.
DM52T90	RU	https://pubmed.ncbi.nlm.nih.gov/16854067

DMPK9LG	DI	DMPK9LG
DMPK9LG	DN	Ac-ICVWQD(5fW)GAHRCT-NH2
DMPK9LG	MI	TTJGY7A
DMPK9LG	MN	Complement C3 (CO3)
DMPK9LG	MT	DTT
DMPK9LG	MA	Inhibitor
DMPK9LG	RN	Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin. J Med Chem. 2006 Jul 27;49(15):4616-22.
DMPK9LG	RU	https://pubmed.ncbi.nlm.nih.gov/16854067

DMPSI26	DI	DMPSI26
DMPSI26	DN	Ac-ICVWQDWGAHRCT-NH2
DMPSI26	MI	TTJGY7A
DMPSI26	MN	Complement C3 (CO3)
DMPSI26	MT	DTT
DMPSI26	MA	Inhibitor
DMPSI26	RN	Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin. J Med Chem. 2006 Jul 27;49(15):4616-22.
DMPSI26	RU	https://pubmed.ncbi.nlm.nih.gov/16854067

DMCU6XV	DI	DMCU6XV
DMCU6XV	DN	Acid blue 25
DMCU6XV	MI	TTK0O6Y
DMCU6XV	MN	Ecto-5'-nucleotidase (CD73)
DMCU6XV	MT	DTT
DMCU6XV	MA	Inhibitor
DMCU6XV	RN	Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold. J Med Chem. 2010 Mar 11;53(5):2076-86.
DMCU6XV	RU	https://pubmed.ncbi.nlm.nih.gov/20146483

DMCU6XV	DI	DMCU6XV
DMCU6XV	DN	Acid blue 25
DMCU6XV	MI	TTOZHQC
DMCU6XV	MN	P2Y purinoceptor 2 (P2RY2)
DMCU6XV	MT	DTT
DMCU6XV	MA	Inhibitor
DMCU6XV	RN	Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold. J Med Chem. 2010 Mar 11;53(5):2076-86.
DMCU6XV	RU	https://pubmed.ncbi.nlm.nih.gov/20146483

DMTOEJX	DI	DMTOEJX
DMTOEJX	DN	Acid-activated omeprazole
DMTOEJX	MI	TT30NW6
DMTOEJX	MN	Chloride channel protein 2 (CLC-2)
DMTOEJX	MT	DTT
DMTOEJX	MA	Activator
DMTOEJX	RN	ClC-2 Cl- channels in human lung epithelia: activation by arachidonic acid, amidation, and acid-activated omeprazole. Am J Physiol Cell Physiol. 2001 Jul;281(1):C46-54.
DMTOEJX	RU	https://pubmed.ncbi.nlm.nih.gov/11401826

DMTOEJX	DI	DMTOEJX
DMTOEJX	DN	Acid-activated omeprazole
DMTOEJX	MI	TTZN7RP
DMTOEJX	MN	Rho-associated protein kinase 1 (ROCK1)
DMTOEJX	MT	DTT
DMTOEJX	MA	Inhibitor
DMTOEJX	RN	Long-term treatment with a specific Rho-kinase inhibitor suppresses cardiac allograft vasculopathy in mice. Circ Res. 2004 Jan 9;94(1):46-52.
DMTOEJX	RU	https://pubmed.ncbi.nlm.nih.gov/14615290

DMKVU8P	DI	DMKVU8P
DMKVU8P	DN	Ac-L-Phe-D-trp-L-Phe-D-pro-NH2
DMKVU8P	MI	TTKWM86
DMKVU8P	MN	Opioid receptor mu (MOP)
DMKVU8P	MT	DTT
DMKVU8P	MA	Inhibitor
DMKVU8P	RN	Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50.
DMKVU8P	RU	https://pubmed.ncbi.nlm.nih.gov/19464172

DMIAYTP	DI	DMIAYTP
DMIAYTP	DN	Ac-Lys-[Leu(8)]-des-Arg(9)-BK
DMIAYTP	MI	TTG5QIA
DMIAYTP	MN	B1 bradykinin receptor (BDKRB1)
DMIAYTP	MT	DTT
DMIAYTP	MA	Antagonist
DMIAYTP	RN	Non-competitive pharmacological antagonism at the rabbit B(1) receptor. Br J Pharmacol. 2000 Nov;131(5):885-92.
DMIAYTP	RU	https://pubmed.ncbi.nlm.nih.gov/11053207

DMRQ70X	DI	DMRQ70X
DMRQ70X	DN	ACMC-1AKLT
DMRQ70X	MI	DEYGVN4
DMRQ70X	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMRQ70X	MT	DME
DMRQ70X	MA	Metabolism
DMRQ70X	RN	Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
DMRQ70X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20620155

DMQCSFB	DI	DMQCSFB
DMQCSFB	DN	ACMC-209cv7
DMQCSFB	MI	DEIVKZ8
DMQCSFB	MN	NADPH-dependent carbonyl reductase 3 (CBR3)
DMQCSFB	MT	DME
DMQCSFB	MA	Metabolism
DMQCSFB	RN	Different functions between human monomeric carbonyl reductase 3 and carbonyl reductase 1. Mol Cell Biochem. 2008 Aug;315(1-2):113-21.
DMQCSFB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18493841

DM3E4QR	DI	DM3E4QR
DM3E4QR	DN	ACN-1052
DM3E4QR	MI	TTJFY5U
DM3E4QR	MN	Adenosine A3 receptor (ADORA3)
DM3E4QR	MT	DTT
DM3E4QR	MA	Antagonist
DM3E4QR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 21).
DM3E4QR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=21

DMLYGPW	DI	DMLYGPW
DMLYGPW	DN	Ac-Nle-c[Asp-His-DNaI(2')-Pro-Trp-Lys]-NH2
DMLYGPW	MI	TT0MV2T
DMLYGPW	MN	Melanocortin receptor 1 (MC1R)
DMLYGPW	MT	DTT
DMLYGPW	MA	Inhibitor
DMLYGPW	RN	Substitution of arginine with proline and proline derivatives in melanocyte-stimulating hormones leads to selectivity for human melanocortin 4 rece... J Med Chem. 2009 Jun 25;52(12):3627-35.
DMLYGPW	RU	https://pubmed.ncbi.nlm.nih.gov/19473029

DMLYGPW	DI	DMLYGPW
DMLYGPW	DN	Ac-Nle-c[Asp-His-DNaI(2')-Pro-Trp-Lys]-NH2
DMLYGPW	MI	TTD0CIQ
DMLYGPW	MN	Melanocortin receptor 4 (MC4R)
DMLYGPW	MT	DTT
DMLYGPW	MA	Inhibitor
DMLYGPW	RN	Substitution of arginine with proline and proline derivatives in melanocyte-stimulating hormones leads to selectivity for human melanocortin 4 rece... J Med Chem. 2009 Jun 25;52(12):3627-35.
DMLYGPW	RU	https://pubmed.ncbi.nlm.nih.gov/19473029

DMOVI7Y	DI	DMOVI7Y
DMOVI7Y	DN	Ac-Nle-c[Asp-His-DNal(2')-Pro-Trp-Lys]-NH2
DMOVI7Y	MI	TTEOSZT
DMOVI7Y	MN	Melanocortin receptor (MCR)
DMOVI7Y	MT	DTT
DMOVI7Y	MA	Inhibitor
DMOVI7Y	RN	Substitution of arginine with proline and proline derivatives in melanocyte-stimulating hormones leads to selectivity for human melanocortin 4 rece... J Med Chem. 2009 Jun 25;52(12):3627-35.
DMOVI7Y	RU	https://pubmed.ncbi.nlm.nih.gov/19473029

DMOVI7Y	DI	DMOVI7Y
DMOVI7Y	DN	Ac-Nle-c[Asp-His-DNal(2')-Pro-Trp-Lys]-NH2
DMOVI7Y	MI	TT0MV2T
DMOVI7Y	MN	Melanocortin receptor 1 (MC1R)
DMOVI7Y	MT	DTT
DMOVI7Y	MA	Inhibitor
DMOVI7Y	RN	Substitution of arginine with proline and proline derivatives in melanocyte-stimulating hormones leads to selectivity for human melanocortin 4 rece... J Med Chem. 2009 Jun 25;52(12):3627-35.
DMOVI7Y	RU	https://pubmed.ncbi.nlm.nih.gov/19473029

DMOVI7Y	DI	DMOVI7Y
DMOVI7Y	DN	Ac-Nle-c[Asp-His-DNal(2')-Pro-Trp-Lys]-NH2
DMOVI7Y	MI	TTNI91K
DMOVI7Y	MN	Melanocortin receptor 3 (MC3R)
DMOVI7Y	MT	DTT
DMOVI7Y	MA	Inhibitor
DMOVI7Y	RN	Substitution of arginine with proline and proline derivatives in melanocyte-stimulating hormones leads to selectivity for human melanocortin 4 rece... J Med Chem. 2009 Jun 25;52(12):3627-35.
DMOVI7Y	RU	https://pubmed.ncbi.nlm.nih.gov/19473029

DMOVI7Y	DI	DMOVI7Y
DMOVI7Y	DN	Ac-Nle-c[Asp-His-DNal(2')-Pro-Trp-Lys]-NH2
DMOVI7Y	MI	TTD0CIQ
DMOVI7Y	MN	Melanocortin receptor 4 (MC4R)
DMOVI7Y	MT	DTT
DMOVI7Y	MA	Inhibitor
DMOVI7Y	RN	Substitution of arginine with proline and proline derivatives in melanocyte-stimulating hormones leads to selectivity for human melanocortin 4 rece... J Med Chem. 2009 Jun 25;52(12):3627-35.
DMOVI7Y	RU	https://pubmed.ncbi.nlm.nih.gov/19473029

DMG418C	DI	DMG418C
DMG418C	DN	AC-Nle-c[Asp-His-DPhe-Pro-Trp-Lys]-NH2
DMG418C	MI	TTD0CIQ
DMG418C	MN	Melanocortin receptor 4 (MC4R)
DMG418C	MT	DTT
DMG418C	MA	Inhibitor
DMG418C	RN	Substitution of arginine with proline and proline derivatives in melanocyte-stimulating hormones leads to selectivity for human melanocortin 4 rece... J Med Chem. 2009 Jun 25;52(12):3627-35.
DMG418C	RU	https://pubmed.ncbi.nlm.nih.gov/19473029

DMZBOQW	DI	DMZBOQW
DMZBOQW	DN	AcNPY(25-36)
DMZBOQW	MI	TTJ6WK9
DMZBOQW	MN	Neuropeptide Y receptor type 2 (NPY2R)
DMZBOQW	MT	DTT
DMZBOQW	MA	Inhibitor
DMZBOQW	RN	Identification of selective neuropeptide Y2 peptide agonists. Bioorg Med Chem Lett. 2007 Jan 15;17(2):538-41.
DMZBOQW	RU	https://pubmed.ncbi.nlm.nih.gov/17055726

DMQ0YW7	DI	DMQ0YW7
DMQ0YW7	DN	Acocantherin
DMQ0YW7	MI	TTWNK8B
DMQ0YW7	MN	HUMAN sodium pump subunit alpha-1 (ATP1A1)
DMQ0YW7	MT	DTT
DMQ0YW7	MA	Inhibitor
DMQ0YW7	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DMQ0YW7	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DMJ5U8C	DI	DMJ5U8C
DMJ5U8C	DN	Aconitate Ion
DMJ5U8C	MI	TTMTF2P
DMJ5U8C	MN	Citrate hydro-lyase (ACO2)
DMJ5U8C	MT	DTT
DMJ5U8C	MA	Inhibitor
DMJ5U8C	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMJ5U8C	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMFOZ60	DI	DMFOZ60
DMFOZ60	DN	aconitine
DMFOZ60	MI	TTLJTUF
DMFOZ60	MN	Voltage-gated sodium channel alpha Nav1.2 (SCN2A)
DMFOZ60	MT	DTT
DMFOZ60	MA	Activator
DMFOZ60	RN	Binding of batrachotoxinin A 20-alpha-benzoate to a receptor site associated with sodium channels in synaptic nerve ending particles. J Biol Chem. 1981 Sep 10;256(17):8922-7.
DMFOZ60	RU	https://pubmed.ncbi.nlm.nih.gov/6114956

DMFOZ60	DI	DMFOZ60
DMFOZ60	DN	aconitine
DMFOZ60	MI	TTZOVE0
DMFOZ60	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DMFOZ60	MT	DTT
DMFOZ60	MA	Activator
DMFOZ60	RN	Properties of aconitine-modified sodium channels in single cells of mouse ventricular myocardium. Gen Physiol Biophys. 1986 Oct;5(5):473-84.
DMFOZ60	RU	https://pubmed.ncbi.nlm.nih.gov/2433183

DMBVHLT	DI	DMBVHLT
DMBVHLT	DN	ACP-106
DMBVHLT	MI	TTJQOD7
DMBVHLT	MN	5-HT 2A receptor (HTR2A)
DMBVHLT	MT	DTT
DMBVHLT	MA	Agonist
DMBVHLT	RN	Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598). J Pharmacol Exp Ther. 1992 Jan;260(1):146-59.
DMBVHLT	RU	https://pubmed.ncbi.nlm.nih.gov/1370538

DMAZLWR	DI	DMAZLWR
DMAZLWR	DN	ACPC
DMAZLWR	MI	TT9IK2Z
DMAZLWR	MN	N-methyl-D-aspartate receptor (NMDAR)
DMAZLWR	MT	DTT
DMAZLWR	MA	Modulator
DMAZLWR	RN	1-Aminocyclopropane carboxylic acid (ACPC) prevents mu and delta opioid tolerance. Life Sci. 1994;55(18):1393-8.
DMAZLWR	RU	https://pubmed.ncbi.nlm.nih.gov/7934650

DM6ONY7	DI	DM6ONY7
DM6ONY7	DN	Ac-Phe-D-Thr(PO3H2)-Pip-Nal-Gln-NH2
DM6ONY7	MI	TTJNTSI
DM6ONY7	MN	Rotamase Pin1 (PIN1)
DM6ONY7	MT	DTT
DM6ONY7	MA	Inhibitor
DM6ONY7	RN	Nanomolar inhibitors of the peptidyl prolyl cis/trans isomerase Pin1 from combinatorial peptide libraries. J Med Chem. 2006 Apr 6;49(7):2147-50.
DM6ONY7	RU	https://pubmed.ncbi.nlm.nih.gov/16570909

DMDXBQA	DI	DMDXBQA
DMDXBQA	DN	Ac-Phe-Phe-NH2
DMDXBQA	MI	TTZPO1L
DMDXBQA	MN	Substance-P receptor (TACR1)
DMDXBQA	MT	DTT
DMDXBQA	MA	Inhibitor
DMDXBQA	RN	Discovery of dipeptides with high affinity to the specific binding site for substance P1-7. J Med Chem. 2010 Mar 25;53(6):2383-9.
DMDXBQA	RU	https://pubmed.ncbi.nlm.nih.gov/20178322

DMSWTPX	DI	DMSWTPX
DMSWTPX	DN	Ac-Phe-Thr(PO3H2)-Pip-Nal-Gln-NH2
DMSWTPX	MI	TTJNTSI
DMSWTPX	MN	Rotamase Pin1 (PIN1)
DMSWTPX	MT	DTT
DMSWTPX	MA	Inhibitor
DMSWTPX	RN	Nanomolar inhibitors of the peptidyl prolyl cis/trans isomerase Pin1 from combinatorial peptide libraries. J Med Chem. 2006 Apr 6;49(7):2147-50.
DMSWTPX	RU	https://pubmed.ncbi.nlm.nih.gov/16570909

DM264XN	DI	DM264XN
DM264XN	DN	ACPT-I
DM264XN	MI	TTICZ1O
DM264XN	MN	Metabotropic glutamate receptor 4 (mGluR4)
DM264XN	MT	DTT
DM264XN	MA	Agonist
DM264XN	RN	Synthesis and pharmacological characterization of aminocyclopentanetricarboxylic acids: new tools to discriminate between metabotropic glutamate receptor subtypes. J Med Chem. 1997 Sep 12;40(19):3119-29.
DM264XN	RU	https://pubmed.ncbi.nlm.nih.gov/9301676

DM264XN	DI	DM264XN
DM264XN	DN	ACPT-I
DM264XN	MI	TTWRP2F
DM264XN	MN	Metabotropic glutamate receptor 6 (mGluR6)
DM264XN	MT	DTT
DM264XN	MA	Agonist
DM264XN	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 294).
DM264XN	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=294

DM264XN	DI	DM264XN
DM264XN	DN	ACPT-I
DM264XN	MI	TT0IFKL
DM264XN	MN	Metabotropic glutamate receptor 8 (mGluR8)
DM264XN	MT	DTT
DM264XN	MA	Agonist
DM264XN	RN	Pharmacological characterization of the rat metabotropic glutamate receptor type 8a revealed strong similarities and slight differences with the type 4a receptor. Eur J Pharmacol. 2000 Apr 7;394(1):17-26.
DM264XN	RU	https://pubmed.ncbi.nlm.nih.gov/10771029

DMDEFPS	DI	DMDEFPS
DMDEFPS	DN	AcPYY(22-36)
DMDEFPS	MI	TTRK9JT
DMDEFPS	MN	Neuropeptide Y receptor type 1 (NPY1R)
DMDEFPS	MT	DTT
DMDEFPS	MA	Inhibitor
DMDEFPS	RN	Identification of selective neuropeptide Y2 peptide agonists. Bioorg Med Chem Lett. 2007 Jan 15;17(2):538-41.
DMDEFPS	RU	https://pubmed.ncbi.nlm.nih.gov/17055726

DMDEFPS	DI	DMDEFPS
DMDEFPS	DN	AcPYY(22-36)
DMDEFPS	MI	TTJ6WK9
DMDEFPS	MN	Neuropeptide Y receptor type 2 (NPY2R)
DMDEFPS	MT	DTT
DMDEFPS	MA	Inhibitor
DMDEFPS	RN	Identification of selective neuropeptide Y2 peptide agonists. Bioorg Med Chem Lett. 2007 Jan 15;17(2):538-41.
DMDEFPS	RU	https://pubmed.ncbi.nlm.nih.gov/17055726

DMRSU2K	DI	DMRSU2K
DMRSU2K	DN	AcPYY(25-36)
DMRSU2K	MI	TTJ6WK9
DMRSU2K	MN	Neuropeptide Y receptor type 2 (NPY2R)
DMRSU2K	MT	DTT
DMRSU2K	MA	Inhibitor
DMRSU2K	RN	Identification of selective neuropeptide Y2 peptide agonists. Bioorg Med Chem Lett. 2007 Jan 15;17(2):538-41.
DMRSU2K	RU	https://pubmed.ncbi.nlm.nih.gov/17055726

DM7RELC	DI	DM7RELC
DM7RELC	DN	AcPYY(26-36)
DM7RELC	MI	TTJ6WK9
DM7RELC	MN	Neuropeptide Y receptor type 2 (NPY2R)
DM7RELC	MT	DTT
DM7RELC	MA	Inhibitor
DM7RELC	RN	Identification of selective neuropeptide Y2 peptide agonists. Bioorg Med Chem Lett. 2007 Jan 15;17(2):538-41.
DM7RELC	RU	https://pubmed.ncbi.nlm.nih.gov/17055726

DMBFUD0	DI	DMBFUD0
DMBFUD0	DN	Ac-R[CEHdFRWC]-NH2
DMBFUD0	MI	TT0MV2T
DMBFUD0	MN	Melanocortin receptor 1 (MC1R)
DMBFUD0	MT	DTT
DMBFUD0	MA	Inhibitor
DMBFUD0	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMBFUD0	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMBFUD0	DI	DMBFUD0
DMBFUD0	DN	Ac-R[CEHdFRWC]-NH2
DMBFUD0	MI	TTNI91K
DMBFUD0	MN	Melanocortin receptor 3 (MC3R)
DMBFUD0	MT	DTT
DMBFUD0	MA	Inhibitor
DMBFUD0	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMBFUD0	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMBFUD0	DI	DMBFUD0
DMBFUD0	DN	Ac-R[CEHdFRWC]-NH2
DMBFUD0	MI	TTD0CIQ
DMBFUD0	MN	Melanocortin receptor 4 (MC4R)
DMBFUD0	MT	DTT
DMBFUD0	MA	Inhibitor
DMBFUD0	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMBFUD0	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMYZJ5B	DI	DMYZJ5B
DMYZJ5B	DN	Acriflavinium chloride
DMYZJ5B	MI	DE6OQ3W
DMYZJ5B	MN	Cytochrome P450 1A1 (CYP1A1)
DMYZJ5B	MT	DME
DMYZJ5B	MA	Metabolism
DMYZJ5B	RN	Activation of the antitumor agent aminoflavone (NSC 686288) is mediated by induction of tumor cell cytochrome P450 1A1/1A2. Mol Pharmacol. 2002 Jul;62(1):143-53.
DMYZJ5B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12065765

DMYZJ5B	DI	DMYZJ5B
DMYZJ5B	DN	Acriflavinium chloride
DMYZJ5B	MI	DEJGDUW
DMYZJ5B	MN	Cytochrome P450 1A2 (CYP1A2)
DMYZJ5B	MT	DME
DMYZJ5B	MA	Metabolism
DMYZJ5B	RN	Activation of the antitumor agent aminoflavone (NSC 686288) is mediated by induction of tumor cell cytochrome P450 1A1/1A2. Mol Pharmacol. 2002 Jul;62(1):143-53.
DMYZJ5B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12065765

DMAMCSR	DI	DMAMCSR
DMAMCSR	DN	acrolein
DMAMCSR	MI	TTELV3W
DMAMCSR	MN	Transformation-sensitive protein p120 (TRPA1)
DMAMCSR	MT	DTT
DMAMCSR	MA	Activator
DMAMCSR	RN	TRPA1 mediates the inflammatory actions of environmental irritants and proalgesic agents. Cell. 2006 Mar 24;124(6):1269-82.
DMAMCSR	RU	https://pubmed.ncbi.nlm.nih.gov/16564016

DM512OP	DI	DM512OP
DM512OP	DN	Ac-RYYRIK-GGG-K-(NH2)-YAFGYPS-GG
DM512OP	MI	TTNT7K8
DM512OP	MN	Nociceptin receptor (OPRL1)
DM512OP	MT	DTT
DM512OP	MA	Inhibitor
DM512OP	RN	Synthesis and receptor binding properties of chimeric peptides containing a mu-opioid receptor ligand and nociceptin/orphanin FQ receptor ligand Ac... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4839-41.
DM512OP	RU	https://pubmed.ncbi.nlm.nih.gov/16814543

DM512OP	DI	DM512OP
DM512OP	DN	Ac-RYYRIK-GGG-K-(NH2)-YAFGYPS-GG
DM512OP	MI	TTKWM86
DM512OP	MN	Opioid receptor mu (MOP)
DM512OP	MT	DTT
DM512OP	MA	Inhibitor
DM512OP	RN	Synthesis and receptor binding properties of chimeric peptides containing a mu-opioid receptor ligand and nociceptin/orphanin FQ receptor ligand Ac... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4839-41.
DM512OP	RU	https://pubmed.ncbi.nlm.nih.gov/16814543

DMAHQIV	DI	DMAHQIV
DMAHQIV	DN	Ac-RYYRIK-GGG-K-(NH2)-YRFB-GGGGG
DMAHQIV	MI	TTNT7K8
DMAHQIV	MN	Nociceptin receptor (OPRL1)
DMAHQIV	MT	DTT
DMAHQIV	MA	Inhibitor
DMAHQIV	RN	Synthesis and receptor binding properties of chimeric peptides containing a mu-opioid receptor ligand and nociceptin/orphanin FQ receptor ligand Ac... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4839-41.
DMAHQIV	RU	https://pubmed.ncbi.nlm.nih.gov/16814543

DMAHQIV	DI	DMAHQIV
DMAHQIV	DN	Ac-RYYRIK-GGG-K-(NH2)-YRFB-GGGGG
DMAHQIV	MI	TTKWM86
DMAHQIV	MN	Opioid receptor mu (MOP)
DMAHQIV	MT	DTT
DMAHQIV	MA	Inhibitor
DMAHQIV	RN	Synthesis and receptor binding properties of chimeric peptides containing a mu-opioid receptor ligand and nociceptin/orphanin FQ receptor ligand Ac... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4839-41.
DMAHQIV	RU	https://pubmed.ncbi.nlm.nih.gov/16814543

DM2ND3U	DI	DM2ND3U
DM2ND3U	DN	Ac-RYYRIK-K-(NH2)-YAFGYPS
DM2ND3U	MI	TTNT7K8
DM2ND3U	MN	Nociceptin receptor (OPRL1)
DM2ND3U	MT	DTT
DM2ND3U	MA	Inhibitor
DM2ND3U	RN	Synthesis and receptor binding properties of chimeric peptides containing a mu-opioid receptor ligand and nociceptin/orphanin FQ receptor ligand Ac... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4839-41.
DM2ND3U	RU	https://pubmed.ncbi.nlm.nih.gov/16814543

DM2ND3U	DI	DM2ND3U
DM2ND3U	DN	Ac-RYYRIK-K-(NH2)-YAFGYPS
DM2ND3U	MI	TTKWM86
DM2ND3U	MN	Opioid receptor mu (MOP)
DM2ND3U	MT	DTT
DM2ND3U	MA	Inhibitor
DM2ND3U	RN	Synthesis and receptor binding properties of chimeric peptides containing a mu-opioid receptor ligand and nociceptin/orphanin FQ receptor ligand Ac... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4839-41.
DM2ND3U	RU	https://pubmed.ncbi.nlm.nih.gov/16814543

DMNA3F4	DI	DMNA3F4
DMNA3F4	DN	Ac-RYYRIK-K-(NH2)-YRFB
DMNA3F4	MI	TTNT7K8
DMNA3F4	MN	Nociceptin receptor (OPRL1)
DMNA3F4	MT	DTT
DMNA3F4	MA	Inhibitor
DMNA3F4	RN	Synthesis and receptor binding properties of chimeric peptides containing a mu-opioid receptor ligand and nociceptin/orphanin FQ receptor ligand Ac... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4839-41.
DMNA3F4	RU	https://pubmed.ncbi.nlm.nih.gov/16814543

DMNA3F4	DI	DMNA3F4
DMNA3F4	DN	Ac-RYYRIK-K-(NH2)-YRFB
DMNA3F4	MI	TTKWM86
DMNA3F4	MN	Opioid receptor mu (MOP)
DMNA3F4	MT	DTT
DMNA3F4	MA	Inhibitor
DMNA3F4	RN	Synthesis and receptor binding properties of chimeric peptides containing a mu-opioid receptor ligand and nociceptin/orphanin FQ receptor ligand Ac... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4839-41.
DMNA3F4	RU	https://pubmed.ncbi.nlm.nih.gov/16814543

DMI87UE	DI	DMI87UE
DMI87UE	DN	Ac-RYYRIK-NH2
DMI87UE	MI	TTNT7K8
DMI87UE	MN	Nociceptin receptor (OPRL1)
DMI87UE	MT	DTT
DMI87UE	MA	Inhibitor
DMI87UE	RN	Synthesis and receptor binding properties of chimeric peptides containing a mu-opioid receptor ligand and nociceptin/orphanin FQ receptor ligand Ac... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4839-41.
DMI87UE	RU	https://pubmed.ncbi.nlm.nih.gov/16814543

DM8XBR1	DI	DM8XBR1
DM8XBR1	DN	Ac-SFWKYS-NH2
DM8XBR1	MI	TTW5UDX
DM8XBR1	MN	Urotensin II receptor (UTS2R)
DM8XBR1	MT	DTT
DM8XBR1	MA	Inhibitor
DM8XBR1	RN	Urotensin-II receptor modulators as potential drugs. J Med Chem. 2010 Apr 8;53(7):2695-708.
DM8XBR1	RU	https://pubmed.ncbi.nlm.nih.gov/20043680

DMPHSU8	DI	DMPHSU8
DMPHSU8	DN	ACTB-1003
DMPHSU8	MI	TTRLW2X
DMPHSU8	MN	Fibroblast growth factor receptor 1 (FGFR1)
DMPHSU8	MT	DTT
DMPHSU8	MA	Inhibitor
DMPHSU8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1808).
DMPHSU8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1808

DMPHSU8	DI	DMPHSU8
DMPHSU8	DN	ACTB-1003
DMPHSU8	MI	TTGJVQM
DMPHSU8	MN	Fibroblast growth factor receptor 2 (FGFR2)
DMPHSU8	MT	DTT
DMPHSU8	MA	Inhibitor
DMPHSU8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1809).
DMPHSU8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1809

DMPHSU8	DI	DMPHSU8
DMPHSU8	DN	ACTB-1003
DMPHSU8	MI	TTST7KB
DMPHSU8	MN	Fibroblast growth factor receptor 3 (FGFR3)
DMPHSU8	MT	DTT
DMPHSU8	MA	Inhibitor
DMPHSU8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1810).
DMPHSU8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1810

DMPHSU8	DI	DMPHSU8
DMPHSU8	DN	ACTB-1003
DMPHSU8	MI	TT5BR7T
DMPHSU8	MN	Fibroblast growth factor receptor 4 (FGFR4)
DMPHSU8	MT	DTT
DMPHSU8	MA	Inhibitor
DMPHSU8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1811).
DMPHSU8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1811

DMPHSU8	DI	DMPHSU8
DMPHSU8	DN	ACTB-1003
DMPHSU8	MI	TTG0U4H
DMPHSU8	MN	Ribosomal protein S6 kinase beta-1 (S6K1)
DMPHSU8	MT	DTT
DMPHSU8	MA	Inhibitor
DMPHSU8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1525).
DMPHSU8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1525

DMXIDS9	DI	DMXIDS9
DMXIDS9	DN	ACTINOPLANIC ACID A
DMXIDS9	MI	TT7WZIJ
DMXIDS9	MN	CAAX farnesyltransferase beta (FNTB)
DMXIDS9	MT	DTT
DMXIDS9	MA	Inhibitor
DMXIDS9	RN	Ras farnesyltransferase: a new therapeutic target. J Med Chem. 1997 Sep 12;40(19):2971-90.
DMXIDS9	RU	https://pubmed.ncbi.nlm.nih.gov/9301658

DMXIDS9	DI	DMXIDS9
DMXIDS9	DN	ACTINOPLANIC ACID A
DMXIDS9	MI	TTXQKM3
DMXIDS9	MN	Farnesyl protein transferase (Ftase)
DMXIDS9	MT	DTT
DMXIDS9	MA	Inhibitor
DMXIDS9	RN	Ras farnesyltransferase: a new therapeutic target. J Med Chem. 1997 Sep 12;40(19):2971-90.
DMXIDS9	RU	https://pubmed.ncbi.nlm.nih.gov/9301658

DMIH5CD	DI	DMIH5CD
DMIH5CD	DN	Ac-Tyr-D-Phe-Arg-2-Nal-NHCH3
DMIH5CD	MI	TT0MV2T
DMIH5CD	MN	Melanocortin receptor 1 (MC1R)
DMIH5CD	MT	DTT
DMIH5CD	MA	Inhibitor
DMIH5CD	RN	Design and synthesis of potent and selective 1,3,4-trisubstituted-2-oxopiperazine based melanocortin-4 receptor agonists. Bioorg Med Chem Lett. 2006 Sep 1;16(17):4668-73.
DMIH5CD	RU	https://pubmed.ncbi.nlm.nih.gov/16766182

DMIH5CD	DI	DMIH5CD
DMIH5CD	DN	Ac-Tyr-D-Phe-Arg-2-Nal-NHCH3
DMIH5CD	MI	TTNI91K
DMIH5CD	MN	Melanocortin receptor 3 (MC3R)
DMIH5CD	MT	DTT
DMIH5CD	MA	Inhibitor
DMIH5CD	RN	Design and synthesis of potent and selective 1,3,4-trisubstituted-2-oxopiperazine based melanocortin-4 receptor agonists. Bioorg Med Chem Lett. 2006 Sep 1;16(17):4668-73.
DMIH5CD	RU	https://pubmed.ncbi.nlm.nih.gov/16766182

DMIH5CD	DI	DMIH5CD
DMIH5CD	DN	Ac-Tyr-D-Phe-Arg-2-Nal-NHCH3
DMIH5CD	MI	TTD0CIQ
DMIH5CD	MN	Melanocortin receptor 4 (MC4R)
DMIH5CD	MT	DTT
DMIH5CD	MA	Inhibitor
DMIH5CD	RN	Design and synthesis of potent and selective 1,3,4-trisubstituted-2-oxopiperazine based melanocortin-4 receptor agonists. Bioorg Med Chem Lett. 2006 Sep 1;16(17):4668-73.
DMIH5CD	RU	https://pubmed.ncbi.nlm.nih.gov/16766182

DM7ZWRN	DI	DM7ZWRN
DM7ZWRN	DN	ACU-0101979
DM7ZWRN	MI	TTE4KHA
DM7ZWRN	MN	Amyloid beta A4 protein (APP)
DM7ZWRN	MT	DTT
DM7ZWRN	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
DM7ZWRN	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402

DMR2MUG	DI	DMR2MUG
DMR2MUG	DN	ACULEACIN A
DMR2MUG	MI	TTZMS1L
DMR2MUG	MN	Fungal Papulacandin B resistance protein 1 (Fung FKS1)
DMR2MUG	MT	DTT
DMR2MUG	MA	Inhibitor
DMR2MUG	RN	Synthesis, anti-fungal and 1,3--D-glucan synthase inhibitory activities of caffeic and quinic acid derivatives. Bioorg Med Chem. 2010 Oct 1;18(19):7009-14.
DMR2MUG	RU	https://pubmed.ncbi.nlm.nih.gov/20813534

DMMQKCV	DI	DMMQKCV
DMMQKCV	DN	Acurea
DMMQKCV	MI	TTZHY6R
DMMQKCV	MN	Glycogen phosphorylase muscle form (GP)
DMMQKCV	MT	DTT
DMMQKCV	MA	Inhibitor
DMMQKCV	RN	Binding of N-acetyl-N '-beta-D-glucopyranosyl urea and N-benzoyl-N '-beta-D-glucopyranosyl urea to glycogen phosphorylase b: kinetic and crystallographic studies. Eur J Biochem. 2002 Mar;269(6):1684-96.
DMMQKCV	RU	https://pubmed.ncbi.nlm.nih.gov/11895439

DMWOYCZ	DI	DMWOYCZ
DMWOYCZ	DN	Ac-VEID-CHO
DMWOYCZ	MI	TTKW4ML
DMWOYCZ	MN	Caspase 6 messenger RNA (CASP6 mRNA)
DMWOYCZ	MT	DTT
DMWOYCZ	MA	Inhibitor
DMWOYCZ	RN	Synthesis and in vitro evaluation of sulfonamide isatin Michael acceptors as small molecule inhibitors of caspase-6. J Med Chem. 2009 Apr 23;52(8):2188-91.
DMWOYCZ	RU	https://pubmed.ncbi.nlm.nih.gov/19326941

DML7Z1H	DI	DML7Z1H
DML7Z1H	DN	ACVR2B
DML7Z1H	MI	TTLFRKS
DML7Z1H	MN	Activin receptor type IIB (ACVR2B)
DML7Z1H	MT	DTT
DML7Z1H	MA	Antagonist
DML7Z1H	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1792).
DML7Z1H	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1792

DMO0W9V	DI	DMO0W9V
DMO0W9V	DN	Ac-VTHRLAGLLSRSGGVVKNNFVPTDVGPFAF-NH2
DMO0W9V	MI	TTVSFJW
DMO0W9V	MN	Calcitonin gene-related peptide 1 (CALCA)
DMO0W9V	MT	DTT
DMO0W9V	MA	Inhibitor
DMO0W9V	RN	Identification of potent, selective, and metabolically stable peptide antagonists to the calcitonin gene-related peptide (CGRP) receptor. J Med Chem. 2008 Dec 25;51(24):7889-97.
DMO0W9V	RU	https://pubmed.ncbi.nlm.nih.gov/19053766

DMWJ2M5	DI	DMWJ2M5
DMWJ2M5	DN	Ac-VTHRLAGLLSRSGGVVRKNFVPTDVGPFAF-NH2
DMWJ2M5	MI	TTVSFJW
DMWJ2M5	MN	Calcitonin gene-related peptide 1 (CALCA)
DMWJ2M5	MT	DTT
DMWJ2M5	MA	Inhibitor
DMWJ2M5	RN	Identification of potent, selective, and metabolically stable peptide antagonists to the calcitonin gene-related peptide (CGRP) receptor. J Med Chem. 2008 Dec 25;51(24):7889-97.
DMWJ2M5	RU	https://pubmed.ncbi.nlm.nih.gov/19053766

DMP89K4	DI	DMP89K4
DMP89K4	DN	Ac-w-F-F-N-Y-Y-W
DMP89K4	MI	TTKRD0G
DMP89K4	MN	Endothelin A receptor (EDNRA)
DMP89K4	MT	DTT
DMP89K4	MA	Inhibitor
DMP89K4	RN	Res-701-1, synthesis and a reevaluation of its effects on the endothelin receptors, Bioorg. Med. Chem. Lett. 5(6):621-626 (1995).
DMP89K4	RU	http://www.sciencedirect.com/science/article/pii/0960894X95000847

DMP89K4	DI	DMP89K4
DMP89K4	DN	Ac-w-F-F-N-Y-Y-W
DMP89K4	MI	TT3ZTGU
DMP89K4	MN	Endothelin B receptor (EDNRB)
DMP89K4	MT	DTT
DMP89K4	MA	Inhibitor
DMP89K4	RN	Res-701-1, synthesis and a reevaluation of its effects on the endothelin receptors, Bioorg. Med. Chem. Lett. 5(6):621-626 (1995).
DMP89K4	RU	http://www.sciencedirect.com/science/article/pii/0960894X95000847

DM7J9O6	DI	DM7J9O6
DM7J9O6	DN	Ac-WKY-NH2
DM7J9O6	MI	TTW5UDX
DM7J9O6	MN	Urotensin II receptor (UTS2R)
DM7J9O6	MT	DTT
DM7J9O6	MA	Inhibitor
DM7J9O6	RN	Urotensin-II receptor modulators as potential drugs. J Med Chem. 2010 Apr 8;53(7):2695-708.
DM7J9O6	RU	https://pubmed.ncbi.nlm.nih.gov/20043680

DM9W21L	DI	DM9W21L
DM9W21L	DN	Ac-WVEHRLKGELSRKGGVV[hArg]KNFVPTDVGPFAF-NH2
DM9W21L	MI	TTVSFJW
DM9W21L	MN	Calcitonin gene-related peptide 1 (CALCA)
DM9W21L	MT	DTT
DM9W21L	MA	Inhibitor
DM9W21L	RN	Identification of potent, selective, and metabolically stable peptide antagonists to the calcitonin gene-related peptide (CGRP) receptor. J Med Chem. 2008 Dec 25;51(24):7889-97.
DM9W21L	RU	https://pubmed.ncbi.nlm.nih.gov/19053766

DMJU4AM	DI	DMJU4AM
DMJU4AM	DN	Ac-WVTH[Cit]LAGLLS[Cit]SGGVVRKNFVPTDVGPFAF-NH2
DMJU4AM	MI	TTVSFJW
DMJU4AM	MN	Calcitonin gene-related peptide 1 (CALCA)
DMJU4AM	MT	DTT
DMJU4AM	MA	Inhibitor
DMJU4AM	RN	Identification of potent, selective, and metabolically stable peptide antagonists to the calcitonin gene-related peptide (CGRP) receptor. J Med Chem. 2008 Dec 25;51(24):7889-97.
DMJU4AM	RU	https://pubmed.ncbi.nlm.nih.gov/19053766

DMR1N53	DI	DMR1N53
DMR1N53	DN	Ac-WVTH[Cit]LAGLLSRSGGVVRKNFVPTDVGPFAF-NH2
DMR1N53	MI	TTVSFJW
DMR1N53	MN	Calcitonin gene-related peptide 1 (CALCA)
DMR1N53	MT	DTT
DMR1N53	MA	Inhibitor
DMR1N53	RN	Identification of potent, selective, and metabolically stable peptide antagonists to the calcitonin gene-related peptide (CGRP) receptor. J Med Chem. 2008 Dec 25;51(24):7889-97.
DMR1N53	RU	https://pubmed.ncbi.nlm.nih.gov/19053766

DM19NMF	DI	DM19NMF
DM19NMF	DN	Ac-WVTH[hArg]LAGLLS[hArg]SGGVVRKNFVPTDVGPFAF-NH2
DM19NMF	MI	TTVSFJW
DM19NMF	MN	Calcitonin gene-related peptide 1 (CALCA)
DM19NMF	MT	DTT
DM19NMF	MA	Inhibitor
DM19NMF	RN	Identification of potent, selective, and metabolically stable peptide antagonists to the calcitonin gene-related peptide (CGRP) receptor. J Med Chem. 2008 Dec 25;51(24):7889-97.
DM19NMF	RU	https://pubmed.ncbi.nlm.nih.gov/19053766

DM3BUP6	DI	DM3BUP6
DM3BUP6	DN	Ac-WVTHQLAGLLSQSGGVVRKNFVPTDVGPFAF-NH2
DM3BUP6	MI	TTVSFJW
DM3BUP6	MN	Calcitonin gene-related peptide 1 (CALCA)
DM3BUP6	MT	DTT
DM3BUP6	MA	Inhibitor
DM3BUP6	RN	Identification of potent, selective, and metabolically stable peptide antagonists to the calcitonin gene-related peptide (CGRP) receptor. J Med Chem. 2008 Dec 25;51(24):7889-97.
DM3BUP6	RU	https://pubmed.ncbi.nlm.nih.gov/19053766

DMKO982	DI	DMKO982
DMKO982	DN	Ac-WVTHRLAGLLS[Cit]SGGVVRKNFVPTDVGPFAF-NH2
DMKO982	MI	TTVSFJW
DMKO982	MN	Calcitonin gene-related peptide 1 (CALCA)
DMKO982	MT	DTT
DMKO982	MA	Inhibitor
DMKO982	RN	Identification of potent, selective, and metabolically stable peptide antagonists to the calcitonin gene-related peptide (CGRP) receptor. J Med Chem. 2008 Dec 25;51(24):7889-97.
DMKO982	RU	https://pubmed.ncbi.nlm.nih.gov/19053766

DMSMVK4	DI	DMSMVK4
DMSMVK4	DN	Ac-WVTHRLAGLLSRSGGVVRKNFVPTDVGPFAF-NH2
DMSMVK4	MI	TTVSFJW
DMSMVK4	MN	Calcitonin gene-related peptide 1 (CALCA)
DMSMVK4	MT	DTT
DMSMVK4	MA	Inhibitor
DMSMVK4	RN	Identification of potent, selective, and metabolically stable peptide antagonists to the calcitonin gene-related peptide (CGRP) receptor. J Med Chem. 2008 Dec 25;51(24):7889-97.
DMSMVK4	RU	https://pubmed.ncbi.nlm.nih.gov/19053766

DMAVPXL	DI	DMAVPXL
DMAVPXL	DN	Ac-YCit[CEHdFRWC]-NH2
DMAVPXL	MI	TT0MV2T
DMAVPXL	MN	Melanocortin receptor 1 (MC1R)
DMAVPXL	MT	DTT
DMAVPXL	MA	Inhibitor
DMAVPXL	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMAVPXL	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMAVPXL	DI	DMAVPXL
DMAVPXL	DN	Ac-YCit[CEHdFRWC]-NH2
DMAVPXL	MI	TTNI91K
DMAVPXL	MN	Melanocortin receptor 3 (MC3R)
DMAVPXL	MT	DTT
DMAVPXL	MA	Inhibitor
DMAVPXL	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMAVPXL	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMAVPXL	DI	DMAVPXL
DMAVPXL	DN	Ac-YCit[CEHdFRWC]-NH2
DMAVPXL	MI	TTD0CIQ
DMAVPXL	MN	Melanocortin receptor 4 (MC4R)
DMAVPXL	MT	DTT
DMAVPXL	MA	Inhibitor
DMAVPXL	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMAVPXL	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMC0TU5	DI	DMC0TU5
DMC0TU5	DN	Ac-YGGFL-NH2
DMC0TU5	MI	TTKWM86
DMC0TU5	MN	Opioid receptor mu (MOP)
DMC0TU5	MT	DTT
DMC0TU5	MA	Inhibitor
DMC0TU5	RN	Internalisation of the mu-opioid receptor by endomorphin-1 and leu-enkephalin is dependant on aromatic amino acid residues. Bioorg Med Chem. 2008 Apr 15;16(8):4341-6.
DMC0TU5	RU	https://pubmed.ncbi.nlm.nih.gov/18329886

DM5SJX8	DI	DM5SJX8
DM5SJX8	DN	Ac-YK[CEHdFRWC]-NH2
DM5SJX8	MI	TT0MV2T
DM5SJX8	MN	Melanocortin receptor 1 (MC1R)
DM5SJX8	MT	DTT
DM5SJX8	MA	Inhibitor
DM5SJX8	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DM5SJX8	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DM5SJX8	DI	DM5SJX8
DM5SJX8	DN	Ac-YK[CEHdFRWC]-NH2
DM5SJX8	MI	TTNI91K
DM5SJX8	MN	Melanocortin receptor 3 (MC3R)
DM5SJX8	MT	DTT
DM5SJX8	MA	Inhibitor
DM5SJX8	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DM5SJX8	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DM5SJX8	DI	DM5SJX8
DM5SJX8	DN	Ac-YK[CEHdFRWC]-NH2
DM5SJX8	MI	TTD0CIQ
DM5SJX8	MN	Melanocortin receptor 4 (MC4R)
DM5SJX8	MT	DTT
DM5SJX8	MA	Inhibitor
DM5SJX8	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DM5SJX8	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMIZ5VO	DI	DMIZ5VO
DMIZ5VO	DN	Acylated Ceftazidime
DMIZ5VO	MI	TTHI19T
DMIZ5VO	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMIZ5VO	MT	DTT
DMIZ5VO	MA	Inhibitor
DMIZ5VO	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMIZ5VO	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM4CYKE	DI	DM4CYKE
DM4CYKE	DN	Acylureido penicillin mezlocillin
DM4CYKE	MI	TT85JMW
DM4CYKE	MN	Bacterial Penicillin binding protein 3 (Bact mrcA)
DM4CYKE	MT	DTT
DM4CYKE	MA	Binder
DM4CYKE	RN	Microbiology, pharmacology, and clinical use of mezlocillin sodium. Pharmacotherapy. 1982 Nov-Dec;2(6):300-12.
DM4CYKE	RU	https://pubmed.ncbi.nlm.nih.gov/6220263

DMJK8QZ	DI	DMJK8QZ
DMJK8QZ	DN	Ac-YR[CE(1-Me-H)dFRWC]-NH2
DMJK8QZ	MI	TTD0CIQ
DMJK8QZ	MN	Melanocortin receptor 4 (MC4R)
DMJK8QZ	MT	DTT
DMJK8QZ	MA	Inhibitor
DMJK8QZ	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMJK8QZ	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMVQ4KG	DI	DMVQ4KG
DMVQ4KG	DN	Ac-YR[CEH(d-2alpha-Nal)RWC]-NH2
DMVQ4KG	MI	TTEOSZT
DMVQ4KG	MN	Melanocortin receptor (MCR)
DMVQ4KG	MT	DTT
DMVQ4KG	MA	Inhibitor
DMVQ4KG	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMVQ4KG	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMVQ4KG	DI	DMVQ4KG
DMVQ4KG	DN	Ac-YR[CEH(d-2alpha-Nal)RWC]-NH2
DMVQ4KG	MI	TT0MV2T
DMVQ4KG	MN	Melanocortin receptor 1 (MC1R)
DMVQ4KG	MT	DTT
DMVQ4KG	MA	Inhibitor
DMVQ4KG	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMVQ4KG	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMVQ4KG	DI	DMVQ4KG
DMVQ4KG	DN	Ac-YR[CEH(d-2alpha-Nal)RWC]-NH2
DMVQ4KG	MI	TTNI91K
DMVQ4KG	MN	Melanocortin receptor 3 (MC3R)
DMVQ4KG	MT	DTT
DMVQ4KG	MA	Inhibitor
DMVQ4KG	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMVQ4KG	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMVQ4KG	DI	DMVQ4KG
DMVQ4KG	DN	Ac-YR[CEH(d-2alpha-Nal)RWC]-NH2
DMVQ4KG	MI	TTD0CIQ
DMVQ4KG	MN	Melanocortin receptor 4 (MC4R)
DMVQ4KG	MT	DTT
DMVQ4KG	MA	Inhibitor
DMVQ4KG	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMVQ4KG	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DM25JXM	DI	DM25JXM
DM25JXM	DN	Ac-YR[CEH(pCl-dF)RWC]-NH2
DM25JXM	MI	TTEOSZT
DM25JXM	MN	Melanocortin receptor (MCR)
DM25JXM	MT	DTT
DM25JXM	MA	Inhibitor
DM25JXM	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DM25JXM	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DM25JXM	DI	DM25JXM
DM25JXM	DN	Ac-YR[CEH(pCl-dF)RWC]-NH2
DM25JXM	MI	TT0MV2T
DM25JXM	MN	Melanocortin receptor 1 (MC1R)
DM25JXM	MT	DTT
DM25JXM	MA	Inhibitor
DM25JXM	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DM25JXM	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DM25JXM	DI	DM25JXM
DM25JXM	DN	Ac-YR[CEH(pCl-dF)RWC]-NH2
DM25JXM	MI	TTNI91K
DM25JXM	MN	Melanocortin receptor 3 (MC3R)
DM25JXM	MT	DTT
DM25JXM	MA	Inhibitor
DM25JXM	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DM25JXM	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DM25JXM	DI	DM25JXM
DM25JXM	DN	Ac-YR[CEH(pCl-dF)RWC]-NH2
DM25JXM	MI	TTD0CIQ
DM25JXM	MN	Melanocortin receptor 4 (MC4R)
DM25JXM	MT	DTT
DM25JXM	MA	Inhibitor
DM25JXM	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DM25JXM	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMXCF9T	DI	DMXCF9T
DMXCF9T	DN	Ac-YR[CEH(pF-dF)RWC]-NH2
DMXCF9T	MI	TTEOSZT
DMXCF9T	MN	Melanocortin receptor (MCR)
DMXCF9T	MT	DTT
DMXCF9T	MA	Inhibitor
DMXCF9T	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMXCF9T	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMXCF9T	DI	DMXCF9T
DMXCF9T	DN	Ac-YR[CEH(pF-dF)RWC]-NH2
DMXCF9T	MI	TT0MV2T
DMXCF9T	MN	Melanocortin receptor 1 (MC1R)
DMXCF9T	MT	DTT
DMXCF9T	MA	Inhibitor
DMXCF9T	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMXCF9T	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMXCF9T	DI	DMXCF9T
DMXCF9T	DN	Ac-YR[CEH(pF-dF)RWC]-NH2
DMXCF9T	MI	TTNI91K
DMXCF9T	MN	Melanocortin receptor 3 (MC3R)
DMXCF9T	MT	DTT
DMXCF9T	MA	Inhibitor
DMXCF9T	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMXCF9T	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMXCF9T	DI	DMXCF9T
DMXCF9T	DN	Ac-YR[CEH(pF-dF)RWC]-NH2
DMXCF9T	MI	TTD0CIQ
DMXCF9T	MN	Melanocortin receptor 4 (MC4R)
DMXCF9T	MT	DTT
DMXCF9T	MA	Inhibitor
DMXCF9T	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMXCF9T	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMBMY73	DI	DMBMY73
DMBMY73	DN	Ac-YR[CEHdFRWC]-NH2
DMBMY73	MI	TT0MV2T
DMBMY73	MN	Melanocortin receptor 1 (MC1R)
DMBMY73	MT	DTT
DMBMY73	MA	Inhibitor
DMBMY73	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMBMY73	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMBMY73	DI	DMBMY73
DMBMY73	DN	Ac-YR[CEHdFRWC]-NH2
DMBMY73	MI	TTNI91K
DMBMY73	MN	Melanocortin receptor 3 (MC3R)
DMBMY73	MT	DTT
DMBMY73	MA	Inhibitor
DMBMY73	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMBMY73	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMBMY73	DI	DMBMY73
DMBMY73	DN	Ac-YR[CEHdFRWC]-NH2
DMBMY73	MI	TTD0CIQ
DMBMY73	MN	Melanocortin receptor 4 (MC4R)
DMBMY73	MT	DTT
DMBMY73	MA	Inhibitor
DMBMY73	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMBMY73	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMDO468	DI	DMDO468
DMDO468	DN	Ac-YR[CEHdFRWC]SPPKD-NH2
DMDO468	MI	TT0MV2T
DMDO468	MN	Melanocortin receptor 1 (MC1R)
DMDO468	MT	DTT
DMDO468	MA	Inhibitor
DMDO468	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMDO468	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMDO468	DI	DMDO468
DMDO468	DN	Ac-YR[CEHdFRWC]SPPKD-NH2
DMDO468	MI	TTNI91K
DMDO468	MN	Melanocortin receptor 3 (MC3R)
DMDO468	MT	DTT
DMDO468	MA	Inhibitor
DMDO468	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMDO468	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMDO468	DI	DMDO468
DMDO468	DN	Ac-YR[CEHdFRWC]SPPKD-NH2
DMDO468	MI	TTD0CIQ
DMDO468	MN	Melanocortin receptor 4 (MC4R)
DMDO468	MT	DTT
DMDO468	MA	Inhibitor
DMDO468	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMDO468	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMH0EAI	DI	DMH0EAI
DMH0EAI	DN	Ac-YR[CEHFRWC]-NH2
DMH0EAI	MI	TT0MV2T
DMH0EAI	MN	Melanocortin receptor 1 (MC1R)
DMH0EAI	MT	DTT
DMH0EAI	MA	Inhibitor
DMH0EAI	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMH0EAI	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMH0EAI	DI	DMH0EAI
DMH0EAI	DN	Ac-YR[CEHFRWC]-NH2
DMH0EAI	MI	TTD0CIQ
DMH0EAI	MN	Melanocortin receptor 4 (MC4R)
DMH0EAI	MT	DTT
DMH0EAI	MA	Inhibitor
DMH0EAI	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMH0EAI	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMWJ8UR	DI	DMWJ8UR
DMWJ8UR	DN	Ac-YRC(Me)*EHdFRWC(Me)NH2
DMWJ8UR	MI	TTEOSZT
DMWJ8UR	MN	Melanocortin receptor (MCR)
DMWJ8UR	MT	DTT
DMWJ8UR	MA	Inhibitor
DMWJ8UR	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMWJ8UR	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMWJ8UR	DI	DMWJ8UR
DMWJ8UR	DN	Ac-YRC(Me)*EHdFRWC(Me)NH2
DMWJ8UR	MI	TT0MV2T
DMWJ8UR	MN	Melanocortin receptor 1 (MC1R)
DMWJ8UR	MT	DTT
DMWJ8UR	MA	Inhibitor
DMWJ8UR	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMWJ8UR	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMWJ8UR	DI	DMWJ8UR
DMWJ8UR	DN	Ac-YRC(Me)*EHdFRWC(Me)NH2
DMWJ8UR	MI	TTNI91K
DMWJ8UR	MN	Melanocortin receptor 3 (MC3R)
DMWJ8UR	MT	DTT
DMWJ8UR	MA	Inhibitor
DMWJ8UR	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMWJ8UR	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMWJ8UR	DI	DMWJ8UR
DMWJ8UR	DN	Ac-YRC(Me)*EHdFRWC(Me)NH2
DMWJ8UR	MI	TTD0CIQ
DMWJ8UR	MN	Melanocortin receptor 4 (MC4R)
DMWJ8UR	MT	DTT
DMWJ8UR	MA	Inhibitor
DMWJ8UR	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMWJ8UR	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMN2UKC	DI	DMN2UKC
DMN2UKC	DN	Ac-YRMEHdFRWG-NH2
DMN2UKC	MI	TTEOSZT
DMN2UKC	MN	Melanocortin receptor (MCR)
DMN2UKC	MT	DTT
DMN2UKC	MA	Inhibitor
DMN2UKC	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMN2UKC	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMN2UKC	DI	DMN2UKC
DMN2UKC	DN	Ac-YRMEHdFRWG-NH2
DMN2UKC	MI	TT0MV2T
DMN2UKC	MN	Melanocortin receptor 1 (MC1R)
DMN2UKC	MT	DTT
DMN2UKC	MA	Inhibitor
DMN2UKC	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMN2UKC	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMN2UKC	DI	DMN2UKC
DMN2UKC	DN	Ac-YRMEHdFRWG-NH2
DMN2UKC	MI	TTNI91K
DMN2UKC	MN	Melanocortin receptor 3 (MC3R)
DMN2UKC	MT	DTT
DMN2UKC	MA	Inhibitor
DMN2UKC	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMN2UKC	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMN2UKC	DI	DMN2UKC
DMN2UKC	DN	Ac-YRMEHdFRWG-NH2
DMN2UKC	MI	TTD0CIQ
DMN2UKC	MN	Melanocortin receptor 4 (MC4R)
DMN2UKC	MT	DTT
DMN2UKC	MA	Inhibitor
DMN2UKC	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMN2UKC	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMDH5B3	DI	DMDH5B3
DMDH5B3	DN	Ac-YRMEHdFRWGSPPKD-NH2
DMDH5B3	MI	TTEOSZT
DMDH5B3	MN	Melanocortin receptor (MCR)
DMDH5B3	MT	DTT
DMDH5B3	MA	Inhibitor
DMDH5B3	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMDH5B3	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMDH5B3	DI	DMDH5B3
DMDH5B3	DN	Ac-YRMEHdFRWGSPPKD-NH2
DMDH5B3	MI	TT0MV2T
DMDH5B3	MN	Melanocortin receptor 1 (MC1R)
DMDH5B3	MT	DTT
DMDH5B3	MA	Inhibitor
DMDH5B3	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMDH5B3	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMDH5B3	DI	DMDH5B3
DMDH5B3	DN	Ac-YRMEHdFRWGSPPKD-NH2
DMDH5B3	MI	TTNI91K
DMDH5B3	MN	Melanocortin receptor 3 (MC3R)
DMDH5B3	MT	DTT
DMDH5B3	MA	Inhibitor
DMDH5B3	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMDH5B3	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMDH5B3	DI	DMDH5B3
DMDH5B3	DN	Ac-YRMEHdFRWGSPPKD-NH2
DMDH5B3	MI	TTD0CIQ
DMDH5B3	MN	Melanocortin receptor 4 (MC4R)
DMDH5B3	MT	DTT
DMDH5B3	MA	Inhibitor
DMDH5B3	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMDH5B3	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DM23QND	DI	DM23QND
DM23QND	DN	AD-0802
DM23QND	MI	TTE4KHA
DM23QND	MN	Amyloid beta A4 protein (APP)
DM23QND	MT	DTT
DM23QND	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
DM23QND	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402

DMYLA29	DI	DMYLA29
DMYLA29	DN	AD10-1025
DMYLA29	MI	TTCBFJO
DMYLA29	MN	Insulin receptor (INSR)
DMYLA29	MT	DTT
DMYLA29	MA	Agonist
DMYLA29	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800).
DMYLA29	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800

DMJMCDP	DI	DMJMCDP
DMJMCDP	DN	AD-412
DMJMCDP	MI	TTT7PJU
DMJMCDP	MN	Janus kinase 3 (JAK-3)
DMJMCDP	MT	DTT
DMJMCDP	MA	Inhibitor
DMJMCDP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2049).
DMJMCDP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2049

DM5WV13	DI	DM5WV13
DM5WV13	DN	AD-5061
DM5WV13	MI	TTJ584C
DM5WV13	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DM5WV13	MT	DTT
DM5WV13	MA	Agonist
DM5WV13	RN	A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes. Eur J Pharmacol. 2004 Jul 8;495(1):17-26.
DM5WV13	RU	https://pubmed.ncbi.nlm.nih.gov/15219816

DM5WV13	DI	DM5WV13
DM5WV13	DN	AD-5061
DM5WV13	MI	TTT2SVW
DM5WV13	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DM5WV13	MT	DTT
DM5WV13	MA	Agonist
DM5WV13	RN	A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes. Eur J Pharmacol. 2004 Jul 8;495(1):17-26.
DM5WV13	RU	https://pubmed.ncbi.nlm.nih.gov/15219816

DMV48L3	DI	DMV48L3
DMV48L3	DN	AD5-10
DMV48L3	MI	TTW20TU
DMV48L3	MN	TRAIL receptor 2 (TRAIL-R2)
DMV48L3	MT	DTT
DMV48L3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1880).
DMV48L3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1880

DMQW612	DI	DMQW612
DMQW612	DN	Ad5f35-LMPd1-2-transduced autologous dendritic cells
DMQW612	MI	TT0BI4Q
DMQW612	MN	Epstein-Barr virus Latent membrane protein 1 (EBV LMP1)
DMQW612	MT	DTT
DMQW612	RN	CA patent application no. 876139, Nanotherapeutics for drug targeting.
DMQW612	RU	http://www.google.com/patents/CA2876139A1?cl=en

DMQW612	DI	DMQW612
DMQW612	DN	Ad5f35-LMPd1-2-transduced autologous dendritic cells
DMQW612	MI	TTBK351
DMQW612	MN	Epstein-Barr virus Latent membrane protein 2 (EBV LMP2)
DMQW612	MT	DTT
DMQW612	RN	CA patent application no. 876139, Nanotherapeutics for drug targeting.
DMQW612	RU	http://www.google.com/patents/CA2876139A1?cl=en

DMKDRVZ	DI	DMKDRVZ
DMKDRVZ	DN	Adamant-1-ylcarbamic Acid Biphenyl-3-yl Ester
DMKDRVZ	MI	TTDP1UC
DMKDRVZ	MN	Fatty acid amide hydrolase (FAAH)
DMKDRVZ	MT	DTT
DMKDRVZ	MA	Inhibitor
DMKDRVZ	RN	Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl a... J Med Chem. 2008 Jun 26;51(12):3487-98.
DMKDRVZ	RU	https://pubmed.ncbi.nlm.nih.gov/18507372

DM4S279	DI	DM4S279
DM4S279	DN	Adamantan-1-yl-(4-ethyl-piperazin-1-yl)-methanone
DM4S279	MI	TTN7BL9
DM4S279	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DM4S279	MT	DTT
DM4S279	MA	Inhibitor
DM4S279	RN	Discovery and biological evaluation of adamantyl amide 11beta-HSD1 inhibitors. Bioorg Med Chem Lett. 2007 May 15;17(10):2838-43.
DM4S279	RU	https://pubmed.ncbi.nlm.nih.gov/17350260

DM5K0EI	DI	DM5K0EI
DM5K0EI	DN	Adamantan-1-yl-piperazin-1-yl-methanone
DM5K0EI	MI	TTN7BL9
DM5K0EI	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DM5K0EI	MT	DTT
DM5K0EI	MA	Inhibitor
DM5K0EI	RN	Discovery and biological evaluation of adamantyl amide 11beta-HSD1 inhibitors. Bioorg Med Chem Lett. 2007 May 15;17(10):2838-43.
DM5K0EI	RU	https://pubmed.ncbi.nlm.nih.gov/17350260

DMTUL9J	DI	DMTUL9J
DMTUL9J	DN	Adamantan-1-yl-piperidin-1-yl-methanone
DMTUL9J	MI	TTN7BL9
DMTUL9J	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMTUL9J	MT	DTT
DMTUL9J	MA	Inhibitor
DMTUL9J	RN	Discovery and biological evaluation of adamantyl amide 11beta-HSD1 inhibitors. Bioorg Med Chem Lett. 2007 May 15;17(10):2838-43.
DMTUL9J	RU	https://pubmed.ncbi.nlm.nih.gov/17350260

DMAEN9Y	DI	DMAEN9Y
DMAEN9Y	DN	Adamantan-1-yl-pyrrolidin-1-yl-methanone
DMAEN9Y	MI	TTN7BL9
DMAEN9Y	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMAEN9Y	MT	DTT
DMAEN9Y	MA	Inhibitor
DMAEN9Y	RN	Discovery and biological evaluation of adamantyl amide 11beta-HSD1 inhibitors. Bioorg Med Chem Lett. 2007 May 15;17(10):2838-43.
DMAEN9Y	RU	https://pubmed.ncbi.nlm.nih.gov/17350260

DMBRAV5	DI	DMBRAV5
DMBRAV5	DN	Adamantan-2-yl-piperidin-1-yl-methanone
DMBRAV5	MI	TTN7BL9
DMBRAV5	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMBRAV5	MT	DTT
DMBRAV5	MA	Inhibitor
DMBRAV5	RN	Discovery and biological evaluation of adamantyl amide 11beta-HSD1 inhibitors. Bioorg Med Chem Lett. 2007 May 15;17(10):2838-43.
DMBRAV5	RU	https://pubmed.ncbi.nlm.nih.gov/17350260

DM1MAVU	DI	DM1MAVU
DM1MAVU	DN	Ada-RYYRIK-NH2
DM1MAVU	MI	TTNT7K8
DM1MAVU	MN	Nociceptin receptor (OPRL1)
DM1MAVU	MT	DTT
DM1MAVU	MA	Inhibitor
DM1MAVU	RN	Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist. Bioorg Med Chem. 2008 Mar 1;16(5):2635-44.
DM1MAVU	RU	https://pubmed.ncbi.nlm.nih.gov/18068993

DMJQM7H	DI	DMJQM7H
DMJQM7H	DN	ADC-1012
DMJQM7H	MI	TT6H4QR
DMJQM7H	MN	Interleukin 23 receptor (IL23R)
DMJQM7H	MT	DTT
DMJQM7H	MA	Antagonist
DMJQM7H	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2293).
DMJQM7H	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2293

DMV761D	DI	DMV761D
DMV761D	DN	ADC-5510
DMV761D	MI	TTKWM86
DMV761D	MN	Opioid receptor mu (MOP)
DMV761D	MT	DTT
DMV761D	MA	Antagonist
DMV761D	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
DMV761D	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319

DM19KY6	DI	DM19KY6
DM19KY6	DN	ADC-7828
DM19KY6	MI	TTPLTSQ
DM19KY6	MN	Neutrophil elastase (NE)
DM19KY6	MT	DTT
DM19KY6	MA	Inhibitor
DM19KY6	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2358).
DM19KY6	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2358

DMY6PMJ	DI	DMY6PMJ
DMY6PMJ	DN	ADC-9971
DMY6PMJ	MI	TTQDMX5
DMY6PMJ	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMY6PMJ	MT	DTT
DMY6PMJ	MA	Antagonist
DMY6PMJ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 339).
DMY6PMJ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=339

DMZYJHV	DI	DMZYJHV
DMZYJHV	DN	AdcAhxArg4Lys(biotin)-PEG-OMe
DMZYJHV	MI	TTW4Y2M
DMZYJHV	MN	cAMP protein kinase type II-beta (PRKAR2B)
DMZYJHV	MT	DTT
DMZYJHV	MA	Inhibitor
DMZYJHV	RN	Liquid-phase synthesis of a pegylated adenosine-oligoarginine conjugate, cell-permeable inhibitor of cAMP-dependent protein kinase. Bioorg Med Chem Lett. 2003 Sep 15;13(18):3035-9.
DMZYJHV	RU	https://pubmed.ncbi.nlm.nih.gov/12941328

DMZYJHV	DI	DMZYJHV
DMZYJHV	DN	AdcAhxArg4Lys(biotin)-PEG-OMe
DMZYJHV	MI	TTNAHEX
DMZYJHV	MN	cAMP-dependent protein kinase A type I (PRKAR1A)
DMZYJHV	MT	DTT
DMZYJHV	MA	Inhibitor
DMZYJHV	RN	Liquid-phase synthesis of a pegylated adenosine-oligoarginine conjugate, cell-permeable inhibitor of cAMP-dependent protein kinase. Bioorg Med Chem Lett. 2003 Sep 15;13(18):3035-9.
DMZYJHV	RU	https://pubmed.ncbi.nlm.nih.gov/12941328

DMQ2C8X	DI	DMQ2C8X
DMQ2C8X	DN	AdcAhxArg4Lys-PEGOMe
DMQ2C8X	MI	TTW4Y2M
DMQ2C8X	MN	cAMP protein kinase type II-beta (PRKAR2B)
DMQ2C8X	MT	DTT
DMQ2C8X	MA	Inhibitor
DMQ2C8X	RN	Liquid-phase synthesis of a pegylated adenosine-oligoarginine conjugate, cell-permeable inhibitor of cAMP-dependent protein kinase. Bioorg Med Chem Lett. 2003 Sep 15;13(18):3035-9.
DMQ2C8X	RU	https://pubmed.ncbi.nlm.nih.gov/12941328

DMQ2C8X	DI	DMQ2C8X
DMQ2C8X	DN	AdcAhxArg4Lys-PEGOMe
DMQ2C8X	MI	TTNAHEX
DMQ2C8X	MN	cAMP-dependent protein kinase A type I (PRKAR1A)
DMQ2C8X	MT	DTT
DMQ2C8X	MA	Inhibitor
DMQ2C8X	RN	Liquid-phase synthesis of a pegylated adenosine-oligoarginine conjugate, cell-permeable inhibitor of cAMP-dependent protein kinase. Bioorg Med Chem Lett. 2003 Sep 15;13(18):3035-9.
DMQ2C8X	RU	https://pubmed.ncbi.nlm.nih.gov/12941328

DMSYMRJ	DI	DMSYMRJ
DMSYMRJ	DN	AdcAhxArg4NH(CH2)6NH2
DMSYMRJ	MI	TTW4Y2M
DMSYMRJ	MN	cAMP protein kinase type II-beta (PRKAR2B)
DMSYMRJ	MT	DTT
DMSYMRJ	MA	Inhibitor
DMSYMRJ	RN	Liquid-phase synthesis of a pegylated adenosine-oligoarginine conjugate, cell-permeable inhibitor of cAMP-dependent protein kinase. Bioorg Med Chem Lett. 2003 Sep 15;13(18):3035-9.
DMSYMRJ	RU	https://pubmed.ncbi.nlm.nih.gov/12941328

DMSYMRJ	DI	DMSYMRJ
DMSYMRJ	DN	AdcAhxArg4NH(CH2)6NH2
DMSYMRJ	MI	TTNAHEX
DMSYMRJ	MN	cAMP-dependent protein kinase A type I (PRKAR1A)
DMSYMRJ	MT	DTT
DMSYMRJ	MA	Inhibitor
DMSYMRJ	RN	Liquid-phase synthesis of a pegylated adenosine-oligoarginine conjugate, cell-permeable inhibitor of cAMP-dependent protein kinase. Bioorg Med Chem Lett. 2003 Sep 15;13(18):3035-9.
DMSYMRJ	RU	https://pubmed.ncbi.nlm.nih.gov/12941328

DM7J3K0	DI	DM7J3K0
DM7J3K0	DN	AdcAhxArg6
DM7J3K0	MI	TTW4Y2M
DM7J3K0	MN	cAMP protein kinase type II-beta (PRKAR2B)
DM7J3K0	MT	DTT
DM7J3K0	MA	Inhibitor
DM7J3K0	RN	Liquid-phase synthesis of a pegylated adenosine-oligoarginine conjugate, cell-permeable inhibitor of cAMP-dependent protein kinase. Bioorg Med Chem Lett. 2003 Sep 15;13(18):3035-9.
DM7J3K0	RU	https://pubmed.ncbi.nlm.nih.gov/12941328

DM7J3K0	DI	DM7J3K0
DM7J3K0	DN	AdcAhxArg6
DM7J3K0	MI	TTNAHEX
DM7J3K0	MN	cAMP-dependent protein kinase A type I (PRKAR1A)
DM7J3K0	MT	DTT
DM7J3K0	MA	Inhibitor
DM7J3K0	RN	Liquid-phase synthesis of a pegylated adenosine-oligoarginine conjugate, cell-permeable inhibitor of cAMP-dependent protein kinase. Bioorg Med Chem Lett. 2003 Sep 15;13(18):3035-9.
DM7J3K0	RU	https://pubmed.ncbi.nlm.nih.gov/12941328

DMV39AW	DI	DMV39AW
DMV39AW	DN	ADENOPHOSTIN A
DMV39AW	MI	TTC9IZL
DMV39AW	MN	Inositol 1,4,5-trisphosphate receptor (ITPR)
DMV39AW	MT	DTT
DMV39AW	MA	Inhibitor
DMV39AW	RN	Synthesis of adenophostin A analogues conjugating an aromatic group at the 5'-position as potent IP3 receptor ligands. J Med Chem. 2006 Sep 21;49(19):5750-8.
DMV39AW	RU	https://pubmed.ncbi.nlm.nih.gov/16970399

DMFUHKP	DI	DMFUHKP
DMFUHKP	DN	adenosine diphosphate
DMFUHKP	MI	TTJ2HKA
DMFUHKP	MN	Long transient receptor potential channel 4 (TRPM4)
DMFUHKP	MT	DTT
DMFUHKP	MA	Inhibitor (gating inhibitor)
DMFUHKP	RN	Intracellular nucleotides and polyamines inhibit the Ca2+-activated cation channel TRPM4b. Pflugers Arch. 2004 Apr;448(1):70-5.
DMFUHKP	RU	https://pubmed.ncbi.nlm.nih.gov/14758478

DMFUHKP	DI	DMFUHKP
DMFUHKP	DN	adenosine diphosphate
DMFUHKP	MI	TTA93TL
DMFUHKP	MN	P2Y purinoceptor 1 (P2RY1)
DMFUHKP	MT	DTT
DMFUHKP	MA	Agonist
DMFUHKP	RN	Quantitation of the P2Y(1) receptor with a high affinity radiolabeled antagonist. Mol Pharmacol. 2002 Nov;62(5):1249-57.
DMFUHKP	RU	https://pubmed.ncbi.nlm.nih.gov/12391289

DMFUHKP	DI	DMFUHKP
DMFUHKP	DN	adenosine diphosphate
DMFUHKP	MI	TTZ1DT0
DMFUHKP	MN	P2Y purinoceptor 12 (P2RY12)
DMFUHKP	MT	DTT
DMFUHKP	MA	Agonist
DMFUHKP	RN	P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med. 2003 May;3(2):113-22.
DMFUHKP	RU	https://pubmed.ncbi.nlm.nih.gov/15199474

DMFUHKP	DI	DMFUHKP
DMFUHKP	DN	adenosine diphosphate
DMFUHKP	MI	TT1FE3L
DMFUHKP	MN	P2Y purinoceptor 13 (P2RY13)
DMFUHKP	MT	DTT
DMFUHKP	MA	Agonist
DMFUHKP	RN	Pharmacological characterization of the human P2Y13 receptor. Mol Pharmacol. 2003 Jul;64(1):104-12.
DMFUHKP	RU	https://pubmed.ncbi.nlm.nih.gov/12815166

DMFUHKP	DI	DMFUHKP
DMFUHKP	DN	adenosine diphosphate
DMFUHKP	MI	TTNVSKA
DMFUHKP	MN	P2Y purinoceptor 6 (P2RY6)
DMFUHKP	MT	DTT
DMFUHKP	MA	Agonist
DMFUHKP	RN	Cloning, functional expression and tissue distribution of the human P2Y6 receptor. Biochem Biophys Res Commun. 1996 May 15;222(2):303-8.
DMFUHKP	RU	https://pubmed.ncbi.nlm.nih.gov/8670200

DMJZPSX	DI	DMJZPSX
DMJZPSX	DN	Adenosine Monotungstate
DMJZPSX	MI	TTMS54D
DMJZPSX	MN	Fragile histidine triad protein (FHIT)
DMJZPSX	MT	DTT
DMJZPSX	MA	Inhibitor
DMJZPSX	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMJZPSX	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMSOVFD	DI	DMSOVFD
DMSOVFD	DN	adenosine-3'-5'-bisphosphate
DMSOVFD	MI	TTA93TL
DMSOVFD	MN	P2Y purinoceptor 1 (P2RY1)
DMSOVFD	MT	DTT
DMSOVFD	MA	Antagonist
DMSOVFD	RN	Identification of competitive antagonists of the P2Y1 receptor. Mol Pharmacol. 1996 Nov;50(5):1323-9.
DMSOVFD	RU	https://pubmed.ncbi.nlm.nih.gov/8913364

DM96LBV	DI	DM96LBV
DM96LBV	DN	Adenosine-5-Diphosphoribose
DM96LBV	MI	TTCNGJ5
DM96LBV	MN	Candida Elongation factor 2 (Candi EFT2)
DM96LBV	MT	DTT
DM96LBV	MA	Inhibitor
DM96LBV	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM96LBV	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMJDO2F	DI	DMJDO2F
DMJDO2F	DN	Adenosine-5'-O-(2-thiodiphosphate)
DMJDO2F	MI	TTQD1SA
DMJDO2F	MN	P2Y purinoceptor (P2RY)
DMJDO2F	MT	DTT
DMJDO2F	MA	Agonist
DMJDO2F	RN	Stimulation of insulin secretion and improvement of glucose tolerance in rat and dog by the P2y-purinoceptor agonist, adenosine-5'-O-(2-thiodiphosphate). Br J Pharmacol. 1993 May;109(1):183-7.
DMJDO2F	RU	https://pubmed.ncbi.nlm.nih.gov/8495239

DMKY7T8	DI	DMKY7T8
DMKY7T8	DN	Adenosine-5'-Rp-Alpha-Thio-Triphosphate
DMKY7T8	MI	TT2QM9D
DMKY7T8	MN	Adenylate cyclase (ADCY)
DMKY7T8	MT	DTT
DMKY7T8	MA	Inhibitor
DMKY7T8	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMKY7T8	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DM0YQ2I	DI	DM0YQ2I
DM0YQ2I	DN	Adenylylsulfate
DM0YQ2I	MI	DEQ63LA
DM0YQ2I	MN	Dinucleosidetriphosphatase (FHIT)
DM0YQ2I	MT	DME
DM0YQ2I	MA	Metabolism
DM0YQ2I	RN	Adenylylsulfate-ammonia adenylyltransferase activity is another inherent property of Fhit proteins. Biosci Rep. 2015 Jun 25;35(4). pii: e00235.
DM0YQ2I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26181368

DM0YQ2I	DI	DM0YQ2I
DM0YQ2I	DN	Adenylylsulfate
DM0YQ2I	MI	DEDG68B
DM0YQ2I	MN	Sulfurylase kinase 1 (PAPSS1)
DM0YQ2I	MT	DME
DM0YQ2I	MA	Metabolism
DM0YQ2I	RN	Human 3'-phosphoadenosine 5'-phosphosulfate synthetase (isoform 1, brain): kinetic properties of the adenosine triphosphate sulfurylase and adenosine 5'-phosphosulfate kinase domains. Biochemistry. 2004 Apr 13;43(14):4356-65.
DM0YQ2I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15065880

DM2XI09	DI	DM2XI09
DM2XI09	DN	Adipate
DM2XI09	MI	TTTQR47
DM2XI09	MN	Solute carrier family 22 member 8 (SLC22A8)
DM2XI09	MT	DTT
DM2XI09	MA	Inhibitor
DM2XI09	RN	Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members. J Biol Chem. 2007 Aug 17;282(33):23841-53.
DM2XI09	RU	https://pubmed.ncbi.nlm.nih.gov/17553798

DMW5HO0	DI	DMW5HO0
DMW5HO0	DN	AdoC(Ahx)Arg6
DMW5HO0	MI	TTW4Y2M
DMW5HO0	MN	cAMP protein kinase type II-beta (PRKAR2B)
DMW5HO0	MT	DTT
DMW5HO0	MA	Inhibitor
DMW5HO0	RN	Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52.
DMW5HO0	RU	https://pubmed.ncbi.nlm.nih.gov/10360754

DMW5HO0	DI	DMW5HO0
DMW5HO0	DN	AdoC(Ahx)Arg6
DMW5HO0	MI	TTNAHEX
DMW5HO0	MN	cAMP-dependent protein kinase A type I (PRKAR1A)
DMW5HO0	MT	DTT
DMW5HO0	MA	Inhibitor
DMW5HO0	RN	Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52.
DMW5HO0	RU	https://pubmed.ncbi.nlm.nih.gov/10360754

DMRSCO2	DI	DMRSCO2
DMRSCO2	DN	AdoC(Aoc)Arg6
DMRSCO2	MI	TTW4Y2M
DMRSCO2	MN	cAMP protein kinase type II-beta (PRKAR2B)
DMRSCO2	MT	DTT
DMRSCO2	MA	Inhibitor
DMRSCO2	RN	Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52.
DMRSCO2	RU	https://pubmed.ncbi.nlm.nih.gov/10360754

DMRSCO2	DI	DMRSCO2
DMRSCO2	DN	AdoC(Aoc)Arg6
DMRSCO2	MI	TTNAHEX
DMRSCO2	MN	cAMP-dependent protein kinase A type I (PRKAR1A)
DMRSCO2	MT	DTT
DMRSCO2	MA	Inhibitor
DMRSCO2	RN	Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52.
DMRSCO2	RU	https://pubmed.ncbi.nlm.nih.gov/10360754

DMDLHAB	DI	DMDLHAB
DMDLHAB	DN	AdoC(Aun)Arg6
DMDLHAB	MI	TTW4Y2M
DMDLHAB	MN	cAMP protein kinase type II-beta (PRKAR2B)
DMDLHAB	MT	DTT
DMDLHAB	MA	Inhibitor
DMDLHAB	RN	Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52.
DMDLHAB	RU	https://pubmed.ncbi.nlm.nih.gov/10360754

DMDLHAB	DI	DMDLHAB
DMDLHAB	DN	AdoC(Aun)Arg6
DMDLHAB	MI	TTNAHEX
DMDLHAB	MN	cAMP-dependent protein kinase A type I (PRKAR1A)
DMDLHAB	MT	DTT
DMDLHAB	MA	Inhibitor
DMDLHAB	RN	Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52.
DMDLHAB	RU	https://pubmed.ncbi.nlm.nih.gov/10360754

DMPUAFC	DI	DMPUAFC
DMPUAFC	DN	AdoC(beta-Ala)2AlaArg6
DMPUAFC	MI	TTW4Y2M
DMPUAFC	MN	cAMP protein kinase type II-beta (PRKAR2B)
DMPUAFC	MT	DTT
DMPUAFC	MA	Inhibitor
DMPUAFC	RN	Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52.
DMPUAFC	RU	https://pubmed.ncbi.nlm.nih.gov/10360754

DMPUAFC	DI	DMPUAFC
DMPUAFC	DN	AdoC(beta-Ala)2AlaArg6
DMPUAFC	MI	TTNAHEX
DMPUAFC	MN	cAMP-dependent protein kinase A type I (PRKAR1A)
DMPUAFC	MT	DTT
DMPUAFC	MA	Inhibitor
DMPUAFC	RN	Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52.
DMPUAFC	RU	https://pubmed.ncbi.nlm.nih.gov/10360754

DMO8D4V	DI	DMO8D4V
DMO8D4V	DN	AdoC(beta-Ala)Arg6
DMO8D4V	MI	TTW4Y2M
DMO8D4V	MN	cAMP protein kinase type II-beta (PRKAR2B)
DMO8D4V	MT	DTT
DMO8D4V	MA	Inhibitor
DMO8D4V	RN	Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52.
DMO8D4V	RU	https://pubmed.ncbi.nlm.nih.gov/10360754

DMO8D4V	DI	DMO8D4V
DMO8D4V	DN	AdoC(beta-Ala)Arg6
DMO8D4V	MI	TTNAHEX
DMO8D4V	MN	cAMP-dependent protein kinase A type I (PRKAR1A)
DMO8D4V	MT	DTT
DMO8D4V	MA	Inhibitor
DMO8D4V	RN	Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52.
DMO8D4V	RU	https://pubmed.ncbi.nlm.nih.gov/10360754

DM65B7Y	DI	DM65B7Y
DM65B7Y	DN	AdoC(betaAsp)2AlaArg6
DM65B7Y	MI	TTW4Y2M
DM65B7Y	MN	cAMP protein kinase type II-beta (PRKAR2B)
DM65B7Y	MT	DTT
DM65B7Y	MA	Inhibitor
DM65B7Y	RN	Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52.
DM65B7Y	RU	https://pubmed.ncbi.nlm.nih.gov/10360754

DM65B7Y	DI	DM65B7Y
DM65B7Y	DN	AdoC(betaAsp)2AlaArg6
DM65B7Y	MI	TTNAHEX
DM65B7Y	MN	cAMP-dependent protein kinase A type I (PRKAR1A)
DM65B7Y	MT	DTT
DM65B7Y	MA	Inhibitor
DM65B7Y	RN	Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52.
DM65B7Y	RU	https://pubmed.ncbi.nlm.nih.gov/10360754

DM2TWSZ	DI	DM2TWSZ
DM2TWSZ	DN	AdoC(Dpr)2AlaArg6
DM2TWSZ	MI	TTW4Y2M
DM2TWSZ	MN	cAMP protein kinase type II-beta (PRKAR2B)
DM2TWSZ	MT	DTT
DM2TWSZ	MA	Inhibitor
DM2TWSZ	RN	Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52.
DM2TWSZ	RU	https://pubmed.ncbi.nlm.nih.gov/10360754

DM2TWSZ	DI	DM2TWSZ
DM2TWSZ	DN	AdoC(Dpr)2AlaArg6
DM2TWSZ	MI	TTNAHEX
DM2TWSZ	MN	cAMP-dependent protein kinase A type I (PRKAR1A)
DM2TWSZ	MT	DTT
DM2TWSZ	MA	Inhibitor
DM2TWSZ	RN	Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52.
DM2TWSZ	RU	https://pubmed.ncbi.nlm.nih.gov/10360754

DM2TWSZ	DI	DM2TWSZ
DM2TWSZ	DN	AdoC(Dpr)2AlaArg6
DM2TWSZ	MI	TTER6YH
DM2TWSZ	MN	Casein kinase II alpha (CSNK2A1)
DM2TWSZ	MT	DTT
DM2TWSZ	MA	Inhibitor
DM2TWSZ	RN	Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52.
DM2TWSZ	RU	https://pubmed.ncbi.nlm.nih.gov/10360754

DMMWNPT	DI	DMMWNPT
DMMWNPT	DN	AdoC(GABA)Arg6
DMMWNPT	MI	TTW4Y2M
DMMWNPT	MN	cAMP protein kinase type II-beta (PRKAR2B)
DMMWNPT	MT	DTT
DMMWNPT	MA	Inhibitor
DMMWNPT	RN	Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52.
DMMWNPT	RU	https://pubmed.ncbi.nlm.nih.gov/10360754

DMMWNPT	DI	DMMWNPT
DMMWNPT	DN	AdoC(GABA)Arg6
DMMWNPT	MI	TTNAHEX
DMMWNPT	MN	cAMP-dependent protein kinase A type I (PRKAR1A)
DMMWNPT	MT	DTT
DMMWNPT	MA	Inhibitor
DMMWNPT	RN	Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52.
DMMWNPT	RU	https://pubmed.ncbi.nlm.nih.gov/10360754

DMVQJP0	DI	DMVQJP0
DMVQJP0	DN	AdoCGlyArg6
DMVQJP0	MI	TTW4Y2M
DMVQJP0	MN	cAMP protein kinase type II-beta (PRKAR2B)
DMVQJP0	MT	DTT
DMVQJP0	MA	Inhibitor
DMVQJP0	RN	Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52.
DMVQJP0	RU	https://pubmed.ncbi.nlm.nih.gov/10360754

DMVQJP0	DI	DMVQJP0
DMVQJP0	DN	AdoCGlyArg6
DMVQJP0	MI	TTNAHEX
DMVQJP0	MN	cAMP-dependent protein kinase A type I (PRKAR1A)
DMVQJP0	MT	DTT
DMVQJP0	MA	Inhibitor
DMVQJP0	RN	Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52.
DMVQJP0	RU	https://pubmed.ncbi.nlm.nih.gov/10360754

DMPOU86	DI	DMPOU86
DMPOU86	DN	ADOCIAQUINONE B
DMPOU86	MI	TTG8HIM
DMPOU86	MN	Dual specificity protein phosphatase 1 (DUSP1)
DMPOU86	MT	DTT
DMPOU86	MA	Inhibitor
DMPOU86	RN	Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases. Bioorg Med Chem. 2009 Mar 15;17(6):2276-81.
DMPOU86	RU	https://pubmed.ncbi.nlm.nih.gov/19028102

DMPOU86	DI	DMPOU86
DMPOU86	DN	ADOCIAQUINONE B
DMPOU86	MI	TTR0SWN
DMPOU86	MN	M-phase inducer phosphatase 2 (MPIP2)
DMPOU86	MT	DTT
DMPOU86	MA	Inhibitor
DMPOU86	RN	Novel naphthoquinone and quinolinedione inhibitors of CDC25 phosphatase activity with antiproliferative properties. Bioorg Med Chem. 2008 Oct 1;16(19):9040-9.
DMPOU86	RU	https://pubmed.ncbi.nlm.nih.gov/18789703

DM6MRSC	DI	DM6MRSC
DM6MRSC	DN	Adociasulfate-2
DM6MRSC	MI	TTBGTCW
DM6MRSC	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DM6MRSC	MT	DTT
DM6MRSC	MA	Inhibitor
DM6MRSC	RN	Inhibition of kinesin motor proteins by adociasulfate-2. J Med Chem. 2006 Aug 10;49(16):4857-60.
DM6MRSC	RU	https://pubmed.ncbi.nlm.nih.gov/16884297

DM9IBHU	DI	DM9IBHU
DM9IBHU	DN	Ado-P-Ch2-P-Ps-Ado
DM9IBHU	MI	TTMS54D
DM9IBHU	MN	Fragile histidine triad protein (FHIT)
DM9IBHU	MT	DTT
DM9IBHU	MA	Inhibitor
DM9IBHU	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9IBHU	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMQ1F7J	DI	DMQ1F7J
DMQ1F7J	DN	ADP ribose
DMQ1F7J	MI	TTEBMN7
DMQ1F7J	MN	Long transient receptor potential channel 2 (TRPM2)
DMQ1F7J	MT	DTT
DMQ1F7J	MA	Activator
DMQ1F7J	RN	ADP-ribose gating of the calcium-permeable LTRPC2 channel revealed by Nudix motif homology. Nature. 2001 May 31;411(6837):595-9.
DMQ1F7J	RU	https://pubmed.ncbi.nlm.nih.gov/11385575

DMVWM75	DI	DMVWM75
DMVWM75	DN	Adp[-Trp-Arg-Nva-Arg-Tyr-NH2]2
DMVWM75	MI	TTRK9JT
DMVWM75	MN	Neuropeptide Y receptor type 1 (NPY1R)
DMVWM75	MT	DTT
DMVWM75	MA	Inhibitor
DMVWM75	RN	Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5.
DMVWM75	RU	https://pubmed.ncbi.nlm.nih.gov/16610810

DMVWM75	DI	DMVWM75
DMVWM75	DN	Adp[-Trp-Arg-Nva-Arg-Tyr-NH2]2
DMVWM75	MI	TTJ6WK9
DMVWM75	MN	Neuropeptide Y receptor type 2 (NPY2R)
DMVWM75	MT	DTT
DMVWM75	MA	Inhibitor
DMVWM75	RN	Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5.
DMVWM75	RU	https://pubmed.ncbi.nlm.nih.gov/16610810

DMVWM75	DI	DMVWM75
DMVWM75	DN	Adp[-Trp-Arg-Nva-Arg-Tyr-NH2]2
DMVWM75	MI	TTW4N16
DMVWM75	MN	Neuropeptide Y receptor type 4 (NPY4R)
DMVWM75	MT	DTT
DMVWM75	MA	Inhibitor
DMVWM75	RN	Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5.
DMVWM75	RU	https://pubmed.ncbi.nlm.nih.gov/16610810

DMQBCPK	DI	DMQBCPK
DMQBCPK	DN	ADR58
DMQBCPK	MI	TTIVXSE
DMQBCPK	MN	Oncostatin-M (OSM)
DMQBCPK	MT	DTT
DMQBCPK	RN	Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60.
DMQBCPK	RU	https://pubmed.ncbi.nlm.nih.gov/18095918

DMP8NSU	DI	DMP8NSU
DMP8NSU	DN	ADRENOGLOMERULOTROPIN
DMP8NSU	MI	TT0K1SC
DMP8NSU	MN	5-HT 2B receptor (HTR2B)
DMP8NSU	MT	DTT
DMP8NSU	MA	Inhibitor
DMP8NSU	RN	Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify no... J Med Chem. 2010 Nov 11;53(21):7573-86.
DMP8NSU	RU	https://pubmed.ncbi.nlm.nih.gov/20958049

DMP7IS0	DI	DMP7IS0
DMP7IS0	DN	ADS-0101
DMP7IS0	MI	TTG043C
DMP7IS0	MN	Tumor necrosis factor receptor type I (TNF-R1)
DMP7IS0	MT	DTT
DMP7IS0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1870).
DMP7IS0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1870

DM7U4OT	DI	DM7U4OT
DM7U4OT	DN	ADS-100380
DM7U4OT	MI	TT6R7JZ
DM7U4OT	MN	Histone deacetylase 1 (HDAC1)
DM7U4OT	MT	DTT
DM7U4OT	MA	Inhibitor
DM7U4OT	RN	Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibit... Bioorg Med Chem Lett. 2007 Jan 15;17(2):363-9.
DM7U4OT	RU	https://pubmed.ncbi.nlm.nih.gov/17107790

DMEU6MH	DI	DMEU6MH
DMEU6MH	DN	ADS-102550
DMEU6MH	MI	TT6R7JZ
DMEU6MH	MN	Histone deacetylase 1 (HDAC1)
DMEU6MH	MT	DTT
DMEU6MH	MA	Inhibitor
DMEU6MH	RN	Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibit... Bioorg Med Chem Lett. 2007 Jan 15;17(2):363-9.
DMEU6MH	RU	https://pubmed.ncbi.nlm.nih.gov/17107790

DMXD0C3	DI	DMXD0C3
DMXD0C3	DN	ADS-102891
DMXD0C3	MI	TTX4RTB
DMXD0C3	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMXD0C3	MT	DTT
DMXD0C3	MA	Inhibitor
DMXD0C3	RN	Quinazoline and benzimidazole MCH-1R antagonists. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1403-7.
DMXD0C3	RU	https://pubmed.ncbi.nlm.nih.gov/17178222

DMMYUB9	DI	DMMYUB9
DMMYUB9	DN	ADS-103168
DMMYUB9	MI	TTX4RTB
DMMYUB9	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMMYUB9	MT	DTT
DMMYUB9	MA	Inhibitor
DMMYUB9	RN	Quinazoline and benzimidazole MCH-1R antagonists. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1403-7.
DMMYUB9	RU	https://pubmed.ncbi.nlm.nih.gov/17178222

DMUMF0B	DI	DMUMF0B
DMUMF0B	DN	ADS-103214
DMUMF0B	MI	TTX4RTB
DMUMF0B	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMUMF0B	MT	DTT
DMUMF0B	MA	Inhibitor
DMUMF0B	RN	Quinazoline and benzimidazole MCH-1R antagonists. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1403-7.
DMUMF0B	RU	https://pubmed.ncbi.nlm.nih.gov/17178222

DMH9A4S	DI	DMH9A4S
DMH9A4S	DN	ADS-103253
DMH9A4S	MI	TT0K1SC
DMH9A4S	MN	5-HT 2B receptor (HTR2B)
DMH9A4S	MT	DTT
DMH9A4S	MA	Inhibitor
DMH9A4S	RN	Quinazoline and benzimidazole MCH-1R antagonists. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1403-7.
DMH9A4S	RU	https://pubmed.ncbi.nlm.nih.gov/17178222

DMH9A4S	DI	DMH9A4S
DMH9A4S	DN	ADS-103253
DMH9A4S	MI	TTX4RTB
DMH9A4S	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMH9A4S	MT	DTT
DMH9A4S	MA	Inhibitor
DMH9A4S	RN	Quinazoline and benzimidazole MCH-1R antagonists. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1403-7.
DMH9A4S	RU	https://pubmed.ncbi.nlm.nih.gov/17178222

DMH9A4S	DI	DMH9A4S
DMH9A4S	DN	ADS-103253
DMH9A4S	MI	TTQ6VDM
DMH9A4S	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMH9A4S	MT	DTT
DMH9A4S	MA	Inhibitor
DMH9A4S	RN	Quinazoline and benzimidazole MCH-1R antagonists. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1403-7.
DMH9A4S	RU	https://pubmed.ncbi.nlm.nih.gov/17178222

DMLIOV2	DI	DMLIOV2
DMLIOV2	DN	ADS-103254
DMLIOV2	MI	TTX4RTB
DMLIOV2	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMLIOV2	MT	DTT
DMLIOV2	MA	Inhibitor
DMLIOV2	RN	Quinazoline and benzimidazole MCH-1R antagonists. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1403-7.
DMLIOV2	RU	https://pubmed.ncbi.nlm.nih.gov/17178222

DMBN6IE	DI	DMBN6IE
DMBN6IE	DN	ADS-103274
DMBN6IE	MI	TT0K1SC
DMBN6IE	MN	5-HT 2B receptor (HTR2B)
DMBN6IE	MT	DTT
DMBN6IE	MA	Inhibitor
DMBN6IE	RN	Quinazoline and benzimidazole MCH-1R antagonists. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1403-7.
DMBN6IE	RU	https://pubmed.ncbi.nlm.nih.gov/17178222

DMBN6IE	DI	DMBN6IE
DMBN6IE	DN	ADS-103274
DMBN6IE	MI	TTX4RTB
DMBN6IE	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMBN6IE	MT	DTT
DMBN6IE	MA	Inhibitor
DMBN6IE	RN	Quinazoline and benzimidazole MCH-1R antagonists. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1403-7.
DMBN6IE	RU	https://pubmed.ncbi.nlm.nih.gov/17178222

DM0C4QD	DI	DM0C4QD
DM0C4QD	DN	ADS-103293
DM0C4QD	MI	TTX4RTB
DM0C4QD	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DM0C4QD	MT	DTT
DM0C4QD	MA	Inhibitor
DM0C4QD	RN	Quinazoline and benzimidazole MCH-1R antagonists. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1403-7.
DM0C4QD	RU	https://pubmed.ncbi.nlm.nih.gov/17178222

DMM2Q9L	DI	DMM2Q9L
DMM2Q9L	DN	ADS-103294
DMM2Q9L	MI	TTX4RTB
DMM2Q9L	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMM2Q9L	MT	DTT
DMM2Q9L	MA	Inhibitor
DMM2Q9L	RN	Quinazoline and benzimidazole MCH-1R antagonists. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1403-7.
DMM2Q9L	RU	https://pubmed.ncbi.nlm.nih.gov/17178222

DMKCOYE	DI	DMKCOYE
DMKCOYE	DN	ADS-103316
DMKCOYE	MI	TTX4RTB
DMKCOYE	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMKCOYE	MT	DTT
DMKCOYE	MA	Inhibitor
DMKCOYE	RN	Quinazoline and benzimidazole MCH-1R antagonists. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1403-7.
DMKCOYE	RU	https://pubmed.ncbi.nlm.nih.gov/17178222

DMA74PO	DI	DMA74PO
DMA74PO	DN	ADX-63365
DMA74PO	MI	TTHS256
DMA74PO	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMA74PO	MT	DTT
DMA74PO	MA	Modulator
DMA74PO	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 293).
DMA74PO	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=293

DM3WAG6	DI	DM3WAG6
DM3WAG6	DN	ADX71743
DM3WAG6	MI	TT0I76D
DM3WAG6	MN	Metabotropic glutamate receptor 7 (mGluR7)
DM3WAG6	MT	DTT
DM3WAG6	MA	Modulator (allosteric modulator)
DM3WAG6	RN	ADX71743, a potent and selective negative allosteric modulator of metabotropic glutamate receptor 7: in vitro and in vivo characterization. J Pharmacol Exp Ther. 2013 Mar;344(3):624-36.
DM3WAG6	RU	https://pubmed.ncbi.nlm.nih.gov/23257312

DM70H6P	DI	DM70H6P
DM70H6P	DN	ADX-88178
DM70H6P	MI	TTICZ1O
DM70H6P	MN	Metabotropic glutamate receptor 4 (mGluR4)
DM70H6P	MT	DTT
DM70H6P	MA	Modulator
DM70H6P	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 292).
DM70H6P	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=292

DMANEH2	DI	DMANEH2
DMANEH2	DN	AE-9C90CB
DMANEH2	MI	TTQ13Z5
DMANEH2	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMANEH2	MT	DTT
DMANEH2	MA	Antagonist
DMANEH2	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 15).
DMANEH2	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=15

DMZ8SV3	DI	DMZ8SV3
DMZ8SV3	DN	AEKKDEGPYRMEHFRWGSPPKD
DMZ8SV3	MI	TTEOSZT
DMZ8SV3	MN	Melanocortin receptor (MCR)
DMZ8SV3	MT	DTT
DMZ8SV3	MA	Inhibitor
DMZ8SV3	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMZ8SV3	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMZ8SV3	DI	DMZ8SV3
DMZ8SV3	DN	AEKKDEGPYRMEHFRWGSPPKD
DMZ8SV3	MI	TT0MV2T
DMZ8SV3	MN	Melanocortin receptor 1 (MC1R)
DMZ8SV3	MT	DTT
DMZ8SV3	MA	Inhibitor
DMZ8SV3	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMZ8SV3	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMZ8SV3	DI	DMZ8SV3
DMZ8SV3	DN	AEKKDEGPYRMEHFRWGSPPKD
DMZ8SV3	MI	TTNI91K
DMZ8SV3	MN	Melanocortin receptor 3 (MC3R)
DMZ8SV3	MT	DTT
DMZ8SV3	MA	Inhibitor
DMZ8SV3	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMZ8SV3	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMZ8SV3	DI	DMZ8SV3
DMZ8SV3	DN	AEKKDEGPYRMEHFRWGSPPKD
DMZ8SV3	MI	TTD0CIQ
DMZ8SV3	MN	Melanocortin receptor 4 (MC4R)
DMZ8SV3	MT	DTT
DMZ8SV3	MA	Inhibitor
DMZ8SV3	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMZ8SV3	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DME0I6U	DI	DME0I6U
DME0I6U	DN	Aerophobin-1
DME0I6U	MI	TT9JNIC
DME0I6U	MN	Histamine H3 receptor (H3R)
DME0I6U	MT	DTT
DME0I6U	MA	Inhibitor
DME0I6U	RN	Verongamine, a novel bromotyrosine-derived histamine H3-antagonist from the marine sponge Verongula gigantea. J Nat Prod. 1994 Jan;57(1):175-7.
DME0I6U	RU	https://pubmed.ncbi.nlm.nih.gov/8158162

DMULWOG	DI	DMULWOG
DMULWOG	DN	AEZS-115
DMULWOG	MI	TT8R70G
DMULWOG	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMULWOG	MT	DTT
DMULWOG	MA	Antagonist
DMULWOG	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 256).
DMULWOG	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=256

DMM52FD	DI	DMM52FD
DMM52FD	DN	AEZS-126
DMM52FD	MI	TTHBTOP
DMM52FD	MN	PI3-kinase gamma (PIK3CG)
DMM52FD	MT	DTT
DMM52FD	MA	Inhibitor
DMM52FD	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2155).
DMM52FD	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2155

DMN9RE5	DI	DMN9RE5
DMN9RE5	DN	AEZS-131
DMN9RE5	MI	TT4TQBX
DMN9RE5	MN	Extracellular signal-regulated kinase 2 (ERK2)
DMN9RE5	MT	DTT
DMN9RE5	MA	Inhibitor
DMN9RE5	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1495).
DMN9RE5	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1495

DMOYADT	DI	DMOYADT
DMOYADT	DN	AF150(S)
DMOYADT	MI	TTZ9SOR
DMOYADT	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMOYADT	MT	DTT
DMOYADT	MA	Agonist
DMOYADT	RN	M1 muscarinic agonists target major hallmarks of Alzheimer's disease--an update. Curr Alzheimer Res. 2007 Dec;4(5):577-80.
DMOYADT	RU	https://pubmed.ncbi.nlm.nih.gov/18220527

DM6B9CK	DI	DM6B9CK
DM6B9CK	DN	AF-3473
DM6B9CK	MI	TT07C3Y
DM6B9CK	MN	5-HT 4 receptor (HTR4)
DM6B9CK	MT	DTT
DM6B9CK	MA	Antagonist
DM6B9CK	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 9).
DM6B9CK	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=9

DMXQ3MO	DI	DMXQ3MO
DMXQ3MO	DN	AF353
DMXQ3MO	MI	TT2THBD
DMXQ3MO	MN	P2X purinoceptor 3 (P2RX3)
DMXQ3MO	MT	DTT
DMXQ3MO	MA	Antagonist
DMXQ3MO	RN	AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist. Br J Pharmacol. 2010 Jul;160(6):1387-98.
DMXQ3MO	RU	https://pubmed.ncbi.nlm.nih.gov/20590629

DM65TUP	DI	DM65TUP
DM65TUP	DN	AFC-5128
DM65TUP	MI	TT473XN
DM65TUP	MN	P2X purinoceptor 7 (P2RX7)
DM65TUP	MT	DTT
DM65TUP	MA	Antagonist
DM65TUP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 484).
DM65TUP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=484

DME9Y8Q	DI	DME9Y8Q
DME9Y8Q	DN	AFD(R)
DME9Y8Q	MI	TT9JZCK
DME9Y8Q	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DME9Y8Q	MT	DTT
DME9Y8Q	MA	Agonist
DME9Y8Q	RN	The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002 Jun 14;277(24):21453-7.
DME9Y8Q	RU	https://pubmed.ncbi.nlm.nih.gov/11967257

DME9Y8Q	DI	DME9Y8Q
DME9Y8Q	DN	AFD(R)
DME9Y8Q	MI	TTDYP7I
DME9Y8Q	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DME9Y8Q	MT	DTT
DME9Y8Q	MA	Agonist
DME9Y8Q	RN	The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002 Jun 14;277(24):21453-7.
DME9Y8Q	RU	https://pubmed.ncbi.nlm.nih.gov/11967257

DME9Y8Q	DI	DME9Y8Q
DME9Y8Q	DN	AFD(R)
DME9Y8Q	MI	TTZ8C5Q
DME9Y8Q	MN	Sphingosine-1-phosphate receptor 4 (S1PR4)
DME9Y8Q	MT	DTT
DME9Y8Q	MA	Agonist
DME9Y8Q	RN	Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem. 2004 Apr 2;279(14):13839-48.
DME9Y8Q	RU	https://pubmed.ncbi.nlm.nih.gov/14732717

DME9Y8Q	DI	DME9Y8Q
DME9Y8Q	DN	AFD(R)
DME9Y8Q	MI	TTDZCKV
DME9Y8Q	MN	Sphingosine-1-phosphate receptor 5 (S1PR5)
DME9Y8Q	MT	DTT
DME9Y8Q	MA	Agonist
DME9Y8Q	RN	Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem. 2004 Apr 2;279(14):13839-48.
DME9Y8Q	RU	https://pubmed.ncbi.nlm.nih.gov/14732717

DMNY8H7	DI	DMNY8H7
DMNY8H7	DN	AF-DX-384
DMNY8H7	MI	TTOXS3C
DMNY8H7	MN	Muscarinic acetylcholine receptor (CHRM)
DMNY8H7	MT	DTT
DMNY8H7	MA	Antagonist
DMNY8H7	RN	Binding of [3H]AF-DX 384 to cloned and native muscarinic receptors. J Pharmacol Exp Ther. 1991 Nov;259(2):601-7.
DMNY8H7	RU	https://pubmed.ncbi.nlm.nih.gov/1941609

DMNY8H7	DI	DMNY8H7
DMNY8H7	DN	AF-DX-384
DMNY8H7	MI	TTYEG6Q
DMNY8H7	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMNY8H7	MT	DTT
DMNY8H7	MA	Modulator
DMNY8H7	RN	M2/M4 muscarinic receptor binding in the anterior cingulate cortex in schizophrenia and mood disorders. Brain Res Bull. 2005 May 15;65(5):397-403.
DMNY8H7	RU	https://www.ncbi.nlm.nih.gov/pubmed/15833594

DMNY8H7	DI	DMNY8H7
DMNY8H7	DN	AF-DX-384
DMNY8H7	MI	TTQ3JTF
DMNY8H7	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DMNY8H7	MT	DTT
DMNY8H7	MA	Modulator
DMNY8H7	RN	M2/M4 muscarinic receptor binding in the anterior cingulate cortex in schizophrenia and mood disorders. Brain Res Bull. 2005 May 15;65(5):397-403.
DMNY8H7	RU	https://www.ncbi.nlm.nih.gov/pubmed/15833594

DM6D3NQ	DI	DM6D3NQ
DM6D3NQ	DN	Affinitak + Cisplatin
DM6D3NQ	MI	TT2MI95
DM6D3NQ	MN	PKC-alpha messenger RNA (PRKCA mRNA)
DM6D3NQ	MT	DTT
DM6D3NQ	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DM6D3NQ	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DMU98ES	DI	DMU98ES
DMU98ES	DN	Affinitak + Gemcitabine
DMU98ES	MI	TT2MI95
DMU98ES	MN	PKC-alpha messenger RNA (PRKCA mRNA)
DMU98ES	MT	DTT
DMU98ES	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DMU98ES	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DM2R5F9	DI	DM2R5F9
DM2R5F9	DN	AFLATREME
DM2R5F9	MI	TTNJYV2
DM2R5F9	MN	Gamma-aminobutyric acid receptor (GAR)
DM2R5F9	MT	DTT
DM2R5F9	MA	Inhibitor
DM2R5F9	RN	Partial structures of the fungal toxin aflatrem, methyl-substituted 6,8-dioxabicyclo[3.2.1]octan-2-ones have anticonvulsant activity, Bioorg. Med. Chem. Lett. 5(3):265-270 (1995).
DM2R5F9	RU	http://www.sciencedirect.com/science/article/pii/0960894X9500021K

DM8U1IW	DI	DM8U1IW
DM8U1IW	DN	AFM-21
DM8U1IW	MI	TTGKNB4
DM8U1IW	MN	Epidermal growth factor receptor (EGFR)
DM8U1IW	MT	DTT
DM8U1IW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
DM8U1IW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797

DM4WVMU	DI	DM4WVMU
DM4WVMU	DN	AFP-07
DM4WVMU	MI	TTOFYT1
DM4WVMU	MN	Prostacyclin receptor (PTGIR)
DM4WVMU	MT	DTT
DM4WVMU	MA	Agonist
DM4WVMU	RN	7,7-Difluoroprostacyclin derivative, AFP-07, a highly selective and potent agonist for the prostacyclin receptor. Prostaglandins. 1997 Feb;53(2):83-90.
DM4WVMU	RU	https://pubmed.ncbi.nlm.nih.gov/9112287

DMF0SPB	DI	DMF0SPB
DMF0SPB	DN	AG 1024
DMF0SPB	MI	TTQFBMY
DMF0SPB	MN	IGF1R messenger RNA (IGF1R mRNA)
DMF0SPB	MT	DTT
DMF0SPB	MA	Inhibitor
DMF0SPB	RN	Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins. Endocrinology. 1997 Apr;138(4):1427-33.
DMF0SPB	RU	https://pubmed.ncbi.nlm.nih.gov/9075698

DMDYS0L	DI	DMDYS0L
DMDYS0L	DN	AG 112
DMDYS0L	MI	TTGKNB4
DMDYS0L	MN	Epidermal growth factor receptor (EGFR)
DMDYS0L	MT	DTT
DMDYS0L	MA	Inhibitor
DMDYS0L	RN	Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors. J Med Chem. 1989 Oct;32(10):2344-52.
DMDYS0L	RU	https://pubmed.ncbi.nlm.nih.gov/2552117

DMSOUI0	DI	DMSOUI0
DMSOUI0	DN	AG 9
DMSOUI0	MI	TTGKNB4
DMSOUI0	MN	Epidermal growth factor receptor (EGFR)
DMSOUI0	MT	DTT
DMSOUI0	MA	Inhibitor
DMSOUI0	RN	Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors. J Med Chem. 1989 Oct;32(10):2344-52.
DMSOUI0	RU	https://pubmed.ncbi.nlm.nih.gov/2552117

DMHFYNE	DI	DMHFYNE
DMHFYNE	DN	AG-014376
DMHFYNE	MI	TTVDSZ0
DMHFYNE	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMHFYNE	MT	DTT
DMHFYNE	MA	Inhibitor
DMHFYNE	RN	Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase. J Med Chem. 2004 Oct 21;47(22):5467-81.
DMHFYNE	RU	https://pubmed.ncbi.nlm.nih.gov/15481984

DMW7H28	DI	DMW7H28
DMW7H28	DN	AG-09/1
DMW7H28	MI	TT5Y4EM
DMW7H28	MN	N-formyl peptide receptor (FPR1)
DMW7H28	MT	DTT
DMW7H28	MA	Agonist
DMW7H28	RN	Identification of novel small-molecule agonists for human formyl peptide receptors and pharmacophore models of their recognition. Mol Pharmacol. 2010 Feb;77(2):159-70.
DMW7H28	RU	https://pubmed.ncbi.nlm.nih.gov/19903830

DMZINUY	DI	DMZINUY
DMZINUY	DN	AG-11/03
DMZINUY	MI	TT5Y4EM
DMZINUY	MN	N-formyl peptide receptor (FPR1)
DMZINUY	MT	DTT
DMZINUY	MA	Agonist
DMZINUY	RN	Molecular docking of 2-(benzimidazol-2-ylthio)-N-phenylacetamide-derived small-molecule agonists of human formyl peptide receptor 1. J Mol Model. 2012 Jun;18(6):2831-43.
DMZINUY	RU	https://pubmed.ncbi.nlm.nih.gov/22127612

DMVR9G0	DI	DMVR9G0
DMVR9G0	DN	AG-14
DMVR9G0	MI	TT5Y4EM
DMVR9G0	MN	N-formyl peptide receptor (FPR1)
DMVR9G0	MT	DTT
DMVR9G0	MA	Agonist
DMVR9G0	RN	High-throughput screening for small-molecule activators of neutrophils: identification of novel N-formyl peptide receptor agonists. Mol Pharmacol. 2007 Apr;71(4):1061-74.
DMVR9G0	RU	https://pubmed.ncbi.nlm.nih.gov/17229869

DMT3ML6	DI	DMT3ML6
DMT3ML6	DN	AG-213
DMT3ML6	MI	TTGKNB4
DMT3ML6	MN	Epidermal growth factor receptor (EGFR)
DMT3ML6	MT	DTT
DMT3ML6	MA	Inhibitor
DMT3ML6	RN	Syntheses of 4-(indole-3-yl)quinazolines: a new class of epidermal growth factor receptor tyrosine kinase inhibitors. Eur J Med Chem. 2008 Jul;43(7):1478-88.
DMT3ML6	RU	https://pubmed.ncbi.nlm.nih.gov/17981366

DMT3ML6	DI	DMT3ML6
DMT3ML6	DN	AG-213
DMT3ML6	MI	TTR5TV4
DMT3ML6	MN	ERBB2 messenger RNA (HER2 mRNA)
DMT3ML6	MT	DTT
DMT3ML6	MA	Inhibitor
DMT3ML6	RN	Syntheses of 4-(indole-3-yl)quinazolines: a new class of epidermal growth factor receptor tyrosine kinase inhibitors. Eur J Med Chem. 2008 Jul;43(7):1478-88.
DMT3ML6	RU	https://pubmed.ncbi.nlm.nih.gov/17981366

DMMFQR2	DI	DMMFQR2
DMMFQR2	DN	AG-26
DMMFQR2	MI	TTOJ1NF
DMMFQR2	MN	FMLP-related receptor I (FPR2)
DMMFQR2	MT	DTT
DMMFQR2	MA	Agonist
DMMFQR2	RN	Identification of novel small-molecule agonists for human formyl peptide receptors and pharmacophore models of their recognition. Mol Pharmacol. 2010 Feb;77(2):159-70.
DMMFQR2	RU	https://pubmed.ncbi.nlm.nih.gov/19903830

DM9KIS8	DI	DM9KIS8
DM9KIS8	DN	AG-538
DM9KIS8	MI	TTGKNB4
DM9KIS8	MN	Epidermal growth factor receptor (EGFR)
DM9KIS8	MT	DTT
DM9KIS8	MA	Inhibitor
DM9KIS8	RN	Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J Nat Prod. 1992 Nov;55(11):1529-60.
DM9KIS8	RU	https://pubmed.ncbi.nlm.nih.gov/1479375

DMAUJOM	DI	DMAUJOM
DMAUJOM	DN	agatoxin 489
DMAUJOM	MI	TTMI6F5
DMAUJOM	MN	Transient receptor potential cation channel V1 (TRPV1)
DMAUJOM	MT	DTT
DMAUJOM	MA	Blocker (channel blocker)
DMAUJOM	RN	An inhibitor of TRPV1 channels isolated from funnel Web spider venom. Biochemistry. 2005 Nov 29;44(47):15544-9.
DMAUJOM	RU	https://pubmed.ncbi.nlm.nih.gov/16300403

DM83951	DI	DM83951
DM83951	DN	AG-E-85378
DM83951	MI	TTUTJGQ
DM83951	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM83951	MT	DTT
DM83951	MA	Inhibitor
DM83951	RN	Discovery of N-phenyl nicotinamides as potent inhibitors of Kdr. Bioorg Med Chem Lett. 2007 Nov 1;17(21):6003-8.
DM83951	RU	https://pubmed.ncbi.nlm.nih.gov/17869515

DMOJ3CW	DI	DMOJ3CW
DMOJ3CW	DN	AGELADINE A
DMOJ3CW	MI	TTXZ0KQ
DMOJ3CW	MN	Matrix metalloproteinase-12 (MMP-12)
DMOJ3CW	MT	DTT
DMOJ3CW	MA	Inhibitor
DMOJ3CW	RN	Synthesis of novel ageladine A analogs showing more potent matrix metalloproteinase (MMP)-12 inhibitory activity than the natural product. Bioorg Med Chem Lett. 2009 Sep 15;19(18):5461-3.
DMOJ3CW	RU	https://pubmed.ncbi.nlm.nih.gov/19665375

DM26AMU	DI	DM26AMU
DM26AMU	DN	AGK2
DM26AMU	MI	TTLKF5M
DM26AMU	MN	NAD-dependent deacetylase sirtuin-2 (SIRT2)
DM26AMU	MT	DTT
DM26AMU	MA	Inhibitor
DM26AMU	RN	Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science. 2007 Jul 27;317(5837):516-9.
DM26AMU	RU	https://pubmed.ncbi.nlm.nih.gov/17588900

DMM9A5N	DI	DMM9A5N
DMM9A5N	DN	AGL 2043
DMM9A5N	MI	TTI7421
DMM9A5N	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMM9A5N	MT	DTT
DMM9A5N	MA	Inhibitor
DMM9A5N	RN	Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit. Bioorg Med Chem. 2003 May 1;11(9):2007-18.
DMM9A5N	RU	https://pubmed.ncbi.nlm.nih.gov/12670652

DMSBZ29	DI	DMSBZ29
DMSBZ29	DN	Agmatine
DMSBZ29	MI	TTLGDIS
DMSBZ29	MN	Acid-sensing ion channel 3 (ASIC3)
DMSBZ29	MT	DTT
DMSBZ29	MA	Activator
DMSBZ29	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 686).
DMSBZ29	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=686

DMSBZ29	DI	DMSBZ29
DMSBZ29	DN	Agmatine
DMSBZ29	MI	DEG5L6E
DMSBZ29	MN	Agmatine ureohydrolase (AGMAT)
DMSBZ29	MT	DME
DMSBZ29	MA	Metabolism
DMSBZ29	RN	Metabolic strategies for the degradation of the neuromodulator agmatine in mammals. Metabolism. 2018 Apr;81:35-44.
DMSBZ29	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29162499

DMSBZ29	DI	DMSBZ29
DMSBZ29	DN	Agmatine
DMSBZ29	MI	DE4LYSA
DMSBZ29	MN	Cytochrome P450 3A4 (CYP3A4)
DMSBZ29	MT	DME
DMSBZ29	MA	Metabolism
DMSBZ29	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DMSBZ29	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DMSBZ29	DI	DMSBZ29
DMSBZ29	DN	Agmatine
DMSBZ29	MI	DE8LBNO
DMSBZ29	MN	Poly [ADP-ribose] polymerase 3 (PARP3)
DMSBZ29	MT	DME
DMSBZ29	MA	Metabolism
DMSBZ29	RN	Mono-ADP-ribosylation catalyzed by arginine-specific ADP-ribosyltransferases. Methods Mol Biol. 2018;1813:149-165.
DMSBZ29	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30097866

DMTPV4Y	DI	DMTPV4Y
DMTPV4Y	DN	AGN 191976
DMTPV4Y	MI	TT2O84V
DMTPV4Y	MN	Thromboxane A2 receptor (TBXA2R)
DMTPV4Y	MT	DTT
DMTPV4Y	MA	Agonist
DMTPV4Y	RN	Evidence for human thromboxane receptor heterogeneity using a novel series of 9,11-cyclic carbonate derivatives of prostaglandin F2 alpha. Br J Pharmacol. 1996 Mar;117(6):1171-80.
DMTPV4Y	RU	https://pubmed.ncbi.nlm.nih.gov/8882612

DM53R94	DI	DM53R94
DM53R94	DN	AGN-190383
DM53R94	MI	TT9V5JH
DM53R94	MN	Phospholipase A2 (PLA2G1B)
DM53R94	MT	DTT
DM53R94	MA	Modulator
DM53R94	RN	AGN 190383, a novel phospholipase inhibitor with topical anti-inflammatory activity. Agents Actions. 1991 Sep;34(1-2):70-2.
DM53R94	RU	https://www.ncbi.nlm.nih.gov/pubmed/1793055

DMIKDAR	DI	DMIKDAR
DMIKDAR	DN	AGN-190744
DMIKDAR	MI	TT5HONZ
DMIKDAR	MN	Calcium channel unspecific (CaC)
DMIKDAR	MT	DTT
DMIKDAR	MA	Modulator
DMIKDAR	RN	The antiinflammatory activity of topically applied novel calcium-channel antagonists. Inflammation. 1995 Apr;19(2):261-75.
DMIKDAR	RU	https://www.ncbi.nlm.nih.gov/pubmed/7601508

DMISJXB	DI	DMISJXB
DMISJXB	DN	AGN192093
DMISJXB	MI	TT2O84V
DMISJXB	MN	Thromboxane A2 receptor (TBXA2R)
DMISJXB	MT	DTT
DMISJXB	MA	Agonist
DMISJXB	RN	Evidence for human thromboxane receptor heterogeneity using a novel series of 9,11-cyclic carbonate derivatives of prostaglandin F2 alpha. Br J Pharmacol. 1996 Mar;117(6):1171-80.
DMISJXB	RU	https://pubmed.ncbi.nlm.nih.gov/8882612

DM946RA	DI	DM946RA
DM946RA	DN	AGN-192172
DM946RA	MI	TTNGILX
DM946RA	MN	Adrenergic receptor alpha-1A (ADRA1A)
DM946RA	MT	DTT
DM946RA	MA	Inhibitor
DM946RA	RN	Analogs of UK 14,304: Structural features responsible for alpha2 adrenoceptor activity, Bioorg. Med. Chem. Lett. 5(15):1745-1750 (1995).
DM946RA	RU	http://www.sciencedirect.com/science/article/pii/0960894X95002955

DM946RA	DI	DM946RA
DM946RA	DN	AGN-192172
DM946RA	MI	TTBRKXS
DM946RA	MN	Adrenergic receptor alpha-1B (ADRA1B)
DM946RA	MT	DTT
DM946RA	MA	Inhibitor
DM946RA	RN	Analogs of UK 14,304: Structural features responsible for alpha2 adrenoceptor activity, Bioorg. Med. Chem. Lett. 5(15):1745-1750 (1995).
DM946RA	RU	http://www.sciencedirect.com/science/article/pii/0960894X95002955

DM946RA	DI	DM946RA
DM946RA	DN	AGN-192172
DM946RA	MI	TT34BHT
DM946RA	MN	Adrenergic receptor alpha-1D (ADRA1D)
DM946RA	MT	DTT
DM946RA	MA	Inhibitor
DM946RA	RN	Analogs of UK 14,304: Structural features responsible for alpha2 adrenoceptor activity, Bioorg. Med. Chem. Lett. 5(15):1745-1750 (1995).
DM946RA	RU	http://www.sciencedirect.com/science/article/pii/0960894X95002955

DMC0YOE	DI	DMC0YOE
DMC0YOE	DN	AGN193109
DMC0YOE	MI	TTW38KT
DMC0YOE	MN	Retinoic acid receptor alpha (RARA)
DMC0YOE	MT	DTT
DMC0YOE	MA	Antagonist
DMC0YOE	RN	Therapeutic applications for ligands of retinoid receptors. Curr Pharm Des. 2000 Jan;6(1):25-58.
DMC0YOE	RU	https://pubmed.ncbi.nlm.nih.gov/10637371

DMC0YOE	DI	DMC0YOE
DMC0YOE	DN	AGN193109
DMC0YOE	MI	TTISP28
DMC0YOE	MN	Retinoic acid receptor beta (RARB)
DMC0YOE	MT	DTT
DMC0YOE	MA	Antagonist
DMC0YOE	RN	Therapeutic applications for ligands of retinoid receptors. Curr Pharm Des. 2000 Jan;6(1):25-58.
DMC0YOE	RU	https://pubmed.ncbi.nlm.nih.gov/10637371

DMC0YOE	DI	DMC0YOE
DMC0YOE	DN	AGN193109
DMC0YOE	MI	TT1Q3IE
DMC0YOE	MN	Retinoic acid receptor gamma (RARG)
DMC0YOE	MT	DTT
DMC0YOE	MA	Antagonist
DMC0YOE	RN	Therapeutic applications for ligands of retinoid receptors. Curr Pharm Des. 2000 Jan;6(1):25-58.
DMC0YOE	RU	https://pubmed.ncbi.nlm.nih.gov/10637371

DMEB93D	DI	DMEB93D
DMEB93D	DN	AGN193836
DMEB93D	MI	TTW38KT
DMEB93D	MN	Retinoic acid receptor alpha (RARA)
DMEB93D	MT	DTT
DMEB93D	MA	Agonist
DMEB93D	RN	Synthesis and biological activity of retinoic acid receptor-alpha specific amides. Bioorg Med Chem Lett. 2002 Nov 4;12(21):3145-8.
DMEB93D	RU	https://pubmed.ncbi.nlm.nih.gov/12372520

DM5ECDM	DI	DM5ECDM
DM5ECDM	DN	AGN-34
DM5ECDM	MI	TTS4UGC
DM5ECDM	MN	Farnesoid X-activated receptor (FXR)
DM5ECDM	MT	DTT
DM5ECDM	MA	Inhibitor
DM5ECDM	RN	Farnesoid X receptor: from structure to potential clinical applications. J Med Chem. 2005 Aug 25;48(17):5383-403.
DM5ECDM	RU	https://pubmed.ncbi.nlm.nih.gov/16107136

DM5ECDM	DI	DM5ECDM
DM5ECDM	DN	AGN-34
DM5ECDM	MI	TT6PEUO
DM5ECDM	MN	Retinoic acid receptor RXR-alpha (RXRA)
DM5ECDM	MT	DTT
DM5ECDM	MA	Inhibitor
DM5ECDM	RN	Farnesoid X receptor: from structure to potential clinical applications. J Med Chem. 2005 Aug 25;48(17):5383-403.
DM5ECDM	RU	https://pubmed.ncbi.nlm.nih.gov/16107136

DM5ECDM	DI	DM5ECDM
DM5ECDM	DN	AGN-34
DM5ECDM	MI	TTKLV96
DM5ECDM	MN	Retinoic acid receptor RXR-beta (RXRB)
DM5ECDM	MT	DTT
DM5ECDM	MA	Inhibitor
DM5ECDM	RN	Farnesoid X receptor: from structure to potential clinical applications. J Med Chem. 2005 Aug 25;48(17):5383-403.
DM5ECDM	RU	https://pubmed.ncbi.nlm.nih.gov/16107136

DM5ECDM	DI	DM5ECDM
DM5ECDM	DN	AGN-34
DM5ECDM	MI	TTH029C
DM5ECDM	MN	Retinoic acid receptor RXR-gamma (RXRG)
DM5ECDM	MT	DTT
DM5ECDM	MA	Inhibitor
DM5ECDM	RN	Farnesoid X receptor: from structure to potential clinical applications. J Med Chem. 2005 Aug 25;48(17):5383-403.
DM5ECDM	RU	https://pubmed.ncbi.nlm.nih.gov/16107136

DMT9FJZ	DI	DMT9FJZ
DMT9FJZ	DN	AGROCLAVINE
DMT9FJZ	MI	TTSQIFT
DMT9FJZ	MN	5-HT 1A receptor (HTR1A)
DMT9FJZ	MT	DTT
DMT9FJZ	MA	Inhibitor
DMT9FJZ	RN	Ergolines as selective 5-HT1 agonists. J Med Chem. 1988 Aug;31(8):1512-9.
DMT9FJZ	RU	https://pubmed.ncbi.nlm.nih.gov/2456389

DMT9FJZ	DI	DMT9FJZ
DMT9FJZ	DN	AGROCLAVINE
DMT9FJZ	MI	TT6MSOK
DMT9FJZ	MN	5-HT 1D receptor (HTR1D)
DMT9FJZ	MT	DTT
DMT9FJZ	MA	Inhibitor
DMT9FJZ	RN	Ergolines as selective 5-HT1 agonists. J Med Chem. 1988 Aug;31(8):1512-9.
DMT9FJZ	RU	https://pubmed.ncbi.nlm.nih.gov/2456389

DMP9QW0	DI	DMP9QW0
DMP9QW0	DN	AGT-2000
DMP9QW0	MI	TTGKNB4
DMP9QW0	MN	Epidermal growth factor receptor (EGFR)
DMP9QW0	MT	DTT
DMP9QW0	MA	Modulator
DMP9QW0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
DMP9QW0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797

DMMO9YR	DI	DMMO9YR
DMMO9YR	DN	AGTAD[CFWKYC]V
DMMO9YR	MI	TTW5UDX
DMMO9YR	MN	Urotensin II receptor (UTS2R)
DMMO9YR	MT	DTT
DMMO9YR	MA	Inhibitor
DMMO9YR	RN	Urotensin-II receptor modulators as potential drugs. J Med Chem. 2010 Apr 8;53(7):2695-708.
DMMO9YR	RU	https://pubmed.ncbi.nlm.nih.gov/20043680

DMF7ZYQ	DI	DMF7ZYQ
DMF7ZYQ	DN	AH 11110
DMF7ZYQ	MI	TTBRKXS
DMF7ZYQ	MN	Adrenergic receptor alpha-1B (ADRA1B)
DMF7ZYQ	MT	DTT
DMF7ZYQ	MA	Antagonist
DMF7ZYQ	RN	Structure activity relationships of a series of buspirone analogs at alpha-1 adrenoceptors: further evidence that rat aorta alpha-1 adrenoceptors are of the alpha-1D-subtype. J Pharmacol Exp Ther. 1996 Jul;278(1):136-44.
DMF7ZYQ	RU	https://pubmed.ncbi.nlm.nih.gov/8764344

DM2VEHG	DI	DM2VEHG
DM2VEHG	DN	AH13205
DM2VEHG	MI	TT1ZAVI
DM2VEHG	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DM2VEHG	MT	DTT
DM2VEHG	MA	Agonist
DM2VEHG	RN	Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
DM2VEHG	RU	https://pubmed.ncbi.nlm.nih.gov/9313928

DM4S1Y6	DI	DM4S1Y6
DM4S1Y6	DN	AH23848
DM4S1Y6	MI	TT79WV3
DM4S1Y6	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DM4S1Y6	MT	DTT
DM4S1Y6	MA	Antagonist
DM4S1Y6	RN	Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41.
DM4S1Y6	RU	https://pubmed.ncbi.nlm.nih.gov/9537820

DM4S1Y6	DI	DM4S1Y6
DM4S1Y6	DN	AH23848
DM4S1Y6	MI	TT2O84V
DM4S1Y6	MN	Thromboxane A2 receptor (TBXA2R)
DM4S1Y6	MT	DTT
DM4S1Y6	MA	Antagonist
DM4S1Y6	RN	The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
DM4S1Y6	RU	https://pubmed.ncbi.nlm.nih.gov/10634944

DMKN3R9	DI	DMKN3R9
DMKN3R9	DN	AH6809
DMKN3R9	MI	TTNVEIR
DMKN3R9	MN	Prostaglandin D2 receptor (PTGDR)
DMKN3R9	MT	DTT
DMKN3R9	MA	Antagonist
DMKN3R9	RN	The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
DMKN3R9	RU	https://pubmed.ncbi.nlm.nih.gov/10634944

DMKN3R9	DI	DMKN3R9
DMKN3R9	DN	AH6809
DMKN3R9	MI	TTG1QMU
DMKN3R9	MN	Prostaglandin E2 receptor EP1 (PTGER1)
DMKN3R9	MT	DTT
DMKN3R9	MA	Antagonist
DMKN3R9	RN	Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41.
DMKN3R9	RU	https://pubmed.ncbi.nlm.nih.gov/9537820

DMKN3R9	DI	DMKN3R9
DMKN3R9	DN	AH6809
DMKN3R9	MI	TT1ZAVI
DMKN3R9	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DMKN3R9	MT	DTT
DMKN3R9	MA	Antagonist
DMKN3R9	RN	The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
DMKN3R9	RU	https://pubmed.ncbi.nlm.nih.gov/10634944

DMKN3R9	DI	DMKN3R9
DMKN3R9	DN	AH6809
DMKN3R9	MI	TTPNGDE
DMKN3R9	MN	Prostaglandin E2 receptor EP3 (PTGER3)
DMKN3R9	MT	DTT
DMKN3R9	MA	Antagonist
DMKN3R9	RN	The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
DMKN3R9	RU	https://pubmed.ncbi.nlm.nih.gov/10634944

DMVZLIB	DI	DMVZLIB
DMVZLIB	DN	AHL
DMVZLIB	MI	TT12KOD
DMVZLIB	MN	P53 messenger RNA (TP53 mRNA)
DMVZLIB	MT	DTT
DMVZLIB	RN	Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia. Cancer. 2012 Jan 15;118(2):418-27.
DMVZLIB	RU	https://pubmed.ncbi.nlm.nih.gov/21717444

DM8G6O4	DI	DM8G6O4
DM8G6O4	DN	AHPN
DM8G6O4	MI	TT1Q3IE
DM8G6O4	MN	Retinoic acid receptor gamma (RARG)
DM8G6O4	MT	DTT
DM8G6O4	MA	Agonist
DM8G6O4	RN	Synthesis, structure-affinity relationships, and biological activities of ligands binding to retinoic acid receptor subtypes. J Med Chem. 1995 Dec 22;38(26):4993-5006.
DM8G6O4	RU	https://pubmed.ncbi.nlm.nih.gov/8544175

DM3LCDK	DI	DM3LCDK
DM3LCDK	DN	AIDA
DM3LCDK	MI	TTVBPDM
DM3LCDK	MN	Metabotropic glutamate receptor 1 (mGluR1)
DM3LCDK	MT	DTT
DM3LCDK	MA	Antagonist
DM3LCDK	RN	[3H]R214127: a novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists. Mol Pharmacol. 2003 May;63(5):1082-93.
DM3LCDK	RU	https://pubmed.ncbi.nlm.nih.gov/12695537

DMUQ6XH	DI	DMUQ6XH
DMUQ6XH	DN	AIKO-151
DMUQ6XH	MI	TTKWM86
DMUQ6XH	MN	Opioid receptor mu (MOP)
DMUQ6XH	MT	DTT
DMUQ6XH	MA	Antagonist
DMUQ6XH	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
DMUQ6XH	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319

DML5Y1Q	DI	DML5Y1Q
DML5Y1Q	DN	AIKO-152
DML5Y1Q	MI	TTKWM86
DML5Y1Q	MN	Opioid receptor mu (MOP)
DML5Y1Q	MT	DTT
DML5Y1Q	MA	Modulator
DML5Y1Q	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
DML5Y1Q	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319

DMHMVOI	DI	DMHMVOI
DMHMVOI	DN	Ajinomoto 1
DMHMVOI	MI	TTXHYV6
DMHMVOI	MN	Voltage-gated L-type calcium channel (L-CaC)
DMHMVOI	MT	DTT
DMHMVOI	MA	Blocker
DMHMVOI	RN	Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95.
DMHMVOI	RU	https://pubmed.ncbi.nlm.nih.gov/19442208

DMZE45V	DI	DMZE45V
DMZE45V	DN	Ajinomoto 2
DMZE45V	MI	TTXHYV6
DMZE45V	MN	Voltage-gated L-type calcium channel (L-CaC)
DMZE45V	MT	DTT
DMZE45V	MA	Blocker
DMZE45V	RN	Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95.
DMZE45V	RU	https://pubmed.ncbi.nlm.nih.gov/19442208

DMG12AE	DI	DMG12AE
DMG12AE	DN	Ajinomoto 3
DMG12AE	MI	TTXHYV6
DMG12AE	MN	Voltage-gated L-type calcium channel (L-CaC)
DMG12AE	MT	DTT
DMG12AE	MA	Blocker
DMG12AE	RN	Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95.
DMG12AE	RU	https://pubmed.ncbi.nlm.nih.gov/19442208

DMWKPJH	DI	DMWKPJH
DMWKPJH	DN	AK198
DMWKPJH	MI	TTFBNVI
DMWKPJH	MN	Aldose reductase (AKR1B1)
DMWKPJH	MT	DTT
DMWKPJH	MA	Inhibitor
DMWKPJH	RN	The Effect of Halogen-to-Hydrogen Bond Substitution on Human Aldose Reductase Inhibition. ACS Chem Biol. 2015 Jul 17;10(7):1637-42.
DMWKPJH	RU	https://pubmed.ncbi.nlm.nih.gov/25919404

DMQ90PJ	DI	DMQ90PJ
DMQ90PJ	DN	AK-41099
DMQ90PJ	MI	DESN3MD
DMQ90PJ	MN	Trans-L-3-hydroxyproline dehydratase (L3HYPDH)
DMQ90PJ	MT	DME
DMQ90PJ	MA	Metabolism
DMQ90PJ	RN	An enzymatic method to estimate the content of L-hydroxyproline. J Biotechnol. 2015 Apr 10;199:9-16.
DMQ90PJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25678137

DMANYU5	DI	DMANYU5
DMANYU5	DN	AKN-028
DMANYU5	MI	TTGJCWZ
DMANYU5	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMANYU5	MT	DTT
DMANYU5	MA	Inhibitor
DMANYU5	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1807).
DMANYU5	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1807

DM4E6H1	DI	DM4E6H1
DM4E6H1	DN	AKNADILACTAM
DM4E6H1	MI	TT27RFC
DM4E6H1	MN	Opioid receptor delta (OPRD1)
DM4E6H1	MT	DTT
DM4E6H1	MA	Inhibitor
DM4E6H1	RN	Hasubanan alkaloids with delta-opioid binding affinity from the aerial parts of Stephania japonica. J Nat Prod. 2010 May 28;73(5):988-91.
DM4E6H1	RU	https://pubmed.ncbi.nlm.nih.gov/20426456

DMDVIT1	DI	DMDVIT1
DMDVIT1	DN	Akt inhibitor VIII
DMDVIT1	MI	TTWTSCV
DMDVIT1	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DMDVIT1	MT	DTT
DMDVIT1	MA	Inhibitor
DMDVIT1	RN	Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg Med Chem Lett. 2005 Feb 1;15(3):761-4.
DMDVIT1	RU	https://pubmed.ncbi.nlm.nih.gov/15664853

DMDVIT1	DI	DMDVIT1
DMDVIT1	DN	Akt inhibitor VIII
DMDVIT1	MI	TTH24WI
DMDVIT1	MN	RAC-beta serine/threonine-protein kinase (AKT2)
DMDVIT1	MT	DTT
DMDVIT1	MA	Inhibitor
DMDVIT1	RN	Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg Med Chem Lett. 2005 Feb 1;15(3):761-4.
DMDVIT1	RU	https://pubmed.ncbi.nlm.nih.gov/15664853

DMDVIT1	DI	DMDVIT1
DMDVIT1	DN	Akt inhibitor VIII
DMDVIT1	MI	TTAZ05C
DMDVIT1	MN	RAC-gamma serine/threonine-protein kinase (AKT3)
DMDVIT1	MT	DTT
DMDVIT1	MA	Inhibitor
DMDVIT1	RN	Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg Med Chem Lett. 2005 Feb 1;15(3):761-4.
DMDVIT1	RU	https://pubmed.ncbi.nlm.nih.gov/15664853

DMJW4I5	DI	DMJW4I5
DMJW4I5	DN	AKUAMMIGINE
DMJW4I5	MI	TTWG9A4
DMJW4I5	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMJW4I5	MT	DTT
DMJW4I5	MA	Inhibitor
DMJW4I5	RN	Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
DMJW4I5	RU	https://pubmed.ncbi.nlm.nih.gov/7562902

DM8DYWN	DI	DM8DYWN
DM8DYWN	DN	AKUAMMINE
DM8DYWN	MI	TTKWM86
DM8DYWN	MN	Opioid receptor mu (MOP)
DM8DYWN	MT	DTT
DM8DYWN	MA	Inhibitor
DM8DYWN	RN	Akuammine and dihydroakuammine, two indolomonoterpene alkaloids displaying affinity for opioid receptors. J Nat Prod. 1992 Mar;55(3):380-4.
DM8DYWN	RU	https://pubmed.ncbi.nlm.nih.gov/1317407

DM0JE4N	DI	DM0JE4N
DM0JE4N	DN	AL12180
DM0JE4N	MI	TTT2ZAR
DM0JE4N	MN	Prostaglandin F2-alpha receptor (PTGFR)
DM0JE4N	MT	DTT
DM0JE4N	MA	Agonist
DM0JE4N	RN	Preclinical pharmacology of AL-12182, a new ocular hypotensive 11-oxa prostaglandin analog. J Ocul Pharmacol Ther. 2006 Oct;22(5):291-309.
DM0JE4N	RU	https://pubmed.ncbi.nlm.nih.gov/17076623

DM7XHDC	DI	DM7XHDC
DM7XHDC	DN	AL-209
DM7XHDC	MI	TTML2WA
DM7XHDC	MN	Tubulin (TUB)
DM7XHDC	MT	DTT
DM7XHDC	MA	Modulator
DM7XHDC	RN	Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects. Curr Pharm Des. 2011;17(25):2603-12.
DM7XHDC	RU	https://pubmed.ncbi.nlm.nih.gov/21728979

DM69X2Z	DI	DM69X2Z
DM69X2Z	DN	AL-309
DM69X2Z	MI	TTML2WA
DM69X2Z	MN	Tubulin (TUB)
DM69X2Z	MT	DTT
DM69X2Z	MA	Modulator
DM69X2Z	RN	Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects. Curr Pharm Des. 2011;17(25):2603-12.
DM69X2Z	RU	https://pubmed.ncbi.nlm.nih.gov/21728979

DMRJ2GK	DI	DMRJ2GK
DMRJ2GK	DN	AL-37350A
DMRJ2GK	MI	TTJQOD7
DMRJ2GK	MN	5-HT 2A receptor (HTR2A)
DMRJ2GK	MT	DTT
DMRJ2GK	MA	Agonist
DMRJ2GK	RN	A novel and selective 5-HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano[3,2-e]indole. J Med Chem. 2003 Sep 11;46(19):4188-95.
DMRJ2GK	RU	https://pubmed.ncbi.nlm.nih.gov/12954071

DMRJ2GK	DI	DMRJ2GK
DMRJ2GK	DN	AL-37350A
DMRJ2GK	MI	TT0K1SC
DMRJ2GK	MN	5-HT 2B receptor (HTR2B)
DMRJ2GK	MT	DTT
DMRJ2GK	MA	Agonist
DMRJ2GK	RN	A novel and selective 5-HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano[3,2-e]indole. J Med Chem. 2003 Sep 11;46(19):4188-95.
DMRJ2GK	RU	https://pubmed.ncbi.nlm.nih.gov/12954071

DMRJ2GK	DI	DMRJ2GK
DMRJ2GK	DN	AL-37350A
DMRJ2GK	MI	TTWJBZ5
DMRJ2GK	MN	5-HT 2C receptor (HTR2C)
DMRJ2GK	MT	DTT
DMRJ2GK	MA	Agonist
DMRJ2GK	RN	A novel and selective 5-HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano[3,2-e]indole. J Med Chem. 2003 Sep 11;46(19):4188-95.
DMRJ2GK	RU	https://pubmed.ncbi.nlm.nih.gov/12954071

DM7K360	DI	DM7K360
DM7K360	DN	AL-408
DM7K360	MI	TTS87KH
DM7K360	MN	Microtubule-associated protein tau (MAPT)
DM7K360	MT	DTT
DM7K360	MA	Modulator
DM7K360	RN	Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des. 2011;17(31):3413-7.
DM7K360	RU	https://pubmed.ncbi.nlm.nih.gov/21902667

DMLEDHR	DI	DMLEDHR
DMLEDHR	DN	AL-43
DMLEDHR	MI	TTKPW01
DMLEDHR	MN	Androgen receptor messenger RNA (AR mRNA)
DMLEDHR	MT	DTT
DMLEDHR	MA	Inhibitor
DMLEDHR	RN	Nonsteroidal selective glucocorticoid modulators: the effect of C-10 substitution on receptor selectivity and functional potency of 5-allyl-2,5-dih... J Med Chem. 2003 Mar 13;46(6):1016-30.
DMLEDHR	RU	https://pubmed.ncbi.nlm.nih.gov/12620078

DMLEDHR	DI	DMLEDHR
DMLEDHR	DN	AL-43
DMLEDHR	MI	TTOZRK6
DMLEDHR	MN	Glucocorticoid receptor messenger RNA (GCR mRNA)
DMLEDHR	MT	DTT
DMLEDHR	MA	Inhibitor
DMLEDHR	RN	Differentiation of in vitro transcriptional repression and activation profiles of selective glucocorticoid modulators. Bioorg Med Chem Lett. 2004 Apr 5;14(7):1721-7.
DMLEDHR	RU	https://pubmed.ncbi.nlm.nih.gov/15026058

DMLEDHR	DI	DMLEDHR
DMLEDHR	DN	AL-43
DMLEDHR	MI	TT26PHO
DMLEDHR	MN	Mineralocorticoid receptor  (MR)
DMLEDHR	MT	DTT
DMLEDHR	MA	Inhibitor
DMLEDHR	RN	Nonsteroidal selective glucocorticoid modulators: the effect of C-10 substitution on receptor selectivity and functional potency of 5-allyl-2,5-dih... J Med Chem. 2003 Mar 13;46(6):1016-30.
DMLEDHR	RU	https://pubmed.ncbi.nlm.nih.gov/12620078

DMLEDHR	DI	DMLEDHR
DMLEDHR	DN	AL-43
DMLEDHR	MI	TTUV8G9
DMLEDHR	MN	Progesterone receptor (PGR)
DMLEDHR	MT	DTT
DMLEDHR	MA	Inhibitor
DMLEDHR	RN	Nonsteroidal selective glucocorticoid modulators: the effect of C-10 substitution on receptor selectivity and functional potency of 5-allyl-2,5-dih... J Med Chem. 2003 Mar 13;46(6):1016-30.
DMLEDHR	RU	https://pubmed.ncbi.nlm.nih.gov/12620078

DMHG54F	DI	DMHG54F
DMHG54F	DN	AL4623
DMHG54F	MI	TTANPDJ
DMHG54F	MN	Carbonic anhydrase II (CA-II)
DMHG54F	MT	DTT
DMHG54F	MA	Inhibitor
DMHG54F	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMHG54F	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM1QJIV	DI	DM1QJIV
DM1QJIV	DN	AL5300
DM1QJIV	MI	TTANPDJ
DM1QJIV	MN	Carbonic anhydrase II (CA-II)
DM1QJIV	MT	DTT
DM1QJIV	MA	Inhibitor
DM1QJIV	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM1QJIV	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMSD2U1	DI	DMSD2U1
DMSD2U1	DN	AL5424
DMSD2U1	MI	TTANPDJ
DMSD2U1	MN	Carbonic anhydrase II (CA-II)
DMSD2U1	MT	DTT
DMSD2U1	MA	Inhibitor
DMSD2U1	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMSD2U1	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM624WO	DI	DM624WO
DM624WO	DN	AL5927
DM624WO	MI	TTANPDJ
DM624WO	MN	Carbonic anhydrase II (CA-II)
DM624WO	MT	DTT
DM624WO	MA	Inhibitor
DM624WO	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM624WO	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMPHTX0	DI	DMPHTX0
DMPHTX0	DN	AL-59640
DMPHTX0	MI	TTZ97H5
DMPHTX0	MN	Phosphodiesterase 4A (PDE4A)
DMPHTX0	MT	DTT
DMPHTX0	MA	Inhibitor
DMPHTX0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1300).
DMPHTX0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1300

DMPHTX0	DI	DMPHTX0
DMPHTX0	DN	AL-59640
DMPHTX0	MI	TTVIAT9
DMPHTX0	MN	Phosphodiesterase 4B (PDE4B)
DMPHTX0	MT	DTT
DMPHTX0	MA	Modulator
DMPHTX0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1301).
DMPHTX0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1301

DMPHTX0	DI	DMPHTX0
DMPHTX0	DN	AL-59640
DMPHTX0	MI	TTSKMI8
DMPHTX0	MN	Phosphodiesterase 4D (PDE4D)
DMPHTX0	MT	DTT
DMPHTX0	MA	Modulator
DMPHTX0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1303).
DMPHTX0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1303

DM1JIVR	DI	DM1JIVR
DM1JIVR	DN	AL6528
DM1JIVR	MI	TTANPDJ
DM1JIVR	MN	Carbonic anhydrase II (CA-II)
DM1JIVR	MT	DTT
DM1JIVR	MA	Inhibitor
DM1JIVR	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM1JIVR	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM3JNRC	DI	DM3JNRC
DM3JNRC	DN	AL-6802
DM3JNRC	MI	TTGKNB4
DM3JNRC	MN	Epidermal growth factor receptor (EGFR)
DM3JNRC	MT	DTT
DM3JNRC	MA	Modulator
DM3JNRC	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
DM3JNRC	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797

DMTXPJI	DI	DMTXPJI
DMTXPJI	DN	Al7089a
DMTXPJI	MI	TTANPDJ
DMTXPJI	MN	Carbonic anhydrase II (CA-II)
DMTXPJI	MT	DTT
DMTXPJI	MA	Inhibitor
DMTXPJI	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMTXPJI	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMRI08C	DI	DMRI08C
DMRI08C	DN	AL7099A
DMRI08C	MI	TTANPDJ
DMRI08C	MN	Carbonic anhydrase II (CA-II)
DMRI08C	MT	DTT
DMRI08C	MA	Inhibitor
DMRI08C	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMRI08C	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMG2D4S	DI	DMG2D4S
DMG2D4S	DN	AL7182
DMG2D4S	MI	TTANPDJ
DMG2D4S	MN	Carbonic anhydrase II (CA-II)
DMG2D4S	MT	DTT
DMG2D4S	MA	Inhibitor
DMG2D4S	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMG2D4S	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMRWLQM	DI	DMRWLQM
DMRWLQM	DN	AL-8810
DMRWLQM	MI	TTT2ZAR
DMRWLQM	MN	Prostaglandin F2-alpha receptor (PTGFR)
DMRWLQM	MT	DTT
DMRWLQM	MA	Agonist
DMRWLQM	RN	AL-8810: a novel prostaglandin F2 alpha analog with selective antagonist effects at the prostaglandin F2 alpha (FP) receptor. J Pharmacol Exp Ther. 1999 Sep;290(3):1278-84.
DMRWLQM	RU	https://pubmed.ncbi.nlm.nih.gov/10454504

DMRWUQ5	DI	DMRWUQ5
DMRWUQ5	DN	Ala(1-naph)-Pro-CN
DMRWUQ5	MI	TTUA38Z
DMRWUQ5	MN	Retinoblastoma-binding protein 9 (RBBP9)
DMRWUQ5	MT	DTT
DMRWUQ5	MA	Inhibitor
DMRWUQ5	RN	A high-throughput, multiplexed assay for superfamily-wide profiling of enzyme activity. Nat Chem Biol. 2014 Aug;10(8):656-63.
DMRWUQ5	RU	https://pubmed.ncbi.nlm.nih.gov/24997602

DMZH4NQ	DI	DMZH4NQ
DMZH4NQ	DN	Ala11-SRIF-14-amide
DMZH4NQ	MI	TTZ6T9E
DMZH4NQ	MN	Somatostatin receptor type 2 (SSTR2)
DMZH4NQ	MT	DTT
DMZH4NQ	MA	Inhibitor
DMZH4NQ	RN	Replacement of Phe6, Phe7, and Phe11 of D-Trp8-somatostatin-14 with L-pyrazinylalanine. Predicted and observed effects on binding affinities at hSS... J Med Chem. 2005 Jun 16;48(12):4025-30.
DMZH4NQ	RU	https://pubmed.ncbi.nlm.nih.gov/15943475

DMZH4NQ	DI	DMZH4NQ
DMZH4NQ	DN	Ala11-SRIF-14-amide
DMZH4NQ	MI	TTAE1BR
DMZH4NQ	MN	Somatostatin receptor type 4 (SSTR4)
DMZH4NQ	MT	DTT
DMZH4NQ	MA	Inhibitor
DMZH4NQ	RN	Replacement of Phe6, Phe7, and Phe11 of D-Trp8-somatostatin-14 with L-pyrazinylalanine. Predicted and observed effects on binding affinities at hSS... J Med Chem. 2005 Jun 16;48(12):4025-30.
DMZH4NQ	RU	https://pubmed.ncbi.nlm.nih.gov/15943475

DM9RQ7E	DI	DM9RQ7E
DM9RQ7E	DN	Ala6-SRIF-14-amide
DM9RQ7E	MI	TTZ6T9E
DM9RQ7E	MN	Somatostatin receptor type 2 (SSTR2)
DM9RQ7E	MT	DTT
DM9RQ7E	MA	Inhibitor
DM9RQ7E	RN	Replacement of Phe6, Phe7, and Phe11 of D-Trp8-somatostatin-14 with L-pyrazinylalanine. Predicted and observed effects on binding affinities at hSS... J Med Chem. 2005 Jun 16;48(12):4025-30.
DM9RQ7E	RU	https://pubmed.ncbi.nlm.nih.gov/15943475

DM9RQ7E	DI	DM9RQ7E
DM9RQ7E	DN	Ala6-SRIF-14-amide
DM9RQ7E	MI	TTAE1BR
DM9RQ7E	MN	Somatostatin receptor type 4 (SSTR4)
DM9RQ7E	MT	DTT
DM9RQ7E	MA	Inhibitor
DM9RQ7E	RN	Replacement of Phe6, Phe7, and Phe11 of D-Trp8-somatostatin-14 with L-pyrazinylalanine. Predicted and observed effects on binding affinities at hSS... J Med Chem. 2005 Jun 16;48(12):4025-30.
DM9RQ7E	RU	https://pubmed.ncbi.nlm.nih.gov/15943475

DMWF8GN	DI	DMWF8GN
DMWF8GN	DN	Ala7-SRIF-14-amide
DMWF8GN	MI	TTZ6T9E
DMWF8GN	MN	Somatostatin receptor type 2 (SSTR2)
DMWF8GN	MT	DTT
DMWF8GN	MA	Inhibitor
DMWF8GN	RN	Replacement of Phe6, Phe7, and Phe11 of D-Trp8-somatostatin-14 with L-pyrazinylalanine. Predicted and observed effects on binding affinities at hSS... J Med Chem. 2005 Jun 16;48(12):4025-30.
DMWF8GN	RU	https://pubmed.ncbi.nlm.nih.gov/15943475

DMTWB54	DI	DMTWB54
DMTWB54	DN	Ala-Pro-Glu
DMTWB54	MI	TTLD29N
DMTWB54	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMTWB54	MT	DTT
DMTWB54	MA	Inhibitor
DMTWB54	RN	New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6.
DMTWB54	RU	https://pubmed.ncbi.nlm.nih.gov/16321525

DMTWB54	DI	DMTWB54
DMTWB54	DN	Ala-Pro-Glu
DMTWB54	MI	TTKJEMQ
DMTWB54	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMTWB54	MT	DTT
DMTWB54	MA	Inhibitor
DMTWB54	RN	New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6.
DMTWB54	RU	https://pubmed.ncbi.nlm.nih.gov/16321525

DMTWB54	DI	DMTWB54
DMTWB54	DN	Ala-Pro-Glu
DMTWB54	MI	TTN9D8E
DMTWB54	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMTWB54	MT	DTT
DMTWB54	MA	Inhibitor
DMTWB54	RN	New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6.
DMTWB54	RU	https://pubmed.ncbi.nlm.nih.gov/16321525

DMO1ZC2	DI	DMO1ZC2
DMO1ZC2	DN	ALBAFURAN A
DMO1ZC2	MI	TTELIN2
DMO1ZC2	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMO1ZC2	MT	DTT
DMO1ZC2	MA	Inhibitor
DMO1ZC2	RN	Protein tyrosine phosphatase 1B inhibitors isolated from Morus bombycis. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6759-61.
DMO1ZC2	RU	https://pubmed.ncbi.nlm.nih.gov/19846295

DMHIW2L	DI	DMHIW2L
DMHIW2L	DN	ALBANOL A
DMHIW2L	MI	TTSZLWK
DMHIW2L	MN	Aromatase (CYP19A1)
DMHIW2L	MT	DTT
DMHIW2L	MA	Inhibitor
DMHIW2L	RN	Aromatase inhibitors from Broussonetia papyrifera. J Nat Prod. 2001 Oct;64(10):1286-93.
DMHIW2L	RU	https://pubmed.ncbi.nlm.nih.gov/11678652

DMQXO5G	DI	DMQXO5G
DMQXO5G	DN	ALD-805
DMQXO5G	MI	TTNDSF4
DMQXO5G	MN	Proto-oncogene c-Met (MET)
DMQXO5G	MT	DTT
DMQXO5G	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
DMQXO5G	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815

DMWBKH1	DI	DMWBKH1
DMWBKH1	DN	ALD-806
DMWBKH1	MI	TTNDSF4
DMWBKH1	MN	Proto-oncogene c-Met (MET)
DMWBKH1	MT	DTT
DMWBKH1	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
DMWBKH1	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815

DMAYGK9	DI	DMAYGK9
DMAYGK9	DN	ALD-901
DMAYGK9	MI	TTEDJN4
DMAYGK9	MN	Low-affinity nerve growth factor receptor (NGFR)
DMAYGK9	MT	DTT
DMAYGK9	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1888).
DMAYGK9	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1888

DMS80DF	DI	DMS80DF
DMS80DF	DN	ALDISIN
DMS80DF	MI	TTIDAPM
DMS80DF	MN	ERK activator kinase 1 (MEK1)
DMS80DF	MT	DTT
DMS80DF	MA	Inhibitor
DMS80DF	RN	Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1). J Med Chem. 2002 Jan 17;45(2):529-32.
DMS80DF	RU	https://pubmed.ncbi.nlm.nih.gov/11784156

DM83CDK	DI	DM83CDK
DM83CDK	DN	Alexa-488-telenzepine
DM83CDK	MI	TTOXS3C
DM83CDK	MN	Muscarinic acetylcholine receptor (CHRM)
DM83CDK	MT	DTT
DM83CDK	MA	Antagonist
DM83CDK	RN	Formation and dissociation of M1 muscarinic receptor dimers seen by total internal reflection fluorescence imaging of single molecules. Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2693-8.
DM83CDK	RU	https://pubmed.ncbi.nlm.nih.gov/20133736

DM53KRA	DI	DM53KRA
DM53KRA	DN	ALF-421
DM53KRA	MI	TTG043C
DM53KRA	MN	Tumor necrosis factor receptor type I (TNF-R1)
DM53KRA	MT	DTT
DM53KRA	MA	Modulator
DM53KRA	RN	Secretion of a TNFR:Fc fusion protein following pulmonary administration of pseudotyped adeno-associated virus vectors. J Virol. 2004 Nov;78(22):12355-65.
DM53KRA	RU	https://pubmed.ncbi.nlm.nih.gov/15507622

DMI4OTW	DI	DMI4OTW
DMI4OTW	DN	ALFAXALONE
DMI4OTW	MI	TTNJYV2
DMI4OTW	MN	Gamma-aminobutyric acid receptor (GAR)
DMI4OTW	MT	DTT
DMI4OTW	MA	Inhibitor
DMI4OTW	RN	Propofol analogues. Synthesis, relationships between structure and affinity at GABAA receptor in rat brain, and differential electrophysiological p... J Med Chem. 1998 May 21;41(11):1846-54.
DMI4OTW	RU	https://pubmed.ncbi.nlm.nih.gov/9599235

DMWMIRL	DI	DMWMIRL
DMWMIRL	DN	Alisporivir
DMWMIRL	MI	TTS41ER
DMWMIRL	MN	HUMAN cyclophilin A (CYPA)
DMWMIRL	MT	DTT
DMWMIRL	MA	Inhibitor
DMWMIRL	RN	Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150.
DMWMIRL	RU	https://pubmed.ncbi.nlm.nih.gov/32127666

DM3DERI	DI	DM3DERI
DM3DERI	DN	alkyl glycerol phosphate 18:1
DM3DERI	MI	TTABCJ6
DM3DERI	MN	Lysophosphatidic acid receptor 5 (LPAR5)
DM3DERI	MT	DTT
DM3DERI	MA	Agonist
DM3DERI	RN	Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation. J Biol Chem. 2009 Jun 19;284(25):17304-19.
DM3DERI	RU	https://pubmed.ncbi.nlm.nih.gov/19366702

DMM19AO	DI	DMM19AO
DMM19AO	DN	alkyl OMPT
DMM19AO	MI	TTE2YJR
DMM19AO	MN	Lysophosphatidate-3 receptor (LPAR3)
DMM19AO	MT	DTT
DMM19AO	MA	Agonist
DMM19AO	RN	Phosphorothioate analogues of alkyl lysophosphatidic acid as LPA3 receptor-selective agonists. ChemMedChem. 2006 Mar;1(3):376-83.
DMM19AO	RU	https://pubmed.ncbi.nlm.nih.gov/16892372

DMM19AO	DI	DMM19AO
DMM19AO	DN	alkyl OMPT
DMM19AO	MI	TTQ6S1K
DMM19AO	MN	Lysophosphatidic acid receptor 1 (LPAR1)
DMM19AO	MT	DTT
DMM19AO	MA	Agonist
DMM19AO	RN	Phosphorothioate analogues of alkyl lysophosphatidic acid as LPA3 receptor-selective agonists. ChemMedChem. 2006 Mar;1(3):376-83.
DMM19AO	RU	https://pubmed.ncbi.nlm.nih.gov/16892372

DMQH481	DI	DMQH481
DMQH481	DN	alkylbenzene sulfonate
DMQH481	MI	TTZ8EM9
DMQH481	MN	Glycine receptor (GlyR)
DMQH481	MT	DTT
DMQH481	RN	Selective actions of a detergent on ligand-gated ion channels expressed in Xenopus oocytes. J Pharmacol Exp Ther. 1998 Jan;284(1):32-6.
DMQH481	RU	https://pubmed.ncbi.nlm.nih.gov/9435157

DMSOJ6H	DI	DMSOJ6H
DMSOJ6H	DN	ALLICIN
DMSOJ6H	MI	TT2SUAQ
DMSOJ6H	MN	Cysteine protease (CYP)
DMSOJ6H	MT	DTT
DMSOJ6H	MA	Inhibitor
DMSOJ6H	RN	Allicin and derivates are cysteine protease inhibitors with antiparasitic activity. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5541-3.
DMSOJ6H	RU	https://pubmed.ncbi.nlm.nih.gov/20692829

DM05AYE	DI	DM05AYE
DM05AYE	DN	alloswitch-1
DM05AYE	MI	TTHS256
DM05AYE	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM05AYE	MT	DTT
DM05AYE	MA	Modulator (allosteric modulator)
DM05AYE	RN	An allosteric modulator to control endogenous G protein-coupled receptors with light. Nat Chem Biol. 2014 Oct;10(10):813-5.
DM05AYE	RU	https://pubmed.ncbi.nlm.nih.gov/25173999

DM7U2BE	DI	DM7U2BE
DM7U2BE	DN	Alloxazine
DM7U2BE	MI	TTM2AOE
DM7U2BE	MN	Adenosine A2a receptor (ADORA2A)
DM7U2BE	MT	DTT
DM7U2BE	MA	Inhibitor
DM7U2BE	RN	2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96.
DM7U2BE	RU	https://pubmed.ncbi.nlm.nih.gov/16250647

DM7U2BE	DI	DM7U2BE
DM7U2BE	DN	Alloxazine
DM7U2BE	MI	TTNE7KG
DM7U2BE	MN	Adenosine A2b receptor (ADORA2B)
DM7U2BE	MT	DTT
DM7U2BE	MA	Inhibitor
DM7U2BE	RN	2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96.
DM7U2BE	RU	https://pubmed.ncbi.nlm.nih.gov/16250647

DMM2R1N	DI	DMM2R1N
DMM2R1N	DN	all-trans-4-oxo-retinoic acid
DMM2R1N	MI	TT2NUT5
DMM2R1N	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMM2R1N	MT	DTT
DMM2R1N	MA	Antagonist
DMM2R1N	RN	Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12.
DMM2R1N	RU	https://pubmed.ncbi.nlm.nih.gov/15771415

DMM2R1N	DI	DMM2R1N
DMM2R1N	DN	all-trans-4-oxo-retinoic acid
DMM2R1N	MI	TTGB2LZ
DMM2R1N	MN	RAR-related orphan receptor-beta (RORB)
DMM2R1N	MT	DTT
DMM2R1N	MA	Antagonist
DMM2R1N	RN	All-trans retinoic acid is a ligand for the orphan nuclear receptor ROR beta. Nat Struct Biol. 2003 Oct;10(10):820-5.
DMM2R1N	RU	https://pubmed.ncbi.nlm.nih.gov/12958591

DM6CEVB	DI	DM6CEVB
DM6CEVB	DN	All-trans-retinal
DM6CEVB	MI	DE2JP1Y
DM6CEVB	MN	Aldehyde dehydrogenase 1 (ALDH1)
DM6CEVB	MT	DME
DM6CEVB	MA	Metabolism
DM6CEVB	RN	Retinoic acid biosynthesis catalyzed by retinal dehydrogenases relies on a rate-limiting conformational transition associated with substrate recognition. Chem Biol Interact. 2013 Feb 25;202(1-3):78-84.
DM6CEVB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23220587

DM6CEVB	DI	DM6CEVB
DM6CEVB	DN	All-trans-retinal
DM6CEVB	MI	TT8SJGB
DM6CEVB	MN	Cyclic nucleotide-gated channel alpha-2 (CNGA2)
DM6CEVB	MT	DTT
DM6CEVB	MA	Inhibitor (gating inhibitor)
DM6CEVB	RN	All-trans-retinal shuts down rod cyclic nucleotide-gated ion channels: a novel role for photoreceptor retinoids in the response to bright light Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8372-7.
DM6CEVB	RU	https://pubmed.ncbi.nlm.nih.gov/12034887

DM8R5AS	DI	DM8R5AS
DM8R5AS	DN	Allyl 4-(2-oxohexadecanamido)butanoate
DM8R5AS	MI	TTT1JVS
DM8R5AS	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DM8R5AS	MT	DTT
DM8R5AS	MA	Inhibitor
DM8R5AS	RN	Structure-activity relationships of natural and non-natural amino acid-based amide and 2-oxoamide inhibitors of human phospholipase A(2) enzymes. Bioorg Med Chem. 2008 Dec 15;16(24):10257-69.
DM8R5AS	RU	https://pubmed.ncbi.nlm.nih.gov/18993078

DMYNKLR	DI	DMYNKLR
DMYNKLR	DN	Allyl 4-(aminosulfonyl)benzoate
DMYNKLR	MI	TTANPDJ
DMYNKLR	MN	Carbonic anhydrase II (CA-II)
DMYNKLR	MT	DTT
DMYNKLR	MA	Inhibitor
DMYNKLR	RN	Synthesis and structure-activity relationships of novel benzene sulfonamides with potent binding affinity for bovine carbonic anhydrase II. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5429-33.
DMYNKLR	RU	https://pubmed.ncbi.nlm.nih.gov/16213706

DMNFGRV	DI	DMNFGRV
DMNFGRV	DN	Allylamines
DMNFGRV	MI	TTE14XG
DMNFGRV	MN	Squalene monooxygenase (SQLE)
DMNFGRV	MT	DTT
DMNFGRV	MA	Inhibitor
DMNFGRV	RN	Differential inhibition of fungal amd mammalian squalene epoxidases by the benzylamine SDZ SBA 586 in comparison with the allylamine terbinafine. Arch Biochem Biophys. 1997 Apr 15;340(2):265-9.
DMNFGRV	RU	https://pubmed.ncbi.nlm.nih.gov/9143330

DMJWZB3	DI	DMJWZB3
DMJWZB3	DN	Allylcarbamic Acid Biphenyl-3-yl Ester
DMJWZB3	MI	TTDP1UC
DMJWZB3	MN	Fatty acid amide hydrolase (FAAH)
DMJWZB3	MT	DTT
DMJWZB3	MA	Inhibitor
DMJWZB3	RN	Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl a... J Med Chem. 2008 Jun 26;51(12):3487-98.
DMJWZB3	RU	https://pubmed.ncbi.nlm.nih.gov/18507372

DM1VHCL	DI	DM1VHCL
DM1VHCL	DN	Allyl-trimethyl-ammonium
DM1VHCL	MI	TT1RS9F
DM1VHCL	MN	Acetylcholinesterase (AChE)
DM1VHCL	MT	DTT
DM1VHCL	MA	Inhibitor
DM1VHCL	RN	Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors. J Med Chem. 1996 Dec 20;39(26):5064-71.
DM1VHCL	RU	https://pubmed.ncbi.nlm.nih.gov/8978837

DMY1OG7	DI	DMY1OG7
DMY1OG7	DN	ALM-301
DMY1OG7	MI	TTWTSCV
DMY1OG7	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DMY1OG7	MT	DTT
DMY1OG7	MA	Inhibitor
DMY1OG7	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479).
DMY1OG7	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1479

DMPTY8S	DI	DMPTY8S
DMPTY8S	DN	Aloe-emodin
DMPTY8S	MI	TTB6UM0
DMPTY8S	MN	Fatty aldehyde dehydrogenase (ALDH3A2)
DMPTY8S	MT	DTT
DMPTY8S	MA	Inhibitor
DMPTY8S	RN	Elgonica-Dimers A and B, Two Potent Alcohol Metabolism Inhibitory Constituents of Aloe arborescens J. Nat. Prod. 60(11):1180-1182 (1997).
DMPTY8S	RU	http://pubs.acs.org/doi/abs/10.1021/np9703104

DM7HGX8	DI	DM7HGX8
DM7HGX8	DN	aloisine
DM7HGX8	MI	TT7HF4W
DM7HGX8	MN	Cyclin-dependent kinase 2 (CDK2)
DM7HGX8	MT	DTT
DM7HGX8	MA	Inhibitor
DM7HGX8	RN	Identification of binding specificity-determining features in protein families. J Med Chem. 2012 Mar 8;55(5):1926-39.
DM7HGX8	RU	https://pubmed.ncbi.nlm.nih.gov/22289061

DM7HGX8	DI	DM7HGX8
DM7HGX8	DN	aloisine
DM7HGX8	MI	TTTEFBV
DM7HGX8	MN	Focal adhesion kinase 2 (PTK2B)
DM7HGX8	MT	DTT
DM7HGX8	MA	Inhibitor
DM7HGX8	RN	Identification of binding specificity-determining features in protein families. J Med Chem. 2012 Mar 8;55(5):1926-39.
DM7HGX8	RU	https://pubmed.ncbi.nlm.nih.gov/22289061

DM7HGX8	DI	DM7HGX8
DM7HGX8	DN	aloisine
DM7HGX8	MI	TTUMHT8
DM7HGX8	MN	Tyrosine-protein kinase ZAP-70 (ZAP-70)
DM7HGX8	MT	DTT
DM7HGX8	MA	Inhibitor
DM7HGX8	RN	Identification of binding specificity-determining features in protein families. J Med Chem. 2012 Mar 8;55(5):1926-39.
DM7HGX8	RU	https://pubmed.ncbi.nlm.nih.gov/22289061

DM5U1LN	DI	DM5U1LN
DM5U1LN	DN	aloisine A
DM5U1LN	MI	TTAMQ62
DM5U1LN	MN	Cyclin A2 (CCNA2)
DM5U1LN	MT	DTT
DM5U1LN	MA	Inhibitor
DM5U1LN	RN	Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem. 2003 Jan 16;46(2):222-36.
DM5U1LN	RU	https://pubmed.ncbi.nlm.nih.gov/12519061

DM5U1LN	DI	DM5U1LN
DM5U1LN	DN	aloisine A
DM5U1LN	MI	TTH6V3D
DM5U1LN	MN	Cyclin-dependent kinase 1 (CDK1)
DM5U1LN	MT	DTT
DM5U1LN	MA	Inhibitor
DM5U1LN	RN	Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem. 2003 Jan 16;46(2):222-36.
DM5U1LN	RU	https://pubmed.ncbi.nlm.nih.gov/12519061

DM5U1LN	DI	DM5U1LN
DM5U1LN	DN	aloisine A
DM5U1LN	MI	TT7HF4W
DM5U1LN	MN	Cyclin-dependent kinase 2 (CDK2)
DM5U1LN	MT	DTT
DM5U1LN	MA	Inhibitor
DM5U1LN	RN	Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem. 2003 Jan 16;46(2):222-36.
DM5U1LN	RU	https://pubmed.ncbi.nlm.nih.gov/12519061

DM5U1LN	DI	DM5U1LN
DM5U1LN	DN	aloisine A
DM5U1LN	MI	TTL4Q97
DM5U1LN	MN	Cyclin-dependent kinase 5 (CDK5)
DM5U1LN	MT	DTT
DM5U1LN	MA	Inhibitor
DM5U1LN	RN	Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem. 2003 Jan 16;46(2):222-36.
DM5U1LN	RU	https://pubmed.ncbi.nlm.nih.gov/12519061

DM5U1LN	DI	DM5U1LN
DM5U1LN	DN	aloisine A
DM5U1LN	MI	TTCEJ4F
DM5U1LN	MN	G1/S-specific cyclin-E1 (CCNE1)
DM5U1LN	MT	DTT
DM5U1LN	MA	Inhibitor
DM5U1LN	RN	Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem. 2003 Jan 16;46(2):222-36.
DM5U1LN	RU	https://pubmed.ncbi.nlm.nih.gov/12519061

DM5U1LN	DI	DM5U1LN
DM5U1LN	DN	aloisine A
DM5U1LN	MI	TTQWAU1
DM5U1LN	MN	GSK3A messenger RNA (GSK3A mRNA)
DM5U1LN	MT	DTT
DM5U1LN	MA	Inhibitor
DM5U1LN	RN	Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem. 2003 Jan 16;46(2):222-36.
DM5U1LN	RU	https://pubmed.ncbi.nlm.nih.gov/12519061

DMHRME4	DI	DMHRME4
DMHRME4	DN	Alpha,beta-methylene-dATP
DMHRME4	MI	TTIU7X1
DMHRME4	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMHRME4	MT	DTT
DMHRME4	MA	Inhibitor
DMHRME4	RN	Alpha,beta-methylene-2'-deoxynucleoside 5'-triphosphates as noncleavable substrates for DNA polymerases: isolation, characterization, and stability... J Med Chem. 2008 Oct 23;51(20):6460-70.
DMHRME4	RU	https://pubmed.ncbi.nlm.nih.gov/18811136

DMJI8TX	DI	DMJI8TX
DMJI8TX	DN	Alpha,beta-methylene-dCTP
DMJI8TX	MI	TTIU7X1
DMJI8TX	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMJI8TX	MT	DTT
DMJI8TX	MA	Inhibitor
DMJI8TX	RN	Alpha,beta-methylene-2'-deoxynucleoside 5'-triphosphates as noncleavable substrates for DNA polymerases: isolation, characterization, and stability... J Med Chem. 2008 Oct 23;51(20):6460-70.
DMJI8TX	RU	https://pubmed.ncbi.nlm.nih.gov/18811136

DMPZS80	DI	DMPZS80
DMPZS80	DN	Alpha,beta-methylene-dGTP
DMPZS80	MI	TTIU7X1
DMPZS80	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMPZS80	MT	DTT
DMPZS80	MA	Inhibitor
DMPZS80	RN	Alpha,beta-methylene-2'-deoxynucleoside 5'-triphosphates as noncleavable substrates for DNA polymerases: isolation, characterization, and stability... J Med Chem. 2008 Oct 23;51(20):6460-70.
DMPZS80	RU	https://pubmed.ncbi.nlm.nih.gov/18811136

DMPAHJF	DI	DMPAHJF
DMPAHJF	DN	Alpha,beta-methylene-dTTP
DMPAHJF	MI	TTIU7X1
DMPAHJF	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMPAHJF	MT	DTT
DMPAHJF	MA	Inhibitor
DMPAHJF	RN	Alpha,beta-methylene-2'-deoxynucleoside 5'-triphosphates as noncleavable substrates for DNA polymerases: isolation, characterization, and stability... J Med Chem. 2008 Oct 23;51(20):6460-70.
DMPAHJF	RU	https://pubmed.ncbi.nlm.nih.gov/18811136

DMLGMTQ	DI	DMLGMTQ
DMLGMTQ	DN	alpha.beta-methylene-2-thio-UDP
DMLGMTQ	MI	TT72OKI
DMLGMTQ	MN	P2Y purinoceptor 14 (P2RY14)
DMLGMTQ	MT	DTT
DMLGMTQ	MA	Agonist
DMLGMTQ	RN	Human P2Y(14) receptor agonists: truncation of the hexose moiety of uridine-5'-diphosphoglucose and its replacement with alkyl and aryl groups. J Med Chem. 2010 Jan 14;53(1):471-80.
DMLGMTQ	RU	https://pubmed.ncbi.nlm.nih.gov/19902968

DM257WX	DI	DM257WX
DM257WX	DN	alpha3IA
DM257WX	MI	TTBMV1G
DM257WX	MN	GABA(A) receptor alpha-2 (GABRA2)
DM257WX	MT	DTT
DM257WX	MA	Modulator (allosteric modulator)
DM257WX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 405).
DM257WX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=405

DM257WX	DI	DM257WX
DM257WX	DN	alpha3IA
DM257WX	MI	TT37EDJ
DM257WX	MN	GABA(A) receptor alpha-3 (GABRA3)
DM257WX	MT	DTT
DM257WX	MA	Modulator (allosteric modulator)
DM257WX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 406).
DM257WX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=406

DM257WX	DI	DM257WX
DM257WX	DN	alpha3IA
DM257WX	MI	TTNZPQ1
DM257WX	MN	GABA(A) receptor alpha-5 (GABRA5)
DM257WX	MT	DTT
DM257WX	MA	Modulator (allosteric modulator)
DM257WX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 408).
DM257WX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=408

DM257WX	DI	DM257WX
DM257WX	DN	alpha3IA
DM257WX	MI	TTEX6LM
DM257WX	MN	GABA(A) receptor gamma-3 (GABRG3)
DM257WX	MT	DTT
DM257WX	MA	Modulator (allosteric modulator)
DM257WX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415).
DM257WX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415

DMTU5QR	DI	DMTU5QR
DMTU5QR	DN	alpha5IA
DMTU5QR	MI	TTBMV1G
DMTU5QR	MN	GABA(A) receptor alpha-2 (GABRA2)
DMTU5QR	MT	DTT
DMTU5QR	MA	Modulator (allosteric modulator)
DMTU5QR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 405).
DMTU5QR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=405

DMTU5QR	DI	DMTU5QR
DMTU5QR	DN	alpha5IA
DMTU5QR	MI	TT37EDJ
DMTU5QR	MN	GABA(A) receptor alpha-3 (GABRA3)
DMTU5QR	MT	DTT
DMTU5QR	MA	Modulator (allosteric modulator)
DMTU5QR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 406).
DMTU5QR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=406

DMTU5QR	DI	DMTU5QR
DMTU5QR	DN	alpha5IA
DMTU5QR	MI	TTNZPQ1
DMTU5QR	MN	GABA(A) receptor alpha-5 (GABRA5)
DMTU5QR	MT	DTT
DMTU5QR	MA	Modulator (allosteric modulator)
DMTU5QR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 408).
DMTU5QR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=408

DMTU5QR	DI	DMTU5QR
DMTU5QR	DN	alpha5IA
DMTU5QR	MI	TTEX6LM
DMTU5QR	MN	GABA(A) receptor gamma-3 (GABRG3)
DMTU5QR	MT	DTT
DMTU5QR	MA	Modulator (allosteric modulator)
DMTU5QR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415).
DMTU5QR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415

DMND5EU	DI	DMND5EU
DMND5EU	DN	Alpha-7-Deoxyhomonojirimycin
DMND5EU	MI	TTLPC70
DMND5EU	MN	Lysosomal alpha-glucosidase (GAA)
DMND5EU	MT	DTT
DMND5EU	MA	Inhibitor
DMND5EU	RN	New polyhydroxylated pyrrolidine, piperidine, and pyrrolizidine alkaloids from Scilla sibirica. J Nat Prod. 2002 Dec;65(12):1875-81.
DMND5EU	RU	https://pubmed.ncbi.nlm.nih.gov/12502331

DMHV14R	DI	DMHV14R
DMHV14R	DN	Alpha-acarviosinyl-(1-->7)-3-alpha-D-glucopyranosylpropen
DMHV14R	MI	TTCGSZ4
DMHV14R	MN	Pancreatic alpha-amylase (AMY2A)
DMHV14R	MT	DTT
DMHV14R	MA	Inhibitor
DMHV14R	RN	Enzymatic synthesis of a selective inhibitor for alpha-glucosidases: alpha-acarviosinyl-(1--&gt;9)-3-alpha-D-glucopyranosylpropen. J Agric Food Chem. 2008 Jul 9;56(13):5324-30.
DMHV14R	RU	https://pubmed.ncbi.nlm.nih.gov/18553919

DM4IXUQ	DI	DM4IXUQ
DM4IXUQ	DN	Alpha-acarviosinyl-(1-->9)-3-alpha-D-glucopyranosylpropen
DM4IXUQ	MI	TTCGSZ4
DM4IXUQ	MN	Pancreatic alpha-amylase (AMY2A)
DM4IXUQ	MT	DTT
DM4IXUQ	MA	Inhibitor
DM4IXUQ	RN	Enzymatic synthesis of a selective inhibitor for alpha-glucosidases: alpha-acarviosinyl-(1--&gt;9)-3-alpha-D-glucopyranosylpropen. J Agric Food Chem. 2008 Jul 9;56(13):5324-30.
DM4IXUQ	RU	https://pubmed.ncbi.nlm.nih.gov/18553919

DMW1LF0	DI	DMW1LF0
DMW1LF0	DN	Alpha-Aminobutyric Acid
DMW1LF0	MI	TT3DQUT
DMW1LF0	MN	Bacterial Lantibiotic mersacidin (Bact glmM)
DMW1LF0	MT	DTT
DMW1LF0	MA	Inhibitor
DMW1LF0	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMW1LF0	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9GXFJ	DI	DM9GXFJ
DM9GXFJ	DN	Alpha-Aminoisobutyric Acid
DM9GXFJ	MI	TTA7YIZ
DM9GXFJ	MN	Corticoliberin (CRH)
DM9GXFJ	MT	DTT
DM9GXFJ	MA	Inhibitor
DM9GXFJ	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM9GXFJ	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM9GXFJ	DI	DM9GXFJ
DM9GXFJ	DN	Alpha-Aminoisobutyric Acid
DM9GXFJ	MI	TT64REZ
DM9GXFJ	MN	Neuropeptide Y (NPY)
DM9GXFJ	MT	DTT
DM9GXFJ	MA	Inhibitor
DM9GXFJ	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM9GXFJ	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMRGFEM	DI	DMRGFEM
DMRGFEM	DN	alphabeta-methyleneADP
DMRGFEM	MI	TTK0O6Y
DMRGFEM	MN	Ecto-5'-nucleotidase (CD73)
DMRGFEM	MT	DTT
DMRGFEM	MA	Inhibitor
DMRGFEM	RN	5'-Nucleotidase from smooth muscle of small intestine and from brain. Inhibition of nucleotides. Biochemistry. 1975 Jun 3;14(11):2362-6.
DMRGFEM	RU	https://pubmed.ncbi.nlm.nih.gov/1169962

DMRGFEM	DI	DMRGFEM
DMRGFEM	DN	alphabeta-methyleneADP
DMRGFEM	MI	TTUTN1I
DMRGFEM	MN	Human Deoxyribonucleic acid (hDNA)
DMRGFEM	MT	DTT
DMRGFEM	MA	Inhibitor
DMRGFEM	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMRGFEM	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM96EJ1	DI	DM96EJ1
DM96EJ1	DN	alpha-conotoxin AuIB
DM96EJ1	MI	TTH18TF
DM96EJ1	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DM96EJ1	MT	DTT
DM96EJ1	MA	Antagonist
DM96EJ1	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 467).
DM96EJ1	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=467

DMHO634	DI	DMHO634
DMHO634	DN	alpha-conotoxin GI
DMHO634	MI	TTH18TF
DMHO634	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMHO634	MT	DTT
DMHO634	MA	Antagonist
DMHO634	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 467).
DMHO634	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=467

DM1QOY0	DI	DM1QOY0
DM1QOY0	DN	alpha-conotoxin PnIA
DM1QOY0	MI	TTH18TF
DM1QOY0	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DM1QOY0	MT	DTT
DM1QOY0	MA	Antagonist
DM1QOY0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 467).
DM1QOY0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=467

DM1QOY0	DI	DM1QOY0
DM1QOY0	DN	alpha-conotoxin PnIA
DM1QOY0	MI	TTH2QRX
DM1QOY0	MN	Neuronal acetylcholine receptor alpha-5 (CHRNA5)
DM1QOY0	MT	DTT
DM1QOY0	MA	Antagonist
DM1QOY0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 466).
DM1QOY0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=466

DM6VH7A	DI	DM6VH7A
DM6VH7A	DN	Alpha-D-Fucose
DM6VH7A	MI	TTSZDQU
DM6VH7A	MN	Lactotransferrin (LTF)
DM6VH7A	MT	DTT
DM6VH7A	MA	Inhibitor
DM6VH7A	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM6VH7A	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD2TPA	DI	DMD2TPA
DMD2TPA	DN	Alpha-D-Glucopyranosyl-2-Carboxylic Acid Amide
DMD2TPA	MI	TTZHY6R
DMD2TPA	MN	Glycogen phosphorylase muscle form (GP)
DMD2TPA	MT	DTT
DMD2TPA	MA	Inhibitor
DMD2TPA	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD2TPA	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM1X3VQ	DI	DM1X3VQ
DM1X3VQ	DN	Alpha-D-glucose
DM1X3VQ	MI	DE63NYG
DM1X3VQ	MN	Galactose mutarotase (GALM)
DM1X3VQ	MT	DME
DM1X3VQ	MA	Metabolism
DM1X3VQ	RN	Identification and characterisation of human aldose 1-epimerase. FEBS Lett. 2003 May 22;543(1-3):21-4.
DM1X3VQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12753898

DMU36HT	DI	DMU36HT
DMU36HT	DN	Alpha-D-Glucose-1-Phosphate
DMU36HT	MI	TTZHY6R
DMU36HT	MN	Glycogen phosphorylase muscle form (GP)
DMU36HT	MT	DTT
DMU36HT	MA	Inhibitor
DMU36HT	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMU36HT	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMU36HT	DI	DMU36HT
DMU36HT	DN	Alpha-D-Glucose-1-Phosphate
DMU36HT	MI	TTLP3GX
DMU36HT	MN	Pseudomonas Phosphomannomutase/phosphoglucomutase (Pseudo algC)
DMU36HT	MT	DTT
DMU36HT	MA	Inhibitor
DMU36HT	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMU36HT	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMR0EVN	DI	DMR0EVN
DMR0EVN	DN	Alpha-D-Glucose-6-Phosphate
DMR0EVN	MI	TTFBNVI
DMR0EVN	MN	Aldose reductase (AKR1B1)
DMR0EVN	MT	DTT
DMR0EVN	MA	Inhibitor
DMR0EVN	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMR0EVN	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMR0EVN	DI	DMR0EVN
DMR0EVN	DN	Alpha-D-Glucose-6-Phosphate
DMR0EVN	MI	TTC67I0
DMR0EVN	MN	Bacterial Glucosamine-6-phosphate synthase (Bact glmS)
DMR0EVN	MT	DTT
DMR0EVN	MA	Inhibitor
DMR0EVN	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMR0EVN	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMR0EVN	DI	DMR0EVN
DMR0EVN	DN	Alpha-D-Glucose-6-Phosphate
DMR0EVN	MI	TTZHY6R
DMR0EVN	MN	Glycogen phosphorylase muscle form (GP)
DMR0EVN	MT	DTT
DMR0EVN	MA	Inhibitor
DMR0EVN	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMR0EVN	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMR0EVN	DI	DMR0EVN
DMR0EVN	DN	Alpha-D-Glucose-6-Phosphate
DMR0EVN	MI	TTLP3GX
DMR0EVN	MN	Pseudomonas Phosphomannomutase/phosphoglucomutase (Pseudo algC)
DMR0EVN	MT	DTT
DMR0EVN	MA	Inhibitor
DMR0EVN	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMR0EVN	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM6ZTOW	DI	DM6ZTOW
DM6ZTOW	DN	Alpha-dihydroaldosterone
DM6ZTOW	MI	DEB3CV1
DM6ZTOW	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DM6ZTOW	MT	DME
DM6ZTOW	MA	Metabolism
DM6ZTOW	RN	Human uridine diphosphate-glucuronosyltransferase UGT2B7 conjugates mineralocorticoid and glucocorticoid metabolites. Endocrinology. 2003 Jun;144(6):2659-68.
DM6ZTOW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12746330

DMF5DLW	DI	DMF5DLW
DMF5DLW	DN	Alpha-D-Mannose
DMF5DLW	MI	TTQICM2
DMF5DLW	MN	ADAM metallopeptidase 33 (ADAM33)
DMF5DLW	MT	DTT
DMF5DLW	MA	Inhibitor
DMF5DLW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMF5DLW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMF5DLW	DI	DMF5DLW
DMF5DLW	DN	Alpha-D-Mannose
DMF5DLW	MI	TTIS03D
DMF5DLW	MN	Alpha-galactosidase A (GLA)
DMF5DLW	MT	DTT
DMF5DLW	MA	Inhibitor
DMF5DLW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMF5DLW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMF5DLW	DI	DMF5DLW
DMF5DLW	DN	Alpha-D-Mannose
DMF5DLW	MI	TT4QPUL
DMF5DLW	MN	Antithrombin-III (ATIII)
DMF5DLW	MT	DTT
DMF5DLW	MA	Inhibitor
DMF5DLW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMF5DLW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMF5DLW	DI	DMF5DLW
DMF5DLW	DN	Alpha-D-Mannose
DMF5DLW	MI	TT2OUI9
DMF5DLW	MN	Beta-2-glycoprotein 1 (APOH)
DMF5DLW	MT	DTT
DMF5DLW	MA	Inhibitor
DMF5DLW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMF5DLW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMF5DLW	DI	DMF5DLW
DMF5DLW	DN	Alpha-D-Mannose
DMF5DLW	MI	TTPT2QI
DMF5DLW	MN	Cathepsin D (CTSD)
DMF5DLW	MT	DTT
DMF5DLW	MA	Inhibitor
DMF5DLW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMF5DLW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMF5DLW	DI	DMF5DLW
DMF5DLW	DN	Alpha-D-Mannose
DMF5DLW	MI	TTEB0GD
DMF5DLW	MN	Cholinesterase (BCHE)
DMF5DLW	MT	DTT
DMF5DLW	MA	Inhibitor
DMF5DLW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMF5DLW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMF5DLW	DI	DMF5DLW
DMF5DLW	DN	Alpha-D-Mannose
DMF5DLW	MI	TTI2S1D
DMF5DLW	MN	Cytotoxic T-lymphocyte protein 4 (CTLA-4)
DMF5DLW	MT	DTT
DMF5DLW	MA	Inhibitor
DMF5DLW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMF5DLW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMF5DLW	DI	DMF5DLW
DMF5DLW	DN	Alpha-D-Mannose
DMF5DLW	MI	TTYWGOJ
DMF5DLW	MN	Deoxyribonuclease I (DNASE1)
DMF5DLW	MT	DTT
DMF5DLW	MA	Inhibitor
DMF5DLW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMF5DLW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMF5DLW	DI	DMF5DLW
DMF5DLW	DN	Alpha-D-Mannose
DMF5DLW	MI	TTDIGC1
DMF5DLW	MN	Dipeptidyl peptidase 4 (DPP-4)
DMF5DLW	MT	DTT
DMF5DLW	MA	Inhibitor
DMF5DLW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMF5DLW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMF5DLW	DI	DMF5DLW
DMF5DLW	DN	Alpha-D-Mannose
DMF5DLW	MI	TTFC29G
DMF5DLW	MN	Glycoprotein hormones alpha (CGA)
DMF5DLW	MT	DTT
DMF5DLW	MA	Inhibitor
DMF5DLW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMF5DLW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMF5DLW	DI	DMF5DLW
DMF5DLW	DN	Alpha-D-Mannose
DMF5DLW	MI	TT8XSKJ
DMF5DLW	MN	Heparin cofactor II (SERPIND1)
DMF5DLW	MT	DTT
DMF5DLW	MA	Inhibitor
DMF5DLW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMF5DLW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMF5DLW	DI	DMF5DLW
DMF5DLW	DN	Alpha-D-Mannose
DMF5DLW	MI	TTDGEC0
DMF5DLW	MN	Immunoglobulin epsilon Fc receptor gamma (FCERG)
DMF5DLW	MT	DTT
DMF5DLW	MA	Inhibitor
DMF5DLW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMF5DLW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMF5DLW	DI	DMF5DLW
DMF5DLW	DN	Alpha-D-Mannose
DMF5DLW	MI	TTF4CAM
DMF5DLW	MN	Influenza Hemagglutinin (Influ HA)
DMF5DLW	MT	DTT
DMF5DLW	MA	Inhibitor
DMF5DLW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMF5DLW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMF5DLW	DI	DMF5DLW
DMF5DLW	DN	Alpha-D-Mannose
DMF5DLW	MI	TT50QJ3
DMF5DLW	MN	Influenza Neuraminidase (Influ NA)
DMF5DLW	MT	DTT
DMF5DLW	MA	Inhibitor
DMF5DLW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMF5DLW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMF5DLW	DI	DMF5DLW
DMF5DLW	DN	Alpha-D-Mannose
DMF5DLW	MI	TTHRID2
DMF5DLW	MN	Insulin-like growth factor I receptor (IGF1R)
DMF5DLW	MT	DTT
DMF5DLW	MA	Inhibitor
DMF5DLW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMF5DLW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMF5DLW	DI	DMF5DLW
DMF5DLW	DN	Alpha-D-Mannose
DMF5DLW	MI	TT0E5SK
DMF5DLW	MN	Interleukin 6 receptor (IL6R)
DMF5DLW	MT	DTT
DMF5DLW	MA	Inhibitor
DMF5DLW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMF5DLW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMF5DLW	DI	DMF5DLW
DMF5DLW	DN	Alpha-D-Mannose
DMF5DLW	MI	TTA0OSE
DMF5DLW	MN	Lactase-phlorizin hydrolase (LCT)
DMF5DLW	MT	DTT
DMF5DLW	MA	Inhibitor
DMF5DLW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMF5DLW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMF5DLW	DI	DMF5DLW
DMF5DLW	DN	Alpha-D-Mannose
DMF5DLW	MI	TTSZDQU
DMF5DLW	MN	Lactotransferrin (LTF)
DMF5DLW	MT	DTT
DMF5DLW	MA	Inhibitor
DMF5DLW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMF5DLW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMF5DLW	DI	DMF5DLW
DMF5DLW	DN	Alpha-D-Mannose
DMF5DLW	MI	TTMF541
DMF5DLW	MN	Liver carboxylesterase (CES1)
DMF5DLW	MT	DTT
DMF5DLW	MA	Inhibitor
DMF5DLW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMF5DLW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMF5DLW	DI	DMF5DLW
DMF5DLW	DN	Alpha-D-Mannose
DMF5DLW	MI	TTH0DUS
DMF5DLW	MN	Low-density lipoprotein receptor (LDL-R)
DMF5DLW	MT	DTT
DMF5DLW	MA	Inhibitor
DMF5DLW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMF5DLW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMF5DLW	DI	DMF5DLW
DMF5DLW	DN	Alpha-D-Mannose
DMF5DLW	MI	TTBXIM9
DMF5DLW	MN	Membrane-associated lectin type-C (CD209)
DMF5DLW	MT	DTT
DMF5DLW	MA	Inhibitor
DMF5DLW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMF5DLW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMF5DLW	DI	DMF5DLW
DMF5DLW	DN	Alpha-D-Mannose
DMF5DLW	MI	TTZUFI5
DMF5DLW	MN	Nitric-oxide synthase brain (NOS1)
DMF5DLW	MT	DTT
DMF5DLW	MA	Inhibitor
DMF5DLW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMF5DLW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMF5DLW	DI	DMF5DLW
DMF5DLW	DN	Alpha-D-Mannose
DMF5DLW	MI	TT9V5JH
DMF5DLW	MN	Phospholipase A2 (PLA2G1B)
DMF5DLW	MT	DTT
DMF5DLW	MA	Inhibitor
DMF5DLW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMF5DLW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMF5DLW	DI	DMF5DLW
DMF5DLW	DN	Alpha-D-Mannose
DMF5DLW	MI	TT8NGED
DMF5DLW	MN	Prostaglandin G/H synthase 1 (COX-1)
DMF5DLW	MT	DTT
DMF5DLW	MA	Inhibitor
DMF5DLW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMF5DLW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMF5DLW	DI	DMF5DLW
DMF5DLW	DN	Alpha-D-Mannose
DMF5DLW	MI	TTVRZUO
DMF5DLW	MN	Reticulon-4 receptor (RTN4R)
DMF5DLW	MT	DTT
DMF5DLW	MA	Inhibitor
DMF5DLW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMF5DLW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMF5DLW	DI	DMF5DLW
DMF5DLW	DN	Alpha-D-Mannose
DMF5DLW	MI	TTH0KSX
DMF5DLW	MN	Rhodopsin (RHO)
DMF5DLW	MT	DTT
DMF5DLW	MA	Inhibitor
DMF5DLW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMF5DLW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMF5DLW	DI	DMF5DLW
DMF5DLW	DN	Alpha-D-Mannose
DMF5DLW	MI	TTJDUNO
DMF5DLW	MN	T-cell surface antigen CD2 (CD2)
DMF5DLW	MT	DTT
DMF5DLW	MA	Inhibitor
DMF5DLW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMF5DLW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM3NCM1	DI	DM3NCM1
DM3NCM1	DN	Alpha-D-Mannose-6-Phosphate
DM3NCM1	MI	TT95ICL
DM3NCM1	MN	Mannose-6-phosphate receptor (M6PR)
DM3NCM1	MT	DTT
DM3NCM1	MA	Inhibitor
DM3NCM1	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM3NCM1	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM3NCM1	DI	DM3NCM1
DM3NCM1	DN	Alpha-D-Mannose-6-Phosphate
DM3NCM1	MI	TTLP3GX
DM3NCM1	MN	Pseudomonas Phosphomannomutase/phosphoglucomutase (Pseudo algC)
DM3NCM1	MT	DTT
DM3NCM1	MA	Inhibitor
DM3NCM1	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM3NCM1	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMULXO3	DI	DMULXO3
DMULXO3	DN	alpha-Emtbl
DMULXO3	MI	TTZ8EM9
DMULXO3	MN	Glycine receptor (GlyR)
DMULXO3	MT	DTT
DMULXO3	RN	Subunit-specific action of an anticonvulsant thiobutyrolactone on recombinant glycine receptors involves a residue in the M2 membrane-spanning region. Mol Pharmacol. 2000 Jul;58(1):11-7.
DMULXO3	RU	https://pubmed.ncbi.nlm.nih.gov/10860922

DMMPOEK	DI	DMMPOEK
DMMPOEK	DN	alpha-ergocryptine
DMMPOEK	MI	TTJS8PY
DMMPOEK	MN	5-HT 6 receptor (HTR6)
DMMPOEK	MT	DTT
DMMPOEK	MA	Antagonist
DMMPOEK	RN	Identification of residues in transmembrane regions III and VI that contribute to the ligand binding site of the serotonin 5-HT6 receptor. J Neurochem. 1998 Nov;71(5):2169-77.
DMMPOEK	RU	https://pubmed.ncbi.nlm.nih.gov/9798944

DMYSCQU	DI	DMYSCQU
DMYSCQU	DN	Alpha-eudesmol
DMYSCQU	MI	TTX4QDJ
DMYSCQU	MN	Voltage-gated calcium channel alpha Cav2.1 (CACNA1A)
DMYSCQU	MT	DTT
DMYSCQU	MA	Blocker
DMYSCQU	RN	Alpha-eudesmol, a P/Q-type Ca(2+) channel blocker, inhibits neurogenic vasodilation and extravasation following electrical stimulation of trigeminal ganglion. Brain Res. 2000 Aug 4;873(1):94-101.
DMYSCQU	RU	https://pubmed.ncbi.nlm.nih.gov/10915814

DM4GLZU	DI	DM4GLZU
DM4GLZU	DN	alpha-fluoromethylenephosphonate
DM4GLZU	MI	TTE2YJR
DM4GLZU	MN	Lysophosphatidate-3 receptor (LPAR3)
DM4GLZU	MT	DTT
DM4GLZU	MA	Agonist
DM4GLZU	RN	Structure-activity relationships of fluorinated lysophosphatidic acid analogues. J Med Chem. 2005 May 5;48(9):3319-27.
DM4GLZU	RU	https://pubmed.ncbi.nlm.nih.gov/15857137

DMT17H0	DI	DMT17H0
DMT17H0	DN	Alpha-Homonojirimycin
DMT17H0	MI	TTLPC70
DMT17H0	MN	Lysosomal alpha-glucosidase (GAA)
DMT17H0	MT	DTT
DMT17H0	MA	Inhibitor
DMT17H0	RN	In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures. Bioorg Med Chem. 2008 Aug 1;16(15):7330-6.
DMT17H0	RU	https://pubmed.ncbi.nlm.nih.gov/18595718

DMIH38V	DI	DMIH38V
DMIH38V	DN	ALPHA-HYDROXYFARNESYLPHOSPHONIC ACID
DMIH38V	MI	TT7WZIJ
DMIH38V	MN	CAAX farnesyltransferase beta (FNTB)
DMIH38V	MT	DTT
DMIH38V	MA	Inhibitor
DMIH38V	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMIH38V	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMIH38V	DI	DMIH38V
DMIH38V	DN	ALPHA-HYDROXYFARNESYLPHOSPHONIC ACID
DMIH38V	MI	TTXQKM3
DMIH38V	MN	Farnesyl protein transferase (Ftase)
DMIH38V	MT	DTT
DMIH38V	MA	Inhibitor
DMIH38V	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMIH38V	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMAQBKX	DI	DMAQBKX
DMAQBKX	DN	Alpha-Hydroxy-Midazolam
DMAQBKX	MI	TTXV4FI
DMAQBKX	MN	Albendazole monooxygenase (CYP3A4)
DMAQBKX	MT	DTT
DMAQBKX	MA	Inhibitor
DMAQBKX	RN	Design and synthesis of a new fluorescent probe for cytochrome P450 3A4 (CYP 3A4). Bioorg Med Chem Lett. 2003 Nov 3;13(21):3643-5.
DMAQBKX	RU	https://pubmed.ncbi.nlm.nih.gov/14552748

DM5LFYN	DI	DM5LFYN
DM5LFYN	DN	Alpha-ketoglutaric acid
DM5LFYN	MI	DEY1CBW
DM5LFYN	MN	Factor inhibiting HIF-1 (HIF1AN)
DM5LFYN	MT	DME
DM5LFYN	MA	Metabolism
DM5LFYN	RN	The facial triad in the alpha-ketoglutarate dependent oxygenase FIH: a role for sterics in linking substrate binding to O2 activation. J Inorg Biochem. 2017 Jan;166:26-33.
DM5LFYN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27815979

DM5LFYN	DI	DM5LFYN
DM5LFYN	DN	Alpha-ketoglutaric acid
DM5LFYN	MI	DEWO724
DM5LFYN	MN	HIF-prolyl hydroxylase 2 (EGLN1)
DM5LFYN	MT	DME
DM5LFYN	MA	Metabolism
DM5LFYN	RN	Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J Biol Chem. 2003 Aug 15;278(33):30772-80.
DM5LFYN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12788921

DM5LFYN	DI	DM5LFYN
DM5LFYN	DN	Alpha-ketoglutaric acid
DM5LFYN	MI	DEMQTKH
DM5LFYN	MN	HIF-prolyl hydroxylase 3 (EGLN3)
DM5LFYN	MT	DME
DM5LFYN	MA	Metabolism
DM5LFYN	RN	Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J Biol Chem. 2003 Aug 15;278(33):30772-80.
DM5LFYN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12788921

DM5LFYN	DI	DM5LFYN
DM5LFYN	DN	Alpha-ketoglutaric acid
DM5LFYN	MI	DT2UQYR
DM5LFYN	MN	Mitochondrial 2-oxodicarboxylate carrier (SLC25A21)
DM5LFYN	MT	DTP
DM5LFYN	MA	Substrate
DM5LFYN	RN	Mitochondrial oxodicarboxylate carrier deficiency is associated with mitochondrial DNA depletion and spinal muscular atrophy-like disease. Genet Med. 2018 Oct;20(10):1224-1235.
DM5LFYN	RU	http://www.ncbi.nlm.nih.gov/pubmed/29517768

DM5LFYN	DI	DM5LFYN
DM5LFYN	DN	Alpha-ketoglutaric acid
DM5LFYN	MI	DT0YAUQ
DM5LFYN	MN	Mitochondrial 2-oxoglutarate/malate carrier (SLC25A11)
DM5LFYN	MT	DTP
DM5LFYN	MA	Substrate
DM5LFYN	RN	The mitochondrial dicarboxylate and 2-oxoglutarate carriers do not transport glutathione. FEBS Lett. 2015 Feb 27;589(5):621-8.
DM5LFYN	RU	http://www.ncbi.nlm.nih.gov/pubmed/25637873

DM5LFYN	DI	DM5LFYN
DM5LFYN	DN	Alpha-ketoglutaric acid
DM5LFYN	MI	TTAS1QK
DM5LFYN	MN	Oxoglutarate receptor (OXGR1)
DM5LFYN	MT	DTT
DM5LFYN	MA	Agonist
DM5LFYN	RN	Screening beta-arrestin recruitment for the identification of natural ligands for orphan G-protein-coupled receptors. J Biomol Screen. 2013 Jun;18(5):599-609.
DM5LFYN	RU	https://pubmed.ncbi.nlm.nih.gov/23396314

DM5LFYN	DI	DM5LFYN
DM5LFYN	DN	Alpha-ketoglutaric acid
DM5LFYN	MI	DEW527E
DM5LFYN	MN	Prolyl 3-hydroxylase 1 (P3H1)
DM5LFYN	MT	DME
DM5LFYN	MA	Metabolism
DM5LFYN	RN	Characterization of recombinant human prolyl 3-hydroxylase isoenzyme 2, an enzyme modifying the basement membrane collagen IV. J Biol Chem. 2008 Jul 11;283(28):19432-9.
DM5LFYN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18487197

DM5LFYN	DI	DM5LFYN
DM5LFYN	DN	Alpha-ketoglutaric acid
DM5LFYN	MI	DELB5PA
DM5LFYN	MN	Prolyl 3-hydroxylase 2 (P3H2)
DM5LFYN	MT	DME
DM5LFYN	MA	Metabolism
DM5LFYN	RN	Characterization of recombinant human prolyl 3-hydroxylase isoenzyme 2, an enzyme modifying the basement membrane collagen IV. J Biol Chem. 2008 Jul 11;283(28):19432-9.
DM5LFYN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18487197

DM5LFYN	DI	DM5LFYN
DM5LFYN	DN	Alpha-ketoglutaric acid
DM5LFYN	MI	DESO5ZY
DM5LFYN	MN	Prolyl 4-hydroxylase alpha-1 (P4HA1)
DM5LFYN	MT	DME
DM5LFYN	MA	Metabolism
DM5LFYN	RN	Prolyl 4-hydroxylases, the key enzymes of collagen biosynthesis. Matrix Biol. 2003 Mar;22(1):15-24.
DM5LFYN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12714038

DM5LFYN	DI	DM5LFYN
DM5LFYN	DN	Alpha-ketoglutaric acid
DM5LFYN	MI	DE5EGK0
DM5LFYN	MN	Prolyl 4-hydroxylase alpha-2 (P4HA2)
DM5LFYN	MT	DME
DM5LFYN	MA	Metabolism
DM5LFYN	RN	Prolyl 4-hydroxylases, the key enzymes of collagen biosynthesis. Matrix Biol. 2003 Mar;22(1):15-24.
DM5LFYN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12714038

DM5LFYN	DI	DM5LFYN
DM5LFYN	DN	Alpha-ketoglutaric acid
DM5LFYN	MI	DE2L4RX
DM5LFYN	MN	Prolyl 4-hydroxylase alpha-3 (P4HA3)
DM5LFYN	MT	DME
DM5LFYN	MA	Metabolism
DM5LFYN	RN	Identification and characterization of a third human, rat, and mouse collagen prolyl 4-hydroxylase isoenzyme. J Biol Chem. 2003 Nov 28;278(48):47685-93.
DM5LFYN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14500733

DM5LFYN	DI	DM5LFYN
DM5LFYN	DN	Alpha-ketoglutaric acid
DM5LFYN	MI	DTKXTPW
DM5LFYN	MN	Sodium/dicarboxylate cotransporter 3 (SLC13A3)
DM5LFYN	MT	DTP
DM5LFYN	MA	Substrate
DM5LFYN	RN	SLC13A3 variants cause acute reversible leukoencephalopathy and -ketoglutarate accumulation. Ann Neurol. 2019 Mar;85(3):385-395.
DM5LFYN	RU	http://www.ncbi.nlm.nih.gov/pubmed/30635937

DM5LFYN	DI	DM5LFYN
DM5LFYN	DN	Alpha-ketoglutaric acid
DM5LFYN	MI	DTFPWJ9
DM5LFYN	MN	Sodium-coupled citrate transporter (SLC13A5)
DM5LFYN	MT	DTP
DM5LFYN	MA	Substrate
DM5LFYN	RN	SLC13 family of Na+ coupled di- and tri-carboxylate/sulfate transporters. Mol Aspects Med. 2013 Apr-Jun;34(2-3):299-312.
DM5LFYN	RU	http://www.ncbi.nlm.nih.gov/pubmed/23506872

DMBZTS5	DI	DMBZTS5
DMBZTS5	DN	Alpha-ketoisovalerate
DMBZTS5	MI	TTF9OQ6
DMBZTS5	MN	Branched-chain-amino-acid transaminase 2 (BCAT2)
DMBZTS5	MT	DTT
DMBZTS5	MA	Inhibitor
DMBZTS5	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMBZTS5	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM2I564	DI	DM2I564
DM2I564	DN	Alpha-l-arabinose
DM2I564	MI	DEBI60T
DM2I564	MN	L-arabinose isomerase (araA)
DM2I564	MT	DME
DM2I564	MA	Metabolism
DM2I564	RN	Protein purification, crystallization and preliminary X-ray diffraction analysis of L-arabinose isomerase from Lactobacillus fermentum CGMCC2921. Acta Crystallogr F Struct Biol Commun. 2015 Jan 1;71(Pt 1):28-33.
DM2I564	RU	https://pubmed.ncbi.nlm.nih.gov/25615964

DMY64HE	DI	DMY64HE
DMY64HE	DN	Alpha-linolenic acid
DMY64HE	MI	DE30GZN
DMY64HE	MN	Carboxylic ester hydrolase (CEH)
DMY64HE	MT	DME
DMY64HE	MA	Metabolism
DMY64HE	RN	Immunogenic inhibition of prominent ruminal bacteria as a means to reduce lipolysis and biohydrogenation activity in vitro. Food Chem. 2017 Mar 1;218:372-377.
DMY64HE	RU	https://pubmed.ncbi.nlm.nih.gov/27719923

DMY64HE	DI	DMY64HE
DMY64HE	DN	Alpha-linolenic acid
DMY64HE	MI	TTB8FUC
DMY64HE	MN	Free fatty acid receptor 1 (GPR40)
DMY64HE	MT	DTT
DMY64HE	MA	Agonist
DMY64HE	RN	Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature. 2003 Mar 13;422(6928):173-6.
DMY64HE	RU	https://pubmed.ncbi.nlm.nih.gov/12629551

DMY64HE	DI	DMY64HE
DMY64HE	DN	Alpha-linolenic acid
DMY64HE	MI	TT08JVB
DMY64HE	MN	G-protein coupled receptor 120 (GPR120)
DMY64HE	MT	DTT
DMY64HE	MA	Agonist
DMY64HE	RN	Cloning and characterization of the rat free fatty acid receptor GPR120: in vivo effect of the natural ligand on GLP-1 secretion and proliferation of pancreatic beta cells. Naunyn Schmiedebergs Arch Pharmacol. 2008 Jun;377(4-6):515-22.
DMY64HE	RU	https://pubmed.ncbi.nlm.nih.gov/18320172

DMY64HE	DI	DMY64HE
DMY64HE	DN	Alpha-linolenic acid
DMY64HE	MI	DE073H6
DMY64HE	MN	Prostaglandin G/H synthase 1 (COX-1)
DMY64HE	MT	DME
DMY64HE	MA	Metabolism
DMY64HE	RN	Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. FASEB J. 2006 Jun;20(8):1097-108.
DMY64HE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16770009

DMY64HE	DI	DMY64HE
DMY64HE	DN	Alpha-linolenic acid
DMY64HE	MI	TTVKILB
DMY64HE	MN	Prostaglandin G/H synthase 2 (COX-2)
DMY64HE	MT	DTT
DMY64HE	MA	Inhibitor
DMY64HE	RN	Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
DMY64HE	RU	https://pubmed.ncbi.nlm.nih.gov/11421736

DMY64HE	DI	DMY64HE
DMY64HE	DN	Alpha-linolenic acid
DMY64HE	MI	DE492CE
DMY64HE	MN	Prostaglandin G/H synthase 2 (COX-2)
DMY64HE	MT	DME
DMY64HE	MA	Metabolism
DMY64HE	RN	Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. FASEB J. 2006 Jun;20(8):1097-108.
DMY64HE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16770009

DMCAYXF	DI	DMCAYXF
DMCAYXF	DN	alpha-methyl-5-HT
DMCAYXF	MI	TT6MSOK
DMCAYXF	MN	5-HT 1D receptor (HTR1D)
DMCAYXF	MT	DTT
DMCAYXF	MA	Agonist
DMCAYXF	RN	Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan. Mol Pharmacol. 1996 Dec;50(6):1567-80.
DMCAYXF	RU	https://pubmed.ncbi.nlm.nih.gov/8967979

DMCAYXF	DI	DMCAYXF
DMCAYXF	DN	alpha-methyl-5-HT
DMCAYXF	MI	TTCPG9S
DMCAYXF	MN	5-HT 1E receptor (HTR1E)
DMCAYXF	MT	DTT
DMCAYXF	MA	Agonist
DMCAYXF	RN	Molecular cloning and pharmacological characterization of the guinea pig 5-HT1E receptor. Eur J Pharmacol. 2004 Jan 26;484(2-3):127-39.
DMCAYXF	RU	https://pubmed.ncbi.nlm.nih.gov/14744596

DMCAYXF	DI	DMCAYXF
DMCAYXF	DN	alpha-methyl-5-HT
DMCAYXF	MI	TT0MI3F
DMCAYXF	MN	5-HT 1F receptor (HTR1F)
DMCAYXF	MT	DTT
DMCAYXF	MA	Agonist
DMCAYXF	RN	Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):408-12.
DMCAYXF	RU	https://pubmed.ncbi.nlm.nih.gov/8380639

DMCAYXF	DI	DMCAYXF
DMCAYXF	DN	alpha-methyl-5-HT
DMCAYXF	MI	TTJQOD7
DMCAYXF	MN	5-HT 2A receptor (HTR2A)
DMCAYXF	MT	DTT
DMCAYXF	MA	Agonist
DMCAYXF	RN	Differential modes of agonist binding to 5-hydroxytryptamine(2A) serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5. Mol Pharmacol. 2000 Nov;58(5):877-86.
DMCAYXF	RU	https://pubmed.ncbi.nlm.nih.gov/11040033

DMCAYXF	DI	DMCAYXF
DMCAYXF	DN	alpha-methyl-5-HT
DMCAYXF	MI	TT0K1SC
DMCAYXF	MN	5-HT 2B receptor (HTR2B)
DMCAYXF	MT	DTT
DMCAYXF	MA	Agonist
DMCAYXF	RN	The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br J Pharmacol. 2004 Nov;143(5):549-60.
DMCAYXF	RU	https://pubmed.ncbi.nlm.nih.gov/15466450

DMCAYXF	DI	DMCAYXF
DMCAYXF	DN	alpha-methyl-5-HT
DMCAYXF	MI	TTWJBZ5
DMCAYXF	MN	5-HT 2C receptor (HTR2C)
DMCAYXF	MT	DTT
DMCAYXF	MA	Agonist
DMCAYXF	RN	High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action. J Neurochem. 1999 May;72(5):2127-34.
DMCAYXF	RU	https://pubmed.ncbi.nlm.nih.gov/10217294

DMCAYXF	DI	DMCAYXF
DMCAYXF	DN	alpha-methyl-5-HT
DMCAYXF	MI	TT07C3Y
DMCAYXF	MN	5-HT 4 receptor (HTR4)
DMCAYXF	MT	DTT
DMCAYXF	MA	Agonist
DMCAYXF	RN	[3H]RS 57639, a high affinity, selective 5-HT4 receptor partial agonist, specifically labels guinea-pig striatal and rat cloned (5-HT4S and 5-HT4L) receptors. Neuropharmacology. 1997 Apr-May;36(4-5):671-9.
DMCAYXF	RU	https://pubmed.ncbi.nlm.nih.gov/9225293

DMCAYXF	DI	DMCAYXF
DMCAYXF	DN	alpha-methyl-5-HT
DMCAYXF	MI	TTJS8PY
DMCAYXF	MN	5-HT 6 receptor (HTR6)
DMCAYXF	MT	DTT
DMCAYXF	MA	Agonist
DMCAYXF	RN	Identification of residues in transmembrane regions III and VI that contribute to the ligand binding site of the serotonin 5-HT6 receptor. J Neurochem. 1998 Nov;71(5):2169-77.
DMCAYXF	RU	https://pubmed.ncbi.nlm.nih.gov/9798944

DM7DBTZ	DI	DM7DBTZ
DM7DBTZ	DN	Alpha-methylalanyl-L-proline butylamide
DM7DBTZ	MI	TTQ7R2V
DM7DBTZ	MN	Tripeptidyl-peptidase II (TPP2)
DM7DBTZ	MT	DTT
DM7DBTZ	MA	Inhibitor
DM7DBTZ	RN	Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach ... J Med Chem. 2005 Nov 17;48(23):7333-42.
DM7DBTZ	RU	https://pubmed.ncbi.nlm.nih.gov/16279793

DM892JF	DI	DM892JF
DM892JF	DN	Alpha-methyl-alpha-phenylsuccinimide (MPS)
DM892JF	MI	TT729IR
DM892JF	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DM892JF	MT	DTT
DM892JF	MA	Blocker
DM892JF	RN	Block of cloned human T-type calcium channels by succinimide antiepileptic drugs. Mol Pharmacol. 2001 Nov;60(5):1121-32.
DM892JF	RU	https://pubmed.ncbi.nlm.nih.gov/11641441

DM0C4GP	DI	DM0C4GP
DM0C4GP	DN	Alpha-methylcubebin
DM0C4GP	MI	TTXV4FI
DM0C4GP	MN	Albendazole monooxygenase (CYP3A4)
DM0C4GP	MT	DTT
DM0C4GP	MA	Inhibitor
DM0C4GP	RN	Potent CYP3A4 inhibitory constituents of Piper cubeba. J Nat Prod. 2005 Jan;68(1):64-8.
DM0C4GP	RU	https://pubmed.ncbi.nlm.nih.gov/15679319

DM3YGWL	DI	DM3YGWL
DM3YGWL	DN	Alpha-Methylisocitric Acid
DM3YGWL	MI	TTMTF2P
DM3YGWL	MN	Citrate hydro-lyase (ACO2)
DM3YGWL	MT	DTT
DM3YGWL	MA	Inhibitor
DM3YGWL	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM3YGWL	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMAUH96	DI	DMAUH96
DMAUH96	DN	alpha-methylphenylalanine
DMAUH96	MI	TTGSVH2
DMAUH96	MN	Phenylalanine hydroxylase (PAH)
DMAUH96	MT	DTT
DMAUH96	MA	Inhibitor
DMAUH96	RN	Alpha-methylphenylalanine, a new inducer of chronic hyperphenylalaninemia in sucling rats. Science. 1976 Jun 4;192(4243):1007-8.
DMAUH96	RU	https://pubmed.ncbi.nlm.nih.gov/944951

DMCIH1X	DI	DMCIH1X
DMCIH1X	DN	alpha-methylserine-O-phosphate
DMCIH1X	MI	TTXJ47W
DMCIH1X	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMCIH1X	MT	DTT
DMCIH1X	MA	Antagonist
DMCIH1X	RN	Characterization of [3H]-(2S,2'R,3'R)-2-(2',3'-dicarboxy-cyclopropyl)glycine ([3H]-DCG IV) binding to metabotropic mGlu2 receptor-transfected cell membranes. Br J Pharmacol. 1998 Feb;123(3):497-504.
DMCIH1X	RU	https://pubmed.ncbi.nlm.nih.gov/9504391

DMCIH1X	DI	DMCIH1X
DMCIH1X	DN	alpha-methylserine-O-phosphate
DMCIH1X	MI	TTWRP2F
DMCIH1X	MN	Metabotropic glutamate receptor 6 (mGluR6)
DMCIH1X	MT	DTT
DMCIH1X	MA	Antagonist
DMCIH1X	RN	The metabotropic glutamate receptors: structure, activation mechanism and pharmacology. Curr Drug Targets CNS Neurol Disord. 2002 Jun;1(3):297-317.
DMCIH1X	RU	https://pubmed.ncbi.nlm.nih.gov/12769621

DMCIH1X	DI	DMCIH1X
DMCIH1X	DN	alpha-methylserine-O-phosphate
DMCIH1X	MI	TT0I76D
DMCIH1X	MN	Metabotropic glutamate receptor 7 (mGluR7)
DMCIH1X	MT	DTT
DMCIH1X	MA	Antagonist
DMCIH1X	RN	Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 2000 Dec;362(6):546-54.
DMCIH1X	RU	https://pubmed.ncbi.nlm.nih.gov/11138847

DMCIH1X	DI	DMCIH1X
DMCIH1X	DN	alpha-methylserine-O-phosphate
DMCIH1X	MI	TT0IFKL
DMCIH1X	MN	Metabotropic glutamate receptor 8 (mGluR8)
DMCIH1X	MT	DTT
DMCIH1X	MA	Antagonist
DMCIH1X	RN	The metabotropic glutamate receptors: structure, activation mechanism and pharmacology. Curr Drug Targets CNS Neurol Disord. 2002 Jun;1(3):297-317.
DMCIH1X	RU	https://pubmed.ncbi.nlm.nih.gov/12769621

DML7SU3	DI	DML7SU3
DML7SU3	DN	Alpha-monofluoromethyl-3,4-dehydroornithine
DML7SU3	MI	TTUMGNO
DML7SU3	MN	Ornithine decarboxylase (ODC1)
DML7SU3	MT	DTT
DML7SU3	MA	Inhibitor
DML7SU3	RN	Plasmodium falciparum and Plasmodium berghei: effects of ornithine decarboxylase inhibitors on erythrocytic schizogony. Exp Parasitol. 1987 Oct;64(2):237-43.
DML7SU3	RU	https://pubmed.ncbi.nlm.nih.gov/3115816

DMJTGZV	DI	DMJTGZV
DMJTGZV	DN	Alpha-monofluoromethyl-3,4-dehydroornithine ethyl ester
DMJTGZV	MI	TTUMGNO
DMJTGZV	MN	Ornithine decarboxylase (ODC1)
DMJTGZV	MT	DTT
DMJTGZV	MA	Inhibitor
DMJTGZV	RN	Plasmodium falciparum and Plasmodium berghei: effects of ornithine decarboxylase inhibitors on erythrocytic schizogony. Exp Parasitol. 1987 Oct;64(2):237-43.
DMJTGZV	RU	https://pubmed.ncbi.nlm.nih.gov/3115816

DMGI9SM	DI	DMGI9SM
DMGI9SM	DN	Alpha-monofluoromethyl-3,4-dehydroornithine methyl ester
DMGI9SM	MI	TTUMGNO
DMGI9SM	MN	Ornithine decarboxylase (ODC1)
DMGI9SM	MT	DTT
DMGI9SM	MA	Inhibitor
DMGI9SM	RN	Plasmodium falciparum and Plasmodium berghei: effects of ornithine decarboxylase inhibitors on erythrocytic schizogony. Exp Parasitol. 1987 Oct;64(2):237-43.
DMGI9SM	RU	https://pubmed.ncbi.nlm.nih.gov/3115816

DMELOIQ	DI	DMELOIQ
DMELOIQ	DN	Alpha-naphthoflavone
DMELOIQ	MI	TTSZLWK
DMELOIQ	MN	Aromatase (CYP19A1)
DMELOIQ	MT	DTT
DMELOIQ	MA	Inhibitor
DMELOIQ	RN	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
DMELOIQ	RU	https://pubmed.ncbi.nlm.nih.gov/20413308

DMELOIQ	DI	DMELOIQ
DMELOIQ	DN	Alpha-naphthoflavone
DMELOIQ	MI	TTK3PY9
DMELOIQ	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMELOIQ	MT	DTT
DMELOIQ	MA	Inhibitor
DMELOIQ	RN	Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85.
DMELOIQ	RU	https://pubmed.ncbi.nlm.nih.gov/15658870

DM0KXN4	DI	DM0KXN4
DM0KXN4	DN	Alpha-oxoadipic acid
DM0KXN4	MI	DT2UQYR
DM0KXN4	MN	Mitochondrial 2-oxodicarboxylate carrier (SLC25A21)
DM0KXN4	MT	DTP
DM0KXN4	MA	Substrate
DM0KXN4	RN	Mitochondrial oxodicarboxylate carrier deficiency is associated with mitochondrial DNA depletion and spinal muscular atrophy-like disease. Genet Med. 2018 Oct;20(10):1224-1235.
DM0KXN4	RU	http://www.ncbi.nlm.nih.gov/pubmed/29517768

DMT6KI7	DI	DMT6KI7
DMT6KI7	DN	Alpha-Phosphoribosylpyrophosphoric Acid
DMT6KI7	MI	TTAFJUD
DMT6KI7	MN	Orotidine 5'-monophosphate decarboxylase (UMPS)
DMT6KI7	MT	DTT
DMT6KI7	MA	Inhibitor
DMT6KI7	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMT6KI7	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMT6KI7	DI	DMT6KI7
DMT6KI7	DN	Alpha-Phosphoribosylpyrophosphoric Acid
DMT6KI7	MI	TTBL49X
DMT6KI7	MN	Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ)
DMT6KI7	MT	DTT
DMT6KI7	MA	Inhibitor
DMT6KI7	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMT6KI7	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMQKMX3	DI	DMQKMX3
DMQKMX3	DN	alpha-propyldopacetamide
DMQKMX3	MI	TT3KLDP
DMQKMX3	MN	L-Tryptophan hydroxylase 2 (TPH2)
DMQKMX3	MT	DTT
DMQKMX3	MA	Inhibitor
DMQKMX3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1242).
DMQKMX3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1242

DMQKMX3	DI	DMQKMX3
DMQKMX3	DN	alpha-propyldopacetamide
DMQKMX3	MI	TTZSJHV
DMQKMX3	MN	Tryptophan 5-hydroxylase 1 (TPH1)
DMQKMX3	MT	DTT
DMQKMX3	MA	Inhibitor
DMQKMX3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1241).
DMQKMX3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1241

DMQKMX3	DI	DMQKMX3
DMQKMX3	DN	alpha-propyldopacetamide
DMQKMX3	MI	TTUHP71
DMQKMX3	MN	Tyrosine 3-monooxygenase (TH)
DMQKMX3	MT	DTT
DMQKMX3	MA	Inhibitor
DMQKMX3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1243).
DMQKMX3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1243

DMWL172	DI	DMWL172
DMWL172	DN	Alpha-Sulfanyl(2,4-dichlorobenzyl)phosphonic acid
DMWL172	MI	TTHI19T
DMWL172	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMWL172	MT	DTT
DMWL172	MA	Inhibitor
DMWL172	RN	Mercaptophosphonate compounds as broad-spectrum inhibitors of the metallo-beta-lactamases. J Med Chem. 2010 Jul 8;53(13):4862-76.
DMWL172	RU	https://pubmed.ncbi.nlm.nih.gov/20527888

DM42M6I	DI	DM42M6I
DM42M6I	DN	Alpha-Sulfanyl(2-methoxybenzyl)phosphonic acid
DM42M6I	MI	TTHI19T
DM42M6I	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DM42M6I	MT	DTT
DM42M6I	MA	Inhibitor
DM42M6I	RN	Mercaptophosphonate compounds as broad-spectrum inhibitors of the metallo-beta-lactamases. J Med Chem. 2010 Jul 8;53(13):4862-76.
DM42M6I	RU	https://pubmed.ncbi.nlm.nih.gov/20527888

DMRIWDV	DI	DMRIWDV
DMRIWDV	DN	Alpha-Sulfanyl(4-bromobenzyl)phosphonic acid
DMRIWDV	MI	TTHI19T
DMRIWDV	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMRIWDV	MT	DTT
DMRIWDV	MA	Inhibitor
DMRIWDV	RN	Mercaptophosphonate compounds as broad-spectrum inhibitors of the metallo-beta-lactamases. J Med Chem. 2010 Jul 8;53(13):4862-76.
DMRIWDV	RU	https://pubmed.ncbi.nlm.nih.gov/20527888

DMP6GXU	DI	DMP6GXU
DMP6GXU	DN	Alpha-Sulfanyl(4-chlorobenzyl)phosphonic acid
DMP6GXU	MI	TTHI19T
DMP6GXU	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMP6GXU	MT	DTT
DMP6GXU	MA	Inhibitor
DMP6GXU	RN	Mercaptophosphonate compounds as broad-spectrum inhibitors of the metallo-beta-lactamases. J Med Chem. 2010 Jul 8;53(13):4862-76.
DMP6GXU	RU	https://pubmed.ncbi.nlm.nih.gov/20527888

DMP9V42	DI	DMP9V42
DMP9V42	DN	Alpha-Sulfanyl(4-fluorobenzyl)phosphonic acid
DMP9V42	MI	TTHI19T
DMP9V42	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMP9V42	MT	DTT
DMP9V42	MA	Inhibitor
DMP9V42	RN	Mercaptophosphonate compounds as broad-spectrum inhibitors of the metallo-beta-lactamases. J Med Chem. 2010 Jul 8;53(13):4862-76.
DMP9V42	RU	https://pubmed.ncbi.nlm.nih.gov/20527888

DMWB07I	DI	DMWB07I
DMWB07I	DN	Alpha-Sulfanylbenzylphosphonic acid
DMWB07I	MI	TTHI19T
DMWB07I	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMWB07I	MT	DTT
DMWB07I	MA	Inhibitor
DMWB07I	RN	Mercaptophosphonate compounds as broad-spectrum inhibitors of the metallo-beta-lactamases. J Med Chem. 2010 Jul 8;53(13):4862-76.
DMWB07I	RU	https://pubmed.ncbi.nlm.nih.gov/20527888

DM19NAI	DI	DM19NAI
DM19NAI	DN	Alpha-Sulfanylpropylphosphonic acid
DM19NAI	MI	TTHI19T
DM19NAI	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DM19NAI	MT	DTT
DM19NAI	MA	Inhibitor
DM19NAI	RN	Mercaptophosphonate compounds as broad-spectrum inhibitors of the metallo-beta-lactamases. J Med Chem. 2010 Jul 8;53(13):4862-76.
DM19NAI	RU	https://pubmed.ncbi.nlm.nih.gov/20527888

DMDI2KH	DI	DMDI2KH
DMDI2KH	DN	alsterpaullone 2-cyanoethyl
DMDI2KH	MI	TTH6V3D
DMDI2KH	MN	Cyclin-dependent kinase 1 (CDK1)
DMDI2KH	MT	DTT
DMDI2KH	MA	Inhibitor
DMDI2KH	RN	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
DMDI2KH	RU	https://pubmed.ncbi.nlm.nih.gov/18077363

DMDI2KH	DI	DMDI2KH
DMDI2KH	DN	alsterpaullone 2-cyanoethyl
DMDI2KH	MI	TTRSMW9
DMDI2KH	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMDI2KH	MT	DTT
DMDI2KH	MA	Inhibitor
DMDI2KH	RN	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
DMDI2KH	RU	https://pubmed.ncbi.nlm.nih.gov/18077363

DM2FLDJ	DI	DM2FLDJ
DM2FLDJ	DN	Alstiphyllanine D
DM2FLDJ	MI	TTF8JAT
DM2FLDJ	MN	SLC5A2 messenger RNA (SLC5A2 mRNA)
DM2FLDJ	MT	DTT
DM2FLDJ	MA	Inhibitor
DM2FLDJ	RN	Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter. Bioorg Med Chem. 2010 Mar 15;18(6):2152-2158.
DM2FLDJ	RU	https://pubmed.ncbi.nlm.nih.gov/20189404

DM2FLDJ	DI	DM2FLDJ
DM2FLDJ	DN	Alstiphyllanine D
DM2FLDJ	MI	TT2UE56
DM2FLDJ	MN	Sodium/glucose cotransporter 1 (SGLT1)
DM2FLDJ	MT	DTT
DM2FLDJ	MA	Inhibitor
DM2FLDJ	RN	Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter. Bioorg Med Chem. 2010 Mar 15;18(6):2152-2158.
DM2FLDJ	RU	https://pubmed.ncbi.nlm.nih.gov/20189404

DMTNQ5E	DI	DMTNQ5E
DMTNQ5E	DN	Alstiphyllanine E
DMTNQ5E	MI	TTF8JAT
DMTNQ5E	MN	SLC5A2 messenger RNA (SLC5A2 mRNA)
DMTNQ5E	MT	DTT
DMTNQ5E	MA	Inhibitor
DMTNQ5E	RN	Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter. Bioorg Med Chem. 2010 Mar 15;18(6):2152-2158.
DMTNQ5E	RU	https://pubmed.ncbi.nlm.nih.gov/20189404

DMTNQ5E	DI	DMTNQ5E
DMTNQ5E	DN	Alstiphyllanine E
DMTNQ5E	MI	TT2UE56
DMTNQ5E	MN	Sodium/glucose cotransporter 1 (SGLT1)
DMTNQ5E	MT	DTT
DMTNQ5E	MA	Inhibitor
DMTNQ5E	RN	Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter. Bioorg Med Chem. 2010 Mar 15;18(6):2152-2158.
DMTNQ5E	RU	https://pubmed.ncbi.nlm.nih.gov/20189404

DMKRAEW	DI	DMKRAEW
DMKRAEW	DN	Alstiphyllanine F
DMKRAEW	MI	TTF8JAT
DMKRAEW	MN	SLC5A2 messenger RNA (SLC5A2 mRNA)
DMKRAEW	MT	DTT
DMKRAEW	MA	Inhibitor
DMKRAEW	RN	Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter. Bioorg Med Chem. 2010 Mar 15;18(6):2152-2158.
DMKRAEW	RU	https://pubmed.ncbi.nlm.nih.gov/20189404

DMKRAEW	DI	DMKRAEW
DMKRAEW	DN	Alstiphyllanine F
DMKRAEW	MI	TT2UE56
DMKRAEW	MN	Sodium/glucose cotransporter 1 (SGLT1)
DMKRAEW	MT	DTT
DMKRAEW	MA	Inhibitor
DMKRAEW	RN	Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter. Bioorg Med Chem. 2010 Mar 15;18(6):2152-2158.
DMKRAEW	RU	https://pubmed.ncbi.nlm.nih.gov/20189404

DMBGAWI	DI	DMBGAWI
DMBGAWI	DN	ALTANSERIN
DMBGAWI	MI	TTJQOD7
DMBGAWI	MN	5-HT 2A receptor (HTR2A)
DMBGAWI	MT	DTT
DMBGAWI	MA	Inhibitor
DMBGAWI	RN	Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET. Bioorg Med Chem. 2009 Apr 15;17(8):2989-3002.
DMBGAWI	RU	https://pubmed.ncbi.nlm.nih.gov/19329329

DMYCS0B	DI	DMYCS0B
DMYCS0B	DN	ALTENUSIN
DMYCS0B	MI	TTL53M6
DMYCS0B	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DMYCS0B	MT	DTT
DMYCS0B	MA	Inhibitor
DMYCS0B	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMYCS0B	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMDLN9S	DI	DMDLN9S
DMDLN9S	DN	ALTU-236
DMDLN9S	MI	TTGSVH2
DMDLN9S	MN	Phenylalanine hydroxylase (PAH)
DMDLN9S	MT	DTT
DMDLN9S	MA	Modulator
DMDLN9S	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1240).
DMDLN9S	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1240

DMP26K9	DI	DMP26K9
DMP26K9	DN	Alx 1393
DMP26K9	MI	TTI0138
DMP26K9	MN	Glycine transporter-2 (SLC6A5)
DMP26K9	MT	DTT
DMP26K9	MA	Inhibitor
DMP26K9	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 936).
DMP26K9	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=936

DMFVGXW	DI	DMFVGXW
DMFVGXW	DN	AM-1241
DMFVGXW	MI	TT6OEDT
DMFVGXW	MN	Cannabinoid receptor 1 (CB1)
DMFVGXW	MT	DTT
DMFVGXW	MA	Inhibitor
DMFVGXW	RN	Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity. J Med Chem. 2010 Jan 14;53(1):295-315.
DMFVGXW	RU	https://pubmed.ncbi.nlm.nih.gov/19921781

DMFVGXW	DI	DMFVGXW
DMFVGXW	DN	AM-1241
DMFVGXW	MI	TTMSFAW
DMFVGXW	MN	Cannabinoid receptor 2 (CB2)
DMFVGXW	MT	DTT
DMFVGXW	MA	Inhibitor
DMFVGXW	RN	Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity. J Med Chem. 2010 Jan 14;53(1):295-315.
DMFVGXW	RU	https://pubmed.ncbi.nlm.nih.gov/19921781

DMGCOQF	DI	DMGCOQF
DMGCOQF	DN	AM-156
DMGCOQF	MI	TTQDMX5
DMGCOQF	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMGCOQF	MT	DTT
DMGCOQF	MA	Antagonist
DMGCOQF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 339).
DMGCOQF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=339

DMO7QUP	DI	DMO7QUP
DMO7QUP	DN	AM-1710
DMO7QUP	MI	TT6OEDT
DMO7QUP	MN	Cannabinoid receptor 1 (CB1)
DMO7QUP	MT	DTT
DMO7QUP	MA	Inhibitor
DMO7QUP	RN	Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. J Med Chem. 2007 Dec 27;50(26):6493-500.
DMO7QUP	RU	https://pubmed.ncbi.nlm.nih.gov/18038967

DMO7QUP	DI	DMO7QUP
DMO7QUP	DN	AM-1710
DMO7QUP	MI	TTMSFAW
DMO7QUP	MN	Cannabinoid receptor 2 (CB2)
DMO7QUP	MT	DTT
DMO7QUP	MA	Inhibitor
DMO7QUP	RN	Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. J Med Chem. 2007 Dec 27;50(26):6493-500.
DMO7QUP	RU	https://pubmed.ncbi.nlm.nih.gov/18038967

DMW9ERM	DI	DMW9ERM
DMW9ERM	DN	AM-1714
DMW9ERM	MI	TT6OEDT
DMW9ERM	MN	Cannabinoid receptor 1 (CB1)
DMW9ERM	MT	DTT
DMW9ERM	MA	Inhibitor
DMW9ERM	RN	Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. J Med Chem. 2007 Dec 27;50(26):6493-500.
DMW9ERM	RU	https://pubmed.ncbi.nlm.nih.gov/18038967

DMW9ERM	DI	DMW9ERM
DMW9ERM	DN	AM-1714
DMW9ERM	MI	TTMSFAW
DMW9ERM	MN	Cannabinoid receptor 2 (CB2)
DMW9ERM	MT	DTT
DMW9ERM	MA	Inhibitor
DMW9ERM	RN	Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. J Med Chem. 2007 Dec 27;50(26):6493-500.
DMW9ERM	RU	https://pubmed.ncbi.nlm.nih.gov/18038967

DMKJQZ4	DI	DMKJQZ4
DMKJQZ4	DN	AM-1715
DMKJQZ4	MI	TT6OEDT
DMKJQZ4	MN	Cannabinoid receptor 1 (CB1)
DMKJQZ4	MT	DTT
DMKJQZ4	MA	Inhibitor
DMKJQZ4	RN	Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. J Med Chem. 2007 Dec 27;50(26):6493-500.
DMKJQZ4	RU	https://pubmed.ncbi.nlm.nih.gov/18038967

DMKJQZ4	DI	DMKJQZ4
DMKJQZ4	DN	AM-1715
DMKJQZ4	MI	TTMSFAW
DMKJQZ4	MN	Cannabinoid receptor 2 (CB2)
DMKJQZ4	MT	DTT
DMKJQZ4	MA	Inhibitor
DMKJQZ4	RN	Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. J Med Chem. 2007 Dec 27;50(26):6493-500.
DMKJQZ4	RU	https://pubmed.ncbi.nlm.nih.gov/18038967

DMTAWHL	DI	DMTAWHL
DMTAWHL	DN	AM251
DMTAWHL	MI	TT6OEDT
DMTAWHL	MN	Cannabinoid receptor 1 (CB1)
DMTAWHL	MT	DTT
DMTAWHL	MA	Antagonist
DMTAWHL	RN	Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception. J Pharmacol Exp Ther. 2004 Apr;309(1):56-63.
DMTAWHL	RU	https://pubmed.ncbi.nlm.nih.gov/14718591

DMOKN27	DI	DMOKN27
DMOKN27	DN	AM-281
DMOKN27	MI	TT6OEDT
DMOKN27	MN	Cannabinoid receptor 1 (CB1)
DMOKN27	MT	DTT
DMOKN27	MA	Inhibitor
DMOKN27	RN	Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists. Bioorg Med Chem. 2009 Apr 1;17(7):2842-51.
DMOKN27	RU	https://pubmed.ncbi.nlm.nih.gov/19278853

DMOKN27	DI	DMOKN27
DMOKN27	DN	AM-281
DMOKN27	MI	TTMSFAW
DMOKN27	MN	Cannabinoid receptor 2 (CB2)
DMOKN27	MT	DTT
DMOKN27	MA	Inhibitor
DMOKN27	RN	Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists. Bioorg Med Chem. 2009 Apr 1;17(7):2842-51.
DMOKN27	RU	https://pubmed.ncbi.nlm.nih.gov/19278853

DMZ46GI	DI	DMZ46GI
DMZ46GI	DN	AM-2S
DMZ46GI	MI	TTUZ2L5
DMZ46GI	MN	Matrix metalloproteinase-3 (MMP-3)
DMZ46GI	MT	DTT
DMZ46GI	MA	Inhibitor
DMZ46GI	RN	Synthesis of hydroxypyrone- and hydroxythiopyrone-based matrix metalloproteinase inhibitors: developing a structure-activity relationship. Bioorg Med Chem Lett. 2009 Apr 1;19(7):1970-6.
DMZ46GI	RU	https://pubmed.ncbi.nlm.nih.gov/19261472

DMZVLJH	DI	DMZVLJH
DMZVLJH	DN	AM-3701
DMZVLJH	MI	TTDZN01
DMZVLJH	MN	Cathepsin K (CTSK)
DMZVLJH	MT	DTT
DMZVLJH	MA	Inhibitor
DMZVLJH	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2350).
DMZVLJH	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2350

DM2AOF8	DI	DM2AOF8
DM2AOF8	DN	AM-3840
DM2AOF8	MI	TTUMQVO
DM2AOF8	MN	Cathepsin S (CTSS)
DM2AOF8	MT	DTT
DM2AOF8	MA	Inhibitor
DM2AOF8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2353).
DM2AOF8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2353

DMBK9PS	DI	DMBK9PS
DMBK9PS	DN	AM-404
DMBK9PS	MI	TT6OEDT
DMBK9PS	MN	Cannabinoid receptor 1 (CB1)
DMBK9PS	MT	DTT
DMBK9PS	MA	Inhibitor
DMBK9PS	RN	Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. J Med Chem. 1996 Oct 25;39(22):4515-9.
DMBK9PS	RU	https://pubmed.ncbi.nlm.nih.gov/8893848

DMBK9PS	DI	DMBK9PS
DMBK9PS	DN	AM-404
DMBK9PS	MI	TTMSFAW
DMBK9PS	MN	Cannabinoid receptor 2 (CB2)
DMBK9PS	MT	DTT
DMBK9PS	MA	Inhibitor
DMBK9PS	RN	New analgesics synthetically derived from the paracetamol metabolite N-(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide. J Med Chem. 2008 Dec 25;51(24):7800-5.
DMBK9PS	RU	https://pubmed.ncbi.nlm.nih.gov/19053765

DMBK9PS	DI	DMBK9PS
DMBK9PS	DN	AM-404
DMBK9PS	MI	TTDP1UC
DMBK9PS	MN	Fatty acid amide hydrolase (FAAH)
DMBK9PS	MT	DTT
DMBK9PS	MA	Inhibitor
DMBK9PS	RN	New analgesics synthetically derived from the paracetamol metabolite N-(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide. J Med Chem. 2008 Dec 25;51(24):7800-5.
DMBK9PS	RU	https://pubmed.ncbi.nlm.nih.gov/19053765

DMU3Y4J	DI	DMU3Y4J
DMU3Y4J	DN	AM-411
DMU3Y4J	MI	TT6OEDT
DMU3Y4J	MN	Cannabinoid receptor 1 (CB1)
DMU3Y4J	MT	DTT
DMU3Y4J	MA	Inhibitor
DMU3Y4J	RN	Heteroadamantyl cannabinoids. J Med Chem. 2010 Aug 12;53(15):5656-66.
DMU3Y4J	RU	https://pubmed.ncbi.nlm.nih.gov/20593789

DMU3Y4J	DI	DMU3Y4J
DMU3Y4J	DN	AM-411
DMU3Y4J	MI	TTMSFAW
DMU3Y4J	MN	Cannabinoid receptor 2 (CB2)
DMU3Y4J	MT	DTT
DMU3Y4J	MA	Inhibitor
DMU3Y4J	RN	Heteroadamantyl cannabinoids. J Med Chem. 2010 Aug 12;53(15):5656-66.
DMU3Y4J	RU	https://pubmed.ncbi.nlm.nih.gov/20593789

DMETXA8	DI	DMETXA8
DMETXA8	DN	AM-4768
DMETXA8	MI	TT6OEDT
DMETXA8	MN	Cannabinoid receptor 1 (CB1)
DMETXA8	MT	DTT
DMETXA8	MA	Inhibitor
DMETXA8	RN	Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. J Med Chem. 2007 Dec 27;50(26):6493-500.
DMETXA8	RU	https://pubmed.ncbi.nlm.nih.gov/18038967

DMETXA8	DI	DMETXA8
DMETXA8	DN	AM-4768
DMETXA8	MI	TTMSFAW
DMETXA8	MN	Cannabinoid receptor 2 (CB2)
DMETXA8	MT	DTT
DMETXA8	MA	Inhibitor
DMETXA8	RN	Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. J Med Chem. 2007 Dec 27;50(26):6493-500.
DMETXA8	RU	https://pubmed.ncbi.nlm.nih.gov/18038967

DM7R605	DI	DM7R605
DM7R605	DN	AM-630
DM7R605	MI	TT6OEDT
DM7R605	MN	Cannabinoid receptor 1 (CB1)
DM7R605	MT	DTT
DM7R605	MA	Inhibitor
DM7R605	RN	New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6505-10.
DM7R605	RU	https://pubmed.ncbi.nlm.nih.gov/17942307

DM7R605	DI	DM7R605
DM7R605	DN	AM-630
DM7R605	MI	TTMSFAW
DM7R605	MN	Cannabinoid receptor 2 (CB2)
DM7R605	MT	DTT
DM7R605	MA	Inhibitor
DM7R605	RN	New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6505-10.
DM7R605	RU	https://pubmed.ncbi.nlm.nih.gov/17942307

DMYVQFN	DI	DMYVQFN
DMYVQFN	DN	AM7
DMYVQFN	MI	TTNDSF4
DMYVQFN	MN	Proto-oncogene c-Met (MET)
DMYVQFN	MT	DTT
DMYVQFN	MA	Inhibitor
DMYVQFN	RN	c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J Biol Chem. 2008 Feb 1;283(5):2675-83.
DMYVQFN	RU	https://pubmed.ncbi.nlm.nih.gov/18055465

DM5JZUB	DI	DM5JZUB
DM5JZUB	DN	AMA
DM5JZUB	MI	TTV9GOF
DM5JZUB	MN	Histidine decarboxylase (HDC)
DM5JZUB	MT	DTT
DM5JZUB	MA	Inhibitor
DM5JZUB	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1274).
DM5JZUB	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1274

DMW9TRD	DI	DMW9TRD
DMW9TRD	DN	AMA-237
DMW9TRD	MI	TTZN7RP
DMW9TRD	MN	Rho-associated protein kinase 1 (ROCK1)
DMW9TRD	MT	DTT
DMW9TRD	MA	Inhibitor
DMW9TRD	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1503).
DMW9TRD	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1503

DMW9TRD	DI	DMW9TRD
DMW9TRD	DN	AMA-237
DMW9TRD	MI	TTGWKQJ
DMW9TRD	MN	Rho-associated protein kinase 2 (ROCK2)
DMW9TRD	MT	DTT
DMW9TRD	MA	Inhibitor
DMW9TRD	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1504).
DMW9TRD	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1504

DMIZQOG	DI	DMIZQOG
DMIZQOG	DN	AMA37
DMIZQOG	MI	TTK3PY9
DMIZQOG	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMIZQOG	MT	DTT
DMIZQOG	MA	Inhibitor
DMIZQOG	RN	Inhibition of mammalian target of rapamycin signaling by 2-(morpholin-1-yl)pyrimido[2,1-alpha]isoquinolin-4-one. J Biol Chem. 2007 Aug 17;282(33):24463-70.
DMIZQOG	RU	https://pubmed.ncbi.nlm.nih.gov/17562705

DM59IT4	DI	DM59IT4
DM59IT4	DN	Amanitin
DM59IT4	MI	DT9C1TS
DM59IT4	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM59IT4	MT	DTP
DM59IT4	MA	Substrate
DM59IT4	RN	Molecular characterization and inhibition of amanitin uptake into human hepatocytes. Toxicol Sci. 2006 May;91(1):140-9.
DM59IT4	RU	http://www.ncbi.nlm.nih.gov/pubmed/16495352

DML9W2V	DI	DML9W2V
DML9W2V	DN	Amarylline
DML9W2V	MI	TTOA6YT
DML9W2V	MN	MERS-CoV RNA-directed RNA polymerase (RdRp)
DML9W2V	MT	DTT
DML9W2V	MA	Inhibitor
DML9W2V	RN	Lycorine: A prospective natural lead for anticancer drug discovery. Biomed Pharmacother. 2018 Nov;107:615-624.
DML9W2V	RU	https://pubmed.ncbi.nlm.nih.gov/30114645

DMAVC9T	DI	DMAVC9T
DMAVC9T	DN	AMBAZONE
DMAVC9T	MI	TTUTN1I
DMAVC9T	MN	Human Deoxyribonucleic acid (hDNA)
DMAVC9T	MT	DTT
DMAVC9T	MA	Binder
DMAVC9T	RN	Ambazone as a membrane active antitumor drug. Biophys Chem. 1990 Apr;35(2-3):287-300.
DMAVC9T	RU	https://pubmed.ncbi.nlm.nih.gov/2204445

DM75UK8	DI	DM75UK8
DM75UK8	DN	AMD3101
DM75UK8	MI	TT2BVUA
DM75UK8	MN	C-X-C chemokine receptor type 6 (CXCR6)
DM75UK8	MT	DTT
DM75UK8	MA	Antagonist
DM75UK8	RN	Opportunities and challenges in targeting HIV entry. Curr Opin Pharmacol. 2002 Oct;2(5):529-33.
DM75UK8	RU	https://pubmed.ncbi.nlm.nih.gov/12324254

DMLRNV2	DI	DMLRNV2
DMLRNV2	DN	AMENTOFLAVONE
DMLRNV2	MI	TT1MPAY
DMLRNV2	MN	GABA(A) receptor alpha-1 (GABRA1)
DMLRNV2	MT	DTT
DMLRNV2	MA	Inhibitor
DMLRNV2	RN	Semisynthetic preparation of amentoflavone: A negative modulator at GABA(A) receptors. Bioorg Med Chem Lett. 2003 Jul 21;13(14):2281-4.
DMLRNV2	RU	https://pubmed.ncbi.nlm.nih.gov/12824018

DMLRNV2	DI	DMLRNV2
DMLRNV2	DN	AMENTOFLAVONE
DMLRNV2	MI	TTBMV1G
DMLRNV2	MN	GABA(A) receptor alpha-2 (GABRA2)
DMLRNV2	MT	DTT
DMLRNV2	MA	Inhibitor
DMLRNV2	RN	Semisynthetic preparation of amentoflavone: A negative modulator at GABA(A) receptors. Bioorg Med Chem Lett. 2003 Jul 21;13(14):2281-4.
DMLRNV2	RU	https://pubmed.ncbi.nlm.nih.gov/12824018

DMLRNV2	DI	DMLRNV2
DMLRNV2	DN	AMENTOFLAVONE
DMLRNV2	MI	TT37EDJ
DMLRNV2	MN	GABA(A) receptor alpha-3 (GABRA3)
DMLRNV2	MT	DTT
DMLRNV2	MA	Inhibitor
DMLRNV2	RN	Semisynthetic preparation of amentoflavone: A negative modulator at GABA(A) receptors. Bioorg Med Chem Lett. 2003 Jul 21;13(14):2281-4.
DMLRNV2	RU	https://pubmed.ncbi.nlm.nih.gov/12824018

DMLRNV2	DI	DMLRNV2
DMLRNV2	DN	AMENTOFLAVONE
DMLRNV2	MI	TTNZPQ1
DMLRNV2	MN	GABA(A) receptor alpha-5 (GABRA5)
DMLRNV2	MT	DTT
DMLRNV2	MA	Inhibitor
DMLRNV2	RN	Semisynthetic preparation of amentoflavone: A negative modulator at GABA(A) receptors. Bioorg Med Chem Lett. 2003 Jul 21;13(14):2281-4.
DMLRNV2	RU	https://pubmed.ncbi.nlm.nih.gov/12824018

DMLRNV2	DI	DMLRNV2
DMLRNV2	DN	AMENTOFLAVONE
DMLRNV2	MI	TTZA1NY
DMLRNV2	MN	GABA(A) receptor beta-2 (GABRB2)
DMLRNV2	MT	DTT
DMLRNV2	MA	Inhibitor
DMLRNV2	RN	Semisynthetic preparation of amentoflavone: A negative modulator at GABA(A) receptors. Bioorg Med Chem Lett. 2003 Jul 21;13(14):2281-4.
DMLRNV2	RU	https://pubmed.ncbi.nlm.nih.gov/12824018

DMLRNV2	DI	DMLRNV2
DMLRNV2	DN	AMENTOFLAVONE
DMLRNV2	MI	TT06RH5
DMLRNV2	MN	GABA(A) receptor gamma-2 (GABRG2)
DMLRNV2	MT	DTT
DMLRNV2	MA	Inhibitor
DMLRNV2	RN	Semisynthetic preparation of amentoflavone: A negative modulator at GABA(A) receptors. Bioorg Med Chem Lett. 2003 Jul 21;13(14):2281-4.
DMLRNV2	RU	https://pubmed.ncbi.nlm.nih.gov/12824018

DMLRNV2	DI	DMLRNV2
DMLRNV2	DN	AMENTOFLAVONE
DMLRNV2	MI	TTNJYV2
DMLRNV2	MN	Gamma-aminobutyric acid receptor (GAR)
DMLRNV2	MT	DTT
DMLRNV2	MA	Inhibitor
DMLRNV2	RN	Semisynthetic preparation of amentoflavone: A negative modulator at GABA(A) receptors. Bioorg Med Chem Lett. 2003 Jul 21;13(14):2281-4.
DMLRNV2	RU	https://pubmed.ncbi.nlm.nih.gov/12824018

DMLRNV2	DI	DMLRNV2
DMLRNV2	DN	AMENTOFLAVONE
DMLRNV2	MI	TTL53M6
DMLRNV2	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DMLRNV2	MT	DTT
DMLRNV2	MA	Inhibitor
DMLRNV2	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMLRNV2	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMLRNV2	DI	DMLRNV2
DMLRNV2	DN	AMENTOFLAVONE
DMLRNV2	MI	TT7RJY8
DMLRNV2	MN	Xanthine dehydrogenase/oxidase (XDH)
DMLRNV2	MT	DTT
DMLRNV2	MA	Inhibitor
DMLRNV2	RN	Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod. 1988 Mar-Apr;51(2):345-8.
DMLRNV2	RU	https://pubmed.ncbi.nlm.nih.gov/3379415

DMDRSFE	DI	DMDRSFE
DMDRSFE	DN	Ametantrone
DMDRSFE	MI	TT0IHXV
DMDRSFE	MN	DNA topoisomerase II (TOP2)
DMDRSFE	MT	DTT
DMDRSFE	MA	Intercalator
DMDRSFE	RN	Interactions of antitumor agents Ametantrone and Mitoxantrone (Novatrone) with double-stranded DNA. Biochem Pharmacol. 1985 Dec 15;34(24):4203-13.
DMDRSFE	RU	https://pubmed.ncbi.nlm.nih.gov/4074383

DM589XV	DI	DM589XV
DM589XV	DN	AMG 9810
DM589XV	MI	TTMI6F5
DM589XV	MN	Transient receptor potential cation channel V1 (TRPV1)
DM589XV	MT	DTT
DM589XV	MA	Blocker (channel blocker)
DM589XV	RN	AMG 9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyp... J Pharmacol Exp Ther. 2005 Apr;313(1):474-84.
DM589XV	RU	https://pubmed.ncbi.nlm.nih.gov/15615864

DMUONK5	DI	DMUONK5
DMUONK5	DN	amg-1
DMUONK5	MI	TTZJYKH
DMUONK5	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMUONK5	MT	DTT
DMUONK5	MA	Inhibitor
DMUONK5	RN	Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors. Biochim Biophys Acta. 2011 Dec;1814(12):1947-54.
DMUONK5	RU	https://pubmed.ncbi.nlm.nih.gov/21835273

DM9H7AZ	DI	DM9H7AZ
DM9H7AZ	DN	AMG-126737
DM9H7AZ	MI	TTM1TDX
DM9H7AZ	MN	Tryptase alpha/beta-1 (Tryptase)
DM9H7AZ	MT	DTT
DM9H7AZ	MA	Inhibitor
DM9H7AZ	RN	Tryptase inhibition blocks airway inflammation in a mouse asthma model. J Immunol. 2002 Feb 15;168(4):1992-2000.
DM9H7AZ	RU	https://pubmed.ncbi.nlm.nih.gov/11823536

DMU6WR9	DI	DMU6WR9
DMU6WR9	DN	AMG-247
DMU6WR9	MI	TT9JZCK
DMU6WR9	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMU6WR9	MT	DTT
DMU6WR9	MA	Antagonist
DMU6WR9	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 275).
DMU6WR9	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=275

DMRD83Q	DI	DMRD83Q
DMRD83Q	DN	AMG-2504
DMRD83Q	MI	TTELV3W
DMRD83Q	MN	Transformation-sensitive protein p120 (TRPA1)
DMRD83Q	MT	DTT
DMRD83Q	MA	Inhibitor
DMRD83Q	RN	Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents. J Med Chem. 2010 Jul 22;53(14):5085-107. 
DMRD83Q	RU	https://pubmed.ncbi.nlm.nih.gov/20356305

DME04BH	DI	DME04BH
DME04BH	DN	AMG-429
DME04BH	MI	TTUTJGQ
DME04BH	MN	Vascular endothelial growth factor receptor 2 (KDR)
DME04BH	MT	DTT
DME04BH	MA	Inhibitor
DME04BH	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1813).
DME04BH	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1813

DMNEVXT	DI	DMNEVXT
DMNEVXT	DN	AMG-5445
DMNEVXT	MI	TTELV3W
DMNEVXT	MN	Transformation-sensitive protein p120 (TRPA1)
DMNEVXT	MT	DTT
DMNEVXT	MA	Inhibitor
DMNEVXT	RN	Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents. J Med Chem. 2010 Jul 22;53(14):5085-107. 
DMNEVXT	RU	https://pubmed.ncbi.nlm.nih.gov/20356305

DMI39YX	DI	DMI39YX
DMI39YX	DN	AMG-628
DMI39YX	MI	TTMI6F5
DMI39YX	MN	Transient receptor potential cation channel V1 (TRPV1)
DMI39YX	MT	DTT
DMI39YX	MA	Inhibitor
DMI39YX	RN	Novel vanilloid receptor-1 antagonists: 3. The identification of a second-generation clinical candidate with improved physicochemical and pharmacok... J Med Chem. 2007 Jul 26;50(15):3528-39.
DMI39YX	RU	https://pubmed.ncbi.nlm.nih.gov/17585751

DMEVNZI	DI	DMEVNZI
DMEVNZI	DN	AMG-7160
DMEVNZI	MI	TTELV3W
DMEVNZI	MN	Transformation-sensitive protein p120 (TRPA1)
DMEVNZI	MT	DTT
DMEVNZI	MA	Inhibitor
DMEVNZI	RN	Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents. J Med Chem. 2010 Jul 22;53(14):5085-107. 
DMEVNZI	RU	https://pubmed.ncbi.nlm.nih.gov/20356305

DMJ6L9U	DI	DMJ6L9U
DMJ6L9U	DN	AMG7703
DMJ6L9U	MI	TT0FYAN
DMJ6L9U	MN	Free fatty acid receptor 2 (FFAR2)
DMJ6L9U	MT	DTT
DMJ6L9U	MA	Modulator (allosteric modulator)
DMJ6L9U	RN	Extracellular loop 2 of the free fatty acid receptor 2 mediates allosterism of a phenylacetamide ago-allosteric modulator. Mol Pharmacol. 2011 Jul;80(1):163-73.
DMJ6L9U	RU	https://pubmed.ncbi.nlm.nih.gov/21498659

DMNHM1B	DI	DMNHM1B
DMNHM1B	DN	AMG-837
DMNHM1B	MI	TTB8FUC
DMNHM1B	MN	Free fatty acid receptor 1 (GPR40)
DMNHM1B	MT	DTT
DMNHM1B	MA	Agonist
DMNHM1B	RN	Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor. Mol Pharmacol. 2012 Nov;82(5):843-59.
DMNHM1B	RU	https://pubmed.ncbi.nlm.nih.gov/22859723

DMU8M0I	DI	DMU8M0I
DMU8M0I	DN	AMG-8563
DMU8M0I	MI	TTMI6F5
DMU8M0I	MN	Transient receptor potential cation channel V1 (TRPV1)
DMU8M0I	MT	DTT
DMU8M0I	MA	Blocker
DMU8M0I	RN	Analgesic potential of TRPV1 antagonists. Biochem Pharmacol. 2009 Aug 1;78(3):211-6.
DMU8M0I	RU	https://pubmed.ncbi.nlm.nih.gov/19481638

DMKP8L9	DI	DMKP8L9
DMKP8L9	DN	AMG-889436
DMKP8L9	MI	TTPJR0G
DMKP8L9	MN	Glutamate receptor AMPA 4 (GRIA4)
DMKP8L9	MT	DTT
DMKP8L9	MA	Agonist
DMKP8L9	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 447).
DMKP8L9	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=447

DM1J46S	DI	DM1J46S
DM1J46S	DN	AMG-9090
DM1J46S	MI	TTELV3W
DM1J46S	MN	Transformation-sensitive protein p120 (TRPA1)
DM1J46S	MT	DTT
DM1J46S	MA	Inhibitor
DM1J46S	RN	Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents. J Med Chem. 2010 Jul 22;53(14):5085-107. 
DM1J46S	RU	https://pubmed.ncbi.nlm.nih.gov/20356305

DMSQ49N	DI	DMSQ49N
DMSQ49N	DN	AMG-JAK2-01
DMSQ49N	MI	TTRMX3V
DMSQ49N	MN	Janus kinase 2 (JAK-2)
DMSQ49N	MT	DTT
DMSQ49N	MA	Inhibitor
DMSQ49N	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2048).
DMSQ49N	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2048

DM4MXOB	DI	DM4MXOB
DM4MXOB	DN	AMI-1
DM4MXOB	MI	TTVOJAI
DM4MXOB	MN	Protein arginine methyltransferase 1 (PRMT1)
DM4MXOB	MT	DTT
DM4MXOB	MA	Inhibitor
DM4MXOB	RN	Small molecule regulators of protein arginine methyltransferases. J Biol Chem. 2004 Jun 4;279(23):23892-9.
DM4MXOB	RU	https://pubmed.ncbi.nlm.nih.gov/15056663

DMST5VW	DI	DMST5VW
DMST5VW	DN	amidephrine
DMST5VW	MI	TT2NUT5
DMST5VW	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMST5VW	MT	DTT
DMST5VW	MA	Agonist
DMST5VW	RN	Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes. Mol Pharmacol. 1994 Nov;46(5):929-36.
DMST5VW	RU	https://pubmed.ncbi.nlm.nih.gov/7969082

DMJ0BEG	DI	DMJ0BEG
DMJ0BEG	DN	AMIFLAMINE
DMJ0BEG	MI	TTAWNKZ
DMJ0BEG	MN	Norepinephrine transporter (NET)
DMJ0BEG	MT	DTT
DMJ0BEG	MA	Inhibitor
DMJ0BEG	RN	Selective monoamine oxidase inhibitors. 3. Cyclic compounds related to 4-aminophenethylamine. Preparation and neuron-selective action of some 5-(2-... J Med Chem. 1986 Aug;29(8):1406-12.
DMJ0BEG	RU	https://pubmed.ncbi.nlm.nih.gov/3735309

DMNGW2M	DI	DMNGW2M
DMNGW2M	DN	Aminobenzoic acid
DMNGW2M	MI	DEZV4AP
DMNGW2M	MN	RNA cytidine acetyltransferase (hALP)
DMNGW2M	MT	DME
DMNGW2M	MA	Metabolism
DMNGW2M	RN	Leukemia inhibitory factor decreases the arylamine N-acetyltransferase activity in human cumulus granulosa cells. J Assist Reprod Genet. 2001 Dec;18(12):660-4.
DMNGW2M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11808848

DMNGW2M	DI	DMNGW2M
DMNGW2M	DN	Aminobenzoic acid
DMNGW2M	MI	DEYWLRK
DMNGW2M	MN	Sulfotransferase 1A1 (SULT1A1)
DMNGW2M	MT	DME
DMNGW2M	MA	Metabolism
DMNGW2M	RN	Activities of drug metabolizing enzymes in bovine colon epithelial cell cultures. Arch Toxicol. 2003 Nov;77(11):621-9.
DMNGW2M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14508638

DMWYS0Z	DI	DMWYS0Z
DMWYS0Z	DN	Aminobenzolamide derivative
DMWYS0Z	MI	TTHQPL7
DMWYS0Z	MN	Carbonic anhydrase I (CA-I)
DMWYS0Z	MT	DTT
DMWYS0Z	MA	Inhibitor
DMWYS0Z	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides d... Bioorg Med Chem Lett. 2004 Dec 6;14(23):5775-80.
DMWYS0Z	RU	https://pubmed.ncbi.nlm.nih.gov/15501039

DMWYS0Z	DI	DMWYS0Z
DMWYS0Z	DN	Aminobenzolamide derivative
DMWYS0Z	MI	TTANPDJ
DMWYS0Z	MN	Carbonic anhydrase II (CA-II)
DMWYS0Z	MT	DTT
DMWYS0Z	MA	Inhibitor
DMWYS0Z	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides d... Bioorg Med Chem Lett. 2004 Dec 6;14(23):5775-80.
DMWYS0Z	RU	https://pubmed.ncbi.nlm.nih.gov/15501039

DMWYS0Z	DI	DMWYS0Z
DMWYS0Z	DN	Aminobenzolamide derivative
DMWYS0Z	MI	TT2LVK8
DMWYS0Z	MN	Carbonic anhydrase IX (CA-IX)
DMWYS0Z	MT	DTT
DMWYS0Z	MA	Inhibitor
DMWYS0Z	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides d... Bioorg Med Chem Lett. 2004 Dec 6;14(23):5775-80.
DMWYS0Z	RU	https://pubmed.ncbi.nlm.nih.gov/15501039

DMCILV7	DI	DMCILV7
DMCILV7	DN	aminobenzovesamicol
DMCILV7	MI	TTV8KWS
DMCILV7	MN	Vesicular acetylcholine transporter (SLC18A3)
DMCILV7	MT	DTT
DMCILV7	MA	Inhibitor
DMCILV7	RN	Vesamicol analogues as sigma ligands. Molecular determinants of selectivity at the vesamicol receptor. Biochem Pharmacol. 1995 Mar 15;49(6):791-7.
DMCILV7	RU	https://pubmed.ncbi.nlm.nih.gov/7702637

DMT13EW	DI	DMT13EW
DMT13EW	DN	AMINOBENZTROPINE
DMT13EW	MI	TTVBI8W
DMT13EW	MN	Dopamine transporter (DAT)
DMT13EW	MT	DTT
DMT13EW	MA	Inhibitor
DMT13EW	RN	3'-Chloro-3 alpha-(diphenylmethoxy)tropane but not 4'-chloro-3 alpha-(diphenylmethoxy)tropane produces a cocaine-like behavioral profile. J Med Chem. 1997 Mar 14;40(6):851-7.
DMT13EW	RU	https://pubmed.ncbi.nlm.nih.gov/9083473

DMT13EW	DI	DMT13EW
DMT13EW	DN	AMINOBENZTROPINE
DMT13EW	MI	TTZ9SOR
DMT13EW	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMT13EW	MT	DTT
DMT13EW	MA	Inhibitor
DMT13EW	RN	3'-Chloro-3 alpha-(diphenylmethoxy)tropane but not 4'-chloro-3 alpha-(diphenylmethoxy)tropane produces a cocaine-like behavioral profile. J Med Chem. 1997 Mar 14;40(6):851-7.
DMT13EW	RU	https://pubmed.ncbi.nlm.nih.gov/9083473

DMCLVOZ	DI	DMCLVOZ
DMCLVOZ	DN	Aminocarbonyl dihydrogen phosphate
DMCLVOZ	MI	TTZHA0O
DMCLVOZ	MN	Carbonic anhydrase IV (CA-IV)
DMCLVOZ	MT	DTT
DMCLVOZ	MA	Inhibitor
DMCLVOZ	RN	Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with organic phosphates and phosphonates. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1683-6.
DMCLVOZ	RU	https://pubmed.ncbi.nlm.nih.gov/15745821

DM79E2K	DI	DM79E2K
DM79E2K	DN	Aminodeoxykanamycin
DM79E2K	MI	TT38DW5
DM79E2K	MN	Bacterial 16S ribosomal RNA (Bact 16S rRNA)
DM79E2K	MT	DTT
DM79E2K	MA	Inhibitor
DM79E2K	RN	RNA as a target for small molecules. Curr Opin Chem Biol. 2000 Dec;4(6):678-86.
DM79E2K	RU	https://pubmed.ncbi.nlm.nih.gov/11102874

DM7Y6AL	DI	DM7Y6AL
DM7Y6AL	DN	AMINOFENTANYL
DM7Y6AL	MI	TT27RFC
DM7Y6AL	MN	Opioid receptor delta (OPRD1)
DM7Y6AL	MT	DTT
DM7Y6AL	MA	Inhibitor
DM7Y6AL	RN	Synthesis and evaluation of 3-aminopropionyl substituted fentanyl analogues for opioid activity. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4946-50.
DM7Y6AL	RU	https://pubmed.ncbi.nlm.nih.gov/16828552

DM7Y6AL	DI	DM7Y6AL
DM7Y6AL	DN	AMINOFENTANYL
DM7Y6AL	MI	TTKWM86
DM7Y6AL	MN	Opioid receptor mu (MOP)
DM7Y6AL	MT	DTT
DM7Y6AL	MA	Inhibitor
DM7Y6AL	RN	Synthesis and evaluation of 3-aminopropionyl substituted fentanyl analogues for opioid activity. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4946-50.
DM7Y6AL	RU	https://pubmed.ncbi.nlm.nih.gov/16828552

DMUN54G	DI	DMUN54G
DMUN54G	DN	Aminohippuric acid
DMUN54G	MI	DT9NXMV
DMUN54G	MN	ATP-binding cassette sub-family A member 8 (ABCA8)
DMUN54G	MT	DTP
DMUN54G	MA	Substrate
DMUN54G	RN	Functional analysis of ABCA8, a new drug transporter. Biochem Biophys Res Commun. 2002 Oct 18;298(1):41-5.
DMUN54G	RU	http://www.ncbi.nlm.nih.gov/pubmed/12379217

DMUN54G	DI	DMUN54G
DMUN54G	DN	Aminohippuric acid
DMUN54G	MI	DTSYQGK
DMUN54G	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMUN54G	MT	DTP
DMUN54G	MA	Substrate
DMUN54G	RN	ATP-dependent para-aminohippurate transport by apical multidrug resistance protein MRP2. Kidney Int. 2000 Apr;57(4):1636-42.
DMUN54G	RU	http://www.ncbi.nlm.nih.gov/pubmed/10760098

DMUN54G	DI	DMUN54G
DMUN54G	DN	Aminohippuric acid
DMUN54G	MI	DTFI42L
DMUN54G	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMUN54G	MT	DTP
DMUN54G	MA	Substrate
DMUN54G	RN	ATP-dependent para-aminohippurate transport by apical multidrug resistance protein MRP2. Kidney Int. 2000 Apr;57(4):1636-42.
DMUN54G	RU	http://www.ncbi.nlm.nih.gov/pubmed/10760098

DMUN54G	DI	DMUN54G
DMUN54G	DN	Aminohippuric acid
DMUN54G	MI	DTCSGPB
DMUN54G	MN	Multidrug resistance-associated protein 4 (ABCC4)
DMUN54G	MT	DTP
DMUN54G	MA	Substrate
DMUN54G	RN	Contribution of multidrug resistance protein 2 (MRP2/ABCC2) to the renal excretion of p-aminohippurate (PAH) and identification of MRP4 (ABCC4) as a novel PAH transporter. J Am Soc Nephrol. 2004 Nov;15(11):2828-35.
DMUN54G	RU	http://www.ncbi.nlm.nih.gov/pubmed/15504935

DMUN54G	DI	DMUN54G
DMUN54G	DN	Aminohippuric acid
DMUN54G	MI	DTQ23VB
DMUN54G	MN	Organic anion transporter 1 (SLC22A6)
DMUN54G	MT	DTP
DMUN54G	MA	Substrate
DMUN54G	RN	Interactions of human organic anion transporter 1 (hOAT1) with substances associated with forensic toxicology. Leg Med (Tokyo). 2011 Jul;13(4):180-5.
DMUN54G	RU	http://www.ncbi.nlm.nih.gov/pubmed/21561794

DMUN54G	DI	DMUN54G
DMUN54G	DN	Aminohippuric acid
DMUN54G	MI	DTVP67E
DMUN54G	MN	Organic anion transporter 3 (SLC22A8)
DMUN54G	MT	DTP
DMUN54G	MA	Substrate
DMUN54G	RN	Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86.
DMUN54G	RU	http://www.ncbi.nlm.nih.gov/pubmed/11306713

DMUN54G	DI	DMUN54G
DMUN54G	DN	Aminohippuric acid
DMUN54G	MI	DTE2B1D
DMUN54G	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMUN54G	MT	DTP
DMUN54G	MA	Substrate
DMUN54G	RN	Characterization and identification of steroid sulfate transporters of human placenta. Am J Physiol Endocrinol Metab. 2003 Feb;284(2):E390-8.
DMUN54G	RU	http://ajpendo.physiology.org/content/284/2/E390.full

DMUN54G	DI	DMUN54G
DMUN54G	DN	Aminohippuric acid
DMUN54G	MI	DTRF4L3
DMUN54G	MN	Sodium-dependent phosphate transport protein 3 (SLC17A2)
DMUN54G	MT	DTP
DMUN54G	MA	Substrate
DMUN54G	RN	Wide expression of type I Na+-phosphate cotransporter 3 (NPT3/SLC17A2), a membrane potential-driven organic anion transporter. Am J Physiol Cell Physiol. 2015 Jul 15;309(2):C71-80.
DMUN54G	RU	http://www.ncbi.nlm.nih.gov/pubmed/25972451

DMUN54G	DI	DMUN54G
DMUN54G	DN	Aminohippuric acid
DMUN54G	MI	DTFOJL7
DMUN54G	MN	Sodium-dependent phosphate transport protein 4 (SLC17A3)
DMUN54G	MT	DTP
DMUN54G	MA	Substrate
DMUN54G	RN	Human sodium phosphate transporter 4 (hNPT4/SLC17A3) as a common renal secretory pathway for drugs and urate. J Biol Chem. 2010 Nov 5;285(45):35123-32.
DMUN54G	RU	http://www.ncbi.nlm.nih.gov/pubmed/20810651

DMUN54G	DI	DMUN54G
DMUN54G	DN	Aminohippuric acid
DMUN54G	MI	TTTQR47
DMUN54G	MN	Solute carrier family 22 member 8 (SLC22A8)
DMUN54G	MT	DTT
DMUN54G	MA	Inhibitor
DMUN54G	RN	Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members. J Biol Chem. 2007 Aug 17;282(33):23841-53.
DMUN54G	RU	https://pubmed.ncbi.nlm.nih.gov/17553798

DMNX9FC	DI	DMNX9FC
DMNX9FC	DN	Aminomethylcyclohexane
DMNX9FC	MI	TTICX3S
DMNX9FC	MN	Bacterial UDP-N-acetylglucosamine carboxyvinyltransferase (Bact murA)
DMNX9FC	MT	DTT
DMNX9FC	MA	Inhibitor
DMNX9FC	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMNX9FC	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMHNDTW	DI	DMHNDTW
DMHNDTW	DN	aminooxyacetic acid
DMHNDTW	MI	TTVZJ7G
DMHNDTW	MN	Cystathionine beta-synthase (CBS)
DMHNDTW	MT	DTT
DMHNDTW	MA	Inhibitor
DMHNDTW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1443).
DMHNDTW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1443

DMHNDTW	DI	DMHNDTW
DMHNDTW	DN	aminooxyacetic acid
DMHNDTW	MI	TTU507L
DMHNDTW	MN	Cytoplasmic aspartate aminotransferase (GOT1)
DMHNDTW	MT	DTT
DMHNDTW	MA	Inhibitor
DMHNDTW	RN	Aspartate aminotransferase isotope exchange reactions: implications for glutamate/glutamine shuttle hypothesis. Am J Physiol Cell Physiol. 2002 Jun;282(6):C1404-13.
DMHNDTW	RU	https://pubmed.ncbi.nlm.nih.gov/11997255

DMEMCQ9	DI	DMEMCQ9
DMEMCQ9	DN	Aminophenol
DMEMCQ9	MI	DED5UR3
DMEMCQ9	MN	Sulfotransferase 1B1 (SULT1B1)
DMEMCQ9	MT	DME
DMEMCQ9	MA	Metabolism
DMEMCQ9	RN	Comparison of 2-aminophenol and 4-nitrophenol as in vitro probe substrates for the major human hepatic sulfotransferase, SULT1A1, demonstrates improved selectivity with 2-aminophenol. Biochem Pharmacol. 2007 Jul 15;74(2):352-8.
DMEMCQ9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17506995

DMT5HOA	DI	DMT5HOA
DMT5HOA	DN	amino-propylphosphinic acid
DMT5HOA	MI	TTDCVZW
DMT5HOA	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMT5HOA	MT	DTT
DMT5HOA	MA	Agonist
DMT5HOA	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 242).
DMT5HOA	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=242

DMKLC3O	DI	DMKLC3O
DMKLC3O	DN	aminopurvalanol A
DMKLC3O	MI	TTH6V3D
DMKLC3O	MN	Cyclin-dependent kinase 1 (CDK1)
DMKLC3O	MT	DTT
DMKLC3O	MA	Inhibitor
DMKLC3O	RN	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
DMKLC3O	RU	https://pubmed.ncbi.nlm.nih.gov/18077363

DMKLC3O	DI	DMKLC3O
DMKLC3O	DN	aminopurvalanol A
DMKLC3O	MI	TT7HF4W
DMKLC3O	MN	Cyclin-dependent kinase 2 (CDK2)
DMKLC3O	MT	DTT
DMKLC3O	MA	Inhibitor
DMKLC3O	RN	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
DMKLC3O	RU	https://pubmed.ncbi.nlm.nih.gov/18077363

DMKLC3O	DI	DMKLC3O
DMKLC3O	DN	aminopurvalanol A
DMKLC3O	MI	TTL4Q97
DMKLC3O	MN	Cyclin-dependent kinase 5 (CDK5)
DMKLC3O	MT	DTT
DMKLC3O	MA	Inhibitor
DMKLC3O	RN	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
DMKLC3O	RU	https://pubmed.ncbi.nlm.nih.gov/18077363

DM94KQP	DI	DM94KQP
DM94KQP	DN	Aminopyridine deriv. 2
DM94KQP	MI	TT3IVG2
DM94KQP	MN	JNK2 messenger RNA (JNK2 mRNA)
DM94KQP	MT	DTT
DM94KQP	MA	Inhibitor
DM94KQP	RN	Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006 Jun 15;49(12):3563-80.
DM94KQP	RU	https://pubmed.ncbi.nlm.nih.gov/16759099

DM94KQP	DI	DM94KQP
DM94KQP	DN	Aminopyridine deriv. 2
DM94KQP	MI	TT0K6EO
DM94KQP	MN	Stress-activated protein kinase JNK1 (JNK1)
DM94KQP	MT	DTT
DM94KQP	MA	Inhibitor
DM94KQP	RN	Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006 Jun 15;49(12):3563-80.
DM94KQP	RU	https://pubmed.ncbi.nlm.nih.gov/16759099

DM94KQP	DI	DM94KQP
DM94KQP	DN	Aminopyridine deriv. 2
DM94KQP	MI	TT056SO
DM94KQP	MN	Stress-activated protein kinase JNK3 (JNK3)
DM94KQP	MT	DTT
DM94KQP	MA	Inhibitor
DM94KQP	RN	Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006 Jun 15;49(12):3563-80.
DM94KQP	RU	https://pubmed.ncbi.nlm.nih.gov/16759099

DMGEVBH	DI	DMGEVBH
DMGEVBH	DN	Aminothiazoline
DMGEVBH	MI	TTF10I9
DMGEVBH	MN	Nitric-oxide synthase inducible (NOS2)
DMGEVBH	MT	DTT
DMGEVBH	MA	Inhibitor
DMGEVBH	RN	The design, synthesis and biological evaluation of 7-alkoxy-4-heteroarylamino-3-cyanoquinolines as dual inhibitors of c-Src and iNOS. Bioorg Med Chem Lett. 2008 Dec 1;18(23):6206-9.
DMGEVBH	RU	https://pubmed.ncbi.nlm.nih.gov/18930653

DMXDUCP	DI	DMXDUCP
DMXDUCP	DN	AMN082
DMXDUCP	MI	TT0I76D
DMXDUCP	MN	Metabotropic glutamate receptor 7 (mGluR7)
DMXDUCP	MT	DTT
DMXDUCP	MA	Modulator (allosteric modulator)
DMXDUCP	RN	A selective metabotropic glutamate receptor 7 agonist: activation of receptor signaling via an allosteric site modulates stress parameters in vivo. Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18712-7.
DMXDUCP	RU	https://pubmed.ncbi.nlm.nih.gov/16339898

DMC15DM	DI	DMC15DM
DMC15DM	DN	Amooranin
DMC15DM	MI	TTEVCT0
DMC15DM	MN	Caspase-8 (CASP8)
DMC15DM	MT	DTT
DMC15DM	MA	Inhibitor
DMC15DM	RN	Glionitrin A, a new diketopiperazine disulfide, activates ATM-ATR-Chk1/2 via 53BP1 phosphorylation in DU145 cells and shows antitumor effect in xenograft model. Biol Pharm Bull. 2014;37(3):378-86.
DMC15DM	RU	https://pubmed.ncbi.nlm.nih.gov/24583858

DM64X25	DI	DM64X25
DM64X25	DN	AMPE4L
DM64X25	MI	TTVIMDE
DM64X25	MN	Glucagon-like peptide 1 receptor (GLP1R)
DM64X25	MT	DTT
DM64X25	MA	Modulator
DM64X25	RN	2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006).
DM64X25	RU	http://www.nature.com/nrd/journal/v11/n1/full/nrd3645.html

DM64X25	DI	DM64X25
DM64X25	DN	AMPE4L
DM64X25	MI	TT0HD6V
DM64X25	MN	Leptin receptor (LEPR)
DM64X25	MT	DTT
DM64X25	MA	Modulator
DM64X25	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1712).
DM64X25	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1712

DMVHOQE	DI	DMVHOQE
DMVHOQE	DN	AMPPL
DMVHOQE	MI	TT0HD6V
DMVHOQE	MN	Leptin receptor (LEPR)
DMVHOQE	MT	DTT
DMVHOQE	MA	Modulator
DMVHOQE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1712).
DMVHOQE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1712

DMTOK1D	DI	DMTOK1D
DMTOK1D	DN	AMP-PNP
DMTOK1D	MI	TTSEOPJ
DMTOK1D	MN	Bacterial Pantothenate kinase (Bact coaA)
DMTOK1D	MT	DTT
DMTOK1D	MA	Inhibitor
DMTOK1D	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMTOK1D	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMTOK1D	DI	DMTOK1D
DMTOK1D	DN	AMP-PNP
DMTOK1D	MI	TTC0G1L
DMTOK1D	MN	DNA repair protein RAD51 homolog 1 (RAD51)
DMTOK1D	MT	DTT
DMTOK1D	MA	Inhibitor
DMTOK1D	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMTOK1D	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMTOK1D	DI	DMTOK1D
DMTOK1D	DN	AMP-PNP
DMTOK1D	MI	TT0IHXV
DMTOK1D	MN	DNA topoisomerase II (TOP2)
DMTOK1D	MT	DTT
DMTOK1D	MA	Inhibitor
DMTOK1D	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMTOK1D	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMTOK1D	DI	DMTOK1D
DMTOK1D	DN	AMP-PNP
DMTOK1D	MI	TT4NVEM
DMTOK1D	MN	DNA topoisomerase II beta (TOP2B)
DMTOK1D	MT	DTT
DMTOK1D	MA	Inhibitor
DMTOK1D	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMTOK1D	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMTOK1D	DI	DMTOK1D
DMTOK1D	DN	AMP-PNP
DMTOK1D	MI	TTRJB2G
DMTOK1D	MN	Ephrin type-A receptor 2 (EPHA2)
DMTOK1D	MT	DTT
DMTOK1D	MA	Inhibitor
DMTOK1D	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMTOK1D	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMTOK1D	DI	DMTOK1D
DMTOK1D	DN	AMP-PNP
DMTOK1D	MI	TTKPV6O
DMTOK1D	MN	Ephrin type-B receptor 2 (EPHB2)
DMTOK1D	MT	DTT
DMTOK1D	MA	Inhibitor
DMTOK1D	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMTOK1D	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMTOK1D	DI	DMTOK1D
DMTOK1D	DN	AMP-PNP
DMTOK1D	MI	TTRSMW9
DMTOK1D	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMTOK1D	MT	DTT
DMTOK1D	MA	Inhibitor
DMTOK1D	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMTOK1D	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMTOK1D	DI	DMTOK1D
DMTOK1D	DN	AMP-PNP
DMTOK1D	MI	TTHRID2
DMTOK1D	MN	Insulin-like growth factor I receptor (IGF1R)
DMTOK1D	MT	DTT
DMTOK1D	MA	Inhibitor
DMTOK1D	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMTOK1D	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMTOK1D	DI	DMTOK1D
DMTOK1D	DN	AMP-PNP
DMTOK1D	MI	TT860QF
DMTOK1D	MN	LCK tyrosine protein kinase (LCK)
DMTOK1D	MT	DTT
DMTOK1D	MA	Inhibitor
DMTOK1D	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMTOK1D	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMTOK1D	DI	DMTOK1D
DMTOK1D	DN	AMP-PNP
DMTOK1D	MI	TTJ2HKA
DMTOK1D	MN	Long transient receptor potential channel 4 (TRPM4)
DMTOK1D	MT	DTT
DMTOK1D	MA	Inhibitor (gating inhibitor)
DMTOK1D	RN	Intracellular nucleotides and polyamines inhibit the Ca2+-activated cation channel TRPM4b. Pflugers Arch. 2004 Apr;448(1):70-5.
DMTOK1D	RU	https://pubmed.ncbi.nlm.nih.gov/14758478

DMTOK1D	DI	DMTOK1D
DMTOK1D	DN	AMP-PNP
DMTOK1D	MI	TTYT93M
DMTOK1D	MN	MAP kinase p38 (MAPK12)
DMTOK1D	MT	DTT
DMTOK1D	MA	Inhibitor
DMTOK1D	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMTOK1D	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMTOK1D	DI	DMTOK1D
DMTOK1D	DN	AMP-PNP
DMTOK1D	MI	TT5B8AX
DMTOK1D	MN	Mycobacterium Thymidine monophosphate kinase (MycB tmk)
DMTOK1D	MT	DTT
DMTOK1D	MA	Inhibitor
DMTOK1D	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMTOK1D	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMTOK1D	DI	DMTOK1D
DMTOK1D	DN	AMP-PNP
DMTOK1D	MI	TT056SO
DMTOK1D	MN	Stress-activated protein kinase JNK3 (JNK3)
DMTOK1D	MT	DTT
DMTOK1D	MA	Inhibitor
DMTOK1D	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMTOK1D	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMXRIUT	DI	DMXRIUT
DMXRIUT	DN	AMPSL
DMXRIUT	MI	TT0HD6V
DMXRIUT	MN	Leptin receptor (LEPR)
DMXRIUT	MT	DTT
DMXRIUT	MA	Modulator
DMXRIUT	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1712).
DMXRIUT	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1712

DM7WTKJ	DI	DM7WTKJ
DM7WTKJ	DN	AMR-SIX-1
DM7WTKJ	MI	TTJS8PY
DM7WTKJ	MN	5-HT 6 receptor (HTR6)
DM7WTKJ	MT	DTT
DM7WTKJ	MA	Modulator
DM7WTKJ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 11).
DM7WTKJ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=11

DMO7EBX	DI	DMO7EBX
DMO7EBX	DN	AMSH
DMO7EBX	MI	TTD0CIQ
DMO7EBX	MN	Melanocortin receptor 4 (MC4R)
DMO7EBX	MT	DTT
DMO7EBX	MA	Agonist
DMO7EBX	RN	Designing drugs for the treatment of female sexual dysfunction. Drug Discov Today. 2007 Sep;12(17-18):757-66.
DMO7EBX	RU	https://pubmed.ncbi.nlm.nih.gov/17826689

DM4OCAH	DI	DM4OCAH
DM4OCAH	DN	AMTB
DM4OCAH	MI	TTXDKTO
DM4OCAH	MN	Long transient receptor potential channel 8 (TRPM8)
DM4OCAH	MT	DTT
DM4OCAH	MA	Blocker (channel blocker)
DM4OCAH	RN	AMTB, a TRPM8 channel blocker: evidence in rats for activity in overactive bladder and painful bladder syndrome. Am J Physiol Renal Physiol. 2008 Sep;295(3):F803-10.
DM4OCAH	RU	https://pubmed.ncbi.nlm.nih.gov/18562636

DMBAX3P	DI	DMBAX3P
DMBAX3P	DN	amthamine
DMBAX3P	MI	TTQHJ1K
DMBAX3P	MN	Histamine H2 receptor (H2R)
DMBAX3P	MT	DTT
DMBAX3P	MA	Agonist
DMBAX3P	RN	N(G)-acylated aminothiazolylpropylguanidines as potent and selective histamine H(2) receptor agonists. ChemMedChem. 2009 Feb;4(2):232-40.
DMBAX3P	RU	https://pubmed.ncbi.nlm.nih.gov/19072936

DMGHXQE	DI	DMGHXQE
DMGHXQE	DN	AMX-256
DMGHXQE	MI	TT1YWO5
DMGHXQE	MN	Glucagon-like peptide 2 receptor (GLP2R)
DMGHXQE	MT	DTT
DMGHXQE	MA	Modulator
DMGHXQE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 250).
DMGHXQE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=250

DMPSRZ0	DI	DMPSRZ0
DMPSRZ0	DN	AMXT-1501
DMPSRZ0	MI	TTUMGNO
DMPSRZ0	MN	Ornithine decarboxylase (ODC1)
DMPSRZ0	MT	DTT
DMPSRZ0	MA	Inhibitor
DMPSRZ0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1276).
DMPSRZ0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1276

DM7SHQ1	DI	DM7SHQ1
DM7SHQ1	DN	Amythiamicin
DM7SHQ1	MI	TTG45NU
DM7SHQ1	MN	Plasmodium Elongation factor 1-alpha 1 (Malaria MEF-1)
DM7SHQ1	MT	DTT
DM7SHQ1	MA	Binder
DM7SHQ1	RN	The apicoplast as an antimalarial drug target. Drug Resist Updat. 2001 Jun;4(3):145-51.
DM7SHQ1	RU	https://pubmed.ncbi.nlm.nih.gov/11768328

DMRS0LA	DI	DMRS0LA
DMRS0LA	DN	AN-207
DMRS0LA	MI	TT8R70G
DMRS0LA	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMRS0LA	MT	DTT
DMRS0LA	MA	Inhibitor
DMRS0LA	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 256).
DMRS0LA	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=256

DMIY134	DI	DMIY134
DMIY134	DN	ANA-04
DMIY134	MI	TT69OHW
DMIY134	MN	Interleukin 17 receptor (IL17R)
DMIY134	MT	DTT
DMIY134	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2294).
DMIY134	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2294

DM3DPSO	DI	DM3DPSO
DM3DPSO	DN	ANA-5
DM3DPSO	MI	TTE4KHA
DM3DPSO	MN	Amyloid beta A4 protein (APP)
DM3DPSO	MT	DTT
DM3DPSO	MA	Inhibitor
DM3DPSO	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
DM3DPSO	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402

DMAS5BI	DI	DMAS5BI
DMAS5BI	DN	anacardic acid
DMAS5BI	MI	TTVK7SB
DMAS5BI	MN	Histone acetyltransferase KAT2B (KAT2B)
DMAS5BI	MT	DTT
DMAS5BI	MA	Inhibitor
DMAS5BI	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2737).
DMAS5BI	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2737

DMAS5BI	DI	DMAS5BI
DMAS5BI	DN	anacardic acid
DMAS5BI	MI	TTH4VJL
DMAS5BI	MN	Histone acetyltransferase KAT6B (KAT6B)
DMAS5BI	MT	DTT
DMAS5BI	MA	Inhibitor
DMAS5BI	RN	Small molecule modulators of histone acetyltransferase p300. J Biol Chem. 2003 May 23;278(21):19134-40.
DMAS5BI	RU	https://pubmed.ncbi.nlm.nih.gov/12624111

DMMKGT4	DI	DMMKGT4
DMMKGT4	DN	analog 3 (Vlattas et al., 1996)
DMMKGT4	MI	TTE5J6X
DMMKGT4	MN	Diphosphomevalonate decarboxylase (MVD)
DMMKGT4	MT	DTT
DMMKGT4	MA	Inhibitor
DMMKGT4	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 642).
DMMKGT4	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=642

DMYW5JX	DI	DMYW5JX
DMYW5JX	DN	ANALOG OF DYNORPHIN A
DMYW5JX	MI	TT27RFC
DMYW5JX	MN	Opioid receptor delta (OPRD1)
DMYW5JX	MT	DTT
DMYW5JX	MA	Inhibitor
DMYW5JX	RN	Design and synthesis of highly potent and selective cyclic dynorphin A analogs. 2. New analogs. J Med Chem. 1993 Mar 19;36(6):750-7.
DMYW5JX	RU	https://pubmed.ncbi.nlm.nih.gov/8096246

DM5JN3P	DI	DM5JN3P
DM5JN3P	DN	ANALOGUE A
DM5JN3P	MI	TTTSOUD
DM5JN3P	MN	Candida Cytochrome P450 51 (Candi ERG11)
DM5JN3P	MT	DTT
DM5JN3P	MA	Inhibitor
DM5JN3P	RN	Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors. Drug Metab Dispos. 2007 Mar;35(3):493-500.
DM5JN3P	RU	https://pubmed.ncbi.nlm.nih.gov/17194716

DMCKH3P	DI	DMCKH3P
DMCKH3P	DN	Anandamide
DMCKH3P	MI	TT6OEDT
DMCKH3P	MN	Cannabinoid receptor 1 (CB1)
DMCKH3P	MT	DTT
DMCKH3P	MA	Agonist
DMCKH3P	RN	Opioid receptor and NO/cGMP pathway as a mechanism of peripheral antinociceptive action of the cannabinoid receptor agonist anandamide. Life Sci. 2009 Aug 26;85(9-10):351-6.
DMCKH3P	RU	https://pubmed.ncbi.nlm.nih.gov/19576231

DMX4P5A	DI	DMX4P5A
DMX4P5A	DN	andarine
DMX4P5A	MI	TTKPW01
DMX4P5A	MN	Androgen receptor messenger RNA (AR mRNA)
DMX4P5A	MT	DTT
DMX4P5A	MA	Agonist
DMX4P5A	RN	Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. J Med Chem. 2009 Jun 25;52(12):3597-617.
DMX4P5A	RU	https://pubmed.ncbi.nlm.nih.gov/19432422

DMHL0ID	DI	DMHL0ID
DMHL0ID	DN	Andromustine
DMHL0ID	MI	TTS64P2
DMHL0ID	MN	Androgen receptor (AR)
DMHL0ID	MT	DTT
DMHL0ID	MA	Modulator
DMHL0ID	RN	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
DMHL0ID	RU	https://www.ncbi.nlm.nih.gov/pubmed/27899562

DMPXF5I	DI	DMPXF5I
DMPXF5I	DN	androstanol
DMPXF5I	MI	TTRANFM
DMPXF5I	MN	Orphan nuclear receptor NR1I3 (NR1I3)
DMPXF5I	MT	DTT
DMPXF5I	MA	Antagonist
DMPXF5I	RN	Androstane metabolites bind to and deactivate the nuclear receptor CAR-beta. Nature. 1998 Oct 8;395(6702):612-5.
DMPXF5I	RU	https://pubmed.ncbi.nlm.nih.gov/9783588

DMPL0BA	DI	DMPL0BA
DMPL0BA	DN	ANDROSTENEDONE
DMPL0BA	MI	TTSZLWK
DMPL0BA	MN	Aromatase (CYP19A1)
DMPL0BA	MT	DTT
DMPL0BA	MA	Inhibitor
DMPL0BA	RN	Effects of steroid D-ring modification on suicide inactivation and competitive inhibition of aromatase by analogues of androsta-1,4-diene-3,17-dione. J Med Chem. 1989 Mar;32(3):651-8.
DMPL0BA	RU	https://pubmed.ncbi.nlm.nih.gov/2918514

DM7RXQ6	DI	DM7RXQ6
DM7RXQ6	DN	androstenol
DM7RXQ6	MI	TTRANFM
DM7RXQ6	MN	Orphan nuclear receptor NR1I3 (NR1I3)
DM7RXQ6	MT	DTT
DM7RXQ6	MA	Antagonist
DM7RXQ6	RN	Androstane metabolites bind to and deactivate the nuclear receptor CAR-beta. Nature. 1998 Oct 8;395(6702):612-5.
DM7RXQ6	RU	https://pubmed.ncbi.nlm.nih.gov/9783588

DMK1IMC	DI	DMK1IMC
DMK1IMC	DN	ANG-2004
DMK1IMC	MI	TT0HD6V
DMK1IMC	MN	Leptin receptor (LEPR)
DMK1IMC	MT	DTT
DMK1IMC	MA	Modulator
DMK1IMC	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1712).
DMK1IMC	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1712

DMDLVH5	DI	DMDLVH5
DMDLVH5	DN	ANG-2684
DMDLVH5	MI	TTVDSZ0
DMDLVH5	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMDLVH5	MT	DTT
DMDLVH5	MA	Inhibitor
DMDLVH5	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2771).
DMDLVH5	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2771

DMQ2TNL	DI	DMQ2TNL
DMQ2TNL	DN	ANG-2864
DMQ2TNL	MI	TTVDSZ0
DMQ2TNL	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMQ2TNL	MT	DTT
DMQ2TNL	MA	Inhibitor
DMQ2TNL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2771).
DMQ2TNL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2771

DMVI93X	DI	DMVI93X
DMVI93X	DN	ANG-3407
DMVI93X	MI	TTRA5BZ
DMVI93X	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMVI93X	MT	DTT
DMVI93X	MA	Inhibitor
DMVI93X	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1361).
DMVI93X	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1361

DM3KZ7P	DI	DM3KZ7P
DM3KZ7P	DN	Angiostatin/paclitaxel/carboplatin
DM3KZ7P	MI	TT63KYR
DM3KZ7P	MN	Tubulin beta-1 chain (TUBB1)
DM3KZ7P	MT	DTT
DM3KZ7P	MA	Modulator
DM3KZ7P	RN	Intravenous hydrophobic drug delivery: a porous particle formulation of paclitaxel (AI-850). Pharm Res. 2005 Mar;22(3):347-55.
DM3KZ7P	RU	https://pubmed.ncbi.nlm.nih.gov/15835739

DMYK0Z9	DI	DMYK0Z9
DMYK0Z9	DN	angiotensin III
DMYK0Z9	MI	TT8DBY3
DMYK0Z9	MN	Angiotensin II receptor type-1 (AGTR1)
DMYK0Z9	MT	DTT
DMYK0Z9	MA	Agonist
DMYK0Z9	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 34).
DMYK0Z9	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=34

DMYK0Z9	DI	DMYK0Z9
DMYK0Z9	DN	angiotensin III
DMYK0Z9	MI	TTQVOEI
DMYK0Z9	MN	Angiotensin II receptor type-2 (AGTR2)
DMYK0Z9	MT	DTT
DMYK0Z9	MA	Agonist
DMYK0Z9	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 35).
DMYK0Z9	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=35

DMR9OD1	DI	DMR9OD1
DMR9OD1	DN	Angiotensin IV
DMR9OD1	MI	TTPHMWB
DMR9OD1	MN	Aminopeptidase N (ANPEP)
DMR9OD1	MT	DTT
DMR9OD1	MA	Inhibitor
DMR9OD1	RN	Ligands to the (IRAP)/AT4 receptor encompassing a 4-hydroxydiphenylmethane scaffold replacing Tyr2. Bioorg Med Chem. 2008 Jul 15;16(14):6924-35.
DMR9OD1	RU	https://pubmed.ncbi.nlm.nih.gov/18556208

DMGRWA3	DI	DMGRWA3
DMGRWA3	DN	ANHYDRORYANIDINE
DMGRWA3	MI	TTU5CIX
DMGRWA3	MN	Ryanodine receptor 1 (RYR1)
DMGRWA3	MT	DTT
DMGRWA3	MA	Inhibitor
DMGRWA3	RN	Amino- and guanidinoacylryanodines: basic ryanodine esters with enhanced affinity for the sarcoplasmic reticulum Ca(2+)-release channel. J Med Chem. 1993 May 14;36(10):1319-23.
DMGRWA3	RU	https://pubmed.ncbi.nlm.nih.gov/8388466

DMJX1G9	DI	DMJX1G9
DMJX1G9	DN	ANIBAMINE
DMJX1G9	MI	TT2CEJG
DMJX1G9	MN	C-C chemokine receptor type 5 (CCR5)
DMJX1G9	MT	DTT
DMJX1G9	MA	Inhibitor
DMJX1G9	RN	Isolation and structure of antagonists of chemokine receptor (CCR5). J Nat Prod. 2004 Jun;67(6):1036-8.
DMJX1G9	RU	https://pubmed.ncbi.nlm.nih.gov/15217290

DMJCWXK	DI	DMJCWXK
DMJCWXK	DN	Anidulafungin
DMJCWXK	MI	TTV1095
DMJCWXK	MN	COVID-19 RNA-directed RNA polymerase (RdRp)
DMJCWXK	MT	DTT
DMJCWXK	MA	Inhibitor
DMJCWXK	RN	Suramin, Penciclovir and Anidulafungin bind nsp12, which governs the RNA-dependent-RNA polymerase activity of SARS-CoV-2, with higher interaction energy than Remdesivir, indicating potential in the treatment of Covid-19 infection. April.21.2020. Doi: 10.31219/osf.io/urxwh
DMJCWXK	RU	https://osf.io/urxwh

DMLCAR9	DI	DMLCAR9
DMLCAR9	DN	Aniline
DMLCAR9	MI	DE4OGUF
DMLCAR9	MN	Cytochrome P450 102A1 (cyp102)
DMLCAR9	MT	DME
DMLCAR9	MA	Metabolism
DMLCAR9	RN	nan
DMLCAR9	RU	nan

DMHA9S3	DI	DMHA9S3
DMHA9S3	DN	ANISOCOUMARIN H
DMHA9S3	MI	TTQW87Y
DMHA9S3	MN	Opioid receptor kappa (OPRK1)
DMHA9S3	MT	DTT
DMHA9S3	MA	Inhibitor
DMHA9S3	RN	Novel coumarin glycoside and phenethyl vanillate from Notopterygium forbesii and their binding affinities for opioid and dopamine receptors. Bioorg Med Chem. 2008 Mar 15;16(6):3218-23.
DMHA9S3	RU	https://pubmed.ncbi.nlm.nih.gov/18166466

DMZKC7S	DI	DMZKC7S
DMZKC7S	DN	Ankinara
DMZKC7S	MI	TTT0Q1F
DMZKC7S	MN	Interleukin-10 (IL10)
DMZKC7S	MT	DTT
DMZKC7S	MA	Activator
DMZKC7S	RN	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
DMZKC7S	RU	https://pubmed.ncbi.nlm.nih.gov/16634702

DM0RUQ8	DI	DM0RUQ8
DM0RUQ8	DN	ANNULIN A
DM0RUQ8	MI	TTZJYKH
DM0RUQ8	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DM0RUQ8	MT	DTT
DM0RUQ8	MA	Inhibitor
DM0RUQ8	RN	Indoleamine 2,3-dioxygenase inhibitors from the Northeastern Pacific Marine Hydroid Garveia annulata. J Nat Prod. 2006 Oct;69(10):1496-9.
DM0RUQ8	RU	https://pubmed.ncbi.nlm.nih.gov/17067170

DMDQXJ2	DI	DMDQXJ2
DMDQXJ2	DN	ANNULIN B
DMDQXJ2	MI	TTZJYKH
DMDQXJ2	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMDQXJ2	MT	DTT
DMDQXJ2	MA	Inhibitor
DMDQXJ2	RN	Indoleamine 2,3-dioxygenase inhibitors from the Northeastern Pacific Marine Hydroid Garveia annulata. J Nat Prod. 2006 Oct;69(10):1496-9.
DMDQXJ2	RU	https://pubmed.ncbi.nlm.nih.gov/17067170

DMTYQDO	DI	DMTYQDO
DMTYQDO	DN	ANNULIN C
DMTYQDO	MI	TTZJYKH
DMTYQDO	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMTYQDO	MT	DTT
DMTYQDO	MA	Inhibitor
DMTYQDO	RN	Indoleamine 2,3-dioxygenase inhibitors from the Northeastern Pacific Marine Hydroid Garveia annulata. J Nat Prod. 2006 Oct;69(10):1496-9.
DMTYQDO	RU	https://pubmed.ncbi.nlm.nih.gov/17067170

DM6DYZ0	DI	DM6DYZ0
DM6DYZ0	DN	ANOLOBINE
DM6DYZ0	MI	TTEX248
DM6DYZ0	MN	Dopamine D2 receptor (D2R)
DM6DYZ0	MT	DTT
DM6DYZ0	MA	Inhibitor
DM6DYZ0	RN	Advances in development of dopaminergic aporphinoids. J Med Chem. 2007 Jan 25;50(2):171-81.
DM6DYZ0	RU	https://pubmed.ncbi.nlm.nih.gov/17228858

DM6DYZ0	DI	DM6DYZ0
DM6DYZ0	DN	ANOLOBINE
DM6DYZ0	MI	TTVBI8W
DM6DYZ0	MN	Dopamine transporter (DAT)
DM6DYZ0	MT	DTT
DM6DYZ0	MA	Inhibitor
DM6DYZ0	RN	Effects of various isoquinoline alkaloids on in vitro 3H-dopamine uptake by rat striatal synaptosomes. J Nat Prod. 1995 Oct;58(10):1475-84.
DM6DYZ0	RU	https://pubmed.ncbi.nlm.nih.gov/8676127

DMM5PEV	DI	DMM5PEV
DMM5PEV	DN	ANONAINE
DMM5PEV	MI	TTEX248
DMM5PEV	MN	Dopamine D2 receptor (D2R)
DMM5PEV	MT	DTT
DMM5PEV	MA	Inhibitor
DMM5PEV	RN	Advances in development of dopaminergic aporphinoids. J Med Chem. 2007 Jan 25;50(2):171-81.
DMM5PEV	RU	https://pubmed.ncbi.nlm.nih.gov/17228858

DMM5PEV	DI	DMM5PEV
DMM5PEV	DN	ANONAINE
DMM5PEV	MI	TTVBI8W
DMM5PEV	MN	Dopamine transporter (DAT)
DMM5PEV	MT	DTT
DMM5PEV	MA	Inhibitor
DMM5PEV	RN	Effects of various isoquinoline alkaloids on in vitro 3H-dopamine uptake by rat striatal synaptosomes. J Nat Prod. 1995 Oct;58(10):1475-84.
DMM5PEV	RU	https://pubmed.ncbi.nlm.nih.gov/8676127

DMGDZ6Q	DI	DMGDZ6Q
DMGDZ6Q	DN	Antanal 1
DMGDZ6Q	MI	TT27RFC
DMGDZ6Q	MN	Opioid receptor delta (OPRD1)
DMGDZ6Q	MT	DTT
DMGDZ6Q	MA	Inhibitor
DMGDZ6Q	RN	Novel opioid peptide derived antagonists containing (2S)-2-methyl-3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid [(2S)-Mdcp]. J Med Chem. 2008 Sep 25;51(18):5866-70.
DMGDZ6Q	RU	https://pubmed.ncbi.nlm.nih.gov/18800771

DMGDZ6Q	DI	DMGDZ6Q
DMGDZ6Q	DN	Antanal 1
DMGDZ6Q	MI	TTKWM86
DMGDZ6Q	MN	Opioid receptor mu (MOP)
DMGDZ6Q	MT	DTT
DMGDZ6Q	MA	Inhibitor
DMGDZ6Q	RN	Novel opioid peptide derived antagonists containing (2S)-2-methyl-3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid [(2S)-Mdcp]. J Med Chem. 2008 Sep 25;51(18):5866-70.
DMGDZ6Q	RU	https://pubmed.ncbi.nlm.nih.gov/18800771

DMZSUHY	DI	DMZSUHY
DMZSUHY	DN	Antanal 2
DMZSUHY	MI	TT27RFC
DMZSUHY	MN	Opioid receptor delta (OPRD1)
DMZSUHY	MT	DTT
DMZSUHY	MA	Inhibitor
DMZSUHY	RN	Novel opioid peptide derived antagonists containing (2S)-2-methyl-3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid [(2S)-Mdcp]. J Med Chem. 2008 Sep 25;51(18):5866-70.
DMZSUHY	RU	https://pubmed.ncbi.nlm.nih.gov/18800771

DMZSUHY	DI	DMZSUHY
DMZSUHY	DN	Antanal 2
DMZSUHY	MI	TTKWM86
DMZSUHY	MN	Opioid receptor mu (MOP)
DMZSUHY	MT	DTT
DMZSUHY	MA	Inhibitor
DMZSUHY	RN	Novel opioid peptide derived antagonists containing (2S)-2-methyl-3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid [(2S)-Mdcp]. J Med Chem. 2008 Sep 25;51(18):5866-70.
DMZSUHY	RU	https://pubmed.ncbi.nlm.nih.gov/18800771

DMA7LUR	DI	DMA7LUR
DMA7LUR	DN	ANTAQ
DMA7LUR	MI	TT371QC
DMA7LUR	MN	Puromycin-sensitive aminopeptidase (NPEPPS)
DMA7LUR	MT	DTT
DMA7LUR	MA	Inhibitor
DMA7LUR	RN	Fluorescent bioprobes for visualization of puromycin-sensitive aminopeptidase in living cells. Bioorg Med Chem Lett. 2003 Jan 6;13(1):83-6.
DMA7LUR	RU	https://pubmed.ncbi.nlm.nih.gov/12467622

DM7TOGW	DI	DM7TOGW
DM7TOGW	DN	antarelix
DM7TOGW	MI	TT8R70G
DM7TOGW	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DM7TOGW	MT	DTT
DM7TOGW	MA	Antagonist
DM7TOGW	RN	Characterization of gonadotropin-releasing hormone analogs based on a sensitive cellular luciferase reporter gene assay. Anal Biochem. 1997 Aug 15;251(1):17-23.
DM7TOGW	RU	https://pubmed.ncbi.nlm.nih.gov/9300077

DMRQVW9	DI	DMRQVW9
DMRQVW9	DN	Anthoptilide C
DMRQVW9	MI	TTK25J1
DMRQVW9	MN	Adenosine A1 receptor (ADORA1)
DMRQVW9	MT	DTT
DMRQVW9	MA	Inhibitor
DMRQVW9	RN	Anthoptilides A-E, new Briarane diterpenes from the Australian sea pen Anthoptilum cf. kukenthali. J Nat Prod. 2000 Mar;63(3):318-21.
DMRQVW9	RU	https://pubmed.ncbi.nlm.nih.gov/10757710

DMGEMQX	DI	DMGEMQX
DMGEMQX	DN	Anthracen-10-yl(10H-phenothiazin-10-yl)methanone
DMGEMQX	MI	TTEB0GD
DMGEMQX	MN	Cholinesterase (BCHE)
DMGEMQX	MT	DTT
DMGEMQX	MA	Inhibitor
DMGEMQX	RN	Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. Bioorg Med Chem. 2007 Oct 1;15(19):6367-78.
DMGEMQX	RU	https://pubmed.ncbi.nlm.nih.gov/17681768

DMRC3OU	DI	DMRC3OU
DMRC3OU	DN	Anthracene-2-carboxylic acid hydroxyamide
DMRC3OU	MI	TT2J34L
DMRC3OU	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMRC3OU	MT	DTT
DMRC3OU	MA	Inhibitor
DMRC3OU	RN	Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8.
DMRC3OU	RU	https://pubmed.ncbi.nlm.nih.gov/2308149

DMN1YFU	DI	DMN1YFU
DMN1YFU	DN	Anthraflavic acid
DMN1YFU	MI	DEYGVN4
DMN1YFU	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMN1YFU	MT	DME
DMN1YFU	MA	Metabolism
DMN1YFU	RN	Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Biol Chem. 2004 Jan 9;279(2):1429-41.
DMN1YFU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14557274

DMN1YFU	DI	DMN1YFU
DMN1YFU	DN	Anthraflavic acid
DMN1YFU	MI	DEZO4N3
DMN1YFU	MN	UDP-glucuronosyltransferase 1A7 (UGT1A7)
DMN1YFU	MT	DME
DMN1YFU	MA	Metabolism
DMN1YFU	RN	Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Biol Chem. 2004 Jan 9;279(2):1429-41.
DMN1YFU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14557274

DMN1YFU	DI	DMN1YFU
DMN1YFU	DN	Anthraflavic acid
DMN1YFU	MI	DE2GB8N
DMN1YFU	MN	UDP-glucuronosyltransferase 1A8 (UGT1A8)
DMN1YFU	MT	DME
DMN1YFU	MA	Metabolism
DMN1YFU	RN	Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Biol Chem. 2004 Jan 9;279(2):1429-41.
DMN1YFU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14557274

DMN1YFU	DI	DMN1YFU
DMN1YFU	DN	Anthraflavic acid
DMN1YFU	MI	DE85D2P
DMN1YFU	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMN1YFU	MT	DME
DMN1YFU	MA	Metabolism
DMN1YFU	RN	Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Biol Chem. 2004 Jan 9;279(2):1429-41.
DMN1YFU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14557274

DMNEGHJ	DI	DMNEGHJ
DMNEGHJ	DN	Anthramycin
DMNEGHJ	MI	TTJP4SM
DMNEGHJ	MN	Bacterial Penicillin binding protein (Bact PBP)
DMNEGHJ	MT	DTT
DMNEGHJ	RN	Crystal structure of a covalent DNA-drug adduct: anthramycin bound to C-C-A-A-C-G-T-T-G-G and a molecular explanation of specificity. Biochemistry. 1994 Nov 22;33(46):13593-610.
DMNEGHJ	RU	https://pubmed.ncbi.nlm.nih.gov/7947769

DM29I0Y	DI	DM29I0Y
DM29I0Y	DN	ANTHRAQUINONE
DM29I0Y	MI	TTR0SWN
DM29I0Y	MN	M-phase inducer phosphatase 2 (MPIP2)
DM29I0Y	MT	DTT
DM29I0Y	MA	Inhibitor
DM29I0Y	RN	Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases. Bioorg Med Chem. 2009 Mar 15;17(6):2276-81.
DM29I0Y	RU	https://pubmed.ncbi.nlm.nih.gov/19028102

DMWZ093	DI	DMWZ093
DMWZ093	DN	ANTHRONE
DMWZ093	MI	TT2J34L
DMWZ093	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMWZ093	MT	DTT
DMWZ093	MA	Inhibitor
DMWZ093	RN	Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80.
DMWZ093	RU	https://pubmed.ncbi.nlm.nih.gov/9371243

DM3IOR0	DI	DM3IOR0
DM3IOR0	DN	anti-BrP-LPA
DM3IOR0	MI	TTQ6S1K
DM3IOR0	MN	Lysophosphatidic acid receptor 1 (LPAR1)
DM3IOR0	MT	DTT
DM3IOR0	MA	Antagonist
DM3IOR0	RN	Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res. 2009 Jul 1;69(13):5441-9.
DM3IOR0	RU	https://pubmed.ncbi.nlm.nih.gov/19509223

DMQJ3ZL	DI	DMQJ3ZL
DMQJ3ZL	DN	Anticalin
DMQJ3ZL	MI	TTE4KHA
DMQJ3ZL	MN	Amyloid beta A4 protein (APP)
DMQJ3ZL	MT	DTT
DMQJ3ZL	MA	Inhibitor
DMQJ3ZL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
DMQJ3ZL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402

DMEHRKA	DI	DMEHRKA
DMEHRKA	DN	Anti-CD20 engineered toxin bodies
DMEHRKA	MI	TTUE541
DMEHRKA	MN	Leukocyte surface antigen Leu-16 (CD20)
DMEHRKA	MT	DTT
DMEHRKA	MA	Modulator
DMEHRKA	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628).
DMEHRKA	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2628

DMCYOPR	DI	DMCYOPR
DMCYOPR	DN	Anti-CD-20 mab
DMCYOPR	MI	TTUE541
DMCYOPR	MN	Leukocyte surface antigen Leu-16 (CD20)
DMCYOPR	MT	DTT
DMCYOPR	MA	Inhibitor
DMCYOPR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628).
DMCYOPR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2628

DM8QIB2	DI	DM8QIB2
DM8QIB2	DN	Anti-CD22/CD19 mab-toxin conjugate
DM8QIB2	MI	TTM6QSK
DM8QIB2	MN	B-cell receptor CD22 (CD22)
DM8QIB2	MT	DTT
DM8QIB2	MA	Modulator
DM8QIB2	RN	Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro. Leukemia. 2000 May;14(5):853-8.
DM8QIB2	RU	https://pubmed.ncbi.nlm.nih.gov/10803517

DM8QIB2	DI	DM8QIB2
DM8QIB2	DN	Anti-CD22/CD19 mab-toxin conjugate
DM8QIB2	MI	TTW640A
DM8QIB2	MN	B-lymphocyte surface antigen B4 (CD19)
DM8QIB2	MT	DTT
DM8QIB2	MA	Modulator
DM8QIB2	RN	Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro. Leukemia. 2000 May;14(5):853-8.
DM8QIB2	RU	https://pubmed.ncbi.nlm.nih.gov/10803517

DM5BH7J	DI	DM5BH7J
DM5BH7J	DN	Anti-CD28
DM5BH7J	MI	TTQ13FT
DM5BH7J	MN	T-cell-specific surface glycoprotein CD28 (CD28)
DM5BH7J	MT	DTT
DM5BH7J	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2863).
DM5BH7J	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2863

DMGZM6V	DI	DMGZM6V
DMGZM6V	DN	Anti-CD40-XTEN
DMGZM6V	MI	TTN6Y9A
DMGZM6V	MN	CD40L receptor (CD40)
DMGZM6V	MT	DTT
DMGZM6V	MA	Antagonist
DMGZM6V	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1874).
DMGZM6V	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1874

DM2X1SG	DI	DM2X1SG
DM2X1SG	DN	Anti-cMET mab
DM2X1SG	MI	TTNDSF4
DM2X1SG	MN	Proto-oncogene c-Met (MET)
DM2X1SG	MT	DTT
DM2X1SG	MA	Inhibitor
DM2X1SG	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
DM2X1SG	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815

DMG7PC0	DI	DMG7PC0
DMG7PC0	DN	Anti-D
DMG7PC0	MI	TTEX248
DMG7PC0	MN	Dopamine D2 receptor (D2R)
DMG7PC0	MT	DTT
DMG7PC0	MA	Antagonist
DMG7PC0	RN	Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54.
DMG7PC0	RU	https://pubmed.ncbi.nlm.nih.gov/18537519

DMWLMV2	DI	DMWLMV2
DMWLMV2	DN	Anti-EGFR humanized mabs
DMWLMV2	MI	TTGKNB4
DMWLMV2	MN	Epidermal growth factor receptor (EGFR)
DMWLMV2	MT	DTT
DMWLMV2	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
DMWLMV2	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797

DMW85FP	DI	DMW85FP
DMW85FP	DN	Anti-EGFR mab
DMW85FP	MI	TTGKNB4
DMW85FP	MN	Epidermal growth factor receptor (EGFR)
DMW85FP	MT	DTT
DMW85FP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
DMW85FP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797

DMXWHDC	DI	DMXWHDC
DMXWHDC	DN	Anti-Fas mabs
DMXWHDC	MI	TT7AOUD
DMXWHDC	MN	Fatty acid synthase (FASN)
DMXWHDC	MT	DTT
DMXWHDC	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2608).
DMXWHDC	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2608

DMP5VZQ	DI	DMP5VZQ
DMP5VZQ	DN	Anti-FGFR1 mab program
DMP5VZQ	MI	TTRLW2X
DMP5VZQ	MN	Fibroblast growth factor receptor 1 (FGFR1)
DMP5VZQ	MT	DTT
DMP5VZQ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1808).
DMP5VZQ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1808

DMMQ3WX	DI	DMMQ3WX
DMMQ3WX	DN	Anti-FGFR2 humanized mab
DMMQ3WX	MI	TTGJVQM
DMMQ3WX	MN	Fibroblast growth factor receptor 2 (FGFR2)
DMMQ3WX	MT	DTT
DMMQ3WX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1809).
DMMQ3WX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1809

DM4HKC8	DI	DM4HKC8
DM4HKC8	DN	Anti-GnRH Spiegelmer
DM4HKC8	MI	TT0ID4A
DM4HKC8	MN	Leutinizing-hormone-releasing hormone (GNRH1)
DM4HKC8	MT	DTT
DM4HKC8	MA	Inhibitor
DM4HKC8	RN	In vivo properties of an anti-GnRH Spiegelmer: an example of an oligonucleotide-based therapeutic substance class. Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8898-902.
DM4HKC8	RU	https://pubmed.ncbi.nlm.nih.gov/12070349

DMVF2YH	DI	DMVF2YH
DMVF2YH	DN	Antileukoprotease (ALP)
DMVF2YH	MI	TTE6GTB
DMVF2YH	MN	Kallikrein-7 (KLK7)
DMVF2YH	MT	DTT
DMVF2YH	MA	Inhibitor
DMVF2YH	RN	Expression of the protease inhibitor antileukoprotease and the serine protease stratum corneum chymotryptic enzyme (SCCE) is coordinated in ovarian tumors. Int J Gynecol Cancer. 2001 Nov-Dec;11(6):454-61.
DMVF2YH	RU	https://pubmed.ncbi.nlm.nih.gov/11906548

DMO41UZ	DI	DMO41UZ
DMO41UZ	DN	Anti-miR-191 modified oligonucleotide
DMO41UZ	MI	TT3ULBR
DMO41UZ	MN	microRNA hsa-miR-191 (MIR191)
DMO41UZ	MT	DTT
DMO41UZ	RN	hsa-miR-191 is a candidate oncogene target for hepatocellular carcinoma therapy. Cancer Res. 2010 Oct 15;70(20):8077-87.
DMO41UZ	RU	https://pubmed.ncbi.nlm.nih.gov/20924108

DM2EMCW	DI	DM2EMCW
DM2EMCW	DN	Antimycin A
DM2EMCW	MI	TT3PQ2Y
DM2EMCW	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DM2EMCW	MT	DTT
DM2EMCW	MA	Inhibitor
DM2EMCW	RN	Effects of atovaquone and other inhibitors on Pneumocystis carinii dihydroorotate dehydrogenase. Antimicrob Agents Chemother. 1995 Feb;39(2):325-8.
DM2EMCW	RU	https://pubmed.ncbi.nlm.nih.gov/7726490

DMUESP8	DI	DMUESP8
DMUESP8	DN	ANTIOQUINE
DMUESP8	MI	TTVBI8W
DMUESP8	MN	Dopamine transporter (DAT)
DMUESP8	MT	DTT
DMUESP8	MA	Inhibitor
DMUESP8	RN	Effects of various isoquinoline alkaloids on in vitro 3H-dopamine uptake by rat striatal synaptosomes. J Nat Prod. 1995 Oct;58(10):1475-84.
DMUESP8	RU	https://pubmed.ncbi.nlm.nih.gov/8676127

DM9THZE	DI	DM9THZE
DM9THZE	DN	Antiproliferative Agent A771726
DM9THZE	MI	TT3PQ2Y
DM9THZE	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DM9THZE	MT	DTT
DM9THZE	MA	Inhibitor
DM9THZE	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9THZE	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMO21T7	DI	DMO21T7
DMO21T7	DN	Anti-PSA mabs
DMO21T7	MI	TTS78AZ
DMO21T7	MN	Prostate specific antigen (KLK3)
DMO21T7	MT	DTT
DMO21T7	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2373).
DMO21T7	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2373

DMXACM2	DI	DMXACM2
DMXACM2	DN	Anti-RON receptor mabs
DMXACM2	MI	TTBQ3OC
DMXACM2	MN	Macrophage-stimulating protein receptor (RON)
DMXACM2	MT	DTT
DMXACM2	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1816).
DMXACM2	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1816

DMN76A4	DI	DMN76A4
DMN76A4	DN	Anti-TLR3 mabs
DMN76A4	MI	TTD24Y0
DMN76A4	MN	Toll-like receptor 3 (TLR3)
DMN76A4	MT	DTT
DMN76A4	MA	Modulator
DMN76A4	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1753).
DMN76A4	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1753

DMYKTF6	DI	DMYKTF6
DMYKTF6	DN	Anti-TNF human mabs
DMYKTF6	MI	TTG043C
DMYKTF6	MN	Tumor necrosis factor receptor type I (TNF-R1)
DMYKTF6	MT	DTT
DMYKTF6	RN	Secretion of a TNFR:Fc fusion protein following pulmonary administration of pseudotyped adeno-associated virus vectors. J Virol. 2004 Nov;78(22):12355-65.
DMYKTF6	RU	https://pubmed.ncbi.nlm.nih.gov/15507622

DMAJ6TC	DI	DMAJ6TC
DMAJ6TC	DN	Anti-VEGFR 3 mab
DMAJ6TC	MI	TTDCBX5
DMAJ6TC	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DMAJ6TC	MT	DTT
DMAJ6TC	MA	Inhibitor
DMAJ6TC	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1814).
DMAJ6TC	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1814

DML1PV3	DI	DML1PV3
DML1PV3	DN	Aom-0763
DML1PV3	MI	TT7RJY8
DML1PV3	MN	Xanthine dehydrogenase/oxidase (XDH)
DML1PV3	MT	DTT
DML1PV3	MA	Inhibitor
DML1PV3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2646).
DML1PV3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2646

DMT4I2W	DI	DMT4I2W
DMT4I2W	DN	Aom-0890
DMT4I2W	MI	TTJ0IQB
DMT4I2W	MN	Phosphodiesterase 5A (PDE5A)
DMT4I2W	MT	DTT
DMT4I2W	MA	Inhibitor
DMT4I2W	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1304).
DMT4I2W	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1304

DMHR3ZG	DI	DMHR3ZG
DMHR3ZG	DN	AP-101
DMHR3ZG	MI	TT9VGXW
DMHR3ZG	MN	Angiopoietin 1 receptor (TEK)
DMHR3ZG	MT	DTT
DMHR3ZG	MA	Modulator
DMHR3ZG	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1842).
DMHR3ZG	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1842

DMRZMKT	DI	DMRZMKT
DMRZMKT	DN	AP-1189
DMRZMKT	MI	TT0MV2T
DMRZMKT	MN	Melanocortin receptor 1 (MC1R)
DMRZMKT	MT	DTT
DMRZMKT	MA	Modulator
DMRZMKT	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 282).
DMRZMKT	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=282

DMCNG74	DI	DMCNG74
DMCNG74	DN	AP-21967
DMCNG74	MI	TTCJG29
DMCNG74	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMCNG74	MT	DTT
DMCNG74	MA	Inhibitor
DMCNG74	RN	The rapamycin-binding domain of the protein kinase mammalian target of rapamycin is a destabilizing domain. J Biol Chem. 2007 May 4;282(18):13395-401.
DMCNG74	RU	https://pubmed.ncbi.nlm.nih.gov/17350953

DMQWIEL	DI	DMQWIEL
DMQWIEL	DN	AP-2238
DMQWIEL	MI	TT1RS9F
DMQWIEL	MN	Acetylcholinesterase (AChE)
DMQWIEL	MT	DTT
DMQWIEL	MA	Inhibitor
DMQWIEL	RN	Targeting Alzheimer's disease: Novel indanone hybrids bearing a pharmacophoric fragment of AP2238. Bioorg Med Chem. 2010 Mar 1;18(5):1749-60.
DMQWIEL	RU	https://pubmed.ncbi.nlm.nih.gov/20171894

DMRYL9X	DI	DMRYL9X
DMRYL9X	DN	AP-2243
DMRYL9X	MI	TT1RS9F
DMRYL9X	MN	Acetylcholinesterase (AChE)
DMRYL9X	MT	DTT
DMRYL9X	MA	Inhibitor
DMRYL9X	RN	Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds. Bioorg Med Chem Lett. 2008 Jan 1;18(1):423-6.
DMRYL9X	RU	https://pubmed.ncbi.nlm.nih.gov/17998161

DMRYL9X	DI	DMRYL9X
DMRYL9X	DN	AP-2243
DMRYL9X	MI	TT8JRS7
DMRYL9X	MN	Beta-secretase (BACE)
DMRYL9X	MT	DTT
DMRYL9X	MA	Inhibitor
DMRYL9X	RN	Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds. Bioorg Med Chem Lett. 2008 Jan 1;18(1):423-6.
DMRYL9X	RU	https://pubmed.ncbi.nlm.nih.gov/17998161

DMVT6Y3	DI	DMVT6Y3
DMVT6Y3	DN	AP-24163
DMVT6Y3	MI	TTIV39N
DMVT6Y3	MN	Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I)
DMVT6Y3	MT	DTT
DMVT6Y3	MA	Inhibitor
DMVT6Y3	RN	Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP2453... J Med Chem. 2010 Jun 24;53(12):4701-19.
DMVT6Y3	RU	https://pubmed.ncbi.nlm.nih.gov/20513156

DMVT6Y3	DI	DMVT6Y3
DMVT6Y3	DN	AP-24163
DMVT6Y3	MI	TT6PKBN
DMVT6Y3	MN	Proto-oncogene c-Src (SRC)
DMVT6Y3	MT	DTT
DMVT6Y3	MA	Inhibitor
DMVT6Y3	RN	9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation. J Med Chem. 2009 Aug 13;52(15):4743-56.
DMVT6Y3	RU	https://pubmed.ncbi.nlm.nih.gov/19572547

DMGTEXD	DI	DMGTEXD
DMGTEXD	DN	AP-24226
DMGTEXD	MI	TT6PKBN
DMGTEXD	MN	Proto-oncogene c-Src (SRC)
DMGTEXD	MT	DTT
DMGTEXD	MA	Inhibitor
DMGTEXD	RN	9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation. J Med Chem. 2009 Aug 13;52(15):4743-56.
DMGTEXD	RU	https://pubmed.ncbi.nlm.nih.gov/19572547

DMGTEXD	DI	DMGTEXD
DMGTEXD	DN	AP-24226
DMGTEXD	MI	TT3PJMV
DMGTEXD	MN	Tyrosine-protein kinase ABL1 (ABL)
DMGTEXD	MT	DTT
DMGTEXD	MA	Inhibitor
DMGTEXD	RN	Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP2453... J Med Chem. 2010 Jun 24;53(12):4701-19.
DMGTEXD	RU	https://pubmed.ncbi.nlm.nih.gov/20513156

DMBU942	DI	DMBU942
DMBU942	DN	AP-7
DMBU942	MI	TTLD29N
DMBU942	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMBU942	MT	DTT
DMBU942	MA	Inhibitor
DMBU942	RN	Bioisosteric replacement of the alpha-amino carboxylic acid functionality in 2-amino-5-phosphonopentanoic acid yields unique 3,4-diamino-3-cyclobut... J Med Chem. 1992 Dec 11;35(25):4720-6.
DMBU942	RU	https://pubmed.ncbi.nlm.nih.gov/1361582

DMBU942	DI	DMBU942
DMBU942	DN	AP-7
DMBU942	MI	TTKJEMQ
DMBU942	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMBU942	MT	DTT
DMBU942	MA	Inhibitor
DMBU942	RN	Bioisosteric replacement of the alpha-amino carboxylic acid functionality in 2-amino-5-phosphonopentanoic acid yields unique 3,4-diamino-3-cyclobut... J Med Chem. 1992 Dec 11;35(25):4720-6.
DMBU942	RU	https://pubmed.ncbi.nlm.nih.gov/1361582

DMBU942	DI	DMBU942
DMBU942	DN	AP-7
DMBU942	MI	TTN9D8E
DMBU942	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMBU942	MT	DTT
DMBU942	MA	Inhibitor
DMBU942	RN	Bioisosteric replacement of the alpha-amino carboxylic acid functionality in 2-amino-5-phosphonopentanoic acid yields unique 3,4-diamino-3-cyclobut... J Med Chem. 1992 Dec 11;35(25):4720-6.
DMBU942	RU	https://pubmed.ncbi.nlm.nih.gov/1361582

DMILA4P	DI	DMILA4P
DMILA4P	DN	AP811
DMILA4P	MI	TTWVLS6
DMILA4P	MN	Natriuretic peptide receptor (NPR3)
DMILA4P	MT	DTT
DMILA4P	MA	Antagonist
DMILA4P	RN	The discovery of non-basic atrial natriuretic peptide clearance receptor antagonists. Part 1. Bioorg Med Chem Lett. 2000 Sep 4;10(17):1949-52.
DMILA4P	RU	https://pubmed.ncbi.nlm.nih.gov/10987424

DMVG3K1	DI	DMVG3K1
DMVG3K1	DN	APA
DMVG3K1	MI	TTUMGNO
DMVG3K1	MN	Ornithine decarboxylase (ODC1)
DMVG3K1	MT	DTT
DMVG3K1	MA	Inhibitor
DMVG3K1	RN	2-substituted 3-(aminooxy)propanamines as inhibitors of ornithine decarboxylase: synthesis and biological activity. J Med Chem. 1992 Apr 17;35(8):1339-44.
DMVG3K1	RU	https://pubmed.ncbi.nlm.nih.gov/1573631

DMYNBK5	DI	DMYNBK5
DMYNBK5	DN	Apamin
DMYNBK5	MI	TT9R6BE
DMYNBK5	MN	Calcium-activated potassium channel KCa2.1 (KCNN1)
DMYNBK5	MT	DTT
DMYNBK5	MA	Blocker (channel blocker)
DMYNBK5	RN	Pharmacological characterization of small-conductance Ca(2+)-activated K(+) channels stably expressed in HEK 293 cells. Br J Pharmacol. 2000 Mar;129(5):991-9.
DMYNBK5	RU	https://pubmed.ncbi.nlm.nih.gov/10696100

DMYNBK5	DI	DMYNBK5
DMYNBK5	DN	Apamin
DMYNBK5	MI	TT2T5M0
DMYNBK5	MN	Calcium-activated potassium channel KCa2.2 (KCNN2)
DMYNBK5	MT	DTT
DMYNBK5	MA	Blocker (channel blocker)
DMYNBK5	RN	SK2 encodes the apamin-sensitive Ca(2+)-activated K(+) channels in the human leukemic T cell line, Jurkat. FEBS Lett. 2000 Mar 10;469(2-3):196-202.
DMYNBK5	RU	https://pubmed.ncbi.nlm.nih.gov/10713270

DMYNBK5	DI	DMYNBK5
DMYNBK5	DN	Apamin
DMYNBK5	MI	TT9JH25
DMYNBK5	MN	Calcium-activated potassium channel KCa2.3 (KCNN3)
DMYNBK5	MT	DTT
DMYNBK5	MA	Blocker (channel blocker)
DMYNBK5	RN	SK3 is an important component of K(+) channels mediating the afterhyperpolarization in cultured rat SCG neurones. J Physiol. 2001 Sep 1;535(Pt 2):323-34.
DMYNBK5	RU	https://pubmed.ncbi.nlm.nih.gov/11533126

DMNIEHV	DI	DMNIEHV
DMNIEHV	DN	APC-300
DMNIEHV	MI	TTW2R9X
DMNIEHV	MN	GTPase NRas (NRAS)
DMNIEHV	MT	DTT
DMNIEHV	MA	Inhibitor
DMNIEHV	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2823).
DMNIEHV	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2823

DMT9Z5A	DI	DMT9Z5A
DMT9Z5A	DN	AP-Cav
DMT9Z5A	MI	TTCM4B3
DMT9Z5A	MN	Nitric-oxide synthase endothelial (NOS3)
DMT9Z5A	MT	DTT
DMT9Z5A	MA	Inhibitor
DMT9Z5A	RN	Endothelial nitric oxide synthase: the Cinderella of inflammation Trends Pharmacol Sci. 2003 Feb;24(2):91-5.
DMT9Z5A	RU	https://pubmed.ncbi.nlm.nih.gov/12559774

DMNQ9M1	DI	DMNQ9M1
DMNQ9M1	DN	APCK-110
DMNQ9M1	MI	TTX41N9
DMNQ9M1	MN	Tyrosine-protein kinase Kit (KIT)
DMNQ9M1	MT	DTT
DMNQ9M1	MA	Inhibitor
DMNQ9M1	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1805).
DMNQ9M1	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1805

DM2CKUZ	DI	DM2CKUZ
DM2CKUZ	DN	apelin-13
DM2CKUZ	MI	TTJ8E43
DM2CKUZ	MN	Apelin receptor (APLNR)
DM2CKUZ	MT	DTT
DM2CKUZ	MA	Agonist
DM2CKUZ	RN	Structural and functional study of the apelin-13 peptide, an endogenous ligand of the HIV-1 coreceptor, APJ. Biochemistry. 2003 Sep 2;42(34):10163-8.
DM2CKUZ	RU	https://pubmed.ncbi.nlm.nih.gov/12939143

DM0JW2V	DI	DM0JW2V
DM0JW2V	DN	APETX2
DM0JW2V	MI	TTLGDIS
DM0JW2V	MN	Acid-sensing ion channel 3 (ASIC3)
DM0JW2V	MT	DTT
DM0JW2V	MA	Blocker
DM0JW2V	RN	Challenges in analgesic drug development. Clin Pharmacol Ther. 2009 Oct;86(4):447-50.
DM0JW2V	RU	https://pubmed.ncbi.nlm.nih.gov/19675542

DMR93WE	DI	DMR93WE
DMR93WE	DN	APG-103
DMR93WE	MI	TTF0RCZ
DMR93WE	MN	Apoptosis mediating surface antigen FAS (FAS)
DMR93WE	MT	DTT
DMR93WE	MA	Inhibitor
DMR93WE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1875).
DMR93WE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1875

DM0BVJN	DI	DM0BVJN
DM0BVJN	DN	APG-201
DM0BVJN	MI	TTDWHC3
DM0BVJN	MN	Interleukin 4 receptor alpha (IL4R)
DM0BVJN	MT	DTT
DM0BVJN	MA	Antagonist
DM0BVJN	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1697).
DM0BVJN	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1697

DMBSDTR	DI	DMBSDTR
DMBSDTR	DN	APG-2305
DMBSDTR	MI	TT6H4QR
DMBSDTR	MN	Interleukin 23 receptor (IL23R)
DMBSDTR	MT	DTT
DMBSDTR	MA	Inhibitor
DMBSDTR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2293).
DMBSDTR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2293

DMYGKW7	DI	DMYGKW7
DMYGKW7	DN	APH-0911
DMYGKW7	MI	TTYFKSZ
DMYGKW7	MN	Tubulin beta (TUBB)
DMYGKW7	MT	DTT
DMYGKW7	MA	Modulator
DMYGKW7	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2640).
DMYGKW7	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2640

DM83WVF	DI	DM83WVF
DM83WVF	DN	Apicidin
DM83WVF	MI	TTBH0VX
DM83WVF	MN	Histone deacetylase (HDAC)
DM83WVF	MT	DTT
DM83WVF	MA	Inhibitor
DM83WVF	RN	Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92.
DM83WVF	RU	https://pubmed.ncbi.nlm.nih.gov/17896917

DMI3491	DI	DMI3491
DMI3491	DN	Apigenin
DMI3491	MI	TTFBNVI
DMI3491	MN	Aldose reductase (AKR1B1)
DMI3491	MT	DTT
DMI3491	MA	Inhibitor
DMI3491	RN	Erigeroflavanone, a flavanone derivative from the flowers of Erigeron annuus with protein glycation and aldose reductase inhibitory activity. J Nat Prod. 2008 Apr;71(4):713-5.
DMI3491	RU	https://pubmed.ncbi.nlm.nih.gov/18298080

DMI3491	DI	DMI3491
DMI3491	DN	Apigenin
DMI3491	MI	TTKPW01
DMI3491	MN	Androgen receptor messenger RNA (AR mRNA)
DMI3491	MT	DTT
DMI3491	MA	Inhibitor
DMI3491	RN	Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4706-10.
DMI3491	RU	https://pubmed.ncbi.nlm.nih.gov/19592245

DMI3491	DI	DMI3491
DMI3491	DN	Apigenin
DMI3491	MI	TTSZLWK
DMI3491	MN	Aromatase (CYP19A1)
DMI3491	MT	DTT
DMI3491	MA	Inhibitor
DMI3491	RN	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
DMI3491	RU	https://pubmed.ncbi.nlm.nih.gov/20413308

DMI3491	DI	DMI3491
DMI3491	DN	Apigenin
DMI3491	MI	TTER6YH
DMI3491	MN	Casein kinase II alpha (CSNK2A1)
DMI3491	MT	DTT
DMI3491	MA	Inhibitor
DMI3491	RN	Structural insight into human CK2alpha in complex with the potent inhibitor ellagic acid. Bioorg Med Chem Lett. 2009 Jun 1;19(11):2920-3.
DMI3491	RU	https://pubmed.ncbi.nlm.nih.gov/19414254

DMI3491	DI	DMI3491
DMI3491	DN	Apigenin
DMI3491	MI	TTO0FDJ
DMI3491	MN	Cyclin-dependent kinase 6 (CDK6)
DMI3491	MT	DTT
DMI3491	MA	Inhibitor
DMI3491	RN	Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin. J Med Chem. 2005 Feb 10;48(3):737-43.
DMI3491	RU	https://pubmed.ncbi.nlm.nih.gov/15689157

DMI3491	DI	DMI3491
DMI3491	DN	Apigenin
DMI3491	MI	TTI84H7
DMI3491	MN	Cytochrome P450 1B1 (CYP1B1)
DMI3491	MT	DTT
DMI3491	MA	Inhibitor
DMI3491	RN	Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5.
DMI3491	RU	https://pubmed.ncbi.nlm.nih.gov/20696580

DMI3491	DI	DMI3491
DMI3491	DN	Apigenin
DMI3491	MI	TTIWB6L
DMI3491	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMI3491	MT	DTT
DMI3491	MA	Inhibitor
DMI3491	RN	Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries. J Med Chem. 2008 Jul 24;51(14):4188-99.
DMI3491	RU	https://pubmed.ncbi.nlm.nih.gov/18533708

DMI3491	DI	DMI3491
DMI3491	DN	Apigenin
DMI3491	MI	TT50QJ3
DMI3491	MN	Influenza Neuraminidase (Influ NA)
DMI3491	MT	DTT
DMI3491	MA	Inhibitor
DMI3491	RN	Neuraminidase inhibitory activities of flavonols isolated from Rhodiola rosea roots and their in vitro anti-influenza viral activities. Bioorg Med Chem. 2009 Oct 1;17(19):6816-23.
DMI3491	RU	https://pubmed.ncbi.nlm.nih.gov/19729316

DMI3491	DI	DMI3491
DMI3491	DN	Apigenin
DMI3491	MI	TTSFWA7
DMI3491	MN	Plasmodium CDK Pfmrk (Malaria Pfmrk)
DMI3491	MT	DTT
DMI3491	MA	Inhibitor
DMI3491	RN	A three-dimensional in silico pharmacophore model for inhibition of Plasmodium falciparum cyclin-dependent kinases and discovery of different class... J Med Chem. 2004 Oct 21;47(22):5418-26.
DMI3491	RU	https://pubmed.ncbi.nlm.nih.gov/15481979

DMIQOXH	DI	DMIQOXH
DMIQOXH	DN	Apigenin-7-O-beta-D-glucuronide
DMIQOXH	MI	TTFBNVI
DMIQOXH	MN	Aldose reductase (AKR1B1)
DMIQOXH	MT	DTT
DMIQOXH	MA	Inhibitor
DMIQOXH	RN	Erigeroflavanone, a flavanone derivative from the flowers of Erigeron annuus with protein glycation and aldose reductase inhibitory activity. J Nat Prod. 2008 Apr;71(4):713-5.
DMIQOXH	RU	https://pubmed.ncbi.nlm.nih.gov/18298080

DMP7J0I	DI	DMP7J0I
DMP7J0I	DN	Apigenin-7-O-beta-D-glucuronide methyl ester
DMP7J0I	MI	TTFBNVI
DMP7J0I	MN	Aldose reductase (AKR1B1)
DMP7J0I	MT	DTT
DMP7J0I	MA	Inhibitor
DMP7J0I	RN	Erigeroflavanone, a flavanone derivative from the flowers of Erigeron annuus with protein glycation and aldose reductase inhibitory activity. J Nat Prod. 2008 Apr;71(4):713-5.
DMP7J0I	RU	https://pubmed.ncbi.nlm.nih.gov/18298080

DM6NM8V	DI	DM6NM8V
DM6NM8V	DN	APLYSAMINE
DM6NM8V	MI	TT9JNIC
DM6NM8V	MN	Histamine H3 receptor (H3R)
DM6NM8V	MT	DTT
DM6NM8V	MA	Inhibitor
DM6NM8V	RN	The alkaloid conessine and analogues as potent histamine H3 receptor antagonists. J Med Chem. 2008 Sep 11;51(17):5423-30.
DM6NM8V	RU	https://pubmed.ncbi.nlm.nih.gov/18683917

DMUPL3J	DI	DMUPL3J
DMUPL3J	DN	Aplysinopsin
DMUPL3J	MI	TTJQOD7
DMUPL3J	MN	5-HT 2A receptor (HTR2A)
DMUPL3J	MT	DTT
DMUPL3J	MA	Inhibitor
DMUPL3J	RN	Synthesis and structure-affinity relationships of novel small molecule natural product derivatives capable of discriminating between serotonin 5-HT1A, 5-HT2A, 5-HT2C receptor subtypes. Bioorg Med Chem. 2010 Jul 1;18(13):4783-92. 
DMUPL3J	RU	https://pubmed.ncbi.nlm.nih.gov/20570529

DMUPL3J	DI	DMUPL3J
DMUPL3J	DN	Aplysinopsin
DMUPL3J	MI	TTWJBZ5
DMUPL3J	MN	5-HT 2C receptor (HTR2C)
DMUPL3J	MT	DTT
DMUPL3J	MA	Inhibitor
DMUPL3J	RN	Synthesis and structure-affinity relationships of novel small molecule natural product derivatives capable of discriminating between serotonin 5-HT1A, 5-HT2A, 5-HT2C receptor subtypes. Bioorg Med Chem. 2010 Jul 1;18(13):4783-92. 
DMUPL3J	RU	https://pubmed.ncbi.nlm.nih.gov/20570529

DMW45GK	DI	DMW45GK
DMW45GK	DN	APNEA
DMW45GK	MI	TTNE7KG
DMW45GK	MN	Adenosine A2b receptor (ADORA2B)
DMW45GK	MT	DTT
DMW45GK	MA	Agonist
DMW45GK	RN	Differences in the order of potency for agonists but not antagonists at human and rat adenosine A2A receptors. Biochem Pharmacol. 1999 Jan 1;57(1):65-75.
DMW45GK	RU	https://pubmed.ncbi.nlm.nih.gov/9920286

DM7OPCH	DI	DM7OPCH
DM7OPCH	DN	Apogossypol
DM7OPCH	MI	TTJGNVC
DM7OPCH	MN	Apoptosis regulator Bcl-2 (BCL-2)
DM7OPCH	MT	DTT
DM7OPCH	MA	Inhibitor
DM7OPCH	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7920).
DM7OPCH	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7920

DMPH7EO	DI	DMPH7EO
DMPH7EO	DN	Apomorphine SL
DMPH7EO	MI	TT0R12H
DMPH7EO	MN	Neuron-specific vesicular protein calcyon (CALY)
DMPH7EO	MT	DTT
DMPH7EO	MA	Activator
DMPH7EO	RN	Dopamine and sexual function. Int J Impot Res. 2001 Aug;13 Suppl 3:S18-28.
DMPH7EO	RU	https://pubmed.ncbi.nlm.nih.gov/11477488

DM0VBUL	DI	DM0VBUL
DM0VBUL	DN	Aprophen
DM0VBUL	MI	TTH18TF
DM0VBUL	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DM0VBUL	MT	DTT
DM0VBUL	MA	Antagonist
DM0VBUL	RN	The muscarinic antagonists aprophen and benactyzine are noncompetitive inhibitors of the nicotinic acetylcholine receptor. Mol Pharmacol. 1987 Nov;32(5):678-85.
DM0VBUL	RU	https://pubmed.ncbi.nlm.nih.gov/3683366

DM8DOBG	DI	DM8DOBG
DM8DOBG	DN	APS-3010
DM8DOBG	MI	TTNDSF4
DM8DOBG	MN	Proto-oncogene c-Met (MET)
DM8DOBG	MT	DTT
DM8DOBG	MA	Inhibitor
DM8DOBG	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
DM8DOBG	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815

DMF1264	DI	DMF1264
DMF1264	DN	Aptiganel HCl
DMF1264	MI	TT9IK2Z
DMF1264	MN	N-methyl-D-aspartate receptor (NMDAR)
DMF1264	MT	DTT
DMF1264	MA	Antagonist
DMF1264	RN	Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2003 Jan;3(1):9-20.
DMF1264	RU	https://pubmed.ncbi.nlm.nih.gov/12507405

DMCOMLS	DI	DMCOMLS
DMCOMLS	DN	APY29
DMCOMLS	MI	TTOJ9QL
DMCOMLS	MN	Endoplasmic reticulum to nucleus signaling 1 (ERN1)
DMCOMLS	MT	DTT
DMCOMLS	MA	Inhibitor
DMCOMLS	RN	Quercetin ameliorates HFD-induced NAFLD by promoting hepatic VLDL assembly and lipophagy via the IRE1a/XBP1s pathway. Food Chem Toxicol. 2018 Apr;114:52-60.
DMCOMLS	RU	https://pubmed.ncbi.nlm.nih.gov/29438776

DMK2XB7	DI	DMK2XB7
DMK2XB7	DN	AR-00341677
DMK2XB7	MI	TTWCGQT
DMK2XB7	MN	Serine/threonine-protein kinase B-raf (BRAF)
DMK2XB7	MT	DTT
DMK2XB7	MA	Inhibitor
DMK2XB7	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5681).
DMK2XB7	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5681

DMUSYKG	DI	DMUSYKG
DMUSYKG	DN	AR-129330
DMUSYKG	MI	TTWG9A4
DMUSYKG	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMUSYKG	MT	DTT
DMUSYKG	MA	Inhibitor
DMUSYKG	RN	Lead optimization of 4-(dimethylamino)quinazolines, potent and selective antagonists for the melanin-concentrating hormone receptor 1. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3853-6.
DMUSYKG	RU	https://pubmed.ncbi.nlm.nih.gov/16002290

DMUSYKG	DI	DMUSYKG
DMUSYKG	DN	AR-129330
DMUSYKG	MI	TTX4RTB
DMUSYKG	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMUSYKG	MT	DTT
DMUSYKG	MA	Inhibitor
DMUSYKG	RN	Lead optimization of 4-(dimethylamino)quinazolines, potent and selective antagonists for the melanin-concentrating hormone receptor 1. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3853-6.
DMUSYKG	RU	https://pubmed.ncbi.nlm.nih.gov/16002290

DMUSYKG	DI	DMUSYKG
DMUSYKG	DN	AR-129330
DMUSYKG	MI	TTY6EWA
DMUSYKG	MN	Neuropeptide Y receptor type 5 (NPY5R)
DMUSYKG	MT	DTT
DMUSYKG	MA	Inhibitor
DMUSYKG	RN	Lead optimization of 4-(dimethylamino)quinazolines, potent and selective antagonists for the melanin-concentrating hormone receptor 1. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3853-6.
DMUSYKG	RU	https://pubmed.ncbi.nlm.nih.gov/16002290

DMN8W46	DI	DMN8W46
DMN8W46	DN	AR231453
DMN8W46	MI	TT7QNVC
DMN8W46	MN	Glucose-dependent insulinotropic receptor (GPR119)
DMN8W46	MT	DTT
DMN8W46	MA	Agonist
DMN8W46	RN	A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology. 2007 Jun;148(6):2601-9.
DMN8W46	RU	https://pubmed.ncbi.nlm.nih.gov/17289847

DMTN10D	DI	DMTN10D
DMTN10D	DN	AR234960
DMTN10D	MI	TTOISYB
DMTN10D	MN	Proto-oncogene Mas (MAS)
DMTN10D	MT	DTT
DMTN10D	MA	Agonist
DMTN10D	RN	Inhibition of Mas G-protein signaling improves coronary blood flow, reduces myocardial infarct size, and provides long-term cardioprotection. Am J Physiol Heart Circ Physiol. 2012 Jan 1;302(1):H299-311.
DMTN10D	RU	https://pubmed.ncbi.nlm.nih.gov/22003054

DM68QY0	DI	DM68QY0
DM68QY0	DN	AR244555
DM68QY0	MI	TTOISYB
DM68QY0	MN	Proto-oncogene Mas (MAS)
DM68QY0	MT	DTT
DM68QY0	MA	Antagonist
DM68QY0	RN	Inhibition of Mas G-protein signaling improves coronary blood flow, reduces myocardial infarct size, and provides long-term cardioprotection. Am J Physiol Heart Circ Physiol. 2012 Jan 1;302(1):H299-311.
DM68QY0	RU	https://pubmed.ncbi.nlm.nih.gov/22003054

DMNJ632	DI	DMNJ632
DMNJ632	DN	AR-534
DMNJ632	MI	TTRZQE3
DMNJ632	MN	Glycogen synthase kinase-3 alpha (GSK-3A)
DMNJ632	MT	DTT
DMNJ632	MA	Inhibitor
DMNJ632	RN	A zebrafish model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation. J Clin Invest. 2009 May;119(5):1382-95. 
DMNJ632	RU	https://pubmed.ncbi.nlm.nih.gov/19363289

DM34P90	DI	DM34P90
DM34P90	DN	AR-7947
DM34P90	MI	TT7QNVC
DM34P90	MN	Glucose-dependent insulinotropic receptor (GPR119)
DM34P90	MT	DTT
DM34P90	MA	Modulator
DM34P90	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 126).
DM34P90	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=126

DMAM619	DI	DMAM619
DMAM619	DN	Arabinose-5-Phosphate
DMAM619	MI	TTVNA43
DMAM619	MN	Bacterial Deoxy-D-manno-octulosonate 8-phosphate synthase (Bact kdsA)
DMAM619	MT	DTT
DMAM619	MA	Inhibitor
DMAM619	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMAM619	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMUOQZD	DI	DMUOQZD
DMUOQZD	DN	Arachidonic acid
DMUOQZD	MI	DEISPU8
DMUOQZD	MN	Arachidonate 12-lipoxygenase (ALOX12B)
DMUOQZD	MT	DME
DMUOQZD	MA	Metabolism
DMUOQZD	RN	Mitochondrial uncoupling reveals a novel therapeutic opportunity for p53-defective cancers. Nat Commun. 2018 Sep 26;9(1):3931.
DMUOQZD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30258081

DMUOQZD	DI	DMUOQZD
DMUOQZD	DN	Arachidonic acid
DMUOQZD	MI	DEH0J8X
DMUOQZD	MN	Arachidonate 15-lipoxygenase (ALOX15)
DMUOQZD	MT	DME
DMUOQZD	MA	Metabolism
DMUOQZD	RN	Effect of human 15-lipoxygenase-1 metabolites on vascular function in mouse mesenteric arteries and hearts. Prostaglandins Other Lipid Mediat. 2013 Oct;106:8-15.
DMUOQZD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23872364

DMUOQZD	DI	DMUOQZD
DMUOQZD	DN	Arachidonic acid
DMUOQZD	MI	DE87OZS
DMUOQZD	MN	Arachidonate 5-lipoxygenase (ALOX5)
DMUOQZD	MT	DME
DMUOQZD	MA	Metabolism
DMUOQZD	RN	A rat air pouch model for evaluating the efficacy and selectivity of 5-lipoxygenase inhibitors. Eur J Pharmacol. 2008 Apr 14;584(1):166-74.
DMUOQZD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18295198

DMUOQZD	DI	DMUOQZD
DMUOQZD	DN	Arachidonic acid
DMUOQZD	MI	DE5IED8
DMUOQZD	MN	Cytochrome P450 2C9 (CYP2C9)
DMUOQZD	MT	DME
DMUOQZD	MA	Metabolism
DMUOQZD	RN	New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
DMUOQZD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20167001

DMUOQZD	DI	DMUOQZD
DMUOQZD	DN	Arachidonic acid
DMUOQZD	MI	DE3GT9C
DMUOQZD	MN	Cytochrome P450 4F2 (CYP4F2)
DMUOQZD	MT	DME
DMUOQZD	MA	Metabolism
DMUOQZD	RN	Role of cytochrome P450 enzymes in the bioactivation of polyunsaturated fatty acids. Biochim Biophys Acta. 2011 Jan;1814(1):210-22.
DMUOQZD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20869469

DMUOQZD	DI	DMUOQZD
DMUOQZD	DN	Arachidonic acid
DMUOQZD	MI	TT8NGED
DMUOQZD	MN	Prostaglandin G/H synthase 1 (COX-1)
DMUOQZD	MT	DTT
DMUOQZD	MA	Inhibitor
DMUOQZD	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMUOQZD	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMUOQZD	DI	DMUOQZD
DMUOQZD	DN	Arachidonic acid
DMUOQZD	MI	DE073H6
DMUOQZD	MN	Prostaglandin G/H synthase 1 (COX-1)
DMUOQZD	MT	DME
DMUOQZD	MA	Metabolism
DMUOQZD	RN	Identification and functional characterization of polymorphisms in human cyclooxygenase-1 (PTGS1). Pharmacogenet Genomics. 2007 Feb;17(2):145-60.
DMUOQZD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17301694

DMUOQZD	DI	DMUOQZD
DMUOQZD	DN	Arachidonic acid
DMUOQZD	MI	DE492CE
DMUOQZD	MN	Prostaglandin G/H synthase 2 (COX-2)
DMUOQZD	MT	DME
DMUOQZD	MA	Metabolism
DMUOQZD	RN	PharmGKB summary: very important pharmacogene information for PTGS2. Pharmacogenet Genomics. 2011 Sep;21(9):607-13.
DMUOQZD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21063235

DMHL48F	DI	DMHL48F
DMHL48F	DN	ARACHIDONYL TRIFLUOROMETHYLKETONE
DMHL48F	MI	TTT1JVS
DMHL48F	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DMHL48F	MT	DTT
DMHL48F	MA	Inhibitor
DMHL48F	RN	85-kDa cPLA(2) plays a critical role in PPAR-mediated gene transcription in human hepatoma cells. Am J Physiol Gastrointest Liver Physiol. 2002 Apr;282(4):G586-97.
DMHL48F	RU	https://pubmed.ncbi.nlm.nih.gov/11897617

DMHL48F	DI	DMHL48F
DMHL48F	DN	ARACHIDONYL TRIFLUOROMETHYLKETONE
DMHL48F	MI	TTDP1UC
DMHL48F	MN	Fatty acid amide hydrolase (FAAH)
DMHL48F	MT	DTT
DMHL48F	MA	Inhibitor
DMHL48F	RN	1-Indol-1-yl-propan-2-ones and related heterocyclic compounds as dual inhibitors of cytosolic phospholipase A(2)alpha and fatty acid amide hydrolase. Bioorg Med Chem. 2010 Jan 15;18(2):945-52.
DMHL48F	RU	https://pubmed.ncbi.nlm.nih.gov/20005725

DMZM5KE	DI	DMZM5KE
DMZM5KE	DN	arachidonylcyclopropylamide
DMZM5KE	MI	TT6OEDT
DMZM5KE	MN	Cannabinoid receptor 1 (CB1)
DMZM5KE	MT	DTT
DMZM5KE	MA	Agonist
DMZM5KE	RN	Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J Pharmacol Exp Ther. 1999 Jun;289(3):1427-33.
DMZM5KE	RU	https://pubmed.ncbi.nlm.nih.gov/10336536

DMZM5KE	DI	DMZM5KE
DMZM5KE	DN	arachidonylcyclopropylamide
DMZM5KE	MI	TTSLJAR
DMZM5KE	MN	N-arachidonyl glycine receptor (GPR18)
DMZM5KE	MT	DTT
DMZM5KE	MA	Agonist
DMZM5KE	RN	Delta(9) -Tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells. Br J Pharmacol. 2012 Apr;165(8):2414-24.
DMZM5KE	RU	https://pubmed.ncbi.nlm.nih.gov/21595653

DMSM1PV	DI	DMSM1PV
DMSM1PV	DN	ARC-069
DMSM1PV	MI	TTE4KHA
DMSM1PV	MN	Amyloid beta A4 protein (APP)
DMSM1PV	MT	DTT
DMSM1PV	MA	Inhibitor
DMSM1PV	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
DMSM1PV	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402

DMWVULN	DI	DMWVULN
DMWVULN	DN	AR-C102222
DMWVULN	MI	TTZUFI5
DMWVULN	MN	Nitric-oxide synthase brain (NOS1)
DMWVULN	MT	DTT
DMWVULN	MA	Inhibitor
DMWVULN	RN	Anchored plasticity opens doors for selective inhibitor design in nitric oxide synthase. Nat Chem Biol. 2008 Nov;4(11):700-7.
DMWVULN	RU	https://pubmed.ncbi.nlm.nih.gov/18849972

DMWVULN	DI	DMWVULN
DMWVULN	DN	AR-C102222
DMWVULN	MI	TTF10I9
DMWVULN	MN	Nitric-oxide synthase inducible (NOS2)
DMWVULN	MT	DTT
DMWVULN	MA	Inhibitor
DMWVULN	RN	Anchored plasticity opens doors for selective inhibitor design in nitric oxide synthase. Nat Chem Biol. 2008 Nov;4(11):700-7.
DMWVULN	RU	https://pubmed.ncbi.nlm.nih.gov/18849972

DM0KDTG	DI	DM0KDTG
DM0KDTG	DN	ARC-1028
DM0KDTG	MI	TTZC6DR
DM0KDTG	MN	cGMP-dependent protein kinase (cGK)
DM0KDTG	MT	DTT
DM0KDTG	MA	Inhibitor
DM0KDTG	RN	Structural analysis of ARC-type inhibitor (ARC-1034) binding to protein kinase A catalytic subunit and rational design of bisubstrate analogue inhi... J Med Chem. 2009 Jan 22;52(2):308-21.
DM0KDTG	RU	https://pubmed.ncbi.nlm.nih.gov/19143565

DMQCPXL	DI	DMQCPXL
DMQCPXL	DN	AR-C118925XX
DMQCPXL	MI	TTOZHQC
DMQCPXL	MN	P2Y purinoceptor 2 (P2RY2)
DMQCPXL	MT	DTT
DMQCPXL	MA	Antagonist
DMQCPXL	RN	Nucleotide-mediated mucin secretion from differentiated human bronchial epithelial cells. Am J Respir Cell Mol Biol. 2004 Oct;31(4):446-55.
DMQCPXL	RU	https://pubmed.ncbi.nlm.nih.gov/15231488

DMP1EWV	DI	DMP1EWV
DMP1EWV	DN	AR-C126313
DMP1EWV	MI	TTOZHQC
DMP1EWV	MN	P2Y purinoceptor 2 (P2RY2)
DMP1EWV	MT	DTT
DMP1EWV	MA	Antagonist
DMP1EWV	RN	Molecular modeling of the human P2Y2 receptor and design of a selective agonist, 2'-amino-2'-deoxy-2-thiouridine 5'-triphosphate. J Med Chem. 2007 Mar 22;50(6):1166-76.
DMP1EWV	RU	https://pubmed.ncbi.nlm.nih.gov/17302398

DM71WQT	DI	DM71WQT
DM71WQT	DN	AR-C133057XX
DM71WQT	MI	TTZUFI5
DM71WQT	MN	Nitric-oxide synthase brain (NOS1)
DM71WQT	MT	DTT
DM71WQT	MA	Inhibitor
DM71WQT	RN	Anchored plasticity opens doors for selective inhibitor design in nitric oxide synthase. Nat Chem Biol. 2008 Nov;4(11):700-7.
DM71WQT	RU	https://pubmed.ncbi.nlm.nih.gov/18849972

DM71WQT	DI	DM71WQT
DM71WQT	DN	AR-C133057XX
DM71WQT	MI	TTF10I9
DM71WQT	MN	Nitric-oxide synthase inducible (NOS2)
DM71WQT	MT	DTT
DM71WQT	MA	Inhibitor
DM71WQT	RN	Anchored plasticity opens doors for selective inhibitor design in nitric oxide synthase. Nat Chem Biol. 2008 Nov;4(11):700-7.
DM71WQT	RU	https://pubmed.ncbi.nlm.nih.gov/18849972

DMAZV5D	DI	DMAZV5D
DMAZV5D	DN	ARC-200
DMAZV5D	MI	TTYFKSZ
DMAZV5D	MN	Tubulin beta (TUBB)
DMAZV5D	MT	DTT
DMAZV5D	MA	Modulator
DMAZV5D	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2640).
DMAZV5D	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2640

DMU3A57	DI	DMU3A57
DMU3A57	DN	AR-C70484XX
DMU3A57	MI	TTT1JVS
DMU3A57	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DMU3A57	MT	DTT
DMU3A57	MA	Inhibitor
DMU3A57	RN	1-Indol-1-yl-propan-2-ones and related heterocyclic compounds as dual inhibitors of cytosolic phospholipase A(2)alpha and fatty acid amide hydrolase. Bioorg Med Chem. 2010 Jan 15;18(2):945-52.
DMU3A57	RU	https://pubmed.ncbi.nlm.nih.gov/20005725

DMU3A57	DI	DMU3A57
DMU3A57	DN	AR-C70484XX
DMU3A57	MI	TTDP1UC
DMU3A57	MN	Fatty acid amide hydrolase (FAAH)
DMU3A57	MT	DTT
DMU3A57	MA	Inhibitor
DMU3A57	RN	1-Indol-1-yl-propan-2-ones and related heterocyclic compounds as dual inhibitors of cytosolic phospholipase A(2)alpha and fatty acid amide hydrolase. Bioorg Med Chem. 2010 Jan 15;18(2):945-52.
DMU3A57	RU	https://pubmed.ncbi.nlm.nih.gov/20005725

DMXOYK0	DI	DMXOYK0
DMXOYK0	DN	Arcaine
DMXOYK0	MI	TTLGDIS
DMXOYK0	MN	Acid-sensing ion channel 3 (ASIC3)
DMXOYK0	MT	DTT
DMXOYK0	MA	Activator
DMXOYK0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 686).
DMXOYK0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=686

DM03E28	DI	DM03E28
DM03E28	DN	ARD-412
DM03E28	MI	TT27RFC
DM03E28	MN	Opioid receptor delta (OPRD1)
DM03E28	MT	DTT
DM03E28	MA	Agonist
DM03E28	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317).
DM03E28	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=317

DMSA6IY	DI	DMSA6IY
DMSA6IY	DN	arecaidine propargyl ester
DMSA6IY	MI	TTOXS3C
DMSA6IY	MN	Muscarinic acetylcholine receptor (CHRM)
DMSA6IY	MT	DTT
DMSA6IY	MA	Agonist
DMSA6IY	RN	Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol. 1997 Jul;52(1):172-9.
DMSA6IY	RU	https://pubmed.ncbi.nlm.nih.gov/9224827

DMSA6IY	DI	DMSA6IY
DMSA6IY	DN	arecaidine propargyl ester
DMSA6IY	MI	TTQ13Z5
DMSA6IY	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMSA6IY	MT	DTT
DMSA6IY	MA	Agonist
DMSA6IY	RN	Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol. 1997 Jul;52(1):172-9.
DMSA6IY	RU	https://pubmed.ncbi.nlm.nih.gov/9224827

DM8KN0Q	DI	DM8KN0Q
DM8KN0Q	DN	ARGENINE VASOPRESSIN
DM8KN0Q	MI	TTSCIUP
DM8KN0Q	MN	Oxytocin receptor (OTR)
DM8KN0Q	MT	DTT
DM8KN0Q	MA	Inhibitor
DM8KN0Q	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DM8KN0Q	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DM8KN0Q	DI	DM8KN0Q
DM8KN0Q	DN	ARGENINE VASOPRESSIN
DM8KN0Q	MI	TT4TFGN
DM8KN0Q	MN	Vasopressin V1a receptor (V1AR)
DM8KN0Q	MT	DTT
DM8KN0Q	MA	Inhibitor
DM8KN0Q	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DM8KN0Q	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DM8KN0Q	DI	DM8KN0Q
DM8KN0Q	DN	ARGENINE VASOPRESSIN
DM8KN0Q	MI	TTL9MHW
DM8KN0Q	MN	Vasopressin V1b receptor (V1BR)
DM8KN0Q	MT	DTT
DM8KN0Q	MA	Inhibitor
DM8KN0Q	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DM8KN0Q	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DM8KN0Q	DI	DM8KN0Q
DM8KN0Q	DN	ARGENINE VASOPRESSIN
DM8KN0Q	MI	TTK8R02
DM8KN0Q	MN	Vasopressin V2 receptor (V2R)
DM8KN0Q	MT	DTT
DM8KN0Q	MA	Inhibitor
DM8KN0Q	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DM8KN0Q	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMQ1DWU	DI	DMQ1DWU
DMQ1DWU	DN	Argiotoxin-636
DMQ1DWU	MI	TTVPQTF
DMQ1DWU	MN	Glutamate receptor AMPA 1 (GRIA1)
DMQ1DWU	MT	DTT
DMQ1DWU	MA	Inhibitor
DMQ1DWU	RN	Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands. Bioorg Med Chem. 2010 Feb 15;18(4):1381-7.
DMQ1DWU	RU	https://pubmed.ncbi.nlm.nih.gov/20096591

DM6PA1S	DI	DM6PA1S
DM6PA1S	DN	Arg-Pro-Lys-Pro-Ala-Gln-Phe-Phe-Gly-Leu-Met-NH2
DM6PA1S	MI	TTZPO1L
DM6PA1S	MN	Substance-P receptor (TACR1)
DM6PA1S	MT	DTT
DM6PA1S	MA	Inhibitor
DM6PA1S	RN	Conformational comparisons of a series of tachykinin peptide analogs. J Med Chem. 2007 Dec 27;50(26):6501-6.
DM6PA1S	RU	https://pubmed.ncbi.nlm.nih.gov/18067242

DMYM91S	DI	DMYM91S
DMYM91S	DN	Arg-Pro-Lys-Pro-Ala-Ser-Phe-Phe-Gly-Leu-Met-NH2
DMYM91S	MI	TTZPO1L
DMYM91S	MN	Substance-P receptor (TACR1)
DMYM91S	MT	DTT
DMYM91S	MA	Inhibitor
DMYM91S	RN	Conformational comparisons of a series of tachykinin peptide analogs. J Med Chem. 2007 Dec 27;50(26):6501-6.
DMYM91S	RU	https://pubmed.ncbi.nlm.nih.gov/18067242

DMA318X	DI	DMA318X
DMA318X	DN	Arg-Pro-Lys-Pro-Gln-Ser-Phe-Phe-Gly-Leu-Met-NH2
DMA318X	MI	TTZPO1L
DMA318X	MN	Substance-P receptor (TACR1)
DMA318X	MT	DTT
DMA318X	MA	Inhibitor
DMA318X	RN	Conformational comparisons of a series of tachykinin peptide analogs. J Med Chem. 2007 Dec 27;50(26):6501-6.
DMA318X	RU	https://pubmed.ncbi.nlm.nih.gov/18067242

DM8NETP	DI	DM8NETP
DM8NETP	DN	ARH-1029
DM8NETP	MI	TTF1QVM
DM8NETP	MN	Gastric H(+)/K(+) ATPase alpha (ATP4A)
DM8NETP	MT	DTT
DM8NETP	MA	Modulator
DM8NETP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 849).
DM8NETP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=849

DM2PRHX	DI	DM2PRHX
DM2PRHX	DN	AR-HO29953XX
DM2PRHX	MI	TTTO43N
DM2PRHX	MN	Endothelial plasminogen activator inhibitor (SERPINE1)
DM2PRHX	MT	DTT
DM2PRHX	MA	Inhibitor
DM2PRHX	RN	Synthesis and SAR of 2-carboxylic acid indoles as inhibitors of plasminogen activator inhibitor-1. Bioorg Med Chem Lett. 2005 Aug 1;15(15):3514-8.
DM2PRHX	RU	https://pubmed.ncbi.nlm.nih.gov/15982877

DMIMD0T	DI	DMIMD0T
DMIMD0T	DN	ARI-3099
DMIMD0T	MI	TTYWEDQ
DMIMD0T	MN	Acylamino-acid-releasing enzyme (APEH)
DMIMD0T	MT	DTT
DMIMD0T	MA	Inhibitor
DMIMD0T	RN	A high-throughput, multiplexed assay for superfamily-wide profiling of enzyme activity. Nat Chem Biol. 2014 Aug;10(8):656-63.
DMIMD0T	RU	https://pubmed.ncbi.nlm.nih.gov/24997602

DMIMD0T	DI	DMIMD0T
DMIMD0T	DN	ARI-3099
DMIMD0T	MI	TTGPQ0F
DMIMD0T	MN	Prolyl endopeptidase FAP (FAP)
DMIMD0T	MT	DTT
DMIMD0T	MA	Inhibitor
DMIMD0T	RN	Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase. J Med Chem. 2013 May 9;56(9):3467-77.
DMIMD0T	RU	https://pubmed.ncbi.nlm.nih.gov/23594271

DMEO82V	DI	DMEO82V
DMEO82V	DN	ARI-3531
DMEO82V	MI	TTNGKET
DMEO82V	MN	Prolyl endopeptidase (PREP)
DMEO82V	MT	DTT
DMEO82V	MA	Inhibitor
DMEO82V	RN	Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase. J Med Chem. 2013 May 9;56(9):3467-77.
DMEO82V	RU	https://pubmed.ncbi.nlm.nih.gov/23594271

DMNPEM4	DI	DMNPEM4
DMNPEM4	DN	ARL66096
DMNPEM4	MI	TTZ1DT0
DMNPEM4	MN	P2Y purinoceptor 12 (P2RY12)
DMNPEM4	MT	DTT
DMNPEM4	MA	Antagonist
DMNPEM4	RN	FPL 66096: a novel, highly potent and selective antagonist at human platelet P2T-purinoceptors. Br J Pharmacol. 1994 Nov;113(3):1057-63.
DMNPEM4	RU	https://pubmed.ncbi.nlm.nih.gov/7858849

DM24MKI	DI	DM24MKI
DM24MKI	DN	AR-mTOR-26
DM24MKI	MI	TTCJG29
DM24MKI	MN	Serine/threonine-protein kinase mTOR (mTOR)
DM24MKI	MT	DTT
DM24MKI	MA	Inhibitor
DM24MKI	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
DM24MKI	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109

DMBE0H8	DI	DMBE0H8
DMBE0H8	DN	ARN-2966
DMBE0H8	MI	TTE4KHA
DMBE0H8	MN	Amyloid beta A4 protein (APP)
DMBE0H8	MT	DTT
DMBE0H8	MA	Inhibitor
DMBE0H8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
DMBE0H8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402

DMMCFEX	DI	DMMCFEX
DMMCFEX	DN	ARN34
DMMCFEX	MI	TTS64P2
DMMCFEX	MN	Androgen receptor (AR)
DMMCFEX	MT	DTT
DMMCFEX	MA	Antagonist
DMMCFEX	RN	Ectopic expression of the amino-terminal peptide of androgen receptor leads to androgen receptor dysfunction and inhibition of androgen receptor-mediated prostate cancer growth. Mol Cell Endocrinol. 2004 Feb 12;214(1-2):175-87.
DMMCFEX	RU	https://pubmed.ncbi.nlm.nih.gov/15062556

DMNAJQY	DI	DMNAJQY
DMNAJQY	DN	ARO 087
DMNAJQY	MI	TT0LF7H
DMNAJQY	MN	Fibroblast growth factor receptor (FGFR)
DMNAJQY	MT	DTT
DMNAJQY	MA	Modulator
DMNAJQY	RN	J Clin Oncol 33, 2015 (suppl; abstr 2545).
DMNAJQY	RU	http://meetinglibrary.asco.org/content/149025-156

DM6KQXF	DI	DM6KQXF
DM6KQXF	DN	ARP100
DM6KQXF	MI	TT6X50U
DM6KQXF	MN	Matrix metalloproteinase-9 (MMP-9)
DM6KQXF	MT	DTT
DM6KQXF	MA	Inhibitor
DM6KQXF	RN	Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxy... Bioorg Med Chem. 2006 Jun 15;14(12):4260-76.
DM6KQXF	RU	https://pubmed.ncbi.nlm.nih.gov/16483784

DMU70YP	DI	DMU70YP
DMU70YP	DN	ARPFAQK-FAM
DMU70YP	MI	TTK3WBU
DMU70YP	MN	XIAP messenger RNA (XIAP mRNA)
DMU70YP	MT	DTT
DMU70YP	MA	Inhibitor
DMU70YP	RN	Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional... J Med Chem. 2004 May 6;47(10):2430-40.
DMU70YP	RU	https://pubmed.ncbi.nlm.nih.gov/15115387

DMB9PDA	DI	DMB9PDA
DMB9PDA	DN	arpromidine
DMB9PDA	MI	TTTIBOJ
DMB9PDA	MN	Histamine H1 receptor (H1R)
DMB9PDA	MT	DTT
DMB9PDA	MA	Antagonist
DMB9PDA	RN	Multiple differences in agonist and antagonist pharmacology between human and guinea pig histamine H1-receptor. J Pharmacol Exp Ther. 2003 Jun;305(3):1104-15.
DMB9PDA	RU	https://pubmed.ncbi.nlm.nih.gov/12626648

DMB9PDA	DI	DMB9PDA
DMB9PDA	DN	arpromidine
DMB9PDA	MI	TTQHJ1K
DMB9PDA	MN	Histamine H2 receptor (H2R)
DMB9PDA	MT	DTT
DMB9PDA	MA	Agonist
DMB9PDA	RN	Probing ligand-specific histamine H1- and H2-receptor conformations with NG-acylated Imidazolylpropylguanidines. J Pharmacol Exp Ther. 2006 Apr;317(1):139-46.
DMB9PDA	RU	https://pubmed.ncbi.nlm.nih.gov/16394198

DMIRTF5	DI	DMIRTF5
DMIRTF5	DN	ARRY-575
DMIRTF5	MI	TTTU902
DMIRTF5	MN	Checkpoint kinase-1 (CHK1)
DMIRTF5	MT	DTT
DMIRTF5	MA	Inhibitor
DMIRTF5	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1987).
DMIRTF5	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1987

DMBCO4Q	DI	DMBCO4Q
DMBCO4Q	DN	Arsenite
DMBCO4Q	MI	DTH6X7Q
DMBCO4Q	MN	Feline leukemia virus subgroup C receptor-related protein 1 (SLC49A1)
DMBCO4Q	MT	DTP
DMBCO4Q	MA	Substrate
DMBCO4Q	RN	The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.1.28.1)
DMBCO4Q	RU	http://www.tcdb.org/search/result.php?tc=2.A.1.28.1

DMBCO4Q	DI	DMBCO4Q
DMBCO4Q	DN	Arsenite
DMBCO4Q	MI	DTG3T6X
DMBCO4Q	MN	Glucose transporter type 1, erythrocyte/brain (SLC2A1)
DMBCO4Q	MT	DTP
DMBCO4Q	MA	Substrate
DMBCO4Q	RN	Mammalian glucose permease GLUT1 facilitates transport of arsenic trioxide and methylarsonous acid. Biochem Biophys Res Commun. 2006 Dec 15;351(2):424-30.
DMBCO4Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/17064664

DMBCO4Q	DI	DMBCO4Q
DMBCO4Q	DN	Arsenite
DMBCO4Q	MI	TTRPDBG
DMBCO4Q	MN	Inhibitor of nuclear factor kappa-B kinase (IKK)
DMBCO4Q	MT	DTT
DMBCO4Q	MA	Inhibitor
DMBCO4Q	RN	Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. J Biol Chem. 2000 Nov 17;275(46):36062-6.
DMBCO4Q	RU	https://pubmed.ncbi.nlm.nih.gov/10967126

DMBCO4Q	DI	DMBCO4Q
DMBCO4Q	DN	Arsenite
DMBCO4Q	MI	DTSYQGK
DMBCO4Q	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMBCO4Q	MT	DTP
DMBCO4Q	MA	Substrate
DMBCO4Q	RN	Comparative Molecular Docking Studies with ABCC1 and Aquaporin 9 in the Arsenite Complex Efflux. Bioinformation. 2014 Aug 30;10(8):474-9.
DMBCO4Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/25258480

DMEVT4I	DI	DMEVT4I
DMEVT4I	DN	ART-144
DMEVT4I	MI	TTR9XHZ
DMEVT4I	MN	Transforming growth factor beta 1 (TGFB1)
DMEVT4I	MT	DTT
DMEVT4I	MA	Modulator
DMEVT4I	RN	Pharmaceutical products of TORREYA partners. December 2011.
DMEVT4I	RU	http://www.availablepharmaproducts.com/app_dec11.pdf

DM8SP4X	DI	DM8SP4X
DM8SP4X	DN	Arteminolide
DM8SP4X	MI	TT7WZIJ
DM8SP4X	MN	CAAX farnesyltransferase beta (FNTB)
DM8SP4X	MT	DTT
DM8SP4X	MA	Inhibitor
DM8SP4X	RN	Modeling of binding modes and inhibition mechanism of some natural ligands of farnesyl transferase using molecular docking. J Med Chem. 2002 Mar 28;45(7):1460-5.
DM8SP4X	RU	https://pubmed.ncbi.nlm.nih.gov/11906287

DMWCDM8	DI	DMWCDM8
DMWCDM8	DN	artepillin C
DMWCDM8	MI	TTELV3W
DMWCDM8	MN	Transformation-sensitive protein p120 (TRPA1)
DMWCDM8	MT	DTT
DMWCDM8	MA	Activator
DMWCDM8	RN	Artepillin C, a major ingredient of Brazilian propolis, induces a pungent taste by activating TRPA1 channels. PLoS One. 2012;7(11):e48072.
DMWCDM8	RU	https://pubmed.ncbi.nlm.nih.gov/23133611

DMB9AR7	DI	DMB9AR7
DMB9AR7	DN	ARTOBILOXANTHONE
DMB9AR7	MI	TTSXVID
DMB9AR7	MN	Nuclear factor NF-kappa-B (NFKB)
DMB9AR7	MT	DTT
DMB9AR7	MA	Inhibitor
DMB9AR7	RN	Cytotoxic and NF-kappaB inhibitory constituents of Artocarpus rigida. J Nat Prod. 2010 May 28;73(5):949-55.
DMB9AR7	RU	https://pubmed.ncbi.nlm.nih.gov/20384315

DMHUXRP	DI	DMHUXRP
DMHUXRP	DN	ARTORIGIDIN A
DMHUXRP	MI	TTSXVID
DMHUXRP	MN	Nuclear factor NF-kappa-B (NFKB)
DMHUXRP	MT	DTT
DMHUXRP	MA	Inhibitor
DMHUXRP	RN	Cytotoxic and NF-kappaB inhibitory constituents of Artocarpus rigida. J Nat Prod. 2010 May 28;73(5):949-55.
DMHUXRP	RU	https://pubmed.ncbi.nlm.nih.gov/20384315

DMO5LUF	DI	DMO5LUF
DMO5LUF	DN	arvanil
DMO5LUF	MI	TTMI6F5
DMO5LUF	MN	Transient receptor potential cation channel V1 (TRPV1)
DMO5LUF	MT	DTT
DMO5LUF	MA	Activator
DMO5LUF	RN	Cloning and pharmacological characterization of mouse TRPV1. Neurosci Lett. 2004 Nov 3;370(1):55-60.
DMO5LUF	RU	https://pubmed.ncbi.nlm.nih.gov/15489017

DM15KLR	DI	DM15KLR
DM15KLR	DN	ARX-AHD
DM15KLR	MI	TTGKNB4
DM15KLR	MN	Epidermal growth factor receptor (EGFR)
DM15KLR	MT	DTT
DM15KLR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
DM15KLR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797

DMWHUKZ	DI	DMWHUKZ
DMWHUKZ	DN	AR-XYZ
DMWHUKZ	MI	TTMSFAW
DMWHUKZ	MN	Cannabinoid receptor 2 (CB2)
DMWHUKZ	MT	DTT
DMWHUKZ	MA	Agonist
DMWHUKZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 57).
DMWHUKZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=57

DMAWJPE	DI	DMAWJPE
DMAWJPE	DN	AS04
DMAWJPE	MI	TTISGCA
DMAWJPE	MN	Toll-like receptor 4 (TLR4)
DMAWJPE	MT	DTT
DMAWJPE	MA	Modulator
DMAWJPE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1754).
DMAWJPE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1754

DMXZ8S9	DI	DMXZ8S9
DMXZ8S9	DN	AS100
DMXZ8S9	MI	TTK25J1
DMXZ8S9	MN	Adenosine A1 receptor (ADORA1)
DMXZ8S9	MT	DTT
DMXZ8S9	MA	Antagonist
DMXZ8S9	RN	Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors. Biochem Pharmacol. 2005 Nov 25;70(11):1601-12.
DMXZ8S9	RU	https://pubmed.ncbi.nlm.nih.gov/16219300

DMXZ8S9	DI	DMXZ8S9
DMXZ8S9	DN	AS100
DMXZ8S9	MI	TTNE7KG
DMXZ8S9	MN	Adenosine A2b receptor (ADORA2B)
DMXZ8S9	MT	DTT
DMXZ8S9	MA	Antagonist
DMXZ8S9	RN	Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors. Biochem Pharmacol. 2005 Nov 25;70(11):1601-12.
DMXZ8S9	RU	https://pubmed.ncbi.nlm.nih.gov/16219300

DM170G5	DI	DM170G5
DM170G5	DN	AS1269574
DM170G5	MI	TT7QNVC
DM170G5	MN	Glucose-dependent insulinotropic receptor (GPR119)
DM170G5	MT	DTT
DM170G5	MA	Agonist
DM170G5	RN	Identification of a novel GPR119 agonist, AS1269574, with in vitro and in vivo glucose-stimulated insulin secretion. Biochem Biophys Res Commun. 2010 Sep 24;400(3):437-41.
DM170G5	RU	https://pubmed.ncbi.nlm.nih.gov/20804735

DMPX5SJ	DI	DMPX5SJ
DMPX5SJ	DN	AS-1397
DMPX5SJ	MI	TTEB0GD
DMPX5SJ	MN	Cholinesterase (BCHE)
DMPX5SJ	MT	DTT
DMPX5SJ	MA	Inhibitor
DMPX5SJ	RN	Novel heterobivalent tacrine derivatives as cholinesterase inhibitors with notable selectivity toward butyrylcholinesterase. J Med Chem. 2006 Dec 14;49(25):7540-4.
DMPX5SJ	RU	https://pubmed.ncbi.nlm.nih.gov/17149883

DM7A8PX	DI	DM7A8PX
DM7A8PX	DN	AS-1522489-00
DM7A8PX	MI	TTHJTF7
DM7A8PX	MN	Glycine transporter GlyT-1 (SLC6A9)
DM7A8PX	MT	DTT
DM7A8PX	MA	Inhibitor
DM7A8PX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 935).
DM7A8PX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=935

DMP0A17	DI	DMP0A17
DMP0A17	DN	AS16
DMP0A17	MI	TTNE7KG
DMP0A17	MN	Adenosine A2b receptor (ADORA2B)
DMP0A17	MT	DTT
DMP0A17	MA	Antagonist
DMP0A17	RN	Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors. Biochem Pharmacol. 2005 Nov 25;70(11):1601-12.
DMP0A17	RU	https://pubmed.ncbi.nlm.nih.gov/16219300

DM6MWDH	DI	DM6MWDH
DM6MWDH	DN	AS-1708727
DM6MWDH	MI	TTHAVTS
DM6MWDH	MN	Forkhead box protein O1A (FOXO1)
DM6MWDH	MT	DTT
DM6MWDH	MA	Modulator
DM6MWDH	RN	Effects of the novel Foxo1 inhibitor AS1708727 on plasma glucose and triglyceride levels in diabetic db/db mice. Eur J Pharmacol. 2010 Oct 25;645(1-3):185-91.
DM6MWDH	RU	https://pubmed.ncbi.nlm.nih.gov/20655898

DMS86PI	DI	DMS86PI
DMS86PI	DN	AS-1892802
DMS86PI	MI	TTZN7RP
DMS86PI	MN	Rho-associated protein kinase 1 (ROCK1)
DMS86PI	MT	DTT
DMS86PI	MA	Inhibitor
DMS86PI	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1503).
DMS86PI	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1503

DMASE5O	DI	DMASE5O
DMASE5O	DN	AS-19
DMASE5O	MI	TTO9X1H
DMASE5O	MN	5-HT 7 receptor (HTR7)
DMASE5O	MT	DTT
DMASE5O	MA	Agonist
DMASE5O	RN	Discovery of aryl-biphenyl-2-ylmethylpiperazines as novel scaffolds for 5-HT(7) ligands and role of the aromatic substituents in binding to the target receptor. Bioorg Med Chem. 2013 May 1;21(9):2568-76.
DMASE5O	RU	https://pubmed.ncbi.nlm.nih.gov/23541835

DM0MAIW	DI	DM0MAIW
DM0MAIW	DN	AS-1907417
DM0MAIW	MI	TT7QNVC
DM0MAIW	MN	Glucose-dependent insulinotropic receptor (GPR119)
DM0MAIW	MT	DTT
DM0MAIW	MA	Agonist
DM0MAIW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 126).
DM0MAIW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=126

DMQ95EB	DI	DMQ95EB
DMQ95EB	DN	AS-601245
DMQ95EB	MI	TTRSMW9
DMQ95EB	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMQ95EB	MT	DTT
DMQ95EB	MA	Inhibitor
DMQ95EB	RN	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
DMQ95EB	RU	https://pubmed.ncbi.nlm.nih.gov/17850214

DMQ95EB	DI	DMQ95EB
DMQ95EB	DN	AS-601245
DMQ95EB	MI	TT3IVG2
DMQ95EB	MN	JNK2 messenger RNA (JNK2 mRNA)
DMQ95EB	MT	DTT
DMQ95EB	MA	Inhibitor
DMQ95EB	RN	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
DMQ95EB	RU	https://pubmed.ncbi.nlm.nih.gov/17850214

DMQ95EB	DI	DMQ95EB
DMQ95EB	DN	AS-601245
DMQ95EB	MI	TT0K6EO
DMQ95EB	MN	Stress-activated protein kinase JNK1 (JNK1)
DMQ95EB	MT	DTT
DMQ95EB	MA	Inhibitor
DMQ95EB	RN	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
DMQ95EB	RU	https://pubmed.ncbi.nlm.nih.gov/17850214

DMQ95EB	DI	DMQ95EB
DMQ95EB	DN	AS-601245
DMQ95EB	MI	TT056SO
DMQ95EB	MN	Stress-activated protein kinase JNK3 (JNK3)
DMQ95EB	MT	DTT
DMQ95EB	MA	Inhibitor
DMQ95EB	RN	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
DMQ95EB	RU	https://pubmed.ncbi.nlm.nih.gov/18077363

DMANU3W	DI	DMANU3W
DMANU3W	DN	AS-602704
DMANU3W	MI	TTE4KHA
DMANU3W	MN	Amyloid beta A4 protein (APP)
DMANU3W	MT	DTT
DMANU3W	MA	Modulator
DMANU3W	RN	Transport characteristics of a beta sheet breaker peptide across excised bovine nasal mucosa. Drug Dev Ind Pharm. 2007 Jan;33(1):71-7.
DMANU3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/17192253

DM9IUSM	DI	DM9IUSM
DM9IUSM	DN	AS-604850
DM9IUSM	MI	TTHBTOP
DM9IUSM	MN	PI3-kinase gamma (PIK3CG)
DM9IUSM	MT	DTT
DM9IUSM	MA	Inhibitor
DM9IUSM	RN	Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med. 2005 Sep;11(9):936-43.
DM9IUSM	RU	https://pubmed.ncbi.nlm.nih.gov/16127437

DM9V5GS	DI	DM9V5GS
DM9V5GS	DN	AS604872
DM9V5GS	MI	TTT2ZAR
DM9V5GS	MN	Prostaglandin F2-alpha receptor (PTGFR)
DM9V5GS	MT	DTT
DM9V5GS	MA	Antagonist
DM9V5GS	RN	Arrest of preterm labor in rat and mouse by an oral and selective nonprostanoid antagonist of the prostaglandin F2alpha receptor (FP). Am J Obstet Gynecol. 2007 Jul;197(1):54.e1-9.
DM9V5GS	RU	https://pubmed.ncbi.nlm.nih.gov/17618756

DM9CIJP	DI	DM9CIJP
DM9CIJP	DN	AS70
DM9CIJP	MI	TTK25J1
DM9CIJP	MN	Adenosine A1 receptor (ADORA1)
DM9CIJP	MT	DTT
DM9CIJP	MA	Antagonist
DM9CIJP	RN	Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors. Biochem Pharmacol. 2005 Nov 25;70(11):1601-12.
DM9CIJP	RU	https://pubmed.ncbi.nlm.nih.gov/16219300

DM9CIJP	DI	DM9CIJP
DM9CIJP	DN	AS70
DM9CIJP	MI	TTNE7KG
DM9CIJP	MN	Adenosine A2b receptor (ADORA2B)
DM9CIJP	MT	DTT
DM9CIJP	MA	Antagonist
DM9CIJP	RN	Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors. Biochem Pharmacol. 2005 Nov 25;70(11):1601-12.
DM9CIJP	RU	https://pubmed.ncbi.nlm.nih.gov/16219300

DMZPHKG	DI	DMZPHKG
DMZPHKG	DN	AS74
DMZPHKG	MI	TTNE7KG
DMZPHKG	MN	Adenosine A2b receptor (ADORA2B)
DMZPHKG	MT	DTT
DMZPHKG	MA	Antagonist
DMZPHKG	RN	Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors. Biochem Pharmacol. 2005 Nov 25;70(11):1601-12.
DMZPHKG	RU	https://pubmed.ncbi.nlm.nih.gov/16219300

DM7WJ6F	DI	DM7WJ6F
DM7WJ6F	DN	AS94
DM7WJ6F	MI	TTNE7KG
DM7WJ6F	MN	Adenosine A2b receptor (ADORA2B)
DM7WJ6F	MT	DTT
DM7WJ6F	MA	Antagonist
DM7WJ6F	RN	Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors. Biochem Pharmacol. 2005 Nov 25;70(11):1601-12.
DM7WJ6F	RU	https://pubmed.ncbi.nlm.nih.gov/16219300

DMN3E9Q	DI	DMN3E9Q
DMN3E9Q	DN	AS95
DMN3E9Q	MI	TTNE7KG
DMN3E9Q	MN	Adenosine A2b receptor (ADORA2B)
DMN3E9Q	MT	DTT
DMN3E9Q	MA	Antagonist
DMN3E9Q	RN	Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors. Biochem Pharmacol. 2005 Nov 25;70(11):1601-12.
DMN3E9Q	RU	https://pubmed.ncbi.nlm.nih.gov/16219300

DML6I8J	DI	DML6I8J
DML6I8J	DN	AS96
DML6I8J	MI	TTNE7KG
DML6I8J	MN	Adenosine A2b receptor (ADORA2B)
DML6I8J	MT	DTT
DML6I8J	MA	Antagonist
DML6I8J	RN	Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors. Biochem Pharmacol. 2005 Nov 25;70(11):1601-12.
DML6I8J	RU	https://pubmed.ncbi.nlm.nih.gov/16219300

DMR01O4	DI	DMR01O4
DMR01O4	DN	AS-9705
DMR01O4	MI	TT4C8EA
DMR01O4	MN	Dopamine D3 receptor (D3R)
DMR01O4	MT	DTT
DMR01O4	MA	Antagonist
DMR01O4	RN	Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar;11(1):137-51.
DMR01O4	RU	https://pubmed.ncbi.nlm.nih.gov/16503832

DMZ7FJN	DI	DMZ7FJN
DMZ7FJN	DN	AS99
DMZ7FJN	MI	TTK25J1
DMZ7FJN	MN	Adenosine A1 receptor (ADORA1)
DMZ7FJN	MT	DTT
DMZ7FJN	MA	Antagonist
DMZ7FJN	RN	Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors. Biochem Pharmacol. 2005 Nov 25;70(11):1601-12.
DMZ7FJN	RU	https://pubmed.ncbi.nlm.nih.gov/16219300

DMZ7FJN	DI	DMZ7FJN
DMZ7FJN	DN	AS99
DMZ7FJN	MI	TTNE7KG
DMZ7FJN	MN	Adenosine A2b receptor (ADORA2B)
DMZ7FJN	MT	DTT
DMZ7FJN	MA	Antagonist
DMZ7FJN	RN	Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors. Biochem Pharmacol. 2005 Nov 25;70(11):1601-12.
DMZ7FJN	RU	https://pubmed.ncbi.nlm.nih.gov/16219300

DM3WVPJ	DI	DM3WVPJ
DM3WVPJ	DN	Asacolitin
DM3WVPJ	MI	DEFHZW7
DM3WVPJ	MN	Arylamine N-acetyltransferase (NAT)
DM3WVPJ	MT	DME
DM3WVPJ	MA	Metabolism
DM3WVPJ	RN	Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: evidence for highly selective acetylation of 5-aminosalicylic acid. J Bacteriol. 2001 Jun;183(11):3417-27.
DM3WVPJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11344150

DM3WVPJ	DI	DM3WVPJ
DM3WVPJ	DN	Asacolitin
DM3WVPJ	MI	DE97F4R
DM3WVPJ	MN	Arylamine N-acetyltransferase (NAT)
DM3WVPJ	MT	DME
DM3WVPJ	MA	Metabolism
DM3WVPJ	RN	Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: evidence for highly selective acetylation of 5-aminosalicylic acid. J Bacteriol. 2001 Jun;183(11):3417-27.
DM3WVPJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11344150

DM3WVPJ	DI	DM3WVPJ
DM3WVPJ	DN	Asacolitin
DM3WVPJ	MI	DEKBP7I
DM3WVPJ	MN	Arylamine N-acetyltransferase (NAT)
DM3WVPJ	MT	DME
DM3WVPJ	MA	Metabolism
DM3WVPJ	RN	Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: evidence for highly selective acetylation of 5-aminosalicylic acid. J Bacteriol. 2001 Jun;183(11):3417-27.
DM3WVPJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11344150

DM3WVPJ	DI	DM3WVPJ
DM3WVPJ	DN	Asacolitin
DM3WVPJ	MI	DEPI0ME
DM3WVPJ	MN	Arylamine N-acetyltransferase (NAT)
DM3WVPJ	MT	DME
DM3WVPJ	MA	Metabolism
DM3WVPJ	RN	Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: evidence for highly selective acetylation of 5-aminosalicylic acid. J Bacteriol. 2001 Jun;183(11):3417-27.
DM3WVPJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11344150

DM3WVPJ	DI	DM3WVPJ
DM3WVPJ	DN	Asacolitin
DM3WVPJ	MI	DE5DY7B
DM3WVPJ	MN	Arylamine N-acetyltransferase (NAT)
DM3WVPJ	MT	DME
DM3WVPJ	MA	Metabolism
DM3WVPJ	RN	Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: evidence for highly selective acetylation of 5-aminosalicylic acid. J Bacteriol. 2001 Jun;183(11):3417-27.
DM3WVPJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11344150

DM3WVPJ	DI	DM3WVPJ
DM3WVPJ	DN	Asacolitin
DM3WVPJ	MI	DE2S6QE
DM3WVPJ	MN	Arylamine N-acetyltransferase (NAT)
DM3WVPJ	MT	DME
DM3WVPJ	MA	Metabolism
DM3WVPJ	RN	Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: evidence for highly selective acetylation of 5-aminosalicylic acid. J Bacteriol. 2001 Jun;183(11):3417-27.
DM3WVPJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11344150

DM3WVPJ	DI	DM3WVPJ
DM3WVPJ	DN	Asacolitin
DM3WVPJ	MI	DEF5JD3
DM3WVPJ	MN	Arylamine N-acetyltransferase (NAT)
DM3WVPJ	MT	DME
DM3WVPJ	MA	Metabolism
DM3WVPJ	RN	Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: evidence for highly selective acetylation of 5-aminosalicylic acid. J Bacteriol. 2001 Jun;183(11):3417-27.
DM3WVPJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11344150

DM3WVPJ	DI	DM3WVPJ
DM3WVPJ	DN	Asacolitin
DM3WVPJ	MI	DE6C3R7
DM3WVPJ	MN	Arylamine N-acetyltransferase (NAT)
DM3WVPJ	MT	DME
DM3WVPJ	MA	Metabolism
DM3WVPJ	RN	Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: evidence for highly selective acetylation of 5-aminosalicylic acid. J Bacteriol. 2001 Jun;183(11):3417-27.
DM3WVPJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11344150

DM3WVPJ	DI	DM3WVPJ
DM3WVPJ	DN	Asacolitin
DM3WVPJ	MI	DE14FI7
DM3WVPJ	MN	Arylamine N-acetyltransferase (NAT)
DM3WVPJ	MT	DME
DM3WVPJ	MA	Metabolism
DM3WVPJ	RN	Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: evidence for highly selective acetylation of 5-aminosalicylic acid. J Bacteriol. 2001 Jun;183(11):3417-27.
DM3WVPJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11344150

DM3WVPJ	DI	DM3WVPJ
DM3WVPJ	DN	Asacolitin
DM3WVPJ	MI	DE8V274
DM3WVPJ	MN	Arylamine N-acetyltransferase (NAT)
DM3WVPJ	MT	DME
DM3WVPJ	MA	Metabolism
DM3WVPJ	RN	Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: evidence for highly selective acetylation of 5-aminosalicylic acid. J Bacteriol. 2001 Jun;183(11):3417-27.
DM3WVPJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11344150

DM3WVPJ	DI	DM3WVPJ
DM3WVPJ	DN	Asacolitin
DM3WVPJ	MI	DEG7L5K
DM3WVPJ	MN	Arylamine N-acetyltransferase (NAT)
DM3WVPJ	MT	DME
DM3WVPJ	MA	Metabolism
DM3WVPJ	RN	Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: evidence for highly selective acetylation of 5-aminosalicylic acid. J Bacteriol. 2001 Jun;183(11):3417-27.
DM3WVPJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11344150

DM3WVPJ	DI	DM3WVPJ
DM3WVPJ	DN	Asacolitin
DM3WVPJ	MI	DEJ01UG
DM3WVPJ	MN	Arylamine N-acetyltransferase (NAT)
DM3WVPJ	MT	DME
DM3WVPJ	MA	Metabolism
DM3WVPJ	RN	Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: evidence for highly selective acetylation of 5-aminosalicylic acid. J Bacteriol. 2001 Jun;183(11):3417-27.
DM3WVPJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11344150

DM3WVPJ	DI	DM3WVPJ
DM3WVPJ	DN	Asacolitin
DM3WVPJ	MI	DE7OAB3
DM3WVPJ	MN	N-acetyltransferase 1 (NAT1)
DM3WVPJ	MT	DME
DM3WVPJ	MA	Metabolism
DM3WVPJ	RN	Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: evidence for highly selective acetylation of 5-aminosalicylic acid. J Bacteriol. 2001 Jun;183(11):3417-27.
DM3WVPJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11344150

DM3WVPJ	DI	DM3WVPJ
DM3WVPJ	DN	Asacolitin
DM3WVPJ	MI	DER7TA0
DM3WVPJ	MN	N-acetyltransferase 2 (NAT2)
DM3WVPJ	MT	DME
DM3WVPJ	MA	Metabolism
DM3WVPJ	RN	Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: evidence for highly selective acetylation of 5-aminosalicylic acid. J Bacteriol. 2001 Jun;183(11):3417-27.
DM3WVPJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11344150

DM5WR0L	DI	DM5WR0L
DM5WR0L	DN	ASC-201
DM5WR0L	MI	TTDIGC1
DM5WR0L	MN	Dipeptidyl peptidase 4 (DPP-4)
DM5WR0L	MT	DTT
DM5WR0L	MA	Inhibitor
DM5WR0L	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1612).
DM5WR0L	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1612

DMYJ87C	DI	DMYJ87C
DMYJ87C	DN	ASC-JMX2
DMYJ87C	MI	TTS64P2
DMYJ87C	MN	Androgen receptor (AR)
DMYJ87C	MT	DTT
DMYJ87C	MA	Antagonist
DMYJ87C	RN	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
DMYJ87C	RU	https://www.ncbi.nlm.nih.gov/pubmed/27899562

DMT5LJN	DI	DMT5LJN
DMT5LJN	DN	ASC-JMZ1
DMT5LJN	MI	TTS64P2
DMT5LJN	MN	Androgen receptor (AR)
DMT5LJN	MT	DTT
DMT5LJN	MA	Modulator
DMT5LJN	RN	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
DMT5LJN	RU	https://www.ncbi.nlm.nih.gov/pubmed/27899562

DMT8Y65	DI	DMT8Y65
DMT8Y65	DN	ASIATIC ACID
DMT8Y65	MI	TTZHY6R
DMT8Y65	MN	Glycogen phosphorylase muscle form (GP)
DMT8Y65	MT	DTT
DMT8Y65	MA	Inhibitor
DMT8Y65	RN	Naturally occurring pentacyclic triterpenes as inhibitors of glycogen phosphorylase: synthesis, structure-activity relationships, and X-ray crystal... J Med Chem. 2008 Jun 26;51(12):3540-54.
DMT8Y65	RU	https://pubmed.ncbi.nlm.nih.gov/18517260

DMTBZUC	DI	DMTBZUC
DMTBZUC	DN	ASKENDOSIDE B
DMTBZUC	MI	TTULVH8
DMTBZUC	MN	Tyrosinase (TYR)
DMTBZUC	MT	DTT
DMTBZUC	MA	Inhibitor
DMTBZUC	RN	New tyrosinase inhibitors selected by atomic linear indices-based classification models. Bioorg Med Chem Lett. 2006 Jan 15;16(2):324-30.
DMTBZUC	RU	https://pubmed.ncbi.nlm.nih.gov/16275084

DM2DPYQ	DI	DM2DPYQ
DM2DPYQ	DN	ASKH95
DM2DPYQ	MI	TTQR74A
DM2DPYQ	MN	Proteinase activated receptor 2 (PAR2)
DM2DPYQ	MT	DTT
DM2DPYQ	MA	Agonist
DM2DPYQ	RN	Essential role for proteinase-activated receptor-2 in arthritis. J Clin Invest. 2003 Jan;111(1):35-41.
DM2DPYQ	RU	https://pubmed.ncbi.nlm.nih.gov/12511586

DMEO3Y4	DI	DMEO3Y4
DMEO3Y4	DN	ASN02563583
DMEO3Y4	MI	TTMPART
DMEO3Y4	MN	Uracil nucleotide/cysteinyl leukotriene receptor (GPR17)
DMEO3Y4	MT	DTT
DMEO3Y4	MA	Agonist
DMEO3Y4	RN	In silico identification of new ligands for GPR17: a promising therapeutic target for neurodegenerative diseases. J Comput Aided Mol Des. 2011 Aug;25(8):743-52.
DMEO3Y4	RU	https://pubmed.ncbi.nlm.nih.gov/21744154

DMC82XN	DI	DMC82XN
DMC82XN	DN	ASN04421891
DMC82XN	MI	TTMPART
DMC82XN	MN	Uracil nucleotide/cysteinyl leukotriene receptor (GPR17)
DMC82XN	MT	DTT
DMC82XN	MA	Agonist
DMC82XN	RN	In silico identification of new ligands for GPR17: a promising therapeutic target for neurodegenerative diseases. J Comput Aided Mol Des. 2011 Aug;25(8):743-52.
DMC82XN	RU	https://pubmed.ncbi.nlm.nih.gov/21744154

DMKR69T	DI	DMKR69T
DMKR69T	DN	ASN04450772
DMKR69T	MI	TTMPART
DMKR69T	MN	Uracil nucleotide/cysteinyl leukotriene receptor (GPR17)
DMKR69T	MT	DTT
DMKR69T	MA	Agonist
DMKR69T	RN	In silico identification of new ligands for GPR17: a promising therapeutic target for neurodegenerative diseases. J Comput Aided Mol Des. 2011 Aug;25(8):743-52.
DMKR69T	RU	https://pubmed.ncbi.nlm.nih.gov/21744154

DMQ0VZ8	DI	DMQ0VZ8
DMQ0VZ8	DN	ASN04885796
DMQ0VZ8	MI	TTMPART
DMQ0VZ8	MN	Uracil nucleotide/cysteinyl leukotriene receptor (GPR17)
DMQ0VZ8	MT	DTT
DMQ0VZ8	MA	Agonist
DMQ0VZ8	RN	In silico identification of new ligands for GPR17: a promising therapeutic target for neurodegenerative diseases. J Comput Aided Mol Des. 2011 Aug;25(8):743-52.
DMQ0VZ8	RU	https://pubmed.ncbi.nlm.nih.gov/21744154

DMA20JP	DI	DMA20JP
DMA20JP	DN	ASN06917370
DMA20JP	MI	TTMPART
DMA20JP	MN	Uracil nucleotide/cysteinyl leukotriene receptor (GPR17)
DMA20JP	MT	DTT
DMA20JP	MA	Agonist
DMA20JP	RN	In silico identification of new ligands for GPR17: a promising therapeutic target for neurodegenerative diseases. J Comput Aided Mol Des. 2011 Aug;25(8):743-52.
DMA20JP	RU	https://pubmed.ncbi.nlm.nih.gov/21744154

DMFNZOI	DI	DMFNZOI
DMFNZOI	DN	ASN-11124542
DMFNZOI	MI	TTXEZJ4
DMFNZOI	MN	Tyrosine-protein kinase EIF2AK2 (p68)
DMFNZOI	MT	DTT
DMFNZOI	MA	Inhibitor
DMFNZOI	RN	Small molecule inhibitors of the RNA-dependent protein kinase. Biochem Biophys Res Commun. 2003 Aug 15;308(1):50-7.
DMFNZOI	RU	https://pubmed.ncbi.nlm.nih.gov/12890478

DM8XT1Y	DI	DM8XT1Y
DM8XT1Y	DN	ASOBAMAST
DM8XT1Y	MI	TTMPGNS
DM8XT1Y	MN	Leukotriene biosynthesis (LT synth)
DM8XT1Y	MT	DTT
DM8XT1Y	MA	Modulator
DM8XT1Y	RN	Regulation of leukotriene biosynthesis. Cancer Metastasis Rev. 1994 Dec;13(3-4):257-67.
DM8XT1Y	RU	https://pubmed.ncbi.nlm.nih.gov/7712588

DM3XCM1	DI	DM3XCM1
DM3XCM1	DN	ASP-2002
DM3XCM1	MI	TT4BT06
DM3XCM1	MN	Integrin alpha-4 (ITGA4)
DM3XCM1	MT	DTT
DM3XCM1	MA	Antagonist
DM3XCM1	RN	Asphelia to Present at C21 BioVentures Conference in Napa, CA. 10th Annual C21 BioVentures. May 15, 2008.
DM3XCM1	RU	http://www.businesswire.com/news/home/20080515005310/en/Asphelia-Present-C21-BioVentures-Conference-Napa-CA#.VhskvPmqpBc

DMZ9GQR	DI	DMZ9GQR
DMZ9GQR	DN	ASP-3258
DMZ9GQR	MI	TTZ97H5
DMZ9GQR	MN	Phosphodiesterase 4A (PDE4A)
DMZ9GQR	MT	DTT
DMZ9GQR	MA	Inhibitor
DMZ9GQR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1300).
DMZ9GQR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1300

DMZ9GQR	DI	DMZ9GQR
DMZ9GQR	DN	ASP-3258
DMZ9GQR	MI	TTVIAT9
DMZ9GQR	MN	Phosphodiesterase 4B (PDE4B)
DMZ9GQR	MT	DTT
DMZ9GQR	MA	Inhibitor
DMZ9GQR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1301).
DMZ9GQR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1301

DMZ9GQR	DI	DMZ9GQR
DMZ9GQR	DN	ASP-3258
DMZ9GQR	MI	TTSKMI8
DMZ9GQR	MN	Phosphodiesterase 4D (PDE4D)
DMZ9GQR	MT	DTT
DMZ9GQR	MA	Inhibitor
DMZ9GQR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1303).
DMZ9GQR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1303

DMFWTOP	DI	DMFWTOP
DMFWTOP	DN	ASP-8370
DMFWTOP	MI	TTMI6F5
DMFWTOP	MN	Transient receptor potential cation channel V1 (TRPV1)
DMFWTOP	MT	DTT
DMFWTOP	MA	Antagonist
DMFWTOP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 507).
DMFWTOP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=507

DMGB90V	DI	DMGB90V
DMGB90V	DN	Aspartate Semialdehyde
DMGB90V	MI	TTQWGU9
DMGB90V	MN	Bacterial Aspartate-semialdehyde dehydrogenase (Bact asd2)
DMGB90V	MT	DTT
DMGB90V	MA	Inhibitor
DMGB90V	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMGB90V	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMK7EYA	DI	DMK7EYA
DMK7EYA	DN	Aspartic acid
DMK7EYA	MI	DT38SZL
DMK7EYA	MN	Organic cation transporter-like 3 (SLC22A13)
DMK7EYA	MT	DTP
DMK7EYA	MA	Substrate
DMK7EYA	RN	SLC22A13 catalyses unidirectional efflux of aspartate and glutamate at the basolateral membrane of type A intercalated cells in the renal collecting duct. Biochem J. 2014 Jan 15;457(2):243-51.
DMK7EYA	RU	http://www.ncbi.nlm.nih.gov/pubmed/24147638

DMK7EYA	DI	DMK7EYA
DMK7EYA	DN	Aspartic acid
DMK7EYA	MI	DT2LGOY
DMK7EYA	MN	Putative sodium-coupled neutral amino acid transporter 10 (SLC38A10)
DMK7EYA	MT	DTP
DMK7EYA	MA	Substrate
DMK7EYA	RN	The neuronal and astrocytic protein SLC38A10 transports glutamine, glutamate, and aspartate, suggesting a role in neurotransmission. FEBS Open Bio. 2017 Apr 26;7(6):730-746.
DMK7EYA	RU	http://www.ncbi.nlm.nih.gov/pubmed/28593130

DMJEZ62	DI	DMJEZ62
DMJEZ62	DN	Asp-BrPmp-Leu
DMJEZ62	MI	TTUS45N
DMJEZ62	MN	Leukocyte common antigen (PTPRC)
DMJEZ62	MT	DTT
DMJEZ62	MA	Inhibitor
DMJEZ62	RN	A protected l-bromophosphonomethylphenylalanine amino acid derivative (BrPmp) for synthesis of irreversible protein tyrosine phosphatase inhibitors. Bioorg Med Chem. 2010 Dec 15;18(24):8679-86.
DMJEZ62	RU	https://pubmed.ncbi.nlm.nih.gov/21055952

DMEW37R	DI	DMEW37R
DMEW37R	DN	Asp-D-Glu-Leu-Glu-Cha-Cys
DMEW37R	MI	TTWXB3E
DMEW37R	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DMEW37R	MT	DTT
DMEW37R	MA	Inhibitor
DMEW37R	RN	Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain. Bioorg Med Chem Lett. 2001 Jan 22;11(2):203-6.
DMEW37R	RU	https://pubmed.ncbi.nlm.nih.gov/11206459

DMAY2N3	DI	DMAY2N3
DMAY2N3	DN	Asperlicin
DMAY2N3	MI	TTCG0AL
DMAY2N3	MN	Cholecystokinin receptor type A (CCKAR)
DMAY2N3	MT	DTT
DMAY2N3	MA	Antagonist
DMAY2N3	RN	Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
DMAY2N3	RU	https://pubmed.ncbi.nlm.nih.gov/18045214

DMLBSNP	DI	DMLBSNP
DMLBSNP	DN	aspirin triggered lipoxin A4
DMLBSNP	MI	TTOJ1NF
DMLBSNP	MN	FMLP-related receptor I (FPR2)
DMLBSNP	MT	DTT
DMLBSNP	MA	Agonist
DMLBSNP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 223).
DMLBSNP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=223

DMOP941	DI	DMOP941
DMOP941	DN	aspirin-triggered resolvin D1
DMOP941	MI	TTOJ1NF
DMOP941	MN	FMLP-related receptor I (FPR2)
DMOP941	MT	DTT
DMOP941	MA	Agonist
DMOP941	RN	Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs. Am J Pathol. 2012 May;180(5):2018-27.
DMOP941	RU	https://pubmed.ncbi.nlm.nih.gov/22449948

DMOP941	DI	DMOP941
DMOP941	DN	aspirin-triggered resolvin D1
DMOP941	MI	TT946IA
DMOP941	MN	Transient receptor potential cation channel V3 (TRPV3)
DMOP941	MT	DTT
DMOP941	MA	Blocker (channel blocker)
DMOP941	RN	17(R)-resolvin D1 specifically inhibits transient receptor potential ion channel vanilloid 3 leading to peripheral antinociception. Br J Pharmacol. 2012 Feb;165(3):683-92.
DMOP941	RU	https://pubmed.ncbi.nlm.nih.gov/21718307

DMKAHYQ	DI	DMKAHYQ
DMKAHYQ	DN	Asp-Tyr(OSO3H)-Met-Gly-Trp-Met-Asp-Phe
DMKAHYQ	MI	TTCG0AL
DMKAHYQ	MN	Cholecystokinin receptor type A (CCKAR)
DMKAHYQ	MT	DTT
DMKAHYQ	MA	Inhibitor
DMKAHYQ	RN	Toward developing peptidomimetics: Successful replacement of backbone amide bonds in tetrapeptide-based CCK-A receptor agonists, Bioorg. Med. Chem. Lett. 3(5):855-860 (1993).
DMKAHYQ	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00806800

DMKAHYQ	DI	DMKAHYQ
DMKAHYQ	DN	Asp-Tyr(OSO3H)-Met-Gly-Trp-Met-Asp-Phe
DMKAHYQ	MI	TTVFO0U
DMKAHYQ	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMKAHYQ	MT	DTT
DMKAHYQ	MA	Inhibitor
DMKAHYQ	RN	The rational design and synthesis of non-peptide hegnylogues of CCK-26-33 - a novel series of CCK-A selective ligands, Bioorg. Med. Chem. Lett. 3(5):889-894 (1993).
DMKAHYQ	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00806873

DME76KU	DI	DME76KU
DME76KU	DN	AST-487
DME76KU	MI	TTGJCWZ
DME76KU	MN	Fms-like tyrosine kinase 3 (FLT-3)
DME76KU	MT	DTT
DME76KU	MA	Inhibitor
DME76KU	RN	Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011 Oct 30;29(11):1046-51.
DME76KU	RU	https://pubmed.ncbi.nlm.nih.gov/22037378

DME76KU	DI	DME76KU
DME76KU	DN	AST-487
DME76KU	MI	TT4DXQT
DME76KU	MN	Proto-oncogene c-Ret (RET)
DME76KU	MT	DTT
DME76KU	MA	Inhibitor
DME76KU	RN	The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. Cancer Res. 2007 Jul 15;67(14):6956-64.
DME76KU	RU	https://pubmed.ncbi.nlm.nih.gov/17638907

DME76KU	DI	DME76KU
DME76KU	DN	AST-487
DME76KU	MI	TTX41N9
DME76KU	MN	Tyrosine-protein kinase Kit (KIT)
DME76KU	MT	DTT
DME76KU	MA	Inhibitor
DME76KU	RN	The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. Cancer Res. 2007 Jul 15;67(14):6956-64.
DME76KU	RU	https://pubmed.ncbi.nlm.nih.gov/17638907

DME76KU	DI	DME76KU
DME76KU	DN	AST-487
DME76KU	MI	TTUTJGQ
DME76KU	MN	Vascular endothelial growth factor receptor 2 (KDR)
DME76KU	MT	DTT
DME76KU	MA	Inhibitor
DME76KU	RN	The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. Cancer Res. 2007 Jul 15;67(14):6956-64.
DME76KU	RU	https://pubmed.ncbi.nlm.nih.gov/17638907

DMJAPFH	DI	DMJAPFH
DMJAPFH	DN	Asterric acid
DMJAPFH	MI	TTKRD0G
DMJAPFH	MN	Endothelin A receptor (EDNRA)
DMJAPFH	MT	DTT
DMJAPFH	MA	Inhibitor
DMJAPFH	RN	New chlorinated diphenyl ethers from an Aspergillus species. J Nat Prod. 2002 Jan;65(1):7-10.
DMJAPFH	RU	https://pubmed.ncbi.nlm.nih.gov/11809055

DMZHWPG	DI	DMZHWPG
DMZHWPG	DN	ASTRAGALIN
DMZHWPG	MI	TTFBNVI
DMZHWPG	MN	Aldose reductase (AKR1B1)
DMZHWPG	MT	DTT
DMZHWPG	MA	Inhibitor
DMZHWPG	RN	Erigeroflavanone, a flavanone derivative from the flowers of Erigeron annuus with protein glycation and aldose reductase inhibitory activity. J Nat Prod. 2008 Apr;71(4):713-5.
DMZHWPG	RU	https://pubmed.ncbi.nlm.nih.gov/18298080

DMZHWPG	DI	DMZHWPG
DMZHWPG	DN	ASTRAGALIN
DMZHWPG	MI	TTL69WB
DMZHWPG	MN	Angiotensin-converting enzyme (ACE)
DMZHWPG	MT	DTT
DMZHWPG	MA	Inhibitor
DMZHWPG	RN	Inhibitory effects of various flavonoids isolated from leaves of persimmon on angiotensin-converting enzyme activity. J Nat Prod. 1987 Jul-Aug;50(4):680-3.
DMZHWPG	RU	https://pubmed.ncbi.nlm.nih.gov/3430165

DMSFLTK	DI	DMSFLTK
DMSFLTK	DN	astressin
DMSFLTK	MI	TTIY658
DMSFLTK	MN	Corticotropin-releasing factor receptor 2 (CRHR2)
DMSFLTK	MT	DTT
DMSFLTK	MA	Antagonist
DMSFLTK	RN	Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of corticotropin-releasing factor receptors. J Pharmacol Exp Ther. 1999 Feb;288(2):729-34.
DMSFLTK	RU	https://pubmed.ncbi.nlm.nih.gov/9918582

DMODLPS	DI	DMODLPS
DMODLPS	DN	AT-008
DMODLPS	MI	TT7HQD0
DMODLPS	MN	C-C chemokine receptor type 4 (CCR4)
DMODLPS	MT	DTT
DMODLPS	MA	Antagonist
DMODLPS	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 61).
DMODLPS	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=61

DMCO2S4	DI	DMCO2S4
DMCO2S4	DN	AT-009
DMCO2S4	MI	TTBID49
DMCO2S4	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMCO2S4	MT	DTT
DMCO2S4	MA	Antagonist
DMCO2S4	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 71).
DMCO2S4	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=71

DMJNQ5G	DI	DMJNQ5G
DMJNQ5G	DN	ATC0065
DMJNQ5G	MI	TTX4RTB
DMJNQ5G	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMJNQ5G	MT	DTT
DMJNQ5G	MA	Antagonist
DMJNQ5G	RN	Anxiolytic- and antidepressant-like profile of ATC0065 and ATC0175: nonpeptidic and orally active melanin-concentrating hormone receptor 1 antagoni... J Pharmacol Exp Ther. 2005 May;313(2):831-9.
DMJNQ5G	RU	https://pubmed.ncbi.nlm.nih.gov/15677346

DMJNQ5G	DI	DMJNQ5G
DMJNQ5G	DN	ATC0065
DMJNQ5G	MI	TTS17MG
DMJNQ5G	MN	Melanin-concentrating hormone receptor 2 (MCHR2)
DMJNQ5G	MT	DTT
DMJNQ5G	MA	Antagonist
DMJNQ5G	RN	Anxiolytic- and antidepressant-like profile of ATC0065 and ATC0175: nonpeptidic and orally active melanin-concentrating hormone receptor 1 antagoni... J Pharmacol Exp Ther. 2005 May;313(2):831-9.
DMJNQ5G	RU	https://pubmed.ncbi.nlm.nih.gov/15677346

DMIA2F1	DI	DMIA2F1
DMIA2F1	DN	ATC-120
DMIA2F1	MI	TTMI6F5
DMIA2F1	MN	Transient receptor potential cation channel V1 (TRPV1)
DMIA2F1	MT	DTT
DMIA2F1	MA	Inhibitor
DMIA2F1	RN	Silicon switch approach in TRPV1 antagonist MK-056 and its analogues. Bioorg Med Chem. 2010 Jan 1;18(1):111-6.
DMIA2F1	RU	https://pubmed.ncbi.nlm.nih.gov/19931463

DMPJRHX	DI	DMPJRHX
DMPJRHX	DN	ATF-HI-8
DMPJRHX	MI	TT2WR1T
DMPJRHX	MN	Cationic trypsinogen (PRSS1)
DMPJRHX	MT	DTT
DMPJRHX	MA	Modulator
DMPJRHX	RN	Inhibitory effect of a conjugate between human urokinase and urinary trypsin inhibitor on tumor cell invasion in vitro. J Biol Chem. 1995 Apr 7;270(14):8361-6.
DMPJRHX	RU	https://www.ncbi.nlm.nih.gov/pubmed/7713945

DMPJRHX	DI	DMPJRHX
DMPJRHX	DN	ATF-HI-8
DMPJRHX	MI	TTGY7WI
DMPJRHX	MN	Urokinase-type plasminogen activator (PLAU)
DMPJRHX	MT	DTT
DMPJRHX	MA	Modulator
DMPJRHX	RN	Inhibitory effect of a conjugate between human urokinase and urinary trypsin inhibitor on tumor cell invasion in vitro. J Biol Chem. 1995 Apr 7;270(14):8361-6.
DMPJRHX	RU	https://www.ncbi.nlm.nih.gov/pubmed/7713945

DMSNBMQ	DI	DMSNBMQ
DMSNBMQ	DN	ATH-90879
DMSNBMQ	MI	TT9JNIC
DMSNBMQ	MN	Histamine H3 receptor (H3R)
DMSNBMQ	MT	DTT
DMSNBMQ	MA	Antagonist
DMSNBMQ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 264).
DMSNBMQ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=264

DMN5VDB	DI	DMN5VDB
DMN5VDB	DN	ATI-1150
DMN5VDB	MI	TTGTQHC
DMN5VDB	MN	DNA topoisomerase I (TOP1)
DMN5VDB	MT	DTT
DMN5VDB	MA	Inhibitor
DMN5VDB	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2636).
DMN5VDB	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2636

DMLDWHP	DI	DMLDWHP
DMLDWHP	DN	ATI-2341
DMLDWHP	MI	TTBID49
DMLDWHP	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMLDWHP	MT	DTT
DMLDWHP	MA	Agonist
DMLDWHP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 71).
DMLDWHP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=71

DMAZ0EQ	DI	DMAZ0EQ
DMAZ0EQ	DN	ATL-801
DMAZ0EQ	MI	TTNE7KG
DMAZ0EQ	MN	Adenosine A2b receptor (ADORA2B)
DMAZ0EQ	MT	DTT
DMAZ0EQ	MA	Antagonist
DMAZ0EQ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 20).
DMAZ0EQ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=20

DMYMCQA	DI	DMYMCQA
DMYMCQA	DN	ATL802
DMYMCQA	MI	TTK25J1
DMYMCQA	MN	Adenosine A1 receptor (ADORA1)
DMYMCQA	MT	DTT
DMYMCQA	MA	Antagonist
DMYMCQA	RN	Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A(2B) adenosine receptors. J Med Chem. 2000 Mar 23;43(6):1165-72.
DMYMCQA	RU	https://pubmed.ncbi.nlm.nih.gov/10737749

DMYMCQA	DI	DMYMCQA
DMYMCQA	DN	ATL802
DMYMCQA	MI	TTNE7KG
DMYMCQA	MN	Adenosine A2b receptor (ADORA2B)
DMYMCQA	MT	DTT
DMYMCQA	MA	Antagonist
DMYMCQA	RN	Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A(2B) adenosine receptors. J Med Chem. 2000 Mar 23;43(6):1165-72.
DMYMCQA	RU	https://pubmed.ncbi.nlm.nih.gov/10737749

DMYMCQA	DI	DMYMCQA
DMYMCQA	DN	ATL802
DMYMCQA	MI	TTJFY5U
DMYMCQA	MN	Adenosine A3 receptor (ADORA3)
DMYMCQA	MT	DTT
DMYMCQA	MA	Antagonist
DMYMCQA	RN	Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A(2B) adenosine receptors. J Med Chem. 2000 Mar 23;43(6):1165-72.
DMYMCQA	RU	https://pubmed.ncbi.nlm.nih.gov/10737749

DM6V9SC	DI	DM6V9SC
DM6V9SC	DN	ATL-844
DM6V9SC	MI	TTNE7KG
DM6V9SC	MN	Adenosine A2b receptor (ADORA2B)
DM6V9SC	MT	DTT
DM6V9SC	MA	Antagonist
DM6V9SC	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 20).
DM6V9SC	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=20

DMA632U	DI	DMA632U
DMA632U	DN	ATLa2
DMA632U	MI	TTOJ1NF
DMA632U	MN	FMLP-related receptor I (FPR2)
DMA632U	MT	DTT
DMA632U	MA	Agonist
DMA632U	RN	Novel 3-oxa lipoxin A4 analogues with enhanced chemical and metabolic stability have anti-inflammatory activity in vivo. J Med Chem. 2004 Apr 8;47(8):2157-65.
DMA632U	RU	https://pubmed.ncbi.nlm.nih.gov/15056011

DMR2M7L	DI	DMR2M7L
DMR2M7L	DN	ATN-658
DMR2M7L	MI	TTGY7WI
DMR2M7L	MN	Urokinase-type plasminogen activator (PLAU)
DMR2M7L	MT	DTT
DMR2M7L	MA	Activator
DMR2M7L	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2393).
DMR2M7L	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2393

DM2DAFS	DI	DM2DAFS
DM2DAFS	DN	ATPA
DM2DAFS	MI	TT0MYE2
DM2DAFS	MN	Glutamate receptor ionotropic kainate 1 (GRIK1)
DM2DAFS	MT	DTT
DM2DAFS	MA	Agonist
DM2DAFS	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 450).
DM2DAFS	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=450

DMXHQIN	DI	DMXHQIN
DMXHQIN	DN	ATPgammaS
DMXHQIN	MI	TTA93TL
DMXHQIN	MN	P2Y purinoceptor 1 (P2RY1)
DMXHQIN	MT	DTT
DMXHQIN	MA	Agonist
DMXHQIN	RN	An examination of deoxyadenosine 5'(alpha-thio)triphosphate as a ligand to define P2Y receptors and its selectivity as a low potency partial agonist of the P2Y1 receptor. Br J Pharmacol. 1997 May;121(2):338-44.
DMXHQIN	RU	https://pubmed.ncbi.nlm.nih.gov/9154346

DMXHQIN	DI	DMXHQIN
DMXHQIN	DN	ATPgammaS
DMXHQIN	MI	TTYXPCO
DMXHQIN	MN	P2Y purinoceptor 11 (P2RY11)
DMXHQIN	MT	DTT
DMXHQIN	MA	Agonist
DMXHQIN	RN	Pharmacological characterization of the human P2Y11 receptor. Br J Pharmacol. 1999 Nov;128(6):1199-206.
DMXHQIN	RU	https://pubmed.ncbi.nlm.nih.gov/10578132

DMXHQIN	DI	DMXHQIN
DMXHQIN	DN	ATPgammaS
DMXHQIN	MI	TT1FE3L
DMXHQIN	MN	P2Y purinoceptor 13 (P2RY13)
DMXHQIN	MT	DTT
DMXHQIN	MA	Agonist
DMXHQIN	RN	Pharmacological characterization of the human P2Y13 receptor. Mol Pharmacol. 2003 Jul;64(1):104-12.
DMXHQIN	RU	https://pubmed.ncbi.nlm.nih.gov/12815166

DMXLS78	DI	DMXLS78
DMXLS78	DN	ATPO
DMXLS78	MI	TTVPQTF
DMXLS78	MN	Glutamate receptor AMPA 1 (GRIA1)
DMXLS78	MT	DTT
DMXLS78	MA	Antagonist
DMXLS78	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 444).
DMXLS78	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=444

DMXLS78	DI	DMXLS78
DMXLS78	DN	ATPO
DMXLS78	MI	TT9HLZ0
DMXLS78	MN	Glutamate receptor AMPA 2 (GRIA2)
DMXLS78	MT	DTT
DMXLS78	MA	Antagonist
DMXLS78	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 445).
DMXLS78	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=445

DMXLS78	DI	DMXLS78
DMXLS78	DN	ATPO
DMXLS78	MI	TT82EZV
DMXLS78	MN	Glutamate receptor AMPA 3 (GRIA3)
DMXLS78	MT	DTT
DMXLS78	MA	Antagonist
DMXLS78	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 446).
DMXLS78	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=446

DMXLS78	DI	DMXLS78
DMXLS78	DN	ATPO
DMXLS78	MI	TTPJR0G
DMXLS78	MN	Glutamate receptor AMPA 4 (GRIA4)
DMXLS78	MT	DTT
DMXLS78	MA	Antagonist
DMXLS78	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 447).
DMXLS78	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=447

DML2MAI	DI	DML2MAI
DML2MAI	DN	ATRIPLICIOLIDTIGLATE
DML2MAI	MI	TTSXVID
DML2MAI	MN	Nuclear factor NF-kappa-B (NFKB)
DML2MAI	MT	DTT
DML2MAI	MA	Inhibitor
DML2MAI	RN	Quantitative structure-activity relationship of sesquiterpene lactones as inhibitors of the transcription factor NF-kappaB. J Med Chem. 2004 Nov 18;47(24):6042-54.
DML2MAI	RU	https://pubmed.ncbi.nlm.nih.gov/15537359

DML3R5Z	DI	DML3R5Z
DML3R5Z	DN	Atropisomer 1
DML3R5Z	MI	TTRMX3V
DML3R5Z	MN	Janus kinase 2 (JAK-2)
DML3R5Z	MT	DTT
DML3R5Z	MA	Inhibitor
DML3R5Z	RN	Janus kinase 2 inhibitors. Synthesis and characterization of a novel polycyclic azaindole. J Med Chem. 2009 Dec 24;52(24):7938-41.
DML3R5Z	RU	https://pubmed.ncbi.nlm.nih.gov/20014869

DML3R5Z	DI	DML3R5Z
DML3R5Z	DN	Atropisomer 1
DML3R5Z	MI	TTT7PJU
DML3R5Z	MN	Janus kinase 3 (JAK-3)
DML3R5Z	MT	DTT
DML3R5Z	MA	Inhibitor
DML3R5Z	RN	Janus kinase 2 inhibitors. Synthesis and characterization of a novel polycyclic azaindole. J Med Chem. 2009 Dec 24;52(24):7938-41.
DML3R5Z	RU	https://pubmed.ncbi.nlm.nih.gov/20014869

DMHEK4U	DI	DMHEK4U
DMHEK4U	DN	ATS-907
DMHEK4U	MI	TTZN7RP
DMHEK4U	MN	Rho-associated protein kinase 1 (ROCK1)
DMHEK4U	MT	DTT
DMHEK4U	MA	Inhibitor
DMHEK4U	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1503).
DMHEK4U	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1503

DMHEK4U	DI	DMHEK4U
DMHEK4U	DN	ATS-907
DMHEK4U	MI	TTGWKQJ
DMHEK4U	MN	Rho-associated protein kinase 2 (ROCK2)
DMHEK4U	MT	DTT
DMHEK4U	MA	Inhibitor
DMHEK4U	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1504).
DMHEK4U	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1504

DMKVDAN	DI	DMKVDAN
DMKVDAN	DN	Augustic acid
DMKVDAN	MI	TTELIN2
DMKVDAN	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMKVDAN	MT	DTT
DMKVDAN	MA	Inhibitor
DMKVDAN	RN	Synthesis and biological evaluation of heterocyclic ring-substituted maslinic acid derivatives as novel inhibitors of protein tyrosine phosphatase 1B. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6618-22.
DMKVDAN	RU	https://pubmed.ncbi.nlm.nih.gov/19846303

DMZNUDT	DI	DMZNUDT
DMZNUDT	DN	Aurachin
DMZNUDT	MI	DE1OW2F
DMZNUDT	MN	Cytochrome P450 RauA (rauA)
DMZNUDT	MT	DME
DMZNUDT	MA	Metabolism
DMZNUDT	RN	nan
DMZNUDT	RU	nan

DMDKH8N	DI	DMDKH8N
DMDKH8N	DN	AURASPERONE A
DMDKH8N	MI	TTQY2EJ
DMDKH8N	MN	TERT messenger RNA (TERT mRNA)
DMDKH8N	MT	DTT
DMDKH8N	MA	Inhibitor
DMDKH8N	RN	New dimeric naphthopyrones from Aspergillus niger. J Nat Prod. 2003 Jan;66(1):136-9.
DMDKH8N	RU	https://pubmed.ncbi.nlm.nih.gov/12542363

DMOIQ4K	DI	DMOIQ4K
DMOIQ4K	DN	Auryntricarboxylic acid (ATA)
DMOIQ4K	MI	TT3SZBT
DMOIQ4K	MN	von Willebrand factor (VWF)
DMOIQ4K	MT	DTT
DMOIQ4K	MA	Inhibitor
DMOIQ4K	RN	Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci. 2002 Jan;23(1):25-32.
DMOIQ4K	RU	https://pubmed.ncbi.nlm.nih.gov/11804648

DMFS4RD	DI	DMFS4RD
DMFS4RD	DN	Autoantibody LKM-3
DMFS4RD	MI	TTO69J7
DMFS4RD	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMFS4RD	MT	DTT
DMFS4RD	MA	Inhibitor
DMFS4RD	RN	Characterization of autoantibodies against uridine-diphosphate glucuronosyltransferase in patients with inflammatory liver diseases. Hepatology. 2001 May;33(5):1053-9.
DMFS4RD	RU	https://pubmed.ncbi.nlm.nih.gov/11343231

DMVGIO5	DI	DMVGIO5
DMVGIO5	DN	AUY954
DMVGIO5	MI	TT9JZCK
DMVGIO5	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMVGIO5	MT	DTT
DMVGIO5	MA	Agonist
DMVGIO5	RN	A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model. Chem Biol. 2006 Nov;13(11):1227-34.
DMVGIO5	RU	https://pubmed.ncbi.nlm.nih.gov/17114004

DMVGIO5	DI	DMVGIO5
DMVGIO5	DN	AUY954
DMVGIO5	MI	TTVSMOH
DMVGIO5	MN	Sphingosine-1-phosphate receptor 2 (S1PR2)
DMVGIO5	MT	DTT
DMVGIO5	MA	Agonist
DMVGIO5	RN	A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model. Chem Biol. 2006 Nov;13(11):1227-34.
DMVGIO5	RU	https://pubmed.ncbi.nlm.nih.gov/17114004

DMVGIO5	DI	DMVGIO5
DMVGIO5	DN	AUY954
DMVGIO5	MI	TTDYP7I
DMVGIO5	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DMVGIO5	MT	DTT
DMVGIO5	MA	Agonist
DMVGIO5	RN	Synthesis and biological evaluation of gamma-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists. Bioorg Med Chem. 2007 Jan 15;15(2):663-77.
DMVGIO5	RU	https://pubmed.ncbi.nlm.nih.gov/17113298

DMVGIO5	DI	DMVGIO5
DMVGIO5	DN	AUY954
DMVGIO5	MI	TTZ8C5Q
DMVGIO5	MN	Sphingosine-1-phosphate receptor 4 (S1PR4)
DMVGIO5	MT	DTT
DMVGIO5	MA	Agonist
DMVGIO5	RN	A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model. Chem Biol. 2006 Nov;13(11):1227-34.
DMVGIO5	RU	https://pubmed.ncbi.nlm.nih.gov/17114004

DMVGIO5	DI	DMVGIO5
DMVGIO5	DN	AUY954
DMVGIO5	MI	TTDZCKV
DMVGIO5	MN	Sphingosine-1-phosphate receptor 5 (S1PR5)
DMVGIO5	MT	DTT
DMVGIO5	MA	Agonist
DMVGIO5	RN	A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model. Chem Biol. 2006 Nov;13(11):1227-34.
DMVGIO5	RU	https://pubmed.ncbi.nlm.nih.gov/17114004

DMF1VS9	DI	DMF1VS9
DMF1VS9	DN	AV-370
DMF1VS9	MI	TTST7KB
DMF1VS9	MN	Fibroblast growth factor receptor 3 (FGFR3)
DMF1VS9	MT	DTT
DMF1VS9	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1810).
DMF1VS9	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1810

DM9R3WT	DI	DM9R3WT
DM9R3WT	DN	AVE 0991
DM9R3WT	MI	TTOISYB
DM9R3WT	MN	Proto-oncogene Mas (MAS)
DM9R3WT	MT	DTT
DM9R3WT	MA	Agonist
DM9R3WT	RN	Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney. Hypertension. 2004 Oct;44(4):490-6.
DM9R3WT	RU	https://pubmed.ncbi.nlm.nih.gov/15326087

DMC0PY5	DI	DMC0PY5
DMC0PY5	DN	AVE-1876
DMC0PY5	MI	TTDCVZW
DMC0PY5	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMC0PY5	MT	DTT
DMC0PY5	MA	Modulator
DMC0PY5	RN	Company report (Sanofi)
DMC0PY5	RU	http://en.sanofi.com/Images/16068_AR_2004_EN.pdf

DMDTONZ	DI	DMDTONZ
DMDTONZ	DN	AVP-13546
DMDTONZ	MI	TT2AST1
DMDTONZ	MN	Macrophage migration inhibitory factor (MIF)
DMDTONZ	MT	DTT
DMDTONZ	MA	Inhibitor
DMDTONZ	RN	MIF in autoimmunity and novel therapeutic approaches. Autoimmun Rev. 2009 Jan;8(3):244-9.
DMDTONZ	RU	https://pubmed.ncbi.nlm.nih.gov/18721909

DMBNDYK	DI	DMBNDYK
DMBNDYK	DN	AVP-13748
DMBNDYK	MI	TT2AST1
DMBNDYK	MN	Macrophage migration inhibitory factor (MIF)
DMBNDYK	MT	DTT
DMBNDYK	MA	Inhibitor
DMBNDYK	RN	MIF in autoimmunity and novel therapeutic approaches. Autoimmun Rev. 2009 Jan;8(3):244-9.
DMBNDYK	RU	https://pubmed.ncbi.nlm.nih.gov/18721909

DMNQ9R4	DI	DMNQ9R4
DMNQ9R4	DN	AVPIAQKSEK-FAM
DMNQ9R4	MI	TTK3WBU
DMNQ9R4	MN	XIAP messenger RNA (XIAP mRNA)
DMNQ9R4	MT	DTT
DMNQ9R4	MA	Inhibitor
DMNQ9R4	RN	Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional... J Med Chem. 2004 May 6;47(10):2430-40.
DMNQ9R4	RU	https://pubmed.ncbi.nlm.nih.gov/15115387

DMK9BMQ	DI	DMK9BMQ
DMK9BMQ	DN	AVVYPWT
DMK9BMQ	MI	TT2THBD
DMK9BMQ	MN	P2X purinoceptor 3 (P2RX3)
DMK9BMQ	MT	DTT
DMK9BMQ	MA	Inhibitor
DMK9BMQ	RN	Structure-activity relationship studies of spinorphin as a potent and selective human P2X(3) receptor antagonist. J Med Chem. 2007 Sep 6;50(18):4543-7.
DMK9BMQ	RU	https://pubmed.ncbi.nlm.nih.gov/17676725

DMG6LJ8	DI	DMG6LJ8
DMG6LJ8	DN	AW-00430
DMG6LJ8	MI	TTG5QB7
DMG6LJ8	MN	Calpain-2 (CAPN2)
DMG6LJ8	MT	DTT
DMG6LJ8	MA	Inhibitor
DMG6LJ8	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMG6LJ8	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMIWMJP	DI	DMIWMJP
DMIWMJP	DN	AwFwLL-NH2
DMIWMJP	MI	TTWDC17
DMIWMJP	MN	Growth hormone secretagogue receptor 1 (GHSR)
DMIWMJP	MT	DTT
DMIWMJP	MA	Inhibitor
DMIWMJP	RN	Identification of an efficacy switch region in the ghrelin receptor responsible for interchange between agonism and inverse agonism. J Biol Chem. 2007 May 25;282(21):15799-811.
DMIWMJP	RU	https://pubmed.ncbi.nlm.nih.gov/17371869

DMDWCY7	DI	DMDWCY7
DMDWCY7	DN	AX-006
DMDWCY7	MI	TTT1JVS
DMDWCY7	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DMDWCY7	MT	DTT
DMDWCY7	MA	Inhibitor
DMDWCY7	RN	2-Oxoamide inhibitors of phospholipase A2 activity and cellular arachidonate release based on dipeptides and pseudodipeptides. Bioorg Med Chem. 2009 Jul 1;17(13):4833-43.
DMDWCY7	RU	https://pubmed.ncbi.nlm.nih.gov/19443224

DMIDXSN	DI	DMIDXSN
DMIDXSN	DN	AX-048
DMIDXSN	MI	TTT1JVS
DMIDXSN	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DMIDXSN	MT	DTT
DMIDXSN	MA	Inhibitor
DMIDXSN	RN	2-Oxoamide inhibitors of phospholipase A2 activity and cellular arachidonate release based on dipeptides and pseudodipeptides. Bioorg Med Chem. 2009 Jul 1;17(13):4833-43.
DMIDXSN	RU	https://pubmed.ncbi.nlm.nih.gov/19443224

DMKCT0M	DI	DMKCT0M
DMKCT0M	DN	AX-9657
DMKCT0M	MI	TTPLTSQ
DMKCT0M	MN	Neutrophil elastase (NE)
DMKCT0M	MT	DTT
DMKCT0M	MA	Inhibitor
DMKCT0M	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2358).
DMKCT0M	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2358

DMT5P8O	DI	DMT5P8O
DMT5P8O	DN	Axogenesis Factor-1
DMT5P8O	MI	TTEDJN4
DMT5P8O	MN	Low-affinity nerve growth factor receptor (NGFR)
DMT5P8O	MT	DTT
DMT5P8O	MA	Modulator
DMT5P8O	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1888).
DMT5P8O	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1888

DMNO6PL	DI	DMNO6PL
DMNO6PL	DN	AZ10417808
DMNO6PL	MI	TTPF2QI
DMNO6PL	MN	Caspase-3 (CASP3)
DMNO6PL	MT	DTT
DMNO6PL	MA	Inhibitor
DMNO6PL	RN	Novel small molecule inhibitors of caspase-3 block cellular and biochemical features of apoptosis. J Pharmacol Exp Ther. 2003 Jan;304(1):433-40.
DMNO6PL	RU	https://pubmed.ncbi.nlm.nih.gov/12490620

DMDRXCP	DI	DMDRXCP
DMDRXCP	DN	AZ11645373
DMDRXCP	MI	TT473XN
DMDRXCP	MN	P2X purinoceptor 7 (P2RX7)
DMDRXCP	MT	DTT
DMDRXCP	MA	Modulator (allosteric modulator)
DMDRXCP	RN	Mechanism of action of species-selective P2X(7) receptor antagonists. Br J Pharmacol. 2009 Apr;156(8):1312-25.
DMDRXCP	RU	https://pubmed.ncbi.nlm.nih.gov/19309360

DMRUA0Y	DI	DMRUA0Y
DMRUA0Y	DN	AZ-11657312
DMRUA0Y	MI	TT473XN
DMRUA0Y	MN	P2X purinoceptor 7 (P2RX7)
DMRUA0Y	MT	DTT
DMRUA0Y	MA	Antagonist
DMRUA0Y	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 484).
DMRUA0Y	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=484

DMVX8LO	DI	DMVX8LO
DMVX8LO	DN	AZ11657312 (salt free)
DMVX8LO	MI	TT473XN
DMVX8LO	MN	P2X purinoceptor 7 (P2RX7)
DMVX8LO	MT	DTT
DMVX8LO	MA	Antagonist
DMVX8LO	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 484).
DMVX8LO	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=484

DM1IN35	DI	DM1IN35
DM1IN35	DN	AZ12216052
DM1IN35	MI	TT0IFKL
DM1IN35	MN	Metabotropic glutamate receptor 8 (mGluR8)
DM1IN35	MT	DTT
DM1IN35	MA	Modulator (allosteric modulator)
DM1IN35	RN	Acute pharmacological modulation of mGluR8 reduces measures of anxiety. Behav Brain Res. 2010 Oct 15;212(2):168-73.
DM1IN35	RU	https://pubmed.ncbi.nlm.nih.gov/20385173

DMQ5H2V	DI	DMQ5H2V
DMQ5H2V	DN	AZ12260493
DMQ5H2V	MI	TTECBXN
DMQ5H2V	MN	Oxysterols receptor LXR-alpha (NR1H3)
DMQ5H2V	MT	DTT
DMQ5H2V	MA	Agonist
DMQ5H2V	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 602).
DMQ5H2V	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=602

DMQ5H2V	DI	DMQ5H2V
DMQ5H2V	DN	AZ12260493
DMQ5H2V	MI	TTXA6PH
DMQ5H2V	MN	Oxysterols receptor LXR-beta (NR1H2)
DMQ5H2V	MT	DTT
DMQ5H2V	MA	Agonist
DMQ5H2V	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 601).
DMQ5H2V	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=601

DMYDWH1	DI	DMYDWH1
DMYDWH1	DN	AZ13483342
DMYDWH1	MI	TTX4RTB
DMYDWH1	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMYDWH1	MT	DTT
DMYDWH1	MA	Antagonist
DMYDWH1	RN	Discovery of cyclopentane- and cyclohexane-trans-1,3-diamines as potent melanin-concentrating hormone receptor 1 antagonists. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4232-41.
DMYDWH1	RU	https://pubmed.ncbi.nlm.nih.gov/17532215

DMNQ3HV	DI	DMNQ3HV
DMNQ3HV	DN	AZ20
DMNQ3HV	MI	TT8ZYBQ
DMNQ3HV	MN	Serine/threonine-protein kinase ATR (FRP1)
DMNQ3HV	MT	DTT
DMNQ3HV	MA	Inhibitor
DMNQ3HV	RN	Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity. J Med Chem. 2013 Mar 14;56(5):2125-38.
DMNQ3HV	RU	https://pubmed.ncbi.nlm.nih.gov/23394205

DMVMW9S	DI	DMVMW9S
DMVMW9S	DN	AZ3971
DMVMW9S	MI	TT8JRS7
DMVMW9S	MN	Beta-secretase (BACE)
DMVMW9S	MT	DTT
DMVMW9S	MA	Inhibitor
DMVMW9S	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2330).
DMVMW9S	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2330

DMATC5P	DI	DMATC5P
DMATC5P	DN	AZ4800
DMATC5P	MI	TTE4KHA
DMATC5P	MN	Amyloid beta A4 protein (APP)
DMATC5P	MT	DTT
DMATC5P	MA	Inhibitor
DMATC5P	RN	First and second generation gamma-secretase modulators (GSMs) modulate amyloid-beta (Abeta) peptide production through different mechanisms. J Biol Chem. 2012 Apr 6;287(15):11810-9.
DMATC5P	RU	https://pubmed.ncbi.nlm.nih.gov/22334705

DM1XE4F	DI	DM1XE4F
DM1XE4F	DN	AZ-599
DM1XE4F	MI	TT6OEDT
DM1XE4F	MN	Cannabinoid receptor 1 (CB1)
DM1XE4F	MT	DTT
DM1XE4F	MA	Agonist
DM1XE4F	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 56).
DM1XE4F	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=56

DMEWQHP	DI	DMEWQHP
DMEWQHP	DN	AZ-628
DMEWQHP	MI	TTWCGQT
DMEWQHP	MN	Serine/threonine-protein kinase B-raf (BRAF)
DMEWQHP	MT	DTT
DMEWQHP	MA	Inhibitor
DMEWQHP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8475).
DMEWQHP	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8475

DM95Y82	DI	DM95Y82
DM95Y82	DN	AZ960
DM95Y82	MI	TTRMX3V
DM95Y82	MN	Janus kinase 2 (JAK-2)
DM95Y82	MT	DTT
DM95Y82	MA	Inhibitor
DM95Y82	RN	Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2. J Biol Chem. 2008 Nov 21;283(47):32334-43.
DM95Y82	RU	https://pubmed.ncbi.nlm.nih.gov/18775810

DMOSI4U	DI	DMOSI4U
DMOSI4U	DN	Aza-C-nucleosides
DMOSI4U	MI	TTMCF1Y
DMOSI4U	MN	Purine nucleoside phosphorylase (PNP)
DMOSI4U	MT	DTT
DMOSI4U	MA	Inhibitor
DMOSI4U	RN	Exploring structure-activity relationships of transition state analogues of human purine nucleoside phosphorylase. J Med Chem. 2003 Jul 17;46(15):3412-23.
DMOSI4U	RU	https://pubmed.ncbi.nlm.nih.gov/12852771

DM61H07	DI	DM61H07
DM61H07	DN	AZAKENPAULLONE
DM61H07	MI	TTH6V3D
DM61H07	MN	Cyclin-dependent kinase 1 (CDK1)
DM61H07	MT	DTT
DM61H07	MA	Inhibitor
DM61H07	RN	1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.
DM61H07	RU	https://pubmed.ncbi.nlm.nih.gov/14698171

DM61H07	DI	DM61H07
DM61H07	DN	AZAKENPAULLONE
DM61H07	MI	TTL4Q97
DM61H07	MN	Cyclin-dependent kinase 5 (CDK5)
DM61H07	MT	DTT
DM61H07	MA	Inhibitor
DM61H07	RN	1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.
DM61H07	RU	https://pubmed.ncbi.nlm.nih.gov/14698171

DM61H07	DI	DM61H07
DM61H07	DN	AZAKENPAULLONE
DM61H07	MI	TT9P6OW
DM61H07	MN	G2/mitotic-specific cyclin B1 (CCNB1)
DM61H07	MT	DTT
DM61H07	MA	Inhibitor
DM61H07	RN	1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.
DM61H07	RU	https://pubmed.ncbi.nlm.nih.gov/14698171

DM61H07	DI	DM61H07
DM61H07	DN	AZAKENPAULLONE
DM61H07	MI	TTRSMW9
DM61H07	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DM61H07	MT	DTT
DM61H07	MA	Inhibitor
DM61H07	RN	1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.
DM61H07	RU	https://pubmed.ncbi.nlm.nih.gov/14698171

DMN861Q	DI	DMN861Q
DMN861Q	DN	AZALINE B
DMN861Q	MI	TT8R70G
DMN861Q	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMN861Q	MT	DTT
DMN861Q	MA	Inhibitor
DMN861Q	RN	Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77.
DMN861Q	RU	https://pubmed.ncbi.nlm.nih.gov/17402723

DM3BXUJ	DI	DM3BXUJ
DM3BXUJ	DN	Azapeptide
DM3BXUJ	MI	TTWXB3E
DM3BXUJ	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DM3BXUJ	MT	DTT
DM3BXUJ	MA	Inhibitor
DM3BXUJ	RN	Azapeptides as inhibitors of the hepatitis C virus NS3 serine protease. Bioorg Med Chem Lett. 2002 Apr 8;12(7):1005-8.
DM3BXUJ	RU	https://pubmed.ncbi.nlm.nih.gov/11909704

DMKI2GJ	DI	DMKI2GJ
DMKI2GJ	DN	Azaperone
DMKI2GJ	MI	TTEX248
DMKI2GJ	MN	Dopamine D2 receptor (D2R)
DMKI2GJ	MT	DTT
DMKI2GJ	MA	Inhibitor
DMKI2GJ	RN	Evaluation of the effects of the enantiomers of reduced haloperidol, azaperol, and related 4-amino-1-arylbutanols on dopamine and sigma receptors. J Med Chem. 1993 Nov 26;36(24):3929-36.
DMKI2GJ	RU	https://pubmed.ncbi.nlm.nih.gov/7902870

DMKI2GJ	DI	DMKI2GJ
DMKI2GJ	DN	Azaperone
DMKI2GJ	MI	TT4C8EA
DMKI2GJ	MN	Dopamine D3 receptor (D3R)
DMKI2GJ	MT	DTT
DMKI2GJ	MA	Inhibitor
DMKI2GJ	RN	Evaluation of the effects of the enantiomers of reduced haloperidol, azaperol, and related 4-amino-1-arylbutanols on dopamine and sigma receptors. J Med Chem. 1993 Nov 26;36(24):3929-36.
DMKI2GJ	RU	https://pubmed.ncbi.nlm.nih.gov/7902870

DML70NC	DI	DML70NC
DML70NC	DN	aza-THIP
DML70NC	MI	TT6XFEU
DML70NC	MN	GABA(A) receptor rho1 (GABRR1)
DML70NC	MT	DTT
DML70NC	MA	Antagonist
DML70NC	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 420).
DML70NC	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=420

DML70NC	DI	DML70NC
DML70NC	DN	aza-THIP
DML70NC	MI	TTQMXLS
DML70NC	MN	GABA(A) receptor rho2 (GABRR2)
DML70NC	MT	DTT
DML70NC	MA	Antagonist
DML70NC	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 421).
DML70NC	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=421

DML70NC	DI	DML70NC
DML70NC	DN	aza-THIP
DML70NC	MI	TT4N6D8
DML70NC	MN	GABA(A) receptor rho3 (GABRR3)
DML70NC	MT	DTT
DML70NC	MA	Antagonist
DML70NC	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 422).
DML70NC	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=422

DM0PVD9	DI	DM0PVD9
DM0PVD9	DN	AZD1332
DM0PVD9	MI	TTKN7QR
DM0PVD9	MN	BDNF/NT-3 growth factors receptor (TrkB)
DM0PVD9	MT	DTT
DM0PVD9	MA	Inhibitor
DM0PVD9	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1818).
DM0PVD9	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1818

DM0PVD9	DI	DM0PVD9
DM0PVD9	DN	AZD1332
DM0PVD9	MI	TTXABCW
DM0PVD9	MN	NT-3 growth factor receptor (TrkC)
DM0PVD9	MT	DTT
DM0PVD9	MA	Inhibitor
DM0PVD9	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1817).
DM0PVD9	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1817

DMAX9C3	DI	DMAX9C3
DMAX9C3	DN	AZD3463
DMAX9C3	MI	TTPMQSO
DMAX9C3	MN	ALK tyrosine kinase receptor (ALK)
DMAX9C3	MT	DTT
DMAX9C3	MA	Inhibitor
DMAX9C3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1839).
DMAX9C3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1839

DMAX9C3	DI	DMAX9C3
DMAX9C3	DN	AZD3463
DMAX9C3	MI	TTQFBMY
DMAX9C3	MN	IGF1R messenger RNA (IGF1R mRNA)
DMAX9C3	MT	DTT
DMAX9C3	MA	Inhibitor
DMAX9C3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1801).
DMAX9C3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1801

DMPIHN6	DI	DMPIHN6
DMPIHN6	DN	AZD5582
DMPIHN6	MI	TTQ5LRD
DMPIHN6	MN	Cellular inhibitor of apoptosis 1 (BIRC2)
DMPIHN6	MT	DTT
DMPIHN6	MA	Antagonist
DMPIHN6	RN	Discovery of a novel class of dimeric Smac mimetics as potent IAP antagonists resulting in a clinical candidate for the treatment of cancer (AZD5582). J Med Chem. 2013 Dec 27;56(24):9897-919.
DMPIHN6	RU	https://pubmed.ncbi.nlm.nih.gov/24320998

DMPIHN6	DI	DMPIHN6
DMPIHN6	DN	AZD5582
DMPIHN6	MI	TTIRY6K
DMPIHN6	MN	Cellular inhibitor of apoptosis 2 (BIRC3)
DMPIHN6	MT	DTT
DMPIHN6	MA	Antagonist
DMPIHN6	RN	Discovery of a novel class of dimeric Smac mimetics as potent IAP antagonists resulting in a clinical candidate for the treatment of cancer (AZD5582). J Med Chem. 2013 Dec 27;56(24):9897-919.
DMPIHN6	RU	https://pubmed.ncbi.nlm.nih.gov/24320998

DMPIHN6	DI	DMPIHN6
DMPIHN6	DN	AZD5582
DMPIHN6	MI	TTK3WBU
DMPIHN6	MN	XIAP messenger RNA (XIAP mRNA)
DMPIHN6	MT	DTT
DMPIHN6	MA	Antagonist
DMPIHN6	RN	Discovery of a novel class of dimeric Smac mimetics as potent IAP antagonists resulting in a clinical candidate for the treatment of cancer (AZD5582). J Med Chem. 2013 Dec 27;56(24):9897-919.
DMPIHN6	RU	https://pubmed.ncbi.nlm.nih.gov/24320998

DMD4YO9	DI	DMD4YO9
DMD4YO9	DN	AZD-6319
DMD4YO9	MI	TTLA931
DMD4YO9	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMD4YO9	MT	DTT
DMD4YO9	MA	Agonist
DMD4YO9	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 468).
DMD4YO9	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=468

DMLJPDW	DI	DMLJPDW
DMLJPDW	DN	AZD-7507
DMLJPDW	MI	TTC70AJ
DMLJPDW	MN	Granulocyte colony-stimulating factor receptor (G-CSF-R)
DMLJPDW	MT	DTT
DMLJPDW	MA	Inhibitor
DMLJPDW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1719).
DMLJPDW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1719

DM34W56	DI	DM34W56
DM34W56	DN	AZD-7806
DM34W56	MI	TTPI1M5
DM34W56	MN	Ileal sodium/bile acid cotransporter (SLC10A2)
DM34W56	MT	DTT
DM34W56	MA	Modulator
DM34W56	RN	Elobixibat for the treatment of constipation. Expert Opin Investig Drugs. 2013 Feb;22(2):277-84.
DM34W56	RU	https://pubmed.ncbi.nlm.nih.gov/23215781

DM0HTXO	DI	DM0HTXO
DM0HTXO	DN	AZD8542
DM0HTXO	MI	TT8J1S3
DM0HTXO	MN	Smoothened homolog (SMO)
DM0HTXO	MT	DTT
DM0HTXO	MA	Antagonist
DM0HTXO	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 239).
DM0HTXO	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=239

DMKSQY1	DI	DMKSQY1
DMKSQY1	DN	Azelaic bishydroxamic acid
DMKSQY1	MI	TTBH0VX
DMKSQY1	MN	Histone deacetylase (HDAC)
DMKSQY1	MT	DTT
DMKSQY1	MA	Inhibitor
DMKSQY1	RN	Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006 Sep;5(9):769-84.
DMKSQY1	RU	https://pubmed.ncbi.nlm.nih.gov/16955068

DMZHV39	DI	DMZHV39
DMZHV39	DN	Azepan-(2Z)-ylideneamine
DMZHV39	MI	TTZUFI5
DMZHV39	MN	Nitric-oxide synthase brain (NOS1)
DMZHV39	MT	DTT
DMZHV39	MA	Inhibitor
DMZHV39	RN	Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3.
DMZHV39	RU	https://pubmed.ncbi.nlm.nih.gov/11551770

DMZHV39	DI	DMZHV39
DMZHV39	DN	Azepan-(2Z)-ylideneamine
DMZHV39	MI	TTCM4B3
DMZHV39	MN	Nitric-oxide synthase endothelial (NOS3)
DMZHV39	MT	DTT
DMZHV39	MA	Inhibitor
DMZHV39	RN	Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3.
DMZHV39	RU	https://pubmed.ncbi.nlm.nih.gov/11551770

DMZHV39	DI	DMZHV39
DMZHV39	DN	Azepan-(2Z)-ylideneamine
DMZHV39	MI	TTF10I9
DMZHV39	MN	Nitric-oxide synthase inducible (NOS2)
DMZHV39	MT	DTT
DMZHV39	MA	Inhibitor
DMZHV39	RN	Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3.
DMZHV39	RU	https://pubmed.ncbi.nlm.nih.gov/11551770

DM5XZYB	DI	DM5XZYB
DM5XZYB	DN	Azide
DM5XZYB	MI	TTHQPL7
DM5XZYB	MN	Carbonic anhydrase I (CA-I)
DM5XZYB	MT	DTT
DM5XZYB	MA	Inhibitor
DM5XZYB	RN	Carbonic anhydrase inhibitors: inhibition of the membrane-bound human isozyme IV with anions. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5769-73.
DM5XZYB	RU	https://pubmed.ncbi.nlm.nih.gov/15501038

DM5XZYB	DI	DM5XZYB
DM5XZYB	DN	Azide
DM5XZYB	MI	TTANPDJ
DM5XZYB	MN	Carbonic anhydrase II (CA-II)
DM5XZYB	MT	DTT
DM5XZYB	MA	Inhibitor
DM5XZYB	RN	Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5435-9.
DM5XZYB	RU	https://pubmed.ncbi.nlm.nih.gov/15454240

DM5XZYB	DI	DM5XZYB
DM5XZYB	DN	Azide
DM5XZYB	MI	TT2LVK8
DM5XZYB	MN	Carbonic anhydrase IX (CA-IX)
DM5XZYB	MT	DTT
DM5XZYB	MA	Inhibitor
DM5XZYB	RN	Carbonic anhydrase inhibitors: inhibition of the membrane-bound human isozyme IV with anions. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5769-73.
DM5XZYB	RU	https://pubmed.ncbi.nlm.nih.gov/15501038

DMD0LCA	DI	DMD0LCA
DMD0LCA	DN	Azidopine
DMD0LCA	MI	DTUGYRD
DMD0LCA	MN	P-glycoprotein 1 (ABCB1)
DMD0LCA	MT	DTP
DMD0LCA	MA	Substrate
DMD0LCA	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMD0LCA	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMD0LCA	DI	DMD0LCA
DMD0LCA	DN	Azidopine
DMD0LCA	MI	TT7RGTM
DMD0LCA	MN	Voltage-gated calcium channel alpha Cav1.3 (CACNA1D)
DMD0LCA	MT	DTT
DMD0LCA	MA	Inhibitor (gating inhibitor)
DMD0LCA	RN	Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol Pharmacol. 2009 Feb;75(2):407-14.
DMD0LCA	RU	https://pubmed.ncbi.nlm.nih.gov/19029287

DM8ZQG3	DI	DM8ZQG3
DM8ZQG3	DN	Azithromycinarylalkylhydroxamic Acid
DM8ZQG3	MI	TT6R7JZ
DM8ZQG3	MN	Histone deacetylase 1 (HDAC1)
DM8ZQG3	MT	DTT
DM8ZQG3	MA	Inhibitor
DM8ZQG3	RN	Non-peptide macrocyclic histone deacetylase inhibitors. J Med Chem. 2009 Jan 22;52(2):456-68.
DM8ZQG3	RU	https://pubmed.ncbi.nlm.nih.gov/19093884

DM8ZQG3	DI	DM8ZQG3
DM8ZQG3	DN	Azithromycinarylalkylhydroxamic Acid
DM8ZQG3	MI	TTT6LFV
DM8ZQG3	MN	Histone deacetylase 8 (HDAC8)
DM8ZQG3	MT	DTT
DM8ZQG3	MA	Inhibitor
DM8ZQG3	RN	Non-peptide macrocyclic histone deacetylase inhibitors. J Med Chem. 2009 Jan 22;52(2):456-68.
DM8ZQG3	RU	https://pubmed.ncbi.nlm.nih.gov/19093884

DMDQ2VN	DI	DMDQ2VN
DMDQ2VN	DN	Azithromycin-N-benzyltriazolyldecahydroxamic Acid
DMDQ2VN	MI	TT6R7JZ
DMDQ2VN	MN	Histone deacetylase 1 (HDAC1)
DMDQ2VN	MT	DTT
DMDQ2VN	MA	Inhibitor
DMDQ2VN	RN	Non-peptide macrocyclic histone deacetylase inhibitors. J Med Chem. 2009 Jan 22;52(2):456-68.
DMDQ2VN	RU	https://pubmed.ncbi.nlm.nih.gov/19093884

DM7KD5Y	DI	DM7KD5Y
DM7KD5Y	DN	Azithromycin-N-benzyltriazolylhexahydroxamic Acid
DM7KD5Y	MI	TT6R7JZ
DM7KD5Y	MN	Histone deacetylase 1 (HDAC1)
DM7KD5Y	MT	DTT
DM7KD5Y	MA	Inhibitor
DM7KD5Y	RN	Non-peptide macrocyclic histone deacetylase inhibitors. J Med Chem. 2009 Jan 22;52(2):456-68.
DM7KD5Y	RU	https://pubmed.ncbi.nlm.nih.gov/19093884

DM7KD5Y	DI	DM7KD5Y
DM7KD5Y	DN	Azithromycin-N-benzyltriazolylhexahydroxamic Acid
DM7KD5Y	MI	TTT6LFV
DM7KD5Y	MN	Histone deacetylase 8 (HDAC8)
DM7KD5Y	MT	DTT
DM7KD5Y	MA	Inhibitor
DM7KD5Y	RN	Non-peptide macrocyclic histone deacetylase inhibitors. J Med Chem. 2009 Jan 22;52(2):456-68.
DM7KD5Y	RU	https://pubmed.ncbi.nlm.nih.gov/19093884

DMW0HXO	DI	DMW0HXO
DMW0HXO	DN	Azithromycin-N-benzyltriazolylnonahydroxamic Acid
DMW0HXO	MI	TT6R7JZ
DMW0HXO	MN	Histone deacetylase 1 (HDAC1)
DMW0HXO	MT	DTT
DMW0HXO	MA	Inhibitor
DMW0HXO	RN	Non-peptide macrocyclic histone deacetylase inhibitors. J Med Chem. 2009 Jan 22;52(2):456-68.
DMW0HXO	RU	https://pubmed.ncbi.nlm.nih.gov/19093884

DMW0HXO	DI	DMW0HXO
DMW0HXO	DN	Azithromycin-N-benzyltriazolylnonahydroxamic Acid
DMW0HXO	MI	TTT6LFV
DMW0HXO	MN	Histone deacetylase 8 (HDAC8)
DMW0HXO	MT	DTT
DMW0HXO	MA	Inhibitor
DMW0HXO	RN	Non-peptide macrocyclic histone deacetylase inhibitors. J Med Chem. 2009 Jan 22;52(2):456-68.
DMW0HXO	RU	https://pubmed.ncbi.nlm.nih.gov/19093884

DMAJ4LI	DI	DMAJ4LI
DMAJ4LI	DN	Azithromycin-N-benzyltriazolyloctahydroxamic Acid
DMAJ4LI	MI	TT6R7JZ
DMAJ4LI	MN	Histone deacetylase 1 (HDAC1)
DMAJ4LI	MT	DTT
DMAJ4LI	MA	Inhibitor
DMAJ4LI	RN	Non-peptide macrocyclic histone deacetylase inhibitors. J Med Chem. 2009 Jan 22;52(2):456-68.
DMAJ4LI	RU	https://pubmed.ncbi.nlm.nih.gov/19093884

DMAJ4LI	DI	DMAJ4LI
DMAJ4LI	DN	Azithromycin-N-benzyltriazolyloctahydroxamic Acid
DMAJ4LI	MI	TTT6LFV
DMAJ4LI	MN	Histone deacetylase 8 (HDAC8)
DMAJ4LI	MT	DTT
DMAJ4LI	MA	Inhibitor
DMAJ4LI	RN	Non-peptide macrocyclic histone deacetylase inhibitors. J Med Chem. 2009 Jan 22;52(2):456-68.
DMAJ4LI	RU	https://pubmed.ncbi.nlm.nih.gov/19093884

DMQ13PZ	DI	DMQ13PZ
DMQ13PZ	DN	Azocan-(2Z)-ylideneamine
DMQ13PZ	MI	TTZUFI5
DMQ13PZ	MN	Nitric-oxide synthase brain (NOS1)
DMQ13PZ	MT	DTT
DMQ13PZ	MA	Inhibitor
DMQ13PZ	RN	Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3.
DMQ13PZ	RU	https://pubmed.ncbi.nlm.nih.gov/11551770

DMQ13PZ	DI	DMQ13PZ
DMQ13PZ	DN	Azocan-(2Z)-ylideneamine
DMQ13PZ	MI	TTF10I9
DMQ13PZ	MN	Nitric-oxide synthase inducible (NOS2)
DMQ13PZ	MT	DTT
DMQ13PZ	MA	Inhibitor
DMQ13PZ	RN	Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3.
DMQ13PZ	RU	https://pubmed.ncbi.nlm.nih.gov/11551770

DMTQSNK	DI	DMTQSNK
DMTQSNK	DN	Azonan-(2Z)-ylideneamine
DMTQSNK	MI	TTZUFI5
DMTQSNK	MN	Nitric-oxide synthase brain (NOS1)
DMTQSNK	MT	DTT
DMTQSNK	MA	Inhibitor
DMTQSNK	RN	2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. J Med Chem. 1996 Feb 2;39(3):669-72.
DMTQSNK	RU	https://pubmed.ncbi.nlm.nih.gov/8576908

DMTQSNK	DI	DMTQSNK
DMTQSNK	DN	Azonan-(2Z)-ylideneamine
DMTQSNK	MI	TTF10I9
DMTQSNK	MN	Nitric-oxide synthase inducible (NOS2)
DMTQSNK	MT	DTT
DMTQSNK	MA	Inhibitor
DMTQSNK	RN	2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. J Med Chem. 1996 Feb 2;39(3):669-72.
DMTQSNK	RU	https://pubmed.ncbi.nlm.nih.gov/8576908

DMD4LGN	DI	DMD4LGN
DMD4LGN	DN	AZ-TAK1
DMD4LGN	MI	TTJQT60
DMD4LGN	MN	TGF-beta-activated kinase 1 (MAP3K7)
DMD4LGN	MT	DTT
DMD4LGN	MA	Inhibitor
DMD4LGN	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2082).
DMD4LGN	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2082

DMXOGE8	DI	DMXOGE8
DMXOGE8	DN	AZUMAMIDE B
DMXOGE8	MI	TT6R7JZ
DMXOGE8	MN	Histone deacetylase 1 (HDAC1)
DMXOGE8	MT	DTT
DMXOGE8	MA	Inhibitor
DMXOGE8	RN	Evaluation of antiangiogenic activity of azumamides by the in vitro vascular organization model using mouse induced pluripotent stem (iPS) cells. Bioorg Med Chem Lett. 2008 May 1;18(9):2982-4.
DMXOGE8	RU	https://pubmed.ncbi.nlm.nih.gov/18397826

DMXOGE8	DI	DMXOGE8
DMXOGE8	DN	AZUMAMIDE B
DMXOGE8	MI	TTTQGH8
DMXOGE8	MN	Histone deacetylase 4 (HDAC4)
DMXOGE8	MT	DTT
DMXOGE8	MA	Inhibitor
DMXOGE8	RN	Evaluation of antiangiogenic activity of azumamides by the in vitro vascular organization model using mouse induced pluripotent stem (iPS) cells. Bioorg Med Chem Lett. 2008 May 1;18(9):2982-4.
DMXOGE8	RU	https://pubmed.ncbi.nlm.nih.gov/18397826

DMEBA61	DI	DMEBA61
DMEBA61	DN	AZUMAMIDE C
DMEBA61	MI	TT6R7JZ
DMEBA61	MN	Histone deacetylase 1 (HDAC1)
DMEBA61	MT	DTT
DMEBA61	MA	Inhibitor
DMEBA61	RN	Evaluation of antiangiogenic activity of azumamides by the in vitro vascular organization model using mouse induced pluripotent stem (iPS) cells. Bioorg Med Chem Lett. 2008 May 1;18(9):2982-4.
DMEBA61	RU	https://pubmed.ncbi.nlm.nih.gov/18397826

DMEBA61	DI	DMEBA61
DMEBA61	DN	AZUMAMIDE C
DMEBA61	MI	TTTQGH8
DMEBA61	MN	Histone deacetylase 4 (HDAC4)
DMEBA61	MT	DTT
DMEBA61	MA	Inhibitor
DMEBA61	RN	Evaluation of antiangiogenic activity of azumamides by the in vitro vascular organization model using mouse induced pluripotent stem (iPS) cells. Bioorg Med Chem Lett. 2008 May 1;18(9):2982-4.
DMEBA61	RU	https://pubmed.ncbi.nlm.nih.gov/18397826

DMAX06G	DI	DMAX06G
DMAX06G	DN	AZUMAMIDE E
DMAX06G	MI	TT6R7JZ
DMAX06G	MN	Histone deacetylase 1 (HDAC1)
DMAX06G	MT	DTT
DMAX06G	MA	Inhibitor
DMAX06G	RN	Evaluation of antiangiogenic activity of azumamides by the in vitro vascular organization model using mouse induced pluripotent stem (iPS) cells. Bioorg Med Chem Lett. 2008 May 1;18(9):2982-4.
DMAX06G	RU	https://pubmed.ncbi.nlm.nih.gov/18397826

DMAX06G	DI	DMAX06G
DMAX06G	DN	AZUMAMIDE E
DMAX06G	MI	TTTQGH8
DMAX06G	MN	Histone deacetylase 4 (HDAC4)
DMAX06G	MT	DTT
DMAX06G	MA	Inhibitor
DMAX06G	RN	Evaluation of antiangiogenic activity of azumamides by the in vitro vascular organization model using mouse induced pluripotent stem (iPS) cells. Bioorg Med Chem Lett. 2008 May 1;18(9):2982-4.
DMAX06G	RU	https://pubmed.ncbi.nlm.nih.gov/18397826

DMN2XTQ	DI	DMN2XTQ
DMN2XTQ	DN	B173
DMN2XTQ	MI	TTCPG9S
DMN2XTQ	MN	5-HT 1E receptor (HTR1E)
DMN2XTQ	MT	DTT
DMN2XTQ	MA	Agonist
DMN2XTQ	RN	The gamma-aminobutyric acid-B receptor agonist baclofen attenuates responding for ethanol in ethanol-dependent rats. Alcohol Clin Exp Res. 2007 Jan;31(1):11-8.
DMN2XTQ	RU	https://pubmed.ncbi.nlm.nih.gov/17207096

DMEGX8H	DI	DMEGX8H
DMEGX8H	DN	B-2-Octylglucoside
DMEGX8H	MI	TTRAMF0
DMEGX8H	MN	Plasmodium Cytochrome B (Malaria MT-CYB)
DMEGX8H	MT	DTT
DMEGX8H	MA	Inhibitor
DMEGX8H	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMEGX8H	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMEGX8H	DI	DMEGX8H
DMEGX8H	DN	B-2-Octylglucoside
DMEGX8H	MI	TTH0KSX
DMEGX8H	MN	Rhodopsin (RHO)
DMEGX8H	MT	DTT
DMEGX8H	MA	Inhibitor
DMEGX8H	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMEGX8H	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMV3H0C	DI	DMV3H0C
DMV3H0C	DN	B3C
DMV3H0C	MI	TTT4N0Q
DMV3H0C	MN	Channel-activating protease 1 (CAP1)
DMV3H0C	MT	DTT
DMV3H0C	MA	Inhibitor
DMV3H0C	RN	Discovery of inhibitors of the channel-activating protease prostasin (CAP1/PRSS8) utilizing structure-based design. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5895-9.
DMV3H0C	RU	https://pubmed.ncbi.nlm.nih.gov/18752942

DMIUD0L	DI	DMIUD0L
DMIUD0L	DN	B-623
DMIUD0L	MI	TTGY7WI
DMIUD0L	MN	Urokinase-type plasminogen activator (PLAU)
DMIUD0L	MT	DTT
DMIUD0L	MA	Modulator
DMIUD0L	RN	Angiostatic activity of synthetic inhibitors of urokinase type plasminogen activator. Oncol Rep. 1999 May-Jun;6(3):523-6.
DMIUD0L	RU	https://www.ncbi.nlm.nih.gov/pubmed/10203585

DMCK5DG	DI	DMCK5DG
DMCK5DG	DN	BADGE
DMCK5DG	MI	TTT2SVW
DMCK5DG	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DMCK5DG	MT	DTT
DMCK5DG	MA	Agonist
DMCK5DG	RN	A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation. J Biol Chem. 2000 Jan 21;275(3):1873-7.
DMCK5DG	RU	https://pubmed.ncbi.nlm.nih.gov/10636887

DMUNK59	DI	DMUNK59
DMUNK59	DN	Bafilomycin A1
DMUNK59	MI	TTTK3BH
DMUNK59	MN	Vacuolar-type proton ATPase (v-ATPase)
DMUNK59	MT	DTT
DMUNK59	MA	Inhibitor
DMUNK59	RN	Molecular basis of V-ATPase inhibition by bafilomycin A1. Nat Commun. 2021 Mar 19;12(1):1782.
DMUNK59	RU	https://pubmed.ncbi.nlm.nih.gov/33741963

DMSWQED	DI	DMSWQED
DMSWQED	DN	bag-1
DMSWQED	MI	TTHYDUM
DMSWQED	MN	Bombesin receptor (BS)
DMSWQED	MT	DTT
DMSWQED	MA	Agonist
DMSWQED	RN	Regulation of energy homeostasis by bombesin receptor subtype-3: selective receptor agonists for the treatment of obesity. Cell Metab. 2010 Feb 3;11(2):101-12.
DMSWQED	RU	https://pubmed.ncbi.nlm.nih.gov/20096642

DMWC34B	DI	DMWC34B
DMWC34B	DN	BAG956
DMWC34B	MI	TTHBTOP
DMWC34B	MN	PI3-kinase gamma (PIK3CG)
DMWC34B	MT	DTT
DMWC34B	MA	Inhibitor
DMWC34B	RN	The PI3K/Akt pathway as a target in the treatment of hematologic malignancies. Anticancer Agents Med Chem. 2009 Jun;9(5):550-9.
DMWC34B	RU	https://pubmed.ncbi.nlm.nih.gov/19519296

DMX6KTO	DI	DMX6KTO
DMX6KTO	DN	BAN-2203
DMX6KTO	MI	TTE4KHA
DMX6KTO	MN	Amyloid beta A4 protein (APP)
DMX6KTO	MT	DTT
DMX6KTO	MA	Modulator
DMX6KTO	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
DMX6KTO	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402

DM4OT8M	DI	DM4OT8M
DM4OT8M	DN	bantag-1
DM4OT8M	MI	TTHYDUM
DM4OT8M	MN	Bombesin receptor (BS)
DM4OT8M	MT	DTT
DM4OT8M	MA	Antagonist
DM4OT8M	RN	Comparative pharmacology of bombesin receptor subtype-3, nonpeptide agonist MK-5046, a universal peptide agonist, and peptide antagonist Bantag-1 for human bombesin receptors. J Pharmacol Exp Ther. 2013 Oct;347(1):100-16.
DM4OT8M	RU	https://pubmed.ncbi.nlm.nih.gov/23892571

DM4OT8M	DI	DM4OT8M
DM4OT8M	DN	bantag-1
DM4OT8M	MI	TTC1MVT
DM4OT8M	MN	Gastrin-releasing peptide receptor (GRPR)
DM4OT8M	MT	DTT
DM4OT8M	MA	Antagonist
DM4OT8M	RN	Comparative pharmacology of bombesin receptor subtype-3, nonpeptide agonist MK-5046, a universal peptide agonist, and peptide antagonist Bantag-1 for human bombesin receptors. J Pharmacol Exp Ther. 2013 Oct;347(1):100-16.
DM4OT8M	RU	https://pubmed.ncbi.nlm.nih.gov/23892571

DM9JXIZ	DI	DM9JXIZ
DM9JXIZ	DN	banyu (I)
DM9JXIZ	MI	TTU3Y87
DM9JXIZ	MN	CCR3 messenger RNA (CCR3 mRNA)
DM9JXIZ	MT	DTT
DM9JXIZ	MA	Antagonist
DM9JXIZ	RN	Identification of full, partial and inverse CC chemokine receptor 3 agonists using [35S]GTPgammaS binding. Eur J Pharmacol. 2002 Dec 5;456(1-3):1-10.
DM9JXIZ	RU	https://pubmed.ncbi.nlm.nih.gov/12450563

DMD26XN	DI	DMD26XN
DMD26XN	DN	Banyu Compound-24
DMD26XN	MI	TTNT7K8
DMD26XN	MN	Nociceptin receptor (OPRL1)
DMD26XN	MT	DTT
DMD26XN	MA	Antagonist
DMD26XN	RN	Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24. Eur J Pharmacol. 2009 Jul 1;614(1-3):50-7.
DMD26XN	RU	https://pubmed.ncbi.nlm.nih.gov/19445927

DM2I19P	DI	DM2I19P
DM2I19P	DN	Barbituric acid derivative
DM2I19P	MI	TT1MPAY
DM2I19P	MN	GABA(A) receptor alpha-1 (GABRA1)
DM2I19P	MT	DTT
DM2I19P	MA	Inhibitor
DM2I19P	RN	Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57.
DM2I19P	RU	https://pubmed.ncbi.nlm.nih.gov/14579514

DM2I19P	DI	DM2I19P
DM2I19P	DN	Barbituric acid derivative
DM2I19P	MI	TTBMV1G
DM2I19P	MN	GABA(A) receptor alpha-2 (GABRA2)
DM2I19P	MT	DTT
DM2I19P	MA	Inhibitor
DM2I19P	RN	Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57.
DM2I19P	RU	https://pubmed.ncbi.nlm.nih.gov/14579514

DM2I19P	DI	DM2I19P
DM2I19P	DN	Barbituric acid derivative
DM2I19P	MI	TT37EDJ
DM2I19P	MN	GABA(A) receptor alpha-3 (GABRA3)
DM2I19P	MT	DTT
DM2I19P	MA	Inhibitor
DM2I19P	RN	Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57.
DM2I19P	RU	https://pubmed.ncbi.nlm.nih.gov/14579514

DM2I19P	DI	DM2I19P
DM2I19P	DN	Barbituric acid derivative
DM2I19P	MI	TTNZPQ1
DM2I19P	MN	GABA(A) receptor alpha-5 (GABRA5)
DM2I19P	MT	DTT
DM2I19P	MA	Inhibitor
DM2I19P	RN	Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57.
DM2I19P	RU	https://pubmed.ncbi.nlm.nih.gov/14579514

DM2I19P	DI	DM2I19P
DM2I19P	DN	Barbituric acid derivative
DM2I19P	MI	TT4H1MQ
DM2I19P	MN	Neuronal acetylcholine receptor alpha-4 (CHRNA4)
DM2I19P	MT	DTT
DM2I19P	MA	Antagonist
DM2I19P	RN	Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57.
DM2I19P	RU	https://pubmed.ncbi.nlm.nih.gov/14579514

DM2I19P	DI	DM2I19P
DM2I19P	DN	Barbituric acid derivative
DM2I19P	MI	TTLA931
DM2I19P	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DM2I19P	MT	DTT
DM2I19P	MA	Antagonist
DM2I19P	RN	Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57.
DM2I19P	RU	https://pubmed.ncbi.nlm.nih.gov/14579514

DMU3D2O	DI	DMU3D2O
DMU3D2O	DN	BARETTIN
DMU3D2O	MI	TTJQOD7
DMU3D2O	MN	5-HT 2A receptor (HTR2A)
DMU3D2O	MT	DTT
DMU3D2O	MA	Inhibitor
DMU3D2O	RN	Brominated cyclodipeptides from the marine sponge Geodia barretti as selective 5-HT ligands. J Nat Prod. 2006 Oct;69(10):1421-4.
DMU3D2O	RU	https://pubmed.ncbi.nlm.nih.gov/17067154

DMU3D2O	DI	DMU3D2O
DMU3D2O	DN	BARETTIN
DMU3D2O	MI	TTWJBZ5
DMU3D2O	MN	5-HT 2C receptor (HTR2C)
DMU3D2O	MT	DTT
DMU3D2O	MA	Inhibitor
DMU3D2O	RN	Brominated cyclodipeptides from the marine sponge Geodia barretti as selective 5-HT ligands. J Nat Prod. 2006 Oct;69(10):1421-4.
DMU3D2O	RU	https://pubmed.ncbi.nlm.nih.gov/17067154

DMU3D2O	DI	DMU3D2O
DMU3D2O	DN	BARETTIN
DMU3D2O	MI	TT07C3Y
DMU3D2O	MN	5-HT 4 receptor (HTR4)
DMU3D2O	MT	DTT
DMU3D2O	MA	Inhibitor
DMU3D2O	RN	Brominated cyclodipeptides from the marine sponge Geodia barretti as selective 5-HT ligands. J Nat Prod. 2006 Oct;69(10):1421-4.
DMU3D2O	RU	https://pubmed.ncbi.nlm.nih.gov/17067154

DMZPKGS	DI	DMZPKGS
DMZPKGS	DN	BAS-00387275
DMZPKGS	MI	TT6PKBN
DMZPKGS	MN	Proto-oncogene c-Src (SRC)
DMZPKGS	MT	DTT
DMZPKGS	MA	Inhibitor
DMZPKGS	RN	A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors. J Med Chem. 2006 Jun 1;49(11):3278-86.
DMZPKGS	RU	https://pubmed.ncbi.nlm.nih.gov/16722646

DMZPKGS	DI	DMZPKGS
DMZPKGS	DN	BAS-00387275
DMZPKGS	MI	TT3PJMV
DMZPKGS	MN	Tyrosine-protein kinase ABL1 (ABL)
DMZPKGS	MT	DTT
DMZPKGS	MA	Inhibitor
DMZPKGS	RN	A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors. J Med Chem. 2006 Jun 1;49(11):3278-86.
DMZPKGS	RU	https://pubmed.ncbi.nlm.nih.gov/16722646

DM4OSFD	DI	DM4OSFD
DM4OSFD	DN	BAS-00387328
DM4OSFD	MI	TT6PKBN
DM4OSFD	MN	Proto-oncogene c-Src (SRC)
DM4OSFD	MT	DTT
DM4OSFD	MA	Inhibitor
DM4OSFD	RN	A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors. J Med Chem. 2006 Jun 1;49(11):3278-86.
DM4OSFD	RU	https://pubmed.ncbi.nlm.nih.gov/16722646

DM4OSFD	DI	DM4OSFD
DM4OSFD	DN	BAS-00387328
DM4OSFD	MI	TT3PJMV
DM4OSFD	MN	Tyrosine-protein kinase ABL1 (ABL)
DM4OSFD	MT	DTT
DM4OSFD	MA	Inhibitor
DM4OSFD	RN	A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors. J Med Chem. 2006 Jun 1;49(11):3278-86.
DM4OSFD	RU	https://pubmed.ncbi.nlm.nih.gov/16722646

DMUF28Q	DI	DMUF28Q
DMUF28Q	DN	BAS-00387347
DMUF28Q	MI	TT6PKBN
DMUF28Q	MN	Proto-oncogene c-Src (SRC)
DMUF28Q	MT	DTT
DMUF28Q	MA	Inhibitor
DMUF28Q	RN	A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors. J Med Chem. 2006 Jun 1;49(11):3278-86.
DMUF28Q	RU	https://pubmed.ncbi.nlm.nih.gov/16722646

DMUF28Q	DI	DMUF28Q
DMUF28Q	DN	BAS-00387347
DMUF28Q	MI	TT3PJMV
DMUF28Q	MN	Tyrosine-protein kinase ABL1 (ABL)
DMUF28Q	MT	DTT
DMUF28Q	MA	Inhibitor
DMUF28Q	RN	A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors. J Med Chem. 2006 Jun 1;49(11):3278-86.
DMUF28Q	RU	https://pubmed.ncbi.nlm.nih.gov/16722646

DM6R4X8	DI	DM6R4X8
DM6R4X8	DN	BAS-00672722
DM6R4X8	MI	TT6PKBN
DM6R4X8	MN	Proto-oncogene c-Src (SRC)
DM6R4X8	MT	DTT
DM6R4X8	MA	Inhibitor
DM6R4X8	RN	A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors. J Med Chem. 2006 Jun 1;49(11):3278-86.
DM6R4X8	RU	https://pubmed.ncbi.nlm.nih.gov/16722646

DM6R4X8	DI	DM6R4X8
DM6R4X8	DN	BAS-00672722
DM6R4X8	MI	TT3PJMV
DM6R4X8	MN	Tyrosine-protein kinase ABL1 (ABL)
DM6R4X8	MT	DTT
DM6R4X8	MA	Inhibitor
DM6R4X8	RN	A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors. J Med Chem. 2006 Jun 1;49(11):3278-86.
DM6R4X8	RU	https://pubmed.ncbi.nlm.nih.gov/16722646

DMNB7CW	DI	DMNB7CW
DMNB7CW	DN	BAS-01047341
DMNB7CW	MI	TT6PKBN
DMNB7CW	MN	Proto-oncogene c-Src (SRC)
DMNB7CW	MT	DTT
DMNB7CW	MA	Inhibitor
DMNB7CW	RN	A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors. J Med Chem. 2006 Jun 1;49(11):3278-86.
DMNB7CW	RU	https://pubmed.ncbi.nlm.nih.gov/16722646

DMC0FLB	DI	DMC0FLB
DMC0FLB	DN	BAS-01047655
DMC0FLB	MI	TT6PKBN
DMC0FLB	MN	Proto-oncogene c-Src (SRC)
DMC0FLB	MT	DTT
DMC0FLB	MA	Inhibitor
DMC0FLB	RN	A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors. J Med Chem. 2006 Jun 1;49(11):3278-86.
DMC0FLB	RU	https://pubmed.ncbi.nlm.nih.gov/16722646

DMZBIC3	DI	DMZBIC3
DMZBIC3	DN	BAS-01373578
DMZBIC3	MI	TT6PKBN
DMZBIC3	MN	Proto-oncogene c-Src (SRC)
DMZBIC3	MT	DTT
DMZBIC3	MA	Inhibitor
DMZBIC3	RN	A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors. J Med Chem. 2006 Jun 1;49(11):3278-86.
DMZBIC3	RU	https://pubmed.ncbi.nlm.nih.gov/16722646

DMZBIC3	DI	DMZBIC3
DMZBIC3	DN	BAS-01373578
DMZBIC3	MI	TT3PJMV
DMZBIC3	MN	Tyrosine-protein kinase ABL1 (ABL)
DMZBIC3	MT	DTT
DMZBIC3	MA	Inhibitor
DMZBIC3	RN	A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors. J Med Chem. 2006 Jun 1;49(11):3278-86.
DMZBIC3	RU	https://pubmed.ncbi.nlm.nih.gov/16722646

DMZGLHJ	DI	DMZGLHJ
DMZGLHJ	DN	BAS-0338868
DMZGLHJ	MI	TT6PKBN
DMZGLHJ	MN	Proto-oncogene c-Src (SRC)
DMZGLHJ	MT	DTT
DMZGLHJ	MA	Inhibitor
DMZGLHJ	RN	Discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents. Bioorg Med Chem Lett. 2008 Feb 1;18(3):1207-11.
DMZGLHJ	RU	https://pubmed.ncbi.nlm.nih.gov/18078752

DMZK0SC	DI	DMZK0SC
DMZK0SC	DN	BAS-0338872
DMZK0SC	MI	TT6PKBN
DMZK0SC	MN	Proto-oncogene c-Src (SRC)
DMZK0SC	MT	DTT
DMZK0SC	MA	Inhibitor
DMZK0SC	RN	Discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents. Bioorg Med Chem Lett. 2008 Feb 1;18(3):1207-11.
DMZK0SC	RU	https://pubmed.ncbi.nlm.nih.gov/18078752

DMZK0SC	DI	DMZK0SC
DMZK0SC	DN	BAS-0338872
DMZK0SC	MI	TT3PJMV
DMZK0SC	MN	Tyrosine-protein kinase ABL1 (ABL)
DMZK0SC	MT	DTT
DMZK0SC	MA	Inhibitor
DMZK0SC	RN	Discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents. Bioorg Med Chem Lett. 2008 Feb 1;18(3):1207-11.
DMZK0SC	RU	https://pubmed.ncbi.nlm.nih.gov/18078752

DMBS8N9	DI	DMBS8N9
DMBS8N9	DN	BAS-0338876
DMBS8N9	MI	TT3PJMV
DMBS8N9	MN	Tyrosine-protein kinase ABL1 (ABL)
DMBS8N9	MT	DTT
DMBS8N9	MA	Inhibitor
DMBS8N9	RN	Discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents. Bioorg Med Chem Lett. 2008 Feb 1;18(3):1207-11.
DMBS8N9	RU	https://pubmed.ncbi.nlm.nih.gov/18078752

DMFMBZ9	DI	DMFMBZ9
DMFMBZ9	DN	BAS-09534324
DMFMBZ9	MI	TT6PKBN
DMFMBZ9	MN	Proto-oncogene c-Src (SRC)
DMFMBZ9	MT	DTT
DMFMBZ9	MA	Inhibitor
DMFMBZ9	RN	A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors. J Med Chem. 2006 Jun 1;49(11):3278-86.
DMFMBZ9	RU	https://pubmed.ncbi.nlm.nih.gov/16722646

DMFMBZ9	DI	DMFMBZ9
DMFMBZ9	DN	BAS-09534324
DMFMBZ9	MI	TT3PJMV
DMFMBZ9	MN	Tyrosine-protein kinase ABL1 (ABL)
DMFMBZ9	MT	DTT
DMFMBZ9	MA	Inhibitor
DMFMBZ9	RN	A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors. J Med Chem. 2006 Jun 1;49(11):3278-86.
DMFMBZ9	RU	https://pubmed.ncbi.nlm.nih.gov/16722646

DMTH1JQ	DI	DMTH1JQ
DMTH1JQ	DN	BAS-450225
DMTH1JQ	MI	TT6PKBN
DMTH1JQ	MN	Proto-oncogene c-Src (SRC)
DMTH1JQ	MT	DTT
DMTH1JQ	MA	Inhibitor
DMTH1JQ	RN	A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors. J Med Chem. 2006 Jun 1;49(11):3278-86.
DMTH1JQ	RU	https://pubmed.ncbi.nlm.nih.gov/16722646

DMFNAKU	DI	DMFNAKU
DMFNAKU	DN	BAS-4844343
DMFNAKU	MI	TT6PKBN
DMFNAKU	MN	Proto-oncogene c-Src (SRC)
DMFNAKU	MT	DTT
DMFNAKU	MA	Inhibitor
DMFNAKU	RN	A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors. J Med Chem. 2006 Jun 1;49(11):3278-86.
DMFNAKU	RU	https://pubmed.ncbi.nlm.nih.gov/16722646

DMTQX1G	DI	DMTQX1G
DMTQX1G	DN	Batimistat
DMTQX1G	MI	TT6AZXG
DMTQX1G	MN	TNF alpha converting enzyme (ADAM17)
DMTQX1G	MT	DTT
DMTQX1G	MA	Inhibitor
DMTQX1G	RN	The secretases that cleave angiotensin converting enzyme and the amyloid precursor protein are distinct from tumour necrosis factor-alpha convertase. FEBS Lett. 1998 Jul 10;431(1):63-5.
DMTQX1G	RU	https://pubmed.ncbi.nlm.nih.gov/9684866

DMYH9SU	DI	DMYH9SU
DMYH9SU	DN	Batrachotoxin
DMYH9SU	MI	TTANOZH
DMYH9SU	MN	SCN1A messenger RNA (SCN1A mRNA)
DMYH9SU	MT	DTT
DMYH9SU	MA	Activator
DMYH9SU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 578).
DMYH9SU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=578

DMYH9SU	DI	DMYH9SU
DMYH9SU	DN	Batrachotoxin
DMYH9SU	MI	TTLJTUF
DMYH9SU	MN	Voltage-gated sodium channel alpha Nav1.2 (SCN2A)
DMYH9SU	MT	DTT
DMYH9SU	MA	Activator
DMYH9SU	RN	Interaction of batrachotoxin with the local anesthetic receptor site in transmembrane segment IVS6 of the voltage-gated sodium channel. Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13947-52.
DMYH9SU	RU	https://pubmed.ncbi.nlm.nih.gov/9811906

DMYH9SU	DI	DMYH9SU
DMYH9SU	DN	Batrachotoxin
DMYH9SU	MI	TTAXZ0K
DMYH9SU	MN	Voltage-gated sodium channel alpha Nav1.3 (SCN3A)
DMYH9SU	MT	DTT
DMYH9SU	MA	Activator
DMYH9SU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 580).
DMYH9SU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=580

DMYH9SU	DI	DMYH9SU
DMYH9SU	DN	Batrachotoxin
DMYH9SU	MI	TT84DRB
DMYH9SU	MN	Voltage-gated sodium channel alpha Nav1.4 (SCN4A)
DMYH9SU	MT	DTT
DMYH9SU	MA	Activator
DMYH9SU	RN	Point mutations in segment I-S6 render voltage-gated Na+ channels resistant to batrachotoxin. Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2653-8.
DMYH9SU	RU	https://pubmed.ncbi.nlm.nih.gov/9482942

DMYH9SU	DI	DMYH9SU
DMYH9SU	DN	Batrachotoxin
DMYH9SU	MI	TTZOVE0
DMYH9SU	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DMYH9SU	MT	DTT
DMYH9SU	MA	Activator
DMYH9SU	RN	Binding of [3H]batrachotoxinin A benzoate to specific sites on rat cardiac sodium channels. Mol Pharmacol. 1986 Dec;30(6):617-23.
DMYH9SU	RU	https://pubmed.ncbi.nlm.nih.gov/2431264

DMYH9SU	DI	DMYH9SU
DMYH9SU	DN	Batrachotoxin
DMYH9SU	MI	TT54ERL
DMYH9SU	MN	Voltage-gated sodium channel alpha Nav1.6 (SCN8A)
DMYH9SU	MT	DTT
DMYH9SU	MA	Activator
DMYH9SU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 583).
DMYH9SU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=583

DMYH9SU	DI	DMYH9SU
DMYH9SU	DN	Batrachotoxin
DMYH9SU	MI	TT4G2JS
DMYH9SU	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DMYH9SU	MT	DTT
DMYH9SU	MA	Activator
DMYH9SU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 584).
DMYH9SU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=584

DMYH9SU	DI	DMYH9SU
DMYH9SU	DN	Batrachotoxin
DMYH9SU	MI	TT90XZ8
DMYH9SU	MN	Voltage-gated sodium channel alpha Nav1.8 (SCN10A)
DMYH9SU	MT	DTT
DMYH9SU	MA	Activator
DMYH9SU	RN	The poison Dart frog's batrachotoxin modulates Nav1.8. FEBS Lett. 2004 Nov 5;577(1-2):245-8.
DMYH9SU	RU	https://pubmed.ncbi.nlm.nih.gov/15527793

DMVP74I	DI	DMVP74I
DMVP74I	DN	BAY 367620
DMVP74I	MI	TTVBPDM
DMVP74I	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMVP74I	MT	DTT
DMVP74I	MA	Modulator (allosteric modulator)
DMVP74I	RN	BAY36-7620: a potent non-competitive mGlu1 receptor antagonist with inverse agonist activity. Mol Pharmacol. 2001 May;59(5):965-73.
DMVP74I	RU	https://pubmed.ncbi.nlm.nih.gov/11306677

DM743XB	DI	DM743XB
DM743XB	DN	BAY 50-7952
DM743XB	MI	TTS7LWX
DM743XB	MN	Bacterial DNA gyrase B (Bact gyrB)
DM743XB	MT	DTT
DM743XB	MA	Inhibitor
DM743XB	RN	seco-Cyclothialidines: new concise synthesis, inhibitory activity toward bacterial and human DNA topoisomerases, and antibacterial properties. J Med Chem. 2001 Feb 15;44(4):619-26.
DM743XB	RU	https://pubmed.ncbi.nlm.nih.gov/11170652

DMRWSGO	DI	DMRWSGO
DMRWSGO	DN	Bay K 8644
DMRWSGO	MI	TTXHYV6
DMRWSGO	MN	Voltage-gated L-type calcium channel (L-CaC)
DMRWSGO	MT	DTT
DMRWSGO	MA	Activator
DMRWSGO	RN	Molecular determinants of drug binding and action on L-type calcium channels. Annu Rev Pharmacol Toxicol. 1997;37:361-96.
DMRWSGO	RU	https://pubmed.ncbi.nlm.nih.gov/9131258

DMQNOFA	DI	DMQNOFA
DMQNOFA	DN	BAY11-7082
DMQNOFA	MI	TTSXVID
DMQNOFA	MN	Nuclear factor NF-kappa-B (NFKB)
DMQNOFA	MT	DTT
DMQNOFA	MA	Inhibitor
DMQNOFA	RN	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
DMQNOFA	RU	https://pubmed.ncbi.nlm.nih.gov/19249983

DM0M59T	DI	DM0M59T
DM0M59T	DN	BAY412272
DM0M59T	MI	TTWNFC2
DM0M59T	MN	Soluble guanylyl cyclase (GUCY2D)
DM0M59T	MT	DTT
DM0M59T	MA	Activator
DM0M59T	RN	NO-independent regulatory site on soluble guanylate cyclase. Nature. 2001 Mar 8;410(6825):212-5.
DM0M59T	RU	https://pubmed.ncbi.nlm.nih.gov/11242081

DMQZ7JD	DI	DMQZ7JD
DMQZ7JD	DN	BAY-60-7550
DMQZ7JD	MI	TTJGW1Z
DMQZ7JD	MN	Phosphodiesterase 2A (PDE2A)
DMQZ7JD	MT	DTT
DMQZ7JD	MA	Inhibitor
DMQZ7JD	RN	The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases. J Med Chem. 2005 May 19;48(10):3449-62.
DMQZ7JD	RU	https://pubmed.ncbi.nlm.nih.gov/15887951

DM5CPJ2	DI	DM5CPJ2
DM5CPJ2	DN	BAY-73-1449
DM5CPJ2	MI	TTOFYT1
DM5CPJ2	MN	Prostacyclin receptor (PTGIR)
DM5CPJ2	MT	DTT
DM5CPJ2	MA	Antagonist
DM5CPJ2	RN	Vascular actions of the prostacyclin receptor antagonist BAY 73-1449 in the portal hypertensive rat. Eur J Pharmacol. 2008 Aug 20;590(1-3):322-6.
DM5CPJ2	RU	https://pubmed.ncbi.nlm.nih.gov/18603238

DMW625B	DI	DMW625B
DMW625B	DN	BAY-85-3474
DMW625B	MI	TTNDSF4
DMW625B	MN	Proto-oncogene c-Met (MET)
DMW625B	MT	DTT
DMW625B	MA	Inhibitor
DMW625B	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
DMW625B	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815

DMKFTZA	DI	DMKFTZA
DMKFTZA	DN	BayCysLT2
DMKFTZA	MI	TTGKOY9
DMKFTZA	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DMKFTZA	MT	DTT
DMKFTZA	MA	Antagonist
DMKFTZA	RN	Synthesis of cysteinyl leukotrienes in human endothelial cells: subcellular localization and autocrine signaling through the CysLT2 receptor. FASEB J. 2011 Oct;25(10):3519-28.
DMKFTZA	RU	https://pubmed.ncbi.nlm.nih.gov/21753081

DMKFTZA	DI	DMKFTZA
DMKFTZA	DN	BayCysLT2
DMKFTZA	MI	TT0PZR5
DMKFTZA	MN	Leukotriene CysLT2 receptor (CYSLTR2)
DMKFTZA	MT	DTT
DMKFTZA	MA	Antagonist
DMKFTZA	RN	Synthesis of cysteinyl leukotrienes in human endothelial cells: subcellular localization and autocrine signaling through the CysLT2 receptor. FASEB J. 2011 Oct;25(10):3519-28.
DMKFTZA	RU	https://pubmed.ncbi.nlm.nih.gov/21753081

DMXQ14V	DI	DMXQ14V
DMXQ14V	DN	BAYu9773
DMXQ14V	MI	TTGKOY9
DMXQ14V	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DMXQ14V	MT	DTT
DMXQ14V	MA	Antagonist
DMXQ14V	RN	Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist. Mol Pharmacol. 2000 Dec;58(6):1601-8.
DMXQ14V	RU	https://pubmed.ncbi.nlm.nih.gov/11093801

DMXQ14V	DI	DMXQ14V
DMXQ14V	DN	BAYu9773
DMXQ14V	MI	TT0PZR5
DMXQ14V	MN	Leukotriene CysLT2 receptor (CYSLTR2)
DMXQ14V	MT	DTT
DMXQ14V	MA	Antagonist
DMXQ14V	RN	BAY u9773, a novel antagonist of cysteinyl-leukotrienes with activity against two receptor subtypes. Eur J Pharmacol. 1994 Nov 3;264(3):317-23.
DMXQ14V	RU	https://pubmed.ncbi.nlm.nih.gov/7698171

DMKDZLG	DI	DMKDZLG
DMKDZLG	DN	BAZ2-ICR
DMKDZLG	MI	TT2MV0R
DMKDZLG	MN	Bromodomain adjacent to zinc finger 2A (BAZ2A)
DMKDZLG	MT	DTT
DMKDZLG	MA	Inhibitor
DMKDZLG	RN	Structure enabled design of BAZ2-ICR, a chemical probe targeting the bromodomains of BAZ2A and BAZ2B. J Med Chem. 2015 Mar 12;58(5):2553-9.
DMKDZLG	RU	https://pubmed.ncbi.nlm.nih.gov/25719566

DMKDZLG	DI	DMKDZLG
DMKDZLG	DN	BAZ2-ICR
DMKDZLG	MI	TT6K8YG
DMKDZLG	MN	Bromodomain adjacent to zinc finger 2B (BAZ2B)
DMKDZLG	MT	DTT
DMKDZLG	MA	Inhibitor
DMKDZLG	RN	Structure enabled design of BAZ2-ICR, a chemical probe targeting the bromodomains of BAZ2A and BAZ2B. J Med Chem. 2015 Mar 12;58(5):2553-9.
DMKDZLG	RU	https://pubmed.ncbi.nlm.nih.gov/25719566

DM5SDV9	DI	DM5SDV9
DM5SDV9	DN	Bb-3497
DM5SDV9	MI	TTICO5G
DM5SDV9	MN	Staphylococcus Peptide deformylase (Stap-coc def)
DM5SDV9	MT	DTT
DM5SDV9	MA	Inhibitor
DM5SDV9	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM5SDV9	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMFBN9O	DI	DMFBN9O
DMFBN9O	DN	BB-78484
DMFBN9O	MI	TT0OFWN
DMFBN9O	MN	Pseudomonas UDP-3-O-acyl-GlcNAc deacetylase (Pseudo lpxC)
DMFBN9O	MT	DTT
DMFBN9O	MA	Inhibitor
DMFBN9O	RN	Antibacterial activities and characterization of novel inhibitors of LpxC. Antimicrob Agents Chemother. 2002 Jun;46(6):1793-9.
DMFBN9O	RU	https://pubmed.ncbi.nlm.nih.gov/12019092

DMJKA3F	DI	DMJKA3F
DMJKA3F	DN	BB-78485
DMJKA3F	MI	TT0OFWN
DMJKA3F	MN	Pseudomonas UDP-3-O-acyl-GlcNAc deacetylase (Pseudo lpxC)
DMJKA3F	MT	DTT
DMJKA3F	MA	Inhibitor
DMJKA3F	RN	Antibacterial activities and characterization of novel inhibitors of LpxC. Antimicrob Agents Chemother. 2002 Jun;46(6):1793-9.
DMJKA3F	RU	https://pubmed.ncbi.nlm.nih.gov/12019092

DMZPL63	DI	DMZPL63
DMZPL63	DN	BB-823
DMZPL63	MI	TTQL5VC
DMZPL63	MN	Platelet-activating factor receptor (PTAFR)
DMZPL63	MT	DTT
DMZPL63	MA	Modulator
DMZPL63	RN	Platelet-activating factor: the effector of protein-rich plasma extravasation and nitric oxide synthase induction in rat immune complex peritonitis. Br J Pharmacol. 1995 Feb;114(4):895-901.
DMZPL63	RU	https://pubmed.ncbi.nlm.nih.gov/7539698

DMMUIQ6	DI	DMMUIQ6
DMMUIQ6	DN	BBI-11008
DMMUIQ6	MI	TT27RFC
DMMUIQ6	MN	Opioid receptor delta (OPRD1)
DMMUIQ6	MT	DTT
DMMUIQ6	MA	Agonist
DMMUIQ6	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317).
DMMUIQ6	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=317

DM85AJ4	DI	DM85AJ4
DM85AJ4	DN	BB-PTH 1-84
DM85AJ4	MI	TTEPJL5
DM85AJ4	MN	Parathyroid hormone receptor (PTH2R)
DM85AJ4	MT	DTT
DM85AJ4	MA	Modulator
DM85AJ4	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 332).
DM85AJ4	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=332

DMMJ4I5	DI	DMMJ4I5
DMMJ4I5	DN	Bbs-Arg-(D-Pip)-Gly-(EQKLISEEDL)-Gly-Hir
DMMJ4I5	MI	TT6L509
DMMJ4I5	MN	Coagulation factor IIa (F2)
DMMJ4I5	MT	DTT
DMMJ4I5	MA	Inhibitor
DMMJ4I5	RN	Transforming bivalent ligands into retractable enzyme inhibitors through polypeptide-protein interactions. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5120-3.
DMMJ4I5	RU	https://pubmed.ncbi.nlm.nih.gov/16202582

DM8TH4B	DI	DM8TH4B
DM8TH4B	DN	Bbs-Arg-(D-Pip)-Gly-(SPH(pY)EKVS)-Gly-Hir
DM8TH4B	MI	TT6L509
DM8TH4B	MN	Coagulation factor IIa (F2)
DM8TH4B	MT	DTT
DM8TH4B	MA	Inhibitor
DM8TH4B	RN	Transforming bivalent ligands into retractable enzyme inhibitors through polypeptide-protein interactions. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5120-3.
DM8TH4B	RU	https://pubmed.ncbi.nlm.nih.gov/16202582

DMQVRHG	DI	DMQVRHG
DMQVRHG	DN	Bbs-Arg-(D-Pip)-Gly-(SPHYEKVS)-Gly-Hir
DMQVRHG	MI	TT6L509
DMQVRHG	MN	Coagulation factor IIa (F2)
DMQVRHG	MT	DTT
DMQVRHG	MA	Inhibitor
DMQVRHG	RN	Transforming bivalent ligands into retractable enzyme inhibitors through polypeptide-protein interactions. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5120-3.
DMQVRHG	RU	https://pubmed.ncbi.nlm.nih.gov/16202582

DMXECFJ	DI	DMXECFJ
DMXECFJ	DN	Bbs-Arg-(D-Pip)-Gly-S-(GS)11-Gly-Hir
DMXECFJ	MI	TT6L509
DMXECFJ	MN	Coagulation factor IIa (F2)
DMXECFJ	MT	DTT
DMXECFJ	MA	Inhibitor
DMXECFJ	RN	Transforming bivalent ligands into retractable enzyme inhibitors through polypeptide-protein interactions. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5120-3.
DMXECFJ	RU	https://pubmed.ncbi.nlm.nih.gov/16202582

DM5N6YE	DI	DM5N6YE
DM5N6YE	DN	Bbs-Arg-(D-Pip)-Gly-S-(GS)13-Gly-Hir
DM5N6YE	MI	TT6L509
DM5N6YE	MN	Coagulation factor IIa (F2)
DM5N6YE	MT	DTT
DM5N6YE	MA	Inhibitor
DM5N6YE	RN	Transforming bivalent ligands into retractable enzyme inhibitors through polypeptide-protein interactions. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5120-3.
DM5N6YE	RU	https://pubmed.ncbi.nlm.nih.gov/16202582

DMTU0HR	DI	DMTU0HR
DMTU0HR	DN	Bbs-Arg-(D-Pip)-Gly-S-(GS)1-Gly-Hir
DMTU0HR	MI	TT6L509
DMTU0HR	MN	Coagulation factor IIa (F2)
DMTU0HR	MT	DTT
DMTU0HR	MA	Inhibitor
DMTU0HR	RN	Transforming bivalent ligands into retractable enzyme inhibitors through polypeptide-protein interactions. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5120-3.
DMTU0HR	RU	https://pubmed.ncbi.nlm.nih.gov/16202582

DMEL2GK	DI	DMEL2GK
DMEL2GK	DN	Bbs-Arg-(D-Pip)-Gly-S-(GS)3-Gly-Hir
DMEL2GK	MI	TT6L509
DMEL2GK	MN	Coagulation factor IIa (F2)
DMEL2GK	MT	DTT
DMEL2GK	MA	Inhibitor
DMEL2GK	RN	Transforming bivalent ligands into retractable enzyme inhibitors through polypeptide-protein interactions. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5120-3.
DMEL2GK	RU	https://pubmed.ncbi.nlm.nih.gov/16202582

DMCN48J	DI	DMCN48J
DMCN48J	DN	Bbs-Arg-(D-Pip)-Gly-S-(GS)5-Gly-Hir
DMCN48J	MI	TT6L509
DMCN48J	MN	Coagulation factor IIa (F2)
DMCN48J	MT	DTT
DMCN48J	MA	Inhibitor
DMCN48J	RN	Transforming bivalent ligands into retractable enzyme inhibitors through polypeptide-protein interactions. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5120-3.
DMCN48J	RU	https://pubmed.ncbi.nlm.nih.gov/16202582

DMLK5I0	DI	DMLK5I0
DMLK5I0	DN	Bbs-Arg-(D-Pip)-Gly-S-(GS)7-Gly-Hir
DMLK5I0	MI	TT6L509
DMLK5I0	MN	Coagulation factor IIa (F2)
DMLK5I0	MT	DTT
DMLK5I0	MA	Inhibitor
DMLK5I0	RN	Transforming bivalent ligands into retractable enzyme inhibitors through polypeptide-protein interactions. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5120-3.
DMLK5I0	RU	https://pubmed.ncbi.nlm.nih.gov/16202582

DMLZ5R6	DI	DMLZ5R6
DMLZ5R6	DN	Bbs-Arg-(D-Pip)-Gly-S-(GS)9-Gly-Hir
DMLZ5R6	MI	TT6L509
DMLZ5R6	MN	Coagulation factor IIa (F2)
DMLZ5R6	MT	DTT
DMLZ5R6	MA	Inhibitor
DMLZ5R6	RN	Transforming bivalent ligands into retractable enzyme inhibitors through polypeptide-protein interactions. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5120-3.
DMLZ5R6	RU	https://pubmed.ncbi.nlm.nih.gov/16202582

DMT0X6Q	DI	DMT0X6Q
DMT0X6Q	DN	BBT-007
DMT0X6Q	MI	TT6MP2Z
DMT0X6Q	MN	GMCSFR-alpha (CSF2RA)
DMT0X6Q	MT	DTT
DMT0X6Q	MA	Stimulator
DMT0X6Q	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1707).
DMT0X6Q	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1707

DM2YTXL	DI	DM2YTXL
DM2YTXL	DN	BBT-009
DM2YTXL	MI	TTAUX24
DM2YTXL	MN	Erythropoietin Receptor (EPOR)
DM2YTXL	MT	DTT
DM2YTXL	MA	Stimulator
DM2YTXL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1718).
DM2YTXL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1718

DMLIT84	DI	DMLIT84
DMLIT84	DN	BBT-021
DMLIT84	MI	TTAUX24
DMLIT84	MN	Erythropoietin Receptor (EPOR)
DMLIT84	MT	DTT
DMLIT84	MA	Stimulator
DMLIT84	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1718).
DMLIT84	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1718

DMQNA7V	DI	DMQNA7V
DMQNA7V	DN	BC11-38
DMQNA7V	MI	TTTWC79
DMQNA7V	MN	Phosphodiesterase 11A (PDE11A)
DMQNA7V	MT	DTT
DMQNA7V	MA	Inhibitor
DMQNA7V	RN	Identification of biologically active PDE11-selective inhibitors using a yeast-based high-throughput screen. Chem Biol. 2012 Jan 27;19(1):155-63.
DMQNA7V	RU	https://pubmed.ncbi.nlm.nih.gov/22284362

DMQWOZ5	DI	DMQWOZ5
DMQWOZ5	DN	BC-264
DMQWOZ5	MI	TTVFO0U
DMQWOZ5	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMQWOZ5	MT	DTT
DMQWOZ5	MA	Agonist
DMQWOZ5	RN	Synthesis and biological characterisation of [3H]BBL454, a new CCK2 selective radiolabelled agonist displaying original pharmacological properties. Bioorg Med Chem Lett. 2004 Jan 19;14(2):369-72.
DMQWOZ5	RU	https://pubmed.ncbi.nlm.nih.gov/14698161

DM047DQ	DI	DM047DQ
DM047DQ	DN	BCEAB
DM047DQ	MI	TT8VUE0
DM047DQ	MN	Chymase (CYM)
DM047DQ	MT	DTT
DM047DQ	MA	Inhibitor
DM047DQ	RN	Development of a chymase inhibitor: pharmacological characterization of a chymase inhibitor in inflamed tissue remodeling and fibrosis. Jpn J Pharmacol. 2002 Nov;90(3):206-9.
DM047DQ	RU	https://pubmed.ncbi.nlm.nih.gov/12499572

DMPG1LJ	DI	DMPG1LJ
DMPG1LJ	DN	Bcecf-Am
DMPG1LJ	MI	DTUGYRD
DMPG1LJ	MN	P-glycoprotein 1 (ABCB1)
DMPG1LJ	MT	DTP
DMPG1LJ	MA	Substrate
DMPG1LJ	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMPG1LJ	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DM9IN0U	DI	DM9IN0U
DM9IN0U	DN	BCH
DM9IN0U	MI	TTPH2JB
DM9IN0U	MN	Large neutral amino acids transporter 1 (SLC7A5)
DM9IN0U	MT	DTT
DM9IN0U	MA	Blocker
DM9IN0U	RN	Amino acid transporter molecule as a drug target. Nippon Yakurigaku Zasshi. 1999 Oct;114 Suppl 1:11P-16P.
DM9IN0U	RU	https://pubmed.ncbi.nlm.nih.gov/10629848

DMT5AGJ	DI	DMT5AGJ
DMT5AGJ	DN	BCTC
DMT5AGJ	MI	TTMI6F5
DMT5AGJ	MN	Transient receptor potential cation channel V1 (TRPV1)
DMT5AGJ	MT	DTT
DMT5AGJ	MA	Blocker
DMT5AGJ	RN	Analgesic potential of TRPV1 antagonists. Biochem Pharmacol. 2009 Aug 1;78(3):211-6.
DMT5AGJ	RU	https://pubmed.ncbi.nlm.nih.gov/19481638

DMVOS2C	DI	DMVOS2C
DMVOS2C	DN	BCX-1827
DMVOS2C	MI	TT50QJ3
DMVOS2C	MN	Influenza Neuraminidase (Influ NA)
DMVOS2C	MT	DTT
DMVOS2C	MA	Inhibitor
DMVOS2C	RN	Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25.
DMVOS2C	RU	https://pubmed.ncbi.nlm.nih.gov/17139286

DM6JB32	DI	DM6JB32
DM6JB32	DN	BCX-1898
DM6JB32	MI	TT50QJ3
DM6JB32	MN	Influenza Neuraminidase (Influ NA)
DM6JB32	MT	DTT
DM6JB32	MA	Inhibitor
DM6JB32	RN	Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25.
DM6JB32	RU	https://pubmed.ncbi.nlm.nih.gov/17139286

DM8G4HS	DI	DM8G4HS
DM8G4HS	DN	BCX-1923
DM8G4HS	MI	TT50QJ3
DM8G4HS	MN	Influenza Neuraminidase (Influ NA)
DM8G4HS	MT	DTT
DM8G4HS	MA	Inhibitor
DM8G4HS	RN	Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25.
DM8G4HS	RU	https://pubmed.ncbi.nlm.nih.gov/17139286

DMFIDA0	DI	DMFIDA0
DMFIDA0	DN	BD-1047
DMFIDA0	MI	TT5TPI6
DMFIDA0	MN	Opioid receptor sigma 1 (OPRS1)
DMFIDA0	MT	DTT
DMFIDA0	MA	Antagonist
DMFIDA0	RN	Characterization of two novel sigma receptor ligands: antidystonic effects in rats suggest sigma receptor antagonism. Eur J Pharmacol. 1995 Jul 14;280(3):301-10.
DMFIDA0	RU	https://pubmed.ncbi.nlm.nih.gov/8566098

DMT0S7M	DI	DMT0S7M
DMT0S7M	DN	BD-NP
DMT0S7M	MI	TTY63XT
DMT0S7M	MN	B-type natriuretic peptide (BNP)
DMT0S7M	MT	DTT
DMT0S7M	MA	Modulator
DMT0S7M	RN	A Novel Designer Natriuretic and Diuretic Peptide Based Upon an Alternatively Spliced BNP Without Vascular Vasodilatory Actions. Circulation, 2006, 114:II_270.
DMT0S7M	RU	http://circ.ahajournals.org/cgi/content/meeting_abstract/114/18_MeetingAbstracts/II_270-a

DMZX57Y	DI	DMZX57Y
DMZX57Y	DN	befetupitant
DMZX57Y	MI	TTZPO1L
DMZX57Y	MN	Substance-P receptor (TACR1)
DMZX57Y	MT	DTT
DMZX57Y	MA	Antagonist
DMZX57Y	RN	Design and synthesis of a novel, achiral class of highly potent and selective, orally active neurokinin-1 receptor antagonists. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1362-5.
DMZX57Y	RU	https://pubmed.ncbi.nlm.nih.gov/16332435

DMV15JC	DI	DMV15JC
DMV15JC	DN	Befunolol
DMV15JC	MI	DECB0K3
DMV15JC	MN	Cytochrome P450 2D6 (CYP2D6)
DMV15JC	MT	DME
DMV15JC	MA	Metabolism
DMV15JC	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DMV15JC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DM0WOS6	DI	DM0WOS6
DM0WOS6	DN	BELFOSDIL
DM0WOS6	MI	TT5HONZ
DM0WOS6	MN	Calcium channel unspecific (CaC)
DM0WOS6	MT	DTT
DM0WOS6	MA	Modulator
DM0WOS6	RN	Determination of belfosdil, a new calcium channel blocker, in human plasma by capillary gas chromatography with nitrogen-phosphorus detection. J Chromatogr. 1990 May 18;527(2):343-50.
DM0WOS6	RU	https://www.ncbi.nlm.nih.gov/pubmed/2387881

DM7H3VY	DI	DM7H3VY
DM7H3VY	DN	Bencyclane
DM7H3VY	MI	DE4LYSA
DM7H3VY	MN	Cytochrome P450 3A4 (CYP3A4)
DM7H3VY	MT	DME
DM7H3VY	MA	Metabolism
DM7H3VY	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DM7H3VY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DMFPSOQ	DI	DMFPSOQ
DMFPSOQ	DN	Benzaldehyde O-4-(decyloxy)phenylcarbamoyl oxime
DMFPSOQ	MI	TTDP1UC
DMFPSOQ	MN	Fatty acid amide hydrolase (FAAH)
DMFPSOQ	MT	DTT
DMFPSOQ	MA	Inhibitor
DMFPSOQ	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DMFPSOQ	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DMU7INH	DI	DMU7INH
DMU7INH	DN	Benzaldehyde O-4-(heptyloxy)phenylcarbamoyl oxime
DMU7INH	MI	TTDP1UC
DMU7INH	MN	Fatty acid amide hydrolase (FAAH)
DMU7INH	MT	DTT
DMU7INH	MA	Inhibitor
DMU7INH	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DMU7INH	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DMOK0U8	DI	DMOK0U8
DMOK0U8	DN	Benzaldehyde O-4-(hexyloxy)phenylcarbamoyl oxime
DMOK0U8	MI	TTDP1UC
DMOK0U8	MN	Fatty acid amide hydrolase (FAAH)
DMOK0U8	MT	DTT
DMOK0U8	MA	Inhibitor
DMOK0U8	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DMOK0U8	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DMIV3S8	DI	DMIV3S8
DMIV3S8	DN	Benzaldehyde O-4-(nonyloxy)phenylcarbamoyl oxime
DMIV3S8	MI	TTDP1UC
DMIV3S8	MN	Fatty acid amide hydrolase (FAAH)
DMIV3S8	MT	DTT
DMIV3S8	MA	Inhibitor
DMIV3S8	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DMIV3S8	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DMBW7PX	DI	DMBW7PX
DMBW7PX	DN	Benzaldehyde O-4-(octyloxy)phenylcarbamoyl oxime
DMBW7PX	MI	TTDP1UC
DMBW7PX	MN	Fatty acid amide hydrolase (FAAH)
DMBW7PX	MT	DTT
DMBW7PX	MA	Inhibitor
DMBW7PX	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DMBW7PX	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DMWEXOY	DI	DMWEXOY
DMWEXOY	DN	Benzaldehyde O-4-(pentyloxy)phenylcarbamoyl oxime
DMWEXOY	MI	TTDP1UC
DMWEXOY	MN	Fatty acid amide hydrolase (FAAH)
DMWEXOY	MT	DTT
DMWEXOY	MA	Inhibitor
DMWEXOY	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DMWEXOY	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DMHUQWN	DI	DMHUQWN
DMHUQWN	DN	Benzaldehyde O-4-butoxyphenylcarbamoyl oxime
DMHUQWN	MI	TTDP1UC
DMHUQWN	MN	Fatty acid amide hydrolase (FAAH)
DMHUQWN	MT	DTT
DMHUQWN	MA	Inhibitor
DMHUQWN	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DMHUQWN	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DMD98YP	DI	DMD98YP
DMD98YP	DN	Benzaldehyde O-4-ethoxyphenylcarbamoyl oxime
DMD98YP	MI	TTDP1UC
DMD98YP	MN	Fatty acid amide hydrolase (FAAH)
DMD98YP	MT	DTT
DMD98YP	MA	Inhibitor
DMD98YP	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DMD98YP	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DMLHKQS	DI	DMLHKQS
DMLHKQS	DN	Benzaldehyde O-4-methoxyphenylcarbamoyl oxime
DMLHKQS	MI	TTDP1UC
DMLHKQS	MN	Fatty acid amide hydrolase (FAAH)
DMLHKQS	MT	DTT
DMLHKQS	MA	Inhibitor
DMLHKQS	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DMLHKQS	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DMARBF9	DI	DMARBF9
DMARBF9	DN	Benzaldehyde O-4-propoxyphenylcarbamoyl oxime
DMARBF9	MI	TTDP1UC
DMARBF9	MN	Fatty acid amide hydrolase (FAAH)
DMARBF9	MT	DTT
DMARBF9	MA	Inhibitor
DMARBF9	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DMARBF9	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DMB7DFT	DI	DMB7DFT
DMB7DFT	DN	Benzaldehyde O-benzoyloxime
DMB7DFT	MI	TTDNFMT
DMB7DFT	MN	Platelet-activating factor acetylhydrolase (PLA2G7)
DMB7DFT	MT	DTT
DMB7DFT	MA	Inhibitor
DMB7DFT	RN	Potent inhibitors of lipoprotein-associated phospholipase A(2): benzaldehyde O-heterocycle-4-carbonyloxime. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5576-9.
DMB7DFT	RU	https://pubmed.ncbi.nlm.nih.gov/16919943

DM37GWL	DI	DM37GWL
DM37GWL	DN	Benzamidine
DM37GWL	MI	TT2WR1T
DM37GWL	MN	Cationic trypsinogen (PRSS1)
DM37GWL	MT	DTT
DM37GWL	MA	Inhibitor
DM37GWL	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM37GWL	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM37GWL	DI	DM37GWL
DM37GWL	DN	Benzamidine
DM37GWL	MI	TTLPF4X
DM37GWL	MN	Kallikrein-6 (KLK6)
DM37GWL	MT	DTT
DM37GWL	MA	Inhibitor
DM37GWL	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM37GWL	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM37GWL	DI	DM37GWL
DM37GWL	DN	Benzamidine
DM37GWL	MI	TTPRO7W
DM37GWL	MN	Suppressor of tumorigenicity 14 protein (ST14)
DM37GWL	MT	DTT
DM37GWL	MA	Inhibitor
DM37GWL	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM37GWL	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM37GWL	DI	DM37GWL
DM37GWL	DN	Benzamidine
DM37GWL	MI	TTGY7WI
DM37GWL	MN	Urokinase-type plasminogen activator (PLAU)
DM37GWL	MT	DTT
DM37GWL	MA	Inhibitor
DM37GWL	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM37GWL	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM57SVW	DI	DM57SVW
DM57SVW	DN	Benzamil
DM57SVW	MI	TTLGDIS
DM57SVW	MN	Acid-sensing ion channel 3 (ASIC3)
DM57SVW	MT	DTT
DM57SVW	MA	Blocker (channel blocker)
DM57SVW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 684).
DM57SVW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=684

DM57SVW	DI	DM57SVW
DM57SVW	DN	Benzamil
DM57SVW	MI	TTQM7TE
DM57SVW	MN	Amiloride-sensitive sodium channel (ENaC)
DM57SVW	MT	DTT
DM57SVW	MA	Blocker (channel blocker)
DM57SVW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 742).
DM57SVW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=742

DM57SVW	DI	DM57SVW
DM57SVW	DN	Benzamil
DM57SVW	MI	DTT79CX
DM57SVW	MN	Organic cation transporter 1 (SLC22A1)
DM57SVW	MT	DTP
DM57SVW	MA	Substrate
DM57SVW	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DM57SVW	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DM57SVW	DI	DM57SVW
DM57SVW	DN	Benzamil
DM57SVW	MI	TTAHD89
DM57SVW	MN	Polycystic kidney disease 2-like 1 (TRPP2)
DM57SVW	MT	DTT
DM57SVW	MA	Blocker (channel blocker)
DM57SVW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 505).
DM57SVW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=505

DMK5QYW	DI	DMK5QYW
DMK5QYW	DN	BENZENEMETHANETHIOL
DMK5QYW	MI	TTZJYKH
DMK5QYW	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMK5QYW	MT	DTT
DMK5QYW	MA	Inhibitor
DMK5QYW	RN	S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9.
DMK5QYW	RU	https://pubmed.ncbi.nlm.nih.gov/20688518

DM3I8A1	DI	DM3I8A1
DM3I8A1	DN	BENZENESULFONAMIDE
DM3I8A1	MI	TTHQPL7
DM3I8A1	MN	Carbonic anhydrase I (CA-I)
DM3I8A1	MT	DTT
DM3I8A1	MA	Inhibitor
DM3I8A1	RN	Ligand-directed tosyl chemistry for protein labeling in vivo. Nat Chem Biol. 2009 May;5(5):341-3.
DM3I8A1	RU	https://pubmed.ncbi.nlm.nih.gov/19330012

DMMBYGE	DI	DMMBYGE
DMMBYGE	DN	Benzenesulfonyl
DMMBYGE	MI	TTXA6PH
DMMBYGE	MN	Oxysterols receptor LXR-beta (NR1H2)
DMMBYGE	MT	DTT
DMMBYGE	MA	Inhibitor
DMMBYGE	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMMBYGE	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM5Y2M8	DI	DM5Y2M8
DM5Y2M8	DN	BENZIL
DM5Y2M8	MI	TTMF541
DM5Y2M8	MN	Liver carboxylesterase (CES1)
DM5Y2M8	MT	DTT
DM5Y2M8	MA	Inhibitor
DM5Y2M8	RN	Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30.
DM5Y2M8	RU	https://pubmed.ncbi.nlm.nih.gov/18023188

DM75U9X	DI	DM75U9X
DM75U9X	DN	Benzimidazole 5-carboxamide
DM75U9X	MI	TT84ETX
DM75U9X	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM75U9X	MT	DTT
DM75U9X	MA	Inhibitor
DM75U9X	RN	Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416.
DM75U9X	RU	https://pubmed.ncbi.nlm.nih.gov/18764719

DM067NL	DI	DM067NL
DM067NL	DN	Benzo[1,3]dioxol-5-ylmethyl-quinazolin-4-yl-amine
DM067NL	MI	TTJ0IQB
DM067NL	MN	Phosphodiesterase 5A (PDE5A)
DM067NL	MT	DTT
DM067NL	MA	Inhibitor
DM067NL	RN	Cyclic GMP phosphodiesterase inhibitors. 2. Requirement of 6-substitution of quinazoline derivatives for potent and selective inhibitory activity. J Med Chem. 1994 Jun 24;37(13):2106-11.
DM067NL	RU	https://pubmed.ncbi.nlm.nih.gov/8027992

DMJQSLW	DI	DMJQSLW
DMJQSLW	DN	Benzo[b]thiophen-2-ylboronic acid
DMJQSLW	MI	TTDP1UC
DMJQSLW	MN	Fatty acid amide hydrolase (FAAH)
DMJQSLW	MT	DTT
DMJQSLW	MA	Inhibitor
DMJQSLW	RN	Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Nov 27;51(22):7057-60.
DMJQSLW	RU	https://pubmed.ncbi.nlm.nih.gov/18983140

DMJQSLW	DI	DMJQSLW
DMJQSLW	DN	Benzo[b]thiophen-2-ylboronic acid
DMJQSLW	MI	TTHI19T
DMJQSLW	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMJQSLW	MT	DTT
DMJQSLW	MA	Inhibitor
DMJQSLW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMJQSLW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMZR02J	DI	DMZR02J
DMZR02J	DN	Benzo[c][1,2]oxaborol-1(3H)-ol
DMZR02J	MI	TTLP6GN
DMZR02J	MN	Bacterial DD-carboxypeptidase (Bact vanYB)
DMZR02J	MT	DTT
DMZR02J	MA	Inhibitor
DMZR02J	RN	Synthesis and evaluation of 3-(dihydroxyboryl)benzoic acids as D,D-carboxypeptidase R39 inhibitors. J Med Chem. 2009 Oct 8;52(19):6097-106.
DMZR02J	RU	https://pubmed.ncbi.nlm.nih.gov/19731939

DMMYGB9	DI	DMMYGB9
DMMYGB9	DN	Benzo[c][1,5]naphthyridin-6(5H)-one
DMMYGB9	MI	TTVDSZ0
DMMYGB9	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMMYGB9	MT	DTT
DMMYGB9	MA	Inhibitor
DMMYGB9	RN	Design, synthesis, and cytoprotective effect of 2-aminothiazole analogues as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2009 Feb 12;52(3):718-25.
DMMYGB9	RU	https://pubmed.ncbi.nlm.nih.gov/19125579

DMISHTB	DI	DMISHTB
DMISHTB	DN	Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine
DMISHTB	MI	TTGKNB4
DMISHTB	MN	Epidermal growth factor receptor (EGFR)
DMISHTB	MT	DTT
DMISHTB	MA	Inhibitor
DMISHTB	RN	Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase acti... J Med Chem. 1996 Feb 16;39(4):918-28.
DMISHTB	RU	https://pubmed.ncbi.nlm.nih.gov/8632415

DM9H34M	DI	DM9H34M
DM9H34M	DN	Benzodiazepine
DM9H34M	MI	DE4LYSA
DM9H34M	MN	Cytochrome P450 3A4 (CYP3A4)
DM9H34M	MT	DME
DM9H34M	MA	Metabolism
DM9H34M	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM9H34M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM9H34M	DI	DM9H34M
DM9H34M	DN	Benzodiazepine
DM9H34M	MI	TTPTXIN
DM9H34M	MN	Translocator protein (TSPO)
DM9H34M	MT	DTT
DM9H34M	MA	Agonist
DM9H34M	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2879).
DM9H34M	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2879

DMF1ZE6	DI	DMF1ZE6
DMF1ZE6	DN	Benzofuran-2-yl(indolin-1-yl)methanone
DMF1ZE6	MI	TT6804T
DMF1ZE6	MN	MIF messenger RNA (MIF mRNA)
DMF1ZE6	MT	DTT
DMF1ZE6	MA	Inhibitor
DMF1ZE6	RN	Discovery of human macrophage migration inhibitory factor (MIF)-CD74 antagonists via virtual screening. J Med Chem. 2009 Jan 22;52(2):416-24.
DMF1ZE6	RU	https://pubmed.ncbi.nlm.nih.gov/19090668

DMQ7I06	DI	DMQ7I06
DMQ7I06	DN	Benzofuran-2-ylboronic acid
DMQ7I06	MI	TTDP1UC
DMQ7I06	MN	Fatty acid amide hydrolase (FAAH)
DMQ7I06	MT	DTT
DMQ7I06	MA	Inhibitor
DMQ7I06	RN	Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Nov 27;51(22):7057-60.
DMQ7I06	RU	https://pubmed.ncbi.nlm.nih.gov/18983140

DMNVG1M	DI	DMNVG1M
DMNVG1M	DN	Benzofuran-3-yl-(indol-3-yl)maleimides
DMNVG1M	MI	TTRZQE3
DMNVG1M	MN	Glycogen synthase kinase-3 alpha (GSK-3A)
DMNVG1M	MT	DTT
DMNVG1M	MA	Inhibitor
DMNVG1M	RN	From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells. J Med Chem. 2009 Apr 9;52(7):1853-63.
DMNVG1M	RU	https://pubmed.ncbi.nlm.nih.gov/19338355

DMAQK0G	DI	DMAQK0G
DMAQK0G	DN	Benzoic acid 2,6-diisopropyl-phenyl ester
DMAQK0G	MI	TTNJYV2
DMAQK0G	MN	Gamma-aminobutyric acid receptor (GAR)
DMAQK0G	MT	DTT
DMAQK0G	MA	Inhibitor
DMAQK0G	RN	Propofol analogues. Synthesis, relationships between structure and affinity at GABAA receptor in rat brain, and differential electrophysiological p... J Med Chem. 1998 May 21;41(11):1846-54.
DMAQK0G	RU	https://pubmed.ncbi.nlm.nih.gov/9599235

DM6T8YM	DI	DM6T8YM
DM6T8YM	DN	Benzoic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester
DM6T8YM	MI	TTZ9SOR
DM6T8YM	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DM6T8YM	MT	DTT
DM6T8YM	MA	Inhibitor
DM6T8YM	RN	6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors. J Med Chem. 2000 Jun 29;43(13):2514-22.
DM6T8YM	RU	https://pubmed.ncbi.nlm.nih.gov/10891110

DM6T8YM	DI	DM6T8YM
DM6T8YM	DN	Benzoic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester
DM6T8YM	MI	TTYEG6Q
DM6T8YM	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DM6T8YM	MT	DTT
DM6T8YM	MA	Inhibitor
DM6T8YM	RN	6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors. J Med Chem. 2000 Jun 29;43(13):2514-22.
DM6T8YM	RU	https://pubmed.ncbi.nlm.nih.gov/10891110

DM6T8YM	DI	DM6T8YM
DM6T8YM	DN	Benzoic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester
DM6T8YM	MI	TTQ13Z5
DM6T8YM	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DM6T8YM	MT	DTT
DM6T8YM	MA	Inhibitor
DM6T8YM	RN	6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors. J Med Chem. 2000 Jun 29;43(13):2514-22.
DM6T8YM	RU	https://pubmed.ncbi.nlm.nih.gov/10891110

DM6T8YM	DI	DM6T8YM
DM6T8YM	DN	Benzoic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester
DM6T8YM	MI	TTQ3JTF
DM6T8YM	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DM6T8YM	MT	DTT
DM6T8YM	MA	Inhibitor
DM6T8YM	RN	6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors. J Med Chem. 2000 Jun 29;43(13):2514-22.
DM6T8YM	RU	https://pubmed.ncbi.nlm.nih.gov/10891110

DM6T8YM	DI	DM6T8YM
DM6T8YM	DN	Benzoic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester
DM6T8YM	MI	TTH18TF
DM6T8YM	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DM6T8YM	MT	DTT
DM6T8YM	MA	Inhibitor
DM6T8YM	RN	6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors. J Med Chem. 2000 Jun 29;43(13):2514-22.
DM6T8YM	RU	https://pubmed.ncbi.nlm.nih.gov/10891110

DM50QMB	DI	DM50QMB
DM50QMB	DN	Benzoin
DM50QMB	MI	TTMF541
DM50QMB	MN	Liver carboxylesterase (CES1)
DM50QMB	MT	DTT
DM50QMB	MA	Inhibitor
DM50QMB	RN	Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17.
DM50QMB	RU	https://pubmed.ncbi.nlm.nih.gov/17399985

DME5QPX	DI	DME5QPX
DME5QPX	DN	BENZOLAMIDE
DME5QPX	MI	TTUNARX
DME5QPX	MN	Carbonic anhydrase (CA)
DME5QPX	MT	DTT
DME5QPX	MA	Inhibitor
DME5QPX	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DME5QPX	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DME5QPX	DI	DME5QPX
DME5QPX	DN	BENZOLAMIDE
DME5QPX	MI	TTHQPL7
DME5QPX	MN	Carbonic anhydrase I (CA-I)
DME5QPX	MT	DTT
DME5QPX	MA	Inhibitor
DME5QPX	RN	Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorg Med Chem. 2009 Jul 15;17(14):5054-8.
DME5QPX	RU	https://pubmed.ncbi.nlm.nih.gov/19520577

DME5QPX	DI	DME5QPX
DME5QPX	DN	BENZOLAMIDE
DME5QPX	MI	TTANPDJ
DME5QPX	MN	Carbonic anhydrase II (CA-II)
DME5QPX	MT	DTT
DME5QPX	MA	Inhibitor
DME5QPX	RN	Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, ... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6649-54.
DME5QPX	RU	https://pubmed.ncbi.nlm.nih.gov/19846301

DME5QPX	DI	DME5QPX
DME5QPX	DN	BENZOLAMIDE
DME5QPX	MI	TTZHA0O
DME5QPX	MN	Carbonic anhydrase IV (CA-IV)
DME5QPX	MT	DTT
DME5QPX	MA	Inhibitor
DME5QPX	RN	Carbonic anhydrase inhibitors: topically acting antiglaucoma sulfonamides incorporating esters and amides of 3- and 4-carboxybenzolamide. Bioorg Med Chem Lett. 2003 Sep 1;13(17):2867-73.
DME5QPX	RU	https://pubmed.ncbi.nlm.nih.gov/14611846

DME5QPX	DI	DME5QPX
DME5QPX	DN	BENZOLAMIDE
DME5QPX	MI	TT2LVK8
DME5QPX	MN	Carbonic anhydrase IX (CA-IX)
DME5QPX	MT	DTT
DME5QPX	MA	Inhibitor
DME5QPX	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DME5QPX	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DME5QPX	DI	DME5QPX
DME5QPX	DN	BENZOLAMIDE
DME5QPX	MI	TTCFSPE
DME5QPX	MN	Carbonic anhydrase VI (CA-VI)
DME5QPX	MT	DTT
DME5QPX	MA	Inhibitor
DME5QPX	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DME5QPX	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DME5QPX	DI	DME5QPX
DME5QPX	DN	BENZOLAMIDE
DME5QPX	MI	TTSYM0R
DME5QPX	MN	Carbonic anhydrase XII (CA-XII)
DME5QPX	MT	DTT
DME5QPX	MA	Inhibitor
DME5QPX	RN	Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglauc... Bioorg Med Chem Lett. 2005 Feb 15;15(4):963-9.
DME5QPX	RU	https://pubmed.ncbi.nlm.nih.gov/15686894

DME5QPX	DI	DME5QPX
DME5QPX	DN	BENZOLAMIDE
DME5QPX	MI	TTEYTKG
DME5QPX	MN	Carbonic anhydrase XIV (CA-XIV)
DME5QPX	MT	DTT
DME5QPX	MA	Inhibitor
DME5QPX	RN	Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33.
DME5QPX	RU	https://pubmed.ncbi.nlm.nih.gov/16039848

DMRE96F	DI	DMRE96F
DMRE96F	DN	Benzomate
DMRE96F	MI	TTHM0R1
DMRE96F	MN	Steryl-sulfatase (STS)
DMRE96F	MT	DTT
DMRE96F	MA	Inhibitor
DMRE96F	RN	Synthesis, in vitro and in vivo activity of benzophenone-based inhibitors of steroid sulfatase. Bioorg Med Chem. 2004 May 15;12(10):2759-72.
DMRE96F	RU	https://pubmed.ncbi.nlm.nih.gov/15110857

DMMKBFN	DI	DMMKBFN
DMMKBFN	DN	benzoquinazolinone 12
DMMKBFN	MI	TTOXS3C
DMMKBFN	MN	Muscarinic acetylcholine receptor (CHRM)
DMMKBFN	MT	DTT
DMMKBFN	MA	Modulator (allosteric modulator)
DMMKBFN	RN	Mechanistic insights into allosteric structure-function relationships at the M1 muscarinic acetylcholine receptor. J Biol Chem. 2014 Nov 28;289(48):33701-11.
DMMKBFN	RU	https://pubmed.ncbi.nlm.nih.gov/25326383

DMNBA0G	DI	DMNBA0G
DMNBA0G	DN	Benzoquinone
DMNBA0G	MI	TT1RS9F
DMNBA0G	MN	Acetylcholinesterase (AChE)
DMNBA0G	MT	DTT
DMNBA0G	MA	Inhibitor
DMNBA0G	RN	Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15.
DMNBA0G	RU	https://pubmed.ncbi.nlm.nih.gov/15828829

DMNBA0G	DI	DMNBA0G
DMNBA0G	DN	Benzoquinone
DMNBA0G	MI	TTEB0GD
DMNBA0G	MN	Cholinesterase (BCHE)
DMNBA0G	MT	DTT
DMNBA0G	MA	Inhibitor
DMNBA0G	RN	Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15.
DMNBA0G	RU	https://pubmed.ncbi.nlm.nih.gov/15828829

DMNBA0G	DI	DMNBA0G
DMNBA0G	DN	Benzoquinone
DMNBA0G	MI	DEAN5EW
DMNBA0G	MN	Nitroreductase (NTR)
DMNBA0G	MT	DME
DMNBA0G	MA	Metabolism
DMNBA0G	RN	Overexpression, isotopic labeling, and spectral characterization of Enterobacter cloacae nitroreductase. Protein Expr Purif. 1998 Jun;13(1):53-60.
DMNBA0G	RU	https://pubmed.ncbi.nlm.nih.gov/9631515

DMNBA0G	DI	DMNBA0G
DMNBA0G	DN	Benzoquinone
DMNBA0G	MI	DEKVGPX
DMNBA0G	MN	Retro-nitroreductase (rNR)
DMNBA0G	MT	DME
DMNBA0G	MA	Metabolism
DMNBA0G	RN	Retro-nitroreductase, a putative evolutionary precursor to Enterobacter cloacae strain 96-3 nitroreductase. Antioxid Redox Signal. 2001 Oct;3(5):747-55.
DMNBA0G	RU	https://pubmed.ncbi.nlm.nih.gov/11761325

DMNBA0G	DI	DMNBA0G
DMNBA0G	DN	Benzoquinone
DMNBA0G	MI	DEGLTNR
DMNBA0G	MN	Sulfide-quinone reductase (SQR)
DMNBA0G	MT	DME
DMNBA0G	MA	Metabolism
DMNBA0G	RN	The quinone-binding site of Acidithiobacillus ferrooxidans sulfide: quinone oxidoreductase controls both sulfide oxidation and quinone reduction. Biochem Cell Biol. 2016 Apr;94(2):159-66.
DMNBA0G	RU	https://pubmed.ncbi.nlm.nih.gov/26914540

DM4OKXI	DI	DM4OKXI
DM4OKXI	DN	Benzotetronic acid
DM4OKXI	MI	DE4LYSA
DM4OKXI	MN	Cytochrome P450 3A4 (CYP3A4)
DM4OKXI	MT	DME
DM4OKXI	MA	Metabolism
DM4OKXI	RN	CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients. Br J Clin Pharmacol. 1995 Jan;39(1):71-6.
DM4OKXI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7756103

DMV7MPL	DI	DMV7MPL
DMV7MPL	DN	BENZOTHIAZOLE
DMV7MPL	MI	TT6L509
DMV7MPL	MN	Coagulation factor IIa (F2)
DMV7MPL	MT	DTT
DMV7MPL	MA	Inhibitor
DMV7MPL	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMV7MPL	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMROP5Q	DI	DMROP5Q
DMROP5Q	DN	Benzothiazole-2-sulfonic acid amide
DMROP5Q	MI	TTUNARX
DMROP5Q	MN	Carbonic anhydrase (CA)
DMROP5Q	MT	DTT
DMROP5Q	MA	Inhibitor
DMROP5Q	RN	Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides. Bioorg Med Chem Lett. 2005 Feb 15;15(4):971-6.
DMROP5Q	RU	https://pubmed.ncbi.nlm.nih.gov/15686895

DMROP5Q	DI	DMROP5Q
DMROP5Q	DN	Benzothiazole-2-sulfonic acid amide
DMROP5Q	MI	TTHQPL7
DMROP5Q	MN	Carbonic anhydrase I (CA-I)
DMROP5Q	MT	DTT
DMROP5Q	MA	Inhibitor
DMROP5Q	RN	Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides. Bioorg Med Chem Lett. 2005 Feb 15;15(4):971-6.
DMROP5Q	RU	https://pubmed.ncbi.nlm.nih.gov/15686895

DMROP5Q	DI	DMROP5Q
DMROP5Q	DN	Benzothiazole-2-sulfonic acid amide
DMROP5Q	MI	TTANPDJ
DMROP5Q	MN	Carbonic anhydrase II (CA-II)
DMROP5Q	MT	DTT
DMROP5Q	MA	Inhibitor
DMROP5Q	RN	Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides. Bioorg Med Chem Lett. 2005 Feb 15;15(4):971-6.
DMROP5Q	RU	https://pubmed.ncbi.nlm.nih.gov/15686895

DMC7TNF	DI	DMC7TNF
DMC7TNF	DN	Benzoyl-Arginine-Alanine-Methyl Ketone
DMC7TNF	MI	TTJOKD1
DMC7TNF	MN	Cathepsin F (CTSF)
DMC7TNF	MT	DTT
DMC7TNF	MA	Inhibitor
DMC7TNF	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMC7TNF	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMC7TNF	DI	DMC7TNF
DMC7TNF	DN	Benzoyl-Arginine-Alanine-Methyl Ketone
DMC7TNF	MI	TTEAID7
DMC7TNF	MN	Trypanosoma Cruzipain (Trypano CYSP)
DMC7TNF	MT	DTT
DMC7TNF	MA	Inhibitor
DMC7TNF	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMC7TNF	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMY5O1U	DI	DMY5O1U
DMY5O1U	DN	BENZOYLENUREA
DMY5O1U	MI	TT06AWU
DMY5O1U	MN	Phosphodiesterase 3A (PDE3A)
DMY5O1U	MT	DTT
DMY5O1U	MA	Inhibitor
DMY5O1U	RN	CODES, a novel procedure for ligand-based virtual screening: PDE7 inhibitors as an application example. Eur J Med Chem. 2008 Jul;43(7):1349-59.
DMY5O1U	RU	https://pubmed.ncbi.nlm.nih.gov/18082290

DMIRD8S	DI	DMIRD8S
DMIRD8S	DN	BENZOYL-TYROSINE-ALANINE-METHYL KETONE
DMIRD8S	MI	TTJOKD1
DMIRD8S	MN	Cathepsin F (CTSF)
DMIRD8S	MT	DTT
DMIRD8S	MA	Inhibitor
DMIRD8S	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMIRD8S	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMT3JYE	DI	DMT3JYE
DMT3JYE	DN	Benzyl 2-hydroxyiminoolean-12-en-28-oate
DMT3JYE	MI	TTZHY6R
DMT3JYE	MN	Glycogen phosphorylase muscle form (GP)
DMT3JYE	MT	DTT
DMT3JYE	MA	Inhibitor
DMT3JYE	RN	Synthesis of 3-deoxypentacyclic triterpene derivatives as inhibitors of glycogen phosphorylase. J Nat Prod. 2009 Aug;72(8):1414-8.
DMT3JYE	RU	https://pubmed.ncbi.nlm.nih.gov/19642687

DMOKVAT	DI	DMOKVAT
DMOKVAT	DN	Benzyl 4-aminobutyl(3-aminopropyl)carbamate
DMOKVAT	MI	TTLD29N
DMOKVAT	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMOKVAT	MT	DTT
DMOKVAT	MA	Inhibitor
DMOKVAT	RN	Polyamines and the NMDA receptor: modifying intrinsic activities with aromatic substituents. Bioorg Med Chem Lett. 2006 Jun 1;16(11):2837-41.
DMOKVAT	RU	https://pubmed.ncbi.nlm.nih.gov/16563762

DMOKVAT	DI	DMOKVAT
DMOKVAT	DN	Benzyl 4-aminobutyl(3-aminopropyl)carbamate
DMOKVAT	MI	TTKJEMQ
DMOKVAT	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMOKVAT	MT	DTT
DMOKVAT	MA	Inhibitor
DMOKVAT	RN	Polyamines and the NMDA receptor: modifying intrinsic activities with aromatic substituents. Bioorg Med Chem Lett. 2006 Jun 1;16(11):2837-41.
DMOKVAT	RU	https://pubmed.ncbi.nlm.nih.gov/16563762

DMOKVAT	DI	DMOKVAT
DMOKVAT	DN	Benzyl 4-aminobutyl(3-aminopropyl)carbamate
DMOKVAT	MI	TTN9D8E
DMOKVAT	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMOKVAT	MT	DTT
DMOKVAT	MA	Inhibitor
DMOKVAT	RN	Polyamines and the NMDA receptor: modifying intrinsic activities with aromatic substituents. Bioorg Med Chem Lett. 2006 Jun 1;16(11):2837-41.
DMOKVAT	RU	https://pubmed.ncbi.nlm.nih.gov/16563762

DM857X2	DI	DM857X2
DM857X2	DN	benzyl bromide
DM857X2	MI	TTELV3W
DM857X2	MN	Transformation-sensitive protein p120 (TRPA1)
DM857X2	MT	DTT
DM857X2	MA	Activator
DM857X2	RN	Transient receptor potential ankyrin 1 antagonists block the noxious effects of toxic industrial isocyanates and tear gases. FASEB J. 2009 Apr;23(4):1102-14.
DM857X2	RU	https://pubmed.ncbi.nlm.nih.gov/19036859

DMX8W4G	DI	DMX8W4G
DMX8W4G	DN	Benzyl derivative of M6G
DMX8W4G	MI	TT27RFC
DMX8W4G	MN	Opioid receptor delta (OPRD1)
DMX8W4G	MT	DTT
DMX8W4G	MA	Inhibitor
DMX8W4G	RN	Synthesis and in vitro biological evaluation of a carbon glycoside analogue of morphine-6-glucuronide. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1583-6.
DMX8W4G	RU	https://pubmed.ncbi.nlm.nih.gov/15745801

DMX8W4G	DI	DMX8W4G
DMX8W4G	DN	Benzyl derivative of M6G
DMX8W4G	MI	TTQW87Y
DMX8W4G	MN	Opioid receptor kappa (OPRK1)
DMX8W4G	MT	DTT
DMX8W4G	MA	Inhibitor
DMX8W4G	RN	Synthesis and in vitro biological evaluation of a carbon glycoside analogue of morphine-6-glucuronide. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1583-6.
DMX8W4G	RU	https://pubmed.ncbi.nlm.nih.gov/15745801

DMX8W4G	DI	DMX8W4G
DMX8W4G	DN	Benzyl derivative of M6G
DMX8W4G	MI	TTKWM86
DMX8W4G	MN	Opioid receptor mu (MOP)
DMX8W4G	MT	DTT
DMX8W4G	MA	Inhibitor
DMX8W4G	RN	Synthesis and in vitro biological evaluation of a carbon glycoside analogue of morphine-6-glucuronide. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1583-6.
DMX8W4G	RU	https://pubmed.ncbi.nlm.nih.gov/15745801

DM6I5MU	DI	DM6I5MU
DM6I5MU	DN	Benzyl-(2-imidazol-1-yl-quinazolin-4-yl)-amine
DM6I5MU	MI	TTZ97H5
DM6I5MU	MN	Phosphodiesterase 4A (PDE4A)
DM6I5MU	MT	DTT
DM6I5MU	MA	Inhibitor
DM6I5MU	RN	Discovery of potent cyclic GMP phosphodiesterase inhibitors. 2-Pyridyl- and 2-imidazolylquinazolines possessing cyclic GMP phosphodiesterase and th... J Med Chem. 1995 Sep 1;38(18):3547-57.
DM6I5MU	RU	https://pubmed.ncbi.nlm.nih.gov/7658441

DM6I5MU	DI	DM6I5MU
DM6I5MU	DN	Benzyl-(2-imidazol-1-yl-quinazolin-4-yl)-amine
DM6I5MU	MI	TTVIAT9
DM6I5MU	MN	Phosphodiesterase 4B (PDE4B)
DM6I5MU	MT	DTT
DM6I5MU	MA	Inhibitor
DM6I5MU	RN	Discovery of potent cyclic GMP phosphodiesterase inhibitors. 2-Pyridyl- and 2-imidazolylquinazolines possessing cyclic GMP phosphodiesterase and th... J Med Chem. 1995 Sep 1;38(18):3547-57.
DM6I5MU	RU	https://pubmed.ncbi.nlm.nih.gov/7658441

DM3X50C	DI	DM3X50C
DM3X50C	DN	Benzyl-(2-phenyl-quinazolin-4-yl)-amine
DM3X50C	MI	TTVBI8W
DM3X50C	MN	Dopamine transporter (DAT)
DM3X50C	MT	DTT
DM3X50C	MA	Inhibitor
DM3X50C	RN	Identification of a novel partial inhibitor of dopamine transporter among 4-substituted 2-phenylquinazolines. Bioorg Med Chem Lett. 2002 Aug 19;12(16):2225-8.
DM3X50C	RU	https://pubmed.ncbi.nlm.nih.gov/12127543

DM3X50C	DI	DM3X50C
DM3X50C	DN	Benzyl-(2-phenyl-quinazolin-4-yl)-amine
DM3X50C	MI	TTZ97H5
DM3X50C	MN	Phosphodiesterase 4A (PDE4A)
DM3X50C	MT	DTT
DM3X50C	MA	Inhibitor
DM3X50C	RN	Discovery of potent cyclic GMP phosphodiesterase inhibitors. 2-Pyridyl- and 2-imidazolylquinazolines possessing cyclic GMP phosphodiesterase and th... J Med Chem. 1995 Sep 1;38(18):3547-57.
DM3X50C	RU	https://pubmed.ncbi.nlm.nih.gov/7658441

DM3X50C	DI	DM3X50C
DM3X50C	DN	Benzyl-(2-phenyl-quinazolin-4-yl)-amine
DM3X50C	MI	TTVIAT9
DM3X50C	MN	Phosphodiesterase 4B (PDE4B)
DM3X50C	MT	DTT
DM3X50C	MA	Inhibitor
DM3X50C	RN	Discovery of potent cyclic GMP phosphodiesterase inhibitors. 2-Pyridyl- and 2-imidazolylquinazolines possessing cyclic GMP phosphodiesterase and th... J Med Chem. 1995 Sep 1;38(18):3547-57.
DM3X50C	RU	https://pubmed.ncbi.nlm.nih.gov/7658441

DMYDGCI	DI	DMYDGCI
DMYDGCI	DN	Benzyl-(2-pyridin-3-yl-quinazolin-4-yl)-amine
DMYDGCI	MI	TTJGW1Z
DMYDGCI	MN	Phosphodiesterase 2A (PDE2A)
DMYDGCI	MT	DTT
DMYDGCI	MA	Inhibitor
DMYDGCI	RN	Discovery of potent cyclic GMP phosphodiesterase inhibitors. 2-Pyridyl- and 2-imidazolylquinazolines possessing cyclic GMP phosphodiesterase and th... J Med Chem. 1995 Sep 1;38(18):3547-57.
DMYDGCI	RU	https://pubmed.ncbi.nlm.nih.gov/7658441

DMYDGCI	DI	DMYDGCI
DMYDGCI	DN	Benzyl-(2-pyridin-3-yl-quinazolin-4-yl)-amine
DMYDGCI	MI	TTZ97H5
DMYDGCI	MN	Phosphodiesterase 4A (PDE4A)
DMYDGCI	MT	DTT
DMYDGCI	MA	Inhibitor
DMYDGCI	RN	Discovery of potent cyclic GMP phosphodiesterase inhibitors. 2-Pyridyl- and 2-imidazolylquinazolines possessing cyclic GMP phosphodiesterase and th... J Med Chem. 1995 Sep 1;38(18):3547-57.
DMYDGCI	RU	https://pubmed.ncbi.nlm.nih.gov/7658441

DMYDGCI	DI	DMYDGCI
DMYDGCI	DN	Benzyl-(2-pyridin-3-yl-quinazolin-4-yl)-amine
DMYDGCI	MI	TTVIAT9
DMYDGCI	MN	Phosphodiesterase 4B (PDE4B)
DMYDGCI	MT	DTT
DMYDGCI	MA	Inhibitor
DMYDGCI	RN	Discovery of potent cyclic GMP phosphodiesterase inhibitors. 2-Pyridyl- and 2-imidazolylquinazolines possessing cyclic GMP phosphodiesterase and th... J Med Chem. 1995 Sep 1;38(18):3547-57.
DMYDGCI	RU	https://pubmed.ncbi.nlm.nih.gov/7658441

DMESVWC	DI	DMESVWC
DMESVWC	DN	Benzyl-(2-pyridin-4-yl-quinazolin-4-yl)-amine
DMESVWC	MI	TTJGW1Z
DMESVWC	MN	Phosphodiesterase 2A (PDE2A)
DMESVWC	MT	DTT
DMESVWC	MA	Inhibitor
DMESVWC	RN	Discovery of potent cyclic GMP phosphodiesterase inhibitors. 2-Pyridyl- and 2-imidazolylquinazolines possessing cyclic GMP phosphodiesterase and th... J Med Chem. 1995 Sep 1;38(18):3547-57.
DMESVWC	RU	https://pubmed.ncbi.nlm.nih.gov/7658441

DMESVWC	DI	DMESVWC
DMESVWC	DN	Benzyl-(2-pyridin-4-yl-quinazolin-4-yl)-amine
DMESVWC	MI	TTZ97H5
DMESVWC	MN	Phosphodiesterase 4A (PDE4A)
DMESVWC	MT	DTT
DMESVWC	MA	Inhibitor
DMESVWC	RN	Discovery of potent cyclic GMP phosphodiesterase inhibitors. 2-Pyridyl- and 2-imidazolylquinazolines possessing cyclic GMP phosphodiesterase and th... J Med Chem. 1995 Sep 1;38(18):3547-57.
DMESVWC	RU	https://pubmed.ncbi.nlm.nih.gov/7658441

DMESVWC	DI	DMESVWC
DMESVWC	DN	Benzyl-(2-pyridin-4-yl-quinazolin-4-yl)-amine
DMESVWC	MI	TTVIAT9
DMESVWC	MN	Phosphodiesterase 4B (PDE4B)
DMESVWC	MT	DTT
DMESVWC	MA	Inhibitor
DMESVWC	RN	Discovery of potent cyclic GMP phosphodiesterase inhibitors. 2-Pyridyl- and 2-imidazolylquinazolines possessing cyclic GMP phosphodiesterase and th... J Med Chem. 1995 Sep 1;38(18):3547-57.
DMESVWC	RU	https://pubmed.ncbi.nlm.nih.gov/7658441

DMH318X	DI	DMH318X
DMH318X	DN	Benzyl-(2-thiophen-2-yl-quinazolin-4-yl)-amine
DMH318X	MI	TTZ97H5
DMH318X	MN	Phosphodiesterase 4A (PDE4A)
DMH318X	MT	DTT
DMH318X	MA	Inhibitor
DMH318X	RN	Discovery of potent cyclic GMP phosphodiesterase inhibitors. 2-Pyridyl- and 2-imidazolylquinazolines possessing cyclic GMP phosphodiesterase and th... J Med Chem. 1995 Sep 1;38(18):3547-57.
DMH318X	RU	https://pubmed.ncbi.nlm.nih.gov/7658441

DMH318X	DI	DMH318X
DMH318X	DN	Benzyl-(2-thiophen-2-yl-quinazolin-4-yl)-amine
DMH318X	MI	TTVIAT9
DMH318X	MN	Phosphodiesterase 4B (PDE4B)
DMH318X	MT	DTT
DMH318X	MA	Inhibitor
DMH318X	RN	Discovery of potent cyclic GMP phosphodiesterase inhibitors. 2-Pyridyl- and 2-imidazolylquinazolines possessing cyclic GMP phosphodiesterase and th... J Med Chem. 1995 Sep 1;38(18):3547-57.
DMH318X	RU	https://pubmed.ncbi.nlm.nih.gov/7658441

DMFTIMS	DI	DMFTIMS
DMFTIMS	DN	Benzyl-(6,7-dimethoxy-quinolin-3-yl)-amine
DMFTIMS	MI	TT8FYO9
DMFTIMS	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMFTIMS	MT	DTT
DMFTIMS	MA	Inhibitor
DMFTIMS	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMFTIMS	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMFTIMS	DI	DMFTIMS
DMFTIMS	DN	Benzyl-(6,7-dimethoxy-quinolin-3-yl)-amine
DMFTIMS	MI	TTI7421
DMFTIMS	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMFTIMS	MT	DTT
DMFTIMS	MA	Inhibitor
DMFTIMS	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DMFTIMS	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DMW167A	DI	DMW167A
DMW167A	DN	Benzyl-(9H-beta-carbolin-6-yl)-amine
DMW167A	MI	TT1MPAY
DMW167A	MN	GABA(A) receptor alpha-1 (GABRA1)
DMW167A	MT	DTT
DMW167A	MA	Inhibitor
DMW167A	RN	Synthesis of novel 3-substituted beta-carbolines as benzodiazepine receptor ligands: probing the benzodiazepine receptor pharmacophore. J Med Chem. 1988 Sep;31(9):1854-61.
DMW167A	RU	https://pubmed.ncbi.nlm.nih.gov/2842507

DMW167A	DI	DMW167A
DMW167A	DN	Benzyl-(9H-beta-carbolin-6-yl)-amine
DMW167A	MI	TTNJYV2
DMW167A	MN	Gamma-aminobutyric acid receptor (GAR)
DMW167A	MT	DTT
DMW167A	MA	Inhibitor
DMW167A	RN	Synthesis of novel 3-substituted beta-carbolines as benzodiazepine receptor ligands: probing the benzodiazepine receptor pharmacophore. J Med Chem. 1988 Sep;31(9):1854-61.
DMW167A	RU	https://pubmed.ncbi.nlm.nih.gov/2842507

DMNE1M3	DI	DMNE1M3
DMNE1M3	DN	Benzyl-(9-isopropyl-9H-purin-6-yl)-amine
DMNE1M3	MI	TT7HF4W
DMNE1M3	MN	Cyclin-dependent kinase 2 (CDK2)
DMNE1M3	MT	DTT
DMNE1M3	MA	Inhibitor
DMNE1M3	RN	Docking-based development of purine-like inhibitors of cyclin-dependent kinase-2. J Med Chem. 2000 Jun 29;43(13):2506-13.
DMNE1M3	RU	https://pubmed.ncbi.nlm.nih.gov/10891109

DMTC4G0	DI	DMTC4G0
DMTC4G0	DN	Benzyl-[2-(1H-indazol-4-yloxy)-ethyl]-amine
DMTC4G0	MI	TTEX248
DMTC4G0	MN	Dopamine D2 receptor (D2R)
DMTC4G0	MT	DTT
DMTC4G0	MA	Inhibitor
DMTC4G0	RN	New generation dopaminergic agents. 7. Heterocyclic bioisosteres that exploit the 3-OH-phenoxyethylamine D2 template. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2593-8.
DMTC4G0	RU	https://pubmed.ncbi.nlm.nih.gov/10498215

DMTC4G0	DI	DMTC4G0
DMTC4G0	DN	Benzyl-[2-(1H-indazol-4-yloxy)-ethyl]-amine
DMTC4G0	MI	TT4C8EA
DMTC4G0	MN	Dopamine D3 receptor (D3R)
DMTC4G0	MT	DTT
DMTC4G0	MA	Inhibitor
DMTC4G0	RN	New generation dopaminergic agents. 7. Heterocyclic bioisosteres that exploit the 3-OH-phenoxyethylamine D2 template. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2593-8.
DMTC4G0	RU	https://pubmed.ncbi.nlm.nih.gov/10498215

DMTC4G0	DI	DMTC4G0
DMTC4G0	DN	Benzyl-[2-(1H-indazol-4-yloxy)-ethyl]-amine
DMTC4G0	MI	TTE0A2F
DMTC4G0	MN	Dopamine D4 receptor (D4R)
DMTC4G0	MT	DTT
DMTC4G0	MA	Inhibitor
DMTC4G0	RN	New generation dopaminergic agents. 7. Heterocyclic bioisosteres that exploit the 3-OH-phenoxyethylamine D2 template. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2593-8.
DMTC4G0	RU	https://pubmed.ncbi.nlm.nih.gov/10498215

DMV6DY7	DI	DMV6DY7
DMV6DY7	DN	Benzyl-[2-(1H-indol-4-yloxy)-ethyl]-amine
DMV6DY7	MI	TTEX248
DMV6DY7	MN	Dopamine D2 receptor (D2R)
DMV6DY7	MT	DTT
DMV6DY7	MA	Inhibitor
DMV6DY7	RN	New generation dopaminergic agents. 7. Heterocyclic bioisosteres that exploit the 3-OH-phenoxyethylamine D2 template. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2593-8.
DMV6DY7	RU	https://pubmed.ncbi.nlm.nih.gov/10498215

DMV6DY7	DI	DMV6DY7
DMV6DY7	DN	Benzyl-[2-(1H-indol-4-yloxy)-ethyl]-amine
DMV6DY7	MI	TT4C8EA
DMV6DY7	MN	Dopamine D3 receptor (D3R)
DMV6DY7	MT	DTT
DMV6DY7	MA	Inhibitor
DMV6DY7	RN	New generation dopaminergic agents. 7. Heterocyclic bioisosteres that exploit the 3-OH-phenoxyethylamine D2 template. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2593-8.
DMV6DY7	RU	https://pubmed.ncbi.nlm.nih.gov/10498215

DMV6DY7	DI	DMV6DY7
DMV6DY7	DN	Benzyl-[2-(1H-indol-4-yloxy)-ethyl]-amine
DMV6DY7	MI	TTE0A2F
DMV6DY7	MN	Dopamine D4 receptor (D4R)
DMV6DY7	MT	DTT
DMV6DY7	MA	Inhibitor
DMV6DY7	RN	New generation dopaminergic agents. 7. Heterocyclic bioisosteres that exploit the 3-OH-phenoxyethylamine D2 template. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2593-8.
DMV6DY7	RU	https://pubmed.ncbi.nlm.nih.gov/10498215

DMRM6ES	DI	DMRM6ES
DMRM6ES	DN	Benzylamine
DMRM6ES	MI	DE6SOC5
DMRM6ES	MN	Copper amine oxidase (AOC3)
DMRM6ES	MT	DME
DMRM6ES	MA	Metabolism
DMRM6ES	RN	The unique substrate specificity of human AOC2, a semicarbazide-sensitive amine oxidase. Cell Mol Life Sci. 2009 Aug;66(16):2743-57.
DMRM6ES	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19588076

DMRM6ES	DI	DMRM6ES
DMRM6ES	DN	Benzylamine
DMRM6ES	MI	DERE4TU
DMRM6ES	MN	Monoamine oxidase type A (MAO-A)
DMRM6ES	MT	DME
DMRM6ES	MA	Metabolism
DMRM6ES	RN	Do monomeric vs dimeric forms of MAO-A make a difference? A direct comparison of the catalytic properties of rat and human MAO-A's. J Neural Transm (Vienna). 2007;114(6):721-4.
DMRM6ES	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17401534

DMRM6ES	DI	DMRM6ES
DMRM6ES	DN	Benzylamine
DMRM6ES	MI	DE8DP90
DMRM6ES	MN	Semicarbazide-sensitive amine oxidase (AOC2)
DMRM6ES	MT	DME
DMRM6ES	MA	Metabolism
DMRM6ES	RN	The unique substrate specificity of human AOC2, a semicarbazide-sensitive amine oxidase. Cell Mol Life Sci. 2009 Aug;66(16):2743-57.
DMRM6ES	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19588076

DMFB4M5	DI	DMFB4M5
DMFB4M5	DN	Benzyl-biphenyl-4-ylmethyl-imidazol-1-yl-amine
DMFB4M5	MI	TTSZLWK
DMFB4M5	MN	Aromatase (CYP19A1)
DMFB4M5	MT	DTT
DMFB4M5	MA	Inhibitor
DMFB4M5	RN	CYP19 (aromatase): exploring the scaffold flexibility for novel selective inhibitors. Bioorg Med Chem. 2008 Sep 15;16(18):8349-58.
DMFB4M5	RU	https://pubmed.ncbi.nlm.nih.gov/18782670

DM7M9O2	DI	DM7M9O2
DM7M9O2	DN	Benzylcarbamic Acid Biphenyl-3-yl Ester
DM7M9O2	MI	TTDP1UC
DM7M9O2	MN	Fatty acid amide hydrolase (FAAH)
DM7M9O2	MT	DTT
DM7M9O2	MA	Inhibitor
DM7M9O2	RN	Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl a... J Med Chem. 2008 Jun 26;51(12):3487-98.
DM7M9O2	RU	https://pubmed.ncbi.nlm.nih.gov/18507372

DMTCYHM	DI	DMTCYHM
DMTCYHM	DN	Benzylcysteine
DMTCYHM	MI	TTJ8DV7
DMTCYHM	MN	O-6-methylguanine-DNA-alkyltransferase (MGMT)
DMTCYHM	MT	DTT
DMTCYHM	MA	Inhibitor
DMTCYHM	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMTCYHM	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMNRHSO	DI	DMNRHSO
DMNRHSO	DN	BENZYLIMIDAZOLE
DMNRHSO	MI	TTIQUX7
DMNRHSO	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMNRHSO	MT	DTT
DMNRHSO	MA	Inhibitor
DMNRHSO	RN	Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25.
DMNRHSO	RU	https://pubmed.ncbi.nlm.nih.gov/20121113

DMQAEOL	DI	DMQAEOL
DMQAEOL	DN	Benzyl-methyl-[1-(1H-pyrrol-2-yl)-vinyl]-amine
DMQAEOL	MI	TTGP7BY
DMQAEOL	MN	Monoamine oxidase type B (MAO-B)
DMQAEOL	MT	DTT
DMQAEOL	MA	Inhibitor
DMQAEOL	RN	Simple, potent, and selective pyrrole inhibitors of monoamine oxidase types A and B. J Med Chem. 2003 Mar 13;46(6):917-20.
DMQAEOL	RU	https://pubmed.ncbi.nlm.nih.gov/12620068

DMLJMOD	DI	DMLJMOD
DMLJMOD	DN	Benzyloxycarbonyl-glycylryanodine
DMLJMOD	MI	TTU5CIX
DMLJMOD	MN	Ryanodine receptor 1 (RYR1)
DMLJMOD	MT	DTT
DMLJMOD	MA	Inhibitor
DMLJMOD	RN	Amino- and guanidinoacylryanodines: basic ryanodine esters with enhanced affinity for the sarcoplasmic reticulum Ca(2+)-release channel. J Med Chem. 1993 May 14;36(10):1319-23.
DMLJMOD	RU	https://pubmed.ncbi.nlm.nih.gov/8388466

DM26SR7	DI	DM26SR7
DM26SR7	DN	Benzyloxyresorufin
DM26SR7	MI	DE4OGUF
DM26SR7	MN	Cytochrome P450 102A1 (cyp102)
DM26SR7	MT	DME
DM26SR7	MA	Metabolism
DM26SR7	RN	The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities. Trends Biotechnol. 2007 Jul;25(7):289-98.
DM26SR7	RU	https://pubmed.ncbi.nlm.nih.gov/17532492

DM26SR7	DI	DM26SR7
DM26SR7	DN	Benzyloxyresorufin
DM26SR7	MI	DE4LYSA
DM26SR7	MN	Cytochrome P450 3A4 (CYP3A4)
DM26SR7	MT	DME
DM26SR7	MA	Metabolism
DM26SR7	RN	P450 enzyme expression patterns in the NCI human tumor cell line panel. Drug Metab Dispos. 2001 Mar;29(3):304-12.
DM26SR7	RU	https://pubmed.ncbi.nlm.nih.gov/11181500

DMRW5J4	DI	DMRW5J4
DMRW5J4	DN	Benzyl-quinazolin-4-yl-amine
DMRW5J4	MI	TTGKNB4
DMRW5J4	MN	Epidermal growth factor receptor (EGFR)
DMRW5J4	MT	DTT
DMRW5J4	MA	Inhibitor
DMRW5J4	RN	Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as poten... J Med Chem. 1995 Sep 1;38(18):3482-7.
DMRW5J4	RU	https://pubmed.ncbi.nlm.nih.gov/7658435

DMHIGDM	DI	DMHIGDM
DMHIGDM	DN	Benzylserine
DMHIGDM	MI	TTF7WRM
DMHIGDM	MN	Alanine/serine/cysteine transporter 2 (SLC1A5)
DMHIGDM	MT	DTT
DMHIGDM	MA	Inhibitor
DMHIGDM	RN	New inhibitors for the neutral amino acid transporter ASCT2 reveal its Na+-dependent anion leak. J Physiol. 2004 Jun 15;557(Pt 3):747-59.
DMHIGDM	RU	https://pubmed.ncbi.nlm.nih.gov/15107471

DM7XK28	DI	DM7XK28
DM7XK28	DN	Benzylsulfinic Acid
DM7XK28	MI	TT8VUE0
DM7XK28	MN	Chymase (CYM)
DM7XK28	MT	DTT
DM7XK28	MA	Inhibitor
DM7XK28	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM7XK28	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM7XK28	DI	DM7XK28
DM7XK28	DN	Benzylsulfinic Acid
DM7XK28	MI	TT25MVL
DM7XK28	MN	Serine protease hepsin (HPN)
DM7XK28	MT	DTT
DM7XK28	MA	Inhibitor
DM7XK28	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM7XK28	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMDITNB	DI	DMDITNB
DMDITNB	DN	BERGAPTOL
DMDITNB	MI	TTXV4FI
DMDITNB	MN	Albendazole monooxygenase (CYP3A4)
DMDITNB	MT	DTT
DMDITNB	MA	Inhibitor
DMDITNB	RN	Radical scavenging and cytochrome P450 3A4 inhibitory activity of bergaptol and geranylcoumarin from grapefruit. Bioorg Med Chem. 2007 Jun 1;15(11):3684-91.
DMDITNB	RU	https://pubmed.ncbi.nlm.nih.gov/17400460

DMP21ZO	DI	DMP21ZO
DMP21ZO	DN	Beta-(2-Naphthyl)-Alanine
DMP21ZO	MI	TT6L509
DMP21ZO	MN	Coagulation factor IIa (F2)
DMP21ZO	MT	DTT
DMP21ZO	MA	Inhibitor
DMP21ZO	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMP21ZO	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMP21ZO	DI	DMP21ZO
DMP21ZO	DN	Beta-(2-Naphthyl)-Alanine
DMP21ZO	MI	TTJNTSI
DMP21ZO	MN	Rotamase Pin1 (PIN1)
DMP21ZO	MT	DTT
DMP21ZO	MA	Inhibitor
DMP21ZO	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMP21ZO	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM6FHQD	DI	DM6FHQD
DM6FHQD	DN	Beta,beta-dimethylmelatonin
DM6FHQD	MI	TT0WAIE
DM6FHQD	MN	Melatonin receptor type 1A (MTNR1A)
DM6FHQD	MT	DTT
DM6FHQD	MA	Inhibitor
DM6FHQD	RN	Mapping the melatonin receptor. 7. Subtype selective ligands based on beta-substituted N-acyl-5-methoxytryptamines and beta-substituted N-acyl-5-me... J Med Chem. 2006 Jun 15;49(12):3509-19.
DM6FHQD	RU	https://pubmed.ncbi.nlm.nih.gov/16759094

DM6FHQD	DI	DM6FHQD
DM6FHQD	DN	Beta,beta-dimethylmelatonin
DM6FHQD	MI	TT32JK8
DM6FHQD	MN	Melatonin receptor type 1B (MTNR1B)
DM6FHQD	MT	DTT
DM6FHQD	MA	Inhibitor
DM6FHQD	RN	Mapping the melatonin receptor. 7. Subtype selective ligands based on beta-substituted N-acyl-5-methoxytryptamines and beta-substituted N-acyl-5-me... J Med Chem. 2006 Jun 15;49(12):3509-19.
DM6FHQD	RU	https://pubmed.ncbi.nlm.nih.gov/16759094

DM6GTBC	DI	DM6GTBC
DM6GTBC	DN	Beta-1-C-butenyl-1-deoxygalactonojirimycin
DM6GTBC	MI	TTIS03D
DM6GTBC	MN	Alpha-galactosidase A (GLA)
DM6GTBC	MT	DTT
DM6GTBC	MA	Inhibitor
DM6GTBC	RN	2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease. Bioorg Med Chem. 2010 Jun 1;18(11):3790-4.
DM6GTBC	RU	https://pubmed.ncbi.nlm.nih.gov/20457528

DMMKDEZ	DI	DMMKDEZ
DMMKDEZ	DN	Beta-1-C-Butyl-1-deoxygalactonojirimycin
DMMKDEZ	MI	TTIS03D
DMMKDEZ	MN	Alpha-galactosidase A (GLA)
DMMKDEZ	MT	DTT
DMMKDEZ	MA	Inhibitor
DMMKDEZ	RN	2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease. Bioorg Med Chem. 2010 Jun 1;18(11):3790-4.
DMMKDEZ	RU	https://pubmed.ncbi.nlm.nih.gov/20457528

DMBAN5P	DI	DMBAN5P
DMBAN5P	DN	beta3-tetrapeptide
DMBAN5P	MI	TTAE1BR
DMBAN5P	MN	Somatostatin receptor type 4 (SSTR4)
DMBAN5P	MT	DTT
DMBAN5P	MA	Agonist
DMBAN5P	RN	Beta(2)/beta(3)-di- and alpha/beta(3)-tetrapeptide derivatives as potent agonists at somatostatin sst(4) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2003 Feb;367(2):95-103.
DMBAN5P	RU	https://pubmed.ncbi.nlm.nih.gov/12595949

DMC64EI	DI	DMC64EI
DMC64EI	DN	Beta-alanine
DMC64EI	MI	TT8RXO5
DMC64EI	MN	GABA transporter-3 (SLC6A11)
DMC64EI	MT	DTT
DMC64EI	MA	Blocker
DMC64EI	RN	Stable expression of a neuronal gamma-aminobutyric acid transporter, GAT-3, in mammalian cells demonstrates unique pharmacological properties and ion dependence. Mol Pharmacol. 1994 Sep;46(3):550-7.
DMC64EI	RU	https://pubmed.ncbi.nlm.nih.gov/7935337

DMC64EI	DI	DMC64EI
DMC64EI	DN	Beta-alanine
DMC64EI	MI	DTX8KP0
DMC64EI	MN	Sodium- and chloride-dependent GABA transporter 2 (SLC6A13)
DMC64EI	MT	DTP
DMC64EI	MA	Substrate
DMC64EI	RN	Astrocytic -aminobutyric acid (GABA) transporters mediate guanidinoacetate transport in rat brain. 2018 Feb;113:1-7.
DMC64EI	RU	http://www.ncbi.nlm.nih.gov/pubmed/29175673

DMC64EI	DI	DMC64EI
DMC64EI	DN	Beta-alanine
DMC64EI	MI	DTXBIQG
DMC64EI	MN	Sodium- and chloride-dependent GABA transporter 3 (SLC6A11)
DMC64EI	MT	DTP
DMC64EI	MA	Substrate
DMC64EI	RN	Astrocytic -aminobutyric acid (GABA) transporters mediate guanidinoacetate transport in rat brain. 2018 Feb;113:1-7.
DMC64EI	RU	http://www.ncbi.nlm.nih.gov/pubmed/29175673

DMC64EI	DI	DMC64EI
DMC64EI	DN	Beta-alanine
DMC64EI	MI	DTHWCVA
DMC64EI	MN	Sodium- and chloride-dependent taurine transporter (SLC6A6)
DMC64EI	MT	DTP
DMC64EI	MA	Substrate
DMC64EI	RN	Astrocytic -aminobutyric acid (GABA) transporters mediate guanidinoacetate transport in rat brain. 2018 Feb;113:1-7.
DMC64EI	RU	http://www.ncbi.nlm.nih.gov/pubmed/29175673

DMN7DJ5	DI	DMN7DJ5
DMN7DJ5	DN	BetaARKct
DMN7DJ5	MI	TTAZ3MN
DMN7DJ5	MN	Beta-adrenergic receptor kinase 1 (ADRBK1)
DMN7DJ5	MT	DTT
DMN7DJ5	MA	Inhibitor
DMN7DJ5	RN	Gene-mediated inhibition of the b-adrenergic receptor kinase: a new therapeutic strategy for heart failure. Minerva Cardioangiol. 2001 Dec;49(6):389-94.
DMN7DJ5	RU	https://pubmed.ncbi.nlm.nih.gov/11733734

DM9LT60	DI	DM9LT60
DM9LT60	DN	Beta-Carboline-3-carboxylic acid t-butyl ester
DM9LT60	MI	TT1MPAY
DM9LT60	MN	GABA(A) receptor alpha-1 (GABRA1)
DM9LT60	MT	DTT
DM9LT60	MA	Inhibitor
DM9LT60	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DM9LT60	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DM9LT60	DI	DM9LT60
DM9LT60	DN	Beta-Carboline-3-carboxylic acid t-butyl ester
DM9LT60	MI	TTBMV1G
DM9LT60	MN	GABA(A) receptor alpha-2 (GABRA2)
DM9LT60	MT	DTT
DM9LT60	MA	Inhibitor
DM9LT60	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DM9LT60	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DM9LT60	DI	DM9LT60
DM9LT60	DN	Beta-Carboline-3-carboxylic acid t-butyl ester
DM9LT60	MI	TT37EDJ
DM9LT60	MN	GABA(A) receptor alpha-3 (GABRA3)
DM9LT60	MT	DTT
DM9LT60	MA	Inhibitor
DM9LT60	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DM9LT60	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DM9LT60	DI	DM9LT60
DM9LT60	DN	Beta-Carboline-3-carboxylic acid t-butyl ester
DM9LT60	MI	TTNZPQ1
DM9LT60	MN	GABA(A) receptor alpha-5 (GABRA5)
DM9LT60	MT	DTT
DM9LT60	MA	Inhibitor
DM9LT60	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DM9LT60	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DM9LT60	DI	DM9LT60
DM9LT60	DN	Beta-Carboline-3-carboxylic acid t-butyl ester
DM9LT60	MI	TT06RH5
DM9LT60	MN	GABA(A) receptor gamma-2 (GABRG2)
DM9LT60	MT	DTT
DM9LT60	MA	Inhibitor
DM9LT60	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DM9LT60	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DM9LT60	DI	DM9LT60
DM9LT60	DN	Beta-Carboline-3-carboxylic acid t-butyl ester
DM9LT60	MI	TTNJYV2
DM9LT60	MN	Gamma-aminobutyric acid receptor (GAR)
DM9LT60	MT	DTT
DM9LT60	MA	Inhibitor
DM9LT60	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DM9LT60	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DM1MFTZ	DI	DM1MFTZ
DM1MFTZ	DN	BETA-CCM
DM1MFTZ	MI	TT1MPAY
DM1MFTZ	MN	GABA(A) receptor alpha-1 (GABRA1)
DM1MFTZ	MT	DTT
DM1MFTZ	MA	Inhibitor
DM1MFTZ	RN	Synthetic routes to 4-amino-3-carboxy-beta-carboline derivatives: incidental formation of novel furo[3,4-c]-beta-carbolin-2-ones displaying high af... J Med Chem. 1995 Jan 6;38(1):189-98.
DM1MFTZ	RU	https://pubmed.ncbi.nlm.nih.gov/7837230

DM1MFTZ	DI	DM1MFTZ
DM1MFTZ	DN	BETA-CCM
DM1MFTZ	MI	TTZA1NY
DM1MFTZ	MN	GABA(A) receptor beta-2 (GABRB2)
DM1MFTZ	MT	DTT
DM1MFTZ	MA	Inhibitor
DM1MFTZ	RN	Four amino acid exchanges convert a diazepam-insensitive, inverse agonist-preferring GABAA receptor into a diazepam-preferring GABAA receptor. J Med Chem. 1994 Dec 23;37(26):4576-80.
DM1MFTZ	RU	https://pubmed.ncbi.nlm.nih.gov/7799410

DM1MFTZ	DI	DM1MFTZ
DM1MFTZ	DN	BETA-CCM
DM1MFTZ	MI	TT06RH5
DM1MFTZ	MN	GABA(A) receptor gamma-2 (GABRG2)
DM1MFTZ	MT	DTT
DM1MFTZ	MA	Inhibitor
DM1MFTZ	RN	beta-Carbolines as benzodiazepine receptor ligands. 1. Synthesis and benzodiazepine receptor interaction of esters of beta-carboline-3-carboxylic a... J Med Chem. 1983 Apr;26(4):499-503.
DM1MFTZ	RU	https://pubmed.ncbi.nlm.nih.gov/6300400

DM1MFTZ	DI	DM1MFTZ
DM1MFTZ	DN	BETA-CCM
DM1MFTZ	MI	TTNJYV2
DM1MFTZ	MN	Gamma-aminobutyric acid receptor (GAR)
DM1MFTZ	MT	DTT
DM1MFTZ	MA	Inhibitor
DM1MFTZ	RN	Synthetic routes to 4-amino-3-carboxy-beta-carboline derivatives: incidental formation of novel furo[3,4-c]-beta-carbolin-2-ones displaying high af... J Med Chem. 1995 Jan 6;38(1):189-98.
DM1MFTZ	RU	https://pubmed.ncbi.nlm.nih.gov/7837230

DMZ2BR9	DI	DMZ2BR9
DMZ2BR9	DN	Beta-D-Glucopyranose Spirohydantoin
DMZ2BR9	MI	TTZHY6R
DMZ2BR9	MN	Glycogen phosphorylase muscle form (GP)
DMZ2BR9	MT	DTT
DMZ2BR9	MA	Inhibitor
DMZ2BR9	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMZ2BR9	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM5IHYP	DI	DM5IHYP
DM5IHYP	DN	Beta-D-Glucose
DM5IHYP	MI	TTHCF4J
DM5IHYP	MN	Alpha-glucosidase (GLA)
DM5IHYP	MT	DTT
DM5IHYP	MA	Inhibitor
DM5IHYP	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM5IHYP	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM5IHYP	DI	DM5IHYP
DM5IHYP	DN	Beta-D-Glucose
DM5IHYP	MI	TTVTX4N
DM5IHYP	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DM5IHYP	MT	DTT
DM5IHYP	MA	Inhibitor
DM5IHYP	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM5IHYP	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM5IHYP	DI	DM5IHYP
DM5IHYP	DN	Beta-D-Glucose
DM5IHYP	MI	TTDLNGZ
DM5IHYP	MN	Glucokinase (GCK)
DM5IHYP	MT	DTT
DM5IHYP	MA	Inhibitor
DM5IHYP	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM5IHYP	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM5IHYP	DI	DM5IHYP
DM5IHYP	DN	Beta-D-Glucose
DM5IHYP	MI	TTZHY6R
DM5IHYP	MN	Glycogen phosphorylase muscle form (GP)
DM5IHYP	MT	DTT
DM5IHYP	MA	Inhibitor
DM5IHYP	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM5IHYP	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM5IHYP	DI	DM5IHYP
DM5IHYP	DN	Beta-D-Glucose
DM5IHYP	MI	TTUTN1I
DM5IHYP	MN	Human Deoxyribonucleic acid (hDNA)
DM5IHYP	MT	DTT
DM5IHYP	MA	Inhibitor
DM5IHYP	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM5IHYP	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM5IHYP	DI	DM5IHYP
DM5IHYP	DN	Beta-D-Glucose
DM5IHYP	MI	TTCGSZ4
DM5IHYP	MN	Pancreatic alpha-amylase (AMY2A)
DM5IHYP	MT	DTT
DM5IHYP	MA	Inhibitor
DM5IHYP	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM5IHYP	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM5IHYP	DI	DM5IHYP
DM5IHYP	DN	Beta-D-Glucose
DM5IHYP	MI	TTNX2CS
DM5IHYP	MN	Plasmodium Enoyl-ACP reductase (Malaria fabI)
DM5IHYP	MT	DTT
DM5IHYP	MA	Inhibitor
DM5IHYP	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM5IHYP	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM5IHYP	DI	DM5IHYP
DM5IHYP	DN	Beta-D-Glucose
DM5IHYP	MI	TT8NGED
DM5IHYP	MN	Prostaglandin G/H synthase 1 (COX-1)
DM5IHYP	MT	DTT
DM5IHYP	MA	Inhibitor
DM5IHYP	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM5IHYP	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMNE4C6	DI	DMNE4C6
DMNE4C6	DN	beta-D-hydroxybutyric acid
DMNE4C6	MI	TTWNV8U
DMNE4C6	MN	Nicotinic acid receptor (HCAR2)
DMNE4C6	MT	DTT
DMNE4C6	MA	Agonist
DMNE4C6	RN	(D)-beta-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. J Biol Chem. 2005 Jul 22;280(29):26649-52.
DMNE4C6	RU	https://pubmed.ncbi.nlm.nih.gov/15929991

DMHIG9K	DI	DMHIG9K
DMHIG9K	DN	Beta-D-Mannose
DMHIG9K	MI	TTEYTKG
DMHIG9K	MN	Carbonic anhydrase XIV (CA-XIV)
DMHIG9K	MT	DTT
DMHIG9K	MA	Inhibitor
DMHIG9K	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMHIG9K	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMHIG9K	DI	DMHIG9K
DMHIG9K	DN	Beta-D-Mannose
DMHIG9K	MI	TTEB0GD
DMHIG9K	MN	Cholinesterase (BCHE)
DMHIG9K	MT	DTT
DMHIG9K	MA	Inhibitor
DMHIG9K	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMHIG9K	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMHIG9K	DI	DMHIG9K
DMHIG9K	DN	Beta-D-Mannose
DMHIG9K	MI	TT50QJ3
DMHIG9K	MN	Influenza Neuraminidase (Influ NA)
DMHIG9K	MT	DTT
DMHIG9K	MA	Inhibitor
DMHIG9K	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMHIG9K	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMHIG9K	DI	DMHIG9K
DMHIG9K	DN	Beta-D-Mannose
DMHIG9K	MI	TT8NGED
DMHIG9K	MN	Prostaglandin G/H synthase 1 (COX-1)
DMHIG9K	MT	DTT
DMHIG9K	MA	Inhibitor
DMHIG9K	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMHIG9K	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMHIG9K	DI	DMHIG9K
DMHIG9K	DN	Beta-D-Mannose
DMHIG9K	MI	TTH0KSX
DMHIG9K	MN	Rhodopsin (RHO)
DMHIG9K	MT	DTT
DMHIG9K	MA	Inhibitor
DMHIG9K	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMHIG9K	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM7XC6B	DI	DM7XC6B
DM7XC6B	DN	Beta-endorphin
DM7XC6B	MI	TT27RFC
DM7XC6B	MN	Opioid receptor delta (OPRD1)
DM7XC6B	MT	DTT
DM7XC6B	MA	Agonist
DM7XC6B	RN	Cross-linking of human [125I]beta-endorphin to opioid receptors in rat striatal membranes: biochemical evidence for the existence of a mu/delta opioid receptor complex. J Pharmacol Exp Ther. 1990 Apr;253(1):419-26.
DM7XC6B	RU	https://pubmed.ncbi.nlm.nih.gov/2158552

DM7XC6B	DI	DM7XC6B
DM7XC6B	DN	Beta-endorphin
DM7XC6B	MI	TTQW87Y
DM7XC6B	MN	Opioid receptor kappa (OPRK1)
DM7XC6B	MT	DTT
DM7XC6B	MA	Antagonist
DM7XC6B	RN	Beta-endorphin is a potent inhibitor of thymidine incorporation into DNA via mu- and kappa-opioid receptors in fetal rat brain cell aggregates in culture. J Neurochem. 1993 Feb;60(2):765-7.
DM7XC6B	RU	https://pubmed.ncbi.nlm.nih.gov/8380443

DM7XC6B	DI	DM7XC6B
DM7XC6B	DN	Beta-endorphin
DM7XC6B	MI	TTKWM86
DM7XC6B	MN	Opioid receptor mu (MOP)
DM7XC6B	MT	DTT
DM7XC6B	MA	Antagonist
DM7XC6B	RN	Beta-endorphin is a potent inhibitor of thymidine incorporation into DNA via mu- and kappa-opioid receptors in fetal rat brain cell aggregates in culture. J Neurochem. 1993 Feb;60(2):765-7.
DM7XC6B	RU	https://pubmed.ncbi.nlm.nih.gov/8380443

DMU3YXR	DI	DMU3YXR
DMU3YXR	DN	beta-ergocriptine
DMU3YXR	MI	TTS2PH3
DMU3YXR	MN	Dopamine D5 receptor (D5R)
DMU3YXR	MT	DTT
DMU3YXR	MA	Agonist
DMU3YXR	RN	Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature. 1991 Apr 18;350(6319):614-9.
DMU3YXR	RU	https://pubmed.ncbi.nlm.nih.gov/1826762

DM25QXM	DI	DM25QXM
DM25QXM	DN	Beta-fructose phosphate
DM25QXM	MI	DEEY674
DM25QXM	MN	PFK/FBPase 3 (PFKFB3)
DM25QXM	MT	DME
DM25QXM	MA	Metabolism
DM25QXM	RN	The kinase activity of human brain 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase is regulated via inhibition by phosphoenolpyruvate. Arch Biochem Biophys. 2005 Jun 15;438(2):125-36.
DM25QXM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15896703

DMJORFK	DI	DMJORFK
DMJORFK	DN	Beta-funaltrexamine
DMJORFK	MI	TTKWM86
DMJORFK	MN	Opioid receptor mu (MOP)
DMJORFK	MT	DTT
DMJORFK	MA	Inhibitor
DMJORFK	RN	Discovery of dermorphin-based affinity labels with subnanomolar affinity for mu opioid receptors. J Med Chem. 2009 Dec 10;52(23):7372-5.
DMJORFK	RU	https://pubmed.ncbi.nlm.nih.gov/19621878

DMO8LPZ	DI	DMO8LPZ
DMO8LPZ	DN	Beta-Hydroxy Aspartic Acid
DMO8LPZ	MI	TTCIHJA
DMO8LPZ	MN	Coagulation factor Xa (F10)
DMO8LPZ	MT	DTT
DMO8LPZ	MA	Inhibitor
DMO8LPZ	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMO8LPZ	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMGP9MN	DI	DMGP9MN
DMGP9MN	DN	BETA-HYDROXYETHYL THEOPHYLLINE
DMGP9MN	MI	TTNE7KG
DMGP9MN	MN	Adenosine A2b receptor (ADORA2B)
DMGP9MN	MT	DTT
DMGP9MN	MA	Inhibitor
DMGP9MN	RN	Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods. Eur J Med Chem. 2010 Aug;45(8):3459-71.
DMGP9MN	RU	https://pubmed.ncbi.nlm.nih.gov/20537438

DM6QV8A	DI	DM6QV8A
DM6QV8A	DN	Beta-ionone
DM6QV8A	MI	DEKYTSB
DM6QV8A	MN	Cytochrome P450 101B1 (cyp101)
DM6QV8A	MT	DME
DM6QV8A	MA	Metabolism
DM6QV8A	RN	nan
DM6QV8A	RU	nan

DM6QV8A	DI	DM6QV8A
DM6QV8A	DN	Beta-ionone
DM6QV8A	MI	DEGJFHV
DM6QV8A	MN	Cytochrome P450 101C1 (cyp101)
DM6QV8A	MT	DME
DM6QV8A	MA	Metabolism
DM6QV8A	RN	nan
DM6QV8A	RU	nan

DM6QV8A	DI	DM6QV8A
DM6QV8A	DN	Beta-ionone
DM6QV8A	MI	DE06B47
DM6QV8A	MN	Cytochrome P450 109B1 (cyp109)
DM6QV8A	MT	DME
DM6QV8A	MA	Metabolism
DM6QV8A	RN	nan
DM6QV8A	RU	nan

DM3BOQA	DI	DM3BOQA
DM3BOQA	DN	Beta-L-fucose
DM3BOQA	MI	TT1RS9F
DM3BOQA	MN	Acetylcholinesterase (AChE)
DM3BOQA	MT	DTT
DM3BOQA	MA	Inhibitor
DM3BOQA	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DM3BOQA	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMA9CSG	DI	DMA9CSG
DMA9CSG	DN	Beta-methoxyamphetamine
DMA9CSG	MI	TTNGILX
DMA9CSG	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMA9CSG	MT	DTT
DMA9CSG	MA	Agonist
DMA9CSG	RN	Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat. Prog Neuropsychopharmacol Biol Psychiatry. 2000 Aug;24(6):955-77.
DMA9CSG	RU	https://pubmed.ncbi.nlm.nih.gov/11041537

DMA9CSG	DI	DMA9CSG
DMA9CSG	DN	Beta-methoxyamphetamine
DMA9CSG	MI	TT34BHT
DMA9CSG	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMA9CSG	MT	DTT
DMA9CSG	MA	Agonist
DMA9CSG	RN	Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat. Prog Neuropsychopharmacol Biol Psychiatry. 2000 Aug;24(6):955-77.
DMA9CSG	RU	https://pubmed.ncbi.nlm.nih.gov/11041537

DMA9CSG	DI	DMA9CSG
DMA9CSG	DN	Beta-methoxyamphetamine
DMA9CSG	MI	TTWG9A4
DMA9CSG	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMA9CSG	MT	DTT
DMA9CSG	MA	Agonist
DMA9CSG	RN	Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat. Prog Neuropsychopharmacol Biol Psychiatry. 2000 Aug;24(6):955-77.
DMA9CSG	RU	https://pubmed.ncbi.nlm.nih.gov/11041537

DMA9CSG	DI	DMA9CSG
DMA9CSG	DN	Beta-methoxyamphetamine
DMA9CSG	MI	DECB0K3
DMA9CSG	MN	Cytochrome P450 2D6 (CYP2D6)
DMA9CSG	MT	DME
DMA9CSG	MA	Metabolism
DMA9CSG	RN	Interactions of amphetamine analogs with human liver CYP2D6. Biochem Pharmacol. 1997 Jun 1;53(11):1605-12.
DMA9CSG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9264312

DMA9CSG	DI	DMA9CSG
DMA9CSG	DN	Beta-methoxyamphetamine
DMA9CSG	MI	TTVBI8W
DMA9CSG	MN	Dopamine transporter (DAT)
DMA9CSG	MT	DTT
DMA9CSG	MA	Antagonist
DMA9CSG	RN	Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat. Prog Neuropsychopharmacol Biol Psychiatry. 2000 Aug;24(6):955-77.
DMA9CSG	RU	https://pubmed.ncbi.nlm.nih.gov/11041537

DMA9CSG	DI	DMA9CSG
DMA9CSG	DN	Beta-methoxyamphetamine
DMA9CSG	MI	TT3WG5C
DMA9CSG	MN	Monoamine oxidase type A (MAO-A)
DMA9CSG	MT	DTT
DMA9CSG	MA	Inhibitor
DMA9CSG	RN	Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat. Prog Neuropsychopharmacol Biol Psychiatry. 2000 Aug;24(6):955-77.
DMA9CSG	RU	https://pubmed.ncbi.nlm.nih.gov/11041537

DMA9CSG	DI	DMA9CSG
DMA9CSG	DN	Beta-methoxyamphetamine
DMA9CSG	MI	TTGP7BY
DMA9CSG	MN	Monoamine oxidase type B (MAO-B)
DMA9CSG	MT	DTT
DMA9CSG	MA	Antagonist
DMA9CSG	RN	Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat. Prog Neuropsychopharmacol Biol Psychiatry. 2000 Aug;24(6):955-77.
DMA9CSG	RU	https://pubmed.ncbi.nlm.nih.gov/11041537

DMA9CSG	DI	DMA9CSG
DMA9CSG	DN	Beta-methoxyamphetamine
DMA9CSG	MI	TT3ROYC
DMA9CSG	MN	Serotonin transporter (SERT)
DMA9CSG	MT	DTT
DMA9CSG	MA	Inhibitor
DMA9CSG	RN	Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat. Prog Neuropsychopharmacol Biol Psychiatry. 2000 Aug;24(6):955-77.
DMA9CSG	RU	https://pubmed.ncbi.nlm.nih.gov/11041537

DMA9CSG	DI	DMA9CSG
DMA9CSG	DN	Beta-methoxyamphetamine
DMA9CSG	MI	TTNZRI3
DMA9CSG	MN	Synaptic vesicle amine transporter (SLC18A2)
DMA9CSG	MT	DTT
DMA9CSG	MA	Antagonist
DMA9CSG	RN	Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat. Prog Neuropsychopharmacol Biol Psychiatry. 2000 Aug;24(6):955-77.
DMA9CSG	RU	https://pubmed.ncbi.nlm.nih.gov/11041537

DMKH32S	DI	DMKH32S
DMKH32S	DN	Beta-methylmelatonin
DMKH32S	MI	TT0WAIE
DMKH32S	MN	Melatonin receptor type 1A (MTNR1A)
DMKH32S	MT	DTT
DMKH32S	MA	Inhibitor
DMKH32S	RN	Mapping the melatonin receptor. 7. Subtype selective ligands based on beta-substituted N-acyl-5-methoxytryptamines and beta-substituted N-acyl-5-me... J Med Chem. 2006 Jun 15;49(12):3509-19.
DMKH32S	RU	https://pubmed.ncbi.nlm.nih.gov/16759094

DMKH32S	DI	DMKH32S
DMKH32S	DN	Beta-methylmelatonin
DMKH32S	MI	TT32JK8
DMKH32S	MN	Melatonin receptor type 1B (MTNR1B)
DMKH32S	MT	DTT
DMKH32S	MA	Inhibitor
DMKH32S	RN	Mapping the melatonin receptor. 7. Subtype selective ligands based on beta-substituted N-acyl-5-methoxytryptamines and beta-substituted N-acyl-5-me... J Med Chem. 2006 Jun 15;49(12):3509-19.
DMKH32S	RU	https://pubmed.ncbi.nlm.nih.gov/16759094

DMZ8Y67	DI	DMZ8Y67
DMZ8Y67	DN	Beta-naphthylboronic acid
DMZ8Y67	MI	TTUNARX
DMZ8Y67	MN	Carbonic anhydrase (CA)
DMZ8Y67	MT	DTT
DMZ8Y67	MA	Inhibitor
DMZ8Y67	RN	Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5.
DMZ8Y67	RU	https://pubmed.ncbi.nlm.nih.gov/19375309

DMZ8Y67	DI	DMZ8Y67
DMZ8Y67	DN	Beta-naphthylboronic acid
DMZ8Y67	MI	TTHQPL7
DMZ8Y67	MN	Carbonic anhydrase I (CA-I)
DMZ8Y67	MT	DTT
DMZ8Y67	MA	Inhibitor
DMZ8Y67	RN	Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5.
DMZ8Y67	RU	https://pubmed.ncbi.nlm.nih.gov/19375309

DMZ8Y67	DI	DMZ8Y67
DMZ8Y67	DN	Beta-naphthylboronic acid
DMZ8Y67	MI	TTANPDJ
DMZ8Y67	MN	Carbonic anhydrase II (CA-II)
DMZ8Y67	MT	DTT
DMZ8Y67	MA	Inhibitor
DMZ8Y67	RN	Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5.
DMZ8Y67	RU	https://pubmed.ncbi.nlm.nih.gov/19375309

DMQXMKB	DI	DMQXMKB
DMQXMKB	DN	Beta-phenyl-D-phenylalanyl-N-propyl-L-prolinamide
DMQXMKB	MI	TT6L509
DMQXMKB	MN	Coagulation factor IIa (F2)
DMQXMKB	MT	DTT
DMQXMKB	MA	Inhibitor
DMQXMKB	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMQXMKB	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM4MZQW	DI	DM4MZQW
DM4MZQW	DN	BETP
DM4MZQW	MI	TTVIMDE
DM4MZQW	MN	Glucagon-like peptide 1 receptor (GLP1R)
DM4MZQW	MT	DTT
DM4MZQW	MA	Modulator (allosteric modulator)
DM4MZQW	RN	A potentiator of orthosteric ligand activity at GLP-1R acts via covalent modification. Nat Chem Biol. 2014 Aug;10(8):629-31.
DM4MZQW	RU	https://pubmed.ncbi.nlm.nih.gov/24997604

DMGQRON	DI	DMGQRON
DMGQRON	DN	BETULIN
DMGQRON	MI	TTZHY6R
DMGQRON	MN	Glycogen phosphorylase muscle form (GP)
DMGQRON	MT	DTT
DMGQRON	MA	Inhibitor
DMGQRON	RN	Naturally occurring pentacyclic triterpenes as inhibitors of glycogen phosphorylase: synthesis, structure-activity relationships, and X-ray crystal... J Med Chem. 2008 Jun 26;51(12):3540-54.
DMGQRON	RU	https://pubmed.ncbi.nlm.nih.gov/18517260

DMOQEZK	DI	DMOQEZK
DMOQEZK	DN	BF/PC-18
DMOQEZK	MI	TTUMQVO
DMOQEZK	MN	Cathepsin S (CTSS)
DMOQEZK	MT	DTT
DMOQEZK	MA	Inhibitor
DMOQEZK	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2353).
DMOQEZK	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2353

DMCWB1V	DI	DMCWB1V
DMCWB1V	DN	BF/PC-21
DMCWB1V	MI	TTDZN01
DMCWB1V	MN	Cathepsin K (CTSK)
DMCWB1V	MT	DTT
DMCWB1V	MA	Inhibitor
DMCWB1V	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2350).
DMCWB1V	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2350

DM4XMZW	DI	DM4XMZW
DM4XMZW	DN	BH4
DM4XMZW	MI	TTGSVH2
DM4XMZW	MN	Phenylalanine hydroxylase (PAH)
DM4XMZW	MT	DTT
DM4XMZW	MA	Modulator
DM4XMZW	RN	Company report of BioMarin
DM4XMZW	RU	http://www.biomarin.com/products/kuvan (Kuvan is the first and only FDA-approved medication for PKU to reduce blood Phe levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin (BH4-) responsive PKU.)

DMP21ST	DI	DMP21ST
DMP21ST	DN	BHF-177
DMP21ST	MI	TTDCVZW
DMP21ST	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMP21ST	MT	DTT
DMP21ST	MA	Modulator
DMP21ST	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 241).
DMP21ST	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=241

DMVH4LK	DI	DMVH4LK
DMVH4LK	DN	Bhg-F-N-Y-Y-W
DMVH4LK	MI	TTKRD0G
DMVH4LK	MN	Endothelin A receptor (EDNRA)
DMVH4LK	MT	DTT
DMVH4LK	MA	Inhibitor
DMVH4LK	RN	Res-701-1, synthesis and a reevaluation of its effects on the endothelin receptors, Bioorg. Med. Chem. Lett. 5(6):621-626 (1995).
DMVH4LK	RU	http://www.sciencedirect.com/science/article/pii/0960894X95000847

DMVH4LK	DI	DMVH4LK
DMVH4LK	DN	Bhg-F-N-Y-Y-W
DMVH4LK	MI	TT3ZTGU
DMVH4LK	MN	Endothelin B receptor (EDNRB)
DMVH4LK	MT	DTT
DMVH4LK	MA	Inhibitor
DMVH4LK	RN	Res-701-1, synthesis and a reevaluation of its effects on the endothelin receptors, Bioorg. Med. Chem. Lett. 5(6):621-626 (1995).
DMVH4LK	RU	http://www.sciencedirect.com/science/article/pii/0960894X95000847

DMZRS7A	DI	DMZRS7A
DMZRS7A	DN	BHT-3034
DMZRS7A	MI	TTH18TF
DMZRS7A	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMZRS7A	MT	DTT
DMZRS7A	MA	Modulator
DMZRS7A	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 467).
DMZRS7A	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=467

DMI3ANC	DI	DMI3ANC
DMI3ANC	DN	BI 7273
DMI3ANC	MI	TTR7L5Y
DMI3ANC	MN	Bromodomain-containing protein 9 (BRD9)
DMI3ANC	MT	DTT
DMI3ANC	MA	Inhibitor
DMI3ANC	RN	Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor. J Med Chem. 2016 May 26;59(10):4462-75.
DMI3ANC	RU	https://pubmed.ncbi.nlm.nih.gov/26914985

DMN052T	DI	DMN052T
DMN052T	DN	BI-32169
DMN052T	MI	TT9O6WS
DMN052T	MN	Glucagon receptor (GCGR)
DMN052T	MT	DTT
DMN052T	MA	Inhibitor
DMN052T	RN	BI-32169, a bicyclic 19-peptide with strong glucagon receptor antagonist activity from Streptomyces sp. J Nat Prod. 2004 Sep;67(9):1528-31.
DMN052T	RU	https://pubmed.ncbi.nlm.nih.gov/15387654

DMRXK5G	DI	DMRXK5G
DMRXK5G	DN	BI6015
DMRXK5G	MI	TT2F3CD
DMRXK5G	MN	Hepatocyte nuclear factor 4-alpha (HNF4A)
DMRXK5G	MT	DTT
DMRXK5G	MA	Antagonist
DMRXK5G	RN	HNF4alpha antagonists discovered by a high-throughput screen for modulators of the human insulin promoter. Chem Biol. 2012 Jul 27;19(7):806-18.
DMRXK5G	RU	https://pubmed.ncbi.nlm.nih.gov/22840769

DM4RZ9A	DI	DM4RZ9A
DM4RZ9A	DN	BIA
DM4RZ9A	MI	TTKWFB8
DM4RZ9A	MN	Catechol-O-methyl-transferase (COMT)
DM4RZ9A	MT	DTT
DM4RZ9A	MA	Inhibitor
DM4RZ9A	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM4RZ9A	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMUWO6D	DI	DMUWO6D
DMUWO6D	DN	BIBF100
DMUWO6D	MI	TTGKIED
DMUWO6D	MN	Fibroblast growth factor-2 (FGF2)
DMUWO6D	MT	DTT
DMUWO6D	MA	Inhibitor
DMUWO6D	RN	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
DMUWO6D	RU	https://pubmed.ncbi.nlm.nih.gov/19249983

DMUWO6D	DI	DMUWO6D
DMUWO6D	DN	BIBF100
DMUWO6D	MI	TT9HKJA
DMUWO6D	MN	Vascular endothelial growth factor (VEGF)
DMUWO6D	MT	DTT
DMUWO6D	MA	Inhibitor
DMUWO6D	RN	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
DMUWO6D	RU	https://pubmed.ncbi.nlm.nih.gov/19249983

DMDTLSP	DI	DMDTLSP
DMDTLSP	DN	BIBF-1202
DMDTLSP	MI	TTUTJGQ
DMDTLSP	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMDTLSP	MT	DTT
DMDTLSP	MA	Inhibitor
DMDTLSP	RN	Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011 Oct 30;29(11):1046-51.
DMDTLSP	RU	https://pubmed.ncbi.nlm.nih.gov/22037378

DML7HFP	DI	DML7HFP
DML7HFP	DN	BIBO3304
DML7HFP	MI	TTRK9JT
DML7HFP	MN	Neuropeptide Y receptor type 1 (NPY1R)
DML7HFP	MT	DTT
DML7HFP	MA	Antagonist
DML7HFP	RN	Neuropeptide Y induced modulation of dopamine synthesis in the striatum. Regul Pept. 2005 Jul 15;129(1-3):73-8.
DML7HFP	RU	https://pubmed.ncbi.nlm.nih.gov/15927700

DMFS2V9	DI	DMFS2V9
DMFS2V9	DN	BIC1
DMFS2V9	MI	TTDP48B
DMFS2V9	MN	Bromodomain-containing protein 2 (BRD2)
DMFS2V9	MT	DTT
DMFS2V9	MA	Inhibitor
DMFS2V9	RN	Real-time imaging of histone H4K12-specific acetylation determines the modes of action of histone deacetylase and bromodomain inhibitors. Chem Biol. 2011 Apr 22;18(4):495-507.
DMFS2V9	RU	https://pubmed.ncbi.nlm.nih.gov/21513886

DMT5E36	DI	DMT5E36
DMT5E36	DN	Bicarbonate
DMT5E36	MI	DTF7GAL
DMT5E36	MN	Anion exchange protein 2 (SLC4A2)
DMT5E36	MT	DTP
DMT5E36	MA	Substrate
DMT5E36	RN	HCO3-/Cl- anion exchanger SLC4A2 is required for proper osteoclast differentiation and function. Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):16934-9.
DMT5E36	RU	http://www.ncbi.nlm.nih.gov/pubmed/18971331

DMT5E36	DI	DMT5E36
DMT5E36	DN	Bicarbonate
DMT5E36	MI	DT4X2AH
DMT5E36	MN	Anion exchange protein 3 (SLC4A3)
DMT5E36	MT	DTP
DMT5E36	MA	Substrate
DMT5E36	RN	The SLC4 family of bicarbonate (HCO??) transporters. Mol Aspects Med. 2013 Apr-Jun;34(2-3):159-82.
DMT5E36	RU	http://www.ncbi.nlm.nih.gov/pubmed/23506864

DMT5E36	DI	DMT5E36
DMT5E36	DN	Bicarbonate
DMT5E36	MI	DTVGOLN
DMT5E36	MN	Anion exchange transporter (SLC26A6)
DMT5E36	MT	DTP
DMT5E36	MA	Substrate
DMT5E36	RN	Metabolon disruption: a mechanism that regulates bicarbonate transport. EMBO J. 2005 Jul 20;24(14):2499-511.
DMT5E36	RU	http://www.ncbi.nlm.nih.gov/pubmed/15990874

DMT5E36	DI	DMT5E36
DMT5E36	DN	Bicarbonate
DMT5E36	MI	DTOTME4
DMT5E36	MN	Anion exchange transporter (SLC26A7)
DMT5E36	MT	DTP
DMT5E36	MA	Substrate
DMT5E36	RN	Vasopressin induces expression of the Cl-/HCO3- exchanger SLC26A7 in kidney medullary collecting ducts of Brattleboro rats. Am J Physiol Renal Physiol. 2006 May;290(5):F1194-201.
DMT5E36	RU	http://www.ncbi.nlm.nih.gov/pubmed/16352747

DMT5E36	DI	DMT5E36
DMT5E36	DN	Bicarbonate
DMT5E36	MI	DT0TZPS
DMT5E36	MN	Anion transporter/exchanger protein 9 (SLC26A9)
DMT5E36	MT	DTP
DMT5E36	MA	Substrate
DMT5E36	RN	SLC26A9 is expressed in gastric surface epithelial cells, mediates Cl-/HCO3- exchange, and is inhibited by NH4+. Am J Physiol Cell Physiol. 2005 Aug;289(2):C493-505.
DMT5E36	RU	http://www.ncbi.nlm.nih.gov/pubmed/15800055

DMT5E36	DI	DMT5E36
DMT5E36	DN	Bicarbonate
DMT5E36	MI	TT2LVK8
DMT5E36	MN	Carbonic anhydrase IX (CA-IX)
DMT5E36	MT	DTT
DMT5E36	MA	Inhibitor
DMT5E36	RN	Carbonic anhydrase inhibitors. Inhibition of isozymes I, II, IV, V, and IX with anions isosteric and isoelectronic with sulfate, nitrate, and carbo... Bioorg Med Chem Lett. 2005 Feb 1;15(3):567-71.
DMT5E36	RU	https://pubmed.ncbi.nlm.nih.gov/15664814

DMT5E36	DI	DMT5E36
DMT5E36	DN	Bicarbonate
DMT5E36	MI	DTJ785O
DMT5E36	MN	Sulfate anion transporter 1 (SLC26A1)
DMT5E36	MT	DTP
DMT5E36	MA	Substrate
DMT5E36	RN	SLC26A Gene Family Participate in pH Regulation during Enamel Maturation. PLoS One. 2015 Dec 15;10(12):e0144703.
DMT5E36	RU	http://www.ncbi.nlm.nih.gov/pubmed/26671068

DMTRDPI	DI	DMTRDPI
DMTRDPI	DN	Bicine
DMTRDPI	MI	TTP86E2
DMTRDPI	MN	Plasminogen (PLG)
DMTRDPI	MT	DTT
DMTRDPI	MA	Inhibitor
DMTRDPI	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMTRDPI	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMA6VQW	DI	DMA6VQW
DMA6VQW	DN	Bicuculline
DMA6VQW	MI	TTNJYV2
DMA6VQW	MN	Gamma-aminobutyric acid receptor (GAR)
DMA6VQW	MT	DTT
DMA6VQW	MA	Antagonist
DMA6VQW	RN	GABA receptors inhibited by benzodiazepines mediate fast inhibitory transmission in the central amygdala. J Neurosci. 1999 Nov 15;19(22):9698-704.
DMA6VQW	RU	https://pubmed.ncbi.nlm.nih.gov/10559379

DMA6VQW	DI	DMA6VQW
DMA6VQW	DN	Bicuculline
DMA6VQW	MI	TTAN6JD
DMA6VQW	MN	Glutamate receptor AMPA (GRIA)
DMA6VQW	MT	DTT
DMA6VQW	MA	Antagonist
DMA6VQW	RN	Effects of subcutaneous administration of the gamma-aminobutyric acid(A) receptor agonist muscimol on water intake in water-deprived rats. Physiol Behav. 2002 Nov;77(2-3):445-50.
DMA6VQW	RU	https://pubmed.ncbi.nlm.nih.gov/12419421

DM4MUXT	DI	DM4MUXT
DM4MUXT	DN	BIFENOX
DM4MUXT	MI	TTLUQ8E
DM4MUXT	MN	Hormone sensitive lipase (LIPE)
DM4MUXT	MT	DTT
DM4MUXT	MA	Inhibitor
DM4MUXT	RN	Combining ligand-based pharmacophore modeling, quantitative structure-activity relationship analysis and in silico screening for the discovery of n... J Med Chem. 2008 Oct 23;51(20):6478-94.
DM4MUXT	RU	https://pubmed.ncbi.nlm.nih.gov/18808096

DML4DQ3	DI	DML4DQ3
DML4DQ3	DN	BIIB-513
DML4DQ3	MI	TTGSEFH
DML4DQ3	MN	Sodium/hydrogen exchanger 1 (SLC9A1)
DML4DQ3	MT	DTT
DML4DQ3	MA	Inhibitor
DML4DQ3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 948).
DML4DQ3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=948

DMR2SEB	DI	DMR2SEB
DMR2SEB	DN	BIIE0246
DMR2SEB	MI	TTJ6WK9
DMR2SEB	MN	Neuropeptide Y receptor type 2 (NPY2R)
DMR2SEB	MT	DTT
DMR2SEB	MA	Antagonist
DMR2SEB	RN	The peptide YY-preferring receptor mediating inhibition of small intestinal secretion is a peripheral Y(2) receptor: pharmacological evidence and molecular cloning. Mol Pharmacol. 2001 Jul;60(1):124-34.
DMR2SEB	RU	https://pubmed.ncbi.nlm.nih.gov/11408607

DMU09E4	DI	DMU09E4
DMU09E4	DN	BIIL 260
DMU09E4	MI	TTVJX54
DMU09E4	MN	Leukotriene B4 receptor 2 (LTB4R2)
DMU09E4	MT	DTT
DMU09E4	MA	Antagonist
DMU09E4	RN	Clinical trial of a leucotriene B4 receptor antagonist, BIIL 284, in patients with rheumatoid arthritis. Ann Rheum Dis. 2007 May;66(5):628-32.
DMU09E4	RU	https://pubmed.ncbi.nlm.nih.gov/17170051

DMIY2HW	DI	DMIY2HW
DMIY2HW	DN	Bile acid
DMIY2HW	MI	TTSDVTR
DMIY2HW	MN	G-protein coupled bile acid receptor 1 (GPBAR1)
DMIY2HW	MT	DTT
DMIY2HW	MA	Inhibitor
DMIY2HW	RN	Synthesis and SAR of 2-aryl-3-aminomethylquinolines as agonists of the bile acid receptor TGR5. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5718-21.
DMIY2HW	RU	https://pubmed.ncbi.nlm.nih.gov/20801037

DMI0V4O	DI	DMI0V4O
DMI0V4O	DN	Bilirubin
DMI0V4O	MI	DTFI42L
DMI0V4O	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMI0V4O	MT	DTP
DMI0V4O	MA	Substrate
DMI0V4O	RN	Transport of monoglucuronosyl and bisglucuronosyl bilirubin by recombinant human and rat multidrug resistance protein 2. Hepatology. 1999 Aug;30(2):485-90.
DMI0V4O	RU	http://www.ncbi.nlm.nih.gov/pubmed/10421658

DMI0V4O	DI	DMI0V4O
DMI0V4O	DN	Bilirubin
DMI0V4O	MI	DT3D8F0
DMI0V4O	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMI0V4O	MT	DTP
DMI0V4O	MA	Substrate
DMI0V4O	RN	Role of organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin. Biochem J. 2003 May 1;371(Pt 3):897-905.
DMI0V4O	RU	http://www.ncbi.nlm.nih.gov/pubmed/12568656

DMI0V4O	DI	DMI0V4O
DMI0V4O	DN	Bilirubin
DMI0V4O	MI	DT9C1TS
DMI0V4O	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMI0V4O	MT	DTP
DMI0V4O	MA	Substrate
DMI0V4O	RN	Role of organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin. Biochem J. 2003 May 1;371(Pt 3):897-905.
DMI0V4O	RU	http://www.ncbi.nlm.nih.gov/pubmed/12568656

DMI0V4O	DI	DMI0V4O
DMI0V4O	DN	Bilirubin
DMI0V4O	MI	DESD26P
DMI0V4O	MN	UDP-glucuronosyltransferase 1A6 (UGT1A6)
DMI0V4O	MT	DME
DMI0V4O	MA	Metabolism
DMI0V4O	RN	Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev. 1999 Nov;31(4):817-99.
DMI0V4O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10575553

DMCA0WJ	DI	DMCA0WJ
DMCA0WJ	DN	Biliverdine Ix Alpha
DMCA0WJ	MI	TTI6V2A
DMCA0WJ	MN	Heme oxygenase 1 (HMOX1)
DMCA0WJ	MT	DTT
DMCA0WJ	MA	Inhibitor
DMCA0WJ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMCA0WJ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM09Z35	DI	DM09Z35
DM09Z35	DN	bilobalide
DM09Z35	MI	TTPC4TU
DM09Z35	MN	5-HT 3A receptor (HTR3A)
DM09Z35	MT	DTT
DM09Z35	MA	Blocker (channel blocker)
DM09Z35	RN	Binding sites for bilobalide, diltiazem, ginkgolide, and picrotoxinin at the 5-HT3 receptor. Mol Pharmacol. 2011 Jul;80(1):183-90.
DM09Z35	RU	https://pubmed.ncbi.nlm.nih.gov/21505038

DM09Z35	DI	DM09Z35
DM09Z35	DN	bilobalide
DM09Z35	MI	TTR6K75
DM09Z35	MN	5-HT 3B receptor (HTR3B)
DM09Z35	MT	DTT
DM09Z35	MA	Blocker (channel blocker)
DM09Z35	RN	Ginkgolide B and bilobalide block the pore of the 5-HT eceptor at a location that overlaps the picrotoxin binding site. Neuropharmacology. 2011 Feb-Mar;60(2-3):488-95.
DM09Z35	RU	https://pubmed.ncbi.nlm.nih.gov/21059362

DM09Z35	DI	DM09Z35
DM09Z35	DN	bilobalide
DM09Z35	MI	TTZ8EM9
DM09Z35	MN	Glycine receptor (GlyR)
DM09Z35	MT	DTT
DM09Z35	MA	Antagonist
DM09Z35	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 427).
DM09Z35	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=427

DMPR14J	DI	DMPR14J
DMPR14J	DN	Bimetopyrole
DMPR14J	MI	TTVKILB
DMPR14J	MN	Prostaglandin G/H synthase 2 (COX-2)
DMPR14J	MT	DTT
DMPR14J	MA	Inhibitor
DMPR14J	RN	Current status of COX-2 inhibitors. Mini Rev Med Chem. 2008 Jan;8(1):73-90.
DMPR14J	RU	https://pubmed.ncbi.nlm.nih.gov/18220987

DM0HPWY	DI	DM0HPWY
DM0HPWY	DN	biochanin A
DM0HPWY	MI	TTSZLWK
DM0HPWY	MN	Aromatase (CYP19A1)
DM0HPWY	MT	DTT
DM0HPWY	MA	Inhibitor
DM0HPWY	RN	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
DM0HPWY	RU	https://pubmed.ncbi.nlm.nih.gov/20413308

DM0HPWY	DI	DM0HPWY
DM0HPWY	DN	biochanin A
DM0HPWY	MI	TTPNQAC
DM0HPWY	MN	Estrogen-related receptor-alpha (ESRRA)
DM0HPWY	MT	DTT
DM0HPWY	MA	Agonist
DM0HPWY	RN	Flavone and isoflavone phytoestrogens are agonists of estrogen-related receptors. Mol Cancer Res. 2003 Nov;1(13):981-91.
DM0HPWY	RU	https://pubmed.ncbi.nlm.nih.gov/14638870

DM0HPWY	DI	DM0HPWY
DM0HPWY	DN	biochanin A
DM0HPWY	MI	TTKF0XS
DM0HPWY	MN	Estrogen-related receptor-beta (ESRRB)
DM0HPWY	MT	DTT
DM0HPWY	MA	Agonist
DM0HPWY	RN	Flavone and isoflavone phytoestrogens are agonists of estrogen-related receptors. Mol Cancer Res. 2003 Nov;1(13):981-91.
DM0HPWY	RU	https://pubmed.ncbi.nlm.nih.gov/14638870

DM0HPWY	DI	DM0HPWY
DM0HPWY	DN	biochanin A
DM0HPWY	MI	TT9ZRHB
DM0HPWY	MN	Estrogen-related receptor-gamma (ESRRG)
DM0HPWY	MT	DTT
DM0HPWY	MA	Agonist
DM0HPWY	RN	Flavone and isoflavone phytoestrogens are agonists of estrogen-related receptors. Mol Cancer Res. 2003 Nov;1(13):981-91.
DM0HPWY	RU	https://pubmed.ncbi.nlm.nih.gov/14638870

DM0HPWY	DI	DM0HPWY
DM0HPWY	DN	biochanin A
DM0HPWY	MI	TT7AOUD
DM0HPWY	MN	Fatty acid synthase (FASN)
DM0HPWY	MT	DTT
DM0HPWY	MA	Inhibitor
DM0HPWY	RN	Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
DM0HPWY	RU	https://pubmed.ncbi.nlm.nih.gov/16722653

DM0HPWY	DI	DM0HPWY
DM0HPWY	DN	biochanin A
DM0HPWY	MI	TTHPFTS
DM0HPWY	MN	Plasmodium Beta-hydroxyacyl-ACP dehydratase (Malaria FabZ)
DM0HPWY	MT	DTT
DM0HPWY	MA	Inhibitor
DM0HPWY	RN	Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
DM0HPWY	RU	https://pubmed.ncbi.nlm.nih.gov/16722653

DMLNQ2F	DI	DMLNQ2F
DMLNQ2F	DN	Biopterin
DMLNQ2F	MI	TT9SL3Q
DMLNQ2F	MN	Polypeptide deformylase (PDF)
DMLNQ2F	MT	DTT
DMLNQ2F	MA	Inhibitor
DMLNQ2F	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMLNQ2F	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMKMCE1	DI	DMKMCE1
DMKMCE1	DN	Biotin
DMKMCE1	MI	DT342ZG
DMKMCE1	MN	Monocarboxylate transporter 1 (SLC16A1)
DMKMCE1	MT	DTP
DMKMCE1	MA	Substrate
DMKMCE1	RN	Biotin. Biofactors. 2009 Jan-Feb;35(1):36-46.
DMKMCE1	RU	http://www.ncbi.nlm.nih.gov/pubmed/19319844

DMKMCE1	DI	DMKMCE1
DMKMCE1	DN	Biotin
DMKMCE1	MI	DTUGYRD
DMKMCE1	MN	P-glycoprotein 1 (ABCB1)
DMKMCE1	MT	DTP
DMKMCE1	MA	Substrate
DMKMCE1	RN	Functional characterization of sodium-dependent multivitamin transporter in MDCK-MDR1 cells and its utilization as a target for drug delivery. Mol Pharm. 2006 May-Jun;3(3):329-39.
DMKMCE1	RU	http://www.ncbi.nlm.nih.gov/pubmed/16749865

DMVOJ0X	DI	DMVOJ0X
DMVOJ0X	DN	BioVant
DMVOJ0X	MI	TT3J5ZI
DMVOJ0X	MN	Cell mediated immunity response (CMIR)
DMVOJ0X	MT	DTT
DMVOJ0X	RN	Calcium Phosphate Nanoparticle Adjuvant. Clin Diagn Lab Immunol. 2000 November; 7(6): 899-903.
DMVOJ0X	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC95982/

DM4D7V6	DI	DM4D7V6
DM4D7V6	DN	Biphenyl-2-ylmethyl-(S)-pyrrolidin-3-yl-amine
DM4D7V6	MI	TTVBI8W
DM4D7V6	MN	Dopamine transporter (DAT)
DM4D7V6	MT	DTT
DM4D7V6	MA	Inhibitor
DM4D7V6	RN	Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modu... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4355-9.
DM4D7V6	RU	https://pubmed.ncbi.nlm.nih.gov/18621528

DM4D7V6	DI	DM4D7V6
DM4D7V6	DN	Biphenyl-2-ylmethyl-(S)-pyrrolidin-3-yl-amine
DM4D7V6	MI	TTAWNKZ
DM4D7V6	MN	Norepinephrine transporter (NET)
DM4D7V6	MT	DTT
DM4D7V6	MA	Inhibitor
DM4D7V6	RN	Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modu... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4355-9.
DM4D7V6	RU	https://pubmed.ncbi.nlm.nih.gov/18621528

DM4D7V6	DI	DM4D7V6
DM4D7V6	DN	Biphenyl-2-ylmethyl-(S)-pyrrolidin-3-yl-amine
DM4D7V6	MI	TT3ROYC
DM4D7V6	MN	Serotonin transporter (SERT)
DM4D7V6	MT	DTT
DM4D7V6	MA	Inhibitor
DM4D7V6	RN	Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modu... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4355-9.
DM4D7V6	RU	https://pubmed.ncbi.nlm.nih.gov/18621528

DMROG71	DI	DMROG71
DMROG71	DN	Biphenyl-3-carboxylic acid hydroxyamide
DMROG71	MI	TT2J34L
DMROG71	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMROG71	MT	DTT
DMROG71	MA	Inhibitor
DMROG71	RN	Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8.
DMROG71	RU	https://pubmed.ncbi.nlm.nih.gov/2308149

DMIAUB1	DI	DMIAUB1
DMIAUB1	DN	Biphenyl-3-ylboronic acid
DMIAUB1	MI	TTDP1UC
DMIAUB1	MN	Fatty acid amide hydrolase (FAAH)
DMIAUB1	MT	DTT
DMIAUB1	MA	Inhibitor
DMIAUB1	RN	Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Nov 27;51(22):7057-60.
DMIAUB1	RU	https://pubmed.ncbi.nlm.nih.gov/18983140

DMYCKGH	DI	DMYCKGH
DMYCKGH	DN	Biphenyl-3-ylcarbamic Acid Biphenyl-3-yl Ester
DMYCKGH	MI	TTDP1UC
DMYCKGH	MN	Fatty acid amide hydrolase (FAAH)
DMYCKGH	MT	DTT
DMYCKGH	MA	Inhibitor
DMYCKGH	RN	Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl a... J Med Chem. 2008 Jun 26;51(12):3487-98.
DMYCKGH	RU	https://pubmed.ncbi.nlm.nih.gov/18507372

DM10AUP	DI	DM10AUP
DM10AUP	DN	Biphenyl-3-ylcarbamic acid cyclohexyl ester
DM10AUP	MI	TTDP1UC
DM10AUP	MN	Fatty acid amide hydrolase (FAAH)
DM10AUP	MT	DTT
DM10AUP	MA	Inhibitor
DM10AUP	RN	Synthesis and in vitro evaluation of N-substituted maleimide derivatives as selective monoglyceride lipase inhibitors. J Med Chem. 2009 Dec 10;52(23):7410-20.
DM10AUP	RU	https://pubmed.ncbi.nlm.nih.gov/19583260

DMK5VYG	DI	DMK5VYG
DMK5VYG	DN	Biphenyl-4-carboxylic acid hydroxyamide
DMK5VYG	MI	TT2J34L
DMK5VYG	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMK5VYG	MT	DTT
DMK5VYG	MA	Inhibitor
DMK5VYG	RN	Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8.
DMK5VYG	RU	https://pubmed.ncbi.nlm.nih.gov/2308149

DM5DPHO	DI	DM5DPHO
DM5DPHO	DN	BIPHENYL-4-YL-ACETALDEHYDE
DM5DPHO	MI	TT36ETB
DM5DPHO	MN	Cathepsin L (CTSL)
DM5DPHO	MT	DTT
DM5DPHO	MA	Inhibitor
DM5DPHO	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM5DPHO	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMIHMP5	DI	DMIHMP5
DMIHMP5	DN	Biphenyl-4-ylboronic acid
DMIHMP5	MI	TTUNARX
DMIHMP5	MN	Carbonic anhydrase (CA)
DMIHMP5	MT	DTT
DMIHMP5	MA	Inhibitor
DMIHMP5	RN	Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5.
DMIHMP5	RU	https://pubmed.ncbi.nlm.nih.gov/19375309

DMIHMP5	DI	DMIHMP5
DMIHMP5	DN	Biphenyl-4-ylboronic acid
DMIHMP5	MI	TTHQPL7
DMIHMP5	MN	Carbonic anhydrase I (CA-I)
DMIHMP5	MT	DTT
DMIHMP5	MA	Inhibitor
DMIHMP5	RN	Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5.
DMIHMP5	RU	https://pubmed.ncbi.nlm.nih.gov/19375309

DMIHMP5	DI	DMIHMP5
DMIHMP5	DN	Biphenyl-4-ylboronic acid
DMIHMP5	MI	TTANPDJ
DMIHMP5	MN	Carbonic anhydrase II (CA-II)
DMIHMP5	MT	DTT
DMIHMP5	MA	Inhibitor
DMIHMP5	RN	Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5.
DMIHMP5	RU	https://pubmed.ncbi.nlm.nih.gov/19375309

DMIHMP5	DI	DMIHMP5
DMIHMP5	DN	Biphenyl-4-ylboronic acid
DMIHMP5	MI	TTDP1UC
DMIHMP5	MN	Fatty acid amide hydrolase (FAAH)
DMIHMP5	MT	DTT
DMIHMP5	MA	Inhibitor
DMIHMP5	RN	Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Nov 27;51(22):7057-60.
DMIHMP5	RU	https://pubmed.ncbi.nlm.nih.gov/18983140

DM2MYKC	DI	DM2MYKC
DM2MYKC	DN	biphenylindanone A
DM2MYKC	MI	TTXJ47W
DM2MYKC	MN	Metabotropic glutamate receptor 2 (mGluR2)
DM2MYKC	MT	DTT
DM2MYKC	MA	Modulator (allosteric modulator)
DM2MYKC	RN	Biphenyl-indanones: allosteric potentiators of the metabotropic glutamate subtype 2 receptor. Bioorg Med Chem Lett. 2005 Oct 1;15(19):4354-8.
DM2MYKC	RU	https://pubmed.ncbi.nlm.nih.gov/16046122

DM4FSXK	DI	DM4FSXK
DM4FSXK	DN	Bip-tyr(3bzl)-thr-pro-lys-thr
DM4FSXK	MI	TTVBI8W
DM4FSXK	MN	Dopamine transporter (DAT)
DM4FSXK	MT	DTT
DM4FSXK	MA	Inhibitor
DM4FSXK	RN	Development of peptidic dopamine transporter inhibitors via aromatic modification-mediated conformational restriction. J Med Chem. 2006 Jul 13;49(14):4048-51.
DM4FSXK	RU	https://pubmed.ncbi.nlm.nih.gov/16821765

DM0VKA2	DI	DM0VKA2
DM0VKA2	DN	Bip-tyr-ala-pro-lys-thr(obzl)-gly
DM0VKA2	MI	TTVBI8W
DM0VKA2	MN	Dopamine transporter (DAT)
DM0VKA2	MT	DTT
DM0VKA2	MA	Inhibitor
DM0VKA2	RN	Development of peptidic dopamine transporter inhibitors via aromatic modification-mediated conformational restriction. J Med Chem. 2006 Jul 13;49(14):4048-51.
DM0VKA2	RU	https://pubmed.ncbi.nlm.nih.gov/16821765

DMUWE81	DI	DMUWE81
DMUWE81	DN	Bip-tyr-thr-ala-pro-phe
DMUWE81	MI	TTVBI8W
DMUWE81	MN	Dopamine transporter (DAT)
DMUWE81	MT	DTT
DMUWE81	MA	Inhibitor
DMUWE81	RN	Development of peptidic dopamine transporter inhibitors via aromatic modification-mediated conformational restriction. J Med Chem. 2006 Jul 13;49(14):4048-51.
DMUWE81	RU	https://pubmed.ncbi.nlm.nih.gov/16821765

DMN38JC	DI	DMN38JC
DMN38JC	DN	Bip-tyr-thr-pro-ala-thr(obzl)-gly
DMN38JC	MI	TTVBI8W
DMN38JC	MN	Dopamine transporter (DAT)
DMN38JC	MT	DTT
DMN38JC	MA	Inhibitor
DMN38JC	RN	Development of peptidic dopamine transporter inhibitors via aromatic modification-mediated conformational restriction. J Med Chem. 2006 Jul 13;49(14):4048-51.
DMN38JC	RU	https://pubmed.ncbi.nlm.nih.gov/16821765

DM7EKH3	DI	DM7EKH3
DM7EKH3	DN	Bip-tyr-thr-pro-lys-thr
DM7EKH3	MI	TTVBI8W
DM7EKH3	MN	Dopamine transporter (DAT)
DM7EKH3	MT	DTT
DM7EKH3	MA	Inhibitor
DM7EKH3	RN	Development of peptidic dopamine transporter inhibitors via aromatic modification-mediated conformational restriction. J Med Chem. 2006 Jul 13;49(14):4048-51.
DM7EKH3	RU	https://pubmed.ncbi.nlm.nih.gov/16821765

DMAPX9G	DI	DMAPX9G
DMAPX9G	DN	Bip-tyr-thr-pro-lys-thr(obzl)-gly
DMAPX9G	MI	TTVBI8W
DMAPX9G	MN	Dopamine transporter (DAT)
DMAPX9G	MT	DTT
DMAPX9G	MA	Inhibitor
DMAPX9G	RN	Development of peptidic dopamine transporter inhibitors via aromatic modification-mediated conformational restriction. J Med Chem. 2006 Jul 13;49(14):4048-51.
DMAPX9G	RU	https://pubmed.ncbi.nlm.nih.gov/16821765

DM4CZ5B	DI	DM4CZ5B
DM4CZ5B	DN	Bip-tyr-thr-pro-thr(obzl)-gly
DM4CZ5B	MI	TTVBI8W
DM4CZ5B	MN	Dopamine transporter (DAT)
DM4CZ5B	MT	DTT
DM4CZ5B	MA	Inhibitor
DM4CZ5B	RN	Development of peptidic dopamine transporter inhibitors via aromatic modification-mediated conformational restriction. J Med Chem. 2006 Jul 13;49(14):4048-51.
DM4CZ5B	RU	https://pubmed.ncbi.nlm.nih.gov/16821765

DM0WKNI	DI	DM0WKNI
DM0WKNI	DN	Bis-((-)-N-propargylmorphinan-3-yl) sebacoylate
DM0WKNI	MI	TT27RFC
DM0WKNI	MN	Opioid receptor delta (OPRD1)
DM0WKNI	MT	DTT
DM0WKNI	MA	Inhibitor
DM0WKNI	RN	Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opio... J Med Chem. 2006 Jan 12;49(1):256-62.
DM0WKNI	RU	https://pubmed.ncbi.nlm.nih.gov/16392810

DM0WKNI	DI	DM0WKNI
DM0WKNI	DN	Bis-((-)-N-propargylmorphinan-3-yl) sebacoylate
DM0WKNI	MI	TTQW87Y
DM0WKNI	MN	Opioid receptor kappa (OPRK1)
DM0WKNI	MT	DTT
DM0WKNI	MA	Inhibitor
DM0WKNI	RN	Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opio... J Med Chem. 2006 Jan 12;49(1):256-62.
DM0WKNI	RU	https://pubmed.ncbi.nlm.nih.gov/16392810

DM0WKNI	DI	DM0WKNI
DM0WKNI	DN	Bis-((-)-N-propargylmorphinan-3-yl) sebacoylate
DM0WKNI	MI	TTKWM86
DM0WKNI	MN	Opioid receptor mu (MOP)
DM0WKNI	MT	DTT
DM0WKNI	MA	Inhibitor
DM0WKNI	RN	Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opio... J Med Chem. 2006 Jan 12;49(1):256-62.
DM0WKNI	RU	https://pubmed.ncbi.nlm.nih.gov/16392810

DMWAS4Q	DI	DMWAS4Q
DMWAS4Q	DN	BIS(12)-HUPERZINE B
DMWAS4Q	MI	TT1RS9F
DMWAS4Q	MN	Acetylcholinesterase (AChE)
DMWAS4Q	MT	DTT
DMWAS4Q	MA	Inhibitor
DMWAS4Q	RN	Bis-huperzine B: highly potent and selective acetylcholinesterase inhibitors. J Med Chem. 2005 Feb 10;48(3):655-7.
DMWAS4Q	RU	https://pubmed.ncbi.nlm.nih.gov/15689148

DM58YDV	DI	DM58YDV
DM58YDV	DN	Bis(14)-Huperzine B
DM58YDV	MI	TT1RS9F
DM58YDV	MN	Acetylcholinesterase (AChE)
DM58YDV	MT	DTT
DM58YDV	MA	Inhibitor
DM58YDV	RN	Bis-huperzine B: highly potent and selective acetylcholinesterase inhibitors. J Med Chem. 2005 Feb 10;48(3):655-7.
DM58YDV	RU	https://pubmed.ncbi.nlm.nih.gov/15689148

DMYQM3B	DI	DMYQM3B
DMYQM3B	DN	BIS(16)-HUPERZINE B
DMYQM3B	MI	TT1RS9F
DMYQM3B	MN	Acetylcholinesterase (AChE)
DMYQM3B	MT	DTT
DMYQM3B	MA	Inhibitor
DMYQM3B	RN	Bis-huperzine B: highly potent and selective acetylcholinesterase inhibitors. J Med Chem. 2005 Feb 10;48(3):655-7.
DMYQM3B	RU	https://pubmed.ncbi.nlm.nih.gov/15689148

DM3W1T4	DI	DM3W1T4
DM3W1T4	DN	BIS(18)-HUPERZINE B
DM3W1T4	MI	TT1RS9F
DM3W1T4	MN	Acetylcholinesterase (AChE)
DM3W1T4	MT	DTT
DM3W1T4	MA	Inhibitor
DM3W1T4	RN	Bis-huperzine B: highly potent and selective acetylcholinesterase inhibitors. J Med Chem. 2005 Feb 10;48(3):655-7.
DM3W1T4	RU	https://pubmed.ncbi.nlm.nih.gov/15689148

DMQ7KR1	DI	DMQ7KR1
DMQ7KR1	DN	Bis(2,3-dibromo-4,5-dihydroxyphenyl)ether
DMQ7KR1	MI	TT58ZYW
DMQ7KR1	MN	Mycobacterium Isocitrate lyase (MycB icl)
DMQ7KR1	MT	DTT
DMQ7KR1	MA	Inhibitor
DMQ7KR1	RN	Bromophenols as Candida albicans isocitrate lyase inhibitors. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6644-8.
DMQ7KR1	RU	https://pubmed.ncbi.nlm.nih.gov/20888765

DMEW49T	DI	DMEW49T
DMEW49T	DN	Bis(2,4-dinitrophenyl)sulfane
DMEW49T	MI	TTR7UJ3
DMEW49T	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMEW49T	MT	DTT
DMEW49T	MA	Inhibitor
DMEW49T	RN	Specific inhibitors of Plasmodium falciparum thioredoxin reductase as potential antimalarial agents. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2283-92.
DMEW49T	RU	https://pubmed.ncbi.nlm.nih.gov/16458512

DMHQKCJ	DI	DMHQKCJ
DMHQKCJ	DN	BIS(20)-HUPERZINE B
DMHQKCJ	MI	TT1RS9F
DMHQKCJ	MN	Acetylcholinesterase (AChE)
DMHQKCJ	MT	DTT
DMHQKCJ	MA	Inhibitor
DMHQKCJ	RN	Bis-huperzine B: highly potent and selective acetylcholinesterase inhibitors. J Med Chem. 2005 Feb 10;48(3):655-7.
DMHQKCJ	RU	https://pubmed.ncbi.nlm.nih.gov/15689148

DMKANOH	DI	DMKANOH
DMKANOH	DN	Bis(31/31')[[Cys(31), Nva(34)]NPY(27-36)-NH(2)]
DMKANOH	MI	TTKAPQ1
DMKANOH	MN	Cholecystokinin receptor (CCKR)
DMKANOH	MT	DTT
DMKANOH	MA	Antagonist
DMKANOH	RN	Cholecystokinin receptor antagonist, loxiglumide, inhibits invasiveness of human pancreatic cancer cell lines. FEBS Lett. 1996 Apr 1;383(3):241-4.
DMKANOH	RU	https://pubmed.ncbi.nlm.nih.gov/8925905

DMKANOH	DI	DMKANOH
DMKANOH	DN	Bis(31/31')[[Cys(31), Nva(34)]NPY(27-36)-NH(2)]
DMKANOH	MI	TTCG0AL
DMKANOH	MN	Cholecystokinin receptor type A (CCKAR)
DMKANOH	MT	DTT
DMKANOH	MA	Antagonist
DMKANOH	RN	Role of CCK(A) receptors in postprandial lower esophageal sphincter function in morbidly obese subjects. Dig Dis Sci. 2002 Nov;47(11):2531-7.
DMKANOH	RU	https://pubmed.ncbi.nlm.nih.gov/12452391

DMKANOH	DI	DMKANOH
DMKANOH	DN	Bis(31/31')[[Cys(31), Nva(34)]NPY(27-36)-NH(2)]
DMKANOH	MI	TTY6EWA
DMKANOH	MN	Neuropeptide Y receptor type 5 (NPY5R)
DMKANOH	MT	DTT
DMKANOH	MA	Agonist
DMKANOH	RN	Bis(31/31')[[Cys(31), Nva(34)]NPY(27-36)-NH(2)]: a neuropeptide Y (NPY) Y(5) receptor selective agonist with a latent stimulatory effect on food intake in rats. Peptides. 2002 Aug;23(8):1485-90.
DMKANOH	RU	https://pubmed.ncbi.nlm.nih.gov/12182951

DMUN50H	DI	DMUN50H
DMUN50H	DN	Bis(3-bromo-4,5-dihydroxyphenyl)methanone
DMUN50H	MI	TT58ZYW
DMUN50H	MN	Mycobacterium Isocitrate lyase (MycB icl)
DMUN50H	MT	DTT
DMUN50H	MA	Inhibitor
DMUN50H	RN	Bromophenols as Candida albicans isocitrate lyase inhibitors. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6644-8.
DMUN50H	RU	https://pubmed.ncbi.nlm.nih.gov/20888765

DM784AU	DI	DM784AU
DM784AU	DN	Bis(3-bromophenyl)(4-hydroxy)thiosemicarbazone
DM784AU	MI	TTF2LRI
DM784AU	MN	Cathepsin B (CTSB)
DM784AU	MT	DTT
DM784AU	MA	Inhibitor
DM784AU	RN	Functionalized benzophenone, thiophene, pyridine, and fluorene thiosemicarbazone derivatives as inhibitors of cathepsin L. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6610-5.
DM784AU	RU	https://pubmed.ncbi.nlm.nih.gov/20933415

DM784AU	DI	DM784AU
DM784AU	DN	Bis(3-bromophenyl)(4-hydroxy)thiosemicarbazone
DM784AU	MI	TT36ETB
DM784AU	MN	Cathepsin L (CTSL)
DM784AU	MT	DTT
DM784AU	MA	Inhibitor
DM784AU	RN	Functionalized benzophenone, thiophene, pyridine, and fluorene thiosemicarbazone derivatives as inhibitors of cathepsin L. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6610-5.
DM784AU	RU	https://pubmed.ncbi.nlm.nih.gov/20933415

DMASNGX	DI	DMASNGX
DMASNGX	DN	Bis(3-bromophenyl)(5-hydroxy)thiosemicarbazone
DMASNGX	MI	TT36ETB
DMASNGX	MN	Cathepsin L (CTSL)
DMASNGX	MT	DTT
DMASNGX	MA	Inhibitor
DMASNGX	RN	Functionalized benzophenone, thiophene, pyridine, and fluorene thiosemicarbazone derivatives as inhibitors of cathepsin L. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6610-5.
DMASNGX	RU	https://pubmed.ncbi.nlm.nih.gov/20933415

DMMJ635	DI	DMMJ635
DMMJ635	DN	Bis(3-Fluorophenyl)-ketone]thiosemicarbazone
DMMJ635	MI	TT36ETB
DMMJ635	MN	Cathepsin L (CTSL)
DMMJ635	MT	DTT
DMMJ635	MA	Inhibitor
DMMJ635	RN	Design, synthesis, and biological evaluation of potent thiosemicarbazone based cathepsin L inhibitors. Bioorg Med Chem Lett. 2010 Feb 15;20(4):1415-9.
DMMJ635	RU	https://pubmed.ncbi.nlm.nih.gov/20089402

DMO6HWJ	DI	DMO6HWJ
DMO6HWJ	DN	Bis(4-fluorophenyl)-2-fluorophenylacetamide
DMO6HWJ	MI	TTMNI76
DMO6HWJ	MN	Calcium-activated potassium channel (KCN)
DMO6HWJ	MT	DTT
DMO6HWJ	MA	Inhibitor
DMO6HWJ	RN	Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82.
DMO6HWJ	RU	https://pubmed.ncbi.nlm.nih.gov/18232633

DM36VKH	DI	DM36VKH
DM36VKH	DN	Bis(5-acetoxybenzo[b]furan-2-yl)methanone
DM36VKH	MI	TTGJCWZ
DM36VKH	MN	Fms-like tyrosine kinase 3 (FLT-3)
DM36VKH	MT	DTT
DM36VKH	MA	Inhibitor
DM36VKH	RN	Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorg Med Chem. 2007 Mar 1;15(5):2187-97.
DM36VKH	RU	https://pubmed.ncbi.nlm.nih.gov/17210255

DM36VKH	DI	DM36VKH
DM36VKH	DN	Bis(5-acetoxybenzo[b]furan-2-yl)methanone
DM36VKH	MI	TTI7421
DM36VKH	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM36VKH	MT	DTT
DM36VKH	MA	Inhibitor
DM36VKH	RN	Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorg Med Chem. 2007 Mar 1;15(5):2187-97.
DM36VKH	RU	https://pubmed.ncbi.nlm.nih.gov/17210255

DMHRGTY	DI	DMHRGTY
DMHRGTY	DN	Bis(5-aminobenzo[b]furan-2-yl)methanone
DMHRGTY	MI	TTGJCWZ
DMHRGTY	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMHRGTY	MT	DTT
DMHRGTY	MA	Inhibitor
DMHRGTY	RN	Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorg Med Chem. 2007 Mar 1;15(5):2187-97.
DMHRGTY	RU	https://pubmed.ncbi.nlm.nih.gov/17210255

DMHRGTY	DI	DMHRGTY
DMHRGTY	DN	Bis(5-aminobenzo[b]furan-2-yl)methanone
DMHRGTY	MI	TTI7421
DMHRGTY	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMHRGTY	MT	DTT
DMHRGTY	MA	Inhibitor
DMHRGTY	RN	Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorg Med Chem. 2007 Mar 1;15(5):2187-97.
DMHRGTY	RU	https://pubmed.ncbi.nlm.nih.gov/17210255

DMTSEXB	DI	DMTSEXB
DMTSEXB	DN	Bis-(5-hydroxy-1H-indol-2-yl)-methanone
DMTSEXB	MI	TTGJCWZ
DMTSEXB	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMTSEXB	MT	DTT
DMTSEXB	MA	Inhibitor
DMTSEXB	RN	Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15.
DMTSEXB	RU	https://pubmed.ncbi.nlm.nih.gov/16722630

DMTSEXB	DI	DMTSEXB
DMTSEXB	DN	Bis-(5-hydroxy-1H-indol-2-yl)-methanone
DMTSEXB	MI	TT8FYO9
DMTSEXB	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMTSEXB	MT	DTT
DMTSEXB	MA	Inhibitor
DMTSEXB	RN	Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15.
DMTSEXB	RU	https://pubmed.ncbi.nlm.nih.gov/16722630

DMTSEXB	DI	DMTSEXB
DMTSEXB	DN	Bis-(5-hydroxy-1H-indol-2-yl)-methanone
DMTSEXB	MI	TTI7421
DMTSEXB	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMTSEXB	MT	DTT
DMTSEXB	MA	Inhibitor
DMTSEXB	RN	Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15.
DMTSEXB	RU	https://pubmed.ncbi.nlm.nih.gov/16722630

DMTSEXB	DI	DMTSEXB
DMTSEXB	DN	Bis-(5-hydroxy-1H-indol-2-yl)-methanone
DMTSEXB	MI	TT3PJMV
DMTSEXB	MN	Tyrosine-protein kinase ABL1 (ABL)
DMTSEXB	MT	DTT
DMTSEXB	MA	Inhibitor
DMTSEXB	RN	Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15.
DMTSEXB	RU	https://pubmed.ncbi.nlm.nih.gov/16722630

DMTSEXB	DI	DMTSEXB
DMTSEXB	DN	Bis-(5-hydroxy-1H-indol-2-yl)-methanone
DMTSEXB	MI	TTX41N9
DMTSEXB	MN	Tyrosine-protein kinase Kit (KIT)
DMTSEXB	MT	DTT
DMTSEXB	MA	Inhibitor
DMTSEXB	RN	Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15.
DMTSEXB	RU	https://pubmed.ncbi.nlm.nih.gov/16722630

DMGRKDP	DI	DMGRKDP
DMGRKDP	DN	Bis(5-hydroxybenzo[b]furan-2-yl)methanone
DMGRKDP	MI	TTGJCWZ
DMGRKDP	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMGRKDP	MT	DTT
DMGRKDP	MA	Inhibitor
DMGRKDP	RN	Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorg Med Chem. 2007 Mar 1;15(5):2187-97.
DMGRKDP	RU	https://pubmed.ncbi.nlm.nih.gov/17210255

DMGRKDP	DI	DMGRKDP
DMGRKDP	DN	Bis(5-hydroxybenzo[b]furan-2-yl)methanone
DMGRKDP	MI	TTI7421
DMGRKDP	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMGRKDP	MT	DTT
DMGRKDP	MA	Inhibitor
DMGRKDP	RN	Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorg Med Chem. 2007 Mar 1;15(5):2187-97.
DMGRKDP	RU	https://pubmed.ncbi.nlm.nih.gov/17210255

DM9XC6A	DI	DM9XC6A
DM9XC6A	DN	Bis(5-methoxybenzo[b]furan-2-yl)methanone
DM9XC6A	MI	TTI7421
DM9XC6A	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM9XC6A	MT	DTT
DM9XC6A	MA	Inhibitor
DM9XC6A	RN	Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorg Med Chem. 2007 Mar 1;15(5):2187-97.
DM9XC6A	RU	https://pubmed.ncbi.nlm.nih.gov/17210255

DMQ98H5	DI	DMQ98H5
DMQ98H5	DN	Bis-(5-pyridin-3-yl-thiophen-2-ylmethyl)-amine
DMQ98H5	MI	TTVG215
DMQ98H5	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DMQ98H5	MT	DTT
DMQ98H5	MA	Inhibitor
DMQ98H5	RN	5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6. J Med Chem. 2005 Jan 13;48(1):224-39.
DMQ98H5	RU	https://pubmed.ncbi.nlm.nih.gov/15634016

DMRGNSQ	DI	DMRGNSQ
DMRGNSQ	DN	Bis(6-hydroxybenzo[b]furan-2-yl)methanone
DMRGNSQ	MI	TTGJCWZ
DMRGNSQ	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMRGNSQ	MT	DTT
DMRGNSQ	MA	Inhibitor
DMRGNSQ	RN	Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorg Med Chem. 2007 Mar 1;15(5):2187-97.
DMRGNSQ	RU	https://pubmed.ncbi.nlm.nih.gov/17210255

DMRGNSQ	DI	DMRGNSQ
DMRGNSQ	DN	Bis(6-hydroxybenzo[b]furan-2-yl)methanone
DMRGNSQ	MI	TTI7421
DMRGNSQ	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMRGNSQ	MT	DTT
DMRGNSQ	MA	Inhibitor
DMRGNSQ	RN	Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorg Med Chem. 2007 Mar 1;15(5):2187-97.
DMRGNSQ	RU	https://pubmed.ncbi.nlm.nih.gov/17210255

DMER5GT	DI	DMER5GT
DMER5GT	DN	BIS(8)-HUPERZINE B
DMER5GT	MI	TT1RS9F
DMER5GT	MN	Acetylcholinesterase (AChE)
DMER5GT	MT	DTT
DMER5GT	MA	Inhibitor
DMER5GT	RN	Bis-huperzine B: highly potent and selective acetylcholinesterase inhibitors. J Med Chem. 2005 Feb 10;48(3):655-7.
DMER5GT	RU	https://pubmed.ncbi.nlm.nih.gov/15689148

DM5WFQM	DI	DM5WFQM
DM5WFQM	DN	BIS(9)-HUPERZINE B
DM5WFQM	MI	TT1RS9F
DM5WFQM	MN	Acetylcholinesterase (AChE)
DM5WFQM	MT	DTT
DM5WFQM	MA	Inhibitor
DM5WFQM	RN	Bis-huperzine B: highly potent and selective acetylcholinesterase inhibitors. J Med Chem. 2005 Feb 10;48(3):655-7.
DM5WFQM	RU	https://pubmed.ncbi.nlm.nih.gov/15689148

DMK2ZG4	DI	DMK2ZG4
DMK2ZG4	DN	Bis(benzo[b]furan-2-yl)methanone
DMK2ZG4	MI	TTGJCWZ
DMK2ZG4	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMK2ZG4	MT	DTT
DMK2ZG4	MA	Inhibitor
DMK2ZG4	RN	Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorg Med Chem. 2007 Mar 1;15(5):2187-97.
DMK2ZG4	RU	https://pubmed.ncbi.nlm.nih.gov/17210255

DMK2ZG4	DI	DMK2ZG4
DMK2ZG4	DN	Bis(benzo[b]furan-2-yl)methanone
DMK2ZG4	MI	TTI7421
DMK2ZG4	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMK2ZG4	MT	DTT
DMK2ZG4	MA	Inhibitor
DMK2ZG4	RN	Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorg Med Chem. 2007 Mar 1;15(5):2187-97.
DMK2ZG4	RU	https://pubmed.ncbi.nlm.nih.gov/17210255

DMYSQ2B	DI	DMYSQ2B
DMYSQ2B	DN	Bis-{[R-(-)-apomorphine-2-oxy]ethyl} ether
DMYSQ2B	MI	TTEX248
DMYSQ2B	MN	Dopamine D2 receptor (D2R)
DMYSQ2B	MT	DTT
DMYSQ2B	MA	Inhibitor
DMYSQ2B	RN	Synthesis and neuropharmacological characterization of 2-O-substituted apomorphines. Bioorg Med Chem. 2008 Apr 15;16(8):4563-8.
DMYSQ2B	RU	https://pubmed.ncbi.nlm.nih.gov/18313931

DMVNC1R	DI	DMVNC1R
DMVNC1R	DN	Bis-7-tacrine
DMVNC1R	MI	TT1RS9F
DMVNC1R	MN	Acetylcholinesterase (AChE)
DMVNC1R	MT	DTT
DMVNC1R	MA	Inhibitor
DMVNC1R	RN	Design, synthesis and evaluation of 2,4-disubstituted pyrimidines as cholinesterase inhibitors. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3606-9.
DMVNC1R	RU	https://pubmed.ncbi.nlm.nih.gov/20472431

DMVNC1R	DI	DMVNC1R
DMVNC1R	DN	Bis-7-tacrine
DMVNC1R	MI	TT8JRS7
DMVNC1R	MN	Beta-secretase (BACE)
DMVNC1R	MT	DTT
DMVNC1R	MA	Inhibitor
DMVNC1R	RN	Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds. J Med Chem. 2009 Sep 10;52(17):5365-79.
DMVNC1R	RU	https://pubmed.ncbi.nlm.nih.gov/19663388

DMVNC1R	DI	DMVNC1R
DMVNC1R	DN	Bis-7-tacrine
DMVNC1R	MI	TTEB0GD
DMVNC1R	MN	Cholinesterase (BCHE)
DMVNC1R	MT	DTT
DMVNC1R	MA	Inhibitor
DMVNC1R	RN	Design, synthesis and evaluation of 2,4-disubstituted pyrimidines as cholinesterase inhibitors. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3606-9.
DMVNC1R	RU	https://pubmed.ncbi.nlm.nih.gov/20472431

DMRSKGC	DI	DMRSKGC
DMRSKGC	DN	bisandrographolide
DMRSKGC	MI	TTKP2SU
DMRSKGC	MN	Transient receptor potential cation channel V4 (TRPV4)
DMRSKGC	MT	DTT
DMRSKGC	MA	Activator
DMRSKGC	RN	Bisandrographolide from Andrographis paniculata activates TRPV4 channels. J Biol Chem. 2006 Oct 6;281(40):29897-904.
DMRSKGC	RU	https://pubmed.ncbi.nlm.nih.gov/16899456

DMF4AHD	DI	DMF4AHD
DMF4AHD	DN	Bis-cyclosal-d4TMP
DMF4AHD	MI	TTEB0GD
DMF4AHD	MN	Cholinesterase (BCHE)
DMF4AHD	MT	DTT
DMF4AHD	MA	Inhibitor
DMF4AHD	RN	Bis-cycloSal-d4T-monophosphates: drugs that deliver two molecules of bioactive nucleotides. J Med Chem. 2007 Mar 22;50(6):1335-46.
DMF4AHD	RU	https://pubmed.ncbi.nlm.nih.gov/17328534

DMVRXH3	DI	DMVRXH3
DMVRXH3	DN	Bishydroxy[2h-1-Benzopyran-2-One,1,2-Benzopyrone]
DMVRXH3	MI	TT8XK6L
DMVRXH3	MN	Quinone reductase 1 (NQO1)
DMVRXH3	MT	DTT
DMVRXH3	MA	Inhibitor
DMVRXH3	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMVRXH3	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM0MK6D	DI	DM0MK6D
DM0MK6D	DN	BIS-IMIDE A
DM0MK6D	MI	TTTU902
DM0MK6D	MN	Checkpoint kinase-1 (CHK1)
DM0MK6D	MT	DTT
DM0MK6D	MA	Inhibitor
DM0MK6D	RN	Synthesis, in vitro antiproliferative activities, and Chk1 inhibitory properties of pyrrolo[3,4-a]carbazole-1,3-diones, pyrrolo[3,4-c]carbazole-1,3... Eur J Med Chem. 2008 Feb;43(2):282-92.
DM0MK6D	RU	https://pubmed.ncbi.nlm.nih.gov/17502122

DMOQJZC	DI	DMOQJZC
DMOQJZC	DN	Bisindolylmaleimide-I
DMOQJZC	MI	TTIQSC1
DMOQJZC	MN	Bacterial Lethal factor (Bact lef)
DMOQJZC	MT	DTT
DMOQJZC	MA	Inhibitor
DMOQJZC	RN	Amiodarone and bepridil inhibit anthrax toxin entry into host cells. Antimicrob Agents Chemother. 2007 Jul;51(7):2403-11.
DMOQJZC	RU	https://pubmed.ncbi.nlm.nih.gov/17485504

DMOQJZC	DI	DMOQJZC
DMOQJZC	DN	Bisindolylmaleimide-I
DMOQJZC	MI	TTTU902
DMOQJZC	MN	Checkpoint kinase-1 (CHK1)
DMOQJZC	MT	DTT
DMOQJZC	MA	Inhibitor
DMOQJZC	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMOQJZC	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMOQJZC	DI	DMOQJZC
DMOQJZC	DN	Bisindolylmaleimide-I
DMOQJZC	MI	TTH6V3D
DMOQJZC	MN	Cyclin-dependent kinase 1 (CDK1)
DMOQJZC	MT	DTT
DMOQJZC	MA	Inhibitor
DMOQJZC	RN	Design of new inhibitors for cdc2 kinase based on a multiple pseudosubstrate structure. Bioorg Med Chem Lett. 1998 May 5;8(9):1019-22.
DMOQJZC	RU	https://pubmed.ncbi.nlm.nih.gov/9871700

DMOQJZC	DI	DMOQJZC
DMOQJZC	DN	Bisindolylmaleimide-I
DMOQJZC	MI	TT4TQBX
DMOQJZC	MN	Extracellular signal-regulated kinase 2 (ERK2)
DMOQJZC	MT	DTT
DMOQJZC	MA	Inhibitor
DMOQJZC	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMOQJZC	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMOQJZC	DI	DMOQJZC
DMOQJZC	DN	Bisindolylmaleimide-I
DMOQJZC	MI	TT9P6OW
DMOQJZC	MN	G2/mitotic-specific cyclin B1 (CCNB1)
DMOQJZC	MT	DTT
DMOQJZC	MA	Inhibitor
DMOQJZC	RN	Design of new inhibitors for cdc2 kinase based on a multiple pseudosubstrate structure. Bioorg Med Chem Lett. 1998 May 5;8(9):1019-22.
DMOQJZC	RU	https://pubmed.ncbi.nlm.nih.gov/9871700

DMOQJZC	DI	DMOQJZC
DMOQJZC	DN	Bisindolylmaleimide-I
DMOQJZC	MI	TTRSMW9
DMOQJZC	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMOQJZC	MT	DTT
DMOQJZC	MA	Inhibitor
DMOQJZC	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMOQJZC	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMOQJZC	DI	DMOQJZC
DMOQJZC	DN	Bisindolylmaleimide-I
DMOQJZC	MI	TT860QF
DMOQJZC	MN	LCK tyrosine protein kinase (LCK)
DMOQJZC	MT	DTT
DMOQJZC	MA	Inhibitor
DMOQJZC	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMOQJZC	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMOQJZC	DI	DMOQJZC
DMOQJZC	DN	Bisindolylmaleimide-I
DMOQJZC	MI	TTYT93M
DMOQJZC	MN	MAP kinase p38 (MAPK12)
DMOQJZC	MT	DTT
DMOQJZC	MA	Inhibitor
DMOQJZC	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMOQJZC	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMOQJZC	DI	DMOQJZC
DMOQJZC	DN	Bisindolylmaleimide-I
DMOQJZC	MI	TT7A1BO
DMOQJZC	MN	PKC-delta messenger RNA (PRKCD mRNA)
DMOQJZC	MT	DTT
DMOQJZC	MA	Inhibitor
DMOQJZC	RN	Protein kinase C epsilon regulates gamma-aminobutyrate type A receptor sensitivity to ethanol and benzodiazepines through phosphorylation of gamma2... J Biol Chem. 2007 Nov 9;282(45):33052-63.
DMOQJZC	RU	https://pubmed.ncbi.nlm.nih.gov/17875639

DMOQJZC	DI	DMOQJZC
DMOQJZC	DN	Bisindolylmaleimide-I
DMOQJZC	MI	TT57MT2
DMOQJZC	MN	PKC-epsilon messenger RNA (PRKCE mRNA)
DMOQJZC	MT	DTT
DMOQJZC	MA	Inhibitor
DMOQJZC	RN	Protein kinase C epsilon regulates gamma-aminobutyrate type A receptor sensitivity to ethanol and benzodiazepines through phosphorylation of gamma2... J Biol Chem. 2007 Nov 9;282(45):33052-63.
DMOQJZC	RU	https://pubmed.ncbi.nlm.nih.gov/17875639

DMOQJZC	DI	DMOQJZC
DMOQJZC	DN	Bisindolylmaleimide-I
DMOQJZC	MI	TTYVX59
DMOQJZC	MN	Protein kinase C (PRKC)
DMOQJZC	MT	DTT
DMOQJZC	MA	Inhibitor
DMOQJZC	RN	Protein kinase epsilon dampens the secretory response of model intestinal epithelia during ischemia. Surgery. 2001 Aug;130(2):310-8.
DMOQJZC	RU	https://pubmed.ncbi.nlm.nih.gov/11490365

DMOQJZC	DI	DMOQJZC
DMOQJZC	DN	Bisindolylmaleimide-I
DMOQJZC	MI	TTRFOXJ
DMOQJZC	MN	Protein kinase C gamma (PRKCG)
DMOQJZC	MT	DTT
DMOQJZC	MA	Inhibitor
DMOQJZC	RN	Protein kinase C epsilon regulates gamma-aminobutyrate type A receptor sensitivity to ethanol and benzodiazepines through phosphorylation of gamma2... J Biol Chem. 2007 Nov 9;282(45):33052-63.
DMOQJZC	RU	https://pubmed.ncbi.nlm.nih.gov/17875639

DMOQJZC	DI	DMOQJZC
DMOQJZC	DN	Bisindolylmaleimide-I
DMOQJZC	MI	TTUWGRA
DMOQJZC	MN	Protein kinase C zeta (PRKCZ)
DMOQJZC	MT	DTT
DMOQJZC	MA	Inhibitor
DMOQJZC	RN	Protein kinase C zeta isoform is critical for proliferation in human glioblastoma cell lines. J Neurooncol. 2000 Apr;47(2):109-15.
DMOQJZC	RU	https://pubmed.ncbi.nlm.nih.gov/10982151

DMOQJZC	DI	DMOQJZC
DMOQJZC	DN	Bisindolylmaleimide-I
DMOQJZC	MI	TTWTSCV
DMOQJZC	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DMOQJZC	MT	DTT
DMOQJZC	MA	Inhibitor
DMOQJZC	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMOQJZC	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMOQJZC	DI	DMOQJZC
DMOQJZC	DN	Bisindolylmaleimide-I
DMOQJZC	MI	TTZN7RP
DMOQJZC	MN	Rho-associated protein kinase 1 (ROCK1)
DMOQJZC	MT	DTT
DMOQJZC	MA	Inhibitor
DMOQJZC	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMOQJZC	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMOQJZC	DI	DMOQJZC
DMOQJZC	DN	Bisindolylmaleimide-I
DMOQJZC	MI	TTTV8EJ
DMOQJZC	MN	Serine/threonine-protein kinase Sgk1 (SGK1)
DMOQJZC	MT	DTT
DMOQJZC	MA	Inhibitor
DMOQJZC	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMOQJZC	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMOQJZC	DI	DMOQJZC
DMOQJZC	DN	Bisindolylmaleimide-I
DMOQJZC	MI	TTQBR95
DMOQJZC	MN	Stress-activated protein kinase 2a (p38 alpha)
DMOQJZC	MT	DTT
DMOQJZC	MA	Inhibitor
DMOQJZC	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMOQJZC	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMOQJZC	DI	DMOQJZC
DMOQJZC	DN	Bisindolylmaleimide-I
DMOQJZC	MI	TT73U6C
DMOQJZC	MN	Stress-activated protein kinase 2b (p38 beta)
DMOQJZC	MT	DTT
DMOQJZC	MA	Inhibitor
DMOQJZC	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMOQJZC	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMOQJZC	DI	DMOQJZC
DMOQJZC	DN	Bisindolylmaleimide-I
DMOQJZC	MI	TT0K6EO
DMOQJZC	MN	Stress-activated protein kinase JNK1 (JNK1)
DMOQJZC	MT	DTT
DMOQJZC	MA	Inhibitor
DMOQJZC	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMOQJZC	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DM0K6QH	DI	DM0K6QH
DM0K6QH	DN	Bis-Napthyl Beta-Ketophosphonic Acid
DM0K6QH	MI	TTQAJF1
DM0K6QH	MN	Cathepsin G (CTSG)
DM0K6QH	MT	DTT
DM0K6QH	MA	Inhibitor
DM0K6QH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM0K6QH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM2ZLD7	DI	DM2ZLD7
DM2ZLD7	DN	Bisphenol A
DM2ZLD7	MI	TTKPW01
DM2ZLD7	MN	Androgen receptor messenger RNA (AR mRNA)
DM2ZLD7	MT	DTT
DM2ZLD7	MA	Antagonist
DM2ZLD7	RN	Structure-activity relationships of bisphenol A analogs at estrogen receptors (ERs): discovery of an ERalpha-selective antagonist. Bioorg Med Chem Lett. 2013 Jul 15;23(14):4031-6.
DM2ZLD7	RU	https://pubmed.ncbi.nlm.nih.gov/23768907

DM2ZLD7	DI	DM2ZLD7
DM2ZLD7	DN	Bisphenol A
DM2ZLD7	MI	TTOM3J0
DM2ZLD7	MN	Estrogen receptor beta (ESR2)
DM2ZLD7	MT	DTT
DM2ZLD7	MA	Agonist
DM2ZLD7	RN	Structure-activity relationships of bisphenol A analogs at estrogen receptors (ERs): discovery of an ERalpha-selective antagonist. Bioorg Med Chem Lett. 2013 Jul 15;23(14):4031-6.
DM2ZLD7	RU	https://pubmed.ncbi.nlm.nih.gov/23768907

DM2ZLD7	DI	DM2ZLD7
DM2ZLD7	DN	Bisphenol A
DM2ZLD7	MI	DE0P6LK
DM2ZLD7	MN	Sulfotransferase 2A1 (SULT2A1)
DM2ZLD7	MT	DME
DM2ZLD7	MA	Metabolism
DM2ZLD7	RN	Sulfation of environmental estrogens by cytosolic human sulfotransferases. Drug Metab Pharmacokinet. 2002;17(3):221-8.
DM2ZLD7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15618673

DMFHY04	DI	DMFHY04
DMFHY04	DN	BIX 02188
DMFHY04	MI	TTV3O87
DMFHY04	MN	ERK activator kinase 5 (MAP2K5)
DMFHY04	MT	DTT
DMFHY04	MA	Inhibitor
DMFHY04	RN	Identification of pharmacological inhibitors of the MEK5/ERK5 pathway. Biochem Biophys Res Commun. 2008 Dec 5;377(1):120-5.
DMFHY04	RU	https://pubmed.ncbi.nlm.nih.gov/18834865

DMNAX1Q	DI	DMNAX1Q
DMNAX1Q	DN	BIX 02565
DMNAX1Q	MI	TTUM2ZR
DMNAX1Q	MN	Ribosomal protein S6 kinase alpha-3 (RSK3)
DMNAX1Q	MT	DTT
DMNAX1Q	MA	Inhibitor
DMNAX1Q	RN	Indole RSK inhibitors. Part 2: optimization of cell potency and kinase selectivity. Bioorg Med Chem Lett. 2012 Jan 1;22(1):738-42.
DMNAX1Q	RU	https://pubmed.ncbi.nlm.nih.gov/22056746

DMGULNZ	DI	DMGULNZ
DMGULNZ	DN	BL-5040
DMGULNZ	MI	TT0HD6V
DMGULNZ	MN	Leptin receptor (LEPR)
DMGULNZ	MT	DTT
DMGULNZ	MA	Antagonist
DMGULNZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1712).
DMGULNZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1712

DMQLJMC	DI	DMQLJMC
DMQLJMC	DN	BL-6020
DMQLJMC	MI	TTD0CIQ
DMQLJMC	MN	Melanocortin receptor 4 (MC4R)
DMQLJMC	MT	DTT
DMQLJMC	MA	Antagonist
DMQLJMC	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 285).
DMQLJMC	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=285

DMBRZ4P	DI	DMBRZ4P
DMBRZ4P	DN	BLV-0703
DMBRZ4P	MI	TTS87KH
DMBRZ4P	MN	Microtubule-associated protein tau (MAPT)
DMBRZ4P	MT	DTT
DMBRZ4P	MA	Modulator
DMBRZ4P	RN	Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des. 2011;17(31):3413-7.
DMBRZ4P	RU	https://pubmed.ncbi.nlm.nih.gov/21902667

DMGB9PN	DI	DMGB9PN
DMGB9PN	DN	BLV-0801
DMGB9PN	MI	TTZJYKH
DMGB9PN	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMGB9PN	MT	DTT
DMGB9PN	MA	Inhibitor
DMGB9PN	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2829).
DMGB9PN	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2829

DM728RW	DI	DM728RW
DM728RW	DN	BLX-301
DM728RW	MI	TTUE541
DM728RW	MN	Leukocyte surface antigen Leu-16 (CD20)
DM728RW	MT	DTT
DM728RW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628).
DM728RW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2628

DMDNPML	DI	DMDNPML
DMDNPML	DN	BM-162115
DMDNPML	MI	TT9V5JH
DMDNPML	MN	Phospholipase A2 (PLA2G1B)
DMDNPML	MT	DTT
DMDNPML	MA	Inhibitor
DMDNPML	RN	Investigation on the effect of experimental phospholipase A2 inhibitors on the formyl-methionyl-leucyl-phenylalanine-stimulated chemotaxis of human leukocytes in vitro. Arzneimittelforschung. 1998 Jan;48(1):77-81.
DMDNPML	RU	https://pubmed.ncbi.nlm.nih.gov/9522038

DMD2H7L	DI	DMD2H7L
DMD2H7L	DN	BM-573
DMD2H7L	MI	TT2O84V
DMD2H7L	MN	Thromboxane A2 receptor (TBXA2R)
DMD2H7L	MT	DTT
DMD2H7L	MA	Inhibitor
DMD2H7L	RN	Synthesis and pharmacological evaluation of novel nitrobenzenic thromboxane modulators as antiplatelet agents acting on both the alpha and beta iso... J Med Chem. 2006 Jun 15;49(12):3701-9.
DMD2H7L	RU	https://pubmed.ncbi.nlm.nih.gov/16759113

DM8AEQX	DI	DM8AEQX
DM8AEQX	DN	Bmab-200
DM8AEQX	MI	TTGKNB4
DM8AEQX	MN	Epidermal growth factor receptor (EGFR)
DM8AEQX	MT	DTT
DM8AEQX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
DM8AEQX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797

DMER2WS	DI	DMER2WS
DMER2WS	DN	BML3-C01
DMER2WS	MI	DE073H6
DMER2WS	MN	Prostaglandin G/H synthase 1 (COX-1)
DMER2WS	MT	DME
DMER2WS	MA	Metabolism
DMER2WS	RN	Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. FASEB J. 2006 Jun;20(8):1097-108.
DMER2WS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16770009

DMER2WS	DI	DMER2WS
DMER2WS	DN	BML3-C01
DMER2WS	MI	DE492CE
DMER2WS	MN	Prostaglandin G/H synthase 2 (COX-2)
DMER2WS	MT	DME
DMER2WS	MA	Metabolism
DMER2WS	RN	Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. FASEB J. 2006 Jun;20(8):1097-108.
DMER2WS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16770009

DMYWEO6	DI	DMYWEO6
DMYWEO6	DN	BMN-103
DMYWEO6	MI	TTXWASR
DMYWEO6	MN	Intestinal maltase-glucoamylase (MGAM)
DMYWEO6	MT	DTT
DMYWEO6	MA	Modulator
DMYWEO6	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2627).
DMYWEO6	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2627

DM0VMZ4	DI	DM0VMZ4
DM0VMZ4	DN	BMN-168
DM0VMZ4	MI	TTGSVH2
DM0VMZ4	MN	Phenylalanine hydroxylase (PAH)
DM0VMZ4	MT	DTT
DM0VMZ4	MA	Modulator
DM0VMZ4	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1240).
DM0VMZ4	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1240

DMR82WI	DI	DMR82WI
DMR82WI	DN	BMS compound 4c
DMR82WI	MI	TTA93TL
DMR82WI	MN	P2Y purinoceptor 1 (P2RY1)
DMR82WI	MT	DTT
DMR82WI	MA	Antagonist
DMR82WI	RN	New azole antagonists with high affinity for the P2Y(1) receptor. Bioorg Med Chem Lett. 2013 Jun 15;23(12):3519-22.
DMR82WI	RU	https://pubmed.ncbi.nlm.nih.gov/23668989

DMJM8OQ	DI	DMJM8OQ
DMJM8OQ	DN	BMS pyrazole inhibitor 7f
DMJM8OQ	MI	TTIZQFJ
DMJM8OQ	MN	Histone-arginine methyltransferase CARM1 (CARM1)
DMJM8OQ	MT	DTT
DMJM8OQ	MA	Inhibitor
DMJM8OQ	RN	Optimization of pyrazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1). Bioorg Med Chem Lett. 2009 Jun 1;19(11):2924-7.
DMJM8OQ	RU	https://pubmed.ncbi.nlm.nih.gov/19419866

DM4D6ZB	DI	DM4D6ZB
DM4D6ZB	DN	BMS-1
DM4D6ZB	MI	TTDP1UC
DM4D6ZB	MN	Fatty acid amide hydrolase (FAAH)
DM4D6ZB	MT	DTT
DM4D6ZB	MA	Inhibitor
DM4D6ZB	RN	Synthesis and evaluation of benzothiazole-based analogues as novel, potent, and selective fatty acid amide hydrolase inhibitors. J Med Chem. 2009 Jan 8;52(1):170-80.
DM4D6ZB	RU	https://pubmed.ncbi.nlm.nih.gov/19072118

DMGE82R	DI	DMGE82R
DMGE82R	DN	BMS184394
DMGE82R	MI	TT1Q3IE
DMGE82R	MN	Retinoic acid receptor gamma (RARG)
DMGE82R	MT	DTT
DMGE82R	MA	Inhibitor
DMGE82R	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMGE82R	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMJ218E	DI	DMJ218E
DMJ218E	DN	BMS-187308
DMJ218E	MI	TTKRD0G
DMJ218E	MN	Endothelin A receptor (EDNRA)
DMJ218E	MT	DTT
DMJ218E	MA	Modulator
DMJ218E	RN	Biphenylsulfonamide endothelin antagonists: structure-activity relationships of a series of mono- and disubstituted analogues and pharmacology of t... J Med Chem. 1998 Dec 17;41(26):5198-218.
DMJ218E	RU	https://www.ncbi.nlm.nih.gov/pubmed/9857090

DM7GUDC	DI	DM7GUDC
DM7GUDC	DN	BMS-189323
DM7GUDC	MI	TTRK9JT
DM7GUDC	MN	Neuropeptide Y receptor type 1 (NPY1R)
DM7GUDC	MT	DTT
DM7GUDC	MA	Inhibitor
DM7GUDC	RN	Isosteric N-arylpiperazine replacements in a series of dihydropyridine NPY1 receptor antagonists. Bioorg Med Chem Lett. 2004 Dec 20;14(24):5975-8.
DM7GUDC	RU	https://pubmed.ncbi.nlm.nih.gov/15546711

DM1ZBU3	DI	DM1ZBU3
DM1ZBU3	DN	BMS-193885
DM1ZBU3	MI	TTRK9JT
DM1ZBU3	MN	Neuropeptide Y receptor type 1 (NPY1R)
DM1ZBU3	MT	DTT
DM1ZBU3	MA	Antagonist
DM1ZBU3	RN	Dihydropyridine neuropeptide Y Y(1) receptor antagonists. Bioorg Med Chem Lett. 2002 Feb 11;12(3):379-82.
DM1ZBU3	RU	https://pubmed.ncbi.nlm.nih.gov/11814801

DM5SNMQ	DI	DM5SNMQ
DM5SNMQ	DN	BMS-245782
DM5SNMQ	MI	TTRK9JT
DM5SNMQ	MN	Neuropeptide Y receptor type 1 (NPY1R)
DM5SNMQ	MT	DTT
DM5SNMQ	MA	Inhibitor
DM5SNMQ	RN	Isosteric N-arylpiperazine replacements in a series of dihydropyridine NPY1 receptor antagonists. Bioorg Med Chem Lett. 2004 Dec 20;14(24):5975-8.
DM5SNMQ	RU	https://pubmed.ncbi.nlm.nih.gov/15546711

DMETNA3	DI	DMETNA3
DMETNA3	DN	BMS-262084
DMETNA3	MI	TTNWD8O
DMETNA3	MN	Delta-tryptase (TPSD1)
DMETNA3	MT	DTT
DMETNA3	MA	Inhibitor
DMETNA3	RN	Synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors. Bioorg Med Chem Lett. 2002 Nov 4;12(21):3229-33.
DMETNA3	RU	https://pubmed.ncbi.nlm.nih.gov/12372540

DMETNA3	DI	DMETNA3
DMETNA3	DN	BMS-262084
DMETNA3	MI	TTM1TDX
DMETNA3	MN	Tryptase alpha/beta-1 (Tryptase)
DMETNA3	MT	DTT
DMETNA3	MA	Inhibitor
DMETNA3	RN	Synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors. Bioorg Med Chem Lett. 2002 Nov 4;12(21):3229-33.
DMETNA3	RU	https://pubmed.ncbi.nlm.nih.gov/12372540

DM6LPIG	DI	DM6LPIG
DM6LPIG	DN	BMS-265246
DM6LPIG	MI	TTH6V3D
DM6LPIG	MN	Cyclin-dependent kinase 1 (CDK1)
DM6LPIG	MT	DTT
DM6LPIG	MA	Inhibitor
DM6LPIG	RN	A robust high-content imaging approach for probing the mechanism of action and phenotypic outcomes of cell-cycle modulators. Mol Cancer Ther. 2011 Feb;10(2):242-54.
DM6LPIG	RU	https://pubmed.ncbi.nlm.nih.gov/21216932

DM6LPIG	DI	DM6LPIG
DM6LPIG	DN	BMS-265246
DM6LPIG	MI	TT7HF4W
DM6LPIG	MN	Cyclin-dependent kinase 2 (CDK2)
DM6LPIG	MT	DTT
DM6LPIG	MA	Inhibitor
DM6LPIG	RN	A robust high-content imaging approach for probing the mechanism of action and phenotypic outcomes of cell-cycle modulators. Mol Cancer Ther. 2011 Feb;10(2):242-54.
DM6LPIG	RU	https://pubmed.ncbi.nlm.nih.gov/21216932

DMZLE0U	DI	DMZLE0U
DMZLE0U	DN	BMS-269223
DMZLE0U	MI	TTCIHJA
DMZLE0U	MN	Coagulation factor Xa (F10)
DMZLE0U	MT	DTT
DMZLE0U	MA	Inhibitor
DMZLE0U	RN	Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6882-9.
DMZLE0U	RU	https://pubmed.ncbi.nlm.nih.gov/19896847

DM82SJP	DI	DM82SJP
DM82SJP	DN	BMS270394
DM82SJP	MI	TT1Q3IE
DM82SJP	MN	Retinoic acid receptor gamma (RARG)
DM82SJP	MT	DTT
DM82SJP	MA	Agonist
DM82SJP	RN	Enantiomer discrimination illustrated by high-resolution crystal structures of the human nuclear receptor hRARgamma. Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6322-7.
DM82SJP	RU	https://pubmed.ncbi.nlm.nih.gov/10841540

DMOLCFQ	DI	DMOLCFQ
DMOLCFQ	DN	BMS-279700
DMOLCFQ	MI	TT6PKBN
DMOLCFQ	MN	Proto-oncogene c-Src (SRC)
DMOLCFQ	MT	DTT
DMOLCFQ	MA	Inhibitor
DMOLCFQ	RN	Synthesis and c-Src inhibitory activity of imidazo[1,5-a]pyrazine derivatives as an agent for treatment of acute ischemic stroke. Bioorg Med Chem. 2007 Jan 15;15(2):868-85.
DMOLCFQ	RU	https://pubmed.ncbi.nlm.nih.gov/17095233

DM21CYI	DI	DM21CYI
DM21CYI	DN	BMS-316810
DM21CYI	MI	TT7WZIJ
DM21CYI	MN	CAAX farnesyltransferase beta (FNTB)
DM21CYI	MT	DTT
DM21CYI	MA	Inhibitor
DM21CYI	RN	Design, synthesis, and structure-activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors. Bioorg Med Chem Lett. 2005 Apr 1;15(7):1895-9.
DM21CYI	RU	https://pubmed.ncbi.nlm.nih.gov/15780629

DM9WRUG	DI	DM9WRUG
DM9WRUG	DN	BMS-344577
DM9WRUG	MI	TT6L509
DM9WRUG	MN	Coagulation factor IIa (F2)
DM9WRUG	MT	DTT
DM9WRUG	MA	Inhibitor
DM9WRUG	RN	Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6882-9.
DM9WRUG	RU	https://pubmed.ncbi.nlm.nih.gov/19896847

DM9WRUG	DI	DM9WRUG
DM9WRUG	DN	BMS-344577
DM9WRUG	MI	TTCIHJA
DM9WRUG	MN	Coagulation factor Xa (F10)
DM9WRUG	MT	DTT
DM9WRUG	MA	Inhibitor
DM9WRUG	RN	Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6882-9.
DM9WRUG	RU	https://pubmed.ncbi.nlm.nih.gov/19896847

DM9WRUG	DI	DM9WRUG
DM9WRUG	DN	BMS-344577
DM9WRUG	MI	TTXAGYU
DM9WRUG	MN	Tissue-type plasminogen activator (PLAT)
DM9WRUG	MT	DTT
DM9WRUG	MA	Inhibitor
DM9WRUG	RN	Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6882-9.
DM9WRUG	RU	https://pubmed.ncbi.nlm.nih.gov/19896847

DM7D519	DI	DM7D519
DM7D519	DN	BMS-345541
DM7D519	MI	TTRPDBG
DM7D519	MN	Inhibitor of nuclear factor kappa-B kinase (IKK)
DM7D519	MT	DTT
DM7D519	MA	Inhibitor
DM7D519	RN	A highly selective inhibitor of I kappa B kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice. Arthritis Rheum. 2003 Sep;48(9):2652-9.
DM7D519	RU	https://pubmed.ncbi.nlm.nih.gov/13130486

DM1ZDFG	DI	DM1ZDFG
DM1ZDFG	DN	BMS-404683
DM1ZDFG	MI	TT7WZIJ
DM1ZDFG	MN	CAAX farnesyltransferase beta (FNTB)
DM1ZDFG	MT	DTT
DM1ZDFG	MA	Inhibitor
DM1ZDFG	RN	Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. J Med Chem. 2005 Jun 2;48(11):3704-13.
DM1ZDFG	RU	https://pubmed.ncbi.nlm.nih.gov/15916422

DM1ZDFG	DI	DM1ZDFG
DM1ZDFG	DN	BMS-404683
DM1ZDFG	MI	TTXQKM3
DM1ZDFG	MN	Farnesyl protein transferase (Ftase)
DM1ZDFG	MT	DTT
DM1ZDFG	MA	Inhibitor
DM1ZDFG	RN	Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. J Med Chem. 2005 Jun 2;48(11):3704-13.
DM1ZDFG	RU	https://pubmed.ncbi.nlm.nih.gov/15916422

DMTPNI4	DI	DMTPNI4
DMTPNI4	DN	BMS-480404
DMTPNI4	MI	TTHWMFZ
DMTPNI4	MN	Fatty acid-binding protein 4 (FABP4)
DMTPNI4	MT	DTT
DMTPNI4	MA	Inhibitor
DMTPNI4	RN	NMR structure of a potent small molecule inhibitor bound to human keratinocyte fatty acid-binding protein. J Med Chem. 2006 Aug 10;49(16):5013-7.
DMTPNI4	RU	https://pubmed.ncbi.nlm.nih.gov/16884313

DMTPNI4	DI	DMTPNI4
DMTPNI4	DN	BMS-480404
DMTPNI4	MI	TTNT2S6
DMTPNI4	MN	Fatty acid-binding protein 5 (FABP5)
DMTPNI4	MT	DTT
DMTPNI4	MA	Inhibitor
DMTPNI4	RN	NMR structure of a potent small molecule inhibitor bound to human keratinocyte fatty acid-binding protein. J Med Chem. 2006 Aug 10;49(16):5013-7.
DMTPNI4	RU	https://pubmed.ncbi.nlm.nih.gov/16884313

DM6Y1QF	DI	DM6Y1QF
DM6Y1QF	DN	BMS-488516
DM6Y1QF	MI	TT3C80U
DM6Y1QF	MN	T-cell-specific kinase (ITK)
DM6Y1QF	MT	DTT
DM6Y1QF	MA	Inhibitor
DM6Y1QF	RN	Treatment of depersonalization with serotonin reuptake blockers. J Clin Psychopharmacol. 1990 Jun;10(3):200-3.
DM6Y1QF	RU	https://pubmed.ncbi.nlm.nih.gov/2115893

DMGH1LX	DI	DMGH1LX
DMGH1LX	DN	BMS-509744
DMGH1LX	MI	TT3C80U
DMGH1LX	MN	T-cell-specific kinase (ITK)
DMGH1LX	MT	DTT
DMGH1LX	MA	Inhibitor
DMGH1LX	RN	Treatment of depersonalization with serotonin reuptake blockers. J Clin Psychopharmacol. 1990 Jun;10(3):200-3.
DMGH1LX	RU	https://pubmed.ncbi.nlm.nih.gov/2115893

DMAY9TM	DI	DMAY9TM
DMAY9TM	DN	BMS-520
DMAY9TM	MI	TT9JZCK
DMAY9TM	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMAY9TM	MT	DTT
DMAY9TM	MA	Agonist
DMAY9TM	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 275).
DMAY9TM	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=275

DMXJB4N	DI	DMXJB4N
DMXJB4N	DN	BMS-536924
DMXJB4N	MI	TTXV4FI
DMXJB4N	MN	Albendazole monooxygenase (CYP3A4)
DMXJB4N	MT	DTT
DMXJB4N	MA	Inhibitor
DMXJB4N	RN	Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)py... J Med Chem. 2008 Oct 9;51(19):5897-900.
DMXJB4N	RU	https://pubmed.ncbi.nlm.nih.gov/18763755

DMXJB4N	DI	DMXJB4N
DMXJB4N	DN	BMS-536924
DMXJB4N	MI	TT7HF4W
DMXJB4N	MN	Cyclin-dependent kinase 2 (CDK2)
DMXJB4N	MT	DTT
DMXJB4N	MA	Inhibitor
DMXJB4N	RN	Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
DMXJB4N	RU	https://pubmed.ncbi.nlm.nih.gov/16134929

DMXJB4N	DI	DMXJB4N
DMXJB4N	DN	BMS-536924
DMXJB4N	MI	TTR5TV4
DMXJB4N	MN	ERBB2 messenger RNA (HER2 mRNA)
DMXJB4N	MT	DTT
DMXJB4N	MA	Inhibitor
DMXJB4N	RN	Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
DMXJB4N	RU	https://pubmed.ncbi.nlm.nih.gov/16134929

DMXJB4N	DI	DMXJB4N
DMXJB4N	DN	BMS-536924
DMXJB4N	MI	TT4TQBX
DMXJB4N	MN	Extracellular signal-regulated kinase 2 (ERK2)
DMXJB4N	MT	DTT
DMXJB4N	MA	Inhibitor
DMXJB4N	RN	Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
DMXJB4N	RU	https://pubmed.ncbi.nlm.nih.gov/16134929

DMXJB4N	DI	DMXJB4N
DMXJB4N	DN	BMS-536924
DMXJB4N	MI	TTON5IT
DMXJB4N	MN	Focal adhesion kinase 1 (FAK)
DMXJB4N	MT	DTT
DMXJB4N	MA	Inhibitor
DMXJB4N	RN	Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
DMXJB4N	RU	https://pubmed.ncbi.nlm.nih.gov/16134929

DMXJB4N	DI	DMXJB4N
DMXJB4N	DN	BMS-536924
DMXJB4N	MI	TTCEJ4F
DMXJB4N	MN	G1/S-specific cyclin-E1 (CCNE1)
DMXJB4N	MT	DTT
DMXJB4N	MA	Inhibitor
DMXJB4N	RN	Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
DMXJB4N	RU	https://pubmed.ncbi.nlm.nih.gov/16134929

DMXJB4N	DI	DMXJB4N
DMXJB4N	DN	BMS-536924
DMXJB4N	MI	TTHRID2
DMXJB4N	MN	Insulin-like growth factor I receptor (IGF1R)
DMXJB4N	MT	DTT
DMXJB4N	MA	Inhibitor
DMXJB4N	RN	SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1744-8.
DMXJB4N	RU	https://pubmed.ncbi.nlm.nih.gov/20153189

DMXJB4N	DI	DMXJB4N
DMXJB4N	DN	BMS-536924
DMXJB4N	MI	TT860QF
DMXJB4N	MN	LCK tyrosine protein kinase (LCK)
DMXJB4N	MT	DTT
DMXJB4N	MA	Inhibitor
DMXJB4N	RN	Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
DMXJB4N	RU	https://pubmed.ncbi.nlm.nih.gov/16134929

DMXJB4N	DI	DMXJB4N
DMXJB4N	DN	BMS-536924
DMXJB4N	MI	TT8FYO9
DMXJB4N	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMXJB4N	MT	DTT
DMXJB4N	MA	Inhibitor
DMXJB4N	RN	Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
DMXJB4N	RU	https://pubmed.ncbi.nlm.nih.gov/16134929

DMXJB4N	DI	DMXJB4N
DMXJB4N	DN	BMS-536924
DMXJB4N	MI	TTI7421
DMXJB4N	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMXJB4N	MT	DTT
DMXJB4N	MA	Inhibitor
DMXJB4N	RN	Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
DMXJB4N	RU	https://pubmed.ncbi.nlm.nih.gov/16134929

DMXJB4N	DI	DMXJB4N
DMXJB4N	DN	BMS-536924
DMXJB4N	MI	TTNDSF4
DMXJB4N	MN	Proto-oncogene c-Met (MET)
DMXJB4N	MT	DTT
DMXJB4N	MA	Inhibitor
DMXJB4N	RN	Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
DMXJB4N	RU	https://pubmed.ncbi.nlm.nih.gov/16134929

DMXJB4N	DI	DMXJB4N
DMXJB4N	DN	BMS-536924
DMXJB4N	MI	TTWTSCV
DMXJB4N	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DMXJB4N	MT	DTT
DMXJB4N	MA	Inhibitor
DMXJB4N	RN	Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
DMXJB4N	RU	https://pubmed.ncbi.nlm.nih.gov/16134929

DMXJB4N	DI	DMXJB4N
DMXJB4N	DN	BMS-536924
DMXJB4N	MI	TTUTJGQ
DMXJB4N	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMXJB4N	MT	DTT
DMXJB4N	MA	Inhibitor
DMXJB4N	RN	Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
DMXJB4N	RU	https://pubmed.ncbi.nlm.nih.gov/16134929

DM3WBKN	DI	DM3WBKN
DM3WBKN	DN	BMS-561388
DM3WBKN	MI	TT7EFHR
DM3WBKN	MN	Corticotropin-releasing factor receptor 1 (CRHR1)
DM3WBKN	MT	DTT
DM3WBKN	MA	Inhibitor
DM3WBKN	RN	8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonists. J Med Chem. 2009 May 14;52(9):3073-83.
DM3WBKN	RU	https://pubmed.ncbi.nlm.nih.gov/19361210

DMILMHZ	DI	DMILMHZ
DMILMHZ	DN	BMS-564929
DMILMHZ	MI	TTKPW01
DMILMHZ	MN	Androgen receptor messenger RNA (AR mRNA)
DMILMHZ	MT	DTT
DMILMHZ	MA	Inhibitor
DMILMHZ	RN	N-aryl-oxazolidin-2-imine muscle selective androgen receptor modulators enhance potency through pharmacophore reorientation. J Med Chem. 2009 May 14;52(9):2794-8.
DMILMHZ	RU	https://pubmed.ncbi.nlm.nih.gov/19351168

DMZWNO9	DI	DMZWNO9
DMZWNO9	DN	BMS614
DMZWNO9	MI	TTW38KT
DMZWNO9	MN	Retinoic acid receptor alpha (RARA)
DMZWNO9	MT	DTT
DMZWNO9	MA	Antagonist
DMZWNO9	RN	Co-regulator recruitment and the mechanism of retinoic acid receptor synergy. Nature. 2002 Jan 10;415(6868):187-92.
DMZWNO9	RU	https://pubmed.ncbi.nlm.nih.gov/11805839

DMRT7G3	DI	DMRT7G3
DMRT7G3	DN	BMS641
DMRT7G3	MI	TTISP28
DMRT7G3	MN	Retinoic acid receptor beta (RARB)
DMRT7G3	MT	DTT
DMRT7G3	MA	Agonist
DMRT7G3	RN	Rational design of RAR-selective ligands revealed by RARbeta crystal stucture. EMBO Rep. 2004 Sep;5(9):877-82.
DMRT7G3	RU	https://pubmed.ncbi.nlm.nih.gov/15319780

DMBTMO9	DI	DMBTMO9
DMBTMO9	DN	BMS-645737
DMBTMO9	MI	TTUTJGQ
DMBTMO9	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMBTMO9	MT	DTT
DMBTMO9	MA	Inhibitor
DMBTMO9	RN	Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]t... Bioorg Med Chem Lett. 2008 May 1;18(9):2985-9.
DMBTMO9	RU	https://pubmed.ncbi.nlm.nih.gov/18395443

DMBTMO9	DI	DMBTMO9
DMBTMO9	DN	BMS-645737
DMBTMO9	MI	TTQ6VDM
DMBTMO9	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMBTMO9	MT	DTT
DMBTMO9	MA	Inhibitor
DMBTMO9	RN	Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]t... Bioorg Med Chem Lett. 2008 May 1;18(9):2985-9.
DMBTMO9	RU	https://pubmed.ncbi.nlm.nih.gov/18395443

DMYAPG5	DI	DMYAPG5
DMYAPG5	DN	BMS-687453
DMYAPG5	MI	TTJ584C
DMYAPG5	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMYAPG5	MT	DTT
DMYAPG5	MA	Inhibitor
DMYAPG5	RN	Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol... J Med Chem. 2010 Apr 8;53(7):2854-64.
DMYAPG5	RU	https://pubmed.ncbi.nlm.nih.gov/20218621

DM8PA3U	DI	DM8PA3U
DM8PA3U	DN	BMS-694153
DM8PA3U	MI	TTY6O0Q
DM8PA3U	MN	Calcitonin gene-related peptide receptor (CGRPR)
DM8PA3U	MT	DTT
DM8PA3U	MA	Inhibitor
DM8PA3U	RN	Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan... J Med Chem. 2008 Aug 28;51(16):4858-61.
DM8PA3U	RU	https://pubmed.ncbi.nlm.nih.gov/18665579

DM8PA3U	DI	DM8PA3U
DM8PA3U	DN	BMS-694153
DM8PA3U	MI	TTVG215
DM8PA3U	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DM8PA3U	MT	DTT
DM8PA3U	MA	Inhibitor
DM8PA3U	RN	Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan... J Med Chem. 2008 Aug 28;51(16):4858-61.
DM8PA3U	RU	https://pubmed.ncbi.nlm.nih.gov/18665579

DMFODQV	DI	DMFODQV
DMFODQV	DN	BMS-739562
DMFODQV	MI	TTLYXIT
DMFODQV	MN	Aurora kinase C (AURKC)
DMFODQV	MT	DTT
DMFODQV	MA	Inhibitor
DMFODQV	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1936).
DMFODQV	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1936

DMQ24TI	DI	DMQ24TI
DMQ24TI	DN	BMS-740808
DMQ24TI	MI	TT6L509
DMQ24TI	MN	Coagulation factor IIa (F2)
DMQ24TI	MT	DTT
DMQ24TI	MA	Inhibitor
DMQ24TI	RN	Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors. Bioorg Med Chem Lett. 2008 Jan 15;18(2):749-54.
DMQ24TI	RU	https://pubmed.ncbi.nlm.nih.gov/18054227

DMQ24TI	DI	DMQ24TI
DMQ24TI	DN	BMS-740808
DMQ24TI	MI	TTCIHJA
DMQ24TI	MN	Coagulation factor Xa (F10)
DMQ24TI	MT	DTT
DMQ24TI	MA	Inhibitor
DMQ24TI	RN	Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS... J Med Chem. 2007 Nov 1;50(22):5339-56.
DMQ24TI	RU	https://pubmed.ncbi.nlm.nih.gov/17914785

DMSX1NF	DI	DMSX1NF
DMSX1NF	DN	BMS753
DMSX1NF	MI	TTW38KT
DMSX1NF	MN	Retinoic acid receptor alpha (RARA)
DMSX1NF	MT	DTT
DMSX1NF	MA	Agonist
DMSX1NF	RN	Structural basis for engineering of retinoic acid receptor isotype-selective agonists and antagonists. Chem Biol. 1999 Aug;6(8):519-29.
DMSX1NF	RU	https://pubmed.ncbi.nlm.nih.gov/10421757

DM1HBF5	DI	DM1HBF5
DM1HBF5	DN	BMS-812204
DM1HBF5	MI	TT6OEDT
DM1HBF5	MN	Cannabinoid receptor 1 (CB1)
DM1HBF5	MT	DTT
DM1HBF5	MA	Antagonist
DM1HBF5	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 56).
DM1HBF5	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=56

DMI796T	DI	DMI796T
DMI796T	DN	BMS-A
DMI796T	MI	TTFZYTO
DMI796T	MN	C-C chemokine receptor type 2 (CCR2)
DMI796T	MT	DTT
DMI796T	MA	Antagonist
DMI796T	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 59).
DMI796T	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=59

DMT02B8	DI	DMT02B8
DMT02B8	DN	BMY 45778
DMT02B8	MI	TTOFYT1
DMT02B8	MN	Prostacyclin receptor (PTGIR)
DMT02B8	MT	DTT
DMT02B8	MA	Agonist
DMT02B8	RN	Relaxant actions of nonprostanoid prostacyclin mimetics on human pulmonary artery. J Cardiovasc Pharmacol. 1997 Apr;29(4):525-35.
DMT02B8	RU	https://pubmed.ncbi.nlm.nih.gov/9156364

DMAMYWL	DI	DMAMYWL
DMAMYWL	DN	BMY-27709
DMAMYWL	MI	TTF4CAM
DMAMYWL	MN	Influenza Hemagglutinin (Influ HA)
DMAMYWL	MT	DTT
DMAMYWL	MA	Inhibitor
DMAMYWL	RN	Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17736-41.
DMAMYWL	RU	https://pubmed.ncbi.nlm.nih.gov/19004788

DM1CNU5	DI	DM1CNU5
DM1CNU5	DN	BN-81,644
DM1CNU5	MI	TTJX3UE
DM1CNU5	MN	Somatostatin receptor type 3 (SSTR3)
DM1CNU5	MT	DTT
DM1CNU5	MA	Agonist
DM1CNU5	RN	Identification of potent non-peptide somatostatin antagonists with sst(3) selectivity. J Med Chem. 2001 Aug 30;44(18):2990-3000.
DM1CNU5	RU	https://pubmed.ncbi.nlm.nih.gov/11520208

DM7RPQ4	DI	DM7RPQ4
DM7RPQ4	DN	BN-81,674
DM7RPQ4	MI	TTJX3UE
DM7RPQ4	MN	Somatostatin receptor type 3 (SSTR3)
DM7RPQ4	MT	DTT
DM7RPQ4	MA	Agonist
DM7RPQ4	RN	Identification of potent non-peptide somatostatin antagonists with sst(3) selectivity. J Med Chem. 2001 Aug 30;44(18):2990-3000.
DM7RPQ4	RU	https://pubmed.ncbi.nlm.nih.gov/11520208

DMXY574	DI	DMXY574
DMXY574	DN	BN-82002
DMXY574	MI	TTESBNC
DMXY574	MN	M-phase inducer phosphatase 3 (MPIP3)
DMXY574	MT	DTT
DMXY574	MA	Inhibitor
DMXY574	RN	Synthesis of small molecule CDC25 phosphatases inhibitors. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5809-12.
DMXY574	RU	https://pubmed.ncbi.nlm.nih.gov/15501045

DMZME4N	DI	DMZME4N
DMZME4N	DN	BN-82685
DMZME4N	MI	TTESBNC
DMZME4N	MN	M-phase inducer phosphatase 3 (MPIP3)
DMZME4N	MT	DTT
DMZME4N	MA	Inhibitor
DMZME4N	RN	Synthesis and biological evaluation of novel heterocyclic quinones as inhibitors of the dual specificity protein phosphatase CDC25C. Bioorg Med Chem Lett. 2006 Jan 1;16(1):171-5.
DMZME4N	RU	https://pubmed.ncbi.nlm.nih.gov/16216500

DMJI1EA	DI	DMJI1EA
DMJI1EA	DN	BND-001
DMJI1EA	MI	TTNT7K8
DMJI1EA	MN	Nociceptin receptor (OPRL1)
DMJI1EA	MT	DTT
DMJI1EA	MA	Antagonist
DMJI1EA	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 320).
DMJI1EA	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=320

DM48VJR	DI	DM48VJR
DM48VJR	DN	B-Nonylglucoside
DM48VJR	MI	TTXMY0J
DM48VJR	MN	Pancreatic triacylglycerol lipase (PNLIP)
DM48VJR	MT	DTT
DM48VJR	MA	Inhibitor
DM48VJR	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM48VJR	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM48VJR	DI	DM48VJR
DM48VJR	DN	B-Nonylglucoside
DM48VJR	MI	TTH0KSX
DM48VJR	MN	Rhodopsin (RHO)
DM48VJR	MT	DTT
DM48VJR	MA	Inhibitor
DM48VJR	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM48VJR	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMJY1KR	DI	DMJY1KR
DMJY1KR	DN	BNP-FIX
DMJY1KR	MI	TTFEZ5Q
DMJY1KR	MN	Coagulation factor IX (F9)
DMJY1KR	MT	DTT
DMJY1KR	MA	Modulator
DMJY1KR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2364).
DMJY1KR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2364

DMIOHMZ	DI	DMIOHMZ
DMIOHMZ	DN	BNV-222
DMIOHMZ	MI	TTFBNVI
DMIOHMZ	MN	Aldose reductase (AKR1B1)
DMIOHMZ	MT	DTT
DMIOHMZ	MA	Modulator
DMIOHMZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2768).
DMIOHMZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2768

DMCUJH5	DI	DMCUJH5
DMCUJH5	DN	Bo(15)PZ
DMCUJH5	MI	TTZ9SOR
DMCUJH5	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMCUJH5	MT	DTT
DMCUJH5	MA	Inhibitor
DMCUJH5	RN	On the use of nonfluorescent dye labeled ligands in FRET-based receptor binding studies. J Med Chem. 2005 Dec 1;48(24):7847-59.
DMCUJH5	RU	https://pubmed.ncbi.nlm.nih.gov/16302823

DMDX8M3	DI	DMDX8M3
DMDX8M3	DN	Boc-Agly-Val-Agly-OEt
DMDX8M3	MI	TTDZN01
DMDX8M3	MN	Cathepsin K (CTSK)
DMDX8M3	MT	DTT
DMDX8M3	MA	Inhibitor
DMDX8M3	RN	Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11.
DMDX8M3	RU	https://pubmed.ncbi.nlm.nih.gov/12213061

DMPJR98	DI	DMPJR98
DMPJR98	DN	Boc-Asp-Tyr(So3-)-Nle-Gly-Trp-Asp-Phe-NH2
DMPJR98	MI	TTCG0AL
DMPJR98	MN	Cholecystokinin receptor type A (CCKAR)
DMPJR98	MT	DTT
DMPJR98	MA	Inhibitor
DMPJR98	RN	Synthesis and biological activities of pseudopeptide analogues of the C-terminal heptapeptide of cholecystokinin. On the importance of the peptide ... J Med Chem. 1987 Aug;30(8):1366-73.
DMPJR98	RU	https://pubmed.ncbi.nlm.nih.gov/2441054

DMPJR98	DI	DMPJR98
DMPJR98	DN	Boc-Asp-Tyr(So3-)-Nle-Gly-Trp-Asp-Phe-NH2
DMPJR98	MI	TTVFO0U
DMPJR98	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMPJR98	MT	DTT
DMPJR98	MA	Inhibitor
DMPJR98	RN	Synthesis and biological activities of pseudopeptide analogues of the C-terminal heptapeptide of cholecystokinin. On the importance of the peptide ... J Med Chem. 1987 Aug;30(8):1366-73.
DMPJR98	RU	https://pubmed.ncbi.nlm.nih.gov/2441054

DMRQVME	DI	DMRQVME
DMRQVME	DN	Boc-cyclo-(Glu-Tyr-Nle-D-Lys)-Trp-Nle-Asp-Phe-NH2
DMRQVME	MI	TTCG0AL
DMRQVME	MN	Cholecystokinin receptor type A (CCKAR)
DMRQVME	MT	DTT
DMRQVME	MA	Inhibitor
DMRQVME	RN	Synthesis and binding affinities of cyclic and related linear analogues of CCK8 selective for central receptors. J Med Chem. 1989 Jun;32(6):1184-90.
DMRQVME	RU	https://pubmed.ncbi.nlm.nih.gov/2724293

DMBCPKF	DI	DMBCPKF
DMBCPKF	DN	Boc-D-Glu-Tyr(SO3H)-Nle-D-Lys-Trp-Nle-Asp-Phe-NH2
DMBCPKF	MI	TTCG0AL
DMBCPKF	MN	Cholecystokinin receptor type A (CCKAR)
DMBCPKF	MT	DTT
DMBCPKF	MA	Inhibitor
DMBCPKF	RN	Synthesis and binding affinities of cyclic and related linear analogues of CCK8 selective for central receptors. J Med Chem. 1989 Jun;32(6):1184-90.
DMBCPKF	RU	https://pubmed.ncbi.nlm.nih.gov/2724293

DM1IXOG	DI	DM1IXOG
DM1IXOG	DN	Boc-D-Glu-Tyr(SO3H)-Nle-D-Nle-Trp-Nle-Asp-Phe-NH2
DM1IXOG	MI	TTCG0AL
DM1IXOG	MN	Cholecystokinin receptor type A (CCKAR)
DM1IXOG	MT	DTT
DM1IXOG	MA	Inhibitor
DM1IXOG	RN	Synthesis and binding affinities of cyclic and related linear analogues of CCK8 selective for central receptors. J Med Chem. 1989 Jun;32(6):1184-90.
DM1IXOG	RU	https://pubmed.ncbi.nlm.nih.gov/2724293

DMFWJC2	DI	DMFWJC2
DMFWJC2	DN	Boceprevir
DMFWJC2	MI	TT1D53B
DMFWJC2	MN	COVID-19 3C-like protease (3CLpro)
DMFWJC2	MT	DTT
DMFWJC2	MA	Inhibitor
DMFWJC2	RN	Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. 2020. April 20. doi: https://doi.org/10.1101/2020.04.20.051581
DMFWJC2	RU	https://www.biorxiv.org/content/10.1101/2020.04.20.051581v1

DMN3EU9	DI	DMN3EU9
DMN3EU9	DN	Boc-Glu-Tyr(SO3H)-Nle-D-Lys-Trp-Nle-Asp-Phe-NH2
DMN3EU9	MI	TTCG0AL
DMN3EU9	MN	Cholecystokinin receptor type A (CCKAR)
DMN3EU9	MT	DTT
DMN3EU9	MA	Inhibitor
DMN3EU9	RN	Synthesis and binding affinities of cyclic and related linear analogues of CCK8 selective for central receptors. J Med Chem. 1989 Jun;32(6):1184-90.
DMN3EU9	RU	https://pubmed.ncbi.nlm.nih.gov/2724293

DMG35MJ	DI	DMG35MJ
DMG35MJ	DN	Boc-Ile-Leu-L-(difluoro)aminobutyric aid
DMG35MJ	MI	TTWXB3E
DMG35MJ	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DMG35MJ	MT	DTT
DMG35MJ	MA	Inhibitor
DMG35MJ	RN	Control of hepatitis C: a medicinal chemistry perspective. J Med Chem. 2005 Jan 13;48(1):1-20.
DMG35MJ	RU	https://pubmed.ncbi.nlm.nih.gov/15633995

DMMO75G	DI	DMMO75G
DMMO75G	DN	B-Octylglucoside
DMMO75G	MI	TTGQA9W
DMMO75G	MN	Apolipoprotein A-II (APOA2)
DMMO75G	MT	DTT
DMMO75G	MA	Inhibitor
DMMO75G	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMMO75G	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMMO75G	DI	DMMO75G
DMMO75G	DN	B-Octylglucoside
DMMO75G	MI	TTKYZA9
DMMO75G	MN	Gastric triacylglycerol lipase (LIPF)
DMMO75G	MT	DTT
DMMO75G	MA	Inhibitor
DMMO75G	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMMO75G	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMMO75G	DI	DMMO75G
DMMO75G	DN	B-Octylglucoside
DMMO75G	MI	TTYRL6O
DMMO75G	MN	Glucocorticoid receptor (NR3C1)
DMMO75G	MT	DTT
DMMO75G	MA	Inhibitor
DMMO75G	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMMO75G	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMMO75G	DI	DMMO75G
DMMO75G	DN	B-Octylglucoside
DMMO75G	MI	TTO8QRU
DMMO75G	MN	Group IIA phospholipase A2 (GIIA sPLA2)
DMMO75G	MT	DTT
DMMO75G	MA	Inhibitor
DMMO75G	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMMO75G	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMMO75G	DI	DMMO75G
DMMO75G	DN	B-Octylglucoside
DMMO75G	MI	TTXT3PU
DMMO75G	MN	Influenza M2 protein (Influ M)
DMMO75G	MT	DTT
DMMO75G	MA	Inhibitor
DMMO75G	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMMO75G	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMMO75G	DI	DMMO75G
DMMO75G	DN	B-Octylglucoside
DMMO75G	MI	TT7O8ZA
DMMO75G	MN	Lanosterol synthase (LSS)
DMMO75G	MT	DTT
DMMO75G	MA	Inhibitor
DMMO75G	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMMO75G	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMMO75G	DI	DMMO75G
DMMO75G	DN	B-Octylglucoside
DMMO75G	MI	TT26PHO
DMMO75G	MN	Mineralocorticoid receptor  (MR)
DMMO75G	MT	DTT
DMMO75G	MA	Inhibitor
DMMO75G	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMMO75G	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMMO75G	DI	DMMO75G
DMMO75G	DN	B-Octylglucoside
DMMO75G	MI	TTF10I9
DMMO75G	MN	Nitric-oxide synthase inducible (NOS2)
DMMO75G	MT	DTT
DMMO75G	MA	Inhibitor
DMMO75G	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMMO75G	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMMO75G	DI	DMMO75G
DMMO75G	DN	B-Octylglucoside
DMMO75G	MI	TTXMY0J
DMMO75G	MN	Pancreatic triacylglycerol lipase (PNLIP)
DMMO75G	MT	DTT
DMMO75G	MA	Inhibitor
DMMO75G	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMMO75G	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMMO75G	DI	DMMO75G
DMMO75G	DN	B-Octylglucoside
DMMO75G	MI	TTRAMF0
DMMO75G	MN	Plasmodium Cytochrome B (Malaria MT-CYB)
DMMO75G	MT	DTT
DMMO75G	MA	Inhibitor
DMMO75G	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMMO75G	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMMO75G	DI	DMMO75G
DMMO75G	DN	B-Octylglucoside
DMMO75G	MI	TT3PQ2Y
DMMO75G	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DMMO75G	MT	DTT
DMMO75G	MA	Inhibitor
DMMO75G	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMMO75G	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMMO75G	DI	DMMO75G
DMMO75G	DN	B-Octylglucoside
DMMO75G	MI	TT8NGED
DMMO75G	MN	Prostaglandin G/H synthase 1 (COX-1)
DMMO75G	MT	DTT
DMMO75G	MA	Inhibitor
DMMO75G	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMMO75G	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMMO75G	DI	DMMO75G
DMMO75G	DN	B-Octylglucoside
DMMO75G	MI	TTVKILB
DMMO75G	MN	Prostaglandin G/H synthase 2 (COX-2)
DMMO75G	MT	DTT
DMMO75G	MA	Inhibitor
DMMO75G	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMMO75G	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMMO75G	DI	DMMO75G
DMMO75G	DN	B-Octylglucoside
DMMO75G	MI	TTELIN2
DMMO75G	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMMO75G	MT	DTT
DMMO75G	MA	Inhibitor
DMMO75G	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMMO75G	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMMO75G	DI	DMMO75G
DMMO75G	DN	B-Octylglucoside
DMMO75G	MI	TTH0KSX
DMMO75G	MN	Rhodopsin (RHO)
DMMO75G	MT	DTT
DMMO75G	MA	Inhibitor
DMMO75G	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMMO75G	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMMO75G	DI	DMMO75G
DMMO75G	DN	B-Octylglucoside
DMMO75G	MI	TTHM0R1
DMMO75G	MN	Steryl-sulfatase (STS)
DMMO75G	MT	DTT
DMMO75G	MA	Inhibitor
DMMO75G	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMMO75G	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMMO75G	DI	DMMO75G
DMMO75G	DN	B-Octylglucoside
DMMO75G	MI	TTQBR95
DMMO75G	MN	Stress-activated protein kinase 2a (p38 alpha)
DMMO75G	MT	DTT
DMMO75G	MA	Inhibitor
DMMO75G	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMMO75G	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMAYWTI	DI	DMAYWTI
DMAYWTI	DN	Boc-Tyr(SO3H)-Nle-Gly-Trp-Nle-Asp-Phe-NH2
DMAYWTI	MI	TTCG0AL
DMAYWTI	MN	Cholecystokinin receptor type A (CCKAR)
DMAYWTI	MT	DTT
DMAYWTI	MA	Inhibitor
DMAYWTI	RN	Synthesis and binding affinities of cyclic and related linear analogues of CCK8 selective for central receptors. J Med Chem. 1989 Jun;32(6):1184-90.
DMAYWTI	RU	https://pubmed.ncbi.nlm.nih.gov/2724293

DMY7CN3	DI	DMY7CN3
DMY7CN3	DN	BODIPY-pirenzepine
DMY7CN3	MI	TTOXS3C
DMY7CN3	MN	Muscarinic acetylcholine receptor (CHRM)
DMY7CN3	MT	DTT
DMY7CN3	MA	Antagonist
DMY7CN3	RN	Pirenzepine promotes the dimerization of muscarinic M1 receptors through a three-step binding process. J Biol Chem. 2009 Jul 17;284(29):19533-43.
DMY7CN3	RU	https://pubmed.ncbi.nlm.nih.gov/19451648

DMLCMA3	DI	DMLCMA3
DMLCMA3	DN	BOHEMINE
DMLCMA3	MI	TT7HF4W
DMLCMA3	MN	Cyclin-dependent kinase 2 (CDK2)
DMLCMA3	MT	DTT
DMLCMA3	MA	Inhibitor
DMLCMA3	RN	Docking-based development of purine-like inhibitors of cyclin-dependent kinase-2. J Med Chem. 2000 Jun 29;43(13):2506-13.
DMLCMA3	RU	https://pubmed.ncbi.nlm.nih.gov/10891109

DM0EKO5	DI	DM0EKO5
DM0EKO5	DN	Boldenone
DM0EKO5	MI	TTS64P2
DM0EKO5	MN	Androgen receptor (AR)
DM0EKO5	MT	DTT
DM0EKO5	MA	Agonist
DM0EKO5	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM0EKO5	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMMVB5P	DI	DMMVB5P
DMMVB5P	DN	BOLDINE
DMMVB5P	MI	TTZFYLI
DMMVB5P	MN	Dopamine D1 receptor (D1R)
DMMVB5P	MT	DTT
DMMVB5P	MA	Inhibitor
DMMVB5P	RN	Halogenated boldine derivatives with enhanced monoamine receptor selectivity. J Nat Prod. 2000 Apr;63(4):480-4.
DMMVB5P	RU	https://pubmed.ncbi.nlm.nih.gov/10785418

DMMVB5P	DI	DMMVB5P
DMMVB5P	DN	BOLDINE
DMMVB5P	MI	TTEX248
DMMVB5P	MN	Dopamine D2 receptor (D2R)
DMMVB5P	MT	DTT
DMMVB5P	MA	Inhibitor
DMMVB5P	RN	Halogenated boldine derivatives with enhanced monoamine receptor selectivity. J Nat Prod. 2000 Apr;63(4):480-4.
DMMVB5P	RU	https://pubmed.ncbi.nlm.nih.gov/10785418

DMMVB5P	DI	DMMVB5P
DMMVB5P	DN	BOLDINE
DMMVB5P	MI	TT4H1MQ
DMMVB5P	MN	Neuronal acetylcholine receptor alpha-4 (CHRNA4)
DMMVB5P	MT	DTT
DMMVB5P	MA	Inhibitor
DMMVB5P	RN	Aporphine metho salts as neuronal nicotinic acetylcholine receptor blockers. Bioorg Med Chem. 2007 May 15;15(10):3368-72.
DMMVB5P	RU	https://pubmed.ncbi.nlm.nih.gov/17391965

DMMVB5P	DI	DMMVB5P
DMMVB5P	DN	BOLDINE
DMMVB5P	MI	TT5KPZR
DMMVB5P	MN	Neuronal acetylcholine receptor beta-2 (CHRNB2)
DMMVB5P	MT	DTT
DMMVB5P	MA	Inhibitor
DMMVB5P	RN	Aporphine metho salts as neuronal nicotinic acetylcholine receptor blockers. Bioorg Med Chem. 2007 May 15;15(10):3368-72.
DMMVB5P	RU	https://pubmed.ncbi.nlm.nih.gov/17391965

DMVB6UG	DI	DMVB6UG
DMVB6UG	DN	BOLINAQUINONE
DMVB6UG	MI	TTO8QRU
DMVB6UG	MN	Group IIA phospholipase A2 (GIIA sPLA2)
DMVB6UG	MT	DTT
DMVB6UG	MA	Inhibitor
DMVB6UG	RN	New sesquiterpene derivatives from the sponge Dysidea species with a selective inhibitor profile against human phospholipase A2 and other leukocyte... J Nat Prod. 2001 May;64(5):612-5.
DMVB6UG	RU	https://pubmed.ncbi.nlm.nih.gov/11374954

DMVB6UG	DI	DMVB6UG
DMVB6UG	DN	BOLINAQUINONE
DMVB6UG	MI	TT9V5JH
DMVB6UG	MN	Phospholipase A2 (PLA2G1B)
DMVB6UG	MT	DTT
DMVB6UG	MA	Inhibitor
DMVB6UG	RN	New sesquiterpene derivatives from the sponge Dysidea species with a selective inhibitor profile against human phospholipase A2 and other leukocyte... J Nat Prod. 2001 May;64(5):612-5.
DMVB6UG	RU	https://pubmed.ncbi.nlm.nih.gov/11374954

DMAW40Y	DI	DMAW40Y
DMAW40Y	DN	BOMA
DMAW40Y	MI	TTHS256
DMAW40Y	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMAW40Y	MT	DTT
DMAW40Y	MA	Modulator (allosteric modulator)
DMAW40Y	RN	Discovery of novel modulators of metabotropic glutamate receptor subtype-5. Bioorg Med Chem. 2004 Jan 2;12(1):17-21.
DMAW40Y	RU	https://pubmed.ncbi.nlm.nih.gov/14697765

DMDFQ0Y	DI	DMDFQ0Y
DMDFQ0Y	DN	bombesin
DMDFQ0Y	MI	TTHYDUM
DMDFQ0Y	MN	Bombesin receptor (BS)
DMDFQ0Y	MT	DTT
DMDFQ0Y	MA	Agonist
DMDFQ0Y	RN	Expression and characterization of cloned human bombesin receptors. Mol Pharmacol. 1995 Jan;47(1):10-20.
DMDFQ0Y	RU	https://pubmed.ncbi.nlm.nih.gov/7838118

DMDFQ0Y	DI	DMDFQ0Y
DMDFQ0Y	DN	bombesin
DMDFQ0Y	MI	TTC1MVT
DMDFQ0Y	MN	Gastrin-releasing peptide receptor (GRPR)
DMDFQ0Y	MT	DTT
DMDFQ0Y	MA	Agonist
DMDFQ0Y	RN	Expression and characterization of cloned human bombesin receptors. Mol Pharmacol. 1995 Jan;47(1):10-20.
DMDFQ0Y	RU	https://pubmed.ncbi.nlm.nih.gov/7838118

DMI75A3	DI	DMI75A3
DMI75A3	DN	BOMPPA
DMI75A3	MI	TT0WAIE
DMI75A3	MN	Melatonin receptor type 1A (MTNR1A)
DMI75A3	MT	DTT
DMI75A3	MA	Agonist
DMI75A3	RN	Development of substituted N-[3-(3-methoxylphenyl)propyl] amides as MT(2)-selective melatonin agonists: improving metabolic stability. Bioorg Med Chem. 2013 Jan 15;21(2):547-52.
DMI75A3	RU	https://pubmed.ncbi.nlm.nih.gov/23228808

DMWALXQ	DI	DMWALXQ
DMWALXQ	DN	bongkrek acid
DMWALXQ	MI	TTU5A6Q
DMWALXQ	MN	Adenine nucleotide translocator 1 (SLC25A4)
DMWALXQ	MT	DTT
DMWALXQ	MA	Inhibitor
DMWALXQ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1062).
DMWALXQ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1062

DMWBV1P	DI	DMWBV1P
DMWBV1P	DN	borneol
DMWBV1P	MI	TT946IA
DMWBV1P	MN	Transient receptor potential cation channel V3 (TRPV3)
DMWBV1P	MT	DTT
DMWBV1P	MA	Activator
DMWBV1P	RN	Monoterpenoid agonists of TRPV3. Br J Pharmacol. 2007 Jun;151(4):530-40.
DMWBV1P	RU	https://pubmed.ncbi.nlm.nih.gov/17420775

DMR70ZO	DI	DMR70ZO
DMR70ZO	DN	Bornyl (3,4,5-trihydroxy)-cinnamate
DMR70ZO	MI	TTPLTSQ
DMR70ZO	MN	Neutrophil elastase (NE)
DMR70ZO	MT	DTT
DMR70ZO	MA	Inhibitor
DMR70ZO	RN	Bornyl (3,4,5-trihydroxy)-cinnamate--an optimized human neutrophil elastase inhibitor designed by free energy calculations. Bioorg Med Chem. 2008 Mar 1;16(5):2385-90.
DMR70ZO	RU	https://pubmed.ncbi.nlm.nih.gov/18078761

DMBSQTR	DI	DMBSQTR
DMBSQTR	DN	Borrelidin
DMBSQTR	MI	TT75YK4
DMBSQTR	MN	Saccharomyces Cell division control protein 28 (Saccha CDC28)
DMBSQTR	MT	DTT
DMBSQTR	MA	Inhibitor
DMBSQTR	RN	Borrelidin inhibits a cyclin-dependent kinase (CDK), Cdc28/Cln2, of Saccharomyces cerevisiae. J Antibiot (Tokyo). 2001 Jan;54(1):84-90.
DMBSQTR	RU	https://pubmed.ncbi.nlm.nih.gov/11269718

DMRELJ0	DI	DMRELJ0
DMRELJ0	DN	Bovinic acid
DMRELJ0	MI	DEVYB4R
DMRELJ0	MN	Linoleic acid reductase (cla-r)
DMRELJ0	MT	DME
DMRELJ0	MA	Metabolism
DMRELJ0	RN	Effect of linoleic acid concentration on conjugated linoleic acid production by Butyrivibrio fibrisolvens A38. Appl Environ Microbiol. 2000 Dec;66(12):5226-30.
DMRELJ0	RU	https://pubmed.ncbi.nlm.nih.gov/11097894

DMGEYFB	DI	DMGEYFB
DMGEYFB	DN	BP-100-1.02
DMGEYFB	MI	TTFOUV4
DMGEYFB	MN	BCL-2 messenger RNA (BCL2 mRNA)
DMGEYFB	MT	DTT
DMGEYFB	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2844).
DMGEYFB	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2844

DMUOS3G	DI	DMUOS3G
DMUOS3G	DN	BPH-252
DMUOS3G	MI	TTIKWV4
DMUOS3G	MN	Geranyltranstransferase (FDPS)
DMUOS3G	MT	DTT
DMUOS3G	MA	Inhibitor
DMUOS3G	RN	Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation. J Med Chem. 2008 Sep 25;51(18):5594-607.
DMUOS3G	RU	https://pubmed.ncbi.nlm.nih.gov/18800762

DM0NQLI	DI	DM0NQLI
DM0NQLI	DN	BPH-608
DM0NQLI	MI	TTIKWV4
DM0NQLI	MN	Geranyltranstransferase (FDPS)
DM0NQLI	MT	DTT
DM0NQLI	MA	Inhibitor
DM0NQLI	RN	Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases. Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10022-7.
DM0NQLI	RU	https://pubmed.ncbi.nlm.nih.gov/17535895

DM0TJ6R	DI	DM0TJ6R
DM0TJ6R	DN	BPH-628
DM0TJ6R	MI	TTIKWV4
DM0TJ6R	MN	Geranyltranstransferase (FDPS)
DM0TJ6R	MT	DTT
DM0TJ6R	MA	Inhibitor
DM0TJ6R	RN	Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation. J Med Chem. 2008 Sep 25;51(18):5594-607.
DM0TJ6R	RU	https://pubmed.ncbi.nlm.nih.gov/18800762

DM49BFM	DI	DM49BFM
DM49BFM	DN	BPH-629
DM49BFM	MI	TTIKWV4
DM49BFM	MN	Geranyltranstransferase (FDPS)
DM49BFM	MT	DTT
DM49BFM	MA	Inhibitor
DM49BFM	RN	Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases. Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10022-7.
DM49BFM	RU	https://pubmed.ncbi.nlm.nih.gov/17535895

DMX4WI7	DI	DMX4WI7
DMX4WI7	DN	BPH-652
DMX4WI7	MI	TTFQEO5
DMX4WI7	MN	Squalene synthetase (FDFT1)
DMX4WI7	MT	DTT
DMX4WI7	MA	Inhibitor
DMX4WI7	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 645).
DMX4WI7	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=645

DM3IPYV	DI	DM3IPYV
DM3IPYV	DN	BPH-675
DM3IPYV	MI	TTIKWV4
DM3IPYV	MN	Geranyltranstransferase (FDPS)
DM3IPYV	MT	DTT
DM3IPYV	MA	Inhibitor
DM3IPYV	RN	Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases. Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10022-7.
DM3IPYV	RU	https://pubmed.ncbi.nlm.nih.gov/17535895

DMPKAEW	DI	DMPKAEW
DMPKAEW	DN	BPH-676
DMPKAEW	MI	TTIKWV4
DMPKAEW	MN	Geranyltranstransferase (FDPS)
DMPKAEW	MT	DTT
DMPKAEW	MA	Inhibitor
DMPKAEW	RN	Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases. Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10022-7.
DMPKAEW	RU	https://pubmed.ncbi.nlm.nih.gov/17535895

DMTHW3F	DI	DMTHW3F
DMTHW3F	DN	BPH-715
DMTHW3F	MI	TTIKWV4
DMTHW3F	MN	Geranyltranstransferase (FDPS)
DMTHW3F	MT	DTT
DMTHW3F	MA	Inhibitor
DMTHW3F	RN	Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation. J Med Chem. 2008 Sep 25;51(18):5594-607.
DMTHW3F	RU	https://pubmed.ncbi.nlm.nih.gov/18800762

DMD0XEO	DI	DMD0XEO
DMD0XEO	DN	BPH-742
DMD0XEO	MI	TTIKWV4
DMD0XEO	MN	Geranyltranstransferase (FDPS)
DMD0XEO	MT	DTT
DMD0XEO	MA	Inhibitor
DMD0XEO	RN	Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation. J Med Chem. 2008 Sep 25;51(18):5594-607.
DMD0XEO	RU	https://pubmed.ncbi.nlm.nih.gov/18800762

DM15L2J	DI	DM15L2J
DM15L2J	DN	BPH-830
DM15L2J	MI	TTFQEO5
DM15L2J	MN	Squalene synthetase (FDFT1)
DM15L2J	MT	DTT
DM15L2J	MA	Inhibitor
DM15L2J	RN	Inhibition of staphyloxanthin virulence factor biosynthesis in Staphylococcus aureus: in vitro, in vivo, and crystallographic results. J Med Chem. 2009 Jul 9;52(13):3869-80.
DM15L2J	RU	https://pubmed.ncbi.nlm.nih.gov/19456099

DMGQXTR	DI	DMGQXTR
DMGQXTR	DN	BPI-704001
DMGQXTR	MI	TTVDSZ0
DMGQXTR	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMGQXTR	MT	DTT
DMGQXTR	MA	Inhibitor
DMGQXTR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2771).
DMGQXTR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2771

DMOSG0Q	DI	DMOSG0Q
DMOSG0Q	DN	BPI-711001
DMOSG0Q	MI	TTDIGC1
DMOSG0Q	MN	Dipeptidyl peptidase 4 (DPP-4)
DMOSG0Q	MT	DTT
DMOSG0Q	MA	Inhibitor
DMOSG0Q	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1612).
DMOSG0Q	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1612

DMNHEUT	DI	DMNHEUT
DMNHEUT	DN	BPIQ-I
DMNHEUT	MI	TTGKNB4
DMNHEUT	MN	Epidermal growth factor receptor (EGFR)
DMNHEUT	MT	DTT
DMNHEUT	MA	Inhibitor
DMNHEUT	RN	Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase acti... J Med Chem. 1996 Feb 16;39(4):918-28.
DMNHEUT	RU	https://pubmed.ncbi.nlm.nih.gov/8632415

DM5OHIY	DI	DM5OHIY
DM5OHIY	DN	BPKDi
DM5OHIY	MI	TTSLUMT
DM5OHIY	MN	Protein kinase D (PRKD1)
DM5OHIY	MT	DTT
DM5OHIY	MA	Inhibitor
DM5OHIY	RN	Protein kinase D as a potential new target for cancer therapy. Biochim Biophys Acta. 2010 Dec;1806(2):183-92.
DM5OHIY	RU	https://pubmed.ncbi.nlm.nih.gov/20580776

DMKX6LY	DI	DMKX6LY
DMKX6LY	DN	BPL-001
DMKX6LY	MI	TTPADOQ
DMKX6LY	MN	HMG-CoA reductase (HMGCR)
DMKX6LY	MT	DTT
DMKX6LY	MA	Inhibitor
DMKX6LY	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 639).
DMKX6LY	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=639

DMJPN8Z	DI	DMJPN8Z
DMJPN8Z	DN	BPR1K-0224
DMJPN8Z	MI	TTLYXIT
DMJPN8Z	MN	Aurora kinase C (AURKC)
DMJPN8Z	MT	DTT
DMJPN8Z	MA	Inhibitor
DMJPN8Z	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1936).
DMJPN8Z	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1936

DMQBRSM	DI	DMQBRSM
DMQBRSM	DN	BQ 3020
DMQBRSM	MI	TT3ZTGU
DMQBRSM	MN	Endothelin B receptor (EDNRB)
DMQBRSM	MT	DTT
DMQBRSM	MA	Agonist
DMQBRSM	RN	Pharmacological differences between rat and human endothelin B receptors. Biochem Biophys Res Commun. 1995 Apr 17;209(2):506-12.
DMQBRSM	RU	https://pubmed.ncbi.nlm.nih.gov/7733918

DMSGIXK	DI	DMSGIXK
DMSGIXK	DN	BQCA
DMSGIXK	MI	TTZ9SOR
DMSGIXK	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMSGIXK	MT	DTT
DMSGIXK	MA	Agonist
DMSGIXK	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5436).
DMSGIXK	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5436

DMBTC23	DI	DMBTC23
DMBTC23	DN	Br-5MPEPy
DMBTC23	MI	TTHS256
DMBTC23	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMBTC23	MT	DTT
DMBTC23	MA	Modulator (allosteric modulator)
DMBTC23	RN	A close structural analog of 2-methyl-6-(phenylethynyl)-pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtyp... Mol Pharmacol. 2005 Dec;68(6):1793-802.
DMBTC23	RU	https://pubmed.ncbi.nlm.nih.gov/16155210

DM0DWSR	DI	DM0DWSR
DM0DWSR	DN	bradyzide
DM0DWSR	MI	TTGY8IW
DM0DWSR	MN	B2 bradykinin receptor (BDKRB2)
DM0DWSR	MT	DTT
DM0DWSR	MA	Antagonist
DM0DWSR	RN	Bradyzide, a potent non-peptide B(2) bradykinin receptor antagonist with long-lasting oral activity in animal models of inflammatory hyperalgesia. Br J Pharmacol. 2000 Jan;129(1):77-86.
DM0DWSR	RU	https://pubmed.ncbi.nlm.nih.gov/10694205

DMIZ9ON	DI	DMIZ9ON
DMIZ9ON	DN	BRD1240
DMIZ9ON	MI	TTTK3BH
DMIZ9ON	MN	Vacuolar-type proton ATPase (v-ATPase)
DMIZ9ON	MT	DTT
DMIZ9ON	MA	Inhibitor
DMIZ9ON	RN	Lysosomes as a therapeutic target. Nat Rev Drug Discov. 2019 Dec;18(12):923-948.
DMIZ9ON	RU	https://pubmed.ncbi.nlm.nih.gov/31477883

DMFAVB5	DI	DMFAVB5
DMFAVB5	DN	BRD9539
DMFAVB5	MI	TTS6RZT
DMFAVB5	MN	Histone-lysine N-methyltransferase EHMT2 (EHMT2)
DMFAVB5	MT	DTT
DMFAVB5	MA	Inhibitor
DMFAVB5	RN	A small-molecule probe of the histone methyltransferase G9a induces cellular senescence in pancreatic adenocarcinoma. ACS Chem Biol. 2012 Jul 20;7(7):1152-7.
DMFAVB5	RU	https://pubmed.ncbi.nlm.nih.gov/22536950

DM21ZBU	DI	DM21ZBU
DM21ZBU	DN	Breceptin
DM21ZBU	MI	TTGY8IW
DM21ZBU	MN	B2 bradykinin receptor (BDKRB2)
DM21ZBU	MT	DTT
DM21ZBU	MA	Modulator
DM21ZBU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 42).
DM21ZBU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=42

DM3EIBU	DI	DM3EIBU
DM3EIBU	DN	BREMAZOCINE
DM3EIBU	MI	TTKWM86
DM3EIBU	MN	Opioid receptor mu (MOP)
DM3EIBU	MT	DTT
DM3EIBU	MA	Inhibitor
DM3EIBU	RN	Electrophilic alpha-methylene-gamma-lactone and isothiocyanate opioid ligands related to etorphine. J Med Chem. 1990 Aug;33(8):2286-96.
DM3EIBU	RU	https://pubmed.ncbi.nlm.nih.gov/2165166

DM2JPX7	DI	DM2JPX7
DM2JPX7	DN	BRIFENTANIL
DM2JPX7	MI	TTN4QDT
DM2JPX7	MN	Opioid receptor (OPR)
DM2JPX7	MT	DTT
DM2JPX7	MA	Modulator
DM2JPX7	RN	Synthesis and pharmacological evaluation of a series of new 3-methyl-1,4-disubstituted-piperidine analgesics. J Med Chem. 1990 Oct;33(10):2876-82.
DM2JPX7	RU	https://pubmed.ncbi.nlm.nih.gov/2170652

DMTM7W0	DI	DMTM7W0
DMTM7W0	DN	BRL 43694A
DMTM7W0	MI	TTNXLKE
DMTM7W0	MN	5-HT 3 receptor (5HT3R)
DMTM7W0	MT	DTT
DMTM7W0	MA	Antagonist
DMTM7W0	RN	BRL 43694A--a 5-hydroxytryptamine receptor blocker as an antiemetic in cytostatic therapy. Schweiz Med Wochenschr. 1989 Jun 10;119(23):831-4.
DMTM7W0	RU	https://pubmed.ncbi.nlm.nih.gov/2549616

DM3WPO4	DI	DM3WPO4
DM3WPO4	DN	BRL 44408
DM3WPO4	MI	TTWG9A4
DM3WPO4	MN	Adrenergic receptor alpha-2A (ADRA2A)
DM3WPO4	MT	DTT
DM3WPO4	MA	Antagonist
DM3WPO4	RN	Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries. Invest Ophthalmol Vis Sci. 2001 Aug;42(9):2049-55.
DM3WPO4	RU	https://pubmed.ncbi.nlm.nih.gov/11481271

DM16GUV	DI	DM16GUV
DM16GUV	DN	BRL 52537 hydrochloride
DM16GUV	MI	TTQW87Y
DM16GUV	MN	Opioid receptor kappa (OPRK1)
DM16GUV	MT	DTT
DM16GUV	MA	Agonist
DM16GUV	RN	Kappa-opioid receptor selectivity for ischemic neuroprotection with BRL 52537 in rats. Anesth Analg. 2003 Dec;97(6):1776-83.
DM16GUV	RU	https://pubmed.ncbi.nlm.nih.gov/14633559

DM6XO72	DI	DM6XO72
DM6XO72	DN	BRL 52974
DM6XO72	MI	TTQW87Y
DM6XO72	MN	Opioid receptor kappa (OPRK1)
DM6XO72	MT	DTT
DM6XO72	MA	Agonist
DM6XO72	RN	The antitussive activity of delta-opioid receptor stimulation in guinea pigs. J Pharmacol Exp Ther. 2000 Feb;292(2):803-9.
DM6XO72	RU	https://pubmed.ncbi.nlm.nih.gov/10640321

DMM61Y2	DI	DMM61Y2
DMM61Y2	DN	BRL-15572
DMM61Y2	MI	TTSQIFT
DMM61Y2	MN	5-HT 1A receptor (HTR1A)
DMM61Y2	MT	DTT
DMM61Y2	MA	Agonist
DMM61Y2	RN	SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20.
DMM61Y2	RU	https://pubmed.ncbi.nlm.nih.gov/9303567

DMM61Y2	DI	DMM61Y2
DMM61Y2	DN	BRL-15572
DMM61Y2	MI	TTK8CXU
DMM61Y2	MN	5-HT 1B receptor (HTR1B)
DMM61Y2	MT	DTT
DMM61Y2	MA	Agonist
DMM61Y2	RN	SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20.
DMM61Y2	RU	https://pubmed.ncbi.nlm.nih.gov/9303567

DMM61Y2	DI	DMM61Y2
DMM61Y2	DN	BRL-15572
DMM61Y2	MI	TT6MSOK
DMM61Y2	MN	5-HT 1D receptor (HTR1D)
DMM61Y2	MT	DTT
DMM61Y2	MA	Agonist
DMM61Y2	RN	SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20.
DMM61Y2	RU	https://pubmed.ncbi.nlm.nih.gov/9303567

DMM61Y2	DI	DMM61Y2
DMM61Y2	DN	BRL-15572
DMM61Y2	MI	TTCPG9S
DMM61Y2	MN	5-HT 1E receptor (HTR1E)
DMM61Y2	MT	DTT
DMM61Y2	MA	Agonist
DMM61Y2	RN	SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20.
DMM61Y2	RU	https://pubmed.ncbi.nlm.nih.gov/9303567

DMM61Y2	DI	DMM61Y2
DMM61Y2	DN	BRL-15572
DMM61Y2	MI	TT0MI3F
DMM61Y2	MN	5-HT 1F receptor (HTR1F)
DMM61Y2	MT	DTT
DMM61Y2	MA	Agonist
DMM61Y2	RN	SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20.
DMM61Y2	RU	https://pubmed.ncbi.nlm.nih.gov/9303567

DMM61Y2	DI	DMM61Y2
DMM61Y2	DN	BRL-15572
DMM61Y2	MI	TTJQOD7
DMM61Y2	MN	5-HT 2A receptor (HTR2A)
DMM61Y2	MT	DTT
DMM61Y2	MA	Agonist
DMM61Y2	RN	SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20.
DMM61Y2	RU	https://pubmed.ncbi.nlm.nih.gov/9303567

DMM61Y2	DI	DMM61Y2
DMM61Y2	DN	BRL-15572
DMM61Y2	MI	TT0K1SC
DMM61Y2	MN	5-HT 2B receptor (HTR2B)
DMM61Y2	MT	DTT
DMM61Y2	MA	Agonist
DMM61Y2	RN	SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20.
DMM61Y2	RU	https://pubmed.ncbi.nlm.nih.gov/9303567

DMM61Y2	DI	DMM61Y2
DMM61Y2	DN	BRL-15572
DMM61Y2	MI	TTWJBZ5
DMM61Y2	MN	5-HT 2C receptor (HTR2C)
DMM61Y2	MT	DTT
DMM61Y2	MA	Agonist
DMM61Y2	RN	SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20.
DMM61Y2	RU	https://pubmed.ncbi.nlm.nih.gov/9303567

DMM61Y2	DI	DMM61Y2
DMM61Y2	DN	BRL-15572
DMM61Y2	MI	TTJS8PY
DMM61Y2	MN	5-HT 6 receptor (HTR6)
DMM61Y2	MT	DTT
DMM61Y2	MA	Agonist
DMM61Y2	RN	SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20.
DMM61Y2	RU	https://pubmed.ncbi.nlm.nih.gov/9303567

DMSB4EW	DI	DMSB4EW
DMSB4EW	DN	BRL-24682
DMSB4EW	MI	TTPC4TU
DMSB4EW	MN	5-HT 3A receptor (HTR3A)
DMSB4EW	MT	DTT
DMSB4EW	MA	Inhibitor
DMSB4EW	RN	Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotoni... J Med Chem. 2003 Feb 27;46(5):702-15.
DMSB4EW	RU	https://pubmed.ncbi.nlm.nih.gov/12593651

DMSB4EW	DI	DMSB4EW
DMSB4EW	DN	BRL-24682
DMSB4EW	MI	TTR6K75
DMSB4EW	MN	5-HT 3B receptor (HTR3B)
DMSB4EW	MT	DTT
DMSB4EW	MA	Inhibitor
DMSB4EW	RN	Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotoni... J Med Chem. 2003 Feb 27;46(5):702-15.
DMSB4EW	RU	https://pubmed.ncbi.nlm.nih.gov/12593651

DMD0YL1	DI	DMD0YL1
DMD0YL1	DN	BRL-25594
DMD0YL1	MI	TTEX248
DMD0YL1	MN	Dopamine D2 receptor (D2R)
DMD0YL1	MT	DTT
DMD0YL1	MA	Inhibitor
DMD0YL1	RN	Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotoni... J Med Chem. 2003 Feb 27;46(5):702-15.
DMD0YL1	RU	https://pubmed.ncbi.nlm.nih.gov/12593651

DMQ4MFY	DI	DMQ4MFY
DMQ4MFY	DN	BRL-26175
DMQ4MFY	MI	TTEX248
DMQ4MFY	MN	Dopamine D2 receptor (D2R)
DMQ4MFY	MT	DTT
DMQ4MFY	MA	Inhibitor
DMQ4MFY	RN	18F-labeled benzamides for studying the dopamine D2 receptor with positron emission tomography. J Med Chem. 1993 Nov 12;36(23):3707-20.
DMQ4MFY	RU	https://pubmed.ncbi.nlm.nih.gov/8246241

DMRI49D	DI	DMRI49D
DMRI49D	DN	BRL-36378
DMRI49D	MI	TTL69WB
DMRI49D	MN	Angiotensin-converting enzyme (ACE)
DMRI49D	MT	DTT
DMRI49D	MA	Modulator
DMRI49D	RN	Antihypertensive and angiotensin converting enzyme inhibitory activities of a novel dihydrobenzofuran analogue. Arzneimittelforschung. 1988 Apr;38(4):531-6.
DMRI49D	RU	https://www.ncbi.nlm.nih.gov/pubmed/2840917

DMT4NM5	DI	DMT4NM5
DMT4NM5	DN	BRL-48482
DMT4NM5	MI	TTT2SVW
DMT4NM5	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DMT4NM5	MT	DTT
DMT4NM5	MA	Inhibitor
DMT4NM5	RN	Non thiazolidinedione antihyperglycaemic agents. 2: alpha-Carbon substituted beta-phenylpropanoic acids1, Bioorg. Med. Chem. Lett. 6(17):2127-2130 (1996).
DMT4NM5	RU	http://www.sciencedirect.com/science/article/pii/0960894X96003824

DMV2XUM	DI	DMV2XUM
DMV2XUM	DN	BRL50481
DMV2XUM	MI	TTWIEY9
DMV2XUM	MN	Phosphodiesterase 7B (PDE7B)
DMV2XUM	MT	DTT
DMV2XUM	MA	Inhibitor
DMV2XUM	RN	New classes of PDE7 inhibitors identified by a fission yeast-based HTS. J Biomol Screen. 2010 Apr;15(4):359-67.
DMV2XUM	RU	https://pubmed.ncbi.nlm.nih.gov/20228279

DM3TWBU	DI	DM3TWBU
DM3TWBU	DN	BRL54443
DM3TWBU	MI	TTCPG9S
DM3TWBU	MN	5-HT 1E receptor (HTR1E)
DM3TWBU	MT	DTT
DM3TWBU	MA	Agonist
DM3TWBU	RN	Characterization of the serotonin receptor mediating contraction in the mouse thoracic aorta and signal pathway coupling. J Pharmacol Exp Ther. 2001 Apr;297(1):88-95.
DM3TWBU	RU	https://pubmed.ncbi.nlm.nih.gov/11259531

DM2J1FA	DI	DM2J1FA
DM2J1FA	DN	BRL-54504AX
DM2J1FA	MI	TTNJYV2
DM2J1FA	MN	Gamma-aminobutyric acid receptor (GAR)
DM2J1FA	MT	DTT
DM2J1FA	MA	Inhibitor
DM2J1FA	RN	Isosteric replacement of the indole nucleus by benzothiophene in a series of pyrido[2,3-b]indoles with potential anxiolytic activity, Bioorg. Med. Chem. Lett. 5(22):2589-2592 (1995).
DM2J1FA	RU	http://www.sciencedirect.com/science/article/pii/0960894X95004508

DMEMZ6Q	DI	DMEMZ6Q
DMEMZ6Q	DN	BRL-55473
DMEMZ6Q	MI	TTZ9SOR
DMEMZ6Q	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMEMZ6Q	MT	DTT
DMEMZ6Q	MA	Inhibitor
DMEMZ6Q	RN	A novel and selective class of azabicyclic muscarinic agonists incorporating an N-methoxy imidoyl halide or nitrile functionality, Bioorg. Med. Chem. Lett. 2(8):791-796 (1992).
DMEMZ6Q	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805338

DMEMZ6Q	DI	DMEMZ6Q
DMEMZ6Q	DN	BRL-55473
DMEMZ6Q	MI	TTYEG6Q
DMEMZ6Q	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMEMZ6Q	MT	DTT
DMEMZ6Q	MA	Inhibitor
DMEMZ6Q	RN	A novel and selective class of azabicyclic muscarinic agonists incorporating an N-methoxy imidoyl halide or nitrile functionality, Bioorg. Med. Chem. Lett. 2(8):791-796 (1992).
DMEMZ6Q	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805338

DMEMZ6Q	DI	DMEMZ6Q
DMEMZ6Q	DN	BRL-55473
DMEMZ6Q	MI	TTQ13Z5
DMEMZ6Q	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMEMZ6Q	MT	DTT
DMEMZ6Q	MA	Inhibitor
DMEMZ6Q	RN	A novel and selective class of azabicyclic muscarinic agonists incorporating an N-methoxy imidoyl halide or nitrile functionality, Bioorg. Med. Chem. Lett. 2(8):791-796 (1992).
DMEMZ6Q	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805338

DMEMZ6Q	DI	DMEMZ6Q
DMEMZ6Q	DN	BRL-55473
DMEMZ6Q	MI	TTQ3JTF
DMEMZ6Q	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DMEMZ6Q	MT	DTT
DMEMZ6Q	MA	Inhibitor
DMEMZ6Q	RN	A novel and selective class of azabicyclic muscarinic agonists incorporating an N-methoxy imidoyl halide or nitrile functionality, Bioorg. Med. Chem. Lett. 2(8):791-796 (1992).
DMEMZ6Q	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805338

DMEMZ6Q	DI	DMEMZ6Q
DMEMZ6Q	DN	BRL-55473
DMEMZ6Q	MI	TTH18TF
DMEMZ6Q	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMEMZ6Q	MT	DTT
DMEMZ6Q	MA	Inhibitor
DMEMZ6Q	RN	A novel and selective class of azabicyclic muscarinic agonists incorporating an N-methoxy imidoyl halide or nitrile functionality, Bioorg. Med. Chem. Lett. 2(8):791-796 (1992).
DMEMZ6Q	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805338

DMZMWVX	DI	DMZMWVX
DMZMWVX	DN	BRN-0471734
DMZMWVX	MI	DED2FW3
DMZMWVX	MN	Aldo-keto reductase 1A1 (AKR1A1)
DMZMWVX	MT	DME
DMZMWVX	MA	Metabolism
DMZMWVX	RN	The C-terminal loop of aldehyde reductase determines the substrate and inhibitor specificity. Biochemistry. 1996 Nov 12;35(45):14276-80.
DMZMWVX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8916913

DMOTU4P	DI	DMOTU4P
DMOTU4P	DN	BRN-1980310
DMOTU4P	MI	DENZ6B1
DMOTU4P	MN	UDP-glucuronosyltransferase 2B15 (UGT2B15)
DMOTU4P	MT	DME
DMOTU4P	MA	Metabolism
DMOTU4P	RN	Importance of UDP-glucuronosyltransferase 1A10 (UGT1A10) in the detoxification of polycyclic aromatic hydrocarbons: decreased glucuronidative activity of the UGT1A10139Lys isoform. Drug Metab Dispos. 2006 Jun;34(6):943-9.
DMOTU4P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16510539

DMOTU4P	DI	DMOTU4P
DMOTU4P	DN	BRN-1980310
DMOTU4P	MI	DEAZDL8
DMOTU4P	MN	UDP-glucuronosyltransferase 2B17 (UGT2B17)
DMOTU4P	MT	DME
DMOTU4P	MA	Metabolism
DMOTU4P	RN	Importance of UDP-glucuronosyltransferase 1A10 (UGT1A10) in the detoxification of polycyclic aromatic hydrocarbons: decreased glucuronidative activity of the UGT1A10139Lys isoform. Drug Metab Dispos. 2006 Jun;34(6):943-9.
DMOTU4P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16510539

DMC9Q4D	DI	DMC9Q4D
DMC9Q4D	DN	BRN-1999480
DMC9Q4D	MI	DESD26P
DMC9Q4D	MN	UDP-glucuronosyltransferase 1A6 (UGT1A6)
DMC9Q4D	MT	DME
DMC9Q4D	MA	Metabolism
DMC9Q4D	RN	Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev. 1999 Nov;31(4):817-99.
DMC9Q4D	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10575553

DM87VP6	DI	DM87VP6
DM87VP6	DN	BRN-2330710
DM87VP6	MI	DEM1HNL
DM87VP6	MN	Alcohol dehydrogenase class-I gamma (ADH1C)
DM87VP6	MT	DME
DM87VP6	MA	Metabolism
DM87VP6	RN	Oxidation of alcohols and reduction of aldehydes derived from methyl- and dimethylpyrenes by cDNA-expressed human alcohol dehydrogenases. Toxicology. 2008 Mar 12;245(1-2):65-75.
DM87VP6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18242813

DM87VP6	DI	DM87VP6
DM87VP6	DN	BRN-2330710
DM87VP6	MI	DEOCWU3
DM87VP6	MN	Alcohol dehydrogenase class-II (ADH4)
DM87VP6	MT	DME
DM87VP6	MA	Metabolism
DM87VP6	RN	Oxidation of alcohols and reduction of aldehydes derived from methyl- and dimethylpyrenes by cDNA-expressed human alcohol dehydrogenases. Toxicology. 2008 Mar 12;245(1-2):65-75.
DM87VP6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18242813

DM4KXT0	DI	DM4KXT0
DM4KXT0	DN	BRN-3548355
DM4KXT0	MI	DE7P2FB
DM4KXT0	MN	Aldo-keto reductase 1C1 (AKR1C1)
DM4KXT0	MT	DME
DM4KXT0	MA	Metabolism
DM4KXT0	RN	Characterization of enzymes participating in carbonyl reduction of 4-methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK) in human placenta. Chem Biol Interact. 2001 Jan 30;130-132(1-3):737-48.
DM4KXT0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11306090

DM4KXT0	DI	DM4KXT0
DM4KXT0	DN	BRN-3548355
DM4KXT0	MI	DEOY5ZM
DM4KXT0	MN	Aldo-keto reductase 1C2 (AKR1C2)
DM4KXT0	MT	DME
DM4KXT0	MA	Metabolism
DM4KXT0	RN	Characterization of enzymes participating in carbonyl reduction of 4-methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK) in human placenta. Chem Biol Interact. 2001 Jan 30;130-132(1-3):737-48.
DM4KXT0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11306090

DM4KXT0	DI	DM4KXT0
DM4KXT0	DN	BRN-3548355
DM4KXT0	MI	DEAJN47
DM4KXT0	MN	Aldo-keto reductase 1C4 (AKR1C4)
DM4KXT0	MT	DME
DM4KXT0	MA	Metabolism
DM4KXT0	RN	Characterization of enzymes participating in carbonyl reduction of 4-methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK) in human placenta. Chem Biol Interact. 2001 Jan 30;130-132(1-3):737-48.
DM4KXT0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11306090

DM4KXT0	DI	DM4KXT0
DM4KXT0	DN	BRN-3548355
DM4KXT0	MI	DE9JFMC
DM4KXT0	MN	NADPH-dependent carbonyl reductase 1 (CBR1)
DM4KXT0	MT	DME
DM4KXT0	MA	Metabolism
DM4KXT0	RN	Characterization of enzymes participating in carbonyl reduction of 4-methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK) in human placenta. Chem Biol Interact. 2001 Jan 30;130-132(1-3):737-48.
DM4KXT0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11306090

DM9UF02	DI	DM9UF02
DM9UF02	DN	Brocresine
DM9UF02	MI	TTV9GOF
DM9UF02	MN	Histidine decarboxylase (HDC)
DM9UF02	MT	DTT
DM9UF02	MA	Inhibitor
DM9UF02	RN	Histamine in brain--its role in regulation of seizure susceptibility. Epilepsy Res. 1991 Nov-Dec;10(2-3):111-8.
DM9UF02	RU	https://pubmed.ncbi.nlm.nih.gov/1817952

DM7OF6N	DI	DM7OF6N
DM7OF6N	DN	Brodimoprim-4,6-Dicarboxylate
DM7OF6N	MI	TT9SL3Q
DM7OF6N	MN	Polypeptide deformylase (PDF)
DM7OF6N	MT	DTT
DM7OF6N	MA	Inhibitor
DM7OF6N	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM7OF6N	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMC4PF0	DI	DMC4PF0
DMC4PF0	DN	Brolamfetamine
DMC4PF0	MI	TTSQIFT
DMC4PF0	MN	5-HT 1A receptor (HTR1A)
DMC4PF0	MT	DTT
DMC4PF0	MA	Inhibitor
DMC4PF0	RN	5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. J Med Chem. 1986 Feb;29(2):194-9.
DMC4PF0	RU	https://pubmed.ncbi.nlm.nih.gov/3950904

DMC4PF0	DI	DMC4PF0
DMC4PF0	DN	Brolamfetamine
DMC4PF0	MI	TT6MSOK
DMC4PF0	MN	5-HT 1D receptor (HTR1D)
DMC4PF0	MT	DTT
DMC4PF0	MA	Inhibitor
DMC4PF0	RN	5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. J Med Chem. 1986 Feb;29(2):194-9.
DMC4PF0	RU	https://pubmed.ncbi.nlm.nih.gov/3950904

DMC4PF0	DI	DMC4PF0
DMC4PF0	DN	Brolamfetamine
DMC4PF0	MI	TTJQOD7
DMC4PF0	MN	5-HT 2A receptor (HTR2A)
DMC4PF0	MT	DTT
DMC4PF0	MA	Inhibitor
DMC4PF0	RN	'Hybrid' benzofuran-benzopyran congeners as rigid analogs of hallucinogenic phenethylamines. Bioorg Med Chem. 2008 Jun 1;16(11):6242-51.
DMC4PF0	RU	https://pubmed.ncbi.nlm.nih.gov/18467103

DMMC4BY	DI	DMMC4BY
DMMC4BY	DN	Brominide tartrate
DMMC4BY	MI	TTQ8AFT
DMMC4BY	MN	Adrenergic receptor Alpha-2 (ADRA2)
DMMC4BY	MT	DTT
DMMC4BY	MA	Agonist
DMMC4BY	RN	Alpha(2A)-adrenoceptor: G(alphai1) protein-mediated pertussis toxin-resistant attenuation of G(s) coupling to the cyclic AMP pathway. Biochem Pharmacol. 2000 Jun 15;59(12):1531-8.
DMMC4BY	RU	https://pubmed.ncbi.nlm.nih.gov/10799649

DMTBO7F	DI	DMTBO7F
DMTBO7F	DN	bromoacetone
DMTBO7F	MI	TTELV3W
DMTBO7F	MN	Transformation-sensitive protein p120 (TRPA1)
DMTBO7F	MT	DTT
DMTBO7F	MA	Activator
DMTBO7F	RN	Transient receptor potential ankyrin 1 antagonists block the noxious effects of toxic industrial isocyanates and tear gases. FASEB J. 2009 Apr;23(4):1102-14.
DMTBO7F	RU	https://pubmed.ncbi.nlm.nih.gov/19036859

DMXTVZ8	DI	DMXTVZ8
DMXTVZ8	DN	bromocresol green
DMXTVZ8	MI	TTKVTQO
DMXTVZ8	MN	Prostaglandin transporter (SLC21A2)
DMXTVZ8	MT	DTT
DMXTVZ8	MA	Inhibitor
DMXTVZ8	RN	Identification and characterization of a prostaglandin transporter. Science. 1995 May 12;268(5212):866-9.
DMXTVZ8	RU	https://pubmed.ncbi.nlm.nih.gov/7754369

DMX2U7G	DI	DMX2U7G
DMX2U7G	DN	bromo-deaza-SAH
DMX2U7G	MI	TTSZ8T1
DMX2U7G	MN	Histone-lysine N-methyltransferase (HLNM)
DMX2U7G	MT	DTT
DMX2U7G	MA	Inhibitor
DMX2U7G	RN	Bromo-deaza-SAH: a potent and selective DOT1L inhibitor. Bioorg Med Chem. 2013 Apr 1;21(7):1787-94.
DMX2U7G	RU	https://pubmed.ncbi.nlm.nih.gov/23433670

DM0D7LA	DI	DM0D7LA
DM0D7LA	DN	BROMODEOXYURIDINE
DM0D7LA	MI	TT5B8AX
DM0D7LA	MN	Mycobacterium Thymidine monophosphate kinase (MycB tmk)
DM0D7LA	MT	DTT
DM0D7LA	MA	Inhibitor
DM0D7LA	RN	Substituted benzyl-pyrimidines targeting thymidine monophosphate kinase of Mycobacterium tuberculosis: synthesis and in vitro anti-mycobacterial ac... Bioorg Med Chem. 2008 Jun 1;16(11):6075-85.
DM0D7LA	RU	https://pubmed.ncbi.nlm.nih.gov/18467107

DMKQ0CA	DI	DMKQ0CA
DMKQ0CA	DN	bromoenol lactone
DMKQ0CA	MI	TTDP1UC
DMKQ0CA	MN	Fatty acid amide hydrolase (FAAH)
DMKQ0CA	MT	DTT
DMKQ0CA	MA	Inhibitor
DMKQ0CA	RN	Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors. J Med Chem. 2008 Dec 11;51(23):7327-43.
DMKQ0CA	RU	https://pubmed.ncbi.nlm.nih.gov/18983142

DMKQ0CA	DI	DMKQ0CA
DMKQ0CA	DN	bromoenol lactone
DMKQ0CA	MI	TT32NQ1
DMKQ0CA	MN	Short transient receptor potential channel 5 (TRPC5)
DMKQ0CA	MT	DTT
DMKQ0CA	MA	Blocker (channel blocker)
DMKQ0CA	RN	Bromoenol lactone inhibits voltage-gated Ca2+ and transient receptor potential canonical channels. J Pharmacol Exp Ther. 2011 Nov;339(2):329-40.
DMKQ0CA	RU	https://pubmed.ncbi.nlm.nih.gov/21795434

DMKFTW8	DI	DMKFTW8
DMKFTW8	DN	Bromo-WR99210
DMKFTW8	MI	TT9SL3Q
DMKFTW8	MN	Polypeptide deformylase (PDF)
DMKFTW8	MT	DTT
DMKFTW8	MA	Inhibitor
DMKFTW8	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMKFTW8	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9W2ZV	DI	DM9W2ZV
DM9W2ZV	DN	Bromsulphthalein
DM9W2ZV	MI	DTE2B1D
DM9W2ZV	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DM9W2ZV	MT	DTP
DM9W2ZV	MA	Substrate
DM9W2ZV	RN	Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
DM9W2ZV	RU	http://www.ncbi.nlm.nih.gov/pubmed/11159893

DM9W2ZV	DI	DM9W2ZV
DM9W2ZV	DN	Bromsulphthalein
DM9W2ZV	MI	DT3D8F0
DM9W2ZV	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM9W2ZV	MT	DTP
DM9W2ZV	MA	Substrate
DM9W2ZV	RN	Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
DM9W2ZV	RU	http://www.ncbi.nlm.nih.gov/pubmed/11159893

DM9W2ZV	DI	DM9W2ZV
DM9W2ZV	DN	Bromsulphthalein
DM9W2ZV	MI	DT9C1TS
DM9W2ZV	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM9W2ZV	MT	DTP
DM9W2ZV	MA	Substrate
DM9W2ZV	RN	Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
DM9W2ZV	RU	http://www.ncbi.nlm.nih.gov/pubmed/11159893

DM9W2ZV	DI	DM9W2ZV
DM9W2ZV	DN	Bromsulphthalein
DM9W2ZV	MI	DTPFTEQ
DM9W2ZV	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DM9W2ZV	MT	DTP
DM9W2ZV	MA	Substrate
DM9W2ZV	RN	Organic anion-transporting polypeptide (OATP) 2B1 contributes to the cellular uptake of theaflavin. Drug Metab Pharmacokinet. 2017 Apr;32(2):145-150.
DM9W2ZV	RU	http://www.ncbi.nlm.nih.gov/pubmed/28190756

DM9W2ZV	DI	DM9W2ZV
DM9W2ZV	DN	Bromsulphthalein
DM9W2ZV	MI	TTKVTQO
DM9W2ZV	MN	Prostaglandin transporter (SLC21A2)
DM9W2ZV	MT	DTT
DM9W2ZV	MA	Inhibitor
DM9W2ZV	RN	Identification and characterization of a prostaglandin transporter. Science. 1995 May 12;268(5212):866-9.
DM9W2ZV	RU	https://pubmed.ncbi.nlm.nih.gov/7754369

DMB9SEI	DI	DMB9SEI
DMB9SEI	DN	Broussoflavonol F
DMB9SEI	MI	TTSZLWK
DMB9SEI	MN	Aromatase (CYP19A1)
DMB9SEI	MT	DTT
DMB9SEI	MA	Inhibitor
DMB9SEI	RN	Aromatase inhibitors from Broussonetia papyrifera. J Nat Prod. 2001 Oct;64(10):1286-93.
DMB9SEI	RU	https://pubmed.ncbi.nlm.nih.gov/11678652

DMXFN6H	DI	DMXFN6H
DMXFN6H	DN	BROUSSONIN A
DMXFN6H	MI	TTZAYWL
DMXFN6H	MN	Estrogen receptor (ESR)
DMXFN6H	MT	DTT
DMXFN6H	MA	Inhibitor
DMXFN6H	RN	New estrogenic compounds isolated from Broussonetia kazinoki. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3764-7.
DMXFN6H	RU	https://pubmed.ncbi.nlm.nih.gov/20493686

DMXFN6H	DI	DMXFN6H
DMXFN6H	DN	BROUSSONIN A
DMXFN6H	MI	TTOM3J0
DMXFN6H	MN	Estrogen receptor beta (ESR2)
DMXFN6H	MT	DTT
DMXFN6H	MA	Inhibitor
DMXFN6H	RN	New estrogenic compounds isolated from Broussonetia kazinoki. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3764-7.
DMXFN6H	RU	https://pubmed.ncbi.nlm.nih.gov/20493686

DMKM9F0	DI	DMKM9F0
DMKM9F0	DN	Broussonin C
DMKM9F0	MI	TTULVH8
DMKM9F0	MN	Tyrosinase (TYR)
DMKM9F0	MT	DTT
DMKM9F0	MA	Inhibitor
DMKM9F0	RN	Tyrosinase inhibitory effects of 1,3-diphenylpropanes from Broussonetia kazinoki. Bioorg Med Chem. 2009 Jan 1;17(1):35-41.
DMKM9F0	RU	https://pubmed.ncbi.nlm.nih.gov/19046886

DMPGEO1	DI	DMPGEO1
DMPGEO1	DN	BrP-LPA
DMPGEO1	MI	TTQ6S1K
DMPGEO1	MN	Lysophosphatidic acid receptor 1 (LPAR1)
DMPGEO1	MT	DTT
DMPGEO1	MA	Antagonist
DMPGEO1	RN	Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res. 2009 Jul 1;69(13):5441-9.
DMPGEO1	RU	https://pubmed.ncbi.nlm.nih.gov/19509223

DMPGEO1	DI	DMPGEO1
DMPGEO1	DN	BrP-LPA
DMPGEO1	MI	TTB7Y8I
DMPGEO1	MN	Lysophosphatidic acid receptor 2 (LPAR2)
DMPGEO1	MT	DTT
DMPGEO1	MA	Antagonist
DMPGEO1	RN	Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res. 2009 Jul 1;69(13):5441-9.
DMPGEO1	RU	https://pubmed.ncbi.nlm.nih.gov/19509223

DM50RUD	DI	DM50RUD
DM50RUD	DN	brucine
DM50RUD	MI	TTOXS3C
DM50RUD	MN	Muscarinic acetylcholine receptor (CHRM)
DM50RUD	MT	DTT
DM50RUD	MA	Modulator (allosteric modulator)
DM50RUD	RN	Subtype-selective positive cooperative interactions between brucine analogues and acetylcholine at muscarinic receptors: radioligand binding studies. Mol Pharmacol. 1998 Mar;53(3):573-89.
DM50RUD	RU	https://pubmed.ncbi.nlm.nih.gov/9495826

DM50RUD	DI	DM50RUD
DM50RUD	DN	brucine
DM50RUD	MI	TTQ13Z5
DM50RUD	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DM50RUD	MT	DTT
DM50RUD	MA	Modulator (allosteric modulator)
DM50RUD	RN	Subtype-selective positive cooperative interactions between brucine analogues and acetylcholine at muscarinic receptors: radioligand binding studies. Mol Pharmacol. 1998 Mar;53(3):573-89.
DM50RUD	RU	https://pubmed.ncbi.nlm.nih.gov/9495826

DMKZM1L	DI	DMKZM1L
DMKZM1L	DN	Brutieridin
DMKZM1L	MI	TTPADOQ
DMKZM1L	MN	HMG-CoA reductase (HMGCR)
DMKZM1L	MT	DTT
DMKZM1L	MA	Inhibitor
DMKZM1L	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 639).
DMKZM1L	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=639

DM1VF6H	DI	DM1VF6H
DM1VF6H	DN	BS 7581
DM1VF6H	MI	TTVG215
DM1VF6H	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DM1VF6H	MT	DTT
DM1VF6H	MA	Inhibitor
DM1VF6H	RN	Catalytic site prediction and virtual screening of cytochrome P450 2D6 substrates by consideration of water and rescoring in automated docking. J Med Chem. 2006 Apr 20;49(8):2417-30.
DM1VF6H	RU	https://pubmed.ncbi.nlm.nih.gov/16610785

DMDYNBT	DI	DMDYNBT
DMDYNBT	DN	BS 7840
DMDYNBT	MI	TTVG215
DMDYNBT	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DMDYNBT	MT	DTT
DMDYNBT	MA	Inhibitor
DMDYNBT	RN	Catalytic site prediction and virtual screening of cytochrome P450 2D6 substrates by consideration of water and rescoring in automated docking. J Med Chem. 2006 Apr 20;49(8):2417-30.
DMDYNBT	RU	https://pubmed.ncbi.nlm.nih.gov/16610785

DMQ2FDA	DI	DMQ2FDA
DMQ2FDA	DN	BS 9106
DMQ2FDA	MI	TTVG215
DMQ2FDA	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DMQ2FDA	MT	DTT
DMQ2FDA	MA	Inhibitor
DMQ2FDA	RN	Catalytic site prediction and virtual screening of cytochrome P450 2D6 substrates by consideration of water and rescoring in automated docking. J Med Chem. 2006 Apr 20;49(8):2417-30.
DMQ2FDA	RU	https://pubmed.ncbi.nlm.nih.gov/16610785

DMLXFHD	DI	DMLXFHD
DMLXFHD	DN	BS-194
DMLXFHD	MI	TTMBO1Z
DMLXFHD	MN	Cyclin-dependent kinase (CDK)
DMLXFHD	MT	DTT
DMLXFHD	MA	Inhibitor
DMLXFHD	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8176).
DMLXFHD	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8176

DMJIKHQ	DI	DMJIKHQ
DMJIKHQ	DN	BsAb cG7-MICA
DMJIKHQ	MI	TTCTYNP
DMJIKHQ	MN	Small cell lung carcinoma cluster 4 antigen (CD24)
DMJIKHQ	MT	DTT
DMJIKHQ	RN	Targeting CD24 for treatment of colorectal and pancreatic cancer by monoclonal antibodies or small interfering RNA. Cancer Res. 2008 Apr 15;68(8):2803-12.
DMJIKHQ	RU	https://pubmed.ncbi.nlm.nih.gov/217546303

DMNM63G	DI	DMNM63G
DMNM63G	DN	BTP2
DMNM63G	MI	TTJ2HKA
DMNM63G	MN	Long transient receptor potential channel 4 (TRPM4)
DMNM63G	MT	DTT
DMNM63G	MA	Activator
DMNM63G	RN	A pyrazole derivative potently inhibits lymphocyte Ca2+ influx and cytokine production by facilitating transient receptor potential melastatin 4 ch... Mol Pharmacol. 2006 Apr;69(4):1413-20.
DMNM63G	RU	https://pubmed.ncbi.nlm.nih.gov/16407466

DMNM63G	DI	DMNM63G
DMNM63G	DN	BTP2
DMNM63G	MI	TTNVC34
DMNM63G	MN	Short transient receptor potential channel 3 (TRPC3)
DMNM63G	MT	DTT
DMNM63G	MA	Blocker (channel blocker)
DMNM63G	RN	A functional link between store-operated and TRPC channels revealed by the 3,5-bis(trifluoromethyl)pyrazole derivative, BTP2. J Biol Chem. 2005 Mar 25;280(12):10997-1006.
DMNM63G	RU	https://pubmed.ncbi.nlm.nih.gov/15647288

DMNM63G	DI	DMNM63G
DMNM63G	DN	BTP2
DMNM63G	MI	TT32NQ1
DMNM63G	MN	Short transient receptor potential channel 5 (TRPC5)
DMNM63G	MT	DTT
DMNM63G	MA	Blocker (channel blocker)
DMNM63G	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 490).
DMNM63G	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=490

DMGFY4X	DI	DMGFY4X
DMGFY4X	DN	BUDDLEDIN A
DMGFY4X	MI	TT2J34L
DMGFY4X	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMGFY4X	MT	DTT
DMGFY4X	MA	Inhibitor
DMGFY4X	RN	Novel and known constituents from Buddleja species and their activity against leukocyte eicosanoid generation. J Nat Prod. 1999 Sep;62(9):1241-5.
DMGFY4X	RU	https://pubmed.ncbi.nlm.nih.gov/10514305

DMQVL2U	DI	DMQVL2U
DMQVL2U	DN	BUDLEIN A
DMQVL2U	MI	TTSXVID
DMQVL2U	MN	Nuclear factor NF-kappa-B (NFKB)
DMQVL2U	MT	DTT
DMQVL2U	MA	Inhibitor
DMQVL2U	RN	Quantitative structure-activity relationship of sesquiterpene lactones as inhibitors of the transcription factor NF-kappaB. J Med Chem. 2004 Nov 18;47(24):6042-54.
DMQVL2U	RU	https://pubmed.ncbi.nlm.nih.gov/15537359

DM1D47I	DI	DM1D47I
DM1D47I	DN	BU-E 47
DM1D47I	MI	TTTIBOJ
DM1D47I	MN	Histamine H1 receptor (H1R)
DM1D47I	MT	DTT
DM1D47I	MA	Antagonist
DM1D47I	RN	Multiple differences in agonist and antagonist pharmacology between human and guinea pig histamine H1-receptor. J Pharmacol Exp Ther. 2003 Jun;305(3):1104-15.
DM1D47I	RU	https://pubmed.ncbi.nlm.nih.gov/12626648

DMD1SY9	DI	DMD1SY9
DMD1SY9	DN	bufotenine
DMD1SY9	MI	TT6MSOK
DMD1SY9	MN	5-HT 1D receptor (HTR1D)
DMD1SY9	MT	DTT
DMD1SY9	MA	Antagonist
DMD1SY9	RN	Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan. Mol Pharmacol. 1996 Dec;50(6):1567-80.
DMD1SY9	RU	https://pubmed.ncbi.nlm.nih.gov/8967979

DMD1SY9	DI	DMD1SY9
DMD1SY9	DN	bufotenine
DMD1SY9	MI	TTJQOD7
DMD1SY9	MN	5-HT 2A receptor (HTR2A)
DMD1SY9	MT	DTT
DMD1SY9	MA	Antagonist
DMD1SY9	RN	Mapping the binding site pocket of the serotonin 5-Hydroxytryptamine2A receptor. Ser3.36(159) provides a second interaction site for the protonated amine of serotonin but not of lysergic acid diethylamide or bufotenin. J Biol Chem. 1996 Jun 21;271(25):14672-5.
DMD1SY9	RU	https://pubmed.ncbi.nlm.nih.gov/8663249

DMD1SY9	DI	DMD1SY9
DMD1SY9	DN	bufotenine
DMD1SY9	MI	TTRUFDT
DMD1SY9	MN	5-HT 5A receptor (HTR5A)
DMD1SY9	MT	DTT
DMD1SY9	MA	Antagonist
DMD1SY9	RN	Expression of functional mouse 5-HT5A serotonin receptor in the methylotrophic yeast Pichia pastoris: pharmacological characterization and localization. FEBS Lett. 1995 Dec 27;377(3):451-6.
DMD1SY9	RU	https://pubmed.ncbi.nlm.nih.gov/8549774

DMD1SY9	DI	DMD1SY9
DMD1SY9	DN	bufotenine
DMD1SY9	MI	TTJS8PY
DMD1SY9	MN	5-HT 6 receptor (HTR6)
DMD1SY9	MT	DTT
DMD1SY9	MA	Antagonist
DMD1SY9	RN	Functional and radioligand binding characterization of rat 5-HT6 receptors stably expressed in HEK293 cells. Neuropharmacology. 1997 Apr-May;36(4-5):713-20.
DMD1SY9	RU	https://pubmed.ncbi.nlm.nih.gov/9225298

DMD1SY9	DI	DMD1SY9
DMD1SY9	DN	bufotenine
DMD1SY9	MI	TTO9X1H
DMD1SY9	MN	5-HT 7 receptor (HTR7)
DMD1SY9	MT	DTT
DMD1SY9	MA	Agonist
DMD1SY9	RN	Molecular cloning of a mammalian serotonin receptor that activates adenylate cyclase. Mol Pharmacol. 1993 Aug;44(2):229-36.
DMD1SY9	RU	https://pubmed.ncbi.nlm.nih.gov/8394987

DM61F5W	DI	DM61F5W
DM61F5W	DN	BUFROLIN
DM61F5W	MI	TTHQENC
DM61F5W	MN	Phosphodiesterase 1 (PDE1)
DM61F5W	MT	DTT
DM61F5W	MA	Inhibitor
DM61F5W	RN	A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem. 1985 May;28(5):537-45.
DM61F5W	RU	https://pubmed.ncbi.nlm.nih.gov/2985781

DMWQ3RH	DI	DMWQ3RH
DMWQ3RH	DN	bufrudin
DMWQ3RH	MI	TT6L509
DMWQ3RH	MN	Coagulation factor IIa (F2)
DMWQ3RH	MT	DTT
DMWQ3RH	MA	Modulator
DMWQ3RH	RN	Leech therapeutic applications.Indian J Pharm Sci.2013 Mar;75(2):127-37.
DMWQ3RH	RU	https://www.ncbi.nlm.nih.gov/pubmed/24019559

DMJSC07	DI	DMJSC07
DMJSC07	DN	Bufuralol
DMJSC07	MI	DECB0K3
DMJSC07	MN	Cytochrome P450 2D6 (CYP2D6)
DMJSC07	MT	DME
DMJSC07	MA	Metabolism
DMJSC07	RN	Cytochrome b5 is a major determinant of human cytochrome P450 CYP2D6 and CYP3A4 activity in vivo. Mol Pharmacol. 2015 Apr;87(4):733-9.
DMJSC07	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25657337

DMUT9IQ	DI	DMUT9IQ
DMUT9IQ	DN	Bupranolol
DMUT9IQ	MI	DECB0K3
DMUT9IQ	MN	Cytochrome P450 2D6 (CYP2D6)
DMUT9IQ	MT	DME
DMUT9IQ	MA	Metabolism
DMUT9IQ	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMUT9IQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMZ2VYG	DI	DMZ2VYG
DMZ2VYG	DN	burimamide
DMZ2VYG	MI	TTQHJ1K
DMZ2VYG	MN	Histamine H2 receptor (H2R)
DMZ2VYG	MT	DTT
DMZ2VYG	MA	Agonist
DMZ2VYG	RN	Constitutive activity and structural instability of the wild-type human H2 receptor. J Neurochem. 1998 Aug;71(2):799-807.
DMZ2VYG	RU	https://pubmed.ncbi.nlm.nih.gov/9681472

DMZ2VYG	DI	DMZ2VYG
DMZ2VYG	DN	burimamide
DMZ2VYG	MI	TT9JNIC
DMZ2VYG	MN	Histamine H3 receptor (H3R)
DMZ2VYG	MT	DTT
DMZ2VYG	MA	Antagonist
DMZ2VYG	RN	Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol. 2001 Mar;59(3):420-6.
DMZ2VYG	RU	https://pubmed.ncbi.nlm.nih.gov/11179434

DMZ2VYG	DI	DMZ2VYG
DMZ2VYG	DN	burimamide
DMZ2VYG	MI	TTXJ178
DMZ2VYG	MN	Histamine H4 receptor (H4R)
DMZ2VYG	MT	DTT
DMZ2VYG	MA	Antagonist
DMZ2VYG	RN	Comparison of human, mouse, rat, and guinea pig histamine H4 receptors reveals substantial pharmacological species variation. J Pharmacol Exp Ther. 2001 Oct;299(1):121-30.
DMZ2VYG	RU	https://pubmed.ncbi.nlm.nih.gov/11561071

DMBO0WI	DI	DMBO0WI
DMBO0WI	DN	Burnamine-17-O-3',4',5'-trimethoxybenzoate
DMBO0WI	MI	TTF8JAT
DMBO0WI	MN	SLC5A2 messenger RNA (SLC5A2 mRNA)
DMBO0WI	MT	DTT
DMBO0WI	MA	Inhibitor
DMBO0WI	RN	Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter. Bioorg Med Chem. 2010 Mar 15;18(6):2152-2158.
DMBO0WI	RU	https://pubmed.ncbi.nlm.nih.gov/20189404

DMBO0WI	DI	DMBO0WI
DMBO0WI	DN	Burnamine-17-O-3',4',5'-trimethoxybenzoate
DMBO0WI	MI	TT2UE56
DMBO0WI	MN	Sodium/glucose cotransporter 1 (SGLT1)
DMBO0WI	MT	DTT
DMBO0WI	MA	Inhibitor
DMBO0WI	RN	Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter. Bioorg Med Chem. 2010 Mar 15;18(6):2152-2158.
DMBO0WI	RU	https://pubmed.ncbi.nlm.nih.gov/20189404

DMJP0QT	DI	DMJP0QT
DMJP0QT	DN	BURTTINONE
DMJP0QT	MI	TTELIN2
DMJP0QT	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMJP0QT	MT	DTT
DMJP0QT	MA	Inhibitor
DMJP0QT	RN	Flavanones from the stem bark of Erythrina abyssinica. Bioorg Med Chem. 2008 Dec 15;16(24):10356-62.
DMJP0QT	RU	https://pubmed.ncbi.nlm.nih.gov/19008110

DMDC7MT	DI	DMDC7MT
DMDC7MT	DN	Bu-RYYRIK-NH2
DMDC7MT	MI	TTNT7K8
DMDC7MT	MN	Nociceptin receptor (OPRL1)
DMDC7MT	MT	DTT
DMDC7MT	MA	Inhibitor
DMDC7MT	RN	Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist. Bioorg Med Chem. 2008 Mar 1;16(5):2635-44.
DMDC7MT	RU	https://pubmed.ncbi.nlm.nih.gov/18068993

DMMHGIN	DI	DMMHGIN
DMMHGIN	DN	But-3-enyl-trimethyl-ammonium bromide
DMMHGIN	MI	TT1RS9F
DMMHGIN	MN	Acetylcholinesterase (AChE)
DMMHGIN	MT	DTT
DMMHGIN	MA	Inhibitor
DMMHGIN	RN	Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors. J Med Chem. 1996 Dec 20;39(26):5064-71.
DMMHGIN	RU	https://pubmed.ncbi.nlm.nih.gov/8978837

DMTAJP7	DI	DMTAJP7
DMTAJP7	DN	Butanoic acid
DMTAJP7	MI	DTI7UX6
DMTAJP7	MN	Breast cancer resistance protein (ABCG2)
DMTAJP7	MT	DTP
DMTAJP7	MA	Substrate
DMTAJP7	RN	The short-chain fatty acid butyrate is a substrate of breast cancer resistance protein. Am J Physiol Cell Physiol. 2011 Nov;301(5):C984-94.
DMTAJP7	RU	https://doi.org/10.1152/ajpcell.00146.2011

DMTAJP7	DI	DMTAJP7
DMTAJP7	DN	Butanoic acid
DMTAJP7	MI	TTEB0GD
DMTAJP7	MN	Cholinesterase (BCHE)
DMTAJP7	MT	DTT
DMTAJP7	MA	Inhibitor
DMTAJP7	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMTAJP7	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMTAJP7	DI	DMTAJP7
DMTAJP7	DN	Butanoic acid
DMTAJP7	MI	DT342ZG
DMTAJP7	MN	Monocarboxylate transporter 1 (SLC16A1)
DMTAJP7	MT	DTP
DMTAJP7	MA	Substrate
DMTAJP7	RN	Overview of the proton-coupled MCT (SLC16A) family of transporters: characterization, function and role in the transport of the drug of abuse gamma-hydroxybutyric acid. AAPS J. 2008 Jun;10(2):311-21.
DMTAJP7	RU	https://doi.org/10.1208/s12248-008-9035-6

DM5MZHP	DI	DM5MZHP
DM5MZHP	DN	butaprost (free acid form)
DM5MZHP	MI	TTOFYT1
DM5MZHP	MN	Prostacyclin receptor (PTGIR)
DM5MZHP	MT	DTT
DM5MZHP	MA	Agonist
DM5MZHP	RN	The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
DM5MZHP	RU	https://pubmed.ncbi.nlm.nih.gov/10634944

DM5MZHP	DI	DM5MZHP
DM5MZHP	DN	butaprost (free acid form)
DM5MZHP	MI	TTNVEIR
DM5MZHP	MN	Prostaglandin D2 receptor (PTGDR)
DM5MZHP	MT	DTT
DM5MZHP	MA	Agonist
DM5MZHP	RN	The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
DM5MZHP	RU	https://pubmed.ncbi.nlm.nih.gov/10634944

DM5MZHP	DI	DM5MZHP
DM5MZHP	DN	butaprost (free acid form)
DM5MZHP	MI	TT1ZAVI
DM5MZHP	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DM5MZHP	MT	DTT
DM5MZHP	MA	Agonist
DM5MZHP	RN	Importance of the extracellular domain for prostaglandin EP(2) receptor function. Mol Pharmacol. 1999 Sep;56(3):545-51.
DM5MZHP	RU	https://pubmed.ncbi.nlm.nih.gov/10462542

DM5MZHP	DI	DM5MZHP
DM5MZHP	DN	butaprost (free acid form)
DM5MZHP	MI	TTPNGDE
DM5MZHP	MN	Prostaglandin E2 receptor EP3 (PTGER3)
DM5MZHP	MT	DTT
DM5MZHP	MA	Agonist
DM5MZHP	RN	The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
DM5MZHP	RU	https://pubmed.ncbi.nlm.nih.gov/10634944

DM5MZHP	DI	DM5MZHP
DM5MZHP	DN	butaprost (free acid form)
DM5MZHP	MI	TT79WV3
DM5MZHP	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DM5MZHP	MT	DTT
DM5MZHP	MA	Agonist
DM5MZHP	RN	Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41.
DM5MZHP	RU	https://pubmed.ncbi.nlm.nih.gov/9537820

DM5MZHP	DI	DM5MZHP
DM5MZHP	DN	butaprost (free acid form)
DM5MZHP	MI	TT2O84V
DM5MZHP	MN	Thromboxane A2 receptor (TBXA2R)
DM5MZHP	MT	DTT
DM5MZHP	MA	Agonist
DM5MZHP	RN	The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
DM5MZHP	RU	https://pubmed.ncbi.nlm.nih.gov/10634944

DM8E54P	DI	DM8E54P
DM8E54P	DN	BUTEIN
DM8E54P	MI	TTL69WB
DM8E54P	MN	Angiotensin-converting enzyme (ACE)
DM8E54P	MT	DTT
DM8E54P	MA	Inhibitor
DM8E54P	RN	The synthesis and angiotensin converting enzyme (ACE) inhibitory activity of chalcones and their pyrazole derivatives. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1990-3.
DM8E54P	RU	https://pubmed.ncbi.nlm.nih.gov/20167484

DM8E54P	DI	DM8E54P
DM8E54P	DN	BUTEIN
DM8E54P	MI	TTNX2CS
DM8E54P	MN	Plasmodium Enoyl-ACP reductase (Malaria fabI)
DM8E54P	MT	DTT
DM8E54P	MA	Inhibitor
DM8E54P	RN	Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR). J Med Chem. 2007 Feb 22;50(4):765-75.
DM8E54P	RU	https://pubmed.ncbi.nlm.nih.gov/17263522

DMJ46CB	DI	DMJ46CB
DMJ46CB	DN	Buthionine sulfoximine
DMJ46CB	MI	TTNFESW
DMJ46CB	MN	Glutamate--cysteine ligase modifier (GCLM)
DMJ46CB	MT	DTT
DMJ46CB	MA	Inhibitor
DMJ46CB	RN	Novel molecular targets for antimalarial chemotherapy. Int J Antimicrob Agents. 2007 Jul;30(1):4-10.
DMJ46CB	RU	https://pubmed.ncbi.nlm.nih.gov/17339102

DMR6GJK	DI	DMR6GJK
DMR6GJK	DN	Butirosin B
DMR6GJK	MI	TT38DW5
DMR6GJK	MN	Bacterial 16S ribosomal RNA (Bact 16S rRNA)
DMR6GJK	MT	DTT
DMR6GJK	MA	Inhibitor
DMR6GJK	RN	RNA as a target for small molecules. Curr Opin Chem Biol. 2000 Dec;4(6):678-86.
DMR6GJK	RU	https://pubmed.ncbi.nlm.nih.gov/11102874

DM82KPQ	DI	DM82KPQ
DM82KPQ	DN	BUTORPHAN
DM82KPQ	MI	TT27RFC
DM82KPQ	MN	Opioid receptor delta (OPRD1)
DM82KPQ	MT	DTT
DM82KPQ	MA	Inhibitor
DM82KPQ	RN	Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1507-9.
DM82KPQ	RU	https://pubmed.ncbi.nlm.nih.gov/20144870

DM82KPQ	DI	DM82KPQ
DM82KPQ	DN	BUTORPHAN
DM82KPQ	MI	TTQW87Y
DM82KPQ	MN	Opioid receptor kappa (OPRK1)
DM82KPQ	MT	DTT
DM82KPQ	MA	Inhibitor
DM82KPQ	RN	Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pha... J Med Chem. 2000 Jan 13;43(1):114-22.
DM82KPQ	RU	https://pubmed.ncbi.nlm.nih.gov/10633042

DM82KPQ	DI	DM82KPQ
DM82KPQ	DN	BUTORPHAN
DM82KPQ	MI	TTKWM86
DM82KPQ	MN	Opioid receptor mu (MOP)
DM82KPQ	MT	DTT
DM82KPQ	MA	Inhibitor
DM82KPQ	RN	Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pha... J Med Chem. 2000 Jan 13;43(1):114-22.
DM82KPQ	RU	https://pubmed.ncbi.nlm.nih.gov/10633042

DM7XN2J	DI	DM7XN2J
DM7XN2J	DN	Butoxamine
DM7XN2J	MI	TT2CJVK
DM7XN2J	MN	Adrenergic receptor beta-2 (ADRB2)
DM7XN2J	MT	DTT
DM7XN2J	MA	Antagonist
DM7XN2J	RN	Partial agonistic effects of carteolol on atypical beta-adrenoceptors in the guinea pig gastric fundus. Jpn J Pharmacol. 2000 Nov;84(3):287-92.
DM7XN2J	RU	https://pubmed.ncbi.nlm.nih.gov/11138729

DMGHEQV	DI	DMGHEQV
DMGHEQV	DN	Butyl 10H-phenothiazine-10-carboxylate
DMGHEQV	MI	TTEB0GD
DMGHEQV	MN	Cholinesterase (BCHE)
DMGHEQV	MT	DTT
DMGHEQV	MA	Inhibitor
DMGHEQV	RN	Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. J Med Chem. 2008 Jul 24;51(14):4200-12.
DMGHEQV	RU	https://pubmed.ncbi.nlm.nih.gov/18570368

DM1CX9Y	DI	DM1CX9Y
DM1CX9Y	DN	Butyl-indol-1-yl-pyridin-4-yl-amine
DM1CX9Y	MI	TTWG9A4
DM1CX9Y	MN	Adrenergic receptor alpha-2A (ADRA2A)
DM1CX9Y	MT	DTT
DM1CX9Y	MA	Inhibitor
DM1CX9Y	RN	Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81.
DM1CX9Y	RU	https://pubmed.ncbi.nlm.nih.gov/8558529

DM1CX9Y	DI	DM1CX9Y
DM1CX9Y	DN	Butyl-indol-1-yl-pyridin-4-yl-amine
DM1CX9Y	MI	TTWM4TY
DM1CX9Y	MN	Adrenergic receptor alpha-2B (ADRA2B)
DM1CX9Y	MT	DTT
DM1CX9Y	MA	Inhibitor
DM1CX9Y	RN	Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81.
DM1CX9Y	RU	https://pubmed.ncbi.nlm.nih.gov/8558529

DM1CX9Y	DI	DM1CX9Y
DM1CX9Y	DN	Butyl-indol-1-yl-pyridin-4-yl-amine
DM1CX9Y	MI	TT2NUT5
DM1CX9Y	MN	Adrenergic receptor alpha-2C (ADRA2C)
DM1CX9Y	MT	DTT
DM1CX9Y	MA	Inhibitor
DM1CX9Y	RN	Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81.
DM1CX9Y	RU	https://pubmed.ncbi.nlm.nih.gov/8558529

DMJUTWG	DI	DMJUTWG
DMJUTWG	DN	Butyl-methyl-prop-2-ynyl-amine hydrochloride
DMJUTWG	MI	TTGP7BY
DMJUTWG	MN	Monoamine oxidase type B (MAO-B)
DMJUTWG	MT	DTT
DMJUTWG	MA	Inhibitor
DMJUTWG	RN	Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors. J Med Chem. 1992 Oct 2;35(20):3705-13.
DMJUTWG	RU	https://pubmed.ncbi.nlm.nih.gov/1433183

DMF5D1N	DI	DMF5D1N
DMF5D1N	DN	Butylphosphonate
DMF5D1N	MI	TT3GKN5
DMF5D1N	MN	Lipase unspecific (LIP)
DMF5D1N	MT	DTT
DMF5D1N	MA	Inhibitor
DMF5D1N	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMF5D1N	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9X2FV	DI	DM9X2FV
DM9X2FV	DN	Butyrfentanyl
DM9X2FV	MI	DECB0K3
DM9X2FV	MN	Cytochrome P450 2D6 (CYP2D6)
DM9X2FV	MT	DME
DM9X2FV	MA	Metabolism
DM9X2FV	RN	Studies on the metabolism of the fentanyl-derived designer drug butyrfentanyl in human in vitro liver preparations and authentic human samples using liquid chromatography-high resolution mass spectrometry (LC-HRMS). Drug Test Anal. 2017 Jul;9(7):1085-1092.
DM9X2FV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27736030

DM9X2FV	DI	DM9X2FV
DM9X2FV	DN	Butyrfentanyl
DM9X2FV	MI	DE4LYSA
DM9X2FV	MN	Cytochrome P450 3A4 (CYP3A4)
DM9X2FV	MT	DME
DM9X2FV	MA	Metabolism
DM9X2FV	RN	Metabolism of butyrylfentanyl in fresh human hepatocytes: chemical synthesis of authentic metabolite standards for definitive identification. Biol Pharm Bull. 2019;42(4):623-630.
DM9X2FV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30930421

DMOBYVL	DI	DMOBYVL
DMOBYVL	DN	Butyrylthiocholine
DMOBYVL	MI	TTEB0GD
DMOBYVL	MN	Cholinesterase (BCHE)
DMOBYVL	MT	DTT
DMOBYVL	MA	Inhibitor
DMOBYVL	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMOBYVL	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMDTV7A	DI	DMDTV7A
DMDTV7A	DN	BV-6
DMDTV7A	MI	TTQ5LRD
DMDTV7A	MN	Cellular inhibitor of apoptosis 1 (BIRC2)
DMDTV7A	MT	DTT
DMDTV7A	MA	Inhibitor
DMDTV7A	RN	IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell. 2007 Nov 16;131(4):669-81.
DMDTV7A	RU	https://pubmed.ncbi.nlm.nih.gov/18022362

DMDTV7A	DI	DMDTV7A
DMDTV7A	DN	BV-6
DMDTV7A	MI	TTK3WBU
DMDTV7A	MN	XIAP messenger RNA (XIAP mRNA)
DMDTV7A	MT	DTT
DMDTV7A	MA	Inhibitor
DMDTV7A	RN	IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell. 2007 Nov 16;131(4):669-81.
DMDTV7A	RU	https://pubmed.ncbi.nlm.nih.gov/18022362

DM10UHA	DI	DM10UHA
DM10UHA	DN	BVB-808
DM10UHA	MI	TTRMX3V
DM10UHA	MN	Janus kinase 2 (JAK-2)
DM10UHA	MT	DTT
DM10UHA	MA	Inhibitor
DM10UHA	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2048).
DM10UHA	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2048

DMI1H3Y	DI	DMI1H3Y
DMI1H3Y	DN	BVDU-MP
DMI1H3Y	MI	TTP3QRF
DMI1H3Y	MN	Thymidine kinase 1 (TK1)
DMI1H3Y	MT	DTT
DMI1H3Y	MA	Inhibitor
DMI1H3Y	RN	Crystal structure of varicella zoster virus thymidine kinase. J Biol Chem. 2003 Jul 4;278(27):24680-7.
DMI1H3Y	RU	https://pubmed.ncbi.nlm.nih.gov/12686543

DM8N7BA	DI	DM8N7BA
DM8N7BA	DN	BVT 933
DM8N7BA	MI	TTWJBZ5
DM8N7BA	MN	5-HT 2C receptor (HTR2C)
DM8N7BA	MT	DTT
DM8N7BA	MA	Antagonist
DM8N7BA	RN	Obesity: pathophysiology and clinical management. Curr Med Chem. 2009;16(4):506-21.
DM8N7BA	RU	https://pubmed.ncbi.nlm.nih.gov/19199918

DMULZOP	DI	DMULZOP
DMULZOP	DN	BVT173187
DMULZOP	MI	TT5Y4EM
DMULZOP	MN	N-formyl peptide receptor (FPR1)
DMULZOP	MT	DTT
DMULZOP	MA	Antagonist
DMULZOP	RN	A non-peptide receptor inhibitor with selectivity for one of the neutrophil formyl peptide receptors, FPR 1. Biochem Pharmacol. 2012 Jun 15;83(12):1655-62.
DMULZOP	RU	https://pubmed.ncbi.nlm.nih.gov/22410002

DMAVDNU	DI	DMAVDNU
DMAVDNU	DN	BVX-20-CD20
DMAVDNU	MI	TTUE541
DMAVDNU	MN	Leukocyte surface antigen Leu-16 (CD20)
DMAVDNU	MT	DTT
DMAVDNU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628).
DMAVDNU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2628

DMA0FO5	DI	DMA0FO5
DMA0FO5	DN	BW 245C
DMA0FO5	MI	TTNVEIR
DMA0FO5	MN	Prostaglandin D2 receptor (PTGDR)
DMA0FO5	MT	DTT
DMA0FO5	MA	Agonist
DMA0FO5	RN	Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
DMA0FO5	RU	https://pubmed.ncbi.nlm.nih.gov/9313928

DMNSLGC	DI	DMNSLGC
DMNSLGC	DN	BW A360C
DMNSLGC	MI	TT2J34L
DMNSLGC	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMNSLGC	MT	DTT
DMNSLGC	MA	Inhibitor
DMNSLGC	RN	Hydroxamic acids and hydroxyureas as novel, selective 5-lipoxygenase inhibitors for possible use in asthma. Agents Actions Suppl. 1991;34:189-99.
DMNSLGC	RU	https://pubmed.ncbi.nlm.nih.gov/1793063

DMHQP84	DI	DMHQP84
DMHQP84	DN	BW B218C
DMHQP84	MI	TT2J34L
DMHQP84	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMHQP84	MT	DTT
DMHQP84	MA	Inhibitor
DMHQP84	RN	Hydroxamic acids and hydroxyureas as novel, selective 5-lipoxygenase inhibitors for possible use in asthma. Agents Actions Suppl. 1991;34:189-99.
DMHQP84	RU	https://pubmed.ncbi.nlm.nih.gov/1793063

DMFKXMT	DI	DMFKXMT
DMFKXMT	DN	BW-202W92
DMFKXMT	MI	TTRK8B9
DMFKXMT	MN	Sodium channel unspecific (NaC)
DMFKXMT	MT	DTT
DMFKXMT	MA	Inhibitor
DMFKXMT	RN	Oxadiazolylindazole sodium channel modulators are neuroprotective toward hippocampal neurones. J Med Chem. 2009 May 14;52(9):2694-707.
DMFKXMT	RU	https://pubmed.ncbi.nlm.nih.gov/19341281

DMFKXMT	DI	DMFKXMT
DMFKXMT	DN	BW-202W92
DMFKXMT	MI	TTAXZ0K
DMFKXMT	MN	Voltage-gated sodium channel alpha Nav1.3 (SCN3A)
DMFKXMT	MT	DTT
DMFKXMT	MA	Inhibitor
DMFKXMT	RN	Oxadiazolylindazole sodium channel modulators are neuroprotective toward hippocampal neurones. J Med Chem. 2009 May 14;52(9):2694-707.
DMFKXMT	RU	https://pubmed.ncbi.nlm.nih.gov/19341281

DMFKXMT	DI	DMFKXMT
DMFKXMT	DN	BW-202W92
DMFKXMT	MI	TT84DRB
DMFKXMT	MN	Voltage-gated sodium channel alpha Nav1.4 (SCN4A)
DMFKXMT	MT	DTT
DMFKXMT	MA	Inhibitor
DMFKXMT	RN	Oxadiazolylindazole sodium channel modulators are neuroprotective toward hippocampal neurones. J Med Chem. 2009 May 14;52(9):2694-707.
DMFKXMT	RU	https://pubmed.ncbi.nlm.nih.gov/19341281

DMFKXMT	DI	DMFKXMT
DMFKXMT	DN	BW-202W92
DMFKXMT	MI	TT90XZ8
DMFKXMT	MN	Voltage-gated sodium channel alpha Nav1.8 (SCN10A)
DMFKXMT	MT	DTT
DMFKXMT	MA	Inhibitor
DMFKXMT	RN	Oxadiazolylindazole sodium channel modulators are neuroprotective toward hippocampal neurones. J Med Chem. 2009 May 14;52(9):2694-707.
DMFKXMT	RU	https://pubmed.ncbi.nlm.nih.gov/19341281

DMQ3AC0	DI	DMQ3AC0
DMQ3AC0	DN	BW284C51
DMQ3AC0	MI	TT1RS9F
DMQ3AC0	MN	Acetylcholinesterase (AChE)
DMQ3AC0	MT	DTT
DMQ3AC0	MA	Inhibitor
DMQ3AC0	RN	Cholinesterases: new roles in brain function and in Alzheimer's disease. Neurochem Res. 2003 Apr;28(3-4):515-22.
DMQ3AC0	RU	https://pubmed.ncbi.nlm.nih.gov/12675140

DME15JU	DI	DME15JU
DME15JU	DN	BW723C86
DME15JU	MI	TTJQOD7
DME15JU	MN	5-HT 2A receptor (HTR2A)
DME15JU	MT	DTT
DME15JU	MA	Agonist
DME15JU	RN	Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
DME15JU	RU	https://pubmed.ncbi.nlm.nih.gov/15322733

DME15JU	DI	DME15JU
DME15JU	DN	BW723C86
DME15JU	MI	TT0K1SC
DME15JU	MN	5-HT 2B receptor (HTR2B)
DME15JU	MT	DTT
DME15JU	MA	Agonist
DME15JU	RN	Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy. Br J Pharmacol. 2003 Sep;140(2):277-84.
DME15JU	RU	https://pubmed.ncbi.nlm.nih.gov/12970106

DME15JU	DI	DME15JU
DME15JU	DN	BW723C86
DME15JU	MI	TTWJBZ5
DME15JU	MN	5-HT 2C receptor (HTR2C)
DME15JU	MT	DTT
DME15JU	MA	Agonist
DME15JU	RN	Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy. Br J Pharmacol. 2003 Sep;140(2):277-84.
DME15JU	RU	https://pubmed.ncbi.nlm.nih.gov/12970106

DMM2WPH	DI	DMM2WPH
DMM2WPH	DN	BW-858C
DMM2WPH	MI	TT2J34L
DMM2WPH	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMM2WPH	MT	DTT
DMM2WPH	MA	Modulator
DMM2WPH	RN	Effect of BW B70C, a novel inhibitor of arachidonic acid 5-lipoxygenase, on allergen-induced bronchoconstriction and late-phase lung eosinophil accumulation in sensitised guinea-pigs. Agents Actions.1993 Jan;38(1-2):8-18.
DMM2WPH	RU	https://pubmed.ncbi.nlm.nih.gov/8480540

DM7SNU0	DI	DM7SNU0
DM7SNU0	DN	BW-A137C
DM7SNU0	MI	TT2J34L
DM7SNU0	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM7SNU0	MT	DTT
DM7SNU0	MA	Modulator
DM7SNU0	RN	Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamic acids: effects on bronchial anaphylaxis in anaesthetized guinea-pigs. Br J Pharmacol. 1988 Jun;94(2):540-6.
DM7SNU0	RU	https://www.ncbi.nlm.nih.gov/pubmed/3395791

DMU9LQW	DI	DMU9LQW
DMU9LQW	DN	BWA868C
DMU9LQW	MI	TTNVEIR
DMU9LQW	MN	Prostaglandin D2 receptor (PTGDR)
DMU9LQW	MT	DTT
DMU9LQW	MA	Antagonist
DMU9LQW	RN	Pharmacology and autoradiography of human DP prostanoid receptors using [(3)H]-BWA868C, a DP receptor-selective antagonist radioligand. Br J Pharmacol. 2000 Nov;131(6):1025-38.
DMU9LQW	RU	https://pubmed.ncbi.nlm.nih.gov/11082108

DMA2B1C	DI	DMA2B1C
DMA2B1C	DN	BX 048
DMA2B1C	MI	TTZ1DT0
DMA2B1C	MN	P2Y purinoceptor 12 (P2RY12)
DMA2B1C	MT	DTT
DMA2B1C	MA	Antagonist
DMA2B1C	RN	Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): pharmacodynamic and pharmacokinetic characterization. Thromb Res. 2008;122(4):533-40.
DMA2B1C	RU	https://pubmed.ncbi.nlm.nih.gov/18539312

DM5CGXB	DI	DM5CGXB
DM5CGXB	DN	BX 471
DM5CGXB	MI	TTC24WT
DM5CGXB	MN	C-C chemokine receptor type 1 (CCR1)
DM5CGXB	MT	DTT
DM5CGXB	MA	Antagonist
DM5CGXB	RN	Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1. J Biol Chem. 2000 Jun 23;275(25):19000-8.
DM5CGXB	RU	https://pubmed.ncbi.nlm.nih.gov/10748002

DMBKVN9	DI	DMBKVN9
DMBKVN9	DN	BX 667
DMBKVN9	MI	TTZ1DT0
DMBKVN9	MN	P2Y purinoceptor 12 (P2RY12)
DMBKVN9	MT	DTT
DMBKVN9	MA	Antagonist
DMBKVN9	RN	Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): pharmacodynamic and pharmacokinetic characterization. Thromb Res. 2008;122(4):533-40.
DMBKVN9	RU	https://pubmed.ncbi.nlm.nih.gov/18539312

DMGK7U5	DI	DMGK7U5
DMGK7U5	DN	BX-201
DMGK7U5	MI	TTYMGWX
DMGK7U5	MN	PDK-1 messenger RNA (PDK-1 mRNA)
DMGK7U5	MT	DTT
DMGK7U5	MA	Inhibitor
DMGK7U5	RN	Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity. Bioorg Med Chem Lett. 2007 Jul 15;17(14):3814-8.
DMGK7U5	RU	https://pubmed.ncbi.nlm.nih.gov/17531483

DMBQIEF	DI	DMBQIEF
DMBQIEF	DN	BX-517
DMBQIEF	MI	TTYMGWX
DMBQIEF	MN	PDK-1 messenger RNA (PDK-1 mRNA)
DMBQIEF	MT	DTT
DMBQIEF	MA	Inhibitor
DMBQIEF	RN	Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity. Bioorg Med Chem Lett. 2007 Jul 15;17(14):3814-8.
DMBQIEF	RU	https://pubmed.ncbi.nlm.nih.gov/17531483

DMBQIEF	DI	DMBQIEF
DMBQIEF	DN	BX-517
DMBQIEF	MI	TTWTSCV
DMBQIEF	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DMBQIEF	MT	DTT
DMBQIEF	MA	Inhibitor
DMBQIEF	RN	Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity. Bioorg Med Chem Lett. 2007 Jul 15;17(14):3814-8.
DMBQIEF	RU	https://pubmed.ncbi.nlm.nih.gov/17531483

DMRIMLJ	DI	DMRIMLJ
DMRIMLJ	DN	BX-795
DMRIMLJ	MI	TTTU902
DMRIMLJ	MN	Checkpoint kinase-1 (CHK1)
DMRIMLJ	MT	DTT
DMRIMLJ	MA	Inhibitor
DMRIMLJ	RN	Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74.
DMRIMLJ	RU	https://pubmed.ncbi.nlm.nih.gov/15772071

DMRIMLJ	DI	DMRIMLJ
DMRIMLJ	DN	BX-795
DMRIMLJ	MI	TT7HF4W
DMRIMLJ	MN	Cyclin-dependent kinase 2 (CDK2)
DMRIMLJ	MT	DTT
DMRIMLJ	MA	Inhibitor
DMRIMLJ	RN	Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74.
DMRIMLJ	RU	https://pubmed.ncbi.nlm.nih.gov/15772071

DMRIMLJ	DI	DMRIMLJ
DMRIMLJ	DN	BX-795
DMRIMLJ	MI	TTYVI76
DMRIMLJ	MN	Fungal Protein kinase A (Fung ypkA)
DMRIMLJ	MT	DTT
DMRIMLJ	MA	Inhibitor
DMRIMLJ	RN	Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74.
DMRIMLJ	RU	https://pubmed.ncbi.nlm.nih.gov/15772071

DMRIMLJ	DI	DMRIMLJ
DMRIMLJ	DN	BX-795
DMRIMLJ	MI	TTRSMW9
DMRIMLJ	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMRIMLJ	MT	DTT
DMRIMLJ	MA	Inhibitor
DMRIMLJ	RN	Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74.
DMRIMLJ	RU	https://pubmed.ncbi.nlm.nih.gov/15772071

DMRIMLJ	DI	DMRIMLJ
DMRIMLJ	DN	BX-795
DMRIMLJ	MI	TT9QBI6
DMRIMLJ	MN	Phosphoinositide dependent protein kinase-1 (PDPK1)
DMRIMLJ	MT	DTT
DMRIMLJ	MA	Inhibitor
DMRIMLJ	RN	Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74.
DMRIMLJ	RU	https://pubmed.ncbi.nlm.nih.gov/15772071

DMRIMLJ	DI	DMRIMLJ
DMRIMLJ	DN	BX-795
DMRIMLJ	MI	TTUTJGQ
DMRIMLJ	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMRIMLJ	MT	DTT
DMRIMLJ	MA	Inhibitor
DMRIMLJ	RN	Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74.
DMRIMLJ	RU	https://pubmed.ncbi.nlm.nih.gov/15772071

DMZA45C	DI	DMZA45C
DMZA45C	DN	BX-912
DMZA45C	MI	TTTU902
DMZA45C	MN	Checkpoint kinase-1 (CHK1)
DMZA45C	MT	DTT
DMZA45C	MA	Inhibitor
DMZA45C	RN	Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74.
DMZA45C	RU	https://pubmed.ncbi.nlm.nih.gov/15772071

DMZA45C	DI	DMZA45C
DMZA45C	DN	BX-912
DMZA45C	MI	TT7HF4W
DMZA45C	MN	Cyclin-dependent kinase 2 (CDK2)
DMZA45C	MT	DTT
DMZA45C	MA	Inhibitor
DMZA45C	RN	Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74.
DMZA45C	RU	https://pubmed.ncbi.nlm.nih.gov/15772071

DMZA45C	DI	DMZA45C
DMZA45C	DN	BX-912
DMZA45C	MI	TTYVI76
DMZA45C	MN	Fungal Protein kinase A (Fung ypkA)
DMZA45C	MT	DTT
DMZA45C	MA	Inhibitor
DMZA45C	RN	Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74.
DMZA45C	RU	https://pubmed.ncbi.nlm.nih.gov/15772071

DMZA45C	DI	DMZA45C
DMZA45C	DN	BX-912
DMZA45C	MI	TTRSMW9
DMZA45C	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMZA45C	MT	DTT
DMZA45C	MA	Inhibitor
DMZA45C	RN	Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74.
DMZA45C	RU	https://pubmed.ncbi.nlm.nih.gov/15772071

DMZA45C	DI	DMZA45C
DMZA45C	DN	BX-912
DMZA45C	MI	TT9QBI6
DMZA45C	MN	Phosphoinositide dependent protein kinase-1 (PDPK1)
DMZA45C	MT	DTT
DMZA45C	MA	Inhibitor
DMZA45C	RN	Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74.
DMZA45C	RU	https://pubmed.ncbi.nlm.nih.gov/15772071

DMZA45C	DI	DMZA45C
DMZA45C	DN	BX-912
DMZA45C	MI	TTUTJGQ
DMZA45C	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMZA45C	MT	DTT
DMZA45C	MA	Inhibitor
DMZA45C	RN	Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74.
DMZA45C	RU	https://pubmed.ncbi.nlm.nih.gov/15772071

DMAWMDN	DI	DMAWMDN
DMAWMDN	DN	BYK-191023
DMAWMDN	MI	TTF10I9
DMAWMDN	MN	Nitric-oxide synthase inducible (NOS2)
DMAWMDN	MT	DTT
DMAWMDN	MA	Inhibitor
DMAWMDN	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1250).
DMAWMDN	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1250

DMN5X17	DI	DMN5X17
DMN5X17	DN	BZ3
DMN5X17	MI	TTVDSZ0
DMN5X17	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMN5X17	MT	DTT
DMN5X17	MA	Inhibitor
DMN5X17	RN	Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clin Cancer Res. 2003 Jul;9(7):2711-8.
DMN5X17	RU	https://pubmed.ncbi.nlm.nih.gov/12855651

DMRXPFM	DI	DMRXPFM
DMRXPFM	DN	BZ5
DMRXPFM	MI	TTVDSZ0
DMRXPFM	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMRXPFM	MT	DTT
DMRXPFM	MA	Inhibitor
DMRXPFM	RN	Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clin Cancer Res. 2003 Jul;9(7):2711-8.
DMRXPFM	RU	https://pubmed.ncbi.nlm.nih.gov/12855651

DMF8UWE	DI	DMF8UWE
DMF8UWE	DN	BZ6
DMF8UWE	MI	TTVDSZ0
DMF8UWE	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMF8UWE	MT	DTT
DMF8UWE	MA	Inhibitor
DMF8UWE	RN	Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clin Cancer Res. 2003 Jul;9(7):2711-8.
DMF8UWE	RU	https://pubmed.ncbi.nlm.nih.gov/12855651

DM37GYA	DI	DM37GYA
DM37GYA	DN	BzATP
DM37GYA	MI	TTJW7B3
DM37GYA	MN	P2X purinoceptor 1 (P2RX1)
DM37GYA	MT	DTT
DM37GYA	MA	Agonist
DM37GYA	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 478).
DM37GYA	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=478

DM37GYA	DI	DM37GYA
DM37GYA	DN	BzATP
DM37GYA	MI	TT2THBD
DM37GYA	MN	P2X purinoceptor 3 (P2RX3)
DM37GYA	MT	DTT
DM37GYA	MA	Agonist
DM37GYA	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 480).
DM37GYA	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=480

DM37GYA	DI	DM37GYA
DM37GYA	DN	BzATP
DM37GYA	MI	TTYXPCO
DM37GYA	MN	P2Y purinoceptor 11 (P2RY11)
DM37GYA	MT	DTT
DM37GYA	MA	Agonist
DM37GYA	RN	Pharmacological characterization of the human P2Y11 receptor. Br J Pharmacol. 1999 Nov;128(6):1199-206.
DM37GYA	RU	https://pubmed.ncbi.nlm.nih.gov/10578132

DMUW87A	DI	DMUW87A
DMUW87A	DN	Bz--RYYRIK-NH2
DMUW87A	MI	TTNT7K8
DMUW87A	MN	Nociceptin receptor (OPRL1)
DMUW87A	MT	DTT
DMUW87A	MA	Inhibitor
DMUW87A	RN	Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist. Bioorg Med Chem. 2008 Mar 1;16(5):2635-44.
DMUW87A	RU	https://pubmed.ncbi.nlm.nih.gov/18068993

DMU13BY	DI	DMU13BY
DMU13BY	DN	BzT-7
DMU13BY	MI	TTRA6BO
DMU13BY	MN	Bromodomain-containing protein 4 (BRD4)
DMU13BY	MT	DTT
DMU13BY	MA	Inhibitor
DMU13BY	RN	Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family. Bioorg Med Chem. 2012 Mar 15;20(6):1878-86.
DMU13BY	RU	https://pubmed.ncbi.nlm.nih.gov/22137933

DMA0GSY	DI	DMA0GSY
DMA0GSY	DN	BZYX
DMA0GSY	MI	TT1RS9F
DMA0GSY	MN	Acetylcholinesterase (AChE)
DMA0GSY	MT	DTT
DMA0GSY	MA	Inhibitor
DMA0GSY	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2465).
DMA0GSY	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2465

DMMPXHQ	DI	DMMPXHQ
DMMPXHQ	DN	C-(1-Azido-Alpha-D-Glucopyranosyl) Formamide
DMMPXHQ	MI	TTZHY6R
DMMPXHQ	MN	Glycogen phosphorylase muscle form (GP)
DMMPXHQ	MT	DTT
DMMPXHQ	MA	Inhibitor
DMMPXHQ	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMMPXHQ	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMDLK9G	DI	DMDLK9G
DMDLK9G	DN	C-(1H-Indol-3-yl)-methylamine
DMDLK9G	MI	TT3WG5C
DMDLK9G	MN	Monoamine oxidase type A (MAO-A)
DMDLK9G	MT	DTT
DMDLK9G	MA	Inhibitor
DMDLK9G	RN	Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
DMDLK9G	RU	https://pubmed.ncbi.nlm.nih.gov/15013009

DMDLK9G	DI	DMDLK9G
DMDLK9G	DN	C-(1H-Indol-3-yl)-methylamine
DMDLK9G	MI	TTGP7BY
DMDLK9G	MN	Monoamine oxidase type B (MAO-B)
DMDLK9G	MT	DTT
DMDLK9G	MA	Inhibitor
DMDLK9G	RN	Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
DMDLK9G	RU	https://pubmed.ncbi.nlm.nih.gov/15013009

DM3VF9M	DI	DM3VF9M
DM3VF9M	DN	C-(1-Hydrogyl-Beta-D-Glucopyranosyl) Formamide
DM3VF9M	MI	TTZHY6R
DM3VF9M	MN	Glycogen phosphorylase muscle form (GP)
DM3VF9M	MT	DTT
DM3VF9M	MA	Inhibitor
DM3VF9M	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM3VF9M	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMNMYWI	DI	DMNMYWI
DMNMYWI	DN	C-(2'-Chloro-biphenyl-2-yl)-methylamine
DMNMYWI	MI	TTDIGC1
DMNMYWI	MN	Dipeptidyl peptidase 4 (DPP-4)
DMNMYWI	MT	DTT
DMNMYWI	MA	Inhibitor
DMNMYWI	RN	In silico fragment-based discovery of DPP-IV S1 pocket binders. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1405-9.
DMNMYWI	RU	https://pubmed.ncbi.nlm.nih.gov/16321524

DM0VKFO	DI	DM0VKFO
DM0VKFO	DN	C-(5-bromo-4,7-dimethoxyindan-1-yl)methylamine
DM0VKFO	MI	TTJQOD7
DM0VKFO	MN	5-HT 2A receptor (HTR2A)
DM0VKFO	MT	DTT
DM0VKFO	MA	Inhibitor
DM0VKFO	RN	1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agoni... J Med Chem. 2006 Sep 21;49(19):5794-803.
DM0VKFO	RU	https://pubmed.ncbi.nlm.nih.gov/16970404

DMDHVY0	DI	DMDHVY0
DMDHVY0	DN	C-(5H-Dibenzo[a,d]cyclohepten-5-yl)-methylamine
DMDHVY0	MI	TTJQOD7
DMDHVY0	MN	5-HT 2A receptor (HTR2A)
DMDHVY0	MT	DTT
DMDHVY0	MA	Inhibitor
DMDHVY0	RN	Exploring the relationship between binding modes of 9-(aminomethyl)-9,10-dihydroanthracene and cyproheptadine analogues at the 5-HT2A serotonin rec... Bioorg Med Chem Lett. 2001 Feb 26;11(4):563-6.
DMDHVY0	RU	https://pubmed.ncbi.nlm.nih.gov/11229772

DMJ6SYI	DI	DMJ6SYI
DMJ6SYI	DN	C-(6-Methoxy-naphthalen-1-yl)-methylamine
DMJ6SYI	MI	TTWG9A4
DMJ6SYI	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMJ6SYI	MT	DTT
DMJ6SYI	MA	Inhibitor
DMJ6SYI	RN	Examination of the role of the acidic hydrogen in imparting selectivity of 7-(aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline (SK&amp;F 29661) toward inh... J Med Chem. 1997 Dec 5;40(25):3997-4005.
DMJ6SYI	RU	https://pubmed.ncbi.nlm.nih.gov/9406590

DMJ6SYI	DI	DMJ6SYI
DMJ6SYI	DN	C-(6-Methoxy-naphthalen-1-yl)-methylamine
DMJ6SYI	MI	TTWM4TY
DMJ6SYI	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMJ6SYI	MT	DTT
DMJ6SYI	MA	Inhibitor
DMJ6SYI	RN	Examination of the role of the acidic hydrogen in imparting selectivity of 7-(aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline (SK&amp;F 29661) toward inh... J Med Chem. 1997 Dec 5;40(25):3997-4005.
DMJ6SYI	RU	https://pubmed.ncbi.nlm.nih.gov/9406590

DMJ6SYI	DI	DMJ6SYI
DMJ6SYI	DN	C-(6-Methoxy-naphthalen-1-yl)-methylamine
DMJ6SYI	MI	TT2NUT5
DMJ6SYI	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMJ6SYI	MT	DTT
DMJ6SYI	MA	Inhibitor
DMJ6SYI	RN	Examination of the role of the acidic hydrogen in imparting selectivity of 7-(aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline (SK&amp;F 29661) toward inh... J Med Chem. 1997 Dec 5;40(25):3997-4005.
DMJ6SYI	RU	https://pubmed.ncbi.nlm.nih.gov/9406590

DMDMA4Z	DI	DMDMA4Z
DMDMA4Z	DN	C-(9H-Thioxanthen-9-yl)-methylamine
DMDMA4Z	MI	TTJQOD7
DMDMA4Z	MN	5-HT 2A receptor (HTR2A)
DMDMA4Z	MT	DTT
DMDMA4Z	MA	Inhibitor
DMDMA4Z	RN	Exploring the relationship between binding modes of 9-(aminomethyl)-9,10-dihydroanthracene and cyproheptadine analogues at the 5-HT2A serotonin rec... Bioorg Med Chem Lett. 2001 Feb 26;11(4):563-6.
DMDMA4Z	RU	https://pubmed.ncbi.nlm.nih.gov/11229772

DMN5YOR	DI	DMN5YOR
DMN5YOR	DN	C-(9H-Xanthen-9-yl)-methylamine
DMN5YOR	MI	TTJQOD7
DMN5YOR	MN	5-HT 2A receptor (HTR2A)
DMN5YOR	MT	DTT
DMN5YOR	MA	Inhibitor
DMN5YOR	RN	Exploring the relationship between binding modes of 9-(aminomethyl)-9,10-dihydroanthracene and cyproheptadine analogues at the 5-HT2A serotonin rec... Bioorg Med Chem Lett. 2001 Feb 26;11(4):563-6.
DMN5YOR	RU	https://pubmed.ncbi.nlm.nih.gov/11229772

DMHNZGP	DI	DMHNZGP
DMHNZGP	DN	C(Arg-Gly-Asp-D-Phe-Val)
DMHNZGP	MI	TTT1R2L
DMHNZGP	MN	Integrin alpha-V (ITGAV)
DMHNZGP	MT	DTT
DMHNZGP	MA	Inhibitor
DMHNZGP	RN	Novel and selective alpha(v)beta3 receptor peptide antagonist: design, synthesis, and biological behavior. J Med Chem. 2006 Jun 1;49(11):3416-20.
DMHNZGP	RU	https://pubmed.ncbi.nlm.nih.gov/16722662

DMHNZGP	DI	DMHNZGP
DMHNZGP	DN	C(Arg-Gly-Asp-D-Phe-Val)
DMHNZGP	MI	TTJA1ZO
DMHNZGP	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMHNZGP	MT	DTT
DMHNZGP	MA	Inhibitor
DMHNZGP	RN	Novel and selective alpha(v)beta3 receptor peptide antagonist: design, synthesis, and biological behavior. J Med Chem. 2006 Jun 1;49(11):3416-20.
DMHNZGP	RU	https://pubmed.ncbi.nlm.nih.gov/16722662

DMTMJAI	DI	DMTMJAI
DMTMJAI	DN	C(-GRGDfL-)
DMTMJAI	MI	TTHIZP9
DMTMJAI	MN	Integrin alpha-5 (ITGA5)
DMTMJAI	MT	DTT
DMTMJAI	MA	Inhibitor
DMTMJAI	RN	Multiple N-methylation by a designed approach enhances receptor selectivity. J Med Chem. 2007 Nov 29;50(24):5878-81.
DMTMJAI	RU	https://pubmed.ncbi.nlm.nih.gov/17973471

DMTMJAI	DI	DMTMJAI
DMTMJAI	DN	C(-GRGDfL-)
DMTMJAI	MI	TTT1R2L
DMTMJAI	MN	Integrin alpha-V (ITGAV)
DMTMJAI	MT	DTT
DMTMJAI	MA	Inhibitor
DMTMJAI	RN	Multiple N-methylation by a designed approach enhances receptor selectivity. J Med Chem. 2007 Nov 29;50(24):5878-81.
DMTMJAI	RU	https://pubmed.ncbi.nlm.nih.gov/17973471

DMTMJAI	DI	DMTMJAI
DMTMJAI	DN	C(-GRGDfL-)
DMTMJAI	MI	TTBVIQC
DMTMJAI	MN	Integrin beta-1 (ITGB1)
DMTMJAI	MT	DTT
DMTMJAI	MA	Inhibitor
DMTMJAI	RN	Multiple N-methylation by a designed approach enhances receptor selectivity. J Med Chem. 2007 Nov 29;50(24):5878-81.
DMTMJAI	RU	https://pubmed.ncbi.nlm.nih.gov/17973471

DMTMJAI	DI	DMTMJAI
DMTMJAI	DN	C(-GRGDfL-)
DMTMJAI	MI	TTJA1ZO
DMTMJAI	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMTMJAI	MT	DTT
DMTMJAI	MA	Inhibitor
DMTMJAI	RN	Multiple N-methylation by a designed approach enhances receptor selectivity. J Med Chem. 2007 Nov 29;50(24):5878-81.
DMTMJAI	RU	https://pubmed.ncbi.nlm.nih.gov/17973471

DMSLYHQ	DI	DMSLYHQ
DMSLYHQ	DN	C(his-D-phe-arg-trp-Abu)
DMSLYHQ	MI	TTD0CIQ
DMSLYHQ	MN	Melanocortin receptor 4 (MC4R)
DMSLYHQ	MT	DTT
DMSLYHQ	MA	Inhibitor
DMSLYHQ	RN	Design of cyclic peptides with agonist activity at melanocortin receptor-4. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3723-6.
DMSLYHQ	RU	https://pubmed.ncbi.nlm.nih.gov/16678415

DM0IJFZ	DI	DM0IJFZ
DM0IJFZ	DN	C(his-D-phe-arg-trp-Ahp)
DM0IJFZ	MI	TTD0CIQ
DM0IJFZ	MN	Melanocortin receptor 4 (MC4R)
DM0IJFZ	MT	DTT
DM0IJFZ	MA	Inhibitor
DM0IJFZ	RN	Design of cyclic peptides with agonist activity at melanocortin receptor-4. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3723-6.
DM0IJFZ	RU	https://pubmed.ncbi.nlm.nih.gov/16678415

DMJKHAB	DI	DMJKHAB
DMJKHAB	DN	C(his-D-phe-arg-trp-Ahx)
DMJKHAB	MI	TTD0CIQ
DMJKHAB	MN	Melanocortin receptor 4 (MC4R)
DMJKHAB	MT	DTT
DMJKHAB	MA	Inhibitor
DMJKHAB	RN	Design of cyclic peptides with agonist activity at melanocortin receptor-4. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3723-6.
DMJKHAB	RU	https://pubmed.ncbi.nlm.nih.gov/16678415

DM5NQUA	DI	DM5NQUA
DM5NQUA	DN	C(his-D-phe-arg-trp-Aoc)
DM5NQUA	MI	TTD0CIQ
DM5NQUA	MN	Melanocortin receptor 4 (MC4R)
DM5NQUA	MT	DTT
DM5NQUA	MA	Inhibitor
DM5NQUA	RN	Design of cyclic peptides with agonist activity at melanocortin receptor-4. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3723-6.
DM5NQUA	RU	https://pubmed.ncbi.nlm.nih.gov/16678415

DMEC2PH	DI	DMEC2PH
DMEC2PH	DN	C(his-L-phe-arg-trp-Aoc)
DMEC2PH	MI	TTD0CIQ
DMEC2PH	MN	Melanocortin receptor 4 (MC4R)
DMEC2PH	MT	DTT
DMEC2PH	MA	Inhibitor
DMEC2PH	RN	Design of cyclic peptides with agonist activity at melanocortin receptor-4. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3723-6.
DMEC2PH	RU	https://pubmed.ncbi.nlm.nih.gov/16678415

DMMBESU	DI	DMMBESU
DMMBESU	DN	C(RGDfF)
DMMBESU	MI	TTT1R2L
DMMBESU	MN	Integrin alpha-V (ITGAV)
DMMBESU	MT	DTT
DMMBESU	MA	Inhibitor
DMMBESU	RN	Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17.
DMMBESU	RU	https://pubmed.ncbi.nlm.nih.gov/16509596

DMMBESU	DI	DMMBESU
DMMBESU	DN	C(RGDfF)
DMMBESU	MI	TTJA1ZO
DMMBESU	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMMBESU	MT	DTT
DMMBESU	MA	Inhibitor
DMMBESU	RN	Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17.
DMMBESU	RU	https://pubmed.ncbi.nlm.nih.gov/16509596

DM8DU42	DI	DM8DU42
DM8DU42	DN	C(RGDfMeF)
DM8DU42	MI	TTT1R2L
DM8DU42	MN	Integrin alpha-V (ITGAV)
DM8DU42	MT	DTT
DM8DU42	MA	Inhibitor
DM8DU42	RN	Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17.
DM8DU42	RU	https://pubmed.ncbi.nlm.nih.gov/16509596

DM8DU42	DI	DM8DU42
DM8DU42	DN	C(RGDfMeF)
DM8DU42	MI	TTJA1ZO
DM8DU42	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DM8DU42	MT	DTT
DM8DU42	MA	Inhibitor
DM8DU42	RN	Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17.
DM8DU42	RU	https://pubmed.ncbi.nlm.nih.gov/16509596

DMY2NU8	DI	DMY2NU8
DMY2NU8	DN	C-[2-(1H-Imidazol-4-yl)-cyclopropyl]-methylamine
DMY2NU8	MI	TT9JNIC
DMY2NU8	MN	Histamine H3 receptor (H3R)
DMY2NU8	MT	DTT
DMY2NU8	MA	Inhibitor
DMY2NU8	RN	Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist f... J Med Chem. 2003 May 8;46(10):1980-8.
DMY2NU8	RU	https://pubmed.ncbi.nlm.nih.gov/12723960

DMPOIDK	DI	DMPOIDK
DMPOIDK	DN	C[-Arg-Gly-Asp-Acpca19-]
DMPOIDK	MI	TTT1R2L
DMPOIDK	MN	Integrin alpha-V (ITGAV)
DMPOIDK	MT	DTT
DMPOIDK	MA	Inhibitor
DMPOIDK	RN	Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87.
DMPOIDK	RU	https://pubmed.ncbi.nlm.nih.gov/16302808

DMPOIDK	DI	DMPOIDK
DMPOIDK	DN	C[-Arg-Gly-Asp-Acpca19-]
DMPOIDK	MI	TTJA1ZO
DMPOIDK	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMPOIDK	MT	DTT
DMPOIDK	MA	Inhibitor
DMPOIDK	RN	Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87.
DMPOIDK	RU	https://pubmed.ncbi.nlm.nih.gov/16302808

DMJVW1N	DI	DMJVW1N
DMJVW1N	DN	C[-Arg-Gly-Asp-Acpca20-]
DMJVW1N	MI	TTT1R2L
DMJVW1N	MN	Integrin alpha-V (ITGAV)
DMJVW1N	MT	DTT
DMJVW1N	MA	Inhibitor
DMJVW1N	RN	Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87.
DMJVW1N	RU	https://pubmed.ncbi.nlm.nih.gov/16302808

DMJVW1N	DI	DMJVW1N
DMJVW1N	DN	C[-Arg-Gly-Asp-Acpca20-]
DMJVW1N	MI	TTJA1ZO
DMJVW1N	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMJVW1N	MT	DTT
DMJVW1N	MA	Inhibitor
DMJVW1N	RN	Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87.
DMJVW1N	RU	https://pubmed.ncbi.nlm.nih.gov/16302808

DMXCUDV	DI	DMXCUDV
DMXCUDV	DN	C[-Arg-Gly-Asp-Acpca21-]
DMXCUDV	MI	TTT1R2L
DMXCUDV	MN	Integrin alpha-V (ITGAV)
DMXCUDV	MT	DTT
DMXCUDV	MA	Inhibitor
DMXCUDV	RN	Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87.
DMXCUDV	RU	https://pubmed.ncbi.nlm.nih.gov/16302808

DMXCUDV	DI	DMXCUDV
DMXCUDV	DN	C[-Arg-Gly-Asp-Acpca21-]
DMXCUDV	MI	TTJA1ZO
DMXCUDV	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMXCUDV	MT	DTT
DMXCUDV	MA	Inhibitor
DMXCUDV	RN	Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87.
DMXCUDV	RU	https://pubmed.ncbi.nlm.nih.gov/16302808

DM6DV90	DI	DM6DV90
DM6DV90	DN	C[-Arg-Gly-Asp-Acpca22-]
DM6DV90	MI	TTT1R2L
DM6DV90	MN	Integrin alpha-V (ITGAV)
DM6DV90	MT	DTT
DM6DV90	MA	Inhibitor
DM6DV90	RN	Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87.
DM6DV90	RU	https://pubmed.ncbi.nlm.nih.gov/16302808

DM6DV90	DI	DM6DV90
DM6DV90	DN	C[-Arg-Gly-Asp-Acpca22-]
DM6DV90	MI	TTJA1ZO
DM6DV90	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DM6DV90	MT	DTT
DM6DV90	MA	Inhibitor
DM6DV90	RN	Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87.
DM6DV90	RU	https://pubmed.ncbi.nlm.nih.gov/16302808

DML0U8B	DI	DML0U8B
DML0U8B	DN	C-[-Arg-Gly-Asp-Acpca30-]
DML0U8B	MI	TTT1R2L
DML0U8B	MN	Integrin alpha-V (ITGAV)
DML0U8B	MT	DTT
DML0U8B	MA	Inhibitor
DML0U8B	RN	Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87.
DML0U8B	RU	https://pubmed.ncbi.nlm.nih.gov/16302808

DML0U8B	DI	DML0U8B
DML0U8B	DN	C-[-Arg-Gly-Asp-Acpca30-]
DML0U8B	MI	TTJA1ZO
DML0U8B	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DML0U8B	MT	DTT
DML0U8B	MA	Inhibitor
DML0U8B	RN	Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87.
DML0U8B	RU	https://pubmed.ncbi.nlm.nih.gov/16302808

DMKENFU	DI	DMKENFU
DMKENFU	DN	C-[-Arg-Gly-Asp-Acpca31-]
DMKENFU	MI	TTT1R2L
DMKENFU	MN	Integrin alpha-V (ITGAV)
DMKENFU	MT	DTT
DMKENFU	MA	Inhibitor
DMKENFU	RN	Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87.
DMKENFU	RU	https://pubmed.ncbi.nlm.nih.gov/16302808

DMKENFU	DI	DMKENFU
DMKENFU	DN	C-[-Arg-Gly-Asp-Acpca31-]
DMKENFU	MI	TTJA1ZO
DMKENFU	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMKENFU	MT	DTT
DMKENFU	MA	Inhibitor
DMKENFU	RN	Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87.
DMKENFU	RU	https://pubmed.ncbi.nlm.nih.gov/16302808

DMVM7B2	DI	DMVM7B2
DMVM7B2	DN	C-[-Arg-Gly-Asp-Acpca32-]
DMVM7B2	MI	TTT1R2L
DMVM7B2	MN	Integrin alpha-V (ITGAV)
DMVM7B2	MT	DTT
DMVM7B2	MA	Inhibitor
DMVM7B2	RN	Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87.
DMVM7B2	RU	https://pubmed.ncbi.nlm.nih.gov/16302808

DMVM7B2	DI	DMVM7B2
DMVM7B2	DN	C-[-Arg-Gly-Asp-Acpca32-]
DMVM7B2	MI	TTJA1ZO
DMVM7B2	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMVM7B2	MT	DTT
DMVM7B2	MA	Inhibitor
DMVM7B2	RN	Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87.
DMVM7B2	RU	https://pubmed.ncbi.nlm.nih.gov/16302808

DMIBGWO	DI	DMIBGWO
DMIBGWO	DN	C-[-Arg-Gly-Asp-Acpca33-]
DMIBGWO	MI	TTT1R2L
DMIBGWO	MN	Integrin alpha-V (ITGAV)
DMIBGWO	MT	DTT
DMIBGWO	MA	Inhibitor
DMIBGWO	RN	Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87.
DMIBGWO	RU	https://pubmed.ncbi.nlm.nih.gov/16302808

DMIBGWO	DI	DMIBGWO
DMIBGWO	DN	C-[-Arg-Gly-Asp-Acpca33-]
DMIBGWO	MI	TTJA1ZO
DMIBGWO	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMIBGWO	MT	DTT
DMIBGWO	MA	Inhibitor
DMIBGWO	RN	Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87.
DMIBGWO	RU	https://pubmed.ncbi.nlm.nih.gov/16302808

DMKHSAV	DI	DMKHSAV
DMKHSAV	DN	C[-Arg-Gly-Asp-Acpca34-]
DMKHSAV	MI	TTT1R2L
DMKHSAV	MN	Integrin alpha-V (ITGAV)
DMKHSAV	MT	DTT
DMKHSAV	MA	Inhibitor
DMKHSAV	RN	Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87.
DMKHSAV	RU	https://pubmed.ncbi.nlm.nih.gov/16302808

DMKHSAV	DI	DMKHSAV
DMKHSAV	DN	C[-Arg-Gly-Asp-Acpca34-]
DMKHSAV	MI	TTJA1ZO
DMKHSAV	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMKHSAV	MT	DTT
DMKHSAV	MA	Inhibitor
DMKHSAV	RN	Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87.
DMKHSAV	RU	https://pubmed.ncbi.nlm.nih.gov/16302808

DMQOY3J	DI	DMQOY3J
DMQOY3J	DN	C[-Arg-Gly-Asp-Acpca35-]
DMQOY3J	MI	TTT1R2L
DMQOY3J	MN	Integrin alpha-V (ITGAV)
DMQOY3J	MT	DTT
DMQOY3J	MA	Inhibitor
DMQOY3J	RN	Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87.
DMQOY3J	RU	https://pubmed.ncbi.nlm.nih.gov/16302808

DMQOY3J	DI	DMQOY3J
DMQOY3J	DN	C[-Arg-Gly-Asp-Acpca35-]
DMQOY3J	MI	TTJA1ZO
DMQOY3J	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMQOY3J	MT	DTT
DMQOY3J	MA	Inhibitor
DMQOY3J	RN	Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87.
DMQOY3J	RU	https://pubmed.ncbi.nlm.nih.gov/16302808

DM7LCPW	DI	DM7LCPW
DM7LCPW	DN	C[-Arg-Gly-Asp-Acpca36-]
DM7LCPW	MI	TTT1R2L
DM7LCPW	MN	Integrin alpha-V (ITGAV)
DM7LCPW	MT	DTT
DM7LCPW	MA	Inhibitor
DM7LCPW	RN	Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87.
DM7LCPW	RU	https://pubmed.ncbi.nlm.nih.gov/16302808

DM7LCPW	DI	DM7LCPW
DM7LCPW	DN	C[-Arg-Gly-Asp-Acpca36-]
DM7LCPW	MI	TTJA1ZO
DM7LCPW	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DM7LCPW	MT	DTT
DM7LCPW	MA	Inhibitor
DM7LCPW	RN	Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87.
DM7LCPW	RU	https://pubmed.ncbi.nlm.nih.gov/16302808

DMISP20	DI	DMISP20
DMISP20	DN	C[Asp22-Lys26][Gly8]GLP-1(7-37)-NH2
DMISP20	MI	TTVIMDE
DMISP20	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMISP20	MT	DTT
DMISP20	MA	Inhibitor
DMISP20	RN	Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo acti... J Med Chem. 2008 May 8;51(9):2758-65.
DMISP20	RU	https://pubmed.ncbi.nlm.nih.gov/18412318

DMHARQX	DI	DMHARQX
DMHARQX	DN	C[CO-(CH2)2-CO-Nle-D-Nal(2)-Arg-Trp-Lys]-NH2
DMHARQX	MI	TTEOSZT
DMHARQX	MN	Melanocortin receptor (MCR)
DMHARQX	MT	DTT
DMHARQX	MA	Inhibitor
DMHARQX	RN	Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95.
DMHARQX	RU	https://pubmed.ncbi.nlm.nih.gov/18088090

DMHARQX	DI	DMHARQX
DMHARQX	DN	C[CO-(CH2)2-CO-Nle-D-Nal(2)-Arg-Trp-Lys]-NH2
DMHARQX	MI	TT0MV2T
DMHARQX	MN	Melanocortin receptor 1 (MC1R)
DMHARQX	MT	DTT
DMHARQX	MA	Inhibitor
DMHARQX	RN	Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95.
DMHARQX	RU	https://pubmed.ncbi.nlm.nih.gov/18088090

DMHARQX	DI	DMHARQX
DMHARQX	DN	C[CO-(CH2)2-CO-Nle-D-Nal(2)-Arg-Trp-Lys]-NH2
DMHARQX	MI	TTNI91K
DMHARQX	MN	Melanocortin receptor 3 (MC3R)
DMHARQX	MT	DTT
DMHARQX	MA	Inhibitor
DMHARQX	RN	Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95.
DMHARQX	RU	https://pubmed.ncbi.nlm.nih.gov/18088090

DMHARQX	DI	DMHARQX
DMHARQX	DN	C[CO-(CH2)2-CO-Nle-D-Nal(2)-Arg-Trp-Lys]-NH2
DMHARQX	MI	TTD0CIQ
DMHARQX	MN	Melanocortin receptor 4 (MC4R)
DMHARQX	MT	DTT
DMHARQX	MA	Inhibitor
DMHARQX	RN	Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95.
DMHARQX	RU	https://pubmed.ncbi.nlm.nih.gov/18088090

DMI3CSJ	DI	DMI3CSJ
DMI3CSJ	DN	C[CO-(CH2)2-CO-Nle-D-Phe-Arg-Trp-Lys]-NH2
DMI3CSJ	MI	TTEOSZT
DMI3CSJ	MN	Melanocortin receptor (MCR)
DMI3CSJ	MT	DTT
DMI3CSJ	MA	Inhibitor
DMI3CSJ	RN	Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95.
DMI3CSJ	RU	https://pubmed.ncbi.nlm.nih.gov/18088090

DMI3CSJ	DI	DMI3CSJ
DMI3CSJ	DN	C[CO-(CH2)2-CO-Nle-D-Phe-Arg-Trp-Lys]-NH2
DMI3CSJ	MI	TTNI91K
DMI3CSJ	MN	Melanocortin receptor 3 (MC3R)
DMI3CSJ	MT	DTT
DMI3CSJ	MA	Inhibitor
DMI3CSJ	RN	Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95.
DMI3CSJ	RU	https://pubmed.ncbi.nlm.nih.gov/18088090

DMI3CSJ	DI	DMI3CSJ
DMI3CSJ	DN	C[CO-(CH2)2-CO-Nle-D-Phe-Arg-Trp-Lys]-NH2
DMI3CSJ	MI	TTD0CIQ
DMI3CSJ	MN	Melanocortin receptor 4 (MC4R)
DMI3CSJ	MT	DTT
DMI3CSJ	MA	Inhibitor
DMI3CSJ	RN	Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95.
DMI3CSJ	RU	https://pubmed.ncbi.nlm.nih.gov/18088090

DMYPHVC	DI	DMYPHVC
DMYPHVC	DN	C[CO-(CH2)3-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2
DMYPHVC	MI	TTEOSZT
DMYPHVC	MN	Melanocortin receptor (MCR)
DMYPHVC	MT	DTT
DMYPHVC	MA	Inhibitor
DMYPHVC	RN	Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95.
DMYPHVC	RU	https://pubmed.ncbi.nlm.nih.gov/18088090

DMYPHVC	DI	DMYPHVC
DMYPHVC	DN	C[CO-(CH2)3-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2
DMYPHVC	MI	TTNI91K
DMYPHVC	MN	Melanocortin receptor 3 (MC3R)
DMYPHVC	MT	DTT
DMYPHVC	MA	Inhibitor
DMYPHVC	RN	Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95.
DMYPHVC	RU	https://pubmed.ncbi.nlm.nih.gov/18088090

DMYPHVC	DI	DMYPHVC
DMYPHVC	DN	C[CO-(CH2)3-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2
DMYPHVC	MI	TTD0CIQ
DMYPHVC	MN	Melanocortin receptor 4 (MC4R)
DMYPHVC	MT	DTT
DMYPHVC	MA	Inhibitor
DMYPHVC	RN	Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95.
DMYPHVC	RU	https://pubmed.ncbi.nlm.nih.gov/18088090

DM0VP79	DI	DM0VP79
DM0VP79	DN	C[CO-(CH2)3-CO-Pro-D-Phe-Arg-Trp-Lys]-NH2
DM0VP79	MI	TTEOSZT
DM0VP79	MN	Melanocortin receptor (MCR)
DM0VP79	MT	DTT
DM0VP79	MA	Inhibitor
DM0VP79	RN	Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95.
DM0VP79	RU	https://pubmed.ncbi.nlm.nih.gov/18088090

DM0VP79	DI	DM0VP79
DM0VP79	DN	C[CO-(CH2)3-CO-Pro-D-Phe-Arg-Trp-Lys]-NH2
DM0VP79	MI	TTNI91K
DM0VP79	MN	Melanocortin receptor 3 (MC3R)
DM0VP79	MT	DTT
DM0VP79	MA	Inhibitor
DM0VP79	RN	Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95.
DM0VP79	RU	https://pubmed.ncbi.nlm.nih.gov/18088090

DM1VCJP	DI	DM1VCJP
DM1VCJP	DN	C[CO-2,3-pyrazine-CO-D-Nal(2)-Arg-Trp-Lys]-NH2
DM1VCJP	MI	TTEOSZT
DM1VCJP	MN	Melanocortin receptor (MCR)
DM1VCJP	MT	DTT
DM1VCJP	MA	Inhibitor
DM1VCJP	RN	Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95.
DM1VCJP	RU	https://pubmed.ncbi.nlm.nih.gov/18088090

DM1VCJP	DI	DM1VCJP
DM1VCJP	DN	C[CO-2,3-pyrazine-CO-D-Nal(2)-Arg-Trp-Lys]-NH2
DM1VCJP	MI	TT0MV2T
DM1VCJP	MN	Melanocortin receptor 1 (MC1R)
DM1VCJP	MT	DTT
DM1VCJP	MA	Inhibitor
DM1VCJP	RN	Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95.
DM1VCJP	RU	https://pubmed.ncbi.nlm.nih.gov/18088090

DM1VCJP	DI	DM1VCJP
DM1VCJP	DN	C[CO-2,3-pyrazine-CO-D-Nal(2)-Arg-Trp-Lys]-NH2
DM1VCJP	MI	TTNI91K
DM1VCJP	MN	Melanocortin receptor 3 (MC3R)
DM1VCJP	MT	DTT
DM1VCJP	MA	Inhibitor
DM1VCJP	RN	Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95.
DM1VCJP	RU	https://pubmed.ncbi.nlm.nih.gov/18088090

DM8AMGF	DI	DM8AMGF
DM8AMGF	DN	C[CO-2,3-pyrazine-CO-D-Phe-Arg-Trp-Lys]-NH2
DM8AMGF	MI	TT0MV2T
DM8AMGF	MN	Melanocortin receptor 1 (MC1R)
DM8AMGF	MT	DTT
DM8AMGF	MA	Inhibitor
DM8AMGF	RN	Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95.
DM8AMGF	RU	https://pubmed.ncbi.nlm.nih.gov/18088090

DM8AMGF	DI	DM8AMGF
DM8AMGF	DN	C[CO-2,3-pyrazine-CO-D-Phe-Arg-Trp-Lys]-NH2
DM8AMGF	MI	TTNI91K
DM8AMGF	MN	Melanocortin receptor 3 (MC3R)
DM8AMGF	MT	DTT
DM8AMGF	MA	Inhibitor
DM8AMGF	RN	Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95.
DM8AMGF	RU	https://pubmed.ncbi.nlm.nih.gov/18088090

DMD6OW4	DI	DMD6OW4
DMD6OW4	DN	C[CO-o-C6H4-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2
DMD6OW4	MI	TTEOSZT
DMD6OW4	MN	Melanocortin receptor (MCR)
DMD6OW4	MT	DTT
DMD6OW4	MA	Inhibitor
DMD6OW4	RN	Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95.
DMD6OW4	RU	https://pubmed.ncbi.nlm.nih.gov/18088090

DMD6OW4	DI	DMD6OW4
DMD6OW4	DN	C[CO-o-C6H4-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2
DMD6OW4	MI	TT0MV2T
DMD6OW4	MN	Melanocortin receptor 1 (MC1R)
DMD6OW4	MT	DTT
DMD6OW4	MA	Inhibitor
DMD6OW4	RN	Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95.
DMD6OW4	RU	https://pubmed.ncbi.nlm.nih.gov/18088090

DMD6OW4	DI	DMD6OW4
DMD6OW4	DN	C[CO-o-C6H4-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2
DMD6OW4	MI	TTNI91K
DMD6OW4	MN	Melanocortin receptor 3 (MC3R)
DMD6OW4	MT	DTT
DMD6OW4	MA	Inhibitor
DMD6OW4	RN	Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95.
DMD6OW4	RU	https://pubmed.ncbi.nlm.nih.gov/18088090

DMD6OW4	DI	DMD6OW4
DMD6OW4	DN	C[CO-o-C6H4-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2
DMD6OW4	MI	TTD0CIQ
DMD6OW4	MN	Melanocortin receptor 4 (MC4R)
DMD6OW4	MT	DTT
DMD6OW4	MA	Inhibitor
DMD6OW4	RN	Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95.
DMD6OW4	RU	https://pubmed.ncbi.nlm.nih.gov/18088090

DMNKT8J	DI	DMNKT8J
DMNKT8J	DN	C[CO-o-C6H4-CO-Pro-D-Phe-Arg-Trp-Lys]-NH2
DMNKT8J	MI	TTD0CIQ
DMNKT8J	MN	Melanocortin receptor 4 (MC4R)
DMNKT8J	MT	DTT
DMNKT8J	MA	Inhibitor
DMNKT8J	RN	Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95.
DMNKT8J	RU	https://pubmed.ncbi.nlm.nih.gov/18088090

DMYIJT1	DI	DMYIJT1
DMYIJT1	DN	C[Cpa19-Lys26][Gly8]GLP-1(7-37)-NH2
DMYIJT1	MI	TTVIMDE
DMYIJT1	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMYIJT1	MT	DTT
DMYIJT1	MA	Inhibitor
DMYIJT1	RN	Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo acti... J Med Chem. 2008 May 8;51(9):2758-65.
DMYIJT1	RU	https://pubmed.ncbi.nlm.nih.gov/18412318

DMJR5UD	DI	DMJR5UD
DMJR5UD	DN	C[Glu18-Lys22][Gly8]GLP-1(7-37)-NH2
DMJR5UD	MI	TTVIMDE
DMJR5UD	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMJR5UD	MT	DTT
DMJR5UD	MA	Inhibitor
DMJR5UD	RN	Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo acti... J Med Chem. 2008 May 8;51(9):2758-65.
DMJR5UD	RU	https://pubmed.ncbi.nlm.nih.gov/18412318

DM6O4EZ	DI	DM6O4EZ
DM6O4EZ	DN	C[Glu19-Lys23][Gly8]GLP-1(7-37)-NH2
DM6O4EZ	MI	TTVIMDE
DM6O4EZ	MN	Glucagon-like peptide 1 receptor (GLP1R)
DM6O4EZ	MT	DTT
DM6O4EZ	MA	Inhibitor
DM6O4EZ	RN	Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo acti... J Med Chem. 2008 May 8;51(9):2758-65.
DM6O4EZ	RU	https://pubmed.ncbi.nlm.nih.gov/18412318

DMA3ZRJ	DI	DMA3ZRJ
DMA3ZRJ	DN	C[Glu21-Lys25][Gly8]GLP-1(7-37)-NH2
DMA3ZRJ	MI	TTVIMDE
DMA3ZRJ	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMA3ZRJ	MT	DTT
DMA3ZRJ	MA	Inhibitor
DMA3ZRJ	RN	Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo acti... J Med Chem. 2008 May 8;51(9):2758-65.
DMA3ZRJ	RU	https://pubmed.ncbi.nlm.nih.gov/18412318

DMPK74W	DI	DMPK74W
DMPK74W	DN	C[Glu21-Lys26][Gly8]GLP-1(7-37)-NH2
DMPK74W	MI	TTVIMDE
DMPK74W	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMPK74W	MT	DTT
DMPK74W	MA	Inhibitor
DMPK74W	RN	Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo acti... J Med Chem. 2008 May 8;51(9):2758-65.
DMPK74W	RU	https://pubmed.ncbi.nlm.nih.gov/18412318

DM8I0CZ	DI	DM8I0CZ
DM8I0CZ	DN	C[Glu22-Lys26][Gly8]GLP-1(7-37)-NH2
DM8I0CZ	MI	TTVIMDE
DM8I0CZ	MN	Glucagon-like peptide 1 receptor (GLP1R)
DM8I0CZ	MT	DTT
DM8I0CZ	MA	Inhibitor
DM8I0CZ	RN	Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo acti... J Med Chem. 2008 May 8;51(9):2758-65.
DM8I0CZ	RU	https://pubmed.ncbi.nlm.nih.gov/18412318

DMMA9GE	DI	DMMA9GE
DMMA9GE	DN	C[Glu22-Orn26][Gly8]GLP-1(7-37)-NH2
DMMA9GE	MI	TTVIMDE
DMMA9GE	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMMA9GE	MT	DTT
DMMA9GE	MA	Inhibitor
DMMA9GE	RN	Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo acti... J Med Chem. 2008 May 8;51(9):2758-65.
DMMA9GE	RU	https://pubmed.ncbi.nlm.nih.gov/18412318

DMWYN87	DI	DMWYN87
DMWYN87	DN	C[Glu23-Lys27][Gly8]GLP-1(7-37)-NH2
DMWYN87	MI	TTVIMDE
DMWYN87	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMWYN87	MT	DTT
DMWYN87	MA	Inhibitor
DMWYN87	RN	Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo acti... J Med Chem. 2008 May 8;51(9):2758-65.
DMWYN87	RU	https://pubmed.ncbi.nlm.nih.gov/18412318

DMKZXV3	DI	DMKZXV3
DMKZXV3	DN	C[Glu24-Lys28][Gly8]GLP-1(7-37)-NH2
DMKZXV3	MI	TTVIMDE
DMKZXV3	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMKZXV3	MT	DTT
DMKZXV3	MA	Inhibitor
DMKZXV3	RN	Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo acti... J Med Chem. 2008 May 8;51(9):2758-65.
DMKZXV3	RU	https://pubmed.ncbi.nlm.nih.gov/18412318

DMX2WCZ	DI	DMX2WCZ
DMX2WCZ	DN	C[Glu26-Lys30][Gly8]GLP-1(7-37)-NH2
DMX2WCZ	MI	TTVIMDE
DMX2WCZ	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMX2WCZ	MT	DTT
DMX2WCZ	MA	Inhibitor
DMX2WCZ	RN	Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo acti... J Med Chem. 2008 May 8;51(9):2758-65.
DMX2WCZ	RU	https://pubmed.ncbi.nlm.nih.gov/18412318

DMTP5YZ	DI	DMTP5YZ
DMTP5YZ	DN	C[hGlu22-Lys26][Gly8]GLP-1(7-37)-NH2
DMTP5YZ	MI	TTVIMDE
DMTP5YZ	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMTP5YZ	MT	DTT
DMTP5YZ	MA	Inhibitor
DMTP5YZ	RN	Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo acti... J Med Chem. 2008 May 8;51(9):2758-65.
DMTP5YZ	RU	https://pubmed.ncbi.nlm.nih.gov/18412318

DM8HK0J	DI	DM8HK0J
DM8HK0J	DN	C[homoPhe-Hca-Glu-Gly-Leu-Glu-Glu]-NH2
DM8HK0J	MI	TT1VAUK
DM8HK0J	MN	VEGFR1 messenger RNA (VEGFR1 mRNA)
DM8HK0J	MT	DTT
DM8HK0J	MA	Inhibitor
DM8HK0J	RN	Rational design, structure, and biological evaluation of cyclic peptides mimicking the vascular endothelial growth factor. J Med Chem. 2007 Oct 18;50(21):5135-46.
DM8HK0J	RU	https://pubmed.ncbi.nlm.nih.gov/17900101

DMHXTWK	DI	DMHXTWK
DMHXTWK	DN	C[L-Ala-D-pro-L-Phe-D-trp]
DMHXTWK	MI	TTQW87Y
DMHXTWK	MN	Opioid receptor kappa (OPRK1)
DMHXTWK	MT	DTT
DMHXTWK	MA	Inhibitor
DMHXTWK	RN	Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50.
DMHXTWK	RU	https://pubmed.ncbi.nlm.nih.gov/19464172

DMHXTWK	DI	DMHXTWK
DMHXTWK	DN	C[L-Ala-D-pro-L-Phe-D-trp]
DMHXTWK	MI	TTKWM86
DMHXTWK	MN	Opioid receptor mu (MOP)
DMHXTWK	MT	DTT
DMHXTWK	MA	Inhibitor
DMHXTWK	RN	Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50.
DMHXTWK	RU	https://pubmed.ncbi.nlm.nih.gov/19464172

DMNHSR0	DI	DMNHSR0
DMNHSR0	DN	C[L-mTyr-D-pro-L-Phe-D-trp]
DMNHSR0	MI	TT27RFC
DMNHSR0	MN	Opioid receptor delta (OPRD1)
DMNHSR0	MT	DTT
DMNHSR0	MA	Inhibitor
DMNHSR0	RN	Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50.
DMNHSR0	RU	https://pubmed.ncbi.nlm.nih.gov/19464172

DMNHSR0	DI	DMNHSR0
DMNHSR0	DN	C[L-mTyr-D-pro-L-Phe-D-trp]
DMNHSR0	MI	TTQW87Y
DMNHSR0	MN	Opioid receptor kappa (OPRK1)
DMNHSR0	MT	DTT
DMNHSR0	MA	Inhibitor
DMNHSR0	RN	Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50.
DMNHSR0	RU	https://pubmed.ncbi.nlm.nih.gov/19464172

DMNHSR0	DI	DMNHSR0
DMNHSR0	DN	C[L-mTyr-D-pro-L-Phe-D-trp]
DMNHSR0	MI	TTKWM86
DMNHSR0	MN	Opioid receptor mu (MOP)
DMNHSR0	MT	DTT
DMNHSR0	MA	Inhibitor
DMNHSR0	RN	Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50.
DMNHSR0	RU	https://pubmed.ncbi.nlm.nih.gov/19464172

DM82ZOM	DI	DM82ZOM
DM82ZOM	DN	C[L-Phe-D-pro-L-mTyr-D-trp]
DM82ZOM	MI	TT27RFC
DM82ZOM	MN	Opioid receptor delta (OPRD1)
DM82ZOM	MT	DTT
DM82ZOM	MA	Inhibitor
DM82ZOM	RN	Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50.
DM82ZOM	RU	https://pubmed.ncbi.nlm.nih.gov/19464172

DM82ZOM	DI	DM82ZOM
DM82ZOM	DN	C[L-Phe-D-pro-L-mTyr-D-trp]
DM82ZOM	MI	TTQW87Y
DM82ZOM	MN	Opioid receptor kappa (OPRK1)
DM82ZOM	MT	DTT
DM82ZOM	MA	Inhibitor
DM82ZOM	RN	Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50.
DM82ZOM	RU	https://pubmed.ncbi.nlm.nih.gov/19464172

DM82ZOM	DI	DM82ZOM
DM82ZOM	DN	C[L-Phe-D-pro-L-mTyr-D-trp]
DM82ZOM	MI	TTKWM86
DM82ZOM	MN	Opioid receptor mu (MOP)
DM82ZOM	MT	DTT
DM82ZOM	MA	Inhibitor
DM82ZOM	RN	Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50.
DM82ZOM	RU	https://pubmed.ncbi.nlm.nih.gov/19464172

DM0NTU5	DI	DM0NTU5
DM0NTU5	DN	C[L-Phe-D-pro-L-Phe-D-trp]
DM0NTU5	MI	TTQW87Y
DM0NTU5	MN	Opioid receptor kappa (OPRK1)
DM0NTU5	MT	DTT
DM0NTU5	MA	Inhibitor
DM0NTU5	RN	Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50.
DM0NTU5	RU	https://pubmed.ncbi.nlm.nih.gov/19464172

DM0NTU5	DI	DM0NTU5
DM0NTU5	DN	C[L-Phe-D-pro-L-Phe-D-trp]
DM0NTU5	MI	TTKWM86
DM0NTU5	MN	Opioid receptor mu (MOP)
DM0NTU5	MT	DTT
DM0NTU5	MA	Inhibitor
DM0NTU5	RN	Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50.
DM0NTU5	RU	https://pubmed.ncbi.nlm.nih.gov/19464172

DMCY4L0	DI	DMCY4L0
DMCY4L0	DN	C[L-Phe-D-pro-L-Phe-L-trp]
DMCY4L0	MI	TT27RFC
DMCY4L0	MN	Opioid receptor delta (OPRD1)
DMCY4L0	MT	DTT
DMCY4L0	MA	Inhibitor
DMCY4L0	RN	Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50.
DMCY4L0	RU	https://pubmed.ncbi.nlm.nih.gov/19464172

DMCY4L0	DI	DMCY4L0
DMCY4L0	DN	C[L-Phe-D-pro-L-Phe-L-trp]
DMCY4L0	MI	TTQW87Y
DMCY4L0	MN	Opioid receptor kappa (OPRK1)
DMCY4L0	MT	DTT
DMCY4L0	MA	Inhibitor
DMCY4L0	RN	Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50.
DMCY4L0	RU	https://pubmed.ncbi.nlm.nih.gov/19464172

DMCY4L0	DI	DMCY4L0
DMCY4L0	DN	C[L-Phe-D-pro-L-Phe-L-trp]
DMCY4L0	MI	TTKWM86
DMCY4L0	MN	Opioid receptor mu (MOP)
DMCY4L0	MT	DTT
DMCY4L0	MA	Inhibitor
DMCY4L0	RN	Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50.
DMCY4L0	RU	https://pubmed.ncbi.nlm.nih.gov/19464172

DM4M3OP	DI	DM4M3OP
DM4M3OP	DN	C[L-Phe-D-pro-L-Tyr(OMe)-D-trp]
DM4M3OP	MI	TTQW87Y
DM4M3OP	MN	Opioid receptor kappa (OPRK1)
DM4M3OP	MT	DTT
DM4M3OP	MA	Inhibitor
DM4M3OP	RN	Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50.
DM4M3OP	RU	https://pubmed.ncbi.nlm.nih.gov/19464172

DM4M3OP	DI	DM4M3OP
DM4M3OP	DN	C[L-Phe-D-pro-L-Tyr(OMe)-D-trp]
DM4M3OP	MI	TTKWM86
DM4M3OP	MN	Opioid receptor mu (MOP)
DM4M3OP	MT	DTT
DM4M3OP	MA	Inhibitor
DM4M3OP	RN	Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50.
DM4M3OP	RU	https://pubmed.ncbi.nlm.nih.gov/19464172

DMADSBT	DI	DMADSBT
DMADSBT	DN	C[L-Phe-D-pro-L-Tyr-D-trp]
DMADSBT	MI	TTQW87Y
DMADSBT	MN	Opioid receptor kappa (OPRK1)
DMADSBT	MT	DTT
DMADSBT	MA	Inhibitor
DMADSBT	RN	Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50.
DMADSBT	RU	https://pubmed.ncbi.nlm.nih.gov/19464172

DMADSBT	DI	DMADSBT
DMADSBT	DN	C[L-Phe-D-pro-L-Tyr-D-trp]
DMADSBT	MI	TTKWM86
DMADSBT	MN	Opioid receptor mu (MOP)
DMADSBT	MT	DTT
DMADSBT	MA	Inhibitor
DMADSBT	RN	Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50.
DMADSBT	RU	https://pubmed.ncbi.nlm.nih.gov/19464172

DMLB6UA	DI	DMLB6UA
DMLB6UA	DN	C[L-Tyr(OMe)-D-pro-L-Phe-D-trp]
DMLB6UA	MI	TTQW87Y
DMLB6UA	MN	Opioid receptor kappa (OPRK1)
DMLB6UA	MT	DTT
DMLB6UA	MA	Inhibitor
DMLB6UA	RN	Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50.
DMLB6UA	RU	https://pubmed.ncbi.nlm.nih.gov/19464172

DMLB6UA	DI	DMLB6UA
DMLB6UA	DN	C[L-Tyr(OMe)-D-pro-L-Phe-D-trp]
DMLB6UA	MI	TTKWM86
DMLB6UA	MN	Opioid receptor mu (MOP)
DMLB6UA	MT	DTT
DMLB6UA	MA	Inhibitor
DMLB6UA	RN	Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50.
DMLB6UA	RU	https://pubmed.ncbi.nlm.nih.gov/19464172

DM7OIY8	DI	DM7OIY8
DM7OIY8	DN	C[L-Tyr-D-pro-L-Phe-D-trp]
DM7OIY8	MI	TTQW87Y
DM7OIY8	MN	Opioid receptor kappa (OPRK1)
DM7OIY8	MT	DTT
DM7OIY8	MA	Inhibitor
DM7OIY8	RN	Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50.
DM7OIY8	RU	https://pubmed.ncbi.nlm.nih.gov/19464172

DM7OIY8	DI	DM7OIY8
DM7OIY8	DN	C[L-Tyr-D-pro-L-Phe-D-trp]
DM7OIY8	MI	TTKWM86
DM7OIY8	MN	Opioid receptor mu (MOP)
DM7OIY8	MT	DTT
DM7OIY8	MA	Inhibitor
DM7OIY8	RN	Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50.
DM7OIY8	RU	https://pubmed.ncbi.nlm.nih.gov/19464172

DMX7IVO	DI	DMX7IVO
DMX7IVO	DN	C[Nle-Arg-D-Nal(2')-Arg-Trp-Glu]-NH2
DMX7IVO	MI	TTEOSZT
DMX7IVO	MN	Melanocortin receptor (MCR)
DMX7IVO	MT	DTT
DMX7IVO	MA	Inhibitor
DMX7IVO	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DMX7IVO	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DMX7IVO	DI	DMX7IVO
DMX7IVO	DN	C[Nle-Arg-D-Nal(2')-Arg-Trp-Glu]-NH2
DMX7IVO	MI	TT0MV2T
DMX7IVO	MN	Melanocortin receptor 1 (MC1R)
DMX7IVO	MT	DTT
DMX7IVO	MA	Inhibitor
DMX7IVO	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DMX7IVO	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DMX7IVO	DI	DMX7IVO
DMX7IVO	DN	C[Nle-Arg-D-Nal(2')-Arg-Trp-Glu]-NH2
DMX7IVO	MI	TTNI91K
DMX7IVO	MN	Melanocortin receptor 3 (MC3R)
DMX7IVO	MT	DTT
DMX7IVO	MA	Inhibitor
DMX7IVO	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DMX7IVO	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DMX7IVO	DI	DMX7IVO
DMX7IVO	DN	C[Nle-Arg-D-Nal(2')-Arg-Trp-Glu]-NH2
DMX7IVO	MI	TTD0CIQ
DMX7IVO	MN	Melanocortin receptor 4 (MC4R)
DMX7IVO	MT	DTT
DMX7IVO	MA	Inhibitor
DMX7IVO	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DMX7IVO	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DMUESCH	DI	DMUESCH
DMUESCH	DN	C[Nle-Arg-D-Phe-Arg-Trp-Glu]-NH2
DMUESCH	MI	TTEOSZT
DMUESCH	MN	Melanocortin receptor (MCR)
DMUESCH	MT	DTT
DMUESCH	MA	Inhibitor
DMUESCH	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DMUESCH	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DMUESCH	DI	DMUESCH
DMUESCH	DN	C[Nle-Arg-D-Phe-Arg-Trp-Glu]-NH2
DMUESCH	MI	TT0MV2T
DMUESCH	MN	Melanocortin receptor 1 (MC1R)
DMUESCH	MT	DTT
DMUESCH	MA	Inhibitor
DMUESCH	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DMUESCH	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DMUESCH	DI	DMUESCH
DMUESCH	DN	C[Nle-Arg-D-Phe-Arg-Trp-Glu]-NH2
DMUESCH	MI	TTNI91K
DMUESCH	MN	Melanocortin receptor 3 (MC3R)
DMUESCH	MT	DTT
DMUESCH	MA	Inhibitor
DMUESCH	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DMUESCH	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DMUESCH	DI	DMUESCH
DMUESCH	DN	C[Nle-Arg-D-Phe-Arg-Trp-Glu]-NH2
DMUESCH	MI	TTD0CIQ
DMUESCH	MN	Melanocortin receptor 4 (MC4R)
DMUESCH	MT	DTT
DMUESCH	MA	Inhibitor
DMUESCH	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DMUESCH	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DM8SXLR	DI	DM8SXLR
DM8SXLR	DN	C[Nle-Asp-D-Nal(2')-Arg-Trp-Glu]-NH2
DM8SXLR	MI	TTEOSZT
DM8SXLR	MN	Melanocortin receptor (MCR)
DM8SXLR	MT	DTT
DM8SXLR	MA	Inhibitor
DM8SXLR	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DM8SXLR	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DM8SXLR	DI	DM8SXLR
DM8SXLR	DN	C[Nle-Asp-D-Nal(2')-Arg-Trp-Glu]-NH2
DM8SXLR	MI	TTNI91K
DM8SXLR	MN	Melanocortin receptor 3 (MC3R)
DM8SXLR	MT	DTT
DM8SXLR	MA	Inhibitor
DM8SXLR	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DM8SXLR	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DM8SXLR	DI	DM8SXLR
DM8SXLR	DN	C[Nle-Asp-D-Nal(2')-Arg-Trp-Glu]-NH2
DM8SXLR	MI	TTD0CIQ
DM8SXLR	MN	Melanocortin receptor 4 (MC4R)
DM8SXLR	MT	DTT
DM8SXLR	MA	Inhibitor
DM8SXLR	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DM8SXLR	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DMXJAOI	DI	DMXJAOI
DMXJAOI	DN	C[Nle-Asp-D-Phe-Arg-Trp-Glu]-NH2
DMXJAOI	MI	TTD0CIQ
DMXJAOI	MN	Melanocortin receptor 4 (MC4R)
DMXJAOI	MT	DTT
DMXJAOI	MA	Inhibitor
DMXJAOI	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DMXJAOI	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DMM19SJ	DI	DMM19SJ
DMM19SJ	DN	C[Nle-Gln-D-Nal(2')-Arg-Trp-Glu]-NH2
DMM19SJ	MI	TTEOSZT
DMM19SJ	MN	Melanocortin receptor (MCR)
DMM19SJ	MT	DTT
DMM19SJ	MA	Inhibitor
DMM19SJ	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DMM19SJ	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DMM19SJ	DI	DMM19SJ
DMM19SJ	DN	C[Nle-Gln-D-Nal(2')-Arg-Trp-Glu]-NH2
DMM19SJ	MI	TT0MV2T
DMM19SJ	MN	Melanocortin receptor 1 (MC1R)
DMM19SJ	MT	DTT
DMM19SJ	MA	Inhibitor
DMM19SJ	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DMM19SJ	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DMM19SJ	DI	DMM19SJ
DMM19SJ	DN	C[Nle-Gln-D-Nal(2')-Arg-Trp-Glu]-NH2
DMM19SJ	MI	TTNI91K
DMM19SJ	MN	Melanocortin receptor 3 (MC3R)
DMM19SJ	MT	DTT
DMM19SJ	MA	Inhibitor
DMM19SJ	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DMM19SJ	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DMM19SJ	DI	DMM19SJ
DMM19SJ	DN	C[Nle-Gln-D-Nal(2')-Arg-Trp-Glu]-NH2
DMM19SJ	MI	TTD0CIQ
DMM19SJ	MN	Melanocortin receptor 4 (MC4R)
DMM19SJ	MT	DTT
DMM19SJ	MA	Inhibitor
DMM19SJ	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DMM19SJ	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DMSGWZE	DI	DMSGWZE
DMSGWZE	DN	C[Nle-Gln-D-Phe-Arg-Trp-Glu]-NH2
DMSGWZE	MI	TTEOSZT
DMSGWZE	MN	Melanocortin receptor (MCR)
DMSGWZE	MT	DTT
DMSGWZE	MA	Inhibitor
DMSGWZE	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DMSGWZE	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DMSGWZE	DI	DMSGWZE
DMSGWZE	DN	C[Nle-Gln-D-Phe-Arg-Trp-Glu]-NH2
DMSGWZE	MI	TT0MV2T
DMSGWZE	MN	Melanocortin receptor 1 (MC1R)
DMSGWZE	MT	DTT
DMSGWZE	MA	Inhibitor
DMSGWZE	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DMSGWZE	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DMSGWZE	DI	DMSGWZE
DMSGWZE	DN	C[Nle-Gln-D-Phe-Arg-Trp-Glu]-NH2
DMSGWZE	MI	TTNI91K
DMSGWZE	MN	Melanocortin receptor 3 (MC3R)
DMSGWZE	MT	DTT
DMSGWZE	MA	Inhibitor
DMSGWZE	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DMSGWZE	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DMHNCAG	DI	DMHNCAG
DMHNCAG	DN	C[Nle-Glu-D-Nal(2')-Arg-Trp-Glu]-NH2
DMHNCAG	MI	TTEOSZT
DMHNCAG	MN	Melanocortin receptor (MCR)
DMHNCAG	MT	DTT
DMHNCAG	MA	Inhibitor
DMHNCAG	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DMHNCAG	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DMHNCAG	DI	DMHNCAG
DMHNCAG	DN	C[Nle-Glu-D-Nal(2')-Arg-Trp-Glu]-NH2
DMHNCAG	MI	TTNI91K
DMHNCAG	MN	Melanocortin receptor 3 (MC3R)
DMHNCAG	MT	DTT
DMHNCAG	MA	Inhibitor
DMHNCAG	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DMHNCAG	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DMHNCAG	DI	DMHNCAG
DMHNCAG	DN	C[Nle-Glu-D-Nal(2')-Arg-Trp-Glu]-NH2
DMHNCAG	MI	TTD0CIQ
DMHNCAG	MN	Melanocortin receptor 4 (MC4R)
DMHNCAG	MT	DTT
DMHNCAG	MA	Inhibitor
DMHNCAG	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DMHNCAG	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DMVWOPG	DI	DMVWOPG
DMVWOPG	DN	C[Nle-Glu-D-Phe-Arg-Trp-Glu]-NH2
DMVWOPG	MI	TTEOSZT
DMVWOPG	MN	Melanocortin receptor (MCR)
DMVWOPG	MT	DTT
DMVWOPG	MA	Inhibitor
DMVWOPG	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DMVWOPG	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DMVWOPG	DI	DMVWOPG
DMVWOPG	DN	C[Nle-Glu-D-Phe-Arg-Trp-Glu]-NH2
DMVWOPG	MI	TTNI91K
DMVWOPG	MN	Melanocortin receptor 3 (MC3R)
DMVWOPG	MT	DTT
DMVWOPG	MA	Inhibitor
DMVWOPG	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DMVWOPG	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DM36HBK	DI	DM36HBK
DM36HBK	DN	C[Nle-His-D-Nal(2')-Arg-Trp-Glu]-NH2
DM36HBK	MI	TTEOSZT
DM36HBK	MN	Melanocortin receptor (MCR)
DM36HBK	MT	DTT
DM36HBK	MA	Inhibitor
DM36HBK	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DM36HBK	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DM36HBK	DI	DM36HBK
DM36HBK	DN	C[Nle-His-D-Nal(2')-Arg-Trp-Glu]-NH2
DM36HBK	MI	TTNI91K
DM36HBK	MN	Melanocortin receptor 3 (MC3R)
DM36HBK	MT	DTT
DM36HBK	MA	Inhibitor
DM36HBK	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DM36HBK	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DM36HBK	DI	DM36HBK
DM36HBK	DN	C[Nle-His-D-Nal(2')-Arg-Trp-Glu]-NH2
DM36HBK	MI	TTD0CIQ
DM36HBK	MN	Melanocortin receptor 4 (MC4R)
DM36HBK	MT	DTT
DM36HBK	MA	Inhibitor
DM36HBK	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DM36HBK	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DM5HRNM	DI	DM5HRNM
DM5HRNM	DN	C[Nle-His-D-Phe-Arg-Trp-Glu]-NH2
DM5HRNM	MI	TTEOSZT
DM5HRNM	MN	Melanocortin receptor (MCR)
DM5HRNM	MT	DTT
DM5HRNM	MA	Inhibitor
DM5HRNM	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DM5HRNM	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DM5HRNM	DI	DM5HRNM
DM5HRNM	DN	C[Nle-His-D-Phe-Arg-Trp-Glu]-NH2
DM5HRNM	MI	TTNI91K
DM5HRNM	MN	Melanocortin receptor 3 (MC3R)
DM5HRNM	MT	DTT
DM5HRNM	MA	Inhibitor
DM5HRNM	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DM5HRNM	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DM5HRNM	DI	DM5HRNM
DM5HRNM	DN	C[Nle-His-D-Phe-Arg-Trp-Glu]-NH2
DM5HRNM	MI	TTD0CIQ
DM5HRNM	MN	Melanocortin receptor 4 (MC4R)
DM5HRNM	MT	DTT
DM5HRNM	MA	Inhibitor
DM5HRNM	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DM5HRNM	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DM73ZMG	DI	DM73ZMG
DM73ZMG	DN	C[Nle-Nle-D-Nal(2')-Arg-Trp-Glu]-NH2
DM73ZMG	MI	TTEOSZT
DM73ZMG	MN	Melanocortin receptor (MCR)
DM73ZMG	MT	DTT
DM73ZMG	MA	Inhibitor
DM73ZMG	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DM73ZMG	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DM73ZMG	DI	DM73ZMG
DM73ZMG	DN	C[Nle-Nle-D-Nal(2')-Arg-Trp-Glu]-NH2
DM73ZMG	MI	TT0MV2T
DM73ZMG	MN	Melanocortin receptor 1 (MC1R)
DM73ZMG	MT	DTT
DM73ZMG	MA	Inhibitor
DM73ZMG	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DM73ZMG	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DM73ZMG	DI	DM73ZMG
DM73ZMG	DN	C[Nle-Nle-D-Nal(2')-Arg-Trp-Glu]-NH2
DM73ZMG	MI	TTNI91K
DM73ZMG	MN	Melanocortin receptor 3 (MC3R)
DM73ZMG	MT	DTT
DM73ZMG	MA	Inhibitor
DM73ZMG	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DM73ZMG	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DM73ZMG	DI	DM73ZMG
DM73ZMG	DN	C[Nle-Nle-D-Nal(2')-Arg-Trp-Glu]-NH2
DM73ZMG	MI	TTD0CIQ
DM73ZMG	MN	Melanocortin receptor 4 (MC4R)
DM73ZMG	MT	DTT
DM73ZMG	MA	Inhibitor
DM73ZMG	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DM73ZMG	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DMDPBVS	DI	DMDPBVS
DMDPBVS	DN	C[Nle-Nle-D-Phe-Arg-Trp-Glu]-NH2
DMDPBVS	MI	TTEOSZT
DMDPBVS	MN	Melanocortin receptor (MCR)
DMDPBVS	MT	DTT
DMDPBVS	MA	Inhibitor
DMDPBVS	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DMDPBVS	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DMDPBVS	DI	DMDPBVS
DMDPBVS	DN	C[Nle-Nle-D-Phe-Arg-Trp-Glu]-NH2
DMDPBVS	MI	TTNI91K
DMDPBVS	MN	Melanocortin receptor 3 (MC3R)
DMDPBVS	MT	DTT
DMDPBVS	MA	Inhibitor
DMDPBVS	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DMDPBVS	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DMDPBVS	DI	DMDPBVS
DMDPBVS	DN	C[Nle-Nle-D-Phe-Arg-Trp-Glu]-NH2
DMDPBVS	MI	TTD0CIQ
DMDPBVS	MN	Melanocortin receptor 4 (MC4R)
DMDPBVS	MT	DTT
DMDPBVS	MA	Inhibitor
DMDPBVS	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DMDPBVS	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DMPZ4VB	DI	DMPZ4VB
DMPZ4VB	DN	C[Nle-Pro-D-Nal(2')-Arg-Trp-Glu]-NH2
DMPZ4VB	MI	TTEOSZT
DMPZ4VB	MN	Melanocortin receptor (MCR)
DMPZ4VB	MT	DTT
DMPZ4VB	MA	Inhibitor
DMPZ4VB	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DMPZ4VB	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DMPZ4VB	DI	DMPZ4VB
DMPZ4VB	DN	C[Nle-Pro-D-Nal(2')-Arg-Trp-Glu]-NH2
DMPZ4VB	MI	TTNI91K
DMPZ4VB	MN	Melanocortin receptor 3 (MC3R)
DMPZ4VB	MT	DTT
DMPZ4VB	MA	Inhibitor
DMPZ4VB	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DMPZ4VB	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DMPZ4VB	DI	DMPZ4VB
DMPZ4VB	DN	C[Nle-Pro-D-Nal(2')-Arg-Trp-Glu]-NH2
DMPZ4VB	MI	TTD0CIQ
DMPZ4VB	MN	Melanocortin receptor 4 (MC4R)
DMPZ4VB	MT	DTT
DMPZ4VB	MA	Inhibitor
DMPZ4VB	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DMPZ4VB	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DMZWMV0	DI	DMZWMV0
DMZWMV0	DN	C[Nle-Pro-D-Phe-Arg-Trp-Glu]-NH2
DMZWMV0	MI	TTEOSZT
DMZWMV0	MN	Melanocortin receptor (MCR)
DMZWMV0	MT	DTT
DMZWMV0	MA	Inhibitor
DMZWMV0	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DMZWMV0	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DMZWMV0	DI	DMZWMV0
DMZWMV0	DN	C[Nle-Pro-D-Phe-Arg-Trp-Glu]-NH2
DMZWMV0	MI	TTNI91K
DMZWMV0	MN	Melanocortin receptor 3 (MC3R)
DMZWMV0	MT	DTT
DMZWMV0	MA	Inhibitor
DMZWMV0	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DMZWMV0	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DMZWMV0	DI	DMZWMV0
DMZWMV0	DN	C[Nle-Pro-D-Phe-Arg-Trp-Glu]-NH2
DMZWMV0	MI	TTD0CIQ
DMZWMV0	MN	Melanocortin receptor 4 (MC4R)
DMZWMV0	MT	DTT
DMZWMV0	MA	Inhibitor
DMZWMV0	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DMZWMV0	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DMSIGJW	DI	DMSIGJW
DMSIGJW	DN	C[Nle-Val-D-Nal(2')-Arg-Trp-Glu]-NH2
DMSIGJW	MI	TTEOSZT
DMSIGJW	MN	Melanocortin receptor (MCR)
DMSIGJW	MT	DTT
DMSIGJW	MA	Inhibitor
DMSIGJW	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DMSIGJW	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DMSIGJW	DI	DMSIGJW
DMSIGJW	DN	C[Nle-Val-D-Nal(2')-Arg-Trp-Glu]-NH2
DMSIGJW	MI	TT0MV2T
DMSIGJW	MN	Melanocortin receptor 1 (MC1R)
DMSIGJW	MT	DTT
DMSIGJW	MA	Inhibitor
DMSIGJW	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DMSIGJW	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DMSIGJW	DI	DMSIGJW
DMSIGJW	DN	C[Nle-Val-D-Nal(2')-Arg-Trp-Glu]-NH2
DMSIGJW	MI	TTNI91K
DMSIGJW	MN	Melanocortin receptor 3 (MC3R)
DMSIGJW	MT	DTT
DMSIGJW	MA	Inhibitor
DMSIGJW	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DMSIGJW	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DMSIGJW	DI	DMSIGJW
DMSIGJW	DN	C[Nle-Val-D-Nal(2')-Arg-Trp-Glu]-NH2
DMSIGJW	MI	TTD0CIQ
DMSIGJW	MN	Melanocortin receptor 4 (MC4R)
DMSIGJW	MT	DTT
DMSIGJW	MA	Inhibitor
DMSIGJW	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DMSIGJW	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DM45ZLW	DI	DM45ZLW
DM45ZLW	DN	C[Nle-Val-D-Phe-Arg-Trp-Glu]-NH2
DM45ZLW	MI	TTEOSZT
DM45ZLW	MN	Melanocortin receptor (MCR)
DM45ZLW	MT	DTT
DM45ZLW	MA	Inhibitor
DM45ZLW	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DM45ZLW	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DM45ZLW	DI	DM45ZLW
DM45ZLW	DN	C[Nle-Val-D-Phe-Arg-Trp-Glu]-NH2
DM45ZLW	MI	TTNI91K
DM45ZLW	MN	Melanocortin receptor 3 (MC3R)
DM45ZLW	MT	DTT
DM45ZLW	MA	Inhibitor
DM45ZLW	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DM45ZLW	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DM45ZLW	DI	DM45ZLW
DM45ZLW	DN	C[Nle-Val-D-Phe-Arg-Trp-Glu]-NH2
DM45ZLW	MI	TTD0CIQ
DM45ZLW	MN	Melanocortin receptor 4 (MC4R)
DM45ZLW	MT	DTT
DM45ZLW	MA	Inhibitor
DM45ZLW	RN	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
DM45ZLW	RU	https://pubmed.ncbi.nlm.nih.gov/16539382

DMF091Y	DI	DMF091Y
DMF091Y	DN	C[RGD-(R)-alpha-TfmfV]
DMF091Y	MI	TTT1R2L
DMF091Y	MN	Integrin alpha-V (ITGAV)
DMF091Y	MT	DTT
DMF091Y	MA	Inhibitor
DMF091Y	RN	Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17.
DMF091Y	RU	https://pubmed.ncbi.nlm.nih.gov/16509596

DMF091Y	DI	DMF091Y
DMF091Y	DN	C[RGD-(R)-alpha-TfmfV]
DMF091Y	MI	TTJA1ZO
DMF091Y	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMF091Y	MT	DTT
DMF091Y	MA	Inhibitor
DMF091Y	RN	Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17.
DMF091Y	RU	https://pubmed.ncbi.nlm.nih.gov/16509596

DMC9G2Y	DI	DMC9G2Y
DMC9G2Y	DN	C[RGD-(S)-alpha-TfmfV]
DMC9G2Y	MI	TTT1R2L
DMC9G2Y	MN	Integrin alpha-V (ITGAV)
DMC9G2Y	MT	DTT
DMC9G2Y	MA	Inhibitor
DMC9G2Y	RN	Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17.
DMC9G2Y	RU	https://pubmed.ncbi.nlm.nih.gov/16509596

DMC9G2Y	DI	DMC9G2Y
DMC9G2Y	DN	C[RGD-(S)-alpha-TfmfV]
DMC9G2Y	MI	TTJA1ZO
DMC9G2Y	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMC9G2Y	MT	DTT
DMC9G2Y	MA	Inhibitor
DMC9G2Y	RN	Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17.
DMC9G2Y	RU	https://pubmed.ncbi.nlm.nih.gov/16509596

DM1DMR2	DI	DM1DMR2
DM1DMR2	DN	C[RGDf-(3R)-Carboxymorpholine]
DM1DMR2	MI	TTT1R2L
DM1DMR2	MN	Integrin alpha-V (ITGAV)
DM1DMR2	MT	DTT
DM1DMR2	MA	Inhibitor
DM1DMR2	RN	Morpholine-based RGD-cyclopentapeptides as alphavbeta3/alphavbeta5 integrin ligands: role of configuration towards receptor binding affinity. Bioorg Med Chem. 2009 Feb 15;17(4):1542-9.
DM1DMR2	RU	https://pubmed.ncbi.nlm.nih.gov/19195898

DM0ULZM	DI	DM0ULZM
DM0ULZM	DN	C[RGDf-(3S)-Carboxymorpholine]
DM0ULZM	MI	TTT1R2L
DM0ULZM	MN	Integrin alpha-V (ITGAV)
DM0ULZM	MT	DTT
DM0ULZM	MA	Inhibitor
DM0ULZM	RN	Morpholine-based RGD-cyclopentapeptides as alphavbeta3/alphavbeta5 integrin ligands: role of configuration towards receptor binding affinity. Bioorg Med Chem. 2009 Feb 15;17(4):1542-9.
DM0ULZM	RU	https://pubmed.ncbi.nlm.nih.gov/19195898

DMXA0JB	DI	DMXA0JB
DMXA0JB	DN	C[RGDf-(R)-alpha-TfmF]
DMXA0JB	MI	TTT1R2L
DMXA0JB	MN	Integrin alpha-V (ITGAV)
DMXA0JB	MT	DTT
DMXA0JB	MA	Inhibitor
DMXA0JB	RN	Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17.
DMXA0JB	RU	https://pubmed.ncbi.nlm.nih.gov/16509596

DMXA0JB	DI	DMXA0JB
DMXA0JB	DN	C[RGDf-(R)-alpha-TfmF]
DMXA0JB	MI	TTJA1ZO
DMXA0JB	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMXA0JB	MT	DTT
DMXA0JB	MA	Inhibitor
DMXA0JB	RN	Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17.
DMXA0JB	RU	https://pubmed.ncbi.nlm.nih.gov/16509596

DM8FGMA	DI	DM8FGMA
DM8FGMA	DN	C[RGDf-(R)-alpha-TfmV]
DM8FGMA	MI	TTT1R2L
DM8FGMA	MN	Integrin alpha-V (ITGAV)
DM8FGMA	MT	DTT
DM8FGMA	MA	Inhibitor
DM8FGMA	RN	Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17.
DM8FGMA	RU	https://pubmed.ncbi.nlm.nih.gov/16509596

DM8FGMA	DI	DM8FGMA
DM8FGMA	DN	C[RGDf-(R)-alpha-TfmV]
DM8FGMA	MI	TTJA1ZO
DM8FGMA	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DM8FGMA	MT	DTT
DM8FGMA	MA	Inhibitor
DM8FGMA	RN	Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17.
DM8FGMA	RU	https://pubmed.ncbi.nlm.nih.gov/16509596

DM4ZWOD	DI	DM4ZWOD
DM4ZWOD	DN	C[RGDf-(R)-N-Me-alpha-TfmF]
DM4ZWOD	MI	TTT1R2L
DM4ZWOD	MN	Integrin alpha-V (ITGAV)
DM4ZWOD	MT	DTT
DM4ZWOD	MA	Inhibitor
DM4ZWOD	RN	Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17.
DM4ZWOD	RU	https://pubmed.ncbi.nlm.nih.gov/16509596

DM4ZWOD	DI	DM4ZWOD
DM4ZWOD	DN	C[RGDf-(R)-N-Me-alpha-TfmF]
DM4ZWOD	MI	TTJA1ZO
DM4ZWOD	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DM4ZWOD	MT	DTT
DM4ZWOD	MA	Inhibitor
DM4ZWOD	RN	Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17.
DM4ZWOD	RU	https://pubmed.ncbi.nlm.nih.gov/16509596

DMCXJOL	DI	DMCXJOL
DMCXJOL	DN	C[RGDf-(S)-alpha-TfmF]
DMCXJOL	MI	TTT1R2L
DMCXJOL	MN	Integrin alpha-V (ITGAV)
DMCXJOL	MT	DTT
DMCXJOL	MA	Inhibitor
DMCXJOL	RN	Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17.
DMCXJOL	RU	https://pubmed.ncbi.nlm.nih.gov/16509596

DMCXJOL	DI	DMCXJOL
DMCXJOL	DN	C[RGDf-(S)-alpha-TfmF]
DMCXJOL	MI	TTJA1ZO
DMCXJOL	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMCXJOL	MT	DTT
DMCXJOL	MA	Inhibitor
DMCXJOL	RN	Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17.
DMCXJOL	RU	https://pubmed.ncbi.nlm.nih.gov/16509596

DMLRYXK	DI	DMLRYXK
DMLRYXK	DN	C[RGDf-(S)-alpha-TfmV]
DMLRYXK	MI	TTT1R2L
DMLRYXK	MN	Integrin alpha-V (ITGAV)
DMLRYXK	MT	DTT
DMLRYXK	MA	Inhibitor
DMLRYXK	RN	Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17.
DMLRYXK	RU	https://pubmed.ncbi.nlm.nih.gov/16509596

DMLRYXK	DI	DMLRYXK
DMLRYXK	DN	C[RGDf-(S)-alpha-TfmV]
DMLRYXK	MI	TTJA1ZO
DMLRYXK	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMLRYXK	MT	DTT
DMLRYXK	MA	Inhibitor
DMLRYXK	RN	Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17.
DMLRYXK	RU	https://pubmed.ncbi.nlm.nih.gov/16509596

DMNS3HC	DI	DMNS3HC
DMNS3HC	DN	C[RGDf-(S)-N-Me-alpha-TfmF]
DMNS3HC	MI	TTT1R2L
DMNS3HC	MN	Integrin alpha-V (ITGAV)
DMNS3HC	MT	DTT
DMNS3HC	MA	Inhibitor
DMNS3HC	RN	Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17.
DMNS3HC	RU	https://pubmed.ncbi.nlm.nih.gov/16509596

DMNS3HC	DI	DMNS3HC
DMNS3HC	DN	C[RGDf-(S)-N-Me-alpha-TfmF]
DMNS3HC	MI	TTJA1ZO
DMNS3HC	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMNS3HC	MT	DTT
DMNS3HC	MA	Inhibitor
DMNS3HC	RN	Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17.
DMNS3HC	RU	https://pubmed.ncbi.nlm.nih.gov/16509596

DMAILK8	DI	DMAILK8
DMAILK8	DN	C[RGDf-(S,R)-alpha-Dfm-F]
DMAILK8	MI	TTT1R2L
DMAILK8	MN	Integrin alpha-V (ITGAV)
DMAILK8	MT	DTT
DMAILK8	MA	Inhibitor
DMAILK8	RN	Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17.
DMAILK8	RU	https://pubmed.ncbi.nlm.nih.gov/16509596

DMAILK8	DI	DMAILK8
DMAILK8	DN	C[RGDf-(S,R)-alpha-Dfm-F]
DMAILK8	MI	TTJA1ZO
DMAILK8	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMAILK8	MT	DTT
DMAILK8	MA	Inhibitor
DMAILK8	RN	Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17.
DMAILK8	RU	https://pubmed.ncbi.nlm.nih.gov/16509596

DMO7BMZ	DI	DMO7BMZ
DMO7BMZ	DN	C[Ser-Tyr-Thr-His-Dphe-Arg-Trp-Thr-Ile-Pro]
DMO7BMZ	MI	TTD0CIQ
DMO7BMZ	MN	Melanocortin receptor 4 (MC4R)
DMO7BMZ	MT	DTT
DMO7BMZ	MA	Inhibitor
DMO7BMZ	RN	Mapping the binding site of melanocortin 4 receptor agonists: a hydrophobic pocket formed by I3.28(125), I3.32(129), and I7.42(291) is critical for... J Med Chem. 2006 Feb 9;49(3):911-22.
DMO7BMZ	RU	https://pubmed.ncbi.nlm.nih.gov/16451057

DMRY95I	DI	DMRY95I
DMRY95I	DN	C[Thr-Tyr-Thr-His-DNaf-Arg-Trp-Thr-Ile-Pro]
DMRY95I	MI	TTD0CIQ
DMRY95I	MN	Melanocortin receptor 4 (MC4R)
DMRY95I	MT	DTT
DMRY95I	MA	Inhibitor
DMRY95I	RN	Mapping the binding site of melanocortin 4 receptor agonists: a hydrophobic pocket formed by I3.28(125), I3.32(129), and I7.42(291) is critical for... J Med Chem. 2006 Feb 9;49(3):911-22.
DMRY95I	RU	https://pubmed.ncbi.nlm.nih.gov/16451057

DM0YLPV	DI	DM0YLPV
DM0YLPV	DN	C[YYAEGLEE]-NH2
DM0YLPV	MI	TT1VAUK
DM0YLPV	MN	VEGFR1 messenger RNA (VEGFR1 mRNA)
DM0YLPV	MT	DTT
DM0YLPV	MA	Inhibitor
DM0YLPV	RN	Biochemical and structural analysis of the binding determinants of a vascular endothelial growth factor receptor peptidic antagonist. J Med Chem. 2010 Jun 10;53(11):4428-40.
DM0YLPV	RU	https://pubmed.ncbi.nlm.nih.gov/20462213

DMSKW8H	DI	DMSKW8H
DMSKW8H	DN	C[YYDEGLEE]-NH2
DMSKW8H	MI	TT1VAUK
DMSKW8H	MN	VEGFR1 messenger RNA (VEGFR1 mRNA)
DMSKW8H	MT	DTT
DMSKW8H	MA	Inhibitor
DMSKW8H	RN	Biochemical and structural analysis of the binding determinants of a vascular endothelial growth factor receptor peptidic antagonist. J Med Chem. 2010 Jun 10;53(11):4428-40.
DMSKW8H	RU	https://pubmed.ncbi.nlm.nih.gov/20462213

DMTHGMR	DI	DMTHGMR
DMTHGMR	DN	C[YYDEKLEE]-NH2
DMTHGMR	MI	TT1VAUK
DMTHGMR	MN	VEGFR1 messenger RNA (VEGFR1 mRNA)
DMTHGMR	MT	DTT
DMTHGMR	MA	Inhibitor
DMTHGMR	RN	Biochemical and structural analysis of the binding determinants of a vascular endothelial growth factor receptor peptidic antagonist. J Med Chem. 2010 Jun 10;53(11):4428-40.
DMTHGMR	RU	https://pubmed.ncbi.nlm.nih.gov/20462213

DMD7OQA	DI	DMD7OQA
DMD7OQA	DN	C-014C
DMD7OQA	MI	TT7HQD0
DMD7OQA	MN	C-C chemokine receptor type 4 (CCR4)
DMD7OQA	MT	DTT
DMD7OQA	MA	Inhibitor
DMD7OQA	RN	Discovery of potent CCR4 antagonists: Synthesis and structure-activity relationship study of 2,4-diaminoquinazolines. Bioorg Med Chem. 2008 Jul 15;16(14):7021-32.
DMD7OQA	RU	https://pubmed.ncbi.nlm.nih.gov/18539035

DMNV1ST	DI	DMNV1ST
DMNV1ST	DN	C-10068
DMNV1ST	MI	TT5TPI6
DMNV1ST	MN	Opioid receptor sigma 1 (OPRS1)
DMNV1ST	MT	DTT
DMNV1ST	MA	Agonist
DMNV1ST	RN	Antitussives and substance abuse. Subst Abuse Rehabil. 2013 Nov 6;4:75-82.
DMNV1ST	RU	https://pubmed.ncbi.nlm.nih.gov/24648790

DMZXE6O	DI	DMZXE6O
DMZXE6O	DN	C-16-(S)-3-methylindolerapamycin
DMZXE6O	MI	TTCJG29
DMZXE6O	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMZXE6O	MT	DTT
DMZXE6O	MA	Inhibitor
DMZXE6O	RN	The rapamycin-binding domain of the protein kinase mammalian target of rapamycin is a destabilizing domain. J Biol Chem. 2007 May 4;282(18):13395-401.
DMZXE6O	RU	https://pubmed.ncbi.nlm.nih.gov/17350953

DM23KNC	DI	DM23KNC
DM23KNC	DN	C16-Fatty-Acyl-Substrate-Mimic
DM23KNC	MI	TTVTX4N
DM23KNC	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DM23KNC	MT	DTT
DM23KNC	MA	Inhibitor
DM23KNC	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM23KNC	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMKGSRZ	DI	DMKGSRZ
DMKGSRZ	DN	C-176
DMKGSRZ	MI	TTT402Y
DMKGSRZ	MN	Stimulator of interferon genes protein (TMEM173)
DMKGSRZ	MT	DTT
DMKGSRZ	MA	Agonist
DMKGSRZ	RN	Stimulator of IFN genes mediates neuroinflammatory injury by suppressing AMPK signal in experimental subarachnoid hemorrhage. J Neuroinflammation. 2020 May 25;17(1):165.
DMKGSRZ	RU	https://pubmed.ncbi.nlm.nih.gov/32450897

DM4FEU8	DI	DM4FEU8
DM4FEU8	DN	C-178
DM4FEU8	MI	TTT402Y
DM4FEU8	MN	Stimulator of interferon genes protein (TMEM173)
DM4FEU8	MT	DTT
DM4FEU8	MA	Agonist
DM4FEU8	RN	Targeting STING with covalent small-molecule inhibitors. Nature. 2018 Jul;559(7713):269-273.
DM4FEU8	RU	https://pubmed.ncbi.nlm.nih.gov/29973723

DMCAO3V	DI	DMCAO3V
DMCAO3V	DN	C-21191
DMCAO3V	MI	TTEX6LM
DMCAO3V	MN	GABA(A) receptor gamma-3 (GABRG3)
DMCAO3V	MT	DTT
DMCAO3V	MA	Modulator
DMCAO3V	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415).
DMCAO3V	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415

DMS87IF	DI	DMS87IF
DMS87IF	DN	C2-MAD
DMS87IF	MI	TTTB4UP
DMS87IF	MN	Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2)
DMS87IF	MT	DTT
DMS87IF	MA	Inhibitor
DMS87IF	RN	Novel mycophenolic adenine bis(phosphonate) analogues as potential differentiation agents against human leukemia. J Med Chem. 2002 Jan 31;45(3):703-12.
DMS87IF	RU	https://pubmed.ncbi.nlm.nih.gov/11806722

DMTCOY9	DI	DMTCOY9
DMTCOY9	DN	C3
DMTCOY9	MI	TTX4RTB
DMTCOY9	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMTCOY9	MT	DTT
DMTCOY9	MA	Agonist
DMTCOY9	RN	SLC-1 receptor mediates effect of melanin-concentrating hormone on feeding behavior in rat: a structure-activity study. J Pharmacol Exp Ther. 2001 Oct;299(1):137-46.
DMTCOY9	RU	https://pubmed.ncbi.nlm.nih.gov/11561073

DMGA9U7	DI	DMGA9U7
DMGA9U7	DN	C4-MAD
DMGA9U7	MI	TTTB4UP
DMGA9U7	MN	Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2)
DMGA9U7	MT	DTT
DMGA9U7	MA	Inhibitor
DMGA9U7	RN	Novel mycophenolic adenine bis(phosphonate) analogues as potential differentiation agents against human leukemia. J Med Chem. 2002 Jan 31;45(3):703-12.
DMGA9U7	RU	https://pubmed.ncbi.nlm.nih.gov/11806722

DM5971G	DI	DM5971G
DM5971G	DN	C4X-101
DM5971G	MI	TT4J8MF
DM5971G	MN	Thyrotropin-releasing hormone receptor (TRHR)
DM5971G	MT	DTT
DM5971G	MA	Inhibitor
DM5971G	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 363).
DM5971G	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=363

DMEK4HZ	DI	DMEK4HZ
DMEK4HZ	DN	C5aR pepducins
DMEK4HZ	MI	TTHXFA1
DMEK4HZ	MN	C5a anaphylatoxin chemotactic receptor (C5AR1)
DMEK4HZ	MT	DTT
DMEK4HZ	MA	Modulator
DMEK4HZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 32).
DMEK4HZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=32

DMCOQKH	DI	DMCOQKH
DMCOQKH	DN	C646
DMCOQKH	MI	TTH4VJL
DMCOQKH	MN	Histone acetyltransferase KAT6B (KAT6B)
DMCOQKH	MT	DTT
DMCOQKH	MA	Inhibitor
DMCOQKH	RN	Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem Biol. 2010 May 28;17(5):471-82.
DMCOQKH	RU	https://pubmed.ncbi.nlm.nih.gov/20534345

DM4LIHQ	DI	DM4LIHQ
DM4LIHQ	DN	C6S
DM4LIHQ	MI	TTKWM86
DM4LIHQ	MN	Opioid receptor mu (MOP)
DM4LIHQ	MT	DTT
DM4LIHQ	MA	Inhibitor
DM4LIHQ	RN	Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5.
DM4LIHQ	RU	https://pubmed.ncbi.nlm.nih.gov/16777416

DM7MNOX	DI	DM7MNOX
DM7MNOX	DN	C7/3-phth
DM7MNOX	MI	TTOXS3C
DM7MNOX	MN	Muscarinic acetylcholine receptor (CHRM)
DM7MNOX	MT	DTT
DM7MNOX	MA	Modulator (allosteric modulator)
DM7MNOX	RN	Characterization of the subtype selectivity of the allosteric modulator heptane-1,7-bis-(dimethyl-3'-phthalimidopropyl) ammonium bromide (C7/3-phth) at cloned muscarinic acetylcholine receptors. Biochem Pharmacol. 1999 Jan 15;57(2):171-9.
DM7MNOX	RU	https://pubmed.ncbi.nlm.nih.gov/9890565

DMHGX1N	DI	DMHGX1N
DMHGX1N	DN	C75
DMHGX1N	MI	TTDL0NY
DMHGX1N	MN	Carnitine O-palmitoyltransferase I (CPT1B)
DMHGX1N	MT	DTT
DMHGX1N	MA	Activator
DMHGX1N	RN	C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity. Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9498-502.
DMHGX1N	RU	https://pubmed.ncbi.nlm.nih.gov/12060712

DMHGX1N	DI	DMHGX1N
DMHGX1N	DN	C75
DMHGX1N	MI	TT7AOUD
DMHGX1N	MN	Fatty acid synthase (FASN)
DMHGX1N	MT	DTT
DMHGX1N	MA	Inhibitor
DMHGX1N	RN	C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity. Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9498-502.
DMHGX1N	RU	https://pubmed.ncbi.nlm.nih.gov/12060712

DMX85E7	DI	DMX85E7
DMX85E7	DN	Ca(2+) chelator
DMX85E7	MI	TTBLN9S
DMX85E7	MN	Sulfur mustard-stimulated protease (SMSP)
DMX85E7	MT	DTT
DMX85E7	MA	Inhibitor
DMX85E7	RN	Sulfur mustard-stimulated protease: a target for antivesicant drugs. J Appl Toxicol. 2002 Mar-Apr;22(2):139-40.
DMX85E7	RU	https://pubmed.ncbi.nlm.nih.gov/11920939

DMP5OSK	DI	DMP5OSK
DMP5OSK	DN	CA-327
DMP5OSK	MI	TT8ZLTI
DMP5OSK	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMP5OSK	MT	DTT
DMP5OSK	MA	Inhibitor
DMP5OSK	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMP5OSK	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMCLN6M	DI	DMCLN6M
DMCLN6M	DN	CA-50040
DMCLN6M	MI	TTF1QVM
DMCLN6M	MN	Gastric H(+)/K(+) ATPase alpha (ATP4A)
DMCLN6M	MT	DTT
DMCLN6M	MA	Modulator
DMCLN6M	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 849).
DMCLN6M	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=849

DMQATPN	DI	DMQATPN
DMQATPN	DN	CAA0225
DMQATPN	MI	TT36ETB
DMQATPN	MN	Cathepsin L (CTSL)
DMQATPN	MT	DTT
DMQATPN	MA	Inhibitor
DMQATPN	RN	Characterization of CAA0225, a novel inhibitor specific for cathepsin L, as a probe for autophagic proteolysis. Biol Pharm Bull. 2009 Mar;32(3):475-9.
DMQATPN	RU	https://pubmed.ncbi.nlm.nih.gov/19252298

DMPKFYZ	DI	DMPKFYZ
DMPKFYZ	DN	CACA
DMPKFYZ	MI	TT6XFEU
DMPKFYZ	MN	GABA(A) receptor rho1 (GABRR1)
DMPKFYZ	MT	DTT
DMPKFYZ	MA	Agonist
DMPKFYZ	RN	Characterization of bicuculline/baclofen-insensitive (rho-like) gamma-aminobutyric acid receptors expressed in Xenopus oocytes. II. Pharmacology of gamma-aminobutyric acidA and gamma-aminobutyric acidB receptor agonists and antagonists. Mol Pharmacol. 1993 Apr;43(4):609-25.
DMPKFYZ	RU	https://pubmed.ncbi.nlm.nih.gov/8386310

DMK4XLD	DI	DMK4XLD
DMK4XLD	DN	Cacodylate Ion
DMK4XLD	MI	TTQWGU9
DMK4XLD	MN	Bacterial Aspartate-semialdehyde dehydrogenase (Bact asd2)
DMK4XLD	MT	DTT
DMK4XLD	MA	Inhibitor
DMK4XLD	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMK4XLD	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMK4XLD	DI	DMK4XLD
DMK4XLD	DN	Cacodylate Ion
DMK4XLD	MI	TTV3NH6
DMK4XLD	MN	Calmodulin (CALM)
DMK4XLD	MT	DTT
DMK4XLD	MA	Inhibitor
DMK4XLD	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMK4XLD	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMK4XLD	DI	DMK4XLD
DMK4XLD	DN	Cacodylate Ion
DMK4XLD	MI	TTCM4B3
DMK4XLD	MN	Nitric-oxide synthase endothelial (NOS3)
DMK4XLD	MT	DTT
DMK4XLD	MA	Inhibitor
DMK4XLD	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMK4XLD	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMK4XLD	DI	DMK4XLD
DMK4XLD	DN	Cacodylate Ion
DMK4XLD	MI	TT0OFWN
DMK4XLD	MN	Pseudomonas UDP-3-O-acyl-GlcNAc deacetylase (Pseudo lpxC)
DMK4XLD	MT	DTT
DMK4XLD	MA	Inhibitor
DMK4XLD	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMK4XLD	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMK4XLD	DI	DMK4XLD
DMK4XLD	DN	Cacodylate Ion
DMK4XLD	MI	TTZJ5U9
DMK4XLD	MN	Thioredoxin (TXN)
DMK4XLD	MT	DTT
DMK4XLD	MA	Inhibitor
DMK4XLD	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMK4XLD	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMK4XLD	DI	DMK4XLD
DMK4XLD	DN	Cacodylate Ion
DMK4XLD	MI	TTGER3L
DMK4XLD	MN	Thyroid hormone receptor beta (THRB)
DMK4XLD	MT	DTT
DMK4XLD	MA	Inhibitor
DMK4XLD	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMK4XLD	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMIPJUS	DI	DMIPJUS
DMIPJUS	DN	CACOSPONGIONOLIDE
DMIPJUS	MI	TTO8QRU
DMIPJUS	MN	Group IIA phospholipase A2 (GIIA sPLA2)
DMIPJUS	MT	DTT
DMIPJUS	MA	Inhibitor
DMIPJUS	RN	A new cacospongionolide inhibitor of human secretory phospholipase A2 from the Tyrrhenian sponge Fasciospongia cavernosa and absolute configuration... J Nat Prod. 1998 Jul;61(7):931-5.
DMIPJUS	RU	https://pubmed.ncbi.nlm.nih.gov/9677277

DMIPJUS	DI	DMIPJUS
DMIPJUS	DN	CACOSPONGIONOLIDE
DMIPJUS	MI	TT9V5JH
DMIPJUS	MN	Phospholipase A2 (PLA2G1B)
DMIPJUS	MT	DTT
DMIPJUS	MA	Inhibitor
DMIPJUS	RN	A new cacospongionolide inhibitor of human secretory phospholipase A2 from the Tyrrhenian sponge Fasciospongia cavernosa and absolute configuration... J Nat Prod. 1998 Jul;61(7):931-5.
DMIPJUS	RU	https://pubmed.ncbi.nlm.nih.gov/9677277

DMCSXNW	DI	DMCSXNW
DMCSXNW	DN	CACOSPONGIONOLIDE B
DMCSXNW	MI	TTO8QRU
DMCSXNW	MN	Group IIA phospholipase A2 (GIIA sPLA2)
DMCSXNW	MT	DTT
DMCSXNW	MA	Inhibitor
DMCSXNW	RN	A new cacospongionolide inhibitor of human secretory phospholipase A2 from the Tyrrhenian sponge Fasciospongia cavernosa and absolute configuration... J Nat Prod. 1998 Jul;61(7):931-5.
DMCSXNW	RU	https://pubmed.ncbi.nlm.nih.gov/9677277

DMCSXNW	DI	DMCSXNW
DMCSXNW	DN	CACOSPONGIONOLIDE B
DMCSXNW	MI	TT9V5JH
DMCSXNW	MN	Phospholipase A2 (PLA2G1B)
DMCSXNW	MT	DTT
DMCSXNW	MA	Inhibitor
DMCSXNW	RN	A new cacospongionolide inhibitor of human secretory phospholipase A2 from the Tyrrhenian sponge Fasciospongia cavernosa and absolute configuration... J Nat Prod. 1998 Jul;61(7):931-5.
DMCSXNW	RU	https://pubmed.ncbi.nlm.nih.gov/9677277

DM2DYAV	DI	DM2DYAV
DM2DYAV	DN	Cacospongionolide E
DM2DYAV	MI	TTO8QRU
DM2DYAV	MN	Group IIA phospholipase A2 (GIIA sPLA2)
DM2DYAV	MT	DTT
DM2DYAV	MA	Inhibitor
DM2DYAV	RN	A new cacospongionolide inhibitor of human secretory phospholipase A2 from the Tyrrhenian sponge Fasciospongia cavernosa and absolute configuration... J Nat Prod. 1998 Jul;61(7):931-5.
DM2DYAV	RU	https://pubmed.ncbi.nlm.nih.gov/9677277

DM2DYAV	DI	DM2DYAV
DM2DYAV	DN	Cacospongionolide E
DM2DYAV	MI	TT9V5JH
DM2DYAV	MN	Phospholipase A2 (PLA2G1B)
DM2DYAV	MT	DTT
DM2DYAV	MA	Inhibitor
DM2DYAV	RN	A new cacospongionolide inhibitor of human secretory phospholipase A2 from the Tyrrhenian sponge Fasciospongia cavernosa and absolute configuration... J Nat Prod. 1998 Jul;61(7):931-5.
DM2DYAV	RU	https://pubmed.ncbi.nlm.nih.gov/9677277

DMLKZQH	DI	DMLKZQH
DMLKZQH	DN	cADPR
DMLKZQH	MI	TTEBMN7
DMLKZQH	MN	Long transient receptor potential channel 2 (TRPM2)
DMLKZQH	MT	DTT
DMLKZQH	MA	Activator
DMLKZQH	RN	Nicotinic acid adenine dinucleotide phosphate and cyclic ADP-ribose regulate TRPM2 channels in T lymphocytes. FASEB J. 2006 May;20(7):962-4.
DMLKZQH	RU	https://pubmed.ncbi.nlm.nih.gov/16585058

DMRJKIV	DI	DMRJKIV
DMRJKIV	DN	Caffeic acid phenethyl ester
DMRJKIV	MI	DEEZYQV
DMRJKIV	MN	Amylosucrase (AMS)
DMRJKIV	MT	DME
DMRJKIV	MA	Metabolism
DMRJKIV	RN	The complete genome and proteome of Laribacter hongkongensis reveal potential mechanisms for adaptations to different temperatures and habitats. PLoS Genet. 2009 Mar;5(3):e1000416.
DMRJKIV	RU	https://pubmed.ncbi.nlm.nih.gov/19283063

DMRJKIV	DI	DMRJKIV
DMRJKIV	DN	Caffeic acid phenethyl ester
DMRJKIV	MI	DEEPQJ8
DMRJKIV	MN	Dextransucrase 1 (dsrF1)
DMRJKIV	MT	DME
DMRJKIV	MA	Metabolism
DMRJKIV	RN	Transglycosylation improved caffeic acid phenethyl ester anti-inflammatory activity and water solubility by Leuconostoc mesenteroides dextransucrase. J Agric Food Chem. 2019 Apr 24;67(16):4505-4512.
DMRJKIV	RU	https://pubmed.ncbi.nlm.nih.gov/30915841

DMRJKIV	DI	DMRJKIV
DMRJKIV	DN	Caffeic acid phenethyl ester
DMRJKIV	MI	DE174E0
DMRJKIV	MN	Dextransucrase 2 (dsrF2)
DMRJKIV	MT	DME
DMRJKIV	MA	Metabolism
DMRJKIV	RN	Transglycosylation improved caffeic acid phenethyl ester anti-inflammatory activity and water solubility by Leuconostoc mesenteroides dextransucrase. J Agric Food Chem. 2019 Apr 24;67(16):4505-4512.
DMRJKIV	RU	https://pubmed.ncbi.nlm.nih.gov/30915841

DMRJKIV	DI	DMRJKIV
DMRJKIV	DN	Caffeic acid phenethyl ester
DMRJKIV	MI	DED68N5
DMRJKIV	MN	Dextransucrase 3 (dsrF3)
DMRJKIV	MT	DME
DMRJKIV	MA	Metabolism
DMRJKIV	RN	Transglycosylation improved caffeic acid phenethyl ester anti-inflammatory activity and water solubility by Leuconostoc mesenteroides dextransucrase. J Agric Food Chem. 2019 Apr 24;67(16):4505-4512.
DMRJKIV	RU	https://pubmed.ncbi.nlm.nih.gov/30915841

DMRJKIV	DI	DMRJKIV
DMRJKIV	DN	Caffeic acid phenethyl ester
DMRJKIV	MI	DE1KTC4
DMRJKIV	MN	Dextransucrase 4 (dsrF4)
DMRJKIV	MT	DME
DMRJKIV	MA	Metabolism
DMRJKIV	RN	Transglycosylation improved caffeic acid phenethyl ester anti-inflammatory activity and water solubility by Leuconostoc mesenteroides dextransucrase. J Agric Food Chem. 2019 Apr 24;67(16):4505-4512.
DMRJKIV	RU	https://pubmed.ncbi.nlm.nih.gov/30915841

DMRJKIV	DI	DMRJKIV
DMRJKIV	DN	Caffeic acid phenethyl ester
DMRJKIV	MI	TTSXVID
DMRJKIV	MN	Nuclear factor NF-kappa-B (NFKB)
DMRJKIV	MT	DTT
DMRJKIV	MA	Inhibitor
DMRJKIV	RN	Beneficial effects of caffeic acid phenethyl ester in a rat model of vascular injury. Br J Pharmacol. 2002 Jun;136(3):353-60.
DMRJKIV	RU	https://pubmed.ncbi.nlm.nih.gov/12023937

DM6NPUM	DI	DM6NPUM
DM6NPUM	DN	CALCEOLARIOSIDE A
DM6NPUM	MI	TTFJ8Q1
DM6NPUM	MN	Protein kinase C alpha (PRKCA)
DM6NPUM	MT	DTT
DM6NPUM	MA	Inhibitor
DM6NPUM	RN	Phenylethanoid glycosides from Digitalis purpurea and Penstemon linarioides with PKCalpha-inhibitory activity. J Nat Prod. 1998 Nov;61(11):1410-2.
DM6NPUM	RU	https://pubmed.ncbi.nlm.nih.gov/9834166

DMEAUK5	DI	DMEAUK5
DMEAUK5	DN	CALCEOLARIOSIDE B
DMEAUK5	MI	TTFJ8Q1
DMEAUK5	MN	Protein kinase C alpha (PRKCA)
DMEAUK5	MT	DTT
DMEAUK5	MA	Inhibitor
DMEAUK5	RN	Phenylethanoid glycosides from Digitalis purpurea and Penstemon linarioides with PKCalpha-inhibitory activity. J Nat Prod. 1998 Nov;61(11):1410-2.
DMEAUK5	RU	https://pubmed.ncbi.nlm.nih.gov/9834166

DML562D	DI	DML562D
DML562D	DN	Calcineurin
DML562D	MI	TTHT87J
DML562D	MN	TWIK-related spinal cord potassium channel (TRESK)
DML562D	MT	DTT
DML562D	MA	Activator
DML562D	RN	TRESK channel as a potential target to treat T-cell mediated immune dysfunction. Biochem Biophys Res Commun. 2009 Dec 25;390(4):1102-5.
DML562D	RU	https://pubmed.ncbi.nlm.nih.gov/19852929

DMZ45M6	DI	DMZ45M6
DMZ45M6	DN	calcitriol-26,23-lactone
DMZ45M6	MI	TTK59TV
DMZ45M6	MN	Vitamin D3 receptor (VDR)
DMZ45M6	MT	DTT
DMZ45M6	MA	Agonist
DMZ45M6	RN	Biological activity of 24,24-difluoro-1 alpha, 25-dihydroxyvitamin D3 and 1 alpha, 25-dihydroxyvitamin D3-26,23-lactone in inducing differentiation of human myeloid leukemia cells. Arch Biochem Biophys. 1983 Jan;220(1):90-4.
DMZ45M6	RU	https://pubmed.ncbi.nlm.nih.gov/6572492

DMJXZD5	DI	DMJXZD5
DMJXZD5	DN	calhex 231
DMJXZD5	MI	TTBUYHA
DMJXZD5	MN	Extracellular calcium-sensing receptor (CASR)
DMJXZD5	MT	DTT
DMJXZD5	MA	Modulator (allosteric modulator)
DMJXZD5	RN	Modeling and mutagenesis of the binding site of Calhex 231, a novel negative allosteric modulator of the extracellular Ca(2+)-sensing receptor. J Biol Chem. 2003 Dec 5;278(49):49487-94.
DMJXZD5	RU	https://pubmed.ncbi.nlm.nih.gov/14506236

DMY9P6E	DI	DMY9P6E
DMY9P6E	DN	calindol
DMY9P6E	MI	TTBUYHA
DMY9P6E	MN	Extracellular calcium-sensing receptor (CASR)
DMY9P6E	MT	DTT
DMY9P6E	MA	Modulator (allosteric modulator)
DMY9P6E	RN	N2-benzyl-N1-(1-(1-naphthyl)ethyl)-3-phenylpropane-1,2-diamines and conformationally restrained indole analogues: development of calindol as a new calcimimetic acting at the calcium sensing receptor.Bioorg Med Chem Lett. 2004 Jun 21;14(12):3345-9.
DMY9P6E	RU	https://pubmed.ncbi.nlm.nih.gov/15149704

DMY9P6E	DI	DMY9P6E
DMY9P6E	DN	calindol
DMY9P6E	MI	TTI1PRE
DMY9P6E	MN	G-protein coupled receptor GPCR33 (GPRC6A)
DMY9P6E	MT	DTT
DMY9P6E	MA	Modulator (allosteric modulator)
DMY9P6E	RN	Molecular determinants of non-competitive antagonist binding to the mouse GPRC6A receptor. Cell Calcium. 2009 Nov-Dec;46(5-6):323-32.
DMY9P6E	RU	https://pubmed.ncbi.nlm.nih.gov/19836834

DM5ZTJL	DI	DM5ZTJL
DM5ZTJL	DN	Calmidazolium
DM5ZTJL	MI	TTV3NH6
DM5ZTJL	MN	Calmodulin (CALM)
DM5ZTJL	MT	DTT
DM5ZTJL	MA	Inhibitor
DM5ZTJL	RN	Calmidazolium evokes high calcium fluctuations in Plasmodium falciparum. Cell Signal. 2016 Mar;28(3):125-135.
DM5ZTJL	RU	https://pubmed.ncbi.nlm.nih.gov/26689736

DMVXKLF	DI	DMVXKLF
DMVXKLF	DN	CALOPOCARPIN
DMVXKLF	MI	TT50QJ3
DMVXKLF	MN	Influenza Neuraminidase (Influ NA)
DMVXKLF	MT	DTT
DMVXKLF	MA	Inhibitor
DMVXKLF	RN	Prenylated pterocarpans as bacterial neuraminidase inhibitors. Bioorg Med Chem. 2010 May 1;18(9):3335-44.
DMVXKLF	RU	https://pubmed.ncbi.nlm.nih.gov/20363636

DMR0CNQ	DI	DMR0CNQ
DMR0CNQ	DN	Calpastatin
DMR0CNQ	MI	TTG5QB7
DMR0CNQ	MN	Calpain-2 (CAPN2)
DMR0CNQ	MT	DTT
DMR0CNQ	MA	Inhibitor
DMR0CNQ	RN	Calpain in the pathophysiology of spinal cord injury: neuroprotection with calpain inhibitors. Brain Res Brain Res Rev. 2003 May;42(2):169-85.
DMR0CNQ	RU	https://pubmed.ncbi.nlm.nih.gov/12738057

DMBK2S8	DI	DMBK2S8
DMBK2S8	DN	Calusterone
DMBK2S8	MI	TTS64P2
DMBK2S8	MN	Androgen receptor (AR)
DMBK2S8	MT	DTT
DMBK2S8	MA	Inhibitor
DMBK2S8	RN	MR appearance of intra-abdominal metastatic melanoma. Magn Reson Imaging. 1992;10(4):705-8.
DMBK2S8	RU	https://pubmed.ncbi.nlm.nih.gov/1501542

DMY29Q8	DI	DMY29Q8
DMY29Q8	DN	Calyculin-A
DMY29Q8	MI	TTS087L
DMY29Q8	MN	Solute carrier family 12 member 1 (SLC12A1)
DMY29Q8	MT	DTT
DMY29Q8	MA	Blocker
DMY29Q8	RN	Involvement of K(+)-Cl(-)-cotransport in the apoptosis induced by N-ethylmaleimide in HepG2 human hepatoblastoma cells. Eur J Pharmacol. 2001 Apr 20;418(1-2):1-5.
DMY29Q8	RU	https://pubmed.ncbi.nlm.nih.gov/11334858

DMMBA70	DI	DMMBA70
DMMBA70	DN	CALYSTEGINE B2
DMMBA70	MI	TTIS03D
DMMBA70	MN	Alpha-galactosidase A (GLA)
DMMBA70	MT	DTT
DMMBA70	MA	Inhibitor
DMMBA70	RN	Identification of the glycosidase inhibitors swainsonine and calystegine B2 in Weir vine (Ipomoea sp. Q6 [aff. calobra]) and correlation with toxicity. J Nat Prod. 1995 Jun;58(6):878-86.
DMMBA70	RU	https://pubmed.ncbi.nlm.nih.gov/7673932

DM4FVDS	DI	DM4FVDS
DM4FVDS	DN	CAM-2036
DM4FVDS	MI	TTVIMDE
DM4FVDS	MN	Glucagon-like peptide 1 receptor (GLP1R)
DM4FVDS	MT	DTT
DM4FVDS	MA	Agonist
DM4FVDS	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249).
DM4FVDS	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=249

DMVAP4T	DI	DMVAP4T
DMVAP4T	DN	Camrelizumab
DMVAP4T	MI	TTVLU5N
DMVAP4T	MN	HUMAN programmed cell death protein 1 (PD-1)
DMVAP4T	MT	DTT
DMVAP4T	MA	Inhibitor
DMVAP4T	RN	ClinicalTrials.gov (NCT04268537) Immunoregulatory Therapy for 2019-nCoV. U.S. National Institutes of Health.
DMVAP4T	RU	https://clinicaltrials.gov/ct2/show/NCT04268537

DMNLTGF	DI	DMNLTGF
DMNLTGF	DN	Canaline
DMNLTGF	MI	TTTSCQ2
DMNLTGF	MN	Ornithine delta-aminotransferase (OAT)
DMNLTGF	MT	DTT
DMNLTGF	MA	Inhibitor
DMNLTGF	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMNLTGF	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMM6A7P	DI	DMM6A7P
DMM6A7P	DN	cannabinol
DMM6A7P	MI	TT6OEDT
DMM6A7P	MN	Cannabinoid receptor 1 (CB1)
DMM6A7P	MT	DTT
DMM6A7P	MA	Agonist
DMM6A7P	RN	Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther. 1996 Sep;278(3):989-99.
DMM6A7P	RU	https://pubmed.ncbi.nlm.nih.gov/8819477

DMM6A7P	DI	DMM6A7P
DMM6A7P	DN	cannabinol
DMM6A7P	MI	TTBECWA
DMM6A7P	MN	Transient receptor potential cation channel V2 (TRPV2)
DMM6A7P	MT	DTT
DMM6A7P	MA	Activator
DMM6A7P	RN	TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. J Neurosci. 2008 Jun 11;28(24):6231-8.
DMM6A7P	RU	https://pubmed.ncbi.nlm.nih.gov/18550765

DME32XU	DI	DME32XU
DME32XU	DN	CANTHARIDIC_ACID
DME32XU	MI	TTFLH0E
DME32XU	MN	Serine/threonine PP1-alpha (PPP1CA)
DME32XU	MT	DTT
DME32XU	MA	Inhibitor
DME32XU	RN	Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies. J Med Chem. 2002 Mar 14;45(6):1151-75.
DME32XU	RU	https://pubmed.ncbi.nlm.nih.gov/11881984

DM9IG2P	DI	DM9IG2P
DM9IG2P	DN	Cantide + Cisplatin
DM9IG2P	MI	TTQY2EJ
DM9IG2P	MN	TERT messenger RNA (TERT mRNA)
DM9IG2P	MT	DTT
DM9IG2P	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DM9IG2P	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DMDZE8N	DI	DMDZE8N
DMDZE8N	DN	CAPROCTAMINE
DMDZE8N	MI	TT1RS9F
DMDZE8N	MN	Acetylcholinesterase (AChE)
DMDZE8N	MT	DTT
DMDZE8N	MA	Inhibitor
DMDZE8N	RN	Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 4. Further investigation on the inne... J Med Chem. 2008 Nov 27;51(22):7308-12.
DMDZE8N	RU	https://pubmed.ncbi.nlm.nih.gov/18954037

DMDZE8N	DI	DMDZE8N
DMDZE8N	DN	CAPROCTAMINE
DMDZE8N	MI	TTEB0GD
DMDZE8N	MN	Cholinesterase (BCHE)
DMDZE8N	MT	DTT
DMDZE8N	MA	Inhibitor
DMDZE8N	RN	Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 4. Further investigation on the inne... J Med Chem. 2008 Nov 27;51(22):7308-12.
DMDZE8N	RU	https://pubmed.ncbi.nlm.nih.gov/18954037

DMLGS82	DI	DMLGS82
DMLGS82	DN	Caprylic acid
DMLGS82	MI	TTPH97Y
DMLGS82	MN	Mycobacterium 3-oxoacyl-[acyl-carrier-protein] synthase 1 (MycB kasA)
DMLGS82	MT	DTT
DMLGS82	MA	Inhibitor
DMLGS82	RN	Characterization of ochratoxin A transport by human organic anion transporters. Life Sci. 2001 Sep 21;69(18):2123-35.
DMLGS82	RU	https://pubmed.ncbi.nlm.nih.gov/11669456

DM4ATCI	DI	DM4ATCI
DM4ATCI	DN	CAPSAZEPINE
DM4ATCI	MI	TTMI6F5
DM4ATCI	MN	Transient receptor potential cation channel V1 (TRPV1)
DM4ATCI	MT	DTT
DM4ATCI	MA	Inhibitor
DM4ATCI	RN	The potential of transient receptor potential vanilloid type 1 channel modulators for the treatment of pain. J Med Chem. 2007 May 31;50(11):2589-96.
DM4ATCI	RU	https://pubmed.ncbi.nlm.nih.gov/17489570

DM4ATCI	DI	DM4ATCI
DM4ATCI	DN	CAPSAZEPINE
DM4ATCI	MI	TTKP2SU
DM4ATCI	MN	Transient receptor potential cation channel V4 (TRPV4)
DM4ATCI	MT	DTT
DM4ATCI	MA	Inhibitor
DM4ATCI	RN	Chain-branched acyclic phenethylthiocarbamates as vanilloid receptor antagonists. Bioorg Med Chem Lett. 2003 May 5;13(9):1549-52.
DM4ATCI	RU	https://pubmed.ncbi.nlm.nih.gov/12699752

DMJFPA9	DI	DMJFPA9
DMJFPA9	DN	CARAMIPEN
DMJFPA9	MI	TTZ9SOR
DMJFPA9	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMJFPA9	MT	DTT
DMJFPA9	MA	Inhibitor
DMJFPA9	RN	Muscarinic receptor binding profile of para-substituted caramiphen analogues. J Med Chem. 1991 Oct;34(10):2984-9.
DMJFPA9	RU	https://pubmed.ncbi.nlm.nih.gov/1920350

DMJFPA9	DI	DMJFPA9
DMJFPA9	DN	CARAMIPEN
DMJFPA9	MI	TTYEG6Q
DMJFPA9	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMJFPA9	MT	DTT
DMJFPA9	MA	Inhibitor
DMJFPA9	RN	Muscarinic receptor binding profile of para-substituted caramiphen analogues. J Med Chem. 1991 Oct;34(10):2984-9.
DMJFPA9	RU	https://pubmed.ncbi.nlm.nih.gov/1920350

DMEKI1J	DI	DMEKI1J
DMEKI1J	DN	Carazolol
DMEKI1J	MI	TTR6W5O
DMEKI1J	MN	Adrenergic receptor beta-1 (ADRB1)
DMEKI1J	MT	DTT
DMEKI1J	MA	Agonist
DMEKI1J	RN	Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404.
DMEKI1J	RU	https://pubmed.ncbi.nlm.nih.gov/9551698

DMEKI1J	DI	DMEKI1J
DMEKI1J	DN	Carazolol
DMEKI1J	MI	TTMXGCW
DMEKI1J	MN	Adrenergic receptor beta-3 (ADRB3)
DMEKI1J	MT	DTT
DMEKI1J	MA	Agonist
DMEKI1J	RN	Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404.
DMEKI1J	RU	https://pubmed.ncbi.nlm.nih.gov/9551698

DMMBQYE	DI	DMMBQYE
DMMBQYE	DN	carbacyclin
DMMBQYE	MI	TTOFYT1
DMMBQYE	MN	Prostacyclin receptor (PTGIR)
DMMBQYE	MT	DTT
DMMBQYE	MA	Agonist
DMMBQYE	RN	The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
DMMBQYE	RU	https://pubmed.ncbi.nlm.nih.gov/10634944

DMMBQYE	DI	DMMBQYE
DMMBQYE	DN	carbacyclin
DMMBQYE	MI	TTNVEIR
DMMBQYE	MN	Prostaglandin D2 receptor (PTGDR)
DMMBQYE	MT	DTT
DMMBQYE	MA	Agonist
DMMBQYE	RN	The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
DMMBQYE	RU	https://pubmed.ncbi.nlm.nih.gov/10634944

DMMBQYE	DI	DMMBQYE
DMMBQYE	DN	carbacyclin
DMMBQYE	MI	TTG1QMU
DMMBQYE	MN	Prostaglandin E2 receptor EP1 (PTGER1)
DMMBQYE	MT	DTT
DMMBQYE	MA	Agonist
DMMBQYE	RN	The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
DMMBQYE	RU	https://pubmed.ncbi.nlm.nih.gov/10634944

DMMBQYE	DI	DMMBQYE
DMMBQYE	DN	carbacyclin
DMMBQYE	MI	TT1ZAVI
DMMBQYE	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DMMBQYE	MT	DTT
DMMBQYE	MA	Agonist
DMMBQYE	RN	The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
DMMBQYE	RU	https://pubmed.ncbi.nlm.nih.gov/10634944

DMMBQYE	DI	DMMBQYE
DMMBQYE	DN	carbacyclin
DMMBQYE	MI	TTPNGDE
DMMBQYE	MN	Prostaglandin E2 receptor EP3 (PTGER3)
DMMBQYE	MT	DTT
DMMBQYE	MA	Agonist
DMMBQYE	RN	Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
DMMBQYE	RU	https://pubmed.ncbi.nlm.nih.gov/9313928

DMMBQYE	DI	DMMBQYE
DMMBQYE	DN	carbacyclin
DMMBQYE	MI	TT79WV3
DMMBQYE	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DMMBQYE	MT	DTT
DMMBQYE	MA	Agonist
DMMBQYE	RN	Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
DMMBQYE	RU	https://pubmed.ncbi.nlm.nih.gov/9313928

DMMBQYE	DI	DMMBQYE
DMMBQYE	DN	carbacyclin
DMMBQYE	MI	TTT2ZAR
DMMBQYE	MN	Prostaglandin F2-alpha receptor (PTGFR)
DMMBQYE	MT	DTT
DMMBQYE	MA	Agonist
DMMBQYE	RN	The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
DMMBQYE	RU	https://pubmed.ncbi.nlm.nih.gov/10634944

DMMBQYE	DI	DMMBQYE
DMMBQYE	DN	carbacyclin
DMMBQYE	MI	TT2O84V
DMMBQYE	MN	Thromboxane A2 receptor (TBXA2R)
DMMBQYE	MT	DTT
DMMBQYE	MA	Agonist
DMMBQYE	RN	The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
DMMBQYE	RU	https://pubmed.ncbi.nlm.nih.gov/10634944

DMJQ3LN	DI	DMJQ3LN
DMJQ3LN	DN	Carbamic Acid
DMJQ3LN	MI	TTHI19T
DMJQ3LN	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMJQ3LN	MT	DTT
DMJQ3LN	MA	Inhibitor
DMJQ3LN	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMJQ3LN	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMZYK1W	DI	DMZYK1W
DMZYK1W	DN	Carbamoyl phosphate disodium
DMZYK1W	MI	TTHQPL7
DMZYK1W	MN	Carbonic anhydrase I (CA-I)
DMZYK1W	MT	DTT
DMZYK1W	MA	Inhibitor
DMZYK1W	RN	Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with phosphates, carbamoyl phosphate, and the phosphonate antiviral dru... Bioorg Med Chem Lett. 2004 Dec 6;14(23):5763-7.
DMZYK1W	RU	https://pubmed.ncbi.nlm.nih.gov/15501037

DMZYK1W	DI	DMZYK1W
DMZYK1W	DN	Carbamoyl phosphate disodium
DMZYK1W	MI	TTZHA0O
DMZYK1W	MN	Carbonic anhydrase IV (CA-IV)
DMZYK1W	MT	DTT
DMZYK1W	MA	Inhibitor
DMZYK1W	RN	Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with phosphates, carbamoyl phosphate, and the phosphonate antiviral dru... Bioorg Med Chem Lett. 2004 Dec 6;14(23):5763-7.
DMZYK1W	RU	https://pubmed.ncbi.nlm.nih.gov/15501037

DMGP4M3	DI	DMGP4M3
DMGP4M3	DN	Carba-Nicotinamide-Adenine-Dinucleotide
DMGP4M3	MI	TTVDSZ0
DMGP4M3	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMGP4M3	MT	DTT
DMGP4M3	MA	Inhibitor
DMGP4M3	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMGP4M3	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMGFLI7	DI	DMGFLI7
DMGFLI7	DN	Carbaphosphonate
DMGFLI7	MI	TTPS7KA
DMGFLI7	MN	Bacterial Dehydroquinate synthase (Bact aroB)
DMGFLI7	MT	DTT
DMGFLI7	MA	Inhibitor
DMGFLI7	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMGFLI7	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMO648T	DI	DMO648T
DMO648T	DN	Carbenoxolone
DMO648T	MI	TTN7BL9
DMO648T	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMO648T	MT	DTT
DMO648T	MA	Inhibitor
DMO648T	RN	Selective inhibition of 11beta-hydroxysteroid dehydrogenase 1 by 18alpha-glycyrrhetinic acid but not 18beta-glycyrrhetinic acid. J Steroid Biochem Mol Biol. 2009 Feb;113(3-5):248-52.
DMO648T	RU	https://pubmed.ncbi.nlm.nih.gov/19429429

DM87SOX	DI	DM87SOX
DM87SOX	DN	Carbocyclic Peptidomimetic
DM87SOX	MI	TT8JRS7
DM87SOX	MN	Beta-secretase (BACE)
DM87SOX	MT	DTT
DM87SOX	MA	Inhibitor
DM87SOX	RN	Structure-based design, synthesis, and memapsin 2 (BACE) inhibitory activity of carbocyclic and heterocyclic peptidomimetics. J Med Chem. 2005 Aug 11;48(16):5175-90.
DM87SOX	RU	https://pubmed.ncbi.nlm.nih.gov/16078837

DM87SOX	DI	DM87SOX
DM87SOX	DN	Carbocyclic Peptidomimetic
DM87SOX	MI	TTPT2QI
DM87SOX	MN	Cathepsin D (CTSD)
DM87SOX	MT	DTT
DM87SOX	MA	Inhibitor
DM87SOX	RN	Structure-based design, synthesis, and memapsin 2 (BACE) inhibitory activity of carbocyclic and heterocyclic peptidomimetics. J Med Chem. 2005 Aug 11;48(16):5175-90.
DM87SOX	RU	https://pubmed.ncbi.nlm.nih.gov/16078837

DMGKSVF	DI	DMGKSVF
DMGKSVF	DN	carbocyclic thromboxane A2
DMGKSVF	MI	TT2O84V
DMGKSVF	MN	Thromboxane A2 receptor (TBXA2R)
DMGKSVF	MT	DTT
DMGKSVF	MA	Agonist
DMGKSVF	RN	Effects of KW-3635, a novel dibenzoxepin derivative of a selective thromboxane A2 antagonist, on human, guinea pig and rat platelets. Jpn J Pharmacol. 1992 Jul;59(3):357-64.
DMGKSVF	RU	https://pubmed.ncbi.nlm.nih.gov/1434130

DMA3FZR	DI	DMA3FZR
DMA3FZR	DN	Carbodine
DMA3FZR	MI	TTN12BZ
DMA3FZR	MN	CTP synthase (CTPS1)
DMA3FZR	MT	DTT
DMA3FZR	MA	Inhibitor
DMA3FZR	RN	Potent activity of 5-fluoro-2'-deoxyuridine and related compounds against thymidine kinase-deficient (TK-) herpes simplex virus: targeted at thymidylate synthase. Mol Pharmacol. 1987 Aug;32(1):286-92.
DMA3FZR	RU	https://pubmed.ncbi.nlm.nih.gov/3039343

DMCNV68	DI	DMCNV68
DMCNV68	DN	Carboron Cluster with phenol
DMCNV68	MI	TTZAYWL
DMCNV68	MN	Estrogen receptor (ESR)
DMCNV68	MT	DTT
DMCNV68	MA	Inhibitor
DMCNV68	RN	Utility of boron clusters for drug design. Relation between estrogen receptor binding affinity and hydrophobicity of phenols bearing various types ... Bioorg Med Chem Lett. 2003 Nov 17;13(22):4089-92.
DMCNV68	RU	https://pubmed.ncbi.nlm.nih.gov/14592514

DMEORTQ	DI	DMEORTQ
DMEORTQ	DN	Carboxyatractyloside
DMEORTQ	MI	TTU5A6Q
DMEORTQ	MN	Adenine nucleotide translocator 1 (SLC25A4)
DMEORTQ	MT	DTT
DMEORTQ	MA	Inhibitor
DMEORTQ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMEORTQ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMTAYMR	DI	DMTAYMR
DMTAYMR	DN	Carboxydichlorofluorescein
DMTAYMR	MI	DTYVM24
DMTAYMR	MN	Multidrug resistance-associated protein 5 (ABCC5)
DMTAYMR	MT	DTP
DMTAYMR	MA	Substrate
DMTAYMR	RN	Kinetic validation of the use of carboxydichlorofluorescein as a drug surrogate for MRP5-mediated transport. Eur J Pharm Sci. 2006 Apr;27(5):524-32.
DMTAYMR	RU	http://www.ncbi.nlm.nih.gov/pubmed/16337112

DMI7Q61	DI	DMI7Q61
DMI7Q61	DN	CARBOXYFENTANYL
DMI7Q61	MI	TT27RFC
DMI7Q61	MN	Opioid receptor delta (OPRD1)
DMI7Q61	MT	DTT
DMI7Q61	MA	Inhibitor
DMI7Q61	RN	Development of novel enkephalin analogues that have enhanced opioid activities at both mu and delta opioid receptors. J Med Chem. 2007 Nov 1;50(22):5528-32.
DMI7Q61	RU	https://pubmed.ncbi.nlm.nih.gov/17927164

DMI7Q61	DI	DMI7Q61
DMI7Q61	DN	CARBOXYFENTANYL
DMI7Q61	MI	TTKWM86
DMI7Q61	MN	Opioid receptor mu (MOP)
DMI7Q61	MT	DTT
DMI7Q61	MA	Inhibitor
DMI7Q61	RN	Development of novel enkephalin analogues that have enhanced opioid activities at both mu and delta opioid receptors. J Med Chem. 2007 Nov 1;50(22):5528-32.
DMI7Q61	RU	https://pubmed.ncbi.nlm.nih.gov/17927164

DM105YR	DI	DM105YR
DM105YR	DN	Carboxylated glucosamine
DM105YR	MI	TT6X50U
DM105YR	MN	Matrix metalloproteinase-9 (MMP-9)
DM105YR	MT	DTT
DM105YR	MA	Inhibitor
DM105YR	RN	Carboxy derivatized glucosamine is a potent inhibitor of matrix metalloproteinase-9 in HT1080 cells. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3105-10.
DM105YR	RU	https://pubmed.ncbi.nlm.nih.gov/16616490

DMCTUR1	DI	DMCTUR1
DMCTUR1	DN	Carboxylic PRPP
DMCTUR1	MI	TTBL49X
DMCTUR1	MN	Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ)
DMCTUR1	MT	DTT
DMCTUR1	MA	Inhibitor
DMCTUR1	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMCTUR1	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMQUKBG	DI	DMQUKBG
DMQUKBG	DN	CARCININE
DMQUKBG	MI	TT9JNIC
DMQUKBG	MN	Histamine H3 receptor (H3R)
DMQUKBG	MT	DTT
DMQUKBG	MA	Inhibitor
DMQUKBG	RN	The alkaloid conessine and analogues as potent histamine H3 receptor antagonists. J Med Chem. 2008 Sep 11;51(17):5423-30.
DMQUKBG	RU	https://pubmed.ncbi.nlm.nih.gov/18683917

DMCSMX4	DI	DMCSMX4
DMCSMX4	DN	Cardiolipin
DMCSMX4	MI	TTU5A6Q
DMCSMX4	MN	Adenine nucleotide translocator 1 (SLC25A4)
DMCSMX4	MT	DTT
DMCSMX4	MA	Inhibitor
DMCSMX4	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMCSMX4	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMUSGYQ	DI	DMUSGYQ
DMUSGYQ	DN	Carinatumins B (2)
DMUSGYQ	MI	TT1RS9F
DMUSGYQ	MN	Acetylcholinesterase (AChE)
DMUSGYQ	MT	DTT
DMUSGYQ	MA	Inhibitor
DMUSGYQ	RN	Carinatumins A-C, new alkaloids from Lycopodium carinatum inhibiting acetylcholinesterase. Bioorg Med Chem. 2007 Feb 15;15(4):1703-7.
DMUSGYQ	RU	https://pubmed.ncbi.nlm.nih.gov/17188496

DMFYCB4	DI	DMFYCB4
DMFYCB4	DN	Carnosine
DMFYCB4	MI	DECY3P8
DMFYCB4	MN	Carnosine N-methyltransferase (CARNMT1)
DMFYCB4	MT	DME
DMFYCB4	MA	Metabolism
DMFYCB4	RN	UPF0586 protein C9orf41 homolog is anserine-producing methyltransferase. J Biol Chem. 2015 Jul 10;290(28):17190-205.
DMFYCB4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26001783

DMFYCB4	DI	DMFYCB4
DMFYCB4	DN	Carnosine
DMFYCB4	MI	DT9G7XN
DMFYCB4	MN	Peptide transporter 1 (SLC15A1)
DMFYCB4	MT	DTP
DMFYCB4	MA	Substrate
DMFYCB4	RN	Transforming dietary peptides in promising lead compounds: the case of bioavailable carnosine analogs. Amino Acids. 2012 Jul;43(1):111-26.
DMFYCB4	RU	https://doi.org/10.1007/s00726-012-1224-z

DMBKQ03	DI	DMBKQ03
DMBKQ03	DN	Carpropamid
DMBKQ03	MI	TT64EPS
DMBKQ03	MN	Fungal Scytalone dehydratase (Fung SDH1)
DMBKQ03	MT	DTT
DMBKQ03	MA	Inhibitor
DMBKQ03	RN	Enzymatic characterization of scytalone dehydratase Val75Met variant found in melanin biosynthesis dehydratase inhibitor (MBI-D) resistant strains of the rice blast fungus. Biosci Biotechnol Biochem.2004 Mar;68(3):615-21.
DMBKQ03	RU	https://pubmed.ncbi.nlm.nih.gov/15056895

DMSKT8G	DI	DMSKT8G
DMSKT8G	DN	Cartazolate
DMSKT8G	MI	TTJ0IQB
DMSKT8G	MN	Phosphodiesterase 5A (PDE5A)
DMSKT8G	MT	DTT
DMSKT8G	MA	Inhibitor
DMSKT8G	RN	Substituted pyrazolopyridines as potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction. J Med Chem. 2001 Mar 29;44(7):1025-7.
DMSKT8G	RU	https://pubmed.ncbi.nlm.nih.gov/11297448

DMINM2D	DI	DMINM2D
DMINM2D	DN	carvacrol
DMINM2D	MI	TTFPVZO
DMINM2D	MN	Long transient receptor potential channel 7 (TRPM7)
DMINM2D	MT	DTT
DMINM2D	MA	Blocker (channel blocker)
DMINM2D	RN	Carvacrol is a novel inhibitor of Drosophila TRPL and mammalian TRPM7 channels. Cell Calcium. 2009 Mar;45(3):300-9.
DMINM2D	RU	https://pubmed.ncbi.nlm.nih.gov/19135721

DMINM2D	DI	DMINM2D
DMINM2D	DN	carvacrol
DMINM2D	MI	TT946IA
DMINM2D	MN	Transient receptor potential cation channel V3 (TRPV3)
DMINM2D	MT	DTT
DMINM2D	MA	Activator
DMINM2D	RN	Oregano, thyme and clove-derived flavors and skin sensitizers activate specific TRP channels. Nat Neurosci. 2006 May;9(5):628-35.
DMINM2D	RU	https://pubmed.ncbi.nlm.nih.gov/16617338

DMXTCE7	DI	DMXTCE7
DMXTCE7	DN	Carvedilol
DMXTCE7	MI	TTDBOI7
DMXTCE7	MN	HUAMN alpha-1 adrenergic receptor (ADRA1)
DMXTCE7	MT	DTT
DMXTCE7	MA	Inhibitor
DMXTCE7	RN	Carvedilol increases the production of interleukin-12 and interferon-gamma and improves the survival of mice infected with the encephalomyocarditis virus. J Am Coll Cardiol. 2003 Jan 15;41(2):340-5.
DMXTCE7	RU	https://pubmed.ncbi.nlm.nih.gov/12535832

DMXTCE7	DI	DMXTCE7
DMXTCE7	DN	Carvedilol
DMXTCE7	MI	TTJB8UY
DMXTCE7	MN	HUMAN beta adrenergic receptor (BAR)
DMXTCE7	MT	DTT
DMXTCE7	MA	Antagonist
DMXTCE7	RN	Can beta-adrenergic blockers be used in the treatment of COVID-19 Med Hypotheses. 2020 May 5;142:109809.
DMXTCE7	RU	https://pubmed.ncbi.nlm.nih.gov/32388480

DMGIZ5U	DI	DMGIZ5U
DMGIZ5U	DN	carveol
DMGIZ5U	MI	TT946IA
DMGIZ5U	MN	Transient receptor potential cation channel V3 (TRPV3)
DMGIZ5U	MT	DTT
DMGIZ5U	MA	Activator
DMGIZ5U	RN	Monoterpenoid agonists of TRPV3. Br J Pharmacol. 2007 Jun;151(4):530-40.
DMGIZ5U	RU	https://pubmed.ncbi.nlm.nih.gov/17420775

DMVD481	DI	DMVD481
DMVD481	DN	Carzenide
DMVD481	MI	TTUNARX
DMVD481	MN	Carbonic anhydrase (CA)
DMVD481	MT	DTT
DMVD481	MA	Inhibitor
DMVD481	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DMVD481	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DMVD481	DI	DMVD481
DMVD481	DN	Carzenide
DMVD481	MI	TTHQPL7
DMVD481	MN	Carbonic anhydrase I (CA-I)
DMVD481	MT	DTT
DMVD481	MA	Inhibitor
DMVD481	RN	Ligand-directed tosyl chemistry for protein labeling in vivo. Nat Chem Biol. 2009 May;5(5):341-3.
DMVD481	RU	https://pubmed.ncbi.nlm.nih.gov/19330012

DMVD481	DI	DMVD481
DMVD481	DN	Carzenide
DMVD481	MI	TTANPDJ
DMVD481	MN	Carbonic anhydrase II (CA-II)
DMVD481	MT	DTT
DMVD481	MA	Inhibitor
DMVD481	RN	Synthesis and structure-activity relationships of novel benzene sulfonamides with potent binding affinity for bovine carbonic anhydrase II. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5429-33.
DMVD481	RU	https://pubmed.ncbi.nlm.nih.gov/16213706

DMVD481	DI	DMVD481
DMVD481	DN	Carzenide
DMVD481	MI	TT2LVK8
DMVD481	MN	Carbonic anhydrase IX (CA-IX)
DMVD481	MT	DTT
DMVD481	MA	Inhibitor
DMVD481	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DMVD481	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DMVD481	DI	DMVD481
DMVD481	DN	Carzenide
DMVD481	MI	TTCFSPE
DMVD481	MN	Carbonic anhydrase VI (CA-VI)
DMVD481	MT	DTT
DMVD481	MA	Inhibitor
DMVD481	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DMVD481	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DMVD481	DI	DMVD481
DMVD481	DN	Carzenide
DMVD481	MI	TTSYM0R
DMVD481	MN	Carbonic anhydrase XII (CA-XII)
DMVD481	MT	DTT
DMVD481	MA	Inhibitor
DMVD481	RN	Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglauc... Bioorg Med Chem Lett. 2005 Feb 15;15(4):963-9.
DMVD481	RU	https://pubmed.ncbi.nlm.nih.gov/15686894

DMVD481	DI	DMVD481
DMVD481	DN	Carzenide
DMVD481	MI	TTEYTKG
DMVD481	MN	Carbonic anhydrase XIV (CA-XIV)
DMVD481	MT	DTT
DMVD481	MA	Inhibitor
DMVD481	RN	Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33.
DMVD481	RU	https://pubmed.ncbi.nlm.nih.gov/16039848

DMW6P4A	DI	DMW6P4A
DMW6P4A	DN	casp 4 inhib
DMW6P4A	MI	TT3VZ8D
DMW6P4A	MN	Caspase-4 (CASP4)
DMW6P4A	MT	DTT
DMW6P4A	MA	Inhibitor
DMW6P4A	RN	Potent and selective nonpeptide inhibitors of caspases 3 and 7. J Med Chem. 2001 Jun 7;44(12):2015-26.
DMW6P4A	RU	https://pubmed.ncbi.nlm.nih.gov/11384246

DM5E21C	DI	DM5E21C
DM5E21C	DN	CASUARIIN
DM5E21C	MI	TT6L509
DM5E21C	MN	Coagulation factor IIa (F2)
DM5E21C	MT	DTT
DM5E21C	MA	Inhibitor
DM5E21C	RN	Effects of tannins from Geum japonicum on the catalytic activity of thrombin and factor Xa of blood coagulation cascade. J Nat Prod. 1998 Nov;61(11):1356-60.
DM5E21C	RU	https://pubmed.ncbi.nlm.nih.gov/9834152

DM5E21C	DI	DM5E21C
DM5E21C	DN	CASUARIIN
DM5E21C	MI	TTCIHJA
DM5E21C	MN	Coagulation factor Xa (F10)
DM5E21C	MT	DTT
DM5E21C	MA	Inhibitor
DM5E21C	RN	Effects of tannins from Geum japonicum on the catalytic activity of thrombin and factor Xa of blood coagulation cascade. J Nat Prod. 1998 Nov;61(11):1356-60.
DM5E21C	RU	https://pubmed.ncbi.nlm.nih.gov/9834152

DMWHP52	DI	DMWHP52
DMWHP52	DN	CAT-2200
DMWHP52	MI	TT69OHW
DMWHP52	MN	Interleukin 17 receptor (IL17R)
DMWHP52	MT	DTT
DMWHP52	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2294).
DMWHP52	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2294

DMY38SB	DI	DMY38SB
DMY38SB	DN	CATECHIN
DMY38SB	MI	TTUNARX
DMY38SB	MN	Carbonic anhydrase (CA)
DMY38SB	MT	DTT
DMY38SB	MA	Inhibitor
DMY38SB	RN	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
DMY38SB	RU	https://pubmed.ncbi.nlm.nih.gov/20674354

DMY38SB	DI	DMY38SB
DMY38SB	DN	CATECHIN
DMY38SB	MI	TTHQPL7
DMY38SB	MN	Carbonic anhydrase I (CA-I)
DMY38SB	MT	DTT
DMY38SB	MA	Inhibitor
DMY38SB	RN	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
DMY38SB	RU	https://pubmed.ncbi.nlm.nih.gov/20674354

DMY38SB	DI	DMY38SB
DMY38SB	DN	CATECHIN
DMY38SB	MI	TTANPDJ
DMY38SB	MN	Carbonic anhydrase II (CA-II)
DMY38SB	MT	DTT
DMY38SB	MA	Inhibitor
DMY38SB	RN	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
DMY38SB	RU	https://pubmed.ncbi.nlm.nih.gov/20674354

DMY38SB	DI	DMY38SB
DMY38SB	DN	CATECHIN
DMY38SB	MI	TTZHA0O
DMY38SB	MN	Carbonic anhydrase IV (CA-IV)
DMY38SB	MT	DTT
DMY38SB	MA	Inhibitor
DMY38SB	RN	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
DMY38SB	RU	https://pubmed.ncbi.nlm.nih.gov/20674354

DMY38SB	DI	DMY38SB
DMY38SB	DN	CATECHIN
DMY38SB	MI	TT2LVK8
DMY38SB	MN	Carbonic anhydrase IX (CA-IX)
DMY38SB	MT	DTT
DMY38SB	MA	Inhibitor
DMY38SB	RN	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
DMY38SB	RU	https://pubmed.ncbi.nlm.nih.gov/20674354

DMY38SB	DI	DMY38SB
DMY38SB	DN	CATECHIN
DMY38SB	MI	TTCFSPE
DMY38SB	MN	Carbonic anhydrase VI (CA-VI)
DMY38SB	MT	DTT
DMY38SB	MA	Inhibitor
DMY38SB	RN	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
DMY38SB	RU	https://pubmed.ncbi.nlm.nih.gov/20674354

DMY38SB	DI	DMY38SB
DMY38SB	DN	CATECHIN
DMY38SB	MI	TTSYM0R
DMY38SB	MN	Carbonic anhydrase XII (CA-XII)
DMY38SB	MT	DTT
DMY38SB	MA	Inhibitor
DMY38SB	RN	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
DMY38SB	RU	https://pubmed.ncbi.nlm.nih.gov/20674354

DMY38SB	DI	DMY38SB
DMY38SB	DN	CATECHIN
DMY38SB	MI	TTEYTKG
DMY38SB	MN	Carbonic anhydrase XIV (CA-XIV)
DMY38SB	MT	DTT
DMY38SB	MA	Inhibitor
DMY38SB	RN	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
DMY38SB	RU	https://pubmed.ncbi.nlm.nih.gov/20674354

DMY38SB	DI	DMY38SB
DMY38SB	DN	CATECHIN
DMY38SB	MI	TT8NGED
DMY38SB	MN	Prostaglandin G/H synthase 1 (COX-1)
DMY38SB	MT	DTT
DMY38SB	MA	Inhibitor
DMY38SB	RN	Mechanism-based inactivation of COX-1 by red wine m-hydroquinones: a structure-activity relationship study. J Nat Prod. 2004 Nov;67(11):1777-82.
DMY38SB	RU	https://pubmed.ncbi.nlm.nih.gov/15568761

DML0YEK	DI	DML0YEK
DML0YEK	DN	Catechol
DML0YEK	MI	TTUNARX
DML0YEK	MN	Carbonic anhydrase (CA)
DML0YEK	MT	DTT
DML0YEK	MA	Inhibitor
DML0YEK	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DML0YEK	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DML0YEK	DI	DML0YEK
DML0YEK	DN	Catechol
DML0YEK	MI	TTANPDJ
DML0YEK	MN	Carbonic anhydrase II (CA-II)
DML0YEK	MT	DTT
DML0YEK	MA	Inhibitor
DML0YEK	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DML0YEK	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DML0YEK	DI	DML0YEK
DML0YEK	DN	Catechol
DML0YEK	MI	TTZHA0O
DML0YEK	MN	Carbonic anhydrase IV (CA-IV)
DML0YEK	MT	DTT
DML0YEK	MA	Inhibitor
DML0YEK	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DML0YEK	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DML0YEK	DI	DML0YEK
DML0YEK	DN	Catechol
DML0YEK	MI	TTSYM0R
DML0YEK	MN	Carbonic anhydrase XII (CA-XII)
DML0YEK	MT	DTT
DML0YEK	MA	Inhibitor
DML0YEK	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DML0YEK	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DML0YEK	DI	DML0YEK
DML0YEK	DN	Catechol
DML0YEK	MI	DEWRN24
DML0YEK	MN	Glucansucrase (gtf106B)
DML0YEK	MT	DME
DML0YEK	MA	Metabolism
DML0YEK	RN	Catechol glucosides act as donor/acceptor substrates of glucansucrase enzymes of Lactobacillus reuteri. Appl Microbiol Biotechnol. 2017 Jun;101(11):4495-4505.
DML0YEK	RU	https://pubmed.ncbi.nlm.nih.gov/28258313

DMLEJHF	DI	DMLEJHF
DMLEJHF	DN	Cation chloride
DMLEJHF	MI	DT1MPHW
DMLEJHF	MN	Electroneutral potassium-chloride cotransporter 4 (SLC12A7)
DMLEJHF	MT	DTP
DMLEJHF	MA	Substrate
DMLEJHF	RN	A molecular analysis of the Na(+)-independent cation chloride cotransporters. Cell Physiol Biochem. 2013;32(7):14-31.
DMLEJHF	RU	http://www.ncbi.nlm.nih.gov/pubmed/24429812

DMF7TBW	DI	DMF7TBW
DMF7TBW	DN	CATPB
DMF7TBW	MI	TT0FYAN
DMF7TBW	MN	Free fatty acid receptor 2 (FFAR2)
DMF7TBW	MT	DTT
DMF7TBW	MA	Antagonist
DMF7TBW	RN	Extracellular ionic locks determine variation in constitutive activity and ligand potency between species orthologs of the free fatty acid receptors FFA2 and FFA3. J Biol Chem. 2012 Nov 30;287(49):41195-209.
DMF7TBW	RU	https://pubmed.ncbi.nlm.nih.gov/23066016

DM4QKVN	DI	DM4QKVN
DM4QKVN	DN	CAULERPIN
DM4QKVN	MI	TTELIN2
DM4QKVN	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DM4QKVN	MT	DTT
DM4QKVN	MA	Inhibitor
DM4QKVN	RN	Two novel aromatic valerenane-type sesquiterpenes from the Chinese green alga Caulerpa taxifolia. Bioorg Med Chem Lett. 2006 Jun 1;16(11):2947-50.
DM4QKVN	RU	https://pubmed.ncbi.nlm.nih.gov/16563751

DM4O69H	DI	DM4O69H
DM4O69H	DN	CAY 10471
DM4O69H	MI	TTQDMX5
DM4O69H	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DM4O69H	MT	DTT
DM4O69H	MA	Agonist
DM4O69H	RN	Minor structural modifications convert the dual TP/CRTH2 antagonist ramatroban into a highly selective and potent CRTH2 antagonist. J Med Chem. 2005 Feb 24;48(4):897-900.
DM4O69H	RU	https://pubmed.ncbi.nlm.nih.gov/15715457

DMT3MBD	DI	DMT3MBD
DMT3MBD	DN	CAY10583
DMT3MBD	MI	TTVJX54
DMT3MBD	MN	Leukotriene B4 receptor 2 (LTB4R2)
DMT3MBD	MT	DTT
DMT3MBD	MA	Agonist
DMT3MBD	RN	Characterization of a mouse second leukotriene B4 receptor, mBLT2: BLT2-dependent ERK activation and cell migration of primary mouse keratinocytes. J Biol Chem. 2005 Jul 1;280(26):24816-23.
DMT3MBD	RU	https://pubmed.ncbi.nlm.nih.gov/15866883

DMSFXZU	DI	DMSFXZU
DMSFXZU	DN	CB-1922
DMSFXZU	MI	TT26PHO
DMSFXZU	MN	Mineralocorticoid receptor  (MR)
DMSFXZU	MT	DTT
DMSFXZU	MA	Inhibitor
DMSFXZU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 626).
DMSFXZU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=626

DMXON4L	DI	DMXON4L
DMXON4L	DN	CB-676475
DMXON4L	MI	TTUTJGQ
DMXON4L	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMXON4L	MT	DTT
DMXON4L	MA	Inhibitor
DMXON4L	RN	Synthesis of a novel biotin-tagged photoaffinity probe for VEGF receptor tyrosine kinases. Bioorg Med Chem Lett. 2006 Jan 1;16(1):129-33.
DMXON4L	RU	https://pubmed.ncbi.nlm.nih.gov/16216503

DMXON4L	DI	DMXON4L
DMXON4L	DN	CB-676475
DMXON4L	MI	TTDCBX5
DMXON4L	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DMXON4L	MT	DTT
DMXON4L	MA	Inhibitor
DMXON4L	RN	Synthesis of a novel biotin-tagged photoaffinity probe for VEGF receptor tyrosine kinases. Bioorg Med Chem Lett. 2006 Jan 1;16(1):129-33.
DMXON4L	RU	https://pubmed.ncbi.nlm.nih.gov/16216503

DMXON4L	DI	DMXON4L
DMXON4L	DN	CB-676475
DMXON4L	MI	TT1VAUK
DMXON4L	MN	VEGFR1 messenger RNA (VEGFR1 mRNA)
DMXON4L	MT	DTT
DMXON4L	MA	Inhibitor
DMXON4L	RN	Synthesis and biological activity of N(4)-phenylsubstituted-6-(2,4-dichloro phenylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as vascular endo... Bioorg Med Chem. 2010 May 15;18(10):3575-87.
DMXON4L	RU	https://pubmed.ncbi.nlm.nih.gov/20403700

DMALVY7	DI	DMALVY7
DMALVY7	DN	CBiPES
DMALVY7	MI	TTXJ47W
DMALVY7	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMALVY7	MT	DTT
DMALVY7	MA	Modulator (allosteric modulator)
DMALVY7	RN	Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and... Psychopharmacology (Berl). 2005 Apr;179(1):271-83.
DMALVY7	RU	https://pubmed.ncbi.nlm.nih.gov/15717213

DMDIW1M	DI	DMDIW1M
DMDIW1M	DN	CBIQ
DMDIW1M	MI	TTRLZHP
DMDIW1M	MN	cAMP-dependent chloride channel (CFTR)
DMDIW1M	MT	DTT
DMDIW1M	MA	Activator
DMDIW1M	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 707).
DMDIW1M	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=707

DMCFR8U	DI	DMCFR8U
DMCFR8U	DN	CBLB-612
DMCFR8U	MI	TTY7ZHS
DMCFR8U	MN	Toll-like receptor 2 (TLR2)
DMCFR8U	MT	DTT
DMCFR8U	MA	Modulator
DMCFR8U	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1752).
DMCFR8U	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1752

DMITY0H	DI	DMITY0H
DMITY0H	DN	CBOBNEA
DMITY0H	MI	TT0WAIE
DMITY0H	MN	Melatonin receptor type 1A (MTNR1A)
DMITY0H	MT	DTT
DMITY0H	MA	Agonist
DMITY0H	RN	Design, synthesis and pharmacological evaluation of novel naphthalenic derivatives as selective MT(1) melatoninergic ligands. Bioorg Med Chem. 2010 May 15;18(10):3426-36.
DMITY0H	RU	https://pubmed.ncbi.nlm.nih.gov/20444610

DM21JVF	DI	DM21JVF
DM21JVF	DN	Cbz-Glu(OtBu)-Ala-LeuVSMe
DM21JVF	MI	TTUMQVO
DM21JVF	MN	Cathepsin S (CTSS)
DM21JVF	MT	DTT
DM21JVF	MA	Inhibitor
DM21JVF	RN	Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and c... J Med Chem. 2006 May 18;49(10):2953-68.
DM21JVF	RU	https://pubmed.ncbi.nlm.nih.gov/16686537

DMV8CJK	DI	DMV8CJK
DMV8CJK	DN	Cbz-Ile-hPhe-Ala-LeuVSMe
DMV8CJK	MI	TTUMQVO
DMV8CJK	MN	Cathepsin S (CTSS)
DMV8CJK	MT	DTT
DMV8CJK	MA	Inhibitor
DMV8CJK	RN	Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and c... J Med Chem. 2006 May 18;49(10):2953-68.
DMV8CJK	RU	https://pubmed.ncbi.nlm.nih.gov/16686537

DMBFLHD	DI	DMBFLHD
DMBFLHD	DN	Cbz-Ile-Leu-Ala-LeuVSMe
DMBFLHD	MI	TTF2LRI
DMBFLHD	MN	Cathepsin B (CTSB)
DMBFLHD	MT	DTT
DMBFLHD	MA	Inhibitor
DMBFLHD	RN	Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and c... J Med Chem. 2006 May 18;49(10):2953-68.
DMBFLHD	RU	https://pubmed.ncbi.nlm.nih.gov/16686537

DMBFLHD	DI	DMBFLHD
DMBFLHD	DN	Cbz-Ile-Leu-Ala-LeuVSMe
DMBFLHD	MI	TTUMQVO
DMBFLHD	MN	Cathepsin S (CTSS)
DMBFLHD	MT	DTT
DMBFLHD	MA	Inhibitor
DMBFLHD	RN	Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and c... J Med Chem. 2006 May 18;49(10):2953-68.
DMBFLHD	RU	https://pubmed.ncbi.nlm.nih.gov/16686537

DMI53WR	DI	DMI53WR
DMI53WR	DN	Cbz-Ile-Leu-L-(difluoro)aminobutyric acid
DMI53WR	MI	TTWXB3E
DMI53WR	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DMI53WR	MT	DTT
DMI53WR	MA	Inhibitor
DMI53WR	RN	Control of hepatitis C: a medicinal chemistry perspective. J Med Chem. 2005 Jan 13;48(1):1-20.
DMI53WR	RU	https://pubmed.ncbi.nlm.nih.gov/15633995

DMY4M3J	DI	DMY4M3J
DMY4M3J	DN	Cbz-Ile-MetO2-Ala-LeuVSMe
DMY4M3J	MI	TTUMQVO
DMY4M3J	MN	Cathepsin S (CTSS)
DMY4M3J	MT	DTT
DMY4M3J	MA	Inhibitor
DMY4M3J	RN	Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and c... J Med Chem. 2006 May 18;49(10):2953-68.
DMY4M3J	RU	https://pubmed.ncbi.nlm.nih.gov/16686537

DM1OAW3	DI	DM1OAW3
DM1OAW3	DN	Cbz-Ile-Phe-Ala-LeuVSMe
DM1OAW3	MI	TTUMQVO
DM1OAW3	MN	Cathepsin S (CTSS)
DM1OAW3	MT	DTT
DM1OAW3	MA	Inhibitor
DM1OAW3	RN	Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and c... J Med Chem. 2006 May 18;49(10):2953-68.
DM1OAW3	RU	https://pubmed.ncbi.nlm.nih.gov/16686537

DM1KDWE	DI	DM1KDWE
DM1KDWE	DN	Cbz-Ile-Pro-Ala-LeuVSMe
DM1KDWE	MI	TTUMQVO
DM1KDWE	MN	Cathepsin S (CTSS)
DM1KDWE	MT	DTT
DM1KDWE	MA	Inhibitor
DM1KDWE	RN	Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and c... J Med Chem. 2006 May 18;49(10):2953-68.
DM1KDWE	RU	https://pubmed.ncbi.nlm.nih.gov/16686537

DMGTFON	DI	DMGTFON
DMGTFON	DN	Cbz-Ile-t-ButylGln-Ala-LeuVSMe
DMGTFON	MI	TTUMQVO
DMGTFON	MN	Cathepsin S (CTSS)
DMGTFON	MT	DTT
DMGTFON	MA	Inhibitor
DMGTFON	RN	Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and c... J Med Chem. 2006 May 18;49(10):2953-68.
DMGTFON	RU	https://pubmed.ncbi.nlm.nih.gov/16686537

DMNKC9J	DI	DMNKC9J
DMNKC9J	DN	Cbz-Ile-t-ButylhomoGlu-Ala-LeuVSMe
DMNKC9J	MI	TTF2LRI
DMNKC9J	MN	Cathepsin B (CTSB)
DMNKC9J	MT	DTT
DMNKC9J	MA	Inhibitor
DMNKC9J	RN	Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and c... J Med Chem. 2006 May 18;49(10):2953-68.
DMNKC9J	RU	https://pubmed.ncbi.nlm.nih.gov/16686537

DMNKC9J	DI	DMNKC9J
DMNKC9J	DN	Cbz-Ile-t-ButylhomoGlu-Ala-LeuVSMe
DMNKC9J	MI	TTUMQVO
DMNKC9J	MN	Cathepsin S (CTSS)
DMNKC9J	MT	DTT
DMNKC9J	MA	Inhibitor
DMNKC9J	RN	Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and c... J Med Chem. 2006 May 18;49(10):2953-68.
DMNKC9J	RU	https://pubmed.ncbi.nlm.nih.gov/16686537

DM6TYRA	DI	DM6TYRA
DM6TYRA	DN	Cbz-Val-Pro-Val-(2-benzoxazole)
DM6TYRA	MI	TTPLTSQ
DM6TYRA	MN	Neutrophil elastase (NE)
DM6TYRA	MT	DTT
DM6TYRA	MA	Inhibitor
DM6TYRA	RN	Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. Bioorg Med Chem. 2008 Feb 15;16(4):1562-95.
DM6TYRA	RU	https://pubmed.ncbi.nlm.nih.gov/18053726

DMSE20Y	DI	DMSE20Y
DMSE20Y	DN	CCACSSKWCRDHSRCC
DMSE20Y	MI	TT84DRB
DMSE20Y	MN	Voltage-gated sodium channel alpha Nav1.4 (SCN4A)
DMSE20Y	MT	DTT
DMSE20Y	MA	Inhibitor
DMSE20Y	RN	Structure/function characterization of micro-conotoxin KIIIA, an analgesic, nearly irreversible blocker of mammalian neuronal sodium channels. J Biol Chem. 2007 Oct 19;282(42):30699-706.
DMSE20Y	RU	https://pubmed.ncbi.nlm.nih.gov/17724025

DMUQJ6X	DI	DMUQJ6X
DMUQJ6X	DN	CCG-50014
DMUQJ6X	MI	TTGTKX9
DMUQJ6X	MN	Regulator of G-protein signaling 4 (RGS4)
DMUQJ6X	MT	DTT
DMUQJ6X	MA	Inhibitor
DMUQJ6X	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2811).
DMUQJ6X	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2811

DMUQJ6X	DI	DMUQJ6X
DMUQJ6X	DN	CCG-50014
DMUQJ6X	MI	TTWME23
DMUQJ6X	MN	Regulator of G-protein signaling 8 (RGS8)
DMUQJ6X	MT	DTT
DMUQJ6X	MA	Inhibitor
DMUQJ6X	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2813).
DMUQJ6X	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2813

DM1N0ED	DI	DM1N0ED
DM1N0ED	DN	CCK-33
DM1N0ED	MI	TTCG0AL
DM1N0ED	MN	Cholecystokinin receptor type A (CCKAR)
DM1N0ED	MT	DTT
DM1N0ED	MA	Agonist
DM1N0ED	RN	Distinct cholecystokinin receptors in brain and pancreas. Proc Natl Acad Sci U S A. 1980 Nov;77(11):6917-21.
DM1N0ED	RU	https://pubmed.ncbi.nlm.nih.gov/6256771

DM1N0ED	DI	DM1N0ED
DM1N0ED	DN	CCK-33
DM1N0ED	MI	TTVFO0U
DM1N0ED	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DM1N0ED	MT	DTT
DM1N0ED	MA	Agonist
DM1N0ED	RN	Functional characterization of a human brain cholecystokinin-B receptor. A trophic effect of cholecystokinin and gastrin. J Biol Chem. 1993 Aug 25;268(24):18300-5.
DM1N0ED	RU	https://pubmed.ncbi.nlm.nih.gov/8349705

DMN0J4W	DI	DMN0J4W
DMN0J4W	DN	CCK-8
DMN0J4W	MI	TTCG0AL
DMN0J4W	MN	Cholecystokinin receptor type A (CCKAR)
DMN0J4W	MT	DTT
DMN0J4W	MA	Agonist
DMN0J4W	RN	Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci U S A. 1990 Sep;87(17):6728-32.
DMN0J4W	RU	https://pubmed.ncbi.nlm.nih.gov/1975695

DMN0J4W	DI	DMN0J4W
DMN0J4W	DN	CCK-8
DMN0J4W	MI	TTVFO0U
DMN0J4W	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMN0J4W	MT	DTT
DMN0J4W	MA	Agonist
DMN0J4W	RN	Functional characterization of a human brain cholecystokinin-B receptor. A trophic effect of cholecystokinin and gastrin. J Biol Chem. 1993 Aug 25;268(24):18300-5.
DMN0J4W	RU	https://pubmed.ncbi.nlm.nih.gov/8349705

DMN0J4W	DI	DMN0J4W
DMN0J4W	DN	CCK-8
DMN0J4W	MI	DTFI42L
DMN0J4W	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMN0J4W	MT	DTP
DMN0J4W	MA	Substrate
DMN0J4W	RN	Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol Pharmacol. 2005 Oct;68(4):1031-8.
DMN0J4W	RU	http://www.ncbi.nlm.nih.gov/pubmed/16046661

DMN0J4W	DI	DMN0J4W
DMN0J4W	DN	CCK-8
DMN0J4W	MI	DT3D8F0
DMN0J4W	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMN0J4W	MT	DTP
DMN0J4W	MA	Substrate
DMN0J4W	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DMN0J4W	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DMN0J4W	DI	DMN0J4W
DMN0J4W	DN	CCK-8
DMN0J4W	MI	DT9C1TS
DMN0J4W	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMN0J4W	MT	DTP
DMN0J4W	MA	Substrate
DMN0J4W	RN	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem. 2012 May 24;55(10):4740-63.
DMN0J4W	RU	http://www.ncbi.nlm.nih.gov/pubmed/22541068

DMRFA5O	DI	DMRFA5O
DMRFA5O	DN	CCNCASKWCRDHSRCC
DMRFA5O	MI	TT84DRB
DMRFA5O	MN	Voltage-gated sodium channel alpha Nav1.4 (SCN4A)
DMRFA5O	MT	DTT
DMRFA5O	MA	Inhibitor
DMRFA5O	RN	Structure/function characterization of micro-conotoxin KIIIA, an analgesic, nearly irreversible blocker of mammalian neuronal sodium channels. J Biol Chem. 2007 Oct 19;282(42):30699-706.
DMRFA5O	RU	https://pubmed.ncbi.nlm.nih.gov/17724025

DMZKJ37	DI	DMZKJ37
DMZKJ37	DN	CCNCSAKWCRDHSRCC
DMZKJ37	MI	TT84DRB
DMZKJ37	MN	Voltage-gated sodium channel alpha Nav1.4 (SCN4A)
DMZKJ37	MT	DTT
DMZKJ37	MA	Inhibitor
DMZKJ37	RN	Structure/function characterization of micro-conotoxin KIIIA, an analgesic, nearly irreversible blocker of mammalian neuronal sodium channels. J Biol Chem. 2007 Oct 19;282(42):30699-706.
DMZKJ37	RU	https://pubmed.ncbi.nlm.nih.gov/17724025

DM96YR2	DI	DM96YR2
DM96YR2	DN	CCNCSSKWCRAHSRCC
DM96YR2	MI	TT84DRB
DM96YR2	MN	Voltage-gated sodium channel alpha Nav1.4 (SCN4A)
DM96YR2	MT	DTT
DM96YR2	MA	Inhibitor
DM96YR2	RN	Structure/function characterization of micro-conotoxin KIIIA, an analgesic, nearly irreversible blocker of mammalian neuronal sodium channels. J Biol Chem. 2007 Oct 19;282(42):30699-706.
DM96YR2	RU	https://pubmed.ncbi.nlm.nih.gov/17724025

DMP0C7B	DI	DMP0C7B
DMP0C7B	DN	CCNCSSKWCRDHARCC
DMP0C7B	MI	TT84DRB
DMP0C7B	MN	Voltage-gated sodium channel alpha Nav1.4 (SCN4A)
DMP0C7B	MT	DTT
DMP0C7B	MA	Inhibitor
DMP0C7B	RN	Structure/function characterization of micro-conotoxin KIIIA, an analgesic, nearly irreversible blocker of mammalian neuronal sodium channels. J Biol Chem. 2007 Oct 19;282(42):30699-706.
DMP0C7B	RU	https://pubmed.ncbi.nlm.nih.gov/17724025

DMBGHTW	DI	DMBGHTW
DMBGHTW	DN	CCNCSSKWCRDHSRCC
DMBGHTW	MI	TTAXZ0K
DMBGHTW	MN	Voltage-gated sodium channel alpha Nav1.3 (SCN3A)
DMBGHTW	MT	DTT
DMBGHTW	MA	Inhibitor
DMBGHTW	RN	Structure/function characterization of micro-conotoxin KIIIA, an analgesic, nearly irreversible blocker of mammalian neuronal sodium channels. J Biol Chem. 2007 Oct 19;282(42):30699-706.
DMBGHTW	RU	https://pubmed.ncbi.nlm.nih.gov/17724025

DMBGHTW	DI	DMBGHTW
DMBGHTW	DN	CCNCSSKWCRDHSRCC
DMBGHTW	MI	TT84DRB
DMBGHTW	MN	Voltage-gated sodium channel alpha Nav1.4 (SCN4A)
DMBGHTW	MT	DTT
DMBGHTW	MA	Inhibitor
DMBGHTW	RN	Structure/function characterization of micro-conotoxin KIIIA, an analgesic, nearly irreversible blocker of mammalian neuronal sodium channels. J Biol Chem. 2007 Oct 19;282(42):30699-706.
DMBGHTW	RU	https://pubmed.ncbi.nlm.nih.gov/17724025

DM2UJM8	DI	DM2UJM8
DM2UJM8	DN	CCP
DM2UJM8	MI	TTMN4HY
DM2UJM8	MN	N-acylethanolamine-hydrolyzing acidamidase (NAAA)
DM2UJM8	MT	DTT
DM2UJM8	MA	Inhibitor
DM2UJM8	RN	N-cyclohexanecarbonylpentadecylamine: a selective inhibitor of the acid amidase hydrolysing N-acylethanolamines, as a tool to distinguish acid amidase from fatty acid amide hydrolase. Biochem J. 2004Apr 1;379(Pt 1):99-106.
DM2UJM8	RU	https://pubmed.ncbi.nlm.nih.gov/14686878

DMZXFT9	DI	DMZXFT9
DMZXFT9	DN	CCT-241533
DMZXFT9	MI	TT9ABMF
DMZXFT9	MN	Serine/threonine-protein kinase Chk2 (RAD53)
DMZXFT9	MT	DTT
DMZXFT9	MA	Inhibitor
DMZXFT9	RN	CCT241533 Is a Potent and Selective Inhibitor of CHK2 that Potentiates the Cytotoxicity of PARP Inhibitors. Cancer Res. 2011 Jan 15;71(2):463-72.
DMZXFT9	RU	https://pubmed.ncbi.nlm.nih.gov/21239475

DMSDH3A	DI	DMSDH3A
DMSDH3A	DN	CCT244747
DMSDH3A	MI	TTV6WMQ
DMSDH3A	MN	BR serine/threonine kinase 1 (BRSK1)
DMSDH3A	MT	DTT
DMSDH3A	MA	Inhibitor
DMSDH3A	RN	Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors. J Med Chem. 2012 Nov 26;55(22):10229-40.
DMSDH3A	RU	https://pubmed.ncbi.nlm.nih.gov/23082860

DMSDH3A	DI	DMSDH3A
DMSDH3A	DN	CCT244747
DMSDH3A	MI	TTHZN4X
DMSDH3A	MN	BR serine/threonine kinase 2 (BRSK2)
DMSDH3A	MT	DTT
DMSDH3A	MA	Inhibitor
DMSDH3A	RN	Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors. J Med Chem. 2012 Nov 26;55(22):10229-40.
DMSDH3A	RU	https://pubmed.ncbi.nlm.nih.gov/23082860

DMSDH3A	DI	DMSDH3A
DMSDH3A	DN	CCT244747
DMSDH3A	MI	TTTU902
DMSDH3A	MN	Checkpoint kinase-1 (CHK1)
DMSDH3A	MT	DTT
DMSDH3A	MA	Inhibitor
DMSDH3A	RN	Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors. J Med Chem. 2012 Nov 26;55(22):10229-40.
DMSDH3A	RU	https://pubmed.ncbi.nlm.nih.gov/23082860

DM6WX1A	DI	DM6WX1A
DM6WX1A	DN	CCX-662
DM6WX1A	MI	TTRQJTC
DM6WX1A	MN	C-X-C chemokine receptor type 7 (ACKR3)
DM6WX1A	MT	DTT
DM6WX1A	MA	Antagonist
DM6WX1A	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 80).
DM6WX1A	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=80

DM9BMDO	DI	DM9BMDO
DM9BMDO	DN	CD154
DM9BMDO	MI	TTN6Y9A
DM9BMDO	MN	CD40L receptor (CD40)
DM9BMDO	MT	DTT
DM9BMDO	MA	Binder
DM9BMDO	RN	Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer. Clin Cancer Res. 2001 Mar;7(3):691-703.
DM9BMDO	RU	https://pubmed.ncbi.nlm.nih.gov/11297266

DMT6M5E	DI	DMT6M5E
DMT6M5E	DN	CD-160130
DMT6M5E	MI	TTZ97H5
DMT6M5E	MN	Phosphodiesterase 4A (PDE4A)
DMT6M5E	MT	DTT
DMT6M5E	MA	Inhibitor
DMT6M5E	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1300).
DMT6M5E	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1300

DMT6M5E	DI	DMT6M5E
DMT6M5E	DN	CD-160130
DMT6M5E	MI	TTVIAT9
DMT6M5E	MN	Phosphodiesterase 4B (PDE4B)
DMT6M5E	MT	DTT
DMT6M5E	MA	Inhibitor
DMT6M5E	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1301).
DMT6M5E	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1301

DMT6M5E	DI	DMT6M5E
DMT6M5E	DN	CD-160130
DMT6M5E	MI	TTSKMI8
DMT6M5E	MN	Phosphodiesterase 4D (PDE4D)
DMT6M5E	MT	DTT
DMT6M5E	MA	Inhibitor
DMT6M5E	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1303).
DMT6M5E	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1303

DM05M9X	DI	DM05M9X
DM05M9X	DN	CD2665
DM05M9X	MI	TT1Q3IE
DM05M9X	MN	Retinoic acid receptor gamma (RARG)
DM05M9X	MT	DTT
DM05M9X	MA	Antagonist
DM05M9X	RN	Induction of apoptosis by retinoids and retinoic acid receptor gamma-selective compounds in mouse thymocytes through a novel apoptosis pathway. Mol Pharmacol. 1997 Jun;51(6):972-82.
DM05M9X	RU	https://pubmed.ncbi.nlm.nih.gov/9187263

DM38MU1	DI	DM38MU1
DM38MU1	DN	CD3254
DM38MU1	MI	TT6PEUO
DM38MU1	MN	Retinoic acid receptor RXR-alpha (RXRA)
DM38MU1	MT	DTT
DM38MU1	MA	Agonist
DM38MU1	RN	Co-regulator recruitment and the mechanism of retinoic acid receptor synergy. Nature. 2002 Jan 10;415(6868):187-92.
DM38MU1	RU	https://pubmed.ncbi.nlm.nih.gov/11805839

DMIV82T	DI	DMIV82T
DMIV82T	DN	CD4 red blood cell electroinsertion
DMIV82T	MI	TTBYP1X
DMIV82T	MN	Human immunodeficiency virus Envelope glycoprotein gp120 (HIV gp120)
DMIV82T	MT	DTT
DMIV82T	MA	Modulator
DMIV82T	RN	Red blood cells bearing CD4 bind to gp120 covered plates and aggregate with cells expressing gp120. J Acquir Immune Defic Syndr. 1990;3(11):1041-5.
DMIV82T	RU	https://www.ncbi.nlm.nih.gov/pubmed/1698964

DMFQVLW	DI	DMFQVLW
DMFQVLW	DN	CD45RB
DMFQVLW	MI	TTE4KHA
DMFQVLW	MN	Amyloid beta A4 protein (APP)
DMFQVLW	MT	DTT
DMFQVLW	MA	Agonist
DMFQVLW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
DMFQVLW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402

DMZ2LPO	DI	DMZ2LPO
DMZ2LPO	DN	CD564
DMZ2LPO	MI	TT1Q3IE
DMZ2LPO	MN	Retinoic acid receptor gamma (RARG)
DMZ2LPO	MT	DTT
DMZ2LPO	MA	Inhibitor
DMZ2LPO	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMZ2LPO	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMC8X9Y	DI	DMC8X9Y
DMC8X9Y	DN	CD666
DMC8X9Y	MI	TTW38KT
DMC8X9Y	MN	Retinoic acid receptor alpha (RARA)
DMC8X9Y	MT	DTT
DMC8X9Y	MA	Agonist
DMC8X9Y	RN	Identification of synthetic retinoids with selectivity for human nuclear retinoic acid receptor gamma. Biochem Biophys Res Commun. 1992 Jul 31;186(2):977-83.
DMC8X9Y	RU	https://pubmed.ncbi.nlm.nih.gov/1323296

DMC8X9Y	DI	DMC8X9Y
DMC8X9Y	DN	CD666
DMC8X9Y	MI	TTISP28
DMC8X9Y	MN	Retinoic acid receptor beta (RARB)
DMC8X9Y	MT	DTT
DMC8X9Y	MA	Agonist
DMC8X9Y	RN	Identification of synthetic retinoids with selectivity for human nuclear retinoic acid receptor gamma. Biochem Biophys Res Commun. 1992 Jul 31;186(2):977-83.
DMC8X9Y	RU	https://pubmed.ncbi.nlm.nih.gov/1323296

DMC8X9Y	DI	DMC8X9Y
DMC8X9Y	DN	CD666
DMC8X9Y	MI	TT1Q3IE
DMC8X9Y	MN	Retinoic acid receptor gamma (RARG)
DMC8X9Y	MT	DTT
DMC8X9Y	MA	Agonist
DMC8X9Y	RN	Identification of synthetic retinoids with selectivity for human nuclear retinoic acid receptor gamma. Biochem Biophys Res Commun. 1992 Jul 31;186(2):977-83.
DMC8X9Y	RU	https://pubmed.ncbi.nlm.nih.gov/1323296

DMWP63C	DI	DMWP63C
DMWP63C	DN	CD79-targeted immunotoxins
DMWP63C	MI	TTBN5I7
DMWP63C	MN	B-cell-specific glycoprotein B29 (CD79B)
DMWP63C	MT	DTT
DMWP63C	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2852).
DMWP63C	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2852

DMFYWE3	DI	DMFYWE3
DMFYWE3	DN	CD-832.HCL
DMFYWE3	MI	TT5HONZ
DMFYWE3	MN	Calcium channel unspecific (CaC)
DMFYWE3	MT	DTT
DMFYWE3	MA	Modulator
DMFYWE3	RN	Actions of a new Ca2+ channel antagonist, CD832, on two types of Ca2+ channels in smooth muscle. Eur J Pharmacol. 1994 Feb 11;252(3):267-74.
DMFYWE3	RU	https://www.ncbi.nlm.nih.gov/pubmed/8162949

DM03NUV	DI	DM03NUV
DM03NUV	DN	CDDO
DM03NUV	MI	TTF10I9
DM03NUV	MN	Nitric-oxide synthase inducible (NOS2)
DM03NUV	MT	DTT
DM03NUV	MA	Inhibitor
DM03NUV	RN	Studies on the reactivity of CDDO, a promising new chemopreventive and chemotherapeutic agent: implications for a molecular mechanism of action. Bioorg Med Chem Lett. 2005 May 2;15(9):2215-9.
DM03NUV	RU	https://pubmed.ncbi.nlm.nih.gov/15837296

DMNW12R	DI	DMNW12R
DMNW12R	DN	Cdk1 inhibitor
DMNW12R	MI	TTH6V3D
DMNW12R	MN	Cyclin-dependent kinase 1 (CDK1)
DMNW12R	MT	DTT
DMNW12R	MA	Inhibitor
DMNW12R	RN	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
DMNW12R	RU	https://pubmed.ncbi.nlm.nih.gov/18077363

DMS62T0	DI	DMS62T0
DMS62T0	DN	Cdk1/2 inhibitor III
DMS62T0	MI	TTH6V3D
DMS62T0	MN	Cyclin-dependent kinase 1 (CDK1)
DMS62T0	MT	DTT
DMS62T0	MA	Inhibitor
DMS62T0	RN	1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities. J Med Chem. 2005 Jun 30;48(13):4208-11.
DMS62T0	RU	https://pubmed.ncbi.nlm.nih.gov/15974571

DMS62T0	DI	DMS62T0
DMS62T0	DN	Cdk1/2 inhibitor III
DMS62T0	MI	TT7HF4W
DMS62T0	MN	Cyclin-dependent kinase 2 (CDK2)
DMS62T0	MT	DTT
DMS62T0	MA	Inhibitor
DMS62T0	RN	1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities. J Med Chem. 2005 Jun 30;48(13):4208-11.
DMS62T0	RU	https://pubmed.ncbi.nlm.nih.gov/15974571

DMS62T0	DI	DMS62T0
DMS62T0	DN	Cdk1/2 inhibitor III
DMS62T0	MI	TT1VAUK
DMS62T0	MN	VEGFR1 messenger RNA (VEGFR1 mRNA)
DMS62T0	MT	DTT
DMS62T0	MA	Inhibitor
DMS62T0	RN	1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities. J Med Chem. 2005 Jun 30;48(13):4208-11.
DMS62T0	RU	https://pubmed.ncbi.nlm.nih.gov/15974571

DMNZJAX	DI	DMNZJAX
DMNZJAX	DN	Cdk4 inhibitor III
DMNZJAX	MI	TT7HF4W
DMNZJAX	MN	Cyclin-dependent kinase 2 (CDK2)
DMNZJAX	MT	DTT
DMNZJAX	MA	Inhibitor
DMNZJAX	RN	5-Arylamino-2-methyl-4,7-dioxobenzothiazoles as inhibitors of cyclin-dependent kinase 4 and cytotoxic agents. Bioorg Med Chem Lett. 2000 Mar 6;10(5):461-4.
DMNZJAX	RU	https://pubmed.ncbi.nlm.nih.gov/10743948

DMNZJAX	DI	DMNZJAX
DMNZJAX	DN	Cdk4 inhibitor III
DMNZJAX	MI	TT0PG8F
DMNZJAX	MN	Cyclin-dependent kinase 4 (CDK4)
DMNZJAX	MT	DTT
DMNZJAX	MA	Inhibitor
DMNZJAX	RN	5-Arylamino-2-methyl-4,7-dioxobenzothiazoles as inhibitors of cyclin-dependent kinase 4 and cytotoxic agents. Bioorg Med Chem Lett. 2000 Mar 6;10(5):461-4.
DMNZJAX	RU	https://pubmed.ncbi.nlm.nih.gov/10743948

DMQDA5W	DI	DMQDA5W
DMQDA5W	DN	CDRI-85/92
DMQDA5W	MI	TTF1QVM
DMQDA5W	MN	Gastric H(+)/K(+) ATPase alpha (ATP4A)
DMQDA5W	MT	DTT
DMQDA5W	MA	Inhibitor
DMQDA5W	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 849).
DMQDA5W	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=849

DMUKGEA	DI	DMUKGEA
DMUKGEA	DN	Cebutolol
DMUKGEA	MI	TTR6W5O
DMUKGEA	MN	Adrenergic receptor beta-1 (ADRB1)
DMUKGEA	MT	DTT
DMUKGEA	MA	Antagonist
DMUKGEA	RN	Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404.
DMUKGEA	RU	https://pubmed.ncbi.nlm.nih.gov/9551698

DMRYX1P	DI	DMRYX1P
DMRYX1P	DN	CEL-1000
DMRYX1P	MI	TTN2JFW
DMRYX1P	MN	T-cell surface glycoprotein CD4 (CD4)
DMRYX1P	MT	DTT
DMRYX1P	RN	A small peptide (CEL-1000) derived from the beta-chain of the human major histocompatibility complex class II molecule induces complete protection against malaria in an antigen-independent manner. Antimicrob Agents Chemother. 2004 Jul;48(7):2455-63.
DMRYX1P	RU	https://pubmed.ncbi.nlm.nih.gov/15215094

DMQ0HCT	DI	DMQ0HCT
DMQ0HCT	DN	CEM-301
DMQ0HCT	MI	TT953CX
DMQ0HCT	MN	Motilin receptor (MLNR)
DMQ0HCT	MT	DTT
DMQ0HCT	MA	Agonist
DMQ0HCT	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 297).
DMQ0HCT	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=297

DMCLXO0	DI	DMCLXO0
DMCLXO0	DN	CENTAUREIDIN
DMCLXO0	MI	TTML2WA
DMCLXO0	MN	Tubulin (TUB)
DMCLXO0	MT	DTT
DMCLXO0	MA	Inhibitor
DMCLXO0	RN	Structure-activity requirements for flavone cytotoxicity and binding to tubulin. J Med Chem. 1998 Jun 18;41(13):2333-8.
DMCLXO0	RU	https://pubmed.ncbi.nlm.nih.gov/9632366

DMCLXO0	DI	DMCLXO0
DMCLXO0	DN	CENTAUREIDIN
DMCLXO0	MI	TTYFKSZ
DMCLXO0	MN	Tubulin beta (TUBB)
DMCLXO0	MT	DTT
DMCLXO0	MA	Inhibitor
DMCLXO0	RN	Structure-activity requirements for flavone cytotoxicity and binding to tubulin. J Med Chem. 1998 Jun 18;41(13):2333-8.
DMCLXO0	RU	https://pubmed.ncbi.nlm.nih.gov/9632366

DMOHELX	DI	DMOHELX
DMOHELX	DN	Centratherin
DMOHELX	MI	TTSXVID
DMOHELX	MN	Nuclear factor NF-kappa-B (NFKB)
DMOHELX	MT	DTT
DMOHELX	MA	Inhibitor
DMOHELX	RN	Development of a structural model for NF-kappaB inhibition of sesquiterpene lactones using self-organizing neural networks. J Med Chem. 2006 Apr 6;49(7):2241-52.
DMOHELX	RU	https://pubmed.ncbi.nlm.nih.gov/16570920

DMA7JO4	DI	DMA7JO4
DMA7JO4	DN	CEP1348
DMA7JO4	MI	TT9FN4J
DMA7JO4	MN	Mixed lineage kinase 2 (MAP3K10)
DMA7JO4	MT	DTT
DMA7JO4	MA	Inhibitor
DMA7JO4	RN	Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
DMA7JO4	RU	https://pubmed.ncbi.nlm.nih.gov/11804650

DMOAZX5	DI	DMOAZX5
DMOAZX5	DN	CEP1349
DMOAZX5	MI	TTETX6Q
DMOAZX5	MN	Mixed lineage kinase 3 (MAP3K11)
DMOAZX5	MT	DTT
DMOAZX5	MA	Inhibitor
DMOAZX5	RN	Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
DMOAZX5	RU	https://pubmed.ncbi.nlm.nih.gov/11804650

DMCIOSM	DI	DMCIOSM
DMCIOSM	DN	CEP-18050
DMCIOSM	MI	TTPMQSO
DMCIOSM	MN	ALK tyrosine kinase receptor (ALK)
DMCIOSM	MT	DTT
DMCIOSM	MA	Inhibitor
DMCIOSM	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1839).
DMCIOSM	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1839

DMAY04M	DI	DMAY04M
DMAY04M	DN	CEP-28122
DMAY04M	MI	TTPMQSO
DMAY04M	MN	ALK tyrosine kinase receptor (ALK)
DMAY04M	MT	DTT
DMAY04M	MA	Inhibitor
DMAY04M	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1839).
DMAY04M	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1839

DMV43GY	DI	DMV43GY
DMV43GY	DN	CEP-5104
DMV43GY	MI	TT2B9KF
DMV43GY	MN	Fyn tyrosine protein kinase (FYN)
DMV43GY	MT	DTT
DMV43GY	MA	Inhibitor
DMV43GY	RN	Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-linea... J Med Chem. 2008 Sep 25;51(18):5680-9.
DMV43GY	RU	https://pubmed.ncbi.nlm.nih.gov/18714982

DMV43GY	DI	DMV43GY
DMV43GY	DN	CEP-5104
DMV43GY	MI	TT860QF
DMV43GY	MN	LCK tyrosine protein kinase (LCK)
DMV43GY	MT	DTT
DMV43GY	MA	Inhibitor
DMV43GY	RN	Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-linea... J Med Chem. 2008 Sep 25;51(18):5680-9.
DMV43GY	RU	https://pubmed.ncbi.nlm.nih.gov/18714982

DMV43GY	DI	DMV43GY
DMV43GY	DN	CEP-5104
DMV43GY	MI	TTUNSIX
DMV43GY	MN	Mixed lineage kinase 1 (MAP3K9)
DMV43GY	MT	DTT
DMV43GY	MA	Inhibitor
DMV43GY	RN	Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-linea... J Med Chem. 2008 Sep 25;51(18):5680-9.
DMV43GY	RU	https://pubmed.ncbi.nlm.nih.gov/18714982

DMV43GY	DI	DMV43GY
DMV43GY	DN	CEP-5104
DMV43GY	MI	TT9FN4J
DMV43GY	MN	Mixed lineage kinase 2 (MAP3K10)
DMV43GY	MT	DTT
DMV43GY	MA	Inhibitor
DMV43GY	RN	Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-linea... J Med Chem. 2008 Sep 25;51(18):5680-9.
DMV43GY	RU	https://pubmed.ncbi.nlm.nih.gov/18714982

DMV43GY	DI	DMV43GY
DMV43GY	DN	CEP-5104
DMV43GY	MI	TTETX6Q
DMV43GY	MN	Mixed lineage kinase 3 (MAP3K11)
DMV43GY	MT	DTT
DMV43GY	MA	Inhibitor
DMV43GY	RN	Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-linea... J Med Chem. 2008 Sep 25;51(18):5680-9.
DMV43GY	RU	https://pubmed.ncbi.nlm.nih.gov/18714982

DMV43GY	DI	DMV43GY
DMV43GY	DN	CEP-5104
DMV43GY	MI	TTTDVOJ
DMV43GY	MN	Tropomyosin-related kinase A (TrkA)
DMV43GY	MT	DTT
DMV43GY	MA	Inhibitor
DMV43GY	RN	Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-linea... J Med Chem. 2008 Sep 25;51(18):5680-9.
DMV43GY	RU	https://pubmed.ncbi.nlm.nih.gov/18714982

DMV43GY	DI	DMV43GY
DMV43GY	DN	CEP-5104
DMV43GY	MI	TTUTJGQ
DMV43GY	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMV43GY	MT	DTT
DMV43GY	MA	Inhibitor
DMV43GY	RN	Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-linea... J Med Chem. 2008 Sep 25;51(18):5680-9.
DMV43GY	RU	https://pubmed.ncbi.nlm.nih.gov/18714982

DMNXBTD	DI	DMNXBTD
DMNXBTD	DN	CEP-6331
DMNXBTD	MI	TT2B9KF
DMNXBTD	MN	Fyn tyrosine protein kinase (FYN)
DMNXBTD	MT	DTT
DMNXBTD	MA	Inhibitor
DMNXBTD	RN	Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-linea... J Med Chem. 2008 Sep 25;51(18):5680-9.
DMNXBTD	RU	https://pubmed.ncbi.nlm.nih.gov/18714982

DMNXBTD	DI	DMNXBTD
DMNXBTD	DN	CEP-6331
DMNXBTD	MI	TTUNSIX
DMNXBTD	MN	Mixed lineage kinase 1 (MAP3K9)
DMNXBTD	MT	DTT
DMNXBTD	MA	Inhibitor
DMNXBTD	RN	Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-linea... J Med Chem. 2008 Sep 25;51(18):5680-9.
DMNXBTD	RU	https://pubmed.ncbi.nlm.nih.gov/18714982

DMNXBTD	DI	DMNXBTD
DMNXBTD	DN	CEP-6331
DMNXBTD	MI	TT9FN4J
DMNXBTD	MN	Mixed lineage kinase 2 (MAP3K10)
DMNXBTD	MT	DTT
DMNXBTD	MA	Inhibitor
DMNXBTD	RN	Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-linea... J Med Chem. 2008 Sep 25;51(18):5680-9.
DMNXBTD	RU	https://pubmed.ncbi.nlm.nih.gov/18714982

DMNXBTD	DI	DMNXBTD
DMNXBTD	DN	CEP-6331
DMNXBTD	MI	TTETX6Q
DMNXBTD	MN	Mixed lineage kinase 3 (MAP3K11)
DMNXBTD	MT	DTT
DMNXBTD	MA	Inhibitor
DMNXBTD	RN	Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-linea... J Med Chem. 2008 Sep 25;51(18):5680-9.
DMNXBTD	RU	https://pubmed.ncbi.nlm.nih.gov/18714982

DMNXBTD	DI	DMNXBTD
DMNXBTD	DN	CEP-6331
DMNXBTD	MI	TTTDVOJ
DMNXBTD	MN	Tropomyosin-related kinase A (TrkA)
DMNXBTD	MT	DTT
DMNXBTD	MA	Inhibitor
DMNXBTD	RN	Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-linea... J Med Chem. 2008 Sep 25;51(18):5680-9.
DMNXBTD	RU	https://pubmed.ncbi.nlm.nih.gov/18714982

DMNXBTD	DI	DMNXBTD
DMNXBTD	DN	CEP-6331
DMNXBTD	MI	TTDCBX5
DMNXBTD	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DMNXBTD	MT	DTT
DMNXBTD	MA	Inhibitor
DMNXBTD	RN	Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-linea... J Med Chem. 2008 Sep 25;51(18):5680-9.
DMNXBTD	RU	https://pubmed.ncbi.nlm.nih.gov/18714982

DMS16BD	DI	DMS16BD
DMS16BD	DN	CEP-6800
DMS16BD	MI	TTVDSZ0
DMS16BD	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMS16BD	MT	DTT
DMS16BD	MA	Inhibitor
DMS16BD	RN	Novel poly(ADP-ribose) polymerase-1 inhibitors. Bioorg Med Chem Lett. 2007 Jan 15;17(2):542-5.
DMS16BD	RU	https://pubmed.ncbi.nlm.nih.gov/17074482

DMYW3ZG	DI	DMYW3ZG
DMYW3ZG	DN	Cephalosporin C
DMYW3ZG	MI	TTLP6GN
DMYW3ZG	MN	Bacterial DD-carboxypeptidase (Bact vanYB)
DMYW3ZG	MT	DTT
DMYW3ZG	MA	Inhibitor
DMYW3ZG	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMYW3ZG	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMYW3ZG	DI	DMYW3ZG
DMYW3ZG	DN	Cephalosporin C
DMYW3ZG	MI	TT85JMW
DMYW3ZG	MN	Bacterial Penicillin binding protein 3 (Bact mrcA)
DMYW3ZG	MT	DTT
DMYW3ZG	MA	Antagonist
DMYW3ZG	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMYW3ZG	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMYW3ZG	DI	DMYW3ZG
DMYW3ZG	DN	Cephalosporin C
DMYW3ZG	MI	TT329FH
DMYW3ZG	MN	Bacterial Penicillin-binding protein 1B (Bact mrcB)
DMYW3ZG	MT	DTT
DMYW3ZG	MA	Antagonist
DMYW3ZG	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMYW3ZG	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMCE3NA	DI	DMCE3NA
DMCE3NA	DN	CEPHARANTINE
DMCE3NA	MI	TTRTKPV
DMCE3NA	MN	Trypanosoma Trypanothione reductase (Trypano TPR)
DMCE3NA	MT	DTT
DMCE3NA	MA	Inhibitor
DMCE3NA	RN	The use of natural product scaffolds as leads in the search for trypanothione reductase inhibitors. Bioorg Med Chem. 2008 Jul 15;16(14):6689-95.
DMCE3NA	RU	https://pubmed.ncbi.nlm.nih.gov/18558492

DMY8LBO	DI	DMY8LBO
DMY8LBO	DN	Ceplene/Peg-Intron/Rebetol
DMY8LBO	MI	TTSYFMA
DMY8LBO	MN	Interferon alpha/beta receptor 1 (IFNAR1)
DMY8LBO	MT	DTT
DMY8LBO	MA	Modulator
DMY8LBO	RN	Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase. Antivir Ther. 2012;17(3):411-23.
DMY8LBO	RU	https://pubmed.ncbi.nlm.nih.gov/22402762

DMSL4FQ	DI	DMSL4FQ
DMSL4FQ	DN	CFGGFTCARKSARK
DMSL4FQ	MI	TTNT7K8
DMSL4FQ	MN	Nociceptin receptor (OPRL1)
DMSL4FQ	MT	DTT
DMSL4FQ	MA	Inhibitor
DMSL4FQ	RN	Structure-activity studies on nociceptin analogues: ORL1 receptor binding and biological activity of cyclic disulfide-containing analogues of nocic... J Med Chem. 2001 Nov 8;44(23):4015-8.
DMSL4FQ	RU	https://pubmed.ncbi.nlm.nih.gov/11689089

DM2B0RX	DI	DM2B0RX
DM2B0RX	DN	CFGGFTGARKCARK
DM2B0RX	MI	TTNT7K8
DM2B0RX	MN	Nociceptin receptor (OPRL1)
DM2B0RX	MT	DTT
DM2B0RX	MA	Inhibitor
DM2B0RX	RN	Structure-activity studies on nociceptin analogues: ORL1 receptor binding and biological activity of cyclic disulfide-containing analogues of nocic... J Med Chem. 2001 Nov 8;44(23):4015-8.
DM2B0RX	RU	https://pubmed.ncbi.nlm.nih.gov/11689089

DMN8B1S	DI	DMN8B1S
DMN8B1S	DN	CFMMC
DMN8B1S	MI	TTVBPDM
DMN8B1S	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMN8B1S	MT	DTT
DMN8B1S	MA	Modulator (allosteric modulator)
DMN8B1S	RN	Identification of a novel transmembrane domain involved in the negative modulation of mGluR1 using a newly discovered allosteric mGluR1 antagonist, 3-cyclohexyl-5-fluoro-6-methyl-7-(2-morpholin-4-ylethoxy)-4H-chromen-4-one. Neuropharmacology. 2009 Sep;57(4):438-45.
DMN8B1S	RU	https://pubmed.ncbi.nlm.nih.gov/19559036

DM9HMP4	DI	DM9HMP4
DM9HMP4	DN	CFMTI
DM9HMP4	MI	TTVBPDM
DM9HMP4	MN	Metabotropic glutamate receptor 1 (mGluR1)
DM9HMP4	MT	DTT
DM9HMP4	MA	Modulator (allosteric modulator)
DM9HMP4	RN	Unique antipsychotic activities of the selective metabotropic glutamate receptor 1 allosteric antagonist 2-cyclopropyl-5-[1-(2-fluoro-3-pyridinyl)-5-methyl-1H-1,2,3-triazol-4-yl]-2,3-dihydro-1H-isoindol-1-one. J Pharmacol Exp Ther. 2009 Jul;330(1):179-90.
DM9HMP4	RU	https://pubmed.ncbi.nlm.nih.gov/19359526

DM8TJW3	DI	DM8TJW3
DM8TJW3	DN	CFTRinh-172
DM8TJW3	MI	TTRLZHP
DM8TJW3	MN	cAMP-dependent chloride channel (CFTR)
DM8TJW3	MT	DTT
DM8TJW3	MA	Blocker (channel blocker)
DM8TJW3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 707).
DM8TJW3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=707

DMGW9QL	DI	DMGW9QL
DMGW9QL	DN	CG-103065
DMGW9QL	MI	TTOU65C
DMGW9QL	MN	Tyrosine-protein kinase SYK (SYK)
DMGW9QL	MT	DTT
DMGW9QL	MA	Inhibitor
DMGW9QL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2230).
DMGW9QL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2230

DMN3YEQ	DI	DMN3YEQ
DMN3YEQ	DN	CG-1521
DMN3YEQ	MI	TTBH0VX
DMN3YEQ	MN	Histone deacetylase (HDAC)
DMN3YEQ	MT	DTT
DMN3YEQ	MA	Inhibitor
DMN3YEQ	RN	Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006 Sep;5(9):769-84.
DMN3YEQ	RU	https://pubmed.ncbi.nlm.nih.gov/16955068

DM4FMPJ	DI	DM4FMPJ
DM4FMPJ	DN	CGEN-855
DM4FMPJ	MI	TT5Y4EM
DM4FMPJ	MN	N-formyl peptide receptor (FPR1)
DM4FMPJ	MT	DTT
DM4FMPJ	MA	Agonist
DM4FMPJ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 222).
DM4FMPJ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=222

DMTPRBX	DI	DMTPRBX
DMTPRBX	DN	CGI-1316
DMTPRBX	MI	TTGM6VW
DMTPRBX	MN	Tyrosine-protein kinase BTK (ATK)
DMTPRBX	MT	DTT
DMTPRBX	MA	Inhibitor
DMTPRBX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1948).
DMTPRBX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1948

DM8OAN9	DI	DM8OAN9
DM8OAN9	DN	CGK733
DM8OAN9	MI	TTKBM7V
DM8OAN9	MN	ATM serine/threonine kinase (ATM)
DM8OAN9	MT	DTT
DM8OAN9	MA	Inhibitor
DM8OAN9	RN	Small molecule-based reversible reprogramming of cellular lifespan. Nat Chem Biol. 2006 Jul;2(7):369-74.
DM8OAN9	RU	https://pubmed.ncbi.nlm.nih.gov/16767085

DM8OAN9	DI	DM8OAN9
DM8OAN9	DN	CGK733
DM8OAN9	MI	TT8ZYBQ
DM8OAN9	MN	Serine/threonine-protein kinase ATR (FRP1)
DM8OAN9	MT	DTT
DM8OAN9	MA	Inhibitor
DM8OAN9	RN	Small molecule-based reversible reprogramming of cellular lifespan. Nat Chem Biol. 2006 Jul;2(7):369-74.
DM8OAN9	RU	https://pubmed.ncbi.nlm.nih.gov/16767085

DMQ3SAY	DI	DMQ3SAY
DMQ3SAY	DN	CGNLSTCBLGTYTQDF[DKFHO]YPQTAIGVGAP-amide
DMQ3SAY	MI	TTLWS2O
DMQ3SAY	MN	Calcitonin receptor (CALCR)
DMQ3SAY	MT	DTT
DMQ3SAY	MA	Inhibitor
DMQ3SAY	RN	Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept fo... J Med Chem. 2002 Feb 28;45(5):1108-21.
DMQ3SAY	RU	https://pubmed.ncbi.nlm.nih.gov/11855991

DMLA384	DI	DMLA384
DMLA384	DN	CGNLSTCBLGTYTQDFNKFHZYPQTAIGVGAP-amide
DMLA384	MI	TTLWS2O
DMLA384	MN	Calcitonin receptor (CALCR)
DMLA384	MT	DTT
DMLA384	MA	Inhibitor
DMLA384	RN	Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept fo... J Med Chem. 2002 Feb 28;45(5):1108-21.
DMLA384	RU	https://pubmed.ncbi.nlm.nih.gov/11855991

DMUGAYT	DI	DMUGAYT
DMUGAYT	DN	CGNLSTCMLGTYTQDFc[DKFHK]FPQTAIGVGAP-amide
DMUGAYT	MI	TTLWS2O
DMUGAYT	MN	Calcitonin receptor (CALCR)
DMUGAYT	MT	DTT
DMUGAYT	MA	Inhibitor
DMUGAYT	RN	Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept fo... J Med Chem. 2002 Feb 28;45(5):1108-21.
DMUGAYT	RU	https://pubmed.ncbi.nlm.nih.gov/11855991

DM3FP47	DI	DM3FP47
DM3FP47	DN	CGNLSTCMLGTYTQDFc[DKFHO]FPQTAIGVGAP-amide
DM3FP47	MI	TTLWS2O
DM3FP47	MN	Calcitonin receptor (CALCR)
DM3FP47	MT	DTT
DM3FP47	MA	Inhibitor
DM3FP47	RN	Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept fo... J Med Chem. 2002 Feb 28;45(5):1108-21.
DM3FP47	RU	https://pubmed.ncbi.nlm.nih.gov/11855991

DMJ9Z31	DI	DMJ9Z31
DMJ9Z31	DN	CGNLSTCMLGTYTQDFNKFHTFPQTAIGVGAP-amide
DMJ9Z31	MI	TTLWS2O
DMJ9Z31	MN	Calcitonin receptor (CALCR)
DMJ9Z31	MT	DTT
DMJ9Z31	MA	Inhibitor
DMJ9Z31	RN	Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept fo... J Med Chem. 2002 Feb 28;45(5):1108-21.
DMJ9Z31	RU	https://pubmed.ncbi.nlm.nih.gov/11855991

DME84PN	DI	DME84PN
DME84PN	DN	CGNLSTCMLGTYTQDFNKPHTFPQTAIGVGAP-amide
DME84PN	MI	TTLWS2O
DME84PN	MN	Calcitonin receptor (CALCR)
DME84PN	MT	DTT
DME84PN	MA	Inhibitor
DME84PN	RN	Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept fo... J Med Chem. 2002 Feb 28;45(5):1108-21.
DME84PN	RU	https://pubmed.ncbi.nlm.nih.gov/11855991

DMV7TE4	DI	DMV7TE4
DMV7TE4	DN	CGNLSTCMLGTYTQDFNPFHTFPQTAIGVGAP-amide
DMV7TE4	MI	TTLWS2O
DMV7TE4	MN	Calcitonin receptor (CALCR)
DMV7TE4	MT	DTT
DMV7TE4	MA	Inhibitor
DMV7TE4	RN	Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept fo... J Med Chem. 2002 Feb 28;45(5):1108-21.
DMV7TE4	RU	https://pubmed.ncbi.nlm.nih.gov/11855991

DMMO8A2	DI	DMMO8A2
DMMO8A2	DN	CGNLSTCMLGTYTQDFNPKHTFPQTAIGVGAP-amide
DMMO8A2	MI	TTLWS2O
DMMO8A2	MN	Calcitonin receptor (CALCR)
DMMO8A2	MT	DTT
DMMO8A2	MA	Inhibitor
DMMO8A2	RN	Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept fo... J Med Chem. 2002 Feb 28;45(5):1108-21.
DMMO8A2	RU	https://pubmed.ncbi.nlm.nih.gov/11855991

DML79NU	DI	DML79NU
DML79NU	DN	CGP 20712A
DML79NU	MI	TTR6W5O
DML79NU	MN	Adrenergic receptor beta-1 (ADRB1)
DML79NU	MT	DTT
DML79NU	MA	Antagonist
DML79NU	RN	Distribution of beta 1- and beta 2-adrenoceptor subtypes in various mouse tissues. Neurosci Lett. 1993 Sep 17;160(1):96-100.
DML79NU	RU	https://pubmed.ncbi.nlm.nih.gov/7902545

DMTECXA	DI	DMTECXA
DMTECXA	DN	CGP 23996
DMTECXA	MI	TTIND6G
DMTECXA	MN	Somatostatin receptor type 1 (SSTR1)
DMTECXA	MT	DTT
DMTECXA	MA	Agonist
DMTECXA	RN	Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies. Naunyn Schmiedebergs Arch Pharmacol. 1999 Nov;360(5):488-99.
DMTECXA	RU	https://pubmed.ncbi.nlm.nih.gov/10598788

DMTECXA	DI	DMTECXA
DMTECXA	DN	CGP 23996
DMTECXA	MI	TTZ6T9E
DMTECXA	MN	Somatostatin receptor type 2 (SSTR2)
DMTECXA	MT	DTT
DMTECXA	MA	Agonist
DMTECXA	RN	[125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors. Eur J Pharmacol. 1998 May 8;348(2-3):311-20.
DMTECXA	RU	https://pubmed.ncbi.nlm.nih.gov/9652348

DMTECXA	DI	DMTECXA
DMTECXA	DN	CGP 23996
DMTECXA	MI	TTJX3UE
DMTECXA	MN	Somatostatin receptor type 3 (SSTR3)
DMTECXA	MT	DTT
DMTECXA	MA	Agonist
DMTECXA	RN	Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies. Naunyn Schmiedebergs Arch Pharmacol. 1999 Nov;360(5):488-99.
DMTECXA	RU	https://pubmed.ncbi.nlm.nih.gov/10598788

DMTECXA	DI	DMTECXA
DMTECXA	DN	CGP 23996
DMTECXA	MI	TTAE1BR
DMTECXA	MN	Somatostatin receptor type 4 (SSTR4)
DMTECXA	MT	DTT
DMTECXA	MA	Agonist
DMTECXA	RN	Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies. Naunyn Schmiedebergs Arch Pharmacol. 1999 Nov;360(5):488-99.
DMTECXA	RU	https://pubmed.ncbi.nlm.nih.gov/10598788

DMTECXA	DI	DMTECXA
DMTECXA	DN	CGP 23996
DMTECXA	MI	TT2BC4G
DMTECXA	MN	Somatostatin receptor type 5 (SSTR5)
DMTECXA	MT	DTT
DMTECXA	MA	Agonist
DMTECXA	RN	[125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors. Eur J Pharmacol. 1998 May 8;348(2-3):311-20.
DMTECXA	RU	https://pubmed.ncbi.nlm.nih.gov/9652348

DMEA5BZ	DI	DMEA5BZ
DMEA5BZ	DN	CGP 40336A
DMEA5BZ	MI	TTT3ZC9
DMEA5BZ	MN	Human immunodeficiency virus Tat protein (HIV tat)
DMEA5BZ	MT	DTT
DMEA5BZ	MA	Inhibitor
DMEA5BZ	RN	RNA as a target for small molecules. Curr Opin Chem Biol. 2000 Dec;4(6):678-86.
DMEA5BZ	RU	https://pubmed.ncbi.nlm.nih.gov/11102874

DMXV6RD	DI	DMXV6RD
DMXV6RD	DN	CGP 46381
DMXV6RD	MI	TTDCVZW
DMXV6RD	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMXV6RD	MT	DTT
DMXV6RD	MA	Antagonist
DMXV6RD	RN	The human GABA(B1b) and GABA(B2) heterodimeric recombinant receptor shows low sensitivity to phaclofen and saclofen. Br J Pharmacol. 2000 Nov;131(6):1050-4.
DMXV6RD	RU	https://pubmed.ncbi.nlm.nih.gov/11082110

DME39UQ	DI	DME39UQ
DME39UQ	DN	CGP 47656
DME39UQ	MI	TTDCVZW
DME39UQ	MN	Gamma-aminobutyric acid B receptor (GABBR)
DME39UQ	MT	DTT
DME39UQ	MA	Agonist
DME39UQ	RN	Expression cloning of GABA(B) receptors uncovers similarity to metabotropic glutamate receptors. Nature. 1997 Mar 20;386(6622):239-46.
DME39UQ	RU	https://pubmed.ncbi.nlm.nih.gov/9069281

DMEHYVS	DI	DMEHYVS
DMEHYVS	DN	CGP 54626A
DMEHYVS	MI	TTDCVZW
DMEHYVS	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMEHYVS	MT	DTT
DMEHYVS	MA	Antagonist
DMEHYVS	RN	GABA(B) receptors function as a heteromeric assembly of the subunits GABA(B)R1 and GABA(B)R2. Nature. 1998 Dec 17;396(6712):674-9.
DMEHYVS	RU	https://pubmed.ncbi.nlm.nih.gov/9872315

DMNMG0I	DI	DMNMG0I
DMNMG0I	DN	CGP 55845
DMNMG0I	MI	TTDCVZW
DMNMG0I	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMNMG0I	MT	DTT
DMNMG0I	MA	Antagonist
DMNMG0I	RN	The human GABA(B1b) and GABA(B2) heterodimeric recombinant receptor shows low sensitivity to phaclofen and saclofen. Br J Pharmacol. 2000 Nov;131(6):1050-4.
DMNMG0I	RU	https://pubmed.ncbi.nlm.nih.gov/11082110

DMR708D	DI	DMR708D
DMR708D	DN	CGP 56999A
DMR708D	MI	TTDCVZW
DMR708D	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMR708D	MT	DTT
DMR708D	MA	Antagonist
DMR708D	RN	Expression cloning of GABA(B) receptors uncovers similarity to metabotropic glutamate receptors. Nature. 1997 Mar 20;386(6622):239-46.
DMR708D	RU	https://pubmed.ncbi.nlm.nih.gov/9069281

DMYXE39	DI	DMYXE39
DMYXE39	DN	CGP 62349
DMYXE39	MI	TTDCVZW
DMYXE39	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMYXE39	MT	DTT
DMYXE39	MA	Antagonist
DMYXE39	RN	Characterisation and partial purification of the GABA(B) receptor from the rat cerebellum using the novel antagonist [3H]CGP 62349. Brain Res Mol Brain Res. 1999 Aug 25;71(2):279-89.
DMYXE39	RU	https://pubmed.ncbi.nlm.nih.gov/10521582

DMR8U1M	DI	DMR8U1M
DMR8U1M	DN	CGP 64213
DMR8U1M	MI	TTDCVZW
DMR8U1M	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMR8U1M	MT	DTT
DMR8U1M	MA	Antagonist
DMR8U1M	RN	Expression cloning of GABA(B) receptors uncovers similarity to metabotropic glutamate receptors. Nature. 1997 Mar 20;386(6622):239-46.
DMR8U1M	RU	https://pubmed.ncbi.nlm.nih.gov/9069281

DMJWED7	DI	DMJWED7
DMJWED7	DN	CGP 71872
DMJWED7	MI	TTDCVZW
DMJWED7	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMJWED7	MT	DTT
DMJWED7	MA	Antagonist
DMJWED7	RN	Expression cloning of GABA(B) receptors uncovers similarity to metabotropic glutamate receptors. Nature. 1997 Mar 20;386(6622):239-46.
DMJWED7	RU	https://pubmed.ncbi.nlm.nih.gov/9069281

DMXH2R3	DI	DMXH2R3
DMXH2R3	DN	CGP 77675
DMXH2R3	MI	TT6PKBN
DMXH2R3	MN	Proto-oncogene c-Src (SRC)
DMXH2R3	MT	DTT
DMXH2R3	MA	Inhibitor
DMXH2R3	RN	A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo. Bone. 1999 May;24(5):437-49.
DMXH2R3	RU	https://pubmed.ncbi.nlm.nih.gov/10321903

DMNUQAG	DI	DMNUQAG
DMNUQAG	DN	CGP-029482
DMNUQAG	MI	TTER6YH
DMNUQAG	MN	Casein kinase II alpha (CSNK2A1)
DMNUQAG	MT	DTT
DMNUQAG	MA	Inhibitor
DMNUQAG	RN	Structural insight into human CK2alpha in complex with the potent inhibitor ellagic acid. Bioorg Med Chem Lett. 2009 Jun 1;19(11):2920-3.
DMNUQAG	RU	https://pubmed.ncbi.nlm.nih.gov/19414254

DMCE6WJ	DI	DMCE6WJ
DMCE6WJ	DN	CGP-191
DMCE6WJ	MI	TT6PKBN
DMCE6WJ	MN	Proto-oncogene c-Src (SRC)
DMCE6WJ	MT	DTT
DMCE6WJ	MA	Inhibitor
DMCE6WJ	RN	Substituted 5,7-diphenyl-pyrrolo[2,3d]pyrimidines: potent inhibitors of the tyrosine kinase c-Src. Bioorg Med Chem Lett. 2000 May 1;10(9):945-9.
DMCE6WJ	RU	https://pubmed.ncbi.nlm.nih.gov/10853665

DMS61KA	DI	DMS61KA
DMS61KA	DN	CGP-29030A
DMS61KA	MI	TTDCVZW
DMS61KA	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMS61KA	MT	DTT
DMS61KA	MA	Modulator
DMS61KA	RN	Effects of a novel piperazine derivative (CGP 29030A) on nociceptive dorsal horn neurons in the rat. Drugs Exp Clin Res. 1992;18(11-12):447-59.
DMS61KA	RU	https://pubmed.ncbi.nlm.nih.gov/1308469

DM84TSH	DI	DM84TSH
DM84TSH	DN	CGP-34938
DM84TSH	MI	TTDCVZW
DM84TSH	MN	Gamma-aminobutyric acid B receptor (GABBR)
DM84TSH	MT	DTT
DM84TSH	MA	Inhibitor
DM84TSH	RN	Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists. J Med Chem. 1995 Aug 18;38(17):3297-312.
DM84TSH	RU	https://pubmed.ncbi.nlm.nih.gov/7650684

DMHKETG	DI	DMHKETG
DMHKETG	DN	CGP-35024
DMHKETG	MI	TTDCVZW
DMHKETG	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMHKETG	MT	DTT
DMHKETG	MA	Inhibitor
DMHKETG	RN	Inhibition of transient LES relaxations and reflux in ferrets by GABA receptor agonists. Am J Physiol. 1999 Oct;277(4 Pt 1):G867-74.
DMHKETG	RU	https://pubmed.ncbi.nlm.nih.gov/10516154

DM3J6HM	DI	DM3J6HM
DM3J6HM	DN	CGP-35582
DM3J6HM	MI	TTDCVZW
DM3J6HM	MN	Gamma-aminobutyric acid B receptor (GABBR)
DM3J6HM	MT	DTT
DM3J6HM	MA	Inhibitor
DM3J6HM	RN	Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists. J Med Chem. 1995 Aug 18;38(17):3297-312.
DM3J6HM	RU	https://pubmed.ncbi.nlm.nih.gov/7650684

DM9U8TO	DI	DM9U8TO
DM9U8TO	DN	CGP-36216
DM9U8TO	MI	TTDCVZW
DM9U8TO	MN	Gamma-aminobutyric acid B receptor (GABBR)
DM9U8TO	MT	DTT
DM9U8TO	MA	Inhibitor
DM9U8TO	RN	Biological activity of 3-aminopropyl (methyl) phosphinic acid, a potent and selective GABAB agonist with CNS activity, Bioorg. Med. Chem. Lett. 3(4):515-518 (1993).
DM9U8TO	RU	http://www.sciencedirect.com/science/article/pii/S0960894X0181218X

DMKF0GH	DI	DMKF0GH
DMKF0GH	DN	CGP-44532
DMKF0GH	MI	TTDCVZW
DMKF0GH	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMKF0GH	MT	DTT
DMKF0GH	MA	Agonist
DMKF0GH	RN	Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
DMKF0GH	RU	https://pubmed.ncbi.nlm.nih.gov/16377242

DM5SATN	DI	DM5SATN
DM5SATN	DN	CGP-49870
DM5SATN	MI	TT8DBY3
DM5SATN	MN	Angiotensin II receptor type-1 (AGTR1)
DM5SATN	MT	DTT
DM5SATN	MA	Modulator
DM5SATN	RN	Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists
DM5SATN	RU	https://www.google.com/patents/US20050288272

DMFPOUC	DI	DMFPOUC
DMFPOUC	DN	CGP-57380
DMFPOUC	MI	TT9RTBL
DMFPOUC	MN	Aurora B messenger RNA (AURKB mRNA)
DMFPOUC	MT	DTT
DMFPOUC	MA	Inhibitor
DMFPOUC	RN	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
DMFPOUC	RU	https://pubmed.ncbi.nlm.nih.gov/17850214

DMFPOUC	DI	DMFPOUC
DMFPOUC	DN	CGP-57380
DMFPOUC	MI	TT860QF
DMFPOUC	MN	LCK tyrosine protein kinase (LCK)
DMFPOUC	MT	DTT
DMFPOUC	MA	Inhibitor
DMFPOUC	RN	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
DMFPOUC	RU	https://pubmed.ncbi.nlm.nih.gov/17850214

DMFPOUC	DI	DMFPOUC
DMFPOUC	DN	CGP-57380
DMFPOUC	MI	TTTV8EJ
DMFPOUC	MN	Serine/threonine-protein kinase Sgk1 (SGK1)
DMFPOUC	MT	DTT
DMFPOUC	MA	Inhibitor
DMFPOUC	RN	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
DMFPOUC	RU	https://pubmed.ncbi.nlm.nih.gov/17850214

DMYZ72J	DI	DMYZ72J
DMYZ72J	DN	CGP-57698
DMYZ72J	MI	TTGKOY9
DMYZ72J	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DMYZ72J	MT	DTT
DMYZ72J	MA	Modulator
DMYZ72J	RN	A kinetic binding study to evaluate the pharmacological profile of a specific leukotriene C(4) binding site not coupled to contraction in human lun... Mol Pharmacol. 2000 Jun;57(6):1182-9.
DMYZ72J	RU	https://www.ncbi.nlm.nih.gov/pubmed/10825389

DMYZ72J	DI	DMYZ72J
DMYZ72J	DN	CGP-57698
DMYZ72J	MI	TT0PZR5
DMYZ72J	MN	Leukotriene CysLT2 receptor (CYSLTR2)
DMYZ72J	MT	DTT
DMYZ72J	MA	Modulator
DMYZ72J	RN	A kinetic binding study to evaluate the pharmacological profile of a specific leukotriene C(4) binding site not coupled to contraction in human lun... Mol Pharmacol. 2000 Jun;57(6):1182-9.
DMYZ72J	RU	https://www.ncbi.nlm.nih.gov/pubmed/10825389

DM8KFZH	DI	DM8KFZH
DM8KFZH	DN	CGP61594
DM8KFZH	MI	TTLD29N
DM8KFZH	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DM8KFZH	MT	DTT
DM8KFZH	MA	Antagonist
DM8KFZH	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455).
DM8KFZH	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=455

DM8KFZH	DI	DM8KFZH
DM8KFZH	DN	CGP61594
DM8KFZH	MI	TTKJEMQ
DM8KFZH	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DM8KFZH	MT	DTT
DM8KFZH	MA	Antagonist
DM8KFZH	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456).
DM8KFZH	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=456

DM8KFZH	DI	DM8KFZH
DM8KFZH	DN	CGP61594
DM8KFZH	MI	TTN9D8E
DM8KFZH	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DM8KFZH	MT	DTT
DM8KFZH	MA	Antagonist
DM8KFZH	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457).
DM8KFZH	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=457

DM8KFZH	DI	DM8KFZH
DM8KFZH	DN	CGP61594
DM8KFZH	MI	TT1M8OW
DM8KFZH	MN	Glutamate receptor ionotropic NMDA 2C (GluN2C)
DM8KFZH	MT	DTT
DM8KFZH	MA	Antagonist
DM8KFZH	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 458).
DM8KFZH	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=458

DM8KFZH	DI	DM8KFZH
DM8KFZH	DN	CGP61594
DM8KFZH	MI	TT5POTG
DM8KFZH	MN	Glutamate receptor ionotropic NMDA 2D (GluN2D)
DM8KFZH	MT	DTT
DM8KFZH	MA	Antagonist
DM8KFZH	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 459).
DM8KFZH	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=459

DMZ34P1	DI	DMZ34P1
DMZ34P1	DN	CGP-62464
DMZ34P1	MI	TT6PKBN
DMZ34P1	MN	Proto-oncogene c-Src (SRC)
DMZ34P1	MT	DTT
DMZ34P1	MA	Inhibitor
DMZ34P1	RN	Substituted 5,7-diphenyl-pyrrolo[2,3d]pyrimidines: potent inhibitors of the tyrosine kinase c-Src. Bioorg Med Chem Lett. 2000 May 1;10(9):945-9.
DMZ34P1	RU	https://pubmed.ncbi.nlm.nih.gov/10853665

DMU5984	DI	DMU5984
DMU5984	DN	CGP74514A
DMU5984	MI	TTH6V3D
DMU5984	MN	Cyclin-dependent kinase 1 (CDK1)
DMU5984	MT	DTT
DMU5984	MA	Inhibitor
DMU5984	RN	2,6,9-trisubstituted purines: optimization towards highly potent and selective CDK1 inhibitors. Bioorg Med Chem Lett. 1999 Jan 4;9(1):91-6.
DMU5984	RU	https://pubmed.ncbi.nlm.nih.gov/9990463

DMZ0TGY	DI	DMZ0TGY
DMZ0TGY	DN	CGS 21680
DMZ0TGY	MI	TTM2AOE
DMZ0TGY	MN	Adenosine A2a receptor (ADORA2A)
DMZ0TGY	MT	DTT
DMZ0TGY	MA	Agonist
DMZ0TGY	RN	Effects of CGS 21680, a selective adenosine A2A receptor agonist, on allergic airways inflammation in the rat. Eur J Pharmacol. 2002 Mar 8;438(3):183-8.
DMZ0TGY	RU	https://pubmed.ncbi.nlm.nih.gov/11909610

DMZ0TGY	DI	DMZ0TGY
DMZ0TGY	DN	CGS 21680
DMZ0TGY	MI	TTNE7KG
DMZ0TGY	MN	Adenosine A2b receptor (ADORA2B)
DMZ0TGY	MT	DTT
DMZ0TGY	MA	Agonist
DMZ0TGY	RN	[3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain. J Pharmacol Exp Ther. 1989 Dec;251(3):888-93.
DMZ0TGY	RU	https://pubmed.ncbi.nlm.nih.gov/2600819

DMRU8G7	DI	DMRU8G7
DMRU8G7	DN	CGS 24012
DMRU8G7	MI	TTNE7KG
DMRU8G7	MN	Adenosine A2b receptor (ADORA2B)
DMRU8G7	MT	DTT
DMRU8G7	MA	Agonist
DMRU8G7	RN	Site-directed mutagenesis identifies residues involved in ligand recognition in the human A2a adenosine receptor. J Biol Chem. 1995 Jun 9;270(23):13987-97.
DMRU8G7	RU	https://pubmed.ncbi.nlm.nih.gov/7775460

DMCHT27	DI	DMCHT27
DMCHT27	DN	CGS 35066
DMCHT27	MI	TTQ9RYT
DMCHT27	MN	Endothelin-converting enzyme 1 (ECE1)
DMCHT27	MT	DTT
DMCHT27	MA	Inhibitor
DMCHT27	RN	The therapeutic potential of endothelin-1 receptor antagonists and endothelin-converting enzyme inhibitors on the cardiovascular system. Expert Opin Investig Drugs. 2002 Nov;11(11):1537-52.
DMCHT27	RU	https://pubmed.ncbi.nlm.nih.gov/12437501

DMCHT27	DI	DMCHT27
DMCHT27	DN	CGS 35066
DMCHT27	MI	TT5U914
DMCHT27	MN	Endothelin-converting enzyme 2 (ECE2)
DMCHT27	MT	DTT
DMCHT27	MA	Inhibitor
DMCHT27	RN	The therapeutic potential of endothelin-1 receptor antagonists and endothelin-converting enzyme inhibitors on the cardiovascular system. Expert Opin Investig Drugs. 2002 Nov;11(11):1537-52.
DMCHT27	RU	https://pubmed.ncbi.nlm.nih.gov/12437501

DM4DSE7	DI	DM4DSE7
DM4DSE7	DN	CGS-13767
DM4DSE7	MI	TT1MPAY
DM4DSE7	MN	GABA(A) receptor alpha-1 (GABRA1)
DM4DSE7	MT	DTT
DM4DSE7	MA	Inhibitor
DM4DSE7	RN	Synthesis and benzodiazepine binding activity of a series of novel [1,2,4]triazolo[1,5-c]quinazolin-5(6H)-ones. J Med Chem. 1991 Jan;34(1):281-90.
DM4DSE7	RU	https://pubmed.ncbi.nlm.nih.gov/1846920

DM4DSE7	DI	DM4DSE7
DM4DSE7	DN	CGS-13767
DM4DSE7	MI	TTZA1NY
DM4DSE7	MN	GABA(A) receptor beta-2 (GABRB2)
DM4DSE7	MT	DTT
DM4DSE7	MA	Inhibitor
DM4DSE7	RN	Synthesis and benzodiazepine binding activity of a series of novel [1,2,4]triazolo[1,5-c]quinazolin-5(6H)-ones. J Med Chem. 1991 Jan;34(1):281-90.
DM4DSE7	RU	https://pubmed.ncbi.nlm.nih.gov/1846920

DM4DSE7	DI	DM4DSE7
DM4DSE7	DN	CGS-13767
DM4DSE7	MI	TT06RH5
DM4DSE7	MN	GABA(A) receptor gamma-2 (GABRG2)
DM4DSE7	MT	DTT
DM4DSE7	MA	Inhibitor
DM4DSE7	RN	Synthesis and benzodiazepine binding activity of a series of novel [1,2,4]triazolo[1,5-c]quinazolin-5(6H)-ones. J Med Chem. 1991 Jan;34(1):281-90.
DM4DSE7	RU	https://pubmed.ncbi.nlm.nih.gov/1846920

DM4DSE7	DI	DM4DSE7
DM4DSE7	DN	CGS-13767
DM4DSE7	MI	TTNJYV2
DM4DSE7	MN	Gamma-aminobutyric acid receptor (GAR)
DM4DSE7	MT	DTT
DM4DSE7	MA	Inhibitor
DM4DSE7	RN	Synthesis and benzodiazepine binding activity of a series of novel [1,2,4]triazolo[1,5-c]quinazolin-5(6H)-ones. J Med Chem. 1991 Jan;34(1):281-90.
DM4DSE7	RU	https://pubmed.ncbi.nlm.nih.gov/1846920

DM2CS5A	DI	DM2CS5A
DM2CS5A	DN	CGS-18320B
DM2CS5A	MI	TTSZLWK
DM2CS5A	MN	Aromatase (CYP19A1)
DM2CS5A	MT	DTT
DM2CS5A	MA	Inhibitor
DM2CS5A	RN	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
DM2CS5A	RU	https://pubmed.ncbi.nlm.nih.gov/20413308

DMDB2KJ	DI	DMDB2KJ
DMDB2KJ	DN	CGS-19281A
DMDB2KJ	MI	TT3WG5C
DMDB2KJ	MN	Monoamine oxidase type A (MAO-A)
DMDB2KJ	MT	DTT
DMDB2KJ	MA	Inhibitor
DMDB2KJ	RN	Pyrazino[1,2-a]indoles as novel high-affinity and selective imidazoline I(2) receptor ligands. Bioorg Med Chem Lett. 2004 Feb 23;14(4):1003-5.
DMDB2KJ	RU	https://pubmed.ncbi.nlm.nih.gov/15013010

DMDB2KJ	DI	DMDB2KJ
DMDB2KJ	DN	CGS-19281A
DMDB2KJ	MI	TTGP7BY
DMDB2KJ	MN	Monoamine oxidase type B (MAO-B)
DMDB2KJ	MT	DTT
DMDB2KJ	MA	Inhibitor
DMDB2KJ	RN	Pyrazino[1,2-a]indoles as novel high-affinity and selective imidazoline I(2) receptor ligands. Bioorg Med Chem Lett. 2004 Feb 23;14(4):1003-5.
DMDB2KJ	RU	https://pubmed.ncbi.nlm.nih.gov/15013010

DMC41UH	DI	DMC41UH
DMC41UH	DN	CGS-19480A
DMC41UH	MI	TTSQIFT
DMC41UH	MN	5-HT 1A receptor (HTR1A)
DMC41UH	MT	DTT
DMC41UH	MA	Modulator
DMC41UH	RN	WO patent application no. 2012,0025,83, Method for treating schizophrenia and related diseases with a combination therapy.
DMC41UH	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20120105&CC=WO&NR=2012002583A1&KC=A1

DM5P7TR	DI	DM5P7TR
DM5P7TR	DN	CGS-23885
DM5P7TR	MI	TT2J34L
DM5P7TR	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM5P7TR	MT	DTT
DM5P7TR	MA	Modulator
DM5P7TR	RN	Inhibition of LTB4 biosynthesis in situ by CGS 23885, a potent 5-lipoxygenase inhibitor, correlates with its pleural fluid concentrations in an exp... Naunyn Schmiedebergs Arch Pharmacol. 1997 Apr;355(4):470-4.
DM5P7TR	RU	https://www.ncbi.nlm.nih.gov/pubmed/9109363

DM514L0	DI	DM514L0
DM514L0	DN	CGS-314447
DM514L0	MI	TT5TKPM
DM514L0	MN	Neutral endopeptidase (MME)
DM514L0	MT	DTT
DM514L0	MA	Inhibitor
DM514L0	RN	Potent non-peptidic dual inhibitors of endothelin-converting enzyme and neutral endopeptidase 24.11, Bioorg. Med. Chem. Lett. 7(8):1059-1064 (1997).
DM514L0	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97001595

DMZKS6Q	DI	DMZKS6Q
DMZKS6Q	DN	CGS-7181
DMZKS6Q	MI	TT1VOHK
DMZKS6Q	MN	Potassium channel unspecific (KC)
DMZKS6Q	MT	DTT
DMZKS6Q	MA	Modulator
DMZKS6Q	RN	Molecular mechanism of pharmacological activation of BK channels
DMZKS6Q	RU	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3295268

DMKY6CU	DI	DMKY6CU
DMKY6CU	DN	CGS-9895
DMKY6CU	MI	TT1MPAY
DMKY6CU	MN	GABA(A) receptor alpha-1 (GABRA1)
DMKY6CU	MT	DTT
DMKY6CU	MA	Inhibitor
DMKY6CU	RN	1,3-Diarylpyrazolo[4,5-c]- and -[5,4-c]quinolin-4-ones. 4. Synthesis and specific inhibition of benzodiazepine receptor binding. J Med Chem. 1987 Oct;30(10):1737-42.
DMKY6CU	RU	https://pubmed.ncbi.nlm.nih.gov/2821257

DMKY6CU	DI	DMKY6CU
DMKY6CU	DN	CGS-9895
DMKY6CU	MI	TT06RH5
DMKY6CU	MN	GABA(A) receptor gamma-2 (GABRG2)
DMKY6CU	MT	DTT
DMKY6CU	MA	Inhibitor
DMKY6CU	RN	1,3-Diarylpyrazolo[4,5-c]- and -[5,4-c]quinolin-4-ones. 4. Synthesis and specific inhibition of benzodiazepine receptor binding. J Med Chem. 1987 Oct;30(10):1737-42.
DMKY6CU	RU	https://pubmed.ncbi.nlm.nih.gov/2821257

DMKY6CU	DI	DMKY6CU
DMKY6CU	DN	CGS-9895
DMKY6CU	MI	TTNJYV2
DMKY6CU	MN	Gamma-aminobutyric acid receptor (GAR)
DMKY6CU	MT	DTT
DMKY6CU	MA	Inhibitor
DMKY6CU	RN	1,3-Diarylpyrazolo[4,5-c]- and -[5,4-c]quinolin-4-ones. 4. Synthesis and specific inhibition of benzodiazepine receptor binding. J Med Chem. 1987 Oct;30(10):1737-42.
DMKY6CU	RU	https://pubmed.ncbi.nlm.nih.gov/2821257

DMMJZYC	DI	DMMJZYC
DMMJZYC	DN	CH-223191
DMMJZYC	MI	TT037IE
DMMJZYC	MN	Aryl hydrocarbon receptor (AHR)
DMMJZYC	MT	DTT
DMMJZYC	MA	Antagonist
DMMJZYC	RN	Novel compound 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)-amide (CH-223191) prevents 2,3,7,8-TCDD-induced toxicity by antagonizing the aryl hydrocarbon receptor. Mol Pharmacol. 2006 Jun;69(6):1871-8.
DMMJZYC	RU	https://pubmed.ncbi.nlm.nih.gov/16540597

DM0RFTJ	DI	DM0RFTJ
DM0RFTJ	DN	CH-3697
DM0RFTJ	MI	TTZ97H5
DM0RFTJ	MN	Phosphodiesterase 4A (PDE4A)
DM0RFTJ	MT	DTT
DM0RFTJ	MA	Inhibitor
DM0RFTJ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1300).
DM0RFTJ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1300

DM0RFTJ	DI	DM0RFTJ
DM0RFTJ	DN	CH-3697
DM0RFTJ	MI	TTVIAT9
DM0RFTJ	MN	Phosphodiesterase 4B (PDE4B)
DM0RFTJ	MT	DTT
DM0RFTJ	MA	Modulator
DM0RFTJ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1301).
DM0RFTJ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1301

DM0RFTJ	DI	DM0RFTJ
DM0RFTJ	DN	CH-3697
DM0RFTJ	MI	TTSKMI8
DM0RFTJ	MN	Phosphodiesterase 4D (PDE4D)
DM0RFTJ	MT	DTT
DM0RFTJ	MA	Modulator
DM0RFTJ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1303).
DM0RFTJ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1303

DMP9UHT	DI	DMP9UHT
DMP9UHT	DN	CH4474
DMP9UHT	MI	TT6AZXG
DMP9UHT	MN	TNF alpha converting enzyme (ADAM17)
DMP9UHT	MT	DTT
DMP9UHT	MA	Inhibitor
DMP9UHT	RN	Tumour necrosis factor-alpha converting enzyme (TACE) activity in human colonic epithelial cells. Clin Exp Immunol. 2004 Jan;135(1):146-53.
DMP9UHT	RU	https://pubmed.ncbi.nlm.nih.gov/14678276

DM1ZF3Y	DI	DM1ZF3Y
DM1ZF3Y	DN	CH-4933468
DM1ZF3Y	MI	TTS64P2
DM1ZF3Y	MN	Androgen receptor (AR)
DM1ZF3Y	MT	DTT
DM1ZF3Y	MA	Antagonist
DM1ZF3Y	RN	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
DM1ZF3Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/27899562

DMBK86L	DI	DMBK86L
DMBK86L	DN	chaetocin
DMBK86L	MI	TTUWQTK
DMBK86L	MN	Lysine N-methyltransferase 1A (SUV39H1)
DMBK86L	MT	DTT
DMBK86L	MA	Inhibitor
DMBK86L	RN	Chaetocin is a nonspecific inhibitor of histone lysine methyltransferases. Nat Chem Biol. 2013 Mar;9(3):136-7.
DMBK86L	RU	https://pubmed.ncbi.nlm.nih.gov/23416387

DM16QTM	DI	DM16QTM
DM16QTM	DN	CHALCONE
DM16QTM	MI	TTGP7BY
DM16QTM	MN	Monoamine oxidase type B (MAO-B)
DM16QTM	MT	DTT
DM16QTM	MA	Inhibitor
DM16QTM	RN	Chalcones: a valid scaffold for monoamine oxidases inhibitors. J Med Chem. 2009 May 14;52(9):2818-24.
DM16QTM	RU	https://pubmed.ncbi.nlm.nih.gov/19378991

DMBZ0QY	DI	DMBZ0QY
DMBZ0QY	DN	CHAP1
DMBZ0QY	MI	TTBH0VX
DMBZ0QY	MN	Histone deacetylase (HDAC)
DMBZ0QY	MT	DTT
DMBZ0QY	MA	Inhibitor
DMBZ0QY	RN	Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92.
DMBZ0QY	RU	https://pubmed.ncbi.nlm.nih.gov/17896917

DMOXRID	DI	DMOXRID
DMOXRID	DN	CHAP31
DMOXRID	MI	TTBH0VX
DMOXRID	MN	Histone deacetylase (HDAC)
DMOXRID	MT	DTT
DMOXRID	MA	Inhibitor
DMOXRID	RN	Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92.
DMOXRID	RU	https://pubmed.ncbi.nlm.nih.gov/17896917

DM0H7AV	DI	DM0H7AV
DM0H7AV	DN	Chebulagic acid
DM0H7AV	MI	TT2J34L
DM0H7AV	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM0H7AV	MT	DTT
DM0H7AV	MA	Inhibitor
DM0H7AV	RN	Chebulagic acid, a COX-LOX dual inhibitor isolated from the fruits of Terminalia chebula Retz., induces apoptosis in COLO-205 cell line. J Ethnopharmacol. 2009 Jul 30;124(3):506-12.
DM0H7AV	RU	https://pubmed.ncbi.nlm.nih.gov/19481594

DMR8HKC	DI	DMR8HKC
DMR8HKC	DN	Chebulinic acid
DMR8HKC	MI	TTE14XG
DMR8HKC	MN	Squalene monooxygenase (SQLE)
DMR8HKC	MT	DTT
DMR8HKC	MA	Inhibitor
DMR8HKC	RN	Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4.
DMR8HKC	RU	https://pubmed.ncbi.nlm.nih.gov/11520216

DMCP1G9	DI	DMCP1G9
DMCP1G9	DN	Chelerythrine
DMCP1G9	MI	TTYVI76
DMCP1G9	MN	Fungal Protein kinase A (Fung ypkA)
DMCP1G9	MT	DTT
DMCP1G9	MA	Inhibitor
DMCP1G9	RN	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
DMCP1G9	RU	https://pubmed.ncbi.nlm.nih.gov/18077363

DMCP1G9	DI	DMCP1G9
DMCP1G9	DN	Chelerythrine
DMCP1G9	MI	DTFI42L
DMCP1G9	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMCP1G9	MT	DTP
DMCP1G9	MA	Substrate
DMCP1G9	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMCP1G9	RU	https://doi.org/10.1007/s11095-012-0935-x

DMCP1G9	DI	DMCP1G9
DMCP1G9	DN	Chelerythrine
DMCP1G9	MI	TT473XN
DMCP1G9	MN	P2X purinoceptor 7 (P2RX7)
DMCP1G9	MT	DTT
DMCP1G9	MA	Modulator (allosteric modulator)
DMCP1G9	RN	Chelerythrine and other benzophenanthridine alkaloids block the human P2X7 receptor. Br J Pharmacol. 2004 Jul;142(6):1015-9.
DMCP1G9	RU	https://pubmed.ncbi.nlm.nih.gov/15210579

DMCP1G9	DI	DMCP1G9
DMCP1G9	DN	Chelerythrine
DMCP1G9	MI	TT57MT2
DMCP1G9	MN	PKC-epsilon messenger RNA (PRKCE mRNA)
DMCP1G9	MT	DTT
DMCP1G9	MA	Inhibitor
DMCP1G9	RN	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
DMCP1G9	RU	https://pubmed.ncbi.nlm.nih.gov/18077363

DMYSG9J	DI	DMYSG9J
DMYSG9J	DN	Chemosensitizers
DMYSG9J	MI	TT0JLSD
DMYSG9J	MN	Multidrug resistance protein (MDR)
DMYSG9J	MT	DTT
DMYSG9J	MA	Inhibitor
DMYSG9J	RN	P-glycoprotein as a drug target in the treatment of multidrug resistant cancer. Curr Drug Targets. 2000 Jul;1(1):85-99.
DMYSG9J	RU	https://pubmed.ncbi.nlm.nih.gov/11475537

DMLJGVX	DI	DMLJGVX
DMLJGVX	DN	CHF-2819
DMLJGVX	MI	TT1RS9F
DMLJGVX	MN	Acetylcholinesterase (AChE)
DMLJGVX	MT	DTT
DMLJGVX	MA	Inhibitor
DMLJGVX	RN	Structural determinants of Torpedo californica acetylcholinesterase inhibition by the novel and orally active carbamate based anti-alzheimer drug g... J Med Chem. 2006 Aug 24;49(17):5051-8.
DMLJGVX	RU	https://pubmed.ncbi.nlm.nih.gov/16913695

DMLJGVX	DI	DMLJGVX
DMLJGVX	DN	CHF-2819
DMLJGVX	MI	TTEB0GD
DMLJGVX	MN	Cholinesterase (BCHE)
DMLJGVX	MT	DTT
DMLJGVX	MA	Inhibitor
DMLJGVX	RN	Novel anticholinesterases based on the molecular skeletons of furobenzofuran and methanobenzodioxepine. J Med Chem. 2005 Feb 24;48(4):986-94.
DMLJGVX	RU	https://pubmed.ncbi.nlm.nih.gov/15715468

DM5T64L	DI	DM5T64L
DM5T64L	DN	CHF-5480
DM5T64L	MI	TTZ97H5
DM5T64L	MN	Phosphodiesterase 4A (PDE4A)
DM5T64L	MT	DTT
DM5T64L	MA	Inhibitor
DM5T64L	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1300).
DM5T64L	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1300

DM5T64L	DI	DM5T64L
DM5T64L	DN	CHF-5480
DM5T64L	MI	TTVIAT9
DM5T64L	MN	Phosphodiesterase 4B (PDE4B)
DM5T64L	MT	DTT
DM5T64L	MA	Inhibitor
DM5T64L	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1301).
DM5T64L	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1301

DM5T64L	DI	DM5T64L
DM5T64L	DN	CHF-5480
DM5T64L	MI	TTSKMI8
DM5T64L	MN	Phosphodiesterase 4D (PDE4D)
DM5T64L	MT	DTT
DM5T64L	MA	Inhibitor
DM5T64L	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1303).
DM5T64L	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1303

DMJATBL	DI	DMJATBL
DMJATBL	DN	Chimeric small nucleolar RNA-TAR decoy
DMJATBL	MI	TTNSXG2
DMJATBL	MN	Human immunodeficiency virus TAR RNA (HIV TAR-RNA)
DMJATBL	MT	DTT
DMJATBL	MA	Inhibitor
DMJATBL	RN	A nucleolar TAR decoy inhibitor of HIV-1 replication. Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14047-52.
DMJATBL	RU	https://pubmed.ncbi.nlm.nih.gov/12376617

DMVEBT6	DI	DMVEBT6
DMVEBT6	DN	CHIR-98014
DMVEBT6	MI	TTRSMW9
DMVEBT6	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMVEBT6	MT	DTT
DMVEBT6	MA	Inhibitor
DMVEBT6	RN	Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95.
DMVEBT6	RU	https://pubmed.ncbi.nlm.nih.gov/12606497

DMVEBT6	DI	DMVEBT6
DMVEBT6	DN	CHIR-98014
DMVEBT6	MI	TTQWAU1
DMVEBT6	MN	GSK3A messenger RNA (GSK3A mRNA)
DMVEBT6	MT	DTT
DMVEBT6	MA	Inhibitor
DMVEBT6	RN	Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95.
DMVEBT6	RU	https://pubmed.ncbi.nlm.nih.gov/12606497

DMFBW1H	DI	DMFBW1H
DMFBW1H	DN	CHIR-98023
DMFBW1H	MI	TTRSMW9
DMFBW1H	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMFBW1H	MT	DTT
DMFBW1H	MA	Inhibitor
DMFBW1H	RN	Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models. Eur J Med Chem. 2009 Jun;44(6):2361-71.
DMFBW1H	RU	https://pubmed.ncbi.nlm.nih.gov/18929433

DMLCZ3D	DI	DMLCZ3D
DMLCZ3D	DN	Chk1-A
DMLCZ3D	MI	TTTU902
DMLCZ3D	MN	Checkpoint kinase-1 (CHK1)
DMLCZ3D	MT	DTT
DMLCZ3D	MA	Inhibitor
DMLCZ3D	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1987).
DMLCZ3D	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1987

DMNSPFG	DI	DMNSPFG
DMNSPFG	DN	Chk2 inhibitor II
DMNSPFG	MI	TT9ABMF
DMNSPFG	MN	Serine/threonine-protein kinase Chk2 (RAD53)
DMNSPFG	MT	DTT
DMNSPFG	MA	Inhibitor
DMNSPFG	RN	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
DMNSPFG	RU	https://pubmed.ncbi.nlm.nih.gov/18077363

DMCHGF1	DI	DMCHGF1
DMCHGF1	DN	CHLORANIL
DMCHGF1	MI	TT1RS9F
DMCHGF1	MN	Acetylcholinesterase (AChE)
DMCHGF1	MT	DTT
DMCHGF1	MA	Inhibitor
DMCHGF1	RN	Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15.
DMCHGF1	RU	https://pubmed.ncbi.nlm.nih.gov/15828829

DMCHGF1	DI	DMCHGF1
DMCHGF1	DN	CHLORANIL
DMCHGF1	MI	TTEB0GD
DMCHGF1	MN	Cholinesterase (BCHE)
DMCHGF1	MT	DTT
DMCHGF1	MA	Inhibitor
DMCHGF1	RN	Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15.
DMCHGF1	RU	https://pubmed.ncbi.nlm.nih.gov/15828829

DMCHGF1	DI	DMCHGF1
DMCHGF1	DN	CHLORANIL
DMCHGF1	MI	TTMF541
DMCHGF1	MN	Liver carboxylesterase (CES1)
DMCHGF1	MT	DTT
DMCHGF1	MA	Inhibitor
DMCHGF1	RN	Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15.
DMCHGF1	RU	https://pubmed.ncbi.nlm.nih.gov/15828829

DMMHU8G	DI	DMMHU8G
DMMHU8G	DN	chlordane
DMMHU8G	MI	TTPNQAC
DMMHU8G	MN	Estrogen-related receptor-alpha (ESRRA)
DMMHU8G	MT	DTT
DMMHU8G	MA	Antagonist
DMMHU8G	RN	Two organochlorine pesticides, toxaphene and chlordane, are antagonists for estrogen-related receptor alpha-1 orphan receptor. Cancer Res. 1999 Sep 15;59(18):4519-24.
DMMHU8G	RU	https://pubmed.ncbi.nlm.nih.gov/10493499

DM64K0A	DI	DM64K0A
DM64K0A	DN	Chlormadinone
DM64K0A	MI	DE4LYSA
DM64K0A	MN	Cytochrome P450 3A4 (CYP3A4)
DM64K0A	MT	DME
DM64K0A	MA	Metabolism
DM64K0A	RN	Drug interactions between rifamycin antibiotics and hormonal contraception: a systematic review. BJOG. 2018 Jun;125(7):804-811.
DM64K0A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29130574

DMY40UB	DI	DMY40UB
DMY40UB	DN	Chloroben
DMY40UB	MI	DEVDYN7
DMY40UB	MN	Cytochrome P450 2E1 (CYP2E1)
DMY40UB	MT	DME
DMY40UB	MA	Metabolism
DMY40UB	RN	Cytochrome P450 catalyzed oxidation of monochlorobenzene, 1,2- and 1,4-dichlorobenzene in rat, mouse, and human liver microsomes. Chem Biol Interact. 1998 Aug 14;115(1):53-70.
DMY40UB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9817075

DMLF7MK	DI	DMLF7MK
DMLF7MK	DN	chlorobenzylidene malononitrile
DMLF7MK	MI	TTELV3W
DMLF7MK	MN	Transformation-sensitive protein p120 (TRPA1)
DMLF7MK	MT	DTT
DMLF7MK	MA	Activator
DMLF7MK	RN	Tear gasses CN, CR, and CS are potent activators of the human TRPA1 receptor. Toxicol Appl Pharmacol. 2008 Sep 1;231(2):150-6.
DMLF7MK	RU	https://pubmed.ncbi.nlm.nih.gov/18501939

DMZA394	DI	DMZA394
DMZA394	DN	CHLOROCYCLINONE A
DMZA394	MI	TTT2SVW
DMZA394	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DMZA394	MT	DTT
DMZA394	MA	Inhibitor
DMZA394	RN	Chlorocyclinones A-D, chlorinated angucyclinones from Streptomyces sp. strongly antagonizing rosiglitazone-induced PPAR-gamma activation. J Nat Prod. 2007 Dec;70(12):1934-8.
DMZA394	RU	https://pubmed.ncbi.nlm.nih.gov/18044841

DMO78QB	DI	DMO78QB
DMO78QB	DN	CHLOROCYCLINONE B
DMO78QB	MI	TTT2SVW
DMO78QB	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DMO78QB	MT	DTT
DMO78QB	MA	Inhibitor
DMO78QB	RN	Chlorocyclinones A-D, chlorinated angucyclinones from Streptomyces sp. strongly antagonizing rosiglitazone-induced PPAR-gamma activation. J Nat Prod. 2007 Dec;70(12):1934-8.
DMO78QB	RU	https://pubmed.ncbi.nlm.nih.gov/18044841

DMX2DQ5	DI	DMX2DQ5
DMX2DQ5	DN	CHLOROCYCLINONE C
DMX2DQ5	MI	TTT2SVW
DMX2DQ5	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DMX2DQ5	MT	DTT
DMX2DQ5	MA	Inhibitor
DMX2DQ5	RN	Chlorocyclinones A-D, chlorinated angucyclinones from Streptomyces sp. strongly antagonizing rosiglitazone-induced PPAR-gamma activation. J Nat Prod. 2007 Dec;70(12):1934-8.
DMX2DQ5	RU	https://pubmed.ncbi.nlm.nih.gov/18044841

DMK7VS1	DI	DMK7VS1
DMK7VS1	DN	CHLOROCYCLINONE D
DMK7VS1	MI	TTT2SVW
DMK7VS1	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DMK7VS1	MT	DTT
DMK7VS1	MA	Inhibitor
DMK7VS1	RN	Chlorocyclinones A-D, chlorinated angucyclinones from Streptomyces sp. strongly antagonizing rosiglitazone-induced PPAR-gamma activation. J Nat Prod. 2007 Dec;70(12):1934-8.
DMK7VS1	RU	https://pubmed.ncbi.nlm.nih.gov/18044841

DMQT3WJ	DI	DMQT3WJ
DMQT3WJ	DN	CHLORODEOXYURIDINE
DMQT3WJ	MI	TT5B8AX
DMQT3WJ	MN	Mycobacterium Thymidine monophosphate kinase (MycB tmk)
DMQT3WJ	MT	DTT
DMQT3WJ	MA	Inhibitor
DMQT3WJ	RN	Substituted benzyl-pyrimidines targeting thymidine monophosphate kinase of Mycobacterium tuberculosis: synthesis and in vitro anti-mycobacterial ac... Bioorg Med Chem. 2008 Jun 1;16(11):6075-85.
DMQT3WJ	RU	https://pubmed.ncbi.nlm.nih.gov/18467107

DMGS3FI	DI	DMGS3FI
DMGS3FI	DN	CHLORODYSINOSIN A
DMGS3FI	MI	TT6L509
DMGS3FI	MN	Coagulation factor IIa (F2)
DMGS3FI	MT	DTT
DMGS3FI	MA	Inhibitor
DMGS3FI	RN	From natural products to achiral drug prototypes: potent thrombin inhibitors based on P2/P3 dihydropyrid-2-one core motifs. Bioorg Med Chem Lett. 2009 Sep 15;19(18):5429-32.
DMGS3FI	RU	https://pubmed.ncbi.nlm.nih.gov/19674897

DMKZIES	DI	DMKZIES
DMKZIES	DN	Chloroethylclonidine
DMKZIES	MI	TTWG9A4
DMKZIES	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMKZIES	MT	DTT
DMKZIES	MA	Agonist
DMKZIES	RN	Selective irreversible binding of chloroethylclonidine at alpha 1- and alpha 2-adrenoceptor subtypes. Mol Pharmacol. 1993 Dec;44(6):1165-70.
DMKZIES	RU	https://pubmed.ncbi.nlm.nih.gov/8264553

DMKZIES	DI	DMKZIES
DMKZIES	DN	Chloroethylclonidine
DMKZIES	MI	TT2NUT5
DMKZIES	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMKZIES	MT	DTT
DMKZIES	MA	Agonist
DMKZIES	RN	Selective irreversible binding of chloroethylclonidine at alpha 1- and alpha 2-adrenoceptor subtypes. Mol Pharmacol. 1993 Dec;44(6):1165-70.
DMKZIES	RU	https://pubmed.ncbi.nlm.nih.gov/8264553

DM2Y3P4	DI	DM2Y3P4
DM2Y3P4	DN	Chlorogenic acid
DM2Y3P4	MI	TT1KPBZ
DM2Y3P4	MN	Glucose-6-phosphate translocase (SLC37A4)
DM2Y3P4	MT	DTT
DM2Y3P4	MA	Inhibitor
DM2Y3P4	RN	Chlorogenic acid and synthetic chlorogenic acid derivatives: novel inhibitors of hepatic glucose-6-phosphate translocase. J Med Chem. 1997 Jan 17;40(2):137-45.
DM2Y3P4	RU	https://pubmed.ncbi.nlm.nih.gov/9003513

DMOA8L2	DI	DMOA8L2
DMOA8L2	DN	Chlorophenylpiperazine
DMOA8L2	MI	TTSQIFT
DMOA8L2	MN	5-HT 1A receptor (HTR1A)
DMOA8L2	MT	DTT
DMOA8L2	MA	Inhibitor
DMOA8L2	RN	Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. J Med Chem. 1989 May;32(5):1052-6.
DMOA8L2	RU	https://pubmed.ncbi.nlm.nih.gov/2565400

DMOA8L2	DI	DMOA8L2
DMOA8L2	DN	Chlorophenylpiperazine
DMOA8L2	MI	TT6MSOK
DMOA8L2	MN	5-HT 1D receptor (HTR1D)
DMOA8L2	MT	DTT
DMOA8L2	MA	Inhibitor
DMOA8L2	RN	Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. J Med Chem. 1989 May;32(5):1052-6.
DMOA8L2	RU	https://pubmed.ncbi.nlm.nih.gov/2565400

DMOA8L2	DI	DMOA8L2
DMOA8L2	DN	Chlorophenylpiperazine
DMOA8L2	MI	TTJQOD7
DMOA8L2	MN	5-HT 2A receptor (HTR2A)
DMOA8L2	MT	DTT
DMOA8L2	MA	Inhibitor
DMOA8L2	RN	Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1128-33.
DMOA8L2	RU	https://pubmed.ncbi.nlm.nih.gov/20022752

DMOA8L2	DI	DMOA8L2
DMOA8L2	DN	Chlorophenylpiperazine
DMOA8L2	MI	TT0K1SC
DMOA8L2	MN	5-HT 2B receptor (HTR2B)
DMOA8L2	MT	DTT
DMOA8L2	MA	Inhibitor
DMOA8L2	RN	Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1128-33.
DMOA8L2	RU	https://pubmed.ncbi.nlm.nih.gov/20022752

DMOA8L2	DI	DMOA8L2
DMOA8L2	DN	Chlorophenylpiperazine
DMOA8L2	MI	TTWJBZ5
DMOA8L2	MN	5-HT 2C receptor (HTR2C)
DMOA8L2	MT	DTT
DMOA8L2	MA	Inhibitor
DMOA8L2	RN	Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1128-33.
DMOA8L2	RU	https://pubmed.ncbi.nlm.nih.gov/20022752

DMOA8L2	DI	DMOA8L2
DMOA8L2	DN	Chlorophenylpiperazine
DMOA8L2	MI	TTJS8PY
DMOA8L2	MN	5-HT 6 receptor (HTR6)
DMOA8L2	MT	DTT
DMOA8L2	MA	Inhibitor
DMOA8L2	RN	Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). J Med Chem. 2003 Jul 3;46(14):2795-812.
DMOA8L2	RU	https://pubmed.ncbi.nlm.nih.gov/12825922

DMSGBQA	DI	DMSGBQA
DMSGBQA	DN	chloropicrin
DMSGBQA	MI	TTELV3W
DMSGBQA	MN	Transformation-sensitive protein p120 (TRPA1)
DMSGBQA	MT	DTT
DMSGBQA	MA	Activator
DMSGBQA	RN	Transient receptor potential ankyrin 1 antagonists block the noxious effects of toxic industrial isocyanates and tear gases. FASEB J. 2009 Apr;23(4):1102-14.
DMSGBQA	RU	https://pubmed.ncbi.nlm.nih.gov/19036859

DM8B0VZ	DI	DM8B0VZ
DM8B0VZ	DN	CHLOROPUUPEHENONE
DM8B0VZ	MI	TT12ABZ
DM8B0VZ	MN	Arachidonate 12-lipoxygenase (12-LOX)
DM8B0VZ	MT	DTT
DM8B0VZ	MA	Inhibitor
DM8B0VZ	RN	Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases. J Nat Prod. 2003 Feb;66(2):230-5.
DM8B0VZ	RU	https://pubmed.ncbi.nlm.nih.gov/12608855

DM8B0VZ	DI	DM8B0VZ
DM8B0VZ	DN	CHLOROPUUPEHENONE
DM8B0VZ	MI	TTN9T81
DM8B0VZ	MN	Arachidonate 15-lipoxygenase (15-LOX)
DM8B0VZ	MT	DTT
DM8B0VZ	MA	Inhibitor
DM8B0VZ	RN	Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases. J Nat Prod. 2003 Feb;66(2):230-5.
DM8B0VZ	RU	https://pubmed.ncbi.nlm.nih.gov/12608855

DMM75WZ	DI	DMM75WZ
DMM75WZ	DN	Chloroxylenol
DMM75WZ	MI	DEJVYAZ
DMM75WZ	MN	Cytochrome P450 2A6 (CYP2A6)
DMM75WZ	MT	DME
DMM75WZ	MA	Metabolism
DMM75WZ	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMM75WZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMM75WZ	DI	DMM75WZ
DMM75WZ	DN	Chloroxylenol
DMM75WZ	MI	DECB0K3
DMM75WZ	MN	Cytochrome P450 2D6 (CYP2D6)
DMM75WZ	MT	DME
DMM75WZ	MA	Metabolism
DMM75WZ	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMM75WZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMM75WZ	DI	DMM75WZ
DMM75WZ	DN	Chloroxylenol
DMM75WZ	MI	DEVDYN7
DMM75WZ	MN	Cytochrome P450 2E1 (CYP2E1)
DMM75WZ	MT	DME
DMM75WZ	MA	Metabolism
DMM75WZ	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMM75WZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMGBT68	DI	DMGBT68
DMGBT68	DN	Chlorphrifos oxon
DMGBT68	MI	TT1RS9F
DMGBT68	MN	Acetylcholinesterase (AChE)
DMGBT68	MT	DTT
DMGBT68	MA	Inhibitor
DMGBT68	RN	Activation of the endocannabinoid system by organophosphorus nerve agents. Nat Chem Biol. 2008 Jun;4(6):373-8.
DMGBT68	RU	https://pubmed.ncbi.nlm.nih.gov/18438404

DMGBT68	DI	DMGBT68
DMGBT68	DN	Chlorphrifos oxon
DMGBT68	MI	TT6OEDT
DMGBT68	MN	Cannabinoid receptor 1 (CB1)
DMGBT68	MT	DTT
DMGBT68	MA	Inhibitor
DMGBT68	RN	Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5875-8.
DMGBT68	RU	https://pubmed.ncbi.nlm.nih.gov/18752948

DMGBT68	DI	DMGBT68
DMGBT68	DN	Chlorphrifos oxon
DMGBT68	MI	TTDP1UC
DMGBT68	MN	Fatty acid amide hydrolase (FAAH)
DMGBT68	MT	DTT
DMGBT68	MA	Inhibitor
DMGBT68	RN	Activation of the endocannabinoid system by organophosphorus nerve agents. Nat Chem Biol. 2008 Jun;4(6):373-8.
DMGBT68	RU	https://pubmed.ncbi.nlm.nih.gov/18438404

DMKPUI6	DI	DMKPUI6
DMKPUI6	DN	Chlorpyrifos
DMKPUI6	MI	TT1RS9F
DMKPUI6	MN	Acetylcholinesterase (AChE)
DMKPUI6	MT	DTT
DMKPUI6	MA	Inhibitor
DMKPUI6	RN	Synthesis of the novel series of bispyridinium compounds bearing (E)-but-2-ene linker and evaluation of their reactivation activity against chlorpy... Bioorg Med Chem Lett. 2006 Feb;16(3):622-7.
DMKPUI6	RU	https://pubmed.ncbi.nlm.nih.gov/16288867

DMKPUI6	DI	DMKPUI6
DMKPUI6	DN	Chlorpyrifos
DMKPUI6	MI	DEMQRS9
DMKPUI6	MN	Cytochrome P450 BM3 (cypBM3)
DMKPUI6	MT	DME
DMKPUI6	MA	Metabolism
DMKPUI6	RN	PEGylation of cytochrome P450 enhances its biocatalytic performance for pesticide transformation. Int J Biol Macromol. 2017 Dec;105(Pt 1):163-170.
DMKPUI6	RU	https://pubmed.ncbi.nlm.nih.gov/28690168

DMZHO3S	DI	DMZHO3S
DMZHO3S	DN	CHO793076
DMZHO3S	MI	TTGTQHC
DMZHO3S	MN	DNA topoisomerase I (TOP1)
DMZHO3S	MT	DTT
DMZHO3S	MA	Inhibitor
DMZHO3S	RN	Synthesis of new camptothecin analogs with improved antitumor activities. Bioorg Med Chem Lett. 2009 Apr 1;19(7):2018-21.
DMZHO3S	RU	https://pubmed.ncbi.nlm.nih.gov/19254843

DMVJMG8	DI	DMVJMG8
DMVJMG8	DN	Cholecystokinin-9
DMVJMG8	MI	TTVFO0U
DMVJMG8	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMVJMG8	MT	DTT
DMVJMG8	MA	Inhibitor
DMVJMG8	RN	5-(tryptophylamino)-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based cholecystokinin receptor antagonists: reversal of CCK1 receptor subtype selectiv... J Med Chem. 2004 Oct 7;47(21):5318-29.
DMVJMG8	RU	https://pubmed.ncbi.nlm.nih.gov/15456276

DMKM3WJ	DI	DMKM3WJ
DMKM3WJ	DN	cholesten
DMKM3WJ	MI	TTS4UGC
DMKM3WJ	MN	Farnesoid X-activated receptor (FXR)
DMKM3WJ	MT	DTT
DMKM3WJ	MA	Agonist
DMKM3WJ	RN	Identification of farnesoid X receptor beta as a novel mammalian nuclear receptor sensing lanosterol. Mol Cell Biol. 2003 Feb;23(3):864-72.
DMKM3WJ	RU	https://pubmed.ncbi.nlm.nih.gov/12529392

DMR3J6S	DI	DMR3J6S
DMR3J6S	DN	Cholesterol
DMR3J6S	MI	DT61TWI
DMR3J6S	MN	ATP-binding cassette sub-family A member 1 (ABCA1)
DMR3J6S	MT	DTP
DMR3J6S	MA	Substrate
DMR3J6S	RN	ABCA1 redistributes membrane cholesterol independent of apolipoprotein interactions. J Lipid Res. 2003 Jul;44(7):1373-80.
DMR3J6S	RU	http://www.ncbi.nlm.nih.gov/pubmed/12700343

DMR3J6S	DI	DMR3J6S
DMR3J6S	DN	Cholesterol
DMR3J6S	MI	DT7LDG0
DMR3J6S	MN	ATP-binding cassette sub-family A member 12 (ABCA12)
DMR3J6S	MT	DTP
DMR3J6S	MA	Substrate
DMR3J6S	RN	ABCA12 regulates ABCA1-dependent cholesterol efflux from macrophages and the development of atherosclerosis. Cell Metab. 2013 Aug 6;18(2):225-38.
DMR3J6S	RU	http://www.ncbi.nlm.nih.gov/pubmed/23931754

DMR3J6S	DI	DMR3J6S
DMR3J6S	DN	Cholesterol
DMR3J6S	MI	DTJ4NEG
DMR3J6S	MN	ATP-binding cassette sub-family A member 2 (ABCA2)
DMR3J6S	MT	DTP
DMR3J6S	MA	Substrate
DMR3J6S	RN	The ATP-binding cassette transporter-2 (ABCA2) regulates cholesterol homeostasis and low-density lipoprotein receptor metabolism in N2a neuroblastoma cells. Biochim Biophys Acta. 2011 Dec;1811(12):1152-64.
DMR3J6S	RU	http://www.ncbi.nlm.nih.gov/pubmed/21810484

DMR3J6S	DI	DMR3J6S
DMR3J6S	DN	Cholesterol
DMR3J6S	MI	DT195NK
DMR3J6S	MN	ATP-binding cassette sub-family A member 5 (ABCA5)
DMR3J6S	MT	DTP
DMR3J6S	MA	Substrate
DMR3J6S	RN	Mutations in the cholesterol transporter gene ABCA5 are associated with excessive hair overgrowth. PLoS Genet. 2014 May 15;10(5):e1004333.
DMR3J6S	RU	http://www.ncbi.nlm.nih.gov/pubmed/24831815

DMR3J6S	DI	DMR3J6S
DMR3J6S	DN	Cholesterol
DMR3J6S	MI	DTLYEPH
DMR3J6S	MN	ATP-binding cassette sub-family G member 1 (ABCG1)
DMR3J6S	MT	DTP
DMR3J6S	MA	Substrate
DMR3J6S	RN	Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler Thromb Vasc Biol. 2010 Feb;30(2):139-43.
DMR3J6S	RU	http://www.ncbi.nlm.nih.gov/pubmed/19797709

DMR3J6S	DI	DMR3J6S
DMR3J6S	DN	Cholesterol
DMR3J6S	MI	DTI7UX6
DMR3J6S	MN	Breast cancer resistance protein (ABCG2)
DMR3J6S	MT	DTP
DMR3J6S	MA	Substrate
DMR3J6S	RN	Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
DMR3J6S	RU	http://www.ncbi.nlm.nih.gov/pubmed/12668685

DMR3J6S	DI	DMR3J6S
DMR3J6S	DN	Cholesterol
DMR3J6S	MI	TTUAIKM
DMR3J6S	MN	Cholinephosphate cytidylyltransferase (PCYT1B)
DMR3J6S	MT	DTT
DMR3J6S	MA	Activator
DMR3J6S	RN	Regulation of CTP: phosphocholine cytidylyltransferase activity by the physical properties of lipid membranes: an important role for stored curvature strain energy. Biochemistry. 2001 Sep 4;40(35):10522-31.
DMR3J6S	RU	https://pubmed.ncbi.nlm.nih.gov/11523994

DMR3J6S	DI	DMR3J6S
DMR3J6S	DN	Cholesterol
DMR3J6S	MI	DT1UMXN
DMR3J6S	MN	Niemann-Pick C1-like protein 1 (SLC65A2)
DMR3J6S	MT	DTP
DMR3J6S	MA	Substrate
DMR3J6S	RN	Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science. 2004 Feb 20;303(5661):1201-4.
DMR3J6S	RU	http://www.ncbi.nlm.nih.gov/pubmed/14976318

DMR3J6S	DI	DMR3J6S
DMR3J6S	DN	Cholesterol
DMR3J6S	MI	DTUGYRD
DMR3J6S	MN	P-glycoprotein 1 (ABCB1)
DMR3J6S	MT	DTP
DMR3J6S	MA	Substrate
DMR3J6S	RN	Cholesterol interaction with the daunorubicin binding site of P-glycoprotein. Biochem Biophys Res Commun. 2000 Oct 5;276(3):909-16.
DMR3J6S	RU	https://doi.org/10.1006/bbrc.2000.3554

DM5D9YK	DI	DM5D9YK
DM5D9YK	DN	Choline
DM5D9YK	MI	DEAHED0
DM5D9YK	MN	Choline dehydrogenase (CHDH)
DM5D9YK	MT	DME
DM5D9YK	MA	Metabolism
DM5D9YK	RN	Usual choline and betaine dietary intake and incident coronary heart disease: the atherosclerosis risk in communities (ARIC) study. BMC Cardiovasc Disord. 2007 Jul 13;7:20.
DM5D9YK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17629908

DM5D9YK	DI	DM5D9YK
DM5D9YK	DN	Choline
DM5D9YK	MI	DEMRAYN
DM5D9YK	MN	Choline kinase alpha (CHKA)
DM5D9YK	MT	DME
DM5D9YK	MA	Metabolism
DM5D9YK	RN	Crystal structures of human choline kinase isoforms in complex with hemicholinium-3: single amino acid near the active site influences inhibitor sensitivity. J Biol Chem. 2010 May 21;285(21):16330-40.
DM5D9YK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20299452

DM5D9YK	DI	DM5D9YK
DM5D9YK	DN	Choline
DM5D9YK	MI	DE5NGOW
DM5D9YK	MN	Choline O-acetyltransferase (CHAT)
DM5D9YK	MT	DME
DM5D9YK	MA	Metabolism
DM5D9YK	RN	The effect of trichlorfon and methylazoxymethanol on the development of guinea pig cerebellum. Toxicol Appl Pharmacol. 2007 Mar;219(2-3):128-35.
DM5D9YK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17150236

DM5D9YK	DI	DM5D9YK
DM5D9YK	DN	Choline
DM5D9YK	MI	DT3I2SU
DM5D9YK	MN	Choline transporter-like protein 1 (SLC44A1)
DM5D9YK	MT	DTP
DM5D9YK	MA	Substrate
DM5D9YK	RN	Decreased biosynthesis of lung surfactant constituent phosphatidylcholine due to inhibition of choline transporter by gefitinib in lung alveolar cells. Pharm Res. 2008 Feb;25(2):417-27.
DM5D9YK	RU	http://www.ncbi.nlm.nih.gov/pubmed/17624579

DM5D9YK	DI	DM5D9YK
DM5D9YK	DN	Choline
DM5D9YK	MI	DTSF91X
DM5D9YK	MN	Choline transporter-like protein 2 (SLC44A2)
DM5D9YK	MT	DTP
DM5D9YK	MA	Substrate
DM5D9YK	RN	The choline transporter-like family SLC44: properties and roles in human diseases. Mol Aspects Med. 2013 Apr-Jun;34(2-3):646-54.
DM5D9YK	RU	http://www.ncbi.nlm.nih.gov/pubmed/23506897

DM5D9YK	DI	DM5D9YK
DM5D9YK	DN	Choline
DM5D9YK	MI	DT8KXR9
DM5D9YK	MN	Choline transporter-like protein 4 (SLC44A4)
DM5D9YK	MT	DTP
DM5D9YK	MA	Substrate
DM5D9YK	RN	SLC44A4 mutation causes autosomal dominant hereditary postlingual non-syndromic mid-frequency hearing loss. Hum Mol Genet. 2017 Jan 15;26(2):383-394.
DM5D9YK	RU	http://www.ncbi.nlm.nih.gov/pubmed/28013291

DM5D9YK	DI	DM5D9YK
DM5D9YK	DN	Choline
DM5D9YK	MI	DTU8NCX
DM5D9YK	MN	Choline transporter-like protein 5 (SLC44A5)
DM5D9YK	MT	DTP
DM5D9YK	MA	Substrate
DM5D9YK	RN	The molecular effects of a polymorphism in the 5'UTR of solute carrier family 44, member 5 that is associated with birth weight in Holsteins. PLoS One. 2012;7(7):e41267.
DM5D9YK	RU	http://www.ncbi.nlm.nih.gov/pubmed/22815983

DM5D9YK	DI	DM5D9YK
DM5D9YK	DN	Choline
DM5D9YK	MI	DEHWR6V
DM5D9YK	MN	Choline/ethanolamine kinase (CHKB)
DM5D9YK	MT	DME
DM5D9YK	MA	Metabolism
DM5D9YK	RN	Crystal structures of human choline kinase isoforms in complex with hemicholinium-3: single amino acid near the active site influences inhibitor sensitivity. J Biol Chem. 2010 May 21;285(21):16330-40.
DM5D9YK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20299452

DM5D9YK	DI	DM5D9YK
DM5D9YK	DN	Choline
DM5D9YK	MI	DEL87ZT
DM5D9YK	MN	Choline/ethanolaminephosphotransferase 1 (CEPT1)
DM5D9YK	MT	DME
DM5D9YK	MA	Metabolism
DM5D9YK	RN	PC and PE synthesis: mixed micellar analysis of the cholinephosphotransferase and ethanolaminephosphotransferase activities of human choline/ethanolamine phosphotransferase 1 (CEPT1). Lipids. 2002 Jul;37(7):663-72.
DM5D9YK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12216837

DM5D9YK	DI	DM5D9YK
DM5D9YK	DN	Choline
DM5D9YK	MI	DTBPTJF
DM5D9YK	MN	Na(+)/Cl(-) betaine/GABA transporter (SLC6A12)
DM5D9YK	MT	DTP
DM5D9YK	MA	Substrate
DM5D9YK	RN	Interpreting metabolomic profiles using unbiased pathway models. PLoS Comput Biol. 2010 Feb 26;6(2):e1000692.
DM5D9YK	RU	http://www.ncbi.nlm.nih.gov/pubmed/20195502

DM5D9YK	DI	DM5D9YK
DM5D9YK	DN	Choline
DM5D9YK	MI	TTF4E0J
DM5D9YK	MN	Neuronal acetylcholine receptor alpha-2 (CHRNA2)
DM5D9YK	MT	DTT
DM5D9YK	MA	Inhibitor
DM5D9YK	RN	Pharmacology of the agonist binding sites of rat neuronal nicotinic receptor subtypes expressed in HEK 293 cells. Bioorg Med Chem Lett. 2004 Apr 19;14(8):1845-8.
DM5D9YK	RU	https://pubmed.ncbi.nlm.nih.gov/15050613

DM5D9YK	DI	DM5D9YK
DM5D9YK	DN	Choline
DM5D9YK	MI	DTT79CX
DM5D9YK	MN	Organic cation transporter 1 (SLC22A1)
DM5D9YK	MT	DTP
DM5D9YK	MA	Substrate
DM5D9YK	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM5D9YK	RU	https://doi.org/10.1007/s11095-012-0935-x

DM5D9YK	DI	DM5D9YK
DM5D9YK	DN	Choline
DM5D9YK	MI	DT9IDPW
DM5D9YK	MN	Organic cation transporter 2 (SLC22A2)
DM5D9YK	MT	DTP
DM5D9YK	MA	Substrate
DM5D9YK	RN	Ventricular choline transport: a role for organic cation transporter 2 expressed in choroid plexus. J Biol Chem. 2001 Nov 9;276(45):41611-9.
DM5D9YK	RU	http://www.ncbi.nlm.nih.gov/pubmed/11553644

DMW6U7K	DI	DMW6U7K
DMW6U7K	DN	CHOLINE IODIDE
DMW6U7K	MI	TT1RS9F
DMW6U7K	MN	Acetylcholinesterase (AChE)
DMW6U7K	MT	DTT
DMW6U7K	MA	Inhibitor
DMW6U7K	RN	Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors. J Med Chem. 1996 Dec 20;39(26):5064-71.
DMW6U7K	RU	https://pubmed.ncbi.nlm.nih.gov/8978837

DMVBQ20	DI	DMVBQ20
DMVBQ20	DN	Cholini alfosceras
DMVBQ20	MI	DEUL532
DMVBQ20	MN	Choline glycerophosphodiester phosphodiesterase (ENPP6)
DMVBQ20	MT	DME
DMVBQ20	MA	Metabolism
DMVBQ20	RN	Biochemical and molecular characterization of a novel choline-specific glycerophosphodiester phosphodiesterase belonging to the nucleotide pyrophosphatase/phosphodiesterase family. J Biol Chem. 2005 Jun 17;280(24):23084-93.
DMVBQ20	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15788404

DMZ956E	DI	DMZ956E
DMZ956E	DN	CHPG
DMZ956E	MI	TTHS256
DMZ956E	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMZ956E	MT	DTT
DMZ956E	MA	Agonist
DMZ956E	RN	Characterization of [(3)H]Quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections. J Neurochem. 2000 Dec;75(6):2590-601.
DMZ956E	RU	https://pubmed.ncbi.nlm.nih.gov/11080213

DMXKU73	DI	DMXKU73
DMXKU73	DN	CHR-4125
DMXKU73	MI	TTIYVQP
DMXKU73	MN	Polo-like kinase 1 (PLK1)
DMXKU73	MT	DTT
DMXKU73	MA	Inhibitor
DMXKU73	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2168).
DMXKU73	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2168

DMVDB7S	DI	DMVDB7S
DMVDB7S	DN	chroman 28
DMVDB7S	MI	TTGY8IW
DMVDB7S	MN	B2 bradykinin receptor (BDKRB2)
DMVDB7S	MT	DTT
DMVDB7S	MA	Antagonist
DMVDB7S	RN	Identification of a nonpeptidic and conformationally restricted bradykinin B1 receptor antagonist with anti-inflammatory activity. J Med Chem. 2007 Feb 22;50(4):607-10.
DMVDB7S	RU	https://pubmed.ncbi.nlm.nih.gov/17243660

DM5JHUN	DI	DM5JHUN
DM5JHUN	DN	CHROMOTROPATE
DM5JHUN	MI	TTELIN2
DM5JHUN	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DM5JHUN	MT	DTT
DM5JHUN	MA	Inhibitor
DM5JHUN	RN	Evans Blue and other dyes as protein tyrosine phosphatase inhibitors. Bioorg Med Chem Lett. 2004 Apr 19;14(8):1923-6.
DM5JHUN	RU	https://pubmed.ncbi.nlm.nih.gov/15050628

DMLEXN0	DI	DMLEXN0
DMLEXN0	DN	Chrysamine -G
DMLEXN0	MI	TTE4KHA
DMLEXN0	MN	Amyloid beta A4 protein (APP)
DMLEXN0	MT	DTT
DMLEXN0	MA	Inhibitor
DMLEXN0	RN	Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. J Med Chem. 2006 Oct 5;49(20):6111-9.
DMLEXN0	RU	https://pubmed.ncbi.nlm.nih.gov/17004725

DM7V2LG	DI	DM7V2LG
DM7V2LG	DN	Chrysin
DM7V2LG	MI	TTFBNVI
DM7V2LG	MN	Aldose reductase (AKR1B1)
DM7V2LG	MT	DTT
DM7V2LG	MA	Inhibitor
DM7V2LG	RN	Synthesis, characterization and vasculoprotective effects of nitric oxide-donating derivatives of chrysin. Bioorg Med Chem. 2010 May 1;18(9):3020-5.
DM7V2LG	RU	https://pubmed.ncbi.nlm.nih.gov/20395149

DM7V2LG	DI	DM7V2LG
DM7V2LG	DN	Chrysin
DM7V2LG	MI	TTSZLWK
DM7V2LG	MN	Aromatase (CYP19A1)
DM7V2LG	MT	DTT
DM7V2LG	MA	Inhibitor
DM7V2LG	RN	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
DM7V2LG	RU	https://pubmed.ncbi.nlm.nih.gov/20413308

DM7V2LG	DI	DM7V2LG
DM7V2LG	DN	Chrysin
DM7V2LG	MI	DTI7UX6
DM7V2LG	MN	Breast cancer resistance protein (ABCG2)
DM7V2LG	MT	DTP
DM7V2LG	MA	Substrate
DM7V2LG	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM7V2LG	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DM7V2LG	DI	DM7V2LG
DM7V2LG	DN	Chrysin
DM7V2LG	MI	TTO0FDJ
DM7V2LG	MN	Cyclin-dependent kinase 6 (CDK6)
DM7V2LG	MT	DTT
DM7V2LG	MA	Inhibitor
DM7V2LG	RN	Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin. J Med Chem. 2005 Feb 10;48(3):737-43.
DM7V2LG	RU	https://pubmed.ncbi.nlm.nih.gov/15689157

DM7V2LG	DI	DM7V2LG
DM7V2LG	DN	Chrysin
DM7V2LG	MI	TTI84H7
DM7V2LG	MN	Cytochrome P450 1B1 (CYP1B1)
DM7V2LG	MT	DTT
DM7V2LG	MA	Inhibitor
DM7V2LG	RN	Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5.
DM7V2LG	RU	https://pubmed.ncbi.nlm.nih.gov/20696580

DM7V2LG	DI	DM7V2LG
DM7V2LG	DN	Chrysin
DM7V2LG	MI	TTBE4IR
DM7V2LG	MN	Plasmodium Oxoacyl-[acyl-carrier protein] reductase (Malaria fabG)
DM7V2LG	MT	DTT
DM7V2LG	MA	Inhibitor
DM7V2LG	RN	Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
DM7V2LG	RU	https://pubmed.ncbi.nlm.nih.gov/16722653

DM7V2LG	DI	DM7V2LG
DM7V2LG	DN	Chrysin
DM7V2LG	MI	DEYGVN4
DM7V2LG	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM7V2LG	MT	DME
DM7V2LG	MA	Metabolism
DM7V2LG	RN	Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Biol Chem. 2004 Jan 9;279(2):1429-41.
DM7V2LG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14557274

DM7V2LG	DI	DM7V2LG
DM7V2LG	DN	Chrysin
DM7V2LG	MI	DEZO4N3
DM7V2LG	MN	UDP-glucuronosyltransferase 1A7 (UGT1A7)
DM7V2LG	MT	DME
DM7V2LG	MA	Metabolism
DM7V2LG	RN	Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Biol Chem. 2004 Jan 9;279(2):1429-41.
DM7V2LG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14557274

DM7V2LG	DI	DM7V2LG
DM7V2LG	DN	Chrysin
DM7V2LG	MI	DE2GB8N
DM7V2LG	MN	UDP-glucuronosyltransferase 1A8 (UGT1A8)
DM7V2LG	MT	DME
DM7V2LG	MA	Metabolism
DM7V2LG	RN	Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Biol Chem. 2004 Jan 9;279(2):1429-41.
DM7V2LG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14557274

DM7V2LG	DI	DM7V2LG
DM7V2LG	DN	Chrysin
DM7V2LG	MI	DE85D2P
DM7V2LG	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DM7V2LG	MT	DME
DM7V2LG	MA	Metabolism
DM7V2LG	RN	Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Biol Chem. 2004 Jan 9;279(2):1429-41.
DM7V2LG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14557274

DM96ECL	DI	DM96ECL
DM96ECL	DN	CHRYSOERIOL
DM96ECL	MI	TTI84H7
DM96ECL	MN	Cytochrome P450 1B1 (CYP1B1)
DM96ECL	MT	DTT
DM96ECL	MA	Inhibitor
DM96ECL	RN	Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5.
DM96ECL	RU	https://pubmed.ncbi.nlm.nih.gov/20696580

DM96ECL	DI	DM96ECL
DM96ECL	DN	CHRYSOERIOL
DM96ECL	MI	TT7RJY8
DM96ECL	MN	Xanthine dehydrogenase/oxidase (XDH)
DM96ECL	MT	DTT
DM96ECL	MA	Inhibitor
DM96ECL	RN	Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod. 1988 Mar-Apr;51(2):345-8.
DM96ECL	RU	https://pubmed.ncbi.nlm.nih.gov/3379415

DMT27QD	DI	DMT27QD
DMT27QD	DN	CHYMOSTATIN
DMT27QD	MI	TT8VUE0
DMT27QD	MN	Chymase (CYM)
DMT27QD	MT	DTT
DMT27QD	MA	Inhibitor
DMT27QD	RN	Identification of 6-substituted 4-arylsulfonyl-1,4-diazepane-2,5-diones as a novel scaffold for human chymase inhibitors. Bioorg Med Chem Lett. 2007 Jun 15;17(12):3431-4.
DMT27QD	RU	https://pubmed.ncbi.nlm.nih.gov/17419055

DMQ5CE1	DI	DMQ5CE1
DMQ5CE1	DN	CI-1015
DMQ5CE1	MI	TTCG0AL
DMQ5CE1	MN	Cholecystokinin receptor type A (CCKAR)
DMQ5CE1	MT	DTT
DMQ5CE1	MA	Antagonist
DMQ5CE1	RN	Second generation "peptoid" CCK-B receptor antagonists: identification and development of N-(adamantyloxycarbonyl)-alpha-methyl-(R)-tryptophan derivative (CI-1015) with an improved pharmacokinetic profile. J Med Chem. 1998 Jan 1;41(1):38-45.
DMQ5CE1	RU	https://pubmed.ncbi.nlm.nih.gov/9438020

DMQ5CE1	DI	DMQ5CE1
DMQ5CE1	DN	CI-1015
DMQ5CE1	MI	TTVFO0U
DMQ5CE1	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMQ5CE1	MT	DTT
DMQ5CE1	MA	Antagonist
DMQ5CE1	RN	Second generation "peptoid" CCK-B receptor antagonists: identification and development of N-(adamantyloxycarbonyl)-alpha-methyl-(R)-tryptophan derivative (CI-1015) with an improved pharmacokinetic profile. J Med Chem. 1998 Jan 1;41(1):38-45.
DMQ5CE1	RU	https://pubmed.ncbi.nlm.nih.gov/9438020

DMTKVDZ	DI	DMTKVDZ
DMTKVDZ	DN	CI-1031
DMTKVDZ	MI	TTCIHJA
DMTKVDZ	MN	Coagulation factor Xa (F10)
DMTKVDZ	MT	DTT
DMTKVDZ	MA	Modulator
DMTKVDZ	RN	Effects of ZK-807834, a novel inhibitor of factor Xa, on arterial and venous thrombosis in rabbits. J Cardiovasc Pharmacol. 2000 May;35(5):796-805.
DMTKVDZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/10813384

DMF3DZX	DI	DMF3DZX
DMF3DZX	DN	CI-1040
DMF3DZX	MI	TTTU902
DMF3DZX	MN	Checkpoint kinase-1 (CHK1)
DMF3DZX	MT	DTT
DMF3DZX	MA	Inhibitor
DMF3DZX	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMF3DZX	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMF3DZX	DI	DMF3DZX
DMF3DZX	DN	CI-1040
DMF3DZX	MI	TT4TQBX
DMF3DZX	MN	Extracellular signal-regulated kinase 2 (ERK2)
DMF3DZX	MT	DTT
DMF3DZX	MA	Inhibitor
DMF3DZX	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMF3DZX	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMF3DZX	DI	DMF3DZX
DMF3DZX	DN	CI-1040
DMF3DZX	MI	TTRSMW9
DMF3DZX	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMF3DZX	MT	DTT
DMF3DZX	MA	Inhibitor
DMF3DZX	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMF3DZX	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMF3DZX	DI	DMF3DZX
DMF3DZX	DN	CI-1040
DMF3DZX	MI	TT860QF
DMF3DZX	MN	LCK tyrosine protein kinase (LCK)
DMF3DZX	MT	DTT
DMF3DZX	MA	Inhibitor
DMF3DZX	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMF3DZX	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMF3DZX	DI	DMF3DZX
DMF3DZX	DN	CI-1040
DMF3DZX	MI	TTYT93M
DMF3DZX	MN	MAP kinase p38 (MAPK12)
DMF3DZX	MT	DTT
DMF3DZX	MA	Inhibitor
DMF3DZX	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMF3DZX	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMF3DZX	DI	DMF3DZX
DMF3DZX	DN	CI-1040
DMF3DZX	MI	TTQBCEJ
DMF3DZX	MN	MAPK/ERK kinase kinase 1 (MAP3K1)
DMF3DZX	MT	DTT
DMF3DZX	MA	Inhibitor
DMF3DZX	RN	Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
DMF3DZX	RU	https://pubmed.ncbi.nlm.nih.gov/11804650

DMF3DZX	DI	DMF3DZX
DMF3DZX	DN	CI-1040
DMF3DZX	MI	TTK1N5G
DMF3DZX	MN	MAPK/ERK kinase kinase 2 (MAP3K2)
DMF3DZX	MT	DTT
DMF3DZX	MA	Inhibitor
DMF3DZX	RN	Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
DMF3DZX	RU	https://pubmed.ncbi.nlm.nih.gov/11804650

DMF3DZX	DI	DMF3DZX
DMF3DZX	DN	CI-1040
DMF3DZX	MI	TTFJ8Q1
DMF3DZX	MN	Protein kinase C alpha (PRKCA)
DMF3DZX	MT	DTT
DMF3DZX	MA	Inhibitor
DMF3DZX	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMF3DZX	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMF3DZX	DI	DMF3DZX
DMF3DZX	DN	CI-1040
DMF3DZX	MI	TTWTSCV
DMF3DZX	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DMF3DZX	MT	DTT
DMF3DZX	MA	Inhibitor
DMF3DZX	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMF3DZX	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMF3DZX	DI	DMF3DZX
DMF3DZX	DN	CI-1040
DMF3DZX	MI	TTZN7RP
DMF3DZX	MN	Rho-associated protein kinase 1 (ROCK1)
DMF3DZX	MT	DTT
DMF3DZX	MA	Inhibitor
DMF3DZX	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMF3DZX	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMF3DZX	DI	DMF3DZX
DMF3DZX	DN	CI-1040
DMF3DZX	MI	TTG0U4H
DMF3DZX	MN	Ribosomal protein S6 kinase beta-1 (S6K1)
DMF3DZX	MT	DTT
DMF3DZX	MA	Inhibitor
DMF3DZX	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMF3DZX	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMF3DZX	DI	DMF3DZX
DMF3DZX	DN	CI-1040
DMF3DZX	MI	TTTV8EJ
DMF3DZX	MN	Serine/threonine-protein kinase Sgk1 (SGK1)
DMF3DZX	MT	DTT
DMF3DZX	MA	Inhibitor
DMF3DZX	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMF3DZX	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMF3DZX	DI	DMF3DZX
DMF3DZX	DN	CI-1040
DMF3DZX	MI	TTQBR95
DMF3DZX	MN	Stress-activated protein kinase 2a (p38 alpha)
DMF3DZX	MT	DTT
DMF3DZX	MA	Inhibitor
DMF3DZX	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMF3DZX	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMF3DZX	DI	DMF3DZX
DMF3DZX	DN	CI-1040
DMF3DZX	MI	TT73U6C
DMF3DZX	MN	Stress-activated protein kinase 2b (p38 beta)
DMF3DZX	MT	DTT
DMF3DZX	MA	Inhibitor
DMF3DZX	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMF3DZX	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMF3DZX	DI	DMF3DZX
DMF3DZX	DN	CI-1040
DMF3DZX	MI	TT0K6EO
DMF3DZX	MN	Stress-activated protein kinase JNK1 (JNK1)
DMF3DZX	MT	DTT
DMF3DZX	MA	Inhibitor
DMF3DZX	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMF3DZX	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMG5D6B	DI	DMG5D6B
DMG5D6B	DN	CI-1044
DMG5D6B	MI	TTZ97H5
DMG5D6B	MN	Phosphodiesterase 4A (PDE4A)
DMG5D6B	MT	DTT
DMG5D6B	MA	Inhibitor
DMG5D6B	RN	Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indol... J Med Chem. 2000 Dec 14;43(25):4850-67.
DMG5D6B	RU	https://pubmed.ncbi.nlm.nih.gov/11123995

DMG5D6B	DI	DMG5D6B
DMG5D6B	DN	CI-1044
DMG5D6B	MI	TTVIAT9
DMG5D6B	MN	Phosphodiesterase 4B (PDE4B)
DMG5D6B	MT	DTT
DMG5D6B	MA	Inhibitor
DMG5D6B	RN	Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indol... J Med Chem. 2000 Dec 14;43(25):4850-67.
DMG5D6B	RU	https://pubmed.ncbi.nlm.nih.gov/11123995

DM0RH3S	DI	DM0RH3S
DM0RH3S	DN	CI-218872
DM0RH3S	MI	TT1MPAY
DM0RH3S	MN	GABA(A) receptor alpha-1 (GABRA1)
DM0RH3S	MT	DTT
DM0RH3S	MA	Inhibitor
DM0RH3S	RN	Four amino acid exchanges convert a diazepam-insensitive, inverse agonist-preferring GABAA receptor into a diazepam-preferring GABAA receptor. J Med Chem. 1994 Dec 23;37(26):4576-80.
DM0RH3S	RU	https://pubmed.ncbi.nlm.nih.gov/7799410

DM0RH3S	DI	DM0RH3S
DM0RH3S	DN	CI-218872
DM0RH3S	MI	TTBMV1G
DM0RH3S	MN	GABA(A) receptor alpha-2 (GABRA2)
DM0RH3S	MT	DTT
DM0RH3S	MA	Inhibitor
DM0RH3S	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DM0RH3S	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DM0RH3S	DI	DM0RH3S
DM0RH3S	DN	CI-218872
DM0RH3S	MI	TT37EDJ
DM0RH3S	MN	GABA(A) receptor alpha-3 (GABRA3)
DM0RH3S	MT	DTT
DM0RH3S	MA	Inhibitor
DM0RH3S	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DM0RH3S	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DM0RH3S	DI	DM0RH3S
DM0RH3S	DN	CI-218872
DM0RH3S	MI	TTNZPQ1
DM0RH3S	MN	GABA(A) receptor alpha-5 (GABRA5)
DM0RH3S	MT	DTT
DM0RH3S	MA	Inhibitor
DM0RH3S	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DM0RH3S	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DM0RH3S	DI	DM0RH3S
DM0RH3S	DN	CI-218872
DM0RH3S	MI	TTZA1NY
DM0RH3S	MN	GABA(A) receptor beta-2 (GABRB2)
DM0RH3S	MT	DTT
DM0RH3S	MA	Inhibitor
DM0RH3S	RN	Four amino acid exchanges convert a diazepam-insensitive, inverse agonist-preferring GABAA receptor into a diazepam-preferring GABAA receptor. J Med Chem. 1994 Dec 23;37(26):4576-80.
DM0RH3S	RU	https://pubmed.ncbi.nlm.nih.gov/7799410

DM0RH3S	DI	DM0RH3S
DM0RH3S	DN	CI-218872
DM0RH3S	MI	TT06RH5
DM0RH3S	MN	GABA(A) receptor gamma-2 (GABRG2)
DM0RH3S	MT	DTT
DM0RH3S	MA	Inhibitor
DM0RH3S	RN	Four amino acid exchanges convert a diazepam-insensitive, inverse agonist-preferring GABAA receptor into a diazepam-preferring GABAA receptor. J Med Chem. 1994 Dec 23;37(26):4576-80.
DM0RH3S	RU	https://pubmed.ncbi.nlm.nih.gov/7799410

DM0RH3S	DI	DM0RH3S
DM0RH3S	DN	CI-218872
DM0RH3S	MI	TTNJYV2
DM0RH3S	MN	Gamma-aminobutyric acid receptor (GAR)
DM0RH3S	MT	DTT
DM0RH3S	MA	Inhibitor
DM0RH3S	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DM0RH3S	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DMWE1N8	DI	DMWE1N8
DMWE1N8	DN	Cibacron blue
DMWE1N8	MI	TTCYE56
DMWE1N8	MN	Glutathione-dependent PGD synthase (HPGDS)
DMWE1N8	MT	DTT
DMWE1N8	MA	Inhibitor
DMWE1N8	RN	A novel method for screening the glutathione transferase inhibitors. BMC Biochem. 2009 Mar 16;10:6.
DMWE1N8	RU	https://pubmed.ncbi.nlm.nih.gov/19291299

DM7ZJ4H	DI	DM7ZJ4H
DM7ZJ4H	DN	cicaprost
DM7ZJ4H	MI	TTOFYT1
DM7ZJ4H	MN	Prostacyclin receptor (PTGIR)
DM7ZJ4H	MT	DTT
DM7ZJ4H	MA	Agonist
DM7ZJ4H	RN	Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
DM7ZJ4H	RU	https://pubmed.ncbi.nlm.nih.gov/9313928

DM7ZJ4H	DI	DM7ZJ4H
DM7ZJ4H	DN	cicaprost
DM7ZJ4H	MI	TTG1QMU
DM7ZJ4H	MN	Prostaglandin E2 receptor EP1 (PTGER1)
DM7ZJ4H	MT	DTT
DM7ZJ4H	MA	Agonist
DM7ZJ4H	RN	The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
DM7ZJ4H	RU	https://pubmed.ncbi.nlm.nih.gov/10634944

DM7ZJ4H	DI	DM7ZJ4H
DM7ZJ4H	DN	cicaprost
DM7ZJ4H	MI	TT1ZAVI
DM7ZJ4H	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DM7ZJ4H	MT	DTT
DM7ZJ4H	MA	Agonist
DM7ZJ4H	RN	Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
DM7ZJ4H	RU	https://pubmed.ncbi.nlm.nih.gov/9313928

DM7ZJ4H	DI	DM7ZJ4H
DM7ZJ4H	DN	cicaprost
DM7ZJ4H	MI	TTPNGDE
DM7ZJ4H	MN	Prostaglandin E2 receptor EP3 (PTGER3)
DM7ZJ4H	MT	DTT
DM7ZJ4H	MA	Agonist
DM7ZJ4H	RN	Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
DM7ZJ4H	RU	https://pubmed.ncbi.nlm.nih.gov/9313928

DM7ZJ4H	DI	DM7ZJ4H
DM7ZJ4H	DN	cicaprost
DM7ZJ4H	MI	TT79WV3
DM7ZJ4H	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DM7ZJ4H	MT	DTT
DM7ZJ4H	MA	Agonist
DM7ZJ4H	RN	The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
DM7ZJ4H	RU	https://pubmed.ncbi.nlm.nih.gov/10634944

DM27S6E	DI	DM27S6E
DM27S6E	DN	cicloprolol
DM27S6E	MI	TTMXGCW
DM27S6E	MN	Adrenergic receptor beta-3 (ADRB3)
DM27S6E	MT	DTT
DM27S6E	MA	Antagonist
DM27S6E	RN	LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors. Eur J Pharmacol. 1999 Feb 19;367(2-3):431-5.
DM27S6E	RU	https://pubmed.ncbi.nlm.nih.gov/10079020

DMP6BU3	DI	DMP6BU3
DMP6BU3	DN	Ciclosporin
DMP6BU3	MI	TT95SAZ
DMP6BU3	MN	HUMAN cyclophilin D (CYP3)
DMP6BU3	MT	DTT
DMP6BU3	MA	Inhibitor
DMP6BU3	RN	Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150.
DMP6BU3	RU	https://pubmed.ncbi.nlm.nih.gov/32127666

DMK6YOP	DI	DMK6YOP
DMK6YOP	DN	CID1172084
DMK6YOP	MI	TTNET8J
DMK6YOP	MN	G-protein coupled receptor 55 (GPR55)
DMK6YOP	MT	DTT
DMK6YOP	MA	Agonist
DMK6YOP	RN	Identification of the GPR55 agonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry. 2011 Jun 28;50(25):5633-47.
DMK6YOP	RU	https://pubmed.ncbi.nlm.nih.gov/21534610

DMLWZRT	DI	DMLWZRT
DMLWZRT	DN	CID16020046
DMLWZRT	MI	TTNET8J
DMLWZRT	MN	G-protein coupled receptor 55 (GPR55)
DMLWZRT	MT	DTT
DMLWZRT	MA	Antagonist
DMLWZRT	RN	A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function. J Pharmacol Exp Ther. 2013 Jul;346(1):54-66.
DMLWZRT	RU	https://pubmed.ncbi.nlm.nih.gov/23639801

DMP6I98	DI	DMP6I98
DMP6I98	DN	CID16197121
DMP6I98	MI	TT2AP5B
DMP6I98	MN	Ras converting CAAX endopeptidase 1 (RCE1)
DMP6I98	MT	DTT
DMP6I98	MA	Inhibitor
DMP6I98	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2412).
DMP6I98	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2412

DMEGZY7	DI	DMEGZY7
DMEGZY7	DN	CID1792197
DMEGZY7	MI	TTNET8J
DMEGZY7	MN	G-protein coupled receptor 55 (GPR55)
DMEGZY7	MT	DTT
DMEGZY7	MA	Agonist
DMEGZY7	RN	Identification of the GPR55 agonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry. 2011 Jun 28;50(25):5633-47.
DMEGZY7	RU	https://pubmed.ncbi.nlm.nih.gov/21534610

DMA3F7S	DI	DMA3F7S
DMA3F7S	DN	CID2440433
DMA3F7S	MI	TTNET8J
DMA3F7S	MN	G-protein coupled receptor 55 (GPR55)
DMA3F7S	MT	DTT
DMA3F7S	MA	Agonist
DMA3F7S	RN	Identification of the GPR55 agonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry. 2011 Jun 28;50(25):5633-47.
DMA3F7S	RU	https://pubmed.ncbi.nlm.nih.gov/21534610

DMSHIQA	DI	DMSHIQA
DMSHIQA	DN	CID755673
DMSHIQA	MI	TTSLUMT
DMSHIQA	MN	Protein kinase D (PRKD1)
DMSHIQA	MT	DTT
DMSHIQA	MA	Inhibitor
DMSHIQA	RN	Protein kinase D as a potential new target for cancer therapy. Biochim Biophys Acta. 2010 Dec;1806(2):183-92.
DMSHIQA	RU	https://pubmed.ncbi.nlm.nih.gov/20580776

DMP35OM	DI	DMP35OM
DMP35OM	DN	CIFEA
DMP35OM	MI	TT0WAIE
DMP35OM	MN	Melatonin receptor type 1A (MTNR1A)
DMP35OM	MT	DTT
DMP35OM	MA	Agonist
DMP35OM	RN	1,6-Dihydro-2H-indeno[5,4-b]furan derivatives: design, synthesis, and pharmacological characterization of a novel class of highly potent MT selective agonists. J Med Chem. 2011 May 12;54(9):3436-44.
DMP35OM	RU	https://pubmed.ncbi.nlm.nih.gov/21473625

DMBVIKY	DI	DMBVIKY
DMBVIKY	DN	Cilostamide
DMBVIKY	MI	TTZCG4L
DMBVIKY	MN	Phosphodiesterase 3 (PDE3)
DMBVIKY	MT	DTT
DMBVIKY	MA	Inhibitor
DMBVIKY	RN	Phosphodiesterase 3 as a potential target for therapy of malignant tumors in the submandibular gland. Anticancer Drugs. 2001 Jan;12(1):79-83.
DMBVIKY	RU	https://pubmed.ncbi.nlm.nih.gov/11272291

DM6TJFU	DI	DM6TJFU
DM6TJFU	DN	CINANSERIN
DM6TJFU	MI	TTJQOD7
DM6TJFU	MN	5-HT 2A receptor (HTR2A)
DM6TJFU	MT	DTT
DM6TJFU	MA	Inhibitor
DM6TJFU	RN	Central serotonin receptors as targets for drug research. J Med Chem. 1987 Jan;30(1):1-12.
DM6TJFU	RU	https://pubmed.ncbi.nlm.nih.gov/3543362

DMOJ917	DI	DMOJ917
DMOJ917	DN	Cinchoninic acid
DMOJ917	MI	TT3PQ2Y
DMOJ917	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DMOJ917	MT	DTT
DMOJ917	MA	Inhibitor
DMOJ917	RN	Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Chem Biol Interact. 2000 Jan 3;124(1):61-76.
DMOJ917	RU	https://pubmed.ncbi.nlm.nih.gov/10658902

DMZDUXG	DI	DMZDUXG
DMZDUXG	DN	cinnamaldehyde
DMZDUXG	MI	TTELV3W
DMZDUXG	MN	Transformation-sensitive protein p120 (TRPA1)
DMZDUXG	MT	DTT
DMZDUXG	MA	Activator
DMZDUXG	RN	Noxious cold ion channel TRPA1 is activated by pungent compounds and bradykinin. Neuron. 2004 Mar 25;41(6):849-57.
DMZDUXG	RU	https://pubmed.ncbi.nlm.nih.gov/15046718

DMZDUXG	DI	DMZDUXG
DMZDUXG	DN	cinnamaldehyde
DMZDUXG	MI	TT946IA
DMZDUXG	MN	Transient receptor potential cation channel V3 (TRPV3)
DMZDUXG	MT	DTT
DMZDUXG	MA	Activator
DMZDUXG	RN	More than cool: promiscuous relationships of menthol and other sensory compounds. Mol Cell Neurosci. 2006 Aug;32(4):335-43.
DMZDUXG	RU	https://pubmed.ncbi.nlm.nih.gov/16829128

DM340FH	DI	DM340FH
DM340FH	DN	Cinnamic acid
DM340FH	MI	TTWNV8U
DM340FH	MN	Nicotinic acid receptor (HCAR2)
DM340FH	MT	DTT
DM340FH	MA	Agonist
DM340FH	RN	Phenolic acids suppress adipocyte lipolysis via activation of the nicotinic acid receptor GPR109A (HM74a/PUMA-G). J Lipid Res. 2009 May;50(5):908-14.
DM340FH	RU	https://pubmed.ncbi.nlm.nih.gov/19136666

DM340FH	DI	DM340FH
DM340FH	DN	Cinnamic acid
DM340FH	MI	TTXMI0C
DM340FH	MN	Phosphomevalonate kinase (PMVK)
DM340FH	MT	DTT
DM340FH	MA	Inhibitor
DM340FH	RN	Inhibition of rat liver mevalonate pyrophosphate decarboxylase and mevalonate phosphate kinase by phenyl and phenolic compounds. Biochem J. 1979 Jul 1;181(1):143-51.
DM340FH	RU	https://pubmed.ncbi.nlm.nih.gov/226078

DMZ2WS9	DI	DMZ2WS9
DMZ2WS9	DN	CIP-137401
DMZ2WS9	MI	TTROQ37
DMZ2WS9	MN	MAPK/ERK kinase kinase (MAP3K)
DMZ2WS9	MT	DTT
DMZ2WS9	MA	Inhibitor
DMZ2WS9	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2063).
DMZ2WS9	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2063

DM9N8WM	DI	DM9N8WM
DM9N8WM	DN	Ciproxifan
DM9N8WM	MI	TTNXLKE
DM9N8WM	MN	5-HT 3 receptor (5HT3R)
DM9N8WM	MT	DTT
DM9N8WM	MA	Antagonist
DM9N8WM	RN	The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20.
DM9N8WM	RU	https://pubmed.ncbi.nlm.nih.gov/15665857

DM9N8WM	DI	DM9N8WM
DM9N8WM	DN	Ciproxifan
DM9N8WM	MI	TTWG9A4
DM9N8WM	MN	Adrenergic receptor alpha-2A (ADRA2A)
DM9N8WM	MT	DTT
DM9N8WM	MA	Antagonist
DM9N8WM	RN	The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20.
DM9N8WM	RU	https://pubmed.ncbi.nlm.nih.gov/15665857

DM9N8WM	DI	DM9N8WM
DM9N8WM	DN	Ciproxifan
DM9N8WM	MI	TT2NUT5
DM9N8WM	MN	Adrenergic receptor alpha-2C (ADRA2C)
DM9N8WM	MT	DTT
DM9N8WM	MA	Antagonist
DM9N8WM	RN	The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20.
DM9N8WM	RU	https://pubmed.ncbi.nlm.nih.gov/15665857

DM9N8WM	DI	DM9N8WM
DM9N8WM	DN	Ciproxifan
DM9N8WM	MI	TT9JNIC
DM9N8WM	MN	Histamine H3 receptor (H3R)
DM9N8WM	MT	DTT
DM9N8WM	MA	Antagonist
DM9N8WM	RN	The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20.
DM9N8WM	RU	https://pubmed.ncbi.nlm.nih.gov/15665857

DMU6JOK	DI	DMU6JOK
DMU6JOK	DN	cirazoline
DMU6JOK	MI	TT2NUT5
DMU6JOK	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMU6JOK	MT	DTT
DMU6JOK	MA	Agonist
DMU6JOK	RN	Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes. Mol Pharmacol. 1994 Nov;46(5):929-36.
DMU6JOK	RU	https://pubmed.ncbi.nlm.nih.gov/7969082

DMM10TG	DI	DMM10TG
DMM10TG	DN	Cirsimarin
DMM10TG	MI	TTK25J1
DMM10TG	MN	Adenosine A1 receptor (ADORA1)
DMM10TG	MT	DTT
DMM10TG	MA	Inhibitor
DMM10TG	RN	Adenosine-1 active ligands: cirsimarin, a flavone glycoside from Microtea debilis. J Nat Prod. 1997 Jun;60(6):638-41.
DMM10TG	RU	https://pubmed.ncbi.nlm.nih.gov/9214739

DMA3N9R	DI	DMA3N9R
DMA3N9R	DN	CIRSIMARITIN
DMA3N9R	MI	TTJFY5U
DMA3N9R	MN	Adenosine A3 receptor (ADORA3)
DMA3N9R	MT	DTT
DMA3N9R	MA	Inhibitor
DMA3N9R	RN	Interactions of flavonoids and other phytochemicals with adenosine receptors. J Med Chem. 1996 Feb 2;39(3):781-8.
DMA3N9R	RU	https://pubmed.ncbi.nlm.nih.gov/8576921

DMWX6J0	DI	DMWX6J0
DMWX6J0	DN	Cis-(+/-)-2-Fluoro-1,2-diphenylcyclopropylamine
DMWX6J0	MI	TT3WG5C
DMWX6J0	MN	Monoamine oxidase type A (MAO-A)
DMWX6J0	MT	DTT
DMWX6J0	MA	Inhibitor
DMWX6J0	RN	Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases... Bioorg Med Chem. 2008 Aug 1;16(15):7148-66.
DMWX6J0	RU	https://pubmed.ncbi.nlm.nih.gov/18640844

DMV3RYK	DI	DMV3RYK
DMV3RYK	DN	Cis-[PtCl(NH3)2(N7-acyclovir)]+
DMV3RYK	MI	TTJP4SM
DMV3RYK	MN	Bacterial Penicillin binding protein (Bact PBP)
DMV3RYK	MT	DTT
DMV3RYK	RN	DNA interactions of a novel platinum drug, cis-[PtCl(NH3)2(N7-acyclovir)]+. Mol Pharmacol. 1998 May;53(5):846-55.
DMV3RYK	RU	https://pubmed.ncbi.nlm.nih.gov/9584210

DMP3F0D	DI	DMP3F0D
DMP3F0D	DN	Cis-1-adamantan-1-yl-3-(4-hydroxycyclohexyl)urea
DMP3F0D	MI	TT7WVHI
DMP3F0D	MN	Soluble epoxide hydrolase (EPHX2)
DMP3F0D	MT	DTT
DMP3F0D	MA	Inhibitor
DMP3F0D	RN	Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem. 2007 Aug 9;50(16):3825-40.
DMP3F0D	RU	https://pubmed.ncbi.nlm.nih.gov/17616115

DM8NX3Q	DI	DM8NX3Q
DM8NX3Q	DN	Cis-1-adamantan-1-yl-3-(4-methoxycyclohexyl)urea
DM8NX3Q	MI	TT7WVHI
DM8NX3Q	MN	Soluble epoxide hydrolase (EPHX2)
DM8NX3Q	MT	DTT
DM8NX3Q	MA	Inhibitor
DM8NX3Q	RN	Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem. 2007 Aug 9;50(16):3825-40.
DM8NX3Q	RU	https://pubmed.ncbi.nlm.nih.gov/17616115

DMVRF9H	DI	DMVRF9H
DMVRF9H	DN	Cis-2-(4-chlorophenyl)-2-fluorocyclopropanamine
DMVRF9H	MI	TTGP7BY
DMVRF9H	MN	Monoamine oxidase type B (MAO-B)
DMVRF9H	MT	DTT
DMVRF9H	MA	Inhibitor
DMVRF9H	RN	Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases... Bioorg Med Chem. 2008 Aug 1;16(15):7148-66.
DMVRF9H	RU	https://pubmed.ncbi.nlm.nih.gov/18640844

DMPZ1LY	DI	DMPZ1LY
DMPZ1LY	DN	Cis-2-(para-fluorophenyl)cyclopropylamine
DMPZ1LY	MI	TTGP7BY
DMPZ1LY	MN	Monoamine oxidase type B (MAO-B)
DMPZ1LY	MT	DTT
DMPZ1LY	MA	Inhibitor
DMPZ1LY	RN	Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases... Bioorg Med Chem. 2008 Aug 1;16(15):7148-66.
DMPZ1LY	RU	https://pubmed.ncbi.nlm.nih.gov/18640844

DMJ3HG9	DI	DMJ3HG9
DMJ3HG9	DN	Cis-2,6-dimethyl-1-methyl sulfonyl piperidine
DMJ3HG9	MI	TT1RS9F
DMJ3HG9	MN	Acetylcholinesterase (AChE)
DMJ3HG9	MT	DTT
DMJ3HG9	MA	Inhibitor
DMJ3HG9	RN	Active site directed docking studies: synthesis and pharmacological evaluation of cis-2,6-dimethyl piperidine sulfonamides as inhibitors of acetylc... Eur J Med Chem. 2009 Oct;44(10):4057-62.
DMJ3HG9	RU	https://pubmed.ncbi.nlm.nih.gov/19493592

DMF10WT	DI	DMF10WT
DMF10WT	DN	Cis-2-aminocyclohexylcarbamoylphosphonic acid
DMF10WT	MI	TTLM12X
DMF10WT	MN	Matrix metalloproteinase-2 (MMP-2)
DMF10WT	MT	DTT
DMF10WT	MA	Inhibitor
DMF10WT	RN	Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic mat... J Med Chem. 2008 Mar 13;51(5):1406-14.
DMF10WT	RU	https://pubmed.ncbi.nlm.nih.gov/18257543

DMNG9B2	DI	DMNG9B2
DMNG9B2	DN	Cis-2-Fluoro-2-(4-methoxyphenyl)cyclopropylamine
DMNG9B2	MI	TTGP7BY
DMNG9B2	MN	Monoamine oxidase type B (MAO-B)
DMNG9B2	MT	DTT
DMNG9B2	MA	Inhibitor
DMNG9B2	RN	Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases... Bioorg Med Chem. 2008 Aug 1;16(15):7148-66.
DMNG9B2	RU	https://pubmed.ncbi.nlm.nih.gov/18640844

DMFSPHE	DI	DMFSPHE
DMFSPHE	DN	Cis-2-fluoro-2-phenylcyclopropanamine
DMFSPHE	MI	TTGP7BY
DMFSPHE	MN	Monoamine oxidase type B (MAO-B)
DMFSPHE	MT	DTT
DMFSPHE	MA	Inhibitor
DMFSPHE	RN	Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases... Bioorg Med Chem. 2008 Aug 1;16(15):7148-66.
DMFSPHE	RU	https://pubmed.ncbi.nlm.nih.gov/18640844

DMKZ32J	DI	DMKZ32J
DMKZ32J	DN	Cis-2-phenylcyclopropylamine
DMKZ32J	MI	TT3WG5C
DMKZ32J	MN	Monoamine oxidase type A (MAO-A)
DMKZ32J	MT	DTT
DMKZ32J	MA	Inhibitor
DMKZ32J	RN	Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases... Bioorg Med Chem. 2008 Aug 1;16(15):7148-66.
DMKZ32J	RU	https://pubmed.ncbi.nlm.nih.gov/18640844

DMKZ32J	DI	DMKZ32J
DMKZ32J	DN	Cis-2-phenylcyclopropylamine
DMKZ32J	MI	TTGP7BY
DMKZ32J	MN	Monoamine oxidase type B (MAO-B)
DMKZ32J	MT	DTT
DMKZ32J	MA	Inhibitor
DMKZ32J	RN	Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases... Bioorg Med Chem. 2008 Aug 1;16(15):7148-66.
DMKZ32J	RU	https://pubmed.ncbi.nlm.nih.gov/18640844

DMQ0EA7	DI	DMQ0EA7
DMQ0EA7	DN	cis-3-ACPBPA
DMQ0EA7	MI	TT6XFEU
DMQ0EA7	MN	GABA(A) receptor rho1 (GABRR1)
DMQ0EA7	MT	DTT
DMQ0EA7	MA	Antagonist
DMQ0EA7	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 420).
DMQ0EA7	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=420

DMQ0EA7	DI	DMQ0EA7
DMQ0EA7	DN	cis-3-ACPBPA
DMQ0EA7	MI	TTQMXLS
DMQ0EA7	MN	GABA(A) receptor rho2 (GABRR2)
DMQ0EA7	MT	DTT
DMQ0EA7	MA	Antagonist
DMQ0EA7	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 421).
DMQ0EA7	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=421

DMQ0EA7	DI	DMQ0EA7
DMQ0EA7	DN	cis-3-ACPBPA
DMQ0EA7	MI	TT4N6D8
DMQ0EA7	MN	GABA(A) receptor rho3 (GABRR3)
DMQ0EA7	MT	DTT
DMQ0EA7	MA	Antagonist
DMQ0EA7	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 422).
DMQ0EA7	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=422

DMTH4BG	DI	DMTH4BG
DMTH4BG	DN	Cis-3-phenoxy-2,3-dihydro-1H-inden-1-amine
DMTH4BG	MI	TTVBI8W
DMTH4BG	MN	Dopamine transporter (DAT)
DMTH4BG	MT	DTT
DMTH4BG	MA	Inhibitor
DMTH4BG	RN	Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI). Bioorg Med Chem Lett. 2008 Jul 15;18(14):4224-7.
DMTH4BG	RU	https://pubmed.ncbi.nlm.nih.gov/18550369

DMTH4BG	DI	DMTH4BG
DMTH4BG	DN	Cis-3-phenoxy-2,3-dihydro-1H-inden-1-amine
DMTH4BG	MI	TTAWNKZ
DMTH4BG	MN	Norepinephrine transporter (NET)
DMTH4BG	MT	DTT
DMTH4BG	MA	Inhibitor
DMTH4BG	RN	Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI). Bioorg Med Chem Lett. 2008 Jul 15;18(14):4224-7.
DMTH4BG	RU	https://pubmed.ncbi.nlm.nih.gov/18550369

DMX07BG	DI	DMX07BG
DMX07BG	DN	Cis-4-hydroxynipecotic acid
DMX07BG	MI	TTV9MQG
DMX07BG	MN	Gamma-aminobutyric acid uptake (GABAU)
DMX07BG	MT	DTT
DMX07BG	MA	Inhibitor
DMX07BG	RN	GABA uptake inhibitors. Synthesis and effects on audiogenic seizures of ester prodrugs of nipecotic acid, guvacine and cis-4-hydroxynipecotic acid. Drug Des Deliv. 1987 Sep;2(1):9-21.
DMX07BG	RU	https://pubmed.ncbi.nlm.nih.gov/3509345

DMRFTB5	DI	DMRFTB5
DMRFTB5	DN	Cis-4-hydroxytamoxifen
DMRFTB5	MI	DEYGVN4
DMRFTB5	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMRFTB5	MT	DME
DMRFTB5	MA	Metabolism
DMRFTB5	RN	Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos. 2007 Nov;35(11):2006-14.
DMRFTB5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17664247

DMRFTB5	DI	DMRFTB5
DMRFTB5	DN	Cis-4-hydroxytamoxifen
DMRFTB5	MI	DE2GB8N
DMRFTB5	MN	UDP-glucuronosyltransferase 1A8 (UGT1A8)
DMRFTB5	MT	DME
DMRFTB5	MA	Metabolism
DMRFTB5	RN	Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos. 2007 Nov;35(11):2006-14.
DMRFTB5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17664247

DMQUB19	DI	DMQUB19
DMQUB19	DN	Cis-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH
DMQUB19	MI	TT27RFC
DMQUB19	MN	Opioid receptor delta (OPRD1)
DMQUB19	MT	DTT
DMQUB19	MA	Inhibitor
DMQUB19	RN	Synthesis of stable and potent delta/mu opioid peptides: analogues of H-Tyr-c[D-Cys-Gly-Phe-D-Cys]-OH by ring-closing metathesis. J Med Chem. 2007 Jun 28;50(13):3138-42.
DMQUB19	RU	https://pubmed.ncbi.nlm.nih.gov/17539621

DMQUB19	DI	DMQUB19
DMQUB19	DN	Cis-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH
DMQUB19	MI	TTQW87Y
DMQUB19	MN	Opioid receptor kappa (OPRK1)
DMQUB19	MT	DTT
DMQUB19	MA	Inhibitor
DMQUB19	RN	Synthesis of stable and potent delta/mu opioid peptides: analogues of H-Tyr-c[D-Cys-Gly-Phe-D-Cys]-OH by ring-closing metathesis. J Med Chem. 2007 Jun 28;50(13):3138-42.
DMQUB19	RU	https://pubmed.ncbi.nlm.nih.gov/17539621

DMQUB19	DI	DMQUB19
DMQUB19	DN	Cis-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH
DMQUB19	MI	TTKWM86
DMQUB19	MN	Opioid receptor mu (MOP)
DMQUB19	MT	DTT
DMQUB19	MA	Inhibitor
DMQUB19	RN	Synthesis of stable and potent delta/mu opioid peptides: analogues of H-Tyr-c[D-Cys-Gly-Phe-D-Cys]-OH by ring-closing metathesis. J Med Chem. 2007 Jun 28;50(13):3138-42.
DMQUB19	RU	https://pubmed.ncbi.nlm.nih.gov/17539621

DM75SO4	DI	DM75SO4
DM75SO4	DN	Cis-N,5-dibenzyl-6-oxomorpholine-3-carboxamide
DM75SO4	MI	TT729IR
DM75SO4	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DM75SO4	MT	DTT
DM75SO4	MA	Inhibitor
DM75SO4	RN	Morpholin-2-one derivatives as novel selective T-type Ca2+ channel blockers. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5244-8.
DM75SO4	RU	https://pubmed.ncbi.nlm.nih.gov/16876404

DM75SO4	DI	DM75SO4
DM75SO4	DN	Cis-N,5-dibenzyl-6-oxomorpholine-3-carboxamide
DM75SO4	MI	TTZPWGN
DM75SO4	MN	Voltage-gated calcium channel alpha Cav3.2 (CACNA1H)
DM75SO4	MT	DTT
DM75SO4	MA	Inhibitor
DM75SO4	RN	Morpholin-2-one derivatives as novel selective T-type Ca2+ channel blockers. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5244-8.
DM75SO4	RU	https://pubmed.ncbi.nlm.nih.gov/16876404

DM7TU1I	DI	DM7TU1I
DM7TU1I	DN	Cis-N-oleoylcyclopropanolamide
DM7TU1I	MI	TT6OEDT
DM7TU1I	MN	Cannabinoid receptor 1 (CB1)
DM7TU1I	MT	DTT
DM7TU1I	MA	Inhibitor
DM7TU1I	RN	Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. J Med Chem. 2009 May 14;52(9):3001-9.
DM7TU1I	RU	https://pubmed.ncbi.nlm.nih.gov/19361197

DM7TU1I	DI	DM7TU1I
DM7TU1I	DN	Cis-N-oleoylcyclopropanolamide
DM7TU1I	MI	TTMSFAW
DM7TU1I	MN	Cannabinoid receptor 2 (CB2)
DM7TU1I	MT	DTT
DM7TU1I	MA	Inhibitor
DM7TU1I	RN	Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. J Med Chem. 2009 May 14;52(9):3001-9.
DM7TU1I	RU	https://pubmed.ncbi.nlm.nih.gov/19361197

DM0N634	DI	DM0N634
DM0N634	DN	CITCO
DM0N634	MI	TTRANFM
DM0N634	MN	Orphan nuclear receptor NR1I3 (NR1I3)
DM0N634	MT	DTT
DM0N634	MA	Agonist
DM0N634	RN	Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes. J Biol Chem. 2003 May 9;278(19):17277-83.
DM0N634	RU	https://pubmed.ncbi.nlm.nih.gov/12611900

DMCIM9A	DI	DMCIM9A
DMCIM9A	DN	Citraconic acid
DMCIM9A	MI	TTHDSE2
DMCIM9A	MN	Bacterial Fumarate reductase flavoprotein (Bact frdA)
DMCIM9A	MT	DTT
DMCIM9A	MA	Inhibitor
DMCIM9A	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMCIM9A	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DM53ZGY	DI	DM53ZGY
DM53ZGY	DN	citral
DM53ZGY	MI	TTBECWA
DM53ZGY	MN	Transient receptor potential cation channel V2 (TRPV2)
DM53ZGY	MT	DTT
DM53ZGY	MA	Blocker (channel blocker)
DM53ZGY	RN	Citral sensing by Transient [corrected] receptor potential channels in dorsal root ganglion neurons. PLoS One. 2008 May 7;3(5):e2082.
DM53ZGY	RU	https://pubmed.ncbi.nlm.nih.gov/18461159

DM53ZGY	DI	DM53ZGY
DM53ZGY	DN	citral
DM53ZGY	MI	TT946IA
DM53ZGY	MN	Transient receptor potential cation channel V3 (TRPV3)
DM53ZGY	MT	DTT
DM53ZGY	MA	Activator
DM53ZGY	RN	Citral sensing by Transient [corrected] receptor potential channels in dorsal root ganglion neurons. PLoS One. 2008 May 7;3(5):e2082.
DM53ZGY	RU	https://pubmed.ncbi.nlm.nih.gov/18461159

DM80YI7	DI	DM80YI7
DM80YI7	DN	citric acid
DM80YI7	MI	TTTSOUD
DM80YI7	MN	Candida Cytochrome P450 51 (Candi ERG11)
DM80YI7	MT	DTT
DM80YI7	MA	Binder
DM80YI7	RN	Chemosensitization of fluconazole resistance in Saccharomyces cerevisiae and pathogenic fungi by a D-octapeptide derivative. Antimicrob Agents Chemother. 2004 Apr;48(4):1256-71.
DM80YI7	RU	https://pubmed.ncbi.nlm.nih.gov/15047528

DM80YI7	DI	DM80YI7
DM80YI7	DN	citric acid
DM80YI7	MI	TTAHD89
DM80YI7	MN	Polycystic kidney disease 2-like 1 (TRPP2)
DM80YI7	MT	DTT
DM80YI7	MA	Activator
DM80YI7	RN	Transient receptor potential family members PKD1L3 and PKD2L1 form a candidate sour taste receptor. Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12569-74.
DM80YI7	RU	https://pubmed.ncbi.nlm.nih.gov/16891422

DM80YI7	DI	DM80YI7
DM80YI7	DN	citric acid
DM80YI7	MI	TTKP2SU
DM80YI7	MN	Transient receptor potential cation channel V4 (TRPV4)
DM80YI7	MT	DTT
DM80YI7	MA	Activator
DM80YI7	RN	Impaired pressure sensation in mice lacking TRPV4. J Biol Chem. 2003 Jun 20;278(25):22664-8.
DM80YI7	RU	https://pubmed.ncbi.nlm.nih.gov/12692122

DMH204Y	DI	DMH204Y
DMH204Y	DN	CKD-533
DMH204Y	MI	TTJ0IQB
DMH204Y	MN	Phosphodiesterase 5A (PDE5A)
DMH204Y	MT	DTT
DMH204Y	MA	Inhibitor
DMH204Y	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1304).
DMH204Y	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1304

DML8MSC	DI	DML8MSC
DML8MSC	DN	CL 385319
DML8MSC	MI	TTF4CAM
DML8MSC	MN	Influenza Hemagglutinin (Influ HA)
DML8MSC	MT	DTT
DML8MSC	MA	Inhibitor
DML8MSC	RN	Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17736-41.
DML8MSC	RU	https://pubmed.ncbi.nlm.nih.gov/19004788

DMB6XUY	DI	DMB6XUY
DMB6XUY	DN	CL-205086
DMB6XUY	MI	DEX5D46
DMB6XUY	MN	Oxygen-insensitive NADPH nitroreductase A (nfsA)
DMB6XUY	MT	DME
DMB6XUY	MA	Metabolism
DMB6XUY	RN	Delamanid is not metabolized by Salmonella or human nitroreductases: a possible mechanism for the lack of mutagenicity. Regul Toxicol Pharmacol. 2017 Mar;84:1-8.
DMB6XUY	RU	https://pubmed.ncbi.nlm.nih.gov/27988333

DMB6XUY	DI	DMB6XUY
DMB6XUY	DN	CL-205086
DMB6XUY	MI	DEOWDK1
DMB6XUY	MN	Oxygen-insensitive NADPH nitroreductase B (nfsB)
DMB6XUY	MT	DME
DMB6XUY	MA	Metabolism
DMB6XUY	RN	Delamanid is not metabolized by Salmonella or human nitroreductases: a possible mechanism for the lack of mutagenicity. Regul Toxicol Pharmacol. 2017 Mar;84:1-8.
DMB6XUY	RU	https://pubmed.ncbi.nlm.nih.gov/27988333

DMW3RLB	DI	DMW3RLB
DMW3RLB	DN	CL-301
DMW3RLB	MI	TTS087L
DMW3RLB	MN	Solute carrier family 12 member 1 (SLC12A1)
DMW3RLB	MT	DTT
DMW3RLB	MA	Modulator
DMW3RLB	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 969).
DMW3RLB	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=969

DMLQZGJ	DI	DMLQZGJ
DMLQZGJ	DN	CL-385004
DMLQZGJ	MI	TT4TFGN
DMLQZGJ	MN	Vasopressin V1a receptor (V1AR)
DMLQZGJ	MT	DTT
DMLQZGJ	MA	Antagonist
DMLQZGJ	RN	Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res. 2002;139:197-210.
DMLQZGJ	RU	https://pubmed.ncbi.nlm.nih.gov/12436936

DMLQZGJ	DI	DMLQZGJ
DMLQZGJ	DN	CL-385004
DMLQZGJ	MI	TTK8R02
DMLQZGJ	MN	Vasopressin V2 receptor (V2R)
DMLQZGJ	MT	DTT
DMLQZGJ	MA	Antagonist
DMLQZGJ	RN	Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res. 2002;139:197-210.
DMLQZGJ	RU	https://pubmed.ncbi.nlm.nih.gov/12436936

DMLKFZC	DI	DMLKFZC
DMLKFZC	DN	CL-387785
DMLKFZC	MI	TTGKNB4
DMLKFZC	MN	Epidermal growth factor receptor (EGFR)
DMLKFZC	MT	DTT
DMLKFZC	MA	Inhibitor
DMLKFZC	RN	Computational studies of epidermal growth factor receptor: docking reliability, three-dimensional quantitative structure-activity relationship anal... J Med Chem. 2009 Feb 26;52(4):964-75.
DMLKFZC	RU	https://pubmed.ncbi.nlm.nih.gov/19170633

DMLKFZC	DI	DMLKFZC
DMLKFZC	DN	CL-387785
DMLKFZC	MI	TTR5TV4
DMLKFZC	MN	ERBB2 messenger RNA (HER2 mRNA)
DMLKFZC	MT	DTT
DMLKFZC	MA	Inhibitor
DMLKFZC	RN	Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB... J Med Chem. 2006 Feb 23;49(4):1475-85.
DMLKFZC	RU	https://pubmed.ncbi.nlm.nih.gov/16480284

DMLKFZC	DI	DMLKFZC
DMLKFZC	DN	CL-387785
DMLKFZC	MI	TTWALCO
DMLKFZC	MN	HER4 messenger RNA (ERBB4 mRNA)
DMLKFZC	MT	DTT
DMLKFZC	MA	Inhibitor
DMLKFZC	RN	Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB... J Med Chem. 2006 Feb 23;49(4):1475-85.
DMLKFZC	RU	https://pubmed.ncbi.nlm.nih.gov/16480284

DM9AFZ3	DI	DM9AFZ3
DM9AFZ3	DN	CL-5343
DM9AFZ3	MI	TTUNARX
DM9AFZ3	MN	Carbonic anhydrase (CA)
DM9AFZ3	MT	DTT
DM9AFZ3	MA	Inhibitor
DM9AFZ3	RN	Carbonic anhydrase inhibitors. The X-ray crystal structure of human isoform II in adduct with an adamantyl analogue of acetazolamide resides in a l... Bioorg Med Chem Lett. 2010 Aug 1;20(15):4376-81.
DM9AFZ3	RU	https://pubmed.ncbi.nlm.nih.gov/20605094

DM9AFZ3	DI	DM9AFZ3
DM9AFZ3	DN	CL-5343
DM9AFZ3	MI	TTHQPL7
DM9AFZ3	MN	Carbonic anhydrase I (CA-I)
DM9AFZ3	MT	DTT
DM9AFZ3	MA	Inhibitor
DM9AFZ3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2597).
DM9AFZ3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2597

DM9AFZ3	DI	DM9AFZ3
DM9AFZ3	DN	CL-5343
DM9AFZ3	MI	TTANPDJ
DM9AFZ3	MN	Carbonic anhydrase II (CA-II)
DM9AFZ3	MT	DTT
DM9AFZ3	MA	Inhibitor
DM9AFZ3	RN	Synthesis, characterization and antiglaucoma activity of some novel pyrazole derivatives of 5-amino-1,3,4-thiadiazole-2-sulfonamide. Eur J Med Chem. 2010 Nov;45(11):4769-73.
DM9AFZ3	RU	https://pubmed.ncbi.nlm.nih.gov/20724038

DM9AFZ3	DI	DM9AFZ3
DM9AFZ3	DN	CL-5343
DM9AFZ3	MI	TTZHA0O
DM9AFZ3	MN	Carbonic anhydrase IV (CA-IV)
DM9AFZ3	MT	DTT
DM9AFZ3	MA	Inhibitor
DM9AFZ3	RN	Carbonic anhydrase inhibitors. The X-ray crystal structure of human isoform II in adduct with an adamantyl analogue of acetazolamide resides in a l... Bioorg Med Chem Lett. 2010 Aug 1;20(15):4376-81.
DM9AFZ3	RU	https://pubmed.ncbi.nlm.nih.gov/20605094

DM9AFZ3	DI	DM9AFZ3
DM9AFZ3	DN	CL-5343
DM9AFZ3	MI	TT2LVK8
DM9AFZ3	MN	Carbonic anhydrase IX (CA-IX)
DM9AFZ3	MT	DTT
DM9AFZ3	MA	Inhibitor
DM9AFZ3	RN	Carbonic anhydrase inhibitors. The X-ray crystal structure of human isoform II in adduct with an adamantyl analogue of acetazolamide resides in a l... Bioorg Med Chem Lett. 2010 Aug 1;20(15):4376-81.
DM9AFZ3	RU	https://pubmed.ncbi.nlm.nih.gov/20605094

DM9AFZ3	DI	DM9AFZ3
DM9AFZ3	DN	CL-5343
DM9AFZ3	MI	TTCFSPE
DM9AFZ3	MN	Carbonic anhydrase VI (CA-VI)
DM9AFZ3	MT	DTT
DM9AFZ3	MA	Inhibitor
DM9AFZ3	RN	Carbonic anhydrase inhibitors. The X-ray crystal structure of human isoform II in adduct with an adamantyl analogue of acetazolamide resides in a l... Bioorg Med Chem Lett. 2010 Aug 1;20(15):4376-81.
DM9AFZ3	RU	https://pubmed.ncbi.nlm.nih.gov/20605094

DM9AFZ3	DI	DM9AFZ3
DM9AFZ3	DN	CL-5343
DM9AFZ3	MI	TTSYM0R
DM9AFZ3	MN	Carbonic anhydrase XII (CA-XII)
DM9AFZ3	MT	DTT
DM9AFZ3	MA	Inhibitor
DM9AFZ3	RN	Carbonic anhydrase inhibitors. The X-ray crystal structure of human isoform II in adduct with an adamantyl analogue of acetazolamide resides in a l... Bioorg Med Chem Lett. 2010 Aug 1;20(15):4376-81.
DM9AFZ3	RU	https://pubmed.ncbi.nlm.nih.gov/20605094

DM9AFZ3	DI	DM9AFZ3
DM9AFZ3	DN	CL-5343
DM9AFZ3	MI	TTEYTKG
DM9AFZ3	MN	Carbonic anhydrase XIV (CA-XIV)
DM9AFZ3	MT	DTT
DM9AFZ3	MA	Inhibitor
DM9AFZ3	RN	Carbonic anhydrase inhibitors. The X-ray crystal structure of human isoform II in adduct with an adamantyl analogue of acetazolamide resides in a l... Bioorg Med Chem Lett. 2010 Aug 1;20(15):4376-81.
DM9AFZ3	RU	https://pubmed.ncbi.nlm.nih.gov/20605094

DMP3MDS	DI	DMP3MDS
DMP3MDS	DN	CL82198
DMP3MDS	MI	TTHY57M
DMP3MDS	MN	Matrix metalloproteinase-13 (MMP-13)
DMP3MDS	MT	DTT
DMP3MDS	MA	Inhibitor
DMP3MDS	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1637).
DMP3MDS	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1637

DMRV89X	DI	DMRV89X
DMRV89X	DN	Cl-amidine
DMRV89X	MI	TTSCHFW
DMRV89X	MN	Peptidyl arginine deiminase type III (PADI3)
DMRV89X	MT	DTT
DMRV89X	MA	Inhibitor
DMRV89X	RN	Identification of multiple structurally distinct, nonpeptidic small molecule inhibitors of protein arginine deiminase 3 using a substrate-based fragment method. J Am Chem Soc. 2015 Mar 18;137(10):3616-21.
DMRV89X	RU	https://pubmed.ncbi.nlm.nih.gov/25742366

DMRV89X	DI	DMRV89X
DMRV89X	DN	Cl-amidine
DMRV89X	MI	TTQHAXM
DMRV89X	MN	Peptidyl arginine deiminase type IV (PADI4)
DMRV89X	MT	DTT
DMRV89X	MA	Inhibitor
DMRV89X	RN	Identification of multiple structurally distinct, nonpeptidic small molecule inhibitors of protein arginine deiminase 3 using a substrate-based fragment method. J Am Chem Soc. 2015 Mar 18;137(10):3616-21.
DMRV89X	RU	https://pubmed.ncbi.nlm.nih.gov/25742366

DMIX347	DI	DMIX347
DMIX347	DN	CLAVARINONE
DMIX347	MI	TT7WZIJ
DMIX347	MN	CAAX farnesyltransferase beta (FNTB)
DMIX347	MT	DTT
DMIX347	MA	Inhibitor
DMIX347	RN	Clavaric acid and steroidal analogues as Ras- and FPP-directed inhibitors of human farnesyl-protein transferase. J Med Chem. 1998 Nov 5;41(23):4492-501.
DMIX347	RU	https://pubmed.ncbi.nlm.nih.gov/9804689

DMIX347	DI	DMIX347
DMIX347	DN	CLAVARINONE
DMIX347	MI	TTXQKM3
DMIX347	MN	Farnesyl protein transferase (Ftase)
DMIX347	MT	DTT
DMIX347	MA	Inhibitor
DMIX347	RN	Clavaric acid and steroidal analogues as Ras- and FPP-directed inhibitors of human farnesyl-protein transferase. J Med Chem. 1998 Nov 5;41(23):4492-501.
DMIX347	RU	https://pubmed.ncbi.nlm.nih.gov/9804689

DMAJNYM	DI	DMAJNYM
DMAJNYM	DN	Clavulanate+Amoxicillin
DMAJNYM	MI	TTHI19T
DMAJNYM	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMAJNYM	MT	DTT
DMAJNYM	MA	Inhibitor
DMAJNYM	RN	Emerging therapies for the treatment and prevention of otitis media. Expert Opin Emerg Drugs. 2006 May;11(2):251-64.
DMAJNYM	RU	https://pubmed.ncbi.nlm.nih.gov/16634700

DMTLOU6	DI	DMTLOU6
DMTLOU6	DN	CLEBOPRIDE
DMTLOU6	MI	TT1RS9F
DMTLOU6	MN	Acetylcholinesterase (AChE)
DMTLOU6	MT	DTT
DMTLOU6	MA	Inhibitor
DMTLOU6	RN	Efficient method for high-throughput virtual screening based on flexible docking: discovery of novel acetylcholinesterase inhibitors. J Med Chem. 2004 Sep 23;47(20):4818-28.
DMTLOU6	RU	https://pubmed.ncbi.nlm.nih.gov/15369385

DMTLOU6	DI	DMTLOU6
DMTLOU6	DN	CLEBOPRIDE
DMTLOU6	MI	TTEX248
DMTLOU6	MN	Dopamine D2 receptor (D2R)
DMTLOU6	MT	DTT
DMTLOU6	MA	Inhibitor
DMTLOU6	RN	Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotoni... J Med Chem. 2003 Feb 27;46(5):702-15.
DMTLOU6	RU	https://pubmed.ncbi.nlm.nih.gov/12593651

DM4SKYA	DI	DM4SKYA
DM4SKYA	DN	CLEMATOMANDSHURICA SAPONIN A
DM4SKYA	MI	TTVKILB
DM4SKYA	MN	Prostaglandin G/H synthase 2 (COX-2)
DM4SKYA	MT	DTT
DM4SKYA	MA	Inhibitor
DM4SKYA	RN	Triterpene saponins from clematis mandshurica. J Nat Prod. 2006 Nov;69(11):1591-5.
DM4SKYA	RU	https://pubmed.ncbi.nlm.nih.gov/17125227

DMNWXOC	DI	DMNWXOC
DMNWXOC	DN	CLEMATOMANDSHURICA SAPONIN B
DMNWXOC	MI	TTVKILB
DMNWXOC	MN	Prostaglandin G/H synthase 2 (COX-2)
DMNWXOC	MT	DTT
DMNWXOC	MA	Inhibitor
DMNWXOC	RN	Triterpene saponins from clematis mandshurica. J Nat Prod. 2006 Nov;69(11):1591-5.
DMNWXOC	RU	https://pubmed.ncbi.nlm.nih.gov/17125227

DM9WUHD	DI	DM9WUHD
DM9WUHD	DN	Clik60
DM9WUHD	MI	TTUMQVO
DM9WUHD	MN	Cathepsin S (CTSS)
DM9WUHD	MT	DTT
DM9WUHD	MA	Inhibitor
DM9WUHD	RN	Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity. J Clin Invest. 2002 Aug;110(3):361-9.
DM9WUHD	RU	https://pubmed.ncbi.nlm.nih.gov/12163455

DMS58P1	DI	DMS58P1
DMS58P1	DN	Clinopodic acid C
DMS58P1	MI	TTLM12X
DMS58P1	MN	Matrix metalloproteinase-2 (MMP-2)
DMS58P1	MT	DTT
DMS58P1	MA	Inhibitor
DMS58P1	RN	Matrix metalloproteinase-2 inhibitors from Clinopodium chinense var. parviflorum. J Nat Prod. 2009 Aug;72(8):1379-84.
DMS58P1	RU	https://pubmed.ncbi.nlm.nih.gov/19711986

DM537OH	DI	DM537OH
DM537OH	DN	Clobenpropit
DM537OH	MI	TT9JNIC
DM537OH	MN	Histamine H3 receptor (H3R)
DM537OH	MT	DTT
DM537OH	MA	Antagonist
DM537OH	RN	The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20.
DM537OH	RU	https://pubmed.ncbi.nlm.nih.gov/15665857

DM537OH	DI	DM537OH
DM537OH	DN	Clobenpropit
DM537OH	MI	TTXJ178
DM537OH	MN	Histamine H4 receptor (H4R)
DM537OH	MT	DTT
DM537OH	MA	Agonist
DM537OH	RN	Clobenpropit analogs as dual activity ligands for the histamine H3 and H4 receptors: synthesis, pharmacological evaluation, and cross-target QSAR s... Bioorg Med Chem. 2009 Jun 1;17(11):3987-94.
DM537OH	RU	https://pubmed.ncbi.nlm.nih.gov/19414267

DMZLMJH	DI	DMZLMJH
DMZLMJH	DN	Clocinnamox
DMZLMJH	MI	TT27RFC
DMZLMJH	MN	Opioid receptor delta (OPRD1)
DMZLMJH	MT	DTT
DMZLMJH	MA	Inhibitor
DMZLMJH	RN	14 beta-O-cinnamoylnaltrexone and related dihydrocodeinones are mu opioid receptor partial agonists with predominant antagonist activity. J Med Chem. 2009 Mar 26;52(6):1553-7.
DMZLMJH	RU	https://pubmed.ncbi.nlm.nih.gov/19253983

DMZLMJH	DI	DMZLMJH
DMZLMJH	DN	Clocinnamox
DMZLMJH	MI	TTQW87Y
DMZLMJH	MN	Opioid receptor kappa (OPRK1)
DMZLMJH	MT	DTT
DMZLMJH	MA	Inhibitor
DMZLMJH	RN	14 beta-O-cinnamoylnaltrexone and related dihydrocodeinones are mu opioid receptor partial agonists with predominant antagonist activity. J Med Chem. 2009 Mar 26;52(6):1553-7.
DMZLMJH	RU	https://pubmed.ncbi.nlm.nih.gov/19253983

DMZLMJH	DI	DMZLMJH
DMZLMJH	DN	Clocinnamox
DMZLMJH	MI	TTKWM86
DMZLMJH	MN	Opioid receptor mu (MOP)
DMZLMJH	MT	DTT
DMZLMJH	MA	Inhibitor
DMZLMJH	RN	14 beta-O-cinnamoylnaltrexone and related dihydrocodeinones are mu opioid receptor partial agonists with predominant antagonist activity. J Med Chem. 2009 Mar 26;52(6):1553-7.
DMZLMJH	RU	https://pubmed.ncbi.nlm.nih.gov/19253983

DMALRU9	DI	DMALRU9
DMALRU9	DN	Clodinafop
DMALRU9	MI	TTYAWV0
DMALRU9	MN	Plasmodium Acetyl-CoA carboxylase 1 (Malaria ACC1)
DMALRU9	MT	DTT
DMALRU9	MA	Binder
DMALRU9	RN	The apicoplast as an antimalarial drug target. Drug Resist Updat. 2001 Jun;4(3):145-51.
DMALRU9	RU	https://pubmed.ncbi.nlm.nih.gov/11768328

DMQ37OP	DI	DMQ37OP
DMQ37OP	DN	clofilium
DMQ37OP	MI	TTW0CMT
DMQ37OP	MN	Voltage-gated potassium channel Kv1.5 (KCNA5)
DMQ37OP	MT	DTT
DMQ37OP	MA	Blocker (channel blocker)
DMQ37OP	RN	Mechanism of clofilium block of the human Kv1.5 delayed rectifier potassium channel. Mol Pharmacol. 1995 Jan;47(1):198-205.
DMQ37OP	RU	https://pubmed.ncbi.nlm.nih.gov/7838129

DMQ37OP	DI	DMQ37OP
DMQ37OP	DN	clofilium
DMQ37OP	MI	TT9XKUC
DMQ37OP	MN	Voltage-gated potassium channel Kv10.1 (KCNH1)
DMQ37OP	MT	DTT
DMQ37OP	MA	Blocker (channel blocker)
DMQ37OP	RN	Inhibition of hEAG1 and hERG1 potassium channels by clofilium and its tertiary analogue LY97241. Br J Pharmacol. 2003 Jan;138(1):161-71.
DMQ37OP	RU	https://pubmed.ncbi.nlm.nih.gov/12522086

DMH01JV	DI	DMH01JV
DMH01JV	DN	cloprostenol
DMH01JV	MI	TTNVEIR
DMH01JV	MN	Prostaglandin D2 receptor (PTGDR)
DMH01JV	MT	DTT
DMH01JV	MA	Agonist
DMH01JV	RN	The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
DMH01JV	RU	https://pubmed.ncbi.nlm.nih.gov/10634944

DMH01JV	DI	DMH01JV
DMH01JV	DN	cloprostenol
DMH01JV	MI	TTG1QMU
DMH01JV	MN	Prostaglandin E2 receptor EP1 (PTGER1)
DMH01JV	MT	DTT
DMH01JV	MA	Agonist
DMH01JV	RN	Cloned human EP1 prostanoid receptor pharmacology characterized using radioligand binding techniques. J Pharm Pharmacol. 2002 Apr;54(4):539-47.
DMH01JV	RU	https://pubmed.ncbi.nlm.nih.gov/11999132

DMH01JV	DI	DMH01JV
DMH01JV	DN	cloprostenol
DMH01JV	MI	TTPNGDE
DMH01JV	MN	Prostaglandin E2 receptor EP3 (PTGER3)
DMH01JV	MT	DTT
DMH01JV	MA	Agonist
DMH01JV	RN	The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
DMH01JV	RU	https://pubmed.ncbi.nlm.nih.gov/10634944

DMH01JV	DI	DMH01JV
DMH01JV	DN	cloprostenol
DMH01JV	MI	TTT2ZAR
DMH01JV	MN	Prostaglandin F2-alpha receptor (PTGFR)
DMH01JV	MT	DTT
DMH01JV	MA	Agonist
DMH01JV	RN	The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
DMH01JV	RU	https://pubmed.ncbi.nlm.nih.gov/10634944

DMH01JV	DI	DMH01JV
DMH01JV	DN	cloprostenol
DMH01JV	MI	TT2O84V
DMH01JV	MN	Thromboxane A2 receptor (TBXA2R)
DMH01JV	MT	DTT
DMH01JV	MA	Agonist
DMH01JV	RN	The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
DMH01JV	RU	https://pubmed.ncbi.nlm.nih.gov/10634944

DMH7GKB	DI	DMH7GKB
DMH7GKB	DN	Cloranolol
DMH7GKB	MI	DECB0K3
DMH7GKB	MN	Cytochrome P450 2D6 (CYP2D6)
DMH7GKB	MT	DME
DMH7GKB	MA	Metabolism
DMH7GKB	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DMH7GKB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DMLPXNC	DI	DMLPXNC
DMLPXNC	DN	Clorindione
DMLPXNC	MI	DE4LYSA
DMLPXNC	MN	Cytochrome P450 3A4 (CYP3A4)
DMLPXNC	MT	DME
DMLPXNC	MA	Metabolism
DMLPXNC	RN	CYP3A time-dependent inhibition risk assessment validated with 400 reference drugs. Drug Metab Dispos. 2011 Jun;39(6):1039-46.
DMLPXNC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21383203

DMD5FIU	DI	DMD5FIU
DMD5FIU	DN	Clorobiocin
DMD5FIU	MI	TT0IHXV
DMD5FIU	MN	DNA topoisomerase II (TOP2)
DMD5FIU	MT	DTT
DMD5FIU	MA	Inhibitor
DMD5FIU	RN	The high-resolution crystal structure of a 24-kDa gyrase B fragment from E.coli complexed with one of the most potent coumarin inhibitors, clorobiocin. Proteins. 1997 May;28(1):41-52.
DMD5FIU	RU	https://pubmed.ncbi.nlm.nih.gov/9144789

DMU6FOG	DI	DMU6FOG
DMU6FOG	DN	Clorsulon
DMU6FOG	MI	TTHJWVK
DMU6FOG	MN	Mycobacterium Bisphosphoglycerate phosphoglycerate mutase (MycB gpmI)
DMU6FOG	MT	DTT
DMU6FOG	MA	Inhibitor
DMU6FOG	RN	Modes of action of anthelmintic drugs. Vet J. 1997 Jul;154(1):11-34.
DMU6FOG	RU	https://pubmed.ncbi.nlm.nih.gov/9265850

DMWTBG8	DI	DMWTBG8
DMWTBG8	DN	Clostridial collagenase
DMWTBG8	MI	TTK982E
DMWTBG8	MN	Collagen (CO)
DMWTBG8	MT	DTT
DMWTBG8	MA	Binder
DMWTBG8	RN	Collagen as a clinical target: nonoperative treatment of Dupuytren's disease. J Hand Surg Am. 2002 Sep;27(5):788-98.
DMWTBG8	RU	https://pubmed.ncbi.nlm.nih.gov/12239666

DM1B0PY	DI	DM1B0PY
DM1B0PY	DN	CLP-635
DM1B0PY	MI	TTH6UZY
DM1B0PY	MN	Solute carrier family 12 member 5 (SLC12A5)
DM1B0PY	MT	DTT
DM1B0PY	MA	Modulator
DM1B0PY	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 972).
DM1B0PY	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=972

DM9LSOW	DI	DM9LSOW
DM9LSOW	DN	CLR-151
DM9LSOW	MI	TTEX248
DM9LSOW	MN	Dopamine D2 receptor (D2R)
DM9LSOW	MT	DTT
DM9LSOW	MA	Antagonist
DM9LSOW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 215).
DM9LSOW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=215

DM7TX3D	DI	DM7TX3D
DM7TX3D	DN	CM-156
DM7TX3D	MI	TT5TPI6
DM7TX3D	MN	Opioid receptor sigma 1 (OPRS1)
DM7TX3D	MT	DTT
DM7TX3D	MA	Antagonist
DM7TX3D	RN	Antitussives and substance abuse. Subst Abuse Rehabil. 2013 Nov 6;4:75-82.
DM7TX3D	RU	https://pubmed.ncbi.nlm.nih.gov/24648790

DMXA8K1	DI	DMXA8K1
DMXA8K1	DN	CM-352
DMXA8K1	MI	TTXLEG7
DMXA8K1	MN	Matrix metalloproteinase-10 (MMP-10)
DMXA8K1	MT	DTT
DMXA8K1	MA	Inhibitor
DMXA8K1	RN	Discovery and safety profiling of a potent preclinical candidate, (4-[4-[[(3R)-3-(hydroxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]sulfonyl]phenoxy]-N-methylbenzamide) (CM-352), for the prevention and treatment of hemorrhage. J Med Chem. 2015 Apr 9;58(7):2941-57.
DMXA8K1	RU	https://pubmed.ncbi.nlm.nih.gov/25686022

DMXA8K1	DI	DMXA8K1
DMXA8K1	DN	CM-352
DMXA8K1	MI	TTUZ2L5
DMXA8K1	MN	Matrix metalloproteinase-3 (MMP-3)
DMXA8K1	MT	DTT
DMXA8K1	MA	Inhibitor
DMXA8K1	RN	Discovery and safety profiling of a potent preclinical candidate, (4-[4-[[(3R)-3-(hydroxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]sulfonyl]phenoxy]-N-methylbenzamide) (CM-352), for the prevention and treatment of hemorrhage. J Med Chem. 2015 Apr 9;58(7):2941-57.
DMXA8K1	RU	https://pubmed.ncbi.nlm.nih.gov/25686022

DM6PFG0	DI	DM6PFG0
DM6PFG0	DN	CMET Avimer polypeptides
DM6PFG0	MI	TTNDSF4
DM6PFG0	MN	Proto-oncogene c-Met (MET)
DM6PFG0	MT	DTT
DM6PFG0	MA	Inhibitor
DM6PFG0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
DM6PFG0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815

DMYPG01	DI	DMYPG01
DMYPG01	DN	CMI-1145
DMYPG01	MI	TTYEG6Q
DMYPG01	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMYPG01	MT	DTT
DMYPG01	MA	Agonist
DMYPG01	RN	Evaluation of muscarinic agonist-induced analgesia in muscarinic acetylcholine receptor knockout mice. Mol Pharmacol. 2002 Nov;62(5):1084-93.
DMYPG01	RU	https://pubmed.ncbi.nlm.nih.gov/12391271

DMYPG01	DI	DMYPG01
DMYPG01	DN	CMI-1145
DMYPG01	MI	TTQ3JTF
DMYPG01	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DMYPG01	MT	DTT
DMYPG01	MA	Agonist
DMYPG01	RN	Evaluation of muscarinic agonist-induced analgesia in muscarinic acetylcholine receptor knockout mice. Mol Pharmacol. 2002 Nov;62(5):1084-93.
DMYPG01	RU	https://pubmed.ncbi.nlm.nih.gov/12391271

DM4PWDJ	DI	DM4PWDJ
DM4PWDJ	DN	CMI-489
DM4PWDJ	MI	TT4H1MQ
DM4PWDJ	MN	Neuronal acetylcholine receptor alpha-4 (CHRNA4)
DM4PWDJ	MT	DTT
DM4PWDJ	MA	Inhibitor
DM4PWDJ	RN	Synthesis and nicotinic acetylcholine receptor binding properties of bridged and fused ring analogues of epibatidine. J Med Chem. 2007 Dec 13;50(25):6383-91.
DM4PWDJ	RU	https://pubmed.ncbi.nlm.nih.gov/17994682

DM4PWDJ	DI	DM4PWDJ
DM4PWDJ	DN	CMI-489
DM4PWDJ	MI	TT5KPZR
DM4PWDJ	MN	Neuronal acetylcholine receptor beta-2 (CHRNB2)
DM4PWDJ	MT	DTT
DM4PWDJ	MA	Inhibitor
DM4PWDJ	RN	Synthesis and nicotinic acetylcholine receptor binding properties of bridged and fused ring analogues of epibatidine. J Med Chem. 2007 Dec 13;50(25):6383-91.
DM4PWDJ	RU	https://pubmed.ncbi.nlm.nih.gov/17994682

DMT9YKG	DI	DMT9YKG
DMT9YKG	DN	CMI-936
DMT9YKG	MI	TTYEG6Q
DMT9YKG	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMT9YKG	MT	DTT
DMT9YKG	MA	Agonist
DMT9YKG	RN	Evaluation of muscarinic agonist-induced analgesia in muscarinic acetylcholine receptor knockout mice. Mol Pharmacol. 2002 Nov;62(5):1084-93.
DMT9YKG	RU	https://pubmed.ncbi.nlm.nih.gov/12391271

DMT9YKG	DI	DMT9YKG
DMT9YKG	DN	CMI-936
DMT9YKG	MI	TTQ3JTF
DMT9YKG	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DMT9YKG	MT	DTT
DMT9YKG	MA	Agonist
DMT9YKG	RN	Evaluation of muscarinic agonist-induced analgesia in muscarinic acetylcholine receptor knockout mice. Mol Pharmacol. 2002 Nov;62(5):1084-93.
DMT9YKG	RU	https://pubmed.ncbi.nlm.nih.gov/12391271

DMM9K5S	DI	DMM9K5S
DMM9K5S	DN	Cmp-2-Keto-3-Deoxy-Octulosonic Acid
DMM9K5S	MI	TTQ8J1V
DMM9K5S	MN	Bacterial Deoxy-manno-octulosonate cytidylyltransferase (Bact kdsB)
DMM9K5S	MT	DTT
DMM9K5S	MA	Inhibitor
DMM9K5S	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMM9K5S	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMBT2ZW	DI	DMBT2ZW
DMBT2ZW	DN	cmp5
DMBT2ZW	MI	TTR1D7X
DMBT2ZW	MN	Protein arginine methyltransferase 5 (PRMT5)
DMBT2ZW	MT	DTT
DMBT2ZW	MA	Inhibitor
DMBT2ZW	RN	Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation. Blood. 2015 Apr 16;125(16):2530-43.
DMBT2ZW	RU	https://pubmed.ncbi.nlm.nih.gov/25742700

DM241YW	DI	DM241YW
DM241YW	DN	CMP-6
DM241YW	MI	TTRMX3V
DM241YW	MN	Janus kinase 2 (JAK-2)
DM241YW	MT	DTT
DM241YW	MA	Inhibitor
DM241YW	RN	Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorg Med Chem Lett. 2002 Apr 22;12(8):1219-23.
DM241YW	RU	https://pubmed.ncbi.nlm.nih.gov/11934592

DM241YW	DI	DM241YW
DM241YW	DN	CMP-6
DM241YW	MI	TTT7PJU
DM241YW	MN	Janus kinase 3 (JAK-3)
DM241YW	MT	DTT
DM241YW	MA	Inhibitor
DM241YW	RN	Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorg Med Chem Lett. 2002 Apr 22;12(8):1219-23.
DM241YW	RU	https://pubmed.ncbi.nlm.nih.gov/11934592

DM241YW	DI	DM241YW
DM241YW	DN	CMP-6
DM241YW	MI	TTBYWP2
DM241YW	MN	TYK2 tyrosine kinase (TYK2)
DM241YW	MT	DTT
DM241YW	MA	Inhibitor
DM241YW	RN	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
DM241YW	RU	https://pubmed.ncbi.nlm.nih.gov/18077363

DMKNUYF	DI	DMKNUYF
DMKNUYF	DN	CMPD1
DMKNUYF	MI	TTMUG9D
DMKNUYF	MN	MAPK-activated protein kinase 2 (MAPKAPK2)
DMKNUYF	MT	DTT
DMKNUYF	MA	Inhibitor
DMKNUYF	RN	Synthesis and in vivo activity of MK2 and MK2 substrate-selective p38alpha(MAPK) inhibitors in Werner syndrome cells. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6832-5.
DMKNUYF	RU	https://pubmed.ncbi.nlm.nih.gov/17964780

DM9IPH4	DI	DM9IPH4
DM9IPH4	DN	CMPD-167
DM9IPH4	MI	TT2CEJG
DM9IPH4	MN	C-C chemokine receptor type 5 (CCR5)
DM9IPH4	MT	DTT
DM9IPH4	MA	Inhibitor
DM9IPH4	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3651).
DM9IPH4	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3651

DMH48YE	DI	DMH48YE
DMH48YE	DN	CMP-sialic acid
DMH48YE	MI	DTVZIRG
DMH48YE	MN	CMP-sialic acid transporter (SLC35A1)
DMH48YE	MT	DTP
DMH48YE	MA	Substrate
DMH48YE	RN	Disease mutations in CMP-sialic acid transporter SLC35A1 result in abnormal -dystroglycan O-mannosylation, independent from sialic acid. Hum Mol Genet. 2015 Apr 15;24(8):2241-6.
DMH48YE	RU	http://www.ncbi.nlm.nih.gov/pubmed/25552652

DMA5Z2G	DI	DMA5Z2G
DMA5Z2G	DN	C-myb
DMA5Z2G	MI	TTVKILB
DMA5Z2G	MN	Prostaglandin G/H synthase 2 (COX-2)
DMA5Z2G	MT	DTT
DMA5Z2G	MA	Regulator (upregulator)
DMA5Z2G	RN	Cyclooxygenase-2, a colorectal cancer nonsteroidal anti-inflammatory drug target, is regulated by c-MYB. Cancer Res. 2000 Apr 1;60(7):1805-9.
DMA5Z2G	RU	https://pubmed.ncbi.nlm.nih.gov/10766162

DMJA8I4	DI	DMJA8I4
DMJA8I4	DN	CN-2097
DMJA8I4	MI	TTN9D8E
DMJA8I4	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMJA8I4	MT	DTT
DMJA8I4	MA	Modulator
DMJA8I4	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457).
DMJA8I4	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=457

DMFW1JC	DI	DMFW1JC
DMFW1JC	DN	C-Naphthalen-1-yl-methylamine
DMFW1JC	MI	TTWG9A4
DMFW1JC	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMFW1JC	MT	DTT
DMFW1JC	MA	Inhibitor
DMFW1JC	RN	Examination of the role of the acidic hydrogen in imparting selectivity of 7-(aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline (SK&amp;F 29661) toward inh... J Med Chem. 1997 Dec 5;40(25):3997-4005.
DMFW1JC	RU	https://pubmed.ncbi.nlm.nih.gov/9406590

DMFW1JC	DI	DMFW1JC
DMFW1JC	DN	C-Naphthalen-1-yl-methylamine
DMFW1JC	MI	TTWM4TY
DMFW1JC	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMFW1JC	MT	DTT
DMFW1JC	MA	Inhibitor
DMFW1JC	RN	Examination of the role of the acidic hydrogen in imparting selectivity of 7-(aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline (SK&amp;F 29661) toward inh... J Med Chem. 1997 Dec 5;40(25):3997-4005.
DMFW1JC	RU	https://pubmed.ncbi.nlm.nih.gov/9406590

DMFW1JC	DI	DMFW1JC
DMFW1JC	DN	C-Naphthalen-1-yl-methylamine
DMFW1JC	MI	TT2NUT5
DMFW1JC	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMFW1JC	MT	DTT
DMFW1JC	MA	Inhibitor
DMFW1JC	RN	Examination of the role of the acidic hydrogen in imparting selectivity of 7-(aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline (SK&amp;F 29661) toward inh... J Med Chem. 1997 Dec 5;40(25):3997-4005.
DMFW1JC	RU	https://pubmed.ncbi.nlm.nih.gov/9406590

DMEVM0J	DI	DMEVM0J
DMEVM0J	DN	CNICIN
DMEVM0J	MI	TTICX3S
DMEVM0J	MN	Bacterial UDP-N-acetylglucosamine carboxyvinyltransferase (Bact murA)
DMEVM0J	MT	DTT
DMEVM0J	MA	Inhibitor
DMEVM0J	RN	Sesquiterpene lactones are potent and irreversible inhibitors of the antibacterial target enzyme MurA. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5605-9.
DMEVM0J	RU	https://pubmed.ncbi.nlm.nih.gov/16945528

DMTEGNB	DI	DMTEGNB
DMTEGNB	DN	CNS-1169
DMTEGNB	MI	TT5TPI6
DMTEGNB	MN	Opioid receptor sigma 1 (OPRS1)
DMTEGNB	MT	DTT
DMTEGNB	MA	Modulator
DMTEGNB	RN	Antitussives and substance abuse. Subst Abuse Rehabil. 2013 Nov 6;4:75-82.
DMTEGNB	RU	https://pubmed.ncbi.nlm.nih.gov/24648790

DMZ57O1	DI	DMZ57O1
DMZ57O1	DN	CNTO-736
DMZ57O1	MI	TTVIMDE
DMZ57O1	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMZ57O1	MT	DTT
DMZ57O1	MA	Modulator
DMZ57O1	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249).
DMZ57O1	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=249

DMDK5BL	DI	DMDK5BL
DMDK5BL	DN	CNX-010
DMDK5BL	MI	TTN7BL9
DMDK5BL	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMDK5BL	MT	DTT
DMDK5BL	MA	Inhibitor
DMDK5BL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2763).
DMDK5BL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2763

DM5T401	DI	DM5T401
DM5T401	DN	CNX-011
DM5T401	MI	TTB8FUC
DM5T401	MN	Free fatty acid receptor 1 (GPR40)
DM5T401	MT	DTT
DM5T401	MA	Agonist
DM5T401	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 225).
DM5T401	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=225

DMTB965	DI	DMTB965
DMTB965	DN	Cobalt Hexammine Ion
DMTB965	MI	TTQAOZR
DMTB965	MN	Bacterial Chorismate synthase (Bact aroC)
DMTB965	MT	DTT
DMTB965	MA	Inhibitor
DMTB965	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMTB965	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMJRSIF	DI	DMJRSIF
DMJRSIF	DN	COCAINE.HCL
DMJRSIF	MI	TTVBI8W
DMJRSIF	MN	Dopamine transporter (DAT)
DMJRSIF	MT	DTT
DMJRSIF	MA	Inhibitor
DMJRSIF	RN	Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31.
DMJRSIF	RU	https://pubmed.ncbi.nlm.nih.gov/17489581

DMJRSIF	DI	DMJRSIF
DMJRSIF	DN	COCAINE.HCL
DMJRSIF	MI	TT3ROYC
DMJRSIF	MN	Serotonin transporter (SERT)
DMJRSIF	MT	DTT
DMJRSIF	MA	Inhibitor
DMJRSIF	RN	Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31.
DMJRSIF	RU	https://pubmed.ncbi.nlm.nih.gov/17489581

DMCSAIJ	DI	DMCSAIJ
DMCSAIJ	DN	COCHINCHINENENE B
DMCSAIJ	MI	TT6L509
DMCSAIJ	MN	Coagulation factor IIa (F2)
DMCSAIJ	MT	DTT
DMCSAIJ	MA	Inhibitor
DMCSAIJ	RN	Anti-Helicobacter pylori and thrombin inhibitory components from Chinese dragon's blood, Dracaena cochinchinensis. J Nat Prod. 2007 Oct;70(10):1570-7.
DMCSAIJ	RU	https://pubmed.ncbi.nlm.nih.gov/17883259

DMIGB7N	DI	DMIGB7N
DMIGB7N	DN	COCHINCHINENIN B
DMIGB7N	MI	TT6L509
DMIGB7N	MN	Coagulation factor IIa (F2)
DMIGB7N	MT	DTT
DMIGB7N	MA	Inhibitor
DMIGB7N	RN	Anti-Helicobacter pylori and thrombin inhibitory components from Chinese dragon's blood, Dracaena cochinchinensis. J Nat Prod. 2007 Oct;70(10):1570-7.
DMIGB7N	RU	https://pubmed.ncbi.nlm.nih.gov/17883259

DMOUSWN	DI	DMOUSWN
DMOUSWN	DN	Cochliobolic acid
DMOUSWN	MI	TTGKNB4
DMOUSWN	MN	Epidermal growth factor receptor (EGFR)
DMOUSWN	MT	DTT
DMOUSWN	MA	Inhibitor
DMOUSWN	RN	Cochliobolic acid, a novel metabolite produced by Cochliobolus lunatus, inhibits binding of TGF-alpha to the EGF receptor in a SPA assay. J Nat Prod. 1997 Jan;60(1):6-8.
DMOUSWN	RU	https://pubmed.ncbi.nlm.nih.gov/9014347

DMZ1VSI	DI	DMZ1VSI
DMZ1VSI	DN	COCLAURINE
DMZ1VSI	MI	TTVBI8W
DMZ1VSI	MN	Dopamine transporter (DAT)
DMZ1VSI	MT	DTT
DMZ1VSI	MA	Inhibitor
DMZ1VSI	RN	Effects of various isoquinoline alkaloids on in vitro 3H-dopamine uptake by rat striatal synaptosomes. J Nat Prod. 1995 Oct;58(10):1475-84.
DMZ1VSI	RU	https://pubmed.ncbi.nlm.nih.gov/8676127

DM08WPL	DI	DM08WPL
DM08WPL	DN	CODEINONE
DM08WPL	MI	TTKWM86
DM08WPL	MN	Opioid receptor mu (MOP)
DM08WPL	MT	DTT
DM08WPL	MA	Inhibitor
DM08WPL	RN	Live cell monitoring of mu-opioid receptor-mediated G-protein activation reveals strong biological activity of close morphine biosynthetic precursors. J Biol Chem. 2007 Sep 14;282(37):27126-32.
DM08WPL	RU	https://pubmed.ncbi.nlm.nih.gov/17616524

DM1I8LU	DI	DM1I8LU
DM1I8LU	DN	Coenzyme A
DM1I8LU	MI	TTSEOPJ
DM1I8LU	MN	Bacterial Pantothenate kinase (Bact coaA)
DM1I8LU	MT	DTT
DM1I8LU	MA	Inhibitor
DM1I8LU	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM1I8LU	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM1I8LU	DI	DM1I8LU
DM1I8LU	DN	Coenzyme A
DM1I8LU	MI	TTC8M31
DM1I8LU	MN	Carnitine acyltransferase (CRAT)
DM1I8LU	MT	DTT
DM1I8LU	MA	Inhibitor
DM1I8LU	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM1I8LU	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM1I8LU	DI	DM1I8LU
DM1I8LU	DN	Coenzyme A
DM1I8LU	MI	DTNU9EW
DM1I8LU	MN	Graves disease carrier protein (SLC25A16)
DM1I8LU	MT	DTP
DM1I8LU	MA	Substrate
DM1I8LU	RN	Biochemical characterization of a new mitochondrial transporter of dephosphocoenzyme A in Drosophila melanogaster. Biochim Biophys Acta Bioenerg. 2017 Feb;1858(2):137-146.
DM1I8LU	RU	http://www.ncbi.nlm.nih.gov/pubmed/27836698

DM1I8LU	DI	DM1I8LU
DM1I8LU	DN	Coenzyme A
DM1I8LU	MI	TTPADOQ
DM1I8LU	MN	HMG-CoA reductase (HMGCR)
DM1I8LU	MT	DTT
DM1I8LU	MA	Inhibitor
DM1I8LU	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM1I8LU	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM1I8LU	DI	DM1I8LU
DM1I8LU	DN	Coenzyme A
DM1I8LU	MI	DTU4HKJ
DM1I8LU	MN	Mitochondrial coenzyme A transporter SLC25A42 (SLC25A42)
DM1I8LU	MT	DTP
DM1I8LU	MA	Substrate
DM1I8LU	RN	A novel member of solute carrier family 25 (SLC25A42) is a transporter of coenzyme A and adenosine 3',5'-diphosphate in human mitochondria. J Biol Chem. 2009 Jul 3;284(27):18152-9.
DM1I8LU	RU	http://www.ncbi.nlm.nih.gov/pubmed/19429682

DM1I8LU	DI	DM1I8LU
DM1I8LU	DN	Coenzyme A
DM1I8LU	MI	DTYR5U7
DM1I8LU	MN	Peroxisomal membrane protein PMP34 (SLC25A17)
DM1I8LU	MT	DTP
DM1I8LU	MA	Substrate
DM1I8LU	RN	The human gene SLC25A17 encodes a peroxisomal transporter of coenzyme A, FAD and NAD+. Biochem J. 2012 Apr 1;443(1):241-7.
DM1I8LU	RU	http://www.ncbi.nlm.nih.gov/pubmed/22185573

DM1I8LU	DI	DM1I8LU
DM1I8LU	DN	Coenzyme A
DM1I8LU	MI	TT4YO0Z
DM1I8LU	MN	Phosphopantetheine adenylyltransferase (PPAT)
DM1I8LU	MT	DTT
DM1I8LU	MA	Inhibitor
DM1I8LU	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM1I8LU	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM1I8LU	DI	DM1I8LU
DM1I8LU	DN	Coenzyme A
DM1I8LU	MI	TT8HWCD
DM1I8LU	MN	Staphylococcus DHNA-CoA synthase (Stap-coc menB)
DM1I8LU	MT	DTT
DM1I8LU	MA	Inhibitor
DM1I8LU	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM1I8LU	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM0ACL9	DI	DM0ACL9
DM0ACL9	DN	Coformycin
DM0ACL9	MI	TTKZ09F
DM0ACL9	MN	Adenosine monophosphate deaminase (AMPD)
DM0ACL9	MT	DTT
DM0ACL9	MA	Inhibitor
DM0ACL9	RN	Mechanisms of cell death induced by 2-chloroadenosine in leukemic B-cells. Biochem Pharmacol. 2008 Apr 1;75(7):1451-60.
DM0ACL9	RU	https://pubmed.ncbi.nlm.nih.gov/18242582

DM326VN	DI	DM326VN
DM326VN	DN	COLCHINOL
DM326VN	MI	TTML2WA
DM326VN	MN	Tubulin (TUB)
DM326VN	MT	DTT
DM326VN	MA	Inhibitor
DM326VN	RN	Synthesis and structure-activity relationships of 1,2,4-triazoles as a novel class of potent tubulin polymerization inhibitors. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5154-9.
DM326VN	RU	https://pubmed.ncbi.nlm.nih.gov/16198562

DM326VN	DI	DM326VN
DM326VN	DN	COLCHINOL
DM326VN	MI	TTYFKSZ
DM326VN	MN	Tubulin beta (TUBB)
DM326VN	MT	DTT
DM326VN	MA	Inhibitor
DM326VN	RN	Synthesis and structure-activity relationships of 1,2,4-triazoles as a novel class of potent tubulin polymerization inhibitors. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5154-9.
DM326VN	RU	https://pubmed.ncbi.nlm.nih.gov/16198562

DMIKD8X	DI	DMIKD8X
DMIKD8X	DN	COMBETASTATIN
DMIKD8X	MI	TTML2WA
DMIKD8X	MN	Tubulin (TUB)
DMIKD8X	MT	DTT
DMIKD8X	MA	Inhibitor
DMIKD8X	RN	Asymmetric synthesis of antimitotic combretadioxolane with potent antitumor activity against multi-drug resistant cells. Bioorg Med Chem Lett. 1998 Aug 4;8(15):1997-2000.
DMIKD8X	RU	https://pubmed.ncbi.nlm.nih.gov/9873473

DMIKD8X	DI	DMIKD8X
DMIKD8X	DN	COMBETASTATIN
DMIKD8X	MI	TTYFKSZ
DMIKD8X	MN	Tubulin beta (TUBB)
DMIKD8X	MT	DTT
DMIKD8X	MA	Inhibitor
DMIKD8X	RN	Asymmetric synthesis of antimitotic combretadioxolane with potent antitumor activity against multi-drug resistant cells. Bioorg Med Chem Lett. 1998 Aug 4;8(15):1997-2000.
DMIKD8X	RU	https://pubmed.ncbi.nlm.nih.gov/9873473

DMC2IYH	DI	DMC2IYH
DMC2IYH	DN	Conantokin-G
DMC2IYH	MI	TTN9D8E
DMC2IYH	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMC2IYH	MT	DTT
DMC2IYH	MA	Inhibitor
DMC2IYH	RN	Novel conantokins from Conus parius venom are specific antagonists of N-methyl-D-aspartate receptors. J Biol Chem. 2007 Dec 21;282(51):36905-13.
DMC2IYH	RU	https://pubmed.ncbi.nlm.nih.gov/17962189

DMN4KJI	DI	DMN4KJI
DMN4KJI	DN	Conantokin-R
DMN4KJI	MI	TTKJEMQ
DMN4KJI	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMN4KJI	MT	DTT
DMN4KJI	MA	Inhibitor
DMN4KJI	RN	Novel conantokins from Conus parius venom are specific antagonists of N-methyl-D-aspartate receptors. J Biol Chem. 2007 Dec 21;282(51):36905-13.
DMN4KJI	RU	https://pubmed.ncbi.nlm.nih.gov/17962189

DMN4KJI	DI	DMN4KJI
DMN4KJI	DN	Conantokin-R
DMN4KJI	MI	TTN9D8E
DMN4KJI	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMN4KJI	MT	DTT
DMN4KJI	MA	Inhibitor
DMN4KJI	RN	Novel conantokins from Conus parius venom are specific antagonists of N-methyl-D-aspartate receptors. J Biol Chem. 2007 Dec 21;282(51):36905-13.
DMN4KJI	RU	https://pubmed.ncbi.nlm.nih.gov/17962189

DMLHF3E	DI	DMLHF3E
DMLHF3E	DN	Conantokins G
DMLHF3E	MI	TTN9D8E
DMLHF3E	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMLHF3E	MT	DTT
DMLHF3E	MA	Antagonist
DMLHF3E	RN	Powerful antinociceptive effects of the cone snail venom-derived subtype-selective NMDA receptor antagonists conantokins G and T. Pain. 2003 Jan;101(1-2):109-16.
DMLHF3E	RU	https://pubmed.ncbi.nlm.nih.gov/12507705

DMV6H5S	DI	DMV6H5S
DMV6H5S	DN	Conantokins T
DMV6H5S	MI	TTN9D8E
DMV6H5S	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMV6H5S	MT	DTT
DMV6H5S	MA	Antagonist
DMV6H5S	RN	Powerful antinociceptive effects of the cone snail venom-derived subtype-selective NMDA receptor antagonists conantokins G and T. Pain. 2003 Jan;101(1-2):109-16.
DMV6H5S	RU	https://pubmed.ncbi.nlm.nih.gov/12507705

DMC5RKY	DI	DMC5RKY
DMC5RKY	DN	Concatameric CTLA4Ig
DMC5RKY	MI	TTI2S1D
DMC5RKY	MN	Cytotoxic T-lymphocyte protein 4 (CTLA-4)
DMC5RKY	MT	DTT
DMC5RKY	MA	Modulator
DMC5RKY	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2743).
DMC5RKY	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2743

DMRPV0A	DI	DMRPV0A
DMRPV0A	DN	Concatameric LAG3Ig
DMRPV0A	MI	TTNVXAW
DMRPV0A	MN	Lymphocyte activation gene 3 protein (LAG3)
DMRPV0A	MT	DTT
DMRPV0A	MA	Modulator
DMRPV0A	RN	IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study. J Immune Based Ther Vaccines. 2007 Mar 29;5:5.
DMRPV0A	RU	https://pubmed.ncbi.nlm.nih.gov/17394654

DM4VYP0	DI	DM4VYP0
DM4VYP0	DN	CONESSINE
DM4VYP0	MI	TT2NUT5
DM4VYP0	MN	Adrenergic receptor alpha-2C (ADRA2C)
DM4VYP0	MT	DTT
DM4VYP0	MA	Inhibitor
DM4VYP0	RN	The alkaloid conessine and analogues as potent histamine H3 receptor antagonists. J Med Chem. 2008 Sep 11;51(17):5423-30.
DM4VYP0	RU	https://pubmed.ncbi.nlm.nih.gov/18683917

DM4VYP0	DI	DM4VYP0
DM4VYP0	DN	CONESSINE
DM4VYP0	MI	TT9JNIC
DM4VYP0	MN	Histamine H3 receptor (H3R)
DM4VYP0	MT	DTT
DM4VYP0	MA	Inhibitor
DM4VYP0	RN	Design of a new histamine H3 receptor antagonist chemotype: (3aR,6aR)-5-alkyl-1-aryl-octahydropyrrolo[3,4-b]pyrroles, synthesis, and structure-acti... J Med Chem. 2009 Aug 13;52(15):4640-9.
DM4VYP0	RU	https://pubmed.ncbi.nlm.nih.gov/19588934

DM4VYP0	DI	DM4VYP0
DM4VYP0	DN	CONESSINE
DM4VYP0	MI	TTRTKPV
DM4VYP0	MN	Trypanosoma Trypanothione reductase (Trypano TPR)
DM4VYP0	MT	DTT
DM4VYP0	MA	Inhibitor
DM4VYP0	RN	The use of natural product scaffolds as leads in the search for trypanothione reductase inhibitors. Bioorg Med Chem. 2008 Jul 15;16(14):6689-95.
DM4VYP0	RU	https://pubmed.ncbi.nlm.nih.gov/18558492

DMQG2MC	DI	DMQG2MC
DMQG2MC	DN	Conotoxin
DMQG2MC	MI	TT4FDG6
DMQG2MC	MN	Voltage-gated calcium channel alpha Cav2.2 (CACNA1B)
DMQG2MC	MT	DTT
DMQG2MC	MA	Blocker
DMQG2MC	RN	Treatment with conotoxin, an 'N-type' calcium channel blocker, in neuronal hypoxic-ischemic injury. Brain Res. 1990 Dec 24;537(1-2):256-62.
DMQG2MC	RU	https://pubmed.ncbi.nlm.nih.gov/2085777

DM5DTZR	DI	DM5DTZR
DM5DTZR	DN	COOH
DM5DTZR	MI	TTT2SVW
DM5DTZR	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DM5DTZR	MT	DTT
DM5DTZR	MA	Agonist
DM5DTZR	RN	PPAR-gamma activation mediates adipose depot-specific effects on gene expression and lipoprotein lipase activity: mechanisms for modulation of postprandial lipemia and differential adipose accretion.Diabetes. 2003 Feb;52(2):291-9.
DM5DTZR	RU	https://pubmed.ncbi.nlm.nih.gov/12540599

DMFH5J9	DI	DMFH5J9
DMFH5J9	DN	cooling agent 10
DMFH5J9	MI	TTXDKTO
DMFH5J9	MN	Long transient receptor potential channel 8 (TRPM8)
DMFH5J9	MT	DTT
DMFH5J9	MA	Activator
DMFH5J9	RN	Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay. Br J Pharmacol. 2004 Feb;141(4):737-45.
DMFH5J9	RU	https://pubmed.ncbi.nlm.nih.gov/14757700

DMT5SED	DI	DMT5SED
DMT5SED	DN	CORDOIN
DMT5SED	MI	TTGP7BY
DMT5SED	MN	Monoamine oxidase type B (MAO-B)
DMT5SED	MT	DTT
DMT5SED	MA	Inhibitor
DMT5SED	RN	Chalcones: a valid scaffold for monoamine oxidases inhibitors. J Med Chem. 2009 May 14;52(9):2818-24.
DMT5SED	RU	https://pubmed.ncbi.nlm.nih.gov/19378991

DM72Y01	DI	DM72Y01
DM72Y01	DN	Cordycepin
DM72Y01	MI	DTZAWTH
DM72Y01	MN	Equilibrative nucleoside transporter 3 (SLC29A3)
DM72Y01	MT	DTP
DM72Y01	MA	Substrate
DM72Y01	RN	Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes. J Biol Chem. 2005 Apr 22;280(16):15880-7.
DM72Y01	RU	http://www.ncbi.nlm.nih.gov/pubmed/15701636

DMAC698	DI	DMAC698
DMAC698	DN	CORILAGIN
DMAC698	MI	TT84ETX
DMAC698	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMAC698	MT	DTT
DMAC698	MA	Inhibitor
DMAC698	RN	HIV and reverse transcriptase inhibition by tanninsOriginal Research. Bioorg. Med. Chem. Lett. 2(12):1529-1534 (1992).
DMAC698	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00804229

DMAC698	DI	DMAC698
DMAC698	DN	CORILAGIN
DMAC698	MI	TTE14XG
DMAC698	MN	Squalene monooxygenase (SQLE)
DMAC698	MT	DTT
DMAC698	MA	Inhibitor
DMAC698	RN	Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4.
DMAC698	RU	https://pubmed.ncbi.nlm.nih.gov/11520216

DMZBUE7	DI	DMZBUE7
DMZBUE7	DN	CORONARIDINE
DMZBUE7	MI	TT1RS9F
DMZBUE7	MN	Acetylcholinesterase (AChE)
DMZBUE7	MT	DTT
DMZBUE7	MA	Inhibitor
DMZBUE7	RN	Indole alkaloids from Ervatamia hainanensis with potent acetylcholinesterase inhibition activities. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6185-7.
DMZBUE7	RU	https://pubmed.ncbi.nlm.nih.gov/20850311

DM563PZ	DI	DM563PZ
DM563PZ	DN	Corosolic acid
DM563PZ	MI	TTN7BL9
DM563PZ	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DM563PZ	MT	DTT
DM563PZ	MA	Inhibitor
DM563PZ	RN	11beta-Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational a... Bioorg Med Chem. 2010 Feb 15;18(4):1507-15.
DM563PZ	RU	https://pubmed.ncbi.nlm.nih.gov/20100662

DM5ISQK	DI	DM5ISQK
DM5ISQK	DN	Correloid
DM5ISQK	MI	TTY3UE6
DM5ISQK	MN	Voltage-gated potassium channel Kv1.3 (KCNA3)
DM5ISQK	MT	DTT
DM5ISQK	MA	Inhibitor
DM5ISQK	RN	Potent Kv1.3 inhibitors from correolide-modification of the C18 position. Bioorg Med Chem Lett. 2005 Jan 17;15(2):447-51.
DM5ISQK	RU	https://pubmed.ncbi.nlm.nih.gov/15603971

DMACH7K	DI	DMACH7K
DMACH7K	DN	correolide
DMACH7K	MI	TTY3UE6
DMACH7K	MN	Voltage-gated potassium channel Kv1.3 (KCNA3)
DMACH7K	MT	DTT
DMACH7K	MA	Blocker (channel blocker)
DMACH7K	RN	Identification and biochemical characterization of a novel nortriterpene inhibitor of the human lymphocyte voltage-gated potassium channel, Kv1.3. Biochemistry. 1999 Apr 20;38(16):4922-30.
DMACH7K	RU	https://pubmed.ncbi.nlm.nih.gov/10213593

DM463S2	DI	DM463S2
DM463S2	DN	CORYMBONE B
DM463S2	MI	TT4J8MF
DM463S2	MN	Thyrotropin-releasing hormone receptor (TRHR)
DM463S2	MT	DTT
DM463S2	MA	Inhibitor
DM463S2	RN	Corymbones A and B, phloroglucinols with thyrotropin releasing hormone receptor 2 binding affinity from the flowers of Corymbia peltata. J Nat Prod. 2008 May;71(5):881-3.
DM463S2	RU	https://pubmed.ncbi.nlm.nih.gov/18412395

DM18CUZ	DI	DM18CUZ
DM18CUZ	DN	CORYNANTHEINE
DM18CUZ	MI	TTNGILX
DM18CUZ	MN	Adrenergic receptor alpha-1A (ADRA1A)
DM18CUZ	MT	DTT
DM18CUZ	MA	Inhibitor
DM18CUZ	RN	Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
DM18CUZ	RU	https://pubmed.ncbi.nlm.nih.gov/15664832

DM18CUZ	DI	DM18CUZ
DM18CUZ	DN	CORYNANTHEINE
DM18CUZ	MI	TTBRKXS
DM18CUZ	MN	Adrenergic receptor alpha-1B (ADRA1B)
DM18CUZ	MT	DTT
DM18CUZ	MA	Inhibitor
DM18CUZ	RN	Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
DM18CUZ	RU	https://pubmed.ncbi.nlm.nih.gov/7562902

DM18CUZ	DI	DM18CUZ
DM18CUZ	DN	CORYNANTHEINE
DM18CUZ	MI	TT34BHT
DM18CUZ	MN	Adrenergic receptor alpha-1D (ADRA1D)
DM18CUZ	MT	DTT
DM18CUZ	MA	Inhibitor
DM18CUZ	RN	Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
DM18CUZ	RU	https://pubmed.ncbi.nlm.nih.gov/7562902

DM18CUZ	DI	DM18CUZ
DM18CUZ	DN	CORYNANTHEINE
DM18CUZ	MI	TTZIFHC
DM18CUZ	MN	Voltage-gated calcium channel alpha Cav1.2 (CACNA1C)
DM18CUZ	MT	DTT
DM18CUZ	MA	Inhibitor
DM18CUZ	RN	Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
DM18CUZ	RU	https://pubmed.ncbi.nlm.nih.gov/7562902

DMSFXJ8	DI	DMSFXJ8
DMSFXJ8	DN	Cosalane derivative
DMSFXJ8	MI	TTC24WT
DMSFXJ8	MN	C-C chemokine receptor type 1 (CCR1)
DMSFXJ8	MT	DTT
DMSFXJ8	MA	Inhibitor
DMSFXJ8	RN	Inhibition of RANTES/CCR1-mediated chemotaxis by cosalane and related compounds. Bioorg Med Chem Lett. 2001 Jan 8;11(1):59-62.
DMSFXJ8	RU	https://pubmed.ncbi.nlm.nih.gov/11140734

DMU6OB4	DI	DMU6OB4
DMU6OB4	DN	Costunolide
DMU6OB4	MI	TT1EDJZ
DMU6OB4	MN	Microtubule-associated protein (MAP)
DMU6OB4	MT	DTT
DMU6OB4	MA	Binder
DMU6OB4	RN	A sesquiterpene lactone, costunolide, interacts with microtubule protein and inhibits the growth of MCF-7 cells. Chem Biol Interact. 2004 Jan 15;147(1):79-86.
DMU6OB4	RU	https://pubmed.ncbi.nlm.nih.gov/14726154

DM7TCPG	DI	DM7TCPG
DM7TCPG	DN	Coumaranone
DM7TCPG	MI	DESDN74
DM7TCPG	MN	Serum paraoxonase/arylesterase 1 (PON1)
DM7TCPG	MT	DME
DM7TCPG	MA	Metabolism
DM7TCPG	RN	Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos. 2000 Nov;28(11):1335-42.
DM7TCPG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11038162

DM0N8ZM	DI	DM0N8ZM
DM0N8ZM	DN	Coumarin
DM0N8ZM	MI	TTUNARX
DM0N8ZM	MN	Carbonic anhydrase (CA)
DM0N8ZM	MT	DTT
DM0N8ZM	MA	Inhibitor
DM0N8ZM	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DM0N8ZM	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DM0N8ZM	DI	DM0N8ZM
DM0N8ZM	DN	Coumarin
DM0N8ZM	MI	TTHQPL7
DM0N8ZM	MN	Carbonic anhydrase I (CA-I)
DM0N8ZM	MT	DTT
DM0N8ZM	MA	Inhibitor
DM0N8ZM	RN	7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and X... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7255-8.
DM0N8ZM	RU	https://pubmed.ncbi.nlm.nih.gov/21067924

DM0N8ZM	DI	DM0N8ZM
DM0N8ZM	DN	Coumarin
DM0N8ZM	MI	TTANPDJ
DM0N8ZM	MN	Carbonic anhydrase II (CA-II)
DM0N8ZM	MT	DTT
DM0N8ZM	MA	Inhibitor
DM0N8ZM	RN	7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and X... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7255-8.
DM0N8ZM	RU	https://pubmed.ncbi.nlm.nih.gov/21067924

DM0N8ZM	DI	DM0N8ZM
DM0N8ZM	DN	Coumarin
DM0N8ZM	MI	TTZHA0O
DM0N8ZM	MN	Carbonic anhydrase IV (CA-IV)
DM0N8ZM	MT	DTT
DM0N8ZM	MA	Inhibitor
DM0N8ZM	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DM0N8ZM	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DM0N8ZM	DI	DM0N8ZM
DM0N8ZM	DN	Coumarin
DM0N8ZM	MI	TT2LVK8
DM0N8ZM	MN	Carbonic anhydrase IX (CA-IX)
DM0N8ZM	MT	DTT
DM0N8ZM	MA	Inhibitor
DM0N8ZM	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DM0N8ZM	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DM0N8ZM	DI	DM0N8ZM
DM0N8ZM	DN	Coumarin
DM0N8ZM	MI	TTCFSPE
DM0N8ZM	MN	Carbonic anhydrase VI (CA-VI)
DM0N8ZM	MT	DTT
DM0N8ZM	MA	Inhibitor
DM0N8ZM	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DM0N8ZM	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DM0N8ZM	DI	DM0N8ZM
DM0N8ZM	DN	Coumarin
DM0N8ZM	MI	TTSYM0R
DM0N8ZM	MN	Carbonic anhydrase XII (CA-XII)
DM0N8ZM	MT	DTT
DM0N8ZM	MA	Inhibitor
DM0N8ZM	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DM0N8ZM	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DM0N8ZM	DI	DM0N8ZM
DM0N8ZM	DN	Coumarin
DM0N8ZM	MI	TTEYTKG
DM0N8ZM	MN	Carbonic anhydrase XIV (CA-XIV)
DM0N8ZM	MT	DTT
DM0N8ZM	MA	Inhibitor
DM0N8ZM	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DM0N8ZM	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DM0N8ZM	DI	DM0N8ZM
DM0N8ZM	DN	Coumarin
DM0N8ZM	MI	DEUWAV0
DM0N8ZM	MN	Cytochrome P450 102D1 (cyp102)
DM0N8ZM	MT	DME
DM0N8ZM	MA	Metabolism
DM0N8ZM	RN	The metagenome of Caracolus marginella gut microbiome using culture independent approaches and shotgun sequencing. Data Brief. 2017 Nov 22;16:501-505.
DM0N8ZM	RU	https://pubmed.ncbi.nlm.nih.gov/29270447

DM0N8ZM	DI	DM0N8ZM
DM0N8ZM	DN	Coumarin
DM0N8ZM	MI	DE5IED8
DM0N8ZM	MN	Cytochrome P450 2C9 (CYP2C9)
DM0N8ZM	MT	DME
DM0N8ZM	MA	Metabolism
DM0N8ZM	RN	Pharmacogenomics of CYP2C9: functional and clinical considerations. J Pers Med. 2017 Dec 28;8(1).
DM0N8ZM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29283396

DMAJNPS	DI	DMAJNPS
DMAJNPS	DN	Coumermycin
DMAJNPS	MI	TTS7LWX
DMAJNPS	MN	Bacterial DNA gyrase B (Bact gyrB)
DMAJNPS	MT	DTT
DMAJNPS	MA	Inhibitor
DMAJNPS	RN	Isolation and characterization of an Escherichia coli strain exhibiting partial tolerance to quinolones. Antimicrob Agents Chemother. 1989 May;33(5):705-9.
DMAJNPS	RU	https://pubmed.ncbi.nlm.nih.gov/2665642

DM40TBU	DI	DM40TBU
DM40TBU	DN	Coumestrol
DM40TBU	MI	DTI7UX6
DM40TBU	MN	Breast cancer resistance protein (ABCG2)
DM40TBU	MT	DTP
DM40TBU	MA	Substrate
DM40TBU	RN	Effect of breast cancer resistance protein (Bcrp/Abcg2) on the disposition of phytoestrogens. Mol Pharmacol. 2007 Oct;72(4):967-75.
DM40TBU	RU	https://doi.org/10.1124/mol.107.034751

DM40TBU	DI	DM40TBU
DM40TBU	DN	Coumestrol
DM40TBU	MI	TTZAYWL
DM40TBU	MN	Estrogen receptor (ESR)
DM40TBU	MT	DTT
DM40TBU	MA	Inhibitor
DM40TBU	RN	Structure-based virtual screening for plant-based ERbeta-selective ligands as potential preventative therapy against age-related neurodegenerative ... J Med Chem. 2005 May 19;48(10):3463-6.
DM40TBU	RU	https://pubmed.ncbi.nlm.nih.gov/15887952

DM40TBU	DI	DM40TBU
DM40TBU	DN	Coumestrol
DM40TBU	MI	TTOM3J0
DM40TBU	MN	Estrogen receptor beta (ESR2)
DM40TBU	MT	DTT
DM40TBU	MA	Inhibitor
DM40TBU	RN	Structure-based virtual screening for plant-based ERbeta-selective ligands as potential preventative therapy against age-related neurodegenerative ... J Med Chem. 2005 May 19;48(10):3463-6.
DM40TBU	RU	https://pubmed.ncbi.nlm.nih.gov/15887952

DM2LWNF	DI	DM2LWNF
DM2LWNF	DN	COV08-0064
DM2LWNF	MI	TTSHG0T
DM2LWNF	MN	Toll-like receptor 9 (TLR9)
DM2LWNF	MT	DTT
DM2LWNF	MA	Agonist
DM2LWNF	RN	The novel TLR9 antagonist COV08-0064 protects from ischemia/reperfusion injury in non-steatotic and steatotic mice livers. Biochem Pharmacol. 2016 Jul 15;112:90-101.
DM2LWNF	RU	https://pubmed.ncbi.nlm.nih.gov/27157410

DMT2RHV	DI	DMT2RHV
DMT2RHV	DN	CP 4010
DMT2RHV	MI	TT51ZGC
DMT2RHV	MN	Herpes simplex virus DNA polymerase POL (HSV POL)
DMT2RHV	MT	DTT
DMT2RHV	MA	Modulator
DMT2RHV	RN	Herpes simplex virus type 1 DNA polymerase. Mechanism of inhibition by acyclovir triphosphate. J Biol Chem. 1989 May 5;264(13):7405-11.
DMT2RHV	RU	https://pubmed.ncbi.nlm.nih.gov/2540193

DMSNVKP	DI	DMSNVKP
DMSNVKP	DN	CP 93129
DMSNVKP	MI	TTSQIFT
DMSNVKP	MN	5-HT 1A receptor (HTR1A)
DMSNVKP	MT	DTT
DMSNVKP	MA	Agonist
DMSNVKP	RN	Agonist activity of antimigraine drugs at recombinant human 5-HT1A receptors: potential implications for prophylactic and acute therapy. Naunyn Schmiedebergs Arch Pharmacol. 1997 Jun;355(6):682-8.
DMSNVKP	RU	https://pubmed.ncbi.nlm.nih.gov/9205951

DMLFNTH	DI	DMLFNTH
DMLFNTH	DN	CP-100263
DMLFNTH	MI	TTZPO1L
DMLFNTH	MN	Substance-P receptor (TACR1)
DMLFNTH	MT	DTT
DMLFNTH	MA	Antagonist
DMLFNTH	RN	Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar;11(1):137-51.
DMLFNTH	RU	https://pubmed.ncbi.nlm.nih.gov/16503832

DM3ZIDT	DI	DM3ZIDT
DM3ZIDT	DN	CP-126998
DM3ZIDT	MI	TT1RS9F
DM3ZIDT	MN	Acetylcholinesterase (AChE)
DM3ZIDT	MT	DTT
DM3ZIDT	MA	Modulator
DM3ZIDT	RN	PET imaging of brain acetylcholinesterase using [11C]CP-126,998, a brain selective enzyme inhibitor. Synapse. 2002 Jul;45(1):1-9.
DM3ZIDT	RU	https://www.ncbi.nlm.nih.gov/pubmed/12112408

DMYHR74	DI	DMYHR74
DMYHR74	DN	CP154,526
DMYHR74	MI	TT7EFHR
DMYHR74	MN	Corticotropin-releasing factor receptor 1 (CRHR1)
DMYHR74	MT	DTT
DMYHR74	MA	Antagonist
DMYHR74	RN	A review of drug options in age-related macular degeneration therapy and potential new agents. Expert Opin Pharmacother. 2006 Dec;7(17):2355-68.
DMYHR74	RU	https://pubmed.ncbi.nlm.nih.gov/17109611

DMGLO2X	DI	DMGLO2X
DMGLO2X	DN	CP-226269
DMGLO2X	MI	TTE0A2F
DMGLO2X	MN	Dopamine D4 receptor (D4R)
DMGLO2X	MT	DTT
DMGLO2X	MA	Agonist
DMGLO2X	RN	Certain 1,4-disubstituted aromatic piperidines and piperazines with extreme selectivity for the dopamine D4 receptor interact with a common recepto... Mol Pharmacol. 2004 Dec;66(6):1491-9.
DMGLO2X	RU	https://pubmed.ncbi.nlm.nih.gov/15448188

DMGN38F	DI	DMGN38F
DMGN38F	DN	CP-271485
DMGN38F	MI	TTXZ0KQ
DMGN38F	MN	Matrix metalloproteinase-12 (MMP-12)
DMGN38F	MT	DTT
DMGN38F	MA	Inhibitor
DMGN38F	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMGN38F	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM6BRLA	DI	DM6BRLA
DM6BRLA	DN	CP-294838
DM6BRLA	MI	TTFQEO5
DM6BRLA	MN	Squalene synthetase (FDFT1)
DM6BRLA	MT	DTT
DM6BRLA	MA	Inhibitor
DM6BRLA	RN	Truncation of human squalene synthase yields active, crystallizable protein. Arch Biochem Biophys. 1998 Feb 15;350(2):283-90.
DM6BRLA	RU	https://pubmed.ncbi.nlm.nih.gov/9473303

DMME6K2	DI	DMME6K2
DMME6K2	DN	CP-305202
DMME6K2	MI	TTB2MXP
DMME6K2	MN	Angiotensinogenase renin (REN)
DMME6K2	MT	DTT
DMME6K2	MA	Inhibitor
DMME6K2	RN	Direct renin inhibitors as a new therapy for hypertension. J Med Chem. 2010 Nov 11;53(21):7490-520.
DMME6K2	RU	https://pubmed.ncbi.nlm.nih.gov/20731374

DMY8O0B	DI	DMY8O0B
DMY8O0B	DN	CP-320626
DMY8O0B	MI	TTTSOUD
DMY8O0B	MN	Candida Cytochrome P450 51 (Candi ERG11)
DMY8O0B	MT	DTT
DMY8O0B	MA	Inhibitor
DMY8O0B	RN	Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors. Drug Metab Dispos. 2007 Mar;35(3):493-500.
DMY8O0B	RU	https://pubmed.ncbi.nlm.nih.gov/17194716

DMTJOWH	DI	DMTJOWH
DMTJOWH	DN	CP-339818
DMTJOWH	MI	TTY3UE6
DMTJOWH	MN	Voltage-gated potassium channel Kv1.3 (KCNA3)
DMTJOWH	MT	DTT
DMTJOWH	MA	Inhibitor
DMTJOWH	RN	Angular methoxy-substituted furo- and pyranoquinolinones as blockers of the voltage-gated potassium channel Kv1.3. J Med Chem. 2001 Apr 12;44(8):1249-56.
DMTJOWH	RU	https://pubmed.ncbi.nlm.nih.gov/11312924

DM93CA4	DI	DM93CA4
DM93CA4	DN	CP-376395
DM93CA4	MI	TT7EFHR
DM93CA4	MN	Corticotropin-releasing factor receptor 1 (CRHR1)
DM93CA4	MT	DTT
DM93CA4	MA	Inhibitor
DM93CA4	RN	2-aryloxy-4-alkylaminopyridines: discovery of novel corticotropin-releasing factor 1 antagonists. J Med Chem. 2008 Mar 13;51(5):1385-92.
DM93CA4	RU	https://pubmed.ncbi.nlm.nih.gov/18288792

DMDPH3W	DI	DMDPH3W
DMDPH3W	DN	CP-394531
DMDPH3W	MI	TTKPW01
DMDPH3W	MN	Androgen receptor messenger RNA (AR mRNA)
DMDPH3W	MT	DTT
DMDPH3W	MA	Inhibitor
DMDPH3W	RN	Discovery of potent, nonsteroidal, and highly selective glucocorticoid receptor antagonists. J Med Chem. 2002 Jun 6;45(12):2417-24.
DMDPH3W	RU	https://pubmed.ncbi.nlm.nih.gov/12036351

DMDPH3W	DI	DMDPH3W
DMDPH3W	DN	CP-394531
DMDPH3W	MI	TTZAYWL
DMDPH3W	MN	Estrogen receptor (ESR)
DMDPH3W	MT	DTT
DMDPH3W	MA	Inhibitor
DMDPH3W	RN	Discovery of potent, nonsteroidal, and highly selective glucocorticoid receptor antagonists. J Med Chem. 2002 Jun 6;45(12):2417-24.
DMDPH3W	RU	https://pubmed.ncbi.nlm.nih.gov/12036351

DMDPH3W	DI	DMDPH3W
DMDPH3W	DN	CP-394531
DMDPH3W	MI	TTOM3J0
DMDPH3W	MN	Estrogen receptor beta (ESR2)
DMDPH3W	MT	DTT
DMDPH3W	MA	Inhibitor
DMDPH3W	RN	Discovery of potent, nonsteroidal, and highly selective glucocorticoid receptor antagonists. J Med Chem. 2002 Jun 6;45(12):2417-24.
DMDPH3W	RU	https://pubmed.ncbi.nlm.nih.gov/12036351

DMDPH3W	DI	DMDPH3W
DMDPH3W	DN	CP-394531
DMDPH3W	MI	TTOZRK6
DMDPH3W	MN	Glucocorticoid receptor messenger RNA (GCR mRNA)
DMDPH3W	MT	DTT
DMDPH3W	MA	Inhibitor
DMDPH3W	RN	Virtual screening for the identification of novel nonsteroidal glucocorticoid modulators. J Med Chem. 2010 Apr 22;53(8):3065-74.
DMDPH3W	RU	https://pubmed.ncbi.nlm.nih.gov/20334371

DM1U6P7	DI	DM1U6P7
DM1U6P7	DN	CP-409069
DM1U6P7	MI	TTKPW01
DM1U6P7	MN	Androgen receptor messenger RNA (AR mRNA)
DM1U6P7	MT	DTT
DM1U6P7	MA	Inhibitor
DM1U6P7	RN	Discovery of potent, nonsteroidal, and highly selective glucocorticoid receptor antagonists. J Med Chem. 2002 Jun 6;45(12):2417-24.
DM1U6P7	RU	https://pubmed.ncbi.nlm.nih.gov/12036351

DM1U6P7	DI	DM1U6P7
DM1U6P7	DN	CP-409069
DM1U6P7	MI	TTZAYWL
DM1U6P7	MN	Estrogen receptor (ESR)
DM1U6P7	MT	DTT
DM1U6P7	MA	Inhibitor
DM1U6P7	RN	Discovery of potent, nonsteroidal, and highly selective glucocorticoid receptor antagonists. J Med Chem. 2002 Jun 6;45(12):2417-24.
DM1U6P7	RU	https://pubmed.ncbi.nlm.nih.gov/12036351

DM1U6P7	DI	DM1U6P7
DM1U6P7	DN	CP-409069
DM1U6P7	MI	TTOM3J0
DM1U6P7	MN	Estrogen receptor beta (ESR2)
DM1U6P7	MT	DTT
DM1U6P7	MA	Inhibitor
DM1U6P7	RN	Discovery of potent, nonsteroidal, and highly selective glucocorticoid receptor antagonists. J Med Chem. 2002 Jun 6;45(12):2417-24.
DM1U6P7	RU	https://pubmed.ncbi.nlm.nih.gov/12036351

DM1U6P7	DI	DM1U6P7
DM1U6P7	DN	CP-409069
DM1U6P7	MI	TTOZRK6
DM1U6P7	MN	Glucocorticoid receptor messenger RNA (GCR mRNA)
DM1U6P7	MT	DTT
DM1U6P7	MA	Inhibitor
DM1U6P7	RN	Virtual screening for the identification of novel nonsteroidal glucocorticoid modulators. J Med Chem. 2010 Apr 22;53(8):3065-74.
DM1U6P7	RU	https://pubmed.ncbi.nlm.nih.gov/20334371

DMROYD7	DI	DMROYD7
DMROYD7	DN	CP-409092
DMROYD7	MI	TTEX6LM
DMROYD7	MN	GABA(A) receptor gamma-3 (GABRG3)
DMROYD7	MT	DTT
DMROYD7	MA	Modulator
DMROYD7	RN	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
DMROYD7	RU	https://www.ncbi.nlm.nih.gov/pubmed/27899562

DMZMKAQ	DI	DMZMKAQ
DMZMKAQ	DN	CP-4200
DMZMKAQ	MI	TT6S2FE
DMZMKAQ	MN	DNA [cytosine-5]-methyltransferase 1 (DNMT1)
DMZMKAQ	MT	DTT
DMZMKAQ	MA	Inhibitor
DMZMKAQ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2605).
DMZMKAQ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2605

DMTHVCA	DI	DMTHVCA
DMTHVCA	DN	CP-4497
DMTHVCA	MI	TT6OEDT
DMTHVCA	MN	Cannabinoid receptor 1 (CB1)
DMTHVCA	MT	DTT
DMTHVCA	MA	Inhibitor
DMTHVCA	RN	Synthesis and pharmacology of 1-methoxy analogs of CP-47,497. Bioorg Med Chem. 2010 Aug 1;18(15):5475-82.
DMTHVCA	RU	https://pubmed.ncbi.nlm.nih.gov/20621488

DMS2RHE	DI	DMS2RHE
DMS2RHE	DN	CP-470,711
DMS2RHE	MI	TTLSRBZ
DMS2RHE	MN	Sorbitoldehydrogenase (SORD)
DMS2RHE	MT	DTT
DMS2RHE	MA	Inhibitor
DMS2RHE	RN	Sorbitol dehydrogenase: a novel target for adjunctive protection of ischemic myocardium. FASEB J. 2003 Dec;17(15):2331-3.
DMS2RHE	RU	https://pubmed.ncbi.nlm.nih.gov/14525943

DMZT7C1	DI	DMZT7C1
DMZT7C1	DN	CP-481,715
DMZT7C1	MI	TT8KLPT
DMZT7C1	MN	C-C chemokine receptor (CCR)
DMZT7C1	MT	DTT
DMZT7C1	MA	Antagonist
DMZT7C1	RN	CP-481,715, a potent and selective CCR1 antagonist with potential therapeutic implications for inflammatory diseases. J Biol Chem. 2003 Oct 17;278(42):40473-80.
DMZT7C1	RU	https://pubmed.ncbi.nlm.nih.gov/12909630

DMKWB31	DI	DMKWB31
DMKWB31	DN	CP55,244
DMKWB31	MI	TTNET8J
DMKWB31	MN	G-protein coupled receptor 55 (GPR55)
DMKWB31	MT	DTT
DMKWB31	MA	Agonist
DMKWB31	RN	Pharmacology of GPR55 in yeast and identification of GSK494581A as a mixed-activity glycine transporter subtype 1 inhibitor and GPR55 agonist. J Pharmacol Exp Ther. 2011 Apr;337(1):236-46.
DMKWB31	RU	https://pubmed.ncbi.nlm.nih.gov/21233197

DMNLD6E	DI	DMNLD6E
DMNLD6E	DN	CP55,667
DMNLD6E	MI	TTNET8J
DMNLD6E	MN	G-protein coupled receptor 55 (GPR55)
DMNLD6E	MT	DTT
DMNLD6E	MA	Antagonist
DMNLD6E	RN	Pharmacology of GPR55 in yeast and identification of GSK494581A as a mixed-activity glycine transporter subtype 1 inhibitor and GPR55 agonist. J Pharmacol Exp Ther. 2011 Apr;337(1):236-46.
DMNLD6E	RU	https://pubmed.ncbi.nlm.nih.gov/21233197

DMTKO7P	DI	DMTKO7P
DMTKO7P	DN	CP608,039
DMTKO7P	MI	TTK25J1
DMTKO7P	MN	Adenosine A1 receptor (ADORA1)
DMTKO7P	MT	DTT
DMTKO7P	MA	Agonist
DMTKO7P	RN	Adenosine receptors as therapeutic targets. Nat Rev Drug Discov. 2006 Mar;5(3):247-64.
DMTKO7P	RU	https://pubmed.ncbi.nlm.nih.gov/16518376

DMTKO7P	DI	DMTKO7P
DMTKO7P	DN	CP608,039
DMTKO7P	MI	TTJFY5U
DMTKO7P	MN	Adenosine A3 receptor (ADORA3)
DMTKO7P	MT	DTT
DMTKO7P	MA	Agonist
DMTKO7P	RN	Novel N6-substituted adenosine 5'-N-methyluronamides with high selectivity for human adenosine A3 receptors reduce ischemic myocardial injury. Am J Physiol Heart Circ Physiol. 2003 Dec;285(6):H2780-7.
DMTKO7P	RU	https://pubmed.ncbi.nlm.nih.gov/12919933

DMO0PS9	DI	DMO0PS9
DMO0PS9	DN	CP-640186
DMO0PS9	MI	TTY84UG
DMO0PS9	MN	Acetyl-CoA carboxylase 2 (ACACB)
DMO0PS9	MT	DTT
DMO0PS9	MA	Inhibitor
DMO0PS9	RN	(4-Piperidinyl)-piperazine: a new platform for acetyl-CoA carboxylase inhibitors. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6645-8.
DMO0PS9	RU	https://pubmed.ncbi.nlm.nih.gov/19853443

DMO0PS9	DI	DMO0PS9
DMO0PS9	DN	CP-640186
DMO0PS9	MI	TTYAWV0
DMO0PS9	MN	Plasmodium Acetyl-CoA carboxylase 1 (Malaria ACC1)
DMO0PS9	MT	DTT
DMO0PS9	MA	Inhibitor
DMO0PS9	RN	Discovery of small molecule isozyme non-specific inhibitors of mammalian acetyl-CoA carboxylase 1 and 2. Bioorg Med Chem Lett. 2010 Apr 1;20(7):2383-8.
DMO0PS9	RU	https://pubmed.ncbi.nlm.nih.gov/20219367

DMVBPRO	DI	DMVBPRO
DMVBPRO	DN	CP-673451
DMVBPRO	MI	TT8FYO9
DMVBPRO	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMVBPRO	MT	DTT
DMVBPRO	MA	Inhibitor
DMVBPRO	RN	Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451. Cancer Res. 2005 Feb 1;65(3):957-66.
DMVBPRO	RU	https://pubmed.ncbi.nlm.nih.gov/15705896

DMVBPRO	DI	DMVBPRO
DMVBPRO	DN	CP-673451
DMVBPRO	MI	TTI7421
DMVBPRO	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMVBPRO	MT	DTT
DMVBPRO	MA	Inhibitor
DMVBPRO	RN	Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451. Cancer Res. 2005 Feb 1;65(3):957-66.
DMVBPRO	RU	https://pubmed.ncbi.nlm.nih.gov/15705896

DMVBPRO	DI	DMVBPRO
DMVBPRO	DN	CP-673451
DMVBPRO	MI	TTX41N9
DMVBPRO	MN	Tyrosine-protein kinase Kit (KIT)
DMVBPRO	MT	DTT
DMVBPRO	MA	Inhibitor
DMVBPRO	RN	Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451. Cancer Res. 2005 Feb 1;65(3):957-66.
DMVBPRO	RU	https://pubmed.ncbi.nlm.nih.gov/15705896

DMBQTZG	DI	DMBQTZG
DMBQTZG	DN	CP-70949
DMBQTZG	MI	TTRSMW9
DMBQTZG	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMBQTZG	MT	DTT
DMBQTZG	MA	Inhibitor
DMBQTZG	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2030).
DMBQTZG	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2030

DM9LYJT	DI	DM9LYJT
DM9LYJT	DN	CP734432
DM9LYJT	MI	TT79WV3
DM9LYJT	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DM9LYJT	MT	DTT
DM9LYJT	MA	Agonist
DM9LYJT	RN	Ocular pharmacokinetics and hypotensive activity of PF-04475270, an EP4 prostaglandin agonist in preclinical models. Exp Eye Res. 2009 Nov;89(5):608-17.
DM9LYJT	RU	https://pubmed.ncbi.nlm.nih.gov/19445930

DMANV7R	DI	DMANV7R
DMANV7R	DN	CP-775146
DMANV7R	MI	TTJ584C
DMANV7R	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMANV7R	MT	DTT
DMANV7R	MA	Agonist
DMANV7R	RN	Molecular characterization of novel and selective peroxisome proliferator-activated receptor alpha agonists with robust hypolipidemic activity in vivo. Mol Pharmacol. 2009 Feb;75(2):296-306.
DMANV7R	RU	https://pubmed.ncbi.nlm.nih.gov/18971326

DM3M1LA	DI	DM3M1LA
DM3M1LA	DN	CP-809101
DM3M1LA	MI	TTWJBZ5
DM3M1LA	MN	5-HT 2C receptor (HTR2C)
DM3M1LA	MT	DTT
DM3M1LA	MA	Agonist
DM3M1LA	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 8).
DM3M1LA	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=8

DMXDG13	DI	DMXDG13
DMXDG13	DN	CP-810123
DMXDG13	MI	TTPC4TU
DMXDG13	MN	5-HT 3A receptor (HTR3A)
DMXDG13	MT	DTT
DMXDG13	MA	Inhibitor
DMXDG13	RN	Discovery of 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a novel alpha 7 nicotinic acetylcholine receptor ag... J Med Chem. 2010 Feb 11;53(3):1222-37.
DMXDG13	RU	https://pubmed.ncbi.nlm.nih.gov/20043678

DMXDG13	DI	DMXDG13
DMXDG13	DN	CP-810123
DMXDG13	MI	TTLA931
DMXDG13	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMXDG13	MT	DTT
DMXDG13	MA	Inhibitor
DMXDG13	RN	Discovery of 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a novel alpha 7 nicotinic acetylcholine receptor ag... J Med Chem. 2010 Feb 11;53(3):1222-37.
DMXDG13	RU	https://pubmed.ncbi.nlm.nih.gov/20043678

DMHN2LT	DI	DMHN2LT
DMHN2LT	DN	CP-94,253
DMHN2LT	MI	TTK8CXU
DMHN2LT	MN	5-HT 1B receptor (HTR1B)
DMHN2LT	MT	DTT
DMHN2LT	MA	Agonist
DMHN2LT	RN	Anxiogenic-like effect of serotonin(1B) receptor stimulation in the rat elevated plus-maze. Pharmacol Biochem Behav. 2002 Apr;71(4):581-7.
DMHN2LT	RU	https://pubmed.ncbi.nlm.nih.gov/11888549

DMVJX21	DI	DMVJX21
DMVJX21	DN	CP-99,994
DMVJX21	MI	TTZPO1L
DMVJX21	MN	Substance-P receptor (TACR1)
DMVJX21	MT	DTT
DMVJX21	MA	Antagonist
DMVJX21	RN	Gabapentin and the neurokinin(1) receptor antagonist CI-1021 act synergistically in two rat models of neuropathic pain. J Pharmacol Exp Ther. 2002 Nov;303(2):730-5.
DMVJX21	RU	https://pubmed.ncbi.nlm.nih.gov/12388658

DMI4WVE	DI	DMI4WVE
DMI4WVE	DN	CPCCOEt
DMI4WVE	MI	TTVBPDM
DMI4WVE	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMI4WVE	MT	DTT
DMI4WVE	MA	Modulator (allosteric modulator)
DMI4WVE	RN	[3H]R214127: a novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists. Mol Pharmacol. 2003 May;63(5):1082-93.
DMI4WVE	RU	https://pubmed.ncbi.nlm.nih.gov/12695537

DMFE5GX	DI	DMFE5GX
DMFE5GX	DN	CPFPX
DMFE5GX	MI	TTK25J1
DMFE5GX	MN	Adenosine A1 receptor (ADORA1)
DMFE5GX	MT	DTT
DMFE5GX	MA	Antagonist
DMFE5GX	RN	Synthesis and evaluation of no-carrier-added 8-cyclopentyl-3-(3-[(18)F]fluoropropyl)-1-propylxanthine ([(18)F]CPFPX): a potent and selective A(1)-adenosine receptor antagonist for in vivo imaging. J Med Chem. 2002 Nov 7;45(23):5150-6.
DMFE5GX	RU	https://pubmed.ncbi.nlm.nih.gov/12408725

DMFE5GX	DI	DMFE5GX
DMFE5GX	DN	CPFPX
DMFE5GX	MI	TTNE7KG
DMFE5GX	MN	Adenosine A2b receptor (ADORA2B)
DMFE5GX	MT	DTT
DMFE5GX	MA	Antagonist
DMFE5GX	RN	Synthesis and evaluation of no-carrier-added 8-cyclopentyl-3-(3-[(18)F]fluoropropyl)-1-propylxanthine ([(18)F]CPFPX): a potent and selective A(1)-adenosine receptor antagonist for in vivo imaging. J Med Chem. 2002 Nov 7;45(23):5150-6.
DMFE5GX	RU	https://pubmed.ncbi.nlm.nih.gov/12408725

DMXSYTA	DI	DMXSYTA
DMXSYTA	DN	CPI-203
DMXSYTA	MI	TTRA6BO
DMXSYTA	MN	Bromodomain-containing protein 4 (BRD4)
DMXSYTA	MT	DTT
DMXSYTA	MA	Inhibitor
DMXSYTA	RN	BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain. Proc Natl Acad Sci U S A. 2012 May 1;109(18):6927-32.
DMXSYTA	RU	https://pubmed.ncbi.nlm.nih.gov/22509028

DMVHX5T	DI	DMVHX5T
DMVHX5T	DN	CPPG
DMVHX5T	MI	TTICZ1O
DMVHX5T	MN	Metabotropic glutamate receptor 4 (mGluR4)
DMVHX5T	MT	DTT
DMVHX5T	MA	Antagonist
DMVHX5T	RN	Ligand binding to the amino-terminal domain of the mGluR4 subtype of metabotropic glutamate receptor. J Biol Chem. 1999 Apr 9;274(15):10008-13.
DMVHX5T	RU	https://pubmed.ncbi.nlm.nih.gov/10187777

DMVHX5T	DI	DMVHX5T
DMVHX5T	DN	CPPG
DMVHX5T	MI	TT0IFKL
DMVHX5T	MN	Metabotropic glutamate receptor 8 (mGluR8)
DMVHX5T	MT	DTT
DMVHX5T	MA	Antagonist
DMVHX5T	RN	Constraints on proper folding of the amino terminal domains of group III metabotropic glutamate receptors. Brain Res Mol Brain Res. 2000 Mar 10;76(1):180-90.
DMVHX5T	RU	https://pubmed.ncbi.nlm.nih.gov/10719229

DMDG2Y9	DI	DMDG2Y9
DMDG2Y9	DN	CPPHA
DMDG2Y9	MI	TTHS256
DMDG2Y9	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMDG2Y9	MT	DTT
DMDG2Y9	MA	Modulator (allosteric modulator)
DMDG2Y9	RN	A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain. J Pharmacol Exp Ther. 2004 May;309(2):568-77.
DMDG2Y9	RU	https://pubmed.ncbi.nlm.nih.gov/14747613

DM9OWG5	DI	DM9OWG5
DM9OWG5	DN	CPPZ
DM9OWG5	MI	TTHS256
DM9OWG5	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM9OWG5	MT	DTT
DM9OWG5	MA	Modulator (allosteric modulator)
DM9OWG5	RN	Preclinical profile of a novel metabotropic glutamate receptor 5 positive allosteric modulator. Eur J Pharmacol. 2011 Jun 1;659(2-3):146-54.
DM9OWG5	RU	https://pubmed.ncbi.nlm.nih.gov/21335002

DMG2NI9	DI	DMG2NI9
DMG2NI9	DN	CPS125
DMG2NI9	MI	TTXDKTO
DMG2NI9	MN	Long transient receptor potential channel 8 (TRPM8)
DMG2NI9	MT	DTT
DMG2NI9	MA	Activator
DMG2NI9	RN	Characterization of selective TRPM8 ligands and their structure activity response (S.A.R) relationship. J Pharm Pharm Sci. 2010;13(2):242-53.
DMG2NI9	RU	https://pubmed.ncbi.nlm.nih.gov/20816009

DMM8FUT	DI	DMM8FUT
DMM8FUT	DN	CPU-228
DMM8FUT	MI	TTZIFHC
DMM8FUT	MN	Voltage-gated calcium channel alpha Cav1.2 (CACNA1C)
DMM8FUT	MT	DTT
DMM8FUT	MA	Modulator
DMM8FUT	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 529).
DMM8FUT	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=529

DMM8FUT	DI	DMM8FUT
DMM8FUT	DN	CPU-228
DMM8FUT	MI	TT7RGTM
DMM8FUT	MN	Voltage-gated calcium channel alpha Cav1.3 (CACNA1D)
DMM8FUT	MT	DTT
DMM8FUT	MA	Modulator
DMM8FUT	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 530).
DMM8FUT	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=530

DMM8FUT	DI	DMM8FUT
DMM8FUT	DN	CPU-228
DMM8FUT	MI	TTX4QDJ
DMM8FUT	MN	Voltage-gated calcium channel alpha Cav2.1 (CACNA1A)
DMM8FUT	MT	DTT
DMM8FUT	MA	Modulator
DMM8FUT	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 532).
DMM8FUT	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=532

DMM8FUT	DI	DMM8FUT
DMM8FUT	DN	CPU-228
DMM8FUT	MI	TT4FDG6
DMM8FUT	MN	Voltage-gated calcium channel alpha Cav2.2 (CACNA1B)
DMM8FUT	MT	DTT
DMM8FUT	MA	Modulator
DMM8FUT	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 533).
DMM8FUT	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=533

DMM8FUT	DI	DMM8FUT
DMM8FUT	DN	CPU-228
DMM8FUT	MI	TTYRP0M
DMM8FUT	MN	Voltage-gated calcium channel alpha Cav2.3 (CACNA1E)
DMM8FUT	MT	DTT
DMM8FUT	MA	Modulator
DMM8FUT	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 534).
DMM8FUT	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=534

DMFG0XS	DI	DMFG0XS
DMFG0XS	DN	CR-2345
DMFG0XS	MI	TTCG0AL
DMFG0XS	MN	Cholecystokinin receptor type A (CCKAR)
DMFG0XS	MT	DTT
DMFG0XS	MA	Inhibitor
DMFG0XS	RN	Biological properties of (R)-4-benzamido-5-oxopentanoic basic derivatives as CCK-antagonists, Bioorg. Med. Chem. Lett. 3(5):861-866 (1993).
DMFG0XS	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00806812

DM3M5AW	DI	DM3M5AW
DM3M5AW	DN	CR-4174
DM3M5AW	MI	TTVKILB
DM3M5AW	MN	Prostaglandin G/H synthase 2 (COX-2)
DM3M5AW	MT	DTT
DM3M5AW	MA	Inhibitor
DM3M5AW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1376).
DM3M5AW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1376

DMXHIFZ	DI	DMXHIFZ
DMXHIFZ	DN	CR-4892
DMXHIFZ	MI	TT90XZ8
DMXHIFZ	MN	Voltage-gated sodium channel alpha Nav1.8 (SCN10A)
DMXHIFZ	MT	DTT
DMXHIFZ	MA	Blocker
DMXHIFZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 585).
DMXHIFZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=585

DME5IJQ	DI	DME5IJQ
DME5IJQ	DN	CR-5259
DME5IJQ	MI	TTXSU2Y
DME5IJQ	MN	Aggrecanase (ADAMTS5)
DME5IJQ	MT	DTT
DME5IJQ	MA	Inhibitor
DME5IJQ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1677).
DME5IJQ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1677

DMY2P5C	DI	DMY2P5C
DMY2P5C	DN	CR-5790
DMY2P5C	MI	TT79WV3
DMY2P5C	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DMY2P5C	MT	DTT
DMY2P5C	MA	Antagonist
DMY2P5C	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 343).
DMY2P5C	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=343

DM70YRT	DI	DM70YRT
DM70YRT	DN	CRA_10655
DM70YRT	MI	TTGY7WI
DM70YRT	MN	Urokinase-type plasminogen activator (PLAU)
DM70YRT	MT	DTT
DM70YRT	MA	Inhibitor
DM70YRT	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM70YRT	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMK54RM	DI	DMK54RM
DMK54RM	DN	CRA_1144
DMK54RM	MI	TT25MVL
DMK54RM	MN	Serine protease hepsin (HPN)
DMK54RM	MT	DTT
DMK54RM	MA	Inhibitor
DMK54RM	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMK54RM	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM3IZOP	DI	DM3IZOP
DM3IZOP	DN	CRA_8696
DM3IZOP	MI	TT6L509
DM3IZOP	MN	Coagulation factor IIa (F2)
DM3IZOP	MT	DTT
DM3IZOP	MA	Inhibitor
DM3IZOP	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM3IZOP	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM3IZOP	DI	DM3IZOP
DM3IZOP	DN	CRA_8696
DM3IZOP	MI	TTGY7WI
DM3IZOP	MN	Urokinase-type plasminogen activator (PLAU)
DM3IZOP	MT	DTT
DM3IZOP	MA	Inhibitor
DM3IZOP	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM3IZOP	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMPWZOK	DI	DMPWZOK
DMPWZOK	DN	CRB-0022
DMPWZOK	MI	TTEDJN4
DMPWZOK	MN	Low-affinity nerve growth factor receptor (NGFR)
DMPWZOK	MT	DTT
DMPWZOK	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1888).
DMPWZOK	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1888

DMLJOGK	DI	DMLJOGK
DMLJOGK	DN	Cremastrine
DMLJOGK	MI	TTZ9SOR
DMLJOGK	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMLJOGK	MT	DTT
DMLJOGK	MA	Inhibitor
DMLJOGK	RN	Cremastrine, a pyrrolizidine alkaloid from Cremastra appendiculata. J Nat Prod. 2005 Apr;68(4):572-3.
DMLJOGK	RU	https://pubmed.ncbi.nlm.nih.gov/15844951

DMLJOGK	DI	DMLJOGK
DMLJOGK	DN	Cremastrine
DMLJOGK	MI	TTQ13Z5
DMLJOGK	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMLJOGK	MT	DTT
DMLJOGK	MA	Inhibitor
DMLJOGK	RN	Cremastrine, a pyrrolizidine alkaloid from Cremastra appendiculata. J Nat Prod. 2005 Apr;68(4):572-3.
DMLJOGK	RU	https://pubmed.ncbi.nlm.nih.gov/15844951

DMLJOGK	DI	DMLJOGK
DMLJOGK	DN	Cremastrine
DMLJOGK	MI	TTQ3JTF
DMLJOGK	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DMLJOGK	MT	DTT
DMLJOGK	MA	Inhibitor
DMLJOGK	RN	Cremastrine, a pyrrolizidine alkaloid from Cremastra appendiculata. J Nat Prod. 2005 Apr;68(4):572-3.
DMLJOGK	RU	https://pubmed.ncbi.nlm.nih.gov/15844951

DMLJOGK	DI	DMLJOGK
DMLJOGK	DN	Cremastrine
DMLJOGK	MI	TTH18TF
DMLJOGK	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMLJOGK	MT	DTT
DMLJOGK	MA	Inhibitor
DMLJOGK	RN	Cremastrine, a pyrrolizidine alkaloid from Cremastra appendiculata. J Nat Prod. 2005 Apr;68(4):572-3.
DMLJOGK	RU	https://pubmed.ncbi.nlm.nih.gov/15844951

DMY0GXM	DI	DMY0GXM
DMY0GXM	DN	CRISNATOL MESILATE
DMY0GXM	MI	TTGTQHC
DMY0GXM	MN	DNA topoisomerase I (TOP1)
DMY0GXM	MT	DTT
DMY0GXM	MA	Modulator
DMY0GXM	RN	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
DMY0GXM	RU	https://www.ncbi.nlm.nih.gov/pubmed/27899562

DMYPLZ8	DI	DMYPLZ8
DMYPLZ8	DN	Cristacarpin
DMYPLZ8	MI	TT50QJ3
DMYPLZ8	MN	Influenza Neuraminidase (Influ NA)
DMYPLZ8	MT	DTT
DMYPLZ8	MA	Inhibitor
DMYPLZ8	RN	Prenylated pterocarpans as bacterial neuraminidase inhibitors. Bioorg Med Chem. 2010 May 1;18(9):3335-44.
DMYPLZ8	RU	https://pubmed.ncbi.nlm.nih.gov/20363636

DMERKU2	DI	DMERKU2
DMERKU2	DN	CRL-37212
DMERKU2	MI	TTPMQSO
DMERKU2	MN	ALK tyrosine kinase receptor (ALK)
DMERKU2	MT	DTT
DMERKU2	MA	Inhibitor
DMERKU2	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1839).
DMERKU2	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1839

DMELUG5	DI	DMELUG5
DMELUG5	DN	Crocusatin-K
DMELUG5	MI	TTULVH8
DMELUG5	MN	Tyrosinase (TYR)
DMELUG5	MT	DTT
DMELUG5	MA	Inhibitor
DMELUG5	RN	Antityrosinase principles and constituents of the petals of Crocus sativus. J Nat Prod. 2004 Mar;67(3):437-40.
DMELUG5	RU	https://pubmed.ncbi.nlm.nih.gov/15043425

DMTWRQI	DI	DMTWRQI
DMTWRQI	DN	crotylaldehyde
DMTWRQI	MI	TTFLN4T
DMTWRQI	MN	Mitochondrial aldehyde dehydrogenase (ALDH2)
DMTWRQI	MT	DTT
DMTWRQI	MA	Inhibitor
DMTWRQI	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMTWRQI	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMTWRQI	DI	DMTWRQI
DMTWRQI	DN	crotylaldehyde
DMTWRQI	MI	TTELV3W
DMTWRQI	MN	Transformation-sensitive protein p120 (TRPA1)
DMTWRQI	MT	DTT
DMTWRQI	MA	Activator
DMTWRQI	RN	Cigarette smoke-induced neurogenic inflammation is mediated by alpha,beta-unsaturated aldehydes and the TRPA1 receptor in rodents. J Clin Invest. 2008 Jul;118(7):2574-82.
DMTWRQI	RU	https://pubmed.ncbi.nlm.nih.gov/18568077

DMVYSAZ	DI	DMVYSAZ
DMVYSAZ	DN	CRT-0004592
DMVYSAZ	MI	TTWJTHX
DMVYSAZ	MN	Protein kinase C iota (PRKCI)
DMVYSAZ	MT	DTT
DMVYSAZ	MA	Inhibitor
DMVYSAZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1490).
DMVYSAZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1490

DMX09KI	DI	DMX09KI
DMX09KI	DN	CRT0066101
DMX09KI	MI	TTSLUMT
DMX09KI	MN	Protein kinase D (PRKD1)
DMX09KI	MT	DTT
DMX09KI	MA	Inhibitor
DMX09KI	RN	Protein kinase D as a potential new target for cancer therapy. Biochim Biophys Acta. 2010 Dec;1806(2):183-92.
DMX09KI	RU	https://pubmed.ncbi.nlm.nih.gov/20580776

DMBV79R	DI	DMBV79R
DMBV79R	DN	CRTX-070
DMBV79R	MI	TTH18TF
DMBV79R	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMBV79R	MT	DTT
DMBV79R	MA	Modulator
DMBV79R	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 467).
DMBV79R	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=467

DMW61UK	DI	DMW61UK
DMW61UK	DN	CRX-526
DMW61UK	MI	TTISGCA
DMW61UK	MN	Toll-like receptor 4 (TLR4)
DMW61UK	MT	DTT
DMW61UK	MA	Inhibitor
DMW61UK	RN	The 'Ethereal' nature of TLR4 agonism and antagonism in the AGP class of lipid A mimetics. Bioorg Med Chem Lett. 2008 Oct 15;18(20):5350-4.
DMW61UK	RU	https://pubmed.ncbi.nlm.nih.gov/18835160

DM92IK8	DI	DM92IK8
DM92IK8	DN	CRYPTADINE B
DM92IK8	MI	TT1RS9F
DM92IK8	MN	Acetylcholinesterase (AChE)
DM92IK8	MT	DTT
DM92IK8	MA	Inhibitor
DM92IK8	RN	Cryptadines A and B, novel C27N3-type pentacyclic alkaloids from Lycopodium cryptomerinum. Bioorg Med Chem. 2007 Dec 15;15(24):7803-8.
DM92IK8	RU	https://pubmed.ncbi.nlm.nih.gov/17904850

DM8W7VL	DI	DM8W7VL
DM8W7VL	DN	CS-6969
DM8W7VL	MI	DEEG96X
DM8W7VL	MN	Oxysterol 7-alpha-hydroxylase (CYP39A1)
DM8W7VL	MT	DME
DM8W7VL	MA	Metabolism
DM8W7VL	RN	Association of CYP39A1, RUNX2 and oxidized alpha-1 antitrypsin expression in relation to cholangiocarcinoma progression. Asian Pac J Cancer Prev. 2014;15(23):10187-92.
DM8W7VL	RU	https://pubmed.ncbi.nlm.nih.gov/25556446

DM6K123	DI	DM6K123
DM6K123	DN	CSC-500297
DM6K123	MI	TTWJBZ5
DM6K123	MN	5-HT 2C receptor (HTR2C)
DM6K123	MT	DTT
DM6K123	MA	Agonist
DM6K123	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 8).
DM6K123	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=8

DMTN1P2	DI	DMTN1P2
DMTN1P2	DN	CSL-324
DMTN1P2	MI	TTC70AJ
DMTN1P2	MN	Granulocyte colony-stimulating factor receptor (G-CSF-R)
DMTN1P2	MT	DTT
DMTN1P2	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1719).
DMTN1P2	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1719

DMYDTO8	DI	DMYDTO8
DMYDTO8	DN	CSNLSTCVLGKLSQELc[DKLHK]YPRTNTGSGTP-amide
DMYDTO8	MI	TTLWS2O
DMYDTO8	MN	Calcitonin receptor (CALCR)
DMYDTO8	MT	DTT
DMYDTO8	MA	Inhibitor
DMYDTO8	RN	Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept fo... J Med Chem. 2002 Feb 28;45(5):1108-21.
DMYDTO8	RU	https://pubmed.ncbi.nlm.nih.gov/11855991

DMQXEHJ	DI	DMQXEHJ
DMQXEHJ	DN	CSNLSTCVLGKLSQELc[DKLHO]YPRTNTGSGTP-amide
DMQXEHJ	MI	TTLWS2O
DMQXEHJ	MN	Calcitonin receptor (CALCR)
DMQXEHJ	MT	DTT
DMQXEHJ	MA	Inhibitor
DMQXEHJ	RN	Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept fo... J Med Chem. 2002 Feb 28;45(5):1108-21.
DMQXEHJ	RU	https://pubmed.ncbi.nlm.nih.gov/11855991

DMMZK89	DI	DMMZK89
DMMZK89	DN	CSNLSTCVLGKLSQELc[DKLQK]YPRTNTGSGTP-amide
DMMZK89	MI	TTLWS2O
DMMZK89	MN	Calcitonin receptor (CALCR)
DMMZK89	MT	DTT
DMMZK89	MA	Inhibitor
DMMZK89	RN	Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept fo... J Med Chem. 2002 Feb 28;45(5):1108-21.
DMMZK89	RU	https://pubmed.ncbi.nlm.nih.gov/11855991

DMTL2BA	DI	DMTL2BA
DMTL2BA	DN	CSNLSTCVLGKLSQELHKLQTYPRTNTGSGTP-amide
DMTL2BA	MI	TTLWS2O
DMTL2BA	MN	Calcitonin receptor (CALCR)
DMTL2BA	MT	DTT
DMTL2BA	MA	Inhibitor
DMTL2BA	RN	Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept fo... J Med Chem. 2002 Feb 28;45(5):1108-21.
DMTL2BA	RU	https://pubmed.ncbi.nlm.nih.gov/11855991

DM61V5W	DI	DM61V5W
DM61V5W	DN	CSNLSTCVLGKLSQELNKLHBYPRTNTGSGTP-amide
DM61V5W	MI	TTLWS2O
DM61V5W	MN	Calcitonin receptor (CALCR)
DM61V5W	MT	DTT
DM61V5W	MA	Inhibitor
DM61V5W	RN	Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept fo... J Med Chem. 2002 Feb 28;45(5):1108-21.
DM61V5W	RU	https://pubmed.ncbi.nlm.nih.gov/11855991

DM3W6PQ	DI	DM3W6PQ
DM3W6PQ	DN	CT-003230
DM3W6PQ	MI	TTE4KHA
DM3W6PQ	MN	Amyloid beta A4 protein (APP)
DM3W6PQ	MT	DTT
DM3W6PQ	MA	Inhibitor
DM3W6PQ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
DM3W6PQ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402

DMIVNMJ	DI	DMIVNMJ
DMIVNMJ	DN	CT-10
DMIVNMJ	MI	TTIKWV4
DMIVNMJ	MN	Geranyltranstransferase (FDPS)
DMIVNMJ	MT	DTT
DMIVNMJ	MA	Inhibitor
DMIVNMJ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 643).
DMIVNMJ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=643

DMUVQFW	DI	DMUVQFW
DMUVQFW	DN	CT301
DMUVQFW	MI	TT4BT06
DMUVQFW	MN	Integrin alpha-4 (ITGA4)
DMUVQFW	MT	DTT
DMUVQFW	MA	Antagonist
DMUVQFW	RN	Prolonged reversal of chronic experimental allergic encephalomyelitis using a small molecule inhibitor of alpha4 integrin. J Neuroimmunol. 2002 Oct;131(1-2):147-59.
DMUVQFW	RU	https://pubmed.ncbi.nlm.nih.gov/12458046

DM6W9LA	DI	DM6W9LA
DM6W9LA	DN	CT-5357
DM6W9LA	MI	TTV5CGO
DM6W9LA	MN	Phosphodiesterase 4 (PDE4)
DM6W9LA	MT	DTT
DM6W9LA	MA	Modulator
DM6W9LA	RN	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
DM6W9LA	RU	https://www.ncbi.nlm.nih.gov/pubmed/27899562

DM6F8DM	DI	DM6F8DM
DM6F8DM	DN	CT-98024
DM6F8DM	MI	TTRSMW9
DM6F8DM	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DM6F8DM	MT	DTT
DM6F8DM	MA	Inhibitor
DM6F8DM	RN	Discovery of potent and bioavailable GSK-3beta inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1693-6.
DM6F8DM	RU	https://pubmed.ncbi.nlm.nih.gov/20138512

DMLON9K	DI	DMLON9K
DMLON9K	DN	CTAP
DMLON9K	MI	TT27RFC
DMLON9K	MN	Opioid receptor delta (OPRD1)
DMLON9K	MT	DTT
DMLON9K	MA	Antagonist
DMLON9K	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317).
DMLON9K	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=317

DMLON9K	DI	DMLON9K
DMLON9K	DN	CTAP
DMLON9K	MI	TTKWM86
DMLON9K	MN	Opioid receptor mu (MOP)
DMLON9K	MT	DTT
DMLON9K	MA	Antagonist
DMLON9K	RN	Potent morphiceptin analogs: structure activity relationships and morphine-like activities. J Pharmacol Exp Ther. 1983 Nov;227(2):403-8.
DMLON9K	RU	https://pubmed.ncbi.nlm.nih.gov/6313901

DMEGZHF	DI	DMEGZHF
DMEGZHF	DN	CTCE-0324
DMEGZHF	MI	TTBID49
DMEGZHF	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMEGZHF	MT	DTT
DMEGZHF	MA	Modulator
DMEGZHF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 71).
DMEGZHF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=71

DMYRVZ8	DI	DMYRVZ8
DMYRVZ8	DN	CTEP
DMYRVZ8	MI	TTHS256
DMYRVZ8	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMYRVZ8	MT	DTT
DMYRVZ8	MA	Antagonist
DMYRVZ8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 293).
DMYRVZ8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=293

DMI3J0F	DI	DMI3J0F
DMI3J0F	DN	CTK1G9578
DMI3J0F	MI	DE4LYSA
DMI3J0F	MN	Cytochrome P450 3A4 (CYP3A4)
DMI3J0F	MT	DME
DMI3J0F	MA	Metabolism
DMI3J0F	RN	Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir. Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18422-7.
DMI3J0F	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20937904

DMKEIAS	DI	DMKEIAS
DMKEIAS	DN	CTLA-4-XTEN
DMKEIAS	MI	TTI2S1D
DMKEIAS	MN	Cytotoxic T-lymphocyte protein 4 (CTLA-4)
DMKEIAS	MT	DTT
DMKEIAS	MA	Modulator
DMKEIAS	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2743).
DMKEIAS	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2743

DM7VAJX	DI	DM7VAJX
DM7VAJX	DN	CTOP
DM7VAJX	MI	TT27RFC
DM7VAJX	MN	Opioid receptor delta (OPRD1)
DM7VAJX	MT	DTT
DM7VAJX	MA	Inhibitor
DM7VAJX	RN	Novel opioid peptide derived antagonists containing (2S)-2-methyl-3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid [(2S)-Mdcp]. J Med Chem. 2008 Sep 25;51(18):5866-70.
DM7VAJX	RU	https://pubmed.ncbi.nlm.nih.gov/18800771

DM7VAJX	DI	DM7VAJX
DM7VAJX	DN	CTOP
DM7VAJX	MI	TTKWM86
DM7VAJX	MN	Opioid receptor mu (MOP)
DM7VAJX	MT	DTT
DM7VAJX	MA	Antagonist
DM7VAJX	RN	Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol Pharmacol. 1994 Feb;45(2):330-4.
DM7VAJX	RU	https://pubmed.ncbi.nlm.nih.gov/8114680

DM4T62U	DI	DM4T62U
DM4T62U	DN	CTP
DM4T62U	MI	TT24DGP
DM4T62U	MN	P2Y purinoceptor 4 (P2RY4)
DM4T62U	MT	DTT
DM4T62U	MA	Agonist
DM4T62U	RN	ATP, an agonist at the rat P2Y(4) receptor, is an antagonist at the human P2Y(4) receptor. Mol Pharmacol. 2000 May;57(5):926-31.
DM4T62U	RU	https://pubmed.ncbi.nlm.nih.gov/10779375

DMQ5JX8	DI	DMQ5JX8
DMQ5JX8	DN	CTT-54
DMQ5JX8	MI	TT9G4N0
DMQ5JX8	MN	Glutamate carboxypeptidase II (GCPII)
DMQ5JX8	MT	DTT
DMQ5JX8	MA	Modulator
DMQ5JX8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1606).
DMQ5JX8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1606

DMDPJWF	DI	DMDPJWF
DMDPJWF	DN	CU201 (B9870)
DMDPJWF	MI	TTDJ4MY
DMDPJWF	MN	Kininogen (KNG1)
DMDPJWF	MT	DTT
DMDPJWF	MA	Inhibitor
DMDPJWF	RN	Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents. Clin Cancer Res. 2002 May;8(5):1280-7.
DMDPJWF	RU	https://pubmed.ncbi.nlm.nih.gov/12006549

DMY1WEM	DI	DMY1WEM
DMY1WEM	DN	CU-906
DMY1WEM	MI	TTHBTOP
DMY1WEM	MN	PI3-kinase gamma (PIK3CG)
DMY1WEM	MT	DTT
DMY1WEM	MA	Inhibitor
DMY1WEM	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2155).
DMY1WEM	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2155

DMY1WEM	DI	DMY1WEM
DMY1WEM	DN	CU-906
DMY1WEM	MI	TTCJG29
DMY1WEM	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMY1WEM	MT	DTT
DMY1WEM	MA	Inhibitor
DMY1WEM	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
DMY1WEM	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109

DMBL46A	DI	DMBL46A
DMBL46A	DN	CUDRATRICUSXANTHONE
DMBL46A	MI	TT50QJ3
DMBL46A	MN	Influenza Neuraminidase (Influ NA)
DMBL46A	MT	DTT
DMBL46A	MA	Inhibitor
DMBL46A	RN	Characteristic of neuraminidase inhibitory xanthones from Cudrania tricuspidata. Bioorg Med Chem. 2009 Apr 1;17(7):2744-50.
DMBL46A	RU	https://pubmed.ncbi.nlm.nih.gov/19285413

DM10BOC	DI	DM10BOC
DM10BOC	DN	Cudratricusxanthone F
DM10BOC	MI	TT50QJ3
DM10BOC	MN	Influenza Neuraminidase (Influ NA)
DM10BOC	MT	DTT
DM10BOC	MA	Inhibitor
DM10BOC	RN	Characteristic of neuraminidase inhibitory xanthones from Cudrania tricuspidata. Bioorg Med Chem. 2009 Apr 1;17(7):2744-50.
DM10BOC	RU	https://pubmed.ncbi.nlm.nih.gov/19285413

DMBQ1VO	DI	DMBQ1VO
DMBQ1VO	DN	Cudraxanthone D
DMBQ1VO	MI	TT50QJ3
DMBQ1VO	MN	Influenza Neuraminidase (Influ NA)
DMBQ1VO	MT	DTT
DMBQ1VO	MA	Inhibitor
DMBQ1VO	RN	Characteristic of neuraminidase inhibitory xanthones from Cudrania tricuspidata. Bioorg Med Chem. 2009 Apr 1;17(7):2744-50.
DMBQ1VO	RU	https://pubmed.ncbi.nlm.nih.gov/19285413

DMP1D5Q	DI	DMP1D5Q
DMP1D5Q	DN	Cudraxanthone L
DMP1D5Q	MI	TT50QJ3
DMP1D5Q	MN	Influenza Neuraminidase (Influ NA)
DMP1D5Q	MT	DTT
DMP1D5Q	MA	Inhibitor
DMP1D5Q	RN	Characteristic of neuraminidase inhibitory xanthones from Cudrania tricuspidata. Bioorg Med Chem. 2009 Apr 1;17(7):2744-50.
DMP1D5Q	RU	https://pubmed.ncbi.nlm.nih.gov/19285413

DMIQFAU	DI	DMIQFAU
DMIQFAU	DN	Cudraxanthone M
DMIQFAU	MI	TT50QJ3
DMIQFAU	MN	Influenza Neuraminidase (Influ NA)
DMIQFAU	MT	DTT
DMIQFAU	MA	Inhibitor
DMIQFAU	RN	Characteristic of neuraminidase inhibitory xanthones from Cudrania tricuspidata. Bioorg Med Chem. 2009 Apr 1;17(7):2744-50.
DMIQFAU	RU	https://pubmed.ncbi.nlm.nih.gov/19285413

DMEB0FX	DI	DMEB0FX
DMEB0FX	DN	CV-11194
DMEB0FX	MI	TT8DBY3
DMEB0FX	MN	Angiotensin II receptor type-1 (AGTR1)
DMEB0FX	MT	DTT
DMEB0FX	MA	Inhibitor
DMEB0FX	RN	Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisoste... J Med Chem. 1996 Dec 20;39(26):5228-35.
DMEB0FX	RU	https://pubmed.ncbi.nlm.nih.gov/8978851

DM9AL7W	DI	DM9AL7W
DM9AL7W	DN	CV-1674
DM9AL7W	MI	TTNE7KG
DM9AL7W	MN	Adenosine A2b receptor (ADORA2B)
DM9AL7W	MT	DTT
DM9AL7W	MA	Agonist
DM9AL7W	RN	Differences in the order of potency for agonists but not antagonists at human and rat adenosine A2A receptors. Biochem Pharmacol. 1999 Jan 1;57(1):65-75.
DM9AL7W	RU	https://pubmed.ncbi.nlm.nih.gov/9920286

DM07VRS	DI	DM07VRS
DM07VRS	DN	CV-1808
DM07VRS	MI	TTNE7KG
DM07VRS	MN	Adenosine A2b receptor (ADORA2B)
DM07VRS	MT	DTT
DM07VRS	MA	Agonist
DM07VRS	RN	Characterization of human A2A adenosine receptors with the antagonist radioligand [3H]-SCH 58261. Br J Pharmacol. 1997 Jun;121(3):353-60.
DM07VRS	RU	https://pubmed.ncbi.nlm.nih.gov/9179373

DMM7RAD	DI	DMM7RAD
DMM7RAD	DN	CV-3988
DMM7RAD	MI	TTQL5VC
DMM7RAD	MN	Platelet-activating factor receptor (PTAFR)
DMM7RAD	MT	DTT
DMM7RAD	MA	Antagonist
DMM7RAD	RN	Inhibition by CV-3988 of the binding of [3H]-platelet activating factor (PAF) to the platelet. Biochem Pharmacol. 1985 May 1;34(9):1491-5.
DMM7RAD	RU	https://pubmed.ncbi.nlm.nih.gov/2986648

DM983QP	DI	DM983QP
DM983QP	DN	CV-4093
DM983QP	MI	DE4LYSA
DM983QP	MN	Cytochrome P450 3A4 (CYP3A4)
DM983QP	MT	DME
DM983QP	MA	Metabolism
DM983QP	RN	Effect of grapefruit juice on the disposition of manidipine enantiomers in healthy subjects. Br J Clin Pharmacol. 2006 May;61(5):533-7.
DM983QP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16669846

DM983QP	DI	DM983QP
DM983QP	DN	CV-4093
DM983QP	MI	TTZIFHC
DM983QP	MN	Voltage-gated calcium channel alpha Cav1.2 (CACNA1C)
DM983QP	MT	DTT
DM983QP	MA	Inhibitor
DM983QP	RN	Dihydropyrimidines: novel calcium antagonists with potent and long-lasting vasodilative and antihypertensive activity. J Med Chem. 1989 Oct;32(10):2399-406.
DM983QP	RU	https://pubmed.ncbi.nlm.nih.gov/2552119

DM983QP	DI	DM983QP
DM983QP	DN	CV-4093
DM983QP	MI	TT7RGTM
DM983QP	MN	Voltage-gated calcium channel alpha Cav1.3 (CACNA1D)
DM983QP	MT	DTT
DM983QP	MA	Inhibitor
DM983QP	RN	Dihydropyrimidines: novel calcium antagonists with potent and long-lasting vasodilative and antihypertensive activity. J Med Chem. 1989 Oct;32(10):2399-406.
DM983QP	RU	https://pubmed.ncbi.nlm.nih.gov/2552119

DMO9WZN	DI	DMO9WZN
DMO9WZN	DN	CV-6504.HCL
DMO9WZN	MI	TTKNWZ4
DMO9WZN	MN	Thromboxane-A synthase (TBXAS1)
DMO9WZN	MT	DTT
DMO9WZN	MA	Modulator
DMO9WZN	RN	Involvement of thromboxane A2, leukotrienes and free radicals in puromycin nephrosis in rats. Kidney Int. 1991 May;39(5):920-9.
DMO9WZN	RU	https://pubmed.ncbi.nlm.nih.gov/2067208

DMO9UMK	DI	DMO9UMK
DMO9UMK	DN	CVS-1578
DMO9UMK	MI	TT6L509
DMO9UMK	MN	Coagulation factor IIa (F2)
DMO9UMK	MT	DTT
DMO9UMK	MA	Modulator
DMO9UMK	RN	Design and construction of novel thrombin inhibitors featuring P3-P4 quaternary lactam dipeptide surrogates. Bioorg Med Chem Lett. 1998 Sep 22;8(18):2501-6.
DMO9UMK	RU	https://www.ncbi.nlm.nih.gov/pubmed/9873569

DMT5R1Q	DI	DMT5R1Q
DMT5R1Q	DN	CVS-2139
DMT5R1Q	MI	TT2WR1T
DMT5R1Q	MN	Cationic trypsinogen (PRSS1)
DMT5R1Q	MT	DTT
DMT5R1Q	MA	Inhibitor
DMT5R1Q	RN	Non-covalent thrombin inhibitors featuring P(3)-heterocycles with P(1)-monocyclic arginine surrogates. Bioorg Med Chem Lett. 2002 Apr 22;12(8):1203-8.
DMT5R1Q	RU	https://pubmed.ncbi.nlm.nih.gov/11934589

DM3KB4H	DI	DM3KB4H
DM3KB4H	DN	CVS-2359
DM3KB4H	MI	TT2WR1T
DM3KB4H	MN	Cationic trypsinogen (PRSS1)
DM3KB4H	MT	DTT
DM3KB4H	MA	Inhibitor
DM3KB4H	RN	Non-covalent thrombin inhibitors featuring P(3)-heterocycles with P(1)-monocyclic arginine surrogates. Bioorg Med Chem Lett. 2002 Apr 22;12(8):1203-8.
DM3KB4H	RU	https://pubmed.ncbi.nlm.nih.gov/11934589

DMDH6PJ	DI	DMDH6PJ
DMDH6PJ	DN	CVT-10216
DMDH6PJ	MI	TTFLN4T
DMDH6PJ	MN	Mitochondrial aldehyde dehydrogenase (ALDH2)
DMDH6PJ	MT	DTT
DMDH6PJ	MA	Antagonist
DMDH6PJ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2595).
DMDH6PJ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2595

DMOCKMZ	DI	DMOCKMZ
DMOCKMZ	DN	CVT-12012
DMOCKMZ	MI	TT6RIOV
DMOCKMZ	MN	Acyl-CoA desaturase (SCD)
DMOCKMZ	MT	DTT
DMOCKMZ	MA	Inhibitor
DMOCKMZ	RN	Potent, orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4070-4.
DMOCKMZ	RU	https://pubmed.ncbi.nlm.nih.gov/19577469

DMSEK5W	DI	DMSEK5W
DMSEK5W	DN	CVT-313
DMSEK5W	MI	TTH6V3D
DMSEK5W	MN	Cyclin-dependent kinase 1 (CDK1)
DMSEK5W	MT	DTT
DMSEK5W	MA	Inhibitor
DMSEK5W	RN	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
DMSEK5W	RU	https://pubmed.ncbi.nlm.nih.gov/18077363

DMSEK5W	DI	DMSEK5W
DMSEK5W	DN	CVT-313
DMSEK5W	MI	TT7HF4W
DMSEK5W	MN	Cyclin-dependent kinase 2 (CDK2)
DMSEK5W	MT	DTT
DMSEK5W	MA	Inhibitor
DMSEK5W	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1973).
DMSEK5W	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1973

DMYC1DW	DI	DMYC1DW
DMYC1DW	DN	CVT-6694
DMYC1DW	MI	TTNE7KG
DMYC1DW	MN	Adenosine A2b receptor (ADORA2B)
DMYC1DW	MT	DTT
DMYC1DW	MA	Inhibitor
DMYC1DW	RN	Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods. Eur J Med Chem. 2010 Aug;45(8):3459-71.
DMYC1DW	RU	https://pubmed.ncbi.nlm.nih.gov/20537438

DM53VA8	DI	DM53VA8
DM53VA8	DN	CVT-7124
DM53VA8	MI	TTNE7KG
DM53VA8	MN	Adenosine A2b receptor (ADORA2B)
DM53VA8	MT	DTT
DM53VA8	MA	Inhibitor
DM53VA8	RN	Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods. Eur J Med Chem. 2010 Aug;45(8):3459-71.
DM53VA8	RU	https://pubmed.ncbi.nlm.nih.gov/20537438

DMXMIT4	DI	DMXMIT4
DMXMIT4	DN	CX-02
DMXMIT4	MI	TTBID49
DMXMIT4	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMXMIT4	MT	DTT
DMXMIT4	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 71).
DMXMIT4	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=71

DM7293Q	DI	DM7293Q
DM7293Q	DN	CX-1001
DM7293Q	MI	TT3ROYC
DM7293Q	MN	Serotonin transporter (SERT)
DM7293Q	MT	DTT
DM7293Q	MA	Binder
DM7293Q	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 928).
DM7293Q	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=928

DMCNEXF	DI	DMCNEXF
DMCNEXF	DN	CX4
DMCNEXF	MI	TTZ4MTQ
DMCNEXF	MN	Voltage-gated potassium channel Kv12.2 (KCNH3)
DMCNEXF	MT	DTT
DMCNEXF	MA	Inhibitor (gating inhibitor)
DMCNEXF	RN	Deletion of the potassium channel Kv12.2 causes hippocampal hyperexcitability and epilepsy. Nat Neurosci. 2010 Sep;13(9):1056-8.
DMCNEXF	RU	https://pubmed.ncbi.nlm.nih.gov/20676103

DMXD1IN	DI	DMXD1IN
DMXD1IN	DN	CX-5011
DMXD1IN	MI	TTER6YH
DMXD1IN	MN	Casein kinase II alpha (CSNK2A1)
DMXD1IN	MT	DTT
DMXD1IN	MA	Inhibitor
DMXD1IN	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1549).
DMXD1IN	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1549

DMNTAV8	DI	DMNTAV8
DMNTAV8	DN	CX-7000
DMNTAV8	MI	TTER6YH
DMNTAV8	MN	Casein kinase II alpha (CSNK2A1)
DMNTAV8	MT	DTT
DMNTAV8	MA	Inhibitor
DMNTAV8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1549).
DMNTAV8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1549

DM526C9	DI	DM526C9
DM526C9	DN	CX-9051
DM526C9	MI	TTVKILB
DM526C9	MN	Prostaglandin G/H synthase 2 (COX-2)
DM526C9	MT	DTT
DM526C9	MA	Inhibitor
DM526C9	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1376).
DM526C9	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1376

DMAPRDE	DI	DMAPRDE
DMAPRDE	DN	CXB-029
DMAPRDE	MI	TT6OEDT
DMAPRDE	MN	Cannabinoid receptor 1 (CB1)
DMAPRDE	MT	DTT
DMAPRDE	MA	Antagonist
DMAPRDE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 56).
DMAPRDE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=56

DMG1SXD	DI	DMG1SXD
DMG1SXD	DN	CXCL8
DMG1SXD	MI	TT30C9G
DMG1SXD	MN	C-X-C chemokine receptor type 2 (CXCR2)
DMG1SXD	MT	DTT
DMG1SXD	MA	Agonist
DMG1SXD	RN	Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11791-6.
DMG1SXD	RU	https://pubmed.ncbi.nlm.nih.gov/15282370

DMG1SXD	DI	DMG1SXD
DMG1SXD	DN	CXCL8
DMG1SXD	MI	TTBID49
DMG1SXD	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMG1SXD	MT	DTT
DMG1SXD	MA	Agonist
DMG1SXD	RN	Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11791-6.
DMG1SXD	RU	https://pubmed.ncbi.nlm.nih.gov/15282370

DMNSUD9	DI	DMNSUD9
DMNSUD9	DN	CXCR4 gene disrupted T cells
DMNSUD9	MI	TTBID49
DMNSUD9	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMNSUD9	MT	DTT
DMNSUD9	MA	Modulator
DMNSUD9	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 71).
DMNSUD9	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=71

DMBKTHI	DI	DMBKTHI
DMBKTHI	DN	Cy3B-telenzepine
DMBKTHI	MI	TTOXS3C
DMBKTHI	MN	Muscarinic acetylcholine receptor (CHRM)
DMBKTHI	MT	DTT
DMBKTHI	MA	Antagonist
DMBKTHI	RN	Formation and dissociation of M1 muscarinic receptor dimers seen by total internal reflection fluorescence imaging of single molecules. Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2693-8.
DMBKTHI	RU	https://pubmed.ncbi.nlm.nih.gov/20133736

DMZ6YPV	DI	DMZ6YPV
DMZ6YPV	DN	Cyamemazine
DMZ6YPV	MI	TTSQIFT
DMZ6YPV	MN	5-HT 1A receptor (HTR1A)
DMZ6YPV	MT	DTT
DMZ6YPV	MA	Antagonist
DMZ6YPV	RN	Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes. Biochem Pharmacol. 2003 Feb 1;65(3):435-40.
DMZ6YPV	RU	https://pubmed.ncbi.nlm.nih.gov/12527336

DMZ6YPV	DI	DMZ6YPV
DMZ6YPV	DN	Cyamemazine
DMZ6YPV	MI	TTJQOD7
DMZ6YPV	MN	5-HT 2A receptor (HTR2A)
DMZ6YPV	MT	DTT
DMZ6YPV	MA	Antagonist
DMZ6YPV	RN	Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes. Biochem Pharmacol. 2003 Feb 1;65(3):435-40.
DMZ6YPV	RU	https://pubmed.ncbi.nlm.nih.gov/12527336

DMZ6YPV	DI	DMZ6YPV
DMZ6YPV	DN	Cyamemazine
DMZ6YPV	MI	TTWJBZ5
DMZ6YPV	MN	5-HT 2C receptor (HTR2C)
DMZ6YPV	MT	DTT
DMZ6YPV	MA	Antagonist
DMZ6YPV	RN	Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes. Biochem Pharmacol. 2003 Feb 1;65(3):435-40.
DMZ6YPV	RU	https://pubmed.ncbi.nlm.nih.gov/12527336

DMZ6YPV	DI	DMZ6YPV
DMZ6YPV	DN	Cyamemazine
DMZ6YPV	MI	TTO9X1H
DMZ6YPV	MN	5-HT 7 receptor (HTR7)
DMZ6YPV	MT	DTT
DMZ6YPV	MA	Antagonist
DMZ6YPV	RN	Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes. Biochem Pharmacol. 2003 Feb 1;65(3):435-40.
DMZ6YPV	RU	https://pubmed.ncbi.nlm.nih.gov/12527336

DMZ6YPV	DI	DMZ6YPV
DMZ6YPV	DN	Cyamemazine
DMZ6YPV	MI	DEJGDUW
DMZ6YPV	MN	Cytochrome P450 1A2 (CYP1A2)
DMZ6YPV	MT	DME
DMZ6YPV	MA	Metabolism
DMZ6YPV	RN	Characterization of human cytochrome P450 enzymes involved in the metabolism of cyamemazine. Eur J Pharm Sci. 2007 Dec;32(4-5):357-66.
DMZ6YPV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17951033

DMZ6YPV	DI	DMZ6YPV
DMZ6YPV	DN	Cyamemazine
DMZ6YPV	MI	DES5XRU
DMZ6YPV	MN	Cytochrome P450 2C8 (CYP2C8)
DMZ6YPV	MT	DME
DMZ6YPV	MA	Metabolism
DMZ6YPV	RN	Characterization of human cytochrome P450 enzymes involved in the metabolism of cyamemazine. Eur J Pharm Sci. 2007 Dec;32(4-5):357-66.
DMZ6YPV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17951033

DMZ6YPV	DI	DMZ6YPV
DMZ6YPV	DN	Cyamemazine
DMZ6YPV	MI	DE5IED8
DMZ6YPV	MN	Cytochrome P450 2C9 (CYP2C9)
DMZ6YPV	MT	DME
DMZ6YPV	MA	Metabolism
DMZ6YPV	RN	Characterization of human cytochrome P450 enzymes involved in the metabolism of cyamemazine. Eur J Pharm Sci. 2007 Dec;32(4-5):357-66.
DMZ6YPV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17951033

DMZ6YPV	DI	DMZ6YPV
DMZ6YPV	DN	Cyamemazine
DMZ6YPV	MI	DE4LYSA
DMZ6YPV	MN	Cytochrome P450 3A4 (CYP3A4)
DMZ6YPV	MT	DME
DMZ6YPV	MA	Metabolism
DMZ6YPV	RN	Characterization of human cytochrome P450 enzymes involved in the metabolism of cyamemazine. Eur J Pharm Sci. 2007 Dec;32(4-5):357-66.
DMZ6YPV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17951033

DM6HQDL	DI	DM6HQDL
DM6HQDL	DN	CYANATE
DM6HQDL	MI	TTHQPL7
DM6HQDL	MN	Carbonic anhydrase I (CA-I)
DM6HQDL	MT	DTT
DM6HQDL	MA	Inhibitor
DM6HQDL	RN	Carbonic anhydrase inhibitors: inhibition of the membrane-bound human isozyme IV with anions. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5769-73.
DM6HQDL	RU	https://pubmed.ncbi.nlm.nih.gov/15501038

DMJE4HK	DI	DMJE4HK
DMJE4HK	DN	Cyanide
DMJE4HK	MI	TT3PQ2Y
DMJE4HK	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DMJE4HK	MT	DTT
DMJE4HK	MA	Inhibitor
DMJE4HK	RN	Effects of atovaquone and other inhibitors on Pneumocystis carinii dihydroorotate dehydrogenase. Antimicrob Agents Chemother. 1995 Feb;39(2):325-8.
DMJE4HK	RU	https://pubmed.ncbi.nlm.nih.gov/7726490

DMZBDO1	DI	DMZBDO1
DMZBDO1	DN	CYANIDIN
DMZBDO1	MI	TTV9A7R
DMZBDO1	MN	Lactoylglutathione lyase (GLO1)
DMZBDO1	MT	DTT
DMZBDO1	MA	Inhibitor
DMZBDO1	RN	Delphinidin, a dietary anthocyanidin in berry fruits, inhibits human glyoxalase I. Bioorg Med Chem. 2010 Oct 1;18(19):7029-33.
DMZBDO1	RU	https://pubmed.ncbi.nlm.nih.gov/20801663

DMIBLGH	DI	DMIBLGH
DMIBLGH	DN	Cyanopindolol
DMIBLGH	MI	TTWT5K7
DMIBLGH	MN	5-HT 1 receptor (5HT1R)
DMIBLGH	MT	DTT
DMIBLGH	MA	Antagonist
DMIBLGH	RN	The inhibitory effect of serotonin on the spontaneous discharge of suprachiasmatic neurons in hypothalamic slice is mediated by 5-HT(7) receptor. Brain Res Bull. 2001 Mar 1;54(4):395-8.
DMIBLGH	RU	https://pubmed.ncbi.nlm.nih.gov/11306191

DMC6DAZ	DI	DMC6DAZ
DMC6DAZ	DN	CYCLAZOCINE
DMC6DAZ	MI	TT27RFC
DMC6DAZ	MN	Opioid receptor delta (OPRD1)
DMC6DAZ	MT	DTT
DMC6DAZ	MA	Inhibitor
DMC6DAZ	RN	Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 7: syntheses and opioid receptor properties of cyclic variants ... Bioorg Med Chem Lett. 2009 Jan 15;19(2):365-8.
DMC6DAZ	RU	https://pubmed.ncbi.nlm.nih.gov/19091564

DMC6DAZ	DI	DMC6DAZ
DMC6DAZ	DN	CYCLAZOCINE
DMC6DAZ	MI	TTQW87Y
DMC6DAZ	MN	Opioid receptor kappa (OPRK1)
DMC6DAZ	MT	DTT
DMC6DAZ	MA	Inhibitor
DMC6DAZ	RN	Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pha... J Med Chem. 2000 Jan 13;43(1):114-22.
DMC6DAZ	RU	https://pubmed.ncbi.nlm.nih.gov/10633042

DMC6DAZ	DI	DMC6DAZ
DMC6DAZ	DN	CYCLAZOCINE
DMC6DAZ	MI	TTKWM86
DMC6DAZ	MN	Opioid receptor mu (MOP)
DMC6DAZ	MT	DTT
DMC6DAZ	MA	Inhibitor
DMC6DAZ	RN	Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pha... J Med Chem. 2000 Jan 13;43(1):114-22.
DMC6DAZ	RU	https://pubmed.ncbi.nlm.nih.gov/10633042

DMPXHO8	DI	DMPXHO8
DMPXHO8	DN	Cyclazosin
DMPXHO8	MI	TTBRKXS
DMPXHO8	MN	Adrenergic receptor alpha-1B (ADRA1B)
DMPXHO8	MT	DTT
DMPXHO8	MA	Antagonist
DMPXHO8	RN	Identification of alpha1-adrenoceptor subtypes involved in contraction of young CD rat epididymal vas deferens. Eur J Pharmacol. 2009 Jan 14;602(2-3):388-94.
DMPXHO8	RU	https://pubmed.ncbi.nlm.nih.gov/19041301

DMVJL8H	DI	DMVJL8H
DMVJL8H	DN	cyclic CMP
DMVJL8H	MI	TT9EUT4
DMVJL8H	MN	Hyperpolarization cyclic nucleotide-gated channel 2 (HCN2)
DMVJL8H	MT	DTT
DMVJL8H	MA	Activator
DMVJL8H	RN	Regulation of hyperpolarization-activated cyclic nucleotide-gated (HCN) channel activity by cCMP. J Biol Chem. 2012 Aug 3;287(32):26506-12.
DMVJL8H	RU	https://pubmed.ncbi.nlm.nih.gov/22715094

DMOU93V	DI	DMOU93V
DMOU93V	DN	Cyclic guanosine monophosphate
DMOU93V	MI	TTNAHEX
DMOU93V	MN	cAMP-dependent protein kinase A type I (PRKAR1A)
DMOU93V	MT	DTT
DMOU93V	MA	Inhibitor
DMOU93V	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMOU93V	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMOU93V	DI	DMOU93V
DMOU93V	DN	Cyclic guanosine monophosphate
DMOU93V	MI	TTJGW1Z
DMOU93V	MN	Phosphodiesterase 2A (PDE2A)
DMOU93V	MT	DTT
DMOU93V	MA	Inhibitor
DMOU93V	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMOU93V	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM2JE5F	DI	DM2JE5F
DM2JE5F	DN	Cyclic LVVYPWT
DM2JE5F	MI	TT2THBD
DM2JE5F	MN	P2X purinoceptor 3 (P2RX3)
DM2JE5F	MT	DTT
DM2JE5F	MA	Inhibitor
DM2JE5F	RN	Structure-activity relationship studies of spinorphin as a potent and selective human P2X(3) receptor antagonist. J Med Chem. 2007 Sep 6;50(18):4543-7.
DM2JE5F	RU	https://pubmed.ncbi.nlm.nih.gov/17676725

DMFUG05	DI	DMFUG05
DMFUG05	DN	Cyclo(1,10)EIYDPGDDIK
DMFUG05	MI	TTJDUNO
DMFUG05	MN	T-cell surface antigen CD2 (CD2)
DMFUG05	MT	DTT
DMFUG05	MA	Inhibitor
DMFUG05	RN	Design of beta-hairpin peptides for modulation of cell adhesion by beta-turn constraint. J Med Chem. 2009 Feb 12;52(3):726-36.
DMFUG05	RU	https://pubmed.ncbi.nlm.nih.gov/19123855

DM5CBQ9	DI	DM5CBQ9
DM5CBQ9	DN	Cyclo(1,10)H-EIYDPGDDIK-OH
DM5CBQ9	MI	TTJDUNO
DM5CBQ9	MN	T-cell surface antigen CD2 (CD2)
DM5CBQ9	MT	DTT
DM5CBQ9	MA	Inhibitor
DM5CBQ9	RN	Design of beta-hairpin peptides for modulation of cell adhesion by beta-turn constraint. J Med Chem. 2009 Feb 12;52(3):726-36.
DM5CBQ9	RU	https://pubmed.ncbi.nlm.nih.gov/19123855

DM4A1TF	DI	DM4A1TF
DM4A1TF	DN	Cyclo(1,11)H-ESIYDPGDDIK-OH
DM4A1TF	MI	TTJDUNO
DM4A1TF	MN	T-cell surface antigen CD2 (CD2)
DM4A1TF	MT	DTT
DM4A1TF	MA	Inhibitor
DM4A1TF	RN	Design of beta-hairpin peptides for modulation of cell adhesion by beta-turn constraint. J Med Chem. 2009 Feb 12;52(3):726-36.
DM4A1TF	RU	https://pubmed.ncbi.nlm.nih.gov/19123855

DMVDS8B	DI	DMVDS8B
DMVDS8B	DN	Cyclo(1,12)PenIYDTKGKNVLC-OH
DMVDS8B	MI	TTJDUNO
DMVDS8B	MN	T-cell surface antigen CD2 (CD2)
DMVDS8B	MT	DTT
DMVDS8B	MA	Inhibitor
DMVDS8B	RN	Structure-activity studies of peptides from the "hot-spot" region of human CD2 protein: development of peptides for immunomodulation. J Med Chem. 2005 Oct 6;48(20):6236-49.
DMVDS8B	RU	https://pubmed.ncbi.nlm.nih.gov/16190751

DMLY8CU	DI	DMLY8CU
DMLY8CU	DN	Cyclo(-D-Ala-D-Arg-L-Arg-L-Nal-Gly-)
DMLY8CU	MI	TTBID49
DMLY8CU	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMLY8CU	MT	DTT
DMLY8CU	MA	Inhibitor
DMLY8CU	RN	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
DMLY8CU	RU	https://pubmed.ncbi.nlm.nih.gov/17228861

DMBKRQ9	DI	DMBKRQ9
DMBKRQ9	DN	Cyclo(-D-MeTyr-D-Arg-L-Arg-L-Nal-Gly-)
DMBKRQ9	MI	TTBID49
DMBKRQ9	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMBKRQ9	MT	DTT
DMBKRQ9	MA	Inhibitor
DMBKRQ9	RN	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
DMBKRQ9	RU	https://pubmed.ncbi.nlm.nih.gov/17228861

DMHI0UL	DI	DMHI0UL
DMHI0UL	DN	Cyclo(-D-MeTyr-L-Arg-L-Arg-L-Nal-Gly-)
DMHI0UL	MI	TTBID49
DMHI0UL	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMHI0UL	MT	DTT
DMHI0UL	MA	Inhibitor
DMHI0UL	RN	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
DMHI0UL	RU	https://pubmed.ncbi.nlm.nih.gov/17228861

DM82C6Q	DI	DM82C6Q
DM82C6Q	DN	Cyclo(-D-Tyr-Arg-Arg-Nal-Gly-)
DM82C6Q	MI	TTBID49
DM82C6Q	MN	C-X-C chemokine receptor type 4 (CXCR4)
DM82C6Q	MT	DTT
DM82C6Q	MA	Inhibitor
DM82C6Q	RN	Identification of novel non-peptide CXCR4 antagonists by ligand-based design approach. Bioorg Med Chem Lett. 2008 Jul 15;18(14):4124-9.
DM82C6Q	RU	https://pubmed.ncbi.nlm.nih.gov/18539453

DM8RKT1	DI	DM8RKT1
DM8RKT1	DN	Cyclo(-D-Tyr-D-Ala-L-Arg-L-Nal-Gly-)
DM8RKT1	MI	TTBID49
DM8RKT1	MN	C-X-C chemokine receptor type 4 (CXCR4)
DM8RKT1	MT	DTT
DM8RKT1	MA	Inhibitor
DM8RKT1	RN	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
DM8RKT1	RU	https://pubmed.ncbi.nlm.nih.gov/17228861

DM8XVAW	DI	DM8XVAW
DM8XVAW	DN	Cyclo(-D-Tyr-D-Arg-L-Arg-L-MeNal-Gly-)
DM8XVAW	MI	TTBID49
DM8XVAW	MN	C-X-C chemokine receptor type 4 (CXCR4)
DM8XVAW	MT	DTT
DM8XVAW	MA	Inhibitor
DM8XVAW	RN	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
DM8XVAW	RU	https://pubmed.ncbi.nlm.nih.gov/17228861

DMWFITM	DI	DMWFITM
DMWFITM	DN	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-beta-Ala-)
DMWFITM	MI	TTBID49
DMWFITM	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMWFITM	MT	DTT
DMWFITM	MA	Inhibitor
DMWFITM	RN	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
DMWFITM	RU	https://pubmed.ncbi.nlm.nih.gov/17228861

DMSA0IW	DI	DMSA0IW
DMSA0IW	DN	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-D-Ala-)
DMSA0IW	MI	TTBID49
DMSA0IW	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMSA0IW	MT	DTT
DMSA0IW	MA	Inhibitor
DMSA0IW	RN	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
DMSA0IW	RU	https://pubmed.ncbi.nlm.nih.gov/17228861

DMGOW1E	DI	DMGOW1E
DMGOW1E	DN	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Gly-)
DMGOW1E	MI	TTBID49
DMGOW1E	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMGOW1E	MT	DTT
DMGOW1E	MA	Inhibitor
DMGOW1E	RN	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
DMGOW1E	RU	https://pubmed.ncbi.nlm.nih.gov/17228861

DM3PRHF	DI	DM3PRHF
DM3PRHF	DN	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Ala-)
DM3PRHF	MI	TTBID49
DM3PRHF	MN	C-X-C chemokine receptor type 4 (CXCR4)
DM3PRHF	MT	DTT
DM3PRHF	MA	Inhibitor
DM3PRHF	RN	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
DM3PRHF	RU	https://pubmed.ncbi.nlm.nih.gov/17228861

DMS9QHI	DI	DMS9QHI
DMS9QHI	DN	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Pic-)
DMS9QHI	MI	TTBID49
DMS9QHI	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMS9QHI	MT	DTT
DMS9QHI	MA	Inhibitor
DMS9QHI	RN	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
DMS9QHI	RU	https://pubmed.ncbi.nlm.nih.gov/17228861

DM3Y1TZ	DI	DM3Y1TZ
DM3Y1TZ	DN	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Sar-)
DM3Y1TZ	MI	TTBID49
DM3Y1TZ	MN	C-X-C chemokine receptor type 4 (CXCR4)
DM3Y1TZ	MT	DTT
DM3Y1TZ	MA	Inhibitor
DM3Y1TZ	RN	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
DM3Y1TZ	RU	https://pubmed.ncbi.nlm.nih.gov/17228861

DMUWC5O	DI	DMUWC5O
DMUWC5O	DN	Cyclo(-D-Tyr-D-Arg-L-MeArg-L-Nal-Gly-)
DMUWC5O	MI	TTBID49
DMUWC5O	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMUWC5O	MT	DTT
DMUWC5O	MA	Inhibitor
DMUWC5O	RN	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
DMUWC5O	RU	https://pubmed.ncbi.nlm.nih.gov/17228861

DM8F5DY	DI	DM8F5DY
DM8F5DY	DN	Cyclo(-D-Tyr-D-MeArg-L-Arg-L-Nal-Gly-)
DM8F5DY	MI	TTBID49
DM8F5DY	MN	C-X-C chemokine receptor type 4 (CXCR4)
DM8F5DY	MT	DTT
DM8F5DY	MA	Inhibitor
DM8F5DY	RN	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
DM8F5DY	RU	https://pubmed.ncbi.nlm.nih.gov/17228861

DMPW9SD	DI	DMPW9SD
DMPW9SD	DN	Cyclo(-D-Tyr-L-Ala-L-Arg-L-Nal-Gly-)
DMPW9SD	MI	TTBID49
DMPW9SD	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMPW9SD	MT	DTT
DMPW9SD	MA	Inhibitor
DMPW9SD	RN	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
DMPW9SD	RU	https://pubmed.ncbi.nlm.nih.gov/17228861

DMOWT4H	DI	DMOWT4H
DMOWT4H	DN	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Ala-Sar-)
DMOWT4H	MI	TTBID49
DMOWT4H	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMOWT4H	MT	DTT
DMOWT4H	MA	Inhibitor
DMOWT4H	RN	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
DMOWT4H	RU	https://pubmed.ncbi.nlm.nih.gov/17228861

DMPZ316	DI	DMPZ316
DMPZ316	DN	Cyclo(-D-Tyr-L-Arg-L-Arg-L-MeNal-Gly-)
DMPZ316	MI	TTBID49
DMPZ316	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMPZ316	MT	DTT
DMPZ316	MA	Inhibitor
DMPZ316	RN	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
DMPZ316	RU	https://pubmed.ncbi.nlm.nih.gov/17228861

DMNQWBS	DI	DMNQWBS
DMNQWBS	DN	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-beta-Ala-)
DMNQWBS	MI	TTBID49
DMNQWBS	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMNQWBS	MT	DTT
DMNQWBS	MA	Inhibitor
DMNQWBS	RN	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
DMNQWBS	RU	https://pubmed.ncbi.nlm.nih.gov/17228861

DMV6C9N	DI	DMV6C9N
DMV6C9N	DN	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-D-Ala-)
DMV6C9N	MI	TTBID49
DMV6C9N	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMV6C9N	MT	DTT
DMV6C9N	MA	Inhibitor
DMV6C9N	RN	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
DMV6C9N	RU	https://pubmed.ncbi.nlm.nih.gov/17228861

DMH9VMO	DI	DMH9VMO
DMH9VMO	DN	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-Gly-)
DMH9VMO	MI	TTBID49
DMH9VMO	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMH9VMO	MT	DTT
DMH9VMO	MA	Inhibitor
DMH9VMO	RN	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
DMH9VMO	RU	https://pubmed.ncbi.nlm.nih.gov/17228861

DM72HW3	DI	DM72HW3
DM72HW3	DN	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-L-Ala-)
DM72HW3	MI	TTBID49
DM72HW3	MN	C-X-C chemokine receptor type 4 (CXCR4)
DM72HW3	MT	DTT
DM72HW3	MA	Inhibitor
DM72HW3	RN	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
DM72HW3	RU	https://pubmed.ncbi.nlm.nih.gov/17228861

DMSPKWD	DI	DMSPKWD
DMSPKWD	DN	Cyclo(-D-Tyr-L-Arg-L-MeArg-L-Nal-Gly-)
DMSPKWD	MI	TTBID49
DMSPKWD	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMSPKWD	MT	DTT
DMSPKWD	MA	Inhibitor
DMSPKWD	RN	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
DMSPKWD	RU	https://pubmed.ncbi.nlm.nih.gov/17228861

DMIUVQ6	DI	DMIUVQ6
DMIUVQ6	DN	Cyclo(-D-Tyr-L-MeArg-L-Arg-L-Nal-Gly-)
DMIUVQ6	MI	TTBID49
DMIUVQ6	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMIUVQ6	MT	DTT
DMIUVQ6	MA	Inhibitor
DMIUVQ6	RN	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
DMIUVQ6	RU	https://pubmed.ncbi.nlm.nih.gov/17228861

DMZF35W	DI	DMZF35W
DMZF35W	DN	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)
DMZF35W	MI	TT6R7JZ
DMZF35W	MN	Histone deacetylase 1 (HDAC1)
DMZF35W	MT	DTT
DMZF35W	MA	Inhibitor
DMZF35W	RN	Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
DMZF35W	RU	https://pubmed.ncbi.nlm.nih.gov/17881232

DMZF35W	DI	DMZF35W
DMZF35W	DN	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)
DMZF35W	MI	TTTQGH8
DMZF35W	MN	Histone deacetylase 4 (HDAC4)
DMZF35W	MT	DTT
DMZF35W	MA	Inhibitor
DMZF35W	RN	Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
DMZF35W	RU	https://pubmed.ncbi.nlm.nih.gov/17881232

DMZF35W	DI	DMZF35W
DMZF35W	DN	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)
DMZF35W	MI	TT5ZKDI
DMZF35W	MN	Histone deacetylase 6 (HDAC6)
DMZF35W	MT	DTT
DMZF35W	MA	Inhibitor
DMZF35W	RN	Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
DMZF35W	RU	https://pubmed.ncbi.nlm.nih.gov/17881232

DMIVREK	DI	DMIVREK
DMIVREK	DN	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)
DMIVREK	MI	TT6R7JZ
DMIVREK	MN	Histone deacetylase 1 (HDAC1)
DMIVREK	MT	DTT
DMIVREK	MA	Inhibitor
DMIVREK	RN	Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
DMIVREK	RU	https://pubmed.ncbi.nlm.nih.gov/17881232

DMIVREK	DI	DMIVREK
DMIVREK	DN	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)
DMIVREK	MI	TTTQGH8
DMIVREK	MN	Histone deacetylase 4 (HDAC4)
DMIVREK	MT	DTT
DMIVREK	MA	Inhibitor
DMIVREK	RN	Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
DMIVREK	RU	https://pubmed.ncbi.nlm.nih.gov/17881232

DMIVREK	DI	DMIVREK
DMIVREK	DN	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)
DMIVREK	MI	TT5ZKDI
DMIVREK	MN	Histone deacetylase 6 (HDAC6)
DMIVREK	MT	DTT
DMIVREK	MA	Inhibitor
DMIVREK	RN	Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
DMIVREK	RU	https://pubmed.ncbi.nlm.nih.gov/17881232

DMLBECR	DI	DMLBECR
DMLBECR	DN	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)
DMLBECR	MI	TT6R7JZ
DMLBECR	MN	Histone deacetylase 1 (HDAC1)
DMLBECR	MT	DTT
DMLBECR	MA	Inhibitor
DMLBECR	RN	Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
DMLBECR	RU	https://pubmed.ncbi.nlm.nih.gov/17881232

DMLBECR	DI	DMLBECR
DMLBECR	DN	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)
DMLBECR	MI	TTTQGH8
DMLBECR	MN	Histone deacetylase 4 (HDAC4)
DMLBECR	MT	DTT
DMLBECR	MA	Inhibitor
DMLBECR	RN	Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
DMLBECR	RU	https://pubmed.ncbi.nlm.nih.gov/17881232

DMLBECR	DI	DMLBECR
DMLBECR	DN	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)
DMLBECR	MI	TT5ZKDI
DMLBECR	MN	Histone deacetylase 6 (HDAC6)
DMLBECR	MT	DTT
DMLBECR	MA	Inhibitor
DMLBECR	RN	Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
DMLBECR	RU	https://pubmed.ncbi.nlm.nih.gov/17881232

DMA76KW	DI	DMA76KW
DMA76KW	DN	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)
DMA76KW	MI	TT6R7JZ
DMA76KW	MN	Histone deacetylase 1 (HDAC1)
DMA76KW	MT	DTT
DMA76KW	MA	Inhibitor
DMA76KW	RN	Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
DMA76KW	RU	https://pubmed.ncbi.nlm.nih.gov/17881232

DMA76KW	DI	DMA76KW
DMA76KW	DN	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)
DMA76KW	MI	TTTQGH8
DMA76KW	MN	Histone deacetylase 4 (HDAC4)
DMA76KW	MT	DTT
DMA76KW	MA	Inhibitor
DMA76KW	RN	Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
DMA76KW	RU	https://pubmed.ncbi.nlm.nih.gov/17881232

DMA76KW	DI	DMA76KW
DMA76KW	DN	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)
DMA76KW	MI	TT5ZKDI
DMA76KW	MN	Histone deacetylase 6 (HDAC6)
DMA76KW	MT	DTT
DMA76KW	MA	Inhibitor
DMA76KW	RN	Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
DMA76KW	RU	https://pubmed.ncbi.nlm.nih.gov/17881232

DMLNJ0O	DI	DMLNJ0O
DMLNJ0O	DN	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)
DMLNJ0O	MI	TT6R7JZ
DMLNJ0O	MN	Histone deacetylase 1 (HDAC1)
DMLNJ0O	MT	DTT
DMLNJ0O	MA	Inhibitor
DMLNJ0O	RN	Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
DMLNJ0O	RU	https://pubmed.ncbi.nlm.nih.gov/17881232

DMLNJ0O	DI	DMLNJ0O
DMLNJ0O	DN	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)
DMLNJ0O	MI	TTTQGH8
DMLNJ0O	MN	Histone deacetylase 4 (HDAC4)
DMLNJ0O	MT	DTT
DMLNJ0O	MA	Inhibitor
DMLNJ0O	RN	Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
DMLNJ0O	RU	https://pubmed.ncbi.nlm.nih.gov/17881232

DMLNJ0O	DI	DMLNJ0O
DMLNJ0O	DN	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)
DMLNJ0O	MI	TT5ZKDI
DMLNJ0O	MN	Histone deacetylase 6 (HDAC6)
DMLNJ0O	MT	DTT
DMLNJ0O	MA	Inhibitor
DMLNJ0O	RN	Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
DMLNJ0O	RU	https://pubmed.ncbi.nlm.nih.gov/17881232

DMTVMWA	DI	DMTVMWA
DMTVMWA	DN	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)
DMTVMWA	MI	TT6R7JZ
DMTVMWA	MN	Histone deacetylase 1 (HDAC1)
DMTVMWA	MT	DTT
DMTVMWA	MA	Inhibitor
DMTVMWA	RN	Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
DMTVMWA	RU	https://pubmed.ncbi.nlm.nih.gov/17881232

DMTVMWA	DI	DMTVMWA
DMTVMWA	DN	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)
DMTVMWA	MI	TTTQGH8
DMTVMWA	MN	Histone deacetylase 4 (HDAC4)
DMTVMWA	MT	DTT
DMTVMWA	MA	Inhibitor
DMTVMWA	RN	Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
DMTVMWA	RU	https://pubmed.ncbi.nlm.nih.gov/17881232

DMTVMWA	DI	DMTVMWA
DMTVMWA	DN	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)
DMTVMWA	MI	TT5ZKDI
DMTVMWA	MN	Histone deacetylase 6 (HDAC6)
DMTVMWA	MT	DTT
DMTVMWA	MA	Inhibitor
DMTVMWA	RN	Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
DMTVMWA	RU	https://pubmed.ncbi.nlm.nih.gov/17881232

DMUSEDF	DI	DMUSEDF
DMUSEDF	DN	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)
DMUSEDF	MI	TT6R7JZ
DMUSEDF	MN	Histone deacetylase 1 (HDAC1)
DMUSEDF	MT	DTT
DMUSEDF	MA	Inhibitor
DMUSEDF	RN	Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
DMUSEDF	RU	https://pubmed.ncbi.nlm.nih.gov/17881232

DMUSEDF	DI	DMUSEDF
DMUSEDF	DN	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)
DMUSEDF	MI	TTTQGH8
DMUSEDF	MN	Histone deacetylase 4 (HDAC4)
DMUSEDF	MT	DTT
DMUSEDF	MA	Inhibitor
DMUSEDF	RN	Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
DMUSEDF	RU	https://pubmed.ncbi.nlm.nih.gov/17881232

DMUSEDF	DI	DMUSEDF
DMUSEDF	DN	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)
DMUSEDF	MI	TT5ZKDI
DMUSEDF	MN	Histone deacetylase 6 (HDAC6)
DMUSEDF	MT	DTT
DMUSEDF	MA	Inhibitor
DMUSEDF	RN	Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
DMUSEDF	RU	https://pubmed.ncbi.nlm.nih.gov/17881232

DMSEQ0W	DI	DMSEQ0W
DMSEQ0W	DN	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)
DMSEQ0W	MI	TT6R7JZ
DMSEQ0W	MN	Histone deacetylase 1 (HDAC1)
DMSEQ0W	MT	DTT
DMSEQ0W	MA	Inhibitor
DMSEQ0W	RN	Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
DMSEQ0W	RU	https://pubmed.ncbi.nlm.nih.gov/17881232

DMSEQ0W	DI	DMSEQ0W
DMSEQ0W	DN	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)
DMSEQ0W	MI	TTTQGH8
DMSEQ0W	MN	Histone deacetylase 4 (HDAC4)
DMSEQ0W	MT	DTT
DMSEQ0W	MA	Inhibitor
DMSEQ0W	RN	Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
DMSEQ0W	RU	https://pubmed.ncbi.nlm.nih.gov/17881232

DMSEQ0W	DI	DMSEQ0W
DMSEQ0W	DN	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)
DMSEQ0W	MI	TT5ZKDI
DMSEQ0W	MN	Histone deacetylase 6 (HDAC6)
DMSEQ0W	MT	DTT
DMSEQ0W	MA	Inhibitor
DMSEQ0W	RN	Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
DMSEQ0W	RU	https://pubmed.ncbi.nlm.nih.gov/17881232

DMBKP48	DI	DMBKP48
DMBKP48	DN	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)
DMBKP48	MI	TT6R7JZ
DMBKP48	MN	Histone deacetylase 1 (HDAC1)
DMBKP48	MT	DTT
DMBKP48	MA	Inhibitor
DMBKP48	RN	Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
DMBKP48	RU	https://pubmed.ncbi.nlm.nih.gov/17881232

DMBKP48	DI	DMBKP48
DMBKP48	DN	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)
DMBKP48	MI	TTTQGH8
DMBKP48	MN	Histone deacetylase 4 (HDAC4)
DMBKP48	MT	DTT
DMBKP48	MA	Inhibitor
DMBKP48	RN	Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
DMBKP48	RU	https://pubmed.ncbi.nlm.nih.gov/17881232

DMBKP48	DI	DMBKP48
DMBKP48	DN	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)
DMBKP48	MI	TT5ZKDI
DMBKP48	MN	Histone deacetylase 6 (HDAC6)
DMBKP48	MT	DTT
DMBKP48	MA	Inhibitor
DMBKP48	RN	Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
DMBKP48	RU	https://pubmed.ncbi.nlm.nih.gov/17881232

DMVY89X	DI	DMVY89X
DMVY89X	DN	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)
DMVY89X	MI	TT6R7JZ
DMVY89X	MN	Histone deacetylase 1 (HDAC1)
DMVY89X	MT	DTT
DMVY89X	MA	Inhibitor
DMVY89X	RN	Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
DMVY89X	RU	https://pubmed.ncbi.nlm.nih.gov/17881232

DMVY89X	DI	DMVY89X
DMVY89X	DN	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)
DMVY89X	MI	TTTQGH8
DMVY89X	MN	Histone deacetylase 4 (HDAC4)
DMVY89X	MT	DTT
DMVY89X	MA	Inhibitor
DMVY89X	RN	Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
DMVY89X	RU	https://pubmed.ncbi.nlm.nih.gov/17881232

DMVY89X	DI	DMVY89X
DMVY89X	DN	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)
DMVY89X	MI	TT5ZKDI
DMVY89X	MN	Histone deacetylase 6 (HDAC6)
DMVY89X	MT	DTT
DMVY89X	MA	Inhibitor
DMVY89X	RN	Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
DMVY89X	RU	https://pubmed.ncbi.nlm.nih.gov/17881232

DMTDIM9	DI	DMTDIM9
DMTDIM9	DN	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)
DMTDIM9	MI	TT6R7JZ
DMTDIM9	MN	Histone deacetylase 1 (HDAC1)
DMTDIM9	MT	DTT
DMTDIM9	MA	Inhibitor
DMTDIM9	RN	Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
DMTDIM9	RU	https://pubmed.ncbi.nlm.nih.gov/17881232

DMTDIM9	DI	DMTDIM9
DMTDIM9	DN	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)
DMTDIM9	MI	TTTQGH8
DMTDIM9	MN	Histone deacetylase 4 (HDAC4)
DMTDIM9	MT	DTT
DMTDIM9	MA	Inhibitor
DMTDIM9	RN	Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
DMTDIM9	RU	https://pubmed.ncbi.nlm.nih.gov/17881232

DMTDIM9	DI	DMTDIM9
DMTDIM9	DN	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)
DMTDIM9	MI	TT5ZKDI
DMTDIM9	MN	Histone deacetylase 6 (HDAC6)
DMTDIM9	MT	DTT
DMTDIM9	MA	Inhibitor
DMTDIM9	RN	Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
DMTDIM9	RU	https://pubmed.ncbi.nlm.nih.gov/17881232

DMV23XD	DI	DMV23XD
DMV23XD	DN	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)
DMV23XD	MI	TT6R7JZ
DMV23XD	MN	Histone deacetylase 1 (HDAC1)
DMV23XD	MT	DTT
DMV23XD	MA	Inhibitor
DMV23XD	RN	Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
DMV23XD	RU	https://pubmed.ncbi.nlm.nih.gov/17881232

DMV23XD	DI	DMV23XD
DMV23XD	DN	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)
DMV23XD	MI	TTTQGH8
DMV23XD	MN	Histone deacetylase 4 (HDAC4)
DMV23XD	MT	DTT
DMV23XD	MA	Inhibitor
DMV23XD	RN	Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
DMV23XD	RU	https://pubmed.ncbi.nlm.nih.gov/17881232

DMV23XD	DI	DMV23XD
DMV23XD	DN	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)
DMV23XD	MI	TT5ZKDI
DMV23XD	MN	Histone deacetylase 6 (HDAC6)
DMV23XD	MT	DTT
DMV23XD	MA	Inhibitor
DMV23XD	RN	Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
DMV23XD	RU	https://pubmed.ncbi.nlm.nih.gov/17881232

DM0VIH4	DI	DM0VIH4
DM0VIH4	DN	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)
DM0VIH4	MI	TT6R7JZ
DM0VIH4	MN	Histone deacetylase 1 (HDAC1)
DM0VIH4	MT	DTT
DM0VIH4	MA	Inhibitor
DM0VIH4	RN	Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
DM0VIH4	RU	https://pubmed.ncbi.nlm.nih.gov/17881232

DM0VIH4	DI	DM0VIH4
DM0VIH4	DN	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)
DM0VIH4	MI	TTTQGH8
DM0VIH4	MN	Histone deacetylase 4 (HDAC4)
DM0VIH4	MT	DTT
DM0VIH4	MA	Inhibitor
DM0VIH4	RN	Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
DM0VIH4	RU	https://pubmed.ncbi.nlm.nih.gov/17881232

DM0VIH4	DI	DM0VIH4
DM0VIH4	DN	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)
DM0VIH4	MI	TT5ZKDI
DM0VIH4	MN	Histone deacetylase 6 (HDAC6)
DM0VIH4	MT	DTT
DM0VIH4	MA	Inhibitor
DM0VIH4	RN	Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
DM0VIH4	RU	https://pubmed.ncbi.nlm.nih.gov/17881232

DM3QVOB	DI	DM3QVOB
DM3QVOB	DN	Cyclo(RGDfV) (control)
DM3QVOB	MI	TTT1R2L
DM3QVOB	MN	Integrin alpha-V (ITGAV)
DM3QVOB	MT	DTT
DM3QVOB	MA	Inhibitor
DM3QVOB	RN	Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75.
DM3QVOB	RU	https://pubmed.ncbi.nlm.nih.gov/16570923

DM3QVOB	DI	DM3QVOB
DM3QVOB	DN	Cyclo(RGDfV) (control)
DM3QVOB	MI	TTJA1ZO
DM3QVOB	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DM3QVOB	MT	DTT
DM3QVOB	MA	Inhibitor
DM3QVOB	RN	Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75.
DM3QVOB	RU	https://pubmed.ncbi.nlm.nih.gov/16570923

DM9ZCWV	DI	DM9ZCWV
DM9ZCWV	DN	Cyclo[(6-bromotryptophan)arginine]
DM9ZCWV	MI	TTWJBZ5
DM9ZCWV	MN	5-HT 2C receptor (HTR2C)
DM9ZCWV	MT	DTT
DM9ZCWV	MA	Inhibitor
DM9ZCWV	RN	Brominated cyclodipeptides from the marine sponge Geodia barretti as selective 5-HT ligands. J Nat Prod. 2006 Oct;69(10):1421-4.
DM9ZCWV	RU	https://pubmed.ncbi.nlm.nih.gov/17067154

DM67CAY	DI	DM67CAY
DM67CAY	DN	Cyclo[Ac-Cys-Ile-Phe]-Lys-Tyr-Tyr
DM67CAY	MI	TT6PKBN
DM67CAY	MN	Proto-oncogene c-Src (SRC)
DM67CAY	MT	DTT
DM67CAY	MA	Inhibitor
DM67CAY	RN	Synthesis and structure-activity relationships of linear and conformationally constrained peptide analogues of CIYKYY as Src tyrosine kinase inhibi... J Med Chem. 2006 Jun 1;49(11):3395-401.
DM67CAY	RU	https://pubmed.ncbi.nlm.nih.gov/16722659

DMB2DV1	DI	DMB2DV1
DMB2DV1	DN	Cyclo[Ac-Cys-Ile-Tyr-Lys-Tyr-Phe]
DMB2DV1	MI	TT6PKBN
DMB2DV1	MN	Proto-oncogene c-Src (SRC)
DMB2DV1	MT	DTT
DMB2DV1	MA	Inhibitor
DMB2DV1	RN	Synthesis and structure-activity relationships of linear and conformationally constrained peptide analogues of CIYKYY as Src tyrosine kinase inhibi... J Med Chem. 2006 Jun 1;49(11):3395-401.
DMB2DV1	RU	https://pubmed.ncbi.nlm.nih.gov/16722659

DMO5V9M	DI	DMO5V9M
DMO5V9M	DN	Cyclo[Ac-Cys-Ile-Tyr-Lys-Tyr-Tyr]
DMO5V9M	MI	TT6PKBN
DMO5V9M	MN	Proto-oncogene c-Src (SRC)
DMO5V9M	MT	DTT
DMO5V9M	MA	Inhibitor
DMO5V9M	RN	Synthesis and structure-activity relationships of linear and conformationally constrained peptide analogues of CIYKYY as Src tyrosine kinase inhibi... J Med Chem. 2006 Jun 1;49(11):3395-401.
DMO5V9M	RU	https://pubmed.ncbi.nlm.nih.gov/16722659

DMVXPUB	DI	DMVXPUB
DMVXPUB	DN	Cyclo-[-Arg-Gly-Asp-Amp21-]
DMVXPUB	MI	TTT1R2L
DMVXPUB	MN	Integrin alpha-V (ITGAV)
DMVXPUB	MT	DTT
DMVXPUB	MA	Inhibitor
DMVXPUB	RN	Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82.
DMVXPUB	RU	https://pubmed.ncbi.nlm.nih.gov/18303826

DMVXPUB	DI	DMVXPUB
DMVXPUB	DN	Cyclo-[-Arg-Gly-Asp-Amp21-]
DMVXPUB	MI	TTJA1ZO
DMVXPUB	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMVXPUB	MT	DTT
DMVXPUB	MA	Inhibitor
DMVXPUB	RN	Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82.
DMVXPUB	RU	https://pubmed.ncbi.nlm.nih.gov/18303826

DMBELJK	DI	DMBELJK
DMBELJK	DN	Cyclo-[-Arg-Gly-Asp-Amp22-]
DMBELJK	MI	TTT1R2L
DMBELJK	MN	Integrin alpha-V (ITGAV)
DMBELJK	MT	DTT
DMBELJK	MA	Inhibitor
DMBELJK	RN	Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82.
DMBELJK	RU	https://pubmed.ncbi.nlm.nih.gov/18303826

DMBELJK	DI	DMBELJK
DMBELJK	DN	Cyclo-[-Arg-Gly-Asp-Amp22-]
DMBELJK	MI	TTJA1ZO
DMBELJK	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMBELJK	MT	DTT
DMBELJK	MA	Inhibitor
DMBELJK	RN	Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82.
DMBELJK	RU	https://pubmed.ncbi.nlm.nih.gov/18303826

DMT29VJ	DI	DMT29VJ
DMT29VJ	DN	Cyclo-[-Arg-Gly-Asp-Amp23-]
DMT29VJ	MI	TTT1R2L
DMT29VJ	MN	Integrin alpha-V (ITGAV)
DMT29VJ	MT	DTT
DMT29VJ	MA	Inhibitor
DMT29VJ	RN	Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82.
DMT29VJ	RU	https://pubmed.ncbi.nlm.nih.gov/18303826

DMT29VJ	DI	DMT29VJ
DMT29VJ	DN	Cyclo-[-Arg-Gly-Asp-Amp23-]
DMT29VJ	MI	TTJA1ZO
DMT29VJ	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMT29VJ	MT	DTT
DMT29VJ	MA	Inhibitor
DMT29VJ	RN	Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82.
DMT29VJ	RU	https://pubmed.ncbi.nlm.nih.gov/18303826

DM35ZLK	DI	DM35ZLK
DM35ZLK	DN	Cyclo-[-Arg-Gly-Asp-Amp24-]
DM35ZLK	MI	TTT1R2L
DM35ZLK	MN	Integrin alpha-V (ITGAV)
DM35ZLK	MT	DTT
DM35ZLK	MA	Inhibitor
DM35ZLK	RN	Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82.
DM35ZLK	RU	https://pubmed.ncbi.nlm.nih.gov/18303826

DM35ZLK	DI	DM35ZLK
DM35ZLK	DN	Cyclo-[-Arg-Gly-Asp-Amp24-]
DM35ZLK	MI	TTJA1ZO
DM35ZLK	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DM35ZLK	MT	DTT
DM35ZLK	MA	Inhibitor
DM35ZLK	RN	Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82.
DM35ZLK	RU	https://pubmed.ncbi.nlm.nih.gov/18303826

DMEIXUQ	DI	DMEIXUQ
DMEIXUQ	DN	Cyclo-[-Arg-Gly-Asp-Amp25-]
DMEIXUQ	MI	TTT1R2L
DMEIXUQ	MN	Integrin alpha-V (ITGAV)
DMEIXUQ	MT	DTT
DMEIXUQ	MA	Inhibitor
DMEIXUQ	RN	Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82.
DMEIXUQ	RU	https://pubmed.ncbi.nlm.nih.gov/18303826

DMEIXUQ	DI	DMEIXUQ
DMEIXUQ	DN	Cyclo-[-Arg-Gly-Asp-Amp25-]
DMEIXUQ	MI	TTJA1ZO
DMEIXUQ	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMEIXUQ	MT	DTT
DMEIXUQ	MA	Inhibitor
DMEIXUQ	RN	Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82.
DMEIXUQ	RU	https://pubmed.ncbi.nlm.nih.gov/18303826

DME5HRW	DI	DME5HRW
DME5HRW	DN	Cyclo-[-Arg-Gly-Asp-Amp26-]
DME5HRW	MI	TTT1R2L
DME5HRW	MN	Integrin alpha-V (ITGAV)
DME5HRW	MT	DTT
DME5HRW	MA	Inhibitor
DME5HRW	RN	Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82.
DME5HRW	RU	https://pubmed.ncbi.nlm.nih.gov/18303826

DME5HRW	DI	DME5HRW
DME5HRW	DN	Cyclo-[-Arg-Gly-Asp-Amp26-]
DME5HRW	MI	TTJA1ZO
DME5HRW	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DME5HRW	MT	DTT
DME5HRW	MA	Inhibitor
DME5HRW	RN	Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82.
DME5HRW	RU	https://pubmed.ncbi.nlm.nih.gov/18303826

DMBNJZ0	DI	DMBNJZ0
DMBNJZ0	DN	Cyclo-[-Arg-Gly-Asp-Amp27-]
DMBNJZ0	MI	TTT1R2L
DMBNJZ0	MN	Integrin alpha-V (ITGAV)
DMBNJZ0	MT	DTT
DMBNJZ0	MA	Inhibitor
DMBNJZ0	RN	Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82.
DMBNJZ0	RU	https://pubmed.ncbi.nlm.nih.gov/18303826

DMBNJZ0	DI	DMBNJZ0
DMBNJZ0	DN	Cyclo-[-Arg-Gly-Asp-Amp27-]
DMBNJZ0	MI	TTJA1ZO
DMBNJZ0	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMBNJZ0	MT	DTT
DMBNJZ0	MA	Inhibitor
DMBNJZ0	RN	Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82.
DMBNJZ0	RU	https://pubmed.ncbi.nlm.nih.gov/18303826

DMJMHAV	DI	DMJMHAV
DMJMHAV	DN	Cyclo-[-Arg-Gly-Asp-Amp28-]
DMJMHAV	MI	TTT1R2L
DMJMHAV	MN	Integrin alpha-V (ITGAV)
DMJMHAV	MT	DTT
DMJMHAV	MA	Inhibitor
DMJMHAV	RN	Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82.
DMJMHAV	RU	https://pubmed.ncbi.nlm.nih.gov/18303826

DMJMHAV	DI	DMJMHAV
DMJMHAV	DN	Cyclo-[-Arg-Gly-Asp-Amp28-]
DMJMHAV	MI	TTJA1ZO
DMJMHAV	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMJMHAV	MT	DTT
DMJMHAV	MA	Inhibitor
DMJMHAV	RN	Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82.
DMJMHAV	RU	https://pubmed.ncbi.nlm.nih.gov/18303826

DMWD5RK	DI	DMWD5RK
DMWD5RK	DN	Cyclo-[Asp6,Lys10]N/OFQ(1-13)NH2
DMWD5RK	MI	TTNT7K8
DMWD5RK	MN	Nociceptin receptor (OPRL1)
DMWD5RK	MT	DTT
DMWD5RK	MA	Inhibitor
DMWD5RK	RN	High affinity conformationally constrained nociceptin/orphanin FQ(1-13) amide analogues. J Med Chem. 2008 Aug 14;51(15):4385-7.
DMWD5RK	RU	https://pubmed.ncbi.nlm.nih.gov/18624395

DMSMH6T	DI	DMSMH6T
DMSMH6T	DN	Cyclo[Cys6,Cys10]N/OFQ(1-13)NH2
DMSMH6T	MI	TTNT7K8
DMSMH6T	MN	Nociceptin receptor (OPRL1)
DMSMH6T	MT	DTT
DMSMH6T	MA	Inhibitor
DMSMH6T	RN	High affinity conformationally constrained nociceptin/orphanin FQ(1-13) amide analogues. J Med Chem. 2008 Aug 14;51(15):4385-7.
DMSMH6T	RU	https://pubmed.ncbi.nlm.nih.gov/18624395

DMI9C57	DI	DMI9C57
DMI9C57	DN	Cyclo[Cys7,Cys10]N/OFQ(1-13)NH2
DMI9C57	MI	TTNT7K8
DMI9C57	MN	Nociceptin receptor (OPRL1)
DMI9C57	MT	DTT
DMI9C57	MA	Inhibitor
DMI9C57	RN	High affinity conformationally constrained nociceptin/orphanin FQ(1-13) amide analogues. J Med Chem. 2008 Aug 14;51(15):4385-7.
DMI9C57	RU	https://pubmed.ncbi.nlm.nih.gov/18624395

DM39UMT	DI	DM39UMT
DM39UMT	DN	Cyclo[DAsp7,Lys10]N/OFQ(1-13)NH2
DM39UMT	MI	TTNT7K8
DM39UMT	MN	Nociceptin receptor (OPRL1)
DM39UMT	MT	DTT
DM39UMT	MA	Inhibitor
DM39UMT	RN	High affinity conformationally constrained nociceptin/orphanin FQ(1-13) amide analogues. J Med Chem. 2008 Aug 14;51(15):4385-7.
DM39UMT	RU	https://pubmed.ncbi.nlm.nih.gov/18624395

DMWYFLD	DI	DMWYFLD
DMWYFLD	DN	Cyclo[RGDfK(cypate)]
DMWYFLD	MI	TTT1R2L
DMWYFLD	MN	Integrin alpha-V (ITGAV)
DMWYFLD	MT	DTT
DMWYFLD	MA	Inhibitor
DMWYFLD	RN	Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75.
DMWYFLD	RU	https://pubmed.ncbi.nlm.nih.gov/16570923

DMWYFLD	DI	DMWYFLD
DMWYFLD	DN	Cyclo[RGDfK(cypate)]
DMWYFLD	MI	TTJA1ZO
DMWYFLD	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMWYFLD	MT	DTT
DMWYFLD	MA	Inhibitor
DMWYFLD	RN	Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75.
DMWYFLD	RU	https://pubmed.ncbi.nlm.nih.gov/16570923

DM35PIJ	DI	DM35PIJ
DM35PIJ	DN	Cyclobutyl
DM35PIJ	MI	TTJS7O4
DM35PIJ	MN	Entamoeba Alcohol dehydrogenase 2 (Entamo ADH2)
DM35PIJ	MT	DTT
DM35PIJ	MA	Inhibitor
DM35PIJ	RN	Entamoeba histolytica alcohol dehydrogenase 2 (EhADH2) as a target for anti-amoebic agents. J Antimicrob Chemother. 2004 Jul;54(1):56-9.
DM35PIJ	RU	https://pubmed.ncbi.nlm.nih.gov/15150165

DMYLA7F	DI	DMYLA7F
DMYLA7F	DN	Cyclobutylcarbamic Acid Biphenyl-3-yl Ester
DMYLA7F	MI	TTDP1UC
DMYLA7F	MN	Fatty acid amide hydrolase (FAAH)
DMYLA7F	MT	DTT
DMYLA7F	MA	Inhibitor
DMYLA7F	RN	Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl a... J Med Chem. 2008 Jun 26;51(12):3487-98.
DMYLA7F	RU	https://pubmed.ncbi.nlm.nih.gov/18507372

DMC520D	DI	DMC520D
DMC520D	DN	Cycloguanil
DMC520D	MI	TT9SL3Q
DMC520D	MN	Polypeptide deformylase (PDF)
DMC520D	MT	DTT
DMC520D	MA	Inhibitor
DMC520D	RN	Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40.
DMC520D	RU	https://pubmed.ncbi.nlm.nih.gov/16138106

DMGDA3C	DI	DMGDA3C
DMGDA3C	DN	Cycloheximide
DMGDA3C	MI	DTUGYRD
DMGDA3C	MN	P-glycoprotein 1 (ABCB1)
DMGDA3C	MT	DTP
DMGDA3C	MA	Substrate
DMGDA3C	RN	Carotenoids reverse multidrug resistance in cancer cells by interfering with ABC-transporters. Phytomedicine. 2012 Aug 15;19(11):977-87.
DMGDA3C	RU	https://doi.org/10.1016/j.phymed.2012.05.010

DMZKH4R	DI	DMZKH4R
DMZKH4R	DN	Cyclohexyl biphenyl-4-ylcarbamate
DMZKH4R	MI	TTDP1UC
DMZKH4R	MN	Fatty acid amide hydrolase (FAAH)
DMZKH4R	MT	DTT
DMZKH4R	MA	Inhibitor
DMZKH4R	RN	The synthesis and biological evaluation of para-substituted phenolic N-alkyl carbamates as endocannabinoid hydrolyzing enzyme inhibitors. Eur J Med Chem. 2009 Jul;44(7):2994-3008.
DMZKH4R	RU	https://pubmed.ncbi.nlm.nih.gov/19232787

DM84ZX5	DI	DM84ZX5
DM84ZX5	DN	Cyclohexyl-(2-phenoxy-9H-purin-6-yl)-amine
DM84ZX5	MI	TTM2AOE
DM84ZX5	MN	Adenosine A2a receptor (ADORA2A)
DM84ZX5	MT	DTT
DM84ZX5	MA	Inhibitor
DM84ZX5	RN	Reversine and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem. 2005 Jul 28;48(15):4910-8.
DM84ZX5	RU	https://pubmed.ncbi.nlm.nih.gov/16033270

DM84ZX5	DI	DM84ZX5
DM84ZX5	DN	Cyclohexyl-(2-phenoxy-9H-purin-6-yl)-amine
DM84ZX5	MI	TTJFY5U
DM84ZX5	MN	Adenosine A3 receptor (ADORA3)
DM84ZX5	MT	DTT
DM84ZX5	MA	Inhibitor
DM84ZX5	RN	Reversine and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem. 2005 Jul 28;48(15):4910-8.
DM84ZX5	RU	https://pubmed.ncbi.nlm.nih.gov/16033270

DMLREDJ	DI	DMLREDJ
DMLREDJ	DN	Cyclohexyl-(2-phenylsulfanyl-9H-purin-6-yl)-amine
DMLREDJ	MI	TTK25J1
DMLREDJ	MN	Adenosine A1 receptor (ADORA1)
DMLREDJ	MT	DTT
DMLREDJ	MA	Inhibitor
DMLREDJ	RN	Reversine and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem. 2005 Jul 28;48(15):4910-8.
DMLREDJ	RU	https://pubmed.ncbi.nlm.nih.gov/16033270

DMLREDJ	DI	DMLREDJ
DMLREDJ	DN	Cyclohexyl-(2-phenylsulfanyl-9H-purin-6-yl)-amine
DMLREDJ	MI	TTM2AOE
DMLREDJ	MN	Adenosine A2a receptor (ADORA2A)
DMLREDJ	MT	DTT
DMLREDJ	MA	Inhibitor
DMLREDJ	RN	Reversine and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem. 2005 Jul 28;48(15):4910-8.
DMLREDJ	RU	https://pubmed.ncbi.nlm.nih.gov/16033270

DMLREDJ	DI	DMLREDJ
DMLREDJ	DN	Cyclohexyl-(2-phenylsulfanyl-9H-purin-6-yl)-amine
DMLREDJ	MI	TTJFY5U
DMLREDJ	MN	Adenosine A3 receptor (ADORA3)
DMLREDJ	MT	DTT
DMLREDJ	MA	Inhibitor
DMLREDJ	RN	Reversine and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem. 2005 Jul 28;48(15):4910-8.
DMLREDJ	RU	https://pubmed.ncbi.nlm.nih.gov/16033270

DMJEN45	DI	DMJEN45
DMJEN45	DN	Cyclohexyl-(3,4-dichloro-phenyl)-acetonitrile
DMJEN45	MI	TT3ROYC
DMJEN45	MN	Serotonin transporter (SERT)
DMJEN45	MT	DTT
DMJEN45	MA	Inhibitor
DMJEN45	RN	Synthesis and evaluation of dopamine and serotonin transporter inhibition by oxacyclic and carbacyclic analogues of methylphenidate. J Med Chem. 2003 Apr 10;46(8):1538-45.
DMJEN45	RU	https://pubmed.ncbi.nlm.nih.gov/12672255

DM1F7I5	DI	DM1F7I5
DM1F7I5	DN	Cyclohexyl-(9-ethyl-9H-purin-6-yl)-amine
DM1F7I5	MI	TTK25J1
DM1F7I5	MN	Adenosine A1 receptor (ADORA1)
DM1F7I5	MT	DTT
DM1F7I5	MA	Inhibitor
DM1F7I5	RN	N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor. J Med Chem. 1991 Sep;34(9):2877-82.
DM1F7I5	RU	https://pubmed.ncbi.nlm.nih.gov/1895305

DMIUCSW	DI	DMIUCSW
DMIUCSW	DN	Cyclohexyl-(9-methyl-9H-purin-6-yl)-amine
DMIUCSW	MI	TTK25J1
DMIUCSW	MN	Adenosine A1 receptor (ADORA1)
DMIUCSW	MT	DTT
DMIUCSW	MA	Inhibitor
DMIUCSW	RN	N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor. J Med Chem. 1991 Sep;34(9):2877-82.
DMIUCSW	RU	https://pubmed.ncbi.nlm.nih.gov/1895305

DMYQH2N	DI	DMYQH2N
DMYQH2N	DN	Cyclohexylammonium Ion
DMYQH2N	MI	TTICX3S
DMYQH2N	MN	Bacterial UDP-N-acetylglucosamine carboxyvinyltransferase (Bact murA)
DMYQH2N	MT	DTT
DMYQH2N	MA	Inhibitor
DMYQH2N	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMYQH2N	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM06OLY	DI	DM06OLY
DM06OLY	DN	Cyclohexylcarbamic acidbiphenyl-3-yl ester
DM06OLY	MI	TTDP1UC
DM06OLY	MN	Fatty acid amide hydrolase (FAAH)
DM06OLY	MT	DTT
DM06OLY	MA	Inhibitor
DM06OLY	RN	Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl a... J Med Chem. 2008 Jun 26;51(12):3487-98.
DM06OLY	RU	https://pubmed.ncbi.nlm.nih.gov/18507372

DMNG4B1	DI	DMNG4B1
DMNG4B1	DN	Cyclohexylglycine-(2S)-cyanopyrrolidine
DMNG4B1	MI	TTDIGC1
DMNG4B1	MN	Dipeptidyl peptidase 4 (DPP-4)
DMNG4B1	MT	DTT
DMNG4B1	MA	Inhibitor
DMNG4B1	RN	2-[3-[2-[(2S)-2-Cyano-1-pyrrolidinyl]-2-oxoethylamino]-3-methyl-1-oxobutyl]- 1,2,3,4-tetrahydroisoquinoline: a potent, selective, and orally bioava... J Med Chem. 2006 Jan 12;49(1):373-80.
DMNG4B1	RU	https://pubmed.ncbi.nlm.nih.gov/16392822

DMEW7AY	DI	DMEW7AY
DMEW7AY	DN	Cyclohexylmethylcarbamic Acid Biphenyl-3-yl Ester
DMEW7AY	MI	TTDP1UC
DMEW7AY	MN	Fatty acid amide hydrolase (FAAH)
DMEW7AY	MT	DTT
DMEW7AY	MA	Inhibitor
DMEW7AY	RN	Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl a... J Med Chem. 2008 Jun 26;51(12):3487-98.
DMEW7AY	RU	https://pubmed.ncbi.nlm.nih.gov/18507372

DM0L6E1	DI	DM0L6E1
DM0L6E1	DN	Cycloleucine
DM0L6E1	MI	TTLD29N
DM0L6E1	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DM0L6E1	MT	DTT
DM0L6E1	MA	Inhibitor
DM0L6E1	RN	Effects of D-cycloserine and cycloleucine, ligands for the NMDA-associated strychnine-insensitive glycine site, on brain-stimulation reward and spontaneous locomotion. Pharmacol Biochem Behav. 1990 Aug;36(4):735-8.
DM0L6E1	RU	https://pubmed.ncbi.nlm.nih.gov/2170997

DMEM2SW	DI	DMEM2SW
DMEM2SW	DN	CYCLOPAMINE
DMEM2SW	MI	TT8J1S3
DMEM2SW	MN	Smoothened homolog (SMO)
DMEM2SW	MT	DTT
DMEM2SW	MA	Inhibitor
DMEM2SW	RN	Identification and structure-activity relationships of ortho-biphenyl carboxamides as potent Smoothened antagonists inhibiting the Hedgehog signali... Bioorg Med Chem Lett. 2009 Jan 15;19(2):328-31.
DMEM2SW	RU	https://pubmed.ncbi.nlm.nih.gov/19091559

DM78PR5	DI	DM78PR5
DM78PR5	DN	Cyclopentane amide derivatives 1
DM78PR5	MI	TT50QJ3
DM78PR5	MN	Influenza Neuraminidase (Influ NA)
DM78PR5	MT	DTT
DM78PR5	MA	Inhibitor
DM78PR5	RN	Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25.
DM78PR5	RU	https://pubmed.ncbi.nlm.nih.gov/17139286

DMGU97P	DI	DMGU97P
DMGU97P	DN	Cyclopentane amide derivatives 2
DMGU97P	MI	TT50QJ3
DMGU97P	MN	Influenza Neuraminidase (Influ NA)
DMGU97P	MT	DTT
DMGU97P	MA	Inhibitor
DMGU97P	RN	Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25.
DMGU97P	RU	https://pubmed.ncbi.nlm.nih.gov/17139286

DMHTVRL	DI	DMHTVRL
DMHTVRL	DN	Cyclopentane amide derivatives 3
DMHTVRL	MI	TT50QJ3
DMHTVRL	MN	Influenza Neuraminidase (Influ NA)
DMHTVRL	MT	DTT
DMHTVRL	MA	Inhibitor
DMHTVRL	RN	Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25.
DMHTVRL	RU	https://pubmed.ncbi.nlm.nih.gov/17139286

DMOA7EP	DI	DMOA7EP
DMOA7EP	DN	Cyclopentane amide derivatives 4
DMOA7EP	MI	TT50QJ3
DMOA7EP	MN	Influenza Neuraminidase (Influ NA)
DMOA7EP	MT	DTT
DMOA7EP	MA	Inhibitor
DMOA7EP	RN	Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25.
DMOA7EP	RU	https://pubmed.ncbi.nlm.nih.gov/17139286

DMMV2LN	DI	DMMV2LN
DMMV2LN	DN	Cyclopentyl 10H-phenothiazine-10-carboxylate
DMMV2LN	MI	TTEB0GD
DMMV2LN	MN	Cholinesterase (BCHE)
DMMV2LN	MT	DTT
DMMV2LN	MA	Inhibitor
DMMV2LN	RN	Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. J Med Chem. 2008 Jul 24;51(14):4200-12.
DMMV2LN	RU	https://pubmed.ncbi.nlm.nih.gov/18570368

DMAKT65	DI	DMAKT65
DMAKT65	DN	Cyclopentyl-(3,4-dichloro-phenyl)-acetonitrile
DMAKT65	MI	TT3ROYC
DMAKT65	MN	Serotonin transporter (SERT)
DMAKT65	MT	DTT
DMAKT65	MA	Inhibitor
DMAKT65	RN	Synthesis and evaluation of dopamine and serotonin transporter inhibition by oxacyclic and carbacyclic analogues of methylphenidate. J Med Chem. 2003 Apr 10;46(8):1538-45.
DMAKT65	RU	https://pubmed.ncbi.nlm.nih.gov/12672255

DM0J9I5	DI	DM0J9I5
DM0J9I5	DN	Cyclopentyl(5-(pyridin-2-yl)oxazol-2-yl)methanone
DM0J9I5	MI	TTDP1UC
DM0J9I5	MN	Fatty acid amide hydrolase (FAAH)
DM0J9I5	MT	DTT
DM0J9I5	MA	Inhibitor
DM0J9I5	RN	Structure-activity relationships of alpha-ketooxazole inhibitors of fatty acid amide hydrolase. J Med Chem. 2007 Jul 12;50(14):3359-68.
DM0J9I5	RU	https://pubmed.ncbi.nlm.nih.gov/17559203

DMBDTFQ	DI	DMBDTFQ
DMBDTFQ	DN	Cyclopentyl-(9-cyclopentyl-9H-purin-6-yl)-amine
DMBDTFQ	MI	TTK25J1
DMBDTFQ	MN	Adenosine A1 receptor (ADORA1)
DMBDTFQ	MT	DTT
DMBDTFQ	MA	Inhibitor
DMBDTFQ	RN	N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor. J Med Chem. 1991 Sep;34(9):2877-82.
DMBDTFQ	RU	https://pubmed.ncbi.nlm.nih.gov/1895305

DMQ6BS2	DI	DMQ6BS2
DMQ6BS2	DN	Cyclopentyl-(9-ethyl-9H-purin-6-yl)-amine
DMQ6BS2	MI	TTK25J1
DMQ6BS2	MN	Adenosine A1 receptor (ADORA1)
DMQ6BS2	MT	DTT
DMQ6BS2	MA	Inhibitor
DMQ6BS2	RN	N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor. J Med Chem. 1991 Sep;34(9):2877-82.
DMQ6BS2	RU	https://pubmed.ncbi.nlm.nih.gov/1895305

DM9DHNZ	DI	DM9DHNZ
DM9DHNZ	DN	Cyclopentyl-(9-methyl-9H-purin-6-yl)-amine
DM9DHNZ	MI	TTK25J1
DM9DHNZ	MN	Adenosine A1 receptor (ADORA1)
DM9DHNZ	MT	DTT
DM9DHNZ	MA	Inhibitor
DM9DHNZ	RN	N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor. J Med Chem. 1991 Sep;34(9):2877-82.
DM9DHNZ	RU	https://pubmed.ncbi.nlm.nih.gov/1895305

DMBJV90	DI	DMBJV90
DMBJV90	DN	Cyclopentyl-(9-phenyl-9H-purin-6-yl)-amine
DMBJV90	MI	TTK25J1
DMBJV90	MN	Adenosine A1 receptor (ADORA1)
DMBJV90	MT	DTT
DMBJV90	MA	Inhibitor
DMBJV90	RN	N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor. J Med Chem. 1991 Sep;34(9):2877-82.
DMBJV90	RU	https://pubmed.ncbi.nlm.nih.gov/1895305

DMQLGFH	DI	DMQLGFH
DMQLGFH	DN	Cyclopentylcarbamic Acid Biphenyl-3-yl Ester
DMQLGFH	MI	TTDP1UC
DMQLGFH	MN	Fatty acid amide hydrolase (FAAH)
DMQLGFH	MT	DTT
DMQLGFH	MA	Inhibitor
DMQLGFH	RN	Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl a... J Med Chem. 2008 Jun 26;51(12):3487-98.
DMQLGFH	RU	https://pubmed.ncbi.nlm.nih.gov/18507372

DM4KZ1W	DI	DM4KZ1W
DM4KZ1W	DN	Cyclopentylcytosine
DM4KZ1W	MI	TTN12BZ
DM4KZ1W	MN	CTP synthase (CTPS1)
DM4KZ1W	MT	DTT
DM4KZ1W	MA	Inhibitor
DM4KZ1W	RN	Molecular approaches for the treatment of hemorrhagic fever virus infections. Antiviral Res. 1993 Sep;22(1):45-75.
DM4KZ1W	RU	https://pubmed.ncbi.nlm.nih.gov/8250543

DMPJ08G	DI	DMPJ08G
DMPJ08G	DN	Cyclopiazonic acid
DMPJ08G	MI	TTZVSJ2
DMPJ08G	MN	Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A)
DMPJ08G	MT	DTT
DMPJ08G	MA	Inhibitor
DMPJ08G	RN	Expression and functional characterization of a Plasmodium falciparum Ca2+-ATPase (PfATP4) belonging to a subclass unique to apicomplexan organisms. J Biol Chem. 2001 Apr 6;276(14):10782-7.
DMPJ08G	RU	https://pubmed.ncbi.nlm.nih.gov/11145964

DMGFEPJ	DI	DMGFEPJ
DMGFEPJ	DN	Cyclopropyl
DMGFEPJ	MI	TTJS7O4
DMGFEPJ	MN	Entamoeba Alcohol dehydrogenase 2 (Entamo ADH2)
DMGFEPJ	MT	DTT
DMGFEPJ	MA	Inhibitor
DMGFEPJ	RN	Entamoeba histolytica alcohol dehydrogenase 2 (EhADH2) as a target for anti-amoebic agents. J Antimicrob Chemother. 2004 Jul;54(1):56-9.
DMGFEPJ	RU	https://pubmed.ncbi.nlm.nih.gov/15150165

DMGZ0KM	DI	DMGZ0KM
DMGZ0KM	DN	Cyclorgdfv
DMGZ0KM	MI	TTT1R2L
DMGZ0KM	MN	Integrin alpha-V (ITGAV)
DMGZ0KM	MT	DTT
DMGZ0KM	MA	Inhibitor
DMGZ0KM	RN	Antiangiogenic effect of dual/selective alpha(5)beta(1)/alpha(v)beta(3) integrin antagonists designed on partially modified retro-inverso cyclotetr... J Med Chem. 2010 Jan 14;53(1):106-18.
DMGZ0KM	RU	https://pubmed.ncbi.nlm.nih.gov/20055426

DMGZ0KM	DI	DMGZ0KM
DMGZ0KM	DN	Cyclorgdfv
DMGZ0KM	MI	TTJA1ZO
DMGZ0KM	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMGZ0KM	MT	DTT
DMGZ0KM	MA	Inhibitor
DMGZ0KM	RN	Antiangiogenic effect of dual/selective alpha(5)beta(1)/alpha(v)beta(3) integrin antagonists designed on partially modified retro-inverso cyclotetr... J Med Chem. 2010 Jan 14;53(1):106-18.
DMGZ0KM	RU	https://pubmed.ncbi.nlm.nih.gov/20055426

DMB1U8V	DI	DMB1U8V
DMB1U8V	DN	CYCLORPHAN
DMB1U8V	MI	TT27RFC
DMB1U8V	MN	Opioid receptor delta (OPRD1)
DMB1U8V	MT	DTT
DMB1U8V	MA	Inhibitor
DMB1U8V	RN	Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18.
DMB1U8V	RU	https://pubmed.ncbi.nlm.nih.gov/19928862

DMB1U8V	DI	DMB1U8V
DMB1U8V	DN	CYCLORPHAN
DMB1U8V	MI	TTQW87Y
DMB1U8V	MN	Opioid receptor kappa (OPRK1)
DMB1U8V	MT	DTT
DMB1U8V	MA	Inhibitor
DMB1U8V	RN	Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pha... J Med Chem. 2000 Jan 13;43(1):114-22.
DMB1U8V	RU	https://pubmed.ncbi.nlm.nih.gov/10633042

DMB1U8V	DI	DMB1U8V
DMB1U8V	DN	CYCLORPHAN
DMB1U8V	MI	TTKWM86
DMB1U8V	MN	Opioid receptor mu (MOP)
DMB1U8V	MT	DTT
DMB1U8V	MA	Inhibitor
DMB1U8V	RN	Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pha... J Med Chem. 2000 Jan 13;43(1):114-22.
DMB1U8V	RU	https://pubmed.ncbi.nlm.nih.gov/10633042

DMLC041	DI	DMLC041
DMLC041	DN	Cyclosal-d4TMP
DMLC041	MI	TTEB0GD
DMLC041	MN	Cholinesterase (BCHE)
DMLC041	MT	DTT
DMLC041	MA	Inhibitor
DMLC041	RN	Bis-cycloSal-d4T-monophosphates: drugs that deliver two molecules of bioactive nucleotides. J Med Chem. 2007 Mar 22;50(6):1335-46.
DMLC041	RU	https://pubmed.ncbi.nlm.nih.gov/17328534

DMFTDPQ	DI	DMFTDPQ
DMFTDPQ	DN	Cyclostellettamine derivative
DMFTDPQ	MI	TTBH0VX
DMFTDPQ	MN	Histone deacetylase (HDAC)
DMFTDPQ	MT	DTT
DMFTDPQ	MA	Inhibitor
DMFTDPQ	RN	Three new cyclostellettamines, which inhibit histone deacetylase, from a marine sponge of the genus Xestospongia. Bioorg Med Chem Lett. 2004 May 17;14(10):2617-20.
DMFTDPQ	RU	https://pubmed.ncbi.nlm.nih.gov/15109664

DMFTDPQ	DI	DMFTDPQ
DMFTDPQ	DN	Cyclostellettamine derivative
DMFTDPQ	MI	TT6R7JZ
DMFTDPQ	MN	Histone deacetylase 1 (HDAC1)
DMFTDPQ	MT	DTT
DMFTDPQ	MA	Inhibitor
DMFTDPQ	RN	Three new cyclostellettamines, which inhibit histone deacetylase, from a marine sponge of the genus Xestospongia. Bioorg Med Chem Lett. 2004 May 17;14(10):2617-20.
DMFTDPQ	RU	https://pubmed.ncbi.nlm.nih.gov/15109664

DMFTDPQ	DI	DMFTDPQ
DMFTDPQ	DN	Cyclostellettamine derivative
DMFTDPQ	MI	TTYHPU6
DMFTDPQ	MN	Histone deacetylase 10 (HDAC10)
DMFTDPQ	MT	DTT
DMFTDPQ	MA	Inhibitor
DMFTDPQ	RN	Three new cyclostellettamines, which inhibit histone deacetylase, from a marine sponge of the genus Xestospongia. Bioorg Med Chem Lett. 2004 May 17;14(10):2617-20.
DMFTDPQ	RU	https://pubmed.ncbi.nlm.nih.gov/15109664

DMFTDPQ	DI	DMFTDPQ
DMFTDPQ	DN	Cyclostellettamine derivative
DMFTDPQ	MI	TTSHTOI
DMFTDPQ	MN	Histone deacetylase 2 (HDAC2)
DMFTDPQ	MT	DTT
DMFTDPQ	MA	Inhibitor
DMFTDPQ	RN	Three new cyclostellettamines, which inhibit histone deacetylase, from a marine sponge of the genus Xestospongia. Bioorg Med Chem Lett. 2004 May 17;14(10):2617-20.
DMFTDPQ	RU	https://pubmed.ncbi.nlm.nih.gov/15109664

DMFTDPQ	DI	DMFTDPQ
DMFTDPQ	DN	Cyclostellettamine derivative
DMFTDPQ	MI	TTTQGH8
DMFTDPQ	MN	Histone deacetylase 4 (HDAC4)
DMFTDPQ	MT	DTT
DMFTDPQ	MA	Inhibitor
DMFTDPQ	RN	Three new cyclostellettamines, which inhibit histone deacetylase, from a marine sponge of the genus Xestospongia. Bioorg Med Chem Lett. 2004 May 17;14(10):2617-20.
DMFTDPQ	RU	https://pubmed.ncbi.nlm.nih.gov/15109664

DMFTDPQ	DI	DMFTDPQ
DMFTDPQ	DN	Cyclostellettamine derivative
DMFTDPQ	MI	TT5ZKDI
DMFTDPQ	MN	Histone deacetylase 6 (HDAC6)
DMFTDPQ	MT	DTT
DMFTDPQ	MA	Inhibitor
DMFTDPQ	RN	Three new cyclostellettamines, which inhibit histone deacetylase, from a marine sponge of the genus Xestospongia. Bioorg Med Chem Lett. 2004 May 17;14(10):2617-20.
DMFTDPQ	RU	https://pubmed.ncbi.nlm.nih.gov/15109664

DMFTDPQ	DI	DMFTDPQ
DMFTDPQ	DN	Cyclostellettamine derivative
DMFTDPQ	MI	TTT6LFV
DMFTDPQ	MN	Histone deacetylase 8 (HDAC8)
DMFTDPQ	MT	DTT
DMFTDPQ	MA	Inhibitor
DMFTDPQ	RN	Three new cyclostellettamines, which inhibit histone deacetylase, from a marine sponge of the genus Xestospongia. Bioorg Med Chem Lett. 2004 May 17;14(10):2617-20.
DMFTDPQ	RU	https://pubmed.ncbi.nlm.nih.gov/15109664

DM8HG0K	DI	DM8HG0K
DM8HG0K	DN	Cyclotheonamide E
DM8HG0K	MI	TT6L509
DM8HG0K	MN	Coagulation factor IIa (F2)
DM8HG0K	MT	DTT
DM8HG0K	MA	Inhibitor
DM8HG0K	RN	Cyclotheonamide E4 and E5, new potent tryptase inhibitors from an Ircinia species of sponge. J Nat Prod. 2002 Mar;65(3):259-61.
DM8HG0K	RU	https://pubmed.ncbi.nlm.nih.gov/11908961

DM2E5VZ	DI	DM2E5VZ
DM2E5VZ	DN	Cyclotheonamide E4
DM2E5VZ	MI	TT6L509
DM2E5VZ	MN	Coagulation factor IIa (F2)
DM2E5VZ	MT	DTT
DM2E5VZ	MA	Inhibitor
DM2E5VZ	RN	Cyclotheonamide E4 and E5, new potent tryptase inhibitors from an Ircinia species of sponge. J Nat Prod. 2002 Mar;65(3):259-61.
DM2E5VZ	RU	https://pubmed.ncbi.nlm.nih.gov/11908961

DMCA76M	DI	DMCA76M
DMCA76M	DN	Cyclotheonamide E5
DMCA76M	MI	TT6L509
DMCA76M	MN	Coagulation factor IIa (F2)
DMCA76M	MT	DTT
DMCA76M	MA	Inhibitor
DMCA76M	RN	Cyclotheonamide E4 and E5, new potent tryptase inhibitors from an Ircinia species of sponge. J Nat Prod. 2002 Mar;65(3):259-61.
DMCA76M	RU	https://pubmed.ncbi.nlm.nih.gov/11908961

DMTS8D5	DI	DMTS8D5
DMTS8D5	DN	CYLINDOL A
DMTS8D5	MI	TT2J34L
DMTS8D5	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMTS8D5	MT	DTT
DMTS8D5	MA	Inhibitor
DMTS8D5	RN	Cylindol A, a novel biphenyl ether with 5-lipoxygenase inhibitory activity, and a related compound from Imperata Cylindrica. J Nat Prod. 1994 Sep;57(9):1290-3.
DMTS8D5	RU	https://pubmed.ncbi.nlm.nih.gov/7798964

DMCRU4H	DI	DMCRU4H
DMCRU4H	DN	CYLINDROL A
DMCRU4H	MI	TT7WZIJ
DMCRU4H	MN	CAAX farnesyltransferase beta (FNTB)
DMCRU4H	MT	DTT
DMCRU4H	MA	Inhibitor
DMCRU4H	RN	Ras farnesyltransferase: a new therapeutic target. J Med Chem. 1997 Sep 12;40(19):2971-90.
DMCRU4H	RU	https://pubmed.ncbi.nlm.nih.gov/9301658

DMQWLIC	DI	DMQWLIC
DMQWLIC	DN	Cylopentenyl cytosine
DMQWLIC	MI	TTN12BZ
DMQWLIC	MN	CTP synthase (CTPS1)
DMQWLIC	MT	DTT
DMQWLIC	MA	Inhibitor
DMQWLIC	RN	Comments on: cylopentenyl cytosine inhibits cytidine triphosphate synthetase in paediatric acute non-lymphocytic leukaemia: a promising target for chemotherapy. A.C. Verschuur et al. Eur J Cancer 2000, 36, 627-635. Eur J Cancer. 2001 Jan;37(2):290.
DMQWLIC	RU	https://pubmed.ncbi.nlm.nih.gov/11243234

DM5NFEA	DI	DM5NFEA
DM5NFEA	DN	CYM2503
DM5NFEA	MI	TTOPAY7
DM5NFEA	MN	Galanin receptor (GAL-R)
DM5NFEA	MT	DTT
DM5NFEA	MA	Modulator (allosteric modulator)
DM5NFEA	RN	GalR2-positive allosteric modulator exhibits anticonvulsant effects in animal models. Proc Natl Acad Sci U S A. 2010 Aug 24;107(34):15229-34.
DM5NFEA	RU	https://pubmed.ncbi.nlm.nih.gov/20660766

DMGTZ9Q	DI	DMGTZ9Q
DMGTZ9Q	DN	CYM5181
DMGTZ9Q	MI	TT9JZCK
DMGTZ9Q	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMGTZ9Q	MT	DTT
DMGTZ9Q	MA	Agonist
DMGTZ9Q	RN	Full pharmacological efficacy of a novel S1P1 agonist that does not require S1P-like headgroup interactions. Mol Pharmacol. 2008 Nov;74(5):1308-18.
DMGTZ9Q	RU	https://pubmed.ncbi.nlm.nih.gov/18708635

DMURD2E	DI	DMURD2E
DMURD2E	DN	CYM5442
DMURD2E	MI	TT9JZCK
DMURD2E	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMURD2E	MT	DTT
DMURD2E	MA	Agonist
DMURD2E	RN	Full pharmacological efficacy of a novel S1P1 agonist that does not require S1P-like headgroup interactions. Mol Pharmacol. 2008 Nov;74(5):1308-18.
DMURD2E	RU	https://pubmed.ncbi.nlm.nih.gov/18708635

DMG0PHU	DI	DMG0PHU
DMG0PHU	DN	CYNAROPICRIN
DMG0PHU	MI	TTICX3S
DMG0PHU	MN	Bacterial UDP-N-acetylglucosamine carboxyvinyltransferase (Bact murA)
DMG0PHU	MT	DTT
DMG0PHU	MA	Inhibitor
DMG0PHU	RN	Sesquiterpene lactones are potent and irreversible inhibitors of the antibacterial target enzyme MurA. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5605-9.
DMG0PHU	RU	https://pubmed.ncbi.nlm.nih.gov/16945528

DMZCA15	DI	DMZCA15
DMZCA15	DN	Cynooxide anion
DMZCA15	MI	TTHQPL7
DMZCA15	MN	Carbonic anhydrase I (CA-I)
DMZCA15	MT	DTT
DMZCA15	MA	Inhibitor
DMZCA15	RN	Carbonic anhydrase inhibitors. Inhibition of the beta-class enzyme from the methanoarchaeon Methanobacterium thermoautotrophicum (Cab) with anions. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4563-7.
DMZCA15	RU	https://pubmed.ncbi.nlm.nih.gov/15357993

DMBTU7G	DI	DMBTU7G
DMBTU7G	DN	Cypate-[(RGD)2-NH2]1
DMBTU7G	MI	TTT1R2L
DMBTU7G	MN	Integrin alpha-V (ITGAV)
DMBTU7G	MT	DTT
DMBTU7G	MA	Inhibitor
DMBTU7G	RN	Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75.
DMBTU7G	RU	https://pubmed.ncbi.nlm.nih.gov/16570923

DMBTU7G	DI	DMBTU7G
DMBTU7G	DN	Cypate-[(RGD)2-NH2]1
DMBTU7G	MI	TTJA1ZO
DMBTU7G	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMBTU7G	MT	DTT
DMBTU7G	MA	Inhibitor
DMBTU7G	RN	Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75.
DMBTU7G	RU	https://pubmed.ncbi.nlm.nih.gov/16570923

DMJNW9P	DI	DMJNW9P
DMJNW9P	DN	Cypate-[(RGD)2-NH2]2
DMJNW9P	MI	TTT1R2L
DMJNW9P	MN	Integrin alpha-V (ITGAV)
DMJNW9P	MT	DTT
DMJNW9P	MA	Inhibitor
DMJNW9P	RN	Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75.
DMJNW9P	RU	https://pubmed.ncbi.nlm.nih.gov/16570923

DMJNW9P	DI	DMJNW9P
DMJNW9P	DN	Cypate-[(RGD)2-NH2]2
DMJNW9P	MI	TTJA1ZO
DMJNW9P	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMJNW9P	MT	DTT
DMJNW9P	MA	Inhibitor
DMJNW9P	RN	Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75.
DMJNW9P	RU	https://pubmed.ncbi.nlm.nih.gov/16570923

DMWINK5	DI	DMWINK5
DMWINK5	DN	Cypate-[(RGD)3-NH2]1
DMWINK5	MI	TTT1R2L
DMWINK5	MN	Integrin alpha-V (ITGAV)
DMWINK5	MT	DTT
DMWINK5	MA	Inhibitor
DMWINK5	RN	Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75.
DMWINK5	RU	https://pubmed.ncbi.nlm.nih.gov/16570923

DMWINK5	DI	DMWINK5
DMWINK5	DN	Cypate-[(RGD)3-NH2]1
DMWINK5	MI	TTJA1ZO
DMWINK5	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMWINK5	MT	DTT
DMWINK5	MA	Inhibitor
DMWINK5	RN	Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75.
DMWINK5	RU	https://pubmed.ncbi.nlm.nih.gov/16570923

DM1SAIX	DI	DM1SAIX
DM1SAIX	DN	Cypate-[(RGD)3-NH2]2
DM1SAIX	MI	TTT1R2L
DM1SAIX	MN	Integrin alpha-V (ITGAV)
DM1SAIX	MT	DTT
DM1SAIX	MA	Inhibitor
DM1SAIX	RN	Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75.
DM1SAIX	RU	https://pubmed.ncbi.nlm.nih.gov/16570923

DM1SAIX	DI	DM1SAIX
DM1SAIX	DN	Cypate-[(RGD)3-NH2]2
DM1SAIX	MI	TTJA1ZO
DM1SAIX	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DM1SAIX	MT	DTT
DM1SAIX	MA	Inhibitor
DM1SAIX	RN	Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75.
DM1SAIX	RU	https://pubmed.ncbi.nlm.nih.gov/16570923

DM3GLMP	DI	DM3GLMP
DM3GLMP	DN	Cypate-[(RGD)4-NH2]1
DM3GLMP	MI	TTT1R2L
DM3GLMP	MN	Integrin alpha-V (ITGAV)
DM3GLMP	MT	DTT
DM3GLMP	MA	Inhibitor
DM3GLMP	RN	Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75.
DM3GLMP	RU	https://pubmed.ncbi.nlm.nih.gov/16570923

DM3GLMP	DI	DM3GLMP
DM3GLMP	DN	Cypate-[(RGD)4-NH2]1
DM3GLMP	MI	TTJA1ZO
DM3GLMP	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DM3GLMP	MT	DTT
DM3GLMP	MA	Inhibitor
DM3GLMP	RN	Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75.
DM3GLMP	RU	https://pubmed.ncbi.nlm.nih.gov/16570923

DMR74OM	DI	DMR74OM
DMR74OM	DN	Cypate-[(RGD)4-NH2]2
DMR74OM	MI	TTT1R2L
DMR74OM	MN	Integrin alpha-V (ITGAV)
DMR74OM	MT	DTT
DMR74OM	MA	Inhibitor
DMR74OM	RN	Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75.
DMR74OM	RU	https://pubmed.ncbi.nlm.nih.gov/16570923

DMR74OM	DI	DMR74OM
DMR74OM	DN	Cypate-[(RGD)4-NH2]2
DMR74OM	MI	TTJA1ZO
DMR74OM	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMR74OM	MT	DTT
DMR74OM	MA	Inhibitor
DMR74OM	RN	Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75.
DMR74OM	RU	https://pubmed.ncbi.nlm.nih.gov/16570923

DM64L9I	DI	DM64L9I
DM64L9I	DN	CyPPA
DM64L9I	MI	TT2T5M0
DM64L9I	MN	Calcium-activated potassium channel KCa2.2 (KCNN2)
DM64L9I	MT	DTT
DM64L9I	MA	Activator
DM64L9I	RN	Selective positive modulation of the SK3 and SK2 subtypes of small conductance Ca2+-activated K+ channels. Br J Pharmacol. 2007 Jul;151(5):655-65.
DM64L9I	RU	https://pubmed.ncbi.nlm.nih.gov/17486140

DM64L9I	DI	DM64L9I
DM64L9I	DN	CyPPA
DM64L9I	MI	TT9JH25
DM64L9I	MN	Calcium-activated potassium channel KCa2.3 (KCNN3)
DM64L9I	MT	DTT
DM64L9I	MA	Activator
DM64L9I	RN	Selective positive modulation of the SK3 and SK2 subtypes of small conductance Ca2+-activated K+ channels. Br J Pharmacol. 2007 Jul;151(5):655-65.
DM64L9I	RU	https://pubmed.ncbi.nlm.nih.gov/17486140

DME9LPO	DI	DME9LPO
DME9LPO	DN	cyPPTS
DME9LPO	MI	TTXJ47W
DME9LPO	MN	Metabotropic glutamate receptor 2 (mGluR2)
DME9LPO	MT	DTT
DME9LPO	MA	Modulator (allosteric modulator)
DME9LPO	RN	Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and... Psychopharmacology (Berl). 2005 Apr;179(1):271-83.
DME9LPO	RU	https://pubmed.ncbi.nlm.nih.gov/15717213

DMJXCVA	DI	DMJXCVA
DMJXCVA	DN	CYPRODIME
DMJXCVA	MI	TTKWM86
DMJXCVA	MN	Opioid receptor mu (MOP)
DMJXCVA	MT	DTT
DMJXCVA	MA	Inhibitor
DMJXCVA	RN	Synthesis and biological evaluation of 14-alkoxymorphinans. 21. Novel 4-alkoxy and 14-phenylpropoxy derivatives of the mu opioid receptor antagonis... J Med Chem. 2004 Jun 3;47(12):3242-7.
DMJXCVA	RU	https://pubmed.ncbi.nlm.nih.gov/15163203

DM7T96M	DI	DM7T96M
DM7T96M	DN	Cyprodine
DM7T96M	MI	TTN4QDT
DM7T96M	MN	Opioid receptor (OPR)
DM7T96M	MT	DTT
DM7T96M	MA	Antagonist
DM7T96M	RN	Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54.
DM7T96M	RU	https://pubmed.ncbi.nlm.nih.gov/17016425

DMS5DHY	DI	DMS5DHY
DMS5DHY	DN	Cystamine
DMS5DHY	MI	TTNFESW
DMS5DHY	MN	Glutamate--cysteine ligase modifier (GCLM)
DMS5DHY	MT	DTT
DMS5DHY	MA	Inhibitor
DMS5DHY	RN	The gamma-glutamylcysteine synthetase of Onchocerca volvulus. Mol Biochem Parasitol. 2000 Dec;111(2):243-51.
DMS5DHY	RU	https://pubmed.ncbi.nlm.nih.gov/11163433

DM4GZUJ	DI	DM4GZUJ
DM4GZUJ	DN	Cysteine Sulfenic Acid
DM4GZUJ	MI	TTJGY7A
DM4GZUJ	MN	Complement C3 (CO3)
DM4GZUJ	MT	DTT
DM4GZUJ	MA	Inhibitor
DM4GZUJ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM4GZUJ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM4GZUJ	DI	DM4GZUJ
DM4GZUJ	DN	Cysteine Sulfenic Acid
DM4GZUJ	MI	TTR0SWN
DM4GZUJ	MN	M-phase inducer phosphatase 2 (MPIP2)
DM4GZUJ	MT	DTT
DM4GZUJ	MA	Inhibitor
DM4GZUJ	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DM4GZUJ	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DM4GZUJ	DI	DM4GZUJ
DM4GZUJ	DN	Cysteine Sulfenic Acid
DM4GZUJ	MI	TT6PKBN
DM4GZUJ	MN	Proto-oncogene c-Src (SRC)
DM4GZUJ	MT	DTT
DM4GZUJ	MA	Inhibitor
DM4GZUJ	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DM4GZUJ	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DM4GZUJ	DI	DM4GZUJ
DM4GZUJ	DN	Cysteine Sulfenic Acid
DM4GZUJ	MI	TTELIN2
DM4GZUJ	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DM4GZUJ	MT	DTT
DM4GZUJ	MA	Inhibitor
DM4GZUJ	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DM4GZUJ	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMXI8FP	DI	DMXI8FP
DMXI8FP	DN	Cysteinesulfonic Acid
DMXI8FP	MI	TT36ETB
DMXI8FP	MN	Cathepsin L (CTSL)
DMXI8FP	MT	DTT
DMXI8FP	MA	Inhibitor
DMXI8FP	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMXI8FP	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMXI8FP	DI	DMXI8FP
DMXI8FP	DN	Cysteinesulfonic Acid
DMXI8FP	MI	TTR0SWN
DMXI8FP	MN	M-phase inducer phosphatase 2 (MPIP2)
DMXI8FP	MT	DTT
DMXI8FP	MA	Inhibitor
DMXI8FP	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMXI8FP	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMXI8FP	DI	DMXI8FP
DMXI8FP	DN	Cysteinesulfonic Acid
DMXI8FP	MI	TTELIN2
DMXI8FP	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMXI8FP	MT	DTT
DMXI8FP	MA	Inhibitor
DMXI8FP	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMXI8FP	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMXI8FP	DI	DMXI8FP
DMXI8FP	DN	Cysteinesulfonic Acid
DMXI8FP	MI	TTICO5G
DMXI8FP	MN	Staphylococcus Peptide deformylase (Stap-coc def)
DMXI8FP	MT	DTT
DMXI8FP	MA	Inhibitor
DMXI8FP	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMXI8FP	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMK0W8E	DI	DMK0W8E
DMK0W8E	DN	Cytidine
DMK0W8E	MI	DENV24I
DMK0W8E	MN	Nicotinamide riboside kinase 1 (NRK1)
DMK0W8E	MT	DME
DMK0W8E	MA	Metabolism
DMK0W8E	RN	Nicotinamide riboside kinase structures reveal new pathways to NAD+. PLoS Biol. 2007 Oct 2;5(10):e263.
DMK0W8E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17914902

DMK0W8E	DI	DMK0W8E
DMK0W8E	DN	Cytidine
DMK0W8E	MI	DE8DJ3N
DMK0W8E	MN	Nicotinamide riboside kinase 2 (NRK2)
DMK0W8E	MT	DME
DMK0W8E	MA	Metabolism
DMK0W8E	RN	Nicotinamide riboside kinase structures reveal new pathways to NAD+. PLoS Biol. 2007 Oct 2;5(10):e263.
DMK0W8E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17914902

DMK0W8E	DI	DMK0W8E
DMK0W8E	DN	Cytidine
DMK0W8E	MI	DE478BP
DMK0W8E	MN	Uridine-cytidine kinase 1 (UCK1)
DMK0W8E	MT	DME
DMK0W8E	MA	Metabolism
DMK0W8E	RN	Phosphorylation of uridine and cytidine nucleoside analogs by two human uridine-cytidine kinases. Mol Pharmacol. 2001 May;59(5):1181-6.
DMK0W8E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11306702

DMK0W8E	DI	DMK0W8E
DMK0W8E	DN	Cytidine
DMK0W8E	MI	DETN1O0
DMK0W8E	MN	Uridine-cytidine kinase 2 (UCK2)
DMK0W8E	MT	DME
DMK0W8E	MA	Metabolism
DMK0W8E	RN	Phosphorylation of uridine and cytidine nucleoside analogs by two human uridine-cytidine kinases. Mol Pharmacol. 2001 May;59(5):1181-6.
DMK0W8E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11306702

DMA5FGS	DI	DMA5FGS
DMA5FGS	DN	Cytidine-5'-Diphosphate
DMA5FGS	MI	TTQ8J1V
DMA5FGS	MN	Bacterial Deoxy-manno-octulosonate cytidylyltransferase (Bact kdsB)
DMA5FGS	MT	DTT
DMA5FGS	MA	Inhibitor
DMA5FGS	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMA5FGS	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMA5FGS	DI	DMA5FGS
DMA5FGS	DN	Cytidine-5'-Diphosphate
DMA5FGS	MI	TTMFYEC
DMA5FGS	MN	Streptococcus Cytidylate kinase (Stre-coc cmk)
DMA5FGS	MT	DTT
DMA5FGS	MA	Inhibitor
DMA5FGS	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMA5FGS	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM6PAXD	DI	DM6PAXD
DM6PAXD	DN	Cytidine-5'-Monophosphate
DM6PAXD	MI	TTQ8J1V
DM6PAXD	MN	Bacterial Deoxy-manno-octulosonate cytidylyltransferase (Bact kdsB)
DM6PAXD	MT	DTT
DM6PAXD	MA	Inhibitor
DM6PAXD	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DM6PAXD	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DM6PAXD	DI	DM6PAXD
DM6PAXD	DN	Cytidine-5'-Monophosphate
DM6PAXD	MI	TTMFYEC
DM6PAXD	MN	Streptococcus Cytidylate kinase (Stre-coc cmk)
DM6PAXD	MT	DTT
DM6PAXD	MA	Inhibitor
DM6PAXD	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DM6PAXD	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMPT4WM	DI	DMPT4WM
DMPT4WM	DN	Cytosine Arabinose-5'-Phosphate
DMPT4WM	MI	TTMFYEC
DMPT4WM	MN	Streptococcus Cytidylate kinase (Stre-coc cmk)
DMPT4WM	MT	DTT
DMPT4WM	MA	Inhibitor
DMPT4WM	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMPT4WM	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM7SVLZ	DI	DM7SVLZ
DM7SVLZ	DN	Cytotoxin Peptide Conjugate
DM7SVLZ	MI	TTIND6G
DM7SVLZ	MN	Somatostatin receptor type 1 (SSTR1)
DM7SVLZ	MT	DTT
DM7SVLZ	MA	Inhibitor
DM7SVLZ	RN	An adjustable release rate linking strategy for cytotoxin-peptide conjugates. Bioorg Med Chem Lett. 2003 Mar 10;13(5):799-803.
DM7SVLZ	RU	https://pubmed.ncbi.nlm.nih.gov/12617894

DM7SVLZ	DI	DM7SVLZ
DM7SVLZ	DN	Cytotoxin Peptide Conjugate
DM7SVLZ	MI	TTZ6T9E
DM7SVLZ	MN	Somatostatin receptor type 2 (SSTR2)
DM7SVLZ	MT	DTT
DM7SVLZ	MA	Inhibitor
DM7SVLZ	RN	An adjustable release rate linking strategy for cytotoxin-peptide conjugates. Bioorg Med Chem Lett. 2003 Mar 10;13(5):799-803.
DM7SVLZ	RU	https://pubmed.ncbi.nlm.nih.gov/12617894

DM7SVLZ	DI	DM7SVLZ
DM7SVLZ	DN	Cytotoxin Peptide Conjugate
DM7SVLZ	MI	TTJX3UE
DM7SVLZ	MN	Somatostatin receptor type 3 (SSTR3)
DM7SVLZ	MT	DTT
DM7SVLZ	MA	Inhibitor
DM7SVLZ	RN	An adjustable release rate linking strategy for cytotoxin-peptide conjugates. Bioorg Med Chem Lett. 2003 Mar 10;13(5):799-803.
DM7SVLZ	RU	https://pubmed.ncbi.nlm.nih.gov/12617894

DM7SVLZ	DI	DM7SVLZ
DM7SVLZ	DN	Cytotoxin Peptide Conjugate
DM7SVLZ	MI	TTAE1BR
DM7SVLZ	MN	Somatostatin receptor type 4 (SSTR4)
DM7SVLZ	MT	DTT
DM7SVLZ	MA	Inhibitor
DM7SVLZ	RN	An adjustable release rate linking strategy for cytotoxin-peptide conjugates. Bioorg Med Chem Lett. 2003 Mar 10;13(5):799-803.
DM7SVLZ	RU	https://pubmed.ncbi.nlm.nih.gov/12617894

DM7SVLZ	DI	DM7SVLZ
DM7SVLZ	DN	Cytotoxin Peptide Conjugate
DM7SVLZ	MI	TT2BC4G
DM7SVLZ	MN	Somatostatin receptor type 5 (SSTR5)
DM7SVLZ	MT	DTT
DM7SVLZ	MA	Inhibitor
DM7SVLZ	RN	An adjustable release rate linking strategy for cytotoxin-peptide conjugates. Bioorg Med Chem Lett. 2003 Mar 10;13(5):799-803.
DM7SVLZ	RU	https://pubmed.ncbi.nlm.nih.gov/12617894

DMLBYFG	DI	DMLBYFG
DMLBYFG	DN	CZC 24832
DMLBYFG	MI	TTHBTOP
DMLBYFG	MN	PI3-kinase gamma (PIK3CG)
DMLBYFG	MT	DTT
DMLBYFG	MA	Inhibitor
DMLBYFG	RN	A selective inhibitor reveals PI3Kgamma dependence of T(H)17 cell differentiation. Nat Chem Biol. 2012 Apr 29;8(6):576-82.
DMLBYFG	RU	https://pubmed.ncbi.nlm.nih.gov/22544264

DMYBL5G	DI	DMYBL5G
DMYBL5G	DN	CZC-19091
DMYBL5G	MI	TTHBTOP
DMYBL5G	MN	PI3-kinase gamma (PIK3CG)
DMYBL5G	MT	DTT
DMYBL5G	MA	Inhibitor
DMYBL5G	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2156).
DMYBL5G	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2156

DM1E5C4	DI	DM1E5C4
DM1E5C4	DN	D 2343
DM1E5C4	MI	TT2CJVK
DM1E5C4	MN	Adrenergic receptor beta-2 (ADRB2)
DM1E5C4	MT	DTT
DM1E5C4	MA	Agonist
DM1E5C4	RN	A new beta 2-adrenoceptor agonist--D 2343--with long duration. Inhalation comparison with terbutaline in asthmatics. Allergy. 1984 Aug;39(6):485-9.
DM1E5C4	RU	https://pubmed.ncbi.nlm.nih.gov/6437263

DMAX7LW	DI	DMAX7LW
DMAX7LW	DN	d(CH2)5[D-Ile2,Ile4]AVP
DMAX7LW	MI	TTK8R02
DMAX7LW	MN	Vasopressin V2 receptor (V2R)
DMAX7LW	MT	DTT
DMAX7LW	MA	Antagonist
DMAX7LW	RN	Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463. Kidney Int. 2000 Oct;58(4):1613-22.
DMAX7LW	RU	https://pubmed.ncbi.nlm.nih.gov/11012895

DMVHMGA	DI	DMVHMGA
DMVHMGA	DN	D(CH2)5[Tyr(Me)2,Thr4,Orn8(5/6C-Flu),Tyr-NH29]VT
DMVHMGA	MI	TTSCIUP
DMVHMGA	MN	Oxytocin receptor (OTR)
DMVHMGA	MT	DTT
DMVHMGA	MA	Inhibitor
DMVHMGA	RN	Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88.
DMVHMGA	RU	https://pubmed.ncbi.nlm.nih.gov/12036367

DMVHMGA	DI	DMVHMGA
DMVHMGA	DN	D(CH2)5[Tyr(Me)2,Thr4,Orn8(5/6C-Flu),Tyr-NH29]VT
DMVHMGA	MI	TT4TFGN
DMVHMGA	MN	Vasopressin V1a receptor (V1AR)
DMVHMGA	MT	DTT
DMVHMGA	MA	Inhibitor
DMVHMGA	RN	Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88.
DMVHMGA	RU	https://pubmed.ncbi.nlm.nih.gov/12036367

DM1BMT7	DI	DM1BMT7
DM1BMT7	DN	D(CH2)5[Tyr(Me)2,Thr4,Orn8,Tyr9-NH2]VT
DM1BMT7	MI	TTSCIUP
DM1BMT7	MN	Oxytocin receptor (OTR)
DM1BMT7	MT	DTT
DM1BMT7	MA	Inhibitor
DM1BMT7	RN	Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88.
DM1BMT7	RU	https://pubmed.ncbi.nlm.nih.gov/12036367

DM1BMT7	DI	DM1BMT7
DM1BMT7	DN	D(CH2)5[Tyr(Me)2,Thr4,Orn8,Tyr9-NH2]VT
DM1BMT7	MI	TT4TFGN
DM1BMT7	MN	Vasopressin V1a receptor (V1AR)
DM1BMT7	MT	DTT
DM1BMT7	MA	Inhibitor
DM1BMT7	RN	Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88.
DM1BMT7	RU	https://pubmed.ncbi.nlm.nih.gov/12036367

DM1BMT7	DI	DM1BMT7
DM1BMT7	DN	D(CH2)5[Tyr(Me)2,Thr4,Orn8,Tyr9-NH2]VT
DM1BMT7	MI	TTK8R02
DM1BMT7	MN	Vasopressin V2 receptor (V2R)
DM1BMT7	MT	DTT
DM1BMT7	MA	Inhibitor
DM1BMT7	RN	Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88.
DM1BMT7	RU	https://pubmed.ncbi.nlm.nih.gov/12036367

DMHTSAX	DI	DMHTSAX
DMHTSAX	DN	d(CH2)5[Tyr(Me)2]AVP
DMHTSAX	MI	TTSCIUP
DMHTSAX	MN	Oxytocin receptor (OTR)
DMHTSAX	MT	DTT
DMHTSAX	MA	Antagonist
DMHTSAX	RN	Characterization of the human oxytocin receptor stably expressed in 293 human embryonic kidney cells. Life Sci. 1995;57(24):2253-61.
DMHTSAX	RU	https://pubmed.ncbi.nlm.nih.gov/7475979

DMHTSAX	DI	DMHTSAX
DMHTSAX	DN	d(CH2)5[Tyr(Me)2]AVP
DMHTSAX	MI	TT4TFGN
DMHTSAX	MN	Vasopressin V1a receptor (V1AR)
DMHTSAX	MT	DTT
DMHTSAX	MA	Antagonist
DMHTSAX	RN	Conserved aromatic residues in the transmembrane region VI of the V1a vasopressin receptor differentiate agonist vs. antagonist ligand binding. Eur J Biochem. 2000 Jul;267(13):4253-63.
DMHTSAX	RU	https://pubmed.ncbi.nlm.nih.gov/10866830

DMHTSAX	DI	DMHTSAX
DMHTSAX	DN	d(CH2)5[Tyr(Me)2]AVP
DMHTSAX	MI	TTL9MHW
DMHTSAX	MN	Vasopressin V1b receptor (V1BR)
DMHTSAX	MT	DTT
DMHTSAX	MA	Antagonist
DMHTSAX	RN	1-desamino-8-D-arginine vasopressin (DDAVP) as an agonist on V1b vasopressin receptor. Biochem Pharmacol. 1997 Jun 1;53(11):1711-7.
DMHTSAX	RU	https://pubmed.ncbi.nlm.nih.gov/9264324

DMHTSAX	DI	DMHTSAX
DMHTSAX	DN	d(CH2)5[Tyr(Me)2]AVP
DMHTSAX	MI	TTK8R02
DMHTSAX	MN	Vasopressin V2 receptor (V2R)
DMHTSAX	MT	DTT
DMHTSAX	MA	Antagonist
DMHTSAX	RN	Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463. Kidney Int. 2000 Oct;58(4):1613-22.
DMHTSAX	RU	https://pubmed.ncbi.nlm.nih.gov/11012895

DMCU8HK	DI	DMCU8HK
DMCU8HK	DN	D[Arg4,Dab8]VP
DMCU8HK	MI	TTSCIUP
DMCU8HK	MN	Oxytocin receptor (OTR)
DMCU8HK	MT	DTT
DMCU8HK	MA	Inhibitor
DMCU8HK	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMCU8HK	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMCU8HK	DI	DMCU8HK
DMCU8HK	DN	D[Arg4,Dab8]VP
DMCU8HK	MI	TT4TFGN
DMCU8HK	MN	Vasopressin V1a receptor (V1AR)
DMCU8HK	MT	DTT
DMCU8HK	MA	Inhibitor
DMCU8HK	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMCU8HK	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMCU8HK	DI	DMCU8HK
DMCU8HK	DN	D[Arg4,Dab8]VP
DMCU8HK	MI	TTL9MHW
DMCU8HK	MN	Vasopressin V1b receptor (V1BR)
DMCU8HK	MT	DTT
DMCU8HK	MA	Inhibitor
DMCU8HK	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMCU8HK	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMCU8HK	DI	DMCU8HK
DMCU8HK	DN	D[Arg4,Dab8]VP
DMCU8HK	MI	TTK8R02
DMCU8HK	MN	Vasopressin V2 receptor (V2R)
DMCU8HK	MT	DTT
DMCU8HK	MA	Inhibitor
DMCU8HK	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMCU8HK	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DM69OVM	DI	DM69OVM
DM69OVM	DN	D[Arg4,Lys8]VP
DM69OVM	MI	TTSCIUP
DM69OVM	MN	Oxytocin receptor (OTR)
DM69OVM	MT	DTT
DM69OVM	MA	Inhibitor
DM69OVM	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DM69OVM	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DM69OVM	DI	DM69OVM
DM69OVM	DN	D[Arg4,Lys8]VP
DM69OVM	MI	TT4TFGN
DM69OVM	MN	Vasopressin V1a receptor (V1AR)
DM69OVM	MT	DTT
DM69OVM	MA	Inhibitor
DM69OVM	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DM69OVM	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DM69OVM	DI	DM69OVM
DM69OVM	DN	D[Arg4,Lys8]VP
DM69OVM	MI	TTL9MHW
DM69OVM	MN	Vasopressin V1b receptor (V1BR)
DM69OVM	MT	DTT
DM69OVM	MA	Inhibitor
DM69OVM	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DM69OVM	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DM69OVM	DI	DM69OVM
DM69OVM	DN	D[Arg4,Lys8]VP
DM69OVM	MI	TTK8R02
DM69OVM	MN	Vasopressin V2 receptor (V2R)
DM69OVM	MT	DTT
DM69OVM	MA	Inhibitor
DM69OVM	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DM69OVM	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DM8D4QT	DI	DM8D4QT
DM8D4QT	DN	D[Arg4,Orn8]VP
DM8D4QT	MI	TTSCIUP
DM8D4QT	MN	Oxytocin receptor (OTR)
DM8D4QT	MT	DTT
DM8D4QT	MA	Inhibitor
DM8D4QT	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DM8D4QT	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DM8D4QT	DI	DM8D4QT
DM8D4QT	DN	D[Arg4,Orn8]VP
DM8D4QT	MI	TT4TFGN
DM8D4QT	MN	Vasopressin V1a receptor (V1AR)
DM8D4QT	MT	DTT
DM8D4QT	MA	Inhibitor
DM8D4QT	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DM8D4QT	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DM8D4QT	DI	DM8D4QT
DM8D4QT	DN	D[Arg4,Orn8]VP
DM8D4QT	MI	TTL9MHW
DM8D4QT	MN	Vasopressin V1b receptor (V1BR)
DM8D4QT	MT	DTT
DM8D4QT	MA	Inhibitor
DM8D4QT	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DM8D4QT	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DM8D4QT	DI	DM8D4QT
DM8D4QT	DN	D[Arg4,Orn8]VP
DM8D4QT	MI	TTK8R02
DM8D4QT	MN	Vasopressin V2 receptor (V2R)
DM8D4QT	MT	DTT
DM8D4QT	MA	Inhibitor
DM8D4QT	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DM8D4QT	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DM76Q2B	DI	DM76Q2B
DM76Q2B	DN	D[Arg4]AVP
DM76Q2B	MI	TTSCIUP
DM76Q2B	MN	Oxytocin receptor (OTR)
DM76Q2B	MT	DTT
DM76Q2B	MA	Inhibitor
DM76Q2B	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DM76Q2B	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DM76Q2B	DI	DM76Q2B
DM76Q2B	DN	D[Arg4]AVP
DM76Q2B	MI	TT4TFGN
DM76Q2B	MN	Vasopressin V1a receptor (V1AR)
DM76Q2B	MT	DTT
DM76Q2B	MA	Inhibitor
DM76Q2B	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DM76Q2B	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DM76Q2B	DI	DM76Q2B
DM76Q2B	DN	D[Arg4]AVP
DM76Q2B	MI	TTL9MHW
DM76Q2B	MN	Vasopressin V1b receptor (V1BR)
DM76Q2B	MT	DTT
DM76Q2B	MA	Inhibitor
DM76Q2B	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DM76Q2B	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DM76Q2B	DI	DM76Q2B
DM76Q2B	DN	D[Arg4]AVP
DM76Q2B	MI	TTK8R02
DM76Q2B	MN	Vasopressin V2 receptor (V2R)
DM76Q2B	MT	DTT
DM76Q2B	MA	Inhibitor
DM76Q2B	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DM76Q2B	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMCLUXI	DI	DMCLUXI
DMCLUXI	DN	D[Cha4,Dab8]VP
DMCLUXI	MI	TTSCIUP
DMCLUXI	MN	Oxytocin receptor (OTR)
DMCLUXI	MT	DTT
DMCLUXI	MA	Inhibitor
DMCLUXI	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMCLUXI	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMCLUXI	DI	DMCLUXI
DMCLUXI	DN	D[Cha4,Dab8]VP
DMCLUXI	MI	TT4TFGN
DMCLUXI	MN	Vasopressin V1a receptor (V1AR)
DMCLUXI	MT	DTT
DMCLUXI	MA	Inhibitor
DMCLUXI	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMCLUXI	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMCLUXI	DI	DMCLUXI
DMCLUXI	DN	D[Cha4,Dab8]VP
DMCLUXI	MI	TTL9MHW
DMCLUXI	MN	Vasopressin V1b receptor (V1BR)
DMCLUXI	MT	DTT
DMCLUXI	MA	Inhibitor
DMCLUXI	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMCLUXI	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMCLUXI	DI	DMCLUXI
DMCLUXI	DN	D[Cha4,Dab8]VP
DMCLUXI	MI	TTK8R02
DMCLUXI	MN	Vasopressin V2 receptor (V2R)
DMCLUXI	MT	DTT
DMCLUXI	MA	Inhibitor
DMCLUXI	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMCLUXI	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMAPZKB	DI	DMAPZKB
DMAPZKB	DN	D[Cha4,Dap8]VP
DMAPZKB	MI	TTSCIUP
DMAPZKB	MN	Oxytocin receptor (OTR)
DMAPZKB	MT	DTT
DMAPZKB	MA	Inhibitor
DMAPZKB	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMAPZKB	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMAPZKB	DI	DMAPZKB
DMAPZKB	DN	D[Cha4,Dap8]VP
DMAPZKB	MI	TT4TFGN
DMAPZKB	MN	Vasopressin V1a receptor (V1AR)
DMAPZKB	MT	DTT
DMAPZKB	MA	Inhibitor
DMAPZKB	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMAPZKB	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMAPZKB	DI	DMAPZKB
DMAPZKB	DN	D[Cha4,Dap8]VP
DMAPZKB	MI	TTL9MHW
DMAPZKB	MN	Vasopressin V1b receptor (V1BR)
DMAPZKB	MT	DTT
DMAPZKB	MA	Inhibitor
DMAPZKB	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMAPZKB	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMAPZKB	DI	DMAPZKB
DMAPZKB	DN	D[Cha4,Dap8]VP
DMAPZKB	MI	TTK8R02
DMAPZKB	MN	Vasopressin V2 receptor (V2R)
DMAPZKB	MT	DTT
DMAPZKB	MA	Inhibitor
DMAPZKB	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMAPZKB	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DM0GO7U	DI	DM0GO7U
DM0GO7U	DN	D[Cha4,Lys8]VP
DM0GO7U	MI	TTSCIUP
DM0GO7U	MN	Oxytocin receptor (OTR)
DM0GO7U	MT	DTT
DM0GO7U	MA	Inhibitor
DM0GO7U	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DM0GO7U	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DM0GO7U	DI	DM0GO7U
DM0GO7U	DN	D[Cha4,Lys8]VP
DM0GO7U	MI	TT4TFGN
DM0GO7U	MN	Vasopressin V1a receptor (V1AR)
DM0GO7U	MT	DTT
DM0GO7U	MA	Inhibitor
DM0GO7U	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DM0GO7U	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DM0GO7U	DI	DM0GO7U
DM0GO7U	DN	D[Cha4,Lys8]VP
DM0GO7U	MI	TTL9MHW
DM0GO7U	MN	Vasopressin V1b receptor (V1BR)
DM0GO7U	MT	DTT
DM0GO7U	MA	Inhibitor
DM0GO7U	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DM0GO7U	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DM0GO7U	DI	DM0GO7U
DM0GO7U	DN	D[Cha4,Lys8]VP
DM0GO7U	MI	TTK8R02
DM0GO7U	MN	Vasopressin V2 receptor (V2R)
DM0GO7U	MT	DTT
DM0GO7U	MA	Inhibitor
DM0GO7U	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DM0GO7U	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMZWTJK	DI	DMZWTJK
DMZWTJK	DN	D[Cha4,Orn8]VP
DMZWTJK	MI	TTSCIUP
DMZWTJK	MN	Oxytocin receptor (OTR)
DMZWTJK	MT	DTT
DMZWTJK	MA	Inhibitor
DMZWTJK	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMZWTJK	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMZWTJK	DI	DMZWTJK
DMZWTJK	DN	D[Cha4,Orn8]VP
DMZWTJK	MI	TT4TFGN
DMZWTJK	MN	Vasopressin V1a receptor (V1AR)
DMZWTJK	MT	DTT
DMZWTJK	MA	Inhibitor
DMZWTJK	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMZWTJK	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMZWTJK	DI	DMZWTJK
DMZWTJK	DN	D[Cha4,Orn8]VP
DMZWTJK	MI	TTL9MHW
DMZWTJK	MN	Vasopressin V1b receptor (V1BR)
DMZWTJK	MT	DTT
DMZWTJK	MA	Inhibitor
DMZWTJK	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMZWTJK	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMZWTJK	DI	DMZWTJK
DMZWTJK	DN	D[Cha4,Orn8]VP
DMZWTJK	MI	TTK8R02
DMZWTJK	MN	Vasopressin V2 receptor (V2R)
DMZWTJK	MT	DTT
DMZWTJK	MA	Inhibitor
DMZWTJK	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMZWTJK	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DM8FCX5	DI	DM8FCX5
DM8FCX5	DN	D[Cha4]AVP
DM8FCX5	MI	TTSCIUP
DM8FCX5	MN	Oxytocin receptor (OTR)
DM8FCX5	MT	DTT
DM8FCX5	MA	Inhibitor
DM8FCX5	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DM8FCX5	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DM8FCX5	DI	DM8FCX5
DM8FCX5	DN	D[Cha4]AVP
DM8FCX5	MI	TT4TFGN
DM8FCX5	MN	Vasopressin V1a receptor (V1AR)
DM8FCX5	MT	DTT
DM8FCX5	MA	Inhibitor
DM8FCX5	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DM8FCX5	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DM8FCX5	DI	DM8FCX5
DM8FCX5	DN	D[Cha4]AVP
DM8FCX5	MI	TTL9MHW
DM8FCX5	MN	Vasopressin V1b receptor (V1BR)
DM8FCX5	MT	DTT
DM8FCX5	MA	Inhibitor
DM8FCX5	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DM8FCX5	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DM8FCX5	DI	DM8FCX5
DM8FCX5	DN	D[Cha4]AVP
DM8FCX5	MI	TTK8R02
DM8FCX5	MN	Vasopressin V2 receptor (V2R)
DM8FCX5	MT	DTT
DM8FCX5	MA	Inhibitor
DM8FCX5	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DM8FCX5	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMD4V6U	DI	DMD4V6U
DMD4V6U	DN	D[D-3-Pal2]AVP
DMD4V6U	MI	TT4TFGN
DMD4V6U	MN	Vasopressin V1a receptor (V1AR)
DMD4V6U	MT	DTT
DMD4V6U	MA	Inhibitor
DMD4V6U	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMD4V6U	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMD4V6U	DI	DMD4V6U
DMD4V6U	DN	D[D-3-Pal2]AVP
DMD4V6U	MI	TTL9MHW
DMD4V6U	MN	Vasopressin V1b receptor (V1BR)
DMD4V6U	MT	DTT
DMD4V6U	MA	Inhibitor
DMD4V6U	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMD4V6U	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMD4V6U	DI	DMD4V6U
DMD4V6U	DN	D[D-3-Pal2]AVP
DMD4V6U	MI	TTK8R02
DMD4V6U	MN	Vasopressin V2 receptor (V2R)
DMD4V6U	MT	DTT
DMD4V6U	MA	Inhibitor
DMD4V6U	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMD4V6U	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMNSXG9	DI	DMNSXG9
DMNSXG9	DN	D[Leu4,Dab8]VP
DMNSXG9	MI	TTSCIUP
DMNSXG9	MN	Oxytocin receptor (OTR)
DMNSXG9	MT	DTT
DMNSXG9	MA	Inhibitor
DMNSXG9	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMNSXG9	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMNSXG9	DI	DMNSXG9
DMNSXG9	DN	D[Leu4,Dab8]VP
DMNSXG9	MI	TT4TFGN
DMNSXG9	MN	Vasopressin V1a receptor (V1AR)
DMNSXG9	MT	DTT
DMNSXG9	MA	Inhibitor
DMNSXG9	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMNSXG9	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMNSXG9	DI	DMNSXG9
DMNSXG9	DN	D[Leu4,Dab8]VP
DMNSXG9	MI	TTL9MHW
DMNSXG9	MN	Vasopressin V1b receptor (V1BR)
DMNSXG9	MT	DTT
DMNSXG9	MA	Inhibitor
DMNSXG9	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMNSXG9	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMNSXG9	DI	DMNSXG9
DMNSXG9	DN	D[Leu4,Dab8]VP
DMNSXG9	MI	TTK8R02
DMNSXG9	MN	Vasopressin V2 receptor (V2R)
DMNSXG9	MT	DTT
DMNSXG9	MA	Inhibitor
DMNSXG9	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMNSXG9	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DME3HK8	DI	DME3HK8
DME3HK8	DN	D[Leu4,Dap8]VP
DME3HK8	MI	TTSCIUP
DME3HK8	MN	Oxytocin receptor (OTR)
DME3HK8	MT	DTT
DME3HK8	MA	Inhibitor
DME3HK8	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DME3HK8	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DME3HK8	DI	DME3HK8
DME3HK8	DN	D[Leu4,Dap8]VP
DME3HK8	MI	TT4TFGN
DME3HK8	MN	Vasopressin V1a receptor (V1AR)
DME3HK8	MT	DTT
DME3HK8	MA	Inhibitor
DME3HK8	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DME3HK8	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DME3HK8	DI	DME3HK8
DME3HK8	DN	D[Leu4,Dap8]VP
DME3HK8	MI	TTL9MHW
DME3HK8	MN	Vasopressin V1b receptor (V1BR)
DME3HK8	MT	DTT
DME3HK8	MA	Inhibitor
DME3HK8	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DME3HK8	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DME3HK8	DI	DME3HK8
DME3HK8	DN	D[Leu4,Dap8]VP
DME3HK8	MI	TTK8R02
DME3HK8	MN	Vasopressin V2 receptor (V2R)
DME3HK8	MT	DTT
DME3HK8	MA	Inhibitor
DME3HK8	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DME3HK8	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMDBU7Q	DI	DMDBU7Q
DMDBU7Q	DN	D[Leu4,Lys8]VP
DMDBU7Q	MI	TTSCIUP
DMDBU7Q	MN	Oxytocin receptor (OTR)
DMDBU7Q	MT	DTT
DMDBU7Q	MA	Inhibitor
DMDBU7Q	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMDBU7Q	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMDBU7Q	DI	DMDBU7Q
DMDBU7Q	DN	D[Leu4,Lys8]VP
DMDBU7Q	MI	TT4TFGN
DMDBU7Q	MN	Vasopressin V1a receptor (V1AR)
DMDBU7Q	MT	DTT
DMDBU7Q	MA	Inhibitor
DMDBU7Q	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMDBU7Q	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMDBU7Q	DI	DMDBU7Q
DMDBU7Q	DN	D[Leu4,Lys8]VP
DMDBU7Q	MI	TTL9MHW
DMDBU7Q	MN	Vasopressin V1b receptor (V1BR)
DMDBU7Q	MT	DTT
DMDBU7Q	MA	Inhibitor
DMDBU7Q	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMDBU7Q	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMDBU7Q	DI	DMDBU7Q
DMDBU7Q	DN	D[Leu4,Lys8]VP
DMDBU7Q	MI	TTK8R02
DMDBU7Q	MN	Vasopressin V2 receptor (V2R)
DMDBU7Q	MT	DTT
DMDBU7Q	MA	Inhibitor
DMDBU7Q	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMDBU7Q	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMJCW8Y	DI	DMJCW8Y
DMJCW8Y	DN	D[Leu4,Orn8]VP
DMJCW8Y	MI	TTSCIUP
DMJCW8Y	MN	Oxytocin receptor (OTR)
DMJCW8Y	MT	DTT
DMJCW8Y	MA	Inhibitor
DMJCW8Y	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMJCW8Y	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMJCW8Y	DI	DMJCW8Y
DMJCW8Y	DN	D[Leu4,Orn8]VP
DMJCW8Y	MI	TT4TFGN
DMJCW8Y	MN	Vasopressin V1a receptor (V1AR)
DMJCW8Y	MT	DTT
DMJCW8Y	MA	Inhibitor
DMJCW8Y	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMJCW8Y	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMJCW8Y	DI	DMJCW8Y
DMJCW8Y	DN	D[Leu4,Orn8]VP
DMJCW8Y	MI	TTL9MHW
DMJCW8Y	MN	Vasopressin V1b receptor (V1BR)
DMJCW8Y	MT	DTT
DMJCW8Y	MA	Inhibitor
DMJCW8Y	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMJCW8Y	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMJCW8Y	DI	DMJCW8Y
DMJCW8Y	DN	D[Leu4,Orn8]VP
DMJCW8Y	MI	TTK8R02
DMJCW8Y	MN	Vasopressin V2 receptor (V2R)
DMJCW8Y	MT	DTT
DMJCW8Y	MA	Inhibitor
DMJCW8Y	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMJCW8Y	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMREZT7	DI	DMREZT7
DMREZT7	DN	D[Leu4]AVP
DMREZT7	MI	TTSCIUP
DMREZT7	MN	Oxytocin receptor (OTR)
DMREZT7	MT	DTT
DMREZT7	MA	Inhibitor
DMREZT7	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMREZT7	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMREZT7	DI	DMREZT7
DMREZT7	DN	D[Leu4]AVP
DMREZT7	MI	TT4TFGN
DMREZT7	MN	Vasopressin V1a receptor (V1AR)
DMREZT7	MT	DTT
DMREZT7	MA	Inhibitor
DMREZT7	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMREZT7	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMREZT7	DI	DMREZT7
DMREZT7	DN	D[Leu4]AVP
DMREZT7	MI	TTL9MHW
DMREZT7	MN	Vasopressin V1b receptor (V1BR)
DMREZT7	MT	DTT
DMREZT7	MA	Inhibitor
DMREZT7	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMREZT7	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMREZT7	DI	DMREZT7
DMREZT7	DN	D[Leu4]AVP
DMREZT7	MI	TTK8R02
DMREZT7	MN	Vasopressin V2 receptor (V2R)
DMREZT7	MT	DTT
DMREZT7	MA	Inhibitor
DMREZT7	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMREZT7	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DME2PKB	DI	DME2PKB
DME2PKB	DN	D[Lys8(5/6-Flu)]VT
DME2PKB	MI	TTSCIUP
DME2PKB	MN	Oxytocin receptor (OTR)
DME2PKB	MT	DTT
DME2PKB	MA	Inhibitor
DME2PKB	RN	Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88.
DME2PKB	RU	https://pubmed.ncbi.nlm.nih.gov/12036367

DME2PKB	DI	DME2PKB
DME2PKB	DN	D[Lys8(5/6-Flu)]VT
DME2PKB	MI	TT4TFGN
DME2PKB	MN	Vasopressin V1a receptor (V1AR)
DME2PKB	MT	DTT
DME2PKB	MA	Inhibitor
DME2PKB	RN	Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88.
DME2PKB	RU	https://pubmed.ncbi.nlm.nih.gov/12036367

DME2PKB	DI	DME2PKB
DME2PKB	DN	D[Lys8(5/6-Flu)]VT
DME2PKB	MI	TTL9MHW
DME2PKB	MN	Vasopressin V1b receptor (V1BR)
DME2PKB	MT	DTT
DME2PKB	MA	Inhibitor
DME2PKB	RN	Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88.
DME2PKB	RU	https://pubmed.ncbi.nlm.nih.gov/12036367

DMNQTBU	DI	DMNQTBU
DMNQTBU	DN	D[Orn4,Lys8]VP
DMNQTBU	MI	TTSCIUP
DMNQTBU	MN	Oxytocin receptor (OTR)
DMNQTBU	MT	DTT
DMNQTBU	MA	Inhibitor
DMNQTBU	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMNQTBU	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMNQTBU	DI	DMNQTBU
DMNQTBU	DN	D[Orn4,Lys8]VP
DMNQTBU	MI	TT4TFGN
DMNQTBU	MN	Vasopressin V1a receptor (V1AR)
DMNQTBU	MT	DTT
DMNQTBU	MA	Inhibitor
DMNQTBU	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMNQTBU	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMNQTBU	DI	DMNQTBU
DMNQTBU	DN	D[Orn4,Lys8]VP
DMNQTBU	MI	TTL9MHW
DMNQTBU	MN	Vasopressin V1b receptor (V1BR)
DMNQTBU	MT	DTT
DMNQTBU	MA	Inhibitor
DMNQTBU	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMNQTBU	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMNQTBU	DI	DMNQTBU
DMNQTBU	DN	D[Orn4,Lys8]VP
DMNQTBU	MI	TTK8R02
DMNQTBU	MN	Vasopressin V2 receptor (V2R)
DMNQTBU	MT	DTT
DMNQTBU	MA	Inhibitor
DMNQTBU	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMNQTBU	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMONV0M	DI	DMONV0M
DMONV0M	DN	D[Orn4,Orn8]VP
DMONV0M	MI	TTSCIUP
DMONV0M	MN	Oxytocin receptor (OTR)
DMONV0M	MT	DTT
DMONV0M	MA	Inhibitor
DMONV0M	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMONV0M	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMONV0M	DI	DMONV0M
DMONV0M	DN	D[Orn4,Orn8]VP
DMONV0M	MI	TT4TFGN
DMONV0M	MN	Vasopressin V1a receptor (V1AR)
DMONV0M	MT	DTT
DMONV0M	MA	Inhibitor
DMONV0M	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMONV0M	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMONV0M	DI	DMONV0M
DMONV0M	DN	D[Orn4,Orn8]VP
DMONV0M	MI	TTL9MHW
DMONV0M	MN	Vasopressin V1b receptor (V1BR)
DMONV0M	MT	DTT
DMONV0M	MA	Inhibitor
DMONV0M	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMONV0M	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMONV0M	DI	DMONV0M
DMONV0M	DN	D[Orn4,Orn8]VP
DMONV0M	MI	TTK8R02
DMONV0M	MN	Vasopressin V2 receptor (V2R)
DMONV0M	MT	DTT
DMONV0M	MA	Inhibitor
DMONV0M	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMONV0M	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMJNT95	DI	DMJNT95
DMJNT95	DN	D[Orn4]AVP
DMJNT95	MI	TTSCIUP
DMJNT95	MN	Oxytocin receptor (OTR)
DMJNT95	MT	DTT
DMJNT95	MA	Inhibitor
DMJNT95	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMJNT95	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMJNT95	DI	DMJNT95
DMJNT95	DN	D[Orn4]AVP
DMJNT95	MI	TT4TFGN
DMJNT95	MN	Vasopressin V1a receptor (V1AR)
DMJNT95	MT	DTT
DMJNT95	MA	Inhibitor
DMJNT95	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMJNT95	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMJNT95	DI	DMJNT95
DMJNT95	DN	D[Orn4]AVP
DMJNT95	MI	TTL9MHW
DMJNT95	MN	Vasopressin V1b receptor (V1BR)
DMJNT95	MT	DTT
DMJNT95	MA	Inhibitor
DMJNT95	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMJNT95	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMJNT95	DI	DMJNT95
DMJNT95	DN	D[Orn4]AVP
DMJNT95	MI	TTK8R02
DMJNT95	MN	Vasopressin V2 receptor (V2R)
DMJNT95	MT	DTT
DMJNT95	MA	Inhibitor
DMJNT95	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DMJNT95	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMH791N	DI	DMH791N
DMH791N	DN	D[Orn8(5/6C-Flu)]VT
DMH791N	MI	TTSCIUP
DMH791N	MN	Oxytocin receptor (OTR)
DMH791N	MT	DTT
DMH791N	MA	Inhibitor
DMH791N	RN	Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88.
DMH791N	RU	https://pubmed.ncbi.nlm.nih.gov/12036367

DMH791N	DI	DMH791N
DMH791N	DN	D[Orn8(5/6C-Flu)]VT
DMH791N	MI	TT4TFGN
DMH791N	MN	Vasopressin V1a receptor (V1AR)
DMH791N	MT	DTT
DMH791N	MA	Inhibitor
DMH791N	RN	Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88.
DMH791N	RU	https://pubmed.ncbi.nlm.nih.gov/12036367

DMH791N	DI	DMH791N
DMH791N	DN	D[Orn8(5/6C-Flu)]VT
DMH791N	MI	TTL9MHW
DMH791N	MN	Vasopressin V1b receptor (V1BR)
DMH791N	MT	DTT
DMH791N	MA	Inhibitor
DMH791N	RN	Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88.
DMH791N	RU	https://pubmed.ncbi.nlm.nih.gov/12036367

DMT8KI6	DI	DMT8KI6
DMT8KI6	DN	d[Pen1,Tyr(Me)2]AVP
DMT8KI6	MI	TT4TFGN
DMT8KI6	MN	Vasopressin V1a receptor (V1AR)
DMT8KI6	MT	DTT
DMT8KI6	MA	Antagonist
DMT8KI6	RN	Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells. Br J Pharmacol. 1998 Dec;125(7):1463-70.
DMT8KI6	RU	https://pubmed.ncbi.nlm.nih.gov/9884074

DMT8KI6	DI	DMT8KI6
DMT8KI6	DN	d[Pen1,Tyr(Me)2]AVP
DMT8KI6	MI	TTL9MHW
DMT8KI6	MN	Vasopressin V1b receptor (V1BR)
DMT8KI6	MT	DTT
DMT8KI6	MA	Antagonist
DMT8KI6	RN	Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells. Br J Pharmacol. 1998 Dec;125(7):1463-70.
DMT8KI6	RU	https://pubmed.ncbi.nlm.nih.gov/9884074

DMT8KI6	DI	DMT8KI6
DMT8KI6	DN	d[Pen1,Tyr(Me)2]AVP
DMT8KI6	MI	TTK8R02
DMT8KI6	MN	Vasopressin V2 receptor (V2R)
DMT8KI6	MT	DTT
DMT8KI6	MA	Antagonist
DMT8KI6	RN	Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463. Kidney Int. 2000 Oct;58(4):1613-22.
DMT8KI6	RU	https://pubmed.ncbi.nlm.nih.gov/11012895

DMS4F8O	DI	DMS4F8O
DMS4F8O	DN	D[Thr4,Lys8(5/6C-Flu)]VT
DMS4F8O	MI	TTSCIUP
DMS4F8O	MN	Oxytocin receptor (OTR)
DMS4F8O	MT	DTT
DMS4F8O	MA	Inhibitor
DMS4F8O	RN	Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88.
DMS4F8O	RU	https://pubmed.ncbi.nlm.nih.gov/12036367

DMS4F8O	DI	DMS4F8O
DMS4F8O	DN	D[Thr4,Lys8(5/6C-Flu)]VT
DMS4F8O	MI	TT4TFGN
DMS4F8O	MN	Vasopressin V1a receptor (V1AR)
DMS4F8O	MT	DTT
DMS4F8O	MA	Inhibitor
DMS4F8O	RN	Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88.
DMS4F8O	RU	https://pubmed.ncbi.nlm.nih.gov/12036367

DMS4F8O	DI	DMS4F8O
DMS4F8O	DN	D[Thr4,Lys8(5/6C-Flu)]VT
DMS4F8O	MI	TTL9MHW
DMS4F8O	MN	Vasopressin V1b receptor (V1BR)
DMS4F8O	MT	DTT
DMS4F8O	MA	Inhibitor
DMS4F8O	RN	Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88.
DMS4F8O	RU	https://pubmed.ncbi.nlm.nih.gov/12036367

DMBDZQA	DI	DMBDZQA
DMBDZQA	DN	D[Thr4,Orn8(5/6C-Flu)]VT
DMBDZQA	MI	TTSCIUP
DMBDZQA	MN	Oxytocin receptor (OTR)
DMBDZQA	MT	DTT
DMBDZQA	MA	Inhibitor
DMBDZQA	RN	Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88.
DMBDZQA	RU	https://pubmed.ncbi.nlm.nih.gov/12036367

DMBDZQA	DI	DMBDZQA
DMBDZQA	DN	D[Thr4,Orn8(5/6C-Flu)]VT
DMBDZQA	MI	TT4TFGN
DMBDZQA	MN	Vasopressin V1a receptor (V1AR)
DMBDZQA	MT	DTT
DMBDZQA	MA	Inhibitor
DMBDZQA	RN	Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88.
DMBDZQA	RU	https://pubmed.ncbi.nlm.nih.gov/12036367

DMBDZQA	DI	DMBDZQA
DMBDZQA	DN	D[Thr4,Orn8(5/6C-Flu)]VT
DMBDZQA	MI	TTL9MHW
DMBDZQA	MN	Vasopressin V1b receptor (V1BR)
DMBDZQA	MT	DTT
DMBDZQA	MA	Inhibitor
DMBDZQA	RN	Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88.
DMBDZQA	RU	https://pubmed.ncbi.nlm.nih.gov/12036367

DM3GM8E	DI	DM3GM8E
DM3GM8E	DN	D[Val4]AVP
DM3GM8E	MI	TTSCIUP
DM3GM8E	MN	Oxytocin receptor (OTR)
DM3GM8E	MT	DTT
DM3GM8E	MA	Inhibitor
DM3GM8E	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DM3GM8E	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DM3GM8E	DI	DM3GM8E
DM3GM8E	DN	D[Val4]AVP
DM3GM8E	MI	TT4TFGN
DM3GM8E	MN	Vasopressin V1a receptor (V1AR)
DM3GM8E	MT	DTT
DM3GM8E	MA	Inhibitor
DM3GM8E	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DM3GM8E	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DM3GM8E	DI	DM3GM8E
DM3GM8E	DN	D[Val4]AVP
DM3GM8E	MI	TTL9MHW
DM3GM8E	MN	Vasopressin V1b receptor (V1BR)
DM3GM8E	MT	DTT
DM3GM8E	MA	Inhibitor
DM3GM8E	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DM3GM8E	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DM3GM8E	DI	DM3GM8E
DM3GM8E	DN	D[Val4]AVP
DM3GM8E	MI	TTK8R02
DM3GM8E	MN	Vasopressin V2 receptor (V2R)
DM3GM8E	MT	DTT
DM3GM8E	MA	Inhibitor
DM3GM8E	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DM3GM8E	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMQJD4P	DI	DMQJD4P
DMQJD4P	DN	D-166A
DMQJD4P	MI	TTVBI8W
DMQJD4P	MN	Dopamine transporter (DAT)
DMQJD4P	MT	DTT
DMQJD4P	MA	Inhibitor
DMQJD4P	RN	Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an ex... Bioorg Med Chem. 2008 Mar 15;16(6):2769-78.
DMQJD4P	RU	https://pubmed.ncbi.nlm.nih.gov/18249549

DMQJD4P	DI	DMQJD4P
DMQJD4P	DN	D-166A
DMQJD4P	MI	TTAWNKZ
DMQJD4P	MN	Norepinephrine transporter (NET)
DMQJD4P	MT	DTT
DMQJD4P	MA	Inhibitor
DMQJD4P	RN	Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an ex... Bioorg Med Chem. 2008 Mar 15;16(6):2769-78.
DMQJD4P	RU	https://pubmed.ncbi.nlm.nih.gov/18249549

DMQJD4P	DI	DMQJD4P
DMQJD4P	DN	D-166A
DMQJD4P	MI	TT3ROYC
DMQJD4P	MN	Serotonin transporter (SERT)
DMQJD4P	MT	DTT
DMQJD4P	MA	Inhibitor
DMQJD4P	RN	Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an ex... Bioorg Med Chem. 2008 Mar 15;16(6):2769-78.
DMQJD4P	RU	https://pubmed.ncbi.nlm.nih.gov/18249549

DMSON1P	DI	DMSON1P
DMSON1P	DN	D17.4
DMSON1P	MI	TTYJQTF
DMSON1P	MN	Immunoglobulin E (IgE)
DMSON1P	MT	DTT
DMSON1P	RN	Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60.
DMSON1P	RU	https://pubmed.ncbi.nlm.nih.gov/18095918

DMU8BJH	DI	DMU8BJH
DMU8BJH	DN	D-189
DMU8BJH	MI	TTEX248
DMU8BJH	MN	Dopamine D2 receptor (D2R)
DMU8BJH	MT	DTT
DMU8BJH	MA	Inhibitor
DMU8BJH	RN	Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly... J Med Chem. 2008 May 22;51(10):3005-19.
DMU8BJH	RU	https://pubmed.ncbi.nlm.nih.gov/18410082

DMU8BJH	DI	DMU8BJH
DMU8BJH	DN	D-189
DMU8BJH	MI	TT4C8EA
DMU8BJH	MN	Dopamine D3 receptor (D3R)
DMU8BJH	MT	DTT
DMU8BJH	MA	Inhibitor
DMU8BJH	RN	Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly... J Med Chem. 2008 May 22;51(10):3005-19.
DMU8BJH	RU	https://pubmed.ncbi.nlm.nih.gov/18410082

DMUMNSW	DI	DMUMNSW
DMUMNSW	DN	D-190
DMUMNSW	MI	TTEX248
DMUMNSW	MN	Dopamine D2 receptor (D2R)
DMUMNSW	MT	DTT
DMUMNSW	MA	Inhibitor
DMUMNSW	RN	Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly... J Med Chem. 2008 May 22;51(10):3005-19.
DMUMNSW	RU	https://pubmed.ncbi.nlm.nih.gov/18410082

DMUMNSW	DI	DMUMNSW
DMUMNSW	DN	D-190
DMUMNSW	MI	TT4C8EA
DMUMNSW	MN	Dopamine D3 receptor (D3R)
DMUMNSW	MT	DTT
DMUMNSW	MA	Inhibitor
DMUMNSW	RN	Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly... J Med Chem. 2008 May 22;51(10):3005-19.
DMUMNSW	RU	https://pubmed.ncbi.nlm.nih.gov/18410082

DM8D26T	DI	DM8D26T
DM8D26T	DN	D-192
DM8D26T	MI	TTEX248
DM8D26T	MN	Dopamine D2 receptor (D2R)
DM8D26T	MT	DTT
DM8D26T	MA	Inhibitor
DM8D26T	RN	Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly... J Med Chem. 2008 May 22;51(10):3005-19.
DM8D26T	RU	https://pubmed.ncbi.nlm.nih.gov/18410082

DM8D26T	DI	DM8D26T
DM8D26T	DN	D-192
DM8D26T	MI	TT4C8EA
DM8D26T	MN	Dopamine D3 receptor (D3R)
DM8D26T	MT	DTT
DM8D26T	MA	Inhibitor
DM8D26T	RN	Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly... J Med Chem. 2008 May 22;51(10):3005-19.
DM8D26T	RU	https://pubmed.ncbi.nlm.nih.gov/18410082

DMU83T7	DI	DMU83T7
DMU83T7	DN	D-193
DMU83T7	MI	TTEX248
DMU83T7	MN	Dopamine D2 receptor (D2R)
DMU83T7	MT	DTT
DMU83T7	MA	Inhibitor
DMU83T7	RN	Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly... J Med Chem. 2008 May 22;51(10):3005-19.
DMU83T7	RU	https://pubmed.ncbi.nlm.nih.gov/18410082

DMU83T7	DI	DMU83T7
DMU83T7	DN	D-193
DMU83T7	MI	TT4C8EA
DMU83T7	MN	Dopamine D3 receptor (D3R)
DMU83T7	MT	DTT
DMU83T7	MA	Inhibitor
DMU83T7	RN	Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly... J Med Chem. 2008 May 22;51(10):3005-19.
DMU83T7	RU	https://pubmed.ncbi.nlm.nih.gov/18410082

DMKPIH0	DI	DMKPIH0
DMKPIH0	DN	D-203
DMKPIH0	MI	TTEX248
DMKPIH0	MN	Dopamine D2 receptor (D2R)
DMKPIH0	MT	DTT
DMKPIH0	MA	Inhibitor
DMKPIH0	RN	Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly... J Med Chem. 2008 May 22;51(10):3005-19.
DMKPIH0	RU	https://pubmed.ncbi.nlm.nih.gov/18410082

DMKPIH0	DI	DMKPIH0
DMKPIH0	DN	D-203
DMKPIH0	MI	TT4C8EA
DMKPIH0	MN	Dopamine D3 receptor (D3R)
DMKPIH0	MT	DTT
DMKPIH0	MA	Inhibitor
DMKPIH0	RN	Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly... J Med Chem. 2008 May 22;51(10):3005-19.
DMKPIH0	RU	https://pubmed.ncbi.nlm.nih.gov/18410082

DMNLE4S	DI	DMNLE4S
DMNLE4S	DN	D-210
DMNLE4S	MI	TTEX248
DMNLE4S	MN	Dopamine D2 receptor (D2R)
DMNLE4S	MT	DTT
DMNLE4S	MA	Inhibitor
DMNLE4S	RN	Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly... J Med Chem. 2008 May 22;51(10):3005-19.
DMNLE4S	RU	https://pubmed.ncbi.nlm.nih.gov/18410082

DMNLE4S	DI	DMNLE4S
DMNLE4S	DN	D-210
DMNLE4S	MI	TT4C8EA
DMNLE4S	MN	Dopamine D3 receptor (D3R)
DMNLE4S	MT	DTT
DMNLE4S	MA	Inhibitor
DMNLE4S	RN	Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly... J Med Chem. 2008 May 22;51(10):3005-19.
DMNLE4S	RU	https://pubmed.ncbi.nlm.nih.gov/18410082

DMIBOAK	DI	DMIBOAK
DMIBOAK	DN	D-211A
DMIBOAK	MI	TTVBI8W
DMIBOAK	MN	Dopamine transporter (DAT)
DMIBOAK	MT	DTT
DMIBOAK	MA	Inhibitor
DMIBOAK	RN	Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an ex... Bioorg Med Chem. 2008 Mar 15;16(6):2769-78.
DMIBOAK	RU	https://pubmed.ncbi.nlm.nih.gov/18249549

DMIBOAK	DI	DMIBOAK
DMIBOAK	DN	D-211A
DMIBOAK	MI	TTAWNKZ
DMIBOAK	MN	Norepinephrine transporter (NET)
DMIBOAK	MT	DTT
DMIBOAK	MA	Inhibitor
DMIBOAK	RN	Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an ex... Bioorg Med Chem. 2008 Mar 15;16(6):2769-78.
DMIBOAK	RU	https://pubmed.ncbi.nlm.nih.gov/18249549

DMIBOAK	DI	DMIBOAK
DMIBOAK	DN	D-211A
DMIBOAK	MI	TT3ROYC
DMIBOAK	MN	Serotonin transporter (SERT)
DMIBOAK	MT	DTT
DMIBOAK	MA	Inhibitor
DMIBOAK	RN	Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an ex... Bioorg Med Chem. 2008 Mar 15;16(6):2769-78.
DMIBOAK	RU	https://pubmed.ncbi.nlm.nih.gov/18249549

DM54CKZ	DI	DM54CKZ
DM54CKZ	DN	D-211B
DM54CKZ	MI	TTVBI8W
DM54CKZ	MN	Dopamine transporter (DAT)
DM54CKZ	MT	DTT
DM54CKZ	MA	Inhibitor
DM54CKZ	RN	Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an ex... Bioorg Med Chem. 2008 Mar 15;16(6):2769-78.
DM54CKZ	RU	https://pubmed.ncbi.nlm.nih.gov/18249549

DM54CKZ	DI	DM54CKZ
DM54CKZ	DN	D-211B
DM54CKZ	MI	TTAWNKZ
DM54CKZ	MN	Norepinephrine transporter (NET)
DM54CKZ	MT	DTT
DM54CKZ	MA	Inhibitor
DM54CKZ	RN	Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an ex... Bioorg Med Chem. 2008 Mar 15;16(6):2769-78.
DM54CKZ	RU	https://pubmed.ncbi.nlm.nih.gov/18249549

DM54CKZ	DI	DM54CKZ
DM54CKZ	DN	D-211B
DM54CKZ	MI	TT3ROYC
DM54CKZ	MN	Serotonin transporter (SERT)
DM54CKZ	MT	DTT
DM54CKZ	MA	Inhibitor
DM54CKZ	RN	Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an ex... Bioorg Med Chem. 2008 Mar 15;16(6):2769-78.
DM54CKZ	RU	https://pubmed.ncbi.nlm.nih.gov/18249549

DMQLT84	DI	DMQLT84
DMQLT84	DN	D-218
DMQLT84	MI	TTEX248
DMQLT84	MN	Dopamine D2 receptor (D2R)
DMQLT84	MT	DTT
DMQLT84	MA	Inhibitor
DMQLT84	RN	Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly... J Med Chem. 2008 May 22;51(10):3005-19.
DMQLT84	RU	https://pubmed.ncbi.nlm.nih.gov/18410082

DMQLT84	DI	DMQLT84
DMQLT84	DN	D-218
DMQLT84	MI	TT4C8EA
DMQLT84	MN	Dopamine D3 receptor (D3R)
DMQLT84	MT	DTT
DMQLT84	MA	Inhibitor
DMQLT84	RN	Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly... J Med Chem. 2008 May 22;51(10):3005-19.
DMQLT84	RU	https://pubmed.ncbi.nlm.nih.gov/18410082

DMQ2U4G	DI	DMQ2U4G
DMQ2U4G	DN	D-219
DMQ2U4G	MI	TTEX248
DMQ2U4G	MN	Dopamine D2 receptor (D2R)
DMQ2U4G	MT	DTT
DMQ2U4G	MA	Inhibitor
DMQ2U4G	RN	Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly... J Med Chem. 2008 May 22;51(10):3005-19.
DMQ2U4G	RU	https://pubmed.ncbi.nlm.nih.gov/18410082

DMQ2U4G	DI	DMQ2U4G
DMQ2U4G	DN	D-219
DMQ2U4G	MI	TT4C8EA
DMQ2U4G	MN	Dopamine D3 receptor (D3R)
DMQ2U4G	MT	DTT
DMQ2U4G	MA	Inhibitor
DMQ2U4G	RN	Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly... J Med Chem. 2008 May 22;51(10):3005-19.
DMQ2U4G	RU	https://pubmed.ncbi.nlm.nih.gov/18410082

DMTUJWN	DI	DMTUJWN
DMTUJWN	DN	D-220
DMTUJWN	MI	TTEX248
DMTUJWN	MN	Dopamine D2 receptor (D2R)
DMTUJWN	MT	DTT
DMTUJWN	MA	Inhibitor
DMTUJWN	RN	Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly... J Med Chem. 2008 May 22;51(10):3005-19.
DMTUJWN	RU	https://pubmed.ncbi.nlm.nih.gov/18410082

DMTUJWN	DI	DMTUJWN
DMTUJWN	DN	D-220
DMTUJWN	MI	TT4C8EA
DMTUJWN	MN	Dopamine D3 receptor (D3R)
DMTUJWN	MT	DTT
DMTUJWN	MA	Inhibitor
DMTUJWN	RN	Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly... J Med Chem. 2008 May 22;51(10):3005-19.
DMTUJWN	RU	https://pubmed.ncbi.nlm.nih.gov/18410082

DMGA48T	DI	DMGA48T
DMGA48T	DN	D-237
DMGA48T	MI	TTEX248
DMGA48T	MN	Dopamine D2 receptor (D2R)
DMGA48T	MT	DTT
DMGA48T	MA	Inhibitor
DMGA48T	RN	Structurally constrained hybrid derivatives containing octahydrobenzo[g or f]quinoline moieties for dopamine D2 and D3 receptors: binding character... J Med Chem. 2008 Dec 25;51(24):7806-19.
DMGA48T	RU	https://pubmed.ncbi.nlm.nih.gov/19053758

DMGA48T	DI	DMGA48T
DMGA48T	DN	D-237
DMGA48T	MI	TT4C8EA
DMGA48T	MN	Dopamine D3 receptor (D3R)
DMGA48T	MT	DTT
DMGA48T	MA	Inhibitor
DMGA48T	RN	Structurally constrained hybrid derivatives containing octahydrobenzo[g or f]quinoline moieties for dopamine D2 and D3 receptors: binding character... J Med Chem. 2008 Dec 25;51(24):7806-19.
DMGA48T	RU	https://pubmed.ncbi.nlm.nih.gov/19053758

DM6KFCO	DI	DM6KFCO
DM6KFCO	DN	D-254C
DM6KFCO	MI	TTVBI8W
DM6KFCO	MN	Dopamine transporter (DAT)
DM6KFCO	MT	DTT
DM6KFCO	MA	Inhibitor
DM6KFCO	RN	Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an ex... Bioorg Med Chem. 2008 Mar 15;16(6):2769-78.
DM6KFCO	RU	https://pubmed.ncbi.nlm.nih.gov/18249549

DM6KFCO	DI	DM6KFCO
DM6KFCO	DN	D-254C
DM6KFCO	MI	TTAWNKZ
DM6KFCO	MN	Norepinephrine transporter (NET)
DM6KFCO	MT	DTT
DM6KFCO	MA	Inhibitor
DM6KFCO	RN	Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an ex... Bioorg Med Chem. 2008 Mar 15;16(6):2769-78.
DM6KFCO	RU	https://pubmed.ncbi.nlm.nih.gov/18249549

DM6KFCO	DI	DM6KFCO
DM6KFCO	DN	D-254C
DM6KFCO	MI	TT3ROYC
DM6KFCO	MN	Serotonin transporter (SERT)
DM6KFCO	MT	DTT
DM6KFCO	MA	Inhibitor
DM6KFCO	RN	Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an ex... Bioorg Med Chem. 2008 Mar 15;16(6):2769-78.
DM6KFCO	RU	https://pubmed.ncbi.nlm.nih.gov/18249549

DMN7E6Y	DI	DMN7E6Y
DMN7E6Y	DN	D-257A
DMN7E6Y	MI	TTVBI8W
DMN7E6Y	MN	Dopamine transporter (DAT)
DMN7E6Y	MT	DTT
DMN7E6Y	MA	Inhibitor
DMN7E6Y	RN	Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an ex... Bioorg Med Chem. 2008 Mar 15;16(6):2769-78.
DMN7E6Y	RU	https://pubmed.ncbi.nlm.nih.gov/18249549

DMN7E6Y	DI	DMN7E6Y
DMN7E6Y	DN	D-257A
DMN7E6Y	MI	TTAWNKZ
DMN7E6Y	MN	Norepinephrine transporter (NET)
DMN7E6Y	MT	DTT
DMN7E6Y	MA	Inhibitor
DMN7E6Y	RN	Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an ex... Bioorg Med Chem. 2008 Mar 15;16(6):2769-78.
DMN7E6Y	RU	https://pubmed.ncbi.nlm.nih.gov/18249549

DMN7E6Y	DI	DMN7E6Y
DMN7E6Y	DN	D-257A
DMN7E6Y	MI	TT3ROYC
DMN7E6Y	MN	Serotonin transporter (SERT)
DMN7E6Y	MT	DTT
DMN7E6Y	MA	Inhibitor
DMN7E6Y	RN	Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an ex... Bioorg Med Chem. 2008 Mar 15;16(6):2769-78.
DMN7E6Y	RU	https://pubmed.ncbi.nlm.nih.gov/18249549

DM5GLJ2	DI	DM5GLJ2
DM5GLJ2	DN	D-257C
DM5GLJ2	MI	TTVBI8W
DM5GLJ2	MN	Dopamine transporter (DAT)
DM5GLJ2	MT	DTT
DM5GLJ2	MA	Inhibitor
DM5GLJ2	RN	Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an ex... Bioorg Med Chem. 2008 Mar 15;16(6):2769-78.
DM5GLJ2	RU	https://pubmed.ncbi.nlm.nih.gov/18249549

DM5GLJ2	DI	DM5GLJ2
DM5GLJ2	DN	D-257C
DM5GLJ2	MI	TTAWNKZ
DM5GLJ2	MN	Norepinephrine transporter (NET)
DM5GLJ2	MT	DTT
DM5GLJ2	MA	Inhibitor
DM5GLJ2	RN	Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an ex... Bioorg Med Chem. 2008 Mar 15;16(6):2769-78.
DM5GLJ2	RU	https://pubmed.ncbi.nlm.nih.gov/18249549

DM5GLJ2	DI	DM5GLJ2
DM5GLJ2	DN	D-257C
DM5GLJ2	MI	TT3ROYC
DM5GLJ2	MN	Serotonin transporter (SERT)
DM5GLJ2	MT	DTT
DM5GLJ2	MA	Inhibitor
DM5GLJ2	RN	Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an ex... Bioorg Med Chem. 2008 Mar 15;16(6):2769-78.
DM5GLJ2	RU	https://pubmed.ncbi.nlm.nih.gov/18249549

DMWLHBQ	DI	DMWLHBQ
DMWLHBQ	DN	D-264
DMWLHBQ	MI	TTEX248
DMWLHBQ	MN	Dopamine D2 receptor (D2R)
DMWLHBQ	MT	DTT
DMWLHBQ	MA	Inhibitor
DMWLHBQ	RN	Investigation of various N-heterocyclic substituted piperazine versions of 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-... Bioorg Med Chem. 2009 Jun 1;17(11):3923-33.
DMWLHBQ	RU	https://pubmed.ncbi.nlm.nih.gov/19427222

DMWLHBQ	DI	DMWLHBQ
DMWLHBQ	DN	D-264
DMWLHBQ	MI	TT4C8EA
DMWLHBQ	MN	Dopamine D3 receptor (D3R)
DMWLHBQ	MT	DTT
DMWLHBQ	MA	Inhibitor
DMWLHBQ	RN	Investigation of various N-heterocyclic substituted piperazine versions of 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-... Bioorg Med Chem. 2009 Jun 1;17(11):3923-33.
DMWLHBQ	RU	https://pubmed.ncbi.nlm.nih.gov/19427222

DMG1CD5	DI	DMG1CD5
DMG1CD5	DN	D-315
DMG1CD5	MI	TTEX248
DMG1CD5	MN	Dopamine D2 receptor (D2R)
DMG1CD5	MT	DTT
DMG1CD5	MA	Inhibitor
DMG1CD5	RN	Further delineation of hydrophobic binding sites in dopamine D(2)/D(3) receptors for N-4 substituents on the piperazine ring of the hybrid template... Bioorg Med Chem. 2010 Aug 1;18(15):5661-74.
DMG1CD5	RU	https://pubmed.ncbi.nlm.nih.gov/20605099

DMG1CD5	DI	DMG1CD5
DMG1CD5	DN	D-315
DMG1CD5	MI	TT4C8EA
DMG1CD5	MN	Dopamine D3 receptor (D3R)
DMG1CD5	MT	DTT
DMG1CD5	MA	Inhibitor
DMG1CD5	RN	Further delineation of hydrophobic binding sites in dopamine D(2)/D(3) receptors for N-4 substituents on the piperazine ring of the hybrid template... Bioorg Med Chem. 2010 Aug 1;18(15):5661-74.
DMG1CD5	RU	https://pubmed.ncbi.nlm.nih.gov/20605099

DMZAM3G	DI	DMZAM3G
DMZAM3G	DN	D-366
DMZAM3G	MI	TTEX248
DMZAM3G	MN	Dopamine D2 receptor (D2R)
DMZAM3G	MT	DTT
DMZAM3G	MA	Inhibitor
DMZAM3G	RN	Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a... J Med Chem. 2010 Feb 11;53(3):1023-37.
DMZAM3G	RU	https://pubmed.ncbi.nlm.nih.gov/20038106

DMZAM3G	DI	DMZAM3G
DMZAM3G	DN	D-366
DMZAM3G	MI	TT4C8EA
DMZAM3G	MN	Dopamine D3 receptor (D3R)
DMZAM3G	MT	DTT
DMZAM3G	MA	Inhibitor
DMZAM3G	RN	Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a... J Med Chem. 2010 Feb 11;53(3):1023-37.
DMZAM3G	RU	https://pubmed.ncbi.nlm.nih.gov/20038106

DM048OG	DI	DM048OG
DM048OG	DN	D-420720
DM048OG	MI	TTDIGC1
DM048OG	MN	Dipeptidyl peptidase 4 (DPP-4)
DM048OG	MT	DTT
DM048OG	MA	Inhibitor
DM048OG	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1612).
DM048OG	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1612

DM0M81E	DI	DM0M81E
DM0M81E	DN	D609
DM0M81E	MI	TT6ERZB
DM0M81E	MN	Bacterial Phosphatidylcholine-specificphospholipase C (Bact plcN)
DM0M81E	MT	DTT
DM0M81E	MA	Inhibitor
DM0M81E	RN	Function of the p55 tumor necrosis factor receptor "death domain" mediated by phosphatidylcholine-specific phospholipase C. J Exp Med. 1996 Aug 1;184(2):725-33.
DM0M81E	RU	https://pubmed.ncbi.nlm.nih.gov/8760826

DM0A54V	DI	DM0A54V
DM0A54V	DN	D-65476
DM0A54V	MI	TT8FYO9
DM0A54V	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DM0A54V	MT	DTT
DM0A54V	MA	Inhibitor
DM0A54V	RN	Bis(1H-2-indolyl)methanones as a novel class of inhibitors of the platelet-derived growth factor receptor kinase. J Med Chem. 2002 Feb 28;45(5):1002-18.
DM0A54V	RU	https://pubmed.ncbi.nlm.nih.gov/11855980

DM54T8J	DI	DM54T8J
DM54T8J	DN	DAB-486-IL-2
DM54T8J	MI	TT9721Y
DM54T8J	MN	Interleukin 2 receptor beta (IL2RB)
DM54T8J	MT	DTT
DM54T8J	MA	Modulator
DM54T8J	RN	Interleukin 2 receptor targeted fusion toxin (DAB486-IL-2) treatment blocks diabetogenic autoimmunity in non-obese diabetic mice. Eur J Immunol. 1992 Mar;22(3):697-702.
DM54T8J	RU	https://www.ncbi.nlm.nih.gov/pubmed/1547815

DMHZKMG	DI	DMHZKMG
DMHZKMG	DN	DABCO
DMHZKMG	MI	TTODZF1
DMHZKMG	MN	Voltage-gated potassium channel Kv3.4 (KCNC4)
DMHZKMG	MT	DTT
DMHZKMG	MA	Blocker (channel blocker)
DMHZKMG	RN	1,4-Diazabicyclo[2.2.2]octane derivatives: a novel class of voltage-gated potassium channel blockers. Mol Pharmacol. 2006 Mar;69(3):718-26.
DMHZKMG	RU	https://pubmed.ncbi.nlm.nih.gov/16317109

DMN3GTF	DI	DMN3GTF
DMN3GTF	DN	DABCO-C16
DMN3GTF	MI	TT5OEKU
DMN3GTF	MN	Voltage-gated potassium channel Kv2.1 (KCNB1)
DMN3GTF	MT	DTT
DMN3GTF	MA	Blocker (channel blocker)
DMN3GTF	RN	1,4-Diazabicyclo[2.2.2]octane derivatives: a novel class of voltage-gated potassium channel blockers. Mol Pharmacol. 2006 Mar;69(3):718-26.
DMN3GTF	RU	https://pubmed.ncbi.nlm.nih.gov/16317109

DMN3GTF	DI	DMN3GTF
DMN3GTF	DN	DABCO-C16
DMN3GTF	MI	TTODZF1
DMN3GTF	MN	Voltage-gated potassium channel Kv3.4 (KCNC4)
DMN3GTF	MT	DTT
DMN3GTF	MA	Blocker (channel blocker)
DMN3GTF	RN	1,4-Diazabicyclo[2.2.2]octane derivatives: a novel class of voltage-gated potassium channel blockers. Mol Pharmacol. 2006 Mar;69(3):718-26.
DMN3GTF	RU	https://pubmed.ncbi.nlm.nih.gov/16317109

DMCNAME	DI	DMCNAME
DMCNAME	DN	DACTHF
DMCNAME	MI	DECWT2V
DMCNAME	MN	Folylpolyglutamate synthase (FPGS)
DMCNAME	MT	DME
DMCNAME	MA	Metabolism
DMCNAME	RN	Role of folylpolyglutamate synthetase in the metabolism and cytotoxicity of 5-deazaacyclotetrahydrofolate, an anti-purine drug. J Biol Chem. 1994 Apr 1;269(13):9714-20.
DMCNAME	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8144562

DMRM0OW	DI	DMRM0OW
DMRM0OW	DN	Dadle
DMRM0OW	MI	TT27RFC
DMRM0OW	MN	Opioid receptor delta (OPRD1)
DMRM0OW	MT	DTT
DMRM0OW	MA	Agonist
DMRM0OW	RN	Delta opioid receptor stimulation mimics ischemic preconditioning in human heart muscle. J Am Coll Cardiol. 2000 Dec;36(7):2296-302.
DMRM0OW	RU	https://pubmed.ncbi.nlm.nih.gov/11127476

DMRM0OW	DI	DMRM0OW
DMRM0OW	DN	Dadle
DMRM0OW	MI	TTKWM86
DMRM0OW	MN	Opioid receptor mu (MOP)
DMRM0OW	MT	DTT
DMRM0OW	MA	Inhibitor
DMRM0OW	RN	Design, synthesis, and biological evaluation of novel bifunctional C-terminal-modified peptides for delta/mu opioid receptor agonists and neurokini... J Med Chem. 2007 Jun 14;50(12):2779-86.
DMRM0OW	RU	https://pubmed.ncbi.nlm.nih.gov/17516639

DMRM0OW	DI	DMRM0OW
DMRM0OW	DN	Dadle
DMRM0OW	MI	DT3D8F0
DMRM0OW	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMRM0OW	MT	DTP
DMRM0OW	MA	Substrate
DMRM0OW	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DMRM0OW	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DMJIFY3	DI	DMJIFY3
DMJIFY3	DN	DADMe-ImmG
DMJIFY3	MI	TTMCF1Y
DMJIFY3	MN	Purine nucleoside phosphorylase (PNP)
DMJIFY3	MT	DTT
DMJIFY3	MA	Inhibitor
DMJIFY3	RN	Achieving the ultimate physiological goal in transition state analogue inhibitors for purine nucleoside phosphorylase. J Biol Chem. 2003 Aug 22;278(34):31465-8.
DMJIFY3	RU	https://pubmed.ncbi.nlm.nih.gov/12842889

DMWR3XL	DI	DMWR3XL
DMWR3XL	DN	DAEDALIN A
DMWR3XL	MI	TTULVH8
DMWR3XL	MN	Tyrosinase (TYR)
DMWR3XL	MT	DTT
DMWR3XL	MA	Inhibitor
DMWR3XL	RN	Asymmetric syntheses of daedalin A and quercinol and their tyrosinase inhibitory activity. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1063-4.
DMWR3XL	RU	https://pubmed.ncbi.nlm.nih.gov/20036119

DMRFTJX	DI	DMRFTJX
DMRFTJX	DN	Daidzein
DMRFTJX	MI	TTFBNVI
DMRFTJX	MN	Aldose reductase (AKR1B1)
DMRFTJX	MT	DTT
DMRFTJX	MA	Inhibitor
DMRFTJX	RN	1-Benzopyran-4-one antioxidants as aldose reductase inhibitors. J Med Chem. 1999 Jun 3;42(11):1881-93.
DMRFTJX	RU	https://pubmed.ncbi.nlm.nih.gov/10354396

DMRFTJX	DI	DMRFTJX
DMRFTJX	DN	Daidzein
DMRFTJX	MI	DTI7UX6
DMRFTJX	MN	Breast cancer resistance protein (ABCG2)
DMRFTJX	MT	DTP
DMRFTJX	MA	Substrate
DMRFTJX	RN	Effect of breast cancer resistance protein (Bcrp/Abcg2) on the disposition of phytoestrogens. Mol Pharmacol. 2007 Oct;72(4):967-75.
DMRFTJX	RU	https://doi.org/10.1124/mol.107.034751

DMRFTJX	DI	DMRFTJX
DMRFTJX	DN	Daidzein
DMRFTJX	MI	DEUWAV0
DMRFTJX	MN	Cytochrome P450 102D1 (cyp102)
DMRFTJX	MT	DME
DMRFTJX	MA	Metabolism
DMRFTJX	RN	The metagenome of Caracolus marginella gut microbiome using culture independent approaches and shotgun sequencing. Data Brief. 2017 Nov 22;16:501-505.
DMRFTJX	RU	https://pubmed.ncbi.nlm.nih.gov/29270447

DMRFTJX	DI	DMRFTJX
DMRFTJX	DN	Daidzein
DMRFTJX	MI	TTZAYWL
DMRFTJX	MN	Estrogen receptor (ESR)
DMRFTJX	MT	DTT
DMRFTJX	MA	Inhibitor
DMRFTJX	RN	Isolation and structure elucidation of an isoflavone and a sesterterpenoic acid from Henriettella fascicularis. J Nat Prod. 2002 Dec;65(12):1749-53.
DMRFTJX	RU	https://pubmed.ncbi.nlm.nih.gov/12502307

DMRFTJX	DI	DMRFTJX
DMRFTJX	DN	Daidzein
DMRFTJX	MI	TTOM3J0
DMRFTJX	MN	Estrogen receptor beta (ESR2)
DMRFTJX	MT	DTT
DMRFTJX	MA	Inhibitor
DMRFTJX	RN	Isolation and structure elucidation of an isoflavone and a sesterterpenoic acid from Henriettella fascicularis. J Nat Prod. 2002 Dec;65(12):1749-53.
DMRFTJX	RU	https://pubmed.ncbi.nlm.nih.gov/12502307

DMRFTJX	DI	DMRFTJX
DMRFTJX	DN	Daidzein
DMRFTJX	MI	TTPNQAC
DMRFTJX	MN	Estrogen-related receptor-alpha (ESRRA)
DMRFTJX	MT	DTT
DMRFTJX	MA	Agonist
DMRFTJX	RN	Flavone and isoflavone phytoestrogens are agonists of estrogen-related receptors. Mol Cancer Res. 2003 Nov;1(13):981-91.
DMRFTJX	RU	https://pubmed.ncbi.nlm.nih.gov/14638870

DMRFTJX	DI	DMRFTJX
DMRFTJX	DN	Daidzein
DMRFTJX	MI	TTKF0XS
DMRFTJX	MN	Estrogen-related receptor-beta (ESRRB)
DMRFTJX	MT	DTT
DMRFTJX	MA	Agonist
DMRFTJX	RN	Flavone and isoflavone phytoestrogens are agonists of estrogen-related receptors. Mol Cancer Res. 2003 Nov;1(13):981-91.
DMRFTJX	RU	https://pubmed.ncbi.nlm.nih.gov/14638870

DMRFTJX	DI	DMRFTJX
DMRFTJX	DN	Daidzein
DMRFTJX	MI	TT9ZRHB
DMRFTJX	MN	Estrogen-related receptor-gamma (ESRRG)
DMRFTJX	MT	DTT
DMRFTJX	MA	Agonist
DMRFTJX	RN	Flavone and isoflavone phytoestrogens are agonists of estrogen-related receptors. Mol Cancer Res. 2003 Nov;1(13):981-91.
DMRFTJX	RU	https://pubmed.ncbi.nlm.nih.gov/14638870

DMRFTJX	DI	DMRFTJX
DMRFTJX	DN	Daidzein
DMRFTJX	MI	TT32NQ1
DMRFTJX	MN	Short transient receptor potential channel 5 (TRPC5)
DMRFTJX	MT	DTT
DMRFTJX	MA	Activator
DMRFTJX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 490).
DMRFTJX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=490

DMRFTJX	DI	DMRFTJX
DMRFTJX	DN	Daidzein
DMRFTJX	MI	DE0P6LK
DMRFTJX	MN	Sulfotransferase 2A1 (SULT2A1)
DMRFTJX	MT	DME
DMRFTJX	MA	Metabolism
DMRFTJX	RN	Sulfation of environmental estrogens by cytosolic human sulfotransferases. Drug Metab Pharmacokinet. 2002;17(3):221-8.
DMRFTJX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15618673

DM3M652	DI	DM3M652
DM3M652	DN	Daio-Orengedokuto (DOT)
DM3M652	MI	TTXMY0J
DM3M652	MN	Pancreatic triacylglycerol lipase (PNLIP)
DM3M652	MT	DTT
DM3M652	MA	Inhibitor
DM3M652	RN	Daio-Orengedokuto inhibits HMG-CoA reductase and pancreatic lipase. Biol Pharm Bull. 2002 Nov;25(11):1442-5.
DM3M652	RU	https://pubmed.ncbi.nlm.nih.gov/12419956

DMVIDQL	DI	DMVIDQL
DMVIDQL	DN	D-alanine
DMVIDQL	MI	TTLP6GN
DMVIDQL	MN	Bacterial DD-carboxypeptidase (Bact vanYB)
DMVIDQL	MT	DTT
DMVIDQL	MA	Inhibitor
DMVIDQL	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMVIDQL	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMS1DVA	DI	DMS1DVA
DMS1DVA	DN	DAMGO
DMS1DVA	MI	TT27RFC
DMS1DVA	MN	Opioid receptor delta (OPRD1)
DMS1DVA	MT	DTT
DMS1DVA	MA	Inhibitor
DMS1DVA	RN	Evaluation of N-substitution in 6,7-benzomorphan compounds. Bioorg Med Chem. 2010 Jul 15;18(14):4975-82. 
DMS1DVA	RU	https://pubmed.ncbi.nlm.nih.gov/20599386

DMS1DVA	DI	DMS1DVA
DMS1DVA	DN	DAMGO
DMS1DVA	MI	TTQW87Y
DMS1DVA	MN	Opioid receptor kappa (OPRK1)
DMS1DVA	MT	DTT
DMS1DVA	MA	Inhibitor
DMS1DVA	RN	Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5.
DMS1DVA	RU	https://pubmed.ncbi.nlm.nih.gov/16777416

DMS1DVA	DI	DMS1DVA
DMS1DVA	DN	DAMGO
DMS1DVA	MI	TTKWM86
DMS1DVA	MN	Opioid receptor mu (MOP)
DMS1DVA	MT	DTT
DMS1DVA	MA	Inhibitor
DMS1DVA	RN	Evaluation of N-substitution in 6,7-benzomorphan compounds. Bioorg Med Chem. 2010 Jul 15;18(14):4975-82. 
DMS1DVA	RU	https://pubmed.ncbi.nlm.nih.gov/20599386

DMXM7JR	DI	DMXM7JR
DMXM7JR	DN	daminozide
DMXM7JR	MI	TT81PFE
DMXM7JR	MN	Histone lysine demethylase PHF8 (PHF8)
DMXM7JR	MT	DTT
DMXM7JR	MA	Inhibitor
DMXM7JR	RN	Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases. J Med Chem. 2012 Jul 26;55(14):6639-43.
DMXM7JR	RU	https://pubmed.ncbi.nlm.nih.gov/22724510

DMXM7JR	DI	DMXM7JR
DMXM7JR	DN	daminozide
DMXM7JR	MI	TT8XTY2
DMXM7JR	MN	Lysine-specific demethylase 2A (KDM2A)
DMXM7JR	MT	DTT
DMXM7JR	MA	Inhibitor
DMXM7JR	RN	Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases. J Med Chem. 2012 Jul 26;55(14):6639-43.
DMXM7JR	RU	https://pubmed.ncbi.nlm.nih.gov/22724510

DMXM7JR	DI	DMXM7JR
DMXM7JR	DN	daminozide
DMXM7JR	MI	TT0NYMP
DMXM7JR	MN	Lysine-specific demethylase 7A (KDM7A)
DMXM7JR	MT	DTT
DMXM7JR	MA	Inhibitor
DMXM7JR	RN	Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases. J Med Chem. 2012 Jul 26;55(14):6639-43.
DMXM7JR	RU	https://pubmed.ncbi.nlm.nih.gov/22724510

DMQ4L1I	DI	DMQ4L1I
DMQ4L1I	DN	Dansylamide
DMQ4L1I	MI	TTANPDJ
DMQ4L1I	MN	Carbonic anhydrase II (CA-II)
DMQ4L1I	MT	DTT
DMQ4L1I	MA	Inhibitor
DMQ4L1I	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMQ4L1I	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM2WS8B	DI	DM2WS8B
DM2WS8B	DN	D-AP4
DM2WS8B	MI	TT0IFKL
DM2WS8B	MN	Metabotropic glutamate receptor 8 (mGluR8)
DM2WS8B	MT	DTT
DM2WS8B	MA	Agonist
DM2WS8B	RN	Group III human metabotropic glutamate receptors 4, 7 and 8: molecular cloning, functional expression, and comparison of pharmacological properties in RGT cells. Brain Res Mol Brain Res. 1998 Jan;53(1-2):88-97.
DM2WS8B	RU	https://pubmed.ncbi.nlm.nih.gov/9473604

DMY5OTN	DI	DMY5OTN
DMY5OTN	DN	d-AP5
DMY5OTN	MI	TTKJEMQ
DMY5OTN	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMY5OTN	MT	DTT
DMY5OTN	MA	Antagonist
DMY5OTN	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456).
DMY5OTN	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=456

DMY5OTN	DI	DMY5OTN
DMY5OTN	DN	d-AP5
DMY5OTN	MI	TTN9D8E
DMY5OTN	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMY5OTN	MT	DTT
DMY5OTN	MA	Antagonist
DMY5OTN	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457).
DMY5OTN	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=457

DMY5OTN	DI	DMY5OTN
DMY5OTN	DN	d-AP5
DMY5OTN	MI	TT1M8OW
DMY5OTN	MN	Glutamate receptor ionotropic NMDA 2C (GluN2C)
DMY5OTN	MT	DTT
DMY5OTN	MA	Antagonist
DMY5OTN	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 458).
DMY5OTN	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=458

DMY5OTN	DI	DMY5OTN
DMY5OTN	DN	d-AP5
DMY5OTN	MI	TT5POTG
DMY5OTN	MN	Glutamate receptor ionotropic NMDA 2D (GluN2D)
DMY5OTN	MT	DTT
DMY5OTN	MA	Antagonist
DMY5OTN	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 459).
DMY5OTN	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=459

DMZ4Q0B	DI	DMZ4Q0B
DMZ4Q0B	DN	Dasatinib
DMZ4Q0B	MI	TTE63HY
DMZ4Q0B	MN	HUMAN fusion protein Bcr-Abl (Bcr-Abl)
DMZ4Q0B	MT	DTT
DMZ4Q0B	MA	Inhibitor
DMZ4Q0B	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DMZ4Q0B	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DM7Z892	DI	DM7Z892
DM7Z892	DN	D-aspartic acid
DM7Z892	MI	TT8WRDA
DM7Z892	MN	Excitatory amino acid transporter 1 (SLC1A3)
DM7Z892	MT	DTT
DM7Z892	MA	Modulator
DM7Z892	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 868).
DM7Z892	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=868

DM7Z892	DI	DM7Z892
DM7Z892	DN	D-aspartic acid
DM7Z892	MI	TT2F078
DM7Z892	MN	Excitatory amino acid transporter 2 (SLC1A2)
DM7Z892	MT	DTT
DM7Z892	MA	Modulator
DM7Z892	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 869).
DM7Z892	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=869

DM7Z892	DI	DM7Z892
DM7Z892	DN	D-aspartic acid
DM7Z892	MI	TTG2A6F
DM7Z892	MN	Excitatory amino acid transporter 3 (SLC1A1)
DM7Z892	MT	DTT
DM7Z892	MA	Modulator
DM7Z892	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 870).
DM7Z892	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=870

DM7Z892	DI	DM7Z892
DM7Z892	DN	D-aspartic acid
DM7Z892	MI	TT6KMPN
DM7Z892	MN	Excitatory amino acid transporter 4 (SLC1A6)
DM7Z892	MT	DTT
DM7Z892	MA	Modulator
DM7Z892	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 871).
DM7Z892	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=871

DM7Z892	DI	DM7Z892
DM7Z892	DN	D-aspartic acid
DM7Z892	MI	TTK41DM
DM7Z892	MN	Excitatory amino acid transporter 5 (SLC1A7)
DM7Z892	MT	DTT
DM7Z892	MA	Modulator
DM7Z892	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 872).
DM7Z892	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=872

DM7Z892	DI	DM7Z892
DM7Z892	DN	D-aspartic acid
DM7Z892	MI	TTLD29N
DM7Z892	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DM7Z892	MT	DTT
DM7Z892	MA	Agonist
DM7Z892	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455).
DM7Z892	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=455

DM7Z892	DI	DM7Z892
DM7Z892	DN	D-aspartic acid
DM7Z892	MI	TTKJEMQ
DM7Z892	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DM7Z892	MT	DTT
DM7Z892	MA	Agonist
DM7Z892	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456).
DM7Z892	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=456

DM7Z892	DI	DM7Z892
DM7Z892	DN	D-aspartic acid
DM7Z892	MI	TTN9D8E
DM7Z892	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DM7Z892	MT	DTT
DM7Z892	MA	Agonist
DM7Z892	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457).
DM7Z892	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=457

DM7Z892	DI	DM7Z892
DM7Z892	DN	D-aspartic acid
DM7Z892	MI	TT1M8OW
DM7Z892	MN	Glutamate receptor ionotropic NMDA 2C (GluN2C)
DM7Z892	MT	DTT
DM7Z892	MA	Agonist
DM7Z892	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 458).
DM7Z892	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=458

DM7Z892	DI	DM7Z892
DM7Z892	DN	D-aspartic acid
DM7Z892	MI	TT5POTG
DM7Z892	MN	Glutamate receptor ionotropic NMDA 2D (GluN2D)
DM7Z892	MT	DTT
DM7Z892	MA	Agonist
DM7Z892	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 459).
DM7Z892	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=459

DMMXFBJ	DI	DMMXFBJ
DMMXFBJ	DN	dATP
DMMXFBJ	MI	TTYXPCO
DMMXFBJ	MN	P2Y purinoceptor 11 (P2RY11)
DMMXFBJ	MT	DTT
DMMXFBJ	MA	Agonist
DMMXFBJ	RN	Pharmacological characterization of the human P2Y11 receptor. Br J Pharmacol. 1999 Nov;128(6):1199-206.
DMMXFBJ	RU	https://pubmed.ncbi.nlm.nih.gov/10578132

DMRDX8U	DI	DMRDX8U
DMRDX8U	DN	dATPalphaS
DMRDX8U	MI	TTA93TL
DMRDX8U	MN	P2Y purinoceptor 1 (P2RY1)
DMRDX8U	MT	DTT
DMRDX8U	MA	Agonist
DMRDX8U	RN	An examination of deoxyadenosine 5'(alpha-thio)triphosphate as a ligand to define P2Y receptors and its selectivity as a low potency partial agonist of the P2Y1 receptor. Br J Pharmacol. 1997 May;121(2):338-44.
DMRDX8U	RU	https://pubmed.ncbi.nlm.nih.gov/9154346

DMT14A7	DI	DMT14A7
DMT14A7	DN	DAU-5750
DMT14A7	MI	TTZ9SOR
DMT14A7	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMT14A7	MT	DTT
DMT14A7	MA	Modulator
DMT14A7	RN	Synthesis, absolute configuration, conformational analysis and binding affinity properties of enantiomeric forms of DAU 5750, a novel M1-M3 muscari... Bioorg Med Chem. 1994 Dec;2(12):1375-83.
DMT14A7	RU	https://www.ncbi.nlm.nih.gov/pubmed/7788300

DMT14A7	DI	DMT14A7
DMT14A7	DN	DAU-5750
DMT14A7	MI	TTQ13Z5
DMT14A7	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMT14A7	MT	DTT
DMT14A7	MA	Modulator
DMT14A7	RN	Synthesis, absolute configuration, conformational analysis and binding affinity properties of enantiomeric forms of DAU 5750, a novel M1-M3 muscari... Bioorg Med Chem. 1994 Dec;2(12):1375-83.
DMT14A7	RU	https://www.ncbi.nlm.nih.gov/pubmed/7788300

DMEZVGK	DI	DMEZVGK
DMEZVGK	DN	DAU-5884
DMEZVGK	MI	TTZ9SOR
DMEZVGK	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMEZVGK	MT	DTT
DMEZVGK	MA	Modulator
DMEZVGK	RN	Doi: 10.1038/bjp.2008.208
DMEZVGK	RU	http://onlinelibrary.wiley.com/doi/10.1038/bjp.2008.208/pdf

DMEZVGK	DI	DMEZVGK
DMEZVGK	DN	DAU-5884
DMEZVGK	MI	TTQ13Z5
DMEZVGK	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMEZVGK	MT	DTT
DMEZVGK	MA	Modulator
DMEZVGK	RN	Doi: 10.1038/bjp.2008.208
DMEZVGK	RU	http://onlinelibrary.wiley.com/doi/10.1038/bjp.2008.208/pdf

DMM5SI1	DI	DMM5SI1
DMM5SI1	DN	DAU-6202
DMM5SI1	MI	TTZ9SOR
DMM5SI1	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMM5SI1	MT	DTT
DMM5SI1	MA	Modulator
DMM5SI1	RN	Characterization of muscarinic receptors in guinea-pig uterus. Eur J Pharmacol. 1993 Dec 7;250(2):223-30.
DMM5SI1	RU	https://www.ncbi.nlm.nih.gov/pubmed/8112383

DMEST0R	DI	DMEST0R
DMEST0R	DN	DB-160
DMEST0R	MI	TTDIGC1
DMEST0R	MN	Dipeptidyl peptidase 4 (DPP-4)
DMEST0R	MT	DTT
DMEST0R	MA	Inhibitor
DMEST0R	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1612).
DMEST0R	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1612

DMGRUN1	DI	DMGRUN1
DMGRUN1	DN	DB-900
DMGRUN1	MI	TTJ584C
DMGRUN1	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMGRUN1	MT	DTT
DMGRUN1	MA	Agonist
DMGRUN1	RN	CN patent application no. 102459215, 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof.
DMGRUN1	RU	http://www.google.com/patents/CN102459215A?cl=en

DMGRUN1	DI	DMGRUN1
DMGRUN1	DN	DB-900
DMGRUN1	MI	TT2JWF6
DMGRUN1	MN	Peroxisome proliferator-activated receptor delta (PPARD)
DMGRUN1	MT	DTT
DMGRUN1	MA	Agonist
DMGRUN1	RN	CN patent application no. 102459215, 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof.
DMGRUN1	RU	http://www.google.com/patents/CN102459215A?cl=en

DMGRUN1	DI	DMGRUN1
DMGRUN1	DN	DB-900
DMGRUN1	MI	TTZMAO3
DMGRUN1	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMGRUN1	MT	DTT
DMGRUN1	MA	Agonist
DMGRUN1	RN	CN patent application no. 102459215, 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof.
DMGRUN1	RU	http://www.google.com/patents/CN102459215A?cl=en

DMFYCQ1	DI	DMFYCQ1
DMFYCQ1	DN	DBT-066
DMFYCQ1	MI	TTMO9HF
DMFYCQ1	MN	Advanced glycosylation end product receptor (AGER)
DMFYCQ1	MT	DTT
DMFYCQ1	MA	Modulator
DMFYCQ1	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2843).
DMFYCQ1	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2843

DM09YI7	DI	DM09YI7
DM09YI7	DN	DBT-1339
DM09YI7	MI	TTE4KHA
DM09YI7	MN	Amyloid beta A4 protein (APP)
DM09YI7	MT	DTT
DM09YI7	MA	Inhibitor
DM09YI7	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
DM09YI7	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402

DMX9FOB	DI	DMX9FOB
DMX9FOB	DN	DC6S
DMX9FOB	MI	TTKWM86
DMX9FOB	MN	Opioid receptor mu (MOP)
DMX9FOB	MT	DTT
DMX9FOB	MA	Inhibitor
DMX9FOB	RN	Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5.
DMX9FOB	RU	https://pubmed.ncbi.nlm.nih.gov/16777416

DM62IBX	DI	DM62IBX
DM62IBX	DN	DC-9703
DM62IBX	MI	TTCBFJO
DM62IBX	MN	Insulin receptor (INSR)
DM62IBX	MT	DTT
DM62IBX	MA	Modulator
DM62IBX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800).
DM62IBX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800

DMHNAJ7	DI	DMHNAJ7
DMHNAJ7	DN	D-carnitine
DMHNAJ7	MI	DT3HUVD
DMHNAJ7	MN	Organic cation/carnitine transporter 2 (SLC22A5)
DMHNAJ7	MT	DTP
DMHNAJ7	MA	Substrate
DMHNAJ7	RN	Functional and pharmacological characterization of human Na(+)-carnitine cotransporter hOCTN2. Am J Physiol Renal Physiol. 2000 Sep;279(3):F584-91.
DMHNAJ7	RU	http://www.ncbi.nlm.nih.gov/pubmed/10966938

DMPRYTW	DI	DMPRYTW
DMPRYTW	DN	DCB-3503
DMPRYTW	MI	TTS7IR5
DMPRYTW	MN	c-Jun messenger RNA (c-Jun mRNA)
DMPRYTW	MT	DTT
DMPRYTW	MA	Inhibitor
DMPRYTW	RN	Structure-activity studies of phenanthroindolizidine alkaloids as potential antitumor agents. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4338-42.
DMPRYTW	RU	https://pubmed.ncbi.nlm.nih.gov/17531481

DM36D0F	DI	DM36D0F
DM36D0F	DN	d-CCPene
DM36D0F	MI	TTKJEMQ
DM36D0F	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DM36D0F	MT	DTT
DM36D0F	MA	Antagonist
DM36D0F	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456).
DM36D0F	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=456

DM36D0F	DI	DM36D0F
DM36D0F	DN	d-CCPene
DM36D0F	MI	TTN9D8E
DM36D0F	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DM36D0F	MT	DTT
DM36D0F	MA	Antagonist
DM36D0F	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457).
DM36D0F	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=457

DM36D0F	DI	DM36D0F
DM36D0F	DN	d-CCPene
DM36D0F	MI	TT1M8OW
DM36D0F	MN	Glutamate receptor ionotropic NMDA 2C (GluN2C)
DM36D0F	MT	DTT
DM36D0F	MA	Antagonist
DM36D0F	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 458).
DM36D0F	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=458

DM36D0F	DI	DM36D0F
DM36D0F	DN	d-CCPene
DM36D0F	MI	TT5POTG
DM36D0F	MN	Glutamate receptor ionotropic NMDA 2D (GluN2D)
DM36D0F	MT	DTT
DM36D0F	MA	Antagonist
DM36D0F	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 459).
DM36D0F	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=459

DMG9BFR	DI	DMG9BFR
DMG9BFR	DN	DCDPC
DMG9BFR	MI	TTOJI4S
DMG9BFR	MN	Calcium-dependent chloride channel anoctamin (ANO)
DMG9BFR	MT	DTT
DMG9BFR	MA	Blocker (channel blocker)
DMG9BFR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 708).
DMG9BFR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=708

DM2T5OV	DI	DM2T5OV
DM2T5OV	DN	DC-EBIO
DM2T5OV	MI	TT2T5M0
DM2T5OV	MN	Calcium-activated potassium channel KCa2.2 (KCNN2)
DM2T5OV	MT	DTT
DM2T5OV	MA	Activator
DM2T5OV	RN	Specific enhancement of SK channel activity selectively potentiates the afterhyperpolarizing current I(AHP) and modulates the firing properties of ... J Biol Chem. 2005 Dec 16;280(50):41404-11.
DM2T5OV	RU	https://pubmed.ncbi.nlm.nih.gov/16239218

DM2T5OV	DI	DM2T5OV
DM2T5OV	DN	DC-EBIO
DM2T5OV	MI	TT9JH25
DM2T5OV	MN	Calcium-activated potassium channel KCa2.3 (KCNN3)
DM2T5OV	MT	DTT
DM2T5OV	MA	Activator
DM2T5OV	RN	Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications. Curr Med Chem. 2007;14(13):1437-57.
DM2T5OV	RU	https://pubmed.ncbi.nlm.nih.gov/17584055

DM2T5OV	DI	DM2T5OV
DM2T5OV	DN	DC-EBIO
DM2T5OV	MI	TT7M9I6
DM2T5OV	MN	Calcium-activated potassium channel KCa3.1 (KCNN4)
DM2T5OV	MT	DTT
DM2T5OV	MA	Activator
DM2T5OV	RN	Benzimidazolone activators of chloride secretion: potential therapeutics for cystic fibrosis and chronic obstructive pulmonary disease. J Pharmacol Exp Ther. 2001 Feb;296(2):600-11.
DM2T5OV	RU	https://pubmed.ncbi.nlm.nih.gov/11160649

DM9HG1Y	DI	DM9HG1Y
DM9HG1Y	DN	DCG IV
DM9HG1Y	MI	TTXJ47W
DM9HG1Y	MN	Metabotropic glutamate receptor 2 (mGluR2)
DM9HG1Y	MT	DTT
DM9HG1Y	MA	Agonist
DM9HG1Y	RN	Attenuation of seizures induced by homocysteic acid in immature rats by metabotropic glutamate group II and group III receptor agonists. Brain Res. 2001 Jul 27;908(2):120-9.
DM9HG1Y	RU	https://pubmed.ncbi.nlm.nih.gov/11454322

DMU287Q	DI	DMU287Q
DMU287Q	DN	Dcp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2
DMU287Q	MI	TT27RFC
DMU287Q	MN	Opioid receptor delta (OPRD1)
DMU287Q	MT	DTT
DMU287Q	MA	Inhibitor
DMU287Q	RN	Replacement of the N-terminal tyrosine residue in opioid peptides with 3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid (Dcp) results in novel opio... J Med Chem. 2006 Aug 24;49(17):5382-5.
DMU287Q	RU	https://pubmed.ncbi.nlm.nih.gov/16913729

DMU287Q	DI	DMU287Q
DMU287Q	DN	Dcp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2
DMU287Q	MI	TTQW87Y
DMU287Q	MN	Opioid receptor kappa (OPRK1)
DMU287Q	MT	DTT
DMU287Q	MA	Inhibitor
DMU287Q	RN	Replacement of the N-terminal tyrosine residue in opioid peptides with 3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid (Dcp) results in novel opio... J Med Chem. 2006 Aug 24;49(17):5382-5.
DMU287Q	RU	https://pubmed.ncbi.nlm.nih.gov/16913729

DMU287Q	DI	DMU287Q
DMU287Q	DN	Dcp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2
DMU287Q	MI	TTKWM86
DMU287Q	MN	Opioid receptor mu (MOP)
DMU287Q	MT	DTT
DMU287Q	MA	Inhibitor
DMU287Q	RN	Replacement of the N-terminal tyrosine residue in opioid peptides with 3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid (Dcp) results in novel opio... J Med Chem. 2006 Aug 24;49(17):5382-5.
DMU287Q	RU	https://pubmed.ncbi.nlm.nih.gov/16913729

DM9NMIY	DI	DM9NMIY
DM9NMIY	DN	DCPIB
DM9NMIY	MI	TT0FC1V
DM9NMIY	MN	Volume regulated chloride channel (VRAC)
DM9NMIY	MT	DTT
DM9NMIY	MA	Blocker (channel blocker)
DM9NMIY	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 710).
DM9NMIY	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=710

DMV0JQG	DI	DMV0JQG
DMV0JQG	DN	DD7
DMV0JQG	MI	TTPLTSQ
DMV0JQG	MN	Neutrophil elastase (NE)
DMV0JQG	MT	DTT
DMV0JQG	RN	Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60.
DMV0JQG	RU	https://pubmed.ncbi.nlm.nih.gov/18095918

DM6GWAC	DI	DM6GWAC
DM6GWAC	DN	DDATHF
DM6GWAC	MI	TTCSJBZ
DM6GWAC	MN	GAR transformylase (GART)
DM6GWAC	MT	DTT
DM6GWAC	MA	Modulator
DM6GWAC	RN	Rational design, synthesis, evaluation, and crystal structure of a potent inhibitor of human GAR Tfase: 10-(trifluoroacetyl)-5,10-dideazaacyclic-5,... Biochemistry. 2003 May 27;42(20):6043-56.
DM6GWAC	RU	https://www.ncbi.nlm.nih.gov/pubmed/12755606

DM6GWAC	DI	DM6GWAC
DM6GWAC	DN	DDATHF
DM6GWAC	MI	TT9SL3Q
DM6GWAC	MN	Polypeptide deformylase (PDF)
DM6GWAC	MT	DTT
DM6GWAC	MA	Inhibitor
DM6GWAC	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM6GWAC	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMHLNA2	DI	DMHLNA2
DMHLNA2	DN	DdCTP SODIUM
DMHLNA2	MI	TTIU7X1
DMHLNA2	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMHLNA2	MT	DTT
DMHLNA2	MA	Inhibitor
DMHLNA2	RN	Acylphloroglucinol derivatives from Mahurea palustris. J Nat Prod. 2005 Jul;68(7):979-84.
DMHLNA2	RU	https://pubmed.ncbi.nlm.nih.gov/16038535

DMDFRTI	DI	DMDFRTI
DMDFRTI	DN	Deamido-NAD
DMDFRTI	MI	TT1NFO3
DMDFRTI	MN	Bacterial Nicotinate-nucleotide adenylyltransferase (Bact nadD)
DMDFRTI	MT	DTT
DMDFRTI	MA	Binder
DMDFRTI	RN	Crystal structures of E. coli nicotinate mononucleotide adenylyltransferase and its complex with deamido-NAD. Structure. 2002 Jan;10(1):69-79.
DMDFRTI	RU	https://pubmed.ncbi.nlm.nih.gov/11796112

DMFTNAP	DI	DMFTNAP
DMFTNAP	DN	Debio-0930
DMFTNAP	MI	TTLAFZV
DMFTNAP	MN	AMP-activated protein kinase (AMPK)
DMFTNAP	MT	DTT
DMFTNAP	MA	Stimulator
DMFTNAP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1540).
DMFTNAP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1540

DMDLER8	DI	DMDLER8
DMDLER8	DN	DEBROMOHYMENIALDISINE
DMDLER8	MI	TTTU902
DMDLER8	MN	Checkpoint kinase-1 (CHK1)
DMDLER8	MT	DTT
DMDLER8	MA	Inhibitor
DMDLER8	RN	Potent inhibition of checkpoint kinase activity by a hymenialdisine-derived indoloazepine. Bioorg Med Chem Lett. 2004 Aug 16;14(16):4319-21.
DMDLER8	RU	https://pubmed.ncbi.nlm.nih.gov/15261294

DMDLER8	DI	DMDLER8
DMDLER8	DN	DEBROMOHYMENIALDISINE
DMDLER8	MI	TTIDAPM
DMDLER8	MN	ERK activator kinase 1 (MEK1)
DMDLER8	MT	DTT
DMDLER8	MA	Inhibitor
DMDLER8	RN	Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1). J Med Chem. 2002 Jan 17;45(2):529-32.
DMDLER8	RU	https://pubmed.ncbi.nlm.nih.gov/11784156

DMDLER8	DI	DMDLER8
DMDLER8	DN	DEBROMOHYMENIALDISINE
DMDLER8	MI	TT4TQBX
DMDLER8	MN	Extracellular signal-regulated kinase 2 (ERK2)
DMDLER8	MT	DTT
DMDLER8	MA	Inhibitor
DMDLER8	RN	Potent inhibition of checkpoint kinase activity by a hymenialdisine-derived indoloazepine. Bioorg Med Chem Lett. 2004 Aug 16;14(16):4319-21.
DMDLER8	RU	https://pubmed.ncbi.nlm.nih.gov/15261294

DMDLER8	DI	DMDLER8
DMDLER8	DN	DEBROMOHYMENIALDISINE
DMDLER8	MI	TTAN5W2
DMDLER8	MN	Raf messenger RNA (Raf mRNA)
DMDLER8	MT	DTT
DMDLER8	MA	Inhibitor
DMDLER8	RN	Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1). J Med Chem. 2002 Jan 17;45(2):529-32.
DMDLER8	RU	https://pubmed.ncbi.nlm.nih.gov/11784156

DMDLER8	DI	DMDLER8
DMDLER8	DN	DEBROMOHYMENIALDISINE
DMDLER8	MI	TT9ABMF
DMDLER8	MN	Serine/threonine-protein kinase Chk2 (RAD53)
DMDLER8	MT	DTT
DMDLER8	MA	Inhibitor
DMDLER8	RN	Potent inhibition of checkpoint kinase activity by a hymenialdisine-derived indoloazepine. Bioorg Med Chem Lett. 2004 Aug 16;14(16):4319-21.
DMDLER8	RU	https://pubmed.ncbi.nlm.nih.gov/15261294

DMWZKLM	DI	DMWZKLM
DMWZKLM	DN	Decanal
DMWZKLM	MI	DE2JP1Y
DMWZKLM	MN	Aldehyde dehydrogenase 1 (ALDH1)
DMWZKLM	MT	DME
DMWZKLM	MA	Metabolism
DMWZKLM	RN	Retinoic acid biosynthesis catalyzed by retinal dehydrogenases relies on a rate-limiting conformational transition associated with substrate recognition. Chem Biol Interact. 2013 Feb 25;202(1-3):78-84.
DMWZKLM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23220587

DM1ESVR	DI	DM1ESVR
DM1ESVR	DN	Decane-1,10-diyl disulfamate
DM1ESVR	MI	TTUNARX
DM1ESVR	MN	Carbonic anhydrase (CA)
DM1ESVR	MT	DTT
DM1ESVR	MA	Inhibitor
DM1ESVR	RN	Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8.
DM1ESVR	RU	https://pubmed.ncbi.nlm.nih.gov/19731956

DM1ESVR	DI	DM1ESVR
DM1ESVR	DN	Decane-1,10-diyl disulfamate
DM1ESVR	MI	TTHQPL7
DM1ESVR	MN	Carbonic anhydrase I (CA-I)
DM1ESVR	MT	DTT
DM1ESVR	MA	Inhibitor
DM1ESVR	RN	Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8.
DM1ESVR	RU	https://pubmed.ncbi.nlm.nih.gov/19731956

DM1ESVR	DI	DM1ESVR
DM1ESVR	DN	Decane-1,10-diyl disulfamate
DM1ESVR	MI	TTANPDJ
DM1ESVR	MN	Carbonic anhydrase II (CA-II)
DM1ESVR	MT	DTT
DM1ESVR	MA	Inhibitor
DM1ESVR	RN	Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8.
DM1ESVR	RU	https://pubmed.ncbi.nlm.nih.gov/19731956

DM1ESVR	DI	DM1ESVR
DM1ESVR	DN	Decane-1,10-diyl disulfamate
DM1ESVR	MI	TTZHA0O
DM1ESVR	MN	Carbonic anhydrase IV (CA-IV)
DM1ESVR	MT	DTT
DM1ESVR	MA	Inhibitor
DM1ESVR	RN	Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8.
DM1ESVR	RU	https://pubmed.ncbi.nlm.nih.gov/19731956

DM1ESVR	DI	DM1ESVR
DM1ESVR	DN	Decane-1,10-diyl disulfamate
DM1ESVR	MI	TT2LVK8
DM1ESVR	MN	Carbonic anhydrase IX (CA-IX)
DM1ESVR	MT	DTT
DM1ESVR	MA	Inhibitor
DM1ESVR	RN	Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8.
DM1ESVR	RU	https://pubmed.ncbi.nlm.nih.gov/19731956

DM1ESVR	DI	DM1ESVR
DM1ESVR	DN	Decane-1,10-diyl disulfamate
DM1ESVR	MI	TTCFSPE
DM1ESVR	MN	Carbonic anhydrase VI (CA-VI)
DM1ESVR	MT	DTT
DM1ESVR	MA	Inhibitor
DM1ESVR	RN	Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8.
DM1ESVR	RU	https://pubmed.ncbi.nlm.nih.gov/19731956

DM1ESVR	DI	DM1ESVR
DM1ESVR	DN	Decane-1,10-diyl disulfamate
DM1ESVR	MI	TTSYM0R
DM1ESVR	MN	Carbonic anhydrase XII (CA-XII)
DM1ESVR	MT	DTT
DM1ESVR	MA	Inhibitor
DM1ESVR	RN	Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8.
DM1ESVR	RU	https://pubmed.ncbi.nlm.nih.gov/19731956

DM1ESVR	DI	DM1ESVR
DM1ESVR	DN	Decane-1,10-diyl disulfamate
DM1ESVR	MI	TTEYTKG
DM1ESVR	MN	Carbonic anhydrase XIV (CA-XIV)
DM1ESVR	MT	DTT
DM1ESVR	MA	Inhibitor
DM1ESVR	RN	Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8.
DM1ESVR	RU	https://pubmed.ncbi.nlm.nih.gov/19731956

DM8FMYL	DI	DM8FMYL
DM8FMYL	DN	Decanoic Acid
DM8FMYL	MI	TTPH97Y
DM8FMYL	MN	Mycobacterium 3-oxoacyl-[acyl-carrier-protein] synthase 1 (MycB kasA)
DM8FMYL	MT	DTT
DM8FMYL	MA	Inhibitor
DM8FMYL	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM8FMYL	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMLT1N3	DI	DMLT1N3
DMLT1N3	DN	decavanadate
DMLT1N3	MI	TT5HWAT
DMLT1N3	MN	IP3 receptor isoform 1 (ITPR1)
DMLT1N3	MT	DTT
DMLT1N3	MA	Antagonist
DMLT1N3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 743).
DMLT1N3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=743

DMLT1N3	DI	DMLT1N3
DMLT1N3	DN	decavanadate
DMLT1N3	MI	TTK9OV3
DMLT1N3	MN	IP3 receptor isoform 2 (IP3R2)
DMLT1N3	MT	DTT
DMLT1N3	MA	Antagonist
DMLT1N3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 744).
DMLT1N3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=744

DMLT1N3	DI	DMLT1N3
DMLT1N3	DN	decavanadate
DMLT1N3	MI	TTH1769
DMLT1N3	MN	IP3 receptor isoform 3 (ITPR3)
DMLT1N3	MT	DTT
DMLT1N3	MA	Antagonist
DMLT1N3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 745).
DMLT1N3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=745

DMLT1N3	DI	DMLT1N3
DMLT1N3	DN	decavanadate
DMLT1N3	MI	TTJ2HKA
DMLT1N3	MN	Long transient receptor potential channel 4 (TRPM4)
DMLT1N3	MT	DTT
DMLT1N3	MA	Activator
DMLT1N3	RN	Decavanadate modulates gating of TRPM4 cation channels. J Physiol. 2004 Nov 1;560(Pt 3):753-65.
DMLT1N3	RU	https://pubmed.ncbi.nlm.nih.gov/15331675

DMLT1N3	DI	DMLT1N3
DMLT1N3	DN	decavanadate
DMLT1N3	MI	TT473XN
DMLT1N3	MN	P2X purinoceptor 7 (P2RX7)
DMLT1N3	MT	DTT
DMLT1N3	MA	Antagonist
DMLT1N3	RN	Decavanadate, a P2X receptor antagonist, and its use to study ligand interactions with P2X7 receptors. Eur J Pharmacol. 2006 Mar 18;534(1-3):19-29.
DMLT1N3	RU	https://pubmed.ncbi.nlm.nih.gov/16487507

DM4SWYX	DI	DM4SWYX
DM4SWYX	DN	DECIDIUM
DM4SWYX	MI	TT1RS9F
DM4SWYX	MN	Acetylcholinesterase (AChE)
DM4SWYX	MT	DTT
DM4SWYX	MA	Inhibitor
DM4SWYX	RN	Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely... J Med Chem. 2008 Jun 12;51(11):3154-70.
DM4SWYX	RU	https://pubmed.ncbi.nlm.nih.gov/18479118

DMHO3N1	DI	DMHO3N1
DMHO3N1	DN	Decoyinine
DMHO3N1	MI	TTCFP0V
DMHO3N1	MN	Glutamine amidotransferase (GMPS)
DMHO3N1	MT	DTT
DMHO3N1	MA	Inhibitor
DMHO3N1	RN	High-level production from a baculovirus expression system and biochemical characterization of human GMP synthetase. Protein Expr Purif. 1995 Aug;6(4):487-95.
DMHO3N1	RU	https://pubmed.ncbi.nlm.nih.gov/8527935

DMNKDT5	DI	DMNKDT5
DMNKDT5	DN	decyl dihydrogen phosphate
DMNKDT5	MI	TTB7Y8I
DMNKDT5	MN	Lysophosphatidic acid receptor 2 (LPAR2)
DMNKDT5	MT	DTT
DMNKDT5	MA	Agonist
DMNKDT5	RN	Fatty alcohol phosphates are subtype-selective agonists and antagonists of lysophosphatidic acid receptors. Mol Pharmacol. 2003 May;63(5):1032-42.
DMNKDT5	RU	https://pubmed.ncbi.nlm.nih.gov/12695531

DMIERWO	DI	DMIERWO
DMIERWO	DN	Decyl sulfamate
DMIERWO	MI	TTUNARX
DMIERWO	MN	Carbonic anhydrase (CA)
DMIERWO	MT	DTT
DMIERWO	MA	Inhibitor
DMIERWO	RN	Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8.
DMIERWO	RU	https://pubmed.ncbi.nlm.nih.gov/19731956

DMIERWO	DI	DMIERWO
DMIERWO	DN	Decyl sulfamate
DMIERWO	MI	TTHQPL7
DMIERWO	MN	Carbonic anhydrase I (CA-I)
DMIERWO	MT	DTT
DMIERWO	MA	Inhibitor
DMIERWO	RN	Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8.
DMIERWO	RU	https://pubmed.ncbi.nlm.nih.gov/19731956

DMIERWO	DI	DMIERWO
DMIERWO	DN	Decyl sulfamate
DMIERWO	MI	TTANPDJ
DMIERWO	MN	Carbonic anhydrase II (CA-II)
DMIERWO	MT	DTT
DMIERWO	MA	Inhibitor
DMIERWO	RN	Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8.
DMIERWO	RU	https://pubmed.ncbi.nlm.nih.gov/19731956

DMIERWO	DI	DMIERWO
DMIERWO	DN	Decyl sulfamate
DMIERWO	MI	TTZHA0O
DMIERWO	MN	Carbonic anhydrase IV (CA-IV)
DMIERWO	MT	DTT
DMIERWO	MA	Inhibitor
DMIERWO	RN	Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8.
DMIERWO	RU	https://pubmed.ncbi.nlm.nih.gov/19731956

DMIERWO	DI	DMIERWO
DMIERWO	DN	Decyl sulfamate
DMIERWO	MI	TT2LVK8
DMIERWO	MN	Carbonic anhydrase IX (CA-IX)
DMIERWO	MT	DTT
DMIERWO	MA	Inhibitor
DMIERWO	RN	Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8.
DMIERWO	RU	https://pubmed.ncbi.nlm.nih.gov/19731956

DMIERWO	DI	DMIERWO
DMIERWO	DN	Decyl sulfamate
DMIERWO	MI	TTCFSPE
DMIERWO	MN	Carbonic anhydrase VI (CA-VI)
DMIERWO	MT	DTT
DMIERWO	MA	Inhibitor
DMIERWO	RN	Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8.
DMIERWO	RU	https://pubmed.ncbi.nlm.nih.gov/19731956

DMIERWO	DI	DMIERWO
DMIERWO	DN	Decyl sulfamate
DMIERWO	MI	TTSYM0R
DMIERWO	MN	Carbonic anhydrase XII (CA-XII)
DMIERWO	MT	DTT
DMIERWO	MA	Inhibitor
DMIERWO	RN	Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8.
DMIERWO	RU	https://pubmed.ncbi.nlm.nih.gov/19731956

DMIERWO	DI	DMIERWO
DMIERWO	DN	Decyl sulfamate
DMIERWO	MI	TTEYTKG
DMIERWO	MN	Carbonic anhydrase XIV (CA-XIV)
DMIERWO	MT	DTT
DMIERWO	MA	Inhibitor
DMIERWO	RN	Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8.
DMIERWO	RU	https://pubmed.ncbi.nlm.nih.gov/19731956

DMQMR3P	DI	DMQMR3P
DMQMR3P	DN	DECYL(DIMETHYL)PHOSPHINE OXIDE
DMQMR3P	MI	TT3WG5C
DMQMR3P	MN	Monoamine oxidase type A (MAO-A)
DMQMR3P	MT	DTT
DMQMR3P	MA	Inhibitor
DMQMR3P	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMQMR3P	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM2WEB9	DI	DM2WEB9
DM2WEB9	DN	Decylamine-N,N-Dimethyl-N-Oxide
DM2WEB9	MI	TT3PQ2Y
DM2WEB9	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DM2WEB9	MT	DTT
DM2WEB9	MA	Inhibitor
DM2WEB9	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM2WEB9	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMFT3J2	DI	DMFT3J2
DMFT3J2	DN	Decyl-phosphonic acid
DMFT3J2	MI	TTQ6S1K
DMFT3J2	MN	Lysophosphatidic acid receptor 1 (LPAR1)
DMFT3J2	MT	DTT
DMFT3J2	MA	Inhibitor
DMFT3J2	RN	Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30.
DMFT3J2	RU	https://pubmed.ncbi.nlm.nih.gov/16033271

DM1ITJ5	DI	DM1ITJ5
DM1ITJ5	DN	Decyltrimethylammonium
DM1ITJ5	MI	TTT1MCF
DM1ITJ5	MN	Permeability pathway (NP pathway)
DM1ITJ5	MT	DTT
DM1ITJ5	MA	Inhibitor
DM1ITJ5	RN	Novel molecular targets for antimalarial drug development. Chem Biol Drug Des. 2008 Apr;71(4):287-97.
DM1ITJ5	RU	https://pubmed.ncbi.nlm.nih.gov/18298458

DMWCTZ7	DI	DMWCTZ7
DMWCTZ7	DN	Decynium 22
DMWCTZ7	MI	TTJLP0R
DMWCTZ7	MN	Quinone reductase 2 (NQO2)
DMWCTZ7	MT	DTT
DMWCTZ7	MA	Inhibitor
DMWCTZ7	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMWCTZ7	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMWCTZ7	DI	DMWCTZ7
DMWCTZ7	DN	Decynium 22
DMWCTZ7	MI	TTTR957
DMWCTZ7	MN	Solute carrier family 29 member 4 (SLC29A4)
DMWCTZ7	MT	DTT
DMWCTZ7	MA	Inhibitor
DMWCTZ7	RN	Interaction of organic cations with a newly identified plasma membrane monoamine transporter. Mol Pharmacol. 2005 Nov;68(5):1397-407.
DMWCTZ7	RU	https://pubmed.ncbi.nlm.nih.gov/16099839

DMKRT20	DI	DMKRT20
DMKRT20	DN	Degraded Cephaloridine
DMKRT20	MI	TTHI19T
DMKRT20	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMKRT20	MT	DTT
DMKRT20	MA	Inhibitor
DMKRT20	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMKRT20	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMXT7WG	DI	DMXT7WG
DMXT7WG	DN	Deguelin
DMXT7WG	MI	TT5LS6T
DMXT7WG	MN	Aurora kinase B (AURKB)
DMXT7WG	MT	DTT
DMXT7WG	MA	Inhibitor
DMXT7WG	RN	An Electrophilic Deguelin Analogue Inhibits STAT3 Signaling in H- Ras-Transformed Human Mammary Epithelial Cells: The Cysteine 259 Residue as a Potential Target. Biomedicines. 2020 Oct 12;8(10):407.
DMXT7WG	RU	https://pubmed.ncbi.nlm.nih.gov/33053804

DMKYQO4	DI	DMKYQO4
DMKYQO4	DN	Dehydroascorbic acid
DMKYQO4	MI	DTG3T6X
DMKYQO4	MN	Glucose transporter type 1, erythrocyte/brain (SLC2A1)
DMKYQO4	MT	DTP
DMKYQO4	MA	Substrate
DMKYQO4	RN	Glucose transporter isoforms GLUT1 and GLUT3 transport dehydroascorbic acid. J Biol Chem. 1997 Jul 25;272(30):18982-9.
DMKYQO4	RU	http://www.ncbi.nlm.nih.gov/pubmed/9228080

DMKYQO4	DI	DMKYQO4
DMKYQO4	DN	Dehydroascorbic acid
DMKYQO4	MI	DT18YD9
DMKYQO4	MN	Glucose transporter type 14 (SLC2A14)
DMKYQO4	MT	DTP
DMKYQO4	MA	Substrate
DMKYQO4	RN	The SLC2A14 gene, encoding the novel glucose/dehydroascorbate transporter GLUT14, is associated with inflammatory bowel disease. Am J Clin Nutr. 2017 Dec;106(6):1508-1513.
DMKYQO4	RU	http://www.ncbi.nlm.nih.gov/pubmed/28971850

DMKYQO4	DI	DMKYQO4
DMKYQO4	DN	Dehydroascorbic acid
DMKYQO4	MI	DEZSNJD
DMKYQO4	MN	Glutathione S-transferase omega-1 (GSTO1)
DMKYQO4	MT	DME
DMKYQO4	MA	Metabolism
DMKYQO4	RN	Structural insights into the dehydroascorbate reductase activity of human omega-class glutathione transferases. J Mol Biol. 2012 Jul 13;420(3):190-203.
DMKYQO4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22522127

DMKYQO4	DI	DMKYQO4
DMKYQO4	DN	Dehydroascorbic acid
DMKYQO4	MI	DEHMPZR
DMKYQO4	MN	Glutathione S-transferase omega-2 (GSTO2)
DMKYQO4	MT	DME
DMKYQO4	MA	Metabolism
DMKYQO4	RN	Structural insights into the dehydroascorbate reductase activity of human omega-class glutathione transferases. J Mol Biol. 2012 Jul 13;420(3):190-203.
DMKYQO4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22522127

DMCDLH2	DI	DMCDLH2
DMCDLH2	DN	Dehydrocholic acid
DMCDLH2	MI	DEOMLHG
DMCDLH2	MN	Beta-hydroxysteroid dehydrogenase (hdhB)
DMCDLH2	MT	DME
DMCDLH2	MA	Metabolism
DMCDLH2	RN	Identification, cloning, heterologous expression, and characterization of a NADPH-dependent 7beta-hydroxysteroid dehydrogenase from Collinsella aerofaciens. Appl Microbiol Biotechnol. 2011 Apr;90(1):127-35.
DMCDLH2	RU	https://pubmed.ncbi.nlm.nih.gov/21181147

DM48KMB	DI	DM48KMB
DM48KMB	DN	Dehydrocorticosterone
DM48KMB	MI	DEZDRQO
DM48KMB	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DM48KMB	MT	DME
DM48KMB	MA	Metabolism
DM48KMB	RN	Comparative enzymology of 11beta-hydroxysteroid dehydrogenase type 1 from six species. J Mol Endocrinol. 2005 Aug;35(1):89-101.
DM48KMB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16087724

DM48KMB	DI	DM48KMB
DM48KMB	DN	Dehydrocorticosterone
DM48KMB	MI	DEDH7FP
DM48KMB	MN	Corticosteroid 11-beta-dehydrogenase 2 (HSD11B2)
DM48KMB	MT	DME
DM48KMB	MA	Metabolism
DM48KMB	RN	Comparative enzymology of 11beta-hydroxysteroid dehydrogenase type 1 from six species. J Mol Endocrinol. 2005 Aug;35(1):89-101.
DM48KMB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16087724

DM0V1NH	DI	DM0V1NH
DM0V1NH	DN	DEHYDROLEUCODIN
DM0V1NH	MI	TTSZLWK
DM0V1NH	MN	Aromatase (CYP19A1)
DM0V1NH	MT	DTT
DM0V1NH	MA	Inhibitor
DM0V1NH	RN	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
DM0V1NH	RU	https://pubmed.ncbi.nlm.nih.gov/20413308

DMIOA9M	DI	DMIOA9M
DMIOA9M	DN	Dehydropipernonaline
DMIOA9M	MI	TTA1L39
DMIOA9M	MN	ICAM1 messenger RNA (ICAM1 mRNA)
DMIOA9M	MT	DTT
DMIOA9M	MA	Inhibitor
DMIOA9M	RN	Alkamides from the fruits of Piper longum and Piper nigrum displaying potent cell adhesion inhibition. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4544-6.
DMIOA9M	RU	https://pubmed.ncbi.nlm.nih.gov/18672369

DM9TWR7	DI	DM9TWR7
DM9TWR7	DN	DEHYDROZINGERONE
DM9TWR7	MI	TTE4KHA
DM9TWR7	MN	Amyloid beta A4 protein (APP)
DM9TWR7	MT	DTT
DM9TWR7	MA	Inhibitor
DM9TWR7	RN	Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. J Med Chem. 2006 Oct 5;49(20):6111-9.
DM9TWR7	RU	https://pubmed.ncbi.nlm.nih.gov/17004725

DMGZ2H5	DI	DMGZ2H5
DMGZ2H5	DN	Del 60 tetramer
DMGZ2H5	MI	TTI2S1D
DMGZ2H5	MN	Cytotoxic T-lymphocyte protein 4 (CTLA-4)
DMGZ2H5	MT	DTT
DMGZ2H5	RN	Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60.
DMGZ2H5	RU	https://pubmed.ncbi.nlm.nih.gov/18095918

DM5ARHI	DI	DM5ARHI
DM5ARHI	DN	DELTA 8-TETRAHYDROCANNOBINOL
DM5ARHI	MI	TT6OEDT
DM5ARHI	MN	Cannabinoid receptor 1 (CB1)
DM5ARHI	MT	DTT
DM5ARHI	MA	Inhibitor
DM5ARHI	RN	Bornyl- and isobornyl-Delta8-tetrahydrocannabinols: a novel class of cannabinergic ligands. J Med Chem. 2008 Oct 23;51(20):6393-9.
DM5ARHI	RU	https://pubmed.ncbi.nlm.nih.gov/18826296

DM5ARHI	DI	DM5ARHI
DM5ARHI	DN	DELTA 8-TETRAHYDROCANNOBINOL
DM5ARHI	MI	TTMSFAW
DM5ARHI	MN	Cannabinoid receptor 2 (CB2)
DM5ARHI	MT	DTT
DM5ARHI	MA	Inhibitor
DM5ARHI	RN	Bornyl- and isobornyl-Delta8-tetrahydrocannabinols: a novel class of cannabinergic ligands. J Med Chem. 2008 Oct 23;51(20):6393-9.
DM5ARHI	RU	https://pubmed.ncbi.nlm.nih.gov/18826296

DMB6ADI	DI	DMB6ADI
DMB6ADI	DN	Delta12-PGJ2
DMB6ADI	MI	TTNVEIR
DMB6ADI	MN	Prostaglandin D2 receptor (PTGDR)
DMB6ADI	MT	DTT
DMB6ADI	MA	Agonist
DMB6ADI	RN	Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist. Br J Pharmacol. 1998 Apr;123(7):1317-24.
DMB6ADI	RU	https://pubmed.ncbi.nlm.nih.gov/9579725

DMB6ADI	DI	DMB6ADI
DMB6ADI	DN	Delta12-PGJ2
DMB6ADI	MI	TTQDMX5
DMB6ADI	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMB6ADI	MT	DTT
DMB6ADI	MA	Agonist
DMB6ADI	RN	Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2. Br J Pharmacol. 2002 Dec;137(8):1163-72.
DMB6ADI	RU	https://pubmed.ncbi.nlm.nih.gov/12466225

DML6MVH	DI	DML6MVH
DML6MVH	DN	Delta1-dihydrotestosterone
DML6MVH	MI	TTS64P2
DML6MVH	MN	Androgen receptor (AR)
DML6MVH	MT	DTT
DML6MVH	MA	Agonist
DML6MVH	RN	17beta-hydroxy-5alpha-androst-1-en-3-one (1-testosterone) is a potent androgen with anabolic properties. Toxicol Lett. 2006 Aug 20;165(2):149-55.
DML6MVH	RU	https://pubmed.ncbi.nlm.nih.gov/16621347

DMV7IAK	DI	DMV7IAK
DMV7IAK	DN	Delta-Amino Valeric Acid
DMV7IAK	MI	TTJHKYD
DMV7IAK	MN	Delta-aminolevulinic acid dehydratase (ALAD)
DMV7IAK	MT	DTT
DMV7IAK	MA	Inhibitor
DMV7IAK	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMV7IAK	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMHOT9P	DI	DMHOT9P
DMHOT9P	DN	DELTORPHIN
DMHOT9P	MI	TT27RFC
DMHOT9P	MN	Opioid receptor delta (OPRD1)
DMHOT9P	MT	DTT
DMHOT9P	MA	Inhibitor
DMHOT9P	RN	Cyclic enkephalin analogs with exceptional potency at peripheral delta opioid receptors. J Med Chem. 1994 Jan 7;37(1):146-50.
DMHOT9P	RU	https://pubmed.ncbi.nlm.nih.gov/8289188

DMHOT9P	DI	DMHOT9P
DMHOT9P	DN	DELTORPHIN
DMHOT9P	MI	TTKWM86
DMHOT9P	MN	Opioid receptor mu (MOP)
DMHOT9P	MT	DTT
DMHOT9P	MA	Inhibitor
DMHOT9P	RN	Synthesis and structure-activity relationships of deltorphin analogues. J Med Chem. 1991 May;34(5):1656-61.
DMHOT9P	RU	https://pubmed.ncbi.nlm.nih.gov/1851843

DM9ZWRK	DI	DM9ZWRK
DM9ZWRK	DN	DELTORPHIN-II
DM9ZWRK	MI	TT27RFC
DM9ZWRK	MN	Opioid receptor delta (OPRD1)
DM9ZWRK	MT	DTT
DM9ZWRK	MA	Inhibitor
DM9ZWRK	RN	Role of 2',6'-dimethyl-l-tyrosine (Dmt) in some opioid lead compounds. Bioorg Med Chem. 2010 Aug 15;18(16):6024-30.
DM9ZWRK	RU	https://pubmed.ncbi.nlm.nih.gov/20637637

DM9ZWRK	DI	DM9ZWRK
DM9ZWRK	DN	DELTORPHIN-II
DM9ZWRK	MI	TTKWM86
DM9ZWRK	MN	Opioid receptor mu (MOP)
DM9ZWRK	MT	DTT
DM9ZWRK	MA	Inhibitor
DM9ZWRK	RN	Role of 2',6'-dimethyl-l-tyrosine (Dmt) in some opioid lead compounds. Bioorg Med Chem. 2010 Aug 15;18(16):6024-30.
DM9ZWRK	RU	https://pubmed.ncbi.nlm.nih.gov/20637637

DMO5UGV	DI	DMO5UGV
DMO5UGV	DN	DEMETHOXYCURCUMIN
DMO5UGV	MI	TT8NGED
DMO5UGV	MN	Prostaglandin G/H synthase 1 (COX-1)
DMO5UGV	MT	DTT
DMO5UGV	MA	Inhibitor
DMO5UGV	RN	Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammator... Bioorg Med Chem Lett. 2005 Apr 1;15(7):1793-7.
DMO5UGV	RU	https://pubmed.ncbi.nlm.nih.gov/15780608

DMJBAEP	DI	DMJBAEP
DMJBAEP	DN	DEMETHYLDEBROMOFLUSTRAMINE B
DMJBAEP	MI	TTEB0GD
DMJBAEP	MN	Cholinesterase (BCHE)
DMJBAEP	MT	DTT
DMJBAEP	MA	Inhibitor
DMJBAEP	RN	Synthesis and biological evaluation of (-)- and (+)-debromoflustramine B and its analogues as selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Sep 11;51(17):5271-84.
DMJBAEP	RU	https://pubmed.ncbi.nlm.nih.gov/18686941

DMUVR5T	DI	DMUVR5T
DMUVR5T	DN	DEMETHYLMEDICARPIN
DMUVR5T	MI	TT50QJ3
DMUVR5T	MN	Influenza Neuraminidase (Influ NA)
DMUVR5T	MT	DTT
DMUVR5T	MA	Inhibitor
DMUVR5T	RN	Prenylated pterocarpans as bacterial neuraminidase inhibitors. Bioorg Med Chem. 2010 May 1;18(9):3335-44.
DMUVR5T	RU	https://pubmed.ncbi.nlm.nih.gov/20363636

DMAMS7R	DI	DMAMS7R
DMAMS7R	DN	DEMETHYLZEYLASTERONE
DMAMS7R	MI	TT0IHXV
DMAMS7R	MN	DNA topoisomerase II (TOP2)
DMAMS7R	MT	DTT
DMAMS7R	MA	Inhibitor
DMAMS7R	RN	Catalytic inhibition of topoisomerase IIalpha by demethylzeylasterone, a 6-oxophenolic triterpenoid from Kokoona zeylanica. J Nat Prod. 2001 Oct;64(10):1294-6.
DMAMS7R	RU	https://pubmed.ncbi.nlm.nih.gov/11678653

DMRICV6	DI	DMRICV6
DMRICV6	DN	Demotensin 1
DMRICV6	MI	TTTUMEP
DMRICV6	MN	Neurotensin receptor type 1 (NTSR1)
DMRICV6	MT	DTT
DMRICV6	MA	Inhibitor
DMRICV6	RN	Toward stable N4-modified neurotensins for NTS1-receptor-targeted tumor imaging with 99mTc. J Med Chem. 2006 Jul 27;49(15):4767-76.
DMRICV6	RU	https://pubmed.ncbi.nlm.nih.gov/16854083

DMW2GA4	DI	DMW2GA4
DMW2GA4	DN	Demotensin 2
DMW2GA4	MI	TTTUMEP
DMW2GA4	MN	Neurotensin receptor type 1 (NTSR1)
DMW2GA4	MT	DTT
DMW2GA4	MA	Inhibitor
DMW2GA4	RN	Toward stable N4-modified neurotensins for NTS1-receptor-targeted tumor imaging with 99mTc. J Med Chem. 2006 Jul 27;49(15):4767-76.
DMW2GA4	RU	https://pubmed.ncbi.nlm.nih.gov/16854083

DMS0V84	DI	DMS0V84
DMS0V84	DN	Demotensin 3
DMS0V84	MI	TTTUMEP
DMS0V84	MN	Neurotensin receptor type 1 (NTSR1)
DMS0V84	MT	DTT
DMS0V84	MA	Inhibitor
DMS0V84	RN	Toward stable N4-modified neurotensins for NTS1-receptor-targeted tumor imaging with 99mTc. J Med Chem. 2006 Jul 27;49(15):4767-76.
DMS0V84	RU	https://pubmed.ncbi.nlm.nih.gov/16854083

DMB2HXM	DI	DMB2HXM
DMB2HXM	DN	Demotensin 4
DMB2HXM	MI	TTTUMEP
DMB2HXM	MN	Neurotensin receptor type 1 (NTSR1)
DMB2HXM	MT	DTT
DMB2HXM	MA	Inhibitor
DMB2HXM	RN	Toward stable N4-modified neurotensins for NTS1-receptor-targeted tumor imaging with 99mTc. J Med Chem. 2006 Jul 27;49(15):4767-76.
DMB2HXM	RU	https://pubmed.ncbi.nlm.nih.gov/16854083

DMNWRV9	DI	DMNWRV9
DMNWRV9	DN	De-O-sulfonated kotalanol
DMNWRV9	MI	TTXWASR
DMNWRV9	MN	Intestinal maltase-glucoamylase (MGAM)
DMNWRV9	MT	DTT
DMNWRV9	MA	Inhibitor
DMNWRV9	RN	Probing the active-site requirements of human intestinal N-terminal maltase-glucoamylase: Synthesis and enzyme inhibitory activities of a six-membe... Bioorg Med Chem. 2010 Nov 15;18(22):7794-8.
DMNWRV9	RU	https://pubmed.ncbi.nlm.nih.gov/20970346

DM5JFKX	DI	DM5JFKX
DM5JFKX	DN	DEOXY SALVINORIN A
DM5JFKX	MI	TTQW87Y
DM5JFKX	MN	Opioid receptor kappa (OPRK1)
DM5JFKX	MT	DTT
DM5JFKX	MA	Inhibitor
DM5JFKX	RN	Synthesis and in vitro evaluation of salvinorin A analogues: effect of configuration at C(2) and substitution at C(18). Bioorg Med Chem Lett. 2006 Sep 1;16(17):4679-85.
DM5JFKX	RU	https://pubmed.ncbi.nlm.nih.gov/16777411

DMS6X1I	DI	DMS6X1I
DMS6X1I	DN	DEOXYADENOSINE
DMS6X1I	MI	TT2QM9D
DMS6X1I	MN	Adenylate cyclase (ADCY)
DMS6X1I	MT	DTT
DMS6X1I	MA	Inhibitor
DMS6X1I	RN	Synthesis of 2',5'-dideoxy-2-fluoroadenosine and 2',5'-dideoxy-2,5'-difluoroadenosine: potent P-site inhibitors of adenylyl cyclase. J Med Chem. 2004 Feb 26;47(5):1207-13.
DMS6X1I	RU	https://pubmed.ncbi.nlm.nih.gov/14971900

DMYAJCG	DI	DMYAJCG
DMYAJCG	DN	Deoxy-Bigchap
DMYAJCG	MI	TTJ584C
DMYAJCG	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMYAJCG	MT	DTT
DMYAJCG	MA	Inhibitor
DMYAJCG	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMYAJCG	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMW6YLS	DI	DMW6YLS
DMW6YLS	DN	Deoxycorticosterone
DMW6YLS	MI	DE6TYUK
DMW6YLS	MN	Aldosterone synthase (CYP11B2)
DMW6YLS	MT	DME
DMW6YLS	MA	Metabolism
DMW6YLS	RN	Functional expression of human mitochondrial CYP11B2 in fission yeast and identification of a new internal electron transfer protein, etp1. Biochemistry. 2002 Feb 19;41(7):2311-21.
DMW6YLS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11841224

DMW6YLS	DI	DMW6YLS
DMW6YLS	DN	Deoxycorticosterone
DMW6YLS	MI	TTOZRK6
DMW6YLS	MN	Glucocorticoid receptor messenger RNA (GCR mRNA)
DMW6YLS	MT	DTT
DMW6YLS	MA	Agonist
DMW6YLS	RN	Functional probing of the human glucocorticoid receptor steroid-interacting surface by site-directed mutagenesis. Gln-642 plays an important role in steroid recognition and binding. J Biol Chem. 2000Jun 23;275(25):19041-9.
DMW6YLS	RU	https://pubmed.ncbi.nlm.nih.gov/10747884

DMW6YLS	DI	DMW6YLS
DMW6YLS	DN	Deoxycorticosterone
DMW6YLS	MI	TT26PHO
DMW6YLS	MN	Mineralocorticoid receptor  (MR)
DMW6YLS	MT	DTT
DMW6YLS	MA	Agonist
DMW6YLS	RN	Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands. Eur J Pharmacol. 1993 Oct 15;247(2):145-54.
DMW6YLS	RU	https://pubmed.ncbi.nlm.nih.gov/8282004

DMW6YLS	DI	DMW6YLS
DMW6YLS	DN	Deoxycorticosterone
DMW6YLS	MI	DEPE0RD
DMW6YLS	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMW6YLS	MT	DME
DMW6YLS	MA	Metabolism
DMW6YLS	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMW6YLS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMKFMRY	DI	DMKFMRY
DMKFMRY	DN	Deoxyfluorothymidine
DMKFMRY	MI	TT84ETX
DMKFMRY	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMKFMRY	MT	DTT
DMKFMRY	MA	Inhibitor
DMKFMRY	RN	Current use of anti-HIV drugs in AIDS. J Antimicrob Chemother. 1993 Jul;32 Suppl A:133-8.
DMKFMRY	RU	https://pubmed.ncbi.nlm.nih.gov/8407695

DMR90HY	DI	DMR90HY
DMR90HY	DN	Deoxythymidine
DMR90HY	MI	TT5B8AX
DMR90HY	MN	Mycobacterium Thymidine monophosphate kinase (MycB tmk)
DMR90HY	MT	DTT
DMR90HY	MA	Inhibitor
DMR90HY	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMR90HY	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMR90HY	DI	DMR90HY
DMR90HY	DN	Deoxythymidine
DMR90HY	MI	TTP3QRF
DMR90HY	MN	Thymidine kinase 1 (TK1)
DMR90HY	MT	DTT
DMR90HY	MA	Inhibitor
DMR90HY	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMR90HY	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMR90HY	DI	DMR90HY
DMR90HY	DN	Deoxythymidine
DMR90HY	MI	DE4HCYL
DMR90HY	MN	Thymidine phosphorylase (TYMP)
DMR90HY	MT	DME
DMR90HY	MA	Metabolism
DMR90HY	RN	Thymidine catabolism as a metabolic strategy for cancer survival. Cell Rep. 2017 May 16;19(7):1313-1321.
DMR90HY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28514652

DMIFMDC	DI	DMIFMDC
DMIFMDC	DN	Deoxyuridine-5'-Diphosphate
DMIFMDC	MI	TTY8KJS
DMIFMDC	MN	Bacterial Deoxyuridine triphosphate nucleotidohydrolase (Bact dut)
DMIFMDC	MT	DTT
DMIFMDC	MA	Inhibitor
DMIFMDC	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMIFMDC	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMCG5V2	DI	DMCG5V2
DMCG5V2	DN	Deoxyuridine-5'-Triphosphate
DMCG5V2	MI	TTY8KJS
DMCG5V2	MN	Bacterial Deoxyuridine triphosphate nucleotidohydrolase (Bact dut)
DMCG5V2	MT	DTT
DMCG5V2	MA	Inhibitor
DMCG5V2	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMCG5V2	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMGHM1L	DI	DMGHM1L
DMGHM1L	DN	Dephospho Coenzyme A
DMGHM1L	MI	TT4YO0Z
DMGHM1L	MN	Phosphopantetheine adenylyltransferase (PPAT)
DMGHM1L	MT	DTT
DMGHM1L	MA	Inhibitor
DMGHM1L	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMGHM1L	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMRFBD0	DI	DMRFBD0
DMRFBD0	DN	Deprenyl
DMRFBD0	MI	TTGP7BY
DMRFBD0	MN	Monoamine oxidase type B (MAO-B)
DMRFBD0	MT	DTT
DMRFBD0	MA	Inhibitor
DMRFBD0	RN	The effect of deprenyl washout in patients with long-standing Parkinson's disease. J Neural Transm. 2002 May;109(5-6):797-803.
DMRFBD0	RU	https://pubmed.ncbi.nlm.nih.gov/12111469

DMH340E	DI	DMH340E
DMH340E	DN	Deprotected cogener of M6G
DMH340E	MI	TT27RFC
DMH340E	MN	Opioid receptor delta (OPRD1)
DMH340E	MT	DTT
DMH340E	MA	Inhibitor
DMH340E	RN	Synthesis and in vitro biological evaluation of a carbon glycoside analogue of morphine-6-glucuronide. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1583-6.
DMH340E	RU	https://pubmed.ncbi.nlm.nih.gov/15745801

DMH340E	DI	DMH340E
DMH340E	DN	Deprotected cogener of M6G
DMH340E	MI	TTQW87Y
DMH340E	MN	Opioid receptor kappa (OPRK1)
DMH340E	MT	DTT
DMH340E	MA	Inhibitor
DMH340E	RN	Synthesis and in vitro biological evaluation of a carbon glycoside analogue of morphine-6-glucuronide. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1583-6.
DMH340E	RU	https://pubmed.ncbi.nlm.nih.gov/15745801

DMH340E	DI	DMH340E
DMH340E	DN	Deprotected cogener of M6G
DMH340E	MI	TTKWM86
DMH340E	MN	Opioid receptor mu (MOP)
DMH340E	MT	DTT
DMH340E	MA	Inhibitor
DMH340E	RN	Synthesis and in vitro biological evaluation of a carbon glycoside analogue of morphine-6-glucuronide. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1583-6.
DMH340E	RU	https://pubmed.ncbi.nlm.nih.gov/15745801

DM4JM50	DI	DM4JM50
DM4JM50	DN	DEPX
DM4JM50	MI	TTK25J1
DM4JM50	MN	Adenosine A1 receptor (ADORA1)
DM4JM50	MT	DTT
DM4JM50	MA	Inhibitor
DM4JM50	RN	125I-labeled 8-phenylxanthine derivatives: antagonist radioligands for adenosine A1 receptors. J Med Chem. 1988 Apr;31(4):745-51.
DM4JM50	RU	https://pubmed.ncbi.nlm.nih.gov/3351850

DM4JM50	DI	DM4JM50
DM4JM50	DN	DEPX
DM4JM50	MI	TTNE7KG
DM4JM50	MN	Adenosine A2b receptor (ADORA2B)
DM4JM50	MT	DTT
DM4JM50	MA	Antagonist
DM4JM50	RN	Characterization of human A(2B) adenosine receptors: radioligand binding, western blotting, and coupling to G(q) in human embryonic kidney 293 cells and HMC-1 mast cells. Mol Pharmacol. 1999 Oct;56(4):705-13.
DM4JM50	RU	https://pubmed.ncbi.nlm.nih.gov/10496952

DM2XT7S	DI	DM2XT7S
DM2XT7S	DN	D-Eritadenine
DM2XT7S	MI	TTE2KUJ
DM2XT7S	MN	Adenosylhomocysteinase (AHCY)
DM2XT7S	MT	DTT
DM2XT7S	MA	Inhibitor
DM2XT7S	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM2XT7S	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMCYQHO	DI	DMCYQHO
DMCYQHO	DN	DERMORPHIN
DMCYQHO	MI	TT27RFC
DMCYQHO	MN	Opioid receptor delta (OPRD1)
DMCYQHO	MT	DTT
DMCYQHO	MA	Inhibitor
DMCYQHO	RN	Conversion of the potent delta-opioid agonist H-Dmt-Tic-NH-CH(2)-bid into delta-opioid antagonists by N(1)-benzimidazole alkylation(1). J Med Chem. 2005 Dec 29;48(26):8112-4.
DMCYQHO	RU	https://pubmed.ncbi.nlm.nih.gov/16366592

DMCYQHO	DI	DMCYQHO
DMCYQHO	DN	DERMORPHIN
DMCYQHO	MI	TTKWM86
DMCYQHO	MN	Opioid receptor mu (MOP)
DMCYQHO	MT	DTT
DMCYQHO	MA	Inhibitor
DMCYQHO	RN	Synthesis and receptor binding properties of chimeric peptides containing a mu-opioid receptor ligand and nociceptin/orphanin FQ receptor ligand Ac... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4839-41.
DMCYQHO	RU	https://pubmed.ncbi.nlm.nih.gov/16814543

DMMWDC5	DI	DMMWDC5
DMMWDC5	DN	Des-AA1,2,4,12,13-[D-Trp8]SRIF
DMMWDC5	MI	TTIND6G
DMMWDC5	MN	Somatostatin receptor type 1 (SSTR1)
DMMWDC5	MT	DTT
DMMWDC5	MA	Inhibitor
DMMWDC5	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DMMWDC5	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DMMWDC5	DI	DMMWDC5
DMMWDC5	DN	Des-AA1,2,4,12,13-[D-Trp8]SRIF
DMMWDC5	MI	TTZ6T9E
DMMWDC5	MN	Somatostatin receptor type 2 (SSTR2)
DMMWDC5	MT	DTT
DMMWDC5	MA	Inhibitor
DMMWDC5	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DMMWDC5	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DMMWDC5	DI	DMMWDC5
DMMWDC5	DN	Des-AA1,2,4,12,13-[D-Trp8]SRIF
DMMWDC5	MI	TTJX3UE
DMMWDC5	MN	Somatostatin receptor type 3 (SSTR3)
DMMWDC5	MT	DTT
DMMWDC5	MA	Inhibitor
DMMWDC5	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DMMWDC5	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DMMWDC5	DI	DMMWDC5
DMMWDC5	DN	Des-AA1,2,4,12,13-[D-Trp8]SRIF
DMMWDC5	MI	TTAE1BR
DMMWDC5	MN	Somatostatin receptor type 4 (SSTR4)
DMMWDC5	MT	DTT
DMMWDC5	MA	Inhibitor
DMMWDC5	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DMMWDC5	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DMMWDC5	DI	DMMWDC5
DMMWDC5	DN	Des-AA1,2,4,12,13-[D-Trp8]SRIF
DMMWDC5	MI	TT2BC4G
DMMWDC5	MN	Somatostatin receptor type 5 (SSTR5)
DMMWDC5	MT	DTT
DMMWDC5	MA	Inhibitor
DMMWDC5	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DMMWDC5	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DMR6Z2N	DI	DMR6Z2N
DMR6Z2N	DN	Des-AA1,2,4,13-[D-Trp8]SRIF
DMR6Z2N	MI	TTIND6G
DMR6Z2N	MN	Somatostatin receptor type 1 (SSTR1)
DMR6Z2N	MT	DTT
DMR6Z2N	MA	Inhibitor
DMR6Z2N	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DMR6Z2N	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DMR6Z2N	DI	DMR6Z2N
DMR6Z2N	DN	Des-AA1,2,4,13-[D-Trp8]SRIF
DMR6Z2N	MI	TTZ6T9E
DMR6Z2N	MN	Somatostatin receptor type 2 (SSTR2)
DMR6Z2N	MT	DTT
DMR6Z2N	MA	Inhibitor
DMR6Z2N	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DMR6Z2N	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DMR6Z2N	DI	DMR6Z2N
DMR6Z2N	DN	Des-AA1,2,4,13-[D-Trp8]SRIF
DMR6Z2N	MI	TTJX3UE
DMR6Z2N	MN	Somatostatin receptor type 3 (SSTR3)
DMR6Z2N	MT	DTT
DMR6Z2N	MA	Inhibitor
DMR6Z2N	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DMR6Z2N	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DMR6Z2N	DI	DMR6Z2N
DMR6Z2N	DN	Des-AA1,2,4,13-[D-Trp8]SRIF
DMR6Z2N	MI	TTAE1BR
DMR6Z2N	MN	Somatostatin receptor type 4 (SSTR4)
DMR6Z2N	MT	DTT
DMR6Z2N	MA	Inhibitor
DMR6Z2N	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DMR6Z2N	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DMR6Z2N	DI	DMR6Z2N
DMR6Z2N	DN	Des-AA1,2,4,13-[D-Trp8]SRIF
DMR6Z2N	MI	TT2BC4G
DMR6Z2N	MN	Somatostatin receptor type 5 (SSTR5)
DMR6Z2N	MT	DTT
DMR6Z2N	MA	Inhibitor
DMR6Z2N	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DMR6Z2N	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DMEVOD2	DI	DMEVOD2
DMEVOD2	DN	Des-AA1,2,4,5,10,12,13-[D-Trp8]SRIF
DMEVOD2	MI	TTJX3UE
DMEVOD2	MN	Somatostatin receptor type 3 (SSTR3)
DMEVOD2	MT	DTT
DMEVOD2	MA	Inhibitor
DMEVOD2	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DMEVOD2	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DMEVOD2	DI	DMEVOD2
DMEVOD2	DN	Des-AA1,2,4,5,10,12,13-[D-Trp8]SRIF
DMEVOD2	MI	TTAE1BR
DMEVOD2	MN	Somatostatin receptor type 4 (SSTR4)
DMEVOD2	MT	DTT
DMEVOD2	MA	Inhibitor
DMEVOD2	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DMEVOD2	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DMJI6BK	DI	DMJI6BK
DMJI6BK	DN	Des-AA1,2,4,5,11,12,13-[D-Trp8]SRIF
DMJI6BK	MI	TTZ6T9E
DMJI6BK	MN	Somatostatin receptor type 2 (SSTR2)
DMJI6BK	MT	DTT
DMJI6BK	MA	Inhibitor
DMJI6BK	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DMJI6BK	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DMYZXEO	DI	DMYZXEO
DMYZXEO	DN	Des-AA1,2,4,5,13-[D-Trp8]-SRIF
DMYZXEO	MI	TTIND6G
DMYZXEO	MN	Somatostatin receptor type 1 (SSTR1)
DMYZXEO	MT	DTT
DMYZXEO	MA	Inhibitor
DMYZXEO	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DMYZXEO	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DMYZXEO	DI	DMYZXEO
DMYZXEO	DN	Des-AA1,2,4,5,13-[D-Trp8]-SRIF
DMYZXEO	MI	TTZ6T9E
DMYZXEO	MN	Somatostatin receptor type 2 (SSTR2)
DMYZXEO	MT	DTT
DMYZXEO	MA	Inhibitor
DMYZXEO	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DMYZXEO	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DMYZXEO	DI	DMYZXEO
DMYZXEO	DN	Des-AA1,2,4,5,13-[D-Trp8]-SRIF
DMYZXEO	MI	TTJX3UE
DMYZXEO	MN	Somatostatin receptor type 3 (SSTR3)
DMYZXEO	MT	DTT
DMYZXEO	MA	Inhibitor
DMYZXEO	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DMYZXEO	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DMYZXEO	DI	DMYZXEO
DMYZXEO	DN	Des-AA1,2,4,5,13-[D-Trp8]-SRIF
DMYZXEO	MI	TTAE1BR
DMYZXEO	MN	Somatostatin receptor type 4 (SSTR4)
DMYZXEO	MT	DTT
DMYZXEO	MA	Inhibitor
DMYZXEO	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DMYZXEO	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DMYZXEO	DI	DMYZXEO
DMYZXEO	DN	Des-AA1,2,4,5,13-[D-Trp8]-SRIF
DMYZXEO	MI	TT2BC4G
DMYZXEO	MN	Somatostatin receptor type 5 (SSTR5)
DMYZXEO	MT	DTT
DMYZXEO	MA	Inhibitor
DMYZXEO	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DMYZXEO	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DM6HZ8D	DI	DM6HZ8D
DM6HZ8D	DN	Des-AA1,2,4,5,6,12,13-[D-Trp8]SRIF
DM6HZ8D	MI	TTZ6T9E
DM6HZ8D	MN	Somatostatin receptor type 2 (SSTR2)
DM6HZ8D	MT	DTT
DM6HZ8D	MA	Inhibitor
DM6HZ8D	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DM6HZ8D	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DM6HZ8D	DI	DM6HZ8D
DM6HZ8D	DN	Des-AA1,2,4,5,6,12,13-[D-Trp8]SRIF
DM6HZ8D	MI	TTAE1BR
DM6HZ8D	MN	Somatostatin receptor type 4 (SSTR4)
DM6HZ8D	MT	DTT
DM6HZ8D	MA	Inhibitor
DM6HZ8D	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DM6HZ8D	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DMEN4G8	DI	DMEN4G8
DMEN4G8	DN	Des-AA1,2,4,5-[D-Trp8]SRIF
DMEN4G8	MI	TTIND6G
DMEN4G8	MN	Somatostatin receptor type 1 (SSTR1)
DMEN4G8	MT	DTT
DMEN4G8	MA	Inhibitor
DMEN4G8	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DMEN4G8	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DMEN4G8	DI	DMEN4G8
DMEN4G8	DN	Des-AA1,2,4,5-[D-Trp8]SRIF
DMEN4G8	MI	TTZ6T9E
DMEN4G8	MN	Somatostatin receptor type 2 (SSTR2)
DMEN4G8	MT	DTT
DMEN4G8	MA	Inhibitor
DMEN4G8	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DMEN4G8	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DMEN4G8	DI	DMEN4G8
DMEN4G8	DN	Des-AA1,2,4,5-[D-Trp8]SRIF
DMEN4G8	MI	TTJX3UE
DMEN4G8	MN	Somatostatin receptor type 3 (SSTR3)
DMEN4G8	MT	DTT
DMEN4G8	MA	Inhibitor
DMEN4G8	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DMEN4G8	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DMEN4G8	DI	DMEN4G8
DMEN4G8	DN	Des-AA1,2,4,5-[D-Trp8]SRIF
DMEN4G8	MI	TTAE1BR
DMEN4G8	MN	Somatostatin receptor type 4 (SSTR4)
DMEN4G8	MT	DTT
DMEN4G8	MA	Inhibitor
DMEN4G8	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DMEN4G8	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DMEN4G8	DI	DMEN4G8
DMEN4G8	DN	Des-AA1,2,4,5-[D-Trp8]SRIF
DMEN4G8	MI	TT2BC4G
DMEN4G8	MN	Somatostatin receptor type 5 (SSTR5)
DMEN4G8	MT	DTT
DMEN4G8	MA	Inhibitor
DMEN4G8	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DMEN4G8	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DMZPXGY	DI	DMZPXGY
DMZPXGY	DN	Des-AA1,2,5,12,13-[D-Trp8,IAmp9]SRIF
DMZPXGY	MI	TTIND6G
DMZPXGY	MN	Somatostatin receptor type 1 (SSTR1)
DMZPXGY	MT	DTT
DMZPXGY	MA	Inhibitor
DMZPXGY	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DMZPXGY	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DMZPXGY	DI	DMZPXGY
DMZPXGY	DN	Des-AA1,2,5,12,13-[D-Trp8,IAmp9]SRIF
DMZPXGY	MI	TTJX3UE
DMZPXGY	MN	Somatostatin receptor type 3 (SSTR3)
DMZPXGY	MT	DTT
DMZPXGY	MA	Inhibitor
DMZPXGY	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DMZPXGY	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DMZPXGY	DI	DMZPXGY
DMZPXGY	DN	Des-AA1,2,5,12,13-[D-Trp8,IAmp9]SRIF
DMZPXGY	MI	TTAE1BR
DMZPXGY	MN	Somatostatin receptor type 4 (SSTR4)
DMZPXGY	MT	DTT
DMZPXGY	MA	Inhibitor
DMZPXGY	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DMZPXGY	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DM1KJAE	DI	DM1KJAE
DM1KJAE	DN	Des-AA1,2,5,12,13-[D-Trp8]SRIF
DM1KJAE	MI	TTIND6G
DM1KJAE	MN	Somatostatin receptor type 1 (SSTR1)
DM1KJAE	MT	DTT
DM1KJAE	MA	Inhibitor
DM1KJAE	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DM1KJAE	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DM1KJAE	DI	DM1KJAE
DM1KJAE	DN	Des-AA1,2,5,12,13-[D-Trp8]SRIF
DM1KJAE	MI	TTZ6T9E
DM1KJAE	MN	Somatostatin receptor type 2 (SSTR2)
DM1KJAE	MT	DTT
DM1KJAE	MA	Inhibitor
DM1KJAE	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DM1KJAE	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DM1KJAE	DI	DM1KJAE
DM1KJAE	DN	Des-AA1,2,5,12,13-[D-Trp8]SRIF
DM1KJAE	MI	TTJX3UE
DM1KJAE	MN	Somatostatin receptor type 3 (SSTR3)
DM1KJAE	MT	DTT
DM1KJAE	MA	Inhibitor
DM1KJAE	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DM1KJAE	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DM1KJAE	DI	DM1KJAE
DM1KJAE	DN	Des-AA1,2,5,12,13-[D-Trp8]SRIF
DM1KJAE	MI	TTAE1BR
DM1KJAE	MN	Somatostatin receptor type 4 (SSTR4)
DM1KJAE	MT	DTT
DM1KJAE	MA	Inhibitor
DM1KJAE	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DM1KJAE	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DM1KJAE	DI	DM1KJAE
DM1KJAE	DN	Des-AA1,2,5,12,13-[D-Trp8]SRIF
DM1KJAE	MI	TT2BC4G
DM1KJAE	MN	Somatostatin receptor type 5 (SSTR5)
DM1KJAE	MT	DTT
DM1KJAE	MA	Inhibitor
DM1KJAE	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DM1KJAE	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DMVYHGI	DI	DMVYHGI
DMVYHGI	DN	Des-AA1,2,5-[(NalphaMe)Cys3,D-Nal8,IAmp9]SRIF
DMVYHGI	MI	TTIND6G
DMVYHGI	MN	Somatostatin receptor type 1 (SSTR1)
DMVYHGI	MT	DTT
DMVYHGI	MA	Inhibitor
DMVYHGI	RN	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
DMVYHGI	RU	https://pubmed.ncbi.nlm.nih.gov/15658864

DMY6NID	DI	DMY6NID
DMY6NID	DN	Des-AA1,2,5-[(NalphaMe)Cys3,D-Trp8,IAmp9]SRIF
DMY6NID	MI	TTIND6G
DMY6NID	MN	Somatostatin receptor type 1 (SSTR1)
DMY6NID	MT	DTT
DMY6NID	MA	Inhibitor
DMY6NID	RN	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
DMY6NID	RU	https://pubmed.ncbi.nlm.nih.gov/15658864

DMQPVGO	DI	DMQPVGO
DMQPVGO	DN	Des-AA1,2,5-[(NalphaMe)D-Nal8,IAmp9]SRIF
DMQPVGO	MI	TTIND6G
DMQPVGO	MN	Somatostatin receptor type 1 (SSTR1)
DMQPVGO	MT	DTT
DMQPVGO	MA	Inhibitor
DMQPVGO	RN	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
DMQPVGO	RU	https://pubmed.ncbi.nlm.nih.gov/15658864

DM478XZ	DI	DM478XZ
DM478XZ	DN	Des-AA1,2,5-[(NalphaMe)Lys4,D-Nal8,IAmp9]SRIF
DM478XZ	MI	TTIND6G
DM478XZ	MN	Somatostatin receptor type 1 (SSTR1)
DM478XZ	MT	DTT
DM478XZ	MA	Inhibitor
DM478XZ	RN	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
DM478XZ	RU	https://pubmed.ncbi.nlm.nih.gov/15658864

DMQOL73	DI	DMQOL73
DMQOL73	DN	Des-AA1,2,5-[D-Nal8,(NalphaMe)IAmp9,Tyr11]SRIF
DMQOL73	MI	TTIND6G
DMQOL73	MN	Somatostatin receptor type 1 (SSTR1)
DMQOL73	MT	DTT
DMQOL73	MA	Inhibitor
DMQOL73	RN	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
DMQOL73	RU	https://pubmed.ncbi.nlm.nih.gov/15658864

DMN4ZYO	DI	DMN4ZYO
DMN4ZYO	DN	Des-AA1,2,5-[D-Nal8,(NalphaMe)IAmp9]SRIF
DMN4ZYO	MI	TTIND6G
DMN4ZYO	MN	Somatostatin receptor type 1 (SSTR1)
DMN4ZYO	MT	DTT
DMN4ZYO	MA	Inhibitor
DMN4ZYO	RN	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
DMN4ZYO	RU	https://pubmed.ncbi.nlm.nih.gov/15658864

DMXD60K	DI	DMXD60K
DMXD60K	DN	Des-AA1,2,5-[D-Nal8,IAmp9,(NalphaMe)Cys14]SRIF
DMXD60K	MI	TTIND6G
DMXD60K	MN	Somatostatin receptor type 1 (SSTR1)
DMXD60K	MT	DTT
DMXD60K	MA	Inhibitor
DMXD60K	RN	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
DMXD60K	RU	https://pubmed.ncbi.nlm.nih.gov/15658864

DM0574W	DI	DM0574W
DM0574W	DN	Des-AA1,2,5-[D-Nal8,IAmp9,(NalphaMe)Phe11]SRIF
DM0574W	MI	TTIND6G
DM0574W	MN	Somatostatin receptor type 1 (SSTR1)
DM0574W	MT	DTT
DM0574W	MA	Inhibitor
DM0574W	RN	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
DM0574W	RU	https://pubmed.ncbi.nlm.nih.gov/15658864

DMOZ9WC	DI	DMOZ9WC
DMOZ9WC	DN	Des-AA1,2,5-[D-Nal8,IAmp9,(NalphaMe)Ser13]SRIF
DMOZ9WC	MI	TTIND6G
DMOZ9WC	MN	Somatostatin receptor type 1 (SSTR1)
DMOZ9WC	MT	DTT
DMOZ9WC	MA	Inhibitor
DMOZ9WC	RN	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
DMOZ9WC	RU	https://pubmed.ncbi.nlm.nih.gov/15658864

DMYFCB0	DI	DMYFCB0
DMYFCB0	DN	Des-AA1,2,5-[D-Nal8,IAmp9,(NalphaMe)Thr12]SRIF
DMYFCB0	MI	TTIND6G
DMYFCB0	MN	Somatostatin receptor type 1 (SSTR1)
DMYFCB0	MT	DTT
DMYFCB0	MA	Inhibitor
DMYFCB0	RN	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
DMYFCB0	RU	https://pubmed.ncbi.nlm.nih.gov/15658864

DMYFCB0	DI	DMYFCB0
DMYFCB0	DN	Des-AA1,2,5-[D-Nal8,IAmp9,(NalphaMe)Thr12]SRIF
DMYFCB0	MI	TTAE1BR
DMYFCB0	MN	Somatostatin receptor type 4 (SSTR4)
DMYFCB0	MT	DTT
DMYFCB0	MA	Inhibitor
DMYFCB0	RN	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
DMYFCB0	RU	https://pubmed.ncbi.nlm.nih.gov/15658864

DM6JAFM	DI	DM6JAFM
DM6JAFM	DN	Des-AA1,2,5-[D-Nal8,IAmp9]SRIF
DM6JAFM	MI	TTIND6G
DM6JAFM	MN	Somatostatin receptor type 1 (SSTR1)
DM6JAFM	MT	DTT
DM6JAFM	MA	Inhibitor
DM6JAFM	RN	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
DM6JAFM	RU	https://pubmed.ncbi.nlm.nih.gov/15658864

DMLHUPY	DI	DMLHUPY
DMLHUPY	DN	Des-AA1,2,5-[D-Trp8,(NalphaMe)IAmp9,Tyr11]SRIF
DMLHUPY	MI	TTIND6G
DMLHUPY	MN	Somatostatin receptor type 1 (SSTR1)
DMLHUPY	MT	DTT
DMLHUPY	MA	Inhibitor
DMLHUPY	RN	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
DMLHUPY	RU	https://pubmed.ncbi.nlm.nih.gov/15658864

DMX2I4P	DI	DMX2I4P
DMX2I4P	DN	Des-AA1,2,5-[D-Trp8,(NalphaMe)IAmp9]SRIF
DMX2I4P	MI	TTIND6G
DMX2I4P	MN	Somatostatin receptor type 1 (SSTR1)
DMX2I4P	MT	DTT
DMX2I4P	MA	Inhibitor
DMX2I4P	RN	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
DMX2I4P	RU	https://pubmed.ncbi.nlm.nih.gov/15658864

DMX2I4P	DI	DMX2I4P
DMX2I4P	DN	Des-AA1,2,5-[D-Trp8,(NalphaMe)IAmp9]SRIF
DMX2I4P	MI	TTJX3UE
DMX2I4P	MN	Somatostatin receptor type 3 (SSTR3)
DMX2I4P	MT	DTT
DMX2I4P	MA	Inhibitor
DMX2I4P	RN	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
DMX2I4P	RU	https://pubmed.ncbi.nlm.nih.gov/15658864

DMX2I4P	DI	DMX2I4P
DMX2I4P	DN	Des-AA1,2,5-[D-Trp8,(NalphaMe)IAmp9]SRIF
DMX2I4P	MI	TTAE1BR
DMX2I4P	MN	Somatostatin receptor type 4 (SSTR4)
DMX2I4P	MT	DTT
DMX2I4P	MA	Inhibitor
DMX2I4P	RN	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
DMX2I4P	RU	https://pubmed.ncbi.nlm.nih.gov/15658864

DMFXKRO	DI	DMFXKRO
DMFXKRO	DN	Des-AA1,2,5-[D-Trp8,IAmp9,(NalphaMe)Cys14]SRIF
DMFXKRO	MI	TTIND6G
DMFXKRO	MN	Somatostatin receptor type 1 (SSTR1)
DMFXKRO	MT	DTT
DMFXKRO	MA	Inhibitor
DMFXKRO	RN	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
DMFXKRO	RU	https://pubmed.ncbi.nlm.nih.gov/15658864

DM9EN01	DI	DM9EN01
DM9EN01	DN	Des-AA1,2,5-[D-Trp8,IAmp9,(NalphaMe)Ser13]SRIF
DM9EN01	MI	TTIND6G
DM9EN01	MN	Somatostatin receptor type 1 (SSTR1)
DM9EN01	MT	DTT
DM9EN01	MA	Inhibitor
DM9EN01	RN	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
DM9EN01	RU	https://pubmed.ncbi.nlm.nih.gov/15658864

DMB10GV	DI	DMB10GV
DMB10GV	DN	Des-AA1,2,5-[D-Trp8,IAmp9,(NalphaMe)Thr12]SRIF
DMB10GV	MI	TTIND6G
DMB10GV	MN	Somatostatin receptor type 1 (SSTR1)
DMB10GV	MT	DTT
DMB10GV	MA	Inhibitor
DMB10GV	RN	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
DMB10GV	RU	https://pubmed.ncbi.nlm.nih.gov/15658864

DMH0DLZ	DI	DMH0DLZ
DMH0DLZ	DN	Des-AA1,2,5-[D-Trp8,IAmp9,m-I-Tyr11]Cbm-SRIF
DMH0DLZ	MI	TTIND6G
DMH0DLZ	MN	Somatostatin receptor type 1 (SSTR1)
DMH0DLZ	MT	DTT
DMH0DLZ	MA	Inhibitor
DMH0DLZ	RN	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
DMH0DLZ	RU	https://pubmed.ncbi.nlm.nih.gov/15658864

DMH0DLZ	DI	DMH0DLZ
DMH0DLZ	DN	Des-AA1,2,5-[D-Trp8,IAmp9,m-I-Tyr11]Cbm-SRIF
DMH0DLZ	MI	TTJX3UE
DMH0DLZ	MN	Somatostatin receptor type 3 (SSTR3)
DMH0DLZ	MT	DTT
DMH0DLZ	MA	Inhibitor
DMH0DLZ	RN	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
DMH0DLZ	RU	https://pubmed.ncbi.nlm.nih.gov/15658864

DMXWF2Z	DI	DMXWF2Z
DMXWF2Z	DN	Des-AA1,2,5-[D-Trp8,IAmp9,Tyr11]Cbm-SRIF
DMXWF2Z	MI	TTIND6G
DMXWF2Z	MN	Somatostatin receptor type 1 (SSTR1)
DMXWF2Z	MT	DTT
DMXWF2Z	MA	Inhibitor
DMXWF2Z	RN	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
DMXWF2Z	RU	https://pubmed.ncbi.nlm.nih.gov/15658864

DMSXILZ	DI	DMSXILZ
DMSXILZ	DN	Des-AA1,2,5-[D-Trp8,IAmp9]SRIF CH-275
DMSXILZ	MI	TTIND6G
DMSXILZ	MN	Somatostatin receptor type 1 (SSTR1)
DMSXILZ	MT	DTT
DMSXILZ	MA	Inhibitor
DMSXILZ	RN	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
DMSXILZ	RU	https://pubmed.ncbi.nlm.nih.gov/15658864

DMSXILZ	DI	DMSXILZ
DMSXILZ	DN	Des-AA1,2,5-[D-Trp8,IAmp9]SRIF CH-275
DMSXILZ	MI	TTJX3UE
DMSXILZ	MN	Somatostatin receptor type 3 (SSTR3)
DMSXILZ	MT	DTT
DMSXILZ	MA	Inhibitor
DMSXILZ	RN	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
DMSXILZ	RU	https://pubmed.ncbi.nlm.nih.gov/15658864

DM7MZ2V	DI	DM7MZ2V
DM7MZ2V	DN	Des-AA1,2,5-[D-Trp8,Tyr11]SRIF
DM7MZ2V	MI	TTIND6G
DM7MZ2V	MN	Somatostatin receptor type 1 (SSTR1)
DM7MZ2V	MT	DTT
DM7MZ2V	MA	Inhibitor
DM7MZ2V	RN	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
DM7MZ2V	RU	https://pubmed.ncbi.nlm.nih.gov/15658864

DM7MZ2V	DI	DM7MZ2V
DM7MZ2V	DN	Des-AA1,2,5-[D-Trp8,Tyr11]SRIF
DM7MZ2V	MI	TTZ6T9E
DM7MZ2V	MN	Somatostatin receptor type 2 (SSTR2)
DM7MZ2V	MT	DTT
DM7MZ2V	MA	Inhibitor
DM7MZ2V	RN	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
DM7MZ2V	RU	https://pubmed.ncbi.nlm.nih.gov/15658864

DM7MZ2V	DI	DM7MZ2V
DM7MZ2V	DN	Des-AA1,2,5-[D-Trp8,Tyr11]SRIF
DM7MZ2V	MI	TTJX3UE
DM7MZ2V	MN	Somatostatin receptor type 3 (SSTR3)
DM7MZ2V	MT	DTT
DM7MZ2V	MA	Inhibitor
DM7MZ2V	RN	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
DM7MZ2V	RU	https://pubmed.ncbi.nlm.nih.gov/15658864

DM7MZ2V	DI	DM7MZ2V
DM7MZ2V	DN	Des-AA1,2,5-[D-Trp8,Tyr11]SRIF
DM7MZ2V	MI	TTAE1BR
DM7MZ2V	MN	Somatostatin receptor type 4 (SSTR4)
DM7MZ2V	MT	DTT
DM7MZ2V	MA	Inhibitor
DM7MZ2V	RN	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
DM7MZ2V	RU	https://pubmed.ncbi.nlm.nih.gov/15658864

DM7MZ2V	DI	DM7MZ2V
DM7MZ2V	DN	Des-AA1,2,5-[D-Trp8,Tyr11]SRIF
DM7MZ2V	MI	TT2BC4G
DM7MZ2V	MN	Somatostatin receptor type 5 (SSTR5)
DM7MZ2V	MT	DTT
DM7MZ2V	MA	Inhibitor
DM7MZ2V	RN	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
DM7MZ2V	RU	https://pubmed.ncbi.nlm.nih.gov/15658864

DMQRUF6	DI	DMQRUF6
DMQRUF6	DN	Des-AA1,2,5-[IAmp9,Tyr11]-SRIF
DMQRUF6	MI	TTIND6G
DMQRUF6	MN	Somatostatin receptor type 1 (SSTR1)
DMQRUF6	MT	DTT
DMQRUF6	MA	Inhibitor
DMQRUF6	RN	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
DMQRUF6	RU	https://pubmed.ncbi.nlm.nih.gov/15658864

DMQRUF6	DI	DMQRUF6
DMQRUF6	DN	Des-AA1,2,5-[IAmp9,Tyr11]-SRIF
DMQRUF6	MI	TTAE1BR
DMQRUF6	MN	Somatostatin receptor type 4 (SSTR4)
DMQRUF6	MT	DTT
DMQRUF6	MA	Inhibitor
DMQRUF6	RN	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
DMQRUF6	RU	https://pubmed.ncbi.nlm.nih.gov/15658864

DMPMAXI	DI	DMPMAXI
DMPMAXI	DN	Des-AA1,4,5,13-[Tyr2,D-Trp8]-SRIF
DMPMAXI	MI	TTIND6G
DMPMAXI	MN	Somatostatin receptor type 1 (SSTR1)
DMPMAXI	MT	DTT
DMPMAXI	MA	Inhibitor
DMPMAXI	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DMPMAXI	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DMPMAXI	DI	DMPMAXI
DMPMAXI	DN	Des-AA1,4,5,13-[Tyr2,D-Trp8]-SRIF
DMPMAXI	MI	TTJX3UE
DMPMAXI	MN	Somatostatin receptor type 3 (SSTR3)
DMPMAXI	MT	DTT
DMPMAXI	MA	Inhibitor
DMPMAXI	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DMPMAXI	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DMFCA05	DI	DMFCA05
DMFCA05	DN	Des-AA1,5-[Tyr2,D-Trp8,(NalphaMe)IAmp9]Cbm-SRIF
DMFCA05	MI	TTIND6G
DMFCA05	MN	Somatostatin receptor type 1 (SSTR1)
DMFCA05	MT	DTT
DMFCA05	MA	Inhibitor
DMFCA05	RN	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
DMFCA05	RU	https://pubmed.ncbi.nlm.nih.gov/15658864

DMFCA05	DI	DMFCA05
DMFCA05	DN	Des-AA1,5-[Tyr2,D-Trp8,(NalphaMe)IAmp9]Cbm-SRIF
DMFCA05	MI	TTAE1BR
DMFCA05	MN	Somatostatin receptor type 4 (SSTR4)
DMFCA05	MT	DTT
DMFCA05	MA	Inhibitor
DMFCA05	RN	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
DMFCA05	RU	https://pubmed.ncbi.nlm.nih.gov/15658864

DMW56NI	DI	DMW56NI
DMW56NI	DN	Des-AA1,5-[Tyr2,D-Trp8,(NalphaMe)IAmp9]SRIF
DMW56NI	MI	TTIND6G
DMW56NI	MN	Somatostatin receptor type 1 (SSTR1)
DMW56NI	MT	DTT
DMW56NI	MA	Inhibitor
DMW56NI	RN	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
DMW56NI	RU	https://pubmed.ncbi.nlm.nih.gov/15658864

DMW56NI	DI	DMW56NI
DMW56NI	DN	Des-AA1,5-[Tyr2,D-Trp8,(NalphaMe)IAmp9]SRIF
DMW56NI	MI	TTAE1BR
DMW56NI	MN	Somatostatin receptor type 4 (SSTR4)
DMW56NI	MT	DTT
DMW56NI	MA	Inhibitor
DMW56NI	RN	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
DMW56NI	RU	https://pubmed.ncbi.nlm.nih.gov/15658864

DMV8EWF	DI	DMV8EWF
DMV8EWF	DN	Des-AA1,5-[Tyr2,D-Trp8,IAmp9]Cbm-SRIF
DMV8EWF	MI	TTIND6G
DMV8EWF	MN	Somatostatin receptor type 1 (SSTR1)
DMV8EWF	MT	DTT
DMV8EWF	MA	Inhibitor
DMV8EWF	RN	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
DMV8EWF	RU	https://pubmed.ncbi.nlm.nih.gov/15658864

DMV8EWF	DI	DMV8EWF
DMV8EWF	DN	Des-AA1,5-[Tyr2,D-Trp8,IAmp9]Cbm-SRIF
DMV8EWF	MI	TTJX3UE
DMV8EWF	MN	Somatostatin receptor type 3 (SSTR3)
DMV8EWF	MT	DTT
DMV8EWF	MA	Inhibitor
DMV8EWF	RN	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
DMV8EWF	RU	https://pubmed.ncbi.nlm.nih.gov/15658864

DMLY7DC	DI	DMLY7DC
DMLY7DC	DN	Des-AA1,5-[Tyr2,D-Trp8,IAmp9]SRIF CH-288
DMLY7DC	MI	TTIND6G
DMLY7DC	MN	Somatostatin receptor type 1 (SSTR1)
DMLY7DC	MT	DTT
DMLY7DC	MA	Inhibitor
DMLY7DC	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DMLY7DC	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DMO3CFV	DI	DMO3CFV
DMO3CFV	DN	Des-AA5-[D-Trp8]SRIF
DMO3CFV	MI	TTIND6G
DMO3CFV	MN	Somatostatin receptor type 1 (SSTR1)
DMO3CFV	MT	DTT
DMO3CFV	MA	Inhibitor
DMO3CFV	RN	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
DMO3CFV	RU	https://pubmed.ncbi.nlm.nih.gov/15658864

DMO3CFV	DI	DMO3CFV
DMO3CFV	DN	Des-AA5-[D-Trp8]SRIF
DMO3CFV	MI	TTZ6T9E
DMO3CFV	MN	Somatostatin receptor type 2 (SSTR2)
DMO3CFV	MT	DTT
DMO3CFV	MA	Inhibitor
DMO3CFV	RN	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
DMO3CFV	RU	https://pubmed.ncbi.nlm.nih.gov/15658864

DMO3CFV	DI	DMO3CFV
DMO3CFV	DN	Des-AA5-[D-Trp8]SRIF
DMO3CFV	MI	TTJX3UE
DMO3CFV	MN	Somatostatin receptor type 3 (SSTR3)
DMO3CFV	MT	DTT
DMO3CFV	MA	Inhibitor
DMO3CFV	RN	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
DMO3CFV	RU	https://pubmed.ncbi.nlm.nih.gov/15658864

DMO3CFV	DI	DMO3CFV
DMO3CFV	DN	Des-AA5-[D-Trp8]SRIF
DMO3CFV	MI	TTAE1BR
DMO3CFV	MN	Somatostatin receptor type 4 (SSTR4)
DMO3CFV	MT	DTT
DMO3CFV	MA	Inhibitor
DMO3CFV	RN	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
DMO3CFV	RU	https://pubmed.ncbi.nlm.nih.gov/15658864

DMO3CFV	DI	DMO3CFV
DMO3CFV	DN	Des-AA5-[D-Trp8]SRIF
DMO3CFV	MI	TT2BC4G
DMO3CFV	MN	Somatostatin receptor type 5 (SSTR5)
DMO3CFV	MT	DTT
DMO3CFV	MA	Inhibitor
DMO3CFV	RN	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
DMO3CFV	RU	https://pubmed.ncbi.nlm.nih.gov/15658864

DMVX9I0	DI	DMVX9I0
DMVX9I0	DN	Des-Arg(9)-[Leu(8)]-BK
DMVX9I0	MI	TTG5QIA
DMVX9I0	MN	B1 bradykinin receptor (BDKRB1)
DMVX9I0	MT	DTT
DMVX9I0	MA	Antagonist
DMVX9I0	RN	Evidence for the participation of kinins in Freund's adjuvant-induced inflammatory and nociceptive responses in kinin B1 and B2 receptor knockout mice. Neuropharmacology. 2001 Dec;41(8):1006-12.
DMVX9I0	RU	https://pubmed.ncbi.nlm.nih.gov/11747905

DMVX9I0	DI	DMVX9I0
DMVX9I0	DN	Des-Arg(9)-[Leu(8)]-BK
DMVX9I0	MI	TT7EFHR
DMVX9I0	MN	Corticotropin-releasing factor receptor 1 (CRHR1)
DMVX9I0	MT	DTT
DMVX9I0	MA	Antagonist
DMVX9I0	RN	A review of drug options in age-related macular degeneration therapy and potential new agents. Expert Opin Pharmacother. 2006 Dec;7(17):2355-68.
DMVX9I0	RU	https://pubmed.ncbi.nlm.nih.gov/17109611

DMZ5Y94	DI	DMZ5Y94
DMZ5Y94	DN	Des-Arg10-Kallidin
DMZ5Y94	MI	TTG5QIA
DMZ5Y94	MN	B1 bradykinin receptor (BDKRB1)
DMZ5Y94	MT	DTT
DMZ5Y94	MA	Inhibitor
DMZ5Y94	RN	Development of an efficient and selective radioligand for bradykinin B1 receptor occupancy studies. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6045-8.
DMZ5Y94	RU	https://pubmed.ncbi.nlm.nih.gov/15546726

DMWO4EI	DI	DMWO4EI
DMWO4EI	DN	Des-Arg10-Leu9-Kallidin
DMWO4EI	MI	TTG5QIA
DMWO4EI	MN	B1 bradykinin receptor (BDKRB1)
DMWO4EI	MT	DTT
DMWO4EI	MA	Inhibitor
DMWO4EI	RN	Development of an efficient and selective radioligand for bradykinin B1 receptor occupancy studies. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6045-8.
DMWO4EI	RU	https://pubmed.ncbi.nlm.nih.gov/15546726

DMIKUBY	DI	DMIKUBY
DMIKUBY	DN	Des-bromoaplysamine-1
DMIKUBY	MI	TT9JNIC
DMIKUBY	MN	Histamine H3 receptor (H3R)
DMIKUBY	MT	DTT
DMIKUBY	MA	Inhibitor
DMIKUBY	RN	Aplysamine-1 and related analogs as histamine H3 receptor antagonists. Bioorg Med Chem Lett. 2006 Feb 15;16(4):897-900.
DMIKUBY	RU	https://pubmed.ncbi.nlm.nih.gov/16300945

DMQER8D	DI	DMQER8D
DMQER8D	DN	Deschloroflavopiridol
DMQER8D	MI	TTO0FDJ
DMQER8D	MN	Cyclin-dependent kinase 6 (CDK6)
DMQER8D	MT	DTT
DMQER8D	MA	Inhibitor
DMQER8D	RN	Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
DMQER8D	RU	https://pubmed.ncbi.nlm.nih.gov/12237154

DMQER8D	DI	DMQER8D
DMQER8D	DN	Deschloroflavopiridol
DMQER8D	MI	TT1LVF2
DMQER8D	MN	Cyclin-dependent kinase 9 (CDK9)
DMQER8D	MT	DTT
DMQER8D	MA	Binder
DMQER8D	RN	Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
DMQER8D	RU	https://pubmed.ncbi.nlm.nih.gov/12237154

DMAB9KG	DI	DMAB9KG
DMAB9KG	DN	Desclasinose Azithromycinarylalkyl Hydroxamate
DMAB9KG	MI	TT6R7JZ
DMAB9KG	MN	Histone deacetylase 1 (HDAC1)
DMAB9KG	MT	DTT
DMAB9KG	MA	Inhibitor
DMAB9KG	RN	Non-peptide macrocyclic histone deacetylase inhibitors. J Med Chem. 2009 Jan 22;52(2):456-68.
DMAB9KG	RU	https://pubmed.ncbi.nlm.nih.gov/19093884

DMAB9KG	DI	DMAB9KG
DMAB9KG	DN	Desclasinose Azithromycinarylalkyl Hydroxamate
DMAB9KG	MI	TTT6LFV
DMAB9KG	MN	Histone deacetylase 8 (HDAC8)
DMAB9KG	MT	DTT
DMAB9KG	MA	Inhibitor
DMAB9KG	RN	Non-peptide macrocyclic histone deacetylase inhibitors. J Med Chem. 2009 Jan 22;52(2):456-68.
DMAB9KG	RU	https://pubmed.ncbi.nlm.nih.gov/19093884

DM47JFS	DI	DM47JFS
DM47JFS	DN	Desethyl isoquine
DM47JFS	MI	TTVG215
DM47JFS	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DM47JFS	MT	DTT
DM47JFS	MA	Inhibitor
DM47JFS	RN	Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for ... J Med Chem. 2009 Mar 12;52(5):1408-15.
DM47JFS	RU	https://pubmed.ncbi.nlm.nih.gov/19222165

DMJK0H5	DI	DMJK0H5
DMJK0H5	DN	DesGly-NH2,d(CH2)5[D-Tyr2,Thr4,Orn8(5/6C-Flu)]VT
DMJK0H5	MI	TTSCIUP
DMJK0H5	MN	Oxytocin receptor (OTR)
DMJK0H5	MT	DTT
DMJK0H5	MA	Inhibitor
DMJK0H5	RN	Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88.
DMJK0H5	RU	https://pubmed.ncbi.nlm.nih.gov/12036367

DMJK0H5	DI	DMJK0H5
DMJK0H5	DN	DesGly-NH2,d(CH2)5[D-Tyr2,Thr4,Orn8(5/6C-Flu)]VT
DMJK0H5	MI	TT4TFGN
DMJK0H5	MN	Vasopressin V1a receptor (V1AR)
DMJK0H5	MT	DTT
DMJK0H5	MA	Inhibitor
DMJK0H5	RN	Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88.
DMJK0H5	RU	https://pubmed.ncbi.nlm.nih.gov/12036367

DMGTAZ4	DI	DMGTAZ4
DMGTAZ4	DN	Des-His1[Glu9]glucagon-NH2
DMGTAZ4	MI	TT9O6WS
DMGTAZ4	MN	Glucagon receptor (GCGR)
DMGTAZ4	MT	DTT
DMGTAZ4	MA	Inhibitor
DMGTAZ4	RN	Discovery and investigation of a novel class of thiophene-derived antagonists of the human glucagon receptor. Bioorg Med Chem Lett. 2005 Mar 1;15(5):1401-5.
DMGTAZ4	RU	https://pubmed.ncbi.nlm.nih.gov/15713396

DMB07WE	DI	DMB07WE
DMB07WE	DN	Desirudine
DMB07WE	MI	TT6L509
DMB07WE	MN	Coagulation factor IIa (F2)
DMB07WE	MT	DTT
DMB07WE	MA	Inhibitor
DMB07WE	RN	New antithrombotic drugs (excluding plasminogen activators. Arch Mal Coeur Vaiss. 2001 Nov;94(11 Suppl):1225-32.
DMB07WE	RU	https://pubmed.ncbi.nlm.nih.gov/11794963

DM58XJN	DI	DM58XJN
DM58XJN	DN	Desmethylastemizole
DM58XJN	MI	DERSX5P
DM58XJN	MN	Cytochrome P450 2J2 (CYP2J2)
DM58XJN	MT	DME
DM58XJN	MA	Metabolism
DM58XJN	RN	Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole. Drug Metab Dispos. 2002 Nov;30(11):1240-5.
DM58XJN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12386130

DM58XJN	DI	DM58XJN
DM58XJN	DN	Desmethylastemizole
DM58XJN	MI	TTQ6VDM
DM58XJN	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DM58XJN	MT	DTT
DM58XJN	MA	Blocker
DM58XJN	RN	Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole. J Cardiovasc Electrophysiol. 1999 Jun;10(6):836-43.
DM58XJN	RU	https://pubmed.ncbi.nlm.nih.gov/10376921

DMIESYM	DI	DMIESYM
DMIESYM	DN	Desmethylclomipramine
DMIESYM	MI	TTJXYQ6
DMIESYM	MN	Monoamine uptake (MA uptake)
DMIESYM	MT	DTT
DMIESYM	MA	Inhibitor
DMIESYM	RN	Do alpha2-adrenoceptors play an integral role in the antinociceptive mechanism of action of antidepressant compounds Eur J Pharmacol. 1999 Aug 6;378(2):161-8.
DMIESYM	RU	https://pubmed.ncbi.nlm.nih.gov/10478628

DMLKBNR	DI	DMLKBNR
DMLKBNR	DN	DESMETHYLOLANZAPINE
DMLKBNR	MI	TTQ6VDM
DMLKBNR	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMLKBNR	MT	DTT
DMLKBNR	MA	Inhibitor
DMLKBNR	RN	Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new ... J Med Chem. 2009 Jul 23;52(14):4266-76.
DMLKBNR	RU	https://pubmed.ncbi.nlm.nih.gov/19534531

DMV8SUM	DI	DMV8SUM
DMV8SUM	DN	Desmosterol
DMV8SUM	MI	DEAXY04
DMV8SUM	MN	Delta(24)-sterol reductase (DHCR24)
DMV8SUM	MT	DME
DMV8SUM	MA	Metabolism
DMV8SUM	RN	Alzheimer's disease: brain desmosterol levels. J Alzheimers Dis. 2013;33(3):881-8.
DMV8SUM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23042211

DMV8SUM	DI	DMV8SUM
DMV8SUM	DN	Desmosterol
DMV8SUM	MI	TTS4UGC
DMV8SUM	MN	Farnesoid X-activated receptor (FXR)
DMV8SUM	MT	DTT
DMV8SUM	MA	Agonist
DMV8SUM	RN	Identification of farnesoid X receptor beta as a novel mammalian nuclear receptor sensing lanosterol. Mol Cell Biol. 2003 Feb;23(3):864-72.
DMV8SUM	RU	https://pubmed.ncbi.nlm.nih.gov/12529392

DMV8SUM	DI	DMV8SUM
DMV8SUM	DN	Desmosterol
DMV8SUM	MI	TTECBXN
DMV8SUM	MN	Oxysterols receptor LXR-alpha (NR1H3)
DMV8SUM	MT	DTT
DMV8SUM	MA	Agonist
DMV8SUM	RN	Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands. J Biol Chem. 2006 Sep 22;281(38):27816-26.
DMV8SUM	RU	https://pubmed.ncbi.nlm.nih.gov/16857673

DMV8SUM	DI	DMV8SUM
DMV8SUM	DN	Desmosterol
DMV8SUM	MI	TTXA6PH
DMV8SUM	MN	Oxysterols receptor LXR-beta (NR1H2)
DMV8SUM	MT	DTT
DMV8SUM	MA	Agonist
DMV8SUM	RN	Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands. J Biol Chem. 2006 Sep 22;281(38):27816-26.
DMV8SUM	RU	https://pubmed.ncbi.nlm.nih.gov/16857673

DMV8SUM	DI	DMV8SUM
DMV8SUM	DN	Desmosterol
DMV8SUM	MI	DEL7GFA
DMV8SUM	MN	Sterol Delta(7)-reductase (DHCR7)
DMV8SUM	MT	DME
DMV8SUM	MA	Metabolism
DMV8SUM	RN	Inhibitors of 7-dehydrocholesterol reductase: screening of a collection of pharmacologically active compounds in Neuro2a cells. Chem Res Toxicol. 2016 May 16;29(5):892-900.
DMV8SUM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27097157

DMW740T	DI	DMW740T
DMW740T	DN	desulfated cholecystokinin-8
DMW740T	MI	TTVFO0U
DMW740T	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMW740T	MT	DTT
DMW740T	MA	Agonist
DMW740T	RN	The human brain cholecystokinin-B/gastrin receptor. Cloning and characterization. J Biol Chem. 1993 Apr 15;268(11):8164-9.
DMW740T	RU	https://pubmed.ncbi.nlm.nih.gov/7681836

DMFWDNJ	DI	DMFWDNJ
DMFWDNJ	DN	detirelix
DMFWDNJ	MI	TT8R70G
DMFWDNJ	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMFWDNJ	MT	DTT
DMFWDNJ	MA	Modulator
DMFWDNJ	RN	Inhibition of follicular development by a potent antagonistic analog of gonadotropin-releasing hormone (detirelix). J Clin Endocrinol Metab. 1991 Apr;72(4):927-33.
DMFWDNJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/2005220

DMPCRSY	DI	DMPCRSY
DMPCRSY	DN	Detrothyronine
DMPCRSY	MI	TTTSEPU
DMPCRSY	MN	Thyroid hormone receptor alpha (THRA)
DMPCRSY	MT	DTT
DMPCRSY	MA	Inhibitor
DMPCRSY	RN	Thyroid receptor ligands. Part 5: novel bicyclic agonist ligands selective for the thyroid hormone receptor beta. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1240-4.
DMPCRSY	RU	https://pubmed.ncbi.nlm.nih.gov/16338239

DMPCRSY	DI	DMPCRSY
DMPCRSY	DN	Detrothyronine
DMPCRSY	MI	TTGER3L
DMPCRSY	MN	Thyroid hormone receptor beta (THRB)
DMPCRSY	MT	DTT
DMPCRSY	MA	Inhibitor
DMPCRSY	RN	Thyroid receptor ligands. Part 5: novel bicyclic agonist ligands selective for the thyroid hormone receptor beta. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1240-4.
DMPCRSY	RU	https://pubmed.ncbi.nlm.nih.gov/16338239

DMD4N2F	DI	DMD4N2F
DMD4N2F	DN	Devazepide
DMD4N2F	MI	TTCG0AL
DMD4N2F	MN	Cholecystokinin receptor type A (CCKAR)
DMD4N2F	MT	DTT
DMD4N2F	MA	Antagonist
DMD4N2F	RN	Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
DMD4N2F	RU	https://pubmed.ncbi.nlm.nih.gov/18045214

DM9P4JW	DI	DM9P4JW
DM9P4JW	DN	Dexverapamil
DM9P4JW	MI	DE4LYSA
DM9P4JW	MN	Cytochrome P450 3A4 (CYP3A4)
DM9P4JW	MT	DME
DM9P4JW	MA	Metabolism
DM9P4JW	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DM9P4JW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DMR8M19	DI	DMR8M19
DMR8M19	DN	DFGYVAE
DMR8M19	MI	TTPADOQ
DMR8M19	MN	HMG-CoA reductase (HMGCR)
DMR8M19	MT	DTT
DMR8M19	MA	Inhibitor
DMR8M19	RN	Peptide fragmentation as an approach in modeling of an active peptide and designing a competitive inhibitory peptide for HMG-CoA reductase. Bioorg Med Chem. 2010 Jun 15;18(12):4300-9.
DMR8M19	RU	https://pubmed.ncbi.nlm.nih.gov/20494585

DMNX5VI	DI	DMNX5VI
DMNX5VI	DN	D-fructose
DMNX5VI	MI	DEA2SU9
DMNX5VI	MN	D-psicose 3-epimerase (DPEase)
DMNX5VI	MT	DME
DMNX5VI	MA	Metabolism
DMNX5VI	RN	nan
DMNX5VI	RU	nan

DMUM84K	DI	DMUM84K
DMUM84K	DN	DFU
DMUM84K	MI	TTVKILB
DMUM84K	MN	Prostaglandin G/H synthase 2 (COX-2)
DMUM84K	MT	DTT
DMUM84K	MA	Inhibitor
DMUM84K	RN	Inhibition of cyclooxygenase-2 improves cardiac function in myocardial infarction. Biochem Biophys Res Commun. 2000 Jul 5;273(2):772-5.
DMUM84K	RU	https://pubmed.ncbi.nlm.nih.gov/10873679

DM527XP	DI	DM527XP
DM527XP	DN	D-Gluconhydroximo-1,5-Lactam
DM527XP	MI	TTA0OSE
DM527XP	MN	Lactase-phlorizin hydrolase (LCT)
DM527XP	MT	DTT
DM527XP	MA	Inhibitor
DM527XP	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM527XP	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMPMYTE	DI	DMPMYTE
DMPMYTE	DN	D-glucosamine-phosphate
DMPMYTE	MI	DE8451N
DMPMYTE	MN	Glucosamine-6-phosphate deaminase 1 (GNPDA1)
DMPMYTE	MT	DME
DMPMYTE	MA	Metabolism
DMPMYTE	RN	Allosteric kinetics of the isoform 1 of human glucosamine-6-phosphate deaminase. Biochim Biophys Acta. 2011 Dec;1814(12):1846-53.
DMPMYTE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21807125

DMPMYTE	DI	DMPMYTE
DMPMYTE	DN	D-glucosamine-phosphate
DMPMYTE	MI	DEPJGQB
DMPMYTE	MN	Glucosamine-6-phosphate deaminase 2 (GNPDA2)
DMPMYTE	MT	DME
DMPMYTE	MA	Metabolism
DMPMYTE	RN	Allosteric kinetics of the isoform 1 of human glucosamine-6-phosphate deaminase. Biochim Biophys Acta. 2011 Dec;1814(12):1846-53.
DMPMYTE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21807125

DMMG2TO	DI	DMMG2TO
DMMG2TO	DN	D-glucose
DMMG2TO	MI	DENZGO4
DMMG2TO	MN	ADP-dependent glucokinase (ADPGK)
DMMG2TO	MT	DME
DMMG2TO	MA	Metabolism
DMMG2TO	RN	The Structural and functional characterization of mammalian ADP-dependent glucokinase. J Biol Chem. 2016 Feb 19;291(8):3694-704.
DMMG2TO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26555263

DMMG2TO	DI	DMMG2TO
DMMG2TO	DN	D-glucose
DMMG2TO	MI	DEKU5HL
DMMG2TO	MN	Alcohol dehydrogenase (ADH)
DMMG2TO	MT	DME
DMMG2TO	MA	Metabolism
DMMG2TO	RN	1,3-Propanediol:NAD+ oxidoreductases of Lactobacillus brevis and Lactobacillus buchneri. Appl Environ Microbiol. 1992 Jun;58(6):2005-10.
DMMG2TO	RU	https://pubmed.ncbi.nlm.nih.gov/1622279

DMMG2TO	DI	DMMG2TO
DMMG2TO	DN	D-glucose
DMMG2TO	MI	DEAMSKV
DMMG2TO	MN	Alpha-glucosidase (aglA)
DMMG2TO	MT	DME
DMMG2TO	MA	Metabolism
DMMG2TO	RN	Administration of Lactobacillus paracasei ameliorates type 2 diabetes in mice. Food Funct. 2018 Jul 17;9(7):3630-3639.
DMMG2TO	RU	https://pubmed.ncbi.nlm.nih.gov/29961787

DMMG2TO	DI	DMMG2TO
DMMG2TO	DN	D-glucose
DMMG2TO	MI	DEDMAGE
DMMG2TO	MN	Brain form hexokinase (HK1)
DMMG2TO	MT	DME
DMMG2TO	MA	Metabolism
DMMG2TO	RN	Nonaggregating mutant of recombinant human hexokinase I exhibits wild-type kinetics and rod-like conformations in solution. Biochemistry. 1999 Jun 29;38(26):8359-66.
DMMG2TO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10387081

DMMG2TO	DI	DMMG2TO
DMMG2TO	DN	D-glucose
DMMG2TO	MI	DEQUGC0
DMMG2TO	MN	D-Lactate dehydrogenase (ldhA)
DMMG2TO	MT	DME
DMMG2TO	MA	Metabolism
DMMG2TO	RN	Presence of lactate dehydrogenase and lactate racemase in Megasphaera elsdenii grown on glucose or lactate. Appl Environ Microbiol. 1993 Jan;59(1):255-9.
DMMG2TO	RU	https://pubmed.ncbi.nlm.nih.gov/8439152

DMMG2TO	DI	DMMG2TO
DMMG2TO	DN	D-glucose
DMMG2TO	MI	DTG3T6X
DMMG2TO	MN	Glucose transporter type 1, erythrocyte/brain (SLC2A1)
DMMG2TO	MT	DTP
DMMG2TO	MA	Substrate
DMMG2TO	RN	The SLC2 (GLUT) family of membrane transporters. Mol Aspects Med. 2013 Apr-Jun;34(2-3):121-38.
DMMG2TO	RU	http://www.ncbi.nlm.nih.gov/pubmed/23506862

DMMG2TO	DI	DMMG2TO
DMMG2TO	DN	D-glucose
DMMG2TO	MI	DTKNH2D
DMMG2TO	MN	Sodium/glucose cotransporter 2 (SLC5A2)
DMMG2TO	MT	DTP
DMMG2TO	MA	Substrate
DMMG2TO	RN	The role of SGLT1 and GLUT2 in intestinal glucose transport and sensing. PLoS One. 2014 Feb 26;9(2):e89977.
DMMG2TO	RU	http://www.ncbi.nlm.nih.gov/pubmed/24587162

DMPW46G	DI	DMPW46G
DMPW46G	DN	D-glucose 1-phosphate
DMPW46G	MI	DEJFMQ8
DMPW46G	MN	Phosphomannomutase 1 (PMM1)
DMPW46G	MT	DME
DMPW46G	MA	Metabolism
DMPW46G	RN	The X-ray crystal structures of human alpha-phosphomannomutase 1 reveal the structural basis of congenital disorder of glycosylation type 1a. J Biol Chem. 2006 May 26;281(21):14918-26.
DMPW46G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16540464

DMPW46G	DI	DMPW46G
DMPW46G	DN	D-glucose 1-phosphate
DMPW46G	MI	DEBRX3L
DMPW46G	MN	Phosphomannomutase 2 (PMM2)
DMPW46G	MT	DME
DMPW46G	MA	Metabolism
DMPW46G	RN	The X-ray crystal structures of human alpha-phosphomannomutase 1 reveal the structural basis of congenital disorder of glycosylation type 1a. J Biol Chem. 2006 May 26;281(21):14918-26.
DMPW46G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16540464

DMPW46G	DI	DMPW46G
DMPW46G	DN	D-glucose 1-phosphate
DMPW46G	MI	DE4U39Y
DMPW46G	MN	UDP-glucose pyrophosphorylase (UGPase)
DMPW46G	MT	DME
DMPW46G	MA	Metabolism
DMPW46G	RN	The crystal structure of human UDP-glucose pyrophosphorylase reveals a latch effect that influences enzymatic activity. Biochem J. 2012 Mar 1;442(2):283-91.
DMPW46G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22132858

DMNRW57	DI	DMNRW57
DMNRW57	DN	D-glucose 6-phosphate
DMNRW57	MI	DEE1B8O
DMNRW57	MN	Glucose-6-phosphatase beta (G6PC3)
DMNRW57	MT	DME
DMNRW57	MA	Metabolism
DMNRW57	RN	Identification and characterisation of a new human glucose-6-phosphatase isoform. FEBS Lett. 2003 Sep 11;551(1-3):159-64.
DMNRW57	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12965222

DM1YBTC	DI	DM1YBTC
DM1YBTC	DN	D-glucuronate
DM1YBTC	MI	DED2FW3
DM1YBTC	MN	Aldo-keto reductase 1A1 (AKR1A1)
DM1YBTC	MT	DME
DM1YBTC	MA	Metabolism
DM1YBTC	RN	The C-terminal loop of aldehyde reductase determines the substrate and inhibitor specificity. Biochemistry. 1996 Nov 12;35(45):14276-80.
DM1YBTC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8916913

DMAYPLE	DI	DMAYPLE
DMAYPLE	DN	D-glyceraldehyde
DMAYPLE	MI	DEX9ZJQ
DMAYPLE	MN	Triokinase/FMN cyclase (TKFC)
DMAYPLE	MT	DME
DMAYPLE	MA	Metabolism
DMAYPLE	RN	Bifunctional homodimeric triokinase/FMN cyclase: contribution of protein domains to the activities of the human enzyme and molecular dynamics simulation of domain movements. J Biol Chem. 2014 Apr 11;289(15):10620-36.
DMAYPLE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24569995

DM7UVOD	DI	DM7UVOD
DM7UVOD	DN	DH97
DM7UVOD	MI	TT0WAIE
DM7UVOD	MN	Melatonin receptor type 1A (MTNR1A)
DM7UVOD	MT	DTT
DM7UVOD	MA	Antagonist
DM7UVOD	RN	Comparison of the structure-activity relationships of melatonin receptor agonists and antagonists: lengthening the N-acyl side-chain has differing effects on potency on Xenopus melanophores. Naunyn Schmiedebergs Arch Pharmacol. 1998 Nov;358(5):522-8.
DM7UVOD	RU	https://pubmed.ncbi.nlm.nih.gov/9840420

DMSN87T	DI	DMSN87T
DMSN87T	DN	Dhp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2
DMSN87T	MI	TT27RFC
DMSN87T	MN	Opioid receptor delta (OPRD1)
DMSN87T	MT	DTT
DMSN87T	MA	Inhibitor
DMSN87T	RN	Replacement of the N-terminal tyrosine residue in opioid peptides with 3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid (Dcp) results in novel opio... J Med Chem. 2006 Aug 24;49(17):5382-5.
DMSN87T	RU	https://pubmed.ncbi.nlm.nih.gov/16913729

DMSN87T	DI	DMSN87T
DMSN87T	DN	Dhp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2
DMSN87T	MI	TTQW87Y
DMSN87T	MN	Opioid receptor kappa (OPRK1)
DMSN87T	MT	DTT
DMSN87T	MA	Inhibitor
DMSN87T	RN	Replacement of the N-terminal tyrosine residue in opioid peptides with 3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid (Dcp) results in novel opio... J Med Chem. 2006 Aug 24;49(17):5382-5.
DMSN87T	RU	https://pubmed.ncbi.nlm.nih.gov/16913729

DMSN87T	DI	DMSN87T
DMSN87T	DN	Dhp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2
DMSN87T	MI	TTKWM86
DMSN87T	MN	Opioid receptor mu (MOP)
DMSN87T	MT	DTT
DMSN87T	MA	Inhibitor
DMSN87T	RN	Replacement of the N-terminal tyrosine residue in opioid peptides with 3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid (Dcp) results in novel opio... J Med Chem. 2006 Aug 24;49(17):5382-5.
DMSN87T	RU	https://pubmed.ncbi.nlm.nih.gov/16913729

DM3DR6J	DI	DM3DR6J
DM3DR6J	DN	Di(1H-indol-2-yl)methanone
DM3DR6J	MI	TTGJCWZ
DM3DR6J	MN	Fms-like tyrosine kinase 3 (FLT-3)
DM3DR6J	MT	DTT
DM3DR6J	MA	Inhibitor
DM3DR6J	RN	Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15.
DM3DR6J	RU	https://pubmed.ncbi.nlm.nih.gov/16722630

DM3DR6J	DI	DM3DR6J
DM3DR6J	DN	Di(1H-indol-2-yl)methanone
DM3DR6J	MI	TT8FYO9
DM3DR6J	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DM3DR6J	MT	DTT
DM3DR6J	MA	Inhibitor
DM3DR6J	RN	Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15.
DM3DR6J	RU	https://pubmed.ncbi.nlm.nih.gov/16722630

DM3DR6J	DI	DM3DR6J
DM3DR6J	DN	Di(1H-indol-2-yl)methanone
DM3DR6J	MI	TTI7421
DM3DR6J	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM3DR6J	MT	DTT
DM3DR6J	MA	Inhibitor
DM3DR6J	RN	Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15.
DM3DR6J	RU	https://pubmed.ncbi.nlm.nih.gov/16722630

DMG21PZ	DI	DMG21PZ
DMG21PZ	DN	Di(2,6-diisopropylphenol)
DMG21PZ	MI	TTANPDJ
DMG21PZ	MN	Carbonic anhydrase II (CA-II)
DMG21PZ	MT	DTT
DMG21PZ	MA	Inhibitor
DMG21PZ	RN	Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols. Bioorg Med Chem. 2009 Apr 15;17(8):3207-11.
DMG21PZ	RU	https://pubmed.ncbi.nlm.nih.gov/19231207

DMZ3EML	DI	DMZ3EML
DMZ3EML	DN	Di(2,6-dimethylphenol)
DMZ3EML	MI	TTANPDJ
DMZ3EML	MN	Carbonic anhydrase II (CA-II)
DMZ3EML	MT	DTT
DMZ3EML	MA	Inhibitor
DMZ3EML	RN	Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols. Bioorg Med Chem. 2009 Apr 15;17(8):3207-11.
DMZ3EML	RU	https://pubmed.ncbi.nlm.nih.gov/19231207

DMO6Z02	DI	DMO6Z02
DMO6Z02	DN	Di(2,6-di-t-butylphenol)
DMO6Z02	MI	TTANPDJ
DMO6Z02	MN	Carbonic anhydrase II (CA-II)
DMO6Z02	MT	DTT
DMO6Z02	MA	Inhibitor
DMO6Z02	RN	Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols. Bioorg Med Chem. 2009 Apr 15;17(8):3207-11.
DMO6Z02	RU	https://pubmed.ncbi.nlm.nih.gov/19231207

DMOCQ9J	DI	DMOCQ9J
DMOCQ9J	DN	Diamide
DMOCQ9J	MI	TTWC6MY
DMOCQ9J	MN	Protein tyrosine phosphatase (PTP)
DMOCQ9J	MT	DTT
DMOCQ9J	MA	Inhibitor
DMOCQ9J	RN	Induction of endothelial cell surface adhesion molecules by tumor necrosis factor is blocked by protein tyrosine phosphatase inhibitors: role of the nuclear transcription factor NF-kappa B. Eur J Immunol. 1997 Sep;27(9):2172-9.
DMOCQ9J	RU	https://pubmed.ncbi.nlm.nih.gov/9341756

DM4EX8Y	DI	DM4EX8Y
DM4EX8Y	DN	diamide 7
DM4EX8Y	MI	TT5Y4EM
DM4EX8Y	MN	N-formyl peptide receptor (FPR1)
DM4EX8Y	MT	DTT
DM4EX8Y	MA	Antagonist
DM4EX8Y	RN	Discovery of small molecule human FPR1 receptor antagonists. Bioorg Med Chem Lett. 2011 May 15;21(10):2991-7.
DM4EX8Y	RU	https://pubmed.ncbi.nlm.nih.gov/21486695

DMDGIT6	DI	DMDGIT6
DMDGIT6	DN	Diaminopropyl sulfate
DMDGIT6	MI	TT6LDTK
DMDGIT6	MN	Bacterial Glutamate-1-semialdehyde aminomutase (Bact hemL)
DMDGIT6	MT	DTT
DMDGIT6	MA	Inhibitor
DMDGIT6	RN	Reactions of glutamate 1-semialdehyde aminomutase with R- and S-enantiomers of a novel, mechanism-based inhibitor, 2,3-diaminopropyl sulfate. Biochemistry. 2000 Mar 21;39(11):3091-6.
DMDGIT6	RU	https://pubmed.ncbi.nlm.nih.gov/10715130

DM14X29	DI	DM14X29
DM14X29	DN	diarylpropionitril
DM14X29	MI	TTOM3J0
DM14X29	MN	Estrogen receptor beta (ESR2)
DM14X29	MT	DTT
DM14X29	MA	Agonist
DM14X29	RN	Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J Med Chem. 2001 Nov 22;44(24):4230-51.
DM14X29	RU	https://pubmed.ncbi.nlm.nih.gov/11708925

DM3CQV6	DI	DM3CQV6
DM3CQV6	DN	DIASTEREOMER 2
DM3CQV6	MI	TTNVEIR
DM3CQV6	MN	Prostaglandin D2 receptor (PTGDR)
DM3CQV6	MT	DTT
DM3CQV6	MA	Inhibitor
DM3CQV6	RN	Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
DM3CQV6	RU	https://pubmed.ncbi.nlm.nih.gov/17300164

DM5UFZX	DI	DM5UFZX
DM5UFZX	DN	Diazaborines
DM5UFZX	MI	TTCH81V
DM5UFZX	MN	Bacterial NADH-dependent enoyl-ACP reductase 1 (Bact fabI1)
DM5UFZX	MT	DTT
DM5UFZX	MA	Inhibitor
DM5UFZX	RN	Lipid biosynthesis as a target for antibacterial agents. Prog Lipid Res. 2001 Nov;40(6):467-97.
DM5UFZX	RU	https://pubmed.ncbi.nlm.nih.gov/11591436

DM5UFZX	DI	DM5UFZX
DM5UFZX	DN	Diazaborines
DM5UFZX	MI	TT283NK
DM5UFZX	MN	Bacterial NADH-dependent enoyl-ACP reductase 2 (Bact fabI2)
DM5UFZX	MT	DTT
DM5UFZX	MA	Inhibitor
DM5UFZX	RN	Lipid biosynthesis as a target for antibacterial agents. Prog Lipid Res. 2001 Nov;40(6):467-97.
DM5UFZX	RU	https://pubmed.ncbi.nlm.nih.gov/11591436

DM5UFZX	DI	DM5UFZX
DM5UFZX	DN	Diazaborines
DM5UFZX	MI	TTNSXG2
DM5UFZX	MN	Human immunodeficiency virus TAR RNA (HIV TAR-RNA)
DM5UFZX	MT	DTT
DM5UFZX	MA	Inhibitor
DM5UFZX	RN	Neomycin B-arginine conjugate, a novel HIV-1 Tat antagonist: synthesis and anti-HIV activities. Biochemistry. 2001 Dec 25;40(51):15612-23.
DM5UFZX	RU	https://pubmed.ncbi.nlm.nih.gov/11747436

DM5UFZX	DI	DM5UFZX
DM5UFZX	DN	Diazaborines
DM5UFZX	MI	TTNX2CS
DM5UFZX	MN	Plasmodium Enoyl-ACP reductase (Malaria fabI)
DM5UFZX	MT	DTT
DM5UFZX	MA	Inhibitor
DM5UFZX	RN	Lipid biosynthesis as a target for antibacterial agents. Prog Lipid Res. 2001 Nov;40(6):467-97.
DM5UFZX	RU	https://pubmed.ncbi.nlm.nih.gov/11591436

DM5DPM4	DI	DM5DPM4
DM5DPM4	DN	Diazacholesterol
DM5DPM4	MI	TTTK0NH
DM5DPM4	MN	Delta(24)-sterol reductase (DHCR24)
DM5DPM4	MT	DTT
DM5DPM4	MA	Inhibitor
DM5DPM4	RN	Antilipemic drug-induced skin manifestations. Hautarzt. 1995 Feb;46(2):76-80.
DM5DPM4	RU	https://pubmed.ncbi.nlm.nih.gov/7706076

DM9KPHZ	DI	DM9KPHZ
DM9KPHZ	DN	diBA-(5)-C4
DM9KPHZ	MI	TT0FC1V
DM9KPHZ	MN	Volume regulated chloride channel (VRAC)
DM9KPHZ	MT	DTT
DM9KPHZ	MA	Blocker (channel blocker)
DM9KPHZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 710).
DM9KPHZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=710

DMOKNXE	DI	DMOKNXE
DMOKNXE	DN	Dibenzo-p-dioxin-2-carboxylic acid
DMOKNXE	MI	TTGTQHC
DMOKNXE	MN	DNA topoisomerase I (TOP1)
DMOKNXE	MT	DTT
DMOKNXE	MA	Binder
DMOKNXE	RN	Comparison of responses of DNA topoisomerase I from Candida albicans and human cells to four new agents which stimulate topoisomerase-dependent DNA nicking. FEMS Microbiol Lett. 1996 May 1;138(2-3):105-11.
DMOKNXE	RU	https://pubmed.ncbi.nlm.nih.gov/9026436

DMEDKA3	DI	DMEDKA3
DMEDKA3	DN	Dibenzothiazepines
DMEDKA3	MI	TT6OEDT
DMEDKA3	MN	Cannabinoid receptor 1 (CB1)
DMEDKA3	MT	DTT
DMEDKA3	MA	Agonist
DMEDKA3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 56).
DMEDKA3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=56

DMD8TWC	DI	DMD8TWC
DMD8TWC	DN	dibenzoxazepine
DMD8TWC	MI	TTELV3W
DMD8TWC	MN	Transformation-sensitive protein p120 (TRPA1)
DMD8TWC	MT	DTT
DMD8TWC	MA	Activator
DMD8TWC	RN	Tear gasses CN, CR, and CS are potent activators of the human TRPA1 receptor. Toxicol Appl Pharmacol. 2008 Sep 1;231(2):150-6.
DMD8TWC	RU	https://pubmed.ncbi.nlm.nih.gov/18501939

DMAYSGI	DI	DMAYSGI
DMAYSGI	DN	Di-Benzyloxycarbonyl-guanidino acetylryanodine
DMAYSGI	MI	TTU5CIX
DMAYSGI	MN	Ryanodine receptor 1 (RYR1)
DMAYSGI	MT	DTT
DMAYSGI	MA	Inhibitor
DMAYSGI	RN	Amino- and guanidinoacylryanodines: basic ryanodine esters with enhanced affinity for the sarcoplasmic reticulum Ca(2+)-release channel. J Med Chem. 1993 May 14;36(10):1319-23.
DMAYSGI	RU	https://pubmed.ncbi.nlm.nih.gov/8388466

DM2G8ON	DI	DM2G8ON
DM2G8ON	DN	Dibutyl 2,2,2-trifluoro-1-phenylethyl phosphate
DM2G8ON	MI	TTMF541
DM2G8ON	MN	Liver carboxylesterase (CES1)
DM2G8ON	MT	DTT
DM2G8ON	MA	Inhibitor
DM2G8ON	RN	Synthesis of organophosphates with fluorine-containing leaving groups as serine esterase inhibitors with potential for Alzheimer disease therapeutics. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5528-30.
DM2G8ON	RU	https://pubmed.ncbi.nlm.nih.gov/19717305

DMEDGKO	DI	DMEDGKO
DMEDGKO	DN	Dibutyl phthalate
DMEDGKO	MI	DE9QHP6
DMEDGKO	MN	Cytochrome P450 1B1 (CYP1B1)
DMEDGKO	MT	DME
DMEDGKO	MA	Metabolism
DMEDGKO	RN	Inhibition of human cytochrome p450 1b1 further clarifies its role in the activation of dibenzo[a,l]pyrene in cells in culture. J Biochem Mol Toxicol. 2007;21(3):101-9.
DMEDGKO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17623886

DMEDGKO	DI	DMEDGKO
DMEDGKO	DN	Dibutyl phthalate
DMEDGKO	MI	TTELV3W
DMEDGKO	MN	Transformation-sensitive protein p120 (TRPA1)
DMEDGKO	MT	DTT
DMEDGKO	MA	Activator
DMEDGKO	RN	TRPA1 and TRPV1 activation is a novel adjuvant effect mechanism in contact hypersensitivity. J Neuroimmunol. 2009 Feb 15;207(1-2):66-74.
DMEDGKO	RU	https://pubmed.ncbi.nlm.nih.gov/19135264

DM4I5Z3	DI	DM4I5Z3
DM4I5Z3	DN	Dicaffeoylquinic acids
DM4I5Z3	MI	TT5FH9Y
DM4I5Z3	MN	Human immunodeficiency virus Integrase (HIV IN)
DM4I5Z3	MT	DTT
DM4I5Z3	MA	Inhibitor
DM4I5Z3	RN	Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase. Antimicrob Agents Chemother. 1998 Jan;42(1):140-6.
DM4I5Z3	RU	https://pubmed.ncbi.nlm.nih.gov/9449274

DMAV0BX	DI	DMAV0BX
DMAV0BX	DN	Dicaffeoyltartaric acids
DMAV0BX	MI	TT5FH9Y
DMAV0BX	MN	Human immunodeficiency virus Integrase (HIV IN)
DMAV0BX	MT	DTT
DMAV0BX	MA	Inhibitor
DMAV0BX	RN	Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase. Antimicrob Agents Chemother. 1998 Jan;42(1):140-6.
DMAV0BX	RU	https://pubmed.ncbi.nlm.nih.gov/9449274

DML3HEM	DI	DML3HEM
DML3HEM	DN	Dicarboxylate
DML3HEM	MI	DTUO05P
DML3HEM	MN	Sodium/dicarboxylate cotransporter 1 (SLC13A2)
DML3HEM	MT	DTP
DML3HEM	MA	Substrate
DML3HEM	RN	Evidence for epistatic interaction between VDR and SLC13A2 genes in the pathogenesis of hypocitraturia in recurrent calcium oxalate stone formers. J Nephrol. 2017 Jun;30(3):411-418.
DML3HEM	RU	http://www.ncbi.nlm.nih.gov/pubmed/27639591

DML3HEM	DI	DML3HEM
DML3HEM	DN	Dicarboxylate
DML3HEM	MI	DTKXTPW
DML3HEM	MN	Sodium/dicarboxylate cotransporter 3 (SLC13A3)
DML3HEM	MT	DTP
DML3HEM	MA	Substrate
DML3HEM	RN	SLC13A3 variants cause acute reversible leukoencephalopathy and -ketoglutarate accumulation. Ann Neurol. 2019 Mar;85(3):385-395.
DML3HEM	RU	http://www.ncbi.nlm.nih.gov/pubmed/30635937

DMXGV63	DI	DMXGV63
DMXGV63	DN	Dichloroallyl lawsone
DMXGV63	MI	TT3PQ2Y
DMXGV63	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DMXGV63	MT	DTT
DMXGV63	MA	Inhibitor
DMXGV63	RN	Malarial dihydroorotate dehydrogenase. Substrate and inhibitor specificity. J Biol Chem. 2002 Nov 1;277(44):41827-34.
DMXGV63	RU	https://pubmed.ncbi.nlm.nih.gov/12189151

DMAU5VM	DI	DMAU5VM
DMAU5VM	DN	Dichloroally-lawsone
DMAU5VM	MI	TT3PQ2Y
DMAU5VM	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DMAU5VM	MT	DTT
DMAU5VM	MA	Inhibitor
DMAU5VM	RN	Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Chem Biol Interact. 2000 Jan 3;124(1):61-76.
DMAU5VM	RU	https://pubmed.ncbi.nlm.nih.gov/10658902

DMAEI51	DI	DMAEI51
DMAEI51	DN	Dichloroindophenol
DMAEI51	MI	DE6NIY9
DMAEI51	MN	Methionine synthase reductase (MTRR)
DMAEI51	MT	DME
DMAEI51	MA	Metabolism
DMAEI51	RN	Differences in the efficiency of reductive activation of methionine synthase and exogenous electron acceptors between the common polymorphic variants of human methionine synthase reductase. Biochemistry. 2002 Nov 12;41(45):13378-85.
DMAEI51	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12416982

DMSZ7UE	DI	DMSZ7UE
DMSZ7UE	DN	Dichloroisoproterenol
DMSZ7UE	MI	TTR6W5O
DMSZ7UE	MN	Adrenergic receptor beta-1 (ADRB1)
DMSZ7UE	MT	DTT
DMSZ7UE	MA	Inhibitor
DMSZ7UE	RN	The [(methyloxy)imino]methyl moiety as a bioisoster of aryl. A novel class of completely aliphatic beta-adrenergic receptor antagonists. J Med Chem. 1994 May 13;37(10):1518-25.
DMSZ7UE	RU	https://pubmed.ncbi.nlm.nih.gov/7910217

DMSZ7UE	DI	DMSZ7UE
DMSZ7UE	DN	Dichloroisoproterenol
DMSZ7UE	MI	TT2CJVK
DMSZ7UE	MN	Adrenergic receptor beta-2 (ADRB2)
DMSZ7UE	MT	DTT
DMSZ7UE	MA	Inhibitor
DMSZ7UE	RN	The [(methyloxy)imino]methyl moiety as a bioisoster of aryl. A novel class of completely aliphatic beta-adrenergic receptor antagonists. J Med Chem. 1994 May 13;37(10):1518-25.
DMSZ7UE	RU	https://pubmed.ncbi.nlm.nih.gov/7910217

DMWADLM	DI	DMWADLM
DMWADLM	DN	Diclofenac glucuronide
DMWADLM	MI	DE9EXRN
DMWADLM	MN	Beta-glucuronidase (uidA)
DMWADLM	MT	DME
DMWADLM	MA	Metabolism
DMWADLM	RN	tructure, function, and inhibition of drug reactivating human gut microbial beta-glucuronidases. Sci Rep. 2019 Jan 29;9(1):825.
DMWADLM	RU	https://pubmed.ncbi.nlm.nih.gov/30696850

DMWADLM	DI	DMWADLM
DMWADLM	DN	Diclofenac glucuronide
DMWADLM	MI	DE7Y39R
DMWADLM	MN	Beta-glucuronidase (uidA)
DMWADLM	MT	DME
DMWADLM	MA	Metabolism
DMWADLM	RN	tructure, function, and inhibition of drug reactivating human gut microbial beta-glucuronidases. Sci Rep. 2019 Jan 29;9(1):825.
DMWADLM	RU	https://pubmed.ncbi.nlm.nih.gov/30696850

DMWADLM	DI	DMWADLM
DMWADLM	DN	Diclofenac glucuronide
DMWADLM	MI	DECW8T2
DMWADLM	MN	Beta-glucuronidase (uidA)
DMWADLM	MT	DME
DMWADLM	MA	Metabolism
DMWADLM	RN	tructure, function, and inhibition of drug reactivating human gut microbial beta-glucuronidases. Sci Rep. 2019 Jan 29;9(1):825.
DMWADLM	RU	https://pubmed.ncbi.nlm.nih.gov/30696850

DMWADLM	DI	DMWADLM
DMWADLM	DN	Diclofenac glucuronide
DMWADLM	MI	DEB8PZ0
DMWADLM	MN	Beta-glucuronidase (uidA)
DMWADLM	MT	DME
DMWADLM	MA	Metabolism
DMWADLM	RN	tructure, function, and inhibition of drug reactivating human gut microbial beta-glucuronidases. Sci Rep. 2019 Jan 29;9(1):825.
DMWADLM	RU	https://pubmed.ncbi.nlm.nih.gov/30696850

DMO3KU5	DI	DMO3KU5
DMO3KU5	DN	Diclosan
DMO3KU5	MI	TTVTX4N
DMO3KU5	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DMO3KU5	MT	DTT
DMO3KU5	MA	Inhibitor
DMO3KU5	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMO3KU5	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9WU3R	DI	DM9WU3R
DM9WU3R	DN	Dideazaacyclotetrahydrofolic acid
DM9WU3R	MI	TTEXB9Z
DM9WU3R	MN	Glycinamide ribonucleotide formyltransferase (GART)
DM9WU3R	MT	DTT
DM9WU3R	MA	Inhibitor
DM9WU3R	RN	Asymmetric synthesis of inhibitors of glycinamide ribonucleotide transformylase. J Med Chem. 2008 Sep 11;51(17):5441-8.
DM9WU3R	RU	https://pubmed.ncbi.nlm.nih.gov/18686942

DMAIOC9	DI	DMAIOC9
DMAIOC9	DN	Dideazafolate
DMAIOC9	MI	TTEXB9Z
DMAIOC9	MN	Glycinamide ribonucleotide formyltransferase (GART)
DMAIOC9	MT	DTT
DMAIOC9	MA	Inhibitor
DMAIOC9	RN	N10-substituted 5,8-dideazafolate inhibitors of glycinamide ribonucleotide transformylase. J Med Chem. 1987 Jul;30(7):1254-6.
DMAIOC9	RU	https://pubmed.ncbi.nlm.nih.gov/3599031

DM2FLRQ	DI	DM2FLRQ
DM2FLRQ	DN	DIDODECANOYLPHLOROGLUCINOL
DM2FLRQ	MI	TTO8QRU
DM2FLRQ	MN	Group IIA phospholipase A2 (GIIA sPLA2)
DM2FLRQ	MT	DTT
DM2FLRQ	MA	Inhibitor
DM2FLRQ	RN	Simplified YM-26734 inhibitors of secreted phospholipase A2 group IIA. Bioorg Med Chem Lett. 2008 Oct 15;18(20):5415-9.
DM2FLRQ	RU	https://pubmed.ncbi.nlm.nih.gov/18818074

DMKSQUB	DI	DMKSQUB
DMKSQUB	DN	DIDS
DMKSQUB	MI	TTOJI4S
DMKSQUB	MN	Calcium-dependent chloride channel anoctamin (ANO)
DMKSQUB	MT	DTT
DMKSQUB	MA	Blocker (channel blocker)
DMKSQUB	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 708).
DMKSQUB	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=708

DMKSQUB	DI	DMKSQUB
DMKSQUB	DN	DIDS
DMKSQUB	MI	TTCJRDO
DMKSQUB	MN	Chloride channel protein 6 (ClC-6)
DMKSQUB	MT	DTT
DMKSQUB	MA	Blocker (channel blocker)
DMKSQUB	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 705).
DMKSQUB	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=705

DMKSQUB	DI	DMKSQUB
DMKSQUB	DN	DIDS
DMKSQUB	MI	TTST1AJ
DMKSQUB	MN	Chloride channel protein 7 (ClC-7)
DMKSQUB	MT	DTT
DMKSQUB	MA	Blocker (channel blocker)
DMKSQUB	RN	The G215R mutation in the Cl-/H+-antiporter ClC-7 found in ADO II osteopetrosis does not abolish function but causes a severe trafficking defect. PLoS One. 2010 Sep 7;5(9):e12585.
DMKSQUB	RU	https://pubmed.ncbi.nlm.nih.gov/20830208

DMKSQUB	DI	DMKSQUB
DMKSQUB	DN	DIDS
DMKSQUB	MI	TT823N1
DMKSQUB	MN	Chloride channel protein ClC-Ka (ClC-K1)
DMKSQUB	MT	DTT
DMKSQUB	MA	Blocker (channel blocker)
DMKSQUB	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 700).
DMKSQUB	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=700

DMKSQUB	DI	DMKSQUB
DMKSQUB	DN	DIDS
DMKSQUB	MI	TTR68GQ
DMKSQUB	MN	Chloride channel protein ClC-Kb (ClC-K2)
DMKSQUB	MT	DTT
DMKSQUB	MA	Blocker (channel blocker)
DMKSQUB	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 701).
DMKSQUB	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=701

DMKSQUB	DI	DMKSQUB
DMKSQUB	DN	DIDS
DMKSQUB	MI	TT0FC1V
DMKSQUB	MN	Volume regulated chloride channel (VRAC)
DMKSQUB	MT	DTT
DMKSQUB	MA	Blocker (channel blocker)
DMKSQUB	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 710).
DMKSQUB	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=710

DMBCK4G	DI	DMBCK4G
DMBCK4G	DN	DIECKOL
DMBCK4G	MI	TT8JRS7
DMBCK4G	MN	Beta-secretase (BACE)
DMBCK4G	MT	DTT
DMBCK4G	MA	Inhibitor
DMBCK4G	RN	Molecular docking studies of phlorotannins from Eisenia bicyclis with BACE1 inhibitory activity. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3211-5.
DMBCK4G	RU	https://pubmed.ncbi.nlm.nih.gov/20462757

DMK7QXA	DI	DMK7QXA
DMK7QXA	DN	DIETHOXYFLOURESCEIN
DMK7QXA	MI	TTXV4FI
DMK7QXA	MN	Albendazole monooxygenase (CYP3A4)
DMK7QXA	MT	DTT
DMK7QXA	MA	Inhibitor
DMK7QXA	RN	Exploration of the amine terminus in a novel series of 1,2,4-triazolo-3-yl-azabicyclo[3.1.0]hexanes as selective dopamine D3 receptor antagonists. J Med Chem. 2010 Oct 14;53(19):7129-39.
DMK7QXA	RU	https://pubmed.ncbi.nlm.nih.gov/20839775

DM7YHBR	DI	DM7YHBR
DM7YHBR	DN	Diethyl 2-((biphenyl-3-ylamino)methylene)malonate
DM7YHBR	MI	TT3PQ2Y
DM7YHBR	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DM7YHBR	MT	DTT
DM7YHBR	MA	Inhibitor
DM7YHBR	RN	Design and synthesis of potent inhibitors of the malaria parasite dihydroorotate dehydrogenase. J Med Chem. 2007 Jan 25;50(2):186-91.
DM7YHBR	RU	https://pubmed.ncbi.nlm.nih.gov/17228860

DMDJ9QA	DI	DMDJ9QA
DMDJ9QA	DN	Diethyl 2,2,2-trifluoro-1-phenylethyl phosphate
DMDJ9QA	MI	TTMF541
DMDJ9QA	MN	Liver carboxylesterase (CES1)
DMDJ9QA	MT	DTT
DMDJ9QA	MA	Inhibitor
DMDJ9QA	RN	Synthesis of organophosphates with fluorine-containing leaving groups as serine esterase inhibitors with potential for Alzheimer disease therapeutics. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5528-30.
DMDJ9QA	RU	https://pubmed.ncbi.nlm.nih.gov/19717305

DMM4QFL	DI	DMM4QFL
DMM4QFL	DN	Diethylphosphono Group
DMM4QFL	MI	TTEB0GD
DMM4QFL	MN	Cholinesterase (BCHE)
DMM4QFL	MT	DTT
DMM4QFL	MA	Inhibitor
DMM4QFL	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMM4QFL	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM8AZQ3	DI	DM8AZQ3
DM8AZQ3	DN	difluoroagomelatine
DM8AZQ3	MI	TT0WAIE
DM8AZQ3	MN	Melatonin receptor type 1A (MTNR1A)
DM8AZQ3	MT	DTT
DM8AZQ3	MA	Agonist
DM8AZQ3	RN	Design, synthesis and pharmacological evaluation of new series of naphthalenic analogues as melatoninergic (MT1/MT2) and serotoninergic 5-HT2C dual ligands (I). Eur J Med Chem. 2012 Mar;49:310-23.
DM8AZQ3	RU	https://pubmed.ncbi.nlm.nih.gov/22301214

DM8ABD6	DI	DM8ABD6
DM8ABD6	DN	Difluorobenztropine
DM8ABD6	MI	TTVBI8W
DM8ABD6	MN	Dopamine transporter (DAT)
DM8ABD6	MT	DTT
DM8ABD6	MA	Inhibitor
DM8ABD6	RN	Structure-activity relationship studies on a novel series of (S)-2beta-substituted 3alpha-[bis(4-fluoro- or 4-chlorophenyl)methoxy]tropane analogue... J Med Chem. 2006 Oct 19;49(21):6391-9.
DM8ABD6	RU	https://pubmed.ncbi.nlm.nih.gov/17034144

DM8ABD6	DI	DM8ABD6
DM8ABD6	DN	Difluorobenztropine
DM8ABD6	MI	TTZ9SOR
DM8ABD6	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DM8ABD6	MT	DTT
DM8ABD6	MA	Inhibitor
DM8ABD6	RN	Structure-activity relationship studies on a novel series of (S)-2beta-substituted 3alpha-[bis(4-fluoro- or 4-chlorophenyl)methoxy]tropane analogue... J Med Chem. 2006 Oct 19;49(21):6391-9.
DM8ABD6	RU	https://pubmed.ncbi.nlm.nih.gov/17034144

DM8ABD6	DI	DM8ABD6
DM8ABD6	DN	Difluorobenztropine
DM8ABD6	MI	TTAWNKZ
DM8ABD6	MN	Norepinephrine transporter (NET)
DM8ABD6	MT	DTT
DM8ABD6	MA	Inhibitor
DM8ABD6	RN	Structure-activity relationship studies on a novel series of (S)-2beta-substituted 3alpha-[bis(4-fluoro- or 4-chlorophenyl)methoxy]tropane analogue... J Med Chem. 2006 Oct 19;49(21):6391-9.
DM8ABD6	RU	https://pubmed.ncbi.nlm.nih.gov/17034144

DM8ABD6	DI	DM8ABD6
DM8ABD6	DN	Difluorobenztropine
DM8ABD6	MI	TT3ROYC
DM8ABD6	MN	Serotonin transporter (SERT)
DM8ABD6	MT	DTT
DM8ABD6	MA	Inhibitor
DM8ABD6	RN	Structure-activity relationship studies on a novel series of (S)-2beta-substituted 3alpha-[bis(4-fluoro- or 4-chlorophenyl)methoxy]tropane analogue... J Med Chem. 2006 Oct 19;49(21):6391-9.
DM8ABD6	RU	https://pubmed.ncbi.nlm.nih.gov/17034144

DM8TG41	DI	DM8TG41
DM8TG41	DN	Difluoromethionine
DM8TG41	MI	TTOJ46K
DM8TG41	MN	Streptococcus Methionyl-tRNA synthetase (Stre-coc metG)
DM8TG41	MT	DTT
DM8TG41	MA	Inhibitor
DM8TG41	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM8TG41	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMXK8BH	DI	DMXK8BH
DMXK8BH	DN	digeranyl bisphosphonate
DMXK8BH	MI	TTIKWV4
DMXK8BH	MN	Geranyltranstransferase (FDPS)
DMXK8BH	MT	DTT
DMXK8BH	MA	Inhibitor
DMXK8BH	RN	Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation. J Med Chem. 2008 Sep 25;51(18):5594-607.
DMXK8BH	RU	https://pubmed.ncbi.nlm.nih.gov/18800762

DM5AOFW	DI	DM5AOFW
DM5AOFW	DN	Digitoxigenin
DM5AOFW	MI	TTWK8D0
DM5AOFW	MN	Sodium pump subunit alpha-1 (ATP1A1)
DM5AOFW	MT	DTT
DM5AOFW	MA	Inhibitor
DM5AOFW	RN	17beta-O-Aminoalkyloximes of 5beta-androstane-3beta,14beta-diol with digitalis-like activity: synthesis, cardiotonic activity, structure-activity r... J Med Chem. 2000 Jun 15;43(12):2332-49.
DM5AOFW	RU	https://pubmed.ncbi.nlm.nih.gov/10882359

DMBAY7P	DI	DMBAY7P
DMBAY7P	DN	Diheptan-3-yl 5-(hydroxymethyl)isophthalate
DMBAY7P	MI	TT7A1BO
DMBAY7P	MN	PKC-delta messenger RNA (PRKCD mRNA)
DMBAY7P	MT	DTT
DMBAY7P	MA	Inhibitor
DMBAY7P	RN	Design, synthesis, and biological activity of isophthalic acid derivatives targeted to the C1 domain of protein kinase C. J Med Chem. 2009 Jul 9;52(13):3969-81.
DMBAY7P	RU	https://pubmed.ncbi.nlm.nih.gov/19438240

DMBAY7P	DI	DMBAY7P
DMBAY7P	DN	Diheptan-3-yl 5-(hydroxymethyl)isophthalate
DMBAY7P	MI	TTFJ8Q1
DMBAY7P	MN	Protein kinase C alpha (PRKCA)
DMBAY7P	MT	DTT
DMBAY7P	MA	Inhibitor
DMBAY7P	RN	Design, synthesis, and biological activity of isophthalic acid derivatives targeted to the C1 domain of protein kinase C. J Med Chem. 2009 Jul 9;52(13):3969-81.
DMBAY7P	RU	https://pubmed.ncbi.nlm.nih.gov/19438240

DM8TBQ9	DI	DM8TBQ9
DM8TBQ9	DN	Dihexan-3-yl 5-(hydroxymethyl)isophthalate
DM8TBQ9	MI	TT7A1BO
DM8TBQ9	MN	PKC-delta messenger RNA (PRKCD mRNA)
DM8TBQ9	MT	DTT
DM8TBQ9	MA	Inhibitor
DM8TBQ9	RN	Design, synthesis, and biological activity of isophthalic acid derivatives targeted to the C1 domain of protein kinase C. J Med Chem. 2009 Jul 9;52(13):3969-81.
DM8TBQ9	RU	https://pubmed.ncbi.nlm.nih.gov/19438240

DM8TBQ9	DI	DM8TBQ9
DM8TBQ9	DN	Dihexan-3-yl 5-(hydroxymethyl)isophthalate
DM8TBQ9	MI	TTFJ8Q1
DM8TBQ9	MN	Protein kinase C alpha (PRKCA)
DM8TBQ9	MT	DTT
DM8TBQ9	MA	Inhibitor
DM8TBQ9	RN	Design, synthesis, and biological activity of isophthalic acid derivatives targeted to the C1 domain of protein kinase C. J Med Chem. 2009 Jul 9;52(13):3969-81.
DM8TBQ9	RU	https://pubmed.ncbi.nlm.nih.gov/19438240

DMW1ALX	DI	DMW1ALX
DMW1ALX	DN	DIHYDROAKUAMMINE
DMW1ALX	MI	TTKWM86
DMW1ALX	MN	Opioid receptor mu (MOP)
DMW1ALX	MT	DTT
DMW1ALX	MA	Inhibitor
DMW1ALX	RN	Akuammine and dihydroakuammine, two indolomonoterpene alkaloids displaying affinity for opioid receptors. J Nat Prod. 1992 Mar;55(3):380-4.
DMW1ALX	RU	https://pubmed.ncbi.nlm.nih.gov/1317407

DMS4U68	DI	DMS4U68
DMS4U68	DN	dihydrocarveol
DMS4U68	MI	TT946IA
DMS4U68	MN	Transient receptor potential cation channel V3 (TRPV3)
DMS4U68	MT	DTT
DMS4U68	MA	Activator
DMS4U68	RN	Monoterpenoid agonists of TRPV3. Br J Pharmacol. 2007 Jun;151(4):530-40.
DMS4U68	RU	https://pubmed.ncbi.nlm.nih.gov/17420775

DMGLX1R	DI	DMGLX1R
DMGLX1R	DN	Dihydrocoumarin
DMGLX1R	MI	DESDN74
DMGLX1R	MN	Serum paraoxonase/arylesterase 1 (PON1)
DMGLX1R	MT	DME
DMGLX1R	MA	Metabolism
DMGLX1R	RN	Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos. 2000 Nov;28(11):1335-42.
DMGLX1R	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11038162

DMZL7R6	DI	DMZL7R6
DMZL7R6	DN	DIHYDROCUBEBIN
DMZL7R6	MI	TTXV4FI
DMZL7R6	MN	Albendazole monooxygenase (CYP3A4)
DMZL7R6	MT	DTT
DMZL7R6	MA	Inhibitor
DMZL7R6	RN	Potent CYP3A4 inhibitory constituents of Piper cubeba. J Nat Prod. 2005 Jan;68(1):64-8.
DMZL7R6	RU	https://pubmed.ncbi.nlm.nih.gov/15679319

DMZL7R6	DI	DMZL7R6
DMZL7R6	DN	DIHYDROCUBEBIN
DMZL7R6	MI	TTVG215
DMZL7R6	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DMZL7R6	MT	DTT
DMZL7R6	MA	Inhibitor
DMZL7R6	RN	Potent CYP3A4 inhibitory constituents of Piper cubeba. J Nat Prod. 2005 Jan;68(1):64-8.
DMZL7R6	RU	https://pubmed.ncbi.nlm.nih.gov/15679319

DMDW2NL	DI	DMDW2NL
DMDW2NL	DN	dihydroergocryptine
DMDW2NL	MI	TT0K1SC
DMDW2NL	MN	5-HT 2B receptor (HTR2B)
DMDW2NL	MT	DTT
DMDW2NL	MA	Agonist
DMDW2NL	RN	Structural features for functional selectivity at serotonin receptors. Science. 2013 May 3;340(6132):615-9.
DMDW2NL	RU	https://pubmed.ncbi.nlm.nih.gov/23519215

DMDW2NL	DI	DMDW2NL
DMDW2NL	DN	dihydroergocryptine
DMDW2NL	MI	TTO9X1H
DMDW2NL	MN	5-HT 7 receptor (HTR7)
DMDW2NL	MT	DTT
DMDW2NL	MA	Antagonist
DMDW2NL	RN	Molecular cloning of a mammalian serotonin receptor that activates adenylate cyclase. Mol Pharmacol. 1993 Aug;44(2):229-36.
DMDW2NL	RU	https://pubmed.ncbi.nlm.nih.gov/8394987

DM1BDM8	DI	DM1BDM8
DM1BDM8	DN	Dihydrofolic Acid
DM1BDM8	MI	TT9SL3Q
DM1BDM8	MN	Polypeptide deformylase (PDF)
DM1BDM8	MT	DTT
DM1BDM8	MA	Inhibitor
DM1BDM8	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM1BDM8	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM73OTF	DI	DM73OTF
DM73OTF	DN	DIHYDROKAEMPFEROL
DM73OTF	MI	TT7RJY8
DM73OTF	MN	Xanthine dehydrogenase/oxidase (XDH)
DM73OTF	MT	DTT
DM73OTF	MA	Inhibitor
DM73OTF	RN	Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod. 1988 Mar-Apr;51(2):345-8.
DM73OTF	RU	https://pubmed.ncbi.nlm.nih.gov/3379415

DM9NO6F	DI	DM9NO6F
DM9NO6F	DN	DIHYDROKAINATE
DM9NO6F	MI	TT0MYE2
DM9NO6F	MN	Glutamate receptor ionotropic kainate 1 (GRIK1)
DM9NO6F	MT	DTT
DM9NO6F	MA	Inhibitor
DM9NO6F	RN	Chemo-enzymatic synthesis of (2S,4R)-2-amino-4-(3-(2,2-diphenylethylamino)-3-oxopropyl)pentanedioic acid: a novel selective inhibitor of human exci... J Med Chem. 2008 Jul 24;51(14):4085-92.
DM9NO6F	RU	https://pubmed.ncbi.nlm.nih.gov/18578477

DMG0PXI	DI	DMG0PXI
DMG0PXI	DN	Dihydrolanosterol
DMG0PXI	MI	DEZNP5G
DMG0PXI	MN	Cytochrome P450 51B1 (cyp51)
DMG0PXI	MT	DME
DMG0PXI	MA	Metabolism
DMG0PXI	RN	Function, essentiality, and expression of cytochrome P450 enzymes and their cognate redox partners in Mycobacterium tuberculosis: are they drug targets? Appl Microbiol Biotechnol. 2019 May;103(9):3597-3614.
DMG0PXI	RU	https://pubmed.ncbi.nlm.nih.gov/30810776

DMG0PXI	DI	DMG0PXI
DMG0PXI	DN	Dihydrolanosterol
DMG0PXI	MI	DEVSF75
DMG0PXI	MN	Cytochrome P450 monooxygenase 51A (cyp51A)
DMG0PXI	MT	DME
DMG0PXI	MA	Metabolism
DMG0PXI	RN	nan
DMG0PXI	RU	nan

DM4TR0D	DI	DM4TR0D
DM4TR0D	DN	Dihydromorphine
DM4TR0D	MI	TT21AKM
DM4TR0D	MN	Corticotropin-lipotropin (POMC)
DM4TR0D	MT	DTT
DM4TR0D	MA	Agonist
DM4TR0D	RN	Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5.
DM4TR0D	RU	https://pubmed.ncbi.nlm.nih.gov/16777416

DM4TR0D	DI	DM4TR0D
DM4TR0D	DN	Dihydromorphine
DM4TR0D	MI	TT27RFC
DM4TR0D	MN	Opioid receptor delta (OPRD1)
DM4TR0D	MT	DTT
DM4TR0D	MA	Agonist
DM4TR0D	RN	Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5.
DM4TR0D	RU	https://pubmed.ncbi.nlm.nih.gov/16777416

DM4TR0D	DI	DM4TR0D
DM4TR0D	DN	Dihydromorphine
DM4TR0D	MI	TTQW87Y
DM4TR0D	MN	Opioid receptor kappa (OPRK1)
DM4TR0D	MT	DTT
DM4TR0D	MA	Agonist
DM4TR0D	RN	Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5.
DM4TR0D	RU	https://pubmed.ncbi.nlm.nih.gov/16777416

DM4TR0D	DI	DM4TR0D
DM4TR0D	DN	Dihydromorphine
DM4TR0D	MI	TTKWM86
DM4TR0D	MN	Opioid receptor mu (MOP)
DM4TR0D	MT	DTT
DM4TR0D	MA	Agonist
DM4TR0D	RN	Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5.
DM4TR0D	RU	https://pubmed.ncbi.nlm.nih.gov/16777416

DM76BGZ	DI	DM76BGZ
DM76BGZ	DN	Dihydroorotate
DM76BGZ	MI	TT09NOX
DM76BGZ	MN	Plasmodium Dihydroorotase (Malaria dho)
DM76BGZ	MT	DTT
DM76BGZ	MA	Inhibitor
DM76BGZ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM76BGZ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM76BGZ	DI	DM76BGZ
DM76BGZ	DN	Dihydroorotate
DM76BGZ	MI	TT3PQ2Y
DM76BGZ	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DM76BGZ	MT	DTT
DM76BGZ	MA	Inhibitor
DM76BGZ	RN	Structure-activity relationships of pyrimidines as dihydroorotate dehydrogenase inhibitors. Biochem Pharmacol. 1988 Oct 15;37(20):3807-16.
DM76BGZ	RU	https://pubmed.ncbi.nlm.nih.gov/2847745

DM0W64U	DI	DM0W64U
DM0W64U	DN	Dihydropyridines
DM0W64U	MI	TTXHYV6
DM0W64U	MN	Voltage-gated L-type calcium channel (L-CaC)
DM0W64U	MT	DTT
DM0W64U	MA	Blocker
DM0W64U	RN	Pharmacology of N-type Ca2+ channels distributed in cardiovascular system (Review). Int J Mol Med. 1999 May;3(5):455-66.
DM0W64U	RU	https://pubmed.ncbi.nlm.nih.gov/10202175

DMYSPMH	DI	DMYSPMH
DMYSPMH	DN	Dihydropyrone
DMYSPMH	MI	TT84ETX
DMYSPMH	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMYSPMH	MT	DTT
DMYSPMH	MA	Inhibitor
DMYSPMH	RN	Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416.
DMYSPMH	RU	https://pubmed.ncbi.nlm.nih.gov/18764719

DM9UK6D	DI	DM9UK6D
DM9UK6D	DN	Dihydro-quinolinone
DM9UK6D	MI	TTQBR95
DM9UK6D	MN	Stress-activated protein kinase 2a (p38 alpha)
DM9UK6D	MT	DTT
DM9UK6D	MA	Inhibitor
DM9UK6D	RN	In silico search for multi-target anti-inflammatories in Chinese herbs and formulas. Bioorg Med Chem. 2010 Mar 15;18(6):2204-2218.
DM9UK6D	RU	https://pubmed.ncbi.nlm.nih.gov/20188577

DM70OIC	DI	DM70OIC
DM70OIC	DN	DIHYDRORALOXIFENE
DM70OIC	MI	TTZAYWL
DM70OIC	MN	Estrogen receptor (ESR)
DM70OIC	MT	DTT
DM70OIC	MA	Inhibitor
DM70OIC	RN	Synthesis and biological activity of trans-2,3-dihydroraloxifene. Bioorg Med Chem Lett. 1999 Apr 19;9(8):1137-40.
DM70OIC	RU	https://pubmed.ncbi.nlm.nih.gov/10328300

DM70OIC	DI	DM70OIC
DM70OIC	DN	DIHYDRORALOXIFENE
DM70OIC	MI	TTOM3J0
DM70OIC	MN	Estrogen receptor beta (ESR2)
DM70OIC	MT	DTT
DM70OIC	MA	Inhibitor
DM70OIC	RN	Synthesis and biological activity of trans-2,3-dihydroraloxifene. Bioorg Med Chem Lett. 1999 Apr 19;9(8):1137-40.
DM70OIC	RU	https://pubmed.ncbi.nlm.nih.gov/10328300

DM58KHY	DI	DM58KHY
DM58KHY	DN	dihydrosphingosine-1-phosphate
DM58KHY	MI	TT2D5VM
DM58KHY	MN	G-protein coupled receptor 63 (GPR63)
DM58KHY	MT	DTT
DM58KHY	MA	Agonist
DM58KHY	RN	Sphingosine 1-phosphate and dioleoylphosphatidic acid are low affinity agonists for the orphan receptor GPR63. Cell Signal. 2003 Apr;15(4):435-46.
DM58KHY	RU	https://pubmed.ncbi.nlm.nih.gov/12618218

DM58KHY	DI	DM58KHY
DM58KHY	DN	dihydrosphingosine-1-phosphate
DM58KHY	MI	TTZ8C5Q
DM58KHY	MN	Sphingosine-1-phosphate receptor 4 (S1PR4)
DM58KHY	MT	DTT
DM58KHY	MA	Agonist
DM58KHY	RN	Phytosphingosine 1-phosphate: a high affinity ligand for the S1P(4)/Edg-6 receptor. Biochem Biophys Res Commun. 2002 Sep 27;297(3):600-6.
DM58KHY	RU	https://pubmed.ncbi.nlm.nih.gov/12270137

DMPDQSV	DI	DMPDQSV
DMPDQSV	DN	Dihydrostreptomycin
DMPDQSV	MI	DE4LYSA
DMPDQSV	MN	Cytochrome P450 3A4 (CYP3A4)
DMPDQSV	MT	DME
DMPDQSV	MA	Metabolism
DMPDQSV	RN	Troglitazone induces CYP3A4 activity leading to falsely abnormal dexamethasone suppression test. J Clin Endocrinol Metab. 2003 Jul;88(7):3113-6.
DMPDQSV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12843151

DMFKWRM	DI	DMFKWRM
DMFKWRM	DN	DIHYDROXANTHOHUMOL
DMFKWRM	MI	TTG5QB7
DMFKWRM	MN	Calpain-2 (CAPN2)
DMFKWRM	MT	DTT
DMFKWRM	MA	Inhibitor
DMFKWRM	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMFKWRM	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DME4NH1	DI	DME4NH1
DME4NH1	DN	Di-imidazole lexitropsin
DME4NH1	MI	TTOVXHF
DME4NH1	MN	Human Deoxyribonucleic acid minor groove (hDNA min)
DME4NH1	MT	DTT
DME4NH1	MA	Binder (minor groove binder)
DME4NH1	RN	Defining GC-specificity in the minor groove: side-by-side binding of the di-imidazole lexitropsin to C-A-T-G-G-C-C-A-T-G. Structure. 1997 Aug 15;5(8):1033-46.
DME4NH1	RU	https://pubmed.ncbi.nlm.nih.gov/9309219

DM917FE	DI	DM917FE
DM917FE	DN	Diiodo-l-thyronine
DM917FE	MI	DEYWLRK
DM917FE	MN	Sulfotransferase 1A1 (SULT1A1)
DM917FE	MT	DME
DM917FE	MA	Metabolism
DM917FE	RN	Characterization of human liver thermostable phenol sulfotransferase (SULT1A1) allozymes with 3,3',5-triiodothyronine as the substrate. J Endocrinol. 2001 Dec;171(3):525-32.
DM917FE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11739018

DMNR439	DI	DMNR439
DMNR439	DN	Diisopropyl 1-mercaptopropylphosphonate
DMNR439	MI	TTHI19T
DMNR439	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMNR439	MT	DTT
DMNR439	MA	Inhibitor
DMNR439	RN	Mercaptophosphonate compounds as broad-spectrum inhibitors of the metallo-beta-lactamases. J Med Chem. 2010 Jul 8;53(13):4862-76.
DMNR439	RU	https://pubmed.ncbi.nlm.nih.gov/20527888

DMVFJAH	DI	DMVFJAH
DMVFJAH	DN	Diisopropyl 2-(sulfanylmethyl)phenylphosphonate
DMVFJAH	MI	TTHI19T
DMVFJAH	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMVFJAH	MT	DTT
DMVFJAH	MA	Inhibitor
DMVFJAH	RN	Mercaptophosphonate compounds as broad-spectrum inhibitors of the metallo-beta-lactamases. J Med Chem. 2010 Jul 8;53(13):4862-76.
DMVFJAH	RU	https://pubmed.ncbi.nlm.nih.gov/20527888

DMHKE3M	DI	DMHKE3M
DMHKE3M	DN	Diisopropyl mercapto(phenyl)methylphosphonate
DMHKE3M	MI	TTHI19T
DMHKE3M	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMHKE3M	MT	DTT
DMHKE3M	MA	Inhibitor
DMHKE3M	RN	Mercaptophosphonate compounds as broad-spectrum inhibitors of the metallo-beta-lactamases. J Med Chem. 2010 Jul 8;53(13):4862-76.
DMHKE3M	RU	https://pubmed.ncbi.nlm.nih.gov/20527888

DMND2AS	DI	DMND2AS
DMND2AS	DN	Diisopropylphosphono Group
DMND2AS	MI	TTDIGC1
DMND2AS	MN	Dipeptidyl peptidase 4 (DPP-4)
DMND2AS	MT	DTT
DMND2AS	MA	Inhibitor
DMND2AS	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMND2AS	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMPKQER	DI	DMPKQER
DMPKQER	DN	Diketonitrile
DMPKQER	MI	TT8DSFC
DMPKQER	MN	Hydroxyphenylpyruvate dioxygenase (HPD)
DMPKQER	MT	DTT
DMPKQER	MA	Inhibitor
DMPKQER	RN	4-Hydroxyphenylpyruvate dioxygenase as a drug discovery target. Drug News Perspect. 2003 Oct;16(8):493-6.
DMPKQER	RU	https://pubmed.ncbi.nlm.nih.gov/14668946

DMOD5Y0	DI	DMOD5Y0
DMOD5Y0	DN	Dilazep
DMOD5Y0	MI	TTLXAKE
DMOD5Y0	MN	Solute carrier family 29 member 1 (SLC29A1)
DMOD5Y0	MT	DTT
DMOD5Y0	MA	Inhibitor
DMOD5Y0	RN	Residues Met89 and Ser160 in the human equilibrative nucleoside transporter 1 affect its affinity for adenosine, guanosine, S6-(4-nitrobenzyl)-merc... Mol Pharmacol. 2005 Mar;67(3):837-44.
DMOD5Y0	RU	https://pubmed.ncbi.nlm.nih.gov/15557207

DMA4NI2	DI	DMA4NI2
DMA4NI2	DN	Dimaprit
DMA4NI2	MI	TTQHJ1K
DMA4NI2	MN	Histamine H2 receptor (H2R)
DMA4NI2	MT	DTT
DMA4NI2	MA	Agonist
DMA4NI2	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMA4NI2	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMV8ZQG	DI	DMV8ZQG
DMV8ZQG	DN	DIMEBOLIN
DMV8ZQG	MI	TTJS8PY
DMV8ZQG	MN	5-HT 6 receptor (HTR6)
DMV8ZQG	MT	DTT
DMV8ZQG	MA	Inhibitor
DMV8ZQG	RN	8-Sulfonyl-substituted tetrahydro-1H-pyrido[4,3-b]indoles as 5-HT6 receptor antagonists. Eur J Med Chem. 2010 Feb;45(2):782-9.
DMV8ZQG	RU	https://pubmed.ncbi.nlm.nih.gov/19939513

DMV8ZQG	DI	DMV8ZQG
DMV8ZQG	DN	DIMEBOLIN
DMV8ZQG	MI	TTTIBOJ
DMV8ZQG	MN	Histamine H1 receptor (H1R)
DMV8ZQG	MT	DTT
DMV8ZQG	MA	Inhibitor
DMV8ZQG	RN	Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles. Bioorg Med Chem Lett. 2010 Jan 1;20(1):78-82.
DMV8ZQG	RU	https://pubmed.ncbi.nlm.nih.gov/19945877

DM2Q3CL	DI	DM2Q3CL
DM2Q3CL	DN	Dimemorfan
DM2Q3CL	MI	TT5TPI6
DM2Q3CL	MN	Opioid receptor sigma 1 (OPRS1)
DM2Q3CL	MT	DTT
DM2Q3CL	MA	Agonist
DM2Q3CL	RN	Dimemorfan protects rats against ischemic stroke through activation of sigma-1 receptor-mediated mechanisms by decreasing glutamate accumulation. J Neurochem. 2008 Jan;104(2):558-72.
DM2Q3CL	RU	https://pubmed.ncbi.nlm.nih.gov/18173806

DMRMHE8	DI	DMRMHE8
DMRMHE8	DN	Dimepheptanol
DMRMHE8	MI	TT27RFC
DMRMHE8	MN	Opioid receptor delta (OPRD1)
DMRMHE8	MT	DTT
DMRMHE8	MA	Inhibitor
DMRMHE8	RN	Synthesis of analogues of acetylmethadol and methadol as potential narcotic antagonists. J Med Chem. 1981 Jul;24(7):903-6.
DMRMHE8	RU	https://pubmed.ncbi.nlm.nih.gov/6268789

DMRMHE8	DI	DMRMHE8
DMRMHE8	DN	Dimepheptanol
DMRMHE8	MI	TTQW87Y
DMRMHE8	MN	Opioid receptor kappa (OPRK1)
DMRMHE8	MT	DTT
DMRMHE8	MA	Inhibitor
DMRMHE8	RN	Synthesis of analogues of acetylmethadol and methadol as potential narcotic antagonists. J Med Chem. 1981 Jul;24(7):903-6.
DMRMHE8	RU	https://pubmed.ncbi.nlm.nih.gov/6268789

DMRMHE8	DI	DMRMHE8
DMRMHE8	DN	Dimepheptanol
DMRMHE8	MI	TTKWM86
DMRMHE8	MN	Opioid receptor mu (MOP)
DMRMHE8	MT	DTT
DMRMHE8	MA	Inhibitor
DMRMHE8	RN	Synthesis of analogues of acetylmethadol and methadol as potential narcotic antagonists. J Med Chem. 1981 Jul;24(7):903-6.
DMRMHE8	RU	https://pubmed.ncbi.nlm.nih.gov/6268789

DMTVA49	DI	DMTVA49
DMTVA49	DN	Dimethyl 2,2,2-trifluoro-1-phenylethyl phosphate
DMTVA49	MI	TTMF541
DMTVA49	MN	Liver carboxylesterase (CES1)
DMTVA49	MT	DTT
DMTVA49	MA	Inhibitor
DMTVA49	RN	Synthesis of organophosphates with fluorine-containing leaving groups as serine esterase inhibitors with potential for Alzheimer disease therapeutics. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5528-30.
DMTVA49	RU	https://pubmed.ncbi.nlm.nih.gov/19717305

DMP5I47	DI	DMP5I47
DMP5I47	DN	Dimethylallyl Diphosphate
DMP5I47	MI	TTIKWV4
DMP5I47	MN	Geranyltranstransferase (FDPS)
DMP5I47	MT	DTT
DMP5I47	MA	Inhibitor
DMP5I47	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMP5I47	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM2HYEN	DI	DM2HYEN
DM2HYEN	DN	dimethylethylamine
DM2HYEN	MI	TTCO25G
DM2HYEN	MN	Trace amine receptor 5 (TAAR5)
DM2HYEN	MT	DTT
DM2HYEN	MA	Agonist
DM2HYEN	RN	Trace amine-associated receptors and their ligands. Br J Pharmacol. 2006 Dec;149(8):967-78.
DM2HYEN	RU	https://pubmed.ncbi.nlm.nih.gov/17088868

DML6O4N	DI	DML6O4N
DML6O4N	DN	Dimethylformamide
DML6O4N	MI	TTB2MXP
DML6O4N	MN	Angiotensinogenase renin (REN)
DML6O4N	MT	DTT
DML6O4N	MA	Inhibitor
DML6O4N	RN	Liver disease associated with occupational exposure to the solvent dimethylformamide. Ann Intern Med. 1988 May;108(5):680-6.
DML6O4N	RU	https://pubmed.ncbi.nlm.nih.gov/3358569

DML6O4N	DI	DML6O4N
DML6O4N	DN	Dimethylformamide
DML6O4N	MI	DEVDYN7
DML6O4N	MN	Cytochrome P450 2E1 (CYP2E1)
DML6O4N	MT	DME
DML6O4N	MA	Metabolism
DML6O4N	RN	Association between CYP2E1 and GOT2 gene polymorphisms and susceptibility and low-dose N,N-dimethylformamide occupational exposure-induced liver injury. Int Arch Occup Environ Health. 2019 Oct;92(7):967-975.
DML6O4N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30993423

DML6O4N	DI	DML6O4N
DML6O4N	DN	Dimethylformamide
DML6O4N	MI	TT3NKIB
DML6O4N	MN	Pancreatic elastase 1 (CELA1)
DML6O4N	MT	DTT
DML6O4N	MA	Inhibitor
DML6O4N	RN	Liver disease associated with occupational exposure to the solvent dimethylformamide. Ann Intern Med. 1988 May;108(5):680-6.
DML6O4N	RU	https://pubmed.ncbi.nlm.nih.gov/3358569

DMW0MTV	DI	DMW0MTV
DMW0MTV	DN	DIMETHYLGRISABINE
DMW0MTV	MI	TTVBI8W
DMW0MTV	MN	Dopamine transporter (DAT)
DMW0MTV	MT	DTT
DMW0MTV	MA	Inhibitor
DMW0MTV	RN	Effects of various isoquinoline alkaloids on in vitro 3H-dopamine uptake by rat striatal synaptosomes. J Nat Prod. 1995 Oct;58(10):1475-84.
DMW0MTV	RU	https://pubmed.ncbi.nlm.nih.gov/8676127

DMY0FVU	DI	DMY0FVU
DMY0FVU	DN	dimethylhistaprodifen
DMY0FVU	MI	TTTIBOJ
DMY0FVU	MN	Histamine H1 receptor (H1R)
DMY0FVU	MT	DTT
DMY0FVU	MA	Agonist
DMY0FVU	RN	Multiple differences in agonist and antagonist pharmacology between human and guinea pig histamine H1-receptor. J Pharmacol Exp Ther. 2003 Jun;305(3):1104-15.
DMY0FVU	RU	https://pubmed.ncbi.nlm.nih.gov/12626648

DMG3WTE	DI	DMG3WTE
DMG3WTE	DN	Dimethylnordihydroguarierate acid
DMG3WTE	MI	TT12ABZ
DMG3WTE	MN	Arachidonate 12-lipoxygenase (12-LOX)
DMG3WTE	MT	DTT
DMG3WTE	MA	Inhibitor
DMG3WTE	RN	Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases. J Nat Prod. 2003 Feb;66(2):230-5.
DMG3WTE	RU	https://pubmed.ncbi.nlm.nih.gov/12608855

DMG3WTE	DI	DMG3WTE
DMG3WTE	DN	Dimethylnordihydroguarierate acid
DMG3WTE	MI	TTN9T81
DMG3WTE	MN	Arachidonate 15-lipoxygenase (15-LOX)
DMG3WTE	MT	DTT
DMG3WTE	MA	Inhibitor
DMG3WTE	RN	Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases. J Nat Prod. 2003 Feb;66(2):230-5.
DMG3WTE	RU	https://pubmed.ncbi.nlm.nih.gov/12608855

DMO0UI8	DI	DMO0UI8
DMO0UI8	DN	Dimethyl-pent-4-enyl-ammonium bromide
DMO0UI8	MI	TT1RS9F
DMO0UI8	MN	Acetylcholinesterase (AChE)
DMO0UI8	MT	DTT
DMO0UI8	MA	Inhibitor
DMO0UI8	RN	Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors. J Med Chem. 1996 Dec 20;39(26):5064-71.
DMO0UI8	RU	https://pubmed.ncbi.nlm.nih.gov/8978837

DM1OKN0	DI	DM1OKN0
DM1OKN0	DN	DIMETHYLSPINGOSINE
DM1OKN0	MI	TTCN0M9
DM1OKN0	MN	Sphingosine kinase 2 (SPHK2)
DM1OKN0	MT	DTT
DM1OKN0	MA	Inhibitor
DM1OKN0	RN	Synthesis and evaluation of sphingosine analogues as inhibitors of sphingosine kinases. J Med Chem. 2009 Jun 25;52(12):3618-26.
DM1OKN0	RU	https://pubmed.ncbi.nlm.nih.gov/19469544

DM7EKAF	DI	DM7EKAF
DM7EKAF	DN	Dimethylthiambutene
DM7EKAF	MI	TT27RFC
DM7EKAF	MN	Opioid receptor delta (OPRD1)
DM7EKAF	MT	DTT
DM7EKAF	MA	Agonist
DM7EKAF	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM7EKAF	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM7EKAF	DI	DM7EKAF
DM7EKAF	DN	Dimethylthiambutene
DM7EKAF	MI	TTKWM86
DM7EKAF	MN	Opioid receptor mu (MOP)
DM7EKAF	MT	DTT
DM7EKAF	MA	Agonist
DM7EKAF	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM7EKAF	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM2Y0AI	DI	DM2Y0AI
DM2Y0AI	DN	Diminazene
DM2Y0AI	MI	TTM3B5R
DM2Y0AI	MN	Diamine oxidase (AOC1)
DM2Y0AI	MT	DTT
DM2Y0AI	MA	Inhibitor
DM2Y0AI	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM2Y0AI	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMJGKND	DI	DMJGKND
DMJGKND	DN	DIMS-9054
DMJGKND	MI	TTSHG0T
DMJGKND	MN	Toll-like receptor 9 (TLR9)
DMJGKND	MT	DTT
DMJGKND	MA	Modulator
DMJGKND	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1759).
DMJGKND	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1759

DM8CSOJ	DI	DM8CSOJ
DM8CSOJ	DN	Dinoterb
DM8CSOJ	MI	DEMQRS9
DM8CSOJ	MN	Cytochrome P450 BM3 (cypBM3)
DM8CSOJ	MT	DME
DM8CSOJ	MA	Metabolism
DM8CSOJ	RN	PEGylation of cytochrome P450 enhances its biocatalytic performance for pesticide transformation. Int J Biol Macromol. 2017 Dec;105(Pt 1):163-170.
DM8CSOJ	RU	https://pubmed.ncbi.nlm.nih.gov/28690168

DMBKJL8	DI	DMBKJL8
DMBKJL8	DN	DIOA
DMBKJL8	MI	TTJ8C67
DMBKJL8	MN	Solute carrier family 12 member 4 (SLC12A4)
DMBKJL8	MT	DTT
DMBKJL8	MA	Inhibitor
DMBKJL8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 971).
DMBKJL8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=971

DMBKJL8	DI	DMBKJL8
DMBKJL8	DN	DIOA
DMBKJL8	MI	TTH6UZY
DMBKJL8	MN	Solute carrier family 12 member 5 (SLC12A5)
DMBKJL8	MT	DTT
DMBKJL8	MA	Inhibitor
DMBKJL8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 972).
DMBKJL8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=972

DMBKJL8	DI	DMBKJL8
DMBKJL8	DN	DIOA
DMBKJL8	MI	TT8DFHE
DMBKJL8	MN	Solute carrier family 12 member 6 (SLC12A6)
DMBKJL8	MT	DTT
DMBKJL8	MA	Inhibitor
DMBKJL8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 973).
DMBKJL8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=973

DMBKJL8	DI	DMBKJL8
DMBKJL8	DN	DIOA
DMBKJL8	MI	TTU2PCD
DMBKJL8	MN	Solute carrier family 12 member 7 (SLC12A7)
DMBKJL8	MT	DTT
DMBKJL8	MA	Inhibitor
DMBKJL8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 974).
DMBKJL8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=974

DM0QY1V	DI	DM0QY1V
DM0QY1V	DN	dioctanoylglycerol pyrophosphate
DM0QY1V	MI	TTO897C
DM0QY1V	MN	G protein coupled receptor 87 (GPR87)
DM0QY1V	MT	DTT
DM0QY1V	MA	Antagonist
DM0QY1V	RN	The orphan GPCR GPR87 was deorphanized and shown to be a lysophosphatidic acid receptor. Biochem Biophys Res Commun. 2007 Nov 23;363(3):861-6.
DM0QY1V	RU	https://pubmed.ncbi.nlm.nih.gov/17905198

DM0QY1V	DI	DM0QY1V
DM0QY1V	DN	dioctanoylglycerol pyrophosphate
DM0QY1V	MI	TTE2YJR
DM0QY1V	MN	Lysophosphatidate-3 receptor (LPAR3)
DM0QY1V	MT	DTT
DM0QY1V	MA	Antagonist
DM0QY1V	RN	Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors. Mol Pharmacol. 2001 Oct;60(4):776-84.
DM0QY1V	RU	https://pubmed.ncbi.nlm.nih.gov/11562440

DM0QY1V	DI	DM0QY1V
DM0QY1V	DN	dioctanoylglycerol pyrophosphate
DM0QY1V	MI	TTQ6S1K
DM0QY1V	MN	Lysophosphatidic acid receptor 1 (LPAR1)
DM0QY1V	MT	DTT
DM0QY1V	MA	Antagonist
DM0QY1V	RN	Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors. Mol Pharmacol. 2001 Oct;60(4):776-84.
DM0QY1V	RU	https://pubmed.ncbi.nlm.nih.gov/11562440

DM0QY1V	DI	DM0QY1V
DM0QY1V	DN	dioctanoylglycerol pyrophosphate
DM0QY1V	MI	TTMFOU6
DM0QY1V	MN	P2Y purinoceptor 10 (P2RY10)
DM0QY1V	MT	DTT
DM0QY1V	MA	Antagonist
DM0QY1V	RN	Identification of the orphan GPCR, P2Y(10) receptor as the sphingosine-1-phosphate and lysophosphatidic acid receptor. Biochem Biophys Res Commun. 2008 Jul 11;371(4):707-12.
DM0QY1V	RU	https://pubmed.ncbi.nlm.nih.gov/18466763

DM7D6JV	DI	DM7D6JV
DM7D6JV	DN	dioleoylphosphatidic acid
DM7D6JV	MI	TT2D5VM
DM7D6JV	MN	G-protein coupled receptor 63 (GPR63)
DM7D6JV	MT	DTT
DM7D6JV	MA	Agonist
DM7D6JV	RN	Sphingosine 1-phosphate and dioleoylphosphatidic acid are low affinity agonists for the orphan receptor GPR63. Cell Signal. 2003 Apr;15(4):435-46.
DM7D6JV	RU	https://pubmed.ncbi.nlm.nih.gov/12618218

DM5G4O7	DI	DM5G4O7
DM5G4O7	DN	DI-O-METHYLENDIANDRIN A
DM5G4O7	MI	TTOZRK6
DM5G4O7	MN	Glucocorticoid receptor messenger RNA (GCR mRNA)
DM5G4O7	MT	DTT
DM5G4O7	MA	Inhibitor
DM5G4O7	RN	Endiandrin A, a potent glucocorticoid receptor binder isolated from the Australian plant Endiandra anthropophagorum. J Nat Prod. 2007 Jul;70(7):1118-21.
DM5G4O7	RU	https://pubmed.ncbi.nlm.nih.gov/17583952

DM4KXIM	DI	DM4KXIM
DM4KXIM	DN	DIOSMETIN
DM4KXIM	MI	TTI84H7
DM4KXIM	MN	Cytochrome P450 1B1 (CYP1B1)
DM4KXIM	MT	DTT
DM4KXIM	MA	Inhibitor
DM4KXIM	RN	Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5.
DM4KXIM	RU	https://pubmed.ncbi.nlm.nih.gov/20696580

DML2B04	DI	DML2B04
DML2B04	DN	DIOXINODEHYDROECKOL
DML2B04	MI	TT8JRS7
DML2B04	MN	Beta-secretase (BACE)
DML2B04	MT	DTT
DML2B04	MA	Inhibitor
DML2B04	RN	Molecular docking studies of phlorotannins from Eisenia bicyclis with BACE1 inhibitory activity. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3211-5.
DML2B04	RU	https://pubmed.ncbi.nlm.nih.gov/20462757

DM93MAB	DI	DM93MAB
DM93MAB	DN	Dioxothiomolybdenum(VI) ion
DM93MAB	MI	TT7RJY8
DM93MAB	MN	Xanthine dehydrogenase/oxidase (XDH)
DM93MAB	MT	DTT
DM93MAB	MA	Inhibitor
DM93MAB	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DM93MAB	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMO4XUC	DI	DMO4XUC
DMO4XUC	DN	Diphenyl(piperidin-4-yl)methanol
DMO4XUC	MI	TTTIBOJ
DMO4XUC	MN	Histamine H1 receptor (H1R)
DMO4XUC	MT	DTT
DMO4XUC	MA	Inhibitor
DMO4XUC	RN	Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs. Bioorg Med Chem Lett. 2009 Sep 1;19(17):5043-7.
DMO4XUC	RU	https://pubmed.ncbi.nlm.nih.gov/19660947

DMP6IHR	DI	DMP6IHR
DMP6IHR	DN	Diphenylacetic Acid
DMP6IHR	MI	TTF2LRI
DMP6IHR	MN	Cathepsin B (CTSB)
DMP6IHR	MT	DTT
DMP6IHR	MA	Inhibitor
DMP6IHR	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMP6IHR	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMBV19T	DI	DMBV19T
DMBV19T	DN	diphenylamine-2-carboxylic acid
DMBV19T	MI	TT30NW6
DMBV19T	MN	Chloride channel protein 2 (CLC-2)
DMBV19T	MT	DTT
DMBV19T	MA	Blocker (channel blocker)
DMBV19T	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 699).
DMBV19T	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=699

DMBV19T	DI	DMBV19T
DMBV19T	DN	diphenylamine-2-carboxylic acid
DMBV19T	MI	TTST1AJ
DMBV19T	MN	Chloride channel protein 7 (ClC-7)
DMBV19T	MT	DTT
DMBV19T	MA	Blocker (channel blocker)
DMBV19T	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 709).
DMBV19T	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=709

DMRQZTS	DI	DMRQZTS
DMRQZTS	DN	diphenylboronic anhydride
DMRQZTS	MI	TTMI6F5
DMRQZTS	MN	Transient receptor potential cation channel V1 (TRPV1)
DMRQZTS	MT	DTT
DMRQZTS	MA	Activator
DMRQZTS	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 507).
DMRQZTS	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=507

DMRQZTS	DI	DMRQZTS
DMRQZTS	DN	diphenylboronic anhydride
DMRQZTS	MI	TTBECWA
DMRQZTS	MN	Transient receptor potential cation channel V2 (TRPV2)
DMRQZTS	MT	DTT
DMRQZTS	MA	Activator
DMRQZTS	RN	Pharmacological characterization and molecular determinants of the activation of transient receptor potential V2 channel orthologs by 2-aminoethoxy... Mol Pharmacol. 2007 Nov;72(5):1258-68.
DMRQZTS	RU	https://pubmed.ncbi.nlm.nih.gov/17673572

DMRQZTS	DI	DMRQZTS
DMRQZTS	DN	diphenylboronic anhydride
DMRQZTS	MI	TT946IA
DMRQZTS	MN	Transient receptor potential cation channel V3 (TRPV3)
DMRQZTS	MT	DTT
DMRQZTS	MA	Activator
DMRQZTS	RN	Biphasic currents evoked by chemical or thermal activation of the heat-gated ion channel, TRPV3. J Biol Chem. 2005 Apr 22;280(16):15928-41.
DMRQZTS	RU	https://pubmed.ncbi.nlm.nih.gov/15722340

DMB75PV	DI	DMB75PV
DMB75PV	DN	diphenyleneiodonium chloride
DMB75PV	MI	TTHZVSK
DMB75PV	MN	G protein-coupled receptor 3 (GPR3)
DMB75PV	MT	DTT
DMB75PV	MA	Agonist
DMB75PV	RN	Identification of a novel small-molecule agonist for human G protein-coupled receptor 3. J Pharmacol Exp Ther. 2014 Jun;349(3):437-43.
DMB75PV	RU	https://pubmed.ncbi.nlm.nih.gov/24633425

DMK8T61	DI	DMK8T61
DMK8T61	DN	diphenyltetrahydrofuran
DMK8T61	MI	TT946IA
DMK8T61	MN	Transient receptor potential cation channel V3 (TRPV3)
DMK8T61	MT	DTT
DMK8T61	MA	Blocker (channel blocker)
DMK8T61	RN	Biphasic currents evoked by chemical or thermal activation of the heat-gated ion channel, TRPV3. J Biol Chem. 2005 Apr 22;280(16):15928-41.
DMK8T61	RU	https://pubmed.ncbi.nlm.nih.gov/15722340

DMHY30B	DI	DMHY30B
DMHY30B	DN	Diphosphate
DMHY30B	MI	TT8WCXO
DMHY30B	MN	Bacterial NH(3)-dependent NAD(+) synthetase (Bact nadE)
DMHY30B	MT	DTT
DMHY30B	MA	Inhibitor
DMHY30B	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMHY30B	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMHY30B	DI	DMHY30B
DMHY30B	DN	Diphosphate
DMHY30B	MI	TT5B8AX
DMHY30B	MN	Mycobacterium Thymidine monophosphate kinase (MycB tmk)
DMHY30B	MT	DTT
DMHY30B	MA	Inhibitor
DMHY30B	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMHY30B	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMHY30B	DI	DMHY30B
DMHY30B	DN	Diphosphate
DMHY30B	MI	TTYQ4AE
DMHY30B	MN	Plasmodium Adenylosuccinate synthetase (Malaria Adss)
DMHY30B	MT	DTT
DMHY30B	MA	Inhibitor
DMHY30B	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMHY30B	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM28NIU	DI	DM28NIU
DM28NIU	DN	diphosphoglycolyl proline
DM28NIU	MI	TTE5J6X
DM28NIU	MN	Diphosphomevalonate decarboxylase (MVD)
DM28NIU	MT	DTT
DM28NIU	MA	Inhibitor
DM28NIU	RN	Human mevalonate diphosphate decarboxylase: characterization, investigation of the mevalonate diphosphate binding site, and crystal structure. Arch Biochem Biophys. 2008 Dec 1;480(1):58-67.
DM28NIU	RU	https://pubmed.ncbi.nlm.nih.gov/18823933

DMYWL89	DI	DMYWL89
DMYWL89	DN	diphosphoric acid
DMYWL89	MI	TTIKWV4
DMYWL89	MN	Geranyltranstransferase (FDPS)
DMYWL89	MT	DTT
DMYWL89	MA	Inhibitor
DMYWL89	RN	Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of hu... J Med Chem. 2008 Apr 10;51(7):2187-95.
DMYWL89	RU	https://pubmed.ncbi.nlm.nih.gov/18327899

DMRWD9M	DI	DMRWD9M
DMRWD9M	DN	Diphthamide
DMRWD9M	MI	TTCNGJ5
DMRWD9M	MN	Candida Elongation factor 2 (Candi EFT2)
DMRWD9M	MT	DTT
DMRWD9M	MA	Inhibitor
DMRWD9M	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMRWD9M	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMIXPU6	DI	DMIXPU6
DMIXPU6	DN	Diprenorphine
DMIXPU6	MI	TT27RFC
DMIXPU6	MN	Opioid receptor delta (OPRD1)
DMIXPU6	MT	DTT
DMIXPU6	MA	Antagonist
DMIXPU6	RN	[6-O-methyl-11C]Diprenorphine Molecular Imaging and Contrast Agent Database (MICAD) [Internet].
DMIXPU6	RU	https://pubmed.ncbi.nlm.nih.gov/20641600

DMIXPU6	DI	DMIXPU6
DMIXPU6	DN	Diprenorphine
DMIXPU6	MI	TTQW87Y
DMIXPU6	MN	Opioid receptor kappa (OPRK1)
DMIXPU6	MT	DTT
DMIXPU6	MA	Antagonist
DMIXPU6	RN	[6-O-methyl-11C]Diprenorphine Molecular Imaging and Contrast Agent Database (MICAD) [Internet].
DMIXPU6	RU	https://pubmed.ncbi.nlm.nih.gov/20641600

DMIXPU6	DI	DMIXPU6
DMIXPU6	DN	Diprenorphine
DMIXPU6	MI	TTKWM86
DMIXPU6	MN	Opioid receptor mu (MOP)
DMIXPU6	MT	DTT
DMIXPU6	MA	Antagonist
DMIXPU6	RN	[6-O-methyl-11C]Diprenorphine Molecular Imaging and Contrast Agent Database (MICAD) [Internet].
DMIXPU6	RU	https://pubmed.ncbi.nlm.nih.gov/20641600

DM9VKXC	DI	DM9VKXC
DM9VKXC	DN	dipropyl-5-CT
DM9VKXC	MI	TTK8CXU
DM9VKXC	MN	5-HT 1B receptor (HTR1B)
DM9VKXC	MT	DTT
DM9VKXC	MA	Agonist
DM9VKXC	RN	Human serotonin 1D receptor is encoded by a subfamily of two distinct genes: 5-HT1D alpha and 5-HT1D beta. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3630-4.
DM9VKXC	RU	https://pubmed.ncbi.nlm.nih.gov/1565658

DM9VKXC	DI	DM9VKXC
DM9VKXC	DN	dipropyl-5-CT
DM9VKXC	MI	TT6MSOK
DM9VKXC	MN	5-HT 1D receptor (HTR1D)
DM9VKXC	MT	DTT
DM9VKXC	MA	Agonist
DM9VKXC	RN	Human serotonin 1D receptor is encoded by a subfamily of two distinct genes: 5-HT1D alpha and 5-HT1D beta. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3630-4.
DM9VKXC	RU	https://pubmed.ncbi.nlm.nih.gov/1565658

DM9VKXC	DI	DM9VKXC
DM9VKXC	DN	dipropyl-5-CT
DM9VKXC	MI	TT0MI3F
DM9VKXC	MN	5-HT 1F receptor (HTR1F)
DM9VKXC	MT	DTT
DM9VKXC	MA	Agonist
DM9VKXC	RN	Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):408-12.
DM9VKXC	RU	https://pubmed.ncbi.nlm.nih.gov/8380639

DM9VKXC	DI	DM9VKXC
DM9VKXC	DN	dipropyl-5-CT
DM9VKXC	MI	TTO9X1H
DM9VKXC	MN	5-HT 7 receptor (HTR7)
DM9VKXC	MT	DTT
DM9VKXC	MA	Agonist
DM9VKXC	RN	Cloning, expression and pharmacology of a truncated splice variant of the human 5-HT7 receptor (h5-HT7b). Br J Pharmacol. 1997 Sep;122(1):126-32.
DM9VKXC	RU	https://pubmed.ncbi.nlm.nih.gov/9298538

DMGBCP0	DI	DMGBCP0
DMGBCP0	DN	DIPROTIN A
DMGBCP0	MI	TTDIGC1
DMGBCP0	MN	Dipeptidyl peptidase 4 (DPP-4)
DMGBCP0	MT	DTT
DMGBCP0	MA	Inhibitor
DMGBCP0	RN	Inhibition of dipeptidyl peptidase-IV (DPP-IV) by atorvastatin. Bioorg Med Chem Lett. 2008 Jan 15;18(2):479-84.
DMGBCP0	RU	https://pubmed.ncbi.nlm.nih.gov/18068977

DM2MV9O	DI	DM2MV9O
DM2MV9O	DN	DIRLOTAPIDE
DM2MV9O	MI	TTUS1RD
DM2MV9O	MN	Microsomal triglyceride transfer protein (MTTP)
DM2MV9O	MT	DTT
DM2MV9O	MA	Inhibitor
DM2MV9O	RN	In vitro and in vivo profile of 5-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-1H-indole-2-carboxylic acid benzylmethyl carbamoylamide (dirlota... Bioorg Med Chem Lett. 2007 Apr 1;17(7):1996-9.
DM2MV9O	RU	https://pubmed.ncbi.nlm.nih.gov/17276061

DMPVNDK	DI	DMPVNDK
DMPVNDK	DN	Distamycin A
DMPVNDK	MI	TTOVXHF
DMPVNDK	MN	Human Deoxyribonucleic acid minor groove (hDNA min)
DMPVNDK	MT	DTT
DMPVNDK	MA	Binder (minor groove binder)
DMPVNDK	RN	Development of distamycin-related DNA binding anticancer drugs. Expert Opin Investig Drugs. 2001 Sep;10(9):1703-14.
DMPVNDK	RU	https://pubmed.ncbi.nlm.nih.gov/11772279

DM0GQJ2	DI	DM0GQJ2
DM0GQJ2	DN	Di-Stearoyl-3-Sn-Phosphatidylcholine
DM0GQJ2	MI	TTU5A6Q
DM0GQJ2	MN	Adenine nucleotide translocator 1 (SLC25A4)
DM0GQJ2	MT	DTT
DM0GQJ2	MA	Inhibitor
DM0GQJ2	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM0GQJ2	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM6TVAX	DI	DM6TVAX
DM6TVAX	DN	Disulergine
DM6TVAX	MI	TTO9X1H
DM6TVAX	MN	5-HT 7 receptor (HTR7)
DM6TVAX	MT	DTT
DM6TVAX	MA	Inhibitor
DM6TVAX	RN	Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). J Med Chem. 2003 Jul 3;46(14):2795-812.
DM6TVAX	RU	https://pubmed.ncbi.nlm.nih.gov/12825922

DMVJYKG	DI	DMVJYKG
DMVJYKG	DN	Dithiazoline
DMVJYKG	MI	DE0KTEM
DMVJYKG	MN	L,D-carboxypeptidase A (ldcA)
DMVJYKG	MT	DME
DMVJYKG	MA	Metabolism
DMVJYKG	RN	Selective inhibition of Neisseria gonorrhoeae by a dithiazoline in mixed infections with Lactobacillus gasseri. Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e00826-18.
DMVJYKG	RU	https://pubmed.ncbi.nlm.nih.gov/30275084

DMVJYKG	DI	DMVJYKG
DMVJYKG	DN	Dithiazoline
DMVJYKG	MI	DE19C8A
DMVJYKG	MN	L,D-carboxypeptidase A (ldcA)
DMVJYKG	MT	DME
DMVJYKG	MA	Metabolism
DMVJYKG	RN	Selective inhibition of Neisseria gonorrhoeae by a dithiazoline in mixed infections with Lactobacillus gasseri. Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e00826-18.
DMVJYKG	RU	https://pubmed.ncbi.nlm.nih.gov/30275084

DMK0VFS	DI	DMK0VFS
DMK0VFS	DN	dithiipin-1,1,4,4-tetroxide analogue 7
DMK0VFS	MI	TTOPAY7
DMK0VFS	MN	Galanin receptor (GAL-R)
DMK0VFS	MT	DTT
DMK0VFS	MA	Antagonist
DMK0VFS	RN	2,3-Dihydro-dithiin and -dithiepine-1,1,4,4-tetroxides: small molecule non-peptide antagonists of the human galanin hGAL-1 receptor. Bioorg Med Chem. 2000 Jun;8(6):1383-91.
DMK0VFS	RU	https://pubmed.ncbi.nlm.nih.gov/10896115

DM0QZ6I	DI	DM0QZ6I
DM0QZ6I	DN	D-kynurenine
DM0QZ6I	MI	TT8WFXV
DM0QZ6I	MN	Hydroxycarboxylic acid receptor 3 (HCAR3)
DM0QZ6I	MT	DTT
DM0QZ6I	MA	Agonist
DM0QZ6I	RN	Aromatic D-amino acids act as chemoattractant factors for human leukocytes through a G protein-coupled receptor, GPR109B. Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3930-4.
DM0QZ6I	RU	https://pubmed.ncbi.nlm.nih.gov/19237584

DME9ODX	DI	DME9ODX
DME9ODX	DN	DL-3
DME9ODX	MI	TTS64P2
DME9ODX	MN	Androgen receptor (AR)
DME9ODX	MT	DTT
DME9ODX	MA	Antagonist
DME9ODX	RN	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
DME9ODX	RU	https://www.ncbi.nlm.nih.gov/pubmed/27899562

DMBNFQ8	DI	DMBNFQ8
DMBNFQ8	DN	D-lactic acid
DMBNFQ8	MI	TTVK4ZO
DMBNFQ8	MN	G protein coupled receptor 81 (HCAR1)
DMBNFQ8	MT	DTT
DMBNFQ8	MA	Agonist
DMBNFQ8	RN	Role of GPR81 in lactate-mediated reduction of adipose lipolysis. Biochem Biophys Res Commun. 2008 Dec 19;377(3):987-91.
DMBNFQ8	RU	https://pubmed.ncbi.nlm.nih.gov/18952058

DMBNFQ8	DI	DMBNFQ8
DMBNFQ8	DN	D-lactic acid
DMBNFQ8	MI	DEINPMH
DMBNFQ8	MN	Lactate racemase (Lsa784)
DMBNFQ8	MT	DME
DMBNFQ8	MA	Metabolism
DMBNFQ8	RN	The effect of sodium acetate on the growth yield, the production of L- and D-lactic acid, and the activity of some enzymes of the glycolytic pathway of Lactobacillus sakei NRIC 1071(T) and Lactobacillus plantarum NRIC 1067(T). J Gen Appl Microbiol. 2002 Apr;48(2):91-102.
DMBNFQ8	RU	https://pubmed.ncbi.nlm.nih.gov/12469305

DMHI9ZJ	DI	DMHI9ZJ
DMHI9ZJ	DN	DL-benzylsuccinic acid
DMHI9ZJ	MI	TT3LJ6G
DMHI9ZJ	MN	Carboxypeptidase A1 (CPA1)
DMHI9ZJ	MT	DTT
DMHI9ZJ	MA	Inhibitor
DMHI9ZJ	RN	A new type of five-membered heterocyclic inhibitors of basic metallocarboxypeptidases. Eur J Med Chem. 2009 Aug;44(8):3266-71.
DMHI9ZJ	RU	https://pubmed.ncbi.nlm.nih.gov/19386397

DMHI9ZJ	DI	DMHI9ZJ
DMHI9ZJ	DN	DL-benzylsuccinic acid
DMHI9ZJ	MI	TTP18AY
DMHI9ZJ	MN	Carboxypeptidase B2 (CPB2)
DMHI9ZJ	MT	DTT
DMHI9ZJ	MA	Inhibitor
DMHI9ZJ	RN	A new type of five-membered heterocyclic inhibitors of basic metallocarboxypeptidases. Eur J Med Chem. 2009 Aug;44(8):3266-71.
DMHI9ZJ	RU	https://pubmed.ncbi.nlm.nih.gov/19386397

DMVN93B	DI	DMVN93B
DMVN93B	DN	D-leucyl-N-(3-chlorobenzyl)-L-prolinamide
DMVN93B	MI	TT6L509
DMVN93B	MN	Coagulation factor IIa (F2)
DMVN93B	MT	DTT
DMVN93B	MA	Inhibitor
DMVN93B	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMVN93B	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMIFCHL	DI	DMIFCHL
DMIFCHL	DN	D-leucyl-N-(4-carbamimidoylbenzyl)-L-prolinamide
DMIFCHL	MI	TT6L509
DMIFCHL	MN	Coagulation factor IIa (F2)
DMIFCHL	MT	DTT
DMIFCHL	MA	Inhibitor
DMIFCHL	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMIFCHL	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMM1GXI	DI	DMM1GXI
DMM1GXI	DN	DL-guanidinoethylmercaptosuccinic acid
DMM1GXI	MI	TTP18AY
DMM1GXI	MN	Carboxypeptidase B2 (CPB2)
DMM1GXI	MT	DTT
DMM1GXI	MA	Inhibitor
DMM1GXI	RN	A new type of five-membered heterocyclic inhibitors of basic metallocarboxypeptidases. Eur J Med Chem. 2009 Aug;44(8):3266-71.
DMM1GXI	RU	https://pubmed.ncbi.nlm.nih.gov/19386397

DM2HGNU	DI	DM2HGNU
DM2HGNU	DN	DL-TBOA
DM2HGNU	MI	TT8WRDA
DM2HGNU	MN	Excitatory amino acid transporter 1 (SLC1A3)
DM2HGNU	MT	DTT
DM2HGNU	MA	Inhibitor
DM2HGNU	RN	DL-threo-beta-benzyloxyaspartate, a potent blocker of excitatory amino acid transporters. Mol Pharmacol. 1998 Feb;53(2):195-201.
DM2HGNU	RU	https://pubmed.ncbi.nlm.nih.gov/9463476

DM2HGNU	DI	DM2HGNU
DM2HGNU	DN	DL-TBOA
DM2HGNU	MI	TT2F078
DM2HGNU	MN	Excitatory amino acid transporter 2 (SLC1A2)
DM2HGNU	MT	DTT
DM2HGNU	MA	Inhibitor
DM2HGNU	RN	DL-threo-beta-benzyloxyaspartate, a potent blocker of excitatory amino acid transporters. Mol Pharmacol. 1998 Feb;53(2):195-201.
DM2HGNU	RU	https://pubmed.ncbi.nlm.nih.gov/9463476

DM2HGNU	DI	DM2HGNU
DM2HGNU	DN	DL-TBOA
DM2HGNU	MI	TTG2A6F
DM2HGNU	MN	Excitatory amino acid transporter 3 (SLC1A1)
DM2HGNU	MT	DTT
DM2HGNU	MA	Inhibitor
DM2HGNU	RN	Syntheses of optically pure beta-hydroxyaspartate derivatives as glutamate transporter blockers. Bioorg Med Chem Lett. 2000 Nov 6;10(21):2407-10.
DM2HGNU	RU	https://pubmed.ncbi.nlm.nih.gov/11078189

DM2HGNU	DI	DM2HGNU
DM2HGNU	DN	DL-TBOA
DM2HGNU	MI	TT6KMPN
DM2HGNU	MN	Excitatory amino acid transporter 4 (SLC1A6)
DM2HGNU	MT	DTT
DM2HGNU	MA	Inhibitor
DM2HGNU	RN	Effects of threo-beta-hydroxyaspartate derivatives on excitatory amino acid transporters (EAAT4 and EAAT5). J Neurochem. 2001 Oct;79(2):297-302.
DM2HGNU	RU	https://pubmed.ncbi.nlm.nih.gov/11677257

DM2HGNU	DI	DM2HGNU
DM2HGNU	DN	DL-TBOA
DM2HGNU	MI	TTK41DM
DM2HGNU	MN	Excitatory amino acid transporter 5 (SLC1A7)
DM2HGNU	MT	DTT
DM2HGNU	MA	Inhibitor
DM2HGNU	RN	Effects of threo-beta-hydroxyaspartate derivatives on excitatory amino acid transporters (EAAT4 and EAAT5). J Neurochem. 2001 Oct;79(2):297-302.
DM2HGNU	RU	https://pubmed.ncbi.nlm.nih.gov/11677257

DMPD2XF	DI	DMPD2XF
DMPD2XF	DN	DLX-521
DMPD2XF	MI	TTPMQSO
DMPD2XF	MN	ALK tyrosine kinase receptor (ALK)
DMPD2XF	MT	DTT
DMPD2XF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1839).
DMPD2XF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1839

DMRYQVJ	DI	DMRYQVJ
DMRYQVJ	DN	DM-107
DMRYQVJ	MI	TTJLNAW
DMRYQVJ	MN	Tissue kallikrein (KLK2)
DMRYQVJ	MT	DTT
DMRYQVJ	MA	Inhibitor
DMRYQVJ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2372).
DMRYQVJ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2372

DMM0VDK	DI	DMM0VDK
DMM0VDK	DN	DM-1451
DMM0VDK	MI	TTJS8PY
DMM0VDK	MN	5-HT 6 receptor (HTR6)
DMM0VDK	MT	DTT
DMM0VDK	MA	Agonist
DMM0VDK	RN	Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology. 1999 Jun;20(6):612-27.
DMM0VDK	RU	https://pubmed.ncbi.nlm.nih.gov/10327430

DMM0VDK	DI	DMM0VDK
DMM0VDK	DN	DM-1451
DMM0VDK	MI	TTO9X1H
DMM0VDK	MN	5-HT 7 receptor (HTR7)
DMM0VDK	MT	DTT
DMM0VDK	MA	Agonist
DMM0VDK	RN	Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology. 1999 Jun;20(6):612-27.
DMM0VDK	RU	https://pubmed.ncbi.nlm.nih.gov/10327430

DMSXI6W	DI	DMSXI6W
DMSXI6W	DN	DM-204
DMSXI6W	MI	TTRSMW9
DMSXI6W	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMSXI6W	MT	DTT
DMSXI6W	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2030).
DMSXI6W	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2030

DM7YXKL	DI	DM7YXKL
DM7YXKL	DN	DM3A6S
DM7YXKL	MI	TTKWM86
DM7YXKL	MN	Opioid receptor mu (MOP)
DM7YXKL	MT	DTT
DM7YXKL	MA	Inhibitor
DM7YXKL	RN	Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5.
DM7YXKL	RU	https://pubmed.ncbi.nlm.nih.gov/16777416

DML68UF	DI	DML68UF
DML68UF	DN	DM3B6S
DML68UF	MI	TTKWM86
DML68UF	MN	Opioid receptor mu (MOP)
DML68UF	MT	DTT
DML68UF	MA	Inhibitor
DML68UF	RN	Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5.
DML68UF	RU	https://pubmed.ncbi.nlm.nih.gov/16777416

DMAJ0Q8	DI	DMAJ0Q8
DMAJ0Q8	DN	DM6S
DMAJ0Q8	MI	TTQW87Y
DMAJ0Q8	MN	Opioid receptor kappa (OPRK1)
DMAJ0Q8	MT	DTT
DMAJ0Q8	MA	Inhibitor
DMAJ0Q8	RN	Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5.
DMAJ0Q8	RU	https://pubmed.ncbi.nlm.nih.gov/16777416

DMAJ0Q8	DI	DMAJ0Q8
DMAJ0Q8	DN	DM6S
DMAJ0Q8	MI	TTKWM86
DMAJ0Q8	MN	Opioid receptor mu (MOP)
DMAJ0Q8	MT	DTT
DMAJ0Q8	MA	Inhibitor
DMAJ0Q8	RN	Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5.
DMAJ0Q8	RU	https://pubmed.ncbi.nlm.nih.gov/16777416

DMT6X03	DI	DMT6X03
DMT6X03	DN	D-mannose
DMT6X03	MI	DE26IS8
DMT6X03	MN	Beta-galactosidase (bgaB)
DMT6X03	MT	DME
DMT6X03	MA	Metabolism
DMT6X03	RN	Genetic diversity of Leptotrichia and description of Leptotrichia goodfellowii sp. nov., Leptotrichia hofstadii sp. nov., Leptotrichia shahii sp. nov. and Leptotrichia wadei sp. nov. Int J Syst Evol Microbiol. 2004 Mar;54(Pt 2):583-592.
DMT6X03	RU	https://pubmed.ncbi.nlm.nih.gov/15023979

DMT6X03	DI	DMT6X03
DMT6X03	DN	D-mannose
DMT6X03	MI	DEXTCU0
DMT6X03	MN	Beta-galactosidase (bgaB)
DMT6X03	MT	DME
DMT6X03	MA	Metabolism
DMT6X03	RN	Genetic diversity of Leptotrichia and description of Leptotrichia goodfellowii sp. nov., Leptotrichia hofstadii sp. nov., Leptotrichia shahii sp. nov. and Leptotrichia wadei sp. nov. Int J Syst Evol Microbiol. 2004 Mar;54(Pt 2):583-592.
DMT6X03	RU	https://pubmed.ncbi.nlm.nih.gov/15023979

DMT6X03	DI	DMT6X03
DMT6X03	DN	D-mannose
DMT6X03	MI	DEVSIE6
DMT6X03	MN	Glyceraldehyde-3-phosphate dehydrogenase (gap)
DMT6X03	MT	DME
DMT6X03	MA	Metabolism
DMT6X03	RN	Cloning, expression and characterization of a mucin-binding GAPDH from Lactobacillus acidophilus. Int J Biol Macromol. 2016 Oct;91:338-46.
DMT6X03	RU	https://pubmed.ncbi.nlm.nih.gov/27180300

DMT6X03	DI	DMT6X03
DMT6X03	DN	D-mannose
DMT6X03	MI	DT1CP40
DMT6X03	MN	Sodium/glucose cotransporter 4 (SLC5A9)
DMT6X03	MT	DTP
DMT6X03	MA	Substrate
DMT6X03	RN	SLC5A9/SGLT4, a new Na+-dependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-D-glucitol, and fructose. Life Sci. 2005 Jan 14;76(9):1039-50.
DMT6X03	RU	http://www.ncbi.nlm.nih.gov/pubmed/15607332

DM7O1IW	DI	DM7O1IW
DM7O1IW	DN	D-mannose 1-phosphate
DM7O1IW	MI	DEJFMQ8
DM7O1IW	MN	Phosphomannomutase 1 (PMM1)
DM7O1IW	MT	DME
DM7O1IW	MA	Metabolism
DM7O1IW	RN	The X-ray crystal structures of human alpha-phosphomannomutase 1 reveal the structural basis of congenital disorder of glycosylation type 1a. J Biol Chem. 2006 May 26;281(21):14918-26.
DM7O1IW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16540464

DM7O1IW	DI	DM7O1IW
DM7O1IW	DN	D-mannose 1-phosphate
DM7O1IW	MI	DEBRX3L
DM7O1IW	MN	Phosphomannomutase 2 (PMM2)
DM7O1IW	MT	DME
DM7O1IW	MA	Metabolism
DM7O1IW	RN	The X-ray crystal structures of human alpha-phosphomannomutase 1 reveal the structural basis of congenital disorder of glycosylation type 1a. J Biol Chem. 2006 May 26;281(21):14918-26.
DM7O1IW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16540464

DM7O1IW	DI	DM7O1IW
DM7O1IW	DN	D-mannose 1-phosphate
DM7O1IW	MI	TTLP3GX
DM7O1IW	MN	Pseudomonas Phosphomannomutase/phosphoglucomutase (Pseudo algC)
DM7O1IW	MT	DTT
DM7O1IW	MA	Inhibitor
DM7O1IW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM7O1IW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMK3WY4	DI	DMK3WY4
DMK3WY4	DN	DMCM
DMK3WY4	MI	TTBMV1G
DMK3WY4	MN	GABA(A) receptor alpha-2 (GABRA2)
DMK3WY4	MT	DTT
DMK3WY4	MA	Modulator (allosteric modulator)
DMK3WY4	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 405).
DMK3WY4	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=405

DMK3WY4	DI	DMK3WY4
DMK3WY4	DN	DMCM
DMK3WY4	MI	TT37EDJ
DMK3WY4	MN	GABA(A) receptor alpha-3 (GABRA3)
DMK3WY4	MT	DTT
DMK3WY4	MA	Modulator (allosteric modulator)
DMK3WY4	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 406).
DMK3WY4	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=406

DMK3WY4	DI	DMK3WY4
DMK3WY4	DN	DMCM
DMK3WY4	MI	TTNZPQ1
DMK3WY4	MN	GABA(A) receptor alpha-5 (GABRA5)
DMK3WY4	MT	DTT
DMK3WY4	MA	Modulator (allosteric modulator)
DMK3WY4	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 408).
DMK3WY4	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=408

DMK3WY4	DI	DMK3WY4
DMK3WY4	DN	DMCM
DMK3WY4	MI	TTEX6LM
DMK3WY4	MN	GABA(A) receptor gamma-3 (GABRG3)
DMK3WY4	MT	DTT
DMK3WY4	MA	Modulator (allosteric modulator)
DMK3WY4	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415).
DMK3WY4	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415

DMOJ92D	DI	DMOJ92D
DMOJ92D	DN	DMI-bisphosphate
DMOJ92D	MI	DEBJ2NL
DMOJ92D	MN	Inositol polyphosphate 4-phosphatase I (INPP4A)
DMOJ92D	MT	DME
DMOJ92D	MA	Metabolism
DMOJ92D	RN	The cDNA cloning and characterization of inositol polyphosphate 4-phosphatase type II. Evidence for conserved alternative splicing in the 4-phosphatase family. J Biol Chem. 1997 Sep 19;272(38):23859-64.
DMOJ92D	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9295334

DM3GYFZ	DI	DM3GYFZ
DM3GYFZ	DN	DMI-trisphosphate
DM3GYFZ	MI	DEBJ2NL
DM3GYFZ	MN	Inositol polyphosphate 4-phosphatase I (INPP4A)
DM3GYFZ	MT	DME
DM3GYFZ	MA	Metabolism
DM3GYFZ	RN	The cDNA cloning and characterization of inositol polyphosphate 4-phosphatase type II. Evidence for conserved alternative splicing in the 4-phosphatase family. J Biol Chem. 1997 Sep 19;272(38):23859-64.
DM3GYFZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9295334

DMNRLA7	DI	DMNRLA7
DMNRLA7	DN	DMP-695/696
DMNRLA7	MI	TT7EFHR
DMNRLA7	MN	Corticotropin-releasing factor receptor 1 (CRHR1)
DMNRLA7	MT	DTT
DMNRLA7	MA	Antagonist
DMNRLA7	RN	A review of drug options in age-related macular degeneration therapy and potential new agents. Expert Opin Pharmacother. 2006 Dec;7(17):2355-68.
DMNRLA7	RU	https://pubmed.ncbi.nlm.nih.gov/17109611

DMUGPD1	DI	DMUGPD1
DMUGPD1	DN	DM-PPP
DMUGPD1	MI	TTVBPDM
DMUGPD1	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMUGPD1	MT	DTT
DMUGPD1	MA	Modulator (allosteric modulator)
DMUGPD1	RN	Synthesis and pharmacological characterisation of 2,4-dicarboxy-pyrroles as selective non-competitive mGluR1 antagonists. Bioorg Med Chem. 2003 Jan 17;11(2):171-83.
DMUGPD1	RU	https://pubmed.ncbi.nlm.nih.gov/12470711

DM5WEFK	DI	DM5WEFK
DM5WEFK	DN	Dmt-Pro-3,5Dmp-Phe-NH2
DM5WEFK	MI	TT27RFC
DM5WEFK	MN	Opioid receptor delta (OPRD1)
DM5WEFK	MT	DTT
DM5WEFK	MA	Inhibitor
DM5WEFK	RN	Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66.
DM5WEFK	RU	https://pubmed.ncbi.nlm.nih.gov/17497839

DM5WEFK	DI	DM5WEFK
DM5WEFK	DN	Dmt-Pro-3,5Dmp-Phe-NH2
DM5WEFK	MI	TTQW87Y
DM5WEFK	MN	Opioid receptor kappa (OPRK1)
DM5WEFK	MT	DTT
DM5WEFK	MA	Inhibitor
DM5WEFK	RN	Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66.
DM5WEFK	RU	https://pubmed.ncbi.nlm.nih.gov/17497839

DM5WEFK	DI	DM5WEFK
DM5WEFK	DN	Dmt-Pro-3,5Dmp-Phe-NH2
DM5WEFK	MI	TTKWM86
DM5WEFK	MN	Opioid receptor mu (MOP)
DM5WEFK	MT	DTT
DM5WEFK	MA	Inhibitor
DM5WEFK	RN	Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66.
DM5WEFK	RU	https://pubmed.ncbi.nlm.nih.gov/17497839

DMGUIR1	DI	DMGUIR1
DMGUIR1	DN	Dmt-Pro-Dmp-Phe-NH2
DMGUIR1	MI	TT27RFC
DMGUIR1	MN	Opioid receptor delta (OPRD1)
DMGUIR1	MT	DTT
DMGUIR1	MA	Inhibitor
DMGUIR1	RN	Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66.
DMGUIR1	RU	https://pubmed.ncbi.nlm.nih.gov/17497839

DMGUIR1	DI	DMGUIR1
DMGUIR1	DN	Dmt-Pro-Dmp-Phe-NH2
DMGUIR1	MI	TTQW87Y
DMGUIR1	MN	Opioid receptor kappa (OPRK1)
DMGUIR1	MT	DTT
DMGUIR1	MA	Inhibitor
DMGUIR1	RN	Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66.
DMGUIR1	RU	https://pubmed.ncbi.nlm.nih.gov/17497839

DMGUIR1	DI	DMGUIR1
DMGUIR1	DN	Dmt-Pro-Dmp-Phe-NH2
DMGUIR1	MI	TTKWM86
DMGUIR1	MN	Opioid receptor mu (MOP)
DMGUIR1	MT	DTT
DMGUIR1	MA	Inhibitor
DMGUIR1	RN	Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66.
DMGUIR1	RU	https://pubmed.ncbi.nlm.nih.gov/17497839

DM4VEU2	DI	DM4VEU2
DM4VEU2	DN	Dmt-Pro-Dmt-Phe-NH2
DM4VEU2	MI	TT27RFC
DM4VEU2	MN	Opioid receptor delta (OPRD1)
DM4VEU2	MT	DTT
DM4VEU2	MA	Inhibitor
DM4VEU2	RN	Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66.
DM4VEU2	RU	https://pubmed.ncbi.nlm.nih.gov/17497839

DM4VEU2	DI	DM4VEU2
DM4VEU2	DN	Dmt-Pro-Dmt-Phe-NH2
DM4VEU2	MI	TTQW87Y
DM4VEU2	MN	Opioid receptor kappa (OPRK1)
DM4VEU2	MT	DTT
DM4VEU2	MA	Inhibitor
DM4VEU2	RN	Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66.
DM4VEU2	RU	https://pubmed.ncbi.nlm.nih.gov/17497839

DM4VEU2	DI	DM4VEU2
DM4VEU2	DN	Dmt-Pro-Dmt-Phe-NH2
DM4VEU2	MI	TTKWM86
DM4VEU2	MN	Opioid receptor mu (MOP)
DM4VEU2	MT	DTT
DM4VEU2	MA	Inhibitor
DM4VEU2	RN	Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66.
DM4VEU2	RU	https://pubmed.ncbi.nlm.nih.gov/17497839

DM06VGY	DI	DM06VGY
DM06VGY	DN	Dmt-Pro-Emp-Phe-NH2
DM06VGY	MI	TT27RFC
DM06VGY	MN	Opioid receptor delta (OPRD1)
DM06VGY	MT	DTT
DM06VGY	MA	Inhibitor
DM06VGY	RN	Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66.
DM06VGY	RU	https://pubmed.ncbi.nlm.nih.gov/17497839

DM06VGY	DI	DM06VGY
DM06VGY	DN	Dmt-Pro-Emp-Phe-NH2
DM06VGY	MI	TTQW87Y
DM06VGY	MN	Opioid receptor kappa (OPRK1)
DM06VGY	MT	DTT
DM06VGY	MA	Inhibitor
DM06VGY	RN	Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66.
DM06VGY	RU	https://pubmed.ncbi.nlm.nih.gov/17497839

DM06VGY	DI	DM06VGY
DM06VGY	DN	Dmt-Pro-Emp-Phe-NH2
DM06VGY	MI	TTKWM86
DM06VGY	MN	Opioid receptor mu (MOP)
DM06VGY	MT	DTT
DM06VGY	MA	Inhibitor
DM06VGY	RN	Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66.
DM06VGY	RU	https://pubmed.ncbi.nlm.nih.gov/17497839

DMXUI1J	DI	DMXUI1J
DMXUI1J	DN	Dmt-Pro-Imp-Phe-NH2
DMXUI1J	MI	TT27RFC
DMXUI1J	MN	Opioid receptor delta (OPRD1)
DMXUI1J	MT	DTT
DMXUI1J	MA	Inhibitor
DMXUI1J	RN	Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66.
DMXUI1J	RU	https://pubmed.ncbi.nlm.nih.gov/17497839

DMXUI1J	DI	DMXUI1J
DMXUI1J	DN	Dmt-Pro-Imp-Phe-NH2
DMXUI1J	MI	TTQW87Y
DMXUI1J	MN	Opioid receptor kappa (OPRK1)
DMXUI1J	MT	DTT
DMXUI1J	MA	Inhibitor
DMXUI1J	RN	Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66.
DMXUI1J	RU	https://pubmed.ncbi.nlm.nih.gov/17497839

DMXUI1J	DI	DMXUI1J
DMXUI1J	DN	Dmt-Pro-Imp-Phe-NH2
DMXUI1J	MI	TTKWM86
DMXUI1J	MN	Opioid receptor mu (MOP)
DMXUI1J	MT	DTT
DMXUI1J	MA	Inhibitor
DMXUI1J	RN	Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66.
DMXUI1J	RU	https://pubmed.ncbi.nlm.nih.gov/17497839

DM78PFN	DI	DM78PFN
DM78PFN	DN	Dmt-Pro-Mmp-Phe-NH2
DM78PFN	MI	TT27RFC
DM78PFN	MN	Opioid receptor delta (OPRD1)
DM78PFN	MT	DTT
DM78PFN	MA	Inhibitor
DM78PFN	RN	Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66.
DM78PFN	RU	https://pubmed.ncbi.nlm.nih.gov/17497839

DM78PFN	DI	DM78PFN
DM78PFN	DN	Dmt-Pro-Mmp-Phe-NH2
DM78PFN	MI	TTQW87Y
DM78PFN	MN	Opioid receptor kappa (OPRK1)
DM78PFN	MT	DTT
DM78PFN	MA	Inhibitor
DM78PFN	RN	Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66.
DM78PFN	RU	https://pubmed.ncbi.nlm.nih.gov/17497839

DM78PFN	DI	DM78PFN
DM78PFN	DN	Dmt-Pro-Mmp-Phe-NH2
DM78PFN	MI	TTKWM86
DM78PFN	MN	Opioid receptor mu (MOP)
DM78PFN	MT	DTT
DM78PFN	MA	Inhibitor
DM78PFN	RN	Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66.
DM78PFN	RU	https://pubmed.ncbi.nlm.nih.gov/17497839

DM0VCWA	DI	DM0VCWA
DM0VCWA	DN	Dmt-Pro-Phe-D-1-Nal-NH2
DM0VCWA	MI	TT27RFC
DM0VCWA	MN	Opioid receptor delta (OPRD1)
DM0VCWA	MT	DTT
DM0VCWA	MA	Inhibitor
DM0VCWA	RN	Synthesis and characterization of potent and selective mu-opioid receptor antagonists, [Dmt(1), D-2-Nal(4)]endomorphin-1 (Antanal-1) and [Dmt(1), D... J Med Chem. 2007 Feb 8;50(3):512-20.
DM0VCWA	RU	https://pubmed.ncbi.nlm.nih.gov/17266203

DM0VCWA	DI	DM0VCWA
DM0VCWA	DN	Dmt-Pro-Phe-D-1-Nal-NH2
DM0VCWA	MI	TTKWM86
DM0VCWA	MN	Opioid receptor mu (MOP)
DM0VCWA	MT	DTT
DM0VCWA	MA	Inhibitor
DM0VCWA	RN	Synthesis and characterization of potent and selective mu-opioid receptor antagonists, [Dmt(1), D-2-Nal(4)]endomorphin-1 (Antanal-1) and [Dmt(1), D... J Med Chem. 2007 Feb 8;50(3):512-20.
DM0VCWA	RU	https://pubmed.ncbi.nlm.nih.gov/17266203

DMRJVE8	DI	DMRJVE8
DMRJVE8	DN	Dmt-Pro-Phe-D-2-Nal-NH2
DMRJVE8	MI	TT27RFC
DMRJVE8	MN	Opioid receptor delta (OPRD1)
DMRJVE8	MT	DTT
DMRJVE8	MA	Inhibitor
DMRJVE8	RN	Synthesis and characterization of potent and selective mu-opioid receptor antagonists, [Dmt(1), D-2-Nal(4)]endomorphin-1 (Antanal-1) and [Dmt(1), D... J Med Chem. 2007 Feb 8;50(3):512-20.
DMRJVE8	RU	https://pubmed.ncbi.nlm.nih.gov/17266203

DMRJVE8	DI	DMRJVE8
DMRJVE8	DN	Dmt-Pro-Phe-D-2-Nal-NH2
DMRJVE8	MI	TTKWM86
DMRJVE8	MN	Opioid receptor mu (MOP)
DMRJVE8	MT	DTT
DMRJVE8	MA	Inhibitor
DMRJVE8	RN	Synthesis and characterization of potent and selective mu-opioid receptor antagonists, [Dmt(1), D-2-Nal(4)]endomorphin-1 (Antanal-1) and [Dmt(1), D... J Med Chem. 2007 Feb 8;50(3):512-20.
DMRJVE8	RU	https://pubmed.ncbi.nlm.nih.gov/17266203

DMM8BIE	DI	DMM8BIE
DMM8BIE	DN	Dmt-Pro-Phe-Phe-NH2
DMM8BIE	MI	TT27RFC
DMM8BIE	MN	Opioid receptor delta (OPRD1)
DMM8BIE	MT	DTT
DMM8BIE	MA	Inhibitor
DMM8BIE	RN	Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66.
DMM8BIE	RU	https://pubmed.ncbi.nlm.nih.gov/17497839

DMM8BIE	DI	DMM8BIE
DMM8BIE	DN	Dmt-Pro-Phe-Phe-NH2
DMM8BIE	MI	TTQW87Y
DMM8BIE	MN	Opioid receptor kappa (OPRK1)
DMM8BIE	MT	DTT
DMM8BIE	MA	Inhibitor
DMM8BIE	RN	Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66.
DMM8BIE	RU	https://pubmed.ncbi.nlm.nih.gov/17497839

DMM8BIE	DI	DMM8BIE
DMM8BIE	DN	Dmt-Pro-Phe-Phe-NH2
DMM8BIE	MI	TTKWM86
DMM8BIE	MN	Opioid receptor mu (MOP)
DMM8BIE	MT	DTT
DMM8BIE	MA	Inhibitor
DMM8BIE	RN	Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66.
DMM8BIE	RU	https://pubmed.ncbi.nlm.nih.gov/17497839

DMEMQAK	DI	DMEMQAK
DMEMQAK	DN	Dmt-Pro-Tmp-Phe-NH2
DMEMQAK	MI	TT27RFC
DMEMQAK	MN	Opioid receptor delta (OPRD1)
DMEMQAK	MT	DTT
DMEMQAK	MA	Inhibitor
DMEMQAK	RN	Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66.
DMEMQAK	RU	https://pubmed.ncbi.nlm.nih.gov/17497839

DMEMQAK	DI	DMEMQAK
DMEMQAK	DN	Dmt-Pro-Tmp-Phe-NH2
DMEMQAK	MI	TTQW87Y
DMEMQAK	MN	Opioid receptor kappa (OPRK1)
DMEMQAK	MT	DTT
DMEMQAK	MA	Inhibitor
DMEMQAK	RN	Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66.
DMEMQAK	RU	https://pubmed.ncbi.nlm.nih.gov/17497839

DMEMQAK	DI	DMEMQAK
DMEMQAK	DN	Dmt-Pro-Tmp-Phe-NH2
DMEMQAK	MI	TTKWM86
DMEMQAK	MN	Opioid receptor mu (MOP)
DMEMQAK	MT	DTT
DMEMQAK	MA	Inhibitor
DMEMQAK	RN	Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66.
DMEMQAK	RU	https://pubmed.ncbi.nlm.nih.gov/17497839

DMKEV5U	DI	DMKEV5U
DMKEV5U	DN	Dmt-Pro-Trp-D-2-Nal-NH2
DMKEV5U	MI	TT27RFC
DMKEV5U	MN	Opioid receptor delta (OPRD1)
DMKEV5U	MT	DTT
DMKEV5U	MA	Inhibitor
DMKEV5U	RN	Synthesis and characterization of potent and selective mu-opioid receptor antagonists, [Dmt(1), D-2-Nal(4)]endomorphin-1 (Antanal-1) and [Dmt(1), D... J Med Chem. 2007 Feb 8;50(3):512-20.
DMKEV5U	RU	https://pubmed.ncbi.nlm.nih.gov/17266203

DMKEV5U	DI	DMKEV5U
DMKEV5U	DN	Dmt-Pro-Trp-D-2-Nal-NH2
DMKEV5U	MI	TTKWM86
DMKEV5U	MN	Opioid receptor mu (MOP)
DMKEV5U	MT	DTT
DMKEV5U	MA	Inhibitor
DMKEV5U	RN	Synthesis and characterization of potent and selective mu-opioid receptor antagonists, [Dmt(1), D-2-Nal(4)]endomorphin-1 (Antanal-1) and [Dmt(1), D... J Med Chem. 2007 Feb 8;50(3):512-20.
DMKEV5U	RU	https://pubmed.ncbi.nlm.nih.gov/17266203

DMHRT0F	DI	DMHRT0F
DMHRT0F	DN	Dmt-Sar-Phe-D-2-Nal-NH
DMHRT0F	MI	TTKWM86
DMHRT0F	MN	Opioid receptor mu (MOP)
DMHRT0F	MT	DTT
DMHRT0F	MA	Inhibitor
DMHRT0F	RN	Novel highly potent mu-opioid receptor antagonist based on endomorphin-2 structure. Bioorg Med Chem Lett. 2008 Feb 15;18(4):1350-3.
DMHRT0F	RU	https://pubmed.ncbi.nlm.nih.gov/18207400

DMNUKIX	DI	DMNUKIX
DMNUKIX	DN	D-myo-inositol 1,4,5-trisphosphate
DMNUKIX	MI	TTC9IZL
DMNUKIX	MN	Inositol 1,4,5-trisphosphate receptor (ITPR)
DMNUKIX	MT	DTT
DMNUKIX	MA	Inhibitor
DMNUKIX	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMNUKIX	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMNUKIX	DI	DMNUKIX
DMNUKIX	DN	D-myo-inositol 1,4,5-trisphosphate
DMNUKIX	MI	DESA9EX
DMNUKIX	MN	Inositol polyphosphate multikinase (IPMK)
DMNUKIX	MT	DME
DMNUKIX	MA	Metabolism
DMNUKIX	RN	The human homologue of yeast ArgRIII protein is an inositol phosphate multikinase with predominantly nuclear localization. Biochem J. 2002 Sep 1;366(Pt 2):549-56.
DMNUKIX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12027805

DMQXPA5	DI	DMQXPA5
DMQXPA5	DN	DNQX
DMQXPA5	MI	TTAN6JD
DMQXPA5	MN	Glutamate receptor AMPA (GRIA)
DMQXPA5	MT	DTT
DMQXPA5	MA	Inhibitor
DMQXPA5	RN	Synthesis of chiral 1-(2'-amino-2'-carboxyethyl)-1,4-dihydro-6,7-quinoxaline-2,3-diones: alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate recep... J Med Chem. 1996 Oct 25;39(22):4430-8.
DMQXPA5	RU	https://pubmed.ncbi.nlm.nih.gov/8893837

DMQXPA5	DI	DMQXPA5
DMQXPA5	DN	DNQX
DMQXPA5	MI	TTVPQTF
DMQXPA5	MN	Glutamate receptor AMPA 1 (GRIA1)
DMQXPA5	MT	DTT
DMQXPA5	MA	Inhibitor
DMQXPA5	RN	Synthesis of chiral 1-(2'-amino-2'-carboxyethyl)-1,4-dihydro-6,7-quinoxaline-2,3-diones: alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate recep... J Med Chem. 1996 Oct 25;39(22):4430-8.
DMQXPA5	RU	https://pubmed.ncbi.nlm.nih.gov/8893837

DMQXPA5	DI	DMQXPA5
DMQXPA5	DN	DNQX
DMQXPA5	MI	TT0MYE2
DMQXPA5	MN	Glutamate receptor ionotropic kainate 1 (GRIK1)
DMQXPA5	MT	DTT
DMQXPA5	MA	Inhibitor
DMQXPA5	RN	Synthesis of chiral 1-(2'-amino-2'-carboxyethyl)-1,4-dihydro-6,7-quinoxaline-2,3-diones: alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate recep... J Med Chem. 1996 Oct 25;39(22):4430-8.
DMQXPA5	RU	https://pubmed.ncbi.nlm.nih.gov/8893837

DMQXPA5	DI	DMQXPA5
DMQXPA5	DN	DNQX
DMQXPA5	MI	TTLD29N
DMQXPA5	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMQXPA5	MT	DTT
DMQXPA5	MA	Inhibitor
DMQXPA5	RN	Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antago... J Med Chem. 1991 Apr;34(4):1243-52.
DMQXPA5	RU	https://pubmed.ncbi.nlm.nih.gov/1826744

DMQXPA5	DI	DMQXPA5
DMQXPA5	DN	DNQX
DMQXPA5	MI	TTKJEMQ
DMQXPA5	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMQXPA5	MT	DTT
DMQXPA5	MA	Inhibitor
DMQXPA5	RN	Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antago... J Med Chem. 1991 Apr;34(4):1243-52.
DMQXPA5	RU	https://pubmed.ncbi.nlm.nih.gov/1826744

DMQXPA5	DI	DMQXPA5
DMQXPA5	DN	DNQX
DMQXPA5	MI	TTN9D8E
DMQXPA5	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMQXPA5	MT	DTT
DMQXPA5	MA	Inhibitor
DMQXPA5	RN	Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antago... J Med Chem. 1991 Apr;34(4):1243-52.
DMQXPA5	RU	https://pubmed.ncbi.nlm.nih.gov/1826744

DMC5RL7	DI	DMC5RL7
DMC5RL7	DN	DNX-2000
DMC5RL7	MI	TTOU65C
DMC5RL7	MN	Tyrosine-protein kinase SYK (SYK)
DMC5RL7	MT	DTT
DMC5RL7	MA	Inhibitor
DMC5RL7	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2230).
DMC5RL7	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2230

DMVCP6X	DI	DMVCP6X
DMVCP6X	DN	Docosapentaenoic acid
DMVCP6X	MI	TTSZLWK
DMVCP6X	MN	Aromatase (CYP19A1)
DMVCP6X	MT	DTT
DMVCP6X	MA	Inhibitor
DMVCP6X	RN	Interference by naturally occurring fatty acids in a noncellular enzyme-based aromatase bioassay. J Nat Prod. 2006 Apr;69(4):700-3.
DMVCP6X	RU	https://pubmed.ncbi.nlm.nih.gov/16643058

DMEKU71	DI	DMEKU71
DMEKU71	DN	Dodeca-2E,4E-dienoic acid isobutylamide
DMEKU71	MI	TTMSFAW
DMEKU71	MN	Cannabinoid receptor 2 (CB2)
DMEKU71	MT	DTT
DMEKU71	MA	Inhibitor
DMEKU71	RN	Self-assembling cannabinomimetics: supramolecular structures of N-alkyl amides. J Nat Prod. 2007 Jun;70(6):1010-5.
DMEKU71	RU	https://pubmed.ncbi.nlm.nih.gov/17497806

DME9CGK	DI	DME9CGK
DME9CGK	DN	Dodecane-1-sulfonyl fluoride
DME9CGK	MI	TT6OEDT
DME9CGK	MN	Cannabinoid receptor 1 (CB1)
DME9CGK	MT	DTT
DME9CGK	MA	Inhibitor
DME9CGK	RN	Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5875-8.
DME9CGK	RU	https://pubmed.ncbi.nlm.nih.gov/18752948

DME9CGK	DI	DME9CGK
DME9CGK	DN	Dodecane-1-sulfonyl fluoride
DME9CGK	MI	TTDP1UC
DME9CGK	MN	Fatty acid amide hydrolase (FAAH)
DME9CGK	MT	DTT
DME9CGK	MA	Inhibitor
DME9CGK	RN	Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5875-8.
DME9CGK	RU	https://pubmed.ncbi.nlm.nih.gov/18752948

DMCNFEL	DI	DMCNFEL
DMCNFEL	DN	Dodecanesulfonate ion
DMCNFEL	MI	TTEB0GD
DMCNFEL	MN	Cholinesterase (BCHE)
DMCNFEL	MT	DTT
DMCNFEL	MA	Inhibitor
DMCNFEL	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMCNFEL	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMUPMCZ	DI	DMUPMCZ
DMUPMCZ	DN	Dodecane-Trimethylamine
DMUPMCZ	MI	TT7WUAV
DMUPMCZ	MN	Protein-tyrosine phosphatase SHP-2 (PTPN11)
DMUPMCZ	MT	DTT
DMUPMCZ	MA	Inhibitor
DMUPMCZ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMUPMCZ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM6TIQX	DI	DM6TIQX
DM6TIQX	DN	Dodecanoic acid adamantan-1-ylamide
DM6TIQX	MI	TT7WVHI
DM6TIQX	MN	Soluble epoxide hydrolase (EPHX2)
DM6TIQX	MT	DTT
DM6TIQX	MA	Inhibitor
DM6TIQX	RN	Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem. 2005 May 19;48(10):3621-9.
DM6TIQX	RU	https://pubmed.ncbi.nlm.nih.gov/15887969

DMMDG92	DI	DMMDG92
DMMDG92	DN	Dodecyl-Alpha-D-Maltoside
DMMDG92	MI	TT1Q3IE
DMMDG92	MN	Retinoic acid receptor gamma (RARG)
DMMDG92	MT	DTT
DMMDG92	MA	Inhibitor
DMMDG92	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMMDG92	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMPCLTW	DI	DMPCLTW
DMPCLTW	DN	dodecylphosphate
DMPCLTW	MI	TTE2YJR
DMPCLTW	MN	Lysophosphatidate-3 receptor (LPAR3)
DMPCLTW	MT	DTT
DMPCLTW	MA	Antagonist
DMPCLTW	RN	Fatty alcohol phosphates are subtype-selective agonists and antagonists of lysophosphatidic acid receptors. Mol Pharmacol. 2003 May;63(5):1032-42.
DMPCLTW	RU	https://pubmed.ncbi.nlm.nih.gov/12695531

DMPCLTW	DI	DMPCLTW
DMPCLTW	DN	dodecylphosphate
DMPCLTW	MI	TTB7Y8I
DMPCLTW	MN	Lysophosphatidic acid receptor 2 (LPAR2)
DMPCLTW	MT	DTT
DMPCLTW	MA	Agonist
DMPCLTW	RN	Fatty alcohol phosphates are subtype-selective agonists and antagonists of lysophosphatidic acid receptors. Mol Pharmacol. 2003 May;63(5):1032-42.
DMPCLTW	RU	https://pubmed.ncbi.nlm.nih.gov/12695531

DMLHKI9	DI	DMLHKI9
DMLHKI9	DN	Dodecyl-phosphonic acid
DMLHKI9	MI	TTQ6S1K
DMLHKI9	MN	Lysophosphatidic acid receptor 1 (LPAR1)
DMLHKI9	MT	DTT
DMLHKI9	MA	Inhibitor
DMLHKI9	RN	Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30.
DMLHKI9	RU	https://pubmed.ncbi.nlm.nih.gov/16033271

DMAJVPI	DI	DMAJVPI
DMAJVPI	DN	dodecyl-thiophosphate
DMAJVPI	MI	TTE2YJR
DMAJVPI	MN	Lysophosphatidate-3 receptor (LPAR3)
DMAJVPI	MT	DTT
DMAJVPI	MA	Antagonist
DMAJVPI	RN	Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30.
DMAJVPI	RU	https://pubmed.ncbi.nlm.nih.gov/16033271

DMAJVPI	DI	DMAJVPI
DMAJVPI	DN	dodecyl-thiophosphate
DMAJVPI	MI	TTQ6S1K
DMAJVPI	MN	Lysophosphatidic acid receptor 1 (LPAR1)
DMAJVPI	MT	DTT
DMAJVPI	MA	Inhibitor
DMAJVPI	RN	Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30.
DMAJVPI	RU	https://pubmed.ncbi.nlm.nih.gov/16033271

DMAJVPI	DI	DMAJVPI
DMAJVPI	DN	dodecyl-thiophosphate
DMAJVPI	MI	TTB7Y8I
DMAJVPI	MN	Lysophosphatidic acid receptor 2 (LPAR2)
DMAJVPI	MT	DTT
DMAJVPI	MA	Agonist
DMAJVPI	RN	Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30.
DMAJVPI	RU	https://pubmed.ncbi.nlm.nih.gov/16033271

DM1YCQF	DI	DM1YCQF
DM1YCQF	DN	dolichol phosphate
DM1YCQF	MI	TT5DFHW
DM1YCQF	MN	Mevalonate kinase (MVK)
DM1YCQF	MT	DTT
DM1YCQF	MA	Inhibitor
DM1YCQF	RN	Post-translational regulation of mevalonate kinase by intermediates of the cholesterol and nonsterol isoprene biosynthetic pathways. J Lipid Res. 1997 Nov;38(11):2216-23.
DM1YCQF	RU	https://pubmed.ncbi.nlm.nih.gov/9392419

DM53KZX	DI	DM53KZX
DM53KZX	DN	DOM
DM53KZX	MI	TTJQOD7
DM53KZX	MN	5-HT 2A receptor (HTR2A)
DM53KZX	MT	DTT
DM53KZX	MA	Inhibitor
DM53KZX	RN	The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands. Bioorg Med Chem. 2008 Apr 15;16(8):4661-9.
DM53KZX	RU	https://pubmed.ncbi.nlm.nih.gov/18296055

DMXJOYH	DI	DMXJOYH
DMXJOYH	DN	DOM-0215
DMXJOYH	MI	TTF8CQI
DMXJOYH	MN	Tumor necrosis factor (TNF)
DMXJOYH	MT	DTT
DMXJOYH	MA	Modulator
DMXJOYH	RN	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
DMXJOYH	RU	https://www.ncbi.nlm.nih.gov/pubmed/27899562

DMYPVO0	DI	DMYPVO0
DMYPVO0	DN	domoic acid
DMYPVO0	MI	TT0MYE2
DMYPVO0	MN	Glutamate receptor ionotropic kainate 1 (GRIK1)
DMYPVO0	MT	DTT
DMYPVO0	MA	Agonist
DMYPVO0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 450).
DMYPVO0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=450

DMYPVO0	DI	DMYPVO0
DMYPVO0	DN	domoic acid
DMYPVO0	MI	TT0K5RG
DMYPVO0	MN	Glutamate receptor ionotropic kainate 2 (GRIK2)
DMYPVO0	MT	DTT
DMYPVO0	MA	Agonist
DMYPVO0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 451).
DMYPVO0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=451

DMYPVO0	DI	DMYPVO0
DMYPVO0	DN	domoic acid
DMYPVO0	MI	TTQV6BO
DMYPVO0	MN	Glutamate receptor ionotropic kainate 4 (GluK4)
DMYPVO0	MT	DTT
DMYPVO0	MA	Agonist
DMYPVO0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 453).
DMYPVO0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=453

DMYPVO0	DI	DMYPVO0
DMYPVO0	DN	domoic acid
DMYPVO0	MI	TTO6LI7
DMYPVO0	MN	Glutamate receptor ionotropic kainate 5 (GRIK5)
DMYPVO0	MT	DTT
DMYPVO0	MA	Agonist
DMYPVO0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 454).
DMYPVO0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=454

DMOJF6D	DI	DMOJF6D
DMOJF6D	DN	Domoric acid
DMOJF6D	MI	TT0MYE2
DMOJF6D	MN	Glutamate receptor ionotropic kainate 1 (GRIK1)
DMOJF6D	MT	DTT
DMOJF6D	MA	Inhibitor
DMOJF6D	RN	Chemo-enzymatic synthesis of a series of 2,4-syn-functionalized (S)-glutamate analogues: new insight into the structure-activity relation of ionotr... J Med Chem. 2008 Jul 24;51(14):4093-103.
DMOJF6D	RU	https://pubmed.ncbi.nlm.nih.gov/18578478

DMKYXJW	DI	DMKYXJW
DMKYXJW	DN	Dorsomorphin
DMKYXJW	MI	TTLAFZV
DMKYXJW	MN	AMP-activated protein kinase (AMPK)
DMKYXJW	MT	DTT
DMKYXJW	MA	Inhibitor
DMKYXJW	RN	The rational design of a novel potent analogue of the 5'-AMP-activated protein kinase inhibitor compound C with improved selectivity and cellular a... Bioorg Med Chem Lett. 2010 Nov 15;20(22):6394-9.
DMKYXJW	RU	https://pubmed.ncbi.nlm.nih.gov/20932747

DM6TU84	DI	DM6TU84
DM6TU84	DN	Double Oxidized Cysteine
DM6TU84	MI	TTHCF4J
DM6TU84	MN	Alpha-glucosidase (GLA)
DM6TU84	MT	DTT
DM6TU84	MA	Inhibitor
DM6TU84	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM6TU84	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM6TU84	DI	DM6TU84
DM6TU84	DN	Double Oxidized Cysteine
DM6TU84	MI	TTDS503
DM6TU84	MN	Beta-crystallin B1 (CRYBB1)
DM6TU84	MT	DTT
DM6TU84	MA	Inhibitor
DM6TU84	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM6TU84	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM6TU84	DI	DM6TU84
DM6TU84	DN	Double Oxidized Cysteine
DM6TU84	MI	TT7HF4W
DM6TU84	MN	Cyclin-dependent kinase 2 (CDK2)
DM6TU84	MT	DTT
DM6TU84	MA	Inhibitor
DM6TU84	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM6TU84	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM6TU84	DI	DM6TU84
DM6TU84	DN	Double Oxidized Cysteine
DM6TU84	MI	TTXWASR
DM6TU84	MN	Intestinal maltase-glucoamylase (MGAM)
DM6TU84	MT	DTT
DM6TU84	MA	Inhibitor
DM6TU84	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM6TU84	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM6TU84	DI	DM6TU84
DM6TU84	DN	Double Oxidized Cysteine
DM6TU84	MI	TTR0SWN
DM6TU84	MN	M-phase inducer phosphatase 2 (MPIP2)
DM6TU84	MT	DTT
DM6TU84	MA	Inhibitor
DM6TU84	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM6TU84	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM6TU84	DI	DM6TU84
DM6TU84	DN	Double Oxidized Cysteine
DM6TU84	MI	TTNGKET
DM6TU84	MN	Prolyl endopeptidase (PREP)
DM6TU84	MT	DTT
DM6TU84	MA	Inhibitor
DM6TU84	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM6TU84	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM6TU84	DI	DM6TU84
DM6TU84	DN	Double Oxidized Cysteine
DM6TU84	MI	TTELIN2
DM6TU84	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DM6TU84	MT	DTT
DM6TU84	MA	Inhibitor
DM6TU84	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM6TU84	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM6TU84	DI	DM6TU84
DM6TU84	DN	Double Oxidized Cysteine
DM6TU84	MI	TTICO5G
DM6TU84	MN	Staphylococcus Peptide deformylase (Stap-coc def)
DM6TU84	MT	DTT
DM6TU84	MA	Inhibitor
DM6TU84	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM6TU84	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMQIK9S	DI	DMQIK9S
DMQIK9S	DN	DOV-51892
DMQIK9S	MI	TTEX6LM
DMQIK9S	MN	GABA(A) receptor gamma-3 (GABRG3)
DMQIK9S	MT	DTT
DMQIK9S	MA	Modulator
DMQIK9S	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415).
DMQIK9S	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415

DMJF6AQ	DI	DMJF6AQ
DMJF6AQ	DN	Doxorubicin-Formaldehyde Conjugate
DMJF6AQ	MI	TTZAYWL
DMJF6AQ	MN	Estrogen receptor (ESR)
DMJF6AQ	MT	DTT
DMJF6AQ	MA	Inhibitor
DMJF6AQ	RN	Design, synthesis, and biological evaluation of doxorubicin-formaldehyde conjugates targeted to breast cancer cells. J Med Chem. 2004 Feb 26;47(5):1193-206.
DMJF6AQ	RU	https://pubmed.ncbi.nlm.nih.gov/14971899

DMJF6AQ	DI	DMJF6AQ
DMJF6AQ	DN	Doxorubicin-Formaldehyde Conjugate
DMJF6AQ	MI	TTOM3J0
DMJF6AQ	MN	Estrogen receptor beta (ESR2)
DMJF6AQ	MT	DTT
DMJF6AQ	MA	Inhibitor
DMJF6AQ	RN	Design, synthesis, and biological evaluation of doxorubicin-formaldehyde conjugates targeted to breast cancer cells. J Med Chem. 2004 Feb 26;47(5):1193-206.
DMJF6AQ	RU	https://pubmed.ncbi.nlm.nih.gov/14971899

DMNJBF8	DI	DMNJBF8
DMNJBF8	DN	doxorubicin-LL2 conjugate
DMNJBF8	MI	TT0IHXV
DMNJBF8	MN	DNA topoisomerase II (TOP2)
DMNJBF8	MT	DTT
DMNJBF8	MA	Modulator
DMNJBF8	RN	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
DMNJBF8	RU	https://www.ncbi.nlm.nih.gov/pubmed/27899562

DMNJBF8	DI	DMNJBF8
DMNJBF8	DN	doxorubicin-LL2 conjugate
DMNJBF8	MI	TTUTN1I
DMNJBF8	MN	Human Deoxyribonucleic acid (hDNA)
DMNJBF8	MT	DTT
DMNJBF8	MA	Modulator
DMNJBF8	RN	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
DMNJBF8	RU	https://www.ncbi.nlm.nih.gov/pubmed/27899562

DM2OCZ8	DI	DM2OCZ8
DM2OCZ8	DN	doxorubicin-peptide-PEG conjugate
DM2OCZ8	MI	TT0IHXV
DM2OCZ8	MN	DNA topoisomerase II (TOP2)
DM2OCZ8	MT	DTT
DM2OCZ8	MA	Modulator
DM2OCZ8	RN	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
DM2OCZ8	RU	https://www.ncbi.nlm.nih.gov/pubmed/27899562

DM2OCZ8	DI	DM2OCZ8
DM2OCZ8	DN	doxorubicin-peptide-PEG conjugate
DM2OCZ8	MI	TTUTN1I
DM2OCZ8	MN	Human Deoxyribonucleic acid (hDNA)
DM2OCZ8	MT	DTT
DM2OCZ8	MA	Modulator
DM2OCZ8	RN	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
DM2OCZ8	RU	https://www.ncbi.nlm.nih.gov/pubmed/27899562

DMXEVA2	DI	DMXEVA2
DMXEVA2	DN	DP-3005
DMXEVA2	MI	TTZPWGN
DMXEVA2	MN	Voltage-gated calcium channel alpha Cav3.2 (CACNA1H)
DMXEVA2	MT	DTT
DMXEVA2	MA	Blocker
DMXEVA2	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 536).
DMXEVA2	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=536

DMFZML9	DI	DMFZML9
DMFZML9	DN	DP-3590
DMFZML9	MI	TTNDSF4
DMFZML9	MN	Proto-oncogene c-Met (MET)
DMFZML9	MT	DTT
DMFZML9	MA	Inhibitor
DMFZML9	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
DMFZML9	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815

DMARTC2	DI	DMARTC2
DMARTC2	DN	DP-802
DMARTC2	MI	TTQBR95
DMARTC2	MN	Stress-activated protein kinase 2a (p38 alpha)
DMARTC2	MT	DTT
DMARTC2	MA	Inhibitor
DMARTC2	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1499).
DMARTC2	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1499

DMIRSNA	DI	DMIRSNA
DMIRSNA	DN	DPDPE
DMIRSNA	MI	TT27RFC
DMIRSNA	MN	Opioid receptor delta (OPRD1)
DMIRSNA	MT	DTT
DMIRSNA	MA	Inhibitor
DMIRSNA	RN	Evaluation of N-substitution in 6,7-benzomorphan compounds. Bioorg Med Chem. 2010 Jul 15;18(14):4975-82. 
DMIRSNA	RU	https://pubmed.ncbi.nlm.nih.gov/20599386

DMIRSNA	DI	DMIRSNA
DMIRSNA	DN	DPDPE
DMIRSNA	MI	TTQW87Y
DMIRSNA	MN	Opioid receptor kappa (OPRK1)
DMIRSNA	MT	DTT
DMIRSNA	MA	Inhibitor
DMIRSNA	RN	Opioid agonist and antagonist activities of morphindoles related to naltrindole. J Med Chem. 1992 Nov 13;35(23):4325-9.
DMIRSNA	RU	https://pubmed.ncbi.nlm.nih.gov/1333013

DMIRSNA	DI	DMIRSNA
DMIRSNA	DN	DPDPE
DMIRSNA	MI	TTKWM86
DMIRSNA	MN	Opioid receptor mu (MOP)
DMIRSNA	MT	DTT
DMIRSNA	MA	Inhibitor
DMIRSNA	RN	Evaluation of N-substitution in 6,7-benzomorphan compounds. Bioorg Med Chem. 2010 Jul 15;18(14):4975-82. 
DMIRSNA	RU	https://pubmed.ncbi.nlm.nih.gov/20599386

DMLK428	DI	DMLK428
DMLK428	DN	D-Phe-Arg-2-Nal-NHCH3
DMLK428	MI	TT0MV2T
DMLK428	MN	Melanocortin receptor 1 (MC1R)
DMLK428	MT	DTT
DMLK428	MA	Inhibitor
DMLK428	RN	Design, synthesis, and evaluation of proline and pyrrolidine based melanocortin receptor agonists. A conformationally restricted dipeptide mimic ap... J Med Chem. 2006 Jul 27;49(15):4745-61.
DMLK428	RU	https://pubmed.ncbi.nlm.nih.gov/16854081

DMLK428	DI	DMLK428
DMLK428	DN	D-Phe-Arg-2-Nal-NHCH3
DMLK428	MI	TTD0CIQ
DMLK428	MN	Melanocortin receptor 4 (MC4R)
DMLK428	MT	DTT
DMLK428	MA	Inhibitor
DMLK428	RN	Design, synthesis, and evaluation of proline and pyrrolidine based melanocortin receptor agonists. A conformationally restricted dipeptide mimic ap... J Med Chem. 2006 Jul 27;49(15):4745-61.
DMLK428	RU	https://pubmed.ncbi.nlm.nih.gov/16854081

DM0YQHM	DI	DM0YQHM
DM0YQHM	DN	D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Asp-NH2
DM0YQHM	MI	TTZ6T9E
DM0YQHM	MN	Somatostatin receptor type 2 (SSTR2)
DM0YQHM	MT	DTT
DM0YQHM	MA	Inhibitor
DM0YQHM	RN	Discovery of iodinated somatostatin analogues selective for hsst2 and hsst5 with excellent inhibition of growth hormone and prolactin release from ... J Med Chem. 2005 Oct 20;48(21):6643-52.
DM0YQHM	RU	https://pubmed.ncbi.nlm.nih.gov/16220980

DM0YQHM	DI	DM0YQHM
DM0YQHM	DN	D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Asp-NH2
DM0YQHM	MI	TT2BC4G
DM0YQHM	MN	Somatostatin receptor type 5 (SSTR5)
DM0YQHM	MT	DTT
DM0YQHM	MA	Inhibitor
DM0YQHM	RN	Discovery of iodinated somatostatin analogues selective for hsst2 and hsst5 with excellent inhibition of growth hormone and prolactin release from ... J Med Chem. 2005 Oct 20;48(21):6643-52.
DM0YQHM	RU	https://pubmed.ncbi.nlm.nih.gov/16220980

DM2EFLA	DI	DM2EFLA
DM2EFLA	DN	D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2(CTAP)
DM2EFLA	MI	TT27RFC
DM2EFLA	MN	Opioid receptor delta (OPRD1)
DM2EFLA	MT	DTT
DM2EFLA	MA	Inhibitor
DM2EFLA	RN	Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors. J Med Chem. 1986 Nov;29(11):2370-5.
DM2EFLA	RU	https://pubmed.ncbi.nlm.nih.gov/2878079

DM2EFLA	DI	DM2EFLA
DM2EFLA	DN	D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2(CTAP)
DM2EFLA	MI	TTKWM86
DM2EFLA	MN	Opioid receptor mu (MOP)
DM2EFLA	MT	DTT
DM2EFLA	MA	Inhibitor
DM2EFLA	RN	Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors. J Med Chem. 1986 Nov;29(11):2370-5.
DM2EFLA	RU	https://pubmed.ncbi.nlm.nih.gov/2878079

DMPQHRC	DI	DMPQHRC
DMPQHRC	DN	D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2(CTP)
DMPQHRC	MI	TT27RFC
DMPQHRC	MN	Opioid receptor delta (OPRD1)
DMPQHRC	MT	DTT
DMPQHRC	MA	Inhibitor
DMPQHRC	RN	Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors. J Med Chem. 1986 Nov;29(11):2370-5.
DMPQHRC	RU	https://pubmed.ncbi.nlm.nih.gov/2878079

DMPQHRC	DI	DMPQHRC
DMPQHRC	DN	D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2(CTP)
DMPQHRC	MI	TTKWM86
DMPQHRC	MN	Opioid receptor mu (MOP)
DMPQHRC	MT	DTT
DMPQHRC	MA	Inhibitor
DMPQHRC	RN	Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors. J Med Chem. 1986 Nov;29(11):2370-5.
DMPQHRC	RU	https://pubmed.ncbi.nlm.nih.gov/2878079

DMX1IYO	DI	DMX1IYO
DMX1IYO	DN	D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2(CTOP)
DMX1IYO	MI	TT27RFC
DMX1IYO	MN	Opioid receptor delta (OPRD1)
DMX1IYO	MT	DTT
DMX1IYO	MA	Inhibitor
DMX1IYO	RN	Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors. J Med Chem. 1986 Nov;29(11):2370-5.
DMX1IYO	RU	https://pubmed.ncbi.nlm.nih.gov/2878079

DMUJC97	DI	DMUJC97
DMUJC97	DN	D-Phe-Cys-Tyr--Trp-Lys-Thr-Pen-Thr-NH2
DMUJC97	MI	TTKWM86
DMUJC97	MN	Opioid receptor mu (MOP)
DMUJC97	MT	DTT
DMUJC97	MA	Inhibitor
DMUJC97	RN	Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors. J Med Chem. 1986 Nov;29(11):2370-5.
DMUJC97	RU	https://pubmed.ncbi.nlm.nih.gov/2878079

DMTUHFX	DI	DMTUHFX
DMTUHFX	DN	D-Phenylalanine
DMTUHFX	MI	TTA7YIZ
DMTUHFX	MN	Corticoliberin (CRH)
DMTUHFX	MT	DTT
DMTUHFX	MA	Inhibitor
DMTUHFX	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMTUHFX	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMGD7JM	DI	DMGD7JM
DMGD7JM	DN	D-phenylalanyl-N-(3-chlorobenzyl)-L-prolinamide
DMGD7JM	MI	TT6L509
DMGD7JM	MN	Coagulation factor IIa (F2)
DMGD7JM	MT	DTT
DMGD7JM	MA	Inhibitor
DMGD7JM	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMGD7JM	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM5XHA6	DI	DM5XHA6
DM5XHA6	DN	D-phenylalanyl-N-(3-fluorobenzyl)-L-prolinamide
DM5XHA6	MI	TT6L509
DM5XHA6	MN	Coagulation factor IIa (F2)
DM5XHA6	MT	DTT
DM5XHA6	MA	Inhibitor
DM5XHA6	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM5XHA6	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMV9RAN	DI	DMV9RAN
DMV9RAN	DN	D-phenylalanyl-N-(3-methylbenzyl)-L-prolinamide
DMV9RAN	MI	TT6L509
DMV9RAN	MN	Coagulation factor IIa (F2)
DMV9RAN	MT	DTT
DMV9RAN	MA	Inhibitor
DMV9RAN	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMV9RAN	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMHNR63	DI	DMHNR63
DMHNR63	DN	D-phenylalanyl-N-benzyl-L-prolinamide
DMHNR63	MI	TT6L509
DMHNR63	MN	Coagulation factor IIa (F2)
DMHNR63	MT	DTT
DMHNR63	MA	Inhibitor
DMHNR63	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMHNR63	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMMXA5K	DI	DMMXA5K
DMMXA5K	DN	D-PhGly-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2
DMMXA5K	MI	TT27RFC
DMMXA5K	MN	Opioid receptor delta (OPRD1)
DMMXA5K	MT	DTT
DMMXA5K	MA	Inhibitor
DMMXA5K	RN	Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors. J Med Chem. 1986 Nov;29(11):2370-5.
DMMXA5K	RU	https://pubmed.ncbi.nlm.nih.gov/2878079

DMMXA5K	DI	DMMXA5K
DMMXA5K	DN	D-PhGly-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2
DMMXA5K	MI	TTKWM86
DMMXA5K	MN	Opioid receptor mu (MOP)
DMMXA5K	MT	DTT
DMMXA5K	MA	Inhibitor
DMMXA5K	RN	Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors. J Med Chem. 1986 Nov;29(11):2370-5.
DMMXA5K	RU	https://pubmed.ncbi.nlm.nih.gov/2878079

DME5S3C	DI	DME5S3C
DME5S3C	DN	DPI-221
DME5S3C	MI	TT27RFC
DME5S3C	MN	Opioid receptor delta (OPRD1)
DME5S3C	MT	DTT
DME5S3C	MA	Agonist
DME5S3C	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317).
DME5S3C	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=317

DMTHZ3B	DI	DMTHZ3B
DMTHZ3B	DN	DPI59
DMTHZ3B	MI	TT6PKBN
DMTHZ3B	MN	Proto-oncogene c-Src (SRC)
DMTHZ3B	MT	DTT
DMTHZ3B	MA	Inhibitor
DMTHZ3B	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMTHZ3B	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMSRUKQ	DI	DMSRUKQ
DMSRUKQ	DN	DPN-205-734
DMSRUKQ	MI	TTUST1O
DMSRUKQ	MN	Phosphodiesterase (PDE)
DMSRUKQ	MT	DTT
DMSRUKQ	MA	Inhibitor
DMSRUKQ	RN	Pharmacological actions of DPN 205-734, a novel cardiotonic agent. J Cardiovasc Pharmacol. 1988 Oct;12(4):451-60.
DMSRUKQ	RU	https://pubmed.ncbi.nlm.nih.gov/2465446

DMHCZP0	DI	DMHCZP0
DMHCZP0	DN	DPO-1
DMHCZP0	MI	TTW0CMT
DMHCZP0	MN	Voltage-gated potassium channel Kv1.5 (KCNA5)
DMHCZP0	MT	DTT
DMHCZP0	MA	Antagonist
DMHCZP0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 542).
DMHCZP0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=542

DMRJQ8X	DI	DMRJQ8X
DMRJQ8X	DN	D-Pro-Phe-Arg chloromethyl ketone
DMRJQ8X	MI	TT6L509
DMRJQ8X	MN	Coagulation factor IIa (F2)
DMRJQ8X	MT	DTT
DMRJQ8X	MA	Inhibitor
DMRJQ8X	RN	Novel 3-carboxamide-coumarins as potent and selective FXIIa inhibitors. J Med Chem. 2008 Jun 12;51(11):3077-80.
DMRJQ8X	RU	https://pubmed.ncbi.nlm.nih.gov/18459730

DMRJQ8X	DI	DMRJQ8X
DMRJQ8X	DN	D-Pro-Phe-Arg chloromethyl ketone
DMRJQ8X	MI	TTCIHJA
DMRJQ8X	MN	Coagulation factor Xa (F10)
DMRJQ8X	MT	DTT
DMRJQ8X	MA	Inhibitor
DMRJQ8X	RN	Novel 3-carboxamide-coumarins as potent and selective FXIIa inhibitors. J Med Chem. 2008 Jun 12;51(11):3077-80.
DMRJQ8X	RU	https://pubmed.ncbi.nlm.nih.gov/18459730

DMRJQ8X	DI	DMRJQ8X
DMRJQ8X	DN	D-Pro-Phe-Arg chloromethyl ketone
DMRJQ8X	MI	TTMF8H9
DMRJQ8X	MN	Plasma kallikrein (KLKB1)
DMRJQ8X	MT	DTT
DMRJQ8X	MA	Inhibitor
DMRJQ8X	RN	Novel 3-carboxamide-coumarins as potent and selective FXIIa inhibitors. J Med Chem. 2008 Jun 12;51(11):3077-80.
DMRJQ8X	RU	https://pubmed.ncbi.nlm.nih.gov/18459730

DMRJQ8X	DI	DMRJQ8X
DMRJQ8X	DN	D-Pro-Phe-Arg chloromethyl ketone
DMRJQ8X	MI	TT38MDJ
DMRJQ8X	MN	Tissue factor (F3)
DMRJQ8X	MT	DTT
DMRJQ8X	MA	Inhibitor
DMRJQ8X	RN	Novel 3-carboxamide-coumarins as potent and selective FXIIa inhibitors. J Med Chem. 2008 Jun 12;51(11):3077-80.
DMRJQ8X	RU	https://pubmed.ncbi.nlm.nih.gov/18459730

DM35CKE	DI	DM35CKE
DM35CKE	DN	DprwFwLL-NH2
DM35CKE	MI	TTWDC17
DM35CKE	MN	Growth hormone secretagogue receptor 1 (GHSR)
DM35CKE	MT	DTT
DM35CKE	MA	Inhibitor
DM35CKE	RN	Identification of an efficacy switch region in the ghrelin receptor responsible for interchange between agonism and inverse agonism. J Biol Chem. 2007 May 25;282(21):15799-811.
DM35CKE	RU	https://pubmed.ncbi.nlm.nih.gov/17371869

DMQLJ3Y	DI	DMQLJ3Y
DMQLJ3Y	DN	DQP-1105
DMQLJ3Y	MI	TTN9D8E
DMQLJ3Y	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMQLJ3Y	MT	DTT
DMQLJ3Y	MA	Modulator (allosteric modulator)
DMQLJ3Y	RN	Mechanism for noncompetitive inhibition by novel GluN2C/D N-methyl-D-aspartate receptor subunit-selective modulators. Mol Pharmacol. 2011 Nov;80(5):782-95.
DMQLJ3Y	RU	https://pubmed.ncbi.nlm.nih.gov/21807990

DMQLJ3Y	DI	DMQLJ3Y
DMQLJ3Y	DN	DQP-1105
DMQLJ3Y	MI	TT1M8OW
DMQLJ3Y	MN	Glutamate receptor ionotropic NMDA 2C (GluN2C)
DMQLJ3Y	MT	DTT
DMQLJ3Y	MA	Modulator (allosteric modulator)
DMQLJ3Y	RN	Mechanism for noncompetitive inhibition by novel GluN2C/D N-methyl-D-aspartate receptor subunit-selective modulators. Mol Pharmacol. 2011 Nov;80(5):782-95.
DMQLJ3Y	RU	https://pubmed.ncbi.nlm.nih.gov/21807990

DMQLJ3Y	DI	DMQLJ3Y
DMQLJ3Y	DN	DQP-1105
DMQLJ3Y	MI	TT5POTG
DMQLJ3Y	MN	Glutamate receptor ionotropic NMDA 2D (GluN2D)
DMQLJ3Y	MT	DTT
DMQLJ3Y	MA	Modulator (allosteric modulator)
DMQLJ3Y	RN	Mechanism for noncompetitive inhibition by novel GluN2C/D N-methyl-D-aspartate receptor subunit-selective modulators. Mol Pharmacol. 2011 Nov;80(5):782-95.
DMQLJ3Y	RU	https://pubmed.ncbi.nlm.nih.gov/21807990

DM1AV5R	DI	DM1AV5R
DM1AV5R	DN	DR2313
DM1AV5R	MI	TTVDSZ0
DM1AV5R	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DM1AV5R	MT	DTT
DM1AV5R	MA	Inhibitor
DM1AV5R	RN	Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov. 2005 May;4(5):421-40.
DM1AV5R	RU	https://pubmed.ncbi.nlm.nih.gov/15864271

DMW8ORN	DI	DMW8ORN
DMW8ORN	DN	DR-4004
DMW8ORN	MI	TTO9X1H
DMW8ORN	MN	5-HT 7 receptor (HTR7)
DMW8ORN	MT	DTT
DMW8ORN	MA	Antagonist
DMW8ORN	RN	Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). J Med Chem. 2003 Jul 3;46(14):2795-812.
DMW8ORN	RU	https://pubmed.ncbi.nlm.nih.gov/12825922

DMX2TZD	DI	DMX2TZD
DMX2TZD	DN	DR-5/DR-4 cross reactive mabs
DMX2TZD	MI	TT5WLRX
DMX2TZD	MN	TRAIL receptor 1 (TRAIL-R1)
DMX2TZD	MT	DTT
DMX2TZD	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1879).
DMX2TZD	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1879

DMX2TZD	DI	DMX2TZD
DMX2TZD	DN	DR-5/DR-4 cross reactive mabs
DMX2TZD	MI	TTW20TU
DMX2TZD	MN	TRAIL receptor 2 (TRAIL-R2)
DMX2TZD	MT	DTT
DMX2TZD	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1880).
DMX2TZD	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1880

DMTFQG3	DI	DMTFQG3
DMTFQG3	DN	DRF 2519
DMTFQG3	MI	TTJ584C
DMTFQG3	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMTFQG3	MT	DTT
DMTFQG3	MA	Agonist
DMTFQG3	RN	Antidiabetic and hypolipidemic potential of DRF 2519--a dual activator of PPAR-alpha and PPAR-gamma. Eur J Pharmacol. 2004 May 3;491(2-3):195-206.
DMTFQG3	RU	https://pubmed.ncbi.nlm.nih.gov/15140637

DMTFQG3	DI	DMTFQG3
DMTFQG3	DN	DRF 2519
DMTFQG3	MI	TTT2SVW
DMTFQG3	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DMTFQG3	MT	DTT
DMTFQG3	MA	Agonist
DMTFQG3	RN	Antidiabetic and hypolipidemic potential of DRF 2519--a dual activator of PPAR-alpha and PPAR-gamma. Eur J Pharmacol. 2004 May 3;491(2-3):195-206.
DMTFQG3	RU	https://pubmed.ncbi.nlm.nih.gov/15140637

DMYOLEV	DI	DMYOLEV
DMYOLEV	DN	D-ribosylnicotinate
DMYOLEV	MI	DENV24I
DMYOLEV	MN	Nicotinamide riboside kinase 1 (NRK1)
DMYOLEV	MT	DME
DMYOLEV	MA	Metabolism
DMYOLEV	RN	Nicotinamide riboside kinase structures reveal new pathways to NAD+. PLoS Biol. 2007 Oct 2;5(10):e263.
DMYOLEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17914902

DMYOLEV	DI	DMYOLEV
DMYOLEV	DN	D-ribosylnicotinate
DMYOLEV	MI	DE8DJ3N
DMYOLEV	MN	Nicotinamide riboside kinase 2 (NRK2)
DMYOLEV	MT	DME
DMYOLEV	MA	Metabolism
DMYOLEV	RN	Nicotinamide riboside kinase structures reveal new pathways to NAD+. PLoS Biol. 2007 Oct 2;5(10):e263.
DMYOLEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17914902

DM5IA9W	DI	DM5IA9W
DM5IA9W	DN	droxinostat
DM5IA9W	MI	TT4YWTO
DM5IA9W	MN	Histone deacetylase 3 (HDAC3)
DM5IA9W	MT	DTT
DM5IA9W	MA	Inhibitor
DM5IA9W	RN	Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands. Mol Cancer Ther. 2010 Jan;9(1):246-56.
DM5IA9W	RU	https://pubmed.ncbi.nlm.nih.gov/20053768

DM5IA9W	DI	DM5IA9W
DM5IA9W	DN	droxinostat
DM5IA9W	MI	TT5ZKDI
DM5IA9W	MN	Histone deacetylase 6 (HDAC6)
DM5IA9W	MT	DTT
DM5IA9W	MA	Inhibitor
DM5IA9W	RN	Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands. Mol Cancer Ther. 2010 Jan;9(1):246-56.
DM5IA9W	RU	https://pubmed.ncbi.nlm.nih.gov/20053768

DM5IA9W	DI	DM5IA9W
DM5IA9W	DN	droxinostat
DM5IA9W	MI	TTT6LFV
DM5IA9W	MN	Histone deacetylase 8 (HDAC8)
DM5IA9W	MT	DTT
DM5IA9W	MA	Inhibitor
DM5IA9W	RN	Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands. Mol Cancer Ther. 2010 Jan;9(1):246-56.
DM5IA9W	RU	https://pubmed.ncbi.nlm.nih.gov/20053768

DMBUH02	DI	DMBUH02
DMBUH02	DN	DRP-049
DMBUH02	MI	TTP4520
DMBUH02	MN	TGF-beta receptor type I (TGFBR1)
DMBUH02	MT	DTT
DMBUH02	MA	Inhibitor
DMBUH02	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1788).
DMBUH02	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1788

DM5QUJV	DI	DM5QUJV
DM5QUJV	DN	Drug 311383
DM5QUJV	MI	TT9W8GU
DM5QUJV	MN	Gamma-secretase (GS)
DM5QUJV	MT	DTT
DM5QUJV	MA	Inhibitor
DM5QUJV	RN	Discovery of a Subnanomolar helical D-tridecapeptide inhibitor of gamma-secretase. J Med Chem. 2004 Jul 29;47(16):3931-3.
DM5QUJV	RU	https://pubmed.ncbi.nlm.nih.gov/15267231

DM5QUJV	DI	DM5QUJV
DM5QUJV	DN	Drug 311383
DM5QUJV	MI	TTZ3S8C
DM5QUJV	MN	Presenilin 1 (PSEN1)
DM5QUJV	MT	DTT
DM5QUJV	MA	Inhibitor
DM5QUJV	RN	Discovery of a Subnanomolar helical D-tridecapeptide inhibitor of gamma-secretase. J Med Chem. 2004 Jul 29;47(16):3931-3.
DM5QUJV	RU	https://pubmed.ncbi.nlm.nih.gov/15267231

DM5QUJV	DI	DM5QUJV
DM5QUJV	DN	Drug 311383
DM5QUJV	MI	TTWN3F4
DM5QUJV	MN	Presenilin 2 (PSEN2)
DM5QUJV	MT	DTT
DM5QUJV	MA	Inhibitor
DM5QUJV	RN	Discovery of a Subnanomolar helical D-tridecapeptide inhibitor of gamma-secretase. J Med Chem. 2004 Jul 29;47(16):3931-3.
DM5QUJV	RU	https://pubmed.ncbi.nlm.nih.gov/15267231

DMOIFBK	DI	DMOIFBK
DMOIFBK	DN	Drug 311440
DMOIFBK	MI	TT9W8GU
DMOIFBK	MN	Gamma-secretase (GS)
DMOIFBK	MT	DTT
DMOIFBK	MA	Inhibitor
DMOIFBK	RN	Discovery of a Subnanomolar helical D-tridecapeptide inhibitor of gamma-secretase. J Med Chem. 2004 Jul 29;47(16):3931-3.
DMOIFBK	RU	https://pubmed.ncbi.nlm.nih.gov/15267231

DMOIFBK	DI	DMOIFBK
DMOIFBK	DN	Drug 311440
DMOIFBK	MI	TTZ3S8C
DMOIFBK	MN	Presenilin 1 (PSEN1)
DMOIFBK	MT	DTT
DMOIFBK	MA	Inhibitor
DMOIFBK	RN	Discovery of a Subnanomolar helical D-tridecapeptide inhibitor of gamma-secretase. J Med Chem. 2004 Jul 29;47(16):3931-3.
DMOIFBK	RU	https://pubmed.ncbi.nlm.nih.gov/15267231

DMOIFBK	DI	DMOIFBK
DMOIFBK	DN	Drug 311440
DMOIFBK	MI	TTWN3F4
DMOIFBK	MN	Presenilin 2 (PSEN2)
DMOIFBK	MT	DTT
DMOIFBK	MA	Inhibitor
DMOIFBK	RN	Discovery of a Subnanomolar helical D-tridecapeptide inhibitor of gamma-secretase. J Med Chem. 2004 Jul 29;47(16):3931-3.
DMOIFBK	RU	https://pubmed.ncbi.nlm.nih.gov/15267231

DMXTCJ1	DI	DMXTCJ1
DMXTCJ1	DN	Drug 311951
DMXTCJ1	MI	TT9W8GU
DMXTCJ1	MN	Gamma-secretase (GS)
DMXTCJ1	MT	DTT
DMXTCJ1	MA	Inhibitor
DMXTCJ1	RN	Discovery of a Subnanomolar helical D-tridecapeptide inhibitor of gamma-secretase. J Med Chem. 2004 Jul 29;47(16):3931-3.
DMXTCJ1	RU	https://pubmed.ncbi.nlm.nih.gov/15267231

DMXTCJ1	DI	DMXTCJ1
DMXTCJ1	DN	Drug 311951
DMXTCJ1	MI	TTZ3S8C
DMXTCJ1	MN	Presenilin 1 (PSEN1)
DMXTCJ1	MT	DTT
DMXTCJ1	MA	Inhibitor
DMXTCJ1	RN	Discovery of a Subnanomolar helical D-tridecapeptide inhibitor of gamma-secretase. J Med Chem. 2004 Jul 29;47(16):3931-3.
DMXTCJ1	RU	https://pubmed.ncbi.nlm.nih.gov/15267231

DMXTCJ1	DI	DMXTCJ1
DMXTCJ1	DN	Drug 311951
DMXTCJ1	MI	TTWN3F4
DMXTCJ1	MN	Presenilin 2 (PSEN2)
DMXTCJ1	MT	DTT
DMXTCJ1	MA	Inhibitor
DMXTCJ1	RN	Discovery of a Subnanomolar helical D-tridecapeptide inhibitor of gamma-secretase. J Med Chem. 2004 Jul 29;47(16):3931-3.
DMXTCJ1	RU	https://pubmed.ncbi.nlm.nih.gov/15267231

DM27ILS	DI	DM27ILS
DM27ILS	DN	Drug 311952
DM27ILS	MI	TT9W8GU
DM27ILS	MN	Gamma-secretase (GS)
DM27ILS	MT	DTT
DM27ILS	MA	Inhibitor
DM27ILS	RN	Discovery of a Subnanomolar helical D-tridecapeptide inhibitor of gamma-secretase. J Med Chem. 2004 Jul 29;47(16):3931-3.
DM27ILS	RU	https://pubmed.ncbi.nlm.nih.gov/15267231

DM27ILS	DI	DM27ILS
DM27ILS	DN	Drug 311952
DM27ILS	MI	TTZ3S8C
DM27ILS	MN	Presenilin 1 (PSEN1)
DM27ILS	MT	DTT
DM27ILS	MA	Inhibitor
DM27ILS	RN	Discovery of a Subnanomolar helical D-tridecapeptide inhibitor of gamma-secretase. J Med Chem. 2004 Jul 29;47(16):3931-3.
DM27ILS	RU	https://pubmed.ncbi.nlm.nih.gov/15267231

DM27ILS	DI	DM27ILS
DM27ILS	DN	Drug 311952
DM27ILS	MI	TTWN3F4
DM27ILS	MN	Presenilin 2 (PSEN2)
DM27ILS	MT	DTT
DM27ILS	MA	Inhibitor
DM27ILS	RN	Discovery of a Subnanomolar helical D-tridecapeptide inhibitor of gamma-secretase. J Med Chem. 2004 Jul 29;47(16):3931-3.
DM27ILS	RU	https://pubmed.ncbi.nlm.nih.gov/15267231

DML4V73	DI	DML4V73
DML4V73	DN	Drug 7684380
DML4V73	MI	TTQW87Y
DML4V73	MN	Opioid receptor kappa (OPRK1)
DML4V73	MT	DTT
DML4V73	MA	Antagonist
DML4V73	RN	FK-506-binding protein: three-dimensional structure of the complex with the antagonist L-685,818. J Biol Chem. 1993 May 25;268(15):11335-9.
DML4V73	RU	https://pubmed.ncbi.nlm.nih.gov/7684380

DME3WBQ	DI	DME3WBQ
DME3WBQ	DN	DS-437
DME3WBQ	MI	TTR1D7X
DME3WBQ	MN	Protein arginine methyltransferase 5 (PRMT5)
DME3WBQ	MT	DTT
DME3WBQ	MA	Inhibitor
DME3WBQ	RN	Discovery of a Dual PRMT5-PRMT7 Inhibitor. ACS Med Chem Lett. 2015 Mar 2;6(4):408-12.
DME3WBQ	RU	https://pubmed.ncbi.nlm.nih.gov/25893041

DME3WBQ	DI	DME3WBQ
DME3WBQ	DN	DS-437
DME3WBQ	MI	TTAR2P0
DME3WBQ	MN	Protein arginine methyltransferase 7 (PRMT7)
DME3WBQ	MT	DTT
DME3WBQ	MA	Inhibitor
DME3WBQ	RN	Discovery of a Dual PRMT5-PRMT7 Inhibitor. ACS Med Chem Lett. 2015 Mar 2;6(4):408-12.
DME3WBQ	RU	https://pubmed.ncbi.nlm.nih.gov/25893041

DMZGWQA	DI	DMZGWQA
DMZGWQA	DN	DS-AH-14
DMZGWQA	MI	TTOXS3C
DMZGWQA	MN	Muscarinic acetylcholine receptor (CHRM)
DMZGWQA	MT	DTT
DMZGWQA	MA	Modulator
DMZGWQA	RN	US patent application no. 5,446,057, Substituted tetrahydropyridine and piperidine carboxylic acids as muscarinic antagonists.
DMZGWQA	RU	http://www.google.com/patents/US5446057

DMSTOB0	DI	DMSTOB0
DMSTOB0	DN	DSLET
DMSTOB0	MI	TT27RFC
DMSTOB0	MN	Opioid receptor delta (OPRD1)
DMSTOB0	MT	DTT
DMSTOB0	MA	Agonist
DMSTOB0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317).
DMSTOB0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=317

DMSTOB0	DI	DMSTOB0
DMSTOB0	DN	DSLET
DMSTOB0	MI	TTKWM86
DMSTOB0	MN	Opioid receptor mu (MOP)
DMSTOB0	MT	DTT
DMSTOB0	MA	Agonist
DMSTOB0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
DMSTOB0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319

DM1LK0C	DI	DM1LK0C
DM1LK0C	DN	DSM1
DM1LK0C	MI	TT3PQ2Y
DM1LK0C	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DM1LK0C	MT	DTT
DM1LK0C	MA	Inhibitor
DM1LK0C	RN	Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy. Infect Disord Drug Targets. 2010 Jun;10(3):226-39.
DM1LK0C	RU	https://pubmed.ncbi.nlm.nih.gov/20334617

DMZYQOB	DI	DMZYQOB
DMZYQOB	DN	DSM2
DMZYQOB	MI	TT3PQ2Y
DMZYQOB	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DMZYQOB	MT	DTT
DMZYQOB	MA	Inhibitor
DMZYQOB	RN	Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy. Infect Disord Drug Targets. 2010 Jun;10(3):226-39.
DMZYQOB	RU	https://pubmed.ncbi.nlm.nih.gov/20334617

DM4EKHR	DI	DM4EKHR
DM4EKHR	DN	DSR-17759
DM4EKHR	MI	TT9O6WS
DM4EKHR	MN	Glucagon receptor (GCGR)
DM4EKHR	MT	DTT
DM4EKHR	MA	Antagonist
DM4EKHR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 251).
DM4EKHR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=251

DMSVP1K	DI	DMSVP1K
DMSVP1K	DN	DSTBULET
DMSVP1K	MI	TT27RFC
DMSVP1K	MN	Opioid receptor delta (OPRD1)
DMSVP1K	MT	DTT
DMSVP1K	MA	Agonist
DMSVP1K	RN	[3H][D-Ser2(O-tert-butyl),Leu5]enkephalyl-Thr6 and [D-Ser2(O-tert-butyl),Leu5]enkephalyl-Thr6(O-tert-butyl). Two new enkephalin analogs with both a good selectivity and a high affinity toward delta-opioid binding sites. J Biol Chem. 1988 Mar 25;263(9):4124-30.
DMSVP1K	RU	https://pubmed.ncbi.nlm.nih.gov/2831220

DMCKQF7	DI	DMCKQF7
DMCKQF7	DN	DT-2228
DMCKQF7	MI	TTXJ47W
DMCKQF7	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMCKQF7	MT	DTT
DMCKQF7	MA	Modulator
DMCKQF7	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 290).
DMCKQF7	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=290

DM3TMUK	DI	DM3TMUK
DM3TMUK	DN	DT-831j
DM3TMUK	MI	TTCIHJA
DM3TMUK	MN	Coagulation factor Xa (F10)
DM3TMUK	MT	DTT
DM3TMUK	MA	Antagonist
DM3TMUK	RN	Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7.
DM3TMUK	RU	https://pubmed.ncbi.nlm.nih.gov/22844656

DM376J2	DI	DM376J2
DM376J2	DN	D-tartaric acid
DM376J2	MI	TTHZQP0
DM376J2	MN	Triggering receptor expressed on monocytes 1 (TREM1)
DM376J2	MT	DTT
DM376J2	MA	Inhibitor
DM376J2	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM376J2	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMPKTB4	DI	DMPKTB4
DMPKTB4	DN	DTD
DMPKTB4	MI	TTSXVID
DMPKTB4	MN	Nuclear factor NF-kappa-B (NFKB)
DMPKTB4	MT	DTT
DMPKTB4	MA	Inhibitor
DMPKTB4	RN	A new ditriazine inhibitor of NF-kappaB modulates chronic inflammation and angiogenesis. Naunyn Schmiedebergs Arch Pharmacol. 2002 May;365(5):357-64.
DMPKTB4	RU	https://pubmed.ncbi.nlm.nih.gov/12012021

DMNS265	DI	DMNS265
DMNS265	DN	DTPA Conjugate
DMNS265	MI	TTN53ZF
DMNS265	MN	Leukotriene B4 receptor 1 (LTB4R)
DMNS265	MT	DTT
DMNS265	MA	Inhibitor
DMNS265	RN	Synthesis of leukotriene B4 antagonists labeled with In-111 or Tc-99m to image infectious and inflammatory foci. J Med Chem. 2005 Oct 6;48(20):6442-53.
DMNS265	RU	https://pubmed.ncbi.nlm.nih.gov/16190770

DM1JL5W	DI	DM1JL5W
DM1JL5W	DN	D-Trp8-SRIF-14
DM1JL5W	MI	TTAE1BR
DM1JL5W	MN	Somatostatin receptor type 4 (SSTR4)
DM1JL5W	MT	DTT
DM1JL5W	MA	Inhibitor
DM1JL5W	RN	Replacement of Phe6, Phe7, and Phe11 of D-Trp8-somatostatin-14 with L-pyrazinylalanine. Predicted and observed effects on binding affinities at hSS... J Med Chem. 2005 Jun 16;48(12):4025-30.
DM1JL5W	RU	https://pubmed.ncbi.nlm.nih.gov/15943475

DMKIML1	DI	DMKIML1
DMKIML1	DN	D-tryptophan
DMKIML1	MI	TT8WFXV
DMKIML1	MN	Hydroxycarboxylic acid receptor 3 (HCAR3)
DMKIML1	MT	DTT
DMKIML1	MA	Agonist
DMKIML1	RN	Aromatic D-amino acids act as chemoattractant factors for human leukocytes through a G protein-coupled receptor, GPR109B. Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3930-4.
DMKIML1	RU	https://pubmed.ncbi.nlm.nih.gov/19237584

DM7PNOK	DI	DM7PNOK
DM7PNOK	DN	DTS-108
DM7PNOK	MI	TTGTQHC
DM7PNOK	MN	DNA topoisomerase I (TOP1)
DM7PNOK	MT	DTT
DM7PNOK	MA	Inhibitor
DM7PNOK	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2636).
DM7PNOK	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2636

DMUKPO3	DI	DMUKPO3
DMUKPO3	DN	Duo3
DMUKPO3	MI	TTOXS3C
DMUKPO3	MN	Muscarinic acetylcholine receptor (CHRM)
DMUKPO3	MT	DTT
DMUKPO3	MA	Modulator (allosteric modulator)
DMUKPO3	RN	Atypical muscarinic allosteric modulation: cooperativity between modulators and their atypical binding topology in muscarinic M2 and M2/M5 chimeric... Mol Pharmacol. 2005 Dec;68(6):1597-610.
DMUKPO3	RU	https://pubmed.ncbi.nlm.nih.gov/16157694

DM0CQIP	DI	DM0CQIP
DM0CQIP	DN	Duocarmycin
DM0CQIP	MI	TTOVXHF
DM0CQIP	MN	Human Deoxyribonucleic acid minor groove (hDNA min)
DM0CQIP	MT	DTT
DM0CQIP	MA	Breaker
DM0CQIP	RN	Structural studies of atom-specific anticancer drugs acting on DNA. Pharmacol Ther. 1999 Sep;83(3):181-215.
DM0CQIP	RU	https://pubmed.ncbi.nlm.nih.gov/10576292

DM29PTO	DI	DM29PTO
DM29PTO	DN	Durhamycin A
DM29PTO	MI	TTT3ZC9
DM29PTO	MN	Human immunodeficiency virus Tat protein (HIV tat)
DM29PTO	MT	DTT
DM29PTO	MA	Inhibitor
DM29PTO	RN	Durhamycin A, a potent inhibitor of HIV Tat transactivation. J Nat Prod. 2002 Aug;65(8):1091-5.
DM29PTO	RU	https://pubmed.ncbi.nlm.nih.gov/12193009

DML7YPS	DI	DML7YPS
DML7YPS	DN	Duroquinone
DML7YPS	MI	TT8XK6L
DML7YPS	MN	Quinone reductase 1 (NQO1)
DML7YPS	MT	DTT
DML7YPS	MA	Inhibitor
DML7YPS	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DML7YPS	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DML4G6K	DI	DML4G6K
DML4G6K	DN	D-Val-L-boroPro
DML4G6K	MI	TTDIGC1
DML4G6K	MN	Dipeptidyl peptidase 4 (DPP-4)
DML4G6K	MT	DTT
DML4G6K	MA	Inhibitor
DML4G6K	RN	Synthesis and characterization of constrained peptidomimetic dipeptidyl peptidase IV inhibitors: amino-lactam boroalanines. J Med Chem. 2007 May 17;50(10):2391-8.
DML4G6K	RU	https://pubmed.ncbi.nlm.nih.gov/17458948

DM53079	DI	DM53079
DM53079	DN	DVDAVP
DM53079	MI	TT4TFGN
DM53079	MN	Vasopressin V1a receptor (V1AR)
DM53079	MT	DTT
DM53079	MA	Inhibitor
DM53079	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DM53079	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DM53079	DI	DM53079
DM53079	DN	DVDAVP
DM53079	MI	TTK8R02
DM53079	MN	Vasopressin V2 receptor (V2R)
DM53079	MT	DTT
DM53079	MA	Inhibitor
DM53079	RN	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
DM53079	RU	https://pubmed.ncbi.nlm.nih.gov/17300166

DMWF9GQ	DI	DMWF9GQ
DMWF9GQ	DN	DVD-Ig
DMWF9GQ	MI	TTRYK0X
DMWF9GQ	MN	Interleukin-1 beta (IL1B)
DMWF9GQ	MT	DTT
DMWF9GQ	MA	Modulator
DMWF9GQ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2623).
DMWF9GQ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2623

DMEUVIP	DI	DMEUVIP
DMEUVIP	DN	DwFwLL-NH2
DMEUVIP	MI	TTWDC17
DMEUVIP	MN	Growth hormone secretagogue receptor 1 (GHSR)
DMEUVIP	MT	DTT
DMEUVIP	MA	Inhibitor
DMEUVIP	RN	Identification of an efficacy switch region in the ghrelin receptor responsible for interchange between agonism and inverse agonism. J Biol Chem. 2007 May 25;282(21):15799-811.
DMEUVIP	RU	https://pubmed.ncbi.nlm.nih.gov/17371869

DMW9GT7	DI	DMW9GT7
DMW9GT7	DN	DwLIP-GCGRrx
DMW9GT7	MI	TT9O6WS
DMW9GT7	MN	Glucagon receptor (GCGR)
DMW9GT7	MT	DTT
DMW9GT7	MA	Binder
DMW9GT7	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009).
DMW9GT7	RU	http://www.isispharm.com/Pipeline/index.htm

DMF9M06	DI	DMF9M06
DMF9M06	DN	DX-2400
DMF9M06	MI	TTJ4QE7
DMF9M06	MN	Matrix metalloproteinase-14 (MMP-14)
DMF9M06	MT	DTT
DMF9M06	MA	Inhibitor
DMF9M06	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1638).
DMF9M06	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1638

DM3BWTM	DI	DM3BWTM
DM3BWTM	DN	DX-2500
DM3BWTM	MI	TTPY4SE
DM3BWTM	MN	Immunoglobulin Fc receptor (FCR)
DM3BWTM	MT	DTT
DM3BWTM	RN	Fully Human Monoclonal Antibody Inhibitors of the Neonatal Fc Receptor Reduce Circulating IgG in Non-Human Primates. Front Immunol. 2015; 6: 176.
DM3BWTM	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407741/

DMZWAQ3	DI	DMZWAQ3
DMZWAQ3	DN	DXL-625
DMZWAQ3	MI	TTUE541
DMZWAQ3	MN	Leukocyte surface antigen Leu-16 (CD20)
DMZWAQ3	MT	DTT
DMZWAQ3	MA	Modulator
DMZWAQ3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628).
DMZWAQ3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2628

DM1ROU7	DI	DM1ROU7
DM1ROU7	DN	D-xylulose
DM1ROU7	MI	DECFU6W
DM1ROU7	MN	Xylulose kinase (XYLB)
DM1ROU7	MT	DME
DM1ROU7	MA	Metabolism
DM1ROU7	RN	Structure and function of human xylulokinase, an enzyme with important roles in carbohydrate metabolism. J Biol Chem. 2013 Jan 18;288(3):1643-52.
DM1ROU7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23179721

DMFJ3VC	DI	DMFJ3VC
DMFJ3VC	DN	DY131
DMFJ3VC	MI	TTKF0XS
DMFJ3VC	MN	Estrogen-related receptor-beta (ESRRB)
DMFJ3VC	MT	DTT
DMFJ3VC	MA	Agonist
DMFJ3VC	RN	Identification of an agonist ligand for estrogen-related receptors ERRbeta/gamma. Bioorg Med Chem Lett. 2005 Mar 1;15(5):1311-3.
DMFJ3VC	RU	https://pubmed.ncbi.nlm.nih.gov/15713377

DMFJ3VC	DI	DMFJ3VC
DMFJ3VC	DN	DY131
DMFJ3VC	MI	TT9ZRHB
DMFJ3VC	MN	Estrogen-related receptor-gamma (ESRRG)
DMFJ3VC	MT	DTT
DMFJ3VC	MA	Agonist
DMFJ3VC	RN	Identification and structure-activity relationship of phenolic acyl hydrazones as selective agonists for the estrogen-related orphan nuclear receptors ERRbeta and ERRgamma. J Med Chem. 2005 May 5;48(9):3107-9.
DMFJ3VC	RU	https://pubmed.ncbi.nlm.nih.gov/15857113

DMSPVLM	DI	DMSPVLM
DMSPVLM	DN	dynorphin B
DMSPVLM	MI	TT27RFC
DMSPVLM	MN	Opioid receptor delta (OPRD1)
DMSPVLM	MT	DTT
DMSPVLM	MA	Agonist
DMSPVLM	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317).
DMSPVLM	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=317

DMSPVLM	DI	DMSPVLM
DMSPVLM	DN	dynorphin B
DMSPVLM	MI	TTQW87Y
DMSPVLM	MN	Opioid receptor kappa (OPRK1)
DMSPVLM	MT	DTT
DMSPVLM	MA	Agonist
DMSPVLM	RN	Cloning and functional comparison of kappa and delta opioid receptors from mouse brain. Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6736-40.
DMSPVLM	RU	https://pubmed.ncbi.nlm.nih.gov/8393575

DMSPVLM	DI	DMSPVLM
DMSPVLM	DN	dynorphin B
DMSPVLM	MI	TTKWM86
DMSPVLM	MN	Opioid receptor mu (MOP)
DMSPVLM	MT	DTT
DMSPVLM	MA	Agonist
DMSPVLM	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
DMSPVLM	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319

DMM92LG	DI	DMM92LG
DMM92LG	DN	Dynorphin(1-8)
DMM92LG	MI	TTQW87Y
DMM92LG	MN	Opioid receptor kappa (OPRK1)
DMM92LG	MT	DTT
DMM92LG	MA	Inhibitor
DMM92LG	RN	Peptides as receptor selectivity modulators of opiate pharmacophores. J Med Chem. 1986 Jul;29(7):1222-5.
DMM92LG	RU	https://pubmed.ncbi.nlm.nih.gov/2879914

DMM92LG	DI	DMM92LG
DMM92LG	DN	Dynorphin(1-8)
DMM92LG	MI	TTKWM86
DMM92LG	MN	Opioid receptor mu (MOP)
DMM92LG	MT	DTT
DMM92LG	MA	Inhibitor
DMM92LG	RN	Peptides as receptor selectivity modulators of opiate pharmacophores. J Med Chem. 1986 Jul;29(7):1222-5.
DMM92LG	RU	https://pubmed.ncbi.nlm.nih.gov/2879914

DMIZQTX	DI	DMIZQTX
DMIZQTX	DN	DYSIDENIN
DMIZQTX	MI	TT12ABZ
DMIZQTX	MN	Arachidonate 12-lipoxygenase (12-LOX)
DMIZQTX	MT	DTT
DMIZQTX	MA	Inhibitor
DMIZQTX	RN	Discovery of platelet-type 12-human lipoxygenase selective inhibitors by high-throughput screening of structurally diverse libraries. Bioorg Med Chem. 2007 Nov 15;15(22):6900-8.
DMIZQTX	RU	https://pubmed.ncbi.nlm.nih.gov/17826100

DMIZQTX	DI	DMIZQTX
DMIZQTX	DN	DYSIDENIN
DMIZQTX	MI	TTN9T81
DMIZQTX	MN	Arachidonate 15-lipoxygenase (15-LOX)
DMIZQTX	MT	DTT
DMIZQTX	MA	Inhibitor
DMIZQTX	RN	Discovery of platelet-type 12-human lipoxygenase selective inhibitors by high-throughput screening of structurally diverse libraries. Bioorg Med Chem. 2007 Nov 15;15(22):6900-8.
DMIZQTX	RU	https://pubmed.ncbi.nlm.nih.gov/17826100

DMNYQL9	DI	DMNYQL9
DMNYQL9	DN	DYSIDINE
DMNYQL9	MI	TTO8QRU
DMNYQL9	MN	Group IIA phospholipase A2 (GIIA sPLA2)
DMNYQL9	MT	DTT
DMNYQL9	MA	Inhibitor
DMNYQL9	RN	New sesquiterpene derivatives from the sponge Dysidea species with a selective inhibitor profile against human phospholipase A2 and other leukocyte... J Nat Prod. 2001 May;64(5):612-5.
DMNYQL9	RU	https://pubmed.ncbi.nlm.nih.gov/11374954

DMNYQL9	DI	DMNYQL9
DMNYQL9	DN	DYSIDINE
DMNYQL9	MI	TTELIN2
DMNYQL9	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMNYQL9	MT	DTT
DMNYQL9	MA	Inhibitor
DMNYQL9	RN	A novel sesquiterpene quinone from Hainan sponge Dysidea villosa. Bioorg Med Chem Lett. 2009 Jan 15;19(2):390-2.
DMNYQL9	RU	https://pubmed.ncbi.nlm.nih.gov/19091557

DM0EBAF	DI	DM0EBAF
DM0EBAF	DN	dysiherbaine
DM0EBAF	MI	TT0MYE2
DM0EBAF	MN	Glutamate receptor ionotropic kainate 1 (GRIK1)
DM0EBAF	MT	DTT
DM0EBAF	MA	Agonist
DM0EBAF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 450).
DM0EBAF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=450

DM0EBAF	DI	DM0EBAF
DM0EBAF	DN	dysiherbaine
DM0EBAF	MI	TT0K5RG
DM0EBAF	MN	Glutamate receptor ionotropic kainate 2 (GRIK2)
DM0EBAF	MT	DTT
DM0EBAF	MA	Agonist
DM0EBAF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 451).
DM0EBAF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=451

DM0EBAF	DI	DM0EBAF
DM0EBAF	DN	dysiherbaine
DM0EBAF	MI	TTNP6O2
DM0EBAF	MN	Glutamate receptor ionotropic kainate 3 (GluK3)
DM0EBAF	MT	DTT
DM0EBAF	MA	Agonist
DM0EBAF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 452).
DM0EBAF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=452

DM0EBAF	DI	DM0EBAF
DM0EBAF	DN	dysiherbaine
DM0EBAF	MI	TTQV6BO
DM0EBAF	MN	Glutamate receptor ionotropic kainate 4 (GluK4)
DM0EBAF	MT	DTT
DM0EBAF	MA	Agonist
DM0EBAF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 453).
DM0EBAF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=453

DM0EBAF	DI	DM0EBAF
DM0EBAF	DN	dysiherbaine
DM0EBAF	MI	TTO6LI7
DM0EBAF	MN	Glutamate receptor ionotropic kainate 5 (GRIK5)
DM0EBAF	MT	DTT
DM0EBAF	MA	Agonist
DM0EBAF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 454).
DM0EBAF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=454

DMU42C1	DI	DMU42C1
DMU42C1	DN	DYSINOSIN A
DMU42C1	MI	TT6L509
DMU42C1	MN	Coagulation factor IIa (F2)
DMU42C1	MT	DTT
DMU42C1	MA	Inhibitor
DMU42C1	RN	From natural products to achiral drug prototypes: potent thrombin inhibitors based on P2/P3 dihydropyrid-2-one core motifs. Bioorg Med Chem Lett. 2009 Sep 15;19(18):5429-32.
DMU42C1	RU	https://pubmed.ncbi.nlm.nih.gov/19674897

DM0JXBK	DI	DM0JXBK
DM0JXBK	DN	DZNep
DM0JXBK	MI	TTE2KUJ
DM0JXBK	MN	Adenosylhomocysteinase (AHCY)
DM0JXBK	MT	DTT
DM0JXBK	MA	Inhibitor
DM0JXBK	RN	3-Deazaneplanocin: a new and potent inhibitor of S-adenosylhomocysteine hydrolase and its effects on human promyelocytic leukemia cell line HL-60. Biochem Biophys Res Commun. 1986 Mar 13;135(2):688-94.
DM0JXBK	RU	https://pubmed.ncbi.nlm.nih.gov/3457563

DM76UJY	DI	DM76UJY
DM76UJY	DN	E[c(RGDyK)]2
DM76UJY	MI	TTT1R2L
DM76UJY	MN	Integrin alpha-V (ITGAV)
DM76UJY	MT	DTT
DM76UJY	MA	Inhibitor
DM76UJY	RN	Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. J Med Chem. 2005 Feb 24;48(4):1098-106.
DM76UJY	RU	https://pubmed.ncbi.nlm.nih.gov/15715477

DM76UJY	DI	DM76UJY
DM76UJY	DN	E[c(RGDyK)]2
DM76UJY	MI	TTJA1ZO
DM76UJY	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DM76UJY	MT	DTT
DM76UJY	MA	Inhibitor
DM76UJY	RN	Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. J Med Chem. 2005 Feb 24;48(4):1098-106.
DM76UJY	RU	https://pubmed.ncbi.nlm.nih.gov/15715477

DMS1LZI	DI	DMS1LZI
DMS1LZI	DN	E[c(RGDyK)]2-PTX conjugate
DMS1LZI	MI	TTT1R2L
DMS1LZI	MN	Integrin alpha-V (ITGAV)
DMS1LZI	MT	DTT
DMS1LZI	MA	Inhibitor
DMS1LZI	RN	Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. J Med Chem. 2005 Feb 24;48(4):1098-106.
DMS1LZI	RU	https://pubmed.ncbi.nlm.nih.gov/15715477

DMS1LZI	DI	DMS1LZI
DMS1LZI	DN	E[c(RGDyK)]2-PTX conjugate
DMS1LZI	MI	TTJA1ZO
DMS1LZI	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMS1LZI	MT	DTT
DMS1LZI	MA	Inhibitor
DMS1LZI	RN	Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. J Med Chem. 2005 Feb 24;48(4):1098-106.
DMS1LZI	RU	https://pubmed.ncbi.nlm.nih.gov/15715477

DMA9CZV	DI	DMA9CZV
DMA9CZV	DN	E-003
DMA9CZV	MI	TTU1E82
DMA9CZV	MN	Apoptosis regulator Bcl-xL (BCL-xL)
DMA9CZV	MT	DTT
DMA9CZV	MA	Modulator
DMA9CZV	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2845).
DMA9CZV	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2845

DMHPFMV	DI	DMHPFMV
DMHPFMV	DN	E-1455
DMHPFMV	MI	TTE0A2F
DMHPFMV	MN	Dopamine D4 receptor (D4R)
DMHPFMV	MT	DTT
DMHPFMV	MA	Modulator
DMHPFMV	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 217).
DMHPFMV	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=217

DME5JBH	DI	DME5JBH
DME5JBH	DN	E-3024
DME5JBH	MI	TTDIGC1
DME5JBH	MN	Dipeptidyl peptidase 4 (DPP-4)
DME5JBH	MT	DTT
DME5JBH	MA	Modulator
DME5JBH	RN	E3024, 3-but-2-ynyl-5-methyl-2-piperazin-1-yl-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-o ne tosylate, is a novel, selective and competitive dipeptidyl peptidase-IV inhibitor.Eur J Pharmacol.2006 Oct 24;548(1-3):181-7.
DME5JBH	RU	https://www.ncbi.nlm.nih.gov/pubmed/16973152

DMGPRT7	DI	DMGPRT7
DMGPRT7	DN	E339-3D6
DMGPRT7	MI	TTJ8E43
DMGPRT7	MN	Apelin receptor (APLNR)
DMGPRT7	MT	DTT
DMGPRT7	MA	Agonist
DMGPRT7	RN	Identification and pharmacological properties of E339-3D6, the first nonpeptidic apelin receptor agonist. FASEB J. 2010 May;24(5):1506-17.
DMGPRT7	RU	https://pubmed.ncbi.nlm.nih.gov/20040517

DMLZU09	DI	DMLZU09
DMLZU09	DN	E-52862
DMLZU09	MI	TTTPE1L
DMLZU09	MN	HUMAN opioid receptor sigma 1 (OPRS1)
DMLZU09	MT	DTT
DMLZU09	MA	Antagonist
DMLZU09	RN	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
DMLZU09	RU	https://www.nature.com/articles/s41586-020-2286-9

DM0O8KR	DI	DM0O8KR
DM0O8KR	DN	E55888
DM0O8KR	MI	TTO9X1H
DM0O8KR	MN	5-HT 7 receptor (HTR7)
DM0O8KR	MT	DTT
DM0O8KR	MA	Agonist
DM0O8KR	RN	5-HT7 receptor activation inhibits mechanical hypersensitivity secondary to capsaicin sensitization in mice. Pain. 2009 Feb;141(3):239-47.
DM0O8KR	RU	https://pubmed.ncbi.nlm.nih.gov/19118950

DM8LPBF	DI	DM8LPBF
DM8LPBF	DN	E5700
DM8LPBF	MI	TTFQEO5
DM8LPBF	MN	Squalene synthetase (FDFT1)
DM8LPBF	MT	DTT
DM8LPBF	MA	Inhibitor
DM8LPBF	RN	Kinetic characterization of squalene synthase from Trypanosoma cruzi: selective inhibition by quinuclidine derivatives. Antimicrob Agents Chemother. 2007 Jun;51(6):2123-9.
DM8LPBF	RU	https://pubmed.ncbi.nlm.nih.gov/17371809

DMMOPAK	DI	DMMOPAK
DMMOPAK	DN	E-64
DMMOPAK	MI	TTUMQVO
DMMOPAK	MN	Cathepsin S (CTSS)
DMMOPAK	MT	DTT
DMMOPAK	MA	Inhibitor
DMMOPAK	RN	Baculoviral expression and characterization of rodent cathepsin S. Protein Expr Purif. 2001 Oct;23(1):45-54.
DMMOPAK	RU	https://pubmed.ncbi.nlm.nih.gov/11570845

DMMOPAK	DI	DMMOPAK
DMMOPAK	DN	E-64
DMMOPAK	MI	TTH9VL3
DMMOPAK	MN	Plasmodium Plasmepsin 1 (Malaria PLA1)
DMMOPAK	MT	DTT
DMMOPAK	MA	Inhibitor
DMMOPAK	RN	Antimalarial synergy of cysteine and aspartic protease inhibitors. Antimicrob Agents Chemother. 1998 Sep;42(9):2254-8.
DMMOPAK	RU	https://pubmed.ncbi.nlm.nih.gov/9736544

DMMOPAK	DI	DMMOPAK
DMMOPAK	DN	E-64
DMMOPAK	MI	TTXMNHO
DMMOPAK	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMMOPAK	MT	DTT
DMMOPAK	MA	Inhibitor
DMMOPAK	RN	Antimalarial synergy of cysteine and aspartic protease inhibitors. Antimicrob Agents Chemother. 1998 Sep;42(9):2254-8.
DMMOPAK	RU	https://pubmed.ncbi.nlm.nih.gov/9736544

DMMOPAK	DI	DMMOPAK
DMMOPAK	DN	E-64
DMMOPAK	MI	TTREV7X
DMMOPAK	MN	Virus Cysteine proteinase (Viru VCATH)
DMMOPAK	MT	DTT
DMMOPAK	MA	Inhibitor
DMMOPAK	RN	Characterization of a cysteine proteinase from Taenia crassiceps cysts. Mol Biochem Parasitol. 1997 Apr;85(2):243-53.
DMMOPAK	RU	https://pubmed.ncbi.nlm.nih.gov/9106197

DM7LGAF	DI	DM7LGAF
DM7LGAF	DN	E6801
DM7LGAF	MI	TTJS8PY
DM7LGAF	MN	5-HT 6 receptor (HTR6)
DM7LGAF	MT	DTT
DM7LGAF	MA	Agonist
DM7LGAF	RN	Medicinal chemistry driven approaches toward novel and selective serotonin 5-HT6 receptor ligands. J Med Chem. 2005 Mar 24;48(6):1781-95.
DM7LGAF	RU	https://pubmed.ncbi.nlm.nih.gov/15771424

DMJ2P0N	DI	DMJ2P0N
DMJ2P0N	DN	E-6837
DMJ2P0N	MI	TTJS8PY
DMJ2P0N	MN	5-HT 6 receptor (HTR6)
DMJ2P0N	MT	DTT
DMJ2P0N	MA	Inhibitor
DMJ2P0N	RN	Indene-based scaffolds. 2. An indole-indene switch: discovery of novel indenylsulfonamides as 5-HT6 serotonin receptor agonists. J Med Chem. 2009 Feb 12;52(3):675-87.
DMJ2P0N	RU	https://pubmed.ncbi.nlm.nih.gov/19159187

DM7ROJI	DI	DM7ROJI
DM7ROJI	DN	E-6-O-p-methoxycinnamoyl scandoside methyl ester
DM7ROJI	MI	TTPLTSQ
DM7ROJI	MN	Neutrophil elastase (NE)
DM7ROJI	MT	DTT
DM7ROJI	MA	Inhibitor
DM7ROJI	RN	Evaluation of human neutrophil elastase inhibitory effect of iridoid glycosides from Hedyotis diffusa. Bioorg Med Chem Lett. 2010 Jan 15;20(2):513-5.
DM7ROJI	RU	https://pubmed.ncbi.nlm.nih.gov/20004577

DMY6DM5	DI	DMY6DM5
DMY6DM5	DN	E-758
DMY6DM5	MI	TTGTQHC
DMY6DM5	MN	DNA topoisomerase I (TOP1)
DMY6DM5	MT	DTT
DMY6DM5	MA	Inhibitor
DMY6DM5	RN	Lycobetaine acts as a selective topoisomerase IIbeta poison and inhibits the growth of human tumour cells. Br J Cancer. 2001 November; 85(10): 1585-1591.
DMY6DM5	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363954/

DMB7685	DI	DMB7685
DMB7685	DN	EAPB0203
DMB7685	MI	TTU1E82
DMB7685	MN	Apoptosis regulator Bcl-xL (BCL-xL)
DMB7685	MT	DTT
DMB7685	MA	Inhibitor
DMB7685	RN	EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase-dependent apoptosis in T-cell lymphomas and HTLV-I-associated adult T-cell leukemia/lymphoma. Blood. 2008 Apr 1;111(7):3770-7.
DMB7685	RU	https://pubmed.ncbi.nlm.nih.gov/18218850

DMB7685	DI	DMB7685
DMB7685	DN	EAPB0203
DMB7685	MI	TTQ5LRD
DMB7685	MN	Cellular inhibitor of apoptosis 1 (BIRC2)
DMB7685	MT	DTT
DMB7685	MA	Inhibitor
DMB7685	RN	EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase-dependent apoptosis in T-cell lymphomas and HTLV-I-associated adult T-cell leukemia/lymphoma. Blood. 2008 Apr 1;111(7):3770-7.
DMB7685	RU	https://pubmed.ncbi.nlm.nih.gov/18218850

DM4UZ6V	DI	DM4UZ6V
DM4UZ6V	DN	EB-47
DM4UZ6V	MI	TTVDSZ0
DM4UZ6V	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DM4UZ6V	MT	DTT
DM4UZ6V	MA	Inhibitor
DM4UZ6V	RN	Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov. 2005 May;4(5):421-40.
DM4UZ6V	RU	https://pubmed.ncbi.nlm.nih.gov/15864271

DMPKI0N	DI	DMPKI0N
DMPKI0N	DN	EBIO
DMPKI0N	MI	TT9R6BE
DMPKI0N	MN	Calcium-activated potassium channel KCa2.1 (KCNN1)
DMPKI0N	MT	DTT
DMPKI0N	MA	Activator
DMPKI0N	RN	Small conductance calcium-activated potassium channels: from structure to function. Prog Neurobiol. 2010 Jul;91(3):242-55.
DMPKI0N	RU	https://pubmed.ncbi.nlm.nih.gov/20359520

DMPKI0N	DI	DMPKI0N
DMPKI0N	DN	EBIO
DMPKI0N	MI	TT2T5M0
DMPKI0N	MN	Calcium-activated potassium channel KCa2.2 (KCNN2)
DMPKI0N	MT	DTT
DMPKI0N	MA	Activator
DMPKI0N	RN	Small conductance calcium-activated potassium channels: from structure to function. Prog Neurobiol. 2010 Jul;91(3):242-55.
DMPKI0N	RU	https://pubmed.ncbi.nlm.nih.gov/20359520

DMPKI0N	DI	DMPKI0N
DMPKI0N	DN	EBIO
DMPKI0N	MI	TT9JH25
DMPKI0N	MN	Calcium-activated potassium channel KCa2.3 (KCNN3)
DMPKI0N	MT	DTT
DMPKI0N	MA	Activator
DMPKI0N	RN	Small conductance calcium-activated potassium channels: from structure to function. Prog Neurobiol. 2010 Jul;91(3):242-55.
DMPKI0N	RU	https://pubmed.ncbi.nlm.nih.gov/20359520

DMPKI0N	DI	DMPKI0N
DMPKI0N	DN	EBIO
DMPKI0N	MI	TT7M9I6
DMPKI0N	MN	Calcium-activated potassium channel KCa3.1 (KCNN4)
DMPKI0N	MT	DTT
DMPKI0N	MA	Activator
DMPKI0N	RN	Small conductance calcium-activated potassium channels: from structure to function. Prog Neurobiol. 2010 Jul;91(3):242-55.
DMPKI0N	RU	https://pubmed.ncbi.nlm.nih.gov/20359520

DMIC372	DI	DMIC372
DMIC372	DN	EC-0565
DMIC372	MI	TTCJG29
DMIC372	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMIC372	MT	DTT
DMIC372	MA	Inhibitor
DMIC372	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
DMIC372	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109

DMK6E10	DI	DMK6E10
DMK6E10	DN	EC-0845
DMK6E10	MI	TTCJG29
DMK6E10	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMK6E10	MT	DTT
DMK6E10	MA	Modulator
DMK6E10	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
DMK6E10	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109

DM61FB0	DI	DM61FB0
DM61FB0	DN	EC18
DM61FB0	MI	TTQP04A
DM61FB0	MN	Hyperpolarization cyclic nucleotide-gated channel 4 (HCN4)
DM61FB0	MT	DTT
DM61FB0	MA	Blocker (channel blocker)
DM61FB0	RN	Novel blockers of hyperpolarization-activated current with isoform selectivity in recombinant cells and native tissue. Br J Pharmacol. 2012 May;166(2):602-16.
DM61FB0	RU	https://pubmed.ncbi.nlm.nih.gov/22091830

DM67549	DI	DM67549
DM67549	DN	EC33
DM67549	MI	TT9PBIL
DM67549	MN	Glutamyl aminopeptidase (ENPEP)
DM67549	MT	DTT
DM67549	MA	Inhibitor
DM67549	RN	Aminopeptidase A, which generates one of the main effector peptides of the brain renin-angiotensin system, angiotensin III, has a key role in central control of arterial blood pressure. Biochem Soc Trans. 2000;28(4):435-40.
DM67549	RU	https://pubmed.ncbi.nlm.nih.gov/10961935

DMIVY0Q	DI	DMIVY0Q
DMIVY0Q	DN	Eckol
DMIVY0Q	MI	TT8JRS7
DMIVY0Q	MN	Beta-secretase (BACE)
DMIVY0Q	MT	DTT
DMIVY0Q	MA	Inhibitor
DMIVY0Q	RN	Molecular docking studies of phlorotannins from Eisenia bicyclis with BACE1 inhibitory activity. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3211-5.
DMIVY0Q	RU	https://pubmed.ncbi.nlm.nih.gov/20462757

DMWKS29	DI	DMWKS29
DMWKS29	DN	ECOPLADIB
DMWKS29	MI	TTT1JVS
DMWKS29	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DMWKS29	MT	DTT
DMWKS29	MA	Inhibitor
DMWKS29	RN	Reactions of functionalized sulfonamides: application to lowering the lipophilicity of cytosolic phospholipase A2alpha inhibitors. J Med Chem. 2009 Feb 26;52(4):1156-71.
DMWKS29	RU	https://pubmed.ncbi.nlm.nih.gov/19178292

DMYZVLN	DI	DMYZVLN
DMYZVLN	DN	EC-SOD
DMYZVLN	MI	TT6RVLG
DMYZVLN	MN	Superoxide dismutase Cu-Zn (SOD Cu-Zn)
DMYZVLN	MT	DTT
DMYZVLN	MA	Modulator
DMYZVLN	RN	Extracellular superoxide dismutase (ecSOD) in vascular biology: an update on exogenous gene transfer and endogenous regulators of ecSOD.Transl Res.2008 Feb;151(2):68-78.
DMYZVLN	RU	https://www.ncbi.nlm.nih.gov/pubmed/18201674

DM5QS17	DI	DM5QS17
DM5QS17	DN	ED1
DM5QS17	MI	TTPLTSQ
DM5QS17	MN	Neutrophil elastase (NE)
DM5QS17	MT	DTT
DM5QS17	RN	Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60.
DM5QS17	RU	https://pubmed.ncbi.nlm.nih.gov/18095918

DMX32JY	DI	DMX32JY
DMX32JY	DN	ED45
DMX32JY	MI	TTPLTSQ
DMX32JY	MN	Neutrophil elastase (NE)
DMX32JY	MT	DTT
DMX32JY	RN	Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60.
DMX32JY	RU	https://pubmed.ncbi.nlm.nih.gov/18095918

DM32O0L	DI	DM32O0L
DM32O0L	DN	Edatrexate
DM32O0L	MI	TT9SL3Q
DM32O0L	MN	Polypeptide deformylase (PDF)
DM32O0L	MT	DTT
DM32O0L	MA	Inhibitor
DM32O0L	RN	Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer. 2003 Feb 20;103(5):587-99.
DM32O0L	RU	https://pubmed.ncbi.nlm.nih.gov/12494465

DM10D85	DI	DM10D85
DM10D85	DN	Edetic acid
DM10D85	MI	TT0VH8G
DM10D85	MN	Elegans Endoprotease bli-4 (Elegans bli-4)
DM10D85	MT	DTT
DM10D85	MA	Inhibitor
DM10D85	RN	Removal of the glycosylphosphatidylinositol anchor from PrP(Sc) by cathepsin D does not reduce prion infectivity. Biochem J. 2006 Apr 15;395(2):443-8.
DM10D85	RU	https://pubmed.ncbi.nlm.nih.gov/16441239

DMS3AXK	DI	DMS3AXK
DMS3AXK	DN	EDMT
DMS3AXK	MI	TTSQIFT
DMS3AXK	MN	5-HT 1A receptor (HTR1A)
DMS3AXK	MT	DTT
DMS3AXK	MA	Agonist
DMS3AXK	RN	2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem. 2000 Mar 9;43(5):1011-8.
DMS3AXK	RU	https://pubmed.ncbi.nlm.nih.gov/10715164

DMS3AXK	DI	DMS3AXK
DMS3AXK	DN	EDMT
DMS3AXK	MI	TT6MSOK
DMS3AXK	MN	5-HT 1D receptor (HTR1D)
DMS3AXK	MT	DTT
DMS3AXK	MA	Agonist
DMS3AXK	RN	2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem. 2000 Mar 9;43(5):1011-8.
DMS3AXK	RU	https://pubmed.ncbi.nlm.nih.gov/10715164

DMS3AXK	DI	DMS3AXK
DMS3AXK	DN	EDMT
DMS3AXK	MI	TTCPG9S
DMS3AXK	MN	5-HT 1E receptor (HTR1E)
DMS3AXK	MT	DTT
DMS3AXK	MA	Agonist
DMS3AXK	RN	2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem. 2000 Mar 9;43(5):1011-8.
DMS3AXK	RU	https://pubmed.ncbi.nlm.nih.gov/10715164

DMS3AXK	DI	DMS3AXK
DMS3AXK	DN	EDMT
DMS3AXK	MI	TTRUFDT
DMS3AXK	MN	5-HT 5A receptor (HTR5A)
DMS3AXK	MT	DTT
DMS3AXK	MA	Agonist
DMS3AXK	RN	2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem. 2000 Mar 9;43(5):1011-8.
DMS3AXK	RU	https://pubmed.ncbi.nlm.nih.gov/10715164

DMS3AXK	DI	DMS3AXK
DMS3AXK	DN	EDMT
DMS3AXK	MI	TTJS8PY
DMS3AXK	MN	5-HT 6 receptor (HTR6)
DMS3AXK	MT	DTT
DMS3AXK	MA	Inhibitor
DMS3AXK	RN	2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem. 2000 Mar 9;43(5):1011-8.
DMS3AXK	RU	https://pubmed.ncbi.nlm.nih.gov/10715164

DMS3AXK	DI	DMS3AXK
DMS3AXK	DN	EDMT
DMS3AXK	MI	TTO9X1H
DMS3AXK	MN	5-HT 7 receptor (HTR7)
DMS3AXK	MT	DTT
DMS3AXK	MA	Agonist
DMS3AXK	RN	2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem. 2000 Mar 9;43(5):1011-8.
DMS3AXK	RU	https://pubmed.ncbi.nlm.nih.gov/10715164

DMHCGIS	DI	DMHCGIS
DMHCGIS	DN	EDN-OL1
DMHCGIS	MI	TTE4KHA
DMHCGIS	MN	Amyloid beta A4 protein (APP)
DMHCGIS	MT	DTT
DMHCGIS	MA	Modulator
DMHCGIS	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
DMHCGIS	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402

DMC7DYX	DI	DMC7DYX
DMC7DYX	DN	Edoxudine
DMC7DYX	MI	TTP3QRF
DMC7DYX	MN	Thymidine kinase 1 (TK1)
DMC7DYX	MT	DTT
DMC7DYX	MA	Inhibitor
DMC7DYX	RN	Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate anal... Antimicrob Agents Chemother. 2007 Jun;51(6):2028-34.
DMC7DYX	RU	https://pubmed.ncbi.nlm.nih.gov/17438061

DMLSMBI	DI	DMLSMBI
DMLSMBI	DN	EDP-13
DMLSMBI	MI	TTGKNB4
DMLSMBI	MN	Epidermal growth factor receptor (EGFR)
DMLSMBI	MT	DTT
DMLSMBI	MA	Antagonist
DMLSMBI	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
DMLSMBI	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797

DMTVRKG	DI	DMTVRKG
DMTVRKG	DN	EDP-18
DMTVRKG	MI	TT946IA
DMTVRKG	MN	Transient receptor potential cation channel V3 (TRPV3)
DMTVRKG	MT	DTT
DMTVRKG	MA	Agonist
DMTVRKG	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 509).
DMTVRKG	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=509

DMMN0GO	DI	DMMN0GO
DMMN0GO	DN	EDP-21
DMMN0GO	MI	TT0HD6V
DMMN0GO	MN	Leptin receptor (LEPR)
DMMN0GO	MT	DTT
DMMN0GO	MA	Agonist
DMMN0GO	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1712).
DMMN0GO	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1712

DMN8JKX	DI	DMN8JKX
DMN8JKX	DN	E-EBU-dM
DMN8JKX	MI	TT84ETX
DMN8JKX	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMN8JKX	MT	DTT
DMN8JKX	MA	Modulator
DMN8JKX	RN	Construction of the chimeric reverse transcriptase of simian immunodeficiency virus sensitive to nonnucleoside reverse transcriptase inhibitor. Microbiol Immunol. 1998;42(3):195-202.
DMN8JKX	RU	https://www.ncbi.nlm.nih.gov/pubmed/9570285

DMXZRND	DI	DMXZRND
DMXZRND	DN	EFFUSOL
DMXZRND	MI	TTZAYWL
DMXZRND	MN	Estrogen receptor (ESR)
DMXZRND	MT	DTT
DMXZRND	MA	Inhibitor
DMXZRND	RN	6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72.
DMXZRND	RU	https://pubmed.ncbi.nlm.nih.gov/16412638

DMXZRND	DI	DMXZRND
DMXZRND	DN	EFFUSOL
DMXZRND	MI	TTOM3J0
DMXZRND	MN	Estrogen receptor beta (ESR2)
DMXZRND	MT	DTT
DMXZRND	MA	Inhibitor
DMXZRND	RN	6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72.
DMXZRND	RU	https://pubmed.ncbi.nlm.nih.gov/16412638

DMOKX76	DI	DMOKX76
DMOKX76	DN	Efomycine M
DMOKX76	MI	TTAU4D6
DMOKX76	MN	E-selectin (SELE)
DMOKX76	MT	DTT
DMOKX76	MA	Inhibitor
DMOKX76	RN	Interfering with leukocyte rolling--a promising therapeutic approach in inflammatory skin disorders Trends Pharmacol Sci. 2003 Feb;24(2):49-52.
DMOKX76	RU	https://pubmed.ncbi.nlm.nih.gov/12559762

DMOKX76	DI	DMOKX76
DMOKX76	DN	Efomycine M
DMOKX76	MI	TTE5VG0
DMOKX76	MN	P-selectin (SELP)
DMOKX76	MT	DTT
DMOKX76	MA	Inhibitor
DMOKX76	RN	Interfering with leukocyte rolling--a promising therapeutic approach in inflammatory skin disorders Trends Pharmacol Sci. 2003 Feb;24(2):49-52.
DMOKX76	RU	https://pubmed.ncbi.nlm.nih.gov/12559762

DMZ2XOH	DI	DMZ2XOH
DMZ2XOH	DN	EFPPEA
DMZ2XOH	MI	TT0WAIE
DMZ2XOH	MN	Melatonin receptor type 1A (MTNR1A)
DMZ2XOH	MT	DTT
DMZ2XOH	MA	Agonist
DMZ2XOH	RN	Synthesis of a novel series of tricyclic dihydrofuran derivatives: discovery of 8,9-dihydrofuro[3,2-c]pyrazolo[1,5-a]pyridines as melatonin receptor (MT1/MT2) ligands. J Med Chem. 2011 Jun 23;54(12):4207-18.
DMZ2XOH	RU	https://pubmed.ncbi.nlm.nih.gov/21568291

DMRP9K3	DI	DMRP9K3
DMRP9K3	DN	EG-10
DMRP9K3	MI	TTJTRMK
DMRP9K3	MN	Interleukin 10 receptor (IL10RB)
DMRP9K3	MT	DTT
DMRP9K3	MA	Modulator
DMRP9K3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1900).
DMRP9K3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1900

DM7AYH4	DI	DM7AYH4
DM7AYH4	DN	EGFR inhibitor
DM7AYH4	MI	TTGKNB4
DM7AYH4	MN	Epidermal growth factor receptor (EGFR)
DM7AYH4	MT	DTT
DM7AYH4	MA	Inhibitor
DM7AYH4	RN	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
DM7AYH4	RU	https://pubmed.ncbi.nlm.nih.gov/18077363

DMLK4X5	DI	DMLK4X5
DMLK4X5	DN	EGIS-7625
DMLK4X5	MI	TTJQOD7
DMLK4X5	MN	5-HT 2A receptor (HTR2A)
DMLK4X5	MT	DTT
DMLK4X5	MA	Antagonist
DMLK4X5	RN	Effects of EGIS-7625, a selective and competitive 5-HT2B receptor antagonist. Cardiovasc Drugs Ther. 2003 Sep-Nov;17(5-6):427-34.
DMLK4X5	RU	https://pubmed.ncbi.nlm.nih.gov/15107597

DMLK4X5	DI	DMLK4X5
DMLK4X5	DN	EGIS-7625
DMLK4X5	MI	TT0K1SC
DMLK4X5	MN	5-HT 2B receptor (HTR2B)
DMLK4X5	MT	DTT
DMLK4X5	MA	Antagonist
DMLK4X5	RN	Effects of EGIS-7625, a selective and competitive 5-HT2B receptor antagonist. Cardiovasc Drugs Ther. 2003 Sep-Nov;17(5-6):427-34.
DMLK4X5	RU	https://pubmed.ncbi.nlm.nih.gov/15107597

DMLK4X5	DI	DMLK4X5
DMLK4X5	DN	EGIS-7625
DMLK4X5	MI	TTWJBZ5
DMLK4X5	MN	5-HT 2C receptor (HTR2C)
DMLK4X5	MT	DTT
DMLK4X5	MA	Antagonist
DMLK4X5	RN	Effects of EGIS-7625, a selective and competitive 5-HT2B receptor antagonist. Cardiovasc Drugs Ther. 2003 Sep-Nov;17(5-6):427-34.
DMLK4X5	RU	https://pubmed.ncbi.nlm.nih.gov/15107597

DMKW0Q3	DI	DMKW0Q3
DMKW0Q3	DN	eGlu
DMKW0Q3	MI	TTXJ47W
DMKW0Q3	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMKW0Q3	MT	DTT
DMKW0Q3	MA	Antagonist
DMKW0Q3	RN	Characterization of [(3)H]-LY354740 binding to rat mGlu2 and mGlu3 receptors expressed in CHO cells using semliki forest virus vectors. Neuropharmacology. 2000 Jul 24;39(10):1700-6.
DMKW0Q3	RU	https://pubmed.ncbi.nlm.nih.gov/10884552

DMKW0Q3	DI	DMKW0Q3
DMKW0Q3	DN	eGlu
DMKW0Q3	MI	TT8A9EF
DMKW0Q3	MN	Metabotropic glutamate receptor 3 (mGluR3)
DMKW0Q3	MT	DTT
DMKW0Q3	MA	Antagonist
DMKW0Q3	RN	Characterization of [(3)H]-LY354740 binding to rat mGlu2 and mGlu3 receptors expressed in CHO cells using semliki forest virus vectors. Neuropharmacology. 2000 Jul 24;39(10):1700-6.
DMKW0Q3	RU	https://pubmed.ncbi.nlm.nih.gov/10884552

DMW9MRO	DI	DMW9MRO
DMW9MRO	DN	EGTA
DMW9MRO	MI	TTBLN9S
DMW9MRO	MN	Sulfur mustard-stimulated protease (SMSP)
DMW9MRO	MT	DTT
DMW9MRO	MA	Inhibitor
DMW9MRO	RN	Sulfur mustard-stimulated protease: a target for antivesicant drugs. J Appl Toxicol. 2002 Mar-Apr;22(2):139-40.
DMW9MRO	RU	https://pubmed.ncbi.nlm.nih.gov/11920939

DM014WS	DI	DM014WS
DM014WS	DN	EHNA
DM014WS	MI	TTLP57V
DM014WS	MN	Adenosine deaminase (ADA)
DM014WS	MT	DTT
DM014WS	MA	Inhibitor
DM014WS	RN	Tight-binding inhibitors--IV. Inhibition of adenosine deaminases by various inhibitors. Biochem Pharmacol. 1977 Mar 1;26(5):359-67.
DM014WS	RU	https://pubmed.ncbi.nlm.nih.gov/849330

DM014WS	DI	DM014WS
DM014WS	DN	EHNA
DM014WS	MI	TTJGW1Z
DM014WS	MN	Phosphodiesterase 2A (PDE2A)
DM014WS	MT	DTT
DM014WS	MA	Inhibitor
DM014WS	RN	Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram. Cell Signal. 1996 Feb;8(2):97-110.
DM014WS	RU	https://pubmed.ncbi.nlm.nih.gov/8730511

DMBQCMU	DI	DMBQCMU
DMBQCMU	DN	EI1
DMBQCMU	MI	TT9MZCQ
DMBQCMU	MN	Enhancer of zeste homolog 2 (EZH2)
DMBQCMU	MT	DTT
DMBQCMU	MA	Inhibitor
DMBQCMU	RN	Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):21360-5.
DMBQCMU	RU	https://pubmed.ncbi.nlm.nih.gov/23236167

DMVJK9W	DI	DMVJK9W
DMVJK9W	DN	Eicosadienoic acid
DMVJK9W	MI	DE073H6
DMVJK9W	MN	Prostaglandin G/H synthase 1 (COX-1)
DMVJK9W	MT	DME
DMVJK9W	MA	Metabolism
DMVJK9W	RN	Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. FASEB J. 2006 Jun;20(8):1097-108.
DMVJK9W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16770009

DMVJK9W	DI	DMVJK9W
DMVJK9W	DN	Eicosadienoic acid
DMVJK9W	MI	DE492CE
DMVJK9W	MN	Prostaglandin G/H synthase 2 (COX-2)
DMVJK9W	MT	DME
DMVJK9W	MA	Metabolism
DMVJK9W	RN	Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. FASEB J. 2006 Jun;20(8):1097-108.
DMVJK9W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16770009

DMAKP20	DI	DMAKP20
DMAKP20	DN	eicosatetranoic acid
DMAKP20	MI	TTJ584C
DMAKP20	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMAKP20	MT	DTT
DMAKP20	MA	Agonist
DMAKP20	RN	PPAR alpha structure-function relationships derived from species-specific differences in responsiveness to hypolipidemic agents. Biol Chem. 1997 Jul;378(7):651-5.
DMAKP20	RU	https://pubmed.ncbi.nlm.nih.gov/9278144

DM03X7D	DI	DM03X7D
DM03X7D	DN	EISAI-1
DM03X7D	MI	TTTUMEP
DM03X7D	MN	Neurotensin receptor type 1 (NTSR1)
DM03X7D	MT	DTT
DM03X7D	MA	Agonist
DM03X7D	RN	Differential involvement of intracellular domains of the rat NTS1 neurotensin receptor in coupling to G proteins: a molecular basis for agonist-directed trafficking of receptor stimulus. Mol Pharmacol. 2003 Aug;64(2):421-9.
DM03X7D	RU	https://pubmed.ncbi.nlm.nih.gov/12869647

DMRHSCQ	DI	DMRHSCQ
DMRHSCQ	DN	ELAEOCARPENINE
DMRHSCQ	MI	TT27RFC
DMRHSCQ	MN	Opioid receptor delta (OPRD1)
DMRHSCQ	MT	DTT
DMRHSCQ	MA	Inhibitor
DMRHSCQ	RN	Synthesis and evaluation of opioid receptor-binding affinity of elaeocarpenine and its analogs. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1601-3.
DMRHSCQ	RU	https://pubmed.ncbi.nlm.nih.gov/20144865

DMRHSCQ	DI	DMRHSCQ
DMRHSCQ	DN	ELAEOCARPENINE
DMRHSCQ	MI	TTQW87Y
DMRHSCQ	MN	Opioid receptor kappa (OPRK1)
DMRHSCQ	MT	DTT
DMRHSCQ	MA	Inhibitor
DMRHSCQ	RN	Synthesis and evaluation of opioid receptor-binding affinity of elaeocarpenine and its analogs. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1601-3.
DMRHSCQ	RU	https://pubmed.ncbi.nlm.nih.gov/20144865

DMRHSCQ	DI	DMRHSCQ
DMRHSCQ	DN	ELAEOCARPENINE
DMRHSCQ	MI	TTKWM86
DMRHSCQ	MN	Opioid receptor mu (MOP)
DMRHSCQ	MT	DTT
DMRHSCQ	MA	Inhibitor
DMRHSCQ	RN	Synthesis and evaluation of opioid receptor-binding affinity of elaeocarpenine and its analogs. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1601-3.
DMRHSCQ	RU	https://pubmed.ncbi.nlm.nih.gov/20144865

DMP8VDT	DI	DMP8VDT
DMP8VDT	DN	Elaidoylamide
DMP8VDT	MI	TTO9X1H
DMP8VDT	MN	5-HT 7 receptor (HTR7)
DMP8VDT	MT	DTT
DMP8VDT	MA	Modulator (allosteric modulator)
DMP8VDT	RN	Allosteric regulation by oleamide of the binding properties of 5-hydroxytryptamine7 receptors. Biochem Pharmacol. 1999 Dec 1;58(11):1807-13.
DMP8VDT	RU	https://pubmed.ncbi.nlm.nih.gov/10571256

DMP8VDT	DI	DMP8VDT
DMP8VDT	DN	Elaidoylamide
DMP8VDT	MI	TTO8QRU
DMP8VDT	MN	Group IIA phospholipase A2 (GIIA sPLA2)
DMP8VDT	MT	DTT
DMP8VDT	MA	Inhibitor
DMP8VDT	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMP8VDT	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMEOJ9W	DI	DMEOJ9W
DMEOJ9W	DN	eledoisin
DMEOJ9W	MI	TTBPGLU
DMEOJ9W	MN	Neuromedin-K receptor (TACR3)
DMEOJ9W	MT	DTT
DMEOJ9W	MA	Agonist
DMEOJ9W	RN	Molecular characterisation, expression and localisation of human neurokinin-3 receptor. FEBS Lett. 1992 Mar 24;299(1):90-5.
DMEOJ9W	RU	https://pubmed.ncbi.nlm.nih.gov/1312036

DMEOJ9W	DI	DMEOJ9W
DMEOJ9W	DN	eledoisin
DMEOJ9W	MI	TTZPO1L
DMEOJ9W	MN	Substance-P receptor (TACR1)
DMEOJ9W	MT	DTT
DMEOJ9W	MA	Agonist
DMEOJ9W	RN	The unpredicted high affinities of a large number of naturally occurring tachykinins for chimeric NK1/NK3 receptors suggest a role for an inhibitory domain in determining receptor specificity. J BiolChem. 1996 Aug 23;271(34):20250-7.
DMEOJ9W	RU	https://pubmed.ncbi.nlm.nih.gov/8702757

DMMVZU0	DI	DMMVZU0
DMMVZU0	DN	Eleutherobin
DMMVZU0	MI	TTML2WA
DMMVZU0	MN	Tubulin (TUB)
DMMVZU0	MT	DTT
DMMVZU0	MA	Inducer
DMMVZU0	RN	Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel (Taxol). Cancer Res. 1998 Mar 15;58(6):1111-5.
DMMVZU0	RU	https://pubmed.ncbi.nlm.nih.gov/9515790

DMX8BS5	DI	DMX8BS5
DMX8BS5	DN	ELLAGIC ACID
DMX8BS5	MI	TTUNARX
DMX8BS5	MN	Carbonic anhydrase (CA)
DMX8BS5	MT	DTT
DMX8BS5	MA	Inhibitor
DMX8BS5	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DMX8BS5	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DMX8BS5	DI	DMX8BS5
DMX8BS5	DN	ELLAGIC ACID
DMX8BS5	MI	TTHQPL7
DMX8BS5	MN	Carbonic anhydrase I (CA-I)
DMX8BS5	MT	DTT
DMX8BS5	MA	Inhibitor
DMX8BS5	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DMX8BS5	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DMX8BS5	DI	DMX8BS5
DMX8BS5	DN	ELLAGIC ACID
DMX8BS5	MI	TTANPDJ
DMX8BS5	MN	Carbonic anhydrase II (CA-II)
DMX8BS5	MT	DTT
DMX8BS5	MA	Inhibitor
DMX8BS5	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DMX8BS5	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DMX8BS5	DI	DMX8BS5
DMX8BS5	DN	ELLAGIC ACID
DMX8BS5	MI	TTZHA0O
DMX8BS5	MN	Carbonic anhydrase IV (CA-IV)
DMX8BS5	MT	DTT
DMX8BS5	MA	Inhibitor
DMX8BS5	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DMX8BS5	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DMX8BS5	DI	DMX8BS5
DMX8BS5	DN	ELLAGIC ACID
DMX8BS5	MI	TT2LVK8
DMX8BS5	MN	Carbonic anhydrase IX (CA-IX)
DMX8BS5	MT	DTT
DMX8BS5	MA	Inhibitor
DMX8BS5	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DMX8BS5	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DMX8BS5	DI	DMX8BS5
DMX8BS5	DN	ELLAGIC ACID
DMX8BS5	MI	TTCFSPE
DMX8BS5	MN	Carbonic anhydrase VI (CA-VI)
DMX8BS5	MT	DTT
DMX8BS5	MA	Inhibitor
DMX8BS5	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DMX8BS5	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DMX8BS5	DI	DMX8BS5
DMX8BS5	DN	ELLAGIC ACID
DMX8BS5	MI	TTSYM0R
DMX8BS5	MN	Carbonic anhydrase XII (CA-XII)
DMX8BS5	MT	DTT
DMX8BS5	MA	Inhibitor
DMX8BS5	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DMX8BS5	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DMX8BS5	DI	DMX8BS5
DMX8BS5	DN	ELLAGIC ACID
DMX8BS5	MI	TTEYTKG
DMX8BS5	MN	Carbonic anhydrase XIV (CA-XIV)
DMX8BS5	MT	DTT
DMX8BS5	MA	Inhibitor
DMX8BS5	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DMX8BS5	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DMX8BS5	DI	DMX8BS5
DMX8BS5	DN	ELLAGIC ACID
DMX8BS5	MI	TTER6YH
DMX8BS5	MN	Casein kinase II alpha (CSNK2A1)
DMX8BS5	MT	DTT
DMX8BS5	MA	Inhibitor
DMX8BS5	RN	Structural insight into human CK2alpha in complex with the potent inhibitor ellagic acid. Bioorg Med Chem Lett. 2009 Jun 1;19(11):2920-3.
DMX8BS5	RU	https://pubmed.ncbi.nlm.nih.gov/19414254

DMX8BS5	DI	DMX8BS5
DMX8BS5	DN	ELLAGIC ACID
DMX8BS5	MI	TTRSMW9
DMX8BS5	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMX8BS5	MT	DTT
DMX8BS5	MA	Inhibitor
DMX8BS5	RN	Identification of ellagic acid as potent inhibitor of protein kinase CK2: a successful example of a virtual screening application. J Med Chem. 2006 Apr 20;49(8):2363-6.
DMX8BS5	RU	https://pubmed.ncbi.nlm.nih.gov/16610779

DMX8BS5	DI	DMX8BS5
DMX8BS5	DN	ELLAGIC ACID
DMX8BS5	MI	TTHYBIX
DMX8BS5	MN	Heat shock protein 70 (HSP70)
DMX8BS5	MT	DTT
DMX8BS5	MA	Inhibitor
DMX8BS5	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMX8BS5	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMX8BS5	DI	DMX8BS5
DMX8BS5	DN	ELLAGIC ACID
DMX8BS5	MI	TTHQZV7
DMX8BS5	MN	Mothers against decapentaplegic homolog 3 (SMAD3)
DMX8BS5	MT	DTT
DMX8BS5	MA	Inhibitor
DMX8BS5	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMX8BS5	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMX8BS5	DI	DMX8BS5
DMX8BS5	DN	ELLAGIC ACID
DMX8BS5	MI	TTE14XG
DMX8BS5	MN	Squalene monooxygenase (SQLE)
DMX8BS5	MT	DTT
DMX8BS5	MA	Inhibitor
DMX8BS5	RN	Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4.
DMX8BS5	RU	https://pubmed.ncbi.nlm.nih.gov/11520216

DMX8BS5	DI	DMX8BS5
DMX8BS5	DN	ELLAGIC ACID
DMX8BS5	MI	TTOU65C
DMX8BS5	MN	Tyrosine-protein kinase SYK (SYK)
DMX8BS5	MT	DTT
DMX8BS5	MA	Inhibitor
DMX8BS5	RN	Identification of ellagic acid as potent inhibitor of protein kinase CK2: a successful example of a virtual screening application. J Med Chem. 2006 Apr 20;49(8):2363-6.
DMX8BS5	RU	https://pubmed.ncbi.nlm.nih.gov/16610779

DMHPYSM	DI	DMHPYSM
DMHPYSM	DN	Ellipticine
DMHPYSM	MI	TT0IHXV
DMHPYSM	MN	DNA topoisomerase II (TOP2)
DMHPYSM	MT	DTT
DMHPYSM	MA	Inhibitor
DMHPYSM	RN	In vitro sensitivity of Trichomonas vaginalis to DNA topoisomerase II inhibitors. Southeast Asian J Trop Med Public Health. 2000 Mar;31(1):118-22.
DMHPYSM	RU	https://pubmed.ncbi.nlm.nih.gov/11023077

DM2DERW	DI	DM2DERW
DM2DERW	DN	ELN-864709
DM2DERW	MI	TT056SO
DM2DERW	MN	Stress-activated protein kinase JNK3 (JNK3)
DM2DERW	MT	DTT
DM2DERW	MA	Inhibitor
DM2DERW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1498).
DM2DERW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1498

DM5G1SF	DI	DM5G1SF
DM5G1SF	DN	ELND-007
DM5G1SF	MI	TTE4KHA
DM5G1SF	MN	Amyloid beta A4 protein (APP)
DM5G1SF	MT	DTT
DM5G1SF	MA	Inhibitor
DM5G1SF	RN	Inhibition of APP gamma-secretase restores Sonic Hedgehog signaling and neurogenesis in the Ts65Dn mouse model of Down syndrome. Neurobiology of Disease Volume 82, October 2015, Pages 385-396.
DM5G1SF	RU	http://www.sciencedirect.com/science/article/pii/S096999611530022X

DMQ63J2	DI	DMQ63J2
DMQ63J2	DN	EM-101
DMQ63J2	MI	TTCJG29
DMQ63J2	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMQ63J2	MT	DTT
DMQ63J2	MA	Inhibitor
DMQ63J2	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
DMQ63J2	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109

DMZ2EL1	DI	DMZ2EL1
DMZ2EL1	DN	EM1396
DMZ2EL1	MI	TT5ZWB6
DMZ2EL1	MN	Dihydrodiol dehydrogenase type I (AKR1C3)
DMZ2EL1	MT	DTT
DMZ2EL1	MA	Inhibitor
DMZ2EL1	RN	Structure-based inhibitor design for an enzyme that binds different steroids: a potent inhibitor for human type 5 17beta-hydroxysteroid dehydrogenase. J Biol Chem. 2007 Mar 16;282(11):8368-79.
DMZ2EL1	RU	https://pubmed.ncbi.nlm.nih.gov/17166832

DMSLHDN	DI	DMSLHDN
DMSLHDN	DN	EM-1424
DMSLHDN	MI	TT5ZWB6
DMSLHDN	MN	Dihydrodiol dehydrogenase type I (AKR1C3)
DMSLHDN	MT	DTT
DMSLHDN	MA	Inhibitor
DMSLHDN	RN	Structure-based inhibitor design for an enzyme that binds different steroids: a potent inhibitor for human type 5 17beta-hydroxysteroid dehydrogenase. J Biol Chem. 2007 Mar 16;282(11):8368-79.
DMSLHDN	RU	https://pubmed.ncbi.nlm.nih.gov/17166832

DM3RSYO	DI	DM3RSYO
DM3RSYO	DN	EM-1745
DM3RSYO	MI	TTIWB6L
DM3RSYO	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DM3RSYO	MT	DTT
DM3RSYO	MA	Inhibitor
DM3RSYO	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM3RSYO	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMC4XJ6	DI	DMC4XJ6
DMC4XJ6	DN	EM-523
DMC4XJ6	MI	TT953CX
DMC4XJ6	MN	Motilin receptor (MLNR)
DMC4XJ6	MT	DTT
DMC4XJ6	MA	Agonist
DMC4XJ6	RN	Desensitization of the human motilin receptor by motilides. J Pharmacol Exp Ther. 2005 Jun;313(3):1397-405.
DMC4XJ6	RU	https://pubmed.ncbi.nlm.nih.gov/15764739

DMFQX1U	DI	DMFQX1U
DMFQX1U	DN	EMATE
DMFQX1U	MI	TTANPDJ
DMFQX1U	MN	Carbonic anhydrase II (CA-II)
DMFQX1U	MT	DTT
DMFQX1U	MA	Inhibitor
DMFQX1U	RN	2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity. J Med Chem. 2006 Dec 28;49(26):7683-96.
DMFQX1U	RU	https://pubmed.ncbi.nlm.nih.gov/17181151

DMFQX1U	DI	DMFQX1U
DMFQX1U	DN	EMATE
DMFQX1U	MI	TTHM0R1
DMFQX1U	MN	Steryl-sulfatase (STS)
DMFQX1U	MT	DTT
DMFQX1U	MA	Inhibitor
DMFQX1U	RN	Thiosemicarbazones of formyl benzoic acids as novel potent inhibitors of estrone sulfatase. J Med Chem. 2007 Jul 26;50(15):3661-6.
DMFQX1U	RU	https://pubmed.ncbi.nlm.nih.gov/17580843

DMUH1JX	DI	DMUH1JX
DMUH1JX	DN	EMC-0901
DMUH1JX	MI	TTDIGC1
DMUH1JX	MN	Dipeptidyl peptidase 4 (DPP-4)
DMUH1JX	MT	DTT
DMUH1JX	MA	Inhibitor
DMUH1JX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1612).
DMUH1JX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1612

DM4SEMA	DI	DM4SEMA
DM4SEMA	DN	EMD 56551
DM4SEMA	MI	TTSQIFT
DM4SEMA	MN	5-HT 1A receptor (HTR1A)
DM4SEMA	MT	DTT
DM4SEMA	MA	Modulator
DM4SEMA	RN	Diagnosis of migraine with aura, depression and anxiety from allelic variations in dopaminergic genes
DM4SEMA	RU	https://www.google.com/patents/WO1998007426A1

DM3AGUQ	DI	DM3AGUQ
DM3AGUQ	DN	EMD-386088
DM3AGUQ	MI	TTJS8PY
DM3AGUQ	MN	5-HT 6 receptor (HTR6)
DM3AGUQ	MT	DTT
DM3AGUQ	MA	Agonist
DM3AGUQ	RN	2-Alkyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles as novel 5-HT6 receptor agonists. Bioorg Med Chem Lett. 2005 Oct 1;15(19):4230-4.
DM3AGUQ	RU	https://pubmed.ncbi.nlm.nih.gov/16055331

DM6O2BR	DI	DM6O2BR
DM6O2BR	DN	EMPA
DM6O2BR	MI	TT9N02I
DM6O2BR	MN	Orexin receptor type 2 (HCRTR2)
DM6O2BR	MT	DTT
DM6O2BR	MA	Antagonist
DM6O2BR	RN	Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX(2) receptor. Br J Pharmacol. 2009 Apr;156(8):1326-41.
DM6O2BR	RU	https://pubmed.ncbi.nlm.nih.gov/19751316

DMQLNZC	DI	DMQLNZC
DMQLNZC	DN	Empagli ozin
DMQLNZC	MI	TTLWPVF
DMQLNZC	MN	Sodium/glucose cotransporter 2 (SGLT2)
DMQLNZC	MT	DTT
DMQLNZC	MA	Modulator
DMQLNZC	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMQLNZC	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMASQWV	DI	DMASQWV
DMASQWV	DN	enantio PAF C-16
DMASQWV	MI	TTQL5VC
DMASQWV	MN	Platelet-activating factor receptor (PTAFR)
DMASQWV	MT	DTT
DMASQWV	MA	Agonist
DMASQWV	RN	A radioreceptor binding assay for platelet-activating factor (PAF) using membranes from CHO cells expressing human PAF receptor. J Immunol Methods. 1995 Oct 26;186(2):225-31.
DMASQWV	RU	https://pubmed.ncbi.nlm.nih.gov/7594622

DMUCZPJ	DI	DMUCZPJ
DMUCZPJ	DN	ENDG-4010
DMUCZPJ	MI	TT3ZTGU
DMUCZPJ	MN	Endothelin B receptor (EDNRB)
DMUCZPJ	MT	DTT
DMUCZPJ	MA	Modulator
DMUCZPJ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 220).
DMUCZPJ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=220

DM7RDGH	DI	DM7RDGH
DM7RDGH	DN	ENDIANDRIN A
DM7RDGH	MI	TTOZRK6
DM7RDGH	MN	Glucocorticoid receptor messenger RNA (GCR mRNA)
DM7RDGH	MT	DTT
DM7RDGH	MA	Inhibitor
DM7RDGH	RN	Endiandrin A, a potent glucocorticoid receptor binder isolated from the Australian plant Endiandra anthropophagorum. J Nat Prod. 2007 Jul;70(7):1118-21.
DM7RDGH	RU	https://pubmed.ncbi.nlm.nih.gov/17583952

DM4AI91	DI	DM4AI91
DM4AI91	DN	Endo-CD
DM4AI91	MI	TT63DI9
DM4AI91	MN	Endostatin (COL18A1)
DM4AI91	MT	DTT
DM4AI91	MA	Modulator
DM4AI91	RN	Dual targeting of tumor angiogenesis and chemotherapy by endostatin-cytosine deaminase-uracil phosphoribosyltransferase.Mol Cancer Ther.2011 Aug;10(8):1327-36.
DM4AI91	RU	https://www.ncbi.nlm.nih.gov/pubmed/21610170

DMOQWBU	DI	DMOQWBU
DMOQWBU	DN	ENDOMORPHIN 2
DMOQWBU	MI	TT27RFC
DMOQWBU	MN	Opioid receptor delta (OPRD1)
DMOQWBU	MT	DTT
DMOQWBU	MA	Inhibitor
DMOQWBU	RN	Synthesis and activity of endomorphin-2 and morphiceptin analogues with proline surrogates in position 2. Eur J Med Chem. 2010 Oct;45(10):4594-600.
DMOQWBU	RU	https://pubmed.ncbi.nlm.nih.gov/20692738

DMOQWBU	DI	DMOQWBU
DMOQWBU	DN	ENDOMORPHIN 2
DMOQWBU	MI	TTQW87Y
DMOQWBU	MN	Opioid receptor kappa (OPRK1)
DMOQWBU	MT	DTT
DMOQWBU	MA	Inhibitor
DMOQWBU	RN	Structure-activity study on the Phe side chain arrangement of endomorphins using conformationally constrained analogues. J Med Chem. 2004 Jan 29;47(3):735-43.
DMOQWBU	RU	https://pubmed.ncbi.nlm.nih.gov/14736254

DMOQWBU	DI	DMOQWBU
DMOQWBU	DN	ENDOMORPHIN 2
DMOQWBU	MI	TTKWM86
DMOQWBU	MN	Opioid receptor mu (MOP)
DMOQWBU	MT	DTT
DMOQWBU	MA	Inhibitor
DMOQWBU	RN	Synthesis and activity of endomorphin-2 and morphiceptin analogues with proline surrogates in position 2. Eur J Med Chem. 2010 Oct;45(10):4594-600.
DMOQWBU	RU	https://pubmed.ncbi.nlm.nih.gov/20692738

DMOQWBU	DI	DMOQWBU
DMOQWBU	DN	ENDOMORPHIN 2
DMOQWBU	MI	TTZPO1L
DMOQWBU	MN	Substance-P receptor (TACR1)
DMOQWBU	MT	DTT
DMOQWBU	MA	Inhibitor
DMOQWBU	RN	Discovery of dipeptides with high affinity to the specific binding site for substance P1-7. J Med Chem. 2010 Mar 25;53(6):2383-9.
DMOQWBU	RU	https://pubmed.ncbi.nlm.nih.gov/20178322

DMBJUEM	DI	DMBJUEM
DMBJUEM	DN	ENDOMORPHIN-1
DMBJUEM	MI	TT27RFC
DMBJUEM	MN	Opioid receptor delta (OPRD1)
DMBJUEM	MT	DTT
DMBJUEM	MA	Inhibitor
DMBJUEM	RN	New endomorphin analogues containing alicyclic beta-amino acids: influence on bioactive conformation and pharmacological profile. J Med Chem. 2008 Jul 24;51(14):4270-9.
DMBJUEM	RU	https://pubmed.ncbi.nlm.nih.gov/18572932

DMBJUEM	DI	DMBJUEM
DMBJUEM	DN	ENDOMORPHIN-1
DMBJUEM	MI	TTQW87Y
DMBJUEM	MN	Opioid receptor kappa (OPRK1)
DMBJUEM	MT	DTT
DMBJUEM	MA	Inhibitor
DMBJUEM	RN	Structure-activity study on the Phe side chain arrangement of endomorphins using conformationally constrained analogues. J Med Chem. 2004 Jan 29;47(3):735-43.
DMBJUEM	RU	https://pubmed.ncbi.nlm.nih.gov/14736254

DMBJUEM	DI	DMBJUEM
DMBJUEM	DN	ENDOMORPHIN-1
DMBJUEM	MI	TTKWM86
DMBJUEM	MN	Opioid receptor mu (MOP)
DMBJUEM	MT	DTT
DMBJUEM	MA	Inhibitor
DMBJUEM	RN	Synthesis and evaluation of new endomorphin analogues modified at the Pro(2) residue. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4115-8.
DMBJUEM	RU	https://pubmed.ncbi.nlm.nih.gov/19560919

DMI2RQS	DI	DMI2RQS
DMI2RQS	DN	Endomorphins
DMI2RQS	MI	TTKWM86
DMI2RQS	MN	Opioid receptor mu (MOP)
DMI2RQS	MT	DTT
DMI2RQS	MA	Modulator
DMI2RQS	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
DMI2RQS	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319

DMOEIYQ	DI	DMOEIYQ
DMOEIYQ	DN	Endothelin-2
DMOEIYQ	MI	TTKRD0G
DMOEIYQ	MN	Endothelin A receptor (EDNRA)
DMOEIYQ	MT	DTT
DMOEIYQ	MA	Inhibitor
DMOEIYQ	RN	5-OHKF and NorKA, depsipeptides from a Hawaiian collection of Bryopsis pennata: binding properties for NorKA to the human neuropeptide Y Y1 receptor. J Nat Prod. 2009 Dec;72(12):2172-6.
DMOEIYQ	RU	https://pubmed.ncbi.nlm.nih.gov/19916528

DM0DM6X	DI	DM0DM6X
DM0DM6X	DN	Endothelin-3
DM0DM6X	MI	TT3ZTGU
DM0DM6X	MN	Endothelin B receptor (EDNRB)
DM0DM6X	MT	DTT
DM0DM6X	MA	Inhibitor
DM0DM6X	RN	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
DM0DM6X	RU	https://pubmed.ncbi.nlm.nih.gov/18983139

DM0STFR	DI	DM0STFR
DM0STFR	DN	ENHYDRIN
DM0STFR	MI	TTSXVID
DM0STFR	MN	Nuclear factor NF-kappa-B (NFKB)
DM0STFR	MT	DTT
DM0STFR	MA	Inhibitor
DM0STFR	RN	Development of a structural model for NF-kappaB inhibition of sesquiterpene lactones using self-organizing neural networks. J Med Chem. 2006 Apr 6;49(7):2241-52.
DM0STFR	RU	https://pubmed.ncbi.nlm.nih.gov/16570920

DMYJ8ZB	DI	DMYJ8ZB
DMYJ8ZB	DN	Enoxaprin
DMYJ8ZB	MI	TT6L509
DMYJ8ZB	MN	Coagulation factor IIa (F2)
DMYJ8ZB	MT	DTT
DMYJ8ZB	MA	Inhibitor
DMYJ8ZB	RN	Low molecular weight heparins and their use in obstetrics and gynecology. Obstet Gynecol Surv. 1994 Jun;49(6):424-31.
DMYJ8ZB	RU	https://pubmed.ncbi.nlm.nih.gov/8090379

DMSPIF2	DI	DMSPIF2
DMSPIF2	DN	EP 157
DMSPIF2	MI	TTOFYT1
DMSPIF2	MN	Prostacyclin receptor (PTGIR)
DMSPIF2	MT	DTT
DMSPIF2	MA	Agonist
DMSPIF2	RN	Prostaglandin endoperoxide analogues which are both thromboxane receptor antagonists and prostacyclin mimetics. Br J Pharmacol. 1986 Mar;87(3):543-51.
DMSPIF2	RU	https://pubmed.ncbi.nlm.nih.gov/3026540

DM7YION	DI	DM7YION
DM7YION	DN	EP 171
DM7YION	MI	TT2O84V
DM7YION	MN	Thromboxane A2 receptor (TBXA2R)
DM7YION	MT	DTT
DM7YION	MA	Agonist
DM7YION	RN	EP 171: a high affinity thromboxane A2-mimetic, the actions of which are slowly reversed by receptor blockade. Br J Pharmacol. 1989 Apr;96(4):875-87.
DM7YION	RU	https://pubmed.ncbi.nlm.nih.gov/2743082

DMAURX5	DI	DMAURX5
DMAURX5	DN	EP-200
DMAURX5	MI	TT2O4W9
DMAURX5	MN	Luteinizing hormone receptor (LHCGR)
DMAURX5	MT	DTT
DMAURX5	MA	Modulator
DMAURX5	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 254).
DMAURX5	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=254

DMHN82B	DI	DMHN82B
DMHN82B	DN	EP-37
DMHN82B	MI	TTCIHJA
DMHN82B	MN	Coagulation factor Xa (F10)
DMHN82B	MT	DTT
DMHN82B	MA	Antagonist
DMHN82B	RN	Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7.
DMHN82B	RU	https://pubmed.ncbi.nlm.nih.gov/22844656

DM01MW7	DI	DM01MW7
DM01MW7	DN	EPALRESTATE
DM01MW7	MI	TTFBNVI
DM01MW7	MN	Aldose reductase (AKR1B1)
DM01MW7	MT	DTT
DM01MW7	MA	Inhibitor
DM01MW7	RN	Erigeroflavanone, a flavanone derivative from the flowers of Erigeron annuus with protein glycation and aldose reductase inhibitory activity. J Nat Prod. 2008 Apr;71(4):713-5.
DM01MW7	RU	https://pubmed.ncbi.nlm.nih.gov/18298080

DMBLSX3	DI	DMBLSX3
DMBLSX3	DN	EPB-415
DMBLSX3	MI	TTCAQMW
DMBLSX3	MN	Inosine-5'-monophosphate dehydrogenase (IMPDH)
DMBLSX3	MT	DTT
DMBLSX3	MA	Modulator
DMBLSX3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2625).
DMBLSX3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2625

DMT7RXZ	DI	DMT7RXZ
DMT7RXZ	DN	E-pentenylbutanedioic acid 32
DMT7RXZ	MI	TT5VER7
DMT7RXZ	MN	Bacterial Undecaprenyl pyrophosphate synthetase (Bact ispU)
DMT7RXZ	MT	DTT
DMT7RXZ	MA	Inhibitor
DMT7RXZ	RN	Synthesis and biological activity of isopentenyl diphosphate analogues. Bioorg Med Chem. 2004 Feb 15;12(4):763-70.
DMT7RXZ	RU	https://pubmed.ncbi.nlm.nih.gov/14759736

DM3F427	DI	DM3F427
DM3F427	DN	EphB4-131
DM3F427	MI	TTI4ZX2
DM3F427	MN	Ephrin type-B receptor 4 (EPHB4)
DM3F427	MT	DTT
DM3F427	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1833).
DM3F427	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1833

DMYWV81	DI	DMYWV81
DMYWV81	DN	EPI-001
DMYWV81	MI	TTS64P2
DMYWV81	MN	Androgen receptor (AR)
DMYWV81	MT	DTT
DMYWV81	MA	Modulator
DMYWV81	RN	EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer. Oncotarget. 2015 Feb 28;6(6):3811-24.
DMYWV81	RU	https://pubmed.ncbi.nlm.nih.gov/25669987

DM72DO1	DI	DM72DO1
DM72DO1	DN	EPI-0030
DM72DO1	MI	TTUTJGQ
DM72DO1	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM72DO1	MT	DTT
DM72DO1	MA	Modulator
DM72DO1	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1813).
DM72DO1	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1813

DMAGZD8	DI	DMAGZD8
DMAGZD8	DN	Epibatidine
DMAGZD8	MI	TTJSZTB
DMAGZD8	MN	Nicotinic acetylcholine receptor (nAChR)
DMAGZD8	MT	DTT
DMAGZD8	MA	Agonist
DMAGZD8	RN	The potential of subtype-selective neuronal nicotinic acetylcholine receptor agonists as therapeutic agents. Life Sci. 1998;62(17-18):1601-6.
DMAGZD8	RU	https://pubmed.ncbi.nlm.nih.gov/9585143

DMFMWA7	DI	DMFMWA7
DMFMWA7	DN	EpiCept
DMFMWA7	MI	TT85JO3
DMFMWA7	MN	5-HT receptor (5HTR)
DMFMWA7	MT	DTT
DMFMWA7	MA	Antagonist
DMFMWA7	RN	Emerging therapies for neuropathic pain. Expert Opin Emerg Drugs. 2005 Feb;10(1):95-108.
DMFMWA7	RU	https://pubmed.ncbi.nlm.nih.gov/15757406

DMGKIYE	DI	DMGKIYE
DMGKIYE	DN	EPIDEPRIDE
DMGKIYE	MI	TTEX248
DMGKIYE	MN	Dopamine D2 receptor (D2R)
DMGKIYE	MT	DTT
DMGKIYE	MA	Inhibitor
DMGKIYE	RN	Fluorinated and iodinated dopamine agents: D2 imaging agents for PET and SPECT. J Med Chem. 1993 Jan 22;36(2):221-8.
DMGKIYE	RU	https://pubmed.ncbi.nlm.nih.gov/8093734

DMVZW92	DI	DMVZW92
DMVZW92	DN	Epierenone
DMVZW92	MI	TTKPW01
DMVZW92	MN	Androgen receptor messenger RNA (AR mRNA)
DMVZW92	MT	DTT
DMVZW92	MA	Inhibitor
DMVZW92	RN	(S)-N-{3-[1-cyclopropyl-1-(2,4-difluoro-phenyl)-ethyl]-1H-indol-7-yl}-methanesulfonamide: a potent, nonsteroidal, functional antagonist of the mine... J Med Chem. 2007 Dec 27;50(26):6443-5.
DMVZW92	RU	https://pubmed.ncbi.nlm.nih.gov/18038968

DMVZW92	DI	DMVZW92
DMVZW92	DN	Epierenone
DMVZW92	MI	TTOZRK6
DMVZW92	MN	Glucocorticoid receptor messenger RNA (GCR mRNA)
DMVZW92	MT	DTT
DMVZW92	MA	Inhibitor
DMVZW92	RN	(S)-N-{3-[1-cyclopropyl-1-(2,4-difluoro-phenyl)-ethyl]-1H-indol-7-yl}-methanesulfonamide: a potent, nonsteroidal, functional antagonist of the mine... J Med Chem. 2007 Dec 27;50(26):6443-5.
DMVZW92	RU	https://pubmed.ncbi.nlm.nih.gov/18038968

DMVZW92	DI	DMVZW92
DMVZW92	DN	Epierenone
DMVZW92	MI	TT26PHO
DMVZW92	MN	Mineralocorticoid receptor  (MR)
DMVZW92	MT	DTT
DMVZW92	MA	Inhibitor
DMVZW92	RN	(S)-N-{3-[1-cyclopropyl-1-(2,4-difluoro-phenyl)-ethyl]-1H-indol-7-yl}-methanesulfonamide: a potent, nonsteroidal, functional antagonist of the mine... J Med Chem. 2007 Dec 27;50(26):6443-5.
DMVZW92	RU	https://pubmed.ncbi.nlm.nih.gov/18038968

DMQAEU8	DI	DMQAEU8
DMQAEU8	DN	EPIMER A
DMQAEU8	MI	TTY6O0Q
DMQAEU8	MN	Calcitonin gene-related peptide receptor (CGRPR)
DMQAEU8	MT	DTT
DMQAEU8	MA	Inhibitor
DMQAEU8	RN	The identification of potent, orally bioavailable tricyclic CGRP receptor antagonists. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4740-2.
DMQAEU8	RU	https://pubmed.ncbi.nlm.nih.gov/19577468

DMW271Q	DI	DMW271Q
DMW271Q	DN	epipregnanolone sulphate
DMW271Q	MI	TTO3TD8
DMW271Q	MN	Long transient receptor potential channel 3 (TRPM3)
DMW271Q	MT	DTT
DMW271Q	MA	Activator
DMW271Q	RN	Cis-isomerism and other chemical requirements of steroidal agonists and partial agonists acting at TRPM3 channels. Br J Pharmacol. 2010 Sep;161(2):430-41.
DMW271Q	RU	https://pubmed.ncbi.nlm.nih.gov/20735426

DM1C8FW	DI	DM1C8FW
DM1C8FW	DN	Epitinib
DM1C8FW	MI	TTGKNB4
DM1C8FW	MN	Epidermal growth factor receptor (EGFR)
DM1C8FW	MT	DTT
DM1C8FW	MA	Inhibitor
DM1C8FW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
DM1C8FW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797

DMVOD03	DI	DMVOD03
DMVOD03	DN	Eplerenone
DMVOD03	MI	TT9P1CK
DMVOD03	MN	HUMAN mineralocorticoid receptor (MR)
DMVOD03	MT	DTT
DMVOD03	MA	Antagonist
DMVOD03	RN	Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov. 2020 Mar 16;6:14.
DMVOD03	RU	https://pubmed.ncbi.nlm.nih.gov/32194980

DMDOR0L	DI	DMDOR0L
DMDOR0L	DN	EPLIVANSERIN MESILATE
DMDOR0L	MI	TTJQOD7
DMDOR0L	MN	5-HT 2A receptor (HTR2A)
DMDOR0L	MT	DTT
DMDOR0L	MA	Modulator
DMDOR0L	RN	Role of 5-HT2A receptor antagonists in the treatment of insomnia
DMDOR0L	RU	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3630942

DMP2QF0	DI	DMP2QF0
DMP2QF0	DN	EPO peptide mimetics
DMP2QF0	MI	TTAUX24
DMP2QF0	MN	Erythropoietin Receptor (EPOR)
DMP2QF0	MT	DTT
DMP2QF0	MA	Modulator
DMP2QF0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1718).
DMP2QF0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1718

DMHQDLX	DI	DMHQDLX
DMHQDLX	DN	EPO-derived peptide
DMHQDLX	MI	TTAUX24
DMHQDLX	MN	Erythropoietin Receptor (EPOR)
DMHQDLX	MT	DTT
DMHQDLX	MA	Modulator
DMHQDLX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1718).
DMHQDLX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1718

DMV8PB4	DI	DMV8PB4
DMV8PB4	DN	Epostane
DMV8PB4	MI	TTZT9R2
DMV8PB4	MN	Hydroxysteroid dehydrogenase 3-beta (HSD3B)
DMV8PB4	MT	DTT
DMV8PB4	MA	Inhibitor
DMV8PB4	RN	Termination of early pregnancy by the 3 beta-hydroxysteroid dehydrogenase inhibitor epostane. N Engl J Med. 1988 Sep 29;319(13):813-7.
DMV8PB4	RU	https://pubmed.ncbi.nlm.nih.gov/3166108

DMK3VID	DI	DMK3VID
DMK3VID	DN	EPPTB
DMK3VID	MI	TTIU98M
DMK3VID	MN	Trace amine-associated receptor-1 (TAAR1)
DMK3VID	MT	DTT
DMK3VID	MA	Antagonist
DMK3VID	RN	The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system. Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):20081-6.
DMK3VID	RU	https://pubmed.ncbi.nlm.nih.gov/19892733

DMLN4V5	DI	DMLN4V5
DMLN4V5	DN	EPZ-004777
DMLN4V5	MI	TTSZ8T1
DMLN4V5	MN	Histone-lysine N-methyltransferase (HLNM)
DMLN4V5	MT	DTT
DMLN4V5	MA	Inhibitor
DMLN4V5	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7377).
DMLN4V5	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7377

DMYISTE	DI	DMYISTE
DMYISTE	DN	EPZ005687
DMYISTE	MI	TT9MZCQ
DMYISTE	MN	Enhancer of zeste homolog 2 (EZH2)
DMYISTE	MT	DTT
DMYISTE	MA	Inhibitor
DMYISTE	RN	A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol. 2012 Nov;8(11):890-6.
DMYISTE	RU	https://pubmed.ncbi.nlm.nih.gov/23023262

DM3INX7	DI	DM3INX7
DM3INX7	DN	EPZ015666
DM3INX7	MI	TTR1D7X
DM3INX7	MN	Protein arginine methyltransferase 5 (PRMT5)
DM3INX7	MT	DTT
DM3INX7	MA	Inhibitor
DM3INX7	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1256).
DM3INX7	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1256

DM2KMNU	DI	DM2KMNU
DM2KMNU	DN	EQ-1280
DM2KMNU	MI	TTN7BL9
DM2KMNU	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DM2KMNU	MT	DTT
DM2KMNU	MA	Inhibitor
DM2KMNU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2763).
DM2KMNU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2763

DMHO56W	DI	DMHO56W
DMHO56W	DN	Equilenin
DMHO56W	MI	DE4LYSA
DMHO56W	MN	Cytochrome P450 3A4 (CYP3A4)
DMHO56W	MT	DME
DMHO56W	MA	Metabolism
DMHO56W	RN	The naphthol selective estrogen receptor modulator (SERM), LY2066948, is oxidized to an o-quinone analogous to the naphthol equine estrogen, equilenin. Chem Biol Interact. 2012 Mar 5;196(1-2):1-10.
DMHO56W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22290292

DMHO56W	DI	DMHO56W
DMHO56W	DN	Equilenin
DMHO56W	MI	TTZT9R2
DMHO56W	MN	Hydroxysteroid dehydrogenase 3-beta (HSD3B)
DMHO56W	MT	DTT
DMHO56W	MA	Inhibitor
DMHO56W	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMHO56W	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9PT03	DI	DM9PT03
DM9PT03	DN	Equilin
DM9PT03	MI	TTIWB6L
DM9PT03	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DM9PT03	MT	DTT
DM9PT03	MA	Inhibitor
DM9PT03	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9PT03	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM2Q19U	DI	DM2Q19U
DM2Q19U	DN	Equilin
DM2Q19U	MI	TTAHMI6
DM2Q19U	MN	HUMAN estrogen receptor (ESR1)
DM2Q19U	MT	DTT
DM2Q19U	MA	Inhibitor
DM2Q19U	RN	Prevention and therapy of COVID-19 via exogenous estrogen treatment for both male and female patients. J Pharm Pharm Sci. 2020;23(1):75-85.
DM2Q19U	RU	https://pubmed.ncbi.nlm.nih.gov/32324533

DMIQ801	DI	DMIQ801
DMIQ801	DN	ER-119884
DMIQ801	MI	TTFQEO5
DMIQ801	MN	Squalene synthetase (FDFT1)
DMIQ801	MT	DTT
DMIQ801	MA	Inhibitor
DMIQ801	RN	Kinetic characterization of squalene synthase from Trypanosoma cruzi: selective inhibition by quinuclidine derivatives. Antimicrob Agents Chemother. 2007 Jun;51(6):2123-9.
DMIQ801	RU	https://pubmed.ncbi.nlm.nih.gov/17371809

DMUNO4R	DI	DMUNO4R
DMUNO4R	DN	ER-21018
DMUNO4R	MI	TT07C3Y
DMUNO4R	MN	5-HT 4 receptor (HTR4)
DMUNO4R	MT	DTT
DMUNO4R	MA	Agonist
DMUNO4R	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 9).
DMUNO4R	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=9

DMAO6JS	DI	DMAO6JS
DMAO6JS	DN	ER-23006
DMAO6JS	MI	TTMXGCW
DMAO6JS	MN	Adrenergic receptor beta-3 (ADRB3)
DMAO6JS	MT	DTT
DMAO6JS	MA	Modulator
DMAO6JS	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 29).
DMAO6JS	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=29

DMSG91J	DI	DMSG91J
DMSG91J	DN	ER819762
DMSG91J	MI	TT79WV3
DMSG91J	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DMSG91J	MT	DTT
DMSG91J	MA	Antagonist
DMSG91J	RN	A novel antagonist of the prostaglandin E(2) EP(4) receptor inhibits Th1 differentiation and Th17 expansion and is orally active in arthritis models. Br J Pharmacol. 2010 May;160(2):292-310.
DMSG91J	RU	https://pubmed.ncbi.nlm.nih.gov/20423341

DMYRDBX	DI	DMYRDBX
DMYRDBX	DN	ERB-002
DMYRDBX	MI	TTOM3J0
DMYRDBX	MN	Estrogen receptor beta (ESR2)
DMYRDBX	MT	DTT
DMYRDBX	MA	Agonist
DMYRDBX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 621).
DMYRDBX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=621

DMD3BEQ	DI	DMD3BEQ
DMD3BEQ	DN	ERIODICTYOL
DMD3BEQ	MI	TTI84H7
DMD3BEQ	MN	Cytochrome P450 1B1 (CYP1B1)
DMD3BEQ	MT	DTT
DMD3BEQ	MA	Inhibitor
DMD3BEQ	RN	Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5.
DMD3BEQ	RU	https://pubmed.ncbi.nlm.nih.gov/20696580

DMB3ROZ	DI	DMB3ROZ
DMB3ROZ	DN	ERK inhibitor III
DMB3ROZ	MI	TT4TQBX
DMB3ROZ	MN	Extracellular signal-regulated kinase 2 (ERK2)
DMB3ROZ	MT	DTT
DMB3ROZ	MA	Inhibitor
DMB3ROZ	RN	Characterization of ATP-independent ERK inhibitors identified through in silico analysis of the active ERK2 structure. Bioorg Med Chem Lett. 2006 Dec 15;16(24):6281-7.
DMB3ROZ	RU	https://pubmed.ncbi.nlm.nih.gov/17000106

DM27FRY	DI	DM27FRY
DM27FRY	DN	Erybreadin b
DM27FRY	MI	TTELIN2
DM27FRY	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DM27FRY	MT	DTT
DM27FRY	MA	Inhibitor
DM27FRY	RN	Cytotoxic and PTP1B inhibitory activities from Erythrina abyssinica. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6745-9.
DM27FRY	RU	https://pubmed.ncbi.nlm.nih.gov/19836230

DMNS976	DI	DMNS976
DMNS976	DN	Erybreadin C
DMNS976	MI	TTELIN2
DMNS976	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMNS976	MT	DTT
DMNS976	MA	Inhibitor
DMNS976	RN	Cytotoxic and PTP1B inhibitory activities from Erythrina abyssinica. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6745-9.
DMNS976	RU	https://pubmed.ncbi.nlm.nih.gov/19836230

DMYG7BM	DI	DMYG7BM
DMYG7BM	DN	Erybreadin D
DMYG7BM	MI	TTELIN2
DMYG7BM	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMYG7BM	MT	DTT
DMYG7BM	MA	Inhibitor
DMYG7BM	RN	Cytotoxic and PTP1B inhibitory activities from Erythrina abyssinica. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6745-9.
DMYG7BM	RU	https://pubmed.ncbi.nlm.nih.gov/19836230

DMCHVIG	DI	DMCHVIG
DMCHVIG	DN	ERYSTAGALLIN A
DMCHVIG	MI	TT50QJ3
DMCHVIG	MN	Influenza Neuraminidase (Influ NA)
DMCHVIG	MT	DTT
DMCHVIG	MA	Inhibitor
DMCHVIG	RN	Prenylated pterocarpans as bacterial neuraminidase inhibitors. Bioorg Med Chem. 2010 May 1;18(9):3335-44.
DMCHVIG	RU	https://pubmed.ncbi.nlm.nih.gov/20363636

DMVA9F7	DI	DMVA9F7
DMVA9F7	DN	Erysubin D
DMVA9F7	MI	TT50QJ3
DMVA9F7	MN	Influenza Neuraminidase (Influ NA)
DMVA9F7	MT	DTT
DMVA9F7	MA	Inhibitor
DMVA9F7	RN	Prenylated pterocarpans as bacterial neuraminidase inhibitors. Bioorg Med Chem. 2010 May 1;18(9):3335-44.
DMVA9F7	RU	https://pubmed.ncbi.nlm.nih.gov/20363636

DMXWK1A	DI	DMXWK1A
DMXWK1A	DN	Erysubin E
DMXWK1A	MI	TT50QJ3
DMXWK1A	MN	Influenza Neuraminidase (Influ NA)
DMXWK1A	MT	DTT
DMXWK1A	MA	Inhibitor
DMXWK1A	RN	Prenylated pterocarpans as bacterial neuraminidase inhibitors. Bioorg Med Chem. 2010 May 1;18(9):3335-44.
DMXWK1A	RU	https://pubmed.ncbi.nlm.nih.gov/20363636

DMXWK1A	DI	DMXWK1A
DMXWK1A	DN	Erysubin E
DMXWK1A	MI	TTELIN2
DMXWK1A	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMXWK1A	MT	DTT
DMXWK1A	MA	Inhibitor
DMXWK1A	RN	Cytotoxic and PTP1B inhibitory activities from Erythrina abyssinica. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6745-9.
DMXWK1A	RU	https://pubmed.ncbi.nlm.nih.gov/19836230

DMLT7FQ	DI	DMLT7FQ
DMLT7FQ	DN	Erythose-4-Phosphate
DMLT7FQ	MI	TTVNA43
DMLT7FQ	MN	Bacterial Deoxy-D-manno-octulosonate 8-phosphate synthase (Bact kdsA)
DMLT7FQ	MT	DTT
DMLT7FQ	MA	Inhibitor
DMLT7FQ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMLT7FQ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM5GEUN	DI	DM5GEUN
DM5GEUN	DN	ERYTHRIBYSSIN A
DM5GEUN	MI	TTELIN2
DM5GEUN	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DM5GEUN	MT	DTT
DM5GEUN	MA	Inhibitor
DM5GEUN	RN	Cytotoxic and PTP1B inhibitory activities from Erythrina abyssinica. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6745-9.
DM5GEUN	RU	https://pubmed.ncbi.nlm.nih.gov/19836230

DMBVSKZ	DI	DMBVSKZ
DMBVSKZ	DN	Erythribyssin D
DMBVSKZ	MI	TT50QJ3
DMBVSKZ	MN	Influenza Neuraminidase (Influ NA)
DMBVSKZ	MT	DTT
DMBVSKZ	MA	Inhibitor
DMBVSKZ	RN	Prenylated pterocarpans as bacterial neuraminidase inhibitors. Bioorg Med Chem. 2010 May 1;18(9):3335-44.
DMBVSKZ	RU	https://pubmed.ncbi.nlm.nih.gov/20363636

DMUL4AP	DI	DMUL4AP
DMUL4AP	DN	Erythribyssin L
DMUL4AP	MI	TT50QJ3
DMUL4AP	MN	Influenza Neuraminidase (Influ NA)
DMUL4AP	MT	DTT
DMUL4AP	MA	Inhibitor
DMUL4AP	RN	Prenylated pterocarpans as bacterial neuraminidase inhibitors. Bioorg Med Chem. 2010 May 1;18(9):3335-44.
DMUL4AP	RU	https://pubmed.ncbi.nlm.nih.gov/20363636

DMWEK8I	DI	DMWEK8I
DMWEK8I	DN	Erythribyssin M
DMWEK8I	MI	TT50QJ3
DMWEK8I	MN	Influenza Neuraminidase (Influ NA)
DMWEK8I	MT	DTT
DMWEK8I	MA	Inhibitor
DMWEK8I	RN	Prenylated pterocarpans as bacterial neuraminidase inhibitors. Bioorg Med Chem. 2010 May 1;18(9):3335-44.
DMWEK8I	RU	https://pubmed.ncbi.nlm.nih.gov/20363636

DM8LEJ4	DI	DM8LEJ4
DM8LEJ4	DN	Erythribyssin O
DM8LEJ4	MI	TT50QJ3
DM8LEJ4	MN	Influenza Neuraminidase (Influ NA)
DM8LEJ4	MT	DTT
DM8LEJ4	MA	Inhibitor
DM8LEJ4	RN	Prenylated pterocarpans as bacterial neuraminidase inhibitors. Bioorg Med Chem. 2010 May 1;18(9):3335-44.
DM8LEJ4	RU	https://pubmed.ncbi.nlm.nih.gov/20363636

DM8UVI3	DI	DM8UVI3
DM8UVI3	DN	Erythro-3,4-dichloromethylphenidate hydrochloride
DM8UVI3	MI	TTVBI8W
DM8UVI3	MN	Dopamine transporter (DAT)
DM8UVI3	MT	DTT
DM8UVI3	MA	Inhibitor
DM8UVI3	RN	Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31.
DM8UVI3	RU	https://pubmed.ncbi.nlm.nih.gov/17489581

DM8UVI3	DI	DM8UVI3
DM8UVI3	DN	Erythro-3,4-dichloromethylphenidate hydrochloride
DM8UVI3	MI	TT3ROYC
DM8UVI3	MN	Serotonin transporter (SERT)
DM8UVI3	MT	DTT
DM8UVI3	MA	Inhibitor
DM8UVI3	RN	Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31.
DM8UVI3	RU	https://pubmed.ncbi.nlm.nih.gov/17489581

DM0PHEW	DI	DM0PHEW
DM0PHEW	DN	Erythromycin salnacedin
DM0PHEW	MI	TTUWYEA
DM0PHEW	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DM0PHEW	MT	DTT
DM0PHEW	MA	Modulator
DM0PHEW	RN	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
DM0PHEW	RU	https://www.ncbi.nlm.nih.gov/pubmed/27899562

DM0PHEW	DI	DM0PHEW
DM0PHEW	DN	Erythromycin salnacedin
DM0PHEW	MI	DE4LYSA
DM0PHEW	MN	Cytochrome P450 3A4 (CYP3A4)
DM0PHEW	MT	DME
DM0PHEW	MA	Metabolism
DM0PHEW	RN	Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function. Br J Clin Pharmacol. 2003 Jan;55(1):86-93.
DM0PHEW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12534644

DM0PHEW	DI	DM0PHEW
DM0PHEW	DN	Erythromycin salnacedin
DM0PHEW	MI	DEIBDNY
DM0PHEW	MN	Cytochrome P450 3A5 (CYP3A5)
DM0PHEW	MT	DME
DM0PHEW	MA	Metabolism
DM0PHEW	RN	Differential regulation of CYP3A4 and CYP3A5 and its implication in drug discovery. Curr Drug Metab. 2017;18(12):1095-1105.
DM0PHEW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28558634

DM0PHEW	DI	DM0PHEW
DM0PHEW	DN	Erythromycin salnacedin
DM0PHEW	MI	DERD86B
DM0PHEW	MN	Cytochrome P450 3A7 (CYP3A7)
DM0PHEW	MT	DME
DM0PHEW	MA	Metabolism
DM0PHEW	RN	Helices F-G are important for the substrate specificities of CYP3A7. Drug Metab Dispos. 2007 Mar;35(3):484-92.
DM0PHEW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17178770

DM3R8YL	DI	DM3R8YL
DM3R8YL	DN	Erythropoietin
DM3R8YL	MI	TTAUX24
DM3R8YL	MN	Erythropoietin Receptor (EPOR)
DM3R8YL	MT	DTT
DM3R8YL	MA	Stimulator
DM3R8YL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1718).
DM3R8YL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1718

DM8BS5C	DI	DM8BS5C
DM8BS5C	DN	Eryvarin D
DM8BS5C	MI	TT50QJ3
DM8BS5C	MN	Influenza Neuraminidase (Influ NA)
DM8BS5C	MT	DTT
DM8BS5C	MA	Inhibitor
DM8BS5C	RN	Prenylated pterocarpans as bacterial neuraminidase inhibitors. Bioorg Med Chem. 2010 May 1;18(9):3335-44.
DM8BS5C	RU	https://pubmed.ncbi.nlm.nih.gov/20363636

DMSNM5O	DI	DMSNM5O
DMSNM5O	DN	ES-6864
DMSNM5O	MI	TTB2MXP
DMSNM5O	MN	Angiotensinogenase renin (REN)
DMSNM5O	MT	DTT
DMSNM5O	MA	Inhibitor
DMSNM5O	RN	A highly potent and long-acting oral inhibitor of human renin. Hypertension. 1988 Jun;11(6 Pt 2):708-12.
DMSNM5O	RU	https://pubmed.ncbi.nlm.nih.gov/3134306

DMIVZ3W	DI	DMIVZ3W
DMIVZ3W	DN	ES-936
DMIVZ3W	MI	TT8XK6L
DMIVZ3W	MN	Quinone reductase 1 (NQO1)
DMIVZ3W	MT	DTT
DMIVZ3W	MA	Inhibitor
DMIVZ3W	RN	Synthesis and evaluation of 3-aryloxymethyl-1,2-dimethylindole-4,7-diones as mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1) ... J Med Chem. 2007 Nov 15;50(23):5780-9.
DMIVZ3W	RU	https://pubmed.ncbi.nlm.nih.gov/17944451

DMPTDHC	DI	DMPTDHC
DMPTDHC	DN	ESCHOLTZINE
DMPTDHC	MI	TTSQIFT
DMPTDHC	MN	5-HT 1A receptor (HTR1A)
DMPTDHC	MT	DTT
DMPTDHC	MA	Inhibitor
DMPTDHC	RN	Alkaloids from Eschscholzia californica and their capacity to inhibit binding of [3H]8-Hydroxy-2-(di-N-propylamino)tetralin to 5-HT1A receptors in ... J Nat Prod. 2006 Mar;69(3):432-5.
DMPTDHC	RU	https://pubmed.ncbi.nlm.nih.gov/16562853

DMANEC9	DI	DMANEC9
DMANEC9	DN	Esculin
DMANEC9	MI	DEX0NP3
DMANEC9	MN	Beta-glucosidase (bglA)
DMANEC9	MT	DME
DMANEC9	MA	Metabolism
DMANEC9	RN	A prodrug approach to the use of coumarins as potential therapeutics for superficial mycoses. PLoS One. 2013 Nov 18;8(11):e80760.
DMANEC9	RU	https://pubmed.ncbi.nlm.nih.gov/24260474

DMANEC9	DI	DMANEC9
DMANEC9	DN	Esculin
DMANEC9	MI	DESLN2J
DMANEC9	MN	Beta-glucosidase (bglA)
DMANEC9	MT	DME
DMANEC9	MA	Metabolism
DMANEC9	RN	Physiological and molecular characterization of atypical isolates of Malassezia furfur. J Clin Microbiol. 2009 Jan;47(1):48-53.
DMANEC9	RU	https://pubmed.ncbi.nlm.nih.gov/18971363

DMANEC9	DI	DMANEC9
DMANEC9	DN	Esculin
DMANEC9	MI	DEAZSKX
DMANEC9	MN	Beta-glucosidase (bglA)
DMANEC9	MT	DME
DMANEC9	MA	Metabolism
DMANEC9	RN	A prodrug approach to the use of coumarins as potential therapeutics for superficial mycoses. PLoS One. 2013 Nov 18;8(11):e80760.
DMANEC9	RU	https://pubmed.ncbi.nlm.nih.gov/24260474

DMANEC9	DI	DMANEC9
DMANEC9	DN	Esculin
DMANEC9	MI	DETQXR5
DMANEC9	MN	Beta-glucosidase (bglA)
DMANEC9	MT	DME
DMANEC9	MA	Metabolism
DMANEC9	RN	nan
DMANEC9	RU	nan

DMANEC9	DI	DMANEC9
DMANEC9	DN	Esculin
DMANEC9	MI	DE3E0VT
DMANEC9	MN	L-glutamine amidohydrolase (GLS)
DMANEC9	MT	DME
DMANEC9	MA	Metabolism
DMANEC9	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (cpd:C09264)
DMANEC9	RU	http://www.genome.jp/dbget-bin/www_bget?cpd:C09264

DMTJDXY	DI	DMTJDXY
DMTJDXY	DN	ESI-09
DMTJDXY	MI	TTOS63B
DMTJDXY	MN	Rap guanine nucleotide exchange factor 4 (EPAC2)
DMTJDXY	MT	DTT
DMTJDXY	MA	Inhibitor
DMTJDXY	RN	A novel EPAC-specific inhibitor suppresses pancreatic cancer cell migration and invasion. Mol Pharmacol. 2013 Jan;83(1):122-8.
DMTJDXY	RU	https://pubmed.ncbi.nlm.nih.gov/23066090

DM7K14V	DI	DM7K14V
DM7K14V	DN	Estradiol 17-O-sulfamate
DM7K14V	MI	TTHM0R1
DM7K14V	MN	Steryl-sulfatase (STS)
DM7K14V	MT	DTT
DM7K14V	MA	Inhibitor
DM7K14V	RN	2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity. J Med Chem. 2006 Dec 28;49(26):7683-96.
DM7K14V	RU	https://pubmed.ncbi.nlm.nih.gov/17181151

DMPM8I5	DI	DMPM8I5
DMPM8I5	DN	Estradiol 3,17-O,O-bis-sulfamate
DMPM8I5	MI	TTHM0R1
DMPM8I5	MN	Steryl-sulfatase (STS)
DMPM8I5	MT	DTT
DMPM8I5	MA	Inhibitor
DMPM8I5	RN	2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity. J Med Chem. 2006 Dec 28;49(26):7683-96.
DMPM8I5	RU	https://pubmed.ncbi.nlm.nih.gov/17181151

DMNXO9C	DI	DMNXO9C
DMNXO9C	DN	Estriol E3
DMNXO9C	MI	TTZAYWL
DMNXO9C	MN	Estrogen receptor (ESR)
DMNXO9C	MT	DTT
DMNXO9C	MA	Modulator
DMNXO9C	RN	Estrogen: estrone (E1), estradiol (E2), estriol (E3) and estetrol (E4). Nihon Rinsho. 2010 Jul;68 Suppl 7:448-61.
DMNXO9C	RU	https://pubmed.ncbi.nlm.nih.gov/20960812

DMH4MBW	DI	DMH4MBW
DMH4MBW	DN	ET bromodomain inhibitor
DMH4MBW	MI	TTDP48B
DMH4MBW	MN	Bromodomain-containing protein 2 (BRD2)
DMH4MBW	MT	DTT
DMH4MBW	MA	Inhibitor
DMH4MBW	RN	Chemical biology. A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes. Science. 2014 Oct 31;346(6209):638-41.
DMH4MBW	RU	https://pubmed.ncbi.nlm.nih.gov/25323695

DM0IYLS	DI	DM0IYLS
DM0IYLS	DN	EtBut-RYYRIK-NH2
DM0IYLS	MI	TTNT7K8
DM0IYLS	MN	Nociceptin receptor (OPRL1)
DM0IYLS	MT	DTT
DM0IYLS	MA	Inhibitor
DM0IYLS	RN	Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist. Bioorg Med Chem. 2008 Mar 1;16(5):2635-44.
DM0IYLS	RU	https://pubmed.ncbi.nlm.nih.gov/18068993

DMMEQUR	DI	DMMEQUR
DMMEQUR	DN	Ethidium
DMMEQUR	MI	TTUTN1I
DMMEQUR	MN	Human Deoxyribonucleic acid (hDNA)
DMMEQUR	MT	DTT
DMMEQUR	MA	Intercalator
DMMEQUR	RN	31P NMR spectra of ethidium, quinacrine, and daunomycin complexes with poly(adenylic acid).poly(uridylic acid) RNA duplex and calf thymus DNA. Biochemistry. 1989 Apr 4;28(7):2804-12.
DMMEQUR	RU	https://pubmed.ncbi.nlm.nih.gov/2472832

DMQTEDP	DI	DMQTEDP
DMQTEDP	DN	ETHIOFENCARB
DMQTEDP	MI	TTLUQ8E
DMQTEDP	MN	Hormone sensitive lipase (LIPE)
DMQTEDP	MT	DTT
DMQTEDP	MA	Inhibitor
DMQTEDP	RN	Combining ligand-based pharmacophore modeling, quantitative structure-activity relationship analysis and in silico screening for the discovery of n... J Med Chem. 2008 Oct 23;51(20):6478-94.
DMQTEDP	RU	https://pubmed.ncbi.nlm.nih.gov/18808096

DMGESUH	DI	DMGESUH
DMGESUH	DN	ETHIONINE
DMGESUH	MI	TTFK1JQ
DMGESUH	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMGESUH	MT	DTT
DMGESUH	MA	Inhibitor
DMGESUH	RN	Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41.
DMGESUH	RU	https://pubmed.ncbi.nlm.nih.gov/16380257

DMDXRP1	DI	DMDXRP1
DMDXRP1	DN	ETHISTERONE
DMDXRP1	MI	TTULVH8
DMDXRP1	MN	Tyrosinase (TYR)
DMDXRP1	MT	DTT
DMDXRP1	MA	Inhibitor
DMDXRP1	RN	TOMOCOMD-CARDD descriptors-based virtual screening of tyrosinase inhibitors: evaluation of different classification model combinations using bond-b... Bioorg Med Chem. 2007 Feb 1;15(3):1483-503.
DMDXRP1	RU	https://pubmed.ncbi.nlm.nih.gov/17110117

DM1MGTX	DI	DM1MGTX
DM1MGTX	DN	ETHOXYCLUSIN
DM1MGTX	MI	TTXV4FI
DM1MGTX	MN	Albendazole monooxygenase (CYP3A4)
DM1MGTX	MT	DTT
DM1MGTX	MA	Inhibitor
DM1MGTX	RN	Potent CYP3A4 inhibitory constituents of Piper cubeba. J Nat Prod. 2005 Jan;68(1):64-8.
DM1MGTX	RU	https://pubmed.ncbi.nlm.nih.gov/15679319

DMSKU4M	DI	DMSKU4M
DMSKU4M	DN	ETHOXYCOUMARIN
DMSKU4M	MI	TTUNARX
DMSKU4M	MN	Carbonic anhydrase (CA)
DMSKU4M	MT	DTT
DMSKU4M	MA	Inhibitor
DMSKU4M	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMSKU4M	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMSKU4M	DI	DMSKU4M
DMSKU4M	DN	ETHOXYCOUMARIN
DMSKU4M	MI	TT2LVK8
DMSKU4M	MN	Carbonic anhydrase IX (CA-IX)
DMSKU4M	MT	DTT
DMSKU4M	MA	Inhibitor
DMSKU4M	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMSKU4M	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMSKU4M	DI	DMSKU4M
DMSKU4M	DN	ETHOXYCOUMARIN
DMSKU4M	MI	TTSYM0R
DMSKU4M	MN	Carbonic anhydrase XII (CA-XII)
DMSKU4M	MT	DTT
DMSKU4M	MA	Inhibitor
DMSKU4M	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMSKU4M	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMSKU4M	DI	DMSKU4M
DMSKU4M	DN	ETHOXYCOUMARIN
DMSKU4M	MI	TTEYTKG
DMSKU4M	MN	Carbonic anhydrase XIV (CA-XIV)
DMSKU4M	MT	DTT
DMSKU4M	MA	Inhibitor
DMSKU4M	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMSKU4M	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMNOTH5	DI	DMNOTH5
DMNOTH5	DN	ETHOXY-IDAZOXAN
DMNOTH5	MI	TT2NUT5
DMNOTH5	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMNOTH5	MT	DTT
DMNOTH5	MA	Modulator
DMNOTH5	RN	Discriminative stimulus properties of ethoxy idazoxan. J Psychopharmacol. 1995 Jan;9(3):228-33.
DMNOTH5	RU	https://pubmed.ncbi.nlm.nih.gov/22297762

DM7390Y	DI	DM7390Y
DM7390Y	DN	ethyketazocine
DM7390Y	MI	TT27RFC
DM7390Y	MN	Opioid receptor delta (OPRD1)
DM7390Y	MT	DTT
DM7390Y	MA	Agonist
DM7390Y	RN	Cloning and functional comparison of kappa and delta opioid receptors from mouse brain. Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6736-40.
DM7390Y	RU	https://pubmed.ncbi.nlm.nih.gov/8393575

DM7390Y	DI	DM7390Y
DM7390Y	DN	ethyketazocine
DM7390Y	MI	TTQW87Y
DM7390Y	MN	Opioid receptor kappa (OPRK1)
DM7390Y	MT	DTT
DM7390Y	MA	Agonist
DM7390Y	RN	Activation of the cloned human kappa opioid receptor by agonists enhances [35S]GTPgammaS binding to membranes: determination of potencies and efficacies of ligands. J Pharmacol Exp Ther. 1997 Aug;282(2):676-84.
DM7390Y	RU	https://pubmed.ncbi.nlm.nih.gov/9262330

DM0O4A2	DI	DM0O4A2
DM0O4A2	DN	ETHYL (1E)-2-PHENYL-N-(SULFOOXY)ETHANIMIDOTHIOATE
DM0O4A2	MI	TTA0OSE
DM0O4A2	MN	Lactase-phlorizin hydrolase (LCT)
DM0O4A2	MT	DTT
DM0O4A2	MA	Inhibitor
DM0O4A2	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM0O4A2	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM3FH02	DI	DM3FH02
DM3FH02	DN	Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate
DM3FH02	MI	TTK3PY9
DM3FH02	MN	DNA-dependent protein kinase catalytic (PRKDC)
DM3FH02	MT	DTT
DM3FH02	MA	Inhibitor
DM3FH02	RN	Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46.
DM3FH02	RU	https://pubmed.ncbi.nlm.nih.gov/16302822

DM3FH02	DI	DM3FH02
DM3FH02	DN	Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate
DM3FH02	MI	TT84ETX
DM3FH02	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM3FH02	MT	DTT
DM3FH02	MA	Inhibitor
DM3FH02	RN	Computer-assisted design, synthesis and biological evaluation of novel pyrrolyl heteroaryl sulfones targeted at HIV-1 reverse transcriptase as non-nucleoside inhibitors. Bioorg Med Chem. 2000 Sep;8(9):2305-9.
DM3FH02	RU	https://pubmed.ncbi.nlm.nih.gov/11026542

DM3FH02	DI	DM3FH02
DM3FH02	DN	Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate
DM3FH02	MI	TT9H4P3
DM3FH02	MN	PI3K p110 beta messenger RNA (PIK3CB mRNA)
DM3FH02	MT	DTT
DM3FH02	MA	Inhibitor
DM3FH02	RN	LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family. Bioorg Med Chem Lett. 2001 Apr 9;11(7):909-13.
DM3FH02	RU	https://pubmed.ncbi.nlm.nih.gov/11294389

DM3FH02	DI	DM3FH02
DM3FH02	DN	Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate
DM3FH02	MI	TTGBPJE
DM3FH02	MN	PI3-kinase delta (PIK3CD)
DM3FH02	MT	DTT
DM3FH02	MA	Inhibitor
DM3FH02	RN	LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family. Bioorg Med Chem Lett. 2001 Apr 9;11(7):909-13.
DM3FH02	RU	https://pubmed.ncbi.nlm.nih.gov/11294389

DM3FH02	DI	DM3FH02
DM3FH02	DN	Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate
DM3FH02	MI	TTHBTOP
DM3FH02	MN	PI3-kinase gamma (PIK3CG)
DM3FH02	MT	DTT
DM3FH02	MA	Inhibitor
DM3FH02	RN	LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family. Bioorg Med Chem Lett. 2001 Apr 9;11(7):909-13.
DM3FH02	RU	https://pubmed.ncbi.nlm.nih.gov/11294389

DM3FH02	DI	DM3FH02
DM3FH02	DN	Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate
DM3FH02	MI	TTCJG29
DM3FH02	MN	Serine/threonine-protein kinase mTOR (mTOR)
DM3FH02	MT	DTT
DM3FH02	MA	Inhibitor
DM3FH02	RN	Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85.
DM3FH02	RU	https://pubmed.ncbi.nlm.nih.gov/15658870

DMQ0XYH	DI	DMQ0XYH
DMQ0XYH	DN	Ethyl 1-[(1H-benzimidazol-5(6)-yl)sulfonyl]-1H-pyrrole-2-carboxylate
DMQ0XYH	MI	TT84ETX
DMQ0XYH	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMQ0XYH	MT	DTT
DMQ0XYH	MA	Inhibitor
DMQ0XYH	RN	Computer-assisted design, synthesis and biological evaluation of novel pyrrolyl heteroaryl sulfones targeted at HIV-1 reverse transcriptase as non-nucleoside inhibitors. Bioorg Med Chem. 2000 Sep;8(9):2305-9.
DMQ0XYH	RU	https://pubmed.ncbi.nlm.nih.gov/11026542

DM82X3J	DI	DM82X3J
DM82X3J	DN	Ethyl 1-[(1H-benzotriazol-5(6)-yl)sulfonyl]-1H-pyrrole-2-carboxylate
DM82X3J	MI	TT84ETX
DM82X3J	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM82X3J	MT	DTT
DM82X3J	MA	Inhibitor
DM82X3J	RN	Computer-assisted design, synthesis and biological evaluation of novel pyrrolyl heteroaryl sulfones targeted at HIV-1 reverse transcriptase as non-nucleoside inhibitors. Bioorg Med Chem. 2000 Sep;8(9):2305-9.
DM82X3J	RU	https://pubmed.ncbi.nlm.nih.gov/11026542

DM762HQ	DI	DM762HQ
DM762HQ	DN	Ethyl 2-(2-oxohexadecanamido)acetate
DM762HQ	MI	TTT1JVS
DM762HQ	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DM762HQ	MT	DTT
DM762HQ	MA	Inhibitor
DM762HQ	RN	Structure-activity relationships of natural and non-natural amino acid-based amide and 2-oxoamide inhibitors of human phospholipase A(2) enzymes. Bioorg Med Chem. 2008 Dec 15;16(24):10257-69.
DM762HQ	RU	https://pubmed.ncbi.nlm.nih.gov/18993078

DMPUCMV	DI	DMPUCMV
DMPUCMV	DN	Ethyl 2beta-hydroxyolean-12-en-28-oate
DMPUCMV	MI	TTZHY6R
DMPUCMV	MN	Glycogen phosphorylase muscle form (GP)
DMPUCMV	MT	DTT
DMPUCMV	MA	Inhibitor
DMPUCMV	RN	Synthesis of 3-deoxypentacyclic triterpene derivatives as inhibitors of glycogen phosphorylase. J Nat Prod. 2009 Aug;72(8):1414-8.
DMPUCMV	RU	https://pubmed.ncbi.nlm.nih.gov/19642687

DM06AQZ	DI	DM06AQZ
DM06AQZ	DN	Ethyl 2-cyano-2-(quinoxalin-2(1H)-ylidene)acetate
DM06AQZ	MI	TTHY57M
DM06AQZ	MN	Matrix metalloproteinase-13 (MMP-13)
DM06AQZ	MT	DTT
DM06AQZ	MA	Inhibitor
DM06AQZ	RN	High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg Med Chem. 2009 Feb 1;17(3):990-1005.
DM06AQZ	RU	https://pubmed.ncbi.nlm.nih.gov/18358729

DM5XYFN	DI	DM5XYFN
DM5XYFN	DN	Ethyl 3-(biphenyl-3-ylamino)-2-cyanoacrylate
DM5XYFN	MI	TT3PQ2Y
DM5XYFN	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DM5XYFN	MT	DTT
DM5XYFN	MA	Inhibitor
DM5XYFN	RN	Design and synthesis of potent inhibitors of the malaria parasite dihydroorotate dehydrogenase. J Med Chem. 2007 Jan 25;50(2):186-91.
DM5XYFN	RU	https://pubmed.ncbi.nlm.nih.gov/17228860

DM4UWYF	DI	DM4UWYF
DM4UWYF	DN	Ethyl 3-(pyridin-4-yl)-1H-indole-6-carboxylate
DM4UWYF	MI	TTTB4UP
DM4UWYF	MN	Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2)
DM4UWYF	MT	DTT
DM4UWYF	MA	Inhibitor
DM4UWYF	RN	Novel indole inhibitors of IMPDH from fragments: synthesis and initial structure-activity relationships. Bioorg Med Chem Lett. 2006 May 1;16(9):2539-42.
DM4UWYF	RU	https://pubmed.ncbi.nlm.nih.gov/16483773

DMKJGLO	DI	DMKJGLO
DMKJGLO	DN	ETHYL 3-[4-(AMINOSULFONYL)PHENYL]PROPANOATE
DMKJGLO	MI	TTHQPL7
DMKJGLO	MN	Carbonic anhydrase I (CA-I)
DMKJGLO	MT	DTT
DMKJGLO	MA	Inhibitor
DMKJGLO	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMKJGLO	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMKJGLO	DI	DMKJGLO
DMKJGLO	DN	ETHYL 3-[4-(AMINOSULFONYL)PHENYL]PROPANOATE
DMKJGLO	MI	TTANPDJ
DMKJGLO	MN	Carbonic anhydrase II (CA-II)
DMKJGLO	MT	DTT
DMKJGLO	MA	Inhibitor
DMKJGLO	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMKJGLO	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM5GLP7	DI	DM5GLP7
DM5GLP7	DN	Ethyl 4-(1-benzyl-1H-indazol-3-yl)benzoate
DM5GLP7	MI	TTD0652
DM5GLP7	MN	Proteinase activated receptor 4 (F2RL3)
DM5GLP7	MT	DTT
DM5GLP7	MA	Inhibitor
DM5GLP7	RN	Synthesis and antiplatelet activity of ethyl 4-(1-benzyl-1H-indazol-3-yl)benzoate (YD-3) derivatives. Bioorg Med Chem. 2008 Feb 1;16(3):1262-78.
DM5GLP7	RU	https://pubmed.ncbi.nlm.nih.gov/17988878

DMQ3LMF	DI	DMQ3LMF
DMQ3LMF	DN	Ethyl 4-(2-oxo-2H-chromene-3-carboxamido)benzoate
DMQ3LMF	MI	TT3WG5C
DMQ3LMF	MN	Monoamine oxidase type A (MAO-A)
DMQ3LMF	MT	DTT
DMQ3LMF	MA	Inhibitor
DMQ3LMF	RN	Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins. J Med Chem. 2009 Apr 9;52(7):1935-42.
DMQ3LMF	RU	https://pubmed.ncbi.nlm.nih.gov/19267475

DMB12M7	DI	DMB12M7
DMB12M7	DN	Ethyl 4-(2-oxohexadecanamido)benzoate
DMB12M7	MI	TTT1JVS
DMB12M7	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DMB12M7	MT	DTT
DMB12M7	MA	Inhibitor
DMB12M7	RN	Structure-activity relationships of natural and non-natural amino acid-based amide and 2-oxoamide inhibitors of human phospholipase A(2) enzymes. Bioorg Med Chem. 2008 Dec 15;16(24):10257-69.
DMB12M7	RU	https://pubmed.ncbi.nlm.nih.gov/18993078

DMK4T5Y	DI	DMK4T5Y
DMK4T5Y	DN	Ethyl 5-benzoyl-4-phenylthiazol-2-ylcarbamate
DMK4T5Y	MI	TTK25J1
DMK4T5Y	MN	Adenosine A1 receptor (ADORA1)
DMK4T5Y	MT	DTT
DMK4T5Y	MA	Inhibitor
DMK4T5Y	RN	2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
DMK4T5Y	RU	https://pubmed.ncbi.nlm.nih.gov/20188574

DMK4T5Y	DI	DMK4T5Y
DMK4T5Y	DN	Ethyl 5-benzoyl-4-phenylthiazol-2-ylcarbamate
DMK4T5Y	MI	TTM2AOE
DMK4T5Y	MN	Adenosine A2a receptor (ADORA2A)
DMK4T5Y	MT	DTT
DMK4T5Y	MA	Inhibitor
DMK4T5Y	RN	2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
DMK4T5Y	RU	https://pubmed.ncbi.nlm.nih.gov/20188574

DMK4T5Y	DI	DMK4T5Y
DMK4T5Y	DN	Ethyl 5-benzoyl-4-phenylthiazol-2-ylcarbamate
DMK4T5Y	MI	TTNE7KG
DMK4T5Y	MN	Adenosine A2b receptor (ADORA2B)
DMK4T5Y	MT	DTT
DMK4T5Y	MA	Inhibitor
DMK4T5Y	RN	2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
DMK4T5Y	RU	https://pubmed.ncbi.nlm.nih.gov/20188574

DMK4T5Y	DI	DMK4T5Y
DMK4T5Y	DN	Ethyl 5-benzoyl-4-phenylthiazol-2-ylcarbamate
DMK4T5Y	MI	TTJFY5U
DMK4T5Y	MN	Adenosine A3 receptor (ADORA3)
DMK4T5Y	MT	DTT
DMK4T5Y	MA	Inhibitor
DMK4T5Y	RN	2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
DMK4T5Y	RU	https://pubmed.ncbi.nlm.nih.gov/20188574

DM5G91Z	DI	DM5G91Z
DM5G91Z	DN	Ethyl 6-iodo-9H-pyrido[3,4-b]indole-3-carboxylate
DM5G91Z	MI	TT1MPAY
DM5G91Z	MN	GABA(A) receptor alpha-1 (GABRA1)
DM5G91Z	MT	DTT
DM5G91Z	MA	Inhibitor
DM5G91Z	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DM5G91Z	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DM5G91Z	DI	DM5G91Z
DM5G91Z	DN	Ethyl 6-iodo-9H-pyrido[3,4-b]indole-3-carboxylate
DM5G91Z	MI	TTBMV1G
DM5G91Z	MN	GABA(A) receptor alpha-2 (GABRA2)
DM5G91Z	MT	DTT
DM5G91Z	MA	Inhibitor
DM5G91Z	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DM5G91Z	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DM5G91Z	DI	DM5G91Z
DM5G91Z	DN	Ethyl 6-iodo-9H-pyrido[3,4-b]indole-3-carboxylate
DM5G91Z	MI	TT37EDJ
DM5G91Z	MN	GABA(A) receptor alpha-3 (GABRA3)
DM5G91Z	MT	DTT
DM5G91Z	MA	Inhibitor
DM5G91Z	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DM5G91Z	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DM5G91Z	DI	DM5G91Z
DM5G91Z	DN	Ethyl 6-iodo-9H-pyrido[3,4-b]indole-3-carboxylate
DM5G91Z	MI	TTNZPQ1
DM5G91Z	MN	GABA(A) receptor alpha-5 (GABRA5)
DM5G91Z	MT	DTT
DM5G91Z	MA	Inhibitor
DM5G91Z	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DM5G91Z	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DM5G91Z	DI	DM5G91Z
DM5G91Z	DN	Ethyl 6-iodo-9H-pyrido[3,4-b]indole-3-carboxylate
DM5G91Z	MI	TT06RH5
DM5G91Z	MN	GABA(A) receptor gamma-2 (GABRG2)
DM5G91Z	MT	DTT
DM5G91Z	MA	Inhibitor
DM5G91Z	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DM5G91Z	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DM5G91Z	DI	DM5G91Z
DM5G91Z	DN	Ethyl 6-iodo-9H-pyrido[3,4-b]indole-3-carboxylate
DM5G91Z	MI	TTNJYV2
DM5G91Z	MN	Gamma-aminobutyric acid receptor (GAR)
DM5G91Z	MT	DTT
DM5G91Z	MA	Inhibitor
DM5G91Z	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DM5G91Z	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DM7FPX8	DI	DM7FPX8
DM7FPX8	DN	Ethyl 7-hydroxy-2-oxo-2H-chromene-3-carboxylate
DM7FPX8	MI	TT6804T
DM7FPX8	MN	MIF messenger RNA (MIF mRNA)
DM7FPX8	MT	DTT
DM7FPX8	MA	Inhibitor
DM7FPX8	RN	Discovery of human macrophage migration inhibitory factor (MIF)-CD74 antagonists via virtual screening. J Med Chem. 2009 Jan 22;52(2):416-24.
DM7FPX8	RU	https://pubmed.ncbi.nlm.nih.gov/19090668

DMWIB0V	DI	DMWIB0V
DMWIB0V	DN	Ethyl 7-methoxy-2-oxo-2H-chromene-3-carboxylate
DMWIB0V	MI	TTUNARX
DMWIB0V	MN	Carbonic anhydrase (CA)
DMWIB0V	MT	DTT
DMWIB0V	MA	Inhibitor
DMWIB0V	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMWIB0V	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMWIB0V	DI	DMWIB0V
DMWIB0V	DN	Ethyl 7-methoxy-2-oxo-2H-chromene-3-carboxylate
DMWIB0V	MI	TTZHA0O
DMWIB0V	MN	Carbonic anhydrase IV (CA-IV)
DMWIB0V	MT	DTT
DMWIB0V	MA	Inhibitor
DMWIB0V	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMWIB0V	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMWIB0V	DI	DMWIB0V
DMWIB0V	DN	Ethyl 7-methoxy-2-oxo-2H-chromene-3-carboxylate
DMWIB0V	MI	TT2LVK8
DMWIB0V	MN	Carbonic anhydrase IX (CA-IX)
DMWIB0V	MT	DTT
DMWIB0V	MA	Inhibitor
DMWIB0V	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMWIB0V	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMWIB0V	DI	DMWIB0V
DMWIB0V	DN	Ethyl 7-methoxy-2-oxo-2H-chromene-3-carboxylate
DMWIB0V	MI	TTCFSPE
DMWIB0V	MN	Carbonic anhydrase VI (CA-VI)
DMWIB0V	MT	DTT
DMWIB0V	MA	Inhibitor
DMWIB0V	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMWIB0V	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMWIB0V	DI	DMWIB0V
DMWIB0V	DN	Ethyl 7-methoxy-2-oxo-2H-chromene-3-carboxylate
DMWIB0V	MI	TTSYM0R
DMWIB0V	MN	Carbonic anhydrase XII (CA-XII)
DMWIB0V	MT	DTT
DMWIB0V	MA	Inhibitor
DMWIB0V	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMWIB0V	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMWIB0V	DI	DMWIB0V
DMWIB0V	DN	Ethyl 7-methoxy-2-oxo-2H-chromene-3-carboxylate
DMWIB0V	MI	TTEYTKG
DMWIB0V	MN	Carbonic anhydrase XIV (CA-XIV)
DMWIB0V	MT	DTT
DMWIB0V	MA	Inhibitor
DMWIB0V	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DMWIB0V	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DMJQTIK	DI	DMJQTIK
DMJQTIK	DN	Ethyl Bis(4-hydroxy-2-oxo-2H-chromen-3-yl)acetate
DMJQTIK	MI	TT8XK6L
DMJQTIK	MN	Quinone reductase 1 (NQO1)
DMJQTIK	MT	DTT
DMJQTIK	MA	Inhibitor
DMJQTIK	RN	Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1). J Med Chem. 2009 Nov 26;52(22):7142-56.
DMJQTIK	RU	https://pubmed.ncbi.nlm.nih.gov/19877692

DMR5Z2A	DI	DMR5Z2A
DMR5Z2A	DN	Ethyl biscoumacetate
DMR5Z2A	MI	DE4LYSA
DMR5Z2A	MN	Cytochrome P450 3A4 (CYP3A4)
DMR5Z2A	MT	DME
DMR5Z2A	MA	Metabolism
DMR5Z2A	RN	Diet Drug Porfimer sodium Safe, Effective, Study Finds.
DMR5Z2A	RU	http://pastande.org/diet-drug-porfimer-sodium-safe-effective-study-finds/

DMW0J3D	DI	DMW0J3D
DMW0J3D	DN	Ethyl Dihydrogen Phosphate
DMW0J3D	MI	TTEB0GD
DMW0J3D	MN	Cholinesterase (BCHE)
DMW0J3D	MT	DTT
DMW0J3D	MA	Inhibitor
DMW0J3D	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMW0J3D	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMXTLJE	DI	DMXTLJE
DMXTLJE	DN	Ethyl estrone-16-methylcarboxylate
DMXTLJE	MI	TTIWB6L
DMXTLJE	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMXTLJE	MT	DTT
DMXTLJE	MA	Inhibitor
DMXTLJE	RN	Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45.
DMXTLJE	RU	https://pubmed.ncbi.nlm.nih.gov/16480268

DMT4XJM	DI	DMT4XJM
DMT4XJM	DN	ETHYL HYDROGEN DIETHYLAMIDOPHOSPHATE
DMT4XJM	MI	TTEB0GD
DMT4XJM	MN	Cholinesterase (BCHE)
DMT4XJM	MT	DTT
DMT4XJM	MA	Inhibitor
DMT4XJM	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMT4XJM	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMXMRK7	DI	DMXMRK7
DMXMRK7	DN	Ethyl octylfluorophosphonate
DMXMRK7	MI	TT1RS9F
DMXMRK7	MN	Acetylcholinesterase (AChE)
DMXMRK7	MT	DTT
DMXMRK7	MA	Inhibitor
DMXMRK7	RN	Activation of the endocannabinoid system by organophosphorus nerve agents. Nat Chem Biol. 2008 Jun;4(6):373-8.
DMXMRK7	RU	https://pubmed.ncbi.nlm.nih.gov/18438404

DMXMRK7	DI	DMXMRK7
DMXMRK7	DN	Ethyl octylfluorophosphonate
DMXMRK7	MI	TTDP1UC
DMXMRK7	MN	Fatty acid amide hydrolase (FAAH)
DMXMRK7	MT	DTT
DMXMRK7	MA	Inhibitor
DMXMRK7	RN	Activation of the endocannabinoid system by organophosphorus nerve agents. Nat Chem Biol. 2008 Jun;4(6):373-8.
DMXMRK7	RU	https://pubmed.ncbi.nlm.nih.gov/18438404

DM9KF0H	DI	DM9KF0H
DM9KF0H	DN	Ethyl Oxo(Piperidin-1-Yl)Acetate
DM9KF0H	MI	TTL2ADK
DM9KF0H	MN	Rotamase A (PPIA)
DM9KF0H	MT	DTT
DM9KF0H	MA	Inhibitor
DM9KF0H	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM9KF0H	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMYFK4L	DI	DMYFK4L
DMYFK4L	DN	Ethyl-(4,5,6,7-tetrahydro-2H-indazol-5-yl)-amine
DMYFK4L	MI	TTEX248
DMYFK4L	MN	Dopamine D2 receptor (D2R)
DMYFK4L	MT	DTT
DMYFK4L	MA	Inhibitor
DMYFK4L	RN	Substituted 5-amino-4,5,6,7-tetrahydroindazoles as partial ergoline structures with dopaminergic activity. J Med Chem. 1989 Oct;32(10):2388-96.
DMYFK4L	RU	https://pubmed.ncbi.nlm.nih.gov/2571732

DMBULX4	DI	DMBULX4
DMBULX4	DN	Ethylene diamine
DMBULX4	MI	TT4ILYC
DMBULX4	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMBULX4	MT	DTT
DMBULX4	MA	Inhibitor
DMBULX4	RN	Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8.
DMBULX4	RU	https://pubmed.ncbi.nlm.nih.gov/17691942

DMBULX4	DI	DMBULX4
DMBULX4	DN	Ethylene diamine
DMBULX4	MI	DEMWO83
DMBULX4	MN	Putrescine acetyltransferase (SSAT1)
DMBULX4	MT	DME
DMBULX4	MA	Metabolism
DMBULX4	RN	Mechanistic and structural analysis of human spermidine/spermine N1-acetyltransferase. Biochemistry. 2007 Jun 19;46(24):7187-95.
DMBULX4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17516632

DMJ6PB8	DI	DMJ6PB8
DMJ6PB8	DN	Ethylgallate
DMJ6PB8	MI	DEWRN24
DMJ6PB8	MN	Glucansucrase (gtf106B)
DMJ6PB8	MT	DME
DMJ6PB8	MA	Metabolism
DMJ6PB8	RN	Exploring the effects of plant odors, from tree species of differing host quality, on the response of Lymantria dispar males to female sex pheromones. J Chem Ecol. 2017 Mar;43(3):243-253.
DMJ6PB8	RU	https://pubmed.ncbi.nlm.nih.gov/28258317

DMJ6PB8	DI	DMJ6PB8
DMJ6PB8	DN	Ethylgallate
DMJ6PB8	MI	TTE14XG
DMJ6PB8	MN	Squalene monooxygenase (SQLE)
DMJ6PB8	MT	DTT
DMJ6PB8	MA	Inhibitor
DMJ6PB8	RN	Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4.
DMJ6PB8	RU	https://pubmed.ncbi.nlm.nih.gov/11520216

DM3CWFR	DI	DM3CWFR
DM3CWFR	DN	Ethyl-indol-1-yl-pyridin-4-yl-amine
DM3CWFR	MI	TTWG9A4
DM3CWFR	MN	Adrenergic receptor alpha-2A (ADRA2A)
DM3CWFR	MT	DTT
DM3CWFR	MA	Inhibitor
DM3CWFR	RN	Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81.
DM3CWFR	RU	https://pubmed.ncbi.nlm.nih.gov/8558529

DM3CWFR	DI	DM3CWFR
DM3CWFR	DN	Ethyl-indol-1-yl-pyridin-4-yl-amine
DM3CWFR	MI	TTWM4TY
DM3CWFR	MN	Adrenergic receptor alpha-2B (ADRA2B)
DM3CWFR	MT	DTT
DM3CWFR	MA	Inhibitor
DM3CWFR	RN	Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81.
DM3CWFR	RU	https://pubmed.ncbi.nlm.nih.gov/8558529

DM3CWFR	DI	DM3CWFR
DM3CWFR	DN	Ethyl-indol-1-yl-pyridin-4-yl-amine
DM3CWFR	MI	TT2NUT5
DM3CWFR	MN	Adrenergic receptor alpha-2C (ADRA2C)
DM3CWFR	MT	DTT
DM3CWFR	MA	Inhibitor
DM3CWFR	RN	Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81.
DM3CWFR	RU	https://pubmed.ncbi.nlm.nih.gov/8558529

DMV9OCU	DI	DMV9OCU
DMV9OCU	DN	Ethylisothiourea
DMV9OCU	MI	TTCM4B3
DMV9OCU	MN	Nitric-oxide synthase endothelial (NOS3)
DMV9OCU	MT	DTT
DMV9OCU	MA	Inhibitor
DMV9OCU	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMV9OCU	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMV9OCU	DI	DMV9OCU
DMV9OCU	DN	Ethylisothiourea
DMV9OCU	MI	TTF10I9
DMV9OCU	MN	Nitric-oxide synthase inducible (NOS2)
DMV9OCU	MT	DTT
DMV9OCU	MA	Inhibitor
DMV9OCU	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMV9OCU	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9YRCU	DI	DM9YRCU
DM9YRCU	DN	ethylketocyclazocine
DM9YRCU	MI	TT27RFC
DM9YRCU	MN	Opioid receptor delta (OPRD1)
DM9YRCU	MT	DTT
DM9YRCU	MA	Agonist
DM9YRCU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317).
DM9YRCU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=317

DM9YRCU	DI	DM9YRCU
DM9YRCU	DN	ethylketocyclazocine
DM9YRCU	MI	TTQW87Y
DM9YRCU	MN	Opioid receptor kappa (OPRK1)
DM9YRCU	MT	DTT
DM9YRCU	MA	Agonist
DM9YRCU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 318).
DM9YRCU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=318

DM9YRCU	DI	DM9YRCU
DM9YRCU	DN	ethylketocyclazocine
DM9YRCU	MI	TTKWM86
DM9YRCU	MN	Opioid receptor mu (MOP)
DM9YRCU	MT	DTT
DM9YRCU	MA	Agonist
DM9YRCU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
DM9YRCU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319

DM0YROF	DI	DM0YROF
DM0YROF	DN	Ethylmorphine
DM0YROF	MI	DEPKLMQ
DM0YROF	MN	Cytochrome P450 2B6 (CYP2B6)
DM0YROF	MT	DME
DM0YROF	MA	Metabolism
DM0YROF	RN	Inhibitory monoclonal antibody to human cytochrome P450 2B6. Biochem Pharmacol. 1998 May 15;55(10):1633-40.
DM0YROF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9633999

DM0YROF	DI	DM0YROF
DM0YROF	DN	Ethylmorphine
DM0YROF	MI	DECB0K3
DM0YROF	MN	Cytochrome P450 2D6 (CYP2D6)
DM0YROF	MT	DME
DM0YROF	MA	Metabolism
DM0YROF	RN	A sensitive LC-MS/MS assay for the determination of dextromethorphan and metabolites in human urine--application for drug interaction studies assessing potential CYP3A and CYP2D6 inhibition. J Pharm Biomed Anal. 2002 Aug 22;30(1):113-24.
DM0YROF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12151071

DM0YROF	DI	DM0YROF
DM0YROF	DN	Ethylmorphine
DM0YROF	MI	DE4LYSA
DM0YROF	MN	Cytochrome P450 3A4 (CYP3A4)
DM0YROF	MT	DME
DM0YROF	MA	Metabolism
DM0YROF	RN	Metabolic activation of aromatic amines by human pancreas. Carcinogenesis. 1997 May;18(5):1085-92.
DM0YROF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9163700

DM0YROF	DI	DM0YROF
DM0YROF	DN	Ethylmorphine
DM0YROF	MI	DERD86B
DM0YROF	MN	Cytochrome P450 3A7 (CYP3A7)
DM0YROF	MT	DME
DM0YROF	MA	Metabolism
DM0YROF	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM0YROF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM0YROF	DI	DM0YROF
DM0YROF	DN	Ethylmorphine
DM0YROF	MI	DEIZLTN
DM0YROF	MN	Docosahexaenoic acid omega-hydroxylase (CYP4F11)
DM0YROF	MT	DME
DM0YROF	MA	Metabolism
DM0YROF	RN	Expression and characterization of human cytochrome P450 4F11: putative role in the metabolism of therapeutic drugs and eicosanoids. Toxicol Appl Pharmacol. 2004 Sep 15;199(3):295-304.
DM0YROF	RU	https://pubmed.ncbi.nlm.nih.gov/15364545

DM0YROF	DI	DM0YROF
DM0YROF	DN	Ethylmorphine
DM0YROF	MI	TTKWM86
DM0YROF	MN	Opioid receptor mu (MOP)
DM0YROF	MT	DTT
DM0YROF	MA	Agonist
DM0YROF	RN	Biotransformation and pharmacokinetics of ethylmorphine after a single oral dose. Br J Clin Pharmacol. 1995 Jun;39(6):611-20.
DM0YROF	RU	https://pubmed.ncbi.nlm.nih.gov/7654478

DMT51QD	DI	DMT51QD
DMT51QD	DN	ETHYLPHENSERINE
DMT51QD	MI	TT1RS9F
DMT51QD	MN	Acetylcholinesterase (AChE)
DMT51QD	MT	DTT
DMT51QD	MA	Inhibitor
DMT51QD	RN	Novel carbamates as orally active acetylcholinesterase inhibitors found to improve scopolamine-induced cognition impairment: pharmacophore-based vi... J Med Chem. 2010 Sep 9;53(17):6490-505.
DMT51QD	RU	https://pubmed.ncbi.nlm.nih.gov/20684567

DM4FW3H	DI	DM4FW3H
DM4FW3H	DN	ETICLOPRIDE
DM4FW3H	MI	TTEX248
DM4FW3H	MN	Dopamine D2 receptor (D2R)
DM4FW3H	MT	DTT
DM4FW3H	MA	Inhibitor
DM4FW3H	RN	Potential antipsychotic agents 5. Synthesis and antidopaminergic properties of substituted 5,6-dimethoxysalicylamides and related compounds. J Med Chem. 1990 Apr;33(4):1155-63.
DM4FW3H	RU	https://pubmed.ncbi.nlm.nih.gov/1969484

DMR9YL6	DI	DMR9YL6
DMR9YL6	DN	Etilamfetamine
DMR9YL6	MI	DECB0K3
DMR9YL6	MN	Cytochrome P450 2D6 (CYP2D6)
DMR9YL6	MT	DME
DMR9YL6	MA	Metabolism
DMR9YL6	RN	Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives. Xenobiotica. 1999 Jul;29(7):719-32.
DMR9YL6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10456690

DMVI9DM	DI	DMVI9DM
DMVI9DM	DN	ETIOCHOLANOLONE
DMVI9DM	MI	TTNJYV2
DMVI9DM	MN	Gamma-aminobutyric acid receptor (GAR)
DMVI9DM	MT	DTT
DMVI9DM	MA	Inhibitor
DMVI9DM	RN	Neurosteroid analogues. 11. Alternative ring system scaffolds: gamma-aminobutyric acid receptor modulation and anesthetic actions of benz[f]indenes. J Med Chem. 2006 Jul 27;49(15):4595-605.
DMVI9DM	RU	https://pubmed.ncbi.nlm.nih.gov/16854065

DMKH8TC	DI	DMKH8TC
DMKH8TC	DN	Etisulergine
DMKH8TC	MI	TTSQIFT
DMKH8TC	MN	5-HT 1A receptor (HTR1A)
DMKH8TC	MT	DTT
DMKH8TC	MA	Inhibitor
DMKH8TC	RN	Resolution and absolute configuration of the potent dopamine agonist N,N-diethyl-N'-[(3 alpha, 4a alpha, 10a beta)-1,2,3,4,4a,5,10,10a- -octahydro-... J Med Chem. 1985 Oct;28(10):1540-2.
DMKH8TC	RU	https://pubmed.ncbi.nlm.nih.gov/4045929

DMKH8TC	DI	DMKH8TC
DMKH8TC	DN	Etisulergine
DMKH8TC	MI	TT6MSOK
DMKH8TC	MN	5-HT 1D receptor (HTR1D)
DMKH8TC	MT	DTT
DMKH8TC	MA	Inhibitor
DMKH8TC	RN	Resolution and absolute configuration of the potent dopamine agonist N,N-diethyl-N'-[(3 alpha, 4a alpha, 10a beta)-1,2,3,4,4a,5,10,10a- -octahydro-... J Med Chem. 1985 Oct;28(10):1540-2.
DMKH8TC	RU	https://pubmed.ncbi.nlm.nih.gov/4045929

DMKH8TC	DI	DMKH8TC
DMKH8TC	DN	Etisulergine
DMKH8TC	MI	TTJQOD7
DMKH8TC	MN	5-HT 2A receptor (HTR2A)
DMKH8TC	MT	DTT
DMKH8TC	MA	Inhibitor
DMKH8TC	RN	Resolution and absolute configuration of the potent dopamine agonist N,N-diethyl-N'-[(3 alpha, 4a alpha, 10a beta)-1,2,3,4,4a,5,10,10a- -octahydro-... J Med Chem. 1985 Oct;28(10):1540-2.
DMKH8TC	RU	https://pubmed.ncbi.nlm.nih.gov/4045929

DMDOX1Z	DI	DMDOX1Z
DMDOX1Z	DN	Etoloxamine
DMDOX1Z	MI	TTZFYLI
DMDOX1Z	MN	Dopamine D1 receptor (D1R)
DMDOX1Z	MT	DTT
DMDOX1Z	MA	Inhibitor
DMDOX1Z	RN	Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
DMDOX1Z	RU	https://pubmed.ncbi.nlm.nih.gov/15293986

DMDOX1Z	DI	DMDOX1Z
DMDOX1Z	DN	Etoloxamine
DMDOX1Z	MI	TTEX248
DMDOX1Z	MN	Dopamine D2 receptor (D2R)
DMDOX1Z	MT	DTT
DMDOX1Z	MA	Inhibitor
DMDOX1Z	RN	Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
DMDOX1Z	RU	https://pubmed.ncbi.nlm.nih.gov/15293986

DMDOX1Z	DI	DMDOX1Z
DMDOX1Z	DN	Etoloxamine
DMDOX1Z	MI	TT4C8EA
DMDOX1Z	MN	Dopamine D3 receptor (D3R)
DMDOX1Z	MT	DTT
DMDOX1Z	MA	Inhibitor
DMDOX1Z	RN	Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
DMDOX1Z	RU	https://pubmed.ncbi.nlm.nih.gov/15293986

DMFR1SE	DI	DMFR1SE
DMFR1SE	DN	ETONITAZENE
DMFR1SE	MI	TT27RFC
DMFR1SE	MN	Opioid receptor delta (OPRD1)
DMFR1SE	MT	DTT
DMFR1SE	MA	Inhibitor
DMFR1SE	RN	Photoactivatable opiate derivatives as irreversible probes of the mu-opioid receptor. J Med Chem. 1990 Sep;33(9):2456-64.
DMFR1SE	RU	https://pubmed.ncbi.nlm.nih.gov/2167979

DMFR1SE	DI	DMFR1SE
DMFR1SE	DN	ETONITAZENE
DMFR1SE	MI	TTQW87Y
DMFR1SE	MN	Opioid receptor kappa (OPRK1)
DMFR1SE	MT	DTT
DMFR1SE	MA	Inhibitor
DMFR1SE	RN	Photoactivatable opiate derivatives as irreversible probes of the mu-opioid receptor. J Med Chem. 1990 Sep;33(9):2456-64.
DMFR1SE	RU	https://pubmed.ncbi.nlm.nih.gov/2167979

DMFR1SE	DI	DMFR1SE
DMFR1SE	DN	ETONITAZENE
DMFR1SE	MI	TTKWM86
DMFR1SE	MN	Opioid receptor mu (MOP)
DMFR1SE	MT	DTT
DMFR1SE	MA	Inhibitor
DMFR1SE	RN	Ligand binding to nucleic acids and proteins: Does selectivity increase with strength Eur J Med Chem. 2008 Nov;43(11):2307-15.
DMFR1SE	RU	https://pubmed.ncbi.nlm.nih.gov/18403056

DM79YZN	DI	DM79YZN
DM79YZN	DN	Etorphine
DM79YZN	MI	TT27RFC
DM79YZN	MN	Opioid receptor delta (OPRD1)
DM79YZN	MT	DTT
DM79YZN	MA	Agonist
DM79YZN	RN	Agonist-, antagonist-, and inverse agonist-regulated trafficking of the delta-opioid receptor correlates with, but does not require, G protein activation. J Pharmacol Exp Ther. 2001 Sep;298(3):1015-20.
DM79YZN	RU	https://pubmed.ncbi.nlm.nih.gov/11504798

DM79YZN	DI	DM79YZN
DM79YZN	DN	Etorphine
DM79YZN	MI	TTKWM86
DM79YZN	MN	Opioid receptor mu (MOP)
DM79YZN	MT	DTT
DM79YZN	MA	Agonist
DM79YZN	RN	Internalization of mu-opioid receptors produced by etorphine in the rat locus coeruleus. Neuroscience. 2001;108(3):467-77.
DM79YZN	RU	https://pubmed.ncbi.nlm.nih.gov/11738260

DM79XSF	DI	DM79XSF
DM79XSF	DN	ETP-45658
DM79XSF	MI	TTWR6YK
DM79XSF	MN	PI3-kinase (PIK3C)
DM79XSF	MT	DTT
DM79XSF	MA	Inhibitor
DM79XSF	RN	A novel phosphatidylinositol 3-kinase (PI3K) inhibitor directs a potent FOXO-dependent, p53-independent cell cycle arrest phenotype characterized by the differential induction of a subset of FOXO-regulated genes. Breast Cancer Res. 2014 Dec 9;16(6):482.
DM79XSF	RU	https://pubmed.ncbi.nlm.nih.gov/25488803

DMO2PY8	DI	DMO2PY8
DMO2PY8	DN	ETP-46321
DMO2PY8	MI	TTEUNMR
DMO2PY8	MN	PI3-kinase alpha (PIK3CA)
DMO2PY8	MT	DTT
DMO2PY8	MA	Inhibitor
DMO2PY8	RN	ETP-46321, a dual p110alpha/ class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis. Biochem Pharmacol. 2016 Apr 15;106:56-69.
DMO2PY8	RU	https://pubmed.ncbi.nlm.nih.gov/26883061

DMO2PY8	DI	DMO2PY8
DMO2PY8	DN	ETP-46321
DMO2PY8	MI	TTGBPJE
DMO2PY8	MN	PI3-kinase delta (PIK3CD)
DMO2PY8	MT	DTT
DMO2PY8	MA	Inhibitor
DMO2PY8	RN	ETP-46321, a dual p110alpha/ class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis. Biochem Pharmacol. 2016 Apr 15;106:56-69.
DMO2PY8	RU	https://pubmed.ncbi.nlm.nih.gov/26883061

DMZ1FCJ	DI	DMZ1FCJ
DMZ1FCJ	DN	EU-517
DMZ1FCJ	MI	TTL53M6
DMZ1FCJ	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DMZ1FCJ	MT	DTT
DMZ1FCJ	MA	Inhibitor
DMZ1FCJ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2847).
DMZ1FCJ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2847

DMR3487	DI	DMR3487
DMR3487	DN	EU-C-001
DMR3487	MI	TTZPO1L
DMR3487	MN	Substance-P receptor (TACR1)
DMR3487	MT	DTT
DMR3487	MA	Modulator
DMR3487	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 360).
DMR3487	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=360

DME5CK3	DI	DME5CK3
DME5CK3	DN	eucalyptol
DME5CK3	MI	TTXDKTO
DME5CK3	MN	Long transient receptor potential channel 8 (TRPM8)
DME5CK3	MT	DTT
DME5CK3	MA	Activator
DME5CK3	RN	Identification of a cold receptor reveals a general role for TRP channels in thermosensation. Nature. 2002 Mar 7;416(6876):52-8.
DME5CK3	RU	https://pubmed.ncbi.nlm.nih.gov/11882888

DMUA485	DI	DMUA485
DMUA485	DN	EUGENIIN
DMUA485	MI	TTE14XG
DMUA485	MN	Squalene monooxygenase (SQLE)
DMUA485	MT	DTT
DMUA485	MA	Inhibitor
DMUA485	RN	Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4.
DMUA485	RU	https://pubmed.ncbi.nlm.nih.gov/11520216

DMLXKZH	DI	DMLXKZH
DMLXKZH	DN	EUPAFOLIN
DMLXKZH	MI	TT86VZE
DMLXKZH	MN	Plasmodium M1-family aminopeptidase (Malaria MFA)
DMLXKZH	MT	DTT
DMLXKZH	MA	Inhibitor
DMLXKZH	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMLXKZH	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DM068CY	DI	DM068CY
DM068CY	DN	EUPATORIOPICRIN
DM068CY	MI	TTICX3S
DM068CY	MN	Bacterial UDP-N-acetylglucosamine carboxyvinyltransferase (Bact murA)
DM068CY	MT	DTT
DM068CY	MA	Inhibitor
DM068CY	RN	Sesquiterpene lactones are potent and irreversible inhibitors of the antibacterial target enzyme MurA. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5605-9.
DM068CY	RU	https://pubmed.ncbi.nlm.nih.gov/16945528

DMO3AZ6	DI	DMO3AZ6
DMO3AZ6	DN	Euro-Celtique 1
DMO3AZ6	MI	TTXHYV6
DMO3AZ6	MN	Voltage-gated L-type calcium channel (L-CaC)
DMO3AZ6	MT	DTT
DMO3AZ6	MA	Blocker
DMO3AZ6	RN	Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95.
DMO3AZ6	RU	https://pubmed.ncbi.nlm.nih.gov/19442208

DMJH4BF	DI	DMJH4BF
DMJH4BF	DN	Euro-Celtique 2
DMJH4BF	MI	TTXHYV6
DMJH4BF	MN	Voltage-gated L-type calcium channel (L-CaC)
DMJH4BF	MT	DTT
DMJH4BF	MA	Blocker
DMJH4BF	RN	Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95.
DMJH4BF	RU	https://pubmed.ncbi.nlm.nih.gov/19442208

DM8VI3T	DI	DM8VI3T
DM8VI3T	DN	Euro-Celtique 3
DM8VI3T	MI	TTXHYV6
DM8VI3T	MN	Voltage-gated L-type calcium channel (L-CaC)
DM8VI3T	MT	DTT
DM8VI3T	MA	Blocker
DM8VI3T	RN	Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95.
DM8VI3T	RU	https://pubmed.ncbi.nlm.nih.gov/19442208

DMO4CEL	DI	DMO4CEL
DMO4CEL	DN	Euro-Celtique 4
DMO4CEL	MI	TTXHYV6
DMO4CEL	MN	Voltage-gated L-type calcium channel (L-CaC)
DMO4CEL	MT	DTT
DMO4CEL	MA	Blocker
DMO4CEL	RN	Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95.
DMO4CEL	RU	https://pubmed.ncbi.nlm.nih.gov/19442208

DMXBGSL	DI	DMXBGSL
DMXBGSL	DN	EUSYNSTYELAMIDE B
DMXBGSL	MI	TTZUFI5
DMXBGSL	MN	Nitric-oxide synthase brain (NOS1)
DMXBGSL	MT	DTT
DMXBGSL	MA	Inhibitor
DMXBGSL	RN	Eusynstyelamides A, B, and C, nNOS inhibitors, from the ascidian Eusynstyela latericius. J Nat Prod. 2009 Jun;72(6):1115-20.
DMXBGSL	RU	https://pubmed.ncbi.nlm.nih.gov/19505081

DM6ODAS	DI	DM6ODAS
DM6ODAS	DN	Eusynstyelamide C
DM6ODAS	MI	TTZUFI5
DM6ODAS	MN	Nitric-oxide synthase brain (NOS1)
DM6ODAS	MT	DTT
DM6ODAS	MA	Inhibitor
DM6ODAS	RN	Eusynstyelamides A, B, and C, nNOS inhibitors, from the ascidian Eusynstyela latericius. J Nat Prod. 2009 Jun;72(6):1115-20.
DM6ODAS	RU	https://pubmed.ncbi.nlm.nih.gov/19505081

DMNMEAW	DI	DMNMEAW
DMNMEAW	DN	Evatak
DMNMEAW	MI	TTMSB0A
DMNMEAW	MN	Integrin alpha-2/beta-1 (ITGA2/B1)
DMNMEAW	MT	DTT
DMNMEAW	MA	Modulator
DMNMEAW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2578).
DMNMEAW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2578

DM17TYR	DI	DM17TYR
DM17TYR	DN	Everolimus
DM17TYR	MI	TT7HQAF
DM17TYR	MN	HUMAN mammalian target of rapamycin (mTOR)
DM17TYR	MT	DTT
DM17TYR	MA	Inhibitor
DM17TYR	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DM17TYR	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DMHMFKE	DI	DMHMFKE
DMHMFKE	DN	EVP-4473
DMHMFKE	MI	TTLA931
DMHMFKE	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMHMFKE	MT	DTT
DMHMFKE	MA	Agonist
DMHMFKE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 468).
DMHMFKE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=468

DM4Q2HZ	DI	DM4Q2HZ
DM4Q2HZ	DN	EVT-501
DM4Q2HZ	MI	TT9JNIC
DM4Q2HZ	MN	Histamine H3 receptor (H3R)
DM4Q2HZ	MT	DTT
DM4Q2HZ	MA	Antagonist
DM4Q2HZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 264).
DM4Q2HZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=264

DMBKM30	DI	DMBKM30
DMBKM30	DN	EX-1311
DMBKM30	MI	TTWDC17
DMBKM30	MN	Growth hormone secretagogue receptor 1 (GHSR)
DMBKM30	MT	DTT
DMBKM30	MA	Antagonist
DMBKM30	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 246).
DMBKM30	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=246

DMWF8U5	DI	DMWF8U5
DMWF8U5	DN	EX-1314
DMWF8U5	MI	TTWDC17
DMWF8U5	MN	Growth hormone secretagogue receptor 1 (GHSR)
DMWF8U5	MT	DTT
DMWF8U5	MA	Agonist
DMWF8U5	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 246).
DMWF8U5	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=246

DMNI6YU	DI	DMNI6YU
DMNI6YU	DN	EX5
DMNI6YU	MI	TTQWOU1
DMNI6YU	MN	MTHFR messenger RNA (MTHFR mRNA)
DMNI6YU	MT	DTT
DMNI6YU	RN	Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36.
DMNI6YU	RU	https://pubmed.ncbi.nlm.nih.gov/21948793

DMSG8RI	DI	DMSG8RI
DMSG8RI	DN	example 131 [WO2009133348]
DMSG8RI	MI	TT5T3P6
DMSG8RI	MN	Tissue kallikrein (KLK1)
DMSG8RI	MT	DTT
DMSG8RI	MA	Inhibitor
DMSG8RI	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2865).
DMSG8RI	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2865

DMY3CKG	DI	DMY3CKG
DMY3CKG	DN	example 166  (WO2014154727)
DMY3CKG	MI	TT5NILS
DMY3CKG	MN	Cathepsin A (CTSA)
DMY3CKG	MT	DTT
DMY3CKG	MA	Inhibitor
DMY3CKG	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1581).
DMY3CKG	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1581

DMU25HZ	DI	DMU25HZ
DMU25HZ	DN	example 2 (WO2013004676)
DMU25HZ	MI	TT8JRS7
DMU25HZ	MN	Beta-secretase (BACE)
DMU25HZ	MT	DTT
DMU25HZ	MA	Inhibitor
DMU25HZ	RN	Cyclopropyl-Fused 1,3-Thiazepines as BACE1 and BACE2 Inhibitors. ACS Med Chem Lett. 2013 Mar 15;4(4):379-80.
DMU25HZ	RU	https://pubmed.ncbi.nlm.nih.gov/24900681

DMU25HZ	DI	DMU25HZ
DMU25HZ	DN	example 2 (WO2013004676)
DMU25HZ	MI	TT69DB8
DMU25HZ	MN	Beta-site APP-cleaving enzyme 2 (BACE2)
DMU25HZ	MT	DTT
DMU25HZ	MA	Inhibitor
DMU25HZ	RN	Cyclopropyl-Fused 1,3-Thiazepines as BACE1 and BACE2 Inhibitors. ACS Med Chem Lett. 2013 Mar 15;4(4):379-80.
DMU25HZ	RU	https://pubmed.ncbi.nlm.nih.gov/24900681

DMF9W41	DI	DMF9W41
DMF9W41	DN	example 20 (WO2010128058)
DMF9W41	MI	TT69DB8
DMF9W41	MN	Beta-site APP-cleaving enzyme 2 (BACE2)
DMF9W41	MT	DTT
DMF9W41	MA	Inhibitor
DMF9W41	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2331).
DMF9W41	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2331

DMP8A5R	DI	DMP8A5R
DMP8A5R	DN	example 373 [WO2012093101]
DMP8A5R	MI	TT8D13I
DMP8A5R	MN	Complement factor D (CFD)
DMP8A5R	MT	DTT
DMP8A5R	MA	Inhibitor
DMP8A5R	RN	Factor D Inhibitors for the Treatment of AMD: Patent Highlight. ACS Med Chem Lett. 2012 Aug 27;3(10):781-2.
DMP8A5R	RU	https://pubmed.ncbi.nlm.nih.gov/24900375

DM2N9Y8	DI	DM2N9Y8
DM2N9Y8	DN	example 41 (WO2012028563)
DM2N9Y8	MI	TT69DB8
DM2N9Y8	MN	Beta-site APP-cleaving enzyme 2 (BACE2)
DM2N9Y8	MT	DTT
DM2N9Y8	MA	Inhibitor
DM2N9Y8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2331).
DM2N9Y8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2331

DMFSHXW	DI	DMFSHXW
DMFSHXW	DN	example 8 [WO1999033801A1]
DMFSHXW	MI	TTQ7R2V
DMFSHXW	MN	Tripeptidyl-peptidase II (TPP2)
DMFSHXW	MT	DTT
DMFSHXW	MA	Inhibitor
DMFSHXW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2423).
DMFSHXW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2423

DMU42CR	DI	DMU42CR
DMU42CR	DN	example 92 (WO2012095521)
DMU42CR	MI	TT69DB8
DMU42CR	MN	Beta-site APP-cleaving enzyme 2 (BACE2)
DMU42CR	MT	DTT
DMU42CR	MA	Inhibitor
DMU42CR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2331).
DMU42CR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2331

DMMZH3Q	DI	DMMZH3Q
DMMZH3Q	DN	Exiguamine A
DMMZH3Q	MI	TTZJYKH
DMMZH3Q	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMMZH3Q	MT	DTT
DMMZH3Q	MA	Inhibitor
DMMZH3Q	RN	Synthesis of indoleamine 2,3-dioxygenase inhibitory analogues of the sponge alkaloid exiguamine A. J Med Chem. 2008 May 8;51(9):2634-7.
DMMZH3Q	RU	https://pubmed.ncbi.nlm.nih.gov/18393489

DME1TGM	DI	DME1TGM
DME1TGM	DN	EXIGUAMINE B
DME1TGM	MI	TTZJYKH
DME1TGM	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DME1TGM	MT	DTT
DME1TGM	MA	Inhibitor
DME1TGM	RN	Biomimetic synthesis of the IDO inhibitors exiguamine A and B. Nat Chem Biol. 2008 Sep;4(9):535-7.
DME1TGM	RU	https://pubmed.ncbi.nlm.nih.gov/18677305

DMWIBFM	DI	DMWIBFM
DMWIBFM	DN	EXP3174
DMWIBFM	MI	TT8DBY3
DMWIBFM	MN	Angiotensin II receptor type-1 (AGTR1)
DMWIBFM	MT	DTT
DMWIBFM	MA	Antagonist
DMWIBFM	RN	Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 1993 Jun;45(2):205-51.
DMWIBFM	RU	https://pubmed.ncbi.nlm.nih.gov/8372104

DMY96KO	DI	DMY96KO
DMY96KO	DN	EXRD-4605
DMY96KO	MI	TT7WVHI
DMY96KO	MN	Soluble epoxide hydrolase (EPHX2)
DMY96KO	MT	DTT
DMY96KO	MA	Inhibitor
DMY96KO	RN	Soluble epoxide hydrolase inhibition does not prevent cardiac remodeling and dysfunction after aortic constriction in rats and mice. J Cardiovasc Pharmacol. 2013 Apr;61(4):291-301.
DMY96KO	RU	https://pubmed.ncbi.nlm.nih.gov/23232840

DM5V3S7	DI	DM5V3S7
DM5V3S7	DN	Ezetimibe-glucuronide
DM5V3S7	MI	TTPD1CN
DM5V3S7	MN	Niemann-Pick C1-like protein 1 (NPC1L1)
DM5V3S7	MT	DTT
DM5V3S7	MA	Inhibitor
DM5V3S7	RN	Spiroimidazolidinone NPC1L1 inhibitors. 1: Discovery by 3D-similarity-based virtual screening. Bioorg Med Chem Lett. 2009 Jun 1;19(11):2965-8.
DM5V3S7	RU	https://pubmed.ncbi.nlm.nih.gov/19410454

DMXV5PM	DI	DMXV5PM
DMXV5PM	DN	EZN-3920
DMXV5PM	MI	TTSINU2
DMXV5PM	MN	ERBB3 messenger RNA (ERBB3 mRNA)
DMXV5PM	MT	DTT
DMXV5PM	MA	Inhibitor
DMXV5PM	RN	Downregulation of HER3 by a novel antisense oligonucleotide, EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine kinase inhibitors in animal models. Mol Cancer Ther. 2013 Apr;12(4):427-37.
DMXV5PM	RU	https://pubmed.ncbi.nlm.nih.gov/23395887

DMTW571	DI	DMTW571
DMTW571	DN	F(4-Fluoro)VAE
DMTW571	MI	TTPADOQ
DMTW571	MN	HMG-CoA reductase (HMGCR)
DMTW571	MT	DTT
DMTW571	MA	Inhibitor
DMTW571	RN	Binding effect and design of a competitive inhibitory peptide for HMG-CoA reductase through modeling of an active peptide backbone. Bioorg Med Chem. 2008 Feb 1;16(3):1309-18.
DMTW571	RU	https://pubmed.ncbi.nlm.nih.gov/17977732

DMXHKE3	DI	DMXHKE3
DMXHKE3	DN	F-12458
DMXHKE3	MI	TT7WZIJ
DMXHKE3	MN	CAAX farnesyltransferase beta (FNTB)
DMXHKE3	MT	DTT
DMXHKE3	MA	Inhibitor
DMXHKE3	RN	Recent progress in protein farnesyltransferase inhibition. IDrugs. 2000 Nov;3(11):1336-45.
DMXHKE3	RU	https://pubmed.ncbi.nlm.nih.gov/16047255

DMHETZN	DI	DMHETZN
DMHETZN	DN	F-18 exendin-4 derivative PET tracers
DMHETZN	MI	TTVIMDE
DMHETZN	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMHETZN	MT	DTT
DMHETZN	MA	Modulator
DMHETZN	RN	2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006).
DMHETZN	RU	http://www.nature.com/nrd/journal/v11/n1/full/nrd3645.html

DM69MKU	DI	DM69MKU
DM69MKU	DN	F3
DM69MKU	MI	TTTIBVP
DM69MKU	MN	Inward rectifier potassium channel Kir3.2 (KCNJ6)
DM69MKU	MT	DTT
DM69MKU	MA	Inhibitor (gating inhibitor)
DM69MKU	RN	Differential effects of general anesthetics on G protein-coupled inwardly rectifying and other potassium channels. Anesthesiology. 2001 Jul;95(1):144-53.
DM69MKU	RU	https://pubmed.ncbi.nlm.nih.gov/11465552

DMD7HO8	DI	DMD7HO8
DMD7HO8	DN	F61F12
DMD7HO8	MI	TTF0RCZ
DMD7HO8	MN	Apoptosis mediating surface antigen FAS (FAS)
DMD7HO8	MT	DTT
DMD7HO8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1875).
DMD7HO8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1875

DMYWERO	DI	DMYWERO
DMYWERO	DN	F-9TG
DMYWERO	MI	TTFEZ5Q
DMYWERO	MN	Coagulation factor IX (F9)
DMYWERO	MT	DTT
DMYWERO	MA	Modulator
DMYWERO	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2364).
DMYWERO	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2364

DMDBO89	DI	DMDBO89
DMDBO89	DN	FA-70
DMDBO89	MI	TT3WG5C
DMDBO89	MN	Monoamine oxidase type A (MAO-A)
DMDBO89	MT	DTT
DMDBO89	MA	Inhibitor
DMDBO89	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2489).
DMDBO89	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2489

DMSQ3I9	DI	DMSQ3I9
DMSQ3I9	DN	Factor IX-XTEN
DMSQ3I9	MI	TTFEZ5Q
DMSQ3I9	MN	Coagulation factor IX (F9)
DMSQ3I9	MT	DTT
DMSQ3I9	MA	Modulator
DMSQ3I9	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2364).
DMSQ3I9	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2364

DM1AYVU	DI	DM1AYVU
DM1AYVU	DN	Factor VIII-XTEN
DM1AYVU	MI	TT1290U
DM1AYVU	MN	Coagulation factor VIII (F8)
DM1AYVU	MT	DTT
DM1AYVU	MA	Modulator
DM1AYVU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2607).
DM1AYVU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2607

DMDWSH1	DI	DMDWSH1
DMDWSH1	DN	Factor-VIIa-XTEN
DMDWSH1	MI	TTF0EGX
DMDWSH1	MN	Coagulation factor VII (F7)
DMDWSH1	MT	DTT
DMDWSH1	MA	Modulator
DMDWSH1	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2363).
DMDWSH1	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2363

DMJFKSU	DI	DMJFKSU
DMJFKSU	DN	FAICAR
DMJFKSU	MI	TT9NVXQ
DMJFKSU	MN	Phosphoribosylaminoimidazolecarboxamide formyltransferase (ATIC)
DMJFKSU	MT	DTT
DMJFKSU	MA	Inhibitor
DMJFKSU	RN	Structure-based design, synthesis, evaluation, and crystal structures of transition state analogue inhibitors of inosine monophosphate cyclohydrolase. J Biol Chem. 2007 Apr 27;282(17):13033-46.
DMJFKSU	RU	https://pubmed.ncbi.nlm.nih.gov/17324932

DMLOV18	DI	DMLOV18
DMLOV18	DN	FALCARINDIOL
DMLOV18	MI	TTO9X1H
DMLOV18	MN	5-HT 7 receptor (HTR7)
DMLOV18	MT	DTT
DMLOV18	MA	Inhibitor
DMLOV18	RN	Serotonergic activity-guided phytochemical investigation of the roots of Angelica sinensis. J Nat Prod. 2006 Apr;69(4):536-41.
DMLOV18	RU	https://pubmed.ncbi.nlm.nih.gov/16643021

DMLOV18	DI	DMLOV18
DMLOV18	DN	FALCARINDIOL
DMLOV18	MI	TTZFYLI
DMLOV18	MN	Dopamine D1 receptor (D1R)
DMLOV18	MT	DTT
DMLOV18	MA	Inhibitor
DMLOV18	RN	Novel coumarin glycoside and phenethyl vanillate from Notopterygium forbesii and their binding affinities for opioid and dopamine receptors. Bioorg Med Chem. 2008 Mar 15;16(6):3218-23.
DMLOV18	RU	https://pubmed.ncbi.nlm.nih.gov/18166466

DMLOV18	DI	DMLOV18
DMLOV18	DN	FALCARINDIOL
DMLOV18	MI	TT27RFC
DMLOV18	MN	Opioid receptor delta (OPRD1)
DMLOV18	MT	DTT
DMLOV18	MA	Inhibitor
DMLOV18	RN	Novel coumarin glycoside and phenethyl vanillate from Notopterygium forbesii and their binding affinities for opioid and dopamine receptors. Bioorg Med Chem. 2008 Mar 15;16(6):3218-23.
DMLOV18	RU	https://pubmed.ncbi.nlm.nih.gov/18166466

DMLOV18	DI	DMLOV18
DMLOV18	DN	FALCARINDIOL
DMLOV18	MI	TTQW87Y
DMLOV18	MN	Opioid receptor kappa (OPRK1)
DMLOV18	MT	DTT
DMLOV18	MA	Inhibitor
DMLOV18	RN	Novel coumarin glycoside and phenethyl vanillate from Notopterygium forbesii and their binding affinities for opioid and dopamine receptors. Bioorg Med Chem. 2008 Mar 15;16(6):3218-23.
DMLOV18	RU	https://pubmed.ncbi.nlm.nih.gov/18166466

DMLOV18	DI	DMLOV18
DMLOV18	DN	FALCARINDIOL
DMLOV18	MI	TTKWM86
DMLOV18	MN	Opioid receptor mu (MOP)
DMLOV18	MT	DTT
DMLOV18	MA	Inhibitor
DMLOV18	RN	Novel coumarin glycoside and phenethyl vanillate from Notopterygium forbesii and their binding affinities for opioid and dopamine receptors. Bioorg Med Chem. 2008 Mar 15;16(6):3218-23.
DMLOV18	RU	https://pubmed.ncbi.nlm.nih.gov/18166466

DMJYNMC	DI	DMJYNMC
DMJYNMC	DN	FAMOXADONE
DMJYNMC	MI	TTRAMF0
DMJYNMC	MN	Plasmodium Cytochrome B (Malaria MT-CYB)
DMJYNMC	MT	DTT
DMJYNMC	MA	Inhibitor
DMJYNMC	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMJYNMC	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM45K8W	DI	DM45K8W
DM45K8W	DN	FANA
DM45K8W	MI	TT50QJ3
DM45K8W	MN	Influenza Neuraminidase (Influ NA)
DM45K8W	MT	DTT
DM45K8W	MA	Inhibitor
DM45K8W	RN	Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25.
DM45K8W	RU	https://pubmed.ncbi.nlm.nih.gov/17139286

DMV2X1B	DI	DMV2X1B
DMV2X1B	DN	Farnesol
DMV2X1B	MI	TTGP7BY
DMV2X1B	MN	Monoamine oxidase type B (MAO-B)
DMV2X1B	MT	DTT
DMV2X1B	MA	Inhibitor
DMV2X1B	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMV2X1B	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMXYWD7	DI	DMXYWD7
DMXYWD7	DN	FARNESYL
DMXYWD7	MI	TT7WZIJ
DMXYWD7	MN	CAAX farnesyltransferase beta (FNTB)
DMXYWD7	MT	DTT
DMXYWD7	MA	Inhibitor
DMXYWD7	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMXYWD7	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMXYWD7	DI	DMXYWD7
DMXYWD7	DN	FARNESYL
DMXYWD7	MI	TTXQKM3
DMXYWD7	MN	Farnesyl protein transferase (Ftase)
DMXYWD7	MT	DTT
DMXYWD7	MA	Inhibitor
DMXYWD7	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMXYWD7	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMRMI0V	DI	DMRMI0V
DMRMI0V	DN	FAS-031
DMRMI0V	MI	TT7AOUD
DMRMI0V	MN	Fatty acid synthase (FASN)
DMRMI0V	MT	DTT
DMRMI0V	MA	Inhibitor
DMRMI0V	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2608).
DMRMI0V	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2608

DMG5OZP	DI	DMG5OZP
DMG5OZP	DN	Fascaplysin
DMG5OZP	MI	TT0PG8F
DMG5OZP	MN	Cyclin-dependent kinase 4 (CDK4)
DMG5OZP	MT	DTT
DMG5OZP	MA	Inhibitor
DMG5OZP	RN	Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
DMG5OZP	RU	https://pubmed.ncbi.nlm.nih.gov/12237154

DMG5OZP	DI	DMG5OZP
DMG5OZP	DN	Fascaplysin
DMG5OZP	MI	TTO0FDJ
DMG5OZP	MN	Cyclin-dependent kinase 6 (CDK6)
DMG5OZP	MT	DTT
DMG5OZP	MA	Inhibitor
DMG5OZP	RN	Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
DMG5OZP	RU	https://pubmed.ncbi.nlm.nih.gov/12237154

DMC8G7X	DI	DMC8G7X
DMC8G7X	DN	fasidotrilat
DMC8G7X	MI	TTL69WB
DMC8G7X	MN	Angiotensin-converting enzyme (ACE)
DMC8G7X	MT	DTT
DMC8G7X	MA	Inhibitor
DMC8G7X	RN	Protease inhibitors in the clinic. Med Chem. 2005 Jan;1(1):71-104.
DMC8G7X	RU	https://pubmed.ncbi.nlm.nih.gov/16789888

DMC8G7X	DI	DMC8G7X
DMC8G7X	DN	fasidotrilat
DMC8G7X	MI	TT5TKPM
DMC8G7X	MN	Neutral endopeptidase (MME)
DMC8G7X	MT	DTT
DMC8G7X	MA	Inhibitor
DMC8G7X	RN	Modelling of aldose reductase inhibitory activity of pyrrol-1-yl-acetic acid derivatives by means of multivariate statistics. Med Chem. 2005 Jul;1(4):321-6.
DMC8G7X	RU	https://pubmed.ncbi.nlm.nih.gov/16789889

DMTCNOM	DI	DMTCNOM
DMTCNOM	DN	Fasudil
DMTCNOM	MI	TTZN7RP
DMTCNOM	MN	Rho-associated protein kinase 1 (ROCK1)
DMTCNOM	MT	DTT
DMTCNOM	MA	Inhibitor
DMTCNOM	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMTCNOM	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMC6J3B	DI	DMC6J3B
DMC6J3B	DN	FAUC 113
DMC6J3B	MI	TTE0A2F
DMC6J3B	MN	Dopamine D4 receptor (D4R)
DMC6J3B	MT	DTT
DMC6J3B	MA	Antagonist
DMC6J3B	RN	Comparative molecular field analysis of dopamine D4 receptor antagonists including 3-[4-(4-chlorophenyl)piperazin-1-ylmethyl]pyrazolo[1,5-a]pyridine (FAUC 113), 3-[4-(4-chlorophenyl)piperazin-1-ylmethyl]-1H-pyrrolo-[2,3-b]pyridine (L-745,870), and clozapine. J Med Chem. 2001 Apr 12;44(8):1151-7.
DMC6J3B	RU	https://pubmed.ncbi.nlm.nih.gov/11312915

DM1LMFG	DI	DM1LMFG
DM1LMFG	DN	FAUC213
DM1LMFG	MI	TTE0A2F
DM1LMFG	MN	Dopamine D4 receptor (D4R)
DM1LMFG	MT	DTT
DM1LMFG	MA	Agonist
DM1LMFG	RN	Certain 1,4-disubstituted aromatic piperidines and piperazines with extreme selectivity for the dopamine D4 receptor interact with a common recepto... Mol Pharmacol. 2004 Dec;66(6):1491-9.
DM1LMFG	RU	https://pubmed.ncbi.nlm.nih.gov/15448188

DM7IEL2	DI	DM7IEL2
DM7IEL2	DN	FD-1
DM7IEL2	MI	TT8R70G
DM7IEL2	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DM7IEL2	MT	DTT
DM7IEL2	MA	Antagonist
DM7IEL2	RN	Amiloride derivatives and a nonpeptidic antagonist bind at two distinct allosteric sites in the human gonadotropin-releasing hormone receptor. Mol Pharmacol. 2008 Jun;73(6):1808-15.
DM7IEL2	RU	https://pubmed.ncbi.nlm.nih.gov/18344315

DMYXA7E	DI	DMYXA7E
DMYXA7E	DN	FdG
DMYXA7E	MI	TTSUKYD
DMYXA7E	MN	Virus RNA-dependent RNA polymerase (Viru RdRP)
DMYXA7E	MT	DTT
DMYXA7E	MA	Inhibitor
DMYXA7E	RN	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob Agents Chemother. 2009 Jan;53(1):202-9.
DMYXA7E	RU	https://pubmed.ncbi.nlm.nih.gov/18955536

DMKVA6Z	DI	DMKVA6Z
DMKVA6Z	DN	FE 999011
DMKVA6Z	MI	TTDIGC1
DMKVA6Z	MN	Dipeptidyl peptidase 4 (DPP-4)
DMKVA6Z	MT	DTT
DMKVA6Z	MA	Inhibitor
DMKVA6Z	RN	Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats. Diabetes. 2002 May;51(5):1461-9.
DMKVA6Z	RU	https://pubmed.ncbi.nlm.nih.gov/11978643

DMBX81R	DI	DMBX81R
DMBX81R	DN	FE-203799
DMBX81R	MI	TT1YWO5
DMBX81R	MN	Glucagon-like peptide 2 receptor (GLP2R)
DMBX81R	MT	DTT
DMBX81R	MA	Modulator
DMBX81R	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 250).
DMBX81R	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=250

DM3UCWM	DI	DM3UCWM
DM3UCWM	DN	FE-999040
DM3UCWM	MI	TTGPQ0F
DM3UCWM	MN	Prolyl endopeptidase FAP (FAP)
DM3UCWM	MT	DTT
DM3UCWM	MA	Inhibitor
DM3UCWM	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2365).
DM3UCWM	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2365

DMN1579	DI	DMN1579
DMN1579	DN	Fedratinib
DMN1579	MI	TT0F5HE
DMN1579	MN	HUMAN janus kinase 2 (JAK-2)
DMN1579	MT	DTT
DMN1579	MA	Inhibitor
DMN1579	RN	TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect. 2020 Mar 11. pii: S1684-1182(20)30065-7.
DMN1579	RU	https://pubmed.ncbi.nlm.nih.gov/32205092

DMUBO3E	DI	DMUBO3E
DMUBO3E	DN	fenclonine
DMUBO3E	MI	TT3KLDP
DMUBO3E	MN	L-Tryptophan hydroxylase 2 (TPH2)
DMUBO3E	MT	DTT
DMUBO3E	MA	Inhibitor
DMUBO3E	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1242).
DMUBO3E	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1242

DMUBO3E	DI	DMUBO3E
DMUBO3E	DN	fenclonine
DMUBO3E	MI	TTGSVH2
DMUBO3E	MN	Phenylalanine hydroxylase (PAH)
DMUBO3E	MT	DTT
DMUBO3E	MA	Inhibitor
DMUBO3E	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1240).
DMUBO3E	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1240

DMUBO3E	DI	DMUBO3E
DMUBO3E	DN	fenclonine
DMUBO3E	MI	TTZSJHV
DMUBO3E	MN	Tryptophan 5-hydroxylase 1 (TPH1)
DMUBO3E	MT	DTT
DMUBO3E	MA	Inhibitor
DMUBO3E	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1241).
DMUBO3E	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1241

DM34V5W	DI	DM34V5W
DM34V5W	DN	Fenethylline
DM34V5W	MI	DEJGDUW
DM34V5W	MN	Cytochrome P450 1A2 (CYP1A2)
DM34V5W	MT	DME
DM34V5W	MA	Metabolism
DM34V5W	RN	PharmGKB summary: caffeine pathway. Pharmacogenet Genomics. 2012 May;22(5):389-95.
DM34V5W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22293536

DMKEG49	DI	DMKEG49
DMKEG49	DN	Fenthion
DMKEG49	MI	DEJVYAZ
DMKEG49	MN	Cytochrome P450 2A6 (CYP2A6)
DMKEG49	MT	DME
DMKEG49	MA	Metabolism
DMKEG49	RN	The participation of human hepatic P450 isoforms, flavin-containing monooxygenases and aldehyde oxidase in the biotransformation of the insecticide fenthion. Toxicol Appl Pharmacol. 2008 Dec 1;233(2):343-52.
DMKEG49	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18845175

DM4OLRS	DI	DM4OLRS
DM4OLRS	DN	Fenthion sulfoxide
DM4OLRS	MI	DEJVYAZ
DM4OLRS	MN	Cytochrome P450 2A6 (CYP2A6)
DM4OLRS	MT	DME
DM4OLRS	MA	Metabolism
DM4OLRS	RN	The participation of human hepatic P450 isoforms, flavin-containing monooxygenases and aldehyde oxidase in the biotransformation of the insecticide fenthion. Toxicol Appl Pharmacol. 2008 Dec 1;233(2):343-52.
DM4OLRS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18845175

DM1TH08	DI	DM1TH08
DM1TH08	DN	Ferricyanide
DM1TH08	MI	DE4A3BL
DM1TH08	MN	Diaphorase-1 (CYB5R3)
DM1TH08	MT	DME
DM1TH08	MA	Metabolism
DM1TH08	RN	Expression of a novel P275L variant of NADH:cytochrome b5 reductase gives functional insight into the conserved motif important for pyridine nucleotide binding. Arch Biochem Biophys. 2006 Mar 1;447(1):59-67.
DM1TH08	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16469290

DM1TH08	DI	DM1TH08
DM1TH08	DN	Ferricyanide
DM1TH08	MI	DE6NIY9
DM1TH08	MN	Methionine synthase reductase (MTRR)
DM1TH08	MT	DME
DM1TH08	MA	Metabolism
DM1TH08	RN	Differences in the efficiency of reductive activation of methionine synthase and exogenous electron acceptors between the common polymorphic variants of human methionine synthase reductase. Biochemistry. 2002 Nov 12;41(45):13378-85.
DM1TH08	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12416982

DMO1N2T	DI	DMO1N2T
DMO1N2T	DN	FETAV
DMO1N2T	MI	TT9PB26
DMO1N2T	MN	Presynaptic density protein 95 (DLG4)
DMO1N2T	MT	DTT
DMO1N2T	MA	Inhibitor
DMO1N2T	RN	Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem. 2008 Oct 23;51(20):6450-9.
DMO1N2T	RU	https://pubmed.ncbi.nlm.nih.gov/18811137

DMWCLQ5	DI	DMWCLQ5
DMWCLQ5	DN	Fexaramine
DMWCLQ5	MI	TTS4UGC
DMWCLQ5	MN	Farnesoid X-activated receptor (FXR)
DMWCLQ5	MT	DTT
DMWCLQ5	MA	Inhibitor
DMWCLQ5	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMWCLQ5	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM1NL3Z	DI	DM1NL3Z
DM1NL3Z	DN	FG-5893
DM1NL3Z	MI	TTSQIFT
DM1NL3Z	MN	5-HT 1A receptor (HTR1A)
DM1NL3Z	MT	DTT
DM1NL3Z	MA	Agonist
DM1NL3Z	RN	Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol. 1998 Aug 21;355(2-3):245-56.
DM1NL3Z	RU	https://pubmed.ncbi.nlm.nih.gov/9760039

DML9IGY	DI	DML9IGY
DML9IGY	DN	FGGFTCARKCARK
DML9IGY	MI	TTNT7K8
DML9IGY	MN	Nociceptin receptor (OPRL1)
DML9IGY	MT	DTT
DML9IGY	MA	Inhibitor
DML9IGY	RN	Structure-activity studies on nociceptin analogues: ORL1 receptor binding and biological activity of cyclic disulfide-containing analogues of nocic... J Med Chem. 2001 Nov 8;44(23):4015-8.
DML9IGY	RU	https://pubmed.ncbi.nlm.nih.gov/11689089

DMMV061	DI	DMMV061
DMMV061	DN	F-G-G-F-T-G-Aib-R-K-S-Aib-R-K-L-A-N-Q-CONH2
DMMV061	MI	TTNT7K8
DMMV061	MN	Nociceptin receptor (OPRL1)
DMMV061	MT	DTT
DMMV061	MA	Inhibitor
DMMV061	RN	Novel, potent ORL-1 receptor agonist peptides containing alpha-Helix-promoting conformational constraints. J Med Chem. 2002 Nov 21;45(24):5280-6.
DMMV061	RU	https://pubmed.ncbi.nlm.nih.gov/12431054

DMN7501	DI	DMN7501
DMN7501	DN	F-G-G-F-T-G-Aib-R-K-S-A-R-K-L-A-N-Q-CONH2
DMN7501	MI	TTNT7K8
DMN7501	MN	Nociceptin receptor (OPRL1)
DMN7501	MT	DTT
DMN7501	MA	Inhibitor
DMN7501	RN	Novel, potent ORL-1 receptor agonist peptides containing alpha-Helix-promoting conformational constraints. J Med Chem. 2002 Nov 21;45(24):5280-6.
DMN7501	RU	https://pubmed.ncbi.nlm.nih.gov/12431054

DMU3IJL	DI	DMU3IJL
DMU3IJL	DN	F-G-G-F-T-G-Aib-R-K-S-A-R-K-L-A-N-Q-COOH
DMU3IJL	MI	TTNT7K8
DMU3IJL	MN	Nociceptin receptor (OPRL1)
DMU3IJL	MT	DTT
DMU3IJL	MA	Inhibitor
DMU3IJL	RN	Novel, potent ORL-1 receptor agonist peptides containing alpha-Helix-promoting conformational constraints. J Med Chem. 2002 Nov 21;45(24):5280-6.
DMU3IJL	RU	https://pubmed.ncbi.nlm.nih.gov/12431054

DMTEO35	DI	DMTEO35
DMTEO35	DN	FGGFTGARKCARKC
DMTEO35	MI	TTNT7K8
DMTEO35	MN	Nociceptin receptor (OPRL1)
DMTEO35	MT	DTT
DMTEO35	MA	Inhibitor
DMTEO35	RN	Structure-activity studies on nociceptin analogues: ORL1 receptor binding and biological activity of cyclic disulfide-containing analogues of nocic... J Med Chem. 2001 Nov 8;44(23):4015-8.
DMTEO35	RU	https://pubmed.ncbi.nlm.nih.gov/11689089

DMIFKPE	DI	DMIFKPE
DMIFKPE	DN	FGGFTGARKRKRKLANQ
DMIFKPE	MI	TTNT7K8
DMIFKPE	MN	Nociceptin receptor (OPRL1)
DMIFKPE	MT	DTT
DMIFKPE	MA	Inhibitor
DMIFKPE	RN	Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem. 2008 Oct 15;16(20):9261-7.
DMIFKPE	RU	https://pubmed.ncbi.nlm.nih.gov/18818087

DM9H80P	DI	DM9H80P
DM9H80P	DN	F-G-G-F-T-G-A-R-K-S-Aib-R-K-L-A-N-Q-CONH2
DM9H80P	MI	TTNT7K8
DM9H80P	MN	Nociceptin receptor (OPRL1)
DM9H80P	MT	DTT
DM9H80P	MA	Inhibitor
DM9H80P	RN	Novel, potent ORL-1 receptor agonist peptides containing alpha-Helix-promoting conformational constraints. J Med Chem. 2002 Nov 21;45(24):5280-6.
DM9H80P	RU	https://pubmed.ncbi.nlm.nih.gov/12431054

DMPRZ8N	DI	DMPRZ8N
DMPRZ8N	DN	F-G-G-F-T-G-A-R-K-S-Aib-R-K-L-A-N-Q-COOH
DMPRZ8N	MI	TTNT7K8
DMPRZ8N	MN	Nociceptin receptor (OPRL1)
DMPRZ8N	MT	DTT
DMPRZ8N	MA	Inhibitor
DMPRZ8N	RN	Novel, potent ORL-1 receptor agonist peptides containing alpha-Helix-promoting conformational constraints. J Med Chem. 2002 Nov 21;45(24):5280-6.
DMPRZ8N	RU	https://pubmed.ncbi.nlm.nih.gov/12431054

DM5W1VF	DI	DM5W1VF
DM5W1VF	DN	FGGFTGARKSARKAANQ
DM5W1VF	MI	TTNT7K8
DM5W1VF	MN	Nociceptin receptor (OPRL1)
DM5W1VF	MT	DTT
DM5W1VF	MA	Inhibitor
DM5W1VF	RN	Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem. 2008 Oct 15;16(20):9261-7.
DM5W1VF	RU	https://pubmed.ncbi.nlm.nih.gov/18818087

DMYJTZ7	DI	DMYJTZ7
DMYJTZ7	DN	FGGFTGARKSARKFANQ
DMYJTZ7	MI	TTNT7K8
DMYJTZ7	MN	Nociceptin receptor (OPRL1)
DMYJTZ7	MT	DTT
DMYJTZ7	MA	Inhibitor
DMYJTZ7	RN	Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem. 2008 Oct 15;16(20):9261-7.
DMYJTZ7	RU	https://pubmed.ncbi.nlm.nih.gov/18818087

DMHG2TB	DI	DMHG2TB
DMHG2TB	DN	FGGFTGARKSARKKANQ
DMHG2TB	MI	TTNT7K8
DMHG2TB	MN	Nociceptin receptor (OPRL1)
DMHG2TB	MT	DTT
DMHG2TB	MA	Inhibitor
DMHG2TB	RN	Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem. 2008 Oct 15;16(20):9261-7.
DMHG2TB	RU	https://pubmed.ncbi.nlm.nih.gov/18818087

DMY347Q	DI	DMY347Q
DMY347Q	DN	FGGFTGARKSARKKKNQ
DMY347Q	MI	TTNT7K8
DMY347Q	MN	Nociceptin receptor (OPRL1)
DMY347Q	MT	DTT
DMY347Q	MA	Inhibitor
DMY347Q	RN	Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem. 2008 Oct 15;16(20):9261-7.
DMY347Q	RU	https://pubmed.ncbi.nlm.nih.gov/18818087

DMPG8NC	DI	DMPG8NC
DMPG8NC	DN	FGGFTGARKSARKKRNQ
DMPG8NC	MI	TTNT7K8
DMPG8NC	MN	Nociceptin receptor (OPRL1)
DMPG8NC	MT	DTT
DMPG8NC	MA	Inhibitor
DMPG8NC	RN	Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem. 2008 Oct 15;16(20):9261-7.
DMPG8NC	RU	https://pubmed.ncbi.nlm.nih.gov/18818087

DMHD6N7	DI	DMHD6N7
DMHD6N7	DN	FGGFTGARKSARKKWNQ
DMHD6N7	MI	TTNT7K8
DMHD6N7	MN	Nociceptin receptor (OPRL1)
DMHD6N7	MT	DTT
DMHD6N7	MA	Inhibitor
DMHD6N7	RN	Discriminatory synergistic effect of Trp-substitutions in superagonist [(Arg/Lys)(14), (Arg/Lys)(15)]nociceptin on ORL1 receptor binding and activa... Bioorg Med Chem. 2009 Aug 1;17(15):5683-7.
DMHD6N7	RU	https://pubmed.ncbi.nlm.nih.gov/19577933

DM78I2W	DI	DM78I2W
DM78I2W	DN	FGGFTGARKSARKL
DM78I2W	MI	TTNT7K8
DM78I2W	MN	Nociceptin receptor (OPRL1)
DM78I2W	MT	DTT
DM78I2W	MA	Inhibitor
DM78I2W	RN	Structure-activity studies on nociceptin analogues: ORL1 receptor binding and biological activity of cyclic disulfide-containing analogues of nocic... J Med Chem. 2001 Nov 8;44(23):4015-8.
DM78I2W	RU	https://pubmed.ncbi.nlm.nih.gov/11689089

DMS5AH4	DI	DMS5AH4
DMS5AH4	DN	FGGFTGARKSARKLADE
DMS5AH4	MI	TTNT7K8
DMS5AH4	MN	Nociceptin receptor (OPRL1)
DMS5AH4	MT	DTT
DMS5AH4	MA	Inhibitor
DMS5AH4	RN	Structure-activity studies on nociceptin analogues: ORL1 receptor binding and biological activity of cyclic disulfide-containing analogues of nocic... J Med Chem. 2001 Nov 8;44(23):4015-8.
DMS5AH4	RU	https://pubmed.ncbi.nlm.nih.gov/11689089

DMKLSBN	DI	DMKLSBN
DMKLSBN	DN	F-G-G-F-T-G-A-R-K-S-A-R-K-L-Aib-N-Q-CONH2
DMKLSBN	MI	TTNT7K8
DMKLSBN	MN	Nociceptin receptor (OPRL1)
DMKLSBN	MT	DTT
DMKLSBN	MA	Inhibitor
DMKLSBN	RN	Novel, potent ORL-1 receptor agonist peptides containing alpha-Helix-promoting conformational constraints. J Med Chem. 2002 Nov 21;45(24):5280-6.
DMKLSBN	RU	https://pubmed.ncbi.nlm.nih.gov/12431054

DMPDMFA	DI	DMPDMFA
DMPDMFA	DN	F-G-G-F-T-G-A-R-K-S-A-R-K-L-Aib-N-Q-COOH
DMPDMFA	MI	TTNT7K8
DMPDMFA	MN	Nociceptin receptor (OPRL1)
DMPDMFA	MT	DTT
DMPDMFA	MA	Inhibitor
DMPDMFA	RN	Novel, potent ORL-1 receptor agonist peptides containing alpha-Helix-promoting conformational constraints. J Med Chem. 2002 Nov 21;45(24):5280-6.
DMPDMFA	RU	https://pubmed.ncbi.nlm.nih.gov/12431054

DMSMK70	DI	DMSMK70
DMSMK70	DN	FGGFTGARKSARKLARK
DMSMK70	MI	TTNT7K8
DMSMK70	MN	Nociceptin receptor (OPRL1)
DMSMK70	MT	DTT
DMSMK70	MA	Inhibitor
DMSMK70	RN	Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem. 2008 Oct 15;16(20):9261-7.
DMSMK70	RU	https://pubmed.ncbi.nlm.nih.gov/18818087

DMLDWFE	DI	DMLDWFE
DMLDWFE	DN	FGGFTGARKSARKLFNQ
DMLDWFE	MI	TTNT7K8
DMLDWFE	MN	Nociceptin receptor (OPRL1)
DMLDWFE	MT	DTT
DMLDWFE	MA	Inhibitor
DMLDWFE	RN	Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem. 2008 Oct 15;16(20):9261-7.
DMLDWFE	RU	https://pubmed.ncbi.nlm.nih.gov/18818087

DMIA2XJ	DI	DMIA2XJ
DMIA2XJ	DN	FGGFTGARKSARKLKNQ
DMIA2XJ	MI	TTNT7K8
DMIA2XJ	MN	Nociceptin receptor (OPRL1)
DMIA2XJ	MT	DTT
DMIA2XJ	MA	Inhibitor
DMIA2XJ	RN	Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem. 2008 Oct 15;16(20):9261-7.
DMIA2XJ	RU	https://pubmed.ncbi.nlm.nih.gov/18818087

DMRVSXG	DI	DMRVSXG
DMRVSXG	DN	FGGFTGARKSARKLLNQ
DMRVSXG	MI	TTNT7K8
DMRVSXG	MN	Nociceptin receptor (OPRL1)
DMRVSXG	MT	DTT
DMRVSXG	MA	Inhibitor
DMRVSXG	RN	Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem. 2008 Oct 15;16(20):9261-7.
DMRVSXG	RU	https://pubmed.ncbi.nlm.nih.gov/18818087

DMD9SOF	DI	DMD9SOF
DMD9SOF	DN	F-G-G-F-T-G-A-R-K-S-A-R-K-L-MeA-N-Q-CONH2
DMD9SOF	MI	TTNT7K8
DMD9SOF	MN	Nociceptin receptor (OPRL1)
DMD9SOF	MT	DTT
DMD9SOF	MA	Inhibitor
DMD9SOF	RN	Novel, potent ORL-1 receptor agonist peptides containing alpha-Helix-promoting conformational constraints. J Med Chem. 2002 Nov 21;45(24):5280-6.
DMD9SOF	RU	https://pubmed.ncbi.nlm.nih.gov/12431054

DMCSN9M	DI	DMCSN9M
DMCSN9M	DN	F-G-G-F-T-G-A-R-K-S-A-R-K-L-MeA-N-Q-COOH
DMCSN9M	MI	TTNT7K8
DMCSN9M	MN	Nociceptin receptor (OPRL1)
DMCSN9M	MT	DTT
DMCSN9M	MA	Inhibitor
DMCSN9M	RN	Novel, potent ORL-1 receptor agonist peptides containing alpha-Helix-promoting conformational constraints. J Med Chem. 2002 Nov 21;45(24):5280-6.
DMCSN9M	RU	https://pubmed.ncbi.nlm.nih.gov/12431054

DMCSTP5	DI	DMCSTP5
DMCSTP5	DN	FGGFTGARKSARKLRNQ
DMCSTP5	MI	TTNT7K8
DMCSTP5	MN	Nociceptin receptor (OPRL1)
DMCSTP5	MT	DTT
DMCSTP5	MA	Inhibitor
DMCSTP5	RN	Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem. 2008 Oct 15;16(20):9261-7.
DMCSTP5	RU	https://pubmed.ncbi.nlm.nih.gov/18818087

DMDEJS6	DI	DMDEJS6
DMDEJS6	DN	FGGFTGARKSARKLVNQ
DMDEJS6	MI	TTNT7K8
DMDEJS6	MN	Nociceptin receptor (OPRL1)
DMDEJS6	MT	DTT
DMDEJS6	MA	Inhibitor
DMDEJS6	RN	Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem. 2008 Oct 15;16(20):9261-7.
DMDEJS6	RU	https://pubmed.ncbi.nlm.nih.gov/18818087

DMV34KQ	DI	DMV34KQ
DMV34KQ	DN	FGGFTGARKSARKLWNQ
DMV34KQ	MI	TTNT7K8
DMV34KQ	MN	Nociceptin receptor (OPRL1)
DMV34KQ	MT	DTT
DMV34KQ	MA	Inhibitor
DMV34KQ	RN	Discriminatory synergistic effect of Trp-substitutions in superagonist [(Arg/Lys)(14), (Arg/Lys)(15)]nociceptin on ORL1 receptor binding and activa... Bioorg Med Chem. 2009 Aug 1;17(15):5683-7.
DMV34KQ	RU	https://pubmed.ncbi.nlm.nih.gov/19577933

DMG5LXT	DI	DMG5LXT
DMG5LXT	DN	FGGFTGARKSARKLYNQ
DMG5LXT	MI	TTNT7K8
DMG5LXT	MN	Nociceptin receptor (OPRL1)
DMG5LXT	MT	DTT
DMG5LXT	MA	Inhibitor
DMG5LXT	RN	Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem. 2008 Oct 15;16(20):9261-7.
DMG5LXT	RU	https://pubmed.ncbi.nlm.nih.gov/18818087

DM21XBO	DI	DM21XBO
DM21XBO	DN	FGGFTGARKSARKRANQ
DM21XBO	MI	TTNT7K8
DM21XBO	MN	Nociceptin receptor (OPRL1)
DM21XBO	MT	DTT
DM21XBO	MA	Inhibitor
DM21XBO	RN	Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem. 2008 Oct 15;16(20):9261-7.
DM21XBO	RU	https://pubmed.ncbi.nlm.nih.gov/18818087

DM9RHXC	DI	DM9RHXC
DM9RHXC	DN	FGGFTGARKSARKRKNQ
DM9RHXC	MI	TTNT7K8
DM9RHXC	MN	Nociceptin receptor (OPRL1)
DM9RHXC	MT	DTT
DM9RHXC	MA	Inhibitor
DM9RHXC	RN	Discriminatory synergistic effect of Trp-substitutions in superagonist [(Arg/Lys)(14), (Arg/Lys)(15)]nociceptin on ORL1 receptor binding and activa... Bioorg Med Chem. 2009 Aug 1;17(15):5683-7.
DM9RHXC	RU	https://pubmed.ncbi.nlm.nih.gov/19577933

DMWK0Z6	DI	DMWK0Z6
DMWK0Z6	DN	FGGFTGARKSARKRKRK
DMWK0Z6	MI	TTNT7K8
DMWK0Z6	MN	Nociceptin receptor (OPRL1)
DMWK0Z6	MT	DTT
DMWK0Z6	MA	Inhibitor
DMWK0Z6	RN	Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem. 2008 Oct 15;16(20):9261-7.
DMWK0Z6	RU	https://pubmed.ncbi.nlm.nih.gov/18818087

DMDMT5U	DI	DMDMT5U
DMDMT5U	DN	FGGFTGARKSARKRRNQ
DMDMT5U	MI	TTNT7K8
DMDMT5U	MN	Nociceptin receptor (OPRL1)
DMDMT5U	MT	DTT
DMDMT5U	MA	Inhibitor
DMDMT5U	RN	Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem. 2008 Oct 15;16(20):9261-7.
DMDMT5U	RU	https://pubmed.ncbi.nlm.nih.gov/18818087

DMEGW7F	DI	DMEGW7F
DMEGW7F	DN	FGGFTGARKSARKRWNQ
DMEGW7F	MI	TTNT7K8
DMEGW7F	MN	Nociceptin receptor (OPRL1)
DMEGW7F	MT	DTT
DMEGW7F	MA	Inhibitor
DMEGW7F	RN	Discriminatory synergistic effect of Trp-substitutions in superagonist [(Arg/Lys)(14), (Arg/Lys)(15)]nociceptin on ORL1 receptor binding and activa... Bioorg Med Chem. 2009 Aug 1;17(15):5683-7.
DMEGW7F	RU	https://pubmed.ncbi.nlm.nih.gov/19577933

DM1QTN5	DI	DM1QTN5
DM1QTN5	DN	FGGFTGARKSARKVANQ
DM1QTN5	MI	TTNT7K8
DM1QTN5	MN	Nociceptin receptor (OPRL1)
DM1QTN5	MT	DTT
DM1QTN5	MA	Inhibitor
DM1QTN5	RN	Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem. 2008 Oct 15;16(20):9261-7.
DM1QTN5	RU	https://pubmed.ncbi.nlm.nih.gov/18818087

DMM17AO	DI	DMM17AO
DMM17AO	DN	FGGFTGARKSARKWANQ
DMM17AO	MI	TTNT7K8
DMM17AO	MN	Nociceptin receptor (OPRL1)
DMM17AO	MT	DTT
DMM17AO	MA	Inhibitor
DMM17AO	RN	Discriminatory synergistic effect of Trp-substitutions in superagonist [(Arg/Lys)(14), (Arg/Lys)(15)]nociceptin on ORL1 receptor binding and activa... Bioorg Med Chem. 2009 Aug 1;17(15):5683-7.
DMM17AO	RU	https://pubmed.ncbi.nlm.nih.gov/19577933

DM1YN0F	DI	DM1YN0F
DM1YN0F	DN	FGGFTGARKSARKWKNQ
DM1YN0F	MI	TTNT7K8
DM1YN0F	MN	Nociceptin receptor (OPRL1)
DM1YN0F	MT	DTT
DM1YN0F	MA	Inhibitor
DM1YN0F	RN	Discriminatory synergistic effect of Trp-substitutions in superagonist [(Arg/Lys)(14), (Arg/Lys)(15)]nociceptin on ORL1 receptor binding and activa... Bioorg Med Chem. 2009 Aug 1;17(15):5683-7.
DM1YN0F	RU	https://pubmed.ncbi.nlm.nih.gov/19577933

DMRLZKJ	DI	DMRLZKJ
DMRLZKJ	DN	FGGFTGARKSARKWRNQ
DMRLZKJ	MI	TTNT7K8
DMRLZKJ	MN	Nociceptin receptor (OPRL1)
DMRLZKJ	MT	DTT
DMRLZKJ	MA	Inhibitor
DMRLZKJ	RN	Discriminatory synergistic effect of Trp-substitutions in superagonist [(Arg/Lys)(14), (Arg/Lys)(15)]nociceptin on ORL1 receptor binding and activa... Bioorg Med Chem. 2009 Aug 1;17(15):5683-7.
DMRLZKJ	RU	https://pubmed.ncbi.nlm.nih.gov/19577933

DM5FRXN	DI	DM5FRXN
DM5FRXN	DN	FGGFTGARKSARKYANQ
DM5FRXN	MI	TTNT7K8
DM5FRXN	MN	Nociceptin receptor (OPRL1)
DM5FRXN	MT	DTT
DM5FRXN	MA	Inhibitor
DM5FRXN	RN	Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem. 2008 Oct 15;16(20):9261-7.
DM5FRXN	RU	https://pubmed.ncbi.nlm.nih.gov/18818087

DMV3ZF1	DI	DMV3ZF1
DMV3ZF1	DN	F-G-G-F-T-G-A-R-K-S-MeA-R-K-L-A-N-Q-CONH2
DMV3ZF1	MI	TTNT7K8
DMV3ZF1	MN	Nociceptin receptor (OPRL1)
DMV3ZF1	MT	DTT
DMV3ZF1	MA	Inhibitor
DMV3ZF1	RN	Novel, potent ORL-1 receptor agonist peptides containing alpha-Helix-promoting conformational constraints. J Med Chem. 2002 Nov 21;45(24):5280-6.
DMV3ZF1	RU	https://pubmed.ncbi.nlm.nih.gov/12431054

DMZI6RD	DI	DMZI6RD
DMZI6RD	DN	F-G-G-F-T-G-A-R-K-S-MeA-R-K-L-A-N-Q-COOH
DMZI6RD	MI	TTNT7K8
DMZI6RD	MN	Nociceptin receptor (OPRL1)
DMZI6RD	MT	DTT
DMZI6RD	MA	Inhibitor
DMZI6RD	RN	Novel, potent ORL-1 receptor agonist peptides containing alpha-Helix-promoting conformational constraints. J Med Chem. 2002 Nov 21;45(24):5280-6.
DMZI6RD	RU	https://pubmed.ncbi.nlm.nih.gov/12431054

DM2PYE7	DI	DM2PYE7
DM2PYE7	DN	FGGFTGCRKSARKC
DM2PYE7	MI	TTNT7K8
DM2PYE7	MN	Nociceptin receptor (OPRL1)
DM2PYE7	MT	DTT
DM2PYE7	MA	Inhibitor
DM2PYE7	RN	Structure-activity studies on nociceptin analogues: ORL1 receptor binding and biological activity of cyclic disulfide-containing analogues of nocic... J Med Chem. 2001 Nov 8;44(23):4015-8.
DM2PYE7	RU	https://pubmed.ncbi.nlm.nih.gov/11689089

DMQX2GK	DI	DMQX2GK
DMQX2GK	DN	FGGFTGCRKSCRK
DMQX2GK	MI	TTNT7K8
DMQX2GK	MN	Nociceptin receptor (OPRL1)
DMQX2GK	MT	DTT
DMQX2GK	MA	Inhibitor
DMQX2GK	RN	Structure-activity studies on nociceptin analogues: ORL1 receptor binding and biological activity of cyclic disulfide-containing analogues of nocic... J Med Chem. 2001 Nov 8;44(23):4015-8.
DMQX2GK	RU	https://pubmed.ncbi.nlm.nih.gov/11689089

DMPHIBZ	DI	DMPHIBZ
DMPHIBZ	DN	F-G-G-F-T-G-MeA-R-K-S-A-R-K-L-A-N-Q-CONH2
DMPHIBZ	MI	TTNT7K8
DMPHIBZ	MN	Nociceptin receptor (OPRL1)
DMPHIBZ	MT	DTT
DMPHIBZ	MA	Inhibitor
DMPHIBZ	RN	Novel, potent ORL-1 receptor agonist peptides containing alpha-Helix-promoting conformational constraints. J Med Chem. 2002 Nov 21;45(24):5280-6.
DMPHIBZ	RU	https://pubmed.ncbi.nlm.nih.gov/12431054

DMXH2D8	DI	DMXH2D8
DMXH2D8	DN	F-G-G-F-T-G-MeA-R-K-S-A-R-K-L-A-N-Q-COOH
DMXH2D8	MI	TTNT7K8
DMXH2D8	MN	Nociceptin receptor (OPRL1)
DMXH2D8	MT	DTT
DMXH2D8	MA	Inhibitor
DMXH2D8	RN	Novel, potent ORL-1 receptor agonist peptides containing alpha-Helix-promoting conformational constraints. J Med Chem. 2002 Nov 21;45(24):5280-6.
DMXH2D8	RU	https://pubmed.ncbi.nlm.nih.gov/12431054

DMD9UQN	DI	DMD9UQN
DMD9UQN	DN	FGGFTRKRKSARKLANQ
DMD9UQN	MI	TTNT7K8
DMD9UQN	MN	Nociceptin receptor (OPRL1)
DMD9UQN	MT	DTT
DMD9UQN	MA	Inhibitor
DMD9UQN	RN	Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem. 2008 Oct 15;16(20):9261-7.
DMD9UQN	RU	https://pubmed.ncbi.nlm.nih.gov/18818087

DM4T5DY	DI	DM4T5DY
DM4T5DY	DN	FGIN-1-27
DM4T5DY	MI	TTPTXIN
DM4T5DY	MN	Translocator protein (TSPO)
DM4T5DY	MT	DTT
DM4T5DY	MA	Binder
DM4T5DY	RN	Specific ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in human colorectal cancer cells. Br J Cancer. 2001 Nov 30;85(11):1771-80.
DM4T5DY	RU	https://pubmed.ncbi.nlm.nih.gov/11742501

DMH7LDX	DI	DMH7LDX
DMH7LDX	DN	FHT-2107
DMH7LDX	MI	TTGKNB4
DMH7LDX	MN	Epidermal growth factor receptor (EGFR)
DMH7LDX	MT	DTT
DMH7LDX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
DMH7LDX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797

DMFNTMY	DI	DMFNTMY
DMFNTMY	DN	Fibrates
DMFNTMY	MI	TTJ584C
DMFNTMY	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMFNTMY	MT	DTT
DMFNTMY	MA	Agonist
DMFNTMY	RN	Emerging antidyslipidemic drugs. Expert Opin Emerg Drugs. 2008 Jun;13(2):363-81.
DMFNTMY	RU	https://pubmed.ncbi.nlm.nih.gov/18537526

DMUX702	DI	DMUX702
DMUX702	DN	Fibronectin extra domain A
DMUX702	MI	TTISGCA
DMUX702	MN	Toll-like receptor 4 (TLR4)
DMUX702	MT	DTT
DMUX702	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1754).
DMUX702	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1754

DMETVLB	DI	DMETVLB
DMETVLB	DN	Fidarestat(Stereoisomer)
DMETVLB	MI	TTFBNVI
DMETVLB	MN	Aldose reductase (AKR1B1)
DMETVLB	MT	DTT
DMETVLB	MA	Inhibitor
DMETVLB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMETVLB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM29TVC	DI	DM29TVC
DM29TVC	DN	FIG 1
DM29TVC	MI	TTN7BL9
DM29TVC	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DM29TVC	MT	DTT
DM29TVC	MA	Inhibitor
DM29TVC	RN	4-Methyl-5-phenyl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type I. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3405-11.
DM29TVC	RU	https://pubmed.ncbi.nlm.nih.gov/18440811

DMP6GNY	DI	DMP6GNY
DMP6GNY	DN	Firocoxib
DMP6GNY	MI	TTVKILB
DMP6GNY	MN	Prostaglandin G/H synthase 2 (COX-2)
DMP6GNY	MT	DTT
DMP6GNY	MA	Inhibitor
DMP6GNY	RN	SAR in the alkoxy lactone series: the discovery of DFP, a potent and orally active COX-2 inhibitor. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2207-12.
DMP6GNY	RU	https://pubmed.ncbi.nlm.nih.gov/10465547

DMW2VOX	DI	DMW2VOX
DMW2VOX	DN	FITC-LMNNAEHINQFYMFI
DMW2VOX	MI	TT7EASG
DMW2VOX	MN	Plasmodium Cysteine protease falcipain-2 (Malaria CPF2)
DMW2VOX	MT	DTT
DMW2VOX	MA	Inhibitor
DMW2VOX	RN	A prodomain peptide of Plasmodium falciparum cysteine protease (falcipain-2) inhibits malaria parasite development. J Med Chem. 2008 Jun 12;51(11):3116-23.
DMW2VOX	RU	https://pubmed.ncbi.nlm.nih.gov/18461922

DM9K834	DI	DM9K834
DM9K834	DN	FKB-001
DM9K834	MI	TTMW94E
DM9K834	MN	FK506-binding protein 1A (FKBP1A)
DM9K834	MT	DTT
DM9K834	MA	Inhibitor
DM9K834	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9K834	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMO7U62	DI	DMO7U62
DMO7U62	DN	FL104
DMO7U62	MI	TTW5UDX
DMO7U62	MN	Urotensin II receptor (UTS2R)
DMO7U62	MT	DTT
DMO7U62	MA	Agonist
DMO7U62	RN	Novel and potent small-molecule urotensin II receptor agonists. Bioorg Med Chem. 2009 Jul 1;17(13):4657-65.
DMO7U62	RU	https://pubmed.ncbi.nlm.nih.gov/19481466

DMNWIYM	DI	DMNWIYM
DMNWIYM	DN	Flavanone
DMNWIYM	MI	DEUX61H
DMNWIYM	MN	Biphenyl dioxygenase (bphC)
DMNWIYM	MT	DME
DMNWIYM	MA	Metabolism
DMNWIYM	RN	Flavonoids biotransformation by bacterial non-heme dioxygenases, biphenyl and naphthalene dioxygenase. Appl Microbiol Biotechnol. 2011 Jul;91(2):219-28.
DMNWIYM	RU	https://pubmed.ncbi.nlm.nih.gov/21626021

DMNWIYM	DI	DMNWIYM
DMNWIYM	DN	Flavanone
DMNWIYM	MI	TTN7BL9
DMNWIYM	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMNWIYM	MT	DTT
DMNWIYM	MA	Inhibitor
DMNWIYM	RN	A rapid screening assay for inhibitors of 11beta-hydroxysteroid dehydrogenases (11beta-HSD): flavanone selectively inhibits 11beta-HSD1 reductase activity. Mol Cell Endocrinol. 2003 Dec 30;212(1-2):41-9.
DMNWIYM	RU	https://pubmed.ncbi.nlm.nih.gov/14654249

DMNWIYM	DI	DMNWIYM
DMNWIYM	DN	Flavanone
DMNWIYM	MI	TTGP7BY
DMNWIYM	MN	Monoamine oxidase type B (MAO-B)
DMNWIYM	MT	DTT
DMNWIYM	MA	Inhibitor
DMNWIYM	RN	A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9.
DMNWIYM	RU	https://pubmed.ncbi.nlm.nih.gov/20045650

DM5S4GK	DI	DM5S4GK
DM5S4GK	DN	Flavin-Adenine Dinucleotide
DM5S4GK	MI	TTNAW8S
DM5S4GK	MN	Bacterial Flavohemoglobin (Bact hmp)
DM5S4GK	MT	DTT
DM5S4GK	MA	Inhibitor
DM5S4GK	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM5S4GK	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM5S4GK	DI	DM5S4GK
DM5S4GK	DN	Flavin-Adenine Dinucleotide
DM5S4GK	MI	TTHDSE2
DM5S4GK	MN	Bacterial Fumarate reductase flavoprotein (Bact frdA)
DM5S4GK	MT	DTT
DM5S4GK	MA	Inhibitor
DM5S4GK	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM5S4GK	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM5S4GK	DI	DM5S4GK
DM5S4GK	DN	Flavin-Adenine Dinucleotide
DM5S4GK	MI	TTAEOJ4
DM5S4GK	MN	Bacterial UDP-N-acetylenolpyruvylglucosamine reductase (Bact murB)
DM5S4GK	MT	DTT
DM5S4GK	MA	Inhibitor
DM5S4GK	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM5S4GK	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM5S4GK	DI	DM5S4GK
DM5S4GK	DN	Flavin-Adenine Dinucleotide
DM5S4GK	MI	TTR7UJ3
DM5S4GK	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DM5S4GK	MT	DTT
DM5S4GK	MA	Inhibitor
DM5S4GK	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM5S4GK	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM5S4GK	DI	DM5S4GK
DM5S4GK	DN	Flavin-Adenine Dinucleotide
DM5S4GK	MI	TTZPS91
DM5S4GK	MN	Dihydrothymine dehydrogenase (DPYD)
DM5S4GK	MT	DTT
DM5S4GK	MA	Inhibitor
DM5S4GK	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM5S4GK	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM5S4GK	DI	DM5S4GK
DM5S4GK	DN	Flavin-Adenine Dinucleotide
DM5S4GK	MI	TTEP6RV
DM5S4GK	MN	Glutathione reductase (GR)
DM5S4GK	MT	DTT
DM5S4GK	MA	Inhibitor
DM5S4GK	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM5S4GK	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM5S4GK	DI	DM5S4GK
DM5S4GK	DN	Flavin-Adenine Dinucleotide
DM5S4GK	MI	TT3WG5C
DM5S4GK	MN	Monoamine oxidase type A (MAO-A)
DM5S4GK	MT	DTT
DM5S4GK	MA	Inhibitor
DM5S4GK	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM5S4GK	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM5S4GK	DI	DM5S4GK
DM5S4GK	DN	Flavin-Adenine Dinucleotide
DM5S4GK	MI	TTGP7BY
DM5S4GK	MN	Monoamine oxidase type B (MAO-B)
DM5S4GK	MT	DTT
DM5S4GK	MA	Inhibitor
DM5S4GK	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM5S4GK	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM5S4GK	DI	DM5S4GK
DM5S4GK	DN	Flavin-Adenine Dinucleotide
DM5S4GK	MI	TTZUFI5
DM5S4GK	MN	Nitric-oxide synthase brain (NOS1)
DM5S4GK	MT	DTT
DM5S4GK	MA	Inhibitor
DM5S4GK	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM5S4GK	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM5S4GK	DI	DM5S4GK
DM5S4GK	DN	Flavin-Adenine Dinucleotide
DM5S4GK	MI	TT8XK6L
DM5S4GK	MN	Quinone reductase 1 (NQO1)
DM5S4GK	MT	DTT
DM5S4GK	MA	Inhibitor
DM5S4GK	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM5S4GK	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM5S4GK	DI	DM5S4GK
DM5S4GK	DN	Flavin-Adenine Dinucleotide
DM5S4GK	MI	TTJLP0R
DM5S4GK	MN	Quinone reductase 2 (NQO2)
DM5S4GK	MT	DTT
DM5S4GK	MA	Inhibitor
DM5S4GK	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM5S4GK	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM5S4GK	DI	DM5S4GK
DM5S4GK	DN	Flavin-Adenine Dinucleotide
DM5S4GK	MI	TTBKQL3
DM5S4GK	MN	Trypanosoma Dihydrolipoamide dehydrogenase (Trypano LPD)
DM5S4GK	MT	DTT
DM5S4GK	MA	Inhibitor
DM5S4GK	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM5S4GK	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM5S4GK	DI	DM5S4GK
DM5S4GK	DN	Flavin-Adenine Dinucleotide
DM5S4GK	MI	TTRTKPV
DM5S4GK	MN	Trypanosoma Trypanothione reductase (Trypano TPR)
DM5S4GK	MT	DTT
DM5S4GK	MA	Inhibitor
DM5S4GK	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM5S4GK	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM5S4GK	DI	DM5S4GK
DM5S4GK	DN	Flavin-Adenine Dinucleotide
DM5S4GK	MI	TT7RJY8
DM5S4GK	MN	Xanthine dehydrogenase/oxidase (XDH)
DM5S4GK	MT	DTT
DM5S4GK	MA	Inhibitor
DM5S4GK	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM5S4GK	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMEQH6J	DI	DMEQH6J
DMEQH6J	DN	Flavone
DMEQH6J	MI	TTK25J1
DMEQH6J	MN	Adenosine A1 receptor (ADORA1)
DMEQH6J	MT	DTT
DMEQH6J	MA	Antagonist
DMEQH6J	RN	Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301.
DMEQH6J	RU	https://pubmed.ncbi.nlm.nih.gov/8691424

DMEQH6J	DI	DMEQH6J
DMEQH6J	DN	Flavone
DMEQH6J	MI	TTNE7KG
DMEQH6J	MN	Adenosine A2b receptor (ADORA2B)
DMEQH6J	MT	DTT
DMEQH6J	MA	Antagonist
DMEQH6J	RN	Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301.
DMEQH6J	RU	https://pubmed.ncbi.nlm.nih.gov/8691424

DMEQH6J	DI	DMEQH6J
DMEQH6J	DN	Flavone
DMEQH6J	MI	TTJFY5U
DMEQH6J	MN	Adenosine A3 receptor (ADORA3)
DMEQH6J	MT	DTT
DMEQH6J	MA	Antagonist
DMEQH6J	RN	Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301.
DMEQH6J	RU	https://pubmed.ncbi.nlm.nih.gov/8691424

DMEQH6J	DI	DMEQH6J
DMEQH6J	DN	Flavone
DMEQH6J	MI	TTKPW01
DMEQH6J	MN	Androgen receptor messenger RNA (AR mRNA)
DMEQH6J	MT	DTT
DMEQH6J	MA	Inhibitor
DMEQH6J	RN	Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4706-10.
DMEQH6J	RU	https://pubmed.ncbi.nlm.nih.gov/19592245

DMEQH6J	DI	DMEQH6J
DMEQH6J	DN	Flavone
DMEQH6J	MI	TTSZLWK
DMEQH6J	MN	Aromatase (CYP19A1)
DMEQH6J	MT	DTT
DMEQH6J	MA	Inhibitor
DMEQH6J	RN	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
DMEQH6J	RU	https://pubmed.ncbi.nlm.nih.gov/20413308

DMEQH6J	DI	DMEQH6J
DMEQH6J	DN	Flavone
DMEQH6J	MI	DEUX61H
DMEQH6J	MN	Biphenyl dioxygenase (bphC)
DMEQH6J	MT	DME
DMEQH6J	MA	Metabolism
DMEQH6J	RN	Flavonoids biotransformation by bacterial non-heme dioxygenases, biphenyl and naphthalene dioxygenase. Appl Microbiol Biotechnol. 2011 Jul;91(2):219-28.
DMEQH6J	RU	https://pubmed.ncbi.nlm.nih.gov/21626021

DMEQH6J	DI	DMEQH6J
DMEQH6J	DN	Flavone
DMEQH6J	MI	DEJVYAZ
DMEQH6J	MN	Cytochrome P450 2A6 (CYP2A6)
DMEQH6J	MT	DME
DMEQH6J	MA	Metabolism
DMEQH6J	RN	Site-specific oxidation of flavanone and flavone by cytochrome P450 2A6 in human liver microsomes. Xenobiotica. 2019 Jul;49(7):791-802.
DMEQH6J	RU	https://pubmed.ncbi.nlm.nih.gov/30048196

DMEQH6J	DI	DMEQH6J
DMEQH6J	DN	Flavone
DMEQH6J	MI	TT1MPAY
DMEQH6J	MN	GABA(A) receptor alpha-1 (GABRA1)
DMEQH6J	MT	DTT
DMEQH6J	MA	Inhibitor
DMEQH6J	RN	Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997).
DMEQH6J	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97003430

DMEQH6J	DI	DMEQH6J
DMEQH6J	DN	Flavone
DMEQH6J	MI	TTNJYV2
DMEQH6J	MN	Gamma-aminobutyric acid receptor (GAR)
DMEQH6J	MT	DTT
DMEQH6J	MA	Inhibitor
DMEQH6J	RN	Refinement and evaluation of a pharmacophore model for flavone derivatives binding to the benzodiazepine site of the GABA(A) receptor. J Med Chem. 2002 Sep 12;45(19):4188-201.
DMEQH6J	RU	https://pubmed.ncbi.nlm.nih.gov/12213060

DMEQH6J	DI	DMEQH6J
DMEQH6J	DN	Flavone
DMEQH6J	MI	DEE76YZ
DMEQH6J	MN	Naphthalene dioxygenase (doxB)
DMEQH6J	MT	DME
DMEQH6J	MA	Metabolism
DMEQH6J	RN	Flavonoids biotransformation by bacterial non-heme dioxygenases, biphenyl and naphthalene dioxygenase. Appl Microbiol Biotechnol. 2011 Jul;91(2):219-28.
DMEQH6J	RU	https://pubmed.ncbi.nlm.nih.gov/21626021

DMQSDM7	DI	DMQSDM7
DMQSDM7	DN	FLUANISONE
DMQSDM7	MI	TTJQOD7
DMQSDM7	MN	5-HT 2A receptor (HTR2A)
DMQSDM7	MT	DTT
DMQSDM7	MA	Inhibitor
DMQSDM7	RN	2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 1. J Med Chem. 1987 Nov;30(11):2099-104.
DMQSDM7	RU	https://pubmed.ncbi.nlm.nih.gov/2889830

DMQSDM7	DI	DMQSDM7
DMQSDM7	DN	FLUANISONE
DMQSDM7	MI	TTNGILX
DMQSDM7	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMQSDM7	MT	DTT
DMQSDM7	MA	Inhibitor
DMQSDM7	RN	2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 1. J Med Chem. 1987 Nov;30(11):2099-104.
DMQSDM7	RU	https://pubmed.ncbi.nlm.nih.gov/2889830

DMQSDM7	DI	DMQSDM7
DMQSDM7	DN	FLUANISONE
DMQSDM7	MI	TTBRKXS
DMQSDM7	MN	Adrenergic receptor alpha-1B (ADRA1B)
DMQSDM7	MT	DTT
DMQSDM7	MA	Inhibitor
DMQSDM7	RN	2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 1. J Med Chem. 1987 Nov;30(11):2099-104.
DMQSDM7	RU	https://pubmed.ncbi.nlm.nih.gov/2889830

DMQSDM7	DI	DMQSDM7
DMQSDM7	DN	FLUANISONE
DMQSDM7	MI	TT34BHT
DMQSDM7	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMQSDM7	MT	DTT
DMQSDM7	MA	Inhibitor
DMQSDM7	RN	2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 1. J Med Chem. 1987 Nov;30(11):2099-104.
DMQSDM7	RU	https://pubmed.ncbi.nlm.nih.gov/2889830

DMQSDM7	DI	DMQSDM7
DMQSDM7	DN	FLUANISONE
DMQSDM7	MI	TTEX248
DMQSDM7	MN	Dopamine D2 receptor (D2R)
DMQSDM7	MT	DTT
DMQSDM7	MA	Inhibitor
DMQSDM7	RN	2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 1. J Med Chem. 1987 Nov;30(11):2099-104.
DMQSDM7	RU	https://pubmed.ncbi.nlm.nih.gov/2889830

DMN8AP0	DI	DMN8AP0
DMN8AP0	DN	flufenamate
DMN8AP0	MI	TTAHD89
DMN8AP0	MN	Polycystic kidney disease 2-like 1 (TRPP2)
DMN8AP0	MT	DTT
DMN8AP0	MA	Blocker (channel blocker)
DMN8AP0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 505).
DMN8AP0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=505

DMN8AP0	DI	DMN8AP0
DMN8AP0	DN	flufenamate
DMN8AP0	MI	TTRBT3W
DMN8AP0	MN	Short transient receptor potential channel 6 (TRPC6)
DMN8AP0	MT	DTT
DMN8AP0	MA	Activator
DMN8AP0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 491).
DMN8AP0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=491

DMW0HOG	DI	DMW0HOG
DMW0HOG	DN	FLUMEZAPINE
DMW0HOG	MI	TTZFYLI
DMW0HOG	MN	Dopamine D1 receptor (D1R)
DMW0HOG	MT	DTT
DMW0HOG	MA	Inhibitor
DMW0HOG	RN	Effects of conformationally restricted 4-piperazinyl-10H-thienobenzodiazepine neuroleptics on central dopaminergic and cholinergic systems. J Med Chem. 1982 Oct;25(10):1133-40.
DMW0HOG	RU	https://pubmed.ncbi.nlm.nih.gov/6128416

DMW0HOG	DI	DMW0HOG
DMW0HOG	DN	FLUMEZAPINE
DMW0HOG	MI	TTEX248
DMW0HOG	MN	Dopamine D2 receptor (D2R)
DMW0HOG	MT	DTT
DMW0HOG	MA	Inhibitor
DMW0HOG	RN	Synthesis and pharmacological evaluation of a series of 4-piperazinylpyrazolo[3,4-b]- and -[4,3-b][1,5]benzodiazepines as potential anxiolytics. J Med Chem. 1989 Dec;32(12):2573-82.
DMW0HOG	RU	https://pubmed.ncbi.nlm.nih.gov/2573732

DMW0HOG	DI	DMW0HOG
DMW0HOG	DN	FLUMEZAPINE
DMW0HOG	MI	TT4C8EA
DMW0HOG	MN	Dopamine D3 receptor (D3R)
DMW0HOG	MT	DTT
DMW0HOG	MA	Inhibitor
DMW0HOG	RN	Effects of conformationally restricted 4-piperazinyl-10H-thienobenzodiazepine neuroleptics on central dopaminergic and cholinergic systems. J Med Chem. 1982 Oct;25(10):1133-40.
DMW0HOG	RU	https://pubmed.ncbi.nlm.nih.gov/6128416

DMW0HOG	DI	DMW0HOG
DMW0HOG	DN	FLUMEZAPINE
DMW0HOG	MI	TTE0A2F
DMW0HOG	MN	Dopamine D4 receptor (D4R)
DMW0HOG	MT	DTT
DMW0HOG	MA	Inhibitor
DMW0HOG	RN	Effects of conformationally restricted 4-piperazinyl-10H-thienobenzodiazepine neuroleptics on central dopaminergic and cholinergic systems. J Med Chem. 1982 Oct;25(10):1133-40.
DMW0HOG	RU	https://pubmed.ncbi.nlm.nih.gov/6128416

DMW0HOG	DI	DMW0HOG
DMW0HOG	DN	FLUMEZAPINE
DMW0HOG	MI	TTS2PH3
DMW0HOG	MN	Dopamine D5 receptor (D5R)
DMW0HOG	MT	DTT
DMW0HOG	MA	Inhibitor
DMW0HOG	RN	Effects of conformationally restricted 4-piperazinyl-10H-thienobenzodiazepine neuroleptics on central dopaminergic and cholinergic systems. J Med Chem. 1982 Oct;25(10):1133-40.
DMW0HOG	RU	https://pubmed.ncbi.nlm.nih.gov/6128416

DMW0HOG	DI	DMW0HOG
DMW0HOG	DN	FLUMEZAPINE
DMW0HOG	MI	TTZ9SOR
DMW0HOG	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMW0HOG	MT	DTT
DMW0HOG	MA	Inhibitor
DMW0HOG	RN	Synthesis and pharmacological evaluation of a series of 4-piperazinylpyrazolo[3,4-b]- and -[4,3-b][1,5]benzodiazepines as potential anxiolytics. J Med Chem. 1989 Dec;32(12):2573-82.
DMW0HOG	RU	https://pubmed.ncbi.nlm.nih.gov/2573732

DMW0HOG	DI	DMW0HOG
DMW0HOG	DN	FLUMEZAPINE
DMW0HOG	MI	TTYEG6Q
DMW0HOG	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMW0HOG	MT	DTT
DMW0HOG	MA	Inhibitor
DMW0HOG	RN	Synthesis and pharmacological evaluation of a series of 4-piperazinylpyrazolo[3,4-b]- and -[4,3-b][1,5]benzodiazepines as potential anxiolytics. J Med Chem. 1989 Dec;32(12):2573-82.
DMW0HOG	RU	https://pubmed.ncbi.nlm.nih.gov/2573732

DMW0HOG	DI	DMW0HOG
DMW0HOG	DN	FLUMEZAPINE
DMW0HOG	MI	TTQ13Z5
DMW0HOG	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMW0HOG	MT	DTT
DMW0HOG	MA	Inhibitor
DMW0HOG	RN	Synthesis and pharmacological evaluation of a series of 4-piperazinylpyrazolo[3,4-b]- and -[4,3-b][1,5]benzodiazepines as potential anxiolytics. J Med Chem. 1989 Dec;32(12):2573-82.
DMW0HOG	RU	https://pubmed.ncbi.nlm.nih.gov/2573732

DMW0HOG	DI	DMW0HOG
DMW0HOG	DN	FLUMEZAPINE
DMW0HOG	MI	TTQ3JTF
DMW0HOG	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DMW0HOG	MT	DTT
DMW0HOG	MA	Inhibitor
DMW0HOG	RN	Synthesis and pharmacological evaluation of a series of 4-piperazinylpyrazolo[3,4-b]- and -[4,3-b][1,5]benzodiazepines as potential anxiolytics. J Med Chem. 1989 Dec;32(12):2573-82.
DMW0HOG	RU	https://pubmed.ncbi.nlm.nih.gov/2573732

DMW0HOG	DI	DMW0HOG
DMW0HOG	DN	FLUMEZAPINE
DMW0HOG	MI	TTH18TF
DMW0HOG	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMW0HOG	MT	DTT
DMW0HOG	MA	Inhibitor
DMW0HOG	RN	Synthesis and pharmacological evaluation of a series of 4-piperazinylpyrazolo[3,4-b]- and -[4,3-b][1,5]benzodiazepines as potential anxiolytics. J Med Chem. 1989 Dec;32(12):2573-82.
DMW0HOG	RU	https://pubmed.ncbi.nlm.nih.gov/2573732

DMLO9FU	DI	DMLO9FU
DMLO9FU	DN	Fluo-3
DMLO9FU	MI	DTSYQGK
DMLO9FU	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMLO9FU	MT	DTP
DMLO9FU	MA	Substrate
DMLO9FU	RN	Export pumps for anionic conjugates encoded by MRP genes. Adv Enzyme Regul. 1999;39:237-46.
DMLO9FU	RU	http://www.ncbi.nlm.nih.gov/pubmed/10470375

DMLO9FU	DI	DMLO9FU
DMLO9FU	DN	Fluo-3
DMLO9FU	MI	DT3D8F0
DMLO9FU	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMLO9FU	MT	DTP
DMLO9FU	MA	Substrate
DMLO9FU	RN	Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65.
DMLO9FU	RU	http://www.ncbi.nlm.nih.gov/pubmed/18321482

DMLO9FU	DI	DMLO9FU
DMLO9FU	DN	Fluo-3
DMLO9FU	MI	DT9C1TS
DMLO9FU	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMLO9FU	MT	DTP
DMLO9FU	MA	Substrate
DMLO9FU	RN	Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65.
DMLO9FU	RU	http://www.ncbi.nlm.nih.gov/pubmed/18321482

DMJS62X	DI	DMJS62X
DMJS62X	DN	Fluoro loxoprofen
DMJS62X	MI	TTVKILB
DMJS62X	MN	Prostaglandin G/H synthase 2 (COX-2)
DMJS62X	MT	DTT
DMJS62X	MA	Inhibitor
DMJS62X	RN	Properties and synthesis of 2-{2-fluoro (or bromo)-4-[(2-oxocyclopentyl)methyl]phenyl}propanoic acid: nonsteroidal anti-inflammatory drugs with low... J Med Chem. 2010 Nov 11;53(21):7879-82.
DMJS62X	RU	https://pubmed.ncbi.nlm.nih.gov/20954731

DM0LR7G	DI	DM0LR7G
DM0LR7G	DN	FLUORO-NEPLANOCIN A
DM0LR7G	MI	TTE2KUJ
DM0LR7G	MN	Adenosylhomocysteinase (AHCY)
DM0LR7G	MT	DTT
DM0LR7G	MA	Inhibitor
DM0LR7G	RN	Synthesis of 5'-substituted fluoro-neplanocin A analogues: importance of a hydrogen bonding donor at 5'-position for the inhibitory activity of S-a... Bioorg Med Chem Lett. 2004 Nov 15;14(22):5641-4.
DM0LR7G	RU	https://pubmed.ncbi.nlm.nih.gov/15482939

DMIRBYE	DI	DMIRBYE
DMIRBYE	DN	Fluoro-Phosphite Ion
DMIRBYE	MI	TTZHY6R
DMIRBYE	MN	Glycogen phosphorylase muscle form (GP)
DMIRBYE	MT	DTT
DMIRBYE	MA	Inhibitor
DMIRBYE	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMIRBYE	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMELB5S	DI	DMELB5S
DMELB5S	DN	Flupentixole
DMELB5S	MI	TTPC4TU
DMELB5S	MN	5-HT 3A receptor (HTR3A)
DMELB5S	MT	DTT
DMELB5S	MA	Inhibitor
DMELB5S	RN	Molecular properties of psychopharmacological drugs determining non-competitive inhibition of 5-HT3A receptors. Eur J Med Chem. 2009 Jun;44(6):2667-72.
DMELB5S	RU	https://pubmed.ncbi.nlm.nih.gov/19144451

DMELB5S	DI	DMELB5S
DMELB5S	DN	Flupentixole
DMELB5S	MI	DTUGYRD
DMELB5S	MN	P-glycoprotein 1 (ABCB1)
DMELB5S	MT	DTP
DMELB5S	MA	Substrate
DMELB5S	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMELB5S	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMEGL84	DI	DMEGL84
DMEGL84	DN	FLUPERAMIDE
DMEGL84	MI	TTNT7K8
DMEGL84	MN	Nociceptin receptor (OPRL1)
DMEGL84	MT	DTT
DMEGL84	MA	Inhibitor
DMEGL84	RN	Design and synthesis of 4-phenyl piperidine compounds targeting the mu receptor. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5275-9.
DMEGL84	RU	https://pubmed.ncbi.nlm.nih.gov/15454210

DMEGL84	DI	DMEGL84
DMEGL84	DN	FLUPERAMIDE
DMEGL84	MI	TTKWM86
DMEGL84	MN	Opioid receptor mu (MOP)
DMEGL84	MT	DTT
DMEGL84	MA	Inhibitor
DMEGL84	RN	Design and synthesis of 4-phenyl piperidine compounds targeting the mu receptor. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5275-9.
DMEGL84	RU	https://pubmed.ncbi.nlm.nih.gov/15454210

DM9KIPU	DI	DM9KIPU
DM9KIPU	DN	fluperlapine
DM9KIPU	MI	TTJS8PY
DM9KIPU	MN	5-HT 6 receptor (HTR6)
DM9KIPU	MT	DTT
DM9KIPU	MA	Antagonist
DM9KIPU	RN	Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 1994 Mar;268(3):1403-10.
DM9KIPU	RU	https://pubmed.ncbi.nlm.nih.gov/7908055

DM9KIPU	DI	DM9KIPU
DM9KIPU	DN	fluperlapine
DM9KIPU	MI	TTO9X1H
DM9KIPU	MN	5-HT 7 receptor (HTR7)
DM9KIPU	MT	DTT
DM9KIPU	MA	Antagonist
DM9KIPU	RN	Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 1994 Mar;268(3):1403-10.
DM9KIPU	RU	https://pubmed.ncbi.nlm.nih.gov/7908055

DM496RP	DI	DM496RP
DM496RP	DN	Fluphenazine
DM496RP	MI	TTAIY2U
DM496RP	MN	HUMAN clathrin-mediated endocytosis (RME)
DM496RP	MT	DTT
DM496RP	MA	Inhibitor
DM496RP	RN	Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93.
DM496RP	RU	https://pubmed.ncbi.nlm.nih.gov/24841273

DM9Q2PG	DI	DM9Q2PG
DM9Q2PG	DN	fluprostenol
DM9Q2PG	MI	TTPNGDE
DM9Q2PG	MN	Prostaglandin E2 receptor EP3 (PTGER3)
DM9Q2PG	MT	DTT
DM9Q2PG	MA	Agonist
DM9Q2PG	RN	The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
DM9Q2PG	RU	https://pubmed.ncbi.nlm.nih.gov/10634944

DM9Q2PG	DI	DM9Q2PG
DM9Q2PG	DN	fluprostenol
DM9Q2PG	MI	TTT2ZAR
DM9Q2PG	MN	Prostaglandin F2-alpha receptor (PTGFR)
DM9Q2PG	MT	DTT
DM9Q2PG	MA	Agonist
DM9Q2PG	RN	Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
DM9Q2PG	RU	https://pubmed.ncbi.nlm.nih.gov/9313928

DM9Q2PG	DI	DM9Q2PG
DM9Q2PG	DN	fluprostenol
DM9Q2PG	MI	TT2O84V
DM9Q2PG	MN	Thromboxane A2 receptor (TBXA2R)
DM9Q2PG	MT	DTT
DM9Q2PG	MA	Agonist
DM9Q2PG	RN	The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
DM9Q2PG	RU	https://pubmed.ncbi.nlm.nih.gov/10634944

DMUOHVL	DI	DMUOHVL
DMUOHVL	DN	FLUTROLINE
DMUOHVL	MI	TTZFYLI
DMUOHVL	MN	Dopamine D1 receptor (D1R)
DMUOHVL	MT	DTT
DMUOHVL	MA	Inhibitor
DMUOHVL	RN	Neuroleptic activity in 5-aryltetrahydro-gamma-carbolines. J Med Chem. 1980 Jun;23(6):635-43.
DMUOHVL	RU	https://pubmed.ncbi.nlm.nih.gov/6104732

DMUOHVL	DI	DMUOHVL
DMUOHVL	DN	FLUTROLINE
DMUOHVL	MI	TTEX248
DMUOHVL	MN	Dopamine D2 receptor (D2R)
DMUOHVL	MT	DTT
DMUOHVL	MA	Inhibitor
DMUOHVL	RN	Neuroleptic activity in 5-aryltetrahydro-gamma-carbolines. J Med Chem. 1980 Jun;23(6):635-43.
DMUOHVL	RU	https://pubmed.ncbi.nlm.nih.gov/6104732

DMUOHVL	DI	DMUOHVL
DMUOHVL	DN	FLUTROLINE
DMUOHVL	MI	TT4C8EA
DMUOHVL	MN	Dopamine D3 receptor (D3R)
DMUOHVL	MT	DTT
DMUOHVL	MA	Inhibitor
DMUOHVL	RN	Neuroleptic activity in 5-aryltetrahydro-gamma-carbolines. J Med Chem. 1980 Jun;23(6):635-43.
DMUOHVL	RU	https://pubmed.ncbi.nlm.nih.gov/6104732

DMUOHVL	DI	DMUOHVL
DMUOHVL	DN	FLUTROLINE
DMUOHVL	MI	TTE0A2F
DMUOHVL	MN	Dopamine D4 receptor (D4R)
DMUOHVL	MT	DTT
DMUOHVL	MA	Inhibitor
DMUOHVL	RN	Neuroleptic activity in 5-aryltetrahydro-gamma-carbolines. J Med Chem. 1980 Jun;23(6):635-43.
DMUOHVL	RU	https://pubmed.ncbi.nlm.nih.gov/6104732

DMUOHVL	DI	DMUOHVL
DMUOHVL	DN	FLUTROLINE
DMUOHVL	MI	TTS2PH3
DMUOHVL	MN	Dopamine D5 receptor (D5R)
DMUOHVL	MT	DTT
DMUOHVL	MA	Inhibitor
DMUOHVL	RN	Neuroleptic activity in 5-aryltetrahydro-gamma-carbolines. J Med Chem. 1980 Jun;23(6):635-43.
DMUOHVL	RU	https://pubmed.ncbi.nlm.nih.gov/6104732

DMXK6EI	DI	DMXK6EI
DMXK6EI	DN	FM-101
DMXK6EI	MI	TT0E5SK
DMXK6EI	MN	Interleukin 6 receptor (IL6R)
DMXK6EI	MT	DTT
DMXK6EI	MA	Modulator
DMXK6EI	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2310).
DMXK6EI	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2310

DM5782Z	DI	DM5782Z
DM5782Z	DN	FM1-10
DM5782Z	MI	TTZ9SOR
DM5782Z	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DM5782Z	MT	DTT
DM5782Z	MA	Inhibitor
DM5782Z	RN	Design and synthesis of a fluorescent muscarinic antagonist. Bioorg Med Chem Lett. 2008 Jan 15;18(2):825-7.
DM5782Z	RU	https://pubmed.ncbi.nlm.nih.gov/18042383

DM5782Z	DI	DM5782Z
DM5782Z	DN	FM1-10
DM5782Z	MI	TTYEG6Q
DM5782Z	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DM5782Z	MT	DTT
DM5782Z	MA	Inhibitor
DM5782Z	RN	Design and synthesis of a fluorescent muscarinic antagonist. Bioorg Med Chem Lett. 2008 Jan 15;18(2):825-7.
DM5782Z	RU	https://pubmed.ncbi.nlm.nih.gov/18042383

DM5782Z	DI	DM5782Z
DM5782Z	DN	FM1-10
DM5782Z	MI	TTQ13Z5
DM5782Z	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DM5782Z	MT	DTT
DM5782Z	MA	Inhibitor
DM5782Z	RN	Design and synthesis of a fluorescent muscarinic antagonist. Bioorg Med Chem Lett. 2008 Jan 15;18(2):825-7.
DM5782Z	RU	https://pubmed.ncbi.nlm.nih.gov/18042383

DM5782Z	DI	DM5782Z
DM5782Z	DN	FM1-10
DM5782Z	MI	TTQ3JTF
DM5782Z	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DM5782Z	MT	DTT
DM5782Z	MA	Inhibitor
DM5782Z	RN	Design and synthesis of a fluorescent muscarinic antagonist. Bioorg Med Chem Lett. 2008 Jan 15;18(2):825-7.
DM5782Z	RU	https://pubmed.ncbi.nlm.nih.gov/18042383

DM5782Z	DI	DM5782Z
DM5782Z	DN	FM1-10
DM5782Z	MI	TTH18TF
DM5782Z	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DM5782Z	MT	DTT
DM5782Z	MA	Inhibitor
DM5782Z	RN	Design and synthesis of a fluorescent muscarinic antagonist. Bioorg Med Chem Lett. 2008 Jan 15;18(2):825-7.
DM5782Z	RU	https://pubmed.ncbi.nlm.nih.gov/18042383

DMAP8VY	DI	DMAP8VY
DMAP8VY	DN	FM1-43
DMAP8VY	MI	TTZ9SOR
DMAP8VY	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMAP8VY	MT	DTT
DMAP8VY	MA	Inhibitor
DMAP8VY	RN	Design and synthesis of a fluorescent muscarinic antagonist. Bioorg Med Chem Lett. 2008 Jan 15;18(2):825-7.
DMAP8VY	RU	https://pubmed.ncbi.nlm.nih.gov/18042383

DMAP8VY	DI	DMAP8VY
DMAP8VY	DN	FM1-43
DMAP8VY	MI	TTYEG6Q
DMAP8VY	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMAP8VY	MT	DTT
DMAP8VY	MA	Inhibitor
DMAP8VY	RN	Design and synthesis of a fluorescent muscarinic antagonist. Bioorg Med Chem Lett. 2008 Jan 15;18(2):825-7.
DMAP8VY	RU	https://pubmed.ncbi.nlm.nih.gov/18042383

DMAP8VY	DI	DMAP8VY
DMAP8VY	DN	FM1-43
DMAP8VY	MI	TTQ13Z5
DMAP8VY	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMAP8VY	MT	DTT
DMAP8VY	MA	Inhibitor
DMAP8VY	RN	Design and synthesis of a fluorescent muscarinic antagonist. Bioorg Med Chem Lett. 2008 Jan 15;18(2):825-7.
DMAP8VY	RU	https://pubmed.ncbi.nlm.nih.gov/18042383

DMAP8VY	DI	DMAP8VY
DMAP8VY	DN	FM1-43
DMAP8VY	MI	TTQ3JTF
DMAP8VY	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DMAP8VY	MT	DTT
DMAP8VY	MA	Inhibitor
DMAP8VY	RN	Design and synthesis of a fluorescent muscarinic antagonist. Bioorg Med Chem Lett. 2008 Jan 15;18(2):825-7.
DMAP8VY	RU	https://pubmed.ncbi.nlm.nih.gov/18042383

DMAP8VY	DI	DMAP8VY
DMAP8VY	DN	FM1-43
DMAP8VY	MI	TTH18TF
DMAP8VY	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMAP8VY	MT	DTT
DMAP8VY	MA	Inhibitor
DMAP8VY	RN	Design and synthesis of a fluorescent muscarinic antagonist. Bioorg Med Chem Lett. 2008 Jan 15;18(2):825-7.
DMAP8VY	RU	https://pubmed.ncbi.nlm.nih.gov/18042383

DMZRI6H	DI	DMZRI6H
DMZRI6H	DN	FM-303
DMZRI6H	MI	TT6H4QR
DMZRI6H	MN	Interleukin 23 receptor (IL23R)
DMZRI6H	MT	DTT
DMZRI6H	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2293).
DMZRI6H	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2293

DMQ391A	DI	DMQ391A
DMQ391A	DN	Fmet-leu-phe
DMQ391A	MI	TTOJ1NF
DMQ391A	MN	FMLP-related receptor I (FPR2)
DMQ391A	MT	DTT
DMQ391A	MA	Agonist
DMQ391A	RN	Multiple domains of the N-formyl peptide receptor are required for high-affinity ligand binding. Construction and analysis of chimeric N-formyl peptide receptors. J Biol Chem. 1993 Aug 25;268(24):18167-75.
DMQ391A	RU	https://pubmed.ncbi.nlm.nih.gov/8349692

DMQ391A	DI	DMQ391A
DMQ391A	DN	Fmet-leu-phe
DMQ391A	MI	TT5Y4EM
DMQ391A	MN	N-formyl peptide receptor (FPR1)
DMQ391A	MT	DTT
DMQ391A	MA	Agonist
DMQ391A	RN	Further studies on the structural requirements for synthetic peptide chemoattractants. Biochemistry. 1980 May 27;19(11):2404-10.
DMQ391A	RU	https://pubmed.ncbi.nlm.nih.gov/7387981

DMW5V9U	DI	DMW5V9U
DMW5V9U	DN	FMP-825
DMW5V9U	MI	TTMXGCW
DMW5V9U	MN	Adrenergic receptor beta-3 (ADRB3)
DMW5V9U	MT	DTT
DMW5V9U	MA	Agonist
DMW5V9U	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 30).
DMW5V9U	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=30

DMQBTL3	DI	DMQBTL3
DMQBTL3	DN	FMS586
DMQBTL3	MI	TTY6EWA
DMQBTL3	MN	Neuropeptide Y receptor type 5 (NPY5R)
DMQBTL3	MT	DTT
DMQBTL3	MA	Antagonist
DMQBTL3	RN	Pharmacological characterization and feeding-suppressive property of FMS586 [3-(5,6,7,8-tetrahydro-9-isopropyl-carbazol-3-yl)-1-methyl-1-(2-pyridin... J Pharmacol Exp Ther. 2006 May;317(2):562-70.
DMQBTL3	RU	https://pubmed.ncbi.nlm.nih.gov/16436501

DMJ4F3Q	DI	DMJ4F3Q
DMJ4F3Q	DN	Folate gamma-hydroxamic acid
DMJ4F3Q	MI	TTLM12X
DMJ4F3Q	MN	Matrix metalloproteinase-2 (MMP-2)
DMJ4F3Q	MT	DTT
DMJ4F3Q	MA	Inhibitor
DMJ4F3Q	RN	Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74.
DMJ4F3Q	RU	https://pubmed.ncbi.nlm.nih.gov/17127067

DMJ4F3Q	DI	DMJ4F3Q
DMJ4F3Q	DN	Folate gamma-hydroxamic acid
DMJ4F3Q	MI	TTMTWOS
DMJ4F3Q	MN	Matrix metalloproteinase-7 (MMP-7)
DMJ4F3Q	MT	DTT
DMJ4F3Q	MA	Inhibitor
DMJ4F3Q	RN	Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74.
DMJ4F3Q	RU	https://pubmed.ncbi.nlm.nih.gov/17127067

DMJ4F3Q	DI	DMJ4F3Q
DMJ4F3Q	DN	Folate gamma-hydroxamic acid
DMJ4F3Q	MI	TT6X50U
DMJ4F3Q	MN	Matrix metalloproteinase-9 (MMP-9)
DMJ4F3Q	MT	DTT
DMJ4F3Q	MA	Inhibitor
DMJ4F3Q	RN	Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74.
DMJ4F3Q	RU	https://pubmed.ncbi.nlm.nih.gov/17127067

DM76AUO	DI	DM76AUO
DM76AUO	DN	Folate gamma-L-phenylalaninehydroxamic acid
DM76AUO	MI	TTMTWOS
DM76AUO	MN	Matrix metalloproteinase-7 (MMP-7)
DM76AUO	MT	DTT
DM76AUO	MA	Inhibitor
DM76AUO	RN	Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74.
DM76AUO	RU	https://pubmed.ncbi.nlm.nih.gov/17127067

DMH5SQV	DI	DMH5SQV
DMH5SQV	DN	Folate gamma-L-proline-hydroxamic acid
DMH5SQV	MI	TTLM12X
DMH5SQV	MN	Matrix metalloproteinase-2 (MMP-2)
DMH5SQV	MT	DTT
DMH5SQV	MA	Inhibitor
DMH5SQV	RN	Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74.
DMH5SQV	RU	https://pubmed.ncbi.nlm.nih.gov/17127067

DMH5SQV	DI	DMH5SQV
DMH5SQV	DN	Folate gamma-L-proline-hydroxamic acid
DMH5SQV	MI	TTMTWOS
DMH5SQV	MN	Matrix metalloproteinase-7 (MMP-7)
DMH5SQV	MT	DTT
DMH5SQV	MA	Inhibitor
DMH5SQV	RN	Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74.
DMH5SQV	RU	https://pubmed.ncbi.nlm.nih.gov/17127067

DMEPZ2I	DI	DMEPZ2I
DMEPZ2I	DN	folipastatin
DMEPZ2I	MI	TT9V5JH
DMEPZ2I	MN	Phospholipase A2 (PLA2G1B)
DMEPZ2I	MT	DTT
DMEPZ2I	MA	Modulator
DMEPZ2I	RN	Folipastatin, a new depsidone compound from Aspergillus unguis as an inhibitor of phospholipase A2.Taxonomy, fermentation, isolation, structure determination and biological properties.J Antibiot (Tokyo).1992 Aug;45(8):1195-201.
DMEPZ2I	RU	https://www.ncbi.nlm.nih.gov/pubmed/1399838

DMSBQL0	DI	DMSBQL0
DMSBQL0	DN	FOLITENOL
DMSBQL0	MI	TTELIN2
DMSBQL0	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMSBQL0	MT	DTT
DMSBQL0	MA	Inhibitor
DMSBQL0	RN	Cytotoxic and PTP1B inhibitory activities from Erythrina abyssinica. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6745-9.
DMSBQL0	RU	https://pubmed.ncbi.nlm.nih.gov/19836230

DM7Q6M0	DI	DM7Q6M0
DM7Q6M0	DN	Formaldehyde
DM7Q6M0	MI	TTLP6GN
DM7Q6M0	MN	Bacterial DD-carboxypeptidase (Bact vanYB)
DM7Q6M0	MT	DTT
DM7Q6M0	MA	Inhibitor
DM7Q6M0	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM7Q6M0	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM7Q6M0	DI	DM7Q6M0
DM7Q6M0	DN	Formaldehyde
DM7Q6M0	MI	TTELV3W
DM7Q6M0	MN	Transformation-sensitive protein p120 (TRPA1)
DM7Q6M0	MT	DTT
DM7Q6M0	MA	Activator
DM7Q6M0	RN	An ion channel essential for sensing chemical damage. J Neurosci. 2007 Oct 17;27(42):11412-5.
DM7Q6M0	RU	https://pubmed.ncbi.nlm.nih.gov/17942735

DMNFZC6	DI	DMNFZC6
DMNFZC6	DN	Formic Acid
DMNFZC6	MI	TTB30PF
DMNFZC6	MN	Bacterial Phosphoshikimate1-carboxyvinyltransferase (Bact aroA)
DMNFZC6	MT	DTT
DMNFZC6	MA	Inhibitor
DMNFZC6	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMNFZC6	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMNFZC6	DI	DMNFZC6
DMNFZC6	DN	Formic Acid
DMNFZC6	MI	TT915ZD
DMNFZC6	MN	Candida Mannose-6-phosphate isomerase (Candi PMI1)
DMNFZC6	MT	DTT
DMNFZC6	MA	Inhibitor
DMNFZC6	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMNFZC6	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMNFZC6	DI	DMNFZC6
DMNFZC6	DN	Formic Acid
DMNFZC6	MI	TTANPDJ
DMNFZC6	MN	Carbonic anhydrase II (CA-II)
DMNFZC6	MT	DTT
DMNFZC6	MA	Inhibitor
DMNFZC6	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMNFZC6	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMNFZC6	DI	DMNFZC6
DMNFZC6	DN	Formic Acid
DMNFZC6	MI	TTJHKYD
DMNFZC6	MN	Delta-aminolevulinic acid dehydratase (ALAD)
DMNFZC6	MT	DTT
DMNFZC6	MA	Inhibitor
DMNFZC6	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMNFZC6	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMNFZC6	DI	DMNFZC6
DMNFZC6	DN	Formic Acid
DMNFZC6	MI	TTCYE56
DMNFZC6	MN	Glutathione-dependent PGD synthase (HPGDS)
DMNFZC6	MT	DTT
DMNFZC6	MA	Inhibitor
DMNFZC6	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMNFZC6	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMNFZC6	DI	DMNFZC6
DMNFZC6	DN	Formic Acid
DMNFZC6	MI	TTI6V2A
DMNFZC6	MN	Heme oxygenase 1 (HMOX1)
DMNFZC6	MT	DTT
DMNFZC6	MA	Inhibitor
DMNFZC6	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMNFZC6	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMNFZC6	DI	DMNFZC6
DMNFZC6	DN	Formic Acid
DMNFZC6	MI	TTMY81X
DMNFZC6	MN	Heparin-binding growth factor 1 (FGF1)
DMNFZC6	MT	DTT
DMNFZC6	MA	Inhibitor
DMNFZC6	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMNFZC6	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMNFZC6	DI	DMNFZC6
DMNFZC6	DN	Formic Acid
DMNFZC6	MI	TTZUFI5
DMNFZC6	MN	Nitric-oxide synthase brain (NOS1)
DMNFZC6	MT	DTT
DMNFZC6	MA	Inhibitor
DMNFZC6	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMNFZC6	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMNFZC6	DI	DMNFZC6
DMNFZC6	DN	Formic Acid
DMNFZC6	MI	TTBL49X
DMNFZC6	MN	Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ)
DMNFZC6	MT	DTT
DMNFZC6	MA	Inhibitor
DMNFZC6	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMNFZC6	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMNFZC6	DI	DMNFZC6
DMNFZC6	DN	Formic Acid
DMNFZC6	MI	TTICO5G
DMNFZC6	MN	Staphylococcus Peptide deformylase (Stap-coc def)
DMNFZC6	MT	DTT
DMNFZC6	MA	Inhibitor
DMNFZC6	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMNFZC6	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM7WFZ8	DI	DM7WFZ8
DM7WFZ8	DN	Formononetin
DM7WFZ8	MI	TTF8JAT
DM7WFZ8	MN	SLC5A2 messenger RNA (SLC5A2 mRNA)
DM7WFZ8	MT	DTT
DM7WFZ8	MA	Inhibitor
DM7WFZ8	RN	Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens. Bioorg Med Chem. 2007 May 15;15(10):3445-9.
DM7WFZ8	RU	https://pubmed.ncbi.nlm.nih.gov/17374486

DMWG0P3	DI	DMWG0P3
DMWG0P3	DN	Formycin
DMWG0P3	MI	TTFSX6G
DMWG0P3	MN	Bacterial MTA/SAH nucleosidase (Bact mtnN)
DMWG0P3	MT	DTT
DMWG0P3	MA	Inhibitor
DMWG0P3	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMWG0P3	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMWG0P3	DI	DMWG0P3
DMWG0P3	DN	Formycin
DMWG0P3	MI	TTDBX7N
DMWG0P3	MN	S-methyl-5'-thioadenosine phosphorylase (MTAP)
DMWG0P3	MT	DTT
DMWG0P3	MA	Inhibitor
DMWG0P3	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMWG0P3	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMHLYUM	DI	DMHLYUM
DMHLYUM	DN	Formycin B
DMHLYUM	MI	TTBL49X
DMHLYUM	MN	Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ)
DMHLYUM	MT	DTT
DMHLYUM	MA	Inhibitor
DMHLYUM	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMHLYUM	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMFOU92	DI	DMFOU92
DMFOU92	DN	FORMYLCHROMONE
DMFOU92	MI	TTELIN2
DMFOU92	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMFOU92	MT	DTT
DMFOU92	MA	Inhibitor
DMFOU92	RN	Synthesis and evaluation of some novel dibenzo[b,d]furan carboxylic acids as potential anti-diabetic agents. Eur J Med Chem. 2010 Sep;45(9):3709-18.
DMFOU92	RU	https://pubmed.ncbi.nlm.nih.gov/20627471

DMVBGAT	DI	DMVBGAT
DMVBGAT	DN	For-RYYRIK-NH2
DMVBGAT	MI	TTNT7K8
DMVBGAT	MN	Nociceptin receptor (OPRL1)
DMVBGAT	MT	DTT
DMVBGAT	MA	Inhibitor
DMVBGAT	RN	Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist. Bioorg Med Chem. 2008 Mar 1;16(5):2635-44.
DMVBGAT	RU	https://pubmed.ncbi.nlm.nih.gov/18068993

DM6ITNG	DI	DM6ITNG
DM6ITNG	DN	Forskolin
DM6ITNG	MI	TTBQ9IM
DM6ITNG	MN	Adenylate cyclase type 2 (ADCY2)
DM6ITNG	MT	DTT
DM6ITNG	MA	Inhibitor
DM6ITNG	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM6ITNG	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMPC568	DI	DMPC568
DMPC568	DN	FORSYTHIASIDE
DMPC568	MI	TTFJ8Q1
DMPC568	MN	Protein kinase C alpha (PRKCA)
DMPC568	MT	DTT
DMPC568	MA	Inhibitor
DMPC568	RN	Phenylethanoid glycosides from Digitalis purpurea and Penstemon linarioides with PKCalpha-inhibitory activity. J Nat Prod. 1998 Nov;61(11):1410-2.
DMPC568	RU	https://pubmed.ncbi.nlm.nih.gov/9834166

DMYBQN9	DI	DMYBQN9
DMYBQN9	DN	FP0429
DMYBQN9	MI	TTICZ1O
DMYBQN9	MN	Metabotropic glutamate receptor 4 (mGluR4)
DMYBQN9	MT	DTT
DMYBQN9	MA	Agonist
DMYBQN9	RN	Amino-pyrrolidine tricarboxylic acids give new insight into group III metabotropic glutamate receptor activation mechanism. Mol Pharmacol. 2007 Mar;71(3):704-12.
DMYBQN9	RU	https://pubmed.ncbi.nlm.nih.gov/17167031

DMGID4T	DI	DMGID4T
DMGID4T	DN	FP-1102
DMGID4T	MI	TT7HC21
DMGID4T	MN	Membrane copper amine oxidase (AOC3)
DMGID4T	MT	DTT
DMGID4T	MA	Inhibitor
DMGID4T	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2767).
DMGID4T	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2767

DMB8U4F	DI	DMB8U4F
DMB8U4F	DN	FPL64176
DMB8U4F	MI	TT94HRF
DMB8U4F	MN	Voltage-gated calcium channel alpha Cav1.1 (CACNA1S)
DMB8U4F	MT	DTT
DMB8U4F	MA	Activator
DMB8U4F	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 528).
DMB8U4F	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=528

DMB8U4F	DI	DMB8U4F
DMB8U4F	DN	FPL64176
DMB8U4F	MI	TTZIFHC
DMB8U4F	MN	Voltage-gated calcium channel alpha Cav1.2 (CACNA1C)
DMB8U4F	MT	DTT
DMB8U4F	MA	Activator
DMB8U4F	RN	The calcium channel ligand FPL 64176 enhances L-type but inhibits N-type neuronal calcium currents. Neuropharmacology. 2003 Aug;45(2):281-92.
DMB8U4F	RU	https://pubmed.ncbi.nlm.nih.gov/12842134

DM0T2LQ	DI	DM0T2LQ
DM0T2LQ	DN	FPT-038
DM0T2LQ	MI	TTCBFJO
DM0T2LQ	MN	Insulin receptor (INSR)
DM0T2LQ	MT	DTT
DM0T2LQ	MA	Modulator
DM0T2LQ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800).
DM0T2LQ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800

DMR2NBK	DI	DMR2NBK
DMR2NBK	DN	FPTQ
DMR2NBK	MI	TTVBPDM
DMR2NBK	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMR2NBK	MT	DTT
DMR2NBK	MA	Modulator (allosteric modulator)
DMR2NBK	RN	Synthesis and evaluation of 6-[1-(2-[(18)F]fluoro-3-pyridyl)-5-methyl-1H-1,2,3-triazol-4-yl]quinoline for positron emission tomography imaging of the metabotropic glutamate receptor type 1 in brain. Bioorg Med Chem. 2011 Jan 1;19(1):102-10.
DMR2NBK	RU	https://pubmed.ncbi.nlm.nih.gov/21172734

DMDUR4C	DI	DMDUR4C
DMDUR4C	DN	FPYVAE peptide
DMDUR4C	MI	TTPADOQ
DMDUR4C	MN	HMG-CoA reductase (HMGCR)
DMDUR4C	MT	DTT
DMDUR4C	MA	Inhibitor
DMDUR4C	RN	Peptide fragmentation as an approach in modeling of an active peptide and designing a competitive inhibitory peptide for HMG-CoA reductase. Bioorg Med Chem. 2010 Jun 15;18(12):4300-9.
DMDUR4C	RU	https://pubmed.ncbi.nlm.nih.gov/20494585

DM7UP4E	DI	DM7UP4E
DM7UP4E	DN	FR-104
DM7UP4E	MI	TTQ13FT
DM7UP4E	MN	T-cell-specific surface glycoprotein CD28 (CD28)
DM7UP4E	MT	DTT
DM7UP4E	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2863).
DM7UP4E	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2863

DM6UWVB	DI	DM6UWVB
DM6UWVB	DN	FR117016
DM6UWVB	MI	TTLP57V
DM6UWVB	MN	Adenosine deaminase (ADA)
DM6UWVB	MT	DTT
DM6UWVB	MA	Inhibitor
DM6UWVB	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM6UWVB	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMAYTWN	DI	DMAYTWN
DMAYTWN	DN	FR122047
DMAYTWN	MI	TT8NGED
DMAYTWN	MN	Prostaglandin G/H synthase 1 (COX-1)
DMAYTWN	MT	DTT
DMAYTWN	MA	Inhibitor
DMAYTWN	RN	The analgesic effect profile of FR122047, a selective cyclooxygenase-1 inhibitor, in chemical nociceptive models. Eur J Pharmacol. 2000 Mar 10;391(1-2):49-54.
DMAYTWN	RU	https://pubmed.ncbi.nlm.nih.gov/10720634

DMNMO83	DI	DMNMO83
DMNMO83	DN	FR-122788
DMNMO83	MI	TT2J34L
DMNMO83	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMNMO83	MT	DTT
DMNMO83	MA	Modulator
DMNMO83	RN	Studies on 5-lipoxygenase inhibitors. I. Synthesis and 5-lipoxygenase-inhibitory activity of novel hydroxamic acid derivatives. Chem Pharm Bull (Tokyo). 1998 Jun;46(6):966-72.
DMNMO83	RU	https://www.ncbi.nlm.nih.gov/pubmed/9658575

DMZSFEP	DI	DMZSFEP
DMZSFEP	DN	FR161282
DMZSFEP	MI	TTK8R02
DMZSFEP	MN	Vasopressin V2 receptor (V2R)
DMZSFEP	MT	DTT
DMZSFEP	MA	Antagonist
DMZSFEP	RN	Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res. 2002;139:197-210.
DMZSFEP	RU	https://pubmed.ncbi.nlm.nih.gov/12436936

DMPCBXT	DI	DMPCBXT
DMPCBXT	DN	FR-166124
DMPCBXT	MI	TTK25J1
DMPCBXT	MN	Adenosine A1 receptor (ADORA1)
DMPCBXT	MT	DTT
DMPCBXT	MA	Inhibitor
DMPCBXT	RN	Discovery of FR166124, a novel water-soluble pyrazolo-[1,5-a]pyridine adenosine A1 receptor antagonist. Bioorg Med Chem Lett. 1999 Jul 19;9(14):1979-84.
DMPCBXT	RU	https://pubmed.ncbi.nlm.nih.gov/10450966

DMPCBXT	DI	DMPCBXT
DMPCBXT	DN	FR-166124
DMPCBXT	MI	TTM2AOE
DMPCBXT	MN	Adenosine A2a receptor (ADORA2A)
DMPCBXT	MT	DTT
DMPCBXT	MA	Inhibitor
DMPCBXT	RN	Discovery of FR166124, a novel water-soluble pyrazolo-[1,5-a]pyridine adenosine A1 receptor antagonist. Bioorg Med Chem Lett. 1999 Jul 19;9(14):1979-84.
DMPCBXT	RU	https://pubmed.ncbi.nlm.nih.gov/10450966

DM2W5VA	DI	DM2W5VA
DM2W5VA	DN	FR167344
DM2W5VA	MI	TTGY8IW
DM2W5VA	MN	B2 bradykinin receptor (BDKRB2)
DM2W5VA	MT	DTT
DM2W5VA	MA	Antagonist
DM2W5VA	RN	Novel subtype-selective nonpeptide bradykinin receptor antagonists FR167344 and FR173657. Mol Pharmacol. 1997 Feb;51(2):171-6.
DM2W5VA	RU	https://pubmed.ncbi.nlm.nih.gov/9203620

DMQDP23	DI	DMQDP23
DMQDP23	DN	FR-175985
DMQDP23	MI	TTCG0AL
DMQDP23	MN	Cholecystokinin receptor type A (CCKAR)
DMQDP23	MT	DTT
DMQDP23	MA	Inhibitor
DMQDP23	RN	Dual CCK-A and -B receptor antagonists (I) C9-methyl-1,4-benzodiazepines, Bioorg. Med. Chem. Lett. 7(2):169-174 (1997).
DMQDP23	RU	http://www.sciencedirect.com/science/article/pii/S0960894X96006099

DM051PI	DI	DM051PI
DM051PI	DN	FR-180204
DM051PI	MI	TT4TQBX
DM051PI	MN	Extracellular signal-regulated kinase 2 (ERK2)
DM051PI	MT	DTT
DM051PI	MA	Inhibitor
DM051PI	RN	Crystal structure of human ERK2 complexed with a pyrazolo[3,4-c]pyridazine derivative. Bioorg Med Chem Lett. 2006 Jan 1;16(1):55-8.
DM051PI	RU	https://pubmed.ncbi.nlm.nih.gov/16242327

DM2V7U1	DI	DM2V7U1
DM2V7U1	DN	FR-181157
DM2V7U1	MI	TTOFYT1
DM2V7U1	MN	Prostacyclin receptor (PTGIR)
DM2V7U1	MT	DTT
DM2V7U1	MA	Inhibitor
DM2V7U1	RN	Replacing the cyclohexene-linker of FR181157 leading to novel IP receptor agonists: orally active prostacyclin mimetics. Part 6. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4861-4.
DM2V7U1	RU	https://pubmed.ncbi.nlm.nih.gov/16837197

DM2V7U1	DI	DM2V7U1
DM2V7U1	DN	FR-181157
DM2V7U1	MI	TTPNGDE
DM2V7U1	MN	Prostaglandin E2 receptor EP3 (PTGER3)
DM2V7U1	MT	DTT
DM2V7U1	MA	Inhibitor
DM2V7U1	RN	Metabolism investigation leading to novel drug design: orally active prostacyclin mimetics. Part 4. Bioorg Med Chem Lett. 2005 Jul 1;15(13):3284-7.
DM2V7U1	RU	https://pubmed.ncbi.nlm.nih.gov/15935659

DM2V7U1	DI	DM2V7U1
DM2V7U1	DN	FR-181157
DM2V7U1	MI	TT79WV3
DM2V7U1	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DM2V7U1	MT	DTT
DM2V7U1	MA	Inhibitor
DM2V7U1	RN	Discovery of diphenyloxazole and Ndelta-Z-ornithine derivatives as highly potent and selective human prostaglandin EP(4) receptor antagonists. J Med Chem. 2005 May 5;48(9):3103-6.
DM2V7U1	RU	https://pubmed.ncbi.nlm.nih.gov/15857112

DM0G4HP	DI	DM0G4HP
DM0G4HP	DN	FR190997
DM0G4HP	MI	TTGY8IW
DM0G4HP	MN	B2 bradykinin receptor (BDKRB2)
DM0G4HP	MT	DTT
DM0G4HP	MA	Agonist
DM0G4HP	RN	Nonpeptide mimic of bradykinin with long-acting properties at the bradykinin B2 receptor. Mol Pharmacol. 1997 Jul;52(1):16-20.
DM0G4HP	RU	https://pubmed.ncbi.nlm.nih.gov/9224807

DM75VHN	DI	DM75VHN
DM75VHN	DN	FR191413
DM75VHN	MI	TTGY8IW
DM75VHN	MN	B2 bradykinin receptor (BDKRB2)
DM75VHN	MT	DTT
DM75VHN	MA	Agonist
DM75VHN	RN	Discovery of the first non-peptide full agonists for the human bradykinin B(2) receptor incorporating 4-(2-picolyloxy)quinoline and 1-(2-picolyl)benzimidazole frameworks. J Med Chem. 2004 May 20;47(11):2853-63.
DM75VHN	RU	https://pubmed.ncbi.nlm.nih.gov/15139763

DM9BS3W	DI	DM9BS3W
DM9BS3W	DN	FR-193262
DM9BS3W	MI	TTOFYT1
DM9BS3W	MN	Prostacyclin receptor (PTGIR)
DM9BS3W	MT	DTT
DM9BS3W	MA	Inhibitor
DM9BS3W	RN	Discovery of new diphenyloxazole derivatives containing a pyrrolidine ring: orally active prostacyclin mimetics. Part 2. Bioorg Med Chem Lett. 2005 Jul 1;15(13):3279-83.
DM9BS3W	RU	https://pubmed.ncbi.nlm.nih.gov/15935660

DMISP7G	DI	DMISP7G
DMISP7G	DN	FR194921
DMISP7G	MI	TTK25J1
DMISP7G	MN	Adenosine A1 receptor (ADORA1)
DMISP7G	MT	DTT
DMISP7G	MA	Antagonist
DMISP7G	RN	Pharmacological characterization of FR194921, a new potent, selective, and orally active antagonist for central adenosine A1 receptors. J Pharmacol Sci. 2004 Sep;96(1):42-52.
DMISP7G	RU	https://pubmed.ncbi.nlm.nih.gov/15351792

DM70UQR	DI	DM70UQR
DM70UQR	DN	FR221647
DM70UQR	MI	TTLP57V
DM70UQR	MN	Adenosine deaminase (ADA)
DM70UQR	MT	DTT
DM70UQR	MA	Inhibitor
DM70UQR	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM70UQR	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMBY3T5	DI	DMBY3T5
DMBY3T5	DN	FR-226928
DMBY3T5	MI	TTY6EWA
DMBY3T5	MN	Neuropeptide Y receptor type 5 (NPY5R)
DMBY3T5	MT	DTT
DMBY3T5	MA	Inhibitor
DMBY3T5	RN	Novel potent antagonists of human neuropeptide Y Y5 receptors. Part 3: 7-methoxy-1-hydroxy-1-substituted tetraline derivatives. Bioorg Med Chem Lett. 2002 Mar 11;12(5):799-802.
DMBY3T5	RU	https://pubmed.ncbi.nlm.nih.gov/11859006

DMKJQWR	DI	DMKJQWR
DMKJQWR	DN	FR-230481
DMKJQWR	MI	TTY6EWA
DMKJQWR	MN	Neuropeptide Y receptor type 5 (NPY5R)
DMKJQWR	MT	DTT
DMKJQWR	MA	Inhibitor
DMKJQWR	RN	Novel potent antagonists of human neuropeptide Y Y5 receptors. Part 3: 7-methoxy-1-hydroxy-1-substituted tetraline derivatives. Bioorg Med Chem Lett. 2002 Mar 11;12(5):799-802.
DMKJQWR	RU	https://pubmed.ncbi.nlm.nih.gov/11859006

DM3V0HA	DI	DM3V0HA
DM3V0HA	DN	FR230513
DM3V0HA	MI	TTLP57V
DM3V0HA	MN	Adenosine deaminase (ADA)
DM3V0HA	MT	DTT
DM3V0HA	MA	Inhibitor
DM3V0HA	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM3V0HA	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMPD16N	DI	DMPD16N
DMPD16N	DN	FR-233118
DMPD16N	MI	TTY6EWA
DMPD16N	MN	Neuropeptide Y receptor type 5 (NPY5R)
DMPD16N	MT	DTT
DMPD16N	MA	Inhibitor
DMPD16N	RN	Novel potent antagonists of human neuropeptide Y Y5 receptors. Part 3: 7-methoxy-1-hydroxy-1-substituted tetraline derivatives. Bioorg Med Chem Lett. 2002 Mar 11;12(5):799-802.
DMPD16N	RU	https://pubmed.ncbi.nlm.nih.gov/11859006

DMR251H	DI	DMR251H
DMR251H	DN	FR233623
DMR251H	MI	TTLP57V
DMR251H	MN	Adenosine deaminase (ADA)
DMR251H	MT	DTT
DMR251H	MA	Inhibitor
DMR251H	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMR251H	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMLH546	DI	DMLH546
DMLH546	DN	FR236913
DMLH546	MI	TTLP57V
DMLH546	MN	Adenosine deaminase (ADA)
DMLH546	MT	DTT
DMLH546	MA	Inhibitor
DMLH546	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMLH546	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMMJDXT	DI	DMMJDXT
DMMJDXT	DN	FR239087
DMMJDXT	MI	TTLP57V
DMMJDXT	MN	Adenosine deaminase (ADA)
DMMJDXT	MT	DTT
DMMJDXT	MA	Inhibitor
DMMJDXT	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMMJDXT	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMSQ6CV	DI	DMSQ6CV
DMSQ6CV	DN	FR260010
DMSQ6CV	MI	TTWJBZ5
DMSQ6CV	MN	5-HT 2C receptor (HTR2C)
DMSQ6CV	MT	DTT
DMSQ6CV	MA	Antagonist
DMSQ6CV	RN	Anxiolytic activity of a novel potent serotonin 5-HT2C receptor antagonist FR260010: a comparison with diazepam and buspirone. Eur J Pharmacol. 2006 Dec 28;553(1-3):171-84.
DMSQ6CV	RU	https://pubmed.ncbi.nlm.nih.gov/17074317

DMV0UM2	DI	DMV0UM2
DMV0UM2	DN	FR-73966
DMV0UM2	MI	TTY6EWA
DMV0UM2	MN	Neuropeptide Y receptor type 5 (NPY5R)
DMV0UM2	MT	DTT
DMV0UM2	MA	Inhibitor
DMV0UM2	RN	Novel potent antagonists of human neuropeptide Y Y5 receptors. Part 3: 7-methoxy-1-hydroxy-1-substituted tetraline derivatives. Bioorg Med Chem Lett. 2002 Mar 11;12(5):799-802.
DMV0UM2	RU	https://pubmed.ncbi.nlm.nih.gov/11859006

DMMGWXQ	DI	DMMGWXQ
DMMGWXQ	DN	FR-900452
DMMGWXQ	MI	TTQL5VC
DMMGWXQ	MN	Platelet-activating factor receptor (PTAFR)
DMMGWXQ	MT	DTT
DMMGWXQ	MA	Modulator
DMMGWXQ	RN	FR-900452, a specific antagonist of platelet activating factor (PAF) produced by Streptomyces phaeofaciens. I. Taxonomy, fermentation, isolation, a... J Antibiot (Tokyo). 1986 Feb;39(2):198-204.
DMMGWXQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/3082838

DMEYNGP	DI	DMEYNGP
DMEYNGP	DN	frescolat MGA
DMEYNGP	MI	TTXDKTO
DMEYNGP	MN	Long transient receptor potential channel 8 (TRPM8)
DMEYNGP	MT	DTT
DMEYNGP	MA	Activator
DMEYNGP	RN	Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay. Br J Pharmacol. 2004 Feb;141(4):737-45.
DMEYNGP	RU	https://pubmed.ncbi.nlm.nih.gov/14757700

DMIBCZJ	DI	DMIBCZJ
DMIBCZJ	DN	frescolat ML
DMIBCZJ	MI	TTXDKTO
DMIBCZJ	MN	Long transient receptor potential channel 8 (TRPM8)
DMIBCZJ	MT	DTT
DMIBCZJ	MA	Activator
DMIBCZJ	RN	Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay. Br J Pharmacol. 2004 Feb;141(4):737-45.
DMIBCZJ	RU	https://pubmed.ncbi.nlm.nih.gov/14757700

DMU5SAF	DI	DMU5SAF
DMU5SAF	DN	Fructose-6-phosphate
DMU5SAF	MI	DEUZYD1
DMU5SAF	MN	ATP-dependent 6-phosphofructokinase (pfkA)
DMU5SAF	MT	DME
DMU5SAF	MA	Metabolism
DMU5SAF	RN	Purification and properties of the phosphofructokinase from Lactobacillus bulgaricus. A non-allosteric analog of the enzyme from Escherichia coli. Eur J Biochem. 1991 Jun 15;198(3):683-7.
DMU5SAF	RU	https://pubmed.ncbi.nlm.nih.gov/1828763

DMU5SAF	DI	DMU5SAF
DMU5SAF	DN	Fructose-6-phosphate
DMU5SAF	MI	TTWHDVK
DMU5SAF	MN	Fructose-1,6-bisphosphatase (FBP)
DMU5SAF	MT	DTT
DMU5SAF	MA	Inhibitor
DMU5SAF	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMU5SAF	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMPRMOD	DI	DMPRMOD
DMPRMOD	DN	FSHR NAM
DMPRMOD	MI	TTZFDBT
DMPRMOD	MN	Follicle-stimulating hormone receptor (FSHR)
DMPRMOD	MT	DTT
DMPRMOD	MA	Modulator
DMPRMOD	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 253).
DMPRMOD	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=253

DM2KUEV	DI	DM2KUEV
DM2KUEV	DN	Fsn-0503
DM2KUEV	MI	TTUMQVO
DM2KUEV	MN	Cathepsin S (CTSS)
DM2KUEV	MT	DTT
DM2KUEV	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2353).
DM2KUEV	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2353

DMN2Q7Y	DI	DMN2Q7Y
DMN2Q7Y	DN	FTI 276
DMN2Q7Y	MI	TT7WZIJ
DMN2Q7Y	MN	CAAX farnesyltransferase beta (FNTB)
DMN2Q7Y	MT	DTT
DMN2Q7Y	MA	Inhibitor
DMN2Q7Y	RN	Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J Biol Chem. 1995 Nov 10;270(45):26802-6.
DMN2Q7Y	RU	https://pubmed.ncbi.nlm.nih.gov/7592920

DM65VLB	DI	DM65VLB
DM65VLB	DN	FTIDC
DM65VLB	MI	TTVBPDM
DM65VLB	MN	Metabotropic glutamate receptor 1 (mGluR1)
DM65VLB	MT	DTT
DM65VLB	MA	Modulator (allosteric modulator)
DM65VLB	RN	Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1-(2-fluoropyridin-... J Pharmacol Exp Ther. 2007 Jun;321(3):1144-53.
DM65VLB	RU	https://pubmed.ncbi.nlm.nih.gov/17360958

DMDZBQH	DI	DMDZBQH
DMDZBQH	DN	FTY720-phosphate
DMDZBQH	MI	TT9JZCK
DMDZBQH	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMDZBQH	MT	DTT
DMDZBQH	MA	Agonist
DMDZBQH	RN	The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002 Jun 14;277(24):21453-7.
DMDZBQH	RU	https://pubmed.ncbi.nlm.nih.gov/11967257

DMDZBQH	DI	DMDZBQH
DMDZBQH	DN	FTY720-phosphate
DMDZBQH	MI	TTDYP7I
DMDZBQH	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DMDZBQH	MT	DTT
DMDZBQH	MA	Agonist
DMDZBQH	RN	Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J Pharmacol Exp Ther. 2004 May;309(2):758-68.
DMDZBQH	RU	https://pubmed.ncbi.nlm.nih.gov/14747617

DMDZBQH	DI	DMDZBQH
DMDZBQH	DN	FTY720-phosphate
DMDZBQH	MI	TTZ8C5Q
DMDZBQH	MN	Sphingosine-1-phosphate receptor 4 (S1PR4)
DMDZBQH	MT	DTT
DMDZBQH	MA	Agonist
DMDZBQH	RN	The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002 Jun 14;277(24):21453-7.
DMDZBQH	RU	https://pubmed.ncbi.nlm.nih.gov/11967257

DMDZBQH	DI	DMDZBQH
DMDZBQH	DN	FTY720-phosphate
DMDZBQH	MI	TTDZCKV
DMDZBQH	MN	Sphingosine-1-phosphate receptor 5 (S1PR5)
DMDZBQH	MT	DTT
DMDZBQH	MA	Agonist
DMDZBQH	RN	Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J Pharmacol Exp Ther. 2004 May;309(2):758-68.
DMDZBQH	RU	https://pubmed.ncbi.nlm.nih.gov/14747617

DMUAYWX	DI	DMUAYWX
DMUAYWX	DN	FUB 349
DMUAYWX	MI	TT9JNIC
DMUAYWX	MN	Histamine H3 receptor (H3R)
DMUAYWX	MT	DTT
DMUAYWX	MA	Antagonist
DMUAYWX	RN	Distinct pharmacology of rat and human histamine H(3) receptors: role of two amino acids in the third transmembrane domain. Br J Pharmacol. 2000 Dec;131(7):1247-50.
DMUAYWX	RU	https://pubmed.ncbi.nlm.nih.gov/11090094

DMCLSE0	DI	DMCLSE0
DMCLSE0	DN	FUB-130
DMCLSE0	MI	TT9JNIC
DMCLSE0	MN	Histamine H3 receptor (H3R)
DMCLSE0	MT	DTT
DMCLSE0	MA	Antagonist
DMCLSE0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 264).
DMCLSE0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=264

DMAHMSV	DI	DMAHMSV
DMAHMSV	DN	Fucose
DMAHMSV	MI	TT1RS9F
DMAHMSV	MN	Acetylcholinesterase (AChE)
DMAHMSV	MT	DTT
DMAHMSV	MA	Inhibitor
DMAHMSV	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMAHMSV	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMAHMSV	DI	DMAHMSV
DMAHMSV	DN	Fucose
DMAHMSV	MI	TTIS03D
DMAHMSV	MN	Alpha-galactosidase A (GLA)
DMAHMSV	MT	DTT
DMAHMSV	MA	Inhibitor
DMAHMSV	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMAHMSV	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMAHMSV	DI	DMAHMSV
DMAHMSV	DN	Fucose
DMAHMSV	MI	TTUMQVO
DMAHMSV	MN	Cathepsin S (CTSS)
DMAHMSV	MT	DTT
DMAHMSV	MA	Inhibitor
DMAHMSV	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMAHMSV	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMAHMSV	DI	DMAHMSV
DMAHMSV	DN	Fucose
DMAHMSV	MI	TTEB0GD
DMAHMSV	MN	Cholinesterase (BCHE)
DMAHMSV	MT	DTT
DMAHMSV	MA	Inhibitor
DMAHMSV	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMAHMSV	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMAHMSV	DI	DMAHMSV
DMAHMSV	DN	Fucose
DMAHMSV	MI	TTF0EGX
DMAHMSV	MN	Coagulation factor VII (F7)
DMAHMSV	MT	DTT
DMAHMSV	MA	Inhibitor
DMAHMSV	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMAHMSV	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMAHMSV	DI	DMAHMSV
DMAHMSV	DN	Fucose
DMAHMSV	MI	TT7LRQH
DMAHMSV	MN	Complement C1s component (C1S)
DMAHMSV	MT	DTT
DMAHMSV	MA	Inhibitor
DMAHMSV	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMAHMSV	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMAHMSV	DI	DMAHMSV
DMAHMSV	DN	Fucose
DMAHMSV	MI	TTI2S1D
DMAHMSV	MN	Cytotoxic T-lymphocyte protein 4 (CTLA-4)
DMAHMSV	MT	DTT
DMAHMSV	MA	Inhibitor
DMAHMSV	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMAHMSV	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMAHMSV	DI	DMAHMSV
DMAHMSV	DN	Fucose
DMAHMSV	MI	TTDIGC1
DMAHMSV	MN	Dipeptidyl peptidase 4 (DPP-4)
DMAHMSV	MT	DTT
DMAHMSV	MA	Inhibitor
DMAHMSV	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMAHMSV	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMAHMSV	DI	DMAHMSV
DMAHMSV	DN	Fucose
DMAHMSV	MI	TTAU4D6
DMAHMSV	MN	E-selectin (SELE)
DMAHMSV	MT	DTT
DMAHMSV	MA	Inhibitor
DMAHMSV	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMAHMSV	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMAHMSV	DI	DMAHMSV
DMAHMSV	DN	Fucose
DMAHMSV	MI	TTDGEC0
DMAHMSV	MN	Immunoglobulin epsilon Fc receptor gamma (FCERG)
DMAHMSV	MT	DTT
DMAHMSV	MA	Inhibitor
DMAHMSV	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMAHMSV	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMAHMSV	DI	DMAHMSV
DMAHMSV	DN	Fucose
DMAHMSV	MI	TT50QJ3
DMAHMSV	MN	Influenza Neuraminidase (Influ NA)
DMAHMSV	MT	DTT
DMAHMSV	MA	Inhibitor
DMAHMSV	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMAHMSV	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMAHMSV	DI	DMAHMSV
DMAHMSV	DN	Fucose
DMAHMSV	MI	TTHRID2
DMAHMSV	MN	Insulin-like growth factor I receptor (IGF1R)
DMAHMSV	MT	DTT
DMAHMSV	MA	Inhibitor
DMAHMSV	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMAHMSV	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMAHMSV	DI	DMAHMSV
DMAHMSV	DN	Fucose
DMAHMSV	MI	TTA0OSE
DMAHMSV	MN	Lactase-phlorizin hydrolase (LCT)
DMAHMSV	MT	DTT
DMAHMSV	MA	Inhibitor
DMAHMSV	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMAHMSV	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMAHMSV	DI	DMAHMSV
DMAHMSV	DN	Fucose
DMAHMSV	MI	TTSZDQU
DMAHMSV	MN	Lactotransferrin (LTF)
DMAHMSV	MT	DTT
DMAHMSV	MA	Inhibitor
DMAHMSV	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMAHMSV	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMAHMSV	DI	DMAHMSV
DMAHMSV	DN	Fucose
DMAHMSV	MI	TTBXIM9
DMAHMSV	MN	Membrane-associated lectin type-C (CD209)
DMAHMSV	MT	DTT
DMAHMSV	MA	Inhibitor
DMAHMSV	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMAHMSV	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMAHMSV	DI	DMAHMSV
DMAHMSV	DN	Fucose
DMAHMSV	MI	TTPLTSQ
DMAHMSV	MN	Neutrophil elastase (NE)
DMAHMSV	MT	DTT
DMAHMSV	MA	Inhibitor
DMAHMSV	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMAHMSV	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMAHMSV	DI	DMAHMSV
DMAHMSV	DN	Fucose
DMAHMSV	MI	TTE5VG0
DMAHMSV	MN	P-selectin (SELP)
DMAHMSV	MT	DTT
DMAHMSV	MA	Inhibitor
DMAHMSV	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMAHMSV	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMAHMSV	DI	DMAHMSV
DMAHMSV	DN	Fucose
DMAHMSV	MI	DTOKC04
DMAHMSV	MN	Sodium/glucose cotransporter 1 (SLC5A1)
DMAHMSV	MT	DTP
DMAHMSV	MA	Substrate
DMAHMSV	RN	The role of SGLT1 and GLUT2 in intestinal glucose transport and sensing. PLoS One. 2014 Feb 26;9(2):e89977.
DMAHMSV	RU	http://www.ncbi.nlm.nih.gov/pubmed/24587162

DMAHMSV	DI	DMAHMSV
DMAHMSV	DN	Fucose
DMAHMSV	MI	TTGY7WI
DMAHMSV	MN	Urokinase-type plasminogen activator (PLAU)
DMAHMSV	MT	DTT
DMAHMSV	MA	Inhibitor
DMAHMSV	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMAHMSV	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMWF82O	DI	DMWF82O
DMWF82O	DN	FUKUGETIN
DMWF82O	MI	TT7RJY8
DMWF82O	MN	Xanthine dehydrogenase/oxidase (XDH)
DMWF82O	MT	DTT
DMWF82O	MA	Inhibitor
DMWF82O	RN	Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod. 1988 Mar-Apr;51(2):345-8.
DMWF82O	RU	https://pubmed.ncbi.nlm.nih.gov/3379415

DM4M91Z	DI	DM4M91Z
DM4M91Z	DN	Full-length Factor VIII molecule
DM4M91Z	MI	TT1290U
DM4M91Z	MN	Coagulation factor VIII (F8)
DM4M91Z	MT	DTT
DM4M91Z	MA	Modulator
DM4M91Z	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2607).
DM4M91Z	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2607

DMA3Y8C	DI	DMA3Y8C
DMA3Y8C	DN	Fumagillin
DMA3Y8C	MI	TTZL0OI
DMA3Y8C	MN	Methionine aminopeptidase 2 (METAP2)
DMA3Y8C	MT	DTT
DMA3Y8C	MA	Binder
DMA3Y8C	RN	Homology modeling and calculation of the cobalt cluster charges of the Encephazlitozoon cuniculi methionine aminopeptidase, a potential target for drug design. Biophys Chem. 2003 Aug 1;105(1):29-43.
DMA3Y8C	RU	https://pubmed.ncbi.nlm.nih.gov/12932577

DM9VLS2	DI	DM9VLS2
DM9VLS2	DN	Fumarate
DM9VLS2	MI	TTHDSE2
DM9VLS2	MN	Bacterial Fumarate reductase flavoprotein (Bact frdA)
DM9VLS2	MT	DTT
DM9VLS2	MA	Inhibitor
DM9VLS2	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9VLS2	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9VLS2	DI	DM9VLS2
DM9VLS2	DN	Fumarate
DM9VLS2	MI	DEQUXZ5
DM9VLS2	MN	Fumarate reductase flavoprotein (frdA)
DM9VLS2	MT	DME
DM9VLS2	MA	Metabolism
DM9VLS2	RN	Wolinella succinogenes quinol:fumarate reductase and its comparison to E. coli succinate:quinone reductase. FEBS Lett. 2003 Nov 27;555(1):21-8.
DM9VLS2	RU	https://pubmed.ncbi.nlm.nih.gov/14630313

DMCFEBW	DI	DMCFEBW
DMCFEBW	DN	furan-1
DMCFEBW	MI	TT8R70G
DMCFEBW	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMCFEBW	MT	DTT
DMCFEBW	MA	Antagonist
DMCFEBW	RN	Biological characterization of a novel, orally active small molecule gonadotropin-releasing hormone (GnRH) antagonist using castrated and intact rats. J Pharmacol Exp Ther. 2003 May;305(2):688-95.
DMCFEBW	RU	https://pubmed.ncbi.nlm.nih.gov/12606616

DM9XPUN	DI	DM9XPUN
DM9XPUN	DN	Furan-2-ylmethylcarbamic Acid Biphenyl-3-yl Ester
DM9XPUN	MI	TTDP1UC
DM9XPUN	MN	Fatty acid amide hydrolase (FAAH)
DM9XPUN	MT	DTT
DM9XPUN	MA	Inhibitor
DM9XPUN	RN	Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl a... J Med Chem. 2008 Jun 26;51(12):3487-98.
DM9XPUN	RU	https://pubmed.ncbi.nlm.nih.gov/18507372

DMPC6YL	DI	DMPC6YL
DMPC6YL	DN	Furan-3-yl(4-(methylsulfonyl)phenyl)methanone
DMPC6YL	MI	TTVKILB
DMPC6YL	MN	Prostaglandin G/H synthase 2 (COX-2)
DMPC6YL	MT	DTT
DMPC6YL	MA	Inhibitor
DMPC6YL	RN	Synthesis, anti-inflammatory activity, and in vitro antitumor effect of a novel class of cyclooxygenase inhibitors: 4-(aryloyl)phenyl methyl sulfones. J Med Chem. 2010 Sep 23;53(18):6560-71.
DMPC6YL	RU	https://pubmed.ncbi.nlm.nih.gov/20804197

DM78NOM	DI	DM78NOM
DM78NOM	DN	furin inhibitor peptide
DM78NOM	MI	TTH9WF6
DM78NOM	MN	Dibasic-processing enzyme (Furin)
DM78NOM	MT	DTT
DM78NOM	MA	Inhibitor
DM78NOM	RN	Targeting host cell furin proprotein convertases as a therapeutic strategy against bacterial toxins and viral pathogens. J Biol Chem. 2007 Jul 20;282(29):20847-53.
DM78NOM	RU	https://pubmed.ncbi.nlm.nih.gov/17537721

DM78NOM	DI	DM78NOM
DM78NOM	DN	furin inhibitor peptide
DM78NOM	MI	TTK3VYC
DM78NOM	MN	Proprotein convertase subtilisin/kexin type 4 (PCSK4)
DM78NOM	MT	DTT
DM78NOM	MA	Inhibitor
DM78NOM	RN	Targeting host cell furin proprotein convertases as a therapeutic strategy against bacterial toxins and viral pathogens. J Biol Chem. 2007 Jul 20;282(29):20847-53.
DM78NOM	RU	https://pubmed.ncbi.nlm.nih.gov/17537721

DM78NOM	DI	DM78NOM
DM78NOM	DN	furin inhibitor peptide
DM78NOM	MI	TTPFWHU
DM78NOM	MN	Proprotein convertase subtilisin/kexin type 5 (PCSK5)
DM78NOM	MT	DTT
DM78NOM	MA	Inhibitor
DM78NOM	RN	Targeting host cell furin proprotein convertases as a therapeutic strategy against bacterial toxins and viral pathogens. J Biol Chem. 2007 Jul 20;282(29):20847-53.
DM78NOM	RU	https://pubmed.ncbi.nlm.nih.gov/17537721

DM78NOM	DI	DM78NOM
DM78NOM	DN	furin inhibitor peptide
DM78NOM	MI	TT75LN9
DM78NOM	MN	Proprotein convertase subtilisin/kexin type 6 (PCSK6)
DM78NOM	MT	DTT
DM78NOM	MA	Inhibitor
DM78NOM	RN	Targeting host cell furin proprotein convertases as a therapeutic strategy against bacterial toxins and viral pathogens. J Biol Chem. 2007 Jul 20;282(29):20847-53.
DM78NOM	RU	https://pubmed.ncbi.nlm.nih.gov/17537721

DM78NOM	DI	DM78NOM
DM78NOM	DN	furin inhibitor peptide
DM78NOM	MI	TTD30LY
DM78NOM	MN	Proprotein convertase subtilisin/kexin type 7 (PCSK7)
DM78NOM	MT	DTT
DM78NOM	MA	Inhibitor
DM78NOM	RN	Targeting host cell furin proprotein convertases as a therapeutic strategy against bacterial toxins and viral pathogens. J Biol Chem. 2007 Jul 20;282(29):20847-53.
DM78NOM	RU	https://pubmed.ncbi.nlm.nih.gov/17537721

DMVYEZ1	DI	DMVYEZ1
DMVYEZ1	DN	Furo[2,3d]Pyrimidine Antifolate
DMVYEZ1	MI	TT9SL3Q
DMVYEZ1	MN	Polypeptide deformylase (PDF)
DMVYEZ1	MT	DTT
DMVYEZ1	MA	Inhibitor
DMVYEZ1	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMVYEZ1	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMVT0JO	DI	DMVT0JO
DMVT0JO	DN	FUROSIN
DMVT0JO	MI	TTE14XG
DMVT0JO	MN	Squalene monooxygenase (SQLE)
DMVT0JO	MT	DTT
DMVT0JO	MA	Inhibitor
DMVT0JO	RN	Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4.
DMVT0JO	RU	https://pubmed.ncbi.nlm.nih.gov/11520216

DM4M3C8	DI	DM4M3C8
DM4M3C8	DN	furtrethonium
DM4M3C8	MI	TTOXS3C
DM4M3C8	MN	Muscarinic acetylcholine receptor (CHRM)
DM4M3C8	MT	DTT
DM4M3C8	MA	Agonist
DM4M3C8	RN	Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol. 1997 Jul;52(1):172-9.
DM4M3C8	RU	https://pubmed.ncbi.nlm.nih.gov/9224827

DM4M3C8	DI	DM4M3C8
DM4M3C8	DN	furtrethonium
DM4M3C8	MI	TTQ13Z5
DM4M3C8	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DM4M3C8	MT	DTT
DM4M3C8	MA	Agonist
DM4M3C8	RN	Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol. 1997 Jul;52(1):172-9.
DM4M3C8	RU	https://pubmed.ncbi.nlm.nih.gov/9224827

DMP3BZH	DI	DMP3BZH
DMP3BZH	DN	Fusion peptide EK1
DMP3BZH	MI	TT854FJ
DMP3BZH	MN	MERS-CoV spike glycoprotein S2' HR1 region (S S2'HR1)
DMP3BZH	MT	DTT
DMP3BZH	MA	Inhibitor
DMP3BZH	RN	A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. Sci Adv. 2019 Apr 10;5(4):eaav4580.
DMP3BZH	RU	https://pubmed.ncbi.nlm.nih.gov/30989115

DMP3BZH	DI	DMP3BZH
DMP3BZH	DN	Fusion peptide EK1
DMP3BZH	MI	TTXMITO
DMP3BZH	MN	SARS-CoV spike glycoprotein S2' HR1 region (S S2'HR1)
DMP3BZH	MT	DTT
DMP3BZH	MA	Inhibitor
DMP3BZH	RN	A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. Sci Adv. 2019 Apr 10;5(4):eaav4580.
DMP3BZH	RU	https://pubmed.ncbi.nlm.nih.gov/30989115

DMFBP7C	DI	DMFBP7C
DMFBP7C	DN	FUTOENONE
DMFBP7C	MI	TTUZ2L5
DMFBP7C	MN	Matrix metalloproteinase-3 (MMP-3)
DMFBP7C	MT	DTT
DMFBP7C	MA	Inhibitor
DMFBP7C	RN	Inhibition of metalloproteinase by futoenone derivatives, Bioorg. Med. Chem. Lett. 5(15):1637-1642 (1995).
DMFBP7C	RU	http://www.sciencedirect.com/science/article/pii/0960894X9500282X

DMEI890	DI	DMEI890
DMEI890	DN	FV-Aib-TDVGPFAF
DMEI890	MI	TTVSFJW
DMEI890	MN	Calcitonin gene-related peptide 1 (CALCA)
DMEI890	MT	DTT
DMEI890	MA	Inhibitor
DMEI890	RN	Identification of potent, selective, and metabolically stable peptide antagonists to the calcitonin gene-related peptide (CGRP) receptor. J Med Chem. 2008 Dec 25;51(24):7889-97.
DMEI890	RU	https://pubmed.ncbi.nlm.nih.gov/19053766

DMEI890	DI	DMEI890
DMEI890	DN	FV-Aib-TDVGPFAF
DMEI890	MI	TTY6O0Q
DMEI890	MN	Calcitonin gene-related peptide receptor (CGRPR)
DMEI890	MT	DTT
DMEI890	MA	Inhibitor
DMEI890	RN	Identification of the key residue of calcitonin gene related peptide (CGRP) 27-37 to obtain antagonists with picomolar affinity at the CGRP receptor. J Med Chem. 2006 Jan 26;49(2):616-24.
DMEI890	RU	https://pubmed.ncbi.nlm.nih.gov/16420047

DMDG1ZX	DI	DMDG1ZX
DMDG1ZX	DN	FVATDVGPFAF
DMDG1ZX	MI	TTY6O0Q
DMDG1ZX	MN	Calcitonin gene-related peptide receptor (CGRPR)
DMDG1ZX	MT	DTT
DMDG1ZX	MA	Inhibitor
DMDG1ZX	RN	Identification of the key residue of calcitonin gene related peptide (CGRP) 27-37 to obtain antagonists with picomolar affinity at the CGRP receptor. J Med Chem. 2006 Jan 26;49(2):616-24.
DMDG1ZX	RU	https://pubmed.ncbi.nlm.nih.gov/16420047

DMXQC6H	DI	DMXQC6H
DMXQC6H	DN	FV-Hyp-TDVGPFAF
DMXQC6H	MI	TTY6O0Q
DMXQC6H	MN	Calcitonin gene-related peptide receptor (CGRPR)
DMXQC6H	MT	DTT
DMXQC6H	MA	Inhibitor
DMXQC6H	RN	Identification of the key residue of calcitonin gene related peptide (CGRP) 27-37 to obtain antagonists with picomolar affinity at the CGRP receptor. J Med Chem. 2006 Jan 26;49(2):616-24.
DMXQC6H	RU	https://pubmed.ncbi.nlm.nih.gov/16420047

DMSD7B1	DI	DMSD7B1
DMSD7B1	DN	FVPTDVGAFAF
DMSD7B1	MI	TTY6O0Q
DMSD7B1	MN	Calcitonin gene-related peptide receptor (CGRPR)
DMSD7B1	MT	DTT
DMSD7B1	MA	Inhibitor
DMSD7B1	RN	Identification of the key residue of calcitonin gene related peptide (CGRP) 27-37 to obtain antagonists with picomolar affinity at the CGRP receptor. J Med Chem. 2006 Jan 26;49(2):616-24.
DMSD7B1	RU	https://pubmed.ncbi.nlm.nih.gov/16420047

DMUVXZQ	DI	DMUVXZQ
DMUVXZQ	DN	FVPTDVGPFAF
DMUVXZQ	MI	TTY6O0Q
DMUVXZQ	MN	Calcitonin gene-related peptide receptor (CGRPR)
DMUVXZQ	MT	DTT
DMUVXZQ	MA	Inhibitor
DMUVXZQ	RN	Identification of the key residue of calcitonin gene related peptide (CGRP) 27-37 to obtain antagonists with picomolar affinity at the CGRP receptor. J Med Chem. 2006 Jan 26;49(2):616-24.
DMUVXZQ	RU	https://pubmed.ncbi.nlm.nih.gov/16420047

DM58JFR	DI	DM58JFR
DM58JFR	DN	FVPTDVG-Tic-FAF-Tic
DM58JFR	MI	TTY6O0Q
DM58JFR	MN	Calcitonin gene-related peptide receptor (CGRPR)
DM58JFR	MT	DTT
DM58JFR	MA	Inhibitor
DM58JFR	RN	Identification of the key residue of calcitonin gene related peptide (CGRP) 27-37 to obtain antagonists with picomolar affinity at the CGRP receptor. J Med Chem. 2006 Jan 26;49(2):616-24.
DM58JFR	RU	https://pubmed.ncbi.nlm.nih.gov/16420047

DMBOE1U	DI	DMBOE1U
DMBOE1U	DN	FV-Tic-TDVGPFAF
DMBOE1U	MI	TTY6O0Q
DMBOE1U	MN	Calcitonin gene-related peptide receptor (CGRPR)
DMBOE1U	MT	DTT
DMBOE1U	MA	Inhibitor
DMBOE1U	RN	Identification of the key residue of calcitonin gene related peptide (CGRP) 27-37 to obtain antagonists with picomolar affinity at the CGRP receptor. J Med Chem. 2006 Jan 26;49(2):616-24.
DMBOE1U	RU	https://pubmed.ncbi.nlm.nih.gov/16420047

DMAZ1NW	DI	DMAZ1NW
DMAZ1NW	DN	FXI-AS1
DMAZ1NW	MI	TTDM4ZU
DMAZ1NW	MN	Factor XI messenger RNA (F11 mRNA)
DMAZ1NW	MT	DTT
DMAZ1NW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2360).
DMAZ1NW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2360

DMUC0F5	DI	DMUC0F5
DMUC0F5	DN	G(D-Pen)-G-H-R-G-D-L-R-C-A
DMUC0F5	MI	TTT1R2L
DMUC0F5	MN	Integrin alpha-V (ITGAV)
DMUC0F5	MT	DTT
DMUC0F5	MA	Inhibitor
DMUC0F5	RN	Design and synthesis of novel cyclic RGD-containing peptides as highly potent and selective integrin alpha IIb beta 3 antagonists. J Med Chem. 1994 Jan 7;37(1):1-8.
DMUC0F5	RU	https://pubmed.ncbi.nlm.nih.gov/7507165

DMXZGKI	DI	DMXZGKI
DMXZGKI	DN	G009
DMXZGKI	MI	TTV0YFR
DMXZGKI	MN	Lipid peroxidation (LPO)
DMXZGKI	MT	DTT
DMXZGKI	MA	Inhibitor
DMXZGKI	RN	Inhibition of lipid peroxidation and oxidative DNA damage by Ganoderma lucidum. Phytother Res. 2001 May;15(3):245-9.
DMXZGKI	RU	https://pubmed.ncbi.nlm.nih.gov/11351361

DMMEC9D	DI	DMMEC9D
DMMEC9D	DN	G15
DMMEC9D	MI	TTDSB34
DMMEC9D	MN	G-protein coupled estrogen receptor 1 (GPER1)
DMMEC9D	MT	DTT
DMMEC9D	MA	Antagonist
DMMEC9D	RN	In vivo effects of a GPR30 antagonist. Nat Chem Biol. 2009 Jun;5(6):421-7.
DMMEC9D	RU	https://pubmed.ncbi.nlm.nih.gov/19430488

DMADOK6	DI	DMADOK6
DMADOK6	DN	G-25
DMADOK6	MI	TTCS8WB
DMADOK6	MN	Plasmodium Choline transporter (Malaria CT)
DMADOK6	MT	DTT
DMADOK6	MA	Blocker
DMADOK6	RN	Novel molecular targets for antimalarial drug development. Chem Biol Drug Des. 2008 Apr;71(4):287-97.
DMADOK6	RU	https://pubmed.ncbi.nlm.nih.gov/18298458

DM3ZBGQ	DI	DM3ZBGQ
DM3ZBGQ	DN	G3139 + cytarabine (ARA-C)
DM3ZBGQ	MI	TTFOUV4
DM3ZBGQ	MN	BCL-2 messenger RNA (BCL2 mRNA)
DM3ZBGQ	MT	DTT
DM3ZBGQ	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DM3ZBGQ	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DMFJ1EI	DI	DMFJ1EI
DMFJ1EI	DN	G3139 + Dacarbazine
DMFJ1EI	MI	TTFOUV4
DMFJ1EI	MN	BCL-2 messenger RNA (BCL2 mRNA)
DMFJ1EI	MT	DTT
DMFJ1EI	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DMFJ1EI	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DMJ9DN3	DI	DMJ9DN3
DMJ9DN3	DN	G3139 + Dexamethasone
DMJ9DN3	MI	TTFOUV4
DMJ9DN3	MN	BCL-2 messenger RNA (BCL2 mRNA)
DMJ9DN3	MT	DTT
DMJ9DN3	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DMJ9DN3	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DMRVLZ4	DI	DMRVLZ4
DMRVLZ4	DN	G3139 + Fludarabine
DMRVLZ4	MI	TTFOUV4
DMRVLZ4	MN	BCL-2 messenger RNA (BCL2 mRNA)
DMRVLZ4	MT	DTT
DMRVLZ4	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DMRVLZ4	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DMH6UOL	DI	DMH6UOL
DMH6UOL	DN	G3139 + G-CSF
DMH6UOL	MI	TTFOUV4
DMH6UOL	MN	BCL-2 messenger RNA (BCL2 mRNA)
DMH6UOL	MT	DTT
DMH6UOL	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DMH6UOL	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DMZLJ21	DI	DMZLJ21
DMZLJ21	DN	G3139 + Irinotecan
DMZLJ21	MI	TTFOUV4
DMZLJ21	MN	BCL-2 messenger RNA (BCL2 mRNA)
DMZLJ21	MT	DTT
DMZLJ21	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DMZLJ21	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DM3MK9Z	DI	DM3MK9Z
DM3MK9Z	DN	G3139 + Paclitaxel
DM3MK9Z	MI	TTFOUV4
DM3MK9Z	MN	BCL-2 messenger RNA (BCL2 mRNA)
DM3MK9Z	MT	DTT
DM3MK9Z	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DM3MK9Z	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DM5KO80	DI	DM5KO80
DM5KO80	DN	G3139 + Thalidomide
DM5KO80	MI	TTFOUV4
DM5KO80	MN	BCL-2 messenger RNA (BCL2 mRNA)
DM5KO80	MT	DTT
DM5KO80	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DM5KO80	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DMDJCIP	DI	DMDJCIP
DMDJCIP	DN	G36
DMDJCIP	MI	TTDSB34
DMDJCIP	MN	G-protein coupled estrogen receptor 1 (GPER1)
DMDJCIP	MT	DTT
DMDJCIP	MA	Antagonist
DMDJCIP	RN	Identification of a GPER/GPR30 antagonist with improved estrogen receptor counterselectivity. J Steroid Biochem Mol Biol. 2011 Nov;127(3-5):358-66.
DMDJCIP	RU	https://pubmed.ncbi.nlm.nih.gov/21782022

DMKTJBU	DI	DMKTJBU
DMKTJBU	DN	G418
DMKTJBU	MI	TT38DW5
DMKTJBU	MN	Bacterial 16S ribosomal RNA (Bact 16S rRNA)
DMKTJBU	MT	DTT
DMKTJBU	MA	Inhibitor
DMKTJBU	RN	RNA as a target for small molecules. Curr Opin Chem Biol. 2000 Dec;4(6):678-86.
DMKTJBU	RU	https://pubmed.ncbi.nlm.nih.gov/11102874

DMKTJBU	DI	DMKTJBU
DMKTJBU	DN	G418
DMKTJBU	MI	TTUMGNO
DMKTJBU	MN	Ornithine decarboxylase (ODC1)
DMKTJBU	MT	DTT
DMKTJBU	MA	Inhibitor
DMKTJBU	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMKTJBU	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMKTJBU	DI	DMKTJBU
DMKTJBU	DN	G418
DMKTJBU	MI	DTUGYRD
DMKTJBU	MN	P-glycoprotein 1 (ABCB1)
DMKTJBU	MT	DTP
DMKTJBU	MA	Substrate
DMKTJBU	RN	ATP-binding cassette transporters as pitfalls in selection of transgenic cells. Anal Biochem. 2010 Apr 15;399(2):246-50.
DMKTJBU	RU	https://doi.org/10.1016/j.ab.2009.12.014

DMC54UG	DI	DMC54UG
DMC54UG	DN	G-573
DMC54UG	MI	TTROQ37
DMC54UG	MN	MAPK/ERK kinase kinase (MAP3K)
DMC54UG	MT	DTT
DMC54UG	MA	Inhibitor
DMC54UG	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2063).
DMC54UG	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2063

DMEZO4M	DI	DMEZO4M
DMEZO4M	DN	G6976
DMEZO4M	MI	TTSXVID
DMEZO4M	MN	Nuclear factor NF-kappa-B (NFKB)
DMEZO4M	MT	DTT
DMEZO4M	MA	Inhibitor
DMEZO4M	RN	Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8542-7.
DMEZO4M	RU	https://pubmed.ncbi.nlm.nih.gov/10900013

DMEZO4M	DI	DMEZO4M
DMEZO4M	DN	G6976
DMEZO4M	MI	TTYVX59
DMEZO4M	MN	Protein kinase C (PRKC)
DMEZO4M	MT	DTT
DMEZO4M	MA	Inhibitor
DMEZO4M	RN	The protein kinase C inhibitor G 6976 is a potent inhibitor of DNA damage-induced S and G2 cell cycle checkpoints. Cancer Res. 2003 Jan 1;63(1):31-5.
DMEZO4M	RU	https://pubmed.ncbi.nlm.nih.gov/12517773

DMEZO4M	DI	DMEZO4M
DMEZO4M	DN	G6976
DMEZO4M	MI	TTUWGRA
DMEZO4M	MN	Protein kinase C zeta (PRKCZ)
DMEZO4M	MT	DTT
DMEZO4M	MA	Inhibitor
DMEZO4M	RN	Protein kinase C zeta isoform is critical for proliferation in human glioblastoma cell lines. J Neurooncol. 2000 Apr;47(2):109-15.
DMEZO4M	RU	https://pubmed.ncbi.nlm.nih.gov/10982151

DMEZO4M	DI	DMEZO4M
DMEZO4M	DN	G6976
DMEZO4M	MI	TTSLUMT
DMEZO4M	MN	Protein kinase D (PRKD1)
DMEZO4M	MT	DTT
DMEZO4M	MA	Inhibitor
DMEZO4M	RN	Protein kinase D as a potential new target for cancer therapy. Biochim Biophys Acta. 2010 Dec;1806(2):183-92.
DMEZO4M	RU	https://pubmed.ncbi.nlm.nih.gov/20580776

DMC7HIS	DI	DMC7HIS
DMC7HIS	DN	G749
DMC7HIS	MI	TTGJCWZ
DMC7HIS	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMC7HIS	MT	DTT
DMC7HIS	MA	Inhibitor
DMC7HIS	RN	G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia. Blood. 2014 Apr 3;123(14):2209-19.
DMC7HIS	RU	https://pubmed.ncbi.nlm.nih.gov/24532805

DMC7HIS	DI	DMC7HIS
DMC7HIS	DN	G749
DMC7HIS	MI	TTO7LKR
DMC7HIS	MN	Tyrosine-protein kinase Mer (MERTK)
DMC7HIS	MT	DTT
DMC7HIS	MA	Inhibitor
DMC7HIS	RN	G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia. Blood. 2014 Apr 3;123(14):2209-19.
DMC7HIS	RU	https://pubmed.ncbi.nlm.nih.gov/24532805

DMOF7JL	DI	DMOF7JL
DMOF7JL	DN	GABA-B receptor PAM
DMOF7JL	MI	TTDCVZW
DMOF7JL	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMOF7JL	MT	DTT
DMOF7JL	MA	Modulator
DMOF7JL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 241).
DMOF7JL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=241

DMDEAWS	DI	DMDEAWS
DMDEAWS	DN	Gababutin
DMDEAWS	MI	TTFK1JQ
DMDEAWS	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMDEAWS	MT	DTT
DMDEAWS	MA	Inhibitor
DMDEAWS	RN	Synthesis and in vivo evaluation of 3-substituted gababutins. Bioorg Med Chem Lett. 2010 Jan 1;20(1):362-5.
DMDEAWS	RU	https://pubmed.ncbi.nlm.nih.gov/19897364

DMH17MU	DI	DMH17MU
DMH17MU	DN	Gabaculine
DMH17MU	MI	TT6LDTK
DMH17MU	MN	Bacterial Glutamate-1-semialdehyde aminomutase (Bact hemL)
DMH17MU	MT	DTT
DMH17MU	MA	Inhibitor
DMH17MU	RN	A suicide vector for allelic recombination involving the gene for glutamate 1-semialdehyde aminotransferase in the cyanobacterium Synechococcus PCC 7942. Mol Gen Genet. 1997 Jul;255(4):392-9.
DMH17MU	RU	https://pubmed.ncbi.nlm.nih.gov/9267435

DM5TQ2O	DI	DM5TQ2O
DM5TQ2O	DN	Galangin
DM5TQ2O	MI	TTM2AOE
DM5TQ2O	MN	Adenosine A2a receptor (ADORA2A)
DM5TQ2O	MT	DTT
DM5TQ2O	MA	Inhibitor
DM5TQ2O	RN	Mutagenesis reveals structure-activity parallels between human A2A adenosine receptors and biogenic amine G protein-coupled receptors. J Med Chem. 1997 Aug 1;40(16):2588-95.
DM5TQ2O	RU	https://pubmed.ncbi.nlm.nih.gov/9258366

DM5TQ2O	DI	DM5TQ2O
DM5TQ2O	DN	Galangin
DM5TQ2O	MI	TTJFY5U
DM5TQ2O	MN	Adenosine A3 receptor (ADORA3)
DM5TQ2O	MT	DTT
DM5TQ2O	MA	Inhibitor
DM5TQ2O	RN	Interactions of flavonoids and other phytochemicals with adenosine receptors. J Med Chem. 1996 Feb 2;39(3):781-8.
DM5TQ2O	RU	https://pubmed.ncbi.nlm.nih.gov/8576921

DM5TQ2O	DI	DM5TQ2O
DM5TQ2O	DN	Galangin
DM5TQ2O	MI	TTI84H7
DM5TQ2O	MN	Cytochrome P450 1B1 (CYP1B1)
DM5TQ2O	MT	DTT
DM5TQ2O	MA	Inhibitor
DM5TQ2O	RN	Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5.
DM5TQ2O	RU	https://pubmed.ncbi.nlm.nih.gov/20696580

DMHPV8A	DI	DMHPV8A
DMHPV8A	DN	GALANIN
DMHPV8A	MI	TTX3HNZ
DMHPV8A	MN	Galanin receptor type 1 (GAL1-R)
DMHPV8A	MT	DTT
DMHPV8A	MA	Inhibitor
DMHPV8A	RN	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
DMHPV8A	RU	https://pubmed.ncbi.nlm.nih.gov/18983139

DMHPV8A	DI	DMHPV8A
DMHPV8A	DN	GALANIN
DMHPV8A	MI	TTBPW3J
DMHPV8A	MN	Galanin receptor type 2 (GAL2-R)
DMHPV8A	MT	DTT
DMHPV8A	MA	Inhibitor
DMHPV8A	RN	Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69.
DMHPV8A	RU	https://pubmed.ncbi.nlm.nih.gov/18588282

DMAFE24	DI	DMAFE24
DMAFE24	DN	Galanthamine derivative
DMAFE24	MI	TT1RS9F
DMAFE24	MN	Acetylcholinesterase (AChE)
DMAFE24	MT	DTT
DMAFE24	MA	Inhibitor
DMAFE24	RN	Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely... J Med Chem. 2008 Jun 12;51(11):3154-70.
DMAFE24	RU	https://pubmed.ncbi.nlm.nih.gov/18479118

DMDZHEO	DI	DMDZHEO
DMDZHEO	DN	GALANTIDE
DMDZHEO	MI	TTX3HNZ
DMDZHEO	MN	Galanin receptor type 1 (GAL1-R)
DMDZHEO	MT	DTT
DMDZHEO	MA	Inhibitor
DMDZHEO	RN	Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5.
DMDZHEO	RU	https://pubmed.ncbi.nlm.nih.gov/20121116

DMDZHEO	DI	DMDZHEO
DMDZHEO	DN	GALANTIDE
DMDZHEO	MI	TTBPW3J
DMDZHEO	MN	Galanin receptor type 2 (GAL2-R)
DMDZHEO	MT	DTT
DMDZHEO	MA	Inhibitor
DMDZHEO	RN	Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5.
DMDZHEO	RU	https://pubmed.ncbi.nlm.nih.gov/20121116

DMGX6UH	DI	DMGX6UH
DMGX6UH	DN	GalB2
DMGX6UH	MI	TTX3HNZ
DMGX6UH	MN	Galanin receptor type 1 (GAL1-R)
DMGX6UH	MT	DTT
DMGX6UH	MA	Inhibitor
DMGX6UH	RN	Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5.
DMGX6UH	RU	https://pubmed.ncbi.nlm.nih.gov/20121116

DMGX6UH	DI	DMGX6UH
DMGX6UH	DN	GalB2
DMGX6UH	MI	TTBPW3J
DMGX6UH	MN	Galanin receptor type 2 (GAL2-R)
DMGX6UH	MT	DTT
DMGX6UH	MA	Inhibitor
DMGX6UH	RN	Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5.
DMGX6UH	RU	https://pubmed.ncbi.nlm.nih.gov/20121116

DM7PR5E	DI	DM7PR5E
DM7PR5E	DN	Gal-B5
DM7PR5E	MI	TTX3HNZ
DM7PR5E	MN	Galanin receptor type 1 (GAL1-R)
DM7PR5E	MT	DTT
DM7PR5E	MA	Inhibitor
DM7PR5E	RN	Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5.
DM7PR5E	RU	https://pubmed.ncbi.nlm.nih.gov/20121116

DM7PR5E	DI	DM7PR5E
DM7PR5E	DN	Gal-B5
DM7PR5E	MI	TTBPW3J
DM7PR5E	MN	Galanin receptor type 2 (GAL2-R)
DM7PR5E	MT	DTT
DM7PR5E	MA	Inhibitor
DM7PR5E	RN	Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5.
DM7PR5E	RU	https://pubmed.ncbi.nlm.nih.gov/20121116

DMNWU83	DI	DMNWU83
DMNWU83	DN	Gallic acid 5,6-dihydroxy-3-carboxyphenylester
DMNWU83	MI	TTIU7X1
DMNWU83	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMNWU83	MT	DTT
DMNWU83	MA	Inhibitor
DMNWU83	RN	Differential inhibition of reverse transcriptase and various DNA polymerases by digallic acid and its derivatives. J Nat Prod. 1990 Sep-Oct;53(5):1234-40.
DMNWU83	RU	https://pubmed.ncbi.nlm.nih.gov/1705574

DM6Y3A0	DI	DM6Y3A0
DM6Y3A0	DN	GALLICACID
DM6Y3A0	MI	TTUNARX
DM6Y3A0	MN	Carbonic anhydrase (CA)
DM6Y3A0	MT	DTT
DM6Y3A0	MA	Inhibitor
DM6Y3A0	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DM6Y3A0	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DM6Y3A0	DI	DM6Y3A0
DM6Y3A0	DN	GALLICACID
DM6Y3A0	MI	TTHQPL7
DM6Y3A0	MN	Carbonic anhydrase I (CA-I)
DM6Y3A0	MT	DTT
DM6Y3A0	MA	Inhibitor
DM6Y3A0	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DM6Y3A0	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DM6Y3A0	DI	DM6Y3A0
DM6Y3A0	DN	GALLICACID
DM6Y3A0	MI	TTANPDJ
DM6Y3A0	MN	Carbonic anhydrase II (CA-II)
DM6Y3A0	MT	DTT
DM6Y3A0	MA	Inhibitor
DM6Y3A0	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DM6Y3A0	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DM6Y3A0	DI	DM6Y3A0
DM6Y3A0	DN	GALLICACID
DM6Y3A0	MI	TTZHA0O
DM6Y3A0	MN	Carbonic anhydrase IV (CA-IV)
DM6Y3A0	MT	DTT
DM6Y3A0	MA	Inhibitor
DM6Y3A0	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DM6Y3A0	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DM6Y3A0	DI	DM6Y3A0
DM6Y3A0	DN	GALLICACID
DM6Y3A0	MI	TT2LVK8
DM6Y3A0	MN	Carbonic anhydrase IX (CA-IX)
DM6Y3A0	MT	DTT
DM6Y3A0	MA	Inhibitor
DM6Y3A0	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DM6Y3A0	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DM6Y3A0	DI	DM6Y3A0
DM6Y3A0	DN	GALLICACID
DM6Y3A0	MI	TTCFSPE
DM6Y3A0	MN	Carbonic anhydrase VI (CA-VI)
DM6Y3A0	MT	DTT
DM6Y3A0	MA	Inhibitor
DM6Y3A0	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DM6Y3A0	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DM6Y3A0	DI	DM6Y3A0
DM6Y3A0	DN	GALLICACID
DM6Y3A0	MI	TTSYM0R
DM6Y3A0	MN	Carbonic anhydrase XII (CA-XII)
DM6Y3A0	MT	DTT
DM6Y3A0	MA	Inhibitor
DM6Y3A0	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DM6Y3A0	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DM6Y3A0	DI	DM6Y3A0
DM6Y3A0	DN	GALLICACID
DM6Y3A0	MI	TTEYTKG
DM6Y3A0	MN	Carbonic anhydrase XIV (CA-XIV)
DM6Y3A0	MT	DTT
DM6Y3A0	MA	Inhibitor
DM6Y3A0	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DM6Y3A0	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DM6Y3A0	DI	DM6Y3A0
DM6Y3A0	DN	GALLICACID
DM6Y3A0	MI	TTE5VG0
DM6Y3A0	MN	P-selectin (SELP)
DM6Y3A0	MT	DTT
DM6Y3A0	MA	Inhibitor
DM6Y3A0	RN	Rational design of novel, potent small molecule pan-selectin antagonists. J Med Chem. 2007 Mar 22;50(6):1101-15.
DM6Y3A0	RU	https://pubmed.ncbi.nlm.nih.gov/17302397

DMX2084	DI	DMX2084
DMX2084	DN	GALLOCATECHIN GALLATE
DMX2084	MI	TT7AOUD
DMX2084	MN	Fatty acid synthase (FASN)
DMX2084	MT	DTT
DMX2084	MA	Inhibitor
DMX2084	RN	Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
DMX2084	RU	https://pubmed.ncbi.nlm.nih.gov/16722653

DMX2084	DI	DMX2084
DMX2084	DN	GALLOCATECHIN GALLATE
DMX2084	MI	TTHPFTS
DMX2084	MN	Plasmodium Beta-hydroxyacyl-ACP dehydratase (Malaria FabZ)
DMX2084	MT	DTT
DMX2084	MA	Inhibitor
DMX2084	RN	Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
DMX2084	RU	https://pubmed.ncbi.nlm.nih.gov/16722653

DMX2084	DI	DMX2084
DMX2084	DN	GALLOCATECHIN GALLATE
DMX2084	MI	TTNX2CS
DMX2084	MN	Plasmodium Enoyl-ACP reductase (Malaria fabI)
DMX2084	MT	DTT
DMX2084	MA	Inhibitor
DMX2084	RN	Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
DMX2084	RU	https://pubmed.ncbi.nlm.nih.gov/16722653

DMX2084	DI	DMX2084
DMX2084	DN	GALLOCATECHIN GALLATE
DMX2084	MI	TTBE4IR
DMX2084	MN	Plasmodium Oxoacyl-[acyl-carrier protein] reductase (Malaria fabG)
DMX2084	MT	DTT
DMX2084	MA	Inhibitor
DMX2084	RN	Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
DMX2084	RU	https://pubmed.ncbi.nlm.nih.gov/16722653

DML9DH8	DI	DML9DH8
DML9DH8	DN	galmic
DML9DH8	MI	TTOPAY7
DML9DH8	MN	Galanin receptor (GAL-R)
DML9DH8	MT	DTT
DML9DH8	MA	Agonist
DML9DH8	RN	Galmic, a nonpeptide galanin receptor agonist, affects behaviors in seizure, pain, and forced-swim tests. Proc Natl Acad Sci U S A. 2004 Jul 13;101(28):10470-5.
DML9DH8	RU	https://pubmed.ncbi.nlm.nih.gov/15240875

DMB8HCW	DI	DMB8HCW
DMB8HCW	DN	Galnon
DMB8HCW	MI	TTX3HNZ
DMB8HCW	MN	Galanin receptor type 1 (GAL1-R)
DMB8HCW	MT	DTT
DMB8HCW	MA	Agonist
DMB8HCW	RN	Anticonvulsant activity of a nonpeptide galanin receptor agonist. Proc Natl Acad Sci U S A. 2002 May 14;99(10):7136-41.
DMB8HCW	RU	https://pubmed.ncbi.nlm.nih.gov/12011470

DMI7RPT	DI	DMI7RPT
DMI7RPT	DN	GalR3ant
DMI7RPT	MI	TTOPAY7
DMI7RPT	MN	Galanin receptor (GAL-R)
DMI7RPT	MT	DTT
DMI7RPT	MA	Antagonist
DMI7RPT	RN	Galanin (2-11) binds to GalR3 in transfected cell lines: limitations for pharmacological definition of receptor subtypes. Neuropeptides. 2005 Jun;39(3):165-7.
DMI7RPT	RU	https://pubmed.ncbi.nlm.nih.gov/15944007

DMFSXOM	DI	DMFSXOM
DMFSXOM	DN	Gamma-acetylenic GABA
DMFSXOM	MI	TTT2LD9
DMFSXOM	MN	GABA transaminase (ABAT)
DMFSXOM	MT	DTT
DMFSXOM	MA	Inhibitor
DMFSXOM	RN	Treatment of Huntington disease with gamma-acetylenic GABA an irreversible inhibitor of GABA-transaminase: increased CSF GABA and homocarnosine without clinical amelioration. Neurology. 1981 Feb;31(2):207-11.
DMFSXOM	RU	https://pubmed.ncbi.nlm.nih.gov/6258106

DMDCZWY	DI	DMDCZWY
DMDCZWY	DN	Gamma-butyrolactone
DMDCZWY	MI	DESDN74
DMDCZWY	MN	Serum paraoxonase/arylesterase 1 (PON1)
DMDCZWY	MT	DME
DMDCZWY	MA	Metabolism
DMDCZWY	RN	Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos. 2000 Nov;28(11):1335-42.
DMDCZWY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11038162

DMZMCT0	DI	DMZMCT0
DMZMCT0	DN	Gamma-Carboxy-Glutamic Acid
DMZMCT0	MI	TT6L509
DMZMCT0	MN	Coagulation factor IIa (F2)
DMZMCT0	MT	DTT
DMZMCT0	MA	Inhibitor
DMZMCT0	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMZMCT0	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMZMCT0	DI	DMZMCT0
DMZMCT0	DN	Gamma-Carboxy-Glutamic Acid
DMZMCT0	MI	TTFEZ5Q
DMZMCT0	MN	Coagulation factor IX (F9)
DMZMCT0	MT	DTT
DMZMCT0	MA	Inhibitor
DMZMCT0	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMZMCT0	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMZMCT0	DI	DMZMCT0
DMZMCT0	DN	Gamma-Carboxy-Glutamic Acid
DMZMCT0	MI	TTCIHJA
DMZMCT0	MN	Coagulation factor Xa (F10)
DMZMCT0	MT	DTT
DMZMCT0	MA	Inhibitor
DMZMCT0	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMZMCT0	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMHNJDE	DI	DMHNJDE
DMHNJDE	DN	Gamma-Glutamyl[S-(2-Iodobenzyl)Cysteinyl]Glycine
DMHNJDE	MI	TTJ0IQB
DMHNJDE	MN	Phosphodiesterase 5A (PDE5A)
DMHNJDE	MT	DTT
DMHNJDE	MA	Inhibitor
DMHNJDE	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMHNJDE	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMC0OVP	DI	DMC0OVP
DMC0OVP	DN	Gamma-mangostin
DMC0OVP	MI	TTSZLWK
DMC0OVP	MN	Aromatase (CYP19A1)
DMC0OVP	MT	DTT
DMC0OVP	MA	Inhibitor
DMC0OVP	RN	Xanthones from the botanical dietary supplement mangosteen (Garcinia mangostana) with aromatase inhibitory activity. J Nat Prod. 2008 Jul;71(7):1161-6.
DMC0OVP	RU	https://pubmed.ncbi.nlm.nih.gov/18558747

DMC0OVP	DI	DMC0OVP
DMC0OVP	DN	Gamma-mangostin
DMC0OVP	MI	TT50QJ3
DMC0OVP	MN	Influenza Neuraminidase (Influ NA)
DMC0OVP	MT	DTT
DMC0OVP	MA	Inhibitor
DMC0OVP	RN	Xanthones with neuraminidase inhibitory activity from the seedcases of Garcinia mangostana. Bioorg Med Chem. 2010 Sep 1;18(17):6258-64.
DMC0OVP	RU	https://pubmed.ncbi.nlm.nih.gov/20696581

DMG7UPR	DI	DMG7UPR
DMG7UPR	DN	Gamma-secretase modulators
DMG7UPR	MI	TTE4KHA
DMG7UPR	MN	Amyloid beta A4 protein (APP)
DMG7UPR	MT	DTT
DMG7UPR	MA	Modulator
DMG7UPR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
DMG7UPR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402

DM83HUI	DI	DM83HUI
DM83HUI	DN	Gamma-thiobutyrolactone
DM83HUI	MI	DESDN74
DM83HUI	MN	Serum paraoxonase/arylesterase 1 (PON1)
DM83HUI	MT	DME
DM83HUI	MA	Metabolism
DM83HUI	RN	Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos. 2000 Nov;28(11):1335-42.
DM83HUI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11038162

DM42EVG	DI	DM42EVG
DM42EVG	DN	Ganoderic acid A
DM42EVG	MI	TT9H85R
DM42EVG	MN	Corticosteroid 11-beta-dehydrogenase 2 (HSD11B2)
DM42EVG	MT	DTT
DM42EVG	MA	Inhibitor
DM42EVG	RN	11beta-Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational a... Bioorg Med Chem. 2010 Feb 15;18(4):1507-15.
DM42EVG	RU	https://pubmed.ncbi.nlm.nih.gov/20100662

DMFT4GU	DI	DMFT4GU
DMFT4GU	DN	GANSTIGMINE
DMFT4GU	MI	TT1RS9F
DMFT4GU	MN	Acetylcholinesterase (AChE)
DMFT4GU	MT	DTT
DMFT4GU	MA	Inhibitor
DMFT4GU	RN	Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely... J Med Chem. 2008 Jun 12;51(11):3154-70.
DMFT4GU	RU	https://pubmed.ncbi.nlm.nih.gov/18479118

DM6B9ZG	DI	DM6B9ZG
DM6B9ZG	DN	garcinol
DM6B9ZG	MI	TTVK7SB
DM6B9ZG	MN	Histone acetyltransferase KAT2B (KAT2B)
DM6B9ZG	MT	DTT
DM6B9ZG	MA	Inhibitor
DM6B9ZG	RN	Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene e... J Biol Chem. 2004 Aug 6;279(32):33716-26.
DM6B9ZG	RU	https://pubmed.ncbi.nlm.nih.gov/15155757

DM6B9ZG	DI	DM6B9ZG
DM6B9ZG	DN	garcinol
DM6B9ZG	MI	TTH4VJL
DM6B9ZG	MN	Histone acetyltransferase KAT6B (KAT6B)
DM6B9ZG	MT	DTT
DM6B9ZG	MA	Inhibitor
DM6B9ZG	RN	Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene e... J Biol Chem. 2004 Aug 6;279(32):33716-26.
DM6B9ZG	RU	https://pubmed.ncbi.nlm.nih.gov/15155757

DMQDV3U	DI	DMQDV3U
DMQDV3U	DN	GARCINONE D
DMQDV3U	MI	TTSZLWK
DMQDV3U	MN	Aromatase (CYP19A1)
DMQDV3U	MT	DTT
DMQDV3U	MA	Inhibitor
DMQDV3U	RN	Xanthones from the botanical dietary supplement mangosteen (Garcinia mangostana) with aromatase inhibitory activity. J Nat Prod. 2008 Jul;71(7):1161-6.
DMQDV3U	RU	https://pubmed.ncbi.nlm.nih.gov/18558747

DMQDV3U	DI	DMQDV3U
DMQDV3U	DN	GARCINONE D
DMQDV3U	MI	TT50QJ3
DMQDV3U	MN	Influenza Neuraminidase (Influ NA)
DMQDV3U	MT	DTT
DMQDV3U	MA	Inhibitor
DMQDV3U	RN	Xanthones with neuraminidase inhibitory activity from the seedcases of Garcinia mangostana. Bioorg Med Chem. 2010 Sep 1;18(17):6258-64.
DMQDV3U	RU	https://pubmed.ncbi.nlm.nih.gov/20696581

DMZ5AD8	DI	DMZ5AD8
DMZ5AD8	DN	GARTANIN
DMZ5AD8	MI	TT50QJ3
DMZ5AD8	MN	Influenza Neuraminidase (Influ NA)
DMZ5AD8	MT	DTT
DMZ5AD8	MA	Inhibitor
DMZ5AD8	RN	Xanthones with neuraminidase inhibitory activity from the seedcases of Garcinia mangostana. Bioorg Med Chem. 2010 Sep 1;18(17):6258-64.
DMZ5AD8	RU	https://pubmed.ncbi.nlm.nih.gov/20696581

DM7GX1S	DI	DM7GX1S
DM7GX1S	DN	GARVEATIN A
DM7GX1S	MI	TTZJYKH
DM7GX1S	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DM7GX1S	MT	DTT
DM7GX1S	MA	Inhibitor
DM7GX1S	RN	Indoleamine 2,3-dioxygenase inhibitors from the Northeastern Pacific Marine Hydroid Garveia annulata. J Nat Prod. 2006 Oct;69(10):1496-9.
DM7GX1S	RU	https://pubmed.ncbi.nlm.nih.gov/17067170

DMXNQ15	DI	DMXNQ15
DMXNQ15	DN	Garveatin C
DMXNQ15	MI	TTZJYKH
DMXNQ15	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMXNQ15	MT	DTT
DMXNQ15	MA	Inhibitor
DMXNQ15	RN	Indoleamine 2,3-dioxygenase inhibitors from the Northeastern Pacific Marine Hydroid Garveia annulata. J Nat Prod. 2006 Oct;69(10):1496-9.
DMXNQ15	RU	https://pubmed.ncbi.nlm.nih.gov/17067170

DMUFZ18	DI	DMUFZ18
DMUFZ18	DN	Garveatin E
DMUFZ18	MI	TTZJYKH
DMUFZ18	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMUFZ18	MT	DTT
DMUFZ18	MA	Inhibitor
DMUFZ18	RN	Indoleamine 2,3-dioxygenase inhibitors from the Northeastern Pacific Marine Hydroid Garveia annulata. J Nat Prod. 2006 Oct;69(10):1496-9.
DMUFZ18	RU	https://pubmed.ncbi.nlm.nih.gov/17067170

DMWFYJ4	DI	DMWFYJ4
DMWFYJ4	DN	GB110
DMWFYJ4	MI	TTQR74A
DMWFYJ4	MN	Proteinase activated receptor 2 (PAR2)
DMWFYJ4	MT	DTT
DMWFYJ4	MA	Agonist
DMWFYJ4	RN	Novel agonists and antagonists for human protease activated receptor 2. J Med Chem. 2010 Oct 28;53(20):7428-40.
DMWFYJ4	RU	https://pubmed.ncbi.nlm.nih.gov/20873792

DM7B5HA	DI	DM7B5HA
DM7B5HA	DN	GB-12819
DM7B5HA	MI	TTVG215
DM7B5HA	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DM7B5HA	MT	DTT
DM7B5HA	MA	Inhibitor
DM7B5HA	RN	Catalytic site prediction and virtual screening of cytochrome P450 2D6 substrates by consideration of water and rescoring in automated docking. J Med Chem. 2006 Apr 20;49(8):2417-30.
DM7B5HA	RU	https://pubmed.ncbi.nlm.nih.gov/16610785

DM7B5HA	DI	DM7B5HA
DM7B5HA	DN	GB-12819
DM7B5HA	MI	TTVBI8W
DM7B5HA	MN	Dopamine transporter (DAT)
DM7B5HA	MT	DTT
DM7B5HA	MA	Inhibitor
DM7B5HA	RN	Synthesis and dopamine transporter binding affinities of 3alpha-benzyl-8-(diarylmethoxyethyl)-8-azabicyclo[3.2.1]octanes. Bioorg Med Chem Lett. 2002 Sep 2;12(17):2387-90.
DM7B5HA	RU	https://pubmed.ncbi.nlm.nih.gov/12161139

DMLDVFM	DI	DMLDVFM
DMLDVFM	DN	GB88
DMLDVFM	MI	TTQR74A
DMLDVFM	MN	Proteinase activated receptor 2 (PAR2)
DMLDVFM	MT	DTT
DMLDVFM	MA	Antagonist
DMLDVFM	RN	Modulating human proteinase activated receptor 2 with a novel antagonist (GB88) and agonist (GB110). Br J Pharmacol. 2012 Mar;165(5):1413-23.
DMLDVFM	RU	https://pubmed.ncbi.nlm.nih.gov/21806599

DMPOML4	DI	DMPOML4
DMPOML4	DN	GBR 12530
DMPOML4	MI	TTVG215
DMPOML4	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DMPOML4	MT	DTT
DMPOML4	MA	Inhibitor
DMPOML4	RN	Catalytic site prediction and virtual screening of cytochrome P450 2D6 substrates by consideration of water and rescoring in automated docking. J Med Chem. 2006 Apr 20;49(8):2417-30.
DMPOML4	RU	https://pubmed.ncbi.nlm.nih.gov/16610785

DM2CUNP	DI	DM2CUNP
DM2CUNP	DN	GBR-12289
DM2CUNP	MI	TTVG215
DM2CUNP	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DM2CUNP	MT	DTT
DM2CUNP	MA	Inhibitor
DM2CUNP	RN	Catalytic site prediction and virtual screening of cytochrome P450 2D6 substrates by consideration of water and rescoring in automated docking. J Med Chem. 2006 Apr 20;49(8):2417-30.
DM2CUNP	RU	https://pubmed.ncbi.nlm.nih.gov/16610785

DMYMGBA	DI	DMYMGBA
DMYMGBA	DN	GC-14
DMYMGBA	MI	TTQWUPT
DMYMGBA	MN	Thyroid hormone receptor (THR)
DMYMGBA	MT	DTT
DMYMGBA	MA	Antagonist
DMYMGBA	RN	Design of thyroid hormone receptor antagonists from first principles. J Steroid Biochem Mol Biol. 2002 Dec;83(1-5):59-73.
DMYMGBA	RU	https://pubmed.ncbi.nlm.nih.gov/12650702

DM46HAS	DI	DM46HAS
DM46HAS	DN	GC-2107
DM46HAS	MI	TTCIHJA
DM46HAS	MN	Coagulation factor Xa (F10)
DM46HAS	MT	DTT
DM46HAS	MA	Inhibitor
DM46HAS	RN	Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7.
DM46HAS	RU	https://pubmed.ncbi.nlm.nih.gov/22844656

DMSF8B9	DI	DMSF8B9
DMSF8B9	DN	GC-24
DMSF8B9	MI	TTGER3L
DMSF8B9	MN	Thyroid hormone receptor beta (THRB)
DMSF8B9	MT	DTT
DMSF8B9	MA	Inhibitor
DMSF8B9	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMSF8B9	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM4BZEC	DI	DM4BZEC
DM4BZEC	DN	GCCSHPACAGNNQHIC*
DM4BZEC	MI	TTLA931
DM4BZEC	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DM4BZEC	MT	DTT
DM4BZEC	MA	Inhibitor
DM4BZEC	RN	Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations. J Med Chem. 2005 Jul 28;48(15):4705-45.
DM4BZEC	RU	https://pubmed.ncbi.nlm.nih.gov/16033252

DM4BZEC	DI	DM4BZEC
DM4BZEC	DN	GCCSHPACAGNNQHIC*
DM4BZEC	MI	TT5KPZR
DM4BZEC	MN	Neuronal acetylcholine receptor beta-2 (CHRNB2)
DM4BZEC	MT	DTT
DM4BZEC	MA	Inhibitor
DM4BZEC	RN	Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations. J Med Chem. 2005 Jul 28;48(15):4705-45.
DM4BZEC	RU	https://pubmed.ncbi.nlm.nih.gov/16033252

DMJ0ICN	DI	DMJ0ICN
DMJ0ICN	DN	GCCSNPVCHLEHSNLC*
DMJ0ICN	MI	TTLA931
DMJ0ICN	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMJ0ICN	MT	DTT
DMJ0ICN	MA	Inhibitor
DMJ0ICN	RN	Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations. J Med Chem. 2005 Jul 28;48(15):4705-45.
DMJ0ICN	RU	https://pubmed.ncbi.nlm.nih.gov/16033252

DMJ0ICN	DI	DMJ0ICN
DMJ0ICN	DN	GCCSNPVCHLEHSNLC*
DMJ0ICN	MI	TT5KPZR
DMJ0ICN	MN	Neuronal acetylcholine receptor beta-2 (CHRNB2)
DMJ0ICN	MT	DTT
DMJ0ICN	MA	Inhibitor
DMJ0ICN	RN	Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations. J Med Chem. 2005 Jul 28;48(15):4705-45.
DMJ0ICN	RU	https://pubmed.ncbi.nlm.nih.gov/16033252

DMJ0ICN	DI	DMJ0ICN
DMJ0ICN	DN	GCCSNPVCHLEHSNLC*
DMJ0ICN	MI	TTTVAFQ
DMJ0ICN	MN	Neuronal acetylcholine receptor beta-4 (CHRNB4)
DMJ0ICN	MT	DTT
DMJ0ICN	MA	Inhibitor
DMJ0ICN	RN	Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations. J Med Chem. 2005 Jul 28;48(15):4705-45.
DMJ0ICN	RU	https://pubmed.ncbi.nlm.nih.gov/16033252

DMVFDYU	DI	DMVFDYU
DMVFDYU	DN	G-CSF
DMVFDYU	MI	TTC70AJ
DMVFDYU	MN	Granulocyte colony-stimulating factor receptor (G-CSF-R)
DMVFDYU	MT	DTT
DMVFDYU	MA	Stimulator
DMVFDYU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1719).
DMVFDYU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1719

DMF6MUB	DI	DMF6MUB
DMF6MUB	DN	GDP-alpha-D-glucose
DMF6MUB	MI	DE9P5K7
DMF6MUB	MN	GDP-D-glucose phosphorylase 1 (GDPGP1)
DMF6MUB	MT	DME
DMF6MUB	MA	Metabolism
DMF6MUB	RN	A novel GDP-D-glucose phosphorylase involved in quality control of the nucleoside diphosphate sugar pool in Caenorhabditis elegans and mammals. J Biol Chem. 2011 Jun 17;286(24):21511-23.
DMF6MUB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21507950

DMZMULS	DI	DMZMULS
DMZMULS	DN	Gdp-Fucose
DMZMULS	MI	DT3LZWR
DMZMULS	MN	GDP-fucose transporter 1 (SLC35C1)
DMZMULS	MT	DTP
DMZMULS	MA	Substrate
DMZMULS	RN	Golgi GDP-fucose transporter-deficient mice mimic congenital disorder of glycosylation IIc/leukocyte adhesion deficiency II. J Biol Chem. 2007 Apr 6;282(14):10762-72.
DMZMULS	RU	http://www.ncbi.nlm.nih.gov/pubmed/17276979

DM9ARQ1	DI	DM9ARQ1
DM9ARQ1	DN	GDP-l-fucose
DM9ARQ1	MI	DEP8X02
DM9ARQ1	MN	Fucosyltransferase X (FUT10)
DM9ARQ1	MT	DME
DM9ARQ1	MA	Metabolism
DM9ARQ1	RN	Activity, splice variants, conserved peptide motifs, and phylogeny of two new alpha1,3-fucosyltransferase families (FUT10 and FUT11). J Biol Chem. 2009 Feb 13;284(7):4723-38.
DM9ARQ1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19088067

DM9ARQ1	DI	DM9ARQ1
DM9ARQ1	DN	GDP-l-fucose
DM9ARQ1	MI	DERG61P
DM9ARQ1	MN	Fucosyltransferase XI (FUT11)
DM9ARQ1	MT	DME
DM9ARQ1	MA	Metabolism
DM9ARQ1	RN	Activity, splice variants, conserved peptide motifs, and phylogeny of two new alpha1,3-fucosyltransferase families (FUT10 and FUT11). J Biol Chem. 2009 Feb 13;284(7):4723-38.
DM9ARQ1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19088067

DMOC25M	DI	DMOC25M
DMOC25M	DN	GDP-mannose
DMOC25M	MI	DE8K7F3
DMOC25M	MN	GDP-mannose 4,6-dehydratase (GMDS)
DMOC25M	MT	DME
DMOC25M	MA	Metabolism
DMOC25M	RN	Structural and enzymatic characterization of human recombinant GDP-D-mannose-4,6-dehydratase. FEBS Lett. 1999 Aug 13;456(3):370-4.
DMOC25M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10462046

DMB813H	DI	DMB813H
DMB813H	DN	GE-137
DMB813H	MI	TTNDSF4
DMB813H	MN	Proto-oncogene c-Met (MET)
DMB813H	MT	DTT
DMB813H	MA	Modulator
DMB813H	RN	Detection of colorectal polyps in humans using an intravenously administered fluorescent peptide targeted against c-Met. Nat Med. 2015 Aug;21(8):955-61.
DMB813H	RU	https://pubmed.ncbi.nlm.nih.gov/26168295

DMBGWEK	DI	DMBGWEK
DMBGWEK	DN	GEA 3162
DMBGWEK	MI	TTEBMN7
DMBGWEK	MN	Long transient receptor potential channel 2 (TRPM2)
DMBGWEK	MT	DTT
DMBGWEK	MA	Activator
DMBGWEK	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 494).
DMBGWEK	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=494

DMUSJ96	DI	DMUSJ96
DMUSJ96	DN	Geldanamycin-estradiol hybrid
DMUSJ96	MI	TTR5TV4
DMUSJ96	MN	ERBB2 messenger RNA (HER2 mRNA)
DMUSJ96	MT	DTT
DMUSJ96	MA	Inhibitor
DMUSJ96	RN	Synthesis and evaluation of geldanamycin-estradiol hybrids. Bioorg Med Chem Lett. 1999 May 3;9(9):1233-8.
DMUSJ96	RU	https://pubmed.ncbi.nlm.nih.gov/10340605

DMUSJ96	DI	DMUSJ96
DMUSJ96	DN	Geldanamycin-estradiol hybrid
DMUSJ96	MI	TTZAYWL
DMUSJ96	MN	Estrogen receptor (ESR)
DMUSJ96	MT	DTT
DMUSJ96	MA	Inhibitor
DMUSJ96	RN	Synthesis and evaluation of geldanamycin-estradiol hybrids. Bioorg Med Chem Lett. 1999 May 3;9(9):1233-8.
DMUSJ96	RU	https://pubmed.ncbi.nlm.nih.gov/10340605

DMUSJ96	DI	DMUSJ96
DMUSJ96	DN	Geldanamycin-estradiol hybrid
DMUSJ96	MI	TTOM3J0
DMUSJ96	MN	Estrogen receptor beta (ESR2)
DMUSJ96	MT	DTT
DMUSJ96	MA	Inhibitor
DMUSJ96	RN	Synthesis and evaluation of geldanamycin-estradiol hybrids. Bioorg Med Chem Lett. 1999 May 3;9(9):1233-8.
DMUSJ96	RU	https://pubmed.ncbi.nlm.nih.gov/10340605

DMUSJ96	DI	DMUSJ96
DMUSJ96	DN	Geldanamycin-estradiol hybrid
DMUSJ96	MI	TT78R5H
DMUSJ96	MN	Heat shock protein 90 alpha (HSP90A)
DMUSJ96	MT	DTT
DMUSJ96	MA	Inhibitor
DMUSJ96	RN	Synthesis and evaluation of geldanamycin-estradiol hybrids. Bioorg Med Chem Lett. 1999 May 3;9(9):1233-8.
DMUSJ96	RU	https://pubmed.ncbi.nlm.nih.gov/10340605

DML0OUY	DI	DML0OUY
DML0OUY	DN	Gelsolin
DML0OUY	MI	TTE4KHA
DML0OUY	MN	Amyloid beta A4 protein (APP)
DML0OUY	MT	DTT
DML0OUY	RN	Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci. 2003 Jan 1;23(1):29-33.
DML0OUY	RU	https://pubmed.ncbi.nlm.nih.gov/12514198

DMETRIS	DI	DMETRIS
DMETRIS	DN	gemini
DMETRIS	MI	TTK59TV
DMETRIS	MN	Vitamin D3 receptor (VDR)
DMETRIS	MT	DTT
DMETRIS	MA	Agonist
DMETRIS	RN	Novel Gemini analogs of 1alpha,25-dihydroxyvitamin D(3) with enhanced transcriptional activity. Biochem Pharmacol. 2004 Apr 1;67(7):1327-36.
DMETRIS	RU	https://pubmed.ncbi.nlm.nih.gov/15013848

DMAUFLQ	DI	DMAUFLQ
DMAUFLQ	DN	GENESERINE
DMAUFLQ	MI	TT1RS9F
DMAUFLQ	MN	Acetylcholinesterase (AChE)
DMAUFLQ	MT	DTT
DMAUFLQ	MA	Inhibitor
DMAUFLQ	RN	Structural determinants of Torpedo californica acetylcholinesterase inhibition by the novel and orally active carbamate based anti-alzheimer drug g... J Med Chem. 2006 Aug 24;49(17):5051-8.
DMAUFLQ	RU	https://pubmed.ncbi.nlm.nih.gov/16913695

DMMLNTW	DI	DMMLNTW
DMMLNTW	DN	Genistein-7-glucoside
DMMLNTW	MI	DTFI42L
DMMLNTW	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMMLNTW	MT	DTP
DMMLNTW	MA	Substrate
DMMLNTW	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMMLNTW	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMB70WC	DI	DMB70WC
DMB70WC	DN	Genz-10850
DMB70WC	MI	TTVTX4N
DMB70WC	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DMB70WC	MT	DTT
DMB70WC	MA	Inhibitor
DMB70WC	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMB70WC	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMB5I03	DI	DMB5I03
DMB5I03	DN	GERANIIN
DMB5I03	MI	TTE14XG
DMB5I03	MN	Squalene monooxygenase (SQLE)
DMB5I03	MT	DTT
DMB5I03	MA	Inhibitor
DMB5I03	RN	Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4.
DMB5I03	RU	https://pubmed.ncbi.nlm.nih.gov/11520216

DMS3CBD	DI	DMS3CBD
DMS3CBD	DN	geraniol
DMS3CBD	MI	TTXDKTO
DMS3CBD	MN	Long transient receptor potential channel 8 (TRPM8)
DMS3CBD	MT	DTT
DMS3CBD	MA	Activator
DMS3CBD	RN	Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay. Br J Pharmacol. 2004 Feb;141(4):737-45.
DMS3CBD	RU	https://pubmed.ncbi.nlm.nih.gov/14757700

DMB9LE1	DI	DMB9LE1
DMB9LE1	DN	Geranyl Diphosphate
DMB9LE1	MI	TTIKWV4
DMB9LE1	MN	Geranyltranstransferase (FDPS)
DMB9LE1	MT	DTT
DMB9LE1	MA	Inhibitor
DMB9LE1	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMB9LE1	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMRPWGL	DI	DMRPWGL
DMRPWGL	DN	Geranylcoumarin
DMRPWGL	MI	TTXV4FI
DMRPWGL	MN	Albendazole monooxygenase (CYP3A4)
DMRPWGL	MT	DTT
DMRPWGL	MA	Inhibitor
DMRPWGL	RN	Radical scavenging and cytochrome P450 3A4 inhibitory activity of bergaptol and geranylcoumarin from grapefruit. Bioorg Med Chem. 2007 Jun 1;15(11):3684-91.
DMRPWGL	RU	https://pubmed.ncbi.nlm.nih.gov/17400460

DMJZ0AM	DI	DMJZ0AM
DMJZ0AM	DN	GERANYLGERANYL DIPHOSPHATE
DMJZ0AM	MI	TT7WZIJ
DMJZ0AM	MN	CAAX farnesyltransferase beta (FNTB)
DMJZ0AM	MT	DTT
DMJZ0AM	MA	Inhibitor
DMJZ0AM	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMJZ0AM	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMJZ0AM	DI	DMJZ0AM
DMJZ0AM	DN	GERANYLGERANYL DIPHOSPHATE
DMJZ0AM	MI	TTXQKM3
DMJZ0AM	MN	Farnesyl protein transferase (Ftase)
DMJZ0AM	MT	DTT
DMJZ0AM	MA	Inhibitor
DMJZ0AM	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMJZ0AM	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMJZ0AM	DI	DMJZ0AM
DMJZ0AM	DN	GERANYLGERANYL DIPHOSPHATE
DMJZ0AM	MI	TTIKWV4
DMJZ0AM	MN	Geranyltranstransferase (FDPS)
DMJZ0AM	MT	DTT
DMJZ0AM	MA	Inhibitor
DMJZ0AM	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMJZ0AM	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMLM02I	DI	DMLM02I
DMLM02I	DN	GFPDGG
DMLM02I	MI	TTPADOQ
DMLM02I	MN	HMG-CoA reductase (HMGCR)
DMLM02I	MT	DTT
DMLM02I	MA	Inhibitor
DMLM02I	RN	Binding effect and design of a competitive inhibitory peptide for HMG-CoA reductase through modeling of an active peptide backbone. Bioorg Med Chem. 2008 Feb 1;16(3):1309-18.
DMLM02I	RU	https://pubmed.ncbi.nlm.nih.gov/17977732

DMGZTQW	DI	DMGZTQW
DMGZTQW	DN	GFPEGG
DMGZTQW	MI	TTPADOQ
DMGZTQW	MN	HMG-CoA reductase (HMGCR)
DMGZTQW	MT	DTT
DMGZTQW	MA	Inhibitor
DMGZTQW	RN	Binding effect and design of a competitive inhibitory peptide for HMG-CoA reductase through modeling of an active peptide backbone. Bioorg Med Chem. 2008 Feb 1;16(3):1309-18.
DMGZTQW	RU	https://pubmed.ncbi.nlm.nih.gov/17977732

DM9D8VH	DI	DM9D8VH
DM9D8VH	DN	GFPTGG
DM9D8VH	MI	TTPADOQ
DM9D8VH	MN	HMG-CoA reductase (HMGCR)
DM9D8VH	MT	DTT
DM9D8VH	MA	Inhibitor
DM9D8VH	RN	Binding effect and design of a competitive inhibitory peptide for HMG-CoA reductase through modeling of an active peptide backbone. Bioorg Med Chem. 2008 Feb 1;16(3):1309-18.
DM9D8VH	RU	https://pubmed.ncbi.nlm.nih.gov/17977732

DMU82JV	DI	DMU82JV
DMU82JV	DN	GG-818
DMU82JV	MI	TTNGILX
DMU82JV	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMU82JV	MT	DTT
DMU82JV	MA	Antagonist
DMU82JV	RN	In situ salt screening--a useful technique for discovery support and preformulation studies. Pharm Dev Technol. 1998 May;3(2):215-23.
DMU82JV	RU	https://pubmed.ncbi.nlm.nih.gov/9653759

DMU92RC	DI	DMU92RC
DMU92RC	DN	GI-3000
DMU92RC	MI	TTGKNB4
DMU92RC	MN	Epidermal growth factor receptor (EGFR)
DMU92RC	MT	DTT
DMU92RC	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
DMU92RC	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797

DMASR6T	DI	DMASR6T
DMASR6T	DN	GIDAZEPAM
DMASR6T	MI	TTEX6LM
DMASR6T	MN	GABA(A) receptor gamma-3 (GABRG3)
DMASR6T	MT	DTT
DMASR6T	MA	Modulator
DMASR6T	RN	Discriminative effects of phenazepam and gidazepam in rats: comparison with other GABA-related drugs. Pharmacol Biochem Behav. 1999 Oct;64(2):397-401.
DMASR6T	RU	https://pubmed.ncbi.nlm.nih.gov/10515320

DMNXYSM	DI	DMNXYSM
DMNXYSM	DN	gingerol
DMNXYSM	MI	TTELV3W
DMNXYSM	MN	Transformation-sensitive protein p120 (TRPA1)
DMNXYSM	MT	DTT
DMNXYSM	MA	Activator
DMNXYSM	RN	Noxious cold ion channel TRPA1 is activated by pungent compounds and bradykinin. Neuron. 2004 Mar 25;41(6):849-57.
DMNXYSM	RU	https://pubmed.ncbi.nlm.nih.gov/15046718

DMKZJ7T	DI	DMKZJ7T
DMKZJ7T	DN	GINKGOLIDE A
DMKZJ7T	MI	TTZ8EM9
DMKZJ7T	MN	Glycine receptor (GlyR)
DMKZJ7T	MT	DTT
DMKZJ7T	MA	Inhibitor
DMKZJ7T	RN	Probing the pharmacophore of ginkgolides as glycine receptor antagonists. J Med Chem. 2007 Apr 5;50(7):1610-7.
DMKZJ7T	RU	https://pubmed.ncbi.nlm.nih.gov/17352465

DMKZJ7T	DI	DMKZJ7T
DMKZJ7T	DN	GINKGOLIDE A
DMKZJ7T	MI	TTF45NW
DMKZJ7T	MN	Strychnine-binding glycine receptor (GLRA1)
DMKZJ7T	MT	DTT
DMKZJ7T	MA	Inhibitor
DMKZJ7T	RN	Probing the pharmacophore of ginkgolides as glycine receptor antagonists. J Med Chem. 2007 Apr 5;50(7):1610-7.
DMKZJ7T	RU	https://pubmed.ncbi.nlm.nih.gov/17352465

DMVN374	DI	DMVN374
DMVN374	DN	Ginkgolide C
DMVN374	MI	TTZ8EM9
DMVN374	MN	Glycine receptor (GlyR)
DMVN374	MT	DTT
DMVN374	MA	Inhibitor
DMVN374	RN	Probing the pharmacophore of ginkgolides as glycine receptor antagonists. J Med Chem. 2007 Apr 5;50(7):1610-7.
DMVN374	RU	https://pubmed.ncbi.nlm.nih.gov/17352465

DMVN374	DI	DMVN374
DMVN374	DN	Ginkgolide C
DMVN374	MI	TTF45NW
DMVN374	MN	Strychnine-binding glycine receptor (GLRA1)
DMVN374	MT	DTT
DMVN374	MA	Inhibitor
DMVN374	RN	Probing the pharmacophore of ginkgolides as glycine receptor antagonists. J Med Chem. 2007 Apr 5;50(7):1610-7.
DMVN374	RU	https://pubmed.ncbi.nlm.nih.gov/17352465

DMUOMP1	DI	DMUOMP1
DMUOMP1	DN	Ginkgolide J
DMUOMP1	MI	TTZ8EM9
DMUOMP1	MN	Glycine receptor (GlyR)
DMUOMP1	MT	DTT
DMUOMP1	MA	Inhibitor
DMUOMP1	RN	Probing the pharmacophore of ginkgolides as glycine receptor antagonists. J Med Chem. 2007 Apr 5;50(7):1610-7.
DMUOMP1	RU	https://pubmed.ncbi.nlm.nih.gov/17352465

DMUOMP1	DI	DMUOMP1
DMUOMP1	DN	Ginkgolide J
DMUOMP1	MI	TTF45NW
DMUOMP1	MN	Strychnine-binding glycine receptor (GLRA1)
DMUOMP1	MT	DTT
DMUOMP1	MA	Inhibitor
DMUOMP1	RN	Probing the pharmacophore of ginkgolides as glycine receptor antagonists. J Med Chem. 2007 Apr 5;50(7):1610-7.
DMUOMP1	RU	https://pubmed.ncbi.nlm.nih.gov/17352465

DMHWIG6	DI	DMHWIG6
DMHWIG6	DN	Ginkgolide M
DMHWIG6	MI	TTZ8EM9
DMHWIG6	MN	Glycine receptor (GlyR)
DMHWIG6	MT	DTT
DMHWIG6	MA	Inhibitor
DMHWIG6	RN	Probing the pharmacophore of ginkgolides as glycine receptor antagonists. J Med Chem. 2007 Apr 5;50(7):1610-7.
DMHWIG6	RU	https://pubmed.ncbi.nlm.nih.gov/17352465

DMHWIG6	DI	DMHWIG6
DMHWIG6	DN	Ginkgolide M
DMHWIG6	MI	TTF45NW
DMHWIG6	MN	Strychnine-binding glycine receptor (GLRA1)
DMHWIG6	MT	DTT
DMHWIG6	MA	Inhibitor
DMHWIG6	RN	Probing the pharmacophore of ginkgolides as glycine receptor antagonists. J Med Chem. 2007 Apr 5;50(7):1610-7.
DMHWIG6	RU	https://pubmed.ncbi.nlm.nih.gov/17352465

DMK543E	DI	DMK543E
DMK543E	DN	ginkgolide X
DMK543E	MI	TTZ8EM9
DMK543E	MN	Glycine receptor (GlyR)
DMK543E	MT	DTT
DMK543E	MA	Antagonist
DMK543E	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 427).
DMK543E	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=427

DMF70AB	DI	DMF70AB
DMF70AB	DN	Ginsenoside Rb1
DMF70AB	MI	DEUO7V8
DMF70AB	MN	Beta-glucosidase (bglA)
DMF70AB	MT	DME
DMF70AB	MA	Metabolism
DMF70AB	RN	Constitutive beta-glucosidases hydrolyzing ginsenoside Rb1 and Rb2 from human intestinal bacteria. Biol Pharm Bull. 2000 Dec;23(12):1481-5.
DMF70AB	RU	https://pubmed.ncbi.nlm.nih.gov/11145182

DMF70AB	DI	DMF70AB
DMF70AB	DN	Ginsenoside Rb1
DMF70AB	MI	DE4LKZ9
DMF70AB	MN	Beta-glucosidase (bglA)
DMF70AB	MT	DME
DMF70AB	MA	Metabolism
DMF70AB	RN	Constitutive beta-glucosidases hydrolyzing ginsenoside Rb1 and Rb2 from human intestinal bacteria. Biol Pharm Bull. 2000 Dec;23(12):1481-5.
DMF70AB	RU	https://pubmed.ncbi.nlm.nih.gov/11145182

DMF70AB	DI	DMF70AB
DMF70AB	DN	Ginsenoside Rb1
DMF70AB	MI	DEM6GYO
DMF70AB	MN	Beta-glucosidase (bglA)
DMF70AB	MT	DME
DMF70AB	MA	Metabolism
DMF70AB	RN	nan
DMF70AB	RU	nan

DMF70AB	DI	DMF70AB
DMF70AB	DN	Ginsenoside Rb1
DMF70AB	MI	DE9N4OU
DMF70AB	MN	Beta-glucosidase (bglA)
DMF70AB	MT	DME
DMF70AB	MA	Metabolism
DMF70AB	RN	Characterization of the ginsenoside-transforming recombinant beta-glucosidase from Actinosynnema mirum and bioconversion of major ginsenosides into minor ginsenosides. Appl Microbiol Biotechnol. 2013 Jan;97(2):649-59.
DMF70AB	RU	https://pubmed.ncbi.nlm.nih.gov/22911093

DMF70AB	DI	DMF70AB
DMF70AB	DN	Ginsenoside Rb1
DMF70AB	MI	DERPJZ6
DMF70AB	MN	Beta-glucosidase (bglA)
DMF70AB	MT	DME
DMF70AB	MA	Metabolism
DMF70AB	RN	Fermentation of protopanaxadiol type ginsenosides (PD) with probiotic Bifidobacterium lactis and Lactobacillus rhamnosus. Appl Microbiol Biotechnol. 2017 Jul;101(13):5427-5437.
DMF70AB	RU	https://pubmed.ncbi.nlm.nih.gov/28478490

DMF70AB	DI	DMF70AB
DMF70AB	DN	Ginsenoside Rb1
DMF70AB	MI	DEVLXCG
DMF70AB	MN	Beta-glucosidase (bglA)
DMF70AB	MT	DME
DMF70AB	MA	Metabolism
DMF70AB	RN	Constitutive beta-glucosidases hydrolyzing ginsenoside Rb1 and Rb2 from human intestinal bacteria. Biol Pharm Bull. 2000 Dec;23(12):1481-5.
DMF70AB	RU	https://pubmed.ncbi.nlm.nih.gov/11145182

DMF70AB	DI	DMF70AB
DMF70AB	DN	Ginsenoside Rb1
DMF70AB	MI	DEUQTKA
DMF70AB	MN	Beta-glucosidase (bglA)
DMF70AB	MT	DME
DMF70AB	MA	Metabolism
DMF70AB	RN	Fermentation of protopanaxadiol type ginsenosides (PD) with probiotic Bifidobacterium lactis and Lactobacillus rhamnosus. Appl Microbiol Biotechnol. 2017 Jul;101(13):5427-5437.
DMF70AB	RU	https://pubmed.ncbi.nlm.nih.gov/28478490

DMF70AB	DI	DMF70AB
DMF70AB	DN	Ginsenoside Rb1
DMF70AB	MI	DEXRUS1
DMF70AB	MN	Beta-glucosidase (bglA)
DMF70AB	MT	DME
DMF70AB	MA	Metabolism
DMF70AB	RN	Developing a metagenomic view of xenobiotic metabolism. Pharmacol Res. 2013 Mar;69(1):21-31.
DMF70AB	RU	https://pubmed.ncbi.nlm.nih.gov/22902524

DMF70AB	DI	DMF70AB
DMF70AB	DN	Ginsenoside Rb1
DMF70AB	MI	DERX7ML
DMF70AB	MN	Beta-glucosidase (bglA)
DMF70AB	MT	DME
DMF70AB	MA	Metabolism
DMF70AB	RN	Developing a metagenomic view of xenobiotic metabolism. Pharmacol Res. 2013 Mar;69(1):21-31.
DMF70AB	RU	https://pubmed.ncbi.nlm.nih.gov/22902524

DMF70AB	DI	DMF70AB
DMF70AB	DN	Ginsenoside Rb1
DMF70AB	MI	DEOHI3U
DMF70AB	MN	Beta-glucosidase (bglA)
DMF70AB	MT	DME
DMF70AB	MA	Metabolism
DMF70AB	RN	Developing a metagenomic view of xenobiotic metabolism. Pharmacol Res. 2013 Mar;69(1):21-31.
DMF70AB	RU	https://pubmed.ncbi.nlm.nih.gov/22902524

DMF70AB	DI	DMF70AB
DMF70AB	DN	Ginsenoside Rb1
DMF70AB	MI	DE46IH1
DMF70AB	MN	Beta-glucosidase (bglA)
DMF70AB	MT	DME
DMF70AB	MA	Metabolism
DMF70AB	RN	Genus Enhydrobacter Staley et al. 1987 should be recognized as a member of the family Rhodospirillaceae within the class Alphaproteobacteria. Microbiol Immunol. 2012 Jan;56(1):21-6.
DMF70AB	RU	https://pubmed.ncbi.nlm.nih.gov/22145860

DMF70AB	DI	DMF70AB
DMF70AB	DN	Ginsenoside Rb1
DMF70AB	MI	DEE8WXK
DMF70AB	MN	Beta-glucosidase (bglA)
DMF70AB	MT	DME
DMF70AB	MA	Metabolism
DMF70AB	RN	Developing a metagenomic view of xenobiotic metabolism. Pharmacol Res. 2013 Mar;69(1):21-31.
DMF70AB	RU	https://pubmed.ncbi.nlm.nih.gov/22902524

DMF70AB	DI	DMF70AB
DMF70AB	DN	Ginsenoside Rb1
DMF70AB	MI	DECBSVP
DMF70AB	MN	Beta-glucosidase (bglA)
DMF70AB	MT	DME
DMF70AB	MA	Metabolism
DMF70AB	RN	Developing a metagenomic view of xenobiotic metabolism. Pharmacol Res. 2013 Mar;69(1):21-31.
DMF70AB	RU	https://pubmed.ncbi.nlm.nih.gov/22902524

DMF70AB	DI	DMF70AB
DMF70AB	DN	Ginsenoside Rb1
DMF70AB	MI	DEAVLU4
DMF70AB	MN	Beta-glucosidase (bglA)
DMF70AB	MT	DME
DMF70AB	MA	Metabolism
DMF70AB	RN	Developing a metagenomic view of xenobiotic metabolism. Pharmacol Res. 2013 Mar;69(1):21-31.
DMF70AB	RU	https://pubmed.ncbi.nlm.nih.gov/22902524

DMF70AB	DI	DMF70AB
DMF70AB	DN	Ginsenoside Rb1
DMF70AB	MI	DEPBQES
DMF70AB	MN	Beta-glucosidase (bglA)
DMF70AB	MT	DME
DMF70AB	MA	Metabolism
DMF70AB	RN	Developing a metagenomic view of xenobiotic metabolism. Pharmacol Res. 2013 Mar;69(1):21-31.
DMF70AB	RU	https://pubmed.ncbi.nlm.nih.gov/22902524

DMF70AB	DI	DMF70AB
DMF70AB	DN	Ginsenoside Rb1
DMF70AB	MI	DEGVUWH
DMF70AB	MN	Beta-glucosidase (bglA)
DMF70AB	MT	DME
DMF70AB	MA	Metabolism
DMF70AB	RN	Developing a metagenomic view of xenobiotic metabolism. Pharmacol Res. 2013 Mar;69(1):21-31.
DMF70AB	RU	https://pubmed.ncbi.nlm.nih.gov/22902524

DMF70AB	DI	DMF70AB
DMF70AB	DN	Ginsenoside Rb1
DMF70AB	MI	DEE8RS0
DMF70AB	MN	Beta-glucosidase (bglA)
DMF70AB	MT	DME
DMF70AB	MA	Metabolism
DMF70AB	RN	Developing a metagenomic view of xenobiotic metabolism. Pharmacol Res. 2013 Mar;69(1):21-31.
DMF70AB	RU	https://pubmed.ncbi.nlm.nih.gov/22902524

DMF70AB	DI	DMF70AB
DMF70AB	DN	Ginsenoside Rb1
DMF70AB	MI	DEC0M8H
DMF70AB	MN	Beta-glucosidase (bglA)
DMF70AB	MT	DME
DMF70AB	MA	Metabolism
DMF70AB	RN	Developing a metagenomic view of xenobiotic metabolism. Pharmacol Res. 2013 Mar;69(1):21-31.
DMF70AB	RU	https://pubmed.ncbi.nlm.nih.gov/22902524

DMF70AB	DI	DMF70AB
DMF70AB	DN	Ginsenoside Rb1
DMF70AB	MI	DE2OMS0
DMF70AB	MN	Beta-glucosidase (bglA)
DMF70AB	MT	DME
DMF70AB	MA	Metabolism
DMF70AB	RN	Developing a metagenomic view of xenobiotic metabolism. Pharmacol Res. 2013 Mar;69(1):21-31.
DMF70AB	RU	https://pubmed.ncbi.nlm.nih.gov/22902524

DMF70AB	DI	DMF70AB
DMF70AB	DN	Ginsenoside Rb1
DMF70AB	MI	DEPUNVR
DMF70AB	MN	Beta-glucosidase (bglA)
DMF70AB	MT	DME
DMF70AB	MA	Metabolism
DMF70AB	RN	Developing a metagenomic view of xenobiotic metabolism. Pharmacol Res. 2013 Mar;69(1):21-31.
DMF70AB	RU	https://pubmed.ncbi.nlm.nih.gov/22902524

DMF70AB	DI	DMF70AB
DMF70AB	DN	Ginsenoside Rb1
DMF70AB	MI	DEX7SAW
DMF70AB	MN	Beta-glucosidase (bglA)
DMF70AB	MT	DME
DMF70AB	MA	Metabolism
DMF70AB	RN	Developing a metagenomic view of xenobiotic metabolism. Pharmacol Res. 2013 Mar;69(1):21-31.
DMF70AB	RU	https://pubmed.ncbi.nlm.nih.gov/22902524

DMF70AB	DI	DMF70AB
DMF70AB	DN	Ginsenoside Rb1
DMF70AB	MI	DEE3I1P
DMF70AB	MN	Beta-glucosidase (bglA)
DMF70AB	MT	DME
DMF70AB	MA	Metabolism
DMF70AB	RN	Developing a metagenomic view of xenobiotic metabolism. Pharmacol Res. 2013 Mar;69(1):21-31.
DMF70AB	RU	https://pubmed.ncbi.nlm.nih.gov/22902524

DMF70AB	DI	DMF70AB
DMF70AB	DN	Ginsenoside Rb1
DMF70AB	MI	DEASJG5
DMF70AB	MN	Beta-glucosidase (bglA)
DMF70AB	MT	DME
DMF70AB	MA	Metabolism
DMF70AB	RN	Developing a metagenomic view of xenobiotic metabolism. Pharmacol Res. 2013 Mar;69(1):21-31.
DMF70AB	RU	https://pubmed.ncbi.nlm.nih.gov/22902524

DMES9Q2	DI	DMES9Q2
DMES9Q2	DN	Ginsenoside Rc
DMES9Q2	MI	DERPJZ6
DMES9Q2	MN	Beta-glucosidase (bglA)
DMES9Q2	MT	DME
DMES9Q2	MA	Metabolism
DMES9Q2	RN	Fermentation of protopanaxadiol type ginsenosides (PD) with probiotic Bifidobacterium lactis and Lactobacillus rhamnosus. Appl Microbiol Biotechnol. 2017 Jul;101(13):5427-5437.
DMES9Q2	RU	https://pubmed.ncbi.nlm.nih.gov/28478490

DMES9Q2	DI	DMES9Q2
DMES9Q2	DN	Ginsenoside Rc
DMES9Q2	MI	DEUQTKA
DMES9Q2	MN	Beta-glucosidase (bglA)
DMES9Q2	MT	DME
DMES9Q2	MA	Metabolism
DMES9Q2	RN	Fermentation of protopanaxadiol type ginsenosides (PD) with probiotic Bifidobacterium lactis and Lactobacillus rhamnosus. Appl Microbiol Biotechnol. 2017 Jul;101(13):5427-5437.
DMES9Q2	RU	https://pubmed.ncbi.nlm.nih.gov/28478490

DM46FVD	DI	DM46FVD
DM46FVD	DN	Ginsenoside Re
DM46FVD	MI	DEBI82Z
DM46FVD	MN	Alpha-L-rhamnosidase (lrA)
DM46FVD	MT	DME
DM46FVD	MA	Metabolism
DM46FVD	RN	Metabolism of rutin and poncirin by human intestinal microbiota and cloning of their metabolizing alpha-L-rhamnosidase from Bifidobacterium dentium. J Microbiol Biotechnol. 2015 Jan;25(1):18-25.
DM46FVD	RU	https://pubmed.ncbi.nlm.nih.gov/25179902

DM46FVD	DI	DM46FVD
DM46FVD	DN	Ginsenoside Re
DM46FVD	MI	DE9N4OU
DM46FVD	MN	Beta-glucosidase (bglA)
DM46FVD	MT	DME
DM46FVD	MA	Metabolism
DM46FVD	RN	Characterization of the ginsenoside-transforming recombinant beta-glucosidase from Actinosynnema mirum and bioconversion of major ginsenosides into minor ginsenosides. Appl Microbiol Biotechnol. 2013 Jan;97(2):649-59.
DM46FVD	RU	https://pubmed.ncbi.nlm.nih.gov/22911093

DMYE2SR	DI	DMYE2SR
DMYE2SR	DN	Ginsenoside Rg1
DMYE2SR	MI	DE9N4OU
DMYE2SR	MN	Beta-glucosidase (bglA)
DMYE2SR	MT	DME
DMYE2SR	MA	Metabolism
DMYE2SR	RN	Characterization of the ginsenoside-transforming recombinant beta-glucosidase from Actinosynnema mirum and bioconversion of major ginsenosides into minor ginsenosides. Appl Microbiol Biotechnol. 2013 Jan;97(2):649-59.
DMYE2SR	RU	https://pubmed.ncbi.nlm.nih.gov/22911093

DMFN58T	DI	DMFN58T
DMFN58T	DN	Ginsenoside RG3
DMFN58T	MI	TTQ6VDM
DMFN58T	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMFN58T	MT	DTT
DMFN58T	MA	Activator
DMFN58T	RN	Ginsenoside Rg(3) decelerates hERG K(+) channel deactivation through Ser631 residue interaction. Eur J Pharmacol. 2011 Aug 1;663(1-3):59-67.
DMFN58T	RU	https://pubmed.ncbi.nlm.nih.gov/21586280

DM9P62Y	DI	DM9P62Y
DM9P62Y	DN	GKA1
DM9P62Y	MI	TTDLNGZ
DM9P62Y	MN	Glucokinase (GCK)
DM9P62Y	MT	DTT
DM9P62Y	MA	Activator
DM9P62Y	RN	Stimulation of hepatocyte glucose metabolism by novel small molecule glucokinase activators. Diabetes. 2004 Mar;53(3):535-41.
DM9P62Y	RU	https://pubmed.ncbi.nlm.nih.gov/14988235

DMIENSW	DI	DMIENSW
DMIENSW	DN	GKA-23
DMIENSW	MI	TTDLNGZ
DMIENSW	MN	Glucokinase (GCK)
DMIENSW	MT	DTT
DMIENSW	MA	Activator
DMIENSW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2798).
DMIENSW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2798

DMSP7V8	DI	DMSP7V8
DMSP7V8	DN	GLAUCINE
DMSP7V8	MI	TTZFYLI
DMSP7V8	MN	Dopamine D1 receptor (D1R)
DMSP7V8	MT	DTT
DMSP7V8	MA	Inhibitor
DMSP7V8	RN	Advances in development of dopaminergic aporphinoids. J Med Chem. 2007 Jan 25;50(2):171-81.
DMSP7V8	RU	https://pubmed.ncbi.nlm.nih.gov/17228858

DMSP7V8	DI	DMSP7V8
DMSP7V8	DN	GLAUCINE
DMSP7V8	MI	TTEX248
DMSP7V8	MN	Dopamine D2 receptor (D2R)
DMSP7V8	MT	DTT
DMSP7V8	MA	Inhibitor
DMSP7V8	RN	Advances in development of dopaminergic aporphinoids. J Med Chem. 2007 Jan 25;50(2):171-81.
DMSP7V8	RU	https://pubmed.ncbi.nlm.nih.gov/17228858

DM4QJPU	DI	DM4QJPU
DM4QJPU	DN	Glaxo-11p
DM4QJPU	MI	TTCG0AL
DM4QJPU	MN	Cholecystokinin receptor type A (CCKAR)
DM4QJPU	MT	DTT
DM4QJPU	MA	Agonist
DM4QJPU	RN	Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity. 1. Optimization of the agonist "trigger". J Med Chem. 1996 Jan 19;39(2):562-9.
DM4QJPU	RU	https://pubmed.ncbi.nlm.nih.gov/8558528

DMNEML0	DI	DMNEML0
DMNEML0	DN	GlaxoSmithKline compound 5h
DMNEML0	MI	TTA93TL
DMNEML0	MN	P2Y purinoceptor 1 (P2RY1)
DMNEML0	MT	DTT
DMNEML0	MA	Antagonist
DMNEML0	RN	Benzofuran-substituted urea derivatives as novel P2Y(1) receptor antagonists. Bioorg Med Chem Lett. 2010 Jul 15;20(14):4104-7.
DMNEML0	RU	https://pubmed.ncbi.nlm.nih.gov/20542694

DM1UAWP	DI	DM1UAWP
DM1UAWP	DN	GlaxoSmithKline compound 6i
DM1UAWP	MI	TTA93TL
DM1UAWP	MN	P2Y purinoceptor 1 (P2RY1)
DM1UAWP	MT	DTT
DM1UAWP	MA	Antagonist
DM1UAWP	RN	Tetrahydro-4-quinolinamines identified as novel P2Y(1) receptor antagonists. Bioorg Med Chem Lett. 2008 Dec 1;18(23):6222-6.
DM1UAWP	RU	https://pubmed.ncbi.nlm.nih.gov/18926700

DM98CSW	DI	DM98CSW
DM98CSW	DN	Glionitrin A
DM98CSW	MI	TTPF2QI
DM98CSW	MN	Caspase-3 (CASP3)
DM98CSW	MT	DTT
DM98CSW	MA	Modulator
DM98CSW	RN	Glionitrin A, a new diketopiperazine disulfide, activates ATM-ATR-Chk1/2 via 53BP1 phosphorylation in DU145 cells and shows antitumor effect in xenograft model. Biol Pharm Bull. 2014;37(3):378-86.
DM98CSW	RU	https://pubmed.ncbi.nlm.nih.gov/24583858

DM98CSW	DI	DM98CSW
DM98CSW	DN	Glionitrin A
DM98CSW	MI	TTEVCT0
DM98CSW	MN	Caspase-8 (CASP8)
DM98CSW	MT	DTT
DM98CSW	MA	Modulator
DM98CSW	RN	Glionitrin A, a new diketopiperazine disulfide, activates ATM-ATR-Chk1/2 via 53BP1 phosphorylation in DU145 cells and shows antitumor effect in xenograft model. Biol Pharm Bull. 2014;37(3):378-86.
DM98CSW	RU	https://pubmed.ncbi.nlm.nih.gov/24583858

DM98CSW	DI	DM98CSW
DM98CSW	DN	Glionitrin A
DM98CSW	MI	TTB6T7O
DM98CSW	MN	Caspase-9 (CASP9)
DM98CSW	MT	DTT
DM98CSW	MA	Modulator
DM98CSW	RN	Glionitrin A, a new diketopiperazine disulfide, activates ATM-ATR-Chk1/2 via 53BP1 phosphorylation in DU145 cells and shows antitumor effect in xenograft model. Biol Pharm Bull. 2014;37(3):378-86.
DM98CSW	RU	https://pubmed.ncbi.nlm.nih.gov/24583858

DMBH18C	DI	DMBH18C
DMBH18C	DN	GLP-17-(7-36) derivative
DMBH18C	MI	TTVIMDE
DMBH18C	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMBH18C	MT	DTT
DMBH18C	MA	Inhibitor
DMBH18C	RN	Identification of CJC-1131-albumin bioconjugate as a stable and bioactive GLP-1(7-36) analog. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4395-8.
DMBH18C	RU	https://pubmed.ncbi.nlm.nih.gov/15357960

DMGTPDA	DI	DMGTPDA
DMGTPDA	DN	GLPDGG peptide
DMGTPDA	MI	TTPADOQ
DMGTPDA	MN	HMG-CoA reductase (HMGCR)
DMGTPDA	MT	DTT
DMGTPDA	MA	Inhibitor
DMGTPDA	RN	Peptide fragmentation as an approach in modeling of an active peptide and designing a competitive inhibitory peptide for HMG-CoA reductase. Bioorg Med Chem. 2010 Jun 15;18(12):4300-9.
DMGTPDA	RU	https://pubmed.ncbi.nlm.nih.gov/20494585

DME2YL6	DI	DME2YL6
DME2YL6	DN	GLPTGG
DME2YL6	MI	TTPADOQ
DME2YL6	MN	HMG-CoA reductase (HMGCR)
DME2YL6	MT	DTT
DME2YL6	MA	Inhibitor
DME2YL6	RN	Binding effect and design of a competitive inhibitory peptide for HMG-CoA reductase through modeling of an active peptide backbone. Bioorg Med Chem. 2008 Feb 1;16(3):1309-18.
DME2YL6	RU	https://pubmed.ncbi.nlm.nih.gov/17977732

DM0HWB1	DI	DM0HWB1
DM0HWB1	DN	Glu20-Lys24][Gly8][GLP-1(7-37)-NH2
DM0HWB1	MI	TTVIMDE
DM0HWB1	MN	Glucagon-like peptide 1 receptor (GLP1R)
DM0HWB1	MT	DTT
DM0HWB1	MA	Inhibitor
DM0HWB1	RN	Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo acti... J Med Chem. 2008 May 8;51(9):2758-65.
DM0HWB1	RU	https://pubmed.ncbi.nlm.nih.gov/18412318

DMVWDHM	DI	DMVWDHM
DMVWDHM	DN	glucagon-(1-6)
DMVWDHM	MI	TT9O6WS
DMVWDHM	MN	Glucagon receptor (GCGR)
DMVWDHM	MT	DTT
DMVWDHM	MA	Agonist
DMVWDHM	RN	Glucagon1-6 binds to the glucagon receptor and activates hepatic adenylate cyclase. J Biol Chem. 1979 Jan 25;254(2):268-9.
DMVWDHM	RU	https://pubmed.ncbi.nlm.nih.gov/216670

DMZLRY2	DI	DMZLRY2
DMZLRY2	DN	Glucagon-like peptide-1 analog
DMZLRY2	MI	TTVIMDE
DMZLRY2	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMZLRY2	MT	DTT
DMZLRY2	MA	Modulator
DMZLRY2	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249).
DMZLRY2	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=249

DMO071E	DI	DMO071E
DMO071E	DN	Gluconolactone
DMO071E	MI	TTA0OSE
DMO071E	MN	Lactase-phlorizin hydrolase (LCT)
DMO071E	MT	DTT
DMO071E	MA	Inhibitor
DMO071E	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMO071E	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMRHYU8	DI	DMRHYU8
DMRHYU8	DN	Glucopyranosyl oleanolate
DMRHYU8	MI	DEVLXCG
DMRHYU8	MN	Beta-glucosidase (bglA)
DMRHYU8	MT	DME
DMRHYU8	MA	Metabolism
DMRHYU8	RN	Constitutive beta-glucosidases hydrolyzing ginsenoside Rb1 and Rb2 from human intestinal bacteria. Biol Pharm Bull. 2000 Dec;23(12):1481-5.
DMRHYU8	RU	https://pubmed.ncbi.nlm.nih.gov/11145182

DMY590Q	DI	DMY590Q
DMY590Q	DN	Glucosamine 6-Phosphate
DMY590Q	MI	TTC67I0
DMY590Q	MN	Bacterial Glucosamine-6-phosphate synthase (Bact glmS)
DMY590Q	MT	DTT
DMY590Q	MA	Inhibitor
DMY590Q	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMY590Q	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMLISP2	DI	DMLISP2
DMLISP2	DN	Glucose analogue
DMLISP2	MI	TTYXA6Z
DMLISP2	MN	Plasmodium Hexose transporter 1 (Malaria ht1)
DMLISP2	MT	DTT
DMLISP2	MA	Binder
DMLISP2	RN	Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40.
DMLISP2	RU	https://pubmed.ncbi.nlm.nih.gov/16138106

DMMJQ7O	DI	DMMJQ7O
DMMJQ7O	DN	Glucose-bisphosphate
DMMJQ7O	MI	DESR17C
DMMJQ7O	MN	L-Lactate dehydrogenase (ldh)
DMMJQ7O	MT	DME
DMMJQ7O	MA	Metabolism
DMMJQ7O	RN	Purification, properties and immunological relationship of L (+)-lactate dehydrogenase from Lactobacillus casei. Eur J Biochem. 1976 Aug 16;67(2):543-55.
DMMJQ7O	RU	https://pubmed.ncbi.nlm.nih.gov/823016

DMXBQRJ	DI	DMXBQRJ
DMXBQRJ	DN	Glu-Leu-Asp-Leu-(CHOH-CH2)-Ala-Ala-Glu-Phe
DMXBQRJ	MI	TT8JRS7
DMXBQRJ	MN	Beta-secretase (BACE)
DMXBQRJ	MT	DTT
DMXBQRJ	MA	Inhibitor
DMXBQRJ	RN	Efficient evaluation of binding free energy using continuum electrostatics solvation. J Med Chem. 2004 Nov 4;47(23):5791-7.
DMXBQRJ	RU	https://pubmed.ncbi.nlm.nih.gov/15509178

DM6EA9B	DI	DM6EA9B
DM6EA9B	DN	Glu-Pro-Gln-F2Pmp-Glu-Glu-Ile-Pro-Ile-Tyr-Leu
DM6EA9B	MI	TT6PKBN
DM6EA9B	MN	Proto-oncogene c-Src (SRC)
DM6EA9B	MT	DTT
DM6EA9B	MA	Inhibitor
DM6EA9B	RN	The Role of 4-phosphonodifluoromethyl- and 4-phosphono-phenylalanine in the selectivity and cellular uptake of SH2 domain ligands, Bioorg. Med. Chem. Lett. 7(14):1909-1914 (1997).
DM6EA9B	RU	http://www.sciencedirect.com/science/article/pii/S0960894X9700334X

DMYZO37	DI	DMYZO37
DMYZO37	DN	Glu-Pro-Gln-pTyr-Glu-Glu-Ile-Pro-Ile-Tyr-Leu
DMYZO37	MI	TT6PKBN
DMYZO37	MN	Proto-oncogene c-Src (SRC)
DMYZO37	MT	DTT
DMYZO37	MA	Inhibitor
DMYZO37	RN	The Role of 4-phosphonodifluoromethyl- and 4-phosphono-phenylalanine in the selectivity and cellular uptake of SH2 domain ligands, Bioorg. Med. Chem. Lett. 7(14):1909-1914 (1997).
DMYZO37	RU	http://www.sciencedirect.com/science/article/pii/S0960894X9700334X

DMT7K0U	DI	DMT7K0U
DMT7K0U	DN	Glutamine Hydroxamate
DMT7K0U	MI	TTC67I0
DMT7K0U	MN	Bacterial Glucosamine-6-phosphate synthase (Bact glmS)
DMT7K0U	MT	DTT
DMT7K0U	MA	Inhibitor
DMT7K0U	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMT7K0U	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMPUFDS	DI	DMPUFDS
DMPUFDS	DN	Glutarate
DMPUFDS	MI	DTQ23VB
DMPUFDS	MN	Organic anion transporter 1 (SLC22A6)
DMPUFDS	MT	DTP
DMPUFDS	MA	Substrate
DMPUFDS	RN	Fluorescence-based assay for the interaction of small molecules with the human renal organic anion transporter 1. Anal Biochem. 2000 Jul 15;283(1):49-55.
DMPUFDS	RU	http://www.ncbi.nlm.nih.gov/pubmed/10929807

DMPUFDS	DI	DMPUFDS
DMPUFDS	DN	Glutarate
DMPUFDS	MI	TTTQR47
DMPUFDS	MN	Solute carrier family 22 member 8 (SLC22A8)
DMPUFDS	MT	DTT
DMPUFDS	MA	Inhibitor
DMPUFDS	RN	Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members. J Biol Chem. 2007 Aug 17;282(33):23841-53.
DMPUFDS	RU	https://pubmed.ncbi.nlm.nih.gov/17553798

DMAV2I7	DI	DMAV2I7
DMAV2I7	DN	Glutathione ester
DMAV2I7	MI	DEPT1ME
DMAV2I7	MN	Gamma-glutamyltranspeptidase 1 (GGT1)
DMAV2I7	MT	DME
DMAV2I7	MA	Metabolism
DMAV2I7	RN	Gamma-glutamyl compounds: substrate specificity of gamma-glutamyl transpeptidase enzymes. Anal Biochem. 2011 Jul 15;414(2):208-14.
DMAV2I7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21447318

DMAV2I7	DI	DMAV2I7
DMAV2I7	DN	Glutathione ester
DMAV2I7	MI	DEH6CAO
DMAV2I7	MN	Gamma-glutamyltranspeptidase 5 (GGT5)
DMAV2I7	MT	DME
DMAV2I7	MA	Metabolism
DMAV2I7	RN	Gamma-glutamyl compounds: substrate specificity of gamma-glutamyl transpeptidase enzymes. Anal Biochem. 2011 Jul 15;414(2):208-14.
DMAV2I7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21447318

DMPX7FR	DI	DMPX7FR
DMPX7FR	DN	Glutathionylspermidine Disulfide
DMPX7FR	MI	TTEP6RV
DMPX7FR	MN	Glutathione reductase (GR)
DMPX7FR	MT	DTT
DMPX7FR	MA	Inhibitor
DMPX7FR	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMPX7FR	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM1Q83B	DI	DM1Q83B
DM1Q83B	DN	Glu-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro
DM1Q83B	MI	TTB2MXP
DM1Q83B	MN	Angiotensinogenase renin (REN)
DM1Q83B	MT	DTT
DM1Q83B	MA	Inhibitor
DM1Q83B	RN	Inhibition of the renin-angiotensin system. A new approach to the therapy of hypertension. J Med Chem. 1981 Apr;24(4):355-61.
DM1Q83B	RU	https://pubmed.ncbi.nlm.nih.gov/6267277

DMO8LAC	DI	DMO8LAC
DMO8LAC	DN	Gly-Amp-Glu
DMO8LAC	MI	TTLD29N
DMO8LAC	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMO8LAC	MT	DTT
DMO8LAC	MA	Inhibitor
DMO8LAC	RN	New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6.
DMO8LAC	RU	https://pubmed.ncbi.nlm.nih.gov/16321525

DMO8LAC	DI	DMO8LAC
DMO8LAC	DN	Gly-Amp-Glu
DMO8LAC	MI	TTKJEMQ
DMO8LAC	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMO8LAC	MT	DTT
DMO8LAC	MA	Inhibitor
DMO8LAC	RN	New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6.
DMO8LAC	RU	https://pubmed.ncbi.nlm.nih.gov/16321525

DMO8LAC	DI	DMO8LAC
DMO8LAC	DN	Gly-Amp-Glu
DMO8LAC	MI	TTN9D8E
DMO8LAC	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMO8LAC	MT	DTT
DMO8LAC	MA	Inhibitor
DMO8LAC	RN	New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6.
DMO8LAC	RU	https://pubmed.ncbi.nlm.nih.gov/16321525

DMACT8D	DI	DMACT8D
DMACT8D	DN	Gly-Arg-Gly-Asp-Ser
DMACT8D	MI	TTT1R2L
DMACT8D	MN	Integrin alpha-V (ITGAV)
DMACT8D	MT	DTT
DMACT8D	MA	Inhibitor
DMACT8D	RN	alphavbeta3 Integrin-targeting Arg-Gly-Asp (RGD) peptidomimetics containing oligoethylene glycol (OEG) spacers. J Med Chem. 2009 Nov 26;52(22):7029-43.
DMACT8D	RU	https://pubmed.ncbi.nlm.nih.gov/19860432

DMACT8D	DI	DMACT8D
DMACT8D	DN	Gly-Arg-Gly-Asp-Ser
DMACT8D	MI	TTJA1ZO
DMACT8D	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMACT8D	MT	DTT
DMACT8D	MA	Inhibitor
DMACT8D	RN	alphavbeta3 Integrin-targeting Arg-Gly-Asp (RGD) peptidomimetics containing oligoethylene glycol (OEG) spacers. J Med Chem. 2009 Nov 26;52(22):7029-43.
DMACT8D	RU	https://pubmed.ncbi.nlm.nih.gov/19860432

DMGOIME	DI	DMGOIME
DMGOIME	DN	Gly-Arg-Gly-Asp-Ser-Pro-Lys
DMGOIME	MI	TTT1R2L
DMGOIME	MN	Integrin alpha-V (ITGAV)
DMGOIME	MT	DTT
DMGOIME	MA	Inhibitor
DMGOIME	RN	N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem. 1999 Aug 12;42(16):3033-40.
DMGOIME	RU	https://pubmed.ncbi.nlm.nih.gov/10447947

DMGOIME	DI	DMGOIME
DMGOIME	DN	Gly-Arg-Gly-Asp-Ser-Pro-Lys
DMGOIME	MI	TTJA1ZO
DMGOIME	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMGOIME	MT	DTT
DMGOIME	MA	Inhibitor
DMGOIME	RN	N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem. 1999 Aug 12;42(16):3033-40.
DMGOIME	RU	https://pubmed.ncbi.nlm.nih.gov/10447947

DM8L09J	DI	DM8L09J
DM8L09J	DN	Gly-b7Pro-Glu
DM8L09J	MI	TTLD29N
DM8L09J	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DM8L09J	MT	DTT
DM8L09J	MA	Inhibitor
DM8L09J	RN	New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6.
DM8L09J	RU	https://pubmed.ncbi.nlm.nih.gov/16321525

DM8L09J	DI	DM8L09J
DM8L09J	DN	Gly-b7Pro-Glu
DM8L09J	MI	TTKJEMQ
DM8L09J	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DM8L09J	MT	DTT
DM8L09J	MA	Inhibitor
DM8L09J	RN	New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6.
DM8L09J	RU	https://pubmed.ncbi.nlm.nih.gov/16321525

DM8L09J	DI	DM8L09J
DM8L09J	DN	Gly-b7Pro-Glu
DM8L09J	MI	TTN9D8E
DM8L09J	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DM8L09J	MT	DTT
DM8L09J	MA	Inhibitor
DM8L09J	RN	New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6.
DM8L09J	RU	https://pubmed.ncbi.nlm.nih.gov/16321525

DM0J5KF	DI	DM0J5KF
DM0J5KF	DN	Glycerol-2-Phosphate
DM0J5KF	MI	TTNS6X4
DM0J5KF	MN	Bacterial Triosephosphate isomerase (Bact TPI)
DM0J5KF	MT	DTT
DM0J5KF	MA	Inhibitor
DM0J5KF	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM0J5KF	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMTCEFV	DI	DMTCEFV
DMTCEFV	DN	Glycinamid
DMTCEFV	MI	TTGA1IV
DMTCEFV	MN	Matrix metalloproteinase-8 (MMP-8)
DMTCEFV	MT	DTT
DMTCEFV	MA	Inhibitor
DMTCEFV	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMTCEFV	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMW180Y	DI	DMW180Y
DMW180Y	DN	Glycinamide Ribonucleotide
DMW180Y	MI	TTEXB9Z
DMW180Y	MN	Glycinamide ribonucleotide formyltransferase (GART)
DMW180Y	MT	DTT
DMW180Y	MA	Inhibitor
DMW180Y	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMW180Y	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM0SXNM	DI	DM0SXNM
DM0SXNM	DN	Glycocholic acid
DM0SXNM	MI	DTI7UX6
DM0SXNM	MN	Breast cancer resistance protein (ABCG2)
DM0SXNM	MT	DTP
DM0SXNM	MA	Substrate
DM0SXNM	RN	Characterization of the role of ABCG2 as a bile acid transporter in liver and placenta. Mol Pharmacol. 2012 Feb;81(2):273-83.
DM0SXNM	RU	https://doi.org/10.1124/mol.111.075143

DM0SXNM	DI	DM0SXNM
DM0SXNM	DN	Glycocholic acid
DM0SXNM	MI	DTFI42L
DM0SXNM	MN	Multidrug resistance-associated protein 2 (ABCC2)
DM0SXNM	MT	DTP
DM0SXNM	MA	Substrate
DM0SXNM	RN	Differential modulation of the human liver conjugate transporters MRP2 and MRP3 by bile acids and organic anions. J Biol Chem. 2003 Jun 27;278(26):23529-37.
DM0SXNM	RU	https://doi.org/10.1074/jbc.M303515200

DM0SXNM	DI	DM0SXNM
DM0SXNM	DN	Glycocholic acid
DM0SXNM	MI	DTQ3ZHF
DM0SXNM	MN	Multidrug resistance-associated protein 3 (ABCC3)
DM0SXNM	MT	DTP
DM0SXNM	MA	Substrate
DM0SXNM	RN	Measurement of transport activities of bile acids in human multidrug resistance-associated protein 3 using liquid chromatography-tandem mass spectrometry. Anal Sci. 2010;26(3):317-23.
DM0SXNM	RU	https://doi.org/10.2116/analsci.26.317

DM0SXNM	DI	DM0SXNM
DM0SXNM	DN	Glycocholic acid
DM0SXNM	MI	DTCSGPB
DM0SXNM	MN	Multidrug resistance-associated protein 4 (ABCC4)
DM0SXNM	MT	DTP
DM0SXNM	MA	Substrate
DM0SXNM	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM0SXNM	RU	https://doi.org/10.1007/s11095-012-0935-x

DM0SXNM	DI	DM0SXNM
DM0SXNM	DN	Glycocholic acid
DM0SXNM	MI	DTE2B1D
DM0SXNM	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DM0SXNM	MT	DTP
DM0SXNM	MA	Substrate
DM0SXNM	RN	Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
DM0SXNM	RU	http://www.ncbi.nlm.nih.gov/pubmed/11159893

DM0SXNM	DI	DM0SXNM
DM0SXNM	DN	Glycocholic acid
DM0SXNM	MI	DT3D8F0
DM0SXNM	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM0SXNM	MT	DTP
DM0SXNM	MA	Substrate
DM0SXNM	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DM0SXNM	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DM0SXNM	DI	DM0SXNM
DM0SXNM	DN	Glycocholic acid
DM0SXNM	MI	DT9C1TS
DM0SXNM	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM0SXNM	MT	DTP
DM0SXNM	MA	Substrate
DM0SXNM	RN	Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
DM0SXNM	RU	http://www.ncbi.nlm.nih.gov/pubmed/11159893

DM1XEJV	DI	DM1XEJV
DM1XEJV	DN	Glycodeoxycholic acid
DM1XEJV	MI	DT7JELC
DM1XEJV	MN	Apical sodium-dependent bile acid transporter (SLC10A2)
DM1XEJV	MT	DTP
DM1XEJV	MA	Substrate
DM1XEJV	RN	Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter. Am J Physiol. 1998 Jan;274(1):G157-69.
DM1XEJV	RU	http://ajpgi.physiology.org/content/274/1/G157.long

DM1XEJV	DI	DM1XEJV
DM1XEJV	DN	Glycodeoxycholic acid
DM1XEJV	MI	DTCSGPB
DM1XEJV	MN	Multidrug resistance-associated protein 4 (ABCC4)
DM1XEJV	MT	DTP
DM1XEJV	MA	Substrate
DM1XEJV	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM1XEJV	RU	https://doi.org/10.1007/s11095-012-0935-x

DM0SCK8	DI	DM0SCK8
DM0SCK8	DN	Glycyl-H 1152
DM0SCK8	MI	TTLYXIT
DM0SCK8	MN	Aurora kinase C (AURKC)
DM0SCK8	MT	DTT
DM0SCK8	MA	Inhibitor
DM0SCK8	RN	Development of specific Rho-kinase inhibitors and their clinical application. Biochim Biophys Acta. 2005 Dec 30;1754(1-2):245-52.
DM0SCK8	RU	https://pubmed.ncbi.nlm.nih.gov/16213195

DM0SCK8	DI	DM0SCK8
DM0SCK8	DN	Glycyl-H 1152
DM0SCK8	MI	TTGWKQJ
DM0SCK8	MN	Rho-associated protein kinase 2 (ROCK2)
DM0SCK8	MT	DTT
DM0SCK8	MA	Inhibitor
DM0SCK8	RN	Development of specific Rho-kinase inhibitors and their clinical application. Biochim Biophys Acta. 2005 Dec 30;1754(1-2):245-52.
DM0SCK8	RU	https://pubmed.ncbi.nlm.nih.gov/16213195

DM8FTJN	DI	DM8FTJN
DM8FTJN	DN	Glycyl-L-Alpha-Amino-Epsilon-Pimelyl-D-Alanine
DM8FTJN	MI	TTLP6GN
DM8FTJN	MN	Bacterial DD-carboxypeptidase (Bact vanYB)
DM8FTJN	MT	DTT
DM8FTJN	MA	Inhibitor
DM8FTJN	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM8FTJN	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMTOCXZ	DI	DMTOCXZ
DMTOCXZ	DN	GLYCYLRYANODINE
DMTOCXZ	MI	TTU5CIX
DMTOCXZ	MN	Ryanodine receptor 1 (RYR1)
DMTOCXZ	MT	DTT
DMTOCXZ	MA	Inhibitor
DMTOCXZ	RN	Amino- and guanidinoacylryanodines: basic ryanodine esters with enhanced affinity for the sarcoplasmic reticulum Ca(2+)-release channel. J Med Chem. 1993 May 14;36(10):1319-23.
DMTOCXZ	RU	https://pubmed.ncbi.nlm.nih.gov/8388466

DM67FQ1	DI	DM67FQ1
DM67FQ1	DN	GlyH-101
DM67FQ1	MI	TTRLZHP
DM67FQ1	MN	cAMP-dependent chloride channel (CFTR)
DM67FQ1	MT	DTT
DM67FQ1	MA	Blocker (channel blocker)
DM67FQ1	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 707).
DM67FQ1	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=707

DM8XR4Y	DI	DM8XR4Y
DM8XR4Y	DN	Gly-Hyp-Glu
DM8XR4Y	MI	TTLD29N
DM8XR4Y	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DM8XR4Y	MT	DTT
DM8XR4Y	MA	Inhibitor
DM8XR4Y	RN	New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6.
DM8XR4Y	RU	https://pubmed.ncbi.nlm.nih.gov/16321525

DM8XR4Y	DI	DM8XR4Y
DM8XR4Y	DN	Gly-Hyp-Glu
DM8XR4Y	MI	TTKJEMQ
DM8XR4Y	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DM8XR4Y	MT	DTT
DM8XR4Y	MA	Inhibitor
DM8XR4Y	RN	New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6.
DM8XR4Y	RU	https://pubmed.ncbi.nlm.nih.gov/16321525

DM8XR4Y	DI	DM8XR4Y
DM8XR4Y	DN	Gly-Hyp-Glu
DM8XR4Y	MI	TTN9D8E
DM8XR4Y	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DM8XR4Y	MT	DTT
DM8XR4Y	MA	Inhibitor
DM8XR4Y	RN	New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6.
DM8XR4Y	RU	https://pubmed.ncbi.nlm.nih.gov/16321525

DMQUP7O	DI	DMQUP7O
DMQUP7O	DN	Glyoxalate, Glyoxylate
DMQUP7O	MI	TT58ZYW
DMQUP7O	MN	Mycobacterium Isocitrate lyase (MycB icl)
DMQUP7O	MT	DTT
DMQUP7O	MA	Inhibitor
DMQUP7O	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMQUP7O	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMJ9XZO	DI	DMJ9XZO
DMJ9XZO	DN	Glyoxylate
DMJ9XZO	MI	DER5HFI
DMJ9XZO	MN	Alanine aminotransferase 1 (GPT)
DMJ9XZO	MT	DME
DMJ9XZO	MA	Metabolism
DMJ9XZO	RN	Recombinant production of eight human cytosolic aminotransferases and assessment of their potential involvement in glyoxylate metabolism. Biochem J. 2009 Aug 13;422(2):265-72.
DMJ9XZO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19545238

DMJ9XZO	DI	DMJ9XZO
DMJ9XZO	DN	Glyoxylate
DMJ9XZO	MI	DEBS17P
DMJ9XZO	MN	Phosphoserine aminotransferase (PSAT1)
DMJ9XZO	MT	DME
DMJ9XZO	MA	Metabolism
DMJ9XZO	RN	Recombinant production of eight human cytosolic aminotransferases and assessment of their potential involvement in glyoxylate metabolism. Biochem J. 2009 Aug 13;422(2):265-72.
DMJ9XZO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19545238

DM0AFY7	DI	DM0AFY7
DM0AFY7	DN	Glyphosate
DM0AFY7	MI	TTB30PF
DM0AFY7	MN	Bacterial Phosphoshikimate1-carboxyvinyltransferase (Bact aroA)
DM0AFY7	MT	DTT
DM0AFY7	MA	Inhibitor
DM0AFY7	RN	Novel molecular targets for antimalarial chemotherapy. Int J Antimicrob Agents. 2007 Jul;30(1):4-10.
DM0AFY7	RU	https://pubmed.ncbi.nlm.nih.gov/17339102

DM0AFY7	DI	DM0AFY7
DM0AFY7	DN	Glyphosate
DM0AFY7	MI	TTVL895
DM0AFY7	MN	Plasmodium Enopyruvyl shikimate phosphate synthase (Malaria ESPS)
DM0AFY7	MT	DTT
DM0AFY7	MA	Inhibitor
DM0AFY7	RN	The apicoplast as an antimalarial drug target. Drug Resist Updat. 2001 Jun;4(3):145-51.
DM0AFY7	RU	https://pubmed.ncbi.nlm.nih.gov/11768328

DMM0JA4	DI	DMM0JA4
DMM0JA4	DN	Gly-Pip-Glu
DMM0JA4	MI	TTLD29N
DMM0JA4	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMM0JA4	MT	DTT
DMM0JA4	MA	Inhibitor
DMM0JA4	RN	New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6.
DMM0JA4	RU	https://pubmed.ncbi.nlm.nih.gov/16321525

DMM0JA4	DI	DMM0JA4
DMM0JA4	DN	Gly-Pip-Glu
DMM0JA4	MI	TTKJEMQ
DMM0JA4	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMM0JA4	MT	DTT
DMM0JA4	MA	Inhibitor
DMM0JA4	RN	New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6.
DMM0JA4	RU	https://pubmed.ncbi.nlm.nih.gov/16321525

DMM0JA4	DI	DMM0JA4
DMM0JA4	DN	Gly-Pip-Glu
DMM0JA4	MI	TTN9D8E
DMM0JA4	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMM0JA4	MT	DTT
DMM0JA4	MA	Inhibitor
DMM0JA4	RN	New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6.
DMM0JA4	RU	https://pubmed.ncbi.nlm.nih.gov/16321525

DMMDU0K	DI	DMMDU0K
DMMDU0K	DN	GM-109
DMMDU0K	MI	TT953CX
DMMDU0K	MN	Motilin receptor (MLNR)
DMMDU0K	MT	DTT
DMMDU0K	MA	Antagonist
DMMDU0K	RN	Design and synthesis of motilin antagonists derived from the [1-4] fragment of porcine motilin. J Med Chem. 2002 Jan 31;45(3):670-5.
DMMDU0K	RU	https://pubmed.ncbi.nlm.nih.gov/11806718

DMM0ZKQ	DI	DMM0ZKQ
DMM0ZKQ	DN	GMQ
DMM0ZKQ	MI	TTLGDIS
DMM0ZKQ	MN	Acid-sensing ion channel 3 (ASIC3)
DMM0ZKQ	MT	DTT
DMM0ZKQ	MA	Activator
DMM0ZKQ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 686).
DMM0ZKQ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=686

DMYWM56	DI	DMYWM56
DMYWM56	DN	GNE-7915
DMYWM56	MI	TTP7EGM
DMYWM56	MN	Dual specificity protein kinase TTK (MPS1)
DMYWM56	MT	DTT
DMYWM56	MA	Inhibitor
DMYWM56	RN	Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. J Med Chem. 2014 Feb 13;57(3):921-36.
DMYWM56	RU	https://pubmed.ncbi.nlm.nih.gov/24354345

DMYWM56	DI	DMYWM56
DMYWM56	DN	GNE-7915
DMYWM56	MI	TTK0FEA
DMYWM56	MN	Leucine-rich repeat kinase 2 (LRRK2)
DMYWM56	MT	DTT
DMYWM56	MA	Inhibitor
DMYWM56	RN	Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. J Med Chem. 2014 Feb 13;57(3):921-36.
DMYWM56	RU	https://pubmed.ncbi.nlm.nih.gov/24354345

DMLXR90	DI	DMLXR90
DMLXR90	DN	GNE-9605
DMLXR90	MI	TTK0FEA
DMLXR90	MN	Leucine-rich repeat kinase 2 (LRRK2)
DMLXR90	MT	DTT
DMLXR90	MA	Inhibitor
DMLXR90	RN	Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. J Med Chem. 2014 Feb 13;57(3):921-36.
DMLXR90	RU	https://pubmed.ncbi.nlm.nih.gov/24354345

DMGLIPV	DI	DMGLIPV
DMGLIPV	DN	GNF-5
DMGLIPV	MI	TT6B75U
DMGLIPV	MN	ABL messenger RNA (ABL mRNA)
DMGLIPV	MT	DTT
DMGLIPV	MA	Inhibitor
DMGLIPV	RN	Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature. 2010 Jan 28;463(7280):501-6.
DMGLIPV	RU	https://pubmed.ncbi.nlm.nih.gov/20072125

DMYJO13	DI	DMYJO13
DMYJO13	DN	GNF-5837
DMYJO13	MI	TTKN7QR
DMYJO13	MN	BDNF/NT-3 growth factors receptor (TrkB)
DMYJO13	MT	DTT
DMYJO13	MA	Inhibitor
DMYJO13	RN	Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models. ACS Med Chem Lett. 2012 Jan 1;3(2):140-5.
DMYJO13	RU	https://pubmed.ncbi.nlm.nih.gov/24900443

DMYJO13	DI	DMYJO13
DMYJO13	DN	GNF-5837
DMYJO13	MI	TTXABCW
DMYJO13	MN	NT-3 growth factor receptor (TrkC)
DMYJO13	MT	DTT
DMYJO13	MA	Inhibitor
DMYJO13	RN	Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models. ACS Med Chem Lett. 2012 Jan 1;3(2):140-5.
DMYJO13	RU	https://pubmed.ncbi.nlm.nih.gov/24900443

DM3INUK	DI	DM3INUK
DM3INUK	DN	GNF-PF-117
DM3INUK	MI	TTML2WA
DM3INUK	MN	Tubulin (TUB)
DM3INUK	MT	DTT
DM3INUK	MA	Inhibitor
DM3INUK	RN	Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agent... J Med Chem. 1993 Apr 30;36(9):1146-56.
DM3INUK	RU	https://pubmed.ncbi.nlm.nih.gov/8387598

DM3INUK	DI	DM3INUK
DM3INUK	DN	GNF-PF-117
DM3INUK	MI	TTYFKSZ
DM3INUK	MN	Tubulin beta (TUBB)
DM3INUK	MT	DTT
DM3INUK	MA	Inhibitor
DM3INUK	RN	Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agent... J Med Chem. 1993 Apr 30;36(9):1146-56.
DM3INUK	RU	https://pubmed.ncbi.nlm.nih.gov/8387598

DM183RV	DI	DM183RV
DM183RV	DN	GNF-PF-1399
DM183RV	MI	TTH8FZW
DM183RV	MN	Signal transducer and activator of transcription 3 (STAT3)
DM183RV	MT	DTT
DM183RV	MA	Inhibitor
DM183RV	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DM183RV	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMVUBGF	DI	DMVUBGF
DMVUBGF	DN	GNF-PF-1550
DMVUBGF	MI	TTX4RTB
DMVUBGF	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMVUBGF	MT	DTT
DMVUBGF	MA	Inhibitor
DMVUBGF	RN	6-Acylamino-2-aminoquinolines as potent melanin-concentrating hormone 1 receptor antagonists. Identification, structure-activity relationship, and ... J Med Chem. 2005 Sep 8;48(18):5684-97.
DMVUBGF	RU	https://pubmed.ncbi.nlm.nih.gov/16134937

DMHCGBZ	DI	DMHCGBZ
DMHCGBZ	DN	GNF-PF-1591
DMHCGBZ	MI	TTL53M6
DMHCGBZ	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DMHCGBZ	MT	DTT
DMHCGBZ	MA	Inhibitor
DMHCGBZ	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMHCGBZ	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DM4JZ9A	DI	DM4JZ9A
DM4JZ9A	DN	GNF-PF-1694
DM4JZ9A	MI	TT2CJVK
DM4JZ9A	MN	Adrenergic receptor beta-2 (ADRB2)
DM4JZ9A	MT	DTT
DM4JZ9A	MA	Inhibitor
DM4JZ9A	RN	Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds. Bioorg Med Chem Lett. 2008 Oct 15;18(20):5391-5.
DM4JZ9A	RU	https://pubmed.ncbi.nlm.nih.gov/18829308

DMUSAYG	DI	DMUSAYG
DMUSAYG	DN	GNF-PF-173
DMUSAYG	MI	TT9SL3Q
DMUSAYG	MN	Polypeptide deformylase (PDF)
DMUSAYG	MT	DTT
DMUSAYG	MA	Inhibitor
DMUSAYG	RN	Synthesis and biological evaluation of poly-gamma-glutamyl metabolites of 10-deazaaminopterin and 10-ethyl-10-deazaaminopterin. J Med Chem. 1988 Jan;31(1):181-5.
DMUSAYG	RU	https://pubmed.ncbi.nlm.nih.gov/2447278

DMGSRLA	DI	DMGSRLA
DMGSRLA	DN	GNF-PF-1967
DMGSRLA	MI	TTZPWGN
DMGSRLA	MN	Voltage-gated calcium channel alpha Cav3.2 (CACNA1H)
DMGSRLA	MT	DTT
DMGSRLA	MA	Inhibitor
DMGSRLA	RN	3D pharmacophore based virtual screening of T-type calcium channel blockers. Bioorg Med Chem. 2007 Jan 15;15(2):1091-105.
DMGSRLA	RU	https://pubmed.ncbi.nlm.nih.gov/17074493

DM9J35R	DI	DM9J35R
DM9J35R	DN	GNF-PF-2094
DM9J35R	MI	TTVG215
DM9J35R	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DM9J35R	MT	DTT
DM9J35R	MA	Inhibitor
DM9J35R	RN	Synthesis and antiplasmodial activity of novel 2,4-diaminopyrimidines. Bioorg Med Chem Lett. 2010 Jan 1;20(1):228-31.
DM9J35R	RU	https://pubmed.ncbi.nlm.nih.gov/19914064

DM26UKN	DI	DM26UKN
DM26UKN	DN	GNF-PF-2224
DM26UKN	MI	TTK25J1
DM26UKN	MN	Adenosine A1 receptor (ADORA1)
DM26UKN	MT	DTT
DM26UKN	MA	Inhibitor
DM26UKN	RN	Minoxidil-induced hair growth is mediated by adenosine in cultured dermal papilla cells: possible involvement of sulfonylurea receptor 2B as a target of minoxidil. J Invest Dermatol. 2001 Dec;117(6):1594-600.
DM26UKN	RU	https://pubmed.ncbi.nlm.nih.gov/11886528

DM26UKN	DI	DM26UKN
DM26UKN	DN	GNF-PF-2224
DM26UKN	MI	TTM2AOE
DM26UKN	MN	Adenosine A2a receptor (ADORA2A)
DM26UKN	MT	DTT
DM26UKN	MA	Inhibitor
DM26UKN	RN	Synthesis and theoretical studies on energetics of novel N- and O- perfluoroalkyl triazole tagged thienopyrimidines--their potential as adenosine r... Eur J Med Chem. 2010 May;45(5):1739-45.
DM26UKN	RU	https://pubmed.ncbi.nlm.nih.gov/20116907

DM26UKN	DI	DM26UKN
DM26UKN	DN	GNF-PF-2224
DM26UKN	MI	TTNE7KG
DM26UKN	MN	Adenosine A2b receptor (ADORA2B)
DM26UKN	MT	DTT
DM26UKN	MA	Inhibitor
DM26UKN	RN	Discovery of FK453, a novel non-xanthine adenosine A1 receptor antagonist, Bioorg. Med. Chem. Lett. 6(17):2059-2062 (1996).
DM26UKN	RU	http://www.sciencedirect.com/science/article/pii/0960894X9600368X

DM26UKN	DI	DM26UKN
DM26UKN	DN	GNF-PF-2224
DM26UKN	MI	TTJFY5U
DM26UKN	MN	Adenosine A3 receptor (ADORA3)
DM26UKN	MT	DTT
DM26UKN	MA	Inhibitor
DM26UKN	RN	Pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as selective human A(1) adenosine receptor ligands. Bioorg Med Chem. 2010 Nov 15;18(22):7890-9.
DM26UKN	RU	https://pubmed.ncbi.nlm.nih.gov/20937560

DM26UKN	DI	DM26UKN
DM26UKN	DN	GNF-PF-2224
DM26UKN	MI	TTSLI08
DM26UKN	MN	Adenosine receptor (ADOR)
DM26UKN	MT	DTT
DM26UKN	MA	Antagonist
DM26UKN	RN	Minoxidil-induced hair growth is mediated by adenosine in cultured dermal papilla cells: possible involvement of sulfonylurea receptor 2B as a target of minoxidil. J Invest Dermatol. 2001 Dec;117(6):1594-600.
DM26UKN	RU	https://pubmed.ncbi.nlm.nih.gov/11886528

DMONK0F	DI	DMONK0F
DMONK0F	DN	GNF-PF-2272
DMONK0F	MI	TT915ZD
DMONK0F	MN	Candida Mannose-6-phosphate isomerase (Candi PMI1)
DMONK0F	MT	DTT
DMONK0F	MA	Inhibitor
DMONK0F	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMONK0F	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMONK0F	DI	DMONK0F
DMONK0F	DN	GNF-PF-2272
DMONK0F	MI	TTHQZV7
DMONK0F	MN	Mothers against decapentaplegic homolog 3 (SMAD3)
DMONK0F	MT	DTT
DMONK0F	MA	Inhibitor
DMONK0F	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMONK0F	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMP6DBX	DI	DMP6DBX
DMP6DBX	DN	GNF-PF-2307
DMP6DBX	MI	TT8DBY3
DMP6DBX	MN	Angiotensin II receptor type-1 (AGTR1)
DMP6DBX	MT	DTT
DMP6DBX	MA	Inhibitor
DMP6DBX	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMP6DBX	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMW93IO	DI	DMW93IO
DMW93IO	DN	GNF-PF-2322
DMW93IO	MI	TTX4RTB
DMW93IO	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMW93IO	MT	DTT
DMW93IO	MA	Inhibitor
DMW93IO	RN	6-Acylamino-2-aminoquinolines as potent melanin-concentrating hormone 1 receptor antagonists. Identification, structure-activity relationship, and ... J Med Chem. 2005 Sep 8;48(18):5684-97.
DMW93IO	RU	https://pubmed.ncbi.nlm.nih.gov/16134937

DMC56YJ	DI	DMC56YJ
DMC56YJ	DN	GNF-PF-2700
DMC56YJ	MI	TTK25J1
DMC56YJ	MN	Adenosine A1 receptor (ADORA1)
DMC56YJ	MT	DTT
DMC56YJ	MA	Inhibitor
DMC56YJ	RN	Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods. Eur J Med Chem. 2010 Aug;45(8):3459-71.
DMC56YJ	RU	https://pubmed.ncbi.nlm.nih.gov/20537438

DMC56YJ	DI	DMC56YJ
DMC56YJ	DN	GNF-PF-2700
DMC56YJ	MI	TTM2AOE
DMC56YJ	MN	Adenosine A2a receptor (ADORA2A)
DMC56YJ	MT	DTT
DMC56YJ	MA	Inhibitor
DMC56YJ	RN	Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods. Eur J Med Chem. 2010 Aug;45(8):3459-71.
DMC56YJ	RU	https://pubmed.ncbi.nlm.nih.gov/20537438

DMC56YJ	DI	DMC56YJ
DMC56YJ	DN	GNF-PF-2700
DMC56YJ	MI	TTNE7KG
DMC56YJ	MN	Adenosine A2b receptor (ADORA2B)
DMC56YJ	MT	DTT
DMC56YJ	MA	Inhibitor
DMC56YJ	RN	Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods. Eur J Med Chem. 2010 Aug;45(8):3459-71.
DMC56YJ	RU	https://pubmed.ncbi.nlm.nih.gov/20537438

DMD1QOH	DI	DMD1QOH
DMD1QOH	DN	GNF-PF-2812
DMD1QOH	MI	TT8DBY3
DMD1QOH	MN	Angiotensin II receptor type-1 (AGTR1)
DMD1QOH	MT	DTT
DMD1QOH	MA	Inhibitor
DMD1QOH	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMD1QOH	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DML5QFZ	DI	DML5QFZ
DML5QFZ	DN	GNF-PF-2857
DML5QFZ	MI	TTWG9A4
DML5QFZ	MN	Adrenergic receptor alpha-2A (ADRA2A)
DML5QFZ	MT	DTT
DML5QFZ	MA	Inhibitor
DML5QFZ	RN	Structure-activity relationship of quinoline derivatives as potent and selective alpha(2C)-adrenoceptor antagonists. J Med Chem. 2006 Oct 19;49(21):6351-63.
DML5QFZ	RU	https://pubmed.ncbi.nlm.nih.gov/17034141

DML5QFZ	DI	DML5QFZ
DML5QFZ	DN	GNF-PF-2857
DML5QFZ	MI	TTWM4TY
DML5QFZ	MN	Adrenergic receptor alpha-2B (ADRA2B)
DML5QFZ	MT	DTT
DML5QFZ	MA	Inhibitor
DML5QFZ	RN	Structure-activity relationship of quinoline derivatives as potent and selective alpha(2C)-adrenoceptor antagonists. J Med Chem. 2006 Oct 19;49(21):6351-63.
DML5QFZ	RU	https://pubmed.ncbi.nlm.nih.gov/17034141

DML5QFZ	DI	DML5QFZ
DML5QFZ	DN	GNF-PF-2857
DML5QFZ	MI	TT2NUT5
DML5QFZ	MN	Adrenergic receptor alpha-2C (ADRA2C)
DML5QFZ	MT	DTT
DML5QFZ	MA	Inhibitor
DML5QFZ	RN	Structure-activity relationship of quinoline derivatives as potent and selective alpha(2C)-adrenoceptor antagonists. J Med Chem. 2006 Oct 19;49(21):6351-63.
DML5QFZ	RU	https://pubmed.ncbi.nlm.nih.gov/17034141

DMLP241	DI	DMLP241
DMLP241	DN	GNF-PF-2893
DMLP241	MI	TTT2SVW
DMLP241	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DMLP241	MT	DTT
DMLP241	MA	Inhibitor
DMLP241	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMLP241	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DM4RZSB	DI	DM4RZSB
DM4RZSB	DN	GNF-PF-3037
DM4RZSB	MI	TTOM3J0
DM4RZSB	MN	Estrogen receptor beta (ESR2)
DM4RZSB	MT	DTT
DM4RZSB	MA	Inhibitor
DM4RZSB	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DM4RZSB	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DM4RZSB	DI	DM4RZSB
DM4RZSB	DN	GNF-PF-3037
DM4RZSB	MI	TTT2SVW
DM4RZSB	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DM4RZSB	MT	DTT
DM4RZSB	MA	Inhibitor
DM4RZSB	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DM4RZSB	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMWAKHD	DI	DMWAKHD
DMWAKHD	DN	GNF-PF-3464
DMWAKHD	MI	TTWXB3E
DMWAKHD	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DMWAKHD	MT	DTT
DMWAKHD	MA	Inhibitor
DMWAKHD	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMWAKHD	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMWAKHD	DI	DMWAKHD
DMWAKHD	DN	GNF-PF-3464
DMWAKHD	MI	TT4FDG6
DMWAKHD	MN	Voltage-gated calcium channel alpha Cav2.2 (CACNA1B)
DMWAKHD	MT	DTT
DMWAKHD	MA	Inhibitor
DMWAKHD	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMWAKHD	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DM17GIV	DI	DM17GIV
DM17GIV	DN	GNF-PF-3645
DM17GIV	MI	TT1MPAY
DM17GIV	MN	GABA(A) receptor alpha-1 (GABRA1)
DM17GIV	MT	DTT
DM17GIV	MA	Inhibitor
DM17GIV	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DM17GIV	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DM17GIV	DI	DM17GIV
DM17GIV	DN	GNF-PF-3645
DM17GIV	MI	TTZA1NY
DM17GIV	MN	GABA(A) receptor beta-2 (GABRB2)
DM17GIV	MT	DTT
DM17GIV	MA	Inhibitor
DM17GIV	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DM17GIV	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DM17GIV	DI	DM17GIV
DM17GIV	DN	GNF-PF-3645
DM17GIV	MI	TT06RH5
DM17GIV	MN	GABA(A) receptor gamma-2 (GABRG2)
DM17GIV	MT	DTT
DM17GIV	MA	Inhibitor
DM17GIV	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DM17GIV	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DM17GIV	DI	DM17GIV
DM17GIV	DN	GNF-PF-3645
DM17GIV	MI	TTNJYV2
DM17GIV	MN	Gamma-aminobutyric acid receptor (GAR)
DM17GIV	MT	DTT
DM17GIV	MA	Inhibitor
DM17GIV	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DM17GIV	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMIY79U	DI	DMIY79U
DMIY79U	DN	GNF-PF-3832
DMIY79U	MI	TT8DBY3
DMIY79U	MN	Angiotensin II receptor type-1 (AGTR1)
DMIY79U	MT	DTT
DMIY79U	MA	Inhibitor
DMIY79U	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMIY79U	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DM7BXHQ	DI	DM7BXHQ
DM7BXHQ	DN	GNF-PF-3878
DM7BXHQ	MI	TTWG9A4
DM7BXHQ	MN	Adrenergic receptor alpha-2A (ADRA2A)
DM7BXHQ	MT	DTT
DM7BXHQ	MA	Inhibitor
DM7BXHQ	RN	Structure-activity relationship of quinoline derivatives as potent and selective alpha(2C)-adrenoceptor antagonists. J Med Chem. 2006 Oct 19;49(21):6351-63.
DM7BXHQ	RU	https://pubmed.ncbi.nlm.nih.gov/17034141

DM7BXHQ	DI	DM7BXHQ
DM7BXHQ	DN	GNF-PF-3878
DM7BXHQ	MI	TTWM4TY
DM7BXHQ	MN	Adrenergic receptor alpha-2B (ADRA2B)
DM7BXHQ	MT	DTT
DM7BXHQ	MA	Inhibitor
DM7BXHQ	RN	Structure-activity relationship of quinoline derivatives as potent and selective alpha(2C)-adrenoceptor antagonists. J Med Chem. 2006 Oct 19;49(21):6351-63.
DM7BXHQ	RU	https://pubmed.ncbi.nlm.nih.gov/17034141

DM7BXHQ	DI	DM7BXHQ
DM7BXHQ	DN	GNF-PF-3878
DM7BXHQ	MI	TT2NUT5
DM7BXHQ	MN	Adrenergic receptor alpha-2C (ADRA2C)
DM7BXHQ	MT	DTT
DM7BXHQ	MA	Inhibitor
DM7BXHQ	RN	Structure-activity relationship of quinoline derivatives as potent and selective alpha(2C)-adrenoceptor antagonists. J Med Chem. 2006 Oct 19;49(21):6351-63.
DM7BXHQ	RU	https://pubmed.ncbi.nlm.nih.gov/17034141

DMOJL61	DI	DMOJL61
DMOJL61	DN	GNF-PF-3955
DMOJL61	MI	TTL53M6
DMOJL61	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DMOJL61	MT	DTT
DMOJL61	MA	Inhibitor
DMOJL61	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMOJL61	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMXWYMH	DI	DMXWYMH
DMXWYMH	DN	GNF-PF-4292
DMXWYMH	MI	TTVG215
DMXWYMH	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DMXWYMH	MT	DTT
DMXWYMH	MA	Inhibitor
DMXWYMH	RN	Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies. J Med Chem. 1993 Apr 30;36(9):1136-45.
DMXWYMH	RU	https://pubmed.ncbi.nlm.nih.gov/8487254

DMV10UH	DI	DMV10UH
DMV10UH	DN	GNF-PF-4421
DMV10UH	MI	TT1MPAY
DMV10UH	MN	GABA(A) receptor alpha-1 (GABRA1)
DMV10UH	MT	DTT
DMV10UH	MA	Inhibitor
DMV10UH	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMV10UH	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMV10UH	DI	DMV10UH
DMV10UH	DN	GNF-PF-4421
DMV10UH	MI	TTZA1NY
DMV10UH	MN	GABA(A) receptor beta-2 (GABRB2)
DMV10UH	MT	DTT
DMV10UH	MA	Inhibitor
DMV10UH	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMV10UH	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMV10UH	DI	DMV10UH
DMV10UH	DN	GNF-PF-4421
DMV10UH	MI	TT06RH5
DMV10UH	MN	GABA(A) receptor gamma-2 (GABRG2)
DMV10UH	MT	DTT
DMV10UH	MA	Inhibitor
DMV10UH	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMV10UH	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMV10UH	DI	DMV10UH
DMV10UH	DN	GNF-PF-4421
DMV10UH	MI	TTNJYV2
DMV10UH	MN	Gamma-aminobutyric acid receptor (GAR)
DMV10UH	MT	DTT
DMV10UH	MA	Inhibitor
DMV10UH	RN	4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33.
DMV10UH	RU	https://pubmed.ncbi.nlm.nih.gov/16610795

DMPYIA3	DI	DMPYIA3
DMPYIA3	DN	GNF-PF-4453
DMPYIA3	MI	TTG5QB7
DMPYIA3	MN	Calpain-2 (CAPN2)
DMPYIA3	MT	DTT
DMPYIA3	MA	Inhibitor
DMPYIA3	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMPYIA3	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMCDU8K	DI	DMCDU8K
DMCDU8K	DN	GNF-PF-4478
DMCDU8K	MI	TT2EDHU
DMCDU8K	MN	Insulin-degrading enzyme (IDE)
DMCDU8K	MT	DTT
DMCDU8K	MA	Inhibitor
DMCDU8K	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMCDU8K	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMCDU8K	DI	DMCDU8K
DMCDU8K	DN	GNF-PF-4478
DMCDU8K	MI	TTEAID7
DMCDU8K	MN	Trypanosoma Cruzipain (Trypano CYSP)
DMCDU8K	MT	DTT
DMCDU8K	MA	Inhibitor
DMCDU8K	RN	Complementarity between a docking and a high-throughput screen in discovering new cruzain inhibitors. J Med Chem. 2010 Jul 8;53(13):4891-905.
DMCDU8K	RU	https://pubmed.ncbi.nlm.nih.gov/20540517

DM1ZMUN	DI	DM1ZMUN
DM1ZMUN	DN	GNF-PF-4599
DM1ZMUN	MI	TTZPWGN
DM1ZMUN	MN	Voltage-gated calcium channel alpha Cav3.2 (CACNA1H)
DM1ZMUN	MT	DTT
DM1ZMUN	MA	Inhibitor
DM1ZMUN	RN	3D pharmacophore based virtual screening of T-type calcium channel blockers. Bioorg Med Chem. 2007 Jan 15;15(2):1091-105.
DM1ZMUN	RU	https://pubmed.ncbi.nlm.nih.gov/17074493

DM7850H	DI	DM7850H
DM7850H	DN	GNF-PF-5134
DM7850H	MI	TT915ZD
DM7850H	MN	Candida Mannose-6-phosphate isomerase (Candi PMI1)
DM7850H	MT	DTT
DM7850H	MA	Inhibitor
DM7850H	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DM7850H	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DM7850H	DI	DM7850H
DM7850H	DN	GNF-PF-5134
DM7850H	MI	TTL53M6
DM7850H	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DM7850H	MT	DTT
DM7850H	MA	Inhibitor
DM7850H	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DM7850H	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMVI4JG	DI	DMVI4JG
DMVI4JG	DN	GNF-PF-5188
DMVI4JG	MI	TTMSFAW
DMVI4JG	MN	Cannabinoid receptor 2 (CB2)
DMVI4JG	MT	DTT
DMVI4JG	MA	Inhibitor
DMVI4JG	RN	Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow. J Med Chem. 2009 Jan 22;52(2):369-78.
DMVI4JG	RU	https://pubmed.ncbi.nlm.nih.gov/19143566

DMZNAEQ	DI	DMZNAEQ
DMZNAEQ	DN	GNF-PF-5411
DMZNAEQ	MI	TTVG215
DMZNAEQ	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DMZNAEQ	MT	DTT
DMZNAEQ	MA	Inhibitor
DMZNAEQ	RN	Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies. J Med Chem. 1993 Apr 30;36(9):1136-45.
DMZNAEQ	RU	https://pubmed.ncbi.nlm.nih.gov/8487254

DMZNAEQ	DI	DMZNAEQ
DMZNAEQ	DN	GNF-PF-5411
DMZNAEQ	MI	DTUGYRD
DMZNAEQ	MN	P-glycoprotein 1 (ABCB1)
DMZNAEQ	MT	DTP
DMZNAEQ	MA	Substrate
DMZNAEQ	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMZNAEQ	RU	https://doi.org/10.1007/s11095-012-0935-x

DMP9AIH	DI	DMP9AIH
DMP9AIH	DN	GNF-PF-5434
DMP9AIH	MI	TTF2LRI
DMP9AIH	MN	Cathepsin B (CTSB)
DMP9AIH	MT	DTT
DMP9AIH	MA	Inhibitor
DMP9AIH	RN	Substrate optimization for monitoring cathepsin C activity in live cells. Bioorg Med Chem. 2009 Feb 1;17(3):1064-70.
DMP9AIH	RU	https://pubmed.ncbi.nlm.nih.gov/18313933

DMP9AIH	DI	DMP9AIH
DMP9AIH	DN	GNF-PF-5434
DMP9AIH	MI	TTDZN01
DMP9AIH	MN	Cathepsin K (CTSK)
DMP9AIH	MT	DTT
DMP9AIH	MA	Inhibitor
DMP9AIH	RN	Substrate optimization for monitoring cathepsin C activity in live cells. Bioorg Med Chem. 2009 Feb 1;17(3):1064-70.
DMP9AIH	RU	https://pubmed.ncbi.nlm.nih.gov/18313933

DMP9AIH	DI	DMP9AIH
DMP9AIH	DN	GNF-PF-5434
DMP9AIH	MI	TTUMQVO
DMP9AIH	MN	Cathepsin S (CTSS)
DMP9AIH	MT	DTT
DMP9AIH	MA	Inhibitor
DMP9AIH	RN	Substrate optimization for monitoring cathepsin C activity in live cells. Bioorg Med Chem. 2009 Feb 1;17(3):1064-70.
DMP9AIH	RU	https://pubmed.ncbi.nlm.nih.gov/18313933

DMP9AIH	DI	DMP9AIH
DMP9AIH	DN	GNF-PF-5434
DMP9AIH	MI	TT4H0V2
DMP9AIH	MN	Dipeptidyl peptidase I (CTSC)
DMP9AIH	MT	DTT
DMP9AIH	MA	Inhibitor
DMP9AIH	RN	Substrate optimization for monitoring cathepsin C activity in live cells. Bioorg Med Chem. 2009 Feb 1;17(3):1064-70.
DMP9AIH	RU	https://pubmed.ncbi.nlm.nih.gov/18313933

DMT8VUS	DI	DMT8VUS
DMT8VUS	DN	GNF-PF-5618
DMT8VUS	MI	TTZ9SOR
DMT8VUS	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMT8VUS	MT	DTT
DMT8VUS	MA	Inhibitor
DMT8VUS	RN	Nocardimicins A, B, C, D, E, and F, siderophores with muscarinic M3 receptor inhibiting activity from Nocardia sp. TP-A0674. J Nat Prod. 2005 Jul;68(7):1061-5.
DMT8VUS	RU	https://pubmed.ncbi.nlm.nih.gov/16038549

DMT8VUS	DI	DMT8VUS
DMT8VUS	DN	GNF-PF-5618
DMT8VUS	MI	TTYEG6Q
DMT8VUS	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMT8VUS	MT	DTT
DMT8VUS	MA	Inhibitor
DMT8VUS	RN	Nocardimicins A, B, C, D, E, and F, siderophores with muscarinic M3 receptor inhibiting activity from Nocardia sp. TP-A0674. J Nat Prod. 2005 Jul;68(7):1061-5.
DMT8VUS	RU	https://pubmed.ncbi.nlm.nih.gov/16038549

DMT8VUS	DI	DMT8VUS
DMT8VUS	DN	GNF-PF-5618
DMT8VUS	MI	TTQ13Z5
DMT8VUS	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMT8VUS	MT	DTT
DMT8VUS	MA	Inhibitor
DMT8VUS	RN	Nocardimicins A, B, C, D, E, and F, siderophores with muscarinic M3 receptor inhibiting activity from Nocardia sp. TP-A0674. J Nat Prod. 2005 Jul;68(7):1061-5.
DMT8VUS	RU	https://pubmed.ncbi.nlm.nih.gov/16038549

DMT8VUS	DI	DMT8VUS
DMT8VUS	DN	GNF-PF-5618
DMT8VUS	MI	TTQ3JTF
DMT8VUS	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DMT8VUS	MT	DTT
DMT8VUS	MA	Inhibitor
DMT8VUS	RN	Nocardimicins A, B, C, D, E, and F, siderophores with muscarinic M3 receptor inhibiting activity from Nocardia sp. TP-A0674. J Nat Prod. 2005 Jul;68(7):1061-5.
DMT8VUS	RU	https://pubmed.ncbi.nlm.nih.gov/16038549

DMT8VUS	DI	DMT8VUS
DMT8VUS	DN	GNF-PF-5618
DMT8VUS	MI	TTH18TF
DMT8VUS	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMT8VUS	MT	DTT
DMT8VUS	MA	Inhibitor
DMT8VUS	RN	Nocardimicins A, B, C, D, E, and F, siderophores with muscarinic M3 receptor inhibiting activity from Nocardia sp. TP-A0674. J Nat Prod. 2005 Jul;68(7):1061-5.
DMT8VUS	RU	https://pubmed.ncbi.nlm.nih.gov/16038549

DMWGXBF	DI	DMWGXBF
DMWGXBF	DN	GNF-PF-600
DMWGXBF	MI	TTIQSC1
DMWGXBF	MN	Bacterial Lethal factor (Bact lef)
DMWGXBF	MT	DTT
DMWGXBF	MA	Inhibitor
DMWGXBF	RN	Anthrax lethal factor protease inhibitors: synthesis, SAR, and structure-based 3D QSAR studies. J Med Chem. 2006 Jan 12;49(1):27-30.
DMWGXBF	RU	https://pubmed.ncbi.nlm.nih.gov/16392787

DMJXE6K	DI	DMJXE6K
DMJXE6K	DN	GNF-PF-607
DMJXE6K	MI	TT9SL3Q
DMJXE6K	MN	Polypeptide deformylase (PDF)
DMJXE6K	MT	DTT
DMJXE6K	MA	Inhibitor
DMJXE6K	RN	CoMFA and CoMSIA analyses of Pneumocystis carinii dihydrofolate reductase, Toxoplasma gondii dihydrofolate reductase, and rat liver dihydrofolate r... J Med Chem. 2005 Mar 10;48(5):1448-69.
DMJXE6K	RU	https://pubmed.ncbi.nlm.nih.gov/15743188

DM3SYH5	DI	DM3SYH5
DM3SYH5	DN	GNF-PF-67
DM3SYH5	MI	TT78R5H
DM3SYH5	MN	Heat shock protein 90 alpha (HSP90A)
DM3SYH5	MT	DTT
DM3SYH5	MA	Inhibitor
DM3SYH5	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DM3SYH5	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DM7SPRJ	DI	DM7SPRJ
DM7SPRJ	DN	GNF-PF-78
DM7SPRJ	MI	TT124R0
DM7SPRJ	MN	Nuclear receptor coactivator 3 (NCOA3)
DM7SPRJ	MT	DTT
DM7SPRJ	MA	Inhibitor
DM7SPRJ	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DM7SPRJ	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DM7SPRJ	DI	DM7SPRJ
DM7SPRJ	DN	GNF-PF-78
DM7SPRJ	MI	TT9JZCK
DM7SPRJ	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DM7SPRJ	MT	DTT
DM7SPRJ	MA	Inhibitor
DM7SPRJ	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DM7SPRJ	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DM37ORC	DI	DM37ORC
DM37ORC	DN	GNF-PF-826
DM37ORC	MI	TT124R0
DM37ORC	MN	Nuclear receptor coactivator 3 (NCOA3)
DM37ORC	MT	DTT
DM37ORC	MA	Inhibitor
DM37ORC	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DM37ORC	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DM37ORC	DI	DM37ORC
DM37ORC	DN	GNF-PF-826
DM37ORC	MI	TT9JZCK
DM37ORC	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DM37ORC	MT	DTT
DM37ORC	MA	Inhibitor
DM37ORC	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DM37ORC	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMB6FN7	DI	DMB6FN7
DMB6FN7	DN	GNF-PF-85
DMB6FN7	MI	TT3PQ2Y
DMB6FN7	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DMB6FN7	MT	DTT
DMB6FN7	MA	Inhibitor
DMB6FN7	RN	Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the malaria parasite Plasmodium falcipa... J Med Chem. 2008 Jun 26;51(12):3649-53.
DMB6FN7	RU	https://pubmed.ncbi.nlm.nih.gov/18522386

DMKVTZN	DI	DMKVTZN
DMKVTZN	DN	Go 6983
DMKVTZN	MI	TT7A1BO
DMKVTZN	MN	PKC-delta messenger RNA (PRKCD mRNA)
DMKVTZN	MT	DTT
DMKVTZN	MA	Inhibitor
DMKVTZN	RN	Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase c isoenzymes. FEBS Lett. 1996 Aug 26;392(2):77-80.
DMKVTZN	RU	https://pubmed.ncbi.nlm.nih.gov/8772178

DMKVTZN	DI	DMKVTZN
DMKVTZN	DN	Go 6983
DMKVTZN	MI	TTBSN0L
DMKVTZN	MN	PKC-zeta messenger RNA (PRKCZ mRNA)
DMKVTZN	MT	DTT
DMKVTZN	MA	Inhibitor
DMKVTZN	RN	Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase c isoenzymes. FEBS Lett. 1996 Aug 26;392(2):77-80.
DMKVTZN	RU	https://pubmed.ncbi.nlm.nih.gov/8772178

DMKVTZN	DI	DMKVTZN
DMKVTZN	DN	Go 6983
DMKVTZN	MI	TTFJ8Q1
DMKVTZN	MN	Protein kinase C alpha (PRKCA)
DMKVTZN	MT	DTT
DMKVTZN	MA	Inhibitor
DMKVTZN	RN	Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase c isoenzymes. FEBS Lett. 1996 Aug 26;392(2):77-80.
DMKVTZN	RU	https://pubmed.ncbi.nlm.nih.gov/8772178

DMKVTZN	DI	DMKVTZN
DMKVTZN	DN	Go 6983
DMKVTZN	MI	TTYPXQF
DMKVTZN	MN	Protein kinase C beta (PRKCB)
DMKVTZN	MT	DTT
DMKVTZN	MA	Inhibitor
DMKVTZN	RN	Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase c isoenzymes. FEBS Lett. 1996 Aug 26;392(2):77-80.
DMKVTZN	RU	https://pubmed.ncbi.nlm.nih.gov/8772178

DMKVTZN	DI	DMKVTZN
DMKVTZN	DN	Go 6983
DMKVTZN	MI	TTRFOXJ
DMKVTZN	MN	Protein kinase C gamma (PRKCG)
DMKVTZN	MT	DTT
DMKVTZN	MA	Inhibitor
DMKVTZN	RN	Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase c isoenzymes. FEBS Lett. 1996 Aug 26;392(2):77-80.
DMKVTZN	RU	https://pubmed.ncbi.nlm.nih.gov/8772178

DMS91OR	DI	DMS91OR
DMS91OR	DN	Go7874
DMS91OR	MI	TTOXS3C
DMS91OR	MN	Muscarinic acetylcholine receptor (CHRM)
DMS91OR	MT	DTT
DMS91OR	MA	Modulator (allosteric modulator)
DMS91OR	RN	Allosteric interactions of staurosporine and other indolocarbazoles with N-[methyl-(3)H]scopolamine and acetylcholine at muscarinic receptor subtypes: identification of a second allosteric site. Mol Pharmacol. 2000 Jul;58(1):194-207.
DMS91OR	RU	https://pubmed.ncbi.nlm.nih.gov/10860942

DMS91OR	DI	DMS91OR
DMS91OR	DN	Go7874
DMS91OR	MI	TTQ13Z5
DMS91OR	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMS91OR	MT	DTT
DMS91OR	MA	Modulator (allosteric modulator)
DMS91OR	RN	Allosteric interactions of staurosporine and other indolocarbazoles with N-[methyl-(3)H]scopolamine and acetylcholine at muscarinic receptor subtypes: identification of a second allosteric site. Mol Pharmacol. 2000 Jul;58(1):194-207.
DMS91OR	RU	https://pubmed.ncbi.nlm.nih.gov/10860942

DMS97A1	DI	DMS97A1
DMS97A1	DN	Gold trichloride sodium chloride
DMS97A1	MI	TTF2LRI
DMS97A1	MN	Cathepsin B (CTSB)
DMS97A1	MT	DTT
DMS97A1	MA	Inhibitor
DMS97A1	RN	Inhibition of lysosomal cysteine proteases by chrysotherapeutic compounds: a possible mechanism for the antiarthritic activity of Au(I). Bioorg Med Chem Lett. 2004 Oct 18;14(20):5113-6.
DMS97A1	RU	https://pubmed.ncbi.nlm.nih.gov/15380210

DMMT05U	DI	DMMT05U
DMMT05U	DN	GOSSYPETIN
DMMT05U	MI	TTSZLWK
DMMT05U	MN	Aromatase (CYP19A1)
DMMT05U	MT	DTT
DMMT05U	MA	Inhibitor
DMMT05U	RN	Screening of herbal constituents for aromatase inhibitory activity. Bioorg Med Chem. 2008 Sep 15;16(18):8466-70.
DMMT05U	RU	https://pubmed.ncbi.nlm.nih.gov/18778944

DMMT05U	DI	DMMT05U
DMMT05U	DN	GOSSYPETIN
DMMT05U	MI	TT50QJ3
DMMT05U	MN	Influenza Neuraminidase (Influ NA)
DMMT05U	MT	DTT
DMMT05U	MA	Inhibitor
DMMT05U	RN	Neuraminidase inhibitory activities of flavonols isolated from Rhodiola rosea roots and their in vitro anti-influenza viral activities. Bioorg Med Chem. 2009 Oct 1;17(19):6816-23.
DMMT05U	RU	https://pubmed.ncbi.nlm.nih.gov/19729316

DMZNUAD	DI	DMZNUAD
DMZNUAD	DN	Go-Y022
DMZNUAD	MI	TTVG215
DMZNUAD	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DMZNUAD	MT	DTT
DMZNUAD	MA	Inhibitor
DMZNUAD	RN	Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues. Eur J Med Chem. 2008 Aug;43(8):1621-31.
DMZNUAD	RU	https://pubmed.ncbi.nlm.nih.gov/18249473

DMUNSLJ	DI	DMUNSLJ
DMUNSLJ	DN	Go-Y026
DMUNSLJ	MI	TTXV4FI
DMUNSLJ	MN	Albendazole monooxygenase (CYP3A4)
DMUNSLJ	MT	DTT
DMUNSLJ	MA	Inhibitor
DMUNSLJ	RN	Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues. Eur J Med Chem. 2008 Aug;43(8):1621-31.
DMUNSLJ	RU	https://pubmed.ncbi.nlm.nih.gov/18249473

DMRUIX3	DI	DMRUIX3
DMRUIX3	DN	GP515
DMRUIX3	MI	TTL732K
DMRUIX3	MN	Adenosine kinase (ADK)
DMRUIX3	MT	DTT
DMRUIX3	MA	Inhibitor
DMRUIX3	RN	Adenosine kinase inhibitor GP515 improves experimental colitis in mice. J Pharmacol Exp Ther. 2001 Jan;296(1):99-105.
DMRUIX3	RU	https://pubmed.ncbi.nlm.nih.gov/11123368

DMRUIX3	DI	DMRUIX3
DMRUIX3	DN	GP515
DMRUIX3	MI	TTTU72V
DMRUIX3	MN	Steroid 5-alpha-reductase 1 (SRD5A1)
DMRUIX3	MT	DTT
DMRUIX3	MA	Inhibitor
DMRUIX3	RN	19-nor-10-azasteroids: a novel class of inhibitors for human steroid 5alpha-reductases 1 and 2. J Med Chem. 1997 Mar 28;40(7):1112-29.
DMRUIX3	RU	https://pubmed.ncbi.nlm.nih.gov/9089333

DMRUIX3	DI	DMRUIX3
DMRUIX3	DN	GP515
DMRUIX3	MI	TTT02K8
DMRUIX3	MN	Steroid 5-alpha-reductase 2 (SRD5A2)
DMRUIX3	MT	DTT
DMRUIX3	MA	Inhibitor
DMRUIX3	RN	19-nor-10-azasteroids: a novel class of inhibitors for human steroid 5alpha-reductases 1 and 2. J Med Chem. 1997 Mar 28;40(7):1112-29.
DMRUIX3	RU	https://pubmed.ncbi.nlm.nih.gov/9089333

DM1W5G9	DI	DM1W5G9
DM1W5G9	DN	GPCR39 pepducins
DM1W5G9	MI	TTTPCNU
DM1W5G9	MN	G-protein coupled receptor 39 (GPR39)
DM1W5G9	MT	DTT
DM1W5G9	MA	Modulator
DM1W5G9	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 105).
DM1W5G9	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=105

DMRJ5OD	DI	DMRJ5OD
DMRJ5OD	DN	GPG-290
DMRJ5OD	MI	TT1290U
DMRJ5OD	MN	Coagulation factor VIII (F8)
DMRJ5OD	MT	DTT
DMRJ5OD	MA	Inhibitor
DMRJ5OD	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2607).
DMRJ5OD	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2607

DMAY48N	DI	DMAY48N
DMAY48N	DN	GPI 18214
DMAY48N	MI	TT39J16
DMAY48N	MN	Poly [ADP-ribose] glycohydrolase (PARG)
DMAY48N	MT	DTT
DMAY48N	MA	Inhibitor
DMAY48N	RN	Treatment with a novel poly(ADP-ribose) glycohydrolase inhibitor reduces development of septic shock-like syndrome induced by zymosan in mice. Crit Care Med. 2004 Jun;32(6):1365-74.
DMAY48N	RU	https://pubmed.ncbi.nlm.nih.gov/15187521

DMLRTPH	DI	DMLRTPH
DMLRTPH	DN	GPYRMEHFRWGSPPKD-NH2
DMLRTPH	MI	TTEOSZT
DMLRTPH	MN	Melanocortin receptor (MCR)
DMLRTPH	MT	DTT
DMLRTPH	MA	Inhibitor
DMLRTPH	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMLRTPH	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMLRTPH	DI	DMLRTPH
DMLRTPH	DN	GPYRMEHFRWGSPPKD-NH2
DMLRTPH	MI	TT0MV2T
DMLRTPH	MN	Melanocortin receptor 1 (MC1R)
DMLRTPH	MT	DTT
DMLRTPH	MA	Inhibitor
DMLRTPH	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMLRTPH	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMLRTPH	DI	DMLRTPH
DMLRTPH	DN	GPYRMEHFRWGSPPKD-NH2
DMLRTPH	MI	TTNI91K
DMLRTPH	MN	Melanocortin receptor 3 (MC3R)
DMLRTPH	MT	DTT
DMLRTPH	MA	Inhibitor
DMLRTPH	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMLRTPH	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMLRTPH	DI	DMLRTPH
DMLRTPH	DN	GPYRMEHFRWGSPPKD-NH2
DMLRTPH	MI	TTD0CIQ
DMLRTPH	MN	Melanocortin receptor 4 (MC4R)
DMLRTPH	MT	DTT
DMLRTPH	MA	Inhibitor
DMLRTPH	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMLRTPH	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMMX7KL	DI	DMMX7KL
DMMX7KL	DN	GR 125,743
DMMX7KL	MI	TTSQIFT
DMMX7KL	MN	5-HT 1A receptor (HTR1A)
DMMX7KL	MT	DTT
DMMX7KL	MA	Antagonist
DMMX7KL	RN	Agonist activity of antimigraine drugs at recombinant human 5-HT1A receptors: potential implications for prophylactic and acute therapy. Naunyn Schmiedebergs Arch Pharmacol. 1997 Jun;355(6):682-8.
DMMX7KL	RU	https://pubmed.ncbi.nlm.nih.gov/9205951

DM72B86	DI	DM72B86
DM72B86	DN	GR 125487
DM72B86	MI	TT07C3Y
DM72B86	MN	5-HT 4 receptor (HTR4)
DM72B86	MT	DTT
DM72B86	MA	Antagonist
DM72B86	RN	Cloning, expression and pharmacology of the mouse 5-HT(4L) receptor. FEBS Lett. 1996 Nov 25;398(1):19-25.
DM72B86	RU	https://pubmed.ncbi.nlm.nih.gov/8946946

DMAI9Y0	DI	DMAI9Y0
DMAI9Y0	DN	GR 128107
DMAI9Y0	MI	TT0WAIE
DMAI9Y0	MN	Melatonin receptor type 1A (MTNR1A)
DMAI9Y0	MT	DTT
DMAI9Y0	MA	Agonist
DMAI9Y0	RN	The putative melatonin receptor antagonist GR128107 is a partial agonist on Xenopus laevis melanophores. Br J Pharmacol. 1999 Mar;126(5):1237-45.
DMAI9Y0	RU	https://pubmed.ncbi.nlm.nih.gov/10205014

DMHAWYJ	DI	DMHAWYJ
DMHAWYJ	DN	GR 196429
DMHAWYJ	MI	TT0WAIE
DMHAWYJ	MN	Melatonin receptor type 1A (MTNR1A)
DMHAWYJ	MT	DTT
DMHAWYJ	MA	Agonist
DMHAWYJ	RN	GR196429: a nonindolic agonist at high-affinity melatonin receptors. J Pharmacol Exp Ther. 1998 Jun;285(3):1239-45.
DMHAWYJ	RU	https://pubmed.ncbi.nlm.nih.gov/9618428

DMP1DO4	DI	DMP1DO4
DMP1DO4	DN	GR100679
DMP1DO4	MI	TTYO0A3
DMP1DO4	MN	Substance-K receptor (TACR2)
DMP1DO4	MT	DTT
DMP1DO4	MA	Antagonist
DMP1DO4	RN	Characterisation, CNS distribution and function of NK2 receptors studied using potent NK2 receptor antagonists. Regul Pept. 1993 Jul 2;46(1-2):9-19.
DMP1DO4	RU	https://pubmed.ncbi.nlm.nih.gov/8210508

DMFU9VH	DI	DMFU9VH
DMFU9VH	DN	GR-113808
DMFU9VH	MI	TT07C3Y
DMFU9VH	MN	5-HT 4 receptor (HTR4)
DMFU9VH	MT	DTT
DMFU9VH	MA	Inhibitor
DMFU9VH	RN	Synthesis of specific bivalent probes that functionally interact with 5-HT(4) receptor dimers. J Med Chem. 2007 Sep 6;50(18):4482-92.
DMFU9VH	RU	https://pubmed.ncbi.nlm.nih.gov/17676726

DMQH8PK	DI	DMQH8PK
DMQH8PK	DN	GR-133686
DMQH8PK	MI	TT2WR1T
DMQH8PK	MN	Cationic trypsinogen (PRSS1)
DMQH8PK	MT	DTT
DMQH8PK	MA	Inhibitor
DMQH8PK	RN	5,5-trans lactone-containing inhibitors of serine proteases: identification of a novel, acylating thrombin inhibitor. Bioorg Med Chem Lett. 1998 Nov 3;8(21):2955-60.
DMQH8PK	RU	https://pubmed.ncbi.nlm.nih.gov/9873654

DMQH8PK	DI	DMQH8PK
DMQH8PK	DN	GR-133686
DMQH8PK	MI	TT6L509
DMQH8PK	MN	Coagulation factor IIa (F2)
DMQH8PK	MT	DTT
DMQH8PK	MA	Inhibitor
DMQH8PK	RN	5,5-trans lactone-containing inhibitors of serine proteases: identification of a novel, acylating thrombin inhibitor. Bioorg Med Chem Lett. 1998 Nov 3;8(21):2955-60.
DMQH8PK	RU	https://pubmed.ncbi.nlm.nih.gov/9873654

DMW8YDR	DI	DMW8YDR
DMW8YDR	DN	GR138676
DMW8YDR	MI	TTBPGLU
DMW8YDR	MN	Neuromedin-K receptor (TACR3)
DMW8YDR	MT	DTT
DMW8YDR	MA	Antagonist
DMW8YDR	RN	GR138676, a novel peptidic tachykinin antagonist which is potent at NK3 receptors. Neuropeptides. 1994 Dec;27(6):333-41.
DMW8YDR	RU	https://pubmed.ncbi.nlm.nih.gov/7534879

DMIY9UF	DI	DMIY9UF
DMIY9UF	DN	GR-38414
DMIY9UF	MI	TTQW87Y
DMIY9UF	MN	Opioid receptor kappa (OPRK1)
DMIY9UF	MT	DTT
DMIY9UF	MA	Modulator
DMIY9UF	RN	A series of novel, highly potent and selective agonists for the kappa-opioid receptor. Br J Pharmacol. 1990 Dec;101(4):944-8.
DMIY9UF	RU	https://www.ncbi.nlm.nih.gov/pubmed/1964823

DM5UOYM	DI	DM5UOYM
DM5UOYM	DN	GR-45809
DM5UOYM	MI	TTQW87Y
DM5UOYM	MN	Opioid receptor kappa (OPRK1)
DM5UOYM	MT	DTT
DM5UOYM	MA	Modulator
DM5UOYM	RN	J. Med. Chem. 1993,36, 2075-2083
DM5UOYM	RU	http://pubs.acs.org/doi/pdf/10.1021/jm00067a004

DM8L1Z2	DI	DM8L1Z2
DM8L1Z2	DN	GR55562
DM8L1Z2	MI	TTK8CXU
DM8L1Z2	MN	5-HT 1B receptor (HTR1B)
DM8L1Z2	MT	DTT
DM8L1Z2	MA	Antagonist
DM8L1Z2	RN	5-hydroxytryptamine receptors mediating contraction in human small muscular pulmonary arteries: importance of the 5-HT1B receptor. Br J Pharmacol. 1999 Oct;128(3):730-4.
DM8L1Z2	RU	https://pubmed.ncbi.nlm.nih.gov/10516655

DMEO7CP	DI	DMEO7CP
DMEO7CP	DN	GR-86014
DMEO7CP	MI	TTQW87Y
DMEO7CP	MN	Opioid receptor kappa (OPRK1)
DMEO7CP	MT	DTT
DMEO7CP	MA	Modulator
DMEO7CP	RN	Neuroprotective actions of GR89696, a highly potent and selective kappa-opioid receptor agonist.
DMEO7CP	RU	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1907793

DM9WY1D	DI	DM9WY1D
DM9WY1D	DN	GR-91272
DM9WY1D	MI	TTQW87Y
DM9WY1D	MN	Opioid receptor kappa (OPRK1)
DM9WY1D	MT	DTT
DM9WY1D	MA	Modulator
DM9WY1D	RN	Neuroprotective actions of GR89696, a highly potent and selective kappa-opioid receptor agonist.
DM9WY1D	RU	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1907793

DMBYK0X	DI	DMBYK0X
DMBYK0X	DN	GR94800
DMBYK0X	MI	TTYO0A3
DMBYK0X	MN	Substance-K receptor (TACR2)
DMBYK0X	MT	DTT
DMBYK0X	MA	Antagonist
DMBYK0X	RN	Synthesis and characterization of selective fluorescent ligands for the neurokinin NK2 receptor. J Med Chem. 1994 Jun 24;37(13):1991-5.
DMBYK0X	RU	https://pubmed.ncbi.nlm.nih.gov/8027981

DMVLQUP	DI	DMVLQUP
DMVLQUP	DN	Grandisine C
DMVLQUP	MI	TT27RFC
DMVLQUP	MN	Opioid receptor delta (OPRD1)
DMVLQUP	MT	DTT
DMVLQUP	MA	Inhibitor
DMVLQUP	RN	Grandisines C-G, indolizidine alkaloids from the Australian rainforest tree Elaeocarpus grandis. J Nat Prod. 2006 Sep;69(9):1295-9.
DMVLQUP	RU	https://pubmed.ncbi.nlm.nih.gov/16989522

DM0JHYF	DI	DM0JHYF
DM0JHYF	DN	Grandisine D
DM0JHYF	MI	TT27RFC
DM0JHYF	MN	Opioid receptor delta (OPRD1)
DM0JHYF	MT	DTT
DM0JHYF	MA	Inhibitor
DM0JHYF	RN	Grandisines C-G, indolizidine alkaloids from the Australian rainforest tree Elaeocarpus grandis. J Nat Prod. 2006 Sep;69(9):1295-9.
DM0JHYF	RU	https://pubmed.ncbi.nlm.nih.gov/16989522

DM04S2P	DI	DM04S2P
DM04S2P	DN	Grandisine F
DM04S2P	MI	TT27RFC
DM04S2P	MN	Opioid receptor delta (OPRD1)
DM04S2P	MT	DTT
DM04S2P	MA	Inhibitor
DM04S2P	RN	Grandisines C-G, indolizidine alkaloids from the Australian rainforest tree Elaeocarpus grandis. J Nat Prod. 2006 Sep;69(9):1295-9.
DM04S2P	RU	https://pubmed.ncbi.nlm.nih.gov/16989522

DM65SQK	DI	DM65SQK
DM65SQK	DN	GRANULATIMIDE
DM65SQK	MI	TTTU902
DM65SQK	MN	Checkpoint kinase-1 (CHK1)
DM65SQK	MT	DTT
DM65SQK	MA	Inhibitor
DM65SQK	RN	Synthesis, in vitro antiproliferative activities, and Chk1 inhibitory properties of pyrrolo[3,4-a]carbazole-1,3-diones, pyrrolo[3,4-c]carbazole-1,3... Eur J Med Chem. 2008 Feb;43(2):282-92.
DM65SQK	RU	https://pubmed.ncbi.nlm.nih.gov/17502122

DM1PWX2	DI	DM1PWX2
DM1PWX2	DN	Grassystatin a
DM1PWX2	MI	TT6KIOT
DM1PWX2	MN	Caspase-11 (CASP11)
DM1PWX2	MT	DTT
DM1PWX2	MA	Inhibitor
DM1PWX2	RN	Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. J Med Chem. 2009 Sep 24;52(18):5732-47.
DM1PWX2	RU	https://pubmed.ncbi.nlm.nih.gov/19715320

DM1PWX2	DI	DM1PWX2
DM1PWX2	DN	Grassystatin a
DM1PWX2	MI	TTPT2QI
DM1PWX2	MN	Cathepsin D (CTSD)
DM1PWX2	MT	DTT
DM1PWX2	MA	Inhibitor
DM1PWX2	RN	Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. J Med Chem. 2009 Sep 24;52(18):5732-47.
DM1PWX2	RU	https://pubmed.ncbi.nlm.nih.gov/19715320

DM1PWX2	DI	DM1PWX2
DM1PWX2	DN	Grassystatin a
DM1PWX2	MI	TT2WR1T
DM1PWX2	MN	Cationic trypsinogen (PRSS1)
DM1PWX2	MT	DTT
DM1PWX2	MA	Inhibitor
DM1PWX2	RN	Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. J Med Chem. 2009 Sep 24;52(18):5732-47.
DM1PWX2	RU	https://pubmed.ncbi.nlm.nih.gov/19715320

DM1PWX2	DI	DM1PWX2
DM1PWX2	DN	Grassystatin a
DM1PWX2	MI	TT3NKIB
DM1PWX2	MN	Pancreatic elastase 1 (CELA1)
DM1PWX2	MT	DTT
DM1PWX2	MA	Inhibitor
DM1PWX2	RN	Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. J Med Chem. 2009 Sep 24;52(18):5732-47.
DM1PWX2	RU	https://pubmed.ncbi.nlm.nih.gov/19715320

DM1PWX2	DI	DM1PWX2
DM1PWX2	DN	Grassystatin a
DM1PWX2	MI	TTP86E2
DM1PWX2	MN	Plasminogen (PLG)
DM1PWX2	MT	DTT
DM1PWX2	MA	Inhibitor
DM1PWX2	RN	Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. J Med Chem. 2009 Sep 24;52(18):5732-47.
DM1PWX2	RU	https://pubmed.ncbi.nlm.nih.gov/19715320

DM1PWX2	DI	DM1PWX2
DM1PWX2	DN	Grassystatin a
DM1PWX2	MI	TTM1TDX
DM1PWX2	MN	Tryptase alpha/beta-1 (Tryptase)
DM1PWX2	MT	DTT
DM1PWX2	MA	Inhibitor
DM1PWX2	RN	Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. J Med Chem. 2009 Sep 24;52(18):5732-47.
DM1PWX2	RU	https://pubmed.ncbi.nlm.nih.gov/19715320

DMXSWF6	DI	DMXSWF6
DMXSWF6	DN	grayanotoxin III
DMXSWF6	MI	TT84DRB
DMXSWF6	MN	Voltage-gated sodium channel alpha Nav1.4 (SCN4A)
DMXSWF6	MT	DTT
DMXSWF6	MA	Activator
DMXSWF6	RN	Novel site on sodium channel alpha-subunit responsible for the differential sensitivity of grayanotoxin in skeletal and cardiac muscle. Mol Pharmacol. 2001 Oct;60(4):865-72.
DMXSWF6	RU	https://pubmed.ncbi.nlm.nih.gov/11562450

DMQHJTF	DI	DMQHJTF
DMQHJTF	DN	Green tea
DMQHJTF	MI	TTYEG6Q
DMQHJTF	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMQHJTF	MT	DTT
DMQHJTF	MA	Agonist
DMQHJTF	RN	Evaluation of muscarinic agonist-induced analgesia in muscarinic acetylcholine receptor knockout mice. Mol Pharmacol. 2002 Nov;62(5):1084-93.
DMQHJTF	RU	https://pubmed.ncbi.nlm.nih.gov/12391271

DMQHJTF	DI	DMQHJTF
DMQHJTF	DN	Green tea
DMQHJTF	MI	TTE14XG
DMQHJTF	MN	Squalene monooxygenase (SQLE)
DMQHJTF	MT	DTT
DMQHJTF	MA	Inhibitor
DMQHJTF	RN	Squalene epoxidase as hypocholesterolemic drug target revisited. Prog Lipid Res. 2003 Jan;42(1):37-50.
DMQHJTF	RU	https://pubmed.ncbi.nlm.nih.gov/12467639

DM3A0TE	DI	DM3A0TE
DM3A0TE	DN	GRI977143
DM3A0TE	MI	TTB7Y8I
DM3A0TE	MN	Lysophosphatidic acid receptor 2 (LPAR2)
DM3A0TE	MT	DTT
DM3A0TE	MA	Agonist
DM3A0TE	RN	Virtual screening for LPA2-specific agonists identifies a nonlipid compound with antiapoptotic actions. Mol Pharmacol. 2012 Dec;82(6):1162-73.
DM3A0TE	RU	https://pubmed.ncbi.nlm.nih.gov/22968304

DMGTRZE	DI	DMGTRZE
DMGTRZE	DN	grifolic acid
DMGTRZE	MI	TT08JVB
DMGTRZE	MN	G-protein coupled receptor 120 (GPR120)
DMGTRZE	MT	DTT
DMGTRZE	MA	Agonist
DMGTRZE	RN	Novel selective ligands for free fatty acid receptors GPR120 and GPR40. Naunyn Schmiedebergs Arch Pharmacol. 2009 Sep;380(3):247-55.
DMGTRZE	RU	https://pubmed.ncbi.nlm.nih.gov/19471906

DML09OS	DI	DML09OS
DML09OS	DN	GRL-0667
DML09OS	MI	TTRGHB2
DML09OS	MN	SARS-CoV papain-like proteinase (PL-PRO)
DML09OS	MT	DTT
DML09OS	MA	Inhibitor
DML09OS	RN	Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: design, synthesis, protein-ligand X-ray structure and biologic... J Med Chem. 2010 Jul 8;53(13):4968-79.
DML09OS	RU	https://pubmed.ncbi.nlm.nih.gov/20527968

DMR93MK	DI	DMR93MK
DMR93MK	DN	GRL-7234
DMR93MK	MI	TT8JRS7
DMR93MK	MN	Beta-secretase (BACE)
DMR93MK	MT	DTT
DMR93MK	MA	Inhibitor
DMR93MK	RN	Design, synthesis, and X-ray structure of potent memapsin 2 (beta-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands. J Med Chem. 2007 May 17;50(10):2399-407.
DMR93MK	RU	https://pubmed.ncbi.nlm.nih.gov/17432843

DMR93MK	DI	DMR93MK
DMR93MK	DN	GRL-7234
DMR93MK	MI	TTPT2QI
DMR93MK	MN	Cathepsin D (CTSD)
DMR93MK	MT	DTT
DMR93MK	MA	Inhibitor
DMR93MK	RN	Design, synthesis, and X-ray structure of potent memapsin 2 (beta-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands. J Med Chem. 2007 May 17;50(10):2399-407.
DMR93MK	RU	https://pubmed.ncbi.nlm.nih.gov/17432843

DMJ47DM	DI	DMJ47DM
DMJ47DM	DN	GRN-529
DMJ47DM	MI	TTHS256
DMJ47DM	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMJ47DM	MT	DTT
DMJ47DM	MA	Modulator
DMJ47DM	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 293).
DMJ47DM	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=293

DMO6IM1	DI	DMO6IM1
DMO6IM1	DN	group E 1682-2106
DMO6IM1	MI	TT5Y4EM
DMO6IM1	MN	N-formyl peptide receptor (FPR1)
DMO6IM1	MT	DTT
DMO6IM1	MA	Antagonist
DMO6IM1	RN	Integration of virtual screening with high-throughput flow cytometry to identify novel small molecule formylpeptide receptor antagonists. Mol Pharmacol. 2005 Nov;68(5):1301-10.
DMO6IM1	RU	https://pubmed.ncbi.nlm.nih.gov/16118363

DMG0OUD	DI	DMG0OUD
DMG0OUD	DN	GS4071
DMG0OUD	MI	TT50QJ3
DMG0OUD	MN	Influenza Neuraminidase (Influ NA)
DMG0OUD	MT	DTT
DMG0OUD	MA	Inhibitor
DMG0OUD	RN	Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25.
DMG0OUD	RU	https://pubmed.ncbi.nlm.nih.gov/17139286

DMEGY3Q	DI	DMEGY3Q
DMEGY3Q	DN	GS-9256 + tegobuvir
DMEGY3Q	MI	TTMVBWH
DMEGY3Q	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMEGY3Q	MT	DTT
DMEGY3Q	MA	Modulator
DMEGY3Q	RN	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
DMEGY3Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/27899562

DMTKGA3	DI	DMTKGA3
DMTKGA3	DN	GSC-1
DMTKGA3	MI	TTXWASR
DMTKGA3	MN	Intestinal maltase-glucoamylase (MGAM)
DMTKGA3	MT	DTT
DMTKGA3	MA	Inhibitor
DMTKGA3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2627).
DMTKGA3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2627

DMC2ZF6	DI	DMC2ZF6
DMC2ZF6	DN	GSK-008A
DMC2ZF6	MI	TTUV8G9
DMC2ZF6	MN	Progesterone receptor (PGR)
DMC2ZF6	MT	DTT
DMC2ZF6	MA	Agonist
DMC2ZF6	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 627).
DMC2ZF6	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=627

DMNIVOX	DI	DMNIVOX
DMNIVOX	DN	GSK-0660
DMNIVOX	MI	TT2JWF6
DMNIVOX	MN	Peroxisome proliferator-activated receptor delta (PPARD)
DMNIVOX	MT	DTT
DMNIVOX	MA	Inhibitor
DMNIVOX	RN	Identification and characterization of 4-chloro-N-(2-{[5-trifluoromethyl)-2-pyridyl]sulfonyl}ethyl)benzamide (GSK3787), a selective and irreversibl... J Med Chem. 2010 Feb 25;53(4):1857-61.
DMNIVOX	RU	https://pubmed.ncbi.nlm.nih.gov/20128594

DMDHZR1	DI	DMDHZR1
DMDHZR1	DN	GSK1016790A
DMDHZR1	MI	TTKP2SU
DMDHZR1	MN	Transient receptor potential cation channel V4 (TRPV4)
DMDHZR1	MT	DTT
DMDHZR1	MA	Activator
DMDHZR1	RN	N-((1S)-1-{[4-((2S)-2-{[(2,4-dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide (GSK1016790A), a novel and potent transient receptor potential vanilloid 4 channel agonist induces urinary bladder contraction and hyperactivity: Part I. J Pharmacol Exp Ther. 2008 Aug;326(2):432-42.
DMDHZR1	RU	https://pubmed.ncbi.nlm.nih.gov/18499743

DMIWY7Q	DI	DMIWY7Q
DMIWY7Q	DN	GSK1331268
DMIWY7Q	MI	TTXJ47W
DMIWY7Q	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMIWY7Q	MT	DTT
DMIWY7Q	MA	Modulator (allosteric modulator)
DMIWY7Q	RN	The identification of structurally novel, selective, orally bioavailable positive modulators of mGluR2. Bioorg Med Chem Lett. 2010 Jan 15;20(2):759-62.
DMIWY7Q	RU	https://pubmed.ncbi.nlm.nih.gov/20005096

DMHBUG5	DI	DMHBUG5
DMHBUG5	DN	GSK-1344386B
DMHBUG5	MI	TTFZYTO
DMHBUG5	MN	C-C chemokine receptor type 2 (CCR2)
DMHBUG5	MT	DTT
DMHBUG5	MA	Antagonist
DMHBUG5	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 59).
DMHBUG5	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=59

DMZUTXW	DI	DMZUTXW
DMZUTXW	DN	GSK1511931
DMZUTXW	MI	TTQFBMY
DMZUTXW	MN	IGF1R messenger RNA (IGF1R mRNA)
DMZUTXW	MT	DTT
DMZUTXW	MA	Inhibitor
DMZUTXW	RN	Optimization of a series of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine inhibitors of IGF-1R: elimination of an acid-mediated decomposition pathway. Bioorg Med Chem Lett. 2009 Jan 15;19(2):373-7.
DMZUTXW	RU	https://pubmed.ncbi.nlm.nih.gov/19081716

DMKN76P	DI	DMKN76P
DMKN76P	DN	GSK-1564023A
DMKN76P	MI	TTUV8G9
DMKN76P	MN	Progesterone receptor (PGR)
DMKN76P	MT	DTT
DMKN76P	MA	Inhibitor
DMKN76P	RN	The identification a novel, selective, non-steroidal, functional glucocorticoid receptor antagonist. Bioorg Med Chem Lett. 2010 Apr 1;20(7):2340-3.
DMKN76P	RU	https://pubmed.ncbi.nlm.nih.gov/20202837

DMG6TL7	DI	DMG6TL7
DMG6TL7	DN	GSK1614343
DMG6TL7	MI	TTWDC17
DMG6TL7	MN	Growth hormone secretagogue receptor 1 (GHSR)
DMG6TL7	MT	DTT
DMG6TL7	MA	Antagonist
DMG6TL7	RN	Discovery process and characterization of novel carbohydrazide derivatives as potent and selective GHSR1a antagonists. ChemMedChem. 2010 Sep 3;5(9):1450-5.
DMG6TL7	RU	https://pubmed.ncbi.nlm.nih.gov/20593439

DM9IZNP	DI	DM9IZNP
DM9IZNP	DN	GSK-172981
DM9IZNP	MI	TTBPGLU
DM9IZNP	MN	Neuromedin-K receptor (TACR3)
DM9IZNP	MT	DTT
DM9IZNP	MA	Antagonist
DM9IZNP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 362).
DM9IZNP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=362

DM4HLK3	DI	DM4HLK3
DM4HLK3	DN	GSK-1838705A
DM4HLK3	MI	TTPMQSO
DM4HLK3	MN	ALK tyrosine kinase receptor (ALK)
DM4HLK3	MT	DTT
DM4HLK3	MA	Inhibitor
DM4HLK3	RN	GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Mol Cancer Ther. 2009 Oct;8(10):2811-20.
DM4HLK3	RU	https://pubmed.ncbi.nlm.nih.gov/19825801

DM4HLK3	DI	DM4HLK3
DM4HLK3	DN	GSK-1838705A
DM4HLK3	MI	TTQFBMY
DM4HLK3	MN	IGF1R messenger RNA (IGF1R mRNA)
DM4HLK3	MT	DTT
DM4HLK3	MA	Inhibitor
DM4HLK3	RN	Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011 Oct 30;29(11):1046-51.
DM4HLK3	RU	https://pubmed.ncbi.nlm.nih.gov/22037378

DM4HLK3	DI	DM4HLK3
DM4HLK3	DN	GSK-1838705A
DM4HLK3	MI	TTCBFJO
DM4HLK3	MN	Insulin receptor (INSR)
DM4HLK3	MT	DTT
DM4HLK3	MA	Inhibitor
DM4HLK3	RN	GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Mol Cancer Ther. 2009 Oct;8(10):2811-20.
DM4HLK3	RU	https://pubmed.ncbi.nlm.nih.gov/19825801

DM4HLK3	DI	DM4HLK3
DM4HLK3	DN	GSK-1838705A
DM4HLK3	MI	TTIXKA4
DM4HLK3	MN	Ribosomal protein S6 kinase alpha-1 (RSK1)
DM4HLK3	MT	DTT
DM4HLK3	MA	Inhibitor
DM4HLK3	RN	GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Mol Cancer Ther. 2009 Oct;8(10):2811-20.
DM4HLK3	RU	https://pubmed.ncbi.nlm.nih.gov/19825801

DM2KT17	DI	DM2KT17
DM2KT17	DN	GSK-1842799C
DM2KT17	MI	TT9JZCK
DM2KT17	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DM2KT17	MT	DTT
DM2KT17	MA	Agonist
DM2KT17	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 275).
DM2KT17	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=275

DMMWBU6	DI	DMMWBU6
DMMWBU6	DN	GSK-188909
DMMWBU6	MI	TT8JRS7
DMMWBU6	MN	Beta-secretase (BACE)
DMMWBU6	MT	DTT
DMMWBU6	MA	Inhibitor
DMMWBU6	RN	Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3664-8.
DMMWBU6	RU	https://pubmed.ncbi.nlm.nih.gov/19428244

DMKXPOL	DI	DMKXPOL
DMKXPOL	DN	GSK189254A
DMKXPOL	MI	TT9JNIC
DMKXPOL	MN	Histamine H3 receptor (H3R)
DMKXPOL	MT	DTT
DMKXPOL	MA	Antagonist
DMKXPOL	RN	The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20.
DMKXPOL	RU	https://pubmed.ncbi.nlm.nih.gov/15665857

DM9GPAU	DI	DM9GPAU
DM9GPAU	DN	GSK2033
DM9GPAU	MI	TTECBXN
DM9GPAU	MN	Oxysterols receptor LXR-alpha (NR1H3)
DM9GPAU	MT	DTT
DM9GPAU	MA	Antagonist
DM9GPAU	RN	Discovery of tertiary sulfonamides as potent liver X receptor antagonists. J Med Chem. 2010 Apr 22;53(8):3412-6.
DM9GPAU	RU	https://pubmed.ncbi.nlm.nih.gov/20345102

DM9GPAU	DI	DM9GPAU
DM9GPAU	DN	GSK2033
DM9GPAU	MI	TTXA6PH
DM9GPAU	MN	Oxysterols receptor LXR-beta (NR1H2)
DM9GPAU	MT	DTT
DM9GPAU	MA	Antagonist
DM9GPAU	RN	Discovery of tertiary sulfonamides as potent liver X receptor antagonists. J Med Chem. 2010 Apr 22;53(8):3412-6.
DM9GPAU	RU	https://pubmed.ncbi.nlm.nih.gov/20345102

DMY2XV3	DI	DMY2XV3
DMY2XV3	DN	GSK2193874
DMY2XV3	MI	TTKP2SU
DMY2XV3	MN	Transient receptor potential cation channel V4 (TRPV4)
DMY2XV3	MT	DTT
DMY2XV3	MA	Blocker (channel blocker)
DMY2XV3	RN	An orally active TRPV4 channel blocker prevents and resolves pulmonary edema induced by heart failure. Sci Transl Med. 2012 Nov 7;4(159):159ra148.
DMY2XV3	RU	https://pubmed.ncbi.nlm.nih.gov/23136043

DMZ2TD9	DI	DMZ2TD9
DMZ2TD9	DN	GSK2194069
DMZ2TD9	MI	TT7AOUD
DMZ2TD9	MN	Fatty acid synthase (FASN)
DMZ2TD9	MT	DTT
DMZ2TD9	MA	Inhibitor
DMZ2TD9	RN	A human fatty acid synthase inhibitor binds beta-ketoacyl reductase in the keto-substrate site. Nat Chem Biol. 2014 Sep;10(9):774-9.
DMZ2TD9	RU	https://pubmed.ncbi.nlm.nih.gov/25086508

DM0DKQN	DI	DM0DKQN
DM0DKQN	DN	GSK-2210875
DM0DKQN	MI	TTHS256
DM0DKQN	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM0DKQN	MT	DTT
DM0DKQN	MA	Antagonist
DM0DKQN	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 293).
DM0DKQN	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=293

DM3BI7R	DI	DM3BI7R
DM3BI7R	DN	GSK-2334470
DM3BI7R	MI	TT9QBI6
DM3BI7R	MN	Phosphoinositide dependent protein kinase-1 (PDPK1)
DM3BI7R	MT	DTT
DM3BI7R	MA	Inhibitor
DM3BI7R	RN	Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf(V600E)::Pten(-/-) melanoma. Oncogene. 2014 Aug 21;33(34):4330-9.
DM3BI7R	RU	https://pubmed.ncbi.nlm.nih.gov/24037523

DMLASOF	DI	DMLASOF
DMLASOF	DN	GSK2606414
DMLASOF	MI	TTHLGB2
DMLASOF	MN	Myosin light chain kinase 2 (MYLK2)
DMLASOF	MT	DTT
DMLASOF	MA	Inhibitor
DMLASOF	RN	Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK). J Med Chem. 2012 Aug 23;55(16):7193-207.
DMLASOF	RU	https://pubmed.ncbi.nlm.nih.gov/22827572

DMLASOF	DI	DMLASOF
DMLASOF	DN	GSK2606414
DMLASOF	MI	TT5OU0D
DMLASOF	MN	PRKR-like endoplasmic reticulum kinase (PERK)
DMLASOF	MT	DTT
DMLASOF	MA	Inhibitor
DMLASOF	RN	Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK). J Med Chem. 2012 Aug 23;55(16):7193-207.
DMLASOF	RU	https://pubmed.ncbi.nlm.nih.gov/22827572

DM325YR	DI	DM325YR
DM325YR	DN	GSK-280
DM325YR	MI	TTQBR95
DM325YR	MN	Stress-activated protein kinase 2a (p38 alpha)
DM325YR	MT	DTT
DM325YR	MA	Inhibitor
DM325YR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1499).
DM325YR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1499

DMDSK9N	DI	DMDSK9N
DMDSK9N	DN	GSK2801
DMDSK9N	MI	TT2MV0R
DMDSK9N	MN	Bromodomain adjacent to zinc finger 2A (BAZ2A)
DMDSK9N	MT	DTT
DMDSK9N	MA	Inhibitor
DMDSK9N	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2721).
DMDSK9N	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2721

DMDSK9N	DI	DMDSK9N
DMDSK9N	DN	GSK2801
DMDSK9N	MI	TT6K8YG
DMDSK9N	MN	Bromodomain adjacent to zinc finger 2B (BAZ2B)
DMDSK9N	MT	DTT
DMDSK9N	MA	Inhibitor
DMDSK9N	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2722).
DMDSK9N	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2722

DM1865H	DI	DM1865H
DM1865H	DN	GSK-325971A
DM1865H	MI	TTUV8G9
DM1865H	MN	Progesterone receptor (PGR)
DM1865H	MT	DTT
DM1865H	MA	Inhibitor
DM1865H	RN	The identification a novel, selective, non-steroidal, functional glucocorticoid receptor antagonist. Bioorg Med Chem Lett. 2010 Apr 1;20(7):2340-3.
DM1865H	RU	https://pubmed.ncbi.nlm.nih.gov/20202837

DM5EO3F	DI	DM5EO3F
DM5EO3F	DN	GSK-334429
DM5EO3F	MI	TT9JNIC
DM5EO3F	MN	Histamine H3 receptor (H3R)
DM5EO3F	MT	DTT
DM5EO3F	MA	Antagonist
DM5EO3F	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 264).
DM5EO3F	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=264

DM9QU5Y	DI	DM9QU5Y
DM9QU5Y	DN	GSK343
DM9QU5Y	MI	TTNJA0C
DM9QU5Y	MN	Enhancer of zeste homolog 1 (EZH1)
DM9QU5Y	MT	DTT
DM9QU5Y	MA	Inhibitor
DM9QU5Y	RN	Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2. ACS Med Chem Lett. 2012 Oct 19;3(12):1091-6.
DM9QU5Y	RU	https://pubmed.ncbi.nlm.nih.gov/24900432

DM9QU5Y	DI	DM9QU5Y
DM9QU5Y	DN	GSK343
DM9QU5Y	MI	TT9MZCQ
DM9QU5Y	MN	Enhancer of zeste homolog 2 (EZH2)
DM9QU5Y	MT	DTT
DM9QU5Y	MA	Inhibitor
DM9QU5Y	RN	Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2. ACS Med Chem Lett. 2012 Oct 19;3(12):1091-6.
DM9QU5Y	RU	https://pubmed.ncbi.nlm.nih.gov/24900432

DMKDLB7	DI	DMKDLB7
DMKDLB7	DN	GSK-3787
DMKDLB7	MI	TT2JWF6
DMKDLB7	MN	Peroxisome proliferator-activated receptor delta (PPARD)
DMKDLB7	MT	DTT
DMKDLB7	MA	Inhibitor
DMKDLB7	RN	Identification and characterization of 4-chloro-N-(2-{[5-trifluoromethyl)-2-pyridyl]sulfonyl}ethyl)benzamide (GSK3787), a selective and irreversibl... J Med Chem. 2010 Feb 25;53(4):1857-61.
DMKDLB7	RU	https://pubmed.ncbi.nlm.nih.gov/20128594

DMQR7TZ	DI	DMQR7TZ
DMQR7TZ	DN	GSK-3beta inhibitor II
DMQR7TZ	MI	TTRSMW9
DMQR7TZ	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMQR7TZ	MT	DTT
DMQR7TZ	MA	Inhibitor
DMQR7TZ	RN	Scaffold hopping and optimization towards libraries of glycogen synthase kinase-3 inhibitors. Bioorg Med Chem Lett. 2002 Jun 3;12(11):1525-8.
DMQR7TZ	RU	https://pubmed.ncbi.nlm.nih.gov/12031334

DM734QB	DI	DM734QB
DM734QB	DN	GSK-3beta inhibitor XI
DM734QB	MI	TTRSMW9
DM734QB	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DM734QB	MT	DTT
DM734QB	MA	Inhibitor
DM734QB	RN	Design, synthesis, and biological evaluation of novel 7-azaindolyl-heteroaryl-maleimides as potent and selective glycogen synthase kinase-3beta (GSK-3beta) inhibitors. Bioorg Med Chem. 2004 Jun 15;12(12):3167-85.
DM734QB	RU	https://pubmed.ncbi.nlm.nih.gov/15158785

DMHUMP9	DI	DMHUMP9
DMHUMP9	DN	GSK4716
DMHUMP9	MI	TT9ZRHB
DMHUMP9	MN	Estrogen-related receptor-gamma (ESRRG)
DMHUMP9	MT	DTT
DMHUMP9	MA	Agonist
DMHUMP9	RN	Identification and structure-activity relationship of phenolic acyl hydrazones as selective agonists for the estrogen-related orphan nuclear receptors ERRbeta and ERRgamma. J Med Chem. 2005 May 5;48(9):3107-9.
DMHUMP9	RU	https://pubmed.ncbi.nlm.nih.gov/15857113

DMMIWHV	DI	DMMIWHV
DMMIWHV	DN	GSK494581A
DMMIWHV	MI	TTNET8J
DMMIWHV	MN	G-protein coupled receptor 55 (GPR55)
DMMIWHV	MT	DTT
DMMIWHV	MA	Agonist
DMMIWHV	RN	Pharmacology of GPR55 in yeast and identification of GSK494581A as a mixed-activity glycine transporter subtype 1 inhibitor and GPR55 agonist. J Pharmacol Exp Ther. 2011 Apr;337(1):236-46.
DMMIWHV	RU	https://pubmed.ncbi.nlm.nih.gov/21233197

DMNGEAY	DI	DMNGEAY
DMNGEAY	DN	GSK-5182
DMNGEAY	MI	TTZAYWL
DMNGEAY	MN	Estrogen receptor (ESR)
DMNGEAY	MT	DTT
DMNGEAY	MA	Inhibitor
DMNGEAY	RN	Structure-guided synthesis of tamoxifen analogs with improved selectivity for the orphan ERRgamma. Bioorg Med Chem Lett. 2006 Feb 15;16(4):821-4.
DMNGEAY	RU	https://pubmed.ncbi.nlm.nih.gov/16307879

DM1I0AN	DI	DM1I0AN
DM1I0AN	DN	GSK575594A
DM1I0AN	MI	TTNET8J
DM1I0AN	MN	G-protein coupled receptor 55 (GPR55)
DM1I0AN	MT	DTT
DM1I0AN	MA	Agonist
DM1I0AN	RN	Pharmacology of GPR55 in yeast and identification of GSK494581A as a mixed-activity glycine transporter subtype 1 inhibitor and GPR55 agonist. J Pharmacol Exp Ther. 2011 Apr;337(1):236-46.
DM1I0AN	RU	https://pubmed.ncbi.nlm.nih.gov/21233197

DMJXHU8	DI	DMJXHU8
DMJXHU8	DN	GSK579289A
DMJXHU8	MI	TT3VZ24
DMJXHU8	MN	NIMA-related kinase 2 (NEK2)
DMJXHU8	MT	DTT
DMJXHU8	MA	Inhibitor
DMJXHU8	RN	Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1694-7.
DMJXHU8	RU	https://pubmed.ncbi.nlm.nih.gov/19237286

DMJXHU8	DI	DMJXHU8
DMJXHU8	DN	GSK579289A
DMJXHU8	MI	TTIYVQP
DMJXHU8	MN	Polo-like kinase 1 (PLK1)
DMJXHU8	MT	DTT
DMJXHU8	MA	Inhibitor
DMJXHU8	RN	Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1694-7.
DMJXHU8	RU	https://pubmed.ncbi.nlm.nih.gov/19237286

DMNRP2L	DI	DMNRP2L
DMNRP2L	DN	GSK-650394
DMNRP2L	MI	TTTV8EJ
DMNRP2L	MN	Serine/threonine-protein kinase Sgk1 (SGK1)
DMNRP2L	MT	DTT
DMNRP2L	MA	Inhibitor
DMNRP2L	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8040).
DMNRP2L	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8040

DMGW42V	DI	DMGW42V
DMGW42V	DN	GSK-8062
DMGW42V	MI	TTXV4FI
DMGW42V	MN	Albendazole monooxygenase (CYP3A4)
DMGW42V	MT	DTT
DMGW42V	MA	Inhibitor
DMGW42V	RN	Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064. Bioorg Med Chem Lett. 2008 Aug 1;18(15):4339-43.
DMGW42V	RU	https://pubmed.ncbi.nlm.nih.gov/18621523

DMT98PA	DI	DMT98PA
DMT98PA	DN	GSK-812397
DMT98PA	MI	TTBID49
DMT98PA	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMT98PA	MT	DTT
DMT98PA	MA	Antagonist
DMT98PA	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 71).
DMT98PA	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=71

DMSOWPE	DI	DMSOWPE
DMSOWPE	DN	GSK-894281
DMSOWPE	MI	TTWDC17
DMSOWPE	MN	Growth hormone secretagogue receptor 1 (GHSR)
DMSOWPE	MT	DTT
DMSOWPE	MA	Agonist
DMSOWPE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 246).
DMSOWPE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=246

DMIDQ8B	DI	DMIDQ8B
DMIDQ8B	DN	GSK931145
DMIDQ8B	MI	TTHJTF7
DMIDQ8B	MN	Glycine transporter GlyT-1 (SLC6A9)
DMIDQ8B	MT	DTT
DMIDQ8B	MA	Inhibitor
DMIDQ8B	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 935).
DMIDQ8B	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=935

DMW9AN1	DI	DMW9AN1
DMW9AN1	DN	GSK-9578
DMW9AN1	MI	TTJ584C
DMW9AN1	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMW9AN1	MT	DTT
DMW9AN1	MA	Inhibitor
DMW9AN1	RN	Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42.
DMW9AN1	RU	https://pubmed.ncbi.nlm.nih.gov/10828060

DMNOU59	DI	DMNOU59
DMNOU59	DN	GSK'963
DMNOU59	MI	TTAIQSN
DMNOU59	MN	Receptor-interacting protein 1 (RIPK1)
DMNOU59	MT	DTT
DMNOU59	MA	Inhibitor
DMNOU59	RN	Characterization of GSK'963: a structurally distinct, potent and selective inhibitor of RIP1 kinase. Cell Death Discov. 2015 Jul 27;1:15009.
DMNOU59	RU	https://pubmed.ncbi.nlm.nih.gov/27551444

DM4WS3R	DI	DM4WS3R
DM4WS3R	DN	GSK-9772
DM4WS3R	MI	TTECBXN
DM4WS3R	MN	Oxysterols receptor LXR-alpha (NR1H3)
DM4WS3R	MT	DTT
DM4WS3R	MA	Inhibitor
DM4WS3R	RN	Structure-guided design of N-phenyl tertiary amines as transrepression-selective liver X receptor modulators with anti-inflammatory activity. J Med Chem. 2008 Sep 25;51(18):5758-65.
DM4WS3R	RU	https://pubmed.ncbi.nlm.nih.gov/18800767

DM4WS3R	DI	DM4WS3R
DM4WS3R	DN	GSK-9772
DM4WS3R	MI	TTXA6PH
DM4WS3R	MN	Oxysterols receptor LXR-beta (NR1H2)
DM4WS3R	MT	DTT
DM4WS3R	MA	Inhibitor
DM4WS3R	RN	Structure-guided design of N-phenyl tertiary amines as transrepression-selective liver X receptor modulators with anti-inflammatory activity. J Med Chem. 2008 Sep 25;51(18):5758-65.
DM4WS3R	RU	https://pubmed.ncbi.nlm.nih.gov/18800767

DMY3SEN	DI	DMY3SEN
DMY3SEN	DN	GSK-J1
DMY3SEN	MI	TTDIJUQ
DMY3SEN	MN	Lysine-specific demethylase 6B (KDM6B)
DMY3SEN	MT	DTT
DMY3SEN	MA	Inhibitor
DMY3SEN	RN	A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature. 2012 Aug 16;488(7411):404-8.
DMY3SEN	RU	https://pubmed.ncbi.nlm.nih.gov/22842901

DMHJU7A	DI	DMHJU7A
DMHJU7A	DN	GSK-LSD1
DMHJU7A	MI	TTNR0UQ
DMHJU7A	MN	Lysine-specific histone demethylase 1 (LSD)
DMHJU7A	MT	DTT
DMHJU7A	MA	Inhibitor
DMHJU7A	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2669).
DMHJU7A	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2669

DMNMITH	DI	DMNMITH
DMNMITH	DN	GT-1282
DMNMITH	MI	TT2CEJG
DMNMITH	MN	C-C chemokine receptor type 5 (CCR5)
DMNMITH	MT	DTT
DMNMITH	MA	Inhibitor
DMNMITH	RN	Reduced cardiac side-effect potential by introduction of polar groups: discovery of NIBR-1282, an orally bioavailable CCR5 antagonist which is acti... Bioorg Med Chem Lett. 2008 Mar 15;18(6):2000-5.
DMNMITH	RU	https://pubmed.ncbi.nlm.nih.gov/18267361

DMH3PDG	DI	DMH3PDG
DMH3PDG	DN	GT2394
DMH3PDG	MI	TT9JNIC
DMH3PDG	MN	Histamine H3 receptor (H3R)
DMH3PDG	MT	DTT
DMH3PDG	MA	Antagonist
DMH3PDG	RN	Characteristics of recombinantly expressed rat and human histamine H3 receptors. Eur J Pharmacol. 2002 Oct 18;453(1):33-41.
DMH3PDG	RU	https://pubmed.ncbi.nlm.nih.gov/12393057

DMW23Y9	DI	DMW23Y9
DMW23Y9	DN	GTP-14564
DMW23Y9	MI	TTVW6QL
DMW23Y9	MN	CSF1R messenger RNA (CSF1R mRNA)
DMW23Y9	MT	DTT
DMW23Y9	MA	Inhibitor
DMW23Y9	RN	Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosin... J Biol Chem. 2003 Aug 29;278(35):32892-8.
DMW23Y9	RU	https://pubmed.ncbi.nlm.nih.gov/12815052

DMW23Y9	DI	DMW23Y9
DMW23Y9	DN	GTP-14564
DMW23Y9	MI	TTGJCWZ
DMW23Y9	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMW23Y9	MT	DTT
DMW23Y9	MA	Inhibitor
DMW23Y9	RN	Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosin... J Biol Chem. 2003 Aug 29;278(35):32892-8.
DMW23Y9	RU	https://pubmed.ncbi.nlm.nih.gov/12815052

DMW23Y9	DI	DMW23Y9
DMW23Y9	DN	GTP-14564
DMW23Y9	MI	TTI7421
DMW23Y9	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMW23Y9	MT	DTT
DMW23Y9	MA	Inhibitor
DMW23Y9	RN	Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosin... J Biol Chem. 2003 Aug 29;278(35):32892-8.
DMW23Y9	RU	https://pubmed.ncbi.nlm.nih.gov/12815052

DMW23Y9	DI	DMW23Y9
DMW23Y9	DN	GTP-14564
DMW23Y9	MI	TTX41N9
DMW23Y9	MN	Tyrosine-protein kinase Kit (KIT)
DMW23Y9	MT	DTT
DMW23Y9	MA	Inhibitor
DMW23Y9	RN	Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosin... J Biol Chem. 2003 Aug 29;278(35):32892-8.
DMW23Y9	RU	https://pubmed.ncbi.nlm.nih.gov/12815052

DMJUXKY	DI	DMJUXKY
DMJUXKY	DN	GTPgammaS
DMJUXKY	MI	TTST1AJ
DMJUXKY	MN	Chloride channel protein 7 (ClC-7)
DMJUXKY	MT	DTT
DMJUXKY	MA	Activator
DMJUXKY	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 709).
DMJUXKY	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=709

DMJUXKY	DI	DMJUXKY
DMJUXKY	DN	GTPgammaS
DMJUXKY	MI	TT0FC1V
DMJUXKY	MN	Volume regulated chloride channel (VRAC)
DMJUXKY	MT	DTT
DMJUXKY	MA	Activator
DMJUXKY	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 710).
DMJUXKY	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=710

DMZQETV	DI	DMZQETV
DMZQETV	DN	GTPL8662
DMZQETV	MI	TTUV8G9
DMZQETV	MN	Progesterone receptor (PGR)
DMZQETV	MT	DTT
DMZQETV	MA	Antagonist
DMZQETV	RN	A new strategy for selective targeting of progesterone receptor with passive antagonists. Mol Endocrinol. 2013 Jun;27(6):909-24.
DMZQETV	RU	https://pubmed.ncbi.nlm.nih.gov/23579486

DM315VL	DI	DM315VL
DM315VL	DN	GTx-027
DM315VL	MI	TTS64P2
DM315VL	MN	Androgen receptor (AR)
DM315VL	MT	DTT
DM315VL	MA	Modulator
DM315VL	RN	Selective androgen receptor modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial:mesenchymal stem cell signaling. PLoS One. 2014 Jul 29;9(7):e103202.
DM315VL	RU	https://pubmed.ncbi.nlm.nih.gov/25072326

DMEIMVW	DI	DMEIMVW
DMEIMVW	DN	GTx-822
DMEIMVW	MI	TTOM3J0
DMEIMVW	MN	Estrogen receptor beta (ESR2)
DMEIMVW	MT	DTT
DMEIMVW	MA	Modulator
DMEIMVW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 621).
DMEIMVW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=621

DMP9OGC	DI	DMP9OGC
DMP9OGC	DN	GTx-878
DMP9OGC	MI	TTOM3J0
DMP9OGC	MN	Estrogen receptor beta (ESR2)
DMP9OGC	MT	DTT
DMP9OGC	MA	Agonist
DMP9OGC	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 621).
DMP9OGC	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=621

DMGYMW4	DI	DMGYMW4
DMGYMW4	DN	Guajazulen
DMGYMW4	MI	DEJGDUW
DMGYMW4	MN	Cytochrome P450 1A2 (CYP1A2)
DMGYMW4	MT	DME
DMGYMW4	MA	Metabolism
DMGYMW4	RN	The influence of the sparteine/debrisoquine genetic polymorphism on the disposition of dexfenfluramine. Br J Clin Pharmacol. 1996 Apr;41(4):311-7.
DMGYMW4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8730977

DM4GO8H	DI	DM4GO8H
DM4GO8H	DN	Guanidine
DM4GO8H	MI	DT6201N
DM4GO8H	MN	Organic cation transporter 3 (SLC22A3)
DM4GO8H	MT	DTP
DM4GO8H	MA	Substrate
DM4GO8H	RN	Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. Am J Physiol Renal Physiol. 2000 Sep;279(3):F449-58.
DM4GO8H	RU	http://www.ncbi.nlm.nih.gov/pubmed/10966924

DMCN56S	DI	DMCN56S
DMCN56S	DN	GUANOSINE-2',3'-O-ETHYLIDENEPHOSPHONATE
DMCN56S	MI	TTMCF1Y
DMCN56S	MN	Purine nucleoside phosphorylase (PNP)
DMCN56S	MT	DTT
DMCN56S	MA	Inhibitor
DMCN56S	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMCN56S	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMRITFU	DI	DMRITFU
DMRITFU	DN	GUANOSINE-2',3'-O-METHYLIDENEPHOSPHONATE
DMRITFU	MI	TTMCF1Y
DMRITFU	MN	Purine nucleoside phosphorylase (PNP)
DMRITFU	MT	DTT
DMRITFU	MA	Inhibitor
DMRITFU	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMRITFU	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMG2ZFV	DI	DMG2ZFV
DMG2ZFV	DN	Guanosine-5',3'-Tetraphosphate
DMG2ZFV	MI	TTBL49X
DMG2ZFV	MN	Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ)
DMG2ZFV	MT	DTT
DMG2ZFV	MA	Inhibitor
DMG2ZFV	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMG2ZFV	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM0MUKQ	DI	DM0MUKQ
DM0MUKQ	DN	Guanosine-5'-Diphosphate
DM0MUKQ	MI	TT4W1VJ
DM0MUKQ	MN	Bacterial Celldivision protein FtsZ (Bact ftsZ)
DM0MUKQ	MT	DTT
DM0MUKQ	MA	Inhibitor
DM0MUKQ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM0MUKQ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM0MUKQ	DI	DM0MUKQ
DM0MUKQ	DN	Guanosine-5'-Diphosphate
DM0MUKQ	MI	TTO3MV6
DM0MUKQ	MN	Bacterial GTP-binding protein YihA (Bact engB)
DM0MUKQ	MT	DTT
DM0MUKQ	MA	Inhibitor
DM0MUKQ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM0MUKQ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM0MUKQ	DI	DM0MUKQ
DM0MUKQ	DN	Guanosine-5'-Diphosphate
DM0MUKQ	MI	TTCNGJ5
DM0MUKQ	MN	Candida Elongation factor 2 (Candi EFT2)
DM0MUKQ	MT	DTT
DM0MUKQ	MA	Inhibitor
DM0MUKQ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM0MUKQ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM0MUKQ	DI	DM0MUKQ
DM0MUKQ	DN	Guanosine-5'-Diphosphate
DM0MUKQ	MI	TTYQ4AE
DM0MUKQ	MN	Plasmodium Adenylosuccinate synthetase (Malaria Adss)
DM0MUKQ	MT	DTT
DM0MUKQ	MA	Inhibitor
DM0MUKQ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM0MUKQ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM0MUKQ	DI	DM0MUKQ
DM0MUKQ	DN	Guanosine-5'-Diphosphate
DM0MUKQ	MI	TTG45NU
DM0MUKQ	MN	Plasmodium Elongation factor 1-alpha 1 (Malaria MEF-1)
DM0MUKQ	MT	DTT
DM0MUKQ	MA	Inhibitor
DM0MUKQ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM0MUKQ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM0MUKQ	DI	DM0MUKQ
DM0MUKQ	DN	Guanosine-5'-Diphosphate
DM0MUKQ	MI	TT958S6
DM0MUKQ	MN	Ras-related protein Rab-9A (RAB9A)
DM0MUKQ	MT	DTT
DM0MUKQ	MA	Inhibitor
DM0MUKQ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM0MUKQ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM0MUKQ	DI	DM0MUKQ
DM0MUKQ	DN	Guanosine-5'-Diphosphate
DM0MUKQ	MI	TT6HP1T
DM0MUKQ	MN	Streptococcus Elongation factor G (Stre-coc fusA)
DM0MUKQ	MT	DTT
DM0MUKQ	MA	Inhibitor
DM0MUKQ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM0MUKQ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM0MUKQ	DI	DM0MUKQ
DM0MUKQ	DN	Guanosine-5'-Diphosphate
DM0MUKQ	MI	TT2F4OL
DM0MUKQ	MN	Tissue transglutaminase (TG2)
DM0MUKQ	MT	DTT
DM0MUKQ	MA	Inhibitor
DM0MUKQ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM0MUKQ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM3SLZK	DI	DM3SLZK
DM3SLZK	DN	Guanosine-5'-Monophosphate
DM3SLZK	MI	TT1U2YM
DM3SLZK	MN	Cytomegalovirus DNA polymerase (CMV UL54)
DM3SLZK	MT	DTT
DM3SLZK	MA	Inhibitor
DM3SLZK	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM3SLZK	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM3SLZK	DI	DM3SLZK
DM3SLZK	DN	Guanosine-5'-Monophosphate
DM3SLZK	MI	TTIU7X1
DM3SLZK	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DM3SLZK	MT	DTT
DM3SLZK	MA	Inhibitor
DM3SLZK	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM3SLZK	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM3SLZK	DI	DM3SLZK
DM3SLZK	DN	Guanosine-5'-Monophosphate
DM3SLZK	MI	TTJ0IQB
DM3SLZK	MN	Phosphodiesterase 5A (PDE5A)
DM3SLZK	MT	DTT
DM3SLZK	MA	Inhibitor
DM3SLZK	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM3SLZK	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM3SLZK	DI	DM3SLZK
DM3SLZK	DN	Guanosine-5'-Monophosphate
DM3SLZK	MI	TTBL49X
DM3SLZK	MN	Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ)
DM3SLZK	MT	DTT
DM3SLZK	MA	Inhibitor
DM3SLZK	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM3SLZK	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM3SLZK	DI	DM3SLZK
DM3SLZK	DN	Guanosine-5'-Monophosphate
DM3SLZK	MI	TT9PB26
DM3SLZK	MN	Presynaptic density protein 95 (DLG4)
DM3SLZK	MT	DTT
DM3SLZK	MA	Inhibitor
DM3SLZK	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM3SLZK	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMV2OJX	DI	DMV2OJX
DMV2OJX	DN	Guanosine-5'-Triphosphate
DMV2OJX	MI	TTO3MV6
DMV2OJX	MN	Bacterial GTP-binding protein YihA (Bact engB)
DMV2OJX	MT	DTT
DMV2OJX	MA	Inhibitor
DMV2OJX	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMV2OJX	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMV2OJX	DI	DMV2OJX
DMV2OJX	DN	Guanosine-5'-Triphosphate
DMV2OJX	MI	TTLSWP6
DMV2OJX	MN	GTP cyclohydrolase-I (GCH1)
DMV2OJX	MT	DTT
DMV2OJX	MA	Inhibitor
DMV2OJX	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMV2OJX	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMV2OJX	DI	DMV2OJX
DMV2OJX	DN	Guanosine-5'-Triphosphate
DMV2OJX	MI	TTSUKYD
DMV2OJX	MN	Virus RNA-dependent RNA polymerase (Viru RdRP)
DMV2OJX	MT	DTT
DMV2OJX	MA	Inhibitor
DMV2OJX	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMV2OJX	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMOUQLB	DI	DMOUQLB
DMOUQLB	DN	guanylpirenzepine
DMOUQLB	MI	TTOXS3C
DMOUQLB	MN	Muscarinic acetylcholine receptor (CHRM)
DMOUQLB	MT	DTT
DMOUQLB	MA	Antagonist
DMOUQLB	RN	Subtypes of muscarinic receptors in rat duodenum: a comparison with rabbit vas deferens, rat atria, guinea-pig ileum and gallbladder by using imperialine. Gen Pharmacol. 1999 Apr;32(4):505-11.
DMOUQLB	RU	https://pubmed.ncbi.nlm.nih.gov/10323493

DMOUQLB	DI	DMOUQLB
DMOUQLB	DN	guanylpirenzepine
DMOUQLB	MI	TTQ13Z5
DMOUQLB	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMOUQLB	MT	DTT
DMOUQLB	MA	Antagonist
DMOUQLB	RN	Binding of the labelled muscarinic toxin 125I-MT1 to rat brain muscarinic M1 receptors. Eur J Pharmacol. 1996 Jun 3;305(1-3):187-92.
DMOUQLB	RU	https://pubmed.ncbi.nlm.nih.gov/8813552

DM89KNT	DI	DM89KNT
DM89KNT	DN	Gue1654
DM89KNT	MI	TT7WBSV
DM89KNT	MN	Oxoeicosanoid receptor 1 (OXER1)
DM89KNT	MT	DTT
DM89KNT	MA	Modulator (allosteric modulator)
DM89KNT	RN	A biased ligand for OXE-R uncouples Galpha and Gbetagamma signaling within a heterotrimer. Nat Chem Biol. 2012 Jul;8(7):631-8.
DM89KNT	RU	https://pubmed.ncbi.nlm.nih.gov/22634634

DMBXGVH	DI	DMBXGVH
DMBXGVH	DN	Guttiferone I
DMBXGVH	MI	TTECBXN
DMBXGVH	MN	Oxysterols receptor LXR-alpha (NR1H3)
DMBXGVH	MT	DTT
DMBXGVH	MA	Inhibitor
DMBXGVH	RN	Guttiferone I, a new prenylated benzophenone from Garcinia humilis as a liver X receptor ligand. J Nat Prod. 2005 Apr;68(4):617-9.
DMBXGVH	RU	https://pubmed.ncbi.nlm.nih.gov/15844964

DM78KYC	DI	DM78KYC
DM78KYC	DN	GW 627368
DM78KYC	MI	TT79WV3
DM78KYC	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DM78KYC	MT	DTT
DM78KYC	MA	Antagonist
DM78KYC	RN	Piglet saphenous vein contains multiple relaxatory prostanoid receptors: evidence for EP4, EP2, DP and IP receptor subtypes. Br J Pharmacol. 2005 Feb;144(3):405-15.
DM78KYC	RU	https://pubmed.ncbi.nlm.nih.gov/15655509

DM3D2R4	DI	DM3D2R4
DM3D2R4	DN	GW0072
DM3D2R4	MI	TTT2SVW
DM3D2R4	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DM3D2R4	MT	DTT
DM3D2R4	MA	Agonist
DM3D2R4	RN	A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. Proc Natl Acad Sci U S A. 1999 May 25;96(11):6102-6.
DM3D2R4	RU	https://pubmed.ncbi.nlm.nih.gov/10339548

DMGKEO5	DI	DMGKEO5
DMGKEO5	DN	GW0742X
DMGKEO5	MI	TT2JWF6
DMGKEO5	MN	Peroxisome proliferator-activated receptor delta (PPARD)
DMGKEO5	MT	DTT
DMGKEO5	MA	Agonist
DMGKEO5	RN	Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)--synthesis and biological activity. Bioorg Med Chem Lett. 2003 May 5;13(9):1517-21.
DMGKEO5	RU	https://pubmed.ncbi.nlm.nih.gov/12699745

DM3DXM0	DI	DM3DXM0
DM3DXM0	DN	GW1100
DM3DXM0	MI	TTB8FUC
DM3DXM0	MN	Free fatty acid receptor 1 (GPR40)
DM3DXM0	MT	DTT
DM3DXM0	MA	Antagonist
DM3DXM0	RN	Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small... Br J Pharmacol. 2006 Jul;148(5):619-28.
DM3DXM0	RU	https://pubmed.ncbi.nlm.nih.gov/16702987

DMOV980	DI	DMOV980
DMOV980	DN	GW1929
DMOV980	MI	TTT2SVW
DMOV980	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DMOV980	MT	DTT
DMOV980	MA	Agonist
DMOV980	RN	A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes. 1999 Jul;48(7):1415-24.
DMOV980	RU	https://pubmed.ncbi.nlm.nih.gov/10389847

DMM8V9E	DI	DMM8V9E
DMM8V9E	DN	GW-2331
DMM8V9E	MI	TTJ584C
DMM8V9E	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMM8V9E	MT	DTT
DMM8V9E	MA	Modulator
DMM8V9E	RN	PPAR-alpha and -gamma but not -delta agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF-kappaB-independe... Br J Pharmacol. 2003 May;139(1):163-71.
DMM8V9E	RU	https://www.ncbi.nlm.nih.gov/pubmed/12746235

DMM8V9E	DI	DMM8V9E
DMM8V9E	DN	GW-2331
DMM8V9E	MI	TTZMAO3
DMM8V9E	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMM8V9E	MT	DTT
DMM8V9E	MA	Modulator
DMM8V9E	RN	PPAR-alpha and -gamma but not -delta agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF-kappaB-independe... Br J Pharmacol. 2003 May;139(1):163-71.
DMM8V9E	RU	https://www.ncbi.nlm.nih.gov/pubmed/12746235

DMEAIQC	DI	DMEAIQC
DMEAIQC	DN	GW2433
DMEAIQC	MI	TT2JWF6
DMEAIQC	MN	Peroxisome proliferator-activated receptor delta (PPARD)
DMEAIQC	MT	DTT
DMEAIQC	MA	Agonist
DMEAIQC	RN	Identification of peroxisome proliferator-activated receptor ligands from a biased chemical library. Chem Biol. 1997 Dec;4(12):909-18.
DMEAIQC	RU	https://pubmed.ncbi.nlm.nih.gov/9427656

DMTW9GM	DI	DMTW9GM
DMTW9GM	DN	GW-2580
DMTW9GM	MI	TTVW6QL
DMTW9GM	MN	CSF1R messenger RNA (CSF1R mRNA)
DMTW9GM	MT	DTT
DMTW9GM	MA	Inhibitor
DMTW9GM	RN	Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16078-83.
DMTW9GM	RU	https://pubmed.ncbi.nlm.nih.gov/16249345

DMG60ET	DI	DMG60ET
DMG60ET	DN	GW-3965
DMG60ET	MI	TTECBXN
DMG60ET	MN	Oxysterols receptor LXR-alpha (NR1H3)
DMG60ET	MT	DTT
DMG60ET	MA	Inhibitor
DMG60ET	RN	Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic tr... J Med Chem. 2008 Nov 27;51(22):7161-8.
DMG60ET	RU	https://pubmed.ncbi.nlm.nih.gov/18973288

DMG60ET	DI	DMG60ET
DMG60ET	DN	GW-3965
DMG60ET	MI	TTXA6PH
DMG60ET	MN	Oxysterols receptor LXR-beta (NR1H2)
DMG60ET	MT	DTT
DMG60ET	MA	Inhibitor
DMG60ET	RN	Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic tr... J Med Chem. 2008 Nov 27;51(22):7161-8.
DMG60ET	RU	https://pubmed.ncbi.nlm.nih.gov/18973288

DMFRP7H	DI	DMFRP7H
DMFRP7H	DN	GW4065
DMFRP7H	MI	TTS4UGC
DMFRP7H	MN	Farnesoid X-activated receptor (FXR)
DMFRP7H	MT	DTT
DMFRP7H	MA	Agonist
DMFRP7H	RN	Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity. J Biol Chem. 2002 Aug 30;277(35):31441-7.
DMFRP7H	RU	https://pubmed.ncbi.nlm.nih.gov/12052824

DMIHOYF	DI	DMIHOYF
DMIHOYF	DN	GW-5074
DMIHOYF	MI	TTAN5W2
DMIHOYF	MN	Raf messenger RNA (Raf mRNA)
DMIHOYF	MT	DTT
DMIHOYF	MA	Inhibitor
DMIHOYF	RN	Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles. Bioorg Med Chem Lett. 2004 Feb 23;14(4):953-7.
DMIHOYF	RU	https://pubmed.ncbi.nlm.nih.gov/15013000

DMIHOYF	DI	DMIHOYF
DMIHOYF	DN	GW-5074
DMIHOYF	MI	TTTDVOJ
DMIHOYF	MN	Tropomyosin-related kinase A (TrkA)
DMIHOYF	MT	DTT
DMIHOYF	MA	Inhibitor
DMIHOYF	RN	Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles. Bioorg Med Chem Lett. 2004 Feb 23;14(4):953-7.
DMIHOYF	RU	https://pubmed.ncbi.nlm.nih.gov/15013000

DMGRKT4	DI	DMGRKT4
DMGRKT4	DN	GW-559768X
DMGRKT4	MI	TT4DXQT
DMGRKT4	MN	Proto-oncogene c-Ret (RET)
DMGRKT4	MT	DTT
DMGRKT4	MA	Inhibitor
DMGRKT4	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2185).
DMGRKT4	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2185

DMCOYF9	DI	DMCOYF9
DMCOYF9	DN	GW-5823
DMCOYF9	MI	TTCG0AL
DMCOYF9	MN	Cholecystokinin receptor type A (CCKAR)
DMCOYF9	MT	DTT
DMCOYF9	MA	Agonist
DMCOYF9	RN	Optimization of 3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines as potent, orally active CCK-A agonists. J Med Chem. 1997 Aug 15;40(17):2706-25.
DMCOYF9	RU	https://pubmed.ncbi.nlm.nih.gov/9276016

DMCOYF9	DI	DMCOYF9
DMCOYF9	DN	GW-5823
DMCOYF9	MI	TTVFO0U
DMCOYF9	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMCOYF9	MT	DTT
DMCOYF9	MA	Antagonist
DMCOYF9	RN	Optimization of 3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines as potent, orally active CCK-A agonists. J Med Chem. 1997 Aug 15;40(17):2706-25.
DMCOYF9	RU	https://pubmed.ncbi.nlm.nih.gov/9276016

DMX59A0	DI	DMX59A0
DMX59A0	DN	GW-637185X
DMX59A0	MI	TTVKILB
DMX59A0	MN	Prostaglandin G/H synthase 2 (COX-2)
DMX59A0	MT	DTT
DMX59A0	MA	Inhibitor
DMX59A0	RN	Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhib... Bioorg Med Chem Lett. 2009 Aug 1;19(15):4504-8.
DMX59A0	RU	https://pubmed.ncbi.nlm.nih.gov/19520573

DMCA4RM	DI	DMCA4RM
DMCA4RM	DN	GW7604
DMCA4RM	MI	TTZAYWL
DMCA4RM	MN	Estrogen receptor (ESR)
DMCA4RM	MT	DTT
DMCA4RM	MA	Antagonist
DMCA4RM	RN	Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen. Endocrinology. 2001 Feb;142(2):838-46.
DMCA4RM	RU	https://pubmed.ncbi.nlm.nih.gov/11159857

DM9RD0C	DI	DM9RD0C
DM9RD0C	DN	GW7647
DM9RD0C	MI	TTJ584C
DM9RD0C	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DM9RD0C	MT	DTT
DM9RD0C	MA	Agonist
DM9RD0C	RN	Identification of a subtype selective human PPARalpha agonist through parallel-array synthesis. Bioorg Med Chem Lett. 2001 May 7;11(9):1225-7.
DM9RD0C	RU	https://pubmed.ncbi.nlm.nih.gov/11354382

DMEK2I4	DI	DMEK2I4
DMEK2I4	DN	GW7845
DMEK2I4	MI	TTZMAO3
DMEK2I4	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMEK2I4	MT	DTT
DMEK2I4	MA	Agonist
DMEK2I4	RN	A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis. Cancer Res. 1999 Nov 15;59(22):5671-3.
DMEK2I4	RU	https://pubmed.ncbi.nlm.nih.gov/10582681

DMIBUW5	DI	DMIBUW5
DMIBUW5	DN	GW-788388
DMIBUW5	MI	TT860QF
DMIBUW5	MN	LCK tyrosine protein kinase (LCK)
DMIBUW5	MT	DTT
DMIBUW5	MA	Inhibitor
DMIBUW5	RN	Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orall... J Med Chem. 2006 Apr 6;49(7):2210-21.
DMIBUW5	RU	https://pubmed.ncbi.nlm.nih.gov/16570917

DMIBUW5	DI	DMIBUW5
DMIBUW5	DN	GW-788388
DMIBUW5	MI	TTQBR95
DMIBUW5	MN	Stress-activated protein kinase 2a (p38 alpha)
DMIBUW5	MT	DTT
DMIBUW5	MA	Inhibitor
DMIBUW5	RN	Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orall... J Med Chem. 2006 Apr 6;49(7):2210-21.
DMIBUW5	RU	https://pubmed.ncbi.nlm.nih.gov/16570917

DMIBUW5	DI	DMIBUW5
DMIBUW5	DN	GW-788388
DMIBUW5	MI	TTP4520
DMIBUW5	MN	TGF-beta receptor type I (TGFBR1)
DMIBUW5	MT	DTT
DMIBUW5	MA	Inhibitor
DMIBUW5	RN	Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orall... J Med Chem. 2006 Apr 6;49(7):2210-21.
DMIBUW5	RU	https://pubmed.ncbi.nlm.nih.gov/16570917

DMWAEJ3	DI	DMWAEJ3
DMWAEJ3	DN	GW803430
DMWAEJ3	MI	TTX4RTB
DMWAEJ3	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMWAEJ3	MT	DTT
DMWAEJ3	MA	Antagonist
DMWAEJ3	RN	The discovery and optimization of pyrimidinone-containing MCH R1 antagonists. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4723-7.
DMWAEJ3	RU	https://pubmed.ncbi.nlm.nih.gov/16870432

DMWAEJ3	DI	DMWAEJ3
DMWAEJ3	DN	GW803430
DMWAEJ3	MI	TTQ6VDM
DMWAEJ3	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMWAEJ3	MT	DTT
DMWAEJ3	MA	Inhibitor
DMWAEJ3	RN	Novel approach for chemotype hopping based on annotated databases of chemically feasible fragments and a prospective case study: new melanin concen... J Med Chem. 2009 Apr 9;52(7):2076-89.
DMWAEJ3	RU	https://pubmed.ncbi.nlm.nih.gov/19290642

DMRL9IN	DI	DMRL9IN
DMRL9IN	DN	GW841819X
DMRL9IN	MI	TTDP48B
DMRL9IN	MN	Bromodomain-containing protein 2 (BRD2)
DMRL9IN	MT	DTT
DMRL9IN	MA	Inhibitor
DMRL9IN	RN	Discovery and characterization of small molecule inhibitors of the BET family bromodomains. J Med Chem. 2011 Jun 9;54(11):3827-38.
DMRL9IN	RU	https://pubmed.ncbi.nlm.nih.gov/21568322

DMRL9IN	DI	DMRL9IN
DMRL9IN	DN	GW841819X
DMRL9IN	MI	TTHE657
DMRL9IN	MN	Bromodomain-containing protein 3 (BRD3)
DMRL9IN	MT	DTT
DMRL9IN	MA	Inhibitor
DMRL9IN	RN	Discovery and characterization of small molecule inhibitors of the BET family bromodomains. J Med Chem. 2011 Jun 9;54(11):3827-38.
DMRL9IN	RU	https://pubmed.ncbi.nlm.nih.gov/21568322

DMRL9IN	DI	DMRL9IN
DMRL9IN	DN	GW841819X
DMRL9IN	MI	TTRA6BO
DMRL9IN	MN	Bromodomain-containing protein 4 (BRD4)
DMRL9IN	MT	DTT
DMRL9IN	MA	Inhibitor
DMRL9IN	RN	Discovery and characterization of small molecule inhibitors of the BET family bromodomains. J Med Chem. 2011 Jun 9;54(11):3827-38.
DMRL9IN	RU	https://pubmed.ncbi.nlm.nih.gov/21568322

DMXA5M9	DI	DMXA5M9
DMXA5M9	DN	GW848687X
DMXA5M9	MI	TTG1QMU
DMXA5M9	MN	Prostaglandin E2 receptor EP1 (PTGER1)
DMXA5M9	MT	DTT
DMXA5M9	MA	Antagonist
DMXA5M9	RN	The discovery of 6-[2-(5-chloro-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclopenten-1-yl]-2-pyridinecarboxylic acid, GW848687X, a potent and s... Bioorg Med Chem Lett. 2007 Jan 15;17(2):385-9.
DMXA5M9	RU	https://pubmed.ncbi.nlm.nih.gov/17084082

DML4UMT	DI	DML4UMT
DML4UMT	DN	GW-8510
DML4UMT	MI	TTAMQ62
DML4UMT	MN	Cyclin A2 (CCNA2)
DML4UMT	MT	DTT
DML4UMT	MA	Inhibitor
DML4UMT	RN	Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles. Bioorg Med Chem Lett. 2004 Feb 23;14(4):953-7.
DML4UMT	RU	https://pubmed.ncbi.nlm.nih.gov/15013000

DML4UMT	DI	DML4UMT
DML4UMT	DN	GW-8510
DML4UMT	MI	TT7HF4W
DML4UMT	MN	Cyclin-dependent kinase 2 (CDK2)
DML4UMT	MT	DTT
DML4UMT	MA	Inhibitor
DML4UMT	RN	Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles. Bioorg Med Chem Lett. 2004 Feb 23;14(4):953-7.
DML4UMT	RU	https://pubmed.ncbi.nlm.nih.gov/15013000

DMITKX8	DI	DMITKX8
DMITKX8	DN	GW853606
DMITKX8	MI	TTIYVQP
DMITKX8	MN	Polo-like kinase 1 (PLK1)
DMITKX8	MT	DTT
DMITKX8	MA	Inhibitor
DMITKX8	RN	Discovery of thiophene inhibitors of polo-like kinase. Bioorg Med Chem Lett. 2009 Feb 1;19(3):1018-21.
DMITKX8	RU	https://pubmed.ncbi.nlm.nih.gov/19097784

DMVKZ5I	DI	DMVKZ5I
DMVKZ5I	DN	GW9508
DMVKZ5I	MI	TTB8FUC
DMVKZ5I	MN	Free fatty acid receptor 1 (GPR40)
DMVKZ5I	MT	DTT
DMVKZ5I	MA	Agonist
DMVKZ5I	RN	Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small... Br J Pharmacol. 2006 Jul;148(5):619-28.
DMVKZ5I	RU	https://pubmed.ncbi.nlm.nih.gov/16702987

DMVKZ5I	DI	DMVKZ5I
DMVKZ5I	DN	GW9508
DMVKZ5I	MI	TT08JVB
DMVKZ5I	MN	G-protein coupled receptor 120 (GPR120)
DMVKZ5I	MT	DTT
DMVKZ5I	MA	Agonist
DMVKZ5I	RN	Free fatty acid receptors and drug discovery. Biol Pharm Bull. 2008 Oct;31(10):1847-51.
DMVKZ5I	RU	https://pubmed.ncbi.nlm.nih.gov/18827341

DMPIRE0	DI	DMPIRE0
DMPIRE0	DN	GwTLNSAGYLLGPHAVGNHRSFSDKNGLTS-CONH2
DMPIRE0	MI	TTX3HNZ
DMPIRE0	MN	Galanin receptor type 1 (GAL1-R)
DMPIRE0	MT	DTT
DMPIRE0	MA	Inhibitor
DMPIRE0	RN	Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5.
DMPIRE0	RU	https://pubmed.ncbi.nlm.nih.gov/20121116

DMPIRE0	DI	DMPIRE0
DMPIRE0	DN	GwTLNSAGYLLGPHAVGNHRSFSDKNGLTS-CONH2
DMPIRE0	MI	TTBPW3J
DMPIRE0	MN	Galanin receptor type 2 (GAL2-R)
DMPIRE0	MT	DTT
DMPIRE0	MA	Inhibitor
DMPIRE0	RN	Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5.
DMPIRE0	RU	https://pubmed.ncbi.nlm.nih.gov/20121116

DMZPRIG	DI	DMZPRIG
DMZPRIG	DN	GWTLNSAGYLLGPHAV-NH2
DMZPRIG	MI	TTX3HNZ
DMZPRIG	MN	Galanin receptor type 1 (GAL1-R)
DMZPRIG	MT	DTT
DMZPRIG	MA	Inhibitor
DMZPRIG	RN	Design, synthesis, and characterization of high-affinity, systemically-active galanin analogues with potent anticonvulsant activities. J Med Chem. 2008 Dec 25;51(24):8038-47.
DMZPRIG	RU	https://pubmed.ncbi.nlm.nih.gov/19053761

DMZPRIG	DI	DMZPRIG
DMZPRIG	DN	GWTLNSAGYLLGPHAV-NH2
DMZPRIG	MI	TTBPW3J
DMZPRIG	MN	Galanin receptor type 2 (GAL2-R)
DMZPRIG	MT	DTT
DMZPRIG	MA	Inhibitor
DMZPRIG	RN	Design, synthesis, and characterization of high-affinity, systemically-active galanin analogues with potent anticonvulsant activities. J Med Chem. 2008 Dec 25;51(24):8038-47.
DMZPRIG	RU	https://pubmed.ncbi.nlm.nih.gov/19053761

DMKFMQ5	DI	DMKFMQ5
DMKFMQ5	DN	GWTLNSAGYLLGPPPALALA-CONH2
DMKFMQ5	MI	TTX3HNZ
DMKFMQ5	MN	Galanin receptor type 1 (GAL1-R)
DMKFMQ5	MT	DTT
DMKFMQ5	MA	Inhibitor
DMKFMQ5	RN	Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5.
DMKFMQ5	RU	https://pubmed.ncbi.nlm.nih.gov/20121116

DMKFMQ5	DI	DMKFMQ5
DMKFMQ5	DN	GWTLNSAGYLLGPPPALALA-CONH2
DMKFMQ5	MI	TTBPW3J
DMKFMQ5	MN	Galanin receptor type 2 (GAL2-R)
DMKFMQ5	MT	DTT
DMKFMQ5	MA	Inhibitor
DMKFMQ5	RN	Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5.
DMKFMQ5	RU	https://pubmed.ncbi.nlm.nih.gov/20121116

DMVWGM2	DI	DMVWGM2
DMVWGM2	DN	GWTLNSAGYLLGPPPGFSPFR-CONH2
DMVWGM2	MI	TTX3HNZ
DMVWGM2	MN	Galanin receptor type 1 (GAL1-R)
DMVWGM2	MT	DTT
DMVWGM2	MA	Inhibitor
DMVWGM2	RN	Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5.
DMVWGM2	RU	https://pubmed.ncbi.nlm.nih.gov/20121116

DMVWGM2	DI	DMVWGM2
DMVWGM2	DN	GWTLNSAGYLLGPPPGFSPFR-CONH2
DMVWGM2	MI	TTBPW3J
DMVWGM2	MN	Galanin receptor type 2 (GAL2-R)
DMVWGM2	MT	DTT
DMVWGM2	MA	Inhibitor
DMVWGM2	RN	Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5.
DMVWGM2	RU	https://pubmed.ncbi.nlm.nih.gov/20121116

DM5YR4S	DI	DM5YR4S
DM5YR4S	DN	GWTLNSAGYLLGPRHYINLITRQRY-CONH2
DM5YR4S	MI	TTX3HNZ
DM5YR4S	MN	Galanin receptor type 1 (GAL1-R)
DM5YR4S	MT	DTT
DM5YR4S	MA	Inhibitor
DM5YR4S	RN	Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5.
DM5YR4S	RU	https://pubmed.ncbi.nlm.nih.gov/20121116

DM5YR4S	DI	DM5YR4S
DM5YR4S	DN	GWTLNSAGYLLGPRHYINLITRQRY-CONH2
DM5YR4S	MI	TTBPW3J
DM5YR4S	MN	Galanin receptor type 2 (GAL2-R)
DM5YR4S	MT	DTT
DM5YR4S	MA	Inhibitor
DM5YR4S	RN	Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5.
DM5YR4S	RU	https://pubmed.ncbi.nlm.nih.gov/20121116

DM48AV3	DI	DM48AV3
DM48AV3	DN	GWTLNSAGYLLGPrPKPQQwFwLL-CONH2
DM48AV3	MI	TTX3HNZ
DM48AV3	MN	Galanin receptor type 1 (GAL1-R)
DM48AV3	MT	DTT
DM48AV3	MA	Inhibitor
DM48AV3	RN	Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5.
DM48AV3	RU	https://pubmed.ncbi.nlm.nih.gov/20121116

DM48AV3	DI	DM48AV3
DM48AV3	DN	GWTLNSAGYLLGPrPKPQQwFwLL-CONH2
DM48AV3	MI	TTBPW3J
DM48AV3	MN	Galanin receptor type 2 (GAL2-R)
DM48AV3	MT	DTT
DM48AV3	MA	Inhibitor
DM48AV3	RN	Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5.
DM48AV3	RU	https://pubmed.ncbi.nlm.nih.gov/20121116

DM8GFJP	DI	DM8GFJP
DM8GFJP	DN	GX-C4
DM8GFJP	MI	TTI2S1D
DM8GFJP	MN	Cytotoxic T-lymphocyte protein 4 (CTLA-4)
DM8GFJP	MT	DTT
DM8GFJP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2743).
DM8GFJP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2743

DM1RY6Q	DI	DM1RY6Q
DM1RY6Q	DN	GX-G6
DM1RY6Q	MI	TTVIMDE
DM1RY6Q	MN	Glucagon-like peptide 1 receptor (GLP1R)
DM1RY6Q	MT	DTT
DM1RY6Q	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249).
DM1RY6Q	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=249

DM7SLAM	DI	DM7SLAM
DM7SLAM	DN	Gymnochrome E
DM7SLAM	MI	TT6R7JZ
DM7SLAM	MN	Histone deacetylase 1 (HDAC1)
DM7SLAM	MT	DTT
DM7SLAM	MA	Inhibitor
DM7SLAM	RN	Gymnochromes E and F, cytotoxic phenanthroperylenequinones from a deep-water crinoid, Holopus rangii. J Nat Prod. 2010 Apr 23;73(4):712-5.
DM7SLAM	RU	https://pubmed.ncbi.nlm.nih.gov/20158243

DM8ENQZ	DI	DM8ENQZ
DM8ENQZ	DN	Gypenoside XVII
DM8ENQZ	MI	DEVLXCG
DM8ENQZ	MN	Beta-glucosidase (bglA)
DM8ENQZ	MT	DME
DM8ENQZ	MA	Metabolism
DM8ENQZ	RN	Constitutive beta-glucosidases hydrolyzing ginsenoside Rb1 and Rb2 from human intestinal bacteria. Biol Pharm Bull. 2000 Dec;23(12):1481-5.
DM8ENQZ	RU	https://pubmed.ncbi.nlm.nih.gov/11145182

DM9XK05	DI	DM9XK05
DM9XK05	DN	H-[Trp-Arg-Nva-Arg-Tyr]2-NH2
DM9XK05	MI	TTRK9JT
DM9XK05	MN	Neuropeptide Y receptor type 1 (NPY1R)
DM9XK05	MT	DTT
DM9XK05	MA	Inhibitor
DM9XK05	RN	Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5.
DM9XK05	RU	https://pubmed.ncbi.nlm.nih.gov/16610810

DM9XK05	DI	DM9XK05
DM9XK05	DN	H-[Trp-Arg-Nva-Arg-Tyr]2-NH2
DM9XK05	MI	TTJ6WK9
DM9XK05	MN	Neuropeptide Y receptor type 2 (NPY2R)
DM9XK05	MT	DTT
DM9XK05	MA	Inhibitor
DM9XK05	RN	Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5.
DM9XK05	RU	https://pubmed.ncbi.nlm.nih.gov/16610810

DM9XK05	DI	DM9XK05
DM9XK05	DN	H-[Trp-Arg-Nva-Arg-Tyr]2-NH2
DM9XK05	MI	TTW4N16
DM9XK05	MN	Neuropeptide Y receptor type 4 (NPY4R)
DM9XK05	MT	DTT
DM9XK05	MA	Inhibitor
DM9XK05	RN	Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5.
DM9XK05	RU	https://pubmed.ncbi.nlm.nih.gov/16610810

DMKH8PF	DI	DMKH8PF
DMKH8PF	DN	H-[Trp-Arg-Nva-Arg-Tyr]3-NH2
DMKH8PF	MI	TTRK9JT
DMKH8PF	MN	Neuropeptide Y receptor type 1 (NPY1R)
DMKH8PF	MT	DTT
DMKH8PF	MA	Inhibitor
DMKH8PF	RN	Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5.
DMKH8PF	RU	https://pubmed.ncbi.nlm.nih.gov/16610810

DMKH8PF	DI	DMKH8PF
DMKH8PF	DN	H-[Trp-Arg-Nva-Arg-Tyr]3-NH2
DMKH8PF	MI	TTJ6WK9
DMKH8PF	MN	Neuropeptide Y receptor type 2 (NPY2R)
DMKH8PF	MT	DTT
DMKH8PF	MA	Inhibitor
DMKH8PF	RN	Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5.
DMKH8PF	RU	https://pubmed.ncbi.nlm.nih.gov/16610810

DMKH8PF	DI	DMKH8PF
DMKH8PF	DN	H-[Trp-Arg-Nva-Arg-Tyr]3-NH2
DMKH8PF	MI	TTW4N16
DMKH8PF	MN	Neuropeptide Y receptor type 4 (NPY4R)
DMKH8PF	MT	DTT
DMKH8PF	MA	Inhibitor
DMKH8PF	RN	Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5.
DMKH8PF	RU	https://pubmed.ncbi.nlm.nih.gov/16610810

DMYOADQ	DI	DMYOADQ
DMYOADQ	DN	H-2',6'-dimethyltyrosine-Tic-OH
DMYOADQ	MI	TT27RFC
DMYOADQ	MN	Opioid receptor delta (OPRD1)
DMYOADQ	MT	DTT
DMYOADQ	MA	Inhibitor
DMYOADQ	RN	Agonist vs antagonist behavior of delta opioid peptides containing novel phenylalanine analogues in place of Tyr(1). J Med Chem. 2009 Nov 12;52(21):6941-5.
DMYOADQ	RU	https://pubmed.ncbi.nlm.nih.gov/19827750

DMYOADQ	DI	DMYOADQ
DMYOADQ	DN	H-2',6'-dimethyltyrosine-Tic-OH
DMYOADQ	MI	TTKWM86
DMYOADQ	MN	Opioid receptor mu (MOP)
DMYOADQ	MT	DTT
DMYOADQ	MA	Inhibitor
DMYOADQ	RN	Agonist vs antagonist behavior of delta opioid peptides containing novel phenylalanine analogues in place of Tyr(1). J Med Chem. 2009 Nov 12;52(21):6941-5.
DMYOADQ	RU	https://pubmed.ncbi.nlm.nih.gov/19827750

DM7IEU2	DI	DM7IEU2
DM7IEU2	DN	H-2',6'-dimethyltyrosine-Tic-Phe-Phe-OH
DM7IEU2	MI	TT27RFC
DM7IEU2	MN	Opioid receptor delta (OPRD1)
DM7IEU2	MT	DTT
DM7IEU2	MA	Inhibitor
DM7IEU2	RN	Agonist vs antagonist behavior of delta opioid peptides containing novel phenylalanine analogues in place of Tyr(1). J Med Chem. 2009 Nov 12;52(21):6941-5.
DM7IEU2	RU	https://pubmed.ncbi.nlm.nih.gov/19827750

DM7IEU2	DI	DM7IEU2
DM7IEU2	DN	H-2',6'-dimethyltyrosine-Tic-Phe-Phe-OH
DM7IEU2	MI	TTKWM86
DM7IEU2	MN	Opioid receptor mu (MOP)
DM7IEU2	MT	DTT
DM7IEU2	MA	Inhibitor
DM7IEU2	RN	Agonist vs antagonist behavior of delta opioid peptides containing novel phenylalanine analogues in place of Tyr(1). J Med Chem. 2009 Nov 12;52(21):6941-5.
DM7IEU2	RU	https://pubmed.ncbi.nlm.nih.gov/19827750

DMOJI0N	DI	DMOJI0N
DMOJI0N	DN	H22xKi-4
DMOJI0N	MI	TT2GM5R
DMOJI0N	MN	Lymphocyte activation antigen CD30 (TNFRSF8)
DMOJI0N	MT	DTT
DMOJI0N	RN	Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma. Blood. 2002 Nov 1;100(9):3101-7.
DMOJI0N	RU	https://pubmed.ncbi.nlm.nih.gov/12384405

DM80QF9	DI	DM80QF9
DM80QF9	DN	H-8
DM80QF9	MI	TTHIQMC
DM80QF9	MN	Cyclic nucleotide-gated channel alpha-1 (CNGA1)
DM80QF9	MT	DTT
DM80QF9	MA	Blocker (channel blocker)
DM80QF9	RN	Direct blockade of both cloned rat rod photoreceptor cyclic nucleotide-gated non-selective cation (CNG) channel alpha-subunit and native CNG channels from Xenopus rod outer segments by H-8, a non-specific cyclic nucleotide-dependent protein kinase inhibitor. Neurosci Lett. 1997 Sep 12;233(1):37-40.
DM80QF9	RU	https://pubmed.ncbi.nlm.nih.gov/9324234

DM43ODJ	DI	DM43ODJ
DM43ODJ	DN	H87/07
DM43ODJ	MI	TTMXGCW
DM43ODJ	MN	Adrenergic receptor beta-3 (ADRB3)
DM43ODJ	MT	DTT
DM43ODJ	MA	Antagonist
DM43ODJ	RN	LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors. Eur J Pharmacol. 1999 Feb 19;367(2-3):431-5.
DM43ODJ	RU	https://pubmed.ncbi.nlm.nih.gov/10079020

DM4RVGO	DI	DM4RVGO
DM4RVGO	DN	H-89
DM4RVGO	MI	TT5U49F
DM4RVGO	MN	PRKACA messenger RNA (PRKACA mRNA)
DM4RVGO	MT	DTT
DM4RVGO	MA	Inhibitor
DM4RVGO	RN	Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. J Biol Chem. 1990 Mar 25;265(9):5267-72.
DM4RVGO	RU	https://pubmed.ncbi.nlm.nih.gov/2156866

DM61G0I	DI	DM61G0I
DM61G0I	DN	H-Aba-ala-Gly-Phe-leu-OH
DM61G0I	MI	TT27RFC
DM61G0I	MN	Opioid receptor delta (OPRD1)
DM61G0I	MT	DTT
DM61G0I	MA	Inhibitor
DM61G0I	RN	Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60.
DM61G0I	RU	https://pubmed.ncbi.nlm.nih.gov/17350835

DM61G0I	DI	DM61G0I
DM61G0I	DN	H-Aba-ala-Gly-Phe-leu-OH
DM61G0I	MI	TTKWM86
DM61G0I	MN	Opioid receptor mu (MOP)
DM61G0I	MT	DTT
DM61G0I	MA	Inhibitor
DM61G0I	RN	Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60.
DM61G0I	RU	https://pubmed.ncbi.nlm.nih.gov/17350835

DMKD94Q	DI	DMKD94Q
DMKD94Q	DN	H-Aba-ala-Gly-Phe-Met-OH
DMKD94Q	MI	TT27RFC
DMKD94Q	MN	Opioid receptor delta (OPRD1)
DMKD94Q	MT	DTT
DMKD94Q	MA	Inhibitor
DMKD94Q	RN	Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60.
DMKD94Q	RU	https://pubmed.ncbi.nlm.nih.gov/17350835

DMKD94Q	DI	DMKD94Q
DMKD94Q	DN	H-Aba-ala-Gly-Phe-Met-OH
DMKD94Q	MI	TTKWM86
DMKD94Q	MN	Opioid receptor mu (MOP)
DMKD94Q	MT	DTT
DMKD94Q	MA	Inhibitor
DMKD94Q	RN	Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60.
DMKD94Q	RU	https://pubmed.ncbi.nlm.nih.gov/17350835

DMH1L3P	DI	DMH1L3P
DMH1L3P	DN	H-Aba-Gly-Gly-Phe-Leu-OH
DMH1L3P	MI	TT27RFC
DMH1L3P	MN	Opioid receptor delta (OPRD1)
DMH1L3P	MT	DTT
DMH1L3P	MA	Inhibitor
DMH1L3P	RN	Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60.
DMH1L3P	RU	https://pubmed.ncbi.nlm.nih.gov/17350835

DMH1L3P	DI	DMH1L3P
DMH1L3P	DN	H-Aba-Gly-Gly-Phe-Leu-OH
DMH1L3P	MI	TTKWM86
DMH1L3P	MN	Opioid receptor mu (MOP)
DMH1L3P	MT	DTT
DMH1L3P	MA	Inhibitor
DMH1L3P	RN	Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60.
DMH1L3P	RU	https://pubmed.ncbi.nlm.nih.gov/17350835

DMFE3J4	DI	DMFE3J4
DMFE3J4	DN	H-Aba-ser-Gly-Phe-Leu-Thr-OH
DMFE3J4	MI	TT27RFC
DMFE3J4	MN	Opioid receptor delta (OPRD1)
DMFE3J4	MT	DTT
DMFE3J4	MA	Inhibitor
DMFE3J4	RN	Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60.
DMFE3J4	RU	https://pubmed.ncbi.nlm.nih.gov/17350835

DMFE3J4	DI	DMFE3J4
DMFE3J4	DN	H-Aba-ser-Gly-Phe-Leu-Thr-OH
DMFE3J4	MI	TTKWM86
DMFE3J4	MN	Opioid receptor mu (MOP)
DMFE3J4	MT	DTT
DMFE3J4	MA	Inhibitor
DMFE3J4	RN	Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60.
DMFE3J4	RU	https://pubmed.ncbi.nlm.nih.gov/17350835

DMQCGRI	DI	DMQCGRI
DMQCGRI	DN	HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG-NH2
DMQCGRI	MI	TTVIMDE
DMQCGRI	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMQCGRI	MT	DTT
DMQCGRI	MA	Inhibitor
DMQCGRI	RN	Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo acti... J Med Chem. 2008 May 8;51(9):2758-65.
DMQCGRI	RU	https://pubmed.ncbi.nlm.nih.gov/18412318

DMN54LS	DI	DMN54LS
DMN54LS	DN	HAEGTFTSDVSSYLEGQAAKEIFAWLVKGR
DMN54LS	MI	TTVIMDE
DMN54LS	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMN54LS	MT	DTT
DMN54LS	MA	Inhibitor
DMN54LS	RN	Search for alpha-helical propensity in the receptor-bound conformation of glucagon-like peptide-1. Bioorg Med Chem. 2008 Dec 1;16(23):10106-12.
DMN54LS	RU	https://pubmed.ncbi.nlm.nih.gov/18952440

DMO6MGJ	DI	DMO6MGJ
DMO6MGJ	DN	Haempatch
DMO6MGJ	MI	TT6L509
DMO6MGJ	MN	Coagulation factor IIa (F2)
DMO6MGJ	MT	DTT
DMO6MGJ	MA	Inhibitor
DMO6MGJ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362).
DMO6MGJ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2362

DM5S4AO	DI	DM5S4AO
DM5S4AO	DN	H-Ala-Pro-Phe-Phe-NH2
DM5S4AO	MI	TTZPO1L
DM5S4AO	MN	Substance-P receptor (TACR1)
DM5S4AO	MT	DTT
DM5S4AO	MA	Inhibitor
DM5S4AO	RN	Discovery of dipeptides with high affinity to the specific binding site for substance P1-7. J Med Chem. 2010 Mar 25;53(6):2383-9.
DM5S4AO	RU	https://pubmed.ncbi.nlm.nih.gov/20178322

DMJB87Q	DI	DMJB87Q
DMJB87Q	DN	Halisulfate 1
DMJB87Q	MI	TTN9T81
DMJB87Q	MN	Arachidonate 15-lipoxygenase (15-LOX)
DMJB87Q	MT	DTT
DMJB87Q	MA	Inhibitor
DMJB87Q	RN	Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases. J Nat Prod. 2003 Feb;66(2):230-5.
DMJB87Q	RU	https://pubmed.ncbi.nlm.nih.gov/12608855

DMJB87Q	DI	DMJB87Q
DMJB87Q	DN	Halisulfate 1
DMJB87Q	MI	TT58ZYW
DMJB87Q	MN	Mycobacterium Isocitrate lyase (MycB icl)
DMJB87Q	MT	DTT
DMJB87Q	MA	Inhibitor
DMJB87Q	RN	Sesterterpene sulfates as isocitrate lyase inhibitors from tropical sponge Hippospongia sp. Bioorg Med Chem Lett. 2007 May 1;17(9):2483-6.
DMJB87Q	RU	https://pubmed.ncbi.nlm.nih.gov/17317180

DMF6V8W	DI	DMF6V8W
DMF6V8W	DN	HALOPEMIDE
DMF6V8W	MI	TTQW170
DMF6V8W	MN	Phospholipase D (PLD)
DMF6V8W	MT	DTT
DMF6V8W	MA	Inhibitor
DMF6V8W	RN	Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat Chem Biol. 2009 Feb;5(2):108-17.
DMF6V8W	RU	https://pubmed.ncbi.nlm.nih.gov/19136975

DMF6V8W	DI	DMF6V8W
DMF6V8W	DN	HALOPEMIDE
DMF6V8W	MI	TT3T17P
DMF6V8W	MN	Phospholipase D1 (PLD1)
DMF6V8W	MT	DTT
DMF6V8W	MA	Inhibitor
DMF6V8W	RN	Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat Chem Biol. 2009 Feb;5(2):108-17.
DMF6V8W	RU	https://pubmed.ncbi.nlm.nih.gov/19136975

DMWCXPK	DI	DMWCXPK
DMWCXPK	DN	Haloperidol
DMWCXPK	MI	TTTPE1L
DMWCXPK	MN	HUMAN opioid receptor sigma 1 (OPRS1)
DMWCXPK	MT	DTT
DMWCXPK	MA	Modulator
DMWCXPK	RN	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
DMWCXPK	RU	https://www.nature.com/articles/s41586-020-2286-9

DMWCXPK	DI	DMWCXPK
DMWCXPK	DN	Haloperidol
DMWCXPK	MI	TTIS0R2
DMWCXPK	MN	HUMAN sigma intracellular receptor 2 (TMEM97)
DMWCXPK	MT	DTT
DMWCXPK	MA	Modulator
DMWCXPK	RN	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
DMWCXPK	RU	https://www.nature.com/articles/s41586-020-2286-9

DM5SULN	DI	DM5SULN
DM5SULN	DN	Haloxyfop
DM5SULN	MI	TTYAWV0
DM5SULN	MN	Plasmodium Acetyl-CoA carboxylase 1 (Malaria ACC1)
DM5SULN	MT	DTT
DM5SULN	MA	Binder
DM5SULN	RN	The apicoplast as an antimalarial drug target. Drug Resist Updat. 2001 Jun;4(3):145-51.
DM5SULN	RU	https://pubmed.ncbi.nlm.nih.gov/11768328

DM4AEGQ	DI	DM4AEGQ
DM4AEGQ	DN	HALOXYSTEROL A
DM4AEGQ	MI	TT1RS9F
DM4AEGQ	MN	Acetylcholinesterase (AChE)
DM4AEGQ	MT	DTT
DM4AEGQ	MA	Inhibitor
DM4AEGQ	RN	Isolation and cholinesterase-inhibition studies of sterols from Haloxylon recurvum. Bioorg Med Chem Lett. 2006 Feb;16(3):573-80.
DM4AEGQ	RU	https://pubmed.ncbi.nlm.nih.gov/16274989

DM4AEGQ	DI	DM4AEGQ
DM4AEGQ	DN	HALOXYSTEROL A
DM4AEGQ	MI	TTEB0GD
DM4AEGQ	MN	Cholinesterase (BCHE)
DM4AEGQ	MT	DTT
DM4AEGQ	MA	Inhibitor
DM4AEGQ	RN	Isolation and cholinesterase-inhibition studies of sterols from Haloxylon recurvum. Bioorg Med Chem Lett. 2006 Feb;16(3):573-80.
DM4AEGQ	RU	https://pubmed.ncbi.nlm.nih.gov/16274989

DMD8O7S	DI	DMD8O7S
DMD8O7S	DN	HALOXYSTEROL B
DMD8O7S	MI	TT1RS9F
DMD8O7S	MN	Acetylcholinesterase (AChE)
DMD8O7S	MT	DTT
DMD8O7S	MA	Inhibitor
DMD8O7S	RN	Isolation and cholinesterase-inhibition studies of sterols from Haloxylon recurvum. Bioorg Med Chem Lett. 2006 Feb;16(3):573-80.
DMD8O7S	RU	https://pubmed.ncbi.nlm.nih.gov/16274989

DMD8O7S	DI	DMD8O7S
DMD8O7S	DN	HALOXYSTEROL B
DMD8O7S	MI	TTEB0GD
DMD8O7S	MN	Cholinesterase (BCHE)
DMD8O7S	MT	DTT
DMD8O7S	MA	Inhibitor
DMD8O7S	RN	Isolation and cholinesterase-inhibition studies of sterols from Haloxylon recurvum. Bioorg Med Chem Lett. 2006 Feb;16(3):573-80.
DMD8O7S	RU	https://pubmed.ncbi.nlm.nih.gov/16274989

DMU1DHM	DI	DMU1DHM
DMU1DHM	DN	Haloxysterol C
DMU1DHM	MI	TT1RS9F
DMU1DHM	MN	Acetylcholinesterase (AChE)
DMU1DHM	MT	DTT
DMU1DHM	MA	Inhibitor
DMU1DHM	RN	Isolation and cholinesterase-inhibition studies of sterols from Haloxylon recurvum. Bioorg Med Chem Lett. 2006 Feb;16(3):573-80.
DMU1DHM	RU	https://pubmed.ncbi.nlm.nih.gov/16274989

DMU1DHM	DI	DMU1DHM
DMU1DHM	DN	Haloxysterol C
DMU1DHM	MI	TTEB0GD
DMU1DHM	MN	Cholinesterase (BCHE)
DMU1DHM	MT	DTT
DMU1DHM	MA	Inhibitor
DMU1DHM	RN	Isolation and cholinesterase-inhibition studies of sterols from Haloxylon recurvum. Bioorg Med Chem Lett. 2006 Feb;16(3):573-80.
DMU1DHM	RU	https://pubmed.ncbi.nlm.nih.gov/16274989

DMWCZLT	DI	DMWCZLT
DMWCZLT	DN	Haloxysterol D
DMWCZLT	MI	TT1RS9F
DMWCZLT	MN	Acetylcholinesterase (AChE)
DMWCZLT	MT	DTT
DMWCZLT	MA	Inhibitor
DMWCZLT	RN	Isolation and cholinesterase-inhibition studies of sterols from Haloxylon recurvum. Bioorg Med Chem Lett. 2006 Feb;16(3):573-80.
DMWCZLT	RU	https://pubmed.ncbi.nlm.nih.gov/16274989

DMWCZLT	DI	DMWCZLT
DMWCZLT	DN	Haloxysterol D
DMWCZLT	MI	TTEB0GD
DMWCZLT	MN	Cholinesterase (BCHE)
DMWCZLT	MT	DTT
DMWCZLT	MA	Inhibitor
DMWCZLT	RN	Isolation and cholinesterase-inhibition studies of sterols from Haloxylon recurvum. Bioorg Med Chem Lett. 2006 Feb;16(3):573-80.
DMWCZLT	RU	https://pubmed.ncbi.nlm.nih.gov/16274989

DMJN0BL	DI	DMJN0BL
DMJN0BL	DN	HAMI3379
DMJN0BL	MI	TT0PZR5
DMJN0BL	MN	Leukotriene CysLT2 receptor (CYSLTR2)
DMJN0BL	MT	DTT
DMJN0BL	MA	Antagonist
DMJN0BL	RN	Pharmacological characterization of the first potent and selective antagonist at the cysteinyl leukotriene 2 (CysLT(2)) receptor. Br J Pharmacol. 2010 May;160(2):399-409.
DMJN0BL	RU	https://pubmed.ncbi.nlm.nih.gov/20423349

DM5SUYP	DI	DM5SUYP
DM5SUYP	DN	H-Apa-ala-Gly-Phe-leu-OH
DM5SUYP	MI	TT27RFC
DM5SUYP	MN	Opioid receptor delta (OPRD1)
DM5SUYP	MT	DTT
DM5SUYP	MA	Inhibitor
DM5SUYP	RN	Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60.
DM5SUYP	RU	https://pubmed.ncbi.nlm.nih.gov/17350835

DM5SUYP	DI	DM5SUYP
DM5SUYP	DN	H-Apa-ala-Gly-Phe-leu-OH
DM5SUYP	MI	TTKWM86
DM5SUYP	MN	Opioid receptor mu (MOP)
DM5SUYP	MT	DTT
DM5SUYP	MA	Inhibitor
DM5SUYP	RN	Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60.
DM5SUYP	RU	https://pubmed.ncbi.nlm.nih.gov/17350835

DM9K6H5	DI	DM9K6H5
DM9K6H5	DN	HAp-IFN
DM9K6H5	MI	TTSIUJ9
DM9K6H5	MN	Interferon-alpha 2 (IFNA2)
DM9K6H5	MT	DTT
DM9K6H5	MA	Modulator
DM9K6H5	RN	CN patent application no. 1921880, Protein drug sustained-release microparticle preparation for injection and process for producing the same.
DM9K6H5	RU	http://www.google.com/patents/CN1921880A?cl=en

DMENVKA	DI	DMENVKA
DMENVKA	DN	H-Arg-Arg-Pro-Tyr-Ile-Aac-OH
DMENVKA	MI	TTTUMEP
DMENVKA	MN	Neurotensin receptor type 1 (NTSR1)
DMENVKA	MT	DTT
DMENVKA	MA	Inhibitor
DMENVKA	RN	Novel insights into GPCR-peptide interactions: mutations in extracellular loop 1, ligand backbone methylations and molecular modeling of neurotensi... Bioorg Med Chem. 2008 Oct 15;16(20):9359-68.
DMENVKA	RU	https://pubmed.ncbi.nlm.nih.gov/18809332

DM4FKR1	DI	DM4FKR1
DM4FKR1	DN	H-Arg-Arg-Pro-Tyr-Ile-N-Me-Leu-OH
DM4FKR1	MI	TTTUMEP
DM4FKR1	MN	Neurotensin receptor type 1 (NTSR1)
DM4FKR1	MT	DTT
DM4FKR1	MA	Inhibitor
DM4FKR1	RN	Novel insights into GPCR-peptide interactions: mutations in extracellular loop 1, ligand backbone methylations and molecular modeling of neurotensi... Bioorg Med Chem. 2008 Oct 15;16(20):9359-68.
DM4FKR1	RU	https://pubmed.ncbi.nlm.nih.gov/18809332

DM107RT	DI	DM107RT
DM107RT	DN	H-Arg-Arg-Pro-Tyr-N-Me-Ile-Leu-OH
DM107RT	MI	TTTUMEP
DM107RT	MN	Neurotensin receptor type 1 (NTSR1)
DM107RT	MT	DTT
DM107RT	MA	Inhibitor
DM107RT	RN	Novel insights into GPCR-peptide interactions: mutations in extracellular loop 1, ligand backbone methylations and molecular modeling of neurotensi... Bioorg Med Chem. 2008 Oct 15;16(20):9359-68.
DM107RT	RU	https://pubmed.ncbi.nlm.nih.gov/18809332

DMSXLKJ	DI	DMSXLKJ
DMSXLKJ	DN	H-Arg-N-Me-Arg-Pro-Tyr-Ile-Leu-OH
DMSXLKJ	MI	TTTUMEP
DMSXLKJ	MN	Neurotensin receptor type 1 (NTSR1)
DMSXLKJ	MT	DTT
DMSXLKJ	MA	Inhibitor
DMSXLKJ	RN	Novel insights into GPCR-peptide interactions: mutations in extracellular loop 1, ligand backbone methylations and molecular modeling of neurotensi... Bioorg Med Chem. 2008 Oct 15;16(20):9359-68.
DMSXLKJ	RU	https://pubmed.ncbi.nlm.nih.gov/18809332

DMJ6N1X	DI	DMJ6N1X
DMJ6N1X	DN	H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-OH
DMJ6N1X	MI	TTZPO1L
DMJ6N1X	MN	Substance-P receptor (TACR1)
DMJ6N1X	MT	DTT
DMJ6N1X	MA	Inhibitor
DMJ6N1X	RN	Discovery of dipeptides with high affinity to the specific binding site for substance P1-7. J Med Chem. 2010 Mar 25;53(6):2383-9.
DMJ6N1X	RU	https://pubmed.ncbi.nlm.nih.gov/20178322

DM5VDU2	DI	DM5VDU2
DM5VDU2	DN	HBN-2
DM5VDU2	MI	TTTUMEP
DM5VDU2	MN	Neurotensin receptor type 1 (NTSR1)
DM5VDU2	MT	DTT
DM5VDU2	MA	Modulator
DM5VDU2	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 309).
DM5VDU2	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=309

DMKDBFL	DI	DMKDBFL
DMKDBFL	DN	HBR-985
DMKDBFL	MI	TTP835K
DMKDBFL	MN	ATP-binding cassette transporter C8 (ABCC8)
DMKDBFL	MT	DTT
DMKDBFL	MA	Inhibitor
DMKDBFL	RN	Cardioselective K(ATP) channel blockers derived from a new series of m-anisamidoethylbenzenesulfonylthioureas. J Med Chem. 2001 Mar 29;44(7):1085-98.
DMKDBFL	RU	https://pubmed.ncbi.nlm.nih.gov/11297455

DMKDBFL	DI	DMKDBFL
DMKDBFL	DN	HBR-985
DMKDBFL	MI	TT329V4
DMKDBFL	MN	Inward rectifier potassium channel Kir6.2 (KCNJ11)
DMKDBFL	MT	DTT
DMKDBFL	MA	Inhibitor
DMKDBFL	RN	Cardioselective K(ATP) channel blockers derived from a new series of m-anisamidoethylbenzenesulfonylthioureas. J Med Chem. 2001 Mar 29;44(7):1085-98.
DMKDBFL	RU	https://pubmed.ncbi.nlm.nih.gov/11297455

DMCQH23	DI	DMCQH23
DMCQH23	DN	H-c[Cys-Phe-DTrp-Lys-Thr-Cys]-OH
DMCQH23	MI	TTZ6T9E
DMCQH23	MN	Somatostatin receptor type 2 (SSTR2)
DMCQH23	MT	DTT
DMCQH23	MA	Inhibitor
DMCQH23	RN	Novel sst2-selective somatostatin agonists. Three-dimensional consensus structure by NMR. J Med Chem. 2006 Jul 27;49(15):4487-96.
DMCQH23	RU	https://pubmed.ncbi.nlm.nih.gov/16854054

DMOY2AI	DI	DMOY2AI
DMOY2AI	DN	HC-030031
DMOY2AI	MI	TT79AOF
DMOY2AI	MN	Transient receptor potential channel (TRP channel)
DMOY2AI	MT	DTT
DMOY2AI	MA	Inhibitor
DMOY2AI	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4211).
DMOY2AI	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4211

DMOG1Q4	DI	DMOG1Q4
DMOG1Q4	DN	HC-056456
DMOG1Q4	MI	TT5CISB
DMOG1Q4	MN	Cation channel sperm-associated protein 1 (CatSper1)
DMOG1Q4	MT	DTT
DMOG1Q4	MA	Blocker (channel blocker)
DMOG1Q4	RN	Pharmacological targeting of native CatSper channels reveals a required role in maintenance of sperm hyperactivation. PLoS One. 2009 Aug 31;4(8):e6844.
DMOG1Q4	RU	https://pubmed.ncbi.nlm.nih.gov/19718436

DMIXY1O	DI	DMIXY1O
DMIXY1O	DN	HC067047
DMIXY1O	MI	TTKP2SU
DMIXY1O	MN	Transient receptor potential cation channel V4 (TRPV4)
DMIXY1O	MT	DTT
DMIXY1O	MA	Blocker (channel blocker)
DMIXY1O	RN	Inhibition of the cation channel TRPV4 improves bladder function in mice and rats with cyclophosphamide-induced cystitis. Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):19084-9.
DMIXY1O	RU	https://pubmed.ncbi.nlm.nih.gov/20956320

DM1BLCX	DI	DM1BLCX
DM1BLCX	DN	HC3-1496
DM1BLCX	MI	TT8D13I
DM1BLCX	MN	Complement factor D (CFD)
DM1BLCX	MT	DTT
DM1BLCX	MA	Modulator
DM1BLCX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2842).
DM1BLCX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2842

DMV751G	DI	DMV751G
DMV751G	DN	H-Cdp-ala-Gly-Phe-leu-OH
DMV751G	MI	TT27RFC
DMV751G	MN	Opioid receptor delta (OPRD1)
DMV751G	MT	DTT
DMV751G	MA	Inhibitor
DMV751G	RN	Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60.
DMV751G	RU	https://pubmed.ncbi.nlm.nih.gov/17350835

DMV751G	DI	DMV751G
DMV751G	DN	H-Cdp-ala-Gly-Phe-leu-OH
DMV751G	MI	TTQW87Y
DMV751G	MN	Opioid receptor kappa (OPRK1)
DMV751G	MT	DTT
DMV751G	MA	Inhibitor
DMV751G	RN	Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60.
DMV751G	RU	https://pubmed.ncbi.nlm.nih.gov/17350835

DMV751G	DI	DMV751G
DMV751G	DN	H-Cdp-ala-Gly-Phe-leu-OH
DMV751G	MI	TTKWM86
DMV751G	MN	Opioid receptor mu (MOP)
DMV751G	MT	DTT
DMV751G	MA	Inhibitor
DMV751G	RN	Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60.
DMV751G	RU	https://pubmed.ncbi.nlm.nih.gov/17350835

DMVEB8C	DI	DMVEB8C
DMVEB8C	DN	H-Cdp-Gly-Gly-Phe-Leu-OH
DMVEB8C	MI	TT27RFC
DMVEB8C	MN	Opioid receptor delta (OPRD1)
DMVEB8C	MT	DTT
DMVEB8C	MA	Inhibitor
DMVEB8C	RN	Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60.
DMVEB8C	RU	https://pubmed.ncbi.nlm.nih.gov/17350835

DMVEB8C	DI	DMVEB8C
DMVEB8C	DN	H-Cdp-Gly-Gly-Phe-Leu-OH
DMVEB8C	MI	TTQW87Y
DMVEB8C	MN	Opioid receptor kappa (OPRK1)
DMVEB8C	MT	DTT
DMVEB8C	MA	Inhibitor
DMVEB8C	RN	Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60.
DMVEB8C	RU	https://pubmed.ncbi.nlm.nih.gov/17350835

DMVEB8C	DI	DMVEB8C
DMVEB8C	DN	H-Cdp-Gly-Gly-Phe-Leu-OH
DMVEB8C	MI	TTKWM86
DMVEB8C	MN	Opioid receptor mu (MOP)
DMVEB8C	MT	DTT
DMVEB8C	MA	Inhibitor
DMVEB8C	RN	Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60.
DMVEB8C	RU	https://pubmed.ncbi.nlm.nih.gov/17350835

DMCDLTV	DI	DMCDLTV
DMCDLTV	DN	H-Cdp-ser-Gly-Phe-Leu-Thr-OH
DMCDLTV	MI	TT27RFC
DMCDLTV	MN	Opioid receptor delta (OPRD1)
DMCDLTV	MT	DTT
DMCDLTV	MA	Inhibitor
DMCDLTV	RN	Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60.
DMCDLTV	RU	https://pubmed.ncbi.nlm.nih.gov/17350835

DMCDLTV	DI	DMCDLTV
DMCDLTV	DN	H-Cdp-ser-Gly-Phe-Leu-Thr-OH
DMCDLTV	MI	TTKWM86
DMCDLTV	MN	Opioid receptor mu (MOP)
DMCDLTV	MT	DTT
DMCDLTV	MA	Inhibitor
DMCDLTV	RN	Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60.
DMCDLTV	RU	https://pubmed.ncbi.nlm.nih.gov/17350835

DM415ZX	DI	DM415ZX
DM415ZX	DN	HCGRPalpha
DM415ZX	MI	TTY6O0Q
DM415ZX	MN	Calcitonin gene-related peptide receptor (CGRPR)
DM415ZX	MT	DTT
DM415ZX	MA	Inhibitor
DM415ZX	RN	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
DM415ZX	RU	https://pubmed.ncbi.nlm.nih.gov/18983139

DM3V4XG	DI	DM3V4XG
DM3V4XG	DN	H-Cpa-c[pen-Gly-Phe-pen]OH
DM3V4XG	MI	TT27RFC
DM3V4XG	MN	Opioid receptor delta (OPRD1)
DM3V4XG	MT	DTT
DM3V4XG	MA	Inhibitor
DM3V4XG	RN	Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60.
DM3V4XG	RU	https://pubmed.ncbi.nlm.nih.gov/17350835

DMU6PV8	DI	DMU6PV8
DMU6PV8	DN	H-Cpa-Gly-Gly-Phe-Met-NH2
DMU6PV8	MI	TT27RFC
DMU6PV8	MN	Opioid receptor delta (OPRD1)
DMU6PV8	MT	DTT
DMU6PV8	MA	Inhibitor
DMU6PV8	RN	Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60.
DMU6PV8	RU	https://pubmed.ncbi.nlm.nih.gov/17350835

DMU6PV8	DI	DMU6PV8
DMU6PV8	DN	H-Cpa-Gly-Gly-Phe-Met-NH2
DMU6PV8	MI	TTQW87Y
DMU6PV8	MN	Opioid receptor kappa (OPRK1)
DMU6PV8	MT	DTT
DMU6PV8	MA	Inhibitor
DMU6PV8	RN	Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60.
DMU6PV8	RU	https://pubmed.ncbi.nlm.nih.gov/17350835

DMU6PV8	DI	DMU6PV8
DMU6PV8	DN	H-Cpa-Gly-Gly-Phe-Met-NH2
DMU6PV8	MI	TTKWM86
DMU6PV8	MN	Opioid receptor mu (MOP)
DMU6PV8	MT	DTT
DMU6PV8	MA	Inhibitor
DMU6PV8	RN	Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60.
DMU6PV8	RU	https://pubmed.ncbi.nlm.nih.gov/17350835

DM154G2	DI	DM154G2
DM154G2	DN	H-Cpa-Gly-Gly-Phe-Met-OH
DM154G2	MI	TT27RFC
DM154G2	MN	Opioid receptor delta (OPRD1)
DM154G2	MT	DTT
DM154G2	MA	Inhibitor
DM154G2	RN	Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60.
DM154G2	RU	https://pubmed.ncbi.nlm.nih.gov/17350835

DM154G2	DI	DM154G2
DM154G2	DN	H-Cpa-Gly-Gly-Phe-Met-OH
DM154G2	MI	TTQW87Y
DM154G2	MN	Opioid receptor kappa (OPRK1)
DM154G2	MT	DTT
DM154G2	MA	Inhibitor
DM154G2	RN	Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60.
DM154G2	RU	https://pubmed.ncbi.nlm.nih.gov/17350835

DM154G2	DI	DM154G2
DM154G2	DN	H-Cpa-Gly-Gly-Phe-Met-OH
DM154G2	MI	TTKWM86
DM154G2	MN	Opioid receptor mu (MOP)
DM154G2	MT	DTT
DM154G2	MA	Inhibitor
DM154G2	RN	Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60.
DM154G2	RU	https://pubmed.ncbi.nlm.nih.gov/17350835

DMPL0BR	DI	DMPL0BR
DMPL0BR	DN	H-Cxp-ala-Gly-Phe-leu-OH
DMPL0BR	MI	TT27RFC
DMPL0BR	MN	Opioid receptor delta (OPRD1)
DMPL0BR	MT	DTT
DMPL0BR	MA	Inhibitor
DMPL0BR	RN	Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60.
DMPL0BR	RU	https://pubmed.ncbi.nlm.nih.gov/17350835

DM6839G	DI	DM6839G
DM6839G	DN	H-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-D-BT-OH(JMV1638)
DM6839G	MI	TTG5QIA
DM6839G	MN	B1 bradykinin receptor (BDKRB1)
DM6839G	MT	DTT
DM6839G	MA	Inhibitor
DM6839G	RN	Synthesis and biological evaluation of bradykinin B(1)/B(2) and selective B(1) receptor antagonists. J Med Chem. 2000 Jun 15;43(12):2382-6.
DM6839G	RU	https://pubmed.ncbi.nlm.nih.gov/10882364

DM6839G	DI	DM6839G
DM6839G	DN	H-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-D-BT-OH(JMV1638)
DM6839G	MI	TTGY8IW
DM6839G	MN	B2 bradykinin receptor (BDKRB2)
DM6839G	MT	DTT
DM6839G	MA	Inhibitor
DM6839G	RN	Synthesis and biological evaluation of bradykinin B(1)/B(2) and selective B(1) receptor antagonists. J Med Chem. 2000 Jun 15;43(12):2382-6.
DM6839G	RU	https://pubmed.ncbi.nlm.nih.gov/10882364

DM9WJZK	DI	DM9WJZK
DM9WJZK	DN	H-Dmt-Aba-Gly-NH-CH2-Bid
DM9WJZK	MI	TT27RFC
DM9WJZK	MN	Opioid receptor delta (OPRD1)
DM9WJZK	MT	DTT
DM9WJZK	MA	Inhibitor
DM9WJZK	RN	New 2',6'-dimethyl-L-tyrosine (Dmt) opioid peptidomimetics based on the Aba-Gly scaffold. Development of unique mu-opioid receptor ligands. J Med Chem. 2006 Jun 29;49(13):3990-3.
DM9WJZK	RU	https://pubmed.ncbi.nlm.nih.gov/16789756

DM9WJZK	DI	DM9WJZK
DM9WJZK	DN	H-Dmt-Aba-Gly-NH-CH2-Bid
DM9WJZK	MI	TTKWM86
DM9WJZK	MN	Opioid receptor mu (MOP)
DM9WJZK	MT	DTT
DM9WJZK	MA	Inhibitor
DM9WJZK	RN	New 2',6'-dimethyl-L-tyrosine (Dmt) opioid peptidomimetics based on the Aba-Gly scaffold. Development of unique mu-opioid receptor ligands. J Med Chem. 2006 Jun 29;49(13):3990-3.
DM9WJZK	RU	https://pubmed.ncbi.nlm.nih.gov/16789756

DM61CMS	DI	DM61CMS
DM61CMS	DN	H-Dmt-Aba-Gly-NH-CH2-Ph
DM61CMS	MI	TT27RFC
DM61CMS	MN	Opioid receptor delta (OPRD1)
DM61CMS	MT	DTT
DM61CMS	MA	Inhibitor
DM61CMS	RN	New 2',6'-dimethyl-L-tyrosine (Dmt) opioid peptidomimetics based on the Aba-Gly scaffold. Development of unique mu-opioid receptor ligands. J Med Chem. 2006 Jun 29;49(13):3990-3.
DM61CMS	RU	https://pubmed.ncbi.nlm.nih.gov/16789756

DM61CMS	DI	DM61CMS
DM61CMS	DN	H-Dmt-Aba-Gly-NH-CH2-Ph
DM61CMS	MI	TTKWM86
DM61CMS	MN	Opioid receptor mu (MOP)
DM61CMS	MT	DTT
DM61CMS	MA	Inhibitor
DM61CMS	RN	New 2',6'-dimethyl-L-tyrosine (Dmt) opioid peptidomimetics based on the Aba-Gly scaffold. Development of unique mu-opioid receptor ligands. J Med Chem. 2006 Jun 29;49(13):3990-3.
DM61CMS	RU	https://pubmed.ncbi.nlm.nih.gov/16789756

DMCQYIJ	DI	DMCQYIJ
DMCQYIJ	DN	H-Dmt-Aba-Gly-NH-Ph
DMCQYIJ	MI	TT27RFC
DMCQYIJ	MN	Opioid receptor delta (OPRD1)
DMCQYIJ	MT	DTT
DMCQYIJ	MA	Inhibitor
DMCQYIJ	RN	New 2',6'-dimethyl-L-tyrosine (Dmt) opioid peptidomimetics based on the Aba-Gly scaffold. Development of unique mu-opioid receptor ligands. J Med Chem. 2006 Jun 29;49(13):3990-3.
DMCQYIJ	RU	https://pubmed.ncbi.nlm.nih.gov/16789756

DMCQYIJ	DI	DMCQYIJ
DMCQYIJ	DN	H-Dmt-Aba-Gly-NH-Ph
DMCQYIJ	MI	TTKWM86
DMCQYIJ	MN	Opioid receptor mu (MOP)
DMCQYIJ	MT	DTT
DMCQYIJ	MA	Inhibitor
DMCQYIJ	RN	New 2',6'-dimethyl-L-tyrosine (Dmt) opioid peptidomimetics based on the Aba-Gly scaffold. Development of unique mu-opioid receptor ligands. J Med Chem. 2006 Jun 29;49(13):3990-3.
DMCQYIJ	RU	https://pubmed.ncbi.nlm.nih.gov/16789756

DMHK70B	DI	DMHK70B
DMHK70B	DN	H-Dmt-D-Arg(NO2)-Phe-Lys(Z)-NH2
DMHK70B	MI	TT27RFC
DMHK70B	MN	Opioid receptor delta (OPRD1)
DMHK70B	MT	DTT
DMHK70B	MA	Inhibitor
DMHK70B	RN	From the potent and selective mu opioid receptor agonist H-Dmt-d-Arg-Phe-Lys-NH(2) to the potent delta antagonist H-Dmt-Tic-Phe-Lys(Z)-OH. J Med Chem. 2005 Aug 25;48(17):5608-11.
DMHK70B	RU	https://pubmed.ncbi.nlm.nih.gov/16107162

DMHK70B	DI	DMHK70B
DMHK70B	DN	H-Dmt-D-Arg(NO2)-Phe-Lys(Z)-NH2
DMHK70B	MI	TTKWM86
DMHK70B	MN	Opioid receptor mu (MOP)
DMHK70B	MT	DTT
DMHK70B	MA	Inhibitor
DMHK70B	RN	From the potent and selective mu opioid receptor agonist H-Dmt-d-Arg-Phe-Lys-NH(2) to the potent delta antagonist H-Dmt-Tic-Phe-Lys(Z)-OH. J Med Chem. 2005 Aug 25;48(17):5608-11.
DMHK70B	RU	https://pubmed.ncbi.nlm.nih.gov/16107162

DMM9EPQ	DI	DMM9EPQ
DMM9EPQ	DN	H-Dmt-D-Arg(NO2)-Phe-Lys(Z)-OH
DMM9EPQ	MI	TT27RFC
DMM9EPQ	MN	Opioid receptor delta (OPRD1)
DMM9EPQ	MT	DTT
DMM9EPQ	MA	Inhibitor
DMM9EPQ	RN	From the potent and selective mu opioid receptor agonist H-Dmt-d-Arg-Phe-Lys-NH(2) to the potent delta antagonist H-Dmt-Tic-Phe-Lys(Z)-OH. J Med Chem. 2005 Aug 25;48(17):5608-11.
DMM9EPQ	RU	https://pubmed.ncbi.nlm.nih.gov/16107162

DMM9EPQ	DI	DMM9EPQ
DMM9EPQ	DN	H-Dmt-D-Arg(NO2)-Phe-Lys(Z)-OH
DMM9EPQ	MI	TTKWM86
DMM9EPQ	MN	Opioid receptor mu (MOP)
DMM9EPQ	MT	DTT
DMM9EPQ	MA	Inhibitor
DMM9EPQ	RN	From the potent and selective mu opioid receptor agonist H-Dmt-d-Arg-Phe-Lys-NH(2) to the potent delta antagonist H-Dmt-Tic-Phe-Lys(Z)-OH. J Med Chem. 2005 Aug 25;48(17):5608-11.
DMM9EPQ	RU	https://pubmed.ncbi.nlm.nih.gov/16107162

DM1ZDJ6	DI	DM1ZDJ6
DM1ZDJ6	DN	H-Dmt-Tic-(2R,3R)-beta-MeCha-Phe-NH2
DM1ZDJ6	MI	TT27RFC
DM1ZDJ6	MN	Opioid receptor delta (OPRD1)
DM1ZDJ6	MT	DTT
DM1ZDJ6	MA	Inhibitor
DM1ZDJ6	RN	Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. J Med Chem. 2007 Jan 25;50(2):328-33.
DM1ZDJ6	RU	https://pubmed.ncbi.nlm.nih.gov/17228874

DM1ZDJ6	DI	DM1ZDJ6
DM1ZDJ6	DN	H-Dmt-Tic-(2R,3R)-beta-MeCha-Phe-NH2
DM1ZDJ6	MI	TTKWM86
DM1ZDJ6	MN	Opioid receptor mu (MOP)
DM1ZDJ6	MT	DTT
DM1ZDJ6	MA	Inhibitor
DM1ZDJ6	RN	Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. J Med Chem. 2007 Jan 25;50(2):328-33.
DM1ZDJ6	RU	https://pubmed.ncbi.nlm.nih.gov/17228874

DMC3APN	DI	DMC3APN
DMC3APN	DN	H-Dmt-Tic-(2R,3R)-beta-MeCha-Phe-OH
DMC3APN	MI	TT27RFC
DMC3APN	MN	Opioid receptor delta (OPRD1)
DMC3APN	MT	DTT
DMC3APN	MA	Inhibitor
DMC3APN	RN	Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. J Med Chem. 2007 Jan 25;50(2):328-33.
DMC3APN	RU	https://pubmed.ncbi.nlm.nih.gov/17228874

DMC3APN	DI	DMC3APN
DMC3APN	DN	H-Dmt-Tic-(2R,3R)-beta-MeCha-Phe-OH
DMC3APN	MI	TTKWM86
DMC3APN	MN	Opioid receptor mu (MOP)
DMC3APN	MT	DTT
DMC3APN	MA	Inhibitor
DMC3APN	RN	Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. J Med Chem. 2007 Jan 25;50(2):328-33.
DMC3APN	RU	https://pubmed.ncbi.nlm.nih.gov/17228874

DMY97TN	DI	DMY97TN
DMY97TN	DN	H-Dmt-Tic-(2R,3S)-beta-MeCha-Phe-NH2
DMY97TN	MI	TT27RFC
DMY97TN	MN	Opioid receptor delta (OPRD1)
DMY97TN	MT	DTT
DMY97TN	MA	Inhibitor
DMY97TN	RN	Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. J Med Chem. 2007 Jan 25;50(2):328-33.
DMY97TN	RU	https://pubmed.ncbi.nlm.nih.gov/17228874

DMY97TN	DI	DMY97TN
DMY97TN	DN	H-Dmt-Tic-(2R,3S)-beta-MeCha-Phe-NH2
DMY97TN	MI	TTKWM86
DMY97TN	MN	Opioid receptor mu (MOP)
DMY97TN	MT	DTT
DMY97TN	MA	Inhibitor
DMY97TN	RN	Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. J Med Chem. 2007 Jan 25;50(2):328-33.
DMY97TN	RU	https://pubmed.ncbi.nlm.nih.gov/17228874

DMGPAM0	DI	DMGPAM0
DMGPAM0	DN	H-Dmt-Tic-(2R,3S)-beta-MeCha-Phe-OH
DMGPAM0	MI	TT27RFC
DMGPAM0	MN	Opioid receptor delta (OPRD1)
DMGPAM0	MT	DTT
DMGPAM0	MA	Inhibitor
DMGPAM0	RN	Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. J Med Chem. 2007 Jan 25;50(2):328-33.
DMGPAM0	RU	https://pubmed.ncbi.nlm.nih.gov/17228874

DMGPAM0	DI	DMGPAM0
DMGPAM0	DN	H-Dmt-Tic-(2R,3S)-beta-MeCha-Phe-OH
DMGPAM0	MI	TTKWM86
DMGPAM0	MN	Opioid receptor mu (MOP)
DMGPAM0	MT	DTT
DMGPAM0	MA	Inhibitor
DMGPAM0	RN	Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. J Med Chem. 2007 Jan 25;50(2):328-33.
DMGPAM0	RU	https://pubmed.ncbi.nlm.nih.gov/17228874

DMOI1U5	DI	DMOI1U5
DMOI1U5	DN	H-Dmt-Tic-(2S,3R)-beta-MeCha-Phe-NH2
DMOI1U5	MI	TT27RFC
DMOI1U5	MN	Opioid receptor delta (OPRD1)
DMOI1U5	MT	DTT
DMOI1U5	MA	Inhibitor
DMOI1U5	RN	Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. J Med Chem. 2007 Jan 25;50(2):328-33.
DMOI1U5	RU	https://pubmed.ncbi.nlm.nih.gov/17228874

DMOI1U5	DI	DMOI1U5
DMOI1U5	DN	H-Dmt-Tic-(2S,3R)-beta-MeCha-Phe-NH2
DMOI1U5	MI	TTKWM86
DMOI1U5	MN	Opioid receptor mu (MOP)
DMOI1U5	MT	DTT
DMOI1U5	MA	Inhibitor
DMOI1U5	RN	Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. J Med Chem. 2007 Jan 25;50(2):328-33.
DMOI1U5	RU	https://pubmed.ncbi.nlm.nih.gov/17228874

DMZBFJ5	DI	DMZBFJ5
DMZBFJ5	DN	H-Dmt-Tic-(2S,3R)-beta-MeCha-Phe-OH
DMZBFJ5	MI	TT27RFC
DMZBFJ5	MN	Opioid receptor delta (OPRD1)
DMZBFJ5	MT	DTT
DMZBFJ5	MA	Inhibitor
DMZBFJ5	RN	Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. J Med Chem. 2007 Jan 25;50(2):328-33.
DMZBFJ5	RU	https://pubmed.ncbi.nlm.nih.gov/17228874

DMZBFJ5	DI	DMZBFJ5
DMZBFJ5	DN	H-Dmt-Tic-(2S,3R)-beta-MeCha-Phe-OH
DMZBFJ5	MI	TTKWM86
DMZBFJ5	MN	Opioid receptor mu (MOP)
DMZBFJ5	MT	DTT
DMZBFJ5	MA	Inhibitor
DMZBFJ5	RN	Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. J Med Chem. 2007 Jan 25;50(2):328-33.
DMZBFJ5	RU	https://pubmed.ncbi.nlm.nih.gov/17228874

DMNS1GX	DI	DMNS1GX
DMNS1GX	DN	H-Dmt-Tic-(2S,3S)-beta-MeCha-Phe-NH2
DMNS1GX	MI	TT27RFC
DMNS1GX	MN	Opioid receptor delta (OPRD1)
DMNS1GX	MT	DTT
DMNS1GX	MA	Inhibitor
DMNS1GX	RN	Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. J Med Chem. 2007 Jan 25;50(2):328-33.
DMNS1GX	RU	https://pubmed.ncbi.nlm.nih.gov/17228874

DMNS1GX	DI	DMNS1GX
DMNS1GX	DN	H-Dmt-Tic-(2S,3S)-beta-MeCha-Phe-NH2
DMNS1GX	MI	TTKWM86
DMNS1GX	MN	Opioid receptor mu (MOP)
DMNS1GX	MT	DTT
DMNS1GX	MA	Inhibitor
DMNS1GX	RN	Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. J Med Chem. 2007 Jan 25;50(2):328-33.
DMNS1GX	RU	https://pubmed.ncbi.nlm.nih.gov/17228874

DMM9TUR	DI	DMM9TUR
DMM9TUR	DN	H-Dmt-Tic-(2S,3S)-beta-MeCha-Phe-OH
DMM9TUR	MI	TT27RFC
DMM9TUR	MN	Opioid receptor delta (OPRD1)
DMM9TUR	MT	DTT
DMM9TUR	MA	Inhibitor
DMM9TUR	RN	Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. J Med Chem. 2007 Jan 25;50(2):328-33.
DMM9TUR	RU	https://pubmed.ncbi.nlm.nih.gov/17228874

DMM9TUR	DI	DMM9TUR
DMM9TUR	DN	H-Dmt-Tic-(2S,3S)-beta-MeCha-Phe-OH
DMM9TUR	MI	TTKWM86
DMM9TUR	MN	Opioid receptor mu (MOP)
DMM9TUR	MT	DTT
DMM9TUR	MA	Inhibitor
DMM9TUR	RN	Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. J Med Chem. 2007 Jan 25;50(2):328-33.
DMM9TUR	RU	https://pubmed.ncbi.nlm.nih.gov/17228874

DM4JP8L	DI	DM4JP8L
DM4JP8L	DN	H-Dmt-Tic-Asp-N(Me)-Ph
DM4JP8L	MI	TT27RFC
DM4JP8L	MN	Opioid receptor delta (OPRD1)
DM4JP8L	MT	DTT
DM4JP8L	MA	Inhibitor
DM4JP8L	RN	Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17.
DM4JP8L	RU	https://pubmed.ncbi.nlm.nih.gov/18680274

DM4JP8L	DI	DM4JP8L
DM4JP8L	DN	H-Dmt-Tic-Asp-N(Me)-Ph
DM4JP8L	MI	TTKWM86
DM4JP8L	MN	Opioid receptor mu (MOP)
DM4JP8L	MT	DTT
DM4JP8L	MA	Inhibitor
DM4JP8L	RN	Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17.
DM4JP8L	RU	https://pubmed.ncbi.nlm.nih.gov/18680274

DMBKOJG	DI	DMBKOJG
DMBKOJG	DN	H-Dmt-Tic-Asp-NH-Bzl
DMBKOJG	MI	TT27RFC
DMBKOJG	MN	Opioid receptor delta (OPRD1)
DMBKOJG	MT	DTT
DMBKOJG	MA	Inhibitor
DMBKOJG	RN	Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17.
DMBKOJG	RU	https://pubmed.ncbi.nlm.nih.gov/18680274

DMBKOJG	DI	DMBKOJG
DMBKOJG	DN	H-Dmt-Tic-Asp-NH-Bzl
DMBKOJG	MI	TTKWM86
DMBKOJG	MN	Opioid receptor mu (MOP)
DMBKOJG	MT	DTT
DMBKOJG	MA	Inhibitor
DMBKOJG	RN	Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17.
DMBKOJG	RU	https://pubmed.ncbi.nlm.nih.gov/18680274

DM3W9FQ	DI	DM3W9FQ
DM3W9FQ	DN	H-Dmt-Tic-Asp-NH-Ph
DM3W9FQ	MI	TT27RFC
DM3W9FQ	MN	Opioid receptor delta (OPRD1)
DM3W9FQ	MT	DTT
DM3W9FQ	MA	Inhibitor
DM3W9FQ	RN	Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17.
DM3W9FQ	RU	https://pubmed.ncbi.nlm.nih.gov/18680274

DM3W9FQ	DI	DM3W9FQ
DM3W9FQ	DN	H-Dmt-Tic-Asp-NH-Ph
DM3W9FQ	MI	TTKWM86
DM3W9FQ	MN	Opioid receptor mu (MOP)
DM3W9FQ	MT	DTT
DM3W9FQ	MA	Inhibitor
DM3W9FQ	RN	Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17.
DM3W9FQ	RU	https://pubmed.ncbi.nlm.nih.gov/18680274

DM483BG	DI	DM483BG
DM483BG	DN	H-Dmt-Tic-D-Asp-N(Me)-Ph
DM483BG	MI	TT27RFC
DM483BG	MN	Opioid receptor delta (OPRD1)
DM483BG	MT	DTT
DM483BG	MA	Inhibitor
DM483BG	RN	Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17.
DM483BG	RU	https://pubmed.ncbi.nlm.nih.gov/18680274

DM483BG	DI	DM483BG
DM483BG	DN	H-Dmt-Tic-D-Asp-N(Me)-Ph
DM483BG	MI	TTKWM86
DM483BG	MN	Opioid receptor mu (MOP)
DM483BG	MT	DTT
DM483BG	MA	Inhibitor
DM483BG	RN	Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17.
DM483BG	RU	https://pubmed.ncbi.nlm.nih.gov/18680274

DMUG7X1	DI	DMUG7X1
DMUG7X1	DN	H-Dmt-Tic-D-Asp-NH-Ph
DMUG7X1	MI	TT27RFC
DMUG7X1	MN	Opioid receptor delta (OPRD1)
DMUG7X1	MT	DTT
DMUG7X1	MA	Inhibitor
DMUG7X1	RN	Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17.
DMUG7X1	RU	https://pubmed.ncbi.nlm.nih.gov/18680274

DMUG7X1	DI	DMUG7X1
DMUG7X1	DN	H-Dmt-Tic-D-Asp-NH-Ph
DMUG7X1	MI	TTKWM86
DMUG7X1	MN	Opioid receptor mu (MOP)
DMUG7X1	MT	DTT
DMUG7X1	MA	Inhibitor
DMUG7X1	RN	Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17.
DMUG7X1	RU	https://pubmed.ncbi.nlm.nih.gov/18680274

DMQSRPD	DI	DMQSRPD
DMQSRPD	DN	H-Dmt-Tic-Glu-Dap(6DMN)-NH(2)
DMQSRPD	MI	TT27RFC
DMQSRPD	MN	Opioid receptor delta (OPRD1)
DMQSRPD	MT	DTT
DMQSRPD	MA	Inhibitor
DMQSRPD	RN	6-N,N-dimethylamino-2,3-naphthalimide: a new environment-sensitive fluorescent probe in delta- and mu-selective opioid peptides. J Med Chem. 2006 Jun 15;49(12):3653-8.
DMQSRPD	RU	https://pubmed.ncbi.nlm.nih.gov/16759107

DMQSRPD	DI	DMQSRPD
DMQSRPD	DN	H-Dmt-Tic-Glu-Dap(6DMN)-NH(2)
DMQSRPD	MI	TTKWM86
DMQSRPD	MN	Opioid receptor mu (MOP)
DMQSRPD	MT	DTT
DMQSRPD	MA	Inhibitor
DMQSRPD	RN	6-N,N-dimethylamino-2,3-naphthalimide: a new environment-sensitive fluorescent probe in delta- and mu-selective opioid peptides. J Med Chem. 2006 Jun 15;49(12):3653-8.
DMQSRPD	RU	https://pubmed.ncbi.nlm.nih.gov/16759107

DMF52SH	DI	DMF52SH
DMF52SH	DN	H-Dmt-Tic-Glu-NH-(CH2)5-NH2
DMF52SH	MI	TT27RFC
DMF52SH	MN	Opioid receptor delta (OPRD1)
DMF52SH	MT	DTT
DMF52SH	MA	Inhibitor
DMF52SH	RN	Highly selective fluorescent analogue of the potent delta-opioid receptor antagonist Dmt-Tic. J Med Chem. 2004 Dec 16;47(26):6541-6.
DMF52SH	RU	https://pubmed.ncbi.nlm.nih.gov/15588089

DMF52SH	DI	DMF52SH
DMF52SH	DN	H-Dmt-Tic-Glu-NH-(CH2)5-NH2
DMF52SH	MI	TTKWM86
DMF52SH	MN	Opioid receptor mu (MOP)
DMF52SH	MT	DTT
DMF52SH	MA	Inhibitor
DMF52SH	RN	Highly selective fluorescent analogue of the potent delta-opioid receptor antagonist Dmt-Tic. J Med Chem. 2004 Dec 16;47(26):6541-6.
DMF52SH	RU	https://pubmed.ncbi.nlm.nih.gov/15588089

DM8A573	DI	DM8A573
DM8A573	DN	H-Dmt-Tic-Glu-NH2
DM8A573	MI	TT27RFC
DM8A573	MN	Opioid receptor delta (OPRD1)
DM8A573	MT	DTT
DM8A573	MA	Inhibitor
DM8A573	RN	Highly selective fluorescent analogue of the potent delta-opioid receptor antagonist Dmt-Tic. J Med Chem. 2004 Dec 16;47(26):6541-6.
DM8A573	RU	https://pubmed.ncbi.nlm.nih.gov/15588089

DM8A573	DI	DM8A573
DM8A573	DN	H-Dmt-Tic-Glu-NH2
DM8A573	MI	TTKWM86
DM8A573	MN	Opioid receptor mu (MOP)
DM8A573	MT	DTT
DM8A573	MA	Inhibitor
DM8A573	RN	Highly selective fluorescent analogue of the potent delta-opioid receptor antagonist Dmt-Tic. J Med Chem. 2004 Dec 16;47(26):6541-6.
DM8A573	RU	https://pubmed.ncbi.nlm.nih.gov/15588089

DMHYKBC	DI	DMHYKBC
DMHYKBC	DN	H-Dmt-Tic-Gly-N(Me)-Ph
DMHYKBC	MI	TT27RFC
DMHYKBC	MN	Opioid receptor delta (OPRD1)
DMHYKBC	MT	DTT
DMHYKBC	MA	Inhibitor
DMHYKBC	RN	Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17.
DMHYKBC	RU	https://pubmed.ncbi.nlm.nih.gov/18680274

DMHYKBC	DI	DMHYKBC
DMHYKBC	DN	H-Dmt-Tic-Gly-N(Me)-Ph
DMHYKBC	MI	TTKWM86
DMHYKBC	MN	Opioid receptor mu (MOP)
DMHYKBC	MT	DTT
DMHYKBC	MA	Inhibitor
DMHYKBC	RN	Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17.
DMHYKBC	RU	https://pubmed.ncbi.nlm.nih.gov/18680274

DMM39YW	DI	DMM39YW
DMM39YW	DN	H-Dmt-Tic-Gly-NH-Bzl
DMM39YW	MI	TT27RFC
DMM39YW	MN	Opioid receptor delta (OPRD1)
DMM39YW	MT	DTT
DMM39YW	MA	Inhibitor
DMM39YW	RN	Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17.
DMM39YW	RU	https://pubmed.ncbi.nlm.nih.gov/18680274

DMM39YW	DI	DMM39YW
DMM39YW	DN	H-Dmt-Tic-Gly-NH-Bzl
DMM39YW	MI	TTKWM86
DMM39YW	MN	Opioid receptor mu (MOP)
DMM39YW	MT	DTT
DMM39YW	MA	Inhibitor
DMM39YW	RN	Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17.
DMM39YW	RU	https://pubmed.ncbi.nlm.nih.gov/18680274

DMH6JOU	DI	DMH6JOU
DMH6JOU	DN	H-Dmt-Tic-Gly-NH-CH2-Bid
DMH6JOU	MI	TT27RFC
DMH6JOU	MN	Opioid receptor delta (OPRD1)
DMH6JOU	MT	DTT
DMH6JOU	MA	Inhibitor
DMH6JOU	RN	New 2',6'-dimethyl-L-tyrosine (Dmt) opioid peptidomimetics based on the Aba-Gly scaffold. Development of unique mu-opioid receptor ligands. J Med Chem. 2006 Jun 29;49(13):3990-3.
DMH6JOU	RU	https://pubmed.ncbi.nlm.nih.gov/16789756

DMH6JOU	DI	DMH6JOU
DMH6JOU	DN	H-Dmt-Tic-Gly-NH-CH2-Bid
DMH6JOU	MI	TTKWM86
DMH6JOU	MN	Opioid receptor mu (MOP)
DMH6JOU	MT	DTT
DMH6JOU	MA	Inhibitor
DMH6JOU	RN	New 2',6'-dimethyl-L-tyrosine (Dmt) opioid peptidomimetics based on the Aba-Gly scaffold. Development of unique mu-opioid receptor ligands. J Med Chem. 2006 Jun 29;49(13):3990-3.
DMH6JOU	RU	https://pubmed.ncbi.nlm.nih.gov/16789756

DMIZ28H	DI	DMIZ28H
DMIZ28H	DN	H-Dmt-Tic-Gly-NH-Ph
DMIZ28H	MI	TT27RFC
DMIZ28H	MN	Opioid receptor delta (OPRD1)
DMIZ28H	MT	DTT
DMIZ28H	MA	Inhibitor
DMIZ28H	RN	Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17.
DMIZ28H	RU	https://pubmed.ncbi.nlm.nih.gov/18680274

DMIZ28H	DI	DMIZ28H
DMIZ28H	DN	H-Dmt-Tic-Gly-NH-Ph
DMIZ28H	MI	TTKWM86
DMIZ28H	MN	Opioid receptor mu (MOP)
DMIZ28H	MT	DTT
DMIZ28H	MA	Inhibitor
DMIZ28H	RN	Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17.
DMIZ28H	RU	https://pubmed.ncbi.nlm.nih.gov/18680274

DM2TY43	DI	DM2TY43
DM2TY43	DN	H-Dmt-Tic-Lys(Ac)-NH-CH2-Ph
DM2TY43	MI	TT27RFC
DM2TY43	MN	Opioid receptor delta (OPRD1)
DM2TY43	MT	DTT
DM2TY43	MA	Inhibitor
DM2TY43	RN	Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7.
DM2TY43	RU	https://pubmed.ncbi.nlm.nih.gov/16942034

DM2TY43	DI	DM2TY43
DM2TY43	DN	H-Dmt-Tic-Lys(Ac)-NH-CH2-Ph
DM2TY43	MI	TTKWM86
DM2TY43	MN	Opioid receptor mu (MOP)
DM2TY43	MT	DTT
DM2TY43	MA	Inhibitor
DM2TY43	RN	Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7.
DM2TY43	RU	https://pubmed.ncbi.nlm.nih.gov/16942034

DMZH9P5	DI	DMZH9P5
DMZH9P5	DN	H-Dmt-Tic-Lys(Ac)-NH-Ph
DMZH9P5	MI	TT27RFC
DMZH9P5	MN	Opioid receptor delta (OPRD1)
DMZH9P5	MT	DTT
DMZH9P5	MA	Inhibitor
DMZH9P5	RN	Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7.
DMZH9P5	RU	https://pubmed.ncbi.nlm.nih.gov/16942034

DMZH9P5	DI	DMZH9P5
DMZH9P5	DN	H-Dmt-Tic-Lys(Ac)-NH-Ph
DMZH9P5	MI	TTKWM86
DMZH9P5	MN	Opioid receptor mu (MOP)
DMZH9P5	MT	DTT
DMZH9P5	MA	Inhibitor
DMZH9P5	RN	Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7.
DMZH9P5	RU	https://pubmed.ncbi.nlm.nih.gov/16942034

DMP8HFA	DI	DMP8HFA
DMP8HFA	DN	H-Dmt-Tic-Lys(Z)-NH-CH2-Ph
DMP8HFA	MI	TT27RFC
DMP8HFA	MN	Opioid receptor delta (OPRD1)
DMP8HFA	MT	DTT
DMP8HFA	MA	Inhibitor
DMP8HFA	RN	Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7.
DMP8HFA	RU	https://pubmed.ncbi.nlm.nih.gov/16942034

DMP8HFA	DI	DMP8HFA
DMP8HFA	DN	H-Dmt-Tic-Lys(Z)-NH-CH2-Ph
DMP8HFA	MI	TTKWM86
DMP8HFA	MN	Opioid receptor mu (MOP)
DMP8HFA	MT	DTT
DMP8HFA	MA	Inhibitor
DMP8HFA	RN	Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7.
DMP8HFA	RU	https://pubmed.ncbi.nlm.nih.gov/16942034

DMBXGLA	DI	DMBXGLA
DMBXGLA	DN	H-Dmt-Tic-Lys(Z)-NH-Ph
DMBXGLA	MI	TT27RFC
DMBXGLA	MN	Opioid receptor delta (OPRD1)
DMBXGLA	MT	DTT
DMBXGLA	MA	Inhibitor
DMBXGLA	RN	Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7.
DMBXGLA	RU	https://pubmed.ncbi.nlm.nih.gov/16942034

DMBXGLA	DI	DMBXGLA
DMBXGLA	DN	H-Dmt-Tic-Lys(Z)-NH-Ph
DMBXGLA	MI	TTKWM86
DMBXGLA	MN	Opioid receptor mu (MOP)
DMBXGLA	MT	DTT
DMBXGLA	MA	Inhibitor
DMBXGLA	RN	Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7.
DMBXGLA	RU	https://pubmed.ncbi.nlm.nih.gov/16942034

DMDJ9PE	DI	DMDJ9PE
DMDJ9PE	DN	H-Dmt-Tic-Lys-NH-CH2-Ph
DMDJ9PE	MI	TT27RFC
DMDJ9PE	MN	Opioid receptor delta (OPRD1)
DMDJ9PE	MT	DTT
DMDJ9PE	MA	Inhibitor
DMDJ9PE	RN	Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7.
DMDJ9PE	RU	https://pubmed.ncbi.nlm.nih.gov/16942034

DMDJ9PE	DI	DMDJ9PE
DMDJ9PE	DN	H-Dmt-Tic-Lys-NH-CH2-Ph
DMDJ9PE	MI	TTKWM86
DMDJ9PE	MN	Opioid receptor mu (MOP)
DMDJ9PE	MT	DTT
DMDJ9PE	MA	Inhibitor
DMDJ9PE	RN	Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7.
DMDJ9PE	RU	https://pubmed.ncbi.nlm.nih.gov/16942034

DMT3Y6E	DI	DMT3Y6E
DMT3Y6E	DN	H-Dmt-Tic-Lys-NH-Ph
DMT3Y6E	MI	TT27RFC
DMT3Y6E	MN	Opioid receptor delta (OPRD1)
DMT3Y6E	MT	DTT
DMT3Y6E	MA	Inhibitor
DMT3Y6E	RN	Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7.
DMT3Y6E	RU	https://pubmed.ncbi.nlm.nih.gov/16942034

DMT3Y6E	DI	DMT3Y6E
DMT3Y6E	DN	H-Dmt-Tic-Lys-NH-Ph
DMT3Y6E	MI	TTKWM86
DMT3Y6E	MN	Opioid receptor mu (MOP)
DMT3Y6E	MT	DTT
DMT3Y6E	MA	Inhibitor
DMT3Y6E	RN	Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7.
DMT3Y6E	RU	https://pubmed.ncbi.nlm.nih.gov/16942034

DMMJ9YN	DI	DMMJ9YN
DMMJ9YN	DN	H-Dmt-Tic-NH-(CH2)6-NH-Dmt-H
DMMJ9YN	MI	TT27RFC
DMMJ9YN	MN	Opioid receptor delta (OPRD1)
DMMJ9YN	MT	DTT
DMMJ9YN	MA	Inhibitor
DMMJ9YN	RN	New series of potent delta-opioid antagonists containing the H-Dmt-Tic-NH-hexyl-NH-R motif. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5517-20.
DMMJ9YN	RU	https://pubmed.ncbi.nlm.nih.gov/16183273

DMMJ9YN	DI	DMMJ9YN
DMMJ9YN	DN	H-Dmt-Tic-NH-(CH2)6-NH-Dmt-H
DMMJ9YN	MI	TTKWM86
DMMJ9YN	MN	Opioid receptor mu (MOP)
DMMJ9YN	MT	DTT
DMMJ9YN	MA	Inhibitor
DMMJ9YN	RN	New series of potent delta-opioid antagonists containing the H-Dmt-Tic-NH-hexyl-NH-R motif. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5517-20.
DMMJ9YN	RU	https://pubmed.ncbi.nlm.nih.gov/16183273

DM0BGNE	DI	DM0BGNE
DM0BGNE	DN	H-Dmt-Tic-NH-(CH2)6-NH-Phe-H
DM0BGNE	MI	TT27RFC
DM0BGNE	MN	Opioid receptor delta (OPRD1)
DM0BGNE	MT	DTT
DM0BGNE	MA	Inhibitor
DM0BGNE	RN	New series of potent delta-opioid antagonists containing the H-Dmt-Tic-NH-hexyl-NH-R motif. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5517-20.
DM0BGNE	RU	https://pubmed.ncbi.nlm.nih.gov/16183273

DM0BGNE	DI	DM0BGNE
DM0BGNE	DN	H-Dmt-Tic-NH-(CH2)6-NH-Phe-H
DM0BGNE	MI	TTKWM86
DM0BGNE	MN	Opioid receptor mu (MOP)
DM0BGNE	MT	DTT
DM0BGNE	MA	Inhibitor
DM0BGNE	RN	New series of potent delta-opioid antagonists containing the H-Dmt-Tic-NH-hexyl-NH-R motif. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5517-20.
DM0BGNE	RU	https://pubmed.ncbi.nlm.nih.gov/16183273

DMQ586T	DI	DMQ586T
DMQ586T	DN	H-Dmt-Tic-NH-(CH2)6-NH-Tic-H
DMQ586T	MI	TT27RFC
DMQ586T	MN	Opioid receptor delta (OPRD1)
DMQ586T	MT	DTT
DMQ586T	MA	Inhibitor
DMQ586T	RN	New series of potent delta-opioid antagonists containing the H-Dmt-Tic-NH-hexyl-NH-R motif. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5517-20.
DMQ586T	RU	https://pubmed.ncbi.nlm.nih.gov/16183273

DMQ586T	DI	DMQ586T
DMQ586T	DN	H-Dmt-Tic-NH-(CH2)6-NH-Tic-H
DMQ586T	MI	TTKWM86
DMQ586T	MN	Opioid receptor mu (MOP)
DMQ586T	MT	DTT
DMQ586T	MA	Inhibitor
DMQ586T	RN	New series of potent delta-opioid antagonists containing the H-Dmt-Tic-NH-hexyl-NH-R motif. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5517-20.
DMQ586T	RU	https://pubmed.ncbi.nlm.nih.gov/16183273

DMAU2H6	DI	DMAU2H6
DMAU2H6	DN	H-Dmt-Tic-NH-(D)-CH[(CH2)4-NH-Z]-Bid
DMAU2H6	MI	TT27RFC
DMAU2H6	MN	Opioid receptor delta (OPRD1)
DMAU2H6	MT	DTT
DMAU2H6	MA	Inhibitor
DMAU2H6	RN	Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7.
DMAU2H6	RU	https://pubmed.ncbi.nlm.nih.gov/16942034

DMAU2H6	DI	DMAU2H6
DMAU2H6	DN	H-Dmt-Tic-NH-(D)-CH[(CH2)4-NH-Z]-Bid
DMAU2H6	MI	TTKWM86
DMAU2H6	MN	Opioid receptor mu (MOP)
DMAU2H6	MT	DTT
DMAU2H6	MA	Inhibitor
DMAU2H6	RN	Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7.
DMAU2H6	RU	https://pubmed.ncbi.nlm.nih.gov/16942034

DM5TZ1J	DI	DM5TZ1J
DM5TZ1J	DN	H-Dmt-Tic-NH-(R)CH(CH2-COOH)-Bid
DM5TZ1J	MI	TT27RFC
DM5TZ1J	MN	Opioid receptor delta (OPRD1)
DM5TZ1J	MT	DTT
DM5TZ1J	MA	Inhibitor
DM5TZ1J	RN	Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17.
DM5TZ1J	RU	https://pubmed.ncbi.nlm.nih.gov/18680274

DM5TZ1J	DI	DM5TZ1J
DM5TZ1J	DN	H-Dmt-Tic-NH-(R)CH(CH2-COOH)-Bid
DM5TZ1J	MI	TTKWM86
DM5TZ1J	MN	Opioid receptor mu (MOP)
DM5TZ1J	MT	DTT
DM5TZ1J	MA	Inhibitor
DM5TZ1J	RN	Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17.
DM5TZ1J	RU	https://pubmed.ncbi.nlm.nih.gov/18680274

DMIDLPT	DI	DMIDLPT
DMIDLPT	DN	H-Dmt-Tic-NH-(R)CH(CH2-COOH)-Bid(N1-Me)
DMIDLPT	MI	TT27RFC
DMIDLPT	MN	Opioid receptor delta (OPRD1)
DMIDLPT	MT	DTT
DMIDLPT	MA	Inhibitor
DMIDLPT	RN	Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17.
DMIDLPT	RU	https://pubmed.ncbi.nlm.nih.gov/18680274

DMIDLPT	DI	DMIDLPT
DMIDLPT	DN	H-Dmt-Tic-NH-(R)CH(CH2-COOH)-Bid(N1-Me)
DMIDLPT	MI	TTKWM86
DMIDLPT	MN	Opioid receptor mu (MOP)
DMIDLPT	MT	DTT
DMIDLPT	MA	Inhibitor
DMIDLPT	RN	Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17.
DMIDLPT	RU	https://pubmed.ncbi.nlm.nih.gov/18680274

DMNEAQ9	DI	DMNEAQ9
DMNEAQ9	DN	H-Dmt-Tic-NH-(S)CH(CH2-COOH)-Bid(N1-Me)
DMNEAQ9	MI	TT27RFC
DMNEAQ9	MN	Opioid receptor delta (OPRD1)
DMNEAQ9	MT	DTT
DMNEAQ9	MA	Inhibitor
DMNEAQ9	RN	Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17.
DMNEAQ9	RU	https://pubmed.ncbi.nlm.nih.gov/18680274

DMNEAQ9	DI	DMNEAQ9
DMNEAQ9	DN	H-Dmt-Tic-NH-(S)CH(CH2-COOH)-Bid(N1-Me)
DMNEAQ9	MI	TTKWM86
DMNEAQ9	MN	Opioid receptor mu (MOP)
DMNEAQ9	MT	DTT
DMNEAQ9	MA	Inhibitor
DMNEAQ9	RN	Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17.
DMNEAQ9	RU	https://pubmed.ncbi.nlm.nih.gov/18680274

DMQEDP5	DI	DMQEDP5
DMQEDP5	DN	H-Dmt-Tic-NH-CH[(CH2)4-NH2]-Bid
DMQEDP5	MI	TT27RFC
DMQEDP5	MN	Opioid receptor delta (OPRD1)
DMQEDP5	MT	DTT
DMQEDP5	MA	Inhibitor
DMQEDP5	RN	Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7.
DMQEDP5	RU	https://pubmed.ncbi.nlm.nih.gov/16942034

DMQEDP5	DI	DMQEDP5
DMQEDP5	DN	H-Dmt-Tic-NH-CH[(CH2)4-NH2]-Bid
DMQEDP5	MI	TTKWM86
DMQEDP5	MN	Opioid receptor mu (MOP)
DMQEDP5	MT	DTT
DMQEDP5	MA	Inhibitor
DMQEDP5	RN	Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7.
DMQEDP5	RU	https://pubmed.ncbi.nlm.nih.gov/16942034

DM8PJ92	DI	DM8PJ92
DM8PJ92	DN	H-Dmt-Tic-NH-CH[(CH2)4-NH-Ac]-Bid
DM8PJ92	MI	TT27RFC
DM8PJ92	MN	Opioid receptor delta (OPRD1)
DM8PJ92	MT	DTT
DM8PJ92	MA	Inhibitor
DM8PJ92	RN	Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7.
DM8PJ92	RU	https://pubmed.ncbi.nlm.nih.gov/16942034

DM8PJ92	DI	DM8PJ92
DM8PJ92	DN	H-Dmt-Tic-NH-CH[(CH2)4-NH-Ac]-Bid
DM8PJ92	MI	TTKWM86
DM8PJ92	MN	Opioid receptor mu (MOP)
DM8PJ92	MT	DTT
DM8PJ92	MA	Inhibitor
DM8PJ92	RN	Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7.
DM8PJ92	RU	https://pubmed.ncbi.nlm.nih.gov/16942034

DMQ4ILK	DI	DMQ4ILK
DMQ4ILK	DN	H-Dmt-Tic-NH-CH[(CH2)4-NH-Z]-Bid
DMQ4ILK	MI	TT27RFC
DMQ4ILK	MN	Opioid receptor delta (OPRD1)
DMQ4ILK	MT	DTT
DMQ4ILK	MA	Inhibitor
DMQ4ILK	RN	Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7.
DMQ4ILK	RU	https://pubmed.ncbi.nlm.nih.gov/16942034

DMQ4ILK	DI	DMQ4ILK
DMQ4ILK	DN	H-Dmt-Tic-NH-CH[(CH2)4-NH-Z]-Bid
DMQ4ILK	MI	TTKWM86
DMQ4ILK	MN	Opioid receptor mu (MOP)
DMQ4ILK	MT	DTT
DMQ4ILK	MA	Inhibitor
DMQ4ILK	RN	Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7.
DMQ4ILK	RU	https://pubmed.ncbi.nlm.nih.gov/16942034

DM4IUCW	DI	DM4IUCW
DM4IUCW	DN	H-Dmt-Tic-NH-CH2-Boa
DM4IUCW	MI	TT27RFC
DM4IUCW	MN	Opioid receptor delta (OPRD1)
DM4IUCW	MT	DTT
DM4IUCW	MA	Inhibitor
DM4IUCW	RN	Role of benzimidazole (Bid) in the delta-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH(2)-Bid (UFP-502). Bioorg Med Chem. 2008 Mar 15;16(6):3032-8.
DM4IUCW	RU	https://pubmed.ncbi.nlm.nih.gov/18178091

DM4IUCW	DI	DM4IUCW
DM4IUCW	DN	H-Dmt-Tic-NH-CH2-Boa
DM4IUCW	MI	TTKWM86
DM4IUCW	MN	Opioid receptor mu (MOP)
DM4IUCW	MT	DTT
DM4IUCW	MA	Inhibitor
DM4IUCW	RN	Role of benzimidazole (Bid) in the delta-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH(2)-Bid (UFP-502). Bioorg Med Chem. 2008 Mar 15;16(6):3032-8.
DM4IUCW	RU	https://pubmed.ncbi.nlm.nih.gov/18178091

DMZ8C0U	DI	DMZ8C0U
DMZ8C0U	DN	H-Dmt-Tic-NH-CH2-Bta
DMZ8C0U	MI	TT27RFC
DMZ8C0U	MN	Opioid receptor delta (OPRD1)
DMZ8C0U	MT	DTT
DMZ8C0U	MA	Inhibitor
DMZ8C0U	RN	Role of benzimidazole (Bid) in the delta-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH(2)-Bid (UFP-502). Bioorg Med Chem. 2008 Mar 15;16(6):3032-8.
DMZ8C0U	RU	https://pubmed.ncbi.nlm.nih.gov/18178091

DMZ8C0U	DI	DMZ8C0U
DMZ8C0U	DN	H-Dmt-Tic-NH-CH2-Bta
DMZ8C0U	MI	TTKWM86
DMZ8C0U	MN	Opioid receptor mu (MOP)
DMZ8C0U	MT	DTT
DMZ8C0U	MA	Inhibitor
DMZ8C0U	RN	Role of benzimidazole (Bid) in the delta-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH(2)-Bid (UFP-502). Bioorg Med Chem. 2008 Mar 15;16(6):3032-8.
DMZ8C0U	RU	https://pubmed.ncbi.nlm.nih.gov/18178091

DMYJAW4	DI	DMYJAW4
DMYJAW4	DN	H-Dmt-Tic-NH-CH2-CH2-NH2
DMYJAW4	MI	TT27RFC
DMYJAW4	MN	Opioid receptor delta (OPRD1)
DMYJAW4	MT	DTT
DMYJAW4	MA	Inhibitor
DMYJAW4	RN	A new opioid designed multiple ligand derived from the micro opioid agonist endomorphin-2 and the delta opioid antagonist pharmacophore Dmt-Tic. Bioorg Med Chem. 2007 Nov 15;15(22):6876-81.
DMYJAW4	RU	https://pubmed.ncbi.nlm.nih.gov/17851080

DMYJAW4	DI	DMYJAW4
DMYJAW4	DN	H-Dmt-Tic-NH-CH2-CH2-NH2
DMYJAW4	MI	TTKWM86
DMYJAW4	MN	Opioid receptor mu (MOP)
DMYJAW4	MT	DTT
DMYJAW4	MA	Inhibitor
DMYJAW4	RN	A new opioid designed multiple ligand derived from the micro opioid agonist endomorphin-2 and the delta opioid antagonist pharmacophore Dmt-Tic. Bioorg Med Chem. 2007 Nov 15;15(22):6876-81.
DMYJAW4	RU	https://pubmed.ncbi.nlm.nih.gov/17851080

DMJ2F8M	DI	DMJ2F8M
DMJ2F8M	DN	H-Dmt-Tic-NH-CH2-Imid
DMJ2F8M	MI	TT27RFC
DMJ2F8M	MN	Opioid receptor delta (OPRD1)
DMJ2F8M	MT	DTT
DMJ2F8M	MA	Inhibitor
DMJ2F8M	RN	Role of benzimidazole (Bid) in the delta-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH(2)-Bid (UFP-502). Bioorg Med Chem. 2008 Mar 15;16(6):3032-8.
DMJ2F8M	RU	https://pubmed.ncbi.nlm.nih.gov/18178091

DMJ2F8M	DI	DMJ2F8M
DMJ2F8M	DN	H-Dmt-Tic-NH-CH2-Imid
DMJ2F8M	MI	TTKWM86
DMJ2F8M	MN	Opioid receptor mu (MOP)
DMJ2F8M	MT	DTT
DMJ2F8M	MA	Inhibitor
DMJ2F8M	RN	Role of benzimidazole (Bid) in the delta-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH(2)-Bid (UFP-502). Bioorg Med Chem. 2008 Mar 15;16(6):3032-8.
DMJ2F8M	RU	https://pubmed.ncbi.nlm.nih.gov/18178091

DMKGIQJ	DI	DMKGIQJ
DMKGIQJ	DN	H-Dmt-Tic-NH-CH2-ImidPh
DMKGIQJ	MI	TT27RFC
DMKGIQJ	MN	Opioid receptor delta (OPRD1)
DMKGIQJ	MT	DTT
DMKGIQJ	MA	Inhibitor
DMKGIQJ	RN	Role of benzimidazole (Bid) in the delta-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH(2)-Bid (UFP-502). Bioorg Med Chem. 2008 Mar 15;16(6):3032-8.
DMKGIQJ	RU	https://pubmed.ncbi.nlm.nih.gov/18178091

DMKGIQJ	DI	DMKGIQJ
DMKGIQJ	DN	H-Dmt-Tic-NH-CH2-ImidPh
DMKGIQJ	MI	TTKWM86
DMKGIQJ	MN	Opioid receptor mu (MOP)
DMKGIQJ	MT	DTT
DMKGIQJ	MA	Inhibitor
DMKGIQJ	RN	Role of benzimidazole (Bid) in the delta-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH(2)-Bid (UFP-502). Bioorg Med Chem. 2008 Mar 15;16(6):3032-8.
DMKGIQJ	RU	https://pubmed.ncbi.nlm.nih.gov/18178091

DMNY3A1	DI	DMNY3A1
DMNY3A1	DN	H-Dmt-Tic-NH-CH2-Indl
DMNY3A1	MI	TT27RFC
DMNY3A1	MN	Opioid receptor delta (OPRD1)
DMNY3A1	MT	DTT
DMNY3A1	MA	Inhibitor
DMNY3A1	RN	Role of benzimidazole (Bid) in the delta-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH(2)-Bid (UFP-502). Bioorg Med Chem. 2008 Mar 15;16(6):3032-8.
DMNY3A1	RU	https://pubmed.ncbi.nlm.nih.gov/18178091

DMNY3A1	DI	DMNY3A1
DMNY3A1	DN	H-Dmt-Tic-NH-CH2-Indl
DMNY3A1	MI	TTKWM86
DMNY3A1	MN	Opioid receptor mu (MOP)
DMNY3A1	MT	DTT
DMNY3A1	MA	Inhibitor
DMNY3A1	RN	Role of benzimidazole (Bid) in the delta-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH(2)-Bid (UFP-502). Bioorg Med Chem. 2008 Mar 15;16(6):3032-8.
DMNY3A1	RU	https://pubmed.ncbi.nlm.nih.gov/18178091

DMZWUFK	DI	DMZWUFK
DMZWUFK	DN	H-Dmt-Tic-NH-CH2-Indn
DMZWUFK	MI	TT27RFC
DMZWUFK	MN	Opioid receptor delta (OPRD1)
DMZWUFK	MT	DTT
DMZWUFK	MA	Inhibitor
DMZWUFK	RN	Role of benzimidazole (Bid) in the delta-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH(2)-Bid (UFP-502). Bioorg Med Chem. 2008 Mar 15;16(6):3032-8.
DMZWUFK	RU	https://pubmed.ncbi.nlm.nih.gov/18178091

DMZWUFK	DI	DMZWUFK
DMZWUFK	DN	H-Dmt-Tic-NH-CH2-Indn
DMZWUFK	MI	TTKWM86
DMZWUFK	MN	Opioid receptor mu (MOP)
DMZWUFK	MT	DTT
DMZWUFK	MA	Inhibitor
DMZWUFK	RN	Role of benzimidazole (Bid) in the delta-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH(2)-Bid (UFP-502). Bioorg Med Chem. 2008 Mar 15;16(6):3032-8.
DMZWUFK	RU	https://pubmed.ncbi.nlm.nih.gov/18178091

DML8S7J	DI	DML8S7J
DML8S7J	DN	H-D-Phe-c[Cys-Ala-D-Trp-Lys-Thr-Cys]-Thr-NH2
DML8S7J	MI	TTZ6T9E
DML8S7J	MN	Somatostatin receptor type 2 (SSTR2)
DML8S7J	MT	DTT
DML8S7J	MA	Inhibitor
DML8S7J	RN	Novel sst2-selective somatostatin agonists. Three-dimensional consensus structure by NMR. J Med Chem. 2006 Jul 27;49(15):4487-96.
DML8S7J	RU	https://pubmed.ncbi.nlm.nih.gov/16854054

DML8S7J	DI	DML8S7J
DML8S7J	DN	H-D-Phe-c[Cys-Ala-D-Trp-Lys-Thr-Cys]-Thr-NH2
DML8S7J	MI	TTJX3UE
DML8S7J	MN	Somatostatin receptor type 3 (SSTR3)
DML8S7J	MT	DTT
DML8S7J	MA	Inhibitor
DML8S7J	RN	Novel sst2-selective somatostatin agonists. Three-dimensional consensus structure by NMR. J Med Chem. 2006 Jul 27;49(15):4487-96.
DML8S7J	RU	https://pubmed.ncbi.nlm.nih.gov/16854054

DML8S7J	DI	DML8S7J
DML8S7J	DN	H-D-Phe-c[Cys-Ala-D-Trp-Lys-Thr-Cys]-Thr-NH2
DML8S7J	MI	TT2BC4G
DML8S7J	MN	Somatostatin receptor type 5 (SSTR5)
DML8S7J	MT	DTT
DML8S7J	MA	Inhibitor
DML8S7J	RN	Novel sst2-selective somatostatin agonists. Three-dimensional consensus structure by NMR. J Med Chem. 2006 Jul 27;49(15):4487-96.
DML8S7J	RU	https://pubmed.ncbi.nlm.nih.gov/16854054

DMLCIZ8	DI	DMLCIZ8
DMLCIZ8	DN	H-DPhe-c[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-NH2
DMLCIZ8	MI	TTZ6T9E
DMLCIZ8	MN	Somatostatin receptor type 2 (SSTR2)
DMLCIZ8	MT	DTT
DMLCIZ8	MA	Inhibitor
DMLCIZ8	RN	Novel sst2-selective somatostatin agonists. Three-dimensional consensus structure by NMR. J Med Chem. 2006 Jul 27;49(15):4487-96.
DMLCIZ8	RU	https://pubmed.ncbi.nlm.nih.gov/16854054

DMLCIZ8	DI	DMLCIZ8
DMLCIZ8	DN	H-DPhe-c[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-NH2
DMLCIZ8	MI	TTJX3UE
DMLCIZ8	MN	Somatostatin receptor type 3 (SSTR3)
DMLCIZ8	MT	DTT
DMLCIZ8	MA	Inhibitor
DMLCIZ8	RN	Novel sst2-selective somatostatin agonists. Three-dimensional consensus structure by NMR. J Med Chem. 2006 Jul 27;49(15):4487-96.
DMLCIZ8	RU	https://pubmed.ncbi.nlm.nih.gov/16854054

DMLCIZ8	DI	DMLCIZ8
DMLCIZ8	DN	H-DPhe-c[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-NH2
DMLCIZ8	MI	TT2BC4G
DMLCIZ8	MN	Somatostatin receptor type 5 (SSTR5)
DMLCIZ8	MT	DTT
DMLCIZ8	MA	Inhibitor
DMLCIZ8	RN	Novel sst2-selective somatostatin agonists. Three-dimensional consensus structure by NMR. J Med Chem. 2006 Jul 27;49(15):4487-96.
DMLCIZ8	RU	https://pubmed.ncbi.nlm.nih.gov/16854054

DM1EGC3	DI	DM1EGC3
DM1EGC3	DN	H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2
DM1EGC3	MI	TTZ6T9E
DM1EGC3	MN	Somatostatin receptor type 2 (SSTR2)
DM1EGC3	MT	DTT
DM1EGC3	MA	Inhibitor
DM1EGC3	RN	Discovery of iodinated somatostatin analogues selective for hsst2 and hsst5 with excellent inhibition of growth hormone and prolactin release from ... J Med Chem. 2005 Oct 20;48(21):6643-52.
DM1EGC3	RU	https://pubmed.ncbi.nlm.nih.gov/16220980

DM1EGC3	DI	DM1EGC3
DM1EGC3	DN	H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2
DM1EGC3	MI	TT2BC4G
DM1EGC3	MN	Somatostatin receptor type 5 (SSTR5)
DM1EGC3	MT	DTT
DM1EGC3	MA	Inhibitor
DM1EGC3	RN	Discovery of iodinated somatostatin analogues selective for hsst2 and hsst5 with excellent inhibition of growth hormone and prolactin release from ... J Med Chem. 2005 Oct 20;48(21):6643-52.
DM1EGC3	RU	https://pubmed.ncbi.nlm.nih.gov/16220980

DMLRUVA	DI	DMLRUVA
DMLRUVA	DN	HDS-029
DMLRUVA	MI	TTGKNB4
DMLRUVA	MN	Epidermal growth factor receptor (EGFR)
DMLRUVA	MT	DTT
DMLRUVA	MA	Inhibitor
DMLRUVA	RN	Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB... J Med Chem. 2006 Feb 23;49(4):1475-85.
DMLRUVA	RU	https://pubmed.ncbi.nlm.nih.gov/16480284

DMLRUVA	DI	DMLRUVA
DMLRUVA	DN	HDS-029
DMLRUVA	MI	TTR5TV4
DMLRUVA	MN	ERBB2 messenger RNA (HER2 mRNA)
DMLRUVA	MT	DTT
DMLRUVA	MA	Inhibitor
DMLRUVA	RN	Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB... J Med Chem. 2006 Feb 23;49(4):1475-85.
DMLRUVA	RU	https://pubmed.ncbi.nlm.nih.gov/16480284

DMLRUVA	DI	DMLRUVA
DMLRUVA	DN	HDS-029
DMLRUVA	MI	TT0JESD
DMLRUVA	MN	Erbb4 tyrosine kinase receptor (Erbb-4)
DMLRUVA	MT	DTT
DMLRUVA	MA	Inhibitor
DMLRUVA	RN	Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB... J Med Chem. 2006 Feb 23;49(4):1475-85.
DMLRUVA	RU	https://pubmed.ncbi.nlm.nih.gov/16480284

DMY4QE6	DI	DMY4QE6
DMY4QE6	DN	H-D-Tca-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2
DMY4QE6	MI	TT27RFC
DMY4QE6	MN	Opioid receptor delta (OPRD1)
DMY4QE6	MT	DTT
DMY4QE6	MA	Inhibitor
DMY4QE6	RN	Opiate aromatic pharmacophore structure-activity relationships in CTAP analogues determined by topographical bias, two-dimensional NMR, and biologi... J Med Chem. 2000 Feb 24;43(4):569-80.
DMY4QE6	RU	https://pubmed.ncbi.nlm.nih.gov/10691683

DMY4QE6	DI	DMY4QE6
DMY4QE6	DN	H-D-Tca-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2
DMY4QE6	MI	TTKWM86
DMY4QE6	MN	Opioid receptor mu (MOP)
DMY4QE6	MT	DTT
DMY4QE6	MA	Inhibitor
DMY4QE6	RN	Opiate aromatic pharmacophore structure-activity relationships in CTAP analogues determined by topographical bias, two-dimensional NMR, and biologi... J Med Chem. 2000 Feb 24;43(4):569-80.
DMY4QE6	RU	https://pubmed.ncbi.nlm.nih.gov/10691683

DM8GC36	DI	DM8GC36
DM8GC36	DN	H-D-Tic-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2
DM8GC36	MI	TT27RFC
DM8GC36	MN	Opioid receptor delta (OPRD1)
DM8GC36	MT	DTT
DM8GC36	MA	Inhibitor
DM8GC36	RN	Opiate aromatic pharmacophore structure-activity relationships in CTAP analogues determined by topographical bias, two-dimensional NMR, and biologi... J Med Chem. 2000 Feb 24;43(4):569-80.
DM8GC36	RU	https://pubmed.ncbi.nlm.nih.gov/10691683

DM8GC36	DI	DM8GC36
DM8GC36	DN	H-D-Tic-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2
DM8GC36	MI	TTKWM86
DM8GC36	MN	Opioid receptor mu (MOP)
DM8GC36	MT	DTT
DM8GC36	MA	Inhibitor
DM8GC36	RN	Opiate aromatic pharmacophore structure-activity relationships in CTAP analogues determined by topographical bias, two-dimensional NMR, and biologi... J Med Chem. 2000 Feb 24;43(4):569-80.
DM8GC36	RU	https://pubmed.ncbi.nlm.nih.gov/10691683

DMNAE6J	DI	DMNAE6J
DMNAE6J	DN	H-D-Trp-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2
DMNAE6J	MI	TT27RFC
DMNAE6J	MN	Opioid receptor delta (OPRD1)
DMNAE6J	MT	DTT
DMNAE6J	MA	Inhibitor
DMNAE6J	RN	Opiate aromatic pharmacophore structure-activity relationships in CTAP analogues determined by topographical bias, two-dimensional NMR, and biologi... J Med Chem. 2000 Feb 24;43(4):569-80.
DMNAE6J	RU	https://pubmed.ncbi.nlm.nih.gov/10691683

DMNAE6J	DI	DMNAE6J
DMNAE6J	DN	H-D-Trp-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2
DMNAE6J	MI	TTKWM86
DMNAE6J	MN	Opioid receptor mu (MOP)
DMNAE6J	MT	DTT
DMNAE6J	MA	Inhibitor
DMNAE6J	RN	Opiate aromatic pharmacophore structure-activity relationships in CTAP analogues determined by topographical bias, two-dimensional NMR, and biologi... J Med Chem. 2000 Feb 24;43(4):569-80.
DMNAE6J	RU	https://pubmed.ncbi.nlm.nih.gov/10691683

DM9I5Y0	DI	DM9I5Y0
DM9I5Y0	DN	Heberkinasa
DM9I5Y0	MI	TT2VCLI
DM9I5Y0	MN	Streptococcus Streptokinase (Stre-coc skc)
DM9I5Y0	MT	DTT
DM9I5Y0	MA	Modulator
DM9I5Y0	RN	Biological Activity Analysis of Native and Recombinant Streptokinase Using Clot Lysis and Chromogenic Substrate Assay
DM9I5Y0	RU	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3813160

DMZ4A0R	DI	DMZ4A0R
DMZ4A0R	DN	Hebervis
DMZ4A0R	MI	TTED8JB
DMZ4A0R	MN	Epidermal growth factor (EGF)
DMZ4A0R	MT	DTT
DMZ4A0R	MA	Modulator
DMZ4A0R	RN	Leadership in BioBusiness. Dr Gurinder S Shahi. Page(36).
DMZ4A0R	RU	https://books.google.com.hk/books?id=6qF0AgAAQBAJ&pg=PA36&lpg=PA36&dq=Hebervis++++Epidermal+growth+factor&source=bl&ots=RD745hdy84&sig=5Z2dTG5PlEIIoiJHRtoqvbq5ny8&hl=zh-CN&sa=X&ved=0CB4Q6AEwAWoVChMI6tqlvJDCyAIVUZGOCh1qkgCl#v=onepage&q=Hebervis%20%20%20%20Epidermal%20growth%20factor&f=false

DMQPCDG	DI	DMQPCDG
DMQPCDG	DN	Helenalin-2-methylbutyrate
DMQPCDG	MI	TTSXVID
DMQPCDG	MN	Nuclear factor NF-kappa-B (NFKB)
DMQPCDG	MT	DTT
DMQPCDG	MA	Inhibitor
DMQPCDG	RN	Development of a structural model for NF-kappaB inhibition of sesquiterpene lactones using self-organizing neural networks. J Med Chem. 2006 Apr 6;49(7):2241-52.
DMQPCDG	RU	https://pubmed.ncbi.nlm.nih.gov/16570920

DMPOALD	DI	DMPOALD
DMPOALD	DN	HELENALINMETHACRYLATE
DMPOALD	MI	TTSXVID
DMPOALD	MN	Nuclear factor NF-kappa-B (NFKB)
DMPOALD	MT	DTT
DMPOALD	MA	Inhibitor
DMPOALD	RN	Development of a structural model for NF-kappaB inhibition of sesquiterpene lactones using self-organizing neural networks. J Med Chem. 2006 Apr 6;49(7):2241-52.
DMPOALD	RU	https://pubmed.ncbi.nlm.nih.gov/16570920

DM5MOLY	DI	DM5MOLY
DM5MOLY	DN	HELENAQUINONE
DM5MOLY	MI	TT9V5JH
DM5MOLY	MN	Phospholipase A2 (PLA2G1B)
DM5MOLY	MT	DTT
DM5MOLY	MA	Inhibitor
DM5MOLY	RN	New bioactive halenaquinone derivatives from South Pacific marine sponges of the genus Xestospongia. Bioorg Med Chem. 2010 Aug 15;18(16):6006-11.
DM5MOLY	RU	https://pubmed.ncbi.nlm.nih.gov/20634081

DMIUABO	DI	DMIUABO
DMIUABO	DN	helodermin
DMIUABO	MI	TT4O5P0
DMIUABO	MN	Helodermin-preferring VIP receptor (VIPR2)
DMIUABO	MT	DTT
DMIUABO	MA	Agonist
DMIUABO	RN	Analogues of VIP, helodermin, and PACAP discriminate between rat and human VIP1 and VIP2 receptors. Ann N Y Acad Sci. 1998 Dec 11;865:247-52.
DMIUABO	RU	https://pubmed.ncbi.nlm.nih.gov/9928018

DMIUABO	DI	DMIUABO
DMIUABO	DN	helodermin
DMIUABO	MI	TTCL30I
DMIUABO	MN	Vasoactive intestinal polypeptide receptor 1 (VIPR1)
DMIUABO	MT	DTT
DMIUABO	MA	Agonist
DMIUABO	RN	Stable expression of the recombinant human VIP1 receptor in clonal Chinese hamster ovary cells: pharmacological, functional and molecular properties. Eur J Pharmacol. 1996 Apr 29;302(1-3):207-14.
DMIUABO	RU	https://pubmed.ncbi.nlm.nih.gov/8791009

DMVK36Q	DI	DMVK36Q
DMVK36Q	DN	Hematoporphyrin
DMVK36Q	MI	DTI7UX6
DMVK36Q	MN	Breast cancer resistance protein (ABCG2)
DMVK36Q	MT	DTP
DMVK36Q	MA	Substrate
DMVK36Q	RN	Cellular phototoxicity evoked through the inhibition of human ABC transporter ABCG2 by cyclin-dependent kinase inhibitors in vitro. Pharm Res. 2009 Feb;26(2):449-58.
DMVK36Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/18841444

DMGC287	DI	DMGC287
DMGC287	DN	Heme
DMGC287	MI	TTXV4FI
DMGC287	MN	Albendazole monooxygenase (CYP3A4)
DMGC287	MT	DTT
DMGC287	MA	Inhibitor
DMGC287	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMGC287	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMGC287	DI	DMGC287
DMGC287	DN	Heme
DMGC287	MI	TT2J34L
DMGC287	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMGC287	MT	DTT
DMGC287	MA	Inhibitor
DMGC287	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMGC287	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMGC287	DI	DMGC287
DMGC287	DN	Heme
DMGC287	MI	TTNAW8S
DMGC287	MN	Bacterial Flavohemoglobin (Bact hmp)
DMGC287	MT	DTT
DMGC287	MA	Inhibitor
DMGC287	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMGC287	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMGC287	DI	DMGC287
DMGC287	DN	Heme
DMGC287	MI	TTHDSE2
DMGC287	MN	Bacterial Fumarate reductase flavoprotein (Bact frdA)
DMGC287	MT	DTT
DMGC287	MA	Inhibitor
DMGC287	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMGC287	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMGC287	DI	DMGC287
DMGC287	DN	Heme
DMGC287	MI	TTVZJ7G
DMGC287	MN	Cystathionine beta-synthase (CBS)
DMGC287	MT	DTT
DMGC287	MA	Inhibitor
DMGC287	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMGC287	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMGC287	DI	DMGC287
DMGC287	DN	Heme
DMGC287	MI	TTI6V2A
DMGC287	MN	Heme oxygenase 1 (HMOX1)
DMGC287	MT	DTT
DMGC287	MA	Inhibitor
DMGC287	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMGC287	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMGC287	DI	DMGC287
DMGC287	DN	Heme
DMGC287	MI	TTQO71U
DMGC287	MN	Hemoglobin (HB)
DMGC287	MT	DTT
DMGC287	MA	Inhibitor
DMGC287	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMGC287	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMGC287	DI	DMGC287
DMGC287	DN	Heme
DMGC287	MI	TTBK0PU
DMGC287	MN	Mycobacterium Cytochrome p450 121 (MycB cyp121)
DMGC287	MT	DTT
DMGC287	MA	Inhibitor
DMGC287	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMGC287	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMGC287	DI	DMGC287
DMGC287	DN	Heme
DMGC287	MI	TTZUFI5
DMGC287	MN	Nitric-oxide synthase brain (NOS1)
DMGC287	MT	DTT
DMGC287	MA	Inhibitor
DMGC287	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMGC287	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMGC287	DI	DMGC287
DMGC287	DN	Heme
DMGC287	MI	TTCM4B3
DMGC287	MN	Nitric-oxide synthase endothelial (NOS3)
DMGC287	MT	DTT
DMGC287	MA	Inhibitor
DMGC287	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMGC287	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMGC287	DI	DMGC287
DMGC287	DN	Heme
DMGC287	MI	TTF10I9
DMGC287	MN	Nitric-oxide synthase inducible (NOS2)
DMGC287	MT	DTT
DMGC287	MA	Inhibitor
DMGC287	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMGC287	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMGC287	DI	DMGC287
DMGC287	DN	Heme
DMGC287	MI	TT8NGED
DMGC287	MN	Prostaglandin G/H synthase 1 (COX-1)
DMGC287	MT	DTT
DMGC287	MA	Inhibitor
DMGC287	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMGC287	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMGC287	DI	DMGC287
DMGC287	DN	Heme
DMGC287	MI	TTVKILB
DMGC287	MN	Prostaglandin G/H synthase 2 (COX-2)
DMGC287	MT	DTT
DMGC287	MA	Inhibitor
DMGC287	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMGC287	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMXP276	DI	DMXP276
DMXP276	DN	Hemi-Babim
DMXP276	MI	TT6L509
DMXP276	MN	Coagulation factor IIa (F2)
DMXP276	MT	DTT
DMXP276	MA	Inhibitor
DMXP276	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMXP276	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMF7X31	DI	DMF7X31
DMF7X31	DN	Hemoparatide
DMF7X31	MI	TTEPJL5
DMF7X31	MN	Parathyroid hormone receptor (PTH2R)
DMF7X31	MT	DTT
DMF7X31	MA	Modulator
DMF7X31	RN	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
DMF7X31	RU	https://www.ncbi.nlm.nih.gov/pubmed/27899562

DMY16VG	DI	DMY16VG
DMY16VG	DN	Heparin Pentasaccharide
DMY16VG	MI	TT4QPUL
DMY16VG	MN	Antithrombin-III (ATIII)
DMY16VG	MT	DTT
DMY16VG	MA	Inhibitor
DMY16VG	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMY16VG	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM7U491	DI	DM7U491
DM7U491	DN	Heparin-Cantithrombin III
DM7U491	MI	TT6L509
DM7U491	MN	Coagulation factor IIa (F2)
DM7U491	MT	DTT
DM7U491	MA	Inhibitor
DM7U491	RN	Thrombin inhibitors in acute coronary artery disease. Eur Heart J. 2002 Aug;23(15):1142-4.
DM7U491	RU	https://pubmed.ncbi.nlm.nih.gov/12127916

DMK846H	DI	DMK846H
DMK846H	DN	HEPT
DMK846H	MI	TT84ETX
DMK846H	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMK846H	MT	DTT
DMK846H	MA	Inhibitor
DMK846H	RN	5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S... Bioorg Med Chem Lett. 2004 Jun 21;14(12):3173-6.
DMK846H	RU	https://pubmed.ncbi.nlm.nih.gov/15149669

DMV4GDI	DI	DMV4GDI
DMV4GDI	DN	Heptane-1,2,3-Triol
DMV4GDI	MI	TTH0KSX
DMV4GDI	MN	Rhodopsin (RHO)
DMV4GDI	MT	DTT
DMV4GDI	MA	Inhibitor
DMV4GDI	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMV4GDI	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMCFTB8	DI	DMCFTB8
DMCFTB8	DN	Heptane-2,3-dione
DMCFTB8	MI	TTMF541
DMCFTB8	MN	Liver carboxylesterase (CES1)
DMCFTB8	MT	DTT
DMCFTB8	MA	Inhibitor
DMCFTB8	RN	Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15.
DMCFTB8	RU	https://pubmed.ncbi.nlm.nih.gov/15828829

DMGEO8N	DI	DMGEO8N
DMGEO8N	DN	HEPTANOATE
DMGEO8N	MI	TTTQR47
DMGEO8N	MN	Solute carrier family 22 member 8 (SLC22A8)
DMGEO8N	MT	DTT
DMGEO8N	MA	Inhibitor
DMGEO8N	RN	Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members. J Biol Chem. 2007 Aug 17;282(33):23841-53.
DMGEO8N	RU	https://pubmed.ncbi.nlm.nih.gov/17553798

DM4NY9H	DI	DM4NY9H
DM4NY9H	DN	Heptanoic Acid
DM4NY9H	MI	TT9V5JH
DM4NY9H	MN	Phospholipase A2 (PLA2G1B)
DM4NY9H	MT	DTT
DM4NY9H	MA	Inhibitor
DM4NY9H	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM4NY9H	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMIAQX4	DI	DMIAQX4
DMIAQX4	DN	Heptulose-2-Phosphate
DMIAQX4	MI	TTZHY6R
DMIAQX4	MN	Glycogen phosphorylase muscle form (GP)
DMIAQX4	MT	DTT
DMIAQX4	MA	Inhibitor
DMIAQX4	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMIAQX4	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMKF762	DI	DMKF762
DMKF762	DN	Heptyl 1-Thiohexopyranoside
DMKF762	MI	TTH0KSX
DMKF762	MN	Rhodopsin (RHO)
DMKF762	MT	DTT
DMKF762	MA	Inhibitor
DMKF762	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMKF762	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMPQBN0	DI	DMPQBN0
DMPQBN0	DN	Heptyl-Beta-D-Glucopyranoside
DMPQBN0	MI	TTMW94E
DMPQBN0	MN	FK506-binding protein 1A (FKBP1A)
DMPQBN0	MT	DTT
DMPQBN0	MA	Inhibitor
DMPQBN0	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMPQBN0	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMPQBN0	DI	DMPQBN0
DMPQBN0	DN	Heptyl-Beta-D-Glucopyranoside
DMPQBN0	MI	TT2JWF6
DMPQBN0	MN	Peroxisome proliferator-activated receptor delta (PPARD)
DMPQBN0	MT	DTT
DMPQBN0	MA	Inhibitor
DMPQBN0	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMPQBN0	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DM1NUO5	DI	DM1NUO5
DM1NUO5	DN	Heptyl-methyl-prop-2-ynyl-amine hydrochloride
DM1NUO5	MI	TTGP7BY
DM1NUO5	MN	Monoamine oxidase type B (MAO-B)
DM1NUO5	MT	DTT
DM1NUO5	MA	Inhibitor
DM1NUO5	RN	Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors. J Med Chem. 1992 Oct 2;35(20):3705-13.
DM1NUO5	RU	https://pubmed.ncbi.nlm.nih.gov/1433183

DM0VC84	DI	DM0VC84
DM0VC84	DN	Her2- and PSA-targeted TGX-D1
DM0VC84	MI	TTHBTOP
DM0VC84	MN	PI3-kinase gamma (PIK3CG)
DM0VC84	MT	DTT
DM0VC84	MA	Inhibitor
DM0VC84	RN	Development of a peptide-drug conjugate for prostate cancer therapy. Mol Pharm. 2011 Jun 6;8(3):901-12.
DM0VC84	RU	https://pubmed.ncbi.nlm.nih.gov/21510670

DM8MD52	DI	DM8MD52
DM8MD52	DN	HERBACETIN
DM8MD52	MI	TT50QJ3
DM8MD52	MN	Influenza Neuraminidase (Influ NA)
DM8MD52	MT	DTT
DM8MD52	MA	Inhibitor
DM8MD52	RN	Neuraminidase inhibitory activities of flavonols isolated from Rhodiola rosea roots and their in vitro anti-influenza viral activities. Bioorg Med Chem. 2009 Oct 1;17(19):6816-23.
DM8MD52	RU	https://pubmed.ncbi.nlm.nih.gov/19729316

DMJXBWV	DI	DMJXBWV
DMJXBWV	DN	HERKINORIN
DMJXBWV	MI	TT27RFC
DMJXBWV	MN	Opioid receptor delta (OPRD1)
DMJXBWV	MT	DTT
DMJXBWV	MA	Inhibitor
DMJXBWV	RN	Herkinorin analogues with differential beta-arrestin-2 interactions. J Med Chem. 2008 Apr 24;51(8):2421-31.
DMJXBWV	RU	https://pubmed.ncbi.nlm.nih.gov/18380425

DMJXBWV	DI	DMJXBWV
DMJXBWV	DN	HERKINORIN
DMJXBWV	MI	TTQW87Y
DMJXBWV	MN	Opioid receptor kappa (OPRK1)
DMJXBWV	MT	DTT
DMJXBWV	MA	Inhibitor
DMJXBWV	RN	Herkinorin analogues with differential beta-arrestin-2 interactions. J Med Chem. 2008 Apr 24;51(8):2421-31.
DMJXBWV	RU	https://pubmed.ncbi.nlm.nih.gov/18380425

DMJXBWV	DI	DMJXBWV
DMJXBWV	DN	HERKINORIN
DMJXBWV	MI	TTKWM86
DMJXBWV	MN	Opioid receptor mu (MOP)
DMJXBWV	MT	DTT
DMJXBWV	MA	Inhibitor
DMJXBWV	RN	Herkinorin analogues with differential beta-arrestin-2 interactions. J Med Chem. 2008 Apr 24;51(8):2421-31.
DMJXBWV	RU	https://pubmed.ncbi.nlm.nih.gov/18380425

DM9UASM	DI	DM9UASM
DM9UASM	DN	HERNIARIN
DM9UASM	MI	TTUNARX
DM9UASM	MN	Carbonic anhydrase (CA)
DM9UASM	MT	DTT
DM9UASM	MA	Inhibitor
DM9UASM	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DM9UASM	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DM9UASM	DI	DM9UASM
DM9UASM	DN	HERNIARIN
DM9UASM	MI	TTHQPL7
DM9UASM	MN	Carbonic anhydrase I (CA-I)
DM9UASM	MT	DTT
DM9UASM	MA	Inhibitor
DM9UASM	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DM9UASM	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DM9UASM	DI	DM9UASM
DM9UASM	DN	HERNIARIN
DM9UASM	MI	TTZHA0O
DM9UASM	MN	Carbonic anhydrase IV (CA-IV)
DM9UASM	MT	DTT
DM9UASM	MA	Inhibitor
DM9UASM	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DM9UASM	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DM9UASM	DI	DM9UASM
DM9UASM	DN	HERNIARIN
DM9UASM	MI	TT2LVK8
DM9UASM	MN	Carbonic anhydrase IX (CA-IX)
DM9UASM	MT	DTT
DM9UASM	MA	Inhibitor
DM9UASM	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DM9UASM	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DM9UASM	DI	DM9UASM
DM9UASM	DN	HERNIARIN
DM9UASM	MI	TTCFSPE
DM9UASM	MN	Carbonic anhydrase VI (CA-VI)
DM9UASM	MT	DTT
DM9UASM	MA	Inhibitor
DM9UASM	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DM9UASM	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DM9UASM	DI	DM9UASM
DM9UASM	DN	HERNIARIN
DM9UASM	MI	TTSYM0R
DM9UASM	MN	Carbonic anhydrase XII (CA-XII)
DM9UASM	MT	DTT
DM9UASM	MA	Inhibitor
DM9UASM	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DM9UASM	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DM9UASM	DI	DM9UASM
DM9UASM	DN	HERNIARIN
DM9UASM	MI	TTEYTKG
DM9UASM	MN	Carbonic anhydrase XIV (CA-XIV)
DM9UASM	MT	DTT
DM9UASM	MA	Inhibitor
DM9UASM	RN	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
DM9UASM	RU	https://pubmed.ncbi.nlm.nih.gov/19911821

DM2CK7B	DI	DM2CK7B
DM2CK7B	DN	HESPERADIN
DM2CK7B	MI	TT9RTBL
DM2CK7B	MN	Aurora B messenger RNA (AURKB mRNA)
DM2CK7B	MT	DTT
DM2CK7B	MA	Inhibitor
DM2CK7B	RN	Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors. J Med Chem. 2006 Feb 9;49(3):955-70.
DM2CK7B	RU	https://pubmed.ncbi.nlm.nih.gov/16451062

DMJCHE1	DI	DMJCHE1
DMJCHE1	DN	Hexadecanal
DMJCHE1	MI	TTH0KSX
DMJCHE1	MN	Rhodopsin (RHO)
DMJCHE1	MT	DTT
DMJCHE1	MA	Inhibitor
DMJCHE1	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMJCHE1	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMWUXDZ	DI	DMWUXDZ
DMWUXDZ	DN	Hexadecanoic acid
DMWUXDZ	MI	TTHWMFZ
DMWUXDZ	MN	Fatty acid-binding protein 4 (FABP4)
DMWUXDZ	MT	DTT
DMWUXDZ	MA	Inhibitor
DMWUXDZ	RN	Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4445-8.
DMWUXDZ	RU	https://pubmed.ncbi.nlm.nih.gov/15357969

DMWUXDZ	DI	DMWUXDZ
DMWUXDZ	DN	Hexadecanoic acid
DMWUXDZ	MI	TTNT2S6
DMWUXDZ	MN	Fatty acid-binding protein 5 (FABP5)
DMWUXDZ	MT	DTT
DMWUXDZ	MA	Inhibitor
DMWUXDZ	RN	Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4445-8.
DMWUXDZ	RU	https://pubmed.ncbi.nlm.nih.gov/15357969

DMWUXDZ	DI	DMWUXDZ
DMWUXDZ	DN	Hexadecanoic acid
DMWUXDZ	MI	TTH0KSX
DMWUXDZ	MN	Rhodopsin (RHO)
DMWUXDZ	MT	DTT
DMWUXDZ	MA	Inhibitor
DMWUXDZ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMWUXDZ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMNZLD6	DI	DMNZLD6
DMNZLD6	DN	Hexahydro-cyclopenta[b]pyrrol-(2Z)-ylideneamine
DMNZLD6	MI	TTZUFI5
DMNZLD6	MN	Nitric-oxide synthase brain (NOS1)
DMNZLD6	MT	DTT
DMNZLD6	MA	Inhibitor
DMNZLD6	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DMNZLD6	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DMG0UVT	DI	DMG0UVT
DMG0UVT	DN	Hexahydro-cyclopenta[c]pyrrol-(1Z)-ylideneamine
DMG0UVT	MI	TTZUFI5
DMG0UVT	MN	Nitric-oxide synthase brain (NOS1)
DMG0UVT	MT	DTT
DMG0UVT	MA	Inhibitor
DMG0UVT	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DMG0UVT	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DMG0UVT	DI	DMG0UVT
DMG0UVT	DN	Hexahydro-cyclopenta[c]pyrrol-(1Z)-ylideneamine
DMG0UVT	MI	TTCM4B3
DMG0UVT	MN	Nitric-oxide synthase endothelial (NOS3)
DMG0UVT	MT	DTT
DMG0UVT	MA	Inhibitor
DMG0UVT	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DMG0UVT	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DMG0UVT	DI	DMG0UVT
DMG0UVT	DN	Hexahydro-cyclopenta[c]pyrrol-(1Z)-ylideneamine
DMG0UVT	MI	TTF10I9
DMG0UVT	MN	Nitric-oxide synthase inducible (NOS2)
DMG0UVT	MT	DTT
DMG0UVT	MA	Inhibitor
DMG0UVT	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DMG0UVT	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DMH25OD	DI	DMH25OD
DMH25OD	DN	hexahydrodifenidol
DMH25OD	MI	TTOXS3C
DMH25OD	MN	Muscarinic acetylcholine receptor (CHRM)
DMH25OD	MT	DTT
DMH25OD	MA	Antagonist
DMH25OD	RN	Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol Pharmacol. 1989 Apr;35(4):469-76.
DMH25OD	RU	https://pubmed.ncbi.nlm.nih.gov/2704370

DMH25OD	DI	DMH25OD
DMH25OD	DN	hexahydrodifenidol
DMH25OD	MI	TTQ13Z5
DMH25OD	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMH25OD	MT	DTT
DMH25OD	MA	Antagonist
DMH25OD	RN	Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol Pharmacol. 1989 Apr;35(4):469-76.
DMH25OD	RU	https://pubmed.ncbi.nlm.nih.gov/2704370

DMIB3J2	DI	DMIB3J2
DMIB3J2	DN	Hexahydro-pyrrolizin-(3E)-ylideneamine
DMIB3J2	MI	TTZUFI5
DMIB3J2	MN	Nitric-oxide synthase brain (NOS1)
DMIB3J2	MT	DTT
DMIB3J2	MA	Inhibitor
DMIB3J2	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DMIB3J2	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DM6UAV7	DI	DM6UAV7
DM6UAV7	DN	hexahydrosiladifenidol
DM6UAV7	MI	TTOXS3C
DM6UAV7	MN	Muscarinic acetylcholine receptor (CHRM)
DM6UAV7	MT	DTT
DM6UAV7	MA	Antagonist
DM6UAV7	RN	Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol Pharmacol. 1989 Apr;35(4):469-76.
DM6UAV7	RU	https://pubmed.ncbi.nlm.nih.gov/2704370

DM6UAV7	DI	DM6UAV7
DM6UAV7	DN	hexahydrosiladifenidol
DM6UAV7	MI	TTQ13Z5
DM6UAV7	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DM6UAV7	MT	DTT
DM6UAV7	MA	Antagonist
DM6UAV7	RN	Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol Pharmacol. 1989 Apr;35(4):469-76.
DM6UAV7	RU	https://pubmed.ncbi.nlm.nih.gov/2704370

DMSHF0K	DI	DMSHF0K
DMSHF0K	DN	Hexane-1,6-diamine
DMSHF0K	MI	TTUNARX
DMSHF0K	MN	Carbonic anhydrase (CA)
DMSHF0K	MT	DTT
DMSHF0K	MA	Inhibitor
DMSHF0K	RN	Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22.
DMSHF0K	RU	https://pubmed.ncbi.nlm.nih.gov/20590092

DMSHF0K	DI	DMSHF0K
DMSHF0K	DN	Hexane-1,6-diamine
DMSHF0K	MI	TTHQPL7
DMSHF0K	MN	Carbonic anhydrase I (CA-I)
DMSHF0K	MT	DTT
DMSHF0K	MA	Inhibitor
DMSHF0K	RN	Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22.
DMSHF0K	RU	https://pubmed.ncbi.nlm.nih.gov/20590092

DMSHF0K	DI	DMSHF0K
DMSHF0K	DN	Hexane-1,6-diamine
DMSHF0K	MI	TTZHA0O
DMSHF0K	MN	Carbonic anhydrase IV (CA-IV)
DMSHF0K	MT	DTT
DMSHF0K	MA	Inhibitor
DMSHF0K	RN	Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22.
DMSHF0K	RU	https://pubmed.ncbi.nlm.nih.gov/20590092

DMSHF0K	DI	DMSHF0K
DMSHF0K	DN	Hexane-1,6-diamine
DMSHF0K	MI	TT2LVK8
DMSHF0K	MN	Carbonic anhydrase IX (CA-IX)
DMSHF0K	MT	DTT
DMSHF0K	MA	Inhibitor
DMSHF0K	RN	Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22.
DMSHF0K	RU	https://pubmed.ncbi.nlm.nih.gov/20590092

DMSHF0K	DI	DMSHF0K
DMSHF0K	DN	Hexane-1,6-diamine
DMSHF0K	MI	TTCFSPE
DMSHF0K	MN	Carbonic anhydrase VI (CA-VI)
DMSHF0K	MT	DTT
DMSHF0K	MA	Inhibitor
DMSHF0K	RN	Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22.
DMSHF0K	RU	https://pubmed.ncbi.nlm.nih.gov/20590092

DMSHF0K	DI	DMSHF0K
DMSHF0K	DN	Hexane-1,6-diamine
DMSHF0K	MI	TTSYM0R
DMSHF0K	MN	Carbonic anhydrase XII (CA-XII)
DMSHF0K	MT	DTT
DMSHF0K	MA	Inhibitor
DMSHF0K	RN	Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22.
DMSHF0K	RU	https://pubmed.ncbi.nlm.nih.gov/20590092

DMSHF0K	DI	DMSHF0K
DMSHF0K	DN	Hexane-1,6-diamine
DMSHF0K	MI	TTEYTKG
DMSHF0K	MN	Carbonic anhydrase XIV (CA-XIV)
DMSHF0K	MT	DTT
DMSHF0K	MA	Inhibitor
DMSHF0K	RN	Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22.
DMSHF0K	RU	https://pubmed.ncbi.nlm.nih.gov/20590092

DMWAPGI	DI	DMWAPGI
DMWAPGI	DN	Hexane-1,6-Diol
DMWAPGI	MI	TTYRL6O
DMWAPGI	MN	Glucocorticoid receptor (NR3C1)
DMWAPGI	MT	DTT
DMWAPGI	MA	Inhibitor
DMWAPGI	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMWAPGI	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMWAPGI	DI	DMWAPGI
DMWAPGI	DN	Hexane-1,6-Diol
DMWAPGI	MI	TT9V5JH
DMWAPGI	MN	Phospholipase A2 (PLA2G1B)
DMWAPGI	MT	DTT
DMWAPGI	MA	Inhibitor
DMWAPGI	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMWAPGI	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMJOZYG	DI	DMJOZYG
DMJOZYG	DN	Hexanoic Acid (2,6-diphenylpyrimidin-4-yl)amide
DMJOZYG	MI	TTK25J1
DMJOZYG	MN	Adenosine A1 receptor (ADORA1)
DMJOZYG	MT	DTT
DMJOZYG	MA	Inhibitor
DMJOZYG	RN	2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40.
DMJOZYG	RU	https://pubmed.ncbi.nlm.nih.gov/15588088

DMJOZYG	DI	DMJOZYG
DMJOZYG	DN	Hexanoic Acid (2,6-diphenylpyrimidin-4-yl)amide
DMJOZYG	MI	TTJFY5U
DMJOZYG	MN	Adenosine A3 receptor (ADORA3)
DMJOZYG	MT	DTT
DMJOZYG	MA	Inhibitor
DMJOZYG	RN	2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40.
DMJOZYG	RU	https://pubmed.ncbi.nlm.nih.gov/15588088

DM4U0L1	DI	DM4U0L1
DM4U0L1	DN	Hexanoic acid 2,5-diphenyl-thiazol-4-yl ester
DM4U0L1	MI	TT2J34L
DM4U0L1	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM4U0L1	MT	DTT
DM4U0L1	MA	Inhibitor
DM4U0L1	RN	4-hydroxythiazole inhibitors of 5-lipoxygenase. J Med Chem. 1991 Jul;34(7):2158-65.
DM4U0L1	RU	https://pubmed.ncbi.nlm.nih.gov/2066989

DM0HS7L	DI	DM0HS7L
DM0HS7L	DN	hexocyclium
DM0HS7L	MI	TTZ9SOR
DM0HS7L	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DM0HS7L	MT	DTT
DM0HS7L	MA	Modulator
DM0HS7L	RN	Hexocyclium derivatives with a high selectivity for smooth muscle muscarinic receptors. Br J Pharmacol. 1990 May;100(1):150-2.
DM0HS7L	RU	https://www.ncbi.nlm.nih.gov/pubmed/2372655

DMHTWN9	DI	DMHTWN9
DMHTWN9	DN	Hex-RYYRIK-NH2
DMHTWN9	MI	TTNT7K8
DMHTWN9	MN	Nociceptin receptor (OPRL1)
DMHTWN9	MT	DTT
DMHTWN9	MA	Inhibitor
DMHTWN9	RN	Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist. Bioorg Med Chem. 2008 Mar 1;16(5):2635-44.
DMHTWN9	RU	https://pubmed.ncbi.nlm.nih.gov/18068993

DMBC8KM	DI	DMBC8KM
DMBC8KM	DN	Hexylacrolein
DMBC8KM	MI	DE8RYV5
DMBC8KM	MN	NADPH:quinone reductase (CRYZ)
DMBC8KM	MT	DME
DMBC8KM	MA	Metabolism
DMBC8KM	RN	Kinetic and structural evidence of the alkenal/one reductase specificity of human crystallin. Cell Mol Life Sci. 2011 Mar;68(6):1065-77.
DMBC8KM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20835842

DM3YFG9	DI	DM3YFG9
DM3YFG9	DN	Hexylcarbamoyl fluorouracil
DM3YFG9	MI	TTNHMO8
DM3YFG9	MN	COVID-19 papain-like proteinase (PL-PRO)
DM3YFG9	MT	DTT
DM3YFG9	MA	Inhibitor
DM3YFG9	RN	Structure of Mpro from COVID-19 virus and discovery of its inhibitors. Nature. 2020 Apr 9.
DM3YFG9	RU	https://pubmed.ncbi.nlm.nih.gov/32272481

DM9EW7V	DI	DM9EW7V
DM9EW7V	DN	Hexyl-trimethyl-ammonium
DM9EW7V	MI	TT1RS9F
DM9EW7V	MN	Acetylcholinesterase (AChE)
DM9EW7V	MT	DTT
DM9EW7V	MA	Inhibitor
DM9EW7V	RN	Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors. J Med Chem. 1996 Dec 20;39(26):5064-71.
DM9EW7V	RU	https://pubmed.ncbi.nlm.nih.gov/8978837

DMM4JCA	DI	DMM4JCA
DMM4JCA	DN	HG-1051
DMM4JCA	MI	TTPW9LJ
DMM4JCA	MN	Co-stimulatory molecule 4-1BB (CD137)
DMM4JCA	MT	DTT
DMM4JCA	MA	Modulator
DMM4JCA	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1878).
DMM4JCA	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1878

DM8FD3Z	DI	DM8FD3Z
DM8FD3Z	DN	HG-9-91-01
DM8FD3Z	MI	TT1H6LC
DM8FD3Z	MN	Salt-inducible kinase 1 (SIK1)
DM8FD3Z	MT	DTT
DM8FD3Z	MA	Inhibitor
DM8FD3Z	RN	Phosphorylation of CRTC3 by the salt-inducible kinases controls the interconversion of classically activated and regulatory macrophages. Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):16986-91.
DM8FD3Z	RU	https://pubmed.ncbi.nlm.nih.gov/23033494

DM8FD3Z	DI	DM8FD3Z
DM8FD3Z	DN	HG-9-91-01
DM8FD3Z	MI	TTCUGZR
DM8FD3Z	MN	Salt-inducible kinase 2 (SIK2)
DM8FD3Z	MT	DTT
DM8FD3Z	MA	Inhibitor
DM8FD3Z	RN	Phosphorylation of CRTC3 by the salt-inducible kinases controls the interconversion of classically activated and regulatory macrophages. Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):16986-91.
DM8FD3Z	RU	https://pubmed.ncbi.nlm.nih.gov/23033494

DM8FD3Z	DI	DM8FD3Z
DM8FD3Z	DN	HG-9-91-01
DM8FD3Z	MI	TTW6L4V
DM8FD3Z	MN	SIK family kinase 3 (SIK3)
DM8FD3Z	MT	DTT
DM8FD3Z	MA	Inhibitor
DM8FD3Z	RN	Phosphorylation of CRTC3 by the salt-inducible kinases controls the interconversion of classically activated and regulatory macrophages. Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):16986-91.
DM8FD3Z	RU	https://pubmed.ncbi.nlm.nih.gov/23033494

DMOIPYD	DI	DMOIPYD
DMOIPYD	DN	hGCGR antagonist
DMOIPYD	MI	TT9O6WS
DMOIPYD	MN	Glucagon receptor (GCGR)
DMOIPYD	MT	DTT
DMOIPYD	MA	Antagonist
DMOIPYD	RN	A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects. Diabetes. 2004 Dec;53(12):3267-73.
DMOIPYD	RU	https://pubmed.ncbi.nlm.nih.gov/15561959

DMX2TGD	DI	DMX2TGD
DMX2TGD	DN	H-Gly-D-dmP-Glu-OH
DMX2TGD	MI	TTLD29N
DMX2TGD	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMX2TGD	MT	DTT
DMX2TGD	MA	Inhibitor
DMX2TGD	RN	The neuroprotective activity of GPE tripeptide analogues does not correlate with glutamate receptor binding affinity. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3396-400.
DMX2TGD	RU	https://pubmed.ncbi.nlm.nih.gov/16650992

DMX2TGD	DI	DMX2TGD
DMX2TGD	DN	H-Gly-D-dmP-Glu-OH
DMX2TGD	MI	TTKJEMQ
DMX2TGD	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMX2TGD	MT	DTT
DMX2TGD	MA	Inhibitor
DMX2TGD	RN	The neuroprotective activity of GPE tripeptide analogues does not correlate with glutamate receptor binding affinity. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3396-400.
DMX2TGD	RU	https://pubmed.ncbi.nlm.nih.gov/16650992

DMX2TGD	DI	DMX2TGD
DMX2TGD	DN	H-Gly-D-dmP-Glu-OH
DMX2TGD	MI	TTN9D8E
DMX2TGD	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMX2TGD	MT	DTT
DMX2TGD	MA	Inhibitor
DMX2TGD	RN	The neuroprotective activity of GPE tripeptide analogues does not correlate with glutamate receptor binding affinity. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3396-400.
DMX2TGD	RU	https://pubmed.ncbi.nlm.nih.gov/16650992

DMOYQPM	DI	DMOYQPM
DMOYQPM	DN	H-Gly-dmP-Glu-OH
DMOYQPM	MI	TTLD29N
DMOYQPM	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMOYQPM	MT	DTT
DMOYQPM	MA	Inhibitor
DMOYQPM	RN	The neuroprotective activity of GPE tripeptide analogues does not correlate with glutamate receptor binding affinity. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3396-400.
DMOYQPM	RU	https://pubmed.ncbi.nlm.nih.gov/16650992

DMOYQPM	DI	DMOYQPM
DMOYQPM	DN	H-Gly-dmP-Glu-OH
DMOYQPM	MI	TTKJEMQ
DMOYQPM	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMOYQPM	MT	DTT
DMOYQPM	MA	Inhibitor
DMOYQPM	RN	The neuroprotective activity of GPE tripeptide analogues does not correlate with glutamate receptor binding affinity. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3396-400.
DMOYQPM	RU	https://pubmed.ncbi.nlm.nih.gov/16650992

DMOYQPM	DI	DMOYQPM
DMOYQPM	DN	H-Gly-dmP-Glu-OH
DMOYQPM	MI	TTN9D8E
DMOYQPM	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMOYQPM	MT	DTT
DMOYQPM	MA	Inhibitor
DMOYQPM	RN	The neuroprotective activity of GPE tripeptide analogues does not correlate with glutamate receptor binding affinity. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3396-400.
DMOYQPM	RU	https://pubmed.ncbi.nlm.nih.gov/16650992

DMCKAWY	DI	DMCKAWY
DMCKAWY	DN	HI-172
DMCKAWY	MI	TT84ETX
DMCKAWY	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMCKAWY	MT	DTT
DMCKAWY	MA	Inhibitor
DMCKAWY	RN	Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistan... Bioorg Med Chem Lett. 1999 Jun 7;9(11):1593-8.
DMCKAWY	RU	https://pubmed.ncbi.nlm.nih.gov/10386942

DM3R4ZF	DI	DM3R4ZF
DM3R4ZF	DN	HI-236
DM3R4ZF	MI	TT84ETX
DM3R4ZF	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM3R4ZF	MT	DTT
DM3R4ZF	MA	Inhibitor
DM3R4ZF	RN	Antioxidant function of phenethyl-5-bromo-pyridyl thiourea compounds with potent anti-HIV activity. Bioorg Med Chem Lett. 2000 Jan 3;10(1):87-90.
DM3R4ZF	RU	https://pubmed.ncbi.nlm.nih.gov/10636251

DMQK5RM	DI	DMQK5RM
DMQK5RM	DN	HI-240
DMQK5RM	MI	TT84ETX
DMQK5RM	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMQK5RM	MT	DTT
DMQK5RM	MA	Inhibitor
DMQK5RM	RN	N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency vi... Bioorg Med Chem Lett. 1999 Dec 20;9(24):3411-6.
DMQK5RM	RU	https://pubmed.ncbi.nlm.nih.gov/10617082

DMTKCW6	DI	DMTKCW6
DMTKCW6	DN	HI-241
DMTKCW6	MI	TT84ETX
DMTKCW6	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMTKCW6	MT	DTT
DMTKCW6	MA	Inhibitor
DMTKCW6	RN	Antioxidant function of phenethyl-5-bromo-pyridyl thiourea compounds with potent anti-HIV activity. Bioorg Med Chem Lett. 2000 Jan 3;10(1):87-90.
DMTKCW6	RU	https://pubmed.ncbi.nlm.nih.gov/10636251

DM0QYLP	DI	DM0QYLP
DM0QYLP	DN	HI-242
DM0QYLP	MI	TT84ETX
DM0QYLP	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM0QYLP	MT	DTT
DM0QYLP	MA	Inhibitor
DM0QYLP	RN	Antioxidant function of phenethyl-5-bromo-pyridyl thiourea compounds with potent anti-HIV activity. Bioorg Med Chem Lett. 2000 Jan 3;10(1):87-90.
DM0QYLP	RU	https://pubmed.ncbi.nlm.nih.gov/10636251

DMG36BD	DI	DMG36BD
DMG36BD	DN	HI-244
DMG36BD	MI	TT84ETX
DMG36BD	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMG36BD	MT	DTT
DMG36BD	MA	Inhibitor
DMG36BD	RN	Anti-HIV activity of aromatic and heterocyclic thiazolyl thiourea compounds. Bioorg Med Chem Lett. 2001 Feb 26;11(4):523-8.
DMG36BD	RU	https://pubmed.ncbi.nlm.nih.gov/11229762

DME4SML	DI	DME4SML
DME4SML	DN	HI-280
DME4SML	MI	TT84ETX
DME4SML	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DME4SML	MT	DTT
DME4SML	MA	Inhibitor
DME4SML	RN	Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistan... Bioorg Med Chem Lett. 1999 Jun 7;9(11):1593-8.
DME4SML	RU	https://pubmed.ncbi.nlm.nih.gov/10386942

DM7K0PH	DI	DM7K0PH
DM7K0PH	DN	HI-281
DM7K0PH	MI	TT84ETX
DM7K0PH	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM7K0PH	MT	DTT
DM7K0PH	MA	Inhibitor
DM7K0PH	RN	Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistan... Bioorg Med Chem Lett. 1999 Jun 7;9(11):1593-8.
DM7K0PH	RU	https://pubmed.ncbi.nlm.nih.gov/10386942

DMSUWD8	DI	DMSUWD8
DMSUWD8	DN	HI-443
DMSUWD8	MI	TT84ETX
DMSUWD8	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMSUWD8	MT	DTT
DMSUWD8	MA	Inhibitor
DMSUWD8	RN	N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency vi... Bioorg Med Chem Lett. 1999 Dec 20;9(24):3411-6.
DMSUWD8	RU	https://pubmed.ncbi.nlm.nih.gov/10617082

DMYP0DE	DI	DMYP0DE
DMYP0DE	DN	HI-445
DMYP0DE	MI	TT84ETX
DMYP0DE	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMYP0DE	MT	DTT
DMYP0DE	MA	Inhibitor
DMYP0DE	RN	Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistan... Bioorg Med Chem Lett. 1999 Jun 7;9(11):1593-8.
DMYP0DE	RU	https://pubmed.ncbi.nlm.nih.gov/10386942

DMD6NZO	DI	DMD6NZO
DMD6NZO	DN	Hinokinin
DMD6NZO	MI	TTXV4FI
DMD6NZO	MN	Albendazole monooxygenase (CYP3A4)
DMD6NZO	MT	DTT
DMD6NZO	MA	Inhibitor
DMD6NZO	RN	Potent CYP3A4 inhibitory constituents of Piper cubeba. J Nat Prod. 2005 Jan;68(1):64-8.
DMD6NZO	RU	https://pubmed.ncbi.nlm.nih.gov/15679319

DMHL9Y6	DI	DMHL9Y6
DMHL9Y6	DN	HINOKITIOL
DMHL9Y6	MI	TTULVH8
DMHL9Y6	MN	Tyrosinase (TYR)
DMHL9Y6	MT	DTT
DMHL9Y6	MA	Inhibitor
DMHL9Y6	RN	Structural insights into the hot spot amino acid residues of mushroom tyrosinase for the bindings of thujaplicins. Bioorg Med Chem. 2010 Nov 15;18(22):8112-8.
DMHL9Y6	RU	https://pubmed.ncbi.nlm.nih.gov/20947360

DM0PV2Y	DI	DM0PV2Y
DM0PV2Y	DN	Hippuristanol
DM0PV2Y	MI	TTIGYVZ
DM0PV2Y	MN	HUMAN eukaryotic initiation factor-4A (eIF4A)
DM0PV2Y	MT	DTT
DM0PV2Y	MA	Inhibitor
DM0PV2Y	RN	Effects of hippuristanol, an inhibitor of eIF4A, on adult T-cell leukemia. Biochem Pharmacol. 2011 Mar 15;81(6):713-22.
DM0PV2Y	RU	https://pubmed.ncbi.nlm.nih.gov/21219881

DMRJGOP	DI	DMRJGOP
DMRJGOP	DN	His-DPhe-Arg-Trp
DMRJGOP	MI	TTD0CIQ
DMRJGOP	MN	Melanocortin receptor 4 (MC4R)
DMRJGOP	MT	DTT
DMRJGOP	MA	Inhibitor
DMRJGOP	RN	Squalene-derived flexible linkers for bioactive peptides. Bioorg Med Chem Lett. 2007 Jun 15;17(12):3310-3.
DMRJGOP	RU	https://pubmed.ncbi.nlm.nih.gov/17448660

DMA9YIB	DI	DMA9YIB
DMA9YIB	DN	histaprodifen
DMA9YIB	MI	TTTIBOJ
DMA9YIB	MN	Histamine H1 receptor (H1R)
DMA9YIB	MT	DTT
DMA9YIB	MA	Agonist
DMA9YIB	RN	Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first pote... J Pharmacol Exp Ther. 2005 Sep;314(3):1310-21.
DMA9YIB	RU	https://pubmed.ncbi.nlm.nih.gov/15947036

DM7MUJ3	DI	DM7MUJ3
DM7MUJ3	DN	HITOPK-032
DM7MUJ3	MI	TTMY6BZ
DM7MUJ3	MN	PDZ binding kinase (PBK)
DM7MUJ3	MT	DTT
DM7MUJ3	MA	Inhibitor
DM7MUJ3	RN	PDZ binding kinase (PBK) is a theranostic target for nasopharyngeal carcinoma: driving tumor growth via ROS signaling and correlating with patient survival.Oncotarget. 2016 May 3;7(18):26604-16. 
DM7MUJ3	RU	https://pubmed.ncbi.nlm.nih.gov/27049917

DMNI5FW	DI	DMNI5FW
DMNI5FW	DN	HJC 0350
DMNI5FW	MI	TTOS63B
DMNI5FW	MN	Rap guanine nucleotide exchange factor 4 (EPAC2)
DMNI5FW	MT	DTT
DMNI5FW	MA	Inhibitor
DMNI5FW	RN	Identification and characterization of small molecules as potent and specific EPAC2 antagonists. J Med Chem. 2013 Feb 14;56(3):952-62.
DMNI5FW	RU	https://pubmed.ncbi.nlm.nih.gov/23286832

DMWIOCY	DI	DMWIOCY
DMWIOCY	DN	HJP-272
DMWIOCY	MI	TTKRD0G
DMWIOCY	MN	Endothelin A receptor (EDNRA)
DMWIOCY	MT	DTT
DMWIOCY	MA	Antagonist
DMWIOCY	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 219).
DMWIOCY	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=219

DME13RQ	DI	DME13RQ
DME13RQ	DN	hK2p01 derivative KLK2 inhibitor
DME13RQ	MI	TTJLNAW
DME13RQ	MN	Tissue kallikrein (KLK2)
DME13RQ	MT	DTT
DME13RQ	MA	Inhibitor
DME13RQ	RN	Novel peptide inhibitors of human kallikrein 2. J Biol Chem. 2006 May 5;281(18):12555-60.
DME13RQ	RU	https://pubmed.ncbi.nlm.nih.gov/16527822

DM5LR2B	DI	DM5LR2B
DM5LR2B	DN	HKI-9924129
DM5LR2B	MI	TT4ILYC
DM5LR2B	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DM5LR2B	MT	DTT
DM5LR2B	MA	Inhibitor
DM5LR2B	RN	Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
DM5LR2B	RU	https://pubmed.ncbi.nlm.nih.gov/15934867

DM5LR2B	DI	DM5LR2B
DM5LR2B	DN	HKI-9924129
DM5LR2B	MI	TTGKNB4
DM5LR2B	MN	Epidermal growth factor receptor (EGFR)
DM5LR2B	MT	DTT
DM5LR2B	MA	Inhibitor
DM5LR2B	RN	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
DM5LR2B	RU	https://pubmed.ncbi.nlm.nih.gov/10974196

DM5LR2B	DI	DM5LR2B
DM5LR2B	DN	HKI-9924129
DM5LR2B	MI	TTRLW2X
DM5LR2B	MN	Fibroblast growth factor receptor 1 (FGFR1)
DM5LR2B	MT	DTT
DM5LR2B	MA	Inhibitor
DM5LR2B	RN	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
DM5LR2B	RU	https://pubmed.ncbi.nlm.nih.gov/10974196

DM5LR2B	DI	DM5LR2B
DM5LR2B	DN	HKI-9924129
DM5LR2B	MI	TTS7G69
DM5LR2B	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DM5LR2B	MT	DTT
DM5LR2B	MA	Inhibitor
DM5LR2B	RN	Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res. 2002 Dec 15;62(24):7149-53.
DM5LR2B	RU	https://pubmed.ncbi.nlm.nih.gov/12499247

DM5LR2B	DI	DM5LR2B
DM5LR2B	DN	HKI-9924129
DM5LR2B	MI	TT860QF
DM5LR2B	MN	LCK tyrosine protein kinase (LCK)
DM5LR2B	MT	DTT
DM5LR2B	MA	Inhibitor
DM5LR2B	RN	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
DM5LR2B	RU	https://pubmed.ncbi.nlm.nih.gov/10974196

DM5LR2B	DI	DM5LR2B
DM5LR2B	DN	HKI-9924129
DM5LR2B	MI	TT8FYO9
DM5LR2B	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DM5LR2B	MT	DTT
DM5LR2B	MA	Inhibitor
DM5LR2B	RN	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
DM5LR2B	RU	https://pubmed.ncbi.nlm.nih.gov/10974196

DM5LR2B	DI	DM5LR2B
DM5LR2B	DN	HKI-9924129
DM5LR2B	MI	TTI7421
DM5LR2B	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM5LR2B	MT	DTT
DM5LR2B	MA	Inhibitor
DM5LR2B	RN	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
DM5LR2B	RU	https://pubmed.ncbi.nlm.nih.gov/10974196

DM5LR2B	DI	DM5LR2B
DM5LR2B	DN	HKI-9924129
DM5LR2B	MI	TT6PKBN
DM5LR2B	MN	Proto-oncogene c-Src (SRC)
DM5LR2B	MT	DTT
DM5LR2B	MA	Inhibitor
DM5LR2B	RN	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
DM5LR2B	RU	https://pubmed.ncbi.nlm.nih.gov/10974196

DMDINX9	DI	DMDINX9
DMDINX9	DN	H-KPPR-OH
DMDINX9	MI	TTIPJCB
DMDINX9	MN	Neuropilin-1 (NRP1)
DMDINX9	MT	DTT
DMDINX9	MA	Inhibitor
DMDINX9	RN	Small molecule inhibitors of the neuropilin-1 vascular endothelial growth factor A (VEGF-A) interaction. J Med Chem. 2010 Mar 11;53(5):2215-26.
DMDINX9	RU	https://pubmed.ncbi.nlm.nih.gov/20151671

DMMW0OF	DI	DMMW0OF
DMMW0OF	DN	HL-034
DMMW0OF	MI	TTIHYA4
DMMW0OF	MN	Thrombopoietin receptor (MPL)
DMMW0OF	MT	DTT
DMMW0OF	MA	Antagonist
DMMW0OF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1722).
DMMW0OF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1722

DMAPWC2	DI	DMAPWC2
DMAPWC2	DN	H-Leu-Phe-NH2
DMAPWC2	MI	TTZPO1L
DMAPWC2	MN	Substance-P receptor (TACR1)
DMAPWC2	MT	DTT
DMAPWC2	MA	Inhibitor
DMAPWC2	RN	Discovery of dipeptides with high affinity to the specific binding site for substance P1-7. J Med Chem. 2010 Mar 25;53(6):2383-9.
DMAPWC2	RU	https://pubmed.ncbi.nlm.nih.gov/20178322

DM2URWO	DI	DM2URWO
DM2URWO	DN	HLL1-Fab-A3B3
DM2URWO	MI	TTY6DTE
DM2URWO	MN	Carcinoembryonic antigen CEA (CD66e)
DM2URWO	MT	DTT
DM2URWO	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2836).
DM2URWO	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2836

DMDXIS7	DI	DMDXIS7
DMDXIS7	DN	H-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-D-BT-OH(JMV1645)
DMDXIS7	MI	TTG5QIA
DMDXIS7	MN	B1 bradykinin receptor (BDKRB1)
DMDXIS7	MT	DTT
DMDXIS7	MA	Inhibitor
DMDXIS7	RN	Synthesis and biological evaluation of bradykinin B(1)/B(2) and selective B(1) receptor antagonists. J Med Chem. 2000 Jun 15;43(12):2382-6.
DMDXIS7	RU	https://pubmed.ncbi.nlm.nih.gov/10882364

DMDXIS7	DI	DMDXIS7
DMDXIS7	DN	H-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-D-BT-OH(JMV1645)
DMDXIS7	MI	TTGY8IW
DMDXIS7	MN	B2 bradykinin receptor (BDKRB2)
DMDXIS7	MT	DTT
DMDXIS7	MA	Inhibitor
DMDXIS7	RN	Synthesis and biological evaluation of bradykinin B(1)/B(2) and selective B(1) receptor antagonists. J Med Chem. 2000 Jun 15;43(12):2382-6.
DMDXIS7	RU	https://pubmed.ncbi.nlm.nih.gov/10882364

DMTGU0L	DI	DMTGU0L
DMTGU0L	DN	H-Lys-Arg-Pro-Hyp-Gly-Thi-Ser-D-BT-OH(JMV1669)
DMTGU0L	MI	TTG5QIA
DMTGU0L	MN	B1 bradykinin receptor (BDKRB1)
DMTGU0L	MT	DTT
DMTGU0L	MA	Inhibitor
DMTGU0L	RN	Synthesis and biological evaluation of bradykinin B(1)/B(2) and selective B(1) receptor antagonists. J Med Chem. 2000 Jun 15;43(12):2382-6.
DMTGU0L	RU	https://pubmed.ncbi.nlm.nih.gov/10882364

DMTGU0L	DI	DMTGU0L
DMTGU0L	DN	H-Lys-Arg-Pro-Hyp-Gly-Thi-Ser-D-BT-OH(JMV1669)
DMTGU0L	MI	TTGY8IW
DMTGU0L	MN	B2 bradykinin receptor (BDKRB2)
DMTGU0L	MT	DTT
DMTGU0L	MA	Inhibitor
DMTGU0L	RN	Synthesis and biological evaluation of bradykinin B(1)/B(2) and selective B(1) receptor antagonists. J Med Chem. 2000 Jun 15;43(12):2382-6.
DMTGU0L	RU	https://pubmed.ncbi.nlm.nih.gov/10882364

DMKHVUE	DI	DMKHVUE
DMKHVUE	DN	HM-5016699
DMKHVUE	MI	TTHBTOP
DMKHVUE	MN	PI3-kinase gamma (PIK3CG)
DMKHVUE	MT	DTT
DMKHVUE	MA	Inhibitor
DMKHVUE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2155).
DMKHVUE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2155

DMKHVUE	DI	DMKHVUE
DMKHVUE	DN	HM-5016699
DMKHVUE	MI	TTCJG29
DMKHVUE	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMKHVUE	MT	DTT
DMKHVUE	MA	Inhibitor
DMKHVUE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
DMKHVUE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109

DMNOFTX	DI	DMNOFTX
DMNOFTX	DN	HM-61713B
DMNOFTX	MI	TTGKNB4
DMNOFTX	MN	Epidermal growth factor receptor (EGFR)
DMNOFTX	MT	DTT
DMNOFTX	MA	Inhibitor
DMNOFTX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
DMNOFTX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797

DM17QMV	DI	DM17QMV
DM17QMV	DN	H-mCpa-ala-Gly-Phe-leu-OH
DM17QMV	MI	TT27RFC
DM17QMV	MN	Opioid receptor delta (OPRD1)
DM17QMV	MT	DTT
DM17QMV	MA	Inhibitor
DM17QMV	RN	Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60.
DM17QMV	RU	https://pubmed.ncbi.nlm.nih.gov/17350835

DM17QMV	DI	DM17QMV
DM17QMV	DN	H-mCpa-ala-Gly-Phe-leu-OH
DM17QMV	MI	TTKWM86
DM17QMV	MN	Opioid receptor mu (MOP)
DM17QMV	MT	DTT
DM17QMV	MA	Inhibitor
DM17QMV	RN	Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60.
DM17QMV	RU	https://pubmed.ncbi.nlm.nih.gov/17350835

DMKAEQP	DI	DMKAEQP
DMKAEQP	DN	H-mCpa-Gly-Gly-Phe-Leu-OH
DMKAEQP	MI	TT27RFC
DMKAEQP	MN	Opioid receptor delta (OPRD1)
DMKAEQP	MT	DTT
DMKAEQP	MA	Inhibitor
DMKAEQP	RN	Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60.
DMKAEQP	RU	https://pubmed.ncbi.nlm.nih.gov/17350835

DM8OUHV	DI	DM8OUHV
DM8OUHV	DN	H-mCpa-ser-Gly-Phe-Leu-Thr-OH
DM8OUHV	MI	TT27RFC
DM8OUHV	MN	Opioid receptor delta (OPRD1)
DM8OUHV	MT	DTT
DM8OUHV	MA	Inhibitor
DM8OUHV	RN	Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60.
DM8OUHV	RU	https://pubmed.ncbi.nlm.nih.gov/17350835

DM8OUHV	DI	DM8OUHV
DM8OUHV	DN	H-mCpa-ser-Gly-Phe-Leu-Thr-OH
DM8OUHV	MI	TTKWM86
DM8OUHV	MN	Opioid receptor mu (MOP)
DM8OUHV	MT	DTT
DM8OUHV	MA	Inhibitor
DM8OUHV	RN	Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60.
DM8OUHV	RU	https://pubmed.ncbi.nlm.nih.gov/17350835

DMXMTA9	DI	DMXMTA9
DMXMTA9	DN	HMR-1556
DMXMTA9	MI	TT846HF
DMXMTA9	MN	Voltage-gated potassium channel Kv7.1 (KCNQ1)
DMXMTA9	MT	DTT
DMXMTA9	MA	Inhibitor
DMXMTA9	RN	Selective optimization of side activities: another way for drug discovery. J Med Chem. 2004 Mar 11;47(6):1303-14.
DMXMTA9	RU	https://pubmed.ncbi.nlm.nih.gov/14998318

DMNXR17	DI	DMNXR17
DMNXR17	DN	HMR1883
DMNXR17	MI	TT1VOHK
DMNXR17	MN	Potassium channel unspecific (KC)
DMNXR17	MT	DTT
DMNXR17	MA	Modulator
DMNXR17	RN	Clamikalant (Aventis). IDrugs. 2000 Nov;3(11):1353-7.
DMNXR17	RU	https://www.ncbi.nlm.nih.gov/pubmed/16047257

DMUPS48	DI	DMUPS48
DMUPS48	DN	HMS3229G13
DMUPS48	MI	TTK0FEA
DMUPS48	MN	Leucine-rich repeat kinase 2 (LRRK2)
DMUPS48	MT	DTT
DMUPS48	MA	Inhibitor
DMUPS48	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2059).
DMUPS48	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2059

DMKOMP2	DI	DMKOMP2
DMKOMP2	DN	HOE-33258
DMKOMP2	MI	TTQY2EJ
DMKOMP2	MN	TERT messenger RNA (TERT mRNA)
DMKOMP2	MT	DTT
DMKOMP2	MA	Inhibitor
DMKOMP2	RN	Nucleic acid-binding ligands identify new mechanisms to inhibit telomerase. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3467-71.
DMKOMP2	RU	https://pubmed.ncbi.nlm.nih.gov/15177454

DMJQI7A	DI	DMJQI7A
DMJQI7A	DN	HO-LVA
DMJQI7A	MI	TT4TFGN
DMJQI7A	MN	Vasopressin V1a receptor (V1AR)
DMJQI7A	MT	DTT
DMJQI7A	MA	Inhibitor
DMJQI7A	RN	Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands. J Med Chem. 2007 Oct 4;50(20):4976-85.
DMJQI7A	RU	https://pubmed.ncbi.nlm.nih.gov/17850055

DMZYB3S	DI	DMZYB3S
DMZYB3S	DN	Hombreol
DMZYB3S	MI	DE36TMY
DMZYB3S	MN	Cytochrome P450 7B1 (CYP7B1)
DMZYB3S	MT	DME
DMZYB3S	MA	Metabolism
DMZYB3S	RN	CYP7B1-mediated metabolism of dehydroepiandrosterone and 5alpha-androstane-3beta,17beta-diol--potential role(s) for estrogen signaling. FEBS J. 2008 Apr;275(8):1778-89.
DMZYB3S	RU	https://pubmed.ncbi.nlm.nih.gov/18331353

DMZYB3S	DI	DMZYB3S
DMZYB3S	DN	Hombreol
DMZYB3S	MI	DEPFD73
DMZYB3S	MN	Dehydrogenase/reductase retSDR2 (HSD17B11)
DMZYB3S	MT	DME
DMZYB3S	MA	Metabolism
DMZYB3S	RN	Transcriptional regulation of type 11 17beta-hydroxysteroid dehydrogenase expression in prostate cancer cells. Mol Cell Endocrinol. 2011 Jun 6;339(1-2):45-53.
DMZYB3S	RU	https://pubmed.ncbi.nlm.nih.gov/21549806

DMH96AI	DI	DMH96AI
DMH96AI	DN	homo-AMPA
DMH96AI	MI	TTWRP2F
DMH96AI	MN	Metabotropic glutamate receptor 6 (mGluR6)
DMH96AI	MT	DTT
DMH96AI	MA	Agonist
DMH96AI	RN	A new highly selective metabotropic excitatory amino acid agonist: 2-amino-4-(3-hydroxy-5-methylisoxazol-4-yl)butyric acid. J Med Chem. 1996 Aug 2;39(16):3188-94.
DMH96AI	RU	https://pubmed.ncbi.nlm.nih.gov/8759641

DMIHFQY	DI	DMIHFQY
DMIHFQY	DN	HOMOAROMOLINE
DMIHFQY	MI	TTVBI8W
DMIHFQY	MN	Dopamine transporter (DAT)
DMIHFQY	MT	DTT
DMIHFQY	MA	Inhibitor
DMIHFQY	RN	Effects of various isoquinoline alkaloids on in vitro 3H-dopamine uptake by rat striatal synaptosomes. J Nat Prod. 1995 Oct;58(10):1475-84.
DMIHFQY	RU	https://pubmed.ncbi.nlm.nih.gov/8676127

DMCIRY0	DI	DMCIRY0
DMCIRY0	DN	Homocamptothecins (hCPTs)
DMCIRY0	MI	TTGTQHC
DMCIRY0	MN	DNA topoisomerase I (TOP1)
DMCIRY0	MT	DTT
DMCIRY0	MA	Inhibitor
DMCIRY0	RN	Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs. Crit Rev Oncol Hematol. 2003 Jan;45(1):91-108.
DMCIRY0	RU	https://pubmed.ncbi.nlm.nih.gov/12482574

DM1SDN8	DI	DM1SDN8
DM1SDN8	DN	HOMOERIODICTYOL
DM1SDN8	MI	TTI84H7
DM1SDN8	MN	Cytochrome P450 1B1 (CYP1B1)
DM1SDN8	MT	DTT
DM1SDN8	MA	Inhibitor
DM1SDN8	RN	Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5.
DM1SDN8	RU	https://pubmed.ncbi.nlm.nih.gov/20696580

DMQD0YW	DI	DMQD0YW
DMQD0YW	DN	Homogentisic acid
DMQD0YW	MI	DESDN74
DMQD0YW	MN	Serum paraoxonase/arylesterase 1 (PON1)
DMQD0YW	MT	DME
DMQD0YW	MA	Metabolism
DMQD0YW	RN	Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos. 2000 Nov;28(11):1335-42.
DMQD0YW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11038162

DMVBTHA	DI	DMVBTHA
DMVBTHA	DN	HOMOPHENYLALANINYLMETHANE
DMVBTHA	MI	TTJOKD1
DMVBTHA	MN	Cathepsin F (CTSF)
DMVBTHA	MT	DTT
DMVBTHA	MA	Inhibitor
DMVBTHA	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMVBTHA	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMBW5DU	DI	DMBW5DU
DMBW5DU	DN	homoquinolinic acid
DMBW5DU	MI	TTLD29N
DMBW5DU	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMBW5DU	MT	DTT
DMBW5DU	MA	Agonist
DMBW5DU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455).
DMBW5DU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=455

DMBW5DU	DI	DMBW5DU
DMBW5DU	DN	homoquinolinic acid
DMBW5DU	MI	TTKJEMQ
DMBW5DU	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMBW5DU	MT	DTT
DMBW5DU	MA	Agonist
DMBW5DU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456).
DMBW5DU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=456

DMBW5DU	DI	DMBW5DU
DMBW5DU	DN	homoquinolinic acid
DMBW5DU	MI	TTN9D8E
DMBW5DU	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMBW5DU	MT	DTT
DMBW5DU	MA	Agonist
DMBW5DU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457).
DMBW5DU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=457

DMBW5DU	DI	DMBW5DU
DMBW5DU	DN	homoquinolinic acid
DMBW5DU	MI	TT1M8OW
DMBW5DU	MN	Glutamate receptor ionotropic NMDA 2C (GluN2C)
DMBW5DU	MT	DTT
DMBW5DU	MA	Agonist
DMBW5DU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 458).
DMBW5DU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=458

DMBW5DU	DI	DMBW5DU
DMBW5DU	DN	homoquinolinic acid
DMBW5DU	MI	TT5POTG
DMBW5DU	MN	Glutamate receptor ionotropic NMDA 2D (GluN2D)
DMBW5DU	MT	DTT
DMBW5DU	MA	Agonist
DMBW5DU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 459).
DMBW5DU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=459

DMX8DC2	DI	DMX8DC2
DMX8DC2	DN	Homorisedronate
DMX8DC2	MI	TTIKWV4
DMX8DC2	MN	Geranyltranstransferase (FDPS)
DMX8DC2	MT	DTT
DMX8DC2	MA	Inhibitor
DMX8DC2	RN	Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase. J Biol Chem. 2001 Sep 7;276(36):33930-7.
DMX8DC2	RU	https://pubmed.ncbi.nlm.nih.gov/11435429

DMTKN4A	DI	DMTKN4A
DMTKN4A	DN	Homoserine Lactone
DMTKN4A	MI	TTGSEFH
DMTKN4A	MN	Sodium/hydrogen exchanger 1 (SLC9A1)
DMTKN4A	MT	DTT
DMTKN4A	MA	Inhibitor
DMTKN4A	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMTKN4A	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM0SHPY	DI	DM0SHPY
DM0SHPY	DN	Homovanillic acid
DM0SHPY	MI	DEJOCPK
DM0SHPY	MN	Homogentisate 1,2-dioxygenase (hmgA)
DM0SHPY	MT	DME
DM0SHPY	MA	Metabolism
DM0SHPY	RN	nan
DM0SHPY	RU	nan

DMI7258	DI	DMI7258
DMI7258	DN	Homspera
DMI7258	MI	TTZPO1L
DMI7258	MN	Substance-P receptor (TACR1)
DMI7258	MT	DTT
DMI7258	MA	Agonist
DMI7258	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 360).
DMI7258	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=360

DMJWT3X	DI	DMJWT3X
DMJWT3X	DN	HONOKIOL
DMJWT3X	MI	TTSJ6Q4
DMJWT3X	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DMJWT3X	MT	DTT
DMJWT3X	MA	Inhibitor
DMJWT3X	RN	Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxyge... Bioorg Med Chem. 2009 Jul 1;17(13):4459-65.
DMJWT3X	RU	https://pubmed.ncbi.nlm.nih.gov/19481465

DMJWT3X	DI	DMJWT3X
DMJWT3X	DN	HONOKIOL
DMJWT3X	MI	TT8NGED
DMJWT3X	MN	Prostaglandin G/H synthase 1 (COX-1)
DMJWT3X	MT	DTT
DMJWT3X	MA	Inhibitor
DMJWT3X	RN	Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxyge... Bioorg Med Chem. 2009 Jul 1;17(13):4459-65.
DMJWT3X	RU	https://pubmed.ncbi.nlm.nih.gov/19481465

DMJWT3X	DI	DMJWT3X
DMJWT3X	DN	HONOKIOL
DMJWT3X	MI	TTVKILB
DMJWT3X	MN	Prostaglandin G/H synthase 2 (COX-2)
DMJWT3X	MT	DTT
DMJWT3X	MA	Inhibitor
DMJWT3X	RN	Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxyge... Bioorg Med Chem. 2009 Jul 1;17(13):4459-65.
DMJWT3X	RU	https://pubmed.ncbi.nlm.nih.gov/19481465

DMHW2DU	DI	DMHW2DU
DMHW2DU	DN	Hoo-Phe-Orn-Pro-hle-Pff-Phe-NH2
DMHW2DU	MI	TTD0CIQ
DMHW2DU	MN	Melanocortin receptor 4 (MC4R)
DMHW2DU	MT	DTT
DMHW2DU	MA	Inhibitor
DMHW2DU	RN	Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92.
DMHW2DU	RU	https://pubmed.ncbi.nlm.nih.gov/16876401

DMHW2DU	DI	DMHW2DU
DMHW2DU	DN	Hoo-Phe-Orn-Pro-hle-Pff-Phe-NH2
DMHW2DU	MI	TTYO0A3
DMHW2DU	MN	Substance-K receptor (TACR2)
DMHW2DU	MT	DTT
DMHW2DU	MA	Inhibitor
DMHW2DU	RN	Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92.
DMHW2DU	RU	https://pubmed.ncbi.nlm.nih.gov/16876401

DMHW2DU	DI	DMHW2DU
DMHW2DU	DN	Hoo-Phe-Orn-Pro-hle-Pff-Phe-NH2
DMHW2DU	MI	TT4TFGN
DMHW2DU	MN	Vasopressin V1a receptor (V1AR)
DMHW2DU	MT	DTT
DMHW2DU	MA	Inhibitor
DMHW2DU	RN	Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92.
DMHW2DU	RU	https://pubmed.ncbi.nlm.nih.gov/16876401

DM2OZBL	DI	DM2OZBL
DM2OZBL	DN	Howiinol A (GHM-10)
DM2OZBL	MI	TT0IHXV
DM2OZBL	MN	DNA topoisomerase II (TOP2)
DM2OZBL	MT	DTT
DM2OZBL	MA	Inhibitor
DM2OZBL	RN	Anticancer effect of Howiinol A and its mechanism of action. J Asian Nat Prod Res. 1999;2(1):1-19.
DM2OZBL	RU	https://pubmed.ncbi.nlm.nih.gov/11261201

DM9IODG	DI	DM9IODG
DM9IODG	DN	H-Phe-NH2
DM9IODG	MI	TTZPO1L
DM9IODG	MN	Substance-P receptor (TACR1)
DM9IODG	MT	DTT
DM9IODG	MA	Inhibitor
DM9IODG	RN	Discovery of dipeptides with high affinity to the specific binding site for substance P1-7. J Med Chem. 2010 Mar 25;53(6):2383-9.
DM9IODG	RU	https://pubmed.ncbi.nlm.nih.gov/20178322

DM0KFW2	DI	DM0KFW2
DM0KFW2	DN	H-Phe-Phe-NH2
DM0KFW2	MI	TTZPO1L
DM0KFW2	MN	Substance-P receptor (TACR1)
DM0KFW2	MT	DTT
DM0KFW2	MA	Inhibitor
DM0KFW2	RN	Discovery of dipeptides with high affinity to the specific binding site for substance P1-7. J Med Chem. 2010 Mar 25;53(6):2383-9.
DM0KFW2	RU	https://pubmed.ncbi.nlm.nih.gov/20178322

DME1CT9	DI	DME1CT9
DME1CT9	DN	H-Poa-ser-Gly-Phe-Leu-Thr-OH
DME1CT9	MI	TT27RFC
DME1CT9	MN	Opioid receptor delta (OPRD1)
DME1CT9	MT	DTT
DME1CT9	MA	Inhibitor
DME1CT9	RN	Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60.
DME1CT9	RU	https://pubmed.ncbi.nlm.nih.gov/17350835

DMXKPQR	DI	DMXKPQR
DMXKPQR	DN	H-Pro-Phe-Phe-NH2
DMXKPQR	MI	TTZPO1L
DMXKPQR	MN	Substance-P receptor (TACR1)
DMXKPQR	MT	DTT
DMXKPQR	MA	Inhibitor
DMXKPQR	RN	Discovery of dipeptides with high affinity to the specific binding site for substance P1-7. J Med Chem. 2010 Mar 25;53(6):2383-9.
DMXKPQR	RU	https://pubmed.ncbi.nlm.nih.gov/20178322

DMRPZD4	DI	DMRPZD4
DMRPZD4	DN	HPTE
DMRPZD4	MI	TTOM3J0
DMRPZD4	MN	Estrogen receptor beta (ESR2)
DMRPZD4	MT	DTT
DMRPZD4	MA	Antagonist
DMRPZD4	RN	Signalling by CXC-chemokine receptors 1 and 2 expressed in CHO cells: a comparison of calcium mobilization, inhibition of adenylyl cyclase and stimulation of GTPgammaS binding induced by IL-8 and GROalpha. Br J Pharmacol. 1999 Feb;126(3):810-8.
DMRPZD4	RU	https://pubmed.ncbi.nlm.nih.gov/10188995

DMSHYQ3	DI	DMSHYQ3
DMSHYQ3	DN	HQL-79
DMSHYQ3	MI	TTCYE56
DMSHYQ3	MN	Glutathione-dependent PGD synthase (HPGDS)
DMSHYQ3	MT	DTT
DMSHYQ3	MA	Inhibitor
DMSHYQ3	RN	Structural and functional characterization of HQL-79, an orally selective inhibitor of human hematopoietic prostaglandin D synthase. J Biol Chem. 2006 Jun 2;281(22):15277-86.
DMSHYQ3	RU	https://pubmed.ncbi.nlm.nih.gov/16547010

DMSTV96	DI	DMSTV96
DMSTV96	DN	H-RYYRIK-NH2
DMSTV96	MI	TTNT7K8
DMSTV96	MN	Nociceptin receptor (OPRL1)
DMSTV96	MT	DTT
DMSTV96	MA	Inhibitor
DMSTV96	RN	Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist. Bioorg Med Chem. 2008 Mar 1;16(5):2635-44.
DMSTV96	RU	https://pubmed.ncbi.nlm.nih.gov/18068993

DMM3FD2	DI	DMM3FD2
DMM3FD2	DN	HS014
DMM3FD2	MI	TTD0CIQ
DMM3FD2	MN	Melanocortin receptor 4 (MC4R)
DMM3FD2	MT	DTT
DMM3FD2	MA	Antagonist
DMM3FD2	RN	Long-term administration of MC4 receptor antagonist HS014 causes hyperphagia and obesity in rats. Neuroreport. 1999 Mar 17;10(4):707-11.
DMM3FD2	RU	https://pubmed.ncbi.nlm.nih.gov/10208535

DM0A2UF	DI	DM0A2UF
DM0A2UF	DN	HS-173
DM0A2UF	MI	TTHBTOP
DM0A2UF	MN	PI3-kinase gamma (PIK3CG)
DM0A2UF	MT	DTT
DM0A2UF	MA	Inhibitor
DM0A2UF	RN	Design and synthesis of imidazopyridine analogues as inhibitors of phosphoinositide 3-kinase signaling and angiogenesis. J Med Chem. 2011 Apr 14;54(7):2455-66.
DM0A2UF	RU	https://pubmed.ncbi.nlm.nih.gov/21388141

DMA91T4	DI	DMA91T4
DMA91T4	DN	H-SMGLPCVVM-OH
DMA91T4	MI	TT7WZIJ
DMA91T4	MN	CAAX farnesyltransferase beta (FNTB)
DMA91T4	MT	DTT
DMA91T4	MA	Inhibitor
DMA91T4	RN	Improvement of biological activity and proteolytic stability of peptides by coupling with a cyclic peptide. Bioorg Med Chem Lett. 2003 Aug 4;13(15):2583-6.
DMA91T4	RU	https://pubmed.ncbi.nlm.nih.gov/12852971

DMZRPM5	DI	DMZRPM5
DMZRPM5	DN	HT1042
DMZRPM5	MI	TTEAD9J
DMZRPM5	MN	Proteasome beta-8 (PS beta-8)
DMZRPM5	MT	DTT
DMZRPM5	MA	Inhibitor
DMZRPM5	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2408).
DMZRPM5	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2408

DMRF73O	DI	DMRF73O
DMRF73O	DN	HT-2678
DMRF73O	MI	TTNZPQ1
DMRF73O	MN	GABA(A) receptor alpha-5 (GABRA5)
DMRF73O	MT	DTT
DMRF73O	MA	Agonist
DMRF73O	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 408).
DMRF73O	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=408

DMPT8JN	DI	DMPT8JN
DMPT8JN	DN	HTMT
DMPT8JN	MI	TTXJ178
DMPT8JN	MN	Histamine H4 receptor (H4R)
DMPT8JN	MT	DTT
DMPT8JN	MA	Agonist
DMPT8JN	RN	Cloning, expression, and pharmacological characterization of a novel human histamine receptor. Mol Pharmacol. 2001 Mar;59(3):434-41.
DMPT8JN	RU	https://pubmed.ncbi.nlm.nih.gov/11179436

DMQ8ADE	DI	DMQ8ADE
DMQ8ADE	DN	HTS-00213
DMQ8ADE	MI	TTGKNB4
DMQ8ADE	MN	Epidermal growth factor receptor (EGFR)
DMQ8ADE	MT	DTT
DMQ8ADE	MA	Inhibitor
DMQ8ADE	RN	Computational studies of epidermal growth factor receptor: docking reliability, three-dimensional quantitative structure-activity relationship anal... J Med Chem. 2009 Feb 26;52(4):964-75.
DMQ8ADE	RU	https://pubmed.ncbi.nlm.nih.gov/19170633

DMXV379	DI	DMXV379
DMXV379	DN	HTS-00798
DMXV379	MI	TTDP1UC
DMXV379	MN	Fatty acid amide hydrolase (FAAH)
DMXV379	MT	DTT
DMXV379	MA	Inhibitor
DMXV379	RN	Fatty acid amide hydrolase inhibitors from virtual screening of the endocannabinoid system. J Med Chem. 2006 Jul 27;49(15):4650-6.
DMXV379	RU	https://pubmed.ncbi.nlm.nih.gov/16854070

DMVUTJ5	DI	DMVUTJ5
DMVUTJ5	DN	HTS-02876
DMVUTJ5	MI	TTGKNB4
DMVUTJ5	MN	Epidermal growth factor receptor (EGFR)
DMVUTJ5	MT	DTT
DMVUTJ5	MA	Inhibitor
DMVUTJ5	RN	Computational studies of epidermal growth factor receptor: docking reliability, three-dimensional quantitative structure-activity relationship anal... J Med Chem. 2009 Feb 26;52(4):964-75.
DMVUTJ5	RU	https://pubmed.ncbi.nlm.nih.gov/19170633

DM3F4IQ	DI	DM3F4IQ
DM3F4IQ	DN	HTS-05058
DM3F4IQ	MI	TTGKNB4
DM3F4IQ	MN	Epidermal growth factor receptor (EGFR)
DM3F4IQ	MT	DTT
DM3F4IQ	MA	Inhibitor
DM3F4IQ	RN	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
DM3F4IQ	RU	https://pubmed.ncbi.nlm.nih.gov/18077363

DM70YTF	DI	DM70YTF
DM70YTF	DN	HTS-466284
DM70YTF	MI	TTP4520
DM70YTF	MN	TGF-beta receptor type I (TGFBR1)
DM70YTF	MT	DTT
DM70YTF	MA	Inhibitor
DM70YTF	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM70YTF	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMX08FL	DI	DMX08FL
DMX08FL	DN	H-Tyr(OMe)-Phe(2-Me)-NH2
DMX08FL	MI	TTZPO1L
DMX08FL	MN	Substance-P receptor (TACR1)
DMX08FL	MT	DTT
DMX08FL	MA	Inhibitor
DMX08FL	RN	Discovery of dipeptides with high affinity to the specific binding site for substance P1-7. J Med Chem. 2010 Mar 25;53(6):2383-9.
DMX08FL	RU	https://pubmed.ncbi.nlm.nih.gov/20178322

DMUHBGC	DI	DMUHBGC
DMUHBGC	DN	H-Tyr-Ala-Phe-Phe-NH2
DMUHBGC	MI	TTZPO1L
DMUHBGC	MN	Substance-P receptor (TACR1)
DMUHBGC	MT	DTT
DMUHBGC	MA	Inhibitor
DMUHBGC	RN	Discovery of dipeptides with high affinity to the specific binding site for substance P1-7. J Med Chem. 2010 Mar 25;53(6):2383-9.
DMUHBGC	RU	https://pubmed.ncbi.nlm.nih.gov/20178322

DMP8KMV	DI	DMP8KMV
DMP8KMV	DN	H-Tyr-c[cys-Gly-Phe(p-NO2)-cys]NH2
DMP8KMV	MI	TT27RFC
DMP8KMV	MN	Opioid receptor delta (OPRD1)
DMP8KMV	MT	DTT
DMP8KMV	MA	Inhibitor
DMP8KMV	RN	Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60.
DMP8KMV	RU	https://pubmed.ncbi.nlm.nih.gov/17350835

DM48XV0	DI	DM48XV0
DM48XV0	DN	H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]NH2
DM48XV0	MI	TT27RFC
DM48XV0	MN	Opioid receptor delta (OPRD1)
DM48XV0	MT	DTT
DM48XV0	MA	Inhibitor
DM48XV0	RN	Dicarba analogues of the cyclic enkephalin peptides H-Tyr-c[D-Cys-Gly-Phe-D(or L)-Cys]NH(2) retain high opioid activity. J Med Chem. 2007 Mar 22;50(6):1414-7.
DM48XV0	RU	https://pubmed.ncbi.nlm.nih.gov/17315860

DM48XV0	DI	DM48XV0
DM48XV0	DN	H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]NH2
DM48XV0	MI	TTQW87Y
DM48XV0	MN	Opioid receptor kappa (OPRK1)
DM48XV0	MT	DTT
DM48XV0	MA	Inhibitor
DM48XV0	RN	Dicarba analogues of the cyclic enkephalin peptides H-Tyr-c[D-Cys-Gly-Phe-D(or L)-Cys]NH(2) retain high opioid activity. J Med Chem. 2007 Mar 22;50(6):1414-7.
DM48XV0	RU	https://pubmed.ncbi.nlm.nih.gov/17315860

DM48XV0	DI	DM48XV0
DM48XV0	DN	H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]NH2
DM48XV0	MI	TTKWM86
DM48XV0	MN	Opioid receptor mu (MOP)
DM48XV0	MT	DTT
DM48XV0	MA	Inhibitor
DM48XV0	RN	Dicarba analogues of the cyclic enkephalin peptides H-Tyr-c[D-Cys-Gly-Phe-D(or L)-Cys]NH(2) retain high opioid activity. J Med Chem. 2007 Mar 22;50(6):1414-7.
DM48XV0	RU	https://pubmed.ncbi.nlm.nih.gov/17315860

DMA2CZL	DI	DMA2CZL
DMA2CZL	DN	H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]-OH
DMA2CZL	MI	TT27RFC
DMA2CZL	MN	Opioid receptor delta (OPRD1)
DMA2CZL	MT	DTT
DMA2CZL	MA	Inhibitor
DMA2CZL	RN	Synthesis of stable and potent delta/mu opioid peptides: analogues of H-Tyr-c[D-Cys-Gly-Phe-D-Cys]-OH by ring-closing metathesis. J Med Chem. 2007 Jun 28;50(13):3138-42.
DMA2CZL	RU	https://pubmed.ncbi.nlm.nih.gov/17539621

DMA2CZL	DI	DMA2CZL
DMA2CZL	DN	H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]-OH
DMA2CZL	MI	TTQW87Y
DMA2CZL	MN	Opioid receptor kappa (OPRK1)
DMA2CZL	MT	DTT
DMA2CZL	MA	Inhibitor
DMA2CZL	RN	Synthesis of stable and potent delta/mu opioid peptides: analogues of H-Tyr-c[D-Cys-Gly-Phe-D-Cys]-OH by ring-closing metathesis. J Med Chem. 2007 Jun 28;50(13):3138-42.
DMA2CZL	RU	https://pubmed.ncbi.nlm.nih.gov/17539621

DMA2CZL	DI	DMA2CZL
DMA2CZL	DN	H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]-OH
DMA2CZL	MI	TTKWM86
DMA2CZL	MN	Opioid receptor mu (MOP)
DMA2CZL	MT	DTT
DMA2CZL	MA	Inhibitor
DMA2CZL	RN	Synthesis of stable and potent delta/mu opioid peptides: analogues of H-Tyr-c[D-Cys-Gly-Phe-D-Cys]-OH by ring-closing metathesis. J Med Chem. 2007 Jun 28;50(13):3138-42.
DMA2CZL	RU	https://pubmed.ncbi.nlm.nih.gov/17539621

DMXPJHB	DI	DMXPJHB
DMXPJHB	DN	H-Tyr-c[D-Allylgly-Gly-Phe-L-Allylgly]NH2
DMXPJHB	MI	TT27RFC
DMXPJHB	MN	Opioid receptor delta (OPRD1)
DMXPJHB	MT	DTT
DMXPJHB	MA	Inhibitor
DMXPJHB	RN	Dicarba analogues of the cyclic enkephalin peptides H-Tyr-c[D-Cys-Gly-Phe-D(or L)-Cys]NH(2) retain high opioid activity. J Med Chem. 2007 Mar 22;50(6):1414-7.
DMXPJHB	RU	https://pubmed.ncbi.nlm.nih.gov/17315860

DMXPJHB	DI	DMXPJHB
DMXPJHB	DN	H-Tyr-c[D-Allylgly-Gly-Phe-L-Allylgly]NH2
DMXPJHB	MI	TTQW87Y
DMXPJHB	MN	Opioid receptor kappa (OPRK1)
DMXPJHB	MT	DTT
DMXPJHB	MA	Inhibitor
DMXPJHB	RN	Dicarba analogues of the cyclic enkephalin peptides H-Tyr-c[D-Cys-Gly-Phe-D(or L)-Cys]NH(2) retain high opioid activity. J Med Chem. 2007 Mar 22;50(6):1414-7.
DMXPJHB	RU	https://pubmed.ncbi.nlm.nih.gov/17315860

DMXPJHB	DI	DMXPJHB
DMXPJHB	DN	H-Tyr-c[D-Allylgly-Gly-Phe-L-Allylgly]NH2
DMXPJHB	MI	TTKWM86
DMXPJHB	MN	Opioid receptor mu (MOP)
DMXPJHB	MT	DTT
DMXPJHB	MA	Inhibitor
DMXPJHB	RN	Dicarba analogues of the cyclic enkephalin peptides H-Tyr-c[D-Cys-Gly-Phe-D(or L)-Cys]NH(2) retain high opioid activity. J Med Chem. 2007 Mar 22;50(6):1414-7.
DMXPJHB	RU	https://pubmed.ncbi.nlm.nih.gov/17315860

DM7QAES	DI	DM7QAES
DM7QAES	DN	H-Tyr-c[D-Cys-Gly-Phe-D-Cys]NH2
DM7QAES	MI	TT27RFC
DM7QAES	MN	Opioid receptor delta (OPRD1)
DM7QAES	MT	DTT
DM7QAES	MA	Inhibitor
DM7QAES	RN	Dicarba analogues of the cyclic enkephalin peptides H-Tyr-c[D-Cys-Gly-Phe-D(or L)-Cys]NH(2) retain high opioid activity. J Med Chem. 2007 Mar 22;50(6):1414-7.
DM7QAES	RU	https://pubmed.ncbi.nlm.nih.gov/17315860

DM7QAES	DI	DM7QAES
DM7QAES	DN	H-Tyr-c[D-Cys-Gly-Phe-D-Cys]NH2
DM7QAES	MI	TTQW87Y
DM7QAES	MN	Opioid receptor kappa (OPRK1)
DM7QAES	MT	DTT
DM7QAES	MA	Inhibitor
DM7QAES	RN	Dicarba analogues of the cyclic enkephalin peptides H-Tyr-c[D-Cys-Gly-Phe-D(or L)-Cys]NH(2) retain high opioid activity. J Med Chem. 2007 Mar 22;50(6):1414-7.
DM7QAES	RU	https://pubmed.ncbi.nlm.nih.gov/17315860

DM7QAES	DI	DM7QAES
DM7QAES	DN	H-Tyr-c[D-Cys-Gly-Phe-D-Cys]NH2
DM7QAES	MI	TTKWM86
DM7QAES	MN	Opioid receptor mu (MOP)
DM7QAES	MT	DTT
DM7QAES	MA	Inhibitor
DM7QAES	RN	Dicarba analogues of the cyclic enkephalin peptides H-Tyr-c[D-Cys-Gly-Phe-D(or L)-Cys]NH(2) retain high opioid activity. J Med Chem. 2007 Mar 22;50(6):1414-7.
DM7QAES	RU	https://pubmed.ncbi.nlm.nih.gov/17315860

DMZSTL5	DI	DMZSTL5
DMZSTL5	DN	H-Tyr-c[D-Cys-Gly-Phe-L-Cys]NH2
DMZSTL5	MI	TT27RFC
DMZSTL5	MN	Opioid receptor delta (OPRD1)
DMZSTL5	MT	DTT
DMZSTL5	MA	Inhibitor
DMZSTL5	RN	Dicarba analogues of the cyclic enkephalin peptides H-Tyr-c[D-Cys-Gly-Phe-D(or L)-Cys]NH(2) retain high opioid activity. J Med Chem. 2007 Mar 22;50(6):1414-7.
DMZSTL5	RU	https://pubmed.ncbi.nlm.nih.gov/17315860

DMZSTL5	DI	DMZSTL5
DMZSTL5	DN	H-Tyr-c[D-Cys-Gly-Phe-L-Cys]NH2
DMZSTL5	MI	TTQW87Y
DMZSTL5	MN	Opioid receptor kappa (OPRK1)
DMZSTL5	MT	DTT
DMZSTL5	MA	Inhibitor
DMZSTL5	RN	Dicarba analogues of the cyclic enkephalin peptides H-Tyr-c[D-Cys-Gly-Phe-D(or L)-Cys]NH(2) retain high opioid activity. J Med Chem. 2007 Mar 22;50(6):1414-7.
DMZSTL5	RU	https://pubmed.ncbi.nlm.nih.gov/17315860

DMZSTL5	DI	DMZSTL5
DMZSTL5	DN	H-Tyr-c[D-Cys-Gly-Phe-L-Cys]NH2
DMZSTL5	MI	TTKWM86
DMZSTL5	MN	Opioid receptor mu (MOP)
DMZSTL5	MT	DTT
DMZSTL5	MA	Inhibitor
DMZSTL5	RN	Dicarba analogues of the cyclic enkephalin peptides H-Tyr-c[D-Cys-Gly-Phe-D(or L)-Cys]NH(2) retain high opioid activity. J Med Chem. 2007 Mar 22;50(6):1414-7.
DMZSTL5	RU	https://pubmed.ncbi.nlm.nih.gov/17315860

DMI7CR9	DI	DMI7CR9
DMI7CR9	DN	H-Tyr-c[D-Orn-(D or L)Atc-Glu]-NH2
DMI7CR9	MI	TT27RFC
DMI7CR9	MN	Opioid receptor delta (OPRD1)
DMI7CR9	MT	DTT
DMI7CR9	MA	Inhibitor
DMI7CR9	RN	Conformational restriction of the phenylalanine residue in a cyclic opioid peptide analogue: effects on receptor selectivity and stereospecificity. J Med Chem. 1991 Oct;34(10):3125-32.
DMI7CR9	RU	https://pubmed.ncbi.nlm.nih.gov/1656045

DMI7CR9	DI	DMI7CR9
DMI7CR9	DN	H-Tyr-c[D-Orn-(D or L)Atc-Glu]-NH2
DMI7CR9	MI	TTKWM86
DMI7CR9	MN	Opioid receptor mu (MOP)
DMI7CR9	MT	DTT
DMI7CR9	MA	Inhibitor
DMI7CR9	RN	Conformational restriction of the phenylalanine residue in a cyclic opioid peptide analogue: effects on receptor selectivity and stereospecificity. J Med Chem. 1991 Oct;34(10):3125-32.
DMI7CR9	RU	https://pubmed.ncbi.nlm.nih.gov/1656045

DMOTI0P	DI	DMOTI0P
DMOTI0P	DN	H-Tyr-c[D-Orn-Aic-Glu]-NH2
DMOTI0P	MI	TT27RFC
DMOTI0P	MN	Opioid receptor delta (OPRD1)
DMOTI0P	MT	DTT
DMOTI0P	MA	Inhibitor
DMOTI0P	RN	Conformational restriction of the phenylalanine residue in a cyclic opioid peptide analogue: effects on receptor selectivity and stereospecificity. J Med Chem. 1991 Oct;34(10):3125-32.
DMOTI0P	RU	https://pubmed.ncbi.nlm.nih.gov/1656045

DMOTI0P	DI	DMOTI0P
DMOTI0P	DN	H-Tyr-c[D-Orn-Aic-Glu]-NH2
DMOTI0P	MI	TTKWM86
DMOTI0P	MN	Opioid receptor mu (MOP)
DMOTI0P	MT	DTT
DMOTI0P	MA	Inhibitor
DMOTI0P	RN	Conformational restriction of the phenylalanine residue in a cyclic opioid peptide analogue: effects on receptor selectivity and stereospecificity. J Med Chem. 1991 Oct;34(10):3125-32.
DMOTI0P	RU	https://pubmed.ncbi.nlm.nih.gov/1656045

DMAKPM1	DI	DMAKPM1
DMAKPM1	DN	H-Tyr-c[pen-Gly-Phe-pen]OH
DMAKPM1	MI	TT27RFC
DMAKPM1	MN	Opioid receptor delta (OPRD1)
DMAKPM1	MT	DTT
DMAKPM1	MA	Inhibitor
DMAKPM1	RN	Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60.
DMAKPM1	RU	https://pubmed.ncbi.nlm.nih.gov/17350835

DMN2AQO	DI	DMN2AQO
DMN2AQO	DN	H-Tyr-D-Ala-(R or S)Atc-Asp-Val-Val-Gly-NH2
DMN2AQO	MI	TTKWM86
DMN2AQO	MN	Opioid receptor mu (MOP)
DMN2AQO	MT	DTT
DMN2AQO	MA	Inhibitor
DMN2AQO	RN	Phe3-substituted analogues of deltorphin C. Spatial conformation and topography of the aromatic ring in peptide recognition by delta opioid receptors. J Med Chem. 1993 Nov 26;36(24):3748-56.
DMN2AQO	RU	https://pubmed.ncbi.nlm.nih.gov/8254604

DM6ZHWS	DI	DM6ZHWS
DM6ZHWS	DN	H-Tyr-D-Ala-Aic-Asp-Val-Val-Gly-NH2
DM6ZHWS	MI	TTKWM86
DM6ZHWS	MN	Opioid receptor mu (MOP)
DM6ZHWS	MT	DTT
DM6ZHWS	MA	Inhibitor
DM6ZHWS	RN	Phe3-substituted analogues of deltorphin C. Spatial conformation and topography of the aromatic ring in peptide recognition by delta opioid receptors. J Med Chem. 1993 Nov 26;36(24):3748-56.
DM6ZHWS	RU	https://pubmed.ncbi.nlm.nih.gov/8254604

DMDF9AS	DI	DMDF9AS
DMDF9AS	DN	H-Tyr-D-Ala-Gly Phe-Pro-Leu-Trp-O-3,5-Bzl(CF3)2
DMDF9AS	MI	TT27RFC
DMDF9AS	MN	Opioid receptor delta (OPRD1)
DMDF9AS	MT	DTT
DMDF9AS	MA	Inhibitor
DMDF9AS	RN	A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid ... J Med Chem. 2008 Mar 13;51(5):1369-76.
DMDF9AS	RU	https://pubmed.ncbi.nlm.nih.gov/18266313

DMDF9AS	DI	DMDF9AS
DMDF9AS	DN	H-Tyr-D-Ala-Gly Phe-Pro-Leu-Trp-O-3,5-Bzl(CF3)2
DMDF9AS	MI	TTKWM86
DMDF9AS	MN	Opioid receptor mu (MOP)
DMDF9AS	MT	DTT
DMDF9AS	MA	Inhibitor
DMDF9AS	RN	A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid ... J Med Chem. 2008 Mar 13;51(5):1369-76.
DMDF9AS	RU	https://pubmed.ncbi.nlm.nih.gov/18266313

DMDF9AS	DI	DMDF9AS
DMDF9AS	DN	H-Tyr-D-Ala-Gly Phe-Pro-Leu-Trp-O-3,5-Bzl(CF3)2
DMDF9AS	MI	TTZPO1L
DMDF9AS	MN	Substance-P receptor (TACR1)
DMDF9AS	MT	DTT
DMDF9AS	MA	Inhibitor
DMDF9AS	RN	A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid ... J Med Chem. 2008 Mar 13;51(5):1369-76.
DMDF9AS	RU	https://pubmed.ncbi.nlm.nih.gov/18266313

DM4VBDW	DI	DM4VBDW
DM4VBDW	DN	H-Tyr-D-Ala-Gly-Phe-NH-NH-(NMe)Phe-Asp-Nle-Trp-Ac
DM4VBDW	MI	TT27RFC
DM4VBDW	MN	Opioid receptor delta (OPRD1)
DM4VBDW	MT	DTT
DM4VBDW	MA	Inhibitor
DM4VBDW	RN	Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem. 2006 Mar 9;49(5):1773-80.
DM4VBDW	RU	https://pubmed.ncbi.nlm.nih.gov/16509592

DM4VBDW	DI	DM4VBDW
DM4VBDW	DN	H-Tyr-D-Ala-Gly-Phe-NH-NH-(NMe)Phe-Asp-Nle-Trp-Ac
DM4VBDW	MI	TTKWM86
DM4VBDW	MN	Opioid receptor mu (MOP)
DM4VBDW	MT	DTT
DM4VBDW	MA	Inhibitor
DM4VBDW	RN	Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem. 2006 Mar 9;49(5):1773-80.
DM4VBDW	RU	https://pubmed.ncbi.nlm.nih.gov/16509592

DM0J8P6	DI	DM0J8P6
DM0J8P6	DN	H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Phe-D-Asp-D-Nle-Trp-H
DM0J8P6	MI	TT27RFC
DM0J8P6	MN	Opioid receptor delta (OPRD1)
DM0J8P6	MT	DTT
DM0J8P6	MA	Inhibitor
DM0J8P6	RN	Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors. J Med Chem. 2007 Jan 11;50(1):165-8.
DM0J8P6	RU	https://pubmed.ncbi.nlm.nih.gov/17201419

DM0J8P6	DI	DM0J8P6
DM0J8P6	DN	H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Phe-D-Asp-D-Nle-Trp-H
DM0J8P6	MI	TTKWM86
DM0J8P6	MN	Opioid receptor mu (MOP)
DM0J8P6	MT	DTT
DM0J8P6	MA	Inhibitor
DM0J8P6	RN	Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors. J Med Chem. 2007 Jan 11;50(1):165-8.
DM0J8P6	RU	https://pubmed.ncbi.nlm.nih.gov/17201419

DMW50ZQ	DI	DMW50ZQ
DMW50ZQ	DN	H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-Bo
DMW50ZQ	MI	TTVFO0U
DMW50ZQ	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMW50ZQ	MT	DTT
DMW50ZQ	MA	Inhibitor
DMW50ZQ	RN	Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors. J Med Chem. 2007 Jan 11;50(1):165-8.
DMW50ZQ	RU	https://pubmed.ncbi.nlm.nih.gov/17201419

DMW50ZQ	DI	DMW50ZQ
DMW50ZQ	DN	H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-Bo
DMW50ZQ	MI	TT27RFC
DMW50ZQ	MN	Opioid receptor delta (OPRD1)
DMW50ZQ	MT	DTT
DMW50ZQ	MA	Inhibitor
DMW50ZQ	RN	Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors. J Med Chem. 2007 Jan 11;50(1):165-8.
DMW50ZQ	RU	https://pubmed.ncbi.nlm.nih.gov/17201419

DMW50ZQ	DI	DMW50ZQ
DMW50ZQ	DN	H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-Bo
DMW50ZQ	MI	TTKWM86
DMW50ZQ	MN	Opioid receptor mu (MOP)
DMW50ZQ	MT	DTT
DMW50ZQ	MA	Inhibitor
DMW50ZQ	RN	Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors. J Med Chem. 2007 Jan 11;50(1):165-8.
DMW50ZQ	RU	https://pubmed.ncbi.nlm.nih.gov/17201419

DMF82C1	DI	DMF82C1
DMF82C1	DN	H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-H
DMF82C1	MI	TTCG0AL
DMF82C1	MN	Cholecystokinin receptor type A (CCKAR)
DMF82C1	MT	DTT
DMF82C1	MA	Inhibitor
DMF82C1	RN	Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors. J Med Chem. 2007 Jan 11;50(1):165-8.
DMF82C1	RU	https://pubmed.ncbi.nlm.nih.gov/17201419

DMF82C1	DI	DMF82C1
DMF82C1	DN	H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-H
DMF82C1	MI	TTVFO0U
DMF82C1	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMF82C1	MT	DTT
DMF82C1	MA	Inhibitor
DMF82C1	RN	Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors. J Med Chem. 2007 Jan 11;50(1):165-8.
DMF82C1	RU	https://pubmed.ncbi.nlm.nih.gov/17201419

DMF82C1	DI	DMF82C1
DMF82C1	DN	H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-H
DMF82C1	MI	TT27RFC
DMF82C1	MN	Opioid receptor delta (OPRD1)
DMF82C1	MT	DTT
DMF82C1	MA	Inhibitor
DMF82C1	RN	Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors. J Med Chem. 2007 Jan 11;50(1):165-8.
DMF82C1	RU	https://pubmed.ncbi.nlm.nih.gov/17201419

DMF82C1	DI	DMF82C1
DMF82C1	DN	H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-H
DMF82C1	MI	TTKWM86
DMF82C1	MN	Opioid receptor mu (MOP)
DMF82C1	MT	DTT
DMF82C1	MA	Inhibitor
DMF82C1	RN	Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors. J Med Chem. 2007 Jan 11;50(1):165-8.
DMF82C1	RU	https://pubmed.ncbi.nlm.nih.gov/17201419

DM6UWKL	DI	DM6UWKL
DM6UWKL	DN	H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-Boc
DM6UWKL	MI	TT27RFC
DM6UWKL	MN	Opioid receptor delta (OPRD1)
DM6UWKL	MT	DTT
DM6UWKL	MA	Inhibitor
DM6UWKL	RN	Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem. 2006 Mar 9;49(5):1773-80.
DM6UWKL	RU	https://pubmed.ncbi.nlm.nih.gov/16509592

DM6UWKL	DI	DM6UWKL
DM6UWKL	DN	H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-Boc
DM6UWKL	MI	TTKWM86
DM6UWKL	MN	Opioid receptor mu (MOP)
DM6UWKL	MT	DTT
DM6UWKL	MA	Inhibitor
DM6UWKL	RN	Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem. 2006 Mar 9;49(5):1773-80.
DM6UWKL	RU	https://pubmed.ncbi.nlm.nih.gov/16509592

DMSXD63	DI	DMSXD63
DMSXD63	DN	H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-H
DMSXD63	MI	TTCG0AL
DMSXD63	MN	Cholecystokinin receptor type A (CCKAR)
DMSXD63	MT	DTT
DMSXD63	MA	Inhibitor
DMSXD63	RN	Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem. 2006 Mar 9;49(5):1773-80.
DMSXD63	RU	https://pubmed.ncbi.nlm.nih.gov/16509592

DMSXD63	DI	DMSXD63
DMSXD63	DN	H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-H
DMSXD63	MI	TTVFO0U
DMSXD63	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMSXD63	MT	DTT
DMSXD63	MA	Inhibitor
DMSXD63	RN	Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem. 2006 Mar 9;49(5):1773-80.
DMSXD63	RU	https://pubmed.ncbi.nlm.nih.gov/16509592

DMSXD63	DI	DMSXD63
DMSXD63	DN	H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-H
DMSXD63	MI	TT27RFC
DMSXD63	MN	Opioid receptor delta (OPRD1)
DMSXD63	MT	DTT
DMSXD63	MA	Inhibitor
DMSXD63	RN	Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem. 2006 Mar 9;49(5):1773-80.
DMSXD63	RU	https://pubmed.ncbi.nlm.nih.gov/16509592

DMSXD63	DI	DMSXD63
DMSXD63	DN	H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-H
DMSXD63	MI	TTKWM86
DMSXD63	MN	Opioid receptor mu (MOP)
DMSXD63	MT	DTT
DMSXD63	MA	Inhibitor
DMSXD63	RN	Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem. 2006 Mar 9;49(5):1773-80.
DMSXD63	RU	https://pubmed.ncbi.nlm.nih.gov/16509592

DMRUD37	DI	DMRUD37
DMRUD37	DN	H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Ac
DMRUD37	MI	TTVFO0U
DMRUD37	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMRUD37	MT	DTT
DMRUD37	MA	Inhibitor
DMRUD37	RN	Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem. 2006 Mar 9;49(5):1773-80.
DMRUD37	RU	https://pubmed.ncbi.nlm.nih.gov/16509592

DMRUD37	DI	DMRUD37
DMRUD37	DN	H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Ac
DMRUD37	MI	TT27RFC
DMRUD37	MN	Opioid receptor delta (OPRD1)
DMRUD37	MT	DTT
DMRUD37	MA	Inhibitor
DMRUD37	RN	Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem. 2006 Mar 9;49(5):1773-80.
DMRUD37	RU	https://pubmed.ncbi.nlm.nih.gov/16509592

DMRUD37	DI	DMRUD37
DMRUD37	DN	H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Ac
DMRUD37	MI	TTKWM86
DMRUD37	MN	Opioid receptor mu (MOP)
DMRUD37	MT	DTT
DMRUD37	MA	Inhibitor
DMRUD37	RN	Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem. 2006 Mar 9;49(5):1773-80.
DMRUD37	RU	https://pubmed.ncbi.nlm.nih.gov/16509592

DMIPXCZ	DI	DMIPXCZ
DMIPXCZ	DN	H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Boc
DMIPXCZ	MI	TTCG0AL
DMIPXCZ	MN	Cholecystokinin receptor type A (CCKAR)
DMIPXCZ	MT	DTT
DMIPXCZ	MA	Inhibitor
DMIPXCZ	RN	Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem. 2006 Mar 9;49(5):1773-80.
DMIPXCZ	RU	https://pubmed.ncbi.nlm.nih.gov/16509592

DMIPXCZ	DI	DMIPXCZ
DMIPXCZ	DN	H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Boc
DMIPXCZ	MI	TTVFO0U
DMIPXCZ	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMIPXCZ	MT	DTT
DMIPXCZ	MA	Inhibitor
DMIPXCZ	RN	Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem. 2006 Mar 9;49(5):1773-80.
DMIPXCZ	RU	https://pubmed.ncbi.nlm.nih.gov/16509592

DMIPXCZ	DI	DMIPXCZ
DMIPXCZ	DN	H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Boc
DMIPXCZ	MI	TT27RFC
DMIPXCZ	MN	Opioid receptor delta (OPRD1)
DMIPXCZ	MT	DTT
DMIPXCZ	MA	Inhibitor
DMIPXCZ	RN	Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem. 2006 Mar 9;49(5):1773-80.
DMIPXCZ	RU	https://pubmed.ncbi.nlm.nih.gov/16509592

DMIPXCZ	DI	DMIPXCZ
DMIPXCZ	DN	H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Boc
DMIPXCZ	MI	TTKWM86
DMIPXCZ	MN	Opioid receptor mu (MOP)
DMIPXCZ	MT	DTT
DMIPXCZ	MA	Inhibitor
DMIPXCZ	RN	Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem. 2006 Mar 9;49(5):1773-80.
DMIPXCZ	RU	https://pubmed.ncbi.nlm.nih.gov/16509592

DMFSKDM	DI	DMFSKDM
DMFSKDM	DN	H-Tyr-D-Ala-Gly-Phe-NH-NH-Trp-D-Nle-D-Asp-D-Phe-H
DMFSKDM	MI	TTCG0AL
DMFSKDM	MN	Cholecystokinin receptor type A (CCKAR)
DMFSKDM	MT	DTT
DMFSKDM	MA	Inhibitor
DMFSKDM	RN	Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors. J Med Chem. 2007 Jan 11;50(1):165-8.
DMFSKDM	RU	https://pubmed.ncbi.nlm.nih.gov/17201419

DMFSKDM	DI	DMFSKDM
DMFSKDM	DN	H-Tyr-D-Ala-Gly-Phe-NH-NH-Trp-D-Nle-D-Asp-D-Phe-H
DMFSKDM	MI	TT27RFC
DMFSKDM	MN	Opioid receptor delta (OPRD1)
DMFSKDM	MT	DTT
DMFSKDM	MA	Inhibitor
DMFSKDM	RN	Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors. J Med Chem. 2007 Jan 11;50(1):165-8.
DMFSKDM	RU	https://pubmed.ncbi.nlm.nih.gov/17201419

DMFSKDM	DI	DMFSKDM
DMFSKDM	DN	H-Tyr-D-Ala-Gly-Phe-NH-NH-Trp-D-Nle-D-Asp-D-Phe-H
DMFSKDM	MI	TTKWM86
DMFSKDM	MN	Opioid receptor mu (MOP)
DMFSKDM	MT	DTT
DMFSKDM	MA	Inhibitor
DMFSKDM	RN	Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors. J Med Chem. 2007 Jan 11;50(1):165-8.
DMFSKDM	RU	https://pubmed.ncbi.nlm.nih.gov/17201419

DM2K16M	DI	DM2K16M
DM2K16M	DN	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-3,5-Bzl(CF3)2
DM2K16M	MI	TT27RFC
DM2K16M	MN	Opioid receptor delta (OPRD1)
DM2K16M	MT	DTT
DM2K16M	MA	Inhibitor
DM2K16M	RN	A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid ... J Med Chem. 2008 Mar 13;51(5):1369-76.
DM2K16M	RU	https://pubmed.ncbi.nlm.nih.gov/18266313

DM2K16M	DI	DM2K16M
DM2K16M	DN	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-3,5-Bzl(CF3)2
DM2K16M	MI	TTKWM86
DM2K16M	MN	Opioid receptor mu (MOP)
DM2K16M	MT	DTT
DM2K16M	MA	Inhibitor
DM2K16M	RN	A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid ... J Med Chem. 2008 Mar 13;51(5):1369-76.
DM2K16M	RU	https://pubmed.ncbi.nlm.nih.gov/18266313

DM2K16M	DI	DM2K16M
DM2K16M	DN	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-3,5-Bzl(CF3)2
DM2K16M	MI	TTZPO1L
DM2K16M	MN	Substance-P receptor (TACR1)
DM2K16M	MT	DTT
DM2K16M	MA	Inhibitor
DM2K16M	RN	A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid ... J Med Chem. 2008 Mar 13;51(5):1369-76.
DM2K16M	RU	https://pubmed.ncbi.nlm.nih.gov/18266313

DMRE4ZI	DI	DMRE4ZI
DMRE4ZI	DN	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-Bzl
DMRE4ZI	MI	TT27RFC
DMRE4ZI	MN	Opioid receptor delta (OPRD1)
DMRE4ZI	MT	DTT
DMRE4ZI	MA	Inhibitor
DMRE4ZI	RN	A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid ... J Med Chem. 2008 Mar 13;51(5):1369-76.
DMRE4ZI	RU	https://pubmed.ncbi.nlm.nih.gov/18266313

DMRE4ZI	DI	DMRE4ZI
DMRE4ZI	DN	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-Bzl
DMRE4ZI	MI	TTKWM86
DMRE4ZI	MN	Opioid receptor mu (MOP)
DMRE4ZI	MT	DTT
DMRE4ZI	MA	Inhibitor
DMRE4ZI	RN	A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid ... J Med Chem. 2008 Mar 13;51(5):1369-76.
DMRE4ZI	RU	https://pubmed.ncbi.nlm.nih.gov/18266313

DMRE4ZI	DI	DMRE4ZI
DMRE4ZI	DN	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-Bzl
DMRE4ZI	MI	TTZPO1L
DMRE4ZI	MN	Substance-P receptor (TACR1)
DMRE4ZI	MT	DTT
DMRE4ZI	MA	Inhibitor
DMRE4ZI	RN	A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid ... J Med Chem. 2008 Mar 13;51(5):1369-76.
DMRE4ZI	RU	https://pubmed.ncbi.nlm.nih.gov/18266313

DM1ESMZ	DI	DM1ESMZ
DM1ESMZ	DN	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-3,5-Bzl(CF3)2
DM1ESMZ	MI	TT27RFC
DM1ESMZ	MN	Opioid receptor delta (OPRD1)
DM1ESMZ	MT	DTT
DM1ESMZ	MA	Inhibitor
DM1ESMZ	RN	A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid ... J Med Chem. 2008 Mar 13;51(5):1369-76.
DM1ESMZ	RU	https://pubmed.ncbi.nlm.nih.gov/18266313

DM1ESMZ	DI	DM1ESMZ
DM1ESMZ	DN	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-3,5-Bzl(CF3)2
DM1ESMZ	MI	TTKWM86
DM1ESMZ	MN	Opioid receptor mu (MOP)
DM1ESMZ	MT	DTT
DM1ESMZ	MA	Inhibitor
DM1ESMZ	RN	A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid ... J Med Chem. 2008 Mar 13;51(5):1369-76.
DM1ESMZ	RU	https://pubmed.ncbi.nlm.nih.gov/18266313

DM1ESMZ	DI	DM1ESMZ
DM1ESMZ	DN	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-3,5-Bzl(CF3)2
DM1ESMZ	MI	TTZPO1L
DM1ESMZ	MN	Substance-P receptor (TACR1)
DM1ESMZ	MT	DTT
DM1ESMZ	MA	Inhibitor
DM1ESMZ	RN	A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid ... J Med Chem. 2008 Mar 13;51(5):1369-76.
DM1ESMZ	RU	https://pubmed.ncbi.nlm.nih.gov/18266313

DM56KDV	DI	DM56KDV
DM56KDV	DN	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-Bzl
DM56KDV	MI	TT27RFC
DM56KDV	MN	Opioid receptor delta (OPRD1)
DM56KDV	MT	DTT
DM56KDV	MA	Inhibitor
DM56KDV	RN	A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid ... J Med Chem. 2008 Mar 13;51(5):1369-76.
DM56KDV	RU	https://pubmed.ncbi.nlm.nih.gov/18266313

DM56KDV	DI	DM56KDV
DM56KDV	DN	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-Bzl
DM56KDV	MI	TTKWM86
DM56KDV	MN	Opioid receptor mu (MOP)
DM56KDV	MT	DTT
DM56KDV	MA	Inhibitor
DM56KDV	RN	A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid ... J Med Chem. 2008 Mar 13;51(5):1369-76.
DM56KDV	RU	https://pubmed.ncbi.nlm.nih.gov/18266313

DM56KDV	DI	DM56KDV
DM56KDV	DN	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-Bzl
DM56KDV	MI	TTZPO1L
DM56KDV	MN	Substance-P receptor (TACR1)
DM56KDV	MT	DTT
DM56KDV	MA	Inhibitor
DM56KDV	RN	A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid ... J Med Chem. 2008 Mar 13;51(5):1369-76.
DM56KDV	RU	https://pubmed.ncbi.nlm.nih.gov/18266313

DMH3YKR	DI	DMH3YKR
DMH3YKR	DN	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-O-Bzl
DMH3YKR	MI	TT27RFC
DMH3YKR	MN	Opioid receptor delta (OPRD1)
DMH3YKR	MT	DTT
DMH3YKR	MA	Inhibitor
DMH3YKR	RN	A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid ... J Med Chem. 2008 Mar 13;51(5):1369-76.
DMH3YKR	RU	https://pubmed.ncbi.nlm.nih.gov/18266313

DMH3YKR	DI	DMH3YKR
DMH3YKR	DN	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-O-Bzl
DMH3YKR	MI	TTKWM86
DMH3YKR	MN	Opioid receptor mu (MOP)
DMH3YKR	MT	DTT
DMH3YKR	MA	Inhibitor
DMH3YKR	RN	A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid ... J Med Chem. 2008 Mar 13;51(5):1369-76.
DMH3YKR	RU	https://pubmed.ncbi.nlm.nih.gov/18266313

DMH3YKR	DI	DMH3YKR
DMH3YKR	DN	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-O-Bzl
DMH3YKR	MI	TTZPO1L
DMH3YKR	MN	Substance-P receptor (TACR1)
DMH3YKR	MT	DTT
DMH3YKR	MA	Inhibitor
DMH3YKR	RN	A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid ... J Med Chem. 2008 Mar 13;51(5):1369-76.
DMH3YKR	RU	https://pubmed.ncbi.nlm.nih.gov/18266313

DMSX8CH	DI	DMSX8CH
DMSX8CH	DN	H-Tyr-D-Ala-Tic-Asp-Val-Val-Gly-NH2
DMSX8CH	MI	TTKWM86
DMSX8CH	MN	Opioid receptor mu (MOP)
DMSX8CH	MT	DTT
DMSX8CH	MA	Inhibitor
DMSX8CH	RN	Phe3-substituted analogues of deltorphin C. Spatial conformation and topography of the aromatic ring in peptide recognition by delta opioid receptors. J Med Chem. 1993 Nov 26;36(24):3748-56.
DMSX8CH	RU	https://pubmed.ncbi.nlm.nih.gov/8254604

DM25KZE	DI	DM25KZE
DM25KZE	DN	HTyr-Gly-Gly-Phe-Leu-Arg-Arg-lle-Arg-Pro-LysNH2
DM25KZE	MI	TT27RFC
DM25KZE	MN	Opioid receptor delta (OPRD1)
DM25KZE	MT	DTT
DM25KZE	MA	Inhibitor
DM25KZE	RN	The effects of C-terminal modifications on the opioid activity of [N-benzylTyr(1)]dynorphin A-(1-11) analogues. J Med Chem. 2009 Nov 12;52(21):6814-21.
DM25KZE	RU	https://pubmed.ncbi.nlm.nih.gov/19807094

DM25KZE	DI	DM25KZE
DM25KZE	DN	HTyr-Gly-Gly-Phe-Leu-Arg-Arg-lle-Arg-Pro-LysNH2
DM25KZE	MI	TTQW87Y
DM25KZE	MN	Opioid receptor kappa (OPRK1)
DM25KZE	MT	DTT
DM25KZE	MA	Inhibitor
DM25KZE	RN	The effects of C-terminal modifications on the opioid activity of [N-benzylTyr(1)]dynorphin A-(1-11) analogues. J Med Chem. 2009 Nov 12;52(21):6814-21.
DM25KZE	RU	https://pubmed.ncbi.nlm.nih.gov/19807094

DM25KZE	DI	DM25KZE
DM25KZE	DN	HTyr-Gly-Gly-Phe-Leu-Arg-Arg-lle-Arg-Pro-LysNH2
DM25KZE	MI	TTKWM86
DM25KZE	MN	Opioid receptor mu (MOP)
DM25KZE	MT	DTT
DM25KZE	MA	Inhibitor
DM25KZE	RN	The effects of C-terminal modifications on the opioid activity of [N-benzylTyr(1)]dynorphin A-(1-11) analogues. J Med Chem. 2009 Nov 12;52(21):6814-21.
DM25KZE	RU	https://pubmed.ncbi.nlm.nih.gov/19807094

DM6D0ZS	DI	DM6D0ZS
DM6D0ZS	DN	H-Tyr-Gly-Gly-Phe-Met-NH2
DM6D0ZS	MI	TT27RFC
DM6D0ZS	MN	Opioid receptor delta (OPRD1)
DM6D0ZS	MT	DTT
DM6D0ZS	MA	Inhibitor
DM6D0ZS	RN	Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60.
DM6D0ZS	RU	https://pubmed.ncbi.nlm.nih.gov/17350835

DM6D0ZS	DI	DM6D0ZS
DM6D0ZS	DN	H-Tyr-Gly-Gly-Phe-Met-NH2
DM6D0ZS	MI	TTQW87Y
DM6D0ZS	MN	Opioid receptor kappa (OPRK1)
DM6D0ZS	MT	DTT
DM6D0ZS	MA	Inhibitor
DM6D0ZS	RN	Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60.
DM6D0ZS	RU	https://pubmed.ncbi.nlm.nih.gov/17350835

DM6D0ZS	DI	DM6D0ZS
DM6D0ZS	DN	H-Tyr-Gly-Gly-Phe-Met-NH2
DM6D0ZS	MI	TTKWM86
DM6D0ZS	MN	Opioid receptor mu (MOP)
DM6D0ZS	MT	DTT
DM6D0ZS	MA	Inhibitor
DM6D0ZS	RN	Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60.
DM6D0ZS	RU	https://pubmed.ncbi.nlm.nih.gov/17350835

DM1NT5G	DI	DM1NT5G
DM1NT5G	DN	H-Tyr-NMe-D-Ala-Phe-Sar-NH2
DM1NT5G	MI	TT27RFC
DM1NT5G	MN	Opioid receptor delta (OPRD1)
DM1NT5G	MT	DTT
DM1NT5G	MA	Inhibitor
DM1NT5G	RN	Blood-brain barrier penetration by two dermorphin tetrapeptide analogues: role of lipophilicity vs structural flexibility. J Med Chem. 2008 Apr 24;51(8):2571-4.
DM1NT5G	RU	https://pubmed.ncbi.nlm.nih.gov/18370374

DMP0CRD	DI	DMP0CRD
DMP0CRD	DN	H-Tyr-Pro-Ala-Phe-NH2
DMP0CRD	MI	TTKWM86
DMP0CRD	MN	Opioid receptor mu (MOP)
DMP0CRD	MT	DTT
DMP0CRD	MA	Inhibitor
DMP0CRD	RN	Internalisation of the mu-opioid receptor by endomorphin-1 and leu-enkephalin is dependant on aromatic amino acid residues. Bioorg Med Chem. 2008 Apr 15;16(8):4341-6.
DMP0CRD	RU	https://pubmed.ncbi.nlm.nih.gov/18329886

DMP0CRD	DI	DMP0CRD
DMP0CRD	DN	H-Tyr-Pro-Ala-Phe-NH2
DMP0CRD	MI	TTZPO1L
DMP0CRD	MN	Substance-P receptor (TACR1)
DMP0CRD	MT	DTT
DMP0CRD	MA	Inhibitor
DMP0CRD	RN	Discovery of dipeptides with high affinity to the specific binding site for substance P1-7. J Med Chem. 2010 Mar 25;53(6):2383-9.
DMP0CRD	RU	https://pubmed.ncbi.nlm.nih.gov/20178322

DMQUNGC	DI	DMQUNGC
DMQUNGC	DN	H-Tyr-Pro-Dap(6DMN)-Phe-NH2
DMQUNGC	MI	TT27RFC
DMQUNGC	MN	Opioid receptor delta (OPRD1)
DMQUNGC	MT	DTT
DMQUNGC	MA	Inhibitor
DMQUNGC	RN	6-N,N-dimethylamino-2,3-naphthalimide: a new environment-sensitive fluorescent probe in delta- and mu-selective opioid peptides. J Med Chem. 2006 Jun 15;49(12):3653-8.
DMQUNGC	RU	https://pubmed.ncbi.nlm.nih.gov/16759107

DMQUNGC	DI	DMQUNGC
DMQUNGC	DN	H-Tyr-Pro-Dap(6DMN)-Phe-NH2
DMQUNGC	MI	TTKWM86
DMQUNGC	MN	Opioid receptor mu (MOP)
DMQUNGC	MT	DTT
DMQUNGC	MA	Inhibitor
DMQUNGC	RN	6-N,N-dimethylamino-2,3-naphthalimide: a new environment-sensitive fluorescent probe in delta- and mu-selective opioid peptides. J Med Chem. 2006 Jun 15;49(12):3653-8.
DMQUNGC	RU	https://pubmed.ncbi.nlm.nih.gov/16759107

DM2F6L9	DI	DM2F6L9
DM2F6L9	DN	H-Tyr-Pro-Phe-Ala-NH2
DM2F6L9	MI	TTZPO1L
DM2F6L9	MN	Substance-P receptor (TACR1)
DM2F6L9	MT	DTT
DM2F6L9	MA	Inhibitor
DM2F6L9	RN	Discovery of dipeptides with high affinity to the specific binding site for substance P1-7. J Med Chem. 2010 Mar 25;53(6):2383-9.
DM2F6L9	RU	https://pubmed.ncbi.nlm.nih.gov/20178322

DM326GJ	DI	DM326GJ
DM326GJ	DN	H-Tyr-Pro-Phe-Phe-NH-(CH2)5-(C=O)-Dap(6DMN)-NH2
DM326GJ	MI	TT27RFC
DM326GJ	MN	Opioid receptor delta (OPRD1)
DM326GJ	MT	DTT
DM326GJ	MA	Inhibitor
DM326GJ	RN	6-N,N-dimethylamino-2,3-naphthalimide: a new environment-sensitive fluorescent probe in delta- and mu-selective opioid peptides. J Med Chem. 2006 Jun 15;49(12):3653-8.
DM326GJ	RU	https://pubmed.ncbi.nlm.nih.gov/16759107

DM326GJ	DI	DM326GJ
DM326GJ	DN	H-Tyr-Pro-Phe-Phe-NH-(CH2)5-(C=O)-Dap(6DMN)-NH2
DM326GJ	MI	TTKWM86
DM326GJ	MN	Opioid receptor mu (MOP)
DM326GJ	MT	DTT
DM326GJ	MA	Inhibitor
DM326GJ	RN	6-N,N-dimethylamino-2,3-naphthalimide: a new environment-sensitive fluorescent probe in delta- and mu-selective opioid peptides. J Med Chem. 2006 Jun 15;49(12):3653-8.
DM326GJ	RU	https://pubmed.ncbi.nlm.nih.gov/16759107

DMXQUKJ	DI	DMXQUKJ
DMXQUKJ	DN	H-Tyr-Pro-Phe-Phe-NH-CH2-CH2-NH Tic Dmt-H
DMXQUKJ	MI	TT27RFC
DMXQUKJ	MN	Opioid receptor delta (OPRD1)
DMXQUKJ	MT	DTT
DMXQUKJ	MA	Inhibitor
DMXQUKJ	RN	A new opioid designed multiple ligand derived from the micro opioid agonist endomorphin-2 and the delta opioid antagonist pharmacophore Dmt-Tic. Bioorg Med Chem. 2007 Nov 15;15(22):6876-81.
DMXQUKJ	RU	https://pubmed.ncbi.nlm.nih.gov/17851080

DMXQUKJ	DI	DMXQUKJ
DMXQUKJ	DN	H-Tyr-Pro-Phe-Phe-NH-CH2-CH2-NH Tic Dmt-H
DMXQUKJ	MI	TTKWM86
DMXQUKJ	MN	Opioid receptor mu (MOP)
DMXQUKJ	MT	DTT
DMXQUKJ	MA	Inhibitor
DMXQUKJ	RN	A new opioid designed multiple ligand derived from the micro opioid agonist endomorphin-2 and the delta opioid antagonist pharmacophore Dmt-Tic. Bioorg Med Chem. 2007 Nov 15;15(22):6876-81.
DMXQUKJ	RU	https://pubmed.ncbi.nlm.nih.gov/17851080

DMUQLRN	DI	DMUQLRN
DMUQLRN	DN	H-Tyr-Pro-Phe-Phe-OH
DMUQLRN	MI	TTZPO1L
DMUQLRN	MN	Substance-P receptor (TACR1)
DMUQLRN	MT	DTT
DMUQLRN	MA	Inhibitor
DMUQLRN	RN	Discovery of dipeptides with high affinity to the specific binding site for substance P1-7. J Med Chem. 2010 Mar 25;53(6):2383-9.
DMUQLRN	RU	https://pubmed.ncbi.nlm.nih.gov/20178322

DM1VFLG	DI	DM1VFLG
DM1VFLG	DN	H-Tyr-Tic-Cha-Phe-OH
DM1VFLG	MI	TT27RFC
DM1VFLG	MN	Opioid receptor delta (OPRD1)
DM1VFLG	MT	DTT
DM1VFLG	MA	Inhibitor
DM1VFLG	RN	Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. J Med Chem. 2007 Jan 25;50(2):328-33.
DM1VFLG	RU	https://pubmed.ncbi.nlm.nih.gov/17228874

DM1VFLG	DI	DM1VFLG
DM1VFLG	DN	H-Tyr-Tic-Cha-Phe-OH
DM1VFLG	MI	TTKWM86
DM1VFLG	MN	Opioid receptor mu (MOP)
DM1VFLG	MT	DTT
DM1VFLG	MA	Inhibitor
DM1VFLG	RN	Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. J Med Chem. 2007 Jan 25;50(2):328-33.
DM1VFLG	RU	https://pubmed.ncbi.nlm.nih.gov/17228874

DMIU52O	DI	DMIU52O
DMIU52O	DN	H-Tyr-Tic-OH
DMIU52O	MI	TT27RFC
DMIU52O	MN	Opioid receptor delta (OPRD1)
DMIU52O	MT	DTT
DMIU52O	MA	Inhibitor
DMIU52O	RN	Agonist vs antagonist behavior of delta opioid peptides containing novel phenylalanine analogues in place of Tyr(1). J Med Chem. 2009 Nov 12;52(21):6941-5.
DMIU52O	RU	https://pubmed.ncbi.nlm.nih.gov/19827750

DMI0U87	DI	DMI0U87
DMI0U87	DN	H-Tyr-Tic-Phe-Phe-OH
DMI0U87	MI	TT27RFC
DMI0U87	MN	Opioid receptor delta (OPRD1)
DMI0U87	MT	DTT
DMI0U87	MA	Inhibitor
DMI0U87	RN	The TIPP opioid peptide family: development of delta antagonists, delta agonists, and mixed mu agonist/delta antagonists. Biopolymers. 1999;51(6):411-25.
DMI0U87	RU	https://pubmed.ncbi.nlm.nih.gov/10797230

DMI0U87	DI	DMI0U87
DMI0U87	DN	H-Tyr-Tic-Phe-Phe-OH
DMI0U87	MI	TTKWM86
DMI0U87	MN	Opioid receptor mu (MOP)
DMI0U87	MT	DTT
DMI0U87	MA	Inhibitor
DMI0U87	RN	Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. J Med Chem. 2007 Jan 25;50(2):328-33.
DMI0U87	RU	https://pubmed.ncbi.nlm.nih.gov/17228874

DM48F3D	DI	DM48F3D
DM48F3D	DN	HU210
DM48F3D	MI	TT6OEDT
DM48F3D	MN	Cannabinoid receptor 1 (CB1)
DM48F3D	MT	DTT
DM48F3D	MA	Agonist
DM48F3D	RN	The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest. 2004 Apr;113(8):1202-9.
DM48F3D	RU	https://pubmed.ncbi.nlm.nih.gov/15085199

DMPLG4R	DI	DMPLG4R
DMPLG4R	DN	HU-433
DMPLG4R	MI	TTMSFAW
DMPLG4R	MN	Cannabinoid receptor 2 (CB2)
DMPLG4R	MT	DTT
DMPLG4R	MA	Activator
DMPLG4R	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 57).
DMPLG4R	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=57

DM8FLVH	DI	DM8FLVH
DM8FLVH	DN	Human CD40 agonist ligand
DM8FLVH	MI	TTN6Y9A
DM8FLVH	MN	CD40L receptor (CD40)
DM8FLVH	MT	DTT
DM8FLVH	MA	Agonist
DM8FLVH	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1874).
DM8FLVH	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1874

DMFV5UL	DI	DMFV5UL
DMFV5UL	DN	human monoclonal antibodies (GM-CSF)
DMFV5UL	MI	TTNYZG2
DMFV5UL	MN	Granulocyte-macrophage colony-stimulating factor (CSF2)
DMFV5UL	MT	DTT
DMFV5UL	MA	Modulator
DMFV5UL	RN	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
DMFV5UL	RU	https://www.ncbi.nlm.nih.gov/pubmed/27899562

DMARY2Z	DI	DMARY2Z
DMARY2Z	DN	Human recombinant factor VIIa
DMARY2Z	MI	TTF0EGX
DMARY2Z	MN	Coagulation factor VII (F7)
DMARY2Z	MT	DTT
DMARY2Z	MA	Modulator
DMARY2Z	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2363).
DMARY2Z	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2363

DMG1BYH	DI	DMG1BYH
DMG1BYH	DN	Human recombinant factor VIII
DMG1BYH	MI	TT1290U
DMG1BYH	MN	Coagulation factor VIII (F8)
DMG1BYH	MT	DTT
DMG1BYH	MA	Modulator
DMG1BYH	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2607).
DMG1BYH	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2607

DM4FIZJ	DI	DM4FIZJ
DM4FIZJ	DN	HuMax-CD38b
DM4FIZJ	MI	TTPURFN
DM4FIZJ	MN	Cyclic ADP-ribose hydrolase 1 (CD38)
DM4FIZJ	MT	DTT
DM4FIZJ	MA	Modulator
DM4FIZJ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2766).
DM4FIZJ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2766

DM8AG5R	DI	DM8AG5R
DM8AG5R	DN	HuMax-cMet
DM8AG5R	MI	TTNDSF4
DM8AG5R	MN	Proto-oncogene c-Met (MET)
DM8AG5R	MT	DTT
DM8AG5R	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
DM8AG5R	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815

DMTPXB6	DI	DMTPXB6
DMTPXB6	DN	Huprine X
DMTPXB6	MI	TT1RS9F
DMTPXB6	MN	Acetylcholinesterase (AChE)
DMTPXB6	MT	DTT
DMTPXB6	MA	Inhibitor
DMTPXB6	RN	Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely... J Med Chem. 2008 Jun 12;51(11):3154-70.
DMTPXB6	RU	https://pubmed.ncbi.nlm.nih.gov/18479118

DMTPXB6	DI	DMTPXB6
DMTPXB6	DN	Huprine X
DMTPXB6	MI	TTEB0GD
DMTPXB6	MN	Cholinesterase (BCHE)
DMTPXB6	MT	DTT
DMTPXB6	MA	Inhibitor
DMTPXB6	RN	Discovery of huperzine A-tacrine hybrids as potent inhibitors of human cholinesterases targeting their midgorge recognition sites. J Med Chem. 2006 Jun 1;49(11):3421-5.
DMTPXB6	RU	https://pubmed.ncbi.nlm.nih.gov/16722663

DMYH0XQ	DI	DMYH0XQ
DMYH0XQ	DN	Huprine Y
DMYH0XQ	MI	TT1RS9F
DMYH0XQ	MN	Acetylcholinesterase (AChE)
DMYH0XQ	MT	DTT
DMYH0XQ	MA	Inhibitor
DMYH0XQ	RN	Synthesis and structure-activity relationship of Huprine derivatives as human acetylcholinesterase inhibitors. Bioorg Med Chem. 2009 Jul 1;17(13):4523-36.
DMYH0XQ	RU	https://pubmed.ncbi.nlm.nih.gov/19473849

DMJ4ME7	DI	DMJ4ME7
DMJ4ME7	DN	Huprine-Tacrine Heterodimer
DMJ4ME7	MI	TT1RS9F
DMJ4ME7	MN	Acetylcholinesterase (AChE)
DMJ4ME7	MT	DTT
DMJ4ME7	MA	Inhibitor
DMJ4ME7	RN	Synthesis and pharmacological evaluation of huprine-tacrine heterodimers: subnanomolar dual binding site acetylcholinesterase inhibitors. J Med Chem. 2005 Mar 24;48(6):1701-4.
DMJ4ME7	RU	https://pubmed.ncbi.nlm.nih.gov/15771413

DMJ4ME7	DI	DMJ4ME7
DMJ4ME7	DN	Huprine-Tacrine Heterodimer
DMJ4ME7	MI	TTEB0GD
DMJ4ME7	MN	Cholinesterase (BCHE)
DMJ4ME7	MT	DTT
DMJ4ME7	MA	Inhibitor
DMJ4ME7	RN	Synthesis and pharmacological evaluation of huprine-tacrine heterodimers: subnanomolar dual binding site acetylcholinesterase inhibitors. J Med Chem. 2005 Mar 24;48(6):1701-4.
DMJ4ME7	RU	https://pubmed.ncbi.nlm.nih.gov/15771413

DM1D5F0	DI	DM1D5F0
DM1D5F0	DN	HwFwLL-NH2
DM1D5F0	MI	TTWDC17
DM1D5F0	MN	Growth hormone secretagogue receptor 1 (GHSR)
DM1D5F0	MT	DTT
DM1D5F0	MA	Inhibitor
DM1D5F0	RN	Identification of an efficacy switch region in the ghrelin receptor responsible for interchange between agonism and inverse agonism. J Biol Chem. 2007 May 25;282(21):15799-811.
DM1D5F0	RU	https://pubmed.ncbi.nlm.nih.gov/17371869

DMJ9KNU	DI	DMJ9KNU
DMJ9KNU	DN	Hyacinthacine B3
DMJ9KNU	MI	TTA0OSE
DMJ9KNU	MN	Lactase-phlorizin hydrolase (LCT)
DMJ9KNU	MT	DTT
DMJ9KNU	MA	Inhibitor
DMJ9KNU	RN	New polyhydroxylated pyrrolidine, piperidine, and pyrrolizidine alkaloids from Scilla sibirica. J Nat Prod. 2002 Dec;65(12):1875-81.
DMJ9KNU	RU	https://pubmed.ncbi.nlm.nih.gov/12502331

DMY5RDI	DI	DMY5RDI
DMY5RDI	DN	HYDAMTIQ
DMY5RDI	MI	TTVDSZ0
DMY5RDI	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMY5RDI	MT	DTT
DMY5RDI	MA	Inhibitor
DMY5RDI	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2771).
DMY5RDI	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2771

DMOTXP1	DI	DMOTXP1
DMOTXP1	DN	Hydantocidin-5'-Monophosphate
DMOTXP1	MI	TTYQ4AE
DMOTXP1	MN	Plasmodium Adenylosuccinate synthetase (Malaria Adss)
DMOTXP1	MT	DTT
DMOTXP1	MA	Inhibitor
DMOTXP1	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMOTXP1	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMARWG5	DI	DMARWG5
DMARWG5	DN	HYDRAZINECARBOXAMIDE
DMARWG5	MI	TT3WG5C
DMARWG5	MN	Monoamine oxidase type A (MAO-A)
DMARWG5	MT	DTT
DMARWG5	MA	Inhibitor
DMARWG5	RN	Fluorinated phenylcyclopropylamines. 2. Effects of aromatic ring substitution and of absolute configuration on inhibition of microbial tyramine oxi... J Med Chem. 2004 Nov 18;47(24):5860-71.
DMARWG5	RU	https://pubmed.ncbi.nlm.nih.gov/15537343

DMARWG5	DI	DMARWG5
DMARWG5	DN	HYDRAZINECARBOXAMIDE
DMARWG5	MI	TTGP7BY
DMARWG5	MN	Monoamine oxidase type B (MAO-B)
DMARWG5	MT	DTT
DMARWG5	MA	Inhibitor
DMARWG5	RN	Fluorinated phenylcyclopropylamines. 2. Effects of aromatic ring substitution and of absolute configuration on inhibition of microbial tyramine oxi... J Med Chem. 2004 Nov 18;47(24):5860-71.
DMARWG5	RU	https://pubmed.ncbi.nlm.nih.gov/15537343

DM0HQF6	DI	DM0HQF6
DM0HQF6	DN	Hydrohalisulfate 1
DM0HQF6	MI	TTN9T81
DM0HQF6	MN	Arachidonate 15-lipoxygenase (15-LOX)
DM0HQF6	MT	DTT
DM0HQF6	MA	Inhibitor
DM0HQF6	RN	Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases. J Nat Prod. 2003 Feb;66(2):230-5.
DM0HQF6	RU	https://pubmed.ncbi.nlm.nih.gov/12608855

DM0HQF6	DI	DM0HQF6
DM0HQF6	DN	Hydrohalisulfate 1
DM0HQF6	MI	TT58ZYW
DM0HQF6	MN	Mycobacterium Isocitrate lyase (MycB icl)
DM0HQF6	MT	DTT
DM0HQF6	MA	Inhibitor
DM0HQF6	RN	Sesterterpene sulfates as isocitrate lyase inhibitors from tropical sponge Hippospongia sp. Bioorg Med Chem Lett. 2007 May 1;17(9):2483-6.
DM0HQF6	RU	https://pubmed.ncbi.nlm.nih.gov/17317180

DMWH92F	DI	DMWH92F
DMWH92F	DN	Hydrolyzed Cephalothin
DMWH92F	MI	TTHI19T
DMWH92F	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMWH92F	MT	DTT
DMWH92F	MA	Inhibitor
DMWH92F	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMWH92F	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMO32HN	DI	DMO32HN
DMO32HN	DN	HYDROSULFIDE
DMO32HN	MI	TTHQPL7
DMO32HN	MN	Carbonic anhydrase I (CA-I)
DMO32HN	MT	DTT
DMO32HN	MA	Inhibitor
DMO32HN	RN	Carbonic anhydrase inhibitors: inhibition of the membrane-bound human isozyme IV with anions. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5769-73.
DMO32HN	RU	https://pubmed.ncbi.nlm.nih.gov/15501038

DMO32HN	DI	DMO32HN
DMO32HN	DN	HYDROSULFIDE
DMO32HN	MI	TTANPDJ
DMO32HN	MN	Carbonic anhydrase II (CA-II)
DMO32HN	MT	DTT
DMO32HN	MA	Inhibitor
DMO32HN	RN	Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5435-9.
DMO32HN	RU	https://pubmed.ncbi.nlm.nih.gov/15454240

DMO32HN	DI	DMO32HN
DMO32HN	DN	HYDROSULFIDE
DMO32HN	MI	TT2LVK8
DMO32HN	MN	Carbonic anhydrase IX (CA-IX)
DMO32HN	MT	DTT
DMO32HN	MA	Inhibitor
DMO32HN	RN	Carbonic anhydrase inhibitors: inhibition of the membrane-bound human isozyme IV with anions. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5769-73.
DMO32HN	RU	https://pubmed.ncbi.nlm.nih.gov/15501038

DMA4SIN	DI	DMA4SIN
DMA4SIN	DN	HYDROXY[3-(6-METHYLPYRIDIN-2-YL)PROPYL]FORMAMIDE
DMA4SIN	MI	TTICO5G
DMA4SIN	MN	Staphylococcus Peptide deformylase (Stap-coc def)
DMA4SIN	MT	DTT
DMA4SIN	MA	Inhibitor
DMA4SIN	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMA4SIN	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMQFBH6	DI	DMQFBH6
DMQFBH6	DN	Hydroxyacetic acid
DMQFBH6	MI	TTKN8W0
DMQFBH6	MN	Glucose-6-phosphate dehydrogenase (G6PD)
DMQFBH6	MT	DTT
DMQFBH6	MA	Inhibitor
DMQFBH6	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMQFBH6	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMQFBH6	DI	DMQFBH6
DMQFBH6	DN	Hydroxyacetic acid
DMQFBH6	MI	DT342ZG
DMQFBH6	MN	Monocarboxylate transporter 1 (SLC16A1)
DMQFBH6	MT	DTP
DMQFBH6	MA	Substrate
DMQFBH6	RN	Cidofovir peptide conjugates as prodrugs. Journal of Organometallic Chemistry, 2005, 690(10):2673-2678.
DMQFBH6	RU	https://doi.org/10.1016/j.jorganchem.2005.03.004

DM5HWZY	DI	DM5HWZY
DM5HWZY	DN	Hydroxyalanine
DM5HWZY	MI	TTBFROQ
DM5HWZY	MN	S-adenosylmethionine decarboxylase proenzyme (AMD1)
DM5HWZY	MT	DTT
DM5HWZY	MA	Inhibitor
DM5HWZY	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DM5HWZY	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMUVCRQ	DI	DMUVCRQ
DMUVCRQ	DN	Hydroxyaminovaline
DMUVCRQ	MI	TTHY57M
DMUVCRQ	MN	Matrix metalloproteinase-13 (MMP-13)
DMUVCRQ	MT	DTT
DMUVCRQ	MA	Inhibitor
DMUVCRQ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMUVCRQ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMUVCRQ	DI	DMUVCRQ
DMUVCRQ	DN	Hydroxyaminovaline
DMUVCRQ	MI	TTUZ2L5
DMUVCRQ	MN	Matrix metalloproteinase-3 (MMP-3)
DMUVCRQ	MT	DTT
DMUVCRQ	MA	Inhibitor
DMUVCRQ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMUVCRQ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9H5EN	DI	DM9H5EN
DM9H5EN	DN	Hydroxybenzo(a)pyrene
DM9H5EN	MI	DENZ6B1
DM9H5EN	MN	UDP-glucuronosyltransferase 2B15 (UGT2B15)
DM9H5EN	MT	DME
DM9H5EN	MA	Metabolism
DM9H5EN	RN	Importance of UDP-glucuronosyltransferase 1A10 (UGT1A10) in the detoxification of polycyclic aromatic hydrocarbons: decreased glucuronidative activity of the UGT1A10139Lys isoform. Drug Metab Dispos. 2006 Jun;34(6):943-9.
DM9H5EN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16510539

DM9H5EN	DI	DM9H5EN
DM9H5EN	DN	Hydroxybenzo(a)pyrene
DM9H5EN	MI	DEAZDL8
DM9H5EN	MN	UDP-glucuronosyltransferase 2B17 (UGT2B17)
DM9H5EN	MT	DME
DM9H5EN	MA	Metabolism
DM9H5EN	RN	Importance of UDP-glucuronosyltransferase 1A10 (UGT1A10) in the detoxification of polycyclic aromatic hydrocarbons: decreased glucuronidative activity of the UGT1A10139Lys isoform. Drug Metab Dispos. 2006 Jun;34(6):943-9.
DM9H5EN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16510539

DMFSKYE	DI	DMFSKYE
DMFSKYE	DN	Hydroxybenzo[a]pyrene
DMFSKYE	MI	DENZ6B1
DMFSKYE	MN	UDP-glucuronosyltransferase 2B15 (UGT2B15)
DMFSKYE	MT	DME
DMFSKYE	MA	Metabolism
DMFSKYE	RN	Importance of UDP-glucuronosyltransferase 1A10 (UGT1A10) in the detoxification of polycyclic aromatic hydrocarbons: decreased glucuronidative activity of the UGT1A10139Lys isoform. Drug Metab Dispos. 2006 Jun;34(6):943-9.
DMFSKYE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16510539

DMFSKYE	DI	DMFSKYE
DMFSKYE	DN	Hydroxybenzo[a]pyrene
DMFSKYE	MI	DEAZDL8
DMFSKYE	MN	UDP-glucuronosyltransferase 2B17 (UGT2B17)
DMFSKYE	MT	DME
DMFSKYE	MA	Metabolism
DMFSKYE	RN	Importance of UDP-glucuronosyltransferase 1A10 (UGT1A10) in the detoxification of polycyclic aromatic hydrocarbons: decreased glucuronidative activity of the UGT1A10139Lys isoform. Drug Metab Dispos. 2006 Jun;34(6):943-9.
DMFSKYE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16510539

DM0PCWZ	DI	DM0PCWZ
DM0PCWZ	DN	Hydroxybutyryl-CoA
DM0PCWZ	MI	DEMK5U6
DM0PCWZ	MN	Acyl-CoA thioesterase 13 (ACOT13)
DM0PCWZ	MT	DME
DM0PCWZ	MA	Metabolism
DM0PCWZ	RN	The mechanisms of human hotdog-fold thioesterase 2 (hTHEM2) substrate recognition and catalysis illuminated by a structure and function based analysis. Biochemistry. 2009 Feb 17;48(6):1293-304.
DM0PCWZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19170545

DM6IEKW	DI	DM6IEKW
DM6IEKW	DN	Hydroxy-cholesten-one
DM6IEKW	MI	DEVON3M
DM6IEKW	MN	Aldo-keto reductase 1D1 (AKR1D1)
DM6IEKW	MT	DME
DM6IEKW	MA	Metabolism
DM6IEKW	RN	The effect of disease associated point mutations on 5-beta-reductase (AKR1D1) enzyme function. Chem Biol Interact. 2011 May 30;191(1-3):250-4.
DM6IEKW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21185810

DMY0A9E	DI	DMY0A9E
DMY0A9E	DN	Hydroxycitric acid
DMY0A9E	MI	TTCGSZ4
DMY0A9E	MN	Pancreatic alpha-amylase (AMY2A)
DMY0A9E	MT	DTT
DMY0A9E	MA	Inhibitor
DMY0A9E	RN	Chemistry, physiological properties, and microbial production of hydroxycitric acid. Appl Microbiol Biotechnol. 2007 Jul;75(5):977-82.
DMY0A9E	RU	https://pubmed.ncbi.nlm.nih.gov/17476502

DMFHCV9	DI	DMFHCV9
DMFHCV9	DN	hydroxycitronellal
DMFHCV9	MI	TTXDKTO
DMFHCV9	MN	Long transient receptor potential channel 8 (TRPM8)
DMFHCV9	MT	DTT
DMFHCV9	MA	Activator
DMFHCV9	RN	Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay. Br J Pharmacol. 2004 Feb;141(4):737-45.
DMFHCV9	RU	https://pubmed.ncbi.nlm.nih.gov/14757700

DM5DOEC	DI	DM5DOEC
DM5DOEC	DN	Hydroxyclemastine
DM5DOEC	MI	TTTIBOJ
DM5DOEC	MN	Histamine H1 receptor (H1R)
DM5DOEC	MT	DTT
DM5DOEC	MA	Antagonist
DM5DOEC	RN	Histamine upregulates keratinocyte MMP-9 production via the histamine H1 receptor. J Invest Dermatol. 2008 Dec;128(12):2783-91.
DM5DOEC	RU	https://pubmed.ncbi.nlm.nih.gov/18548114

DMPS2B1	DI	DMPS2B1
DMPS2B1	DN	Hydroxydimethylarsine Oxide
DMPS2B1	MI	TTFBNVI
DMPS2B1	MN	Aldose reductase (AKR1B1)
DMPS2B1	MT	DTT
DMPS2B1	MA	Inhibitor
DMPS2B1	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMPS2B1	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMPS2B1	DI	DMPS2B1
DMPS2B1	DN	Hydroxydimethylarsine Oxide
DMPS2B1	MI	TTCM4B3
DMPS2B1	MN	Nitric-oxide synthase endothelial (NOS3)
DMPS2B1	MT	DTT
DMPS2B1	MA	Inhibitor
DMPS2B1	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMPS2B1	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMJXQME	DI	DMJXQME
DMJXQME	DN	Hydroxyestradiol
DMJXQME	MI	DESD26P
DMJXQME	MN	UDP-glucuronosyltransferase 1A6 (UGT1A6)
DMJXQME	MT	DME
DMJXQME	MA	Metabolism
DMJXQME	RN	Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev. 1999 Nov;31(4):817-99.
DMJXQME	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10575553

DMBO7ZD	DI	DMBO7ZD
DMBO7ZD	DN	Hydroxyestrone
DMBO7ZD	MI	DESD26P
DMBO7ZD	MN	UDP-glucuronosyltransferase 1A6 (UGT1A6)
DMBO7ZD	MT	DME
DMBO7ZD	MA	Metabolism
DMBO7ZD	RN	Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev. 1999 Nov;31(4):817-99.
DMBO7ZD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10575553

DMPGAR2	DI	DMPGAR2
DMPGAR2	DN	Hydroxymethylpyrene
DMPGAR2	MI	DEM1HNL
DMPGAR2	MN	Alcohol dehydrogenase class-I gamma (ADH1C)
DMPGAR2	MT	DME
DMPGAR2	MA	Metabolism
DMPGAR2	RN	Oxidation of alcohols and reduction of aldehydes derived from methyl- and dimethylpyrenes by cDNA-expressed human alcohol dehydrogenases. Toxicology. 2008 Mar 12;245(1-2):65-75.
DMPGAR2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18242813

DMPGAR2	DI	DMPGAR2
DMPGAR2	DN	Hydroxymethylpyrene
DMPGAR2	MI	DEOCWU3
DMPGAR2	MN	Alcohol dehydrogenase class-II (ADH4)
DMPGAR2	MT	DME
DMPGAR2	MA	Metabolism
DMPGAR2	RN	Oxidation of alcohols and reduction of aldehydes derived from methyl- and dimethylpyrenes by cDNA-expressed human alcohol dehydrogenases. Toxicology. 2008 Mar 12;245(1-2):65-75.
DMPGAR2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18242813

DMZN3GP	DI	DMZN3GP
DMZN3GP	DN	Hydroxytryptophol
DMZN3GP	MI	DESD26P
DMZN3GP	MN	UDP-glucuronosyltransferase 1A6 (UGT1A6)
DMZN3GP	MT	DME
DMZN3GP	MA	Metabolism
DMZN3GP	RN	Evaluation of 5-hydroxytryptophol and other endogenous serotonin (5-hydroxytryptamine) analogs as substrates for UDP-glucuronosyltransferase 1A6. Drug Metab Dispos. 2004 Aug;32(8):862-9.
DMZN3GP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15258112

DM7XISZ	DI	DM7XISZ
DM7XISZ	DN	HYG-440
DM7XISZ	MI	TTS64P2
DM7XISZ	MN	Androgen receptor (AR)
DM7XISZ	MT	DTT
DM7XISZ	MA	Antagonist
DM7XISZ	RN	Clinical pipeline report, company report or official report of Hygeia Therapeutics.
DM7XISZ	RU	http://www.hygeiatherapeutics.com/HYG-440.html

DMEZ92A	DI	DMEZ92A
DMEZ92A	DN	Hygromycin B
DMEZ92A	MI	TT38DW5
DMEZ92A	MN	Bacterial 16S ribosomal RNA (Bact 16S rRNA)
DMEZ92A	MT	DTT
DMEZ92A	MA	Inhibitor
DMEZ92A	RN	RNA as a target for small molecules. Curr Opin Chem Biol. 2000 Dec;4(6):678-86.
DMEZ92A	RU	https://pubmed.ncbi.nlm.nih.gov/11102874

DMEZ92A	DI	DMEZ92A
DMEZ92A	DN	Hygromycin B
DMEZ92A	MI	TTPEFM3
DMEZ92A	MN	Bacterial Ribosomal ATPase RbbA (Bact rbbA)
DMEZ92A	MT	DTT
DMEZ92A	MA	Inhibitor
DMEZ92A	RN	A ribosomal ATPase is a target for hygromycin B inhibition on Escherichia coli ribosomes. Antimicrob Agents Chemother. 2001 Oct;45(10):2813-9.
DMEZ92A	RU	https://pubmed.ncbi.nlm.nih.gov/11557474

DMETS37	DI	DMETS37
DMETS37	DN	HYNIC Analogue
DMETS37	MI	TTN53ZF
DMETS37	MN	Leukotriene B4 receptor 1 (LTB4R)
DMETS37	MT	DTT
DMETS37	MA	Inhibitor
DMETS37	RN	Synthesis of leukotriene B4 antagonists labeled with In-111 or Tc-99m to image infectious and inflammatory foci. J Med Chem. 2005 Oct 6;48(20):6442-53.
DMETS37	RU	https://pubmed.ncbi.nlm.nih.gov/16190770

DMSIWD0	DI	DMSIWD0
DMSIWD0	DN	Hyodeoxycholic acid
DMSIWD0	MI	DESD26P
DMSIWD0	MN	UDP-glucuronosyltransferase 1A6 (UGT1A6)
DMSIWD0	MT	DME
DMSIWD0	MA	Metabolism
DMSIWD0	RN	Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev. 1999 Nov;31(4):817-99.
DMSIWD0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10575553

DMSIWD0	DI	DMSIWD0
DMSIWD0	DN	Hyodeoxycholic acid
DMSIWD0	MI	DEWBT6H
DMSIWD0	MN	UDP-glucuronosyltransferase 2A3 (UGT2A3)
DMSIWD0	MT	DME
DMSIWD0	MA	Metabolism
DMSIWD0	RN	Novel polymorphic human UDP-glucuronosyltransferase 2A3: cloning, functional characterization of enzyme variants, comparative tissue expression, and gene induction. Mol Pharmacol. 2008 Sep;74(3):744-54.
DMSIWD0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18523138

DM0U8IV	DI	DM0U8IV
DM0U8IV	DN	hyp 9
DM0U8IV	MI	TTRBT3W
DM0U8IV	MN	Short transient receptor potential channel 6 (TRPC6)
DM0U8IV	MT	DTT
DM0U8IV	MA	Activator
DM0U8IV	RN	Simple 2,4-diacylphloroglucinols as classic transient receptor potential-6 activators--identification of a novel pharmacophore. Mol Pharmacol. 2010 Mar;77(3):368-77.
DM0U8IV	RU	https://pubmed.ncbi.nlm.nih.gov/20008516

DMW9HTL	DI	DMW9HTL
DMW9HTL	DN	HYP-10
DMW9HTL	MI	TTZPWGN
DMW9HTL	MN	Voltage-gated calcium channel alpha Cav3.2 (CACNA1H)
DMW9HTL	MT	DTT
DMW9HTL	MA	Blocker
DMW9HTL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 536).
DMW9HTL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=536

DM2L3PE	DI	DM2L3PE
DM2L3PE	DN	Hyperforin
DM2L3PE	MI	TT2J34L
DM2L3PE	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM2L3PE	MT	DTT
DM2L3PE	MA	Inhibitor
DM2L3PE	RN	Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase. Biochem Pharmacol. 2002 Dec 15;64(12):1767-75.
DM2L3PE	RU	https://pubmed.ncbi.nlm.nih.gov/12445866

DM2L3PE	DI	DM2L3PE
DM2L3PE	DN	Hyperforin
DM2L3PE	MI	TT7LCTF
DM2L3PE	MN	Pregnane X receptor (NR1I2)
DM2L3PE	MT	DTT
DM2L3PE	MA	Binder
DM2L3PE	RN	Pregnane X receptor (PXR) regulates P-glycoprotein at the blood-brain barrier: functional similarities between pig and human PXR. J Pharmacol Exp Ther. 2009 Apr;329(1):141-9.
DM2L3PE	RU	https://pubmed.ncbi.nlm.nih.gov/19147857

DM2L3PE	DI	DM2L3PE
DM2L3PE	DN	Hyperforin
DM2L3PE	MI	TT8NGED
DM2L3PE	MN	Prostaglandin G/H synthase 1 (COX-1)
DM2L3PE	MT	DTT
DM2L3PE	MA	Inhibitor
DM2L3PE	RN	Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase. Biochem Pharmacol. 2002 Dec 15;64(12):1767-75.
DM2L3PE	RU	https://pubmed.ncbi.nlm.nih.gov/12445866

DMJKIUX	DI	DMJKIUX
DMJKIUX	DN	hypoglaucin A
DMJKIUX	MI	TT1UCIJ
DMJKIUX	MN	C-X-C chemokine receptor type 3 (CXCR3)
DMJKIUX	MT	DTT
DMJKIUX	MA	Antagonist
DMJKIUX	RN	Discovery of structurally diverse natural product antagonists of chemokine receptor CXCR3. Mol Divers. 2005;9(1-3):123-9.
DMJKIUX	RU	https://pubmed.ncbi.nlm.nih.gov/15789559

DMLSABI	DI	DMLSABI
DMLSABI	DN	Hypoxanthine
DMLSABI	MI	DEJGDUW
DMLSABI	MN	Cytochrome P450 1A2 (CYP1A2)
DMLSABI	MT	DME
DMLSABI	MA	Metabolism
DMLSABI	RN	Rapid determination of five probe drugs and their metabolites in human plasma and urine by liquid chromatography/tandem mass spectrometry: application to cytochrome P450 phenotyping studies. Rapid Commun Mass Spectrom. 2004;18(23):2921-33.
DMLSABI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15529418

DMLSABI	DI	DMLSABI
DMLSABI	DN	Hypoxanthine
DMLSABI	MI	TTMCF1Y
DMLSABI	MN	Purine nucleoside phosphorylase (PNP)
DMLSABI	MT	DTT
DMLSABI	MA	Inhibitor
DMLSABI	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMLSABI	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMWLJ5S	DI	DMWLJ5S
DMWLJ5S	DN	Hyrtiosulawesine
DMWLJ5S	MI	TT9V5JH
DMWLJ5S	MN	Phospholipase A2 (PLA2G1B)
DMWLJ5S	MT	DTT
DMWLJ5S	MA	Inhibitor
DMWLJ5S	RN	Hyrtiazepine, an azepino-indole-type alkaloid from the Red Sea marine sponge Hyrtios erectus. J Nat Prod. 2006 Dec;69(12):1676-9.
DMWLJ5S	RU	https://pubmed.ncbi.nlm.nih.gov/17190441

DMLU6VM	DI	DMLU6VM
DMLU6VM	DN	HZ-166
DMLU6VM	MI	TTEX6LM
DMLU6VM	MN	GABA(A) receptor gamma-3 (GABRG3)
DMLU6VM	MT	DTT
DMLU6VM	MA	Modulator
DMLU6VM	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415).
DMLU6VM	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415

DM7QE51	DI	DM7QE51
DM7QE51	DN	I-309
DM7QE51	MI	TTE836A
DM7QE51	MN	C-C chemokine receptor type 8 (CCR8)
DM7QE51	MT	DTT
DM7QE51	MA	Binder
DM7QE51	RN	The chemokine receptor CCR8 is preferentially expressed in Th2 but not Th1 cells. J Immunol. 1998 Jul 15;161(2):547-51.
DM7QE51	RU	https://pubmed.ncbi.nlm.nih.gov/9670926

DM1TQ7N	DI	DM1TQ7N
DM1TQ7N	DN	I-5
DM1TQ7N	MI	TTRSMW9
DM1TQ7N	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DM1TQ7N	MT	DTT
DM1TQ7N	MA	Inhibitor
DM1TQ7N	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM1TQ7N	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMFSAK3	DI	DMFSAK3
DMFSAK3	DN	IAA-94
DMFSAK3	MI	TT0FC1V
DMFSAK3	MN	Volume regulated chloride channel (VRAC)
DMFSAK3	MT	DTT
DMFSAK3	MA	Blocker (channel blocker)
DMFSAK3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 710).
DMFSAK3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=710

DMIJ2GV	DI	DMIJ2GV
DMIJ2GV	DN	I-ABA
DMIJ2GV	MI	TTJFY5U
DMIJ2GV	MN	Adenosine A3 receptor (ADORA3)
DMIJ2GV	MT	DTT
DMIJ2GV	MA	Agonist
DMIJ2GV	RN	Molecular cloning and characterization of the human A3 adenosine receptor. Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10365-9.
DMIJ2GV	RU	https://pubmed.ncbi.nlm.nih.gov/8234299

DM5X0JS	DI	DM5X0JS
DM5X0JS	DN	I-ABOPX
DM5X0JS	MI	TTNE7KG
DM5X0JS	MN	Adenosine A2b receptor (ADORA2B)
DM5X0JS	MT	DTT
DM5X0JS	MA	Antagonist
DM5X0JS	RN	Characterization of human A(2B) adenosine receptors: radioligand binding, western blotting, and coupling to G(q) in human embryonic kidney 293 cells and HMC-1 mast cells. Mol Pharmacol. 1999 Oct;56(4):705-13.
DM5X0JS	RU	https://pubmed.ncbi.nlm.nih.gov/10496952

DM5X0JS	DI	DM5X0JS
DM5X0JS	DN	I-ABOPX
DM5X0JS	MI	TTJFY5U
DM5X0JS	MN	Adenosine A3 receptor (ADORA3)
DM5X0JS	MT	DTT
DM5X0JS	MA	Antagonist
DM5X0JS	RN	Molecular cloning and characterization of the human A3 adenosine receptor. Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10365-9.
DM5X0JS	RU	https://pubmed.ncbi.nlm.nih.gov/8234299

DMOQIDG	DI	DMOQIDG
DMOQIDG	DN	IAI-100
DMOQIDG	MI	TTOMWSY
DMOQIDG	MN	Mammalian disintegrin-metalloprotease (ADAM10)
DMOQIDG	MT	DTT
DMOQIDG	MA	Inhibitor
DMOQIDG	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8679).
DMOQIDG	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8679

DM8U4HE	DI	DM8U4HE
DM8U4HE	DN	IATX-FVIII
DM8U4HE	MI	TT1290U
DM8U4HE	MN	Coagulation factor VIII (F8)
DM8U4HE	MT	DTT
DM8U4HE	MA	Inhibitor
DM8U4HE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2607).
DM8U4HE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2607

DM8J24A	DI	DM8J24A
DM8J24A	DN	IBC 293
DM8J24A	MI	TT8WFXV
DM8J24A	MN	Hydroxycarboxylic acid receptor 3 (HCAR3)
DM8J24A	MT	DTT
DM8J24A	MA	Agonist
DM8J24A	RN	1-Alkyl-benzotriazole-5-carboxylic acids are highly selective agonists of the human orphan G-protein-coupled receptor GPR109b. J Med Chem. 2006 Feb 23;49(4):1227-30.
DM8J24A	RU	https://pubmed.ncbi.nlm.nih.gov/16480258

DMRIG3O	DI	DMRIG3O
DMRIG3O	DN	iberiotoxin
DMRIG3O	MI	TTGJFK1
DMRIG3O	MN	Calcium-activated potassium channel KCa4.1 (KCNT1)
DMRIG3O	MT	DTT
DMRIG3O	MA	Inhibitor
DMRIG3O	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 385).
DMRIG3O	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=385

DMRIG3O	DI	DMRIG3O
DMRIG3O	DN	iberiotoxin
DMRIG3O	MI	TTLU5FO
DMRIG3O	MN	Calcium-activated potassium channel KCa4.2 (KCNT2)
DMRIG3O	MT	DTT
DMRIG3O	MA	Inhibitor
DMRIG3O	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 386).
DMRIG3O	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=386

DMRIG3O	DI	DMRIG3O
DMRIG3O	DN	iberiotoxin
DMRIG3O	MI	TTI9XK6
DMRIG3O	MN	Calcium-activated potassium channel KCa5.1 (KCNU1)
DMRIG3O	MT	DTT
DMRIG3O	MA	Inhibitor
DMRIG3O	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 387).
DMRIG3O	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=387

DMRIG3O	DI	DMRIG3O
DMRIG3O	DN	iberiotoxin
DMRIG3O	MI	TT1AQ50
DMRIG3O	MN	Charybdotoxin receptor beta-4 (BKbeta4)
DMRIG3O	MT	DTT
DMRIG3O	MA	Inhibitor
DMRIG3O	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 380).
DMRIG3O	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=380

DMYRUH2	DI	DMYRUH2
DMYRUH2	DN	I-BET151
DMYRUH2	MI	TTDP48B
DMYRUH2	MN	Bromodomain-containing protein 2 (BRD2)
DMYRUH2	MT	DTT
DMYRUH2	MA	Inhibitor
DMYRUH2	RN	Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature. 2011 Oct 2;478(7370):529-33.
DMYRUH2	RU	https://pubmed.ncbi.nlm.nih.gov/21964340

DMYRUH2	DI	DMYRUH2
DMYRUH2	DN	I-BET151
DMYRUH2	MI	TTHE657
DMYRUH2	MN	Bromodomain-containing protein 3 (BRD3)
DMYRUH2	MT	DTT
DMYRUH2	MA	Inhibitor
DMYRUH2	RN	Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature. 2011 Oct 2;478(7370):529-33.
DMYRUH2	RU	https://pubmed.ncbi.nlm.nih.gov/21964340

DMYRUH2	DI	DMYRUH2
DMYRUH2	DN	I-BET151
DMYRUH2	MI	TTRA6BO
DMYRUH2	MN	Bromodomain-containing protein 4 (BRD4)
DMYRUH2	MT	DTT
DMYRUH2	MA	Inhibitor
DMYRUH2	RN	Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature. 2011 Oct 2;478(7370):529-33.
DMYRUH2	RU	https://pubmed.ncbi.nlm.nih.gov/21964340

DM3HJX7	DI	DM3HJX7
DM3HJX7	DN	Ibogaine
DM3HJX7	MI	TTMT0HG
DM3HJX7	MN	Neuronal acetylcholine receptor alpha-2/alpha-3 (CHRNA2/A3)
DM3HJX7	MT	DTT
DM3HJX7	MA	Antagonist
DM3HJX7	RN	Antagonism of alpha 3 beta 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration. Eur J Pharmacol. 2002 Mar 1;438(1-2):99-105.
DM3HJX7	RU	https://pubmed.ncbi.nlm.nih.gov/11906717

DMJAPML	DI	DMJAPML
DMJAPML	DN	I-BOP
DMJAPML	MI	TTPNGDE
DMJAPML	MN	Prostaglandin E2 receptor EP3 (PTGER3)
DMJAPML	MT	DTT
DMJAPML	MA	Agonist
DMJAPML	RN	Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
DMJAPML	RU	https://pubmed.ncbi.nlm.nih.gov/9313928

DMJAPML	DI	DMJAPML
DMJAPML	DN	I-BOP
DMJAPML	MI	TTT2ZAR
DMJAPML	MN	Prostaglandin F2-alpha receptor (PTGFR)
DMJAPML	MT	DTT
DMJAPML	MA	Agonist
DMJAPML	RN	Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
DMJAPML	RU	https://pubmed.ncbi.nlm.nih.gov/9313928

DMJAPML	DI	DMJAPML
DMJAPML	DN	I-BOP
DMJAPML	MI	TT2O84V
DMJAPML	MN	Thromboxane A2 receptor (TBXA2R)
DMJAPML	MT	DTT
DMJAPML	MA	Agonist
DMJAPML	RN	Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
DMJAPML	RU	https://pubmed.ncbi.nlm.nih.gov/9313928

DM8RZE0	DI	DM8RZE0
DM8RZE0	DN	ibotenate
DM8RZE0	MI	TTVBPDM
DM8RZE0	MN	Metabotropic glutamate receptor 1 (mGluR1)
DM8RZE0	MT	DTT
DM8RZE0	MA	Agonist
DM8RZE0	RN	Characterization of [(3)H]Quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections. J Neurochem. 2000 Dec;75(6):2590-601.
DM8RZE0	RU	https://pubmed.ncbi.nlm.nih.gov/11080213

DM8RZE0	DI	DM8RZE0
DM8RZE0	DN	ibotenate
DM8RZE0	MI	TTHS256
DM8RZE0	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM8RZE0	MT	DTT
DM8RZE0	MA	Agonist
DM8RZE0	RN	Characterization of [(3)H]Quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections. J Neurochem. 2000 Dec;75(6):2590-601.
DM8RZE0	RU	https://pubmed.ncbi.nlm.nih.gov/11080213

DM9C8FP	DI	DM9C8FP
DM9C8FP	DN	I-BRD9
DM9C8FP	MI	TTR7L5Y
DM9C8FP	MN	Bromodomain-containing protein 9 (BRD9)
DM9C8FP	MT	DTT
DM9C8FP	MA	Inhibitor
DM9C8FP	RN	Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition. J Med Chem. 2016 Feb 25;59(4):1425-39.
DM9C8FP	RU	https://pubmed.ncbi.nlm.nih.gov/25856009

DMUSRJ8	DI	DMUSRJ8
DMUSRJ8	DN	IBZM
DMUSRJ8	MI	TTZFYLI
DMUSRJ8	MN	Dopamine D1 receptor (D1R)
DMUSRJ8	MT	DTT
DMUSRJ8	MA	Inhibitor
DMUSRJ8	RN	In vitro affinities of various halogenated benzamide derivatives as potential radioligands for non-invasive quantification of D(2)-like dopamine re... Bioorg Med Chem. 2007 Nov 1;15(21):6819-29.
DMUSRJ8	RU	https://pubmed.ncbi.nlm.nih.gov/17765546

DMUSRJ8	DI	DMUSRJ8
DMUSRJ8	DN	IBZM
DMUSRJ8	MI	TTEX248
DMUSRJ8	MN	Dopamine D2 receptor (D2R)
DMUSRJ8	MT	DTT
DMUSRJ8	MA	Inhibitor
DMUSRJ8	RN	Fluorinated and iodinated dopamine agents: D2 imaging agents for PET and SPECT. J Med Chem. 1993 Jan 22;36(2):221-8.
DMUSRJ8	RU	https://pubmed.ncbi.nlm.nih.gov/8093734

DMRF5LU	DI	DMRF5LU
DMRF5LU	DN	IC-041
DMRF5LU	MI	TT3ZS42
DMRF5LU	MN	Phosphodiesterase 1B (PDE1B)
DMRF5LU	MT	DTT
DMRF5LU	MA	Inhibitor
DMRF5LU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1295).
DMRF5LU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1295

DMWRVGE	DI	DMWRVGE
DMWRVGE	DN	IC86621
DMWRVGE	MI	TTK3PY9
DMWRVGE	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMWRVGE	MT	DTT
DMWRVGE	MA	Inhibitor
DMWRVGE	RN	Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family. Bioorg Med Chem Lett. 2012 Sep 1;22(17):5352-9.
DMWRVGE	RU	https://pubmed.ncbi.nlm.nih.gov/22835870

DMM50ED	DI	DMM50ED
DMM50ED	DN	IC87114
DMM50ED	MI	TTGBPJE
DMM50ED	MN	PI3-kinase delta (PIK3CD)
DMM50ED	MT	DTT
DMM50ED	MA	Inhibitor
DMM50ED	RN	Selective role of PI3K delta in neutrophil inflammatory responses. Biochem Biophys Res Commun. 2003 Sep 5;308(4):764-9.
DMM50ED	RU	https://pubmed.ncbi.nlm.nih.gov/12927784

DM8L6WB	DI	DM8L6WB
DM8L6WB	DN	IC980033
DM8L6WB	MI	TTGBPJE
DM8L6WB	MN	PI3-kinase delta (PIK3CD)
DM8L6WB	MT	DTT
DM8L6WB	MA	Inhibitor
DM8L6WB	RN	Selective role of PI3K delta in neutrophil inflammatory responses. Biochem Biophys Res Commun. 2003 Sep 5;308(4):764-9.
DM8L6WB	RU	https://pubmed.ncbi.nlm.nih.gov/12927784

DMS9H2P	DI	DMS9H2P
DMS9H2P	DN	ICA-105574
DMS9H2P	MI	TT9XKUC
DMS9H2P	MN	Voltage-gated potassium channel Kv10.1 (KCNH1)
DMS9H2P	MT	DTT
DMS9H2P	MA	Inhibitor (gating inhibitor)
DMS9H2P	RN	ICA-105574 interacts with a common binding site to elicit opposite effects on inactivation gating of EAG and ERG potassium channels. Mol Pharmacol. 2013 Apr;83(4):805-13.
DMS9H2P	RU	https://pubmed.ncbi.nlm.nih.gov/23319419

DMS9H2P	DI	DMS9H2P
DMS9H2P	DN	ICA-105574
DMS9H2P	MI	TTQ6VDM
DMS9H2P	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMS9H2P	MT	DTT
DMS9H2P	MA	Activator
DMS9H2P	RN	Pharmacological removal of human ether- -go-go-related gene potassium channel inactivation by 3-nitro-N-(4-phenoxyphenyl) benzamide (ICA-105574). Mol Pharmacol. 2010 Jan;77(1):58-68.
DMS9H2P	RU	https://pubmed.ncbi.nlm.nih.gov/19805508

DMO0N3Q	DI	DMO0N3Q
DMO0N3Q	DN	ICA-27243
DMO0N3Q	MI	TTPXI3S
DMO0N3Q	MN	Voltage-gated potassium channel Kv7.2 (KCNQ2)
DMO0N3Q	MT	DTT
DMO0N3Q	MA	Activator
DMO0N3Q	RN	The KCNQ2/3 selective channel opener ICA-27243 binds to a novel voltage-sensor domain site. Neurosci Lett. 2009 Nov 13;465(2):138-42.
DMO0N3Q	RU	https://pubmed.ncbi.nlm.nih.gov/19733209

DM3DB8X	DI	DM3DB8X
DM3DB8X	DN	Icariside II
DM3DB8X	MI	TTJ0IQB
DM3DB8X	MN	Phosphodiesterase 5A (PDE5A)
DM3DB8X	MT	DTT
DM3DB8X	MA	Inhibitor
DM3DB8X	RN	Potent inhibition of human phosphodiesterase-5 by icariin derivatives. J Nat Prod. 2008 Sep;71(9):1513-7.
DM3DB8X	RU	https://pubmed.ncbi.nlm.nih.gov/18778098

DMQX3W6	DI	DMQX3W6
DMQX3W6	DN	I-CBP112
DMQX3W6	MI	TTFRCTK
DMQX3W6	MN	CREB-binding protein (CREBBP)
DMQX3W6	MT	DTT
DMQX3W6	MA	Inhibitor
DMQX3W6	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2734).
DMQX3W6	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2734

DMQX3W6	DI	DMQX3W6
DMQX3W6	DN	I-CBP112
DMQX3W6	MI	TTH4VJL
DMQX3W6	MN	Histone acetyltransferase KAT6B (KAT6B)
DMQX3W6	MT	DTT
DMQX3W6	MA	Inhibitor
DMQX3W6	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2735).
DMQX3W6	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2735

DMN6UET	DI	DMN6UET
DMN6UET	DN	ICI 154129
DMN6UET	MI	TT27RFC
DMN6UET	MN	Opioid receptor delta (OPRD1)
DMN6UET	MT	DTT
DMN6UET	MA	Antagonist
DMN6UET	RN	In vivo evidence for the selectivity of ICI 154129 for the delta-opioid receptor. Neuropharmacology. 1985 Feb;24(2):107-10.
DMN6UET	RU	https://pubmed.ncbi.nlm.nih.gov/2986029

DMLPZ3N	DI	DMLPZ3N
DMLPZ3N	DN	ICI 200,355
DMLPZ3N	MI	TTPLTSQ
DMLPZ3N	MN	Neutrophil elastase (NE)
DMLPZ3N	MT	DTT
DMLPZ3N	MA	Inhibitor
DMLPZ3N	RN	Role of neutrophil elastase in hypersecretion in asthma. Eur Respir J. 1999 Jan;13(1):190-6.
DMLPZ3N	RU	https://pubmed.ncbi.nlm.nih.gov/10836347

DM0PQ37	DI	DM0PQ37
DM0PQ37	DN	ICI 200,880
DM0PQ37	MI	TTPLTSQ
DM0PQ37	MN	Neutrophil elastase (NE)
DM0PQ37	MT	DTT
DM0PQ37	MA	Inhibitor
DM0PQ37	RN	Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs. 2002 Jul;11(7):965-80.
DM0PQ37	RU	https://pubmed.ncbi.nlm.nih.gov/12084007

DM1D6CQ	DI	DM1D6CQ
DM1D6CQ	DN	ICI-174864
DM1D6CQ	MI	TT27RFC
DM1D6CQ	MN	Opioid receptor delta (OPRD1)
DM1D6CQ	MT	DTT
DM1D6CQ	MA	Inhibitor
DM1D6CQ	RN	Highly potent and selective phenylmorphan-based inverse agonists of the opioid delta receptor. J Med Chem. 2006 Sep 7;49(18):5597-609.
DM1D6CQ	RU	https://pubmed.ncbi.nlm.nih.gov/16942033

DMW4L3K	DI	DMW4L3K
DMW4L3K	DN	ICI-198583
DMW4L3K	MI	TT5FOMZ
DMW4L3K	MN	Thymidylate synthase (TYMS)
DMW4L3K	MT	DTT
DMW4L3K	MA	Modulator
DMW4L3K	RN	The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583). Biochem Pharmacol. 1991 Oct 24;42(10):1885-95.
DMW4L3K	RU	https://www.ncbi.nlm.nih.gov/pubmed/1741766

DMEWZ80	DI	DMEWZ80
DMEWZ80	DN	ICI-199441
DMEWZ80	MI	TTVG215
DMEWZ80	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DMEWZ80	MT	DTT
DMEWZ80	MA	Inhibitor
DMEWZ80	RN	Arylacetamide kappa opioid receptor agonists with reduced cytochrome P450 2D6 inhibitory activity. Bioorg Med Chem Lett. 2005 May 16;15(10):2647-52.
DMEWZ80	RU	https://pubmed.ncbi.nlm.nih.gov/15863335

DMEWZ80	DI	DMEWZ80
DMEWZ80	DN	ICI-199441
DMEWZ80	MI	TT27RFC
DMEWZ80	MN	Opioid receptor delta (OPRD1)
DMEWZ80	MT	DTT
DMEWZ80	MA	Inhibitor
DMEWZ80	RN	Arylacetamide kappa opioid receptor agonists with reduced cytochrome P450 2D6 inhibitory activity. Bioorg Med Chem Lett. 2005 May 16;15(10):2647-52.
DMEWZ80	RU	https://pubmed.ncbi.nlm.nih.gov/15863335

DMEWZ80	DI	DMEWZ80
DMEWZ80	DN	ICI-199441
DMEWZ80	MI	TTQW87Y
DMEWZ80	MN	Opioid receptor kappa (OPRK1)
DMEWZ80	MT	DTT
DMEWZ80	MA	Inhibitor
DMEWZ80	RN	Arylacetamide-derived fluorescent probes: synthesis, biological evaluation, and direct fluorescent labeling of kappa opioid receptors in mouse micr... J Med Chem. 1996 Apr 12;39(8):1729-35.
DMEWZ80	RU	https://pubmed.ncbi.nlm.nih.gov/8648612

DMEWZ80	DI	DMEWZ80
DMEWZ80	DN	ICI-199441
DMEWZ80	MI	TTKWM86
DMEWZ80	MN	Opioid receptor mu (MOP)
DMEWZ80	MT	DTT
DMEWZ80	MA	Inhibitor
DMEWZ80	RN	Isothiocyanate-substituted kappa-selective opioid receptor ligands derived from N-methyl-N-[(1S)-1-phenyl-2-(1-pyrrolidinyl)ethyl] phenylacetamide. J Med Chem. 1994 Sep 2;37(18):2856-64.
DMEWZ80	RU	https://pubmed.ncbi.nlm.nih.gov/8071934

DMEWZ80	DI	DMEWZ80
DMEWZ80	DN	ICI-199441
DMEWZ80	MI	TTW5UDX
DMEWZ80	MN	Urotensin II receptor (UTS2R)
DMEWZ80	MT	DTT
DMEWZ80	MA	Inhibitor
DMEWZ80	RN	Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3716-9.
DMEWZ80	RU	https://pubmed.ncbi.nlm.nih.gov/18524591

DMNA8RS	DI	DMNA8RS
DMNA8RS	DN	ICI-204448
DMNA8RS	MI	TTQW87Y
DMNA8RS	MN	Opioid receptor kappa (OPRK1)
DMNA8RS	MT	DTT
DMNA8RS	MA	Modulator
DMNA8RS	RN	ICI 204448: a kappa-opioid agonist with limited access to the CNS.
DMNA8RS	RU	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1854424

DMYRILU	DI	DMYRILU
DMYRILU	DN	ICI-211965
DMYRILU	MI	TT2J34L
DMYRILU	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMYRILU	MT	DTT
DMYRILU	MA	Modulator
DMYRILU	RN	DOI: 10.1517/13543776.2.11.1817
DMYRILU	RU	http://www.tandfonline.com/doi/abs/10.1517/13543776.2.11.1817?journalCode=ietp19

DMYVOL9	DI	DMYVOL9
DMYVOL9	DN	icilin
DMYVOL9	MI	TTXDKTO
DMYVOL9	MN	Long transient receptor potential channel 8 (TRPM8)
DMYVOL9	MT	DTT
DMYVOL9	MA	Activator
DMYVOL9	RN	Evolution of thermal response properties in a cold-activated TRP channel. PLoS One. 2009 May 29;4(5):e5741.
DMYVOL9	RU	https://pubmed.ncbi.nlm.nih.gov/19492038

DMYVOL9	DI	DMYVOL9
DMYVOL9	DN	icilin
DMYVOL9	MI	TTELV3W
DMYVOL9	MN	Transformation-sensitive protein p120 (TRPA1)
DMYVOL9	MT	DTT
DMYVOL9	MA	Activator
DMYVOL9	RN	ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures. Cell. 2003 Mar 21;112(6):819-29.
DMYVOL9	RU	https://pubmed.ncbi.nlm.nih.gov/12654248

DMF1CM7	DI	DMF1CM7
DMF1CM7	DN	Icosapentum
DMF1CM7	MI	DE073H6
DMF1CM7	MN	Prostaglandin G/H synthase 1 (COX-1)
DMF1CM7	MT	DME
DMF1CM7	MA	Metabolism
DMF1CM7	RN	Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. FASEB J. 2006 Jun;20(8):1097-108.
DMF1CM7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16770009

DMF1CM7	DI	DMF1CM7
DMF1CM7	DN	Icosapentum
DMF1CM7	MI	DE492CE
DMF1CM7	MN	Prostaglandin G/H synthase 2 (COX-2)
DMF1CM7	MT	DME
DMF1CM7	MA	Metabolism
DMF1CM7	RN	Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. FASEB J. 2006 Jun;20(8):1097-108.
DMF1CM7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16770009

DMH4KGX	DI	DMH4KGX
DMH4KGX	DN	ICR 62
DMH4KGX	MI	TTGKNB4
DMH4KGX	MN	Epidermal growth factor receptor (EGFR)
DMH4KGX	MT	DTT
DMH4KGX	RN	Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer. 2002 Mar 1;94(5):1593-611.
DMH4KGX	RU	https://pubmed.ncbi.nlm.nih.gov/11920518

DM9DXRL	DI	DM9DXRL
DM9DXRL	DN	ICRF-154
DM9DXRL	MI	TT0IHXV
DM9DXRL	MN	DNA topoisomerase II (TOP2)
DM9DXRL	MT	DTT
DM9DXRL	MA	Inhibitor
DM9DXRL	RN	The catalytic DNA topoisomerase II inhibitor ICRF-193 and all-trans retinoic acid cooperatively induce granulocytic differentiation of acute promyelocytic leukemia cells: candidate drugs for chemo-differentiation therapy against acute promyelocytic leukemia. Exp Hematol. 2002 Nov;30(11):1273-82.
DM9DXRL	RU	https://pubmed.ncbi.nlm.nih.gov/12423680

DMPH8E9	DI	DMPH8E9
DMPH8E9	DN	ICT-037
DMPH8E9	MI	TTY6DTE
DMPH8E9	MN	Carcinoembryonic antigen CEA (CD66e)
DMPH8E9	MT	DTT
DMPH8E9	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2836).
DMPH8E9	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2836

DM3P7W5	DI	DM3P7W5
DM3P7W5	DN	IDD552
DM3P7W5	MI	TTFBNVI
DM3P7W5	MN	Aldose reductase (AKR1B1)
DM3P7W5	MT	DTT
DM3P7W5	MA	Inhibitor
DM3P7W5	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM3P7W5	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMDHLG3	DI	DMDHLG3
DMDHLG3	DN	IDD594
DMDHLG3	MI	TTFBNVI
DMDHLG3	MN	Aldose reductase (AKR1B1)
DMDHLG3	MT	DTT
DMDHLG3	MA	Inhibitor
DMDHLG3	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMDHLG3	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMBFX5H	DI	DMBFX5H
DMBFX5H	DN	IDDBCP226234
DMBFX5H	MI	TT69J2Z
DMBFX5H	MN	Serine/threonine-protein kinase pim-2 (PIM2)
DMBFX5H	MT	DTT
DMBFX5H	MA	Inhibitor
DMBFX5H	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2159).
DMBFX5H	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2159

DMRQSN2	DI	DMRQSN2
DMRQSN2	DN	IDN-1965
DMRQSN2	MI	TTZY5KP
DMRQSN2	MN	Caspase (CASP)
DMRQSN2	MT	DTT
DMRQSN2	MA	Inhibitor
DMRQSN2	RN	Inhibition of cardiac myocyte apoptosis improves cardiac function and abolishes mortality in the peripartum cardiomyopathy of Galpha(q) transgenic ... Circulation. 2003 Dec 16;108(24):3036-41.
DMRQSN2	RU	https://pubmed.ncbi.nlm.nih.gov/14638549

DMNS9KW	DI	DMNS9KW
DMNS9KW	DN	IDN-5174
DMNS9KW	MI	TTGTQHC
DMNS9KW	MN	DNA topoisomerase I (TOP1)
DMNS9KW	MT	DTT
DMNS9KW	MA	Inhibitor
DMNS9KW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2636).
DMNS9KW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2636

DM1OMSW	DI	DM1OMSW
DM1OMSW	DN	IDN-5390
DM1OMSW	MI	TTYFKSZ
DM1OMSW	MN	Tubulin beta (TUBB)
DM1OMSW	MT	DTT
DM1OMSW	MA	Modulator
DM1OMSW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2640).
DM1OMSW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2640

DM6TEWZ	DI	DM6TEWZ
DM6TEWZ	DN	IDN-6384
DM6TEWZ	MI	TTGTQHC
DM6TEWZ	MN	DNA topoisomerase I (TOP1)
DM6TEWZ	MT	DTT
DM6TEWZ	MA	Inhibitor
DM6TEWZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2636).
DM6TEWZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2636

DMOU234	DI	DMOU234
DMOU234	DN	IGEL1.2
DMOU234	MI	TTYJQTF
DMOU234	MN	Immunoglobulin E (IgE)
DMOU234	MT	DTT
DMOU234	RN	Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60.
DMOU234	RU	https://pubmed.ncbi.nlm.nih.gov/18095918

DMFMY1L	DI	DMFMY1L
DMFMY1L	DN	IGERNELLIN
DMFMY1L	MI	TTN9T81
DMFMY1L	MN	Arachidonate 15-lipoxygenase (15-LOX)
DMFMY1L	MT	DTT
DMFMY1L	MA	Inhibitor
DMFMY1L	RN	Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases. J Nat Prod. 2003 Feb;66(2):230-5.
DMFMY1L	RU	https://pubmed.ncbi.nlm.nih.gov/12608855

DMLYIBO	DI	DMLYIBO
DMLYIBO	DN	IIK7
DMLYIBO	MI	TT0WAIE
DMLYIBO	MN	Melatonin receptor type 1A (MTNR1A)
DMLYIBO	MT	DTT
DMLYIBO	MA	Agonist
DMLYIBO	RN	Mapping the melatonin receptor. 6. Melatonin agonists and antagonists derived from 6H-isoindolo[2,1-a]indoles, 5,6-dihydroindolo[2,1-a]isoquinolines, and 6,7-dihydro-5H-benzo[c]azepino[2,1-a]indoles.J Med Chem. 2000 Mar 23;43(6):1050-61.
DMLYIBO	RU	https://pubmed.ncbi.nlm.nih.gov/10737738

DMJA4UE	DI	DMJA4UE
DMJA4UE	DN	IK-862
DMJA4UE	MI	TTQICM2
DMJA4UE	MN	ADAM metallopeptidase 33 (ADAM33)
DMJA4UE	MT	DTT
DMJA4UE	MA	Inhibitor
DMJA4UE	RN	Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge. Bioorg Med Chem. 2008 Oct 1;16(19):8781-94.
DMJA4UE	RU	https://pubmed.ncbi.nlm.nih.gov/18790648

DMJA4UE	DI	DMJA4UE
DMJA4UE	DN	IK-862
DMJA4UE	MI	TTHY57M
DMJA4UE	MN	Matrix metalloproteinase-13 (MMP-13)
DMJA4UE	MT	DTT
DMJA4UE	MA	Inhibitor
DMJA4UE	RN	Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structu... J Med Chem. 2002 Nov 7;45(23):4954-7.
DMJA4UE	RU	https://pubmed.ncbi.nlm.nih.gov/12408705

DMJA4UE	DI	DMJA4UE
DMJA4UE	DN	IK-862
DMJA4UE	MI	TTJ4QE7
DMJA4UE	MN	Matrix metalloproteinase-14 (MMP-14)
DMJA4UE	MT	DTT
DMJA4UE	MA	Inhibitor
DMJA4UE	RN	Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structu... J Med Chem. 2002 Nov 7;45(23):4954-7.
DMJA4UE	RU	https://pubmed.ncbi.nlm.nih.gov/12408705

DMJA4UE	DI	DMJA4UE
DMJA4UE	DN	IK-862
DMJA4UE	MI	TTLM12X
DMJA4UE	MN	Matrix metalloproteinase-2 (MMP-2)
DMJA4UE	MT	DTT
DMJA4UE	MA	Inhibitor
DMJA4UE	RN	Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structu... J Med Chem. 2002 Nov 7;45(23):4954-7.
DMJA4UE	RU	https://pubmed.ncbi.nlm.nih.gov/12408705

DMJA4UE	DI	DMJA4UE
DMJA4UE	DN	IK-862
DMJA4UE	MI	TTYRF5E
DMJA4UE	MN	Matrix metalloproteinase-21 (MMP-21)
DMJA4UE	MT	DTT
DMJA4UE	MA	Inhibitor
DMJA4UE	RN	Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structu... J Med Chem. 2002 Nov 7;45(23):4954-7.
DMJA4UE	RU	https://pubmed.ncbi.nlm.nih.gov/12408705

DMJA4UE	DI	DMJA4UE
DMJA4UE	DN	IK-862
DMJA4UE	MI	TTUZ2L5
DMJA4UE	MN	Matrix metalloproteinase-3 (MMP-3)
DMJA4UE	MT	DTT
DMJA4UE	MA	Inhibitor
DMJA4UE	RN	Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structu... J Med Chem. 2002 Nov 7;45(23):4954-7.
DMJA4UE	RU	https://pubmed.ncbi.nlm.nih.gov/12408705

DMJA4UE	DI	DMJA4UE
DMJA4UE	DN	IK-862
DMJA4UE	MI	TTMTWOS
DMJA4UE	MN	Matrix metalloproteinase-7 (MMP-7)
DMJA4UE	MT	DTT
DMJA4UE	MA	Inhibitor
DMJA4UE	RN	Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structu... J Med Chem. 2002 Nov 7;45(23):4954-7.
DMJA4UE	RU	https://pubmed.ncbi.nlm.nih.gov/12408705

DMJA4UE	DI	DMJA4UE
DMJA4UE	DN	IK-862
DMJA4UE	MI	TTGA1IV
DMJA4UE	MN	Matrix metalloproteinase-8 (MMP-8)
DMJA4UE	MT	DTT
DMJA4UE	MA	Inhibitor
DMJA4UE	RN	Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structu... J Med Chem. 2002 Nov 7;45(23):4954-7.
DMJA4UE	RU	https://pubmed.ncbi.nlm.nih.gov/12408705

DMJA4UE	DI	DMJA4UE
DMJA4UE	DN	IK-862
DMJA4UE	MI	TT6X50U
DMJA4UE	MN	Matrix metalloproteinase-9 (MMP-9)
DMJA4UE	MT	DTT
DMJA4UE	MA	Inhibitor
DMJA4UE	RN	Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structu... J Med Chem. 2002 Nov 7;45(23):4954-7.
DMJA4UE	RU	https://pubmed.ncbi.nlm.nih.gov/12408705

DMJA4UE	DI	DMJA4UE
DMJA4UE	DN	IK-862
DMJA4UE	MI	TT6AZXG
DMJA4UE	MN	TNF alpha converting enzyme (ADAM17)
DMJA4UE	MT	DTT
DMJA4UE	MA	Inhibitor
DMJA4UE	RN	Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge. Bioorg Med Chem. 2008 Oct 1;16(19):8781-94.
DMJA4UE	RU	https://pubmed.ncbi.nlm.nih.gov/18790648

DMJA4UE	DI	DMJA4UE
DMJA4UE	DN	IK-862
DMJA4UE	MI	TTF8CQI
DMJA4UE	MN	Tumor necrosis factor (TNF)
DMJA4UE	MT	DTT
DMJA4UE	MA	Inhibitor
DMJA4UE	RN	Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structu... J Med Chem. 2002 Nov 7;45(23):4954-7.
DMJA4UE	RU	https://pubmed.ncbi.nlm.nih.gov/12408705

DM2X3EV	DI	DM2X3EV
DM2X3EV	DN	IkappaB-alphaM
DM2X3EV	MI	TTSXVID
DM2X3EV	MN	Nuclear factor NF-kappa-B (NFKB)
DM2X3EV	MT	DTT
DM2X3EV	MA	Inhibitor
DM2X3EV	RN	An IkappaB-alpha mutant inhibits cytokine gene expression and proliferation in human vascular smooth muscle cells. J Surg Res. 2002 Feb;102(2):198-206.
DM2X3EV	RU	https://pubmed.ncbi.nlm.nih.gov/11796019

DM94AIL	DI	DM94AIL
DM94AIL	DN	IKH-25
DM94AIL	MI	TT5ZKDI
DM94AIL	MN	Histone deacetylase 6 (HDAC6)
DM94AIL	MT	DTT
DM94AIL	MA	Inhibitor
DM94AIL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2618).
DM94AIL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2618

DM8GQ9X	DI	DM8GQ9X
DM8GQ9X	DN	IKI-1
DM8GQ9X	MI	TTWLVKG
DM8GQ9X	MN	Inhibitor of nuclear factor kappa-B kinase alpha (IKKA)
DM8GQ9X	MT	DTT
DM8GQ9X	MA	Inhibitor
DM8GQ9X	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1989).
DM8GQ9X	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1989

DMLY5IF	DI	DMLY5IF
DMLY5IF	DN	IKs124
DMLY5IF	MI	TT846HF
DMLY5IF	MN	Voltage-gated potassium channel Kv7.1 (KCNQ1)
DMLY5IF	MT	DTT
DMLY5IF	MA	Blocker (channel blocker)
DMLY5IF	RN	Heteromeric KCNE2/KCNQ1 potassium channels in the luminal membrane of gastric parietal cells. J Physiol. 2004 Dec 1;561(Pt 2):547-57.
DMLY5IF	RU	https://pubmed.ncbi.nlm.nih.gov/15579540

DMU6AMP	DI	DMU6AMP
DMU6AMP	DN	IL-2 antibody (anti-tumor)
DMU6AMP	MI	TTF89GD
DMU6AMP	MN	Interleukin-2 (IL2)
DMU6AMP	MT	DTT
DMU6AMP	MA	Modulator
DMU6AMP	RN	An anti-IL-2 antibody increases serum half-life and improves anti-tumor efficacy of human recombinant interleukin-2. Immunopharmacology. 1994 Nov-Dec;28(3):223-32.
DMU6AMP	RU	https://www.ncbi.nlm.nih.gov/pubmed/7852053

DM10Z5W	DI	DM10Z5W
DM10Z5W	DN	Il-8((3-73))K11R
DM10Z5W	MI	TTMWT8Z
DM10Z5W	MN	C-X-C chemokine receptor type 1 (CXCR1)
DM10Z5W	MT	DTT
DM10Z5W	MA	Agonist
DM10Z5W	RN	Il-8((3-73))K11R is a high affinity agonist of the neutrophil CXCR1 and CXCR2. Biochem Biophys Res Commun. 2001 Aug 24;286(3):595-600.
DM10Z5W	RU	https://pubmed.ncbi.nlm.nih.gov/11511101

DM10Z5W	DI	DM10Z5W
DM10Z5W	DN	Il-8((3-73))K11R
DM10Z5W	MI	TT30C9G
DM10Z5W	MN	C-X-C chemokine receptor type 2 (CXCR2)
DM10Z5W	MT	DTT
DM10Z5W	MA	Agonist
DM10Z5W	RN	Il-8((3-73))K11R is a high affinity agonist of the neutrophil CXCR1 and CXCR2. Biochem Biophys Res Commun. 2001 Aug 24;286(3):595-600.
DM10Z5W	RU	https://pubmed.ncbi.nlm.nih.gov/11511101

DMPNQ27	DI	DMPNQ27
DMPNQ27	DN	Il-94
DMPNQ27	MI	TTFN95D
DMPNQ27	MN	PAK-1 protein kinase (PAK1)
DMPNQ27	MT	DTT
DMPNQ27	MA	Inhibitor
DMPNQ27	RN	PAK1: A Therapeutic Target for Cancer Treatment. ACS Med Chem Lett. 2013 Mar 19;4(5):431-2.
DMPNQ27	RU	https://pubmed.ncbi.nlm.nih.gov/24900689

DMPNQ27	DI	DMPNQ27
DMPNQ27	DN	Il-94
DMPNQ27	MI	TT279WO
DMPNQ27	MN	PAK-2 protein kinase (PAK2)
DMPNQ27	MT	DTT
DMPNQ27	MA	Inhibitor
DMPNQ27	RN	PAK1: A Therapeutic Target for Cancer Treatment. ACS Med Chem Lett. 2013 Mar 19;4(5):431-2.
DMPNQ27	RU	https://pubmed.ncbi.nlm.nih.gov/24900689

DMPIV1G	DI	DMPIV1G
DMPIV1G	DN	Ilatreotide
DMPIV1G	MI	TTOMNR9
DMPIV1G	MN	Somatostatin receptor (SSTR)
DMPIV1G	MT	DTT
DMPIV1G	MA	Modulator
DMPIV1G	RN	Inhibitory effect of intraduodenal administration of somatostatin analogue SDZ CO 611 on rat pancreatic exocrine secretion. Pancreas. 1993 Jul;8(4):471-5.
DMPIV1G	RU	https://www.ncbi.nlm.nih.gov/pubmed/8361968

DMZW0YO	DI	DMZW0YO
DMZW0YO	DN	IM-023911
DMZW0YO	MI	TTUTJGQ
DMZW0YO	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMZW0YO	MT	DTT
DMZW0YO	MA	Inhibitor
DMZW0YO	RN	Arylphthalazines: identification of a new phthalazine chemotype as inhibitors of VEGFR kinase. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4696-8.
DMZW0YO	RU	https://pubmed.ncbi.nlm.nih.gov/16143524

DMTFV65	DI	DMTFV65
DMTFV65	DN	IM-094261
DMTFV65	MI	TTUTJGQ
DMTFV65	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMTFV65	MT	DTT
DMTFV65	MA	Inhibitor
DMTFV65	RN	Arylphthalazines: identification of a new phthalazine chemotype as inhibitors of VEGFR kinase. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4696-8.
DMTFV65	RU	https://pubmed.ncbi.nlm.nih.gov/16143524

DMTFV65	DI	DMTFV65
DMTFV65	DN	IM-094261
DMTFV65	MI	TT1VAUK
DMTFV65	MN	VEGFR1 messenger RNA (VEGFR1 mRNA)
DMTFV65	MT	DTT
DMTFV65	MA	Inhibitor
DMTFV65	RN	Arylphthalazines: identification of a new phthalazine chemotype as inhibitors of VEGFR kinase. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4696-8.
DMTFV65	RU	https://pubmed.ncbi.nlm.nih.gov/16143524

DMO18YN	DI	DMO18YN
DMO18YN	DN	IM-094882
DMO18YN	MI	TTUTJGQ
DMO18YN	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMO18YN	MT	DTT
DMO18YN	MA	Inhibitor
DMO18YN	RN	Arylphthalazines. Part 2: 1-(Isoquinolin-5-yl)-4-arylamino phthalazines as potent inhibitors of VEGF receptors I and II. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1579-81.
DMO18YN	RU	https://pubmed.ncbi.nlm.nih.gov/16386418

DMO18YN	DI	DMO18YN
DMO18YN	DN	IM-094882
DMO18YN	MI	TT1VAUK
DMO18YN	MN	VEGFR1 messenger RNA (VEGFR1 mRNA)
DMO18YN	MT	DTT
DMO18YN	MA	Inhibitor
DMO18YN	RN	Arylphthalazines. Part 2: 1-(Isoquinolin-5-yl)-4-arylamino phthalazines as potent inhibitors of VEGF receptors I and II. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1579-81.
DMO18YN	RU	https://pubmed.ncbi.nlm.nih.gov/16386418

DM58DGY	DI	DM58DGY
DM58DGY	DN	IM-12
DM58DGY	MI	TTRSMW9
DM58DGY	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DM58DGY	MT	DTT
DM58DGY	MA	Inhibitor
DM58DGY	RN	Novel indolylmaleimide acts as GSK-3beta inhibitor in human neural progenitor cells. Bioorg Med Chem. 2010 Sep 15;18(18):6785-95.
DM58DGY	RU	https://pubmed.ncbi.nlm.nih.gov/20708937

DMUQO86	DI	DMUQO86
DMUQO86	DN	IM-491
DMUQO86	MI	TT6AZXG
DMUQO86	MN	TNF alpha converting enzyme (ADAM17)
DMUQO86	MT	DTT
DMUQO86	MA	Inhibitor
DMUQO86	RN	Discovery of beta-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitors. Bioorg Med Chem Lett. 2008 Jan 1;18(1):241-6.
DMUQO86	RU	https://pubmed.ncbi.nlm.nih.gov/18032037

DMPKWUO	DI	DMPKWUO
DMPKWUO	DN	imbutamine
DMPKWUO	MI	TT9JNIC
DMPKWUO	MN	Histamine H3 receptor (H3R)
DMPKWUO	MT	DTT
DMPKWUO	MA	Agonist
DMPKWUO	RN	Synthesis and structure-activity relationships of conformationally constrained histamine H(3) receptor agonists. J Med Chem. 2003 Dec 4;46(25):5445-57.
DMPKWUO	RU	https://pubmed.ncbi.nlm.nih.gov/14640553

DMMJ6NS	DI	DMMJ6NS
DMMJ6NS	DN	Imetit
DMMJ6NS	MI	TT9JNIC
DMMJ6NS	MN	Histamine H3 receptor (H3R)
DMMJ6NS	MT	DTT
DMMJ6NS	MA	Agonist
DMMJ6NS	RN	The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20.
DMMJ6NS	RU	https://pubmed.ncbi.nlm.nih.gov/15665857

DMMJ6NS	DI	DMMJ6NS
DMMJ6NS	DN	Imetit
DMMJ6NS	MI	TTXJ178
DMMJ6NS	MN	Histamine H4 receptor (H4R)
DMMJ6NS	MT	DTT
DMMJ6NS	MA	Agonist
DMMJ6NS	RN	Histamine excites neonatal rat sympathetic preganglionic neurons in vitro via activation of H1 receptors. J Neurophysiol. 2006 Apr;95(4):2492-500.
DMMJ6NS	RU	https://pubmed.ncbi.nlm.nih.gov/16354729

DMTGRAF	DI	DMTGRAF
DMTGRAF	DN	Imidazolidin-2-ylidene-o-tolyl-amine
DMTGRAF	MI	TTNGILX
DMTGRAF	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMTGRAF	MT	DTT
DMTGRAF	MA	Inhibitor
DMTGRAF	RN	Analogs of UK 14,304: Structural features responsible for alpha2 adrenoceptor activity, Bioorg. Med. Chem. Lett. 5(15):1745-1750 (1995).
DMTGRAF	RU	http://www.sciencedirect.com/science/article/pii/0960894X95002955

DMTGRAF	DI	DMTGRAF
DMTGRAF	DN	Imidazolidin-2-ylidene-o-tolyl-amine
DMTGRAF	MI	TTBRKXS
DMTGRAF	MN	Adrenergic receptor alpha-1B (ADRA1B)
DMTGRAF	MT	DTT
DMTGRAF	MA	Inhibitor
DMTGRAF	RN	Analogs of UK 14,304: Structural features responsible for alpha2 adrenoceptor activity, Bioorg. Med. Chem. Lett. 5(15):1745-1750 (1995).
DMTGRAF	RU	http://www.sciencedirect.com/science/article/pii/0960894X95002955

DMTGRAF	DI	DMTGRAF
DMTGRAF	DN	Imidazolidin-2-ylidene-o-tolyl-amine
DMTGRAF	MI	TT34BHT
DMTGRAF	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMTGRAF	MT	DTT
DMTGRAF	MA	Inhibitor
DMTGRAF	RN	Analogs of UK 14,304: Structural features responsible for alpha2 adrenoceptor activity, Bioorg. Med. Chem. Lett. 5(15):1745-1750 (1995).
DMTGRAF	RU	http://www.sciencedirect.com/science/article/pii/0960894X95002955

DMZ5ISH	DI	DMZ5ISH
DMZ5ISH	DN	Imidazolidin-2-ylidene-quinoxalin-6-yl-amine
DMZ5ISH	MI	TTNGILX
DMZ5ISH	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMZ5ISH	MT	DTT
DMZ5ISH	MA	Inhibitor
DMZ5ISH	RN	Analogs of UK 14,304: Structural features responsible for alpha2 adrenoceptor activity, Bioorg. Med. Chem. Lett. 5(15):1745-1750 (1995).
DMZ5ISH	RU	http://www.sciencedirect.com/science/article/pii/0960894X95002955

DMZ5ISH	DI	DMZ5ISH
DMZ5ISH	DN	Imidazolidin-2-ylidene-quinoxalin-6-yl-amine
DMZ5ISH	MI	TTBRKXS
DMZ5ISH	MN	Adrenergic receptor alpha-1B (ADRA1B)
DMZ5ISH	MT	DTT
DMZ5ISH	MA	Inhibitor
DMZ5ISH	RN	Analogs of UK 14,304: Structural features responsible for alpha2 adrenoceptor activity, Bioorg. Med. Chem. Lett. 5(15):1745-1750 (1995).
DMZ5ISH	RU	http://www.sciencedirect.com/science/article/pii/0960894X95002955

DMZ5ISH	DI	DMZ5ISH
DMZ5ISH	DN	Imidazolidin-2-ylidene-quinoxalin-6-yl-amine
DMZ5ISH	MI	TT34BHT
DMZ5ISH	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMZ5ISH	MT	DTT
DMZ5ISH	MA	Inhibitor
DMZ5ISH	RN	Analogs of UK 14,304: Structural features responsible for alpha2 adrenoceptor activity, Bioorg. Med. Chem. Lett. 5(15):1745-1750 (1995).
DMZ5ISH	RU	http://www.sciencedirect.com/science/article/pii/0960894X95002955

DMS4D96	DI	DMS4D96
DMS4D96	DN	imiloxan
DMS4D96	MI	TTWM4TY
DMS4D96	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMS4D96	MT	DTT
DMS4D96	MA	Antagonist
DMS4D96	RN	Assessment of imiloxan as a selective alpha 2B-adrenoceptor antagonist. Br J Pharmacol. 1990 Mar;99(3):560-4.
DMS4D96	RU	https://pubmed.ncbi.nlm.nih.gov/1970500

DMSINGH	DI	DMSINGH
DMSINGH	DN	Imino sugars
DMSINGH	MI	TTXWASR
DMSINGH	MN	Intestinal maltase-glucoamylase (MGAM)
DMSINGH	MT	DTT
DMSINGH	MA	Modulator
DMSINGH	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2627).
DMSINGH	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2627

DMZKABS	DI	DMZKABS
DMZKABS	DN	Imipramine oxide
DMZKABS	MI	DEJGDUW
DMZKABS	MN	Cytochrome P450 1A2 (CYP1A2)
DMZKABS	MT	DME
DMZKABS	MA	Metabolism
DMZKABS	RN	Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol Pharmacol. 1993 May;43(5):827-32.
DMZKABS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8502233

DMZKABS	DI	DMZKABS
DMZKABS	DN	Imipramine oxide
DMZKABS	MI	DE4LYSA
DMZKABS	MN	Cytochrome P450 3A4 (CYP3A4)
DMZKABS	MT	DME
DMZKABS	MA	Metabolism
DMZKABS	RN	Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol Pharmacol. 1993 May;43(5):827-32.
DMZKABS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8502233

DMDM3Y1	DI	DMDM3Y1
DMDM3Y1	DN	Immepip
DMDM3Y1	MI	TT9JNIC
DMDM3Y1	MN	Histamine H3 receptor (H3R)
DMDM3Y1	MT	DTT
DMDM3Y1	MA	Agonist
DMDM3Y1	RN	The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20.
DMDM3Y1	RU	https://pubmed.ncbi.nlm.nih.gov/15665857

DM7YQ26	DI	DM7YQ26
DM7YQ26	DN	Immethridine
DM7YQ26	MI	TT9JNIC
DM7YQ26	MN	Histamine H3 receptor (H3R)
DM7YQ26	MT	DTT
DM7YQ26	MA	Agonist
DM7YQ26	RN	The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20.
DM7YQ26	RU	https://pubmed.ncbi.nlm.nih.gov/15665857

DMX2NKO	DI	DMX2NKO
DMX2NKO	DN	Immucillin-G
DMX2NKO	MI	TTMCF1Y
DMX2NKO	MN	Purine nucleoside phosphorylase (PNP)
DMX2NKO	MT	DTT
DMX2NKO	MA	Inhibitor
DMX2NKO	RN	Exploring structure-activity relationships of transition state analogues of human purine nucleoside phosphorylase. J Med Chem. 2003 Jul 17;46(15):3412-23.
DMX2NKO	RU	https://pubmed.ncbi.nlm.nih.gov/12852771

DM1TQXO	DI	DM1TQXO
DM1TQXO	DN	IMP-731
DM1TQXO	MI	TTNVXAW
DM1TQXO	MN	Lymphocyte activation gene 3 protein (LAG3)
DM1TQXO	MT	DTT
DM1TQXO	MA	Modulator
DM1TQXO	RN	IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study. J Immune Based Ther Vaccines. 2007 Mar 29;5:5.
DM1TQXO	RU	https://pubmed.ncbi.nlm.nih.gov/17394654

DMPJXZN	DI	DMPJXZN
DMPJXZN	DN	impentamine
DMPJXZN	MI	TT9JNIC
DMPJXZN	MN	Histamine H3 receptor (H3R)
DMPJXZN	MT	DTT
DMPJXZN	MA	Agonist
DMPJXZN	RN	Synthesis and structure-activity relationships of conformationally constrained histamine H(3) receptor agonists. J Med Chem. 2003 Dec 4;46(25):5445-57.
DMPJXZN	RU	https://pubmed.ncbi.nlm.nih.gov/14640553

DMVLW6R	DI	DMVLW6R
DMVLW6R	DN	IMPERATORIN
DMVLW6R	MI	TTO9X1H
DMVLW6R	MN	5-HT 7 receptor (HTR7)
DMVLW6R	MT	DTT
DMVLW6R	MA	Inhibitor
DMVLW6R	RN	Serotonergic activity-guided phytochemical investigation of the roots of Angelica sinensis. J Nat Prod. 2006 Apr;69(4):536-41.
DMVLW6R	RU	https://pubmed.ncbi.nlm.nih.gov/16643021

DMQ4ICU	DI	DMQ4ICU
DMQ4ICU	DN	improgan
DMQ4ICU	MI	TTXJ178
DMQ4ICU	MN	Histamine H4 receptor (H4R)
DMQ4ICU	MT	DTT
DMQ4ICU	MA	Agonist
DMQ4ICU	RN	Cloning, expression, and pharmacological characterization of a novel human histamine receptor. Mol Pharmacol. 2001 Mar;59(3):434-41.
DMQ4ICU	RU	https://pubmed.ncbi.nlm.nih.gov/11179436

DMTDRPM	DI	DMTDRPM
DMTDRPM	DN	impromidine
DMTDRPM	MI	TTTIBOJ
DMTDRPM	MN	Histamine H1 receptor (H1R)
DMTDRPM	MT	DTT
DMTDRPM	MA	Antagonist
DMTDRPM	RN	Probing ligand-specific histamine H1- and H2-receptor conformations with NG-acylated Imidazolylpropylguanidines. J Pharmacol Exp Ther. 2006 Apr;317(1):139-46.
DMTDRPM	RU	https://pubmed.ncbi.nlm.nih.gov/16394198

DMTDRPM	DI	DMTDRPM
DMTDRPM	DN	impromidine
DMTDRPM	MI	TTQHJ1K
DMTDRPM	MN	Histamine H2 receptor (H2R)
DMTDRPM	MT	DTT
DMTDRPM	MA	Agonist
DMTDRPM	RN	Probing ligand-specific histamine H1- and H2-receptor conformations with NG-acylated Imidazolylpropylguanidines. J Pharmacol Exp Ther. 2006 Apr;317(1):139-46.
DMTDRPM	RU	https://pubmed.ncbi.nlm.nih.gov/16394198

DMTDRPM	DI	DMTDRPM
DMTDRPM	DN	impromidine
DMTDRPM	MI	TT9JNIC
DMTDRPM	MN	Histamine H3 receptor (H3R)
DMTDRPM	MT	DTT
DMTDRPM	MA	Agonist
DMTDRPM	RN	Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol. 2001 Mar;59(3):420-6.
DMTDRPM	RU	https://pubmed.ncbi.nlm.nih.gov/11179434

DMTDRPM	DI	DMTDRPM
DMTDRPM	DN	impromidine
DMTDRPM	MI	TTXJ178
DMTDRPM	MN	Histamine H4 receptor (H4R)
DMTDRPM	MT	DTT
DMTDRPM	MA	Agonist
DMTDRPM	RN	Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first pote... J Pharmacol Exp Ther. 2005 Sep;314(3):1310-21.
DMTDRPM	RU	https://pubmed.ncbi.nlm.nih.gov/15947036

DM3YJXF	DI	DM3YJXF
DM3YJXF	DN	IN-1130
DM3YJXF	MI	TTQBR95
DM3YJXF	MN	Stress-activated protein kinase 2a (p38 alpha)
DM3YJXF	MT	DTT
DM3YJXF	MA	Inhibitor
DM3YJXF	RN	Synthesis and biological evaluation of trisubstituted imidazole derivatives as inhibitors of p38alpha mitogen-activated protein kinase. Bioorg Med Chem Lett. 2008 Jul 15;18(14):4006-10.
DM3YJXF	RU	https://pubmed.ncbi.nlm.nih.gov/18571921

DM3YJXF	DI	DM3YJXF
DM3YJXF	DN	IN-1130
DM3YJXF	MI	TTP4520
DM3YJXF	MN	TGF-beta receptor type I (TGFBR1)
DM3YJXF	MT	DTT
DM3YJXF	MA	Inhibitor
DM3YJXF	RN	Synthesis and biological evaluation of 4(5)-(6-methylpyridin-2-yl)imidazoles and -pyrazoles as transforming growth factor-beta type 1 receptor kina... Bioorg Med Chem. 2010 Jun 15;18(12):4459-67.
DM3YJXF	RU	https://pubmed.ncbi.nlm.nih.gov/20472445

DMMS6D3	DI	DMMS6D3
DMMS6D3	DN	IN-1166
DMMS6D3	MI	TT3IVG2
DMMS6D3	MN	JNK2 messenger RNA (JNK2 mRNA)
DMMS6D3	MT	DTT
DMMS6D3	MA	Inhibitor
DMMS6D3	RN	Synthesis and biological evaluation of 4(5)-(6-alkylpyridin-2-yl)imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors. J Med Chem. 2007 Jun 28;50(13):3143-7.
DMMS6D3	RU	https://pubmed.ncbi.nlm.nih.gov/17552507

DMMS6D3	DI	DMMS6D3
DMMS6D3	DN	IN-1166
DMMS6D3	MI	TTQBR95
DMMS6D3	MN	Stress-activated protein kinase 2a (p38 alpha)
DMMS6D3	MT	DTT
DMMS6D3	MA	Inhibitor
DMMS6D3	RN	Synthesis and biological evaluation of trisubstituted imidazole derivatives as inhibitors of p38alpha mitogen-activated protein kinase. Bioorg Med Chem Lett. 2008 Jul 15;18(14):4006-10.
DMMS6D3	RU	https://pubmed.ncbi.nlm.nih.gov/18571921

DMMS6D3	DI	DMMS6D3
DMMS6D3	DN	IN-1166
DMMS6D3	MI	TTP4520
DMMS6D3	MN	TGF-beta receptor type I (TGFBR1)
DMMS6D3	MT	DTT
DMMS6D3	MA	Inhibitor
DMMS6D3	RN	Synthesis and biological evaluation of 4(5)-(6-alkylpyridin-2-yl)imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors. J Med Chem. 2007 Jun 28;50(13):3143-7.
DMMS6D3	RU	https://pubmed.ncbi.nlm.nih.gov/17552507

DM4JNUH	DI	DM4JNUH
DM4JNUH	DN	IN1479
DM4JNUH	MI	TTGJCWZ
DM4JNUH	MN	Fms-like tyrosine kinase 3 (FLT-3)
DM4JNUH	MT	DTT
DM4JNUH	MA	Inhibitor
DM4JNUH	RN	Aromatic interactions with phenylalanine 691 and cysteine 828: a concept for FMS-like tyrosine kinase-3 inhibition. Application to the discovery of a new class of potential antileukemia agents. J MedChem. 2006 Jul 27;49(15):4451-4.
DM4JNUH	RU	https://pubmed.ncbi.nlm.nih.gov/16854049

DMKFE6X	DI	DMKFE6X
DMKFE6X	DN	IN1535
DMKFE6X	MI	TTH6V3D
DMKFE6X	MN	Cyclin-dependent kinase 1 (CDK1)
DMKFE6X	MT	DTT
DMKFE6X	MA	Binder
DMKFE6X	RN	M-phase regulation of the recruitment of mRNAs onto polysomes using the CDK1/cyclin B inhibitor aminopurvalanol. Biochem Biophys Res Commun. 2003 Jul 11;306(4):880-6.
DMKFE6X	RU	https://pubmed.ncbi.nlm.nih.gov/12821124

DMENHMU	DI	DMENHMU
DMENHMU	DN	IN-3
DMENHMU	MI	TT8R70G
DMENHMU	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMENHMU	MT	DTT
DMENHMU	MA	Antagonist
DMENHMU	RN	Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: misrouted proteins as a novel disease etiology and therapeutic target. JClin Endocrinol Metab. 2002 Jul;87(7):3255-62.
DMENHMU	RU	https://pubmed.ncbi.nlm.nih.gov/12107234

DM8E4HB	DI	DM8E4HB
DM8E4HB	DN	INC-106
DM8E4HB	MI	TT8DBY3
DM8E4HB	MN	Angiotensin II receptor type-1 (AGTR1)
DM8E4HB	MT	DTT
DM8E4HB	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 34).
DM8E4HB	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=34

DMZCHSD	DI	DMZCHSD
DMZCHSD	DN	INCB-10820
DMZCHSD	MI	TTFZYTO
DMZCHSD	MN	C-C chemokine receptor type 2 (CCR2)
DMZCHSD	MT	DTT
DMZCHSD	MA	Antagonist
DMZCHSD	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 59).
DMZCHSD	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=59

DMONMHK	DI	DMONMHK
DMONMHK	DN	incensole acetate
DMONMHK	MI	TT946IA
DMONMHK	MN	Transient receptor potential cation channel V3 (TRPV3)
DMONMHK	MT	DTT
DMONMHK	MA	Activator
DMONMHK	RN	Incensole acetate, an incense component, elicits psychoactivity by activating TRPV3 channels in the brain. FASEB J. 2008 Aug;22(8):3024-34.
DMONMHK	RU	https://pubmed.ncbi.nlm.nih.gov/18492727

DMMLQZJ	DI	DMMLQZJ
DMMLQZJ	DN	Indan-1-ol
DMMLQZJ	MI	DEGQTXO
DMMLQZJ	MN	Aldo-keto reductase 1C3 (AKR1C3)
DMMLQZJ	MT	DME
DMMLQZJ	MA	Metabolism
DMMLQZJ	RN	Expression and characterization of four recombinant human dihydrodiol dehydrogenase isoforms: oxidation of trans-7, 8-dihydroxy-7,8-dihydrobenzo[a]pyrene to the activated o-quinone metabolite benzo[a]pyrene-7,8-dione. Biochemistry. 1998 May 12;37(19):6781-90.
DMMLQZJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9578563

DMVZMBU	DI	DMVZMBU
DMVZMBU	DN	Indan-2-ylcarbamic Acid Biphenyl-3-yl Ester
DMVZMBU	MI	TTDP1UC
DMVZMBU	MN	Fatty acid amide hydrolase (FAAH)
DMVZMBU	MT	DTT
DMVZMBU	MA	Inhibitor
DMVZMBU	RN	Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl a... J Med Chem. 2008 Jun 26;51(12):3487-98.
DMVZMBU	RU	https://pubmed.ncbi.nlm.nih.gov/18507372

DM4S81A	DI	DM4S81A
DM4S81A	DN	indanidine
DM4S81A	MI	TT2NUT5
DM4S81A	MN	Adrenergic receptor alpha-2C (ADRA2C)
DM4S81A	MT	DTT
DM4S81A	MA	Agonist
DM4S81A	RN	Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes. Mol Pharmacol. 1994 Nov;46(5):929-36.
DM4S81A	RU	https://pubmed.ncbi.nlm.nih.gov/7969082

DMIP9DN	DI	DMIP9DN
DMIP9DN	DN	Indatraline
DMIP9DN	MI	TTVBI8W
DMIP9DN	MN	Dopamine transporter (DAT)
DMIP9DN	MT	DTT
DMIP9DN	MA	Inhibitor
DMIP9DN	RN	Effects of indatraline and buprenorphine on self-administration of speedball combinations of cocaine and heroin by rhesus monkeys. Neuropsychopharmacology. 2001 Jul;25(1):104-17.
DMIP9DN	RU	https://pubmed.ncbi.nlm.nih.gov/11377924

DMYLVQF	DI	DMYLVQF
DMYLVQF	DN	indirubin deriv. 8a
DMYLVQF	MI	TTRSMW9
DMYLVQF	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMYLVQF	MT	DTT
DMYLVQF	MA	Inhibitor
DMYLVQF	RN	Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J Med Chem. 2004 Feb 12;47(4):935-46.
DMYLVQF	RU	https://pubmed.ncbi.nlm.nih.gov/14761195

DMYLVQF	DI	DMYLVQF
DMYLVQF	DN	indirubin deriv. 8a
DMYLVQF	MI	TTQWAU1
DMYLVQF	MN	GSK3A messenger RNA (GSK3A mRNA)
DMYLVQF	MT	DTT
DMYLVQF	MA	Inhibitor
DMYLVQF	RN	Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J Med Chem. 2004 Feb 12;47(4):935-46.
DMYLVQF	RU	https://pubmed.ncbi.nlm.nih.gov/14761195

DMFP1C5	DI	DMFP1C5
DMFP1C5	DN	indirubin derivative E804
DMFP1C5	MI	TTXEZJ4
DMFP1C5	MN	Tyrosine-protein kinase EIF2AK2 (p68)
DMFP1C5	MT	DTT
DMFP1C5	MA	Inhibitor
DMFP1C5	RN	Identification of new inhibitors of protein kinase R guided by statistical modeling. Bioorg Med Chem Lett. 2011 Jul 1;21(13):4108-14.
DMFP1C5	RU	https://pubmed.ncbi.nlm.nih.gov/21632247

DM3UR1E	DI	DM3UR1E
DM3UR1E	DN	Indirubin-3-acetoxime
DM3UR1E	MI	TT9RTBL
DM3UR1E	MN	Aurora B messenger RNA (AURKB mRNA)
DM3UR1E	MT	DTT
DM3UR1E	MA	Inhibitor
DM3UR1E	RN	An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37.
DM3UR1E	RU	https://pubmed.ncbi.nlm.nih.gov/17665890

DM3UR1E	DI	DM3UR1E
DM3UR1E	DN	Indirubin-3-acetoxime
DM3UR1E	MI	TTPS3C0
DM3UR1E	MN	Aurora kinase A (AURKA)
DM3UR1E	MT	DTT
DM3UR1E	MA	Inhibitor
DM3UR1E	RN	An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37.
DM3UR1E	RU	https://pubmed.ncbi.nlm.nih.gov/17665890

DM3UR1E	DI	DM3UR1E
DM3UR1E	DN	Indirubin-3-acetoxime
DM3UR1E	MI	TTLYXIT
DM3UR1E	MN	Aurora kinase C (AURKC)
DM3UR1E	MT	DTT
DM3UR1E	MA	Inhibitor
DM3UR1E	RN	An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37.
DM3UR1E	RU	https://pubmed.ncbi.nlm.nih.gov/17665890

DMZ5ODC	DI	DMZ5ODC
DMZ5ODC	DN	Indirubin-3-methoxime
DMZ5ODC	MI	TT9RTBL
DMZ5ODC	MN	Aurora B messenger RNA (AURKB mRNA)
DMZ5ODC	MT	DTT
DMZ5ODC	MA	Inhibitor
DMZ5ODC	RN	An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37.
DMZ5ODC	RU	https://pubmed.ncbi.nlm.nih.gov/17665890

DMZ5ODC	DI	DMZ5ODC
DMZ5ODC	DN	Indirubin-3-methoxime
DMZ5ODC	MI	TTPS3C0
DMZ5ODC	MN	Aurora kinase A (AURKA)
DMZ5ODC	MT	DTT
DMZ5ODC	MA	Inhibitor
DMZ5ODC	RN	An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37.
DMZ5ODC	RU	https://pubmed.ncbi.nlm.nih.gov/17665890

DMZ5ODC	DI	DMZ5ODC
DMZ5ODC	DN	Indirubin-3-methoxime
DMZ5ODC	MI	TTLYXIT
DMZ5ODC	MN	Aurora kinase C (AURKC)
DMZ5ODC	MT	DTT
DMZ5ODC	MA	Inhibitor
DMZ5ODC	RN	An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37.
DMZ5ODC	RU	https://pubmed.ncbi.nlm.nih.gov/17665890

DMLRQH0	DI	DMLRQH0
DMLRQH0	DN	Indirubin-3'-monoxime
DMLRQH0	MI	TT9RTBL
DMLRQH0	MN	Aurora B messenger RNA (AURKB mRNA)
DMLRQH0	MT	DTT
DMLRQH0	MA	Inhibitor
DMLRQH0	RN	An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37.
DMLRQH0	RU	https://pubmed.ncbi.nlm.nih.gov/17665890

DMLRQH0	DI	DMLRQH0
DMLRQH0	DN	Indirubin-3'-monoxime
DMLRQH0	MI	TTPS3C0
DMLRQH0	MN	Aurora kinase A (AURKA)
DMLRQH0	MT	DTT
DMLRQH0	MA	Inhibitor
DMLRQH0	RN	An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37.
DMLRQH0	RU	https://pubmed.ncbi.nlm.nih.gov/17665890

DMLRQH0	DI	DMLRQH0
DMLRQH0	DN	Indirubin-3'-monoxime
DMLRQH0	MI	TTLYXIT
DMLRQH0	MN	Aurora kinase C (AURKC)
DMLRQH0	MT	DTT
DMLRQH0	MA	Inhibitor
DMLRQH0	RN	An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37.
DMLRQH0	RU	https://pubmed.ncbi.nlm.nih.gov/17665890

DMLRQH0	DI	DMLRQH0
DMLRQH0	DN	Indirubin-3'-monoxime
DMLRQH0	MI	TTH6V3D
DMLRQH0	MN	Cyclin-dependent kinase 1 (CDK1)
DMLRQH0	MT	DTT
DMLRQH0	MA	Binder
DMLRQH0	RN	The kinase inhibitor indirubin-3'-oxime prevents germinal vesicle breakdown and reduces parthenogenetic development of pig oocytes. Theriogenology. 2006 Mar 1;65(4):744-56.
DMLRQH0	RU	https://pubmed.ncbi.nlm.nih.gov/16105677

DMLRQH0	DI	DMLRQH0
DMLRQH0	DN	Indirubin-3'-monoxime
DMLRQH0	MI	TT7HF4W
DMLRQH0	MN	Cyclin-dependent kinase 2 (CDK2)
DMLRQH0	MT	DTT
DMLRQH0	MA	Inhibitor
DMLRQH0	RN	Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
DMLRQH0	RU	https://pubmed.ncbi.nlm.nih.gov/12237154

DMLRQH0	DI	DMLRQH0
DMLRQH0	DN	Indirubin-3'-monoxime
DMLRQH0	MI	TTL4Q97
DMLRQH0	MN	Cyclin-dependent kinase 5 (CDK5)
DMLRQH0	MT	DTT
DMLRQH0	MA	Inhibitor
DMLRQH0	RN	Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
DMLRQH0	RU	https://pubmed.ncbi.nlm.nih.gov/12237154

DM08VHZ	DI	DM08VHZ
DM08VHZ	DN	Indirubin-5-sulfonate
DM08VHZ	MI	TTH6V3D
DM08VHZ	MN	Cyclin-dependent kinase 1 (CDK1)
DM08VHZ	MT	DTT
DM08VHZ	MA	Binder
DM08VHZ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM08VHZ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM08VHZ	DI	DM08VHZ
DM08VHZ	DN	Indirubin-5-sulfonate
DM08VHZ	MI	TT7HF4W
DM08VHZ	MN	Cyclin-dependent kinase 2 (CDK2)
DM08VHZ	MT	DTT
DM08VHZ	MA	Inhibitor
DM08VHZ	RN	Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
DM08VHZ	RU	https://pubmed.ncbi.nlm.nih.gov/12237154

DM08VHZ	DI	DM08VHZ
DM08VHZ	DN	Indirubin-5-sulfonate
DM08VHZ	MI	TTL4Q97
DM08VHZ	MN	Cyclin-dependent kinase 5 (CDK5)
DM08VHZ	MT	DTT
DM08VHZ	MA	Inhibitor
DM08VHZ	RN	Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
DM08VHZ	RU	https://pubmed.ncbi.nlm.nih.gov/12237154

DM08VHZ	DI	DM08VHZ
DM08VHZ	DN	Indirubin-5-sulfonate
DM08VHZ	MI	TTZHY6R
DM08VHZ	MN	Glycogen phosphorylase muscle form (GP)
DM08VHZ	MT	DTT
DM08VHZ	MA	Inhibitor
DM08VHZ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM08VHZ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM08VHZ	DI	DM08VHZ
DM08VHZ	DN	Indirubin-5-sulfonate
DM08VHZ	MI	TT9PCE0
DM08VHZ	MN	Plasmodium CDK PfPK5 (Malaria PfPK5)
DM08VHZ	MT	DTT
DM08VHZ	MA	Inhibitor
DM08VHZ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM08VHZ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMJB876	DI	DMJB876
DMJB876	DN	Indol-1-yl-methyl-pyridin-4-yl-amine
DMJB876	MI	TTWG9A4
DMJB876	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMJB876	MT	DTT
DMJB876	MA	Inhibitor
DMJB876	RN	Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81.
DMJB876	RU	https://pubmed.ncbi.nlm.nih.gov/8558529

DMJB876	DI	DMJB876
DMJB876	DN	Indol-1-yl-methyl-pyridin-4-yl-amine
DMJB876	MI	TTWM4TY
DMJB876	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMJB876	MT	DTT
DMJB876	MA	Inhibitor
DMJB876	RN	Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81.
DMJB876	RU	https://pubmed.ncbi.nlm.nih.gov/8558529

DMJB876	DI	DMJB876
DMJB876	DN	Indol-1-yl-methyl-pyridin-4-yl-amine
DMJB876	MI	TT2NUT5
DMJB876	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMJB876	MT	DTT
DMJB876	MA	Inhibitor
DMJB876	RN	Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81.
DMJB876	RU	https://pubmed.ncbi.nlm.nih.gov/8558529

DMR9GNW	DI	DMR9GNW
DMR9GNW	DN	Indol-1-yl-prop-2-ynyl-pyridin-4-yl-amine
DMR9GNW	MI	TTWG9A4
DMR9GNW	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMR9GNW	MT	DTT
DMR9GNW	MA	Inhibitor
DMR9GNW	RN	Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81.
DMR9GNW	RU	https://pubmed.ncbi.nlm.nih.gov/8558529

DMR9GNW	DI	DMR9GNW
DMR9GNW	DN	Indol-1-yl-prop-2-ynyl-pyridin-4-yl-amine
DMR9GNW	MI	TTWM4TY
DMR9GNW	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMR9GNW	MT	DTT
DMR9GNW	MA	Inhibitor
DMR9GNW	RN	Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81.
DMR9GNW	RU	https://pubmed.ncbi.nlm.nih.gov/8558529

DMR9GNW	DI	DMR9GNW
DMR9GNW	DN	Indol-1-yl-prop-2-ynyl-pyridin-4-yl-amine
DMR9GNW	MI	TT2NUT5
DMR9GNW	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMR9GNW	MT	DTT
DMR9GNW	MA	Inhibitor
DMR9GNW	RN	Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81.
DMR9GNW	RU	https://pubmed.ncbi.nlm.nih.gov/8558529

DM1F53L	DI	DM1F53L
DM1F53L	DN	Indol-1-yl-pyridin-4-yl-amine
DM1F53L	MI	TTWG9A4
DM1F53L	MN	Adrenergic receptor alpha-2A (ADRA2A)
DM1F53L	MT	DTT
DM1F53L	MA	Inhibitor
DM1F53L	RN	Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81.
DM1F53L	RU	https://pubmed.ncbi.nlm.nih.gov/8558529

DM1F53L	DI	DM1F53L
DM1F53L	DN	Indol-1-yl-pyridin-4-yl-amine
DM1F53L	MI	TTWM4TY
DM1F53L	MN	Adrenergic receptor alpha-2B (ADRA2B)
DM1F53L	MT	DTT
DM1F53L	MA	Inhibitor
DM1F53L	RN	Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81.
DM1F53L	RU	https://pubmed.ncbi.nlm.nih.gov/8558529

DM1F53L	DI	DM1F53L
DM1F53L	DN	Indol-1-yl-pyridin-4-yl-amine
DM1F53L	MI	TT2NUT5
DM1F53L	MN	Adrenergic receptor alpha-2C (ADRA2C)
DM1F53L	MT	DTT
DM1F53L	MA	Inhibitor
DM1F53L	RN	Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81.
DM1F53L	RU	https://pubmed.ncbi.nlm.nih.gov/8558529

DMP543H	DI	DMP543H
DMP543H	DN	INDOLACTUM
DMP543H	MI	TT9WJ8U
DMP543H	MN	Protein kinase C delta (PRKCD)
DMP543H	MT	DTT
DMP543H	MA	Inhibitor
DMP543H	RN	Structural basis of RasGRP binding to high-affinity PKC ligands. J Med Chem. 2002 Feb 14;45(4):853-60.
DMP543H	RU	https://pubmed.ncbi.nlm.nih.gov/11831896

DMEHI15	DI	DMEHI15
DMEHI15	DN	Indole N -acetamide
DMEHI15	MI	TT84ETX
DMEHI15	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMEHI15	MT	DTT
DMEHI15	MA	Inhibitor
DMEHI15	RN	Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416.
DMEHI15	RU	https://pubmed.ncbi.nlm.nih.gov/18764719

DMB4ZNW	DI	DMB4ZNW
DMB4ZNW	DN	Indole Naphthyridinone
DMB4ZNW	MI	TTVTX4N
DMB4ZNW	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DMB4ZNW	MT	DTT
DMB4ZNW	MA	Inhibitor
DMB4ZNW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMB4ZNW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMB4ZNW	DI	DMB4ZNW
DMB4ZNW	DN	Indole Naphthyridinone
DMB4ZNW	MI	TTNX2CS
DMB4ZNW	MN	Plasmodium Enoyl-ACP reductase (Malaria fabI)
DMB4ZNW	MT	DTT
DMB4ZNW	MA	Inhibitor
DMB4ZNW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMB4ZNW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMF0VAG	DI	DMF0VAG
DMF0VAG	DN	indole-3-propionic acid
DMF0VAG	MI	TTUYIZW
DMF0VAG	MN	Solute carrier family 36 member 1 (SLC36A1)
DMF0VAG	MT	DTT
DMF0VAG	MA	Inhibitor
DMF0VAG	RN	Serotonin, L-tryptophan, and tryptamine are effective inhibitors of the amino acid transport system PAT1. FASEB J. 2005 Sep;19(11):1468-73.
DMF0VAG	RU	https://pubmed.ncbi.nlm.nih.gov/16126914

DMML9AY	DI	DMML9AY
DMML9AY	DN	Indolin-2-one deriv. 4b
DMML9AY	MI	TTUTJGQ
DMML9AY	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMML9AY	MT	DTT
DMML9AY	MA	Inhibitor
DMML9AY	RN	Identification of substituted 3-[(4,5,6, 7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rbeta tyrosine kinases. J Med Chem. 2000 Jul 13;43(14):2655-63.
DMML9AY	RU	https://pubmed.ncbi.nlm.nih.gov/10893303

DMSBENK	DI	DMSBENK
DMSBENK	DN	Indomethacin glucuronide
DMSBENK	MI	DE9RA0I
DMSBENK	MN	Beta-glucuronidase (uidA)
DMSBENK	MT	DME
DMSBENK	MA	Metabolism
DMSBENK	RN	Bidirectional interactions between indomethacin and the murine intestinal microbiota. Elife. 2015 Dec 23;4:e08973.
DMSBENK	RU	https://pubmed.ncbi.nlm.nih.gov/26701907

DMSBENK	DI	DMSBENK
DMSBENK	DN	Indomethacin glucuronide
DMSBENK	MI	DEGA738
DMSBENK	MN	Beta-glucuronidase (uidA)
DMSBENK	MT	DME
DMSBENK	MA	Metabolism
DMSBENK	RN	Developing a metagenomic view of xenobiotic metabolism. Pharmacol Res. 2013 Mar;69(1):21-31.
DMSBENK	RU	https://pubmed.ncbi.nlm.nih.gov/22902524

DMSBENK	DI	DMSBENK
DMSBENK	DN	Indomethacin glucuronide
DMSBENK	MI	DE68SAL
DMSBENK	MN	Beta-glucuronidase (uidA)
DMSBENK	MT	DME
DMSBENK	MA	Metabolism
DMSBENK	RN	Developing a metagenomic view of xenobiotic metabolism. Pharmacol Res. 2013 Mar;69(1):21-31.
DMSBENK	RU	https://pubmed.ncbi.nlm.nih.gov/22902524

DMSBENK	DI	DMSBENK
DMSBENK	DN	Indomethacin glucuronide
DMSBENK	MI	DEKRUCA
DMSBENK	MN	Beta-glucuronidase (uidA)
DMSBENK	MT	DME
DMSBENK	MA	Metabolism
DMSBENK	RN	Developing a metagenomic view of xenobiotic metabolism. Pharmacol Res. 2013 Mar;69(1):21-31.
DMSBENK	RU	https://pubmed.ncbi.nlm.nih.gov/22902524

DMSBENK	DI	DMSBENK
DMSBENK	DN	Indomethacin glucuronide
DMSBENK	MI	DE473X0
DMSBENK	MN	Beta-glucuronidase (uidA)
DMSBENK	MT	DME
DMSBENK	MA	Metabolism
DMSBENK	RN	Developing a metagenomic view of xenobiotic metabolism. Pharmacol Res. 2013 Mar;69(1):21-31.
DMSBENK	RU	https://pubmed.ncbi.nlm.nih.gov/22902524

DMBOQ6M	DI	DMBOQ6M
DMBOQ6M	DN	INDUS-815B
DMBOQ6M	MI	TTSLUMT
DMBOQ6M	MN	Protein kinase D (PRKD1)
DMBOQ6M	MT	DTT
DMBOQ6M	MA	Modulator
DMBOQ6M	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1489).
DMBOQ6M	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1489

DMLJ645	DI	DMLJ645
DMLJ645	DN	INDUS-815C
DMLJ645	MI	TTLKF5M
DMLJ645	MN	NAD-dependent deacetylase sirtuin-2 (SIRT2)
DMLJ645	MT	DTT
DMLJ645	MA	Inhibitor
DMLJ645	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2708).
DMLJ645	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2708

DMV6UJ5	DI	DMV6UJ5
DMV6UJ5	DN	Infractopicrin
DMV6UJ5	MI	TT1RS9F
DMV6UJ5	MN	Acetylcholinesterase (AChE)
DMV6UJ5	MT	DTT
DMV6UJ5	MA	Inhibitor
DMV6UJ5	RN	Acetylcholinesterase inhibitors from the toadstool Cortinarius infractus. Bioorg Med Chem. 2010 Mar 15;18(6):2173-2177.
DMV6UJ5	RU	https://pubmed.ncbi.nlm.nih.gov/20176490

DM487FU	DI	DM487FU
DM487FU	DN	Ingenol-3-bezoate
DM487FU	MI	TT9WJ8U
DM487FU	MN	Protein kinase C delta (PRKCD)
DM487FU	MT	DTT
DM487FU	MA	Inhibitor
DM487FU	RN	Structural basis of binding of high-affinity ligands to protein kinase C: prediction of the binding modes through a new molecular dynamics method a... J Med Chem. 2001 May 24;44(11):1690-701.
DM487FU	RU	https://pubmed.ncbi.nlm.nih.gov/11356104

DMUQHMP	DI	DMUQHMP
DMUQHMP	DN	Inhibitor 1 [Colombo et al., 2012]
DMUQHMP	MI	TTWHYC8
DMUQHMP	MN	Airway trypsin-like protease (TMPRSS11D)
DMUQHMP	MT	DTT
DMUQHMP	MA	Inhibitor
DMUQHMP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2420).
DMUQHMP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2420

DMUQHMP	DI	DMUQHMP
DMUQHMP	DN	Inhibitor 1 [Colombo et al., 2012]
DMUQHMP	MI	TTPRO7W
DMUQHMP	MN	Suppressor of tumorigenicity 14 protein (ST14)
DMUQHMP	MT	DTT
DMUQHMP	MA	Inhibitor
DMUQHMP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2418).
DMUQHMP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2418

DMUQHMP	DI	DMUQHMP
DMUQHMP	DN	Inhibitor 1 [Colombo et al., 2012]
DMUQHMP	MI	TTL9KE7
DMUQHMP	MN	Transmembrane protease serine 6 (TMPRSS6)
DMUQHMP	MT	DTT
DMUQHMP	MA	Inhibitor
DMUQHMP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2422).
DMUQHMP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2422

DMWIHRX	DI	DMWIHRX
DMWIHRX	DN	inhibitor 19
DMWIHRX	MI	TTY2KP7
DMWIHRX	MN	Leucyl-cysteinyl aminopeptidase (LNPEP)
DMWIHRX	MT	DTT
DMWIHRX	MA	Inhibitor
DMWIHRX	RN	Potent macrocyclic inhibitors of insulin-regulated aminopeptidase (IRAP) by olefin ring-closing metathesis. J Med Chem. 2011 Jun 9;54(11):3779-92.
DMWIHRX	RU	https://pubmed.ncbi.nlm.nih.gov/21476495

DMBQY3C	DI	DMBQY3C
DMBQY3C	DN	Inhibitor Idd 384
DMBQY3C	MI	TTFBNVI
DMBQY3C	MN	Aldose reductase (AKR1B1)
DMBQY3C	MT	DTT
DMBQY3C	MA	Inhibitor
DMBQY3C	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMBQY3C	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMI5N23	DI	DMI5N23
DMI5N23	DN	IN-N01
DMI5N23	MI	TTE4KHA
DMI5N23	MN	Amyloid beta A4 protein (APP)
DMI5N23	MT	DTT
DMI5N23	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
DMI5N23	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402

DMZEXY9	DI	DMZEXY9
DMZEXY9	DN	INO-1002
DMZEXY9	MI	TTVDSZ0
DMZEXY9	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMZEXY9	MT	DTT
DMZEXY9	MA	Inhibitor
DMZEXY9	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2771).
DMZEXY9	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2771

DMY65AR	DI	DMY65AR
DMY65AR	DN	Inosine
DMY65AR	MI	DE1DOKJ
DMY65AR	MN	Cytosolic 5'-nucleotidase II (NT5C2)
DMY65AR	MT	DME
DMY65AR	MA	Metabolism
DMY65AR	RN	Phosphorylation of ribavirin and viramidine by adenosine kinase and cytosolic 5'-nucleotidase II: Implications for ribavirin metabolism in erythrocytes. Antimicrob Agents Chemother. 2005 Jun;49(6):2164-71.
DMY65AR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15917509

DMLR86H	DI	DMLR86H
DMLR86H	DN	Inosinic Acid
DMLR86H	MI	TTZHY6R
DMLR86H	MN	Glycogen phosphorylase muscle form (GP)
DMLR86H	MT	DTT
DMLR86H	MA	Inhibitor
DMLR86H	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMLR86H	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMLR86H	DI	DMLR86H
DMLR86H	DN	Inosinic Acid
DMLR86H	MI	TTL7C8Q
DMLR86H	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMLR86H	MT	DTT
DMLR86H	MA	Inhibitor
DMLR86H	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMLR86H	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMLR86H	DI	DMLR86H
DMLR86H	DN	Inosinic Acid
DMLR86H	MI	TTTB4UP
DMLR86H	MN	Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2)
DMLR86H	MT	DTT
DMLR86H	MA	Inhibitor
DMLR86H	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMLR86H	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMLR86H	DI	DMLR86H
DMLR86H	DN	Inosinic Acid
DMLR86H	MI	TTYQ4AE
DMLR86H	MN	Plasmodium Adenylosuccinate synthetase (Malaria Adss)
DMLR86H	MT	DTT
DMLR86H	MA	Inhibitor
DMLR86H	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMLR86H	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMLR86H	DI	DMLR86H
DMLR86H	DN	Inosinic Acid
DMLR86H	MI	TTBL49X
DMLR86H	MN	Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ)
DMLR86H	MT	DTT
DMLR86H	MA	Inhibitor
DMLR86H	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMLR86H	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMIFD35	DI	DMIFD35
DMIFD35	DN	Inositol 1,3,4,5-tetrakisphosphate
DMIFD35	MI	DE5Q1SP
DMIFD35	MN	Inositol tetrakisphosphate 3-phosphatase (MIPP)
DMIFD35	MT	DME
DMIFD35	MA	Metabolism
DMIFD35	RN	The human and rat forms of multiple inositol polyphosphate phosphatase: functional homology with a histidine acid phosphatase up-regulated during endochondral ossification. FEBS Lett. 1999 Jan 8;442(1):99-104.
DMIFD35	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9923613

DMIFD35	DI	DMIFD35
DMIFD35	DN	Inositol 1,3,4,5-tetrakisphosphate
DMIFD35	MI	TTWTSCV
DMIFD35	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DMIFD35	MT	DTT
DMIFD35	MA	Inhibitor
DMIFD35	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMIFD35	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMIFD35	DI	DMIFD35
DMIFD35	DN	Inositol 1,3,4,5-tetrakisphosphate
DMIFD35	MI	TTGM6VW
DMIFD35	MN	Tyrosine-protein kinase BTK (ATK)
DMIFD35	MT	DTT
DMIFD35	MA	Inhibitor
DMIFD35	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMIFD35	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM43G5Z	DI	DM43G5Z
DM43G5Z	DN	inositol 2,4,5-trisphosphate
DM43G5Z	MI	TT5HWAT
DM43G5Z	MN	IP3 receptor isoform 1 (ITPR1)
DM43G5Z	MT	DTT
DM43G5Z	MA	Activator
DM43G5Z	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 743).
DM43G5Z	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=743

DM43G5Z	DI	DM43G5Z
DM43G5Z	DN	inositol 2,4,5-trisphosphate
DM43G5Z	MI	TTK9OV3
DM43G5Z	MN	IP3 receptor isoform 2 (IP3R2)
DM43G5Z	MT	DTT
DM43G5Z	MA	Activator
DM43G5Z	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 744).
DM43G5Z	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=744

DMAQU71	DI	DMAQU71
DMAQU71	DN	Ins(3,4,5,6)P4
DMAQU71	MI	TTOJI4S
DMAQU71	MN	Calcium-dependent chloride channel anoctamin (ANO)
DMAQU71	MT	DTT
DMAQU71	MA	Blocker (channel blocker)
DMAQU71	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 708).
DMAQU71	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=708

DMLZFTH	DI	DMLZFTH
DMLZFTH	DN	INS48823
DMLZFTH	MI	TTNVSKA
DMLZFTH	MN	P2Y purinoceptor 6 (P2RY6)
DMLZFTH	MT	DTT
DMLZFTH	MA	Agonist
DMLZFTH	RN	P2 receptors activated by uracil nucleotides--an update. Curr Med Chem. 2006;13(3):289-312.
DMLZFTH	RU	https://pubmed.ncbi.nlm.nih.gov/16475938

DM95BL8	DI	DM95BL8
DM95BL8	DN	INS49266
DM95BL8	MI	TTZ1DT0
DM95BL8	MN	P2Y purinoceptor 12 (P2RY12)
DM95BL8	MT	DTT
DM95BL8	MA	Antagonist
DM95BL8	RN	Lipophilic modifications to dinucleoside polyphosphates and nucleotides that confer antagonist properties at the platelet P2Y12 receptor. J Med Chem. 2008 Feb 28;51(4):1007-25.
DM95BL8	RU	https://pubmed.ncbi.nlm.nih.gov/18232657

DMFU92Z	DI	DMFU92Z
DMFU92Z	DN	Insulin molecules, Novo
DMFU92Z	MI	TTZOPHG
DMFU92Z	MN	Insulin (INS)
DMFU92Z	MT	DTT
DMFU92Z	MA	Modulator
DMFU92Z	RN	Long-term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen. Diabetologia. 1995 May;38(5):592-8.
DMFU92Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/7489843

DMTPB8A	DI	DMTPB8A
DMTPB8A	DN	INT-777
DMTPB8A	MI	TTSDVTR
DMTPB8A	MN	G-protein coupled bile acid receptor 1 (GPBAR1)
DMTPB8A	MT	DTT
DMTPB8A	MA	Agonist
DMTPB8A	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 37).
DMTPB8A	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=37

DMB9AIX	DI	DMB9AIX
DMB9AIX	DN	Interleukin-1-alpha - Amgen/Roche
DMB9AIX	MI	TTPM6HI
DMB9AIX	MN	Interleukin-1 alpha (IL1A)
DMB9AIX	MT	DTT
DMB9AIX	MA	Modulator
DMB9AIX	RN	Identification of regions in interleukin-1 alpha important for activity. J Biol Chem. 1993 Oct 15;268(29):22105-11.
DMB9AIX	RU	https://www.ncbi.nlm.nih.gov/pubmed/8408069

DM3D9XY	DI	DM3D9XY
DM3D9XY	DN	interleukin-2, Roussel Uclaf
DM3D9XY	MI	TTF89GD
DM3D9XY	MN	Interleukin-2 (IL2)
DM3D9XY	MT	DTT
DM3D9XY	MA	Modulator
DM3D9XY	RN	Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission. Eur Cytokine Netw. 2000 Mar;11(1):91-8.
DM3D9XY	RU	https://www.ncbi.nlm.nih.gov/pubmed/10705305

DM8BZVI	DI	DM8BZVI
DM8BZVI	DN	INV-311
DM8BZVI	MI	TTVCZPI
DM8BZVI	MN	Myeloperoxidase (MPO)
DM8BZVI	MT	DTT
DM8BZVI	MA	Inhibitor
DM8BZVI	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2789).
DM8BZVI	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2789

DM3FZ6P	DI	DM3FZ6P
DM3FZ6P	DN	IODIDE
DM3FZ6P	MI	TTHQPL7
DM3FZ6P	MN	Carbonic anhydrase I (CA-I)
DM3FZ6P	MT	DTT
DM3FZ6P	MA	Inhibitor
DM3FZ6P	RN	Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5435-9.
DM3FZ6P	RU	https://pubmed.ncbi.nlm.nih.gov/15454240

DM3FZ6P	DI	DM3FZ6P
DM3FZ6P	DN	IODIDE
DM3FZ6P	MI	TTANPDJ
DM3FZ6P	MN	Carbonic anhydrase II (CA-II)
DM3FZ6P	MT	DTT
DM3FZ6P	MA	Inhibitor
DM3FZ6P	RN	Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5435-9.
DM3FZ6P	RU	https://pubmed.ncbi.nlm.nih.gov/15454240

DMM4XVL	DI	DMM4XVL
DMM4XVL	DN	Iodoacetamide
DMM4XVL	MI	TT9INHD
DMM4XVL	MN	Creatine kinase (CK)
DMM4XVL	MT	DTT
DMM4XVL	MA	Inhibitor
DMM4XVL	RN	Creatine kinase inhibitor iodoacetamide antagonizes calcium-stimulated inotropy in cardiomyocytes. Clin Exp Pharmacol Physiol. 2009 Feb;36(2):141-5.
DMM4XVL	RU	https://pubmed.ncbi.nlm.nih.gov/18761665

DM7AHNF	DI	DM7AHNF
DM7AHNF	DN	iodoaminopotentidine
DM7AHNF	MI	TTQHJ1K
DM7AHNF	MN	Histamine H2 receptor (H2R)
DM7AHNF	MT	DTT
DM7AHNF	MA	Antagonist
DM7AHNF	RN	Heterologous expression of rat epitope-tagged histamine H2 receptors in insect Sf9 cells. Br J Pharmacol. 1997 Nov;122(5):867-74.
DM7AHNF	RU	https://pubmed.ncbi.nlm.nih.gov/9384502

DMOA2J8	DI	DMOA2J8
DMOA2J8	DN	iodocyanopindolol
DMOA2J8	MI	TTMXGCW
DMOA2J8	MN	Adrenergic receptor beta-3 (ADRB3)
DMOA2J8	MT	DTT
DMOA2J8	MA	Antagonist
DMOA2J8	RN	Markedly reduced effects of (-)-isoprenaline but not of (-)-CGP12177 and unchanged affinity of beta-blockers at Gly389-beta1-adrenoceptors compared... Br J Pharmacol. 2004 May;142(1):51-6.
DMOA2J8	RU	https://pubmed.ncbi.nlm.nih.gov/15037517

DM3BL0G	DI	DM3BL0G
DM3BL0G	DN	IODOINDOMETHACIN
DM3BL0G	MI	TT8NGED
DM3BL0G	MN	Prostaglandin G/H synthase 1 (COX-1)
DM3BL0G	MT	DTT
DM3BL0G	MA	Inhibitor
DM3BL0G	RN	In silico search for multi-target anti-inflammatories in Chinese herbs and formulas. Bioorg Med Chem. 2010 Mar 15;18(6):2204-2218.
DM3BL0G	RU	https://pubmed.ncbi.nlm.nih.gov/20188577

DMF8EJ6	DI	DMF8EJ6
DMF8EJ6	DN	Iodo-Phenylalanine
DMF8EJ6	MI	TTDIGC1
DMF8EJ6	MN	Dipeptidyl peptidase 4 (DPP-4)
DMF8EJ6	MT	DTT
DMF8EJ6	MA	Inhibitor
DMF8EJ6	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMF8EJ6	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM0749Z	DI	DM0749Z
DM0749Z	DN	IODOPRIDE
DM0749Z	MI	TTEX248
DM0749Z	MN	Dopamine D2 receptor (D2R)
DM0749Z	MT	DTT
DM0749Z	MA	Inhibitor
DM0749Z	RN	Fluorinated and iodinated dopamine agents: D2 imaging agents for PET and SPECT. J Med Chem. 1993 Jan 22;36(2):221-8.
DM0749Z	RU	https://pubmed.ncbi.nlm.nih.gov/8093734

DMDA6VL	DI	DMDA6VL
DMDA6VL	DN	IODOPROXYFAN
DMDA6VL	MI	TT9JNIC
DMDA6VL	MN	Histamine H3 receptor (H3R)
DMDA6VL	MT	DTT
DMDA6VL	MA	Inhibitor
DMDA6VL	RN	Different antagonist binding properties of human and rat histamine H3 receptors. Bioorg Med Chem Lett. 2001 Apr 9;11(7):951-4.
DMDA6VL	RU	https://pubmed.ncbi.nlm.nih.gov/11294398

DMXYFMB	DI	DMXYFMB
DMXYFMB	DN	IODOSULPIRIDE
DMXYFMB	MI	TTEX248
DMXYFMB	MN	Dopamine D2 receptor (D2R)
DMXYFMB	MT	DTT
DMXYFMB	MA	Inhibitor
DMXYFMB	RN	Fluorinated and iodinated dopamine agents: D2 imaging agents for PET and SPECT. J Med Chem. 1993 Jan 22;36(2):221-8.
DMXYFMB	RU	https://pubmed.ncbi.nlm.nih.gov/8093734

DMOE8LT	DI	DMOE8LT
DMOE8LT	DN	IODOSUPROFEN
DMOE8LT	MI	TT8NGED
DMOE8LT	MN	Prostaglandin G/H synthase 1 (COX-1)
DMOE8LT	MT	DTT
DMOE8LT	MA	Inhibitor
DMOE8LT	RN	In silico search for multi-target anti-inflammatories in Chinese herbs and formulas. Bioorg Med Chem. 2010 Mar 15;18(6):2204-2218.
DMOE8LT	RU	https://pubmed.ncbi.nlm.nih.gov/20188577

DMQMH6S	DI	DMQMH6S
DMQMH6S	DN	Iodotubercidin
DMQMH6S	MI	TTL732K
DMQMH6S	MN	Adenosine kinase (ADK)
DMQMH6S	MT	DTT
DMQMH6S	MA	Inhibitor
DMQMH6S	RN	Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36.
DMQMH6S	RU	https://pubmed.ncbi.nlm.nih.gov/21948793

DMO73M9	DI	DMO73M9
DMO73M9	DN	Iodyl-benzene
DMO73M9	MI	TTELIN2
DMO73M9	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMO73M9	MT	DTT
DMO73M9	MA	Inhibitor
DMO73M9	RN	Periodinates: a new class of protein tyrosine phosphatase inhibitors. Bioorg Med Chem Lett. 1999 Feb 8;9(3):353-6.
DMO73M9	RU	https://pubmed.ncbi.nlm.nih.gov/10091683

DMYG0M5	DI	DMYG0M5
DMYG0M5	DN	IOX1
DMYG0M5	MI	TT9ISBX
DMYG0M5	MN	HIF-prolyl hydroxylase 2 (HPH-2)
DMYG0M5	MT	DTT
DMYG0M5	MA	Inhibitor
DMYG0M5	RN	A cell-permeable ester derivative of the JmjC histone demethylase inhibitor IOX1. ChemMedChem. 2014 Mar;9(3):566-71.
DMYG0M5	RU	https://pubmed.ncbi.nlm.nih.gov/24504543

DMYG0M5	DI	DMYG0M5
DMYG0M5	DN	IOX1
DMYG0M5	MI	TTKXS4A
DMYG0M5	MN	Lysine-specific demethylase 3A (KDM3A)
DMYG0M5	MT	DTT
DMYG0M5	MA	Inhibitor
DMYG0M5	RN	A cell-permeable ester derivative of the JmjC histone demethylase inhibitor IOX1. ChemMedChem. 2014 Mar;9(3):566-71.
DMYG0M5	RU	https://pubmed.ncbi.nlm.nih.gov/24504543

DMYG0M5	DI	DMYG0M5
DMYG0M5	DN	IOX1
DMYG0M5	MI	TTV8CRH
DMYG0M5	MN	Lysine-specific demethylase 4C (KDM4C)
DMYG0M5	MT	DTT
DMYG0M5	MA	Inhibitor
DMYG0M5	RN	A cell-permeable ester derivative of the JmjC histone demethylase inhibitor IOX1. ChemMedChem. 2014 Mar;9(3):566-71.
DMYG0M5	RU	https://pubmed.ncbi.nlm.nih.gov/24504543

DMYG0M5	DI	DMYG0M5
DMYG0M5	DN	IOX1
DMYG0M5	MI	TTDIJUQ
DMYG0M5	MN	Lysine-specific demethylase 6B (KDM6B)
DMYG0M5	MT	DTT
DMYG0M5	MA	Inhibitor
DMYG0M5	RN	A cell-permeable ester derivative of the JmjC histone demethylase inhibitor IOX1. ChemMedChem. 2014 Mar;9(3):566-71.
DMYG0M5	RU	https://pubmed.ncbi.nlm.nih.gov/24504543

DMQ0X7I	DI	DMQ0X7I
DMQ0X7I	DN	IOX2
DMQ0X7I	MI	TT9ISBX
DMQ0X7I	MN	HIF-prolyl hydroxylase 2 (HPH-2)
DMQ0X7I	MT	DTT
DMQ0X7I	MA	Inhibitor
DMQ0X7I	RN	Selective small molecule probes for the hypoxia inducible factor (HIF) prolyl hydroxylases. ACS Chem Biol. 2013 Jul 19;8(7):1488-96.
DMQ0X7I	RU	https://pubmed.ncbi.nlm.nih.gov/23683440

DMQ0X7I	DI	DMQ0X7I
DMQ0X7I	DN	IOX2
DMQ0X7I	MI	TT8XTY2
DMQ0X7I	MN	Lysine-specific demethylase 2A (KDM2A)
DMQ0X7I	MT	DTT
DMQ0X7I	MA	Inhibitor
DMQ0X7I	RN	Selective small molecule probes for the hypoxia inducible factor (HIF) prolyl hydroxylases. ACS Chem Biol. 2013 Jul 19;8(7):1488-96.
DMQ0X7I	RU	https://pubmed.ncbi.nlm.nih.gov/23683440

DMQ0X7I	DI	DMQ0X7I
DMQ0X7I	DN	IOX2
DMQ0X7I	MI	TT94UCF
DMQ0X7I	MN	Lysine-specific demethylase 5C (KDM5C)
DMQ0X7I	MT	DTT
DMQ0X7I	MA	Inhibitor
DMQ0X7I	RN	Selective small molecule probes for the hypoxia inducible factor (HIF) prolyl hydroxylases. ACS Chem Biol. 2013 Jul 19;8(7):1488-96.
DMQ0X7I	RU	https://pubmed.ncbi.nlm.nih.gov/23683440

DMIX7CP	DI	DMIX7CP
DMIX7CP	DN	IP-1200
DMIX7CP	MI	TT9B4N3
DMIX7CP	MN	Prostaglandin receptor (PTGR)
DMIX7CP	MT	DTT
DMIX7CP	MA	Modulator
DMIX7CP	RN	Clinical pipeline report, company report or official report of Immunologic.
DMIX7CP	RU	http://www.immunologic.nl/products/antibodies/i/

DMB2YXN	DI	DMB2YXN
DMB2YXN	DN	Ip5I
DMB2YXN	MI	TTJW7B3
DMB2YXN	MN	P2X purinoceptor 1 (P2RX1)
DMB2YXN	MT	DTT
DMB2YXN	MA	Antagonist
DMB2YXN	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 478).
DMB2YXN	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=478

DM6OHVU	DI	DM6OHVU
DM6OHVU	DN	iperoxo
DM6OHVU	MI	TTOXS3C
DM6OHVU	MN	Muscarinic acetylcholine receptor (CHRM)
DM6OHVU	MT	DTT
DM6OHVU	MA	Agonist
DM6OHVU	RN	Agonists with supraphysiological efficacy at the muscarinic M2 ACh receptor. Br J Pharmacol. 2013 May;169(2):357-70.
DM6OHVU	RU	https://pubmed.ncbi.nlm.nih.gov/23062057

DM42ENF	DI	DM42ENF
DM42ENF	DN	IPRONIAZIDE
DM42ENF	MI	TT3WG5C
DM42ENF	MN	Monoamine oxidase type A (MAO-A)
DM42ENF	MT	DTT
DM42ENF	MA	Inhibitor
DM42ENF	RN	Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1659-64.
DM42ENF	RU	https://pubmed.ncbi.nlm.nih.gov/20117937

DM42ENF	DI	DM42ENF
DM42ENF	DN	IPRONIAZIDE
DM42ENF	MI	TTGP7BY
DM42ENF	MN	Monoamine oxidase type B (MAO-B)
DM42ENF	MT	DTT
DM42ENF	MA	Inhibitor
DM42ENF	RN	Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1659-64.
DM42ENF	RU	https://pubmed.ncbi.nlm.nih.gov/20117937

DM0T8ZU	DI	DM0T8ZU
DM0T8ZU	DN	IPS-01003
DM0T8ZU	MI	TTGKNB4
DM0T8ZU	MN	Epidermal growth factor receptor (EGFR)
DM0T8ZU	MT	DTT
DM0T8ZU	MA	Antagonist
DM0T8ZU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
DM0T8ZU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797

DMYEM59	DI	DMYEM59
DMYEM59	DN	Ipsalazide
DMYEM59	MI	DEEHWOG
DMYEM59	MN	Azoreductase (azoR)
DMYEM59	MT	DME
DMYEM59	MA	Metabolism
DMYEM59	RN	Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide. Dig Dis Sci. 1983 Jul;28(7):609-15.
DMYEM59	RU	https://pubmed.ncbi.nlm.nih.gov/6345112

DM2MXIK	DI	DM2MXIK
DM2MXIK	DN	IQM-97423
DM2MXIK	MI	TTCG0AL
DM2MXIK	MN	Cholecystokinin receptor type A (CCKAR)
DM2MXIK	MT	DTT
DM2MXIK	MA	Antagonist
DM2MXIK	RN	Pharmacological study of IQM-97,423, a potent and selective CCK1 receptor antagonist with protective effect in experimental acute pancreatitis. Pharmacology. 2004 Oct;72(2):68-76.
DM2MXIK	RU	https://pubmed.ncbi.nlm.nih.gov/15331911

DMOQBGP	DI	DMOQBGP
DMOQBGP	DN	IRAK-1/4 inhibitor
DMOQBGP	MI	TTXAJWN
DMOQBGP	MN	IL-1 receptor-associated kinase 1 (IRAK1)
DMOQBGP	MT	DTT
DMOQBGP	MA	Inhibitor
DMOQBGP	RN	Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4. Bioorg Med Chem Lett. 2006 Jun 1;16(11):2842-5.
DMOQBGP	RU	https://pubmed.ncbi.nlm.nih.gov/16563752

DMOQBGP	DI	DMOQBGP
DMOQBGP	DN	IRAK-1/4 inhibitor
DMOQBGP	MI	TTKFVXR
DMOQBGP	MN	Renal carcinoma antigen NY-REN-64 (IRAK-4)
DMOQBGP	MT	DTT
DMOQBGP	MA	Inhibitor
DMOQBGP	RN	Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4. Bioorg Med Chem Lett. 2006 Jun 1;16(11):2842-5.
DMOQBGP	RU	https://pubmed.ncbi.nlm.nih.gov/16563752

DMC80TA	DI	DMC80TA
DMC80TA	DN	IRAK4 inhibitor 4b
DMC80TA	MI	TTKFVXR
DMC80TA	MN	Renal carcinoma antigen NY-REN-64 (IRAK-4)
DMC80TA	MT	DTT
DMC80TA	MA	Inhibitor
DMC80TA	RN	IRAK-4 inhibitors. Part 1: a series of amides. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3211-4.
DMC80TA	RU	https://pubmed.ncbi.nlm.nih.gov/18474425

DM1XHNW	DI	DM1XHNW
DM1XHNW	DN	IRAK4 inhibitor rac-45
DM1XHNW	MI	TTKFVXR
DM1XHNW	MN	Renal carcinoma antigen NY-REN-64 (IRAK-4)
DM1XHNW	MT	DTT
DM1XHNW	MA	Inhibitor
DM1XHNW	RN	IRAK-4 inhibitors. Part III: a series of imidazo[1,2-a]pyridines. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3656-60.
DM1XHNW	RU	https://pubmed.ncbi.nlm.nih.gov/18501603

DM5S7IG	DI	DM5S7IG
DM5S7IG	DN	Irbesartan
DM5S7IG	MI	TTPKMXQ
DM5S7IG	MN	HUMAN type-1 angiotensin II receptor (AGTR1)
DM5S7IG	MT	DTT
DM5S7IG	MA	Antagonist
DM5S7IG	RN	Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020 Mar 4.
DM5S7IG	RU	https://pubmed.ncbi.nlm.nih.gov/32129518

DMMGQZ8	DI	DMMGQZ8
DMMGQZ8	DN	IRL-1722
DMMGQZ8	MI	TT3ZTGU
DMMGQZ8	MN	Endothelin B receptor (EDNRB)
DMMGQZ8	MT	DTT
DMMGQZ8	MA	Inhibitor
DMMGQZ8	RN	IRL 2500: A potent ETB selective endothelin antagonist, Bioorg. Med. Chem. Lett. 6(19):2323-2328 (1996).
DMMGQZ8	RU	http://www.sciencedirect.com/science/article/pii/0960894X96004210

DML0S7V	DI	DML0S7V
DML0S7V	DN	IRL-1841
DML0S7V	MI	TT3ZTGU
DML0S7V	MN	Endothelin B receptor (EDNRB)
DML0S7V	MT	DTT
DML0S7V	MA	Inhibitor
DML0S7V	RN	IRL 2500: A potent ETB selective endothelin antagonist, Bioorg. Med. Chem. Lett. 6(19):2323-2328 (1996).
DML0S7V	RU	http://www.sciencedirect.com/science/article/pii/0960894X96004210

DMNF70P	DI	DMNF70P
DMNF70P	DN	IS1
DMNF70P	MI	TTB9CIL
DMNF70P	MN	Prokineticin receptor-1 (PROKR1)
DMNF70P	MT	DTT
DMNF70P	MA	Agonist
DMNF70P	RN	Discovery and cardioprotective effects of the first non-Peptide agonists of the G protein-coupled prokineticin receptor-1. PLoS One. 2015 Apr 1;10(4):e0121027.
DMNF70P	RU	https://pubmed.ncbi.nlm.nih.gov/25831128

DMQ5GA9	DI	DMQ5GA9
DMQ5GA9	DN	IS20
DMQ5GA9	MI	TTB9CIL
DMQ5GA9	MN	Prokineticin receptor-1 (PROKR1)
DMQ5GA9	MT	DTT
DMQ5GA9	MA	Agonist
DMQ5GA9	RN	Discovery and cardioprotective effects of the first non-Peptide agonists of the G protein-coupled prokineticin receptor-1. PLoS One. 2015 Apr 1;10(4):e0121027.
DMQ5GA9	RU	https://pubmed.ncbi.nlm.nih.gov/25831128

DMXPMA6	DI	DMXPMA6
DMXPMA6	DN	IS20I
DMXPMA6	MI	TT69TQN
DMXPMA6	MN	Integrin alpha-V/beta-3 (ITGAV/B3)
DMXPMA6	MT	DTT
DMXPMA6	MA	Antagonist
DMXPMA6	RN	IS20I, a specific alphavbeta3 integrin inhibitor, reduces glioma growth in vivo. Neurosurgery. 2003 Jan;52(1):177-85; discussion 185-6.
DMXPMA6	RU	https://pubmed.ncbi.nlm.nih.gov/12493116

DMU6QXV	DI	DMU6QXV
DMU6QXV	DN	ISA-2011B
DMU6QXV	MI	TTA7DU1
DMU6QXV	MN	PtdIns(4)P-5-kinase 1 alpha (PIP5K1A)
DMU6QXV	MT	DTT
DMU6QXV	MA	Inhibitor
DMU6QXV	RN	The role of PI3K/AKT-related PIP5K1alpha and the discovery of its selective inhibitor for treatment of advanced prostate cancer. Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):E3689-98.
DMU6QXV	RU	https://pubmed.ncbi.nlm.nih.gov/25071204

DMD6U4F	DI	DMD6U4F
DMD6U4F	DN	ISAINDIGOTONE
DMD6U4F	MI	TTSJ6Q4
DMD6U4F	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DMD6U4F	MT	DTT
DMD6U4F	MA	Inhibitor
DMD6U4F	RN	Inhibition of leukocyte functions by the alkaloid isaindigotone from Isatis indigotica and some new synthetic derivatives. J Nat Prod. 2001 Oct;64(10):1297-300.
DMD6U4F	RU	https://pubmed.ncbi.nlm.nih.gov/11678654

DMJ2FQA	DI	DMJ2FQA
DMJ2FQA	DN	I-SAP
DMJ2FQA	MI	TT2O84V
DMJ2FQA	MN	Thromboxane A2 receptor (TBXA2R)
DMJ2FQA	MT	DTT
DMJ2FQA	MA	Antagonist
DMJ2FQA	RN	7-[(1R,2S,3S,5R)-6,6-dimethyl-3-(4- iodobenzenesulfonylamino)bicyclo[3.1.1]hept-2-yl]-5(Z)-heptenoic acid: a novel high-affinity radiolabeled antagonist for platelet thromboxane A2/prostaglandin H2 receptors. J Pharmacol Exp Ther. 1992 Aug;262(2):632-7.
DMJ2FQA	RU	https://pubmed.ncbi.nlm.nih.gov/1386885

DMH6YVD	DI	DMH6YVD
DMH6YVD	DN	ISC-4
DMH6YVD	MI	TTAZ05C
DMH6YVD	MN	RAC-gamma serine/threonine-protein kinase (AKT3)
DMH6YVD	MT	DTT
DMH6YVD	MA	Inhibitor
DMH6YVD	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2286).
DMH6YVD	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2286

DMM2I9G	DI	DMM2I9G
DMM2I9G	DN	ischemin
DMM2I9G	MI	TTFRCTK
DMM2I9G	MN	CREB-binding protein (CREBBP)
DMM2I9G	MT	DTT
DMM2I9G	MA	Inhibitor
DMM2I9G	RN	A small molecule binding to the coactivator CREB-binding protein blocks apoptosis in cardiomyocytes. Chem Biol. 2011 Apr 22;18(4):531-41.
DMM2I9G	RU	https://pubmed.ncbi.nlm.nih.gov/21513889

DMIB6JL	DI	DMIB6JL
DMIB6JL	DN	ISIS 100742
DMIB6JL	MI	TTVXEGU
DMIB6JL	MN	ADAM10 messenger RNA (ADAM10 mRNA)
DMIB6JL	MT	DTT
DMIB6JL	RN	US patent application no. 6,228,648, Antisense modulation of ADAM10 expression.
DMIB6JL	RU	http://www.patentbuddy.com/Patent/6228648?ft=true&sr=true

DMI7PGZ	DI	DMI7PGZ
DMI7PGZ	DN	ISIS 100743
DMI7PGZ	MI	TTVXEGU
DMI7PGZ	MN	ADAM10 messenger RNA (ADAM10 mRNA)
DMI7PGZ	MT	DTT
DMI7PGZ	RN	US patent application no. 6,228,648, Antisense modulation of ADAM10 expression.
DMI7PGZ	RU	http://www.patentbuddy.com/Patent/6228648?ft=true&sr=true

DMFW5VK	DI	DMFW5VK
DMFW5VK	DN	ISIS 100748
DMFW5VK	MI	TTVXEGU
DMFW5VK	MN	ADAM10 messenger RNA (ADAM10 mRNA)
DMFW5VK	MT	DTT
DMFW5VK	RN	US patent application no. 6,228,648, Antisense modulation of ADAM10 expression.
DMFW5VK	RU	http://www.patentbuddy.com/Patent/6228648?ft=true&sr=true

DMSMJ37	DI	DMSMJ37
DMSMJ37	DN	ISIS 100749
DMSMJ37	MI	TTVXEGU
DMSMJ37	MN	ADAM10 messenger RNA (ADAM10 mRNA)
DMSMJ37	MT	DTT
DMSMJ37	RN	US patent application no. 6,228,648, Antisense modulation of ADAM10 expression.
DMSMJ37	RU	http://www.patentbuddy.com/Patent/6228648?ft=true&sr=true

DMFJES5	DI	DMFJES5
DMFJES5	DN	ISIS 100750
DMFJES5	MI	TTVXEGU
DMFJES5	MN	ADAM10 messenger RNA (ADAM10 mRNA)
DMFJES5	MT	DTT
DMFJES5	RN	US patent application no. 6,228,648, Antisense modulation of ADAM10 expression.
DMFJES5	RU	http://www.patentbuddy.com/Patent/6228648?ft=true&sr=true

DMZV5A7	DI	DMZV5A7
DMZV5A7	DN	ISIS 100913
DMZV5A7	MI	TTW8TJI
DMZV5A7	MN	MEKK1 messenger RNA (MAP3K1 mRNA)
DMZV5A7	MT	DTT
DMZV5A7	RN	US patent application no. 6,168,950, Antisense modulation of MEKK1 expression.
DMZV5A7	RU	http://www.patentbuddy.com/Patent/6168950?ft=true&sr=true

DMUMVIF	DI	DMUMVIF
DMUMVIF	DN	ISIS 100929
DMUMVIF	MI	TTW8TJI
DMUMVIF	MN	MEKK1 messenger RNA (MAP3K1 mRNA)
DMUMVIF	MT	DTT
DMUMVIF	RN	US patent application no. 6,168,950, Antisense modulation of MEKK1 expression.
DMUMVIF	RU	http://www.patentbuddy.com/Patent/6168950?ft=true&sr=true

DMHUC1X	DI	DMHUC1X
DMHUC1X	DN	ISIS 100935
DMHUC1X	MI	TTW8TJI
DMHUC1X	MN	MEKK1 messenger RNA (MAP3K1 mRNA)
DMHUC1X	MT	DTT
DMHUC1X	RN	US patent application no. 6,168,950, Antisense modulation of MEKK1 expression.
DMHUC1X	RU	http://www.patentbuddy.com/Patent/6168950?ft=true&sr=true

DM67Q3C	DI	DM67Q3C
DM67Q3C	DN	ISIS 100939
DM67Q3C	MI	TTW8TJI
DM67Q3C	MN	MEKK1 messenger RNA (MAP3K1 mRNA)
DM67Q3C	MT	DTT
DM67Q3C	RN	US patent application no. 6,168,950, Antisense modulation of MEKK1 expression.
DM67Q3C	RU	http://www.patentbuddy.com/Patent/6168950?ft=true&sr=true

DMS6JD4	DI	DMS6JD4
DMS6JD4	DN	ISIS 101952
DMS6JD4	MI	TTON5JB
DMS6JD4	MN	MADH6 messenger RNA (MADH6 mRNA)
DMS6JD4	MT	DTT
DMS6JD4	RN	US patent application no. 6,277,636, Antisense inhibition of MADH6 expression.
DMS6JD4	RU	http://www.patentbuddy.com/Patent/6277636?ft=true&sr=true

DMEWXR2	DI	DMEWXR2
DMEWXR2	DN	ISIS 101960
DMEWXR2	MI	TTON5JB
DMEWXR2	MN	MADH6 messenger RNA (MADH6 mRNA)
DMEWXR2	MT	DTT
DMEWXR2	RN	US patent application no. 6,277,636, Antisense inhibition of MADH6 expression.
DMEWXR2	RU	http://www.patentbuddy.com/Patent/6277636?ft=true&sr=true

DMV9PI7	DI	DMV9PI7
DMV9PI7	DN	ISIS 101983
DMV9PI7	MI	TTON5JB
DMV9PI7	MN	MADH6 messenger RNA (MADH6 mRNA)
DMV9PI7	MT	DTT
DMV9PI7	RN	US patent application no. 6,277,636, Antisense inhibition of MADH6 expression.
DMV9PI7	RU	http://www.patentbuddy.com/Patent/6277636?ft=true&sr=true

DMYZ5CX	DI	DMYZ5CX
DMYZ5CX	DN	ISIS 101984
DMYZ5CX	MI	TTON5JB
DMYZ5CX	MN	MADH6 messenger RNA (MADH6 mRNA)
DMYZ5CX	MT	DTT
DMYZ5CX	RN	US patent application no. 6,277,636, Antisense inhibition of MADH6 expression.
DMYZ5CX	RU	http://www.patentbuddy.com/Patent/6277636?ft=true&sr=true

DM8CN2M	DI	DM8CN2M
DM8CN2M	DN	ISIS 101985
DM8CN2M	MI	TTON5JB
DM8CN2M	MN	MADH6 messenger RNA (MADH6 mRNA)
DM8CN2M	MT	DTT
DM8CN2M	RN	US patent application no. 6,277,636, Antisense inhibition of MADH6 expression.
DM8CN2M	RU	http://www.patentbuddy.com/Patent/6277636?ft=true&sr=true

DM5PTQX	DI	DM5PTQX
DM5PTQX	DN	ISIS 101986
DM5PTQX	MI	TTON5JB
DM5PTQX	MN	MADH6 messenger RNA (MADH6 mRNA)
DM5PTQX	MT	DTT
DM5PTQX	RN	US patent application no. 6,277,636, Antisense inhibition of MADH6 expression.
DM5PTQX	RU	http://www.patentbuddy.com/Patent/6277636?ft=true&sr=true

DMWCK8Q	DI	DMWCK8Q
DMWCK8Q	DN	ISIS 101987
DMWCK8Q	MI	TTON5JB
DMWCK8Q	MN	MADH6 messenger RNA (MADH6 mRNA)
DMWCK8Q	MT	DTT
DMWCK8Q	RN	US patent application no. 6,277,636, Antisense inhibition of MADH6 expression.
DMWCK8Q	RU	http://www.patentbuddy.com/Patent/6277636?ft=true&sr=true

DM3EMLB	DI	DM3EMLB
DM3EMLB	DN	ISIS 101995
DM3EMLB	MI	TTON5JB
DM3EMLB	MN	MADH6 messenger RNA (MADH6 mRNA)
DM3EMLB	MT	DTT
DM3EMLB	RN	US patent application no. 6,277,636, Antisense inhibition of MADH6 expression.
DM3EMLB	RU	http://www.patentbuddy.com/Patent/6277636?ft=true&sr=true

DM5APGL	DI	DM5APGL
DM5APGL	DN	ISIS 101996
DM5APGL	MI	TTON5JB
DM5APGL	MN	MADH6 messenger RNA (MADH6 mRNA)
DM5APGL	MT	DTT
DM5APGL	RN	US patent application no. 6,277,636, Antisense inhibition of MADH6 expression.
DM5APGL	RU	http://www.patentbuddy.com/Patent/6277636?ft=true&sr=true

DMUZJCD	DI	DMUZJCD
DMUZJCD	DN	ISIS 101997
DMUZJCD	MI	TTON5JB
DMUZJCD	MN	MADH6 messenger RNA (MADH6 mRNA)
DMUZJCD	MT	DTT
DMUZJCD	RN	US patent application no. 6,277,636, Antisense inhibition of MADH6 expression.
DMUZJCD	RU	http://www.patentbuddy.com/Patent/6277636?ft=true&sr=true

DMEH6G1	DI	DMEH6G1
DMEH6G1	DN	ISIS 101998
DMEH6G1	MI	TTON5JB
DMEH6G1	MN	MADH6 messenger RNA (MADH6 mRNA)
DMEH6G1	MT	DTT
DMEH6G1	RN	US patent application no. 6,277,636, Antisense inhibition of MADH6 expression.
DMEH6G1	RU	http://www.patentbuddy.com/Patent/6277636?ft=true&sr=true

DMESKQX	DI	DMESKQX
DMESKQX	DN	ISIS 10228
DMESKQX	MI	TT5TURO
DMESKQX	MN	A-Raf messenger RNA (ARAF mRNA)
DMESKQX	MT	DTT
DMESKQX	RN	US patent application no. 5,952,229, Antisense oligonucleotide modulation of raf gene expression.
DMESKQX	RU	http://www.patentbuddy.com/Patent/5952229?ft=true&sr=true

DML40N3	DI	DML40N3
DML40N3	DN	ISIS 102450
DML40N3	MI	TT5U49F
DML40N3	MN	PRKACA messenger RNA (PRKACA mRNA)
DML40N3	MT	DTT
DML40N3	RN	US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression.
DML40N3	RU	http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true

DMNSEH1	DI	DMNSEH1
DMNSEH1	DN	ISIS 102454
DMNSEH1	MI	TT5U49F
DMNSEH1	MN	PRKACA messenger RNA (PRKACA mRNA)
DMNSEH1	MT	DTT
DMNSEH1	RN	US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression.
DMNSEH1	RU	http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true

DMBUTFN	DI	DMBUTFN
DMBUTFN	DN	ISIS 102458
DMBUTFN	MI	TT5U49F
DMBUTFN	MN	PRKACA messenger RNA (PRKACA mRNA)
DMBUTFN	MT	DTT
DMBUTFN	RN	US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression.
DMBUTFN	RU	http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true

DMXNC0B	DI	DMXNC0B
DMXNC0B	DN	ISIS 102462
DMXNC0B	MI	TT5U49F
DMXNC0B	MN	PRKACA messenger RNA (PRKACA mRNA)
DMXNC0B	MT	DTT
DMXNC0B	RN	US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression.
DMXNC0B	RU	http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true

DMAG8QO	DI	DMAG8QO
DMAG8QO	DN	ISIS 102466
DMAG8QO	MI	TT5U49F
DMAG8QO	MN	PRKACA messenger RNA (PRKACA mRNA)
DMAG8QO	MT	DTT
DMAG8QO	RN	US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression.
DMAG8QO	RU	http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true

DMU70ND	DI	DMU70ND
DMU70ND	DN	ISIS 102478
DMU70ND	MI	TT5U49F
DMU70ND	MN	PRKACA messenger RNA (PRKACA mRNA)
DMU70ND	MT	DTT
DMU70ND	RN	US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression.
DMU70ND	RU	http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true

DMMBJWK	DI	DMMBJWK
DMMBJWK	DN	ISIS 102482
DMMBJWK	MI	TT5U49F
DMMBJWK	MN	PRKACA messenger RNA (PRKACA mRNA)
DMMBJWK	MT	DTT
DMMBJWK	RN	US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression.
DMMBJWK	RU	http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true

DMTMBEX	DI	DMTMBEX
DMTMBEX	DN	ISIS 102486
DMTMBEX	MI	TT5U49F
DMTMBEX	MN	PRKACA messenger RNA (PRKACA mRNA)
DMTMBEX	MT	DTT
DMTMBEX	RN	US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression.
DMTMBEX	RU	http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true

DMMWVCH	DI	DMMWVCH
DMMWVCH	DN	ISIS 102490
DMMWVCH	MI	TT5U49F
DMMWVCH	MN	PRKACA messenger RNA (PRKACA mRNA)
DMMWVCH	MT	DTT
DMMWVCH	RN	US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression.
DMMWVCH	RU	http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true

DMYJO7T	DI	DMYJO7T
DMYJO7T	DN	ISIS 102558
DMYJO7T	MI	TT5U49F
DMYJO7T	MN	PRKACA messenger RNA (PRKACA mRNA)
DMYJO7T	MT	DTT
DMYJO7T	RN	US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression.
DMYJO7T	RU	http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true

DMTHMF0	DI	DMTHMF0
DMTHMF0	DN	ISIS 102563
DMTHMF0	MI	TT5U49F
DMTHMF0	MN	PRKACA messenger RNA (PRKACA mRNA)
DMTHMF0	MT	DTT
DMTHMF0	RN	US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression.
DMTHMF0	RU	http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true

DMEDFLA	DI	DMEDFLA
DMEDFLA	DN	ISIS 102584
DMEDFLA	MI	TT5U49F
DMEDFLA	MN	PRKACA messenger RNA (PRKACA mRNA)
DMEDFLA	MT	DTT
DMEDFLA	RN	US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression.
DMEDFLA	RU	http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true

DM3RVUY	DI	DM3RVUY
DM3RVUY	DN	ISIS 102599
DM3RVUY	MI	TT5U49F
DM3RVUY	MN	PRKACA messenger RNA (PRKACA mRNA)
DM3RVUY	MT	DTT
DM3RVUY	RN	US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression.
DM3RVUY	RU	http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true

DMZ6X9B	DI	DMZ6X9B
DMZ6X9B	DN	ISIS 102604
DMZ6X9B	MI	TT5U49F
DMZ6X9B	MN	PRKACA messenger RNA (PRKACA mRNA)
DMZ6X9B	MT	DTT
DMZ6X9B	RN	US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression.
DMZ6X9B	RU	http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true

DM60LT9	DI	DM60LT9
DM60LT9	DN	ISIS 102609
DM60LT9	MI	TT5U49F
DM60LT9	MN	PRKACA messenger RNA (PRKACA mRNA)
DM60LT9	MT	DTT
DM60LT9	RN	US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression.
DM60LT9	RU	http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true

DMEB36I	DI	DMEB36I
DMEB36I	DN	ISIS 102614
DMEB36I	MI	TT5U49F
DMEB36I	MN	PRKACA messenger RNA (PRKACA mRNA)
DMEB36I	MT	DTT
DMEB36I	RN	US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression.
DMEB36I	RU	http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true

DMXH9IT	DI	DMXH9IT
DMXH9IT	DN	ISIS 102619
DMXH9IT	MI	TT5U49F
DMXH9IT	MN	PRKACA messenger RNA (PRKACA mRNA)
DMXH9IT	MT	DTT
DMXH9IT	RN	US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression.
DMXH9IT	RU	http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true

DMGO4TZ	DI	DMGO4TZ
DMGO4TZ	DN	ISIS 102624
DMGO4TZ	MI	TT5U49F
DMGO4TZ	MN	PRKACA messenger RNA (PRKACA mRNA)
DMGO4TZ	MT	DTT
DMGO4TZ	RN	US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression.
DMGO4TZ	RU	http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true

DMNSZPX	DI	DMNSZPX
DMNSZPX	DN	ISIS 102629
DMNSZPX	MI	TT5U49F
DMNSZPX	MN	PRKACA messenger RNA (PRKACA mRNA)
DMNSZPX	MT	DTT
DMNSZPX	RN	US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression.
DMNSZPX	RU	http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true

DMWT7BK	DI	DMWT7BK
DMWT7BK	DN	ISIS 102633
DMWT7BK	MI	TT5U49F
DMWT7BK	MN	PRKACA messenger RNA (PRKACA mRNA)
DMWT7BK	MT	DTT
DMWT7BK	RN	US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression.
DMWT7BK	RU	http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true

DM6KUV9	DI	DM6KUV9
DM6KUV9	DN	ISIS 102660
DM6KUV9	MI	TT5U49F
DM6KUV9	MN	PRKACA messenger RNA (PRKACA mRNA)
DM6KUV9	MT	DTT
DM6KUV9	RN	US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression.
DM6KUV9	RU	http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true

DMKI6L5	DI	DMKI6L5
DMKI6L5	DN	ISIS 102664
DMKI6L5	MI	TT5U49F
DMKI6L5	MN	PRKACA messenger RNA (PRKACA mRNA)
DMKI6L5	MT	DTT
DMKI6L5	RN	US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression.
DMKI6L5	RU	http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true

DMY87QX	DI	DMY87QX
DMY87QX	DN	ISIS 102668
DMY87QX	MI	TT5U49F
DMY87QX	MN	PRKACA messenger RNA (PRKACA mRNA)
DMY87QX	MT	DTT
DMY87QX	RN	US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression.
DMY87QX	RU	http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true

DMFP598	DI	DMFP598
DMFP598	DN	ISIS 102676
DMFP598	MI	TT5U49F
DMFP598	MN	PRKACA messenger RNA (PRKACA mRNA)
DMFP598	MT	DTT
DMFP598	RN	US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression.
DMFP598	RU	http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true

DM205TE	DI	DM205TE
DM205TE	DN	ISIS 10303
DM205TE	MI	TT7A1BO
DM205TE	MN	PKC-delta messenger RNA (PRKCD mRNA)
DM205TE	MT	DTT
DM205TE	RN	US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C.
DM205TE	RU	http://www.patentbuddy.com/Patent/5959096?ft=true&sr=true

DMT6H9S	DI	DMT6H9S
DMT6H9S	DN	ISIS 10310
DMT6H9S	MI	TT7A1BO
DMT6H9S	MN	PKC-delta messenger RNA (PRKCD mRNA)
DMT6H9S	MT	DTT
DMT6H9S	RN	US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C.
DMT6H9S	RU	http://www.patentbuddy.com/Patent/5959096?ft=true&sr=true

DMQ3KUV	DI	DMQ3KUV
DMQ3KUV	DN	ISIS 10311
DMQ3KUV	MI	TT7A1BO
DMQ3KUV	MN	PKC-delta messenger RNA (PRKCD mRNA)
DMQ3KUV	MT	DTT
DMQ3KUV	RN	US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C.
DMQ3KUV	RU	http://www.patentbuddy.com/Patent/5959096?ft=true&sr=true

DMX835E	DI	DMX835E
DMX835E	DN	ISIS 103375
DMX835E	MI	TTK0TF2
DMX835E	MN	DUSP8 messenger RNA (DUSP8 mRNA)
DMX835E	MT	DTT
DMX835E	RN	US patent application no. 6,482,644, Antisense modulation of dual specific phosphatase 8 expression.
DMX835E	RU	http://www.patentbuddy.com/Patent/6482644?ft=true&sr=true

DMBAM5K	DI	DMBAM5K
DMBAM5K	DN	ISIS 103386
DMBAM5K	MI	TTK0TF2
DMBAM5K	MN	DUSP8 messenger RNA (DUSP8 mRNA)
DMBAM5K	MT	DTT
DMBAM5K	RN	US patent application no. 6,482,644, Antisense modulation of dual specific phosphatase 8 expression.
DMBAM5K	RU	http://www.patentbuddy.com/Patent/6482644?ft=true&sr=true

DMW8GIT	DI	DMW8GIT
DMW8GIT	DN	ISIS 103387
DMW8GIT	MI	TTK0TF2
DMW8GIT	MN	DUSP8 messenger RNA (DUSP8 mRNA)
DMW8GIT	MT	DTT
DMW8GIT	RN	US patent application no. 6,482,644, Antisense modulation of dual specific phosphatase 8 expression.
DMW8GIT	RU	http://www.patentbuddy.com/Patent/6482644?ft=true&sr=true

DM86KWU	DI	DM86KWU
DM86KWU	DN	ISIS 103471
DM86KWU	MI	TT1GV6C
DM86KWU	MN	DUSP9 messenger RNA (DUSP9 mRNA)
DM86KWU	MT	DTT
DM86KWU	RN	US patent application no. 6,566,133, Antisense inhibition of dual specific phosphatase 9 expression.
DM86KWU	RU	http://www.patentbuddy.com/Patent/6566133?ft=true&sr=true

DMQRP32	DI	DMQRP32
DMQRP32	DN	ISIS 103473
DMQRP32	MI	TT1GV6C
DMQRP32	MN	DUSP9 messenger RNA (DUSP9 mRNA)
DMQRP32	MT	DTT
DMQRP32	RN	US patent application no. 6,566,133, Antisense inhibition of dual specific phosphatase 9 expression.
DMQRP32	RU	http://www.patentbuddy.com/Patent/6566133?ft=true&sr=true

DM5BSVQ	DI	DM5BSVQ
DM5BSVQ	DN	ISIS 103486
DM5BSVQ	MI	TT1GV6C
DM5BSVQ	MN	DUSP9 messenger RNA (DUSP9 mRNA)
DM5BSVQ	MT	DTT
DM5BSVQ	RN	US patent application no. 6,566,133, Antisense inhibition of dual specific phosphatase 9 expression.
DM5BSVQ	RU	http://www.patentbuddy.com/Patent/6566133?ft=true&sr=true

DM6ZME7	DI	DM6ZME7
DM6ZME7	DN	ISIS 103489
DM6ZME7	MI	TT1GV6C
DM6ZME7	MN	DUSP9 messenger RNA (DUSP9 mRNA)
DM6ZME7	MT	DTT
DM6ZME7	RN	US patent application no. 6,566,133, Antisense inhibition of dual specific phosphatase 9 expression.
DM6ZME7	RU	http://www.patentbuddy.com/Patent/6566133?ft=true&sr=true

DME9Q8L	DI	DME9Q8L
DME9Q8L	DN	ISIS 103582
DME9Q8L	MI	TTBWMKT
DME9Q8L	MN	WWP1 messenger RNA (WWP1 mRNA)
DME9Q8L	MT	DTT
DME9Q8L	RN	US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression.
DME9Q8L	RU	http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true

DM6BH7K	DI	DM6BH7K
DM6BH7K	DN	ISIS 103601
DM6BH7K	MI	TTBWMKT
DM6BH7K	MN	WWP1 messenger RNA (WWP1 mRNA)
DM6BH7K	MT	DTT
DM6BH7K	RN	US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression.
DM6BH7K	RU	http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true

DM298KT	DI	DM298KT
DM298KT	DN	ISIS 103612
DM298KT	MI	TTBWMKT
DM298KT	MN	WWP1 messenger RNA (WWP1 mRNA)
DM298KT	MT	DTT
DM298KT	RN	US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression.
DM298KT	RU	http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true

DMNPMW4	DI	DMNPMW4
DMNPMW4	DN	ISIS 103613
DMNPMW4	MI	TTBWMKT
DMNPMW4	MN	WWP1 messenger RNA (WWP1 mRNA)
DMNPMW4	MT	DTT
DMNPMW4	RN	US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression.
DMNPMW4	RU	http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true

DMGTX6O	DI	DMGTX6O
DMGTX6O	DN	ISIS 103615
DMGTX6O	MI	TTBWMKT
DMGTX6O	MN	WWP1 messenger RNA (WWP1 mRNA)
DMGTX6O	MT	DTT
DMGTX6O	RN	US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression.
DMGTX6O	RU	http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true

DM3PK2G	DI	DM3PK2G
DM3PK2G	DN	ISIS 103616
DM3PK2G	MI	TTBWMKT
DM3PK2G	MN	WWP1 messenger RNA (WWP1 mRNA)
DM3PK2G	MT	DTT
DM3PK2G	RN	US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression.
DM3PK2G	RU	http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true

DMERJAV	DI	DMERJAV
DMERJAV	DN	ISIS 103619
DMERJAV	MI	TTBWMKT
DMERJAV	MN	WWP1 messenger RNA (WWP1 mRNA)
DMERJAV	MT	DTT
DMERJAV	RN	US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression.
DMERJAV	RU	http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true

DM61FYM	DI	DM61FYM
DM61FYM	DN	ISIS 103620
DM61FYM	MI	TTBWMKT
DM61FYM	MN	WWP1 messenger RNA (WWP1 mRNA)
DM61FYM	MT	DTT
DM61FYM	RN	US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression.
DM61FYM	RU	http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true

DMP7VJL	DI	DMP7VJL
DMP7VJL	DN	ISIS 103621
DMP7VJL	MI	TTBWMKT
DMP7VJL	MN	WWP1 messenger RNA (WWP1 mRNA)
DMP7VJL	MT	DTT
DMP7VJL	RN	US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression.
DMP7VJL	RU	http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true

DM9J4I3	DI	DM9J4I3
DM9J4I3	DN	ISIS 103622
DM9J4I3	MI	TTBWMKT
DM9J4I3	MN	WWP1 messenger RNA (WWP1 mRNA)
DM9J4I3	MT	DTT
DM9J4I3	RN	US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression.
DM9J4I3	RU	http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true

DMST2QW	DI	DMST2QW
DMST2QW	DN	ISIS 103624
DMST2QW	MI	TTBWMKT
DMST2QW	MN	WWP1 messenger RNA (WWP1 mRNA)
DMST2QW	MT	DTT
DMST2QW	RN	US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression.
DMST2QW	RU	http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true

DMJLHE7	DI	DMJLHE7
DMJLHE7	DN	ISIS 103629
DMJLHE7	MI	TTBWMKT
DMJLHE7	MN	WWP1 messenger RNA (WWP1 mRNA)
DMJLHE7	MT	DTT
DMJLHE7	RN	US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression.
DMJLHE7	RU	http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true

DMOK9FA	DI	DMOK9FA
DMOK9FA	DN	ISIS 103631
DMOK9FA	MI	TTBWMKT
DMOK9FA	MN	WWP1 messenger RNA (WWP1 mRNA)
DMOK9FA	MT	DTT
DMOK9FA	RN	US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression.
DMOK9FA	RU	http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true

DMVW7N5	DI	DMVW7N5
DMVW7N5	DN	ISIS 103635
DMVW7N5	MI	TTBWMKT
DMVW7N5	MN	WWP1 messenger RNA (WWP1 mRNA)
DMVW7N5	MT	DTT
DMVW7N5	RN	US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression.
DMVW7N5	RU	http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true

DM3TIJD	DI	DM3TIJD
DM3TIJD	DN	ISIS 103669
DM3TIJD	MI	TT6TU05
DM3TIJD	MN	WWP2 messenger RNA (WWP2 mRNA)
DM3TIJD	MT	DTT
DM3TIJD	RN	US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression.
DM3TIJD	RU	http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true

DMF9JAH	DI	DMF9JAH
DMF9JAH	DN	ISIS 103671
DMF9JAH	MI	TT6TU05
DMF9JAH	MN	WWP2 messenger RNA (WWP2 mRNA)
DMF9JAH	MT	DTT
DMF9JAH	RN	US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression.
DMF9JAH	RU	http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true

DMQ48YZ	DI	DMQ48YZ
DMQ48YZ	DN	ISIS 103701
DMQ48YZ	MI	TT6TU05
DMQ48YZ	MN	WWP2 messenger RNA (WWP2 mRNA)
DMQ48YZ	MT	DTT
DMQ48YZ	RN	US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression.
DMQ48YZ	RU	http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true

DMLVPOA	DI	DMLVPOA
DMLVPOA	DN	ISIS 103708
DMLVPOA	MI	TT6TU05
DMLVPOA	MN	WWP2 messenger RNA (WWP2 mRNA)
DMLVPOA	MT	DTT
DMLVPOA	RN	US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression.
DMLVPOA	RU	http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true

DM60CBI	DI	DM60CBI
DM60CBI	DN	ISIS 10373
DM60CBI	MI	TT53XHB
DM60CBI	MN	CD86 messenger RNA (CD86 mRNA)
DM60CBI	MT	DTT
DM60CBI	RN	US patent application no. 6,319,906, Oligonucleotide compositions and methods for the modulation of the expression of B7 protein.
DM60CBI	RU	http://www.patentbuddy.com/Patent/6319906?ft=true&sr=true

DMKI6JF	DI	DMKI6JF
DMKI6JF	DN	ISIS 103736
DMKI6JF	MI	TT6TU05
DMKI6JF	MN	WWP2 messenger RNA (WWP2 mRNA)
DMKI6JF	MT	DTT
DMKI6JF	RN	US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression.
DMKI6JF	RU	http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true

DM7DOY3	DI	DM7DOY3
DM7DOY3	DN	ISIS 103747
DM7DOY3	MI	TT6TU05
DM7DOY3	MN	WWP2 messenger RNA (WWP2 mRNA)
DM7DOY3	MT	DTT
DM7DOY3	RN	US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression.
DM7DOY3	RU	http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true

DMBZVW0	DI	DMBZVW0
DMBZVW0	DN	ISIS 103752
DMBZVW0	MI	TT6TU05
DMBZVW0	MN	WWP2 messenger RNA (WWP2 mRNA)
DMBZVW0	MT	DTT
DMBZVW0	RN	US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression.
DMBZVW0	RU	http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true

DM8HDW6	DI	DM8HDW6
DM8HDW6	DN	ISIS 103771
DM8HDW6	MI	TT6TU05
DM8HDW6	MN	WWP2 messenger RNA (WWP2 mRNA)
DM8HDW6	MT	DTT
DM8HDW6	RN	US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression.
DM8HDW6	RU	http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true

DMVL8O0	DI	DMVL8O0
DMVL8O0	DN	ISIS 103803
DMVL8O0	MI	TT6TU05
DMVL8O0	MN	WWP2 messenger RNA (WWP2 mRNA)
DMVL8O0	MT	DTT
DMVL8O0	RN	US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression.
DMVL8O0	RU	http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true

DMA0D8I	DI	DMA0D8I
DMA0D8I	DN	ISIS 103806
DMA0D8I	MI	TT6TU05
DMA0D8I	MN	WWP2 messenger RNA (WWP2 mRNA)
DMA0D8I	MT	DTT
DMA0D8I	RN	US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression.
DMA0D8I	RU	http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true

DMFQ10R	DI	DMFQ10R
DMFQ10R	DN	ISIS 103819
DMFQ10R	MI	TT6TU05
DMFQ10R	MN	WWP2 messenger RNA (WWP2 mRNA)
DMFQ10R	MT	DTT
DMFQ10R	RN	US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression.
DMFQ10R	RU	http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true

DMPKQ61	DI	DMPKQ61
DMPKQ61	DN	ISIS 104211
DMPKQ61	MI	TTCQ2E5
DMPKQ61	MN	RIP2 messenger RNA (RIP2 mRNA)
DMPKQ61	MT	DTT
DMPKQ61	RN	US patent application no. 6,426,221, Antisense modulation of RIP2 expression.
DMPKQ61	RU	http://www.patentbuddy.com/Patent/6426221?ft=true&sr=true

DMME8JP	DI	DMME8JP
DMME8JP	DN	ISIS 104253
DMME8JP	MI	TTCQ2E5
DMME8JP	MN	RIP2 messenger RNA (RIP2 mRNA)
DMME8JP	MT	DTT
DMME8JP	RN	US patent application no. 6,426,221, Antisense modulation of RIP2 expression.
DMME8JP	RU	http://www.patentbuddy.com/Patent/6426221?ft=true&sr=true

DMDEI9X	DI	DMDEI9X
DMDEI9X	DN	ISIS 104254
DMDEI9X	MI	TTCQ2E5
DMDEI9X	MN	RIP2 messenger RNA (RIP2 mRNA)
DMDEI9X	MT	DTT
DMDEI9X	RN	US patent application no. 6,426,221, Antisense modulation of RIP2 expression.
DMDEI9X	RU	http://www.patentbuddy.com/Patent/6426221?ft=true&sr=true

DMAI5B8	DI	DMAI5B8
DMAI5B8	DN	ISIS 104255
DMAI5B8	MI	TTCQ2E5
DMAI5B8	MN	RIP2 messenger RNA (RIP2 mRNA)
DMAI5B8	MT	DTT
DMAI5B8	RN	US patent application no. 6,426,221, Antisense modulation of RIP2 expression.
DMAI5B8	RU	http://www.patentbuddy.com/Patent/6426221?ft=true&sr=true

DMHUX9A	DI	DMHUX9A
DMHUX9A	DN	ISIS 104256
DMHUX9A	MI	TTCQ2E5
DMHUX9A	MN	RIP2 messenger RNA (RIP2 mRNA)
DMHUX9A	MT	DTT
DMHUX9A	RN	US patent application no. 6,426,221, Antisense modulation of RIP2 expression.
DMHUX9A	RU	http://www.patentbuddy.com/Patent/6426221?ft=true&sr=true

DMSDCGV	DI	DMSDCGV
DMSDCGV	DN	ISIS 104257
DMSDCGV	MI	TTCQ2E5
DMSDCGV	MN	RIP2 messenger RNA (RIP2 mRNA)
DMSDCGV	MT	DTT
DMSDCGV	RN	US patent application no. 6,426,221, Antisense modulation of RIP2 expression.
DMSDCGV	RU	http://www.patentbuddy.com/Patent/6426221?ft=true&sr=true

DMUC3L0	DI	DMUC3L0
DMUC3L0	DN	ISIS 104258
DMUC3L0	MI	TTCQ2E5
DMUC3L0	MN	RIP2 messenger RNA (RIP2 mRNA)
DMUC3L0	MT	DTT
DMUC3L0	RN	US patent application no. 6,426,221, Antisense modulation of RIP2 expression.
DMUC3L0	RU	http://www.patentbuddy.com/Patent/6426221?ft=true&sr=true

DMB5F9H	DI	DMB5F9H
DMB5F9H	DN	ISIS 10582
DMB5F9H	MI	TTS7IR5
DMB5F9H	MN	c-Jun messenger RNA (c-Jun mRNA)
DMB5F9H	MT	DTT
DMB5F9H	RN	US patent application no. 6,312,900, Antisense oligonucleotide compositions and methods for the modulation of activating protein 1.
DMB5F9H	RU	http://www.patentbuddy.com/Patent/6312900?ft=true&sr=true

DMIGV0H	DI	DMIGV0H
DMIGV0H	DN	ISIS 105987
DMIGV0H	MI	TTT2SVW
DMIGV0H	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DMIGV0H	MT	DTT
DMIGV0H	RN	US patent application no. 6,159,734, Antisense modulation of peroxisome proliferator-activated receptor gamma expression.
DMIGV0H	RU	http://www.patentbuddy.com/Patent/6159734?ft=true&sr=true

DMFOSYU	DI	DMFOSYU
DMFOSYU	DN	ISIS 105989
DMFOSYU	MI	TTT2SVW
DMFOSYU	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DMFOSYU	MT	DTT
DMFOSYU	RN	US patent application no. 6,159,734, Antisense modulation of peroxisome proliferator-activated receptor gamma expression.
DMFOSYU	RU	http://www.patentbuddy.com/Patent/6159734?ft=true&sr=true

DM8FY3H	DI	DM8FY3H
DM8FY3H	DN	ISIS 105990
DM8FY3H	MI	TTT2SVW
DM8FY3H	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DM8FY3H	MT	DTT
DM8FY3H	RN	US patent application no. 7,425,545, Modulation of C-reactive protein expression.
DM8FY3H	RU	http://www.patentbuddy.com/Patent/7425545?ft=true&sr=true

DMTY6O9	DI	DMTY6O9
DMTY6O9	DN	ISIS 106008
DMTY6O9	MI	TTT2SVW
DMTY6O9	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DMTY6O9	MT	DTT
DMTY6O9	RN	US patent application no. 6,159,734, Antisense modulation of peroxisome proliferator-activated receptor gamma expression.
DMTY6O9	RU	http://www.patentbuddy.com/Patent/6159734?ft=true&sr=true

DM4YJQG	DI	DM4YJQG
DM4YJQG	DN	ISIS 10639
DM4YJQG	MI	TTOM5AU
DM4YJQG	MN	c-Fos messenger RNA (c-Fos mRNA)
DM4YJQG	MT	DTT
DM4YJQG	RN	US patent application no. 6,312,900, Antisense oligonucleotide compositions and methods for the modulation of activating protein 1.
DM4YJQG	RU	http://www.patentbuddy.com/Patent/6312900?ft=true&sr=true

DMYG5IO	DI	DMYG5IO
DMYG5IO	DN	ISIS 10707
DMYG5IO	MI	TTAN5W2
DMYG5IO	MN	Raf messenger RNA (Raf mRNA)
DMYG5IO	MT	DTT
DMYG5IO	RN	US patent application no. 5,952,229, Antisense oligonucleotide modulation of raf gene expression.
DMYG5IO	RU	http://www.patentbuddy.com/Patent/5952229?ft=true&sr=true

DMBWCZR	DI	DMBWCZR
DMBWCZR	DN	ISIS 107612
DMBWCZR	MI	TT6SZNG
DMBWCZR	MN	Caspase 8 messenger RNA (CASP8 mRNA)
DMBWCZR	MT	DTT
DMBWCZR	RN	US patent application no. 6,258,600, Antisense modulation of caspase 8 expression.
DMBWCZR	RU	http://www.patentbuddy.com/Patent/6258600?ft=true&sr=true

DMPR7OD	DI	DMPR7OD
DMPR7OD	DN	ISIS 107642
DMPR7OD	MI	TT6SZNG
DMPR7OD	MN	Caspase 8 messenger RNA (CASP8 mRNA)
DMPR7OD	MT	DTT
DMPR7OD	RN	US patent application no. 6,258,600, Antisense modulation of caspase 8 expression.
DMPR7OD	RU	http://www.patentbuddy.com/Patent/6258600?ft=true&sr=true

DMOX8JF	DI	DMOX8JF
DMOX8JF	DN	ISIS 107652
DMOX8JF	MI	TT6SZNG
DMOX8JF	MN	Caspase 8 messenger RNA (CASP8 mRNA)
DMOX8JF	MT	DTT
DMOX8JF	RN	US patent application no. 6,258,600, Antisense modulation of caspase 8 expression.
DMOX8JF	RU	http://www.patentbuddy.com/Patent/6258600?ft=true&sr=true

DMUE64H	DI	DMUE64H
DMUE64H	DN	ISIS 107676
DMUE64H	MI	TT6SZNG
DMUE64H	MN	Caspase 8 messenger RNA (CASP8 mRNA)
DMUE64H	MT	DTT
DMUE64H	RN	US patent application no. 6,258,600, Antisense modulation of caspase 8 expression.
DMUE64H	RU	http://www.patentbuddy.com/Patent/6258600?ft=true&sr=true

DMB9VFS	DI	DMB9VFS
DMB9VFS	DN	ISIS 107681
DMB9VFS	MI	TT6SZNG
DMB9VFS	MN	Caspase 8 messenger RNA (CASP8 mRNA)
DMB9VFS	MT	DTT
DMB9VFS	RN	US patent application no. 6,258,600, Antisense modulation of caspase 8 expression.
DMB9VFS	RU	http://www.patentbuddy.com/Patent/6258600?ft=true&sr=true

DM37VYR	DI	DM37VYR
DM37VYR	DN	ISIS 107772
DM37VYR	MI	TTELIN2
DM37VYR	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DM37VYR	MT	DTT
DM37VYR	RN	US patent application no. 6,261,840, Antisense modulation of PTP1B expression.
DM37VYR	RU	http://www.patentbuddy.com/Patent/6261840?ft=true&sr=true

DMA3ZGH	DI	DMA3ZGH
DMA3ZGH	DN	ISIS 107773
DMA3ZGH	MI	TTELIN2
DMA3ZGH	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMA3ZGH	MT	DTT
DMA3ZGH	RN	US patent application no. 6,261,840, Antisense modulation of PTP1B expression.
DMA3ZGH	RU	http://www.patentbuddy.com/Patent/6261840?ft=true&sr=true

DMFOTQY	DI	DMFOTQY
DMFOTQY	DN	ISIS 107774
DMFOTQY	MI	TTELIN2
DMFOTQY	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMFOTQY	MT	DTT
DMFOTQY	RN	US patent application no. 6,261,840, Antisense modulation of PTP1B expression.
DMFOTQY	RU	http://www.patentbuddy.com/Patent/6261840?ft=true&sr=true

DMLBX9Z	DI	DMLBX9Z
DMLBX9Z	DN	ISIS 107775
DMLBX9Z	MI	TTELIN2
DMLBX9Z	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMLBX9Z	MT	DTT
DMLBX9Z	RN	US patent application no. 6,261,840, Antisense modulation of PTP1B expression.
DMLBX9Z	RU	http://www.patentbuddy.com/Patent/6261840?ft=true&sr=true

DMNHBGJ	DI	DMNHBGJ
DMNHBGJ	DN	ISIS 107776
DMNHBGJ	MI	TTELIN2
DMNHBGJ	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMNHBGJ	MT	DTT
DMNHBGJ	RN	US patent application no. 6,261,840, Antisense modulation of PTP1B expression.
DMNHBGJ	RU	http://www.patentbuddy.com/Patent/6261840?ft=true&sr=true

DMVTU63	DI	DMVTU63
DMVTU63	DN	ISIS 107791
DMVTU63	MI	TTELIN2
DMVTU63	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMVTU63	MT	DTT
DMVTU63	RN	US patent application no. 6,261,840, Antisense modulation of PTP1B expression.
DMVTU63	RU	http://www.patentbuddy.com/Patent/6261840?ft=true&sr=true

DMV87MP	DI	DMV87MP
DMV87MP	DN	ISIS 107792
DMV87MP	MI	TTELIN2
DMV87MP	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMV87MP	MT	DTT
DMV87MP	RN	US patent application no. 6,261,840, Antisense modulation of PTP1B expression.
DMV87MP	RU	http://www.patentbuddy.com/Patent/6261840?ft=true&sr=true

DM83TLC	DI	DM83TLC
DM83TLC	DN	ISIS 109110
DM83TLC	MI	TTQSMFG
DM83TLC	MN	Talin messenger RNA (TLN1 mRNA)
DM83TLC	MT	DTT
DM83TLC	RN	US patent application no. 6,372,492, Antisense modulation of talin expression.
DM83TLC	RU	http://www.patentbuddy.com/Patent/6372492?ft=true&sr=true

DM0UOL3	DI	DM0UOL3
DM0UOL3	DN	ISIS 109111
DM0UOL3	MI	TTQSMFG
DM0UOL3	MN	Talin messenger RNA (TLN1 mRNA)
DM0UOL3	MT	DTT
DM0UOL3	RN	US patent application no. 6,372,492, Antisense modulation of talin expression.
DM0UOL3	RU	http://www.patentbuddy.com/Patent/6372492?ft=true&sr=true

DM6R5YW	DI	DM6R5YW
DM6R5YW	DN	ISIS 109112
DM6R5YW	MI	TTQSMFG
DM6R5YW	MN	Talin messenger RNA (TLN1 mRNA)
DM6R5YW	MT	DTT
DM6R5YW	RN	US patent application no. 6,372,492, Antisense modulation of talin expression.
DM6R5YW	RU	http://www.patentbuddy.com/Patent/6372492?ft=true&sr=true

DM58XT1	DI	DM58XT1
DM58XT1	DN	ISIS 109113
DM58XT1	MI	TTQSMFG
DM58XT1	MN	Talin messenger RNA (TLN1 mRNA)
DM58XT1	MT	DTT
DM58XT1	RN	US patent application no. 6,372,492, Antisense modulation of talin expression.
DM58XT1	RU	http://www.patentbuddy.com/Patent/6372492?ft=true&sr=true

DMUDFZN	DI	DMUDFZN
DMUDFZN	DN	ISIS 109114
DMUDFZN	MI	TTQSMFG
DMUDFZN	MN	Talin messenger RNA (TLN1 mRNA)
DMUDFZN	MT	DTT
DMUDFZN	RN	US patent application no. 6,372,492, Antisense modulation of talin expression.
DMUDFZN	RU	http://www.patentbuddy.com/Patent/6372492?ft=true&sr=true

DMBMDG7	DI	DMBMDG7
DMBMDG7	DN	ISIS 109115
DMBMDG7	MI	TTQSMFG
DMBMDG7	MN	Talin messenger RNA (TLN1 mRNA)
DMBMDG7	MT	DTT
DMBMDG7	RN	US patent application no. 6,372,492, Antisense modulation of talin expression.
DMBMDG7	RU	http://www.patentbuddy.com/Patent/6372492?ft=true&sr=true

DMQ8K9J	DI	DMQ8K9J
DMQ8K9J	DN	ISIS 109116
DMQ8K9J	MI	TTQSMFG
DMQ8K9J	MN	Talin messenger RNA (TLN1 mRNA)
DMQ8K9J	MT	DTT
DMQ8K9J	RN	US patent application no. 6,372,492, Antisense modulation of talin expression.
DMQ8K9J	RU	http://www.patentbuddy.com/Patent/6372492?ft=true&sr=true

DM508BS	DI	DM508BS
DM508BS	DN	ISIS 109351
DM508BS	MI	TT1MS7X
DM508BS	MN	PKC-theta messenger RNA (PRKCQ mRNA)
DM508BS	MT	DTT
DM508BS	RN	US patent application no. 6,190,869, Antisense inhibition of protein kinase C-theta expression.
DM508BS	RU	http://www.patentbuddy.com/Patent/6190869?ft=true&sr=true

DMWK1XC	DI	DMWK1XC
DMWK1XC	DN	ISIS 109352
DMWK1XC	MI	TT1MS7X
DMWK1XC	MN	PKC-theta messenger RNA (PRKCQ mRNA)
DMWK1XC	MT	DTT
DMWK1XC	RN	US patent application no. 6,190,869, Antisense inhibition of protein kinase C-theta expression.
DMWK1XC	RU	http://www.patentbuddy.com/Patent/6190869?ft=true&sr=true

DM6AJMC	DI	DM6AJMC
DM6AJMC	DN	ISIS 109353
DM6AJMC	MI	TT1MS7X
DM6AJMC	MN	PKC-theta messenger RNA (PRKCQ mRNA)
DM6AJMC	MT	DTT
DM6AJMC	RN	US patent application no. 6,190,869, Antisense inhibition of protein kinase C-theta expression.
DM6AJMC	RU	http://www.patentbuddy.com/Patent/6190869?ft=true&sr=true

DM1REKQ	DI	DM1REKQ
DM1REKQ	DN	ISIS 109354
DM1REKQ	MI	TT1MS7X
DM1REKQ	MN	PKC-theta messenger RNA (PRKCQ mRNA)
DM1REKQ	MT	DTT
DM1REKQ	RN	US patent application no. 6,190,869, Antisense inhibition of protein kinase C-theta expression.
DM1REKQ	RU	http://www.patentbuddy.com/Patent/6190869?ft=true&sr=true

DMFIQGW	DI	DMFIQGW
DMFIQGW	DN	ISIS 109355
DMFIQGW	MI	TT1MS7X
DMFIQGW	MN	PKC-theta messenger RNA (PRKCQ mRNA)
DMFIQGW	MT	DTT
DMFIQGW	RN	US patent application no. 6,190,869, Antisense inhibition of protein kinase C-theta expression.
DMFIQGW	RU	http://www.patentbuddy.com/Patent/6190869?ft=true&sr=true

DMDVE6A	DI	DMDVE6A
DMDVE6A	DN	ISIS 109490
DMDVE6A	MI	TT3K9S2
DMDVE6A	MN	RANK messenger RNA (RANK mRNA)
DMDVE6A	MT	DTT
DMDVE6A	RN	US patent application no. 6,171,860, Antisense inhibition of rank expression.
DMDVE6A	RU	http://www.patentbuddy.com/Patent/6171860?ft=true&sr=true

DMISNWV	DI	DMISNWV
DMISNWV	DN	ISIS 109491
DMISNWV	MI	TT3K9S2
DMISNWV	MN	RANK messenger RNA (RANK mRNA)
DMISNWV	MT	DTT
DMISNWV	RN	US patent application no. 6,171,860, Antisense inhibition of rank expression.
DMISNWV	RU	http://www.patentbuddy.com/Patent/6171860?ft=true&sr=true

DMRPMN6	DI	DMRPMN6
DMRPMN6	DN	ISIS 109502
DMRPMN6	MI	TT3K9S2
DMRPMN6	MN	RANK messenger RNA (RANK mRNA)
DMRPMN6	MT	DTT
DMRPMN6	RN	US patent application no. 6,171,860, Antisense inhibition of rank expression.
DMRPMN6	RU	http://www.patentbuddy.com/Patent/6171860?ft=true&sr=true

DMJ7EDV	DI	DMJ7EDV
DMJ7EDV	DN	ISIS 109524
DMJ7EDV	MI	TT3K9S2
DMJ7EDV	MN	RANK messenger RNA (RANK mRNA)
DMJ7EDV	MT	DTT
DMJ7EDV	RN	US patent application no. 6,171,860, Antisense inhibition of rank expression.
DMJ7EDV	RU	http://www.patentbuddy.com/Patent/6171860?ft=true&sr=true

DMB28D3	DI	DMB28D3
DMB28D3	DN	ISIS 109525
DMB28D3	MI	TT3K9S2
DMB28D3	MN	RANK messenger RNA (RANK mRNA)
DMB28D3	MT	DTT
DMB28D3	RN	US patent application no. 6,171,860, Antisense inhibition of rank expression.
DMB28D3	RU	http://www.patentbuddy.com/Patent/6171860?ft=true&sr=true

DMZN60F	DI	DMZN60F
DMZN60F	DN	ISIS 109526
DMZN60F	MI	TT3K9S2
DMZN60F	MN	RANK messenger RNA (RANK mRNA)
DMZN60F	MT	DTT
DMZN60F	RN	US patent application no. 6,171,860, Antisense inhibition of rank expression.
DMZN60F	RU	http://www.patentbuddy.com/Patent/6171860?ft=true&sr=true

DMXNG1S	DI	DMXNG1S
DMXNG1S	DN	ISIS 110064
DMXNG1S	MI	TTK1V5Q
DMXNG1S	MN	Nucleolin messenger RNA (NCL mRNA)
DMXNG1S	MT	DTT
DMXNG1S	RN	US patent application no. 6,165,786, Antisense modulation of nucleolin expression.
DMXNG1S	RU	http://www.patentbuddy.com/Patent/6165786?ft=true&sr=true

DMBOU16	DI	DMBOU16
DMBOU16	DN	ISIS 110065
DMBOU16	MI	TTK1V5Q
DMBOU16	MN	Nucleolin messenger RNA (NCL mRNA)
DMBOU16	MT	DTT
DMBOU16	RN	US patent application no. 6,165,786, Antisense modulation of nucleolin expression.
DMBOU16	RU	http://www.patentbuddy.com/Patent/6165786?ft=true&sr=true

DM4B35Y	DI	DM4B35Y
DM4B35Y	DN	ISIS 110066
DM4B35Y	MI	TTK1V5Q
DM4B35Y	MN	Nucleolin messenger RNA (NCL mRNA)
DM4B35Y	MT	DTT
DM4B35Y	RN	US patent application no. 6,165,786, Antisense modulation of nucleolin expression.
DM4B35Y	RU	http://www.patentbuddy.com/Patent/6165786?ft=true&sr=true

DM0EFHM	DI	DM0EFHM
DM0EFHM	DN	ISIS 110067
DM0EFHM	MI	TTK1V5Q
DM0EFHM	MN	Nucleolin messenger RNA (NCL mRNA)
DM0EFHM	MT	DTT
DM0EFHM	RN	US patent application no. 6,165,786, Antisense modulation of nucleolin expression.
DM0EFHM	RU	http://www.patentbuddy.com/Patent/6165786?ft=true&sr=true

DMSLOKM	DI	DMSLOKM
DMSLOKM	DN	ISIS 110068
DMSLOKM	MI	TTK1V5Q
DMSLOKM	MN	Nucleolin messenger RNA (NCL mRNA)
DMSLOKM	MT	DTT
DMSLOKM	RN	US patent application no. 6,165,786, Antisense modulation of nucleolin expression.
DMSLOKM	RU	http://www.patentbuddy.com/Patent/6165786?ft=true&sr=true

DMUG4HJ	DI	DMUG4HJ
DMUG4HJ	DN	ISIS 110073
DMUG4HJ	MI	TTK1V5Q
DMUG4HJ	MN	Nucleolin messenger RNA (NCL mRNA)
DMUG4HJ	MT	DTT
DMUG4HJ	RN	US patent application no. 6,165,786, Antisense modulation of nucleolin expression.
DMUG4HJ	RU	http://www.patentbuddy.com/Patent/6165786?ft=true&sr=true

DM2KECW	DI	DM2KECW
DM2KECW	DN	ISIS 110074
DM2KECW	MI	TTK1V5Q
DM2KECW	MN	Nucleolin messenger RNA (NCL mRNA)
DM2KECW	MT	DTT
DM2KECW	RN	US patent application no. 6,165,786, Antisense modulation of nucleolin expression.
DM2KECW	RU	http://www.patentbuddy.com/Patent/6165786?ft=true&sr=true

DMNKY2R	DI	DMNKY2R
DMNKY2R	DN	ISIS 11061
DMNKY2R	MI	TTAN5W2
DMNKY2R	MN	Raf messenger RNA (Raf mRNA)
DMNKY2R	MT	DTT
DMNKY2R	RN	US patent application no. 5,952,229, Antisense oligonucleotide modulation of raf gene expression.
DMNKY2R	RU	http://www.patentbuddy.com/Patent/5952229?ft=true&sr=true

DMF4V58	DI	DMF4V58
DMF4V58	DN	ISIS 111084
DMF4V58	MI	TTOM97J
DMF4V58	MN	Cytohesin-2 messenger RNA (CYTH2 mRNA)
DMF4V58	MT	DTT
DMF4V58	RN	US patent application no. 6,271,029, Antisense inhibition of cytohesin-2 expression.
DMF4V58	RU	http://www.patentbuddy.com/Patent/6271029?ft=true&sr=true

DMJQS5O	DI	DMJQS5O
DMJQS5O	DN	ISIS 111085
DMJQS5O	MI	TTOM97J
DMJQS5O	MN	Cytohesin-2 messenger RNA (CYTH2 mRNA)
DMJQS5O	MT	DTT
DMJQS5O	RN	US patent application no. 6,271,029, Antisense inhibition of cytohesin-2 expression.
DMJQS5O	RU	http://www.patentbuddy.com/Patent/6271029?ft=true&sr=true

DMJ86U4	DI	DMJ86U4
DMJ86U4	DN	ISIS 111086
DMJ86U4	MI	TTOM97J
DMJ86U4	MN	Cytohesin-2 messenger RNA (CYTH2 mRNA)
DMJ86U4	MT	DTT
DMJ86U4	RN	US patent application no. 6,271,029, Antisense inhibition of cytohesin-2 expression.
DMJ86U4	RU	http://www.patentbuddy.com/Patent/6271029?ft=true&sr=true

DM2VNUW	DI	DM2VNUW
DM2VNUW	DN	ISIS 111105
DM2VNUW	MI	TTOM97J
DM2VNUW	MN	Cytohesin-2 messenger RNA (CYTH2 mRNA)
DM2VNUW	MT	DTT
DM2VNUW	RN	US patent application no. 6,271,029, Antisense inhibition of cytohesin-2 expression.
DM2VNUW	RU	http://www.patentbuddy.com/Patent/6271029?ft=true&sr=true

DMAVQK3	DI	DMAVQK3
DMAVQK3	DN	ISIS 111117
DMAVQK3	MI	TTOM97J
DMAVQK3	MN	Cytohesin-2 messenger RNA (CYTH2 mRNA)
DMAVQK3	MT	DTT
DMAVQK3	RN	US patent application no. 6,271,029, Antisense inhibition of cytohesin-2 expression.
DMAVQK3	RU	http://www.patentbuddy.com/Patent/6271029?ft=true&sr=true

DM2N8JX	DI	DM2N8JX
DM2N8JX	DN	ISIS 111118
DM2N8JX	MI	TTOM97J
DM2N8JX	MN	Cytohesin-2 messenger RNA (CYTH2 mRNA)
DM2N8JX	MT	DTT
DM2N8JX	RN	US patent application no. 6,271,029, Antisense inhibition of cytohesin-2 expression.
DM2N8JX	RU	http://www.patentbuddy.com/Patent/6271029?ft=true&sr=true

DM019LA	DI	DM019LA
DM019LA	DN	ISIS 111119
DM019LA	MI	TTOM97J
DM019LA	MN	Cytohesin-2 messenger RNA (CYTH2 mRNA)
DM019LA	MT	DTT
DM019LA	RN	US patent application no. 6,271,029, Antisense inhibition of cytohesin-2 expression.
DM019LA	RU	http://www.patentbuddy.com/Patent/6271029?ft=true&sr=true

DM3W8R0	DI	DM3W8R0
DM3W8R0	DN	ISIS 111120
DM3W8R0	MI	TTOM97J
DM3W8R0	MN	Cytohesin-2 messenger RNA (CYTH2 mRNA)
DM3W8R0	MT	DTT
DM3W8R0	RN	US patent application no. 6,271,029, Antisense inhibition of cytohesin-2 expression.
DM3W8R0	RU	http://www.patentbuddy.com/Patent/6271029?ft=true&sr=true

DMIHTPC	DI	DMIHTPC
DMIHTPC	DN	ISIS 111121
DMIHTPC	MI	TTOM97J
DMIHTPC	MN	Cytohesin-2 messenger RNA (CYTH2 mRNA)
DMIHTPC	MT	DTT
DMIHTPC	RN	US patent application no. 6,271,029, Antisense inhibition of cytohesin-2 expression.
DMIHTPC	RU	http://www.patentbuddy.com/Patent/6271029?ft=true&sr=true

DMB31GR	DI	DMB31GR
DMB31GR	DN	ISIS 11155
DMB31GR	MI	TTQFZWR
DMB31GR	MN	Hepatitis C virus Core protein messenger RNA (HCV Core mRNA)
DMB31GR	MT	DTT
DMB31GR	RN	US patent application no. 6,391,542, Compositions and methods for treatment of Hepatitis C virus-associated diseases.
DMB31GR	RU	http://www.patentbuddy.com/Patent/6391542?ft=true&sr=true

DMX1OI8	DI	DMX1OI8
DMX1OI8	DN	ISIS 11158
DMX1OI8	MI	TTA1L39
DMX1OI8	MN	ICAM1 messenger RNA (ICAM1 mRNA)
DMX1OI8	MT	DTT
DMX1OI8	RN	US patent application no. 5,789,573, Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2.
DMX1OI8	RU	http://www.patentbuddy.com/Patent/5789573?ft=true&sr=true

DM9V6FW	DI	DM9V6FW
DM9V6FW	DN	ISIS 11159
DM9V6FW	MI	TTA1L39
DM9V6FW	MN	ICAM1 messenger RNA (ICAM1 mRNA)
DM9V6FW	MT	DTT
DM9V6FW	RN	US patent application no. 5,789,573, Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2.
DM9V6FW	RU	http://www.patentbuddy.com/Patent/5789573?ft=true&sr=true

DMNIBTG	DI	DMNIBTG
DMNIBTG	DN	ISIS 111992
DMNIBTG	MI	TTPJ9XK
DMNIBTG	MN	hnRNP A1 messenger RNA (HNRNPA1 mRNA)
DMNIBTG	MT	DTT
DMNIBTG	RN	US patent application no. 6,165,789, Antisense modulation of hnRNP A1 expression.
DMNIBTG	RU	http://www.patentbuddy.com/Patent/6165789?ft=true&sr=true

DMVMDAZ	DI	DMVMDAZ
DMVMDAZ	DN	ISIS 111993
DMVMDAZ	MI	TTPJ9XK
DMVMDAZ	MN	hnRNP A1 messenger RNA (HNRNPA1 mRNA)
DMVMDAZ	MT	DTT
DMVMDAZ	RN	US patent application no. 6,165,789, Antisense modulation of hnRNP A1 expression.
DMVMDAZ	RU	http://www.patentbuddy.com/Patent/6165789?ft=true&sr=true

DMSXTRI	DI	DMSXTRI
DMSXTRI	DN	ISIS 111997
DMSXTRI	MI	TTPJ9XK
DMSXTRI	MN	hnRNP A1 messenger RNA (HNRNPA1 mRNA)
DMSXTRI	MT	DTT
DMSXTRI	RN	US patent application no. 6,165,789, Antisense modulation of hnRNP A1 expression.
DMSXTRI	RU	http://www.patentbuddy.com/Patent/6165789?ft=true&sr=true

DM1NHJ8	DI	DM1NHJ8
DM1NHJ8	DN	ISIS 112000
DM1NHJ8	MI	TTPJ9XK
DM1NHJ8	MN	hnRNP A1 messenger RNA (HNRNPA1 mRNA)
DM1NHJ8	MT	DTT
DM1NHJ8	RN	US patent application no. 6,165,789, Antisense modulation of hnRNP A1 expression.
DM1NHJ8	RU	http://www.patentbuddy.com/Patent/6165789?ft=true&sr=true

DM2K74C	DI	DM2K74C
DM2K74C	DN	ISIS 112001
DM2K74C	MI	TTPJ9XK
DM2K74C	MN	hnRNP A1 messenger RNA (HNRNPA1 mRNA)
DM2K74C	MT	DTT
DM2K74C	RN	US patent application no. 6,165,789, Antisense modulation of hnRNP A1 expression.
DM2K74C	RU	http://www.patentbuddy.com/Patent/6165789?ft=true&sr=true

DMPROW5	DI	DMPROW5
DMPROW5	DN	ISIS 112002
DMPROW5	MI	TTPJ9XK
DMPROW5	MN	hnRNP A1 messenger RNA (HNRNPA1 mRNA)
DMPROW5	MT	DTT
DMPROW5	RN	US patent application no. 6,165,789, Antisense modulation of hnRNP A1 expression.
DMPROW5	RU	http://www.patentbuddy.com/Patent/6165789?ft=true&sr=true

DMHRLYJ	DI	DMHRLYJ
DMHRLYJ	DN	ISIS 112003
DMHRLYJ	MI	TTPJ9XK
DMHRLYJ	MN	hnRNP A1 messenger RNA (HNRNPA1 mRNA)
DMHRLYJ	MT	DTT
DMHRLYJ	RN	US patent application no. 6,165,789, Antisense modulation of hnRNP A1 expression.
DMHRLYJ	RU	http://www.patentbuddy.com/Patent/6165789?ft=true&sr=true

DMRJ1L6	DI	DMRJ1L6
DMRJ1L6	DN	ISIS 112004
DMRJ1L6	MI	TTPJ9XK
DMRJ1L6	MN	hnRNP A1 messenger RNA (HNRNPA1 mRNA)
DMRJ1L6	MT	DTT
DMRJ1L6	RN	US patent application no. 6,165,789, Antisense modulation of hnRNP A1 expression.
DMRJ1L6	RU	http://www.patentbuddy.com/Patent/6165789?ft=true&sr=true

DMDZY8F	DI	DMDZY8F
DMDZY8F	DN	ISIS 112005
DMDZY8F	MI	TTPJ9XK
DMDZY8F	MN	hnRNP A1 messenger RNA (HNRNPA1 mRNA)
DMDZY8F	MT	DTT
DMDZY8F	RN	US patent application no. 6,165,789, Antisense modulation of hnRNP A1 expression.
DMDZY8F	RU	http://www.patentbuddy.com/Patent/6165789?ft=true&sr=true

DMN6IBS	DI	DMN6IBS
DMN6IBS	DN	ISIS 112019
DMN6IBS	MI	TTPJ9XK
DMN6IBS	MN	hnRNP A1 messenger RNA (HNRNPA1 mRNA)
DMN6IBS	MT	DTT
DMN6IBS	RN	US patent application no. 6,165,789, Antisense modulation of hnRNP A1 expression.
DMN6IBS	RU	http://www.patentbuddy.com/Patent/6165789?ft=true&sr=true

DMO2FY8	DI	DMO2FY8
DMO2FY8	DN	ISIS 112020
DMO2FY8	MI	TTPJ9XK
DMO2FY8	MN	hnRNP A1 messenger RNA (HNRNPA1 mRNA)
DMO2FY8	MT	DTT
DMO2FY8	RN	US patent application no. 6,165,789, Antisense modulation of hnRNP A1 expression.
DMO2FY8	RU	http://www.patentbuddy.com/Patent/6165789?ft=true&sr=true

DM0E1SH	DI	DM0E1SH
DM0E1SH	DN	ISIS 112021
DM0E1SH	MI	TTPJ9XK
DM0E1SH	MN	hnRNP A1 messenger RNA (HNRNPA1 mRNA)
DM0E1SH	MT	DTT
DM0E1SH	RN	US patent application no. 6,165,789, Antisense modulation of hnRNP A1 expression.
DM0E1SH	RU	http://www.patentbuddy.com/Patent/6165789?ft=true&sr=true

DM7R53M	DI	DM7R53M
DM7R53M	DN	ISIS 112022
DM7R53M	MI	TTPJ9XK
DM7R53M	MN	hnRNP A1 messenger RNA (HNRNPA1 mRNA)
DM7R53M	MT	DTT
DM7R53M	RN	US patent application no. 6,165,789, Antisense modulation of hnRNP A1 expression.
DM7R53M	RU	http://www.patentbuddy.com/Patent/6165789?ft=true&sr=true

DM5F4Q6	DI	DM5F4Q6
DM5F4Q6	DN	ISIS 112023
DM5F4Q6	MI	TTPJ9XK
DM5F4Q6	MN	hnRNP A1 messenger RNA (HNRNPA1 mRNA)
DM5F4Q6	MT	DTT
DM5F4Q6	RN	US patent application no. 6,165,789, Antisense modulation of hnRNP A1 expression.
DM5F4Q6	RU	http://www.patentbuddy.com/Patent/6165789?ft=true&sr=true

DMVLHN9	DI	DMVLHN9
DMVLHN9	DN	ISIS 112024
DMVLHN9	MI	TTPJ9XK
DMVLHN9	MN	hnRNP A1 messenger RNA (HNRNPA1 mRNA)
DMVLHN9	MT	DTT
DMVLHN9	RN	US patent application no. 6,165,789, Antisense modulation of hnRNP A1 expression.
DMVLHN9	RU	http://www.patentbuddy.com/Patent/6165789?ft=true&sr=true

DMW3145	DI	DMW3145
DMW3145	DN	ISIS 11219
DMW3145	MI	TTRE6AX
DMW3145	MN	Bcl-x messenger RNA (BCL2L1 mRNA)
DMW3145	MT	DTT
DMW3145	RN	US patent application no. 7,148,204, Antisense modulation of bcl-x expression.
DMW3145	RU	http://www.patentbuddy.com/Patent/7148204?ft=true&sr=true

DMNJS0K	DI	DMNJS0K
DMNJS0K	DN	ISIS 11220
DMNJS0K	MI	TTRE6AX
DMNJS0K	MN	Bcl-x messenger RNA (BCL2L1 mRNA)
DMNJS0K	MT	DTT
DMNJS0K	RN	US patent application no. 7,148,204, Antisense modulation of bcl-x expression.
DMNJS0K	RU	http://www.patentbuddy.com/Patent/7148204?ft=true&sr=true

DMDUIG3	DI	DMDUIG3
DMDUIG3	DN	ISIS 11221
DMDUIG3	MI	TTRE6AX
DMDUIG3	MN	Bcl-x messenger RNA (BCL2L1 mRNA)
DMDUIG3	MT	DTT
DMDUIG3	RN	US patent application no. 7,148,204, Antisense modulation of bcl-x expression.
DMDUIG3	RU	http://www.patentbuddy.com/Patent/7148204?ft=true&sr=true

DM7LPI4	DI	DM7LPI4
DM7LPI4	DN	ISIS 11223
DM7LPI4	MI	TTRE6AX
DM7LPI4	MN	Bcl-x messenger RNA (BCL2L1 mRNA)
DM7LPI4	MT	DTT
DM7LPI4	RN	US patent application no. 7,148,204, Antisense modulation of bcl-x expression.
DM7LPI4	RU	http://www.patentbuddy.com/Patent/7148204?ft=true&sr=true

DMMGA6K	DI	DMMGA6K
DMMGA6K	DN	ISIS 11224
DMMGA6K	MI	TTRE6AX
DMMGA6K	MN	Bcl-x messenger RNA (BCL2L1 mRNA)
DMMGA6K	MT	DTT
DMMGA6K	RN	US patent application no. 7,148,204, Antisense modulation of bcl-x expression.
DMMGA6K	RU	http://www.patentbuddy.com/Patent/7148204?ft=true&sr=true

DMXHQSG	DI	DMXHQSG
DMXHQSG	DN	ISIS 112580
DMXHQSG	MI	TT6804T
DMXHQSG	MN	MIF messenger RNA (MIF mRNA)
DMXHQSG	MT	DTT
DMXHQSG	RN	US patent application no. 6,268,151, Antisense modulation of macrophage migration inhibitory factor expression.
DMXHQSG	RU	http://www.patentbuddy.com/Patent/6268151?ft=true&sr=true

DMU5QRX	DI	DMU5QRX
DMU5QRX	DN	ISIS 112590
DMU5QRX	MI	TT6804T
DMU5QRX	MN	MIF messenger RNA (MIF mRNA)
DMU5QRX	MT	DTT
DMU5QRX	RN	US patent application no. 6,268,151, Antisense modulation of macrophage migration inhibitory factor expression.
DMU5QRX	RU	http://www.patentbuddy.com/Patent/6268151?ft=true&sr=true

DM9OPJW	DI	DM9OPJW
DM9OPJW	DN	ISIS 112592
DM9OPJW	MI	TT6804T
DM9OPJW	MN	MIF messenger RNA (MIF mRNA)
DM9OPJW	MT	DTT
DM9OPJW	RN	US patent application no. 6,268,151, Antisense modulation of macrophage migration inhibitory factor expression.
DM9OPJW	RU	http://www.patentbuddy.com/Patent/6268151?ft=true&sr=true

DMIYCMF	DI	DMIYCMF
DMIYCMF	DN	ISIS 112599
DMIYCMF	MI	TT6804T
DMIYCMF	MN	MIF messenger RNA (MIF mRNA)
DMIYCMF	MT	DTT
DMIYCMF	RN	US patent application no. 6,268,151, Antisense modulation of macrophage migration inhibitory factor expression.
DMIYCMF	RU	http://www.patentbuddy.com/Patent/6268151?ft=true&sr=true

DM6PO0N	DI	DM6PO0N
DM6PO0N	DN	ISIS 112690
DM6PO0N	MI	TT6804T
DM6PO0N	MN	MIF messenger RNA (MIF mRNA)
DM6PO0N	MT	DTT
DM6PO0N	RN	US patent application no. 6,268,151, Antisense modulation of macrophage migration inhibitory factor expression.
DM6PO0N	RU	http://www.patentbuddy.com/Patent/6268151?ft=true&sr=true

DMA4635	DI	DMA4635
DMA4635	DN	ISIS 112694
DMA4635	MI	TT6804T
DMA4635	MN	MIF messenger RNA (MIF mRNA)
DMA4635	MT	DTT
DMA4635	RN	US patent application no. 6,268,151, Antisense modulation of macrophage migration inhibitory factor expression.
DMA4635	RU	http://www.patentbuddy.com/Patent/6268151?ft=true&sr=true

DMXZS4Y	DI	DMXZS4Y
DMXZS4Y	DN	ISIS 112696
DMXZS4Y	MI	TT6804T
DMXZS4Y	MN	MIF messenger RNA (MIF mRNA)
DMXZS4Y	MT	DTT
DMXZS4Y	RN	US patent application no. 6,268,151, Antisense modulation of macrophage migration inhibitory factor expression.
DMXZS4Y	RU	http://www.patentbuddy.com/Patent/6268151?ft=true&sr=true

DMIE0GJ	DI	DMIE0GJ
DMIE0GJ	DN	ISIS 112699
DMIE0GJ	MI	TT6804T
DMIE0GJ	MN	MIF messenger RNA (MIF mRNA)
DMIE0GJ	MT	DTT
DMIE0GJ	RN	US patent application no. 6,268,151, Antisense modulation of macrophage migration inhibitory factor expression.
DMIE0GJ	RU	http://www.patentbuddy.com/Patent/6268151?ft=true&sr=true

DM52UGS	DI	DM52UGS
DM52UGS	DN	ISIS 112711
DM52UGS	MI	TT6804T
DM52UGS	MN	MIF messenger RNA (MIF mRNA)
DM52UGS	MT	DTT
DM52UGS	RN	US patent application no. 6,268,151, Antisense modulation of macrophage migration inhibitory factor expression.
DM52UGS	RU	http://www.patentbuddy.com/Patent/6268151?ft=true&sr=true

DMB2O1Y	DI	DMB2O1Y
DMB2O1Y	DN	ISIS 112724
DMB2O1Y	MI	TT6804T
DMB2O1Y	MN	MIF messenger RNA (MIF mRNA)
DMB2O1Y	MT	DTT
DMB2O1Y	RN	US patent application no. 6,268,151, Antisense modulation of macrophage migration inhibitory factor expression.
DMB2O1Y	RU	http://www.patentbuddy.com/Patent/6268151?ft=true&sr=true

DMVCYBG	DI	DMVCYBG
DMVCYBG	DN	ISIS 113019
DMVCYBG	MI	TTASI04
DMVCYBG	MN	E2F1 messenger RNA (E2F1 mRNA)
DMVCYBG	MT	DTT
DMVCYBG	RN	US patent application no. 6,187,587, Antisense inhibition of e2f transcription factor 1 expression.
DMVCYBG	RU	http://www.patentbuddy.com/Patent/6187587?ft=true&sr=true

DMUXN8P	DI	DMUXN8P
DMUXN8P	DN	ISIS 113020
DMUXN8P	MI	TTASI04
DMUXN8P	MN	E2F1 messenger RNA (E2F1 mRNA)
DMUXN8P	MT	DTT
DMUXN8P	RN	US patent application no. 6,187,587, Antisense inhibition of e2f transcription factor 1 expression.
DMUXN8P	RU	http://www.patentbuddy.com/Patent/6187587?ft=true&sr=true

DMQ4GL6	DI	DMQ4GL6
DMQ4GL6	DN	ISIS 113021
DMQ4GL6	MI	TTASI04
DMQ4GL6	MN	E2F1 messenger RNA (E2F1 mRNA)
DMQ4GL6	MT	DTT
DMQ4GL6	RN	US patent application no. 6,187,587, Antisense inhibition of e2f transcription factor 1 expression.
DMQ4GL6	RU	http://www.patentbuddy.com/Patent/6187587?ft=true&sr=true

DMOQ0XD	DI	DMOQ0XD
DMOQ0XD	DN	ISIS 113022
DMOQ0XD	MI	TTASI04
DMOQ0XD	MN	E2F1 messenger RNA (E2F1 mRNA)
DMOQ0XD	MT	DTT
DMOQ0XD	RN	US patent application no. 6,187,587, Antisense inhibition of e2f transcription factor 1 expression.
DMOQ0XD	RU	http://www.patentbuddy.com/Patent/6187587?ft=true&sr=true

DMKTNVJ	DI	DMKTNVJ
DMKTNVJ	DN	ISIS 113048
DMKTNVJ	MI	TTASI04
DMKTNVJ	MN	E2F1 messenger RNA (E2F1 mRNA)
DMKTNVJ	MT	DTT
DMKTNVJ	RN	US patent application no. 6,187,587, Antisense inhibition of e2f transcription factor 1 expression.
DMKTNVJ	RU	http://www.patentbuddy.com/Patent/6187587?ft=true&sr=true

DM063XM	DI	DM063XM
DM063XM	DN	ISIS 113131
DM063XM	MI	TT53XHB
DM063XM	MN	CD86 messenger RNA (CD86 mRNA)
DM063XM	MT	DTT
DM063XM	RN	US patent application no. 7,425,545, Modulation of C-reactive protein expression.
DM063XM	RU	http://www.patentbuddy.com/Patent/7425545?ft=true&sr=true

DM5QEP4	DI	DM5QEP4
DM5QEP4	DN	ISIS 113176
DM5QEP4	MI	TTHJT3X
DM5QEP4	MN	STAT3 messenger RNA (STAT3 mRNA)
DM5QEP4	MT	DTT
DM5QEP4	RN	US patent application no. 7,098,192, Antisense oligonucleotide modulation of STAT3 expression.
DM5QEP4	RU	http://www.patentbuddy.com/Patent/7098192?ft=true&sr=true

DM4E6Y8	DI	DM4E6Y8
DM4E6Y8	DN	ISIS 113187
DM4E6Y8	MI	TTHJT3X
DM4E6Y8	MN	STAT3 messenger RNA (STAT3 mRNA)
DM4E6Y8	MT	DTT
DM4E6Y8	RN	US patent application no. 7,098,192, Antisense oligonucleotide modulation of STAT3 expression.
DM4E6Y8	RU	http://www.patentbuddy.com/Patent/7098192?ft=true&sr=true

DMGVN7A	DI	DMGVN7A
DMGVN7A	DN	ISIS 113209
DMGVN7A	MI	TTHJT3X
DMGVN7A	MN	STAT3 messenger RNA (STAT3 mRNA)
DMGVN7A	MT	DTT
DMGVN7A	RN	US patent application no. 7,098,192, Antisense oligonucleotide modulation of STAT3 expression.
DMGVN7A	RU	http://www.patentbuddy.com/Patent/7098192?ft=true&sr=true

DMZWH6E	DI	DMZWH6E
DMZWH6E	DN	ISIS 113210
DMZWH6E	MI	TTHJT3X
DMZWH6E	MN	STAT3 messenger RNA (STAT3 mRNA)
DMZWH6E	MT	DTT
DMZWH6E	RN	US patent application no. 7,098,192, Antisense oligonucleotide modulation of STAT3 expression.
DMZWH6E	RU	http://www.patentbuddy.com/Patent/7098192?ft=true&sr=true

DM9D3F1	DI	DM9D3F1
DM9D3F1	DN	ISIS 113858
DM9D3F1	MI	TTIX0ZU
DM9D3F1	MN	MEKK2 messenger RNA (MAP3K2 mRNA)
DM9D3F1	MT	DTT
DM9D3F1	RN	US patent application no. 6,287,860, Antisense inhibition of MEKK2 expression.
DM9D3F1	RU	http://www.patentbuddy.com/Patent/6287860?ft=true&sr=true

DMTEUDL	DI	DMTEUDL
DMTEUDL	DN	ISIS 113871
DMTEUDL	MI	TTIX0ZU
DMTEUDL	MN	MEKK2 messenger RNA (MAP3K2 mRNA)
DMTEUDL	MT	DTT
DMTEUDL	RN	US patent application no. 6,287,860, Antisense inhibition of MEKK2 expression.
DMTEUDL	RU	http://www.patentbuddy.com/Patent/6287860?ft=true&sr=true

DMR05YO	DI	DMR05YO
DMR05YO	DN	ISIS 113872
DMR05YO	MI	TTIX0ZU
DMR05YO	MN	MEKK2 messenger RNA (MAP3K2 mRNA)
DMR05YO	MT	DTT
DMR05YO	RN	US patent application no. 6,287,860, Antisense inhibition of MEKK2 expression.
DMR05YO	RU	http://www.patentbuddy.com/Patent/6287860?ft=true&sr=true

DMHUC3Q	DI	DMHUC3Q
DMHUC3Q	DN	ISIS 113873
DMHUC3Q	MI	TTIX0ZU
DMHUC3Q	MN	MEKK2 messenger RNA (MAP3K2 mRNA)
DMHUC3Q	MT	DTT
DMHUC3Q	RN	US patent application no. 6,287,860, Antisense inhibition of MEKK2 expression.
DMHUC3Q	RU	http://www.patentbuddy.com/Patent/6287860?ft=true&sr=true

DMEMSW1	DI	DMEMSW1
DMEMSW1	DN	ISIS 113874
DMEMSW1	MI	TTIX0ZU
DMEMSW1	MN	MEKK2 messenger RNA (MAP3K2 mRNA)
DMEMSW1	MT	DTT
DMEMSW1	RN	US patent application no. 6,287,860, Antisense inhibition of MEKK2 expression.
DMEMSW1	RU	http://www.patentbuddy.com/Patent/6287860?ft=true&sr=true

DMI8NYF	DI	DMI8NYF
DMI8NYF	DN	ISIS 113902
DMI8NYF	MI	TTIX0ZU
DMI8NYF	MN	MEKK2 messenger RNA (MAP3K2 mRNA)
DMI8NYF	MT	DTT
DMI8NYF	RN	US patent application no. 6,287,860, Antisense inhibition of MEKK2 expression.
DMI8NYF	RU	http://www.patentbuddy.com/Patent/6287860?ft=true&sr=true

DM56A89	DI	DM56A89
DM56A89	DN	ISIS 113903
DM56A89	MI	TTIX0ZU
DM56A89	MN	MEKK2 messenger RNA (MAP3K2 mRNA)
DM56A89	MT	DTT
DM56A89	RN	US patent application no. 6,287,860, Antisense inhibition of MEKK2 expression.
DM56A89	RU	http://www.patentbuddy.com/Patent/6287860?ft=true&sr=true

DMBM7HD	DI	DMBM7HD
DMBM7HD	DN	ISIS 113904
DMBM7HD	MI	TTIX0ZU
DMBM7HD	MN	MEKK2 messenger RNA (MAP3K2 mRNA)
DMBM7HD	MT	DTT
DMBM7HD	RN	US patent application no. 6,287,860, Antisense inhibition of MEKK2 expression.
DMBM7HD	RU	http://www.patentbuddy.com/Patent/6287860?ft=true&sr=true

DMPRDXO	DI	DMPRDXO
DMPRDXO	DN	ISIS 113905
DMPRDXO	MI	TTIX0ZU
DMPRDXO	MN	MEKK2 messenger RNA (MAP3K2 mRNA)
DMPRDXO	MT	DTT
DMPRDXO	RN	US patent application no. 6,287,860, Antisense inhibition of MEKK2 expression.
DMPRDXO	RU	http://www.patentbuddy.com/Patent/6287860?ft=true&sr=true

DMPJAB5	DI	DMPJAB5
DMPJAB5	DN	ISIS 113906
DMPJAB5	MI	TTIX0ZU
DMPJAB5	MN	MEKK2 messenger RNA (MAP3K2 mRNA)
DMPJAB5	MT	DTT
DMPJAB5	RN	US patent application no. 6,287,860, Antisense inhibition of MEKK2 expression.
DMPJAB5	RU	http://www.patentbuddy.com/Patent/6287860?ft=true&sr=true

DMP6WE0	DI	DMP6WE0
DMP6WE0	DN	ISIS 113907
DMP6WE0	MI	TTIX0ZU
DMP6WE0	MN	MEKK2 messenger RNA (MAP3K2 mRNA)
DMP6WE0	MT	DTT
DMP6WE0	RN	US patent application no. 6,287,860, Antisense inhibition of MEKK2 expression.
DMP6WE0	RU	http://www.patentbuddy.com/Patent/6287860?ft=true&sr=true

DMKLZ2H	DI	DMKLZ2H
DMKLZ2H	DN	ISIS 113908
DMKLZ2H	MI	TTIX0ZU
DMKLZ2H	MN	MEKK2 messenger RNA (MAP3K2 mRNA)
DMKLZ2H	MT	DTT
DMKLZ2H	RN	US patent application no. 6,287,860, Antisense inhibition of MEKK2 expression.
DMKLZ2H	RU	http://www.patentbuddy.com/Patent/6287860?ft=true&sr=true

DM0B9V5	DI	DM0B9V5
DM0B9V5	DN	ISIS 113909
DM0B9V5	MI	TTIX0ZU
DM0B9V5	MN	MEKK2 messenger RNA (MAP3K2 mRNA)
DM0B9V5	MT	DTT
DM0B9V5	RN	US patent application no. 6,287,860, Antisense inhibition of MEKK2 expression.
DM0B9V5	RU	http://www.patentbuddy.com/Patent/6287860?ft=true&sr=true

DMUVS0E	DI	DMUVS0E
DMUVS0E	DN	ISIS 114170
DMUVS0E	MI	TTWIJYH
DMUVS0E	MN	E2F3 messenger RNA (E2F3 mRNA)
DMUVS0E	MT	DTT
DMUVS0E	RN	US patent application no. 6,165,791, Antisense inhibition of E2F transcription factor 3 expression.
DMUVS0E	RU	http://www.patentbuddy.com/Patent/6165791?ft=true&sr=true

DM60V4N	DI	DM60V4N
DM60V4N	DN	ISIS 114184
DM60V4N	MI	TTWIJYH
DM60V4N	MN	E2F3 messenger RNA (E2F3 mRNA)
DM60V4N	MT	DTT
DM60V4N	RN	US patent application no. 6,165,791, Antisense inhibition of E2F transcription factor 3 expression.
DM60V4N	RU	http://www.patentbuddy.com/Patent/6165791?ft=true&sr=true

DMVJN4B	DI	DMVJN4B
DMVJN4B	DN	ISIS 114197
DMVJN4B	MI	TTWIJYH
DMVJN4B	MN	E2F3 messenger RNA (E2F3 mRNA)
DMVJN4B	MT	DTT
DMVJN4B	RN	US patent application no. 6,165,791, Antisense inhibition of E2F transcription factor 3 expression.
DMVJN4B	RU	http://www.patentbuddy.com/Patent/6165791?ft=true&sr=true

DM2GH8X	DI	DM2GH8X
DM2GH8X	DN	ISIS 114232
DM2GH8X	MI	TTWIJYH
DM2GH8X	MN	E2F3 messenger RNA (E2F3 mRNA)
DM2GH8X	MT	DTT
DM2GH8X	RN	US patent application no. 6,165,791, Antisense inhibition of E2F transcription factor 3 expression.
DM2GH8X	RU	http://www.patentbuddy.com/Patent/6165791?ft=true&sr=true

DMBO3YT	DI	DMBO3YT
DMBO3YT	DN	ISIS 114371
DMBO3YT	MI	TT8OY02
DMBO3YT	MN	ARA70 messenger RNA (NCOA4 mRNA)
DMBO3YT	MT	DTT
DMBO3YT	RN	US patent application no. 6,255,110, Antisense modulation of ARA70 expression.
DMBO3YT	RU	http://www.patentbuddy.com/Patent/6255110?ft=true&sr=true

DMNTRKI	DI	DMNTRKI
DMNTRKI	DN	ISIS 114372
DMNTRKI	MI	TT8OY02
DMNTRKI	MN	ARA70 messenger RNA (NCOA4 mRNA)
DMNTRKI	MT	DTT
DMNTRKI	RN	US patent application no. 6,255,110, Antisense modulation of ARA70 expression.
DMNTRKI	RU	http://www.patentbuddy.com/Patent/6255110?ft=true&sr=true

DMIZH16	DI	DMIZH16
DMIZH16	DN	ISIS 114388
DMIZH16	MI	TT8OY02
DMIZH16	MN	ARA70 messenger RNA (NCOA4 mRNA)
DMIZH16	MT	DTT
DMIZH16	RN	US patent application no. 6,255,110, Antisense modulation of ARA70 expression.
DMIZH16	RU	http://www.patentbuddy.com/Patent/6255110?ft=true&sr=true

DM1H428	DI	DM1H428
DM1H428	DN	ISIS 114390
DM1H428	MI	TT8OY02
DM1H428	MN	ARA70 messenger RNA (NCOA4 mRNA)
DM1H428	MT	DTT
DM1H428	RN	US patent application no. 6,255,110, Antisense modulation of ARA70 expression.
DM1H428	RU	http://www.patentbuddy.com/Patent/6255110?ft=true&sr=true

DMCBXQK	DI	DMCBXQK
DMCBXQK	DN	ISIS 114397
DMCBXQK	MI	TT8OY02
DMCBXQK	MN	ARA70 messenger RNA (NCOA4 mRNA)
DMCBXQK	MT	DTT
DMCBXQK	RN	US patent application no. 6,255,110, Antisense modulation of ARA70 expression.
DMCBXQK	RU	http://www.patentbuddy.com/Patent/6255110?ft=true&sr=true

DMZVE0S	DI	DMZVE0S
DMZVE0S	DN	ISIS 114399
DMZVE0S	MI	TT8OY02
DMZVE0S	MN	ARA70 messenger RNA (NCOA4 mRNA)
DMZVE0S	MT	DTT
DMZVE0S	RN	US patent application no. 6,255,110, Antisense modulation of ARA70 expression.
DMZVE0S	RU	http://www.patentbuddy.com/Patent/6255110?ft=true&sr=true

DMIOWBH	DI	DMIOWBH
DMIOWBH	DN	ISIS 114404
DMIOWBH	MI	TT8OY02
DMIOWBH	MN	ARA70 messenger RNA (NCOA4 mRNA)
DMIOWBH	MT	DTT
DMIOWBH	RN	US patent application no. 6,255,110, Antisense modulation of ARA70 expression.
DMIOWBH	RU	http://www.patentbuddy.com/Patent/6255110?ft=true&sr=true

DMCVP5G	DI	DMCVP5G
DMCVP5G	DN	ISIS 114442
DMCVP5G	MI	TT8OY02
DMCVP5G	MN	ARA70 messenger RNA (NCOA4 mRNA)
DMCVP5G	MT	DTT
DMCVP5G	RN	US patent application no. 6,255,110, Antisense modulation of ARA70 expression.
DMCVP5G	RU	http://www.patentbuddy.com/Patent/6255110?ft=true&sr=true

DM1OVSW	DI	DM1OVSW
DM1OVSW	DN	ISIS 114527
DM1OVSW	MI	TTY3BRA
DM1OVSW	MN	ZNF217 messenger RNA (ZNF217 mRNA)
DM1OVSW	MT	DTT
DM1OVSW	RN	US patent application no. 6,242,590, Antisense modulation of zinc finger protein-217 expression.
DM1OVSW	RU	http://www.patentbuddy.com/Patent/6242590?ft=true&sr=true

DMSEQ61	DI	DMSEQ61
DMSEQ61	DN	ISIS 114530
DMSEQ61	MI	TTY3BRA
DMSEQ61	MN	ZNF217 messenger RNA (ZNF217 mRNA)
DMSEQ61	MT	DTT
DMSEQ61	RN	US patent application no. 6,242,590, Antisense modulation of zinc finger protein-217 expression.
DMSEQ61	RU	http://www.patentbuddy.com/Patent/6242590?ft=true&sr=true

DMZSUA9	DI	DMZSUA9
DMZSUA9	DN	ISIS 114531
DMZSUA9	MI	TTY3BRA
DMZSUA9	MN	ZNF217 messenger RNA (ZNF217 mRNA)
DMZSUA9	MT	DTT
DMZSUA9	RN	US patent application no. 6,242,590, Antisense modulation of zinc finger protein-217 expression.
DMZSUA9	RU	http://www.patentbuddy.com/Patent/6242590?ft=true&sr=true

DMJ7BOL	DI	DMJ7BOL
DMJ7BOL	DN	ISIS 114532
DMJ7BOL	MI	TTY3BRA
DMJ7BOL	MN	ZNF217 messenger RNA (ZNF217 mRNA)
DMJ7BOL	MT	DTT
DMJ7BOL	RN	US patent application no. 6,242,590, Antisense modulation of zinc finger protein-217 expression.
DMJ7BOL	RU	http://www.patentbuddy.com/Patent/6242590?ft=true&sr=true

DMD9O2H	DI	DMD9O2H
DMD9O2H	DN	ISIS 114537
DMD9O2H	MI	TTY3BRA
DMD9O2H	MN	ZNF217 messenger RNA (ZNF217 mRNA)
DMD9O2H	MT	DTT
DMD9O2H	RN	US patent application no. 6,242,590, Antisense modulation of zinc finger protein-217 expression.
DMD9O2H	RU	http://www.patentbuddy.com/Patent/6242590?ft=true&sr=true

DMMOPUK	DI	DMMOPUK
DMMOPUK	DN	ISIS 114559
DMMOPUK	MI	TTY3BRA
DMMOPUK	MN	ZNF217 messenger RNA (ZNF217 mRNA)
DMMOPUK	MT	DTT
DMMOPUK	RN	US patent application no. 6,242,590, Antisense modulation of zinc finger protein-217 expression.
DMMOPUK	RU	http://www.patentbuddy.com/Patent/6242590?ft=true&sr=true

DMD2J3Q	DI	DMD2J3Q
DMD2J3Q	DN	ISIS 114563
DMD2J3Q	MI	TTY3BRA
DMD2J3Q	MN	ZNF217 messenger RNA (ZNF217 mRNA)
DMD2J3Q	MT	DTT
DMD2J3Q	RN	US patent application no. 6,242,590, Antisense modulation of zinc finger protein-217 expression.
DMD2J3Q	RU	http://www.patentbuddy.com/Patent/6242590?ft=true&sr=true

DM280AE	DI	DM280AE
DM280AE	DN	ISIS 116359
DM280AE	MI	TTGECUM
DM280AE	MN	Cot oncogene messenger RNA (MAP3K8 mRNA)
DM280AE	MT	DTT
DM280AE	RN	US patent application no. 6,265,216, Antisense modulation of cot oncogene expression.
DM280AE	RU	http://www.patentbuddy.com/Patent/6265216?ft=true&sr=true

DMFEZHM	DI	DMFEZHM
DMFEZHM	DN	ISIS 116360
DMFEZHM	MI	TTGECUM
DMFEZHM	MN	Cot oncogene messenger RNA (MAP3K8 mRNA)
DMFEZHM	MT	DTT
DMFEZHM	RN	US patent application no. 6,265,216, Antisense modulation of cot oncogene expression.
DMFEZHM	RU	http://www.patentbuddy.com/Patent/6265216?ft=true&sr=true

DMWBQHS	DI	DMWBQHS
DMWBQHS	DN	ISIS 116361
DMWBQHS	MI	TTGECUM
DMWBQHS	MN	Cot oncogene messenger RNA (MAP3K8 mRNA)
DMWBQHS	MT	DTT
DMWBQHS	RN	US patent application no. 6,265,216, Antisense modulation of cot oncogene expression.
DMWBQHS	RU	http://www.patentbuddy.com/Patent/6265216?ft=true&sr=true

DM7M1UB	DI	DM7M1UB
DM7M1UB	DN	ISIS 116362
DM7M1UB	MI	TTGECUM
DM7M1UB	MN	Cot oncogene messenger RNA (MAP3K8 mRNA)
DM7M1UB	MT	DTT
DM7M1UB	RN	US patent application no. 6,265,216, Antisense modulation of cot oncogene expression.
DM7M1UB	RU	http://www.patentbuddy.com/Patent/6265216?ft=true&sr=true

DMXKAJP	DI	DMXKAJP
DMXKAJP	DN	ISIS 116363
DMXKAJP	MI	TTGECUM
DMXKAJP	MN	Cot oncogene messenger RNA (MAP3K8 mRNA)
DMXKAJP	MT	DTT
DMXKAJP	RN	US patent application no. 6,265,216, Antisense modulation of cot oncogene expression.
DMXKAJP	RU	http://www.patentbuddy.com/Patent/6265216?ft=true&sr=true

DM4Q3JO	DI	DM4Q3JO
DM4Q3JO	DN	ISIS 116414
DM4Q3JO	MI	TTGECUM
DM4Q3JO	MN	Cot oncogene messenger RNA (MAP3K8 mRNA)
DM4Q3JO	MT	DTT
DM4Q3JO	RN	US patent application no. 6,265,216, Antisense modulation of cot oncogene expression.
DM4Q3JO	RU	http://www.patentbuddy.com/Patent/6265216?ft=true&sr=true

DMVE5UH	DI	DMVE5UH
DMVE5UH	DN	ISIS 116505
DMVE5UH	MI	TTUI35N
DMVE5UH	MN	C/EBP beta messenger RNA (CEBPB mRNA)
DMVE5UH	MT	DTT
DMVE5UH	RN	US patent application no. 6,271,030, Antisense inhibition of C/EBP beta expression.
DMVE5UH	RU	http://www.patentbuddy.com/Patent/6271030?ft=true&sr=true

DM76CYG	DI	DM76CYG
DM76CYG	DN	ISIS 116507
DM76CYG	MI	TTUI35N
DM76CYG	MN	C/EBP beta messenger RNA (CEBPB mRNA)
DM76CYG	MT	DTT
DM76CYG	RN	US patent application no. 6,271,030, Antisense inhibition of C/EBP beta expression.
DM76CYG	RU	http://www.patentbuddy.com/Patent/6271030?ft=true&sr=true

DM3XHBR	DI	DM3XHBR
DM3XHBR	DN	ISIS 116508
DM3XHBR	MI	TTUI35N
DM3XHBR	MN	C/EBP beta messenger RNA (CEBPB mRNA)
DM3XHBR	MT	DTT
DM3XHBR	RN	US patent application no. 6,271,030, Antisense inhibition of C/EBP beta expression.
DM3XHBR	RU	http://www.patentbuddy.com/Patent/6271030?ft=true&sr=true

DMIJES1	DI	DMIJES1
DMIJES1	DN	ISIS 116625
DMIJES1	MI	TTQWAU1
DMIJES1	MN	GSK3A messenger RNA (GSK3A mRNA)
DMIJES1	MT	DTT
DMIJES1	RN	US patent application no. 6,316,259, Antisense inhibition of glycogen synthase kinase 3 alpha expression.
DMIJES1	RU	http://www.patentbuddy.com/Patent/6316259?ft=true&sr=true

DM2X5RT	DI	DM2X5RT
DM2X5RT	DN	ISIS 116631
DM2X5RT	MI	TTQWAU1
DM2X5RT	MN	GSK3A messenger RNA (GSK3A mRNA)
DM2X5RT	MT	DTT
DM2X5RT	RN	US patent application no. 6,316,259, Antisense inhibition of glycogen synthase kinase 3 alpha expression.
DM2X5RT	RU	http://www.patentbuddy.com/Patent/6316259?ft=true&sr=true

DMW2Q4T	DI	DMW2Q4T
DMW2Q4T	DN	ISIS 116632
DMW2Q4T	MI	TTQWAU1
DMW2Q4T	MN	GSK3A messenger RNA (GSK3A mRNA)
DMW2Q4T	MT	DTT
DMW2Q4T	RN	US patent application no. 6,316,259, Antisense inhibition of glycogen synthase kinase 3 alpha expression.
DMW2Q4T	RU	http://www.patentbuddy.com/Patent/6316259?ft=true&sr=true

DMUOB3S	DI	DMUOB3S
DMUOB3S	DN	ISIS 116648
DMUOB3S	MI	TTQWAU1
DMUOB3S	MN	GSK3A messenger RNA (GSK3A mRNA)
DMUOB3S	MT	DTT
DMUOB3S	RN	US patent application no. 6,316,259, Antisense inhibition of glycogen synthase kinase 3 alpha expression.
DMUOB3S	RU	http://www.patentbuddy.com/Patent/6316259?ft=true&sr=true

DMYWINR	DI	DMYWINR
DMYWINR	DN	ISIS 11665
DMYWINR	MI	TTA1L39
DMYWINR	MN	ICAM1 messenger RNA (ICAM1 mRNA)
DMYWINR	MT	DTT
DMYWINR	RN	US patent application no. 5,789,573, Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2.
DMYWINR	RU	http://www.patentbuddy.com/Patent/5789573?ft=true&sr=true

DMBJU2X	DI	DMBJU2X
DMBJU2X	DN	ISIS 116654
DMBJU2X	MI	TTQWAU1
DMBJU2X	MN	GSK3A messenger RNA (GSK3A mRNA)
DMBJU2X	MT	DTT
DMBJU2X	RN	US patent application no. 6,316,259, Antisense inhibition of glycogen synthase kinase 3 alpha expression.
DMBJU2X	RU	http://www.patentbuddy.com/Patent/6316259?ft=true&sr=true

DM9R51M	DI	DM9R51M
DM9R51M	DN	ISIS 116670
DM9R51M	MI	TTQWAU1
DM9R51M	MN	GSK3A messenger RNA (GSK3A mRNA)
DM9R51M	MT	DTT
DM9R51M	RN	US patent application no. 6,316,259, Antisense inhibition of glycogen synthase kinase 3 alpha expression.
DM9R51M	RU	http://www.patentbuddy.com/Patent/6316259?ft=true&sr=true

DMIS715	DI	DMIS715
DMIS715	DN	ISIS 119262
DMIS715	MI	TTKS60G
DMIS715	MN	STXBP4 messenger RNA (STXBP4 mRNA)
DMIS715	MT	DTT
DMIS715	RN	US patent application no. 6,503,756, Antisense modulation of syntaxin 4 interacting protein expression.
DMIS715	RU	http://www.patentbuddy.com/Patent/6503756?ft=true&sr=true

DMD3M9J	DI	DMD3M9J
DMD3M9J	DN	ISIS 119263
DMD3M9J	MI	TTKS60G
DMD3M9J	MN	STXBP4 messenger RNA (STXBP4 mRNA)
DMD3M9J	MT	DTT
DMD3M9J	RN	US patent application no. 6,503,756, Antisense modulation of syntaxin 4 interacting protein expression.
DMD3M9J	RU	http://www.patentbuddy.com/Patent/6503756?ft=true&sr=true

DM0P3R5	DI	DM0P3R5
DM0P3R5	DN	ISIS 119264
DM0P3R5	MI	TTKS60G
DM0P3R5	MN	STXBP4 messenger RNA (STXBP4 mRNA)
DM0P3R5	MT	DTT
DM0P3R5	RN	US patent application no. 6,503,756, Antisense modulation of syntaxin 4 interacting protein expression.
DM0P3R5	RU	http://www.patentbuddy.com/Patent/6503756?ft=true&sr=true

DMFPM5S	DI	DMFPM5S
DMFPM5S	DN	ISIS 119281
DMFPM5S	MI	TTKS60G
DMFPM5S	MN	STXBP4 messenger RNA (STXBP4 mRNA)
DMFPM5S	MT	DTT
DMFPM5S	RN	US patent application no. 6,503,756, Antisense modulation of syntaxin 4 interacting protein expression.
DMFPM5S	RU	http://www.patentbuddy.com/Patent/6503756?ft=true&sr=true

DMLND5S	DI	DMLND5S
DMLND5S	DN	ISIS 119282
DMLND5S	MI	TTKS60G
DMLND5S	MN	STXBP4 messenger RNA (STXBP4 mRNA)
DMLND5S	MT	DTT
DMLND5S	RN	US patent application no. 6,503,756, Antisense modulation of syntaxin 4 interacting protein expression.
DMLND5S	RU	http://www.patentbuddy.com/Patent/6503756?ft=true&sr=true

DMKJ57H	DI	DMKJ57H
DMKJ57H	DN	ISIS 119283
DMKJ57H	MI	TTKS60G
DMKJ57H	MN	STXBP4 messenger RNA (STXBP4 mRNA)
DMKJ57H	MT	DTT
DMKJ57H	RN	US patent application no. 6,503,756, Antisense modulation of syntaxin 4 interacting protein expression.
DMKJ57H	RU	http://www.patentbuddy.com/Patent/6503756?ft=true&sr=true

DM7CTVE	DI	DM7CTVE
DM7CTVE	DN	ISIS 119284
DM7CTVE	MI	TTKS60G
DM7CTVE	MN	STXBP4 messenger RNA (STXBP4 mRNA)
DM7CTVE	MT	DTT
DM7CTVE	RN	US patent application no. 6,503,756, Antisense modulation of syntaxin 4 interacting protein expression.
DM7CTVE	RU	http://www.patentbuddy.com/Patent/6503756?ft=true&sr=true

DMYQR3A	DI	DMYQR3A
DMYQR3A	DN	ISIS 119285
DMYQR3A	MI	TTKS60G
DMYQR3A	MN	STXBP4 messenger RNA (STXBP4 mRNA)
DMYQR3A	MT	DTT
DMYQR3A	RN	US patent application no. 6,503,756, Antisense modulation of syntaxin 4 interacting protein expression.
DMYQR3A	RU	http://www.patentbuddy.com/Patent/6503756?ft=true&sr=true

DM42LSO	DI	DM42LSO
DM42LSO	DN	ISIS 119286
DM42LSO	MI	TTKS60G
DM42LSO	MN	STXBP4 messenger RNA (STXBP4 mRNA)
DM42LSO	MT	DTT
DM42LSO	RN	US patent application no. 6,503,756, Antisense modulation of syntaxin 4 interacting protein expression.
DM42LSO	RU	http://www.patentbuddy.com/Patent/6503756?ft=true&sr=true

DMZYOPD	DI	DMZYOPD
DMZYOPD	DN	ISIS 11929
DMZYOPD	MI	TT1PL7M
DMZYOPD	MN	E-selectin messenger RNA (SELE mRNA)
DMZYOPD	MT	DTT
DMZYOPD	RN	US patent application no. 5,789,573, Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2.
DMZYOPD	RU	http://www.patentbuddy.com/Patent/5789573?ft=true&sr=true

DM0LMQH	DI	DM0LMQH
DM0LMQH	DN	ISIS 122970
DM0LMQH	MI	TTJZNIG
DM0LMQH	MN	MEKK3 messenger RNA (MAP3K3 mRNA)
DM0LMQH	MT	DTT
DM0LMQH	RN	US patent application no. 6,498,035, Antisense modulation of MEKK3 expression.
DM0LMQH	RU	http://www.patentbuddy.com/Patent/6498035?ft=true&sr=true

DM4NBX0	DI	DM4NBX0
DM4NBX0	DN	ISIS 122971
DM4NBX0	MI	TTJZNIG
DM4NBX0	MN	MEKK3 messenger RNA (MAP3K3 mRNA)
DM4NBX0	MT	DTT
DM4NBX0	RN	US patent application no. 6,498,035, Antisense modulation of MEKK3 expression.
DM4NBX0	RU	http://www.patentbuddy.com/Patent/6498035?ft=true&sr=true

DMLHA6K	DI	DMLHA6K
DMLHA6K	DN	ISIS 122974
DMLHA6K	MI	TTJZNIG
DMLHA6K	MN	MEKK3 messenger RNA (MAP3K3 mRNA)
DMLHA6K	MT	DTT
DMLHA6K	RN	US patent application no. 6,498,035, Antisense modulation of MEKK3 expression.
DMLHA6K	RU	http://www.patentbuddy.com/Patent/6498035?ft=true&sr=true

DM4Y8EQ	DI	DM4Y8EQ
DM4Y8EQ	DN	ISIS 122975
DM4Y8EQ	MI	TTJZNIG
DM4Y8EQ	MN	MEKK3 messenger RNA (MAP3K3 mRNA)
DM4Y8EQ	MT	DTT
DM4Y8EQ	RN	US patent application no. 6,498,035, Antisense modulation of MEKK3 expression.
DM4Y8EQ	RU	http://www.patentbuddy.com/Patent/6498035?ft=true&sr=true

DM7OSZI	DI	DM7OSZI
DM7OSZI	DN	ISIS 122976
DM7OSZI	MI	TTJZNIG
DM7OSZI	MN	MEKK3 messenger RNA (MAP3K3 mRNA)
DM7OSZI	MT	DTT
DM7OSZI	RN	US patent application no. 6,498,035, Antisense modulation of MEKK3 expression.
DM7OSZI	RU	http://www.patentbuddy.com/Patent/6498035?ft=true&sr=true

DMVZS1D	DI	DMVZS1D
DMVZS1D	DN	ISIS 122984
DMVZS1D	MI	TTJZNIG
DMVZS1D	MN	MEKK3 messenger RNA (MAP3K3 mRNA)
DMVZS1D	MT	DTT
DMVZS1D	RN	US patent application no. 6,498,035, Antisense modulation of MEKK3 expression.
DMVZS1D	RU	http://www.patentbuddy.com/Patent/6498035?ft=true&sr=true

DM6JVOP	DI	DM6JVOP
DM6JVOP	DN	ISIS 122985
DM6JVOP	MI	TTJZNIG
DM6JVOP	MN	MEKK3 messenger RNA (MAP3K3 mRNA)
DM6JVOP	MT	DTT
DM6JVOP	RN	US patent application no. 6,498,035, Antisense modulation of MEKK3 expression.
DM6JVOP	RU	http://www.patentbuddy.com/Patent/6498035?ft=true&sr=true

DMU79FD	DI	DMU79FD
DMU79FD	DN	ISIS 122986
DMU79FD	MI	TTJZNIG
DMU79FD	MN	MEKK3 messenger RNA (MAP3K3 mRNA)
DMU79FD	MT	DTT
DMU79FD	RN	US patent application no. 6,498,035, Antisense modulation of MEKK3 expression.
DMU79FD	RU	http://www.patentbuddy.com/Patent/6498035?ft=true&sr=true

DMLN8XS	DI	DMLN8XS
DMLN8XS	DN	ISIS 122990
DMLN8XS	MI	TTJZNIG
DMLN8XS	MN	MEKK3 messenger RNA (MAP3K3 mRNA)
DMLN8XS	MT	DTT
DMLN8XS	RN	US patent application no. 6,498,035, Antisense modulation of MEKK3 expression.
DMLN8XS	RU	http://www.patentbuddy.com/Patent/6498035?ft=true&sr=true

DMHAWMV	DI	DMHAWMV
DMHAWMV	DN	ISIS 122991
DMHAWMV	MI	TTJZNIG
DMHAWMV	MN	MEKK3 messenger RNA (MAP3K3 mRNA)
DMHAWMV	MT	DTT
DMHAWMV	RN	US patent application no. 6,498,035, Antisense modulation of MEKK3 expression.
DMHAWMV	RU	http://www.patentbuddy.com/Patent/6498035?ft=true&sr=true

DMZGKHO	DI	DMZGKHO
DMZGKHO	DN	ISIS 12659
DMZGKHO	MI	TT4SCBE
DMZGKHO	MN	Cytomegalovirus IE2 region messenger RNA (CMV IE2 mRNA)
DMZGKHO	MT	DTT
DMZGKHO	RN	US patent application no. 5,767,102, Antisense composition and method for treatment of CMV infection.
DMZGKHO	RU	http://www.patentbuddy.com/Patent/5767102?ft=true&sr=true

DMNOPWB	DI	DMNOPWB
DMNOPWB	DN	ISIS 12660
DMNOPWB	MI	TT4SCBE
DMNOPWB	MN	Cytomegalovirus IE2 region messenger RNA (CMV IE2 mRNA)
DMNOPWB	MT	DTT
DMNOPWB	RN	US patent application no. 5,767,102, Antisense composition and method for treatment of CMV infection.
DMNOPWB	RU	http://www.patentbuddy.com/Patent/5767102?ft=true&sr=true

DMAXB8T	DI	DMAXB8T
DMAXB8T	DN	ISIS 12882
DMAXB8T	MI	TTR5TV4
DMAXB8T	MN	ERBB2 messenger RNA (HER2 mRNA)
DMAXB8T	MT	DTT
DMAXB8T	RN	US patent application no. 5,968,748, Antisense oligonucleotide modulation of human HER-2 expression.
DMAXB8T	RU	http://www.patentbuddy.com/Patent/5968748?ft=true&sr=true

DMND0JL	DI	DMND0JL
DMND0JL	DN	ISIS 12883
DMND0JL	MI	TTR5TV4
DMND0JL	MN	ERBB2 messenger RNA (HER2 mRNA)
DMND0JL	MT	DTT
DMND0JL	RN	US patent application no. 5,968,748, Antisense oligonucleotide modulation of human HER-2 expression.
DMND0JL	RU	http://www.patentbuddy.com/Patent/5968748?ft=true&sr=true

DMS15A3	DI	DMS15A3
DMS15A3	DN	ISIS 12884
DMS15A3	MI	TTR5TV4
DMS15A3	MN	ERBB2 messenger RNA (HER2 mRNA)
DMS15A3	MT	DTT
DMS15A3	RN	US patent application no. 5,968,748, Antisense oligonucleotide modulation of human HER-2 expression.
DMS15A3	RU	http://www.patentbuddy.com/Patent/5968748?ft=true&sr=true

DMKY5LI	DI	DMKY5LI
DMKY5LI	DN	ISIS 133206
DMKY5LI	MI	TTZN92A
DMKY5LI	MN	DUSP5 messenger RNA (DUSP5 mRNA)
DMKY5LI	MT	DTT
DMKY5LI	RN	US patent application no. 6,867,039, Antisense modulation of dual specific phosphatase 5 expression.
DMKY5LI	RU	http://www.patentbuddy.com/Patent/6867039?ft=true&sr=true

DMR3KLF	DI	DMR3KLF
DMR3KLF	DN	ISIS 133207
DMR3KLF	MI	TTZN92A
DMR3KLF	MN	DUSP5 messenger RNA (DUSP5 mRNA)
DMR3KLF	MT	DTT
DMR3KLF	RN	US patent application no. 6,867,039, Antisense modulation of dual specific phosphatase 5 expression.
DMR3KLF	RU	http://www.patentbuddy.com/Patent/6867039?ft=true&sr=true

DMTSKQZ	DI	DMTSKQZ
DMTSKQZ	DN	ISIS 133208
DMTSKQZ	MI	TTZN92A
DMTSKQZ	MN	DUSP5 messenger RNA (DUSP5 mRNA)
DMTSKQZ	MT	DTT
DMTSKQZ	RN	US patent application no. 6,867,039, Antisense modulation of dual specific phosphatase 5 expression.
DMTSKQZ	RU	http://www.patentbuddy.com/Patent/6867039?ft=true&sr=true

DMCGF2P	DI	DMCGF2P
DMCGF2P	DN	ISIS 133211
DMCGF2P	MI	TTZN92A
DMCGF2P	MN	DUSP5 messenger RNA (DUSP5 mRNA)
DMCGF2P	MT	DTT
DMCGF2P	RN	US patent application no. 6,867,039, Antisense modulation of dual specific phosphatase 5 expression.
DMCGF2P	RU	http://www.patentbuddy.com/Patent/6867039?ft=true&sr=true

DMP60XE	DI	DMP60XE
DMP60XE	DN	ISIS 133242
DMP60XE	MI	TTZN92A
DMP60XE	MN	DUSP5 messenger RNA (DUSP5 mRNA)
DMP60XE	MT	DTT
DMP60XE	RN	US patent application no. 6,867,039, Antisense modulation of dual specific phosphatase 5 expression.
DMP60XE	RU	http://www.patentbuddy.com/Patent/6867039?ft=true&sr=true

DM2PIAZ	DI	DM2PIAZ
DM2PIAZ	DN	ISIS 133243
DM2PIAZ	MI	TTZN92A
DM2PIAZ	MN	DUSP5 messenger RNA (DUSP5 mRNA)
DM2PIAZ	MT	DTT
DM2PIAZ	RN	US patent application no. 6,867,039, Antisense modulation of dual specific phosphatase 5 expression.
DM2PIAZ	RU	http://www.patentbuddy.com/Patent/6867039?ft=true&sr=true

DMTGFXI	DI	DMTGFXI
DMTGFXI	DN	ISIS 133244
DMTGFXI	MI	TTZN92A
DMTGFXI	MN	DUSP5 messenger RNA (DUSP5 mRNA)
DMTGFXI	MT	DTT
DMTGFXI	RN	US patent application no. 6,867,039, Antisense modulation of dual specific phosphatase 5 expression.
DMTGFXI	RU	http://www.patentbuddy.com/Patent/6867039?ft=true&sr=true

DMO09DU	DI	DMO09DU
DMO09DU	DN	ISIS 133245
DMO09DU	MI	TTZN92A
DMO09DU	MN	DUSP5 messenger RNA (DUSP5 mRNA)
DMO09DU	MT	DTT
DMO09DU	RN	US patent application no. 6,867,039, Antisense modulation of dual specific phosphatase 5 expression.
DMO09DU	RU	http://www.patentbuddy.com/Patent/6867039?ft=true&sr=true

DMDZ3FU	DI	DMDZ3FU
DMDZ3FU	DN	ISIS 133712
DMDZ3FU	MI	TTWRN6M
DMDZ3FU	MN	CRP messenger RNA (CRP mRNA)
DMDZ3FU	MT	DTT
DMDZ3FU	RN	US patent application no. 7,425,545, Modulation of C-reactive protein expression.
DMDZ3FU	RU	http://www.patentbuddy.com/Patent/7425545?ft=true&sr=true

DMJ56XU	DI	DMJ56XU
DMJ56XU	DN	ISIS 133726
DMJ56XU	MI	TTWRN6M
DMJ56XU	MN	CRP messenger RNA (CRP mRNA)
DMJ56XU	MT	DTT
DMJ56XU	RN	US patent application no. 7,425,545, Modulation of C-reactive protein expression.
DMJ56XU	RU	http://www.patentbuddy.com/Patent/7425545?ft=true&sr=true

DM90TOR	DI	DM90TOR
DM90TOR	DN	ISIS 134499
DM90TOR	MI	TTKW4ML
DM90TOR	MN	Caspase 6 messenger RNA (CASP6 mRNA)
DM90TOR	MT	DTT
DM90TOR	RN	US patent application no. 6,566,135, Antisense modulation of caspase 6 expression.
DM90TOR	RU	http://www.patentbuddy.com/Patent/6566135?ft=true&sr=true

DMFCOA5	DI	DMFCOA5
DMFCOA5	DN	ISIS 134524
DMFCOA5	MI	TTKW4ML
DMFCOA5	MN	Caspase 6 messenger RNA (CASP6 mRNA)
DMFCOA5	MT	DTT
DMFCOA5	RN	US patent application no. 6,566,135, Antisense modulation of caspase 6 expression.
DMFCOA5	RU	http://www.patentbuddy.com/Patent/6566135?ft=true&sr=true

DMYZNIW	DI	DMYZNIW
DMYZNIW	DN	ISIS 134528
DMYZNIW	MI	TTKW4ML
DMYZNIW	MN	Caspase 6 messenger RNA (CASP6 mRNA)
DMYZNIW	MT	DTT
DMYZNIW	RN	US patent application no. 6,566,135, Antisense modulation of caspase 6 expression.
DMYZNIW	RU	http://www.patentbuddy.com/Patent/6566135?ft=true&sr=true

DMRFMVL	DI	DMRFMVL
DMRFMVL	DN	ISIS 134532
DMRFMVL	MI	TTKW4ML
DMRFMVL	MN	Caspase 6 messenger RNA (CASP6 mRNA)
DMRFMVL	MT	DTT
DMRFMVL	RN	US patent application no. 6,566,135, Antisense modulation of caspase 6 expression.
DMRFMVL	RU	http://www.patentbuddy.com/Patent/6566135?ft=true&sr=true

DMWRYA1	DI	DMWRYA1
DMWRYA1	DN	ISIS 134563
DMWRYA1	MI	TTKW4ML
DMWRYA1	MN	Caspase 6 messenger RNA (CASP6 mRNA)
DMWRYA1	MT	DTT
DMWRYA1	RN	US patent application no. 6,566,135, Antisense modulation of caspase 6 expression.
DMWRYA1	RU	http://www.patentbuddy.com/Patent/6566135?ft=true&sr=true

DM8J24F	DI	DM8J24F
DM8J24F	DN	ISIS 134564
DM8J24F	MI	TTKW4ML
DM8J24F	MN	Caspase 6 messenger RNA (CASP6 mRNA)
DM8J24F	MT	DTT
DM8J24F	RN	US patent application no. 6,566,135, Antisense modulation of caspase 6 expression.
DM8J24F	RU	http://www.patentbuddy.com/Patent/6566135?ft=true&sr=true

DM9FR3A	DI	DM9FR3A
DM9FR3A	DN	ISIS 134565
DM9FR3A	MI	TTKW4ML
DM9FR3A	MN	Caspase 6 messenger RNA (CASP6 mRNA)
DM9FR3A	MT	DTT
DM9FR3A	RN	US patent application no. 6,566,135, Antisense modulation of caspase 6 expression.
DM9FR3A	RU	http://www.patentbuddy.com/Patent/6566135?ft=true&sr=true

DMCM2S4	DI	DMCM2S4
DMCM2S4	DN	ISIS 134566
DMCM2S4	MI	TTKW4ML
DMCM2S4	MN	Caspase 6 messenger RNA (CASP6 mRNA)
DMCM2S4	MT	DTT
DMCM2S4	RN	US patent application no. 6,566,135, Antisense modulation of caspase 6 expression.
DMCM2S4	RU	http://www.patentbuddy.com/Patent/6566135?ft=true&sr=true

DM0HWRN	DI	DM0HWRN
DM0HWRN	DN	ISIS 134583
DM0HWRN	MI	TTKW4ML
DM0HWRN	MN	Caspase 6 messenger RNA (CASP6 mRNA)
DM0HWRN	MT	DTT
DM0HWRN	RN	US patent application no. 6,566,135, Antisense modulation of caspase 6 expression.
DM0HWRN	RU	http://www.patentbuddy.com/Patent/6566135?ft=true&sr=true

DMNP8HG	DI	DMNP8HG
DMNP8HG	DN	ISIS 134601
DMNP8HG	MI	TTKW4ML
DMNP8HG	MN	Caspase 6 messenger RNA (CASP6 mRNA)
DMNP8HG	MT	DTT
DMNP8HG	RN	US patent application no. 6,566,135, Antisense modulation of caspase 6 expression.
DMNP8HG	RU	http://www.patentbuddy.com/Patent/6566135?ft=true&sr=true

DMDS4BP	DI	DMDS4BP
DMDS4BP	DN	ISIS 134602
DMDS4BP	MI	TTKW4ML
DMDS4BP	MN	Caspase 6 messenger RNA (CASP6 mRNA)
DMDS4BP	MT	DTT
DMDS4BP	RN	US patent application no. 6,566,135, Antisense modulation of caspase 6 expression.
DMDS4BP	RU	http://www.patentbuddy.com/Patent/6566135?ft=true&sr=true

DM01UDZ	DI	DM01UDZ
DM01UDZ	DN	ISIS 134603
DM01UDZ	MI	TTKW4ML
DM01UDZ	MN	Caspase 6 messenger RNA (CASP6 mRNA)
DM01UDZ	MT	DTT
DM01UDZ	RN	US patent application no. 6,566,135, Antisense modulation of caspase 6 expression.
DM01UDZ	RU	http://www.patentbuddy.com/Patent/6566135?ft=true&sr=true

DM32XGR	DI	DM32XGR
DM32XGR	DN	ISIS 134604
DM32XGR	MI	TTKW4ML
DM32XGR	MN	Caspase 6 messenger RNA (CASP6 mRNA)
DM32XGR	MT	DTT
DM32XGR	RN	US patent application no. 6,566,135, Antisense modulation of caspase 6 expression.
DM32XGR	RU	http://www.patentbuddy.com/Patent/6566135?ft=true&sr=true

DMCPKV9	DI	DMCPKV9
DMCPKV9	DN	ISIS 134605
DMCPKV9	MI	TTKW4ML
DMCPKV9	MN	Caspase 6 messenger RNA (CASP6 mRNA)
DMCPKV9	MT	DTT
DMCPKV9	RN	US patent application no. 6,566,135, Antisense modulation of caspase 6 expression.
DMCPKV9	RU	http://www.patentbuddy.com/Patent/6566135?ft=true&sr=true

DM4OF6C	DI	DM4OF6C
DM4OF6C	DN	ISIS 134606
DM4OF6C	MI	TTKW4ML
DM4OF6C	MN	Caspase 6 messenger RNA (CASP6 mRNA)
DM4OF6C	MT	DTT
DM4OF6C	RN	US patent application no. 6,566,135, Antisense modulation of caspase 6 expression.
DM4OF6C	RU	http://www.patentbuddy.com/Patent/6566135?ft=true&sr=true

DMZDJF3	DI	DMZDJF3
DMZDJF3	DN	ISIS 134607
DMZDJF3	MI	TTKW4ML
DMZDJF3	MN	Caspase 6 messenger RNA (CASP6 mRNA)
DMZDJF3	MT	DTT
DMZDJF3	RN	US patent application no. 6,566,135, Antisense modulation of caspase 6 expression.
DMZDJF3	RU	http://www.patentbuddy.com/Patent/6566135?ft=true&sr=true

DMVX9IT	DI	DMVX9IT
DMVX9IT	DN	ISIS 134608
DMVX9IT	MI	TTKW4ML
DMVX9IT	MN	Caspase 6 messenger RNA (CASP6 mRNA)
DMVX9IT	MT	DTT
DMVX9IT	RN	US patent application no. 6,566,135, Antisense modulation of caspase 6 expression.
DMVX9IT	RU	http://www.patentbuddy.com/Patent/6566135?ft=true&sr=true

DMYODMN	DI	DMYODMN
DMYODMN	DN	ISIS 134609
DMYODMN	MI	TTKW4ML
DMYODMN	MN	Caspase 6 messenger RNA (CASP6 mRNA)
DMYODMN	MT	DTT
DMYODMN	RN	US patent application no. 6,566,135, Antisense modulation of caspase 6 expression.
DMYODMN	RU	http://www.patentbuddy.com/Patent/6566135?ft=true&sr=true

DMCDW4H	DI	DMCDW4H
DMCDW4H	DN	ISIS 13727
DMCDW4H	MI	TT0EOB8
DMCDW4H	MN	B-Raf messenger RNA (BRAF mRNA)
DMCDW4H	MT	DTT
DMCDW4H	RN	US patent application no. 5,981,731, Antisense oligonucleotide modulation of B-raf gene expression.
DMCDW4H	RU	http://www.patentbuddy.com/Patent/5981731?ft=true&sr=true

DMRJBH4	DI	DMRJBH4
DMRJBH4	DN	ISIS 13730
DMRJBH4	MI	TT0EOB8
DMRJBH4	MN	B-Raf messenger RNA (BRAF mRNA)
DMRJBH4	MT	DTT
DMRJBH4	RN	US patent application no. 5,981,731, Antisense oligonucleotide modulation of B-raf gene expression.
DMRJBH4	RU	http://www.patentbuddy.com/Patent/5981731?ft=true&sr=true

DM5Q12D	DI	DM5Q12D
DM5Q12D	DN	ISIS 13740
DM5Q12D	MI	TT0EOB8
DM5Q12D	MN	B-Raf messenger RNA (BRAF mRNA)
DM5Q12D	MT	DTT
DM5Q12D	RN	US patent application no. 5,981,731, Antisense oligonucleotide modulation of B-raf gene expression.
DM5Q12D	RU	http://www.patentbuddy.com/Patent/5981731?ft=true&sr=true

DMC7Q38	DI	DMC7Q38
DMC7Q38	DN	ISIS 13741
DMC7Q38	MI	TT0EOB8
DMC7Q38	MN	B-Raf messenger RNA (BRAF mRNA)
DMC7Q38	MT	DTT
DMC7Q38	RN	US patent application no. 5,981,731, Antisense oligonucleotide modulation of B-raf gene expression.
DMC7Q38	RU	http://www.patentbuddy.com/Patent/5981731?ft=true&sr=true

DMO6R1I	DI	DMO6R1I
DMO6R1I	DN	ISIS 13743
DMO6R1I	MI	TT0EOB8
DMO6R1I	MN	B-Raf messenger RNA (BRAF mRNA)
DMO6R1I	MT	DTT
DMO6R1I	RN	US patent application no. 5,981,731, Antisense oligonucleotide modulation of B-raf gene expression.
DMO6R1I	RU	http://www.patentbuddy.com/Patent/5981731?ft=true&sr=true

DMLVKPD	DI	DMLVKPD
DMLVKPD	DN	ISIS 13805
DMLVKPD	MI	TT89Z17
DMLVKPD	MN	B7 translation initiation codon region messenger RNA (CD80 mRNA)
DMLVKPD	MT	DTT
DMLVKPD	RN	US patent application no. 6,319,906, Oligonucleotide compositions and methods for the modulation of the expression of B7 protein.
DMLVKPD	RU	http://www.patentbuddy.com/Patent/6319906?ft=true&sr=true

DMPXCZ7	DI	DMPXCZ7
DMPXCZ7	DN	ISIS 13812
DMPXCZ7	MI	TT89Z17
DMPXCZ7	MN	B7 translation initiation codon region messenger RNA (CD80 mRNA)
DMPXCZ7	MT	DTT
DMPXCZ7	RN	US patent application no. 6,319,906, Oligonucleotide compositions and methods for the modulation of the expression of B7 protein.
DMPXCZ7	RU	http://www.patentbuddy.com/Patent/6319906?ft=true&sr=true

DMLE7YQ	DI	DMLE7YQ
DMLE7YQ	DN	ISIS 138612
DMLE7YQ	MI	TTTEOPU
DMLE7YQ	MN	Helicase-moi messenger RNA (DICER1 mRNA)
DMLE7YQ	MT	DTT
DMLE7YQ	RN	US patent application no. 7,427,470, Antisense modulation of helicase-moi expression.
DMLE7YQ	RU	http://www.patentbuddy.com/Patent/7427470?ft=true&sr=true

DMN3L0Y	DI	DMN3L0Y
DMN3L0Y	DN	ISIS 138613
DMN3L0Y	MI	TTTEOPU
DMN3L0Y	MN	Helicase-moi messenger RNA (DICER1 mRNA)
DMN3L0Y	MT	DTT
DMN3L0Y	RN	US patent application no. 7,427,470, Antisense modulation of helicase-moi expression.
DMN3L0Y	RU	http://www.patentbuddy.com/Patent/7427470?ft=true&sr=true

DM1FX7N	DI	DM1FX7N
DM1FX7N	DN	ISIS 138616
DM1FX7N	MI	TTTEOPU
DM1FX7N	MN	Helicase-moi messenger RNA (DICER1 mRNA)
DM1FX7N	MT	DTT
DM1FX7N	RN	US patent application no. 7,427,470, Antisense modulation of helicase-moi expression.
DM1FX7N	RU	http://www.patentbuddy.com/Patent/7427470?ft=true&sr=true

DM73NIE	DI	DM73NIE
DM73NIE	DN	ISIS 138647
DM73NIE	MI	TTTEOPU
DM73NIE	MN	Helicase-moi messenger RNA (DICER1 mRNA)
DM73NIE	MT	DTT
DM73NIE	RN	US patent application no. 7,427,470, Antisense modulation of helicase-moi expression.
DM73NIE	RU	http://www.patentbuddy.com/Patent/7427470?ft=true&sr=true

DMSUKAO	DI	DMSUKAO
DMSUKAO	DN	ISIS 138648
DMSUKAO	MI	TTTEOPU
DMSUKAO	MN	Helicase-moi messenger RNA (DICER1 mRNA)
DMSUKAO	MT	DTT
DMSUKAO	RN	US patent application no. 7,427,470, Antisense modulation of helicase-moi expression.
DMSUKAO	RU	http://www.patentbuddy.com/Patent/7427470?ft=true&sr=true

DMNFYZL	DI	DMNFYZL
DMNFYZL	DN	ISIS 138649
DMNFYZL	MI	TTTEOPU
DMNFYZL	MN	Helicase-moi messenger RNA (DICER1 mRNA)
DMNFYZL	MT	DTT
DMNFYZL	RN	US patent application no. 7,427,470, Antisense modulation of helicase-moi expression.
DMNFYZL	RU	http://www.patentbuddy.com/Patent/7427470?ft=true&sr=true

DMB7E4X	DI	DMB7E4X
DMB7E4X	DN	ISIS 138678
DMB7E4X	MI	TTTEOPU
DMB7E4X	MN	Helicase-moi messenger RNA (DICER1 mRNA)
DMB7E4X	MT	DTT
DMB7E4X	RN	US patent application no. 7,427,470, Antisense modulation of helicase-moi expression.
DMB7E4X	RU	http://www.patentbuddy.com/Patent/7427470?ft=true&sr=true

DM4PM1G	DI	DM4PM1G
DM4PM1G	DN	ISIS 13920
DM4PM1G	MI	TT28ZON
DM4PM1G	MN	H-ras messenger RNA (HRAS mRNA)
DM4PM1G	MT	DTT
DM4PM1G	RN	US patent application no. 7,425,545, Modulation of C-reactive protein expression.
DM4PM1G	RU	http://www.patentbuddy.com/Patent/7425545?ft=true&sr=true

DMKYWQ2	DI	DMKYWQ2
DMKYWQ2	DN	ISIS 140148
DMKYWQ2	MI	TTAK0IN
DMKYWQ2	MN	SOAT2 messenger RNA (SOAT2 mRNA)
DMKYWQ2	MT	DTT
DMKYWQ2	RN	US patent application no. 7,202,357, Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression.
DMKYWQ2	RU	http://www.patentbuddy.com/Patent/7202357?ft=true&sr=true

DMD60BA	DI	DMD60BA
DMD60BA	DN	ISIS 140153
DMD60BA	MI	TTAK0IN
DMD60BA	MN	SOAT2 messenger RNA (SOAT2 mRNA)
DMD60BA	MT	DTT
DMD60BA	RN	US patent application no. 7,202,357, Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression.
DMD60BA	RU	http://www.patentbuddy.com/Patent/7202357?ft=true&sr=true

DMG2P7B	DI	DMG2P7B
DMG2P7B	DN	ISIS 140157
DMG2P7B	MI	TTAK0IN
DMG2P7B	MN	SOAT2 messenger RNA (SOAT2 mRNA)
DMG2P7B	MT	DTT
DMG2P7B	RN	US patent application no. 7,202,357, Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression.
DMG2P7B	RU	http://www.patentbuddy.com/Patent/7202357?ft=true&sr=true

DMO87PG	DI	DMO87PG
DMO87PG	DN	ISIS 140158
DMO87PG	MI	TTAK0IN
DMO87PG	MN	SOAT2 messenger RNA (SOAT2 mRNA)
DMO87PG	MT	DTT
DMO87PG	RN	US patent application no. 7,202,357, Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression.
DMO87PG	RU	http://www.patentbuddy.com/Patent/7202357?ft=true&sr=true

DMRHSY6	DI	DMRHSY6
DMRHSY6	DN	ISIS 140161
DMRHSY6	MI	TTAK0IN
DMRHSY6	MN	SOAT2 messenger RNA (SOAT2 mRNA)
DMRHSY6	MT	DTT
DMRHSY6	RN	US patent application no. 7,202,357, Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression.
DMRHSY6	RU	http://www.patentbuddy.com/Patent/7202357?ft=true&sr=true

DMP9WOZ	DI	DMP9WOZ
DMP9WOZ	DN	ISIS 140180
DMP9WOZ	MI	TTWRN6M
DMP9WOZ	MN	CRP messenger RNA (CRP mRNA)
DMP9WOZ	MT	DTT
DMP9WOZ	RN	US patent application no. 7,425,545, Modulation of C-reactive protein expression.
DMP9WOZ	RU	http://www.patentbuddy.com/Patent/7425545?ft=true&sr=true

DMWIKD5	DI	DMWIKD5
DMWIKD5	DN	ISIS 14144
DMWIKD5	MI	TT0EOB8
DMWIKD5	MN	B-Raf messenger RNA (BRAF mRNA)
DMWIKD5	MT	DTT
DMWIKD5	RN	US patent application no. 5,981,731, Antisense oligonucleotide modulation of B-raf gene expression.
DMWIKD5	RU	http://www.patentbuddy.com/Patent/5981731?ft=true&sr=true

DMJW4C5	DI	DMJW4C5
DMJW4C5	DN	ISIS 144368
DMJW4C5	MI	TT5S8DR
DMJW4C5	MN	APOA1 messenger RNA (APOA1 mRNA)
DMJW4C5	MT	DTT
DMJW4C5	RN	US patent application no. 7,259,150, Modulation of apolipoprotein (a) expression.
DMJW4C5	RU	http://www.patentbuddy.com/Patent/7259150?ft=true&sr=true

DM1QLB0	DI	DM1QLB0
DM1QLB0	DN	ISIS 144379
DM1QLB0	MI	TT5S8DR
DM1QLB0	MN	APOA1 messenger RNA (APOA1 mRNA)
DM1QLB0	MT	DTT
DM1QLB0	RN	US patent application no. 7,259,150, Modulation of apolipoprotein (a) expression.
DM1QLB0	RU	http://www.patentbuddy.com/Patent/7259150?ft=true&sr=true

DMY34RB	DI	DMY34RB
DMY34RB	DN	ISIS 144396
DMY34RB	MI	TT5S8DR
DMY34RB	MN	APOA1 messenger RNA (APOA1 mRNA)
DMY34RB	MT	DTT
DMY34RB	RN	US patent application no. 7,259,150, Modulation of apolipoprotein (a) expression.
DMY34RB	RU	http://www.patentbuddy.com/Patent/7259150?ft=true&sr=true

DMHWGL0	DI	DMHWGL0
DMHWGL0	DN	ISIS 14548
DMHWGL0	MI	TTY3BRA
DMHWGL0	MN	ZNF217 messenger RNA (ZNF217 mRNA)
DMHWGL0	MT	DTT
DMHWGL0	RN	US patent application no. 6,242,590, Antisense modulation of zinc finger protein-217 expression.
DMHWGL0	RU	http://www.patentbuddy.com/Patent/6242590?ft=true&sr=true

DMNMXKC	DI	DMNMXKC
DMNMXKC	DN	ISIS 147483
DMNMXKC	MI	TTN1IE2
DMNMXKC	MN	APOB messenger RNA (APOB mRNA)
DMNMXKC	MT	DTT
DMNMXKC	RN	US patent application no. 7,407,943, Antisense modulation of apolipoprotein B expression.
DMNMXKC	RU	http://www.patentbuddy.com/Patent/7407943?ft=true&sr=true

DM1Z5W8	DI	DM1Z5W8
DM1Z5W8	DN	ISIS 147788
DM1Z5W8	MI	TTN1IE2
DM1Z5W8	MN	APOB messenger RNA (APOB mRNA)
DM1Z5W8	MT	DTT
DM1Z5W8	RN	US patent application no. 7,407,943, Antisense modulation of apolipoprotein B expression.
DM1Z5W8	RU	http://www.patentbuddy.com/Patent/7407943?ft=true&sr=true

DMTE3FJ	DI	DMTE3FJ
DMTE3FJ	DN	ISIS 147919
DMTE3FJ	MI	TT6RIOV
DMTE3FJ	MN	Acyl-CoA desaturase (SCD)
DMTE3FJ	MT	DTT
DMTE3FJ	RN	US patent application no. 7,132,529, Antisense modulation of stearoyl-CoA desaturase expression.
DMTE3FJ	RU	http://www.patentbuddy.com/Patent/7132529?ft=true&sr=true

DMSB27R	DI	DMSB27R
DMSB27R	DN	ISIS 148715
DMSB27R	MI	TTOJY1B
DMSB27R	MN	Jagged2 messenger RNA (JAG2 mRNA)
DMSB27R	MT	DTT
DMSB27R	RN	US patent application no. 7,425,545, Modulation of C-reactive protein expression.
DMSB27R	RU	http://www.patentbuddy.com/Patent/7425545?ft=true&sr=true

DMMBW13	DI	DMMBW13
DMMBW13	DN	ISIS 150450
DMMBW13	MI	TTP9K3Q
DMMBW13	MN	SOD1 messenger RNA (SOD1 mRNA)
DMMBW13	MT	DTT
DMMBW13	RN	US patent application no. 7,132,530, Antisense modulation of superoxide dismutase 1, soluble expression.
DMMBW13	RU	http://www.patentbuddy.com/Patent/7132530?ft=true&sr=true

DM1DCFP	DI	DM1DCFP
DM1DCFP	DN	ISIS 150451
DM1DCFP	MI	TTP9K3Q
DM1DCFP	MN	SOD1 messenger RNA (SOD1 mRNA)
DM1DCFP	MT	DTT
DM1DCFP	RN	US patent application no. 7,132,530, Antisense modulation of superoxide dismutase 1, soluble expression.
DM1DCFP	RU	http://www.patentbuddy.com/Patent/7132530?ft=true&sr=true

DMQE7BH	DI	DMQE7BH
DMQE7BH	DN	ISIS 150452
DMQE7BH	MI	TTP9K3Q
DMQE7BH	MN	SOD1 messenger RNA (SOD1 mRNA)
DMQE7BH	MT	DTT
DMQE7BH	RN	US patent application no. 7,132,530, Antisense modulation of superoxide dismutase 1, soluble expression.
DMQE7BH	RU	http://www.patentbuddy.com/Patent/7132530?ft=true&sr=true

DMKCG41	DI	DMKCG41
DMKCG41	DN	ISIS 150453
DMKCG41	MI	TTP9K3Q
DMKCG41	MN	SOD1 messenger RNA (SOD1 mRNA)
DMKCG41	MT	DTT
DMKCG41	RN	US patent application no. 7,132,530, Antisense modulation of superoxide dismutase 1, soluble expression.
DMKCG41	RU	http://www.patentbuddy.com/Patent/7132530?ft=true&sr=true

DMW0Y75	DI	DMW0Y75
DMW0Y75	DN	ISIS 150454
DMW0Y75	MI	TTP9K3Q
DMW0Y75	MN	SOD1 messenger RNA (SOD1 mRNA)
DMW0Y75	MT	DTT
DMW0Y75	RN	US patent application no. 7,132,530, Antisense modulation of superoxide dismutase 1, soluble expression.
DMW0Y75	RU	http://www.patentbuddy.com/Patent/7132530?ft=true&sr=true

DMFUM62	DI	DMFUM62
DMFUM62	DN	ISIS 150463
DMFUM62	MI	TTP9K3Q
DMFUM62	MN	SOD1 messenger RNA (SOD1 mRNA)
DMFUM62	MT	DTT
DMFUM62	RN	US patent application no. 7,132,530, Antisense modulation of superoxide dismutase 1, soluble expression.
DMFUM62	RU	http://www.patentbuddy.com/Patent/7132530?ft=true&sr=true

DM1IC54	DI	DM1IC54
DM1IC54	DN	ISIS 150464
DM1IC54	MI	TTP9K3Q
DM1IC54	MN	SOD1 messenger RNA (SOD1 mRNA)
DM1IC54	MT	DTT
DM1IC54	RN	US patent application no. 7,132,530, Antisense modulation of superoxide dismutase 1, soluble expression.
DM1IC54	RU	http://www.patentbuddy.com/Patent/7132530?ft=true&sr=true

DMPB3FH	DI	DMPB3FH
DMPB3FH	DN	ISIS 156449
DMPB3FH	MI	TTILUKB
DMPB3FH	MN	IRAK4 messenger RNA (IRAK4 mRNA)
DMPB3FH	MT	DTT
DMPB3FH	RN	US patent application no. 6,692,959, Antisense modulation of IL-1 receptor-associated kinase-4 expression.
DMPB3FH	RU	http://www.patentbuddy.com/Patent/6692959?ft=true&sr=true

DMPH2W7	DI	DMPH2W7
DMPH2W7	DN	ISIS 156451
DMPH2W7	MI	TTILUKB
DMPH2W7	MN	IRAK4 messenger RNA (IRAK4 mRNA)
DMPH2W7	MT	DTT
DMPH2W7	RN	US patent application no. 6,692,959, Antisense modulation of IL-1 receptor-associated kinase-4 expression.
DMPH2W7	RU	http://www.patentbuddy.com/Patent/6692959?ft=true&sr=true

DMCU6RF	DI	DMCU6RF
DMCU6RF	DN	ISIS 156452
DMCU6RF	MI	TTILUKB
DMCU6RF	MN	IRAK4 messenger RNA (IRAK4 mRNA)
DMCU6RF	MT	DTT
DMCU6RF	RN	US patent application no. 6,692,959, Antisense modulation of IL-1 receptor-associated kinase-4 expression.
DMCU6RF	RU	http://www.patentbuddy.com/Patent/6692959?ft=true&sr=true

DMQ9018	DI	DMQ9018
DMQ9018	DN	ISIS 156453
DMQ9018	MI	TTILUKB
DMQ9018	MN	IRAK4 messenger RNA (IRAK4 mRNA)
DMQ9018	MT	DTT
DMQ9018	RN	US patent application no. 6,692,959, Antisense modulation of IL-1 receptor-associated kinase-4 expression.
DMQ9018	RU	http://www.patentbuddy.com/Patent/6692959?ft=true&sr=true

DMM9ARP	DI	DMM9ARP
DMM9ARP	DN	ISIS 156471
DMM9ARP	MI	TTILUKB
DMM9ARP	MN	IRAK4 messenger RNA (IRAK4 mRNA)
DMM9ARP	MT	DTT
DMM9ARP	RN	US patent application no. 6,692,959, Antisense modulation of IL-1 receptor-associated kinase-4 expression.
DMM9ARP	RU	http://www.patentbuddy.com/Patent/6692959?ft=true&sr=true

DM3U0Z6	DI	DM3U0Z6
DM3U0Z6	DN	ISIS 156472
DM3U0Z6	MI	TTILUKB
DM3U0Z6	MN	IRAK4 messenger RNA (IRAK4 mRNA)
DM3U0Z6	MT	DTT
DM3U0Z6	RN	US patent application no. 6,692,959, Antisense modulation of IL-1 receptor-associated kinase-4 expression.
DM3U0Z6	RU	http://www.patentbuddy.com/Patent/6692959?ft=true&sr=true

DMDFUS8	DI	DMDFUS8
DMDFUS8	DN	ISIS 156473
DMDFUS8	MI	TTILUKB
DMDFUS8	MN	IRAK4 messenger RNA (IRAK4 mRNA)
DMDFUS8	MT	DTT
DMDFUS8	RN	US patent application no. 6,692,959, Antisense modulation of IL-1 receptor-associated kinase-4 expression.
DMDFUS8	RU	http://www.patentbuddy.com/Patent/6692959?ft=true&sr=true

DMCXP9T	DI	DMCXP9T
DMCXP9T	DN	ISIS 156474
DMCXP9T	MI	TTILUKB
DMCXP9T	MN	IRAK4 messenger RNA (IRAK4 mRNA)
DMCXP9T	MT	DTT
DMCXP9T	RN	US patent application no. 6,692,959, Antisense modulation of IL-1 receptor-associated kinase-4 expression.
DMCXP9T	RU	http://www.patentbuddy.com/Patent/6692959?ft=true&sr=true

DMNB4UJ	DI	DMNB4UJ
DMNB4UJ	DN	ISIS 156475
DMNB4UJ	MI	TTILUKB
DMNB4UJ	MN	IRAK4 messenger RNA (IRAK4 mRNA)
DMNB4UJ	MT	DTT
DMNB4UJ	RN	US patent application no. 6,692,959, Antisense modulation of IL-1 receptor-associated kinase-4 expression.
DMNB4UJ	RU	http://www.patentbuddy.com/Patent/6692959?ft=true&sr=true

DMJCXHM	DI	DMJCXHM
DMJCXHM	DN	ISIS 15770
DMJCXHM	MI	TTAN5W2
DMJCXHM	MN	Raf messenger RNA (Raf mRNA)
DMJCXHM	MT	DTT
DMJCXHM	RN	US patent application no. 7,425,545, Modulation of C-reactive protein expression.
DMJCXHM	RU	http://www.patentbuddy.com/Patent/7425545?ft=true&sr=true

DMAQ9EB	DI	DMAQ9EB
DMAQ9EB	DN	ISIS 15998
DMAQ9EB	MI	TTRE6AX
DMAQ9EB	MN	Bcl-x messenger RNA (BCL2L1 mRNA)
DMAQ9EB	MT	DTT
DMAQ9EB	RN	US patent application no. 7,148,204, Antisense modulation of bcl-x expression.
DMAQ9EB	RU	http://www.patentbuddy.com/Patent/7148204?ft=true&sr=true

DMMEP6J	DI	DMMEP6J
DMMEP6J	DN	ISIS 15999
DMMEP6J	MI	TTRE6AX
DMMEP6J	MN	Bcl-x messenger RNA (BCL2L1 mRNA)
DMMEP6J	MT	DTT
DMMEP6J	RN	US patent application no. 7,148,204, Antisense modulation of bcl-x expression.
DMMEP6J	RU	http://www.patentbuddy.com/Patent/7148204?ft=true&sr=true

DMDORHA	DI	DMDORHA
DMDORHA	DN	ISIS 16005
DMDORHA	MI	TTRE6AX
DMDORHA	MN	Bcl-x messenger RNA (BCL2L1 mRNA)
DMDORHA	MT	DTT
DMDORHA	RN	US patent application no. 7,148,204, Antisense modulation of bcl-x expression.
DMDORHA	RU	http://www.patentbuddy.com/Patent/7148204?ft=true&sr=true

DMBRKFC	DI	DMBRKFC
DMBRKFC	DN	ISIS 16009
DMBRKFC	MI	TTRE6AX
DMBRKFC	MN	Bcl-x messenger RNA (BCL2L1 mRNA)
DMBRKFC	MT	DTT
DMBRKFC	RN	US patent application no. 7,148,204, Antisense modulation of bcl-x expression.
DMBRKFC	RU	http://www.patentbuddy.com/Patent/7148204?ft=true&sr=true

DMZID0W	DI	DMZID0W
DMZID0W	DN	ISIS 16010
DMZID0W	MI	TTRE6AX
DMZID0W	MN	Bcl-x messenger RNA (BCL2L1 mRNA)
DMZID0W	MT	DTT
DMZID0W	RN	US patent application no. 7,148,204, Antisense modulation of bcl-x expression.
DMZID0W	RU	http://www.patentbuddy.com/Patent/7148204?ft=true&sr=true

DM7VQH8	DI	DM7VQH8
DM7VQH8	DN	ISIS 16108
DM7VQH8	MI	TTHMYB1
DM7VQH8	MN	E2A-Pbx1 messenger RNA (E2A-Pbx1 mRNA)
DM7VQH8	MT	DTT
DM7VQH8	RN	US patent application no. 6,607,915, Antisense inhibition of E2A-Pbx1 expression.
DM7VQH8	RU	http://www.patentbuddy.com/Patent/6607915?ft=true&sr=true

DMS7HQN	DI	DMS7HQN
DMS7HQN	DN	ISIS 16112
DMS7HQN	MI	TTHMYB1
DMS7HQN	MN	E2A-Pbx1 messenger RNA (E2A-Pbx1 mRNA)
DMS7HQN	MT	DTT
DMS7HQN	RN	US patent application no. 6,607,915, Antisense inhibition of E2A-Pbx1 expression.
DMS7HQN	RU	http://www.patentbuddy.com/Patent/6607915?ft=true&sr=true

DM71H65	DI	DM71H65
DM71H65	DN	ISIS 16121
DM71H65	MI	TTHMYB1
DM71H65	MN	E2A-Pbx1 messenger RNA (E2A-Pbx1 mRNA)
DM71H65	MT	DTT
DM71H65	RN	US patent application no. 6,607,915, Antisense inhibition of E2A-Pbx1 expression.
DM71H65	RU	http://www.patentbuddy.com/Patent/6607915?ft=true&sr=true

DM0AC3S	DI	DM0AC3S
DM0AC3S	DN	ISIS 16123
DM0AC3S	MI	TTHMYB1
DM0AC3S	MN	E2A-Pbx1 messenger RNA (E2A-Pbx1 mRNA)
DM0AC3S	MT	DTT
DM0AC3S	RN	US patent application no. 6,607,915, Antisense inhibition of E2A-Pbx1 expression.
DM0AC3S	RU	http://www.patentbuddy.com/Patent/6607915?ft=true&sr=true

DMYGOT7	DI	DMYGOT7
DMYGOT7	DN	ISIS 16124
DMYGOT7	MI	TTHMYB1
DMYGOT7	MN	E2A-Pbx1 messenger RNA (E2A-Pbx1 mRNA)
DMYGOT7	MT	DTT
DMYGOT7	RN	US patent application no. 6,607,915, Antisense inhibition of E2A-Pbx1 expression.
DMYGOT7	RU	http://www.patentbuddy.com/Patent/6607915?ft=true&sr=true

DMOTMVP	DI	DMOTMVP
DMOTMVP	DN	ISIS 16179
DMOTMVP	MI	TTO7014
DMOTMVP	MN	FasL messenger RNA (FASLG mRNA)
DMOTMVP	MT	DTT
DMOTMVP	RN	US patent application no. 6,204,055, Antisense inhibition of Fas mediated signaling.
DMOTMVP	RU	http://www.patentbuddy.com/Patent/6204055?ft=true&sr=true

DMK69ZR	DI	DMK69ZR
DMK69ZR	DN	ISIS 16507
DMK69ZR	MI	TT9TE0O
DMK69ZR	MN	Mdm2 messenger RNA (MDM2 mRNA)
DMK69ZR	MT	DTT
DMK69ZR	RN	US patent application no. 6,238,921, Antisense oligonucleotide modulation of human mdm2 expression.
DMK69ZR	RU	http://www.patentbuddy.com/Patent/6238921?ft=true&sr=true

DM24L0S	DI	DM24L0S
DM24L0S	DN	ISIS 16518
DM24L0S	MI	TT9TE0O
DM24L0S	MN	Mdm2 messenger RNA (MDM2 mRNA)
DM24L0S	MT	DTT
DM24L0S	RN	US patent application no. 6,238,921, Antisense oligonucleotide modulation of human mdm2 expression.
DM24L0S	RU	http://www.patentbuddy.com/Patent/6238921?ft=true&sr=true

DMXMHJV	DI	DMXMHJV
DMXMHJV	DN	ISIS 17020
DMXMHJV	MI	TT7LTUJ
DMXMHJV	MN	Fas messenger RNA (FAS mRNA)
DMXMHJV	MT	DTT
DMXMHJV	RN	US patent application no. 6,204,055, Antisense inhibition of Fas mediated signaling.
DMXMHJV	RU	http://www.patentbuddy.com/Patent/6204055?ft=true&sr=true

DMPZ9D3	DI	DMPZ9D3
DMPZ9D3	DN	ISIS 17148
DMPZ9D3	MI	TTHJT3X
DMPZ9D3	MN	STAT3 messenger RNA (STAT3 mRNA)
DMPZ9D3	MT	DTT
DMPZ9D3	RN	US patent application no. 7,098,192, Antisense oligonucleotide modulation of STAT3 expression.
DMPZ9D3	RU	http://www.patentbuddy.com/Patent/7098192?ft=true&sr=true

DME7VZG	DI	DME7VZG
DME7VZG	DN	ISIS 17152
DME7VZG	MI	TTHJT3X
DME7VZG	MN	STAT3 messenger RNA (STAT3 mRNA)
DME7VZG	MT	DTT
DME7VZG	RN	US patent application no. 7,098,192, Antisense oligonucleotide modulation of STAT3 expression.
DME7VZG	RU	http://www.patentbuddy.com/Patent/7098192?ft=true&sr=true

DMW40NK	DI	DMW40NK
DMW40NK	DN	ISIS 17252
DMW40NK	MI	TT7A1BO
DMW40NK	MN	PKC-delta messenger RNA (PRKCD mRNA)
DMW40NK	MT	DTT
DMW40NK	RN	US patent application no. 6,235,723, Antisense oligonucleotide modulation of human protein kinase C-.delta. expression.
DMW40NK	RU	http://www.patentbuddy.com/Patent/6235723?ft=true&sr=true

DM8ITFJ	DI	DM8ITFJ
DM8ITFJ	DN	ISIS 173813
DM8ITFJ	MI	TT9RTBL
DM8ITFJ	MN	Aurora B messenger RNA (AURKB mRNA)
DM8ITFJ	MT	DTT
DM8ITFJ	RN	US patent application no. 7,375,212, Modulation of Aurora B expression.
DM8ITFJ	RU	http://www.patentbuddy.com/Patent/7375212?ft=true&sr=true

DM9Y5NX	DI	DM9Y5NX
DM9Y5NX	DN	ISIS 173831
DM9Y5NX	MI	TT9RTBL
DM9Y5NX	MN	Aurora B messenger RNA (AURKB mRNA)
DM9Y5NX	MT	DTT
DM9Y5NX	RN	US patent application no. 7,375,212, Modulation of Aurora B expression.
DM9Y5NX	RU	http://www.patentbuddy.com/Patent/7375212?ft=true&sr=true

DMIU0QJ	DI	DMIU0QJ
DMIU0QJ	DN	ISIS 173840
DMIU0QJ	MI	TT9RTBL
DMIU0QJ	MN	Aurora B messenger RNA (AURKB mRNA)
DMIU0QJ	MT	DTT
DMIU0QJ	RN	US patent application no. 7,375,212, Modulation of Aurora B expression.
DMIU0QJ	RU	http://www.patentbuddy.com/Patent/7375212?ft=true&sr=true

DMSG1NI	DI	DMSG1NI
DMSG1NI	DN	ISIS 173848
DMSG1NI	MI	TT9RTBL
DMSG1NI	MN	Aurora B messenger RNA (AURKB mRNA)
DMSG1NI	MT	DTT
DMSG1NI	RN	US patent application no. 7,375,212, Modulation of Aurora B expression.
DMSG1NI	RU	http://www.patentbuddy.com/Patent/7375212?ft=true&sr=true

DMBFK8A	DI	DMBFK8A
DMBFK8A	DN	ISIS 1751
DMBFK8A	MI	TTF3I4E
DMBFK8A	MN	Human papillomavirus E2 region messenger RNA (HPV E2 mRNA)
DMBFK8A	MT	DTT
DMBFK8A	RN	US patent application no. 5,665,580, Antisense oligonucleotide inhibition of papillomavirus transformed cells.
DMBFK8A	RU	http://www.patentbuddy.com/Patent/5665580?ft=true&sr=true

DMKWT6F	DI	DMKWT6F
DMKWT6F	DN	ISIS 1753
DMKWT6F	MI	TTF3I4E
DMKWT6F	MN	Human papillomavirus E2 region messenger RNA (HPV E2 mRNA)
DMKWT6F	MT	DTT
DMKWT6F	RN	US patent application no. 5,665,580, Antisense oligonucleotide inhibition of papillomavirus transformed cells.
DMKWT6F	RU	http://www.patentbuddy.com/Patent/5665580?ft=true&sr=true

DMPAXR4	DI	DMPAXR4
DMPAXR4	DN	ISIS 175510
DMPAXR4	MI	TTSN6QU
DMPAXR4	MN	HIF1-alpha messenger RNA (HIF1A mRNA)
DMPAXR4	MT	DTT
DMPAXR4	RN	US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression.
DMPAXR4	RU	http://www.patentbuddy.com/Patent/7217572?ft=true&sr=true

DMHZPJ0	DI	DMHZPJ0
DMHZPJ0	DN	ISIS 18078
DMHZPJ0	MI	TT3IVG2
DMHZPJ0	MN	JNK2 messenger RNA (JNK2 mRNA)
DMHZPJ0	MT	DTT
DMHZPJ0	RN	US patent application no. 7,425,545, Modulation of C-reactive protein expression.
DMHZPJ0	RU	http://www.patentbuddy.com/Patent/7425545?ft=true&sr=true

DMQ5A4Y	DI	DMQ5A4Y
DMQ5A4Y	DN	ISIS 1820
DMQ5A4Y	MI	TTSJ6Q4
DMQ5A4Y	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DMQ5A4Y	MT	DTT
DMQ5A4Y	RN	US patent application no. 5,530,114, Oligonucleotide modulation of arachidonic acid metabolism.
DMQ5A4Y	RU	http://www.patentbuddy.com/Patent/5530114?ft=true&sr=true

DMUG2PN	DI	DMUG2PN
DMUG2PN	DN	ISIS 1821
DMUG2PN	MI	TTSJ6Q4
DMUG2PN	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DMUG2PN	MT	DTT
DMUG2PN	RN	US patent application no. 5,530,114, Oligonucleotide modulation of arachidonic acid metabolism.
DMUG2PN	RU	http://www.patentbuddy.com/Patent/5530114?ft=true&sr=true

DMLJBU8	DI	DMLJBU8
DMLJBU8	DN	ISIS 1822
DMLJBU8	MI	TTSJ6Q4
DMLJBU8	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DMLJBU8	MT	DTT
DMLJBU8	RN	US patent application no. 5,530,114, Oligonucleotide modulation of arachidonic acid metabolism.
DMLJBU8	RU	http://www.patentbuddy.com/Patent/5530114?ft=true&sr=true

DMPHWMO	DI	DMPHWMO
DMPHWMO	DN	ISIS 1827
DMPHWMO	MI	TTSJ6Q4
DMPHWMO	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DMPHWMO	MT	DTT
DMPHWMO	RN	US patent application no. 5,530,114, Oligonucleotide modulation of arachidonic acid metabolism.
DMPHWMO	RU	http://www.patentbuddy.com/Patent/5530114?ft=true&sr=true

DM1LWGI	DI	DM1LWGI
DM1LWGI	DN	ISIS 1831
DM1LWGI	MI	TTSJ6Q4
DM1LWGI	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DM1LWGI	MT	DTT
DM1LWGI	RN	US patent application no. 5,530,114, Oligonucleotide modulation of arachidonic acid metabolism.
DM1LWGI	RU	http://www.patentbuddy.com/Patent/5530114?ft=true&sr=true

DMOU9EP	DI	DMOU9EP
DMOU9EP	DN	ISIS 183881
DMOU9EP	MI	TTBGTCW
DMOU9EP	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DMOU9EP	MT	DTT
DMOU9EP	RN	US patent application no. 7,407,943, Antisense modulation of apolipoprotein B expression.
DMOU9EP	RU	http://www.patentbuddy.com/Patent/7407943?ft=true&sr=true

DMT3YI5	DI	DMT3YI5
DMT3YI5	DN	ISIS 183882
DMT3YI5	MI	TTBGTCW
DMT3YI5	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DMT3YI5	MT	DTT
DMT3YI5	RN	US patent application no. 7,163,927, Antisense modulation of kinesin-like 1 expression.
DMT3YI5	RU	http://www.patentbuddy.com/Patent/7163927?ft=true&sr=true

DMA46S1	DI	DMA46S1
DMA46S1	DN	ISIS 183883
DMA46S1	MI	TTBGTCW
DMA46S1	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DMA46S1	MT	DTT
DMA46S1	RN	US patent application no. 7,163,927, Antisense modulation of kinesin-like 1 expression.
DMA46S1	RU	http://www.patentbuddy.com/Patent/7163927?ft=true&sr=true

DMS172K	DI	DMS172K
DMS172K	DN	ISIS 183897
DMS172K	MI	TTBGTCW
DMS172K	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DMS172K	MT	DTT
DMS172K	RN	US patent application no. 7,163,927, Antisense modulation of kinesin-like 1 expression.
DMS172K	RU	http://www.patentbuddy.com/Patent/7163927?ft=true&sr=true

DMSEJZK	DI	DMSEJZK
DMSEJZK	DN	ISIS 183901
DMSEJZK	MI	TTBGTCW
DMSEJZK	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DMSEJZK	MT	DTT
DMSEJZK	RN	US patent application no. 7,163,927, Antisense modulation of kinesin-like 1 expression.
DMSEJZK	RU	http://www.patentbuddy.com/Patent/7163927?ft=true&sr=true

DMMQ2L7	DI	DMMQ2L7
DMMQ2L7	DN	ISIS 183910
DMMQ2L7	MI	TTBGTCW
DMMQ2L7	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DMMQ2L7	MT	DTT
DMMQ2L7	RN	US patent application no. 7,163,927, Antisense modulation of kinesin-like 1 expression.
DMMQ2L7	RU	http://www.patentbuddy.com/Patent/7163927?ft=true&sr=true

DMTB350	DI	DMTB350
DMTB350	DN	ISIS 183911
DMTB350	MI	TTBGTCW
DMTB350	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DMTB350	MT	DTT
DMTB350	RN	US patent application no. 7,163,927, Antisense modulation of kinesin-like 1 expression.
DMTB350	RU	http://www.patentbuddy.com/Patent/7163927?ft=true&sr=true

DM5QWED	DI	DM5QWED
DM5QWED	DN	ISIS 183912
DM5QWED	MI	TTBGTCW
DM5QWED	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DM5QWED	MT	DTT
DM5QWED	RN	US patent application no. 7,163,927, Antisense modulation of kinesin-like 1 expression.
DM5QWED	RU	http://www.patentbuddy.com/Patent/7163927?ft=true&sr=true

DMR6QNA	DI	DMR6QNA
DMR6QNA	DN	ISIS 18473
DMR6QNA	MI	TT405FP
DMR6QNA	MN	FAP-1 messenger RNA (PTPN13 mRNA)
DMR6QNA	MT	DTT
DMR6QNA	RN	US patent application no. 6,204,055, Antisense inhibition of Fas mediated signaling.
DMR6QNA	RU	http://www.patentbuddy.com/Patent/6204055?ft=true&sr=true

DM0BAX4	DI	DM0BAX4
DM0BAX4	DN	ISIS 188755
DM0BAX4	MI	TTLRVIA
DM0BAX4	MN	Forkhead box O1A messenger RNA (FOXO1 mRNA)
DM0BAX4	MT	DTT
DM0BAX4	RN	US patent application no. 7,229,976, Modulation of forkhead box O1A expression.
DM0BAX4	RU	http://www.patentbuddy.com/Patent/7229976?ft=true&sr=true

DMFTJD5	DI	DMFTJD5
DMFTJD5	DN	ISIS 188757
DMFTJD5	MI	TTLRVIA
DMFTJD5	MN	Forkhead box O1A messenger RNA (FOXO1 mRNA)
DMFTJD5	MT	DTT
DMFTJD5	RN	US patent application no. 7,229,976, Modulation of forkhead box O1A expression.
DMFTJD5	RU	http://www.patentbuddy.com/Patent/7229976?ft=true&sr=true

DMM8G03	DI	DMM8G03
DMM8G03	DN	ISIS 188759
DMM8G03	MI	TTLRVIA
DMM8G03	MN	Forkhead box O1A messenger RNA (FOXO1 mRNA)
DMM8G03	MT	DTT
DMM8G03	RN	US patent application no. 7,229,976, Modulation of forkhead box O1A expression.
DMM8G03	RU	http://www.patentbuddy.com/Patent/7229976?ft=true&sr=true

DMTY3N6	DI	DMTY3N6
DMTY3N6	DN	ISIS 188761
DMTY3N6	MI	TTLRVIA
DMTY3N6	MN	Forkhead box O1A messenger RNA (FOXO1 mRNA)
DMTY3N6	MT	DTT
DMTY3N6	RN	US patent application no. 7,229,976, Modulation of forkhead box O1A expression.
DMTY3N6	RU	http://www.patentbuddy.com/Patent/7229976?ft=true&sr=true

DMOJBHC	DI	DMOJBHC
DMOJBHC	DN	ISIS 188763
DMOJBHC	MI	TTLRVIA
DMOJBHC	MN	Forkhead box O1A messenger RNA (FOXO1 mRNA)
DMOJBHC	MT	DTT
DMOJBHC	RN	US patent application no. 7,229,976, Modulation of forkhead box O1A expression.
DMOJBHC	RU	http://www.patentbuddy.com/Patent/7229976?ft=true&sr=true

DMP9YD3	DI	DMP9YD3
DMP9YD3	DN	ISIS 188778
DMP9YD3	MI	TTLRVIA
DMP9YD3	MN	Forkhead box O1A messenger RNA (FOXO1 mRNA)
DMP9YD3	MT	DTT
DMP9YD3	RN	US patent application no. 7,229,976, Modulation of forkhead box O1A expression.
DMP9YD3	RU	http://www.patentbuddy.com/Patent/7229976?ft=true&sr=true

DMVZTU0	DI	DMVZTU0
DMVZTU0	DN	ISIS 188780
DMVZTU0	MI	TTLRVIA
DMVZTU0	MN	Forkhead box O1A messenger RNA (FOXO1 mRNA)
DMVZTU0	MT	DTT
DMVZTU0	RN	US patent application no. 7,229,976, Modulation of forkhead box O1A expression.
DMVZTU0	RU	http://www.patentbuddy.com/Patent/7229976?ft=true&sr=true

DMOYINM	DI	DMOYINM
DMOYINM	DN	ISIS 188781
DMOYINM	MI	TTLRVIA
DMOYINM	MN	Forkhead box O1A messenger RNA (FOXO1 mRNA)
DMOYINM	MT	DTT
DMOYINM	RN	US patent application no. 7,229,976, Modulation of forkhead box O1A expression.
DMOYINM	RU	http://www.patentbuddy.com/Patent/7229976?ft=true&sr=true

DM5O4L8	DI	DM5O4L8
DM5O4L8	DN	ISIS 188782
DM5O4L8	MI	TTLRVIA
DM5O4L8	MN	Forkhead box O1A messenger RNA (FOXO1 mRNA)
DM5O4L8	MT	DTT
DM5O4L8	RN	US patent application no. 7,229,976, Modulation of forkhead box O1A expression.
DM5O4L8	RU	http://www.patentbuddy.com/Patent/7229976?ft=true&sr=true

DMOQ27M	DI	DMOQ27M
DMOQ27M	DN	ISIS 191729
DMOQ27M	MI	TT0GV3R
DMOQ27M	MN	DGAT1 messenger RNA (DGAT1 mRNA)
DMOQ27M	MT	DTT
DMOQ27M	RN	US patent application no. 7,414,033, Modulation of diacylglycerol acyltransferase 1 expression.
DMOQ27M	RU	http://www.patentbuddy.com/Patent/7414033?ft=true&sr=true

DM52ZWB	DI	DM52ZWB
DM52ZWB	DN	ISIS 191731
DM52ZWB	MI	TT0GV3R
DM52ZWB	MN	DGAT1 messenger RNA (DGAT1 mRNA)
DM52ZWB	MT	DTT
DM52ZWB	RN	US patent application no. 7,414,033, Modulation of diacylglycerol acyltransferase 1 expression.
DM52ZWB	RU	http://www.patentbuddy.com/Patent/7414033?ft=true&sr=true

DMHWMFP	DI	DMHWMFP
DMHWMFP	DN	ISIS 191755
DMHWMFP	MI	TT0GV3R
DMHWMFP	MN	DGAT1 messenger RNA (DGAT1 mRNA)
DMHWMFP	MT	DTT
DMHWMFP	RN	US patent application no. 7,414,033, Modulation of diacylglycerol acyltransferase 1 expression.
DMHWMFP	RU	http://www.patentbuddy.com/Patent/7414033?ft=true&sr=true

DMQRZX8	DI	DMQRZX8
DMQRZX8	DN	ISIS 191756
DMQRZX8	MI	TT0GV3R
DMQRZX8	MN	DGAT1 messenger RNA (DGAT1 mRNA)
DMQRZX8	MT	DTT
DMQRZX8	RN	US patent application no. 7,414,033, Modulation of diacylglycerol acyltransferase 1 expression.
DMQRZX8	RU	http://www.patentbuddy.com/Patent/7414033?ft=true&sr=true

DMHPENR	DI	DMHPENR
DMHPENR	DN	ISIS 191759
DMHPENR	MI	TT0GV3R
DMHPENR	MN	DGAT1 messenger RNA (DGAT1 mRNA)
DMHPENR	MT	DTT
DMHPENR	RN	US patent application no. 7,414,033, Modulation of diacylglycerol acyltransferase 1 expression.
DMHPENR	RU	http://www.patentbuddy.com/Patent/7414033?ft=true&sr=true

DM0VAUR	DI	DM0VAUR
DM0VAUR	DN	ISIS 191761
DM0VAUR	MI	TT0GV3R
DM0VAUR	MN	DGAT1 messenger RNA (DGAT1 mRNA)
DM0VAUR	MT	DTT
DM0VAUR	RN	US patent application no. 7,414,033, Modulation of diacylglycerol acyltransferase 1 expression.
DM0VAUR	RU	http://www.patentbuddy.com/Patent/7414033?ft=true&sr=true

DMKFCD5	DI	DMKFCD5
DMKFCD5	DN	ISIS 19211
DMKFCD5	MI	TT1ERKL
DMKFCD5	MN	CD40 messenger RNA (CD40 mRNA)
DMKFCD5	MT	DTT
DMKFCD5	RN	US patent application no. 6,197,584, Antisense modulation of CD40 expression.
DMKFCD5	RU	http://www.patentbuddy.com/Patent/6197584?ft=true&sr=true

DMLQT5F	DI	DMLQT5F
DMLQT5F	DN	ISIS 19212
DMLQT5F	MI	TT1ERKL
DMLQT5F	MN	CD40 messenger RNA (CD40 mRNA)
DMLQT5F	MT	DTT
DMLQT5F	RN	US patent application no. 6,197,584, Antisense modulation of CD40 expression.
DMLQT5F	RU	http://www.patentbuddy.com/Patent/6197584?ft=true&sr=true

DMD1JVZ	DI	DMD1JVZ
DMD1JVZ	DN	ISIS 19213
DMD1JVZ	MI	TT1ERKL
DMD1JVZ	MN	CD40 messenger RNA (CD40 mRNA)
DMD1JVZ	MT	DTT
DMD1JVZ	RN	US patent application no. 6,197,584, Antisense modulation of CD40 expression.
DMD1JVZ	RU	http://www.patentbuddy.com/Patent/6197584?ft=true&sr=true

DMQK0AL	DI	DMQK0AL
DMQK0AL	DN	ISIS 19217
DMQK0AL	MI	TT1ERKL
DMQK0AL	MN	CD40 messenger RNA (CD40 mRNA)
DMQK0AL	MT	DTT
DMQK0AL	RN	US patent application no. 6,197,584, Antisense modulation of CD40 expression.
DMQK0AL	RU	http://www.patentbuddy.com/Patent/6197584?ft=true&sr=true

DMX4I5A	DI	DMX4I5A
DMX4I5A	DN	ISIS 19218
DMX4I5A	MI	TT1ERKL
DMX4I5A	MN	CD40 messenger RNA (CD40 mRNA)
DMX4I5A	MT	DTT
DMX4I5A	RN	US patent application no. 6,197,584, Antisense modulation of CD40 expression.
DMX4I5A	RU	http://www.patentbuddy.com/Patent/6197584?ft=true&sr=true

DMFAWGX	DI	DMFAWGX
DMFAWGX	DN	ISIS 19219
DMFAWGX	MI	TT1ERKL
DMFAWGX	MN	CD40 messenger RNA (CD40 mRNA)
DMFAWGX	MT	DTT
DMFAWGX	RN	US patent application no. 6,197,584, Antisense modulation of CD40 expression.
DMFAWGX	RU	http://www.patentbuddy.com/Patent/6197584?ft=true&sr=true

DMIKEXD	DI	DMIKEXD
DMIKEXD	DN	ISIS 19220
DMIKEXD	MI	TT1ERKL
DMIKEXD	MN	CD40 messenger RNA (CD40 mRNA)
DMIKEXD	MT	DTT
DMIKEXD	RN	US patent application no. 6,197,584, Antisense modulation of CD40 expression.
DMIKEXD	RU	http://www.patentbuddy.com/Patent/6197584?ft=true&sr=true

DMKOFNX	DI	DMKOFNX
DMKOFNX	DN	ISIS 19221
DMKOFNX	MI	TT1ERKL
DMKOFNX	MN	CD40 messenger RNA (CD40 mRNA)
DMKOFNX	MT	DTT
DMKOFNX	RN	US patent application no. 6,197,584, Antisense modulation of CD40 expression.
DMKOFNX	RU	http://www.patentbuddy.com/Patent/6197584?ft=true&sr=true

DMBMQNI	DI	DMBMQNI
DMBMQNI	DN	ISIS 1931
DMBMQNI	MI	TTA1L39
DMBMQNI	MN	ICAM1 messenger RNA (ICAM1 mRNA)
DMBMQNI	MT	DTT
DMBMQNI	RN	US patent application no. 6,300,491, Oligonucleotide inhibition of cell adhesion.
DMBMQNI	RU	http://www.patentbuddy.com/Patent/6300491?ft=true&sr=true

DM1NJD7	DI	DM1NJD7
DM1NJD7	DN	ISIS 196103
DM1NJD7	MI	TTJA1ZO
DM1NJD7	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DM1NJD7	MT	DTT
DM1NJD7	RN	US patent application no. 7,425,545, Modulation of C-reactive protein expression.
DM1NJD7	RU	http://www.patentbuddy.com/Patent/7425545?ft=true&sr=true

DMVOSN1	DI	DMVOSN1
DMVOSN1	DN	ISIS 19634
DMVOSN1	MI	TTWALCO
DMVOSN1	MN	HER4 messenger RNA (ERBB4 mRNA)
DMVOSN1	MT	DTT
DMVOSN1	RN	US patent application no. 6,255,111, Antisense modulation of Her-4 expression.
DMVOSN1	RU	http://www.patentbuddy.com/Patent/6255111?ft=true&sr=true

DMAW4OE	DI	DMAW4OE
DMAW4OE	DN	ISIS 19639
DMAW4OE	MI	TTWALCO
DMAW4OE	MN	HER4 messenger RNA (ERBB4 mRNA)
DMAW4OE	MT	DTT
DMAW4OE	RN	US patent application no. 6,255,111, Antisense modulation of Her-4 expression.
DMAW4OE	RU	http://www.patentbuddy.com/Patent/6255111?ft=true&sr=true

DMS5PZ0	DI	DMS5PZ0
DMS5PZ0	DN	ISIS 19647
DMS5PZ0	MI	TTWALCO
DMS5PZ0	MN	HER4 messenger RNA (ERBB4 mRNA)
DMS5PZ0	MT	DTT
DMS5PZ0	RN	US patent application no. 6,255,111, Antisense modulation of Her-4 expression.
DMS5PZ0	RU	http://www.patentbuddy.com/Patent/6255111?ft=true&sr=true

DMBEPGU	DI	DMBEPGU
DMBEPGU	DN	ISIS 19649
DMBEPGU	MI	TTWALCO
DMBEPGU	MN	HER4 messenger RNA (ERBB4 mRNA)
DMBEPGU	MT	DTT
DMBEPGU	RN	US patent application no. 6,255,111, Antisense modulation of Her-4 expression.
DMBEPGU	RU	http://www.patentbuddy.com/Patent/6255111?ft=true&sr=true

DMCZLK1	DI	DMCZLK1
DMCZLK1	DN	ISIS 19650
DMCZLK1	MI	TTWALCO
DMCZLK1	MN	HER4 messenger RNA (ERBB4 mRNA)
DMCZLK1	MT	DTT
DMCZLK1	RN	US patent application no. 6,255,111, Antisense modulation of Her-4 expression.
DMCZLK1	RU	http://www.patentbuddy.com/Patent/6255111?ft=true&sr=true

DM8O7EM	DI	DM8O7EM
DM8O7EM	DN	ISIS 19651
DM8O7EM	MI	TTWALCO
DM8O7EM	MN	HER4 messenger RNA (ERBB4 mRNA)
DM8O7EM	MT	DTT
DM8O7EM	RN	US patent application no. 6,255,111, Antisense modulation of Her-4 expression.
DM8O7EM	RU	http://www.patentbuddy.com/Patent/6255111?ft=true&sr=true

DMGIMH8	DI	DMGIMH8
DMGIMH8	DN	ISIS 19657
DMGIMH8	MI	TTWALCO
DMGIMH8	MN	HER4 messenger RNA (ERBB4 mRNA)
DMGIMH8	MT	DTT
DMGIMH8	RN	US patent application no. 6,255,111, Antisense modulation of Her-4 expression.
DMGIMH8	RU	http://www.patentbuddy.com/Patent/6255111?ft=true&sr=true

DM8WC4A	DI	DM8WC4A
DM8WC4A	DN	ISIS 19658
DM8WC4A	MI	TTWALCO
DM8WC4A	MN	HER4 messenger RNA (ERBB4 mRNA)
DM8WC4A	MT	DTT
DM8WC4A	RN	US patent application no. 6,255,111, Antisense modulation of Her-4 expression.
DM8WC4A	RU	http://www.patentbuddy.com/Patent/6255111?ft=true&sr=true

DMQ5UA3	DI	DMQ5UA3
DMQ5UA3	DN	ISIS 19659
DMQ5UA3	MI	TTWALCO
DMQ5UA3	MN	HER4 messenger RNA (ERBB4 mRNA)
DMQ5UA3	MT	DTT
DMQ5UA3	RN	US patent application no. 6,255,111, Antisense modulation of Her-4 expression.
DMQ5UA3	RU	http://www.patentbuddy.com/Patent/6255111?ft=true&sr=true

DMB5LNC	DI	DMB5LNC
DMB5LNC	DN	ISIS 19675
DMB5LNC	MI	TTWALCO
DMB5LNC	MN	HER4 messenger RNA (ERBB4 mRNA)
DMB5LNC	MT	DTT
DMB5LNC	RN	US patent application no. 6,255,111, Antisense modulation of Her-4 expression.
DMB5LNC	RU	http://www.patentbuddy.com/Patent/6255111?ft=true&sr=true

DMYEMST	DI	DMYEMST
DMYEMST	DN	ISIS 19676
DMYEMST	MI	TTWALCO
DMYEMST	MN	HER4 messenger RNA (ERBB4 mRNA)
DMYEMST	MT	DTT
DMYEMST	RN	US patent application no. 6,255,111, Antisense modulation of Her-4 expression.
DMYEMST	RU	http://www.patentbuddy.com/Patent/6255111?ft=true&sr=true

DMN0DR2	DI	DMN0DR2
DMN0DR2	DN	ISIS 19677
DMN0DR2	MI	TTWALCO
DMN0DR2	MN	HER4 messenger RNA (ERBB4 mRNA)
DMN0DR2	MT	DTT
DMN0DR2	RN	US patent application no. 6,255,111, Antisense modulation of Her-4 expression.
DMN0DR2	RU	http://www.patentbuddy.com/Patent/6255111?ft=true&sr=true

DM76H35	DI	DM76H35
DM76H35	DN	ISIS 20577
DM76H35	MI	TTSRXJW
DM76H35	MN	G-alpha-11 messenger RNA (GNA11 mRNA)
DM76H35	MT	DTT
DM76H35	RN	US patent application no. 5,951,455, Antisense modulation of G-alpha-11 expression.
DM76H35	RU	http://www.patentbuddy.com/Patent/5951455?ft=true&sr=true

DM6X9RQ	DI	DM6X9RQ
DM6X9RQ	DN	ISIS 20579
DM6X9RQ	MI	TTSRXJW
DM6X9RQ	MN	G-alpha-11 messenger RNA (GNA11 mRNA)
DM6X9RQ	MT	DTT
DM6X9RQ	RN	US patent application no. 5,951,455, Antisense modulation of G-alpha-11 expression.
DM6X9RQ	RU	http://www.patentbuddy.com/Patent/5951455?ft=true&sr=true

DMJRNWK	DI	DMJRNWK
DMJRNWK	DN	ISIS 20585
DMJRNWK	MI	TTSRXJW
DMJRNWK	MN	G-alpha-11 messenger RNA (GNA11 mRNA)
DMJRNWK	MT	DTT
DMJRNWK	RN	US patent application no. 5,951,455, Antisense modulation of G-alpha-11 expression.
DMJRNWK	RU	http://www.patentbuddy.com/Patent/5951455?ft=true&sr=true

DMHVQ0S	DI	DMHVQ0S
DMHVQ0S	DN	ISIS 20586
DMHVQ0S	MI	TTSRXJW
DMHVQ0S	MN	G-alpha-11 messenger RNA (GNA11 mRNA)
DMHVQ0S	MT	DTT
DMHVQ0S	RN	US patent application no. 5,951,455, Antisense modulation of G-alpha-11 expression.
DMHVQ0S	RU	http://www.patentbuddy.com/Patent/5951455?ft=true&sr=true

DMLWO70	DI	DMLWO70
DMLWO70	DN	ISIS 20990
DMLWO70	MI	TTSRXJW
DMLWO70	MN	G-alpha-11 messenger RNA (GNA11 mRNA)
DMLWO70	MT	DTT
DMLWO70	RN	US patent application no. 5,951,455, Antisense modulation of G-alpha-11 expression.
DMLWO70	RU	http://www.patentbuddy.com/Patent/5951455?ft=true&sr=true

DMFYDE4	DI	DMFYDE4
DMFYDE4	DN	ISIS 20993
DMFYDE4	MI	TTSRXJW
DMFYDE4	MN	G-alpha-11 messenger RNA (GNA11 mRNA)
DMFYDE4	MT	DTT
DMFYDE4	RN	US patent application no. 5,951,455, Antisense modulation of G-alpha-11 expression.
DMFYDE4	RU	http://www.patentbuddy.com/Patent/5951455?ft=true&sr=true

DM85EV7	DI	DM85EV7
DM85EV7	DN	ISIS 20994
DM85EV7	MI	TTSRXJW
DM85EV7	MN	G-alpha-11 messenger RNA (GNA11 mRNA)
DM85EV7	MT	DTT
DM85EV7	RN	US patent application no. 5,951,455, Antisense modulation of G-alpha-11 expression.
DM85EV7	RU	http://www.patentbuddy.com/Patent/5951455?ft=true&sr=true

DMCXVPG	DI	DMCXVPG
DMCXVPG	DN	ISIS 20995
DMCXVPG	MI	TTSRXJW
DMCXVPG	MN	G-alpha-11 messenger RNA (GNA11 mRNA)
DMCXVPG	MT	DTT
DMCXVPG	RN	US patent application no. 5,951,455, Antisense modulation of G-alpha-11 expression.
DMCXVPG	RU	http://www.patentbuddy.com/Patent/5951455?ft=true&sr=true

DM4VZPU	DI	DM4VZPU
DM4VZPU	DN	ISIS 2177
DM4VZPU	MI	TTSJ6Q4
DM4VZPU	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DM4VZPU	MT	DTT
DM4VZPU	RN	US patent application no. 5,530,114, Oligonucleotide modulation of arachidonic acid metabolism.
DM4VZPU	RU	http://www.patentbuddy.com/Patent/5530114?ft=true&sr=true

DMD7HA3	DI	DMD7HA3
DMD7HA3	DN	ISIS 222001
DMD7HA3	MI	TTWPA54
DMD7HA3	MN	HIF2-alpha messenger RNA (EPAS1 mRNA)
DMD7HA3	MT	DTT
DMD7HA3	RN	US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression.
DMD7HA3	RU	http://www.patentbuddy.com/Patent/7217572?ft=true&sr=true

DMQY2EA	DI	DMQY2EA
DMQY2EA	DN	ISIS 222035
DMQY2EA	MI	TTWPA54
DMQY2EA	MN	HIF2-alpha messenger RNA (EPAS1 mRNA)
DMQY2EA	MT	DTT
DMQY2EA	RN	US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression.
DMQY2EA	RU	http://www.patentbuddy.com/Patent/7217572?ft=true&sr=true

DMVL1SN	DI	DMVL1SN
DMVL1SN	DN	ISIS 222039
DMVL1SN	MI	TTWPA54
DMVL1SN	MN	HIF2-alpha messenger RNA (EPAS1 mRNA)
DMVL1SN	MT	DTT
DMVL1SN	RN	US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression.
DMVL1SN	RU	http://www.patentbuddy.com/Patent/7217572?ft=true&sr=true

DMS03TR	DI	DMS03TR
DMS03TR	DN	ISIS 222041
DMS03TR	MI	TTWPA54
DMS03TR	MN	HIF2-alpha messenger RNA (EPAS1 mRNA)
DMS03TR	MT	DTT
DMS03TR	RN	US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression.
DMS03TR	RU	http://www.patentbuddy.com/Patent/7217572?ft=true&sr=true

DM26M7E	DI	DM26M7E
DM26M7E	DN	ISIS 222043
DM26M7E	MI	TTWPA54
DM26M7E	MN	HIF2-alpha messenger RNA (EPAS1 mRNA)
DM26M7E	MT	DTT
DM26M7E	RN	US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression.
DM26M7E	RU	http://www.patentbuddy.com/Patent/7217572?ft=true&sr=true

DMREFCY	DI	DMREFCY
DMREFCY	DN	ISIS 2324
DMREFCY	MI	TTF3I4E
DMREFCY	MN	Human papillomavirus E2 region messenger RNA (HPV E2 mRNA)
DMREFCY	MT	DTT
DMREFCY	RN	US patent application no. 5,457,189, Antisense oligonucleotide inhibition of papillomavirus.
DMREFCY	RU	http://www.patentbuddy.com/Patent/5457189?ft=true&sr=true

DMYEPV8	DI	DMYEPV8
DMYEPV8	DN	ISIS 232828
DMYEPV8	MI	TTNBTCW
DMYEPV8	MN	eIF4E-BP2 messenger RNA (eIF4E-BP2 mRNA)
DMYEPV8	MT	DTT
DMYEPV8	RN	US patent application no. 7,468,431, Modulation of eIF4E-BP2 expression.
DMYEPV8	RU	http://www.patentbuddy.com/Patent/7468431?ft=true&sr=true

DMJ0LB1	DI	DMJ0LB1
DMJ0LB1	DN	ISIS 23412
DMJ0LB1	MI	TTAIWZN
DMJ0LB1	MN	Apoptosis-2 messenger RNA (BIRC3 mRNA)
DMJ0LB1	MT	DTT
DMJ0LB1	RN	US patent application no. 5,958,771, Antisense modulation of cellular inhibitor of Apoptosis-2 expression.
DMJ0LB1	RU	http://www.patentbuddy.com/Patent/5958771?ft=true&sr=true

DMOC0DT	DI	DMOC0DT
DMOC0DT	DN	ISIS 23414
DMOC0DT	MI	TTAIWZN
DMOC0DT	MN	Apoptosis-2 messenger RNA (BIRC3 mRNA)
DMOC0DT	MT	DTT
DMOC0DT	RN	US patent application no. 5,958,771, Antisense modulation of cellular inhibitor of Apoptosis-2 expression.
DMOC0DT	RU	http://www.patentbuddy.com/Patent/5958771?ft=true&sr=true

DMHQD76	DI	DMHQD76
DMHQD76	DN	ISIS 23416
DMHQD76	MI	TTAIWZN
DMHQD76	MN	Apoptosis-2 messenger RNA (BIRC3 mRNA)
DMHQD76	MT	DTT
DMHQD76	RN	US patent application no. 5,958,771, Antisense modulation of cellular inhibitor of Apoptosis-2 expression.
DMHQD76	RU	http://www.patentbuddy.com/Patent/5958771?ft=true&sr=true

DM17G39	DI	DM17G39
DM17G39	DN	ISIS 23452
DM17G39	MI	TTAIWZN
DM17G39	MN	Apoptosis-2 messenger RNA (BIRC3 mRNA)
DM17G39	MT	DTT
DM17G39	RN	US patent application no. 5,958,771, Antisense modulation of cellular inhibitor of Apoptosis-2 expression.
DM17G39	RU	http://www.patentbuddy.com/Patent/5958771?ft=true&sr=true

DM7FPZV	DI	DM7FPZV
DM7FPZV	DN	ISIS 23454
DM7FPZV	MI	TTAIWZN
DM7FPZV	MN	Apoptosis-2 messenger RNA (BIRC3 mRNA)
DM7FPZV	MT	DTT
DM7FPZV	RN	US patent application no. 5,958,771, Antisense modulation of cellular inhibitor of Apoptosis-2 expression.
DM7FPZV	RU	http://www.patentbuddy.com/Patent/5958771?ft=true&sr=true

DM4PGRU	DI	DM4PGRU
DM4PGRU	DN	ISIS 23459
DM4PGRU	MI	TTAIWZN
DM4PGRU	MN	Apoptosis-2 messenger RNA (BIRC3 mRNA)
DM4PGRU	MT	DTT
DM4PGRU	RN	US patent application no. 5,958,771, Antisense modulation of cellular inhibitor of Apoptosis-2 expression.
DM4PGRU	RU	http://www.patentbuddy.com/Patent/5958771?ft=true&sr=true

DMDHY37	DI	DMDHY37
DMDHY37	DN	ISIS 23544
DMDHY37	MI	TT1F8OQ
DMDHY37	MN	IKKA messenger RNA (IKKA mRNA)
DMDHY37	MT	DTT
DMDHY37	RN	US patent application no. 6,395,545, Antisense modulation of inhibitor-kappa B kinase-alpha expression.
DMDHY37	RU	http://www.patentbuddy.com/Patent/6395545?ft=true&sr=true

DM7NKRO	DI	DM7NKRO
DM7NKRO	DN	ISIS 23559
DM7NKRO	MI	TT1F8OQ
DM7NKRO	MN	IKKA messenger RNA (IKKA mRNA)
DM7NKRO	MT	DTT
DM7NKRO	RN	US patent application no. 6,395,545, Antisense modulation of inhibitor-kappa B kinase-alpha expression.
DM7NKRO	RU	http://www.patentbuddy.com/Patent/6395545?ft=true&sr=true

DM5LBQM	DI	DM5LBQM
DM5LBQM	DN	ISIS 23705
DM5LBQM	MI	TTEWOHV
DM5LBQM	MN	Survivin messenger RNA (Survivin mRNA)
DM5LBQM	MT	DTT
DM5LBQM	RN	US patent application no. 6,165,788, Antisense modulation of Survivin expression.
DM5LBQM	RU	http://www.patentbuddy.com/Patent/6165788?ft=true&sr=true

DMIK0GR	DI	DMIK0GR
DMIK0GR	DN	ISIS 23707
DMIK0GR	MI	TTEWOHV
DMIK0GR	MN	Survivin messenger RNA (Survivin mRNA)
DMIK0GR	MT	DTT
DMIK0GR	RN	US patent application no. 6,165,788, Antisense modulation of Survivin expression.
DMIK0GR	RU	http://www.patentbuddy.com/Patent/6165788?ft=true&sr=true

DM1SDN3	DI	DM1SDN3
DM1SDN3	DN	ISIS 23718
DM1SDN3	MI	TTEWOHV
DM1SDN3	MN	Survivin messenger RNA (Survivin mRNA)
DM1SDN3	MT	DTT
DM1SDN3	RN	US patent application no. 6,165,788, Antisense modulation of Survivin expression.
DM1SDN3	RU	http://www.patentbuddy.com/Patent/6165788?ft=true&sr=true

DMLHQ2J	DI	DMLHQ2J
DMLHQ2J	DN	ISIS 24448
DMLHQ2J	MI	TTJMF9P
DMLHQ2J	MN	ITGA4 messenger RNA (ITGA4 mRNA)
DMLHQ2J	MT	DTT
DMLHQ2J	RN	US patent application no. 6,258,790, Antisense modulation of integrin .alpha.4 expression.
DMLHQ2J	RU	http://www.patentbuddy.com/Patent/6258790?ft=true&sr=true

DM45WUZ	DI	DM45WUZ
DM45WUZ	DN	ISIS 24453
DM45WUZ	MI	TTJMF9P
DM45WUZ	MN	ITGA4 messenger RNA (ITGA4 mRNA)
DM45WUZ	MT	DTT
DM45WUZ	RN	US patent application no. 6,258,790, Antisense modulation of integrin .alpha.4 expression.
DM45WUZ	RU	http://www.patentbuddy.com/Patent/6258790?ft=true&sr=true

DMDE3J1	DI	DMDE3J1
DMDE3J1	DN	ISIS 24454
DMDE3J1	MI	TTJMF9P
DMDE3J1	MN	ITGA4 messenger RNA (ITGA4 mRNA)
DMDE3J1	MT	DTT
DMDE3J1	RN	US patent application no. 6,258,790, Antisense modulation of integrin .alpha.4 expression.
DMDE3J1	RU	http://www.patentbuddy.com/Patent/6258790?ft=true&sr=true

DMBKZOQ	DI	DMBKZOQ
DMBKZOQ	DN	ISIS 24475
DMBKZOQ	MI	TTJMF9P
DMBKZOQ	MN	ITGA4 messenger RNA (ITGA4 mRNA)
DMBKZOQ	MT	DTT
DMBKZOQ	RN	US patent application no. 6,258,790, Antisense modulation of integrin .alpha.4 expression.
DMBKZOQ	RU	http://www.patentbuddy.com/Patent/6258790?ft=true&sr=true

DMCNBIL	DI	DMCNBIL
DMCNBIL	DN	ISIS 24477
DMCNBIL	MI	TTJMF9P
DMCNBIL	MN	ITGA4 messenger RNA (ITGA4 mRNA)
DMCNBIL	MT	DTT
DMCNBIL	RN	US patent application no. 6,258,790, Antisense modulation of integrin .alpha.4 expression.
DMCNBIL	RU	http://www.patentbuddy.com/Patent/6258790?ft=true&sr=true

DMYEC3M	DI	DMYEC3M
DMYEC3M	DN	ISIS 2490
DMYEC3M	MI	TT7OU0X
DMYEC3M	MN	Human papillomavirus-18 E6 region messenger RNA (HPV-18 E6 mRNA)
DMYEC3M	MT	DTT
DMYEC3M	RN	US patent application no. 5,457,189, Antisense oligonucleotide inhibition of papillomavirus.
DMYEC3M	RU	http://www.patentbuddy.com/Patent/5457189?ft=true&sr=true

DMVI1D0	DI	DMVI1D0
DMVI1D0	DN	ISIS 2491
DMVI1D0	MI	TTWMK2G
DMVI1D0	MN	Human papillomavirus-18 E7 region messenger RNA (HPV-18 E7 mRNA)
DMVI1D0	MT	DTT
DMVI1D0	RN	US patent application no. 5,457,189, Antisense oligonucleotide inhibition of papillomavirus.
DMVI1D0	RU	http://www.patentbuddy.com/Patent/5457189?ft=true&sr=true

DMYTXBS	DI	DMYTXBS
DMYTXBS	DN	ISIS 2502
DMYTXBS	MI	TT28ZON
DMYTXBS	MN	H-ras messenger RNA (HRAS mRNA)
DMYTXBS	MT	DTT
DMYTXBS	RN	US patent application no. 5,965,722, Antisense inhibition of ras gene with chimeric and alternating oligonucleotides.
DMYTXBS	RU	http://www.patentbuddy.com/Patent/5965722?ft=true&sr=true

DMUMEST	DI	DMUMEST
DMUMEST	DN	ISIS 25073
DMUMEST	MI	TT8H9GB
DMUMEST	MN	MEK2 messenger RNA (MEK2 mRNA)
DMUMEST	MT	DTT
DMUMEST	RN	US patent application no. 5,959,097, Antisense modulation of MEK2 expression.
DMUMEST	RU	http://www.patentbuddy.com/Patent/5959097?ft=true&sr=true

DMM0GUN	DI	DMM0GUN
DMM0GUN	DN	ISIS 25074
DMM0GUN	MI	TT8H9GB
DMM0GUN	MN	MEK2 messenger RNA (MEK2 mRNA)
DMM0GUN	MT	DTT
DMM0GUN	RN	US patent application no. 5,959,097, Antisense modulation of MEK2 expression.
DMM0GUN	RU	http://www.patentbuddy.com/Patent/5959097?ft=true&sr=true

DM1EPLC	DI	DM1EPLC
DM1EPLC	DN	ISIS 25075
DM1EPLC	MI	TT8H9GB
DM1EPLC	MN	MEK2 messenger RNA (MEK2 mRNA)
DM1EPLC	MT	DTT
DM1EPLC	RN	US patent application no. 5,959,097, Antisense modulation of MEK2 expression.
DM1EPLC	RU	http://www.patentbuddy.com/Patent/5959097?ft=true&sr=true

DMSZRY0	DI	DMSZRY0
DMSZRY0	DN	ISIS 25078
DMSZRY0	MI	TT8H9GB
DMSZRY0	MN	MEK2 messenger RNA (MEK2 mRNA)
DMSZRY0	MT	DTT
DMSZRY0	RN	US patent application no. 5,959,097, Antisense modulation of MEK2 expression.
DMSZRY0	RU	http://www.patentbuddy.com/Patent/5959097?ft=true&sr=true

DMAKTCH	DI	DMAKTCH
DMAKTCH	DN	ISIS 25079
DMAKTCH	MI	TT8H9GB
DMAKTCH	MN	MEK2 messenger RNA (MEK2 mRNA)
DMAKTCH	MT	DTT
DMAKTCH	RN	US patent application no. 5,959,097, Antisense modulation of MEK2 expression.
DMAKTCH	RU	http://www.patentbuddy.com/Patent/5959097?ft=true&sr=true

DMEI28S	DI	DMEI28S
DMEI28S	DN	ISIS 25080
DMEI28S	MI	TT8H9GB
DMEI28S	MN	MEK2 messenger RNA (MEK2 mRNA)
DMEI28S	MT	DTT
DMEI28S	RN	US patent application no. 5,959,097, Antisense modulation of MEK2 expression.
DMEI28S	RU	http://www.patentbuddy.com/Patent/5959097?ft=true&sr=true

DM4AZG9	DI	DM4AZG9
DM4AZG9	DN	ISIS 25081
DM4AZG9	MI	TT8H9GB
DM4AZG9	MN	MEK2 messenger RNA (MEK2 mRNA)
DM4AZG9	MT	DTT
DM4AZG9	RN	US patent application no. 5,959,097, Antisense modulation of MEK2 expression.
DM4AZG9	RU	http://www.patentbuddy.com/Patent/5959097?ft=true&sr=true

DM04CUL	DI	DM04CUL
DM04CUL	DN	ISIS 25082
DM04CUL	MI	TT8H9GB
DM04CUL	MN	MEK2 messenger RNA (MEK2 mRNA)
DM04CUL	MT	DTT
DM04CUL	RN	US patent application no. 5,959,097, Antisense modulation of MEK2 expression.
DM04CUL	RU	http://www.patentbuddy.com/Patent/5959097?ft=true&sr=true

DM3IR7W	DI	DM3IR7W
DM3IR7W	DN	ISIS 25113
DM3IR7W	MI	TT8H9GB
DM3IR7W	MN	MEK2 messenger RNA (MEK2 mRNA)
DM3IR7W	MT	DTT
DM3IR7W	RN	US patent application no. 5,959,097, Antisense modulation of MEK2 expression.
DM3IR7W	RU	http://www.patentbuddy.com/Patent/5959097?ft=true&sr=true

DMG6SYP	DI	DMG6SYP
DMG6SYP	DN	ISIS 25114
DMG6SYP	MI	TT8H9GB
DMG6SYP	MN	MEK2 messenger RNA (MEK2 mRNA)
DMG6SYP	MT	DTT
DMG6SYP	RN	US patent application no. 5,959,097, Antisense modulation of MEK2 expression.
DMG6SYP	RU	http://www.patentbuddy.com/Patent/5959097?ft=true&sr=true

DMDH943	DI	DMDH943
DMDH943	DN	ISIS 25115
DMDH943	MI	TT8H9GB
DMDH943	MN	MEK2 messenger RNA (MEK2 mRNA)
DMDH943	MT	DTT
DMDH943	RN	US patent application no. 5,959,097, Antisense modulation of MEK2 expression.
DMDH943	RU	http://www.patentbuddy.com/Patent/5959097?ft=true&sr=true

DM8AHJC	DI	DM8AHJC
DM8AHJC	DN	ISIS 25116
DM8AHJC	MI	TT8H9GB
DM8AHJC	MN	MEK2 messenger RNA (MEK2 mRNA)
DM8AHJC	MT	DTT
DM8AHJC	RN	US patent application no. 5,959,097, Antisense modulation of MEK2 expression.
DM8AHJC	RU	http://www.patentbuddy.com/Patent/5959097?ft=true&sr=true

DMAN94P	DI	DMAN94P
DMAN94P	DN	ISIS 25117
DMAN94P	MI	TT8H9GB
DMAN94P	MN	MEK2 messenger RNA (MEK2 mRNA)
DMAN94P	MT	DTT
DMAN94P	RN	US patent application no. 5,959,097, Antisense modulation of MEK2 expression.
DMAN94P	RU	http://www.patentbuddy.com/Patent/5959097?ft=true&sr=true

DMA7KV8	DI	DMA7KV8
DMA7KV8	DN	ISIS 25118
DMA7KV8	MI	TT8H9GB
DMA7KV8	MN	MEK2 messenger RNA (MEK2 mRNA)
DMA7KV8	MT	DTT
DMA7KV8	RN	US patent application no. 5,959,097, Antisense modulation of MEK2 expression.
DMA7KV8	RU	http://www.patentbuddy.com/Patent/5959097?ft=true&sr=true

DMFQO21	DI	DMFQO21
DMFQO21	DN	ISIS 25123
DMFQO21	MI	TT8H9GB
DMFQO21	MN	MEK2 messenger RNA (MEK2 mRNA)
DMFQO21	MT	DTT
DMFQO21	RN	US patent application no. 5,959,097, Antisense modulation of MEK2 expression.
DMFQO21	RU	http://www.patentbuddy.com/Patent/5959097?ft=true&sr=true

DMEI8L2	DI	DMEI8L2
DMEI8L2	DN	ISIS 25124
DMEI8L2	MI	TT8H9GB
DMEI8L2	MN	MEK2 messenger RNA (MEK2 mRNA)
DMEI8L2	MT	DTT
DMEI8L2	RN	US patent application no. 5,959,097, Antisense modulation of MEK2 expression.
DMEI8L2	RU	http://www.patentbuddy.com/Patent/5959097?ft=true&sr=true

DML2F3N	DI	DML2F3N
DML2F3N	DN	ISIS 25125
DML2F3N	MI	TT8H9GB
DML2F3N	MN	MEK2 messenger RNA (MEK2 mRNA)
DML2F3N	MT	DTT
DML2F3N	RN	US patent application no. 5,959,097, Antisense modulation of MEK2 expression.
DML2F3N	RU	http://www.patentbuddy.com/Patent/5959097?ft=true&sr=true

DM8K4DP	DI	DM8K4DP
DM8K4DP	DN	ISIS 25126
DM8K4DP	MI	TT8H9GB
DM8K4DP	MN	MEK2 messenger RNA (MEK2 mRNA)
DM8K4DP	MT	DTT
DM8K4DP	RN	US patent application no. 5,959,097, Antisense modulation of MEK2 expression.
DM8K4DP	RU	http://www.patentbuddy.com/Patent/5959097?ft=true&sr=true

DM6AQ2X	DI	DM6AQ2X
DM6AQ2X	DN	ISIS 25127
DM6AQ2X	MI	TT8H9GB
DM6AQ2X	MN	MEK2 messenger RNA (MEK2 mRNA)
DM6AQ2X	MT	DTT
DM6AQ2X	RN	US patent application no. 5,959,097, Antisense modulation of MEK2 expression.
DM6AQ2X	RU	http://www.patentbuddy.com/Patent/5959097?ft=true&sr=true

DMH3C01	DI	DMH3C01
DMH3C01	DN	ISIS 25128
DMH3C01	MI	TT8H9GB
DMH3C01	MN	MEK2 messenger RNA (MEK2 mRNA)
DMH3C01	MT	DTT
DMH3C01	RN	US patent application no. 5,959,097, Antisense modulation of MEK2 expression.
DMH3C01	RU	http://www.patentbuddy.com/Patent/5959097?ft=true&sr=true

DMD75MP	DI	DMD75MP
DMD75MP	DN	ISIS 25237
DMD75MP	MI	TTJA1ZO
DMD75MP	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMD75MP	MT	DTT
DMD75MP	RN	US patent application no. 7,425,545, Modulation of C-reactive protein expression.
DMD75MP	RU	http://www.patentbuddy.com/Patent/7425545?ft=true&sr=true

DMB9DWH	DI	DMB9DWH
DMB9DWH	DN	ISIS 25544
DMB9DWH	MI	TTP2U16
DMB9DWH	MN	RhoA messenger RNA (RHOA mRNA)
DMB9DWH	MT	DTT
DMB9DWH	RN	US patent application no. 5,945,290, Antisense modulation of RhoA expression.
DMB9DWH	RU	http://www.patentbuddy.com/Patent/5945290?ft=true&sr=true

DM4P15C	DI	DM4P15C
DM4P15C	DN	ISIS 25547
DM4P15C	MI	TTP2U16
DM4P15C	MN	RhoA messenger RNA (RHOA mRNA)
DM4P15C	MT	DTT
DM4P15C	RN	US patent application no. 5,945,290, Antisense modulation of RhoA expression.
DM4P15C	RU	http://www.patentbuddy.com/Patent/5945290?ft=true&sr=true

DMWXQPG	DI	DMWXQPG
DMWXQPG	DN	ISIS 25549
DMWXQPG	MI	TTP2U16
DMWXQPG	MN	RhoA messenger RNA (RHOA mRNA)
DMWXQPG	MT	DTT
DMWXQPG	RN	US patent application no. 5,945,290, Antisense modulation of RhoA expression.
DMWXQPG	RU	http://www.patentbuddy.com/Patent/5945290?ft=true&sr=true

DM41B62	DI	DM41B62
DM41B62	DN	ISIS 25551
DM41B62	MI	TTP2U16
DM41B62	MN	RhoA messenger RNA (RHOA mRNA)
DM41B62	MT	DTT
DM41B62	RN	US patent application no. 5,945,290, Antisense modulation of RhoA expression.
DM41B62	RU	http://www.patentbuddy.com/Patent/5945290?ft=true&sr=true

DMO8IVA	DI	DMO8IVA
DMO8IVA	DN	ISIS 25552
DMO8IVA	MI	TTP2U16
DMO8IVA	MN	RhoA messenger RNA (RHOA mRNA)
DMO8IVA	MT	DTT
DMO8IVA	RN	US patent application no. 5,945,290, Antisense modulation of RhoA expression.
DMO8IVA	RU	http://www.patentbuddy.com/Patent/5945290?ft=true&sr=true

DM5PXN4	DI	DM5PXN4
DM5PXN4	DN	ISIS 25554
DM5PXN4	MI	TTP2U16
DM5PXN4	MN	RhoA messenger RNA (RHOA mRNA)
DM5PXN4	MT	DTT
DM5PXN4	RN	US patent application no. 5,945,290, Antisense modulation of RhoA expression.
DM5PXN4	RU	http://www.patentbuddy.com/Patent/5945290?ft=true&sr=true

DMBI2PH	DI	DMBI2PH
DMBI2PH	DN	ISIS 25563
DMBI2PH	MI	TTP2U16
DMBI2PH	MN	RhoA messenger RNA (RHOA mRNA)
DMBI2PH	MT	DTT
DMBI2PH	RN	US patent application no. 5,945,290, Antisense modulation of RhoA expression.
DMBI2PH	RU	http://www.patentbuddy.com/Patent/5945290?ft=true&sr=true

DMMZW8J	DI	DMMZW8J
DMMZW8J	DN	ISIS 25564
DMMZW8J	MI	TTP2U16
DMMZW8J	MN	RhoA messenger RNA (RHOA mRNA)
DMMZW8J	MT	DTT
DMMZW8J	RN	US patent application no. 5,945,290, Antisense modulation of RhoA expression.
DMMZW8J	RU	http://www.patentbuddy.com/Patent/5945290?ft=true&sr=true

DMB0CJ4	DI	DMB0CJ4
DMB0CJ4	DN	ISIS 25565
DMB0CJ4	MI	TTP2U16
DMB0CJ4	MN	RhoA messenger RNA (RHOA mRNA)
DMB0CJ4	MT	DTT
DMB0CJ4	RN	US patent application no. 5,945,290, Antisense modulation of RhoA expression.
DMB0CJ4	RU	http://www.patentbuddy.com/Patent/5945290?ft=true&sr=true

DMUR2TH	DI	DMUR2TH
DMUR2TH	DN	ISIS 25566
DMUR2TH	MI	TTP2U16
DMUR2TH	MN	RhoA messenger RNA (RHOA mRNA)
DMUR2TH	MT	DTT
DMUR2TH	RN	US patent application no. 5,945,290, Antisense modulation of RhoA expression.
DMUR2TH	RU	http://www.patentbuddy.com/Patent/5945290?ft=true&sr=true

DMX72T6	DI	DMX72T6
DMX72T6	DN	ISIS 25567
DMX72T6	MI	TTP2U16
DMX72T6	MN	RhoA messenger RNA (RHOA mRNA)
DMX72T6	MT	DTT
DMX72T6	RN	US patent application no. 5,945,290, Antisense modulation of RhoA expression.
DMX72T6	RU	http://www.patentbuddy.com/Patent/5945290?ft=true&sr=true

DMRUEM8	DI	DMRUEM8
DMRUEM8	DN	ISIS 2674
DMRUEM8	MI	TT1PL7M
DMRUEM8	MN	E-selectin messenger RNA (SELE mRNA)
DMRUEM8	MT	DTT
DMRUEM8	RN	US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion.
DMRUEM8	RU	http://www.patentbuddy.com/Patent/5843738?ft=true&sr=true

DMZP5VG	DI	DMZP5VG
DMZP5VG	DN	ISIS 2678
DMZP5VG	MI	TT1PL7M
DMZP5VG	MN	E-selectin messenger RNA (SELE mRNA)
DMZP5VG	MT	DTT
DMZP5VG	RN	US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion.
DMZP5VG	RU	http://www.patentbuddy.com/Patent/5843738?ft=true&sr=true

DM78BDU	DI	DM78BDU
DM78BDU	DN	ISIS 2686
DM78BDU	MI	TT1PL7M
DM78BDU	MN	E-selectin messenger RNA (SELE mRNA)
DM78BDU	MT	DTT
DM78BDU	RN	US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion.
DM78BDU	RU	http://www.patentbuddy.com/Patent/5843738?ft=true&sr=true

DMGMKH3	DI	DMGMKH3
DMGMKH3	DN	ISIS 28405
DMGMKH3	MI	TT9GR53
DMGMKH3	MN	Smad1 messenger RNA (SMAD1 mRNA)
DMGMKH3	MT	DTT
DMGMKH3	RN	US patent application no. 6,159,697, Antisense modulation of Smad7 expression.
DMGMKH3	RU	http://www.patentbuddy.com/Patent/6159697?ft=true&sr=true

DMXKRWN	DI	DMXKRWN
DMXKRWN	DN	ISIS 28407
DMXKRWN	MI	TT9GR53
DMXKRWN	MN	Smad1 messenger RNA (SMAD1 mRNA)
DMXKRWN	MT	DTT
DMXKRWN	RN	US patent application no. 6,159,697, Antisense modulation of Smad7 expression.
DMXKRWN	RU	http://www.patentbuddy.com/Patent/6159697?ft=true&sr=true

DMR24BS	DI	DMR24BS
DMR24BS	DN	ISIS 28425
DMR24BS	MI	TT9GR53
DMR24BS	MN	Smad1 messenger RNA (SMAD1 mRNA)
DMR24BS	MT	DTT
DMR24BS	RN	US patent application no. 6,159,697, Antisense modulation of Smad7 expression.
DMR24BS	RU	http://www.patentbuddy.com/Patent/6159697?ft=true&sr=true

DMQ5JNT	DI	DMQ5JNT
DMQ5JNT	DN	ISIS 28465
DMQ5JNT	MI	TT0J32Z
DMQ5JNT	MN	Smad7 messenger RNA (Smad7 mRNA)
DMQ5JNT	MT	DTT
DMQ5JNT	RN	US patent application no. 6,159,697, Antisense modulation of Smad7 expression.
DMQ5JNT	RU	http://www.patentbuddy.com/Patent/6159697?ft=true&sr=true

DMH96UP	DI	DMH96UP
DMH96UP	DN	ISIS 28466
DMH96UP	MI	TT0J32Z
DMH96UP	MN	Smad7 messenger RNA (Smad7 mRNA)
DMH96UP	MT	DTT
DMH96UP	RN	US patent application no. 6,159,697, Antisense modulation of Smad7 expression.
DMH96UP	RU	http://www.patentbuddy.com/Patent/6159697?ft=true&sr=true

DMA4U2P	DI	DMA4U2P
DMA4U2P	DN	ISIS 28472
DMA4U2P	MI	TT0J32Z
DMA4U2P	MN	Smad7 messenger RNA (Smad7 mRNA)
DMA4U2P	MT	DTT
DMA4U2P	RN	US patent application no. 6,159,697, Antisense modulation of Smad7 expression.
DMA4U2P	RU	http://www.patentbuddy.com/Patent/6159697?ft=true&sr=true

DMMOV9U	DI	DMMOV9U
DMMOV9U	DN	ISIS 28477
DMMOV9U	MI	TT0J32Z
DMMOV9U	MN	Smad7 messenger RNA (Smad7 mRNA)
DMMOV9U	MT	DTT
DMMOV9U	RN	US patent application no. 6,159,697, Antisense modulation of Smad7 expression.
DMMOV9U	RU	http://www.patentbuddy.com/Patent/6159697?ft=true&sr=true

DMECMA6	DI	DMECMA6
DMECMA6	DN	ISIS 29112
DMECMA6	MI	TTO6SGY
DMECMA6	MN	AKT3 messenger RNA (AKT3 mRNA)
DMECMA6	MT	DTT
DMECMA6	RN	US patent application no. 6,187,586, Antisense modulation of AKT-3 expression.
DMECMA6	RU	http://www.patentbuddy.com/Patent/6187586?ft=true&sr=true

DMGJURC	DI	DMGJURC
DMGJURC	DN	ISIS 29135
DMGJURC	MI	TTO6SGY
DMGJURC	MN	AKT3 messenger RNA (AKT3 mRNA)
DMGJURC	MT	DTT
DMGJURC	RN	US patent application no. 6,187,586, Antisense modulation of AKT-3 expression.
DMGJURC	RU	http://www.patentbuddy.com/Patent/6187586?ft=true&sr=true

DMAMTLR	DI	DMAMTLR
DMAMTLR	DN	ISIS 29136
DMAMTLR	MI	TTO6SGY
DMAMTLR	MN	AKT3 messenger RNA (AKT3 mRNA)
DMAMTLR	MT	DTT
DMAMTLR	RN	US patent application no. 6,187,586, Antisense modulation of AKT-3 expression.
DMAMTLR	RU	http://www.patentbuddy.com/Patent/6187586?ft=true&sr=true

DMAR1D6	DI	DMAR1D6
DMAR1D6	DN	ISIS 29137
DMAR1D6	MI	TTO6SGY
DMAR1D6	MN	AKT3 messenger RNA (AKT3 mRNA)
DMAR1D6	MT	DTT
DMAR1D6	RN	US patent application no. 6,187,586, Antisense modulation of AKT-3 expression.
DMAR1D6	RU	http://www.patentbuddy.com/Patent/6187586?ft=true&sr=true

DMBY1RS	DI	DMBY1RS
DMBY1RS	DN	ISIS 29138
DMBY1RS	MI	TTO6SGY
DMBY1RS	MN	AKT3 messenger RNA (AKT3 mRNA)
DMBY1RS	MT	DTT
DMBY1RS	RN	US patent application no. 6,187,586, Antisense modulation of AKT-3 expression.
DMBY1RS	RU	http://www.patentbuddy.com/Patent/6187586?ft=true&sr=true

DM2K0RD	DI	DM2K0RD
DM2K0RD	DN	ISIS 29139
DM2K0RD	MI	TTO6SGY
DM2K0RD	MN	AKT3 messenger RNA (AKT3 mRNA)
DM2K0RD	MT	DTT
DM2K0RD	RN	US patent application no. 6,187,586, Antisense modulation of AKT-3 expression.
DM2K0RD	RU	http://www.patentbuddy.com/Patent/6187586?ft=true&sr=true

DMT9F15	DI	DMT9F15
DMT9F15	DN	ISIS 29154
DMT9F15	MI	TTO6SGY
DMT9F15	MN	AKT3 messenger RNA (AKT3 mRNA)
DMT9F15	MT	DTT
DMT9F15	RN	US patent application no. 6,187,586, Antisense modulation of AKT-3 expression.
DMT9F15	RU	http://www.patentbuddy.com/Patent/6187586?ft=true&sr=true

DMSVN1B	DI	DMSVN1B
DMSVN1B	DN	ISIS 29155
DMSVN1B	MI	TTO6SGY
DMSVN1B	MN	AKT3 messenger RNA (AKT3 mRNA)
DMSVN1B	MT	DTT
DMSVN1B	RN	US patent application no. 6,187,586, Antisense modulation of AKT-3 expression.
DMSVN1B	RU	http://www.patentbuddy.com/Patent/6187586?ft=true&sr=true

DMD8KXB	DI	DMD8KXB
DMD8KXB	DN	ISIS 29156
DMD8KXB	MI	TTO6SGY
DMD8KXB	MN	AKT3 messenger RNA (AKT3 mRNA)
DMD8KXB	MT	DTT
DMD8KXB	RN	US patent application no. 6,187,586, Antisense modulation of AKT-3 expression.
DMD8KXB	RU	http://www.patentbuddy.com/Patent/6187586?ft=true&sr=true

DMLE1IJ	DI	DMLE1IJ
DMLE1IJ	DN	ISIS 29159
DMLE1IJ	MI	TTO6SGY
DMLE1IJ	MN	AKT3 messenger RNA (AKT3 mRNA)
DMLE1IJ	MT	DTT
DMLE1IJ	RN	US patent application no. 6,187,586, Antisense modulation of AKT-3 expression.
DMLE1IJ	RU	http://www.patentbuddy.com/Patent/6187586?ft=true&sr=true

DM9NB1A	DI	DM9NB1A
DM9NB1A	DN	ISIS 29160
DM9NB1A	MI	TTO6SGY
DM9NB1A	MN	AKT3 messenger RNA (AKT3 mRNA)
DM9NB1A	MT	DTT
DM9NB1A	RN	US patent application no. 6,187,586, Antisense modulation of AKT-3 expression.
DM9NB1A	RU	http://www.patentbuddy.com/Patent/6187586?ft=true&sr=true

DMPS6OQ	DI	DMPS6OQ
DMPS6OQ	DN	ISIS 29161
DMPS6OQ	MI	TTO6SGY
DMPS6OQ	MN	AKT3 messenger RNA (AKT3 mRNA)
DMPS6OQ	MT	DTT
DMPS6OQ	RN	US patent application no. 6,187,586, Antisense modulation of AKT-3 expression.
DMPS6OQ	RU	http://www.patentbuddy.com/Patent/6187586?ft=true&sr=true

DMVLU5J	DI	DMVLU5J
DMVLU5J	DN	ISIS 29176
DMVLU5J	MI	TTO6SGY
DMVLU5J	MN	AKT3 messenger RNA (AKT3 mRNA)
DMVLU5J	MT	DTT
DMVLU5J	RN	US patent application no. 6,187,586, Antisense modulation of AKT-3 expression.
DMVLU5J	RU	http://www.patentbuddy.com/Patent/6187586?ft=true&sr=true

DMSUWVE	DI	DMSUWVE
DMSUWVE	DN	ISIS 29177
DMSUWVE	MI	TTO6SGY
DMSUWVE	MN	AKT3 messenger RNA (AKT3 mRNA)
DMSUWVE	MT	DTT
DMSUWVE	RN	US patent application no. 6,187,586, Antisense modulation of AKT-3 expression.
DMSUWVE	RU	http://www.patentbuddy.com/Patent/6187586?ft=true&sr=true

DMTE7BJ	DI	DMTE7BJ
DMTE7BJ	DN	ISIS 29178
DMTE7BJ	MI	TTO6SGY
DMTE7BJ	MN	AKT3 messenger RNA (AKT3 mRNA)
DMTE7BJ	MT	DTT
DMTE7BJ	RN	US patent application no. 6,187,586, Antisense modulation of AKT-3 expression.
DMTE7BJ	RU	http://www.patentbuddy.com/Patent/6187586?ft=true&sr=true

DMJTHXY	DI	DMJTHXY
DMJTHXY	DN	ISIS 2918
DMJTHXY	MI	TT4SCBE
DMJTHXY	MN	Cytomegalovirus IE2 region messenger RNA (CMV IE2 mRNA)
DMJTHXY	MT	DTT
DMJTHXY	RN	US patent application no. 5,442,049, Oligonucleotides for modulating the effects of cytomegalovirus infections.
DMJTHXY	RU	http://www.patentbuddy.com/Patent/5442049?ft=true&sr=true

DMVMF5X	DI	DMVMF5X
DMVMF5X	DN	ISIS 2919
DMVMF5X	MI	TT4SCBE
DMVMF5X	MN	Cytomegalovirus IE2 region messenger RNA (CMV IE2 mRNA)
DMVMF5X	MT	DTT
DMVMF5X	RN	US patent application no. 5,442,049, Oligonucleotides for modulating the effects of cytomegalovirus infections.
DMVMF5X	RU	http://www.patentbuddy.com/Patent/5442049?ft=true&sr=true

DMJFLK0	DI	DMJFLK0
DMJFLK0	DN	ISIS 2920
DMJFLK0	MI	TT4SCBE
DMJFLK0	MN	Cytomegalovirus IE2 region messenger RNA (CMV IE2 mRNA)
DMJFLK0	MT	DTT
DMJFLK0	RN	US patent application no. 5,442,049, Oligonucleotides for modulating the effects of cytomegalovirus infections.
DMJFLK0	RU	http://www.patentbuddy.com/Patent/5442049?ft=true&sr=true

DMN1LHI	DI	DMN1LHI
DMN1LHI	DN	ISIS 29200
DMN1LHI	MI	TTO6SGY
DMN1LHI	MN	AKT3 messenger RNA (AKT3 mRNA)
DMN1LHI	MT	DTT
DMN1LHI	RN	US patent application no. 6,187,586, Antisense modulation of AKT-3 expression.
DMN1LHI	RU	http://www.patentbuddy.com/Patent/6187586?ft=true&sr=true

DMSKVWG	DI	DMSKVWG
DMSKVWG	DN	ISIS 29201
DMSKVWG	MI	TTO6SGY
DMSKVWG	MN	AKT3 messenger RNA (AKT3 mRNA)
DMSKVWG	MT	DTT
DMSKVWG	RN	US patent application no. 6,187,586, Antisense modulation of AKT-3 expression.
DMSKVWG	RU	http://www.patentbuddy.com/Patent/6187586?ft=true&sr=true

DMDR8V9	DI	DMDR8V9
DMDR8V9	DN	ISIS 29202
DMDR8V9	MI	TTO6SGY
DMDR8V9	MN	AKT3 messenger RNA (AKT3 mRNA)
DMDR8V9	MT	DTT
DMDR8V9	RN	US patent application no. 6,187,586, Antisense modulation of AKT-3 expression.
DMDR8V9	RU	http://www.patentbuddy.com/Patent/6187586?ft=true&sr=true

DMDZAKS	DI	DMDZAKS
DMDZAKS	DN	ISIS 2921
DMDZAKS	MI	TT4SCBE
DMDZAKS	MN	Cytomegalovirus IE2 region messenger RNA (CMV IE2 mRNA)
DMDZAKS	MT	DTT
DMDZAKS	RN	US patent application no. 5,442,049, Oligonucleotides for modulating the effects of cytomegalovirus infections.
DMDZAKS	RU	http://www.patentbuddy.com/Patent/5442049?ft=true&sr=true

DM37R5F	DI	DM37R5F
DM37R5F	DN	ISIS 29219
DM37R5F	MI	TTYMGWX
DM37R5F	MN	PDK-1 messenger RNA (PDK-1 mRNA)
DM37R5F	MT	DTT
DM37R5F	RN	US patent application no. 6,124,272, Antisense modulation of PDK-1 expression.
DM37R5F	RU	http://www.patentbuddy.com/Patent/6124272?ft=true&sr=true

DMK8FPR	DI	DMK8FPR
DMK8FPR	DN	ISIS 2922 + foscarnet 3' -azido-3'-deoxythymidine 2'-3'-dideoxycytidine
DMK8FPR	MI	TT4SCBE
DMK8FPR	MN	Cytomegalovirus IE2 region messenger RNA (CMV IE2 mRNA)
DMK8FPR	MT	DTT
DMK8FPR	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DMK8FPR	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DMVT2CJ	DI	DMVT2CJ
DMVT2CJ	DN	ISIS 2922 + Ganciclovir
DMVT2CJ	MI	TT4SCBE
DMVT2CJ	MN	Cytomegalovirus IE2 region messenger RNA (CMV IE2 mRNA)
DMVT2CJ	MT	DTT
DMVT2CJ	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DMVT2CJ	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DMMQPFE	DI	DMMQPFE
DMMQPFE	DN	ISIS 29223
DMMQPFE	MI	TTYMGWX
DMMQPFE	MN	PDK-1 messenger RNA (PDK-1 mRNA)
DMMQPFE	MT	DTT
DMMQPFE	RN	US patent application no. 6,124,272, Antisense modulation of PDK-1 expression.
DMMQPFE	RU	http://www.patentbuddy.com/Patent/6124272?ft=true&sr=true

DM9UNWE	DI	DM9UNWE
DM9UNWE	DN	ISIS 29224
DM9UNWE	MI	TTYMGWX
DM9UNWE	MN	PDK-1 messenger RNA (PDK-1 mRNA)
DM9UNWE	MT	DTT
DM9UNWE	RN	US patent application no. 6,124,272, Antisense modulation of PDK-1 expression.
DM9UNWE	RU	http://www.patentbuddy.com/Patent/6124272?ft=true&sr=true

DMLES7J	DI	DMLES7J
DMLES7J	DN	ISIS 29232
DMLES7J	MI	TTYMGWX
DMLES7J	MN	PDK-1 messenger RNA (PDK-1 mRNA)
DMLES7J	MT	DTT
DMLES7J	RN	US patent application no. 6,124,272, Antisense modulation of PDK-1 expression.
DMLES7J	RU	http://www.patentbuddy.com/Patent/6124272?ft=true&sr=true

DMGV4O7	DI	DMGV4O7
DMGV4O7	DN	ISIS 29233
DMGV4O7	MI	TTYMGWX
DMGV4O7	MN	PDK-1 messenger RNA (PDK-1 mRNA)
DMGV4O7	MT	DTT
DMGV4O7	RN	US patent application no. 6,124,272, Antisense modulation of PDK-1 expression.
DMGV4O7	RU	http://www.patentbuddy.com/Patent/6124272?ft=true&sr=true

DM1XAPO	DI	DM1XAPO
DM1XAPO	DN	ISIS 29234
DM1XAPO	MI	TTYMGWX
DM1XAPO	MN	PDK-1 messenger RNA (PDK-1 mRNA)
DM1XAPO	MT	DTT
DM1XAPO	RN	US patent application no. 6,124,272, Antisense modulation of PDK-1 expression.
DM1XAPO	RU	http://www.patentbuddy.com/Patent/6124272?ft=true&sr=true

DMAXD7P	DI	DMAXD7P
DMAXD7P	DN	ISIS 29236
DMAXD7P	MI	TTYMGWX
DMAXD7P	MN	PDK-1 messenger RNA (PDK-1 mRNA)
DMAXD7P	MT	DTT
DMAXD7P	RN	US patent application no. 6,124,272, Antisense modulation of PDK-1 expression.
DMAXD7P	RU	http://www.patentbuddy.com/Patent/6124272?ft=true&sr=true

DMPYJEB	DI	DMPYJEB
DMPYJEB	DN	ISIS 29237
DMPYJEB	MI	TTYMGWX
DMPYJEB	MN	PDK-1 messenger RNA (PDK-1 mRNA)
DMPYJEB	MT	DTT
DMPYJEB	RN	US patent application no. 6,124,272, Antisense modulation of PDK-1 expression.
DMPYJEB	RU	http://www.patentbuddy.com/Patent/6124272?ft=true&sr=true

DMHQF1J	DI	DMHQF1J
DMHQF1J	DN	ISIS 29239
DMHQF1J	MI	TTYMGWX
DMHQF1J	MN	PDK-1 messenger RNA (PDK-1 mRNA)
DMHQF1J	MT	DTT
DMHQF1J	RN	US patent application no. 6,124,272, Antisense modulation of PDK-1 expression.
DMHQF1J	RU	http://www.patentbuddy.com/Patent/6124272?ft=true&sr=true

DMZ7UM2	DI	DMZ7UM2
DMZ7UM2	DN	ISIS 29243
DMZ7UM2	MI	TTYMGWX
DMZ7UM2	MN	PDK-1 messenger RNA (PDK-1 mRNA)
DMZ7UM2	MT	DTT
DMZ7UM2	RN	US patent application no. 6,124,272, Antisense modulation of PDK-1 expression.
DMZ7UM2	RU	http://www.patentbuddy.com/Patent/6124272?ft=true&sr=true

DMTHVEL	DI	DMTHVEL
DMTHVEL	DN	ISIS 29244
DMTHVEL	MI	TTYMGWX
DMTHVEL	MN	PDK-1 messenger RNA (PDK-1 mRNA)
DMTHVEL	MT	DTT
DMTHVEL	RN	US patent application no. 6,124,272, Antisense modulation of PDK-1 expression.
DMTHVEL	RU	http://www.patentbuddy.com/Patent/6124272?ft=true&sr=true

DM0DG1K	DI	DM0DG1K
DM0DG1K	DN	ISIS 29246
DM0DG1K	MI	TTYMGWX
DM0DG1K	MN	PDK-1 messenger RNA (PDK-1 mRNA)
DM0DG1K	MT	DTT
DM0DG1K	RN	US patent application no. 6,124,272, Antisense modulation of PDK-1 expression.
DM0DG1K	RU	http://www.patentbuddy.com/Patent/6124272?ft=true&sr=true

DMK2QPU	DI	DMK2QPU
DMK2QPU	DN	ISIS 29255
DMK2QPU	MI	TTYMGWX
DMK2QPU	MN	PDK-1 messenger RNA (PDK-1 mRNA)
DMK2QPU	MT	DTT
DMK2QPU	RN	US patent application no. 6,124,272, Antisense modulation of PDK-1 expression.
DMK2QPU	RU	http://www.patentbuddy.com/Patent/6124272?ft=true&sr=true

DMF1MJ2	DI	DMF1MJ2
DMF1MJ2	DN	ISIS 29256
DMF1MJ2	MI	TTYMGWX
DMF1MJ2	MN	PDK-1 messenger RNA (PDK-1 mRNA)
DMF1MJ2	MT	DTT
DMF1MJ2	RN	US patent application no. 6,124,272, Antisense modulation of PDK-1 expression.
DMF1MJ2	RU	http://www.patentbuddy.com/Patent/6124272?ft=true&sr=true

DMUM2H1	DI	DMUM2H1
DMUM2H1	DN	ISIS 29257
DMUM2H1	MI	TTYMGWX
DMUM2H1	MN	PDK-1 messenger RNA (PDK-1 mRNA)
DMUM2H1	MT	DTT
DMUM2H1	RN	US patent application no. 6,124,272, Antisense modulation of PDK-1 expression.
DMUM2H1	RU	http://www.patentbuddy.com/Patent/6124272?ft=true&sr=true

DMVCFQ5	DI	DMVCFQ5
DMVCFQ5	DN	ISIS 29469
DMVCFQ5	MI	TTYMGWX
DMVCFQ5	MN	PDK-1 messenger RNA (PDK-1 mRNA)
DMVCFQ5	MT	DTT
DMVCFQ5	RN	US patent application no. 6,124,272, Antisense modulation of PDK-1 expression.
DMVCFQ5	RU	http://www.patentbuddy.com/Patent/6124272?ft=true&sr=true

DMPCK7Y	DI	DMPCK7Y
DMPCK7Y	DN	ISIS 29470
DMPCK7Y	MI	TTYMGWX
DMPCK7Y	MN	PDK-1 messenger RNA (PDK-1 mRNA)
DMPCK7Y	MT	DTT
DMPCK7Y	RN	US patent application no. 6,124,272, Antisense modulation of PDK-1 expression.
DMPCK7Y	RU	http://www.patentbuddy.com/Patent/6124272?ft=true&sr=true

DMG4RMZ	DI	DMG4RMZ
DMG4RMZ	DN	ISIS 29471
DMG4RMZ	MI	TTYMGWX
DMG4RMZ	MN	PDK-1 messenger RNA (PDK-1 mRNA)
DMG4RMZ	MT	DTT
DMG4RMZ	RN	US patent application no. 6,124,272, Antisense modulation of PDK-1 expression.
DMG4RMZ	RU	http://www.patentbuddy.com/Patent/6124272?ft=true&sr=true

DMEBQUN	DI	DMEBQUN
DMEBQUN	DN	ISIS 29475
DMEBQUN	MI	TTYMGWX
DMEBQUN	MN	PDK-1 messenger RNA (PDK-1 mRNA)
DMEBQUN	MT	DTT
DMEBQUN	RN	US patent application no. 6,124,272, Antisense modulation of PDK-1 expression.
DMEBQUN	RU	http://www.patentbuddy.com/Patent/6124272?ft=true&sr=true

DMKQMXV	DI	DMKQMXV
DMKQMXV	DN	ISIS 29477
DMKQMXV	MI	TTYMGWX
DMKQMXV	MN	PDK-1 messenger RNA (PDK-1 mRNA)
DMKQMXV	MT	DTT
DMKQMXV	RN	US patent application no. 6,124,272, Antisense modulation of PDK-1 expression.
DMKQMXV	RU	http://www.patentbuddy.com/Patent/6124272?ft=true&sr=true

DM7K19L	DI	DM7K19L
DM7K19L	DN	ISIS 2974
DM7K19L	MI	TTA1L39
DM7K19L	MN	ICAM1 messenger RNA (ICAM1 mRNA)
DM7K19L	MT	DTT
DM7K19L	RN	US patent application no. 6,300,491, Oligonucleotide inhibition of cell adhesion.
DM7K19L	RU	http://www.patentbuddy.com/Patent/6300491?ft=true&sr=true

DM0WH1L	DI	DM0WH1L
DM0WH1L	DN	ISIS 298697
DM0WH1L	MI	TTSN6QU
DM0WH1L	MN	HIF1-alpha messenger RNA (HIF1A mRNA)
DM0WH1L	MT	DTT
DM0WH1L	RN	US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression.
DM0WH1L	RU	http://www.patentbuddy.com/Patent/7217572?ft=true&sr=true

DMB28JW	DI	DMB28JW
DMB28JW	DN	ISIS 298699
DMB28JW	MI	TTSN6QU
DMB28JW	MN	HIF1-alpha messenger RNA (HIF1A mRNA)
DMB28JW	MT	DTT
DMB28JW	RN	US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression.
DMB28JW	RU	http://www.patentbuddy.com/Patent/7217572?ft=true&sr=true

DM3DE98	DI	DM3DE98
DM3DE98	DN	ISIS 298700
DM3DE98	MI	TTSN6QU
DM3DE98	MN	HIF1-alpha messenger RNA (HIF1A mRNA)
DM3DE98	MT	DTT
DM3DE98	RN	US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression.
DM3DE98	RU	http://www.patentbuddy.com/Patent/7217572?ft=true&sr=true

DMVIXND	DI	DMVIXND
DMVIXND	DN	ISIS 298701
DMVIXND	MI	TTSN6QU
DMVIXND	MN	HIF1-alpha messenger RNA (HIF1A mRNA)
DMVIXND	MT	DTT
DMVIXND	RN	US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression.
DMVIXND	RU	http://www.patentbuddy.com/Patent/7217572?ft=true&sr=true

DM4L7NE	DI	DM4L7NE
DM4L7NE	DN	ISIS 298702
DM4L7NE	MI	TTSN6QU
DM4L7NE	MN	HIF1-alpha messenger RNA (HIF1A mRNA)
DM4L7NE	MT	DTT
DM4L7NE	RN	US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression.
DM4L7NE	RU	http://www.patentbuddy.com/Patent/7217572?ft=true&sr=true

DMCDWSG	DI	DMCDWSG
DMCDWSG	DN	ISIS 298711
DMCDWSG	MI	TTSN6QU
DMCDWSG	MN	HIF1-alpha messenger RNA (HIF1A mRNA)
DMCDWSG	MT	DTT
DMCDWSG	RN	US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression.
DMCDWSG	RU	http://www.patentbuddy.com/Patent/7217572?ft=true&sr=true

DMGJ4AO	DI	DMGJ4AO
DMGJ4AO	DN	ISIS 298712
DMGJ4AO	MI	TTSN6QU
DMGJ4AO	MN	HIF1-alpha messenger RNA (HIF1A mRNA)
DMGJ4AO	MT	DTT
DMGJ4AO	RN	US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression.
DMGJ4AO	RU	http://www.patentbuddy.com/Patent/7217572?ft=true&sr=true

DMD3NSQ	DI	DMD3NSQ
DMD3NSQ	DN	ISIS 298743
DMD3NSQ	MI	TTSN6QU
DMD3NSQ	MN	HIF1-alpha messenger RNA (HIF1A mRNA)
DMD3NSQ	MT	DTT
DMD3NSQ	RN	US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression.
DMD3NSQ	RU	http://www.patentbuddy.com/Patent/7217572?ft=true&sr=true

DM8VMQ4	DI	DM8VMQ4
DM8VMQ4	DN	ISIS 298744
DM8VMQ4	MI	TTSN6QU
DM8VMQ4	MN	HIF1-alpha messenger RNA (HIF1A mRNA)
DM8VMQ4	MT	DTT
DM8VMQ4	RN	US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression.
DM8VMQ4	RU	http://www.patentbuddy.com/Patent/7217572?ft=true&sr=true

DM9YMPI	DI	DM9YMPI
DM9YMPI	DN	ISIS 298745
DM9YMPI	MI	TTSN6QU
DM9YMPI	MN	HIF1-alpha messenger RNA (HIF1A mRNA)
DM9YMPI	MT	DTT
DM9YMPI	RN	US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression.
DM9YMPI	RU	http://www.patentbuddy.com/Patent/7217572?ft=true&sr=true

DMHOJ0Z	DI	DMHOJ0Z
DMHOJ0Z	DN	ISIS 298746
DMHOJ0Z	MI	TTSN6QU
DMHOJ0Z	MN	HIF1-alpha messenger RNA (HIF1A mRNA)
DMHOJ0Z	MT	DTT
DMHOJ0Z	RN	US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression.
DMHOJ0Z	RU	http://www.patentbuddy.com/Patent/7217572?ft=true&sr=true

DMC9OL7	DI	DMC9OL7
DMC9OL7	DN	ISIS 3067
DMC9OL7	MI	TTA1L39
DMC9OL7	MN	ICAM1 messenger RNA (ICAM1 mRNA)
DMC9OL7	MT	DTT
DMC9OL7	RN	US patent application no. 5,789,573, Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2.
DMC9OL7	RU	http://www.patentbuddy.com/Patent/5789573?ft=true&sr=true

DMOHZKW	DI	DMOHZKW
DMOHZKW	DN	ISIS 31963
DMOHZKW	MI	TT9H4P3
DMOHZKW	MN	PI3K p110 beta messenger RNA (PIK3CB mRNA)
DMOHZKW	MT	DTT
DMOHZKW	RN	US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression.
DMOHZKW	RU	http://www.patentbuddy.com/Patent/6133032?ft=true&sr=true

DMP9IR2	DI	DMP9IR2
DMP9IR2	DN	ISIS 31982
DMP9IR2	MI	TT9H4P3
DMP9IR2	MN	PI3K p110 beta messenger RNA (PIK3CB mRNA)
DMP9IR2	MT	DTT
DMP9IR2	RN	US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression.
DMP9IR2	RU	http://www.patentbuddy.com/Patent/6133032?ft=true&sr=true

DM21ZCQ	DI	DM21ZCQ
DM21ZCQ	DN	ISIS 31996
DM21ZCQ	MI	TT9H4P3
DM21ZCQ	MN	PI3K p110 beta messenger RNA (PIK3CB mRNA)
DM21ZCQ	MT	DTT
DM21ZCQ	RN	US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression.
DM21ZCQ	RU	http://www.patentbuddy.com/Patent/6133032?ft=true&sr=true

DM0O9WM	DI	DM0O9WM
DM0O9WM	DN	ISIS 32000
DM0O9WM	MI	TT9H4P3
DM0O9WM	MN	PI3K p110 beta messenger RNA (PIK3CB mRNA)
DM0O9WM	MT	DTT
DM0O9WM	RN	US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression.
DM0O9WM	RU	http://www.patentbuddy.com/Patent/6133032?ft=true&sr=true

DMEAXV3	DI	DMEAXV3
DMEAXV3	DN	ISIS 32002
DMEAXV3	MI	TT9H4P3
DMEAXV3	MN	PI3K p110 beta messenger RNA (PIK3CB mRNA)
DMEAXV3	MT	DTT
DMEAXV3	RN	US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression.
DMEAXV3	RU	http://www.patentbuddy.com/Patent/6133032?ft=true&sr=true

DM7EVQX	DI	DM7EVQX
DM7EVQX	DN	ISIS 32003
DM7EVQX	MI	TT9H4P3
DM7EVQX	MN	PI3K p110 beta messenger RNA (PIK3CB mRNA)
DM7EVQX	MT	DTT
DM7EVQX	RN	US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression.
DM7EVQX	RU	http://www.patentbuddy.com/Patent/6133032?ft=true&sr=true

DME7VX6	DI	DME7VX6
DME7VX6	DN	ISIS 32004
DME7VX6	MI	TT9H4P3
DME7VX6	MN	PI3K p110 beta messenger RNA (PIK3CB mRNA)
DME7VX6	MT	DTT
DME7VX6	RN	US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression.
DME7VX6	RU	http://www.patentbuddy.com/Patent/6133032?ft=true&sr=true

DMT8GWX	DI	DMT8GWX
DMT8GWX	DN	ISIS 32005
DMT8GWX	MI	TT9H4P3
DMT8GWX	MN	PI3K p110 beta messenger RNA (PIK3CB mRNA)
DMT8GWX	MT	DTT
DMT8GWX	RN	US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression.
DMT8GWX	RU	http://www.patentbuddy.com/Patent/6133032?ft=true&sr=true

DMFKLUS	DI	DMFKLUS
DMFKLUS	DN	ISIS 32006
DMFKLUS	MI	TT9H4P3
DMFKLUS	MN	PI3K p110 beta messenger RNA (PIK3CB mRNA)
DMFKLUS	MT	DTT
DMFKLUS	RN	US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression.
DMFKLUS	RU	http://www.patentbuddy.com/Patent/6133032?ft=true&sr=true

DME1KXM	DI	DME1KXM
DME1KXM	DN	ISIS 32008
DME1KXM	MI	TT9H4P3
DME1KXM	MN	PI3K p110 beta messenger RNA (PIK3CB mRNA)
DME1KXM	MT	DTT
DME1KXM	RN	US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression.
DME1KXM	RU	http://www.patentbuddy.com/Patent/6133032?ft=true&sr=true

DM8PBCA	DI	DM8PBCA
DM8PBCA	DN	ISIS 32010
DM8PBCA	MI	TT9H4P3
DM8PBCA	MN	PI3K p110 beta messenger RNA (PIK3CB mRNA)
DM8PBCA	MT	DTT
DM8PBCA	RN	US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression.
DM8PBCA	RU	http://www.patentbuddy.com/Patent/6133032?ft=true&sr=true

DMF5SK8	DI	DMF5SK8
DMF5SK8	DN	ISIS 32014
DMF5SK8	MI	TT9H4P3
DMF5SK8	MN	PI3K p110 beta messenger RNA (PIK3CB mRNA)
DMF5SK8	MT	DTT
DMF5SK8	RN	US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression.
DMF5SK8	RU	http://www.patentbuddy.com/Patent/6133032?ft=true&sr=true

DMMV4WX	DI	DMMV4WX
DMMV4WX	DN	ISIS 32015
DMMV4WX	MI	TT9H4P3
DMMV4WX	MN	PI3K p110 beta messenger RNA (PIK3CB mRNA)
DMMV4WX	MT	DTT
DMMV4WX	RN	US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression.
DMMV4WX	RU	http://www.patentbuddy.com/Patent/6133032?ft=true&sr=true

DMXL9IY	DI	DMXL9IY
DMXL9IY	DN	ISIS 32020
DMXL9IY	MI	TT9H4P3
DMXL9IY	MN	PI3K p110 beta messenger RNA (PIK3CB mRNA)
DMXL9IY	MT	DTT
DMXL9IY	RN	US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression.
DMXL9IY	RU	http://www.patentbuddy.com/Patent/6133032?ft=true&sr=true

DMISB5V	DI	DMISB5V
DMISB5V	DN	ISIS 32021
DMISB5V	MI	TT9H4P3
DMISB5V	MN	PI3K p110 beta messenger RNA (PIK3CB mRNA)
DMISB5V	MT	DTT
DMISB5V	RN	US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression.
DMISB5V	RU	http://www.patentbuddy.com/Patent/6133032?ft=true&sr=true

DMPKGIU	DI	DMPKGIU
DMPKGIU	DN	ISIS 32024
DMPKGIU	MI	TT9H4P3
DMPKGIU	MN	PI3K p110 beta messenger RNA (PIK3CB mRNA)
DMPKGIU	MT	DTT
DMPKGIU	RN	US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression.
DMPKGIU	RU	http://www.patentbuddy.com/Patent/6133032?ft=true&sr=true

DMATWDO	DI	DMATWDO
DMATWDO	DN	ISIS 32028
DMATWDO	MI	TT9H4P3
DMATWDO	MN	PI3K p110 beta messenger RNA (PIK3CB mRNA)
DMATWDO	MT	DTT
DMATWDO	RN	US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression.
DMATWDO	RU	http://www.patentbuddy.com/Patent/6133032?ft=true&sr=true

DM47B2O	DI	DM47B2O
DM47B2O	DN	ISIS 32035
DM47B2O	MI	TT9H4P3
DM47B2O	MN	PI3K p110 beta messenger RNA (PIK3CB mRNA)
DM47B2O	MT	DTT
DM47B2O	RN	US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression.
DM47B2O	RU	http://www.patentbuddy.com/Patent/6133032?ft=true&sr=true

DMY1R0Q	DI	DMY1R0Q
DMY1R0Q	DN	ISIS 32039
DMY1R0Q	MI	TT9H4P3
DMY1R0Q	MN	PI3K p110 beta messenger RNA (PIK3CB mRNA)
DMY1R0Q	MT	DTT
DMY1R0Q	RN	US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression.
DMY1R0Q	RU	http://www.patentbuddy.com/Patent/6133032?ft=true&sr=true

DMAFEYG	DI	DMAFEYG
DMAFEYG	DN	ISIS 3224
DMAFEYG	MI	TTA1L39
DMAFEYG	MN	ICAM1 messenger RNA (ICAM1 mRNA)
DMAFEYG	MT	DTT
DMAFEYG	RN	US patent application no. 5,789,573, Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2.
DMAFEYG	RU	http://www.patentbuddy.com/Patent/5789573?ft=true&sr=true

DM56EZC	DI	DM56EZC
DM56EZC	DN	ISIS 3246
DM56EZC	MI	TT4SCBE
DM56EZC	MN	Cytomegalovirus IE2 region messenger RNA (CMV IE2 mRNA)
DM56EZC	MT	DTT
DM56EZC	RN	US patent application no. 5,442,049, Oligonucleotides for modulating the effects of cytomegalovirus infections.
DM56EZC	RU	http://www.patentbuddy.com/Patent/5442049?ft=true&sr=true

DMA96KW	DI	DMA96KW
DMA96KW	DN	ISIS 329956
DMA96KW	MI	TTWRN6M
DMA96KW	MN	CRP messenger RNA (CRP mRNA)
DMA96KW	MT	DTT
DMA96KW	RN	US patent application no. 7,425,545, Modulation of C-reactive protein expression.
DMA96KW	RU	http://www.patentbuddy.com/Patent/7425545?ft=true&sr=true

DM2TIO1	DI	DM2TIO1
DM2TIO1	DN	ISIS 3300
DM2TIO1	MI	TT4SCBE
DM2TIO1	MN	Cytomegalovirus IE2 region messenger RNA (CMV IE2 mRNA)
DM2TIO1	MT	DTT
DM2TIO1	RN	US patent application no. 5,767,102, Antisense composition and method for treatment of CMV infection.
DM2TIO1	RU	http://www.patentbuddy.com/Patent/5767102?ft=true&sr=true

DMWIVS9	DI	DMWIVS9
DMWIVS9	DN	ISIS 330012
DMWIVS9	MI	TTWRN6M
DMWIVS9	MN	CRP messenger RNA (CRP mRNA)
DMWIVS9	MT	DTT
DMWIVS9	RN	US patent application no. 7,425,545, Modulation of C-reactive protein expression.
DMWIVS9	RU	http://www.patentbuddy.com/Patent/7425545?ft=true&sr=true

DM35WFL	DI	DM35WFL
DM35WFL	DN	ISIS 330031
DM35WFL	MI	TTWRN6M
DM35WFL	MN	CRP messenger RNA (CRP mRNA)
DM35WFL	MT	DTT
DM35WFL	RN	US patent application no. 7,425,545, Modulation of C-reactive protein expression.
DM35WFL	RU	http://www.patentbuddy.com/Patent/7425545?ft=true&sr=true

DM0W47U	DI	DM0W47U
DM0W47U	DN	ISIS 3303
DM0W47U	MI	TTSC4OM
DM0W47U	MN	Influenza PB2 messenger RNA (Influ PB2 mRNA)
DM0W47U	MT	DTT
DM0W47U	RN	US patent application no. 5,580,767, Inhibition of influenza viruses by antisense oligonucleotides.
DM0W47U	RU	http://www.patentbuddy.com/Patent/5580767?ft=true&sr=true

DM1K6DX	DI	DM1K6DX
DM1K6DX	DN	ISIS 3304
DM1K6DX	MI	TT6HV2K
DM1K6DX	MN	Influenza PB1 messenger RNA (Influ PB1 mRNA)
DM1K6DX	MT	DTT
DM1K6DX	RN	US patent application no. 5,580,767, Inhibition of influenza viruses by antisense oligonucleotides.
DM1K6DX	RU	http://www.patentbuddy.com/Patent/5580767?ft=true&sr=true

DMWD1XH	DI	DMWD1XH
DMWD1XH	DN	ISIS 3306
DMWD1XH	MI	TTZSY8Q
DMWD1XH	MN	Influenza HA messenger RNA (Influ HA mRNA)
DMWD1XH	MT	DTT
DMWD1XH	RN	US patent application no. 5,580,767, Inhibition of influenza viruses by antisense oligonucleotides.
DMWD1XH	RU	http://www.patentbuddy.com/Patent/5580767?ft=true&sr=true

DMXRL2J	DI	DMXRL2J
DMXRL2J	DN	ISIS 3307
DMXRL2J	MI	TTRG72O
DMXRL2J	MN	Influenza NP messenger RNA (Influ NP mRNA)
DMXRL2J	MT	DTT
DMXRL2J	RN	US patent application no. 5,580,767, Inhibition of influenza viruses by antisense oligonucleotides.
DMXRL2J	RU	http://www.patentbuddy.com/Patent/5580767?ft=true&sr=true

DMSIBWP	DI	DMSIBWP
DMSIBWP	DN	ISIS 3308
DMSIBWP	MI	TTM27B5
DMSIBWP	MN	Influenza NA messenger RNA (Influenza NA mRNA)
DMSIBWP	MT	DTT
DMSIBWP	RN	US patent application no. 5,580,767, Inhibition of influenza viruses by antisense oligonucleotides.
DMSIBWP	RU	http://www.patentbuddy.com/Patent/5580767?ft=true&sr=true

DMDSMJU	DI	DMDSMJU
DMDSMJU	DN	ISIS 3309
DMDSMJU	MI	TTXAUJ8
DMDSMJU	MN	Influenza M messenger RNA (Influenza M mRNA)
DMDSMJU	MT	DTT
DMDSMJU	RN	US patent application no. 5,580,767, Inhibition of influenza viruses by antisense oligonucleotides.
DMDSMJU	RU	http://www.patentbuddy.com/Patent/5580767?ft=true&sr=true

DMOYBFQ	DI	DMOYBFQ
DMOYBFQ	DN	ISIS 341881
DMOYBFQ	MI	TTEWOHV
DMOYBFQ	MN	Survivin messenger RNA (Survivin mRNA)
DMOYBFQ	MT	DTT
DMOYBFQ	RN	US patent application no. 7,541,344, Modulation of survivin expression.
DMOYBFQ	RU	http://www.patentbuddy.com/Patent/7541344?ft=true&sr=true

DMO7492	DI	DMO7492
DMO7492	DN	ISIS 343867
DMO7492	MI	TTEWOHV
DMO7492	MN	Survivin messenger RNA (Survivin mRNA)
DMO7492	MT	DTT
DMO7492	RN	US patent application no. 7,541,344, Modulation of survivin expression.
DMO7492	RU	http://www.patentbuddy.com/Patent/7541344?ft=true&sr=true

DMAFEX8	DI	DMAFEX8
DMAFEX8	DN	ISIS 347573
DMAFEX8	MI	TTNBTCW
DMAFEX8	MN	eIF4E-BP2 messenger RNA (eIF4E-BP2 mRNA)
DMAFEX8	MT	DTT
DMAFEX8	RN	US patent application no. 7,468,431, Modulation of eIF4E-BP2 expression.
DMAFEX8	RU	http://www.patentbuddy.com/Patent/7468431?ft=true&sr=true

DM36SRT	DI	DM36SRT
DM36SRT	DN	ISIS 347577
DM36SRT	MI	TTNBTCW
DM36SRT	MN	eIF4E-BP2 messenger RNA (eIF4E-BP2 mRNA)
DM36SRT	MT	DTT
DM36SRT	RN	US patent application no. 7,468,431, Modulation of eIF4E-BP2 expression.
DM36SRT	RU	http://www.patentbuddy.com/Patent/7468431?ft=true&sr=true

DMBE1T8	DI	DMBE1T8
DMBE1T8	DN	ISIS 3792
DMBE1T8	MI	TTHCEF6
DMBE1T8	MN	VCAM-1 messenger RNA (VCAM1 mRNA)
DMBE1T8	MT	DTT
DMBE1T8	RN	US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion.
DMBE1T8	RU	http://www.patentbuddy.com/Patent/5843738?ft=true&sr=true

DMJDWX5	DI	DMJDWX5
DMJDWX5	DN	ISIS 3801
DMJDWX5	MI	TTHCEF6
DMJDWX5	MN	VCAM-1 messenger RNA (VCAM1 mRNA)
DMJDWX5	MT	DTT
DMJDWX5	RN	US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion.
DMJDWX5	RU	http://www.patentbuddy.com/Patent/5843738?ft=true&sr=true

DM7VAT0	DI	DM7VAT0
DM7VAT0	DN	ISIS 3804
DM7VAT0	MI	TTHCEF6
DM7VAT0	MN	VCAM-1 messenger RNA (VCAM1 mRNA)
DM7VAT0	MT	DTT
DM7VAT0	RN	US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion.
DM7VAT0	RU	http://www.patentbuddy.com/Patent/5843738?ft=true&sr=true

DMX927V	DI	DMX927V
DMX927V	DN	ISIS 3805
DMX927V	MI	TTHCEF6
DMX927V	MN	VCAM-1 messenger RNA (VCAM1 mRNA)
DMX927V	MT	DTT
DMX927V	RN	US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion.
DMX927V	RU	http://www.patentbuddy.com/Patent/5843738?ft=true&sr=true

DMN8OHG	DI	DMN8OHG
DMN8OHG	DN	ISIS 4189
DMN8OHG	MI	TT2MI95
DMN8OHG	MN	PKC-alpha messenger RNA (PRKCA mRNA)
DMN8OHG	MT	DTT
DMN8OHG	RN	US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C.
DMN8OHG	RU	http://www.patentbuddy.com/Patent/5959096?ft=true&sr=true

DMXNBGP	DI	DMXNBGP
DMXNBGP	DN	ISIS 4719
DMXNBGP	MI	TT1PL7M
DMXNBGP	MN	E-selectin messenger RNA (SELE mRNA)
DMXNBGP	MT	DTT
DMXNBGP	RN	US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion.
DMXNBGP	RU	http://www.patentbuddy.com/Patent/5843738?ft=true&sr=true

DMD67YO	DI	DMD67YO
DMD67YO	DN	ISIS 4729
DMD67YO	MI	TT1PL7M
DMD67YO	MN	E-selectin messenger RNA (SELE mRNA)
DMD67YO	MT	DTT
DMD67YO	RN	US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion.
DMD67YO	RU	http://www.patentbuddy.com/Patent/5843738?ft=true&sr=true

DMKU1PN	DI	DMKU1PN
DMKU1PN	DN	ISIS 4730
DMKU1PN	MI	TT1PL7M
DMKU1PN	MN	E-selectin messenger RNA (SELE mRNA)
DMKU1PN	MT	DTT
DMKU1PN	RN	US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion.
DMKU1PN	RU	http://www.patentbuddy.com/Patent/5843738?ft=true&sr=true

DMCZK1U	DI	DMCZK1U
DMCZK1U	DN	ISIS 4756
DMCZK1U	MI	TT1PL7M
DMCZK1U	MN	E-selectin messenger RNA (SELE mRNA)
DMCZK1U	MT	DTT
DMCZK1U	RN	US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion.
DMCZK1U	RU	http://www.patentbuddy.com/Patent/5843738?ft=true&sr=true

DM3PZUX	DI	DM3PZUX
DM3PZUX	DN	ISIS 4759
DM3PZUX	MI	TT1PL7M
DM3PZUX	MN	E-selectin messenger RNA (SELE mRNA)
DM3PZUX	MT	DTT
DM3PZUX	RN	US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion.
DM3PZUX	RU	http://www.patentbuddy.com/Patent/5843738?ft=true&sr=true

DMLA5I9	DI	DMLA5I9
DMLA5I9	DN	ISIS 4764
DMLA5I9	MI	TT1PL7M
DMLA5I9	MN	E-selectin messenger RNA (SELE mRNA)
DMLA5I9	MT	DTT
DMLA5I9	RN	US patent application no. 5,789,573, Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2.
DMLA5I9	RU	http://www.patentbuddy.com/Patent/5789573?ft=true&sr=true

DMYVST6	DI	DMYVST6
DMYVST6	DN	ISIS 5874
DMYVST6	MI	TTHCEF6
DMYVST6	MN	VCAM-1 messenger RNA (VCAM1 mRNA)
DMYVST6	MT	DTT
DMYVST6	RN	US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion.
DMYVST6	RU	http://www.patentbuddy.com/Patent/5843738?ft=true&sr=true

DM8T1Z4	DI	DM8T1Z4
DM8T1Z4	DN	ISIS 5875
DM8T1Z4	MI	TTHCEF6
DM8T1Z4	MN	VCAM-1 messenger RNA (VCAM1 mRNA)
DM8T1Z4	MT	DTT
DM8T1Z4	RN	US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion.
DM8T1Z4	RU	http://www.patentbuddy.com/Patent/5843738?ft=true&sr=true

DMRATOH	DI	DMRATOH
DMRATOH	DN	ISIS 5876
DMRATOH	MI	TTHCEF6
DMRATOH	MN	VCAM-1 messenger RNA (VCAM1 mRNA)
DMRATOH	MT	DTT
DMRATOH	RN	US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion.
DMRATOH	RU	http://www.patentbuddy.com/Patent/5843738?ft=true&sr=true

DME7698	DI	DME7698
DME7698	DN	ISIS 5884
DME7698	MI	TTHCEF6
DME7698	MN	VCAM-1 messenger RNA (VCAM1 mRNA)
DME7698	MT	DTT
DME7698	RN	US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion.
DME7698	RU	http://www.patentbuddy.com/Patent/5843738?ft=true&sr=true

DMH7LPO	DI	DMH7LPO
DMH7LPO	DN	ISIS 6186
DMH7LPO	MI	TT28ZON
DMH7LPO	MN	H-ras messenger RNA (HRAS mRNA)
DMH7LPO	MT	DTT
DMH7LPO	RN	US patent application no. 5,965,722, Antisense inhibition of ras gene with chimeric and alternating oligonucleotides.
DMH7LPO	RU	http://www.patentbuddy.com/Patent/5965722?ft=true&sr=true

DMEUCI2	DI	DMEUCI2
DMEUCI2	DN	ISIS 6431
DMEUCI2	MI	TTONI0R
DMEUCI2	MN	PKC-eta messenger RNA (PRKCH mRNA)
DMEUCI2	MT	DTT
DMEUCI2	RN	US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C.
DMEUCI2	RU	http://www.patentbuddy.com/Patent/5959096?ft=true&sr=true

DMQHN43	DI	DMQHN43
DMQHN43	DN	ISIS 6432
DMQHN43	MI	TTONI0R
DMQHN43	MN	PKC-eta messenger RNA (PRKCH mRNA)
DMQHN43	MT	DTT
DMQHN43	RN	US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C.
DMQHN43	RU	http://www.patentbuddy.com/Patent/5959096?ft=true&sr=true

DMNVLE2	DI	DMNVLE2
DMNVLE2	DN	ISIS 6434
DMNVLE2	MI	TTONI0R
DMNVLE2	MN	PKC-eta messenger RNA (PRKCH mRNA)
DMNVLE2	MT	DTT
DMNVLE2	RN	US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C.
DMNVLE2	RU	http://www.patentbuddy.com/Patent/5959096?ft=true&sr=true

DMI7JQG	DI	DMI7JQG
DMI7JQG	DN	ISIS 6435
DMI7JQG	MI	TTONI0R
DMI7JQG	MN	PKC-eta messenger RNA (PRKCH mRNA)
DMI7JQG	MT	DTT
DMI7JQG	RN	US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C.
DMI7JQG	RU	http://www.patentbuddy.com/Patent/5959096?ft=true&sr=true

DM7KSRG	DI	DM7KSRG
DM7KSRG	DN	ISIS 6442
DM7KSRG	MI	TTONI0R
DM7KSRG	MN	PKC-eta messenger RNA (PRKCH mRNA)
DM7KSRG	MT	DTT
DM7KSRG	RN	US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C.
DM7KSRG	RU	http://www.patentbuddy.com/Patent/5959096?ft=true&sr=true

DMGN051	DI	DMGN051
DMGN051	DN	ISIS 6443
DMGN051	MI	TTONI0R
DMGN051	MN	PKC-eta messenger RNA (PRKCH mRNA)
DMGN051	MT	DTT
DMGN051	RN	US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C.
DMGN051	RU	http://www.patentbuddy.com/Patent/5959096?ft=true&sr=true

DMXJ4SO	DI	DMXJ4SO
DMXJ4SO	DN	ISIS 6445
DMXJ4SO	MI	TTONI0R
DMXJ4SO	MN	PKC-eta messenger RNA (PRKCH mRNA)
DMXJ4SO	MT	DTT
DMXJ4SO	RN	US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C.
DMXJ4SO	RU	http://www.patentbuddy.com/Patent/5959096?ft=true&sr=true

DM5L387	DI	DM5L387
DM5L387	DN	ISIS 6553
DM5L387	MI	TTONI0R
DM5L387	MN	PKC-eta messenger RNA (PRKCH mRNA)
DM5L387	MT	DTT
DM5L387	RN	US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C.
DM5L387	RU	http://www.patentbuddy.com/Patent/5959096?ft=true&sr=true

DMEAVPQ	DI	DMEAVPQ
DMEAVPQ	DN	ISIS 6581
DMEAVPQ	MI	TTONI0R
DMEAVPQ	MN	PKC-eta messenger RNA (PRKCH mRNA)
DMEAVPQ	MT	DTT
DMEAVPQ	RN	US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C.
DMEAVPQ	RU	http://www.patentbuddy.com/Patent/5959096?ft=true&sr=true

DMVXC7W	DI	DMVXC7W
DMVXC7W	DN	ISIS 6603
DMVXC7W	MI	TTONI0R
DMVXC7W	MN	PKC-eta messenger RNA (PRKCH mRNA)
DMVXC7W	MT	DTT
DMVXC7W	RN	US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C.
DMVXC7W	RU	http://www.patentbuddy.com/Patent/5959096?ft=true&sr=true

DM5KGQO	DI	DM5KGQO
DM5KGQO	DN	ISIS 6717
DM5KGQO	MI	TTAN5W2
DM5KGQO	MN	Raf messenger RNA (Raf mRNA)
DM5KGQO	MT	DTT
DM5KGQO	RN	US patent application no. 5,952,229, Antisense oligonucleotide modulation of raf gene expression.
DM5KGQO	RU	http://www.patentbuddy.com/Patent/5952229?ft=true&sr=true

DMJS6B0	DI	DMJS6B0
DMJS6B0	DN	ISIS 6720
DMJS6B0	MI	TTAN5W2
DMJS6B0	MN	Raf messenger RNA (Raf mRNA)
DMJS6B0	MT	DTT
DMJS6B0	RN	US patent application no. 5,952,229, Antisense oligonucleotide modulation of raf gene expression.
DMJS6B0	RU	http://www.patentbuddy.com/Patent/5952229?ft=true&sr=true

DMWZOQJ	DI	DMWZOQJ
DMWZOQJ	DN	ISIS 6729
DMWZOQJ	MI	TTAN5W2
DMWZOQJ	MN	Raf messenger RNA (Raf mRNA)
DMWZOQJ	MT	DTT
DMWZOQJ	RN	US patent application no. 5,952,229, Antisense oligonucleotide modulation of raf gene expression.
DMWZOQJ	RU	http://www.patentbuddy.com/Patent/5952229?ft=true&sr=true

DM0B4RD	DI	DM0B4RD
DM0B4RD	DN	ISIS 6739
DM0B4RD	MI	TTBLG3H
DM0B4RD	MN	P120 messenger RNA (NOP2 mRNA)
DM0B4RD	MT	DTT
DM0B4RD	RN	US patent application no. 5,814,619, Oligonucleotide inhibition of P120.
DM0B4RD	RU	http://www.patentbuddy.com/Patent/5814619?ft=true&sr=true

DMQONPU	DI	DMQONPU
DMQONPU	DN	ISIS 6748
DMQONPU	MI	TTBLG3H
DMQONPU	MN	P120 messenger RNA (NOP2 mRNA)
DMQONPU	MT	DTT
DMQONPU	RN	US patent application no. 5,814,619, Oligonucleotide inhibition of P120.
DMQONPU	RU	http://www.patentbuddy.com/Patent/5814619?ft=true&sr=true

DM4LD1Y	DI	DM4LD1Y
DM4LD1Y	DN	ISIS 6755
DM4LD1Y	MI	TTBLG3H
DM4LD1Y	MN	P120 messenger RNA (NOP2 mRNA)
DM4LD1Y	MT	DTT
DM4LD1Y	RN	US patent application no. 5,814,619, Oligonucleotide inhibition of P120.
DM4LD1Y	RU	http://www.patentbuddy.com/Patent/5814619?ft=true&sr=true

DMRM5QH	DI	DMRM5QH
DMRM5QH	DN	ISIS 6756
DMRM5QH	MI	TTBLG3H
DMRM5QH	MN	P120 messenger RNA (NOP2 mRNA)
DMRM5QH	MT	DTT
DMRM5QH	RN	US patent application no. 5,814,619, Oligonucleotide inhibition of P120.
DMRM5QH	RU	http://www.patentbuddy.com/Patent/5814619?ft=true&sr=true

DMTHO4A	DI	DMTHO4A
DMTHO4A	DN	ISIS 6957
DMTHO4A	MI	TTM8FR7
DMTHO4A	MN	KRAS messenger RNA (KRAS mRNA)
DMTHO4A	MT	DTT
DMTHO4A	RN	Antisense oligonucleotides demonstrate a dominant role of c-Ki-RAS proteins in regulating the proliferation of diploid human fibroblasts. J Biol Chem. 1996 Nov 8;271(45):28259-65.
DMTHO4A	RU	https://pubmed.ncbi.nlm.nih.gov/8910444

DM83EK9	DI	DM83EK9
DM83EK9	DN	ISIS 6958
DM83EK9	MI	TTM8FR7
DM83EK9	MN	KRAS messenger RNA (KRAS mRNA)
DM83EK9	MT	DTT
DM83EK9	RN	US patent application no. 5,965,722, Antisense inhibition of ras gene with chimeric and alternating oligonucleotides.
DM83EK9	RU	http://www.patentbuddy.com/Patent/5965722?ft=true&sr=true

DMOX7FJ	DI	DMOX7FJ
DMOX7FJ	DN	ISIS 7453
DMOX7FJ	MI	TTM8FR7
DMOX7FJ	MN	KRAS messenger RNA (KRAS mRNA)
DMOX7FJ	MT	DTT
DMOX7FJ	RN	US patent application no. 5,965,722, Antisense inhibition of ras gene with chimeric and alternating oligonucleotides.
DMOX7FJ	RU	http://www.patentbuddy.com/Patent/5965722?ft=true&sr=true

DMTN1D7	DI	DMTN1D7
DMTN1D7	DN	ISIS 7847
DMTN1D7	MI	TTAN5W2
DMTN1D7	MN	Raf messenger RNA (Raf mRNA)
DMTN1D7	MT	DTT
DMTN1D7	RN	US patent application no. 5,952,229, Antisense oligonucleotide modulation of raf gene expression.
DMTN1D7	RU	http://www.patentbuddy.com/Patent/5952229?ft=true&sr=true

DMOXBDT	DI	DMOXBDT
DMOXBDT	DN	ISIS 7848
DMOXBDT	MI	TTAN5W2
DMOXBDT	MN	Raf messenger RNA (Raf mRNA)
DMOXBDT	MT	DTT
DMOXBDT	RN	US patent application no. 5,952,229, Antisense oligonucleotide modulation of raf gene expression.
DMOXBDT	RU	http://www.patentbuddy.com/Patent/5952229?ft=true&sr=true

DMQYB7A	DI	DMQYB7A
DMQYB7A	DN	ISIS 7849
DMQYB7A	MI	TTAN5W2
DMQYB7A	MN	Raf messenger RNA (Raf mRNA)
DMQYB7A	MT	DTT
DMQYB7A	RN	US patent application no. 5,952,229, Antisense oligonucleotide modulation of raf gene expression.
DMQYB7A	RU	http://www.patentbuddy.com/Patent/5952229?ft=true&sr=true

DMJKC45	DI	DMJKC45
DMJKC45	DN	ISIS 7851
DMJKC45	MI	TTAN5W2
DMJKC45	MN	Raf messenger RNA (Raf mRNA)
DMJKC45	MT	DTT
DMJKC45	RN	US patent application no. 5,952,229, Antisense oligonucleotide modulation of raf gene expression.
DMJKC45	RU	http://www.patentbuddy.com/Patent/5952229?ft=true&sr=true

DM12E76	DI	DM12E76
DM12E76	DN	ISIS 7853
DM12E76	MI	TTAN5W2
DM12E76	MN	Raf messenger RNA (Raf mRNA)
DM12E76	MT	DTT
DM12E76	RN	US patent application no. 5,952,229, Antisense oligonucleotide modulation of raf gene expression.
DM12E76	RU	http://www.patentbuddy.com/Patent/5952229?ft=true&sr=true

DMKAQ6U	DI	DMKAQ6U
DMKAQ6U	DN	ISIS 7855
DMKAQ6U	MI	TTAN5W2
DMKAQ6U	MN	Raf messenger RNA (Raf mRNA)
DMKAQ6U	MT	DTT
DMKAQ6U	RN	US patent application no. 5,952,229, Antisense oligonucleotide modulation of raf gene expression.
DMKAQ6U	RU	http://www.patentbuddy.com/Patent/5952229?ft=true&sr=true

DMN0A1R	DI	DMN0A1R
DMN0A1R	DN	ISIS 7942
DMN0A1R	MI	TT57MT2
DMN0A1R	MN	PKC-epsilon messenger RNA (PRKCE mRNA)
DMN0A1R	MT	DTT
DMN0A1R	RN	US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C.
DMN0A1R	RU	http://www.patentbuddy.com/Patent/5959096?ft=true&sr=true

DMYZE8R	DI	DMYZE8R
DMYZE8R	DN	ISIS 7948
DMYZE8R	MI	TT57MT2
DMYZE8R	MN	PKC-epsilon messenger RNA (PRKCE mRNA)
DMYZE8R	MT	DTT
DMYZE8R	RN	US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C.
DMYZE8R	RU	http://www.patentbuddy.com/Patent/5959096?ft=true&sr=true

DMLIRKY	DI	DMLIRKY
DMLIRKY	DN	ISIS 9002
DMLIRKY	MI	TTR5TV4
DMLIRKY	MN	ERBB2 messenger RNA (HER2 mRNA)
DMLIRKY	MT	DTT
DMLIRKY	RN	US patent application no. 5,968,748, Antisense oligonucleotide modulation of human HER-2 expression.
DMLIRKY	RU	http://www.patentbuddy.com/Patent/5968748?ft=true&sr=true

DMBL2CG	DI	DMBL2CG
DMBL2CG	DN	ISIS 9003
DMBL2CG	MI	TTR5TV4
DMBL2CG	MN	ERBB2 messenger RNA (HER2 mRNA)
DMBL2CG	MT	DTT
DMBL2CG	RN	US patent application no. 5,968,748, Antisense oligonucleotide modulation of human HER-2 expression.
DMBL2CG	RU	http://www.patentbuddy.com/Patent/5968748?ft=true&sr=true

DM3PVGC	DI	DM3PVGC
DM3PVGC	DN	ISIS 9005
DM3PVGC	MI	TTR5TV4
DM3PVGC	MN	ERBB2 messenger RNA (HER2 mRNA)
DM3PVGC	MT	DTT
DM3PVGC	RN	US patent application no. 5,968,748, Antisense oligonucleotide modulation of human HER-2 expression.
DM3PVGC	RU	http://www.patentbuddy.com/Patent/5968748?ft=true&sr=true

DMGK2TQ	DI	DMGK2TQ
DMGK2TQ	DN	ISIS 9007
DMGK2TQ	MI	TTBSN0L
DMGK2TQ	MN	PKC-zeta messenger RNA (PRKCZ mRNA)
DMGK2TQ	MT	DTT
DMGK2TQ	RN	US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C.
DMGK2TQ	RU	http://www.patentbuddy.com/Patent/5959096?ft=true&sr=true

DMQDZF2	DI	DMQDZF2
DMQDZF2	DN	ISIS 9008
DMQDZF2	MI	TTBSN0L
DMQDZF2	MN	PKC-zeta messenger RNA (PRKCZ mRNA)
DMQDZF2	MT	DTT
DMQDZF2	RN	US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C.
DMQDZF2	RU	http://www.patentbuddy.com/Patent/5959096?ft=true&sr=true

DM7TRSB	DI	DM7TRSB
DM7TRSB	DN	ISIS 9022
DM7TRSB	MI	TTBSN0L
DM7TRSB	MN	PKC-zeta messenger RNA (PRKCZ mRNA)
DM7TRSB	MT	DTT
DM7TRSB	RN	US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C.
DM7TRSB	RU	http://www.patentbuddy.com/Patent/5959096?ft=true&sr=true

DMO2V5C	DI	DMO2V5C
DMO2V5C	DN	ISIS 9023
DMO2V5C	MI	TTBSN0L
DMO2V5C	MN	PKC-zeta messenger RNA (PRKCZ mRNA)
DMO2V5C	MT	DTT
DMO2V5C	RN	US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C.
DMO2V5C	RU	http://www.patentbuddy.com/Patent/5959096?ft=true&sr=true

DMAQ7XH	DI	DMAQ7XH
DMAQ7XH	DN	ISIS 9025
DMAQ7XH	MI	TTBSN0L
DMAQ7XH	MN	PKC-zeta messenger RNA (PRKCZ mRNA)
DMAQ7XH	MT	DTT
DMAQ7XH	RN	US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C.
DMAQ7XH	RU	http://www.patentbuddy.com/Patent/5959096?ft=true&sr=true

DMD1MEZ	DI	DMD1MEZ
DMD1MEZ	DN	ISIS 9058
DMD1MEZ	MI	TTAN5W2
DMD1MEZ	MN	Raf messenger RNA (Raf mRNA)
DMD1MEZ	MT	DTT
DMD1MEZ	RN	US patent application no. 5,952,229, Antisense oligonucleotide modulation of raf gene expression.
DMD1MEZ	RU	http://www.patentbuddy.com/Patent/5952229?ft=true&sr=true

DMZL7SW	DI	DMZL7SW
DMZL7SW	DN	ISIS 9060
DMZL7SW	MI	TT5TURO
DMZL7SW	MN	A-Raf messenger RNA (ARAF mRNA)
DMZL7SW	MT	DTT
DMZL7SW	RN	US patent application no. 5,563,255, Antisense oligonucleotide modulation of raf gene expression.
DMZL7SW	RU	http://www.patentbuddy.com/Patent/5563255?ft=true&sr=true

DMFAL2E	DI	DMFAL2E
DMFAL2E	DN	ISIS 9061
DMFAL2E	MI	TT5TURO
DMFAL2E	MN	A-Raf messenger RNA (ARAF mRNA)
DMFAL2E	MT	DTT
DMFAL2E	RN	US patent application no. 5,563,255, Antisense oligonucleotide modulation of raf gene expression.
DMFAL2E	RU	http://www.patentbuddy.com/Patent/5563255?ft=true&sr=true

DM5ZGSO	DI	DM5ZGSO
DM5ZGSO	DN	ISIS 9062
DM5ZGSO	MI	TT5TURO
DM5ZGSO	MN	A-Raf messenger RNA (ARAF mRNA)
DM5ZGSO	MT	DTT
DM5ZGSO	RN	US patent application no. 5,563,255, Antisense oligonucleotide modulation of raf gene expression.
DM5ZGSO	RU	http://www.patentbuddy.com/Patent/5563255?ft=true&sr=true

DM8E5RO	DI	DM8E5RO
DM8E5RO	DN	ISIS 9063
DM8E5RO	MI	TT5TURO
DM8E5RO	MN	A-Raf messenger RNA (ARAF mRNA)
DM8E5RO	MT	DTT
DM8E5RO	RN	US patent application no. 5,563,255, Antisense oligonucleotide modulation of raf gene expression.
DM8E5RO	RU	http://www.patentbuddy.com/Patent/5563255?ft=true&sr=true

DMBMTGP	DI	DMBMTGP
DMBMTGP	DN	ISIS 9064
DMBMTGP	MI	TT5TURO
DMBMTGP	MN	A-Raf messenger RNA (ARAF mRNA)
DMBMTGP	MT	DTT
DMBMTGP	RN	US patent application no. 5,563,255, Antisense oligonucleotide modulation of raf gene expression.
DMBMTGP	RU	http://www.patentbuddy.com/Patent/5563255?ft=true&sr=true

DMH50RX	DI	DMH50RX
DMH50RX	DN	ISIS 9065
DMH50RX	MI	TT5TURO
DMH50RX	MN	A-Raf messenger RNA (ARAF mRNA)
DMH50RX	MT	DTT
DMH50RX	RN	US patent application no. 5,563,255, Antisense oligonucleotide modulation of raf gene expression.
DMH50RX	RU	http://www.patentbuddy.com/Patent/5563255?ft=true&sr=true

DMB8MH0	DI	DMB8MH0
DMB8MH0	DN	ISIS 9066
DMB8MH0	MI	TT5TURO
DMB8MH0	MN	A-Raf messenger RNA (ARAF mRNA)
DMB8MH0	MT	DTT
DMB8MH0	RN	US patent application no. 5,563,255, Antisense oligonucleotide modulation of raf gene expression.
DMB8MH0	RU	http://www.patentbuddy.com/Patent/5563255?ft=true&sr=true

DML8HCZ	DI	DML8HCZ
DML8HCZ	DN	ISIS 9067
DML8HCZ	MI	TT5TURO
DML8HCZ	MN	A-Raf messenger RNA (ARAF mRNA)
DML8HCZ	MT	DTT
DML8HCZ	RN	US patent application no. 5,563,255, Antisense oligonucleotide modulation of raf gene expression.
DML8HCZ	RU	http://www.patentbuddy.com/Patent/5563255?ft=true&sr=true

DM953VY	DI	DM953VY
DM953VY	DN	ISIS 9068
DM953VY	MI	TT5TURO
DM953VY	MN	A-Raf messenger RNA (ARAF mRNA)
DM953VY	MT	DTT
DM953VY	RN	US patent application no. 5,563,255, Antisense oligonucleotide modulation of raf gene expression.
DM953VY	RU	http://www.patentbuddy.com/Patent/5563255?ft=true&sr=true

DM5C86M	DI	DM5C86M
DM5C86M	DN	ISIS 9069
DM5C86M	MI	TT5TURO
DM5C86M	MN	A-Raf messenger RNA (ARAF mRNA)
DM5C86M	MT	DTT
DM5C86M	RN	US patent application no. 5,563,255, Antisense oligonucleotide modulation of raf gene expression.
DM5C86M	RU	http://www.patentbuddy.com/Patent/5563255?ft=true&sr=true

DMU0HQF	DI	DMU0HQF
DMU0HQF	DN	ISIS 9070
DMU0HQF	MI	TT5TURO
DMU0HQF	MN	A-Raf messenger RNA (ARAF mRNA)
DMU0HQF	MT	DTT
DMU0HQF	RN	US patent application no. 5,563,255, Antisense oligonucleotide modulation of raf gene expression.
DMU0HQF	RU	http://www.patentbuddy.com/Patent/5563255?ft=true&sr=true

DMWY2XB	DI	DMWY2XB
DMWY2XB	DN	ISIS 9071
DMWY2XB	MI	TT5TURO
DMWY2XB	MN	A-Raf messenger RNA (ARAF mRNA)
DMWY2XB	MT	DTT
DMWY2XB	RN	US patent application no. 5,563,255, Antisense oligonucleotide modulation of raf gene expression.
DMWY2XB	RU	http://www.patentbuddy.com/Patent/5563255?ft=true&sr=true

DMDKB1I	DI	DMDKB1I
DMDKB1I	DN	ISIS 9133
DMDKB1I	MI	TT53XHB
DMDKB1I	MN	CD86 messenger RNA (CD86 mRNA)
DMDKB1I	MT	DTT
DMDKB1I	RN	US patent application no. 6,319,906, Oligonucleotide compositions and methods for the modulation of the expression of B7 protein.
DMDKB1I	RU	http://www.patentbuddy.com/Patent/6319906?ft=true&sr=true

DMGOPHN	DI	DMGOPHN
DMGOPHN	DN	ISIS 9139
DMGOPHN	MI	TT53XHB
DMGOPHN	MN	CD86 messenger RNA (CD86 mRNA)
DMGOPHN	MT	DTT
DMGOPHN	RN	US patent application no. 6,319,906, Oligonucleotide compositions and methods for the modulation of the expression of B7 protein.
DMGOPHN	RU	http://www.patentbuddy.com/Patent/6319906?ft=true&sr=true

DM052M3	DI	DM052M3
DM052M3	DN	ISIS 9606
DM052M3	MI	TT2MI95
DM052M3	MN	PKC-alpha messenger RNA (PRKCA mRNA)
DM052M3	MT	DTT
DM052M3	RN	US patent application no. 6,300,320, Modulation of c-jun using inhibitors of protein kinase C.
DM052M3	RU	http://www.patentbuddy.com/Patent/6300320?ft=true&sr=true

DM054SL	DI	DM054SL
DM054SL	DN	ISIS 9984
DM054SL	MI	TT1PL7M
DM054SL	MN	E-selectin messenger RNA (SELE mRNA)
DM054SL	MT	DTT
DM054SL	RN	US patent application no. 5,789,573, Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2.
DM054SL	RU	http://www.patentbuddy.com/Patent/5789573?ft=true&sr=true

DMGN4OQ	DI	DMGN4OQ
DMGN4OQ	DN	ISIS-1939
DMGN4OQ	MI	TTCT6F7
DMGN4OQ	MN	Intercellular adhesion molecule ICAM-1 (ICAM1)
DMGN4OQ	MT	DTT
DMGN4OQ	MA	Modulator
DMGN4OQ	RN	Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J Biol Chem. 1991 Sep 25;266(27):18162-71.
DMGN4OQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/1680858

DMU64W8	DI	DMU64W8
DMU64W8	DN	ISO24
DMU64W8	MI	TT6PKBN
DMU64W8	MN	Proto-oncogene c-Src (SRC)
DMU64W8	MT	DTT
DMU64W8	MA	Inhibitor
DMU64W8	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMU64W8	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMGNFXY	DI	DMGNFXY
DMGNFXY	DN	isoamyl-agomelatine
DMGNFXY	MI	TT0WAIE
DMGNFXY	MN	Melatonin receptor type 1A (MTNR1A)
DMGNFXY	MT	DTT
DMGNFXY	MA	Agonist
DMGNFXY	RN	Design, synthesis and pharmacological evaluation of new series of naphthalenic analogues as melatoninergic (MT1/MT2) and serotoninergic 5-HT2C dual ligands (I). Eur J Med Chem. 2012 Mar;49:310-23.
DMGNFXY	RU	https://pubmed.ncbi.nlm.nih.gov/22301214

DMTEDHP	DI	DMTEDHP
DMTEDHP	DN	isoamylamine
DMTEDHP	MI	TTVX9SH
DMTEDHP	MN	Trace amine receptor 3 (TAAR3)
DMTEDHP	MT	DTT
DMTEDHP	MA	Agonist
DMTEDHP	RN	A second class of chemosensory receptors in the olfactory epithelium. Nature. 2006 Aug 10;442(7103):645-50.
DMTEDHP	RU	https://pubmed.ncbi.nlm.nih.gov/16878137

DM0B7NO	DI	DM0B7NO
DM0B7NO	DN	Isoarnebin 4
DM0B7NO	MI	TTNHMO8
DM0B7NO	MN	COVID-19 papain-like proteinase (PL-PRO)
DM0B7NO	MT	DTT
DM0B7NO	MA	Inhibitor
DM0B7NO	RN	Structure of Mpro from COVID-19 virus and discovery of its inhibitors. Nature. 2020 Apr 9.
DM0B7NO	RU	https://pubmed.ncbi.nlm.nih.gov/32272481

DMV8OCF	DI	DMV8OCF
DMV8OCF	DN	IsoBu-RYYRIK-NH2
DMV8OCF	MI	TTNT7K8
DMV8OCF	MN	Nociceptin receptor (OPRL1)
DMV8OCF	MT	DTT
DMV8OCF	MA	Inhibitor
DMV8OCF	RN	Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist. Bioorg Med Chem. 2008 Mar 1;16(5):2635-44.
DMV8OCF	RU	https://pubmed.ncbi.nlm.nih.gov/18068993

DM293XH	DI	DM293XH
DM293XH	DN	Isobutyl-(4-methyl-benzyl)-piperidin-4-yl-amine
DM293XH	MI	TTAWNKZ
DM293XH	MN	Norepinephrine transporter (NET)
DM293XH	MT	DTT
DM293XH	MA	Inhibitor
DM293XH	RN	N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake. Bioorg Med Chem Lett. 2006 May 15;16(10):2714-8.
DM293XH	RU	https://pubmed.ncbi.nlm.nih.gov/16497500

DM293XH	DI	DM293XH
DM293XH	DN	Isobutyl-(4-methyl-benzyl)-piperidin-4-yl-amine
DM293XH	MI	TT3ROYC
DM293XH	MN	Serotonin transporter (SERT)
DM293XH	MT	DTT
DM293XH	MA	Inhibitor
DM293XH	RN	N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake. Bioorg Med Chem Lett. 2006 May 15;16(10):2714-8.
DM293XH	RU	https://pubmed.ncbi.nlm.nih.gov/16497500

DM46F5X	DI	DM46F5X
DM46F5X	DN	isobutylmethylxanthine
DM46F5X	MI	TTK25J1
DM46F5X	MN	Adenosine A1 receptor (ADORA1)
DM46F5X	MT	DTT
DM46F5X	MA	Antagonist
DM46F5X	RN	Species difference in the G protein selectivity of the human and bovine A1-adenosine receptor. J Biol Chem. 1994 Dec 23;269(51):32077-84.
DM46F5X	RU	https://pubmed.ncbi.nlm.nih.gov/7798201

DM46F5X	DI	DM46F5X
DM46F5X	DN	isobutylmethylxanthine
DM46F5X	MI	TTM2AOE
DM46F5X	MN	Adenosine A2a receptor (ADORA2A)
DM46F5X	MT	DTT
DM46F5X	MA	Inhibitor
DM46F5X	RN	Analogues of caffeine and theophylline: effect of structural alterations on affinity at adenosine receptors. J Med Chem. 1986 Jul;29(7):1305-8.
DM46F5X	RU	https://pubmed.ncbi.nlm.nih.gov/3806581

DM46F5X	DI	DM46F5X
DM46F5X	DN	isobutylmethylxanthine
DM46F5X	MI	TTNE7KG
DM46F5X	MN	Adenosine A2b receptor (ADORA2B)
DM46F5X	MT	DTT
DM46F5X	MA	Inhibitor
DM46F5X	RN	Adenosine receptors: targets for future drugs. J Med Chem. 1982 Mar;25(3):197-207.
DM46F5X	RU	https://pubmed.ncbi.nlm.nih.gov/6279840

DM46F5X	DI	DM46F5X
DM46F5X	DN	isobutylmethylxanthine
DM46F5X	MI	TTJFY5U
DM46F5X	MN	Adenosine A3 receptor (ADORA3)
DM46F5X	MT	DTT
DM46F5X	MA	Inhibitor
DM46F5X	RN	Adenosine receptors: targets for future drugs. J Med Chem. 1982 Mar;25(3):197-207.
DM46F5X	RU	https://pubmed.ncbi.nlm.nih.gov/6279840

DM46F5X	DI	DM46F5X
DM46F5X	DN	isobutylmethylxanthine
DM46F5X	MI	TTHQENC
DM46F5X	MN	Phosphodiesterase 1 (PDE1)
DM46F5X	MT	DTT
DM46F5X	MA	Inhibitor
DM46F5X	RN	A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem. 1985 May;28(5):537-45.
DM46F5X	RU	https://pubmed.ncbi.nlm.nih.gov/2985781

DM46F5X	DI	DM46F5X
DM46F5X	DN	isobutylmethylxanthine
DM46F5X	MI	TTJGW1Z
DM46F5X	MN	Phosphodiesterase 2A (PDE2A)
DM46F5X	MT	DTT
DM46F5X	MA	Inhibitor
DM46F5X	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM46F5X	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM46F5X	DI	DM46F5X
DM46F5X	DN	isobutylmethylxanthine
DM46F5X	MI	TT06AWU
DM46F5X	MN	Phosphodiesterase 3A (PDE3A)
DM46F5X	MT	DTT
DM46F5X	MA	Inhibitor
DM46F5X	RN	A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem. 1985 May;28(5):537-45.
DM46F5X	RU	https://pubmed.ncbi.nlm.nih.gov/2985781

DM46F5X	DI	DM46F5X
DM46F5X	DN	isobutylmethylxanthine
DM46F5X	MI	TTZ97H5
DM46F5X	MN	Phosphodiesterase 4A (PDE4A)
DM46F5X	MT	DTT
DM46F5X	MA	Inhibitor
DM46F5X	RN	A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem. 1985 May;28(5):537-45.
DM46F5X	RU	https://pubmed.ncbi.nlm.nih.gov/2985781

DM46F5X	DI	DM46F5X
DM46F5X	DN	isobutylmethylxanthine
DM46F5X	MI	TTVIAT9
DM46F5X	MN	Phosphodiesterase 4B (PDE4B)
DM46F5X	MT	DTT
DM46F5X	MA	Inhibitor
DM46F5X	RN	A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem. 1985 May;28(5):537-45.
DM46F5X	RU	https://pubmed.ncbi.nlm.nih.gov/2985781

DM46F5X	DI	DM46F5X
DM46F5X	DN	isobutylmethylxanthine
DM46F5X	MI	TTSKMI8
DM46F5X	MN	Phosphodiesterase 4D (PDE4D)
DM46F5X	MT	DTT
DM46F5X	MA	Inhibitor
DM46F5X	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM46F5X	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM46F5X	DI	DM46F5X
DM46F5X	DN	isobutylmethylxanthine
DM46F5X	MI	TTJ0IQB
DM46F5X	MN	Phosphodiesterase 5A (PDE5A)
DM46F5X	MT	DTT
DM46F5X	MA	Inhibitor
DM46F5X	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM46F5X	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMX4VY9	DI	DMX4VY9
DMX4VY9	DN	isobutyric acid
DMX4VY9	MI	TT0FYAN
DMX4VY9	MN	Free fatty acid receptor 2 (FFAR2)
DMX4VY9	MT	DTT
DMX4VY9	MA	Agonist
DMX4VY9	RN	Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem. 2003 Jul 11;278(28):25481-9.
DMX4VY9	RU	https://pubmed.ncbi.nlm.nih.gov/12711604

DMX4VY9	DI	DMX4VY9
DMX4VY9	DN	isobutyric acid
DMX4VY9	MI	TTXDOHN
DMX4VY9	MN	Free fatty acid receptor 3 (FFAR3)
DMX4VY9	MT	DTT
DMX4VY9	MA	Agonist
DMX4VY9	RN	Short-chain fatty acids stimulate leptin production in adipocytes through the G protein-coupled receptor GPR41. Proc Natl Acad Sci U S A. 2004 Jan 27;101(4):1045-50.
DMX4VY9	RU	https://pubmed.ncbi.nlm.nih.gov/14722361

DM861DU	DI	DM861DU
DM861DU	DN	Iso-caffeine
DM861DU	MI	TTV5CGO
DM861DU	MN	Phosphodiesterase 4 (PDE4)
DM861DU	MT	DTT
DM861DU	MA	Inhibitor
DM861DU	RN	Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol. 1994 Jun 2;258(1-2):85-94.
DM861DU	RU	https://pubmed.ncbi.nlm.nih.gov/7925603

DMZR7W6	DI	DMZR7W6
DMZR7W6	DN	isocarbacyclin
DMZR7W6	MI	TTOFYT1
DMZR7W6	MN	Prostacyclin receptor (PTGIR)
DMZR7W6	MT	DTT
DMZR7W6	MA	Agonist
DMZR7W6	RN	Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
DMZR7W6	RU	https://pubmed.ncbi.nlm.nih.gov/9313928

DMZR7W6	DI	DMZR7W6
DMZR7W6	DN	isocarbacyclin
DMZR7W6	MI	TT1ZAVI
DMZR7W6	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DMZR7W6	MT	DTT
DMZR7W6	MA	Agonist
DMZR7W6	RN	Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
DMZR7W6	RU	https://pubmed.ncbi.nlm.nih.gov/9313928

DMZR7W6	DI	DMZR7W6
DMZR7W6	DN	isocarbacyclin
DMZR7W6	MI	TTPNGDE
DMZR7W6	MN	Prostaglandin E2 receptor EP3 (PTGER3)
DMZR7W6	MT	DTT
DMZR7W6	MA	Agonist
DMZR7W6	RN	Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
DMZR7W6	RU	https://pubmed.ncbi.nlm.nih.gov/9313928

DMUB187	DI	DMUB187
DMUB187	DN	Isochroman mono-carboxylic acid
DMUB187	MI	TTELIN2
DMUB187	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMUB187	MT	DTT
DMUB187	MA	Inhibitor
DMUB187	RN	Synthesis and evaluation of some novel dibenzo[b,d]furan carboxylic acids as potential anti-diabetic agents. Eur J Med Chem. 2010 Sep;45(9):3709-18.
DMUB187	RU	https://pubmed.ncbi.nlm.nih.gov/20627471

DMJKW4S	DI	DMJKW4S
DMJKW4S	DN	Isocitric Acid
DMJKW4S	MI	TTMTF2P
DMJKW4S	MN	Citrate hydro-lyase (ACO2)
DMJKW4S	MT	DTT
DMJKW4S	MA	Inhibitor
DMJKW4S	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMJKW4S	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM52CPU	DI	DM52CPU
DM52CPU	DN	ISOCLOZAPINE
DM52CPU	MI	TTJQOD7
DM52CPU	MN	5-HT 2A receptor (HTR2A)
DM52CPU	MT	DTT
DM52CPU	MA	Inhibitor
DM52CPU	RN	Synthesis and pharmacological evaluation of triflate-substituted analogues of clozapine: identification of a novel atypical neuroleptic. J Med Chem. 1997 Dec 5;40(25):4146-53.
DM52CPU	RU	https://pubmed.ncbi.nlm.nih.gov/9406603

DM52CPU	DI	DM52CPU
DM52CPU	DN	ISOCLOZAPINE
DM52CPU	MI	TTNGILX
DM52CPU	MN	Adrenergic receptor alpha-1A (ADRA1A)
DM52CPU	MT	DTT
DM52CPU	MA	Inhibitor
DM52CPU	RN	Synthesis and pharmacological evaluation of triflate-substituted analogues of clozapine: identification of a novel atypical neuroleptic. J Med Chem. 1997 Dec 5;40(25):4146-53.
DM52CPU	RU	https://pubmed.ncbi.nlm.nih.gov/9406603

DM52CPU	DI	DM52CPU
DM52CPU	DN	ISOCLOZAPINE
DM52CPU	MI	TTBRKXS
DM52CPU	MN	Adrenergic receptor alpha-1B (ADRA1B)
DM52CPU	MT	DTT
DM52CPU	MA	Inhibitor
DM52CPU	RN	Synthesis and pharmacological evaluation of triflate-substituted analogues of clozapine: identification of a novel atypical neuroleptic. J Med Chem. 1997 Dec 5;40(25):4146-53.
DM52CPU	RU	https://pubmed.ncbi.nlm.nih.gov/9406603

DM52CPU	DI	DM52CPU
DM52CPU	DN	ISOCLOZAPINE
DM52CPU	MI	TT34BHT
DM52CPU	MN	Adrenergic receptor alpha-1D (ADRA1D)
DM52CPU	MT	DTT
DM52CPU	MA	Inhibitor
DM52CPU	RN	Synthesis and pharmacological evaluation of triflate-substituted analogues of clozapine: identification of a novel atypical neuroleptic. J Med Chem. 1997 Dec 5;40(25):4146-53.
DM52CPU	RU	https://pubmed.ncbi.nlm.nih.gov/9406603

DM52CPU	DI	DM52CPU
DM52CPU	DN	ISOCLOZAPINE
DM52CPU	MI	TTZFYLI
DM52CPU	MN	Dopamine D1 receptor (D1R)
DM52CPU	MT	DTT
DM52CPU	MA	Inhibitor
DM52CPU	RN	Synthesis and pharmacological evaluation of triflate-substituted analogues of clozapine: identification of a novel atypical neuroleptic. J Med Chem. 1997 Dec 5;40(25):4146-53.
DM52CPU	RU	https://pubmed.ncbi.nlm.nih.gov/9406603

DM52CPU	DI	DM52CPU
DM52CPU	DN	ISOCLOZAPINE
DM52CPU	MI	TTEX248
DM52CPU	MN	Dopamine D2 receptor (D2R)
DM52CPU	MT	DTT
DM52CPU	MA	Inhibitor
DM52CPU	RN	Synthesis and pharmacological evaluation of triflate-substituted analogues of clozapine: identification of a novel atypical neuroleptic. J Med Chem. 1997 Dec 5;40(25):4146-53.
DM52CPU	RU	https://pubmed.ncbi.nlm.nih.gov/9406603

DM52CPU	DI	DM52CPU
DM52CPU	DN	ISOCLOZAPINE
DM52CPU	MI	TT4C8EA
DM52CPU	MN	Dopamine D3 receptor (D3R)
DM52CPU	MT	DTT
DM52CPU	MA	Inhibitor
DM52CPU	RN	Affinity of 10-(4-methylpiperazino)dibenz[b,f]oxepins for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1982 Jul;25(7):855-8.
DM52CPU	RU	https://pubmed.ncbi.nlm.nih.gov/7108902

DM52CPU	DI	DM52CPU
DM52CPU	DN	ISOCLOZAPINE
DM52CPU	MI	TTE0A2F
DM52CPU	MN	Dopamine D4 receptor (D4R)
DM52CPU	MT	DTT
DM52CPU	MA	Inhibitor
DM52CPU	RN	Affinity of 10-(4-methylpiperazino)dibenz[b,f]oxepins for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1982 Jul;25(7):855-8.
DM52CPU	RU	https://pubmed.ncbi.nlm.nih.gov/7108902

DM52CPU	DI	DM52CPU
DM52CPU	DN	ISOCLOZAPINE
DM52CPU	MI	TTS2PH3
DM52CPU	MN	Dopamine D5 receptor (D5R)
DM52CPU	MT	DTT
DM52CPU	MA	Inhibitor
DM52CPU	RN	Affinity of 10-(4-methylpiperazino)dibenz[b,f]oxepins for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1982 Jul;25(7):855-8.
DM52CPU	RU	https://pubmed.ncbi.nlm.nih.gov/7108902

DM52CPU	DI	DM52CPU
DM52CPU	DN	ISOCLOZAPINE
DM52CPU	MI	TTZ9SOR
DM52CPU	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DM52CPU	MT	DTT
DM52CPU	MA	Inhibitor
DM52CPU	RN	Chloro-substituted, sterically hindered 5,11-dicarbo analogues of clozapine as potential chiral antipsychotic agents. J Med Chem. 1990 Feb;33(2):809-14.
DM52CPU	RU	https://pubmed.ncbi.nlm.nih.gov/1967652

DM52CPU	DI	DM52CPU
DM52CPU	DN	ISOCLOZAPINE
DM52CPU	MI	TTYEG6Q
DM52CPU	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DM52CPU	MT	DTT
DM52CPU	MA	Inhibitor
DM52CPU	RN	Chloro-substituted, sterically hindered 5,11-dicarbo analogues of clozapine as potential chiral antipsychotic agents. J Med Chem. 1990 Feb;33(2):809-14.
DM52CPU	RU	https://pubmed.ncbi.nlm.nih.gov/1967652

DM52CPU	DI	DM52CPU
DM52CPU	DN	ISOCLOZAPINE
DM52CPU	MI	TTQ13Z5
DM52CPU	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DM52CPU	MT	DTT
DM52CPU	MA	Inhibitor
DM52CPU	RN	Chloro-substituted, sterically hindered 5,11-dicarbo analogues of clozapine as potential chiral antipsychotic agents. J Med Chem. 1990 Feb;33(2):809-14.
DM52CPU	RU	https://pubmed.ncbi.nlm.nih.gov/1967652

DM52CPU	DI	DM52CPU
DM52CPU	DN	ISOCLOZAPINE
DM52CPU	MI	TTQ3JTF
DM52CPU	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DM52CPU	MT	DTT
DM52CPU	MA	Inhibitor
DM52CPU	RN	Chloro-substituted, sterically hindered 5,11-dicarbo analogues of clozapine as potential chiral antipsychotic agents. J Med Chem. 1990 Feb;33(2):809-14.
DM52CPU	RU	https://pubmed.ncbi.nlm.nih.gov/1967652

DM52CPU	DI	DM52CPU
DM52CPU	DN	ISOCLOZAPINE
DM52CPU	MI	TTH18TF
DM52CPU	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DM52CPU	MT	DTT
DM52CPU	MA	Inhibitor
DM52CPU	RN	Chloro-substituted, sterically hindered 5,11-dicarbo analogues of clozapine as potential chiral antipsychotic agents. J Med Chem. 1990 Feb;33(2):809-14.
DM52CPU	RU	https://pubmed.ncbi.nlm.nih.gov/1967652

DMMF1HX	DI	DMMF1HX
DMMF1HX	DN	ISOCONAZOLE
DMMF1HX	MI	TTRA5BZ
DMMF1HX	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMMF1HX	MT	DTT
DMMF1HX	MA	Inhibitor
DMMF1HX	RN	Three dimensional pharmacophore modeling of human CYP17 inhibitors. Potential agents for prostate cancer therapy. J Med Chem. 2003 Jun 5;46(12):2345-51.
DMMF1HX	RU	https://pubmed.ncbi.nlm.nih.gov/12773039

DM7ZSVD	DI	DM7ZSVD
DM7ZSVD	DN	ISODISPAR B
DM7ZSVD	MI	TT84ETX
DM7ZSVD	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM7ZSVD	MT	DTT
DM7ZSVD	MA	Inhibitor
DM7ZSVD	RN	4-Phenylcoumarins as HIV transcription inhibitors. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4447-50.
DM7ZSVD	RU	https://pubmed.ncbi.nlm.nih.gov/16137881

DMSLO71	DI	DMSLO71
DMSLO71	DN	Isoelaeocarpine
DMSLO71	MI	TT27RFC
DMSLO71	MN	Opioid receptor delta (OPRD1)
DMSLO71	MT	DTT
DMSLO71	MA	Inhibitor
DMSLO71	RN	Indolizidine alkaloids with delta-opioid receptor binding affinity from the leaves of Elaeocarpus fuscoides. J Nat Prod. 2007 May;70(5):872-5.
DMSLO71	RU	https://pubmed.ncbi.nlm.nih.gov/17451272

DMN23KT	DI	DMN23KT
DMN23KT	DN	isoferulic acid
DMN23KT	MI	TTXMI0C
DMN23KT	MN	Phosphomevalonate kinase (PMVK)
DMN23KT	MT	DTT
DMN23KT	MA	Inhibitor
DMN23KT	RN	Inhibition of rat liver mevalonate pyrophosphate decarboxylase and mevalonate phosphate kinase by phenyl and phenolic compounds. Biochem J. 1979 Jul 1;181(1):143-51.
DMN23KT	RU	https://pubmed.ncbi.nlm.nih.gov/226078

DM5CMA8	DI	DM5CMA8
DM5CMA8	DN	ISOFORMONENTIN
DM5CMA8	MI	TTFLN4T
DM5CMA8	MN	Mitochondrial aldehyde dehydrogenase (ALDH2)
DM5CMA8	MT	DTT
DM5CMA8	MA	Inhibitor
DM5CMA8	RN	Structure of daidzin, a naturally occurring anti-alcohol-addiction agent, in complex with human mitochondrial aldehyde dehydrogenase. J Med Chem. 2008 Aug 14;51(15):4482-7.
DM5CMA8	RU	https://pubmed.ncbi.nlm.nih.gov/18613661

DM31AXO	DI	DM31AXO
DM31AXO	DN	Isogemichalcone C
DM31AXO	MI	TTSZLWK
DM31AXO	MN	Aromatase (CYP19A1)
DM31AXO	MT	DTT
DM31AXO	MA	Inhibitor
DM31AXO	RN	Aromatase inhibitors from Broussonetia papyrifera. J Nat Prod. 2001 Oct;64(10):1286-93.
DM31AXO	RU	https://pubmed.ncbi.nlm.nih.gov/11678652

DMCF1ZD	DI	DMCF1ZD
DMCF1ZD	DN	ISOGOIAZENSOLIDE
DMCF1ZD	MI	TTSXVID
DMCF1ZD	MN	Nuclear factor NF-kappa-B (NFKB)
DMCF1ZD	MT	DTT
DMCF1ZD	MA	Inhibitor
DMCF1ZD	RN	Quantitative structure-activity relationship of sesquiterpene lactones as inhibitors of the transcription factor NF-kappaB. J Med Chem. 2004 Nov 18;47(24):6042-54.
DMCF1ZD	RU	https://pubmed.ncbi.nlm.nih.gov/15537359

DMI6NJ1	DI	DMI6NJ1
DMI6NJ1	DN	Isogranulatimide
DMI6NJ1	MI	TTTU902
DMI6NJ1	MN	Checkpoint kinase-1 (CHK1)
DMI6NJ1	MT	DTT
DMI6NJ1	MA	Inhibitor
DMI6NJ1	RN	Synthesis, in vitro antiproliferative activities, and Chk1 inhibitory properties of pyrrolo[3,4-a]carbazole-1,3-diones, pyrrolo[3,4-c]carbazole-1,3... Eur J Med Chem. 2008 Feb;43(2):282-92.
DMI6NJ1	RU	https://pubmed.ncbi.nlm.nih.gov/17502122

DMAFLCJ	DI	DMAFLCJ
DMAFLCJ	DN	Isoguanosine
DMAFLCJ	MI	TTK25J1
DMAFLCJ	MN	Adenosine A1 receptor (ADORA1)
DMAFLCJ	MT	DTT
DMAFLCJ	MA	Inhibitor
DMAFLCJ	RN	High selectivity of novel isoguanosine analogues for the adenosine A1 receptor. Bioorg. Med. Chem. Lett. 1(9):481-486 (1991).
DMAFLCJ	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01811100

DMAFLCJ	DI	DMAFLCJ
DMAFLCJ	DN	Isoguanosine
DMAFLCJ	MI	TTM2AOE
DMAFLCJ	MN	Adenosine A2a receptor (ADORA2A)
DMAFLCJ	MT	DTT
DMAFLCJ	MA	Inhibitor
DMAFLCJ	RN	High selectivity of novel isoguanosine analogues for the adenosine A1 receptor. Bioorg. Med. Chem. Lett. 1(9):481-486 (1991).
DMAFLCJ	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01811100

DMAFLCJ	DI	DMAFLCJ
DMAFLCJ	DN	Isoguanosine
DMAFLCJ	MI	TTNE7KG
DMAFLCJ	MN	Adenosine A2b receptor (ADORA2B)
DMAFLCJ	MT	DTT
DMAFLCJ	MA	Inhibitor
DMAFLCJ	RN	High selectivity of novel isoguanosine analogues for the adenosine A1 receptor. Bioorg. Med. Chem. Lett. 1(9):481-486 (1991).
DMAFLCJ	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01811100

DMZH9PW	DI	DMZH9PW
DMZH9PW	DN	Isohelenin
DMZH9PW	MI	TTSXVID
DMZH9PW	MN	Nuclear factor NF-kappa-B (NFKB)
DMZH9PW	MT	DTT
DMZH9PW	MA	Inhibitor
DMZH9PW	RN	Protective effects of isohelenin, an inhibitor of nuclear factor kappaB, in endotoxic shock in rats. J Endotoxin Res. 2002;8(2):99-107.
DMZH9PW	RU	https://pubmed.ncbi.nlm.nih.gov/12028749

DMQC4HV	DI	DMQC4HV
DMQC4HV	DN	Isoindolinone Urea derivative
DMQC4HV	MI	TTUTJGQ
DMQC4HV	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMQC4HV	MT	DTT
DMQC4HV	MA	Inhibitor
DMQC4HV	RN	Isoindolinone ureas: a novel class of KDR kinase inhibitors. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4505-9.
DMQC4HV	RU	https://pubmed.ncbi.nlm.nih.gov/15357981

DMHTBDN	DI	DMHTBDN
DMHTBDN	DN	Isojaspic acid
DMHTBDN	MI	TT12ABZ
DMHTBDN	MN	Arachidonate 12-lipoxygenase (12-LOX)
DMHTBDN	MT	DTT
DMHTBDN	MA	Inhibitor
DMHTBDN	RN	Using enzyme assays to evaluate the structure and bioactivity of sponge-derived meroterpenes. J Nat Prod. 2009 Oct;72(10):1857-63.
DMHTBDN	RU	https://pubmed.ncbi.nlm.nih.gov/19848434

DMHTBDN	DI	DMHTBDN
DMHTBDN	DN	Isojaspic acid
DMHTBDN	MI	TTN9T81
DMHTBDN	MN	Arachidonate 15-lipoxygenase (15-LOX)
DMHTBDN	MT	DTT
DMHTBDN	MA	Inhibitor
DMHTBDN	RN	Using enzyme assays to evaluate the structure and bioactivity of sponge-derived meroterpenes. J Nat Prod. 2009 Oct;72(10):1857-63.
DMHTBDN	RU	https://pubmed.ncbi.nlm.nih.gov/19848434

DMHTBDN	DI	DMHTBDN
DMHTBDN	DN	Isojaspic acid
DMHTBDN	MI	TTSJ6Q4
DMHTBDN	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DMHTBDN	MT	DTT
DMHTBDN	MA	Inhibitor
DMHTBDN	RN	Using enzyme assays to evaluate the structure and bioactivity of sponge-derived meroterpenes. J Nat Prod. 2009 Oct;72(10):1857-63.
DMHTBDN	RU	https://pubmed.ncbi.nlm.nih.gov/19848434

DMYEGBC	DI	DMYEGBC
DMYEGBC	DN	ISOLICOFLAVONOL
DMYEGBC	MI	TTSZLWK
DMYEGBC	MN	Aromatase (CYP19A1)
DMYEGBC	MT	DTT
DMYEGBC	MA	Inhibitor
DMYEGBC	RN	Aromatase inhibitors from Broussonetia papyrifera. J Nat Prod. 2001 Oct;64(10):1286-93.
DMYEGBC	RU	https://pubmed.ncbi.nlm.nih.gov/11678652

DMXWOBE	DI	DMXWOBE
DMXWOBE	DN	ISOLONGIFOLOL
DMXWOBE	MI	TTO69J7
DMXWOBE	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMXWOBE	MT	DTT
DMXWOBE	MA	Inhibitor
DMXWOBE	RN	Isoform-selective inhibition of the human UDP-glucuronosyltransferase 2B7 by isolongifolol derivatives. J Med Chem. 2007 May 31;50(11):2655-64.
DMXWOBE	RU	https://pubmed.ncbi.nlm.nih.gov/17474732

DMH1BN4	DI	DMH1BN4
DMH1BN4	DN	ISOLOXAPINE
DMH1BN4	MI	TTZFYLI
DMH1BN4	MN	Dopamine D1 receptor (D1R)
DMH1BN4	MT	DTT
DMH1BN4	MA	Inhibitor
DMH1BN4	RN	Synthesis of clozapine analogues and their affinity for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1981 Sep;24(9):1021-6.
DMH1BN4	RU	https://pubmed.ncbi.nlm.nih.gov/7288815

DMH1BN4	DI	DMH1BN4
DMH1BN4	DN	ISOLOXAPINE
DMH1BN4	MI	TTEX248
DMH1BN4	MN	Dopamine D2 receptor (D2R)
DMH1BN4	MT	DTT
DMH1BN4	MA	Inhibitor
DMH1BN4	RN	Synthesis of clozapine analogues and their affinity for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1981 Sep;24(9):1021-6.
DMH1BN4	RU	https://pubmed.ncbi.nlm.nih.gov/7288815

DMH1BN4	DI	DMH1BN4
DMH1BN4	DN	ISOLOXAPINE
DMH1BN4	MI	TT4C8EA
DMH1BN4	MN	Dopamine D3 receptor (D3R)
DMH1BN4	MT	DTT
DMH1BN4	MA	Inhibitor
DMH1BN4	RN	Synthesis of clozapine analogues and their affinity for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1981 Sep;24(9):1021-6.
DMH1BN4	RU	https://pubmed.ncbi.nlm.nih.gov/7288815

DMH1BN4	DI	DMH1BN4
DMH1BN4	DN	ISOLOXAPINE
DMH1BN4	MI	TTE0A2F
DMH1BN4	MN	Dopamine D4 receptor (D4R)
DMH1BN4	MT	DTT
DMH1BN4	MA	Inhibitor
DMH1BN4	RN	Synthesis of clozapine analogues and their affinity for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1981 Sep;24(9):1021-6.
DMH1BN4	RU	https://pubmed.ncbi.nlm.nih.gov/7288815

DMH1BN4	DI	DMH1BN4
DMH1BN4	DN	ISOLOXAPINE
DMH1BN4	MI	TTS2PH3
DMH1BN4	MN	Dopamine D5 receptor (D5R)
DMH1BN4	MT	DTT
DMH1BN4	MA	Inhibitor
DMH1BN4	RN	Synthesis of clozapine analogues and their affinity for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1981 Sep;24(9):1021-6.
DMH1BN4	RU	https://pubmed.ncbi.nlm.nih.gov/7288815

DMH1BN4	DI	DMH1BN4
DMH1BN4	DN	ISOLOXAPINE
DMH1BN4	MI	TTZ9SOR
DMH1BN4	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMH1BN4	MT	DTT
DMH1BN4	MA	Inhibitor
DMH1BN4	RN	Synthesis of clozapine analogues and their affinity for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1981 Sep;24(9):1021-6.
DMH1BN4	RU	https://pubmed.ncbi.nlm.nih.gov/7288815

DMH1BN4	DI	DMH1BN4
DMH1BN4	DN	ISOLOXAPINE
DMH1BN4	MI	TTYEG6Q
DMH1BN4	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMH1BN4	MT	DTT
DMH1BN4	MA	Inhibitor
DMH1BN4	RN	Synthesis of clozapine analogues and their affinity for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1981 Sep;24(9):1021-6.
DMH1BN4	RU	https://pubmed.ncbi.nlm.nih.gov/7288815

DMH1BN4	DI	DMH1BN4
DMH1BN4	DN	ISOLOXAPINE
DMH1BN4	MI	TTQ13Z5
DMH1BN4	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMH1BN4	MT	DTT
DMH1BN4	MA	Inhibitor
DMH1BN4	RN	Synthesis of clozapine analogues and their affinity for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1981 Sep;24(9):1021-6.
DMH1BN4	RU	https://pubmed.ncbi.nlm.nih.gov/7288815

DMH1BN4	DI	DMH1BN4
DMH1BN4	DN	ISOLOXAPINE
DMH1BN4	MI	TTQ3JTF
DMH1BN4	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DMH1BN4	MT	DTT
DMH1BN4	MA	Inhibitor
DMH1BN4	RN	Synthesis of clozapine analogues and their affinity for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1981 Sep;24(9):1021-6.
DMH1BN4	RU	https://pubmed.ncbi.nlm.nih.gov/7288815

DMH1BN4	DI	DMH1BN4
DMH1BN4	DN	ISOLOXAPINE
DMH1BN4	MI	TTH18TF
DMH1BN4	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMH1BN4	MT	DTT
DMH1BN4	MA	Inhibitor
DMH1BN4	RN	Synthesis of clozapine analogues and their affinity for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1981 Sep;24(9):1021-6.
DMH1BN4	RU	https://pubmed.ncbi.nlm.nih.gov/7288815

DMD1KSW	DI	DMD1KSW
DMD1KSW	DN	Isomaltose
DMD1KSW	MI	DEST6E5
DMD1KSW	MN	Alpha-glucosidase (aglA)
DMD1KSW	MT	DME
DMD1KSW	MA	Metabolism
DMD1KSW	RN	Novel alpha-glucosidase from human gut microbiome: substrate specificities and their switch. FASEB J. 2010 Oct;24(10):3939-49.
DMD1KSW	RU	https://pubmed.ncbi.nlm.nih.gov/20581222

DMOJ52F	DI	DMOJ52F
DMOJ52F	DN	ISOMER A
DMOJ52F	MI	TTY6O0Q
DMOJ52F	MN	Calcitonin gene-related peptide receptor (CGRPR)
DMOJ52F	MT	DTT
DMOJ52F	MA	Inhibitor
DMOJ52F	RN	The identification of potent, orally bioavailable tricyclic CGRP receptor antagonists. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4740-2.
DMOJ52F	RU	https://pubmed.ncbi.nlm.nih.gov/19577468

DM69XT3	DI	DM69XT3
DM69XT3	DN	ISONEORAUTENOL
DM69XT3	MI	TT50QJ3
DM69XT3	MN	Influenza Neuraminidase (Influ NA)
DM69XT3	MT	DTT
DM69XT3	MA	Inhibitor
DM69XT3	RN	Prenylated pterocarpans as bacterial neuraminidase inhibitors. Bioorg Med Chem. 2010 May 1;18(9):3335-44.
DM69XT3	RU	https://pubmed.ncbi.nlm.nih.gov/20363636

DMUVAIF	DI	DMUVAIF
DMUVAIF	DN	ISONICOTINIC ACID
DMUVAIF	MI	TTWNV8U
DMUVAIF	MN	Nicotinic acid receptor (HCAR2)
DMUVAIF	MT	DTT
DMUVAIF	MA	Inhibitor
DMUVAIF	RN	Pyrazole derivatives as partial agonists for the nicotinic acid receptor. J Med Chem. 2003 Aug 28;46(18):3945-51.
DMUVAIF	RU	https://pubmed.ncbi.nlm.nih.gov/12930155

DM5DKUY	DI	DM5DKUY
DM5DKUY	DN	ISONIPECOTAMIDE
DM5DKUY	MI	TTT1R2L
DM5DKUY	MN	Integrin alpha-V (ITGAV)
DM5DKUY	MT	DTT
DM5DKUY	MA	Inhibitor
DM5DKUY	RN	Piperidine-containing beta-arylpropionic acids as potent antagonists of alphavbeta3/alphavbeta5 integrins. Bioorg Med Chem Lett. 2004 Oct 18;14(20):5227-32.
DM5DKUY	RU	https://pubmed.ncbi.nlm.nih.gov/15380233

DM5DKUY	DI	DM5DKUY
DM5DKUY	DN	ISONIPECOTAMIDE
DM5DKUY	MI	TTJA1ZO
DM5DKUY	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DM5DKUY	MT	DTT
DM5DKUY	MA	Inhibitor
DM5DKUY	RN	Piperidine-containing beta-arylpropionic acids as potent antagonists of alphavbeta3/alphavbeta5 integrins. Bioorg Med Chem Lett. 2004 Oct 18;14(20):5227-32.
DM5DKUY	RU	https://pubmed.ncbi.nlm.nih.gov/15380233

DMO1ZHE	DI	DMO1ZHE
DMO1ZHE	DN	Isonipecotic acid
DMO1ZHE	MI	TTBMV1G
DMO1ZHE	MN	GABA(A) receptor alpha-2 (GABRA2)
DMO1ZHE	MT	DTT
DMO1ZHE	MA	Agonist
DMO1ZHE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 405).
DMO1ZHE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=405

DMO1ZHE	DI	DMO1ZHE
DMO1ZHE	DN	Isonipecotic acid
DMO1ZHE	MI	TT37EDJ
DMO1ZHE	MN	GABA(A) receptor alpha-3 (GABRA3)
DMO1ZHE	MT	DTT
DMO1ZHE	MA	Agonist
DMO1ZHE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 406).
DMO1ZHE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=406

DMO1ZHE	DI	DMO1ZHE
DMO1ZHE	DN	Isonipecotic acid
DMO1ZHE	MI	TTNZPQ1
DMO1ZHE	MN	GABA(A) receptor alpha-5 (GABRA5)
DMO1ZHE	MT	DTT
DMO1ZHE	MA	Agonist
DMO1ZHE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 408).
DMO1ZHE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=408

DMO1ZHE	DI	DMO1ZHE
DMO1ZHE	DN	Isonipecotic acid
DMO1ZHE	MI	TTEX6LM
DMO1ZHE	MN	GABA(A) receptor gamma-3 (GABRG3)
DMO1ZHE	MT	DTT
DMO1ZHE	MA	Agonist
DMO1ZHE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415).
DMO1ZHE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415

DMO1ZHE	DI	DMO1ZHE
DMO1ZHE	DN	Isonipecotic acid
DMO1ZHE	MI	TT6XFEU
DMO1ZHE	MN	GABA(A) receptor rho1 (GABRR1)
DMO1ZHE	MT	DTT
DMO1ZHE	MA	Antagonist
DMO1ZHE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 420).
DMO1ZHE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=420

DMO1ZHE	DI	DMO1ZHE
DMO1ZHE	DN	Isonipecotic acid
DMO1ZHE	MI	TTQMXLS
DMO1ZHE	MN	GABA(A) receptor rho2 (GABRR2)
DMO1ZHE	MT	DTT
DMO1ZHE	MA	Antagonist
DMO1ZHE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 421).
DMO1ZHE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=421

DMO1ZHE	DI	DMO1ZHE
DMO1ZHE	DN	Isonipecotic acid
DMO1ZHE	MI	TT4N6D8
DMO1ZHE	MN	GABA(A) receptor rho3 (GABRR3)
DMO1ZHE	MT	DTT
DMO1ZHE	MA	Antagonist
DMO1ZHE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 422).
DMO1ZHE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=422

DMO1ZHE	DI	DMO1ZHE
DMO1ZHE	DN	Isonipecotic acid
DMO1ZHE	MI	TTNJYV2
DMO1ZHE	MN	Gamma-aminobutyric acid receptor (GAR)
DMO1ZHE	MT	DTT
DMO1ZHE	MA	Inhibitor
DMO1ZHE	RN	Hydroxy- and amino-substituted piperidinecarboxylic acids as gamma-aminobutyric acid agonists and uptake inhibitors. J Med Chem. 1982 Oct;25(10):1157-62.
DMO1ZHE	RU	https://pubmed.ncbi.nlm.nih.gov/6292417

DMFX16H	DI	DMFX16H
DMFX16H	DN	Iso-OMPA
DMFX16H	MI	TT1RS9F
DMFX16H	MN	Acetylcholinesterase (AChE)
DMFX16H	MT	DTT
DMFX16H	MA	Inhibitor
DMFX16H	RN	Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9.
DMFX16H	RU	https://pubmed.ncbi.nlm.nih.gov/18817366

DMFX16H	DI	DMFX16H
DMFX16H	DN	Iso-OMPA
DMFX16H	MI	TTEB0GD
DMFX16H	MN	Cholinesterase (BCHE)
DMFX16H	MT	DTT
DMFX16H	MA	Inhibitor
DMFX16H	RN	Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9.
DMFX16H	RU	https://pubmed.ncbi.nlm.nih.gov/18817366

DMTU05Y	DI	DMTU05Y
DMTU05Y	DN	ISOPENTENYL PYROPHOSPHATE
DMTU05Y	MI	TT5VER7
DMTU05Y	MN	Bacterial Undecaprenyl pyrophosphate synthetase (Bact ispU)
DMTU05Y	MT	DTT
DMTU05Y	MA	Inhibitor
DMTU05Y	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMTU05Y	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMTU05Y	DI	DMTU05Y
DMTU05Y	DN	ISOPENTENYL PYROPHOSPHATE
DMTU05Y	MI	TTIKWV4
DMTU05Y	MN	Geranyltranstransferase (FDPS)
DMTU05Y	MT	DTT
DMTU05Y	MA	Inhibitor
DMTU05Y	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMTU05Y	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM9J5IS	DI	DM9J5IS
DM9J5IS	DN	Isopentyl Pyrophosphate
DM9J5IS	MI	TTIKWV4
DM9J5IS	MN	Geranyltranstransferase (FDPS)
DM9J5IS	MT	DTT
DM9J5IS	MA	Inhibitor
DM9J5IS	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9J5IS	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9ERD6	DI	DM9ERD6
DM9ERD6	DN	ISOPILINE
DM9ERD6	MI	TTVBI8W
DM9ERD6	MN	Dopamine transporter (DAT)
DM9ERD6	MT	DTT
DM9ERD6	MA	Inhibitor
DM9ERD6	RN	Effects of various isoquinoline alkaloids on in vitro 3H-dopamine uptake by rat striatal synaptosomes. J Nat Prod. 1995 Oct;58(10):1475-84.
DM9ERD6	RU	https://pubmed.ncbi.nlm.nih.gov/8676127

DMWI0M8	DI	DMWI0M8
DMWI0M8	DN	ISOPPADS
DMWI0M8	MI	TT2THBD
DMWI0M8	MN	P2X purinoceptor 3 (P2RX3)
DMWI0M8	MT	DTT
DMWI0M8	MA	Inhibitor
DMWI0M8	RN	Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors. J Med Chem. 2001 Feb 1;44(3):340-9.
DMWI0M8	RU	https://pubmed.ncbi.nlm.nih.gov/11462975

DMWI0M8	DI	DMWI0M8
DMWI0M8	DN	ISOPPADS
DMWI0M8	MI	TT473XN
DMWI0M8	MN	P2X purinoceptor 7 (P2RX7)
DMWI0M8	MT	DTT
DMWI0M8	MA	Inhibitor
DMWI0M8	RN	Structure-activity relationship studies of spinorphin as a potent and selective human P2X(3) receptor antagonist. J Med Chem. 2007 Sep 6;50(18):4543-7.
DMWI0M8	RU	https://pubmed.ncbi.nlm.nih.gov/17676725

DMH67J2	DI	DMH67J2
DMH67J2	DN	Isopropyl 10H-phenothiazine-10-carboxylate
DMH67J2	MI	TTEB0GD
DMH67J2	MN	Cholinesterase (BCHE)
DMH67J2	MT	DTT
DMH67J2	MA	Inhibitor
DMH67J2	RN	Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. J Med Chem. 2008 Jul 24;51(14):4200-12.
DMH67J2	RU	https://pubmed.ncbi.nlm.nih.gov/18570368

DMS8MBI	DI	DMS8MBI
DMS8MBI	DN	Isopropyl 3-(phenylthio)-1H-indole-2-carboxylate
DMS8MBI	MI	TTML2WA
DMS8MBI	MN	Tubulin (TUB)
DMS8MBI	MT	DTT
DMS8MBI	MA	Inhibitor
DMS8MBI	RN	New arylthioindoles: potent inhibitors of tubulin polymerization. 2. Structure-activity relationships and molecular modeling studies. J Med Chem. 2006 Feb 9;49(3):947-54.
DMS8MBI	RU	https://pubmed.ncbi.nlm.nih.gov/16451061

DMS8MBI	DI	DMS8MBI
DMS8MBI	DN	Isopropyl 3-(phenylthio)-1H-indole-2-carboxylate
DMS8MBI	MI	TTYFKSZ
DMS8MBI	MN	Tubulin beta (TUBB)
DMS8MBI	MT	DTT
DMS8MBI	MA	Inhibitor
DMS8MBI	RN	New arylthioindoles: potent inhibitors of tubulin polymerization. 2. Structure-activity relationships and molecular modeling studies. J Med Chem. 2006 Feb 9;49(3):947-54.
DMS8MBI	RU	https://pubmed.ncbi.nlm.nih.gov/16451061

DM2VJF4	DI	DM2VJF4
DM2VJF4	DN	Isopropyl 4-nitrophenyl dodecylphosphonate
DM2VJF4	MI	TT6OEDT
DM2VJF4	MN	Cannabinoid receptor 1 (CB1)
DM2VJF4	MT	DTT
DM2VJF4	MA	Inhibitor
DM2VJF4	RN	Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5875-8.
DM2VJF4	RU	https://pubmed.ncbi.nlm.nih.gov/18752948

DM2VJF4	DI	DM2VJF4
DM2VJF4	DN	Isopropyl 4-nitrophenyl dodecylphosphonate
DM2VJF4	MI	TTDP1UC
DM2VJF4	MN	Fatty acid amide hydrolase (FAAH)
DM2VJF4	MT	DTT
DM2VJF4	MA	Inhibitor
DM2VJF4	RN	Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5875-8.
DM2VJF4	RU	https://pubmed.ncbi.nlm.nih.gov/18752948

DML54EA	DI	DML54EA
DML54EA	DN	Isopropyl dodecylfluorophosphonate
DML54EA	MI	TT1RS9F
DML54EA	MN	Acetylcholinesterase (AChE)
DML54EA	MT	DTT
DML54EA	MA	Inhibitor
DML54EA	RN	Activation of the endocannabinoid system by organophosphorus nerve agents. Nat Chem Biol. 2008 Jun;4(6):373-8.
DML54EA	RU	https://pubmed.ncbi.nlm.nih.gov/18438404

DML54EA	DI	DML54EA
DML54EA	DN	Isopropyl dodecylfluorophosphonate
DML54EA	MI	TT6OEDT
DML54EA	MN	Cannabinoid receptor 1 (CB1)
DML54EA	MT	DTT
DML54EA	MA	Inhibitor
DML54EA	RN	Activation of the endocannabinoid system by organophosphorus nerve agents. Nat Chem Biol. 2008 Jun;4(6):373-8.
DML54EA	RU	https://pubmed.ncbi.nlm.nih.gov/18438404

DML54EA	DI	DML54EA
DML54EA	DN	Isopropyl dodecylfluorophosphonate
DML54EA	MI	TTDP1UC
DML54EA	MN	Fatty acid amide hydrolase (FAAH)
DML54EA	MT	DTT
DML54EA	MA	Inhibitor
DML54EA	RN	Activation of the endocannabinoid system by organophosphorus nerve agents. Nat Chem Biol. 2008 Jun;4(6):373-8.
DML54EA	RU	https://pubmed.ncbi.nlm.nih.gov/18438404

DMBR8P1	DI	DMBR8P1
DMBR8P1	DN	Isopropylcarbamic Acid Biphenyl-3-yl Ester
DMBR8P1	MI	TTDP1UC
DMBR8P1	MN	Fatty acid amide hydrolase (FAAH)
DMBR8P1	MT	DTT
DMBR8P1	MA	Inhibitor
DMBR8P1	RN	Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl a... J Med Chem. 2008 Jun 26;51(12):3487-98.
DMBR8P1	RU	https://pubmed.ncbi.nlm.nih.gov/18507372

DM92F6Z	DI	DM92F6Z
DM92F6Z	DN	Isopropyl-methyl-prop-2-ynyl-amine hydrochloride
DM92F6Z	MI	TTGP7BY
DM92F6Z	MN	Monoamine oxidase type B (MAO-B)
DM92F6Z	MT	DTT
DM92F6Z	MA	Inhibitor
DM92F6Z	RN	Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors. J Med Chem. 1992 Oct 2;35(20):3705-13.
DM92F6Z	RU	https://pubmed.ncbi.nlm.nih.gov/1433183

DMPYAMU	DI	DMPYAMU
DMPYAMU	DN	isopulegol
DMPYAMU	MI	TTXDKTO
DMPYAMU	MN	Long transient receptor potential channel 8 (TRPM8)
DMPYAMU	MT	DTT
DMPYAMU	MA	Activator
DMPYAMU	RN	Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay. Br J Pharmacol. 2004 Feb;141(4):737-45.
DMPYAMU	RU	https://pubmed.ncbi.nlm.nih.gov/14757700

DMDF26N	DI	DMDF26N
DMDF26N	DN	Isoquinolin-1-yl-(3-phenyl-propyl)-amine
DMDF26N	MI	TT64EPS
DMDF26N	MN	Fungal Scytalone dehydratase (Fung SDH1)
DMDF26N	MT	DTT
DMDF26N	MA	Inhibitor
DMDF26N	RN	A diazine heterocycle replaces a six-membered hydrogen-bonded array in the active site of scytalone dehydratase, Bioorg. Med. Chem. Lett. 3(8):1605-1608 (1993).
DMDF26N	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00800268

DMT4RI2	DI	DMT4RI2
DMT4RI2	DN	Isoquinoline-1,3,4(2H)-trione
DMT4RI2	MI	TTZY5KP
DMT4RI2	MN	Caspase (CASP)
DMT4RI2	MT	DTT
DMT4RI2	MA	Inhibitor
DMT4RI2	RN	Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors. J Med Chem. 2006 Mar 9;49(5):1613-23.
DMT4RI2	RU	https://pubmed.ncbi.nlm.nih.gov/16509578

DMT4RI2	DI	DMT4RI2
DMT4RI2	DN	Isoquinoline-1,3,4(2H)-trione
DMT4RI2	MI	TTKW4ML
DMT4RI2	MN	Caspase 6 messenger RNA (CASP6 mRNA)
DMT4RI2	MT	DTT
DMT4RI2	MA	Inhibitor
DMT4RI2	RN	Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors. J Med Chem. 2006 Mar 9;49(5):1613-23.
DMT4RI2	RU	https://pubmed.ncbi.nlm.nih.gov/16509578

DMT4RI2	DI	DMT4RI2
DMT4RI2	DN	Isoquinoline-1,3,4(2H)-trione
DMT4RI2	MI	TT6SZNG
DMT4RI2	MN	Caspase 8 messenger RNA (CASP8 mRNA)
DMT4RI2	MT	DTT
DMT4RI2	MA	Inhibitor
DMT4RI2	RN	Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors. J Med Chem. 2006 Mar 9;49(5):1613-23.
DMT4RI2	RU	https://pubmed.ncbi.nlm.nih.gov/16509578

DMT4RI2	DI	DMT4RI2
DMT4RI2	DN	Isoquinoline-1,3,4(2H)-trione
DMT4RI2	MI	TTPF2QI
DMT4RI2	MN	Caspase-3 (CASP3)
DMT4RI2	MT	DTT
DMT4RI2	MA	Inhibitor
DMT4RI2	RN	Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors. J Med Chem. 2006 Mar 9;49(5):1613-23.
DMT4RI2	RU	https://pubmed.ncbi.nlm.nih.gov/16509578

DMWIMUZ	DI	DMWIMUZ
DMWIMUZ	DN	Isoquinoline-3-carboxylic acid methyl ester
DMWIMUZ	MI	TT1MPAY
DMWIMUZ	MN	GABA(A) receptor alpha-1 (GABRA1)
DMWIMUZ	MT	DTT
DMWIMUZ	MA	Inhibitor
DMWIMUZ	RN	Synthesis of novel 3-substituted beta-carbolines as benzodiazepine receptor ligands: probing the benzodiazepine receptor pharmacophore. J Med Chem. 1988 Sep;31(9):1854-61.
DMWIMUZ	RU	https://pubmed.ncbi.nlm.nih.gov/2842507

DMWIMUZ	DI	DMWIMUZ
DMWIMUZ	DN	Isoquinoline-3-carboxylic acid methyl ester
DMWIMUZ	MI	TTNJYV2
DMWIMUZ	MN	Gamma-aminobutyric acid receptor (GAR)
DMWIMUZ	MT	DTT
DMWIMUZ	MA	Inhibitor
DMWIMUZ	RN	Synthesis of novel 3-substituted beta-carbolines as benzodiazepine receptor ligands: probing the benzodiazepine receptor pharmacophore. J Med Chem. 1988 Sep;31(9):1854-61.
DMWIMUZ	RU	https://pubmed.ncbi.nlm.nih.gov/2842507

DMQ4Z6E	DI	DMQ4Z6E
DMQ4Z6E	DN	ISORHAMNETIN
DMQ4Z6E	MI	TTI84H7
DMQ4Z6E	MN	Cytochrome P450 1B1 (CYP1B1)
DMQ4Z6E	MT	DTT
DMQ4Z6E	MA	Inhibitor
DMQ4Z6E	RN	Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5.
DMQ4Z6E	RU	https://pubmed.ncbi.nlm.nih.gov/20696580

DMQ4Z6E	DI	DMQ4Z6E
DMQ4Z6E	DN	ISORHAMNETIN
DMQ4Z6E	MI	TTNX2CS
DMQ4Z6E	MN	Plasmodium Enoyl-ACP reductase (Malaria fabI)
DMQ4Z6E	MT	DTT
DMQ4Z6E	MA	Inhibitor
DMQ4Z6E	RN	Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
DMQ4Z6E	RU	https://pubmed.ncbi.nlm.nih.gov/16722653

DMQ4Z6E	DI	DMQ4Z6E
DMQ4Z6E	DN	ISORHAMNETIN
DMQ4Z6E	MI	TTBE4IR
DMQ4Z6E	MN	Plasmodium Oxoacyl-[acyl-carrier protein] reductase (Malaria fabG)
DMQ4Z6E	MT	DTT
DMQ4Z6E	MA	Inhibitor
DMQ4Z6E	RN	Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
DMQ4Z6E	RU	https://pubmed.ncbi.nlm.nih.gov/16722653

DMFKQ0B	DI	DMFKQ0B
DMFKQ0B	DN	Isorhamnetin 3,7-disulfate
DMFKQ0B	MI	TTFBNVI
DMFKQ0B	MN	Aldose reductase (AKR1B1)
DMFKQ0B	MT	DTT
DMFKQ0B	MA	Inhibitor
DMFKQ0B	RN	Effect of Polygonum hydropiper sulfated flavonoids on lens aldose reductase and related enzymes. J Nat Prod. 1996 Apr;59(4):443-5.
DMFKQ0B	RU	https://pubmed.ncbi.nlm.nih.gov/8699190

DMZQUY4	DI	DMZQUY4
DMZQUY4	DN	Isorhamnetin 3-O-rhamnoside
DMZQUY4	MI	TTFBNVI
DMZQUY4	MN	Aldose reductase (AKR1B1)
DMZQUY4	MT	DTT
DMZQUY4	MA	Inhibitor
DMZQUY4	RN	New flavonol oligoglycosides and polyacylated sucroses with inhibitory effects on aldose reductase and platelet aggregation from the flowers of Pru... J Nat Prod. 2002 Aug;65(8):1151-5.
DMZQUY4	RU	https://pubmed.ncbi.nlm.nih.gov/12193020

DMJS7MV	DI	DMJS7MV
DMJS7MV	DN	ISOSAKUTANETIN
DMJS7MV	MI	TTI84H7
DMJS7MV	MN	Cytochrome P450 1B1 (CYP1B1)
DMJS7MV	MT	DTT
DMJS7MV	MA	Inhibitor
DMJS7MV	RN	Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5.
DMJS7MV	RU	https://pubmed.ncbi.nlm.nih.gov/20696580

DMNM2SQ	DI	DMNM2SQ
DMNM2SQ	DN	ISOSCOPOLETIN
DMNM2SQ	MI	TTN9T81
DMNM2SQ	MN	Arachidonate 15-lipoxygenase (15-LOX)
DMNM2SQ	MT	DTT
DMNM2SQ	MA	Inhibitor
DMNM2SQ	RN	Lipoxygenase inhibitory constituents of the fruits of noni (Morinda citrifolia) collected in Tahiti. J Nat Prod. 2007 May;70(5):859-62.
DMNM2SQ	RU	https://pubmed.ncbi.nlm.nih.gov/17378609

DMTRCSV	DI	DMTRCSV
DMTRCSV	DN	Isosorbide-2-(benzylcarbamate)-5-benzoate
DMTRCSV	MI	TTEB0GD
DMTRCSV	MN	Cholinesterase (BCHE)
DMTRCSV	MT	DTT
DMTRCSV	MA	Inhibitor
DMTRCSV	RN	Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9.
DMTRCSV	RU	https://pubmed.ncbi.nlm.nih.gov/18817366

DMG0TW2	DI	DMG0TW2
DMG0TW2	DN	Isosorbide-2-(benzylcarbamate)-5-mononitrate
DMG0TW2	MI	TTEB0GD
DMG0TW2	MN	Cholinesterase (BCHE)
DMG0TW2	MT	DTT
DMG0TW2	MA	Inhibitor
DMG0TW2	RN	Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9.
DMG0TW2	RU	https://pubmed.ncbi.nlm.nih.gov/18817366

DM1ZH2U	DI	DM1ZH2U
DM1ZH2U	DN	Isosorbide-2-(butylcarbamate)-5-benzoate
DM1ZH2U	MI	TTEB0GD
DM1ZH2U	MN	Cholinesterase (BCHE)
DM1ZH2U	MT	DTT
DM1ZH2U	MA	Inhibitor
DM1ZH2U	RN	Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9.
DM1ZH2U	RU	https://pubmed.ncbi.nlm.nih.gov/18817366

DMUDS12	DI	DMUDS12
DMUDS12	DN	Isosorbide-2-(butylcarbamate)-5-mononitrate
DMUDS12	MI	TTEB0GD
DMUDS12	MN	Cholinesterase (BCHE)
DMUDS12	MT	DTT
DMUDS12	MA	Inhibitor
DMUDS12	RN	Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9.
DMUDS12	RU	https://pubmed.ncbi.nlm.nih.gov/18817366

DM4ZYRP	DI	DM4ZYRP
DM4ZYRP	DN	Isosorbide-2-(cyclohexylcarbamate)-5-mononitrate
DM4ZYRP	MI	TTEB0GD
DM4ZYRP	MN	Cholinesterase (BCHE)
DM4ZYRP	MT	DTT
DM4ZYRP	MA	Inhibitor
DM4ZYRP	RN	Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9.
DM4ZYRP	RU	https://pubmed.ncbi.nlm.nih.gov/18817366

DMMH70I	DI	DMMH70I
DMMH70I	DN	Isosorbide-2-(ethylcarbamate)-5-mononitrate
DMMH70I	MI	TTEB0GD
DMMH70I	MN	Cholinesterase (BCHE)
DMMH70I	MT	DTT
DMMH70I	MA	Inhibitor
DMMH70I	RN	Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9.
DMMH70I	RU	https://pubmed.ncbi.nlm.nih.gov/18817366

DMC7MLN	DI	DMC7MLN
DMC7MLN	DN	Isosorbide-2-(methylcarbamate)-5-benzoate
DMC7MLN	MI	TT1RS9F
DMC7MLN	MN	Acetylcholinesterase (AChE)
DMC7MLN	MT	DTT
DMC7MLN	MA	Inhibitor
DMC7MLN	RN	Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9.
DMC7MLN	RU	https://pubmed.ncbi.nlm.nih.gov/18817366

DMC7MLN	DI	DMC7MLN
DMC7MLN	DN	Isosorbide-2-(methylcarbamate)-5-benzoate
DMC7MLN	MI	TTEB0GD
DMC7MLN	MN	Cholinesterase (BCHE)
DMC7MLN	MT	DTT
DMC7MLN	MA	Inhibitor
DMC7MLN	RN	Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9.
DMC7MLN	RU	https://pubmed.ncbi.nlm.nih.gov/18817366

DMEKMOF	DI	DMEKMOF
DMEKMOF	DN	Isosorbide-2-(methylcarbamate)-5-mononitrate
DMEKMOF	MI	TT1RS9F
DMEKMOF	MN	Acetylcholinesterase (AChE)
DMEKMOF	MT	DTT
DMEKMOF	MA	Inhibitor
DMEKMOF	RN	Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9.
DMEKMOF	RU	https://pubmed.ncbi.nlm.nih.gov/18817366

DMEKMOF	DI	DMEKMOF
DMEKMOF	DN	Isosorbide-2-(methylcarbamate)-5-mononitrate
DMEKMOF	MI	TTEB0GD
DMEKMOF	MN	Cholinesterase (BCHE)
DMEKMOF	MT	DTT
DMEKMOF	MA	Inhibitor
DMEKMOF	RN	Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9.
DMEKMOF	RU	https://pubmed.ncbi.nlm.nih.gov/18817366

DMQAEZP	DI	DMQAEZP
DMQAEZP	DN	Isosorbide-2-(propylcarbamate)-5-mononitrate
DMQAEZP	MI	TTEB0GD
DMQAEZP	MN	Cholinesterase (BCHE)
DMQAEZP	MT	DTT
DMQAEZP	MA	Inhibitor
DMQAEZP	RN	Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9.
DMQAEZP	RU	https://pubmed.ncbi.nlm.nih.gov/18817366

DM6FVDO	DI	DM6FVDO
DM6FVDO	DN	Isosorbide-2-benzyl carbamate
DM6FVDO	MI	TTEB0GD
DM6FVDO	MN	Cholinesterase (BCHE)
DM6FVDO	MT	DTT
DM6FVDO	MA	Inhibitor
DM6FVDO	RN	Isosorbide-2-benzyl carbamate-5-salicylate, a peripheral anionic site binding subnanomolar selective butyrylcholinesterase inhibitor. J Med Chem. 2010 Feb 11;53(3):1190-9.
DM6FVDO	RU	https://pubmed.ncbi.nlm.nih.gov/20067290

DM5XEZI	DI	DM5XEZI
DM5XEZI	DN	Isosorbide-2-benzylcarbamate-5-(o-toluate)
DM5XEZI	MI	TTEB0GD
DM5XEZI	MN	Cholinesterase (BCHE)
DM5XEZI	MT	DTT
DM5XEZI	MA	Inhibitor
DM5XEZI	RN	Isosorbide-2-benzyl carbamate-5-salicylate, a peripheral anionic site binding subnanomolar selective butyrylcholinesterase inhibitor. J Med Chem. 2010 Feb 11;53(3):1190-9.
DM5XEZI	RU	https://pubmed.ncbi.nlm.nih.gov/20067290

DMD4WRH	DI	DMD4WRH
DMD4WRH	DN	Isosorbide-2-benzylcarbamate-5-acetate
DMD4WRH	MI	TTEB0GD
DMD4WRH	MN	Cholinesterase (BCHE)
DMD4WRH	MT	DTT
DMD4WRH	MA	Inhibitor
DMD4WRH	RN	Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9.
DMD4WRH	RU	https://pubmed.ncbi.nlm.nih.gov/18817366

DMWDQ90	DI	DMWDQ90
DMWDQ90	DN	Isosorbide-2-benzylcarbamate-5-cyclopentanoate
DMWDQ90	MI	TT1RS9F
DMWDQ90	MN	Acetylcholinesterase (AChE)
DMWDQ90	MT	DTT
DMWDQ90	MA	Inhibitor
DMWDQ90	RN	Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9.
DMWDQ90	RU	https://pubmed.ncbi.nlm.nih.gov/18817366

DMWDQ90	DI	DMWDQ90
DMWDQ90	DN	Isosorbide-2-benzylcarbamate-5-cyclopentanoate
DMWDQ90	MI	TTEB0GD
DMWDQ90	MN	Cholinesterase (BCHE)
DMWDQ90	MT	DTT
DMWDQ90	MA	Inhibitor
DMWDQ90	RN	Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9.
DMWDQ90	RU	https://pubmed.ncbi.nlm.nih.gov/18817366

DM8E2L6	DI	DM8E2L6
DM8E2L6	DN	Isosorbide-2-benzylcarbamate-5-cyclopropanoate
DM8E2L6	MI	TT1RS9F
DM8E2L6	MN	Acetylcholinesterase (AChE)
DM8E2L6	MT	DTT
DM8E2L6	MA	Inhibitor
DM8E2L6	RN	Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9.
DM8E2L6	RU	https://pubmed.ncbi.nlm.nih.gov/18817366

DM8E2L6	DI	DM8E2L6
DM8E2L6	DN	Isosorbide-2-benzylcarbamate-5-cyclopropanoate
DM8E2L6	MI	TTEB0GD
DM8E2L6	MN	Cholinesterase (BCHE)
DM8E2L6	MT	DTT
DM8E2L6	MA	Inhibitor
DM8E2L6	RN	Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9.
DM8E2L6	RU	https://pubmed.ncbi.nlm.nih.gov/18817366

DMQ3Z17	DI	DMQ3Z17
DMQ3Z17	DN	Isosorbide-2-benzylcarbamate-5-isonicotinate
DMQ3Z17	MI	TTEB0GD
DMQ3Z17	MN	Cholinesterase (BCHE)
DMQ3Z17	MT	DTT
DMQ3Z17	MA	Inhibitor
DMQ3Z17	RN	Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9.
DMQ3Z17	RU	https://pubmed.ncbi.nlm.nih.gov/18817366

DMY49DN	DI	DMY49DN
DMY49DN	DN	Isosorbide-2-benzylcarbamate-5-nicotinate
DMY49DN	MI	TTEB0GD
DMY49DN	MN	Cholinesterase (BCHE)
DMY49DN	MT	DTT
DMY49DN	MA	Inhibitor
DMY49DN	RN	Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9.
DMY49DN	RU	https://pubmed.ncbi.nlm.nih.gov/18817366

DMSQ538	DI	DMSQ538
DMSQ538	DN	Isosorbide-2-benzylcarbamate-5-pentanoate
DMSQ538	MI	TTEB0GD
DMSQ538	MN	Cholinesterase (BCHE)
DMSQ538	MT	DTT
DMSQ538	MA	Inhibitor
DMSQ538	RN	Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9.
DMSQ538	RU	https://pubmed.ncbi.nlm.nih.gov/18817366

DMP6E34	DI	DMP6E34
DMP6E34	DN	Isosorbide-2-benzylcarbamate-5-propionate
DMP6E34	MI	TTEB0GD
DMP6E34	MN	Cholinesterase (BCHE)
DMP6E34	MT	DTT
DMP6E34	MA	Inhibitor
DMP6E34	RN	Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9.
DMP6E34	RU	https://pubmed.ncbi.nlm.nih.gov/18817366

DMCHSWQ	DI	DMCHSWQ
DMCHSWQ	DN	Isosorbide-2-benzylcarbamate-5-tosylate
DMCHSWQ	MI	TT1RS9F
DMCHSWQ	MN	Acetylcholinesterase (AChE)
DMCHSWQ	MT	DTT
DMCHSWQ	MA	Inhibitor
DMCHSWQ	RN	Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9.
DMCHSWQ	RU	https://pubmed.ncbi.nlm.nih.gov/18817366

DMG69IX	DI	DMG69IX
DMG69IX	DN	Isosorbide-2-benzylcarbamate-5-triflate
DMG69IX	MI	TTEB0GD
DMG69IX	MN	Cholinesterase (BCHE)
DMG69IX	MT	DTT
DMG69IX	MA	Inhibitor
DMG69IX	RN	Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9.
DMG69IX	RU	https://pubmed.ncbi.nlm.nih.gov/18817366

DMPA2ON	DI	DMPA2ON
DMPA2ON	DN	Isosorbide-di-(4-nitrophenyl carbamate)
DMPA2ON	MI	TT1RS9F
DMPA2ON	MN	Acetylcholinesterase (AChE)
DMPA2ON	MT	DTT
DMPA2ON	MA	Inhibitor
DMPA2ON	RN	Isosorbide-based cholinesterase inhibitors; replacement of 5-ester groups leading to increased stability. Bioorg Med Chem. 2010 Feb;18(3):1045-53.
DMPA2ON	RU	https://pubmed.ncbi.nlm.nih.gov/20093035

DMFVN71	DI	DMFVN71
DMFVN71	DN	Isosorbide-di-(benzylcarbamate)
DMFVN71	MI	TT1RS9F
DMFVN71	MN	Acetylcholinesterase (AChE)
DMFVN71	MT	DTT
DMFVN71	MA	Inhibitor
DMFVN71	RN	Isosorbide-based cholinesterase inhibitors; replacement of 5-ester groups leading to increased stability. Bioorg Med Chem. 2010 Feb;18(3):1045-53.
DMFVN71	RU	https://pubmed.ncbi.nlm.nih.gov/20093035

DMFVN71	DI	DMFVN71
DMFVN71	DN	Isosorbide-di-(benzylcarbamate)
DMFVN71	MI	TTEB0GD
DMFVN71	MN	Cholinesterase (BCHE)
DMFVN71	MT	DTT
DMFVN71	MA	Inhibitor
DMFVN71	RN	Isosorbide-based cholinesterase inhibitors; replacement of 5-ester groups leading to increased stability. Bioorg Med Chem. 2010 Feb;18(3):1045-53.
DMFVN71	RU	https://pubmed.ncbi.nlm.nih.gov/20093035

DMNSTKD	DI	DMNSTKD
DMNSTKD	DN	Isosorbide-di-(butylcarbamate)
DMNSTKD	MI	TTEB0GD
DMNSTKD	MN	Cholinesterase (BCHE)
DMNSTKD	MT	DTT
DMNSTKD	MA	Inhibitor
DMNSTKD	RN	Isosorbide-based cholinesterase inhibitors; replacement of 5-ester groups leading to increased stability. Bioorg Med Chem. 2010 Feb;18(3):1045-53.
DMNSTKD	RU	https://pubmed.ncbi.nlm.nih.gov/20093035

DMTHWXO	DI	DMTHWXO
DMTHWXO	DN	Isosorbide-di-(ethylcarbamate)
DMTHWXO	MI	TT1RS9F
DMTHWXO	MN	Acetylcholinesterase (AChE)
DMTHWXO	MT	DTT
DMTHWXO	MA	Inhibitor
DMTHWXO	RN	Isosorbide-based cholinesterase inhibitors; replacement of 5-ester groups leading to increased stability. Bioorg Med Chem. 2010 Feb;18(3):1045-53.
DMTHWXO	RU	https://pubmed.ncbi.nlm.nih.gov/20093035

DMTHWXO	DI	DMTHWXO
DMTHWXO	DN	Isosorbide-di-(ethylcarbamate)
DMTHWXO	MI	TTEB0GD
DMTHWXO	MN	Cholinesterase (BCHE)
DMTHWXO	MT	DTT
DMTHWXO	MA	Inhibitor
DMTHWXO	RN	Isosorbide-based cholinesterase inhibitors; replacement of 5-ester groups leading to increased stability. Bioorg Med Chem. 2010 Feb;18(3):1045-53.
DMTHWXO	RU	https://pubmed.ncbi.nlm.nih.gov/20093035

DMV1GLP	DI	DMV1GLP
DMV1GLP	DN	Isosorbide-di-(propylcarbamate)
DMV1GLP	MI	TTEB0GD
DMV1GLP	MN	Cholinesterase (BCHE)
DMV1GLP	MT	DTT
DMV1GLP	MA	Inhibitor
DMV1GLP	RN	Isosorbide-based cholinesterase inhibitors; replacement of 5-ester groups leading to increased stability. Bioorg Med Chem. 2010 Feb;18(3):1045-53.
DMV1GLP	RU	https://pubmed.ncbi.nlm.nih.gov/20093035

DMT1ZGM	DI	DMT1ZGM
DMT1ZGM	DN	Isosorbide-di-phenylcarbamate
DMT1ZGM	MI	TT1RS9F
DMT1ZGM	MN	Acetylcholinesterase (AChE)
DMT1ZGM	MT	DTT
DMT1ZGM	MA	Inhibitor
DMT1ZGM	RN	Isosorbide-based cholinesterase inhibitors; replacement of 5-ester groups leading to increased stability. Bioorg Med Chem. 2010 Feb;18(3):1045-53.
DMT1ZGM	RU	https://pubmed.ncbi.nlm.nih.gov/20093035

DM21K0E	DI	DM21K0E
DM21K0E	DN	ISOTETRANDRINE
DM21K0E	MI	TTVBI8W
DM21K0E	MN	Dopamine transporter (DAT)
DM21K0E	MT	DTT
DM21K0E	MA	Inhibitor
DM21K0E	RN	Effects of various isoquinoline alkaloids on in vitro 3H-dopamine uptake by rat striatal synaptosomes. J Nat Prod. 1995 Oct;58(10):1475-84.
DM21K0E	RU	https://pubmed.ncbi.nlm.nih.gov/8676127

DMKTBEH	DI	DMKTBEH
DMKTBEH	DN	ISOTHIAZOLIDINONE ANALOG
DMKTBEH	MI	TTELIN2
DMKTBEH	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMKTBEH	MT	DTT
DMKTBEH	MA	Inhibitor
DMKTBEH	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMKTBEH	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMAYOTF	DI	DMAYOTF
DMAYOTF	DN	isothiourea-1a
DMAYOTF	MI	TTBID49
DMAYOTF	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMAYOTF	MT	DTT
DMAYOTF	MA	Antagonist
DMAYOTF	RN	Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in vitro and in vivo. J Med Chem. 2008 Dec 25;51(24):7915-20.
DMAYOTF	RU	https://pubmed.ncbi.nlm.nih.gov/19053768

DMBX4WR	DI	DMBX4WR
DMBX4WR	DN	isothiourea-1t
DMBX4WR	MI	TTBID49
DMBX4WR	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMBX4WR	MT	DTT
DMBX4WR	MA	Antagonist
DMBX4WR	RN	Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in vitro and in vivo. J Med Chem. 2008 Dec 25;51(24):7915-20.
DMBX4WR	RU	https://pubmed.ncbi.nlm.nih.gov/19053768

DMNL0BK	DI	DMNL0BK
DMNL0BK	DN	IsoVa-RYYRIK-NH2
DMNL0BK	MI	TTNT7K8
DMNL0BK	MN	Nociceptin receptor (OPRL1)
DMNL0BK	MT	DTT
DMNL0BK	MA	Inhibitor
DMNL0BK	RN	Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist. Bioorg Med Chem. 2008 Mar 1;16(5):2635-44.
DMNL0BK	RU	https://pubmed.ncbi.nlm.nih.gov/18068993

DMTRGAP	DI	DMTRGAP
DMTRGAP	DN	isovelleral
DMTRGAP	MI	TTELV3W
DMTRGAP	MN	Transformation-sensitive protein p120 (TRPA1)
DMTRGAP	MT	DTT
DMTRGAP	MA	Activator
DMTRGAP	RN	TRPA1 mediates the noxious effects of natural sesquiterpene deterrents. J Biol Chem. 2008 Aug 29;283(35):24136-44.
DMTRGAP	RU	https://pubmed.ncbi.nlm.nih.gov/18550530

DMXAD8E	DI	DMXAD8E
DMXAD8E	DN	Isoxazol
DMXAD8E	MI	TT3PQ2Y
DMXAD8E	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DMXAD8E	MT	DTT
DMXAD8E	MA	Inhibitor
DMXAD8E	RN	Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Chem Biol Interact. 2000 Jan 3;124(1):61-76.
DMXAD8E	RU	https://pubmed.ncbi.nlm.nih.gov/10658902

DMAFC3R	DI	DMAFC3R
DMAFC3R	DN	isoxazole azepine compound 3
DMAFC3R	MI	TTRA6BO
DMAFC3R	MN	Bromodomain-containing protein 4 (BRD4)
DMAFC3R	MT	DTT
DMAFC3R	MA	Inhibitor
DMAFC3R	RN	Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors. ACS Med Chem Lett. 2013 Jul 16;4(9):835-40.
DMAFC3R	RU	https://pubmed.ncbi.nlm.nih.gov/24900758

DMPZURH	DI	DMPZURH
DMPZURH	DN	Isoxazolecarboxylic acid
DMPZURH	MI	TTELIN2
DMPZURH	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMPZURH	MT	DTT
DMPZURH	MA	Inhibitor
DMPZURH	RN	Synthesis and evaluation of some novel dibenzo[b,d]furan carboxylic acids as potential anti-diabetic agents. Eur J Med Chem. 2010 Sep;45(9):3709-18.
DMPZURH	RU	https://pubmed.ncbi.nlm.nih.gov/20627471

DMA8F4N	DI	DMA8F4N
DMA8F4N	DN	ITdU
DMA8F4N	MI	TTP3QRF
DMA8F4N	MN	Thymidine kinase 1 (TK1)
DMA8F4N	MT	DTT
DMA8F4N	MA	Inhibitor
DMA8F4N	RN	Trichomonas vaginalis thymidine kinase: purification, characterization and search for inhibitors. Biochem J. 1998 Aug 15;334 ( Pt 1):15-22.
DMA8F4N	RU	https://pubmed.ncbi.nlm.nih.gov/9693096

DMVFITX	DI	DMVFITX
DMVFITX	DN	ITP
DMVFITX	MI	TT24DGP
DMVFITX	MN	P2Y purinoceptor 4 (P2RY4)
DMVFITX	MT	DTT
DMVFITX	MA	Agonist
DMVFITX	RN	ATP, an agonist at the rat P2Y(4) receptor, is an antagonist at the human P2Y(4) receptor. Mol Pharmacol. 2000 May;57(5):926-31.
DMVFITX	RU	https://pubmed.ncbi.nlm.nih.gov/10779375

DMWTDS8	DI	DMWTDS8
DMWTDS8	DN	ITRI-305
DMWTDS8	MI	TT4DXQT
DMWTDS8	MN	Proto-oncogene c-Ret (RET)
DMWTDS8	MT	DTT
DMWTDS8	MA	Inhibitor
DMWTDS8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2185).
DMWTDS8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2185

DMFMYIH	DI	DMFMYIH
DMFMYIH	DN	Iva-His-Pro-Phe-His-ACHPA-Leu-Phe-NH2
DMFMYIH	MI	TTB2MXP
DMFMYIH	MN	Angiotensinogenase renin (REN)
DMFMYIH	MT	DTT
DMFMYIH	MA	Inhibitor
DMFMYIH	RN	Renin inhibitors. Syntheses of subnanomolar, competitive, transition-state analogue inhibitors containing a novel analogue of statine. J Med Chem. 1985 Dec;28(12):1779-90.
DMFMYIH	RU	https://pubmed.ncbi.nlm.nih.gov/3906131

DMZTIU3	DI	DMZTIU3
DMZTIU3	DN	Iva-His-Pro-Phe-His-AHPPA-Leu-Phe-NH2
DMZTIU3	MI	TTB2MXP
DMZTIU3	MN	Angiotensinogenase renin (REN)
DMZTIU3	MT	DTT
DMZTIU3	MA	Inhibitor
DMZTIU3	RN	Renin inhibitors. Syntheses of subnanomolar, competitive, transition-state analogue inhibitors containing a novel analogue of statine. J Med Chem. 1985 Dec;28(12):1779-90.
DMZTIU3	RU	https://pubmed.ncbi.nlm.nih.gov/3906131

DM92QIW	DI	DM92QIW
DM92QIW	DN	Iva-His-Pro-Phe-His-Sta-Leu-Phe-NH2
DM92QIW	MI	TTB2MXP
DM92QIW	MN	Angiotensinogenase renin (REN)
DM92QIW	MT	DTT
DM92QIW	MA	Inhibitor
DM92QIW	RN	Renin inhibitors. Syntheses of subnanomolar, competitive, transition-state analogue inhibitors containing a novel analogue of statine. J Med Chem. 1985 Dec;28(12):1779-90.
DM92QIW	RU	https://pubmed.ncbi.nlm.nih.gov/3906131

DMBTWF0	DI	DMBTWF0
DMBTWF0	DN	IW-1221
DMBTWF0	MI	TTQDMX5
DMBTWF0	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMBTWF0	MT	DTT
DMBTWF0	MA	Inhibitor
DMBTWF0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 339).
DMBTWF0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=339

DMQSB6N	DI	DMQSB6N
DMQSB6N	DN	J-009747
DMQSB6N	MI	DE8RYV5
DMQSB6N	MN	NADPH:quinone reductase (CRYZ)
DMQSB6N	MT	DME
DMQSB6N	MA	Metabolism
DMQSB6N	RN	Kinetic and structural evidence of the alkenal/one reductase specificity of human crystallin. Cell Mol Life Sci. 2011 Mar;68(6):1065-77.
DMQSB6N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20835842

DMQ8J3M	DI	DMQ8J3M
DMQ8J3M	DN	J-104118
DMQ8J3M	MI	TTFQEO5
DMQ8J3M	MN	Squalene synthetase (FDFT1)
DMQ8J3M	MT	DTT
DMQ8J3M	MA	Inhibitor
DMQ8J3M	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 645).
DMQ8J3M	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=645

DMWF7RO	DI	DMWF7RO
DMWF7RO	DN	J-104123
DMWF7RO	MI	TTFQEO5
DMWF7RO	MN	Squalene synthetase (FDFT1)
DMWF7RO	MT	DTT
DMWF7RO	MA	Inhibitor
DMWF7RO	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 645).
DMWF7RO	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=645

DMAEQS9	DI	DMAEQS9
DMAEQS9	DN	J-104135
DMAEQS9	MI	TTQ13Z5
DMAEQS9	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMAEQS9	MT	DTT
DMAEQS9	MA	Agonist
DMAEQS9	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 15).
DMAEQS9	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=15

DMCS4BL	DI	DMCS4BL
DMCS4BL	DN	J-104870
DMCS4BL	MI	TTRK9JT
DMCS4BL	MN	Neuropeptide Y receptor type 1 (NPY1R)
DMCS4BL	MT	DTT
DMCS4BL	MA	Antagonist
DMCS4BL	RN	The novel neuropeptide Y Y(1) receptor antagonist J-104870: a potent feeding suppressant with oral bioavailability. Biochem Biophys Res Commun. 1999 Dec 9;266(1):88-91.
DMCS4BL	RU	https://pubmed.ncbi.nlm.nih.gov/10581170

DM9SFGB	DI	DM9SFGB
DM9SFGB	DN	J-109,390
DM9SFGB	MI	TTX20QP
DM9SFGB	MN	Geranylgeranyl transferase I (GGTase-I)
DM9SFGB	MT	DTT
DM9SFGB	MA	Inhibitor
DM9SFGB	RN	Geranylgeranyltransferase I of Candida albicans: null mutants or enzyme inhibitors produce unexpected phenotypes. J Bacteriol. 2000 Feb;182(3):704-13.
DM9SFGB	RU	https://pubmed.ncbi.nlm.nih.gov/10633104

DMXC319	DI	DMXC319
DMXC319	DN	J591-Ac-225
DMXC319	MI	TT9G4N0
DMXC319	MN	Glutamate carboxypeptidase II (GCPII)
DMXC319	MT	DTT
DMXC319	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1606).
DMXC319	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1606

DMJAEMT	DI	DMJAEMT
DMJAEMT	DN	JASPAQUINOL
DMJAEMT	MI	TTN9T81
DMJAEMT	MN	Arachidonate 15-lipoxygenase (15-LOX)
DMJAEMT	MT	DTT
DMJAEMT	MA	Inhibitor
DMJAEMT	RN	Using enzyme assays to evaluate the structure and bioactivity of sponge-derived meroterpenes. J Nat Prod. 2009 Oct;72(10):1857-63.
DMJAEMT	RU	https://pubmed.ncbi.nlm.nih.gov/19848434

DMJAEMT	DI	DMJAEMT
DMJAEMT	DN	JASPAQUINOL
DMJAEMT	MI	TTSJ6Q4
DMJAEMT	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DMJAEMT	MT	DTT
DMJAEMT	MA	Inhibitor
DMJAEMT	RN	Using enzyme assays to evaluate the structure and bioactivity of sponge-derived meroterpenes. J Nat Prod. 2009 Oct;72(10):1857-63.
DMJAEMT	RU	https://pubmed.ncbi.nlm.nih.gov/19848434

DMOF0TB	DI	DMOF0TB
DMOF0TB	DN	Jaspic acid
DMOF0TB	MI	TT12ABZ
DMOF0TB	MN	Arachidonate 12-lipoxygenase (12-LOX)
DMOF0TB	MT	DTT
DMOF0TB	MA	Inhibitor
DMOF0TB	RN	Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases. J Nat Prod. 2003 Feb;66(2):230-5.
DMOF0TB	RU	https://pubmed.ncbi.nlm.nih.gov/12608855

DMOF0TB	DI	DMOF0TB
DMOF0TB	DN	Jaspic acid
DMOF0TB	MI	TTN9T81
DMOF0TB	MN	Arachidonate 15-lipoxygenase (15-LOX)
DMOF0TB	MT	DTT
DMOF0TB	MA	Inhibitor
DMOF0TB	RN	Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases. J Nat Prod. 2003 Feb;66(2):230-5.
DMOF0TB	RU	https://pubmed.ncbi.nlm.nih.gov/12608855

DMYFNW9	DI	DMYFNW9
DMYFNW9	DN	JATRORRHIZINE
DMYFNW9	MI	TTXV4FI
DMYFNW9	MN	Albendazole monooxygenase (CYP3A4)
DMYFNW9	MT	DTT
DMYFNW9	MA	Inhibitor
DMYFNW9	RN	Cytochrome P3A4 inhibitors and other constituents of Fibraurea tinctoria. J Nat Prod. 2007 Dec;70(12):1930-3.
DMYFNW9	RU	https://pubmed.ncbi.nlm.nih.gov/17994701

DMPRTVX	DI	DMPRTVX
DMPRTVX	DN	JB 98064
DMPRTVX	MI	TT9JNIC
DMPRTVX	MN	Histamine H3 receptor (H3R)
DMPRTVX	MT	DTT
DMPRTVX	MA	Antagonist
DMPRTVX	RN	Characteristics of recombinantly expressed rat and human histamine H3 receptors. Eur J Pharmacol. 2002 Oct 18;453(1):33-41.
DMPRTVX	RU	https://pubmed.ncbi.nlm.nih.gov/12393057

DM38L1B	DI	DM38L1B
DM38L1B	DN	JB-1
DM38L1B	MI	TTHRID2
DM38L1B	MN	Insulin-like growth factor I receptor (IGF1R)
DM38L1B	MT	DTT
DM38L1B	MA	Inhibitor
DM38L1B	RN	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
DM38L1B	RU	https://pubmed.ncbi.nlm.nih.gov/19249983

DM0KMPN	DI	DM0KMPN
DM0KMPN	DN	JBP-1
DM0KMPN	MI	TTHCF4J
DM0KMPN	MN	Alpha-glucosidase (GLA)
DM0KMPN	MT	DTT
DM0KMPN	MA	Modulator
DM0KMPN	RN	US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT.
DM0KMPN	RU	http://www.patentbuddy.com/Patent/20120251516?ft=true&sr=true

DM0KMPN	DI	DM0KMPN
DM0KMPN	DN	JBP-1
DM0KMPN	MI	TT2WR1T
DM0KMPN	MN	Cationic trypsinogen (PRSS1)
DM0KMPN	MT	DTT
DM0KMPN	MA	Modulator
DM0KMPN	RN	US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT.
DM0KMPN	RU	http://www.patentbuddy.com/Patent/20120251516?ft=true&sr=true

DM0KMPN	DI	DM0KMPN
DM0KMPN	DN	JBP-1
DM0KMPN	MI	TT7MRGU
DM0KMPN	MN	Chymotrypsin (CTR)
DM0KMPN	MT	DTT
DM0KMPN	MA	Modulator
DM0KMPN	RN	US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT.
DM0KMPN	RU	http://www.patentbuddy.com/Patent/20120251516?ft=true&sr=true

DMYF7AE	DI	DMYF7AE
DMYF7AE	DN	JCF 109
DMYF7AE	MI	TTY6EWA
DMYF7AE	MN	Neuropeptide Y receptor type 5 (NPY5R)
DMYF7AE	MT	DTT
DMYF7AE	MA	Antagonist
DMYF7AE	RN	Development and characterization of a highly selective neuropeptide Y Y5 receptor agonist radioligand: [125I][hPP1-17, Ala31, Aib32]NPY. Br J Pharmacol. 2003 Aug;139(7):1360-8.
DMYF7AE	RU	https://pubmed.ncbi.nlm.nih.gov/12890716

DMLBX3Q	DI	DMLBX3Q
DMLBX3Q	DN	JD-0100
DMLBX3Q	MI	TTGP7BY
DMLBX3Q	MN	Monoamine oxidase type B (MAO-B)
DMLBX3Q	MT	DTT
DMLBX3Q	MA	Inhibitor
DMLBX3Q	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2490).
DMLBX3Q	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2490

DMQP4VG	DI	DMQP4VG
DMQP4VG	DN	JG-365
DMQP4VG	MI	TT5FNQT
DMQP4VG	MN	Human immunodeficiency virus Protease (HIV PR)
DMQP4VG	MT	DTT
DMQP4VG	MA	Modulator
DMQP4VG	RN	[Mechanism of action of aspartic proteases. III. Conformational characteristics of HIV-1 protease inhibitor JG-365]. Bioorg Khim. 1999 Jun;25(6):418-22.
DMQP4VG	RU	https://www.ncbi.nlm.nih.gov/pubmed/10505229

DM0LD3F	DI	DM0LD3F
DM0LD3F	DN	JL-18
DM0LD3F	MI	TTE0A2F
DM0LD3F	MN	Dopamine D4 receptor (D4R)
DM0LD3F	MT	DTT
DM0LD3F	MA	Inhibitor
DM0LD3F	RN	(S)-(-)-4-[4-[2-(isochroman-1-yl)ethyl]-piperazin-1-yl] benzenesulfonamide, a selective dopamine D4 antagonist. J Med Chem. 1996 Jun 21;39(13):2435-7.
DM0LD3F	RU	https://pubmed.ncbi.nlm.nih.gov/8691438

DMWMRO2	DI	DMWMRO2
DMWMRO2	DN	JM-1232(-)
DMWMRO2	MI	TTEX6LM
DMWMRO2	MN	GABA(A) receptor gamma-3 (GABRG3)
DMWMRO2	MT	DTT
DMWMRO2	MA	Agonist
DMWMRO2	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415).
DMWMRO2	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415

DMP1B9D	DI	DMP1B9D
DMP1B9D	DN	JMV 1535
DMP1B9D	MI	TTC1MVT
DMP1B9D	MN	Gastrin-releasing peptide receptor (GRPR)
DMP1B9D	MT	DTT
DMP1B9D	MA	Inhibitor
DMP1B9D	RN	Synthesis and biological evaluation of bombesin constrained analogues. J Med Chem. 2000 Jun 15;43(12):2356-61.
DMP1B9D	RU	https://pubmed.ncbi.nlm.nih.gov/10882361

DMARTN3	DI	DMARTN3
DMARTN3	DN	JMV 1693
DMARTN3	MI	TTC1MVT
DMARTN3	MN	Gastrin-releasing peptide receptor (GRPR)
DMARTN3	MT	DTT
DMARTN3	MA	Inhibitor
DMARTN3	RN	Synthesis and biological evaluation of bombesin constrained analogues. J Med Chem. 2000 Jun 15;43(12):2356-61.
DMARTN3	RU	https://pubmed.ncbi.nlm.nih.gov/10882361

DM82HW9	DI	DM82HW9
DM82HW9	DN	JMV 1719
DM82HW9	MI	TTC1MVT
DM82HW9	MN	Gastrin-releasing peptide receptor (GRPR)
DM82HW9	MT	DTT
DM82HW9	MA	Inhibitor
DM82HW9	RN	Synthesis and biological evaluation of bombesin constrained analogues. J Med Chem. 2000 Jun 15;43(12):2356-61.
DM82HW9	RU	https://pubmed.ncbi.nlm.nih.gov/10882361

DMX3P68	DI	DMX3P68
DMX3P68	DN	JMV 1799
DMX3P68	MI	TTC1MVT
DMX3P68	MN	Gastrin-releasing peptide receptor (GRPR)
DMX3P68	MT	DTT
DMX3P68	MA	Inhibitor
DMX3P68	RN	Synthesis and biological evaluation of bombesin constrained analogues. J Med Chem. 2000 Jun 15;43(12):2356-61.
DMX3P68	RU	https://pubmed.ncbi.nlm.nih.gov/10882361

DMTX694	DI	DMTX694
DMTX694	DN	JMV 1801
DMTX694	MI	TTC1MVT
DMTX694	MN	Gastrin-releasing peptide receptor (GRPR)
DMTX694	MT	DTT
DMTX694	MA	Inhibitor
DMTX694	RN	Synthesis and biological evaluation of bombesin constrained analogues. J Med Chem. 2000 Jun 15;43(12):2356-61.
DMTX694	RU	https://pubmed.ncbi.nlm.nih.gov/10882361

DMGT6DN	DI	DMGT6DN
DMGT6DN	DN	JMV 1802
DMGT6DN	MI	TTC1MVT
DMGT6DN	MN	Gastrin-releasing peptide receptor (GRPR)
DMGT6DN	MT	DTT
DMGT6DN	MA	Inhibitor
DMGT6DN	RN	Synthesis and biological evaluation of bombesin constrained analogues. J Med Chem. 2000 Jun 15;43(12):2356-61.
DMGT6DN	RU	https://pubmed.ncbi.nlm.nih.gov/10882361

DM248HC	DI	DM248HC
DM248HC	DN	JMV 1803
DM248HC	MI	TTC1MVT
DM248HC	MN	Gastrin-releasing peptide receptor (GRPR)
DM248HC	MT	DTT
DM248HC	MA	Inhibitor
DM248HC	RN	Synthesis and biological evaluation of bombesin constrained analogues. J Med Chem. 2000 Jun 15;43(12):2356-61.
DM248HC	RU	https://pubmed.ncbi.nlm.nih.gov/10882361

DMSICYK	DI	DMSICYK
DMSICYK	DN	JMV 1813
DMSICYK	MI	TTC1MVT
DMSICYK	MN	Gastrin-releasing peptide receptor (GRPR)
DMSICYK	MT	DTT
DMSICYK	MA	Inhibitor
DMSICYK	RN	Synthesis and biological evaluation of bombesin constrained analogues. J Med Chem. 2000 Jun 15;43(12):2356-61.
DMSICYK	RU	https://pubmed.ncbi.nlm.nih.gov/10882361

DMAR3M2	DI	DMAR3M2
DMAR3M2	DN	JMV1431
DMAR3M2	MI	TTG5QIA
DMAR3M2	MN	B1 bradykinin receptor (BDKRB1)
DMAR3M2	MT	DTT
DMAR3M2	MA	Inhibitor
DMAR3M2	RN	Synthesis and biological evaluation of bradykinin B(1)/B(2) and selective B(1) receptor antagonists. J Med Chem. 2000 Jun 15;43(12):2382-6.
DMAR3M2	RU	https://pubmed.ncbi.nlm.nih.gov/10882364

DMAR3M2	DI	DMAR3M2
DMAR3M2	DN	JMV1431
DMAR3M2	MI	TTGY8IW
DMAR3M2	MN	B2 bradykinin receptor (BDKRB2)
DMAR3M2	MT	DTT
DMAR3M2	MA	Antagonist
DMAR3M2	RN	Synthesis and biological evaluation of bradykinin B(1)/B(2) and selective B(1) receptor antagonists. J Med Chem. 2000 Jun 15;43(12):2382-6.
DMAR3M2	RU	https://pubmed.ncbi.nlm.nih.gov/10882364

DM5G0IM	DI	DM5G0IM
DM5G0IM	DN	JMV180
DM5G0IM	MI	TTCG0AL
DM5G0IM	MN	Cholecystokinin receptor type A (CCKAR)
DM5G0IM	MT	DTT
DM5G0IM	MA	Agonist
DM5G0IM	RN	Identification of a region of the N-terminal of the human CCKA receptor essential for the high affinity interaction with agonist CCK. Biochem Biophys Res Commun. 1995 Aug 24;213(3):845-52.
DM5G0IM	RU	https://pubmed.ncbi.nlm.nih.gov/7654246

DMB9U17	DI	DMB9U17
DMB9U17	DN	JMV3008
DMB9U17	MI	TTWDC17
DMB9U17	MN	Growth hormone secretagogue receptor 1 (GHSR)
DMB9U17	MT	DTT
DMB9U17	MA	Antagonist
DMB9U17	RN	Toward potent ghrelin receptor ligands based on trisubstituted 1,2,4-triazole structure. 2. Synthesis and pharmacological in vitro and in vivo eval... J Med Chem. 2007 Nov 15;50(23):5790-806.
DMB9U17	RU	https://pubmed.ncbi.nlm.nih.gov/17927165

DME9GF8	DI	DME9GF8
DME9GF8	DN	JMV449
DME9GF8	MI	TTTUMEP
DME9GF8	MN	Neurotensin receptor type 1 (NTSR1)
DME9GF8	MT	DTT
DME9GF8	MA	Agonist
DME9GF8	RN	Differential involvement of intracellular domains of the rat NTS1 neurotensin receptor in coupling to G proteins: a molecular basis for agonist-directed trafficking of receptor stimulus. Mol Pharmacol. 2003 Aug;64(2):421-9.
DME9GF8	RU	https://pubmed.ncbi.nlm.nih.gov/12869647

DMC1ARG	DI	DMC1ARG
DMC1ARG	DN	JMV458
DMC1ARG	MI	TTTUMEP
DMC1ARG	MN	Neurotensin receptor type 1 (NTSR1)
DMC1ARG	MT	DTT
DMC1ARG	MA	Agonist
DMC1ARG	RN	Agonism, inverse agonism, and neutral antagonism at the constitutively active human neurotensin receptor 2. Mol Pharmacol. 2001 Dec;60(6):1392-8.
DMC1ARG	RU	https://pubmed.ncbi.nlm.nih.gov/11723247

DMC1ARG	DI	DMC1ARG
DMC1ARG	DN	JMV458
DMC1ARG	MI	TT31Q0V
DMC1ARG	MN	Neurotensin receptor type 2 (NTSR2)
DMC1ARG	MT	DTT
DMC1ARG	MA	Agonist
DMC1ARG	RN	Agonism, inverse agonism, and neutral antagonism at the constitutively active human neurotensin receptor 2. Mol Pharmacol. 2001 Dec;60(6):1392-8.
DMC1ARG	RU	https://pubmed.ncbi.nlm.nih.gov/11723247

DMFU76I	DI	DMFU76I
DMFU76I	DN	JN-711
DMFU76I	MI	TTLA931
DMFU76I	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMFU76I	MT	DTT
DMFU76I	MA	Agonist
DMFU76I	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 468).
DMFU76I	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=468

DM6P1UA	DI	DM6P1UA
DM6P1UA	DN	JNJ-10191584
DM6P1UA	MI	TTXJ178
DM6P1UA	MN	Histamine H4 receptor (H4R)
DM6P1UA	MT	DTT
DM6P1UA	MA	Antagonist
DM6P1UA	RN	Synthesis and structure-activity relationships of indole and benzimidazole piperazines as histamine H(4) receptor antagonists. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5251-6.
DM6P1UA	RU	https://pubmed.ncbi.nlm.nih.gov/15454206

DM9GDP5	DI	DM9GDP5
DM9GDP5	DN	JNJ-10198409
DM9GDP5	MI	TT2B9KF
DM9GDP5	MN	Fyn tyrosine protein kinase (FYN)
DM9GDP5	MT	DTT
DM9GDP5	MA	Inhibitor
DM9GDP5	RN	(6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad ant... J Med Chem. 2005 Dec 29;48(26):8163-73.
DM9GDP5	RU	https://pubmed.ncbi.nlm.nih.gov/16366598

DM9GDP5	DI	DM9GDP5
DM9GDP5	DN	JNJ-10198409
DM9GDP5	MI	TT860QF
DM9GDP5	MN	LCK tyrosine protein kinase (LCK)
DM9GDP5	MT	DTT
DM9GDP5	MA	Inhibitor
DM9GDP5	RN	(6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad ant... J Med Chem. 2005 Dec 29;48(26):8163-73.
DM9GDP5	RU	https://pubmed.ncbi.nlm.nih.gov/16366598

DM9GDP5	DI	DM9GDP5
DM9GDP5	DN	JNJ-10198409
DM9GDP5	MI	TT8FYO9
DM9GDP5	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DM9GDP5	MT	DTT
DM9GDP5	MA	Inhibitor
DM9GDP5	RN	(6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad ant... J Med Chem. 2005 Dec 29;48(26):8163-73.
DM9GDP5	RU	https://pubmed.ncbi.nlm.nih.gov/16366598

DM9GDP5	DI	DM9GDP5
DM9GDP5	DN	JNJ-10198409
DM9GDP5	MI	TTI7421
DM9GDP5	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM9GDP5	MT	DTT
DM9GDP5	MA	Inhibitor
DM9GDP5	RN	(6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad ant... J Med Chem. 2005 Dec 29;48(26):8163-73.
DM9GDP5	RU	https://pubmed.ncbi.nlm.nih.gov/16366598

DM9GDP5	DI	DM9GDP5
DM9GDP5	DN	JNJ-10198409
DM9GDP5	MI	TT6PKBN
DM9GDP5	MN	Proto-oncogene c-Src (SRC)
DM9GDP5	MT	DTT
DM9GDP5	MA	Inhibitor
DM9GDP5	RN	(6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad ant... J Med Chem. 2005 Dec 29;48(26):8163-73.
DM9GDP5	RU	https://pubmed.ncbi.nlm.nih.gov/16366598

DM9GDP5	DI	DM9GDP5
DM9GDP5	DN	JNJ-10198409
DM9GDP5	MI	TT3PJMV
DM9GDP5	MN	Tyrosine-protein kinase ABL1 (ABL)
DM9GDP5	MT	DTT
DM9GDP5	MA	Inhibitor
DM9GDP5	RN	(6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad ant... J Med Chem. 2005 Dec 29;48(26):8163-73.
DM9GDP5	RU	https://pubmed.ncbi.nlm.nih.gov/16366598

DMBRJ3C	DI	DMBRJ3C
DMBRJ3C	DN	JNJ-10329670
DMBRJ3C	MI	TTUMQVO
DMBRJ3C	MN	Cathepsin S (CTSS)
DMBRJ3C	MT	DTT
DMBRJ3C	MA	Inhibitor
DMBRJ3C	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2353).
DMBRJ3C	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2353

DMZH0K8	DI	DMZH0K8
DMZH0K8	DN	JNJ-10392980
DMZH0K8	MI	TTSQIFT
DMZH0K8	MN	5-HT 1A receptor (HTR1A)
DMZH0K8	MT	DTT
DMZH0K8	MA	Inhibitor
DMZH0K8	RN	Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69.
DMZH0K8	RU	https://pubmed.ncbi.nlm.nih.gov/18588282

DMZH0K8	DI	DMZH0K8
DMZH0K8	DN	JNJ-10392980
DMZH0K8	MI	TTXZEAJ
DMZH0K8	MN	Leukotriene A-4 hydrolase (LTA4H)
DMZH0K8	MT	DTT
DMZH0K8	MA	Inhibitor
DMZH0K8	RN	Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69.
DMZH0K8	RU	https://pubmed.ncbi.nlm.nih.gov/18588282

DMZH0K8	DI	DMZH0K8
DMZH0K8	DN	JNJ-10392980
DMZH0K8	MI	TTQ6VDM
DMZH0K8	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMZH0K8	MT	DTT
DMZH0K8	MA	Inhibitor
DMZH0K8	RN	Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69.
DMZH0K8	RU	https://pubmed.ncbi.nlm.nih.gov/18588282

DMZ8M0K	DI	DMZ8M0K
DMZ8M0K	DN	JNJ-10397049
DMZ8M0K	MI	TT9N02I
DMZ8M0K	MN	Orexin receptor type 2 (HCRTR2)
DMZ8M0K	MT	DTT
DMZ8M0K	MA	Modulator
DMZ8M0K	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 322).
DMZ8M0K	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=322

DMXNFU5	DI	DMXNFU5
DMXNFU5	DN	JNJ-16567083
DMXNFU5	MI	TTVBPDM
DMXNFU5	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMXNFU5	MT	DTT
DMXNFU5	MA	Modulator (allosteric modulator)
DMXNFU5	RN	A positron emission tomography radioligand for the in vivo labeling of metabotropic glutamate 1 receptor: (3-ethyl-2-[11C]methyl-6-quinolinyl)(cis- 4-methoxycyclohexyl)methanone. J Med Chem. 2005 Aug11;48(16):5096-9.
DMXNFU5	RU	https://pubmed.ncbi.nlm.nih.gov/16078827

DM3ZNF9	DI	DM3ZNF9
DM3ZNF9	DN	JNJ-1661010
DM3ZNF9	MI	TTDP1UC
DM3ZNF9	MN	Fatty acid amide hydrolase (FAAH)
DM3ZNF9	MT	DTT
DM3ZNF9	MA	Inhibitor
DM3ZNF9	RN	Thiadiazolopiperazinyl ureas as inhibitors of fatty acid amide hydrolase. Bioorg Med Chem Lett. 2008 Sep 1;18(17):4838-43.
DM3ZNF9	RU	https://pubmed.ncbi.nlm.nih.gov/18693015

DMJ1DE9	DI	DMJ1DE9
DMJ1DE9	DN	JNJ-17148066
DMJ1DE9	MI	TTZAYWL
DMJ1DE9	MN	Estrogen receptor (ESR)
DMJ1DE9	MT	DTT
DMJ1DE9	MA	Inhibitor
DMJ1DE9	RN	Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symp... J Med Chem. 2009 Dec 10;52(23):7544-69.
DMJ1DE9	RU	https://pubmed.ncbi.nlm.nih.gov/19366247

DMIXUNB	DI	DMIXUNB
DMIXUNB	DN	JNJ-17156516
DMIXUNB	MI	TTCG0AL
DMIXUNB	MN	Cholecystokinin receptor type A (CCKAR)
DMIXUNB	MT	DTT
DMIXUNB	MA	Antagonist
DMIXUNB	RN	3-[5-(3,4-Dichloro-phenyl)-1-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-2-m-tolyl-propionate (JNJ-17156516), a novel, potent, and selective cholecystokini... J Pharmacol Exp Ther. 2007 Nov;323(2):562-9.
DMIXUNB	RU	https://pubmed.ncbi.nlm.nih.gov/17684117

DMDUWBF	DI	DMDUWBF
DMDUWBF	DN	JNJ-17203212
DMDUWBF	MI	TTMI6F5
DMDUWBF	MN	Transient receptor potential cation channel V1 (TRPV1)
DMDUWBF	MT	DTT
DMDUWBF	MA	Inhibitor
DMDUWBF	RN	The potential of transient receptor potential vanilloid type 1 channel modulators for the treatment of pain. J Med Chem. 2007 May 31;50(11):2589-96.
DMDUWBF	RU	https://pubmed.ncbi.nlm.nih.gov/17489570

DMKH9O7	DI	DMKH9O7
DMKH9O7	DN	JNJ-1930942
DMKH9O7	MI	TTLA931
DMKH9O7	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMKH9O7	MT	DTT
DMKH9O7	MA	Modulator
DMKH9O7	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 468).
DMKH9O7	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=468

DM94IJC	DI	DM94IJC
DM94IJC	DN	JNJ-19398990
DM94IJC	MI	TTZAYWL
DM94IJC	MN	Estrogen receptor (ESR)
DM94IJC	MT	DTT
DM94IJC	MA	Inhibitor
DM94IJC	RN	Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symp... J Med Chem. 2009 Dec 10;52(23):7544-69.
DM94IJC	RU	https://pubmed.ncbi.nlm.nih.gov/19366247

DMK6TVN	DI	DMK6TVN
DMK6TVN	DN	JNJ-26529126
DMK6TVN	MI	TTZAYWL
DMK6TVN	MN	Estrogen receptor (ESR)
DMK6TVN	MT	DTT
DMK6TVN	MA	Inhibitor
DMK6TVN	RN	Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symp... J Med Chem. 2009 Dec 10;52(23):7544-69.
DMK6TVN	RU	https://pubmed.ncbi.nlm.nih.gov/19366247

DMBZ7MA	DI	DMBZ7MA
DMBZ7MA	DN	JNJ-26529152
DMBZ7MA	MI	TTZAYWL
DMBZ7MA	MN	Estrogen receptor (ESR)
DMBZ7MA	MT	DTT
DMBZ7MA	MA	Inhibitor
DMBZ7MA	RN	Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symp... J Med Chem. 2009 Dec 10;52(23):7544-69.
DMBZ7MA	RU	https://pubmed.ncbi.nlm.nih.gov/19366247

DMCMH7O	DI	DMCMH7O
DMCMH7O	DN	JNJ-28312141
DMCMH7O	MI	TTVW6QL
DMCMH7O	MN	CSF1R messenger RNA (CSF1R mRNA)
DMCMH7O	MT	DTT
DMCMH7O	MA	Inhibitor
DMCMH7O	RN	Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011 Oct 30;29(11):1046-51.
DMCMH7O	RU	https://pubmed.ncbi.nlm.nih.gov/22037378

DMCMH7O	DI	DMCMH7O
DMCMH7O	DN	JNJ-28312141
DMCMH7O	MI	TTGJCWZ
DMCMH7O	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMCMH7O	MT	DTT
DMCMH7O	MA	Inhibitor
DMCMH7O	RN	JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. Mol Cancer Ther. 2009 Nov;8(11):3151-61.
DMCMH7O	RU	https://pubmed.ncbi.nlm.nih.gov/19887542

DMCMH7O	DI	DMCMH7O
DMCMH7O	DN	JNJ-28312141
DMCMH7O	MI	TT860QF
DMCMH7O	MN	LCK tyrosine protein kinase (LCK)
DMCMH7O	MT	DTT
DMCMH7O	MA	Inhibitor
DMCMH7O	RN	JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. Mol Cancer Ther. 2009 Nov;8(11):3151-61.
DMCMH7O	RU	https://pubmed.ncbi.nlm.nih.gov/19887542

DMCMH7O	DI	DMCMH7O
DMCMH7O	DN	JNJ-28312141
DMCMH7O	MI	TTXABCW
DMCMH7O	MN	NT-3 growth factor receptor (TrkC)
DMCMH7O	MT	DTT
DMCMH7O	MA	Inhibitor
DMCMH7O	RN	JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. Mol Cancer Ther. 2009 Nov;8(11):3151-61.
DMCMH7O	RU	https://pubmed.ncbi.nlm.nih.gov/19887542

DMCMH7O	DI	DMCMH7O
DMCMH7O	DN	JNJ-28312141
DMCMH7O	MI	TTX41N9
DMCMH7O	MN	Tyrosine-protein kinase Kit (KIT)
DMCMH7O	MT	DTT
DMCMH7O	MA	Inhibitor
DMCMH7O	RN	JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. Mol Cancer Ther. 2009 Nov;8(11):3151-61.
DMCMH7O	RU	https://pubmed.ncbi.nlm.nih.gov/19887542

DM84PWI	DI	DM84PWI
DM84PWI	DN	JNJ-28318706
DM84PWI	MI	TTW5UDX
DM84PWI	MN	Urotensin II receptor (UTS2R)
DM84PWI	MT	DTT
DM84PWI	MA	Inhibitor
DM84PWI	RN	Nonpeptide urotensin-II receptor antagonists: a new ligand class based on piperazino-phthalimide and piperazino-isoindolinone subunits. J Med Chem. 2009 Dec 10;52(23):7432-45.
DM84PWI	RU	https://pubmed.ncbi.nlm.nih.gov/19731961

DM5LEOR	DI	DM5LEOR
DM5LEOR	DN	JNJ-28583867
DM5LEOR	MI	TT9JNIC
DM5LEOR	MN	Histamine H3 receptor (H3R)
DM5LEOR	MT	DTT
DM5LEOR	MA	Inhibitor
DM5LEOR	RN	Synthesis and biological activity of piperazine and diazepane amides that are histamine H3 antagonists and serotonin reuptake inhibitors. Bioorg Med Chem Lett. 2008 Jan 1;18(1):39-43.
DM5LEOR	RU	https://pubmed.ncbi.nlm.nih.gov/18060777

DM5LEOR	DI	DM5LEOR
DM5LEOR	DN	JNJ-28583867
DM5LEOR	MI	TT3ROYC
DM5LEOR	MN	Serotonin transporter (SERT)
DM5LEOR	MT	DTT
DM5LEOR	MA	Inhibitor
DM5LEOR	RN	Synthesis and biological activity of piperazine and diazepane amides that are histamine H3 antagonists and serotonin reuptake inhibitors. Bioorg Med Chem Lett. 2008 Jan 1;18(1):39-43.
DM5LEOR	RU	https://pubmed.ncbi.nlm.nih.gov/18060777

DM48Y9E	DI	DM48Y9E
DM48Y9E	DN	JNJ-38158471
DM48Y9E	MI	TTUTJGQ
DM48Y9E	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM48Y9E	MT	DTT
DM48Y9E	MA	Inhibitor
DM48Y9E	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1813).
DM48Y9E	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1813

DMLOQ92	DI	DMLOQ92
DMLOQ92	DN	JNJ-42153605
DMLOQ92	MI	TTXJ47W
DMLOQ92	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMLOQ92	MT	DTT
DMLOQ92	MA	Modulator (allosteric modulator)
DMLOQ92	RN	Discovery of 3-cyclopropylmethyl-7-(4-phenylpiperidin-1-yl)-8-trifluoromethyl[1,2,4]triazolo[4,3-a]pyridine (JNJ-42153605): a positive allosteric modulator of the metabotropic glutamate 2 receptor. JMed Chem. 2012 Oct 25;55(20):8770-89.
DMLOQ92	RU	https://pubmed.ncbi.nlm.nih.gov/23072213

DMWYU5C	DI	DMWYU5C
DMWYU5C	DN	JNJ-5207787
DMWYU5C	MI	TTJ6WK9
DMWYU5C	MN	Neuropeptide Y receptor type 2 (NPY2R)
DMWYU5C	MT	DTT
DMWYU5C	MA	Antagonist
DMWYU5C	RN	Characterization of N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-3-(3-cyano-phenyl)-N-[1-(2-cyclopentyl-ethyl)-piperidin-4yl]acrylamide (JNJ-5207787), a ... J Pharmacol Exp Ther. 2004 Mar;308(3):1130-7.
DMWYU5C	RU	https://pubmed.ncbi.nlm.nih.gov/14617685

DM5L23N	DI	DM5L23N
DM5L23N	DN	JNJ-5207852
DM5L23N	MI	TT9JNIC
DM5L23N	MN	Histamine H3 receptor (H3R)
DM5L23N	MT	DTT
DM5L23N	MA	Antagonist
DM5L23N	RN	The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20.
DM5L23N	RU	https://pubmed.ncbi.nlm.nih.gov/15665857

DMHTYBS	DI	DMHTYBS
DMHTYBS	DN	JNJ-7706621
DMHTYBS	MI	DTI7UX6
DMHTYBS	MN	Breast cancer resistance protein (ABCG2)
DMHTYBS	MT	DTP
DMHTYBS	MA	Substrate
DMHTYBS	RN	Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor. Mol Cancer Ther. 2006 Oct;5(10):2459-67.
DMHTYBS	RU	https://doi.org/10.1158/1535-7163.MCT-06-0339

DMHTYBS	DI	DMHTYBS
DMHTYBS	DN	JNJ-7706621
DMHTYBS	MI	TTH6V3D
DMHTYBS	MN	Cyclin-dependent kinase 1 (CDK1)
DMHTYBS	MT	DTT
DMHTYBS	MA	Inhibitor
DMHTYBS	RN	Synthesis and evaluation of N-acyl sulfonamides as potential prodrugs of cyclin-dependent kinase inhibitor JNJ-7706621. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3639-41.
DMHTYBS	RU	https://pubmed.ncbi.nlm.nih.gov/16682186

DMHTYBS	DI	DMHTYBS
DMHTYBS	DN	JNJ-7706621
DMHTYBS	MI	TT7HF4W
DMHTYBS	MN	Cyclin-dependent kinase 2 (CDK2)
DMHTYBS	MT	DTT
DMHTYBS	MA	Inhibitor
DMHTYBS	RN	Synthesis and evaluation of N-acyl sulfonamides as potential prodrugs of cyclin-dependent kinase inhibitor JNJ-7706621. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3639-41.
DMHTYBS	RU	https://pubmed.ncbi.nlm.nih.gov/16682186

DMLWYJB	DI	DMLWYJB
DMLWYJB	DN	JNK-IN-8
DMLWYJB	MI	TT3IVG2
DMLWYJB	MN	JNK2 messenger RNA (JNK2 mRNA)
DMLWYJB	MT	DTT
DMLWYJB	MA	Inhibitor
DMLWYJB	RN	Discovery of potent and selective covalent inhibitors of JNK. Chem Biol. 2012 Jan 27;19(1):140-54.
DMLWYJB	RU	https://pubmed.ncbi.nlm.nih.gov/22284361

DMLWYJB	DI	DMLWYJB
DMLWYJB	DN	JNK-IN-8
DMLWYJB	MI	TT0K6EO
DMLWYJB	MN	Stress-activated protein kinase JNK1 (JNK1)
DMLWYJB	MT	DTT
DMLWYJB	MA	Inhibitor
DMLWYJB	RN	Discovery of potent and selective covalent inhibitors of JNK. Chem Biol. 2012 Jan 27;19(1):140-54.
DMLWYJB	RU	https://pubmed.ncbi.nlm.nih.gov/22284361

DMLWYJB	DI	DMLWYJB
DMLWYJB	DN	JNK-IN-8
DMLWYJB	MI	TT056SO
DMLWYJB	MN	Stress-activated protein kinase JNK3 (JNK3)
DMLWYJB	MT	DTT
DMLWYJB	MA	Inhibitor
DMLWYJB	RN	Discovery of potent and selective covalent inhibitors of JNK. Chem Biol. 2012 Jan 27;19(1):140-54.
DMLWYJB	RU	https://pubmed.ncbi.nlm.nih.gov/22284361

DMYBJ4K	DI	DMYBJ4K
DMYBJ4K	DN	joro toxin
DMYBJ4K	MI	TTVPQTF
DMYBJ4K	MN	Glutamate receptor AMPA 1 (GRIA1)
DMYBJ4K	MT	DTT
DMYBJ4K	MA	Blocker (channel blocker)
DMYBJ4K	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 444).
DMYBJ4K	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=444

DMYBJ4K	DI	DMYBJ4K
DMYBJ4K	DN	joro toxin
DMYBJ4K	MI	TT82EZV
DMYBJ4K	MN	Glutamate receptor AMPA 3 (GRIA3)
DMYBJ4K	MT	DTT
DMYBJ4K	MA	Blocker (channel blocker)
DMYBJ4K	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 446).
DMYBJ4K	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=446

DMYBJ4K	DI	DMYBJ4K
DMYBJ4K	DN	joro toxin
DMYBJ4K	MI	TTPJR0G
DMYBJ4K	MN	Glutamate receptor AMPA 4 (GRIA4)
DMYBJ4K	MT	DTT
DMYBJ4K	MA	Blocker (channel blocker)
DMYBJ4K	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 447).
DMYBJ4K	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=447

DMMVBK6	DI	DMMVBK6
DMMVBK6	DN	JP1302
DMMVBK6	MI	TTWG9A4
DMMVBK6	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMMVBK6	MT	DTT
DMMVBK6	MA	Inhibitor
DMMVBK6	RN	Structure-activity relationship of quinoline derivatives as potent and selective alpha(2C)-adrenoceptor antagonists. J Med Chem. 2006 Oct 19;49(21):6351-63.
DMMVBK6	RU	https://pubmed.ncbi.nlm.nih.gov/17034141

DMMVBK6	DI	DMMVBK6
DMMVBK6	DN	JP1302
DMMVBK6	MI	TTWM4TY
DMMVBK6	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMMVBK6	MT	DTT
DMMVBK6	MA	Inhibitor
DMMVBK6	RN	Structure-activity relationship of quinoline derivatives as potent and selective alpha(2C)-adrenoceptor antagonists. J Med Chem. 2006 Oct 19;49(21):6351-63.
DMMVBK6	RU	https://pubmed.ncbi.nlm.nih.gov/17034141

DMMVBK6	DI	DMMVBK6
DMMVBK6	DN	JP1302
DMMVBK6	MI	TT2NUT5
DMMVBK6	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMMVBK6	MT	DTT
DMMVBK6	MA	Antagonist
DMMVBK6	RN	Pharmacological characterization and CNS effects of a novel highly selective alpha2C-adrenoceptor antagonist JP-1302. Br J Pharmacol. 2007 Feb;150(4):391-402.
DMMVBK6	RU	https://pubmed.ncbi.nlm.nih.gov/17220913

DM3XQDH	DI	DM3XQDH
DM3XQDH	DN	JQ1
DM3XQDH	MI	TTNISW6
DM3XQDH	MN	HUMAN bromodomain-containing protein 2 (BRD2)
DM3XQDH	MT	DTT
DM3XQDH	MA	Inhibitor
DM3XQDH	RN	Uncovering the Role of BRD2 in COVID-19. 2020-03-19
DM3XQDH	RU	https://www.caymanchem.com/news/uncovering-the-role-of-brd2-in-covid-19

DMD9W0B	DI	DMD9W0B
DMD9W0B	DN	JT-2724
DMD9W0B	MI	TTB2MXP
DMD9W0B	MN	Angiotensinogenase renin (REN)
DMD9W0B	MT	DTT
DMD9W0B	MA	Modulator
DMD9W0B	RN	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
DMD9W0B	RU	https://www.ncbi.nlm.nih.gov/pubmed/27899562

DMXZ9RF	DI	DMXZ9RF
DMXZ9RF	DN	JWB-1-84-1
DMXZ9RF	MI	TTH18TF
DMXZ9RF	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMXZ9RF	MT	DTT
DMXZ9RF	MA	Modulator
DMXZ9RF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 467).
DMXZ9RF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=467

DMYX30S	DI	DMYX30S
DMYX30S	DN	JWH-051
DMYX30S	MI	TTMSFAW
DMYX30S	MN	Cannabinoid receptor 2 (CB2)
DMYX30S	MT	DTT
DMYX30S	MA	Agonist
DMYX30S	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 57).
DMYX30S	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=57

DM7JQDS	DI	DM7JQDS
DM7JQDS	DN	JWH-120
DM7JQDS	MI	TT6OEDT
DM7JQDS	MN	Cannabinoid receptor 1 (CB1)
DM7JQDS	MT	DTT
DM7JQDS	MA	Inhibitor
DM7JQDS	RN	Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow. J Med Chem. 2009 Jan 22;52(2):369-78.
DM7JQDS	RU	https://pubmed.ncbi.nlm.nih.gov/19143566

DM7JQDS	DI	DM7JQDS
DM7JQDS	DN	JWH-120
DM7JQDS	MI	TTMSFAW
DM7JQDS	MN	Cannabinoid receptor 2 (CB2)
DM7JQDS	MT	DTT
DM7JQDS	MA	Inhibitor
DM7JQDS	RN	Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow. J Med Chem. 2009 Jan 22;52(2):369-78.
DM7JQDS	RU	https://pubmed.ncbi.nlm.nih.gov/19143566

DM1DEYU	DI	DM1DEYU
DM1DEYU	DN	JWH-133
DM1DEYU	MI	TT6OEDT
DM1DEYU	MN	Cannabinoid receptor 1 (CB1)
DM1DEYU	MT	DTT
DM1DEYU	MA	Inhibitor
DM1DEYU	RN	1-Bromo-3-(1',1'-dimethylalkyl)-1-deoxy-(8)-tetrahydrocannabinols: New selective ligands for the cannabinoid CB(2) receptor. Bioorg Med Chem. 2010 Nov 15;18(22):7809-15.
DM1DEYU	RU	https://pubmed.ncbi.nlm.nih.gov/20943404

DM1DEYU	DI	DM1DEYU
DM1DEYU	DN	JWH-133
DM1DEYU	MI	TTMSFAW
DM1DEYU	MN	Cannabinoid receptor 2 (CB2)
DM1DEYU	MT	DTT
DM1DEYU	MA	Inhibitor
DM1DEYU	RN	Design, synthesis, and biological evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB2 ... J Med Chem. 2006 Oct 5;49(20):5947-57.
DM1DEYU	RU	https://pubmed.ncbi.nlm.nih.gov/17004710

DMZQ31O	DI	DMZQ31O
DMZQ31O	DN	JWH-145
DMZQ31O	MI	TT6OEDT
DMZQ31O	MN	Cannabinoid receptor 1 (CB1)
DMZQ31O	MT	DTT
DMZQ31O	MA	Inhibitor
DMZQ31O	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DMZQ31O	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DMZQ31O	DI	DMZQ31O
DMZQ31O	DN	JWH-145
DMZQ31O	MI	TTMSFAW
DMZQ31O	MN	Cannabinoid receptor 2 (CB2)
DMZQ31O	MT	DTT
DMZQ31O	MA	Inhibitor
DMZQ31O	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DMZQ31O	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DMU7E6A	DI	DMU7E6A
DMU7E6A	DN	JWH-146
DMU7E6A	MI	TT6OEDT
DMU7E6A	MN	Cannabinoid receptor 1 (CB1)
DMU7E6A	MT	DTT
DMU7E6A	MA	Inhibitor
DMU7E6A	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DMU7E6A	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DMU7E6A	DI	DMU7E6A
DMU7E6A	DN	JWH-146
DMU7E6A	MI	TTMSFAW
DMU7E6A	MN	Cannabinoid receptor 2 (CB2)
DMU7E6A	MT	DTT
DMU7E6A	MA	Inhibitor
DMU7E6A	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DMU7E6A	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DMEX9GV	DI	DMEX9GV
DMEX9GV	DN	JWH-147
DMEX9GV	MI	TT6OEDT
DMEX9GV	MN	Cannabinoid receptor 1 (CB1)
DMEX9GV	MT	DTT
DMEX9GV	MA	Inhibitor
DMEX9GV	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DMEX9GV	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DMEX9GV	DI	DMEX9GV
DMEX9GV	DN	JWH-147
DMEX9GV	MI	TTMSFAW
DMEX9GV	MN	Cannabinoid receptor 2 (CB2)
DMEX9GV	MT	DTT
DMEX9GV	MA	Inhibitor
DMEX9GV	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DMEX9GV	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DM86OZD	DI	DM86OZD
DM86OZD	DN	JWH-150
DM86OZD	MI	TT6OEDT
DM86OZD	MN	Cannabinoid receptor 1 (CB1)
DM86OZD	MT	DTT
DM86OZD	MA	Inhibitor
DM86OZD	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DM86OZD	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DM86OZD	DI	DM86OZD
DM86OZD	DN	JWH-150
DM86OZD	MI	TTMSFAW
DM86OZD	MN	Cannabinoid receptor 2 (CB2)
DM86OZD	MT	DTT
DM86OZD	MA	Inhibitor
DM86OZD	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DM86OZD	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DMGPN61	DI	DMGPN61
DMGPN61	DN	JWH-151
DMGPN61	MI	TTMSFAW
DMGPN61	MN	Cannabinoid receptor 2 (CB2)
DMGPN61	MT	DTT
DMGPN61	MA	Inhibitor
DMGPN61	RN	Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow. J Med Chem. 2009 Jan 22;52(2):369-78.
DMGPN61	RU	https://pubmed.ncbi.nlm.nih.gov/19143566

DMWGSQO	DI	DMWGSQO
DMWGSQO	DN	JWH-156
DMWGSQO	MI	TT6OEDT
DMWGSQO	MN	Cannabinoid receptor 1 (CB1)
DMWGSQO	MT	DTT
DMWGSQO	MA	Inhibitor
DMWGSQO	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DMWGSQO	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DMWGSQO	DI	DMWGSQO
DMWGSQO	DN	JWH-156
DMWGSQO	MI	TTMSFAW
DMWGSQO	MN	Cannabinoid receptor 2 (CB2)
DMWGSQO	MT	DTT
DMWGSQO	MA	Inhibitor
DMWGSQO	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DMWGSQO	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DMLDOYV	DI	DMLDOYV
DMLDOYV	DN	JWH-167
DMLDOYV	MI	TTMSFAW
DMLDOYV	MN	Cannabinoid receptor 2 (CB2)
DMLDOYV	MT	DTT
DMLDOYV	MA	Inhibitor
DMLDOYV	RN	1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3.
DMLDOYV	RU	https://pubmed.ncbi.nlm.nih.gov/16005223

DMC2XSU	DI	DMC2XSU
DMC2XSU	DN	JWH-201
DMC2XSU	MI	TTMSFAW
DMC2XSU	MN	Cannabinoid receptor 2 (CB2)
DMC2XSU	MT	DTT
DMC2XSU	MA	Inhibitor
DMC2XSU	RN	1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3.
DMC2XSU	RU	https://pubmed.ncbi.nlm.nih.gov/16005223

DMQU2SV	DI	DMQU2SV
DMQU2SV	DN	JWH-202
DMQU2SV	MI	TTMSFAW
DMQU2SV	MN	Cannabinoid receptor 2 (CB2)
DMQU2SV	MT	DTT
DMQU2SV	MA	Inhibitor
DMQU2SV	RN	1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3.
DMQU2SV	RU	https://pubmed.ncbi.nlm.nih.gov/16005223

DMEJ8YA	DI	DMEJ8YA
DMEJ8YA	DN	JWH-203
DMEJ8YA	MI	TTMSFAW
DMEJ8YA	MN	Cannabinoid receptor 2 (CB2)
DMEJ8YA	MT	DTT
DMEJ8YA	MA	Inhibitor
DMEJ8YA	RN	1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3.
DMEJ8YA	RU	https://pubmed.ncbi.nlm.nih.gov/16005223

DMDTILC	DI	DMDTILC
DMDTILC	DN	JWH-204
DMDTILC	MI	TTMSFAW
DMDTILC	MN	Cannabinoid receptor 2 (CB2)
DMDTILC	MT	DTT
DMDTILC	MA	Inhibitor
DMDTILC	RN	1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3.
DMDTILC	RU	https://pubmed.ncbi.nlm.nih.gov/16005223

DMKIR63	DI	DMKIR63
DMKIR63	DN	JWH-205
DMKIR63	MI	TTMSFAW
DMKIR63	MN	Cannabinoid receptor 2 (CB2)
DMKIR63	MT	DTT
DMKIR63	MA	Inhibitor
DMKIR63	RN	1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3.
DMKIR63	RU	https://pubmed.ncbi.nlm.nih.gov/16005223

DMGFSQB	DI	DMGFSQB
DMGFSQB	DN	JWH-206
DMGFSQB	MI	TTMSFAW
DMGFSQB	MN	Cannabinoid receptor 2 (CB2)
DMGFSQB	MT	DTT
DMGFSQB	MA	Inhibitor
DMGFSQB	RN	1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3.
DMGFSQB	RU	https://pubmed.ncbi.nlm.nih.gov/16005223

DMF70IM	DI	DMF70IM
DMF70IM	DN	JWH-207
DMF70IM	MI	TTMSFAW
DMF70IM	MN	Cannabinoid receptor 2 (CB2)
DMF70IM	MT	DTT
DMF70IM	MA	Inhibitor
DMF70IM	RN	1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3.
DMF70IM	RU	https://pubmed.ncbi.nlm.nih.gov/16005223

DMLYHUN	DI	DMLYHUN
DMLYHUN	DN	JWH-208
DMLYHUN	MI	TTMSFAW
DMLYHUN	MN	Cannabinoid receptor 2 (CB2)
DMLYHUN	MT	DTT
DMLYHUN	MA	Inhibitor
DMLYHUN	RN	1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3.
DMLYHUN	RU	https://pubmed.ncbi.nlm.nih.gov/16005223

DMDXCIV	DI	DMDXCIV
DMDXCIV	DN	JWH-209
DMDXCIV	MI	TTMSFAW
DMDXCIV	MN	Cannabinoid receptor 2 (CB2)
DMDXCIV	MT	DTT
DMDXCIV	MA	Inhibitor
DMDXCIV	RN	1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3.
DMDXCIV	RU	https://pubmed.ncbi.nlm.nih.gov/16005223

DMMKYGP	DI	DMMKYGP
DMMKYGP	DN	JWH-229
DMMKYGP	MI	TT6OEDT
DMMKYGP	MN	Cannabinoid receptor 1 (CB1)
DMMKYGP	MT	DTT
DMMKYGP	MA	Inhibitor
DMMKYGP	RN	Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow. J Med Chem. 2009 Jan 22;52(2):369-78.
DMMKYGP	RU	https://pubmed.ncbi.nlm.nih.gov/19143566

DMMKYGP	DI	DMMKYGP
DMMKYGP	DN	JWH-229
DMMKYGP	MI	TTMSFAW
DMMKYGP	MN	Cannabinoid receptor 2 (CB2)
DMMKYGP	MT	DTT
DMMKYGP	MA	Inhibitor
DMMKYGP	RN	Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow. J Med Chem. 2009 Jan 22;52(2):369-78.
DMMKYGP	RU	https://pubmed.ncbi.nlm.nih.gov/19143566

DMRQOL5	DI	DMRQOL5
DMRQOL5	DN	JWH-237
DMRQOL5	MI	TTMSFAW
DMRQOL5	MN	Cannabinoid receptor 2 (CB2)
DMRQOL5	MT	DTT
DMRQOL5	MA	Inhibitor
DMRQOL5	RN	1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3.
DMRQOL5	RU	https://pubmed.ncbi.nlm.nih.gov/16005223

DMGD73A	DI	DMGD73A
DMGD73A	DN	JWH-243
DMGD73A	MI	TT6OEDT
DMGD73A	MN	Cannabinoid receptor 1 (CB1)
DMGD73A	MT	DTT
DMGD73A	MA	Inhibitor
DMGD73A	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DMGD73A	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DMGD73A	DI	DMGD73A
DMGD73A	DN	JWH-243
DMGD73A	MI	TTMSFAW
DMGD73A	MN	Cannabinoid receptor 2 (CB2)
DMGD73A	MT	DTT
DMGD73A	MA	Inhibitor
DMGD73A	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DMGD73A	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DMETAOU	DI	DMETAOU
DMETAOU	DN	JWH-244
DMETAOU	MI	TT6OEDT
DMETAOU	MN	Cannabinoid receptor 1 (CB1)
DMETAOU	MT	DTT
DMETAOU	MA	Inhibitor
DMETAOU	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DMETAOU	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DMETAOU	DI	DMETAOU
DMETAOU	DN	JWH-244
DMETAOU	MI	TTMSFAW
DMETAOU	MN	Cannabinoid receptor 2 (CB2)
DMETAOU	MT	DTT
DMETAOU	MA	Inhibitor
DMETAOU	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DMETAOU	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DMC5RZ9	DI	DMC5RZ9
DMC5RZ9	DN	JWH-245
DMC5RZ9	MI	TT6OEDT
DMC5RZ9	MN	Cannabinoid receptor 1 (CB1)
DMC5RZ9	MT	DTT
DMC5RZ9	MA	Inhibitor
DMC5RZ9	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DMC5RZ9	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DMC5RZ9	DI	DMC5RZ9
DMC5RZ9	DN	JWH-245
DMC5RZ9	MI	TTMSFAW
DMC5RZ9	MN	Cannabinoid receptor 2 (CB2)
DMC5RZ9	MT	DTT
DMC5RZ9	MA	Inhibitor
DMC5RZ9	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DMC5RZ9	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DMGTEYB	DI	DMGTEYB
DMGTEYB	DN	JWH-246
DMGTEYB	MI	TT6OEDT
DMGTEYB	MN	Cannabinoid receptor 1 (CB1)
DMGTEYB	MT	DTT
DMGTEYB	MA	Inhibitor
DMGTEYB	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DMGTEYB	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DMGTEYB	DI	DMGTEYB
DMGTEYB	DN	JWH-246
DMGTEYB	MI	TTMSFAW
DMGTEYB	MN	Cannabinoid receptor 2 (CB2)
DMGTEYB	MT	DTT
DMGTEYB	MA	Inhibitor
DMGTEYB	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DMGTEYB	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DMURL8D	DI	DMURL8D
DMURL8D	DN	JWH-248
DMURL8D	MI	TTMSFAW
DMURL8D	MN	Cannabinoid receptor 2 (CB2)
DMURL8D	MT	DTT
DMURL8D	MA	Inhibitor
DMURL8D	RN	1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3.
DMURL8D	RU	https://pubmed.ncbi.nlm.nih.gov/16005223

DMTOUCL	DI	DMTOUCL
DMTOUCL	DN	JWH-249
DMTOUCL	MI	TTMSFAW
DMTOUCL	MN	Cannabinoid receptor 2 (CB2)
DMTOUCL	MT	DTT
DMTOUCL	MA	Inhibitor
DMTOUCL	RN	1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3.
DMTOUCL	RU	https://pubmed.ncbi.nlm.nih.gov/16005223

DMWVS5X	DI	DMWVS5X
DMWVS5X	DN	JWH-250
DMWVS5X	MI	TTMSFAW
DMWVS5X	MN	Cannabinoid receptor 2 (CB2)
DMWVS5X	MT	DTT
DMWVS5X	MA	Inhibitor
DMWVS5X	RN	1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3.
DMWVS5X	RU	https://pubmed.ncbi.nlm.nih.gov/16005223

DMOJAUI	DI	DMOJAUI
DMOJAUI	DN	JWH-251
DMOJAUI	MI	TTMSFAW
DMOJAUI	MN	Cannabinoid receptor 2 (CB2)
DMOJAUI	MT	DTT
DMOJAUI	MA	Inhibitor
DMOJAUI	RN	1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3.
DMOJAUI	RU	https://pubmed.ncbi.nlm.nih.gov/16005223

DM6IWCZ	DI	DM6IWCZ
DM6IWCZ	DN	JWH-252
DM6IWCZ	MI	TTMSFAW
DM6IWCZ	MN	Cannabinoid receptor 2 (CB2)
DM6IWCZ	MT	DTT
DM6IWCZ	MA	Inhibitor
DM6IWCZ	RN	1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3.
DM6IWCZ	RU	https://pubmed.ncbi.nlm.nih.gov/16005223

DML1UMX	DI	DML1UMX
DML1UMX	DN	JWH-253
DML1UMX	MI	TTMSFAW
DML1UMX	MN	Cannabinoid receptor 2 (CB2)
DML1UMX	MT	DTT
DML1UMX	MA	Inhibitor
DML1UMX	RN	1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3.
DML1UMX	RU	https://pubmed.ncbi.nlm.nih.gov/16005223

DM07XBG	DI	DM07XBG
DM07XBG	DN	JWH-268
DM07XBG	MI	TT6OEDT
DM07XBG	MN	Cannabinoid receptor 1 (CB1)
DM07XBG	MT	DTT
DM07XBG	MA	Inhibitor
DM07XBG	RN	Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow. J Med Chem. 2009 Jan 22;52(2):369-78.
DM07XBG	RU	https://pubmed.ncbi.nlm.nih.gov/19143566

DM07XBG	DI	DM07XBG
DM07XBG	DN	JWH-268
DM07XBG	MI	TTMSFAW
DM07XBG	MN	Cannabinoid receptor 2 (CB2)
DM07XBG	MT	DTT
DM07XBG	MA	Inhibitor
DM07XBG	RN	Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow. J Med Chem. 2009 Jan 22;52(2):369-78.
DM07XBG	RU	https://pubmed.ncbi.nlm.nih.gov/19143566

DM5FAUY	DI	DM5FAUY
DM5FAUY	DN	JWH-292
DM5FAUY	MI	TT6OEDT
DM5FAUY	MN	Cannabinoid receptor 1 (CB1)
DM5FAUY	MT	DTT
DM5FAUY	MA	Inhibitor
DM5FAUY	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DM5FAUY	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DM5FAUY	DI	DM5FAUY
DM5FAUY	DN	JWH-292
DM5FAUY	MI	TTMSFAW
DM5FAUY	MN	Cannabinoid receptor 2 (CB2)
DM5FAUY	MT	DTT
DM5FAUY	MA	Inhibitor
DM5FAUY	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DM5FAUY	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DMCK1XR	DI	DMCK1XR
DMCK1XR	DN	JWH-293
DMCK1XR	MI	TT6OEDT
DMCK1XR	MN	Cannabinoid receptor 1 (CB1)
DMCK1XR	MT	DTT
DMCK1XR	MA	Inhibitor
DMCK1XR	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DMCK1XR	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DMCK1XR	DI	DMCK1XR
DMCK1XR	DN	JWH-293
DMCK1XR	MI	TTMSFAW
DMCK1XR	MN	Cannabinoid receptor 2 (CB2)
DMCK1XR	MT	DTT
DMCK1XR	MA	Inhibitor
DMCK1XR	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DMCK1XR	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DMTMF8X	DI	DMTMF8X
DMTMF8X	DN	JWH-294
DMTMF8X	MI	TTMSFAW
DMTMF8X	MN	Cannabinoid receptor 2 (CB2)
DMTMF8X	MT	DTT
DMTMF8X	MA	Inhibitor
DMTMF8X	RN	Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35.
DMTMF8X	RU	https://pubmed.ncbi.nlm.nih.gov/17919913

DMUMJGD	DI	DMUMJGD
DMUMJGD	DN	JWH-295
DMUMJGD	MI	TTMSFAW
DMUMJGD	MN	Cannabinoid receptor 2 (CB2)
DMUMJGD	MT	DTT
DMUMJGD	MA	Inhibitor
DMUMJGD	RN	Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35.
DMUMJGD	RU	https://pubmed.ncbi.nlm.nih.gov/17919913

DMNRXJU	DI	DMNRXJU
DMNRXJU	DN	JWH-296
DMNRXJU	MI	TTMSFAW
DMNRXJU	MN	Cannabinoid receptor 2 (CB2)
DMNRXJU	MT	DTT
DMNRXJU	MA	Inhibitor
DMNRXJU	RN	Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35.
DMNRXJU	RU	https://pubmed.ncbi.nlm.nih.gov/17919913

DM4A761	DI	DM4A761
DM4A761	DN	JWH-297
DM4A761	MI	TT6OEDT
DM4A761	MN	Cannabinoid receptor 1 (CB1)
DM4A761	MT	DTT
DM4A761	MA	Inhibitor
DM4A761	RN	Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35.
DM4A761	RU	https://pubmed.ncbi.nlm.nih.gov/17919913

DM4A761	DI	DM4A761
DM4A761	DN	JWH-297
DM4A761	MI	TTMSFAW
DM4A761	MN	Cannabinoid receptor 2 (CB2)
DM4A761	MT	DTT
DM4A761	MA	Inhibitor
DM4A761	RN	Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35.
DM4A761	RU	https://pubmed.ncbi.nlm.nih.gov/17919913

DMI7LF1	DI	DMI7LF1
DMI7LF1	DN	JWH-302
DMI7LF1	MI	TTMSFAW
DMI7LF1	MN	Cannabinoid receptor 2 (CB2)
DMI7LF1	MT	DTT
DMI7LF1	MA	Inhibitor
DMI7LF1	RN	1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3.
DMI7LF1	RU	https://pubmed.ncbi.nlm.nih.gov/16005223

DMCLAHR	DI	DMCLAHR
DMCLAHR	DN	JWH-303
DMCLAHR	MI	TTMSFAW
DMCLAHR	MN	Cannabinoid receptor 2 (CB2)
DMCLAHR	MT	DTT
DMCLAHR	MA	Inhibitor
DMCLAHR	RN	1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3.
DMCLAHR	RU	https://pubmed.ncbi.nlm.nih.gov/16005223

DM36W9M	DI	DM36W9M
DM36W9M	DN	JWH-305
DM36W9M	MI	TTMSFAW
DM36W9M	MN	Cannabinoid receptor 2 (CB2)
DM36W9M	MT	DTT
DM36W9M	MA	Inhibitor
DM36W9M	RN	1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3.
DM36W9M	RU	https://pubmed.ncbi.nlm.nih.gov/16005223

DMPDJKG	DI	DMPDJKG
DMPDJKG	DN	JWH-306
DMPDJKG	MI	TTMSFAW
DMPDJKG	MN	Cannabinoid receptor 2 (CB2)
DMPDJKG	MT	DTT
DMPDJKG	MA	Inhibitor
DMPDJKG	RN	1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3.
DMPDJKG	RU	https://pubmed.ncbi.nlm.nih.gov/16005223

DM23RUZ	DI	DM23RUZ
DM23RUZ	DN	JWH-307
DM23RUZ	MI	TT6OEDT
DM23RUZ	MN	Cannabinoid receptor 1 (CB1)
DM23RUZ	MT	DTT
DM23RUZ	MA	Inhibitor
DM23RUZ	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DM23RUZ	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DM23RUZ	DI	DM23RUZ
DM23RUZ	DN	JWH-307
DM23RUZ	MI	TTMSFAW
DM23RUZ	MN	Cannabinoid receptor 2 (CB2)
DM23RUZ	MT	DTT
DM23RUZ	MA	Inhibitor
DM23RUZ	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DM23RUZ	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DMV5ASE	DI	DMV5ASE
DMV5ASE	DN	JWH-308
DMV5ASE	MI	TT6OEDT
DMV5ASE	MN	Cannabinoid receptor 1 (CB1)
DMV5ASE	MT	DTT
DMV5ASE	MA	Inhibitor
DMV5ASE	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DMV5ASE	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DMV5ASE	DI	DMV5ASE
DMV5ASE	DN	JWH-308
DMV5ASE	MI	TTMSFAW
DMV5ASE	MN	Cannabinoid receptor 2 (CB2)
DMV5ASE	MT	DTT
DMV5ASE	MA	Inhibitor
DMV5ASE	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DMV5ASE	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DMTV1B9	DI	DMTV1B9
DMTV1B9	DN	JWH-309
DMTV1B9	MI	TT6OEDT
DMTV1B9	MN	Cannabinoid receptor 1 (CB1)
DMTV1B9	MT	DTT
DMTV1B9	MA	Inhibitor
DMTV1B9	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DMTV1B9	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DMTV1B9	DI	DMTV1B9
DMTV1B9	DN	JWH-309
DMTV1B9	MI	TTMSFAW
DMTV1B9	MN	Cannabinoid receptor 2 (CB2)
DMTV1B9	MT	DTT
DMTV1B9	MA	Inhibitor
DMTV1B9	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DMTV1B9	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DMLABGW	DI	DMLABGW
DMLABGW	DN	JWH-311
DMLABGW	MI	TTMSFAW
DMLABGW	MN	Cannabinoid receptor 2 (CB2)
DMLABGW	MT	DTT
DMLABGW	MA	Inhibitor
DMLABGW	RN	1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3.
DMLABGW	RU	https://pubmed.ncbi.nlm.nih.gov/16005223

DMYIGCU	DI	DMYIGCU
DMYIGCU	DN	JWH-312
DMYIGCU	MI	TTMSFAW
DMYIGCU	MN	Cannabinoid receptor 2 (CB2)
DMYIGCU	MT	DTT
DMYIGCU	MA	Inhibitor
DMYIGCU	RN	1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3.
DMYIGCU	RU	https://pubmed.ncbi.nlm.nih.gov/16005223

DMWBHZL	DI	DMWBHZL
DMWBHZL	DN	JWH-313
DMWBHZL	MI	TTMSFAW
DMWBHZL	MN	Cannabinoid receptor 2 (CB2)
DMWBHZL	MT	DTT
DMWBHZL	MA	Inhibitor
DMWBHZL	RN	1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3.
DMWBHZL	RU	https://pubmed.ncbi.nlm.nih.gov/16005223

DMCEKNJ	DI	DMCEKNJ
DMCEKNJ	DN	JWH-314
DMCEKNJ	MI	TTMSFAW
DMCEKNJ	MN	Cannabinoid receptor 2 (CB2)
DMCEKNJ	MT	DTT
DMCEKNJ	MA	Inhibitor
DMCEKNJ	RN	1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3.
DMCEKNJ	RU	https://pubmed.ncbi.nlm.nih.gov/16005223

DMWHN56	DI	DMWHN56
DMWHN56	DN	JWH-315
DMWHN56	MI	TTMSFAW
DMWHN56	MN	Cannabinoid receptor 2 (CB2)
DMWHN56	MT	DTT
DMWHN56	MA	Inhibitor
DMWHN56	RN	1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3.
DMWHN56	RU	https://pubmed.ncbi.nlm.nih.gov/16005223

DM63LOX	DI	DM63LOX
DM63LOX	DN	JWH-323
DM63LOX	MI	TTMSFAW
DM63LOX	MN	Cannabinoid receptor 2 (CB2)
DM63LOX	MT	DTT
DM63LOX	MA	Inhibitor
DM63LOX	RN	Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35.
DM63LOX	RU	https://pubmed.ncbi.nlm.nih.gov/17919913

DMJ2EI9	DI	DMJ2EI9
DMJ2EI9	DN	JWH-324
DMJ2EI9	MI	TT6OEDT
DMJ2EI9	MN	Cannabinoid receptor 1 (CB1)
DMJ2EI9	MT	DTT
DMJ2EI9	MA	Inhibitor
DMJ2EI9	RN	Synthesis and pharmacology of 1-methoxy analogs of CP-47,497. Bioorg Med Chem. 2010 Aug 1;18(15):5475-82.
DMJ2EI9	RU	https://pubmed.ncbi.nlm.nih.gov/20621488

DMJ2EI9	DI	DMJ2EI9
DMJ2EI9	DN	JWH-324
DMJ2EI9	MI	TTMSFAW
DMJ2EI9	MN	Cannabinoid receptor 2 (CB2)
DMJ2EI9	MT	DTT
DMJ2EI9	MA	Inhibitor
DMJ2EI9	RN	Synthesis and pharmacology of 1-methoxy analogs of CP-47,497. Bioorg Med Chem. 2010 Aug 1;18(15):5475-82.
DMJ2EI9	RU	https://pubmed.ncbi.nlm.nih.gov/20621488

DMHNTZ8	DI	DMHNTZ8
DMHNTZ8	DN	JWH-325
DMHNTZ8	MI	TT6OEDT
DMHNTZ8	MN	Cannabinoid receptor 1 (CB1)
DMHNTZ8	MT	DTT
DMHNTZ8	MA	Inhibitor
DMHNTZ8	RN	Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35.
DMHNTZ8	RU	https://pubmed.ncbi.nlm.nih.gov/17919913

DMHNTZ8	DI	DMHNTZ8
DMHNTZ8	DN	JWH-325
DMHNTZ8	MI	TTMSFAW
DMHNTZ8	MN	Cannabinoid receptor 2 (CB2)
DMHNTZ8	MT	DTT
DMHNTZ8	MA	Inhibitor
DMHNTZ8	RN	Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35.
DMHNTZ8	RU	https://pubmed.ncbi.nlm.nih.gov/17919913

DMK3DUZ	DI	DMK3DUZ
DMK3DUZ	DN	JWH-337
DMK3DUZ	MI	TT6OEDT
DMK3DUZ	MN	Cannabinoid receptor 1 (CB1)
DMK3DUZ	MT	DTT
DMK3DUZ	MA	Inhibitor
DMK3DUZ	RN	Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35.
DMK3DUZ	RU	https://pubmed.ncbi.nlm.nih.gov/17919913

DMK3DUZ	DI	DMK3DUZ
DMK3DUZ	DN	JWH-337
DMK3DUZ	MI	TTMSFAW
DMK3DUZ	MN	Cannabinoid receptor 2 (CB2)
DMK3DUZ	MT	DTT
DMK3DUZ	MA	Inhibitor
DMK3DUZ	RN	Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35.
DMK3DUZ	RU	https://pubmed.ncbi.nlm.nih.gov/17919913

DMTSZFB	DI	DMTSZFB
DMTSZFB	DN	JWH-342
DMTSZFB	MI	TT6OEDT
DMTSZFB	MN	Cannabinoid receptor 1 (CB1)
DMTSZFB	MT	DTT
DMTSZFB	MA	Inhibitor
DMTSZFB	RN	Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35.
DMTSZFB	RU	https://pubmed.ncbi.nlm.nih.gov/17919913

DMTSZFB	DI	DMTSZFB
DMTSZFB	DN	JWH-342
DMTSZFB	MI	TTMSFAW
DMTSZFB	MN	Cannabinoid receptor 2 (CB2)
DMTSZFB	MT	DTT
DMTSZFB	MA	Inhibitor
DMTSZFB	RN	Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35.
DMTSZFB	RU	https://pubmed.ncbi.nlm.nih.gov/17919913

DMEU1NS	DI	DMEU1NS
DMEU1NS	DN	JWH-343
DMEU1NS	MI	TTMSFAW
DMEU1NS	MN	Cannabinoid receptor 2 (CB2)
DMEU1NS	MT	DTT
DMEU1NS	MA	Inhibitor
DMEU1NS	RN	Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35.
DMEU1NS	RU	https://pubmed.ncbi.nlm.nih.gov/17919913

DM6VZ3T	DI	DM6VZ3T
DM6VZ3T	DN	JWH-344
DM6VZ3T	MI	TT6OEDT
DM6VZ3T	MN	Cannabinoid receptor 1 (CB1)
DM6VZ3T	MT	DTT
DM6VZ3T	MA	Inhibitor
DM6VZ3T	RN	Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35.
DM6VZ3T	RU	https://pubmed.ncbi.nlm.nih.gov/17919913

DM6VZ3T	DI	DM6VZ3T
DM6VZ3T	DN	JWH-344
DM6VZ3T	MI	TTMSFAW
DM6VZ3T	MN	Cannabinoid receptor 2 (CB2)
DM6VZ3T	MT	DTT
DM6VZ3T	MA	Inhibitor
DM6VZ3T	RN	Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35.
DM6VZ3T	RU	https://pubmed.ncbi.nlm.nih.gov/17919913

DML53SK	DI	DML53SK
DML53SK	DN	JWH-345
DML53SK	MI	TT6OEDT
DML53SK	MN	Cannabinoid receptor 1 (CB1)
DML53SK	MT	DTT
DML53SK	MA	Inhibitor
DML53SK	RN	Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35.
DML53SK	RU	https://pubmed.ncbi.nlm.nih.gov/17919913

DML53SK	DI	DML53SK
DML53SK	DN	JWH-345
DML53SK	MI	TTMSFAW
DML53SK	MN	Cannabinoid receptor 2 (CB2)
DML53SK	MT	DTT
DML53SK	MA	Inhibitor
DML53SK	RN	Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35.
DML53SK	RU	https://pubmed.ncbi.nlm.nih.gov/17919913

DMHNILP	DI	DMHNILP
DMHNILP	DN	JWH-346
DMHNILP	MI	TT6OEDT
DMHNILP	MN	Cannabinoid receptor 1 (CB1)
DMHNILP	MT	DTT
DMHNILP	MA	Inhibitor
DMHNILP	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DMHNILP	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DMHNILP	DI	DMHNILP
DMHNILP	DN	JWH-346
DMHNILP	MI	TTMSFAW
DMHNILP	MN	Cannabinoid receptor 2 (CB2)
DMHNILP	MT	DTT
DMHNILP	MA	Inhibitor
DMHNILP	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DMHNILP	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DMK2NQ1	DI	DMK2NQ1
DMK2NQ1	DN	JWH-347
DMK2NQ1	MI	TT6OEDT
DMK2NQ1	MN	Cannabinoid receptor 1 (CB1)
DMK2NQ1	MT	DTT
DMK2NQ1	MA	Inhibitor
DMK2NQ1	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DMK2NQ1	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DMK2NQ1	DI	DMK2NQ1
DMK2NQ1	DN	JWH-347
DMK2NQ1	MI	TTMSFAW
DMK2NQ1	MN	Cannabinoid receptor 2 (CB2)
DMK2NQ1	MT	DTT
DMK2NQ1	MA	Inhibitor
DMK2NQ1	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DMK2NQ1	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DMQIVPK	DI	DMQIVPK
DMQIVPK	DN	JWH-348
DMQIVPK	MI	TT6OEDT
DMQIVPK	MN	Cannabinoid receptor 1 (CB1)
DMQIVPK	MT	DTT
DMQIVPK	MA	Inhibitor
DMQIVPK	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DMQIVPK	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DMQIVPK	DI	DMQIVPK
DMQIVPK	DN	JWH-348
DMQIVPK	MI	TTMSFAW
DMQIVPK	MN	Cannabinoid receptor 2 (CB2)
DMQIVPK	MT	DTT
DMQIVPK	MA	Inhibitor
DMQIVPK	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DMQIVPK	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DMFLB1Z	DI	DMFLB1Z
DMFLB1Z	DN	JWH-363
DMFLB1Z	MI	TT6OEDT
DMFLB1Z	MN	Cannabinoid receptor 1 (CB1)
DMFLB1Z	MT	DTT
DMFLB1Z	MA	Inhibitor
DMFLB1Z	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DMFLB1Z	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DMFLB1Z	DI	DMFLB1Z
DMFLB1Z	DN	JWH-363
DMFLB1Z	MI	TTMSFAW
DMFLB1Z	MN	Cannabinoid receptor 2 (CB2)
DMFLB1Z	MT	DTT
DMFLB1Z	MA	Inhibitor
DMFLB1Z	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DMFLB1Z	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DMP6C4D	DI	DMP6C4D
DMP6C4D	DN	JWH-364
DMP6C4D	MI	TT6OEDT
DMP6C4D	MN	Cannabinoid receptor 1 (CB1)
DMP6C4D	MT	DTT
DMP6C4D	MA	Inhibitor
DMP6C4D	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DMP6C4D	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DMP6C4D	DI	DMP6C4D
DMP6C4D	DN	JWH-364
DMP6C4D	MI	TTMSFAW
DMP6C4D	MN	Cannabinoid receptor 2 (CB2)
DMP6C4D	MT	DTT
DMP6C4D	MA	Inhibitor
DMP6C4D	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DMP6C4D	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DM2ZXBR	DI	DM2ZXBR
DM2ZXBR	DN	JWH-365
DM2ZXBR	MI	TT6OEDT
DM2ZXBR	MN	Cannabinoid receptor 1 (CB1)
DM2ZXBR	MT	DTT
DM2ZXBR	MA	Inhibitor
DM2ZXBR	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DM2ZXBR	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DM2ZXBR	DI	DM2ZXBR
DM2ZXBR	DN	JWH-365
DM2ZXBR	MI	TTMSFAW
DM2ZXBR	MN	Cannabinoid receptor 2 (CB2)
DM2ZXBR	MT	DTT
DM2ZXBR	MA	Inhibitor
DM2ZXBR	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DM2ZXBR	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DMSNLFJ	DI	DMSNLFJ
DMSNLFJ	DN	JWH-366
DMSNLFJ	MI	TT6OEDT
DMSNLFJ	MN	Cannabinoid receptor 1 (CB1)
DMSNLFJ	MT	DTT
DMSNLFJ	MA	Inhibitor
DMSNLFJ	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DMSNLFJ	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DMSNLFJ	DI	DMSNLFJ
DMSNLFJ	DN	JWH-366
DMSNLFJ	MI	TTMSFAW
DMSNLFJ	MN	Cannabinoid receptor 2 (CB2)
DMSNLFJ	MT	DTT
DMSNLFJ	MA	Inhibitor
DMSNLFJ	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DMSNLFJ	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DM7ZF2K	DI	DM7ZF2K
DM7ZF2K	DN	JWH-367
DM7ZF2K	MI	TT6OEDT
DM7ZF2K	MN	Cannabinoid receptor 1 (CB1)
DM7ZF2K	MT	DTT
DM7ZF2K	MA	Inhibitor
DM7ZF2K	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DM7ZF2K	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DM7ZF2K	DI	DM7ZF2K
DM7ZF2K	DN	JWH-367
DM7ZF2K	MI	TTMSFAW
DM7ZF2K	MN	Cannabinoid receptor 2 (CB2)
DM7ZF2K	MT	DTT
DM7ZF2K	MA	Inhibitor
DM7ZF2K	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DM7ZF2K	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DMK0FNX	DI	DMK0FNX
DMK0FNX	DN	JWH-368
DMK0FNX	MI	TT6OEDT
DMK0FNX	MN	Cannabinoid receptor 1 (CB1)
DMK0FNX	MT	DTT
DMK0FNX	MA	Inhibitor
DMK0FNX	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DMK0FNX	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DMK0FNX	DI	DMK0FNX
DMK0FNX	DN	JWH-368
DMK0FNX	MI	TTMSFAW
DMK0FNX	MN	Cannabinoid receptor 2 (CB2)
DMK0FNX	MT	DTT
DMK0FNX	MA	Inhibitor
DMK0FNX	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DMK0FNX	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DMPDTWY	DI	DMPDTWY
DMPDTWY	DN	JWH-369
DMPDTWY	MI	TT6OEDT
DMPDTWY	MN	Cannabinoid receptor 1 (CB1)
DMPDTWY	MT	DTT
DMPDTWY	MA	Inhibitor
DMPDTWY	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DMPDTWY	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DMPDTWY	DI	DMPDTWY
DMPDTWY	DN	JWH-369
DMPDTWY	MI	TTMSFAW
DMPDTWY	MN	Cannabinoid receptor 2 (CB2)
DMPDTWY	MT	DTT
DMPDTWY	MA	Inhibitor
DMPDTWY	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DMPDTWY	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DM6IG7P	DI	DM6IG7P
DM6IG7P	DN	JWH-370
DM6IG7P	MI	TT6OEDT
DM6IG7P	MN	Cannabinoid receptor 1 (CB1)
DM6IG7P	MT	DTT
DM6IG7P	MA	Inhibitor
DM6IG7P	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DM6IG7P	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DM6IG7P	DI	DM6IG7P
DM6IG7P	DN	JWH-370
DM6IG7P	MI	TTMSFAW
DM6IG7P	MN	Cannabinoid receptor 2 (CB2)
DM6IG7P	MT	DTT
DM6IG7P	MA	Inhibitor
DM6IG7P	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DM6IG7P	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DME0URP	DI	DME0URP
DME0URP	DN	JWH-371
DME0URP	MI	TT6OEDT
DME0URP	MN	Cannabinoid receptor 1 (CB1)
DME0URP	MT	DTT
DME0URP	MA	Inhibitor
DME0URP	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DME0URP	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DME0URP	DI	DME0URP
DME0URP	DN	JWH-371
DME0URP	MI	TTMSFAW
DME0URP	MN	Cannabinoid receptor 2 (CB2)
DME0URP	MT	DTT
DME0URP	MA	Inhibitor
DME0URP	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DME0URP	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DM9D3GM	DI	DM9D3GM
DM9D3GM	DN	JWH-372
DM9D3GM	MI	TT6OEDT
DM9D3GM	MN	Cannabinoid receptor 1 (CB1)
DM9D3GM	MT	DTT
DM9D3GM	MA	Inhibitor
DM9D3GM	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DM9D3GM	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DM9D3GM	DI	DM9D3GM
DM9D3GM	DN	JWH-372
DM9D3GM	MI	TTMSFAW
DM9D3GM	MN	Cannabinoid receptor 2 (CB2)
DM9D3GM	MT	DTT
DM9D3GM	MA	Inhibitor
DM9D3GM	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DM9D3GM	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DMWP84R	DI	DMWP84R
DMWP84R	DN	JWH-373
DMWP84R	MI	TT6OEDT
DMWP84R	MN	Cannabinoid receptor 1 (CB1)
DMWP84R	MT	DTT
DMWP84R	MA	Inhibitor
DMWP84R	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DMWP84R	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DMWP84R	DI	DMWP84R
DMWP84R	DN	JWH-373
DMWP84R	MI	TTMSFAW
DMWP84R	MN	Cannabinoid receptor 2 (CB2)
DMWP84R	MT	DTT
DMWP84R	MA	Inhibitor
DMWP84R	RN	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
DMWP84R	RU	https://pubmed.ncbi.nlm.nih.gov/16889960

DMU1HA7	DI	DMU1HA7
DMU1HA7	DN	JWH-385
DMU1HA7	MI	TT6OEDT
DMU1HA7	MN	Cannabinoid receptor 1 (CB1)
DMU1HA7	MT	DTT
DMU1HA7	MA	Inhibitor
DMU1HA7	RN	Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35.
DMU1HA7	RU	https://pubmed.ncbi.nlm.nih.gov/17919913

DMU1HA7	DI	DMU1HA7
DMU1HA7	DN	JWH-385
DMU1HA7	MI	TTMSFAW
DMU1HA7	MN	Cannabinoid receptor 2 (CB2)
DMU1HA7	MT	DTT
DMU1HA7	MA	Inhibitor
DMU1HA7	RN	Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35.
DMU1HA7	RU	https://pubmed.ncbi.nlm.nih.gov/17919913

DMMUBIF	DI	DMMUBIF
DMMUBIF	DN	JWH-392
DMMUBIF	MI	TT6OEDT
DMMUBIF	MN	Cannabinoid receptor 1 (CB1)
DMMUBIF	MT	DTT
DMMUBIF	MA	Inhibitor
DMMUBIF	RN	Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35.
DMMUBIF	RU	https://pubmed.ncbi.nlm.nih.gov/17919913

DMMUBIF	DI	DMMUBIF
DMMUBIF	DN	JWH-392
DMMUBIF	MI	TTMSFAW
DMMUBIF	MN	Cannabinoid receptor 2 (CB2)
DMMUBIF	MT	DTT
DMMUBIF	MA	Inhibitor
DMMUBIF	RN	Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35.
DMMUBIF	RU	https://pubmed.ncbi.nlm.nih.gov/17919913

DMFL6B9	DI	DMFL6B9
DMFL6B9	DN	JWH-401
DMFL6B9	MI	TT6OEDT
DMFL6B9	MN	Cannabinoid receptor 1 (CB1)
DMFL6B9	MT	DTT
DMFL6B9	MA	Inhibitor
DMFL6B9	RN	Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35.
DMFL6B9	RU	https://pubmed.ncbi.nlm.nih.gov/17919913

DMFL6B9	DI	DMFL6B9
DMFL6B9	DN	JWH-401
DMFL6B9	MI	TTMSFAW
DMFL6B9	MN	Cannabinoid receptor 2 (CB2)
DMFL6B9	MT	DTT
DMFL6B9	MA	Inhibitor
DMFL6B9	RN	Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35.
DMFL6B9	RU	https://pubmed.ncbi.nlm.nih.gov/17919913

DM8TQIF	DI	DM8TQIF
DM8TQIF	DN	JWH-402
DM8TQIF	MI	TT6OEDT
DM8TQIF	MN	Cannabinoid receptor 1 (CB1)
DM8TQIF	MT	DTT
DM8TQIF	MA	Inhibitor
DM8TQIF	RN	Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35.
DM8TQIF	RU	https://pubmed.ncbi.nlm.nih.gov/17919913

DM8TQIF	DI	DM8TQIF
DM8TQIF	DN	JWH-402
DM8TQIF	MI	TTMSFAW
DM8TQIF	MN	Cannabinoid receptor 2 (CB2)
DM8TQIF	MT	DTT
DM8TQIF	MA	Inhibitor
DM8TQIF	RN	Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35.
DM8TQIF	RU	https://pubmed.ncbi.nlm.nih.gov/17919913

DMRG1VI	DI	DMRG1VI
DMRG1VI	DN	JWH-403
DMRG1VI	MI	TT6OEDT
DMRG1VI	MN	Cannabinoid receptor 1 (CB1)
DMRG1VI	MT	DTT
DMRG1VI	MA	Inhibitor
DMRG1VI	RN	Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35.
DMRG1VI	RU	https://pubmed.ncbi.nlm.nih.gov/17919913

DMRG1VI	DI	DMRG1VI
DMRG1VI	DN	JWH-403
DMRG1VI	MI	TTMSFAW
DMRG1VI	MN	Cannabinoid receptor 2 (CB2)
DMRG1VI	MT	DTT
DMRG1VI	MA	Inhibitor
DMRG1VI	RN	Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35.
DMRG1VI	RU	https://pubmed.ncbi.nlm.nih.gov/17919913

DM3KWER	DI	DM3KWER
DM3KWER	DN	JWH-404
DM3KWER	MI	TT6OEDT
DM3KWER	MN	Cannabinoid receptor 1 (CB1)
DM3KWER	MT	DTT
DM3KWER	MA	Inhibitor
DM3KWER	RN	Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35.
DM3KWER	RU	https://pubmed.ncbi.nlm.nih.gov/17919913

DM3KWER	DI	DM3KWER
DM3KWER	DN	JWH-404
DM3KWER	MI	TTMSFAW
DM3KWER	MN	Cannabinoid receptor 2 (CB2)
DM3KWER	MT	DTT
DM3KWER	MA	Inhibitor
DM3KWER	RN	Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35.
DM3KWER	RU	https://pubmed.ncbi.nlm.nih.gov/17919913

DM57TN3	DI	DM57TN3
DM57TN3	DN	JWH-405
DM57TN3	MI	TT6OEDT
DM57TN3	MN	Cannabinoid receptor 1 (CB1)
DM57TN3	MT	DTT
DM57TN3	MA	Inhibitor
DM57TN3	RN	Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35.
DM57TN3	RU	https://pubmed.ncbi.nlm.nih.gov/17919913

DM57TN3	DI	DM57TN3
DM57TN3	DN	JWH-405
DM57TN3	MI	TTMSFAW
DM57TN3	MN	Cannabinoid receptor 2 (CB2)
DM57TN3	MT	DTT
DM57TN3	MA	Inhibitor
DM57TN3	RN	Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35.
DM57TN3	RU	https://pubmed.ncbi.nlm.nih.gov/17919913

DMNP7GD	DI	DMNP7GD
DMNP7GD	DN	JWH-406
DMNP7GD	MI	TT6OEDT
DMNP7GD	MN	Cannabinoid receptor 1 (CB1)
DMNP7GD	MT	DTT
DMNP7GD	MA	Inhibitor
DMNP7GD	RN	Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35.
DMNP7GD	RU	https://pubmed.ncbi.nlm.nih.gov/17919913

DMNP7GD	DI	DMNP7GD
DMNP7GD	DN	JWH-406
DMNP7GD	MI	TTMSFAW
DMNP7GD	MN	Cannabinoid receptor 2 (CB2)
DMNP7GD	MT	DTT
DMNP7GD	MA	Inhibitor
DMNP7GD	RN	Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35.
DMNP7GD	RU	https://pubmed.ncbi.nlm.nih.gov/17919913

DMZQ0V9	DI	DMZQ0V9
DMZQ0V9	DN	JWH-407
DMZQ0V9	MI	TT6OEDT
DMZQ0V9	MN	Cannabinoid receptor 1 (CB1)
DMZQ0V9	MT	DTT
DMZQ0V9	MA	Inhibitor
DMZQ0V9	RN	Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35.
DMZQ0V9	RU	https://pubmed.ncbi.nlm.nih.gov/17919913

DMZQ0V9	DI	DMZQ0V9
DMZQ0V9	DN	JWH-407
DMZQ0V9	MI	TTMSFAW
DMZQ0V9	MN	Cannabinoid receptor 2 (CB2)
DMZQ0V9	MT	DTT
DMZQ0V9	MA	Inhibitor
DMZQ0V9	RN	Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35.
DMZQ0V9	RU	https://pubmed.ncbi.nlm.nih.gov/17919913

DM89602	DI	DM89602
DM89602	DN	JWH-440
DM89602	MI	TT6OEDT
DM89602	MN	Cannabinoid receptor 1 (CB1)
DM89602	MT	DTT
DM89602	MA	Inhibitor
DM89602	RN	Synthesis and pharmacology of 1-methoxy analogs of CP-47,497. Bioorg Med Chem. 2010 Aug 1;18(15):5475-82.
DM89602	RU	https://pubmed.ncbi.nlm.nih.gov/20621488

DM89602	DI	DM89602
DM89602	DN	JWH-440
DM89602	MI	TTMSFAW
DM89602	MN	Cannabinoid receptor 2 (CB2)
DM89602	MT	DTT
DM89602	MA	Inhibitor
DM89602	RN	Synthesis and pharmacology of 1-methoxy analogs of CP-47,497. Bioorg Med Chem. 2010 Aug 1;18(15):5475-82.
DM89602	RU	https://pubmed.ncbi.nlm.nih.gov/20621488

DM7R1XS	DI	DM7R1XS
DM7R1XS	DN	JWH-441
DM7R1XS	MI	TTMSFAW
DM7R1XS	MN	Cannabinoid receptor 2 (CB2)
DM7R1XS	MT	DTT
DM7R1XS	MA	Inhibitor
DM7R1XS	RN	Synthesis and pharmacology of 1-methoxy analogs of CP-47,497. Bioorg Med Chem. 2010 Aug 1;18(15):5475-82.
DM7R1XS	RU	https://pubmed.ncbi.nlm.nih.gov/20621488

DMX6F1L	DI	DMX6F1L
DMX6F1L	DN	JWH-442
DMX6F1L	MI	TT6OEDT
DMX6F1L	MN	Cannabinoid receptor 1 (CB1)
DMX6F1L	MT	DTT
DMX6F1L	MA	Inhibitor
DMX6F1L	RN	Synthesis and pharmacology of 1-methoxy analogs of CP-47,497. Bioorg Med Chem. 2010 Aug 1;18(15):5475-82.
DMX6F1L	RU	https://pubmed.ncbi.nlm.nih.gov/20621488

DMX6F1L	DI	DMX6F1L
DMX6F1L	DN	JWH-442
DMX6F1L	MI	TTMSFAW
DMX6F1L	MN	Cannabinoid receptor 2 (CB2)
DMX6F1L	MT	DTT
DMX6F1L	MA	Inhibitor
DMX6F1L	RN	Synthesis and pharmacology of 1-methoxy analogs of CP-47,497. Bioorg Med Chem. 2010 Aug 1;18(15):5475-82.
DMX6F1L	RU	https://pubmed.ncbi.nlm.nih.gov/20621488

DMWA8B0	DI	DMWA8B0
DMWA8B0	DN	JZL184
DMWA8B0	MI	TTZ963I
DMWA8B0	MN	Monoglyceride lipase (MAGL)
DMWA8B0	MT	DTT
DMWA8B0	MA	Inhibitor
DMWA8B0	RN	Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol. 2009 Jan;5(1):37-44.
DMWA8B0	RU	https://pubmed.ncbi.nlm.nih.gov/19029917

DMEOCKZ	DI	DMEOCKZ
DMEOCKZ	DN	JZL195
DMEOCKZ	MI	TT2EJXQ
DMEOCKZ	MN	Acyloxyacyl hydrolase (neutrophil)
DMEOCKZ	MT	DTT
DMEOCKZ	MA	Inhibitor
DMEOCKZ	RN	A high-throughput, multiplexed assay for superfamily-wide profiling of enzyme activity. Nat Chem Biol. 2014 Aug;10(8):656-63.
DMEOCKZ	RU	https://pubmed.ncbi.nlm.nih.gov/24997602

DMP8M9Q	DI	DMP8M9Q
DMP8M9Q	DN	K00024
DMP8M9Q	MI	TTH6V3D
DMP8M9Q	MN	Cyclin-dependent kinase 1 (CDK1)
DMP8M9Q	MT	DTT
DMP8M9Q	MA	Inhibitor
DMP8M9Q	RN	Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors. J Med Chem. 2003 May 22;46(11):2027-30.
DMP8M9Q	RU	https://pubmed.ncbi.nlm.nih.gov/12747775

DMP8M9Q	DI	DMP8M9Q
DMP8M9Q	DN	K00024
DMP8M9Q	MI	TT7HF4W
DMP8M9Q	MN	Cyclin-dependent kinase 2 (CDK2)
DMP8M9Q	MT	DTT
DMP8M9Q	MA	Inhibitor
DMP8M9Q	RN	Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors. J Med Chem. 2003 May 22;46(11):2027-30.
DMP8M9Q	RU	https://pubmed.ncbi.nlm.nih.gov/12747775

DMP8M9Q	DI	DMP8M9Q
DMP8M9Q	DN	K00024
DMP8M9Q	MI	TT0PG8F
DMP8M9Q	MN	Cyclin-dependent kinase 4 (CDK4)
DMP8M9Q	MT	DTT
DMP8M9Q	MA	Inhibitor
DMP8M9Q	RN	Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors. J Med Chem. 2003 May 22;46(11):2027-30.
DMP8M9Q	RU	https://pubmed.ncbi.nlm.nih.gov/12747775

DM2BKU8	DI	DM2BKU8
DM2BKU8	DN	K00244
DM2BKU8	MI	TTLYXIT
DM2BKU8	MN	Aurora kinase C (AURKC)
DM2BKU8	MT	DTT
DM2BKU8	MA	Inhibitor
DM2BKU8	RN	The discovery of the potent aurora inhibitor MK-0457 (VX-680). Bioorg Med Chem Lett. 2009 Jul 1;19(13):3586-92.
DM2BKU8	RU	https://pubmed.ncbi.nlm.nih.gov/19447622

DM2BKU8	DI	DM2BKU8
DM2BKU8	DN	K00244
DM2BKU8	MI	TTRSMW9
DM2BKU8	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DM2BKU8	MT	DTT
DM2BKU8	MA	Inhibitor
DM2BKU8	RN	The discovery of the potent aurora inhibitor MK-0457 (VX-680). Bioorg Med Chem Lett. 2009 Jul 1;19(13):3586-92.
DM2BKU8	RU	https://pubmed.ncbi.nlm.nih.gov/19447622

DM2BKU8	DI	DM2BKU8
DM2BKU8	DN	K00244
DM2BKU8	MI	TT6PKBN
DM2BKU8	MN	Proto-oncogene c-Src (SRC)
DM2BKU8	MT	DTT
DM2BKU8	MA	Inhibitor
DM2BKU8	RN	The discovery of the potent aurora inhibitor MK-0457 (VX-680). Bioorg Med Chem Lett. 2009 Jul 1;19(13):3586-92.
DM2BKU8	RU	https://pubmed.ncbi.nlm.nih.gov/19447622

DMWZJG6	DI	DMWZJG6
DMWZJG6	DN	K00248
DMWZJG6	MI	TTYPXQF
DMWZJG6	MN	Protein kinase C beta (PRKCB)
DMWZJG6	MT	DTT
DMWZJG6	MA	Inhibitor
DMWZJG6	RN	Synthesis of anilino-monoindolylmaleimides as potent and selective PKCbeta inhibitors. Bioorg Med Chem Lett. 2004 Oct 18;14(20):5171-4.
DMWZJG6	RU	https://pubmed.ncbi.nlm.nih.gov/15380221

DM1RP5Q	DI	DM1RP5Q
DM1RP5Q	DN	K00592a
DM1RP5Q	MI	TTOU65C
DM1RP5Q	MN	Tyrosine-protein kinase SYK (SYK)
DM1RP5Q	MT	DTT
DM1RP5Q	MA	Inhibitor
DM1RP5Q	RN	Synthetic studies on novel Syk inhibitors. Part 1: Synthesis and structure-activity relationships of pyrimidine-5-carboxamide derivatives. Bioorg Med Chem. 2005 Aug 15;13(16):4936-51.
DM1RP5Q	RU	https://pubmed.ncbi.nlm.nih.gov/15990316

DM1RP5Q	DI	DM1RP5Q
DM1RP5Q	DN	K00592a
DM1RP5Q	MI	TTUMHT8
DM1RP5Q	MN	Tyrosine-protein kinase ZAP-70 (ZAP-70)
DM1RP5Q	MT	DTT
DM1RP5Q	MA	Inhibitor
DM1RP5Q	RN	Synthetic studies on novel Syk inhibitors. Part 1: Synthesis and structure-activity relationships of pyrimidine-5-carboxamide derivatives. Bioorg Med Chem. 2005 Aug 15;13(16):4936-51.
DM1RP5Q	RU	https://pubmed.ncbi.nlm.nih.gov/15990316

DME65H8	DI	DME65H8
DME65H8	DN	K185
DME65H8	MI	TT0WAIE
DME65H8	MN	Melatonin receptor type 1A (MTNR1A)
DME65H8	MT	DTT
DME65H8	MA	Antagonist
DME65H8	RN	Mapping the melatonin receptor. 6. Melatonin agonists and antagonists derived from 6H-isoindolo[2,1-a]indoles, 5,6-dihydroindolo[2,1-a]isoquinolines, and 6,7-dihydro-5H-benzo[c]azepino[2,1-a]indoles.J Med Chem. 2000 Mar 23;43(6):1050-61.
DME65H8	RU	https://pubmed.ncbi.nlm.nih.gov/10737738

DMT68RG	DI	DMT68RG
DMT68RG	DN	K252a
DMT68RG	MI	TTSLUMT
DMT68RG	MN	Protein kinase D (PRKD1)
DMT68RG	MT	DTT
DMT68RG	MA	Inhibitor
DMT68RG	RN	Protein kinase D as a potential new target for cancer therapy. Biochim Biophys Acta. 2010 Dec;1806(2):183-92.
DMT68RG	RU	https://pubmed.ncbi.nlm.nih.gov/20580776

DMCZPH4	DI	DMCZPH4
DMCZPH4	DN	K-252a analogue
DMCZPH4	MI	TTTDVOJ
DMCZPH4	MN	Tropomyosin-related kinase A (TrkA)
DMCZPH4	MT	DTT
DMCZPH4	MA	Inhibitor
DMCZPH4	RN	Synthesis, modeling, and in vitro activity of (3'S)-epi-K-252a analogues. Elucidating the stereochemical requirements of the 3'-sugar alcohol on tr... J Med Chem. 2005 Jun 2;48(11):3776-83.
DMCZPH4	RU	https://pubmed.ncbi.nlm.nih.gov/15916429

DMCZPH4	DI	DMCZPH4
DMCZPH4	DN	K-252a analogue
DMCZPH4	MI	TTUTJGQ
DMCZPH4	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMCZPH4	MT	DTT
DMCZPH4	MA	Inhibitor
DMCZPH4	RN	Synthesis, modeling, and in vitro activity of (3'S)-epi-K-252a analogues. Elucidating the stereochemical requirements of the 3'-sugar alcohol on tr... J Med Chem. 2005 Jun 2;48(11):3776-83.
DMCZPH4	RU	https://pubmed.ncbi.nlm.nih.gov/15916429

DMYSMWI	DI	DMYSMWI
DMYSMWI	DN	K-454
DMYSMWI	MI	TTRMX3V
DMYSMWI	MN	Janus kinase 2 (JAK-2)
DMYSMWI	MT	DTT
DMYSMWI	MA	Inhibitor
DMYSMWI	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2048).
DMYSMWI	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2048

DMUKTBF	DI	DMUKTBF
DMUKTBF	DN	K-6015
DMUKTBF	MI	DEASPQ0
DMUKTBF	MN	Beta-glycosidase (glyB)
DMUKTBF	MT	DME
DMUKTBF	MA	Metabolism
DMUKTBF	RN	Comparison of anti-Campylobacter activity of free thymol and thymol-beta-D-glucopyranoside in absence or presence of beta-glycoside-hydrolysing gut bacteria. Food Chem. 2015 Apr 15;173:92-8.
DMUKTBF	RU	https://pubmed.ncbi.nlm.nih.gov/25465999

DMIFCMW	DI	DMIFCMW
DMIFCMW	DN	K-777
DMIFCMW	MI	TT2SUAQ
DMIFCMW	MN	Cysteine protease (CYP)
DMIFCMW	MT	DTT
DMIFCMW	MA	Inhibitor
DMIFCMW	RN	Novel non-peptidic vinylsulfones targeting the S2 and S3 subsites of parasite cysteine proteases. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6218-21.
DMIFCMW	RU	https://pubmed.ncbi.nlm.nih.gov/19773167

DMIFCMW	DI	DMIFCMW
DMIFCMW	DN	K-777
DMIFCMW	MI	TTEAID7
DMIFCMW	MN	Trypanosoma Cruzipain (Trypano CYSP)
DMIFCMW	MT	DTT
DMIFCMW	MA	Inhibitor
DMIFCMW	RN	Novel non-peptidic vinylsulfones targeting the S2 and S3 subsites of parasite cysteine proteases. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6218-21.
DMIFCMW	RU	https://pubmed.ncbi.nlm.nih.gov/19773167

DM4GSHY	DI	DM4GSHY
DM4GSHY	DN	KA-10X
DM4GSHY	MI	TTW2R9X
DM4GSHY	MN	GTPase NRas (NRAS)
DM4GSHY	MT	DTT
DM4GSHY	MA	Antagonist
DM4GSHY	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2823).
DM4GSHY	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2823

DMUWA2G	DI	DMUWA2G
DMUWA2G	DN	KAEMPFERIDE
DMUWA2G	MI	TTI84H7
DMUWA2G	MN	Cytochrome P450 1B1 (CYP1B1)
DMUWA2G	MT	DTT
DMUWA2G	MA	Inhibitor
DMUWA2G	RN	Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5.
DMUWA2G	RU	https://pubmed.ncbi.nlm.nih.gov/20696580

DMHEMUB	DI	DMHEMUB
DMHEMUB	DN	Kaempferol
DMHEMUB	MI	TTFBNVI
DMHEMUB	MN	Aldose reductase (AKR1B1)
DMHEMUB	MT	DTT
DMHEMUB	MA	Inhibitor
DMHEMUB	RN	Erigeroflavanone, a flavanone derivative from the flowers of Erigeron annuus with protein glycation and aldose reductase inhibitory activity. J Nat Prod. 2008 Apr;71(4):713-5.
DMHEMUB	RU	https://pubmed.ncbi.nlm.nih.gov/18298080

DMHEMUB	DI	DMHEMUB
DMHEMUB	DN	Kaempferol
DMHEMUB	MI	TTKPW01
DMHEMUB	MN	Androgen receptor messenger RNA (AR mRNA)
DMHEMUB	MT	DTT
DMHEMUB	MA	Inhibitor
DMHEMUB	RN	Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4706-10.
DMHEMUB	RU	https://pubmed.ncbi.nlm.nih.gov/19592245

DMHEMUB	DI	DMHEMUB
DMHEMUB	DN	Kaempferol
DMHEMUB	MI	TTN9T81
DMHEMUB	MN	Arachidonate 15-lipoxygenase (15-LOX)
DMHEMUB	MT	DTT
DMHEMUB	MA	Inhibitor
DMHEMUB	RN	Lipoxygenase inhibitory constituents of the fruits of noni (Morinda citrifolia) collected in Tahiti. J Nat Prod. 2007 May;70(5):859-62.
DMHEMUB	RU	https://pubmed.ncbi.nlm.nih.gov/17378609

DMHEMUB	DI	DMHEMUB
DMHEMUB	DN	Kaempferol
DMHEMUB	MI	TTI84H7
DMHEMUB	MN	Cytochrome P450 1B1 (CYP1B1)
DMHEMUB	MT	DTT
DMHEMUB	MA	Inhibitor
DMHEMUB	RN	Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5.
DMHEMUB	RU	https://pubmed.ncbi.nlm.nih.gov/20696580

DMHEMUB	DI	DMHEMUB
DMHEMUB	DN	Kaempferol
DMHEMUB	MI	TTIWB6L
DMHEMUB	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMHEMUB	MT	DTT
DMHEMUB	MA	Inhibitor
DMHEMUB	RN	Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries. J Med Chem. 2008 Jul 24;51(14):4188-99.
DMHEMUB	RU	https://pubmed.ncbi.nlm.nih.gov/18533708

DMHEMUB	DI	DMHEMUB
DMHEMUB	DN	Kaempferol
DMHEMUB	MI	TT50QJ3
DMHEMUB	MN	Influenza Neuraminidase (Influ NA)
DMHEMUB	MT	DTT
DMHEMUB	MA	Inhibitor
DMHEMUB	RN	Neuraminidase inhibitory activities of flavonols isolated from Rhodiola rosea roots and their in vitro anti-influenza viral activities. Bioorg Med Chem. 2009 Oct 1;17(19):6816-23.
DMHEMUB	RU	https://pubmed.ncbi.nlm.nih.gov/19729316

DMHEMUB	DI	DMHEMUB
DMHEMUB	DN	Kaempferol
DMHEMUB	MI	TTV9A7R
DMHEMUB	MN	Lactoylglutathione lyase (GLO1)
DMHEMUB	MT	DTT
DMHEMUB	MA	Inhibitor
DMHEMUB	RN	Structure-activity relationship of human GLO I inhibitory natural flavonoids and their growth inhibitory effects. Bioorg Med Chem. 2008 Apr 1;16(7):3969-75.
DMHEMUB	RU	https://pubmed.ncbi.nlm.nih.gov/18258440

DMHEMUB	DI	DMHEMUB
DMHEMUB	DN	Kaempferol
DMHEMUB	MI	TTSJ6Q4
DMHEMUB	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DMHEMUB	MT	DTT
DMHEMUB	MA	Inhibitor
DMHEMUB	RN	Lipoxygenase inhibitory constituents of the fruits of noni (Morinda citrifolia) collected in Tahiti. J Nat Prod. 2007 May;70(5):859-62.
DMHEMUB	RU	https://pubmed.ncbi.nlm.nih.gov/17378609

DMHEMUB	DI	DMHEMUB
DMHEMUB	DN	Kaempferol
DMHEMUB	MI	TTBE4IR
DMHEMUB	MN	Plasmodium Oxoacyl-[acyl-carrier protein] reductase (Malaria fabG)
DMHEMUB	MT	DTT
DMHEMUB	MA	Inhibitor
DMHEMUB	RN	Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
DMHEMUB	RU	https://pubmed.ncbi.nlm.nih.gov/16722653

DMUCZ3F	DI	DMUCZ3F
DMUCZ3F	DN	Kaempferol-3-O-(2''-O-galloyl)-glucoside
DMUCZ3F	MI	TTL69WB
DMUCZ3F	MN	Angiotensin-converting enzyme (ACE)
DMUCZ3F	MT	DTT
DMUCZ3F	MA	Inhibitor
DMUCZ3F	RN	Inhibitory effects of various flavonoids isolated from leaves of persimmon on angiotensin-converting enzyme activity. J Nat Prod. 1987 Jul-Aug;50(4):680-3.
DMUCZ3F	RU	https://pubmed.ncbi.nlm.nih.gov/3430165

DMBG7X1	DI	DMBG7X1
DMBG7X1	DN	Kaempferol-3-O-methyl ether
DMBG7X1	MI	TTVG215
DMBG7X1	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DMBG7X1	MT	DTT
DMBG7X1	MA	Inhibitor
DMBG7X1	RN	Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities. J Nat Prod. 2004 Jul;67(7):1079-83.
DMBG7X1	RU	https://pubmed.ncbi.nlm.nih.gov/15270556

DMN4EUB	DI	DMN4EUB
DMN4EUB	DN	KAG-308
DMN4EUB	MI	TT79WV3
DMN4EUB	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DMN4EUB	MT	DTT
DMN4EUB	MA	Agonist
DMN4EUB	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 343).
DMN4EUB	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=343

DMRT6OP	DI	DMRT6OP
DMRT6OP	DN	kallidin
DMRT6OP	MI	TTGY8IW
DMRT6OP	MN	B2 bradykinin receptor (BDKRB2)
DMRT6OP	MT	DTT
DMRT6OP	MA	Agonist
DMRT6OP	RN	Differential pharmacology of cloned human and mouse B2 bradykinin receptors. Mol Pharmacol. 1994 Jan;45(1):1-8.
DMRT6OP	RU	https://pubmed.ncbi.nlm.nih.gov/8302267

DM7YAE0	DI	DM7YAE0
DM7YAE0	DN	kallstroemin D
DM7YAE0	MI	TT1UCIJ
DM7YAE0	MN	C-X-C chemokine receptor type 3 (CXCR3)
DM7YAE0	MT	DTT
DM7YAE0	MA	Antagonist
DM7YAE0	RN	Discovery of structurally diverse natural product antagonists of chemokine receptor CXCR3. Mol Divers. 2005;9(1-3):123-9.
DM7YAE0	RU	https://pubmed.ncbi.nlm.nih.gov/15789559

DMFR79L	DI	DMFR79L
DMFR79L	DN	Kaltostat
DMFR79L	MI	DE65RJO
DMFR79L	MN	Beta-glucuronidase (uidA)
DMFR79L	MT	DME
DMFR79L	MA	Metabolism
DMFR79L	RN	Active site flexibility revealed in crystal structures of Parabacteroides merdae beta-glucuronidase from the human gut microbiome. Protein Sci. 2018 Dec;27(12):2010-2022.
DMFR79L	RU	https://pubmed.ncbi.nlm.nih.gov/30230652

DMXAK75	DI	DMXAK75
DMXAK75	DN	KAR-1880
DMXAK75	MI	TTSHTOI
DMXAK75	MN	Histone deacetylase 2 (HDAC2)
DMXAK75	MT	DTT
DMXAK75	MA	Inhibitor
DMXAK75	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2616).
DMXAK75	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2616

DMMIA38	DI	DMMIA38
DMMIA38	DN	kassinin
DMMIA38	MI	TTBPGLU
DMMIA38	MN	Neuromedin-K receptor (TACR3)
DMMIA38	MT	DTT
DMMIA38	MA	Agonist
DMMIA38	RN	The unpredicted high affinities of a large number of naturally occurring tachykinins for chimeric NK1/NK3 receptors suggest a role for an inhibitory domain in determining receptor specificity. J BiolChem. 1996 Aug 23;271(34):20250-7.
DMMIA38	RU	https://pubmed.ncbi.nlm.nih.gov/8702757

DMMIA38	DI	DMMIA38
DMMIA38	DN	kassinin
DMMIA38	MI	TTZPO1L
DMMIA38	MN	Substance-P receptor (TACR1)
DMMIA38	MT	DTT
DMMIA38	MA	Agonist
DMMIA38	RN	The unpredicted high affinities of a large number of naturally occurring tachykinins for chimeric NK1/NK3 receptors suggest a role for an inhibitory domain in determining receptor specificity. J BiolChem. 1996 Aug 23;271(34):20250-7.
DMMIA38	RU	https://pubmed.ncbi.nlm.nih.gov/8702757

DM513QY	DI	DM513QY
DM513QY	DN	KATSUMADAIN A
DM513QY	MI	TT50QJ3
DM513QY	MN	Influenza Neuraminidase (Influ NA)
DM513QY	MT	DTT
DM513QY	MA	Inhibitor
DM513QY	RN	Antiviral potential and molecular insight into neuraminidase inhibiting diarylheptanoids from Alpinia katsumadai. J Med Chem. 2010 Jan 28;53(2):778-86.
DM513QY	RU	https://pubmed.ncbi.nlm.nih.gov/20014777

DMS527J	DI	DMS527J
DMS527J	DN	Kazinol C
DMS527J	MI	TTULVH8
DMS527J	MN	Tyrosinase (TYR)
DMS527J	MT	DTT
DMS527J	MA	Inhibitor
DMS527J	RN	Tyrosinase inhibitory effects of 1,3-diphenylpropanes from Broussonetia kazinoki. Bioorg Med Chem. 2009 Jan 1;17(1):35-41.
DMS527J	RU	https://pubmed.ncbi.nlm.nih.gov/19046886

DMFVT81	DI	DMFVT81
DMFVT81	DN	Kazinol F
DMFVT81	MI	TTULVH8
DMFVT81	MN	Tyrosinase (TYR)
DMFVT81	MT	DTT
DMFVT81	MA	Inhibitor
DMFVT81	RN	Tyrosinase inhibitory effects of 1,3-diphenylpropanes from Broussonetia kazinoki. Bioorg Med Chem. 2009 Jan 1;17(1):35-41.
DMFVT81	RU	https://pubmed.ncbi.nlm.nih.gov/19046886

DMEV2AL	DI	DMEV2AL
DMEV2AL	DN	KAZINOL S
DMEV2AL	MI	TTULVH8
DMEV2AL	MN	Tyrosinase (TYR)
DMEV2AL	MT	DTT
DMEV2AL	MA	Inhibitor
DMEV2AL	RN	Tyrosinase inhibitory effects of 1,3-diphenylpropanes from Broussonetia kazinoki. Bioorg Med Chem. 2009 Jan 1;17(1):35-41.
DMEV2AL	RU	https://pubmed.ncbi.nlm.nih.gov/19046886

DMO72XF	DI	DMO72XF
DMO72XF	DN	KB-130015
DMO72XF	MI	TTQ6VDM
DMO72XF	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMO72XF	MT	DTT
DMO72XF	MA	Activator
DMO72XF	RN	The amiodarone derivative KB130015 activates hERG1 potassium channels via a novel mechanism. Eur J Pharmacol. 2010 Apr 25;632(1-3):52-9.
DMO72XF	RU	https://pubmed.ncbi.nlm.nih.gov/20097192

DMCQRA3	DI	DMCQRA3
DMCQRA3	DN	KB-9520
DMCQRA3	MI	TTOM3J0
DMCQRA3	MN	Estrogen receptor beta (ESR2)
DMCQRA3	MT	DTT
DMCQRA3	MA	Agonist
DMCQRA3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 621).
DMCQRA3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=621

DMMD5W3	DI	DMMD5W3
DMMD5W3	DN	KB-R7943
DMMD5W3	MI	TTNVC34
DMMD5W3	MN	Short transient receptor potential channel 3 (TRPC3)
DMMD5W3	MT	DTT
DMMD5W3	MA	Blocker (channel blocker)
DMMD5W3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 488).
DMMD5W3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=488

DMMD5W3	DI	DMMD5W3
DMMD5W3	DN	KB-R7943
DMMD5W3	MI	TT32NQ1
DMMD5W3	MN	Short transient receptor potential channel 5 (TRPC5)
DMMD5W3	MT	DTT
DMMD5W3	MA	Blocker (channel blocker)
DMMD5W3	RN	The Na+/Ca2+ exchange inhibitor KB-R7943 potently blocks TRPC channels. Biochem Biophys Res Commun. 2007 Sep 14;361(1):230-6.
DMMD5W3	RU	https://pubmed.ncbi.nlm.nih.gov/17658472

DMMD5W3	DI	DMMD5W3
DMMD5W3	DN	KB-R7943
DMMD5W3	MI	TTRBT3W
DMMD5W3	MN	Short transient receptor potential channel 6 (TRPC6)
DMMD5W3	MT	DTT
DMMD5W3	MA	Blocker (channel blocker)
DMMD5W3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 491).
DMMD5W3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=491

DMY6QOR	DI	DMY6QOR
DMY6QOR	DN	KC-12291
DMY6QOR	MI	TTZOVE0
DMY6QOR	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DMY6QOR	MT	DTT
DMY6QOR	MA	Inhibitor
DMY6QOR	RN	Sodium late current blockers in ischemia reperfusion: is the bullet magic J Med Chem. 2008 Jul 10;51(13):3856-66.
DMY6QOR	RU	https://pubmed.ncbi.nlm.nih.gov/18529044

DMJ2X64	DI	DMJ2X64
DMJ2X64	DN	KD-7332
DMJ2X64	MI	TTF10I9
DMJ2X64	MN	Nitric-oxide synthase inducible (NOS2)
DMJ2X64	MT	DTT
DMJ2X64	MA	Inhibitor
DMJ2X64	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1250).
DMJ2X64	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1250

DMOX8FD	DI	DMOX8FD
DMOX8FD	DN	KELATORPHAN
DMOX8FD	MI	TTPHMWB
DMOX8FD	MN	Aminopeptidase N (ANPEP)
DMOX8FD	MT	DTT
DMOX8FD	MA	Inhibitor
DMOX8FD	RN	Retro-inverso concept applied to the complete inhibitors of enkephalin-degrading enzymes. J Med Chem. 1988 Sep;31(9):1825-31.
DMOX8FD	RU	https://pubmed.ncbi.nlm.nih.gov/2900898

DMOX8FD	DI	DMOX8FD
DMOX8FD	DN	KELATORPHAN
DMOX8FD	MI	TT9PBIL
DMOX8FD	MN	Glutamyl aminopeptidase (ENPEP)
DMOX8FD	MT	DTT
DMOX8FD	MA	Inhibitor
DMOX8FD	RN	Retro-inverso concept applied to the complete inhibitors of enkephalin-degrading enzymes. J Med Chem. 1988 Sep;31(9):1825-31.
DMOX8FD	RU	https://pubmed.ncbi.nlm.nih.gov/2900898

DM0RC8M	DI	DM0RC8M
DM0RC8M	DN	KETOCYCLAZOCINE
DM0RC8M	MI	TTQW87Y
DM0RC8M	MN	Opioid receptor kappa (OPRK1)
DM0RC8M	MT	DTT
DM0RC8M	MA	Inhibitor
DM0RC8M	RN	Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8.
DM0RC8M	RU	https://pubmed.ncbi.nlm.nih.gov/19027293

DM0RC8M	DI	DM0RC8M
DM0RC8M	DN	KETOCYCLAZOCINE
DM0RC8M	MI	TTKWM86
DM0RC8M	MN	Opioid receptor mu (MOP)
DM0RC8M	MT	DTT
DM0RC8M	MA	Inhibitor
DM0RC8M	RN	Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8.
DM0RC8M	RU	https://pubmed.ncbi.nlm.nih.gov/19027293

DMX2FL3	DI	DMX2FL3
DMX2FL3	DN	Ketoprofen glucuronide
DMX2FL3	MI	DE9RA0I
DMX2FL3	MN	Beta-glucuronidase (uidA)
DMX2FL3	MT	DME
DMX2FL3	MA	Metabolism
DMX2FL3	RN	Bacterial beta-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: mode of action and pharmacokinetics. Xenobiotica. 2014 Jan;44(1):28-35.
DMX2FL3	RU	https://pubmed.ncbi.nlm.nih.gov/23829165

DM7W9MT	DI	DM7W9MT
DM7W9MT	DN	KF 17837S
DM7W9MT	MI	TTNE7KG
DM7W9MT	MN	Adenosine A2b receptor (ADORA2B)
DM7W9MT	MT	DTT
DM7W9MT	MA	Antagonist
DM7W9MT	RN	Characterization of human A2A adenosine receptors with the antagonist radioligand [3H]-SCH 58261. Br J Pharmacol. 1997 Jun;121(3):353-60.
DM7W9MT	RU	https://pubmed.ncbi.nlm.nih.gov/9179373

DMK6SMW	DI	DMK6SMW
DMK6SMW	DN	KF24345
DMK6SMW	MI	TTLXAKE
DMK6SMW	MN	Solute carrier family 29 member 1 (SLC29A1)
DMK6SMW	MT	DTT
DMK6SMW	MA	Inhibitor
DMK6SMW	RN	Interaction of the novel adenosine uptake inhibitor 3-[1-(6,7-diethoxy-2-morpholinoquinazolin-4-yl)piperidin-4-yl]-1,6-dimethyl-2,4(1H,3H)-quinazol... J Pharmacol Exp Ther. 2004 Mar;308(3):1083-93.
DMK6SMW	RU	https://pubmed.ncbi.nlm.nih.gov/14634039

DMPBDW0	DI	DMPBDW0
DMPBDW0	DN	KF26777
DMPBDW0	MI	TTK25J1
DMPBDW0	MN	Adenosine A1 receptor (ADORA1)
DMPBDW0	MT	DTT
DMPBDW0	MA	Antagonist
DMPBDW0	RN	KF26777 (2-(4-bromophenyl)-7,8-dihydro-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one dihydrochloride), a new potent and selective adenosine A3 receptor antagonist. Eur J Pharmacol. 2002 May 31;444(3):133-41.
DMPBDW0	RU	https://pubmed.ncbi.nlm.nih.gov/12063073

DMPBDW0	DI	DMPBDW0
DMPBDW0	DN	KF26777
DMPBDW0	MI	TTNE7KG
DMPBDW0	MN	Adenosine A2b receptor (ADORA2B)
DMPBDW0	MT	DTT
DMPBDW0	MA	Antagonist
DMPBDW0	RN	KF26777 (2-(4-bromophenyl)-7,8-dihydro-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one dihydrochloride), a new potent and selective adenosine A3 receptor antagonist. Eur J Pharmacol. 2002 May 31;444(3):133-41.
DMPBDW0	RU	https://pubmed.ncbi.nlm.nih.gov/12063073

DMPBDW0	DI	DMPBDW0
DMPBDW0	DN	KF26777
DMPBDW0	MI	TTJFY5U
DMPBDW0	MN	Adenosine A3 receptor (ADORA3)
DMPBDW0	MT	DTT
DMPBDW0	MA	Antagonist
DMPBDW0	RN	KF26777 (2-(4-bromophenyl)-7,8-dihydro-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one dihydrochloride), a new potent and selective adenosine A3 receptor antagonist. Eur J Pharmacol. 2002 May 31;444(3):133-41.
DMPBDW0	RU	https://pubmed.ncbi.nlm.nih.gov/12063073

DMOUW0A	DI	DMOUW0A
DMOUW0A	DN	KF-66490
DMOUW0A	MI	TTZ97H5
DMOUW0A	MN	Phosphodiesterase 4A (PDE4A)
DMOUW0A	MT	DTT
DMOUW0A	MA	Inhibitor
DMOUW0A	RN	Effect of orally administered KF66490, a phosphodiesterase 4 inhibitor, on dermatitis in mouse models. Int Immunopharmacol. 2009 Jan;9(1):55-62.
DMOUW0A	RU	https://pubmed.ncbi.nlm.nih.gov/18854230

DMOUW0A	DI	DMOUW0A
DMOUW0A	DN	KF-66490
DMOUW0A	MI	TTVIAT9
DMOUW0A	MN	Phosphodiesterase 4B (PDE4B)
DMOUW0A	MT	DTT
DMOUW0A	MA	Inhibitor
DMOUW0A	RN	Effect of orally administered KF66490, a phosphodiesterase 4 inhibitor, on dermatitis in mouse models. Int Immunopharmacol. 2009 Jan;9(1):55-62.
DMOUW0A	RU	https://pubmed.ncbi.nlm.nih.gov/18854230

DMOUW0A	DI	DMOUW0A
DMOUW0A	DN	KF-66490
DMOUW0A	MI	TTSKMI8
DMOUW0A	MN	Phosphodiesterase 4D (PDE4D)
DMOUW0A	MT	DTT
DMOUW0A	MA	Inhibitor
DMOUW0A	RN	Effect of orally administered KF66490, a phosphodiesterase 4 inhibitor, on dermatitis in mouse models. Int Immunopharmacol. 2009 Jan;9(1):55-62.
DMOUW0A	RU	https://pubmed.ncbi.nlm.nih.gov/18854230

DMFBMYG	DI	DMFBMYG
DMFBMYG	DN	KF-A5
DMFBMYG	MI	TTAWNKZ
DMFBMYG	MN	Norepinephrine transporter (NET)
DMFBMYG	MT	DTT
DMFBMYG	MA	Inhibitor
DMFBMYG	RN	Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum. Antimicrob Agents Chemother. 2007 Nov;51(11):4133-40.
DMFBMYG	RU	https://pubmed.ncbi.nlm.nih.gov/17846138

DMFBMYG	DI	DMFBMYG
DMFBMYG	DN	KF-A5
DMFBMYG	MI	TT3ROYC
DMFBMYG	MN	Serotonin transporter (SERT)
DMFBMYG	MT	DTT
DMFBMYG	MA	Inhibitor
DMFBMYG	RN	Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum. Antimicrob Agents Chemother. 2007 Nov;51(11):4133-40.
DMFBMYG	RU	https://pubmed.ncbi.nlm.nih.gov/17846138

DMQJ3T5	DI	DMQJ3T5
DMQJ3T5	DN	KF-A6
DMQJ3T5	MI	TTTIBOJ
DMQJ3T5	MN	Histamine H1 receptor (H1R)
DMQJ3T5	MT	DTT
DMQJ3T5	MA	Inhibitor
DMQJ3T5	RN	Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum. Antimicrob Agents Chemother. 2007 Nov;51(11):4133-40.
DMQJ3T5	RU	https://pubmed.ncbi.nlm.nih.gov/17846138

DMQJ3T5	DI	DMQJ3T5
DMQJ3T5	DN	KF-A6
DMQJ3T5	MI	TT3ROYC
DMQJ3T5	MN	Serotonin transporter (SERT)
DMQJ3T5	MT	DTT
DMQJ3T5	MA	Inhibitor
DMQJ3T5	RN	Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum. Antimicrob Agents Chemother. 2007 Nov;51(11):4133-40.
DMQJ3T5	RU	https://pubmed.ncbi.nlm.nih.gov/17846138

DMCE8Q9	DI	DMCE8Q9
DMCE8Q9	DN	KH-164
DMCE8Q9	MI	TT5FNQT
DMCE8Q9	MN	Human immunodeficiency virus Protease (HIV PR)
DMCE8Q9	MT	DTT
DMCE8Q9	MA	Modulator
DMCE8Q9	RN	Impeded progression of Friend disease in mice by an inhibitor of retroviral proteases. J Acquir Immune Defic Syndr. 1993 Jan;6(1):24-31.
DMCE8Q9	RU	https://www.ncbi.nlm.nih.gov/pubmed/8093263

DMSOB3U	DI	DMSOB3U
DMSOB3U	DN	KH-CB19
DMSOB3U	MI	TTE6YDG
DMSOB3U	MN	CDC-like kinase 1 (CLK1)
DMSOB3U	MT	DTT
DMSOB3U	MA	Inhibitor
DMSOB3U	RN	Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chem Biol. 2011 Jan 28;18(1):67-76.
DMSOB3U	RU	https://pubmed.ncbi.nlm.nih.gov/21276940

DMSOB3U	DI	DMSOB3U
DMSOB3U	DN	KH-CB19
DMSOB3U	MI	TTQPE1U
DMSOB3U	MN	CDC-like kinase 3 (CLK3)
DMSOB3U	MT	DTT
DMSOB3U	MA	Inhibitor
DMSOB3U	RN	Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chem Biol. 2011 Jan 28;18(1):67-76.
DMSOB3U	RU	https://pubmed.ncbi.nlm.nih.gov/21276940

DMSOB3U	DI	DMSOB3U
DMSOB3U	DN	KH-CB19
DMSOB3U	MI	TTSBVFO
DMSOB3U	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DMSOB3U	MT	DTT
DMSOB3U	MA	Inhibitor
DMSOB3U	RN	Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chem Biol. 2011 Jan 28;18(1):67-76.
DMSOB3U	RU	https://pubmed.ncbi.nlm.nih.gov/21276940

DMLG2EA	DI	DMLG2EA
DMLG2EA	DN	Ki-11502
DMLG2EA	MI	TTI7421
DMLG2EA	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMLG2EA	MT	DTT
DMLG2EA	MA	Inhibitor
DMLG2EA	RN	Identification of potent and selective inhibitors of PDGF receptor autophosphorylation. J Med Chem. 2006 Apr 6;49(7):2186-92.
DMLG2EA	RU	https://pubmed.ncbi.nlm.nih.gov/16570914

DMJTDK9	DI	DMJTDK9
DMJTDK9	DN	Ki16425
DMJTDK9	MI	TTO897C
DMJTDK9	MN	G protein coupled receptor 87 (GPR87)
DMJTDK9	MT	DTT
DMJTDK9	MA	Antagonist
DMJTDK9	RN	The orphan GPCR GPR87 was deorphanized and shown to be a lysophosphatidic acid receptor. Biochem Biophys Res Commun. 2007 Nov 23;363(3):861-6.
DMJTDK9	RU	https://pubmed.ncbi.nlm.nih.gov/17905198

DMJTDK9	DI	DMJTDK9
DMJTDK9	DN	Ki16425
DMJTDK9	MI	TTE2YJR
DMJTDK9	MN	Lysophosphatidate-3 receptor (LPAR3)
DMJTDK9	MT	DTT
DMJTDK9	MA	Antagonist
DMJTDK9	RN	Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol Pharmacol. 2003 Oct;64(4):994-1005.
DMJTDK9	RU	https://pubmed.ncbi.nlm.nih.gov/14500756

DMJTDK9	DI	DMJTDK9
DMJTDK9	DN	Ki16425
DMJTDK9	MI	TTQ6S1K
DMJTDK9	MN	Lysophosphatidic acid receptor 1 (LPAR1)
DMJTDK9	MT	DTT
DMJTDK9	MA	Antagonist
DMJTDK9	RN	Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis. Int J Oncol. 2012 Apr;40(4):1133-41.
DMJTDK9	RU	https://pubmed.ncbi.nlm.nih.gov/22200658

DMJTDK9	DI	DMJTDK9
DMJTDK9	DN	Ki16425
DMJTDK9	MI	TTB7Y8I
DMJTDK9	MN	Lysophosphatidic acid receptor 2 (LPAR2)
DMJTDK9	MT	DTT
DMJTDK9	MA	Antagonist
DMJTDK9	RN	Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol Pharmacol. 2003 Oct;64(4):994-1005.
DMJTDK9	RU	https://pubmed.ncbi.nlm.nih.gov/14500756

DM9M3VC	DI	DM9M3VC
DM9M3VC	DN	Ki-20227
DM9M3VC	MI	TTVW6QL
DM9M3VC	MN	CSF1R messenger RNA (CSF1R mRNA)
DM9M3VC	MT	DTT
DM9M3VC	MA	Inhibitor
DM9M3VC	RN	Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011 Oct 30;29(11):1046-51.
DM9M3VC	RU	https://pubmed.ncbi.nlm.nih.gov/22037378

DM9M3VC	DI	DM9M3VC
DM9M3VC	DN	Ki-20227
DM9M3VC	MI	TTI7421
DM9M3VC	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM9M3VC	MT	DTT
DM9M3VC	MA	Inhibitor
DM9M3VC	RN	A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol Cancer Ther. 2006 Nov;5(11):2634-43.
DM9M3VC	RU	https://pubmed.ncbi.nlm.nih.gov/17121910

DM9M3VC	DI	DM9M3VC
DM9M3VC	DN	Ki-20227
DM9M3VC	MI	TTX41N9
DM9M3VC	MN	Tyrosine-protein kinase Kit (KIT)
DM9M3VC	MT	DTT
DM9M3VC	MA	Inhibitor
DM9M3VC	RN	A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol Cancer Ther. 2006 Nov;5(11):2634-43.
DM9M3VC	RU	https://pubmed.ncbi.nlm.nih.gov/17121910

DM9M3VC	DI	DM9M3VC
DM9M3VC	DN	Ki-20227
DM9M3VC	MI	TTUTJGQ
DM9M3VC	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM9M3VC	MT	DTT
DM9M3VC	MA	Inhibitor
DM9M3VC	RN	A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol Cancer Ther. 2006 Nov;5(11):2634-43.
DM9M3VC	RU	https://pubmed.ncbi.nlm.nih.gov/17121910

DMHEOBY	DI	DMHEOBY
DMHEOBY	DN	KIN-3031
DMHEOBY	MI	TTKWM86
DMHEOBY	MN	Opioid receptor mu (MOP)
DMHEOBY	MT	DTT
DMHEOBY	MA	Modulator
DMHEOBY	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
DMHEOBY	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319

DMO8JQM	DI	DMO8JQM
DMO8JQM	DN	KIN-4044
DMO8JQM	MI	TTKWM86
DMO8JQM	MN	Opioid receptor mu (MOP)
DMO8JQM	MT	DTT
DMO8JQM	MA	Antagonist
DMO8JQM	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
DMO8JQM	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319

DMDL21W	DI	DMDL21W
DMDL21W	DN	kisspeptin-10
DMDL21W	MI	TT3KBZY
DMDL21W	MN	G-protein coupled receptor 54 (KISS1R)
DMDL21W	MT	DTT
DMDL21W	MA	Agonist
DMDL21W	RN	The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. J Biol Chem. 2001 Sep 14;276(37):34631-6.
DMDL21W	RU	https://pubmed.ncbi.nlm.nih.gov/11457843

DMPJKBV	DI	DMPJKBV
DMPJKBV	DN	KJM429
DMPJKBV	MI	TTMI6F5
DMPJKBV	MN	Transient receptor potential cation channel V1 (TRPV1)
DMPJKBV	MT	DTT
DMPJKBV	MA	Antagonist
DMPJKBV	RN	High affinity antagonists of the vanilloid receptor. Mol Pharmacol. 2002 Oct;62(4):947-56.
DMPJKBV	RU	https://pubmed.ncbi.nlm.nih.gov/12237342

DMAU1SZ	DI	DMAU1SZ
DMAU1SZ	DN	KKHT-10318
DMAU1SZ	MI	TT729IR
DMAU1SZ	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DMAU1SZ	MT	DTT
DMAU1SZ	MA	Inhibitor
DMAU1SZ	RN	Novel T-type calcium channel blockers: dioxoquinazoline carboxamide derivatives. Bioorg Med Chem. 2007 Jan 1;15(1):365-73.
DMAU1SZ	RU	https://pubmed.ncbi.nlm.nih.gov/17035033

DMYT381	DI	DMYT381
DMYT381	DN	KKHT-10608
DMYT381	MI	TT729IR
DMYT381	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DMYT381	MT	DTT
DMYT381	MA	Inhibitor
DMYT381	RN	Novel T-type calcium channel blockers: dioxoquinazoline carboxamide derivatives. Bioorg Med Chem. 2007 Jan 1;15(1):365-73.
DMYT381	RU	https://pubmed.ncbi.nlm.nih.gov/17035033

DMMI1H0	DI	DMMI1H0
DMMI1H0	DN	KKHT-10609
DMMI1H0	MI	TT729IR
DMMI1H0	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DMMI1H0	MT	DTT
DMMI1H0	MA	Inhibitor
DMMI1H0	RN	Novel T-type calcium channel blockers: dioxoquinazoline carboxamide derivatives. Bioorg Med Chem. 2007 Jan 1;15(1):365-73.
DMMI1H0	RU	https://pubmed.ncbi.nlm.nih.gov/17035033

DM1H5TO	DI	DM1H5TO
DM1H5TO	DN	KKHT-10613
DM1H5TO	MI	TT729IR
DM1H5TO	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DM1H5TO	MT	DTT
DM1H5TO	MA	Inhibitor
DM1H5TO	RN	Novel T-type calcium channel blockers: dioxoquinazoline carboxamide derivatives. Bioorg Med Chem. 2007 Jan 1;15(1):365-73.
DM1H5TO	RU	https://pubmed.ncbi.nlm.nih.gov/17035033

DMW704S	DI	DMW704S
DMW704S	DN	KKHT-10618
DMW704S	MI	TT729IR
DMW704S	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DMW704S	MT	DTT
DMW704S	MA	Inhibitor
DMW704S	RN	Novel T-type calcium channel blockers: dioxoquinazoline carboxamide derivatives. Bioorg Med Chem. 2007 Jan 1;15(1):365-73.
DMW704S	RU	https://pubmed.ncbi.nlm.nih.gov/17035033

DM4F96I	DI	DM4F96I
DM4F96I	DN	KKHT-11018
DM4F96I	MI	TT729IR
DM4F96I	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DM4F96I	MT	DTT
DM4F96I	MA	Inhibitor
DM4F96I	RN	Novel T-type calcium channel blockers: dioxoquinazoline carboxamide derivatives. Bioorg Med Chem. 2007 Jan 1;15(1):365-73.
DM4F96I	RU	https://pubmed.ncbi.nlm.nih.gov/17035033

DMLB4TU	DI	DMLB4TU
DMLB4TU	DN	KKHT-20718
DMLB4TU	MI	TT729IR
DMLB4TU	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DMLB4TU	MT	DTT
DMLB4TU	MA	Inhibitor
DMLB4TU	RN	Novel T-type calcium channel blockers: dioxoquinazoline carboxamide derivatives. Bioorg Med Chem. 2007 Jan 1;15(1):365-73.
DMLB4TU	RU	https://pubmed.ncbi.nlm.nih.gov/17035033

DMP1A3C	DI	DMP1A3C
DMP1A3C	DN	KKHT-20818
DMP1A3C	MI	TT729IR
DMP1A3C	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DMP1A3C	MT	DTT
DMP1A3C	MA	Inhibitor
DMP1A3C	RN	Novel T-type calcium channel blockers: dioxoquinazoline carboxamide derivatives. Bioorg Med Chem. 2007 Jan 1;15(1):365-73.
DMP1A3C	RU	https://pubmed.ncbi.nlm.nih.gov/17035033

DMTW4Q1	DI	DMTW4Q1
DMTW4Q1	DN	KKHT-20918
DMTW4Q1	MI	TT729IR
DMTW4Q1	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DMTW4Q1	MT	DTT
DMTW4Q1	MA	Inhibitor
DMTW4Q1	RN	Novel T-type calcium channel blockers: dioxoquinazoline carboxamide derivatives. Bioorg Med Chem. 2007 Jan 1;15(1):365-73.
DMTW4Q1	RU	https://pubmed.ncbi.nlm.nih.gov/17035033

DMG3FDE	DI	DMG3FDE
DMG3FDE	DN	KL044
DMG3FDE	MI	TT5MLZR
DMG3FDE	MN	Cryptochrome circadian clock 1 (CRY1)
DMG3FDE	MT	DTT
DMG3FDE	MA	Modulator
DMG3FDE	RN	Development of Small-Molecule Cryptochrome Stabilizer Derivatives as Modulators of the Circadian Clock. ChemMedChem. 2015 Sep;10(9):1489-97.
DMG3FDE	RU	https://pubmed.ncbi.nlm.nih.gov/26174033

DMG594K	DI	DMG594K
DMG594K	DN	KM-01221
DMG594K	MI	TT8VUE0
DMG594K	MN	Chymase (CYM)
DMG594K	MT	DTT
DMG594K	MA	Inhibitor
DMG594K	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2340).
DMG594K	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2340

DMZSYKC	DI	DMZSYKC
DMZSYKC	DN	KM-233
DMZSYKC	MI	TT6OEDT
DMZSYKC	MN	Cannabinoid receptor 1 (CB1)
DMZSYKC	MT	DTT
DMZSYKC	MA	Inhibitor
DMZSYKC	RN	Exploring the substituent effects on a novel series of C1'-dimethyl-aryl Delta8-tetrahydrocannabinol analogs. Bioorg Med Chem. 2008 Jul 1;16(13):6489-500.
DMZSYKC	RU	https://pubmed.ncbi.nlm.nih.gov/18524604

DMZSYKC	DI	DMZSYKC
DMZSYKC	DN	KM-233
DMZSYKC	MI	TTMSFAW
DMZSYKC	MN	Cannabinoid receptor 2 (CB2)
DMZSYKC	MT	DTT
DMZSYKC	MA	Inhibitor
DMZSYKC	RN	Exploring the substituent effects on a novel series of C1'-dimethyl-aryl Delta8-tetrahydrocannabinol analogs. Bioorg Med Chem. 2008 Jul 1;16(13):6489-500.
DMZSYKC	RU	https://pubmed.ncbi.nlm.nih.gov/18524604

DMK4IBO	DI	DMK4IBO
DMK4IBO	DN	KM-233-M
DMK4IBO	MI	TT6OEDT
DMK4IBO	MN	Cannabinoid receptor 1 (CB1)
DMK4IBO	MT	DTT
DMK4IBO	MA	Inhibitor
DMK4IBO	RN	Exploring the substituent effects on a novel series of C1'-dimethyl-aryl Delta8-tetrahydrocannabinol analogs. Bioorg Med Chem. 2008 Jul 1;16(13):6489-500.
DMK4IBO	RU	https://pubmed.ncbi.nlm.nih.gov/18524604

DMK4IBO	DI	DMK4IBO
DMK4IBO	DN	KM-233-M
DMK4IBO	MI	TTMSFAW
DMK4IBO	MN	Cannabinoid receptor 2 (CB2)
DMK4IBO	MT	DTT
DMK4IBO	MA	Inhibitor
DMK4IBO	RN	Exploring the substituent effects on a novel series of C1'-dimethyl-aryl Delta8-tetrahydrocannabinol analogs. Bioorg Med Chem. 2008 Jul 1;16(13):6489-500.
DMK4IBO	RU	https://pubmed.ncbi.nlm.nih.gov/18524604

DMK17GN	DI	DMK17GN
DMK17GN	DN	KM-4056
DMK17GN	MI	TTTSGRH
DMK17GN	MN	Leucine-rich repeat-containing GPCR 5 (LGR5)
DMK17GN	MT	DTT
DMK17GN	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 148).
DMK17GN	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=148

DMLRVEJ	DI	DMLRVEJ
DMLRVEJ	DN	KMI-172
DMLRVEJ	MI	TT8JRS7
DMLRVEJ	MN	Beta-secretase (BACE)
DMLRVEJ	MT	DTT
DMLRVEJ	MA	Inhibitor
DMLRVEJ	RN	Design and synthesis of BACE1 inhibitors containing a novel norstatine derivative (2R,3R)-3-amino-2-hydroxy-4-(phenylthio)butyric acid. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1629-33.
DMLRVEJ	RU	https://pubmed.ncbi.nlm.nih.gov/17251016

DMQ4WNB	DI	DMQ4WNB
DMQ4WNB	DN	KMI-494
DMQ4WNB	MI	TT8JRS7
DMQ4WNB	MN	Beta-secretase (BACE)
DMQ4WNB	MT	DTT
DMQ4WNB	MA	Inhibitor
DMQ4WNB	RN	Design and synthesis of BACE1 inhibitors containing a novel norstatine derivative (2R,3R)-3-amino-2-hydroxy-4-(phenylthio)butyric acid. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1629-33.
DMQ4WNB	RU	https://pubmed.ncbi.nlm.nih.gov/17251016

DMX9EA7	DI	DMX9EA7
DMX9EA7	DN	KMI-538
DMX9EA7	MI	TT8JRS7
DMX9EA7	MN	Beta-secretase (BACE)
DMX9EA7	MT	DTT
DMX9EA7	MA	Inhibitor
DMX9EA7	RN	Design and synthesis of BACE1 inhibitors containing a novel norstatine derivative (2R,3R)-3-amino-2-hydroxy-4-(phenylthio)butyric acid. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1629-33.
DMX9EA7	RU	https://pubmed.ncbi.nlm.nih.gov/17251016

DMXUETW	DI	DMXUETW
DMXUETW	DN	KMI-596
DMXUETW	MI	TT8JRS7
DMXUETW	MN	Beta-secretase (BACE)
DMXUETW	MT	DTT
DMXUETW	MA	Inhibitor
DMXUETW	RN	Design of pentapeptidic BACE1 inhibitors with carboxylic acid bioisosteres at P1' and P4 positions. Bioorg Med Chem. 2010 May 1;18(9):3175-86.
DMXUETW	RU	https://pubmed.ncbi.nlm.nih.gov/20381362

DMP1GQB	DI	DMP1GQB
DMP1GQB	DN	KMJ-372
DMP1GQB	MI	TTMI6F5
DMP1GQB	MN	Transient receptor potential cation channel V1 (TRPV1)
DMP1GQB	MT	DTT
DMP1GQB	MA	Antagonist
DMP1GQB	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 507).
DMP1GQB	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=507

DMFVS16	DI	DMFVS16
DMFVS16	DN	KML110
DMFVS16	MI	TT6A5ZL
DMFVS16	MN	Nucleobindin-1 (NUCB1)
DMFVS16	MT	DTT
DMFVS16	MA	Antagonist
DMFVS16	RN	A Global Map of Lipid-Binding Proteins and Their Ligandability in Cells. Cell. 2015 Jun 18;161(7):1668-80.
DMFVS16	RU	https://pubmed.ncbi.nlm.nih.gov/26091042

DM2K81B	DI	DM2K81B
DM2K81B	DN	KMS-88009
DM2K81B	MI	TTE4KHA
DM2K81B	MN	Amyloid beta A4 protein (APP)
DM2K81B	MT	DTT
DM2K81B	MA	Inhibitor
DM2K81B	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
DM2K81B	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402

DMLZ89P	DI	DMLZ89P
DMLZ89P	DN	KN-62
DMLZ89P	MI	TTTU902
DMLZ89P	MN	Checkpoint kinase-1 (CHK1)
DMLZ89P	MT	DTT
DMLZ89P	MA	Inhibitor
DMLZ89P	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMLZ89P	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMLZ89P	DI	DMLZ89P
DMLZ89P	DN	KN-62
DMLZ89P	MI	TT4TQBX
DMLZ89P	MN	Extracellular signal-regulated kinase 2 (ERK2)
DMLZ89P	MT	DTT
DMLZ89P	MA	Inhibitor
DMLZ89P	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMLZ89P	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMLZ89P	DI	DMLZ89P
DMLZ89P	DN	KN-62
DMLZ89P	MI	TT860QF
DMLZ89P	MN	LCK tyrosine protein kinase (LCK)
DMLZ89P	MT	DTT
DMLZ89P	MA	Inhibitor
DMLZ89P	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMLZ89P	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMLZ89P	DI	DMLZ89P
DMLZ89P	DN	KN-62
DMLZ89P	MI	TTYT93M
DMLZ89P	MN	MAP kinase p38 (MAPK12)
DMLZ89P	MT	DTT
DMLZ89P	MA	Inhibitor
DMLZ89P	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMLZ89P	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMLZ89P	DI	DMLZ89P
DMLZ89P	DN	KN-62
DMLZ89P	MI	TT473XN
DMLZ89P	MN	P2X purinoceptor 7 (P2RX7)
DMLZ89P	MT	DTT
DMLZ89P	MA	Inhibitor
DMLZ89P	RN	Synthesis and structure-activity relationships of pyrazolodiazepine derivatives as human P2X7 receptor antagonists. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6053-8.
DMLZ89P	RU	https://pubmed.ncbi.nlm.nih.gov/19800793

DMLZ89P	DI	DMLZ89P
DMLZ89P	DN	KN-62
DMLZ89P	MI	TTFJ8Q1
DMLZ89P	MN	Protein kinase C alpha (PRKCA)
DMLZ89P	MT	DTT
DMLZ89P	MA	Inhibitor
DMLZ89P	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMLZ89P	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMLZ89P	DI	DMLZ89P
DMLZ89P	DN	KN-62
DMLZ89P	MI	TTWTSCV
DMLZ89P	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DMLZ89P	MT	DTT
DMLZ89P	MA	Inhibitor
DMLZ89P	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMLZ89P	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMLZ89P	DI	DMLZ89P
DMLZ89P	DN	KN-62
DMLZ89P	MI	TTZN7RP
DMLZ89P	MN	Rho-associated protein kinase 1 (ROCK1)
DMLZ89P	MT	DTT
DMLZ89P	MA	Inhibitor
DMLZ89P	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMLZ89P	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMLZ89P	DI	DMLZ89P
DMLZ89P	DN	KN-62
DMLZ89P	MI	TTG0U4H
DMLZ89P	MN	Ribosomal protein S6 kinase beta-1 (S6K1)
DMLZ89P	MT	DTT
DMLZ89P	MA	Inhibitor
DMLZ89P	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMLZ89P	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMLZ89P	DI	DMLZ89P
DMLZ89P	DN	KN-62
DMLZ89P	MI	TTTV8EJ
DMLZ89P	MN	Serine/threonine-protein kinase Sgk1 (SGK1)
DMLZ89P	MT	DTT
DMLZ89P	MA	Inhibitor
DMLZ89P	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMLZ89P	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMLZ89P	DI	DMLZ89P
DMLZ89P	DN	KN-62
DMLZ89P	MI	TTQBR95
DMLZ89P	MN	Stress-activated protein kinase 2a (p38 alpha)
DMLZ89P	MT	DTT
DMLZ89P	MA	Inhibitor
DMLZ89P	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMLZ89P	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMLZ89P	DI	DMLZ89P
DMLZ89P	DN	KN-62
DMLZ89P	MI	TT73U6C
DMLZ89P	MN	Stress-activated protein kinase 2b (p38 beta)
DMLZ89P	MT	DTT
DMLZ89P	MA	Inhibitor
DMLZ89P	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMLZ89P	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMLZ89P	DI	DMLZ89P
DMLZ89P	DN	KN-62
DMLZ89P	MI	TT0K6EO
DMLZ89P	MN	Stress-activated protein kinase JNK1 (JNK1)
DMLZ89P	MT	DTT
DMLZ89P	MA	Inhibitor
DMLZ89P	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMLZ89P	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMPTMKH	DI	DMPTMKH
DMPTMKH	DN	KN-93
DMPTMKH	MI	TTFYL58
DMPTMKH	MN	CaM-kinase II (CAMK2)
DMPTMKH	MT	DTT
DMPTMKH	MA	Inhibitor
DMPTMKH	RN	Discovery of a 3-amino-6-phenyl-pyridazine derivative as a new synthetic antineuroinflammatory compound. J Med Chem. 2002 Jan 31;45(3):563-6.
DMPTMKH	RU	https://pubmed.ncbi.nlm.nih.gov/11806708

DMMISH6	DI	DMMISH6
DMMISH6	DN	KNI-10006
DMMISH6	MI	TTPT2QI
DMMISH6	MN	Cathepsin D (CTSD)
DMMISH6	MT	DTT
DMMISH6	MA	Inhibitor
DMMISH6	RN	alpha-Substituted norstatines as the transition-state mimic in inhibitors of multiple digestive vacuole malaria aspartic proteases. Bioorg Med Chem. 2009 Aug 15;17(16):5933-49.
DMMISH6	RU	https://pubmed.ncbi.nlm.nih.gov/19635672

DMMISH6	DI	DMMISH6
DMMISH6	DN	KNI-10006
DMMISH6	MI	TTH9VL3
DMMISH6	MN	Plasmodium Plasmepsin 1 (Malaria PLA1)
DMMISH6	MT	DTT
DMMISH6	MA	Inhibitor
DMMISH6	RN	alpha-Substituted norstatines as the transition-state mimic in inhibitors of multiple digestive vacuole malaria aspartic proteases. Bioorg Med Chem. 2009 Aug 15;17(16):5933-49.
DMMISH6	RU	https://pubmed.ncbi.nlm.nih.gov/19635672

DMMISH6	DI	DMMISH6
DMMISH6	DN	KNI-10006
DMMISH6	MI	TTXMNHO
DMMISH6	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMMISH6	MT	DTT
DMMISH6	MA	Inhibitor
DMMISH6	RN	Improvement of both plasmepsin inhibitory activity and antimalarial activity by 2-aminoethylamino substitution. Bioorg Med Chem Lett. 2010 Aug 15;20(16):4836-9.
DMMISH6	RU	https://pubmed.ncbi.nlm.nih.gov/20634066

DMLOXMQ	DI	DMLOXMQ
DMLOXMQ	DN	KNI-10033
DMLOXMQ	MI	TTXMNHO
DMLOXMQ	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMLOXMQ	MT	DTT
DMLOXMQ	MA	Inhibitor
DMLOXMQ	RN	Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3048-52.
DMLOXMQ	RU	https://pubmed.ncbi.nlm.nih.gov/17400453

DMMZ6AO	DI	DMMZ6AO
DMMZ6AO	DN	KNI-10061
DMMZ6AO	MI	TTXMNHO
DMMZ6AO	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMMZ6AO	MT	DTT
DMMZ6AO	MA	Inhibitor
DMMZ6AO	RN	Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3048-52.
DMMZ6AO	RU	https://pubmed.ncbi.nlm.nih.gov/17400453

DMYSDN4	DI	DMYSDN4
DMYSDN4	DN	KNI-10062
DMYSDN4	MI	TTXMNHO
DMYSDN4	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMYSDN4	MT	DTT
DMYSDN4	MA	Inhibitor
DMYSDN4	RN	Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3048-52.
DMYSDN4	RU	https://pubmed.ncbi.nlm.nih.gov/17400453

DMM5SDT	DI	DMM5SDT
DMM5SDT	DN	KNI-10074
DMM5SDT	MI	TTXMNHO
DMM5SDT	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMM5SDT	MT	DTT
DMM5SDT	MA	Inhibitor
DMM5SDT	RN	Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60.
DMM5SDT	RU	https://pubmed.ncbi.nlm.nih.gov/18952439

DMCZOX9	DI	DMCZOX9
DMCZOX9	DN	KNI-10079
DMCZOX9	MI	TTXMNHO
DMCZOX9	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMCZOX9	MT	DTT
DMCZOX9	MA	Inhibitor
DMCZOX9	RN	Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60.
DMCZOX9	RU	https://pubmed.ncbi.nlm.nih.gov/18952439

DMEN4DZ	DI	DMEN4DZ
DMEN4DZ	DN	KNI-10080
DMEN4DZ	MI	TTXMNHO
DMEN4DZ	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMEN4DZ	MT	DTT
DMEN4DZ	MA	Inhibitor
DMEN4DZ	RN	Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60.
DMEN4DZ	RU	https://pubmed.ncbi.nlm.nih.gov/18952439

DM1Z7QK	DI	DM1Z7QK
DM1Z7QK	DN	KNI-10081
DM1Z7QK	MI	TTXMNHO
DM1Z7QK	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DM1Z7QK	MT	DTT
DM1Z7QK	MA	Inhibitor
DM1Z7QK	RN	Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60.
DM1Z7QK	RU	https://pubmed.ncbi.nlm.nih.gov/18952439

DMYN2U4	DI	DMYN2U4
DMYN2U4	DN	KNI-10087
DMYN2U4	MI	TTXMNHO
DMYN2U4	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMYN2U4	MT	DTT
DMYN2U4	MA	Inhibitor
DMYN2U4	RN	Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60.
DMYN2U4	RU	https://pubmed.ncbi.nlm.nih.gov/18952439

DM4GASE	DI	DM4GASE
DM4GASE	DN	KNI-10088
DM4GASE	MI	TTXMNHO
DM4GASE	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DM4GASE	MT	DTT
DM4GASE	MA	Inhibitor
DM4GASE	RN	Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60.
DM4GASE	RU	https://pubmed.ncbi.nlm.nih.gov/18952439

DMV1KI2	DI	DMV1KI2
DMV1KI2	DN	KNI-10092
DMV1KI2	MI	TTXMNHO
DMV1KI2	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMV1KI2	MT	DTT
DMV1KI2	MA	Inhibitor
DMV1KI2	RN	Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60.
DMV1KI2	RU	https://pubmed.ncbi.nlm.nih.gov/18952439

DMGY5Z0	DI	DMGY5Z0
DMGY5Z0	DN	KNI-10093
DMGY5Z0	MI	TTXMNHO
DMGY5Z0	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMGY5Z0	MT	DTT
DMGY5Z0	MA	Inhibitor
DMGY5Z0	RN	Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60.
DMGY5Z0	RU	https://pubmed.ncbi.nlm.nih.gov/18952439

DMJIQG2	DI	DMJIQG2
DMJIQG2	DN	KNI-10094
DMJIQG2	MI	TTXMNHO
DMJIQG2	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMJIQG2	MT	DTT
DMJIQG2	MA	Inhibitor
DMJIQG2	RN	Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60.
DMJIQG2	RU	https://pubmed.ncbi.nlm.nih.gov/18952439

DMEHPVF	DI	DMEHPVF
DMEHPVF	DN	KNI-10095
DMEHPVF	MI	TTXMNHO
DMEHPVF	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMEHPVF	MT	DTT
DMEHPVF	MA	Inhibitor
DMEHPVF	RN	Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60.
DMEHPVF	RU	https://pubmed.ncbi.nlm.nih.gov/18952439

DMBTRHG	DI	DMBTRHG
DMBTRHG	DN	KNI-10106
DMBTRHG	MI	TTXMNHO
DMBTRHG	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMBTRHG	MT	DTT
DMBTRHG	MA	Inhibitor
DMBTRHG	RN	Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60.
DMBTRHG	RU	https://pubmed.ncbi.nlm.nih.gov/18952439

DM78A6F	DI	DM78A6F
DM78A6F	DN	KNI-10113
DM78A6F	MI	TTXMNHO
DM78A6F	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DM78A6F	MT	DTT
DM78A6F	MA	Inhibitor
DM78A6F	RN	Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60.
DM78A6F	RU	https://pubmed.ncbi.nlm.nih.gov/18952439

DMA9104	DI	DMA9104
DMA9104	DN	KNI-10124
DMA9104	MI	TTXMNHO
DMA9104	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMA9104	MT	DTT
DMA9104	MA	Inhibitor
DMA9104	RN	Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60.
DMA9104	RU	https://pubmed.ncbi.nlm.nih.gov/18952439

DMDBERC	DI	DMDBERC
DMDBERC	DN	KNI-10125
DMDBERC	MI	TTXMNHO
DMDBERC	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMDBERC	MT	DTT
DMDBERC	MA	Inhibitor
DMDBERC	RN	Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60.
DMDBERC	RU	https://pubmed.ncbi.nlm.nih.gov/18952439

DMNBUS4	DI	DMNBUS4
DMNBUS4	DN	KNI-10152
DMNBUS4	MI	TTXMNHO
DMNBUS4	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMNBUS4	MT	DTT
DMNBUS4	MA	Inhibitor
DMNBUS4	RN	Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60.
DMNBUS4	RU	https://pubmed.ncbi.nlm.nih.gov/18952439

DM1PKWA	DI	DM1PKWA
DM1PKWA	DN	KNI-10155
DM1PKWA	MI	TTXMNHO
DM1PKWA	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DM1PKWA	MT	DTT
DM1PKWA	MA	Inhibitor
DM1PKWA	RN	Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60.
DM1PKWA	RU	https://pubmed.ncbi.nlm.nih.gov/18952439

DM64NBG	DI	DM64NBG
DM64NBG	DN	KNI-10216
DM64NBG	MI	TTXMNHO
DM64NBG	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DM64NBG	MT	DTT
DM64NBG	MA	Inhibitor
DM64NBG	RN	Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60.
DM64NBG	RU	https://pubmed.ncbi.nlm.nih.gov/18952439

DMHLFAE	DI	DMHLFAE
DMHLFAE	DN	KNI-10217
DMHLFAE	MI	TTXMNHO
DMHLFAE	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMHLFAE	MT	DTT
DMHLFAE	MA	Inhibitor
DMHLFAE	RN	Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60.
DMHLFAE	RU	https://pubmed.ncbi.nlm.nih.gov/18952439

DMQY1ST	DI	DMQY1ST
DMQY1ST	DN	KNI-10232
DMQY1ST	MI	TTXMNHO
DMQY1ST	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMQY1ST	MT	DTT
DMQY1ST	MA	Inhibitor
DMQY1ST	RN	Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3048-52.
DMQY1ST	RU	https://pubmed.ncbi.nlm.nih.gov/17400453

DMV3U9Z	DI	DMV3U9Z
DMV3U9Z	DN	KNI-10255
DMV3U9Z	MI	TTXMNHO
DMV3U9Z	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMV3U9Z	MT	DTT
DMV3U9Z	MA	Inhibitor
DMV3U9Z	RN	Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60.
DMV3U9Z	RU	https://pubmed.ncbi.nlm.nih.gov/18952439

DMZFVHT	DI	DMZFVHT
DMZFVHT	DN	KNI-10256
DMZFVHT	MI	TTXMNHO
DMZFVHT	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMZFVHT	MT	DTT
DMZFVHT	MA	Inhibitor
DMZFVHT	RN	Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60.
DMZFVHT	RU	https://pubmed.ncbi.nlm.nih.gov/18952439

DMZXI6U	DI	DMZXI6U
DMZXI6U	DN	KNI-10260
DMZXI6U	MI	TTXMNHO
DMZXI6U	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMZXI6U	MT	DTT
DMZXI6U	MA	Inhibitor
DMZXI6U	RN	Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60.
DMZXI6U	RU	https://pubmed.ncbi.nlm.nih.gov/18952439

DMQLB3T	DI	DMQLB3T
DMQLB3T	DN	KNI-10265
DMQLB3T	MI	TTXMNHO
DMQLB3T	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMQLB3T	MT	DTT
DMQLB3T	MA	Inhibitor
DMQLB3T	RN	Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60.
DMQLB3T	RU	https://pubmed.ncbi.nlm.nih.gov/18952439

DMP2E3I	DI	DMP2E3I
DMP2E3I	DN	KNI-10266
DMP2E3I	MI	TTXMNHO
DMP2E3I	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMP2E3I	MT	DTT
DMP2E3I	MA	Inhibitor
DMP2E3I	RN	Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60.
DMP2E3I	RU	https://pubmed.ncbi.nlm.nih.gov/18952439

DMAR35H	DI	DMAR35H
DMAR35H	DN	KNI-10282
DMAR35H	MI	TTXMNHO
DMAR35H	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMAR35H	MT	DTT
DMAR35H	MA	Inhibitor
DMAR35H	RN	Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60.
DMAR35H	RU	https://pubmed.ncbi.nlm.nih.gov/18952439

DMGVBIT	DI	DMGVBIT
DMGVBIT	DN	KNI-10283
DMGVBIT	MI	TTXMNHO
DMGVBIT	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMGVBIT	MT	DTT
DMGVBIT	MA	Inhibitor
DMGVBIT	RN	Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60.
DMGVBIT	RU	https://pubmed.ncbi.nlm.nih.gov/18952439

DMP7M8O	DI	DMP7M8O
DMP7M8O	DN	KNI-10313
DMP7M8O	MI	TTXMNHO
DMP7M8O	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMP7M8O	MT	DTT
DMP7M8O	MA	Inhibitor
DMP7M8O	RN	Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3048-52.
DMP7M8O	RU	https://pubmed.ncbi.nlm.nih.gov/17400453

DMYGNZA	DI	DMYGNZA
DMYGNZA	DN	KNI-10314
DMYGNZA	MI	TTXMNHO
DMYGNZA	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMYGNZA	MT	DTT
DMYGNZA	MA	Inhibitor
DMYGNZA	RN	Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3048-52.
DMYGNZA	RU	https://pubmed.ncbi.nlm.nih.gov/17400453

DM1OPYT	DI	DM1OPYT
DM1OPYT	DN	KNI-10315
DM1OPYT	MI	TTXMNHO
DM1OPYT	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DM1OPYT	MT	DTT
DM1OPYT	MA	Inhibitor
DM1OPYT	RN	Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3048-52.
DM1OPYT	RU	https://pubmed.ncbi.nlm.nih.gov/17400453

DMMIDCG	DI	DMMIDCG
DMMIDCG	DN	KNI-10316
DMMIDCG	MI	TTXMNHO
DMMIDCG	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMMIDCG	MT	DTT
DMMIDCG	MA	Inhibitor
DMMIDCG	RN	Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3048-52.
DMMIDCG	RU	https://pubmed.ncbi.nlm.nih.gov/17400453

DMKVPMS	DI	DMKVPMS
DMKVPMS	DN	KNI-10332
DMKVPMS	MI	TTXMNHO
DMKVPMS	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMKVPMS	MT	DTT
DMKVPMS	MA	Inhibitor
DMKVPMS	RN	Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3048-52.
DMKVPMS	RU	https://pubmed.ncbi.nlm.nih.gov/17400453

DMF9P25	DI	DMF9P25
DMF9P25	DN	KNI-10341
DMF9P25	MI	TTXMNHO
DMF9P25	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMF9P25	MT	DTT
DMF9P25	MA	Inhibitor
DMF9P25	RN	Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3048-52.
DMF9P25	RU	https://pubmed.ncbi.nlm.nih.gov/17400453

DMDM5BL	DI	DMDM5BL
DMDM5BL	DN	KNI-10342
DMDM5BL	MI	TTXMNHO
DMDM5BL	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMDM5BL	MT	DTT
DMDM5BL	MA	Inhibitor
DMDM5BL	RN	Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3048-52.
DMDM5BL	RU	https://pubmed.ncbi.nlm.nih.gov/17400453

DM8SIRL	DI	DM8SIRL
DM8SIRL	DN	KNI-10368
DM8SIRL	MI	TTXMNHO
DM8SIRL	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DM8SIRL	MT	DTT
DM8SIRL	MA	Inhibitor
DM8SIRL	RN	Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3048-52.
DM8SIRL	RU	https://pubmed.ncbi.nlm.nih.gov/17400453

DM97STY	DI	DM97STY
DM97STY	DN	KNI-10369
DM97STY	MI	TTXMNHO
DM97STY	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DM97STY	MT	DTT
DM97STY	MA	Inhibitor
DM97STY	RN	Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60.
DM97STY	RU	https://pubmed.ncbi.nlm.nih.gov/18952439

DM4AUCE	DI	DM4AUCE
DM4AUCE	DN	KNI-10372
DM4AUCE	MI	TTXMNHO
DM4AUCE	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DM4AUCE	MT	DTT
DM4AUCE	MA	Inhibitor
DM4AUCE	RN	Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3048-52.
DM4AUCE	RU	https://pubmed.ncbi.nlm.nih.gov/17400453

DMEN2L3	DI	DMEN2L3
DMEN2L3	DN	KNI-10526
DMEN2L3	MI	TTXMNHO
DMEN2L3	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMEN2L3	MT	DTT
DMEN2L3	MA	Inhibitor
DMEN2L3	RN	Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60.
DMEN2L3	RU	https://pubmed.ncbi.nlm.nih.gov/18952439

DMU4K7O	DI	DMU4K7O
DMU4K7O	DN	KNI-10527
DMU4K7O	MI	TTXMNHO
DMU4K7O	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMU4K7O	MT	DTT
DMU4K7O	MA	Inhibitor
DMU4K7O	RN	Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60.
DMU4K7O	RU	https://pubmed.ncbi.nlm.nih.gov/18952439

DMDRWYG	DI	DMDRWYG
DMDRWYG	DN	KNI-10529
DMDRWYG	MI	TTXMNHO
DMDRWYG	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMDRWYG	MT	DTT
DMDRWYG	MA	Inhibitor
DMDRWYG	RN	Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60.
DMDRWYG	RU	https://pubmed.ncbi.nlm.nih.gov/18952439

DM7XEIY	DI	DM7XEIY
DM7XEIY	DN	KNI-10538
DM7XEIY	MI	TTXMNHO
DM7XEIY	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DM7XEIY	MT	DTT
DM7XEIY	MA	Inhibitor
DM7XEIY	RN	Improvement of both plasmepsin inhibitory activity and antimalarial activity by 2-aminoethylamino substitution. Bioorg Med Chem Lett. 2010 Aug 15;20(16):4836-9.
DM7XEIY	RU	https://pubmed.ncbi.nlm.nih.gov/20634066

DMLWOFY	DI	DMLWOFY
DMLWOFY	DN	KNI-10539
DMLWOFY	MI	TTXMNHO
DMLWOFY	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMLWOFY	MT	DTT
DMLWOFY	MA	Inhibitor
DMLWOFY	RN	Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60.
DMLWOFY	RU	https://pubmed.ncbi.nlm.nih.gov/18952439

DMP87U4	DI	DMP87U4
DMP87U4	DN	KNI-10541
DMP87U4	MI	TTXMNHO
DMP87U4	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMP87U4	MT	DTT
DMP87U4	MA	Inhibitor
DMP87U4	RN	Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60.
DMP87U4	RU	https://pubmed.ncbi.nlm.nih.gov/18952439

DMGUABP	DI	DMGUABP
DMGUABP	DN	KNI-10737
DMGUABP	MI	TTXMNHO
DMGUABP	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMGUABP	MT	DTT
DMGUABP	MA	Inhibitor
DMGUABP	RN	Improvement of both plasmepsin inhibitory activity and antimalarial activity by 2-aminoethylamino substitution. Bioorg Med Chem Lett. 2010 Aug 15;20(16):4836-9.
DMGUABP	RU	https://pubmed.ncbi.nlm.nih.gov/20634066

DMPWY6H	DI	DMPWY6H
DMPWY6H	DN	KNI-10740
DMPWY6H	MI	TTXMNHO
DMPWY6H	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMPWY6H	MT	DTT
DMPWY6H	MA	Inhibitor
DMPWY6H	RN	Improvement of both plasmepsin inhibitory activity and antimalarial activity by 2-aminoethylamino substitution. Bioorg Med Chem Lett. 2010 Aug 15;20(16):4836-9.
DMPWY6H	RU	https://pubmed.ncbi.nlm.nih.gov/20634066

DM7TW4C	DI	DM7TW4C
DM7TW4C	DN	KNI-10741
DM7TW4C	MI	TTXMNHO
DM7TW4C	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DM7TW4C	MT	DTT
DM7TW4C	MA	Inhibitor
DM7TW4C	RN	Improvement of both plasmepsin inhibitory activity and antimalarial activity by 2-aminoethylamino substitution. Bioorg Med Chem Lett. 2010 Aug 15;20(16):4836-9.
DM7TW4C	RU	https://pubmed.ncbi.nlm.nih.gov/20634066

DM4D9T3	DI	DM4D9T3
DM4D9T3	DN	KNI-10742
DM4D9T3	MI	TTXMNHO
DM4D9T3	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DM4D9T3	MT	DTT
DM4D9T3	MA	Inhibitor
DM4D9T3	RN	Improvement of both plasmepsin inhibitory activity and antimalarial activity by 2-aminoethylamino substitution. Bioorg Med Chem Lett. 2010 Aug 15;20(16):4836-9.
DM4D9T3	RU	https://pubmed.ncbi.nlm.nih.gov/20634066

DM0VSPE	DI	DM0VSPE
DM0VSPE	DN	KNI-10743
DM0VSPE	MI	TTXMNHO
DM0VSPE	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DM0VSPE	MT	DTT
DM0VSPE	MA	Inhibitor
DM0VSPE	RN	Improvement of both plasmepsin inhibitory activity and antimalarial activity by 2-aminoethylamino substitution. Bioorg Med Chem Lett. 2010 Aug 15;20(16):4836-9.
DM0VSPE	RU	https://pubmed.ncbi.nlm.nih.gov/20634066

DMM2A5Q	DI	DMM2A5Q
DMM2A5Q	DN	KNI-10758
DMM2A5Q	MI	TTXMNHO
DMM2A5Q	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMM2A5Q	MT	DTT
DMM2A5Q	MA	Inhibitor
DMM2A5Q	RN	Improvement of both plasmepsin inhibitory activity and antimalarial activity by 2-aminoethylamino substitution. Bioorg Med Chem Lett. 2010 Aug 15;20(16):4836-9.
DMM2A5Q	RU	https://pubmed.ncbi.nlm.nih.gov/20634066

DMAF1W3	DI	DMAF1W3
DMAF1W3	DN	KNI-10759
DMAF1W3	MI	TTXMNHO
DMAF1W3	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMAF1W3	MT	DTT
DMAF1W3	MA	Inhibitor
DMAF1W3	RN	Improvement of both plasmepsin inhibitory activity and antimalarial activity by 2-aminoethylamino substitution. Bioorg Med Chem Lett. 2010 Aug 15;20(16):4836-9.
DMAF1W3	RU	https://pubmed.ncbi.nlm.nih.gov/20634066

DMT5FIP	DI	DMT5FIP
DMT5FIP	DN	KNI-10760
DMT5FIP	MI	TTXMNHO
DMT5FIP	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMT5FIP	MT	DTT
DMT5FIP	MA	Inhibitor
DMT5FIP	RN	Improvement of both plasmepsin inhibitory activity and antimalarial activity by 2-aminoethylamino substitution. Bioorg Med Chem Lett. 2010 Aug 15;20(16):4836-9.
DMT5FIP	RU	https://pubmed.ncbi.nlm.nih.gov/20634066

DMXUTWZ	DI	DMXUTWZ
DMXUTWZ	DN	KNI-10761
DMXUTWZ	MI	TTXMNHO
DMXUTWZ	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMXUTWZ	MT	DTT
DMXUTWZ	MA	Inhibitor
DMXUTWZ	RN	Improvement of both plasmepsin inhibitory activity and antimalarial activity by 2-aminoethylamino substitution. Bioorg Med Chem Lett. 2010 Aug 15;20(16):4836-9.
DMXUTWZ	RU	https://pubmed.ncbi.nlm.nih.gov/20634066

DM73WB2	DI	DM73WB2
DM73WB2	DN	KNI-10762
DM73WB2	MI	TTXMNHO
DM73WB2	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DM73WB2	MT	DTT
DM73WB2	MA	Inhibitor
DM73WB2	RN	Improvement of both plasmepsin inhibitory activity and antimalarial activity by 2-aminoethylamino substitution. Bioorg Med Chem Lett. 2010 Aug 15;20(16):4836-9.
DM73WB2	RU	https://pubmed.ncbi.nlm.nih.gov/20634066

DMKAY5G	DI	DMKAY5G
DMKAY5G	DN	KNI-10763
DMKAY5G	MI	TTXMNHO
DMKAY5G	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMKAY5G	MT	DTT
DMKAY5G	MA	Inhibitor
DMKAY5G	RN	Improvement of both plasmepsin inhibitory activity and antimalarial activity by 2-aminoethylamino substitution. Bioorg Med Chem Lett. 2010 Aug 15;20(16):4836-9.
DMKAY5G	RU	https://pubmed.ncbi.nlm.nih.gov/20634066

DMZX430	DI	DMZX430
DMZX430	DN	KNI-1293
DMZX430	MI	TTXMNHO
DMZX430	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMZX430	MT	DTT
DMZX430	MA	Inhibitor
DMZX430	RN	Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60.
DMZX430	RU	https://pubmed.ncbi.nlm.nih.gov/18952439

DMS61DB	DI	DMS61DB
DMS61DB	DN	KNI-227
DMS61DB	MI	TTXMNHO
DMS61DB	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMS61DB	MT	DTT
DMS61DB	MA	Inhibitor
DMS61DB	RN	Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3048-52.
DMS61DB	RU	https://pubmed.ncbi.nlm.nih.gov/17400453

DM105NU	DI	DM105NU
DM105NU	DN	KNI-727
DM105NU	MI	TTXMNHO
DM105NU	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DM105NU	MT	DTT
DM105NU	MA	Inhibitor
DM105NU	RN	Identification and characterization of allophenylnorstatine-based inhibitors of plasmepsin II, an antimalarial target. Biochemistry. 2002 Feb 19;41(7):2273-80.
DM105NU	RU	https://pubmed.ncbi.nlm.nih.gov/11841219

DMZF3E9	DI	DMZF3E9
DMZF3E9	DN	KNT-5
DMZF3E9	MI	TTKWM86
DMZF3E9	MN	Opioid receptor mu (MOP)
DMZF3E9	MT	DTT
DMZF3E9	MA	Inhibitor
DMZF3E9	RN	Investigation of Beckett-Casy model 1: synthesis of novel 16,17-seco-naltrexone derivatives and their pharmacology. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1055-8.
DMZF3E9	RU	https://pubmed.ncbi.nlm.nih.gov/20056539

DM9M5HC	DI	DM9M5HC
DM9M5HC	DN	KNT-62
DM9M5HC	MI	TTQW87Y
DM9M5HC	MN	Opioid receptor kappa (OPRK1)
DM9M5HC	MT	DTT
DM9M5HC	MA	Inhibitor
DM9M5HC	RN	Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4.
DM9M5HC	RU	https://pubmed.ncbi.nlm.nih.gov/19962305

DM9M5HC	DI	DM9M5HC
DM9M5HC	DN	KNT-62
DM9M5HC	MI	TTKWM86
DM9M5HC	MN	Opioid receptor mu (MOP)
DM9M5HC	MT	DTT
DM9M5HC	MA	Inhibitor
DM9M5HC	RN	Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4.
DM9M5HC	RU	https://pubmed.ncbi.nlm.nih.gov/19962305

DM0U5N9	DI	DM0U5N9
DM0U5N9	DN	KNT-63
DM0U5N9	MI	TTQW87Y
DM0U5N9	MN	Opioid receptor kappa (OPRK1)
DM0U5N9	MT	DTT
DM0U5N9	MA	Inhibitor
DM0U5N9	RN	Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4.
DM0U5N9	RU	https://pubmed.ncbi.nlm.nih.gov/19962305

DM0U5N9	DI	DM0U5N9
DM0U5N9	DN	KNT-63
DM0U5N9	MI	TTKWM86
DM0U5N9	MN	Opioid receptor mu (MOP)
DM0U5N9	MT	DTT
DM0U5N9	MA	Inhibitor
DM0U5N9	RN	Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4.
DM0U5N9	RU	https://pubmed.ncbi.nlm.nih.gov/19962305

DMNWXCA	DI	DMNWXCA
DMNWXCA	DN	KNX-Monoclonal204
DMNWXCA	MI	TTE4KHA
DMNWXCA	MN	Amyloid beta A4 protein (APP)
DMNWXCA	MT	DTT
DMNWXCA	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
DMNWXCA	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402

DMVGNZJ	DI	DMVGNZJ
DMVGNZJ	DN	KO-286011
DMVGNZJ	MI	TTQL5VC
DMVGNZJ	MN	Platelet-activating factor receptor (PTAFR)
DMVGNZJ	MT	DTT
DMVGNZJ	MA	Modulator
DMVGNZJ	RN	Platelet-activating factor (PAF) inhibitory profile of KO-286011 on blood platelets in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol. 1990 Dec;342(6):713-8.
DMVGNZJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/2096302

DMAJKRX	DI	DMAJKRX
DMAJKRX	DN	Kodaistatin A
DMAJKRX	MI	TT1KPBZ
DMAJKRX	MN	Glucose-6-phosphate translocase (SLC37A4)
DMAJKRX	MT	DTT
DMAJKRX	MA	Inhibitor
DMAJKRX	RN	Kodaistatins, novel inhibitors of glucose-6-phosphate translocase T1 from Aspergillus terreus thom DSM 11247. Isolation and structural elucidation. J Antibiot (Tokyo). 2000 Jul;53(7):677-86.
DMAJKRX	RU	https://pubmed.ncbi.nlm.nih.gov/10994809

DM72WQ3	DI	DM72WQ3
DM72WQ3	DN	Kodaistatin C
DM72WQ3	MI	TT1KPBZ
DM72WQ3	MN	Glucose-6-phosphate translocase (SLC37A4)
DM72WQ3	MT	DTT
DM72WQ3	MA	Inhibitor
DM72WQ3	RN	Kodaistatins, novel inhibitors of glucose-6-phosphate translocase T1 from Aspergillus terreus thom DSM 11247. Isolation and structural elucidation. J Antibiot (Tokyo). 2000 Jul;53(7):677-86.
DM72WQ3	RU	https://pubmed.ncbi.nlm.nih.gov/10994809

DMP84CS	DI	DMP84CS
DMP84CS	DN	KOJIC ACID
DMP84CS	MI	TTULVH8
DMP84CS	MN	Tyrosinase (TYR)
DMP84CS	MT	DTT
DMP84CS	MA	Inhibitor
DMP84CS	RN	A novel ring-expanded product with enhanced tyrosinase inhibitory activity from classical Fe-catalyzed oxidation of rosmarinic acid, a potent antio... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7393-6.
DMP84CS	RU	https://pubmed.ncbi.nlm.nih.gov/21041086

DMRB1AT	DI	DMRB1AT
DMRB1AT	DN	Kojic acid-phenylalanine amide
DMRB1AT	MI	TTULVH8
DMRB1AT	MN	Tyrosinase (TYR)
DMRB1AT	MT	DTT
DMRB1AT	MA	Inhibitor
DMRB1AT	RN	Kojic acid-amino acid conjugates as tyrosinase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5586-9.
DMRB1AT	RU	https://pubmed.ncbi.nlm.nih.gov/19700313

DMYDGA7	DI	DMYDGA7
DMYDGA7	DN	KOS1326
DMYDGA7	MI	TT953CX
DMYDGA7	MN	Motilin receptor (MLNR)
DMYDGA7	MT	DTT
DMYDGA7	MA	Agonist
DMYDGA7	RN	Desensitization of the human motilin receptor by motilides. J Pharmacol Exp Ther. 2005 Jun;313(3):1397-405.
DMYDGA7	RU	https://pubmed.ncbi.nlm.nih.gov/15764739

DM1SKNP	DI	DM1SKNP
DM1SKNP	DN	KOSN1559
DM1SKNP	MI	TT78R5H
DM1SKNP	MN	Heat shock protein 90 alpha (HSP90A)
DM1SKNP	MT	DTT
DM1SKNP	MA	Inhibitor
DM1SKNP	RN	Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008 Oct;8(7):761-82.
DM1SKNP	RU	https://pubmed.ncbi.nlm.nih.gov/18855578

DMT1H9Z	DI	DMT1H9Z
DMT1H9Z	DN	KOTALANOL
DMT1H9Z	MI	TTXWASR
DMT1H9Z	MN	Intestinal maltase-glucoamylase (MGAM)
DMT1H9Z	MT	DTT
DMT1H9Z	MA	Inhibitor
DMT1H9Z	RN	Probing the active-site requirements of human intestinal N-terminal maltase-glucoamylase: Synthesis and enzyme inhibitory activities of a six-membe... Bioorg Med Chem. 2010 Nov 15;18(22):7794-8.
DMT1H9Z	RU	https://pubmed.ncbi.nlm.nih.gov/20970346

DMUZSJ2	DI	DMUZSJ2
DMUZSJ2	DN	KP772
DMUZSJ2	MI	TT0JLSD
DMUZSJ2	MN	Multidrug resistance protein (MDR)
DMUZSJ2	MT	DTT
DMUZSJ2	MA	Inhibitor
DMUZSJ2	RN	Thiazolides: a new class of antiviral drugs. Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):667-74.
DMUZSJ2	RU	https://pubmed.ncbi.nlm.nih.gov/19442032

DMC4YGT	DI	DMC4YGT
DMC4YGT	DN	KR-33889
DMC4YGT	MI	TTVDSZ0
DMC4YGT	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMC4YGT	MT	DTT
DMC4YGT	MA	Inhibitor
DMC4YGT	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2771).
DMC4YGT	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2771

DMIEKJ4	DI	DMIEKJ4
DMIEKJ4	DN	KR61639
DMIEKJ4	MI	TTELIN2
DMIEKJ4	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMIEKJ4	MT	DTT
DMIEKJ4	MA	Inhibitor
DMIEKJ4	RN	Discovery of a novel protein tyrosine phosphatase-1B inhibitor, KR61639: potential development as an antihyperglycemic agent. Eur J Pharmacol. 2004 Feb 6;485(1-3):333-9.
DMIEKJ4	RU	https://pubmed.ncbi.nlm.nih.gov/14757158

DM7G8KR	DI	DM7G8KR
DM7G8KR	DN	KR-62436
DM7G8KR	MI	TTDIGC1
DM7G8KR	MN	Dipeptidyl peptidase 4 (DPP-4)
DM7G8KR	MT	DTT
DM7G8KR	MA	Inhibitor
DM7G8KR	RN	Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes. Bioorg Med Chem. 2009 Mar 1;17(5):1783-802.
DM7G8KR	RU	https://pubmed.ncbi.nlm.nih.gov/19217790

DMXFBER	DI	DMXFBER
DMXFBER	DN	KRH-102053
DMXFBER	MI	TT9ISBX
DMXFBER	MN	HIF-prolyl hydroxylase 2 (HPH-2)
DMXFBER	MT	DTT
DMXFBER	MA	Activator
DMXFBER	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2833).
DMXFBER	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2833

DMLIK7X	DI	DMLIK7X
DMLIK7X	DN	KRP 203-phosphate
DMLIK7X	MI	TT9JZCK
DMLIK7X	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMLIK7X	MT	DTT
DMLIK7X	MA	Agonist
DMLIK7X	RN	A novel sphingosine 1-phosphate receptor agonist, 2-amino-2-propanediol hydrochloride (KRP-203), regulates chronic colitis in interleukin-10 gene-d... J Pharmacol Exp Ther. 2008 Jan;324(1):276-83.
DMLIK7X	RU	https://pubmed.ncbi.nlm.nih.gov/17898319

DMLIK7X	DI	DMLIK7X
DMLIK7X	DN	KRP 203-phosphate
DMLIK7X	MI	TTZ8C5Q
DMLIK7X	MN	Sphingosine-1-phosphate receptor 4 (S1PR4)
DMLIK7X	MT	DTT
DMLIK7X	MA	Agonist
DMLIK7X	RN	A novel sphingosine 1-phosphate receptor agonist, 2-amino-2-propanediol hydrochloride (KRP-203), regulates chronic colitis in interleukin-10 gene-d... J Pharmacol Exp Ther. 2008 Jan;324(1):276-83.
DMLIK7X	RU	https://pubmed.ncbi.nlm.nih.gov/17898319

DMJX9E1	DI	DMJX9E1
DMJX9E1	DN	KRP-100
DMJX9E1	MI	TTKWM86
DMJX9E1	MN	Opioid receptor mu (MOP)
DMJX9E1	MT	DTT
DMJX9E1	MA	Antagonist
DMJX9E1	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
DMJX9E1	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319

DM5KFBP	DI	DM5KFBP
DM5KFBP	DN	KRP-107
DM5KFBP	MI	TT9JZCK
DM5KFBP	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DM5KFBP	MT	DTT
DM5KFBP	MA	Modulator
DM5KFBP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 275).
DM5KFBP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=275

DME9HZC	DI	DME9HZC
DME9HZC	DN	KRP-110
DME9HZC	MI	TTKWM86
DME9HZC	MN	Opioid receptor mu (MOP)
DME9HZC	MT	DTT
DME9HZC	MA	Modulator
DME9HZC	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
DME9HZC	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319

DMC92ER	DI	DMC92ER
DMC92ER	DN	KSG-504
DMC92ER	MI	TTCG0AL
DMC92ER	MN	Cholecystokinin receptor type A (CCKAR)
DMC92ER	MT	DTT
DMC92ER	MA	Antagonist
DMC92ER	RN	Effects of KSG-504, a new CCK-A receptor antagonist, on gallbladder and gastrointestinal functions. Nihon Yakurigaku Zasshi. 1996 Jan;107(1):33-44.
DMC92ER	RU	https://pubmed.ncbi.nlm.nih.gov/8720296

DM5DTMQ	DI	DM5DTMQ
DM5DTMQ	DN	KSG-LDTKNYKQTSV
DM5DTMQ	MI	TT9PB26
DM5DTMQ	MN	Presynaptic density protein 95 (DLG4)
DM5DTMQ	MT	DTT
DM5DTMQ	MA	Inhibitor
DM5DTMQ	RN	Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem. 2008 Oct 23;51(20):6450-9.
DM5DTMQ	RU	https://pubmed.ncbi.nlm.nih.gov/18811137

DMPLFRC	DI	DMPLFRC
DMPLFRC	DN	KSG-YEKLSSIESDV
DMPLFRC	MI	TT9PB26
DMPLFRC	MN	Presynaptic density protein 95 (DLG4)
DMPLFRC	MT	DTT
DMPLFRC	MA	Inhibitor
DMPLFRC	RN	Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem. 2008 Oct 23;51(20):6450-9.
DMPLFRC	RU	https://pubmed.ncbi.nlm.nih.gov/18811137

DMXBITO	DI	DMXBITO
DMXBITO	DN	KSP-BCS-1-alpha-CHF2-1624F2-2
DMXBITO	MI	TTK59TV
DMXBITO	MN	Vitamin D3 receptor (VDR)
DMXBITO	MT	DTT
DMXBITO	MA	Inhibitor
DMXBITO	RN	Low-calcemic, highly antiproliferative, 1-difluoromethyl hybrid analogs of the natural hormone 1alpha,25-dihydroxyvitamin D3: design, synthesis, an... J Med Chem. 2006 Dec 14;49(25):7513-7.
DMXBITO	RU	https://pubmed.ncbi.nlm.nih.gov/17149880

DMJV3R7	DI	DMJV3R7
DMJV3R7	DN	KSP-BCS-1-alpha-CHF2-20-epi-22-oxabishomo-26-OH
DMJV3R7	MI	TTK59TV
DMJV3R7	MN	Vitamin D3 receptor (VDR)
DMJV3R7	MT	DTT
DMJV3R7	MA	Inhibitor
DMJV3R7	RN	Low-calcemic, highly antiproliferative, 1-difluoromethyl hybrid analogs of the natural hormone 1alpha,25-dihydroxyvitamin D3: design, synthesis, an... J Med Chem. 2006 Dec 14;49(25):7513-7.
DMJV3R7	RU	https://pubmed.ncbi.nlm.nih.gov/17149880

DMT0CR5	DI	DMT0CR5
DMT0CR5	DN	KST-5468
DMT0CR5	MI	TTZPWGN
DMT0CR5	MN	Voltage-gated calcium channel alpha Cav3.2 (CACNA1H)
DMT0CR5	MT	DTT
DMT0CR5	MA	Antagonist
DMT0CR5	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 536).
DMT0CR5	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=536

DMOBYU3	DI	DMOBYU3
DMOBYU3	DN	KT 5823
DMOBYU3	MI	TTOXS3C
DMOBYU3	MN	Muscarinic acetylcholine receptor (CHRM)
DMOBYU3	MT	DTT
DMOBYU3	MA	Modulator (allosteric modulator)
DMOBYU3	RN	Allosteric interactions of staurosporine and other indolocarbazoles with N-[methyl-(3)H]scopolamine and acetylcholine at muscarinic receptor subtypes: identification of a second allosteric site. Mol Pharmacol. 2000 Jul;58(1):194-207.
DMOBYU3	RU	https://pubmed.ncbi.nlm.nih.gov/10860942

DM9J50F	DI	DM9J50F
DM9J50F	DN	KT-5720
DM9J50F	MI	TT4TQBX
DM9J50F	MN	Extracellular signal-regulated kinase 2 (ERK2)
DM9J50F	MT	DTT
DM9J50F	MA	Inhibitor
DM9J50F	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DM9J50F	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DM9J50F	DI	DM9J50F
DM9J50F	DN	KT-5720
DM9J50F	MI	TTYT93M
DM9J50F	MN	MAP kinase p38 (MAPK12)
DM9J50F	MT	DTT
DM9J50F	MA	Inhibitor
DM9J50F	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DM9J50F	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DM9J50F	DI	DM9J50F
DM9J50F	DN	KT-5720
DM9J50F	MI	TTFJ8Q1
DM9J50F	MN	Protein kinase C alpha (PRKCA)
DM9J50F	MT	DTT
DM9J50F	MA	Inhibitor
DM9J50F	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DM9J50F	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DM9J50F	DI	DM9J50F
DM9J50F	DN	KT-5720
DM9J50F	MI	TTZN7RP
DM9J50F	MN	Rho-associated protein kinase 1 (ROCK1)
DM9J50F	MT	DTT
DM9J50F	MA	Inhibitor
DM9J50F	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DM9J50F	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DM9J50F	DI	DM9J50F
DM9J50F	DN	KT-5720
DM9J50F	MI	TTG0U4H
DM9J50F	MN	Ribosomal protein S6 kinase beta-1 (S6K1)
DM9J50F	MT	DTT
DM9J50F	MA	Inhibitor
DM9J50F	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DM9J50F	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DM9J50F	DI	DM9J50F
DM9J50F	DN	KT-5720
DM9J50F	MI	TTQBR95
DM9J50F	MN	Stress-activated protein kinase 2a (p38 alpha)
DM9J50F	MT	DTT
DM9J50F	MA	Inhibitor
DM9J50F	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DM9J50F	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DM9J50F	DI	DM9J50F
DM9J50F	DN	KT-5720
DM9J50F	MI	TT73U6C
DM9J50F	MN	Stress-activated protein kinase 2b (p38 beta)
DM9J50F	MT	DTT
DM9J50F	MA	Inhibitor
DM9J50F	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DM9J50F	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DM9J50F	DI	DM9J50F
DM9J50F	DN	KT-5720
DM9J50F	MI	TT0K6EO
DM9J50F	MN	Stress-activated protein kinase JNK1 (JNK1)
DM9J50F	MT	DTT
DM9J50F	MA	Inhibitor
DM9J50F	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DM9J50F	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMXIUO5	DI	DMXIUO5
DMXIUO5	DN	KT6006
DMXIUO5	MI	TTGTQHC
DMXIUO5	MN	DNA topoisomerase I (TOP1)
DMXIUO5	MT	DTT
DMXIUO5	MA	Inducer
DMXIUO5	RN	Induction of mammalian DNA topoisomerase I mediated DNA cleavage by antitumor indolocarbazole derivatives. Biochemistry. 1992 Dec 8;31(48):12069-75.
DMXIUO5	RU	https://pubmed.ncbi.nlm.nih.gov/1333791

DMRDZ7I	DI	DMRDZ7I
DMRDZ7I	DN	KT6528
DMRDZ7I	MI	TTGTQHC
DMRDZ7I	MN	DNA topoisomerase I (TOP1)
DMRDZ7I	MT	DTT
DMRDZ7I	MA	Inducer
DMRDZ7I	RN	Induction of mammalian DNA topoisomerase I mediated DNA cleavage by antitumor indolocarbazole derivatives. Biochemistry. 1992 Dec 8;31(48):12069-75.
DMRDZ7I	RU	https://pubmed.ncbi.nlm.nih.gov/1333791

DMQWS6U	DI	DMQWS6U
DMQWS6U	DN	KU-0060648
DMQWS6U	MI	TTK3PY9
DMQWS6U	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMQWS6U	MT	DTT
DMQWS6U	MA	Inhibitor
DMQWS6U	RN	1-substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activity. J Med Chem. 2013 Aug 22;56(16):6386-401.
DMQWS6U	RU	https://pubmed.ncbi.nlm.nih.gov/23855836

DMQWS6U	DI	DMQWS6U
DMQWS6U	DN	KU-0060648
DMQWS6U	MI	TTTHBCA
DMQWS6U	MN	PI3-kinase beta (PIK3CB)
DMQWS6U	MT	DTT
DMQWS6U	MA	Inhibitor
DMQWS6U	RN	1-substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activity. J Med Chem. 2013 Aug 22;56(16):6386-401.
DMQWS6U	RU	https://pubmed.ncbi.nlm.nih.gov/23855836

DMQWS6U	DI	DMQWS6U
DMQWS6U	DN	KU-0060648
DMQWS6U	MI	TTHBTOP
DMQWS6U	MN	PI3-kinase gamma (PIK3CG)
DMQWS6U	MT	DTT
DMQWS6U	MA	Inhibitor
DMQWS6U	RN	1-substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activity. J Med Chem. 2013 Aug 22;56(16):6386-401.
DMQWS6U	RU	https://pubmed.ncbi.nlm.nih.gov/23855836

DMDT42X	DI	DMDT42X
DMDT42X	DN	KU-55933
DMDT42X	MI	TTK3PY9
DMDT42X	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMDT42X	MT	DTT
DMDT42X	MA	Inhibitor
DMDT42X	RN	Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72.
DMDT42X	RU	https://pubmed.ncbi.nlm.nih.gov/17371003

DMVGY6K	DI	DMVGY6K
DMVGY6K	DN	KU-58684
DMVGY6K	MI	TTVDSZ0
DMVGY6K	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMVGY6K	MT	DTT
DMVGY6K	MA	Inhibitor
DMVGY6K	RN	Design, synthesis, and cytoprotective effect of 2-aminothiazole analogues as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2009 Feb 12;52(3):718-25.
DMVGY6K	RU	https://pubmed.ncbi.nlm.nih.gov/19125579

DMAVM94	DI	DMAVM94
DMAVM94	DN	Kuanoniamine D
DMAVM94	MI	TTK25J1
DMAVM94	MN	Adenosine A1 receptor (ADORA1)
DMAVM94	MT	DTT
DMAVM94	MA	Inhibitor
DMAVM94	RN	Bioactive pyridoacridine alkaloids from the micronesian sponge Oceanapia sp. J Nat Prod. 1998 Feb;61(2):301-5.
DMAVM94	RU	https://pubmed.ncbi.nlm.nih.gov/9514015

DMAVM94	DI	DMAVM94
DMAVM94	DN	Kuanoniamine D
DMAVM94	MI	TTM2AOE
DMAVM94	MN	Adenosine A2a receptor (ADORA2A)
DMAVM94	MT	DTT
DMAVM94	MA	Inhibitor
DMAVM94	RN	Bioactive pyridoacridine alkaloids from the micronesian sponge Oceanapia sp. J Nat Prod. 1998 Feb;61(2):301-5.
DMAVM94	RU	https://pubmed.ncbi.nlm.nih.gov/9514015

DMLDUJ1	DI	DMLDUJ1
DMLDUJ1	DN	Kuraidin
DMLDUJ1	MI	TT06AWU
DMLDUJ1	MN	Phosphodiesterase 3A (PDE3A)
DMLDUJ1	MT	DTT
DMLDUJ1	MA	Inhibitor
DMLDUJ1	RN	A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5. Bioorg Med Chem Lett. 2002 Sep 2;12(17):2313-6.
DMLDUJ1	RU	https://pubmed.ncbi.nlm.nih.gov/12161123

DMLDUJ1	DI	DMLDUJ1
DMLDUJ1	DN	Kuraidin
DMLDUJ1	MI	TTZ97H5
DMLDUJ1	MN	Phosphodiesterase 4A (PDE4A)
DMLDUJ1	MT	DTT
DMLDUJ1	MA	Inhibitor
DMLDUJ1	RN	A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5. Bioorg Med Chem Lett. 2002 Sep 2;12(17):2313-6.
DMLDUJ1	RU	https://pubmed.ncbi.nlm.nih.gov/12161123

DMLDUJ1	DI	DMLDUJ1
DMLDUJ1	DN	Kuraidin
DMLDUJ1	MI	TTVIAT9
DMLDUJ1	MN	Phosphodiesterase 4B (PDE4B)
DMLDUJ1	MT	DTT
DMLDUJ1	MA	Inhibitor
DMLDUJ1	RN	A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5. Bioorg Med Chem Lett. 2002 Sep 2;12(17):2313-6.
DMLDUJ1	RU	https://pubmed.ncbi.nlm.nih.gov/12161123

DMLDUJ1	DI	DMLDUJ1
DMLDUJ1	DN	Kuraidin
DMLDUJ1	MI	TTJ0IQB
DMLDUJ1	MN	Phosphodiesterase 5A (PDE5A)
DMLDUJ1	MT	DTT
DMLDUJ1	MA	Inhibitor
DMLDUJ1	RN	A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5. Bioorg Med Chem Lett. 2002 Sep 2;12(17):2313-6.
DMLDUJ1	RU	https://pubmed.ncbi.nlm.nih.gov/12161123

DMLDUJ1	DI	DMLDUJ1
DMLDUJ1	DN	Kuraidin
DMLDUJ1	MI	TTF8JAT
DMLDUJ1	MN	SLC5A2 messenger RNA (SLC5A2 mRNA)
DMLDUJ1	MT	DTT
DMLDUJ1	MA	Inhibitor
DMLDUJ1	RN	Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens. Bioorg Med Chem. 2007 May 15;15(10):3445-9.
DMLDUJ1	RU	https://pubmed.ncbi.nlm.nih.gov/17374486

DMLDUJ1	DI	DMLDUJ1
DMLDUJ1	DN	Kuraidin
DMLDUJ1	MI	TT2UE56
DMLDUJ1	MN	Sodium/glucose cotransporter 1 (SGLT1)
DMLDUJ1	MT	DTT
DMLDUJ1	MA	Inhibitor
DMLDUJ1	RN	Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens. Bioorg Med Chem. 2007 May 15;15(10):3445-9.
DMLDUJ1	RU	https://pubmed.ncbi.nlm.nih.gov/17374486

DMRV5YE	DI	DMRV5YE
DMRV5YE	DN	KURARINOL
DMRV5YE	MI	TT06AWU
DMRV5YE	MN	Phosphodiesterase 3A (PDE3A)
DMRV5YE	MT	DTT
DMRV5YE	MA	Inhibitor
DMRV5YE	RN	A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5. Bioorg Med Chem Lett. 2002 Sep 2;12(17):2313-6.
DMRV5YE	RU	https://pubmed.ncbi.nlm.nih.gov/12161123

DMRV5YE	DI	DMRV5YE
DMRV5YE	DN	KURARINOL
DMRV5YE	MI	TTZ97H5
DMRV5YE	MN	Phosphodiesterase 4A (PDE4A)
DMRV5YE	MT	DTT
DMRV5YE	MA	Inhibitor
DMRV5YE	RN	A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5. Bioorg Med Chem Lett. 2002 Sep 2;12(17):2313-6.
DMRV5YE	RU	https://pubmed.ncbi.nlm.nih.gov/12161123

DMRV5YE	DI	DMRV5YE
DMRV5YE	DN	KURARINOL
DMRV5YE	MI	TTVIAT9
DMRV5YE	MN	Phosphodiesterase 4B (PDE4B)
DMRV5YE	MT	DTT
DMRV5YE	MA	Inhibitor
DMRV5YE	RN	A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5. Bioorg Med Chem Lett. 2002 Sep 2;12(17):2313-6.
DMRV5YE	RU	https://pubmed.ncbi.nlm.nih.gov/12161123

DMRV5YE	DI	DMRV5YE
DMRV5YE	DN	KURARINOL
DMRV5YE	MI	TTJ0IQB
DMRV5YE	MN	Phosphodiesterase 5A (PDE5A)
DMRV5YE	MT	DTT
DMRV5YE	MA	Inhibitor
DMRV5YE	RN	A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5. Bioorg Med Chem Lett. 2002 Sep 2;12(17):2313-6.
DMRV5YE	RU	https://pubmed.ncbi.nlm.nih.gov/12161123

DMH0G8W	DI	DMH0G8W
DMH0G8W	DN	Kurarinone
DMH0G8W	MI	TT8JRS7
DMH0G8W	MN	Beta-secretase (BACE)
DMH0G8W	MT	DTT
DMH0G8W	MA	Inhibitor
DMH0G8W	RN	BACE1 inhibitory effects of lavandulyl flavanones from Sophora flavescens. Bioorg Med Chem. 2008 Jul 15;16(14):6669-74.
DMH0G8W	RU	https://pubmed.ncbi.nlm.nih.gov/18565755

DMH0G8W	DI	DMH0G8W
DMH0G8W	DN	Kurarinone
DMH0G8W	MI	TTF8JAT
DMH0G8W	MN	SLC5A2 messenger RNA (SLC5A2 mRNA)
DMH0G8W	MT	DTT
DMH0G8W	MA	Inhibitor
DMH0G8W	RN	Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens. Bioorg Med Chem. 2007 May 15;15(10):3445-9.
DMH0G8W	RU	https://pubmed.ncbi.nlm.nih.gov/17374486

DMH0G8W	DI	DMH0G8W
DMH0G8W	DN	Kurarinone
DMH0G8W	MI	TT2UE56
DMH0G8W	MN	Sodium/glucose cotransporter 1 (SGLT1)
DMH0G8W	MT	DTT
DMH0G8W	MA	Inhibitor
DMH0G8W	RN	Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens. Bioorg Med Chem. 2007 May 15;15(10):3445-9.
DMH0G8W	RU	https://pubmed.ncbi.nlm.nih.gov/17374486

DMPKDJ4	DI	DMPKDJ4
DMPKDJ4	DN	KUR-CXCR4
DMPKDJ4	MI	TTBID49
DMPKDJ4	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMPKDJ4	MT	DTT
DMPKDJ4	MA	Modulator
DMPKDJ4	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 71).
DMPKDJ4	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=71

DMCFHPD	DI	DMCFHPD
DMCFHPD	DN	KUSHENOL A
DMCFHPD	MI	TT8JRS7
DMCFHPD	MN	Beta-secretase (BACE)
DMCFHPD	MT	DTT
DMCFHPD	MA	Inhibitor
DMCFHPD	RN	BACE1 inhibitory effects of lavandulyl flavanones from Sophora flavescens. Bioorg Med Chem. 2008 Jul 15;16(14):6669-74.
DMCFHPD	RU	https://pubmed.ncbi.nlm.nih.gov/18565755

DMY13UR	DI	DMY13UR
DMY13UR	DN	Kushenol N
DMY13UR	MI	TTF8JAT
DMY13UR	MN	SLC5A2 messenger RNA (SLC5A2 mRNA)
DMY13UR	MT	DTT
DMY13UR	MA	Inhibitor
DMY13UR	RN	Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens. Bioorg Med Chem. 2007 May 15;15(10):3445-9.
DMY13UR	RU	https://pubmed.ncbi.nlm.nih.gov/17374486

DMY13UR	DI	DMY13UR
DMY13UR	DN	Kushenol N
DMY13UR	MI	TT2UE56
DMY13UR	MN	Sodium/glucose cotransporter 1 (SGLT1)
DMY13UR	MT	DTT
DMY13UR	MA	Inhibitor
DMY13UR	RN	Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens. Bioorg Med Chem. 2007 May 15;15(10):3445-9.
DMY13UR	RU	https://pubmed.ncbi.nlm.nih.gov/17374486

DMVQDNR	DI	DMVQDNR
DMVQDNR	DN	kuwanon H
DMVQDNR	MI	TTHYDUM
DMVQDNR	MN	Bombesin receptor (BS)
DMVQDNR	MT	DTT
DMVQDNR	MA	Antagonist
DMVQDNR	RN	Non-peptide bombesin receptor antagonists, kuwanon G and H, isolated from mulberry. Biochem Biophys Res Commun. 1995 Aug 15;213(2):594-9.
DMVQDNR	RU	https://pubmed.ncbi.nlm.nih.gov/7646517

DMVQDNR	DI	DMVQDNR
DMVQDNR	DN	kuwanon H
DMVQDNR	MI	TTC1MVT
DMVQDNR	MN	Gastrin-releasing peptide receptor (GRPR)
DMVQDNR	MT	DTT
DMVQDNR	MA	Antagonist
DMVQDNR	RN	Non-peptide bombesin receptor antagonists, kuwanon G and H, isolated from mulberry. Biochem Biophys Res Commun. 1995 Aug 15;213(2):594-9.
DMVQDNR	RU	https://pubmed.ncbi.nlm.nih.gov/7646517

DMFSUJB	DI	DMFSUJB
DMFSUJB	DN	Kuwanon J
DMFSUJB	MI	TTELIN2
DMFSUJB	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMFSUJB	MT	DTT
DMFSUJB	MA	Inhibitor
DMFSUJB	RN	Protein tyrosine phosphatase 1B inhibitors isolated from Morus bombycis. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6759-61.
DMFSUJB	RU	https://pubmed.ncbi.nlm.nih.gov/19846295

DMX4D1Q	DI	DMX4D1Q
DMX4D1Q	DN	Kuwanon L
DMX4D1Q	MI	TTELIN2
DMX4D1Q	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMX4D1Q	MT	DTT
DMX4D1Q	MA	Inhibitor
DMX4D1Q	RN	Protein tyrosine phosphatase 1B inhibitors from Morus root bark. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1426-9.
DMX4D1Q	RU	https://pubmed.ncbi.nlm.nih.gov/16356713

DMEZOT9	DI	DMEZOT9
DMEZOT9	DN	Kuwanon R
DMEZOT9	MI	TTELIN2
DMEZOT9	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMEZOT9	MT	DTT
DMEZOT9	MA	Inhibitor
DMEZOT9	RN	Protein tyrosine phosphatase 1B inhibitors isolated from Morus bombycis. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6759-61.
DMEZOT9	RU	https://pubmed.ncbi.nlm.nih.gov/19846295

DM84M20	DI	DM84M20
DM84M20	DN	Kuwanon V
DM84M20	MI	TTELIN2
DM84M20	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DM84M20	MT	DTT
DM84M20	MA	Inhibitor
DM84M20	RN	Protein tyrosine phosphatase 1B inhibitors isolated from Morus bombycis. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6759-61.
DM84M20	RU	https://pubmed.ncbi.nlm.nih.gov/19846295

DM7RFUC	DI	DM7RFUC
DM7RFUC	DN	KwFwLL-NH2
DM7RFUC	MI	TTWDC17
DM7RFUC	MN	Growth hormone secretagogue receptor 1 (GHSR)
DM7RFUC	MT	DTT
DM7RFUC	MA	Inhibitor
DM7RFUC	RN	Identification of an efficacy switch region in the ghrelin receptor responsible for interchange between agonism and inverse agonism. J Biol Chem. 2007 May 25;282(21):15799-811.
DM7RFUC	RU	https://pubmed.ncbi.nlm.nih.gov/17371869

DMA9VBD	DI	DMA9VBD
DMA9VBD	DN	KY-382
DMA9VBD	MI	TTMF541
DMA9VBD	MN	Liver carboxylesterase (CES1)
DMA9VBD	MT	DTT
DMA9VBD	MA	Modulator
DMA9VBD	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2592).
DMA9VBD	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2592

DM3MID9	DI	DM3MID9
DM3MID9	DN	KYS-05001
DM3MID9	MI	TT729IR
DM3MID9	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DM3MID9	MT	DTT
DM3MID9	MA	Inhibitor
DM3MID9	RN	Discovery of potent T-type calcium channel blocker. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5740-3.
DM3MID9	RU	https://pubmed.ncbi.nlm.nih.gov/17869104

DM3MID9	DI	DM3MID9
DM3MID9	DN	KYS-05001
DM3MID9	MI	TTZPWGN
DM3MID9	MN	Voltage-gated calcium channel alpha Cav3.2 (CACNA1H)
DM3MID9	MT	DTT
DM3MID9	MA	Inhibitor
DM3MID9	RN	3,4-Dihydroquinazoline derivatives as novel selective T-type Ca2+ channel blockers. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3379-84.
DM3MID9	RU	https://pubmed.ncbi.nlm.nih.gov/15177437

DM1JU8F	DI	DM1JU8F
DM1JU8F	DN	KYS-05040
DM1JU8F	MI	TT729IR
DM1JU8F	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DM1JU8F	MT	DTT
DM1JU8F	MA	Inhibitor
DM1JU8F	RN	3,4-Dihydroquinazoline derivatives as novel selective T-type Ca2+ channel blockers. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3379-84.
DM1JU8F	RU	https://pubmed.ncbi.nlm.nih.gov/15177437

DM1JU8F	DI	DM1JU8F
DM1JU8F	DN	KYS-05040
DM1JU8F	MI	TTZPWGN
DM1JU8F	MN	Voltage-gated calcium channel alpha Cav3.2 (CACNA1H)
DM1JU8F	MT	DTT
DM1JU8F	MA	Inhibitor
DM1JU8F	RN	3,4-Dihydroquinazoline derivatives as novel selective T-type Ca2+ channel blockers. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3379-84.
DM1JU8F	RU	https://pubmed.ncbi.nlm.nih.gov/15177437

DMVA6LH	DI	DMVA6LH
DMVA6LH	DN	KYS-05041
DMVA6LH	MI	TT729IR
DMVA6LH	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DMVA6LH	MT	DTT
DMVA6LH	MA	Inhibitor
DMVA6LH	RN	3D pharmacophore based virtual screening of T-type calcium channel blockers. Bioorg Med Chem. 2007 Jan 15;15(2):1091-105.
DMVA6LH	RU	https://pubmed.ncbi.nlm.nih.gov/17074493

DMVA6LH	DI	DMVA6LH
DMVA6LH	DN	KYS-05041
DMVA6LH	MI	TTZPWGN
DMVA6LH	MN	Voltage-gated calcium channel alpha Cav3.2 (CACNA1H)
DMVA6LH	MT	DTT
DMVA6LH	MA	Inhibitor
DMVA6LH	RN	3,4-Dihydroquinazoline derivatives as novel selective T-type Ca2+ channel blockers. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3379-84.
DMVA6LH	RU	https://pubmed.ncbi.nlm.nih.gov/15177437

DMM6G4H	DI	DMM6G4H
DMM6G4H	DN	KYS-05042
DMM6G4H	MI	TT729IR
DMM6G4H	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DMM6G4H	MT	DTT
DMM6G4H	MA	Inhibitor
DMM6G4H	RN	T-type Ca2+ channel blockers suppress the growth of human cancer cells. Bioorg Med Chem Lett. 2008 Jul 15;18(14):3899-901.
DMM6G4H	RU	https://pubmed.ncbi.nlm.nih.gov/18585035

DMM6G4H	DI	DMM6G4H
DMM6G4H	DN	KYS-05042
DMM6G4H	MI	TTZPWGN
DMM6G4H	MN	Voltage-gated calcium channel alpha Cav3.2 (CACNA1H)
DMM6G4H	MT	DTT
DMM6G4H	MA	Inhibitor
DMM6G4H	RN	3,4-Dihydroquinazoline derivatives as novel selective T-type Ca2+ channel blockers. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3379-84.
DMM6G4H	RU	https://pubmed.ncbi.nlm.nih.gov/15177437

DMXR3V4	DI	DMXR3V4
DMXR3V4	DN	KYS-05050
DMXR3V4	MI	TT729IR
DMXR3V4	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DMXR3V4	MT	DTT
DMXR3V4	MA	Inhibitor
DMXR3V4	RN	Synthesis and biological evaluation of novel T-type calcium channel blockers. Bioorg Med Chem Lett. 2007 Jan 15;17(2):471-5.
DMXR3V4	RU	https://pubmed.ncbi.nlm.nih.gov/17064894

DMXR3V4	DI	DMXR3V4
DMXR3V4	DN	KYS-05050
DMXR3V4	MI	TTZPWGN
DMXR3V4	MN	Voltage-gated calcium channel alpha Cav3.2 (CACNA1H)
DMXR3V4	MT	DTT
DMXR3V4	MA	Inhibitor
DMXR3V4	RN	Synthesis and biological evaluation of novel T-type calcium channel blockers. Bioorg Med Chem Lett. 2007 Jan 15;17(2):471-5.
DMXR3V4	RU	https://pubmed.ncbi.nlm.nih.gov/17064894

DMRVOT7	DI	DMRVOT7
DMRVOT7	DN	KYS-05055
DMRVOT7	MI	TT729IR
DMRVOT7	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DMRVOT7	MT	DTT
DMRVOT7	MA	Inhibitor
DMRVOT7	RN	T-type Ca2+ channel blockers suppress the growth of human cancer cells. Bioorg Med Chem Lett. 2008 Jul 15;18(14):3899-901.
DMRVOT7	RU	https://pubmed.ncbi.nlm.nih.gov/18585035

DMP6S0L	DI	DMP6S0L
DMP6S0L	DN	KYS-05056
DMP6S0L	MI	TT729IR
DMP6S0L	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DMP6S0L	MT	DTT
DMP6S0L	MA	Inhibitor
DMP6S0L	RN	T-type Ca2+ channel blockers suppress the growth of human cancer cells. Bioorg Med Chem Lett. 2008 Jul 15;18(14):3899-901.
DMP6S0L	RU	https://pubmed.ncbi.nlm.nih.gov/18585035

DM7BYG8	DI	DM7BYG8
DM7BYG8	DN	KYS-05057
DM7BYG8	MI	TT729IR
DM7BYG8	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DM7BYG8	MT	DTT
DM7BYG8	MA	Inhibitor
DM7BYG8	RN	T-type Ca2+ channel blockers suppress the growth of human cancer cells. Bioorg Med Chem Lett. 2008 Jul 15;18(14):3899-901.
DM7BYG8	RU	https://pubmed.ncbi.nlm.nih.gov/18585035

DM61GPQ	DI	DM61GPQ
DM61GPQ	DN	KYS-05064
DM61GPQ	MI	TT729IR
DM61GPQ	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DM61GPQ	MT	DTT
DM61GPQ	MA	Inhibitor
DM61GPQ	RN	3D pharmacophore based virtual screening of T-type calcium channel blockers. Bioorg Med Chem. 2007 Jan 15;15(2):1091-105.
DM61GPQ	RU	https://pubmed.ncbi.nlm.nih.gov/17074493

DMA8LFD	DI	DMA8LFD
DMA8LFD	DN	KYS-05065
DMA8LFD	MI	TT729IR
DMA8LFD	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DMA8LFD	MT	DTT
DMA8LFD	MA	Inhibitor
DMA8LFD	RN	T-type Ca2+ channel blockers suppress the growth of human cancer cells. Bioorg Med Chem Lett. 2008 Jul 15;18(14):3899-901.
DMA8LFD	RU	https://pubmed.ncbi.nlm.nih.gov/18585035

DMRJQY3	DI	DMRJQY3
DMRJQY3	DN	KYS-05070
DMRJQY3	MI	TT729IR
DMRJQY3	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DMRJQY3	MT	DTT
DMRJQY3	MA	Inhibitor
DMRJQY3	RN	Growth inhibition of human cancer cells in vitro by T-type calcium channel blockers. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5014-7.
DMRJQY3	RU	https://pubmed.ncbi.nlm.nih.gov/16876410

DM7K5Z3	DI	DM7K5Z3
DM7K5Z3	DN	KYS-05071
DM7K5Z3	MI	TT729IR
DM7K5Z3	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DM7K5Z3	MT	DTT
DM7K5Z3	MA	Inhibitor
DM7K5Z3	RN	Growth inhibition of human cancer cells in vitro by T-type calcium channel blockers. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5014-7.
DM7K5Z3	RU	https://pubmed.ncbi.nlm.nih.gov/16876410

DMYRWQ3	DI	DMYRWQ3
DMYRWQ3	DN	KYS-05074
DMYRWQ3	MI	TT729IR
DMYRWQ3	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DMYRWQ3	MT	DTT
DMYRWQ3	MA	Inhibitor
DMYRWQ3	RN	Growth inhibition of human cancer cells in vitro by T-type calcium channel blockers. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5014-7.
DMYRWQ3	RU	https://pubmed.ncbi.nlm.nih.gov/16876410

DMHW40F	DI	DMHW40F
DMHW40F	DN	KYS-05077
DMHW40F	MI	TT729IR
DMHW40F	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DMHW40F	MT	DTT
DMHW40F	MA	Inhibitor
DMHW40F	RN	Synthesis and biological evaluation of novel T-type calcium channel blockers. Bioorg Med Chem Lett. 2007 Jan 15;17(2):471-5.
DMHW40F	RU	https://pubmed.ncbi.nlm.nih.gov/17064894

DMHW40F	DI	DMHW40F
DMHW40F	DN	KYS-05077
DMHW40F	MI	TTZPWGN
DMHW40F	MN	Voltage-gated calcium channel alpha Cav3.2 (CACNA1H)
DMHW40F	MT	DTT
DMHW40F	MA	Inhibitor
DMHW40F	RN	Synthesis and biological evaluation of novel T-type calcium channel blockers. Bioorg Med Chem Lett. 2007 Jan 15;17(2):471-5.
DMHW40F	RU	https://pubmed.ncbi.nlm.nih.gov/17064894

DM57BXZ	DI	DM57BXZ
DM57BXZ	DN	KYS-05080
DM57BXZ	MI	TT729IR
DM57BXZ	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DM57BXZ	MT	DTT
DM57BXZ	MA	Inhibitor
DM57BXZ	RN	T-type Ca2+ channel blockers suppress the growth of human cancer cells. Bioorg Med Chem Lett. 2008 Jul 15;18(14):3899-901.
DM57BXZ	RU	https://pubmed.ncbi.nlm.nih.gov/18585035

DM57BXZ	DI	DM57BXZ
DM57BXZ	DN	KYS-05080
DM57BXZ	MI	TTZPWGN
DM57BXZ	MN	Voltage-gated calcium channel alpha Cav3.2 (CACNA1H)
DM57BXZ	MT	DTT
DM57BXZ	MA	Inhibitor
DM57BXZ	RN	Synthesis and biological evaluation of novel T-type calcium channel blockers. Bioorg Med Chem Lett. 2007 Jan 15;17(2):471-5.
DM57BXZ	RU	https://pubmed.ncbi.nlm.nih.gov/17064894

DM92RHP	DI	DM92RHP
DM92RHP	DN	KYS-05090
DM92RHP	MI	TT4FDG6
DM92RHP	MN	Voltage-gated calcium channel alpha Cav2.2 (CACNA1B)
DM92RHP	MT	DTT
DM92RHP	MA	Inhibitor
DM92RHP	RN	Discovery of potent T-type calcium channel blocker. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5740-3.
DM92RHP	RU	https://pubmed.ncbi.nlm.nih.gov/17869104

DM92RHP	DI	DM92RHP
DM92RHP	DN	KYS-05090
DM92RHP	MI	TT729IR
DM92RHP	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DM92RHP	MT	DTT
DM92RHP	MA	Inhibitor
DM92RHP	RN	T-type Ca2+ channel blockers suppress the growth of human cancer cells. Bioorg Med Chem Lett. 2008 Jul 15;18(14):3899-901.
DM92RHP	RU	https://pubmed.ncbi.nlm.nih.gov/18585035

DMB73Y4	DI	DMB73Y4
DMB73Y4	DN	L 691121
DMB73Y4	MI	TT1VOHK
DMB73Y4	MN	Potassium channel unspecific (KC)
DMB73Y4	MT	DTT
DMB73Y4	MA	Modulator
DMB73Y4	RN	Embryotoxic effects of L-691,121, a class III antiarrhythmic agent, in rats. Arch Toxicol. 1994;69(1):65-71.
DMB73Y4	RU	https://www.ncbi.nlm.nih.gov/pubmed/7717857

DMK07MI	DI	DMK07MI
DMK07MI	DN	L-(cis)-diltiazem
DMK07MI	MI	TTHIQMC
DMK07MI	MN	Cyclic nucleotide-gated channel alpha-1 (CNGA1)
DMK07MI	MT	DTT
DMK07MI	MA	Blocker (channel blocker)
DMK07MI	RN	A new subunit of the cyclic nucleotide-gated cation channel in retinal rods. Nature. 1993 Apr 22;362(6422):764-7.
DMK07MI	RU	https://pubmed.ncbi.nlm.nih.gov/7682292

DMK07MI	DI	DMK07MI
DMK07MI	DN	L-(cis)-diltiazem
DMK07MI	MI	TT8SJGB
DMK07MI	MN	Cyclic nucleotide-gated channel alpha-2 (CNGA2)
DMK07MI	MT	DTT
DMK07MI	MA	Blocker (channel blocker)
DMK07MI	RN	Primary structure and functional expression of a cyclic nucleotide-activated channel from olfactory neurons. Nature. 1990 Sep 13;347(6289):184-7.
DMK07MI	RU	https://pubmed.ncbi.nlm.nih.gov/1697649

DMK07MI	DI	DMK07MI
DMK07MI	DN	L-(cis)-diltiazem
DMK07MI	MI	TTW0QOV
DMK07MI	MN	Cyclic nucleotide-gated channel alpha-3 (CNGA3)
DMK07MI	MT	DTT
DMK07MI	MA	Inhibitor
DMK07MI	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 396).
DMK07MI	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=396

DMK07MI	DI	DMK07MI
DMK07MI	DN	L-(cis)-diltiazem
DMK07MI	MI	TT0LJCG
DMK07MI	MN	Cyclic nucleotide-gated channel beta-3 (CNGB3)
DMK07MI	MT	DTT
DMK07MI	MA	Blocker (channel blocker)
DMK07MI	RN	Molecular cloning and functional characterization of a new modulatory cyclic nucleotide-gated channel subunit from mouse retina. J Neurosci. 2000 Feb 15;20(4):1324-32.
DMK07MI	RU	https://pubmed.ncbi.nlm.nih.gov/10662822

DMK07MI	DI	DMK07MI
DMK07MI	DN	L-(cis)-diltiazem
DMK07MI	MI	TTJ0SO4
DMK07MI	MN	Voltage-gated calcium channel alpha Cav1.4 (CACNA1F)
DMK07MI	MT	DTT
DMK07MI	MA	Inhibitor (gating inhibitor)
DMK07MI	RN	Functional characterization of the L-type Ca2+ channel Cav1.4alpha1 from mouse retina. Invest Ophthalmol Vis Sci. 2004 Feb;45(2):708-13.
DMK07MI	RU	https://pubmed.ncbi.nlm.nih.gov/14744918

DMYWD6C	DI	DMYWD6C
DMYWD6C	DN	L000021649
DMYWD6C	MI	TTUTJGQ
DMYWD6C	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMYWD6C	MT	DTT
DMYWD6C	MA	Inhibitor
DMYWD6C	RN	Optimization of a pyrazolo[1,5-a]pyrimidine class of KDR kinase inhibitors: improvements in physical properties enhance cellular activity and pharm... Bioorg Med Chem Lett. 2002 Dec 16;12(24):3537-41.
DMYWD6C	RU	https://pubmed.ncbi.nlm.nih.gov/12443771

DM9KWUR	DI	DM9KWUR
DM9KWUR	DN	L023103
DM9KWUR	MI	TTSCIUP
DM9KWUR	MN	Oxytocin receptor (OTR)
DM9KWUR	MT	DTT
DM9KWUR	MA	Antagonist
DM9KWUR	RN	Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonists. J Med Chem. 2005 Dec 1;48(24):7882-905.
DM9KWUR	RU	https://pubmed.ncbi.nlm.nih.gov/16302826

DM9KWUR	DI	DM9KWUR
DM9KWUR	DN	L023103
DM9KWUR	MI	TT4TFGN
DM9KWUR	MN	Vasopressin V1a receptor (V1AR)
DM9KWUR	MT	DTT
DM9KWUR	MA	Antagonist
DM9KWUR	RN	Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonists. J Med Chem. 2005 Dec 1;48(24):7882-905.
DM9KWUR	RU	https://pubmed.ncbi.nlm.nih.gov/16302826

DMQR6ZX	DI	DMQR6ZX
DMQR6ZX	DN	L-054,522
DMQR6ZX	MI	TTZ6T9E
DMQR6ZX	MN	Somatostatin receptor type 2 (SSTR2)
DMQR6ZX	MT	DTT
DMQR6ZX	MA	Agonist
DMQR6ZX	RN	Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2. Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10836-41.
DMQR6ZX	RU	https://pubmed.ncbi.nlm.nih.gov/9724791

DMXB7G5	DI	DMXB7G5
DMXB7G5	DN	L-054852
DMXB7G5	MI	TTZ6T9E
DMXB7G5	MN	Somatostatin receptor type 2 (SSTR2)
DMXB7G5	MT	DTT
DMXB7G5	MA	Agonist
DMXB7G5	RN	Treatment strategies for acromegaly. Expert Opin Emerg Drugs. 2005 Nov;10(4):875-90.
DMXB7G5	RU	https://pubmed.ncbi.nlm.nih.gov/16262568

DMWNJV0	DI	DMWNJV0
DMWNJV0	DN	L-136662
DMWNJV0	MI	TTGP7BY
DMWNJV0	MN	Monoamine oxidase type B (MAO-B)
DMWNJV0	MT	DTT
DMWNJV0	MA	Inhibitor
DMWNJV0	RN	Identification of novel monoamine oxidase B inhibitors by structure-based virtual screening. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5295-8.
DMWNJV0	RU	https://pubmed.ncbi.nlm.nih.gov/20650633

DMVGX7Z	DI	DMVGX7Z
DMVGX7Z	DN	L-152,804
DMVGX7Z	MI	TTY6EWA
DMVGX7Z	MN	Neuropeptide Y receptor type 5 (NPY5R)
DMVGX7Z	MT	DTT
DMVGX7Z	MA	Antagonist
DMVGX7Z	RN	L-152,804: orally active and selective neuropeptide Y Y5 receptor antagonist. Biochem Biophys Res Commun. 2000 May 27;272(1):169-73.
DMVGX7Z	RU	https://pubmed.ncbi.nlm.nih.gov/10872822

DMOX8JE	DI	DMOX8JE
DMOX8JE	DN	L-159093
DMOX8JE	MI	TT8DBY3
DMOX8JE	MN	Angiotensin II receptor type-1 (AGTR1)
DMOX8JE	MT	DTT
DMOX8JE	MA	Inhibitor
DMOX8JE	RN	Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.
DMOX8JE	RU	https://pubmed.ncbi.nlm.nih.gov/16220969

DMOX8JE	DI	DMOX8JE
DMOX8JE	DN	L-159093
DMOX8JE	MI	TTQVOEI
DMOX8JE	MN	Angiotensin II receptor type-2 (AGTR2)
DMOX8JE	MT	DTT
DMOX8JE	MA	Inhibitor
DMOX8JE	RN	A potent, orally active, balanced affinity angiotensin II AT1 antagonist and AT2 binding inhibitor. J Med Chem. 1993 Oct 15;36(21):3207-10.
DMOX8JE	RU	https://pubmed.ncbi.nlm.nih.gov/8230109

DMZOW96	DI	DMZOW96
DMZOW96	DN	L-162313
DMZOW96	MI	TT8DBY3
DMZOW96	MN	Angiotensin II receptor type-1 (AGTR1)
DMZOW96	MT	DTT
DMZOW96	MA	Inhibitor
DMZOW96	RN	Selective angiotensin II AT2 receptor agonists: Benzamide structure-activity relationships. Bioorg Med Chem. 2008 Jul 15;16(14):6841-9.
DMZOW96	RU	https://pubmed.ncbi.nlm.nih.gov/18599297

DMZOW96	DI	DMZOW96
DMZOW96	DN	L-162313
DMZOW96	MI	TTQVOEI
DMZOW96	MN	Angiotensin II receptor type-2 (AGTR2)
DMZOW96	MT	DTT
DMZOW96	MA	Inhibitor
DMZOW96	RN	Selective angiotensin II AT(2) receptor agonists with reduced CYP 450 inhibition. Bioorg Med Chem. 2010 Jun 15;18(12):4570-90.
DMZOW96	RU	https://pubmed.ncbi.nlm.nih.gov/20493713

DMWSP6H	DI	DMWSP6H
DMWSP6H	DN	L-162782
DMWSP6H	MI	TT8DBY3
DMWSP6H	MN	Angiotensin II receptor type-1 (AGTR1)
DMWSP6H	MT	DTT
DMWSP6H	MA	Inhibitor
DMWSP6H	RN	Selective angiotensin II AT2 receptor agonists: Benzamide structure-activity relationships. Bioorg Med Chem. 2008 Jul 15;16(14):6841-9.
DMWSP6H	RU	https://pubmed.ncbi.nlm.nih.gov/18599297

DMYC7AK	DI	DMYC7AK
DMYC7AK	DN	L-163,101
DMYC7AK	MI	TT8DBY3
DMYC7AK	MN	Angiotensin II receptor type-1 (AGTR1)
DMYC7AK	MT	DTT
DMYC7AK	MA	Agonist
DMYC7AK	RN	Structural model of antagonist and agonist binding to the angiotensin II, AT1 subtype, G protein coupled receptor. Chem Biol. 1994 Dec;1(4):211-21.
DMYC7AK	RU	https://pubmed.ncbi.nlm.nih.gov/9383393

DMZP7YM	DI	DMZP7YM
DMZP7YM	DN	L-165041
DMZP7YM	MI	TT2JWF6
DMZP7YM	MN	Peroxisome proliferator-activated receptor delta (PPARD)
DMZP7YM	MT	DTT
DMZP7YM	MA	Agonist
DMZP7YM	RN	Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J Biol Chem. 1999 Mar 5;274(10):6718-25.
DMZP7YM	RU	https://pubmed.ncbi.nlm.nih.gov/10037770

DMKBSGN	DI	DMKBSGN
DMKBSGN	DN	L-165461
DMKBSGN	MI	TTJ584C
DMKBSGN	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMKBSGN	MT	DTT
DMKBSGN	MA	Inhibitor
DMKBSGN	RN	Phenylacetic acid derivatives as hPPAR agonists. Bioorg Med Chem Lett. 2003 Apr 7;13(7):1277-80.
DMKBSGN	RU	https://pubmed.ncbi.nlm.nih.gov/12657263

DMKBSGN	DI	DMKBSGN
DMKBSGN	DN	L-165461
DMKBSGN	MI	TT2JWF6
DMKBSGN	MN	Peroxisome proliferator-activated receptor delta (PPARD)
DMKBSGN	MT	DTT
DMKBSGN	MA	Inhibitor
DMKBSGN	RN	Phenylacetic acid derivatives as hPPAR agonists. Bioorg Med Chem Lett. 2003 Apr 7;13(7):1277-80.
DMKBSGN	RU	https://pubmed.ncbi.nlm.nih.gov/12657263

DMKBSGN	DI	DMKBSGN
DMKBSGN	DN	L-165461
DMKBSGN	MI	TTT2SVW
DMKBSGN	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DMKBSGN	MT	DTT
DMKBSGN	MA	Inhibitor
DMKBSGN	RN	Phenylacetic acid derivatives as hPPAR agonists. Bioorg Med Chem Lett. 2003 Apr 7;13(7):1277-80.
DMKBSGN	RU	https://pubmed.ncbi.nlm.nih.gov/12657263

DM3UGMD	DI	DM3UGMD
DM3UGMD	DN	L-168049
DM3UGMD	MI	TT9O6WS
DM3UGMD	MN	Glucagon receptor (GCGR)
DM3UGMD	MT	DTT
DM3UGMD	MA	Antagonist
DM3UGMD	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 251).
DM3UGMD	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=251

DMZ4KO0	DI	DMZ4KO0
DMZ4KO0	DN	L17
DMZ4KO0	MI	TT5FH9Y
DMZ4KO0	MN	Human immunodeficiency virus Integrase (HIV IN)
DMZ4KO0	MT	DTT
DMZ4KO0	MA	Inhibitor
DMZ4KO0	RN	Specific inhibition of human immunodeficiency virus type 1 (HIV-1) integration in cell culture: putative inhibitors of HIV-1 integrase. Antimicrob Agents Chemother. 2001 Sep;45(9):2510-6.
DMZ4KO0	RU	https://pubmed.ncbi.nlm.nih.gov/11502522

DMEK65F	DI	DMEK65F
DMEK65F	DN	L-249313
DMEK65F	MI	TTK25J1
DMEK65F	MN	Adenosine A1 receptor (ADORA1)
DMEK65F	MT	DTT
DMEK65F	MA	Inhibitor
DMEK65F	RN	2-Alkynyl-8-aryl-9-methyladenines as novel adenosine receptor antagonists: their synthesis and structure-activity relationships toward hepatic gluc... J Med Chem. 2001 Jan 18;44(2):170-9.
DMEK65F	RU	https://pubmed.ncbi.nlm.nih.gov/11170626

DMEK65F	DI	DMEK65F
DMEK65F	DN	L-249313
DMEK65F	MI	TTJFY5U
DMEK65F	MN	Adenosine A3 receptor (ADORA3)
DMEK65F	MT	DTT
DMEK65F	MA	Inhibitor
DMEK65F	RN	The utilization of a unified pharmacophore query in the discovery of new antagonists of the adenosine receptor family. Bioorg Med Chem Lett. 2000 Jan 3;10(1):31-4.
DMEK65F	RU	https://pubmed.ncbi.nlm.nih.gov/10636237

DMV6018	DI	DMV6018
DMV6018	DN	L-269,289
DMV6018	MI	TTX20QP
DMV6018	MN	Geranylgeranyl transferase I (GGTase-I)
DMV6018	MT	DTT
DMV6018	MA	Inhibitor
DMV6018	RN	Geranylgeranyltransferase I of Candida albicans: null mutants or enzyme inhibitors produce unexpected phenotypes. J Bacteriol. 2000 Feb;182(3):704-13.
DMV6018	RU	https://pubmed.ncbi.nlm.nih.gov/10633104

DMWQCRD	DI	DMWQCRD
DMWQCRD	DN	L-2-Amino-4-(Guanidinooxy)Butyric Acid
DMWQCRD	MI	TTCM4B3
DMWQCRD	MN	Nitric-oxide synthase endothelial (NOS3)
DMWQCRD	MT	DTT
DMWQCRD	MA	Inhibitor
DMWQCRD	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMWQCRD	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM1WMHO	DI	DM1WMHO
DM1WMHO	DN	L-365,209
DM1WMHO	MI	TTSCIUP
DM1WMHO	MN	Oxytocin receptor (OTR)
DM1WMHO	MT	DTT
DM1WMHO	MA	Antagonist
DM1WMHO	RN	Characterization of the human oxytocin receptor stably expressed in 293 human embryonic kidney cells. Life Sci. 1995;57(24):2253-61.
DM1WMHO	RU	https://pubmed.ncbi.nlm.nih.gov/7475979

DMGQE1B	DI	DMGQE1B
DMGQE1B	DN	L-366,509
DMGQE1B	MI	TTSCIUP
DMGQE1B	MN	Oxytocin receptor (OTR)
DMGQE1B	MT	DTT
DMGQE1B	MA	Antagonist
DMGQE1B	RN	Characterization of the human oxytocin receptor stably expressed in 293 human embryonic kidney cells. Life Sci. 1995;57(24):2253-61.
DMGQE1B	RU	https://pubmed.ncbi.nlm.nih.gov/7475979

DMAS5P8	DI	DMAS5P8
DMAS5P8	DN	L-366,682
DMAS5P8	MI	TTSCIUP
DMAS5P8	MN	Oxytocin receptor (OTR)
DMAS5P8	MT	DTT
DMAS5P8	MA	Antagonist
DMAS5P8	RN	Characterization of the human oxytocin receptor stably expressed in 293 human embryonic kidney cells. Life Sci. 1995;57(24):2253-61.
DMAS5P8	RU	https://pubmed.ncbi.nlm.nih.gov/7475979

DM31NXF	DI	DM31NXF
DM31NXF	DN	L-366,948
DM31NXF	MI	TTSCIUP
DM31NXF	MN	Oxytocin receptor (OTR)
DM31NXF	MT	DTT
DM31NXF	MA	Antagonist
DM31NXF	RN	Characterization of the human oxytocin receptor stably expressed in 293 human embryonic kidney cells. Life Sci. 1995;57(24):2253-61.
DM31NXF	RU	https://pubmed.ncbi.nlm.nih.gov/7475979

DMQ369D	DI	DMQ369D
DMQ369D	DN	L-367,773
DMQ369D	MI	TTSCIUP
DMQ369D	MN	Oxytocin receptor (OTR)
DMQ369D	MT	DTT
DMQ369D	MA	Antagonist
DMQ369D	RN	Characterization of the human oxytocin receptor stably expressed in 293 human embryonic kidney cells. Life Sci. 1995;57(24):2253-61.
DMQ369D	RU	https://pubmed.ncbi.nlm.nih.gov/7475979

DMC1Z0L	DI	DMC1Z0L
DMC1Z0L	DN	L-370,518
DMC1Z0L	MI	TT6L509
DMC1Z0L	MN	Coagulation factor IIa (F2)
DMC1Z0L	MT	DTT
DMC1Z0L	MA	Inhibitor
DMC1Z0L	RN	Assessment of thrombin inhibitor efficacy in a novel rabbit model of simultaneous arterial and venous thrombosis. Thromb Haemost. 1998 Mar;79(3):656-62.
DMC1Z0L	RU	https://pubmed.ncbi.nlm.nih.gov/9531058

DMQV974	DI	DMQV974
DMQV974	DN	L-372662
DMQV974	MI	TTSCIUP
DMQV974	MN	Oxytocin receptor (OTR)
DMQV974	MT	DTT
DMQV974	MA	Inhibitor
DMQV974	RN	Oral oxytocin antagonists. J Med Chem. 2010 Sep 23;53(18):6525-38.
DMQV974	RU	https://pubmed.ncbi.nlm.nih.gov/20550119

DMQV974	DI	DMQV974
DMQV974	DN	L-372662
DMQV974	MI	TT4TFGN
DMQV974	MN	Vasopressin V1a receptor (V1AR)
DMQV974	MT	DTT
DMQV974	MA	Inhibitor
DMQV974	RN	Oral oxytocin antagonists. J Med Chem. 2010 Sep 23;53(18):6525-38.
DMQV974	RU	https://pubmed.ncbi.nlm.nih.gov/20550119

DMQV974	DI	DMQV974
DMQV974	DN	L-372662
DMQV974	MI	TTK8R02
DMQV974	MN	Vasopressin V2 receptor (V2R)
DMQV974	MT	DTT
DMQV974	MA	Inhibitor
DMQV974	RN	Oral oxytocin antagonists. J Med Chem. 2010 Sep 23;53(18):6525-38.
DMQV974	RU	https://pubmed.ncbi.nlm.nih.gov/20550119

DMQWKPM	DI	DMQWKPM
DMQWKPM	DN	L-375378
DMQWKPM	MI	TT2WR1T
DMQWKPM	MN	Cationic trypsinogen (PRSS1)
DMQWKPM	MT	DTT
DMQWKPM	MA	Inhibitor
DMQWKPM	RN	Small, low nanomolar, noncovalent thrombin inhibitors lacking a group to fill the 'distal binding pocket'. Bioorg Med Chem Lett. 2003 Jan 20;13(2):161-4.
DMQWKPM	RU	https://pubmed.ncbi.nlm.nih.gov/12482415

DMQWKPM	DI	DMQWKPM
DMQWKPM	DN	L-375378
DMQWKPM	MI	TT6L509
DMQWKPM	MN	Coagulation factor IIa (F2)
DMQWKPM	MT	DTT
DMQWKPM	MA	Inhibitor
DMQWKPM	RN	Small, low nanomolar, noncovalent thrombin inhibitors lacking a group to fill the 'distal binding pocket'. Bioorg Med Chem Lett. 2003 Jan 20;13(2):161-4.
DMQWKPM	RU	https://pubmed.ncbi.nlm.nih.gov/12482415

DM0P4V6	DI	DM0P4V6
DM0P4V6	DN	L-454560
DM0P4V6	MI	TTZ97H5
DM0P4V6	MN	Phosphodiesterase 4A (PDE4A)
DM0P4V6	MT	DTT
DM0P4V6	MA	Inhibitor
DM0P4V6	RN	The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5502-5.
DM0P4V6	RU	https://pubmed.ncbi.nlm.nih.gov/20709547

DM0P4V6	DI	DM0P4V6
DM0P4V6	DN	L-454560
DM0P4V6	MI	TTVIAT9
DM0P4V6	MN	Phosphodiesterase 4B (PDE4B)
DM0P4V6	MT	DTT
DM0P4V6	MA	Inhibitor
DM0P4V6	RN	The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5502-5.
DM0P4V6	RU	https://pubmed.ncbi.nlm.nih.gov/20709547

DM0P4V6	DI	DM0P4V6
DM0P4V6	DN	L-454560
DM0P4V6	MI	TTSKMI8
DM0P4V6	MN	Phosphodiesterase 4D (PDE4D)
DM0P4V6	MT	DTT
DM0P4V6	MA	Inhibitor
DM0P4V6	RN	The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5502-5.
DM0P4V6	RU	https://pubmed.ncbi.nlm.nih.gov/20709547

DMHL901	DI	DMHL901
DMHL901	DN	L-5-(bromovinyl)deoxyuridine
DMHL901	MI	TTP3QRF
DMHL901	MN	Thymidine kinase 1 (TK1)
DMHL901	MT	DTT
DMHL901	MA	Inhibitor
DMHL901	RN	Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate anal... Antimicrob Agents Chemother. 2007 Jun;51(6):2028-34.
DMHL901	RU	https://pubmed.ncbi.nlm.nih.gov/17438061

DM3Q0JL	DI	DM3Q0JL
DM3Q0JL	DN	L-5-iodo-2'-deoxyuridine
DM3Q0JL	MI	TTP3QRF
DM3Q0JL	MN	Thymidine kinase 1 (TK1)
DM3Q0JL	MT	DTT
DM3Q0JL	MA	Inhibitor
DM3Q0JL	RN	Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate anal... Antimicrob Agents Chemother. 2007 Jun;51(6):2028-34.
DM3Q0JL	RU	https://pubmed.ncbi.nlm.nih.gov/17438061

DMENUOD	DI	DMENUOD
DMENUOD	DN	L-644,698
DMENUOD	MI	TTNVEIR
DMENUOD	MN	Prostaglandin D2 receptor (PTGDR)
DMENUOD	MT	DTT
DMENUOD	MA	Agonist
DMENUOD	RN	A novel biological role for prostaglandin D2 is suggested by distribution studies of the rat DP prostanoid receptor. Eur J Pharmacol. 1999 Jul 14;377(1):101-15.
DMENUOD	RU	https://pubmed.ncbi.nlm.nih.gov/10448933

DMA23LP	DI	DMA23LP
DMA23LP	DN	L-652,343
DMA23LP	MI	TT2J34L
DMA23LP	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMA23LP	MT	DTT
DMA23LP	MA	Inhibitor
DMA23LP	RN	Pharmacology of the dual inhibitor of cyclooxygenase and 5-lipoxygenase 3-hydroxy-5-trifluoromethyl-N-(2-(2-thienyl)-2-phenyl-ethenyl)-benzo (b)thiophene-2-carboxamide. Arzneimittelforschung. 1988 Mar;38(3):372-8.
DMA23LP	RU	https://pubmed.ncbi.nlm.nih.gov/3132928

DM360VU	DI	DM360VU
DM360VU	DN	L-652731
DM360VU	MI	TTQL5VC
DM360VU	MN	Platelet-activating factor receptor (PTAFR)
DM360VU	MT	DTT
DM360VU	MA	Inhibitor
DM360VU	RN	Development, synthesis, and biological evaluation of (-)-trans-(2S,5S)-2-[3-[(2-oxopropyl)sulfonyl]-4-n-propoxy-5-(3- hydroxypropoxy)-phenyl]-5-(3,... J Med Chem. 1992 Sep 18;35(19):3474-82.
DM360VU	RU	https://pubmed.ncbi.nlm.nih.gov/1404229

DM4CDIB	DI	DM4CDIB
DM4CDIB	DN	L-655708
DM4CDIB	MI	TT1MPAY
DM4CDIB	MN	GABA(A) receptor alpha-1 (GABRA1)
DM4CDIB	MT	DTT
DM4CDIB	MA	Inhibitor
DM4CDIB	RN	3-phenyl-6-(2-pyridyl)methyloxy-1,2,4-triazolo[3,4-a]phthalazines and analogues: high-affinity gamma-aminobutyric acid-A benzodiazepine receptor li... J Med Chem. 2004 Mar 25;47(7):1807-22.
DM4CDIB	RU	https://pubmed.ncbi.nlm.nih.gov/15027873

DM4CDIB	DI	DM4CDIB
DM4CDIB	DN	L-655708
DM4CDIB	MI	TTBMV1G
DM4CDIB	MN	GABA(A) receptor alpha-2 (GABRA2)
DM4CDIB	MT	DTT
DM4CDIB	MA	Inhibitor
DM4CDIB	RN	3-phenyl-6-(2-pyridyl)methyloxy-1,2,4-triazolo[3,4-a]phthalazines and analogues: high-affinity gamma-aminobutyric acid-A benzodiazepine receptor li... J Med Chem. 2004 Mar 25;47(7):1807-22.
DM4CDIB	RU	https://pubmed.ncbi.nlm.nih.gov/15027873

DM4CDIB	DI	DM4CDIB
DM4CDIB	DN	L-655708
DM4CDIB	MI	TT37EDJ
DM4CDIB	MN	GABA(A) receptor alpha-3 (GABRA3)
DM4CDIB	MT	DTT
DM4CDIB	MA	Inhibitor
DM4CDIB	RN	3-phenyl-6-(2-pyridyl)methyloxy-1,2,4-triazolo[3,4-a]phthalazines and analogues: high-affinity gamma-aminobutyric acid-A benzodiazepine receptor li... J Med Chem. 2004 Mar 25;47(7):1807-22.
DM4CDIB	RU	https://pubmed.ncbi.nlm.nih.gov/15027873

DM4CDIB	DI	DM4CDIB
DM4CDIB	DN	L-655708
DM4CDIB	MI	TTNZPQ1
DM4CDIB	MN	GABA(A) receptor alpha-5 (GABRA5)
DM4CDIB	MT	DTT
DM4CDIB	MA	Inhibitor
DM4CDIB	RN	3-phenyl-6-(2-pyridyl)methyloxy-1,2,4-triazolo[3,4-a]phthalazines and analogues: high-affinity gamma-aminobutyric acid-A benzodiazepine receptor li... J Med Chem. 2004 Mar 25;47(7):1807-22.
DM4CDIB	RU	https://pubmed.ncbi.nlm.nih.gov/15027873

DM4CDIB	DI	DM4CDIB
DM4CDIB	DN	L-655708
DM4CDIB	MI	TT06RH5
DM4CDIB	MN	GABA(A) receptor gamma-2 (GABRG2)
DM4CDIB	MT	DTT
DM4CDIB	MA	Inhibitor
DM4CDIB	RN	3-phenyl-6-(2-pyridyl)methyloxy-1,2,4-triazolo[3,4-a]phthalazines and analogues: high-affinity gamma-aminobutyric acid-A benzodiazepine receptor li... J Med Chem. 2004 Mar 25;47(7):1807-22.
DM4CDIB	RU	https://pubmed.ncbi.nlm.nih.gov/15027873

DM4CDIB	DI	DM4CDIB
DM4CDIB	DN	L-655708
DM4CDIB	MI	TTNJYV2
DM4CDIB	MN	Gamma-aminobutyric acid receptor (GAR)
DM4CDIB	MT	DTT
DM4CDIB	MA	Inhibitor
DM4CDIB	RN	3-phenyl-6-(2-pyridyl)methyloxy-1,2,4-triazolo[3,4-a]phthalazines and analogues: high-affinity gamma-aminobutyric acid-A benzodiazepine receptor li... J Med Chem. 2004 Mar 25;47(7):1807-22.
DM4CDIB	RU	https://pubmed.ncbi.nlm.nih.gov/15027873

DMY0IQ6	DI	DMY0IQ6
DMY0IQ6	DN	L-658,758
DMY0IQ6	MI	TTPLTSQ
DMY0IQ6	MN	Neutrophil elastase (NE)
DMY0IQ6	MT	DTT
DMY0IQ6	MA	Inhibitor
DMY0IQ6	RN	Neutrophil elastase promotes lung microvascular injury and proteolysis of endothelial cadherins. Am J Physiol. 1998 Aug;275(2 Pt 2):H385-92.
DMY0IQ6	RU	https://pubmed.ncbi.nlm.nih.gov/9683424

DMDF0KZ	DI	DMDF0KZ
DMDF0KZ	DN	L-659,699
DMDF0KZ	MI	TTQF4TK
DMDF0KZ	MN	Hydroxymethylglutaryl-CoA synthase 1 (HMGCS1)
DMDF0KZ	MT	DTT
DMDF0KZ	MA	Inhibitor
DMDF0KZ	RN	Inhibition of 3-hydroxy-3-methylglutaryl-CoA synthase and cholesterol biosynthesis by beta-lactone inhibitors and binding of these inhibitors to the enzyme. Biochem J. 1993 Feb 1;289 ( Pt 3):889-95.
DMDF0KZ	RU	https://pubmed.ncbi.nlm.nih.gov/8094614

DMP4QCJ	DI	DMP4QCJ
DMP4QCJ	DN	L-671,480
DMP4QCJ	MI	TTDMBF5
DMP4QCJ	MN	Arachidonate 5-lipoxygenase activating protein (FLAP)
DMP4QCJ	MT	DTT
DMP4QCJ	MA	Inhibitor
DMP4QCJ	RN	5-Lipoxygenase-activating protein is the target of a quinoline class of leukotriene synthesis inhibitors. Mol Pharmacol. 1991 Jul;40(1):22-7.
DMP4QCJ	RU	https://pubmed.ncbi.nlm.nih.gov/1857337

DMJUQT1	DI	DMJUQT1
DMJUQT1	DN	L-685,818
DMJUQT1	MI	TTA4LDE
DMJUQT1	MN	Calcineurin (PPP3CA)
DMJUQT1	MT	DTT
DMJUQT1	MA	Inhibitor
DMJUQT1	RN	Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. Antimicrob Agents Chemother. 2000 Mar;44(3):739-46.
DMJUQT1	RU	https://pubmed.ncbi.nlm.nih.gov/10681348

DMJUQT1	DI	DMJUQT1
DMJUQT1	DN	L-685,818
DMJUQT1	MI	TTQW87Y
DMJUQT1	MN	Opioid receptor kappa (OPRK1)
DMJUQT1	MT	DTT
DMJUQT1	MA	Antagonist
DMJUQT1	RN	FK-506-binding protein: three-dimensional structure of the complex with the antagonist L-685,818. J Biol Chem. 1993 May 25;268(15):11335-9.
DMJUQT1	RU	https://pubmed.ncbi.nlm.nih.gov/7684380

DMCH3ZK	DI	DMCH3ZK
DMCH3ZK	DN	L-689,037
DMCH3ZK	MI	TTDMBF5
DMCH3ZK	MN	Arachidonate 5-lipoxygenase activating protein (FLAP)
DMCH3ZK	MT	DTT
DMCH3ZK	MA	Inhibitor
DMCH3ZK	RN	5-Lipoxygenase-activating protein is the target of a novel hybrid of two classes of leukotriene biosynthesis inhibitors. Mol Pharmacol. 1992 Feb;41(2):267-72.
DMCH3ZK	RU	https://pubmed.ncbi.nlm.nih.gov/1538707

DM42BGX	DI	DM42BGX
DM42BGX	DN	L-689065
DM42BGX	MI	TTSJ6Q4
DM42BGX	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DM42BGX	MT	DTT
DM42BGX	MA	Inhibitor
DM42BGX	RN	Substituted thiopyrano[2,3,4-c,d]indoles as potent, selective, and orally active inhibitors of 5-lipoxygenase. Synthesis and biological evaluation ... J Med Chem. 1993 Sep 17;36(19):2771-87.
DM42BGX	RU	https://pubmed.ncbi.nlm.nih.gov/8410991

DMAB1RW	DI	DMAB1RW
DMAB1RW	DN	L-692289
DMAB1RW	MI	TTZMS1L
DMAB1RW	MN	Fungal Papulacandin B resistance protein 1 (Fung FKS1)
DMAB1RW	MT	DTT
DMAB1RW	MA	Inhibitor
DMAB1RW	RN	Antifungal lipopeptides: Structure-activity relationships of 3-hydroxyglutamine-modified pneumocandin B0 derivatives, Bioorg. Med. Chem. Lett. 5(20):2357-2362 (1995).
DMAB1RW	RU	http://www.sciencedirect.com/science/article/pii/0960894X9500407K

DMMUYHX	DI	DMMUYHX
DMMUYHX	DN	L-693612
DMMUYHX	MI	TTHQPL7
DMMUYHX	MN	Carbonic anhydrase I (CA-I)
DMMUYHX	MT	DTT
DMMUYHX	MA	Modulator
DMMUYHX	RN	Dose-dependent pharmacokinetics of L-693,612, a carbonic anhydrase inhibitor, following oral administration in rats. Pharm Res. 1994 Mar;11(3):438-41.
DMMUYHX	RU	https://pubmed.ncbi.nlm.nih.gov/8008713

DM92X5T	DI	DM92X5T
DM92X5T	DN	L-702-539
DM92X5T	MI	TTSJ6Q4
DM92X5T	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DM92X5T	MT	DTT
DM92X5T	MA	Inhibitor
DM92X5T	RN	Substituted (pyridylmethoxy)naphthalenes as potent and orally active 5-lipoxygenase inhibitors; synthesis, biological profile, and pharmacokinetics... J Med Chem. 1997 Aug 29;40(18):2866-75.
DM92X5T	RU	https://pubmed.ncbi.nlm.nih.gov/9288168

DMUOPRT	DI	DMUOPRT
DMUOPRT	DN	L-703,606
DMUOPRT	MI	TTZPO1L
DMUOPRT	MN	Substance-P receptor (TACR1)
DMUOPRT	MT	DTT
DMUOPRT	MA	Antagonist
DMUOPRT	RN	The unpredicted high affinities of a large number of naturally occurring tachykinins for chimeric NK1/NK3 receptors suggest a role for an inhibitory domain in determining receptor specificity. J BiolChem. 1996 Aug 23;271(34):20250-7.
DMUOPRT	RU	https://pubmed.ncbi.nlm.nih.gov/8702757

DMWYIJ3	DI	DMWYIJ3
DMWYIJ3	DN	L-708,906
DMWYIJ3	MI	TT5FH9Y
DMWYIJ3	MN	Human immunodeficiency virus Integrase (HIV IN)
DMWYIJ3	MT	DTT
DMWYIJ3	MA	Inhibitor
DMWYIJ3	RN	Specific inhibition of human immunodeficiency virus type 1 (HIV-1) integration in cell culture: putative inhibitors of HIV-1 integrase. Antimicrob Agents Chemother. 2001 Sep;45(9):2510-6.
DMWYIJ3	RU	https://pubmed.ncbi.nlm.nih.gov/11502522

DM3QUCS	DI	DM3QUCS
DM3QUCS	DN	L-708474
DM3QUCS	MI	TTCG0AL
DM3QUCS	MN	Cholecystokinin receptor type A (CCKAR)
DM3QUCS	MT	DTT
DM3QUCS	MA	Inhibitor
DM3QUCS	RN	High-affinity and potent, water-soluble 5-amino-1,4-benzodiazepine CCKB/gastrin receptor antagonists containing a cationic solubilizing group. J Med Chem. 1994 Mar 18;37(6):719-21.
DM3QUCS	RU	https://pubmed.ncbi.nlm.nih.gov/8145219

DMLMV9P	DI	DMLMV9P
DMLMV9P	DN	L-708568
DMLMV9P	MI	TTZPO1L
DMLMV9P	MN	Substance-P receptor (TACR1)
DMLMV9P	MT	DTT
DMLMV9P	MA	Inhibitor
DMLMV9P	RN	N-acyl-L-tryptophan benzyl esters: potent substance P receptor antagonists. J Med Chem. 1993 Jul 9;36(14):2044-5.
DMLMV9P	RU	https://pubmed.ncbi.nlm.nih.gov/8393115

DM9KCYQ	DI	DM9KCYQ
DM9KCYQ	DN	L-709,587
DM9KCYQ	MI	TTMW94E
DM9KCYQ	MN	FK506-binding protein 1A (FKBP1A)
DM9KCYQ	MT	DTT
DM9KCYQ	MA	Inhibitor
DM9KCYQ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9KCYQ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM7YVUT	DI	DM7YVUT
DM7YVUT	DN	L-731,988
DM7YVUT	MI	TT5FH9Y
DM7YVUT	MN	Human immunodeficiency virus Integrase (HIV IN)
DM7YVUT	MT	DTT
DM7YVUT	MA	Inhibitor
DM7YVUT	RN	Specific inhibition of human immunodeficiency virus type 1 (HIV-1) integration in cell culture: putative inhibitors of HIV-1 integrase. Antimicrob Agents Chemother. 2001 Sep;45(9):2510-6.
DM7YVUT	RU	https://pubmed.ncbi.nlm.nih.gov/11502522

DM8WCUY	DI	DM8WCUY
DM8WCUY	DN	L-731120
DM8WCUY	MI	TTFQEO5
DM8WCUY	MN	Squalene synthetase (FDFT1)
DM8WCUY	MT	DTT
DM8WCUY	MA	Inhibitor
DM8WCUY	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 645).
DM8WCUY	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=645

DMTHLUN	DI	DMTHLUN
DMTHLUN	DN	L-731128
DMTHLUN	MI	TTFQEO5
DMTHLUN	MN	Squalene synthetase (FDFT1)
DMTHLUN	MT	DTT
DMTHLUN	MA	Inhibitor
DMTHLUN	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 645).
DMTHLUN	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=645

DMDNVTF	DI	DMDNVTF
DMDNVTF	DN	L-734115
DMDNVTF	MI	TTJA1ZO
DMDNVTF	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMDNVTF	MT	DTT
DMDNVTF	MA	Inhibitor
DMDNVTF	RN	Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J Med Chem. 2000 Sep 21;43(19):3453-73.
DMDNVTF	RU	https://pubmed.ncbi.nlm.nih.gov/10999999

DMY60MG	DI	DMY60MG
DMY60MG	DN	L-735,821
DMY60MG	MI	TT846HF
DMY60MG	MN	Voltage-gated potassium channel Kv7.1 (KCNQ1)
DMY60MG	MT	DTT
DMY60MG	MA	Blocker
DMY60MG	RN	Molecular determinants of KCNQ1 channel block by a benzodiazepine. Mol Pharmacol. 2003 Jul;64(1):70-7.
DMY60MG	RU	https://pubmed.ncbi.nlm.nih.gov/12815162

DM8BVJQ	DI	DM8BVJQ
DM8BVJQ	DN	L-735021
DM8BVJQ	MI	TTFQEO5
DM8BVJQ	MN	Squalene synthetase (FDFT1)
DM8BVJQ	MT	DTT
DM8BVJQ	MA	Inhibitor
DM8BVJQ	RN	Structure-activity relationships of C1 and C6 side chains of zaragozic acid A derivatives. J Med Chem. 1994 Nov 11;37(23):4031-51.
DM8BVJQ	RU	https://pubmed.ncbi.nlm.nih.gov/7966163

DMJNLSI	DI	DMJNLSI
DMJNLSI	DN	L-736281
DMJNLSI	MI	TTZPO1L
DMJNLSI	MN	Substance-P receptor (TACR1)
DMJNLSI	MT	DTT
DMJNLSI	MA	Inhibitor
DMJNLSI	RN	N-heteroaryl-2-phenyl-3-(benzyloxy)piperidines: a novel class of potent orally active human NK1 antagonists. J Med Chem. 1996 Jul 19;39(15):2907-14.
DMJNLSI	RU	https://pubmed.ncbi.nlm.nih.gov/8709125

DMM5AYL	DI	DMM5AYL
DMM5AYL	DN	L-736380
DMM5AYL	MI	TTCG0AL
DMM5AYL	MN	Cholecystokinin receptor type A (CCKAR)
DMM5AYL	MT	DTT
DMM5AYL	MA	Antagonist
DMM5AYL	RN	Controlled modification of acidity in cholecystokinin B receptor antagonists: N-(1,4-benzodiazepin-3-yl)-N'-[3-(tetrazol-5-ylamino) phenyl]ureas. J Med Chem. 1996 Feb 16;39(4):842-9.
DMM5AYL	RU	https://pubmed.ncbi.nlm.nih.gov/8632408

DMAHC9Z	DI	DMAHC9Z
DMAHC9Z	DN	L-739750
DMAHC9Z	MI	TT7WZIJ
DMAHC9Z	MN	CAAX farnesyltransferase beta (FNTB)
DMAHC9Z	MT	DTT
DMAHC9Z	MA	Inhibitor
DMAHC9Z	RN	Ras farnesyltransferase: a new therapeutic target. J Med Chem. 1997 Sep 12;40(19):2971-90.
DMAHC9Z	RU	https://pubmed.ncbi.nlm.nih.gov/9301658

DM5IAXN	DI	DM5IAXN
DM5IAXN	DN	L-739758
DM5IAXN	MI	TTJA1ZO
DM5IAXN	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DM5IAXN	MT	DTT
DM5IAXN	MA	Inhibitor
DM5IAXN	RN	Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J Med Chem. 2000 Sep 21;43(19):3453-73.
DM5IAXN	RU	https://pubmed.ncbi.nlm.nih.gov/10999999

DMVA2D0	DI	DMVA2D0
DMVA2D0	DN	L-740093
DMVA2D0	MI	TTCG0AL
DMVA2D0	MN	Cholecystokinin receptor type A (CCKAR)
DMVA2D0	MT	DTT
DMVA2D0	MA	Inhibitor
DMVA2D0	RN	C5-piperazinyl-1,4-benzodiazepines, water-soluble, orally bioa vailable CCKB/gastrin receptor antagonists, Bioorg. Med. Chem. Lett. 5(24):3023-3026 (1995).
DMVA2D0	RU	http://www.sciencedirect.com/science/article/pii/0960894X95005300

DMCYQJF	DI	DMCYQJF
DMCYQJF	DN	L-741626
DMCYQJF	MI	TTEX248
DMCYQJF	MN	Dopamine D2 receptor (D2R)
DMCYQJF	MT	DTT
DMCYQJF	MA	Inhibitor
DMCYQJF	RN	Synthesis and characterization of selective dopamine D2 receptor antagonists. 2. Azaindole, benzofuran, and benzothiophene analogs of L-741,626. Bioorg Med Chem. 2010 Jul 15;18(14):5291-300. 
DMCYQJF	RU	https://pubmed.ncbi.nlm.nih.gov/20542439

DMCYQJF	DI	DMCYQJF
DMCYQJF	DN	L-741626
DMCYQJF	MI	TT4C8EA
DMCYQJF	MN	Dopamine D3 receptor (D3R)
DMCYQJF	MT	DTT
DMCYQJF	MA	Inhibitor
DMCYQJF	RN	Synthesis and characterization of selective dopamine D2 receptor antagonists. 2. Azaindole, benzofuran, and benzothiophene analogs of L-741,626. Bioorg Med Chem. 2010 Jul 15;18(14):5291-300. 
DMCYQJF	RU	https://pubmed.ncbi.nlm.nih.gov/20542439

DMCYQJF	DI	DMCYQJF
DMCYQJF	DN	L-741626
DMCYQJF	MI	TTE0A2F
DMCYQJF	MN	Dopamine D4 receptor (D4R)
DMCYQJF	MT	DTT
DMCYQJF	MA	Inhibitor
DMCYQJF	RN	Synthesis and characterization of selective dopamine D2 receptor antagonists. 2. Azaindole, benzofuran, and benzothiophene analogs of L-741,626. Bioorg Med Chem. 2010 Jul 15;18(14):5291-300. 
DMCYQJF	RU	https://pubmed.ncbi.nlm.nih.gov/20542439

DMP75YK	DI	DMP75YK
DMP75YK	DN	L-741742
DMP75YK	MI	TT4C8EA
DMP75YK	MN	Dopamine D3 receptor (D3R)
DMP75YK	MT	DTT
DMP75YK	MA	Inhibitor
DMP75YK	RN	5-(4-Chlorophenyl)-4-methyl-3-(1-(2-phenylethyl)piperidin-4-yl)isoxazole: a potent, selective antagonist at human cloned dopamine D4 receptors. J Med Chem. 1996 May 10;39(10):1943-5.
DMP75YK	RU	https://pubmed.ncbi.nlm.nih.gov/8642551

DMP75YK	DI	DMP75YK
DMP75YK	DN	L-741742
DMP75YK	MI	TTE0A2F
DMP75YK	MN	Dopamine D4 receptor (D4R)
DMP75YK	MT	DTT
DMP75YK	MA	Inhibitor
DMP75YK	RN	5-(4-Chlorophenyl)-4-methyl-3-(1-(2-phenylethyl)piperidin-4-yl)isoxazole: a potent, selective antagonist at human cloned dopamine D4 receptors. J Med Chem. 1996 May 10;39(10):1943-5.
DMP75YK	RU	https://pubmed.ncbi.nlm.nih.gov/8642551

DMP75YK	DI	DMP75YK
DMP75YK	DN	L-741742
DMP75YK	MI	TTRK8B9
DMP75YK	MN	Sodium channel unspecific (NaC)
DMP75YK	MT	DTT
DMP75YK	MA	Inhibitor
DMP75YK	RN	1-(3-Cyanobenzylpiperidin-4-yl)-5-methyl-4-phenyl-1, 3-dihydroimidazol-2-one: a selective high-affinity antagonist for the human dopamine D(4) rece... J Med Chem. 1999 Jul 15;42(14):2706-15.
DMP75YK	RU	https://pubmed.ncbi.nlm.nih.gov/10411491

DMP75YK	DI	DMP75YK
DMP75YK	DN	L-741742
DMP75YK	MI	TTAXZ0K
DMP75YK	MN	Voltage-gated sodium channel alpha Nav1.3 (SCN3A)
DMP75YK	MT	DTT
DMP75YK	MA	Inhibitor
DMP75YK	RN	1-(3-Cyanobenzylpiperidin-4-yl)-5-methyl-4-phenyl-1, 3-dihydroimidazol-2-one: a selective high-affinity antagonist for the human dopamine D(4) rece... J Med Chem. 1999 Jul 15;42(14):2706-15.
DMP75YK	RU	https://pubmed.ncbi.nlm.nih.gov/10411491

DMRC8MT	DI	DMRC8MT
DMRC8MT	DN	L-746233
DMRC8MT	MI	TTJA1ZO
DMRC8MT	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMRC8MT	MT	DTT
DMRC8MT	MA	Inhibitor
DMRC8MT	RN	Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J Med Chem. 2000 Sep 21;43(19):3453-73.
DMRC8MT	RU	https://pubmed.ncbi.nlm.nih.gov/10999999

DMUY8MP	DI	DMUY8MP
DMUY8MP	DN	L-746530
DMUY8MP	MI	TTSJ6Q4
DMUY8MP	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DMUY8MP	MT	DTT
DMUY8MP	MA	Inhibitor
DMUY8MP	RN	Substituted coumarins as potent 5-lipoxygenase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2528-31.
DMUY8MP	RU	https://pubmed.ncbi.nlm.nih.gov/16464579

DMBPWSJ	DI	DMBPWSJ
DMBPWSJ	DN	L-747201
DMBPWSJ	MI	TTK8CXU
DMBPWSJ	MN	5-HT 1B receptor (HTR1B)
DMBPWSJ	MT	DTT
DMBPWSJ	MA	Inhibitor
DMBPWSJ	RN	Selective, orally active 5-HT1D receptor agonists as potential antimigraine agents. J Med Chem. 1997 Oct 24;40(22):3501-3.
DMBPWSJ	RU	https://pubmed.ncbi.nlm.nih.gov/9357515

DMBPWSJ	DI	DMBPWSJ
DMBPWSJ	DN	L-747201
DMBPWSJ	MI	TT6MSOK
DMBPWSJ	MN	5-HT 1D receptor (HTR1D)
DMBPWSJ	MT	DTT
DMBPWSJ	MA	Inhibitor
DMBPWSJ	RN	Selective, orally active 5-HT1D receptor agonists as potential antimigraine agents. J Med Chem. 1997 Oct 24;40(22):3501-3.
DMBPWSJ	RU	https://pubmed.ncbi.nlm.nih.gov/9357515

DMEGU5J	DI	DMEGU5J
DMEGU5J	DN	L748328
DMEGU5J	MI	TTMXGCW
DMEGU5J	MN	Adrenergic receptor beta-3 (ADRB3)
DMEGU5J	MT	DTT
DMEGU5J	MA	Antagonist
DMEGU5J	RN	Potent and selective human beta(3)-adrenergic receptor antagonists. J Pharmacol Exp Ther. 1999 Aug;290(2):649-55.
DMEGU5J	RU	https://pubmed.ncbi.nlm.nih.gov/10411574

DM7CPBU	DI	DM7CPBU
DM7CPBU	DN	L-748337
DM7CPBU	MI	TTMXGCW
DM7CPBU	MN	Adrenergic receptor beta-3 (ADRB3)
DM7CPBU	MT	DTT
DM7CPBU	MA	Antagonist
DM7CPBU	RN	Potent and selective human beta(3)-adrenergic receptor antagonists. J Pharmacol Exp Ther. 1999 Aug;290(2):649-55.
DM7CPBU	RU	https://pubmed.ncbi.nlm.nih.gov/10411574

DMJZXAF	DI	DMJZXAF
DMJZXAF	DN	L-748780
DMJZXAF	MI	TTVKILB
DMJZXAF	MN	Prostaglandin G/H synthase 2 (COX-2)
DMJZXAF	MT	DTT
DMJZXAF	MA	Inhibitor
DMJZXAF	RN	From indomethacin to a selective COX-2 inhibitor: Development of indolalkanoic acids as potent and selective cyclooxygenase-2 inhibitors, Bioorg. Med. Chem. Lett. 6(6):725-730 (1996).
DMJZXAF	RU	http://www.sciencedirect.com/science/article/pii/0960894X9600100X

DM2WUKF	DI	DM2WUKF
DM2WUKF	DN	L-750,667
DM2WUKF	MI	TTE0A2F
DM2WUKF	MN	Dopamine D4 receptor (D4R)
DM2WUKF	MT	DTT
DM2WUKF	MA	Antagonist
DM2WUKF	RN	Nonconserved residues in the second transmembrane-spanning domain of the D(4) dopamine receptor are molecular determinants of D(4)-selective pharmacology. Mol Pharmacol. 2000 Jan;57(1):144-52.
DM2WUKF	RU	https://pubmed.ncbi.nlm.nih.gov/10617689

DM9QAP4	DI	DM9QAP4
DM9QAP4	DN	L-750034
DM9QAP4	MI	TTJA1ZO
DM9QAP4	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DM9QAP4	MT	DTT
DM9QAP4	MA	Inhibitor
DM9QAP4	RN	Molecular model of the alpha(IIb)beta(3) integrin. J Med Chem. 2003 Dec 4;46(25):5316-25.
DM9QAP4	RU	https://pubmed.ncbi.nlm.nih.gov/14640540

DMEQWSB	DI	DMEQWSB
DMEQWSB	DN	L-756568
DMEQWSB	MI	TTJA1ZO
DMEQWSB	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMEQWSB	MT	DTT
DMEQWSB	MA	Inhibitor
DMEQWSB	RN	Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J Med Chem. 2000 Sep 21;43(19):3453-73.
DMEQWSB	RU	https://pubmed.ncbi.nlm.nih.gov/10999999

DMQJNDX	DI	DMQJNDX
DMQJNDX	DN	L-759,633
DMQJNDX	MI	TTMSFAW
DMQJNDX	MN	Cannabinoid receptor 2 (CB2)
DMQJNDX	MT	DTT
DMQJNDX	MA	Agonist
DMQJNDX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 57).
DMQJNDX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=57

DM5SOR4	DI	DM5SOR4
DM5SOR4	DN	L-759,656
DM5SOR4	MI	TTMSFAW
DM5SOR4	MN	Cannabinoid receptor 2 (CB2)
DM5SOR4	MT	DTT
DM5SOR4	MA	Agonist
DM5SOR4	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 57).
DM5SOR4	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=57

DMA9VDN	DI	DMA9VDN
DMA9VDN	DN	L-760790
DMA9VDN	MI	TT6MSOK
DMA9VDN	MN	5-HT 1D receptor (HTR1D)
DMA9VDN	MT	DTT
DMA9VDN	MA	Inhibitor
DMA9VDN	RN	3-(Piperazinylpropyl)indoles: selective, orally bioavailable h5-HT1D receptor agonists as potential antimigraine agents. J Med Chem. 1999 Feb 25;42(4):691-705.
DMA9VDN	RU	https://pubmed.ncbi.nlm.nih.gov/10052976

DM0A2MG	DI	DM0A2MG
DM0A2MG	DN	L-761000
DM0A2MG	MI	TTVKILB
DM0A2MG	MN	Prostaglandin G/H synthase 2 (COX-2)
DM0A2MG	MT	DTT
DM0A2MG	MA	Inhibitor
DM0A2MG	RN	From indomethacin to a selective COX-2 inhibitor: Development of indolalkanoic acids as potent and selective cyclooxygenase-2 inhibitors, Bioorg. Med. Chem. Lett. 6(6):725-730 (1996).
DM0A2MG	RU	http://www.sciencedirect.com/science/article/pii/0960894X9600100X

DMG5KVS	DI	DMG5KVS
DMG5KVS	DN	L-764406
DMG5KVS	MI	TTT2SVW
DMG5KVS	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DMG5KVS	MT	DTT
DMG5KVS	MA	Agonist
DMG5KVS	RN	L-764406 is a partial agonist of human peroxisome proliferator-activated receptor gamma. The role of Cys313 in ligand binding. J Biol Chem. 1999 Mar 19;274(12):7913-22.
DMG5KVS	RU	https://pubmed.ncbi.nlm.nih.gov/10075686

DMH0TUZ	DI	DMH0TUZ
DMH0TUZ	DN	L-765314
DMH0TUZ	MI	TTNGILX
DMH0TUZ	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMH0TUZ	MT	DTT
DMH0TUZ	MA	Inhibitor
DMH0TUZ	RN	Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
DMH0TUZ	RU	https://pubmed.ncbi.nlm.nih.gov/15664832

DM96SPJ	DI	DM96SPJ
DM96SPJ	DN	L-767679
DM96SPJ	MI	TTJA1ZO
DM96SPJ	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DM96SPJ	MT	DTT
DM96SPJ	MA	Inhibitor
DM96SPJ	RN	Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J Med Chem. 2000 Sep 21;43(19):3453-73.
DM96SPJ	RU	https://pubmed.ncbi.nlm.nih.gov/10999999

DM5O0CM	DI	DM5O0CM
DM5O0CM	DN	L-772,405
DM5O0CM	MI	TTSQIFT
DM5O0CM	MN	5-HT 1A receptor (HTR1A)
DM5O0CM	MT	DTT
DM5O0CM	MA	Agonist
DM5O0CM	RN	3-[3-(Piperidin-1-yl)propyl]indoles as highly selective h5-HT(1D) receptor agonists. J Med Chem. 1999 Dec 2;42(24):4981-5001.
DM5O0CM	RU	https://pubmed.ncbi.nlm.nih.gov/10585208

DM5O0CM	DI	DM5O0CM
DM5O0CM	DN	L-772,405
DM5O0CM	MI	TTK8CXU
DM5O0CM	MN	5-HT 1B receptor (HTR1B)
DM5O0CM	MT	DTT
DM5O0CM	MA	Agonist
DM5O0CM	RN	3-[3-(Piperidin-1-yl)propyl]indoles as highly selective h5-HT(1D) receptor agonists. J Med Chem. 1999 Dec 2;42(24):4981-5001.
DM5O0CM	RU	https://pubmed.ncbi.nlm.nih.gov/10585208

DM5O0CM	DI	DM5O0CM
DM5O0CM	DN	L-772,405
DM5O0CM	MI	TT6MSOK
DM5O0CM	MN	5-HT 1D receptor (HTR1D)
DM5O0CM	MT	DTT
DM5O0CM	MA	Antagonist
DM5O0CM	RN	3-[3-(Piperidin-1-yl)propyl]indoles as highly selective h5-HT(1D) receptor agonists. J Med Chem. 1999 Dec 2;42(24):4981-5001.
DM5O0CM	RU	https://pubmed.ncbi.nlm.nih.gov/10585208

DMMUAW5	DI	DMMUAW5
DMMUAW5	DN	L-779,976
DMMUAW5	MI	TTZ6T9E
DMMUAW5	MN	Somatostatin receptor type 2 (SSTR2)
DMMUAW5	MT	DTT
DMMUAW5	MA	Agonist
DMMUAW5	RN	Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science. 1998 Oct 23;282(5389):737-40.
DMMUAW5	RU	https://pubmed.ncbi.nlm.nih.gov/9784130

DM51B74	DI	DM51B74
DM51B74	DN	L-779450
DM51B74	MI	TT0EOB8
DM51B74	MN	B-Raf messenger RNA (BRAF mRNA)
DM51B74	MT	DTT
DM51B74	MA	Inhibitor
DM51B74	RN	The identification of potent and selective imidazole-based inhibitors of B-Raf kinase. Bioorg Med Chem Lett. 2006 Jan 15;16(2):378-81.
DM51B74	RU	https://pubmed.ncbi.nlm.nih.gov/16260133

DM51B74	DI	DM51B74
DM51B74	DN	L-779450
DM51B74	MI	TTRSMW9
DM51B74	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DM51B74	MT	DTT
DM51B74	MA	Inhibitor
DM51B74	RN	The identification of potent and selective imidazole-based inhibitors of B-Raf kinase. Bioorg Med Chem Lett. 2006 Jan 15;16(2):378-81.
DM51B74	RU	https://pubmed.ncbi.nlm.nih.gov/16260133

DM51B74	DI	DM51B74
DM51B74	DN	L-779450
DM51B74	MI	TT860QF
DM51B74	MN	LCK tyrosine protein kinase (LCK)
DM51B74	MT	DTT
DM51B74	MA	Inhibitor
DM51B74	RN	The identification of potent and selective imidazole-based inhibitors of B-Raf kinase. Bioorg Med Chem Lett. 2006 Jan 15;16(2):378-81.
DM51B74	RU	https://pubmed.ncbi.nlm.nih.gov/16260133

DM51B74	DI	DM51B74
DM51B74	DN	L-779450
DM51B74	MI	TTQBR95
DM51B74	MN	Stress-activated protein kinase 2a (p38 alpha)
DM51B74	MT	DTT
DM51B74	MA	Inhibitor
DM51B74	RN	The identification of potent and selective imidazole-based inhibitors of B-Raf kinase. Bioorg Med Chem Lett. 2006 Jan 15;16(2):378-81.
DM51B74	RU	https://pubmed.ncbi.nlm.nih.gov/16260133

DM51B74	DI	DM51B74
DM51B74	DN	L-779450
DM51B74	MI	TT73U6C
DM51B74	MN	Stress-activated protein kinase 2b (p38 beta)
DM51B74	MT	DTT
DM51B74	MA	Inhibitor
DM51B74	RN	The identification of potent and selective imidazole-based inhibitors of B-Raf kinase. Bioorg Med Chem Lett. 2006 Jan 15;16(2):378-81.
DM51B74	RU	https://pubmed.ncbi.nlm.nih.gov/16260133

DM6OTGE	DI	DM6OTGE
DM6OTGE	DN	L-783483
DM6OTGE	MI	TTECBXN
DM6OTGE	MN	Oxysterols receptor LXR-alpha (NR1H3)
DM6OTGE	MT	DTT
DM6OTGE	MA	Agonist
DM6OTGE	RN	A novel liver X receptor agonist establishes species differences in the regulation of cholesterol 7alpha-hydroxylase (CYP7a). Endocrinology. 2002 Jul;143(7):2548-58.
DM6OTGE	RU	https://pubmed.ncbi.nlm.nih.gov/12072387

DM6OTGE	DI	DM6OTGE
DM6OTGE	DN	L-783483
DM6OTGE	MI	TTXA6PH
DM6OTGE	MN	Oxysterols receptor LXR-beta (NR1H2)
DM6OTGE	MT	DTT
DM6OTGE	MA	Agonist
DM6OTGE	RN	A novel liver X receptor agonist establishes species differences in the regulation of cholesterol 7alpha-hydroxylase (CYP7a). Endocrinology. 2002 Jul;143(7):2548-58.
DM6OTGE	RU	https://pubmed.ncbi.nlm.nih.gov/12072387

DM6OTGE	DI	DM6OTGE
DM6OTGE	DN	L-783483
DM6OTGE	MI	TT2JWF6
DM6OTGE	MN	Peroxisome proliferator-activated receptor delta (PPARD)
DM6OTGE	MT	DTT
DM6OTGE	MA	Agonist
DM6OTGE	RN	Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J Biol Chem. 1999 Mar 5;274(10):6718-25.
DM6OTGE	RU	https://pubmed.ncbi.nlm.nih.gov/10037770

DM6OTGE	DI	DM6OTGE
DM6OTGE	DN	L-783483
DM6OTGE	MI	TTT2SVW
DM6OTGE	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DM6OTGE	MT	DTT
DM6OTGE	MA	Agonist
DM6OTGE	RN	Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J Biol Chem. 1999 Mar 5;274(10):6718-25.
DM6OTGE	RU	https://pubmed.ncbi.nlm.nih.gov/10037770

DMJKAQR	DI	DMJKAQR
DMJKAQR	DN	L-790070
DMJKAQR	MI	TTAN5W2
DMJKAQR	MN	Raf messenger RNA (Raf mRNA)
DMJKAQR	MT	DTT
DMJKAQR	MA	Inhibitor
DMJKAQR	RN	Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of ... J Med Chem. 2008 Jul 24;51(14):4122-49.
DMJKAQR	RU	https://pubmed.ncbi.nlm.nih.gov/18578517

DM5D892	DI	DM5D892
DM5D892	DN	L-791943
DM5D892	MI	TTZ97H5
DM5D892	MN	Phosphodiesterase 4A (PDE4A)
DM5D892	MT	DTT
DM5D892	MA	Inhibitor
DM5D892	RN	Discovery of L-791,943: a potent, selective, non emetic and orally active phosphodiesterase-4 inhibitor. Bioorg Med Chem Lett. 2002 Jun 3;12(11):1457-61.
DM5D892	RU	https://pubmed.ncbi.nlm.nih.gov/12031319

DMINOFE	DI	DMINOFE
DMINOFE	DN	L-796,778
DMINOFE	MI	TTJX3UE
DMINOFE	MN	Somatostatin receptor type 3 (SSTR3)
DMINOFE	MT	DTT
DMINOFE	MA	Agonist
DMINOFE	RN	Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science. 1998 Oct 23;282(5389):737-40.
DMINOFE	RU	https://pubmed.ncbi.nlm.nih.gov/9784130

DMWTGQM	DI	DMWTGQM
DMWTGQM	DN	L-796449
DMWTGQM	MI	TTJ584C
DMWTGQM	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMWTGQM	MT	DTT
DMWTGQM	MA	Inhibitor
DMWTGQM	RN	Phenylacetic acid derivatives as hPPAR agonists. Bioorg Med Chem Lett. 2003 Apr 7;13(7):1277-80.
DMWTGQM	RU	https://pubmed.ncbi.nlm.nih.gov/12657263

DMWTGQM	DI	DMWTGQM
DMWTGQM	DN	L-796449
DMWTGQM	MI	TT2JWF6
DMWTGQM	MN	Peroxisome proliferator-activated receptor delta (PPARD)
DMWTGQM	MT	DTT
DMWTGQM	MA	Inhibitor
DMWTGQM	RN	Phenylacetic acid derivatives as hPPAR agonists. Bioorg Med Chem Lett. 2003 Apr 7;13(7):1277-80.
DMWTGQM	RU	https://pubmed.ncbi.nlm.nih.gov/12657263

DMWTGQM	DI	DMWTGQM
DMWTGQM	DN	L-796449
DMWTGQM	MI	TTT2SVW
DMWTGQM	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DMWTGQM	MT	DTT
DMWTGQM	MA	Inhibitor
DMWTGQM	RN	Phenylacetic acid derivatives as hPPAR agonists. Bioorg Med Chem Lett. 2003 Apr 7;13(7):1277-80.
DMWTGQM	RU	https://pubmed.ncbi.nlm.nih.gov/12657263

DM96ASN	DI	DM96ASN
DM96ASN	DN	L-797,591
DM96ASN	MI	TTIND6G
DM96ASN	MN	Somatostatin receptor type 1 (SSTR1)
DM96ASN	MT	DTT
DM96ASN	MA	Agonist
DM96ASN	RN	Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science. 1998 Oct 23;282(5389):737-40.
DM96ASN	RU	https://pubmed.ncbi.nlm.nih.gov/9784130

DM4FMGJ	DI	DM4FMGJ
DM4FMGJ	DN	L-798,106
DM4FMGJ	MI	TTPNGDE
DM4FMGJ	MN	Prostaglandin E2 receptor EP3 (PTGER3)
DM4FMGJ	MT	DTT
DM4FMGJ	MA	Antagonist
DM4FMGJ	RN	Dual modulation of urinary bladder activity and urine flow by prostanoid EP3 receptors in the conscious rat. Br J Pharmacol. 2009 Sep;158(1):372-81.
DM4FMGJ	RU	https://pubmed.ncbi.nlm.nih.gov/19486006

DMWBRDK	DI	DMWBRDK
DMWBRDK	DN	L-803,087
DMWBRDK	MI	TTAE1BR
DMWBRDK	MN	Somatostatin receptor type 4 (SSTR4)
DMWBRDK	MT	DTT
DMWBRDK	MA	Agonist
DMWBRDK	RN	Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science. 1998 Oct 23;282(5389):737-40.
DMWBRDK	RU	https://pubmed.ncbi.nlm.nih.gov/9784130

DM8YT7X	DI	DM8YT7X
DM8YT7X	DN	L-817,818
DM8YT7X	MI	TTIND6G
DM8YT7X	MN	Somatostatin receptor type 1 (SSTR1)
DM8YT7X	MT	DTT
DM8YT7X	MA	Agonist
DM8YT7X	RN	Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science. 1998 Oct 23;282(5389):737-40.
DM8YT7X	RU	https://pubmed.ncbi.nlm.nih.gov/9784130

DM8YT7X	DI	DM8YT7X
DM8YT7X	DN	L-817,818
DM8YT7X	MI	TT2BC4G
DM8YT7X	MN	Somatostatin receptor type 5 (SSTR5)
DM8YT7X	MT	DTT
DM8YT7X	MA	Agonist
DM8YT7X	RN	Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science. 1998 Oct 23;282(5389):737-40.
DM8YT7X	RU	https://pubmed.ncbi.nlm.nih.gov/9784130

DMYJ6QZ	DI	DMYJ6QZ
DMYJ6QZ	DN	L-826266
DMYJ6QZ	MI	TTPNGDE
DMYJ6QZ	MN	Prostaglandin E2 receptor EP3 (PTGER3)
DMYJ6QZ	MT	DTT
DMYJ6QZ	MA	Antagonist
DMYJ6QZ	RN	Roles of affinity and lipophilicity in the slow kinetics of prostanoid receptor antagonists on isolated smooth muscle preparations. Br J Pharmacol. 2011 Feb;162(4):863-79.
DMYJ6QZ	RU	https://pubmed.ncbi.nlm.nih.gov/20973775

DMKEDU6	DI	DMKEDU6
DMKEDU6	DN	L-869298
DMKEDU6	MI	TTZ97H5
DMKEDU6	MN	Phosphodiesterase 4A (PDE4A)
DMKEDU6	MT	DTT
DMKEDU6	MA	Inhibitor
DMKEDU6	RN	Enantiomer discrimination illustrated by the high resolution crystal structures of type 4 phosphodiesterase. J Med Chem. 2006 Mar 23;49(6):1867-73.
DMKEDU6	RU	https://pubmed.ncbi.nlm.nih.gov/16539372

DMKEDU6	DI	DMKEDU6
DMKEDU6	DN	L-869298
DMKEDU6	MI	TTVIAT9
DMKEDU6	MN	Phosphodiesterase 4B (PDE4B)
DMKEDU6	MT	DTT
DMKEDU6	MA	Inhibitor
DMKEDU6	RN	Enantiomer discrimination illustrated by the high resolution crystal structures of type 4 phosphodiesterase. J Med Chem. 2006 Mar 23;49(6):1867-73.
DMKEDU6	RU	https://pubmed.ncbi.nlm.nih.gov/16539372

DMKEDU6	DI	DMKEDU6
DMKEDU6	DN	L-869298
DMKEDU6	MI	TTSKMI8
DMKEDU6	MN	Phosphodiesterase 4D (PDE4D)
DMKEDU6	MT	DTT
DMKEDU6	MA	Inhibitor
DMKEDU6	RN	Enantiomer discrimination illustrated by the high resolution crystal structures of type 4 phosphodiesterase. J Med Chem. 2006 Mar 23;49(6):1867-73.
DMKEDU6	RU	https://pubmed.ncbi.nlm.nih.gov/16539372

DMUP516	DI	DMUP516
DMUP516	DN	L-873724
DMUP516	MI	TTF2LRI
DMUP516	MN	Cathepsin B (CTSB)
DMUP516	MT	DTT
DMUP516	MA	Inhibitor
DMUP516	RN	The identification of potent, selective, and bioavailable cathepsin S inhibitors. Bioorg Med Chem Lett. 2007 Sep 1;17(17):4929-33.
DMUP516	RU	https://pubmed.ncbi.nlm.nih.gov/17590332

DMUP516	DI	DMUP516
DMUP516	DN	L-873724
DMUP516	MI	TTDZN01
DMUP516	MN	Cathepsin K (CTSK)
DMUP516	MT	DTT
DMUP516	MA	Inhibitor
DMUP516	RN	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett. 2008 Feb 1;18(3):923-8.
DMUP516	RU	https://pubmed.ncbi.nlm.nih.gov/18226527

DMUP516	DI	DMUP516
DMUP516	DN	L-873724
DMUP516	MI	TT36ETB
DMUP516	MN	Cathepsin L (CTSL)
DMUP516	MT	DTT
DMUP516	MA	Inhibitor
DMUP516	RN	The identification of potent, selective, and bioavailable cathepsin S inhibitors. Bioorg Med Chem Lett. 2007 Sep 1;17(17):4929-33.
DMUP516	RU	https://pubmed.ncbi.nlm.nih.gov/17590332

DMUP516	DI	DMUP516
DMUP516	DN	L-873724
DMUP516	MI	TTUMQVO
DMUP516	MN	Cathepsin S (CTSS)
DMUP516	MT	DTT
DMUP516	MA	Inhibitor
DMUP516	RN	The identification of potent, selective, and bioavailable cathepsin S inhibitors. Bioorg Med Chem Lett. 2007 Sep 1;17(17):4929-33.
DMUP516	RU	https://pubmed.ncbi.nlm.nih.gov/17590332

DMMAIQ2	DI	DMMAIQ2
DMMAIQ2	DN	L-888,291
DMMAIQ2	MI	TTNVEIR
DMMAIQ2	MN	Prostaglandin D2 receptor (PTGDR)
DMMAIQ2	MT	DTT
DMMAIQ2	MA	Agonist
DMMAIQ2	RN	Identification of a potent and selective synthetic agonist at the CRTH2 receptor. Mol Pharmacol. 2005 Jun;67(6):1834-9.
DMMAIQ2	RU	https://pubmed.ncbi.nlm.nih.gov/15755909

DMMAIQ2	DI	DMMAIQ2
DMMAIQ2	DN	L-888,291
DMMAIQ2	MI	TTQDMX5
DMMAIQ2	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMMAIQ2	MT	DTT
DMMAIQ2	MA	Agonist
DMMAIQ2	RN	Identification of a potent and selective synthetic agonist at the CRTH2 receptor. Mol Pharmacol. 2005 Jun;67(6):1834-9.
DMMAIQ2	RU	https://pubmed.ncbi.nlm.nih.gov/15755909

DMJCTWO	DI	DMJCTWO
DMJCTWO	DN	L-888607
DMJCTWO	MI	TTQDMX5
DMJCTWO	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMJCTWO	MT	DTT
DMJCTWO	MA	Inhibitor
DMJCTWO	RN	Indole-3-acetic acid antagonists of the prostaglandin D2 receptor CRTH2. J Med Chem. 2005 Oct 6;48(20):6174-7.
DMJCTWO	RU	https://pubmed.ncbi.nlm.nih.gov/16190744

DMIORW9	DI	DMIORW9
DMIORW9	DN	L902688
DMIORW9	MI	TT79WV3
DMIORW9	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DMIORW9	MT	DTT
DMIORW9	MA	Agonist
DMIORW9	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 343).
DMIORW9	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=343

DMYDR2N	DI	DMYDR2N
DMYDR2N	DN	L-97-1 intravenous
DMYDR2N	MI	TTK25J1
DMYDR2N	MN	Adenosine A1 receptor (ADORA1)
DMYDR2N	MT	DTT
DMYDR2N	MA	Modulator
DMYDR2N	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 18).
DMYDR2N	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=18

DMY6K2A	DI	DMY6K2A
DMY6K2A	DN	LA22-radioimmunoconjugates
DMY6K2A	MI	TTGKNB4
DMY6K2A	MN	Epidermal growth factor receptor (EGFR)
DMY6K2A	MT	DTT
DMY6K2A	MA	Modulator
DMY6K2A	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
DMY6K2A	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797

DMP1V8Y	DI	DMP1V8Y
DMP1V8Y	DN	LA-480
DMP1V8Y	MI	TTNDSF4
DMP1V8Y	MN	Proto-oncogene c-Met (MET)
DMP1V8Y	MT	DTT
DMP1V8Y	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
DMP1V8Y	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815

DMJIU3Y	DI	DMJIU3Y
DMJIU3Y	DN	Lactoferrin
DMJIU3Y	MI	TTM1TDX
DMJIU3Y	MN	Tryptase alpha/beta-1 (Tryptase)
DMJIU3Y	MT	DTT
DMJIU3Y	MA	Inhibitor
DMJIU3Y	RN	Inhibitors of tryptase for the treatment of mast cell-mediated diseases. Curr Pharm Des. 1998 Oct;4(5):381-96.
DMJIU3Y	RU	https://pubmed.ncbi.nlm.nih.gov/10197050

DMZ0O1X	DI	DMZ0O1X
DMZ0O1X	DN	Lactoquinomycin
DMZ0O1X	MI	TTWTSCV
DMZ0O1X	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DMZ0O1X	MT	DTT
DMZ0O1X	MA	Inhibitor
DMZ0O1X	RN	The PI3K/Akt pathway as a target in the treatment of hematologic malignancies. Anticancer Agents Med Chem. 2009 Jun;9(5):550-9.
DMZ0O1X	RU	https://pubmed.ncbi.nlm.nih.gov/19519296

DMM0Z6Y	DI	DMM0Z6Y
DMM0Z6Y	DN	Lactose
DMM0Z6Y	MI	TT50QJ3
DMM0Z6Y	MN	Influenza Neuraminidase (Influ NA)
DMM0Z6Y	MT	DTT
DMM0Z6Y	MA	Inhibitor
DMM0Z6Y	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMM0Z6Y	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMTZ17V	DI	DMTZ17V
DMTZ17V	DN	Laevulinic Acid
DMTZ17V	MI	TTJHKYD
DMTZ17V	MN	Delta-aminolevulinic acid dehydratase (ALAD)
DMTZ17V	MT	DTT
DMTZ17V	MA	Inhibitor
DMTZ17V	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMTZ17V	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMH6XTP	DI	DMH6XTP
DMH6XTP	DN	L-Ala-L-boroPro
DMH6XTP	MI	TTDIGC1
DMH6XTP	MN	Dipeptidyl peptidase 4 (DPP-4)
DMH6XTP	MT	DTT
DMH6XTP	MA	Inhibitor
DMH6XTP	RN	Synthesis and characterization of constrained peptidomimetic dipeptidyl peptidase IV inhibitors: amino-lactam boroalanines. J Med Chem. 2007 May 17;50(10):2391-8.
DMH6XTP	RU	https://pubmed.ncbi.nlm.nih.gov/17458948

DMLGK27	DI	DMLGK27
DMLGK27	DN	LA-N8
DMLGK27	MI	TT1290U
DMLGK27	MN	Coagulation factor VIII (F8)
DMLGK27	MT	DTT
DMLGK27	MA	Modulator
DMLGK27	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2607).
DMLGK27	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2607

DMHN74V	DI	DMHN74V
DMHN74V	DN	Lanosterol
DMHN74V	MI	DEZNP5G
DMHN74V	MN	Cytochrome P450 51B1 (cyp51)
DMHN74V	MT	DME
DMHN74V	MA	Metabolism
DMHN74V	RN	Function, essentiality, and expression of cytochrome P450 enzymes and their cognate redox partners in Mycobacterium tuberculosis: are they drug targets? Appl Microbiol Biotechnol. 2019 May;103(9):3597-3614.
DMHN74V	RU	https://pubmed.ncbi.nlm.nih.gov/30810776

DMHN74V	DI	DMHN74V
DMHN74V	DN	Lanosterol
DMHN74V	MI	DEVSF75
DMHN74V	MN	Cytochrome P450 monooxygenase 51A (cyp51A)
DMHN74V	MT	DME
DMHN74V	MA	Metabolism
DMHN74V	RN	The fungal CYP51s: their functions, structures, related drug resistance, and inhibitors. Front Microbiol. 2019 Apr 24;10:691.
DMHN74V	RU	https://pubmed.ncbi.nlm.nih.gov/31068906

DMHN74V	DI	DMHN74V
DMHN74V	DN	Lanosterol
DMHN74V	MI	TT7O8ZA
DMHN74V	MN	Lanosterol synthase (LSS)
DMHN74V	MT	DTT
DMHN74V	MA	Inhibitor
DMHN74V	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMHN74V	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMPJFGI	DI	DMPJFGI
DMPJFGI	DN	L-AP4
DMPJFGI	MI	TTICZ1O
DMPJFGI	MN	Metabotropic glutamate receptor 4 (mGluR4)
DMPJFGI	MT	DTT
DMPJFGI	MA	Agonist
DMPJFGI	RN	Ligand binding to the amino-terminal domain of the mGluR4 subtype of metabotropic glutamate receptor. J Biol Chem. 1999 Apr 9;274(15):10008-13.
DMPJFGI	RU	https://pubmed.ncbi.nlm.nih.gov/10187777

DMPJFGI	DI	DMPJFGI
DMPJFGI	DN	L-AP4
DMPJFGI	MI	TTWRP2F
DMPJFGI	MN	Metabotropic glutamate receptor 6 (mGluR6)
DMPJFGI	MT	DTT
DMPJFGI	MA	Agonist
DMPJFGI	RN	Cloning, distribution and functional expression of the human mGlu6 metabotropic glutamate receptor. Neuropharmacology. 1997 Feb;36(2):145-52.
DMPJFGI	RU	https://pubmed.ncbi.nlm.nih.gov/9144651

DMPJFGI	DI	DMPJFGI
DMPJFGI	DN	L-AP4
DMPJFGI	MI	TT0I76D
DMPJFGI	MN	Metabotropic glutamate receptor 7 (mGluR7)
DMPJFGI	MT	DTT
DMPJFGI	MA	Agonist
DMPJFGI	RN	Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 2000 Dec;362(6):546-54.
DMPJFGI	RU	https://pubmed.ncbi.nlm.nih.gov/11138847

DMPJFGI	DI	DMPJFGI
DMPJFGI	DN	L-AP4
DMPJFGI	MI	TT0IFKL
DMPJFGI	MN	Metabotropic glutamate receptor 8 (mGluR8)
DMPJFGI	MT	DTT
DMPJFGI	MA	Agonist
DMPJFGI	RN	Cloning and functional expression of alternative spliced variants of the human metabotropic glutamate receptor 8. Brain Res Mol Brain Res. 1999 Apr 20;67(2):201-10.
DMPJFGI	RU	https://pubmed.ncbi.nlm.nih.gov/10216218

DMSYLIJ	DI	DMSYLIJ
DMSYLIJ	DN	LARGAZOLE
DMSYLIJ	MI	TT6R7JZ
DMSYLIJ	MN	Histone deacetylase 1 (HDAC1)
DMSYLIJ	MT	DTT
DMSYLIJ	MA	Inhibitor
DMSYLIJ	RN	Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues. J Med Chem. 2010 Jun 24;53(12):4654-67.
DMSYLIJ	RU	https://pubmed.ncbi.nlm.nih.gov/20491440

DMSYLIJ	DI	DMSYLIJ
DMSYLIJ	DN	LARGAZOLE
DMSYLIJ	MI	TTTQGH8
DMSYLIJ	MN	Histone deacetylase 4 (HDAC4)
DMSYLIJ	MT	DTT
DMSYLIJ	MA	Inhibitor
DMSYLIJ	RN	Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues. J Med Chem. 2010 Jun 24;53(12):4654-67.
DMSYLIJ	RU	https://pubmed.ncbi.nlm.nih.gov/20491440

DMWGPO6	DI	DMWGPO6
DMWGPO6	DN	L-aspartic acid
DMWGPO6	MI	TTLD29N
DMWGPO6	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMWGPO6	MT	DTT
DMWGPO6	MA	Agonist
DMWGPO6	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455).
DMWGPO6	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=455

DMWGPO6	DI	DMWGPO6
DMWGPO6	DN	L-aspartic acid
DMWGPO6	MI	TTKJEMQ
DMWGPO6	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMWGPO6	MT	DTT
DMWGPO6	MA	Agonist
DMWGPO6	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456).
DMWGPO6	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=456

DMWGPO6	DI	DMWGPO6
DMWGPO6	DN	L-aspartic acid
DMWGPO6	MI	TTN9D8E
DMWGPO6	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMWGPO6	MT	DTT
DMWGPO6	MA	Agonist
DMWGPO6	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457).
DMWGPO6	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=457

DMWGPO6	DI	DMWGPO6
DMWGPO6	DN	L-aspartic acid
DMWGPO6	MI	TT1M8OW
DMWGPO6	MN	Glutamate receptor ionotropic NMDA 2C (GluN2C)
DMWGPO6	MT	DTT
DMWGPO6	MA	Agonist
DMWGPO6	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 458).
DMWGPO6	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=458

DMWGPO6	DI	DMWGPO6
DMWGPO6	DN	L-aspartic acid
DMWGPO6	MI	TT5POTG
DMWGPO6	MN	Glutamate receptor ionotropic NMDA 2D (GluN2D)
DMWGPO6	MT	DTT
DMWGPO6	MA	Agonist
DMWGPO6	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 459).
DMWGPO6	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=459

DMYNL40	DI	DMYNL40
DMYNL40	DN	LASSBio-881
DMYNL40	MI	TTMI6F5
DMYNL40	MN	Transient receptor potential cation channel V1 (TRPV1)
DMYNL40	MT	DTT
DMYNL40	MA	Agonist
DMYNL40	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 507).
DMYNL40	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=507

DMMDZ4B	DI	DMMDZ4B
DMMDZ4B	DN	LAU-0901
DMMDZ4B	MI	TTQL5VC
DMMDZ4B	MN	Platelet-activating factor receptor (PTAFR)
DMMDZ4B	MT	DTT
DMMDZ4B	MA	Antagonist
DMMDZ4B	RN	Superior Neuroprotective Efficacy of LAU-0901, a Novel Platelet-Activating Factor Antagonist, in Experimental Stroke. Transl Stroke Res. 2012 Mar;3(1):154-63.
DMMDZ4B	RU	https://pubmed.ncbi.nlm.nih.gov/22408693

DM9C8KQ	DI	DM9C8KQ
DM9C8KQ	DN	Lauric Acid
DM9C8KQ	MI	TTRFV0W
DM9C8KQ	MN	Bacterial Oxoacyl-[acyl-carrier-protein] synthase II (Bact fabF)
DM9C8KQ	MT	DTT
DM9C8KQ	MA	Inhibitor
DM9C8KQ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9C8KQ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9C8KQ	DI	DM9C8KQ
DM9C8KQ	DN	Lauric Acid
DM9C8KQ	MI	DECT13Q
DM9C8KQ	MN	Cytochrome P450 107L2 (cyp107)
DM9C8KQ	MT	DME
DM9C8KQ	MA	Metabolism
DM9C8KQ	RN	The metagenome of Caracolus marginella gut microbiome using culture independent approaches and shotgun sequencing. Data Brief. 2017 Nov 22;16:501-505.
DM9C8KQ	RU	https://pubmed.ncbi.nlm.nih.gov/29270447

DM9C8KQ	DI	DM9C8KQ
DM9C8KQ	DN	Lauric Acid
DM9C8KQ	MI	TTO8QRU
DM9C8KQ	MN	Group IIA phospholipase A2 (GIIA sPLA2)
DM9C8KQ	MT	DTT
DM9C8KQ	MA	Inhibitor
DM9C8KQ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9C8KQ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9C8KQ	DI	DM9C8KQ
DM9C8KQ	DN	Lauric Acid
DM9C8KQ	MI	TT2F3CD
DM9C8KQ	MN	Hepatocyte nuclear factor 4-alpha (HNF4A)
DM9C8KQ	MT	DTT
DM9C8KQ	MA	Inhibitor
DM9C8KQ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9C8KQ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9C8KQ	DI	DM9C8KQ
DM9C8KQ	DN	Lauric Acid
DM9C8KQ	MI	TTSZDQU
DM9C8KQ	MN	Lactotransferrin (LTF)
DM9C8KQ	MT	DTT
DM9C8KQ	MA	Inhibitor
DM9C8KQ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9C8KQ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9C8KQ	DI	DM9C8KQ
DM9C8KQ	DN	Lauric Acid
DM9C8KQ	MI	TT8S9AV
DM9C8KQ	MN	Lymphocyte antigen 96 (LY96)
DM9C8KQ	MT	DTT
DM9C8KQ	MA	Inhibitor
DM9C8KQ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9C8KQ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9C8KQ	DI	DM9C8KQ
DM9C8KQ	DN	Lauric Acid
DM9C8KQ	MI	TTPH97Y
DM9C8KQ	MN	Mycobacterium 3-oxoacyl-[acyl-carrier-protein] synthase 1 (MycB kasA)
DM9C8KQ	MT	DTT
DM9C8KQ	MA	Inhibitor
DM9C8KQ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9C8KQ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9C8KQ	DI	DM9C8KQ
DM9C8KQ	DN	Lauric Acid
DM9C8KQ	MI	TTISGCA
DM9C8KQ	MN	Toll-like receptor 4 (TLR4)
DM9C8KQ	MT	DTT
DM9C8KQ	MA	Inhibitor
DM9C8KQ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9C8KQ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9C8KQ	DI	DM9C8KQ
DM9C8KQ	DN	Lauric Acid
DM9C8KQ	MI	TTVBE0F
DM9C8KQ	MN	Virus Genome polyprotein (Viru POL)
DM9C8KQ	MT	DTT
DM9C8KQ	MA	Inhibitor
DM9C8KQ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9C8KQ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM3W2OE	DI	DM3W2OE
DM3W2OE	DN	Lauryl Dimethylamine-N-Oxide
DM3W2OE	MI	TTGP7BY
DM3W2OE	MN	Monoamine oxidase type B (MAO-B)
DM3W2OE	MT	DTT
DM3W2OE	MA	Inhibitor
DM3W2OE	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM3W2OE	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM3W2OE	DI	DM3W2OE
DM3W2OE	DN	Lauryl Dimethylamine-N-Oxide
DM3W2OE	MI	TT3PQ2Y
DM3W2OE	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DM3W2OE	MT	DTT
DM3W2OE	MA	Inhibitor
DM3W2OE	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM3W2OE	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM3W2OE	DI	DM3W2OE
DM3W2OE	DN	Lauryl Dimethylamine-N-Oxide
DM3W2OE	MI	TTH0KSX
DM3W2OE	MN	Rhodopsin (RHO)
DM3W2OE	MT	DTT
DM3W2OE	MA	Inhibitor
DM3W2OE	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM3W2OE	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMH3X06	DI	DMH3X06
DMH3X06	DN	LAVENDUSTIN A
DMH3X06	MI	TTGKNB4
DMH3X06	MN	Epidermal growth factor receptor (EGFR)
DMH3X06	MT	DTT
DMH3X06	MA	Inhibitor
DMH3X06	RN	Novel antiproliferative agents derived from lavendustin A. J Med Chem. 1994 Nov 25;37(24):4079-84.
DMH3X06	RU	https://pubmed.ncbi.nlm.nih.gov/7990108

DMH3X06	DI	DMH3X06
DMH3X06	DN	LAVENDUSTIN A
DMH3X06	MI	TT860QF
DMH3X06	MN	LCK tyrosine protein kinase (LCK)
DMH3X06	MT	DTT
DMH3X06	MA	Inhibitor
DMH3X06	RN	Non-amine based analogues of lavendustin A as protein-tyrosine kinase inhibitors. J Med Chem. 1993 Oct 1;36(20):3010-4.
DMH3X06	RU	https://pubmed.ncbi.nlm.nih.gov/8105084

DMOK6IP	DI	DMOK6IP
DMOK6IP	DN	LAVYPWT
DMOK6IP	MI	TT2THBD
DMOK6IP	MN	P2X purinoceptor 3 (P2RX3)
DMOK6IP	MT	DTT
DMOK6IP	MA	Inhibitor
DMOK6IP	RN	Structure-activity relationship studies of spinorphin as a potent and selective human P2X(3) receptor antagonist. J Med Chem. 2007 Sep 6;50(18):4543-7.
DMOK6IP	RU	https://pubmed.ncbi.nlm.nih.gov/17676725

DM5GNFO	DI	DM5GNFO
DM5GNFO	DN	LAWSARITOL
DM5GNFO	MI	TT1RS9F
DM5GNFO	MN	Acetylcholinesterase (AChE)
DM5GNFO	MT	DTT
DM5GNFO	MA	Inhibitor
DM5GNFO	RN	Isolation and cholinesterase-inhibition studies of sterols from Haloxylon recurvum. Bioorg Med Chem Lett. 2006 Feb;16(3):573-80.
DM5GNFO	RU	https://pubmed.ncbi.nlm.nih.gov/16274989

DM5GNFO	DI	DM5GNFO
DM5GNFO	DN	LAWSARITOL
DM5GNFO	MI	TTEB0GD
DM5GNFO	MN	Cholinesterase (BCHE)
DM5GNFO	MT	DTT
DM5GNFO	MA	Inhibitor
DM5GNFO	RN	Isolation and cholinesterase-inhibition studies of sterols from Haloxylon recurvum. Bioorg Med Chem Lett. 2006 Feb;16(3):573-80.
DM5GNFO	RU	https://pubmed.ncbi.nlm.nih.gov/16274989

DM3H9ZY	DI	DM3H9ZY
DM3H9ZY	DN	LB30812
DM3H9ZY	MI	TT6L509
DM3H9ZY	MN	Coagulation factor IIa (F2)
DM3H9ZY	MT	DTT
DM3H9ZY	MA	Inhibitor
DM3H9ZY	RN	Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide. J Med Chem. 2003 Aug 14;46(17):3612-22.
DM3H9ZY	RU	https://pubmed.ncbi.nlm.nih.gov/12904065

DM6RH19	DI	DM6RH19
DM6RH19	DN	LB42908
DM6RH19	MI	TT7WZIJ
DM6RH19	MN	CAAX farnesyltransferase beta (FNTB)
DM6RH19	MT	DTT
DM6RH19	MA	Inhibitor
DM6RH19	RN	A novel class of highly potent, selective, and non-peptidic inhibitor of Ras farnesyltransferase (FTase). Bioorg Med Chem Lett. 2001 Dec 3;11(23):3069-72.
DM6RH19	RU	https://pubmed.ncbi.nlm.nih.gov/11714612

DMENM1B	DI	DMENM1B
DMENM1B	DN	L-beta-BA
DMENM1B	MI	TTG2A6F
DMENM1B	MN	Excitatory amino acid transporter 3 (SLC1A1)
DMENM1B	MT	DTT
DMENM1B	MA	Inhibitor
DMENM1B	RN	The substituted aspartate analogue L-beta-threo-benzyl-aspartate preferentially inhibits the neuronal excitatory amino acid transporter EAAT3. Neuropharmacology. 2005 Nov;49(6):850-61.
DMENM1B	RU	https://pubmed.ncbi.nlm.nih.gov/16183084

DMTNQCE	DI	DMTNQCE
DMTNQCE	DN	L-betagamma-meATP
DMTNQCE	MI	TTCBFJO
DMTNQCE	MN	Insulin receptor (INSR)
DMTNQCE	MT	DTT
DMTNQCE	MA	Inhibitor
DMTNQCE	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMTNQCE	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMTNQCE	DI	DMTNQCE
DMTNQCE	DN	L-betagamma-meATP
DMTNQCE	MI	TTJW7B3
DMTNQCE	MN	P2X purinoceptor 1 (P2RX1)
DMTNQCE	MT	DTT
DMTNQCE	MA	Agonist
DMTNQCE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 478).
DMTNQCE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=478

DMTNQCE	DI	DMTNQCE
DMTNQCE	DN	L-betagamma-meATP
DMTNQCE	MI	TTXI3KF
DMTNQCE	MN	Pyridoxal kinase (PDXK)
DMTNQCE	MT	DTT
DMTNQCE	MA	Inhibitor
DMTNQCE	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMTNQCE	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMQ2DFN	DI	DMQ2DFN
DMQ2DFN	DN	LBQ657
DMQ2DFN	MI	TT5TKPM
DMQ2DFN	MN	Neutral endopeptidase (MME)
DMQ2DFN	MT	DTT
DMQ2DFN	MA	Inhibitor
DMQ2DFN	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1611).
DMQ2DFN	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1611

DMGWSCI	DI	DMGWSCI
DMGWSCI	DN	LC34AD3
DMGWSCI	MI	TT7QNVC
DMGWSCI	MN	Glucose-dependent insulinotropic receptor (GPR119)
DMGWSCI	MT	DTT
DMGWSCI	MA	Agonist
DMGWSCI	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 126).
DMGWSCI	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=126

DMYONVF	DI	DMYONVF
DMYONVF	DN	LC-445
DMYONVF	MI	TTIYVQP
DMYONVF	MN	Polo-like kinase 1 (PLK1)
DMYONVF	MT	DTT
DMYONVF	MA	Inhibitor
DMYONVF	RN	Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009 Jun;14(6):559-70.
DMYONVF	RU	https://pubmed.ncbi.nlm.nih.gov/19474163

DMPZ8XH	DI	DMPZ8XH
DMPZ8XH	DN	L-CCG-I
DMPZ8XH	MI	TTVBPDM
DMPZ8XH	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMPZ8XH	MT	DTT
DMPZ8XH	MA	Agonist
DMPZ8XH	RN	Characterization of [(3)H]Quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections. J Neurochem. 2000 Dec;75(6):2590-601.
DMPZ8XH	RU	https://pubmed.ncbi.nlm.nih.gov/11080213

DMPZ8XH	DI	DMPZ8XH
DMPZ8XH	DN	L-CCG-I
DMPZ8XH	MI	TTXJ47W
DMPZ8XH	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMPZ8XH	MT	DTT
DMPZ8XH	MA	Agonist
DMPZ8XH	RN	[3H]-LY341495 as a novel antagonist radioligand for group II metabotropic glutamate (mGlu) receptors: characterization of binding to membranes of mGlu receptor subtype expressing cells. Neuropharmacology. 1999 Oct;38(10):1519-29.
DMPZ8XH	RU	https://pubmed.ncbi.nlm.nih.gov/10530814

DMPZ8XH	DI	DMPZ8XH
DMPZ8XH	DN	L-CCG-I
DMPZ8XH	MI	TT8A9EF
DMPZ8XH	MN	Metabotropic glutamate receptor 3 (mGluR3)
DMPZ8XH	MT	DTT
DMPZ8XH	MA	Agonist
DMPZ8XH	RN	[3H]-LY341495 as a novel antagonist radioligand for group II metabotropic glutamate (mGlu) receptors: characterization of binding to membranes of mGlu receptor subtype expressing cells. Neuropharmacology. 1999 Oct;38(10):1519-29.
DMPZ8XH	RU	https://pubmed.ncbi.nlm.nih.gov/10530814

DMPZ8XH	DI	DMPZ8XH
DMPZ8XH	DN	L-CCG-I
DMPZ8XH	MI	TTICZ1O
DMPZ8XH	MN	Metabotropic glutamate receptor 4 (mGluR4)
DMPZ8XH	MT	DTT
DMPZ8XH	MA	Agonist
DMPZ8XH	RN	Agonist analysis of 2-(carboxycyclopropyl)glycine isomers for cloned metabotropic glutamate receptor subtypes expressed in Chinese hamster ovary cells. Br J Pharmacol. 1992 Oct;107(2):539-43.
DMPZ8XH	RU	https://pubmed.ncbi.nlm.nih.gov/1330184

DMPZ8XH	DI	DMPZ8XH
DMPZ8XH	DN	L-CCG-I
DMPZ8XH	MI	TTHS256
DMPZ8XH	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMPZ8XH	MT	DTT
DMPZ8XH	MA	Agonist
DMPZ8XH	RN	Characterization of [(3)H]Quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections. J Neurochem. 2000 Dec;75(6):2590-601.
DMPZ8XH	RU	https://pubmed.ncbi.nlm.nih.gov/11080213

DMPZ8XH	DI	DMPZ8XH
DMPZ8XH	DN	L-CCG-I
DMPZ8XH	MI	TTWRP2F
DMPZ8XH	MN	Metabotropic glutamate receptor 6 (mGluR6)
DMPZ8XH	MT	DTT
DMPZ8XH	MA	Agonist
DMPZ8XH	RN	Comparative effect of L-CCG-I, DCG-IV and gamma-carboxy-L-glutamate on all cloned metabotropic glutamate receptor subtypes. Neuropharmacology. 1998 Aug;37(8):1043-51.
DMPZ8XH	RU	https://pubmed.ncbi.nlm.nih.gov/9833633

DMPZ8XH	DI	DMPZ8XH
DMPZ8XH	DN	L-CCG-I
DMPZ8XH	MI	TT0I76D
DMPZ8XH	MN	Metabotropic glutamate receptor 7 (mGluR7)
DMPZ8XH	MT	DTT
DMPZ8XH	MA	Agonist
DMPZ8XH	RN	Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 2000 Dec;362(6):546-54.
DMPZ8XH	RU	https://pubmed.ncbi.nlm.nih.gov/11138847

DMPZ8XH	DI	DMPZ8XH
DMPZ8XH	DN	L-CCG-I
DMPZ8XH	MI	TT0IFKL
DMPZ8XH	MN	Metabotropic glutamate receptor 8 (mGluR8)
DMPZ8XH	MT	DTT
DMPZ8XH	MA	Agonist
DMPZ8XH	RN	Cloning and functional expression of alternative spliced variants of the human metabotropic glutamate receptor 8. Brain Res Mol Brain Res. 1999 Apr 20;67(2):201-10.
DMPZ8XH	RU	https://pubmed.ncbi.nlm.nih.gov/10216218

DME4TUQ	DI	DME4TUQ
DME4TUQ	DN	Lck inhibitor
DME4TUQ	MI	TT860QF
DME4TUQ	MN	LCK tyrosine protein kinase (LCK)
DME4TUQ	MT	DTT
DME4TUQ	MA	Inhibitor
DME4TUQ	RN	Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck II. Bioorg Med Chem Lett. 2000 Oct 2;10(19):2171-4.
DME4TUQ	RU	https://pubmed.ncbi.nlm.nih.gov/11012022

DMD5GO0	DI	DMD5GO0
DMD5GO0	DN	LD-101
DMD5GO0	MI	TTWTSCV
DMD5GO0	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DMD5GO0	MT	DTT
DMD5GO0	MA	Inhibitor
DMD5GO0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479).
DMD5GO0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1479

DMC5XQ6	DI	DMC5XQ6
DMC5XQ6	DN	LD201t1
DMC5XQ6	MI	TT2IYXF
DMC5XQ6	MN	L-selectin (SELL)
DMC5XQ6	MT	DTT
DMC5XQ6	RN	Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60.
DMC5XQ6	RU	https://pubmed.ncbi.nlm.nih.gov/18095918

DMH7R6L	DI	DMH7R6L
DMH7R6L	DN	LDC1267
DMH7R6L	MI	TTIEMFN
DMH7R6L	MN	TYRO3 tyrosine kinase receptor (TYRO3)
DMH7R6L	MT	DTT
DMH7R6L	MA	Inhibitor
DMH7R6L	RN	The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature. 2014 Mar 27;507(7493):508-12.
DMH7R6L	RU	https://pubmed.ncbi.nlm.nih.gov/24553136

DMH7R6L	DI	DMH7R6L
DMH7R6L	DN	LDC1267
DMH7R6L	MI	TTO7LKR
DMH7R6L	MN	Tyrosine-protein kinase Mer (MERTK)
DMH7R6L	MT	DTT
DMH7R6L	MA	Inhibitor
DMH7R6L	RN	The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature. 2014 Mar 27;507(7493):508-12.
DMH7R6L	RU	https://pubmed.ncbi.nlm.nih.gov/24553136

DMH7R6L	DI	DMH7R6L
DMH7R6L	DN	LDC1267
DMH7R6L	MI	TTZPY6J
DMH7R6L	MN	Tyrosine-protein kinase UFO (AXL)
DMH7R6L	MT	DTT
DMH7R6L	MA	Inhibitor
DMH7R6L	RN	The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature. 2014 Mar 27;507(7493):508-12.
DMH7R6L	RU	https://pubmed.ncbi.nlm.nih.gov/24553136

DM57Z8J	DI	DM57Z8J
DM57Z8J	DN	LDN-214117
DM57Z8J	MI	TTJNBQA
DM57Z8J	MN	Activin receptor-like kinase 2 (ALK-2)
DM57Z8J	MT	DTT
DM57Z8J	MA	Inhibitor
DM57Z8J	RN	Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants. J Med Chem. 2014 Oct 9;57(19):7900-15.
DM57Z8J	RU	https://pubmed.ncbi.nlm.nih.gov/25101911

DM57Z8J	DI	DM57Z8J
DM57Z8J	DN	LDN-214117
DM57Z8J	MI	TTGYPTC
DM57Z8J	MN	Activin receptor-like kinase-1 (ACVRL1)
DM57Z8J	MT	DTT
DM57Z8J	MA	Inhibitor
DM57Z8J	RN	Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants. J Med Chem. 2014 Oct 9;57(19):7900-15.
DM57Z8J	RU	https://pubmed.ncbi.nlm.nih.gov/25101911

DM57Z8J	DI	DM57Z8J
DM57Z8J	DN	LDN-214117
DM57Z8J	MI	TTGKF90
DM57Z8J	MN	Bone morphogenetic protein receptor (BMPR2)
DM57Z8J	MT	DTT
DM57Z8J	MA	Inhibitor
DM57Z8J	RN	Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants. J Med Chem. 2014 Oct 9;57(19):7900-15.
DM57Z8J	RU	https://pubmed.ncbi.nlm.nih.gov/25101911

DM57Z8J	DI	DM57Z8J
DM57Z8J	DN	LDN-214117
DM57Z8J	MI	TTP4520
DM57Z8J	MN	TGF-beta receptor type I (TGFBR1)
DM57Z8J	MT	DTT
DM57Z8J	MA	Inhibitor
DM57Z8J	RN	Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants. J Med Chem. 2014 Oct 9;57(19):7900-15.
DM57Z8J	RU	https://pubmed.ncbi.nlm.nih.gov/25101911

DMTSLGF	DI	DMTSLGF
DMTSLGF	DN	LDN-91946
DMTSLGF	MI	TTX9IFP
DMTSLGF	MN	Ubiquitin thioesterase L1 (UCHL1)
DMTSLGF	MT	DTT
DMTSLGF	MA	Inhibitor
DMTSLGF	RN	Structure-activity relationship, kinetic mechanism, and selectivity for a new class of ubiquitin C-terminal hydrolase-L1 (UCH-L1) inhibitors. Bioorg Med Chem Lett. 2007 Jul 1;17(13):3729-32.
DMTSLGF	RU	https://pubmed.ncbi.nlm.nih.gov/17449248

DMZ21HU	DI	DMZ21HU
DMZ21HU	DN	LEACHIANONE A
DMZ21HU	MI	TT8JRS7
DMZ21HU	MN	Beta-secretase (BACE)
DMZ21HU	MT	DTT
DMZ21HU	MA	Inhibitor
DMZ21HU	RN	BACE1 inhibitory effects of lavandulyl flavanones from Sophora flavescens. Bioorg Med Chem. 2008 Jul 15;16(14):6669-74.
DMZ21HU	RU	https://pubmed.ncbi.nlm.nih.gov/18565755

DML0GZ2	DI	DML0GZ2
DML0GZ2	DN	Lead acetate
DML0GZ2	MI	TTQ6VF4
DML0GZ2	MN	Ferrochelatase (FECH)
DML0GZ2	MT	DTT
DML0GZ2	MA	Inhibitor
DML0GZ2	RN	Ferrochelatase, a novel target for photodynamic therapy of cancer. Oncol Rep. 1999 Nov-Dec;6(6):1439-42.
DML0GZ2	RU	https://pubmed.ncbi.nlm.nih.gov/10523727

DMZ7OHP	DI	DMZ7OHP
DMZ7OHP	DN	Lecanindole D
DMZ7OHP	MI	TTUV8G9
DMZ7OHP	MN	Progesterone receptor (PGR)
DMZ7OHP	MT	DTT
DMZ7OHP	MA	Inhibitor
DMZ7OHP	RN	The lecanindoles, nonsteroidal progestins from the terrestrial fungus Verticillium lecanii 6144. J Nat Prod. 2009 Nov;72(11):1944-8.
DMZ7OHP	RU	https://pubmed.ncbi.nlm.nih.gov/19863083

DM0CEY3	DI	DM0CEY3
DM0CEY3	DN	Lefaxin
DM0CEY3	MI	TTCIHJA
DM0CEY3	MN	Coagulation factor Xa (F10)
DM0CEY3	MT	DTT
DM0CEY3	MA	Inhibitor
DM0CEY3	RN	Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci. 2002 Jan;23(1):25-32.
DM0CEY3	RU	https://pubmed.ncbi.nlm.nih.gov/11804648

DM5LY1H	DI	DM5LY1H
DM5LY1H	DN	Leptin
DM5LY1H	MI	TT0HD6V
DM5LY1H	MN	Leptin receptor (LEPR)
DM5LY1H	MT	DTT
DM5LY1H	MA	Modulator
DM5LY1H	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1712).
DM5LY1H	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1712

DME91CG	DI	DME91CG
DME91CG	DN	Lerdelimumab
DME91CG	MI	TTY9TWO
DME91CG	MN	Transforming growth factor beta 2 (TGFB2)
DME91CG	MT	DTT
DME91CG	RN	A phase III study of subconjunctival human anti-transforming growth factor beta(2) monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy. Ophthalmology. 2007 Oct;114(10):1822-30.
DME91CG	RU	https://pubmed.ncbi.nlm.nih.gov/17908591

DMDV67S	DI	DMDV67S
DMDV67S	DN	lergotrile
DMDV67S	MI	TTJS8PY
DMDV67S	MN	5-HT 6 receptor (HTR6)
DMDV67S	MT	DTT
DMDV67S	MA	Agonist
DMDV67S	RN	Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol. 1993 Mar;43(3):320-7.
DMDV67S	RU	https://pubmed.ncbi.nlm.nih.gov/7680751

DMV4OKR	DI	DMV4OKR
DMV4OKR	DN	L-erythro-3-hydroxyaspartate
DMV4OKR	MI	TTZFUY6
DMV4OKR	MN	Serine Racemase (SRR)
DMV4OKR	MT	DTT
DMV4OKR	MA	Inhibitor
DMV4OKR	RN	Inhibition of human serine racemase, an emerging target for medicinal chemistry. Curr Drug Targets. 2011 Jun;12(7):1037-55.
DMV4OKR	RU	https://pubmed.ncbi.nlm.nih.gov/21291385

DMV40XH	DI	DMV40XH
DMV40XH	DN	leualacin
DMV40XH	MI	TT5HONZ
DMV40XH	MN	Calcium channel unspecific (CaC)
DMV40XH	MT	DTT
DMV40XH	MA	Modulator
DMV40XH	RN	Leualacin, a novel calcium blocker from Hapsidospora irregularis. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties. J Antibiot (Tokyo). 1992 Jun;45(6):899-905.
DMV40XH	RU	https://www.ncbi.nlm.nih.gov/pubmed/1500357

DM94JXH	DI	DM94JXH
DM94JXH	DN	Leucettamidine
DM94JXH	MI	TTN53ZF
DM94JXH	MN	Leukotriene B4 receptor 1 (LTB4R)
DM94JXH	MT	DTT
DM94JXH	MA	Inhibitor
DM94JXH	RN	New leukotriene B4 receptor antagonist: leucettamine A and related imidazole alkaloids from the marine sponge Leucetta microraphis. J Nat Prod. 1993 Jan;56(1):116-21.
DM94JXH	RU	https://pubmed.ncbi.nlm.nih.gov/8383730

DMIZVA6	DI	DMIZVA6
DMIZVA6	DN	LEUCETTAMINE A
DMIZVA6	MI	TTN53ZF
DMIZVA6	MN	Leukotriene B4 receptor 1 (LTB4R)
DMIZVA6	MT	DTT
DMIZVA6	MA	Inhibitor
DMIZVA6	RN	New leukotriene B4 receptor antagonist: leucettamine A and related imidazole alkaloids from the marine sponge Leucetta microraphis. J Nat Prod. 1993 Jan;56(1):116-21.
DMIZVA6	RU	https://pubmed.ncbi.nlm.nih.gov/8383730

DMFQEWM	DI	DMFQEWM
DMFQEWM	DN	LEUCETTAMINE B
DMFQEWM	MI	TTRSMW9
DMFQEWM	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMFQEWM	MT	DTT
DMFQEWM	MA	Inhibitor
DMFQEWM	RN	Synthesis and preliminary biological evaluation of new derivatives of the marine alkaloid leucettamine B as kinase inhibitors. Eur J Med Chem. 2010 Feb;45(2):805-10.
DMFQEWM	RU	https://pubmed.ncbi.nlm.nih.gov/19879673

DMFQEWM	DI	DMFQEWM
DMFQEWM	DN	LEUCETTAMINE B
DMFQEWM	MI	TTQWAU1
DMFQEWM	MN	GSK3A messenger RNA (GSK3A mRNA)
DMFQEWM	MT	DTT
DMFQEWM	MA	Inhibitor
DMFQEWM	RN	Synthesis and preliminary biological evaluation of new derivatives of the marine alkaloid leucettamine B as kinase inhibitors. Eur J Med Chem. 2010 Feb;45(2):805-10.
DMFQEWM	RU	https://pubmed.ncbi.nlm.nih.gov/19879673

DMBYND6	DI	DMBYND6
DMBYND6	DN	leucettine L41
DMBYND6	MI	TTE6YDG
DMBYND6	MN	CDC-like kinase 1 (CLK1)
DMBYND6	MT	DTT
DMBYND6	MA	Inhibitor
DMBYND6	RN	Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing. J Med Chem. 2011 Jun 23;54(12):4172-86.
DMBYND6	RU	https://pubmed.ncbi.nlm.nih.gov/21615147

DMBYND6	DI	DMBYND6
DMBYND6	DN	leucettine L41
DMBYND6	MI	TTQPE1U
DMBYND6	MN	CDC-like kinase 3 (CLK3)
DMBYND6	MT	DTT
DMBYND6	MA	Inhibitor
DMBYND6	RN	Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing. J Med Chem. 2011 Jun 23;54(12):4172-86.
DMBYND6	RU	https://pubmed.ncbi.nlm.nih.gov/21615147

DMBYND6	DI	DMBYND6
DMBYND6	DN	leucettine L41
DMBYND6	MI	TTSBVFO
DMBYND6	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DMBYND6	MT	DTT
DMBYND6	MA	Inhibitor
DMBYND6	RN	Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing. J Med Chem. 2011 Jun 23;54(12):4172-86.
DMBYND6	RU	https://pubmed.ncbi.nlm.nih.gov/21615147

DMBYND6	DI	DMBYND6
DMBYND6	DN	leucettine L41
DMBYND6	MI	TT84OS6
DMBYND6	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 2 (DYRK2)
DMBYND6	MT	DTT
DMBYND6	MA	Inhibitor
DMBYND6	RN	Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing. J Med Chem. 2011 Jun 23;54(12):4172-86.
DMBYND6	RU	https://pubmed.ncbi.nlm.nih.gov/21615147

DMBYND6	DI	DMBYND6
DMBYND6	DN	leucettine L41
DMBYND6	MI	TTCLIHJ
DMBYND6	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 4 (DYRK4)
DMBYND6	MT	DTT
DMBYND6	MA	Inhibitor
DMBYND6	RN	Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B. J Med Chem. 2012 Nov 8;55(21):9312-30.
DMBYND6	RU	https://pubmed.ncbi.nlm.nih.gov/22998443

DMBYND6	DI	DMBYND6
DMBYND6	DN	leucettine L41
DMBYND6	MI	TTTN5QW
DMBYND6	MN	Serine/threonine-protein kinase pim-1 (PIM1)
DMBYND6	MT	DTT
DMBYND6	MA	Inhibitor
DMBYND6	RN	Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing. J Med Chem. 2011 Jun 23;54(12):4172-86.
DMBYND6	RU	https://pubmed.ncbi.nlm.nih.gov/21615147

DMT2CZK	DI	DMT2CZK
DMT2CZK	DN	Leucine-enkephalin
DMT2CZK	MI	TT27RFC
DMT2CZK	MN	Opioid receptor delta (OPRD1)
DMT2CZK	MT	DTT
DMT2CZK	MA	Agonist
DMT2CZK	RN	Inverse agonist action of Leu-enkephalin at delta(2)-opioid receptors mediates spinal antianalgesia. J Pharmacol Exp Ther. 2001 May;297(2):582-9.
DMT2CZK	RU	https://pubmed.ncbi.nlm.nih.gov/11303046

DMT2CZK	DI	DMT2CZK
DMT2CZK	DN	Leucine-enkephalin
DMT2CZK	MI	TTKWM86
DMT2CZK	MN	Opioid receptor mu (MOP)
DMT2CZK	MT	DTT
DMT2CZK	MA	Inhibitor
DMT2CZK	RN	Peptides as receptor selectivity modulators of opiate pharmacophores. J Med Chem. 1986 Jul;29(7):1222-5.
DMT2CZK	RU	https://pubmed.ncbi.nlm.nih.gov/2879914

DM6W27F	DI	DM6W27F
DM6W27F	DN	LEUCOSCEPTOSIDE A
DM6W27F	MI	TTFJ8Q1
DM6W27F	MN	Protein kinase C alpha (PRKCA)
DM6W27F	MT	DTT
DM6W27F	MA	Inhibitor
DM6W27F	RN	Phenylethanoid glycosides from Digitalis purpurea and Penstemon linarioides with PKCalpha-inhibitory activity. J Nat Prod. 1998 Nov;61(11):1410-2.
DM6W27F	RU	https://pubmed.ncbi.nlm.nih.gov/9834166

DMYX2NJ	DI	DMYX2NJ
DMYX2NJ	DN	Leukotoxin
DMYX2NJ	MI	TT48WR6
DMYX2NJ	MN	Integrin alpha-L (ITGAL)
DMYX2NJ	MT	DTT
DMYX2NJ	MA	Modulator
DMYX2NJ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2451).
DMYX2NJ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2451

DMU075F	DI	DMU075F
DMU075F	DN	Leupeptin
DMU075F	MI	DTUGYRD
DMU075F	MN	P-glycoprotein 1 (ABCB1)
DMU075F	MT	DTP
DMU075F	MA	Substrate
DMU075F	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMU075F	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMU075F	DI	DMU075F
DMU075F	DN	Leupeptin
DMU075F	MI	TTJNPTK
DMU075F	MN	Plasmodium Cysteine protease falcipain (Malaria CPF)
DMU075F	MT	DTT
DMU075F	MA	Inhibitor
DMU075F	RN	Novel molecular targets for antimalarial chemotherapy. Int J Antimicrob Agents. 2007 Jul;30(1):4-10.
DMU075F	RU	https://pubmed.ncbi.nlm.nih.gov/17339102

DMU075F	DI	DMU075F
DMU075F	DN	Leupeptin
DMU075F	MI	TT7EASG
DMU075F	MN	Plasmodium Cysteine protease falcipain-2 (Malaria CPF2)
DMU075F	MT	DTT
DMU075F	MA	Inhibitor
DMU075F	RN	Novel molecular targets for antimalarial drug development. Chem Biol Drug Des. 2008 Apr;71(4):287-97.
DMU075F	RU	https://pubmed.ncbi.nlm.nih.gov/18298458

DMU075F	DI	DMU075F
DMU075F	DN	Leupeptin
DMU075F	MI	TTH9VL3
DMU075F	MN	Plasmodium Plasmepsin 1 (Malaria PLA1)
DMU075F	MT	DTT
DMU075F	MA	Inhibitor
DMU075F	RN	Novel molecular targets for antimalarial chemotherapy. Int J Antimicrob Agents. 2007 Jul;30(1):4-10.
DMU075F	RU	https://pubmed.ncbi.nlm.nih.gov/17339102

DMU075F	DI	DMU075F
DMU075F	DN	Leupeptin
DMU075F	MI	TTXMNHO
DMU075F	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMU075F	MT	DTT
DMU075F	MA	Inhibitor
DMU075F	RN	Novel molecular targets for antimalarial chemotherapy. Int J Antimicrob Agents. 2007 Jul;30(1):4-10.
DMU075F	RU	https://pubmed.ncbi.nlm.nih.gov/17339102

DMPYSIT	DI	DMPYSIT
DMPYSIT	DN	levetimide
DMPYSIT	MI	TTOXS3C
DMPYSIT	MN	Muscarinic acetylcholine receptor (CHRM)
DMPYSIT	MT	DTT
DMPYSIT	MA	Antagonist
DMPYSIT	RN	Pharmacological comparison of the cloned human and rat M2 muscarinic receptor genes expressed in the murine fibroblast (B82) cell line. J Pharmacol Exp Ther. 1998 Feb;284(2):500-7.
DMPYSIT	RU	https://pubmed.ncbi.nlm.nih.gov/9454790

DMWDJ0H	DI	DMWDJ0H
DMWDJ0H	DN	LEVONORDEFRIN
DMWDJ0H	MI	TTNGILX
DMWDJ0H	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMWDJ0H	MT	DTT
DMWDJ0H	MA	Inhibitor
DMWDJ0H	RN	Medetomidine analogs as alpha 2-adrenergic ligands. 2. Design, synthesis, and biological activity of conformationally restricted naphthalene deriva... J Med Chem. 1996 Jul 19;39(15):3001-13.
DMWDJ0H	RU	https://pubmed.ncbi.nlm.nih.gov/8709134

DMWDJ0H	DI	DMWDJ0H
DMWDJ0H	DN	LEVONORDEFRIN
DMWDJ0H	MI	TTBRKXS
DMWDJ0H	MN	Adrenergic receptor alpha-1B (ADRA1B)
DMWDJ0H	MT	DTT
DMWDJ0H	MA	Inhibitor
DMWDJ0H	RN	Medetomidine analogs as alpha 2-adrenergic ligands. 2. Design, synthesis, and biological activity of conformationally restricted naphthalene deriva... J Med Chem. 1996 Jul 19;39(15):3001-13.
DMWDJ0H	RU	https://pubmed.ncbi.nlm.nih.gov/8709134

DMWDJ0H	DI	DMWDJ0H
DMWDJ0H	DN	LEVONORDEFRIN
DMWDJ0H	MI	TT34BHT
DMWDJ0H	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMWDJ0H	MT	DTT
DMWDJ0H	MA	Inhibitor
DMWDJ0H	RN	Medetomidine analogs as alpha 2-adrenergic ligands. 2. Design, synthesis, and biological activity of conformationally restricted naphthalene deriva... J Med Chem. 1996 Jul 19;39(15):3001-13.
DMWDJ0H	RU	https://pubmed.ncbi.nlm.nih.gov/8709134

DMV3P89	DI	DMV3P89
DMV3P89	DN	Levoverbenone
DMV3P89	MI	DEJVYAZ
DMV3P89	MN	Cytochrome P450 2A6 (CYP2A6)
DMV3P89	MT	DME
DMV3P89	MA	Metabolism
DMV3P89	RN	Roles of human CYP2A6 and 2B6 and rat CYP2C11 and 2B1 in the 10-hydroxylation of (-)-verbenone by liver microsomes. Drug Metab Dispos. 2003 Aug;31(8):1049-53.
DMV3P89	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12867494

DMV3P89	DI	DMV3P89
DMV3P89	DN	Levoverbenone
DMV3P89	MI	DEPKLMQ
DMV3P89	MN	Cytochrome P450 2B6 (CYP2B6)
DMV3P89	MT	DME
DMV3P89	MA	Metabolism
DMV3P89	RN	Roles of human CYP2A6 and 2B6 and rat CYP2C11 and 2B1 in the 10-hydroxylation of (-)-verbenone by liver microsomes. Drug Metab Dispos. 2003 Aug;31(8):1049-53.
DMV3P89	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12867494

DMOEQTN	DI	DMOEQTN
DMOEQTN	DN	LF-160335
DMOEQTN	MI	TTGY8IW
DMOEQTN	MN	B2 bradykinin receptor (BDKRB2)
DMOEQTN	MT	DTT
DMOEQTN	MA	Modulator
DMOEQTN	RN	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
DMOEQTN	RU	https://www.ncbi.nlm.nih.gov/pubmed/27899562

DM5G307	DI	DM5G307
DM5G307	DN	LFA703
DM5G307	MI	TT48WR6
DM5G307	MN	Integrin alpha-L (ITGAL)
DM5G307	MT	DTT
DM5G307	MA	Inhibitor
DM5G307	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM5G307	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMTXWCZ	DI	DMTXWCZ
DMTXWCZ	DN	LFM-A13
DMTXWCZ	MI	TTGM6VW
DMTXWCZ	MN	Tyrosine-protein kinase BTK (ATK)
DMTXWCZ	MT	DTT
DMTXWCZ	MA	Inhibitor
DMTXWCZ	RN	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
DMTXWCZ	RU	https://pubmed.ncbi.nlm.nih.gov/18077363

DMEK4FY	DI	DMEK4FY
DMEK4FY	DN	LG100754
DMEK4FY	MI	TTT2SVW
DMEK4FY	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DMEK4FY	MT	DTT
DMEK4FY	MA	Agonist
DMEK4FY	RN	The antidiabetic agent LG100754 sensitizes cells to low concentrations of peroxisome proliferator-activated receptor gamma ligands. J Biol Chem. 2002 Apr 12;277(15):12503-6.
DMEK4FY	RU	https://pubmed.ncbi.nlm.nih.gov/11877384

DMEK4FY	DI	DMEK4FY
DMEK4FY	DN	LG100754
DMEK4FY	MI	TT6PEUO
DMEK4FY	MN	Retinoic acid receptor RXR-alpha (RXRA)
DMEK4FY	MT	DTT
DMEK4FY	MA	Antagonist
DMEK4FY	RN	The rexinoid LG100754 is a novel RXR:PPARgamma agonist and decreases glucose levels in vivo. Mol Endocrinol. 2001 Aug;15(8):1360-9.
DMEK4FY	RU	https://pubmed.ncbi.nlm.nih.gov/11463859

DMEK4FY	DI	DMEK4FY
DMEK4FY	DN	LG100754
DMEK4FY	MI	TTKLV96
DMEK4FY	MN	Retinoic acid receptor RXR-beta (RXRB)
DMEK4FY	MT	DTT
DMEK4FY	MA	Antagonist
DMEK4FY	RN	Activation of specific RXR heterodimers by an antagonist of RXR homodimers. Nature. 1996 Oct 3;383(6599):450-3.
DMEK4FY	RU	https://pubmed.ncbi.nlm.nih.gov/8837780

DMEK4FY	DI	DMEK4FY
DMEK4FY	DN	LG100754
DMEK4FY	MI	TTH029C
DMEK4FY	MN	Retinoic acid receptor RXR-gamma (RXRG)
DMEK4FY	MT	DTT
DMEK4FY	MA	Antagonist
DMEK4FY	RN	Activation of specific RXR heterodimers by an antagonist of RXR homodimers. Nature. 1996 Oct 3;383(6599):450-3.
DMEK4FY	RU	https://pubmed.ncbi.nlm.nih.gov/8837780

DMG1UOR	DI	DMG1UOR
DMG1UOR	DN	LG-120838
DMG1UOR	MI	TTKPW01
DMG1UOR	MN	Androgen receptor messenger RNA (AR mRNA)
DMG1UOR	MT	DTT
DMG1UOR	MA	Inhibitor
DMG1UOR	RN	5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists. J Med Chem. 1998 Oct 22;41(22):4354-9.
DMG1UOR	RU	https://pubmed.ncbi.nlm.nih.gov/9784110

DMG1UOR	DI	DMG1UOR
DMG1UOR	DN	LG-120838
DMG1UOR	MI	TTOZRK6
DMG1UOR	MN	Glucocorticoid receptor messenger RNA (GCR mRNA)
DMG1UOR	MT	DTT
DMG1UOR	MA	Inhibitor
DMG1UOR	RN	5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists. J Med Chem. 1998 Oct 22;41(22):4354-9.
DMG1UOR	RU	https://pubmed.ncbi.nlm.nih.gov/9784110

DMG1UOR	DI	DMG1UOR
DMG1UOR	DN	LG-120838
DMG1UOR	MI	TT26PHO
DMG1UOR	MN	Mineralocorticoid receptor  (MR)
DMG1UOR	MT	DTT
DMG1UOR	MA	Inhibitor
DMG1UOR	RN	5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists. J Med Chem. 1998 Oct 22;41(22):4354-9.
DMG1UOR	RU	https://pubmed.ncbi.nlm.nih.gov/9784110

DMMHYQ4	DI	DMMHYQ4
DMMHYQ4	DN	LG-121071
DMMHYQ4	MI	TTKPW01
DMMHYQ4	MN	Androgen receptor messenger RNA (AR mRNA)
DMMHYQ4	MT	DTT
DMMHYQ4	MA	Inhibitor
DMMHYQ4	RN	Novel series of potent, nonsteroidal, selective androgen receptor modulators based on 7H-[1,4]oxazino[3,2-g]quinolin-7-ones. J Med Chem. 2007 May 17;50(10):2486-96.
DMMHYQ4	RU	https://pubmed.ncbi.nlm.nih.gov/17439112

DMO1FCU	DI	DMO1FCU
DMO1FCU	DN	LG190178
DMO1FCU	MI	TTK59TV
DMO1FCU	MN	Vitamin D3 receptor (VDR)
DMO1FCU	MT	DTT
DMO1FCU	MA	Agonist
DMO1FCU	RN	Novel nonsecosteroidal vitamin D mimics exert VDR-modulating activities with less calcium mobilization than 1,25-dihydroxyvitamin D3. Chem Biol. 1999 May;6(5):265-75.
DMO1FCU	RU	https://pubmed.ncbi.nlm.nih.gov/10322128

DM1W8Y0	DI	DM1W8Y0
DM1W8Y0	DN	LG-888
DM1W8Y0	MI	TT1290U
DM1W8Y0	MN	Coagulation factor VIII (F8)
DM1W8Y0	MT	DTT
DM1W8Y0	MA	Stimulator
DM1W8Y0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2607).
DM1W8Y0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2607

DMIHDEB	DI	DMIHDEB
DMIHDEB	DN	LG-889
DMIHDEB	MI	TT1290U
DMIHDEB	MN	Coagulation factor VIII (F8)
DMIHDEB	MT	DTT
DMIHDEB	MA	Modulator
DMIHDEB	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2607).
DMIHDEB	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2607

DMKRSZY	DI	DMKRSZY
DMKRSZY	DN	LGD-2226
DMKRSZY	MI	TTKPW01
DMKRSZY	MN	Androgen receptor messenger RNA (AR mRNA)
DMKRSZY	MT	DTT
DMKRSZY	MA	Inhibitor
DMKRSZY	RN	Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1527-31.
DMKRSZY	RU	https://pubmed.ncbi.nlm.nih.gov/17267219

DM67KWM	DI	DM67KWM
DM67KWM	DN	LGD-5552
DM67KWM	MI	TTKPW01
DM67KWM	MN	Androgen receptor messenger RNA (AR mRNA)
DM67KWM	MT	DTT
DM67KWM	MA	Inhibitor
DM67KWM	RN	Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile. Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19244-9.
DM67KWM	RU	https://pubmed.ncbi.nlm.nih.gov/18032610

DM67KWM	DI	DM67KWM
DM67KWM	DN	LGD-5552
DM67KWM	MI	TTOZRK6
DM67KWM	MN	Glucocorticoid receptor messenger RNA (GCR mRNA)
DM67KWM	MT	DTT
DM67KWM	MA	Inhibitor
DM67KWM	RN	Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile. Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19244-9.
DM67KWM	RU	https://pubmed.ncbi.nlm.nih.gov/18032610

DM67KWM	DI	DM67KWM
DM67KWM	DN	LGD-5552
DM67KWM	MI	TT26PHO
DM67KWM	MN	Mineralocorticoid receptor  (MR)
DM67KWM	MT	DTT
DM67KWM	MA	Inhibitor
DM67KWM	RN	Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile. Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19244-9.
DM67KWM	RU	https://pubmed.ncbi.nlm.nih.gov/18032610

DM67KWM	DI	DM67KWM
DM67KWM	DN	LGD-5552
DM67KWM	MI	TTUV8G9
DM67KWM	MN	Progesterone receptor (PGR)
DM67KWM	MT	DTT
DM67KWM	MA	Inhibitor
DM67KWM	RN	Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile. Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19244-9.
DM67KWM	RU	https://pubmed.ncbi.nlm.nih.gov/18032610

DMKI70D	DI	DMKI70D
DMKI70D	DN	LHD-4
DMKI70D	MI	TT4QPUL
DMKI70D	MN	Antithrombin-III (ATIII)
DMKI70D	MT	DTT
DMKI70D	MA	Modulator
DMKI70D	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2632).
DMKI70D	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2632

DML83XP	DI	DML83XP
DML83XP	DN	L-homoarginine
DML83XP	MI	DT96BT4
DML83XP	MN	Mitochondrial ornithine transporter 3 (SLC25A29)
DML83XP	MT	DTP
DML83XP	MA	Substrate
DML83XP	RN	The human gene SLC25A29, of solute carrier family 25, encodes a mitochondrial transporter of basic amino acids. J Biol Chem. 2014 May 9;289(19):13374-84.
DML83XP	RU	http://www.ncbi.nlm.nih.gov/pubmed/24652292

DML83XP	DI	DML83XP
DML83XP	DN	L-homoarginine
DML83XP	MI	TTCM4B3
DML83XP	MN	Nitric-oxide synthase endothelial (NOS3)
DML83XP	MT	DTT
DML83XP	MA	Inhibitor
DML83XP	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DML83XP	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMB4ACY	DI	DMB4ACY
DMB4ACY	DN	LHRH
DMB4ACY	MI	TT8R70G
DMB4ACY	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMB4ACY	MT	DTT
DMB4ACY	MA	Inhibitor
DMB4ACY	RN	Discovery of a novel, potent, and orally active nonpeptide antagonist of the human luteinizing hormone-releasing hormone (LHRH) receptor. J Med Chem. 1998 Oct 22;41(22):4190-5.
DMB4ACY	RU	https://pubmed.ncbi.nlm.nih.gov/9784092

DMWY0TN	DI	DMWY0TN
DMWY0TN	DN	LICOAGROCHACONE A
DMWY0TN	MI	TTELIN2
DMWY0TN	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMWY0TN	MT	DTT
DMWY0TN	MA	Inhibitor
DMWY0TN	RN	Inhibitory effect of chalcones and their derivatives from Glycyrrhiza inflata on protein tyrosine phosphatase 1B. Bioorg Med Chem Lett. 2009 Sep 1;19(17):5155-7.
DMWY0TN	RU	https://pubmed.ncbi.nlm.nih.gov/19632832

DMY65ZP	DI	DMY65ZP
DMY65ZP	DN	LICOAGROCHALCONE A
DMY65ZP	MI	TTELIN2
DMY65ZP	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMY65ZP	MT	DTT
DMY65ZP	MA	Inhibitor
DMY65ZP	RN	Isoprenylated flavonoids from the stem bark of Erythrina abyssinica. J Nat Prod. 2007 Jun;70(6):1039-42.
DMY65ZP	RU	https://pubmed.ncbi.nlm.nih.gov/17489632

DM2UBQ8	DI	DM2UBQ8
DM2UBQ8	DN	LIM-5310
DM2UBQ8	MI	TTU81IF
DM2UBQ8	MN	Transporter unspecfic (TP)
DM2UBQ8	MT	DTT
DM2UBQ8	MA	Activator
DM2UBQ8	RN	Limerick BioPharma, Inc. Pharmaceuticals & Healthcare. Deals and Alliances Profile. Limerick BioPharma, Inc. Nov-2014.
DM2UBQ8	RU	http://store.globaldata.com/company-reports/pharmaceuticals-and-healthcare/limerick-biopharma-inc-pharmaceuticals--healthcare-deals-and-alliances-profile#.Vh39_qToumQ

DMGZQ5P	DI	DMGZQ5P
DMGZQ5P	DN	Linalool
DMGZQ5P	MI	DEQOJDP
DMGZQ5P	MN	Cytochrome P450 111A2 (cyp111)
DMGZQ5P	MT	DME
DMGZQ5P	MA	Metabolism
DMGZQ5P	RN	Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology. 2003 Nov;38(5):1250-7.
DMGZQ5P	RU	https://pubmed.ncbi.nlm.nih.gov/14578864

DMGZQ5P	DI	DMGZQ5P
DMGZQ5P	DN	Linalool
DMGZQ5P	MI	TTXDKTO
DMGZQ5P	MN	Long transient receptor potential channel 8 (TRPM8)
DMGZQ5P	MT	DTT
DMGZQ5P	MA	Activator
DMGZQ5P	RN	Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay. Br J Pharmacol. 2004 Feb;141(4):737-45.
DMGZQ5P	RU	https://pubmed.ncbi.nlm.nih.gov/14757700

DMD3AJH	DI	DMD3AJH
DMD3AJH	DN	Linear peptide of RES-701-1
DMD3AJH	MI	TT3ZTGU
DMD3AJH	MN	Endothelin B receptor (EDNRB)
DMD3AJH	MT	DTT
DMD3AJH	MA	Inhibitor
DMD3AJH	RN	RES-701-1/endothelin-1 hybrid peptide having a potent binding activity for type B receptor, Bioorg. Med. Chem. Lett. 7(13):1715-1720 (1997).
DMD3AJH	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97002965

DMDGPY9	DI	DMDGPY9
DMDGPY9	DN	Linoleic acid
DMDGPY9	MI	TTHWMFZ
DMDGPY9	MN	Fatty acid-binding protein 4 (FABP4)
DMDGPY9	MT	DTT
DMDGPY9	MA	Inhibitor
DMDGPY9	RN	Discovery of highly selective inhibitors of human fatty acid binding protein 4 (FABP4) by virtual screening. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3675-9.
DMDGPY9	RU	https://pubmed.ncbi.nlm.nih.gov/20471252

DMDGPY9	DI	DMDGPY9
DMDGPY9	DN	Linoleic acid
DMDGPY9	MI	DEWD860
DMDGPY9	MN	Linoleate 10-hydratase (10-LAH)
DMDGPY9	MT	DME
DMDGPY9	MA	Metabolism
DMDGPY9	RN	Characterization of linoleate 10-hydratase of Lactobacillus plantarum and novel antifungal metabolites. Front Microbiol. 2016 Oct 4;7:1561. eCollection 2016.
DMDGPY9	RU	https://pubmed.ncbi.nlm.nih.gov/27757104

DMDGPY9	DI	DMDGPY9
DMDGPY9	DN	Linoleic acid
DMDGPY9	MI	DEQ58KF
DMDGPY9	MN	Linoleate isomerase (lai)
DMDGPY9	MT	DME
DMDGPY9	MA	Metabolism
DMDGPY9	RN	Cell-associated alpha-amylases of butyrate-producing Firmicute bacteria from the human colon. Microbiology. 2006 Nov;152(Pt 11):3281-3290.
DMDGPY9	RU	https://pubmed.ncbi.nlm.nih.gov/17074899

DMW9Z7N	DI	DMW9Z7N
DMW9Z7N	DN	Lipid Fragment
DMW9Z7N	MI	TTUTN1I
DMW9Z7N	MN	Human Deoxyribonucleic acid (hDNA)
DMW9Z7N	MT	DTT
DMW9Z7N	MA	Inhibitor
DMW9Z7N	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMW9Z7N	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMUIVCX	DI	DMUIVCX
DMUIVCX	DN	LIPOCRINE
DMUIVCX	MI	TT1RS9F
DMUIVCX	MN	Acetylcholinesterase (AChE)
DMUIVCX	MT	DTT
DMUIVCX	MA	Inhibitor
DMUIVCX	RN	Toward a rational design of multitarget-directed antioxidants: merging memoquin and lipoic acid molecular frameworks. J Med Chem. 2009 Dec 10;52(23):7883-6.
DMUIVCX	RU	https://pubmed.ncbi.nlm.nih.gov/19813747

DMUIVCX	DI	DMUIVCX
DMUIVCX	DN	LIPOCRINE
DMUIVCX	MI	TTEB0GD
DMUIVCX	MN	Cholinesterase (BCHE)
DMUIVCX	MT	DTT
DMUIVCX	MA	Inhibitor
DMUIVCX	RN	Toward a rational design of multitarget-directed antioxidants: merging memoquin and lipoic acid molecular frameworks. J Med Chem. 2009 Dec 10;52(23):7883-6.
DMUIVCX	RU	https://pubmed.ncbi.nlm.nih.gov/19813747

DM6YSG3	DI	DM6YSG3
DM6YSG3	DN	LIQUIRTIGENIN
DM6YSG3	MI	TTSZLWK
DM6YSG3	MN	Aromatase (CYP19A1)
DM6YSG3	MT	DTT
DM6YSG3	MA	Inhibitor
DM6YSG3	RN	Screening of herbal constituents for aromatase inhibitory activity. Bioorg Med Chem. 2008 Sep 15;16(18):8466-70.
DM6YSG3	RU	https://pubmed.ncbi.nlm.nih.gov/18778944

DM6YSG3	DI	DM6YSG3
DM6YSG3	DN	LIQUIRTIGENIN
DM6YSG3	MI	TT7RJY8
DM6YSG3	MN	Xanthine dehydrogenase/oxidase (XDH)
DM6YSG3	MT	DTT
DM6YSG3	MA	Inhibitor
DM6YSG3	RN	Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod. 1988 Mar-Apr;51(2):345-8.
DM6YSG3	RU	https://pubmed.ncbi.nlm.nih.gov/3379415

DM54D1G	DI	DM54D1G
DM54D1G	DN	Lisinopril
DM54D1G	MI	TTGFNPD
DM54D1G	MN	HUMAN angiotensin-converting enzyme (ACE)
DM54D1G	MT	DTT
DM54D1G	MA	Inhibitor
DM54D1G	RN	Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J Am Heart Assoc. 2020 Apr 7;9(7):e016219.
DM54D1G	RU	https://pubmed.ncbi.nlm.nih.gov/32233755

DMQ42KU	DI	DMQ42KU
DMQ42KU	DN	lisinopril-tryptophan
DMQ42KU	MI	TTL69WB
DMQ42KU	MN	Angiotensin-converting enzyme (ACE)
DMQ42KU	MT	DTT
DMQ42KU	MA	Inhibitor
DMQ42KU	RN	Characterization of domain-selective inhibitor binding in angiotensin-converting enzyme using a novel derivative of lisinopril. Biochem J. 2010 Apr 28;428(1):67-74.
DMQ42KU	RU	https://pubmed.ncbi.nlm.nih.gov/20233165

DM26AB4	DI	DM26AB4
DM26AB4	DN	L-Iso-Aspartate
DM26AB4	MI	TTICX3S
DM26AB4	MN	Bacterial UDP-N-acetylglucosamine carboxyvinyltransferase (Bact murA)
DM26AB4	MT	DTT
DM26AB4	MA	Inhibitor
DM26AB4	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM26AB4	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM6RKOC	DI	DM6RKOC
DM6RKOC	DN	L-Isofagomine
DM6RKOC	MI	TT1B5PU
DM6RKOC	MN	Glucosylceramidase (GBA)
DM6RKOC	MT	DTT
DM6RKOC	MA	Inhibitor
DM6RKOC	RN	In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures. Bioorg Med Chem. 2008 Aug 1;16(15):7330-6.
DM6RKOC	RU	https://pubmed.ncbi.nlm.nih.gov/18595718

DM4B6H3	DI	DM4B6H3
DM4B6H3	DN	L-isoleucine
DM4B6H3	MI	DTBMSWG
DM4B6H3	MN	L-type amino acid transporter 3 (SLC43A1)
DM4B6H3	MT	DTP
DM4B6H3	MA	Substrate
DM4B6H3	RN	Identification of a novel system L amino acid transporter structurally distinct from heterodimeric amino acid transporters. J Biol Chem. 2003 Oct 31;278(44):43838-45.
DM4B6H3	RU	http://www.ncbi.nlm.nih.gov/pubmed/12930836

DM4B6H3	DI	DM4B6H3
DM4B6H3	DN	L-isoleucine
DM4B6H3	MI	DTK02I1
DM4B6H3	MN	L-type amino acid transporter 4 (SLC43A2)
DM4B6H3	MT	DTP
DM4B6H3	MA	Substrate
DM4B6H3	RN	Anticipation of food intake induces phosphorylation switch to regulate basolateral amino acid transporter LAT4 (SLC43A2) function. J Physiol. 2019 Jan;597(2):521-542.
DM4B6H3	RU	http://www.ncbi.nlm.nih.gov/pubmed/30379325

DMVSAUL	DI	DMVSAUL
DMVSAUL	DN	L-isoleucyl-L-prolinamide
DMVSAUL	MI	TTQ7R2V
DMVSAUL	MN	Tripeptidyl-peptidase II (TPP2)
DMVSAUL	MT	DTT
DMVSAUL	MA	Inhibitor
DMVSAUL	RN	Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach ... J Med Chem. 2005 Nov 17;48(23):7333-42.
DMVSAUL	RU	https://pubmed.ncbi.nlm.nih.gov/16279793

DMHYLQ2	DI	DMHYLQ2
DMHYLQ2	DN	Lithium chloride
DMHYLQ2	MI	TTRZQE3
DMHYLQ2	MN	Glycogen synthase kinase-3 alpha (GSK-3A)
DMHYLQ2	MT	DTT
DMHYLQ2	MA	Inhibitor
DMHYLQ2	RN	Glycogen synthase kinase 3 beta (GSK-3 beta) as a therapeutic target in neuroAIDS. J Neuroimmune Pharmacol. 2007 Mar;2(1):93-6.
DMHYLQ2	RU	https://pubmed.ncbi.nlm.nih.gov/18040831

DME76CQ	DI	DME76CQ
DME76CQ	DN	lithocholylcholine
DME76CQ	MI	TTOXS3C
DME76CQ	MN	Muscarinic acetylcholine receptor (CHRM)
DME76CQ	MT	DTT
DME76CQ	MA	Antagonist
DME76CQ	RN	Lithocholylcholine, a bile acid/acetylcholine hybrid, is a muscarinic receptor antagonist. J Pharmacol Exp Ther. 2002 Oct;303(1):29-35.
DME76CQ	RU	https://pubmed.ncbi.nlm.nih.gov/12235229

DME76CQ	DI	DME76CQ
DME76CQ	DN	lithocholylcholine
DME76CQ	MI	TTQ13Z5
DME76CQ	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DME76CQ	MT	DTT
DME76CQ	MA	Antagonist
DME76CQ	RN	Lithocholylcholine, a bile acid/acetylcholine hybrid, is a muscarinic receptor antagonist. J Pharmacol Exp Ther. 2002 Oct;303(1):29-35.
DME76CQ	RU	https://pubmed.ncbi.nlm.nih.gov/12235229

DMPAKQV	DI	DMPAKQV
DMPAKQV	DN	Lithospermic acid
DMPAKQV	MI	TTLM12X
DMPAKQV	MN	Matrix metalloproteinase-2 (MMP-2)
DMPAKQV	MT	DTT
DMPAKQV	MA	Inhibitor
DMPAKQV	RN	Matrix metalloproteinase-2 inhibitors from Clinopodium chinense var. parviflorum. J Nat Prod. 2009 Aug;72(8):1379-84.
DMPAKQV	RU	https://pubmed.ncbi.nlm.nih.gov/19711986

DM6J1BY	DI	DM6J1BY
DM6J1BY	DN	LIVIDOMYCIN A
DM6J1BY	MI	TTQY2EJ
DM6J1BY	MN	TERT messenger RNA (TERT mRNA)
DM6J1BY	MT	DTT
DM6J1BY	MA	Inhibitor
DM6J1BY	RN	Nucleic acid-binding ligands identify new mechanisms to inhibit telomerase. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3467-71.
DM6J1BY	RU	https://pubmed.ncbi.nlm.nih.gov/15177454

DMJ108U	DI	DMJ108U
DMJ108U	DN	LJP-1207
DMJ108U	MI	TT7HC21
DMJ108U	MN	Membrane copper amine oxidase (AOC3)
DMJ108U	MT	DTT
DMJ108U	MA	Inhibitor
DMJ108U	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2767).
DMJ108U	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2767

DMLVTXM	DI	DMLVTXM
DMLVTXM	DN	LK 204-545
DMLVTXM	MI	TTMXGCW
DMLVTXM	MN	Adrenergic receptor beta-3 (ADRB3)
DMLVTXM	MT	DTT
DMLVTXM	MA	Antagonist
DMLVTXM	RN	LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors. Eur J Pharmacol. 1999 Feb 19;367(2-3):431-5.
DMLVTXM	RU	https://pubmed.ncbi.nlm.nih.gov/10079020

DM6RCES	DI	DM6RCES
DM6RCES	DN	LL-6531
DM6RCES	MI	TTJ584C
DM6RCES	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DM6RCES	MT	DTT
DM6RCES	MA	Modulator
DM6RCES	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 593).
DM6RCES	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=593

DMO1Z5Q	DI	DMO1Z5Q
DMO1Z5Q	DN	L-lactic acid
DMO1Z5Q	MI	TTVK4ZO
DMO1Z5Q	MN	G protein coupled receptor 81 (HCAR1)
DMO1Z5Q	MT	DTT
DMO1Z5Q	MA	Agonist
DMO1Z5Q	RN	Screening beta-arrestin recruitment for the identification of natural ligands for orphan G-protein-coupled receptors. J Biomol Screen. 2013 Jun;18(5):599-609.
DMO1Z5Q	RU	https://pubmed.ncbi.nlm.nih.gov/23396314

DMO1Z5Q	DI	DMO1Z5Q
DMO1Z5Q	DN	L-lactic acid
DMO1Z5Q	MI	DEQG7F9
DMO1Z5Q	MN	Lactate dehydrogenase C (LDHC)
DMO1Z5Q	MT	DME
DMO1Z5Q	MA	Metabolism
DMO1Z5Q	RN	Kinetic characterization of lactate dehydrogenase in normal and malignant human breast tissues. Cancer Cell Int. 2015 Feb 15;15:19.
DMO1Z5Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25705126

DMQHN7I	DI	DMQHN7I
DMQHN7I	DN	L-leucine
DMQHN7I	MI	DEP7BTH
DMQHN7I	MN	Leucyl-tRNA synthetase (LARS2)
DMQHN7I	MT	DME
DMQHN7I	MA	Metabolism
DMQHN7I	RN	Expression and characterization of the human mitochondrial leucyl-tRNA synthetase. Biochim Biophys Acta. 2000 Feb 29;1490(3):245-58.
DMQHN7I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10684970

DMQHN7I	DI	DMQHN7I
DMQHN7I	DN	L-leucine
DMQHN7I	MI	DT48T0N
DMQHN7I	MN	L-type amino acid transporter 1 (SLC7A5)
DMQHN7I	MT	DTP
DMQHN7I	MA	Substrate
DMQHN7I	RN	Bidirectional transport of amino acids regulates mTOR and autophagy. Cell. 2009 Feb 6;136(3):521-34.
DMQHN7I	RU	http://www.ncbi.nlm.nih.gov/pubmed/19203585

DMQHN7I	DI	DMQHN7I
DMQHN7I	DN	L-leucine
DMQHN7I	MI	DTBMSWG
DMQHN7I	MN	L-type amino acid transporter 3 (SLC43A1)
DMQHN7I	MT	DTP
DMQHN7I	MA	Substrate
DMQHN7I	RN	Identification of a novel system L amino acid transporter structurally distinct from heterodimeric amino acid transporters. J Biol Chem. 2003 Oct 31;278(44):43838-45.
DMQHN7I	RU	http://www.ncbi.nlm.nih.gov/pubmed/12930836

DMQHN7I	DI	DMQHN7I
DMQHN7I	DN	L-leucine
DMQHN7I	MI	DTK02I1
DMQHN7I	MN	L-type amino acid transporter 4 (SLC43A2)
DMQHN7I	MT	DTP
DMQHN7I	MA	Substrate
DMQHN7I	RN	Anticipation of food intake induces phosphorylation switch to regulate basolateral amino acid transporter LAT4 (SLC43A2) function. J Physiol. 2019 Jan;597(2):521-542.
DMQHN7I	RU	http://www.ncbi.nlm.nih.gov/pubmed/30379325

DM41MS3	DI	DM41MS3
DM41MS3	DN	L-leucyl-L-prolinamide
DM41MS3	MI	TTQ7R2V
DM41MS3	MN	Tripeptidyl-peptidase II (TPP2)
DM41MS3	MT	DTT
DM41MS3	MA	Inhibitor
DM41MS3	RN	Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach ... J Med Chem. 2005 Nov 17;48(23):7333-42.
DM41MS3	RU	https://pubmed.ncbi.nlm.nih.gov/16279793

DMOD5CK	DI	DMOD5CK
DMOD5CK	DN	L-lysine
DMOD5CK	MI	TTI1PRE
DMOD5CK	MN	G-protein coupled receptor GPCR33 (GPRC6A)
DMOD5CK	MT	DTT
DMOD5CK	MA	Agonist
DMOD5CK	RN	Deorphanization of GPRC6A: a promiscuous L-alpha-amino acid receptor with preference for basic amino acids. Mol Pharmacol. 2005 Mar;67(3):589-97.
DMOD5CK	RU	https://pubmed.ncbi.nlm.nih.gov/15576628

DMOD5CK	DI	DMOD5CK
DMOD5CK	DN	L-lysine
DMOD5CK	MI	DT96BT4
DMOD5CK	MN	Mitochondrial ornithine transporter 3 (SLC25A29)
DMOD5CK	MT	DTP
DMOD5CK	MA	Substrate
DMOD5CK	RN	The human gene SLC25A29, of solute carrier family 25, encodes a mitochondrial transporter of basic amino acids. J Biol Chem. 2014 May 9;289(19):13374-84.
DMOD5CK	RU	http://www.ncbi.nlm.nih.gov/pubmed/24652292

DMOGZLU	DI	DMOGZLU
DMOGZLU	DN	LLZ16406
DMOGZLU	MI	TTQBCEJ
DMOGZLU	MN	MAPK/ERK kinase kinase 1 (MAP3K1)
DMOGZLU	MT	DTT
DMOGZLU	MA	Inhibitor
DMOGZLU	RN	Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
DMOGZLU	RU	https://pubmed.ncbi.nlm.nih.gov/11804650

DM783BP	DI	DM783BP
DM783BP	DN	LLZ16407
DM783BP	MI	TTK1N5G
DM783BP	MN	MAPK/ERK kinase kinase 2 (MAP3K2)
DM783BP	MT	DTT
DM783BP	MA	Inhibitor
DM783BP	RN	Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
DM783BP	RU	https://pubmed.ncbi.nlm.nih.gov/11804650

DMWLMTD	DI	DMWLMTD
DMWLMTD	DN	LM-4108
DMWLMTD	MI	TTVKILB
DMWLMTD	MN	Prostaglandin G/H synthase 2 (COX-2)
DMWLMTD	MT	DTT
DMWLMTD	MA	Inhibitor
DMWLMTD	RN	Discovery of 3-(4-bromophenyl)-6-nitrobenzo[1.3.2]dithiazolium ylide 1,1-dioxide as a novel dual cyclooxygenase/5-lipoxygenase inhibitor that also ... Bioorg Med Chem. 2010 Jan 15;18(2):597-604.
DMWLMTD	RU	https://pubmed.ncbi.nlm.nih.gov/20056549

DMK12C0	DI	DMK12C0
DMK12C0	DN	L-mannitol derivative
DMK12C0	MI	TTH9VL3
DMK12C0	MN	Plasmodium Plasmepsin 1 (Malaria PLA1)
DMK12C0	MT	DTT
DMK12C0	MA	Inhibitor
DMK12C0	RN	Synthesis of malarial plasmepsin inhibitors and prediction of binding modes by molecular dynamics simulations. J Med Chem. 2005 Sep 22;48(19):6090-106.
DMK12C0	RU	https://pubmed.ncbi.nlm.nih.gov/16162010

DME8G1U	DI	DME8G1U
DME8G1U	DN	L-methionine
DME8G1U	MI	DER6EU8
DME8G1U	MN	Homoserine-O-transsuccinylase (metAA)
DME8G1U	MT	DME
DME8G1U	MA	Metabolism
DME8G1U	RN	Regulation of the methionine feedback-sensitive enzyme in mutants of Salmonella typhimurium. J Bacteriol. 1972 Jan;109(1):8-11.
DME8G1U	RU	https://pubmed.ncbi.nlm.nih.gov/4550678

DME8G1U	DI	DME8G1U
DME8G1U	DN	L-methionine
DME8G1U	MI	DEKF1OH
DME8G1U	MN	Methionine adenosyltransferase II beta (MAT2B)
DME8G1U	MT	DME
DME8G1U	MA	Metabolism
DME8G1U	RN	How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DME8G1U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17139284

DME8G1U	DI	DME8G1U
DME8G1U	DN	L-methionine
DME8G1U	MI	DEFADPU
DME8G1U	MN	Methionine-R-sulfoxide reductase B1 (MSRB1)
DME8G1U	MT	DME
DME8G1U	MA	Metabolism
DME8G1U	RN	Catalytic advantages provided by selenocysteine in methionine-S-sulfoxide reductases. Biochemistry. 2006 Nov 21;45(46):13697-704.
DME8G1U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17105189

DME8G1U	DI	DME8G1U
DME8G1U	DN	L-methionine
DME8G1U	MI	DEMQOF7
DME8G1U	MN	Methionine-R-sulfoxide reductase B2 (MSRB2)
DME8G1U	MT	DME
DME8G1U	MA	Metabolism
DME8G1U	RN	The X-ray structure of the N-terminal domain of PILB from Neisseria meningitidis reveals a thioredoxin-fold. J Mol Biol. 2006 Apr 28;358(2):443-54.
DME8G1U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16530221

DME8G1U	DI	DME8G1U
DME8G1U	DN	L-methionine
DME8G1U	MI	DE0K52I
DME8G1U	MN	Methionine-tRNA ligase cytoplasmic (MARS)
DME8G1U	MT	DME
DME8G1U	MA	Metabolism
DME8G1U	RN	Mutations in methylenetetrahydrofolate reductase or cystathionine beta-synthase gene, or a high-methionine diet, increase homocysteine thiolactone levels in humans and mice. FASEB J. 2007 Jun;21(8):1707-13.
DME8G1U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17327360

DME8G1U	DI	DME8G1U
DME8G1U	DN	L-methionine
DME8G1U	MI	DEEH5Y9
DME8G1U	MN	Methionine-tRNA ligase mitochondrial (MARS2)
DME8G1U	MT	DME
DME8G1U	MA	Metabolism
DME8G1U	RN	How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DME8G1U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17139284

DME8G1U	DI	DME8G1U
DME8G1U	DN	L-methionine
DME8G1U	MI	DEU2ZBY
DME8G1U	MN	Peptide methionine sulfoxide reductase (MSRA)
DME8G1U	MT	DME
DME8G1U	MA	Metabolism
DME8G1U	RN	Characterization of the amino acids involved in substrate specificity of methionine sulfoxide reductase A. J Biol Chem. 2007 Jul 13;282(28):20484-91.
DME8G1U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17500063

DME8G1U	DI	DME8G1U
DME8G1U	DN	L-methionine
DME8G1U	MI	DEQ6NC9
DME8G1U	MN	S-adenosylmethionine synthase 1 (MAT1A)
DME8G1U	MT	DME
DME8G1U	MA	Metabolism
DME8G1U	RN	Role of methionine adenosyltransferase 2A and S-adenosylmethionine in mitogen-induced growth of human colon cancer cells. Gastroenterology. 2007 Jul;133(1):207-18.
DME8G1U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17631143

DME8G1U	DI	DME8G1U
DME8G1U	DN	L-methionine
DME8G1U	MI	DE76G8C
DME8G1U	MN	S-adenosylmethionine synthase 2 (MAT2A)
DME8G1U	MT	DME
DME8G1U	MA	Metabolism
DME8G1U	RN	Role of methionine adenosyltransferase 2A and S-adenosylmethionine in mitogen-induced growth of human colon cancer cells. Gastroenterology. 2007 Jul;133(1):207-18.
DME8G1U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17631143

DM8LVQF	DI	DM8LVQF
DM8LVQF	DN	L-Myo-Inositol-1-Phosphate
DM8LVQF	MI	TTXWL6D
DM8LVQF	MN	Inositol-1(or4)-monophosphatase (IMPA2)
DM8LVQF	MT	DTT
DM8LVQF	MA	Inhibitor
DM8LVQF	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM8LVQF	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DME9FAV	DI	DME9FAV
DME9FAV	DN	L-NIO
DME9FAV	MI	TTZUFI5
DME9FAV	MN	Nitric-oxide synthase brain (NOS1)
DME9FAV	MT	DTT
DME9FAV	MA	Inhibitor
DME9FAV	RN	Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9.
DME9FAV	RU	https://pubmed.ncbi.nlm.nih.gov/19013076

DME9FAV	DI	DME9FAV
DME9FAV	DN	L-NIO
DME9FAV	MI	TTCM4B3
DME9FAV	MN	Nitric-oxide synthase endothelial (NOS3)
DME9FAV	MT	DTT
DME9FAV	MA	Inhibitor
DME9FAV	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DME9FAV	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DME9FAV	DI	DME9FAV
DME9FAV	DN	L-NIO
DME9FAV	MI	TTF10I9
DME9FAV	MN	Nitric-oxide synthase inducible (NOS2)
DME9FAV	MT	DTT
DME9FAV	MA	Inhibitor
DME9FAV	RN	Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9.
DME9FAV	RU	https://pubmed.ncbi.nlm.nih.gov/19013076

DM7V30L	DI	DM7V30L
DM7V30L	DN	L-norleucyl-L-prolinamide
DM7V30L	MI	TTQ7R2V
DM7V30L	MN	Tripeptidyl-peptidase II (TPP2)
DM7V30L	MT	DTT
DM7V30L	MA	Inhibitor
DM7V30L	RN	Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach ... J Med Chem. 2005 Nov 17;48(23):7333-42.
DM7V30L	RU	https://pubmed.ncbi.nlm.nih.gov/16279793

DMIXFGC	DI	DMIXFGC
DMIXFGC	DN	L-norvalyl-L-prolinamide
DMIXFGC	MI	TTQ7R2V
DMIXFGC	MN	Tripeptidyl-peptidase II (TPP2)
DMIXFGC	MT	DTT
DMIXFGC	MA	Inhibitor
DMIXFGC	RN	Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach ... J Med Chem. 2005 Nov 17;48(23):7333-42.
DMIXFGC	RU	https://pubmed.ncbi.nlm.nih.gov/16279793

DM2GBEW	DI	DM2GBEW
DM2GBEW	DN	Lobatamide A
DM2GBEW	MI	TTTK3BH
DM2GBEW	MN	Vacuolar-type proton ATPase (v-ATPase)
DM2GBEW	MT	DTT
DM2GBEW	MA	Inhibitor
DM2GBEW	RN	Discovery of a novel antitumor benzolactone enamide class that selectively inhibits mammalian vacuolar-type (H+)-atpases. J Pharmacol Exp Ther. 2001 Apr;297(1):114-20.
DM2GBEW	RU	https://pubmed.ncbi.nlm.nih.gov/11259534

DMD91RI	DI	DMD91RI
DMD91RI	DN	Lobatamide B
DMD91RI	MI	TTTK3BH
DMD91RI	MN	Vacuolar-type proton ATPase (v-ATPase)
DMD91RI	MT	DTT
DMD91RI	MA	Inhibitor
DMD91RI	RN	Discovery of a novel antitumor benzolactone enamide class that selectively inhibits mammalian vacuolar-type (H+)-atpases. J Pharmacol Exp Ther. 2001 Apr;297(1):114-20.
DMD91RI	RU	https://pubmed.ncbi.nlm.nih.gov/11259534

DMFIDJS	DI	DMFIDJS
DMFIDJS	DN	Lobatamide C
DMFIDJS	MI	TTTK3BH
DMFIDJS	MN	Vacuolar-type proton ATPase (v-ATPase)
DMFIDJS	MT	DTT
DMFIDJS	MA	Inhibitor
DMFIDJS	RN	Discovery of a novel antitumor benzolactone enamide class that selectively inhibits mammalian vacuolar-type (H+)-atpases. J Pharmacol Exp Ther. 2001 Apr;297(1):114-20.
DMFIDJS	RU	https://pubmed.ncbi.nlm.nih.gov/11259534

DMG706J	DI	DMG706J
DMG706J	DN	Lobatamide D
DMG706J	MI	TTTK3BH
DMG706J	MN	Vacuolar-type proton ATPase (v-ATPase)
DMG706J	MT	DTT
DMG706J	MA	Inhibitor
DMG706J	RN	Discovery of a novel antitumor benzolactone enamide class that selectively inhibits mammalian vacuolar-type (H+)-atpases. J Pharmacol Exp Ther. 2001 Apr;297(1):114-20.
DMG706J	RU	https://pubmed.ncbi.nlm.nih.gov/11259534

DM6BWGQ	DI	DM6BWGQ
DM6BWGQ	DN	Lobatamide F
DM6BWGQ	MI	TTTK3BH
DM6BWGQ	MN	Vacuolar-type proton ATPase (v-ATPase)
DM6BWGQ	MT	DTT
DM6BWGQ	MA	Inhibitor
DM6BWGQ	RN	Discovery of a novel antitumor benzolactone enamide class that selectively inhibits mammalian vacuolar-type (H+)-atpases. J Pharmacol Exp Ther. 2001 Apr;297(1):114-20.
DM6BWGQ	RU	https://pubmed.ncbi.nlm.nih.gov/11259534

DMR2WQE	DI	DMR2WQE
DMR2WQE	DN	LOFENTANIL
DMR2WQE	MI	TT27RFC
DMR2WQE	MN	Opioid receptor delta (OPRD1)
DMR2WQE	MT	DTT
DMR2WQE	MA	Inhibitor
DMR2WQE	RN	Potential affinity labels for the opiate receptor based on fentanyl and related compounds. J Med Chem. 1982 Aug;25(8):913-9.
DMR2WQE	RU	https://pubmed.ncbi.nlm.nih.gov/6288945

DMR2WQE	DI	DMR2WQE
DMR2WQE	DN	LOFENTANIL
DMR2WQE	MI	TTQW87Y
DMR2WQE	MN	Opioid receptor kappa (OPRK1)
DMR2WQE	MT	DTT
DMR2WQE	MA	Inhibitor
DMR2WQE	RN	Potential affinity labels for the opiate receptor based on fentanyl and related compounds. J Med Chem. 1982 Aug;25(8):913-9.
DMR2WQE	RU	https://pubmed.ncbi.nlm.nih.gov/6288945

DMR2WQE	DI	DMR2WQE
DMR2WQE	DN	LOFENTANIL
DMR2WQE	MI	TTKWM86
DMR2WQE	MN	Opioid receptor mu (MOP)
DMR2WQE	MT	DTT
DMR2WQE	MA	Inhibitor
DMR2WQE	RN	Potential affinity labels for the opiate receptor based on fentanyl and related compounds. J Med Chem. 1982 Aug;25(8):913-9.
DMR2WQE	RU	https://pubmed.ncbi.nlm.nih.gov/6288945

DMWFAPJ	DI	DMWFAPJ
DMWFAPJ	DN	LONCHOCARPUSONE
DMWFAPJ	MI	TTUMGNO
DMWFAPJ	MN	Ornithine decarboxylase (ODC1)
DMWFAPJ	MT	DTT
DMWFAPJ	MA	Inhibitor
DMWFAPJ	RN	New bioactive flavonoids and stilbenes in cub resin insecticide. J Nat Prod. 1999 Feb;62(2):205-10.
DMWFAPJ	RU	https://pubmed.ncbi.nlm.nih.gov/10075742

DMAH0RZ	DI	DMAH0RZ
DMAH0RZ	DN	Long-acting Factor VII conjugate
DMAH0RZ	MI	TTF0EGX
DMAH0RZ	MN	Coagulation factor VII (F7)
DMAH0RZ	MT	DTT
DMAH0RZ	MA	Modulator
DMAH0RZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2363).
DMAH0RZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2363

DMZUSJD	DI	DMZUSJD
DMZUSJD	DN	Long-acting factor VIII
DMZUSJD	MI	TT1290U
DMZUSJD	MN	Coagulation factor VIII (F8)
DMZUSJD	MT	DTT
DMZUSJD	MA	Modulator
DMZUSJD	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2607).
DMZUSJD	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2607

DMD32IN	DI	DMD32IN
DMD32IN	DN	Long-acting FSH conjugate
DMD32IN	MI	TTZFDBT
DMD32IN	MN	Follicle-stimulating hormone receptor (FSHR)
DMD32IN	MT	DTT
DMD32IN	MA	Modulator
DMD32IN	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 253).
DMD32IN	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=253

DMH106Y	DI	DMH106Y
DMH106Y	DN	LONGANINE
DMH106Y	MI	TT27RFC
DMH106Y	MN	Opioid receptor delta (OPRD1)
DMH106Y	MT	DTT
DMH106Y	MA	Inhibitor
DMH106Y	RN	Hasubanan alkaloids with delta-opioid binding affinity from the aerial parts of Stephania japonica. J Nat Prod. 2010 May 28;73(5):988-91.
DMH106Y	RU	https://pubmed.ncbi.nlm.nih.gov/20426456

DM5OHVN	DI	DM5OHVN
DM5OHVN	DN	Lophocladine a
DM5OHVN	MI	TT27RFC
DM5OHVN	MN	Opioid receptor delta (OPRD1)
DM5OHVN	MT	DTT
DM5OHVN	MA	Inhibitor
DM5OHVN	RN	Lophocladines, bioactive alkaloids from the red alga Lophocladia sp. J Nat Prod. 2006 Apr;69(4):640-4.
DM5OHVN	RU	https://pubmed.ncbi.nlm.nih.gov/16643042

DMASPV9	DI	DMASPV9
DMASPV9	DN	Lopinavir + ritonavir + interferon beta
DMASPV9	MI	TTWOH4Q
DMASPV9	MN	MERS-CoV 3C-like proteinase (3CLpro)
DMASPV9	MT	DTT
DMASPV9	MA	Inhibitor
DMASPV9	RN	Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381.
DMASPV9	RU	https://pubmed.ncbi.nlm.nih.gov/32205870

DM71BIC	DI	DM71BIC
DM71BIC	DN	LOR-220
DM71BIC	MI	TTHBTOP
DM71BIC	MN	PI3-kinase gamma (PIK3CG)
DM71BIC	MT	DTT
DM71BIC	MA	Inhibitor
DM71BIC	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2155).
DM71BIC	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2155

DM0ECUK	DI	DM0ECUK
DM0ECUK	DN	LORNEIC ACID A
DM0ECUK	MI	TTJ0IQB
DM0ECUK	MN	Phosphodiesterase 5A (PDE5A)
DM0ECUK	MT	DTT
DM0ECUK	MA	Inhibitor
DM0ECUK	RN	Lorneic acids, trialkyl-substituted aromatic acids from a marine-derived actinomycete. J Nat Prod. 2009 Nov;72(11):2046-8.
DM0ECUK	RU	https://pubmed.ncbi.nlm.nih.gov/19856955

DMHKGCM	DI	DMHKGCM
DMHKGCM	DN	L-Ornithine
DMHKGCM	MI	DTWY9RT
DMHKGCM	MN	Cationic amino acid transporter 2 (SLC7A2)
DMHKGCM	MT	DTP
DMHKGCM	MA	Substrate
DMHKGCM	RN	Genetic basis for plasma amino acid concentrations based on absolute quantification: a genome-wide association study in the Japanese population. Eur J Hum Genet. 2019 Apr;27(4):621-630.
DMHKGCM	RU	http://www.ncbi.nlm.nih.gov/pubmed/30659259

DMHKGCM	DI	DMHKGCM
DMHKGCM	DN	L-Ornithine
DMHKGCM	MI	TTI1PRE
DMHKGCM	MN	G-protein coupled receptor GPCR33 (GPRC6A)
DMHKGCM	MT	DTT
DMHKGCM	MA	Agonist
DMHKGCM	RN	Deorphanization of GPRC6A: a promiscuous L-alpha-amino acid receptor with preference for basic amino acids. Mol Pharmacol. 2005 Mar;67(3):589-97.
DMHKGCM	RU	https://pubmed.ncbi.nlm.nih.gov/15576628

DMK5J9M	DI	DMK5J9M
DMK5J9M	DN	Lorpiprazole
DMK5J9M	MI	DECB0K3
DMK5J9M	MN	Cytochrome P450 2D6 (CYP2D6)
DMK5J9M	MT	DME
DMK5J9M	MA	Metabolism
DMK5J9M	RN	[Trazodon--the antidepressant: mechanism of action and its position in the treatment of depression]. Psychiatr Pol. 2011 Jul-Aug;45(4):611-25.
DMK5J9M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22232986

DMWTJ3E	DI	DMWTJ3E
DMWTJ3E	DN	LP-0067
DMWTJ3E	MI	TTBID49
DMWTJ3E	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMWTJ3E	MT	DTT
DMWTJ3E	MA	Antagonist
DMWTJ3E	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 71).
DMWTJ3E	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=71

DM8ZR17	DI	DM8ZR17
DM8ZR17	DN	LP-12
DM8ZR17	MI	TTSQIFT
DM8ZR17	MN	5-HT 1A receptor (HTR1A)
DM8ZR17	MT	DTT
DM8ZR17	MA	Agonist
DM8ZR17	RN	Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2. J Med Chem. 2007 Aug 23;50(17):4214-21.
DM8ZR17	RU	https://pubmed.ncbi.nlm.nih.gov/17649988

DM8ZR17	DI	DM8ZR17
DM8ZR17	DN	LP-12
DM8ZR17	MI	TTJQOD7
DM8ZR17	MN	5-HT 2A receptor (HTR2A)
DM8ZR17	MT	DTT
DM8ZR17	MA	Agonist
DM8ZR17	RN	Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2. J Med Chem. 2007 Aug 23;50(17):4214-21.
DM8ZR17	RU	https://pubmed.ncbi.nlm.nih.gov/17649988

DM8ZR17	DI	DM8ZR17
DM8ZR17	DN	LP-12
DM8ZR17	MI	TTO9X1H
DM8ZR17	MN	5-HT 7 receptor (HTR7)
DM8ZR17	MT	DTT
DM8ZR17	MA	Agonist
DM8ZR17	RN	Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2. J Med Chem. 2007 Aug 23;50(17):4214-21.
DM8ZR17	RU	https://pubmed.ncbi.nlm.nih.gov/17649988

DM8ZR17	DI	DM8ZR17
DM8ZR17	DN	LP-12
DM8ZR17	MI	TTEX248
DM8ZR17	MN	Dopamine D2 receptor (D2R)
DM8ZR17	MT	DTT
DM8ZR17	MA	Agonist
DM8ZR17	RN	Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2. J Med Chem. 2007 Aug 23;50(17):4214-21.
DM8ZR17	RU	https://pubmed.ncbi.nlm.nih.gov/17649988

DMKDGLA	DI	DMKDGLA
DMKDGLA	DN	LP-211
DMKDGLA	MI	TTSQIFT
DMKDGLA	MN	5-HT 1A receptor (HTR1A)
DMKDGLA	MT	DTT
DMKDGLA	MA	Agonist
DMKDGLA	RN	Structural modifications of N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides: influence on lipophilicity and 5-HT7 receptor act... J Med Chem. 2008 Sep 25;51(18):5813-22.
DMKDGLA	RU	https://pubmed.ncbi.nlm.nih.gov/18800769

DMKDGLA	DI	DMKDGLA
DMKDGLA	DN	LP-211
DMKDGLA	MI	TTO9X1H
DMKDGLA	MN	5-HT 7 receptor (HTR7)
DMKDGLA	MT	DTT
DMKDGLA	MA	Agonist
DMKDGLA	RN	Structural modifications of N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides: influence on lipophilicity and 5-HT7 receptor act... J Med Chem. 2008 Sep 25;51(18):5813-22.
DMKDGLA	RU	https://pubmed.ncbi.nlm.nih.gov/18800769

DMKDGLA	DI	DMKDGLA
DMKDGLA	DN	LP-211
DMKDGLA	MI	TTEX248
DMKDGLA	MN	Dopamine D2 receptor (D2R)
DMKDGLA	MT	DTT
DMKDGLA	MA	Agonist
DMKDGLA	RN	Structural modifications of N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides: influence on lipophilicity and 5-HT7 receptor act... J Med Chem. 2008 Sep 25;51(18):5813-22.
DMKDGLA	RU	https://pubmed.ncbi.nlm.nih.gov/18800769

DMIWMZY	DI	DMIWMZY
DMIWMZY	DN	LP-403812
DMIWMZY	MI	TT9LGO5
DMIWMZY	MN	Sodium-dependent proline transporter (SLC6A7)
DMIWMZY	MT	DTT
DMIWMZY	MA	Inhibitor
DMIWMZY	RN	Discovery and characterization of potent small molecule inhibitors of the high affinity proline transporter. Neurosci Lett. 2009 Feb 27;451(3):212-6.
DMIWMZY	RU	https://pubmed.ncbi.nlm.nih.gov/19159658

DM0C3SF	DI	DM0C3SF
DM0C3SF	DN	LP-44
DM0C3SF	MI	TTSQIFT
DM0C3SF	MN	5-HT 1A receptor (HTR1A)
DM0C3SF	MT	DTT
DM0C3SF	MA	Agonist
DM0C3SF	RN	Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2. J Med Chem. 2007 Aug 23;50(17):4214-21.
DM0C3SF	RU	https://pubmed.ncbi.nlm.nih.gov/17649988

DM0C3SF	DI	DM0C3SF
DM0C3SF	DN	LP-44
DM0C3SF	MI	TTJQOD7
DM0C3SF	MN	5-HT 2A receptor (HTR2A)
DM0C3SF	MT	DTT
DM0C3SF	MA	Agonist
DM0C3SF	RN	Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2. J Med Chem. 2007 Aug 23;50(17):4214-21.
DM0C3SF	RU	https://pubmed.ncbi.nlm.nih.gov/17649988

DM0C3SF	DI	DM0C3SF
DM0C3SF	DN	LP-44
DM0C3SF	MI	TTO9X1H
DM0C3SF	MN	5-HT 7 receptor (HTR7)
DM0C3SF	MT	DTT
DM0C3SF	MA	Agonist
DM0C3SF	RN	Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2. J Med Chem. 2007 Aug 23;50(17):4214-21.
DM0C3SF	RU	https://pubmed.ncbi.nlm.nih.gov/17649988

DM0C3SF	DI	DM0C3SF
DM0C3SF	DN	LP-44
DM0C3SF	MI	TTEX248
DM0C3SF	MN	Dopamine D2 receptor (D2R)
DM0C3SF	MT	DTT
DM0C3SF	MA	Agonist
DM0C3SF	RN	Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2. J Med Chem. 2007 Aug 23;50(17):4214-21.
DM0C3SF	RU	https://pubmed.ncbi.nlm.nih.gov/17649988

DMGMO3Q	DI	DMGMO3Q
DMGMO3Q	DN	LP-661438
DMGMO3Q	MI	TTJOCE4
DMGMO3Q	MN	Deoxycytidine kinase (DCK)
DMGMO3Q	MT	DTT
DMGMO3Q	MA	Modulator
DMGMO3Q	RN	236th ACS National Meeting
DMGMO3Q	RU	http://www.amriglobal.com/img/document_files/TR_aug08a.pdf

DMTZYQ3	DI	DMTZYQ3
DMTZYQ3	DN	LP99
DMTZYQ3	MI	TT07ZS1
DMTZYQ3	MN	Bromodomain-containing protein 7 (BRD7)
DMTZYQ3	MT	DTT
DMTZYQ3	MA	Inhibitor
DMTZYQ3	RN	LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor. Angew Chem Int Ed Engl. 2015 May 18;54(21):6217-21.
DMTZYQ3	RU	https://pubmed.ncbi.nlm.nih.gov/25864491

DMTZYQ3	DI	DMTZYQ3
DMTZYQ3	DN	LP99
DMTZYQ3	MI	TTR7L5Y
DMTZYQ3	MN	Bromodomain-containing protein 9 (BRD9)
DMTZYQ3	MT	DTT
DMTZYQ3	MA	Inhibitor
DMTZYQ3	RN	LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor. Angew Chem Int Ed Engl. 2015 May 18;54(21):6217-21.
DMTZYQ3	RU	https://pubmed.ncbi.nlm.nih.gov/25864491

DMI5XR1	DI	DMI5XR1
DMI5XR1	DN	LPA
DMI5XR1	MI	TTO897C
DMI5XR1	MN	G protein coupled receptor 87 (GPR87)
DMI5XR1	MT	DTT
DMI5XR1	MA	Agonist
DMI5XR1	RN	Identification of the orphan GPCR, P2Y(10) receptor as the sphingosine-1-phosphate and lysophosphatidic acid receptor. Biochem Biophys Res Commun. 2008 Jul 11;371(4):707-12.
DMI5XR1	RU	https://pubmed.ncbi.nlm.nih.gov/18466763

DMI5XR1	DI	DMI5XR1
DMI5XR1	DN	LPA
DMI5XR1	MI	TTE2YJR
DMI5XR1	MN	Lysophosphatidate-3 receptor (LPAR3)
DMI5XR1	MT	DTT
DMI5XR1	MA	Agonist
DMI5XR1	RN	Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid. J Biol Chem. 1999 Sep 24;274(39):27776-85.
DMI5XR1	RU	https://pubmed.ncbi.nlm.nih.gov/10488122

DMI5XR1	DI	DMI5XR1
DMI5XR1	DN	LPA
DMI5XR1	MI	TTQ6S1K
DMI5XR1	MN	Lysophosphatidic acid receptor 1 (LPAR1)
DMI5XR1	MT	DTT
DMI5XR1	MA	Agonist
DMI5XR1	RN	Diversity of lysophosphatidic acid receptor-mediated intracellular calcium signaling in early cortical neurogenesis. J Neurosci. 2010 May 26;30(21):7300-9.
DMI5XR1	RU	https://pubmed.ncbi.nlm.nih.gov/20505096

DMI5XR1	DI	DMI5XR1
DMI5XR1	DN	LPA
DMI5XR1	MI	TTB7Y8I
DMI5XR1	MN	Lysophosphatidic acid receptor 2 (LPAR2)
DMI5XR1	MT	DTT
DMI5XR1	MA	Agonist
DMI5XR1	RN	Synthesis and biological evaluation of phosphonic and thiophosphoric acid derivatives of lysophosphatidic acid. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3473-6.
DMI5XR1	RU	https://pubmed.ncbi.nlm.nih.gov/15177455

DMI5XR1	DI	DMI5XR1
DMI5XR1	DN	LPA
DMI5XR1	MI	TT7ZMY4
DMI5XR1	MN	Lysophosphatidic acid receptor 4 (LPAR4)
DMI5XR1	MT	DTT
DMI5XR1	MA	Agonist
DMI5XR1	RN	Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J Biol Chem. 2003 Jul 11;278(28):25600-6.
DMI5XR1	RU	https://pubmed.ncbi.nlm.nih.gov/12724320

DMI5XR1	DI	DMI5XR1
DMI5XR1	DN	LPA
DMI5XR1	MI	TTABCJ6
DMI5XR1	MN	Lysophosphatidic acid receptor 5 (LPAR5)
DMI5XR1	MT	DTT
DMI5XR1	MA	Agonist
DMI5XR1	RN	Screening beta-arrestin recruitment for the identification of natural ligands for orphan G-protein-coupled receptors. J Biomol Screen. 2013 Jun;18(5):599-609.
DMI5XR1	RU	https://pubmed.ncbi.nlm.nih.gov/23396314

DMI5XR1	DI	DMI5XR1
DMI5XR1	DN	LPA
DMI5XR1	MI	TTZDAGB
DMI5XR1	MN	Lysophosphatidic acid receptor 6 (LPAR6)
DMI5XR1	MT	DTT
DMI5XR1	MA	Agonist
DMI5XR1	RN	G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth. Nat Genet. 2008 Mar;40(3):329-34.
DMI5XR1	RU	https://pubmed.ncbi.nlm.nih.gov/18297070

DMI5XR1	DI	DMI5XR1
DMI5XR1	DN	LPA
DMI5XR1	MI	TTMFOU6
DMI5XR1	MN	P2Y purinoceptor 10 (P2RY10)
DMI5XR1	MT	DTT
DMI5XR1	MA	Agonist
DMI5XR1	RN	Identification of the orphan GPCR, P2Y(10) receptor as the sphingosine-1-phosphate and lysophosphatidic acid receptor. Biochem Biophys Res Commun. 2008 Jul 11;371(4):707-12.
DMI5XR1	RU	https://pubmed.ncbi.nlm.nih.gov/18466763

DMI5XR1	DI	DMI5XR1
DMI5XR1	DN	LPA
DMI5XR1	MI	TT9JZCK
DMI5XR1	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMI5XR1	MT	DTT
DMI5XR1	MA	Agonist
DMI5XR1	RN	Lysophosphatidic acid stimulates the G-protein-coupled receptor EDG-1 as a low affinity agonist. J Biol Chem. 1998 Aug 21;273(34):22105-12.
DMI5XR1	RU	https://pubmed.ncbi.nlm.nih.gov/9705355

DM1JGDM	DI	DM1JGDM
DM1JGDM	DN	Lpc-Ether
DM1JGDM	MI	TT9V5JH
DM1JGDM	MN	Phospholipase A2 (PLA2G1B)
DM1JGDM	MT	DTT
DM1JGDM	MA	Inhibitor
DM1JGDM	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM1JGDM	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMY1807	DI	DMY1807
DMY1807	DN	LRHYLNLLTRQRY-NH2
DMY1807	MI	TTRK9JT
DMY1807	MN	Neuropeptide Y receptor type 1 (NPY1R)
DMY1807	MT	DTT
DMY1807	MA	Inhibitor
DMY1807	RN	A long-acting selective neuropeptide Y2 receptor PEGylated peptide agonist reduces food intake in mice. Bioorg Med Chem Lett. 2007 Apr 1;17(7):1916-9.
DMY1807	RU	https://pubmed.ncbi.nlm.nih.gov/17292607

DMY1807	DI	DMY1807
DMY1807	DN	LRHYLNLLTRQRY-NH2
DMY1807	MI	TTJ6WK9
DMY1807	MN	Neuropeptide Y receptor type 2 (NPY2R)
DMY1807	MT	DTT
DMY1807	MA	Inhibitor
DMY1807	RN	A long-acting selective neuropeptide Y2 receptor PEGylated peptide agonist reduces food intake in mice. Bioorg Med Chem Lett. 2007 Apr 1;17(7):1916-9.
DMY1807	RU	https://pubmed.ncbi.nlm.nih.gov/17292607

DMUBF53	DI	DMUBF53
DMUBF53	DN	LS-192629
DMUBF53	MI	TTSCIUP
DMUBF53	MN	Oxytocin receptor (OTR)
DMUBF53	MT	DTT
DMUBF53	MA	Antagonist
DMUBF53	RN	Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a ... J Pharmacol Exp Ther. 2003 Jul;306(1):253-61.
DMUBF53	RU	https://pubmed.ncbi.nlm.nih.gov/12660315

DMUBF53	DI	DMUBF53
DMUBF53	DN	LS-192629
DMUBF53	MI	TT4TFGN
DMUBF53	MN	Vasopressin V1a receptor (V1AR)
DMUBF53	MT	DTT
DMUBF53	MA	Antagonist
DMUBF53	RN	Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a ... J Pharmacol Exp Ther. 2003 Jul;306(1):253-61.
DMUBF53	RU	https://pubmed.ncbi.nlm.nih.gov/12660315

DM6WPIS	DI	DM6WPIS
DM6WPIS	DN	L-Serine
DM6WPIS	MI	TTI1PRE
DM6WPIS	MN	G-protein coupled receptor GPCR33 (GPRC6A)
DM6WPIS	MT	DTT
DM6WPIS	MA	Agonist
DM6WPIS	RN	Deorphanization of GPRC6A: a promiscuous L-alpha-amino acid receptor with preference for basic amino acids. Mol Pharmacol. 2005 Mar;67(3):589-97.
DM6WPIS	RU	https://pubmed.ncbi.nlm.nih.gov/15576628

DMTJ1NH	DI	DMTJ1NH
DMTJ1NH	DN	L-serine-O-phosphate
DMTJ1NH	MI	TTZHY6R
DMTJ1NH	MN	Glycogen phosphorylase muscle form (GP)
DMTJ1NH	MT	DTT
DMTJ1NH	MA	Inhibitor
DMTJ1NH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMTJ1NH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMTJ1NH	DI	DMTJ1NH
DMTJ1NH	DN	L-serine-O-phosphate
DMTJ1NH	MI	TTICZ1O
DMTJ1NH	MN	Metabotropic glutamate receptor 4 (mGluR4)
DMTJ1NH	MT	DTT
DMTJ1NH	MA	Agonist
DMTJ1NH	RN	Serine-O-phosphate has affinity for type IV, but not type I, metabotropic glutamate receptor. Neuroreport. 1993 Sep;4(9):1099-101.
DMTJ1NH	RU	https://pubmed.ncbi.nlm.nih.gov/8106006

DMTJ1NH	DI	DMTJ1NH
DMTJ1NH	DN	L-serine-O-phosphate
DMTJ1NH	MI	TTWRP2F
DMTJ1NH	MN	Metabotropic glutamate receptor 6 (mGluR6)
DMTJ1NH	MT	DTT
DMTJ1NH	MA	Agonist
DMTJ1NH	RN	Cloning, distribution and functional expression of the human mGlu6 metabotropic glutamate receptor. Neuropharmacology. 1997 Feb;36(2):145-52.
DMTJ1NH	RU	https://pubmed.ncbi.nlm.nih.gov/9144651

DMTJ1NH	DI	DMTJ1NH
DMTJ1NH	DN	L-serine-O-phosphate
DMTJ1NH	MI	TT0I76D
DMTJ1NH	MN	Metabotropic glutamate receptor 7 (mGluR7)
DMTJ1NH	MT	DTT
DMTJ1NH	MA	Agonist
DMTJ1NH	RN	Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 2000 Dec;362(6):546-54.
DMTJ1NH	RU	https://pubmed.ncbi.nlm.nih.gov/11138847

DMTJ1NH	DI	DMTJ1NH
DMTJ1NH	DN	L-serine-O-phosphate
DMTJ1NH	MI	TT0IFKL
DMTJ1NH	MN	Metabotropic glutamate receptor 8 (mGluR8)
DMTJ1NH	MT	DTT
DMTJ1NH	MA	Agonist
DMTJ1NH	RN	Cloning and functional expression of alternative spliced variants of the human metabotropic glutamate receptor 8. Brain Res Mol Brain Res. 1999 Apr 20;67(2):201-10.
DMTJ1NH	RU	https://pubmed.ncbi.nlm.nih.gov/10216218

DMTJ1NH	DI	DMTJ1NH
DMTJ1NH	DN	L-serine-O-phosphate
DMTJ1NH	MI	TT9QBI6
DMTJ1NH	MN	Phosphoinositide dependent protein kinase-1 (PDPK1)
DMTJ1NH	MT	DTT
DMTJ1NH	MA	Inhibitor
DMTJ1NH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMTJ1NH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMTJ1NH	DI	DMTJ1NH
DMTJ1NH	DN	L-serine-O-phosphate
DMTJ1NH	MI	TT8QL1J
DMTJ1NH	MN	Protein kinase C theta (PRKCQ)
DMTJ1NH	MT	DTT
DMTJ1NH	MA	Inhibitor
DMTJ1NH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMTJ1NH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMTJ1NH	DI	DMTJ1NH
DMTJ1NH	DN	L-serine-O-phosphate
DMTJ1NH	MI	TTLP3GX
DMTJ1NH	MN	Pseudomonas Phosphomannomutase/phosphoglucomutase (Pseudo algC)
DMTJ1NH	MT	DTT
DMTJ1NH	MA	Inhibitor
DMTJ1NH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMTJ1NH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMTJ1NH	DI	DMTJ1NH
DMTJ1NH	DN	L-serine-O-phosphate
DMTJ1NH	MI	TTH0KSX
DMTJ1NH	MN	Rhodopsin (RHO)
DMTJ1NH	MT	DTT
DMTJ1NH	MA	Inhibitor
DMTJ1NH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMTJ1NH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMWVTS3	DI	DMWVTS3
DMWVTS3	DN	LSN2463359
DMWVTS3	MI	TTHS256
DMWVTS3	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMWVTS3	MT	DTT
DMWVTS3	MA	Modulator (allosteric modulator)
DMWVTS3	RN	In vitro characterisation of the novel positive allosteric modulators of the mGlu receptor, LSN2463359 and LSN2814617, and their effects on sleep architecture and operant responding in the rat. Neuropharmacology. 2013 Jan;64:224-39.
DMWVTS3	RU	https://pubmed.ncbi.nlm.nih.gov/22884720

DMV9NP6	DI	DMV9NP6
DMV9NP6	DN	LSN2814617
DMV9NP6	MI	TTHS256
DMV9NP6	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMV9NP6	MT	DTT
DMV9NP6	MA	Modulator (allosteric modulator)
DMV9NP6	RN	In vitro characterisation of the novel positive allosteric modulators of the mGlu receptor, LSN2463359 and LSN2814617, and their effects on sleep architecture and operant responding in the rat. Neuropharmacology. 2013 Jan;64:224-39.
DMV9NP6	RU	https://pubmed.ncbi.nlm.nih.gov/22884720

DM74J10	DI	DM74J10
DM74J10	DN	LSP1-2111
DM74J10	MI	TTICZ1O
DM74J10	MN	Metabotropic glutamate receptor 4 (mGluR4)
DM74J10	MT	DTT
DM74J10	MA	Agonist
DM74J10	RN	Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism. FASEB J. 2009 Oct;23(10):3619-28.
DM74J10	RU	https://pubmed.ncbi.nlm.nih.gov/19525404

DM74J10	DI	DM74J10
DM74J10	DN	LSP1-2111
DM74J10	MI	TTWRP2F
DM74J10	MN	Metabotropic glutamate receptor 6 (mGluR6)
DM74J10	MT	DTT
DM74J10	MA	Agonist
DM74J10	RN	Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism. FASEB J. 2009 Oct;23(10):3619-28.
DM74J10	RU	https://pubmed.ncbi.nlm.nih.gov/19525404

DM74J10	DI	DM74J10
DM74J10	DN	LSP1-2111
DM74J10	MI	TT0I76D
DM74J10	MN	Metabotropic glutamate receptor 7 (mGluR7)
DM74J10	MT	DTT
DM74J10	MA	Agonist
DM74J10	RN	Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism. FASEB J. 2009 Oct;23(10):3619-28.
DM74J10	RU	https://pubmed.ncbi.nlm.nih.gov/19525404

DMBWHGP	DI	DMBWHGP
DMBWHGP	DN	LSP4-2022
DMBWHGP	MI	TTICZ1O
DMBWHGP	MN	Metabotropic glutamate receptor 4 (mGluR4)
DMBWHGP	MT	DTT
DMBWHGP	MA	Agonist
DMBWHGP	RN	A novel selective metabotropic glutamate receptor 4 agonist reveals new possibilities for developing subtype selective ligands with therapeutic potential. FASEB J. 2012 Apr;26(4):1682-93.
DMBWHGP	RU	https://pubmed.ncbi.nlm.nih.gov/22223752

DMBWHGP	DI	DMBWHGP
DMBWHGP	DN	LSP4-2022
DMBWHGP	MI	TTWRP2F
DMBWHGP	MN	Metabotropic glutamate receptor 6 (mGluR6)
DMBWHGP	MT	DTT
DMBWHGP	MA	Agonist
DMBWHGP	RN	A novel selective metabotropic glutamate receptor 4 agonist reveals new possibilities for developing subtype selective ligands with therapeutic potential. FASEB J. 2012 Apr;26(4):1682-93.
DMBWHGP	RU	https://pubmed.ncbi.nlm.nih.gov/22223752

DMBWHGP	DI	DMBWHGP
DMBWHGP	DN	LSP4-2022
DMBWHGP	MI	TT0I76D
DMBWHGP	MN	Metabotropic glutamate receptor 7 (mGluR7)
DMBWHGP	MT	DTT
DMBWHGP	MA	Agonist
DMBWHGP	RN	A novel selective metabotropic glutamate receptor 4 agonist reveals new possibilities for developing subtype selective ligands with therapeutic potential. FASEB J. 2012 Apr;26(4):1682-93.
DMBWHGP	RU	https://pubmed.ncbi.nlm.nih.gov/22223752

DM702WR	DI	DM702WR
DM702WR	DN	LTC4
DM702WR	MI	DEPT1ME
DM702WR	MN	Gamma-glutamyltranspeptidase 1 (GGT1)
DM702WR	MT	DME
DM702WR	MA	Metabolism
DM702WR	RN	Gamma-glutamyl compounds: substrate specificity of gamma-glutamyl transpeptidase enzymes. Anal Biochem. 2011 Jul 15;414(2):208-14.
DM702WR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21447318

DM702WR	DI	DM702WR
DM702WR	DN	LTC4
DM702WR	MI	DEH6CAO
DM702WR	MN	Gamma-glutamyltranspeptidase 5 (GGT5)
DM702WR	MT	DME
DM702WR	MA	Metabolism
DM702WR	RN	Gamma-glutamyl compounds: substrate specificity of gamma-glutamyl transpeptidase enzymes. Anal Biochem. 2011 Jul 15;414(2):208-14.
DM702WR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21447318

DM702WR	DI	DM702WR
DM702WR	DN	LTC4
DM702WR	MI	TTGKOY9
DM702WR	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DM702WR	MT	DTT
DM702WR	MA	Agonist
DM702WR	RN	Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature. 1999 Jun 24;399(6738):789-93.
DM702WR	RU	https://pubmed.ncbi.nlm.nih.gov/10391245

DM702WR	DI	DM702WR
DM702WR	DN	LTC4
DM702WR	MI	TT0PZR5
DM702WR	MN	Leukotriene CysLT2 receptor (CYSLTR2)
DM702WR	MT	DTT
DM702WR	MA	Agonist
DM702WR	RN	Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist. Mol Pharmacol. 2000 Dec;58(6):1601-8.
DM702WR	RU	https://pubmed.ncbi.nlm.nih.gov/11093801

DM702WR	DI	DM702WR
DM702WR	DN	LTC4
DM702WR	MI	TTMPART
DM702WR	MN	Uracil nucleotide/cysteinyl leukotriene receptor (GPR17)
DM702WR	MT	DTT
DM702WR	MA	Agonist
DM702WR	RN	The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO J. 2006 Oct 4;25(19):4615-27.
DM702WR	RU	https://pubmed.ncbi.nlm.nih.gov/16990797

DMIUZX3	DI	DMIUZX3
DMIUZX3	DN	LTD4
DMIUZX3	MI	TTGKOY9
DMIUZX3	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DMIUZX3	MT	DTT
DMIUZX3	MA	Agonist
DMIUZX3	RN	Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. Mol Pharmacol. 1999 Sep;56(3):657-63.
DMIUZX3	RU	https://pubmed.ncbi.nlm.nih.gov/10462554

DMIUZX3	DI	DMIUZX3
DMIUZX3	DN	LTD4
DMIUZX3	MI	TT0PZR5
DMIUZX3	MN	Leukotriene CysLT2 receptor (CYSLTR2)
DMIUZX3	MT	DTT
DMIUZX3	MA	Agonist
DMIUZX3	RN	Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist. Mol Pharmacol. 2000 Dec;58(6):1601-8.
DMIUZX3	RU	https://pubmed.ncbi.nlm.nih.gov/11093801

DMIUZX3	DI	DMIUZX3
DMIUZX3	DN	LTD4
DMIUZX3	MI	TTMPART
DMIUZX3	MN	Uracil nucleotide/cysteinyl leukotriene receptor (GPR17)
DMIUZX3	MT	DTT
DMIUZX3	MA	Agonist
DMIUZX3	RN	The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO J. 2006 Oct 4;25(19):4615-27.
DMIUZX3	RU	https://pubmed.ncbi.nlm.nih.gov/16990797

DMCPB0Q	DI	DMCPB0Q
DMCPB0Q	DN	LTE4
DMCPB0Q	MI	TTGKOY9
DMCPB0Q	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DMCPB0Q	MT	DTT
DMCPB0Q	MA	Agonist
DMCPB0Q	RN	Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature. 1999 Jun 24;399(6738):789-93.
DMCPB0Q	RU	https://pubmed.ncbi.nlm.nih.gov/10391245

DMCPB0Q	DI	DMCPB0Q
DMCPB0Q	DN	LTE4
DMCPB0Q	MI	TT0PZR5
DMCPB0Q	MN	Leukotriene CysLT2 receptor (CYSLTR2)
DMCPB0Q	MT	DTT
DMCPB0Q	MA	Agonist
DMCPB0Q	RN	Differential signaling of cysteinyl leukotrienes and a novel cysteinyl leukotriene receptor 2 (CysLT agonist, N-methyl-leukotriene C in calcium reporter and beta arrestin assays. Mol Pharmacol. 2011 Feb;79(2):270-8.
DMCPB0Q	RU	https://pubmed.ncbi.nlm.nih.gov/21078884

DMCPB0Q	DI	DMCPB0Q
DMCPB0Q	DN	LTE4
DMCPB0Q	MI	DTSYQGK
DMCPB0Q	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMCPB0Q	MT	DTP
DMCPB0Q	MA	Substrate
DMCPB0Q	RN	Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res. 1996 Mar 1;56(5):988-94.
DMCPB0Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/8640791

DMCPB0Q	DI	DMCPB0Q
DMCPB0Q	DN	LTE4
DMCPB0Q	MI	DT3D8F0
DMCPB0Q	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMCPB0Q	MT	DTP
DMCPB0Q	MA	Substrate
DMCPB0Q	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DMCPB0Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DMCPB0Q	DI	DMCPB0Q
DMCPB0Q	DN	LTE4
DMCPB0Q	MI	TTAS1QK
DMCPB0Q	MN	Oxoglutarate receptor (OXGR1)
DMCPB0Q	MT	DTT
DMCPB0Q	MA	Agonist
DMCPB0Q	RN	Identification of GPR99 protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E4 ligand. J Biol Chem. 2013 Apr 19;288(16):10967-72.
DMCPB0Q	RU	https://pubmed.ncbi.nlm.nih.gov/23504326

DMCPB0Q	DI	DMCPB0Q
DMCPB0Q	DN	LTE4
DMCPB0Q	MI	TTMPART
DMCPB0Q	MN	Uracil nucleotide/cysteinyl leukotriene receptor (GPR17)
DMCPB0Q	MT	DTT
DMCPB0Q	MA	Agonist
DMCPB0Q	RN	The recently identified P2Y-like receptor GPR17 is a sensor of brain damage and a new target for brain repair. PLoS One. 2008;3(10):e3579.
DMCPB0Q	RU	https://pubmed.ncbi.nlm.nih.gov/18974869

DMDU6F4	DI	DMDU6F4
DMDU6F4	DN	LTERHKILHRLLQEGSPSD
DMDU6F4	MI	TTZAYWL
DMDU6F4	MN	Estrogen receptor (ESR)
DMDU6F4	MT	DTT
DMDU6F4	MA	Inhibitor
DMDU6F4	RN	Bicyclo[2.2.2]octanes: close structural mimics of the nuclear receptor-binding motif of steroid receptor coactivators. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4118-22.
DMDU6F4	RU	https://pubmed.ncbi.nlm.nih.gov/17560105

DMP8O6R	DI	DMP8O6R
DMP8O6R	DN	L-Thiocitrulline
DMP8O6R	MI	TTF10I9
DMP8O6R	MN	Nitric-oxide synthase inducible (NOS2)
DMP8O6R	MT	DTT
DMP8O6R	MA	Inhibitor
DMP8O6R	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMP8O6R	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMFHTBX	DI	DMFHTBX
DMFHTBX	DN	L-threonine
DMFHTBX	MI	DTW7AE3
DMFHTBX	MN	Alanine/serine/cysteine/threonine transporter 2 (SLC1A5)
DMFHTBX	MT	DTP
DMFHTBX	MA	Substrate
DMFHTBX	RN	D-Serine Is a Substrate for Neutral Amino Acid Transporters ASCT1/SLC1A4 and ASCT2/SLC1A5, and Is Transported by Both Subtypes in Rat Hippocampal Astrocyte Cultures. PLoS One. 2016 Jun 7;11(6):e0156551.
DMFHTBX	RU	http://www.ncbi.nlm.nih.gov/pubmed/27272177

DM83HWL	DI	DM83HWL
DM83HWL	DN	L-thyroxine
DM83HWL	MI	DEYWLRK
DM83HWL	MN	Sulfotransferase 1A1 (SULT1A1)
DM83HWL	MT	DME
DM83HWL	MA	Metabolism
DM83HWL	RN	Characterization of human liver thermostable phenol sulfotransferase (SULT1A1) allozymes with 3,3',5-triiodothyronine as the substrate. J Endocrinol. 2001 Dec;171(3):525-32.
DM83HWL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11739018

DM83HWL	DI	DM83HWL
DM83HWL	DN	L-thyroxine
DM83HWL	MI	DET89OV
DM83HWL	MN	Thyroxine 5-deiodinase (DIO3)
DM83HWL	MT	DME
DM83HWL	MA	Metabolism
DM83HWL	RN	Substitution of cysteine for selenocysteine in the catalytic center of type III iodothyronine deiodinase reduces catalytic efficiency and alters substrate preference. Endocrinology. 2003 Jun;144(6):2505-13.
DM83HWL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12746313

DMW09LB	DI	DMW09LB
DMW09LB	DN	LTK-14
DMW09LB	MI	TTVK7SB
DMW09LB	MN	Histone acetyltransferase KAT2B (KAT2B)
DMW09LB	MT	DTT
DMW09LB	MA	Inhibitor
DMW09LB	RN	Specific inhibition of p300-HAT alters global gene expression and represses HIV replication. Chem Biol. 2007 Jun;14(6):645-57.
DMW09LB	RU	https://pubmed.ncbi.nlm.nih.gov/17584612

DMYLONS	DI	DMYLONS
DMYLONS	DN	L-Tryptophan-L-2-aminoadipic acid
DMYLONS	MI	TTT2SVW
DMYLONS	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DMYLONS	MT	DTT
DMYLONS	MA	Inhibitor
DMYLONS	RN	Tryptophan-containing dipeptide derivatives as potent PPARgamma antagonists: design, synthesis, biological evaluation, and molecular modeling. Eur J Med Chem. 2008 Dec;43(12):2699-716.
DMYLONS	RU	https://pubmed.ncbi.nlm.nih.gov/18329752

DMYU65F	DI	DMYU65F
DMYU65F	DN	L-Tryptophan-L-arginine
DMYU65F	MI	TTT2SVW
DMYU65F	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DMYU65F	MT	DTT
DMYU65F	MA	Inhibitor
DMYU65F	RN	Tryptophan-containing dipeptide derivatives as potent PPARgamma antagonists: design, synthesis, biological evaluation, and molecular modeling. Eur J Med Chem. 2008 Dec;43(12):2699-716.
DMYU65F	RU	https://pubmed.ncbi.nlm.nih.gov/18329752

DMWZMCA	DI	DMWZMCA
DMWZMCA	DN	L-Tryptophan-L-asparagine
DMWZMCA	MI	TTT2SVW
DMWZMCA	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DMWZMCA	MT	DTT
DMWZMCA	MA	Inhibitor
DMWZMCA	RN	Tryptophan-containing dipeptide derivatives as potent PPARgamma antagonists: design, synthesis, biological evaluation, and molecular modeling. Eur J Med Chem. 2008 Dec;43(12):2699-716.
DMWZMCA	RU	https://pubmed.ncbi.nlm.nih.gov/18329752

DMVFAD5	DI	DMVFAD5
DMVFAD5	DN	L-Tryptophan-L-aspartic acid
DMVFAD5	MI	TTT2SVW
DMVFAD5	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DMVFAD5	MT	DTT
DMVFAD5	MA	Inhibitor
DMVFAD5	RN	Tryptophan-containing dipeptide derivatives as potent PPARgamma antagonists: design, synthesis, biological evaluation, and molecular modeling. Eur J Med Chem. 2008 Dec;43(12):2699-716.
DMVFAD5	RU	https://pubmed.ncbi.nlm.nih.gov/18329752

DMNMRHX	DI	DMNMRHX
DMNMRHX	DN	L-Tryptophan-L-glutamine
DMNMRHX	MI	TTT2SVW
DMNMRHX	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DMNMRHX	MT	DTT
DMNMRHX	MA	Inhibitor
DMNMRHX	RN	Tryptophan-containing dipeptide derivatives as potent PPARgamma antagonists: design, synthesis, biological evaluation, and molecular modeling. Eur J Med Chem. 2008 Dec;43(12):2699-716.
DMNMRHX	RU	https://pubmed.ncbi.nlm.nih.gov/18329752

DMPV5D0	DI	DMPV5D0
DMPV5D0	DN	L-Tryptophan-L-leucine
DMPV5D0	MI	TTT2SVW
DMPV5D0	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DMPV5D0	MT	DTT
DMPV5D0	MA	Inhibitor
DMPV5D0	RN	Tryptophan-containing dipeptide derivatives as potent PPARgamma antagonists: design, synthesis, biological evaluation, and molecular modeling. Eur J Med Chem. 2008 Dec;43(12):2699-716.
DMPV5D0	RU	https://pubmed.ncbi.nlm.nih.gov/18329752

DMGVELK	DI	DMGVELK
DMGVELK	DN	L-Tyrosinamide
DMGVELK	MI	TT64REZ
DMGVELK	MN	Neuropeptide Y (NPY)
DMGVELK	MT	DTT
DMGVELK	MA	Inhibitor
DMGVELK	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMGVELK	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMGVELK	DI	DMGVELK
DMGVELK	DN	L-Tyrosinamide
DMGVELK	MI	TTTZ3EU
DMGVELK	MN	Valacyclovir hydrolase (BPHL)
DMGVELK	MT	DTT
DMGVELK	MA	Inhibitor
DMGVELK	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMGVELK	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMH693E	DI	DMH693E
DMH693E	DN	Lu AF21934
DMH693E	MI	TTICZ1O
DMH693E	MN	Metabotropic glutamate receptor 4 (mGluR4)
DMH693E	MT	DTT
DMH693E	MA	Modulator (allosteric modulator)
DMH693E	RN	Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia. Neuropharmacology. 2013 Mar;66:158-69.
DMH693E	RU	https://pubmed.ncbi.nlm.nih.gov/22491024

DM7F3SE	DI	DM7F3SE
DM7F3SE	DN	LU302872
DM7F3SE	MI	TTKRD0G
DM7F3SE	MN	Endothelin A receptor (EDNRA)
DM7F3SE	MT	DTT
DM7F3SE	MA	Antagonist
DM7F3SE	RN	Influence of endothelin receptor antagonists on myocardial protein kinase C isoforms in uraemic cardiomyopathy. Clin Sci (Lond). 2002 Aug;103 Suppl 48:276S-279S.
DM7F3SE	RU	https://pubmed.ncbi.nlm.nih.gov/12193103

DM7F3SE	DI	DM7F3SE
DM7F3SE	DN	LU302872
DM7F3SE	MI	TT3ZTGU
DM7F3SE	MN	Endothelin B receptor (EDNRB)
DM7F3SE	MT	DTT
DM7F3SE	MA	Antagonist
DM7F3SE	RN	Influence of endothelin receptor antagonists on myocardial protein kinase C isoforms in uraemic cardiomyopathy. Clin Sci (Lond). 2002 Aug;103 Suppl 48:276S-279S.
DM7F3SE	RU	https://pubmed.ncbi.nlm.nih.gov/12193103

DM2YOVC	DI	DM2YOVC
DM2YOVC	DN	LU32-176B
DM2YOVC	MI	TTPRKM0
DM2YOVC	MN	GABA transporter GAT-1 (SLC6A1)
DM2YOVC	MT	DTT
DM2YOVC	MA	Inhibitor
DM2YOVC	RN	First demonstration of a functional role for central nervous system betaine/{gamma}-aminobutyric acid transporter (mGAT2) based on synergistic anti... J Pharmacol Exp Ther. 2005 Feb;312(2):866-74.
DM2YOVC	RU	https://pubmed.ncbi.nlm.nih.gov/15550575

DM2YOVC	DI	DM2YOVC
DM2YOVC	DN	LU32-176B
DM2YOVC	MI	TTQBMPI
DM2YOVC	MN	Na(+)/Cl(-) betaine/GABA transporter (SLC6A12)
DM2YOVC	MT	DTT
DM2YOVC	MA	Inhibitor
DM2YOVC	RN	First demonstration of a functional role for central nervous system betaine/{gamma}-aminobutyric acid transporter (mGAT2) based on synergistic anti... J Pharmacol Exp Ther. 2005 Feb;312(2):866-74.
DM2YOVC	RU	https://pubmed.ncbi.nlm.nih.gov/15550575

DMGYBSC	DI	DMGYBSC
DMGYBSC	DN	LU-53439
DMGYBSC	MI	TTGP7BY
DMGYBSC	MN	Monoamine oxidase type B (MAO-B)
DMGYBSC	MT	DTT
DMGYBSC	MA	Modulator
DMGYBSC	RN	Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy. J Pharmacol Exp Ther. 1999 Mar;288(3):984-92.
DMGYBSC	RU	https://www.ncbi.nlm.nih.gov/pubmed/10027835

DM34AYV	DI	DM34AYV
DM34AYV	DN	LU-AA33810
DM34AYV	MI	TTY6EWA
DM34AYV	MN	Neuropeptide Y receptor type 5 (NPY5R)
DM34AYV	MT	DTT
DM34AYV	MA	Antagonist
DM34AYV	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 308).
DM34AYV	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=308

DMI9VNO	DI	DMI9VNO
DMI9VNO	DN	LUDARTIN
DMI9VNO	MI	TTSZLWK
DMI9VNO	MN	Aromatase (CYP19A1)
DMI9VNO	MT	DTT
DMI9VNO	MA	Inhibitor
DMI9VNO	RN	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
DMI9VNO	RU	https://pubmed.ncbi.nlm.nih.gov/20413308

DMUPQED	DI	DMUPQED
DMUPQED	DN	LUF-5417
DMUPQED	MI	TTK25J1
DMUPQED	MN	Adenosine A1 receptor (ADORA1)
DMUPQED	MT	DTT
DMUPQED	MA	Inhibitor
DMUPQED	RN	2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
DMUPQED	RU	https://pubmed.ncbi.nlm.nih.gov/20188574

DMUPQED	DI	DMUPQED
DMUPQED	DN	LUF-5417
DMUPQED	MI	TTM2AOE
DMUPQED	MN	Adenosine A2a receptor (ADORA2A)
DMUPQED	MT	DTT
DMUPQED	MA	Inhibitor
DMUPQED	RN	2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
DMUPQED	RU	https://pubmed.ncbi.nlm.nih.gov/20188574

DMUPQED	DI	DMUPQED
DMUPQED	DN	LUF-5417
DMUPQED	MI	TTJFY5U
DMUPQED	MN	Adenosine A3 receptor (ADORA3)
DMUPQED	MT	DTT
DMUPQED	MA	Inhibitor
DMUPQED	RN	2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
DMUPQED	RU	https://pubmed.ncbi.nlm.nih.gov/20188574

DME4O5D	DI	DME4O5D
DME4O5D	DN	LUF-5433
DME4O5D	MI	TTK25J1
DME4O5D	MN	Adenosine A1 receptor (ADORA1)
DME4O5D	MT	DTT
DME4O5D	MA	Inhibitor
DME4O5D	RN	2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
DME4O5D	RU	https://pubmed.ncbi.nlm.nih.gov/20188574

DME4O5D	DI	DME4O5D
DME4O5D	DN	LUF-5433
DME4O5D	MI	TTM2AOE
DME4O5D	MN	Adenosine A2a receptor (ADORA2A)
DME4O5D	MT	DTT
DME4O5D	MA	Inhibitor
DME4O5D	RN	2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
DME4O5D	RU	https://pubmed.ncbi.nlm.nih.gov/20188574

DME4O5D	DI	DME4O5D
DME4O5D	DN	LUF-5433
DME4O5D	MI	TTJFY5U
DME4O5D	MN	Adenosine A3 receptor (ADORA3)
DME4O5D	MT	DTT
DME4O5D	MA	Inhibitor
DME4O5D	RN	2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
DME4O5D	RU	https://pubmed.ncbi.nlm.nih.gov/20188574

DM0DRO8	DI	DM0DRO8
DM0DRO8	DN	LUF-5437
DM0DRO8	MI	TTM2AOE
DM0DRO8	MN	Adenosine A2a receptor (ADORA2A)
DM0DRO8	MT	DTT
DM0DRO8	MA	Inhibitor
DM0DRO8	RN	Thiazole and thiadiazole analogues as a novel class of adenosine receptor antagonists. J Med Chem. 2001 Mar 1;44(5):749-62.
DM0DRO8	RU	https://pubmed.ncbi.nlm.nih.gov/11262085

DM89FBX	DI	DM89FBX
DM89FBX	DN	LUF-5735
DM89FBX	MI	TTK25J1
DM89FBX	MN	Adenosine A1 receptor (ADORA1)
DM89FBX	MT	DTT
DM89FBX	MA	Inhibitor
DM89FBX	RN	2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40.
DM89FBX	RU	https://pubmed.ncbi.nlm.nih.gov/15588088

DMXFD3S	DI	DMXFD3S
DMXFD3S	DN	LUF-5737
DMXFD3S	MI	TTK25J1
DMXFD3S	MN	Adenosine A1 receptor (ADORA1)
DMXFD3S	MT	DTT
DMXFD3S	MA	Inhibitor
DMXFD3S	RN	2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40.
DMXFD3S	RU	https://pubmed.ncbi.nlm.nih.gov/15588088

DMQ3VHR	DI	DMQ3VHR
DMQ3VHR	DN	LUF-5764
DMQ3VHR	MI	TTK25J1
DMQ3VHR	MN	Adenosine A1 receptor (ADORA1)
DMQ3VHR	MT	DTT
DMQ3VHR	MA	Inhibitor
DMQ3VHR	RN	2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40.
DMQ3VHR	RU	https://pubmed.ncbi.nlm.nih.gov/15588088

DMP08QO	DI	DMP08QO
DMP08QO	DN	LUF-5767
DMP08QO	MI	TTK25J1
DMP08QO	MN	Adenosine A1 receptor (ADORA1)
DMP08QO	MT	DTT
DMP08QO	MA	Inhibitor
DMP08QO	RN	2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40.
DMP08QO	RU	https://pubmed.ncbi.nlm.nih.gov/15588088

DMP08QO	DI	DMP08QO
DMP08QO	DN	LUF-5767
DMP08QO	MI	TTM2AOE
DMP08QO	MN	Adenosine A2a receptor (ADORA2A)
DMP08QO	MT	DTT
DMP08QO	MA	Inhibitor
DMP08QO	RN	2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40.
DMP08QO	RU	https://pubmed.ncbi.nlm.nih.gov/15588088

DMP08QO	DI	DMP08QO
DMP08QO	DN	LUF-5767
DMP08QO	MI	TTJFY5U
DMP08QO	MN	Adenosine A3 receptor (ADORA3)
DMP08QO	MT	DTT
DMP08QO	MA	Inhibitor
DMP08QO	RN	2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40.
DMP08QO	RU	https://pubmed.ncbi.nlm.nih.gov/15588088

DMQZDMH	DI	DMQZDMH
DMQZDMH	DN	LUF-5816
DMQZDMH	MI	TTK25J1
DMQZDMH	MN	Adenosine A1 receptor (ADORA1)
DMQZDMH	MT	DTT
DMQZDMH	MA	Inhibitor
DMQZDMH	RN	2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34.
DMQZDMH	RU	https://pubmed.ncbi.nlm.nih.gov/17300165

DMQZDMH	DI	DMQZDMH
DMQZDMH	DN	LUF-5816
DMQZDMH	MI	TTNE7KG
DMQZDMH	MN	Adenosine A2b receptor (ADORA2B)
DMQZDMH	MT	DTT
DMQZDMH	MA	Inhibitor
DMQZDMH	RN	2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34.
DMQZDMH	RU	https://pubmed.ncbi.nlm.nih.gov/17300165

DMQZDMH	DI	DMQZDMH
DMQZDMH	DN	LUF-5816
DMQZDMH	MI	TTJFY5U
DMQZDMH	MN	Adenosine A3 receptor (ADORA3)
DMQZDMH	MT	DTT
DMQZDMH	MA	Inhibitor
DMQZDMH	RN	2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34.
DMQZDMH	RU	https://pubmed.ncbi.nlm.nih.gov/17300165

DMYZGIK	DI	DMYZGIK
DMYZGIK	DN	LUF5831
DMYZGIK	MI	TTK25J1
DMYZGIK	MN	Adenosine A1 receptor (ADORA1)
DMYZGIK	MT	DTT
DMYZGIK	MA	Agonist
DMYZGIK	RN	Allosteric modulation, thermodynamics and binding to wild-type and mutant (T277A) adenosine A1 receptors of LUF5831, a novel nonadenosine-like agonist. Br J Pharmacol. 2006 Mar;147(5):533-41.
DMYZGIK	RU	https://pubmed.ncbi.nlm.nih.gov/16444290

DMDHUL8	DI	DMDHUL8
DMDHUL8	DN	LUF-5833
DMDHUL8	MI	TTJFY5U
DMDHUL8	MN	Adenosine A3 receptor (ADORA3)
DMDHUL8	MT	DTT
DMDHUL8	MA	Enhancer
DMDHUL8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 21).
DMDHUL8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=21

DMZQU90	DI	DMZQU90
DMZQU90	DN	LUF-5853
DMZQU90	MI	TTK25J1
DMZQU90	MN	Adenosine A1 receptor (ADORA1)
DMZQU90	MT	DTT
DMZQU90	MA	Inhibitor
DMZQU90	RN	A new generation of adenosine receptor antagonists: from di- to trisubstituted aminopyrimidines. Bioorg Med Chem. 2008 Mar 15;16(6):2741-52.
DMZQU90	RU	https://pubmed.ncbi.nlm.nih.gov/18258439

DMG4YWM	DI	DMG4YWM
DMG4YWM	DN	LUF-5956
DMG4YWM	MI	TTK25J1
DMG4YWM	MN	Adenosine A1 receptor (ADORA1)
DMG4YWM	MT	DTT
DMG4YWM	MA	Inhibitor
DMG4YWM	RN	2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7.
DMG4YWM	RU	https://pubmed.ncbi.nlm.nih.gov/16686529

DMG4YWM	DI	DMG4YWM
DMG4YWM	DN	LUF-5956
DMG4YWM	MI	TTM2AOE
DMG4YWM	MN	Adenosine A2a receptor (ADORA2A)
DMG4YWM	MT	DTT
DMG4YWM	MA	Inhibitor
DMG4YWM	RN	2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7.
DMG4YWM	RU	https://pubmed.ncbi.nlm.nih.gov/16686529

DMG4YWM	DI	DMG4YWM
DMG4YWM	DN	LUF-5956
DMG4YWM	MI	TTJFY5U
DMG4YWM	MN	Adenosine A3 receptor (ADORA3)
DMG4YWM	MT	DTT
DMG4YWM	MA	Inhibitor
DMG4YWM	RN	2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7.
DMG4YWM	RU	https://pubmed.ncbi.nlm.nih.gov/16686529

DMJFMH9	DI	DMJFMH9
DMJFMH9	DN	LUF-5957
DMJFMH9	MI	TTK25J1
DMJFMH9	MN	Adenosine A1 receptor (ADORA1)
DMJFMH9	MT	DTT
DMJFMH9	MA	Inhibitor
DMJFMH9	RN	2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7.
DMJFMH9	RU	https://pubmed.ncbi.nlm.nih.gov/16686529

DMJFMH9	DI	DMJFMH9
DMJFMH9	DN	LUF-5957
DMJFMH9	MI	TTM2AOE
DMJFMH9	MN	Adenosine A2a receptor (ADORA2A)
DMJFMH9	MT	DTT
DMJFMH9	MA	Inhibitor
DMJFMH9	RN	2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7.
DMJFMH9	RU	https://pubmed.ncbi.nlm.nih.gov/16686529

DMJFMH9	DI	DMJFMH9
DMJFMH9	DN	LUF-5957
DMJFMH9	MI	TTJFY5U
DMJFMH9	MN	Adenosine A3 receptor (ADORA3)
DMJFMH9	MT	DTT
DMJFMH9	MA	Inhibitor
DMJFMH9	RN	2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7.
DMJFMH9	RU	https://pubmed.ncbi.nlm.nih.gov/16686529

DMR6LIE	DI	DMR6LIE
DMR6LIE	DN	LUF-5962
DMR6LIE	MI	TTK25J1
DMR6LIE	MN	Adenosine A1 receptor (ADORA1)
DMR6LIE	MT	DTT
DMR6LIE	MA	Inhibitor
DMR6LIE	RN	2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7.
DMR6LIE	RU	https://pubmed.ncbi.nlm.nih.gov/16686529

DMR6LIE	DI	DMR6LIE
DMR6LIE	DN	LUF-5962
DMR6LIE	MI	TTM2AOE
DMR6LIE	MN	Adenosine A2a receptor (ADORA2A)
DMR6LIE	MT	DTT
DMR6LIE	MA	Inhibitor
DMR6LIE	RN	2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7.
DMR6LIE	RU	https://pubmed.ncbi.nlm.nih.gov/16686529

DMR6LIE	DI	DMR6LIE
DMR6LIE	DN	LUF-5962
DMR6LIE	MI	TTJFY5U
DMR6LIE	MN	Adenosine A3 receptor (ADORA3)
DMR6LIE	MT	DTT
DMR6LIE	MA	Inhibitor
DMR6LIE	RN	2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7.
DMR6LIE	RU	https://pubmed.ncbi.nlm.nih.gov/16686529

DMCTM3L	DI	DMCTM3L
DMCTM3L	DN	LUF-5978
DMCTM3L	MI	TTK25J1
DMCTM3L	MN	Adenosine A1 receptor (ADORA1)
DMCTM3L	MT	DTT
DMCTM3L	MA	Inhibitor
DMCTM3L	RN	2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34.
DMCTM3L	RU	https://pubmed.ncbi.nlm.nih.gov/17300165

DMCTM3L	DI	DMCTM3L
DMCTM3L	DN	LUF-5978
DMCTM3L	MI	TTM2AOE
DMCTM3L	MN	Adenosine A2a receptor (ADORA2A)
DMCTM3L	MT	DTT
DMCTM3L	MA	Inhibitor
DMCTM3L	RN	2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34.
DMCTM3L	RU	https://pubmed.ncbi.nlm.nih.gov/17300165

DMCTM3L	DI	DMCTM3L
DMCTM3L	DN	LUF-5978
DMCTM3L	MI	TTNE7KG
DMCTM3L	MN	Adenosine A2b receptor (ADORA2B)
DMCTM3L	MT	DTT
DMCTM3L	MA	Inhibitor
DMCTM3L	RN	2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34.
DMCTM3L	RU	https://pubmed.ncbi.nlm.nih.gov/17300165

DMCTM3L	DI	DMCTM3L
DMCTM3L	DN	LUF-5978
DMCTM3L	MI	TTJFY5U
DMCTM3L	MN	Adenosine A3 receptor (ADORA3)
DMCTM3L	MT	DTT
DMCTM3L	MA	Inhibitor
DMCTM3L	RN	2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34.
DMCTM3L	RU	https://pubmed.ncbi.nlm.nih.gov/17300165

DMGOIF5	DI	DMGOIF5
DMGOIF5	DN	LUF-5980
DMGOIF5	MI	TTK25J1
DMGOIF5	MN	Adenosine A1 receptor (ADORA1)
DMGOIF5	MT	DTT
DMGOIF5	MA	Inhibitor
DMGOIF5	RN	2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34.
DMGOIF5	RU	https://pubmed.ncbi.nlm.nih.gov/17300165

DMGOIF5	DI	DMGOIF5
DMGOIF5	DN	LUF-5980
DMGOIF5	MI	TTM2AOE
DMGOIF5	MN	Adenosine A2a receptor (ADORA2A)
DMGOIF5	MT	DTT
DMGOIF5	MA	Inhibitor
DMGOIF5	RN	2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34.
DMGOIF5	RU	https://pubmed.ncbi.nlm.nih.gov/17300165

DMGOIF5	DI	DMGOIF5
DMGOIF5	DN	LUF-5980
DMGOIF5	MI	TTNE7KG
DMGOIF5	MN	Adenosine A2b receptor (ADORA2B)
DMGOIF5	MT	DTT
DMGOIF5	MA	Inhibitor
DMGOIF5	RN	2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34.
DMGOIF5	RU	https://pubmed.ncbi.nlm.nih.gov/17300165

DMGOIF5	DI	DMGOIF5
DMGOIF5	DN	LUF-5980
DMGOIF5	MI	TTJFY5U
DMGOIF5	MN	Adenosine A3 receptor (ADORA3)
DMGOIF5	MT	DTT
DMGOIF5	MA	Inhibitor
DMGOIF5	RN	2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34.
DMGOIF5	RU	https://pubmed.ncbi.nlm.nih.gov/17300165

DMHO3XL	DI	DMHO3XL
DMHO3XL	DN	LUF-5981
DMHO3XL	MI	TTK25J1
DMHO3XL	MN	Adenosine A1 receptor (ADORA1)
DMHO3XL	MT	DTT
DMHO3XL	MA	Inhibitor
DMHO3XL	RN	2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34.
DMHO3XL	RU	https://pubmed.ncbi.nlm.nih.gov/17300165

DMHO3XL	DI	DMHO3XL
DMHO3XL	DN	LUF-5981
DMHO3XL	MI	TTM2AOE
DMHO3XL	MN	Adenosine A2a receptor (ADORA2A)
DMHO3XL	MT	DTT
DMHO3XL	MA	Inhibitor
DMHO3XL	RN	2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34.
DMHO3XL	RU	https://pubmed.ncbi.nlm.nih.gov/17300165

DMHO3XL	DI	DMHO3XL
DMHO3XL	DN	LUF-5981
DMHO3XL	MI	TTNE7KG
DMHO3XL	MN	Adenosine A2b receptor (ADORA2B)
DMHO3XL	MT	DTT
DMHO3XL	MA	Inhibitor
DMHO3XL	RN	2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34.
DMHO3XL	RU	https://pubmed.ncbi.nlm.nih.gov/17300165

DMHO3XL	DI	DMHO3XL
DMHO3XL	DN	LUF-5981
DMHO3XL	MI	TTJFY5U
DMHO3XL	MN	Adenosine A3 receptor (ADORA3)
DMHO3XL	MT	DTT
DMHO3XL	MA	Inhibitor
DMHO3XL	RN	2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34.
DMHO3XL	RU	https://pubmed.ncbi.nlm.nih.gov/17300165

DM0K75N	DI	DM0K75N
DM0K75N	DN	LUF-6258
DM0K75N	MI	TTK25J1
DM0K75N	MN	Adenosine A1 receptor (ADORA1)
DM0K75N	MT	DTT
DM0K75N	MA	Inhibitor
DM0K75N	RN	Hybrid ortho/allosteric ligands for the adenosine A(1) receptor. J Med Chem. 2010 Apr 22;53(8):3028-37.
DM0K75N	RU	https://pubmed.ncbi.nlm.nih.gov/20345101

DMYRCHV	DI	DMYRCHV
DMYRCHV	DN	LUFFARIELLOLIDE
DMYRCHV	MI	TTO8QRU
DMYRCHV	MN	Group IIA phospholipase A2 (GIIA sPLA2)
DMYRCHV	MT	DTT
DMYRCHV	MA	Inhibitor
DMYRCHV	RN	Phospholipase A2 inhibitors from marine organisms. J Nat Prod. 1992 Dec;55(12):1701-17.
DMYRCHV	RU	https://pubmed.ncbi.nlm.nih.gov/1294693

DM4ZLUH	DI	DM4ZLUH
DM4ZLUH	DN	LUPEOL
DM4ZLUH	MI	TT0IHXV
DM4ZLUH	MN	DNA topoisomerase II (TOP2)
DM4ZLUH	MT	DTT
DM4ZLUH	MA	Inhibitor
DM4ZLUH	RN	Screening of triterpenoids isolated from Phyllanthus flexuosus for DNA topoisomerase inhibitory activity. J Nat Prod. 2001 Dec;64(12):1545-7.
DM4ZLUH	RU	https://pubmed.ncbi.nlm.nih.gov/11754608

DM68RPD	DI	DM68RPD
DM68RPD	DN	L-valine
DM68RPD	MI	DE9B45K
DM68RPD	MN	Cytosolic branched aminotransferase (BCAT1)
DM68RPD	MT	DME
DM68RPD	MA	Metabolism
DM68RPD	RN	Purification, crystallization and preliminary X-ray crystallographic analysis of branched-chain aminotransferase from Deinococcus radiodurans. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007 Jun 1;63(Pt 6):492-4.
DM68RPD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17554170

DM68RPD	DI	DM68RPD
DM68RPD	DN	L-valine
DM68RPD	MI	DTBMSWG
DM68RPD	MN	L-type amino acid transporter 3 (SLC43A1)
DM68RPD	MT	DTP
DM68RPD	MA	Substrate
DM68RPD	RN	Identification of a novel system L amino acid transporter structurally distinct from heterodimeric amino acid transporters. J Biol Chem. 2003 Oct 31;278(44):43838-45.
DM68RPD	RU	http://www.ncbi.nlm.nih.gov/pubmed/12930836

DM68RPD	DI	DM68RPD
DM68RPD	DN	L-valine
DM68RPD	MI	DTK02I1
DM68RPD	MN	L-type amino acid transporter 4 (SLC43A2)
DM68RPD	MT	DTP
DM68RPD	MA	Substrate
DM68RPD	RN	Anticipation of food intake induces phosphorylation switch to regulate basolateral amino acid transporter LAT4 (SLC43A2) function. J Physiol. 2019 Jan;597(2):521-542.
DM68RPD	RU	http://www.ncbi.nlm.nih.gov/pubmed/30379325

DM68RPD	DI	DM68RPD
DM68RPD	DN	L-valine
DM68RPD	MI	DESWQMH
DM68RPD	MN	Propionyl-CoA carboxylase beta (PCCB)
DM68RPD	MT	DME
DM68RPD	MA	Metabolism
DM68RPD	RN	How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM68RPD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17139284

DM68RPD	DI	DM68RPD
DM68RPD	DN	L-valine
DM68RPD	MI	DEUPF5K
DM68RPD	MN	Valyl-tRNA synthetase (VARS)
DM68RPD	MT	DME
DM68RPD	MA	Metabolism
DM68RPD	RN	A present-day aminoacyl-tRNA synthetase with ancestral editing properties. RNA. 2007 Jan;13(1):15-21.
DM68RPD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17095543

DMPGT80	DI	DMPGT80
DMPGT80	DN	L-Val-L-boroPro
DMPGT80	MI	TTDIGC1
DMPGT80	MN	Dipeptidyl peptidase 4 (DPP-4)
DMPGT80	MT	DTT
DMPGT80	MA	Inhibitor
DMPGT80	RN	Synthesis and characterization of constrained peptidomimetic dipeptidyl peptidase IV inhibitors: amino-lactam boroalanines. J Med Chem. 2007 May 17;50(10):2391-8.
DMPGT80	RU	https://pubmed.ncbi.nlm.nih.gov/17458948

DMH7TNA	DI	DMH7TNA
DMH7TNA	DN	L-valyl-L-prolinamide
DMH7TNA	MI	TTQ7R2V
DMH7TNA	MN	Tripeptidyl-peptidase II (TPP2)
DMH7TNA	MT	DTT
DMH7TNA	MA	Inhibitor
DMH7TNA	RN	Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach ... J Med Chem. 2005 Nov 17;48(23):7333-42.
DMH7TNA	RU	https://pubmed.ncbi.nlm.nih.gov/16279793

DMQZ13A	DI	DMQZ13A
DMQZ13A	DN	L-valyl-L-proline benzylamide
DMQZ13A	MI	TTQ7R2V
DMQZ13A	MN	Tripeptidyl-peptidase II (TPP2)
DMQZ13A	MT	DTT
DMQZ13A	MA	Inhibitor
DMQZ13A	RN	Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach ... J Med Chem. 2005 Nov 17;48(23):7333-42.
DMQZ13A	RU	https://pubmed.ncbi.nlm.nih.gov/16279793

DMX4DRV	DI	DMX4DRV
DMX4DRV	DN	L-valyl-L-proline hexylamide
DMX4DRV	MI	TTQ7R2V
DMX4DRV	MN	Tripeptidyl-peptidase II (TPP2)
DMX4DRV	MT	DTT
DMX4DRV	MA	Inhibitor
DMX4DRV	RN	Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach ... J Med Chem. 2005 Nov 17;48(23):7333-42.
DMX4DRV	RU	https://pubmed.ncbi.nlm.nih.gov/16279793

DMIO405	DI	DMIO405
DMIO405	DN	LVAYPWT
DMIO405	MI	TT2THBD
DMIO405	MN	P2X purinoceptor 3 (P2RX3)
DMIO405	MT	DTT
DMIO405	MA	Inhibitor
DMIO405	RN	Structure-activity relationship studies of spinorphin as a potent and selective human P2X(3) receptor antagonist. J Med Chem. 2007 Sep 6;50(18):4543-7.
DMIO405	RU	https://pubmed.ncbi.nlm.nih.gov/17676725

DM78Z9D	DI	DM78Z9D
DM78Z9D	DN	LVVAPWT
DM78Z9D	MI	TT2THBD
DM78Z9D	MN	P2X purinoceptor 3 (P2RX3)
DM78Z9D	MT	DTT
DM78Z9D	MA	Inhibitor
DM78Z9D	RN	Structure-activity relationship studies of spinorphin as a potent and selective human P2X(3) receptor antagonist. J Med Chem. 2007 Sep 6;50(18):4543-7.
DM78Z9D	RU	https://pubmed.ncbi.nlm.nih.gov/17676725

DM1QPG7	DI	DM1QPG7
DM1QPG7	DN	LVVYPWT
DM1QPG7	MI	TT2THBD
DM1QPG7	MN	P2X purinoceptor 3 (P2RX3)
DM1QPG7	MT	DTT
DM1QPG7	MA	Inhibitor
DM1QPG7	RN	Structure-activity relationship studies of spinorphin as a potent and selective human P2X(3) receptor antagonist. J Med Chem. 2007 Sep 6;50(18):4543-7.
DM1QPG7	RU	https://pubmed.ncbi.nlm.nih.gov/17676725

DMGSVL0	DI	DMGSVL0
DMGSVL0	DN	LXA4
DMGSVL0	MI	TTOJ1NF
DMGSVL0	MN	FMLP-related receptor I (FPR2)
DMGSVL0	MT	DTT
DMGSVL0	MA	Agonist
DMGSVL0	RN	Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1660-5.
DMGSVL0	RU	https://pubmed.ncbi.nlm.nih.gov/20080636

DMGSVL0	DI	DMGSVL0
DMGSVL0	DN	LXA4
DMGSVL0	MI	TT7OCUB
DMGSVL0	MN	G-protein coupled receptor 32 (GPR32)
DMGSVL0	MT	DTT
DMGSVL0	MA	Agonist
DMGSVL0	RN	Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1660-5.
DMGSVL0	RU	https://pubmed.ncbi.nlm.nih.gov/20080636

DMGSVL0	DI	DMGSVL0
DMGSVL0	DN	LXA4
DMGSVL0	MI	TT16TM5
DMGSVL0	MN	N-formyl peptide receptor 3 (FPR3)
DMGSVL0	MT	DTT
DMGSVL0	MA	Agonist
DMGSVL0	RN	Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors. J Exp Med. 1997 May 5;185(9):1693-704.
DMGSVL0	RU	https://pubmed.ncbi.nlm.nih.gov/9151906

DM0LKPE	DI	DM0LKPE
DM0LKPE	DN	LXT-101
DM0LKPE	MI	TT8R70G
DM0LKPE	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DM0LKPE	MT	DTT
DM0LKPE	MA	Antagonist
DM0LKPE	RN	In vivo characterization of a novel GnRH (gonadotropin-releasing hormone) antagonist, LXT-101, in normal male rats. Regul Pept. 2006 Sep 11;136(1-3):122-9.
DM0LKPE	RU	https://pubmed.ncbi.nlm.nih.gov/16828893

DM9IU21	DI	DM9IU21
DM9IU21	DN	LY 165,163
DM9IU21	MI	TTSQIFT
DM9IU21	MN	5-HT 1A receptor (HTR1A)
DM9IU21	MT	DTT
DM9IU21	MA	Agonist
DM9IU21	RN	Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol. 1998 Aug 21;355(2-3):245-56.
DM9IU21	RU	https://pubmed.ncbi.nlm.nih.gov/9760039

DM9IU21	DI	DM9IU21
DM9IU21	DN	LY 165,163
DM9IU21	MI	TTJS8PY
DM9IU21	MN	5-HT 6 receptor (HTR6)
DM9IU21	MT	DTT
DM9IU21	MA	Agonist
DM9IU21	RN	Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol. 1993 Mar;43(3):320-7.
DM9IU21	RU	https://pubmed.ncbi.nlm.nih.gov/7680751

DMNB82L	DI	DMNB82L
DMNB82L	DN	LY063518
DMNB82L	MI	TTJQOD7
DMNB82L	MN	5-HT 2A receptor (HTR2A)
DMNB82L	MT	DTT
DMNB82L	MA	Antagonist
DMNB82L	RN	A novel class of 5-HT2A receptor antagonists: aryl aminoguanidines. Life Sci. 1996;59(15):1259-68.
DMNB82L	RU	https://pubmed.ncbi.nlm.nih.gov/8845011

DMYNCQR	DI	DMYNCQR
DMYNCQR	DN	LY108742
DMYNCQR	MI	TTJQOD7
DMYNCQR	MN	5-HT 2A receptor (HTR2A)
DMYNCQR	MT	DTT
DMYNCQR	MA	Antagonist
DMYNCQR	RN	Species variations in transmembrane region V of the 5-hydroxytryptamine type 2A receptor alter the structure-activity relationship of certain ergolines and tryptamines. Mol Pharmacol. 1994 Feb;45(2):277-86.
DMYNCQR	RU	https://pubmed.ncbi.nlm.nih.gov/8114677

DMT0JXC	DI	DMT0JXC
DMT0JXC	DN	LY134046
DMT0JXC	MI	TT0NZIC
DMT0JXC	MN	Phenylethanolamine N-methyltransferase (PNMT)
DMT0JXC	MT	DTT
DMT0JXC	MA	Inhibitor
DMT0JXC	RN	Properties of 8,9-dichloro-2,3,4,5-tetrahydro-1H-2-benzazepine, an inhibitor of norepinephrine N-methyltransferase. Biochem Pharmacol. 1981 Jun 1;30(11):1345-52.
DMT0JXC	RU	https://pubmed.ncbi.nlm.nih.gov/6268095

DMI01YM	DI	DMI01YM
DMI01YM	DN	LY178002
DMI01YM	MI	TT9V5JH
DMI01YM	MN	Phospholipase A2 (PLA2G1B)
DMI01YM	MT	DTT
DMI01YM	MA	Inhibitor
DMI01YM	RN	The anti-inflammatory effects of LY178002 and LY256548. Agents Actions. 1989 Jun;27(3-4):300-2.
DMI01YM	RU	https://pubmed.ncbi.nlm.nih.gov/2508442

DMVHQGF	DI	DMVHQGF
DMVHQGF	DN	LY2033298
DMVHQGF	MI	TTOXS3C
DMVHQGF	MN	Muscarinic acetylcholine receptor (CHRM)
DMVHQGF	MT	DTT
DMVHQGF	MA	Modulator (allosteric modulator)
DMVHQGF	RN	Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10978-83.
DMVHQGF	RU	https://pubmed.ncbi.nlm.nih.gov/18678919

DMIS82X	DI	DMIS82X
DMIS82X	DN	LY2087101
DMIS82X	MI	TTF4E0J
DMIS82X	MN	Neuronal acetylcholine receptor alpha-2 (CHRNA2)
DMIS82X	MT	DTT
DMIS82X	MA	Modulator (allosteric modulator)
DMIS82X	RN	Identification and pharmacological profile of a new class of selective nicotinic acetylcholine receptor potentiators. J Pharmacol Exp Ther. 2006 Sep;318(3):1108-17.
DMIS82X	RU	https://pubmed.ncbi.nlm.nih.gov/16738207

DMIS82X	DI	DMIS82X
DMIS82X	DN	LY2087101
DMIS82X	MI	TTLA931
DMIS82X	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMIS82X	MT	DTT
DMIS82X	MA	Modulator (allosteric modulator)
DMIS82X	RN	Identification and pharmacological profile of a new class of selective nicotinic acetylcholine receptor potentiators. J Pharmacol Exp Ther. 2006 Sep;318(3):1108-17.
DMIS82X	RU	https://pubmed.ncbi.nlm.nih.gov/16738207

DMIS82X	DI	DMIS82X
DMIS82X	DN	LY2087101
DMIS82X	MI	TT5KPZR
DMIS82X	MN	Neuronal acetylcholine receptor beta-2 (CHRNB2)
DMIS82X	MT	DTT
DMIS82X	MA	Modulator (allosteric modulator)
DMIS82X	RN	Identification and pharmacological profile of a new class of selective nicotinic acetylcholine receptor potentiators. J Pharmacol Exp Ther. 2006 Sep;318(3):1108-17.
DMIS82X	RU	https://pubmed.ncbi.nlm.nih.gov/16738207

DMAWTG3	DI	DMAWTG3
DMAWTG3	DN	LY2109761
DMAWTG3	MI	TTP4520
DMAWTG3	MN	TGF-beta receptor type I (TGFBR1)
DMAWTG3	MT	DTT
DMAWTG3	MA	Inhibitor
DMAWTG3	RN	LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther. 2008 Apr;7(4):829-40.
DMAWTG3	RU	https://pubmed.ncbi.nlm.nih.gov/18413796

DMAWTG3	DI	DMAWTG3
DMAWTG3	DN	LY2109761
DMAWTG3	MI	TTZE3P7
DMAWTG3	MN	TGF-beta receptor type II (TGFBR2)
DMAWTG3	MT	DTT
DMAWTG3	MA	Inhibitor
DMAWTG3	RN	LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther. 2008 Apr;7(4):829-40.
DMAWTG3	RU	https://pubmed.ncbi.nlm.nih.gov/18413796

DM4IELQ	DI	DM4IELQ
DM4IELQ	DN	LY2119620
DM4IELQ	MI	TTOXS3C
DM4IELQ	MN	Muscarinic acetylcholine receptor (CHRM)
DM4IELQ	MT	DTT
DM4IELQ	MA	Modulator (allosteric modulator)
DM4IELQ	RN	Characterization of the novel positive allosteric modulator, LY2119620, at the muscarinic M(2) and M(4) receptors. Mol Pharmacol. 2014 Jul;86(1):106-15.
DM4IELQ	RU	https://pubmed.ncbi.nlm.nih.gov/24807965

DMKZJVA	DI	DMKZJVA
DMKZJVA	DN	LY214352
DMKZJVA	MI	TT3PQ2Y
DMKZJVA	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DMKZJVA	MT	DTT
DMKZJVA	MA	Inhibitor
DMKZJVA	RN	Identification of a new antifungal target site through a dual biochemical and molecular-genetics approach. Curr Genet. 1996 Jul 31;30(2):159-65.
DMKZJVA	RU	https://pubmed.ncbi.nlm.nih.gov/8660469

DM5RG7J	DI	DM5RG7J
DM5RG7J	DN	LY215840
DM5RG7J	MI	TTJQOD7
DM5RG7J	MN	5-HT 2A receptor (HTR2A)
DM5RG7J	MT	DTT
DM5RG7J	MA	Antagonist
DM5RG7J	RN	Species variations in transmembrane region V of the 5-hydroxytryptamine type 2A receptor alter the structure-activity relationship of certain ergolines and tryptamines. Mol Pharmacol. 1994 Feb;45(2):277-86.
DM5RG7J	RU	https://pubmed.ncbi.nlm.nih.gov/8114677

DM8SU6N	DI	DM8SU6N
DM8SU6N	DN	LY-2183240
DM8SU6N	MI	TTDP1UC
DM8SU6N	MN	Fatty acid amide hydrolase (FAAH)
DM8SU6N	MT	DTT
DM8SU6N	MA	Inhibitor
DM8SU6N	RN	Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors. J Med Chem. 2008 Dec 11;51(23):7327-43.
DM8SU6N	RU	https://pubmed.ncbi.nlm.nih.gov/18983142

DM5VWCI	DI	DM5VWCI
DM5VWCI	DN	Ly231514 Tetra Glu
DM5VWCI	MI	TTU6BFZ
DM5VWCI	MN	Candida Thymidylate synthase (Candi TMP1)
DM5VWCI	MT	DTT
DM5VWCI	MA	Inhibitor
DM5VWCI	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM5VWCI	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMPV6N9	DI	DMPV6N9
DMPV6N9	DN	LY-2318912
DMPV6N9	MI	TTDP1UC
DMPV6N9	MN	Fatty acid amide hydrolase (FAAH)
DMPV6N9	MT	DTT
DMPV6N9	MA	Inhibitor
DMPV6N9	RN	Carbamoyl tetrazoles as inhibitors of endocannabinoid inactivation: a critical revisitation. Eur J Med Chem. 2008 Jan;43(1):62-72.
DMPV6N9	RU	https://pubmed.ncbi.nlm.nih.gov/17452063

DMC82DA	DI	DMC82DA
DMC82DA	DN	LY233053
DMC82DA	MI	TTKJEMQ
DMC82DA	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMC82DA	MT	DTT
DMC82DA	MA	Antagonist
DMC82DA	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456).
DMC82DA	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=456

DMC82DA	DI	DMC82DA
DMC82DA	DN	LY233053
DMC82DA	MI	TTN9D8E
DMC82DA	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMC82DA	MT	DTT
DMC82DA	MA	Antagonist
DMC82DA	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457).
DMC82DA	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=457

DMC82DA	DI	DMC82DA
DMC82DA	DN	LY233053
DMC82DA	MI	TT1M8OW
DMC82DA	MN	Glutamate receptor ionotropic NMDA 2C (GluN2C)
DMC82DA	MT	DTT
DMC82DA	MA	Antagonist
DMC82DA	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 458).
DMC82DA	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=458

DMC82DA	DI	DMC82DA
DMC82DA	DN	LY233053
DMC82DA	MI	TT5POTG
DMC82DA	MN	Glutamate receptor ionotropic NMDA 2D (GluN2D)
DMC82DA	MT	DTT
DMC82DA	MA	Antagonist
DMC82DA	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 459).
DMC82DA	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=459

DMBFLOJ	DI	DMBFLOJ
DMBFLOJ	DN	LY2365109
DMBFLOJ	MI	TTHJTF7
DMBFLOJ	MN	Glycine transporter GlyT-1 (SLC6A9)
DMBFLOJ	MT	DTT
DMBFLOJ	MA	Inhibitor
DMBFLOJ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 935).
DMBFLOJ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=935

DM1KCHN	DI	DM1KCHN
DM1KCHN	DN	LY256548
DM1KCHN	MI	TT9V5JH
DM1KCHN	MN	Phospholipase A2 (PLA2G1B)
DM1KCHN	MT	DTT
DM1KCHN	MA	Binder
DM1KCHN	RN	The anti-inflammatory effects of LY178002 and LY256548. Agents Actions. 1989 Jun;27(3-4):300-2.
DM1KCHN	RU	https://pubmed.ncbi.nlm.nih.gov/2508442

DMX5H3T	DI	DMX5H3T
DMX5H3T	DN	LY-266111
DMX5H3T	MI	TTTU72V
DMX5H3T	MN	Steroid 5-alpha-reductase 1 (SRD5A1)
DMX5H3T	MT	DTT
DMX5H3T	MA	Inhibitor
DMX5H3T	RN	Simple bi- and tricyclic inhibitors of human steroid 5alpha-reductase. Bioorg Med Chem Lett. 2000 Sep 4;10(17):1909-11.
DMX5H3T	RU	https://pubmed.ncbi.nlm.nih.gov/10987415

DMHC853	DI	DMHC853
DMHC853	DN	LY266500
DMHC853	MI	TTYX5QR
DMHC853	MN	Pseudomonas Histidine kinase AlgR2 (Pseudo algQ)
DMHC853	MT	DTT
DMHC853	MA	Inhibitor
DMHC853	RN	Histidine kinases as targets for new antimicrobial agents. Bioorg Med Chem. 2002 Apr;10(4):855-67.
DMHC853	RU	https://pubmed.ncbi.nlm.nih.gov/11836091

DMBSFDE	DI	DMBSFDE
DMBSFDE	DN	LY-282210
DMBSFDE	MI	TTN53ZF
DMBSFDE	MN	Leukotriene B4 receptor 1 (LTB4R)
DMBSFDE	MT	DTT
DMBSFDE	MA	Inhibitor
DMBSFDE	RN	Biphenylyl-substituted xanthones: highly potent leukotriene B4 receptor antagonists. J Med Chem. 1993 Nov 26;36(24):3982-4.
DMBSFDE	RU	https://pubmed.ncbi.nlm.nih.gov/8254628

DMBSFDE	DI	DMBSFDE
DMBSFDE	DN	LY-282210
DMBSFDE	MI	TTVJX54
DMBSFDE	MN	Leukotriene B4 receptor 2 (LTB4R2)
DMBSFDE	MT	DTT
DMBSFDE	MA	Inhibitor
DMBSFDE	RN	Biphenylyl-substituted xanthones: highly potent leukotriene B4 receptor antagonists. J Med Chem. 1993 Nov 26;36(24):3982-4.
DMBSFDE	RU	https://pubmed.ncbi.nlm.nih.gov/8254628

DML36ZE	DI	DML36ZE
DML36ZE	DN	LY-292223
DML36ZE	MI	TTL69WB
DML36ZE	MN	Angiotensin-converting enzyme (ACE)
DML36ZE	MT	DTT
DML36ZE	MA	Inhibitor
DML36ZE	RN	Endothelin-converting enzyme-1 inhibition and growth of human glioblastoma cells. J Med Chem. 2005 Jan 27;48(2):483-98.
DML36ZE	RU	https://pubmed.ncbi.nlm.nih.gov/15658862

DML36ZE	DI	DML36ZE
DML36ZE	DN	LY-292223
DML36ZE	MI	TTK3PY9
DML36ZE	MN	DNA-dependent protein kinase catalytic (PRKDC)
DML36ZE	MT	DTT
DML36ZE	MA	Inhibitor
DML36ZE	RN	Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6083-7.
DML36ZE	RU	https://pubmed.ncbi.nlm.nih.gov/15546735

DML36ZE	DI	DML36ZE
DML36ZE	DN	LY-292223
DML36ZE	MI	TTQ9RYT
DML36ZE	MN	Endothelin-converting enzyme 1 (ECE1)
DML36ZE	MT	DTT
DML36ZE	MA	Inhibitor
DML36ZE	RN	Endothelin-converting enzyme-1 inhibition and growth of human glioblastoma cells. J Med Chem. 2005 Jan 27;48(2):483-98.
DML36ZE	RU	https://pubmed.ncbi.nlm.nih.gov/15658862

DML36ZE	DI	DML36ZE
DML36ZE	DN	LY-292223
DML36ZE	MI	TT9H4P3
DML36ZE	MN	PI3K p110 beta messenger RNA (PIK3CB mRNA)
DML36ZE	MT	DTT
DML36ZE	MA	Inhibitor
DML36ZE	RN	LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family. Bioorg Med Chem Lett. 2001 Apr 9;11(7):909-13.
DML36ZE	RU	https://pubmed.ncbi.nlm.nih.gov/11294389

DML36ZE	DI	DML36ZE
DML36ZE	DN	LY-292223
DML36ZE	MI	TTGBPJE
DML36ZE	MN	PI3-kinase delta (PIK3CD)
DML36ZE	MT	DTT
DML36ZE	MA	Inhibitor
DML36ZE	RN	LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family. Bioorg Med Chem Lett. 2001 Apr 9;11(7):909-13.
DML36ZE	RU	https://pubmed.ncbi.nlm.nih.gov/11294389

DML36ZE	DI	DML36ZE
DML36ZE	DN	LY-292223
DML36ZE	MI	TTHBTOP
DML36ZE	MN	PI3-kinase gamma (PIK3CG)
DML36ZE	MT	DTT
DML36ZE	MA	Inhibitor
DML36ZE	RN	LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family. Bioorg Med Chem Lett. 2001 Apr 9;11(7):909-13.
DML36ZE	RU	https://pubmed.ncbi.nlm.nih.gov/11294389

DM2HQ9O	DI	DM2HQ9O
DM2HQ9O	DN	LY301875
DM2HQ9O	MI	TT8DBY3
DM2HQ9O	MN	Angiotensin II receptor type-1 (AGTR1)
DM2HQ9O	MT	DTT
DM2HQ9O	MA	Antagonist
DM2HQ9O	RN	Inhibition of angiotensin II-induced inositol phosphate production by triacid nonpeptide antagonists in CHO cells expressing human AT1 receptors. Pharm Res. 2000 Dec;17(12):1482-8.
DM2HQ9O	RU	https://pubmed.ncbi.nlm.nih.gov/11303957

DMY9WTE	DI	DMY9WTE
DMY9WTE	DN	LY303336
DMY9WTE	MI	TT8DBY3
DMY9WTE	MN	Angiotensin II receptor type-1 (AGTR1)
DMY9WTE	MT	DTT
DMY9WTE	MA	Antagonist
DMY9WTE	RN	Inhibition of angiotensin II-induced inositol phosphate production by triacid nonpeptide antagonists in CHO cells expressing human AT1 receptors. Pharm Res. 2000 Dec;17(12):1482-8.
DMY9WTE	RU	https://pubmed.ncbi.nlm.nih.gov/11303957

DMWAHYX	DI	DMWAHYX
DMWAHYX	DN	LY314228
DMWAHYX	MI	TTJQOD7
DMWAHYX	MN	5-HT 2A receptor (HTR2A)
DMWAHYX	MT	DTT
DMWAHYX	MA	Antagonist
DMWAHYX	RN	A novel class of 5-HT2A receptor antagonists: aryl aminoguanidines. Life Sci. 1996;59(15):1259-68.
DMWAHYX	RU	https://pubmed.ncbi.nlm.nih.gov/8845011

DMD2J97	DI	DMD2J97
DMD2J97	DN	LY-314657
DMD2J97	MI	TTAN6JD
DMD2J97	MN	Glutamate receptor AMPA (GRIA)
DMD2J97	MT	DTT
DMD2J97	MA	Modulator
DMD2J97	RN	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
DMD2J97	RU	https://www.ncbi.nlm.nih.gov/pubmed/27899562

DMK3Y5U	DI	DMK3Y5U
DMK3Y5U	DN	LY320135
DMK3Y5U	MI	TT6OEDT
DMK3Y5U	MN	Cannabinoid receptor 1 (CB1)
DMK3Y5U	MT	DTT
DMK3Y5U	MA	Antagonist
DMK3Y5U	RN	LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J Pharmacol Exp Ther. 1998 Jan;284(1):291-7.
DMK3Y5U	RU	https://pubmed.ncbi.nlm.nih.gov/9435190

DM3DOI7	DI	DM3DOI7
DM3DOI7	DN	LY320954
DM3DOI7	MI	TTJQOD7
DM3DOI7	MN	5-HT 2A receptor (HTR2A)
DM3DOI7	MT	DTT
DM3DOI7	MA	Antagonist
DM3DOI7	RN	A novel class of 5-HT2A receptor antagonists: aryl aminoguanidines. Life Sci. 1996;59(15):1259-68.
DM3DOI7	RU	https://pubmed.ncbi.nlm.nih.gov/8845011

DMN53M4	DI	DMN53M4
DMN53M4	DN	LY-326449
DMN53M4	MI	TT7A1BO
DMN53M4	MN	PKC-delta messenger RNA (PRKCD mRNA)
DMN53M4	MT	DTT
DMN53M4	MA	Inhibitor
DMN53M4	RN	(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H... J Med Chem. 1996 Jul 5;39(14):2664-71.
DMN53M4	RU	https://pubmed.ncbi.nlm.nih.gov/8709095

DMN53M4	DI	DMN53M4
DMN53M4	DN	LY-326449
DMN53M4	MI	TTONI0R
DMN53M4	MN	PKC-eta messenger RNA (PRKCH mRNA)
DMN53M4	MT	DTT
DMN53M4	MA	Inhibitor
DMN53M4	RN	(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H... J Med Chem. 1996 Jul 5;39(14):2664-71.
DMN53M4	RU	https://pubmed.ncbi.nlm.nih.gov/8709095

DMN53M4	DI	DMN53M4
DMN53M4	DN	LY-326449
DMN53M4	MI	TTBSN0L
DMN53M4	MN	PKC-zeta messenger RNA (PRKCZ mRNA)
DMN53M4	MT	DTT
DMN53M4	MA	Inhibitor
DMN53M4	RN	(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H... J Med Chem. 1996 Jul 5;39(14):2664-71.
DMN53M4	RU	https://pubmed.ncbi.nlm.nih.gov/8709095

DMN53M4	DI	DMN53M4
DMN53M4	DN	LY-326449
DMN53M4	MI	TTFJ8Q1
DMN53M4	MN	Protein kinase C alpha (PRKCA)
DMN53M4	MT	DTT
DMN53M4	MA	Inhibitor
DMN53M4	RN	(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H... J Med Chem. 1996 Jul 5;39(14):2664-71.
DMN53M4	RU	https://pubmed.ncbi.nlm.nih.gov/8709095

DMN53M4	DI	DMN53M4
DMN53M4	DN	LY-326449
DMN53M4	MI	TTYPXQF
DMN53M4	MN	Protein kinase C beta (PRKCB)
DMN53M4	MT	DTT
DMN53M4	MA	Inhibitor
DMN53M4	RN	(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H... J Med Chem. 1996 Jul 5;39(14):2664-71.
DMN53M4	RU	https://pubmed.ncbi.nlm.nih.gov/8709095

DMN53M4	DI	DMN53M4
DMN53M4	DN	LY-326449
DMN53M4	MI	TT9WJ8U
DMN53M4	MN	Protein kinase C delta (PRKCD)
DMN53M4	MT	DTT
DMN53M4	MA	Inhibitor
DMN53M4	RN	(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H... J Med Chem. 1996 Jul 5;39(14):2664-71.
DMN53M4	RU	https://pubmed.ncbi.nlm.nih.gov/8709095

DMN53M4	DI	DMN53M4
DMN53M4	DN	LY-326449
DMN53M4	MI	TTBZ7OD
DMN53M4	MN	Protein kinase C epsilon (PRKCE)
DMN53M4	MT	DTT
DMN53M4	MA	Inhibitor
DMN53M4	RN	(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H... J Med Chem. 1996 Jul 5;39(14):2664-71.
DMN53M4	RU	https://pubmed.ncbi.nlm.nih.gov/8709095

DMN53M4	DI	DMN53M4
DMN53M4	DN	LY-326449
DMN53M4	MI	TTRFOXJ
DMN53M4	MN	Protein kinase C gamma (PRKCG)
DMN53M4	MT	DTT
DMN53M4	MA	Inhibitor
DMN53M4	RN	(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H... J Med Chem. 1996 Jul 5;39(14):2664-71.
DMN53M4	RU	https://pubmed.ncbi.nlm.nih.gov/8709095

DMN53M4	DI	DMN53M4
DMN53M4	DN	LY-326449
DMN53M4	MI	TT8QL1J
DMN53M4	MN	Protein kinase C theta (PRKCQ)
DMN53M4	MT	DTT
DMN53M4	MA	Inhibitor
DMN53M4	RN	(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H... J Med Chem. 1996 Jul 5;39(14):2664-71.
DMN53M4	RU	https://pubmed.ncbi.nlm.nih.gov/8709095

DMN53M4	DI	DMN53M4
DMN53M4	DN	LY-326449
DMN53M4	MI	TTUWGRA
DMN53M4	MN	Protein kinase C zeta (PRKCZ)
DMN53M4	MT	DTT
DMN53M4	MA	Inhibitor
DMN53M4	RN	(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H... J Med Chem. 1996 Jul 5;39(14):2664-71.
DMN53M4	RU	https://pubmed.ncbi.nlm.nih.gov/8709095

DMFHT3U	DI	DMFHT3U
DMFHT3U	DN	LY334362
DMFHT3U	MI	TTWJBZ5
DMFHT3U	MN	5-HT 2C receptor (HTR2C)
DMFHT3U	MT	DTT
DMFHT3U	MA	Antagonist
DMFHT3U	RN	A novel class of 5-HT2A receptor antagonists: aryl aminoguanidines. Life Sci. 1996;59(15):1259-68.
DMFHT3U	RU	https://pubmed.ncbi.nlm.nih.gov/8845011

DMUXFZQ	DI	DMUXFZQ
DMUXFZQ	DN	LY-3390334
DMUXFZQ	MI	TTVBPDM
DMUXFZQ	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMUXFZQ	MT	DTT
DMUXFZQ	MA	Modulator
DMUXFZQ	RN	Inhibition of group I metabotropic glutamate receptor responses in vivo in rats by a new generation of carboxyphenylglycine-like amino acid antagon... Neurosci Lett. 2002 Sep 20;330(2):127-30.
DMUXFZQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/12231428

DMUXFZQ	DI	DMUXFZQ
DMUXFZQ	DN	LY-3390334
DMUXFZQ	MI	TTHS256
DMUXFZQ	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMUXFZQ	MT	DTT
DMUXFZQ	MA	Modulator
DMUXFZQ	RN	Inhibition of group I metabotropic glutamate receptor responses in vivo in rats by a new generation of carboxyphenylglycine-like amino acid antagon... Neurosci Lett. 2002 Sep 20;330(2):127-30.
DMUXFZQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/12231428

DM8S7AO	DI	DM8S7AO
DM8S7AO	DN	LY339434
DM8S7AO	MI	TT0MYE2
DM8S7AO	MN	Glutamate receptor ionotropic kainate 1 (GRIK1)
DM8S7AO	MT	DTT
DM8S7AO	MA	Agonist
DM8S7AO	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 450).
DM8S7AO	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=450

DMS7KW8	DI	DMS7KW8
DMS7KW8	DN	LY341770
DMS7KW8	MI	TTU6BFZ
DMS7KW8	MN	Candida Thymidylate synthase (Candi TMP1)
DMS7KW8	MT	DTT
DMS7KW8	MA	Inhibitor
DMS7KW8	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMS7KW8	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM8LSQP	DI	DM8LSQP
DM8LSQP	DN	LY344864
DM8LSQP	MI	TT0MI3F
DM8LSQP	MN	5-HT 1F receptor (HTR1F)
DM8LSQP	MT	DTT
DM8LSQP	MA	Agonist
DM8LSQP	RN	5-Hydroxytryptamine(1F) receptors do not participate in vasoconstriction: lack of vasoconstriction to LY344864, a selective serotonin(1F) receptor agonist in rabbit saphenous vein. J Pharmacol Exp Ther. 1999 Sep;290(3):935-9.
DM8LSQP	RU	https://pubmed.ncbi.nlm.nih.gov/10454462

DMME40U	DI	DMME40U
DMME40U	DN	LY-379268
DMME40U	MI	TTXJ47W
DMME40U	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMME40U	MT	DTT
DMME40U	MA	Inhibitor
DMME40U	RN	Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identif... J Med Chem. 2007 Jan 25;50(2):233-40.
DMME40U	RU	https://pubmed.ncbi.nlm.nih.gov/17228865

DMME40U	DI	DMME40U
DMME40U	DN	LY-379268
DMME40U	MI	TT8A9EF
DMME40U	MN	Metabotropic glutamate receptor 3 (mGluR3)
DMME40U	MT	DTT
DMME40U	MA	Inhibitor
DMME40U	RN	Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identif... J Med Chem. 2007 Jan 25;50(2):233-40.
DMME40U	RU	https://pubmed.ncbi.nlm.nih.gov/17228865

DMWKYFO	DI	DMWKYFO
DMWKYFO	DN	LY382884
DMWKYFO	MI	TT0MYE2
DMWKYFO	MN	Glutamate receptor ionotropic kainate 1 (GRIK1)
DMWKYFO	MT	DTT
DMWKYFO	MA	Antagonist
DMWKYFO	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 450).
DMWKYFO	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=450

DM6Y2XG	DI	DM6Y2XG
DM6Y2XG	DN	LY-389795
DM6Y2XG	MI	TTXJ47W
DM6Y2XG	MN	Metabotropic glutamate receptor 2 (mGluR2)
DM6Y2XG	MT	DTT
DM6Y2XG	MA	Inhibitor
DM6Y2XG	RN	Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identif... J Med Chem. 2007 Jan 25;50(2):233-40.
DM6Y2XG	RU	https://pubmed.ncbi.nlm.nih.gov/17228865

DM6Y2XG	DI	DM6Y2XG
DM6Y2XG	DN	LY-389795
DM6Y2XG	MI	TT8A9EF
DM6Y2XG	MN	Metabotropic glutamate receptor 3 (mGluR3)
DM6Y2XG	MT	DTT
DM6Y2XG	MA	Inhibitor
DM6Y2XG	RN	Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identif... J Med Chem. 2007 Jan 25;50(2):233-40.
DM6Y2XG	RU	https://pubmed.ncbi.nlm.nih.gov/17228865

DM1KW0L	DI	DM1KW0L
DM1KW0L	DN	LY-392098
DM1KW0L	MI	TTAN6JD
DM1KW0L	MN	Glutamate receptor AMPA (GRIA)
DM1KW0L	MT	DTT
DM1KW0L	MA	Modulator
DM1KW0L	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4251).
DM1KW0L	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4251

DMHQ0T2	DI	DMHQ0T2
DMHQ0T2	DN	LY433221
DMHQ0T2	MI	TTSQIFT
DMHQ0T2	MN	5-HT 1A receptor (HTR1A)
DMHQ0T2	MT	DTT
DMHQ0T2	MA	Antagonist
DMHQ0T2	RN	Serotonin reuptake inhibitors: the corner stone in treatment of depression for half a century--a medicinal chemistry survey. Curr Top Med Chem. 2006;6(17):1801-23.
DMHQ0T2	RU	https://pubmed.ncbi.nlm.nih.gov/17017959

DMP8OXG	DI	DMP8OXG
DMP8OXG	DN	LY433222
DMP8OXG	MI	TTJQOD7
DMP8OXG	MN	5-HT 2A receptor (HTR2A)
DMP8OXG	MT	DTT
DMP8OXG	MA	Inhibitor
DMP8OXG	RN	Serotonin reuptake inhibitors: the corner stone in treatment of depression for half a century--a medicinal chemistry survey. Curr Top Med Chem. 2006;6(17):1801-23.
DMP8OXG	RU	https://pubmed.ncbi.nlm.nih.gov/17017959

DM86Y1V	DI	DM86Y1V
DM86Y1V	DN	LY456066
DM86Y1V	MI	TTVBPDM
DM86Y1V	MN	Metabotropic glutamate receptor 1 (mGluR1)
DM86Y1V	MT	DTT
DM86Y1V	MA	Modulator (allosteric modulator)
DM86Y1V	RN	Identification of a novel transmembrane domain involved in the negative modulation of mGluR1 using a newly discovered allosteric mGluR1 antagonist, 3-cyclohexyl-5-fluoro-6-methyl-7-(2-morpholin-4-ylethoxy)-4H-chromen-4-one. Neuropharmacology. 2009 Sep;57(4):438-45.
DM86Y1V	RU	https://pubmed.ncbi.nlm.nih.gov/19559036

DMROFX8	DI	DMROFX8
DMROFX8	DN	LY456236
DMROFX8	MI	TTVBPDM
DMROFX8	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMROFX8	MT	DTT
DMROFX8	MA	Modulator (allosteric modulator)
DMROFX8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 289).
DMROFX8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=289

DMK64AZ	DI	DMK64AZ
DMK64AZ	DN	LY-465608
DMK64AZ	MI	TTJ584C
DMK64AZ	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMK64AZ	MT	DTT
DMK64AZ	MA	Agonist
DMK64AZ	RN	Design and synthesis of alpha-aryloxy-alpha-methylhydrocinnamic acids: a novel class of dual peroxisome proliferator-activated receptor alpha/gamma agonists. J Med Chem. 2004 May 6;47(10):2422-5.
DMK64AZ	RU	https://pubmed.ncbi.nlm.nih.gov/15115385

DMK64AZ	DI	DMK64AZ
DMK64AZ	DN	LY-465608
DMK64AZ	MI	TTT2SVW
DMK64AZ	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DMK64AZ	MT	DTT
DMK64AZ	MA	Agonist
DMK64AZ	RN	Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists. J Med Chem. 2001 Jun 21;44(13):2061-4.
DMK64AZ	RU	https://pubmed.ncbi.nlm.nih.gov/11405642

DM97NBO	DI	DM97NBO
DM97NBO	DN	LY466195
DM97NBO	MI	TT0MYE2
DM97NBO	MN	Glutamate receptor ionotropic kainate 1 (GRIK1)
DM97NBO	MT	DTT
DM97NBO	MA	Antagonist
DM97NBO	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 450).
DM97NBO	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=450

DMQVF41	DI	DMQVF41
DMQVF41	DN	LY-593039
DMQVF41	MI	TTZ9SOR
DMQVF41	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMQVF41	MT	DTT
DMQVF41	MA	Agonist
DMQVF41	RN	Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur J Pharmacol. 2009 Mar 1;605(1-3):53-6.
DMQVF41	RU	https://pubmed.ncbi.nlm.nih.gov/19168056

DMQE89J	DI	DMQE89J
DMQE89J	DN	LY593093
DMQE89J	MI	TTOXS3C
DMQE89J	MN	Muscarinic acetylcholine receptor (CHRM)
DMQE89J	MT	DTT
DMQE89J	MA	Agonist
DMQE89J	RN	Pharmacological characterization of LY593093, an M1 muscarinic acetylcholine receptor-selective partial orthosteric agonist. J Pharmacol Exp Ther. 2011 Aug;338(2):622-32.
DMQE89J	RU	https://pubmed.ncbi.nlm.nih.gov/21558436

DM5TYMG	DI	DM5TYMG
DM5TYMG	DN	LY86057
DM5TYMG	MI	TTJQOD7
DM5TYMG	MN	5-HT 2A receptor (HTR2A)
DM5TYMG	MT	DTT
DM5TYMG	MA	Antagonist
DM5TYMG	RN	Species variations in transmembrane region V of the 5-hydroxytryptamine type 2A receptor alter the structure-activity relationship of certain ergolines and tryptamines. Mol Pharmacol. 1994 Feb;45(2):277-86.
DM5TYMG	RU	https://pubmed.ncbi.nlm.nih.gov/8114677

DM5TYMG	DI	DM5TYMG
DM5TYMG	DN	LY86057
DM5TYMG	MI	TT0K1SC
DM5TYMG	MN	5-HT 2B receptor (HTR2B)
DM5TYMG	MT	DTT
DM5TYMG	MA	Antagonist
DM5TYMG	RN	Pharmacological characteristics of the newly cloned rat 5-hydroxytryptamine2F receptor. Mol Pharmacol. 1993 Mar;43(3):419-26.
DM5TYMG	RU	https://pubmed.ncbi.nlm.nih.gov/8450835

DMTNVP4	DI	DMTNVP4
DMTNVP4	DN	LY97241
DMTNVP4	MI	TT9XKUC
DMTNVP4	MN	Voltage-gated potassium channel Kv10.1 (KCNH1)
DMTNVP4	MT	DTT
DMTNVP4	MA	Blocker (channel blocker)
DMTNVP4	RN	Inhibition of hEAG1 and hERG1 potassium channels by clofilium and its tertiary analogue LY97241. Br J Pharmacol. 2003 Jan;138(1):161-71.
DMTNVP4	RU	https://pubmed.ncbi.nlm.nih.gov/12522086

DMTNVP4	DI	DMTNVP4
DMTNVP4	DN	LY97241
DMTNVP4	MI	TTX8LQ0
DMTNVP4	MN	Voltage-gated potassium channel Kv10.2 (KCNH5)
DMTNVP4	MT	DTT
DMTNVP4	MA	Blocker (channel blocker)
DMTNVP4	RN	Molecular determinants for high-affinity block of human EAG potassium channels by antiarrhythmic agents. Mol Pharmacol. 2004 May;65(5):1120-9.
DMTNVP4	RU	https://pubmed.ncbi.nlm.nih.gov/15102940

DMVX19Q	DI	DMVX19Q
DMVX19Q	DN	LYCOGARUBIN B
DMVX19Q	MI	TT1VAUK
DMVX19Q	MN	VEGFR1 messenger RNA (VEGFR1 mRNA)
DMVX19Q	MT	DTT
DMVX19Q	MA	Inhibitor
DMVX19Q	RN	New cytotoxic bisindole alkaloids with protein tyrosine kinase inhibitory activity from a myxomycete Lycogala epidendrum. Bioorg Med Chem Lett. 2005 Jun 2;15(11):2776-80.
DMVX19Q	RU	https://pubmed.ncbi.nlm.nih.gov/15911254

DMH0Q9V	DI	DMH0Q9V
DMH0Q9V	DN	Lys[Z(NO2)]-Lys[Z(NO2)]
DMH0Q9V	MI	TT27Q3A
DMH0Q9V	MN	Solute carrier family 15 member 2 (SLC15A2)
DMH0Q9V	MT	DTT
DMH0Q9V	MA	Inhibitor
DMH0Q9V	RN	Defining minimal structural features in substrates of the H(+)/peptide cotransporter PEPT2 using novel amino acid and dipeptide derivatives. Mol Pharmacol. 2002 Jan;61(1):214-21.
DMH0Q9V	RU	https://pubmed.ncbi.nlm.nih.gov/11752223

DMJX4GA	DI	DMJX4GA
DMJX4GA	DN	Lys[Z(NO2)]-Pro
DMJX4GA	MI	TT5LF3C
DMJX4GA	MN	Solute carrier family 15 member 1 (SLC15A1)
DMJX4GA	MT	DTT
DMJX4GA	MA	Inhibitor
DMJX4GA	RN	A novel inhibitor of the mammalian peptide transporter PEPT1. Biochemistry. 2001 Apr 10;40(14):4454-8.
DMJX4GA	RU	https://pubmed.ncbi.nlm.nih.gov/11284702

DMJX4GA	DI	DMJX4GA
DMJX4GA	DN	Lys[Z(NO2)]-Pro
DMJX4GA	MI	TT27Q3A
DMJX4GA	MN	Solute carrier family 15 member 2 (SLC15A2)
DMJX4GA	MT	DTT
DMJX4GA	MA	Inhibitor
DMJX4GA	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 985).
DMJX4GA	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=985

DM4MGAQ	DI	DM4MGAQ
DM4MGAQ	DN	lysergic acid
DM4MGAQ	MI	TT6MSOK
DM4MGAQ	MN	5-HT 1D receptor (HTR1D)
DM4MGAQ	MT	DTT
DM4MGAQ	MA	Agonist
DM4MGAQ	RN	Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan. Mol Pharmacol. 1996 Dec;50(6):1567-80.
DM4MGAQ	RU	https://pubmed.ncbi.nlm.nih.gov/8967979

DM4MGAQ	DI	DM4MGAQ
DM4MGAQ	DN	lysergic acid
DM4MGAQ	MI	TTRUFDT
DM4MGAQ	MN	5-HT 5A receptor (HTR5A)
DM4MGAQ	MT	DTT
DM4MGAQ	MA	Agonist
DM4MGAQ	RN	Expression of functional mouse 5-HT5A serotonin receptor in the methylotrophic yeast Pichia pastoris: pharmacological characterization and localization. FEBS Lett. 1995 Dec 27;377(3):451-6.
DM4MGAQ	RU	https://pubmed.ncbi.nlm.nih.gov/8549774

DM1OHF8	DI	DM1OHF8
DM1OHF8	DN	lysergol
DM1OHF8	MI	TTK8CXU
DM1OHF8	MN	5-HT 1B receptor (HTR1B)
DM1OHF8	MT	DTT
DM1OHF8	MA	Agonist
DM1OHF8	RN	Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors. J Neurochem. 1996 Nov;67(5):2096-103.
DM1OHF8	RU	https://pubmed.ncbi.nlm.nih.gov/8863519

DM1OHF8	DI	DM1OHF8
DM1OHF8	DN	lysergol
DM1OHF8	MI	TT6MSOK
DM1OHF8	MN	5-HT 1D receptor (HTR1D)
DM1OHF8	MT	DTT
DM1OHF8	MA	Agonist
DM1OHF8	RN	Human serotonin 1D receptor is encoded by a subfamily of two distinct genes: 5-HT1D alpha and 5-HT1D beta. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3630-4.
DM1OHF8	RU	https://pubmed.ncbi.nlm.nih.gov/1565658

DM1OHF8	DI	DM1OHF8
DM1OHF8	DN	lysergol
DM1OHF8	MI	TTCPG9S
DM1OHF8	MN	5-HT 1E receptor (HTR1E)
DM1OHF8	MT	DTT
DM1OHF8	MA	Agonist
DM1OHF8	RN	Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors. J Neurochem. 1996 Nov;67(5):2096-103.
DM1OHF8	RU	https://pubmed.ncbi.nlm.nih.gov/8863519

DMIZQW6	DI	DMIZQW6
DMIZQW6	DN	LYSICAMINE
DMIZQW6	MI	TT1RS9F
DMIZQW6	MN	Acetylcholinesterase (AChE)
DMIZQW6	MT	DTT
DMIZQW6	MA	Inhibitor
DMIZQW6	RN	Characterization of Acetylcholinesterase Inhibitory Constituents from Annona glabra Assisted by HPLC Microfractionation. J Nat Prod. 2010 Oct 22;73(10):1632-5. 
DMIZQW6	RU	https://pubmed.ncbi.nlm.nih.gov/20828184

DMW1YK3	DI	DMW1YK3
DMW1YK3	DN	Lysine Nz-Carboxylic Acid
DMW1YK3	MI	TT7HF4W
DMW1YK3	MN	Cyclin-dependent kinase 2 (CDK2)
DMW1YK3	MT	DTT
DMW1YK3	MA	Inhibitor
DMW1YK3	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMW1YK3	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMW1YK3	DI	DMW1YK3
DMW1YK3	DN	Lysine Nz-Carboxylic Acid
DMW1YK3	MI	TT6TMZU
DMW1YK3	MN	Mycobacterium Biosynthetic alanine racemase (MycB alr)
DMW1YK3	MT	DTT
DMW1YK3	MA	Inhibitor
DMW1YK3	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMW1YK3	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMW1YK3	DI	DMW1YK3
DMW1YK3	DN	Lysine Nz-Carboxylic Acid
DMW1YK3	MI	TT09NOX
DMW1YK3	MN	Plasmodium Dihydroorotase (Malaria dho)
DMW1YK3	MT	DTT
DMW1YK3	MA	Inhibitor
DMW1YK3	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMW1YK3	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMOGFVH	DI	DMOGFVH
DMOGFVH	DN	Lysophosphatidylcholine
DMOGFVH	MI	DT5G94L
DMOGFVH	MN	Major facilitator superfamily domain-containing protein 2A (SLC59A1)
DMOGFVH	MT	DTP
DMOGFVH	MA	Substrate
DMOGFVH	RN	Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid. Nature. 2014 May 22;509(7501):503-6.
DMOGFVH	RU	http://www.ncbi.nlm.nih.gov/pubmed/24828044

DMOGFVH	DI	DMOGFVH
DMOGFVH	DN	Lysophosphatidylcholine
DMOGFVH	MI	TT32NQ1
DMOGFVH	MN	Short transient receptor potential channel 5 (TRPC5)
DMOGFVH	MT	DTT
DMOGFVH	MA	Activator
DMOGFVH	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 490).
DMOGFVH	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=490

DMOGFVH	DI	DMOGFVH
DMOGFVH	DN	Lysophosphatidylcholine
DMOGFVH	MI	TTRBT3W
DMOGFVH	MN	Short transient receptor potential channel 6 (TRPC6)
DMOGFVH	MT	DTT
DMOGFVH	MA	Activator
DMOGFVH	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 491).
DMOGFVH	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=491

DMOGFVH	DI	DMOGFVH
DMOGFVH	DN	Lysophosphatidylcholine
DMOGFVH	MI	TTBECWA
DMOGFVH	MN	Transient receptor potential cation channel V2 (TRPV2)
DMOGFVH	MT	DTT
DMOGFVH	MA	Activator
DMOGFVH	RN	Lysophospholipids stimulate prostate cancer cell migration via TRPV2 channel activation. Biochim Biophys Acta. 2009 Mar;1793(3):528-39.
DMOGFVH	RU	https://pubmed.ncbi.nlm.nih.gov/19321128

DMI4FKH	DI	DMI4FKH
DMI4FKH	DN	lysophosphatidylethanolamine
DMI4FKH	MI	TT7QNVC
DMI4FKH	MN	Glucose-dependent insulinotropic receptor (GPR119)
DMI4FKH	MT	DTT
DMI4FKH	MA	Agonist
DMI4FKH	RN	Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem Biophys Res Commun. 2005 Jan 28;326(4):744-51.
DMI4FKH	RU	https://pubmed.ncbi.nlm.nih.gov/15607732

DMETM3R	DI	DMETM3R
DMETM3R	DN	lysophosphatidylinositol
DMETM3R	MI	TT7QNVC
DMETM3R	MN	Glucose-dependent insulinotropic receptor (GPR119)
DMETM3R	MT	DTT
DMETM3R	MA	Agonist
DMETM3R	RN	Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem Biophys Res Commun. 2005 Jan 28;326(4):744-51.
DMETM3R	RU	https://pubmed.ncbi.nlm.nih.gov/15607732

DMETM3R	DI	DMETM3R
DMETM3R	DN	lysophosphatidylinositol
DMETM3R	MI	TTNET8J
DMETM3R	MN	G-protein coupled receptor 55 (GPR55)
DMETM3R	MT	DTT
DMETM3R	MA	Agonist
DMETM3R	RN	Screening beta-arrestin recruitment for the identification of natural ligands for orphan G-protein-coupled receptors. J Biomol Screen. 2013 Jun;18(5):599-609.
DMETM3R	RU	https://pubmed.ncbi.nlm.nih.gov/23396314

DMETM3R	DI	DMETM3R
DMETM3R	DN	lysophosphatidylinositol
DMETM3R	MI	TTBECWA
DMETM3R	MN	Transient receptor potential cation channel V2 (TRPV2)
DMETM3R	MT	DTT
DMETM3R	MA	Activator
DMETM3R	RN	Lysophospholipids stimulate prostate cancer cell migration via TRPV2 channel activation. Biochim Biophys Acta. 2009 Mar;1793(3):528-39.
DMETM3R	RU	https://pubmed.ncbi.nlm.nih.gov/19321128

DMKG7J2	DI	DMKG7J2
DMKG7J2	DN	lysophosphatidylserine
DMKG7J2	MI	TTYUB4M
DMKG7J2	MN	G-protein coupled receptor 174 (GPR174)
DMKG7J2	MT	DTT
DMKG7J2	MA	Agonist
DMKG7J2	RN	TGFalpha shedding assay: an accurate and versatile method for detecting GPCR activation. Nat Methods. 2012 Oct;9(10):1021-9.
DMKG7J2	RU	https://pubmed.ncbi.nlm.nih.gov/22983457

DMKG7J2	DI	DMKG7J2
DMKG7J2	DN	lysophosphatidylserine
DMKG7J2	MI	TTVXSTQ
DMKG7J2	MN	G-protein coupled receptor 34 (GPR34)
DMKG7J2	MT	DTT
DMKG7J2	MA	Agonist
DMKG7J2	RN	GPR34 is a receptor for lysophosphatidylserine with a fatty acid at the sn-2 position. J Biochem. 2012 May;151(5):511-8.
DMKG7J2	RU	https://pubmed.ncbi.nlm.nih.gov/22343749

DMIG3FX	DI	DMIG3FX
DMIG3FX	DN	Lysophosphotidylserine
DMIG3FX	MI	TT6L509
DMIG3FX	MN	Coagulation factor IIa (F2)
DMIG3FX	MT	DTT
DMIG3FX	MA	Inhibitor
DMIG3FX	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMIG3FX	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DME15MN	DI	DME15MN
DME15MN	DN	Lys-thiol
DME15MN	MI	TTD74YX
DME15MN	MN	Arginyl aminopeptidase (RNPEP)
DME15MN	MT	DTT
DME15MN	MA	Inhibitor
DME15MN	RN	L-lysinethiol: a subnanomolar inhibitor of aminopeptidase B. Biochem Biophys Res Commun. 1987 Jun 30;145(3):1038-42.
DME15MN	RU	https://pubmed.ncbi.nlm.nih.gov/3111463

DMJQG82	DI	DMJQG82
DMJQG82	DN	M&B 28767
DMJQG82	MI	TTG1QMU
DMJQG82	MN	Prostaglandin E2 receptor EP1 (PTGER1)
DMJQG82	MT	DTT
DMJQG82	MA	Agonist
DMJQG82	RN	Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
DMJQG82	RU	https://pubmed.ncbi.nlm.nih.gov/9313928

DMJQG82	DI	DMJQG82
DMJQG82	DN	M&B 28767
DMJQG82	MI	TT1ZAVI
DMJQG82	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DMJQG82	MT	DTT
DMJQG82	MA	Agonist
DMJQG82	RN	Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41.
DMJQG82	RU	https://pubmed.ncbi.nlm.nih.gov/9537820

DMJQG82	DI	DMJQG82
DMJQG82	DN	M&B 28767
DMJQG82	MI	TTPNGDE
DMJQG82	MN	Prostaglandin E2 receptor EP3 (PTGER3)
DMJQG82	MT	DTT
DMJQG82	MA	Agonist
DMJQG82	RN	Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
DMJQG82	RU	https://pubmed.ncbi.nlm.nih.gov/9313928

DMJQG82	DI	DMJQG82
DMJQG82	DN	M&B 28767
DMJQG82	MI	TT79WV3
DMJQG82	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DMJQG82	MT	DTT
DMJQG82	MA	Agonist
DMJQG82	RN	Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
DMJQG82	RU	https://pubmed.ncbi.nlm.nih.gov/9313928

DMJQG82	DI	DMJQG82
DMJQG82	DN	M&B 28767
DMJQG82	MI	TTT2ZAR
DMJQG82	MN	Prostaglandin F2-alpha receptor (PTGFR)
DMJQG82	MT	DTT
DMJQG82	MA	Agonist
DMJQG82	RN	Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
DMJQG82	RU	https://pubmed.ncbi.nlm.nih.gov/9313928

DMJQG82	DI	DMJQG82
DMJQG82	DN	M&B 28767
DMJQG82	MI	TT2O84V
DMJQG82	MN	Thromboxane A2 receptor (TBXA2R)
DMJQG82	MT	DTT
DMJQG82	MA	Agonist
DMJQG82	RN	The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
DMJQG82	RU	https://pubmed.ncbi.nlm.nih.gov/10634944

DMYU3Z7	DI	DMYU3Z7
DMYU3Z7	DN	M372049
DMYU3Z7	MI	TTWVLS6
DMYU3Z7	MN	Natriuretic peptide receptor (NPR3)
DMYU3Z7	MT	DTT
DMYU3Z7	MA	Antagonist
DMYU3Z7	RN	Natriuretic peptide receptor-C regulates coronary blood flow and prevents myocardial ischemia/reperfusion injury: novel cardioprotective role for e... Circulation. 2004 Sep 7;110(10):1231-5.
DMYU3Z7	RU	https://pubmed.ncbi.nlm.nih.gov/15337698

DMJK1RE	DI	DMJK1RE
DMJK1RE	DN	M3A6S
DMJK1RE	MI	TTQW87Y
DMJK1RE	MN	Opioid receptor kappa (OPRK1)
DMJK1RE	MT	DTT
DMJK1RE	MA	Inhibitor
DMJK1RE	RN	Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5.
DMJK1RE	RU	https://pubmed.ncbi.nlm.nih.gov/16777416

DMJK1RE	DI	DMJK1RE
DMJK1RE	DN	M3A6S
DMJK1RE	MI	TTKWM86
DMJK1RE	MN	Opioid receptor mu (MOP)
DMJK1RE	MT	DTT
DMJK1RE	MA	Inhibitor
DMJK1RE	RN	Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5.
DMJK1RE	RU	https://pubmed.ncbi.nlm.nih.gov/16777416

DMAHGBF	DI	DMAHGBF
DMAHGBF	DN	M3B6S
DMAHGBF	MI	TTKWM86
DMAHGBF	MN	Opioid receptor mu (MOP)
DMAHGBF	MT	DTT
DMAHGBF	MA	Inhibitor
DMAHGBF	RN	Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5.
DMAHGBF	RU	https://pubmed.ncbi.nlm.nih.gov/16777416

DM0UOF1	DI	DM0UOF1
DM0UOF1	DN	M3IBu6S
DM0UOF1	MI	TTQW87Y
DM0UOF1	MN	Opioid receptor kappa (OPRK1)
DM0UOF1	MT	DTT
DM0UOF1	MA	Inhibitor
DM0UOF1	RN	Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5.
DM0UOF1	RU	https://pubmed.ncbi.nlm.nih.gov/16777416

DM0UOF1	DI	DM0UOF1
DM0UOF1	DN	M3IBu6S
DM0UOF1	MI	TTKWM86
DM0UOF1	MN	Opioid receptor mu (MOP)
DM0UOF1	MT	DTT
DM0UOF1	MA	Inhibitor
DM0UOF1	RN	Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5.
DM0UOF1	RU	https://pubmed.ncbi.nlm.nih.gov/16777416

DMXT87E	DI	DMXT87E
DMXT87E	DN	M3P6S
DMXT87E	MI	TTQW87Y
DMXT87E	MN	Opioid receptor kappa (OPRK1)
DMXT87E	MT	DTT
DMXT87E	MA	Inhibitor
DMXT87E	RN	Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5.
DMXT87E	RU	https://pubmed.ncbi.nlm.nih.gov/16777416

DMXT87E	DI	DMXT87E
DMXT87E	DN	M3P6S
DMXT87E	MI	TTKWM86
DMXT87E	MN	Opioid receptor mu (MOP)
DMXT87E	MT	DTT
DMXT87E	MA	Inhibitor
DMXT87E	RN	Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5.
DMXT87E	RU	https://pubmed.ncbi.nlm.nih.gov/16777416

DMMC8RN	DI	DMMC8RN
DMMC8RN	DN	M3Pr6S
DMMC8RN	MI	TTQW87Y
DMMC8RN	MN	Opioid receptor kappa (OPRK1)
DMMC8RN	MT	DTT
DMMC8RN	MA	Inhibitor
DMMC8RN	RN	Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5.
DMMC8RN	RU	https://pubmed.ncbi.nlm.nih.gov/16777416

DMMC8RN	DI	DMMC8RN
DMMC8RN	DN	M3Pr6S
DMMC8RN	MI	TTKWM86
DMMC8RN	MN	Opioid receptor mu (MOP)
DMMC8RN	MT	DTT
DMMC8RN	MA	Inhibitor
DMMC8RN	RN	Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5.
DMMC8RN	RU	https://pubmed.ncbi.nlm.nih.gov/16777416

DMWADOY	DI	DMWADOY
DMWADOY	DN	M3S
DMWADOY	MI	TTKWM86
DMWADOY	MN	Opioid receptor mu (MOP)
DMWADOY	MT	DTT
DMWADOY	MA	Inhibitor
DMWADOY	RN	Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5.
DMWADOY	RU	https://pubmed.ncbi.nlm.nih.gov/16777416

DM3IX2E	DI	DM3IX2E
DM3IX2E	DN	M5
DM3IX2E	MI	TTP86E2
DM3IX2E	MN	Plasminogen (PLG)
DM3IX2E	MT	DTT
DM3IX2E	MA	Activator
DM3IX2E	RN	Tranexamic acid in trauma: how should we use it. J Trauma Acute Care Surg. 2013 Jun;74(6):1575-86.
DM3IX2E	RU	https://pubmed.ncbi.nlm.nih.gov/23694890

DMM5X8Z	DI	DMM5X8Z
DMM5X8Z	DN	M55113
DMM5X8Z	MI	TTCIHJA
DMM5X8Z	MN	Coagulation factor Xa (F10)
DMM5X8Z	MT	DTT
DMM5X8Z	MA	Inhibitor
DMM5X8Z	RN	Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as factor Xa inhibitor. Chem Pharm Bull (Tokyo). 2001 Oct;49(10):1237-44.
DMM5X8Z	RU	https://pubmed.ncbi.nlm.nih.gov/11605647

DMFS7QK	DI	DMFS7QK
DMFS7QK	DN	M-5MPEP
DMFS7QK	MI	TTHS256
DMFS7QK	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMFS7QK	MT	DTT
DMFS7QK	MA	Modulator (allosteric modulator)
DMFS7QK	RN	A close structural analog of 2-methyl-6-(phenylethynyl)-pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtyp... Mol Pharmacol. 2005 Dec;68(6):1793-802.
DMFS7QK	RU	https://pubmed.ncbi.nlm.nih.gov/16155210

DMRB4YV	DI	DMRB4YV
DMRB4YV	DN	M6G thiosaccharide analogue
DMRB4YV	MI	TT27RFC
DMRB4YV	MN	Opioid receptor delta (OPRD1)
DMRB4YV	MT	DTT
DMRB4YV	MA	Inhibitor
DMRB4YV	RN	Synthesis and in vitro biological evaluation of a carbon glycoside analogue of morphine-6-glucuronide. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1583-6.
DMRB4YV	RU	https://pubmed.ncbi.nlm.nih.gov/15745801

DMRB4YV	DI	DMRB4YV
DMRB4YV	DN	M6G thiosaccharide analogue
DMRB4YV	MI	TTQW87Y
DMRB4YV	MN	Opioid receptor kappa (OPRK1)
DMRB4YV	MT	DTT
DMRB4YV	MA	Inhibitor
DMRB4YV	RN	Synthesis and in vitro biological evaluation of a carbon glycoside analogue of morphine-6-glucuronide. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1583-6.
DMRB4YV	RU	https://pubmed.ncbi.nlm.nih.gov/15745801

DMRB4YV	DI	DMRB4YV
DMRB4YV	DN	M6G thiosaccharide analogue
DMRB4YV	MI	TTKWM86
DMRB4YV	MN	Opioid receptor mu (MOP)
DMRB4YV	MT	DTT
DMRB4YV	MA	Inhibitor
DMRB4YV	RN	Synthesis and in vitro biological evaluation of a carbon glycoside analogue of morphine-6-glucuronide. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1583-6.
DMRB4YV	RU	https://pubmed.ncbi.nlm.nih.gov/15745801

DMFCUN4	DI	DMFCUN4
DMFCUN4	DN	M6S
DMFCUN4	MI	TTQW87Y
DMFCUN4	MN	Opioid receptor kappa (OPRK1)
DMFCUN4	MT	DTT
DMFCUN4	MA	Inhibitor
DMFCUN4	RN	Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5.
DMFCUN4	RU	https://pubmed.ncbi.nlm.nih.gov/16777416

DMFCUN4	DI	DMFCUN4
DMFCUN4	DN	M6S
DMFCUN4	MI	TTKWM86
DMFCUN4	MN	Opioid receptor mu (MOP)
DMFCUN4	MT	DTT
DMFCUN4	MA	Inhibitor
DMFCUN4	RN	Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5.
DMFCUN4	RU	https://pubmed.ncbi.nlm.nih.gov/16777416

DM9NPE4	DI	DM9NPE4
DM9NPE4	DN	M826
DM9NPE4	MI	TTCQIBE
DM9NPE4	MN	Caspase-1 (CASP1)
DM9NPE4	MT	DTT
DM9NPE4	MA	Inhibitor
DM9NPE4	RN	Novel pyrazinone mono-amides as potent and reversible caspase-3 inhibitors. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1173-80.
DM9NPE4	RU	https://pubmed.ncbi.nlm.nih.gov/15686936

DM9NPE4	DI	DM9NPE4
DM9NPE4	DN	M826
DM9NPE4	MI	TTPF2QI
DM9NPE4	MN	Caspase-3 (CASP3)
DM9NPE4	MT	DTT
DM9NPE4	MA	Inhibitor
DM9NPE4	RN	Novel pyrazinone mono-amides as potent and reversible caspase-3 inhibitors. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1173-80.
DM9NPE4	RU	https://pubmed.ncbi.nlm.nih.gov/15686936

DM9NPE4	DI	DM9NPE4
DM9NPE4	DN	M826
DM9NPE4	MI	TT3VZ8D
DM9NPE4	MN	Caspase-4 (CASP4)
DM9NPE4	MT	DTT
DM9NPE4	MA	Inhibitor
DM9NPE4	RN	Novel pyrazinone mono-amides as potent and reversible caspase-3 inhibitors. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1173-80.
DM9NPE4	RU	https://pubmed.ncbi.nlm.nih.gov/15686936

DM9NPE4	DI	DM9NPE4
DM9NPE4	DN	M826
DM9NPE4	MI	TTWR48J
DM9NPE4	MN	Caspase-5 (CASP5)
DM9NPE4	MT	DTT
DM9NPE4	MA	Inhibitor
DM9NPE4	RN	Novel pyrazinone mono-amides as potent and reversible caspase-3 inhibitors. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1173-80.
DM9NPE4	RU	https://pubmed.ncbi.nlm.nih.gov/15686936

DM9NPE4	DI	DM9NPE4
DM9NPE4	DN	M826
DM9NPE4	MI	TTM7Y45
DM9NPE4	MN	Caspase-7 (CASP7)
DM9NPE4	MT	DTT
DM9NPE4	MA	Inhibitor
DM9NPE4	RN	Novel pyrazinone mono-amides as potent and reversible caspase-3 inhibitors. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1173-80.
DM9NPE4	RU	https://pubmed.ncbi.nlm.nih.gov/15686936

DM8I0TY	DI	DM8I0TY
DM8I0TY	DN	M8-B
DM8I0TY	MI	TTXDKTO
DM8I0TY	MN	Long transient receptor potential channel 8 (TRPM8)
DM8I0TY	MT	DTT
DM8I0TY	MA	Blocker (channel blocker)
DM8I0TY	RN	Pharmacological blockade of the cold receptor TRPM8 attenuates autonomic and behavioral cold defenses and decreases deep body temperature. J Neurosci. 2012 Feb 8;32(6):2086-99.
DM8I0TY	RU	https://pubmed.ncbi.nlm.nih.gov/22323721

DMKWQ52	DI	DMKWQ52
DMKWQ52	DN	MA-2029
DMKWQ52	MI	TT953CX
DMKWQ52	MN	Motilin receptor (MLNR)
DMKWQ52	MT	DTT
DMKWQ52	MA	Antagonist
DMKWQ52	RN	Oral administration of MA-2029, a novel selective and competitive motilin receptor antagonist, inhibits motilin-induced intestinal contractions and visceral pain in rabbits. Eur J Pharmacol. 2008 Mar10;581(3):296-305.
DMKWQ52	RU	https://pubmed.ncbi.nlm.nih.gov/18164286

DMDHGM2	DI	DMDHGM2
DMDHGM2	DN	Maackiain
DMDHGM2	MI	TTF8JAT
DMDHGM2	MN	SLC5A2 messenger RNA (SLC5A2 mRNA)
DMDHGM2	MT	DTT
DMDHGM2	MA	Inhibitor
DMDHGM2	RN	Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens. Bioorg Med Chem. 2007 May 15;15(10):3445-9.
DMDHGM2	RU	https://pubmed.ncbi.nlm.nih.gov/17374486

DM1ICOW	DI	DM1ICOW
DM1ICOW	DN	mab 224G11
DM1ICOW	MI	TTNDSF4
DM1ICOW	MN	Proto-oncogene c-Met (MET)
DM1ICOW	MT	DTT
DM1ICOW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
DM1ICOW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815

DMJX2CS	DI	DMJX2CS
DMJX2CS	DN	mabionHER2
DMJX2CS	MI	TTGKNB4
DMJX2CS	MN	Epidermal growth factor receptor (EGFR)
DMJX2CS	MT	DTT
DMJX2CS	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
DMJX2CS	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797

DMDLF0J	DI	DMDLF0J
DMDLF0J	DN	Macbecin
DMDLF0J	MI	TT78R5H
DMDLF0J	MN	Heat shock protein 90 alpha (HSP90A)
DMDLF0J	MT	DTT
DMDLF0J	MA	Inhibitor
DMDLF0J	RN	Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008 Oct;8(7):761-82.
DMDLF0J	RU	https://pubmed.ncbi.nlm.nih.gov/18855578

DMOMG7S	DI	DMOMG7S
DMOMG7S	DN	MACLURAXANTHONE
DMOMG7S	MI	TT50QJ3
DMOMG7S	MN	Influenza Neuraminidase (Influ NA)
DMOMG7S	MT	DTT
DMOMG7S	MA	Inhibitor
DMOMG7S	RN	Characteristic of neuraminidase inhibitory xanthones from Cudrania tricuspidata. Bioorg Med Chem. 2009 Apr 1;17(7):2744-50.
DMOMG7S	RU	https://pubmed.ncbi.nlm.nih.gov/19285413

DMFULZO	DI	DMFULZO
DMFULZO	DN	Macrocyclic tripeptide motif
DMFULZO	MI	TT2WR1T
DMFULZO	MN	Cationic trypsinogen (PRSS1)
DMFULZO	MT	DTT
DMFULZO	MA	Inhibitor
DMFULZO	RN	Novel thrombin inhibitors that are based on a macrocyclic tripeptide motif, Bioorg. Med. Chem. Lett. 6(24):2947-2952 (1996).
DMFULZO	RU	http://www.sciencedirect.com/science/article/pii/S0960894X96005549

DMFULZO	DI	DMFULZO
DMFULZO	DN	Macrocyclic tripeptide motif
DMFULZO	MI	TT6L509
DMFULZO	MN	Coagulation factor IIa (F2)
DMFULZO	MT	DTT
DMFULZO	MA	Inhibitor
DMFULZO	RN	Novel thrombin inhibitors that are based on a macrocyclic tripeptide motif, Bioorg. Med. Chem. Lett. 6(24):2947-2952 (1996).
DMFULZO	RU	http://www.sciencedirect.com/science/article/pii/S0960894X96005549

DMSQL19	DI	DMSQL19
DMSQL19	DN	MAGGIEMYCIN
DMSQL19	MI	TTSJ542
DMSQL19	MN	Integrin alpha-2 (ITGA2)
DMSQL19	MT	DTT
DMSQL19	MA	Inhibitor
DMSQL19	RN	Small molecule designed to target metal binding site in the alpha2I domain inhibits integrin function. J Med Chem. 2007 May 31;50(11):2742-6.
DMSQL19	RU	https://pubmed.ncbi.nlm.nih.gov/17447751

DM5WNH8	DI	DM5WNH8
DM5WNH8	DN	Mahureone D
DM5WNH8	MI	TTIU7X1
DM5WNH8	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DM5WNH8	MT	DTT
DM5WNH8	MA	Inhibitor
DM5WNH8	RN	Acylphloroglucinol derivatives from Mahurea palustris. J Nat Prod. 2005 Jul;68(7):979-84.
DM5WNH8	RU	https://pubmed.ncbi.nlm.nih.gov/16038535

DMKE03Q	DI	DMKE03Q
DMKE03Q	DN	Makaluvamine N
DMKE03Q	MI	TT0IHXV
DMKE03Q	MN	DNA topoisomerase II (TOP2)
DMKE03Q	MT	DTT
DMKE03Q	MA	Inhibitor
DMKE03Q	RN	Makaluvamine N: a new pyrroloiminoquinone from Zyzzya fuliginosa. J Nat Prod. 1997 Apr;60(4):408-10.
DMKE03Q	RU	https://pubmed.ncbi.nlm.nih.gov/9134749

DMMCJLH	DI	DMMCJLH
DMMCJLH	DN	Malate
DMMCJLH	MI	DEIRBUF
DMMCJLH	MN	L-malate:NADP(+) oxidoreductase (maeB)
DMMCJLH	MT	DME
DMMCJLH	MA	Metabolism
DMMCJLH	RN	nan
DMMCJLH	RU	nan

DMMCJLH	DI	DMMCJLH
DMMCJLH	DN	Malate
DMMCJLH	MI	DE97WM8
DMMCJLH	MN	NADP-dependent malic enzyme (ME1)
DMMCJLH	MT	DME
DMMCJLH	MA	Metabolism
DMMCJLH	RN	Structural characteristics of the nonallosteric human cytosolic malic enzyme. Biochim Biophys Acta. 2014 Oct;1844(10):1773-83.
DMMCJLH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24998673

DM4OQWZ	DI	DM4OQWZ
DM4OQWZ	DN	Malate Like Intermediate
DM4OQWZ	MI	TTHDSE2
DM4OQWZ	MN	Bacterial Fumarate reductase flavoprotein (Bact frdA)
DM4OQWZ	MT	DTT
DM4OQWZ	MA	Inhibitor
DM4OQWZ	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DM4OQWZ	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DM4L0R7	DI	DM4L0R7
DM4L0R7	DN	Maleic Acid
DM4L0R7	MI	TTU507L
DM4L0R7	MN	Cytoplasmic aspartate aminotransferase (GOT1)
DM4L0R7	MT	DTT
DM4L0R7	MA	Inhibitor
DM4L0R7	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM4L0R7	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM4L0R7	DI	DM4L0R7
DM4L0R7	DN	Maleic Acid
DM4L0R7	MI	TTRTKPV
DM4L0R7	MN	Trypanosoma Trypanothione reductase (Trypano TPR)
DM4L0R7	MT	DTT
DM4L0R7	MA	Inhibitor
DM4L0R7	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM4L0R7	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMU3O5H	DI	DMU3O5H
DMU3O5H	DN	malic acid
DMU3O5H	MI	TTAHD89
DMU3O5H	MN	Polycystic kidney disease 2-like 1 (TRPP2)
DMU3O5H	MT	DTT
DMU3O5H	MA	Activator
DMU3O5H	RN	Transient receptor potential family members PKD1L3 and PKD2L1 form a candidate sour taste receptor. Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12569-74.
DMU3O5H	RU	https://pubmed.ncbi.nlm.nih.gov/16891422

DM9ECWN	DI	DM9ECWN
DM9ECWN	DN	Mallotinic acid
DM9ECWN	MI	TTE14XG
DM9ECWN	MN	Squalene monooxygenase (SQLE)
DM9ECWN	MT	DTT
DM9ECWN	MA	Inhibitor
DM9ECWN	RN	Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4.
DM9ECWN	RU	https://pubmed.ncbi.nlm.nih.gov/11520216

DMHX9P8	DI	DMHX9P8
DMHX9P8	DN	Mallotusinic acid
DMHX9P8	MI	TTE14XG
DMHX9P8	MN	Squalene monooxygenase (SQLE)
DMHX9P8	MT	DTT
DMHX9P8	MA	Inhibitor
DMHX9P8	RN	Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4.
DMHX9P8	RU	https://pubmed.ncbi.nlm.nih.gov/11520216

DMAJDU7	DI	DMAJDU7
DMAJDU7	DN	Malonate sodium
DMAJDU7	MI	TTZHA0O
DMAJDU7	MN	Carbonic anhydrase IV (CA-IV)
DMAJDU7	MT	DTT
DMAJDU7	MA	Inhibitor
DMAJDU7	RN	Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with carboxylates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):573-8.
DMAJDU7	RU	https://pubmed.ncbi.nlm.nih.gov/15664815

DMM5QXL	DI	DMM5QXL
DMM5QXL	DN	Malonic acid
DMM5QXL	MI	TTZFUY6
DMM5QXL	MN	Serine Racemase (SRR)
DMM5QXL	MT	DTT
DMM5QXL	MA	Inhibitor
DMM5QXL	RN	Inhibition of human serine racemase, an emerging target for medicinal chemistry. Curr Drug Targets. 2011 Jun;12(7):1037-55.
DMM5QXL	RU	https://pubmed.ncbi.nlm.nih.gov/21291385

DMMY542	DI	DMMY542
DMMY542	DN	Maltosyl-Alpha (1,4)-D-Gluconhydroximo-1,5-Lactam
DMMY542	MI	TTCGSZ4
DMMY542	MN	Pancreatic alpha-amylase (AMY2A)
DMMY542	MT	DTT
DMMY542	MA	Inhibitor
DMMY542	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMMY542	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DM213MD	DI	DM213MD
DM213MD	DN	M-Aminophenylboronic Acid
DM213MD	MI	TTHI19T
DM213MD	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DM213MD	MT	DTT
DM213MD	MA	Inhibitor
DM213MD	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM213MD	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMNUA6S	DI	DMNUA6S
DMNUA6S	DN	Man-b-4MU
DMNUA6S	MI	DE12T80
DMNUA6S	MN	Beta-mannosidase (manB)
DMNUA6S	MT	DME
DMNUA6S	MA	Metabolism
DMNUA6S	RN	Structure and function of Bs164 beta-mannosidase from Bacteroides salyersiae the founding member of glycoside hydrolase family GH164. J Biol Chem. 2020 Mar 27;295(13):4316-4326.
DMNUA6S	RU	https://pubmed.ncbi.nlm.nih.gov/31871050

DMKT129	DI	DMKT129
DMKT129	DN	Manganese
DMKT129	MI	DTVKMHD
DMKT129	MN	Natural resistance-associated macrophage protein 2 (SLC11A2)
DMKT129	MT	DTP
DMKT129	MA	Substrate
DMKT129	RN	Transmembrane topology of the mammalian Slc11a2 iron transporter. Biochemistry. 2009 Sep 8;48(35):8422-34.
DMKT129	RU	http://www.ncbi.nlm.nih.gov/pubmed/19621945

DMWAF5Z	DI	DMWAF5Z
DMWAF5Z	DN	MANGIFERIN
DMWAF5Z	MI	TTFBNVI
DMWAF5Z	MN	Aldose reductase (AKR1B1)
DMWAF5Z	MT	DTT
DMWAF5Z	MA	Inhibitor
DMWAF5Z	RN	Structures of new friedelane-type triterpenes and eudesmane-type sesquiterpene and aldose reductase inhibitors from Salacia chinensis. J Nat Prod. 2003 Sep;66(9):1191-6.
DMWAF5Z	RU	https://pubmed.ncbi.nlm.nih.gov/14510595

DMWAF5Z	DI	DMWAF5Z
DMWAF5Z	DN	MANGIFERIN
DMWAF5Z	MI	TT50QJ3
DMWAF5Z	MN	Influenza Neuraminidase (Influ NA)
DMWAF5Z	MT	DTT
DMWAF5Z	MA	Inhibitor
DMWAF5Z	RN	Characteristic of neuraminidase inhibitory xanthones from Cudrania tricuspidata. Bioorg Med Chem. 2009 Apr 1;17(7):2744-50.
DMWAF5Z	RU	https://pubmed.ncbi.nlm.nih.gov/19285413

DMOWZUB	DI	DMOWZUB
DMOWZUB	DN	MANGOSTANIN
DMOWZUB	MI	TT50QJ3
DMOWZUB	MN	Influenza Neuraminidase (Influ NA)
DMOWZUB	MT	DTT
DMOWZUB	MA	Inhibitor
DMOWZUB	RN	Xanthones with neuraminidase inhibitory activity from the seedcases of Garcinia mangostana. Bioorg Med Chem. 2010 Sep 1;18(17):6258-64.
DMOWZUB	RU	https://pubmed.ncbi.nlm.nih.gov/20696581

DMG3DUE	DI	DMG3DUE
DMG3DUE	DN	MANGOSTANOL
DMG3DUE	MI	TT50QJ3
DMG3DUE	MN	Influenza Neuraminidase (Influ NA)
DMG3DUE	MT	DTT
DMG3DUE	MA	Inhibitor
DMG3DUE	RN	Xanthones with neuraminidase inhibitory activity from the seedcases of Garcinia mangostana. Bioorg Med Chem. 2010 Sep 1;18(17):6258-64.
DMG3DUE	RU	https://pubmed.ncbi.nlm.nih.gov/20696581

DMNRZ3S	DI	DMNRZ3S
DMNRZ3S	DN	MANGOSTENONE F
DMNRZ3S	MI	TT50QJ3
DMNRZ3S	MN	Influenza Neuraminidase (Influ NA)
DMNRZ3S	MT	DTT
DMNRZ3S	MA	Inhibitor
DMNRZ3S	RN	Xanthones with neuraminidase inhibitory activity from the seedcases of Garcinia mangostana. Bioorg Med Chem. 2010 Sep 1;18(17):6258-64.
DMNRZ3S	RU	https://pubmed.ncbi.nlm.nih.gov/20696581

DM4I2NR	DI	DM4I2NR
DM4I2NR	DN	MANGOSTENONE G
DM4I2NR	MI	TT50QJ3
DM4I2NR	MN	Influenza Neuraminidase (Influ NA)
DM4I2NR	MT	DTT
DM4I2NR	MA	Inhibitor
DM4I2NR	RN	Xanthones with neuraminidase inhibitory activity from the seedcases of Garcinia mangostana. Bioorg Med Chem. 2010 Sep 1;18(17):6258-64.
DM4I2NR	RU	https://pubmed.ncbi.nlm.nih.gov/20696581

DMYQGDV	DI	DMYQGDV
DMYQGDV	DN	MANGOSTIN
DMYQGDV	MI	TT12ABZ
DMYQGDV	MN	Arachidonate 12-lipoxygenase (12-LOX)
DMYQGDV	MT	DTT
DMYQGDV	MA	Inhibitor
DMYQGDV	RN	Discovery of platelet-type 12-human lipoxygenase selective inhibitors by high-throughput screening of structurally diverse libraries. Bioorg Med Chem. 2007 Nov 15;15(22):6900-8.
DMYQGDV	RU	https://pubmed.ncbi.nlm.nih.gov/17826100

DMYQGDV	DI	DMYQGDV
DMYQGDV	DN	MANGOSTIN
DMYQGDV	MI	TTN9T81
DMYQGDV	MN	Arachidonate 15-lipoxygenase (15-LOX)
DMYQGDV	MT	DTT
DMYQGDV	MA	Inhibitor
DMYQGDV	RN	Discovery of platelet-type 12-human lipoxygenase selective inhibitors by high-throughput screening of structurally diverse libraries. Bioorg Med Chem. 2007 Nov 15;15(22):6900-8.
DMYQGDV	RU	https://pubmed.ncbi.nlm.nih.gov/17826100

DMYQGDV	DI	DMYQGDV
DMYQGDV	DN	MANGOSTIN
DMYQGDV	MI	TT50QJ3
DMYQGDV	MN	Influenza Neuraminidase (Influ NA)
DMYQGDV	MT	DTT
DMYQGDV	MA	Inhibitor
DMYQGDV	RN	Xanthones with neuraminidase inhibitory activity from the seedcases of Garcinia mangostana. Bioorg Med Chem. 2010 Sep 1;18(17):6258-64.
DMYQGDV	RU	https://pubmed.ncbi.nlm.nih.gov/20696581

DMSO8EU	DI	DMSO8EU
DMSO8EU	DN	Mannotetraose
DMSO8EU	MI	DE12T80
DMSO8EU	MN	Beta-mannosidase (manB)
DMSO8EU	MT	DME
DMSO8EU	MA	Metabolism
DMSO8EU	RN	Structure and function of Bs164 beta-mannosidase from Bacteroides salyersiae the founding member of glycoside hydrolase family GH164. J Biol Chem. 2020 Mar 27;295(13):4316-4326.
DMSO8EU	RU	https://pubmed.ncbi.nlm.nih.gov/31871050

DMB3GNC	DI	DMB3GNC
DMB3GNC	DN	MANZAMINE A
DMB3GNC	MI	TTL4Q97
DMB3GNC	MN	Cyclin-dependent kinase 5 (CDK5)
DMB3GNC	MT	DTT
DMB3GNC	MA	Inhibitor
DMB3GNC	RN	Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for ... J Nat Prod. 2007 Sep;70(9):1397-405.
DMB3GNC	RU	https://pubmed.ncbi.nlm.nih.gov/17708655

DMB3GNC	DI	DMB3GNC
DMB3GNC	DN	MANZAMINE A
DMB3GNC	MI	TTRSMW9
DMB3GNC	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMB3GNC	MT	DTT
DMB3GNC	MA	Inhibitor
DMB3GNC	RN	2-N-Methyl modifications and SAR studies of manzamine A. Bioorg Med Chem. 2008 Jul 15;16(14):6702-6.
DMB3GNC	RU	https://pubmed.ncbi.nlm.nih.gov/18595720

DMOI9RT	DI	DMOI9RT
DMOI9RT	DN	Manzamine E
DMOI9RT	MI	TTRSMW9
DMOI9RT	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMOI9RT	MT	DTT
DMOI9RT	MA	Inhibitor
DMOI9RT	RN	Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical p... J Nat Prod. 2006 Jul;69(7):1034-40.
DMOI9RT	RU	https://pubmed.ncbi.nlm.nih.gov/16872140

DMC7ADZ	DI	DMC7ADZ
DMC7ADZ	DN	Manzamine Y
DMC7ADZ	MI	TTRSMW9
DMC7ADZ	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMC7ADZ	MT	DTT
DMC7ADZ	MA	Inhibitor
DMC7ADZ	RN	Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical p... J Nat Prod. 2006 Jul;69(7):1034-40.
DMC7ADZ	RU	https://pubmed.ncbi.nlm.nih.gov/16872140

DMUCE93	DI	DMUCE93
DMUCE93	DN	MAP4
DMUCE93	MI	TTICZ1O
DMUCE93	MN	Metabotropic glutamate receptor 4 (mGluR4)
DMUCE93	MT	DTT
DMUCE93	MA	Antagonist
DMUCE93	RN	Ligand binding to the amino-terminal domain of the mGluR4 subtype of metabotropic glutamate receptor. J Biol Chem. 1999 Apr 9;274(15):10008-13.
DMUCE93	RU	https://pubmed.ncbi.nlm.nih.gov/10187777

DMUCE93	DI	DMUCE93
DMUCE93	DN	MAP4
DMUCE93	MI	TTWRP2F
DMUCE93	MN	Metabotropic glutamate receptor 6 (mGluR6)
DMUCE93	MT	DTT
DMUCE93	MA	Antagonist
DMUCE93	RN	The metabotropic glutamate receptors: structure, activation mechanism and pharmacology. Curr Drug Targets CNS Neurol Disord. 2002 Jun;1(3):297-317.
DMUCE93	RU	https://pubmed.ncbi.nlm.nih.gov/12769621

DMUCE93	DI	DMUCE93
DMUCE93	DN	MAP4
DMUCE93	MI	TT0I76D
DMUCE93	MN	Metabotropic glutamate receptor 7 (mGluR7)
DMUCE93	MT	DTT
DMUCE93	MA	Antagonist
DMUCE93	RN	Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 2000 Dec;362(6):546-54.
DMUCE93	RU	https://pubmed.ncbi.nlm.nih.gov/11138847

DMUCE93	DI	DMUCE93
DMUCE93	DN	MAP4
DMUCE93	MI	TT0IFKL
DMUCE93	MN	Metabotropic glutamate receptor 8 (mGluR8)
DMUCE93	MT	DTT
DMUCE93	MA	Antagonist
DMUCE93	RN	Constraints on proper folding of the amino terminal domains of group III metabotropic glutamate receptors. Brain Res Mol Brain Res. 2000 Mar 10;76(1):180-90.
DMUCE93	RU	https://pubmed.ncbi.nlm.nih.gov/10719229

DMKT21X	DI	DMKT21X
DMKT21X	DN	MAR-531
DMKT21X	MI	TT9O6WS
DMKT21X	MN	Glucagon receptor (GCGR)
DMKT21X	MT	DTT
DMKT21X	MA	Modulator
DMKT21X	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 251).
DMKT21X	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=251

DMGF7XC	DI	DMGF7XC
DMGF7XC	DN	MAR--99
DMGF7XC	MI	TTTWGIX
DMGF7XC	MN	Leukotriene receptor (LTR)
DMGF7XC	MT	DTT
DMGF7XC	MA	Modulator
DMGF7XC	RN	Effect of 1,6-dihydro-2[2-(2-methylpropoxy)anilino]-6-oxo-5-pyrimidineca rboxyli c acid on ethanol-induced microvascular injury in rats. Arzneimittelforschung. 1996 Aug;46(8):779-83.
DMGF7XC	RU	https://pubmed.ncbi.nlm.nih.gov/9125278

DMN9UX3	DI	DMN9UX3
DMN9UX3	DN	MASLINIC ACID
DMN9UX3	MI	TTELIN2
DMN9UX3	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMN9UX3	MT	DTT
DMN9UX3	MA	Inhibitor
DMN9UX3	RN	Synthesis and biological evaluation of heterocyclic ring-substituted maslinic acid derivatives as novel inhibitors of protein tyrosine phosphatase 1B. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6618-22.
DMN9UX3	RU	https://pubmed.ncbi.nlm.nih.gov/19846303

DMDZIHT	DI	DMDZIHT
DMDZIHT	DN	mast cell degranulating peptide
DMDZIHT	MI	TTS3DIK
DMDZIHT	MN	Voltage-gated potassium channel Kv1.1 (KCNA1)
DMDZIHT	MT	DTT
DMDZIHT	MA	Blocker (channel blocker)
DMDZIHT	RN	Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol. 1994 Jun;45(6):1227-34.
DMDZIHT	RU	https://pubmed.ncbi.nlm.nih.gov/7517498

DMDZIHT	DI	DMDZIHT
DMDZIHT	DN	mast cell degranulating peptide
DMDZIHT	MI	TTVFB0O
DMDZIHT	MN	Voltage-gated potassium channel Kv1.2 (KCNA2)
DMDZIHT	MT	DTT
DMDZIHT	MA	Blocker (channel blocker)
DMDZIHT	RN	Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol. 1994 Jun;45(6):1227-34.
DMDZIHT	RU	https://pubmed.ncbi.nlm.nih.gov/7517498

DMDZIHT	DI	DMDZIHT
DMDZIHT	DN	mast cell degranulating peptide
DMDZIHT	MI	TTJ2W69
DMDZIHT	MN	Voltage-gated potassium channel Kv1.6 (KCNA6)
DMDZIHT	MT	DTT
DMDZIHT	MA	Blocker (channel blocker)
DMDZIHT	RN	Cloning and expression of a human voltage-gated potassium channel. A novel member of the RCK potassium channel family. EMBO J. 1990 Jun;9(6):1749-56.
DMDZIHT	RU	https://pubmed.ncbi.nlm.nih.gov/2347305

DM9KLQC	DI	DM9KLQC
DM9KLQC	DN	MB-03966
DM9KLQC	MI	TTL732K
DM9KLQC	MN	Adenosine kinase (ADK)
DM9KLQC	MT	DTT
DM9KLQC	MA	Inhibitor
DM9KLQC	RN	Engineered Adenosine-Releasing Cells for Epilepsy Therapy: Human Mesenchymal Stem Cells and Human Embryonic Stem Cells. Neurotherapeutics. 2009 April; 6(2): 278-283.
DM9KLQC	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2682344/

DMNRMKA	DI	DMNRMKA
DMNRMKA	DN	MB-3
DMNRMKA	MI	TTVK7SB
DMNRMKA	MN	Histone acetyltransferase KAT2B (KAT2B)
DMNRMKA	MT	DTT
DMNRMKA	MA	Inhibitor
DMNRMKA	RN	Design, synthesis, and biological evaluation of a small-molecule inhibitor of the histone acetyltransferase Gcn5. Angew Chem Int Ed Engl. 2004 Jul 26;43(30):3974-6.
DMNRMKA	RU	https://pubmed.ncbi.nlm.nih.gov/15274229

DM89WA1	DI	DM89WA1
DM89WA1	DN	MBX-3254
DM89WA1	MI	TT7QNVC
DM89WA1	MN	Glucose-dependent insulinotropic receptor (GPR119)
DM89WA1	MT	DTT
DM89WA1	MA	Modulator
DM89WA1	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 126).
DM89WA1	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=126

DMPTNUQ	DI	DMPTNUQ
DMPTNUQ	DN	MC-113
DMPTNUQ	MI	TT5TPI6
DMPTNUQ	MN	Opioid receptor sigma 1 (OPRS1)
DMPTNUQ	MT	DTT
DMPTNUQ	MA	Agonist
DMPTNUQ	RN	Antitussives and substance abuse. Subst Abuse Rehabil. 2013 Nov 6;4:75-82.
DMPTNUQ	RU	https://pubmed.ncbi.nlm.nih.gov/24648790

DMQC9UB	DI	DMQC9UB
DMQC9UB	DN	MC-116
DMQC9UB	MI	TT5TPI6
DMQC9UB	MN	Opioid receptor sigma 1 (OPRS1)
DMQC9UB	MT	DTT
DMQC9UB	MA	Agonist
DMQC9UB	RN	Antitussives and substance abuse. Subst Abuse Rehabil. 2013 Nov 6;4:75-82.
DMQC9UB	RU	https://pubmed.ncbi.nlm.nih.gov/24648790

DM5RVO0	DI	DM5RVO0
DM5RVO0	DN	MC-1301
DM5RVO0	MI	TTK59TV
DM5RVO0	MN	Vitamin D3 receptor (VDR)
DM5RVO0	MT	DTT
DM5RVO0	MA	Modulator
DM5RVO0	RN	Effects of 1,25-dihydroxyvitamin D3 and its 20-epi analogues (MC 1288, MC 1301, KH 1060), on clonal keratinocyte growth: evidence for differentiati... Br J Pharmacol. 1997 Mar;120(6):1119-27.
DM5RVO0	RU	https://www.ncbi.nlm.nih.gov/pubmed/9134225

DM6J2UZ	DI	DM6J2UZ
DM6J2UZ	DN	MCC950
DM6J2UZ	MI	TT4EN8X
DM6J2UZ	MN	Caterpiller protein 1.1 (NLRP3)
DM6J2UZ	MT	DTT
DM6J2UZ	MA	Inhibitor
DM6J2UZ	RN	A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015 Mar;21(3):248-55.
DM6J2UZ	RU	https://pubmed.ncbi.nlm.nih.gov/25686105

DMAHN4L	DI	DMAHN4L
DMAHN4L	DN	MC-CAM
DMAHN4L	MI	TT27RFC
DMAHN4L	MN	Opioid receptor delta (OPRD1)
DMAHN4L	MT	DTT
DMAHN4L	MA	Inhibitor
DMAHN4L	RN	14beta-Arylpropiolylamino-17-cyclopropylmethyl-7,8-dihydronormorphinones and related opioids. Further examples of pseudoirreversible mu opioid rece... J Med Chem. 2009 Nov 12;52(21):6926-30.
DMAHN4L	RU	https://pubmed.ncbi.nlm.nih.gov/19842669

DMAHN4L	DI	DMAHN4L
DMAHN4L	DN	MC-CAM
DMAHN4L	MI	TTQW87Y
DMAHN4L	MN	Opioid receptor kappa (OPRK1)
DMAHN4L	MT	DTT
DMAHN4L	MA	Inhibitor
DMAHN4L	RN	14beta-Arylpropiolylamino-17-cyclopropylmethyl-7,8-dihydronormorphinones and related opioids. Further examples of pseudoirreversible mu opioid rece... J Med Chem. 2009 Nov 12;52(21):6926-30.
DMAHN4L	RU	https://pubmed.ncbi.nlm.nih.gov/19842669

DMAHN4L	DI	DMAHN4L
DMAHN4L	DN	MC-CAM
DMAHN4L	MI	TTKWM86
DMAHN4L	MN	Opioid receptor mu (MOP)
DMAHN4L	MT	DTT
DMAHN4L	MA	Inhibitor
DMAHN4L	RN	14beta-Arylpropiolylamino-17-cyclopropylmethyl-7,8-dihydronormorphinones and related opioids. Further examples of pseudoirreversible mu opioid rece... J Med Chem. 2009 Nov 12;52(21):6926-30.
DMAHN4L	RU	https://pubmed.ncbi.nlm.nih.gov/19842669

DMKTX1A	DI	DMKTX1A
DMKTX1A	DN	MCCG
DMKTX1A	MI	TT0I76D
DMKTX1A	MN	Metabotropic glutamate receptor 7 (mGluR7)
DMKTX1A	MT	DTT
DMKTX1A	MA	Antagonist
DMKTX1A	RN	Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 2000 Dec;362(6):546-54.
DMKTX1A	RU	https://pubmed.ncbi.nlm.nih.gov/11138847

DMM1J2D	DI	DMM1J2D
DMM1J2D	DN	m-chlorophenylpiperazine
DMM1J2D	MI	TT6MSOK
DMM1J2D	MN	5-HT 1D receptor (HTR1D)
DMM1J2D	MT	DTT
DMM1J2D	MA	Antagonist
DMM1J2D	RN	Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143-8.
DMM1J2D	RU	https://pubmed.ncbi.nlm.nih.gov/1652050

DMM1J2D	DI	DMM1J2D
DMM1J2D	DN	m-chlorophenylpiperazine
DMM1J2D	MI	TTCPG9S
DMM1J2D	MN	5-HT 1E receptor (HTR1E)
DMM1J2D	MT	DTT
DMM1J2D	MA	Agonist
DMM1J2D	RN	Molecular cloning and pharmacological characterization of the guinea pig 5-HT1E receptor. Eur J Pharmacol. 2004 Jan 26;484(2-3):127-39.
DMM1J2D	RU	https://pubmed.ncbi.nlm.nih.gov/14744596

DMM1J2D	DI	DMM1J2D
DMM1J2D	DN	m-chlorophenylpiperazine
DMM1J2D	MI	TTJQOD7
DMM1J2D	MN	5-HT 2A receptor (HTR2A)
DMM1J2D	MT	DTT
DMM1J2D	MA	Agonist
DMM1J2D	RN	Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, -HT(2B) and 5-HT2C receptors. Naunyn Schmiedebergs Arch Pharmacol. 1999 Jan;359(1):1-6.
DMM1J2D	RU	https://pubmed.ncbi.nlm.nih.gov/9933142

DMM1J2D	DI	DMM1J2D
DMM1J2D	DN	m-chlorophenylpiperazine
DMM1J2D	MI	TT0K1SC
DMM1J2D	MN	5-HT 2B receptor (HTR2B)
DMM1J2D	MT	DTT
DMM1J2D	MA	Agonist
DMM1J2D	RN	Pharmacological characteristics of the newly cloned rat 5-hydroxytryptamine2F receptor. Mol Pharmacol. 1993 Mar;43(3):419-26.
DMM1J2D	RU	https://pubmed.ncbi.nlm.nih.gov/8450835

DMM1J2D	DI	DMM1J2D
DMM1J2D	DN	m-chlorophenylpiperazine
DMM1J2D	MI	TTWJBZ5
DMM1J2D	MN	5-HT 2C receptor (HTR2C)
DMM1J2D	MT	DTT
DMM1J2D	MA	Agonist
DMM1J2D	RN	Pharmacological profile of YM348, a novel, potent and orally active 5-HT2C receptor agonist. Eur J Pharmacol. 2004 Jan 1;483(1):37-43.
DMM1J2D	RU	https://pubmed.ncbi.nlm.nih.gov/14709324

DMM1J2D	DI	DMM1J2D
DMM1J2D	DN	m-chlorophenylpiperazine
DMM1J2D	MI	TTJS8PY
DMM1J2D	MN	5-HT 6 receptor (HTR6)
DMM1J2D	MT	DTT
DMM1J2D	MA	Agonist
DMM1J2D	RN	Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol. 1993 Mar;43(3):320-7.
DMM1J2D	RU	https://pubmed.ncbi.nlm.nih.gov/7680751

DMM1J2D	DI	DMM1J2D
DMM1J2D	DN	m-chlorophenylpiperazine
DMM1J2D	MI	TTO9X1H
DMM1J2D	MN	5-HT 7 receptor (HTR7)
DMM1J2D	MT	DTT
DMM1J2D	MA	Agonist
DMM1J2D	RN	Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype. J Biol Chem. 1993 Aug 25;268(24):18200-4.
DMM1J2D	RU	https://pubmed.ncbi.nlm.nih.gov/8394362

DMZ1YGI	DI	DMZ1YGI
DMZ1YGI	DN	MCI
DMZ1YGI	MI	TT85JO3
DMZ1YGI	MN	5-HT receptor (5HTR)
DMZ1YGI	MT	DTT
DMZ1YGI	MA	Antagonist
DMZ1YGI	RN	Effect of a serotonin receptor antagonist on interleukin-6-induced pulmonary hypertension in rats. Chest. 2001 Feb;119(2):554-61.
DMZ1YGI	RU	https://pubmed.ncbi.nlm.nih.gov/11171737

DMFTPMX	DI	DMFTPMX
DMFTPMX	DN	MCL0129
DMFTPMX	MI	TTD0CIQ
DMFTPMX	MN	Melanocortin receptor 4 (MC4R)
DMFTPMX	MT	DTT
DMFTPMX	MA	Antagonist
DMFTPMX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 285).
DMFTPMX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=285

DMQIGZ7	DI	DMQIGZ7
DMQIGZ7	DN	MCL-117
DMQIGZ7	MI	TT27RFC
DMQIGZ7	MN	Opioid receptor delta (OPRD1)
DMQIGZ7	MT	DTT
DMQIGZ7	MA	Inhibitor
DMQIGZ7	RN	Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opio... J Med Chem. 2006 Jan 12;49(1):256-62.
DMQIGZ7	RU	https://pubmed.ncbi.nlm.nih.gov/16392810

DMQIGZ7	DI	DMQIGZ7
DMQIGZ7	DN	MCL-117
DMQIGZ7	MI	TTQW87Y
DMQIGZ7	MN	Opioid receptor kappa (OPRK1)
DMQIGZ7	MT	DTT
DMQIGZ7	MA	Inhibitor
DMQIGZ7	RN	Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opio... J Med Chem. 2006 Jan 12;49(1):256-62.
DMQIGZ7	RU	https://pubmed.ncbi.nlm.nih.gov/16392810

DMQIGZ7	DI	DMQIGZ7
DMQIGZ7	DN	MCL-117
DMQIGZ7	MI	TTKWM86
DMQIGZ7	MN	Opioid receptor mu (MOP)
DMQIGZ7	MT	DTT
DMQIGZ7	MA	Inhibitor
DMQIGZ7	RN	Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opio... J Med Chem. 2006 Jan 12;49(1):256-62.
DMQIGZ7	RU	https://pubmed.ncbi.nlm.nih.gov/16392810

DMQZC0U	DI	DMQZC0U
DMQZC0U	DN	MCL-129
DMQZC0U	MI	TTD0CIQ
DMQZC0U	MN	Melanocortin receptor 4 (MC4R)
DMQZC0U	MT	DTT
DMQZC0U	MA	Inhibitor
DMQZC0U	RN	Structure-activity relationships of novel piperazines as antagonists for the melanocortin-4 receptor. Bioorg Med Chem. 2007 Mar 1;15(5):1989-2005.
DMQZC0U	RU	https://pubmed.ncbi.nlm.nih.gov/17234422

DMQ1BDZ	DI	DMQ1BDZ
DMQ1BDZ	DN	MCL-139
DMQ1BDZ	MI	TT27RFC
DMQ1BDZ	MN	Opioid receptor delta (OPRD1)
DMQ1BDZ	MT	DTT
DMQ1BDZ	MA	Inhibitor
DMQ1BDZ	RN	Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opio... J Med Chem. 2006 Jan 12;49(1):256-62.
DMQ1BDZ	RU	https://pubmed.ncbi.nlm.nih.gov/16392810

DMQ1BDZ	DI	DMQ1BDZ
DMQ1BDZ	DN	MCL-139
DMQ1BDZ	MI	TTQW87Y
DMQ1BDZ	MN	Opioid receptor kappa (OPRK1)
DMQ1BDZ	MT	DTT
DMQ1BDZ	MA	Inhibitor
DMQ1BDZ	RN	Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opio... J Med Chem. 2006 Jan 12;49(1):256-62.
DMQ1BDZ	RU	https://pubmed.ncbi.nlm.nih.gov/16392810

DMQ1BDZ	DI	DMQ1BDZ
DMQ1BDZ	DN	MCL-139
DMQ1BDZ	MI	TTKWM86
DMQ1BDZ	MN	Opioid receptor mu (MOP)
DMQ1BDZ	MT	DTT
DMQ1BDZ	MA	Inhibitor
DMQ1BDZ	RN	Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opio... J Med Chem. 2006 Jan 12;49(1):256-62.
DMQ1BDZ	RU	https://pubmed.ncbi.nlm.nih.gov/16392810

DMW7ZF8	DI	DMW7ZF8
DMW7ZF8	DN	MCL-144
DMW7ZF8	MI	TT27RFC
DMW7ZF8	MN	Opioid receptor delta (OPRD1)
DMW7ZF8	MT	DTT
DMW7ZF8	MA	Inhibitor
DMW7ZF8	RN	Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands. J Med Chem. 2009 Dec 10;52(23):7389-96.
DMW7ZF8	RU	https://pubmed.ncbi.nlm.nih.gov/19634902

DMW7ZF8	DI	DMW7ZF8
DMW7ZF8	DN	MCL-144
DMW7ZF8	MI	TTQW87Y
DMW7ZF8	MN	Opioid receptor kappa (OPRK1)
DMW7ZF8	MT	DTT
DMW7ZF8	MA	Inhibitor
DMW7ZF8	RN	Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands. J Med Chem. 2009 Dec 10;52(23):7389-96.
DMW7ZF8	RU	https://pubmed.ncbi.nlm.nih.gov/19634902

DMW7ZF8	DI	DMW7ZF8
DMW7ZF8	DN	MCL-144
DMW7ZF8	MI	TTKWM86
DMW7ZF8	MN	Opioid receptor mu (MOP)
DMW7ZF8	MT	DTT
DMW7ZF8	MA	Inhibitor
DMW7ZF8	RN	Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands. J Med Chem. 2009 Dec 10;52(23):7389-96.
DMW7ZF8	RU	https://pubmed.ncbi.nlm.nih.gov/19634902

DMJXU67	DI	DMJXU67
DMJXU67	DN	MCL-145
DMJXU67	MI	TT27RFC
DMJXU67	MN	Opioid receptor delta (OPRD1)
DMJXU67	MT	DTT
DMJXU67	MA	Inhibitor
DMJXU67	RN	Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opio... J Med Chem. 2006 Jan 12;49(1):256-62.
DMJXU67	RU	https://pubmed.ncbi.nlm.nih.gov/16392810

DMJXU67	DI	DMJXU67
DMJXU67	DN	MCL-145
DMJXU67	MI	TTQW87Y
DMJXU67	MN	Opioid receptor kappa (OPRK1)
DMJXU67	MT	DTT
DMJXU67	MA	Inhibitor
DMJXU67	RN	Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opio... J Med Chem. 2006 Jan 12;49(1):256-62.
DMJXU67	RU	https://pubmed.ncbi.nlm.nih.gov/16392810

DMJXU67	DI	DMJXU67
DMJXU67	DN	MCL-145
DMJXU67	MI	TTKWM86
DMJXU67	MN	Opioid receptor mu (MOP)
DMJXU67	MT	DTT
DMJXU67	MA	Inhibitor
DMJXU67	RN	Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opio... J Med Chem. 2006 Jan 12;49(1):256-62.
DMJXU67	RU	https://pubmed.ncbi.nlm.nih.gov/16392810

DMH5SMT	DI	DMH5SMT
DMH5SMT	DN	MCL-147
DMH5SMT	MI	TT27RFC
DMH5SMT	MN	Opioid receptor delta (OPRD1)
DMH5SMT	MT	DTT
DMH5SMT	MA	Inhibitor
DMH5SMT	RN	In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12.
DMH5SMT	RU	https://pubmed.ncbi.nlm.nih.gov/17433695

DMH5SMT	DI	DMH5SMT
DMH5SMT	DN	MCL-147
DMH5SMT	MI	TTQW87Y
DMH5SMT	MN	Opioid receptor kappa (OPRK1)
DMH5SMT	MT	DTT
DMH5SMT	MA	Inhibitor
DMH5SMT	RN	In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12.
DMH5SMT	RU	https://pubmed.ncbi.nlm.nih.gov/17433695

DMH5SMT	DI	DMH5SMT
DMH5SMT	DN	MCL-147
DMH5SMT	MI	TTKWM86
DMH5SMT	MN	Opioid receptor mu (MOP)
DMH5SMT	MT	DTT
DMH5SMT	MA	Inhibitor
DMH5SMT	RN	In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12.
DMH5SMT	RU	https://pubmed.ncbi.nlm.nih.gov/17433695

DMTWY94	DI	DMTWY94
DMTWY94	DN	MCL-149
DMTWY94	MI	TT27RFC
DMTWY94	MN	Opioid receptor delta (OPRD1)
DMTWY94	MT	DTT
DMTWY94	MA	Inhibitor
DMTWY94	RN	In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12.
DMTWY94	RU	https://pubmed.ncbi.nlm.nih.gov/17433695

DMTWY94	DI	DMTWY94
DMTWY94	DN	MCL-149
DMTWY94	MI	TTQW87Y
DMTWY94	MN	Opioid receptor kappa (OPRK1)
DMTWY94	MT	DTT
DMTWY94	MA	Inhibitor
DMTWY94	RN	In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12.
DMTWY94	RU	https://pubmed.ncbi.nlm.nih.gov/17433695

DMTWY94	DI	DMTWY94
DMTWY94	DN	MCL-149
DMTWY94	MI	TTKWM86
DMTWY94	MN	Opioid receptor mu (MOP)
DMTWY94	MT	DTT
DMTWY94	MA	Inhibitor
DMTWY94	RN	In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12.
DMTWY94	RU	https://pubmed.ncbi.nlm.nih.gov/17433695

DMCPW5F	DI	DMCPW5F
DMCPW5F	DN	MCL-153
DMCPW5F	MI	TT27RFC
DMCPW5F	MN	Opioid receptor delta (OPRD1)
DMCPW5F	MT	DTT
DMCPW5F	MA	Inhibitor
DMCPW5F	RN	Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1507-9.
DMCPW5F	RU	https://pubmed.ncbi.nlm.nih.gov/20144870

DMCPW5F	DI	DMCPW5F
DMCPW5F	DN	MCL-153
DMCPW5F	MI	TTQW87Y
DMCPW5F	MN	Opioid receptor kappa (OPRK1)
DMCPW5F	MT	DTT
DMCPW5F	MA	Inhibitor
DMCPW5F	RN	Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1507-9.
DMCPW5F	RU	https://pubmed.ncbi.nlm.nih.gov/20144870

DMCPW5F	DI	DMCPW5F
DMCPW5F	DN	MCL-153
DMCPW5F	MI	TTKWM86
DMCPW5F	MN	Opioid receptor mu (MOP)
DMCPW5F	MT	DTT
DMCPW5F	MA	Inhibitor
DMCPW5F	RN	Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1507-9.
DMCPW5F	RU	https://pubmed.ncbi.nlm.nih.gov/20144870

DM3PIHV	DI	DM3PIHV
DM3PIHV	DN	MCL-154
DM3PIHV	MI	TT27RFC
DM3PIHV	MN	Opioid receptor delta (OPRD1)
DM3PIHV	MT	DTT
DM3PIHV	MA	Inhibitor
DM3PIHV	RN	Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1507-9.
DM3PIHV	RU	https://pubmed.ncbi.nlm.nih.gov/20144870

DM3PIHV	DI	DM3PIHV
DM3PIHV	DN	MCL-154
DM3PIHV	MI	TTQW87Y
DM3PIHV	MN	Opioid receptor kappa (OPRK1)
DM3PIHV	MT	DTT
DM3PIHV	MA	Inhibitor
DM3PIHV	RN	Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1507-9.
DM3PIHV	RU	https://pubmed.ncbi.nlm.nih.gov/20144870

DM3PIHV	DI	DM3PIHV
DM3PIHV	DN	MCL-154
DM3PIHV	MI	TTKWM86
DM3PIHV	MN	Opioid receptor mu (MOP)
DM3PIHV	MT	DTT
DM3PIHV	MA	Inhibitor
DM3PIHV	RN	Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1507-9.
DM3PIHV	RU	https://pubmed.ncbi.nlm.nih.gov/20144870

DM39YW1	DI	DM39YW1
DM39YW1	DN	MCL-182
DM39YW1	MI	TT27RFC
DM39YW1	MN	Opioid receptor delta (OPRD1)
DM39YW1	MT	DTT
DM39YW1	MA	Inhibitor
DM39YW1	RN	In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12.
DM39YW1	RU	https://pubmed.ncbi.nlm.nih.gov/17433695

DM39YW1	DI	DM39YW1
DM39YW1	DN	MCL-182
DM39YW1	MI	TTQW87Y
DM39YW1	MN	Opioid receptor kappa (OPRK1)
DM39YW1	MT	DTT
DM39YW1	MA	Inhibitor
DM39YW1	RN	In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12.
DM39YW1	RU	https://pubmed.ncbi.nlm.nih.gov/17433695

DM39YW1	DI	DM39YW1
DM39YW1	DN	MCL-182
DM39YW1	MI	TTKWM86
DM39YW1	MN	Opioid receptor mu (MOP)
DM39YW1	MT	DTT
DM39YW1	MA	Inhibitor
DM39YW1	RN	In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12.
DM39YW1	RU	https://pubmed.ncbi.nlm.nih.gov/17433695

DMVR51Z	DI	DMVR51Z
DMVR51Z	DN	MCL-183
DMVR51Z	MI	TT27RFC
DMVR51Z	MN	Opioid receptor delta (OPRD1)
DMVR51Z	MT	DTT
DMVR51Z	MA	Inhibitor
DMVR51Z	RN	In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12.
DMVR51Z	RU	https://pubmed.ncbi.nlm.nih.gov/17433695

DMVR51Z	DI	DMVR51Z
DMVR51Z	DN	MCL-183
DMVR51Z	MI	TTQW87Y
DMVR51Z	MN	Opioid receptor kappa (OPRK1)
DMVR51Z	MT	DTT
DMVR51Z	MA	Inhibitor
DMVR51Z	RN	In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12.
DMVR51Z	RU	https://pubmed.ncbi.nlm.nih.gov/17433695

DMVR51Z	DI	DMVR51Z
DMVR51Z	DN	MCL-183
DMVR51Z	MI	TTKWM86
DMVR51Z	MN	Opioid receptor mu (MOP)
DMVR51Z	MT	DTT
DMVR51Z	MA	Inhibitor
DMVR51Z	RN	In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12.
DMVR51Z	RU	https://pubmed.ncbi.nlm.nih.gov/17433695

DM78F6A	DI	DM78F6A
DM78F6A	DN	MCL-1-specific antisense oligonucleotide + midostaurin(PKC412)
DM78F6A	MI	TTN6ORK
DM78F6A	MN	Mcl-1 messenger RNA (MCL-1 mRNA)
DM78F6A	MT	DTT
DM78F6A	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DM78F6A	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DM72GLY	DI	DM72GLY
DM72GLY	DN	MCL-1-specific antisense oligonucleotide + nilotinib (AMN107)
DM72GLY	MI	TTN6ORK
DM72GLY	MN	Mcl-1 messenger RNA (MCL-1 mRNA)
DM72GLY	MT	DTT
DM72GLY	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DM72GLY	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DMXBHE4	DI	DMXBHE4
DMXBHE4	DN	MCL-428
DMXBHE4	MI	TT27RFC
DMXBHE4	MN	Opioid receptor delta (OPRD1)
DMXBHE4	MT	DTT
DMXBHE4	MA	Inhibitor
DMXBHE4	RN	High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11.
DMXBHE4	RU	https://pubmed.ncbi.nlm.nih.gov/17276685

DMXBHE4	DI	DMXBHE4
DMXBHE4	DN	MCL-428
DMXBHE4	MI	TTQW87Y
DMXBHE4	MN	Opioid receptor kappa (OPRK1)
DMXBHE4	MT	DTT
DMXBHE4	MA	Inhibitor
DMXBHE4	RN	High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11.
DMXBHE4	RU	https://pubmed.ncbi.nlm.nih.gov/17276685

DMXBHE4	DI	DMXBHE4
DMXBHE4	DN	MCL-428
DMXBHE4	MI	TTKWM86
DMXBHE4	MN	Opioid receptor mu (MOP)
DMXBHE4	MT	DTT
DMXBHE4	MA	Inhibitor
DMXBHE4	RN	High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11.
DMXBHE4	RU	https://pubmed.ncbi.nlm.nih.gov/17276685

DM1XH04	DI	DM1XH04
DM1XH04	DN	MCL-429
DM1XH04	MI	TT27RFC
DM1XH04	MN	Opioid receptor delta (OPRD1)
DM1XH04	MT	DTT
DM1XH04	MA	Inhibitor
DM1XH04	RN	High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11.
DM1XH04	RU	https://pubmed.ncbi.nlm.nih.gov/17276685

DM1XH04	DI	DM1XH04
DM1XH04	DN	MCL-429
DM1XH04	MI	TTQW87Y
DM1XH04	MN	Opioid receptor kappa (OPRK1)
DM1XH04	MT	DTT
DM1XH04	MA	Inhibitor
DM1XH04	RN	High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11.
DM1XH04	RU	https://pubmed.ncbi.nlm.nih.gov/17276685

DM1XH04	DI	DM1XH04
DM1XH04	DN	MCL-429
DM1XH04	MI	TTKWM86
DM1XH04	MN	Opioid receptor mu (MOP)
DM1XH04	MT	DTT
DM1XH04	MA	Inhibitor
DM1XH04	RN	High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11.
DM1XH04	RU	https://pubmed.ncbi.nlm.nih.gov/17276685

DMISHCW	DI	DMISHCW
DMISHCW	DN	MCL-431
DMISHCW	MI	TT27RFC
DMISHCW	MN	Opioid receptor delta (OPRD1)
DMISHCW	MT	DTT
DMISHCW	MA	Inhibitor
DMISHCW	RN	High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11.
DMISHCW	RU	https://pubmed.ncbi.nlm.nih.gov/17276685

DMISHCW	DI	DMISHCW
DMISHCW	DN	MCL-431
DMISHCW	MI	TTQW87Y
DMISHCW	MN	Opioid receptor kappa (OPRK1)
DMISHCW	MT	DTT
DMISHCW	MA	Inhibitor
DMISHCW	RN	High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11.
DMISHCW	RU	https://pubmed.ncbi.nlm.nih.gov/17276685

DMISHCW	DI	DMISHCW
DMISHCW	DN	MCL-431
DMISHCW	MI	TTKWM86
DMISHCW	MN	Opioid receptor mu (MOP)
DMISHCW	MT	DTT
DMISHCW	MA	Inhibitor
DMISHCW	RN	High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11.
DMISHCW	RU	https://pubmed.ncbi.nlm.nih.gov/17276685

DMPOFAR	DI	DMPOFAR
DMPOFAR	DN	MCL-432
DMPOFAR	MI	TT27RFC
DMPOFAR	MN	Opioid receptor delta (OPRD1)
DMPOFAR	MT	DTT
DMPOFAR	MA	Inhibitor
DMPOFAR	RN	High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11.
DMPOFAR	RU	https://pubmed.ncbi.nlm.nih.gov/17276685

DMPOFAR	DI	DMPOFAR
DMPOFAR	DN	MCL-432
DMPOFAR	MI	TTQW87Y
DMPOFAR	MN	Opioid receptor kappa (OPRK1)
DMPOFAR	MT	DTT
DMPOFAR	MA	Inhibitor
DMPOFAR	RN	High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11.
DMPOFAR	RU	https://pubmed.ncbi.nlm.nih.gov/17276685

DMPOFAR	DI	DMPOFAR
DMPOFAR	DN	MCL-432
DMPOFAR	MI	TTKWM86
DMPOFAR	MN	Opioid receptor mu (MOP)
DMPOFAR	MT	DTT
DMPOFAR	MA	Inhibitor
DMPOFAR	RN	High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11.
DMPOFAR	RU	https://pubmed.ncbi.nlm.nih.gov/17276685

DMD3OAQ	DI	DMD3OAQ
DMD3OAQ	DN	MCL-433
DMD3OAQ	MI	TT27RFC
DMD3OAQ	MN	Opioid receptor delta (OPRD1)
DMD3OAQ	MT	DTT
DMD3OAQ	MA	Inhibitor
DMD3OAQ	RN	High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11.
DMD3OAQ	RU	https://pubmed.ncbi.nlm.nih.gov/17276685

DMD3OAQ	DI	DMD3OAQ
DMD3OAQ	DN	MCL-433
DMD3OAQ	MI	TTQW87Y
DMD3OAQ	MN	Opioid receptor kappa (OPRK1)
DMD3OAQ	MT	DTT
DMD3OAQ	MA	Inhibitor
DMD3OAQ	RN	High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11.
DMD3OAQ	RU	https://pubmed.ncbi.nlm.nih.gov/17276685

DMD3OAQ	DI	DMD3OAQ
DMD3OAQ	DN	MCL-433
DMD3OAQ	MI	TTKWM86
DMD3OAQ	MN	Opioid receptor mu (MOP)
DMD3OAQ	MT	DTT
DMD3OAQ	MA	Inhibitor
DMD3OAQ	RN	High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11.
DMD3OAQ	RU	https://pubmed.ncbi.nlm.nih.gov/17276685

DMR31VO	DI	DMR31VO
DMR31VO	DN	MCL-434
DMR31VO	MI	TT27RFC
DMR31VO	MN	Opioid receptor delta (OPRD1)
DMR31VO	MT	DTT
DMR31VO	MA	Inhibitor
DMR31VO	RN	High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11.
DMR31VO	RU	https://pubmed.ncbi.nlm.nih.gov/17276685

DMR31VO	DI	DMR31VO
DMR31VO	DN	MCL-434
DMR31VO	MI	TTQW87Y
DMR31VO	MN	Opioid receptor kappa (OPRK1)
DMR31VO	MT	DTT
DMR31VO	MA	Inhibitor
DMR31VO	RN	High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11.
DMR31VO	RU	https://pubmed.ncbi.nlm.nih.gov/17276685

DMR31VO	DI	DMR31VO
DMR31VO	DN	MCL-434
DMR31VO	MI	TTKWM86
DMR31VO	MN	Opioid receptor mu (MOP)
DMR31VO	MT	DTT
DMR31VO	MA	Inhibitor
DMR31VO	RN	High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11.
DMR31VO	RU	https://pubmed.ncbi.nlm.nih.gov/17276685

DMLSYD9	DI	DMLSYD9
DMLSYD9	DN	MCL-435
DMLSYD9	MI	TT27RFC
DMLSYD9	MN	Opioid receptor delta (OPRD1)
DMLSYD9	MT	DTT
DMLSYD9	MA	Inhibitor
DMLSYD9	RN	High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11.
DMLSYD9	RU	https://pubmed.ncbi.nlm.nih.gov/17276685

DMLSYD9	DI	DMLSYD9
DMLSYD9	DN	MCL-435
DMLSYD9	MI	TTQW87Y
DMLSYD9	MN	Opioid receptor kappa (OPRK1)
DMLSYD9	MT	DTT
DMLSYD9	MA	Inhibitor
DMLSYD9	RN	High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11.
DMLSYD9	RU	https://pubmed.ncbi.nlm.nih.gov/17276685

DMLSYD9	DI	DMLSYD9
DMLSYD9	DN	MCL-435
DMLSYD9	MI	TTKWM86
DMLSYD9	MN	Opioid receptor mu (MOP)
DMLSYD9	MT	DTT
DMLSYD9	MA	Inhibitor
DMLSYD9	RN	High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11.
DMLSYD9	RU	https://pubmed.ncbi.nlm.nih.gov/17276685

DM8LTQ4	DI	DM8LTQ4
DM8LTQ4	DN	MCL-443
DM8LTQ4	MI	TT27RFC
DM8LTQ4	MN	Opioid receptor delta (OPRD1)
DM8LTQ4	MT	DTT
DM8LTQ4	MA	Inhibitor
DM8LTQ4	RN	High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11.
DM8LTQ4	RU	https://pubmed.ncbi.nlm.nih.gov/17276685

DM8LTQ4	DI	DM8LTQ4
DM8LTQ4	DN	MCL-443
DM8LTQ4	MI	TTQW87Y
DM8LTQ4	MN	Opioid receptor kappa (OPRK1)
DM8LTQ4	MT	DTT
DM8LTQ4	MA	Inhibitor
DM8LTQ4	RN	High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11.
DM8LTQ4	RU	https://pubmed.ncbi.nlm.nih.gov/17276685

DM8LTQ4	DI	DM8LTQ4
DM8LTQ4	DN	MCL-443
DM8LTQ4	MI	TTKWM86
DM8LTQ4	MN	Opioid receptor mu (MOP)
DM8LTQ4	MT	DTT
DM8LTQ4	MA	Inhibitor
DM8LTQ4	RN	High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11.
DM8LTQ4	RU	https://pubmed.ncbi.nlm.nih.gov/17276685

DM8HALS	DI	DM8HALS
DM8HALS	DN	MCL-444
DM8HALS	MI	TT27RFC
DM8HALS	MN	Opioid receptor delta (OPRD1)
DM8HALS	MT	DTT
DM8HALS	MA	Inhibitor
DM8HALS	RN	High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11.
DM8HALS	RU	https://pubmed.ncbi.nlm.nih.gov/17276685

DM8HALS	DI	DM8HALS
DM8HALS	DN	MCL-444
DM8HALS	MI	TTQW87Y
DM8HALS	MN	Opioid receptor kappa (OPRK1)
DM8HALS	MT	DTT
DM8HALS	MA	Inhibitor
DM8HALS	RN	High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11.
DM8HALS	RU	https://pubmed.ncbi.nlm.nih.gov/17276685

DM8HALS	DI	DM8HALS
DM8HALS	DN	MCL-444
DM8HALS	MI	TTKWM86
DM8HALS	MN	Opioid receptor mu (MOP)
DM8HALS	MT	DTT
DM8HALS	MA	Inhibitor
DM8HALS	RN	High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11.
DM8HALS	RU	https://pubmed.ncbi.nlm.nih.gov/17276685

DMR2K4F	DI	DMR2K4F
DMR2K4F	DN	MCL-445
DMR2K4F	MI	TT27RFC
DMR2K4F	MN	Opioid receptor delta (OPRD1)
DMR2K4F	MT	DTT
DMR2K4F	MA	Inhibitor
DMR2K4F	RN	In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12.
DMR2K4F	RU	https://pubmed.ncbi.nlm.nih.gov/17433695

DMR2K4F	DI	DMR2K4F
DMR2K4F	DN	MCL-445
DMR2K4F	MI	TTQW87Y
DMR2K4F	MN	Opioid receptor kappa (OPRK1)
DMR2K4F	MT	DTT
DMR2K4F	MA	Inhibitor
DMR2K4F	RN	In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12.
DMR2K4F	RU	https://pubmed.ncbi.nlm.nih.gov/17433695

DMR2K4F	DI	DMR2K4F
DMR2K4F	DN	MCL-445
DMR2K4F	MI	TTKWM86
DMR2K4F	MN	Opioid receptor mu (MOP)
DMR2K4F	MT	DTT
DMR2K4F	MA	Inhibitor
DMR2K4F	RN	In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12.
DMR2K4F	RU	https://pubmed.ncbi.nlm.nih.gov/17433695

DMXF73G	DI	DMXF73G
DMXF73G	DN	MCL-446
DMXF73G	MI	TT27RFC
DMXF73G	MN	Opioid receptor delta (OPRD1)
DMXF73G	MT	DTT
DMXF73G	MA	Inhibitor
DMXF73G	RN	In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12.
DMXF73G	RU	https://pubmed.ncbi.nlm.nih.gov/17433695

DMXF73G	DI	DMXF73G
DMXF73G	DN	MCL-446
DMXF73G	MI	TTQW87Y
DMXF73G	MN	Opioid receptor kappa (OPRK1)
DMXF73G	MT	DTT
DMXF73G	MA	Inhibitor
DMXF73G	RN	In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12.
DMXF73G	RU	https://pubmed.ncbi.nlm.nih.gov/17433695

DMXF73G	DI	DMXF73G
DMXF73G	DN	MCL-446
DMXF73G	MI	TTKWM86
DMXF73G	MN	Opioid receptor mu (MOP)
DMXF73G	MT	DTT
DMXF73G	MA	Inhibitor
DMXF73G	RN	In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12.
DMXF73G	RU	https://pubmed.ncbi.nlm.nih.gov/17433695

DMSTGNH	DI	DMSTGNH
DMSTGNH	DN	MCL-447
DMSTGNH	MI	TT27RFC
DMSTGNH	MN	Opioid receptor delta (OPRD1)
DMSTGNH	MT	DTT
DMSTGNH	MA	Inhibitor
DMSTGNH	RN	In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12.
DMSTGNH	RU	https://pubmed.ncbi.nlm.nih.gov/17433695

DMSTGNH	DI	DMSTGNH
DMSTGNH	DN	MCL-447
DMSTGNH	MI	TTQW87Y
DMSTGNH	MN	Opioid receptor kappa (OPRK1)
DMSTGNH	MT	DTT
DMSTGNH	MA	Inhibitor
DMSTGNH	RN	In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12.
DMSTGNH	RU	https://pubmed.ncbi.nlm.nih.gov/17433695

DMSTGNH	DI	DMSTGNH
DMSTGNH	DN	MCL-447
DMSTGNH	MI	TTKWM86
DMSTGNH	MN	Opioid receptor mu (MOP)
DMSTGNH	MT	DTT
DMSTGNH	MA	Inhibitor
DMSTGNH	RN	In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12.
DMSTGNH	RU	https://pubmed.ncbi.nlm.nih.gov/17433695

DMSJGA9	DI	DMSJGA9
DMSJGA9	DN	MCL-448
DMSJGA9	MI	TT27RFC
DMSJGA9	MN	Opioid receptor delta (OPRD1)
DMSJGA9	MT	DTT
DMSJGA9	MA	Inhibitor
DMSJGA9	RN	In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12.
DMSJGA9	RU	https://pubmed.ncbi.nlm.nih.gov/17433695

DMSJGA9	DI	DMSJGA9
DMSJGA9	DN	MCL-448
DMSJGA9	MI	TTQW87Y
DMSJGA9	MN	Opioid receptor kappa (OPRK1)
DMSJGA9	MT	DTT
DMSJGA9	MA	Inhibitor
DMSJGA9	RN	In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12.
DMSJGA9	RU	https://pubmed.ncbi.nlm.nih.gov/17433695

DMSJGA9	DI	DMSJGA9
DMSJGA9	DN	MCL-448
DMSJGA9	MI	TTKWM86
DMSJGA9	MN	Opioid receptor mu (MOP)
DMSJGA9	MT	DTT
DMSJGA9	MA	Inhibitor
DMSJGA9	RN	In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12.
DMSJGA9	RU	https://pubmed.ncbi.nlm.nih.gov/17433695

DMQ890N	DI	DMQ890N
DMQ890N	DN	MCL-449
DMQ890N	MI	TT27RFC
DMQ890N	MN	Opioid receptor delta (OPRD1)
DMQ890N	MT	DTT
DMQ890N	MA	Inhibitor
DMQ890N	RN	High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11.
DMQ890N	RU	https://pubmed.ncbi.nlm.nih.gov/17276685

DMQ890N	DI	DMQ890N
DMQ890N	DN	MCL-449
DMQ890N	MI	TTQW87Y
DMQ890N	MN	Opioid receptor kappa (OPRK1)
DMQ890N	MT	DTT
DMQ890N	MA	Inhibitor
DMQ890N	RN	High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11.
DMQ890N	RU	https://pubmed.ncbi.nlm.nih.gov/17276685

DMQ890N	DI	DMQ890N
DMQ890N	DN	MCL-449
DMQ890N	MI	TTKWM86
DMQ890N	MN	Opioid receptor mu (MOP)
DMQ890N	MT	DTT
DMQ890N	MA	Inhibitor
DMQ890N	RN	High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11.
DMQ890N	RU	https://pubmed.ncbi.nlm.nih.gov/17276685

DM7I6U8	DI	DM7I6U8
DM7I6U8	DN	MCL-450
DM7I6U8	MI	TT27RFC
DM7I6U8	MN	Opioid receptor delta (OPRD1)
DM7I6U8	MT	DTT
DM7I6U8	MA	Inhibitor
DM7I6U8	RN	New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores. J Med Chem. 2006 Sep 7;49(18):5640-3.
DM7I6U8	RU	https://pubmed.ncbi.nlm.nih.gov/16942040

DM7I6U8	DI	DM7I6U8
DM7I6U8	DN	MCL-450
DM7I6U8	MI	TTQW87Y
DM7I6U8	MN	Opioid receptor kappa (OPRK1)
DM7I6U8	MT	DTT
DM7I6U8	MA	Inhibitor
DM7I6U8	RN	New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores. J Med Chem. 2006 Sep 7;49(18):5640-3.
DM7I6U8	RU	https://pubmed.ncbi.nlm.nih.gov/16942040

DM7I6U8	DI	DM7I6U8
DM7I6U8	DN	MCL-450
DM7I6U8	MI	TTKWM86
DM7I6U8	MN	Opioid receptor mu (MOP)
DM7I6U8	MT	DTT
DM7I6U8	MA	Inhibitor
DM7I6U8	RN	New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores. J Med Chem. 2006 Sep 7;49(18):5640-3.
DM7I6U8	RU	https://pubmed.ncbi.nlm.nih.gov/16942040

DMP523A	DI	DMP523A
DMP523A	DN	MCL-451
DMP523A	MI	TT27RFC
DMP523A	MN	Opioid receptor delta (OPRD1)
DMP523A	MT	DTT
DMP523A	MA	Inhibitor
DMP523A	RN	New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores. J Med Chem. 2006 Sep 7;49(18):5640-3.
DMP523A	RU	https://pubmed.ncbi.nlm.nih.gov/16942040

DMP523A	DI	DMP523A
DMP523A	DN	MCL-451
DMP523A	MI	TTQW87Y
DMP523A	MN	Opioid receptor kappa (OPRK1)
DMP523A	MT	DTT
DMP523A	MA	Inhibitor
DMP523A	RN	New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores. J Med Chem. 2006 Sep 7;49(18):5640-3.
DMP523A	RU	https://pubmed.ncbi.nlm.nih.gov/16942040

DMP523A	DI	DMP523A
DMP523A	DN	MCL-451
DMP523A	MI	TTKWM86
DMP523A	MN	Opioid receptor mu (MOP)
DMP523A	MT	DTT
DMP523A	MA	Inhibitor
DMP523A	RN	New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores. J Med Chem. 2006 Sep 7;49(18):5640-3.
DMP523A	RU	https://pubmed.ncbi.nlm.nih.gov/16942040

DMORMGU	DI	DMORMGU
DMORMGU	DN	MCL-457
DMORMGU	MI	TTQW87Y
DMORMGU	MN	Opioid receptor kappa (OPRK1)
DMORMGU	MT	DTT
DMORMGU	MA	Inhibitor
DMORMGU	RN	In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12.
DMORMGU	RU	https://pubmed.ncbi.nlm.nih.gov/17433695

DMORMGU	DI	DMORMGU
DMORMGU	DN	MCL-457
DMORMGU	MI	TTKWM86
DMORMGU	MN	Opioid receptor mu (MOP)
DMORMGU	MT	DTT
DMORMGU	MA	Inhibitor
DMORMGU	RN	In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12.
DMORMGU	RU	https://pubmed.ncbi.nlm.nih.gov/17433695

DMZN93Y	DI	DMZN93Y
DMZN93Y	DN	MCL-458
DMZN93Y	MI	TT27RFC
DMZN93Y	MN	Opioid receptor delta (OPRD1)
DMZN93Y	MT	DTT
DMZN93Y	MA	Inhibitor
DMZN93Y	RN	In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12.
DMZN93Y	RU	https://pubmed.ncbi.nlm.nih.gov/17433695

DMZN93Y	DI	DMZN93Y
DMZN93Y	DN	MCL-458
DMZN93Y	MI	TTQW87Y
DMZN93Y	MN	Opioid receptor kappa (OPRK1)
DMZN93Y	MT	DTT
DMZN93Y	MA	Inhibitor
DMZN93Y	RN	In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12.
DMZN93Y	RU	https://pubmed.ncbi.nlm.nih.gov/17433695

DMZN93Y	DI	DMZN93Y
DMZN93Y	DN	MCL-458
DMZN93Y	MI	TTKWM86
DMZN93Y	MN	Opioid receptor mu (MOP)
DMZN93Y	MT	DTT
DMZN93Y	MA	Inhibitor
DMZN93Y	RN	In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12.
DMZN93Y	RU	https://pubmed.ncbi.nlm.nih.gov/17433695

DMTB8D4	DI	DMTB8D4
DMTB8D4	DN	MCL-515
DMTB8D4	MI	TTEX248
DMTB8D4	MN	Dopamine D2 receptor (D2R)
DMTB8D4	MT	DTT
DMTB8D4	MA	Inhibitor
DMTB8D4	RN	Synthesis and neuropharmacological evaluation of esters of R(-)-N-alkyl-11-hydroxy-2-methoxynoraporphines. Bioorg Med Chem Lett. 2009 Jan 1;19(1):51-3.
DMTB8D4	RU	https://pubmed.ncbi.nlm.nih.gov/19058967

DMQA7ZI	DI	DMQA7ZI
DMQA7ZI	DN	MCL-516
DMQA7ZI	MI	TTSQIFT
DMQA7ZI	MN	5-HT 1A receptor (HTR1A)
DMQA7ZI	MT	DTT
DMQA7ZI	MA	Inhibitor
DMQA7ZI	RN	Synthesis and pharmacological investigation of novel 2-aminothiazole-privileged aporphines. Bioorg Med Chem. 2008 Jul 15;16(14):6675-81.
DMQA7ZI	RU	https://pubmed.ncbi.nlm.nih.gov/18562201

DMQA7ZI	DI	DMQA7ZI
DMQA7ZI	DN	MCL-516
DMQA7ZI	MI	TTZFYLI
DMQA7ZI	MN	Dopamine D1 receptor (D1R)
DMQA7ZI	MT	DTT
DMQA7ZI	MA	Inhibitor
DMQA7ZI	RN	Synthesis and neuropharmacological evaluation of esters of R(-)-N-alkyl-11-hydroxy-2-methoxynoraporphines. Bioorg Med Chem Lett. 2009 Jan 1;19(1):51-3.
DMQA7ZI	RU	https://pubmed.ncbi.nlm.nih.gov/19058967

DMQA7ZI	DI	DMQA7ZI
DMQA7ZI	DN	MCL-516
DMQA7ZI	MI	TTEX248
DMQA7ZI	MN	Dopamine D2 receptor (D2R)
DMQA7ZI	MT	DTT
DMQA7ZI	MA	Inhibitor
DMQA7ZI	RN	Synthesis and neuropharmacological evaluation of esters of R(-)-N-alkyl-11-hydroxy-2-methoxynoraporphines. Bioorg Med Chem Lett. 2009 Jan 1;19(1):51-3.
DMQA7ZI	RU	https://pubmed.ncbi.nlm.nih.gov/19058967

DML3AZG	DI	DML3AZG
DML3AZG	DN	McN-A-343
DML3AZG	MI	TTOXS3C
DML3AZG	MN	Muscarinic acetylcholine receptor (CHRM)
DML3AZG	MT	DTT
DML3AZG	MA	Agonist
DML3AZG	RN	Pharmacological characterization of the M1 muscarinic receptors expressed in murine fibroblast B82 cells. J Pharmacol Exp Ther. 1989 Feb;248(2):661-70.
DML3AZG	RU	https://pubmed.ncbi.nlm.nih.gov/2537406

DML3AZG	DI	DML3AZG
DML3AZG	DN	McN-A-343
DML3AZG	MI	TTQ13Z5
DML3AZG	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DML3AZG	MT	DTT
DML3AZG	MA	Agonist
DML3AZG	RN	Human muscarinic receptors expressed in A9L and CHO cells: activation by full and partial agonists. Br J Pharmacol. 1995 Mar;114(6):1241-9.
DML3AZG	RU	https://pubmed.ncbi.nlm.nih.gov/7620715

DM0GLYB	DI	DM0GLYB
DM0GLYB	DN	MCP-203
DM0GLYB	MI	TT27RFC
DM0GLYB	MN	Opioid receptor delta (OPRD1)
DM0GLYB	MT	DTT
DM0GLYB	MA	Agonist
DM0GLYB	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317).
DM0GLYB	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=317

DM0RZDF	DI	DM0RZDF
DM0RZDF	DN	MCP-204
DM0RZDF	MI	TT27RFC
DM0RZDF	MN	Opioid receptor delta (OPRD1)
DM0RZDF	MT	DTT
DM0RZDF	MA	Agonist
DM0RZDF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317).
DM0RZDF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=317

DM3RYUZ	DI	DM3RYUZ
DM3RYUZ	DN	MCP-205
DM3RYUZ	MI	TT27RFC
DM3RYUZ	MN	Opioid receptor delta (OPRD1)
DM3RYUZ	MT	DTT
DM3RYUZ	MA	Agonist
DM3RYUZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317).
DM3RYUZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=317

DMEUWB8	DI	DMEUWB8
DMEUWB8	DN	MDA-19
DMEUWB8	MI	TTMSFAW
DMEUWB8	MN	Cannabinoid receptor 2 (CB2)
DMEUWB8	MT	DTT
DMEUWB8	MA	Agonist
DMEUWB8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 57).
DMEUWB8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=57

DMZJPOB	DI	DMZJPOB
DMZJPOB	DN	MDDR 287569
DMZJPOB	MI	TT07C3Y
DMZJPOB	MN	5-HT 4 receptor (HTR4)
DMZJPOB	MT	DTT
DMZJPOB	MA	Modulator
DMZJPOB	RN	Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF Prostate Cancer Clinical Trials Consortium. Invest New Drugs. 2012 April; 30(2): 749-757.
DMZJPOB	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3175265/

DMLI5VH	DI	DMLI5VH
DMLI5VH	DN	MDL 100,453
DMLI5VH	MI	TTKJEMQ
DMLI5VH	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMLI5VH	MT	DTT
DMLI5VH	MA	Antagonist
DMLI5VH	RN	Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys. J Pharmacol Exp Ther. 1999 Sep;290(3):1034-40.
DMLI5VH	RU	https://pubmed.ncbi.nlm.nih.gov/10454475

DMTVOWC	DI	DMTVOWC
DMTVOWC	DN	MDL-18962
DMTVOWC	MI	TTSZLWK
DMTVOWC	MN	Aromatase (CYP19A1)
DMTVOWC	MT	DTT
DMTVOWC	MA	Inhibitor
DMTVOWC	RN	6 beta-Propynyl-substituted steroids: mechanism-based enzyme-activated irreversible inhibitors of aromatase. J Med Chem. 1997 Sep 26;40(20):3263-70.
DMTVOWC	RU	https://pubmed.ncbi.nlm.nih.gov/9379446

DMUHJ2C	DI	DMUHJ2C
DMUHJ2C	DN	MDL-28163
DMUHJ2C	MI	TTTIBOJ
DMUHJ2C	MN	Histamine H1 receptor (H1R)
DMUHJ2C	MT	DTT
DMUHJ2C	MA	Inhibitor
DMUHJ2C	RN	Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.
DMUHJ2C	RU	https://pubmed.ncbi.nlm.nih.gov/16220969

DMUHJ2C	DI	DMUHJ2C
DMUHJ2C	DN	MDL-28163
DMUHJ2C	MI	TTZPO1L
DMUHJ2C	MN	Substance-P receptor (TACR1)
DMUHJ2C	MT	DTT
DMUHJ2C	MA	Inhibitor
DMUHJ2C	RN	Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.
DMUHJ2C	RU	https://pubmed.ncbi.nlm.nih.gov/16220969

DMF76M8	DI	DMF76M8
DMF76M8	DN	MDL-28618
DMF76M8	MI	TTAWNKZ
DMF76M8	MN	Norepinephrine transporter (NET)
DMF76M8	MT	DTT
DMF76M8	MA	Inhibitor
DMF76M8	RN	Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4495-8.
DMF76M8	RU	https://pubmed.ncbi.nlm.nih.gov/18667309

DMF76M8	DI	DMF76M8
DMF76M8	DN	MDL-28618
DMF76M8	MI	TT3ROYC
DMF76M8	MN	Serotonin transporter (SERT)
DMF76M8	MT	DTT
DMF76M8	MA	Inhibitor
DMF76M8	RN	Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4495-8.
DMF76M8	RU	https://pubmed.ncbi.nlm.nih.gov/18667309

DMF8VX3	DI	DMF8VX3
DMF8VX3	DN	MDL-74156
DMF8VX3	MI	TTQ6VDM
DMF8VX3	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMF8VX3	MT	DTT
DMF8VX3	MA	Inhibitor
DMF8VX3	RN	Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. Bioorg Med Chem Lett. 2003 Aug 18;13(16):2773-5.
DMF8VX3	RU	https://pubmed.ncbi.nlm.nih.gov/12873512

DM8ZK12	DI	DM8ZK12
DM8ZK12	DN	MDP-01
DM8ZK12	MI	TTGKNB4
DM8ZK12	MN	Epidermal growth factor receptor (EGFR)
DM8ZK12	MT	DTT
DM8ZK12	MA	Inhibitor
DM8ZK12	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
DM8ZK12	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797

DMSF4UI	DI	DMSF4UI
DMSF4UI	DN	MDT-006
DMSF4UI	MI	TTOZHQC
DMSF4UI	MN	P2Y purinoceptor 2 (P2RY2)
DMSF4UI	MT	DTT
DMSF4UI	MA	Agonist
DMSF4UI	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 324).
DMSF4UI	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=324

DM9ZTX4	DI	DM9ZTX4
DM9ZTX4	DN	MDX-1147
DM9ZTX4	MI	TT9G4N0
DM9ZTX4	MN	Glutamate carboxypeptidase II (GCPII)
DM9ZTX4	MT	DTT
DM9ZTX4	MA	Modulator
DM9ZTX4	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1606).
DM9ZTX4	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1606

DMMFYP9	DI	DMMFYP9
DMMFYP9	DN	ME bromodomain inhibitor
DMMFYP9	MI	TTDP48B
DMMFYP9	MN	Bromodomain-containing protein 2 (BRD2)
DMMFYP9	MT	DTT
DMMFYP9	MA	Inhibitor
DMMFYP9	RN	Chemical biology. A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes. Science. 2014 Oct 31;346(6209):638-41.
DMMFYP9	RU	https://pubmed.ncbi.nlm.nih.gov/25323695

DMCLT1V	DI	DMCLT1V
DMCLT1V	DN	ME0328
DMCLT1V	MI	TTVDSZ0
DMCLT1V	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMCLT1V	MT	DTT
DMCLT1V	MA	Inhibitor
DMCLT1V	RN	Chemical probes to study ADP-ribosylation: synthesis and biochemical evaluation of inhibitors of the human ADP-ribosyltransferase ARTD3/PARP3. J Med Chem. 2013 Dec 12;56(23):9556-68.
DMCLT1V	RU	https://pubmed.ncbi.nlm.nih.gov/24188023

DMCLT1V	DI	DMCLT1V
DMCLT1V	DN	ME0328
DMCLT1V	MI	TTD8MEH
DMCLT1V	MN	Poly [ADP-ribose] polymerase 3 (PARP3)
DMCLT1V	MT	DTT
DMCLT1V	MA	Inhibitor
DMCLT1V	RN	Chemical probes to study ADP-ribosylation: synthesis and biochemical evaluation of inhibitors of the human ADP-ribosyltransferase ARTD3/PARP3. J Med Chem. 2013 Dec 12;56(23):9556-68.
DMCLT1V	RU	https://pubmed.ncbi.nlm.nih.gov/24188023

DMOZAQ6	DI	DMOZAQ6
DMOZAQ6	DN	ME36
DMOZAQ6	MI	TT953CX
DMOZAQ6	MN	Motilin receptor (MLNR)
DMOZAQ6	MT	DTT
DMOZAQ6	MA	Agonist
DMOZAQ6	RN	Desensitization of the human motilin receptor by motilides. J Pharmacol Exp Ther. 2005 Jun;313(3):1397-405.
DMOZAQ6	RU	https://pubmed.ncbi.nlm.nih.gov/15764739

DMO5E2L	DI	DMO5E2L
DMO5E2L	DN	ME4
DMO5E2L	MI	TT953CX
DMO5E2L	MN	Motilin receptor (MLNR)
DMO5E2L	MT	DTT
DMO5E2L	MA	Agonist
DMO5E2L	RN	Desensitization of the human motilin receptor by motilides. J Pharmacol Exp Ther. 2005 Jun;313(3):1397-405.
DMO5E2L	RU	https://pubmed.ncbi.nlm.nih.gov/15764739

DM3C6X2	DI	DM3C6X2
DM3C6X2	DN	ME67
DM3C6X2	MI	TT953CX
DM3C6X2	MN	Motilin receptor (MLNR)
DM3C6X2	MT	DTT
DM3C6X2	MA	Agonist
DM3C6X2	RN	Desensitization of the human motilin receptor by motilides. J Pharmacol Exp Ther. 2005 Jun;313(3):1397-405.
DM3C6X2	RU	https://pubmed.ncbi.nlm.nih.gov/15764739

DM0P59E	DI	DM0P59E
DM0P59E	DN	MEBUDIPINE
DM0P59E	MI	TTZIFHC
DM0P59E	MN	Voltage-gated calcium channel alpha Cav1.2 (CACNA1C)
DM0P59E	MT	DTT
DM0P59E	MA	Inhibitor
DM0P59E	RN	Antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarboxylates toward voltage-dependent L-type Ca2+ channels Ca V 1.3 and Ca V 1.2. Bioorg Med Chem. 2010 May 1;18(9):3147-58.
DM0P59E	RU	https://pubmed.ncbi.nlm.nih.gov/20382537

DM0P59E	DI	DM0P59E
DM0P59E	DN	MEBUDIPINE
DM0P59E	MI	TT7RGTM
DM0P59E	MN	Voltage-gated calcium channel alpha Cav1.3 (CACNA1D)
DM0P59E	MT	DTT
DM0P59E	MA	Inhibitor
DM0P59E	RN	Antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarboxylates toward voltage-dependent L-type Ca2+ channels Ca V 1.3 and Ca V 1.2. Bioorg Med Chem. 2010 May 1;18(9):3147-58.
DM0P59E	RU	https://pubmed.ncbi.nlm.nih.gov/20382537

DMYQOKX	DI	DMYQOKX
DMYQOKX	DN	MeBut-RYYRIK-NH2
DMYQOKX	MI	TTNT7K8
DMYQOKX	MN	Nociceptin receptor (OPRL1)
DMYQOKX	MT	DTT
DMYQOKX	MA	Inhibitor
DMYQOKX	RN	Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist. Bioorg Med Chem. 2008 Mar 1;16(5):2635-44.
DMYQOKX	RU	https://pubmed.ncbi.nlm.nih.gov/18068993

DMNKSX3	DI	DMNKSX3
DMNKSX3	DN	Medazepam
DMNKSX3	MI	DE4LYSA
DMNKSX3	MN	Cytochrome P450 3A4 (CYP3A4)
DMNKSX3	MT	DME
DMNKSX3	MA	Metabolism
DMNKSX3	RN	Midazolam and other benzodiazepines. Handb Exp Pharmacol. 2008;(182):335-60.
DMNKSX3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18175099

DMNKSX3	DI	DMNKSX3
DMNKSX3	DN	Medazepam
DMNKSX3	MI	DEGTFWK
DMNKSX3	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMNKSX3	MT	DME
DMNKSX3	MA	Metabolism
DMNKSX3	RN	Midazolam and other benzodiazepines. Handb Exp Pharmacol. 2008;(182):335-60.
DMNKSX3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18175099

DMQ5S9C	DI	DMQ5S9C
DMQ5S9C	DN	MEDI-552
DMQ5S9C	MI	TTUE541
DMQ5S9C	MN	Leukocyte surface antigen Leu-16 (CD20)
DMQ5S9C	MT	DTT
DMQ5S9C	MA	Modulator
DMQ5S9C	RN	Anti CD37 antibodies
DMQ5S9C	RU	https://www.google.com/patents/US9078879

DM960DQ	DI	DM960DQ
DM960DQ	DN	MEDI-553
DM960DQ	MI	TTM6QSK
DM960DQ	MN	B-cell receptor CD22 (CD22)
DM960DQ	MT	DTT
DM960DQ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2786).
DM960DQ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2786

DML2GFB	DI	DML2GFB
DML2GFB	DN	medica 16
DML2GFB	MI	TTB8FUC
DML2GFB	MN	Free fatty acid receptor 1 (GPR40)
DML2GFB	MT	DTT
DML2GFB	MA	Agonist
DML2GFB	RN	A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs. Biochem Biophys Res Commun. 2003 Feb 7;301(2):406-10.
DML2GFB	RU	https://pubmed.ncbi.nlm.nih.gov/12565875

DMDJ6RE	DI	DMDJ6RE
DMDJ6RE	DN	MEDIORESINOL
DMDJ6RE	MI	TTXV4FI
DMDJ6RE	MN	Albendazole monooxygenase (CYP3A4)
DMDJ6RE	MT	DTT
DMDJ6RE	MA	Inhibitor
DMDJ6RE	RN	Potent CYP3A4 inhibitory constituents of Piper cubeba. J Nat Prod. 2005 Jan;68(1):64-8.
DMDJ6RE	RU	https://pubmed.ncbi.nlm.nih.gov/15679319

DMNEAJG	DI	DMNEAJG
DMNEAJG	DN	Medrogestone
DMNEAJG	MI	DE4LYSA
DMNEAJG	MN	Cytochrome P450 3A4 (CYP3A4)
DMNEAJG	MT	DME
DMNEAJG	MA	Metabolism
DMNEAJG	RN	Metabolism of medroxyprogesterone acetate (MPA) via CYP enzymes in vitro and effect of MPA on bleeding time in female rats in dependence on CYP activity in vivo. Life Sci. 2003 Nov 7;73(25):3201-12.
DMNEAJG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14561525

DMYJI90	DI	DMYJI90
DMYJI90	DN	MEK inhibitor I
DMYJI90	MI	TTROQ37
DMYJI90	MN	MAPK/ERK kinase kinase (MAP3K)
DMYJI90	MT	DTT
DMYJI90	MA	Inhibitor
DMYJI90	RN	Beyond U0126. Dianion chemistry leading to the rapid synthesis of a series of potent MEK inhibitors. Bioorg Med Chem Lett. 2004 Mar 22;14(6):1483-6.
DMYJI90	RU	https://pubmed.ncbi.nlm.nih.gov/15006386

DM08SVH	DI	DM08SVH
DM08SVH	DN	MEL57A
DM08SVH	MI	TTNB6UQ
DM08SVH	MN	Hyperpolarization cyclic nucleotide-gated channel 1 (HCN1)
DM08SVH	MT	DTT
DM08SVH	MA	Blocker (channel blocker)
DM08SVH	RN	Novel blockers of hyperpolarization-activated current with isoform selectivity in recombinant cells and native tissue. Br J Pharmacol. 2012 May;166(2):602-16.
DM08SVH	RU	https://pubmed.ncbi.nlm.nih.gov/22091830

DMY57L0	DI	DMY57L0
DMY57L0	DN	melanin-concentrating hormone
DMY57L0	MI	TTX4RTB
DMY57L0	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMY57L0	MT	DTT
DMY57L0	MA	Agonist
DMY57L0	RN	[125I]-S36057: a new and highly potent radioligand for the melanin-concentrating hormone receptor. Br J Pharmacol. 2001 Jun;133(3):371-8.
DMY57L0	RU	https://pubmed.ncbi.nlm.nih.gov/11375253

DMY57L0	DI	DMY57L0
DMY57L0	DN	melanin-concentrating hormone
DMY57L0	MI	TTS17MG
DMY57L0	MN	Melanin-concentrating hormone receptor 2 (MCHR2)
DMY57L0	MT	DTT
DMY57L0	MA	Agonist
DMY57L0	RN	Identification and characterization of a second melanin-concentrating hormone receptor, MCH-2R. Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7564-9.
DMY57L0	RU	https://pubmed.ncbi.nlm.nih.gov/11404457

DM2ES7Z	DI	DM2ES7Z
DM2ES7Z	DN	Melanocortin-4 Receptor antagonist
DM2ES7Z	MI	TTD0CIQ
DM2ES7Z	MN	Melanocortin receptor 4 (MC4R)
DM2ES7Z	MT	DTT
DM2ES7Z	MA	Antagonist
DM2ES7Z	RN	Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36.
DM2ES7Z	RU	https://pubmed.ncbi.nlm.nih.gov/16634704

DMTKLH8	DI	DMTKLH8
DMTKLH8	DN	Melibiose
DMTKLH8	MI	DEUOBTJ
DMTKLH8	MN	Alpha-galactosidase (melA)
DMTKLH8	MT	DME
DMTKLH8	MA	Metabolism
DMTKLH8	RN	Use of an alpha-galactosidase gene as a food-grade selection marker for Streptococcus thermophilus. J Dairy Sci. 2005 Jul;88(7):2341-7.
DMTKLH8	RU	https://pubmed.ncbi.nlm.nih.gov/15956297

DMTKLH8	DI	DMTKLH8
DMTKLH8	DN	Melibiose
DMTKLH8	MI	DEKI69B
DMTKLH8	MN	Alpha-galactosidase (melA)
DMTKLH8	MT	DME
DMTKLH8	MA	Metabolism
DMTKLH8	RN	Alpha-glactosidase activity of lactobacilli. Appl Microbiol. 1973 Nov;26(5):783-8.
DMTKLH8	RU	https://pubmed.ncbi.nlm.nih.gov/4796954

DMTKLH8	DI	DMTKLH8
DMTKLH8	DN	Melibiose
DMTKLH8	MI	DEBK21A
DMTKLH8	MN	Alpha-galactosidase (melA)
DMTKLH8	MT	DME
DMTKLH8	MA	Metabolism
DMTKLH8	RN	Alpha-glactosidase activity of lactobacilli. Appl Microbiol. 1973 Nov;26(5):783-8.
DMTKLH8	RU	https://pubmed.ncbi.nlm.nih.gov/4796954

DMTKLH8	DI	DMTKLH8
DMTKLH8	DN	Melibiose
DMTKLH8	MI	DEY2UXF
DMTKLH8	MN	Alpha-galactosidase (melA)
DMTKLH8	MT	DME
DMTKLH8	MA	Metabolism
DMTKLH8	RN	Alpha-glactosidase activity of lactobacilli. Appl Microbiol. 1973 Nov;26(5):783-8.
DMTKLH8	RU	https://pubmed.ncbi.nlm.nih.gov/4796954

DMTKLH8	DI	DMTKLH8
DMTKLH8	DN	Melibiose
DMTKLH8	MI	DE3N1MH
DMTKLH8	MN	Alpha-galactosidase (melA)
DMTKLH8	MT	DME
DMTKLH8	MA	Metabolism
DMTKLH8	RN	Alpha-glactosidase activity of lactobacilli. Appl Microbiol. 1973 Nov;26(5):783-8.
DMTKLH8	RU	https://pubmed.ncbi.nlm.nih.gov/4796954

DMTKLH8	DI	DMTKLH8
DMTKLH8	DN	Melibiose
DMTKLH8	MI	DE5EODL
DMTKLH8	MN	Beta-fructofuranosidase (BFRU)
DMTKLH8	MT	DME
DMTKLH8	MA	Metabolism
DMTKLH8	RN	Alpha-glactosidase activity of lactobacilli. Appl Microbiol. 1973 Nov;26(5):783-8.
DMTKLH8	RU	https://pubmed.ncbi.nlm.nih.gov/4796954

DMTKLH8	DI	DMTKLH8
DMTKLH8	DN	Melibiose
DMTKLH8	MI	DER8TO2
DMTKLH8	MN	Beta-fructofuranosidase (BFRU)
DMTKLH8	MT	DME
DMTKLH8	MA	Metabolism
DMTKLH8	RN	Alpha-glactosidase activity of lactobacilli. Appl Microbiol. 1973 Nov;26(5):783-8.
DMTKLH8	RU	https://pubmed.ncbi.nlm.nih.gov/4796954

DMTKLH8	DI	DMTKLH8
DMTKLH8	DN	Melibiose
DMTKLH8	MI	DEET5ZQ
DMTKLH8	MN	Beta-fructofuranosidase (BFRU)
DMTKLH8	MT	DME
DMTKLH8	MA	Metabolism
DMTKLH8	RN	Alpha-glactosidase activity of lactobacilli. Appl Microbiol. 1973 Nov;26(5):783-8.
DMTKLH8	RU	https://pubmed.ncbi.nlm.nih.gov/4796954

DME54M7	DI	DME54M7
DME54M7	DN	Melogatran
DME54M7	MI	TT6L509
DME54M7	MN	Coagulation factor IIa (F2)
DME54M7	MT	DTT
DME54M7	MA	Inhibitor
DME54M7	RN	Thrombin inhibitors in acute coronary artery disease. Eur Heart J. 2002 Aug;23(15):1142-4.
DME54M7	RU	https://pubmed.ncbi.nlm.nih.gov/12127916

DM3492O	DI	DM3492O
DM3492O	DN	MELOSMINE
DM3492O	MI	TTZFYLI
DM3492O	MN	Dopamine D1 receptor (D1R)
DM3492O	MT	DTT
DM3492O	MA	Inhibitor
DM3492O	RN	Advances in development of dopaminergic aporphinoids. J Med Chem. 2007 Jan 25;50(2):171-81.
DM3492O	RU	https://pubmed.ncbi.nlm.nih.gov/17228858

DM9S30P	DI	DM9S30P
DM9S30P	DN	MEMOQUIN
DM9S30P	MI	TT1RS9F
DM9S30P	MN	Acetylcholinesterase (AChE)
DM9S30P	MT	DTT
DM9S30P	MA	Inhibitor
DM9S30P	RN	Toward a rational design of multitarget-directed antioxidants: merging memoquin and lipoic acid molecular frameworks. J Med Chem. 2009 Dec 10;52(23):7883-6.
DM9S30P	RU	https://pubmed.ncbi.nlm.nih.gov/19813747

DM9S30P	DI	DM9S30P
DM9S30P	DN	MEMOQUIN
DM9S30P	MI	TTEB0GD
DM9S30P	MN	Cholinesterase (BCHE)
DM9S30P	MT	DTT
DM9S30P	MA	Inhibitor
DM9S30P	RN	Toward a rational design of multitarget-directed antioxidants: merging memoquin and lipoic acid molecular frameworks. J Med Chem. 2009 Dec 10;52(23):7883-6.
DM9S30P	RU	https://pubmed.ncbi.nlm.nih.gov/19813747

DMEIRDX	DI	DMEIRDX
DMEIRDX	DN	MEN-14295
DMEIRDX	MI	TTGTQHC
DMEIRDX	MN	DNA topoisomerase I (TOP1)
DMEIRDX	MT	DTT
DMEIRDX	MA	Inhibitor
DMEIRDX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2636).
DMEIRDX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2636

DMU8L7C	DI	DMU8L7C
DMU8L7C	DN	Mepacrine
DMU8L7C	MI	DTI7UX6
DMU8L7C	MN	Breast cancer resistance protein (ABCG2)
DMU8L7C	MT	DTP
DMU8L7C	MA	Substrate
DMU8L7C	RN	Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). Biochem J. 2005 Jan 15;385(Pt 2):419-26.
DMU8L7C	RU	https://doi.org/10.1042/BJ20040791

DMU8L7C	DI	DMU8L7C
DMU8L7C	DN	Mepacrine
DMU8L7C	MI	DE4LYSA
DMU8L7C	MN	Cytochrome P450 3A4 (CYP3A4)
DMU8L7C	MT	DME
DMU8L7C	MA	Metabolism
DMU8L7C	RN	Quinacrine is mainly metabolized to mono-desethyl quinacrine by CYP3A4/5 and its brain accumulation is limited by P-glycoprotein. Drug Metab Dispos. 2006 Jul;34(7):1136-44.
DMU8L7C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16581945

DMU8L7C	DI	DMU8L7C
DMU8L7C	DN	Mepacrine
DMU8L7C	MI	DEIBDNY
DMU8L7C	MN	Cytochrome P450 3A5 (CYP3A5)
DMU8L7C	MT	DME
DMU8L7C	MA	Metabolism
DMU8L7C	RN	Quinacrine is mainly metabolized to mono-desethyl quinacrine by CYP3A4/5 and its brain accumulation is limited by P-glycoprotein. Drug Metab Dispos. 2006 Jul;34(7):1136-44.
DMU8L7C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16581945

DMU8L7C	DI	DMU8L7C
DMU8L7C	DN	Mepacrine
DMU8L7C	MI	TT9V5JH
DMU8L7C	MN	Phospholipase A2 (PLA2G1B)
DMU8L7C	MT	DTT
DMU8L7C	MA	Inhibitor
DMU8L7C	RN	Involvement of protein kinase C activation in L-leucine-induced stimulation of protein synthesis in l6 myotubes. Cytotechnology. 2003 Nov;43(1-3):97-103.
DMU8L7C	RU	https://pubmed.ncbi.nlm.nih.gov/19003213

DMZIA1R	DI	DMZIA1R
DMZIA1R	DN	mercaptoacrylate inhibitor of calpain 1
DMZIA1R	MI	TTG5QB7
DMZIA1R	MN	Calpain-2 (CAPN2)
DMZIA1R	MT	DTT
DMZIA1R	MA	Inhibitor
DMZIA1R	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2336).
DMZIA1R	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2336

DM68FZK	DI	DM68FZK
DM68FZK	DN	Mercaptosuccinate
DM68FZK	MI	DEVNY51
DM68FZK	MN	Mercaptosuccinate dioxygenase (efe)
DM68FZK	MT	DME
DM68FZK	MA	Metabolism
DM68FZK	RN	Mercaptosuccinate dioxygenase, a cysteine dioxygenase homologue, from Variovorax paradoxus strain B4 is the key enzyme of mercaptosuccinate degradation. J Biol Chem. 2014 Oct 31;289(44):30800-9.
DM68FZK	RU	https://pubmed.ncbi.nlm.nih.gov/25228698

DMD25I6	DI	DMD25I6
DMD25I6	DN	MERCK-544
DMD25I6	MI	TTN7BL9
DMD25I6	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMD25I6	MT	DTT
DMD25I6	MA	Inhibitor
DMD25I6	RN	Azabicyclic sulfonamides as potent 11beta-HSD1 inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1551-4.
DMD25I6	RU	https://pubmed.ncbi.nlm.nih.gov/20149650

DMT56ER	DI	DMT56ER
DMT56ER	DN	Mercuribenzoic Acid
DMT56ER	MI	TTANPDJ
DMT56ER	MN	Carbonic anhydrase II (CA-II)
DMT56ER	MT	DTT
DMT56ER	MA	Inhibitor
DMT56ER	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMT56ER	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMPZ0XJ	DI	DMPZ0XJ
DMPZ0XJ	DN	Merimepodib
DMPZ0XJ	MI	TTTU6X1
DMPZ0XJ	MN	HUMAN inosine-5'-monophosphate dehydrogenase 2 (IMPDH2)
DMPZ0XJ	MT	DTT
DMPZ0XJ	MA	Inhibitor
DMPZ0XJ	RN	The IMPDH inhibitor merimepodib suppresses SARS-CoV-2 replication in vitro. April 09, 2020. doi: https://doi.org/10.1101/2020.04.07.028589
DMPZ0XJ	RU	https://www.biorxiv.org/content/10.1101/2020.04.07.028589v1

DMJT93H	DI	DMJT93H
DMJT93H	DN	MERIOLIN 1
DMJT93H	MI	TTAMQ62
DMJT93H	MN	Cyclin A2 (CCNA2)
DMJT93H	MT	DTT
DMJT93H	MA	Inhibitor
DMJT93H	RN	Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
DMJT93H	RU	https://pubmed.ncbi.nlm.nih.gov/18232649

DMJT93H	DI	DMJT93H
DMJT93H	DN	MERIOLIN 1
DMJT93H	MI	TT7HF4W
DMJT93H	MN	Cyclin-dependent kinase 2 (CDK2)
DMJT93H	MT	DTT
DMJT93H	MA	Inhibitor
DMJT93H	RN	Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
DMJT93H	RU	https://pubmed.ncbi.nlm.nih.gov/18232649

DMJT93H	DI	DMJT93H
DMJT93H	DN	MERIOLIN 1
DMJT93H	MI	TT1LVF2
DMJT93H	MN	Cyclin-dependent kinase 9 (CDK9)
DMJT93H	MT	DTT
DMJT93H	MA	Inhibitor
DMJT93H	RN	Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
DMJT93H	RU	https://pubmed.ncbi.nlm.nih.gov/18232649

DM413XJ	DI	DM413XJ
DM413XJ	DN	MERIOLIN 2
DM413XJ	MI	TTAMQ62
DM413XJ	MN	Cyclin A2 (CCNA2)
DM413XJ	MT	DTT
DM413XJ	MA	Inhibitor
DM413XJ	RN	Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
DM413XJ	RU	https://pubmed.ncbi.nlm.nih.gov/18232649

DM413XJ	DI	DM413XJ
DM413XJ	DN	MERIOLIN 2
DM413XJ	MI	TT7HF4W
DM413XJ	MN	Cyclin-dependent kinase 2 (CDK2)
DM413XJ	MT	DTT
DM413XJ	MA	Inhibitor
DM413XJ	RN	Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
DM413XJ	RU	https://pubmed.ncbi.nlm.nih.gov/18232649

DM413XJ	DI	DM413XJ
DM413XJ	DN	MERIOLIN 2
DM413XJ	MI	TT1LVF2
DM413XJ	MN	Cyclin-dependent kinase 9 (CDK9)
DM413XJ	MT	DTT
DM413XJ	MA	Inhibitor
DM413XJ	RN	Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
DM413XJ	RU	https://pubmed.ncbi.nlm.nih.gov/18232649

DMVE95S	DI	DMVE95S
DMVE95S	DN	MERIOLIN 3
DMVE95S	MI	TTAMQ62
DMVE95S	MN	Cyclin A2 (CCNA2)
DMVE95S	MT	DTT
DMVE95S	MA	Inhibitor
DMVE95S	RN	Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
DMVE95S	RU	https://pubmed.ncbi.nlm.nih.gov/18232649

DMVE95S	DI	DMVE95S
DMVE95S	DN	MERIOLIN 3
DMVE95S	MI	TT7HF4W
DMVE95S	MN	Cyclin-dependent kinase 2 (CDK2)
DMVE95S	MT	DTT
DMVE95S	MA	Inhibitor
DMVE95S	RN	Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
DMVE95S	RU	https://pubmed.ncbi.nlm.nih.gov/18232649

DMVE95S	DI	DMVE95S
DMVE95S	DN	MERIOLIN 3
DMVE95S	MI	TT1LVF2
DMVE95S	MN	Cyclin-dependent kinase 9 (CDK9)
DMVE95S	MT	DTT
DMVE95S	MA	Inhibitor
DMVE95S	RN	Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
DMVE95S	RU	https://pubmed.ncbi.nlm.nih.gov/18232649

DMIJMZQ	DI	DMIJMZQ
DMIJMZQ	DN	MERIOLIN 4
DMIJMZQ	MI	TTAMQ62
DMIJMZQ	MN	Cyclin A2 (CCNA2)
DMIJMZQ	MT	DTT
DMIJMZQ	MA	Inhibitor
DMIJMZQ	RN	Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
DMIJMZQ	RU	https://pubmed.ncbi.nlm.nih.gov/18232649

DMIJMZQ	DI	DMIJMZQ
DMIJMZQ	DN	MERIOLIN 4
DMIJMZQ	MI	TT7HF4W
DMIJMZQ	MN	Cyclin-dependent kinase 2 (CDK2)
DMIJMZQ	MT	DTT
DMIJMZQ	MA	Inhibitor
DMIJMZQ	RN	Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
DMIJMZQ	RU	https://pubmed.ncbi.nlm.nih.gov/18232649

DMIJMZQ	DI	DMIJMZQ
DMIJMZQ	DN	MERIOLIN 4
DMIJMZQ	MI	TT1LVF2
DMIJMZQ	MN	Cyclin-dependent kinase 9 (CDK9)
DMIJMZQ	MT	DTT
DMIJMZQ	MA	Inhibitor
DMIJMZQ	RN	Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
DMIJMZQ	RU	https://pubmed.ncbi.nlm.nih.gov/18232649

DMGVLR0	DI	DMGVLR0
DMGVLR0	DN	MERIOLIN 5
DMGVLR0	MI	TTAMQ62
DMGVLR0	MN	Cyclin A2 (CCNA2)
DMGVLR0	MT	DTT
DMGVLR0	MA	Inhibitor
DMGVLR0	RN	Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
DMGVLR0	RU	https://pubmed.ncbi.nlm.nih.gov/18232649

DMGVLR0	DI	DMGVLR0
DMGVLR0	DN	MERIOLIN 5
DMGVLR0	MI	TT7HF4W
DMGVLR0	MN	Cyclin-dependent kinase 2 (CDK2)
DMGVLR0	MT	DTT
DMGVLR0	MA	Inhibitor
DMGVLR0	RN	Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
DMGVLR0	RU	https://pubmed.ncbi.nlm.nih.gov/18232649

DMGVLR0	DI	DMGVLR0
DMGVLR0	DN	MERIOLIN 5
DMGVLR0	MI	TT1LVF2
DMGVLR0	MN	Cyclin-dependent kinase 9 (CDK9)
DMGVLR0	MT	DTT
DMGVLR0	MA	Inhibitor
DMGVLR0	RN	Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
DMGVLR0	RU	https://pubmed.ncbi.nlm.nih.gov/18232649

DMW5AXC	DI	DMW5AXC
DMW5AXC	DN	MERIOLIN 6
DMW5AXC	MI	TTAMQ62
DMW5AXC	MN	Cyclin A2 (CCNA2)
DMW5AXC	MT	DTT
DMW5AXC	MA	Inhibitor
DMW5AXC	RN	Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
DMW5AXC	RU	https://pubmed.ncbi.nlm.nih.gov/18232649

DMW5AXC	DI	DMW5AXC
DMW5AXC	DN	MERIOLIN 6
DMW5AXC	MI	TT7HF4W
DMW5AXC	MN	Cyclin-dependent kinase 2 (CDK2)
DMW5AXC	MT	DTT
DMW5AXC	MA	Inhibitor
DMW5AXC	RN	Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
DMW5AXC	RU	https://pubmed.ncbi.nlm.nih.gov/18232649

DMW5AXC	DI	DMW5AXC
DMW5AXC	DN	MERIOLIN 6
DMW5AXC	MI	TT1LVF2
DMW5AXC	MN	Cyclin-dependent kinase 9 (CDK9)
DMW5AXC	MT	DTT
DMW5AXC	MA	Inhibitor
DMW5AXC	RN	Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
DMW5AXC	RU	https://pubmed.ncbi.nlm.nih.gov/18232649

DM8D3NY	DI	DM8D3NY
DM8D3NY	DN	MERIOLIN 7
DM8D3NY	MI	TTAMQ62
DM8D3NY	MN	Cyclin A2 (CCNA2)
DM8D3NY	MT	DTT
DM8D3NY	MA	Inhibitor
DM8D3NY	RN	Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
DM8D3NY	RU	https://pubmed.ncbi.nlm.nih.gov/18232649

DM8D3NY	DI	DM8D3NY
DM8D3NY	DN	MERIOLIN 7
DM8D3NY	MI	TT1LVF2
DM8D3NY	MN	Cyclin-dependent kinase 9 (CDK9)
DM8D3NY	MT	DTT
DM8D3NY	MA	Inhibitor
DM8D3NY	RN	Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
DM8D3NY	RU	https://pubmed.ncbi.nlm.nih.gov/18232649

DM0E95B	DI	DM0E95B
DM0E95B	DN	MERIOLIN 8
DM0E95B	MI	TTAMQ62
DM0E95B	MN	Cyclin A2 (CCNA2)
DM0E95B	MT	DTT
DM0E95B	MA	Inhibitor
DM0E95B	RN	Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
DM0E95B	RU	https://pubmed.ncbi.nlm.nih.gov/18232649

DM0E95B	DI	DM0E95B
DM0E95B	DN	MERIOLIN 8
DM0E95B	MI	TT7HF4W
DM0E95B	MN	Cyclin-dependent kinase 2 (CDK2)
DM0E95B	MT	DTT
DM0E95B	MA	Inhibitor
DM0E95B	RN	Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
DM0E95B	RU	https://pubmed.ncbi.nlm.nih.gov/18232649

DM0E95B	DI	DM0E95B
DM0E95B	DN	MERIOLIN 8
DM0E95B	MI	TT1LVF2
DM0E95B	MN	Cyclin-dependent kinase 9 (CDK9)
DM0E95B	MT	DTT
DM0E95B	MA	Inhibitor
DM0E95B	RN	Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
DM0E95B	RU	https://pubmed.ncbi.nlm.nih.gov/18232649

DMYVUCE	DI	DMYVUCE
DMYVUCE	DN	MESCALINE
DMYVUCE	MI	TTJQOD7
DMYVUCE	MN	5-HT 2A receptor (HTR2A)
DMYVUCE	MT	DTT
DMYVUCE	MA	Inhibitor
DMYVUCE	RN	The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands. Bioorg Med Chem. 2008 Apr 15;16(8):4661-9.
DMYVUCE	RU	https://pubmed.ncbi.nlm.nih.gov/18296055

DM86WRO	DI	DM86WRO
DM86WRO	DN	meso-DAP
DM86WRO	MI	TTYSRXM
DM86WRO	MN	Pattern recognition receptor NOD1 (NOD1)
DM86WRO	MT	DTT
DM86WRO	MA	Agonist
DM86WRO	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1762).
DM86WRO	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1762

DMZ12GE	DI	DMZ12GE
DMZ12GE	DN	MESUAGENIN A
DMZ12GE	MI	TT1RS9F
DMZ12GE	MN	Acetylcholinesterase (AChE)
DMZ12GE	MT	DTT
DMZ12GE	MA	Inhibitor
DMZ12GE	RN	4-Phenylcoumarins from Mesua elegans with acetylcholinesterase inhibitory activity. Bioorg Med Chem. 2010 Nov 15;18(22):7873-7.
DMZ12GE	RU	https://pubmed.ncbi.nlm.nih.gov/20943395

DMKXG3V	DI	DMKXG3V
DMKXG3V	DN	MESUAGENIN B
DMKXG3V	MI	TT1RS9F
DMKXG3V	MN	Acetylcholinesterase (AChE)
DMKXG3V	MT	DTT
DMKXG3V	MA	Inhibitor
DMKXG3V	RN	4-Phenylcoumarins from Mesua elegans with acetylcholinesterase inhibitory activity. Bioorg Med Chem. 2010 Nov 15;18(22):7873-7.
DMKXG3V	RU	https://pubmed.ncbi.nlm.nih.gov/20943395

DMLZGO7	DI	DMLZGO7
DMLZGO7	DN	Mesuagenin D
DMLZGO7	MI	TT1RS9F
DMLZGO7	MN	Acetylcholinesterase (AChE)
DMLZGO7	MT	DTT
DMLZGO7	MA	Inhibitor
DMLZGO7	RN	4-Phenylcoumarins from Mesua elegans with acetylcholinesterase inhibitory activity. Bioorg Med Chem. 2010 Nov 15;18(22):7873-7.
DMLZGO7	RU	https://pubmed.ncbi.nlm.nih.gov/20943395

DMKGWAH	DI	DMKGWAH
DMKGWAH	DN	MESULERGINE
DMKGWAH	MI	TTPC4TU
DMKGWAH	MN	5-HT 3A receptor (HTR3A)
DMKGWAH	MT	DTT
DMKGWAH	MA	Inhibitor
DMKGWAH	RN	Novel and highly potent 5-HT3 receptor agonists based on a pyrroloquinoxaline structure. J Med Chem. 1997 Oct 24;40(22):3670-8.
DMKGWAH	RU	https://pubmed.ncbi.nlm.nih.gov/9357534

DMKGWAH	DI	DMKGWAH
DMKGWAH	DN	MESULERGINE
DMKGWAH	MI	TTR6K75
DMKGWAH	MN	5-HT 3B receptor (HTR3B)
DMKGWAH	MT	DTT
DMKGWAH	MA	Inhibitor
DMKGWAH	RN	Novel and highly potent 5-HT3 receptor agonists based on a pyrroloquinoxaline structure. J Med Chem. 1997 Oct 24;40(22):3670-8.
DMKGWAH	RU	https://pubmed.ncbi.nlm.nih.gov/9357534

DMKGWAH	DI	DMKGWAH
DMKGWAH	DN	MESULERGINE
DMKGWAH	MI	TTO9X1H
DMKGWAH	MN	5-HT 7 receptor (HTR7)
DMKGWAH	MT	DTT
DMKGWAH	MA	Inhibitor
DMKGWAH	RN	Synthesis of new serotonin 5-HT7 receptor ligands. Determinants of 5-HT7/5-HT1A receptor selectivity. J Med Chem. 2009 Apr 23;52(8):2384-92.
DMKGWAH	RU	https://pubmed.ncbi.nlm.nih.gov/19326916

DMKGWAH	DI	DMKGWAH
DMKGWAH	DN	MESULERGINE
DMKGWAH	MI	TTJFY5U
DMKGWAH	MN	Adenosine A3 receptor (ADORA3)
DMKGWAH	MT	DTT
DMKGWAH	MA	Inhibitor
DMKGWAH	RN	2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96.
DMKGWAH	RU	https://pubmed.ncbi.nlm.nih.gov/16250647

DMEA8GP	DI	DMEA8GP
DMEA8GP	DN	meta-chlorphenylbiguanide
DMEA8GP	MI	TTPC4TU
DMEA8GP	MN	5-HT 3A receptor (HTR3A)
DMEA8GP	MT	DTT
DMEA8GP	MA	Agonist
DMEA8GP	RN	Different efficacy of specific agonists at 5-HT3 receptor splice variants: the role of the extra six amino acid segment. Br J Pharmacol. 1998 Feb;123(4):661-6.
DMEA8GP	RU	https://pubmed.ncbi.nlm.nih.gov/9517385

DMEA8GP	DI	DMEA8GP
DMEA8GP	DN	meta-chlorphenylbiguanide
DMEA8GP	MI	TTR6K75
DMEA8GP	MN	5-HT 3B receptor (HTR3B)
DMEA8GP	MT	DTT
DMEA8GP	MA	Agonist
DMEA8GP	RN	Pharmacological comparison of human homomeric 5-HT3A receptors versus heteromeric 5-HT3A/3B receptors. Neuropharmacology. 2001 Aug;41(2):282-4.
DMEA8GP	RU	https://pubmed.ncbi.nlm.nih.gov/11489465

DMTGMB1	DI	DMTGMB1
DMTGMB1	DN	Metanephrine
DMTGMB1	MI	TTJ6ESR
DMTGMB1	MN	Catecholamine uptake (CA uptake)
DMTGMB1	MT	DTT
DMTGMB1	MA	Inhibitor
DMTGMB1	RN	Catecholamine uptake blockade in anaesthetized dogs: influence on cardiovascular responses. J Pharm Pharmacol. 1979 Nov;31(11):761-6.
DMTGMB1	RU	https://pubmed.ncbi.nlm.nih.gov/41908

DMITMN9	DI	DMITMN9
DMITMN9	DN	Meta-Nitro-Tyrosine
DMITMN9	MI	TTEP6RV
DMITMN9	MN	Glutathione reductase (GR)
DMITMN9	MT	DTT
DMITMN9	MA	Inhibitor
DMITMN9	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMITMN9	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMSK0QX	DI	DMSK0QX
DMSK0QX	DN	Meta-sirtinol
DMSK0QX	MI	TTUF2HO
DMSK0QX	MN	NAD-dependent deacetylase sirtuin-1 (SIRT1)
DMSK0QX	MT	DTT
DMSK0QX	MA	Inhibitor
DMSK0QX	RN	Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (Sirtuin) inhibitors. J Med Chem. 2005 Dec 1;48(24):7789-95.
DMSK0QX	RU	https://pubmed.ncbi.nlm.nih.gov/16302818

DM0748C	DI	DM0748C
DM0748C	DN	Meta-Tyrosine
DM0748C	MI	TTUHP71
DM0748C	MN	Tyrosine 3-monooxygenase (TH)
DM0748C	MT	DTT
DM0748C	MA	Inhibitor
DM0748C	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM0748C	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMQBGH9	DI	DMQBGH9
DMQBGH9	DN	Metazamide
DMQBGH9	MI	TTKN8W0
DMQBGH9	MN	Glucose-6-phosphate dehydrogenase (G6PD)
DMQBGH9	MT	DTT
DMQBGH9	MA	Inhibitor
DMQBGH9	RN	Glucose utilization and activity of glucose-6-phosphate dehydrogenase, isocitrate dehydrogenase and malate dehydrogenase in rat erythrocytes after treatment with tuberculostatic agents. Vopr Med Khim. 1986 Sep-Oct;32(5):32-5.
DMQBGH9	RU	https://pubmed.ncbi.nlm.nih.gov/3776114

DMB6T23	DI	DMB6T23
DMB6T23	DN	METAZOCINE
DMB6T23	MI	TT27RFC
DMB6T23	MN	Opioid receptor delta (OPRD1)
DMB6T23	MT	DTT
DMB6T23	MA	Inhibitor
DMB6T23	RN	Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8.
DMB6T23	RU	https://pubmed.ncbi.nlm.nih.gov/19027293

DMB6T23	DI	DMB6T23
DMB6T23	DN	METAZOCINE
DMB6T23	MI	TTQW87Y
DMB6T23	MN	Opioid receptor kappa (OPRK1)
DMB6T23	MT	DTT
DMB6T23	MA	Inhibitor
DMB6T23	RN	Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8.
DMB6T23	RU	https://pubmed.ncbi.nlm.nih.gov/19027293

DMB6T23	DI	DMB6T23
DMB6T23	DN	METAZOCINE
DMB6T23	MI	TTKWM86
DMB6T23	MN	Opioid receptor mu (MOP)
DMB6T23	MT	DTT
DMB6T23	MA	Inhibitor
DMB6T23	RN	Synthesis and biological evaluation of a metazocine-containing enkephalinamide. Evidence for nonidentical roles of the tyramine moiety in opiates a... J Med Chem. 1982 Dec;25(12):1423-7.
DMB6T23	RU	https://pubmed.ncbi.nlm.nih.gov/7154002

DMDASC6	DI	DMDASC6
DMDASC6	DN	Metformin
DMDASC6	MI	TTKV8W5
DMDASC6	MN	HUMAN mannose receptor (MRC1)
DMDASC6	MT	DTT
DMDASC6	MA	Inhibitor
DMDASC6	RN	A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing. March 2020
DMDASC6	RU	https://www.researchgate.net/publication/340097421_A_SARS-CoV-2-Human_Protein-Protein_Interaction_Map_Reveals_Drug_Targets_and_Potential_Drug-Repurposing

DMZVF6M	DI	DMZVF6M
DMZVF6M	DN	Methanandamide
DMZVF6M	MI	TT6OEDT
DMZVF6M	MN	Cannabinoid receptor 1 (CB1)
DMZVF6M	MT	DTT
DMZVF6M	MA	Antagonist
DMZVF6M	RN	Methanandamide attenuates cocaine-induced hyperthermia in rats by a cannabinoid CB1-dopamine D2 receptor mechanism. Brain Res. 2009 Mar 13;1260:7-14.
DMZVF6M	RU	https://pubmed.ncbi.nlm.nih.gov/19401177

DMVQSEH	DI	DMVQSEH
DMVQSEH	DN	Methimepip
DMVQSEH	MI	TT9JNIC
DMVQSEH	MN	Histamine H3 receptor (H3R)
DMVQSEH	MT	DTT
DMVQSEH	MA	Agonist
DMVQSEH	RN	The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20.
DMVQSEH	RU	https://pubmed.ncbi.nlm.nih.gov/15665857

DMEIP6H	DI	DMEIP6H
DMEIP6H	DN	methionine benzimidazole 6
DMEIP6H	MI	TT5Y4EM
DMEIP6H	MN	N-formyl peptide receptor (FPR1)
DMEIP6H	MT	DTT
DMEIP6H	MA	Antagonist
DMEIP6H	RN	Discovery of small molecule human FPR1 receptor antagonists. Bioorg Med Chem Lett. 2011 May 15;21(10):2991-7.
DMEIP6H	RU	https://pubmed.ncbi.nlm.nih.gov/21486695

DMOUTNA	DI	DMOUTNA
DMOUTNA	DN	Methionine Phosphonate
DMOUTNA	MI	TTOJ46K
DMOUTNA	MN	Streptococcus Methionyl-tRNA synthetase (Stre-coc metG)
DMOUTNA	MT	DTT
DMOUTNA	MA	Inhibitor
DMOUTNA	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMOUTNA	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMKE18W	DI	DMKE18W
DMKE18W	DN	Methionine Sulfoxide
DMKE18W	MI	TTE4KHA
DMKE18W	MN	Amyloid beta A4 protein (APP)
DMKE18W	MT	DTT
DMKE18W	MA	Inhibitor
DMKE18W	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMKE18W	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMKE18W	DI	DMKE18W
DMKE18W	DN	Methionine Sulfoxide
DMKE18W	MI	TTU6BFZ
DMKE18W	MN	Candida Thymidylate synthase (Candi TMP1)
DMKE18W	MT	DTT
DMKE18W	MA	Inhibitor
DMKE18W	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMKE18W	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMMC0I7	DI	DMMC0I7
DMMC0I7	DN	METHIOTHEPIN
DMMC0I7	MI	TTRUFDT
DMMC0I7	MN	5-HT 5A receptor (HTR5A)
DMMC0I7	MT	DTT
DMMC0I7	MA	Inhibitor
DMMC0I7	RN	Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). J Med Chem. 2003 Jul 3;46(14):2795-812.
DMMC0I7	RU	https://pubmed.ncbi.nlm.nih.gov/12825922

DMMC0I7	DI	DMMC0I7
DMMC0I7	DN	METHIOTHEPIN
DMMC0I7	MI	TTJS8PY
DMMC0I7	MN	5-HT 6 receptor (HTR6)
DMMC0I7	MT	DTT
DMMC0I7	MA	Inhibitor
DMMC0I7	RN	5-Cyclic amine-3-arylsulfonylindazoles as novel 5-HT6 receptor antagonists. J Med Chem. 2010 Mar 25;53(6):2521-7.
DMMC0I7	RU	https://pubmed.ncbi.nlm.nih.gov/20170099

DMMC0I7	DI	DMMC0I7
DMMC0I7	DN	METHIOTHEPIN
DMMC0I7	MI	TTO9X1H
DMMC0I7	MN	5-HT 7 receptor (HTR7)
DMMC0I7	MT	DTT
DMMC0I7	MA	Inhibitor
DMMC0I7	RN	Novel quinazolinone derivatives as 5-HT7 receptor ligands. Bioorg Med Chem. 2008 Mar 1;16(5):2570-8.
DMMC0I7	RU	https://pubmed.ncbi.nlm.nih.gov/18083580

DMH2CKX	DI	DMH2CKX
DMH2CKX	DN	METHOCTRAMINE
DMH2CKX	MI	TTJFY5U
DMH2CKX	MN	Adenosine A3 receptor (ADORA3)
DMH2CKX	MT	DTT
DMH2CKX	MA	Inhibitor
DMH2CKX	RN	2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96.
DMH2CKX	RU	https://pubmed.ncbi.nlm.nih.gov/16250647

DMH2CKX	DI	DMH2CKX
DMH2CKX	DN	METHOCTRAMINE
DMH2CKX	MI	TTYEG6Q
DMH2CKX	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMH2CKX	MT	DTT
DMH2CKX	MA	Inhibitor
DMH2CKX	RN	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
DMH2CKX	RU	https://pubmed.ncbi.nlm.nih.gov/18983139

DM58A0W	DI	DM58A0W
DM58A0W	DN	methoprene acid
DM58A0W	MI	TT6PEUO
DM58A0W	MN	Retinoic acid receptor RXR-alpha (RXRA)
DM58A0W	MT	DTT
DM58A0W	MA	Agonist
DM58A0W	RN	Activation of mammalian retinoid X receptors by the insect growth regulator methoprene. Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):6157-60.
DM58A0W	RU	https://pubmed.ncbi.nlm.nih.gov/7597096

DM8P526	DI	DM8P526
DM8P526	DN	Methotrexate gamma-hydroxamic acid
DM8P526	MI	TTLM12X
DM8P526	MN	Matrix metalloproteinase-2 (MMP-2)
DM8P526	MT	DTT
DM8P526	MA	Inhibitor
DM8P526	RN	Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74.
DM8P526	RU	https://pubmed.ncbi.nlm.nih.gov/17127067

DM8P526	DI	DM8P526
DM8P526	DN	Methotrexate gamma-hydroxamic acid
DM8P526	MI	TT6X50U
DM8P526	MN	Matrix metalloproteinase-9 (MMP-9)
DM8P526	MT	DTT
DM8P526	MA	Inhibitor
DM8P526	RN	Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74.
DM8P526	RU	https://pubmed.ncbi.nlm.nih.gov/17127067

DMELK2A	DI	DMELK2A
DMELK2A	DN	Methotrexate gamma-L-phenylalaninehydroxamic acid
DMELK2A	MI	TT6X50U
DMELK2A	MN	Matrix metalloproteinase-9 (MMP-9)
DMELK2A	MT	DTT
DMELK2A	MA	Inhibitor
DMELK2A	RN	Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74.
DMELK2A	RU	https://pubmed.ncbi.nlm.nih.gov/17127067

DMPYJLA	DI	DMPYJLA
DMPYJLA	DN	Methotrexate gamma-L-proline-hydroxamic acid
DMPYJLA	MI	TTLM12X
DMPYJLA	MN	Matrix metalloproteinase-2 (MMP-2)
DMPYJLA	MT	DTT
DMPYJLA	MA	Inhibitor
DMPYJLA	RN	Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74.
DMPYJLA	RU	https://pubmed.ncbi.nlm.nih.gov/17127067

DMPYJLA	DI	DMPYJLA
DMPYJLA	DN	Methotrexate gamma-L-proline-hydroxamic acid
DMPYJLA	MI	TT6X50U
DMPYJLA	MN	Matrix metalloproteinase-9 (MMP-9)
DMPYJLA	MT	DTT
DMPYJLA	MA	Inhibitor
DMPYJLA	RN	Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74.
DMPYJLA	RU	https://pubmed.ncbi.nlm.nih.gov/17127067

DMX8QK0	DI	DMX8QK0
DMX8QK0	DN	Methoxy arachidonyl fluorophosphonate
DMX8QK0	MI	TTDP1UC
DMX8QK0	MN	Fatty acid amide hydrolase (FAAH)
DMX8QK0	MT	DTT
DMX8QK0	MA	Inhibitor
DMX8QK0	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMX8QK0	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMN8HRU	DI	DMN8HRU
DMN8HRU	DN	Methoxyphenamine
DMN8HRU	MI	DECB0K3
DMN8HRU	MN	Cytochrome P450 2D6 (CYP2D6)
DMN8HRU	MT	DME
DMN8HRU	MA	Metabolism
DMN8HRU	RN	Metabolism of methoxyphenamine and 2-methoxyamphetamine in P4502D6-transfected cells and cell preparations. Xenobiotica. 1995 Sep;25(9):895-906.
DMN8HRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8553683

DMY0O7X	DI	DMY0O7X
DMY0O7X	DN	METHOXYUNDECYLPHOSPHINIC ACID
DMY0O7X	MI	TTXMY0J
DMY0O7X	MN	Pancreatic triacylglycerol lipase (PNLIP)
DMY0O7X	MT	DTT
DMY0O7X	MA	Inhibitor
DMY0O7X	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMY0O7X	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMGYZHU	DI	DMGYZHU
DMGYZHU	DN	Methyl 10H-phenothiazine-10-carboxylate
DMGYZHU	MI	TTEB0GD
DMGYZHU	MN	Cholinesterase (BCHE)
DMGYZHU	MT	DTT
DMGYZHU	MA	Inhibitor
DMGYZHU	RN	Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. J Med Chem. 2008 Jul 24;51(14):4200-12.
DMGYZHU	RU	https://pubmed.ncbi.nlm.nih.gov/18570368

DMV1AL5	DI	DMV1AL5
DMV1AL5	DN	Methyl 14-(3-n-butylureido)tetradec-8(Z)-enoate
DMV1AL5	MI	TT7WVHI
DMV1AL5	MN	Soluble epoxide hydrolase (EPHX2)
DMV1AL5	MT	DTT
DMV1AL5	MA	Inhibitor
DMV1AL5	RN	14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxi... J Med Chem. 2009 Aug 27;52(16):5069-75.
DMV1AL5	RU	https://pubmed.ncbi.nlm.nih.gov/19653681

DMBKU9M	DI	DMBKU9M
DMBKU9M	DN	Methyl 2-(2-oxo-8-phenyloctanamido)acetate
DMBKU9M	MI	TTT1JVS
DMBKU9M	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DMBKU9M	MT	DTT
DMBKU9M	MA	Inhibitor
DMBKU9M	RN	Structure-activity relationships of natural and non-natural amino acid-based amide and 2-oxoamide inhibitors of human phospholipase A(2) enzymes. Bioorg Med Chem. 2008 Dec 15;16(24):10257-69.
DMBKU9M	RU	https://pubmed.ncbi.nlm.nih.gov/18993078

DMVYGBU	DI	DMVYGBU
DMVYGBU	DN	Methyl 2-(2-oxohexadecanamido)acetate
DMVYGBU	MI	TTT1JVS
DMVYGBU	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DMVYGBU	MT	DTT
DMVYGBU	MA	Inhibitor
DMVYGBU	RN	Structure-activity relationships of natural and non-natural amino acid-based amide and 2-oxoamide inhibitors of human phospholipase A(2) enzymes. Bioorg Med Chem. 2008 Dec 15;16(24):10257-69.
DMVYGBU	RU	https://pubmed.ncbi.nlm.nih.gov/18993078

DMA82IQ	DI	DMA82IQ
DMA82IQ	DN	Methyl 2-(4-chloro-2-cyclohexylphenoxy)acetate
DMA82IQ	MI	TTQDMX5
DMA82IQ	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMA82IQ	MT	DTT
DMA82IQ	MA	Inhibitor
DMA82IQ	RN	2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4347-50.
DMA82IQ	RU	https://pubmed.ncbi.nlm.nih.gov/17531480

DMP06I3	DI	DMP06I3
DMP06I3	DN	Methyl 2-(7-phenylheptanoyl)oxazole-4-carboxylate
DMP06I3	MI	TTDP1UC
DMP06I3	MN	Fatty acid amide hydrolase (FAAH)
DMP06I3	MT	DTT
DMP06I3	MA	Inhibitor
DMP06I3	RN	Exploration of a fundamental substituent effect of alpha-ketoheterocycle enzyme inhibitors: Potent and selective inhibitors of fatty acid amide hyd... Bioorg Med Chem Lett. 2008 Nov 15;18(22):5842-6.
DMP06I3	RU	https://pubmed.ncbi.nlm.nih.gov/18639454

DM9FA26	DI	DM9FA26
DM9FA26	DN	Methyl 2-(7-phenylheptanoyl)oxazole-5-carboxylate
DM9FA26	MI	TTDP1UC
DM9FA26	MN	Fatty acid amide hydrolase (FAAH)
DM9FA26	MT	DTT
DM9FA26	MA	Inhibitor
DM9FA26	RN	Optimization of the central heterocycle of alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Aug 14;51(15):4392-403.
DM9FA26	RU	https://pubmed.ncbi.nlm.nih.gov/18630870

DMB1PXR	DI	DMB1PXR
DMB1PXR	DN	Methyl 2-(Benzylamino)-1H-indole-3-carboxylate
DMB1PXR	MI	TTSJ6Q4
DMB1PXR	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DMB1PXR	MT	DTT
DMB1PXR	MA	Inhibitor
DMB1PXR	RN	Structural optimization and biological evaluation of 2-substituted 5-hydroxyindole-3-carboxylates as potent inhibitors of human 5-lipoxygenase. J Med Chem. 2009 Jun 11;52(11):3474-83.
DMB1PXR	RU	https://pubmed.ncbi.nlm.nih.gov/19492852

DMB74WP	DI	DMB74WP
DMB74WP	DN	Methyl 2-(Diallylamino)-1H-indole-3-carboxylate
DMB74WP	MI	TTSJ6Q4
DMB74WP	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DMB74WP	MT	DTT
DMB74WP	MA	Inhibitor
DMB74WP	RN	Structural optimization and biological evaluation of 2-substituted 5-hydroxyindole-3-carboxylates as potent inhibitors of human 5-lipoxygenase. J Med Chem. 2009 Jun 11;52(11):3474-83.
DMB74WP	RU	https://pubmed.ncbi.nlm.nih.gov/19492852

DMF6MRS	DI	DMF6MRS
DMF6MRS	DN	Methyl 2-(naphthalen-2-yl)benzoate
DMF6MRS	MI	TTVBI8W
DMF6MRS	MN	Dopamine transporter (DAT)
DMF6MRS	MT	DTT
DMF6MRS	MA	Inhibitor
DMF6MRS	RN	Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters. Bioorg Med Chem. 2007 Jun 15;15(12):4159-74.
DMF6MRS	RU	https://pubmed.ncbi.nlm.nih.gov/17446076

DMWM814	DI	DMWM814
DMWM814	DN	Methyl 3-(1-Benzyl-1H-imidazol-5-yl)-propanoate
DMWM814	MI	TTIQUX7
DMWM814	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMWM814	MT	DTT
DMWM814	MA	Inhibitor
DMWM814	RN	Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25.
DMWM814	RU	https://pubmed.ncbi.nlm.nih.gov/20121113

DMWG9BE	DI	DMWG9BE
DMWG9BE	DN	Methyl 3beta-hydroxyolean-12-en-28-oate
DMWG9BE	MI	TTELIN2
DMWG9BE	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMWG9BE	MT	DTT
DMWG9BE	MA	Inhibitor
DMWG9BE	RN	Protein tyrosine phosphatase 1B inhibitory activity of triterpenes isolated from Astilbe koreana. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3273-6.
DMWG9BE	RU	https://pubmed.ncbi.nlm.nih.gov/16580200

DM9S210	DI	DM9S210
DM9S210	DN	Methyl 4-(3-cyclohexylureido)butanoate
DM9S210	MI	TT7WVHI
DM9S210	MN	Soluble epoxide hydrolase (EPHX2)
DM9S210	MT	DTT
DM9S210	MA	Inhibitor
DM9S210	RN	Peptidyl-urea based inhibitors of soluble epoxide hydrolases. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5439-44.
DM9S210	RU	https://pubmed.ncbi.nlm.nih.gov/16908134

DMUROGX	DI	DMUROGX
DMUROGX	DN	Methyl 4-(4-hydroxybenzylideneamino)benzoate
DMUROGX	MI	TTANPDJ
DMUROGX	MN	Carbonic anhydrase II (CA-II)
DMUROGX	MT	DTT
DMUROGX	MA	Inhibitor
DMUROGX	RN	Carbonic anhydrase II-induced selection of inhibitors from a dynamic combinatorial library of Schiff's bases. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6014-7.
DMUROGX	RU	https://pubmed.ncbi.nlm.nih.gov/19796939

DMSBCL6	DI	DMSBCL6
DMSBCL6	DN	Methyl 4-(4-tert-butylbenzylideneamino)benzoate
DMSBCL6	MI	TTANPDJ
DMSBCL6	MN	Carbonic anhydrase II (CA-II)
DMSBCL6	MT	DTT
DMSBCL6	MA	Inhibitor
DMSBCL6	RN	Carbonic anhydrase II-induced selection of inhibitors from a dynamic combinatorial library of Schiff's bases. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6014-7.
DMSBCL6	RU	https://pubmed.ncbi.nlm.nih.gov/19796939

DM9BPQ1	DI	DM9BPQ1
DM9BPQ1	DN	Methyl 6-(3-cyclohexylureido)hexanoate
DM9BPQ1	MI	TT7WVHI
DM9BPQ1	MN	Soluble epoxide hydrolase (EPHX2)
DM9BPQ1	MT	DTT
DM9BPQ1	MA	Inhibitor
DM9BPQ1	RN	Peptidyl-urea based inhibitors of soluble epoxide hydrolases. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5439-44.
DM9BPQ1	RU	https://pubmed.ncbi.nlm.nih.gov/16908134

DMBLW1A	DI	DMBLW1A
DMBLW1A	DN	Methyl 7-methoxy-4-phenylbenzofuran-2-ylcarbamate
DMBLW1A	MI	TTM2AOE
DMBLW1A	MN	Adenosine A2a receptor (ADORA2A)
DMBLW1A	MT	DTT
DMBLW1A	MA	Inhibitor
DMBLW1A	RN	Synthetic studies on selective adenosine A2A receptor antagonists: synthesis and structure-activity relationships of novel benzofuran derivatives. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1090-3.
DMBLW1A	RU	https://pubmed.ncbi.nlm.nih.gov/20034788

DM9HLXD	DI	DM9HLXD
DM9HLXD	DN	Methyl 7-tert-butyl-9H-carbazole-3-carboxylate
DM9HLXD	MI	TTBGTCW
DM9HLXD	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DM9HLXD	MT	DTT
DM9HLXD	MA	Inhibitor
DM9HLXD	RN	Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8.
DM9HLXD	RU	https://pubmed.ncbi.nlm.nih.gov/20521839

DM4DIS3	DI	DM4DIS3
DM4DIS3	DN	Methyl 9H-carbazole-2-carboxylate
DM4DIS3	MI	TTBGTCW
DM4DIS3	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DM4DIS3	MT	DTT
DM4DIS3	MA	Inhibitor
DM4DIS3	RN	Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8.
DM4DIS3	RU	https://pubmed.ncbi.nlm.nih.gov/20521839

DMAXEH3	DI	DMAXEH3
DMAXEH3	DN	Methyl arachidonyl fluorophosphonate
DMAXEH3	MI	TTT1JVS
DMAXEH3	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DMAXEH3	MT	DTT
DMAXEH3	MA	Inhibitor
DMAXEH3	RN	85-kDa cPLA(2) plays a critical role in PPAR-mediated gene transcription in human hepatoma cells. Am J Physiol Gastrointest Liver Physiol. 2002 Apr;282(4):G586-97.
DMAXEH3	RU	https://pubmed.ncbi.nlm.nih.gov/11897617

DMG8XD1	DI	DMG8XD1
DMG8XD1	DN	Methyl estradiol-16-beta-carboxylate
DMG8XD1	MI	TTIWB6L
DMG8XD1	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMG8XD1	MT	DTT
DMG8XD1	MA	Inhibitor
DMG8XD1	RN	Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45.
DMG8XD1	RU	https://pubmed.ncbi.nlm.nih.gov/16480268

DM9O5S6	DI	DM9O5S6
DM9O5S6	DN	Methyl icosylphosphonofluoridate
DM9O5S6	MI	TT6OEDT
DM9O5S6	MN	Cannabinoid receptor 1 (CB1)
DM9O5S6	MT	DTT
DM9O5S6	MA	Inhibitor
DM9O5S6	RN	Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5875-8.
DM9O5S6	RU	https://pubmed.ncbi.nlm.nih.gov/18752948

DM9O5S6	DI	DM9O5S6
DM9O5S6	DN	Methyl icosylphosphonofluoridate
DM9O5S6	MI	TTDP1UC
DM9O5S6	MN	Fatty acid amide hydrolase (FAAH)
DM9O5S6	MT	DTT
DM9O5S6	MA	Inhibitor
DM9O5S6	RN	Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5875-8.
DM9O5S6	RU	https://pubmed.ncbi.nlm.nih.gov/18752948

DME4JGF	DI	DME4JGF
DME4JGF	DN	methyl isocyanate
DME4JGF	MI	TTELV3W
DME4JGF	MN	Transformation-sensitive protein p120 (TRPA1)
DME4JGF	MT	DTT
DME4JGF	MA	Activator
DME4JGF	RN	Transient receptor potential ankyrin 1 antagonists block the noxious effects of toxic industrial isocyanates and tear gases. FASEB J. 2009 Apr;23(4):1102-14.
DME4JGF	RU	https://pubmed.ncbi.nlm.nih.gov/19036859

DMBHUKV	DI	DMBHUKV
DMBHUKV	DN	Methyl L-phenylalaninate
DMBHUKV	MI	TT6L509
DMBHUKV	MN	Coagulation factor IIa (F2)
DMBHUKV	MT	DTT
DMBHUKV	MA	Inhibitor
DMBHUKV	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMBHUKV	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM6YEW4	DI	DM6YEW4
DM6YEW4	DN	Methyl Mercury Ion
DM6YEW4	MI	TTANPDJ
DM6YEW4	MN	Carbonic anhydrase II (CA-II)
DM6YEW4	MT	DTT
DM6YEW4	MA	Inhibitor
DM6YEW4	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM6YEW4	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM6YEW4	DI	DM6YEW4
DM6YEW4	DN	Methyl Mercury Ion
DM6YEW4	MI	TTR0SWN
DM6YEW4	MN	M-phase inducer phosphatase 2 (MPIP2)
DM6YEW4	MT	DTT
DM6YEW4	MA	Inhibitor
DM6YEW4	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM6YEW4	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMOCXLW	DI	DMOCXLW
DMOCXLW	DN	Methyl Methylsulfinylmethyl Sulfide
DMOCXLW	MI	TTMW94E
DMOCXLW	MN	FK506-binding protein 1A (FKBP1A)
DMOCXLW	MT	DTT
DMOCXLW	MA	Inhibitor
DMOCXLW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMOCXLW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM096SI	DI	DM096SI
DM096SI	DN	Methyl Phosphinic Acid
DM096SI	MI	TT1RS9F
DM096SI	MN	Acetylcholinesterase (AChE)
DM096SI	MT	DTT
DM096SI	MA	Inhibitor
DM096SI	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM096SI	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM096SI	DI	DM096SI
DM096SI	DN	Methyl Phosphinic Acid
DM096SI	MI	TTEB0GD
DM096SI	MN	Cholinesterase (BCHE)
DM096SI	MT	DTT
DM096SI	MA	Inhibitor
DM096SI	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM096SI	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMO58UW	DI	DMO58UW
DMO58UW	DN	methyl p-hydroxybenzoate
DMO58UW	MI	TTELV3W
DMO58UW	MN	Transformation-sensitive protein p120 (TRPA1)
DMO58UW	MT	DTT
DMO58UW	MA	Activator
DMO58UW	RN	Methyl p-hydroxybenzoate causes pain sensation through activation of TRPA1 channels. Br J Pharmacol. 2007 May;151(1):153-60.
DMO58UW	RU	https://pubmed.ncbi.nlm.nih.gov/17351650

DMW2R3M	DI	DMW2R3M
DMW2R3M	DN	Methyl piperate
DMW2R3M	MI	TTGP7BY
DMW2R3M	MN	Monoamine oxidase type B (MAO-B)
DMW2R3M	MT	DTT
DMW2R3M	MA	Inhibitor
DMW2R3M	RN	Proposed structural basis of interaction of piperine and related compounds with monoamine oxidases. Bioorg Med Chem Lett. 2010 Jan 15;20(2):537-40.
DMW2R3M	RU	https://pubmed.ncbi.nlm.nih.gov/19969454

DMKCG8H	DI	DMKCG8H
DMKCG8H	DN	methyl salicylate
DMKCG8H	MI	TTELV3W
DMKCG8H	MN	Transformation-sensitive protein p120 (TRPA1)
DMKCG8H	MT	DTT
DMKCG8H	MA	Activator
DMKCG8H	RN	Noxious cold ion channel TRPA1 is activated by pungent compounds and bradykinin. Neuron. 2004 Mar 25;41(6):849-57.
DMKCG8H	RU	https://pubmed.ncbi.nlm.nih.gov/15046718

DM9Y4FL	DI	DM9Y4FL
DM9Y4FL	DN	Methyl-(1,2,3,4-tetrahydro-naphthalen-1-yl)-amine
DM9Y4FL	MI	TTGP7BY
DM9Y4FL	MN	Monoamine oxidase type B (MAO-B)
DM9Y4FL	MT	DTT
DM9Y4FL	MA	Inhibitor
DM9Y4FL	RN	Stereoisomers of allenic amines as inactivators of monoamine oxidase type B. Stereochemical probes of the active site. J Med Chem. 1988 Aug;31(8):1558-66.
DM9Y4FL	RU	https://pubmed.ncbi.nlm.nih.gov/3397993

DMQU9VD	DI	DMQU9VD
DMQU9VD	DN	Methyl-(5-pyridin-3-yl-thiophen-2-yl)-amine
DMQU9VD	MI	TTXV4FI
DMQU9VD	MN	Albendazole monooxygenase (CYP3A4)
DMQU9VD	MT	DTT
DMQU9VD	MA	Inhibitor
DMQU9VD	RN	5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6. J Med Chem. 2005 Jan 13;48(1):224-39.
DMQU9VD	RU	https://pubmed.ncbi.nlm.nih.gov/15634016

DMQU9VD	DI	DMQU9VD
DMQU9VD	DN	Methyl-(5-pyridin-3-yl-thiophen-2-yl)-amine
DMQU9VD	MI	TTVG215
DMQU9VD	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DMQU9VD	MT	DTT
DMQU9VD	MA	Inhibitor
DMQU9VD	RN	5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6. J Med Chem. 2005 Jan 13;48(1):224-39.
DMQU9VD	RU	https://pubmed.ncbi.nlm.nih.gov/15634016

DMZVBLT	DI	DMZVBLT
DMZVBLT	DN	Methyl[4'-(trifluoromethyl)-4-biphenylyl]amine
DMZVBLT	MI	TTBGTCW
DMZVBLT	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DMZVBLT	MT	DTT
DMZVBLT	MA	Inhibitor
DMZVBLT	RN	Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52.
DMZVBLT	RU	https://pubmed.ncbi.nlm.nih.gov/17725339

DMOA54M	DI	DMOA54M
DMOA54M	DN	Methyl3beta-hydroxyolean-12-en-27-oate
DMOA54M	MI	TTELIN2
DMOA54M	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMOA54M	MT	DTT
DMOA54M	MA	Inhibitor
DMOA54M	RN	Protein tyrosine phosphatase 1B inhibitory activity of triterpenes isolated from Astilbe koreana. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3273-6.
DMOA54M	RU	https://pubmed.ncbi.nlm.nih.gov/16580200

DMTPL4W	DI	DMTPL4W
DMTPL4W	DN	Methylamine
DMTPL4W	MI	DE6SOC5
DMTPL4W	MN	Copper amine oxidase (AOC3)
DMTPL4W	MT	DME
DMTPL4W	MA	Metabolism
DMTPL4W	RN	The unique substrate specificity of human AOC2, a semicarbazide-sensitive amine oxidase. Cell Mol Life Sci. 2009 Aug;66(16):2743-57.
DMTPL4W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19588076

DMTPL4W	DI	DMTPL4W
DMTPL4W	DN	Methylamine
DMTPL4W	MI	DE8DP90
DMTPL4W	MN	Semicarbazide-sensitive amine oxidase (AOC2)
DMTPL4W	MT	DME
DMTPL4W	MA	Metabolism
DMTPL4W	RN	The unique substrate specificity of human AOC2, a semicarbazide-sensitive amine oxidase. Cell Mol Life Sci. 2009 Aug;66(16):2743-57.
DMTPL4W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19588076

DM9JECY	DI	DM9JECY
DM9JECY	DN	METHYLAMINO-PHENYLALANYL-LEUCYL-HYDROXAMIC ACID
DM9JECY	MI	TTMX39J
DM9JECY	MN	Matrix metalloproteinase-1 (MMP-1)
DM9JECY	MT	DTT
DM9JECY	MA	Inhibitor
DM9JECY	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM9JECY	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM9JECY	DI	DM9JECY
DM9JECY	DN	METHYLAMINO-PHENYLALANYL-LEUCYL-HYDROXAMIC ACID
DM9JECY	MI	TTGA1IV
DM9JECY	MN	Matrix metalloproteinase-8 (MMP-8)
DM9JECY	MT	DTT
DM9JECY	MA	Inhibitor
DM9JECY	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM9JECY	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMDP84X	DI	DMDP84X
DMDP84X	DN	Methylcarbamic Acid Biphenyl-3-yl Ester
DMDP84X	MI	TTDP1UC
DMDP84X	MN	Fatty acid amide hydrolase (FAAH)
DMDP84X	MT	DTT
DMDP84X	MA	Inhibitor
DMDP84X	RN	Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl a... J Med Chem. 2008 Jun 26;51(12):3487-98.
DMDP84X	RU	https://pubmed.ncbi.nlm.nih.gov/18507372

DMV865Q	DI	DMV865Q
DMV865Q	DN	methylcarbamyl PAF
DMV865Q	MI	TTQL5VC
DMV865Q	MN	Platelet-activating factor receptor (PTAFR)
DMV865Q	MT	DTT
DMV865Q	MA	Agonist
DMV865Q	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 334).
DMV865Q	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=334

DMP204G	DI	DMP204G
DMP204G	DN	Methylenedioxyamphetamine
DMP204G	MI	TTVBI8W
DMP204G	MN	Dopamine transporter (DAT)
DMP204G	MT	DTT
DMP204G	MA	Inhibitor
DMP204G	RN	Synthesis and in vitro toxicity of 4-MTA, its characteristic clandestine synthesis byproducts and related sulfur substituted alpha-alkylthioampheta... Bioorg Med Chem. 2010 Jun 1;18(11):4009-31.
DMP204G	RU	https://pubmed.ncbi.nlm.nih.gov/20466553

DMP204G	DI	DMP204G
DMP204G	DN	Methylenedioxyamphetamine
DMP204G	MI	TTAWNKZ
DMP204G	MN	Norepinephrine transporter (NET)
DMP204G	MT	DTT
DMP204G	MA	Inhibitor
DMP204G	RN	Synthesis and in vitro toxicity of 4-MTA, its characteristic clandestine synthesis byproducts and related sulfur substituted alpha-alkylthioampheta... Bioorg Med Chem. 2010 Jun 1;18(11):4009-31.
DMP204G	RU	https://pubmed.ncbi.nlm.nih.gov/20466553

DMP204G	DI	DMP204G
DMP204G	DN	Methylenedioxyamphetamine
DMP204G	MI	TT3ROYC
DMP204G	MN	Serotonin transporter (SERT)
DMP204G	MT	DTT
DMP204G	MA	Inhibitor
DMP204G	RN	Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88.
DMP204G	RU	https://pubmed.ncbi.nlm.nih.gov/19717215

DMYVU47	DI	DMYVU47
DMYVU47	DN	Methylenedioxymethamphetamine
DMYVU47	MI	TTJQOD7
DMYVU47	MN	5-HT 2A receptor (HTR2A)
DMYVU47	MT	DTT
DMYVU47	MA	Agonist
DMYVU47	RN	The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. Addiction. 2006 Sep;101(9):1241-5.
DMYVU47	RU	https://pubmed.ncbi.nlm.nih.gov/16911722

DMYVU47	DI	DMYVU47
DMYVU47	DN	Methylenedioxymethamphetamine
DMYVU47	MI	TT0K1SC
DMYVU47	MN	5-HT 2B receptor (HTR2B)
DMYVU47	MT	DTT
DMYVU47	MA	Agonist
DMYVU47	RN	The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. Addiction. 2006 Sep;101(9):1241-5.
DMYVU47	RU	https://pubmed.ncbi.nlm.nih.gov/16911722

DMYVU47	DI	DMYVU47
DMYVU47	DN	Methylenedioxymethamphetamine
DMYVU47	MI	TTWJBZ5
DMYVU47	MN	5-HT 2C receptor (HTR2C)
DMYVU47	MT	DTT
DMYVU47	MA	Agonist
DMYVU47	RN	The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. Addiction. 2006 Sep;101(9):1241-5.
DMYVU47	RU	https://pubmed.ncbi.nlm.nih.gov/16911722

DMYVU47	DI	DMYVU47
DMYVU47	DN	Methylenedioxymethamphetamine
DMYVU47	MI	DEV3T4A
DMYVU47	MN	Catechol O-methyltransferase (COMT)
DMYVU47	MT	DME
DMYVU47	MA	Metabolism
DMYVU47	RN	Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit. 2004 Apr;26(2):137-44.
DMYVU47	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15228154

DMYVU47	DI	DMYVU47
DMYVU47	DN	Methylenedioxymethamphetamine
DMYVU47	MI	DE4OGUF
DMYVU47	MN	Cytochrome P450 102A1 (cyp102)
DMYVU47	MT	DME
DMYVU47	MA	Metabolism
DMYVU47	RN	The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities. Trends Biotechnol. 2007 Jul;25(7):289-98.
DMYVU47	RU	https://pubmed.ncbi.nlm.nih.gov/17532492

DMYVU47	DI	DMYVU47
DMYVU47	DN	Methylenedioxymethamphetamine
DMYVU47	MI	DECB0K3
DMYVU47	MN	Cytochrome P450 2D6 (CYP2D6)
DMYVU47	MT	DME
DMYVU47	MA	Metabolism
DMYVU47	RN	Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit. 2004 Apr;26(2):137-44.
DMYVU47	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15228154

DMYVU47	DI	DMYVU47
DMYVU47	DN	Methylenedioxymethamphetamine
DMYVU47	MI	TTVBI8W
DMYVU47	MN	Dopamine transporter (DAT)
DMYVU47	MT	DTT
DMYVU47	MA	Inhibitor
DMYVU47	RN	The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. Addiction. 2006 Sep;101(9):1241-5.
DMYVU47	RU	https://pubmed.ncbi.nlm.nih.gov/16911722

DMYVU47	DI	DMYVU47
DMYVU47	DN	Methylenedioxymethamphetamine
DMYVU47	MI	TTAWNKZ
DMYVU47	MN	Norepinephrine transporter (NET)
DMYVU47	MT	DTT
DMYVU47	MA	Inhibitor
DMYVU47	RN	The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. Addiction. 2006 Sep;101(9):1241-5.
DMYVU47	RU	https://pubmed.ncbi.nlm.nih.gov/16911722

DMYVU47	DI	DMYVU47
DMYVU47	DN	Methylenedioxymethamphetamine
DMYVU47	MI	TT3ROYC
DMYVU47	MN	Serotonin transporter (SERT)
DMYVU47	MT	DTT
DMYVU47	MA	Inhibitor
DMYVU47	RN	The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. Addiction. 2006 Sep;101(9):1241-5.
DMYVU47	RU	https://pubmed.ncbi.nlm.nih.gov/16911722

DMYVU47	DI	DMYVU47
DMYVU47	DN	Methylenedioxymethamphetamine
DMYVU47	MI	TTNZRI3
DMYVU47	MN	Synaptic vesicle amine transporter (SLC18A2)
DMYVU47	MT	DTT
DMYVU47	MA	Antagonist
DMYVU47	RN	The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. Addiction. 2006 Sep;101(9):1241-5.
DMYVU47	RU	https://pubmed.ncbi.nlm.nih.gov/16911722

DMZ318I	DI	DMZ318I
DMZ318I	DN	methylfurmethide
DMZ318I	MI	TTOXS3C
DMZ318I	MN	Muscarinic acetylcholine receptor (CHRM)
DMZ318I	MT	DTT
DMZ318I	MA	Agonist
DMZ318I	RN	Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol. 1997 Jul;52(1):172-9.
DMZ318I	RU	https://pubmed.ncbi.nlm.nih.gov/9224827

DMZ318I	DI	DMZ318I
DMZ318I	DN	methylfurmethide
DMZ318I	MI	TTQ13Z5
DMZ318I	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMZ318I	MT	DTT
DMZ318I	MA	Agonist
DMZ318I	RN	Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol. 1997 Jul;52(1):172-9.
DMZ318I	RU	https://pubmed.ncbi.nlm.nih.gov/9224827

DMUBY4J	DI	DMUBY4J
DMUBY4J	DN	Methylglyoxal
DMUBY4J	MI	DE05IKP
DMUBY4J	MN	Hydroxyacylglutathione hydrolase (HAGH)
DMUBY4J	MT	DME
DMUBY4J	MA	Metabolism
DMUBY4J	RN	Weak association of glyoxalase 1 (GLO1) variants with autism spectrum disorder. Eur Child Adolesc Psychiatry. 2015 Jan;24(1):75-82.
DMUBY4J	RU	https://pubmed.ncbi.nlm.nih.gov/24671236

DMRC3OZ	DI	DMRC3OZ
DMRC3OZ	DN	methylglyoxal
DMRC3OZ	MI	TT9V5JH
DMRC3OZ	MN	Phospholipase A2 (PLA2G1B)
DMRC3OZ	MT	DTT
DMRC3OZ	MA	Inhibitor
DMRC3OZ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMRC3OZ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMRC3OZ	DI	DMRC3OZ
DMRC3OZ	DN	methylglyoxal
DMRC3OZ	MI	TTELV3W
DMRC3OZ	MN	Transformation-sensitive protein p120 (TRPA1)
DMRC3OZ	MT	DTT
DMRC3OZ	MA	Activator
DMRC3OZ	RN	Inhibiting TRPA1 ion channel reduces loss of cutaneous nerve fiber function in diabetic animals: sustained activation of the TRPA1 channel contributes to the pathogenesis of peripheral diabetic neuropathy. Pharmacol Res. 2012 Jan;65(1):149-58.
DMRC3OZ	RU	https://pubmed.ncbi.nlm.nih.gov/22133672

DM7PRDY	DI	DM7PRDY
DM7PRDY	DN	methylhistaprodifen
DM7PRDY	MI	TTTIBOJ
DM7PRDY	MN	Histamine H1 receptor (H1R)
DM7PRDY	MT	DTT
DM7PRDY	MA	Agonist
DM7PRDY	RN	Multiple differences in agonist and antagonist pharmacology between human and guinea pig histamine H1-receptor. J Pharmacol Exp Ther. 2003 Jun;305(3):1104-15.
DM7PRDY	RU	https://pubmed.ncbi.nlm.nih.gov/12626648

DM9YE6K	DI	DM9YE6K
DM9YE6K	DN	METHYLHONOKIOL
DM9YE6K	MI	TTSJ6Q4
DM9YE6K	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DM9YE6K	MT	DTT
DM9YE6K	MA	Inhibitor
DM9YE6K	RN	Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxyge... Bioorg Med Chem. 2009 Jul 1;17(13):4459-65.
DM9YE6K	RU	https://pubmed.ncbi.nlm.nih.gov/19481465

DM9YE6K	DI	DM9YE6K
DM9YE6K	DN	METHYLHONOKIOL
DM9YE6K	MI	TT8NGED
DM9YE6K	MN	Prostaglandin G/H synthase 1 (COX-1)
DM9YE6K	MT	DTT
DM9YE6K	MA	Inhibitor
DM9YE6K	RN	Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxyge... Bioorg Med Chem. 2009 Jul 1;17(13):4459-65.
DM9YE6K	RU	https://pubmed.ncbi.nlm.nih.gov/19481465

DM9YE6K	DI	DM9YE6K
DM9YE6K	DN	METHYLHONOKIOL
DM9YE6K	MI	TTVKILB
DM9YE6K	MN	Prostaglandin G/H synthase 2 (COX-2)
DM9YE6K	MT	DTT
DM9YE6K	MA	Inhibitor
DM9YE6K	RN	Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxyge... Bioorg Med Chem. 2009 Jul 1;17(13):4459-65.
DM9YE6K	RU	https://pubmed.ncbi.nlm.nih.gov/19481465

DMOWMPL	DI	DMOWMPL
DMOWMPL	DN	METHYLNORADRENALINE
DMOWMPL	MI	TTWG9A4
DMOWMPL	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMOWMPL	MT	DTT
DMOWMPL	MA	Inhibitor
DMOWMPL	RN	alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs. J Med Chem. 1982 Dec;25(12):1389-401.
DMOWMPL	RU	https://pubmed.ncbi.nlm.nih.gov/6296387

DMOWMPL	DI	DMOWMPL
DMOWMPL	DN	METHYLNORADRENALINE
DMOWMPL	MI	TTWM4TY
DMOWMPL	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMOWMPL	MT	DTT
DMOWMPL	MA	Inhibitor
DMOWMPL	RN	alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs. J Med Chem. 1982 Dec;25(12):1389-401.
DMOWMPL	RU	https://pubmed.ncbi.nlm.nih.gov/6296387

DMOWMPL	DI	DMOWMPL
DMOWMPL	DN	METHYLNORADRENALINE
DMOWMPL	MI	TT2NUT5
DMOWMPL	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMOWMPL	MT	DTT
DMOWMPL	MA	Inhibitor
DMOWMPL	RN	alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs. J Med Chem. 1982 Dec;25(12):1389-401.
DMOWMPL	RU	https://pubmed.ncbi.nlm.nih.gov/6296387

DMQ7THK	DI	DMQ7THK
DMQ7THK	DN	Methyl-pentyl-prop-2-ynyl-amine oxalic acid
DMQ7THK	MI	TTGP7BY
DMQ7THK	MN	Monoamine oxidase type B (MAO-B)
DMQ7THK	MT	DTT
DMQ7THK	MA	Inhibitor
DMQ7THK	RN	Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors. J Med Chem. 1992 Oct 2;35(20):3705-13.
DMQ7THK	RU	https://pubmed.ncbi.nlm.nih.gov/1433183

DMR7HV3	DI	DMR7HV3
DMR7HV3	DN	METHYL-PHE-PRO-AMINO-CYCLOHEXYLGLYCINE
DMR7HV3	MI	TT6L509
DMR7HV3	MN	Coagulation factor IIa (F2)
DMR7HV3	MT	DTT
DMR7HV3	MA	Inhibitor
DMR7HV3	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMR7HV3	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMKTOPJ	DI	DMKTOPJ
DMKTOPJ	DN	methyl-piperidino-pyrazole
DMKTOPJ	MI	TTZAYWL
DMKTOPJ	MN	Estrogen receptor (ESR)
DMKTOPJ	MT	DTT
DMKTOPJ	MA	Antagonist
DMKTOPJ	RN	Antagonists selective for estrogen receptor alpha. Endocrinology. 2002 Mar;143(3):941-7.
DMKTOPJ	RU	https://pubmed.ncbi.nlm.nih.gov/11861516

DMU3JBL	DI	DMU3JBL
DMU3JBL	DN	Methylthioribose phosphate
DMU3JBL	MI	DES378D
DMU3JBL	MN	Methylthioribose kinase (mtnK)
DMU3JBL	MT	DME
DMU3JBL	MA	Metabolism
DMU3JBL	RN	Selective killing of Klebsiella pneumoniae by 5-trifluoromethylthioribose. Chemotherapeutic exploitation of the enzyme 5-methylthioribose kinase. J Biol Chem. 1990 Jan 15;265(2):831-7.
DMU3JBL	RU	https://pubmed.ncbi.nlm.nih.gov/2153115

DMAEQB6	DI	DMAEQB6
DMAEQB6	DN	Methylurea
DMAEQB6	MI	DTMF8LB
DMAEQB6	MN	Urea transporter 1 (SLC14A1)
DMAEQB6	MT	DTP
DMAEQB6	MA	Substrate
DMAEQB6	RN	Comparative transport efficiencies of urea analogues through urea transporter UT-B. Biochim Biophys Acta. 2007 Jul;1768(7):1815-21.
DMAEQB6	RU	http://www.ncbi.nlm.nih.gov/pubmed/17506977

DMAEQB6	DI	DMAEQB6
DMAEQB6	DN	Methylurea
DMAEQB6	MI	DT8QC7K
DMAEQB6	MN	Urea transporter 2 (SLC14A2)
DMAEQB6	MT	DTP
DMAEQB6	MA	Substrate
DMAEQB6	RN	Urea transporter physiology studied in knockout mice. Front Physiol. 2012 Jun 26;3:217.
DMAEQB6	RU	http://www.ncbi.nlm.nih.gov/pubmed/22745630

DMO7JGS	DI	DMO7JGS
DMO7JGS	DN	Metiamide
DMO7JGS	MI	TTQHJ1K
DMO7JGS	MN	Histamine H2 receptor (H2R)
DMO7JGS	MT	DTT
DMO7JGS	MA	Antagonist
DMO7JGS	RN	Metiamide--an orally active histamine H2-receptor antagonist. 1973. Agents Actions. 1994 Dec;43(3-4):91-5; discussion 96.
DMO7JGS	RU	https://pubmed.ncbi.nlm.nih.gov/7725982

DMZBLQD	DI	DMZBLQD
DMZBLQD	DN	Met-Lys-bradykinin
DMZBLQD	MI	TTGY8IW
DMZBLQD	MN	B2 bradykinin receptor (BDKRB2)
DMZBLQD	MT	DTT
DMZBLQD	MA	Agonist
DMZBLQD	RN	Expression cloning of a human B1 bradykinin receptor. J Biol Chem. 1994 Aug 26;269(34):21583-6.
DMZBLQD	RU	https://pubmed.ncbi.nlm.nih.gov/8063797

DM70RDZ	DI	DM70RDZ
DM70RDZ	DN	Metrenperone
DM70RDZ	MI	TTYSN63
DM70RDZ	MN	5-HT 2 receptor (5HT2R)
DM70RDZ	MT	DTT
DM70RDZ	MA	Antagonist
DM70RDZ	RN	Cardiovascular response to intravenous administration of 5-hydroxytryptamine after type-2 receptor blockade, by metrenperone, in healthy calves. Vet J. 1999 Jan;157(1):31-7.
DM70RDZ	RU	https://pubmed.ncbi.nlm.nih.gov/10030126

DMGH8WV	DI	DMGH8WV
DMGH8WV	DN	MeTRH
DMGH8WV	MI	TT4J8MF
DMGH8WV	MN	Thyrotropin-releasing hormone receptor (TRHR)
DMGH8WV	MT	DTT
DMGH8WV	MA	Agonist
DMGH8WV	RN	Thyrotropin-releasing hormone receptor type 1 (TRH-R1), not TRH-R2, primarily mediates taltirelin actions in the CNS of mice. Neuropsychopharmacology. 2013 May;38(6):950-6.
DMGH8WV	RU	https://pubmed.ncbi.nlm.nih.gov/23303050

DMHTGCR	DI	DMHTGCR
DMHTGCR	DN	METYRAPOL
DMHTGCR	MI	TTIQUX7
DMHTGCR	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMHTGCR	MT	DTT
DMHTGCR	MA	Inhibitor
DMHTGCR	RN	Structure-activity relationship study of the inhibition of adrenal cortical 11 beta-hydroxylase by new metyrapone analogues. J Med Chem. 1984 Jan;27(1):15-9.
DMHTGCR	RU	https://pubmed.ncbi.nlm.nih.gov/6606707

DMVYWJS	DI	DMVYWJS
DMVYWJS	DN	MEZILAMINE
DMVYWJS	MI	TTWG9A4
DMVYWJS	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMVYWJS	MT	DTT
DMVYWJS	MA	Inhibitor
DMVYWJS	RN	4-Amino-6-chloro-2-piperazinopyrimidines with selective affinity for alpha 2-adrenoceptors. J Med Chem. 1986 Aug;29(8):1394-8.
DMVYWJS	RU	https://pubmed.ncbi.nlm.nih.gov/3016265

DMVYWJS	DI	DMVYWJS
DMVYWJS	DN	MEZILAMINE
DMVYWJS	MI	TTWM4TY
DMVYWJS	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMVYWJS	MT	DTT
DMVYWJS	MA	Inhibitor
DMVYWJS	RN	4-Amino-6-chloro-2-piperazinopyrimidines with selective affinity for alpha 2-adrenoceptors. J Med Chem. 1986 Aug;29(8):1394-8.
DMVYWJS	RU	https://pubmed.ncbi.nlm.nih.gov/3016265

DMVYWJS	DI	DMVYWJS
DMVYWJS	DN	MEZILAMINE
DMVYWJS	MI	TT2NUT5
DMVYWJS	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMVYWJS	MT	DTT
DMVYWJS	MA	Inhibitor
DMVYWJS	RN	4-Amino-6-chloro-2-piperazinopyrimidines with selective affinity for alpha 2-adrenoceptors. J Med Chem. 1986 Aug;29(8):1394-8.
DMVYWJS	RU	https://pubmed.ncbi.nlm.nih.gov/3016265

DMBLUSA	DI	DMBLUSA
DMBLUSA	DN	MF-152
DMBLUSA	MI	TT6RIOV
DMBLUSA	MN	Acyl-CoA desaturase (SCD)
DMBLUSA	MT	DTT
DMBLUSA	MA	Inhibitor
DMBLUSA	RN	SAR and optimization of thiazole analogs as potent stearoyl-CoA desaturase inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1593-7.
DMBLUSA	RU	https://pubmed.ncbi.nlm.nih.gov/20137926

DMSYQP9	DI	DMSYQP9
DMSYQP9	DN	MF266-1
DMSYQP9	MI	TTG1QMU
DMSYQP9	MN	Prostaglandin E2 receptor EP1 (PTGER1)
DMSYQP9	MT	DTT
DMSYQP9	MA	Antagonist
DMSYQP9	RN	MF498 [N-{[4-(5,9-Diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a selective E prostanoid receptor 4 antagonist, relieves joint inflammation and pain in rodent models of rheumatoid and osteoarthritis. J Pharmacol Exp Ther. 2008 May;325(2):425-34.
DMSYQP9	RU	https://pubmed.ncbi.nlm.nih.gov/18287210

DM1FEVB	DI	DM1FEVB
DM1FEVB	DN	MF-8623
DM1FEVB	MI	TTEB0GD
DM1FEVB	MN	Cholinesterase (BCHE)
DM1FEVB	MT	DTT
DM1FEVB	MA	Inhibitor
DM1FEVB	RN	A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase. Curr Med Res Opin. 2001;17(3):159-65.
DM1FEVB	RU	https://pubmed.ncbi.nlm.nih.gov/11900310

DM3RUT8	DI	DM3RUT8
DM3RUT8	DN	MG-101
DM3RUT8	MI	TTU7ZMG
DM3RUT8	MN	Proteasome (PS)
DM3RUT8	MT	DTT
DM3RUT8	MA	Modulator
DM3RUT8	RN	Covalent complexes of proteasome model with peptide aldehyde inhibitors MG132 and MG101: docking and molecular dynamics study.J Mol Model.2009 Dec;15(12):1481-90.
DM3RUT8	RU	https://www.ncbi.nlm.nih.gov/pubmed/19440739

DM710KZ	DI	DM710KZ
DM710KZ	DN	MG-1101
DM710KZ	MI	TT6F7GZ
DM710KZ	MN	Parathyroid hormone (PTH)
DM710KZ	MT	DTT
DM710KZ	MA	Modulator
DM710KZ	RN	Daily parathyroid hormone 1-34 replacement therapy for hypoparathyroidism induces marked changes in bone turnover and structure.J Bone Miner Res.2012 Aug;27(8):1811-20.
DM710KZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/22492501

DMHR1GX	DI	DMHR1GX
DMHR1GX	DN	MG-1104
DMHR1GX	MI	TTFEZ5Q
DMHR1GX	MN	Coagulation factor IX (F9)
DMHR1GX	MT	DTT
DMHR1GX	MA	Modulator
DMHR1GX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2364).
DMHR1GX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2364

DMG56EU	DI	DMG56EU
DMG56EU	DN	MG-111
DMG56EU	MI	TTGKNB4
DMG56EU	MN	Epidermal growth factor receptor (EGFR)
DMG56EU	MT	DTT
DMG56EU	MA	Modulator
DMG56EU	RN	Effects of hEGF (MG111) on gastric mucosal potential difference in rats. Scand J Gastroenterol Suppl. 1989;162:198-201.
DMG56EU	RU	https://www.ncbi.nlm.nih.gov/pubmed/2595297

DM7V58G	DI	DM7V58G
DM7V58G	DN	MG149
DM7V58G	MI	TTH4VJL
DM7V58G	MN	Histone acetyltransferase KAT6B (KAT6B)
DM7V58G	MT	DTT
DM7V58G	MA	Inhibitor
DM7V58G	RN	6-alkylsalicylates are selective Tip60 inhibitors and target the acetyl-CoA binding site. Eur J Med Chem. 2012 Jan;47(1):337-44.
DM7V58G	RU	https://pubmed.ncbi.nlm.nih.gov/22100137

DMN1F7Z	DI	DMN1F7Z
DMN1F7Z	DN	MG-28
DMN1F7Z	MI	TT7AOUD
DMN1F7Z	MN	Fatty acid synthase (FASN)
DMN1F7Z	MT	DTT
DMN1F7Z	MA	Inhibitor
DMN1F7Z	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2608).
DMN1F7Z	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2608

DMIMKFZ	DI	DMIMKFZ
DMIMKFZ	DN	MGS0028
DMIMKFZ	MI	TTXJ47W
DMIMKFZ	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMIMKFZ	MT	DTT
DMIMKFZ	MA	Agonist
DMIMKFZ	RN	Synthesis, SARs, and pharmacological characterization of 2-amino-3 or 6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent, selective, and orally active group II metabotropic glutamate receptor agonists. J Med Chem. 2000 Dec 14;43(25):4893-909.
DMIMKFZ	RU	https://pubmed.ncbi.nlm.nih.gov/11123999

DMZ9MCR	DI	DMZ9MCR
DMZ9MCR	DN	MHL cyclohexylthiosemicarbazone
DMZ9MCR	MI	TTHM0R1
DMZ9MCR	MN	Steryl-sulfatase (STS)
DMZ9MCR	MT	DTT
DMZ9MCR	MA	Inhibitor
DMZ9MCR	RN	Thiosemicarbazones of formyl benzoic acids as novel potent inhibitors of estrone sulfatase. J Med Chem. 2007 Jul 26;50(15):3661-6.
DMZ9MCR	RU	https://pubmed.ncbi.nlm.nih.gov/17580843

DMCN91V	DI	DMCN91V
DMCN91V	DN	MI-1148
DMCN91V	MI	TTH9WF6
DMCN91V	MN	Dibasic-processing enzyme (Furin)
DMCN91V	MT	DTT
DMCN91V	MA	Inhibitor
DMCN91V	RN	Novel Furin Inhibitors with Potent Anti-infectious Activity. ChemMedChem. 2015 Jul;10(7):1218-31.
DMCN91V	RU	https://pubmed.ncbi.nlm.nih.gov/25974265

DM196LK	DI	DM196LK
DM196LK	DN	MI-219
DM196LK	MI	TT08GJW
DM196LK	MN	Ubiquitin-protein ligase E3 Mdm2 (MDM2)
DM196LK	MT	DTT
DM196LK	MA	Inhibitor
DM196LK	RN	MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy. Oncogene. 2011 Jan 6;30(1):117-26.
DM196LK	RU	https://pubmed.ncbi.nlm.nih.gov/20818437

DMJ4D1P	DI	DMJ4D1P
DMJ4D1P	DN	Micrococcin
DMJ4D1P	MI	TTLFGBV
DMJ4D1P	MN	Bacterial 23S ribosomal RNA (Bact 23S rRNA)
DMJ4D1P	MT	DTT
DMJ4D1P	MA	Binder
DMJ4D1P	RN	The apicoplast as an antimalarial drug target. Drug Resist Updat. 2001 Jun;4(3):145-51.
DMJ4D1P	RU	https://pubmed.ncbi.nlm.nih.gov/11768328

DMTMLRN	DI	DMTMLRN
DMTMLRN	DN	Microcystin-LR
DMTMLRN	MI	TTFLH0E
DMTMLRN	MN	Serine/threonine PP1-alpha (PPP1CA)
DMTMLRN	MT	DTT
DMTMLRN	MA	Inhibitor
DMTMLRN	RN	Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies. J Med Chem. 2002 Mar 14;45(6):1151-75.
DMTMLRN	RU	https://pubmed.ncbi.nlm.nih.gov/11881984

DM7Y9AD	DI	DM7Y9AD
DM7Y9AD	DN	Microxine
DM7Y9AD	MI	TTH6V3D
DM7Y9AD	MN	Cyclin-dependent kinase 1 (CDK1)
DM7Y9AD	MT	DTT
DM7Y9AD	MA	Inhibitor
DM7Y9AD	RN	Microxine, a new cdc2 kinase inhibitor from the Australian marine sponge Microxina species. J Nat Prod. 2001 Apr;64(4):525-6.
DM7Y9AD	RU	https://pubmed.ncbi.nlm.nih.gov/11325241

DM7Y9AD	DI	DM7Y9AD
DM7Y9AD	DN	Microxine
DM7Y9AD	MI	TTVKILB
DM7Y9AD	MN	Prostaglandin G/H synthase 2 (COX-2)
DM7Y9AD	MT	DTT
DM7Y9AD	MA	Inhibitor
DM7Y9AD	RN	Inhibition of cell cycle oscillation of DNA replication by a selective inhibitor of the cdc2 kinase family, butyrolactone I, in Xenopus egg extracts. Biochem Biophys Res Commun. 1994 Jan 28;198(2):536-45.
DM7Y9AD	RU	https://pubmed.ncbi.nlm.nih.gov/8297363

DM462BT	DI	DM462BT
DM462BT	DN	Milchsaure
DM462BT	MI	DT342ZG
DM462BT	MN	Monocarboxylate transporter 1 (SLC16A1)
DM462BT	MT	DTP
DM462BT	MA	Substrate
DM462BT	RN	Distribution of monocarboxylate transporters MCT1-MCT8 in rat tissues and human skeletal muscle. Appl Physiol Nutr Metab. 2006 Feb;31(1):31-9.
DM462BT	RU	http://www.ncbi.nlm.nih.gov/pubmed/16604139

DM462BT	DI	DM462BT
DM462BT	DN	Milchsaure
DM462BT	MI	DTLT3UG
DM462BT	MN	Monocarboxylate transporter 2 (SLC16A7)
DM462BT	MT	DTP
DM462BT	MA	Substrate
DM462BT	RN	Characterization of the high-affinity monocarboxylate transporter MCT2 in Xenopus laevis oocytes. Biochem J. 1999 Aug 1;341 ( Pt 3):529-35.
DM462BT	RU	http://www.ncbi.nlm.nih.gov/pubmed/10417314

DM462BT	DI	DM462BT
DM462BT	DN	Milchsaure
DM462BT	MI	DTAKRNM
DM462BT	MN	Monocarboxylate transporter 4 (SLC16A3)
DM462BT	MT	DTP
DM462BT	MA	Substrate
DM462BT	RN	The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells. Biochem J. 2000 Aug 15;350 Pt 1:219-27.
DM462BT	RU	http://www.ncbi.nlm.nih.gov/pubmed/10926847

DM6BANS	DI	DM6BANS
DM6BANS	DN	Miller-9E-enolide
DM6BANS	MI	TTSXVID
DM6BANS	MN	Nuclear factor NF-kappa-B (NFKB)
DM6BANS	MT	DTT
DM6BANS	MA	Inhibitor
DM6BANS	RN	Development of a structural model for NF-kappaB inhibition of sesquiterpene lactones using self-organizing neural networks. J Med Chem. 2006 Apr 6;49(7):2241-52.
DM6BANS	RU	https://pubmed.ncbi.nlm.nih.gov/16570920

DMFMOX5	DI	DMFMOX5
DMFMOX5	DN	Miller-9Z-enolide
DMFMOX5	MI	TTSXVID
DMFMOX5	MN	Nuclear factor NF-kappa-B (NFKB)
DMFMOX5	MT	DTT
DMFMOX5	MA	Inhibitor
DMFMOX5	RN	Development of a structural model for NF-kappaB inhibition of sesquiterpene lactones using self-organizing neural networks. J Med Chem. 2006 Apr 6;49(7):2241-52.
DMFMOX5	RU	https://pubmed.ncbi.nlm.nih.gov/16570920

DM7DT20	DI	DM7DT20
DM7DT20	DN	Mimovax
DM7DT20	MI	TTE4KHA
DM7DT20	MN	Amyloid beta A4 protein (APP)
DM7DT20	MT	DTT
DM7DT20	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
DM7DT20	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402

DMDQK9G	DI	DMDQK9G
DMDQK9G	DN	Miocamycin
DMDQK9G	MI	DE4LYSA
DMDQK9G	MN	Cytochrome P450 3A4 (CYP3A4)
DMDQK9G	MT	DME
DMDQK9G	MA	Metabolism
DMDQK9G	RN	Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. Clin Pharmacol Ther. 1998 Sep;64(3):278-85.
DMDQK9G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9757151

DM2IGD1	DI	DM2IGD1
DM2IGD1	DN	MIP-1231
DM2IGD1	MI	TTGPQ0F
DM2IGD1	MN	Prolyl endopeptidase FAP (FAP)
DM2IGD1	MT	DTT
DM2IGD1	MA	Antagonist
DM2IGD1	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2365).
DM2IGD1	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2365

DM0J38I	DI	DM0J38I
DM0J38I	DN	MIP-1375
DM0J38I	MI	TT9G4N0
DM0J38I	MN	Glutamate carboxypeptidase II (GCPII)
DM0J38I	MT	DTT
DM0J38I	MA	Inhibitor
DM0J38I	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1606).
DM0J38I	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1606

DM4P9LJ	DI	DM4P9LJ
DM4P9LJ	DN	MiR-375
DM4P9LJ	MI	TTYMGWX
DM4P9LJ	MN	PDK-1 messenger RNA (PDK-1 mRNA)
DM4P9LJ	MT	DTT
DM4P9LJ	MA	Binder
DM4P9LJ	RN	miR-375 targets 3'-phosphoinositide-dependent protein kinase-1 and regulates glucose-induced biological responses in pancreatic beta-cells. Diabetes. 2008 Oct;57(10):2708-17.
DM4P9LJ	RU	https://pubmed.ncbi.nlm.nih.gov/18591395

DMYB0HK	DI	DMYB0HK
DMYB0HK	DN	Misonidazole
DMYB0HK	MI	DE0QLUZ
DMYB0HK	MN	Oxygen-insensitive NADPH nitroreductase B (nfsB)
DMYB0HK	MT	DME
DMYB0HK	MA	Metabolism
DMYB0HK	RN	Metronidazole (flagyl) and misonidazole (Ro-07-0582): reduction by facultative anaerobes and cytotoxic action on hypoxic bacteria and mammalian cells in vivo. Br J Cancer Suppl. 1978 Jun;3:132-5.
DMYB0HK	RU	https://pubmed.ncbi.nlm.nih.gov/354677

DM13TUY	DI	DM13TUY
DM13TUY	DN	MIV-710
DM13TUY	MI	TTDZN01
DM13TUY	MN	Cathepsin K (CTSK)
DM13TUY	MT	DTT
DM13TUY	MA	Modulator
DM13TUY	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2350).
DM13TUY	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2350

DMMP6YH	DI	DMMP6YH
DMMP6YH	DN	MJ-451
DMMP6YH	MI	TT1VOHK
DMMP6YH	MN	Potassium channel unspecific (KC)
DMMP6YH	MT	DTT
DMMP6YH	MA	Modulator
DMMP6YH	RN	Pharmacological characteristics of MJ-451, a new benzopyran- derived ATP-sensitive potassium channel opener, in guinea pig isolated trachea. Pharmacology. 1998 Dec;57(6):314-22.
DMMP6YH	RU	https://www.ncbi.nlm.nih.gov/pubmed/9792972

DMRSBWT	DI	DMRSBWT
DMRSBWT	DN	MJN228
DMRSBWT	MI	TT6A5ZL
DMRSBWT	MN	Nucleobindin-1 (NUCB1)
DMRSBWT	MT	DTT
DMRSBWT	MA	Antagonist
DMRSBWT	RN	A Global Map of Lipid-Binding Proteins and Their Ligandability in Cells. Cell. 2015 Jun 18;161(7):1668-80.
DMRSBWT	RU	https://pubmed.ncbi.nlm.nih.gov/26091042

DMTFRLO	DI	DMTFRLO
DMTFRLO	DN	MK-0343
DMTFRLO	MI	TTBMV1G
DMTFRLO	MN	GABA(A) receptor alpha-2 (GABRA2)
DMTFRLO	MT	DTT
DMTFRLO	MA	Modulator
DMTFRLO	RN	Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA(A) alpha2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers.J Psychopharmacol.2008 Jan;22(1):24-32.
DMTFRLO	RU	https://www.ncbi.nlm.nih.gov/pubmed/18187530

DMTFRLO	DI	DMTFRLO
DMTFRLO	DN	MK-0343
DMTFRLO	MI	TT37EDJ
DMTFRLO	MN	GABA(A) receptor alpha-3 (GABRA3)
DMTFRLO	MT	DTT
DMTFRLO	MA	Modulator
DMTFRLO	RN	Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA(A) alpha2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers.J Psychopharmacol.2008 Jan;22(1):24-32.
DMTFRLO	RU	https://www.ncbi.nlm.nih.gov/pubmed/18187530

DMVBFJP	DI	DMVBFJP
DMVBFJP	DN	MK-0668
DMVBFJP	MI	TTBVIQC
DMVBFJP	MN	Integrin beta-1 (ITGB1)
DMVBFJP	MT	DTT
DMVBFJP	MA	Inhibitor
DMVBFJP	RN	Discovery of N-{N-[(3-cyanobenzene) sulfonyl]-4(R)-(3,3-difluoropiperidin-1-yl)-(l)-prolyl}-4-[(3',5'-dichloro-isonicotinoyl) amino]-(l)-phenylalan... Bioorg Med Chem Lett. 2009 Oct 1;19(19):5803-6.
DMVBFJP	RU	https://pubmed.ncbi.nlm.nih.gov/19713111

DMVBFJP	DI	DMVBFJP
DMVBFJP	DN	MK-0668
DMVBFJP	MI	TTJMF9P
DMVBFJP	MN	ITGA4 messenger RNA (ITGA4 mRNA)
DMVBFJP	MT	DTT
DMVBFJP	MA	Inhibitor
DMVBFJP	RN	Discovery of N-{N-[(3-cyanobenzene) sulfonyl]-4(R)-(3,3-difluoropiperidin-1-yl)-(l)-prolyl}-4-[(3',5'-dichloro-isonicotinoyl) amino]-(l)-phenylalan... Bioorg Med Chem Lett. 2009 Oct 1;19(19):5803-6.
DMVBFJP	RU	https://pubmed.ncbi.nlm.nih.gov/19713111

DMI7859	DI	DMI7859
DMI7859	DN	MK-10
DMI7859	MI	TTEOSZT
DMI7859	MN	Melanocortin receptor (MCR)
DMI7859	MT	DTT
DMI7859	MA	Inhibitor
DMI7859	RN	Novel cyclic templates of alpha-MSH give highly selective and potent antagonists/agonists for human melanocortin-3/4 receptors. J Med Chem. 2002 Jun 6;45(12):2644-50.
DMI7859	RU	https://pubmed.ncbi.nlm.nih.gov/12036373

DMI7859	DI	DMI7859
DMI7859	DN	MK-10
DMI7859	MI	TTNI91K
DMI7859	MN	Melanocortin receptor 3 (MC3R)
DMI7859	MT	DTT
DMI7859	MA	Inhibitor
DMI7859	RN	Novel cyclic templates of alpha-MSH give highly selective and potent antagonists/agonists for human melanocortin-3/4 receptors. J Med Chem. 2002 Jun 6;45(12):2644-50.
DMI7859	RU	https://pubmed.ncbi.nlm.nih.gov/12036373

DMI7859	DI	DMI7859
DMI7859	DN	MK-10
DMI7859	MI	TTD0CIQ
DMI7859	MN	Melanocortin receptor 4 (MC4R)
DMI7859	MT	DTT
DMI7859	MA	Inhibitor
DMI7859	RN	Novel cyclic templates of alpha-MSH give highly selective and potent antagonists/agonists for human melanocortin-3/4 receptors. J Med Chem. 2002 Jun 6;45(12):2644-50.
DMI7859	RU	https://pubmed.ncbi.nlm.nih.gov/12036373

DM4FG32	DI	DM4FG32
DM4FG32	DN	MK-11
DM4FG32	MI	TTEOSZT
DM4FG32	MN	Melanocortin receptor (MCR)
DM4FG32	MT	DTT
DM4FG32	MA	Inhibitor
DM4FG32	RN	Novel cyclic templates of alpha-MSH give highly selective and potent antagonists/agonists for human melanocortin-3/4 receptors. J Med Chem. 2002 Jun 6;45(12):2644-50.
DM4FG32	RU	https://pubmed.ncbi.nlm.nih.gov/12036373

DM4FG32	DI	DM4FG32
DM4FG32	DN	MK-11
DM4FG32	MI	TTNI91K
DM4FG32	MN	Melanocortin receptor 3 (MC3R)
DM4FG32	MT	DTT
DM4FG32	MA	Inhibitor
DM4FG32	RN	Novel cyclic templates of alpha-MSH give highly selective and potent antagonists/agonists for human melanocortin-3/4 receptors. J Med Chem. 2002 Jun 6;45(12):2644-50.
DM4FG32	RU	https://pubmed.ncbi.nlm.nih.gov/12036373

DM4FG32	DI	DM4FG32
DM4FG32	DN	MK-11
DM4FG32	MI	TTD0CIQ
DM4FG32	MN	Melanocortin receptor 4 (MC4R)
DM4FG32	MT	DTT
DM4FG32	MA	Inhibitor
DM4FG32	RN	Novel cyclic templates of alpha-MSH give highly selective and potent antagonists/agonists for human melanocortin-3/4 receptors. J Med Chem. 2002 Jun 6;45(12):2644-50.
DM4FG32	RU	https://pubmed.ncbi.nlm.nih.gov/12036373

DM3NDWK	DI	DM3NDWK
DM3NDWK	DN	MK-1925
DM3NDWK	MI	TTQW87Y
DM3NDWK	MN	Opioid receptor kappa (OPRK1)
DM3NDWK	MT	DTT
DM3NDWK	MA	Inhibitor
DM3NDWK	RN	Identification of MK-1925: a selective, orally active and brain-penetrable opioid receptor-like 1 (ORL1) antagonist. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4729-32.
DM3NDWK	RU	https://pubmed.ncbi.nlm.nih.gov/19564110

DM3NDWK	DI	DM3NDWK
DM3NDWK	DN	MK-1925
DM3NDWK	MI	TTQ6VDM
DM3NDWK	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DM3NDWK	MT	DTT
DM3NDWK	MA	Inhibitor
DM3NDWK	RN	Identification of MK-1925: a selective, orally active and brain-penetrable opioid receptor-like 1 (ORL1) antagonist. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4729-32.
DM3NDWK	RU	https://pubmed.ncbi.nlm.nih.gov/19564110

DMYO8T6	DI	DMYO8T6
DMYO8T6	DN	MK-212
DMYO8T6	MI	TTWJBZ5
DMYO8T6	MN	5-HT 2C receptor (HTR2C)
DMYO8T6	MT	DTT
DMYO8T6	MA	Modulator
DMYO8T6	RN	[Agonists of 5HT2C-receptors SCH 23390 and MK 212 incresase the force of rat aorta contraction in the presence of vasopressin and angiotensin II].Patol Fiziol Eksp Ter.2014 Oct-Dec;(4):17-29.
DMYO8T6	RU	https://www.ncbi.nlm.nih.gov/pubmed/25980223

DMP4Q0J	DI	DMP4Q0J
DMP4Q0J	DN	MK-2894
DMP4Q0J	MI	TT79WV3
DMP4Q0J	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DMP4Q0J	MT	DTT
DMP4Q0J	MA	Antagonist
DMP4Q0J	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 343).
DMP4Q0J	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=343

DM5EQ7F	DI	DM5EQ7F
DM5EQ7F	DN	MK-3901
DM5EQ7F	MI	TT2THBD
DM5EQ7F	MN	P2X purinoceptor 3 (P2RX3)
DM5EQ7F	MT	DTT
DM5EQ7F	MA	Antagonist
DM5EQ7F	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 480).
DM5EQ7F	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=480

DMS7C6R	DI	DMS7C6R
DMS7C6R	DN	MK-5046
DMS7C6R	MI	TTHYDUM
DMS7C6R	MN	Bombesin receptor (BS)
DMS7C6R	MT	DTT
DMS7C6R	MA	Agonist
DMS7C6R	RN	Antiobesity effect of MK-5046, a novel bombesin receptor subtype-3 agonist. J Pharmacol Exp Ther. 2011 Feb;336(2):356-64.
DMS7C6R	RU	https://pubmed.ncbi.nlm.nih.gov/21036912

DMS7C6R	DI	DMS7C6R
DMS7C6R	DN	MK-5046
DMS7C6R	MI	TTC1MVT
DMS7C6R	MN	Gastrin-releasing peptide receptor (GRPR)
DMS7C6R	MT	DTT
DMS7C6R	MA	Agonist
DMS7C6R	RN	Comparative pharmacology of bombesin receptor subtype-3, nonpeptide agonist MK-5046, a universal peptide agonist, and peptide antagonist Bantag-1 for human bombesin receptors. J Pharmacol Exp Ther. 2013 Oct;347(1):100-16.
DMS7C6R	RU	https://pubmed.ncbi.nlm.nih.gov/23892571

DMU8VRB	DI	DMU8VRB
DMU8VRB	DN	MK-5435
DMU8VRB	MI	TTVBPDM
DMU8VRB	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMU8VRB	MT	DTT
DMU8VRB	MA	Modulator (allosteric modulator)
DMU8VRB	RN	Synthesis, characterization, and monkey PET studies of [ ]MK-1312, a PET tracer for quantification of mGluR1 receptor occupancy by MK-5435. Synapse. 2011 Feb;65(2):125-35.
DMU8VRB	RU	https://pubmed.ncbi.nlm.nih.gov/20524178

DMLWMZ4	DI	DMLWMZ4
DMLWMZ4	DN	MK-5596
DMLWMZ4	MI	TT6OEDT
DMLWMZ4	MN	Cannabinoid receptor 1 (CB1)
DMLWMZ4	MT	DTT
DMLWMZ4	MA	Agonist
DMLWMZ4	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 56).
DMLWMZ4	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=56

DMR9C4Q	DI	DMR9C4Q
DMR9C4Q	DN	MK-6892
DMR9C4Q	MI	TTWNV8U
DMR9C4Q	MN	Nicotinic acid receptor (HCAR2)
DMR9C4Q	MT	DTT
DMR9C4Q	MA	Agonist
DMR9C4Q	RN	Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia. ACS Med Chem Lett. 2011 Nov 24;3(1):63-8.
DMR9C4Q	RU	https://pubmed.ncbi.nlm.nih.gov/24900372

DM4YQV0	DI	DM4YQV0
DM4YQV0	DN	MK-771
DM4YQV0	MI	TT4J8MF
DM4YQV0	MN	Thyrotropin-releasing hormone receptor (TRHR)
DM4YQV0	MT	DTT
DM4YQV0	MA	Modulator
DM4YQV0	RN	TRH analog MK-771 reverses neurochemical and learning deficits in medial septal-lesioned rats. Peptides. 1989 Jan-Feb;10(1):121-4.
DM4YQV0	RU	https://www.ncbi.nlm.nih.gov/pubmed/2501767

DM3EP59	DI	DM3EP59
DM3EP59	DN	MK-7725
DM3EP59	MI	TTKYEPM
DM3EP59	MN	Bombesin-like receptor 3 (BRS3)
DM3EP59	MT	DTT
DM3EP59	MA	Agonist
DM3EP59	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8502).
DM3EP59	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8502

DMKEG2B	DI	DMKEG2B
DMKEG2B	DN	MK-9
DMKEG2B	MI	TTNI91K
DMKEG2B	MN	Melanocortin receptor 3 (MC3R)
DMKEG2B	MT	DTT
DMKEG2B	MA	Inhibitor
DMKEG2B	RN	Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95.
DMKEG2B	RU	https://pubmed.ncbi.nlm.nih.gov/18088090

DM4ZNOU	DI	DM4ZNOU
DM4ZNOU	DN	ML 10375
DM4ZNOU	MI	TT07C3Y
DM4ZNOU	MN	5-HT 4 receptor (HTR4)
DM4ZNOU	MT	DTT
DM4ZNOU	MA	Antagonist
DM4ZNOU	RN	Exploration of the ligand binding site of the human 5-HT(4) receptor by site-directed mutagenesis and molecular modeling. Br J Pharmacol. 2000 Jun;130(3):527-38.
DM4ZNOU	RU	https://pubmed.ncbi.nlm.nih.gov/10821780

DMM5P8Q	DI	DMM5P8Q
DMM5P8Q	DN	ML-10302
DMM5P8Q	MI	TT07C3Y
DMM5P8Q	MN	5-HT 4 receptor (HTR4)
DMM5P8Q	MT	DTT
DMM5P8Q	MA	Modulator
DMM5P8Q	RN	Intestinal motor stimulation by the 5-HT4 receptor agonist ML10302: differential involvement of tachykininergic pathways in the canine small bowel ... Neurogastroenterol Motil. 2001 Dec;13(6):543-53.
DMM5P8Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/11903915

DMPB7EL	DI	DMPB7EL
DMPB7EL	DN	ML169
DMPB7EL	MI	TTOXS3C
DMPB7EL	MN	Muscarinic acetylcholine receptor (CHRM)
DMPB7EL	MT	DTT
DMPB7EL	MA	Modulator (allosteric modulator)
DMPB7EL	RN	Targeting selective activation of M(1) for the treatment of Alzheimer's disease: further chemical optimization and pharmacological characterization of the M(1) positive allosteric modulator ML169. ACS Chem Neurosci. 2012 Nov 21;3(11):884-95.
DMPB7EL	RU	https://pubmed.ncbi.nlm.nih.gov/23173069

DMHJCN6	DI	DMHJCN6
DMHJCN6	DN	ML-18
DMHJCN6	MI	TTHYDUM
DMHJCN6	MN	Bombesin receptor (BS)
DMHJCN6	MT	DTT
DMHJCN6	MA	Antagonist
DMHJCN6	RN	ML-18 is a non-peptide bombesin receptor subtype-3 antagonist which inhibits lung cancer growth. Peptides. 2015 Feb;64:55-61.
DMHJCN6	RU	https://pubmed.ncbi.nlm.nih.gov/25554218

DM15YL0	DI	DM15YL0
DM15YL0	DN	ML204
DM15YL0	MI	TTX0H5W
DM15YL0	MN	Short transient receptor potential channel 4 (TRPC4)
DM15YL0	MT	DTT
DM15YL0	MA	Blocker (channel blocker)
DM15YL0	RN	Identification of ML204, a novel potent antagonist that selectively modulates native TRPC4/C5 ion channels. J Biol Chem. 2011 Sep 23;286(38):33436-46.
DM15YL0	RU	https://pubmed.ncbi.nlm.nih.gov/21795696

DM15YL0	DI	DM15YL0
DM15YL0	DN	ML204
DM15YL0	MI	TT32NQ1
DM15YL0	MN	Short transient receptor potential channel 5 (TRPC5)
DM15YL0	MT	DTT
DM15YL0	MA	Blocker (channel blocker)
DM15YL0	RN	Identification of ML204, a novel potent antagonist that selectively modulates native TRPC4/C5 ion channels. J Biol Chem. 2011 Sep 23;286(38):33436-46.
DM15YL0	RU	https://pubmed.ncbi.nlm.nih.gov/21795696

DMFAUGP	DI	DMFAUGP
DMFAUGP	DN	ML213
DMFAUGP	MI	TT8HGRW
DMFAUGP	MN	Voltage-gated potassium channel Kv7.4 (KCNQ4)
DMFAUGP	MT	DTT
DMFAUGP	MA	Activator
DMFAUGP	RN	Discovery, Synthesis, and Structure Activity Relationship of a Series of N-Aryl- bicyclo[2.2.1]heptane-2-carboxamides: Characterization of ML213 as a Novel KCNQ2 and KCNQ4 Potassium Channel Opener. ACS Chem Neurosci. 2011 Oct 19;2(10):572-577.
DMFAUGP	RU	https://pubmed.ncbi.nlm.nih.gov/22125664

DM3D21X	DI	DM3D21X
DM3D21X	DN	ML218
DM3D21X	MI	TT729IR
DM3D21X	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DM3D21X	MT	DTT
DM3D21X	MA	Blocker (channel blocker)
DM3D21X	RN	The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson's Disease. ACS Chem Neurosci. 2011 Dec 21;2(12):730-742.
DM3D21X	RU	https://pubmed.ncbi.nlm.nih.gov/22368764

DM3D21X	DI	DM3D21X
DM3D21X	DN	ML218
DM3D21X	MI	TTZPWGN
DM3D21X	MN	Voltage-gated calcium channel alpha Cav3.2 (CACNA1H)
DM3D21X	MT	DTT
DM3D21X	MA	Blocker (channel blocker)
DM3D21X	RN	The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson's Disease. ACS Chem Neurosci. 2011 Dec 21;2(12):730-742.
DM3D21X	RU	https://pubmed.ncbi.nlm.nih.gov/22368764

DM3D21X	DI	DM3D21X
DM3D21X	DN	ML218
DM3D21X	MI	TTQZFTH
DM3D21X	MN	Voltage-gated calcium channel alpha Cav3.3 (CACNA1I)
DM3D21X	MT	DTT
DM3D21X	MA	Blocker (channel blocker)
DM3D21X	RN	The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson's Disease. ACS Chem Neurosci. 2011 Dec 21;2(12):730-742.
DM3D21X	RU	https://pubmed.ncbi.nlm.nih.gov/22368764

DM3OEP4	DI	DM3OEP4
DM3OEP4	DN	ML221
DM3OEP4	MI	TTJ8E43
DM3OEP4	MN	Apelin receptor (APLNR)
DM3OEP4	MT	DTT
DM3OEP4	MA	Antagonist
DM3OEP4	RN	Discovery of 4-oxo-6-((pyrimidin-2-ylthio)methyl)-4H-pyran-3-yl 4-nitrobenzoate (ML221) as a functional antagonist of the apelin (APJ) receptor. Bioorg Med Chem Lett. 2012 Nov 1;22(21):6656-60.
DM3OEP4	RU	https://pubmed.ncbi.nlm.nih.gov/23010269

DM8CIE4	DI	DM8CIE4
DM8CIE4	DN	ML233
DM8CIE4	MI	TTJ8E43
DM8CIE4	MN	Apelin receptor (APLNR)
DM8CIE4	MT	DTT
DM8CIE4	MA	Agonist
DM8CIE4	RN	Functional Agonists of the Apelin (APJ) Receptor. Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010.
DM8CIE4	RU	https://pubmed.ncbi.nlm.nih.gov/22834038

DMK6YC1	DI	DMK6YC1
DMK6YC1	DN	ML-253764
DMK6YC1	MI	TTD0CIQ
DMK6YC1	MN	Melanocortin receptor 4 (MC4R)
DMK6YC1	MT	DTT
DMK6YC1	MA	Inhibitor
DMK6YC1	RN	Mapping the binding site of melanocortin 4 receptor agonists: a hydrophobic pocket formed by I3.28(125), I3.32(129), and I7.42(291) is critical for... J Med Chem. 2006 Feb 9;49(3):911-22.
DMK6YC1	RU	https://pubmed.ncbi.nlm.nih.gov/16451057

DMQ98RS	DI	DMQ98RS
DMQ98RS	DN	ML277
DMQ98RS	MI	TT846HF
DMQ98RS	MN	Voltage-gated potassium channel Kv7.1 (KCNQ1)
DMQ98RS	MT	DTT
DMQ98RS	MA	Activator
DMQ98RS	RN	Identification of (R)-N-(4-(4-methoxyphenyl)thiazol-2-yl)-1-tosylpiperidine-2-carboxamide, ML277, as a novel, potent and selective K(v)7.1 (KCNQ1) potassium channel activator. Bioorg Med Chem Lett. 2012 Sep 15;22(18):5936-41.
DMQ98RS	RU	https://pubmed.ncbi.nlm.nih.gov/22910039

DMPOX4Q	DI	DMPOX4Q
DMPOX4Q	DN	ML290
DMPOX4Q	MI	TTMAHD1
DMPOX4Q	MN	Relaxin receptor 1 (RXFP1)
DMPOX4Q	MT	DTT
DMPOX4Q	MA	Modulator (allosteric modulator)
DMPOX4Q	RN	Discovery, optimization, and biological activity of the first potent and selective small-molecule agonist series of human relaxin receptor 1 (RXFP1). Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010.
DMPOX4Q	RU	https://pubmed.ncbi.nlm.nih.gov/23905199

DMY40UG	DI	DMY40UG
DMY40UG	DN	ML297
DMY40UG	MI	TTGM19J
DMY40UG	MN	Inward rectifier potassium channel Kir3.1 (KCNJ3)
DMY40UG	MT	DTT
DMY40UG	MA	Activator
DMY40UG	RN	ML297 (VU0456810), the first potent and selective activator of the GIRK potassium channel, displays antiepileptic properties in mice. ACS Chem Neurosci. 2013 Sep 18;4(9):1278-86.
DMY40UG	RU	https://pubmed.ncbi.nlm.nih.gov/23730969

DMNOREK	DI	DMNOREK
DMNOREK	DN	ML315
DMNOREK	MI	TTE6YDG
DMNOREK	MN	CDC-like kinase 1 (CLK1)
DMNOREK	MT	DTT
DMNOREK	MA	Inhibitor
DMNOREK	RN	Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315. Bioorg Med Chem Lett. 2013 Jun15;23(12):3654-61.
DMNOREK	RU	https://pubmed.ncbi.nlm.nih.gov/23642479

DMNOREK	DI	DMNOREK
DMNOREK	DN	ML315
DMNOREK	MI	TT85TPS
DMNOREK	MN	CDC-like kinase 2 (CLK2)
DMNOREK	MT	DTT
DMNOREK	MA	Inhibitor
DMNOREK	RN	Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315. Bioorg Med Chem Lett. 2013 Jun15;23(12):3654-61.
DMNOREK	RU	https://pubmed.ncbi.nlm.nih.gov/23642479

DMNOREK	DI	DMNOREK
DMNOREK	DN	ML315
DMNOREK	MI	TT1RFQP
DMNOREK	MN	CDC-like kinase 4 (CLK4)
DMNOREK	MT	DTT
DMNOREK	MA	Inhibitor
DMNOREK	RN	Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315. Bioorg Med Chem Lett. 2013 Jun15;23(12):3654-61.
DMNOREK	RU	https://pubmed.ncbi.nlm.nih.gov/23642479

DMNOREK	DI	DMNOREK
DMNOREK	DN	ML315
DMNOREK	MI	TTSBVFO
DMNOREK	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DMNOREK	MT	DTT
DMNOREK	MA	Inhibitor
DMNOREK	RN	Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315. Bioorg Med Chem Lett. 2013 Jun15;23(12):3654-61.
DMNOREK	RU	https://pubmed.ncbi.nlm.nih.gov/23642479

DM3S5UC	DI	DM3S5UC
DM3S5UC	DN	ML-3163
DM3S5UC	MI	TTXV4FI
DM3S5UC	MN	Albendazole monooxygenase (CYP3A4)
DM3S5UC	MT	DTT
DM3S5UC	MA	Inhibitor
DM3S5UC	RN	Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J Med Chem. 2003 Jul 17;46(15):3230-44.
DM3S5UC	RU	https://pubmed.ncbi.nlm.nih.gov/12852754

DM3S5UC	DI	DM3S5UC
DM3S5UC	DN	ML-3163
DM3S5UC	MI	TTVG215
DM3S5UC	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DM3S5UC	MT	DTT
DM3S5UC	MA	Inhibitor
DM3S5UC	RN	Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J Med Chem. 2003 Jul 17;46(15):3230-44.
DM3S5UC	RU	https://pubmed.ncbi.nlm.nih.gov/12852754

DM3S5UC	DI	DM3S5UC
DM3S5UC	DN	ML-3163
DM3S5UC	MI	TTYT93M
DM3S5UC	MN	MAP kinase p38 (MAPK12)
DM3S5UC	MT	DTT
DM3S5UC	MA	Inhibitor
DM3S5UC	RN	From imidazoles to pyrimidines: new inhibitors of cytokine release. J Med Chem. 2002 Jun 20;45(13):2733-40.
DM3S5UC	RU	https://pubmed.ncbi.nlm.nih.gov/12061876

DM3S5UC	DI	DM3S5UC
DM3S5UC	DN	ML-3163
DM3S5UC	MI	TTQBR95
DM3S5UC	MN	Stress-activated protein kinase 2a (p38 alpha)
DM3S5UC	MT	DTT
DM3S5UC	MA	Inhibitor
DM3S5UC	RN	From imidazoles to pyrimidines: new inhibitors of cytokine release. J Med Chem. 2002 Jun 20;45(13):2733-40.
DM3S5UC	RU	https://pubmed.ncbi.nlm.nih.gov/12061876

DM3S5UC	DI	DM3S5UC
DM3S5UC	DN	ML-3163
DM3S5UC	MI	TT73U6C
DM3S5UC	MN	Stress-activated protein kinase 2b (p38 beta)
DM3S5UC	MT	DTT
DM3S5UC	MA	Inhibitor
DM3S5UC	RN	From imidazoles to pyrimidines: new inhibitors of cytokine release. J Med Chem. 2002 Jun 20;45(13):2733-40.
DM3S5UC	RU	https://pubmed.ncbi.nlm.nih.gov/12061876

DMVELYW	DI	DMVELYW
DMVELYW	DN	ML321
DMVELYW	MI	TTEX248
DMVELYW	MN	Dopamine D2 receptor (D2R)
DMVELYW	MT	DTT
DMVELYW	MA	Antagonist
DMVELYW	RN	Discovery, optimization, and characterization of a novel series of dopamine D2 versus D3 receptor selective antagonists. Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010.
DMVELYW	RU	https://pubmed.ncbi.nlm.nih.gov/24260782

DMXJY6W	DI	DMXJY6W
DMXJY6W	DN	ML-3375
DMXJY6W	MI	TTXV4FI
DMXJY6W	MN	Albendazole monooxygenase (CYP3A4)
DMXJY6W	MT	DTT
DMXJY6W	MA	Inhibitor
DMXJY6W	RN	Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J Med Chem. 2003 Jul 17;46(15):3230-44.
DMXJY6W	RU	https://pubmed.ncbi.nlm.nih.gov/12852754

DMXJY6W	DI	DMXJY6W
DMXJY6W	DN	ML-3375
DMXJY6W	MI	TTYT93M
DMXJY6W	MN	MAP kinase p38 (MAPK12)
DMXJY6W	MT	DTT
DMXJY6W	MA	Inhibitor
DMXJY6W	RN	Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J Med Chem. 2003 Jul 17;46(15):3230-44.
DMXJY6W	RU	https://pubmed.ncbi.nlm.nih.gov/12852754

DMXJY6W	DI	DMXJY6W
DMXJY6W	DN	ML-3375
DMXJY6W	MI	TTQBR95
DMXJY6W	MN	Stress-activated protein kinase 2a (p38 alpha)
DMXJY6W	MT	DTT
DMXJY6W	MA	Inhibitor
DMXJY6W	RN	Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J Med Chem. 2003 Jul 17;46(15):3230-44.
DMXJY6W	RU	https://pubmed.ncbi.nlm.nih.gov/12852754

DMXJY6W	DI	DMXJY6W
DMXJY6W	DN	ML-3375
DMXJY6W	MI	TT73U6C
DMXJY6W	MN	Stress-activated protein kinase 2b (p38 beta)
DMXJY6W	MT	DTT
DMXJY6W	MA	Inhibitor
DMXJY6W	RN	Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J Med Chem. 2003 Jul 17;46(15):3230-44.
DMXJY6W	RU	https://pubmed.ncbi.nlm.nih.gov/12852754

DMTQWI8	DI	DMTQWI8
DMTQWI8	DN	ML-3403
DMTQWI8	MI	TTXV4FI
DMTQWI8	MN	Albendazole monooxygenase (CYP3A4)
DMTQWI8	MT	DTT
DMTQWI8	MA	Inhibitor
DMTQWI8	RN	Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J Med Chem. 2003 Jul 17;46(15):3230-44.
DMTQWI8	RU	https://pubmed.ncbi.nlm.nih.gov/12852754

DMTQWI8	DI	DMTQWI8
DMTQWI8	DN	ML-3403
DMTQWI8	MI	TTYT93M
DMTQWI8	MN	MAP kinase p38 (MAPK12)
DMTQWI8	MT	DTT
DMTQWI8	MA	Inhibitor
DMTQWI8	RN	Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J Med Chem. 2003 Jul 17;46(15):3230-44.
DMTQWI8	RU	https://pubmed.ncbi.nlm.nih.gov/12852754

DMTQWI8	DI	DMTQWI8
DMTQWI8	DN	ML-3403
DMTQWI8	MI	TTQBR95
DMTQWI8	MN	Stress-activated protein kinase 2a (p38 alpha)
DMTQWI8	MT	DTT
DMTQWI8	MA	Inhibitor
DMTQWI8	RN	Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J Med Chem. 2003 Jul 17;46(15):3230-44.
DMTQWI8	RU	https://pubmed.ncbi.nlm.nih.gov/12852754

DMTQWI8	DI	DMTQWI8
DMTQWI8	DN	ML-3403
DMTQWI8	MI	TT73U6C
DMTQWI8	MN	Stress-activated protein kinase 2b (p38 beta)
DMTQWI8	MT	DTT
DMTQWI8	MA	Inhibitor
DMTQWI8	RN	Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J Med Chem. 2003 Jul 17;46(15):3230-44.
DMTQWI8	RU	https://pubmed.ncbi.nlm.nih.gov/12852754

DMR8N36	DI	DMR8N36
DMR8N36	DN	ML347
DMR8N36	MI	TTJNBQA
DMR8N36	MN	Activin receptor-like kinase 2 (ALK-2)
DMR8N36	MT	DTT
DMR8N36	MA	Inhibitor
DMR8N36	RN	Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.
DMR8N36	RU	https://pubmed.ncbi.nlm.nih.gov/23639540

DMR8N36	DI	DMR8N36
DMR8N36	DN	ML347
DMR8N36	MI	TTGYPTC
DMR8N36	MN	Activin receptor-like kinase-1 (ACVRL1)
DMR8N36	MT	DTT
DMR8N36	MA	Inhibitor
DMR8N36	RN	Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.
DMR8N36	RU	https://pubmed.ncbi.nlm.nih.gov/23639540

DMR8N36	DI	DMR8N36
DMR8N36	DN	ML347
DMR8N36	MI	TTGKF90
DMR8N36	MN	Bone morphogenetic protein receptor (BMPR2)
DMR8N36	MT	DTT
DMR8N36	MA	Inhibitor
DMR8N36	RN	Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.
DMR8N36	RU	https://pubmed.ncbi.nlm.nih.gov/23639540

DMXJASC	DI	DMXJASC
DMXJASC	DN	ML375
DMXJASC	MI	TTOXS3C
DMXJASC	MN	Muscarinic acetylcholine receptor (CHRM)
DMXJASC	MT	DTT
DMXJASC	MA	Modulator (allosteric modulator)
DMXJASC	RN	Discovery of the first M5-selective and CNS penetrant negative allosteric modulator (NAM) of a muscarinic acetylcholine receptor: (S)-9b-(4-chlorophenyl)-1-(3,4-difluorobenzoyl)-2,3-dihydro-1H-imidazo[2,1-a]isoindol-5(9bH)-one (ML375). J Med Chem. 2013 Nov 27;56(22):9351-5.
DMXJASC	RU	https://pubmed.ncbi.nlm.nih.gov/24164599

DMQROC3	DI	DMQROC3
DMQROC3	DN	ML380
DMQROC3	MI	TTOXS3C
DMQROC3	MN	Muscarinic acetylcholine receptor (CHRM)
DMQROC3	MT	DTT
DMQROC3	MA	Modulator (allosteric modulator)
DMQROC3	RN	Development of a highly potent, novel M5 positive allosteric modulator (PAM) demonstrating CNS exposure: 1-((1H-indazol-5-yl)sulfoneyl)-N-ethyl-N-(2-(trifluoromethyl)benzyl)piperidine-4-carboxamide (ML380). J Med Chem. 2014 Sep 25;57(18):7804-10.
DMQROC3	RU	https://pubmed.ncbi.nlm.nih.gov/25147929

DMKCIP0	DI	DMKCIP0
DMKCIP0	DN	ML381
DMKCIP0	MI	TTOXS3C
DMKCIP0	MN	Muscarinic acetylcholine receptor (CHRM)
DMKCIP0	MT	DTT
DMKCIP0	MA	Antagonist
DMKCIP0	RN	Discovery, synthesis and characterization of a highly muscarinic acetylcholine receptor (mAChR)-selective M5-orthosteric antagonist, VU0488130 (ML381): a novel molecular probe. ChemMedChem. 2014 Aug;9(8):1677-82.
DMKCIP0	RU	https://pubmed.ncbi.nlm.nih.gov/24692176

DMKCIP0	DI	DMKCIP0
DMKCIP0	DN	ML381
DMKCIP0	MI	TTQ13Z5
DMKCIP0	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMKCIP0	MT	DTT
DMKCIP0	MA	Antagonist
DMKCIP0	RN	Discovery, synthesis and characterization of a highly muscarinic acetylcholine receptor (mAChR)-selective M5-orthosteric antagonist, VU0488130 (ML381): a novel molecular probe. ChemMedChem. 2014 Aug;9(8):1677-82.
DMKCIP0	RU	https://pubmed.ncbi.nlm.nih.gov/24692176

DMA0E2Q	DI	DMA0E2Q
DMA0E2Q	DN	ML398
DMA0E2Q	MI	TTE0A2F
DMA0E2Q	MN	Dopamine D4 receptor (D4R)
DMA0E2Q	MT	DTT
DMA0E2Q	MA	Antagonist
DMA0E2Q	RN	Discovery and Characterization of ML398, a Potent and Selective Antagonist of the D4 Receptor with in Vivo Activity. ACS Med Chem Lett. 2014 Jul 9;5(9):1060-4.
DMA0E2Q	RU	https://pubmed.ncbi.nlm.nih.gov/25221667

DMP13VE	DI	DMP13VE
DMP13VE	DN	ML9
DMP13VE	MI	TTRBT3W
DMP13VE	MN	Short transient receptor potential channel 6 (TRPC6)
DMP13VE	MT	DTT
DMP13VE	MA	Blocker (channel blocker)
DMP13VE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 491).
DMP13VE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=491

DMTU0IG	DI	DMTU0IG
DMTU0IG	DN	MLN-0905
DMTU0IG	MI	TTIYVQP
DMTU0IG	MN	Polo-like kinase 1 (PLK1)
DMTU0IG	MT	DTT
DMTU0IG	MA	Inhibitor
DMTU0IG	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2168).
DMTU0IG	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2168

DMYKNSP	DI	DMYKNSP
DMYKNSP	DN	MLN-120B
DMYKNSP	MI	TTRPDBG
DMYKNSP	MN	Inhibitor of nuclear factor kappa-B kinase (IKK)
DMYKNSP	MT	DTT
DMYKNSP	MA	Inhibitor
DMYKNSP	RN	A selective small molecule IkappaB Kinase beta inhibitor blocks nuclear factor kappaB-mediated inflammatory responses in human fibroblast-like syno... J Pharmacol Exp Ther. 2006 Jun;317(3):989-1001.
DMYKNSP	RU	https://pubmed.ncbi.nlm.nih.gov/16525037

DMPTBJZ	DI	DMPTBJZ
DMPTBJZ	DN	MLS1547
DMPTBJZ	MI	TTEX248
DMPTBJZ	MN	Dopamine D2 receptor (D2R)
DMPTBJZ	MT	DTT
DMPTBJZ	MA	Agonist
DMPTBJZ	RN	Discovery and characterization of a G protein-biased agonist that inhibits beta-arrestin recruitment to the D2 dopamine receptor. Mol Pharmacol. 2014 Jul;86(1):96-105.
DMPTBJZ	RU	https://pubmed.ncbi.nlm.nih.gov/24755247

DMT1NP8	DI	DMT1NP8
DMT1NP8	DN	MM 11253
DMT1NP8	MI	TT1Q3IE
DMT1NP8	MN	Retinoic acid receptor gamma (RARG)
DMT1NP8	MT	DTT
DMT1NP8	MA	Antagonist
DMT1NP8	RN	Modulation of retinoic acid receptor function alters the growth inhibitory response of oral SCC cells to retinoids. Oncogene. 2000 Mar 9;19(11):1457-65.
DMT1NP8	RU	https://pubmed.ncbi.nlm.nih.gov/10723137

DMB74MS	DI	DMB74MS
DMB74MS	DN	MM3A6S
DMB74MS	MI	TTKWM86
DMB74MS	MN	Opioid receptor mu (MOP)
DMB74MS	MT	DTT
DMB74MS	MA	Inhibitor
DMB74MS	RN	Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5.
DMB74MS	RU	https://pubmed.ncbi.nlm.nih.gov/16777416

DM9PGQI	DI	DM9PGQI
DM9PGQI	DN	MM3B6S
DM9PGQI	MI	TTKWM86
DM9PGQI	MN	Opioid receptor mu (MOP)
DM9PGQI	MT	DTT
DM9PGQI	MA	Inhibitor
DM9PGQI	RN	Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5.
DM9PGQI	RU	https://pubmed.ncbi.nlm.nih.gov/16777416

DMUL4PE	DI	DMUL4PE
DMUL4PE	DN	MMB-4
DMUL4PE	MI	TT1RS9F
DMUL4PE	MN	Acetylcholinesterase (AChE)
DMUL4PE	MT	DTT
DMUL4PE	MA	Activator
DMUL4PE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2465).
DMUL4PE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2465

DMUWVGP	DI	DMUWVGP
DMUWVGP	DN	MMDA
DMUWVGP	MI	TTJQOD7
DMUWVGP	MN	5-HT 2A receptor (HTR2A)
DMUWVGP	MT	DTT
DMUWVGP	MA	Agonist
DMUWVGP	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMUWVGP	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMUWVGP	DI	DMUWVGP
DMUWVGP	DN	MMDA
DMUWVGP	MI	TTVBI8W
DMUWVGP	MN	Dopamine transporter (DAT)
DMUWVGP	MT	DTT
DMUWVGP	MA	Modulator
DMUWVGP	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMUWVGP	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMUWVGP	DI	DMUWVGP
DMUWVGP	DN	MMDA
DMUWVGP	MI	TT3WG5C
DMUWVGP	MN	Monoamine oxidase type A (MAO-A)
DMUWVGP	MT	DTT
DMUWVGP	MA	Antagonist
DMUWVGP	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMUWVGP	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMUWVGP	DI	DMUWVGP
DMUWVGP	DN	MMDA
DMUWVGP	MI	TTGP7BY
DMUWVGP	MN	Monoamine oxidase type B (MAO-B)
DMUWVGP	MT	DTT
DMUWVGP	MA	Antagonist
DMUWVGP	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMUWVGP	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMUWVGP	DI	DMUWVGP
DMUWVGP	DN	MMDA
DMUWVGP	MI	TTAWNKZ
DMUWVGP	MN	Norepinephrine transporter (NET)
DMUWVGP	MT	DTT
DMUWVGP	MA	Modulator
DMUWVGP	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMUWVGP	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMUWVGP	DI	DMUWVGP
DMUWVGP	DN	MMDA
DMUWVGP	MI	TT3ROYC
DMUWVGP	MN	Serotonin transporter (SERT)
DMUWVGP	MT	DTT
DMUWVGP	MA	Modulator
DMUWVGP	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMUWVGP	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMUWVGP	DI	DMUWVGP
DMUWVGP	DN	MMDA
DMUWVGP	MI	TTNZRI3
DMUWVGP	MN	Synaptic vesicle amine transporter (SLC18A2)
DMUWVGP	MT	DTT
DMUWVGP	MA	Antagonist
DMUWVGP	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMUWVGP	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMH1YN6	DI	DMH1YN6
DMH1YN6	DN	MMI-175
DMH1YN6	MI	TT8JRS7
DMH1YN6	MN	Beta-secretase (BACE)
DMH1YN6	MT	DTT
DMH1YN6	MA	Inhibitor
DMH1YN6	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMH1YN6	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM38N2K	DI	DM38N2K
DM38N2K	DN	MMI270
DM38N2K	MI	TTYG6BU
DM38N2K	MN	Aggrecanase-1 (ADAMTS4)
DM38N2K	MT	DTT
DM38N2K	MA	Inhibitor
DM38N2K	RN	Synthesis and biological evaluation of biphenylsulfonamide carboxylate aggrecanase-1 inhibitors. Bioorg Med Chem Lett. 2006 Jan 15;16(2):311-6.
DM38N2K	RU	https://pubmed.ncbi.nlm.nih.gov/16275085

DM38N2K	DI	DM38N2K
DM38N2K	DN	MMI270
DM38N2K	MI	TTIQSC1
DM38N2K	MN	Bacterial Lethal factor (Bact lef)
DM38N2K	MT	DTT
DM38N2K	MA	Inhibitor
DM38N2K	RN	The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection. Bioorg Med Chem Lett. 2006 Feb 15;16(4):964-8.
DM38N2K	RU	https://pubmed.ncbi.nlm.nih.gov/16338135

DM38N2K	DI	DM38N2K
DM38N2K	DN	MMI270
DM38N2K	MI	TTANPDJ
DM38N2K	MN	Carbonic anhydrase II (CA-II)
DM38N2K	MT	DTT
DM38N2K	MA	Inhibitor
DM38N2K	RN	Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with su... Bioorg Med Chem. 2007 Mar 15;15(6):2298-311.
DM38N2K	RU	https://pubmed.ncbi.nlm.nih.gov/17276072

DM38N2K	DI	DM38N2K
DM38N2K	DN	MMI270
DM38N2K	MI	TT2LVK8
DM38N2K	MN	Carbonic anhydrase IX (CA-IX)
DM38N2K	MT	DTT
DM38N2K	MA	Inhibitor
DM38N2K	RN	Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with su... Bioorg Med Chem. 2007 Mar 15;15(6):2298-311.
DM38N2K	RU	https://pubmed.ncbi.nlm.nih.gov/17276072

DM38N2K	DI	DM38N2K
DM38N2K	DN	MMI270
DM38N2K	MI	TTMX39J
DM38N2K	MN	Matrix metalloproteinase-1 (MMP-1)
DM38N2K	MT	DTT
DM38N2K	MA	Inhibitor
DM38N2K	RN	The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection. Bioorg Med Chem Lett. 2006 Feb 15;16(4):964-8.
DM38N2K	RU	https://pubmed.ncbi.nlm.nih.gov/16338135

DM38N2K	DI	DM38N2K
DM38N2K	DN	MMI270
DM38N2K	MI	TTHY57M
DM38N2K	MN	Matrix metalloproteinase-13 (MMP-13)
DM38N2K	MT	DTT
DM38N2K	MA	Inhibitor
DM38N2K	RN	Heterocycle-based MMP inhibitors with P2' substituents. Bioorg Med Chem Lett. 2001 Apr 23;11(8):1009-13.
DM38N2K	RU	https://pubmed.ncbi.nlm.nih.gov/11327577

DM38N2K	DI	DM38N2K
DM38N2K	DN	MMI270
DM38N2K	MI	TTJ4QE7
DM38N2K	MN	Matrix metalloproteinase-14 (MMP-14)
DM38N2K	MT	DTT
DM38N2K	MA	Inhibitor
DM38N2K	RN	Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74.
DM38N2K	RU	https://pubmed.ncbi.nlm.nih.gov/17127067

DM38N2K	DI	DM38N2K
DM38N2K	DN	MMI270
DM38N2K	MI	TTLM12X
DM38N2K	MN	Matrix metalloproteinase-2 (MMP-2)
DM38N2K	MT	DTT
DM38N2K	MA	Inhibitor
DM38N2K	RN	Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors. Bioorg Med Chem Lett. 1999 Jun 21;9(12):1691-6.
DM38N2K	RU	https://pubmed.ncbi.nlm.nih.gov/10397503

DM38N2K	DI	DM38N2K
DM38N2K	DN	MMI270
DM38N2K	MI	TTUZ2L5
DM38N2K	MN	Matrix metalloproteinase-3 (MMP-3)
DM38N2K	MT	DTT
DM38N2K	MA	Inhibitor
DM38N2K	RN	Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002 Sep;2(9):657-72.
DM38N2K	RU	https://pubmed.ncbi.nlm.nih.gov/12209155

DM38N2K	DI	DM38N2K
DM38N2K	DN	MMI270
DM38N2K	MI	TTMTWOS
DM38N2K	MN	Matrix metalloproteinase-7 (MMP-7)
DM38N2K	MT	DTT
DM38N2K	MA	Inhibitor
DM38N2K	RN	Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74.
DM38N2K	RU	https://pubmed.ncbi.nlm.nih.gov/17127067

DM38N2K	DI	DM38N2K
DM38N2K	DN	MMI270
DM38N2K	MI	TTGA1IV
DM38N2K	MN	Matrix metalloproteinase-8 (MMP-8)
DM38N2K	MT	DTT
DM38N2K	MA	Inhibitor
DM38N2K	RN	Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors. J Med Chem. 1999 Nov 4;42(22):4547-62.
DM38N2K	RU	https://pubmed.ncbi.nlm.nih.gov/10579818

DM38N2K	DI	DM38N2K
DM38N2K	DN	MMI270
DM38N2K	MI	TT6X50U
DM38N2K	MN	Matrix metalloproteinase-9 (MMP-9)
DM38N2K	MT	DTT
DM38N2K	MA	Inhibitor
DM38N2K	RN	Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors. Bioorg Med Chem Lett. 1999 Jun 21;9(12):1691-6.
DM38N2K	RU	https://pubmed.ncbi.nlm.nih.gov/10397503

DMVCNBH	DI	DMVCNBH
DMVCNBH	DN	MMP-408
DMVCNBH	MI	TTXZ0KQ
DMVCNBH	MN	Matrix metalloproteinase-12 (MMP-12)
DMVCNBH	MT	DTT
DMVCNBH	MA	Inhibitor
DMVCNBH	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1636).
DMVCNBH	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1636

DMWMZL7	DI	DMWMZL7
DMWMZL7	DN	MMPIP
DMWMZL7	MI	TT0I76D
DMWMZL7	MN	Metabotropic glutamate receptor 7 (mGluR7)
DMWMZL7	MT	DTT
DMWMZL7	MA	Modulator (allosteric modulator)
DMWMZL7	RN	Context-dependent pharmacology exhibited by negative allosteric modulators of metabotropic glutamate receptor 7. Mol Pharmacol. 2010 Mar;77(3):459-68.
DMWMZL7	RU	https://pubmed.ncbi.nlm.nih.gov/20026717

DM1XY5F	DI	DM1XY5F
DM1XY5F	DN	MN-462
DM1XY5F	MI	TTP18AY
DM1XY5F	MN	Carboxypeptidase B2 (CPB2)
DM1XY5F	MT	DTT
DM1XY5F	MA	Inhibitor
DM1XY5F	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1594).
DM1XY5F	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1594

DMBJFH9	DI	DMBJFH9
DMBJFH9	DN	MNI-135
DMBJFH9	MI	TTXJ47W
DMBJFH9	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMBJFH9	MT	DTT
DMBJFH9	MA	Modulator (allosteric modulator)
DMBJFH9	RN	A novel family of potent negative allosteric modulators of group II metabotropic glutamate receptors. J Pharmacol Exp Ther. 2007 Jul;322(1):254-64.
DMBJFH9	RU	https://pubmed.ncbi.nlm.nih.gov/17416742

DMBJFH9	DI	DMBJFH9
DMBJFH9	DN	MNI-135
DMBJFH9	MI	TT8A9EF
DMBJFH9	MN	Metabotropic glutamate receptor 3 (mGluR3)
DMBJFH9	MT	DTT
DMBJFH9	MA	Modulator (allosteric modulator)
DMBJFH9	RN	A novel family of potent negative allosteric modulators of group II metabotropic glutamate receptors. J Pharmacol Exp Ther. 2007 Jul;322(1):254-64.
DMBJFH9	RU	https://pubmed.ncbi.nlm.nih.gov/17416742

DM5C9VI	DI	DM5C9VI
DM5C9VI	DN	MNI-136
DM5C9VI	MI	TTXJ47W
DM5C9VI	MN	Metabotropic glutamate receptor 2 (mGluR2)
DM5C9VI	MT	DTT
DM5C9VI	MA	Modulator (allosteric modulator)
DM5C9VI	RN	A novel family of potent negative allosteric modulators of group II metabotropic glutamate receptors. J Pharmacol Exp Ther. 2007 Jul;322(1):254-64.
DM5C9VI	RU	https://pubmed.ncbi.nlm.nih.gov/17416742

DM5C9VI	DI	DM5C9VI
DM5C9VI	DN	MNI-136
DM5C9VI	MI	TT8A9EF
DM5C9VI	MN	Metabotropic glutamate receptor 3 (mGluR3)
DM5C9VI	MT	DTT
DM5C9VI	MA	Modulator (allosteric modulator)
DM5C9VI	RN	A novel family of potent negative allosteric modulators of group II metabotropic glutamate receptors. J Pharmacol Exp Ther. 2007 Jul;322(1):254-64.
DM5C9VI	RU	https://pubmed.ncbi.nlm.nih.gov/17416742

DMKRI1J	DI	DMKRI1J
DMKRI1J	DN	MNI-137
DMKRI1J	MI	TTXJ47W
DMKRI1J	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMKRI1J	MT	DTT
DMKRI1J	MA	Modulator (allosteric modulator)
DMKRI1J	RN	A novel family of potent negative allosteric modulators of group II metabotropic glutamate receptors. J Pharmacol Exp Ther. 2007 Jul;322(1):254-64.
DMKRI1J	RU	https://pubmed.ncbi.nlm.nih.gov/17416742

DMKRI1J	DI	DMKRI1J
DMKRI1J	DN	MNI-137
DMKRI1J	MI	TT8A9EF
DMKRI1J	MN	Metabotropic glutamate receptor 3 (mGluR3)
DMKRI1J	MT	DTT
DMKRI1J	MA	Modulator (allosteric modulator)
DMKRI1J	RN	A novel family of potent negative allosteric modulators of group II metabotropic glutamate receptors. J Pharmacol Exp Ther. 2007 Jul;322(1):254-64.
DMKRI1J	RU	https://pubmed.ncbi.nlm.nih.gov/17416742

DMLYVQB	DI	DMLYVQB
DMLYVQB	DN	MOD-3012
DMLYVQB	MI	TTFEZ5Q
DMLYVQB	MN	Coagulation factor IX (F9)
DMLYVQB	MT	DTT
DMLYVQB	MA	Modulator
DMLYVQB	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2364).
DMLYVQB	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2364

DMKWBNA	DI	DMKWBNA
DMKWBNA	DN	MOD-5023
DMKWBNA	MI	TTF0EGX
DMKWBNA	MN	Coagulation factor VII (F7)
DMKWBNA	MT	DTT
DMKWBNA	MA	Modulator
DMKWBNA	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2363).
DMKWBNA	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2363

DMB5OG8	DI	DMB5OG8
DMB5OG8	DN	modified HA14-1 compounds (cancer)
DMB5OG8	MI	TTJGNVC
DMB5OG8	MN	Apoptosis regulator Bcl-2 (BCL-2)
DMB5OG8	MT	DTT
DMB5OG8	MA	Modulator
DMB5OG8	RN	The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism. Mol Cancer Ther. 2004 Dec;3(12):1513-24.
DMB5OG8	RU	https://pubmed.ncbi.nlm.nih.gov/15634644

DMPYBHI	DI	DMPYBHI
DMPYBHI	DN	moexiprilat
DMPYBHI	MI	TTL69WB
DMPYBHI	MN	Angiotensin-converting enzyme (ACE)
DMPYBHI	MT	DTT
DMPYBHI	MA	Modulator
DMPYBHI	RN	Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril. J Pharmacol Exp Ther. 1995 Nov;275(2):854-63.
DMPYBHI	RU	https://www.ncbi.nlm.nih.gov/pubmed/7473177

DMSF8UC	DI	DMSF8UC
DMSF8UC	DN	MOL 6131
DMSF8UC	MI	TTM1TDX
DMSF8UC	MN	Tryptase alpha/beta-1 (Tryptase)
DMSF8UC	MT	DTT
DMSF8UC	MA	Inhibitor
DMSF8UC	RN	Tryptase inhibition blocks airway inflammation in a mouse asthma model. J Immunol. 2002 Feb 15;168(4):1992-2000.
DMSF8UC	RU	https://pubmed.ncbi.nlm.nih.gov/11823536

DM0OWTS	DI	DM0OWTS
DM0OWTS	DN	MOLASSAMIDE
DM0OWTS	MI	TT3NKIB
DM0OWTS	MN	Pancreatic elastase 1 (CELA1)
DM0OWTS	MT	DTT
DM0OWTS	MA	Inhibitor
DM0OWTS	RN	Molassamide, a depsipeptide serine protease inhibitor from the marine cyanobacterium Dichothrix utahensis. J Nat Prod. 2010 Mar 26;73(3):459-62.
DM0OWTS	RU	https://pubmed.ncbi.nlm.nih.gov/20020755

DMZ6H1X	DI	DMZ6H1X
DMZ6H1X	DN	Molecule 11
DMZ6H1X	MI	TTCIHJA
DMZ6H1X	MN	Coagulation factor Xa (F10)
DMZ6H1X	MT	DTT
DMZ6H1X	MA	Inhibitor
DMZ6H1X	RN	Role of tissue factor pathway inhibitor in the regulation of tissue factor-dependent blood coagulation. Cardiovasc Drug Rev. 2002 Winter;20(1):67-80.
DMZ6H1X	RU	https://pubmed.ncbi.nlm.nih.gov/12070535

DMA7T0N	DI	DMA7T0N
DMA7T0N	DN	Molecule 21
DMA7T0N	MI	TTPNGDE
DMA7T0N	MN	Prostaglandin E2 receptor EP3 (PTGER3)
DMA7T0N	MT	DTT
DMA7T0N	MA	Antagonist
DMA7T0N	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 342).
DMA7T0N	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=342

DM4OLAZ	DI	DM4OLAZ
DM4OLAZ	DN	MOLEPHANTIN
DM4OLAZ	MI	TTSXVID
DM4OLAZ	MN	Nuclear factor NF-kappa-B (NFKB)
DM4OLAZ	MT	DTT
DM4OLAZ	MA	Inhibitor
DM4OLAZ	RN	Quantitative structure-activity relationship of sesquiterpene lactones as inhibitors of the transcription factor NF-kappaB. J Med Chem. 2004 Nov 18;47(24):6042-54.
DM4OLAZ	RU	https://pubmed.ncbi.nlm.nih.gov/15537359

DMGNX6M	DI	DMGNX6M
DMGNX6M	DN	MOLEPHANTININ
DMGNX6M	MI	TTSXVID
DMGNX6M	MN	Nuclear factor NF-kappa-B (NFKB)
DMGNX6M	MT	DTT
DMGNX6M	MA	Inhibitor
DMGNX6M	RN	Quantitative structure-activity relationship of sesquiterpene lactones as inhibitors of the transcription factor NF-kappaB. J Med Chem. 2004 Nov 18;47(24):6042-54.
DMGNX6M	RU	https://pubmed.ncbi.nlm.nih.gov/15537359

DMLSEJN	DI	DMLSEJN
DMLSEJN	DN	Monastrol
DMLSEJN	MI	TTTRP0H
DMLSEJN	MN	Kinesin-like protein KIF11 (KIF11)
DMLSEJN	MT	DTT
DMLSEJN	MA	Inhibitor
DMLSEJN	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMLSEJN	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMNWCPB	DI	DMNWCPB
DMNWCPB	DN	Monocarboxylic acids
DMNWCPB	MI	DT8ZFIO
DMNWCPB	MN	Monocarboxylate transporter 7 (SLC16A6)
DMNWCPB	MT	DTP
DMNWCPB	MA	Substrate
DMNWCPB	RN	The Monocarboxylate Transporter SLC16A6 Regulates Adult Length in Zebrafish and Is Associated With Height in Humans. Front Physiol. 2019 Jan 14;9:1936.
DMNWCPB	RU	http://www.ncbi.nlm.nih.gov/pubmed/30692937

DM31YGM	DI	DM31YGM
DM31YGM	DN	Monoctanoin component C
DM31YGM	MI	TTRFOXJ
DM31YGM	MN	Protein kinase C gamma (PRKCG)
DM31YGM	MT	DTT
DM31YGM	MA	Inhibitor
DM31YGM	RN	Synthesis and characterization of the second cysteine-rich region of mouse skin PKCGh, Bioorg. Med. Chem. Lett. 6(4):353-356 (1996).
DM31YGM	RU	http://www.sciencedirect.com/science/article/pii/0960894X96000261

DM59CR0	DI	DM59CR0
DM59CR0	DN	MONODICTYOCHROMONE B
DM59CR0	MI	TTSZLWK
DM59CR0	MN	Aromatase (CYP19A1)
DM59CR0	MT	DTT
DM59CR0	MA	Inhibitor
DM59CR0	RN	Monodictyochromes A and B, dimeric xanthone derivatives from the marine algicolous fungus Monodictys putredinis. J Nat Prod. 2008 Nov;71(11):1793-9.
DM59CR0	RU	https://pubmed.ncbi.nlm.nih.gov/18939864

DMNJXHF	DI	DMNJXHF
DMNJXHF	DN	Monoisopropyl Ester Phosphonic Acid Group
DMNJXHF	MI	TTEB0GD
DMNJXHF	MN	Cholinesterase (BCHE)
DMNJXHF	MT	DTT
DMNJXHF	MA	Inhibitor
DMNJXHF	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMNJXHF	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMNJXHF	DI	DMNJXHF
DMNJXHF	DN	Monoisopropyl Ester Phosphonic Acid Group
DMNJXHF	MI	TT5DOVB
DMNJXHF	MN	Cytomegalovirus Protease (CMV UL80)
DMNJXHF	MT	DTT
DMNJXHF	MA	Inhibitor
DMNJXHF	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMNJXHF	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM0OFT6	DI	DM0OFT6
DM0OFT6	DN	Monoisopropylphosphorylserine
DM0OFT6	MI	TT1RS9F
DM0OFT6	MN	Acetylcholinesterase (AChE)
DM0OFT6	MT	DTT
DM0OFT6	MA	Inhibitor
DM0OFT6	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM0OFT6	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMU4JWM	DI	DMU4JWM
DMU4JWM	DN	monomethylfumarate
DMU4JWM	MI	TTWNV8U
DMU4JWM	MN	Nicotinic acid receptor (HCAR2)
DMU4JWM	MT	DTT
DMU4JWM	MA	Agonist
DMU4JWM	RN	The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist. Biochem Biophys Res Commun. 2008 Oct 31;375(4):562-5.
DMU4JWM	RU	https://pubmed.ncbi.nlm.nih.gov/18722346

DM4QO9G	DI	DM4QO9G
DM4QO9G	DN	Mononitrophenol
DM4QO9G	MI	DE4OGUF
DM4QO9G	MN	Cytochrome P450 102A1 (cyp102)
DM4QO9G	MT	DME
DM4QO9G	MA	Metabolism
DM4QO9G	RN	nan
DM4QO9G	RU	nan

DM4QO9G	DI	DM4QO9G
DM4QO9G	DN	Mononitrophenol
DM4QO9G	MI	DE0K82S
DM4QO9G	MN	Nitroreductase (NTR)
DM4QO9G	MT	DME
DM4QO9G	MA	Metabolism
DM4QO9G	RN	nan
DM4QO9G	RU	nan

DM4QO9G	DI	DM4QO9G
DM4QO9G	DN	Mononitrophenol
DM4QO9G	MI	DERUZL7
DM4QO9G	MN	Sulfotransferase 1A2 (SULT1A2)
DM4QO9G	MT	DME
DM4QO9G	MA	Metabolism
DM4QO9G	RN	cDNA cloning and expression of a new form of human aryl sulfotransferase. Int J Biochem Cell Biol. 1996 May;28(5):565-71.
DM4QO9G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8697101

DM4QO9G	DI	DM4QO9G
DM4QO9G	DN	Mononitrophenol
DM4QO9G	MI	DED5UR3
DM4QO9G	MN	Sulfotransferase 1B1 (SULT1B1)
DM4QO9G	MT	DME
DM4QO9G	MA	Metabolism
DM4QO9G	RN	Comparison of 2-aminophenol and 4-nitrophenol as in vitro probe substrates for the major human hepatic sulfotransferase, SULT1A1, demonstrates improved selectivity with 2-aminophenol. Biochem Pharmacol. 2007 Jul 15;74(2):352-8.
DM4QO9G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17506995

DMENSOZ	DI	DMENSOZ
DMENSOZ	DN	Monothioglycerol
DMENSOZ	MI	TTNGKET
DMENSOZ	MN	Prolyl endopeptidase (PREP)
DMENSOZ	MT	DTT
DMENSOZ	MA	Inhibitor
DMENSOZ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMENSOZ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMWR0J1	DI	DMWR0J1
DMWR0J1	DN	MORACHALCONE A
DMWR0J1	MI	TTSZLWK
DMWR0J1	MN	Aromatase (CYP19A1)
DMWR0J1	MT	DTT
DMWR0J1	MA	Inhibitor
DMWR0J1	RN	Aromatase inhibitors from Broussonetia papyrifera. J Nat Prod. 2001 Oct;64(10):1286-93.
DMWR0J1	RU	https://pubmed.ncbi.nlm.nih.gov/11678652

DM2OGZ5	DI	DM2OGZ5
DM2OGZ5	DN	Morin
DM2OGZ5	MI	TTOM3J0
DM2OGZ5	MN	Estrogen receptor beta (ESR2)
DM2OGZ5	MT	DTT
DM2OGZ5	MA	Inhibitor
DM2OGZ5	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DM2OGZ5	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DM2OGZ5	DI	DM2OGZ5
DM2OGZ5	DN	Morin
DM2OGZ5	MI	TT7AOUD
DM2OGZ5	MN	Fatty acid synthase (FASN)
DM2OGZ5	MT	DTT
DM2OGZ5	MA	Inhibitor
DM2OGZ5	RN	Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
DM2OGZ5	RU	https://pubmed.ncbi.nlm.nih.gov/16722653

DM2OGZ5	DI	DM2OGZ5
DM2OGZ5	DN	Morin
DM2OGZ5	MI	TTL53M6
DM2OGZ5	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DM2OGZ5	MT	DTT
DM2OGZ5	MA	Inhibitor
DM2OGZ5	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DM2OGZ5	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DM2OGZ5	DI	DM2OGZ5
DM2OGZ5	DN	Morin
DM2OGZ5	MI	TTHPFTS
DM2OGZ5	MN	Plasmodium Beta-hydroxyacyl-ACP dehydratase (Malaria FabZ)
DM2OGZ5	MT	DTT
DM2OGZ5	MA	Inhibitor
DM2OGZ5	RN	Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
DM2OGZ5	RU	https://pubmed.ncbi.nlm.nih.gov/16722653

DM2OGZ5	DI	DM2OGZ5
DM2OGZ5	DN	Morin
DM2OGZ5	MI	TTNX2CS
DM2OGZ5	MN	Plasmodium Enoyl-ACP reductase (Malaria fabI)
DM2OGZ5	MT	DTT
DM2OGZ5	MA	Inhibitor
DM2OGZ5	RN	Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
DM2OGZ5	RU	https://pubmed.ncbi.nlm.nih.gov/16722653

DM2OGZ5	DI	DM2OGZ5
DM2OGZ5	DN	Morin
DM2OGZ5	MI	TTBE4IR
DM2OGZ5	MN	Plasmodium Oxoacyl-[acyl-carrier protein] reductase (Malaria fabG)
DM2OGZ5	MT	DTT
DM2OGZ5	MA	Inhibitor
DM2OGZ5	RN	Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
DM2OGZ5	RU	https://pubmed.ncbi.nlm.nih.gov/16722653

DM2OGZ5	DI	DM2OGZ5
DM2OGZ5	DN	Morin
DM2OGZ5	MI	TTA592U
DM2OGZ5	MN	Urate anion exchanger 1 (URAT1)
DM2OGZ5	MT	DTT
DM2OGZ5	MA	Inhibitor
DM2OGZ5	RN	Morin (3,5,7,2',4'-pentahydroxyflavone) exhibits potent inhibitory actions on urate transport by the human urate anion transporter (hURAT1) express... Drug Metab Dispos. 2007 Jun;35(6):981-6.
DM2OGZ5	RU	https://pubmed.ncbi.nlm.nih.gov/17325024

DMB91UL	DI	DMB91UL
DMB91UL	DN	morphanthridine
DMB91UL	MI	TTELV3W
DMB91UL	MN	Transformation-sensitive protein p120 (TRPA1)
DMB91UL	MT	DTT
DMB91UL	MA	Activator
DMB91UL	RN	Tear gasses CN, CR, and CS are potent activators of the human TRPA1 receptor. Toxicol Appl Pharmacol. 2008 Sep 1;231(2):150-6.
DMB91UL	RU	https://pubmed.ncbi.nlm.nih.gov/18501939

DM9A1RY	DI	DM9A1RY
DM9A1RY	DN	MORPHICEPTIN
DM9A1RY	MI	TTKWM86
DM9A1RY	MN	Opioid receptor mu (MOP)
DM9A1RY	MT	DTT
DM9A1RY	MA	Inhibitor
DM9A1RY	RN	Synthesis and activity of endomorphin-2 and morphiceptin analogues with proline surrogates in position 2. Eur J Med Chem. 2010 Oct;45(10):4594-600.
DM9A1RY	RU	https://pubmed.ncbi.nlm.nih.gov/20692738

DMTHFSE	DI	DMTHFSE
DMTHFSE	DN	Morphinan Cyclic Imine analogue
DMTHFSE	MI	TTQW87Y
DMTHFSE	MN	Opioid receptor kappa (OPRK1)
DMTHFSE	MT	DTT
DMTHFSE	MA	Inhibitor
DMTHFSE	RN	Morphinan cyclic imines and pyrrolidines containing a constrained phenyl group: High affinity opioid agonists, Bioorg. Med. Chem. Lett. 5(24):2969-2974 (1995).
DMTHFSE	RU	http://www.sciencedirect.com/science/article/pii/0960894X95005221

DM9LQIA	DI	DM9LQIA
DM9LQIA	DN	MORPHINONE
DM9LQIA	MI	TTKWM86
DM9LQIA	MN	Opioid receptor mu (MOP)
DM9LQIA	MT	DTT
DM9LQIA	MA	Inhibitor
DM9LQIA	RN	Live cell monitoring of mu-opioid receptor-mediated G-protein activation reveals strong biological activity of close morphine biosynthetic precursors. J Biol Chem. 2007 Sep 14;282(37):27126-32.
DM9LQIA	RU	https://pubmed.ncbi.nlm.nih.gov/17616524

DM05L3S	DI	DM05L3S
DM05L3S	DN	Morpholino(1'H-phenothiazin-1'-yl)methanone
DM05L3S	MI	TTEB0GD
DM05L3S	MN	Cholinesterase (BCHE)
DM05L3S	MT	DTT
DM05L3S	MA	Inhibitor
DM05L3S	RN	Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorg Med Chem. 2010 Mar 15;18(6):2232-2244.
DM05L3S	RU	https://pubmed.ncbi.nlm.nih.gov/20181484

DMV5T1I	DI	DMV5T1I
DMV5T1I	DN	MP-529
DMV5T1I	MI	TTLYXIT
DMV5T1I	MN	Aurora kinase C (AURKC)
DMV5T1I	MT	DTT
DMV5T1I	MA	Inhibitor
DMV5T1I	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1936).
DMV5T1I	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1936

DMONDP1	DI	DMONDP1
DMONDP1	DN	MPC-MECA
DMONDP1	MI	TTJFY5U
DMONDP1	MN	Adenosine A3 receptor (ADORA3)
DMONDP1	MT	DTT
DMONDP1	MA	Agonist
DMONDP1	RN	[(3)H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors. Mol Pharmacol. 2000 May;57(5):968-75.
DMONDP1	RU	https://pubmed.ncbi.nlm.nih.gov/10779381

DMYX31S	DI	DMYX31S
DMYX31S	DN	MPDT
DMYX31S	MI	TTSQIFT
DMYX31S	MN	5-HT 1A receptor (HTR1A)
DMYX31S	MT	DTT
DMYX31S	MA	Antagonist
DMYX31S	RN	2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem. 2000 Mar 9;43(5):1011-8.
DMYX31S	RU	https://pubmed.ncbi.nlm.nih.gov/10715164

DMYX31S	DI	DMYX31S
DMYX31S	DN	MPDT
DMYX31S	MI	TT6MSOK
DMYX31S	MN	5-HT 1D receptor (HTR1D)
DMYX31S	MT	DTT
DMYX31S	MA	Antagonist
DMYX31S	RN	2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem. 2000 Mar 9;43(5):1011-8.
DMYX31S	RU	https://pubmed.ncbi.nlm.nih.gov/10715164

DMYX31S	DI	DMYX31S
DMYX31S	DN	MPDT
DMYX31S	MI	TTJQOD7
DMYX31S	MN	5-HT 2A receptor (HTR2A)
DMYX31S	MT	DTT
DMYX31S	MA	Antagonist
DMYX31S	RN	2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem. 2000 Mar 9;43(5):1011-8.
DMYX31S	RU	https://pubmed.ncbi.nlm.nih.gov/10715164

DMYX31S	DI	DMYX31S
DMYX31S	DN	MPDT
DMYX31S	MI	TTWJBZ5
DMYX31S	MN	5-HT 2C receptor (HTR2C)
DMYX31S	MT	DTT
DMYX31S	MA	Antagonist
DMYX31S	RN	2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem. 2000 Mar 9;43(5):1011-8.
DMYX31S	RU	https://pubmed.ncbi.nlm.nih.gov/10715164

DMYX31S	DI	DMYX31S
DMYX31S	DN	MPDT
DMYX31S	MI	TTRUFDT
DMYX31S	MN	5-HT 5A receptor (HTR5A)
DMYX31S	MT	DTT
DMYX31S	MA	Antagonist
DMYX31S	RN	2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem. 2000 Mar 9;43(5):1011-8.
DMYX31S	RU	https://pubmed.ncbi.nlm.nih.gov/10715164

DMYX31S	DI	DMYX31S
DMYX31S	DN	MPDT
DMYX31S	MI	TTJS8PY
DMYX31S	MN	5-HT 6 receptor (HTR6)
DMYX31S	MT	DTT
DMYX31S	MA	Antagonist
DMYX31S	RN	2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem. 2000 Mar 9;43(5):1011-8.
DMYX31S	RU	https://pubmed.ncbi.nlm.nih.gov/10715164

DMYX31S	DI	DMYX31S
DMYX31S	DN	MPDT
DMYX31S	MI	TTO9X1H
DMYX31S	MN	5-HT 7 receptor (HTR7)
DMYX31S	MT	DTT
DMYX31S	MA	Antagonist
DMYX31S	RN	2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem. 2000 Mar 9;43(5):1011-8.
DMYX31S	RU	https://pubmed.ncbi.nlm.nih.gov/10715164

DMJRK47	DI	DMJRK47
DMJRK47	DN	M-Phenoxybenzoic Acid For Cis-Isomer
DMJRK47	MI	TT5ZWB6
DMJRK47	MN	Dihydrodiol dehydrogenase type I (AKR1C3)
DMJRK47	MT	DTT
DMJRK47	MA	Inhibitor
DMJRK47	RN	Nonsteroidal anti-inflammatory drugs and their analogues as inhibitors of aldo-keto reductase AKR1C3: new lead compounds for the development of ant... Bioorg Med Chem Lett. 2005 Dec 1;15(23):5170-5.
DMJRK47	RU	https://pubmed.ncbi.nlm.nih.gov/16183274

DMJHQ9T	DI	DMJHQ9T
DMJHQ9T	DN	MPPG
DMJHQ9T	MI	TTICZ1O
DMJHQ9T	MN	Metabotropic glutamate receptor 4 (mGluR4)
DMJHQ9T	MT	DTT
DMJHQ9T	MA	Antagonist
DMJHQ9T	RN	Ligand binding to the amino-terminal domain of the mGluR4 subtype of metabotropic glutamate receptor. J Biol Chem. 1999 Apr 9;274(15):10008-13.
DMJHQ9T	RU	https://pubmed.ncbi.nlm.nih.gov/10187777

DMJHQ9T	DI	DMJHQ9T
DMJHQ9T	DN	MPPG
DMJHQ9T	MI	TTWRP2F
DMJHQ9T	MN	Metabotropic glutamate receptor 6 (mGluR6)
DMJHQ9T	MT	DTT
DMJHQ9T	MA	Antagonist
DMJHQ9T	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 294).
DMJHQ9T	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=294

DMJHQ9T	DI	DMJHQ9T
DMJHQ9T	DN	MPPG
DMJHQ9T	MI	TT0I76D
DMJHQ9T	MN	Metabotropic glutamate receptor 7 (mGluR7)
DMJHQ9T	MT	DTT
DMJHQ9T	MA	Antagonist
DMJHQ9T	RN	Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 2000 Dec;362(6):546-54.
DMJHQ9T	RU	https://pubmed.ncbi.nlm.nih.gov/11138847

DMJHQ9T	DI	DMJHQ9T
DMJHQ9T	DN	MPPG
DMJHQ9T	MI	TT0IFKL
DMJHQ9T	MN	Metabotropic glutamate receptor 8 (mGluR8)
DMJHQ9T	MT	DTT
DMJHQ9T	MA	Antagonist
DMJHQ9T	RN	Group III human metabotropic glutamate receptors 4, 7 and 8: molecular cloning, functional expression, and comparison of pharmacological properties in RGT cells. Brain Res Mol Brain Res. 1998 Jan;53(1-2):88-97.
DMJHQ9T	RU	https://pubmed.ncbi.nlm.nih.gov/9473604

DMFKG7C	DI	DMFKG7C
DMFKG7C	DN	MP-RM-1
DMFKG7C	MI	TTDC8N2
DMFKG7C	MN	Erbb3 tyrosine kinase receptor (Erbb-3)
DMFKG7C	MT	DTT
DMFKG7C	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1798).
DMFKG7C	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1798

DMWUK9G	DI	DMWUK9G
DMWUK9G	DN	MPrP
DMWUK9G	MI	TTZAYWL
DMWUK9G	MN	Estrogen receptor (ESR)
DMWUK9G	MT	DTT
DMWUK9G	MA	Inhibitor
DMWUK9G	RN	Analogs of methyl-piperidinopyrazole (MPP): antiestrogens with estrogen receptor alpha selective activity. Bioorg Med Chem Lett. 2009 Jan 1;19(1):108-10.
DMWUK9G	RU	https://pubmed.ncbi.nlm.nih.gov/19014882

DMQ357C	DI	DMQ357C
DMQ357C	DN	MQ1
DMQ357C	MI	TTX4RTB
DMQ357C	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMQ357C	MT	DTT
DMQ357C	MA	Modulator (allosteric modulator)
DMQ357C	RN	The MCH(1) receptor, an anti-obesity target, is allosterically inhibited by 8-methylquinoline derivatives possessing subnanomolar binding and long residence times. Br J Pharmacol. 2014 Mar;171(5):1287-98.
DMQ357C	RU	https://pubmed.ncbi.nlm.nih.gov/24670150

DMS7FC6	DI	DMS7FC6
DMS7FC6	DN	MR-1029
DMS7FC6	MI	TTQW87Y
DMS7FC6	MN	Opioid receptor kappa (OPRK1)
DMS7FC6	MT	DTT
DMS7FC6	MA	Inhibitor
DMS7FC6	RN	Electrophilic gamma-lactone kappa-opioid receptor probes. Analogues of 2'-hydroxy-2-tetrahydrofurfuryl-5,9-dimethyl-6,7-benzomorphan diastereomers. J Med Chem. 1991 Aug;34(8):2438-44.
DMS7FC6	RU	https://pubmed.ncbi.nlm.nih.gov/1652019

DMS7FC6	DI	DMS7FC6
DMS7FC6	DN	MR-1029
DMS7FC6	MI	TTKWM86
DMS7FC6	MN	Opioid receptor mu (MOP)
DMS7FC6	MT	DTT
DMS7FC6	MA	Inhibitor
DMS7FC6	RN	Electrophilic gamma-lactone kappa-opioid receptor probes. Analogues of 2'-hydroxy-2-tetrahydrofurfuryl-5,9-dimethyl-6,7-benzomorphan diastereomers. J Med Chem. 1991 Aug;34(8):2438-44.
DMS7FC6	RU	https://pubmed.ncbi.nlm.nih.gov/1652019

DM5WMXJ	DI	DM5WMXJ
DM5WMXJ	DN	MR-1526
DM5WMXJ	MI	TTQW87Y
DM5WMXJ	MN	Opioid receptor kappa (OPRK1)
DM5WMXJ	MT	DTT
DM5WMXJ	MA	Inhibitor
DM5WMXJ	RN	Electrophilic gamma-lactone kappa-opioid receptor probes. Analogues of 2'-hydroxy-2-tetrahydrofurfuryl-5,9-dimethyl-6,7-benzomorphan diastereomers. J Med Chem. 1991 Aug;34(8):2438-44.
DM5WMXJ	RU	https://pubmed.ncbi.nlm.nih.gov/1652019

DM5WMXJ	DI	DM5WMXJ
DM5WMXJ	DN	MR-1526
DM5WMXJ	MI	TTKWM86
DM5WMXJ	MN	Opioid receptor mu (MOP)
DM5WMXJ	MT	DTT
DM5WMXJ	MA	Inhibitor
DM5WMXJ	RN	Electrophilic gamma-lactone kappa-opioid receptor probes. Analogues of 2'-hydroxy-2-tetrahydrofurfuryl-5,9-dimethyl-6,7-benzomorphan diastereomers. J Med Chem. 1991 Aug;34(8):2438-44.
DM5WMXJ	RU	https://pubmed.ncbi.nlm.nih.gov/1652019

DMM2WG7	DI	DMM2WG7
DMM2WG7	DN	MR-16089
DMM2WG7	MI	TTSZLWK
DMM2WG7	MN	Aromatase (CYP19A1)
DMM2WG7	MT	DTT
DMM2WG7	MA	Inhibitor
DMM2WG7	RN	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
DMM2WG7	RU	https://pubmed.ncbi.nlm.nih.gov/20413308

DMF04AG	DI	DMF04AG
DMF04AG	DN	MR-2034
DMF04AG	MI	TTQW87Y
DMF04AG	MN	Opioid receptor kappa (OPRK1)
DMF04AG	MT	DTT
DMF04AG	MA	Inhibitor
DMF04AG	RN	Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8.
DMF04AG	RU	https://pubmed.ncbi.nlm.nih.gov/19027293

DMF04AG	DI	DMF04AG
DMF04AG	DN	MR-2034
DMF04AG	MI	TTKWM86
DMF04AG	MN	Opioid receptor mu (MOP)
DMF04AG	MT	DTT
DMF04AG	MA	Inhibitor
DMF04AG	RN	Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8.
DMF04AG	RU	https://pubmed.ncbi.nlm.nih.gov/19027293

DMEBQLK	DI	DMEBQLK
DMEBQLK	DN	MR-20492
DMEBQLK	MI	TTSZLWK
DMEBQLK	MN	Aromatase (CYP19A1)
DMEBQLK	MT	DTT
DMEBQLK	MA	Inhibitor
DMEBQLK	RN	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
DMEBQLK	RU	https://pubmed.ncbi.nlm.nih.gov/20413308

DMC79YF	DI	DMC79YF
DMC79YF	DN	MR-20494
DMC79YF	MI	TTSZLWK
DMC79YF	MN	Aromatase (CYP19A1)
DMC79YF	MT	DTT
DMC79YF	MA	Inhibitor
DMC79YF	RN	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
DMC79YF	RU	https://pubmed.ncbi.nlm.nih.gov/20413308

DMTCG8M	DI	DMTCG8M
DMTCG8M	DN	MR-20496
DMTCG8M	MI	TTSZLWK
DMTCG8M	MN	Aromatase (CYP19A1)
DMTCG8M	MT	DTT
DMTCG8M	MA	Inhibitor
DMTCG8M	RN	Design and synthesis of a new type of non steroidal human aromatase inhibitors. Bioorg Med Chem Lett. 1998 May 5;8(9):1041-4.
DMTCG8M	RU	https://pubmed.ncbi.nlm.nih.gov/9871704

DMSR3OI	DI	DMSR3OI
DMSR3OI	DN	MR-20814
DMSR3OI	MI	TTSZLWK
DMSR3OI	MN	Aromatase (CYP19A1)
DMSR3OI	MT	DTT
DMSR3OI	MA	Inhibitor
DMSR3OI	RN	Design and synthesis of a new type of non steroidal human aromatase inhibitors. Bioorg Med Chem Lett. 1998 May 5;8(9):1041-4.
DMSR3OI	RU	https://pubmed.ncbi.nlm.nih.gov/9871704

DMIQ8GL	DI	DMIQ8GL
DMIQ8GL	DN	MR-22388
DMIQ8GL	MI	TTML2WA
DMIQ8GL	MN	Tubulin (TUB)
DMIQ8GL	MT	DTT
DMIQ8GL	MA	Inhibitor
DMIQ8GL	RN	Design, synthesis, and evaluation of novel thienopyrrolizinones as antitubulin agents. J Med Chem. 2004 Mar 11;47(6):1448-64.
DMIQ8GL	RU	https://pubmed.ncbi.nlm.nih.gov/14998333

DMIQ8GL	DI	DMIQ8GL
DMIQ8GL	DN	MR-22388
DMIQ8GL	MI	TTYFKSZ
DMIQ8GL	MN	Tubulin beta (TUBB)
DMIQ8GL	MT	DTT
DMIQ8GL	MA	Inhibitor
DMIQ8GL	RN	Design, synthesis, and evaluation of novel thienopyrrolizinones as antitubulin agents. J Med Chem. 2004 Mar 11;47(6):1448-64.
DMIQ8GL	RU	https://pubmed.ncbi.nlm.nih.gov/14998333

DMXWSIU	DI	DMXWSIU
DMXWSIU	DN	MR-2266
DMXWSIU	MI	TTQW87Y
DMXWSIU	MN	Opioid receptor kappa (OPRK1)
DMXWSIU	MT	DTT
DMXWSIU	MA	Inhibitor
DMXWSIU	RN	Electrophilic gamma-lactone kappa-opioid receptor probes. Analogues of 2'-hydroxy-2-tetrahydrofurfuryl-5,9-dimethyl-6,7-benzomorphan diastereomers. J Med Chem. 1991 Aug;34(8):2438-44.
DMXWSIU	RU	https://pubmed.ncbi.nlm.nih.gov/1652019

DMXWSIU	DI	DMXWSIU
DMXWSIU	DN	MR-2266
DMXWSIU	MI	TTKWM86
DMXWSIU	MN	Opioid receptor mu (MOP)
DMXWSIU	MT	DTT
DMXWSIU	MA	Inhibitor
DMXWSIU	RN	Electrophilic gamma-lactone kappa-opioid receptor probes. Analogues of 2'-hydroxy-2-tetrahydrofurfuryl-5,9-dimethyl-6,7-benzomorphan diastereomers. J Med Chem. 1991 Aug;34(8):2438-44.
DMXWSIU	RU	https://pubmed.ncbi.nlm.nih.gov/1652019

DMUK1PA	DI	DMUK1PA
DMUK1PA	DN	MRE 2029F20
DMUK1PA	MI	TTK25J1
DMUK1PA	MN	Adenosine A1 receptor (ADORA1)
DMUK1PA	MT	DTT
DMUK1PA	MA	Antagonist
DMUK1PA	RN	Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists. J Med Chem. 2004 Mar 11;47(6):1434-47.
DMUK1PA	RU	https://pubmed.ncbi.nlm.nih.gov/14998332

DMUK1PA	DI	DMUK1PA
DMUK1PA	DN	MRE 2029F20
DMUK1PA	MI	TTNE7KG
DMUK1PA	MN	Adenosine A2b receptor (ADORA2B)
DMUK1PA	MT	DTT
DMUK1PA	MA	Antagonist
DMUK1PA	RN	Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists. J Med Chem. 2004 Mar 11;47(6):1434-47.
DMUK1PA	RU	https://pubmed.ncbi.nlm.nih.gov/14998332

DMUK1PA	DI	DMUK1PA
DMUK1PA	DN	MRE 2029F20
DMUK1PA	MI	TTJFY5U
DMUK1PA	MN	Adenosine A3 receptor (ADORA3)
DMUK1PA	MT	DTT
DMUK1PA	MA	Antagonist
DMUK1PA	RN	Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists. J Med Chem. 2004 Mar 11;47(6):1434-47.
DMUK1PA	RU	https://pubmed.ncbi.nlm.nih.gov/14998332

DM72US0	DI	DM72US0
DM72US0	DN	MRE 3008F20
DM72US0	MI	TTK25J1
DM72US0	MN	Adenosine A1 receptor (ADORA1)
DM72US0	MT	DTT
DM72US0	MA	Antagonist
DM72US0	RN	Adenosine receptors as therapeutic targets. Nat Rev Drug Discov. 2006 Mar;5(3):247-64.
DM72US0	RU	https://pubmed.ncbi.nlm.nih.gov/16518376

DM72US0	DI	DM72US0
DM72US0	DN	MRE 3008F20
DM72US0	MI	TTNE7KG
DM72US0	MN	Adenosine A2b receptor (ADORA2B)
DM72US0	MT	DTT
DM72US0	MA	Antagonist
DM72US0	RN	Adenosine receptors as therapeutic targets. Nat Rev Drug Discov. 2006 Mar;5(3):247-64.
DM72US0	RU	https://pubmed.ncbi.nlm.nih.gov/16518376

DM72US0	DI	DM72US0
DM72US0	DN	MRE 3008F20
DM72US0	MI	TTJFY5U
DM72US0	MN	Adenosine A3 receptor (ADORA3)
DM72US0	MT	DTT
DM72US0	MA	Agonist
DM72US0	RN	[(3)H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors. Mol Pharmacol. 2000 May;57(5):968-75.
DM72US0	RU	https://pubmed.ncbi.nlm.nih.gov/10779381

DMMFJA8	DI	DMMFJA8
DMMFJA8	DN	MRE 3010F20
DMMFJA8	MI	TTJFY5U
DMMFJA8	MN	Adenosine A3 receptor (ADORA3)
DMMFJA8	MT	DTT
DMMFJA8	MA	Antagonist
DMMFJA8	RN	[(3)H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors. Mol Pharmacol. 2000 May;57(5):968-75.
DMMFJA8	RU	https://pubmed.ncbi.nlm.nih.gov/10779381

DM7VQTO	DI	DM7VQTO
DM7VQTO	DN	MRK016
DM7VQTO	MI	TTBMV1G
DM7VQTO	MN	GABA(A) receptor alpha-2 (GABRA2)
DM7VQTO	MT	DTT
DM7VQTO	MA	Modulator
DM7VQTO	RN	A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia.Biol Psychiatry.2011 Mar 1;69(5):442-9.
DM7VQTO	RU	https://www.ncbi.nlm.nih.gov/pubmed/21145041

DM7VQTO	DI	DM7VQTO
DM7VQTO	DN	MRK016
DM7VQTO	MI	TT37EDJ
DM7VQTO	MN	GABA(A) receptor alpha-3 (GABRA3)
DM7VQTO	MT	DTT
DM7VQTO	MA	Modulator
DM7VQTO	RN	A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia.Biol Psychiatry.2011 Mar 1;69(5):442-9.
DM7VQTO	RU	https://www.ncbi.nlm.nih.gov/pubmed/21145041

DM7IK68	DI	DM7IK68
DM7IK68	DN	MRS 2219
DM7IK68	MI	TTJW7B3
DM7IK68	MN	P2X purinoceptor 1 (P2RX1)
DM7IK68	MT	DTT
DM7IK68	MA	Modulator (allosteric modulator)
DM7IK68	RN	A pyridoxine cyclic phosphate and its 6-azoaryl derivative selectively potentiate and antagonize activation of P2X1 receptors. J Med Chem. 1998 Jun 18;41(13):2201-6.
DM7IK68	RU	https://pubmed.ncbi.nlm.nih.gov/9632352

DMBXKYR	DI	DMBXKYR
DMBXKYR	DN	MRS1041
DMBXKYR	MI	TTK25J1
DMBXKYR	MN	Adenosine A1 receptor (ADORA1)
DMBXKYR	MT	DTT
DMBXKYR	MA	Antagonist
DMBXKYR	RN	Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301.
DMBXKYR	RU	https://pubmed.ncbi.nlm.nih.gov/8691424

DMBXKYR	DI	DMBXKYR
DMBXKYR	DN	MRS1041
DMBXKYR	MI	TTNE7KG
DMBXKYR	MN	Adenosine A2b receptor (ADORA2B)
DMBXKYR	MT	DTT
DMBXKYR	MA	Antagonist
DMBXKYR	RN	Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301.
DMBXKYR	RU	https://pubmed.ncbi.nlm.nih.gov/8691424

DMBXKYR	DI	DMBXKYR
DMBXKYR	DN	MRS1041
DMBXKYR	MI	TTJFY5U
DMBXKYR	MN	Adenosine A3 receptor (ADORA3)
DMBXKYR	MT	DTT
DMBXKYR	MA	Antagonist
DMBXKYR	RN	Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301.
DMBXKYR	RU	https://pubmed.ncbi.nlm.nih.gov/8691424

DMVT865	DI	DMVT865
DMVT865	DN	MRS1042
DMVT865	MI	TTK25J1
DMVT865	MN	Adenosine A1 receptor (ADORA1)
DMVT865	MT	DTT
DMVT865	MA	Antagonist
DMVT865	RN	Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301.
DMVT865	RU	https://pubmed.ncbi.nlm.nih.gov/8691424

DMVT865	DI	DMVT865
DMVT865	DN	MRS1042
DMVT865	MI	TTNE7KG
DMVT865	MN	Adenosine A2b receptor (ADORA2B)
DMVT865	MT	DTT
DMVT865	MA	Antagonist
DMVT865	RN	Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301.
DMVT865	RU	https://pubmed.ncbi.nlm.nih.gov/8691424

DMVT865	DI	DMVT865
DMVT865	DN	MRS1042
DMVT865	MI	TTJFY5U
DMVT865	MN	Adenosine A3 receptor (ADORA3)
DMVT865	MT	DTT
DMVT865	MA	Antagonist
DMVT865	RN	Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301.
DMVT865	RU	https://pubmed.ncbi.nlm.nih.gov/8691424

DM50QBR	DI	DM50QBR
DM50QBR	DN	MRS1062
DM50QBR	MI	TTK25J1
DM50QBR	MN	Adenosine A1 receptor (ADORA1)
DM50QBR	MT	DTT
DM50QBR	MA	Antagonist
DM50QBR	RN	Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301.
DM50QBR	RU	https://pubmed.ncbi.nlm.nih.gov/8691424

DMYAHU3	DI	DMYAHU3
DMYAHU3	DN	MRS1065
DMYAHU3	MI	TTK25J1
DMYAHU3	MN	Adenosine A1 receptor (ADORA1)
DMYAHU3	MT	DTT
DMYAHU3	MA	Antagonist
DMYAHU3	RN	Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301.
DMYAHU3	RU	https://pubmed.ncbi.nlm.nih.gov/8691424

DMYAHU3	DI	DMYAHU3
DMYAHU3	DN	MRS1065
DMYAHU3	MI	TTNE7KG
DMYAHU3	MN	Adenosine A2b receptor (ADORA2B)
DMYAHU3	MT	DTT
DMYAHU3	MA	Antagonist
DMYAHU3	RN	Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301.
DMYAHU3	RU	https://pubmed.ncbi.nlm.nih.gov/8691424

DMAEW9M	DI	DMAEW9M
DMAEW9M	DN	MRS1067
DMAEW9M	MI	TTJFY5U
DMAEW9M	MN	Adenosine A3 receptor (ADORA3)
DMAEW9M	MT	DTT
DMAEW9M	MA	Antagonist
DMAEW9M	RN	Pharmacological characterization of novel A3 adenosine receptor-selective antagonists. Neuropharmacology. 1997 Sep;36(9):1157-65.
DMAEW9M	RU	https://pubmed.ncbi.nlm.nih.gov/9364471

DMKELWG	DI	DMKELWG
DMKELWG	DN	MRS1084
DMKELWG	MI	TTK25J1
DMKELWG	MN	Adenosine A1 receptor (ADORA1)
DMKELWG	MT	DTT
DMKELWG	MA	Antagonist
DMKELWG	RN	Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301.
DMKELWG	RU	https://pubmed.ncbi.nlm.nih.gov/8691424

DMKELWG	DI	DMKELWG
DMKELWG	DN	MRS1084
DMKELWG	MI	TTNE7KG
DMKELWG	MN	Adenosine A2b receptor (ADORA2B)
DMKELWG	MT	DTT
DMKELWG	MA	Antagonist
DMKELWG	RN	Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301.
DMKELWG	RU	https://pubmed.ncbi.nlm.nih.gov/8691424

DM1K5E2	DI	DM1K5E2
DM1K5E2	DN	MRS1086
DM1K5E2	MI	TTK25J1
DM1K5E2	MN	Adenosine A1 receptor (ADORA1)
DM1K5E2	MT	DTT
DM1K5E2	MA	Antagonist
DM1K5E2	RN	Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301.
DM1K5E2	RU	https://pubmed.ncbi.nlm.nih.gov/8691424

DM1K5E2	DI	DM1K5E2
DM1K5E2	DN	MRS1086
DM1K5E2	MI	TTNE7KG
DM1K5E2	MN	Adenosine A2b receptor (ADORA2B)
DM1K5E2	MT	DTT
DM1K5E2	MA	Antagonist
DM1K5E2	RN	Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301.
DM1K5E2	RU	https://pubmed.ncbi.nlm.nih.gov/8691424

DMSKWL7	DI	DMSKWL7
DMSKWL7	DN	MRS1088
DMSKWL7	MI	TTNE7KG
DMSKWL7	MN	Adenosine A2b receptor (ADORA2B)
DMSKWL7	MT	DTT
DMSKWL7	MA	Antagonist
DMSKWL7	RN	Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301.
DMSKWL7	RU	https://pubmed.ncbi.nlm.nih.gov/8691424

DMSKWL7	DI	DMSKWL7
DMSKWL7	DN	MRS1088
DMSKWL7	MI	TTJFY5U
DMSKWL7	MN	Adenosine A3 receptor (ADORA3)
DMSKWL7	MT	DTT
DMSKWL7	MA	Antagonist
DMSKWL7	RN	Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301.
DMSKWL7	RU	https://pubmed.ncbi.nlm.nih.gov/8691424

DM801AO	DI	DM801AO
DM801AO	DN	MRS1093
DM801AO	MI	TTK25J1
DM801AO	MN	Adenosine A1 receptor (ADORA1)
DM801AO	MT	DTT
DM801AO	MA	Antagonist
DM801AO	RN	Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301.
DM801AO	RU	https://pubmed.ncbi.nlm.nih.gov/8691424

DM801AO	DI	DM801AO
DM801AO	DN	MRS1093
DM801AO	MI	TTNE7KG
DM801AO	MN	Adenosine A2b receptor (ADORA2B)
DM801AO	MT	DTT
DM801AO	MA	Antagonist
DM801AO	RN	Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301.
DM801AO	RU	https://pubmed.ncbi.nlm.nih.gov/8691424

DM801AO	DI	DM801AO
DM801AO	DN	MRS1093
DM801AO	MI	TTJFY5U
DM801AO	MN	Adenosine A3 receptor (ADORA3)
DM801AO	MT	DTT
DM801AO	MA	Antagonist
DM801AO	RN	Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301.
DM801AO	RU	https://pubmed.ncbi.nlm.nih.gov/8691424

DMLOHAZ	DI	DMLOHAZ
DMLOHAZ	DN	MRS1097
DMLOHAZ	MI	TTJFY5U
DMLOHAZ	MN	Adenosine A3 receptor (ADORA3)
DMLOHAZ	MT	DTT
DMLOHAZ	MA	Antagonist
DMLOHAZ	RN	Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: selectivity for A3 receptors. J Med Chem. 1996 Jul 19;39(15):2980-9.
DMLOHAZ	RU	https://pubmed.ncbi.nlm.nih.gov/8709132

DMY4C0G	DI	DMY4C0G
DMY4C0G	DN	MRS1132
DMY4C0G	MI	TTK25J1
DMY4C0G	MN	Adenosine A1 receptor (ADORA1)
DMY4C0G	MT	DTT
DMY4C0G	MA	Antagonist
DMY4C0G	RN	Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301.
DMY4C0G	RU	https://pubmed.ncbi.nlm.nih.gov/8691424

DMY4C0G	DI	DMY4C0G
DMY4C0G	DN	MRS1132
DMY4C0G	MI	TTNE7KG
DMY4C0G	MN	Adenosine A2b receptor (ADORA2B)
DMY4C0G	MT	DTT
DMY4C0G	MA	Antagonist
DMY4C0G	RN	Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301.
DMY4C0G	RU	https://pubmed.ncbi.nlm.nih.gov/8691424

DMBXTPU	DI	DMBXTPU
DMBXTPU	DN	MRS1177
DMBXTPU	MI	TTJFY5U
DMBXTPU	MN	Adenosine A3 receptor (ADORA3)
DMBXTPU	MT	DTT
DMBXTPU	MA	Antagonist
DMBXTPU	RN	Derivatives of the triazoloquinazoline adenosine antagonist (CGS15943) are selective for the human A3 receptor subtype. J Med Chem. 1996 Oct 11;39(21):4142-8.
DMBXTPU	RU	https://pubmed.ncbi.nlm.nih.gov/8863790

DMGJ0IE	DI	DMGJ0IE
DMGJ0IE	DN	MRS1186
DMGJ0IE	MI	TTJFY5U
DMGJ0IE	MN	Adenosine A3 receptor (ADORA3)
DMGJ0IE	MT	DTT
DMGJ0IE	MA	Antagonist
DMGJ0IE	RN	Derivatives of the triazoloquinazoline adenosine antagonist (CGS15943) are selective for the human A3 receptor subtype. J Med Chem. 1996 Oct 11;39(21):4142-8.
DMGJ0IE	RU	https://pubmed.ncbi.nlm.nih.gov/8863790

DM9WX3C	DI	DM9WX3C
DM9WX3C	DN	MRS1191
DM9WX3C	MI	TTK25J1
DM9WX3C	MN	Adenosine A1 receptor (ADORA1)
DM9WX3C	MT	DTT
DM9WX3C	MA	Antagonist
DM9WX3C	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 18).
DM9WX3C	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=18

DM9WX3C	DI	DM9WX3C
DM9WX3C	DN	MRS1191
DM9WX3C	MI	TTNE7KG
DM9WX3C	MN	Adenosine A2b receptor (ADORA2B)
DM9WX3C	MT	DTT
DM9WX3C	MA	Antagonist
DM9WX3C	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 20).
DM9WX3C	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=20

DM9WX3C	DI	DM9WX3C
DM9WX3C	DN	MRS1191
DM9WX3C	MI	TTJFY5U
DM9WX3C	MN	Adenosine A3 receptor (ADORA3)
DM9WX3C	MT	DTT
DM9WX3C	MA	Antagonist
DM9WX3C	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 21).
DM9WX3C	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=21

DMT6JH9	DI	DMT6JH9
DMT6JH9	DN	MRS-1220
DMT6JH9	MI	TTJFY5U
DMT6JH9	MN	Adenosine A3 receptor (ADORA3)
DMT6JH9	MT	DTT
DMT6JH9	MA	Antagonist
DMT6JH9	RN	A(3) adenosine receptor activation attenuates neutrophil function and neutrophil-mediated reperfusion injury. Am J Physiol. 1999 Nov;277(5 Pt 2):H1895-905.
DMT6JH9	RU	https://pubmed.ncbi.nlm.nih.gov/10564145

DMLQYN7	DI	DMLQYN7
DMLQYN7	DN	MRS1476
DMLQYN7	MI	TTJFY5U
DMLQYN7	MN	Adenosine A3 receptor (ADORA3)
DMLQYN7	MT	DTT
DMLQYN7	MA	Antagonist
DMLQYN7	RN	Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. J Med Chem. 1998 Aug 13;41(17):3186-201.
DMLQYN7	RU	https://pubmed.ncbi.nlm.nih.gov/9703464

DMFJHMQ	DI	DMFJHMQ
DMFJHMQ	DN	MRS1486
DMFJHMQ	MI	TTJFY5U
DMFJHMQ	MN	Adenosine A3 receptor (ADORA3)
DMFJHMQ	MT	DTT
DMFJHMQ	MA	Antagonist
DMFJHMQ	RN	Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. J Med Chem. 1998 Aug 13;41(17):3186-201.
DMFJHMQ	RU	https://pubmed.ncbi.nlm.nih.gov/9703464

DM3Q5NO	DI	DM3Q5NO
DM3Q5NO	DN	MRS1505
DM3Q5NO	MI	TTJFY5U
DM3Q5NO	MN	Adenosine A3 receptor (ADORA3)
DM3Q5NO	MT	DTT
DM3Q5NO	MA	Antagonist
DM3Q5NO	RN	Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. J Med Chem. 1998 Aug 13;41(17):3186-201.
DM3Q5NO	RU	https://pubmed.ncbi.nlm.nih.gov/9703464

DM4AONZ	DI	DM4AONZ
DM4AONZ	DN	MRS1523
DM4AONZ	MI	TTK25J1
DM4AONZ	MN	Adenosine A1 receptor (ADORA1)
DM4AONZ	MT	DTT
DM4AONZ	MA	Antagonist
DM4AONZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 18).
DM4AONZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=18

DM4AONZ	DI	DM4AONZ
DM4AONZ	DN	MRS1523
DM4AONZ	MI	TTNE7KG
DM4AONZ	MN	Adenosine A2b receptor (ADORA2B)
DM4AONZ	MT	DTT
DM4AONZ	MA	Antagonist
DM4AONZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 20).
DM4AONZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=20

DM4AONZ	DI	DM4AONZ
DM4AONZ	DN	MRS1523
DM4AONZ	MI	TTJFY5U
DM4AONZ	MN	Adenosine A3 receptor (ADORA3)
DM4AONZ	MT	DTT
DM4AONZ	MA	Antagonist
DM4AONZ	RN	Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. J Med Chem. 1998 Aug 13;41(17):3186-201.
DM4AONZ	RU	https://pubmed.ncbi.nlm.nih.gov/9703464

DM5I7PL	DI	DM5I7PL
DM5I7PL	DN	MRS1706
DM5I7PL	MI	TTNE7KG
DM5I7PL	MN	Adenosine A2b receptor (ADORA2B)
DM5I7PL	MT	DTT
DM5I7PL	MA	Antagonist
DM5I7PL	RN	Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A(2B) adenosine receptors. J Med Chem. 2000 Mar 23;43(6):1165-72.
DM5I7PL	RU	https://pubmed.ncbi.nlm.nih.gov/10737749

DMHJ47A	DI	DMHJ47A
DMHJ47A	DN	MRS-2160
DMHJ47A	MI	TT1NLOA
DMHJ47A	MN	P2X purinoceptor 4 (P2RX4)
DMHJ47A	MT	DTT
DMHJ47A	MA	Inhibitor
DMHJ47A	RN	Purine and pyrimidine (P2) receptors as drug targets. J Med Chem. 2002 Sep 12;45(19):4057-93.
DMHJ47A	RU	https://pubmed.ncbi.nlm.nih.gov/12213051

DMIVGHB	DI	DMIVGHB
DMIVGHB	DN	MRS-2179
DMIVGHB	MI	TTA93TL
DMIVGHB	MN	P2Y purinoceptor 1 (P2RY1)
DMIVGHB	MT	DTT
DMIVGHB	MA	Antagonist
DMIVGHB	RN	The P2Y(1) receptor as a target for new antithrombotic drugs: a review of the P2Y(1) antagonist MRS-2179. Cardiovasc Drug Rev. 2003 Spring;21(1):67-76.
DMIVGHB	RU	https://pubmed.ncbi.nlm.nih.gov/12595918

DM2G5ZE	DI	DM2G5ZE
DM2G5ZE	DN	MRS2211
DM2G5ZE	MI	TT1FE3L
DM2G5ZE	MN	P2Y purinoceptor 13 (P2RY13)
DM2G5ZE	MT	DTT
DM2G5ZE	MA	Antagonist
DM2G5ZE	RN	Synthesis of pyridoxal phosphate derivatives with antagonist activity at the P2Y13 receptor. Biochem Pharmacol. 2005 Jul 15;70(2):266-74.
DM2G5ZE	RU	https://pubmed.ncbi.nlm.nih.gov/15913566

DM0QGF3	DI	DM0QGF3
DM0QGF3	DN	MRS2279
DM0QGF3	MI	TTA93TL
DM0QGF3	MN	P2Y purinoceptor 1 (P2RY1)
DM0QGF3	MT	DTT
DM0QGF3	MA	Antagonist
DM0QGF3	RN	Quantitation of the P2Y(1) receptor with a high affinity radiolabeled antagonist. Mol Pharmacol. 2002 Nov;62(5):1249-57.
DM0QGF3	RU	https://pubmed.ncbi.nlm.nih.gov/12391289

DMZ6EGA	DI	DMZ6EGA
DMZ6EGA	DN	MRS2298
DMZ6EGA	MI	TTA93TL
DMZ6EGA	MN	P2Y purinoceptor 1 (P2RY1)
DMZ6EGA	MT	DTT
DMZ6EGA	MA	Antagonist
DMZ6EGA	RN	Antiaggregatory activity in human platelets of potent antagonists of the P2Y 1 receptor. Biochem Pharmacol. 2004 Nov 15;68(10):1995-2002.
DMZ6EGA	RU	https://pubmed.ncbi.nlm.nih.gov/15476670

DM0CS3V	DI	DM0CS3V
DM0CS3V	DN	MRS2365
DM0CS3V	MI	TTA93TL
DM0CS3V	MN	P2Y purinoceptor 1 (P2RY1)
DM0CS3V	MT	DTT
DM0CS3V	MA	Agonist
DM0CS3V	RN	Induction of novel agonist selectivity for the ADP-activated P2Y1 receptor versus the ADP-activated P2Y12 and P2Y13 receptors by conformational con... J Pharmacol Exp Ther. 2004 Dec;311(3):1038-43.
DM0CS3V	RU	https://pubmed.ncbi.nlm.nih.gov/15345752

DM0CAKS	DI	DM0CAKS
DM0CAKS	DN	MRS2496
DM0CAKS	MI	TTA93TL
DM0CAKS	MN	P2Y purinoceptor 1 (P2RY1)
DM0CAKS	MT	DTT
DM0CAKS	MA	Antagonist
DM0CAKS	RN	Antiaggregatory activity in human platelets of potent antagonists of the P2Y 1 receptor. Biochem Pharmacol. 2004 Nov 15;68(10):1995-2002.
DM0CAKS	RU	https://pubmed.ncbi.nlm.nih.gov/15476670

DMNGTOY	DI	DMNGTOY
DMNGTOY	DN	MRS2500
DMNGTOY	MI	TTA93TL
DMNGTOY	MN	P2Y purinoceptor 1 (P2RY1)
DMNGTOY	MT	DTT
DMNGTOY	MA	Antagonist
DMNGTOY	RN	2-Substitution of adenine nucleotide analogues containing a bicyclo[3.1.0]hexane ring system locked in a northern conformation: enhanced potency as P2Y1 receptor antagonists. J Med Chem. 2003 Nov 6;46(23):4974-87.
DMNGTOY	RU	https://pubmed.ncbi.nlm.nih.gov/14584948

DMUJEA9	DI	DMUJEA9
DMUJEA9	DN	MRS2567
DMUJEA9	MI	TTNVSKA
DMUJEA9	MN	P2Y purinoceptor 6 (P2RY6)
DMUJEA9	MT	DTT
DMUJEA9	MA	Antagonist
DMUJEA9	RN	Diisothiocyanate derivatives as potent, insurmountable antagonists of P2Y6 nucleotide receptors. Biochem Pharmacol. 2004 May 1;67(9):1763-70.
DMUJEA9	RU	https://pubmed.ncbi.nlm.nih.gov/15081875

DMKMPS6	DI	DMKMPS6
DMKMPS6	DN	MRS2578
DMKMPS6	MI	TTNVSKA
DMKMPS6	MN	P2Y purinoceptor 6 (P2RY6)
DMKMPS6	MT	DTT
DMKMPS6	MA	Antagonist
DMKMPS6	RN	Diisothiocyanate derivatives as potent, insurmountable antagonists of P2Y6 nucleotide receptors. Biochem Pharmacol. 2004 May 1;67(9):1763-70.
DMKMPS6	RU	https://pubmed.ncbi.nlm.nih.gov/15081875

DMNGC79	DI	DMNGC79
DMNGC79	DN	MRS2603
DMNGC79	MI	TT1FE3L
DMNGC79	MN	P2Y purinoceptor 13 (P2RY13)
DMNGC79	MT	DTT
DMNGC79	MA	Antagonist
DMNGC79	RN	Synthesis of pyridoxal phosphate derivatives with antagonist activity at the P2Y13 receptor. Biochem Pharmacol. 2005 Jul 15;70(2):266-74.
DMNGC79	RU	https://pubmed.ncbi.nlm.nih.gov/15913566

DMNS3RT	DI	DMNS3RT
DMNS3RT	DN	MRS2690
DMNS3RT	MI	TT72OKI
DMNS3RT	MN	P2Y purinoceptor 14 (P2RY14)
DMNS3RT	MT	DTT
DMNS3RT	MA	Agonist
DMNS3RT	RN	The role of P2Y(14) and other P2Y receptors in degranulation of human LAD2 mast cells. Purinergic Signal. 2013 Mar;9(1):31-40.
DMNS3RT	RU	https://pubmed.ncbi.nlm.nih.gov/22825617

DM2L3CJ	DI	DM2L3CJ
DM2L3CJ	DN	MRS2693
DM2L3CJ	MI	TTNVSKA
DM2L3CJ	MN	P2Y purinoceptor 6 (P2RY6)
DM2L3CJ	MT	DTT
DM2L3CJ	MA	Agonist
DM2L3CJ	RN	Structure-activity relationships of uridine 5'-diphosphate analogues at the human P2Y6 receptor. J Med Chem. 2006 Sep 7;49(18):5532-43.
DM2L3CJ	RU	https://pubmed.ncbi.nlm.nih.gov/16942026

DM7EZBU	DI	DM7EZBU
DM7EZBU	DN	MRS2698
DM7EZBU	MI	TTOZHQC
DM7EZBU	MN	P2Y purinoceptor 2 (P2RY2)
DM7EZBU	MT	DTT
DM7EZBU	MA	Agonist
DM7EZBU	RN	Molecular modeling of the human P2Y2 receptor and design of a selective agonist, 2'-amino-2'-deoxy-2-thiouridine 5'-triphosphate. J Med Chem. 2007 Mar 22;50(6):1166-76.
DM7EZBU	RU	https://pubmed.ncbi.nlm.nih.gov/17302398

DMO5J39	DI	DMO5J39
DMO5J39	DN	MRS2768
DMO5J39	MI	TTOZHQC
DMO5J39	MN	P2Y purinoceptor 2 (P2RY2)
DMO5J39	MT	DTT
DMO5J39	MA	Agonist
DMO5J39	RN	Synthesis and potency of novel uracil nucleotides and derivatives as P2Y2 and P2Y6 receptor agonists. Bioorg Med Chem. 2008 Jun 15;16(12):6319-32.
DMO5J39	RU	https://pubmed.ncbi.nlm.nih.gov/18514530

DMZSO4R	DI	DMZSO4R
DMZSO4R	DN	MRS2782
DMZSO4R	MI	TTNVSKA
DMZSO4R	MN	P2Y purinoceptor 6 (P2RY6)
DMZSO4R	MT	DTT
DMZSO4R	MA	Agonist
DMZSO4R	RN	Synthesis and potency of novel uracil nucleotides and derivatives as P2Y2 and P2Y6 receptor agonists. Bioorg Med Chem. 2008 Jun 15;16(12):6319-32.
DMZSO4R	RU	https://pubmed.ncbi.nlm.nih.gov/18514530

DMWKZCY	DI	DMWKZCY
DMWKZCY	DN	MRS2802
DMWKZCY	MI	TT72OKI
DMWKZCY	MN	P2Y purinoceptor 14 (P2RY14)
DMWKZCY	MT	DTT
DMWKZCY	MA	Agonist
DMWKZCY	RN	Human P2Y(14) receptor agonists: truncation of the hexose moiety of uridine-5'-diphosphoglucose and its replacement with alkyl and aryl groups. J Med Chem. 2010 Jan 14;53(1):471-80.
DMWKZCY	RU	https://pubmed.ncbi.nlm.nih.gov/19902968

DMGCPHO	DI	DMGCPHO
DMGCPHO	DN	MRS2905
DMGCPHO	MI	TT72OKI
DMGCPHO	MN	P2Y purinoceptor 14 (P2RY14)
DMGCPHO	MT	DTT
DMGCPHO	MA	Agonist
DMGCPHO	RN	Pharmacochemistry of the platelet purinergic receptors. Purinergic Signal. 2011 Sep;7(3):305-24.
DMGCPHO	RU	https://pubmed.ncbi.nlm.nih.gov/21484092

DMB2A7Q	DI	DMB2A7Q
DMB2A7Q	DN	MRS2927
DMB2A7Q	MI	TT24DGP
DMB2A7Q	MN	P2Y purinoceptor 4 (P2RY4)
DMB2A7Q	MT	DTT
DMB2A7Q	MA	Agonist
DMB2A7Q	RN	Pyrimidine nucleotides with 4-alkyloxyimino and terminal tetraphosphate delta-ester modifications as selective agonists of the P2Y(4) receptor. J Med Chem. 2011 Jun 23;54(12):4018-33.
DMB2A7Q	RU	https://pubmed.ncbi.nlm.nih.gov/21528910

DMDSB1F	DI	DMDSB1F
DMDSB1F	DN	MRS2950
DMDSB1F	MI	TTA93TL
DMDSB1F	MN	P2Y purinoceptor 1 (P2RY1)
DMDSB1F	MT	DTT
DMDSB1F	MA	Antagonist
DMDSB1F	RN	Virtual screening leads to the discovery of novel non-nucleotide P2Y receptor antagonists. Bioorg Med Chem. 2012 Sep 1;20(17):5254-61.
DMDSB1F	RU	https://pubmed.ncbi.nlm.nih.gov/22831801

DMROQP6	DI	DMROQP6
DMROQP6	DN	MRS2957
DMROQP6	MI	TTNVSKA
DMROQP6	MN	P2Y purinoceptor 6 (P2RY6)
DMROQP6	MT	DTT
DMROQP6	MA	Agonist
DMROQP6	RN	Pyrimidine ribonucleotides with enhanced selectivity as P2Y(6) receptor agonists: novel 4-alkyloxyimino, (S)-methanocarba, and 5'-triphosphate gamma-ester modifications. J Med Chem. 2010 Jun 10;53(11):4488-501.
DMROQP6	RU	https://pubmed.ncbi.nlm.nih.gov/20446735

DMWKXGP	DI	DMWKXGP
DMWKXGP	DN	MRS4062
DMWKXGP	MI	TT24DGP
DMWKXGP	MN	P2Y purinoceptor 4 (P2RY4)
DMWKXGP	MT	DTT
DMWKXGP	MA	Agonist
DMWKXGP	RN	Pyrimidine nucleotides with 4-alkyloxyimino and terminal tetraphosphate delta-ester modifications as selective agonists of the P2Y(4) receptor. J Med Chem. 2011 Jun 23;54(12):4018-33.
DMWKXGP	RU	https://pubmed.ncbi.nlm.nih.gov/21528910

DM1GUTC	DI	DM1GUTC
DM1GUTC	DN	MRS5151
DM1GUTC	MI	TTK25J1
DM1GUTC	MN	Adenosine A1 receptor (ADORA1)
DM1GUTC	MT	DTT
DM1GUTC	MA	Agonist
DM1GUTC	RN	Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists. Bioorg Med Chem Lett. 2008 May 1;18(9):2813-9.
DM1GUTC	RU	https://pubmed.ncbi.nlm.nih.gov/18424135

DM1GUTC	DI	DM1GUTC
DM1GUTC	DN	MRS5151
DM1GUTC	MI	TTNE7KG
DM1GUTC	MN	Adenosine A2b receptor (ADORA2B)
DM1GUTC	MT	DTT
DM1GUTC	MA	Agonist
DM1GUTC	RN	Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists. Bioorg Med Chem Lett. 2008 May 1;18(9):2813-9.
DM1GUTC	RU	https://pubmed.ncbi.nlm.nih.gov/18424135

DM1GUTC	DI	DM1GUTC
DM1GUTC	DN	MRS5151
DM1GUTC	MI	TTJFY5U
DM1GUTC	MN	Adenosine A3 receptor (ADORA3)
DM1GUTC	MT	DTT
DM1GUTC	MA	Agonist
DM1GUTC	RN	Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists. Bioorg Med Chem Lett. 2008 May 1;18(9):2813-9.
DM1GUTC	RU	https://pubmed.ncbi.nlm.nih.gov/18424135

DMDF6WG	DI	DMDF6WG
DMDF6WG	DN	MRS5698
DMDF6WG	MI	TTJFY5U
DMDF6WG	MN	Adenosine A3 receptor (ADORA3)
DMDF6WG	MT	DTT
DMDF6WG	MA	Agonist
DMDF6WG	RN	Structure-guided design of A(3) adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions. J Med Chem. 2012 May 24;55(10):4847-60.
DMDF6WG	RU	https://pubmed.ncbi.nlm.nih.gov/22559880

DMMN42V	DI	DMMN42V
DMMN42V	DN	MRS923
DMMN42V	MI	TTK25J1
DMMN42V	MN	Adenosine A1 receptor (ADORA1)
DMMN42V	MT	DTT
DMMN42V	MA	Antagonist
DMMN42V	RN	Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301.
DMMN42V	RU	https://pubmed.ncbi.nlm.nih.gov/8691424

DMMN42V	DI	DMMN42V
DMMN42V	DN	MRS923
DMMN42V	MI	TTNE7KG
DMMN42V	MN	Adenosine A2b receptor (ADORA2B)
DMMN42V	MT	DTT
DMMN42V	MA	Antagonist
DMMN42V	RN	Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301.
DMMN42V	RU	https://pubmed.ncbi.nlm.nih.gov/8691424

DMKJ9WM	DI	DMKJ9WM
DMKJ9WM	DN	MRS928
DMKJ9WM	MI	TTK25J1
DMKJ9WM	MN	Adenosine A1 receptor (ADORA1)
DMKJ9WM	MT	DTT
DMKJ9WM	MA	Antagonist
DMKJ9WM	RN	Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301.
DMKJ9WM	RU	https://pubmed.ncbi.nlm.nih.gov/8691424

DMKJ9WM	DI	DMKJ9WM
DMKJ9WM	DN	MRS928
DMKJ9WM	MI	TTNE7KG
DMKJ9WM	MN	Adenosine A2b receptor (ADORA2B)
DMKJ9WM	MT	DTT
DMKJ9WM	MA	Antagonist
DMKJ9WM	RN	Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301.
DMKJ9WM	RU	https://pubmed.ncbi.nlm.nih.gov/8691424

DMKJ9WM	DI	DMKJ9WM
DMKJ9WM	DN	MRS928
DMKJ9WM	MI	TTJFY5U
DMKJ9WM	MN	Adenosine A3 receptor (ADORA3)
DMKJ9WM	MT	DTT
DMKJ9WM	MA	Antagonist
DMKJ9WM	RN	Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301.
DMKJ9WM	RU	https://pubmed.ncbi.nlm.nih.gov/8691424

DMYRCHG	DI	DMYRCHG
DMYRCHG	DN	MRT67307
DMYRCHG	MI	TTRPDBG
DMYRCHG	MN	Inhibitor of nuclear factor kappa-B kinase (IKK)
DMYRCHG	MT	DTT
DMYRCHG	MA	Inhibitor
DMYRCHG	RN	Novel cross-talk within the IKK family controls innate immunity. Biochem J. 2011 Feb 15;434(1):93-104.
DMYRCHG	RU	https://pubmed.ncbi.nlm.nih.gov/21138416

DMYRCHG	DI	DMYRCHG
DMYRCHG	DN	MRT67307
DMYRCHG	MI	TTH5TC2
DMYRCHG	MN	NF-kappa-B-activating kinase (TBK1)
DMYRCHG	MT	DTT
DMYRCHG	MA	Inhibitor
DMYRCHG	RN	Novel cross-talk within the IKK family controls innate immunity. Biochem J. 2011 Feb 15;434(1):93-104.
DMYRCHG	RU	https://pubmed.ncbi.nlm.nih.gov/21138416

DMTPGQ3	DI	DMTPGQ3
DMTPGQ3	DN	MS1943
DMTPGQ3	MI	TT9MZCQ
DMTPGQ3	MN	Enhancer of zeste homolog 2 (EZH2)
DMTPGQ3	MT	DTT
DMTPGQ3	MA	Degrader
DMTPGQ3	RN	Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021 Apr;20(4):265-286.
DMTPGQ3	RU	https://pubmed.ncbi.nlm.nih.gov/33469207

DMXC30P	DI	DMXC30P
DMXC30P	DN	MS417
DMXC30P	MI	TTRA6BO
DMXC30P	MN	Bromodomain-containing protein 4 (BRD4)
DMXC30P	MT	DTT
DMXC30P	MA	Inhibitor
DMXC30P	RN	Down-regulation of NF- B transcriptional activity in HIV-associated kidney disease by BRD4 inhibition. J Biol Chem. 2012 Aug 17;287(34):28840-51.
DMXC30P	RU	https://pubmed.ncbi.nlm.nih.gov/22645123

DMNBFX0	DI	DMNBFX0
DMNBFX0	DN	MS436
DMNBFX0	MI	TTRA6BO
DMNBFX0	MN	Bromodomain-containing protein 4 (BRD4)
DMNBFX0	MT	DTT
DMNBFX0	MA	Inhibitor
DMNBFX0	RN	Structure-guided design of potent diazobenzene inhibitors for the BET bromodomains. J Med Chem. 2013 Nov 27;56(22):9251-64.
DMNBFX0	RU	https://pubmed.ncbi.nlm.nih.gov/24144283

DMBTPDL	DI	DMBTPDL
DMBTPDL	DN	MS453
DMBTPDL	MI	TTGC95K
DMBTPDL	MN	SET domain containing 8 (KMT5A)
DMBTPDL	MT	DTT
DMBTPDL	MA	Inhibitor
DMBTPDL	RN	Structure-Based Design of a Covalent Inhibitor of the SET Domain-Containing Protein 8 (SETD8) Lysine Methyltransferase. J Med Chem. 2016 Nov 10;59(21):9881-9889.
DMBTPDL	RU	https://pubmed.ncbi.nlm.nih.gov/27804297

DMS3O9H	DI	DMS3O9H
DMS3O9H	DN	MSC2032964A
DMS3O9H	MI	TTOQCD8
DMS3O9H	MN	Apoptosis signal-regulating kinase 1 (MAP3K5)
DMS3O9H	MT	DTT
DMS3O9H	MA	Inhibitor
DMS3O9H	RN	Regulation of the severity of neuroinflammation and demyelination by TLR-ASK1-p38 pathway. EMBO Mol Med. 2010 Dec;2(12):504-15.
DMS3O9H	RU	https://pubmed.ncbi.nlm.nih.gov/21064192

DMU67CE	DI	DMU67CE
DMU67CE	DN	MSOPPE
DMU67CE	MI	TT0I76D
DMU67CE	MN	Metabotropic glutamate receptor 7 (mGluR7)
DMU67CE	MT	DTT
DMU67CE	MA	Antagonist
DMU67CE	RN	Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 2000 Dec;362(6):546-54.
DMU67CE	RU	https://pubmed.ncbi.nlm.nih.gov/11138847

DMUKWJ2	DI	DMUKWJ2
DMUKWJ2	DN	MST-400
DMUKWJ2	MI	TT7ALZG
DMUKWJ2	MN	Integrin-linked protein kinase 1 (ILK)
DMUKWJ2	MT	DTT
DMUKWJ2	MA	Inhibitor
DMUKWJ2	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2041).
DMUKWJ2	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2041

DM4KM91	DI	DM4KM91
DM4KM91	DN	MSVIII-19
DM4KM91	MI	TT0MYE2
DM4KM91	MN	Glutamate receptor ionotropic kainate 1 (GRIK1)
DM4KM91	MT	DTT
DM4KM91	MA	Antagonist
DM4KM91	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 450).
DM4KM91	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=450

DMF9HYI	DI	DMF9HYI
DMF9HYI	DN	MSX-3
DMF9HYI	MI	TTM2AOE
DMF9HYI	MN	Adenosine A2a receptor (ADORA2A)
DMF9HYI	MT	DTT
DMF9HYI	MA	Modulator
DMF9HYI	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5610).
DMF9HYI	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5610

DM7KIVX	DI	DM7KIVX
DM7KIVX	DN	MT-001
DM7KIVX	MI	TTPADOQ
DM7KIVX	MN	HMG-CoA reductase (HMGCR)
DM7KIVX	MT	DTT
DM7KIVX	MA	Modulator
DM7KIVX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 639).
DM7KIVX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=639

DMDK6BP	DI	DMDK6BP
DMDK6BP	DN	MT-061
DMDK6BP	MI	TT7AOUD
DMDK6BP	MN	Fatty acid synthase (FASN)
DMDK6BP	MT	DTT
DMDK6BP	MA	Inhibitor
DMDK6BP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2608).
DMDK6BP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2608

DM5PD0G	DI	DM5PD0G
DM5PD0G	DN	MT-062
DM5PD0G	MI	TTGKNB4
DM5PD0G	MN	Epidermal growth factor receptor (EGFR)
DM5PD0G	MT	DTT
DM5PD0G	MA	Inhibitor
DM5PD0G	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
DM5PD0G	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797

DMKT1DA	DI	DMKT1DA
DMKT1DA	DN	MT-II
DMKT1DA	MI	TTEOSZT
DMKT1DA	MN	Melanocortin receptor (MCR)
DMKT1DA	MT	DTT
DMKT1DA	MA	Inhibitor
DMKT1DA	RN	Substitution of arginine with proline and proline derivatives in melanocyte-stimulating hormones leads to selectivity for human melanocortin 4 rece... J Med Chem. 2009 Jun 25;52(12):3627-35.
DMKT1DA	RU	https://pubmed.ncbi.nlm.nih.gov/19473029

DMKT1DA	DI	DMKT1DA
DMKT1DA	DN	MT-II
DMKT1DA	MI	TT0MV2T
DMKT1DA	MN	Melanocortin receptor 1 (MC1R)
DMKT1DA	MT	DTT
DMKT1DA	MA	Agonist
DMKT1DA	RN	Design of potent linear alpha-melanotropin 4-10 analogues modified in positions 5 and 10. J Med Chem. 1989 Jan;32(1):174-9.
DMKT1DA	RU	https://pubmed.ncbi.nlm.nih.gov/2535874

DMKT1DA	DI	DMKT1DA
DMKT1DA	DN	MT-II
DMKT1DA	MI	TTNI91K
DMKT1DA	MN	Melanocortin receptor 3 (MC3R)
DMKT1DA	MT	DTT
DMKT1DA	MA	Agonist
DMKT1DA	RN	Characterization of melanocortin receptor ligands on cloned brain melanocortin receptors and on grooming behavior in the rat. Eur J Pharmacol. 1999 Aug 13;378(3):249-58.
DMKT1DA	RU	https://pubmed.ncbi.nlm.nih.gov/10493100

DMKT1DA	DI	DMKT1DA
DMKT1DA	DN	MT-II
DMKT1DA	MI	TTD0CIQ
DMKT1DA	MN	Melanocortin receptor 4 (MC4R)
DMKT1DA	MT	DTT
DMKT1DA	MA	Agonist
DMKT1DA	RN	Molecular determinants of ligand binding to the human melanocortin-4 receptor. Biochemistry. 2000 Dec 5;39(48):14900-11.
DMKT1DA	RU	https://pubmed.ncbi.nlm.nih.gov/11101306

DMKT1DA	DI	DMKT1DA
DMKT1DA	DN	MT-II
DMKT1DA	MI	TT6QAJ3
DMKT1DA	MN	Melanocortin receptor 5 (MC5R)
DMKT1DA	MT	DTT
DMKT1DA	MA	Agonist
DMKT1DA	RN	The role of melanocortins in body weight regulation: opportunities for the treatment of obesity. Eur J Pharmacol. 2002 Apr 12;440(2-3):141-57.
DMKT1DA	RU	https://pubmed.ncbi.nlm.nih.gov/12007532

DMK2FOX	DI	DMK2FOX
DMK2FOX	DN	MT-Immucillin-H
DMK2FOX	MI	TTMCF1Y
DMK2FOX	MN	Purine nucleoside phosphorylase (PNP)
DMK2FOX	MT	DTT
DMK2FOX	MA	Inhibitor
DMK2FOX	RN	Plasmodium falciparum purine nucleoside phosphorylase: crystal structures, immucillin inhibitors, and dual catalytic function. J Biol Chem. 2004 Apr 30;279(18):18103-6.
DMK2FOX	RU	https://pubmed.ncbi.nlm.nih.gov/14982926

DMXPIKT	DI	DMXPIKT
DMXPIKT	DN	M-tolyl 10H-phenothiazine-10-carboxylate
DMXPIKT	MI	TTEB0GD
DMXPIKT	MN	Cholinesterase (BCHE)
DMXPIKT	MT	DTT
DMXPIKT	MA	Inhibitor
DMXPIKT	RN	Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. J Med Chem. 2008 Jul 24;51(14):4200-12.
DMXPIKT	RU	https://pubmed.ncbi.nlm.nih.gov/18570368

DM8KPWM	DI	DM8KPWM
DM8KPWM	DN	MTSEA
DM8KPWM	MI	TTELV3W
DM8KPWM	MN	Transformation-sensitive protein p120 (TRPA1)
DM8KPWM	MT	DTT
DM8KPWM	MA	Activator
DM8KPWM	RN	Noxious compounds activate TRPA1 ion channels through covalent modification of cysteines. Nature. 2007 Feb 1;445(7127):541-5.
DM8KPWM	RU	https://pubmed.ncbi.nlm.nih.gov/17237762

DM16F75	DI	DM16F75
DM16F75	DN	MUG trihydrate
DM16F75	MI	DE5Z9QK
DM16F75	MN	Beta-glucuronidase (uidA)
DM16F75	MT	DME
DM16F75	MA	Metabolism
DM16F75	RN	Three structurally and functionally distinct beta-glucuronidases from the human gut microbe Bacteroides uniformis. J Biol Chem. 2018 Nov 30;293(48):18559-18573.
DM16F75	RU	https://pubmed.ncbi.nlm.nih.gov/30301767

DM16F75	DI	DM16F75
DM16F75	DN	MUG trihydrate
DM16F75	MI	DELQJ5O
DM16F75	MN	Beta-glucuronidase (uidA)
DM16F75	MT	DME
DM16F75	MA	Metabolism
DM16F75	RN	Three structurally and functionally distinct beta-glucuronidases from the human gut microbe Bacteroides uniformis. J Biol Chem. 2018 Nov 30;293(48):18559-18573.
DM16F75	RU	https://pubmed.ncbi.nlm.nih.gov/30301767

DMYV49C	DI	DMYV49C
DMYV49C	DN	Mulberrofuran C
DMYV49C	MI	TTELIN2
DMYV49C	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMYV49C	MT	DTT
DMYV49C	MA	Inhibitor
DMYV49C	RN	Protein tyrosine phosphatase 1B inhibitors from Morus root bark. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1426-9.
DMYV49C	RU	https://pubmed.ncbi.nlm.nih.gov/16356713

DMMKH72	DI	DMMKH72
DMMKH72	DN	Mulberrofuran D
DMMKH72	MI	TTELIN2
DMMKH72	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMMKH72	MT	DTT
DMMKH72	MA	Inhibitor
DMMKH72	RN	Protein tyrosine phosphatase 1B inhibitors isolated from Morus bombycis. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6759-61.
DMMKH72	RU	https://pubmed.ncbi.nlm.nih.gov/19846295

DMTV9P3	DI	DMTV9P3
DMTV9P3	DN	Mulberrofuran W
DMTV9P3	MI	TTELIN2
DMTV9P3	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMTV9P3	MT	DTT
DMTV9P3	MA	Inhibitor
DMTV9P3	RN	Protein tyrosine phosphatase 1B inhibitors isolated from Morus bombycis. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6759-61.
DMTV9P3	RU	https://pubmed.ncbi.nlm.nih.gov/19846295

DMW2Z4I	DI	DMW2Z4I
DMW2Z4I	DN	Multiform PI3K inhibitors
DMW2Z4I	MI	TTHBTOP
DMW2Z4I	MN	PI3-kinase gamma (PIK3CG)
DMW2Z4I	MT	DTT
DMW2Z4I	MA	Inhibitor
DMW2Z4I	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2155).
DMW2Z4I	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2155

DM6SYMH	DI	DM6SYMH
DM6SYMH	DN	Mumbaistatin
DM6SYMH	MI	TT1KPBZ
DM6SYMH	MN	Glucose-6-phosphate translocase (SLC37A4)
DM6SYMH	MT	DTT
DM6SYMH	MA	Inhibitor
DM6SYMH	RN	Studies toward the total synthesis of mumbaistatin, a highly potent glucose-6-phosphate translocase inhibitor. Synthesis of a mumbaistatin analogue. J Org Chem. 2002 Dec 27;67(26):9248-56.
DM6SYMH	RU	https://pubmed.ncbi.nlm.nih.gov/12492326

DM4FR71	DI	DM4FR71
DM4FR71	DN	muramyl dipeptide
DM4FR71	MI	TTQX29T
DM4FR71	MN	NLR pyrin domain containing 1 (NLRP1)
DM4FR71	MT	DTT
DM4FR71	MA	Agonist
DM4FR71	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1768).
DM4FR71	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1768

DM4FR71	DI	DM4FR71
DM4FR71	DN	muramyl dipeptide
DM4FR71	MI	TTYPUHA
DM4FR71	MN	Pattern recognition receptor NOD2 (NOD2)
DM4FR71	MT	DTT
DM4FR71	MA	Agonist
DM4FR71	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1763).
DM4FR71	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1763

DMNDUJ5	DI	DMNDUJ5
DMNDUJ5	DN	Muscarine
DMNDUJ5	MI	TTH18TF
DMNDUJ5	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMNDUJ5	MT	DTT
DMNDUJ5	MA	Agonist
DMNDUJ5	RN	The effects of the antagonists of muscarinic acetylcholine receptor subtypes in rat brain on urinary bladder contraction. Nippon Hinyokika Gakkai Zasshi. 2002 Mar;93(3):427-34.
DMNDUJ5	RU	https://pubmed.ncbi.nlm.nih.gov/11968796

DMNTF2O	DI	DMNTF2O
DMNTF2O	DN	Muscimol
DMNTF2O	MI	TTNJYV2
DMNTF2O	MN	Gamma-aminobutyric acid receptor (GAR)
DMNTF2O	MT	DTT
DMNTF2O	MA	Agonist
DMNTF2O	RN	THIP treatment of Huntington's disease. Neurology. 1983 May;33(5):637-9.
DMNTF2O	RU	https://pubmed.ncbi.nlm.nih.gov/6221200

DMNTF2O	DI	DMNTF2O
DMNTF2O	DN	Muscimol
DMNTF2O	MI	TTAN6JD
DMNTF2O	MN	Glutamate receptor AMPA (GRIA)
DMNTF2O	MT	DTT
DMNTF2O	MA	Agonist
DMNTF2O	RN	GABA(A) receptor ligands and their therapeutic potentials. Curr Top Med Chem. 2002 Aug;2(8):817-32.
DMNTF2O	RU	https://pubmed.ncbi.nlm.nih.gov/12171573

DMAY50R	DI	DMAY50R
DMAY50R	DN	Mutated growth hormone
DMAY50R	MI	TTG4R8V
DMAY50R	MN	Growth hormone-releasing hormone receptor (GHRHR)
DMAY50R	MT	DTT
DMAY50R	MA	Agonist
DMAY50R	RN	Treatment strategies for acromegaly. Expert Opin Emerg Drugs. 2005 Nov;10(4):875-90.
DMAY50R	RU	https://pubmed.ncbi.nlm.nih.gov/16262568

DMU65NK	DI	DMU65NK
DMU65NK	DN	Mycophenolic acid
DMU65NK	MI	TTYJOLE
DMU65NK	MN	MERS-CoV papain-like proteinase (PL-PRO)
DMU65NK	MT	DTT
DMU65NK	MA	Inhibitor
DMU65NK	RN	SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016 Aug;14(8):523-34.
DMU65NK	RU	https://pubmed.ncbi.nlm.nih.gov/27344959

DMUQP3J	DI	DMUQP3J
DMUQP3J	DN	Mycophenolic bis(sulfonamide)
DMUQP3J	MI	TTZFTY4
DMUQP3J	MN	Amidophosphoribosyltransferase (PPAT)
DMUQP3J	MT	DTT
DMUQP3J	MA	Inhibitor
DMUQP3J	RN	Bis(sulfonamide) isosters of mycophenolic adenine dinucleotide analogues: inhibition of inosine monophosphate dehydrogenase. Bioorg Med Chem. 2008 Aug 1;16(15):7462-9.
DMUQP3J	RU	https://pubmed.ncbi.nlm.nih.gov/18583139

DMUQP3J	DI	DMUQP3J
DMUQP3J	DN	Mycophenolic bis(sulfonamide)
DMUQP3J	MI	TTTB4UP
DMUQP3J	MN	Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2)
DMUQP3J	MT	DTT
DMUQP3J	MA	Inhibitor
DMUQP3J	RN	Bis(sulfonamide) isosters of mycophenolic adenine dinucleotide analogues: inhibition of inosine monophosphate dehydrogenase. Bioorg Med Chem. 2008 Aug 1;16(15):7462-9.
DMUQP3J	RU	https://pubmed.ncbi.nlm.nih.gov/18583139

DM4YRAH	DI	DM4YRAH
DM4YRAH	DN	Mycophenolic hydroxamic acid
DM4YRAH	MI	TTZFTY4
DM4YRAH	MN	Amidophosphoribosyltransferase (PPAT)
DM4YRAH	MT	DTT
DM4YRAH	MA	Inhibitor
DM4YRAH	RN	Structure-activity relationships for inhibition of inosine monophosphate dehydrogenase and differentiation induction of K562 cells among the mycoph... Bioorg Med Chem. 2010 Nov 15;18(22):8106-11.
DM4YRAH	RU	https://pubmed.ncbi.nlm.nih.gov/20934342

DM4YRAH	DI	DM4YRAH
DM4YRAH	DN	Mycophenolic hydroxamic acid
DM4YRAH	MI	TTTB4UP
DM4YRAH	MN	Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2)
DM4YRAH	MT	DTT
DM4YRAH	MA	Inhibitor
DM4YRAH	RN	Structure-activity relationships for inhibition of inosine monophosphate dehydrogenase and differentiation induction of K562 cells among the mycoph... Bioorg Med Chem. 2010 Nov 15;18(22):8106-11.
DM4YRAH	RU	https://pubmed.ncbi.nlm.nih.gov/20934342

DMX1POR	DI	DMX1POR
DMX1POR	DN	MYOSEVERIN
DMX1POR	MI	TTML2WA
DMX1POR	MN	Tubulin (TUB)
DMX1POR	MT	DTT
DMX1POR	MA	Inhibitor
DMX1POR	RN	Synthesis and biological evaluation of myoseverin derivatives: microtubule assembly inhibitors. J Med Chem. 2001 Dec 20;44(26):4497-500.
DMX1POR	RU	https://pubmed.ncbi.nlm.nih.gov/11741468

DMX1POR	DI	DMX1POR
DMX1POR	DN	MYOSEVERIN
DMX1POR	MI	TTYFKSZ
DMX1POR	MN	Tubulin beta (TUBB)
DMX1POR	MT	DTT
DMX1POR	MA	Inhibitor
DMX1POR	RN	Synthesis and biological evaluation of myoseverin derivatives: microtubule assembly inhibitors. J Med Chem. 2001 Dec 20;44(26):4497-500.
DMX1POR	RU	https://pubmed.ncbi.nlm.nih.gov/11741468

DMTV4L0	DI	DMTV4L0
DMTV4L0	DN	Myricetin
DMTV4L0	MI	TTHBTOP
DMTV4L0	MN	PI3-kinase gamma (PIK3CG)
DMTV4L0	MT	DTT
DMTV4L0	MA	Inhibitor
DMTV4L0	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMTV4L0	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMVXW4L	DI	DMVXW4L
DMVXW4L	DN	MYRIOCIN
DMVXW4L	MI	TTWTSCV
DMVXW4L	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DMVXW4L	MT	DTT
DMVXW4L	MA	Inhibitor
DMVXW4L	RN	Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activation. Nat Chem Biol. 2008 Sep;4(9):538-47.
DMVXW4L	RU	https://pubmed.ncbi.nlm.nih.gov/18641634

DMVMHTC	DI	DMVMHTC
DMVMHTC	DN	Myrisglycerol-phosphate
DMVMHTC	MI	DER5U19
DMVMHTC	MN	Bifunctional epoxide hydrolase 2 (EPHX2)
DMVMHTC	MT	DME
DMVMHTC	MA	Metabolism
DMVMHTC	RN	Role of soluble epoxide hydrolase phosphatase activity in the metabolism of lysophosphatidic acids. Biochem Biophys Res Commun. 2012 Mar 23;419(4):796-800.
DMVMHTC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22387545

DMYX0BL	DI	DMYX0BL
DMYX0BL	DN	MYRISTIC ACID
DMYX0BL	MI	TTV3NH6
DMYX0BL	MN	Calmodulin (CALM)
DMYX0BL	MT	DTT
DMYX0BL	MA	Inhibitor
DMYX0BL	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMYX0BL	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMYX0BL	DI	DMYX0BL
DMYX0BL	DN	MYRISTIC ACID
DMYX0BL	MI	TTMW94E
DMYX0BL	MN	FK506-binding protein 1A (FKBP1A)
DMYX0BL	MT	DTT
DMYX0BL	MA	Inhibitor
DMYX0BL	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMYX0BL	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMYX0BL	DI	DMYX0BL
DMYX0BL	DN	MYRISTIC ACID
DMYX0BL	MI	TT2F3CD
DMYX0BL	MN	Hepatocyte nuclear factor 4-alpha (HNF4A)
DMYX0BL	MT	DTT
DMYX0BL	MA	Inhibitor
DMYX0BL	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMYX0BL	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMYX0BL	DI	DMYX0BL
DMYX0BL	DN	MYRISTIC ACID
DMYX0BL	MI	TT4NXYM
DMYX0BL	MN	Human immunodeficiency virus Negative factor (HIV nef)
DMYX0BL	MT	DTT
DMYX0BL	MA	Inhibitor
DMYX0BL	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMYX0BL	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMYX0BL	DI	DMYX0BL
DMYX0BL	DN	MYRISTIC ACID
DMYX0BL	MI	TT8S9AV
DMYX0BL	MN	Lymphocyte antigen 96 (LY96)
DMYX0BL	MT	DTT
DMYX0BL	MA	Inhibitor
DMYX0BL	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMYX0BL	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMYX0BL	DI	DMYX0BL
DMYX0BL	DN	MYRISTIC ACID
DMYX0BL	MI	TT0OFWN
DMYX0BL	MN	Pseudomonas UDP-3-O-acyl-GlcNAc deacetylase (Pseudo lpxC)
DMYX0BL	MT	DTT
DMYX0BL	MA	Inhibitor
DMYX0BL	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMYX0BL	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMYX0BL	DI	DMYX0BL
DMYX0BL	DN	MYRISTIC ACID
DMYX0BL	MI	TTDQTEY
DMYX0BL	MN	Recoverin (RCVRN)
DMYX0BL	MT	DTT
DMYX0BL	MA	Inhibitor
DMYX0BL	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMYX0BL	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMYX0BL	DI	DMYX0BL
DMYX0BL	DN	MYRISTIC ACID
DMYX0BL	MI	TTISGCA
DMYX0BL	MN	Toll-like receptor 4 (TLR4)
DMYX0BL	MT	DTT
DMYX0BL	MA	Inhibitor
DMYX0BL	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMYX0BL	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMYX0BL	DI	DMYX0BL
DMYX0BL	DN	MYRISTIC ACID
DMYX0BL	MI	TT3PJMV
DMYX0BL	MN	Tyrosine-protein kinase ABL1 (ABL)
DMYX0BL	MT	DTT
DMYX0BL	MA	Inhibitor
DMYX0BL	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMYX0BL	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMYX0BL	DI	DMYX0BL
DMYX0BL	DN	MYRISTIC ACID
DMYX0BL	MI	TTVBE0F
DMYX0BL	MN	Virus Genome polyprotein (Viru POL)
DMYX0BL	MT	DTT
DMYX0BL	MA	Inhibitor
DMYX0BL	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMYX0BL	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMV7NGS	DI	DMV7NGS
DMV7NGS	DN	Myristoyl-Coa
DMV7NGS	MI	TTBAF05
DMV7NGS	MN	Candida Peptide N-myristoyltransferase (Candi NMT1)
DMV7NGS	MT	DTT
DMV7NGS	MA	Inhibitor
DMV7NGS	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMV7NGS	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMGJYIZ	DI	DMGJYIZ
DMGJYIZ	DN	MystiLol
DMGJYIZ	MI	TTMXGCW
DMGJYIZ	MN	Adrenergic receptor beta-3 (ADRB3)
DMGJYIZ	MT	DTT
DMGJYIZ	MA	Blocker
DMGJYIZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 29).
DMGJYIZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=29

DM16SVM	DI	DM16SVM
DM16SVM	DN	Myxopyronin B
DM16SVM	MI	TTS31JH
DM16SVM	MN	Staphylococcus Plastid RNA polymerase beta (Stap-coc rpoB)
DM16SVM	MT	DTT
DM16SVM	MA	Inhibitor
DM16SVM	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM16SVM	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM093GO	DI	DM093GO
DM093GO	DN	N-((1H-indol-2-yl)methyl)(phenyl)methanamine
DM093GO	MI	TT3WG5C
DM093GO	MN	Monoamine oxidase type A (MAO-A)
DM093GO	MT	DTT
DM093GO	MA	Inhibitor
DM093GO	RN	Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40.
DM093GO	RU	https://pubmed.ncbi.nlm.nih.gov/18951803

DMYUAXR	DI	DMYUAXR
DMYUAXR	DN	N-((1H-indol-2-yl)methyl)-2-phenylethanamine
DMYUAXR	MI	TT3WG5C
DMYUAXR	MN	Monoamine oxidase type A (MAO-A)
DMYUAXR	MT	DTT
DMYUAXR	MA	Inhibitor
DMYUAXR	RN	Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40.
DMYUAXR	RU	https://pubmed.ncbi.nlm.nih.gov/18951803

DMBQ5NS	DI	DMBQ5NS
DMBQ5NS	DN	N-(1-((cyanomethyl)carbamoyl)cyclohexyl)benzamide
DMBQ5NS	MI	TTDZN01
DMBQ5NS	MN	Cathepsin K (CTSK)
DMBQ5NS	MT	DTT
DMBQ5NS	MA	Inhibitor
DMBQ5NS	RN	Beta-substituted cyclohexanecarboxamide: a nonpeptidic framework for the design of potent inhibitors of cathepsin K. J Med Chem. 2006 Feb 9;49(3):1066-79.
DMBQ5NS	RU	https://pubmed.ncbi.nlm.nih.gov/16451072

DMJWTH9	DI	DMJWTH9
DMJWTH9	DN	N-(1-(1-phenylethyl)piperidin-4-yl)-1-naphthamide
DMJWTH9	MI	TTJQOD7
DMJWTH9	MN	5-HT 2A receptor (HTR2A)
DMJWTH9	MT	DTT
DMJWTH9	MA	Inhibitor
DMJWTH9	RN	Synthesis and in vitro binding studies of substituted piperidine naphthamides. Part I: Influence of the substitution on the basic nitrogen and the ... Bioorg Med Chem Lett. 2007 Mar 15;17(6):1565-9.
DMJWTH9	RU	https://pubmed.ncbi.nlm.nih.gov/17254782

DMMCGL3	DI	DMMCGL3
DMMCGL3	DN	N-(1-(1-phenylethyl)piperidin-4-yl)-2-naphthamide
DMMCGL3	MI	TTJQOD7
DMMCGL3	MN	5-HT 2A receptor (HTR2A)
DMMCGL3	MT	DTT
DMMCGL3	MA	Inhibitor
DMMCGL3	RN	Synthesis and in vitro binding studies of substituted piperidine naphthamides. Part I: Influence of the substitution on the basic nitrogen and the ... Bioorg Med Chem Lett. 2007 Mar 15;17(6):1565-9.
DMMCGL3	RU	https://pubmed.ncbi.nlm.nih.gov/17254782

DMGYLC1	DI	DMGYLC1
DMGYLC1	DN	N-(1-(3-bromobenzyl)piperidin-4-yl)-1-naphthamide
DMGYLC1	MI	TTJQOD7
DMGYLC1	MN	5-HT 2A receptor (HTR2A)
DMGYLC1	MT	DTT
DMGYLC1	MA	Inhibitor
DMGYLC1	RN	Synthesis and in vitro binding studies of substituted piperidine naphthamides. Part II: Influence of the substitution on the benzyl moiety on the a... Bioorg Med Chem Lett. 2007 Mar 15;17(6):1570-4.
DMGYLC1	RU	https://pubmed.ncbi.nlm.nih.gov/17251022

DMRQKYC	DI	DMRQKYC
DMRQKYC	DN	N-(1-(3-bromobenzyl)piperidin-4-yl)-2-naphthamide
DMRQKYC	MI	TTJQOD7
DMRQKYC	MN	5-HT 2A receptor (HTR2A)
DMRQKYC	MT	DTT
DMRQKYC	MA	Inhibitor
DMRQKYC	RN	Synthesis and in vitro binding studies of substituted piperidine naphthamides. Part II: Influence of the substitution on the benzyl moiety on the a... Bioorg Med Chem Lett. 2007 Mar 15;17(6):1570-4.
DMRQKYC	RU	https://pubmed.ncbi.nlm.nih.gov/17251022

DMS9RDW	DI	DMS9RDW
DMS9RDW	DN	N-(1-(4-bromobenzyl)piperidin-4-yl)-2-naphthamide
DMS9RDW	MI	TTJQOD7
DMS9RDW	MN	5-HT 2A receptor (HTR2A)
DMS9RDW	MT	DTT
DMS9RDW	MA	Inhibitor
DMS9RDW	RN	Synthesis and in vitro binding studies of substituted piperidine naphthamides. Part II: Influence of the substitution on the benzyl moiety on the a... Bioorg Med Chem Lett. 2007 Mar 15;17(6):1570-4.
DMS9RDW	RU	https://pubmed.ncbi.nlm.nih.gov/17251022

DMAP4R8	DI	DMAP4R8
DMAP4R8	DN	N-(1-(4-nitrobenzyl)piperidin-4-yl)-2-naphthamide
DMAP4R8	MI	TTJQOD7
DMAP4R8	MN	5-HT 2A receptor (HTR2A)
DMAP4R8	MT	DTT
DMAP4R8	MA	Inhibitor
DMAP4R8	RN	Synthesis and in vitro binding studies of substituted piperidine naphthamides. Part II: Influence of the substitution on the benzyl moiety on the a... Bioorg Med Chem Lett. 2007 Mar 15;17(6):1570-4.
DMAP4R8	RU	https://pubmed.ncbi.nlm.nih.gov/17251022

DMQSLJI	DI	DMQSLJI
DMQSLJI	DN	N-(1-(4-phenylbutyl)piperidin-4-yl)-1-naphthamide
DMQSLJI	MI	TTJQOD7
DMQSLJI	MN	5-HT 2A receptor (HTR2A)
DMQSLJI	MT	DTT
DMQSLJI	MA	Inhibitor
DMQSLJI	RN	Synthesis and in vitro binding studies of substituted piperidine naphthamides. Part I: Influence of the substitution on the basic nitrogen and the ... Bioorg Med Chem Lett. 2007 Mar 15;17(6):1565-9.
DMQSLJI	RU	https://pubmed.ncbi.nlm.nih.gov/17254782

DMZ84JH	DI	DMZ84JH
DMZ84JH	DN	N-(1-(4-phenylbutyl)piperidin-4-yl)-2-naphthamide
DMZ84JH	MI	TTJQOD7
DMZ84JH	MN	5-HT 2A receptor (HTR2A)
DMZ84JH	MT	DTT
DMZ84JH	MA	Inhibitor
DMZ84JH	RN	Synthesis and in vitro binding studies of substituted piperidine naphthamides. Part I: Influence of the substitution on the basic nitrogen and the ... Bioorg Med Chem Lett. 2007 Mar 15;17(6):1565-9.
DMZ84JH	RU	https://pubmed.ncbi.nlm.nih.gov/17254782

DMWP6OZ	DI	DMWP6OZ
DMWP6OZ	DN	N-(1,3,4-thiadiazol-2-yl)benzamide
DMWP6OZ	MI	TTSJ6Q4
DMWP6OZ	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DMWP6OZ	MT	DTT
DMWP6OZ	MA	Inhibitor
DMWP6OZ	RN	Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. J Med Chem. 2007 May 31;50(11):2640-6.
DMWP6OZ	RU	https://pubmed.ncbi.nlm.nih.gov/17461565

DMDW8VX	DI	DMDW8VX
DMDW8VX	DN	N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide
DMDW8VX	MI	TTHS256
DMDW8VX	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMDW8VX	MT	DTT
DMDW8VX	MA	Inhibitor
DMDW8VX	RN	Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat... J Med Chem. 2006 Jun 1;49(11):3332-44.
DMDW8VX	RU	https://pubmed.ncbi.nlm.nih.gov/16722652

DMEDJ7X	DI	DMEDJ7X
DMEDJ7X	DN	N-(1,4-diphenyl-1H-pyrazol-5-yl)benzamide
DMEDJ7X	MI	TTHS256
DMEDJ7X	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMEDJ7X	MT	DTT
DMEDJ7X	MA	Inhibitor
DMEDJ7X	RN	Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat... J Med Chem. 2006 Jun 1;49(11):3332-44.
DMEDJ7X	RU	https://pubmed.ncbi.nlm.nih.gov/16722652

DMW460V	DI	DMW460V
DMW460V	DN	N-(14-methylallyl)norgalanthamine
DMW460V	MI	TT1RS9F
DMW460V	MN	Acetylcholinesterase (AChE)
DMW460V	MT	DTT
DMW460V	MA	Inhibitor
DMW460V	RN	N-Alkylated galanthamine derivatives: Potent acetylcholinesterase inhibitors from Leucojum aestivum. Bioorg Med Chem Lett. 2008 Apr 1;18(7):2263-6.
DMW460V	RU	https://pubmed.ncbi.nlm.nih.gov/18356045

DMFRQ2U	DI	DMFRQ2U
DMFRQ2U	DN	N-(17-Methylmorphinan-3-yl)-N'-phenylurea
DMFRQ2U	MI	TT27RFC
DMFRQ2U	MN	Opioid receptor delta (OPRD1)
DMFRQ2U	MT	DTT
DMFRQ2U	MA	Inhibitor
DMFRQ2U	RN	Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18.
DMFRQ2U	RU	https://pubmed.ncbi.nlm.nih.gov/19928862

DMFRQ2U	DI	DMFRQ2U
DMFRQ2U	DN	N-(17-Methylmorphinan-3-yl)-N'-phenylurea
DMFRQ2U	MI	TTQW87Y
DMFRQ2U	MN	Opioid receptor kappa (OPRK1)
DMFRQ2U	MT	DTT
DMFRQ2U	MA	Inhibitor
DMFRQ2U	RN	Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18.
DMFRQ2U	RU	https://pubmed.ncbi.nlm.nih.gov/19928862

DMFRQ2U	DI	DMFRQ2U
DMFRQ2U	DN	N-(17-Methylmorphinan-3-yl)-N'-phenylurea
DMFRQ2U	MI	TTKWM86
DMFRQ2U	MN	Opioid receptor mu (MOP)
DMFRQ2U	MT	DTT
DMFRQ2U	MA	Inhibitor
DMFRQ2U	RN	Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18.
DMFRQ2U	RU	https://pubmed.ncbi.nlm.nih.gov/19928862

DMD6N8V	DI	DMD6N8V
DMD6N8V	DN	N-(1-Adamantyl)-N'-(4-Guanidinobenzyl)Urea
DMD6N8V	MI	TTGY7WI
DMD6N8V	MN	Urokinase-type plasminogen activator (PLAU)
DMD6N8V	MT	DTT
DMD6N8V	MA	Inhibitor
DMD6N8V	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD6N8V	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM29QT4	DI	DM29QT4
DM29QT4	DN	N-(1-adamantyl)-N'-propylsulfamide
DM29QT4	MI	TT6OEDT
DM29QT4	MN	Cannabinoid receptor 1 (CB1)
DM29QT4	MT	DTT
DM29QT4	MA	Inhibitor
DM29QT4	RN	Synthesis and pharmacological evaluation of sulfamide-based analogues of anandamide. Eur J Med Chem. 2009 Dec;44(12):4889-95.
DM29QT4	RU	https://pubmed.ncbi.nlm.nih.gov/19762126

DM3WBZP	DI	DM3WBZP
DM3WBZP	DN	N-(1-benzofuran-3-ylmethyl)sulfamide
DM3WBZP	MI	TTANPDJ
DM3WBZP	MN	Carbonic anhydrase II (CA-II)
DM3WBZP	MT	DTT
DM3WBZP	MA	Inhibitor
DM3WBZP	RN	Novel, broad-spectrum anticonvulsants containing a sulfamide group: advancement of N-((benzo[b]thien-3-yl)methyl)sulfamide (JNJ-26990990) into huma... J Med Chem. 2009 Dec 10;52(23):7528-36.
DM3WBZP	RU	https://pubmed.ncbi.nlm.nih.gov/19388676

DMP9A7L	DI	DMP9A7L
DMP9A7L	DN	N-(1-Benzyl-2-oxo-ethyl)-benzamide
DMP9A7L	MI	TTG5QB7
DMP9A7L	MN	Calpain-2 (CAPN2)
DMP9A7L	MT	DTT
DMP9A7L	MA	Inhibitor
DMP9A7L	RN	Alpha-diketone and alpha-keto ester derivatives of N-protected amino acids and peptides as novel inhibitors of cysteine and serine proteinases. J Med Chem. 1990 Jan;33(1):11-3.
DMP9A7L	RU	https://pubmed.ncbi.nlm.nih.gov/2296008

DM4HB7S	DI	DM4HB7S
DM4HB7S	DN	N-(1-benzylpiperidin-4-yl)-3,5-dimethoxybenzamide
DM4HB7S	MI	TTX4RTB
DM4HB7S	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DM4HB7S	MT	DTT
DM4HB7S	MA	Inhibitor
DM4HB7S	RN	Identification of substituted 4-aminopiperidines and 3-aminopyrrolidines as potent MCH-R1 antagonists for the treatment of obesity. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5445-50.
DM4HB7S	RU	https://pubmed.ncbi.nlm.nih.gov/16879961

DMEKSHG	DI	DMEKSHG
DMEKSHG	DN	N-(1-benzylpiperidin-4-yl)-4-sulfanylbutanamide
DMEKSHG	MI	TT8JRS7
DMEKSHG	MN	Beta-secretase (BACE)
DMEKSHG	MT	DTT
DMEKSHG	MA	Inhibitor
DMEKSHG	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMEKSHG	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMUQ6P4	DI	DMUQ6P4
DMUQ6P4	DN	N-(1-benzylpiperidine-4-yl)-2-naphthamide
DMUQ6P4	MI	TTJQOD7
DMUQ6P4	MN	5-HT 2A receptor (HTR2A)
DMUQ6P4	MT	DTT
DMUQ6P4	MA	Inhibitor
DMUQ6P4	RN	Synthesis and in vitro binding studies of substituted piperidine naphthamides. Part II: Influence of the substitution on the benzyl moiety on the a... Bioorg Med Chem Lett. 2007 Mar 15;17(6):1570-4.
DMUQ6P4	RU	https://pubmed.ncbi.nlm.nih.gov/17251022

DM054NF	DI	DM054NF
DM054NF	DN	N-(1H-benzo[d]imidazol-2-yl)-3-cyanobenzamide
DM054NF	MI	TTILUKB
DM054NF	MN	IRAK4 messenger RNA (IRAK4 mRNA)
DM054NF	MT	DTT
DM054NF	MA	Inhibitor
DM054NF	RN	Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4. Bioorg Med Chem Lett. 2006 Jun 1;16(11):2842-5.
DM054NF	RU	https://pubmed.ncbi.nlm.nih.gov/16563752

DM0CWPX	DI	DM0CWPX
DM0CWPX	DN	N-(1H-benzo[d]imidazol-2-yl)-3-nitrobenzamide
DM0CWPX	MI	TTILUKB
DM0CWPX	MN	IRAK4 messenger RNA (IRAK4 mRNA)
DM0CWPX	MT	DTT
DM0CWPX	MA	Inhibitor
DM0CWPX	RN	Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4. Bioorg Med Chem Lett. 2006 Jun 1;16(11):2842-5.
DM0CWPX	RU	https://pubmed.ncbi.nlm.nih.gov/16563752

DMIMJNU	DI	DMIMJNU
DMIMJNU	DN	N-(1H-indazol-5-yl)acetamide
DMIMJNU	MI	TT8NGED
DMIMJNU	MN	Prostaglandin G/H synthase 1 (COX-1)
DMIMJNU	MT	DTT
DMIMJNU	MA	Inhibitor
DMIMJNU	RN	New analgesics synthetically derived from the paracetamol metabolite N-(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide. J Med Chem. 2008 Dec 25;51(24):7800-5.
DMIMJNU	RU	https://pubmed.ncbi.nlm.nih.gov/19053765

DMIMJNU	DI	DMIMJNU
DMIMJNU	DN	N-(1H-indazol-5-yl)acetamide
DMIMJNU	MI	TTVKILB
DMIMJNU	MN	Prostaglandin G/H synthase 2 (COX-2)
DMIMJNU	MT	DTT
DMIMJNU	MA	Inhibitor
DMIMJNU	RN	New analgesics synthetically derived from the paracetamol metabolite N-(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide. J Med Chem. 2008 Dec 25;51(24):7800-5.
DMIMJNU	RU	https://pubmed.ncbi.nlm.nih.gov/19053765

DM63YJV	DI	DM63YJV
DM63YJV	DN	N-(1H-indazol-5-yl)icosa-5,8,11,14-tetraenamide
DM63YJV	MI	TT6OEDT
DM63YJV	MN	Cannabinoid receptor 1 (CB1)
DM63YJV	MT	DTT
DM63YJV	MA	Inhibitor
DM63YJV	RN	New analgesics synthetically derived from the paracetamol metabolite N-(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide. J Med Chem. 2008 Dec 25;51(24):7800-5.
DM63YJV	RU	https://pubmed.ncbi.nlm.nih.gov/19053765

DM63YJV	DI	DM63YJV
DM63YJV	DN	N-(1H-indazol-5-yl)icosa-5,8,11,14-tetraenamide
DM63YJV	MI	TTMSFAW
DM63YJV	MN	Cannabinoid receptor 2 (CB2)
DM63YJV	MT	DTT
DM63YJV	MA	Inhibitor
DM63YJV	RN	New analgesics synthetically derived from the paracetamol metabolite N-(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide. J Med Chem. 2008 Dec 25;51(24):7800-5.
DM63YJV	RU	https://pubmed.ncbi.nlm.nih.gov/19053765

DMHAGSW	DI	DMHAGSW
DMHAGSW	DN	N-(1H-Indol-2-ylmethyl)-N-(4-phenylbutyl)amine
DMHAGSW	MI	TT3WG5C
DMHAGSW	MN	Monoamine oxidase type A (MAO-A)
DMHAGSW	MT	DTT
DMHAGSW	MA	Inhibitor
DMHAGSW	RN	Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40.
DMHAGSW	RU	https://pubmed.ncbi.nlm.nih.gov/18951803

DMCM51R	DI	DMCM51R
DMCM51R	DN	N-(1H-Indol-2-ylmethyl)-N-methyl-N-phenylamine
DMCM51R	MI	TT3WG5C
DMCM51R	MN	Monoamine oxidase type A (MAO-A)
DMCM51R	MT	DTT
DMCM51R	MA	Inhibitor
DMCM51R	RN	Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40.
DMCM51R	RU	https://pubmed.ncbi.nlm.nih.gov/18951803

DMCM51R	DI	DMCM51R
DMCM51R	DN	N-(1H-Indol-2-ylmethyl)-N-methyl-N-phenylamine
DMCM51R	MI	TTGP7BY
DMCM51R	MN	Monoamine oxidase type B (MAO-B)
DMCM51R	MT	DTT
DMCM51R	MA	Inhibitor
DMCM51R	RN	Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40.
DMCM51R	RU	https://pubmed.ncbi.nlm.nih.gov/18951803

DMXD592	DI	DMXD592
DMXD592	DN	N-(1H-Indol-2-ylmethyl)-N-phenylamine
DMXD592	MI	TT3WG5C
DMXD592	MN	Monoamine oxidase type A (MAO-A)
DMXD592	MT	DTT
DMXD592	MA	Inhibitor
DMXD592	RN	Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40.
DMXD592	RU	https://pubmed.ncbi.nlm.nih.gov/18951803

DMXD592	DI	DMXD592
DMXD592	DN	N-(1H-Indol-2-ylmethyl)-N-phenylamine
DMXD592	MI	TTGP7BY
DMXD592	MN	Monoamine oxidase type B (MAO-B)
DMXD592	MT	DTT
DMXD592	MA	Inhibitor
DMXD592	RN	Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40.
DMXD592	RU	https://pubmed.ncbi.nlm.nih.gov/18951803

DMY3UZH	DI	DMY3UZH
DMY3UZH	DN	N-(1-Methyl-1H-indol-2-ylmethyl)-N-phenylamine
DMY3UZH	MI	TT3WG5C
DMY3UZH	MN	Monoamine oxidase type A (MAO-A)
DMY3UZH	MT	DTT
DMY3UZH	MA	Inhibitor
DMY3UZH	RN	Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40.
DMY3UZH	RU	https://pubmed.ncbi.nlm.nih.gov/18951803

DMI1HBR	DI	DMI1HBR
DMI1HBR	DN	N-(1-oxobutan-2-yl)-3-(trifluoromethyl)benzamide
DMI1HBR	MI	TTUMQVO
DMI1HBR	MN	Cathepsin S (CTSS)
DMI1HBR	MT	DTT
DMI1HBR	MA	Inhibitor
DMI1HBR	RN	Trifluoromethylphenyl as P2 for ketoamide-based cathepsin S inhibitors. Bioorg Med Chem Lett. 2010 Dec 1;20(23):6890-4.
DMI1HBR	RU	https://pubmed.ncbi.nlm.nih.gov/21030256

DMU9YF6	DI	DMU9YF6
DMU9YF6	DN	N-(1-phenethylpiperidin-4-yl)-1-naphthamide
DMU9YF6	MI	TTJQOD7
DMU9YF6	MN	5-HT 2A receptor (HTR2A)
DMU9YF6	MT	DTT
DMU9YF6	MA	Inhibitor
DMU9YF6	RN	Synthesis and in vitro binding studies of substituted piperidine naphthamides. Part I: Influence of the substitution on the basic nitrogen and the ... Bioorg Med Chem Lett. 2007 Mar 15;17(6):1565-9.
DMU9YF6	RU	https://pubmed.ncbi.nlm.nih.gov/17254782

DM9QA7Z	DI	DM9QA7Z
DM9QA7Z	DN	N-(1-phenethylpiperidin-4-yl)-2-naphthamide
DM9QA7Z	MI	TTJQOD7
DM9QA7Z	MN	5-HT 2A receptor (HTR2A)
DM9QA7Z	MT	DTT
DM9QA7Z	MA	Inhibitor
DM9QA7Z	RN	Synthesis and in vitro binding studies of substituted piperidine naphthamides. Part I: Influence of the substitution on the basic nitrogen and the ... Bioorg Med Chem Lett. 2007 Mar 15;17(6):1565-9.
DM9QA7Z	RU	https://pubmed.ncbi.nlm.nih.gov/17254782

DM6DEZ4	DI	DM6DEZ4
DM6DEZ4	DN	N-(1'-Phenyl-ethyl) estradiol-16-carboxamide
DM6DEZ4	MI	TTIWB6L
DM6DEZ4	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DM6DEZ4	MT	DTT
DM6DEZ4	MA	Inhibitor
DM6DEZ4	RN	Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45.
DM6DEZ4	RU	https://pubmed.ncbi.nlm.nih.gov/16480268

DMSHWYU	DI	DMSHWYU
DMSHWYU	DN	N-(1-PHENYL-PROPYL)-FORMAMIDE
DMSHWYU	MI	TT5DOVB
DMSHWYU	MN	Cytomegalovirus Protease (CMV UL80)
DMSHWYU	MT	DTT
DMSHWYU	MA	Inhibitor
DMSHWYU	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMSHWYU	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM6NC8G	DI	DM6NC8G
DM6NC8G	DN	N-(2-(1H-Indol-3-yl)ethyl)biphenyl-4-carboxamide
DM6NC8G	MI	TT0PG8F
DM6NC8G	MN	Cyclin-dependent kinase 4 (CDK4)
DM6NC8G	MT	DTT
DM6NC8G	MA	Inhibitor
DM6NC8G	RN	Design, synthesis and biological evaluation of new tryptamine and tetrahydro-beta-carboline-based selective inhibitors of CDK4. Bioorg Med Chem. 2008 Aug 15;16(16):7728-39.
DM6NC8G	RU	https://pubmed.ncbi.nlm.nih.gov/18650093

DM97Q6T	DI	DM97Q6T
DM97Q6T	DN	N-(2-(4-chlorobenzyloxy)-5-bromobenzyl)ethanamine
DM97Q6T	MI	TT2CEJG
DM97Q6T	MN	C-C chemokine receptor type 5 (CCR5)
DM97Q6T	MT	DTT
DM97Q6T	MA	Inhibitor
DM97Q6T	RN	CCR5 receptor antagonists: discovery and SAR of novel 4-hydroxypiperidine derivatives. Bioorg Med Chem Lett. 2007 Apr 1;17(7):1883-7.
DM97Q6T	RU	https://pubmed.ncbi.nlm.nih.gov/17314043

DM57GQN	DI	DM57GQN
DM57GQN	DN	N-(2-(4-hexyl-2-hydroxyphenoxy)phenyl)acetamide
DM57GQN	MI	TTVTX4N
DM57GQN	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DM57GQN	MT	DTT
DM57GQN	MA	Inhibitor
DM57GQN	RN	Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33.
DM57GQN	RU	https://pubmed.ncbi.nlm.nih.gov/18457948

DM4V7AS	DI	DM4V7AS
DM4V7AS	DN	N-(2-(5-methoxybenzofuran-3-yl)ethyl)acetamide
DM4V7AS	MI	TT0WAIE
DM4V7AS	MN	Melatonin receptor type 1A (MTNR1A)
DM4V7AS	MT	DTT
DM4V7AS	MA	Inhibitor
DM4V7AS	RN	Design and synthesis of benzofuranic derivatives as new ligands at the melatonin-binding site MT3. Bioorg Med Chem. 2008 May 1;16(9):4954-62.
DM4V7AS	RU	https://pubmed.ncbi.nlm.nih.gov/18372181

DM4V7AS	DI	DM4V7AS
DM4V7AS	DN	N-(2-(5-methoxybenzofuran-3-yl)ethyl)acetamide
DM4V7AS	MI	TT32JK8
DM4V7AS	MN	Melatonin receptor type 1B (MTNR1B)
DM4V7AS	MT	DTT
DM4V7AS	MA	Inhibitor
DM4V7AS	RN	Design and synthesis of benzofuranic derivatives as new ligands at the melatonin-binding site MT3. Bioorg Med Chem. 2008 May 1;16(9):4954-62.
DM4V7AS	RU	https://pubmed.ncbi.nlm.nih.gov/18372181

DMLTROU	DI	DMLTROU
DMLTROU	DN	N-(2-(furan-2-yl)-3,4'-bipyridin-6-yl)acetamide
DMLTROU	MI	TTK25J1
DMLTROU	MN	Adenosine A1 receptor (ADORA1)
DMLTROU	MT	DTT
DMLTROU	MA	Inhibitor
DMLTROU	RN	Discovery of N-(5,6-diarylpyridin-2-yl)amide derivatives as potent and selective A(2B) adenosine receptor antagonists. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1697-700.
DMLTROU	RU	https://pubmed.ncbi.nlm.nih.gov/20137946

DMLTROU	DI	DMLTROU
DMLTROU	DN	N-(2-(furan-2-yl)-3,4'-bipyridin-6-yl)acetamide
DMLTROU	MI	TTM2AOE
DMLTROU	MN	Adenosine A2a receptor (ADORA2A)
DMLTROU	MT	DTT
DMLTROU	MA	Inhibitor
DMLTROU	RN	Discovery of N-(5,6-diarylpyridin-2-yl)amide derivatives as potent and selective A(2B) adenosine receptor antagonists. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1697-700.
DMLTROU	RU	https://pubmed.ncbi.nlm.nih.gov/20137946

DMLTROU	DI	DMLTROU
DMLTROU	DN	N-(2-(furan-2-yl)-3,4'-bipyridin-6-yl)acetamide
DMLTROU	MI	TTNE7KG
DMLTROU	MN	Adenosine A2b receptor (ADORA2B)
DMLTROU	MT	DTT
DMLTROU	MA	Inhibitor
DMLTROU	RN	Discovery of N-(5,6-diarylpyridin-2-yl)amide derivatives as potent and selective A(2B) adenosine receptor antagonists. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1697-700.
DMLTROU	RU	https://pubmed.ncbi.nlm.nih.gov/20137946

DMLTROU	DI	DMLTROU
DMLTROU	DN	N-(2-(furan-2-yl)-3,4'-bipyridin-6-yl)acetamide
DMLTROU	MI	TTJFY5U
DMLTROU	MN	Adenosine A3 receptor (ADORA3)
DMLTROU	MT	DTT
DMLTROU	MA	Inhibitor
DMLTROU	RN	Discovery of N-(5,6-diarylpyridin-2-yl)amide derivatives as potent and selective A(2B) adenosine receptor antagonists. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1697-700.
DMLTROU	RU	https://pubmed.ncbi.nlm.nih.gov/20137946

DMWC70I	DI	DMWC70I
DMWC70I	DN	N-(2,3,4,9-Tetrahydro-1H-carbazol-3-yl)-acetamide
DMWC70I	MI	TT0WAIE
DMWC70I	MN	Melatonin receptor type 1A (MTNR1A)
DMWC70I	MT	DTT
DMWC70I	MA	Inhibitor
DMWC70I	RN	Mapping the melatonin receptor. 2. synthesis and biological activity of indole derived melatonin analogues with restricted conformations of the C-3 amidoethane side chain, Bioorg. Med. Chem. Lett. 4(13):1559-1564 (1994).
DMWC70I	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01805667

DMWC70I	DI	DMWC70I
DMWC70I	DN	N-(2,3,4,9-Tetrahydro-1H-carbazol-3-yl)-acetamide
DMWC70I	MI	TT32JK8
DMWC70I	MN	Melatonin receptor type 1B (MTNR1B)
DMWC70I	MT	DTT
DMWC70I	MA	Inhibitor
DMWC70I	RN	Mapping the melatonin receptor. 2. synthesis and biological activity of indole derived melatonin analogues with restricted conformations of the C-3 amidoethane side chain, Bioorg. Med. Chem. Lett. 4(13):1559-1564 (1994).
DMWC70I	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01805667

DMUZL3J	DI	DMUZL3J
DMUZL3J	DN	N-(2,3-DIFLUORO-BENZYL)-4-SULFAMOYL-BENZAMIDE
DMUZL3J	MI	TTANPDJ
DMUZL3J	MN	Carbonic anhydrase II (CA-II)
DMUZL3J	MT	DTT
DMUZL3J	MA	Inhibitor
DMUZL3J	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMUZL3J	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMTLPDZ	DI	DMTLPDZ
DMTLPDZ	DN	N-(2,3-dihydro-1H-inden-2-yl)isoquinolin-1-amine
DMTLPDZ	MI	TTVBPDM
DMTLPDZ	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMTLPDZ	MT	DTT
DMTLPDZ	MA	Inhibitor
DMTLPDZ	RN	In vitro and in vivo SAR of pyrido[3,4-d]pyramid-4-ylamine based mGluR1 antagonists. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2190-4.
DMTLPDZ	RU	https://pubmed.ncbi.nlm.nih.gov/19289283

DMJ6LI8	DI	DMJ6LI8
DMJ6LI8	DN	N-(2,3-dihydro-1H-inden-2-yl)quinazolin-4-amine
DMJ6LI8	MI	TTVBPDM
DMJ6LI8	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMJ6LI8	MT	DTT
DMJ6LI8	MA	Inhibitor
DMJ6LI8	RN	In vitro and in vivo SAR of pyrido[3,4-d]pyramid-4-ylamine based mGluR1 antagonists. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2190-4.
DMJ6LI8	RU	https://pubmed.ncbi.nlm.nih.gov/19289283

DMPL26K	DI	DMPL26K
DMPL26K	DN	N-(2,3-Dihydro-1H-phenalen-2-yl)-acetamide
DMPL26K	MI	TT0WAIE
DMPL26K	MN	Melatonin receptor type 1A (MTNR1A)
DMPL26K	MT	DTT
DMPL26K	MA	Inhibitor
DMPL26K	RN	Synthesis of 2-amido-2,3-dihydro-1H-phenalene derivatives as new conformationally restricted ligands for melatonin receptors. J Med Chem. 1996 Aug 2;39(16):3089-95.
DMPL26K	RU	https://pubmed.ncbi.nlm.nih.gov/8759629

DM5R3ZG	DI	DM5R3ZG
DM5R3ZG	DN	N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide
DM5R3ZG	MI	TTBH0VX
DM5R3ZG	MN	Histone deacetylase (HDAC)
DM5R3ZG	MT	DTT
DM5R3ZG	MA	Inhibitor
DM5R3ZG	RN	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50.
DM5R3ZG	RU	https://pubmed.ncbi.nlm.nih.gov/20143840

DM5R3ZG	DI	DM5R3ZG
DM5R3ZG	DN	N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide
DM5R3ZG	MI	TT6R7JZ
DM5R3ZG	MN	Histone deacetylase 1 (HDAC1)
DM5R3ZG	MT	DTT
DM5R3ZG	MA	Inhibitor
DM5R3ZG	RN	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50.
DM5R3ZG	RU	https://pubmed.ncbi.nlm.nih.gov/20143840

DMHI4Y6	DI	DMHI4Y6
DMHI4Y6	DN	N-(2,4-Dichloro-benzoyl)-benzenesulfonamide
DMHI4Y6	MI	TTUTJGQ
DMHI4Y6	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMHI4Y6	MT	DTT
DMHI4Y6	MA	Inhibitor
DMHI4Y6	RN	Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80.
DMHI4Y6	RU	https://pubmed.ncbi.nlm.nih.gov/15481975

DMHI4Y6	DI	DMHI4Y6
DMHI4Y6	DN	N-(2,4-Dichloro-benzoyl)-benzenesulfonamide
DMHI4Y6	MI	TTDCBX5
DMHI4Y6	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DMHI4Y6	MT	DTT
DMHI4Y6	MA	Inhibitor
DMHI4Y6	RN	Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80.
DMHI4Y6	RU	https://pubmed.ncbi.nlm.nih.gov/15481975

DMHI4Y6	DI	DMHI4Y6
DMHI4Y6	DN	N-(2,4-Dichloro-benzoyl)-benzenesulfonamide
DMHI4Y6	MI	TT1VAUK
DMHI4Y6	MN	VEGFR1 messenger RNA (VEGFR1 mRNA)
DMHI4Y6	MT	DTT
DMHI4Y6	MA	Inhibitor
DMHI4Y6	RN	Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80.
DMHI4Y6	RU	https://pubmed.ncbi.nlm.nih.gov/15481975

DM5COQ9	DI	DM5COQ9
DM5COQ9	DN	N-(2,4-dichlorophenyl)-2-nitrobenzamide
DM5COQ9	MI	TTVTX4N
DM5COQ9	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DM5COQ9	MT	DTT
DM5COQ9	MA	Inhibitor
DM5COQ9	RN	Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening. Eur J Med Chem. 2009 Sep;44(9):3718-30.
DM5COQ9	RU	https://pubmed.ncbi.nlm.nih.gov/19428156

DMHJOBQ	DI	DMHJOBQ
DMHJOBQ	DN	N-(2,4-dichlorophenyl)-4-methyl-3-nitrobenzamide
DMHJOBQ	MI	TTVTX4N
DMHJOBQ	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DMHJOBQ	MT	DTT
DMHJOBQ	MA	Inhibitor
DMHJOBQ	RN	Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening. Eur J Med Chem. 2009 Sep;44(9):3718-30.
DMHJOBQ	RU	https://pubmed.ncbi.nlm.nih.gov/19428156

DMNT3JV	DI	DMNT3JV
DMNT3JV	DN	N-(2,4-dihydroxybenzyl)-3,4,5-trihydroxybenzamide
DMNT3JV	MI	TTULVH8
DMNT3JV	MN	Tyrosinase (TYR)
DMNT3JV	MT	DTT
DMNT3JV	MA	Inhibitor
DMNT3JV	RN	N-Benzylbenzamides: a new class of potent tyrosinase inhibitors. Bioorg Med Chem Lett. 2006 May 15;16(10):2682-4.
DMNT3JV	RU	https://pubmed.ncbi.nlm.nih.gov/16513349

DM3IMXF	DI	DM3IMXF
DM3IMXF	DN	N-(2,4-dihydroxybenzyl)-3,4-dihydroxybenzamide
DM3IMXF	MI	TTULVH8
DM3IMXF	MN	Tyrosinase (TYR)
DM3IMXF	MT	DTT
DM3IMXF	MA	Inhibitor
DM3IMXF	RN	N-Benzylbenzamides: a new class of potent tyrosinase inhibitors. Bioorg Med Chem Lett. 2006 May 15;16(10):2682-4.
DM3IMXF	RU	https://pubmed.ncbi.nlm.nih.gov/16513349

DM6U8SL	DI	DM6U8SL
DM6U8SL	DN	N-(2,4-dihydroxybenzyl)-3,5-dihydroxybenzamide
DM6U8SL	MI	TTULVH8
DM6U8SL	MN	Tyrosinase (TYR)
DM6U8SL	MT	DTT
DM6U8SL	MA	Inhibitor
DM6U8SL	RN	N-Benzylbenzamides: a new class of potent tyrosinase inhibitors. Bioorg Med Chem Lett. 2006 May 15;16(10):2682-4.
DM6U8SL	RU	https://pubmed.ncbi.nlm.nih.gov/16513349

DM3QWZU	DI	DM3QWZU
DM3QWZU	DN	N-(2,4-dimethoxyphenethyl)docos-13-enamide
DM3QWZU	MI	TT6OEDT
DM3QWZU	MN	Cannabinoid receptor 1 (CB1)
DM3QWZU	MT	DTT
DM3QWZU	MA	Inhibitor
DM3QWZU	RN	New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies. Bioorg Med Chem Lett. 2006 Jan 1;16(1):138-41.
DM3QWZU	RU	https://pubmed.ncbi.nlm.nih.gov/16213718

DMRQSD2	DI	DMRQSD2
DMRQSD2	DN	N-(2,4-dimethoxyphenethyl)oleamide
DMRQSD2	MI	TT6OEDT
DMRQSD2	MN	Cannabinoid receptor 1 (CB1)
DMRQSD2	MT	DTT
DMRQSD2	MA	Inhibitor
DMRQSD2	RN	New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies. Bioorg Med Chem Lett. 2006 Jan 1;16(1):138-41.
DMRQSD2	RU	https://pubmed.ncbi.nlm.nih.gov/16213718

DME0YBF	DI	DME0YBF
DME0YBF	DN	N-(2,4-Dimethoxy-phenyl)-3,5-dimethoxy-benzamide
DME0YBF	MI	TTI84H7
DME0YBF	MN	Cytochrome P450 1B1 (CYP1B1)
DME0YBF	MT	DTT
DME0YBF	MA	Inhibitor
DME0YBF	RN	Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors. J Med Chem. 2002 Jan 3;45(1):160-4.
DME0YBF	RU	https://pubmed.ncbi.nlm.nih.gov/11754588

DMFZAS9	DI	DMFZAS9
DMFZAS9	DN	N-(2,4-dimethylphenyl)-2-nitrobenzamide
DMFZAS9	MI	TTVTX4N
DMFZAS9	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DMFZAS9	MT	DTT
DMFZAS9	MA	Inhibitor
DMFZAS9	RN	Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening. Eur J Med Chem. 2009 Sep;44(9):3718-30.
DMFZAS9	RU	https://pubmed.ncbi.nlm.nih.gov/19428156

DMXA9MR	DI	DMXA9MR
DMXA9MR	DN	N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide
DMXA9MR	MI	TTBH0VX
DMXA9MR	MN	Histone deacetylase (HDAC)
DMXA9MR	MT	DTT
DMXA9MR	MA	Inhibitor
DMXA9MR	RN	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50.
DMXA9MR	RU	https://pubmed.ncbi.nlm.nih.gov/20143840

DMXA9MR	DI	DMXA9MR
DMXA9MR	DN	N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide
DMXA9MR	MI	TT6R7JZ
DMXA9MR	MN	Histone deacetylase 1 (HDAC1)
DMXA9MR	MT	DTT
DMXA9MR	MA	Inhibitor
DMXA9MR	RN	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50.
DMXA9MR	RU	https://pubmed.ncbi.nlm.nih.gov/20143840

DMUVSM1	DI	DMUVSM1
DMUVSM1	DN	N-(2,5-dichlorophenyl)-4-methoxy-3-nitrobenzamide
DMUVSM1	MI	TTVTX4N
DMUVSM1	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DMUVSM1	MT	DTT
DMUVSM1	MA	Inhibitor
DMUVSM1	RN	Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening. Eur J Med Chem. 2009 Sep;44(9):3718-30.
DMUVSM1	RU	https://pubmed.ncbi.nlm.nih.gov/19428156

DMOL79W	DI	DMOL79W
DMOL79W	DN	N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide
DMOL79W	MI	TTBH0VX
DMOL79W	MN	Histone deacetylase (HDAC)
DMOL79W	MT	DTT
DMOL79W	MA	Inhibitor
DMOL79W	RN	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50.
DMOL79W	RU	https://pubmed.ncbi.nlm.nih.gov/20143840

DMOL79W	DI	DMOL79W
DMOL79W	DN	N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide
DMOL79W	MI	TT6R7JZ
DMOL79W	MN	Histone deacetylase 1 (HDAC1)
DMOL79W	MT	DTT
DMOL79W	MA	Inhibitor
DMOL79W	RN	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50.
DMOL79W	RU	https://pubmed.ncbi.nlm.nih.gov/20143840

DM9ATQ6	DI	DM9ATQ6
DM9ATQ6	DN	N-(2,6-Diflouro-Benzyl)-4-Sulfamoyl-Benzamide
DM9ATQ6	MI	TTANPDJ
DM9ATQ6	MN	Carbonic anhydrase II (CA-II)
DM9ATQ6	MT	DTT
DM9ATQ6	MA	Inhibitor
DM9ATQ6	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9ATQ6	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMTBAPH	DI	DMTBAPH
DMTBAPH	DN	N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide
DMTBAPH	MI	TTBH0VX
DMTBAPH	MN	Histone deacetylase (HDAC)
DMTBAPH	MT	DTT
DMTBAPH	MA	Inhibitor
DMTBAPH	RN	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50.
DMTBAPH	RU	https://pubmed.ncbi.nlm.nih.gov/20143840

DMTBAPH	DI	DMTBAPH
DMTBAPH	DN	N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide
DMTBAPH	MI	TT6R7JZ
DMTBAPH	MN	Histone deacetylase 1 (HDAC1)
DMTBAPH	MT	DTT
DMTBAPH	MA	Inhibitor
DMTBAPH	RN	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50.
DMTBAPH	RU	https://pubmed.ncbi.nlm.nih.gov/20143840

DMK5AU4	DI	DMK5AU4
DMK5AU4	DN	N-(2,6-diphenylpyrimidin-4-yl)-2-ethylbutyramide
DMK5AU4	MI	TTK25J1
DMK5AU4	MN	Adenosine A1 receptor (ADORA1)
DMK5AU4	MT	DTT
DMK5AU4	MA	Inhibitor
DMK5AU4	RN	2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40.
DMK5AU4	RU	https://pubmed.ncbi.nlm.nih.gov/15588088

DMK5AU4	DI	DMK5AU4
DMK5AU4	DN	N-(2,6-diphenylpyrimidin-4-yl)-2-ethylbutyramide
DMK5AU4	MI	TTM2AOE
DMK5AU4	MN	Adenosine A2a receptor (ADORA2A)
DMK5AU4	MT	DTT
DMK5AU4	MA	Inhibitor
DMK5AU4	RN	2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40.
DMK5AU4	RU	https://pubmed.ncbi.nlm.nih.gov/15588088

DM6HGK4	DI	DM6HGK4
DM6HGK4	DN	N-(2,6-diphenylpyrimidin-4-yl)-3-methylbutyramide
DM6HGK4	MI	TTK25J1
DM6HGK4	MN	Adenosine A1 receptor (ADORA1)
DM6HGK4	MT	DTT
DM6HGK4	MA	Inhibitor
DM6HGK4	RN	2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40.
DM6HGK4	RU	https://pubmed.ncbi.nlm.nih.gov/15588088

DM6HGK4	DI	DM6HGK4
DM6HGK4	DN	N-(2,6-diphenylpyrimidin-4-yl)-3-methylbutyramide
DM6HGK4	MI	TTM2AOE
DM6HGK4	MN	Adenosine A2a receptor (ADORA2A)
DM6HGK4	MT	DTT
DM6HGK4	MA	Inhibitor
DM6HGK4	RN	2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40.
DM6HGK4	RU	https://pubmed.ncbi.nlm.nih.gov/15588088

DM6HGK4	DI	DM6HGK4
DM6HGK4	DN	N-(2,6-diphenylpyrimidin-4-yl)-3-methylbutyramide
DM6HGK4	MI	TTJFY5U
DM6HGK4	MN	Adenosine A3 receptor (ADORA3)
DM6HGK4	MT	DTT
DM6HGK4	MA	Inhibitor
DM6HGK4	RN	2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40.
DM6HGK4	RU	https://pubmed.ncbi.nlm.nih.gov/15588088

DMQ0DMU	DI	DMQ0DMU
DMQ0DMU	DN	N-(2,6-diphenylpyrimidin-4-yl)acetamide
DMQ0DMU	MI	TTK25J1
DMQ0DMU	MN	Adenosine A1 receptor (ADORA1)
DMQ0DMU	MT	DTT
DMQ0DMU	MA	Inhibitor
DMQ0DMU	RN	2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40.
DMQ0DMU	RU	https://pubmed.ncbi.nlm.nih.gov/15588088

DMQ0DMU	DI	DMQ0DMU
DMQ0DMU	DN	N-(2,6-diphenylpyrimidin-4-yl)acetamide
DMQ0DMU	MI	TTM2AOE
DMQ0DMU	MN	Adenosine A2a receptor (ADORA2A)
DMQ0DMU	MT	DTT
DMQ0DMU	MA	Inhibitor
DMQ0DMU	RN	2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40.
DMQ0DMU	RU	https://pubmed.ncbi.nlm.nih.gov/15588088

DMQ0DMU	DI	DMQ0DMU
DMQ0DMU	DN	N-(2,6-diphenylpyrimidin-4-yl)acetamide
DMQ0DMU	MI	TTJFY5U
DMQ0DMU	MN	Adenosine A3 receptor (ADORA3)
DMQ0DMU	MT	DTT
DMQ0DMU	MA	Inhibitor
DMQ0DMU	RN	2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40.
DMQ0DMU	RU	https://pubmed.ncbi.nlm.nih.gov/15588088

DMBW752	DI	DMBW752
DMBW752	DN	N-(2,6-diphenylpyrimidin-4-yl)benzamide
DMBW752	MI	TTK25J1
DMBW752	MN	Adenosine A1 receptor (ADORA1)
DMBW752	MT	DTT
DMBW752	MA	Inhibitor
DMBW752	RN	2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40.
DMBW752	RU	https://pubmed.ncbi.nlm.nih.gov/15588088

DMBW752	DI	DMBW752
DMBW752	DN	N-(2,6-diphenylpyrimidin-4-yl)benzamide
DMBW752	MI	TTJFY5U
DMBW752	MN	Adenosine A3 receptor (ADORA3)
DMBW752	MT	DTT
DMBW752	MA	Inhibitor
DMBW752	RN	2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40.
DMBW752	RU	https://pubmed.ncbi.nlm.nih.gov/15588088

DM5EF71	DI	DM5EF71
DM5EF71	DN	N-(2,6-diphenylpyrimidin-4-yl)butyramide
DM5EF71	MI	TTK25J1
DM5EF71	MN	Adenosine A1 receptor (ADORA1)
DM5EF71	MT	DTT
DM5EF71	MA	Inhibitor
DM5EF71	RN	2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40.
DM5EF71	RU	https://pubmed.ncbi.nlm.nih.gov/15588088

DM5EF71	DI	DM5EF71
DM5EF71	DN	N-(2,6-diphenylpyrimidin-4-yl)butyramide
DM5EF71	MI	TTM2AOE
DM5EF71	MN	Adenosine A2a receptor (ADORA2A)
DM5EF71	MT	DTT
DM5EF71	MA	Inhibitor
DM5EF71	RN	2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40.
DM5EF71	RU	https://pubmed.ncbi.nlm.nih.gov/15588088

DM5EF71	DI	DM5EF71
DM5EF71	DN	N-(2,6-diphenylpyrimidin-4-yl)butyramide
DM5EF71	MI	TTJFY5U
DM5EF71	MN	Adenosine A3 receptor (ADORA3)
DM5EF71	MT	DTT
DM5EF71	MA	Inhibitor
DM5EF71	RN	2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40.
DM5EF71	RU	https://pubmed.ncbi.nlm.nih.gov/15588088

DMWPZCS	DI	DMWPZCS
DMWPZCS	DN	N-(2,6-diphenylpyrimidin-4-yl)isobutyramide
DMWPZCS	MI	TTK25J1
DMWPZCS	MN	Adenosine A1 receptor (ADORA1)
DMWPZCS	MT	DTT
DMWPZCS	MA	Inhibitor
DMWPZCS	RN	2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40.
DMWPZCS	RU	https://pubmed.ncbi.nlm.nih.gov/15588088

DMWPZCS	DI	DMWPZCS
DMWPZCS	DN	N-(2,6-diphenylpyrimidin-4-yl)isobutyramide
DMWPZCS	MI	TTM2AOE
DMWPZCS	MN	Adenosine A2a receptor (ADORA2A)
DMWPZCS	MT	DTT
DMWPZCS	MA	Inhibitor
DMWPZCS	RN	2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40.
DMWPZCS	RU	https://pubmed.ncbi.nlm.nih.gov/15588088

DMWPZCS	DI	DMWPZCS
DMWPZCS	DN	N-(2,6-diphenylpyrimidin-4-yl)isobutyramide
DMWPZCS	MI	TTJFY5U
DMWPZCS	MN	Adenosine A3 receptor (ADORA3)
DMWPZCS	MT	DTT
DMWPZCS	MA	Inhibitor
DMWPZCS	RN	2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40.
DMWPZCS	RU	https://pubmed.ncbi.nlm.nih.gov/15588088

DM89NGE	DI	DM89NGE
DM89NGE	DN	N-(2,6-diphenylpyrimidin-4-yl)propionamide
DM89NGE	MI	TTK25J1
DM89NGE	MN	Adenosine A1 receptor (ADORA1)
DM89NGE	MT	DTT
DM89NGE	MA	Inhibitor
DM89NGE	RN	2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40.
DM89NGE	RU	https://pubmed.ncbi.nlm.nih.gov/15588088

DM89NGE	DI	DM89NGE
DM89NGE	DN	N-(2,6-diphenylpyrimidin-4-yl)propionamide
DM89NGE	MI	TTM2AOE
DM89NGE	MN	Adenosine A2a receptor (ADORA2A)
DM89NGE	MT	DTT
DM89NGE	MA	Inhibitor
DM89NGE	RN	2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40.
DM89NGE	RU	https://pubmed.ncbi.nlm.nih.gov/15588088

DM89NGE	DI	DM89NGE
DM89NGE	DN	N-(2,6-diphenylpyrimidin-4-yl)propionamide
DM89NGE	MI	TTJFY5U
DM89NGE	MN	Adenosine A3 receptor (ADORA3)
DM89NGE	MT	DTT
DM89NGE	MA	Inhibitor
DM89NGE	RN	2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40.
DM89NGE	RU	https://pubmed.ncbi.nlm.nih.gov/15588088

DM7D3GL	DI	DM7D3GL
DM7D3GL	DN	N-(2-Acetamido)Iminodiacetic Acid
DM7D3GL	MI	TTICO5G
DM7D3GL	MN	Staphylococcus Peptide deformylase (Stap-coc def)
DM7D3GL	MT	DTT
DM7D3GL	MA	Inhibitor
DM7D3GL	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM7D3GL	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM6QZPH	DI	DM6QZPH
DM6QZPH	DN	N-(2-adamantyl)-N'-propylsulfamide
DM6QZPH	MI	TT6OEDT
DM6QZPH	MN	Cannabinoid receptor 1 (CB1)
DM6QZPH	MT	DTT
DM6QZPH	MA	Inhibitor
DM6QZPH	RN	Synthesis and pharmacological evaluation of sulfamide-based analogues of anandamide. Eur J Med Chem. 2009 Dec;44(12):4889-95.
DM6QZPH	RU	https://pubmed.ncbi.nlm.nih.gov/19762126

DM7VN9P	DI	DM7VN9P
DM7VN9P	DN	N-(2-amino-5-(benzofuran-2-yl)phenyl)benzamide
DM7VN9P	MI	TTSHTOI
DM7VN9P	MN	Histone deacetylase 2 (HDAC2)
DM7VN9P	MT	DTT
DM7VN9P	MA	Inhibitor
DM7VN9P	RN	Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5.
DM7VN9P	RU	https://pubmed.ncbi.nlm.nih.gov/20392638

DMY9HO8	DI	DMY9HO8
DMY9HO8	DN	N-(2-amino-5-(furan-2-yl)phenyl)benzamide
DMY9HO8	MI	TTSHTOI
DMY9HO8	MN	Histone deacetylase 2 (HDAC2)
DMY9HO8	MT	DTT
DMY9HO8	MA	Inhibitor
DMY9HO8	RN	Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5.
DMY9HO8	RU	https://pubmed.ncbi.nlm.nih.gov/20392638

DMI7W9N	DI	DMI7W9N
DMI7W9N	DN	N-(2-amino-5-(furan-3-yl)phenyl)benzamide
DMI7W9N	MI	TTSHTOI
DMI7W9N	MN	Histone deacetylase 2 (HDAC2)
DMI7W9N	MT	DTT
DMI7W9N	MA	Inhibitor
DMI7W9N	RN	Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5.
DMI7W9N	RU	https://pubmed.ncbi.nlm.nih.gov/20392638

DM1KVPG	DI	DM1KVPG
DM1KVPG	DN	N-(2-amino-5-(pyridin-4-yl)phenyl)benzamide
DM1KVPG	MI	TTSHTOI
DM1KVPG	MN	Histone deacetylase 2 (HDAC2)
DM1KVPG	MT	DTT
DM1KVPG	MA	Inhibitor
DM1KVPG	RN	Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5.
DM1KVPG	RU	https://pubmed.ncbi.nlm.nih.gov/20392638

DM2K0AJ	DI	DM2K0AJ
DM2K0AJ	DN	N-(2-amino-5-(thiazol-2-yl)phenyl)benzamide
DM2K0AJ	MI	TTSHTOI
DM2K0AJ	MN	Histone deacetylase 2 (HDAC2)
DM2K0AJ	MT	DTT
DM2K0AJ	MA	Inhibitor
DM2K0AJ	RN	Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5.
DM2K0AJ	RU	https://pubmed.ncbi.nlm.nih.gov/20392638

DMFYG79	DI	DMFYG79
DMFYG79	DN	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide
DMFYG79	MI	TTBH0VX
DMFYG79	MN	Histone deacetylase (HDAC)
DMFYG79	MT	DTT
DMFYG79	MA	Inhibitor
DMFYG79	RN	Bioorg Med Chem Lett. 2008 Dec 1;18(23):6104-9. Epub 2008 Oct 14.SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2).
DMFYG79	RU	https://pubmed.ncbi.nlm.nih.gov/18951790

DMFYG79	DI	DMFYG79
DMFYG79	DN	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide
DMFYG79	MI	TT6R7JZ
DMFYG79	MN	Histone deacetylase 1 (HDAC1)
DMFYG79	MT	DTT
DMFYG79	MA	Inhibitor
DMFYG79	RN	Bioorg Med Chem Lett. 2008 Dec 1;18(23):6104-9. Epub 2008 Oct 14.SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2).
DMFYG79	RU	https://pubmed.ncbi.nlm.nih.gov/18951790

DMFYG79	DI	DMFYG79
DMFYG79	DN	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide
DMFYG79	MI	TTSHTOI
DMFYG79	MN	Histone deacetylase 2 (HDAC2)
DMFYG79	MT	DTT
DMFYG79	MA	Inhibitor
DMFYG79	RN	Bioorg Med Chem Lett. 2008 Dec 1;18(23):6104-9. Epub 2008 Oct 14.SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2).
DMFYG79	RU	https://pubmed.ncbi.nlm.nih.gov/18951790

DMRK4FA	DI	DMRK4FA
DMRK4FA	DN	N-(2-aminoethyl)-1-aziridine-ethanamine
DMRK4FA	MI	TTYRG7F
DMRK4FA	MN	HUMAN angiotensin-converting enzyme 2 (ACE2)
DMRK4FA	MT	DTT
DMRK4FA	MA	Inhibitor
DMRK4FA	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DMRK4FA	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DM7SUTQ	DI	DM7SUTQ
DM7SUTQ	DN	N-(2-aminoethyl)-2-oxo-2H-chromene-3-carboxamide
DM7SUTQ	MI	TTGP7BY
DM7SUTQ	MN	Monoamine oxidase type B (MAO-B)
DM7SUTQ	MT	DTT
DM7SUTQ	MA	Inhibitor
DM7SUTQ	RN	Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins. J Med Chem. 2009 Apr 9;52(7):1935-42.
DM7SUTQ	RU	https://pubmed.ncbi.nlm.nih.gov/19267475

DMG2MSX	DI	DMG2MSX
DMG2MSX	DN	N-(2-aminoethyl)isoquinoline-5-sulfonamide
DMG2MSX	MI	TTSFWA7
DMG2MSX	MN	Plasmodium CDK Pfmrk (Malaria Pfmrk)
DMG2MSX	MT	DTT
DMG2MSX	MA	Inhibitor
DMG2MSX	RN	Evaluation of broad spectrum protein kinase inhibitors to probe the architecture of the malarial cyclin dependent protein kinase Pfmrk. Bioorg Med Chem Lett. 2007 Sep 1;17(17):4961-6.
DMG2MSX	RU	https://pubmed.ncbi.nlm.nih.gov/17588749

DMLSFQI	DI	DMLSFQI
DMLSFQI	DN	N-(2-aminoethyl)-p-chlorobenzamide
DMLSFQI	MI	TTGP7BY
DMLSFQI	MN	Monoamine oxidase type B (MAO-B)
DMLSFQI	MT	DTT
DMLSFQI	MA	Inhibitor
DMLSFQI	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMLSFQI	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMT7JUC	DI	DMT7JUC
DMT7JUC	DN	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide
DMT7JUC	MI	TT6R7JZ
DMT7JUC	MN	Histone deacetylase 1 (HDAC1)
DMT7JUC	MT	DTT
DMT7JUC	MA	Inhibitor
DMT7JUC	RN	N-(2-Amino-phenyl)-4-(heteroarylmethyl)-benzamides as new histone deacetylase inhibitors. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6729-33.
DMT7JUC	RU	https://pubmed.ncbi.nlm.nih.gov/17977726

DMTKWUM	DI	DMTKWUM
DMTKWUM	DN	N-(2-aminophenyl)-4-methoxybenzamide
DMTKWUM	MI	TTBH0VX
DMTKWUM	MN	Histone deacetylase (HDAC)
DMTKWUM	MT	DTT
DMTKWUM	MA	Inhibitor
DMTKWUM	RN	Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem. 2007 Nov 15;50(23):5543-6.
DMTKWUM	RU	https://pubmed.ncbi.nlm.nih.gov/17941625

DMTKWUM	DI	DMTKWUM
DMTKWUM	DN	N-(2-aminophenyl)-4-methoxybenzamide
DMTKWUM	MI	TT6R7JZ
DMTKWUM	MN	Histone deacetylase 1 (HDAC1)
DMTKWUM	MT	DTT
DMTKWUM	MA	Inhibitor
DMTKWUM	RN	Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem. 2007 Nov 15;50(23):5543-6.
DMTKWUM	RU	https://pubmed.ncbi.nlm.nih.gov/17941625

DMTKWUM	DI	DMTKWUM
DMTKWUM	DN	N-(2-aminophenyl)-4-methoxybenzamide
DMTKWUM	MI	TTSHTOI
DMTKWUM	MN	Histone deacetylase 2 (HDAC2)
DMTKWUM	MT	DTT
DMTKWUM	MA	Inhibitor
DMTKWUM	RN	Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem. 2007 Nov 15;50(23):5543-6.
DMTKWUM	RU	https://pubmed.ncbi.nlm.nih.gov/17941625

DM8PB90	DI	DM8PB90
DM8PB90	DN	N-(2-aminophenyl)benzamide
DM8PB90	MI	TTSHTOI
DM8PB90	MN	Histone deacetylase 2 (HDAC2)
DM8PB90	MT	DTT
DM8PB90	MA	Inhibitor
DM8PB90	RN	Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5.
DM8PB90	RU	https://pubmed.ncbi.nlm.nih.gov/20392638

DMRDQ1B	DI	DMRDQ1B
DMRDQ1B	DN	N-(2-aminophenyl)nicotinamide
DMRDQ1B	MI	TTBH0VX
DMRDQ1B	MN	Histone deacetylase (HDAC)
DMRDQ1B	MT	DTT
DMRDQ1B	MA	Inhibitor
DMRDQ1B	RN	Bioorg Med Chem Lett. 2008 Dec 1;18(23):6104-9. Epub 2008 Oct 14.SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2).
DMRDQ1B	RU	https://pubmed.ncbi.nlm.nih.gov/18951790

DMRDQ1B	DI	DMRDQ1B
DMRDQ1B	DN	N-(2-aminophenyl)nicotinamide
DMRDQ1B	MI	TT6R7JZ
DMRDQ1B	MN	Histone deacetylase 1 (HDAC1)
DMRDQ1B	MT	DTT
DMRDQ1B	MA	Inhibitor
DMRDQ1B	RN	Bioorg Med Chem Lett. 2008 Dec 1;18(23):6104-9. Epub 2008 Oct 14.SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2).
DMRDQ1B	RU	https://pubmed.ncbi.nlm.nih.gov/18951790

DMRDQ1B	DI	DMRDQ1B
DMRDQ1B	DN	N-(2-aminophenyl)nicotinamide
DMRDQ1B	MI	TTSHTOI
DMRDQ1B	MN	Histone deacetylase 2 (HDAC2)
DMRDQ1B	MT	DTT
DMRDQ1B	MA	Inhibitor
DMRDQ1B	RN	Bioorg Med Chem Lett. 2008 Dec 1;18(23):6104-9. Epub 2008 Oct 14.SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2).
DMRDQ1B	RU	https://pubmed.ncbi.nlm.nih.gov/18951790

DMJXV7C	DI	DMJXV7C
DMJXV7C	DN	N-(2-aminophenyl)quinoxaline-6-carboxamide
DMJXV7C	MI	TT6R7JZ
DMJXV7C	MN	Histone deacetylase 1 (HDAC1)
DMJXV7C	MT	DTT
DMJXV7C	MA	Inhibitor
DMJXV7C	RN	Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem. 2007 Nov 15;50(23):5543-6.
DMJXV7C	RU	https://pubmed.ncbi.nlm.nih.gov/17941625

DMJXV7C	DI	DMJXV7C
DMJXV7C	DN	N-(2-aminophenyl)quinoxaline-6-carboxamide
DMJXV7C	MI	TTSHTOI
DMJXV7C	MN	Histone deacetylase 2 (HDAC2)
DMJXV7C	MT	DTT
DMJXV7C	MA	Inhibitor
DMJXV7C	RN	Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem. 2007 Nov 15;50(23):5543-6.
DMJXV7C	RU	https://pubmed.ncbi.nlm.nih.gov/17941625

DM72BSO	DI	DM72BSO
DM72BSO	DN	N-(2-benzyl),N-(1-methylpyrrol-2-ylmethyl)amine
DM72BSO	MI	TT3WG5C
DM72BSO	MN	Monoamine oxidase type A (MAO-A)
DM72BSO	MT	DTT
DM72BSO	MA	Inhibitor
DM72BSO	RN	New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J Med Chem. 2007 Mar 8;50(5):922-31.
DM72BSO	RU	https://pubmed.ncbi.nlm.nih.gov/17256833

DMW5XLG	DI	DMW5XLG
DMW5XLG	DN	N-(2-benzyloxy-4-nitrophenyl)methanesulfonamide
DMW5XLG	MI	TTSZLWK
DMW5XLG	MN	Aromatase (CYP19A1)
DMW5XLG	MT	DTT
DMW5XLG	MA	Inhibitor
DMW5XLG	RN	Synthesis and biological evaluation of selective aromatase expression regulators in breast cancer cells. J Med Chem. 2007 Apr 5;50(7):1635-44.
DMW5XLG	RU	https://pubmed.ncbi.nlm.nih.gov/17315855

DMFC564	DI	DMFC564
DMFC564	DN	N-(2-bromobenzoyloxy)-4-chlorobenzamide
DMFC564	MI	TT6804T
DMFC564	MN	MIF messenger RNA (MIF mRNA)
DMFC564	MT	DTT
DMFC564	MA	Inhibitor
DMFC564	RN	An integrative in silico methodology for the identification of modulators of macrophage migration inhibitory factor (MIF) tautomerase activity. Bioorg Med Chem. 2010 Jul 15;18(14):5425-40. 
DMFC564	RU	https://pubmed.ncbi.nlm.nih.gov/20639113

DM4IEWG	DI	DM4IEWG
DM4IEWG	DN	N-(2-chlorobenzyl)-5-(4-chlorophenyl)nicotinamide
DM4IEWG	MI	TT90XZ8
DM4IEWG	MN	Voltage-gated sodium channel alpha Nav1.8 (SCN10A)
DM4IEWG	MT	DTT
DM4IEWG	MA	Inhibitor
DM4IEWG	RN	Subtype-selective Na(v)1.8 sodium channel blockers: identification of potent, orally active nicotinamide derivatives. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6812-5.
DM4IEWG	RU	https://pubmed.ncbi.nlm.nih.gov/20855211

DMU5R2O	DI	DMU5R2O
DMU5R2O	DN	N-(2-chloroethyl)icosa-5,8,11,14-tetraenamide
DMU5R2O	MI	TT6OEDT
DMU5R2O	MN	Cannabinoid receptor 1 (CB1)
DMU5R2O	MT	DTT
DMU5R2O	MA	Inhibitor
DMU5R2O	RN	New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6505-10.
DMU5R2O	RU	https://pubmed.ncbi.nlm.nih.gov/17942307

DMU5R2O	DI	DMU5R2O
DMU5R2O	DN	N-(2-chloroethyl)icosa-5,8,11,14-tetraenamide
DMU5R2O	MI	TTMSFAW
DMU5R2O	MN	Cannabinoid receptor 2 (CB2)
DMU5R2O	MT	DTT
DMU5R2O	MA	Inhibitor
DMU5R2O	RN	New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6505-10.
DMU5R2O	RU	https://pubmed.ncbi.nlm.nih.gov/17942307

DMZ4A2X	DI	DMZ4A2X
DMZ4A2X	DN	N-(2-Diethylamino-ethyl)-4-hexyloxy-benzamide
DMZ4A2X	MI	TT846HF
DMZ4A2X	MN	Voltage-gated potassium channel Kv7.1 (KCNQ1)
DMZ4A2X	MT	DTT
DMZ4A2X	MA	Inhibitor
DMZ4A2X	RN	Design and synthesis of 4-substituted benzamides as potent, selective, and orally bioavailable I(Ks) blockers. J Med Chem. 2001 Nov 8;44(23):3764-7.
DMZ4A2X	RU	https://pubmed.ncbi.nlm.nih.gov/11689063

DMMDXEO	DI	DMMDXEO
DMMDXEO	DN	N-(2-Ethylphenyl)-5-methylbenzo[d]oxazol-2-amine
DMMDXEO	MI	TT2J34L
DMMDXEO	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMMDXEO	MT	DTT
DMMDXEO	MA	Inhibitor
DMMDXEO	RN	Synthesis and evaluation of benzoxazole derivatives as 5-lipoxygenase inhibitors. Bioorg Med Chem. 2010 Nov 1;18(21):7580-5.
DMMDXEO	RU	https://pubmed.ncbi.nlm.nih.gov/20870413

DMDM50P	DI	DMDM50P
DMDM50P	DN	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide
DMDM50P	MI	TTBH0VX
DMDM50P	MN	Histone deacetylase (HDAC)
DMDM50P	MT	DTT
DMDM50P	MA	Inhibitor
DMDM50P	RN	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50.
DMDM50P	RU	https://pubmed.ncbi.nlm.nih.gov/20143840

DMDM50P	DI	DMDM50P
DMDM50P	DN	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide
DMDM50P	MI	TT6R7JZ
DMDM50P	MN	Histone deacetylase 1 (HDAC1)
DMDM50P	MT	DTT
DMDM50P	MA	Inhibitor
DMDM50P	RN	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50.
DMDM50P	RU	https://pubmed.ncbi.nlm.nih.gov/20143840

DM3CZVW	DI	DM3CZVW
DM3CZVW	DN	N-(2-Flouro-Benzyl)-4-Sulfamoyl-Benzamide
DM3CZVW	MI	TTANPDJ
DM3CZVW	MN	Carbonic anhydrase II (CA-II)
DM3CZVW	MT	DTT
DM3CZVW	MA	Inhibitor
DM3CZVW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM3CZVW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM7BKUQ	DI	DM7BKUQ
DM7BKUQ	DN	N'-(2-fluorobenzoyl)-2-naphthohydrazide
DM7BKUQ	MI	TTSFWA7
DM7BKUQ	MN	Plasmodium CDK Pfmrk (Malaria Pfmrk)
DM7BKUQ	MT	DTT
DM7BKUQ	MA	Inhibitor
DM7BKUQ	RN	Activity of substituted thiophene sulfonamides against malarial and mammalian cyclin dependent protein kinases, Bioorg. Med. Chem. Lett. 20(13):3863-3867 (2010).
DM7BKUQ	RU	http://www.sciencedirect.com/science/article/pii/S0960894X10006803

DM27L53	DI	DM27L53
DM27L53	DN	N-(2-hexyloxy-4-nitrophenyl)methanesulfonamide
DM27L53	MI	TTSZLWK
DM27L53	MN	Aromatase (CYP19A1)
DM27L53	MT	DTT
DM27L53	MA	Inhibitor
DM27L53	RN	Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition. J Med Chem. 2006 Feb 23;49(4):1413-9.
DM27L53	RU	https://pubmed.ncbi.nlm.nih.gov/16480277

DM97MGE	DI	DM97MGE
DM97MGE	DN	N-(2-hydroxyethyl)linoleoylamide
DM97MGE	MI	TTDP1UC
DM97MGE	MN	Fatty acid amide hydrolase (FAAH)
DM97MGE	MT	DTT
DM97MGE	MA	Inhibitor
DM97MGE	RN	Radiosynthesis, in vitro and in vivo evaluation of 123I-labeled anandamide analogues for mapping brain FAAH. Bioorg Med Chem. 2009 Jan 1;17(1):49-56.
DM97MGE	RU	https://pubmed.ncbi.nlm.nih.gov/19054678

DM8ORQ4	DI	DM8ORQ4
DM8ORQ4	DN	N-(2-iodethyl)arachidonylamide
DM8ORQ4	MI	TTDP1UC
DM8ORQ4	MN	Fatty acid amide hydrolase (FAAH)
DM8ORQ4	MT	DTT
DM8ORQ4	MA	Inhibitor
DM8ORQ4	RN	Radiosynthesis, in vitro and in vivo evaluation of 123I-labeled anandamide analogues for mapping brain FAAH. Bioorg Med Chem. 2009 Jan 1;17(1):49-56.
DM8ORQ4	RU	https://pubmed.ncbi.nlm.nih.gov/19054678

DMV84PQ	DI	DMV84PQ
DMV84PQ	DN	N-(2-iodoethyl)linoleoylamide
DMV84PQ	MI	TTDP1UC
DMV84PQ	MN	Fatty acid amide hydrolase (FAAH)
DMV84PQ	MT	DTT
DMV84PQ	MA	Inhibitor
DMV84PQ	RN	Radiosynthesis, in vitro and in vivo evaluation of 123I-labeled anandamide analogues for mapping brain FAAH. Bioorg Med Chem. 2009 Jan 1;17(1):49-56.
DMV84PQ	RU	https://pubmed.ncbi.nlm.nih.gov/19054678

DM0GOPV	DI	DM0GOPV
DM0GOPV	DN	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide
DM0GOPV	MI	TTBH0VX
DM0GOPV	MN	Histone deacetylase (HDAC)
DM0GOPV	MT	DTT
DM0GOPV	MA	Inhibitor
DM0GOPV	RN	Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72.
DM0GOPV	RU	https://pubmed.ncbi.nlm.nih.gov/15808449

DM0GOPV	DI	DM0GOPV
DM0GOPV	DN	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide
DM0GOPV	MI	TT6R7JZ
DM0GOPV	MN	Histone deacetylase 1 (HDAC1)
DM0GOPV	MT	DTT
DM0GOPV	MA	Inhibitor
DM0GOPV	RN	Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72.
DM0GOPV	RU	https://pubmed.ncbi.nlm.nih.gov/15808449

DM0GOPV	DI	DM0GOPV
DM0GOPV	DN	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide
DM0GOPV	MI	TTYHPU6
DM0GOPV	MN	Histone deacetylase 10 (HDAC10)
DM0GOPV	MT	DTT
DM0GOPV	MA	Inhibitor
DM0GOPV	RN	Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72.
DM0GOPV	RU	https://pubmed.ncbi.nlm.nih.gov/15808449

DM0GOPV	DI	DM0GOPV
DM0GOPV	DN	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide
DM0GOPV	MI	TTSHTOI
DM0GOPV	MN	Histone deacetylase 2 (HDAC2)
DM0GOPV	MT	DTT
DM0GOPV	MA	Inhibitor
DM0GOPV	RN	Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72.
DM0GOPV	RU	https://pubmed.ncbi.nlm.nih.gov/15808449

DM0GOPV	DI	DM0GOPV
DM0GOPV	DN	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide
DM0GOPV	MI	TTTQGH8
DM0GOPV	MN	Histone deacetylase 4 (HDAC4)
DM0GOPV	MT	DTT
DM0GOPV	MA	Inhibitor
DM0GOPV	RN	Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72.
DM0GOPV	RU	https://pubmed.ncbi.nlm.nih.gov/15808449

DM0GOPV	DI	DM0GOPV
DM0GOPV	DN	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide
DM0GOPV	MI	TT5ZKDI
DM0GOPV	MN	Histone deacetylase 6 (HDAC6)
DM0GOPV	MT	DTT
DM0GOPV	MA	Inhibitor
DM0GOPV	RN	Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72.
DM0GOPV	RU	https://pubmed.ncbi.nlm.nih.gov/15808449

DM0GOPV	DI	DM0GOPV
DM0GOPV	DN	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide
DM0GOPV	MI	TTT6LFV
DM0GOPV	MN	Histone deacetylase 8 (HDAC8)
DM0GOPV	MT	DTT
DM0GOPV	MA	Inhibitor
DM0GOPV	RN	Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72.
DM0GOPV	RU	https://pubmed.ncbi.nlm.nih.gov/15808449

DMJLFOQ	DI	DMJLFOQ
DMJLFOQ	DN	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide
DMJLFOQ	MI	TTBH0VX
DMJLFOQ	MN	Histone deacetylase (HDAC)
DMJLFOQ	MT	DTT
DMJLFOQ	MA	Inhibitor
DMJLFOQ	RN	Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72.
DMJLFOQ	RU	https://pubmed.ncbi.nlm.nih.gov/15808449

DMJLFOQ	DI	DMJLFOQ
DMJLFOQ	DN	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide
DMJLFOQ	MI	TT6R7JZ
DMJLFOQ	MN	Histone deacetylase 1 (HDAC1)
DMJLFOQ	MT	DTT
DMJLFOQ	MA	Inhibitor
DMJLFOQ	RN	Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72.
DMJLFOQ	RU	https://pubmed.ncbi.nlm.nih.gov/15808449

DMJLFOQ	DI	DMJLFOQ
DMJLFOQ	DN	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide
DMJLFOQ	MI	TTYHPU6
DMJLFOQ	MN	Histone deacetylase 10 (HDAC10)
DMJLFOQ	MT	DTT
DMJLFOQ	MA	Inhibitor
DMJLFOQ	RN	Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72.
DMJLFOQ	RU	https://pubmed.ncbi.nlm.nih.gov/15808449

DMJLFOQ	DI	DMJLFOQ
DMJLFOQ	DN	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide
DMJLFOQ	MI	TTSHTOI
DMJLFOQ	MN	Histone deacetylase 2 (HDAC2)
DMJLFOQ	MT	DTT
DMJLFOQ	MA	Inhibitor
DMJLFOQ	RN	Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72.
DMJLFOQ	RU	https://pubmed.ncbi.nlm.nih.gov/15808449

DMJLFOQ	DI	DMJLFOQ
DMJLFOQ	DN	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide
DMJLFOQ	MI	TTTQGH8
DMJLFOQ	MN	Histone deacetylase 4 (HDAC4)
DMJLFOQ	MT	DTT
DMJLFOQ	MA	Inhibitor
DMJLFOQ	RN	Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72.
DMJLFOQ	RU	https://pubmed.ncbi.nlm.nih.gov/15808449

DMJLFOQ	DI	DMJLFOQ
DMJLFOQ	DN	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide
DMJLFOQ	MI	TT5ZKDI
DMJLFOQ	MN	Histone deacetylase 6 (HDAC6)
DMJLFOQ	MT	DTT
DMJLFOQ	MA	Inhibitor
DMJLFOQ	RN	Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72.
DMJLFOQ	RU	https://pubmed.ncbi.nlm.nih.gov/15808449

DMJLFOQ	DI	DMJLFOQ
DMJLFOQ	DN	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide
DMJLFOQ	MI	TTT6LFV
DMJLFOQ	MN	Histone deacetylase 8 (HDAC8)
DMJLFOQ	MT	DTT
DMJLFOQ	MA	Inhibitor
DMJLFOQ	RN	Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72.
DMJLFOQ	RU	https://pubmed.ncbi.nlm.nih.gov/15808449

DM06S5Z	DI	DM06S5Z
DM06S5Z	DN	N-(2-methoxybenzyl)cinnamamidine
DM06S5Z	MI	TTLD29N
DM06S5Z	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DM06S5Z	MT	DTT
DM06S5Z	MA	Inhibitor
DM06S5Z	RN	Indole-2-carboxamidines as novel NR2B selective NMDA receptor antagonists. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5439-41.
DM06S5Z	RU	https://pubmed.ncbi.nlm.nih.gov/16213709

DM06S5Z	DI	DM06S5Z
DM06S5Z	DN	N-(2-methoxybenzyl)cinnamamidine
DM06S5Z	MI	TTKJEMQ
DM06S5Z	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DM06S5Z	MT	DTT
DM06S5Z	MA	Inhibitor
DM06S5Z	RN	Indole-2-carboxamidines as novel NR2B selective NMDA receptor antagonists. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5439-41.
DM06S5Z	RU	https://pubmed.ncbi.nlm.nih.gov/16213709

DM06S5Z	DI	DM06S5Z
DM06S5Z	DN	N-(2-methoxybenzyl)cinnamamidine
DM06S5Z	MI	TTN9D8E
DM06S5Z	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DM06S5Z	MT	DTT
DM06S5Z	MA	Inhibitor
DM06S5Z	RN	Indole-2-carboxamidines as novel NR2B selective NMDA receptor antagonists. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5439-41.
DM06S5Z	RU	https://pubmed.ncbi.nlm.nih.gov/16213709

DMH42YF	DI	DMH42YF
DMH42YF	DN	N-(2-Methyl-1H-indol-5-yl)benzamide
DMH42YF	MI	TTGP7BY
DMH42YF	MN	Monoamine oxidase type B (MAO-B)
DMH42YF	MT	DTT
DMH42YF	MA	Inhibitor
DMH42YF	RN	Inhibition of monoamine oxidase by indole and benzofuran derivatives. Eur J Med Chem. 2010 Oct;45(10):4458-66.
DMH42YF	RU	https://pubmed.ncbi.nlm.nih.gov/20674099

DM3SF5M	DI	DM3SF5M
DM3SF5M	DN	N-(2-Methyl-1H-indol-5-yl)cyclohexanecarboxamide
DM3SF5M	MI	TT3WG5C
DM3SF5M	MN	Monoamine oxidase type A (MAO-A)
DM3SF5M	MT	DTT
DM3SF5M	MA	Inhibitor
DM3SF5M	RN	Inhibition of monoamine oxidase by indole and benzofuran derivatives. Eur J Med Chem. 2010 Oct;45(10):4458-66.
DM3SF5M	RU	https://pubmed.ncbi.nlm.nih.gov/20674099

DM3SF5M	DI	DM3SF5M
DM3SF5M	DN	N-(2-Methyl-1H-indol-5-yl)cyclohexanecarboxamide
DM3SF5M	MI	TTGP7BY
DM3SF5M	MN	Monoamine oxidase type B (MAO-B)
DM3SF5M	MT	DTT
DM3SF5M	MA	Inhibitor
DM3SF5M	RN	Inhibition of monoamine oxidase by indole and benzofuran derivatives. Eur J Med Chem. 2010 Oct;45(10):4458-66.
DM3SF5M	RU	https://pubmed.ncbi.nlm.nih.gov/20674099

DMXRSM1	DI	DMXRSM1
DMXRSM1	DN	N-(2-methyl-2-phenylpropyl)pyrazine-2-carboxamide
DMXRSM1	MI	TTVBPDM
DMXRSM1	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMXRSM1	MT	DTT
DMXRSM1	MA	Inhibitor
DMXRSM1	RN	Structure-activity relationships of novel non-competitive mGluR1 antagonists: a potential treatment for chronic pain. Bioorg Med Chem Lett. 2007 Jan 15;17(2):486-90.
DMXRSM1	RU	https://pubmed.ncbi.nlm.nih.gov/17064898

DMI4KNB	DI	DMI4KNB
DMI4KNB	DN	N-(2-morpholinophenyl)-5-nitrofuran-2-carboxamide
DMI4KNB	MI	TTC70AJ
DMI4KNB	MN	Granulocyte colony-stimulating factor receptor (G-CSF-R)
DMI4KNB	MT	DTT
DMI4KNB	MA	Inhibitor
DMI4KNB	RN	Potent 2'-aminoanilide inhibitors of cFMS as potential anti-inflammatory agents. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6070-4.
DMI4KNB	RU	https://pubmed.ncbi.nlm.nih.gov/17904845

DMF5N4O	DI	DMF5N4O
DMF5N4O	DN	N-(2-naphthylsulfonyl)-glycyl-glycine-nitrile
DMF5N4O	MI	TTUMQVO
DMF5N4O	MN	Cathepsin S (CTSS)
DMF5N4O	MT	DTT
DMF5N4O	MA	Inhibitor
DMF5N4O	RN	Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707.
DMF5N4O	RU	https://pubmed.ncbi.nlm.nih.gov/16302809

DMU6FPL	DI	DMU6FPL
DMU6FPL	DN	N-(2-nonyloxy-4-nitrophenyl)methanesulfonamide
DMU6FPL	MI	TTSZLWK
DMU6FPL	MN	Aromatase (CYP19A1)
DMU6FPL	MT	DTT
DMU6FPL	MA	Inhibitor
DMU6FPL	RN	Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition. J Med Chem. 2006 Feb 23;49(4):1413-9.
DMU6FPL	RU	https://pubmed.ncbi.nlm.nih.gov/16480277

DMVGP02	DI	DMVGP02
DMVGP02	DN	N-(2-oxazolemethyl)milnacipran
DMVGP02	MI	TTAWNKZ
DMVGP02	MN	Norepinephrine transporter (NET)
DMVGP02	MT	DTT
DMVGP02	MA	Inhibitor
DMVGP02	RN	Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Feb 15;18(4):1346-9.
DMVGP02	RU	https://pubmed.ncbi.nlm.nih.gov/18207394

DMVGP02	DI	DMVGP02
DMVGP02	DN	N-(2-oxazolemethyl)milnacipran
DMVGP02	MI	TT3ROYC
DMVGP02	MN	Serotonin transporter (SERT)
DMVGP02	MT	DTT
DMVGP02	MA	Inhibitor
DMVGP02	RN	Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Feb 15;18(4):1346-9.
DMVGP02	RU	https://pubmed.ncbi.nlm.nih.gov/18207394

DMBR1MX	DI	DMBR1MX
DMBR1MX	DN	N'-(2-phenylallyl)hydrazine hydrochloride
DMBR1MX	MI	TT3WG5C
DMBR1MX	MN	Monoamine oxidase type A (MAO-A)
DMBR1MX	MT	DTT
DMBR1MX	MA	Inhibitor
DMBR1MX	RN	Design, synthesis, and biological evaluation of semicarbazide-sensitive amine oxidase (SSAO) inhibitors with anti-inflammatory activity. J Med Chem. 2006 Apr 6;49(7):2166-73.
DMBR1MX	RU	https://pubmed.ncbi.nlm.nih.gov/16570912

DM1ADE5	DI	DM1ADE5
DM1ADE5	DN	N-(2-phenylethyl),N-(pyrrol-2-ylmethyl)amine
DM1ADE5	MI	TT3WG5C
DM1ADE5	MN	Monoamine oxidase type A (MAO-A)
DM1ADE5	MT	DTT
DM1ADE5	MA	Inhibitor
DM1ADE5	RN	New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J Med Chem. 2007 Mar 8;50(5):922-31.
DM1ADE5	RU	https://pubmed.ncbi.nlm.nih.gov/17256833

DM1ADE5	DI	DM1ADE5
DM1ADE5	DN	N-(2-phenylethyl),N-(pyrrol-2-ylmethyl)amine
DM1ADE5	MI	TTGP7BY
DM1ADE5	MN	Monoamine oxidase type B (MAO-B)
DM1ADE5	MT	DTT
DM1ADE5	MA	Inhibitor
DM1ADE5	RN	New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J Med Chem. 2007 Mar 8;50(5):922-31.
DM1ADE5	RU	https://pubmed.ncbi.nlm.nih.gov/17256833

DMJCO7F	DI	DMJCO7F
DMJCO7F	DN	N-(2-Phenylethyl)-1H-indole-2-carboxamide
DMJCO7F	MI	TT3WG5C
DMJCO7F	MN	Monoamine oxidase type A (MAO-A)
DMJCO7F	MT	DTT
DMJCO7F	MA	Inhibitor
DMJCO7F	RN	Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40.
DMJCO7F	RU	https://pubmed.ncbi.nlm.nih.gov/18951803

DMJCO7F	DI	DMJCO7F
DMJCO7F	DN	N-(2-Phenylethyl)-1H-indole-2-carboxamide
DMJCO7F	MI	TTGP7BY
DMJCO7F	MN	Monoamine oxidase type B (MAO-B)
DMJCO7F	MT	DTT
DMJCO7F	MA	Inhibitor
DMJCO7F	RN	Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40.
DMJCO7F	RU	https://pubmed.ncbi.nlm.nih.gov/18951803

DMUILX8	DI	DMUILX8
DMUILX8	DN	N-(2-phenylimidazo[1,2-a]pyridin-3-yl)benzamide
DMUILX8	MI	TTHS256
DMUILX8	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMUILX8	MT	DTT
DMUILX8	MA	Inhibitor
DMUILX8	RN	Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat... J Med Chem. 2006 Jun 1;49(11):3332-44.
DMUILX8	RU	https://pubmed.ncbi.nlm.nih.gov/16722652

DMA1LRF	DI	DMA1LRF
DMA1LRF	DN	N-(2-phenylpropyl)quinoxaline-2-carboxamide
DMA1LRF	MI	TTVBPDM
DMA1LRF	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMA1LRF	MT	DTT
DMA1LRF	MA	Inhibitor
DMA1LRF	RN	Structure-activity relationships of novel non-competitive mGluR1 antagonists: a potential treatment for chronic pain. Bioorg Med Chem Lett. 2007 Jan 15;17(2):486-90.
DMA1LRF	RU	https://pubmed.ncbi.nlm.nih.gov/17064898

DMAQMXJ	DI	DMAQMXJ
DMAQMXJ	DN	N-(2-Propyloxy-4-nitrophenyl)methanesulfonamide
DMAQMXJ	MI	TTSZLWK
DMAQMXJ	MN	Aromatase (CYP19A1)
DMAQMXJ	MT	DTT
DMAQMXJ	MA	Inhibitor
DMAQMXJ	RN	Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition. J Med Chem. 2006 Feb 23;49(4):1413-9.
DMAQMXJ	RU	https://pubmed.ncbi.nlm.nih.gov/16480277

DME9HNO	DI	DME9HNO
DME9HNO	DN	N-(2-Thienylmethyl)-2,5-Thiophenedisulfonamide
DME9HNO	MI	TTANPDJ
DME9HNO	MN	Carbonic anhydrase II (CA-II)
DME9HNO	MT	DTT
DME9HNO	MA	Inhibitor
DME9HNO	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DME9HNO	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM0JE7H	DI	DM0JE7H
DM0JE7H	DN	N-(3-(1H-indol-4-yloxy)propyl)cyclohexanamine
DM0JE7H	MI	TTSQIFT
DM0JE7H	MN	5-HT 1A receptor (HTR1A)
DM0JE7H	MT	DTT
DM0JE7H	MA	Inhibitor
DM0JE7H	RN	Indoloxypropanolamine analogues as 5-HT(1A) receptor antagonists. Bioorg Med Chem Lett. 2007 Oct 15;17(20):5600-4.
DM0JE7H	RU	https://pubmed.ncbi.nlm.nih.gov/17804228

DM2URTK	DI	DM2URTK
DM2URTK	DN	N-(3-(1H-indol-4-yloxy)propyl)cyclopentanamine
DM2URTK	MI	TTSQIFT
DM2URTK	MN	5-HT 1A receptor (HTR1A)
DM2URTK	MT	DTT
DM2URTK	MA	Inhibitor
DM2URTK	RN	Indoloxypropanolamine analogues as 5-HT(1A) receptor antagonists. Bioorg Med Chem Lett. 2007 Oct 15;17(20):5600-4.
DM2URTK	RU	https://pubmed.ncbi.nlm.nih.gov/17804228

DM4ZTF1	DI	DM4ZTF1
DM4ZTF1	DN	N-(3-(2,5-dimethoxyphenyl)propyl)acetamide
DM4ZTF1	MI	TT0WAIE
DM4ZTF1	MN	Melatonin receptor type 1A (MTNR1A)
DM4ZTF1	MT	DTT
DM4ZTF1	MA	Inhibitor
DM4ZTF1	RN	Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT(2)-selective melatonin ligands. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2582-5.
DM4ZTF1	RU	https://pubmed.ncbi.nlm.nih.gov/20227878

DM4ZTF1	DI	DM4ZTF1
DM4ZTF1	DN	N-(3-(2,5-dimethoxyphenyl)propyl)acetamide
DM4ZTF1	MI	TT32JK8
DM4ZTF1	MN	Melatonin receptor type 1B (MTNR1B)
DM4ZTF1	MT	DTT
DM4ZTF1	MA	Inhibitor
DM4ZTF1	RN	Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT(2)-selective melatonin ligands. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2582-5.
DM4ZTF1	RU	https://pubmed.ncbi.nlm.nih.gov/20227878

DMP8547	DI	DMP8547
DMP8547	DN	N-(3-(2-aminoethyl)phenyl)benzenesulfonamide
DMP8547	MI	TTJS8PY
DMP8547	MN	5-HT 6 receptor (HTR6)
DMP8547	MT	DTT
DMP8547	MA	Inhibitor
DMP8547	RN	Binding of sulfonyl-containing arylalkylamines at human 5-HT6 serotonin receptors. J Med Chem. 2006 Aug 24;49(17):5217-25.
DMP8547	RU	https://pubmed.ncbi.nlm.nih.gov/16913710

DMLWGPC	DI	DMLWGPC
DMLWGPC	DN	N-(3-(2-ethoxy-5-methoxyphenyl)propyl)acetamide
DMLWGPC	MI	TT0WAIE
DMLWGPC	MN	Melatonin receptor type 1A (MTNR1A)
DMLWGPC	MT	DTT
DMLWGPC	MA	Inhibitor
DMLWGPC	RN	Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT(2)-selective melatonin ligands. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2582-5.
DMLWGPC	RU	https://pubmed.ncbi.nlm.nih.gov/20227878

DMLWGPC	DI	DMLWGPC
DMLWGPC	DN	N-(3-(2-ethoxy-5-methoxyphenyl)propyl)acetamide
DMLWGPC	MI	TT32JK8
DMLWGPC	MN	Melatonin receptor type 1B (MTNR1B)
DMLWGPC	MT	DTT
DMLWGPC	MA	Inhibitor
DMLWGPC	RN	Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT(2)-selective melatonin ligands. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2582-5.
DMLWGPC	RU	https://pubmed.ncbi.nlm.nih.gov/20227878

DMI452E	DI	DMI452E
DMI452E	DN	N-(3-(2-hydroxy-5-methoxyphenyl)propyl)acetamide
DMI452E	MI	TT0WAIE
DMI452E	MN	Melatonin receptor type 1A (MTNR1A)
DMI452E	MT	DTT
DMI452E	MA	Inhibitor
DMI452E	RN	Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT(2)-selective melatonin ligands. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2582-5.
DMI452E	RU	https://pubmed.ncbi.nlm.nih.gov/20227878

DMI452E	DI	DMI452E
DMI452E	DN	N-(3-(2-hydroxy-5-methoxyphenyl)propyl)acetamide
DMI452E	MI	TT32JK8
DMI452E	MN	Melatonin receptor type 1B (MTNR1B)
DMI452E	MT	DTT
DMI452E	MA	Inhibitor
DMI452E	RN	Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT(2)-selective melatonin ligands. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2582-5.
DMI452E	RU	https://pubmed.ncbi.nlm.nih.gov/20227878

DMW59AY	DI	DMW59AY
DMW59AY	DN	N-(3-(3-aminopropyl)phenyl)benzenesulfonamide
DMW59AY	MI	TTJS8PY
DMW59AY	MN	5-HT 6 receptor (HTR6)
DMW59AY	MT	DTT
DMW59AY	MA	Inhibitor
DMW59AY	RN	Binding of sulfonyl-containing arylalkylamines at human 5-HT6 serotonin receptors. J Med Chem. 2006 Aug 24;49(17):5217-25.
DMW59AY	RU	https://pubmed.ncbi.nlm.nih.gov/16913710

DMXL70A	DI	DMXL70A
DMXL70A	DN	N-(3-(3-cyanobenzamido)phenyl)-2-methoxybenzamide
DMXL70A	MI	TTHS256
DMXL70A	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMXL70A	MT	DTT
DMXL70A	MA	Inhibitor
DMXL70A	RN	Synthesis and SAR of novel, non-MPEP chemotype mGluR5 NAMs identified by functional HTS. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6502-6.
DMXL70A	RU	https://pubmed.ncbi.nlm.nih.gov/19875287

DMH0LOT	DI	DMH0LOT
DMH0LOT	DN	N-(3-(3-methoxyphenyl)-3-phenylallyl)acetamide
DMH0LOT	MI	TT0WAIE
DMH0LOT	MN	Melatonin receptor type 1A (MTNR1A)
DMH0LOT	MT	DTT
DMH0LOT	MA	Inhibitor
DMH0LOT	RN	2-[(2,3-dihydro-1H-indol-1-yl)methyl]melatonin analogues: a novel class of MT2-selective melatonin receptor antagonists. J Med Chem. 2009 Feb 12;52(3):826-33.
DMH0LOT	RU	https://pubmed.ncbi.nlm.nih.gov/19193160

DMH0LOT	DI	DMH0LOT
DMH0LOT	DN	N-(3-(3-methoxyphenyl)-3-phenylallyl)acetamide
DMH0LOT	MI	TT32JK8
DMH0LOT	MN	Melatonin receptor type 1B (MTNR1B)
DMH0LOT	MT	DTT
DMH0LOT	MA	Inhibitor
DMH0LOT	RN	2-[(2,3-dihydro-1H-indol-1-yl)methyl]melatonin analogues: a novel class of MT2-selective melatonin receptor antagonists. J Med Chem. 2009 Feb 12;52(3):826-33.
DMH0LOT	RU	https://pubmed.ncbi.nlm.nih.gov/19193160

DMSZ03N	DI	DMSZ03N
DMSZ03N	DN	N-(3-(3-methoxyphenyl)propyl)acetamide
DMSZ03N	MI	TT0WAIE
DMSZ03N	MN	Melatonin receptor type 1A (MTNR1A)
DMSZ03N	MT	DTT
DMSZ03N	MA	Inhibitor
DMSZ03N	RN	Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT(2)-selective melatonin ligands. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2582-5.
DMSZ03N	RU	https://pubmed.ncbi.nlm.nih.gov/20227878

DMSZ03N	DI	DMSZ03N
DMSZ03N	DN	N-(3-(3-methoxyphenyl)propyl)acetamide
DMSZ03N	MI	TT32JK8
DMSZ03N	MN	Melatonin receptor type 1B (MTNR1B)
DMSZ03N	MT	DTT
DMSZ03N	MA	Inhibitor
DMSZ03N	RN	Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT(2)-selective melatonin ligands. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2582-5.
DMSZ03N	RU	https://pubmed.ncbi.nlm.nih.gov/20227878

DMKSM5A	DI	DMKSM5A
DMKSM5A	DN	N-(3-(3-methoxyphenyl)propyl)propionamide
DMKSM5A	MI	TT0WAIE
DMKSM5A	MN	Melatonin receptor type 1A (MTNR1A)
DMKSM5A	MT	DTT
DMKSM5A	MA	Inhibitor
DMKSM5A	RN	Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT(2)-selective melatonin ligands. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2582-5.
DMKSM5A	RU	https://pubmed.ncbi.nlm.nih.gov/20227878

DMKSM5A	DI	DMKSM5A
DMKSM5A	DN	N-(3-(3-methoxyphenyl)propyl)propionamide
DMKSM5A	MI	TT32JK8
DMKSM5A	MN	Melatonin receptor type 1B (MTNR1B)
DMKSM5A	MT	DTT
DMKSM5A	MA	Inhibitor
DMKSM5A	RN	Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT(2)-selective melatonin ligands. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2582-5.
DMKSM5A	RU	https://pubmed.ncbi.nlm.nih.gov/20227878

DMOCZVB	DI	DMOCZVB
DMOCZVB	DN	N-(3-(4-hexyl-2-hydroxyphenoxy)phenyl)acetamide
DMOCZVB	MI	TTVTX4N
DMOCZVB	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DMOCZVB	MT	DTT
DMOCZVB	MA	Inhibitor
DMOCZVB	RN	Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33.
DMOCZVB	RU	https://pubmed.ncbi.nlm.nih.gov/18457948

DMILWPS	DI	DMILWPS
DMILWPS	DN	N-(3-(4-hydroxy-3-methoxyphenyl)propyl)acetamide
DMILWPS	MI	TT0WAIE
DMILWPS	MN	Melatonin receptor type 1A (MTNR1A)
DMILWPS	MT	DTT
DMILWPS	MA	Inhibitor
DMILWPS	RN	Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT(2)-selective melatonin ligands. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2582-5.
DMILWPS	RU	https://pubmed.ncbi.nlm.nih.gov/20227878

DMILWPS	DI	DMILWPS
DMILWPS	DN	N-(3-(4-hydroxy-3-methoxyphenyl)propyl)acetamide
DMILWPS	MI	TT32JK8
DMILWPS	MN	Melatonin receptor type 1B (MTNR1B)
DMILWPS	MT	DTT
DMILWPS	MA	Inhibitor
DMILWPS	RN	Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT(2)-selective melatonin ligands. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2582-5.
DMILWPS	RU	https://pubmed.ncbi.nlm.nih.gov/20227878

DMHM0WI	DI	DMHM0WI
DMHM0WI	DN	N-(3-(5-methoxy-2-propoxyphenyl)propyl)acetamide
DMHM0WI	MI	TT0WAIE
DMHM0WI	MN	Melatonin receptor type 1A (MTNR1A)
DMHM0WI	MT	DTT
DMHM0WI	MA	Inhibitor
DMHM0WI	RN	Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT(2)-selective melatonin ligands. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2582-5.
DMHM0WI	RU	https://pubmed.ncbi.nlm.nih.gov/20227878

DMHM0WI	DI	DMHM0WI
DMHM0WI	DN	N-(3-(5-methoxy-2-propoxyphenyl)propyl)acetamide
DMHM0WI	MI	TT32JK8
DMHM0WI	MN	Melatonin receptor type 1B (MTNR1B)
DMHM0WI	MT	DTT
DMHM0WI	MA	Inhibitor
DMHM0WI	RN	Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT(2)-selective melatonin ligands. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2582-5.
DMHM0WI	RU	https://pubmed.ncbi.nlm.nih.gov/20227878

DMSC862	DI	DMSC862
DMSC862	DN	N-(3-(aminomethyl)phenyl)benzenesulfonamide
DMSC862	MI	TTJS8PY
DMSC862	MN	5-HT 6 receptor (HTR6)
DMSC862	MT	DTT
DMSC862	MA	Inhibitor
DMSC862	RN	Binding of sulfonyl-containing arylalkylamines at human 5-HT6 serotonin receptors. J Med Chem. 2006 Aug 24;49(17):5217-25.
DMSC862	RU	https://pubmed.ncbi.nlm.nih.gov/16913710

DMSJX1H	DI	DMSJX1H
DMSJX1H	DN	N-(3-(phenylthio)pyridin-4-yl)methanesulfonamide
DMSJX1H	MI	TT8NGED
DMSJX1H	MN	Prostaglandin G/H synthase 1 (COX-1)
DMSJX1H	MT	DTT
DMSJX1H	MA	Inhibitor
DMSJX1H	RN	Pyridine analogues of nimesulide: design, synthesis, and in vitro and in vivo pharmacological evaluation as promising cyclooxygenase 1 and 2 inhibi... J Med Chem. 2009 Oct 8;52(19):5864-71.
DMSJX1H	RU	https://pubmed.ncbi.nlm.nih.gov/19791801

DMSJX1H	DI	DMSJX1H
DMSJX1H	DN	N-(3-(phenylthio)pyridin-4-yl)methanesulfonamide
DMSJX1H	MI	TTVKILB
DMSJX1H	MN	Prostaglandin G/H synthase 2 (COX-2)
DMSJX1H	MT	DTT
DMSJX1H	MA	Inhibitor
DMSJX1H	RN	Pyridine analogues of nimesulide: design, synthesis, and in vitro and in vivo pharmacological evaluation as promising cyclooxygenase 1 and 2 inhibi... J Med Chem. 2009 Oct 8;52(19):5864-71.
DMSJX1H	RU	https://pubmed.ncbi.nlm.nih.gov/19791801

DM6UC8Y	DI	DM6UC8Y
DM6UC8Y	DN	N-(3-(trifluoromethoxy)benzyl)-4-phenoxybenzamide
DM6UC8Y	MI	TTQBR95
DM6UC8Y	MN	Stress-activated protein kinase 2a (p38 alpha)
DM6UC8Y	MT	DTT
DM6UC8Y	MA	Inhibitor
DM6UC8Y	RN	Two classes of p38alpha MAP kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5274-9.
DM6UC8Y	RU	https://pubmed.ncbi.nlm.nih.gov/16169718

DMSMRF9	DI	DMSMRF9
DMSMRF9	DN	N-(3-(trifluoromethyl)benzyl)-4-phenoxybenzamide
DMSMRF9	MI	TTQBR95
DMSMRF9	MN	Stress-activated protein kinase 2a (p38 alpha)
DMSMRF9	MT	DTT
DMSMRF9	MA	Inhibitor
DMSMRF9	RN	Two classes of p38alpha MAP kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5274-9.
DMSMRF9	RU	https://pubmed.ncbi.nlm.nih.gov/16169718

DM2Y5AP	DI	DM2Y5AP
DM2Y5AP	DN	N-(3,3-Dimethyl-butyl)-4-hexyloxy-benzamide
DM2Y5AP	MI	TT846HF
DM2Y5AP	MN	Voltage-gated potassium channel Kv7.1 (KCNQ1)
DM2Y5AP	MT	DTT
DM2Y5AP	MA	Inhibitor
DM2Y5AP	RN	Design and synthesis of 4-substituted benzamides as potent, selective, and orally bioavailable I(Ks) blockers. J Med Chem. 2001 Nov 8;44(23):3764-7.
DM2Y5AP	RU	https://pubmed.ncbi.nlm.nih.gov/11689063

DMEUXOQ	DI	DMEUXOQ
DMEUXOQ	DN	N-(3,3-Dimethyl-butyl)-4-indol-1-yl-benzamide
DMEUXOQ	MI	TT846HF
DMEUXOQ	MN	Voltage-gated potassium channel Kv7.1 (KCNQ1)
DMEUXOQ	MT	DTT
DMEUXOQ	MA	Inhibitor
DMEUXOQ	RN	Design and synthesis of 4-substituted benzamides as potent, selective, and orally bioavailable I(Ks) blockers. J Med Chem. 2001 Nov 8;44(23):3764-7.
DMEUXOQ	RU	https://pubmed.ncbi.nlm.nih.gov/11689063

DM6EJQ4	DI	DM6EJQ4
DM6EJQ4	DN	N-(3,3-Dimethyl-cyclopentyl)-4-hexyloxy-benzamide
DM6EJQ4	MI	TT846HF
DM6EJQ4	MN	Voltage-gated potassium channel Kv7.1 (KCNQ1)
DM6EJQ4	MT	DTT
DM6EJQ4	MA	Inhibitor
DM6EJQ4	RN	Design and synthesis of 4-substituted benzamides as potent, selective, and orally bioavailable I(Ks) blockers. J Med Chem. 2001 Nov 8;44(23):3764-7.
DM6EJQ4	RU	https://pubmed.ncbi.nlm.nih.gov/11689063

DMAXLVQ	DI	DMAXLVQ
DMAXLVQ	DN	N-(3,3-Diphenyl)propyl-2,2-diphenylacetamide
DMAXLVQ	MI	TT6OEDT
DMAXLVQ	MN	Cannabinoid receptor 1 (CB1)
DMAXLVQ	MT	DTT
DMAXLVQ	MA	Inhibitor
DMAXLVQ	RN	Novel sterically hindered cannabinoid CB1 receptor ligands. Bioorg Med Chem. 2008 Aug 1;16(15):7510-5.
DMAXLVQ	RU	https://pubmed.ncbi.nlm.nih.gov/18579386

DMAXLVQ	DI	DMAXLVQ
DMAXLVQ	DN	N-(3,3-Diphenyl)propyl-2,2-diphenylacetamide
DMAXLVQ	MI	TTMSFAW
DMAXLVQ	MN	Cannabinoid receptor 2 (CB2)
DMAXLVQ	MT	DTT
DMAXLVQ	MA	Inhibitor
DMAXLVQ	RN	Novel sterically hindered cannabinoid CB1 receptor ligands. Bioorg Med Chem. 2008 Aug 1;16(15):7510-5.
DMAXLVQ	RU	https://pubmed.ncbi.nlm.nih.gov/18579386

DMBX0K1	DI	DMBX0K1
DMBX0K1	DN	N-(3,3-Diphenyl)propyl-2-phenylacetamide
DMBX0K1	MI	TT6OEDT
DMBX0K1	MN	Cannabinoid receptor 1 (CB1)
DMBX0K1	MT	DTT
DMBX0K1	MA	Inhibitor
DMBX0K1	RN	Novel sterically hindered cannabinoid CB1 receptor ligands. Bioorg Med Chem. 2008 Aug 1;16(15):7510-5.
DMBX0K1	RU	https://pubmed.ncbi.nlm.nih.gov/18579386

DM4PTR3	DI	DM4PTR3
DM4PTR3	DN	N-(3,3-Diphenyl-propyl)-2-pyridine-3-ylacetamide
DM4PTR3	MI	TT7WVHI
DM4PTR3	MN	Soluble epoxide hydrolase (EPHX2)
DM4PTR3	MT	DTT
DM4PTR3	MA	Inhibitor
DM4PTR3	RN	Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase. J Med Chem. 2009 Oct 8;52(19):5880-95.
DM4PTR3	RU	https://pubmed.ncbi.nlm.nih.gov/19746975

DMOXR4K	DI	DMOXR4K
DMOXR4K	DN	N-(3,3-Diphenyl-propyl)-isonicotinamide
DMOXR4K	MI	TT7WVHI
DMOXR4K	MN	Soluble epoxide hydrolase (EPHX2)
DMOXR4K	MT	DTT
DMOXR4K	MA	Inhibitor
DMOXR4K	RN	Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase. J Med Chem. 2009 Oct 8;52(19):5880-95.
DMOXR4K	RU	https://pubmed.ncbi.nlm.nih.gov/19746975

DMDYZ9K	DI	DMDYZ9K
DMDYZ9K	DN	N-(3,3-diphenyl-propyl)-nicotinamide
DMDYZ9K	MI	TT7WVHI
DMDYZ9K	MN	Soluble epoxide hydrolase (EPHX2)
DMDYZ9K	MT	DTT
DMDYZ9K	MA	Inhibitor
DMDYZ9K	RN	Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase. J Med Chem. 2009 Oct 8;52(19):5880-95.
DMDYZ9K	RU	https://pubmed.ncbi.nlm.nih.gov/19746975

DMQ5USA	DI	DMQ5USA
DMQ5USA	DN	N-(3,4,5-trihydroxyphenethyl)oleamide
DMQ5USA	MI	TTIQSC1
DMQ5USA	MN	Bacterial Lethal factor (Bact lef)
DMQ5USA	MT	DTT
DMQ5USA	MA	Inhibitor
DMQ5USA	RN	Inhibitors of anthrax lethal factor. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4575-8.
DMQ5USA	RU	https://pubmed.ncbi.nlm.nih.gov/17574849

DMTERF6	DI	DMTERF6
DMTERF6	DN	N-(3,4-Dichlorophenyl)propyl-ETAV
DMTERF6	MI	TT9PB26
DMTERF6	MN	Presynaptic density protein 95 (DLG4)
DMTERF6	MT	DTT
DMTERF6	MA	Inhibitor
DMTERF6	RN	Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem. 2008 Oct 23;51(20):6450-9.
DMTERF6	RU	https://pubmed.ncbi.nlm.nih.gov/18811137

DMF2D4O	DI	DMF2D4O
DMF2D4O	DN	N-(3,4-Difluorophenyl)propyl-ETAV
DMF2D4O	MI	TT9PB26
DMF2D4O	MN	Presynaptic density protein 95 (DLG4)
DMF2D4O	MT	DTT
DMF2D4O	MA	Inhibitor
DMF2D4O	RN	Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem. 2008 Oct 23;51(20):6450-9.
DMF2D4O	RU	https://pubmed.ncbi.nlm.nih.gov/18811137

DM67XSW	DI	DM67XSW
DM67XSW	DN	N-(3,4-dihydroxybenzyl)oleamide
DM67XSW	MI	TTIQSC1
DM67XSW	MN	Bacterial Lethal factor (Bact lef)
DM67XSW	MT	DTT
DM67XSW	MA	Inhibitor
DM67XSW	RN	Inhibitors of anthrax lethal factor based upon N-oleoyldopamine. Bioorg Med Chem Lett. 2008 Apr 1;18(7):2467-70.
DM67XSW	RU	https://pubmed.ncbi.nlm.nih.gov/18314330

DMEP2VM	DI	DMEP2VM
DMEP2VM	DN	N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide
DMEP2VM	MI	TTBH0VX
DMEP2VM	MN	Histone deacetylase (HDAC)
DMEP2VM	MT	DTT
DMEP2VM	MA	Inhibitor
DMEP2VM	RN	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50.
DMEP2VM	RU	https://pubmed.ncbi.nlm.nih.gov/20143840

DMEP2VM	DI	DMEP2VM
DMEP2VM	DN	N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide
DMEP2VM	MI	TT6R7JZ
DMEP2VM	MN	Histone deacetylase 1 (HDAC1)
DMEP2VM	MT	DTT
DMEP2VM	MA	Inhibitor
DMEP2VM	RN	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50.
DMEP2VM	RU	https://pubmed.ncbi.nlm.nih.gov/20143840

DM9B1ID	DI	DM9B1ID
DM9B1ID	DN	N-(3,5-dichlorophenyl)-2-methyl-3-nitrobenzamide
DM9B1ID	MI	TT3PQ2Y
DM9B1ID	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DM9B1ID	MT	DTT
DM9B1ID	MA	Inhibitor
DM9B1ID	RN	Design and synthesis of potent inhibitors of the malaria parasite dihydroorotate dehydrogenase. J Med Chem. 2007 Jan 25;50(2):186-91.
DM9B1ID	RU	https://pubmed.ncbi.nlm.nih.gov/17228860

DMDNUCL	DI	DMDNUCL
DMDNUCL	DN	N-(3,5-dichlorophenyl)-2-nitrobenzamide
DMDNUCL	MI	TTVTX4N
DMDNUCL	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DMDNUCL	MT	DTT
DMDNUCL	MA	Inhibitor
DMDNUCL	RN	Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening. Eur J Med Chem. 2009 Sep;44(9):3718-30.
DMDNUCL	RU	https://pubmed.ncbi.nlm.nih.gov/19428156

DM8DAGL	DI	DM8DAGL
DM8DAGL	DN	N-(3,5-dichlorophenyl)-4-methoxy-3-nitrobenzamide
DM8DAGL	MI	TTVTX4N
DM8DAGL	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DM8DAGL	MT	DTT
DM8DAGL	MA	Inhibitor
DM8DAGL	RN	Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening. Eur J Med Chem. 2009 Sep;44(9):3718-30.
DM8DAGL	RU	https://pubmed.ncbi.nlm.nih.gov/19428156

DMQ0LF2	DI	DMQ0LF2
DMQ0LF2	DN	N-(3,5-dichlorophenyl)imidodicarbonimidic diamide
DMQ0LF2	MI	TTT1R2L
DMQ0LF2	MN	Integrin alpha-V (ITGAV)
DMQ0LF2	MT	DTT
DMQ0LF2	MA	Inhibitor
DMQ0LF2	RN	Emerging targets in osteoporosis disease modification. J Med Chem. 2010 Jun 10;53(11):4332-53.
DMQ0LF2	RU	https://pubmed.ncbi.nlm.nih.gov/20218623

DMQ0LF2	DI	DMQ0LF2
DMQ0LF2	DN	N-(3,5-dichlorophenyl)imidodicarbonimidic diamide
DMQ0LF2	MI	TTJA1ZO
DMQ0LF2	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMQ0LF2	MT	DTT
DMQ0LF2	MA	Inhibitor
DMQ0LF2	RN	Emerging targets in osteoporosis disease modification. J Med Chem. 2010 Jun 10;53(11):4332-53.
DMQ0LF2	RU	https://pubmed.ncbi.nlm.nih.gov/20218623

DM95SJU	DI	DM95SJU
DM95SJU	DN	N-(3,5-dimethoxyphenethyl)docos-13-enamide
DM95SJU	MI	TT6OEDT
DM95SJU	MN	Cannabinoid receptor 1 (CB1)
DM95SJU	MT	DTT
DM95SJU	MA	Inhibitor
DM95SJU	RN	New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies. Bioorg Med Chem Lett. 2006 Jan 1;16(1):138-41.
DM95SJU	RU	https://pubmed.ncbi.nlm.nih.gov/16213718

DM1C40H	DI	DM1C40H
DM1C40H	DN	N-(3,5-dimethoxyphenethyl)oleamide
DM1C40H	MI	TT6OEDT
DM1C40H	MN	Cannabinoid receptor 1 (CB1)
DM1C40H	MT	DTT
DM1C40H	MA	Inhibitor
DM1C40H	RN	New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies. Bioorg Med Chem Lett. 2006 Jan 1;16(1):138-41.
DM1C40H	RU	https://pubmed.ncbi.nlm.nih.gov/16213718

DM43QHV	DI	DM43QHV
DM43QHV	DN	N-(3,5-dimethoxyphenyl)-4-methyl-2-nitrobenzamide
DM43QHV	MI	TTVTX4N
DM43QHV	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DM43QHV	MT	DTT
DM43QHV	MA	Inhibitor
DM43QHV	RN	Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening. Eur J Med Chem. 2009 Sep;44(9):3718-30.
DM43QHV	RU	https://pubmed.ncbi.nlm.nih.gov/19428156

DM1L3FM	DI	DM1L3FM
DM1L3FM	DN	N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide
DM1L3FM	MI	TTBH0VX
DM1L3FM	MN	Histone deacetylase (HDAC)
DM1L3FM	MT	DTT
DM1L3FM	MA	Inhibitor
DM1L3FM	RN	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50.
DM1L3FM	RU	https://pubmed.ncbi.nlm.nih.gov/20143840

DM1L3FM	DI	DM1L3FM
DM1L3FM	DN	N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide
DM1L3FM	MI	TT6R7JZ
DM1L3FM	MN	Histone deacetylase 1 (HDAC1)
DM1L3FM	MT	DTT
DM1L3FM	MA	Inhibitor
DM1L3FM	RN	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50.
DM1L3FM	RU	https://pubmed.ncbi.nlm.nih.gov/20143840

DMH3R21	DI	DMH3R21
DMH3R21	DN	N-(3-acetamidophenyl)-3-chlorobenzamide
DMH3R21	MI	TTHS256
DMH3R21	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMH3R21	MT	DTT
DMH3R21	MA	Inhibitor
DMH3R21	RN	Synthesis and SAR of novel, non-MPEP chemotype mGluR5 NAMs identified by functional HTS. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6502-6.
DMH3R21	RU	https://pubmed.ncbi.nlm.nih.gov/19875287

DMYJB1A	DI	DMYJB1A
DMYJB1A	DN	N-(3'-acetyl-4-aminobiphenyl-3-yl)benzamide
DMYJB1A	MI	TTSHTOI
DMYJB1A	MN	Histone deacetylase 2 (HDAC2)
DMYJB1A	MT	DTT
DMYJB1A	MA	Inhibitor
DMYJB1A	RN	Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5.
DMYJB1A	RU	https://pubmed.ncbi.nlm.nih.gov/20392638

DMJ6FP7	DI	DMJ6FP7
DMJ6FP7	DN	N-(3-aminophenyl)benzenesulfonamide
DMJ6FP7	MI	TTJS8PY
DMJ6FP7	MN	5-HT 6 receptor (HTR6)
DMJ6FP7	MT	DTT
DMJ6FP7	MA	Inhibitor
DMJ6FP7	RN	Binding of sulfonyl-containing arylalkylamines at human 5-HT6 serotonin receptors. J Med Chem. 2006 Aug 24;49(17):5217-25.
DMJ6FP7	RU	https://pubmed.ncbi.nlm.nih.gov/16913710

DMYSURL	DI	DMYSURL
DMYSURL	DN	N-(3-Benzooxazol-7-yl-propyl)-acetamide
DMYSURL	MI	TT32JK8
DMYSURL	MN	Melatonin receptor type 1B (MTNR1B)
DMYSURL	MT	DTT
DMYSURL	MA	Inhibitor
DMYSURL	RN	Synthesis and structure-activity relationship of novel benzoxazole derivatives as melatonin receptor agonists. Bioorg Med Chem Lett. 2004 Jul 16;14(14):3799-802.
DMYSURL	RU	https://pubmed.ncbi.nlm.nih.gov/15203165

DMKMESD	DI	DMKMESD
DMKMESD	DN	N-(3-Benzooxazol-7-yl-propyl)-butyramide
DMKMESD	MI	TT32JK8
DMKMESD	MN	Melatonin receptor type 1B (MTNR1B)
DMKMESD	MT	DTT
DMKMESD	MA	Inhibitor
DMKMESD	RN	Synthesis and structure-activity relationship of novel benzoxazole derivatives as melatonin receptor agonists. Bioorg Med Chem Lett. 2004 Jul 16;14(14):3799-802.
DMKMESD	RU	https://pubmed.ncbi.nlm.nih.gov/15203165

DMEMYS1	DI	DMEMYS1
DMEMYS1	DN	N-(3-Benzooxazol-7-yl-propyl)-propionamide
DMEMYS1	MI	TT32JK8
DMEMYS1	MN	Melatonin receptor type 1B (MTNR1B)
DMEMYS1	MT	DTT
DMEMYS1	MA	Inhibitor
DMEMYS1	RN	Synthesis and structure-activity relationship of novel benzoxazole derivatives as melatonin receptor agonists. Bioorg Med Chem Lett. 2004 Jul 16;14(14):3799-802.
DMEMYS1	RU	https://pubmed.ncbi.nlm.nih.gov/15203165

DMOQ08F	DI	DMOQ08F
DMOQ08F	DN	N-(3-Bromo-benzoyl)-4-chloro-benzenesulfonamide
DMOQ08F	MI	TTUTJGQ
DMOQ08F	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMOQ08F	MT	DTT
DMOQ08F	MA	Inhibitor
DMOQ08F	RN	Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80.
DMOQ08F	RU	https://pubmed.ncbi.nlm.nih.gov/15481975

DMOQ08F	DI	DMOQ08F
DMOQ08F	DN	N-(3-Bromo-benzoyl)-4-chloro-benzenesulfonamide
DMOQ08F	MI	TTDCBX5
DMOQ08F	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DMOQ08F	MT	DTT
DMOQ08F	MA	Inhibitor
DMOQ08F	RN	Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80.
DMOQ08F	RU	https://pubmed.ncbi.nlm.nih.gov/15481975

DMOQ08F	DI	DMOQ08F
DMOQ08F	DN	N-(3-Bromo-benzoyl)-4-chloro-benzenesulfonamide
DMOQ08F	MI	TT1VAUK
DMOQ08F	MN	VEGFR1 messenger RNA (VEGFR1 mRNA)
DMOQ08F	MT	DTT
DMOQ08F	MA	Inhibitor
DMOQ08F	RN	Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80.
DMOQ08F	RU	https://pubmed.ncbi.nlm.nih.gov/15481975

DM0Z1HJ	DI	DM0Z1HJ
DM0Z1HJ	DN	N-(3-Bromophenyl)-5-methoxybenzo[d]oxazol-2-amine
DM0Z1HJ	MI	TT2J34L
DM0Z1HJ	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM0Z1HJ	MT	DTT
DM0Z1HJ	MA	Inhibitor
DM0Z1HJ	RN	Synthesis and evaluation of benzoxazole derivatives as 5-lipoxygenase inhibitors. Bioorg Med Chem. 2010 Nov 1;18(21):7580-5.
DM0Z1HJ	RU	https://pubmed.ncbi.nlm.nih.gov/20870413

DMEWQCN	DI	DMEWQCN
DMEWQCN	DN	N-(3-bromophenyl)-6-chloroquinazolin-4-amine
DMEWQCN	MI	TTVBPDM
DMEWQCN	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMEWQCN	MT	DTT
DMEWQCN	MA	Inhibitor
DMEWQCN	RN	Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6.
DMEWQCN	RU	https://pubmed.ncbi.nlm.nih.gov/19854049

DMEWQCN	DI	DMEWQCN
DMEWQCN	DN	N-(3-bromophenyl)-6-chloroquinazolin-4-amine
DMEWQCN	MI	TTHS256
DMEWQCN	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMEWQCN	MT	DTT
DMEWQCN	MA	Inhibitor
DMEWQCN	RN	Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6.
DMEWQCN	RU	https://pubmed.ncbi.nlm.nih.gov/19854049

DMRIK7P	DI	DMRIK7P
DMRIK7P	DN	N-(3-bromophenyl)-6-fluoroquinazolin-4-amine
DMRIK7P	MI	TTVBPDM
DMRIK7P	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMRIK7P	MT	DTT
DMRIK7P	MA	Inhibitor
DMRIK7P	RN	Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6.
DMRIK7P	RU	https://pubmed.ncbi.nlm.nih.gov/19854049

DMRIK7P	DI	DMRIK7P
DMRIK7P	DN	N-(3-bromophenyl)-6-fluoroquinazolin-4-amine
DMRIK7P	MI	TTHS256
DMRIK7P	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMRIK7P	MT	DTT
DMRIK7P	MA	Inhibitor
DMRIK7P	RN	Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6.
DMRIK7P	RU	https://pubmed.ncbi.nlm.nih.gov/19854049

DME6IKT	DI	DME6IKT
DME6IKT	DN	N-(3-Chloro-phenyl)-2-cyclohexyl-acetamide
DME6IKT	MI	TT7WVHI
DME6IKT	MN	Soluble epoxide hydrolase (EPHX2)
DME6IKT	MT	DTT
DME6IKT	MA	Inhibitor
DME6IKT	RN	Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem. 2005 May 19;48(10):3621-9.
DME6IKT	RU	https://pubmed.ncbi.nlm.nih.gov/15887969

DM3RQHG	DI	DM3RQHG
DM3RQHG	DN	N-(3-chlorophenyl)-3-cyano-5-fluorobenzamide
DM3RQHG	MI	TTHS256
DM3RQHG	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM3RQHG	MT	DTT
DM3RQHG	MA	Inhibitor
DM3RQHG	RN	3-Cyano-5-fluoro-N-arylbenzamides as negative allosteric modulators of mGlu(5): Identification of easily prepared tool compounds with CNS exposure ... Bioorg Med Chem Lett. 2010 Aug 1;20(15):4390-4.
DM3RQHG	RU	https://pubmed.ncbi.nlm.nih.gov/20598884

DM3AGJH	DI	DM3AGJH
DM3AGJH	DN	N-(3-chlorophenyl)-6-fluoroquinazolin-4-amine
DM3AGJH	MI	TTHS256
DM3AGJH	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM3AGJH	MT	DTT
DM3AGJH	MA	Inhibitor
DM3AGJH	RN	Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6.
DM3AGJH	RU	https://pubmed.ncbi.nlm.nih.gov/19854049

DMQEPV0	DI	DMQEPV0
DMQEPV0	DN	N-(3-chlorophenyl)-6-methoxyquinazolin-4-amine
DMQEPV0	MI	TTHS256
DMQEPV0	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMQEPV0	MT	DTT
DMQEPV0	MA	Inhibitor
DMQEPV0	RN	Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6.
DMQEPV0	RU	https://pubmed.ncbi.nlm.nih.gov/19854049

DMIKP5Y	DI	DMIKP5Y
DMIKP5Y	DN	N-(3-chlorophenyl)-6-nitroquinazolin-4-amine
DMIKP5Y	MI	TTHS256
DMIKP5Y	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMIKP5Y	MT	DTT
DMIKP5Y	MA	Inhibitor
DMIKP5Y	RN	Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6.
DMIKP5Y	RU	https://pubmed.ncbi.nlm.nih.gov/19854049

DMC5G6Y	DI	DMC5G6Y
DMC5G6Y	DN	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide
DMC5G6Y	MI	TTBH0VX
DMC5G6Y	MN	Histone deacetylase (HDAC)
DMC5G6Y	MT	DTT
DMC5G6Y	MA	Inhibitor
DMC5G6Y	RN	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50.
DMC5G6Y	RU	https://pubmed.ncbi.nlm.nih.gov/20143840

DMC5G6Y	DI	DMC5G6Y
DMC5G6Y	DN	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide
DMC5G6Y	MI	TT6R7JZ
DMC5G6Y	MN	Histone deacetylase 1 (HDAC1)
DMC5G6Y	MT	DTT
DMC5G6Y	MA	Inhibitor
DMC5G6Y	RN	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50.
DMC5G6Y	RU	https://pubmed.ncbi.nlm.nih.gov/20143840

DM0H8CK	DI	DM0H8CK
DM0H8CK	DN	N-(3-Methanesulfonyl-4-methoxy-benzoyl)-guanidine
DM0H8CK	MI	TTGSEFH
DM0H8CK	MN	Sodium/hydrogen exchanger 1 (SLC9A1)
DM0H8CK	MT	DTT
DM0H8CK	MA	Inhibitor
DM0H8CK	RN	(2-Methyl-5-(methylsulfonyl)benzoyl)guanidine Na+/H+ antiporter inhibitors. J Med Chem. 1997 Jun 20;40(13):2017-34.
DM0H8CK	RU	https://pubmed.ncbi.nlm.nih.gov/9207943

DM0H8CK	DI	DM0H8CK
DM0H8CK	DN	N-(3-Methanesulfonyl-4-methoxy-benzoyl)-guanidine
DM0H8CK	MI	TTFZVPO
DM0H8CK	MN	Sodium/hydrogen exchanger 3 (SLC9A3)
DM0H8CK	MT	DTT
DM0H8CK	MA	Inhibitor
DM0H8CK	RN	(2-Methyl-5-(methylsulfonyl)benzoyl)guanidine Na+/H+ antiporter inhibitors. J Med Chem. 1997 Jun 20;40(13):2017-34.
DM0H8CK	RU	https://pubmed.ncbi.nlm.nih.gov/9207943

DMSVQJP	DI	DMSVQJP
DMSVQJP	DN	N-(3-Methanesulfonyl-4-methyl-benzoyl)-guanidine
DMSVQJP	MI	TTGSEFH
DMSVQJP	MN	Sodium/hydrogen exchanger 1 (SLC9A1)
DMSVQJP	MT	DTT
DMSVQJP	MA	Inhibitor
DMSVQJP	RN	(2-Methyl-5-(methylsulfonyl)benzoyl)guanidine Na+/H+ antiporter inhibitors. J Med Chem. 1997 Jun 20;40(13):2017-34.
DMSVQJP	RU	https://pubmed.ncbi.nlm.nih.gov/9207943

DMSVQJP	DI	DMSVQJP
DMSVQJP	DN	N-(3-Methanesulfonyl-4-methyl-benzoyl)-guanidine
DMSVQJP	MI	TTFZVPO
DMSVQJP	MN	Sodium/hydrogen exchanger 3 (SLC9A3)
DMSVQJP	MT	DTT
DMSVQJP	MA	Inhibitor
DMSVQJP	RN	(2-Methyl-5-(methylsulfonyl)benzoyl)guanidine Na+/H+ antiporter inhibitors. J Med Chem. 1997 Jun 20;40(13):2017-34.
DMSVQJP	RU	https://pubmed.ncbi.nlm.nih.gov/9207943

DM2D4KY	DI	DM2D4KY
DM2D4KY	DN	N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE
DM2D4KY	MI	TT7HF4W
DM2D4KY	MN	Cyclin-dependent kinase 2 (CDK2)
DM2D4KY	MT	DTT
DM2D4KY	MA	Inhibitor
DM2D4KY	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM2D4KY	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMHZU8K	DI	DMHZU8K
DMHZU8K	DN	N-(3-phenethoxybenzyl)-4-hydroxybenzamide
DMHZU8K	MI	TTN9D8E
DMHZU8K	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMHZU8K	MT	DTT
DMHZU8K	MA	Inhibitor
DMHZU8K	RN	Structure-activity relationship study of novel NR2B-selective antagonists with arylamides to avoid reactive metabolites formation. Bioorg Med Chem Lett. 2007 Oct 15;17(20):5537-42.
DMHZU8K	RU	https://pubmed.ncbi.nlm.nih.gov/17766107

DMXF46V	DI	DMXF46V
DMXF46V	DN	N-(3-phenoxy-4-pyridinyl)ethanesulfonamide
DMXF46V	MI	TT8NGED
DMXF46V	MN	Prostaglandin G/H synthase 1 (COX-1)
DMXF46V	MT	DTT
DMXF46V	MA	Inhibitor
DMXF46V	RN	Design, synthesis, and pharmacological evaluation of pyridinic analogues of nimesulide as cyclooxygenase-2 selective inhibitors. J Med Chem. 2004 Dec 30;47(27):6749-59.
DMXF46V	RU	https://pubmed.ncbi.nlm.nih.gov/15615524

DMXF46V	DI	DMXF46V
DMXF46V	DN	N-(3-phenoxy-4-pyridinyl)ethanesulfonamide
DMXF46V	MI	TTVKILB
DMXF46V	MN	Prostaglandin G/H synthase 2 (COX-2)
DMXF46V	MT	DTT
DMXF46V	MA	Inhibitor
DMXF46V	RN	Design, synthesis, and pharmacological evaluation of pyridinic analogues of nimesulide as cyclooxygenase-2 selective inhibitors. J Med Chem. 2004 Dec 30;47(27):6749-59.
DMXF46V	RU	https://pubmed.ncbi.nlm.nih.gov/15615524

DMN1DPJ	DI	DMN1DPJ
DMN1DPJ	DN	N-(3-phenoxy-4-pyridinyl)propanesulfonamide
DMN1DPJ	MI	TT8NGED
DMN1DPJ	MN	Prostaglandin G/H synthase 1 (COX-1)
DMN1DPJ	MT	DTT
DMN1DPJ	MA	Inhibitor
DMN1DPJ	RN	Design, synthesis, and pharmacological evaluation of pyridinic analogues of nimesulide as cyclooxygenase-2 selective inhibitors. J Med Chem. 2004 Dec 30;47(27):6749-59.
DMN1DPJ	RU	https://pubmed.ncbi.nlm.nih.gov/15615524

DM7CM3F	DI	DM7CM3F
DM7CM3F	DN	N-(3-phenoxypyridin-4-yl)methanesulfonamide
DM7CM3F	MI	TT8NGED
DM7CM3F	MN	Prostaglandin G/H synthase 1 (COX-1)
DM7CM3F	MT	DTT
DM7CM3F	MA	Inhibitor
DM7CM3F	RN	Pyridine analogues of nimesulide: design, synthesis, and in vitro and in vivo pharmacological evaluation as promising cyclooxygenase 1 and 2 inhibi... J Med Chem. 2009 Oct 8;52(19):5864-71.
DM7CM3F	RU	https://pubmed.ncbi.nlm.nih.gov/19791801

DMSNF7W	DI	DMSNF7W
DMSNF7W	DN	N-(3-Phenyl)propyl-2-(4-bromophenylacetamide)
DMSNF7W	MI	TT6OEDT
DMSNF7W	MN	Cannabinoid receptor 1 (CB1)
DMSNF7W	MT	DTT
DMSNF7W	MA	Inhibitor
DMSNF7W	RN	Novel sterically hindered cannabinoid CB1 receptor ligands. Bioorg Med Chem. 2008 Aug 1;16(15):7510-5.
DMSNF7W	RU	https://pubmed.ncbi.nlm.nih.gov/18579386

DMSNF7W	DI	DMSNF7W
DMSNF7W	DN	N-(3-Phenyl)propyl-2-(4-bromophenylacetamide)
DMSNF7W	MI	TTMSFAW
DMSNF7W	MN	Cannabinoid receptor 2 (CB2)
DMSNF7W	MT	DTT
DMSNF7W	MA	Inhibitor
DMSNF7W	RN	Novel sterically hindered cannabinoid CB1 receptor ligands. Bioorg Med Chem. 2008 Aug 1;16(15):7510-5.
DMSNF7W	RU	https://pubmed.ncbi.nlm.nih.gov/18579386

DM9XH18	DI	DM9XH18
DM9XH18	DN	N-(3-Phenyl)propyl-2,2-diphenylacetamide
DM9XH18	MI	TT6OEDT
DM9XH18	MN	Cannabinoid receptor 1 (CB1)
DM9XH18	MT	DTT
DM9XH18	MA	Inhibitor
DM9XH18	RN	Novel sterically hindered cannabinoid CB1 receptor ligands. Bioorg Med Chem. 2008 Aug 1;16(15):7510-5.
DM9XH18	RU	https://pubmed.ncbi.nlm.nih.gov/18579386

DM4IA92	DI	DM4IA92
DM4IA92	DN	N-(3-Phenyl-[1,2,4]thiadiazol-5-yl)-benzamide
DM4IA92	MI	TTM2AOE
DM4IA92	MN	Adenosine A2a receptor (ADORA2A)
DM4IA92	MT	DTT
DM4IA92	MA	Inhibitor
DM4IA92	RN	Thiazole and thiadiazole analogues as a novel class of adenosine receptor antagonists. J Med Chem. 2001 Mar 1;44(5):749-62.
DM4IA92	RU	https://pubmed.ncbi.nlm.nih.gov/11262085

DMJB7SE	DI	DMJB7SE
DMJB7SE	DN	N-(3-phenylamino-4-pyridinyl)methanesulfonamide
DMJB7SE	MI	TT8NGED
DMJB7SE	MN	Prostaglandin G/H synthase 1 (COX-1)
DMJB7SE	MT	DTT
DMJB7SE	MA	Inhibitor
DMJB7SE	RN	Pyridine analogues of nimesulide: design, synthesis, and in vitro and in vivo pharmacological evaluation as promising cyclooxygenase 1 and 2 inhibi... J Med Chem. 2009 Oct 8;52(19):5864-71.
DMJB7SE	RU	https://pubmed.ncbi.nlm.nih.gov/19791801

DMJB7SE	DI	DMJB7SE
DMJB7SE	DN	N-(3-phenylamino-4-pyridinyl)methanesulfonamide
DMJB7SE	MI	TTVKILB
DMJB7SE	MN	Prostaglandin G/H synthase 2 (COX-2)
DMJB7SE	MT	DTT
DMJB7SE	MA	Inhibitor
DMJB7SE	RN	Pyridine analogues of nimesulide: design, synthesis, and in vitro and in vivo pharmacological evaluation as promising cyclooxygenase 1 and 2 inhibi... J Med Chem. 2009 Oct 8;52(19):5864-71.
DMJB7SE	RU	https://pubmed.ncbi.nlm.nih.gov/19791801

DMKAX3Q	DI	DMKAX3Q
DMKAX3Q	DN	N-(3-Phenylpropyl)-1H-indole-2-carboxamide
DMKAX3Q	MI	TT3WG5C
DMKAX3Q	MN	Monoamine oxidase type A (MAO-A)
DMKAX3Q	MT	DTT
DMKAX3Q	MA	Inhibitor
DMKAX3Q	RN	Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40.
DMKAX3Q	RU	https://pubmed.ncbi.nlm.nih.gov/18951803

DMKAX3Q	DI	DMKAX3Q
DMKAX3Q	DN	N-(3-Phenylpropyl)-1H-indole-2-carboxamide
DMKAX3Q	MI	TTGP7BY
DMKAX3Q	MN	Monoamine oxidase type B (MAO-B)
DMKAX3Q	MT	DTT
DMKAX3Q	MA	Inhibitor
DMKAX3Q	RN	Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40.
DMKAX3Q	RU	https://pubmed.ncbi.nlm.nih.gov/18951803

DMZ3I6U	DI	DMZ3I6U
DMZ3I6U	DN	N-(3-phenylpropyl)-1H-pyrrole-2-carboxamide
DMZ3I6U	MI	TT3WG5C
DMZ3I6U	MN	Monoamine oxidase type A (MAO-A)
DMZ3I6U	MT	DTT
DMZ3I6U	MA	Inhibitor
DMZ3I6U	RN	New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J Med Chem. 2007 Mar 8;50(5):922-31.
DMZ3I6U	RU	https://pubmed.ncbi.nlm.nih.gov/17256833

DMA7X62	DI	DMA7X62
DMA7X62	DN	N-(3-Phenyl-propyl)-nicotinamide
DMA7X62	MI	TT7WVHI
DMA7X62	MN	Soluble epoxide hydrolase (EPHX2)
DMA7X62	MT	DTT
DMA7X62	MA	Inhibitor
DMA7X62	RN	Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase. J Med Chem. 2009 Oct 8;52(19):5880-95.
DMA7X62	RU	https://pubmed.ncbi.nlm.nih.gov/19746975

DM1V83P	DI	DM1V83P
DM1V83P	DN	N-(4-(2-aminoethyl)phenyl)benzenesulfonamide
DM1V83P	MI	TTJS8PY
DM1V83P	MN	5-HT 6 receptor (HTR6)
DM1V83P	MT	DTT
DM1V83P	MA	Inhibitor
DM1V83P	RN	Binding of sulfonyl-containing arylalkylamines at human 5-HT6 serotonin receptors. J Med Chem. 2006 Aug 24;49(17):5217-25.
DM1V83P	RU	https://pubmed.ncbi.nlm.nih.gov/16913710

DMRH987	DI	DMRH987
DMRH987	DN	N-(4-(3-(pyridin-2-yl)acryloyl)phenyl)acetamide
DMRH987	MI	TTYFKSZ
DMRH987	MN	Tubulin beta (TUBB)
DMRH987	MT	DTT
DMRH987	MA	Inhibitor
DMRH987	RN	Design and biological evaluation of novel tubulin inhibitors as antimitotic agents using a pharmacophore binding model with tubulin. J Med Chem. 2006 Sep 21;49(19):5664-70.
DMRH987	RU	https://pubmed.ncbi.nlm.nih.gov/16970393

DMRH987	DI	DMRH987
DMRH987	DN	N-(4-(3-(pyridin-2-yl)acryloyl)phenyl)acetamide
DMRH987	MI	TTJ2PTI
DMRH987	MN	Tubulin beta-2 chain (TUBB2)
DMRH987	MT	DTT
DMRH987	MA	Inhibitor
DMRH987	RN	Design and biological evaluation of novel tubulin inhibitors as antimitotic agents using a pharmacophore binding model with tubulin. J Med Chem. 2006 Sep 21;49(19):5664-70.
DMRH987	RU	https://pubmed.ncbi.nlm.nih.gov/16970393

DMQDI5H	DI	DMQDI5H
DMQDI5H	DN	N-(4-(4-hexyl-2-hydroxyphenoxy)phenyl)acetamide
DMQDI5H	MI	TTVTX4N
DMQDI5H	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DMQDI5H	MT	DTT
DMQDI5H	MA	Inhibitor
DMQDI5H	RN	Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33.
DMQDI5H	RU	https://pubmed.ncbi.nlm.nih.gov/18457948

DMIPKNQ	DI	DMIPKNQ
DMIPKNQ	DN	N-(4-(benzyloxy)phenethyl)pyridin-4-amine
DMIPKNQ	MI	TTN9D8E
DMIPKNQ	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMIPKNQ	MT	DTT
DMIPKNQ	MA	Inhibitor
DMIPKNQ	RN	Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetr... J Med Chem. 2007 Feb 22;50(4):807-19.
DMIPKNQ	RU	https://pubmed.ncbi.nlm.nih.gov/17249648

DMIPKNQ	DI	DMIPKNQ
DMIPKNQ	DN	N-(4-(benzyloxy)phenethyl)pyridin-4-amine
DMIPKNQ	MI	TTQ6VDM
DMIPKNQ	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMIPKNQ	MT	DTT
DMIPKNQ	MA	Inhibitor
DMIPKNQ	RN	Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetr... J Med Chem. 2007 Feb 22;50(4):807-19.
DMIPKNQ	RU	https://pubmed.ncbi.nlm.nih.gov/17249648

DMZAOVG	DI	DMZAOVG
DMZAOVG	DN	N-(4-(diethylamino)phenyl)-2-nitrobenzamide
DMZAOVG	MI	TTVTX4N
DMZAOVG	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DMZAOVG	MT	DTT
DMZAOVG	MA	Inhibitor
DMZAOVG	RN	Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening. Eur J Med Chem. 2009 Sep;44(9):3718-30.
DMZAOVG	RU	https://pubmed.ncbi.nlm.nih.gov/19428156

DMI74KM	DI	DMI74KM
DMI74KM	DN	N-(4-(phenylamino)quinazolin-6-yl)acrylamide
DMI74KM	MI	TTGKNB4
DMI74KM	MN	Epidermal growth factor receptor (EGFR)
DMI74KM	MT	DTT
DMI74KM	MA	Inhibitor
DMI74KM	RN	Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nat Chem Biol. 2007 Apr;3(4):229-38.
DMI74KM	RU	https://pubmed.ncbi.nlm.nih.gov/17334377

DMI74KM	DI	DMI74KM
DMI74KM	DN	N-(4-(phenylamino)quinazolin-6-yl)acrylamide
DMI74KM	MI	TT6PKBN
DMI74KM	MN	Proto-oncogene c-Src (SRC)
DMI74KM	MT	DTT
DMI74KM	MA	Inhibitor
DMI74KM	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMI74KM	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMZ0V8O	DI	DMZ0V8O
DMZ0V8O	DN	N-(4-(trifluoromethyl)benzyl)-4-phenoxybenzamide
DMZ0V8O	MI	TTQBR95
DMZ0V8O	MN	Stress-activated protein kinase 2a (p38 alpha)
DMZ0V8O	MT	DTT
DMZ0V8O	MA	Inhibitor
DMZ0V8O	RN	Two classes of p38alpha MAP kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5274-9.
DMZ0V8O	RU	https://pubmed.ncbi.nlm.nih.gov/16169718

DM086VJ	DI	DM086VJ
DM086VJ	DN	N-(4,4-Diphenyl-butyl)-nicotinamide
DM086VJ	MI	TT7WVHI
DM086VJ	MN	Soluble epoxide hydrolase (EPHX2)
DM086VJ	MT	DTT
DM086VJ	MA	Inhibitor
DM086VJ	RN	Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase. J Med Chem. 2009 Oct 8;52(19):5880-95.
DM086VJ	RU	https://pubmed.ncbi.nlm.nih.gov/19746975

DM34R10	DI	DM34R10
DM34R10	DN	N-(4,5-diphenylpyrimidin-2-yl)acetamide
DM34R10	MI	TTK25J1
DM34R10	MN	Adenosine A1 receptor (ADORA1)
DM34R10	MT	DTT
DM34R10	MA	Inhibitor
DM34R10	RN	2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40.
DM34R10	RU	https://pubmed.ncbi.nlm.nih.gov/15588088

DM34R10	DI	DM34R10
DM34R10	DN	N-(4,5-diphenylpyrimidin-2-yl)acetamide
DM34R10	MI	TTJFY5U
DM34R10	MN	Adenosine A3 receptor (ADORA3)
DM34R10	MT	DTT
DM34R10	MA	Inhibitor
DM34R10	RN	2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40.
DM34R10	RU	https://pubmed.ncbi.nlm.nih.gov/15588088

DMDP1QG	DI	DMDP1QG
DMDP1QG	DN	N-(4,6-diphenylpyrimidin-2-yl)-2-ethylbutyramide
DMDP1QG	MI	TTK25J1
DMDP1QG	MN	Adenosine A1 receptor (ADORA1)
DMDP1QG	MT	DTT
DMDP1QG	MA	Inhibitor
DMDP1QG	RN	2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40.
DMDP1QG	RU	https://pubmed.ncbi.nlm.nih.gov/15588088

DMQVPK9	DI	DMQVPK9
DMQVPK9	DN	N-(4,6-diphenylpyrimidin-2-yl)-3-chlorobenzamide
DMQVPK9	MI	TTK25J1
DMQVPK9	MN	Adenosine A1 receptor (ADORA1)
DMQVPK9	MT	DTT
DMQVPK9	MA	Inhibitor
DMQVPK9	RN	2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40.
DMQVPK9	RU	https://pubmed.ncbi.nlm.nih.gov/15588088

DMOAPJ1	DI	DMOAPJ1
DMOAPJ1	DN	N-(4,6-diphenylpyrimidin-2-yl)-3-methylbutyramide
DMOAPJ1	MI	TTK25J1
DMOAPJ1	MN	Adenosine A1 receptor (ADORA1)
DMOAPJ1	MT	DTT
DMOAPJ1	MA	Inhibitor
DMOAPJ1	RN	2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40.
DMOAPJ1	RU	https://pubmed.ncbi.nlm.nih.gov/15588088

DM1PSR7	DI	DM1PSR7
DM1PSR7	DN	N-(4,6-diphenylpyrimidin-2-yl)-4-chlorobenzamide
DM1PSR7	MI	TTJFY5U
DM1PSR7	MN	Adenosine A3 receptor (ADORA3)
DM1PSR7	MT	DTT
DM1PSR7	MA	Inhibitor
DM1PSR7	RN	2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40.
DM1PSR7	RU	https://pubmed.ncbi.nlm.nih.gov/15588088

DMA214F	DI	DMA214F
DMA214F	DN	N-(4,6-diphenylpyrimidin-2-yl)benzamide
DMA214F	MI	TTK25J1
DMA214F	MN	Adenosine A1 receptor (ADORA1)
DMA214F	MT	DTT
DMA214F	MA	Inhibitor
DMA214F	RN	2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40.
DMA214F	RU	https://pubmed.ncbi.nlm.nih.gov/15588088

DMJZ2IP	DI	DMJZ2IP
DMJZ2IP	DN	N-(4,6-diphenylpyrimidin-2-yl)propionamide
DMJZ2IP	MI	TTK25J1
DMJZ2IP	MN	Adenosine A1 receptor (ADORA1)
DMJZ2IP	MT	DTT
DMJZ2IP	MA	Inhibitor
DMJZ2IP	RN	2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40.
DMJZ2IP	RU	https://pubmed.ncbi.nlm.nih.gov/15588088

DMJZ2IP	DI	DMJZ2IP
DMJZ2IP	DN	N-(4,6-diphenylpyrimidin-2-yl)propionamide
DMJZ2IP	MI	TTM2AOE
DMJZ2IP	MN	Adenosine A2a receptor (ADORA2A)
DMJZ2IP	MT	DTT
DMJZ2IP	MA	Inhibitor
DMJZ2IP	RN	2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40.
DMJZ2IP	RU	https://pubmed.ncbi.nlm.nih.gov/15588088

DMJZ2IP	DI	DMJZ2IP
DMJZ2IP	DN	N-(4,6-diphenylpyrimidin-2-yl)propionamide
DMJZ2IP	MI	TTJFY5U
DMJZ2IP	MN	Adenosine A3 receptor (ADORA3)
DMJZ2IP	MT	DTT
DMJZ2IP	MA	Inhibitor
DMJZ2IP	RN	2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40.
DMJZ2IP	RU	https://pubmed.ncbi.nlm.nih.gov/15588088

DMIJLX6	DI	DMIJLX6
DMIJLX6	DN	N-(4'-acetyl-4-aminobiphenyl-3-yl)benzamide
DMIJLX6	MI	TTSHTOI
DMIJLX6	MN	Histone deacetylase 2 (HDAC2)
DMIJLX6	MT	DTT
DMIJLX6	MA	Inhibitor
DMIJLX6	RN	Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5.
DMIJLX6	RU	https://pubmed.ncbi.nlm.nih.gov/20392638

DMCLRBK	DI	DMCLRBK
DMCLRBK	DN	N-(4-amino-2-propylquinolin-6-yl)cinnamamide
DMCLRBK	MI	TTX4RTB
DMCLRBK	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMCLRBK	MT	DTT
DMCLRBK	MA	Inhibitor
DMCLRBK	RN	4-Aminoquinoline melanin-concentrating hormone 1-receptor (MCH1R) antagonists. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5275-9.
DMCLRBK	RU	https://pubmed.ncbi.nlm.nih.gov/16919453

DMV6154	DI	DMV6154
DMV6154	DN	N-(4-amino-3'-methoxybiphenyl-3-yl)benzamide
DMV6154	MI	TTSHTOI
DMV6154	MN	Histone deacetylase 2 (HDAC2)
DMV6154	MT	DTT
DMV6154	MA	Inhibitor
DMV6154	RN	Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5.
DMV6154	RU	https://pubmed.ncbi.nlm.nih.gov/20392638

DM910BF	DI	DM910BF
DM910BF	DN	N-(4-amino-3'-methylbiphenyl-3-yl)benzamide
DM910BF	MI	TTSHTOI
DM910BF	MN	Histone deacetylase 2 (HDAC2)
DM910BF	MT	DTT
DM910BF	MA	Inhibitor
DM910BF	RN	Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5.
DM910BF	RU	https://pubmed.ncbi.nlm.nih.gov/20392638

DMIAGS8	DI	DMIAGS8
DMIAGS8	DN	N-(4-amino-4'-bromobiphenyl-3-yl)benzamide
DMIAGS8	MI	TTSHTOI
DMIAGS8	MN	Histone deacetylase 2 (HDAC2)
DMIAGS8	MT	DTT
DMIAGS8	MA	Inhibitor
DMIAGS8	RN	Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5.
DMIAGS8	RU	https://pubmed.ncbi.nlm.nih.gov/20392638

DMR5D16	DI	DMR5D16
DMR5D16	DN	N-(4-amino-4'-fluorobiphenyl-3-yl)benzamide
DMR5D16	MI	TTSHTOI
DMR5D16	MN	Histone deacetylase 2 (HDAC2)
DMR5D16	MT	DTT
DMR5D16	MA	Inhibitor
DMR5D16	RN	Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5.
DMR5D16	RU	https://pubmed.ncbi.nlm.nih.gov/20392638

DM93PDA	DI	DM93PDA
DM93PDA	DN	N-(4-amino-4'-methoxybiphenyl-3-yl)benzamide
DM93PDA	MI	TTSHTOI
DM93PDA	MN	Histone deacetylase 2 (HDAC2)
DM93PDA	MT	DTT
DM93PDA	MA	Inhibitor
DM93PDA	RN	Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5.
DM93PDA	RU	https://pubmed.ncbi.nlm.nih.gov/20392638

DMSUJDH	DI	DMSUJDH
DMSUJDH	DN	N-(4-amino-4'-vinylbiphenyl-3-yl)benzamide
DMSUJDH	MI	TTSHTOI
DMSUJDH	MN	Histone deacetylase 2 (HDAC2)
DMSUJDH	MT	DTT
DMSUJDH	MA	Inhibitor
DMSUJDH	RN	Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5.
DMSUJDH	RU	https://pubmed.ncbi.nlm.nih.gov/20392638

DMY1FMG	DI	DMY1FMG
DMY1FMG	DN	N-(4-amino-5-cyano-6-ethoxypyridin-2-yl)acetamide
DMY1FMG	MI	TT3IVG2
DMY1FMG	MN	JNK2 messenger RNA (JNK2 mRNA)
DMY1FMG	MT	DTT
DMY1FMG	MA	Inhibitor
DMY1FMG	RN	Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006 Jun 15;49(12):3563-80.
DMY1FMG	RU	https://pubmed.ncbi.nlm.nih.gov/16759099

DMY1FMG	DI	DMY1FMG
DMY1FMG	DN	N-(4-amino-5-cyano-6-ethoxypyridin-2-yl)acetamide
DMY1FMG	MI	TT0K6EO
DMY1FMG	MN	Stress-activated protein kinase JNK1 (JNK1)
DMY1FMG	MT	DTT
DMY1FMG	MA	Inhibitor
DMY1FMG	RN	Discovery of potent, highly selective, and orally bioavailable pyridine carboxamide c-Jun NH2-terminal kinase inhibitors. J Med Chem. 2006 Jul 27;49(15):4455-8.
DMY1FMG	RU	https://pubmed.ncbi.nlm.nih.gov/16854050

DMY1FMG	DI	DMY1FMG
DMY1FMG	DN	N-(4-amino-5-cyano-6-ethoxypyridin-2-yl)acetamide
DMY1FMG	MI	TT056SO
DMY1FMG	MN	Stress-activated protein kinase JNK3 (JNK3)
DMY1FMG	MT	DTT
DMY1FMG	MA	Inhibitor
DMY1FMG	RN	Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006 Jun 15;49(12):3563-80.
DMY1FMG	RU	https://pubmed.ncbi.nlm.nih.gov/16759099

DMUFVM6	DI	DMUFVM6
DMUFVM6	DN	N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide
DMUFVM6	MI	TT7HF4W
DMUFVM6	MN	Cyclin-dependent kinase 2 (CDK2)
DMUFVM6	MT	DTT
DMUFVM6	MA	Inhibitor
DMUFVM6	RN	Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006 Jun 15;49(12):3563-80.
DMUFVM6	RU	https://pubmed.ncbi.nlm.nih.gov/16759099

DMUFVM6	DI	DMUFVM6
DMUFVM6	DN	N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide
DMUFVM6	MI	TT1F8OQ
DMUFVM6	MN	IKKA messenger RNA (IKKA mRNA)
DMUFVM6	MT	DTT
DMUFVM6	MA	Inhibitor
DMUFVM6	RN	Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006 Jun 15;49(12):3563-80.
DMUFVM6	RU	https://pubmed.ncbi.nlm.nih.gov/16759099

DMUFVM6	DI	DMUFVM6
DMUFVM6	DN	N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide
DMUFVM6	MI	TT3IVG2
DMUFVM6	MN	JNK2 messenger RNA (JNK2 mRNA)
DMUFVM6	MT	DTT
DMUFVM6	MA	Inhibitor
DMUFVM6	RN	Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006 Jun 15;49(12):3563-80.
DMUFVM6	RU	https://pubmed.ncbi.nlm.nih.gov/16759099

DMUFVM6	DI	DMUFVM6
DMUFVM6	DN	N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide
DMUFVM6	MI	TT0K6EO
DMUFVM6	MN	Stress-activated protein kinase JNK1 (JNK1)
DMUFVM6	MT	DTT
DMUFVM6	MA	Inhibitor
DMUFVM6	RN	Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006 Jun 15;49(12):3563-80.
DMUFVM6	RU	https://pubmed.ncbi.nlm.nih.gov/16759099

DMUFVM6	DI	DMUFVM6
DMUFVM6	DN	N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide
DMUFVM6	MI	TT056SO
DMUFVM6	MN	Stress-activated protein kinase JNK3 (JNK3)
DMUFVM6	MT	DTT
DMUFVM6	MA	Inhibitor
DMUFVM6	RN	Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006 Jun 15;49(12):3563-80.
DMUFVM6	RU	https://pubmed.ncbi.nlm.nih.gov/16759099

DMSAD87	DI	DMSAD87
DMSAD87	DN	N-(4-amino-6-butoxy-5-cyanopyridin-2-yl)acetamide
DMSAD87	MI	TT3IVG2
DMSAD87	MN	JNK2 messenger RNA (JNK2 mRNA)
DMSAD87	MT	DTT
DMSAD87	MA	Inhibitor
DMSAD87	RN	Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006 Jun 15;49(12):3563-80.
DMSAD87	RU	https://pubmed.ncbi.nlm.nih.gov/16759099

DMSAD87	DI	DMSAD87
DMSAD87	DN	N-(4-amino-6-butoxy-5-cyanopyridin-2-yl)acetamide
DMSAD87	MI	TT0K6EO
DMSAD87	MN	Stress-activated protein kinase JNK1 (JNK1)
DMSAD87	MT	DTT
DMSAD87	MA	Inhibitor
DMSAD87	RN	Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006 Jun 15;49(12):3563-80.
DMSAD87	RU	https://pubmed.ncbi.nlm.nih.gov/16759099

DMLA92O	DI	DMLA92O
DMLA92O	DN	N-(4-aminobiphenyl-3-yl)benzamide
DMLA92O	MI	TTSHTOI
DMLA92O	MN	Histone deacetylase 2 (HDAC2)
DMLA92O	MT	DTT
DMLA92O	MA	Inhibitor
DMLA92O	RN	Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5.
DMLA92O	RU	https://pubmed.ncbi.nlm.nih.gov/20392638

DMXVZIY	DI	DMXVZIY
DMXVZIY	DN	N-(4-aminobiphenyl-3-yl)nicotinamide
DMXVZIY	MI	TTBH0VX
DMXVZIY	MN	Histone deacetylase (HDAC)
DMXVZIY	MT	DTT
DMXVZIY	MA	Inhibitor
DMXVZIY	RN	Bioorg Med Chem Lett. 2008 Dec 1;18(23):6104-9. Epub 2008 Oct 14.SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2).
DMXVZIY	RU	https://pubmed.ncbi.nlm.nih.gov/18951790

DMXVZIY	DI	DMXVZIY
DMXVZIY	DN	N-(4-aminobiphenyl-3-yl)nicotinamide
DMXVZIY	MI	TT6R7JZ
DMXVZIY	MN	Histone deacetylase 1 (HDAC1)
DMXVZIY	MT	DTT
DMXVZIY	MA	Inhibitor
DMXVZIY	RN	Bioorg Med Chem Lett. 2008 Dec 1;18(23):6104-9. Epub 2008 Oct 14.SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2).
DMXVZIY	RU	https://pubmed.ncbi.nlm.nih.gov/18951790

DMXVZIY	DI	DMXVZIY
DMXVZIY	DN	N-(4-aminobiphenyl-3-yl)nicotinamide
DMXVZIY	MI	TTSHTOI
DMXVZIY	MN	Histone deacetylase 2 (HDAC2)
DMXVZIY	MT	DTT
DMXVZIY	MA	Inhibitor
DMXVZIY	RN	Bioorg Med Chem Lett. 2008 Dec 1;18(23):6104-9. Epub 2008 Oct 14.SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2).
DMXVZIY	RU	https://pubmed.ncbi.nlm.nih.gov/18951790

DMSNZV1	DI	DMSNZV1
DMSNZV1	DN	N-(4-bromo-2-methylphenyl)-2-naphthamide
DMSNZV1	MI	TT3PQ2Y
DMSNZV1	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DMSNZV1	MT	DTT
DMSNZV1	MA	Inhibitor
DMSNZV1	RN	Design and synthesis of potent inhibitors of the malaria parasite dihydroorotate dehydrogenase. J Med Chem. 2007 Jan 25;50(2):186-91.
DMSNZV1	RU	https://pubmed.ncbi.nlm.nih.gov/17228860

DMWHYOJ	DI	DMWHYOJ
DMWHYOJ	DN	N-(4'-bromo-3,3'-difluoro-4-biphenylyl)urea
DMWHYOJ	MI	TTBGTCW
DMWHYOJ	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DMWHYOJ	MT	DTT
DMWHYOJ	MA	Inhibitor
DMWHYOJ	RN	Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52.
DMWHYOJ	RU	https://pubmed.ncbi.nlm.nih.gov/17725339

DMC28SN	DI	DMC28SN
DMC28SN	DN	N-(4-Bromo-3-methanesulfonyl-benzoyl)-guanidine
DMC28SN	MI	TTGSEFH
DMC28SN	MN	Sodium/hydrogen exchanger 1 (SLC9A1)
DMC28SN	MT	DTT
DMC28SN	MA	Inhibitor
DMC28SN	RN	(2-Methyl-5-(methylsulfonyl)benzoyl)guanidine Na+/H+ antiporter inhibitors. J Med Chem. 1997 Jun 20;40(13):2017-34.
DMC28SN	RU	https://pubmed.ncbi.nlm.nih.gov/9207943

DMC28SN	DI	DMC28SN
DMC28SN	DN	N-(4-Bromo-3-methanesulfonyl-benzoyl)-guanidine
DMC28SN	MI	TTFZVPO
DMC28SN	MN	Sodium/hydrogen exchanger 3 (SLC9A3)
DMC28SN	MT	DTT
DMC28SN	MA	Inhibitor
DMC28SN	RN	(2-Methyl-5-(methylsulfonyl)benzoyl)guanidine Na+/H+ antiporter inhibitors. J Med Chem. 1997 Jun 20;40(13):2017-34.
DMC28SN	RU	https://pubmed.ncbi.nlm.nih.gov/9207943

DMFG6MU	DI	DMFG6MU
DMFG6MU	DN	N-(4-Chloro-3-methanesulfonyl-benzoyl)-guanidine
DMFG6MU	MI	TTGSEFH
DMFG6MU	MN	Sodium/hydrogen exchanger 1 (SLC9A1)
DMFG6MU	MT	DTT
DMFG6MU	MA	Inhibitor
DMFG6MU	RN	(2-Methyl-5-(methylsulfonyl)benzoyl)guanidine Na+/H+ antiporter inhibitors. J Med Chem. 1997 Jun 20;40(13):2017-34.
DMFG6MU	RU	https://pubmed.ncbi.nlm.nih.gov/9207943

DMFG6MU	DI	DMFG6MU
DMFG6MU	DN	N-(4-Chloro-3-methanesulfonyl-benzoyl)-guanidine
DMFG6MU	MI	TTFZVPO
DMFG6MU	MN	Sodium/hydrogen exchanger 3 (SLC9A3)
DMFG6MU	MT	DTT
DMFG6MU	MA	Inhibitor
DMFG6MU	RN	(2-Methyl-5-(methylsulfonyl)benzoyl)guanidine Na+/H+ antiporter inhibitors. J Med Chem. 1997 Jun 20;40(13):2017-34.
DMFG6MU	RU	https://pubmed.ncbi.nlm.nih.gov/9207943

DM0ARP8	DI	DM0ARP8
DM0ARP8	DN	N-(4'-chloro-4-biphenylyl)methanesulfonamide
DM0ARP8	MI	TTBGTCW
DM0ARP8	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DM0ARP8	MT	DTT
DM0ARP8	MA	Inhibitor
DM0ARP8	RN	Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52.
DM0ARP8	RU	https://pubmed.ncbi.nlm.nih.gov/17725339

DMNO46U	DI	DMNO46U
DMNO46U	DN	N-(4-Chloro-7-p-tolyl-isoquinolin-1-yl)-guanidine
DMNO46U	MI	TTP86E2
DMNO46U	MN	Plasminogen (PLG)
DMNO46U	MT	DTT
DMNO46U	MA	Inhibitor
DMNO46U	RN	Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-isoquinolinylguanidines. Bioorg Med Chem Lett. 2004 Jun 21;14(12):3227-30.
DMNO46U	RU	https://pubmed.ncbi.nlm.nih.gov/15149680

DMNO46U	DI	DMNO46U
DMNO46U	DN	N-(4-Chloro-7-p-tolyl-isoquinolin-1-yl)-guanidine
DMNO46U	MI	TTXAGYU
DMNO46U	MN	Tissue-type plasminogen activator (PLAT)
DMNO46U	MT	DTT
DMNO46U	MA	Inhibitor
DMNO46U	RN	Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-isoquinolinylguanidines. Bioorg Med Chem Lett. 2004 Jun 21;14(12):3227-30.
DMNO46U	RU	https://pubmed.ncbi.nlm.nih.gov/15149680

DMGI9EA	DI	DMGI9EA
DMGI9EA	DN	N-(4-Cyano-3-methanesulfonyl-benzoyl)-guanidine
DMGI9EA	MI	TTGSEFH
DMGI9EA	MN	Sodium/hydrogen exchanger 1 (SLC9A1)
DMGI9EA	MT	DTT
DMGI9EA	MA	Inhibitor
DMGI9EA	RN	(2-Methyl-5-(methylsulfonyl)benzoyl)guanidine Na+/H+ antiporter inhibitors. J Med Chem. 1997 Jun 20;40(13):2017-34.
DMGI9EA	RU	https://pubmed.ncbi.nlm.nih.gov/9207943

DMGI9EA	DI	DMGI9EA
DMGI9EA	DN	N-(4-Cyano-3-methanesulfonyl-benzoyl)-guanidine
DMGI9EA	MI	TTFZVPO
DMGI9EA	MN	Sodium/hydrogen exchanger 3 (SLC9A3)
DMGI9EA	MT	DTT
DMGI9EA	MA	Inhibitor
DMGI9EA	RN	(2-Methyl-5-(methylsulfonyl)benzoyl)guanidine Na+/H+ antiporter inhibitors. J Med Chem. 1997 Jun 20;40(13):2017-34.
DMGI9EA	RU	https://pubmed.ncbi.nlm.nih.gov/9207943

DMW8S2D	DI	DMW8S2D
DMW8S2D	DN	N-(4-cyanophenyl)sulfamide
DMW8S2D	MI	TTHQPL7
DMW8S2D	MN	Carbonic anhydrase I (CA-I)
DMW8S2D	MT	DTT
DMW8S2D	MA	Inhibitor
DMW8S2D	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with N-hydroxy... Bioorg Med Chem Lett. 2005 May 2;15(9):2353-8.
DMW8S2D	RU	https://pubmed.ncbi.nlm.nih.gov/15837324

DMW8S2D	DI	DMW8S2D
DMW8S2D	DN	N-(4-cyanophenyl)sulfamide
DMW8S2D	MI	TTANPDJ
DMW8S2D	MN	Carbonic anhydrase II (CA-II)
DMW8S2D	MT	DTT
DMW8S2D	MA	Inhibitor
DMW8S2D	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with N-hydroxy... Bioorg Med Chem Lett. 2005 May 2;15(9):2353-8.
DMW8S2D	RU	https://pubmed.ncbi.nlm.nih.gov/15837324

DMW8S2D	DI	DMW8S2D
DMW8S2D	DN	N-(4-cyanophenyl)sulfamide
DMW8S2D	MI	TT2LVK8
DMW8S2D	MN	Carbonic anhydrase IX (CA-IX)
DMW8S2D	MT	DTT
DMW8S2D	MA	Inhibitor
DMW8S2D	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with N-hydroxy... Bioorg Med Chem Lett. 2005 May 2;15(9):2353-8.
DMW8S2D	RU	https://pubmed.ncbi.nlm.nih.gov/15837324

DMW8S2D	DI	DMW8S2D
DMW8S2D	DN	N-(4-cyanophenyl)sulfamide
DMW8S2D	MI	TTSYM0R
DMW8S2D	MN	Carbonic anhydrase XII (CA-XII)
DMW8S2D	MT	DTT
DMW8S2D	MA	Inhibitor
DMW8S2D	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with N-hydroxy... Bioorg Med Chem Lett. 2005 May 2;15(9):2353-8.
DMW8S2D	RU	https://pubmed.ncbi.nlm.nih.gov/15837324

DMB3E7H	DI	DMB3E7H
DMB3E7H	DN	N-(4-Dimethylamino-but-2-ynyl)-N-methyl-acetamide
DMB3E7H	MI	TTZ9SOR
DMB3E7H	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMB3E7H	MT	DTT
DMB3E7H	MA	Inhibitor
DMB3E7H	RN	Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992).
DMB3E7H	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805351

DMB3E7H	DI	DMB3E7H
DMB3E7H	DN	N-(4-Dimethylamino-but-2-ynyl)-N-methyl-acetamide
DMB3E7H	MI	TTYEG6Q
DMB3E7H	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMB3E7H	MT	DTT
DMB3E7H	MA	Inhibitor
DMB3E7H	RN	Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992).
DMB3E7H	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805351

DMB3E7H	DI	DMB3E7H
DMB3E7H	DN	N-(4-Dimethylamino-but-2-ynyl)-N-methyl-acetamide
DMB3E7H	MI	TTQ13Z5
DMB3E7H	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMB3E7H	MT	DTT
DMB3E7H	MA	Inhibitor
DMB3E7H	RN	Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992).
DMB3E7H	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805351

DMB3E7H	DI	DMB3E7H
DMB3E7H	DN	N-(4-Dimethylamino-but-2-ynyl)-N-methyl-acetamide
DMB3E7H	MI	TTQ3JTF
DMB3E7H	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DMB3E7H	MT	DTT
DMB3E7H	MA	Inhibitor
DMB3E7H	RN	Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992).
DMB3E7H	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805351

DMB3E7H	DI	DMB3E7H
DMB3E7H	DN	N-(4-Dimethylamino-but-2-ynyl)-N-methyl-acetamide
DMB3E7H	MI	TTH18TF
DMB3E7H	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMB3E7H	MT	DTT
DMB3E7H	MA	Inhibitor
DMB3E7H	RN	Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992).
DMB3E7H	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805351

DMU1ATH	DI	DMU1ATH
DMU1ATH	DN	N-(4-Dipropylaminobutyl)-4-biphenylcarboxamide
DMU1ATH	MI	TTZFYLI
DMU1ATH	MN	Dopamine D1 receptor (D1R)
DMU1ATH	MT	DTT
DMU1ATH	MA	Inhibitor
DMU1ATH	RN	Novel D3 selective dopaminergics incorporating enyne units as nonaromatic catechol bioisosteres: synthesis, bioactivity, and mutagenesis studies. J Med Chem. 2008 Nov 13;51(21):6829-38.
DMU1ATH	RU	https://pubmed.ncbi.nlm.nih.gov/18834111

DMU1ATH	DI	DMU1ATH
DMU1ATH	DN	N-(4-Dipropylaminobutyl)-4-biphenylcarboxamide
DMU1ATH	MI	TTEX248
DMU1ATH	MN	Dopamine D2 receptor (D2R)
DMU1ATH	MT	DTT
DMU1ATH	MA	Inhibitor
DMU1ATH	RN	Novel D3 selective dopaminergics incorporating enyne units as nonaromatic catechol bioisosteres: synthesis, bioactivity, and mutagenesis studies. J Med Chem. 2008 Nov 13;51(21):6829-38.
DMU1ATH	RU	https://pubmed.ncbi.nlm.nih.gov/18834111

DMU1ATH	DI	DMU1ATH
DMU1ATH	DN	N-(4-Dipropylaminobutyl)-4-biphenylcarboxamide
DMU1ATH	MI	TT4C8EA
DMU1ATH	MN	Dopamine D3 receptor (D3R)
DMU1ATH	MT	DTT
DMU1ATH	MA	Inhibitor
DMU1ATH	RN	Novel D3 selective dopaminergics incorporating enyne units as nonaromatic catechol bioisosteres: synthesis, bioactivity, and mutagenesis studies. J Med Chem. 2008 Nov 13;51(21):6829-38.
DMU1ATH	RU	https://pubmed.ncbi.nlm.nih.gov/18834111

DMU1ATH	DI	DMU1ATH
DMU1ATH	DN	N-(4-Dipropylaminobutyl)-4-biphenylcarboxamide
DMU1ATH	MI	TTE0A2F
DMU1ATH	MN	Dopamine D4 receptor (D4R)
DMU1ATH	MT	DTT
DMU1ATH	MA	Inhibitor
DMU1ATH	RN	Novel D3 selective dopaminergics incorporating enyne units as nonaromatic catechol bioisosteres: synthesis, bioactivity, and mutagenesis studies. J Med Chem. 2008 Nov 13;51(21):6829-38.
DMU1ATH	RU	https://pubmed.ncbi.nlm.nih.gov/18834111

DM012TN	DI	DM012TN
DM012TN	DN	N-(4-Ethoxybutyl)-2-oxohexadecanamide
DM012TN	MI	TTT1JVS
DM012TN	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DM012TN	MT	DTT
DM012TN	MA	Inhibitor
DM012TN	RN	Structure-activity relationships of natural and non-natural amino acid-based amide and 2-oxoamide inhibitors of human phospholipase A(2) enzymes. Bioorg Med Chem. 2008 Dec 15;16(24):10257-69.
DM012TN	RU	https://pubmed.ncbi.nlm.nih.gov/18993078

DMWTVJH	DI	DMWTVJH
DMWTVJH	DN	N-(4-Ethylphenyl)-2-oxo-2H-chromene-3-carboxamide
DMWTVJH	MI	TT3WG5C
DMWTVJH	MN	Monoamine oxidase type A (MAO-A)
DMWTVJH	MT	DTT
DMWTVJH	MA	Inhibitor
DMWTVJH	RN	Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins. J Med Chem. 2009 Apr 9;52(7):1935-42.
DMWTVJH	RU	https://pubmed.ncbi.nlm.nih.gov/19267475

DMWTVJH	DI	DMWTVJH
DMWTVJH	DN	N-(4-Ethylphenyl)-2-oxo-2H-chromene-3-carboxamide
DMWTVJH	MI	TTGP7BY
DMWTVJH	MN	Monoamine oxidase type B (MAO-B)
DMWTVJH	MT	DTT
DMWTVJH	MA	Inhibitor
DMWTVJH	RN	Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins. J Med Chem. 2009 Apr 9;52(7):1935-42.
DMWTVJH	RU	https://pubmed.ncbi.nlm.nih.gov/19267475

DMIWNAY	DI	DMIWNAY
DMIWNAY	DN	N-(4-Ethylphenyl)-5-methylbenzo[d]oxazol-2-amine
DMIWNAY	MI	TT2J34L
DMIWNAY	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMIWNAY	MT	DTT
DMIWNAY	MA	Inhibitor
DMIWNAY	RN	Synthesis and evaluation of benzoxazole derivatives as 5-lipoxygenase inhibitors. Bioorg Med Chem. 2010 Nov 1;18(21):7580-5.
DMIWNAY	RU	https://pubmed.ncbi.nlm.nih.gov/20870413

DMJ73T6	DI	DMJ73T6
DMJ73T6	DN	N-(4-Ethylphenyl)benzo[d]oxazol-2-amine
DMJ73T6	MI	TT2J34L
DMJ73T6	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMJ73T6	MT	DTT
DMJ73T6	MA	Inhibitor
DMJ73T6	RN	Synthesis and evaluation of benzoxazole derivatives as 5-lipoxygenase inhibitors. Bioorg Med Chem. 2010 Nov 1;18(21):7580-5.
DMJ73T6	RU	https://pubmed.ncbi.nlm.nih.gov/20870413

DMKN8U6	DI	DMKN8U6
DMKN8U6	DN	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide
DMKN8U6	MI	TTBH0VX
DMKN8U6	MN	Histone deacetylase (HDAC)
DMKN8U6	MT	DTT
DMKN8U6	MA	Inhibitor
DMKN8U6	RN	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50.
DMKN8U6	RU	https://pubmed.ncbi.nlm.nih.gov/20143840

DMKN8U6	DI	DMKN8U6
DMKN8U6	DN	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide
DMKN8U6	MI	TT6R7JZ
DMKN8U6	MN	Histone deacetylase 1 (HDAC1)
DMKN8U6	MT	DTT
DMKN8U6	MA	Inhibitor
DMKN8U6	RN	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50.
DMKN8U6	RU	https://pubmed.ncbi.nlm.nih.gov/20143840

DMP1ICB	DI	DMP1ICB
DMP1ICB	DN	N-(4-fluorobenzyl)-N-(pyridin-4-yl)-2-naphthamide
DMP1ICB	MI	TTQBR95
DMP1ICB	MN	Stress-activated protein kinase 2a (p38 alpha)
DMP1ICB	MT	DTT
DMP1ICB	MA	Inhibitor
DMP1ICB	RN	Amide-based inhibitors of p38alpha MAP kinase. Part 2: design, synthesis and SAR of potent N-pyrimidyl amides. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2560-3.
DMP1ICB	RU	https://pubmed.ncbi.nlm.nih.gov/20346659

DM7O5WS	DI	DM7O5WS
DM7O5WS	DN	N-(4-hydroxybenzyl)icosa-5,8,11,14-tetraenamide
DM7O5WS	MI	TT6OEDT
DM7O5WS	MN	Cannabinoid receptor 1 (CB1)
DM7O5WS	MT	DTT
DM7O5WS	MA	Inhibitor
DM7O5WS	RN	New analgesics synthetically derived from the paracetamol metabolite N-(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide. J Med Chem. 2008 Dec 25;51(24):7800-5.
DM7O5WS	RU	https://pubmed.ncbi.nlm.nih.gov/19053765

DM7O5WS	DI	DM7O5WS
DM7O5WS	DN	N-(4-hydroxybenzyl)icosa-5,8,11,14-tetraenamide
DM7O5WS	MI	TTMSFAW
DM7O5WS	MN	Cannabinoid receptor 2 (CB2)
DM7O5WS	MT	DTT
DM7O5WS	MA	Inhibitor
DM7O5WS	RN	New analgesics synthetically derived from the paracetamol metabolite N-(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide. J Med Chem. 2008 Dec 25;51(24):7800-5.
DM7O5WS	RU	https://pubmed.ncbi.nlm.nih.gov/19053765

DM7O5WS	DI	DM7O5WS
DM7O5WS	DN	N-(4-hydroxybenzyl)icosa-5,8,11,14-tetraenamide
DM7O5WS	MI	TTDP1UC
DM7O5WS	MN	Fatty acid amide hydrolase (FAAH)
DM7O5WS	MT	DTT
DM7O5WS	MA	Inhibitor
DM7O5WS	RN	New analgesics synthetically derived from the paracetamol metabolite N-(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide. J Med Chem. 2008 Dec 25;51(24):7800-5.
DM7O5WS	RU	https://pubmed.ncbi.nlm.nih.gov/19053765

DMC5H8G	DI	DMC5H8G
DMC5H8G	DN	N-(4-hydroxybiphenyl-3-yl)benzamide
DMC5H8G	MI	TT6R7JZ
DMC5H8G	MN	Histone deacetylase 1 (HDAC1)
DMC5H8G	MT	DTT
DMC5H8G	MA	Inhibitor
DMC5H8G	RN	Bioorg Med Chem Lett. 2008 Dec 1;18(23):6104-9. Epub 2008 Oct 14.SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2).
DMC5H8G	RU	https://pubmed.ncbi.nlm.nih.gov/18951790

DMC5H8G	DI	DMC5H8G
DMC5H8G	DN	N-(4-hydroxybiphenyl-3-yl)benzamide
DMC5H8G	MI	TTSHTOI
DMC5H8G	MN	Histone deacetylase 2 (HDAC2)
DMC5H8G	MT	DTT
DMC5H8G	MA	Inhibitor
DMC5H8G	RN	Bioorg Med Chem Lett. 2008 Dec 1;18(23):6104-9. Epub 2008 Oct 14.SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2).
DMC5H8G	RU	https://pubmed.ncbi.nlm.nih.gov/18951790

DM4QR2C	DI	DM4QR2C
DM4QR2C	DN	N-(4-hydroxyphenylpropanyl)-spermine
DM4QR2C	MI	TTAN6JD
DM4QR2C	MN	Glutamate receptor AMPA (GRIA)
DM4QR2C	MT	DTT
DM4QR2C	MA	Inhibitor
DM4QR2C	RN	Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands. Bioorg Med Chem. 2010 Feb 15;18(4):1381-7.
DM4QR2C	RU	https://pubmed.ncbi.nlm.nih.gov/20096591

DM4QR2C	DI	DM4QR2C
DM4QR2C	DN	N-(4-hydroxyphenylpropanyl)-spermine
DM4QR2C	MI	TTVPQTF
DM4QR2C	MN	Glutamate receptor AMPA 1 (GRIA1)
DM4QR2C	MT	DTT
DM4QR2C	MA	Inhibitor
DM4QR2C	RN	Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands. Bioorg Med Chem. 2010 Feb 15;18(4):1381-7.
DM4QR2C	RU	https://pubmed.ncbi.nlm.nih.gov/20096591

DM6GFRP	DI	DM6GFRP
DM6GFRP	DN	N-(4-iodophenyl)-4-(trifluoromethoxy)benzamide
DM6GFRP	MI	TTMI6F5
DM6GFRP	MN	Transient receptor potential cation channel V1 (TRPV1)
DM6GFRP	MT	DTT
DM6GFRP	MA	Inhibitor
DM6GFRP	RN	Synthesis of benzamide derivatives as TRPV1 antagonists. Bioorg Med Chem Lett. 2008 Feb 1;18(3):1072-8.
DM6GFRP	RU	https://pubmed.ncbi.nlm.nih.gov/18155908

DMK9FQG	DI	DMK9FQG
DMK9FQG	DN	N-(4-iodophenyl)-4-(trifluoromethyl)benzamide
DMK9FQG	MI	TTMI6F5
DMK9FQG	MN	Transient receptor potential cation channel V1 (TRPV1)
DMK9FQG	MT	DTT
DMK9FQG	MA	Inhibitor
DMK9FQG	RN	Synthesis of benzamide derivatives as TRPV1 antagonists. Bioorg Med Chem Lett. 2008 Feb 1;18(3):1072-8.
DMK9FQG	RU	https://pubmed.ncbi.nlm.nih.gov/18155908

DMHANU5	DI	DMHANU5
DMHANU5	DN	N-(4-Iodophenyl)-N'-(17-methylmorphinan-3-yl)urea
DMHANU5	MI	TT27RFC
DMHANU5	MN	Opioid receptor delta (OPRD1)
DMHANU5	MT	DTT
DMHANU5	MA	Inhibitor
DMHANU5	RN	Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18.
DMHANU5	RU	https://pubmed.ncbi.nlm.nih.gov/19928862

DMHANU5	DI	DMHANU5
DMHANU5	DN	N-(4-Iodophenyl)-N'-(17-methylmorphinan-3-yl)urea
DMHANU5	MI	TTQW87Y
DMHANU5	MN	Opioid receptor kappa (OPRK1)
DMHANU5	MT	DTT
DMHANU5	MA	Inhibitor
DMHANU5	RN	Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18.
DMHANU5	RU	https://pubmed.ncbi.nlm.nih.gov/19928862

DMHANU5	DI	DMHANU5
DMHANU5	DN	N-(4-Iodophenyl)-N'-(17-methylmorphinan-3-yl)urea
DMHANU5	MI	TTKWM86
DMHANU5	MN	Opioid receptor mu (MOP)
DMHANU5	MT	DTT
DMHANU5	MA	Inhibitor
DMHANU5	RN	Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18.
DMHANU5	RU	https://pubmed.ncbi.nlm.nih.gov/19928862

DM2N3TG	DI	DM2N3TG
DM2N3TG	DN	N-(4'-Isonicotinoylbiphenyl-3-yl)acetamide
DM2N3TG	MI	TTIQUX7
DM2N3TG	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM2N3TG	MT	DTT
DM2N3TG	MA	Inhibitor
DM2N3TG	RN	Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
DM2N3TG	RU	https://pubmed.ncbi.nlm.nih.gov/20684610

DM2N3TG	DI	DM2N3TG
DM2N3TG	DN	N-(4'-Isonicotinoylbiphenyl-3-yl)acetamide
DM2N3TG	MI	TTRA5BZ
DM2N3TG	MN	Steroid 17-alpha-monooxygenase (S17AH)
DM2N3TG	MT	DTT
DM2N3TG	MA	Inhibitor
DM2N3TG	RN	Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
DM2N3TG	RU	https://pubmed.ncbi.nlm.nih.gov/20684610

DM2MGSO	DI	DM2MGSO
DM2MGSO	DN	N-(4'-isopropyl-4-biphenylyl)urea
DM2MGSO	MI	TTBGTCW
DM2MGSO	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DM2MGSO	MT	DTT
DM2MGSO	MA	Inhibitor
DM2MGSO	RN	Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52.
DM2MGSO	RU	https://pubmed.ncbi.nlm.nih.gov/17725339

DMHM3LC	DI	DMHM3LC
DMHM3LC	DN	N-(4-methoxybenzyl)oleamide
DMHM3LC	MI	TT6OEDT
DMHM3LC	MN	Cannabinoid receptor 1 (CB1)
DMHM3LC	MT	DTT
DMHM3LC	MA	Inhibitor
DMHM3LC	RN	New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies. Bioorg Med Chem Lett. 2006 Jan 1;16(1):138-41.
DMHM3LC	RU	https://pubmed.ncbi.nlm.nih.gov/16213718

DM5NOSM	DI	DM5NOSM
DM5NOSM	DN	N-(4-methoxyphenethyl)oleamide
DM5NOSM	MI	TT6OEDT
DM5NOSM	MN	Cannabinoid receptor 1 (CB1)
DM5NOSM	MT	DTT
DM5NOSM	MA	Inhibitor
DM5NOSM	RN	New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies. Bioorg Med Chem Lett. 2006 Jan 1;16(1):138-41.
DM5NOSM	RU	https://pubmed.ncbi.nlm.nih.gov/16213718

DMJVPK6	DI	DMJVPK6
DMJVPK6	DN	N-(4-methoxyphenyl)oleamide
DMJVPK6	MI	TT6OEDT
DMJVPK6	MN	Cannabinoid receptor 1 (CB1)
DMJVPK6	MT	DTT
DMJVPK6	MA	Inhibitor
DMJVPK6	RN	New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies. Bioorg Med Chem Lett. 2006 Jan 1;16(1):138-41.
DMJVPK6	RU	https://pubmed.ncbi.nlm.nih.gov/16213718

DMO8L57	DI	DMO8L57
DMO8L57	DN	N-(4'-methyl-4-biphenylyl)urea
DMO8L57	MI	TTBGTCW
DMO8L57	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DMO8L57	MT	DTT
DMO8L57	MA	Inhibitor
DMO8L57	RN	Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52.
DMO8L57	RU	https://pubmed.ncbi.nlm.nih.gov/17725339

DMCZD37	DI	DMCZD37
DMCZD37	DN	N-(4-Methyl-benzoyl)-N'-phenethyl-guanidine
DMCZD37	MI	TTZOVE0
DMCZD37	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DMCZD37	MT	DTT
DMCZD37	MA	Inhibitor
DMCZD37	RN	Solution-phase, parallel synthesis and pharmacological evaluation of acylguanidine derivatives as potential sodium channel blockers. Bioorg Med Chem Lett. 2001 Dec 17;11(24):3151-5.
DMCZD37	RU	https://pubmed.ncbi.nlm.nih.gov/11720863

DMZX2BH	DI	DMZX2BH
DMZX2BH	DN	N-(4-methyl-benzyl)-4-phenoxy-benzamide
DMZX2BH	MI	TTQBR95
DMZX2BH	MN	Stress-activated protein kinase 2a (p38 alpha)
DMZX2BH	MT	DTT
DMZX2BH	MA	Inhibitor
DMZX2BH	RN	Two classes of p38alpha MAP kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5274-9.
DMZX2BH	RU	https://pubmed.ncbi.nlm.nih.gov/16169718

DMXNMTD	DI	DMXNMTD
DMXNMTD	DN	N-(4'-methyl-piperazinyl) estradiol-16-carboxamide
DMXNMTD	MI	TTIWB6L
DMXNMTD	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMXNMTD	MT	DTT
DMXNMTD	MA	Inhibitor
DMXNMTD	RN	Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45.
DMXNMTD	RU	https://pubmed.ncbi.nlm.nih.gov/16480268

DM03VXN	DI	DM03VXN
DM03VXN	DN	N-(4-methylthiazol-2-yl)-2-phenylacetamide
DM03VXN	MI	TTSJ6Q4
DM03VXN	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DM03VXN	MT	DTT
DM03VXN	MA	Inhibitor
DM03VXN	RN	Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. J Med Chem. 2007 May 31;50(11):2640-6.
DM03VXN	RU	https://pubmed.ncbi.nlm.nih.gov/17461565

DMTCA2Z	DI	DMTCA2Z
DMTCA2Z	DN	N-(4-methylthiazol-2-yl)benzamide
DMTCA2Z	MI	TTSJ6Q4
DMTCA2Z	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DMTCA2Z	MT	DTT
DMTCA2Z	MA	Inhibitor
DMTCA2Z	RN	Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. J Med Chem. 2007 May 31;50(11):2640-6.
DMTCA2Z	RU	https://pubmed.ncbi.nlm.nih.gov/17461565

DMGRFYV	DI	DMGRFYV
DMGRFYV	DN	N-(4-morpholinophenyl)docos-13-enamide
DMGRFYV	MI	TT6OEDT
DMGRFYV	MN	Cannabinoid receptor 1 (CB1)
DMGRFYV	MT	DTT
DMGRFYV	MA	Inhibitor
DMGRFYV	RN	New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies. Bioorg Med Chem Lett. 2006 Jan 1;16(1):138-41.
DMGRFYV	RU	https://pubmed.ncbi.nlm.nih.gov/16213718

DMEBGF1	DI	DMEBGF1
DMEBGF1	DN	N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide
DMEBGF1	MI	TTGKNB4
DMEBGF1	MN	Epidermal growth factor receptor (EGFR)
DMEBGF1	MT	DTT
DMEBGF1	MA	Inhibitor
DMEBGF1	RN	Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP... J Med Chem. 1999 May 20;42(10):1803-15.
DMEBGF1	RU	https://pubmed.ncbi.nlm.nih.gov/10346932

DMEBGF1	DI	DMEBGF1
DMEBGF1	DN	N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide
DMEBGF1	MI	TTR5TV4
DMEBGF1	MN	ERBB2 messenger RNA (HER2 mRNA)
DMEBGF1	MT	DTT
DMEBGF1	MA	Inhibitor
DMEBGF1	RN	Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP... J Med Chem. 1999 May 20;42(10):1803-15.
DMEBGF1	RU	https://pubmed.ncbi.nlm.nih.gov/10346932

DMG6RTJ	DI	DMG6RTJ
DMG6RTJ	DN	N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide
DMG6RTJ	MI	TTGKNB4
DMG6RTJ	MN	Epidermal growth factor receptor (EGFR)
DMG6RTJ	MT	DTT
DMG6RTJ	MA	Inhibitor
DMG6RTJ	RN	Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP... J Med Chem. 1999 May 20;42(10):1803-15.
DMG6RTJ	RU	https://pubmed.ncbi.nlm.nih.gov/10346932

DMUJS4Y	DI	DMUJS4Y
DMUJS4Y	DN	N-(4-phenylbenzoyl)-phenylalanyl-glycine-nitrile
DMUJS4Y	MI	TTDZN01
DMUJS4Y	MN	Cathepsin K (CTSK)
DMUJS4Y	MT	DTT
DMUJS4Y	MA	Inhibitor
DMUJS4Y	RN	Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707.
DMUJS4Y	RU	https://pubmed.ncbi.nlm.nih.gov/16302809

DMUJS4Y	DI	DMUJS4Y
DMUJS4Y	DN	N-(4-phenylbenzoyl)-phenylalanyl-glycine-nitrile
DMUJS4Y	MI	TT36ETB
DMUJS4Y	MN	Cathepsin L (CTSL)
DMUJS4Y	MT	DTT
DMUJS4Y	MA	Inhibitor
DMUJS4Y	RN	Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707.
DMUJS4Y	RU	https://pubmed.ncbi.nlm.nih.gov/16302809

DMUJS4Y	DI	DMUJS4Y
DMUJS4Y	DN	N-(4-phenylbenzoyl)-phenylalanyl-glycine-nitrile
DMUJS4Y	MI	TTUMQVO
DMUJS4Y	MN	Cathepsin S (CTSS)
DMUJS4Y	MT	DTT
DMUJS4Y	MA	Inhibitor
DMUJS4Y	RN	Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707.
DMUJS4Y	RU	https://pubmed.ncbi.nlm.nih.gov/16302809

DMTCMUG	DI	DMTCMUG
DMTCMUG	DN	N-(4-Phenylbutyl)-1H-indole-2-carboxamide
DMTCMUG	MI	TT3WG5C
DMTCMUG	MN	Monoamine oxidase type A (MAO-A)
DMTCMUG	MT	DTT
DMTCMUG	MA	Inhibitor
DMTCMUG	RN	Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40.
DMTCMUG	RU	https://pubmed.ncbi.nlm.nih.gov/18951803

DMTCMUG	DI	DMTCMUG
DMTCMUG	DN	N-(4-Phenylbutyl)-1H-indole-2-carboxamide
DMTCMUG	MI	TTGP7BY
DMTCMUG	MN	Monoamine oxidase type B (MAO-B)
DMTCMUG	MT	DTT
DMTCMUG	MA	Inhibitor
DMTCMUG	RN	Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40.
DMTCMUG	RU	https://pubmed.ncbi.nlm.nih.gov/18951803

DMSREW5	DI	DMSREW5
DMSREW5	DN	N-(4-phenylbutyl)-1H-pyrrole-2-carboxamide
DMSREW5	MI	TT3WG5C
DMSREW5	MN	Monoamine oxidase type A (MAO-A)
DMSREW5	MT	DTT
DMSREW5	MA	Inhibitor
DMSREW5	RN	New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J Med Chem. 2007 Mar 8;50(5):922-31.
DMSREW5	RU	https://pubmed.ncbi.nlm.nih.gov/17256833

DMYD4PC	DI	DMYD4PC
DMYD4PC	DN	N-(4-Phenyl-pyridin-2-yl)-guanidine
DMYD4PC	MI	TTXAGYU
DMYD4PC	MN	Tissue-type plasminogen activator (PLAT)
DMYD4PC	MT	DTT
DMYD4PC	MA	Inhibitor
DMYD4PC	RN	Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 1: 2-Pyridinylguanidines. Bioorg Med Chem Lett. 2002 Jan 21;12(2):181-4.
DMYD4PC	RU	https://pubmed.ncbi.nlm.nih.gov/11755349

DMQS9OH	DI	DMQS9OH
DMQS9OH	DN	N-(4-phenylsulfamoyl-naphthalen-1-yl)-benzamide
DMQS9OH	MI	TTE836A
DMQS9OH	MN	C-C chemokine receptor type 8 (CCR8)
DMQS9OH	MT	DTT
DMQS9OH	MA	Inhibitor
DMQS9OH	RN	Design, synthesis, and evaluation of naphthalene-sulfonamide antagonists of human CCR8. J Med Chem. 2007 Feb 8;50(3):566-84.
DMQS9OH	RU	https://pubmed.ncbi.nlm.nih.gov/17266208

DMPA91F	DI	DMPA91F
DMPA91F	DN	N-(4-Phenyl-thiazol-2-yl)-benzamide
DMPA91F	MI	TTK25J1
DMPA91F	MN	Adenosine A1 receptor (ADORA1)
DMPA91F	MT	DTT
DMPA91F	MA	Inhibitor
DMPA91F	RN	Substituted 4-phenyl-2-(phenylcarboxamido)-1,3-thiazole derivatives as antagonists for the adenosine A(1) receptor. Bioorg Med Chem Lett. 2001 Aug 6;11(15):2017-9.
DMPA91F	RU	https://pubmed.ncbi.nlm.nih.gov/11454470

DM2OHVJ	DI	DM2OHVJ
DM2OHVJ	DN	N-(4-Phenylthiazol-2-yl)isonicotinamide
DM2OHVJ	MI	TTVDSZ0
DM2OHVJ	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DM2OHVJ	MT	DTT
DM2OHVJ	MA	Inhibitor
DM2OHVJ	RN	Design, synthesis, and cytoprotective effect of 2-aminothiazole analogues as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2009 Feb 12;52(3):718-25.
DM2OHVJ	RU	https://pubmed.ncbi.nlm.nih.gov/19125579

DMG9D7A	DI	DMG9D7A
DMG9D7A	DN	N-(4-Propylaminobutyl)-4-biphenylcarboxamide
DMG9D7A	MI	TTZFYLI
DMG9D7A	MN	Dopamine D1 receptor (D1R)
DMG9D7A	MT	DTT
DMG9D7A	MA	Inhibitor
DMG9D7A	RN	Novel D3 selective dopaminergics incorporating enyne units as nonaromatic catechol bioisosteres: synthesis, bioactivity, and mutagenesis studies. J Med Chem. 2008 Nov 13;51(21):6829-38.
DMG9D7A	RU	https://pubmed.ncbi.nlm.nih.gov/18834111

DMG9D7A	DI	DMG9D7A
DMG9D7A	DN	N-(4-Propylaminobutyl)-4-biphenylcarboxamide
DMG9D7A	MI	TT4C8EA
DMG9D7A	MN	Dopamine D3 receptor (D3R)
DMG9D7A	MT	DTT
DMG9D7A	MA	Inhibitor
DMG9D7A	RN	Novel D3 selective dopaminergics incorporating enyne units as nonaromatic catechol bioisosteres: synthesis, bioactivity, and mutagenesis studies. J Med Chem. 2008 Nov 13;51(21):6829-38.
DMG9D7A	RU	https://pubmed.ncbi.nlm.nih.gov/18834111

DMG9D7A	DI	DMG9D7A
DMG9D7A	DN	N-(4-Propylaminobutyl)-4-biphenylcarboxamide
DMG9D7A	MI	TTE0A2F
DMG9D7A	MN	Dopamine D4 receptor (D4R)
DMG9D7A	MT	DTT
DMG9D7A	MA	Inhibitor
DMG9D7A	RN	Novel D3 selective dopaminergics incorporating enyne units as nonaromatic catechol bioisosteres: synthesis, bioactivity, and mutagenesis studies. J Med Chem. 2008 Nov 13;51(21):6829-38.
DMG9D7A	RU	https://pubmed.ncbi.nlm.nih.gov/18834111

DMHBWM9	DI	DMHBWM9
DMHBWM9	DN	N-(4-Pyridin-2-yl-thiazol-2-yl)-benzamide
DMHBWM9	MI	TTM2AOE
DMHBWM9	MN	Adenosine A2a receptor (ADORA2A)
DMHBWM9	MT	DTT
DMHBWM9	MA	Inhibitor
DMHBWM9	RN	Thiazole and thiadiazole analogues as a novel class of adenosine receptor antagonists. J Med Chem. 2001 Mar 1;44(5):749-62.
DMHBWM9	RU	https://pubmed.ncbi.nlm.nih.gov/11262085

DMOMYDV	DI	DMOMYDV
DMOMYDV	DN	N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide
DMOMYDV	MI	TT7HF4W
DMOMYDV	MN	Cyclin-dependent kinase 2 (CDK2)
DMOMYDV	MT	DTT
DMOMYDV	MA	Inhibitor
DMOMYDV	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMOMYDV	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMZDACT	DI	DMZDACT
DMZDACT	DN	N-(4-Sulfamoyl-phenyl)-benzamide
DMZDACT	MI	TTHQPL7
DMZDACT	MN	Carbonic anhydrase I (CA-I)
DMZDACT	MT	DTT
DMZDACT	MA	Inhibitor
DMZDACT	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DMZDACT	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DMZDACT	DI	DMZDACT
DMZDACT	DN	N-(4-Sulfamoyl-phenyl)-benzamide
DMZDACT	MI	TTANPDJ
DMZDACT	MN	Carbonic anhydrase II (CA-II)
DMZDACT	MT	DTT
DMZDACT	MA	Inhibitor
DMZDACT	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DMZDACT	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DMZDACT	DI	DMZDACT
DMZDACT	DN	N-(4-Sulfamoyl-phenyl)-benzamide
DMZDACT	MI	TT2LVK8
DMZDACT	MN	Carbonic anhydrase IX (CA-IX)
DMZDACT	MT	DTT
DMZDACT	MA	Inhibitor
DMZDACT	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DMZDACT	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DMZDACT	DI	DMZDACT
DMZDACT	DN	N-(4-Sulfamoyl-phenyl)-benzamide
DMZDACT	MI	TTSYM0R
DMZDACT	MN	Carbonic anhydrase XII (CA-XII)
DMZDACT	MT	DTT
DMZDACT	MA	Inhibitor
DMZDACT	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DMZDACT	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DM3FW9Q	DI	DM3FW9Q
DM3FW9Q	DN	N-(4-Sulfamoyl-phenyl)-butyramide
DM3FW9Q	MI	TTHQPL7
DM3FW9Q	MN	Carbonic anhydrase I (CA-I)
DM3FW9Q	MT	DTT
DM3FW9Q	MA	Inhibitor
DM3FW9Q	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DM3FW9Q	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DM3FW9Q	DI	DM3FW9Q
DM3FW9Q	DN	N-(4-Sulfamoyl-phenyl)-butyramide
DM3FW9Q	MI	TTANPDJ
DM3FW9Q	MN	Carbonic anhydrase II (CA-II)
DM3FW9Q	MT	DTT
DM3FW9Q	MA	Inhibitor
DM3FW9Q	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DM3FW9Q	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DM3FW9Q	DI	DM3FW9Q
DM3FW9Q	DN	N-(4-Sulfamoyl-phenyl)-butyramide
DM3FW9Q	MI	TT2LVK8
DM3FW9Q	MN	Carbonic anhydrase IX (CA-IX)
DM3FW9Q	MT	DTT
DM3FW9Q	MA	Inhibitor
DM3FW9Q	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DM3FW9Q	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DM3FW9Q	DI	DM3FW9Q
DM3FW9Q	DN	N-(4-Sulfamoyl-phenyl)-butyramide
DM3FW9Q	MI	TTSYM0R
DM3FW9Q	MN	Carbonic anhydrase XII (CA-XII)
DM3FW9Q	MT	DTT
DM3FW9Q	MA	Inhibitor
DM3FW9Q	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DM3FW9Q	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DMJCXYQ	DI	DMJCXYQ
DMJCXYQ	DN	N-(4-Sulfamoyl-phenyl)-isobutyramide
DMJCXYQ	MI	TTANPDJ
DMJCXYQ	MN	Carbonic anhydrase II (CA-II)
DMJCXYQ	MT	DTT
DMJCXYQ	MA	Inhibitor
DMJCXYQ	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DMJCXYQ	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DMJCXYQ	DI	DMJCXYQ
DMJCXYQ	DN	N-(4-Sulfamoyl-phenyl)-isobutyramide
DMJCXYQ	MI	TT2LVK8
DMJCXYQ	MN	Carbonic anhydrase IX (CA-IX)
DMJCXYQ	MT	DTT
DMJCXYQ	MA	Inhibitor
DMJCXYQ	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DMJCXYQ	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DMJCXYQ	DI	DMJCXYQ
DMJCXYQ	DN	N-(4-Sulfamoyl-phenyl)-isobutyramide
DMJCXYQ	MI	TTSYM0R
DMJCXYQ	MN	Carbonic anhydrase XII (CA-XII)
DMJCXYQ	MT	DTT
DMJCXYQ	MA	Inhibitor
DMJCXYQ	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DMJCXYQ	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DM7MHQD	DI	DM7MHQD
DM7MHQD	DN	N-(4-Sulfamoyl-phenyl)-propionamide
DM7MHQD	MI	TTHQPL7
DM7MHQD	MN	Carbonic anhydrase I (CA-I)
DM7MHQD	MT	DTT
DM7MHQD	MA	Inhibitor
DM7MHQD	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DM7MHQD	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DM7MHQD	DI	DM7MHQD
DM7MHQD	DN	N-(4-Sulfamoyl-phenyl)-propionamide
DM7MHQD	MI	TTANPDJ
DM7MHQD	MN	Carbonic anhydrase II (CA-II)
DM7MHQD	MT	DTT
DM7MHQD	MA	Inhibitor
DM7MHQD	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DM7MHQD	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DM7MHQD	DI	DM7MHQD
DM7MHQD	DN	N-(4-Sulfamoyl-phenyl)-propionamide
DM7MHQD	MI	TT2LVK8
DM7MHQD	MN	Carbonic anhydrase IX (CA-IX)
DM7MHQD	MT	DTT
DM7MHQD	MA	Inhibitor
DM7MHQD	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DM7MHQD	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DM7MHQD	DI	DM7MHQD
DM7MHQD	DN	N-(4-Sulfamoyl-phenyl)-propionamide
DM7MHQD	MI	TTSYM0R
DM7MHQD	MN	Carbonic anhydrase XII (CA-XII)
DM7MHQD	MT	DTT
DM7MHQD	MA	Inhibitor
DM7MHQD	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DM7MHQD	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DM7QX03	DI	DM7QX03
DM7QX03	DN	N-(4-sulfamoylphenylethyl)-4-sulfamoylbenzamide
DM7QX03	MI	TTHQPL7
DM7QX03	MN	Carbonic anhydrase I (CA-I)
DM7QX03	MT	DTT
DM7QX03	MA	Inhibitor
DM7QX03	RN	Pteridine-sulfonamide conjugates as dual inhibitors of carbonic anhydrases and dihydrofolate reductase with potential antitumor activity. Bioorg Med Chem. 2010 Jul 15;18(14):5081-9. 
DM7QX03	RU	https://pubmed.ncbi.nlm.nih.gov/20580561

DM7QX03	DI	DM7QX03
DM7QX03	DN	N-(4-sulfamoylphenylethyl)-4-sulfamoylbenzamide
DM7QX03	MI	TTANPDJ
DM7QX03	MN	Carbonic anhydrase II (CA-II)
DM7QX03	MT	DTT
DM7QX03	MA	Inhibitor
DM7QX03	RN	Pteridine-sulfonamide conjugates as dual inhibitors of carbonic anhydrases and dihydrofolate reductase with potential antitumor activity. Bioorg Med Chem. 2010 Jul 15;18(14):5081-9. 
DM7QX03	RU	https://pubmed.ncbi.nlm.nih.gov/20580561

DM7QX03	DI	DM7QX03
DM7QX03	DN	N-(4-sulfamoylphenylethyl)-4-sulfamoylbenzamide
DM7QX03	MI	TT2LVK8
DM7QX03	MN	Carbonic anhydrase IX (CA-IX)
DM7QX03	MT	DTT
DM7QX03	MA	Inhibitor
DM7QX03	RN	Pteridine-sulfonamide conjugates as dual inhibitors of carbonic anhydrases and dihydrofolate reductase with potential antitumor activity. Bioorg Med Chem. 2010 Jul 15;18(14):5081-9. 
DM7QX03	RU	https://pubmed.ncbi.nlm.nih.gov/20580561

DMHX4F2	DI	DMHX4F2
DMHX4F2	DN	N-(4'-t-butyl-4-biphenylyl)urea
DMHX4F2	MI	TTBGTCW
DMHX4F2	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DMHX4F2	MT	DTT
DMHX4F2	MA	Inhibitor
DMHX4F2	RN	Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52.
DMHX4F2	RU	https://pubmed.ncbi.nlm.nih.gov/17725339

DMN6DAZ	DI	DMN6DAZ
DMN6DAZ	DN	N-(4-tert-butylphenyl)-4-(pyridin-2-yl)benzamide
DMN6DAZ	MI	TTMI6F5
DMN6DAZ	MN	Transient receptor potential cation channel V1 (TRPV1)
DMN6DAZ	MT	DTT
DMN6DAZ	MA	Inhibitor
DMN6DAZ	RN	From arylureas to biarylamides to aminoquinazolines: discovery of a novel, potent TRPV1 antagonist. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5217-21.
DMN6DAZ	RU	https://pubmed.ncbi.nlm.nih.gov/16870426

DMFUBQ8	DI	DMFUBQ8
DMFUBQ8	DN	N-(4-tert-butylthiazol-2-yl)-1H-indol-4-amine
DMFUBQ8	MI	TT7HQD0
DMFUBQ8	MN	C-C chemokine receptor type 4 (CCR4)
DMFUBQ8	MT	DTT
DMFUBQ8	MA	Inhibitor
DMFUBQ8	RN	Optimization of 2-aminothiazole derivatives as CCR4 antagonists. Bioorg Med Chem Lett. 2006 May 15;16(10):2800-3.
DMFUBQ8	RU	https://pubmed.ncbi.nlm.nih.gov/16497499

DMMUX86	DI	DMMUX86
DMMUX86	DN	N-(4-tert-butylthiazol-2-yl)isoquinolin-5-amine
DMMUX86	MI	TT7HQD0
DMMUX86	MN	C-C chemokine receptor type 4 (CCR4)
DMMUX86	MT	DTT
DMMUX86	MA	Inhibitor
DMMUX86	RN	Optimization of 2-aminothiazole derivatives as CCR4 antagonists. Bioorg Med Chem Lett. 2006 May 15;16(10):2800-3.
DMMUX86	RU	https://pubmed.ncbi.nlm.nih.gov/16497499

DMBMAKG	DI	DMBMAKG
DMBMAKG	DN	N-(4-tert-butylthiazol-2-yl)quinolin-5-amine
DMBMAKG	MI	TT7HQD0
DMBMAKG	MN	C-C chemokine receptor type 4 (CCR4)
DMBMAKG	MT	DTT
DMBMAKG	MA	Inhibitor
DMBMAKG	RN	Optimization of 2-aminothiazole derivatives as CCR4 antagonists. Bioorg Med Chem Lett. 2006 May 15;16(10):2800-3.
DMBMAKG	RU	https://pubmed.ncbi.nlm.nih.gov/16497499

DMEW3L0	DI	DMEW3L0
DMEW3L0	DN	N-(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)GLYCINE
DMEW3L0	MI	TTTU902
DMEW3L0	MN	Checkpoint kinase-1 (CHK1)
DMEW3L0	MT	DTT
DMEW3L0	MA	Inhibitor
DMEW3L0	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMEW3L0	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM47XR8	DI	DM47XR8
DM47XR8	DN	N-(5-Amino-6-oxo-heptyl)-acetamidine
DM47XR8	MI	TTZUFI5
DM47XR8	MN	Nitric-oxide synthase brain (NOS1)
DM47XR8	MT	DTT
DM47XR8	MA	Inhibitor
DM47XR8	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DM47XR8	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DM47XR8	DI	DM47XR8
DM47XR8	DN	N-(5-Amino-6-oxo-heptyl)-acetamidine
DM47XR8	MI	TTCM4B3
DM47XR8	MN	Nitric-oxide synthase endothelial (NOS3)
DM47XR8	MT	DTT
DM47XR8	MA	Inhibitor
DM47XR8	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DM47XR8	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DM47XR8	DI	DM47XR8
DM47XR8	DN	N-(5-Amino-6-oxo-heptyl)-acetamidine
DM47XR8	MI	TTF10I9
DM47XR8	MN	Nitric-oxide synthase inducible (NOS2)
DM47XR8	MT	DTT
DM47XR8	MA	Inhibitor
DM47XR8	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DM47XR8	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DMTF8US	DI	DMTF8US
DMTF8US	DN	N-(5-Benzoyl-4-phenylthiazol-2-yl)benzamide
DMTF8US	MI	TTK25J1
DMTF8US	MN	Adenosine A1 receptor (ADORA1)
DMTF8US	MT	DTT
DMTF8US	MA	Inhibitor
DMTF8US	RN	2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
DMTF8US	RU	https://pubmed.ncbi.nlm.nih.gov/20188574

DMTF8US	DI	DMTF8US
DMTF8US	DN	N-(5-Benzoyl-4-phenylthiazol-2-yl)benzamide
DMTF8US	MI	TTM2AOE
DMTF8US	MN	Adenosine A2a receptor (ADORA2A)
DMTF8US	MT	DTT
DMTF8US	MA	Inhibitor
DMTF8US	RN	2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
DMTF8US	RU	https://pubmed.ncbi.nlm.nih.gov/20188574

DMTF8US	DI	DMTF8US
DMTF8US	DN	N-(5-Benzoyl-4-phenylthiazol-2-yl)benzamide
DMTF8US	MI	TTJFY5U
DMTF8US	MN	Adenosine A3 receptor (ADORA3)
DMTF8US	MT	DTT
DMTF8US	MA	Inhibitor
DMTF8US	RN	2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
DMTF8US	RU	https://pubmed.ncbi.nlm.nih.gov/20188574

DMGAITY	DI	DMGAITY
DMGAITY	DN	N-(5-Benzyloxy-isoquinolin-1-yl)-guanidine
DMGAITY	MI	TTXAGYU
DMGAITY	MN	Tissue-type plasminogen activator (PLAT)
DMGAITY	MT	DTT
DMGAITY	MA	Inhibitor
DMGAITY	RN	Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-isoquinolinylguanidines. Bioorg Med Chem Lett. 2004 Jun 21;14(12):3227-30.
DMGAITY	RU	https://pubmed.ncbi.nlm.nih.gov/15149680

DMD5E8G	DI	DMD5E8G
DMD5E8G	DN	N-(5-Bromo-quinoxalin-6-yl)-guanidine
DMD5E8G	MI	TTNGILX
DMD5E8G	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMD5E8G	MT	DTT
DMD5E8G	MA	Inhibitor
DMD5E8G	RN	Analogs of UK 14,304: Structural features responsible for alpha2 adrenoceptor activity, Bioorg. Med. Chem. Lett. 5(15):1745-1750 (1995).
DMD5E8G	RU	http://www.sciencedirect.com/science/article/pii/0960894X95002955

DMD5E8G	DI	DMD5E8G
DMD5E8G	DN	N-(5-Bromo-quinoxalin-6-yl)-guanidine
DMD5E8G	MI	TTBRKXS
DMD5E8G	MN	Adrenergic receptor alpha-1B (ADRA1B)
DMD5E8G	MT	DTT
DMD5E8G	MA	Inhibitor
DMD5E8G	RN	Analogs of UK 14,304: Structural features responsible for alpha2 adrenoceptor activity, Bioorg. Med. Chem. Lett. 5(15):1745-1750 (1995).
DMD5E8G	RU	http://www.sciencedirect.com/science/article/pii/0960894X95002955

DMD5E8G	DI	DMD5E8G
DMD5E8G	DN	N-(5-Bromo-quinoxalin-6-yl)-guanidine
DMD5E8G	MI	TT34BHT
DMD5E8G	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMD5E8G	MT	DTT
DMD5E8G	MA	Inhibitor
DMD5E8G	RN	Analogs of UK 14,304: Structural features responsible for alpha2 adrenoceptor activity, Bioorg. Med. Chem. Lett. 5(15):1745-1750 (1995).
DMD5E8G	RU	http://www.sciencedirect.com/science/article/pii/0960894X95002955

DMHZ256	DI	DMHZ256
DMHZ256	DN	N-(5-chloro-2-(phenylthio)phenyl)butyramide
DMHZ256	MI	TTRTKPV
DMHZ256	MN	Trypanosoma Trypanothione reductase (Trypano TPR)
DMHZ256	MT	DTT
DMHZ256	MA	Inhibitor
DMHZ256	RN	Antitrypanosomal, antileishmanial, and antimalarial activities of quaternary arylalkylammonium 2-amino-4-chlorophenyl phenyl sulfides, a new class ... J Med Chem. 2005 Dec 15;48(25):8087-97.
DMHZ256	RU	https://pubmed.ncbi.nlm.nih.gov/16335933

DM2TFJE	DI	DM2TFJE
DM2TFJE	DN	N-(5-chlorobenzo[d]oxazol-2-yl)benzenesulfonamide
DM2TFJE	MI	TTWHDVK
DM2TFJE	MN	Fructose-1,6-bisphosphatase (FBP)
DM2TFJE	MT	DTT
DM2TFJE	MA	Inhibitor
DM2TFJE	RN	Benzoxazole benzenesulfonamides as allosteric inhibitors of fructose-1,6-bisphosphatase. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1807-10.
DM2TFJE	RU	https://pubmed.ncbi.nlm.nih.gov/16446092

DM9JCD3	DI	DM9JCD3
DM9JCD3	DN	N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide
DM9JCD3	MI	TT7HF4W
DM9JCD3	MN	Cyclin-dependent kinase 2 (CDK2)
DM9JCD3	MT	DTT
DM9JCD3	MA	Inhibitor
DM9JCD3	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9JCD3	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMNQDLC	DI	DMNQDLC
DMNQDLC	DN	N-(5-ethyl-1,3,4-thiadiazol-2-yl)sulfamide
DMNQDLC	MI	TTUNARX
DMNQDLC	MN	Carbonic anhydrase (CA)
DMNQDLC	MT	DTT
DMNQDLC	MA	Inhibitor
DMNQDLC	RN	Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5.
DMNQDLC	RU	https://pubmed.ncbi.nlm.nih.gov/18990571

DMNQDLC	DI	DMNQDLC
DMNQDLC	DN	N-(5-ethyl-1,3,4-thiadiazol-2-yl)sulfamide
DMNQDLC	MI	TTHQPL7
DMNQDLC	MN	Carbonic anhydrase I (CA-I)
DMNQDLC	MT	DTT
DMNQDLC	MA	Inhibitor
DMNQDLC	RN	Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5.
DMNQDLC	RU	https://pubmed.ncbi.nlm.nih.gov/18990571

DMNQDLC	DI	DMNQDLC
DMNQDLC	DN	N-(5-ethyl-1,3,4-thiadiazol-2-yl)sulfamide
DMNQDLC	MI	TTANPDJ
DMNQDLC	MN	Carbonic anhydrase II (CA-II)
DMNQDLC	MT	DTT
DMNQDLC	MA	Inhibitor
DMNQDLC	RN	Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5.
DMNQDLC	RU	https://pubmed.ncbi.nlm.nih.gov/18990571

DMNQDLC	DI	DMNQDLC
DMNQDLC	DN	N-(5-ethyl-1,3,4-thiadiazol-2-yl)sulfamide
DMNQDLC	MI	TTZHA0O
DMNQDLC	MN	Carbonic anhydrase IV (CA-IV)
DMNQDLC	MT	DTT
DMNQDLC	MA	Inhibitor
DMNQDLC	RN	Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5.
DMNQDLC	RU	https://pubmed.ncbi.nlm.nih.gov/18990571

DMUHKYW	DI	DMUHKYW
DMUHKYW	DN	N-(5-Hydroxycarbamoyl-pentyl)-4-methoxy-benzamide
DMUHKYW	MI	TTBH0VX
DMUHKYW	MN	Histone deacetylase (HDAC)
DMUHKYW	MT	DTT
DMUHKYW	MA	Inhibitor
DMUHKYW	RN	Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. J Med Chem. 1999 Nov 4;42(22):4669-79.
DMUHKYW	RU	https://pubmed.ncbi.nlm.nih.gov/10579829

DMSUW7M	DI	DMSUW7M
DMSUW7M	DN	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide
DMSUW7M	MI	TTBH0VX
DMSUW7M	MN	Histone deacetylase (HDAC)
DMSUW7M	MT	DTT
DMSUW7M	MA	Inhibitor
DMSUW7M	RN	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
DMSUW7M	RU	https://pubmed.ncbi.nlm.nih.gov/11831887

DMSUW7M	DI	DMSUW7M
DMSUW7M	DN	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide
DMSUW7M	MI	TT6R7JZ
DMSUW7M	MN	Histone deacetylase 1 (HDAC1)
DMSUW7M	MT	DTT
DMSUW7M	MA	Inhibitor
DMSUW7M	RN	Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
DMSUW7M	RU	https://pubmed.ncbi.nlm.nih.gov/14613312

DMSUW7M	DI	DMSUW7M
DMSUW7M	DN	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide
DMSUW7M	MI	TTYHPU6
DMSUW7M	MN	Histone deacetylase 10 (HDAC10)
DMSUW7M	MT	DTT
DMSUW7M	MA	Inhibitor
DMSUW7M	RN	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
DMSUW7M	RU	https://pubmed.ncbi.nlm.nih.gov/11831887

DMSUW7M	DI	DMSUW7M
DMSUW7M	DN	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide
DMSUW7M	MI	TTSHTOI
DMSUW7M	MN	Histone deacetylase 2 (HDAC2)
DMSUW7M	MT	DTT
DMSUW7M	MA	Inhibitor
DMSUW7M	RN	Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
DMSUW7M	RU	https://pubmed.ncbi.nlm.nih.gov/14613312

DMSUW7M	DI	DMSUW7M
DMSUW7M	DN	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide
DMSUW7M	MI	TTTQGH8
DMSUW7M	MN	Histone deacetylase 4 (HDAC4)
DMSUW7M	MT	DTT
DMSUW7M	MA	Inhibitor
DMSUW7M	RN	Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
DMSUW7M	RU	https://pubmed.ncbi.nlm.nih.gov/14613312

DMSUW7M	DI	DMSUW7M
DMSUW7M	DN	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide
DMSUW7M	MI	TT5ZKDI
DMSUW7M	MN	Histone deacetylase 6 (HDAC6)
DMSUW7M	MT	DTT
DMSUW7M	MA	Inhibitor
DMSUW7M	RN	Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
DMSUW7M	RU	https://pubmed.ncbi.nlm.nih.gov/14613312

DMSUW7M	DI	DMSUW7M
DMSUW7M	DN	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide
DMSUW7M	MI	TTT6LFV
DMSUW7M	MN	Histone deacetylase 8 (HDAC8)
DMSUW7M	MT	DTT
DMSUW7M	MA	Inhibitor
DMSUW7M	RN	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
DMSUW7M	RU	https://pubmed.ncbi.nlm.nih.gov/11831887

DMZSGPB	DI	DMZSGPB
DMZSGPB	DN	N-(5-Hydroxycarbamoyl-pentyl)-benzamide
DMZSGPB	MI	TTBH0VX
DMZSGPB	MN	Histone deacetylase (HDAC)
DMZSGPB	MT	DTT
DMZSGPB	MA	Inhibitor
DMZSGPB	RN	Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. J Med Chem. 1999 Nov 4;42(22):4669-79.
DMZSGPB	RU	https://pubmed.ncbi.nlm.nih.gov/10579829

DMSQEXP	DI	DMSQEXP
DMSQEXP	DN	N-(5-Mercapto-[1,3,4]thiadiazol-2-yl)-acetamide
DMSQEXP	MI	TTHQPL7
DMSQEXP	MN	Carbonic anhydrase I (CA-I)
DMSQEXP	MT	DTT
DMSQEXP	MA	Inhibitor
DMSQEXP	RN	Carbonic anhydrase inhibitors. Inhibition of the cytosolic and tumor-associated carbonic anhydrase isozymes I, II, and IX with a series of 1,3,4-th... Bioorg Med Chem Lett. 2005 May 2;15(9):2347-52.
DMSQEXP	RU	https://pubmed.ncbi.nlm.nih.gov/15837323

DMSQEXP	DI	DMSQEXP
DMSQEXP	DN	N-(5-Mercapto-[1,3,4]thiadiazol-2-yl)-acetamide
DMSQEXP	MI	TTANPDJ
DMSQEXP	MN	Carbonic anhydrase II (CA-II)
DMSQEXP	MT	DTT
DMSQEXP	MA	Inhibitor
DMSQEXP	RN	Carbonic anhydrase inhibitors. Inhibition of the cytosolic and tumor-associated carbonic anhydrase isozymes I, II, and IX with a series of 1,3,4-th... Bioorg Med Chem Lett. 2005 May 2;15(9):2347-52.
DMSQEXP	RU	https://pubmed.ncbi.nlm.nih.gov/15837323

DMSQEXP	DI	DMSQEXP
DMSQEXP	DN	N-(5-Mercapto-[1,3,4]thiadiazol-2-yl)-acetamide
DMSQEXP	MI	TT2LVK8
DMSQEXP	MN	Carbonic anhydrase IX (CA-IX)
DMSQEXP	MT	DTT
DMSQEXP	MA	Inhibitor
DMSQEXP	RN	Carbonic anhydrase inhibitors. Inhibition of the cytosolic and tumor-associated carbonic anhydrase isozymes I, II, and IX with a series of 1,3,4-th... Bioorg Med Chem Lett. 2005 May 2;15(9):2347-52.
DMSQEXP	RU	https://pubmed.ncbi.nlm.nih.gov/15837323

DM91463	DI	DM91463
DM91463	DN	N-(5-Methanesulfonyl-2-methyl-benzoyl)-guanidine
DM91463	MI	TTGSEFH
DM91463	MN	Sodium/hydrogen exchanger 1 (SLC9A1)
DM91463	MT	DTT
DM91463	MA	Inhibitor
DM91463	RN	(2-Methyl-5-(methylsulfonyl)benzoyl)guanidine Na+/H+ antiporter inhibitors. J Med Chem. 1997 Jun 20;40(13):2017-34.
DM91463	RU	https://pubmed.ncbi.nlm.nih.gov/9207943

DM91463	DI	DM91463
DM91463	DN	N-(5-Methanesulfonyl-2-methyl-benzoyl)-guanidine
DM91463	MI	TTFZVPO
DM91463	MN	Sodium/hydrogen exchanger 3 (SLC9A3)
DM91463	MT	DTT
DM91463	MA	Inhibitor
DM91463	RN	(2-Methyl-5-(methylsulfonyl)benzoyl)guanidine Na+/H+ antiporter inhibitors. J Med Chem. 1997 Jun 20;40(13):2017-34.
DM91463	RU	https://pubmed.ncbi.nlm.nih.gov/9207943

DM8PNKC	DI	DM8PNKC
DM8PNKC	DN	N-(5-methylthiazol-2-yl)-2-phenylacetamide
DM8PNKC	MI	TTSJ6Q4
DM8PNKC	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DM8PNKC	MT	DTT
DM8PNKC	MA	Inhibitor
DM8PNKC	RN	Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. J Med Chem. 2007 May 31;50(11):2640-6.
DM8PNKC	RU	https://pubmed.ncbi.nlm.nih.gov/17461565

DMFI057	DI	DMFI057
DMFI057	DN	N-(5-methylthiazol-2-yl)benzamide
DMFI057	MI	TTSJ6Q4
DMFI057	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DMFI057	MT	DTT
DMFI057	MA	Inhibitor
DMFI057	RN	Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. J Med Chem. 2007 May 31;50(11):2640-6.
DMFI057	RU	https://pubmed.ncbi.nlm.nih.gov/17461565

DMS2X69	DI	DMS2X69
DMS2X69	DN	N-(5-m-Tolyl-furan-2-carbonyl)-guanidine
DMS2X69	MI	TTGSEFH
DMS2X69	MN	Sodium/hydrogen exchanger 1 (SLC9A1)
DMS2X69	MT	DTT
DMS2X69	MA	Inhibitor
DMS2X69	RN	(5-Arylfuran-2-ylcarbonyl)guanidines as cardioprotectives through the inhibition of Na+/H+ exchanger isoform-1. J Med Chem. 2005 Apr 21;48(8):2882-91.
DMS2X69	RU	https://pubmed.ncbi.nlm.nih.gov/15828827

DMFNZSL	DI	DMFNZSL
DMFNZSL	DN	N-(5-o-Tolyl-furan-2-carbonyl)-guanidine
DMFNZSL	MI	TTGSEFH
DMFNZSL	MN	Sodium/hydrogen exchanger 1 (SLC9A1)
DMFNZSL	MT	DTT
DMFNZSL	MA	Inhibitor
DMFNZSL	RN	(5-Arylfuran-2-ylcarbonyl)guanidines as cardioprotectives through the inhibition of Na+/H+ exchanger isoform-1. J Med Chem. 2005 Apr 21;48(8):2882-91.
DMFNZSL	RU	https://pubmed.ncbi.nlm.nih.gov/15828827

DMA21WB	DI	DMA21WB
DMA21WB	DN	N-(5-phenyl-1,3,4-thiadiazol-2-yl)sulfamide
DMA21WB	MI	TTUNARX
DMA21WB	MN	Carbonic anhydrase (CA)
DMA21WB	MT	DTT
DMA21WB	MA	Inhibitor
DMA21WB	RN	Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5.
DMA21WB	RU	https://pubmed.ncbi.nlm.nih.gov/18990571

DMA21WB	DI	DMA21WB
DMA21WB	DN	N-(5-phenyl-1,3,4-thiadiazol-2-yl)sulfamide
DMA21WB	MI	TTHQPL7
DMA21WB	MN	Carbonic anhydrase I (CA-I)
DMA21WB	MT	DTT
DMA21WB	MA	Inhibitor
DMA21WB	RN	Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5.
DMA21WB	RU	https://pubmed.ncbi.nlm.nih.gov/18990571

DMA21WB	DI	DMA21WB
DMA21WB	DN	N-(5-phenyl-1,3,4-thiadiazol-2-yl)sulfamide
DMA21WB	MI	TTANPDJ
DMA21WB	MN	Carbonic anhydrase II (CA-II)
DMA21WB	MT	DTT
DMA21WB	MA	Inhibitor
DMA21WB	RN	Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5.
DMA21WB	RU	https://pubmed.ncbi.nlm.nih.gov/18990571

DMA21WB	DI	DMA21WB
DMA21WB	DN	N-(5-phenyl-1,3,4-thiadiazol-2-yl)sulfamide
DMA21WB	MI	TTZHA0O
DMA21WB	MN	Carbonic anhydrase IV (CA-IV)
DMA21WB	MT	DTT
DMA21WB	MA	Inhibitor
DMA21WB	RN	Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5.
DMA21WB	RU	https://pubmed.ncbi.nlm.nih.gov/18990571

DMNU68D	DI	DMNU68D
DMNU68D	DN	N-(5-Phenyl-furan-2-carbonyl)-guanidine
DMNU68D	MI	TTGSEFH
DMNU68D	MN	Sodium/hydrogen exchanger 1 (SLC9A1)
DMNU68D	MT	DTT
DMNU68D	MA	Inhibitor
DMNU68D	RN	(5-Arylfuran-2-ylcarbonyl)guanidines as cardioprotectives through the inhibition of Na+/H+ exchanger isoform-1. J Med Chem. 2005 Apr 21;48(8):2882-91.
DMNU68D	RU	https://pubmed.ncbi.nlm.nih.gov/15828827

DM3FCAI	DI	DM3FCAI
DM3FCAI	DN	N-(5'-Phosphopyridoxyl)-D-Alanine
DM3FCAI	MI	TT6TMZU
DM3FCAI	MN	Mycobacterium Biosynthetic alanine racemase (MycB alr)
DM3FCAI	MT	DTT
DM3FCAI	MA	Inhibitor
DM3FCAI	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM3FCAI	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMDZ9BY	DI	DMDZ9BY
DMDZ9BY	DN	N-(5-Sulfamoyl-[1,3,4]thiadiazol-2-yl)-benzamide
DMDZ9BY	MI	TTZHA0O
DMDZ9BY	MN	Carbonic anhydrase IV (CA-IV)
DMDZ9BY	MT	DTT
DMDZ9BY	MA	Inhibitor
DMDZ9BY	RN	Carbonic anhydrase inhibitors: anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties. J Med Chem. 2002 Jan 17;45(2):312-20.
DMDZ9BY	RU	https://pubmed.ncbi.nlm.nih.gov/11784136

DM5E7OC	DI	DM5E7OC
DM5E7OC	DN	N-(5-tert-butyl-1,3,4-thiadiazol-2-yl)sulfamide
DM5E7OC	MI	TTUNARX
DM5E7OC	MN	Carbonic anhydrase (CA)
DM5E7OC	MT	DTT
DM5E7OC	MA	Inhibitor
DM5E7OC	RN	Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5.
DM5E7OC	RU	https://pubmed.ncbi.nlm.nih.gov/18990571

DM5E7OC	DI	DM5E7OC
DM5E7OC	DN	N-(5-tert-butyl-1,3,4-thiadiazol-2-yl)sulfamide
DM5E7OC	MI	TTHQPL7
DM5E7OC	MN	Carbonic anhydrase I (CA-I)
DM5E7OC	MT	DTT
DM5E7OC	MA	Inhibitor
DM5E7OC	RN	Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5.
DM5E7OC	RU	https://pubmed.ncbi.nlm.nih.gov/18990571

DM5E7OC	DI	DM5E7OC
DM5E7OC	DN	N-(5-tert-butyl-1,3,4-thiadiazol-2-yl)sulfamide
DM5E7OC	MI	TTANPDJ
DM5E7OC	MN	Carbonic anhydrase II (CA-II)
DM5E7OC	MT	DTT
DM5E7OC	MA	Inhibitor
DM5E7OC	RN	Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5.
DM5E7OC	RU	https://pubmed.ncbi.nlm.nih.gov/18990571

DM5E7OC	DI	DM5E7OC
DM5E7OC	DN	N-(5-tert-butyl-1,3,4-thiadiazol-2-yl)sulfamide
DM5E7OC	MI	TTZHA0O
DM5E7OC	MN	Carbonic anhydrase IV (CA-IV)
DM5E7OC	MT	DTT
DM5E7OC	MA	Inhibitor
DM5E7OC	RN	Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5.
DM5E7OC	RU	https://pubmed.ncbi.nlm.nih.gov/18990571

DMDCX5O	DI	DMDCX5O
DMDCX5O	DN	N-(6-(2-chlorophenyl)-1H-indazol-3-yl)butyramide
DMDCX5O	MI	TTRSMW9
DMDCX5O	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMDCX5O	MT	DTT
DMDCX5O	MA	Inhibitor
DMDCX5O	RN	Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9.
DMDCX5O	RU	https://pubmed.ncbi.nlm.nih.gov/20167481

DMKGBZA	DI	DMKGBZA
DMKGBZA	DN	N-(6-(3-hydroxyphenyl)-1H-indazol-3-yl)butyramide
DMKGBZA	MI	TTRSMW9
DMKGBZA	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMKGBZA	MT	DTT
DMKGBZA	MA	Inhibitor
DMKGBZA	RN	Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9.
DMKGBZA	RU	https://pubmed.ncbi.nlm.nih.gov/20167481

DMDQEZG	DI	DMDQEZG
DMDQEZG	DN	N-(6-(4-aminophenyl)-1H-indazol-3-yl)butyramide
DMDQEZG	MI	TTRSMW9
DMDQEZG	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMDQEZG	MT	DTT
DMDQEZG	MA	Inhibitor
DMDQEZG	RN	Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9.
DMDQEZG	RU	https://pubmed.ncbi.nlm.nih.gov/20167481

DMP7UZB	DI	DMP7UZB
DMP7UZB	DN	N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYACETAMIDE (ENANTIOMERIC MIX)
DMP7UZB	MI	TT6OEDT
DMP7UZB	MN	Cannabinoid receptor 1 (CB1)
DMP7UZB	MT	DTT
DMP7UZB	MA	Inhibitor
DMP7UZB	RN	Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4.
DMP7UZB	RU	https://pubmed.ncbi.nlm.nih.gov/20483606

DMP7UZB	DI	DMP7UZB
DMP7UZB	DN	N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYACETAMIDE (ENANTIOMERIC MIX)
DMP7UZB	MI	TTMSFAW
DMP7UZB	MN	Cannabinoid receptor 2 (CB2)
DMP7UZB	MT	DTT
DMP7UZB	MA	Inhibitor
DMP7UZB	RN	Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4.
DMP7UZB	RU	https://pubmed.ncbi.nlm.nih.gov/20483606

DMDPXUA	DI	DMDPXUA
DMDPXUA	DN	N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-3-HYDROXY-2,2-DIMETHYLPROPANAMIDE (ENANTIOMERIC MIX)
DMDPXUA	MI	TT6OEDT
DMDPXUA	MN	Cannabinoid receptor 1 (CB1)
DMDPXUA	MT	DTT
DMDPXUA	MA	Inhibitor
DMDPXUA	RN	Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4.
DMDPXUA	RU	https://pubmed.ncbi.nlm.nih.gov/20483606

DMDPXUA	DI	DMDPXUA
DMDPXUA	DN	N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-3-HYDROXY-2,2-DIMETHYLPROPANAMIDE (ENANTIOMERIC MIX)
DMDPXUA	MI	TTMSFAW
DMDPXUA	MN	Cannabinoid receptor 2 (CB2)
DMDPXUA	MT	DTT
DMDPXUA	MA	Inhibitor
DMDPXUA	RN	Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4.
DMDPXUA	RU	https://pubmed.ncbi.nlm.nih.gov/20483606

DMSX5DI	DI	DMSX5DI
DMSX5DI	DN	N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-3-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX)
DMSX5DI	MI	TT6OEDT
DMSX5DI	MN	Cannabinoid receptor 1 (CB1)
DMSX5DI	MT	DTT
DMSX5DI	MA	Inhibitor
DMSX5DI	RN	Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4.
DMSX5DI	RU	https://pubmed.ncbi.nlm.nih.gov/20483606

DMSX5DI	DI	DMSX5DI
DMSX5DI	DN	N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-3-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX)
DMSX5DI	MI	TTMSFAW
DMSX5DI	MN	Cannabinoid receptor 2 (CB2)
DMSX5DI	MT	DTT
DMSX5DI	MA	Inhibitor
DMSX5DI	RN	Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4.
DMSX5DI	RU	https://pubmed.ncbi.nlm.nih.gov/20483606

DMSX5DI	DI	DMSX5DI
DMSX5DI	DN	N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-3-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX)
DMSX5DI	MI	TTQ6VDM
DMSX5DI	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMSX5DI	MT	DTT
DMSX5DI	MA	Inhibitor
DMSX5DI	RN	Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4.
DMSX5DI	RU	https://pubmed.ncbi.nlm.nih.gov/20483606

DM4M12J	DI	DM4M12J
DM4M12J	DN	N-(6-(4-fluorophenyl)-1H-indazol-3-yl)butyramide
DM4M12J	MI	TTRSMW9
DM4M12J	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DM4M12J	MT	DTT
DM4M12J	MA	Inhibitor
DM4M12J	RN	Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9.
DM4M12J	RU	https://pubmed.ncbi.nlm.nih.gov/20167481

DM8JLR4	DI	DM8JLR4
DM8JLR4	DN	N-(6-(4-hydroxyphenyl)-1H-indazol-3-yl)butyramide
DM8JLR4	MI	TTRSMW9
DM8JLR4	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DM8JLR4	MT	DTT
DM8JLR4	MA	Inhibitor
DM8JLR4	RN	Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9.
DM8JLR4	RU	https://pubmed.ncbi.nlm.nih.gov/20167481

DMRGQTM	DI	DMRGQTM
DMRGQTM	DN	N-(6-(furan-3-yl)-1H-indazol-3-yl)butyramide
DMRGQTM	MI	TTRSMW9
DMRGQTM	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMRGQTM	MT	DTT
DMRGQTM	MA	Inhibitor
DMRGQTM	RN	Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9.
DMRGQTM	RU	https://pubmed.ncbi.nlm.nih.gov/20167481

DM3FOKL	DI	DM3FOKL
DM3FOKL	DN	N-(6-(pyridin-3-yl)-1H-indazol-3-yl)butyramide
DM3FOKL	MI	TTRSMW9
DM3FOKL	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DM3FOKL	MT	DTT
DM3FOKL	MA	Inhibitor
DM3FOKL	RN	Design of potent and selective GSK3beta inhibitors with acceptable safety profile and pharmacokinetics. Bioorg Med Chem Lett. 2010 Apr 1;20(7):2344-9.
DM3FOKL	RU	https://pubmed.ncbi.nlm.nih.gov/20189807

DM4GRK8	DI	DM4GRK8
DM4GRK8	DN	N-(6-(pyridin-4-yl)-1H-indazol-3-yl)butyramide
DM4GRK8	MI	TTRSMW9
DM4GRK8	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DM4GRK8	MT	DTT
DM4GRK8	MA	Inhibitor
DM4GRK8	RN	Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9.
DM4GRK8	RU	https://pubmed.ncbi.nlm.nih.gov/20167481

DMNRSYP	DI	DMNRSYP
DMNRSYP	DN	N-(6-(thiophen-3-yl)-1H-indazol-3-yl)butyramide
DMNRSYP	MI	TTRSMW9
DMNRSYP	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMNRSYP	MT	DTT
DMNRSYP	MA	Inhibitor
DMNRSYP	RN	Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9.
DMNRSYP	RU	https://pubmed.ncbi.nlm.nih.gov/20167481

DMMHD9Z	DI	DMMHD9Z
DMMHD9Z	DN	N-(6-(trifluoromethyl)-1H-indazol-3-yl)butyramide
DMMHD9Z	MI	TTRSMW9
DMMHD9Z	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMMHD9Z	MT	DTT
DMMHD9Z	MA	Inhibitor
DMMHD9Z	RN	Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9.
DMMHD9Z	RU	https://pubmed.ncbi.nlm.nih.gov/20167481

DMHINE0	DI	DMHINE0
DMHINE0	DN	N(6)-cyclohexyladenosine
DMHINE0	MI	TTK25J1
DMHINE0	MN	Adenosine A1 receptor (ADORA1)
DMHINE0	MT	DTT
DMHINE0	MA	Agonist
DMHINE0	RN	Structure-activity relationships for 2-substituted adenosines at A1 and A2 adenosine receptors. Pharmacology. 1993;46(2):91-100.
DMHINE0	RU	https://pubmed.ncbi.nlm.nih.gov/8441759

DMHINE0	DI	DMHINE0
DMHINE0	DN	N(6)-cyclohexyladenosine
DMHINE0	MI	TTNE7KG
DMHINE0	MN	Adenosine A2b receptor (ADORA2B)
DMHINE0	MT	DTT
DMHINE0	MA	Agonist
DMHINE0	RN	Adenosine receptor activation in human fibroblasts: nucleoside agonists and antagonists. Can J Physiol Pharmacol. 1980 Jun;58(6):673-91.
DMHINE0	RU	https://pubmed.ncbi.nlm.nih.gov/6253037

DMHINE0	DI	DMHINE0
DMHINE0	DN	N(6)-cyclohexyladenosine
DMHINE0	MI	TTJFY5U
DMHINE0	MN	Adenosine A3 receptor (ADORA3)
DMHINE0	MT	DTT
DMHINE0	MA	Agonist
DMHINE0	RN	Inhibition of TNF-alpha expression by adenosine: role of A3 adenosine receptors. J Immunol. 1996 May 1;156(9):3435-42.
DMHINE0	RU	https://pubmed.ncbi.nlm.nih.gov/8617970

DMKWYMP	DI	DMKWYMP
DMKWYMP	DN	N-(6)-methyl-2'-deoxyadenosine-3',5'-bisphosphate
DMKWYMP	MI	TTA93TL
DMKWYMP	MN	P2Y purinoceptor 1 (P2RY1)
DMKWYMP	MT	DTT
DMKWYMP	MA	Antagonist
DMKWYMP	RN	Key role of the P2Y(1) receptor in tissue factor-induced thrombin-dependent acute thromboembolism: studies in P2Y(1)-knockout mice and mice treated with a P2Y(1) antagonist. Circulation. 2001 Feb 6;103(5):718-23.
DMKWYMP	RU	https://pubmed.ncbi.nlm.nih.gov/11156884

DM0OCLU	DI	DM0OCLU
DM0OCLU	DN	N-(6-benzyl-1H-indazol-3-yl)butyramide
DM0OCLU	MI	TTRSMW9
DM0OCLU	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DM0OCLU	MT	DTT
DM0OCLU	MA	Inhibitor
DM0OCLU	RN	Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9.
DM0OCLU	RU	https://pubmed.ncbi.nlm.nih.gov/20167481

DMJPL7E	DI	DMJPL7E
DMJPL7E	DN	N-(6-bromo-1H-indazol-3-yl)butyramide
DMJPL7E	MI	TTRSMW9
DMJPL7E	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMJPL7E	MT	DTT
DMJPL7E	MA	Inhibitor
DMJPL7E	RN	Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9.
DMJPL7E	RU	https://pubmed.ncbi.nlm.nih.gov/20167481

DMHGXPY	DI	DMHGXPY
DMHGXPY	DN	N-(6-chloro-1H-indazol-3-yl)butyramide
DMHGXPY	MI	TTRSMW9
DMHGXPY	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMHGXPY	MT	DTT
DMHGXPY	MA	Inhibitor
DMHGXPY	RN	Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9.
DMHGXPY	RU	https://pubmed.ncbi.nlm.nih.gov/20167481

DMJV3UO	DI	DMJV3UO
DMJV3UO	DN	N-(6-chloro-5-phenyl-1H-indazol-3-yl)butyramide
DMJV3UO	MI	TTRSMW9
DMJV3UO	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMJV3UO	MT	DTT
DMJV3UO	MA	Inhibitor
DMJV3UO	RN	Design of potent and selective GSK3beta inhibitors with acceptable safety profile and pharmacokinetics. Bioorg Med Chem Lett. 2010 Apr 1;20(7):2344-9.
DMJV3UO	RU	https://pubmed.ncbi.nlm.nih.gov/20189807

DMIN128	DI	DMIN128
DMIN128	DN	N-(6-chloro-5-p-tolyl-1H-indazol-3-yl)butyramide
DMIN128	MI	TTRSMW9
DMIN128	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMIN128	MT	DTT
DMIN128	MA	Inhibitor
DMIN128	RN	Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9.
DMIN128	RU	https://pubmed.ncbi.nlm.nih.gov/20167481

DM90KGB	DI	DM90KGB
DM90KGB	DN	N-(6-ethoxypyridin-2-yl)acetamide
DM90KGB	MI	TT0K6EO
DM90KGB	MN	Stress-activated protein kinase JNK1 (JNK1)
DM90KGB	MT	DTT
DM90KGB	MA	Inhibitor
DM90KGB	RN	Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006 Jun 15;49(12):3563-80.
DM90KGB	RU	https://pubmed.ncbi.nlm.nih.gov/16759099

DMIZVMT	DI	DMIZVMT
DMIZVMT	DN	N-(6-Hydroxycarbamoyl-hexyl)-benzamide
DMIZVMT	MI	TTBH0VX
DMIZVMT	MN	Histone deacetylase (HDAC)
DMIZVMT	MT	DTT
DMIZVMT	MA	Inhibitor
DMIZVMT	RN	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
DMIZVMT	RU	https://pubmed.ncbi.nlm.nih.gov/11831887

DMIZVMT	DI	DMIZVMT
DMIZVMT	DN	N-(6-Hydroxycarbamoyl-hexyl)-benzamide
DMIZVMT	MI	TT6R7JZ
DMIZVMT	MN	Histone deacetylase 1 (HDAC1)
DMIZVMT	MT	DTT
DMIZVMT	MA	Inhibitor
DMIZVMT	RN	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
DMIZVMT	RU	https://pubmed.ncbi.nlm.nih.gov/11831887

DMIZVMT	DI	DMIZVMT
DMIZVMT	DN	N-(6-Hydroxycarbamoyl-hexyl)-benzamide
DMIZVMT	MI	TTYHPU6
DMIZVMT	MN	Histone deacetylase 10 (HDAC10)
DMIZVMT	MT	DTT
DMIZVMT	MA	Inhibitor
DMIZVMT	RN	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
DMIZVMT	RU	https://pubmed.ncbi.nlm.nih.gov/11831887

DMIZVMT	DI	DMIZVMT
DMIZVMT	DN	N-(6-Hydroxycarbamoyl-hexyl)-benzamide
DMIZVMT	MI	TTSHTOI
DMIZVMT	MN	Histone deacetylase 2 (HDAC2)
DMIZVMT	MT	DTT
DMIZVMT	MA	Inhibitor
DMIZVMT	RN	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
DMIZVMT	RU	https://pubmed.ncbi.nlm.nih.gov/11831887

DMIZVMT	DI	DMIZVMT
DMIZVMT	DN	N-(6-Hydroxycarbamoyl-hexyl)-benzamide
DMIZVMT	MI	TTTQGH8
DMIZVMT	MN	Histone deacetylase 4 (HDAC4)
DMIZVMT	MT	DTT
DMIZVMT	MA	Inhibitor
DMIZVMT	RN	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
DMIZVMT	RU	https://pubmed.ncbi.nlm.nih.gov/11831887

DMIZVMT	DI	DMIZVMT
DMIZVMT	DN	N-(6-Hydroxycarbamoyl-hexyl)-benzamide
DMIZVMT	MI	TT5ZKDI
DMIZVMT	MN	Histone deacetylase 6 (HDAC6)
DMIZVMT	MT	DTT
DMIZVMT	MA	Inhibitor
DMIZVMT	RN	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
DMIZVMT	RU	https://pubmed.ncbi.nlm.nih.gov/11831887

DMIZVMT	DI	DMIZVMT
DMIZVMT	DN	N-(6-Hydroxycarbamoyl-hexyl)-benzamide
DMIZVMT	MI	TTT6LFV
DMIZVMT	MN	Histone deacetylase 8 (HDAC8)
DMIZVMT	MT	DTT
DMIZVMT	MA	Inhibitor
DMIZVMT	RN	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
DMIZVMT	RU	https://pubmed.ncbi.nlm.nih.gov/11831887

DM01Y37	DI	DM01Y37
DM01Y37	DN	N-(6-Mercapto-hexyl)-benzamide
DM01Y37	MI	TTBH0VX
DM01Y37	MN	Histone deacetylase (HDAC)
DM01Y37	MT	DTT
DM01Y37	MA	Inhibitor
DM01Y37	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DM01Y37	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DM01Y37	DI	DM01Y37
DM01Y37	DN	N-(6-Mercapto-hexyl)-benzamide
DM01Y37	MI	TT6R7JZ
DM01Y37	MN	Histone deacetylase 1 (HDAC1)
DM01Y37	MT	DTT
DM01Y37	MA	Inhibitor
DM01Y37	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DM01Y37	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DM01Y37	DI	DM01Y37
DM01Y37	DN	N-(6-Mercapto-hexyl)-benzamide
DM01Y37	MI	TTYHPU6
DM01Y37	MN	Histone deacetylase 10 (HDAC10)
DM01Y37	MT	DTT
DM01Y37	MA	Inhibitor
DM01Y37	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DM01Y37	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DM01Y37	DI	DM01Y37
DM01Y37	DN	N-(6-Mercapto-hexyl)-benzamide
DM01Y37	MI	TTSHTOI
DM01Y37	MN	Histone deacetylase 2 (HDAC2)
DM01Y37	MT	DTT
DM01Y37	MA	Inhibitor
DM01Y37	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DM01Y37	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DM01Y37	DI	DM01Y37
DM01Y37	DN	N-(6-Mercapto-hexyl)-benzamide
DM01Y37	MI	TTTQGH8
DM01Y37	MN	Histone deacetylase 4 (HDAC4)
DM01Y37	MT	DTT
DM01Y37	MA	Inhibitor
DM01Y37	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DM01Y37	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DM01Y37	DI	DM01Y37
DM01Y37	DN	N-(6-Mercapto-hexyl)-benzamide
DM01Y37	MI	TT5ZKDI
DM01Y37	MN	Histone deacetylase 6 (HDAC6)
DM01Y37	MT	DTT
DM01Y37	MA	Inhibitor
DM01Y37	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DM01Y37	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DM01Y37	DI	DM01Y37
DM01Y37	DN	N-(6-Mercapto-hexyl)-benzamide
DM01Y37	MI	TTT6LFV
DM01Y37	MN	Histone deacetylase 8 (HDAC8)
DM01Y37	MT	DTT
DM01Y37	MA	Inhibitor
DM01Y37	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DM01Y37	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMQRE5D	DI	DMQRE5D
DMQRE5D	DN	N-(6-methylpyridin-2-yl)-5-phenylpicolinamide
DMQRE5D	MI	TTHS256
DMQRE5D	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMQRE5D	MT	DTT
DMQRE5D	MA	Inhibitor
DMQRE5D	RN	Design and synthesis of novel heterobiaryl amides as metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Apr 1;17(7):2074-9.
DMQRE5D	RU	https://pubmed.ncbi.nlm.nih.gov/17336520

DMQZMRG	DI	DMQZMRG
DMQZMRG	DN	N-(6-methylpyridin-2-yl)-6-phenylnicotinamide
DMQZMRG	MI	TTHS256
DMQZMRG	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMQZMRG	MT	DTT
DMQZMRG	MA	Inhibitor
DMQZMRG	RN	Structure-activity relationships comparing N-(6-methylpyridin-yl)-substituted aryl amides to 2-methyl-6-(substituted-arylethynyl)pyridines or 2-met... J Med Chem. 2009 Jun 11;52(11):3563-75.
DMQZMRG	RU	https://pubmed.ncbi.nlm.nih.gov/19445453

DMBNJ2L	DI	DMBNJ2L
DMBNJ2L	DN	N-(6-methylpyridin-2-yl)biphenyl-3-carboxamide
DMBNJ2L	MI	TTHS256
DMBNJ2L	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMBNJ2L	MT	DTT
DMBNJ2L	MA	Inhibitor
DMBNJ2L	RN	Structure-activity relationships comparing N-(6-methylpyridin-yl)-substituted aryl amides to 2-methyl-6-(substituted-arylethynyl)pyridines or 2-met... J Med Chem. 2009 Jun 11;52(11):3563-75.
DMBNJ2L	RU	https://pubmed.ncbi.nlm.nih.gov/19445453

DM9K4WP	DI	DM9K4WP
DM9K4WP	DN	N-(6-phenethyl-1H-indazol-3-yl)butyramide
DM9K4WP	MI	TTRSMW9
DM9K4WP	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DM9K4WP	MT	DTT
DM9K4WP	MA	Inhibitor
DM9K4WP	RN	Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9.
DM9K4WP	RU	https://pubmed.ncbi.nlm.nih.gov/20167481

DM2E5OX	DI	DM2E5OX
DM2E5OX	DN	N-(6-phenoxypyridin-3-yl)-1H-indole-3-carboxamide
DM2E5OX	MI	TTWJBZ5
DM2E5OX	MN	5-HT 2C receptor (HTR2C)
DM2E5OX	MT	DTT
DM2E5OX	MA	Inhibitor
DM2E5OX	RN	Synthesis and structure-activity relationship of 1H-indole-3-carboxylic acid pyridine-3-ylamides: a novel series of 5-HT2C receptor antagonists. Bioorg Med Chem Lett. 2008 Jul 15;18(14):3844-7.
DM2E5OX	RU	https://pubmed.ncbi.nlm.nih.gov/18602261

DMVCPLU	DI	DMVCPLU
DMVCPLU	DN	N-(6-phenyl-1H-indazol-3-yl)butyramide
DMVCPLU	MI	TTRSMW9
DMVCPLU	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMVCPLU	MT	DTT
DMVCPLU	MA	Inhibitor
DMVCPLU	RN	Design of potent and selective GSK3beta inhibitors with acceptable safety profile and pharmacokinetics. Bioorg Med Chem Lett. 2010 Apr 1;20(7):2344-9.
DMVCPLU	RU	https://pubmed.ncbi.nlm.nih.gov/20189807

DMO3Y0B	DI	DMO3Y0B
DMO3Y0B	DN	N-(7-(2-CHLOROPHENYL)-6-(4-CHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYACETAMIDE (ENANTIOMERIC MIX)
DMO3Y0B	MI	TT6OEDT
DMO3Y0B	MN	Cannabinoid receptor 1 (CB1)
DMO3Y0B	MT	DTT
DMO3Y0B	MA	Inhibitor
DMO3Y0B	RN	Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4.
DMO3Y0B	RU	https://pubmed.ncbi.nlm.nih.gov/20483606

DMO3Y0B	DI	DMO3Y0B
DMO3Y0B	DN	N-(7-(2-CHLOROPHENYL)-6-(4-CHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYACETAMIDE (ENANTIOMERIC MIX)
DMO3Y0B	MI	TTMSFAW
DMO3Y0B	MN	Cannabinoid receptor 2 (CB2)
DMO3Y0B	MT	DTT
DMO3Y0B	MA	Inhibitor
DMO3Y0B	RN	Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4.
DMO3Y0B	RU	https://pubmed.ncbi.nlm.nih.gov/20483606

DM5F27T	DI	DM5F27T
DM5F27T	DN	N-(7'-(2-CHLOROPHENYL)-6'-(4-CHLOROPHENYL)-3',4'-DIHYDROSPIRO[CYCLOHEXANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YL)-2-HYDROXY-2-METHYLPROPANAMIDE (ENANTIOMERIC MIX)
DM5F27T	MI	TT6OEDT
DM5F27T	MN	Cannabinoid receptor 1 (CB1)
DM5F27T	MT	DTT
DM5F27T	MA	Inhibitor
DM5F27T	RN	Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4.
DM5F27T	RU	https://pubmed.ncbi.nlm.nih.gov/20483606

DM5F27T	DI	DM5F27T
DM5F27T	DN	N-(7'-(2-CHLOROPHENYL)-6'-(4-CHLOROPHENYL)-3',4'-DIHYDROSPIRO[CYCLOHEXANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YL)-2-HYDROXY-2-METHYLPROPANAMIDE (ENANTIOMERIC MIX)
DM5F27T	MI	TTMSFAW
DM5F27T	MN	Cannabinoid receptor 2 (CB2)
DM5F27T	MT	DTT
DM5F27T	MA	Inhibitor
DM5F27T	RN	Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4.
DM5F27T	RU	https://pubmed.ncbi.nlm.nih.gov/20483606

DMPMBC2	DI	DMPMBC2
DMPMBC2	DN	N-(7-Benzyloxy-isoquinolin-1-yl)-guanidine
DMPMBC2	MI	TTXAGYU
DMPMBC2	MN	Tissue-type plasminogen activator (PLAT)
DMPMBC2	MT	DTT
DMPMBC2	MA	Inhibitor
DMPMBC2	RN	Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-isoquinolinylguanidines. Bioorg Med Chem Lett. 2004 Jun 21;14(12):3227-30.
DMPMBC2	RU	https://pubmed.ncbi.nlm.nih.gov/15149680

DMH42L8	DI	DMH42L8
DMH42L8	DN	N-(7-methoxy-4-phenylbenzofuran-2-yl)acetamide
DMH42L8	MI	TTM2AOE
DMH42L8	MN	Adenosine A2a receptor (ADORA2A)
DMH42L8	MT	DTT
DMH42L8	MA	Inhibitor
DMH42L8	RN	Synthetic studies on selective adenosine A2A receptor antagonists: synthesis and structure-activity relationships of novel benzofuran derivatives. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1090-3.
DMH42L8	RU	https://pubmed.ncbi.nlm.nih.gov/20034788

DMHFPE3	DI	DMHFPE3
DMHFPE3	DN	N-(8-(3-cyanophenyl)-9H-purin-6-yl)pentanamide
DMHFPE3	MI	TTRSMW9
DMHFPE3	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMHFPE3	MT	DTT
DMHFPE3	MA	Inhibitor
DMHFPE3	RN	Novel 8-arylated purines as inhibitors of glycogen synthase kinase. Eur J Med Chem. 2010 Aug;45(8):3389-93.
DMHFPE3	RU	https://pubmed.ncbi.nlm.nih.gov/20472330

DMBD52I	DI	DMBD52I
DMBD52I	DN	N-(9H-beta-Carbolin-3-yl)-acetamide
DMBD52I	MI	TT1MPAY
DMBD52I	MN	GABA(A) receptor alpha-1 (GABRA1)
DMBD52I	MT	DTT
DMBD52I	MA	Inhibitor
DMBD52I	RN	3-Amino-beta-carboline derivatives and the benzodiazepine receptor. Synthesis of a selective antagonist of the sedative action of diazepam. J Med Chem. 1985 Jun;28(6):824-8.
DMBD52I	RU	https://pubmed.ncbi.nlm.nih.gov/2989520

DMBD52I	DI	DMBD52I
DMBD52I	DN	N-(9H-beta-Carbolin-3-yl)-acetamide
DMBD52I	MI	TTNJYV2
DMBD52I	MN	Gamma-aminobutyric acid receptor (GAR)
DMBD52I	MT	DTT
DMBD52I	MA	Inhibitor
DMBD52I	RN	3-Amino-beta-carboline derivatives and the benzodiazepine receptor. Synthesis of a selective antagonist of the sedative action of diazepam. J Med Chem. 1985 Jun;28(6):824-8.
DMBD52I	RU	https://pubmed.ncbi.nlm.nih.gov/2989520

DM3KNSY	DI	DM3KNSY
DM3KNSY	DN	N-(9H-beta-Carbolin-3-yl)-formamide
DM3KNSY	MI	TT1MPAY
DM3KNSY	MN	GABA(A) receptor alpha-1 (GABRA1)
DM3KNSY	MT	DTT
DM3KNSY	MA	Inhibitor
DM3KNSY	RN	3-Amino-beta-carboline derivatives and the benzodiazepine receptor. Synthesis of a selective antagonist of the sedative action of diazepam. J Med Chem. 1985 Jun;28(6):824-8.
DM3KNSY	RU	https://pubmed.ncbi.nlm.nih.gov/2989520

DM3KNSY	DI	DM3KNSY
DM3KNSY	DN	N-(9H-beta-Carbolin-3-yl)-formamide
DM3KNSY	MI	TTNJYV2
DM3KNSY	MN	Gamma-aminobutyric acid receptor (GAR)
DM3KNSY	MT	DTT
DM3KNSY	MA	Inhibitor
DM3KNSY	RN	3-Amino-beta-carboline derivatives and the benzodiazepine receptor. Synthesis of a selective antagonist of the sedative action of diazepam. J Med Chem. 1985 Jun;28(6):824-8.
DM3KNSY	RU	https://pubmed.ncbi.nlm.nih.gov/2989520

DMFONC1	DI	DMFONC1
DMFONC1	DN	N-(Adamant-1-yl)-1'H-phenothiazine-1'-carboxamide
DMFONC1	MI	TTEB0GD
DMFONC1	MN	Cholinesterase (BCHE)
DMFONC1	MT	DTT
DMFONC1	MA	Inhibitor
DMFONC1	RN	Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorg Med Chem. 2010 Mar 15;18(6):2232-2244.
DMFONC1	RU	https://pubmed.ncbi.nlm.nih.gov/20181484

DM87YJW	DI	DM87YJW
DM87YJW	DN	N-(benzyl),N-(pyrrol-2-ylmethyl)amine
DM87YJW	MI	TT3WG5C
DM87YJW	MN	Monoamine oxidase type A (MAO-A)
DM87YJW	MT	DTT
DM87YJW	MA	Inhibitor
DM87YJW	RN	New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J Med Chem. 2007 Mar 8;50(5):922-31.
DM87YJW	RU	https://pubmed.ncbi.nlm.nih.gov/17256833

DM87YJW	DI	DM87YJW
DM87YJW	DN	N-(benzyl),N-(pyrrol-2-ylmethyl)amine
DM87YJW	MI	TTGP7BY
DM87YJW	MN	Monoamine oxidase type B (MAO-B)
DM87YJW	MT	DTT
DM87YJW	MA	Inhibitor
DM87YJW	RN	New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J Med Chem. 2007 Mar 8;50(5):922-31.
DM87YJW	RU	https://pubmed.ncbi.nlm.nih.gov/17256833

DMR18YI	DI	DMR18YI
DMR18YI	DN	N-(benzyloxycarbonyl)-leucyl-glycine-nitrile
DMR18YI	MI	TTDZN01
DMR18YI	MN	Cathepsin K (CTSK)
DMR18YI	MT	DTT
DMR18YI	MA	Inhibitor
DMR18YI	RN	Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707.
DMR18YI	RU	https://pubmed.ncbi.nlm.nih.gov/16302809

DMR18YI	DI	DMR18YI
DMR18YI	DN	N-(benzyloxycarbonyl)-leucyl-glycine-nitrile
DMR18YI	MI	TT36ETB
DMR18YI	MN	Cathepsin L (CTSL)
DMR18YI	MT	DTT
DMR18YI	MA	Inhibitor
DMR18YI	RN	Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707.
DMR18YI	RU	https://pubmed.ncbi.nlm.nih.gov/16302809

DMR18YI	DI	DMR18YI
DMR18YI	DN	N-(benzyloxycarbonyl)-leucyl-glycine-nitrile
DMR18YI	MI	TTUMQVO
DMR18YI	MN	Cathepsin S (CTSS)
DMR18YI	MT	DTT
DMR18YI	MA	Inhibitor
DMR18YI	RN	Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707.
DMR18YI	RU	https://pubmed.ncbi.nlm.nih.gov/16302809

DMRCYB8	DI	DMRCYB8
DMRCYB8	DN	N-(biphenyl-3-yl)-6-(sulfamoylamino)hexanamide
DMRCYB8	MI	TT5ZKDI
DMRCYB8	MN	Histone deacetylase 6 (HDAC6)
DMRCYB8	MT	DTT
DMRCYB8	MA	Inhibitor
DMRCYB8	RN	Sulfamides as novel histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):336-40.
DMRCYB8	RU	https://pubmed.ncbi.nlm.nih.gov/19084395

DM2ZQBS	DI	DM2ZQBS
DM2ZQBS	DN	N-(biphenyl-3-yl)benzo[d]isoxazol-3-amine
DM2ZQBS	MI	TT7WVHI
DM2ZQBS	MN	Soluble epoxide hydrolase (EPHX2)
DM2ZQBS	MT	DTT
DM2ZQBS	MA	Inhibitor
DM2ZQBS	RN	A strategy of employing aminoheterocycles as amide mimics to identify novel, potent and bioavailable soluble epoxide hydrolase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5716-21.
DM2ZQBS	RU	https://pubmed.ncbi.nlm.nih.gov/19700315

DMSO7FW	DI	DMSO7FW
DMSO7FW	DN	N-(Biphenyl-4-yl)-2-cyano-3-hydroxybut-2-enamide
DMSO7FW	MI	TT3PQ2Y
DMSO7FW	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DMSO7FW	MT	DTT
DMSO7FW	MA	Inhibitor
DMSO7FW	RN	Structure-based design, synthesis, and characterization of inhibitors of human and Plasmodium falciparum dihydroorotate dehydrogenases. J Med Chem. 2009 May 14;52(9):2683-93.
DMSO7FW	RU	https://pubmed.ncbi.nlm.nih.gov/19351152

DML10NT	DI	DML10NT
DML10NT	DN	N-(biphenyl-4-yl)benzo[d]isoxazol-3-amine
DML10NT	MI	TT7WVHI
DML10NT	MN	Soluble epoxide hydrolase (EPHX2)
DML10NT	MT	DTT
DML10NT	MA	Inhibitor
DML10NT	RN	A strategy of employing aminoheterocycles as amide mimics to identify novel, potent and bioavailable soluble epoxide hydrolase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5716-21.
DML10NT	RU	https://pubmed.ncbi.nlm.nih.gov/19700315

DMHPITZ	DI	DMHPITZ
DMHPITZ	DN	N-(biphenyl-4-ylsulfonyl)-D-leucine
DMHPITZ	MI	TTXZ0KQ
DMHPITZ	MN	Matrix metalloproteinase-12 (MMP-12)
DMHPITZ	MT	DTT
DMHPITZ	MA	Inhibitor
DMHPITZ	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMHPITZ	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMFGSLO	DI	DMFGSLO
DMFGSLO	DN	N-(Chlorophenyl)-N'-Hydroxyguanidine
DMFGSLO	MI	TTCM4B3
DMFGSLO	MN	Nitric-oxide synthase endothelial (NOS3)
DMFGSLO	MT	DTT
DMFGSLO	MA	Inhibitor
DMFGSLO	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMFGSLO	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM1TA5R	DI	DM1TA5R
DM1TA5R	DN	N-(cis-9-cis-12-octadecadienyl)sulfamide
DM1TA5R	MI	TT6OEDT
DM1TA5R	MN	Cannabinoid receptor 1 (CB1)
DM1TA5R	MT	DTT
DM1TA5R	MA	Inhibitor
DM1TA5R	RN	Synthesis and pharmacological evaluation of sulfamide-based analogues of anandamide. Eur J Med Chem. 2009 Dec;44(12):4889-95.
DM1TA5R	RU	https://pubmed.ncbi.nlm.nih.gov/19762126

DMTKREZ	DI	DMTKREZ
DMTKREZ	DN	N-(cyanomethyl)cyclohex-1-ene-1-carboxamide
DMTKREZ	MI	TTDZN01
DMTKREZ	MN	Cathepsin K (CTSK)
DMTKREZ	MT	DTT
DMTKREZ	MA	Inhibitor
DMTKREZ	RN	Beta-substituted cyclohexanecarboxamide: a nonpeptidic framework for the design of potent inhibitors of cathepsin K. J Med Chem. 2006 Feb 9;49(3):1066-79.
DMTKREZ	RU	https://pubmed.ncbi.nlm.nih.gov/16451072

DMI245K	DI	DMI245K
DMI245K	DN	N-(dibenzo[b,d]thiophen-3-ylsulfonyl)-L-valine
DMI245K	MI	TTXZ0KQ
DMI245K	MN	Matrix metalloproteinase-12 (MMP-12)
DMI245K	MT	DTT
DMI245K	MA	Inhibitor
DMI245K	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMI245K	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMJ6U4H	DI	DMJ6U4H
DMJ6U4H	DN	N-(Ethylphosphoryl)-L-isoleucyl-L-Trp-NHCH3
DMJ6U4H	MI	TTMX39J
DMJ6U4H	MN	Matrix metalloproteinase-1 (MMP-1)
DMJ6U4H	MT	DTT
DMJ6U4H	MA	Inhibitor
DMJ6U4H	RN	Phosphoramidate peptide inhibitors of human skin fibroblast collagenase. J Med Chem. 1990 Jan;33(1):263-73.
DMJ6U4H	RU	https://pubmed.ncbi.nlm.nih.gov/2153207

DMLJZGD	DI	DMLJZGD
DMLJZGD	DN	N-(furan-2-ylmethyl)estradiol-16-carboxamide
DMLJZGD	MI	TTIWB6L
DMLJZGD	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMLJZGD	MT	DTT
DMLJZGD	MA	Inhibitor
DMLJZGD	RN	Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45.
DMLJZGD	RU	https://pubmed.ncbi.nlm.nih.gov/16480268

DM0DZ9J	DI	DM0DZ9J
DM0DZ9J	DN	N-(furan-2-ylmethyl)-estrone-16-methyl carboxamide
DM0DZ9J	MI	TTIWB6L
DM0DZ9J	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DM0DZ9J	MT	DTT
DM0DZ9J	MA	Inhibitor
DM0DZ9J	RN	Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45.
DM0DZ9J	RU	https://pubmed.ncbi.nlm.nih.gov/16480268

DMW378C	DI	DMW378C
DMW378C	DN	N-(naphthalen-1-yl)-4-neopentylthiazol-2-amine
DMW378C	MI	TT7HQD0
DMW378C	MN	C-C chemokine receptor type 4 (CCR4)
DMW378C	MT	DTT
DMW378C	MA	Inhibitor
DMW378C	RN	Optimization of 2-aminothiazole derivatives as CCR4 antagonists. Bioorg Med Chem Lett. 2006 May 15;16(10):2800-3.
DMW378C	RU	https://pubmed.ncbi.nlm.nih.gov/16497499

DMFZPCD	DI	DMFZPCD
DMFZPCD	DN	N-(naphthalen-1-yl)-4-phenylthiazol-2-amine
DMFZPCD	MI	TT7HQD0
DMFZPCD	MN	C-C chemokine receptor type 4 (CCR4)
DMFZPCD	MT	DTT
DMFZPCD	MA	Inhibitor
DMFZPCD	RN	Optimization of 2-aminothiazole derivatives as CCR4 antagonists. Bioorg Med Chem Lett. 2006 May 15;16(10):2800-3.
DMFZPCD	RU	https://pubmed.ncbi.nlm.nih.gov/16497499

DM2CBNG	DI	DM2CBNG
DM2CBNG	DN	N-(naphthalen-1-yl)benzo[d]isoxazol-3-amine
DM2CBNG	MI	TT7WVHI
DM2CBNG	MN	Soluble epoxide hydrolase (EPHX2)
DM2CBNG	MT	DTT
DM2CBNG	MA	Inhibitor
DM2CBNG	RN	A strategy of employing aminoheterocycles as amide mimics to identify novel, potent and bioavailable soluble epoxide hydrolase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5716-21.
DM2CBNG	RU	https://pubmed.ncbi.nlm.nih.gov/19700315

DM2NHVX	DI	DM2NHVX
DM2NHVX	DN	N-(naphthalen-2-yl)benzo[d]isoxazol-3-amine
DM2NHVX	MI	TT7WVHI
DM2NHVX	MN	Soluble epoxide hydrolase (EPHX2)
DM2NHVX	MT	DTT
DM2NHVX	MA	Inhibitor
DM2NHVX	RN	A strategy of employing aminoheterocycles as amide mimics to identify novel, potent and bioavailable soluble epoxide hydrolase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5716-21.
DM2NHVX	RU	https://pubmed.ncbi.nlm.nih.gov/19700315

DMG8KXR	DI	DMG8KXR
DMG8KXR	DN	N-(Naphthalene-2-yl)ethyl-ETAV
DMG8KXR	MI	TT9PB26
DMG8KXR	MN	Presynaptic density protein 95 (DLG4)
DMG8KXR	MT	DTT
DMG8KXR	MA	Inhibitor
DMG8KXR	RN	Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem. 2008 Oct 23;51(20):6450-9.
DMG8KXR	RU	https://pubmed.ncbi.nlm.nih.gov/18811137

DME45J8	DI	DME45J8
DME45J8	DN	N-(pentafluorophenyl)sulfamide
DME45J8	MI	TTHQPL7
DME45J8	MN	Carbonic anhydrase I (CA-I)
DME45J8	MT	DTT
DME45J8	MA	Inhibitor
DME45J8	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with N-hydroxy... Bioorg Med Chem Lett. 2005 May 2;15(9):2353-8.
DME45J8	RU	https://pubmed.ncbi.nlm.nih.gov/15837324

DME45J8	DI	DME45J8
DME45J8	DN	N-(pentafluorophenyl)sulfamide
DME45J8	MI	TTANPDJ
DME45J8	MN	Carbonic anhydrase II (CA-II)
DME45J8	MT	DTT
DME45J8	MA	Inhibitor
DME45J8	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with N-hydroxy... Bioorg Med Chem Lett. 2005 May 2;15(9):2353-8.
DME45J8	RU	https://pubmed.ncbi.nlm.nih.gov/15837324

DME45J8	DI	DME45J8
DME45J8	DN	N-(pentafluorophenyl)sulfamide
DME45J8	MI	TT2LVK8
DME45J8	MN	Carbonic anhydrase IX (CA-IX)
DME45J8	MT	DTT
DME45J8	MA	Inhibitor
DME45J8	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with N-hydroxy... Bioorg Med Chem Lett. 2005 May 2;15(9):2353-8.
DME45J8	RU	https://pubmed.ncbi.nlm.nih.gov/15837324

DME45J8	DI	DME45J8
DME45J8	DN	N-(pentafluorophenyl)sulfamide
DME45J8	MI	TTSYM0R
DME45J8	MN	Carbonic anhydrase XII (CA-XII)
DME45J8	MT	DTT
DME45J8	MA	Inhibitor
DME45J8	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with N-hydroxy... Bioorg Med Chem Lett. 2005 May 2;15(9):2353-8.
DME45J8	RU	https://pubmed.ncbi.nlm.nih.gov/15837324

DMJO3B1	DI	DMJO3B1
DMJO3B1	DN	N'-(phenylsulfonyl)benzofuran-2-carbohydrazide
DMJO3B1	MI	TTF9OQ6
DMJO3B1	MN	Branched-chain-amino-acid transaminase 2 (BCAT2)
DMJO3B1	MT	DTT
DMJO3B1	MA	Inhibitor
DMJO3B1	RN	The design and synthesis of human branched-chain amino acid aminotransferase inhibitors for treatment of neurodegenerative diseases. Bioorg Med Chem Lett. 2006 May 1;16(9):2337-40.
DMJO3B1	RU	https://pubmed.ncbi.nlm.nih.gov/16143519

DMQETUY	DI	DMQETUY
DMQETUY	DN	N'-(phenylsulfonyl)quinoline-6-carbohydrazide
DMQETUY	MI	TTF9OQ6
DMQETUY	MN	Branched-chain-amino-acid transaminase 2 (BCAT2)
DMQETUY	MT	DTT
DMQETUY	MA	Inhibitor
DMQETUY	RN	The design and synthesis of human branched-chain amino acid aminotransferase inhibitors for treatment of neurodegenerative diseases. Bioorg Med Chem Lett. 2006 May 1;16(9):2337-40.
DMQETUY	RU	https://pubmed.ncbi.nlm.nih.gov/16143519

DMGHQJ8	DI	DMGHQJ8
DMGHQJ8	DN	N-(phosphonacetyl)-L-aspartate
DMGHQJ8	MI	TT2YT1K
DMGHQJ8	MN	Aspartate carbamoyltransferase (CAD)
DMGHQJ8	MT	DTT
DMGHQJ8	MA	Inhibitor
DMGHQJ8	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMGHQJ8	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMGHQJ8	DI	DMGHQJ8
DMGHQJ8	DN	N-(phosphonacetyl)-L-aspartate
DMGHQJ8	MI	TTANPDJ
DMGHQJ8	MN	Carbonic anhydrase II (CA-II)
DMGHQJ8	MT	DTT
DMGHQJ8	MA	Inhibitor
DMGHQJ8	RN	Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with organic phosphates and phosphonates. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1683-6.
DMGHQJ8	RU	https://pubmed.ncbi.nlm.nih.gov/15745821

DMGHQJ8	DI	DMGHQJ8
DMGHQJ8	DN	N-(phosphonacetyl)-L-aspartate
DMGHQJ8	MI	TTZHA0O
DMGHQJ8	MN	Carbonic anhydrase IV (CA-IV)
DMGHQJ8	MT	DTT
DMGHQJ8	MA	Inhibitor
DMGHQJ8	RN	Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with organic phosphates and phosphonates. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1683-6.
DMGHQJ8	RU	https://pubmed.ncbi.nlm.nih.gov/15745821

DMGHQJ8	DI	DMGHQJ8
DMGHQJ8	DN	N-(phosphonacetyl)-L-aspartate
DMGHQJ8	MI	TTDRBPW
DMGHQJ8	MN	Pseudomonas Aspartate carbamoyltransferase (Pseudo pyrB)
DMGHQJ8	MT	DTT
DMGHQJ8	MA	Inhibitor
DMGHQJ8	RN	Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid. Cancer Res. 1981 Mar;41(3):894-904.
DMGHQJ8	RU	https://pubmed.ncbi.nlm.nih.gov/7459875

DM9QIH4	DI	DM9QIH4
DM9QIH4	DN	N-(piperidin-4-yl)-N-propyl-2-naphthamide
DM9QIH4	MI	TT3ROYC
DM9QIH4	MN	Serotonin transporter (SERT)
DM9QIH4	MT	DTT
DM9QIH4	MA	Inhibitor
DM9QIH4	RN	Bioorg Med Chem Lett. 2009 Oct 15;19(20):5893-7. Epub 2009 Aug 21.Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.
DM9QIH4	RU	https://pubmed.ncbi.nlm.nih.gov/19740658

DM9QIH4	DI	DM9QIH4
DM9QIH4	DN	N-(piperidin-4-yl)-N-propyl-2-naphthamide
DM9QIH4	MI	TTQ6VDM
DM9QIH4	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DM9QIH4	MT	DTT
DM9QIH4	MA	Inhibitor
DM9QIH4	RN	Bioorg Med Chem Lett. 2009 Oct 15;19(20):5893-7. Epub 2009 Aug 21.Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.
DM9QIH4	RU	https://pubmed.ncbi.nlm.nih.gov/19740658

DMULBO9	DI	DMULBO9
DMULBO9	DN	N-(p-methylbenzyl)-5-nitroindol-3-ylglyoxylamide
DMULBO9	MI	TT1MPAY
DMULBO9	MN	GABA(A) receptor alpha-1 (GABRA1)
DMULBO9	MT	DTT
DMULBO9	MA	Inhibitor
DMULBO9	RN	Novel N-substituted indol-3-ylglyoxylamides probing the LDi and L1/L2 lipophilic regions of the benzodiazepine receptor site in search for subtype-... J Med Chem. 2007 Apr 5;50(7):1627-34.
DMULBO9	RU	https://pubmed.ncbi.nlm.nih.gov/17335185

DMULBO9	DI	DMULBO9
DMULBO9	DN	N-(p-methylbenzyl)-5-nitroindol-3-ylglyoxylamide
DMULBO9	MI	TTZA1NY
DMULBO9	MN	GABA(A) receptor beta-2 (GABRB2)
DMULBO9	MT	DTT
DMULBO9	MA	Inhibitor
DMULBO9	RN	Novel N-substituted indol-3-ylglyoxylamides probing the LDi and L1/L2 lipophilic regions of the benzodiazepine receptor site in search for subtype-... J Med Chem. 2007 Apr 5;50(7):1627-34.
DMULBO9	RU	https://pubmed.ncbi.nlm.nih.gov/17335185

DMULBO9	DI	DMULBO9
DMULBO9	DN	N-(p-methylbenzyl)-5-nitroindol-3-ylglyoxylamide
DMULBO9	MI	TT06RH5
DMULBO9	MN	GABA(A) receptor gamma-2 (GABRG2)
DMULBO9	MT	DTT
DMULBO9	MA	Inhibitor
DMULBO9	RN	Novel N-substituted indol-3-ylglyoxylamides probing the LDi and L1/L2 lipophilic regions of the benzodiazepine receptor site in search for subtype-... J Med Chem. 2007 Apr 5;50(7):1627-34.
DMULBO9	RU	https://pubmed.ncbi.nlm.nih.gov/17335185

DMTJ5WL	DI	DMTJ5WL
DMTJ5WL	DN	N-(propargyl),N-(pyrrol-2-ylmethyl)amine
DMTJ5WL	MI	TT3WG5C
DMTJ5WL	MN	Monoamine oxidase type A (MAO-A)
DMTJ5WL	MT	DTT
DMTJ5WL	MA	Inhibitor
DMTJ5WL	RN	New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J Med Chem. 2007 Mar 8;50(5):922-31.
DMTJ5WL	RU	https://pubmed.ncbi.nlm.nih.gov/17256833

DMTJ5WL	DI	DMTJ5WL
DMTJ5WL	DN	N-(propargyl),N-(pyrrol-2-ylmethyl)amine
DMTJ5WL	MI	TTGP7BY
DMTJ5WL	MN	Monoamine oxidase type B (MAO-B)
DMTJ5WL	MT	DTT
DMTJ5WL	MA	Inhibitor
DMTJ5WL	RN	New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J Med Chem. 2007 Mar 8;50(5):922-31.
DMTJ5WL	RU	https://pubmed.ncbi.nlm.nih.gov/17256833

DMXI4V8	DI	DMXI4V8
DMXI4V8	DN	N-(Propylamide-acetophenone)-1-deoxynojirimycin
DMXI4V8	MI	TT1B5PU
DMXI4V8	MN	Glucosylceramidase (GBA)
DMXI4V8	MT	DTT
DMXI4V8	MA	Inhibitor
DMXI4V8	RN	Nanomolar affinity, iminosugar-based chemical probes for specific labeling of lysosomal glucocerebrosidase. Bioorg Med Chem. 2010 Jan 1;18(1):267-73.
DMXI4V8	RU	https://pubmed.ncbi.nlm.nih.gov/19931460

DMCZHBI	DI	DMCZHBI
DMCZHBI	DN	N-(Propylamide-benzophenone)-1-deoxynojirimycin
DMCZHBI	MI	TT1B5PU
DMCZHBI	MN	Glucosylceramidase (GBA)
DMCZHBI	MT	DTT
DMCZHBI	MA	Inhibitor
DMCZHBI	RN	Nanomolar affinity, iminosugar-based chemical probes for specific labeling of lysosomal glucocerebrosidase. Bioorg Med Chem. 2010 Jan 1;18(1):267-73.
DMCZHBI	RU	https://pubmed.ncbi.nlm.nih.gov/19931460

DMTHJL4	DI	DMTHJL4
DMTHJL4	DN	N-(pyridin-3-yl)indoline-1-carboxamide
DMTHJL4	MI	TTWJBZ5
DMTHJL4	MN	5-HT 2C receptor (HTR2C)
DMTHJL4	MT	DTT
DMTHJL4	MA	Inhibitor
DMTHJL4	RN	Synthesis and structure-affinity relationships of novel small molecule natural product derivatives capable of discriminating between serotonin 5-HT1A, 5-HT2A, 5-HT2C receptor subtypes. Bioorg Med Chem. 2010 Jul 1;18(13):4783-92. 
DMTHJL4	RU	https://pubmed.ncbi.nlm.nih.gov/20570529

DMBJKH1	DI	DMBJKH1
DMBJKH1	DN	N-(pyridin-3-ylmethyl) estradiol-16-carboxamide
DMBJKH1	MI	TTIWB6L
DMBJKH1	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMBJKH1	MT	DTT
DMBJKH1	MA	Inhibitor
DMBJKH1	RN	Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45.
DMBJKH1	RU	https://pubmed.ncbi.nlm.nih.gov/16480268

DMIN60B	DI	DMIN60B
DMIN60B	DN	N-(pyridin-3-ylmethyl)aniline
DMIN60B	MI	TTXZEAJ
DMIN60B	MN	Leukotriene A-4 hydrolase (LTA4H)
DMIN60B	MT	DTT
DMIN60B	MA	Inhibitor
DMIN60B	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMIN60B	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMYFAQV	DI	DMYFAQV
DMYFAQV	DN	N-(pyridin-4-ylmethyl) estradiol-16-carboxamide
DMYFAQV	MI	TTIWB6L
DMYFAQV	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMYFAQV	MT	DTT
DMYFAQV	MA	Inhibitor
DMYFAQV	RN	Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45.
DMYFAQV	RU	https://pubmed.ncbi.nlm.nih.gov/16480268

DMYEQXH	DI	DMYEQXH
DMYEQXH	DN	N-(quinolin-3-yl)-6-(sulfamoylamino)hexanamide
DMYEQXH	MI	TT5ZKDI
DMYEQXH	MN	Histone deacetylase 6 (HDAC6)
DMYEQXH	MT	DTT
DMYEQXH	MA	Inhibitor
DMYEQXH	RN	Sulfamides as novel histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):336-40.
DMYEQXH	RU	https://pubmed.ncbi.nlm.nih.gov/19084395

DMFC3XI	DI	DMFC3XI
DMFC3XI	DN	N-(quinolin-6-yl)-6-(sulfamoylamino)hexanamide
DMFC3XI	MI	TT5ZKDI
DMFC3XI	MN	Histone deacetylase 6 (HDAC6)
DMFC3XI	MT	DTT
DMFC3XI	MA	Inhibitor
DMFC3XI	RN	Sulfamides as novel histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):336-40.
DMFC3XI	RU	https://pubmed.ncbi.nlm.nih.gov/19084395

DML8EVA	DI	DML8EVA
DML8EVA	DN	N-(quinolin-8-yl)-6-(sulfamoylamino)hexanamide
DML8EVA	MI	TT5ZKDI
DML8EVA	MN	Histone deacetylase 6 (HDAC6)
DML8EVA	MT	DTT
DML8EVA	MA	Inhibitor
DML8EVA	RN	Sulfamides as novel histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):336-40.
DML8EVA	RU	https://pubmed.ncbi.nlm.nih.gov/19084395

DM7O1F3	DI	DM7O1F3
DM7O1F3	DN	N-(quinolin-8-yl)thiophene-2-sulfonamide
DM7O1F3	MI	TTSXVID
DM7O1F3	MN	Nuclear factor NF-kappa-B (NFKB)
DM7O1F3	MT	DTT
DM7O1F3	MA	Inhibitor
DM7O1F3	RN	Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFkappaB activity within two separate high-throughput s... Bioorg Med Chem Lett. 2008 Jan 1;18(1):329-35.
DM7O1F3	RU	https://pubmed.ncbi.nlm.nih.gov/18024113

DM2SNXB	DI	DM2SNXB
DM2SNXB	DN	N-(R-Carboxy-Ethyl)-Alpha-(S)-(2-Phenylethyl)
DM2SNXB	MI	TTXMNHO
DM2SNXB	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DM2SNXB	MT	DTT
DM2SNXB	MA	Inhibitor
DM2SNXB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM2SNXB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMWJDYZ	DI	DMWJDYZ
DMWJDYZ	DN	N-(Sulfanylacetyl)Tyrosylprolylmethioninamide
DMWJDYZ	MI	TTIQSC1
DMWJDYZ	MN	Bacterial Lethal factor (Bact lef)
DMWJDYZ	MT	DTT
DMWJDYZ	MA	Inhibitor
DMWJDYZ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMWJDYZ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMJ0S5C	DI	DMJ0S5C
DMJ0S5C	DN	N-(tert-butoxycarbonyl)-isoleucyl-glycine-nitrile
DMJ0S5C	MI	TTDZN01
DMJ0S5C	MN	Cathepsin K (CTSK)
DMJ0S5C	MT	DTT
DMJ0S5C	MA	Inhibitor
DMJ0S5C	RN	Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707.
DMJ0S5C	RU	https://pubmed.ncbi.nlm.nih.gov/16302809

DMJ0S5C	DI	DMJ0S5C
DMJ0S5C	DN	N-(tert-butoxycarbonyl)-isoleucyl-glycine-nitrile
DMJ0S5C	MI	TT36ETB
DMJ0S5C	MN	Cathepsin L (CTSL)
DMJ0S5C	MT	DTT
DMJ0S5C	MA	Inhibitor
DMJ0S5C	RN	Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707.
DMJ0S5C	RU	https://pubmed.ncbi.nlm.nih.gov/16302809

DMJ0S5C	DI	DMJ0S5C
DMJ0S5C	DN	N-(tert-butoxycarbonyl)-isoleucyl-glycine-nitrile
DMJ0S5C	MI	TTUMQVO
DMJ0S5C	MN	Cathepsin S (CTSS)
DMJ0S5C	MT	DTT
DMJ0S5C	MA	Inhibitor
DMJ0S5C	RN	Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707.
DMJ0S5C	RU	https://pubmed.ncbi.nlm.nih.gov/16302809

DMXYQWG	DI	DMXYQWG
DMXYQWG	DN	N-(tert-butoxycarbonyl)-leucyl-glycine-nitrile
DMXYQWG	MI	TTDZN01
DMXYQWG	MN	Cathepsin K (CTSK)
DMXYQWG	MT	DTT
DMXYQWG	MA	Inhibitor
DMXYQWG	RN	Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707.
DMXYQWG	RU	https://pubmed.ncbi.nlm.nih.gov/16302809

DMXYQWG	DI	DMXYQWG
DMXYQWG	DN	N-(tert-butoxycarbonyl)-leucyl-glycine-nitrile
DMXYQWG	MI	TT36ETB
DMXYQWG	MN	Cathepsin L (CTSL)
DMXYQWG	MT	DTT
DMXYQWG	MA	Inhibitor
DMXYQWG	RN	Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707.
DMXYQWG	RU	https://pubmed.ncbi.nlm.nih.gov/16302809

DMXYQWG	DI	DMXYQWG
DMXYQWG	DN	N-(tert-butoxycarbonyl)-leucyl-glycine-nitrile
DMXYQWG	MI	TTUMQVO
DMXYQWG	MN	Cathepsin S (CTSS)
DMXYQWG	MT	DTT
DMXYQWG	MA	Inhibitor
DMXYQWG	RN	Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707.
DMXYQWG	RU	https://pubmed.ncbi.nlm.nih.gov/16302809

DM3I0WZ	DI	DM3I0WZ
DM3I0WZ	DN	N-(tert-butoxycarbonyl)-methionyl-glycine-nitrile
DM3I0WZ	MI	TTDZN01
DM3I0WZ	MN	Cathepsin K (CTSK)
DM3I0WZ	MT	DTT
DM3I0WZ	MA	Inhibitor
DM3I0WZ	RN	Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707.
DM3I0WZ	RU	https://pubmed.ncbi.nlm.nih.gov/16302809

DM3I0WZ	DI	DM3I0WZ
DM3I0WZ	DN	N-(tert-butoxycarbonyl)-methionyl-glycine-nitrile
DM3I0WZ	MI	TT36ETB
DM3I0WZ	MN	Cathepsin L (CTSL)
DM3I0WZ	MT	DTT
DM3I0WZ	MA	Inhibitor
DM3I0WZ	RN	Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707.
DM3I0WZ	RU	https://pubmed.ncbi.nlm.nih.gov/16302809

DM3I0WZ	DI	DM3I0WZ
DM3I0WZ	DN	N-(tert-butoxycarbonyl)-methionyl-glycine-nitrile
DM3I0WZ	MI	TTUMQVO
DM3I0WZ	MN	Cathepsin S (CTSS)
DM3I0WZ	MT	DTT
DM3I0WZ	MA	Inhibitor
DM3I0WZ	RN	Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707.
DM3I0WZ	RU	https://pubmed.ncbi.nlm.nih.gov/16302809

DMGF4XC	DI	DMGF4XC
DMGF4XC	DN	N-(tert-butoxycarbonyl)-norleucyl-glycine-nitrile
DMGF4XC	MI	TTDZN01
DMGF4XC	MN	Cathepsin K (CTSK)
DMGF4XC	MT	DTT
DMGF4XC	MA	Inhibitor
DMGF4XC	RN	Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707.
DMGF4XC	RU	https://pubmed.ncbi.nlm.nih.gov/16302809

DMGF4XC	DI	DMGF4XC
DMGF4XC	DN	N-(tert-butoxycarbonyl)-norleucyl-glycine-nitrile
DMGF4XC	MI	TT36ETB
DMGF4XC	MN	Cathepsin L (CTSL)
DMGF4XC	MT	DTT
DMGF4XC	MA	Inhibitor
DMGF4XC	RN	Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707.
DMGF4XC	RU	https://pubmed.ncbi.nlm.nih.gov/16302809

DMGF4XC	DI	DMGF4XC
DMGF4XC	DN	N-(tert-butoxycarbonyl)-norleucyl-glycine-nitrile
DMGF4XC	MI	TTUMQVO
DMGF4XC	MN	Cathepsin S (CTSS)
DMGF4XC	MT	DTT
DMGF4XC	MA	Inhibitor
DMGF4XC	RN	Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707.
DMGF4XC	RU	https://pubmed.ncbi.nlm.nih.gov/16302809

DMOP5N7	DI	DMOP5N7
DMOP5N7	DN	N-(tert-butoxycarbonyl)-norvalyl-glycine-nitrile
DMOP5N7	MI	TTDZN01
DMOP5N7	MN	Cathepsin K (CTSK)
DMOP5N7	MT	DTT
DMOP5N7	MA	Inhibitor
DMOP5N7	RN	Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707.
DMOP5N7	RU	https://pubmed.ncbi.nlm.nih.gov/16302809

DMOP5N7	DI	DMOP5N7
DMOP5N7	DN	N-(tert-butoxycarbonyl)-norvalyl-glycine-nitrile
DMOP5N7	MI	TTUMQVO
DMOP5N7	MN	Cathepsin S (CTSS)
DMOP5N7	MT	DTT
DMOP5N7	MA	Inhibitor
DMOP5N7	RN	Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707.
DMOP5N7	RU	https://pubmed.ncbi.nlm.nih.gov/16302809

DMP9JVT	DI	DMP9JVT
DMP9JVT	DN	N-(tert-butoxycarbonyl)-tyrosyl-glycine-nitrile
DMP9JVT	MI	TT36ETB
DMP9JVT	MN	Cathepsin L (CTSL)
DMP9JVT	MT	DTT
DMP9JVT	MA	Inhibitor
DMP9JVT	RN	Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707.
DMP9JVT	RU	https://pubmed.ncbi.nlm.nih.gov/16302809

DMP9JVT	DI	DMP9JVT
DMP9JVT	DN	N-(tert-butoxycarbonyl)-tyrosyl-glycine-nitrile
DMP9JVT	MI	TTUMQVO
DMP9JVT	MN	Cathepsin S (CTSS)
DMP9JVT	MT	DTT
DMP9JVT	MA	Inhibitor
DMP9JVT	RN	Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707.
DMP9JVT	RU	https://pubmed.ncbi.nlm.nih.gov/16302809

DMUQBOP	DI	DMUQBOP
DMUQBOP	DN	N-(tert-butoxycarbonyl)-valyl-glycine-nitrile
DMUQBOP	MI	TTDZN01
DMUQBOP	MN	Cathepsin K (CTSK)
DMUQBOP	MT	DTT
DMUQBOP	MA	Inhibitor
DMUQBOP	RN	Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707.
DMUQBOP	RU	https://pubmed.ncbi.nlm.nih.gov/16302809

DMUQBOP	DI	DMUQBOP
DMUQBOP	DN	N-(tert-butoxycarbonyl)-valyl-glycine-nitrile
DMUQBOP	MI	TT36ETB
DMUQBOP	MN	Cathepsin L (CTSL)
DMUQBOP	MT	DTT
DMUQBOP	MA	Inhibitor
DMUQBOP	RN	Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707.
DMUQBOP	RU	https://pubmed.ncbi.nlm.nih.gov/16302809

DMUQBOP	DI	DMUQBOP
DMUQBOP	DN	N-(tert-butoxycarbonyl)-valyl-glycine-nitrile
DMUQBOP	MI	TTUMQVO
DMUQBOP	MN	Cathepsin S (CTSS)
DMUQBOP	MT	DTT
DMUQBOP	MA	Inhibitor
DMUQBOP	RN	Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707.
DMUQBOP	RU	https://pubmed.ncbi.nlm.nih.gov/16302809

DM1N7AG	DI	DM1N7AG
DM1N7AG	DN	N-(thiazol-2-yl)benzamide
DM1N7AG	MI	TTSJ6Q4
DM1N7AG	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DM1N7AG	MT	DTT
DM1N7AG	MA	Inhibitor
DM1N7AG	RN	Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. J Med Chem. 2007 May 31;50(11):2640-6.
DM1N7AG	RU	https://pubmed.ncbi.nlm.nih.gov/17461565

DM8JQEO	DI	DM8JQEO
DM8JQEO	DN	N*1*-(5-Methyl-2-nitro-phenyl)-butane-1,4-diamine
DM8JQEO	MI	TTZUFI5
DM8JQEO	MN	Nitric-oxide synthase brain (NOS1)
DM8JQEO	MT	DTT
DM8JQEO	MA	Inhibitor
DM8JQEO	RN	Nitroaromatic amino acids as inhibitors of neuronal nitric oxide synthase. J Med Chem. 1998 Jul 2;41(14):2636-42.
DM8JQEO	RU	https://pubmed.ncbi.nlm.nih.gov/9651169

DME8KXT	DI	DME8KXT
DME8KXT	DN	N*1*-(6-Nitro-quinolin-2-yl)-ethane-1,2-diamine
DME8KXT	MI	TT3ROYC
DME8KXT	MN	Serotonin transporter (SERT)
DME8KXT	MT	DTT
DME8KXT	MA	Inhibitor
DME8KXT	RN	Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 1. Bioorg Med Chem Lett. 2000 Jul 17;10(14):1559-62.
DME8KXT	RU	https://pubmed.ncbi.nlm.nih.gov/10915050

DM41TQB	DI	DM41TQB
DM41TQB	DN	N*2*-Benzyl-N*6*-cyclohexyl-9H-purine-2,6-diamine
DM41TQB	MI	TTJFY5U
DM41TQB	MN	Adenosine A3 receptor (ADORA3)
DM41TQB	MT	DTT
DM41TQB	MA	Inhibitor
DM41TQB	RN	Reversine and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem. 2005 Jul 28;48(15):4910-8.
DM41TQB	RU	https://pubmed.ncbi.nlm.nih.gov/16033270

DMFWN5U	DI	DMFWN5U
DMFWN5U	DN	N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine
DMFWN5U	MI	TTGKNB4
DMFWN5U	MN	Epidermal growth factor receptor (EGFR)
DMFWN5U	MT	DTT
DMFWN5U	MA	Inhibitor
DMFWN5U	RN	Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase acti... J Med Chem. 1996 Feb 16;39(4):918-28.
DMFWN5U	RU	https://pubmed.ncbi.nlm.nih.gov/8632415

DMUI8RC	DI	DMUI8RC
DMUI8RC	DN	N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine
DMUI8RC	MI	TTGKNB4
DMUI8RC	MN	Epidermal growth factor receptor (EGFR)
DMUI8RC	MT	DTT
DMUI8RC	MA	Inhibitor
DMUI8RC	RN	Synthesis of a prodrug designed to release multiple inhibitors of the epidermal growth factor receptor tyrosine kinase and an alkylating agent: a n... J Med Chem. 2003 Dec 4;46(25):5546-51.
DMUI8RC	RU	https://pubmed.ncbi.nlm.nih.gov/14640561

DMO56XY	DI	DMO56XY
DMO56XY	DN	N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine
DMO56XY	MI	TTGKNB4
DMO56XY	MN	Epidermal growth factor receptor (EGFR)
DMO56XY	MT	DTT
DMO56XY	MA	Inhibitor
DMO56XY	RN	Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as poten... J Med Chem. 1995 Sep 1;38(18):3482-7.
DMO56XY	RU	https://pubmed.ncbi.nlm.nih.gov/7658435

DMNGSQK	DI	DMNGSQK
DMNGSQK	DN	N*4*-Benzyl-6-chloro-pyrimidine-2,4-diamine
DMNGSQK	MI	TT2GPK3
DMNGSQK	MN	DNA topoisomerase (TOP)
DMNGSQK	MT	DTT
DMNGSQK	MA	Inhibitor
DMNGSQK	RN	Inhibitors of Bacillus subtilis DNA polymerase III. Influence of modifications in the pyrimidine ring of anilino- and (benzylamino)pyrimidines. J Med Chem. 1986 May;29(5):676-81.
DMNGSQK	RU	https://pubmed.ncbi.nlm.nih.gov/3084785

DMK674I	DI	DMK674I
DMK674I	DN	N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine
DMK674I	MI	TTGKNB4
DMK674I	MN	Epidermal growth factor receptor (EGFR)
DMK674I	MT	DTT
DMK674I	MA	Inhibitor
DMK674I	RN	Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinas... J Med Chem. 1996 Apr 26;39(9):1823-35.
DMK674I	RU	https://pubmed.ncbi.nlm.nih.gov/8627606

DMRNGV0	DI	DMRNGV0
DMRNGV0	DN	N*6*-Benzyl-quinazoline-2,4,6-triamine
DMRNGV0	MI	TT9SL3Q
DMRNGV0	MN	Polypeptide deformylase (PDF)
DMRNGV0	MT	DTT
DMRNGV0	MA	Inhibitor
DMRNGV0	RN	CoMFA and CoMSIA analyses of Pneumocystis carinii dihydrofolate reductase, Toxoplasma gondii dihydrofolate reductase, and rat liver dihydrofolate r... J Med Chem. 2005 Mar 10;48(5):1448-69.
DMRNGV0	RU	https://pubmed.ncbi.nlm.nih.gov/15743188

DM1K2A4	DI	DM1K2A4
DM1K2A4	DN	N*6*-Cyclohexyl-N*2*-ethyl-9H-purine-2,6-diamine
DM1K2A4	MI	TTK25J1
DM1K2A4	MN	Adenosine A1 receptor (ADORA1)
DM1K2A4	MT	DTT
DM1K2A4	MA	Inhibitor
DM1K2A4	RN	Reversine and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem. 2005 Jul 28;48(15):4910-8.
DM1K2A4	RU	https://pubmed.ncbi.nlm.nih.gov/16033270

DM1K2A4	DI	DM1K2A4
DM1K2A4	DN	N*6*-Cyclohexyl-N*2*-ethyl-9H-purine-2,6-diamine
DM1K2A4	MI	TTJFY5U
DM1K2A4	MN	Adenosine A3 receptor (ADORA3)
DM1K2A4	MT	DTT
DM1K2A4	MA	Inhibitor
DM1K2A4	RN	Reversine and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem. 2005 Jul 28;48(15):4910-8.
DM1K2A4	RU	https://pubmed.ncbi.nlm.nih.gov/16033270

DM3C8PJ	DI	DM3C8PJ
DM3C8PJ	DN	N*6*-Cyclohexyl-N*2*-phenyl-9H-purine-2,6-diamine
DM3C8PJ	MI	TTK25J1
DM3C8PJ	MN	Adenosine A1 receptor (ADORA1)
DM3C8PJ	MT	DTT
DM3C8PJ	MA	Inhibitor
DM3C8PJ	RN	Reversine and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem. 2005 Jul 28;48(15):4910-8.
DM3C8PJ	RU	https://pubmed.ncbi.nlm.nih.gov/16033270

DM3C8PJ	DI	DM3C8PJ
DM3C8PJ	DN	N*6*-Cyclohexyl-N*2*-phenyl-9H-purine-2,6-diamine
DM3C8PJ	MI	TTM2AOE
DM3C8PJ	MN	Adenosine A2a receptor (ADORA2A)
DM3C8PJ	MT	DTT
DM3C8PJ	MA	Inhibitor
DM3C8PJ	RN	Reversine and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem. 2005 Jul 28;48(15):4910-8.
DM3C8PJ	RU	https://pubmed.ncbi.nlm.nih.gov/16033270

DM3C8PJ	DI	DM3C8PJ
DM3C8PJ	DN	N*6*-Cyclohexyl-N*2*-phenyl-9H-purine-2,6-diamine
DM3C8PJ	MI	TTJFY5U
DM3C8PJ	MN	Adenosine A3 receptor (ADORA3)
DM3C8PJ	MT	DTT
DM3C8PJ	MA	Inhibitor
DM3C8PJ	RN	Reversine and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem. 2005 Jul 28;48(15):4910-8.
DM3C8PJ	RU	https://pubmed.ncbi.nlm.nih.gov/16033270

DMCOPR3	DI	DMCOPR3
DMCOPR3	DN	N*6*-Cyclooctyl-N*2*-phenyl-9H-purine-2,6-diamine
DMCOPR3	MI	TTK25J1
DMCOPR3	MN	Adenosine A1 receptor (ADORA1)
DMCOPR3	MT	DTT
DMCOPR3	MA	Inhibitor
DMCOPR3	RN	Reversine and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem. 2005 Jul 28;48(15):4910-8.
DMCOPR3	RU	https://pubmed.ncbi.nlm.nih.gov/16033270

DMCOPR3	DI	DMCOPR3
DMCOPR3	DN	N*6*-Cyclooctyl-N*2*-phenyl-9H-purine-2,6-diamine
DMCOPR3	MI	TTJFY5U
DMCOPR3	MN	Adenosine A3 receptor (ADORA3)
DMCOPR3	MT	DTT
DMCOPR3	MA	Inhibitor
DMCOPR3	RN	Reversine and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem. 2005 Jul 28;48(15):4910-8.
DMCOPR3	RU	https://pubmed.ncbi.nlm.nih.gov/16033270

DMWKRJX	DI	DMWKRJX
DMWKRJX	DN	N',2-diphenylquinoline-4-carbohydrazide
DMWKRJX	MI	TTBPGLU
DMWKRJX	MN	Neuromedin-K receptor (TACR3)
DMWKRJX	MT	DTT
DMWKRJX	MA	Antagonist
DMWKRJX	RN	N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5748-51.
DMWKRJX	RU	https://pubmed.ncbi.nlm.nih.gov/16950620

DMNJA3C	DI	DMNJA3C
DMNJA3C	DN	N',2-diphenylquinoline-4-carbohydrazide 8m
DMNJA3C	MI	TTBPGLU
DMNJA3C	MN	Neuromedin-K receptor (TACR3)
DMNJA3C	MT	DTT
DMNJA3C	MA	Antagonist
DMNJA3C	RN	N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists II. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5752-6.
DMNJA3C	RU	https://pubmed.ncbi.nlm.nih.gov/16950617

DMOG37L	DI	DMOG37L
DMOG37L	DN	N,4-dibenzhydrylpiperazine-1-carboxamide
DMOG37L	MI	TTFK1JQ
DMOG37L	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMOG37L	MT	DTT
DMOG37L	MA	Inhibitor
DMOG37L	RN	Scaffold-based design and synthesis of potent N-type calcium channel blockers. Bioorg Med Chem Lett. 2009 Nov 15;19(22):6467-72.
DMOG37L	RU	https://pubmed.ncbi.nlm.nih.gov/19815411

DMMTQ3N	DI	DMMTQ3N
DMMTQ3N	DN	N,4-dimethyl-3,4-dihydroquinazolin-2-amine
DMMTQ3N	MI	TTRUFDT
DMMTQ3N	MN	5-HT 5A receptor (HTR5A)
DMMTQ3N	MT	DTT
DMMTQ3N	MA	Inhibitor
DMMTQ3N	RN	Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: optimising brain penetration. Bioorg Med Chem Lett. 2008 Jan 1;18(1):262-6.
DMMTQ3N	RU	https://pubmed.ncbi.nlm.nih.gov/18023344

DM8G0WX	DI	DM8G0WX
DM8G0WX	DN	N,8-dihydroxy-8-(naphthalen-2-yl)octanamide
DM8G0WX	MI	TT6R7JZ
DM8G0WX	MN	Histone deacetylase 1 (HDAC1)
DM8G0WX	MT	DTT
DM8G0WX	MA	Inhibitor
DM8G0WX	RN	3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. Eur J Med Chem. 2009 Jul;44(7):2868-76.
DM8G0WX	RU	https://pubmed.ncbi.nlm.nih.gov/19136179

DMZXF36	DI	DMZXF36
DMZXF36	DN	N,8-diphenyl-9H-purin-6-amine
DMZXF36	MI	TTRSMW9
DMZXF36	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMZXF36	MT	DTT
DMZXF36	MA	Inhibitor
DMZXF36	RN	Novel 8-arylated purines as inhibitors of glycogen synthase kinase. Eur J Med Chem. 2010 Aug;45(8):3389-93.
DMZXF36	RU	https://pubmed.ncbi.nlm.nih.gov/20472330

DMIX0CT	DI	DMIX0CT
DMIX0CT	DN	N,N'-(1',10'-decylene)-bis-(-)-nor-MEP
DMIX0CT	MI	TT1RS9F
DMIX0CT	MN	Acetylcholinesterase (AChE)
DMIX0CT	MT	DTT
DMIX0CT	MA	Inhibitor
DMIX0CT	RN	Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36.
DMIX0CT	RU	https://pubmed.ncbi.nlm.nih.gov/18333606

DMIX0CT	DI	DMIX0CT
DMIX0CT	DN	N,N'-(1',10'-decylene)-bis-(-)-nor-MEP
DMIX0CT	MI	TTEB0GD
DMIX0CT	MN	Cholinesterase (BCHE)
DMIX0CT	MT	DTT
DMIX0CT	MA	Inhibitor
DMIX0CT	RN	Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36.
DMIX0CT	RU	https://pubmed.ncbi.nlm.nih.gov/18333606

DM5NVIO	DI	DM5NVIO
DM5NVIO	DN	N,N'-(1',11'-undecydene)-bis-(-)-nor-MEP
DM5NVIO	MI	TT1RS9F
DM5NVIO	MN	Acetylcholinesterase (AChE)
DM5NVIO	MT	DTT
DM5NVIO	MA	Inhibitor
DM5NVIO	RN	Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36.
DM5NVIO	RU	https://pubmed.ncbi.nlm.nih.gov/18333606

DM5NVIO	DI	DM5NVIO
DM5NVIO	DN	N,N'-(1',11'-undecydene)-bis-(-)-nor-MEP
DM5NVIO	MI	TTEB0GD
DM5NVIO	MN	Cholinesterase (BCHE)
DM5NVIO	MT	DTT
DM5NVIO	MA	Inhibitor
DM5NVIO	RN	Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36.
DM5NVIO	RU	https://pubmed.ncbi.nlm.nih.gov/18333606

DMWI06H	DI	DMWI06H
DMWI06H	DN	N,N'-(1',12'-dodecydene)-bis-(-)-nor-MEP
DMWI06H	MI	TT1RS9F
DMWI06H	MN	Acetylcholinesterase (AChE)
DMWI06H	MT	DTT
DMWI06H	MA	Inhibitor
DMWI06H	RN	Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36.
DMWI06H	RU	https://pubmed.ncbi.nlm.nih.gov/18333606

DMWI06H	DI	DMWI06H
DMWI06H	DN	N,N'-(1',12'-dodecydene)-bis-(-)-nor-MEP
DMWI06H	MI	TTEB0GD
DMWI06H	MN	Cholinesterase (BCHE)
DMWI06H	MT	DTT
DMWI06H	MA	Inhibitor
DMWI06H	RN	Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36.
DMWI06H	RU	https://pubmed.ncbi.nlm.nih.gov/18333606

DM1LKEP	DI	DM1LKEP
DM1LKEP	DN	N,N'-(1',2'-ethylene)-bis-(-)-nor-MEP
DM1LKEP	MI	TTEB0GD
DM1LKEP	MN	Cholinesterase (BCHE)
DM1LKEP	MT	DTT
DM1LKEP	MA	Inhibitor
DM1LKEP	RN	Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36.
DM1LKEP	RU	https://pubmed.ncbi.nlm.nih.gov/18333606

DM4G6BT	DI	DM4G6BT
DM4G6BT	DN	N,N'-(1',3'-propylene)-bis-(-)-nor-MEP
DM4G6BT	MI	TTEB0GD
DM4G6BT	MN	Cholinesterase (BCHE)
DM4G6BT	MT	DTT
DM4G6BT	MA	Inhibitor
DM4G6BT	RN	Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36.
DM4G6BT	RU	https://pubmed.ncbi.nlm.nih.gov/18333606

DMZHBTA	DI	DMZHBTA
DMZHBTA	DN	N,N'-(1',4'-butylene)-bis-(-)-nor-MEP
DMZHBTA	MI	TTEB0GD
DMZHBTA	MN	Cholinesterase (BCHE)
DMZHBTA	MT	DTT
DMZHBTA	MA	Inhibitor
DMZHBTA	RN	Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36.
DMZHBTA	RU	https://pubmed.ncbi.nlm.nih.gov/18333606

DMBPC0K	DI	DMBPC0K
DMBPC0K	DN	N,N'-(1',5'-pentylene)-bis-(-)-nor-MEP
DMBPC0K	MI	TT1RS9F
DMBPC0K	MN	Acetylcholinesterase (AChE)
DMBPC0K	MT	DTT
DMBPC0K	MA	Inhibitor
DMBPC0K	RN	Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36.
DMBPC0K	RU	https://pubmed.ncbi.nlm.nih.gov/18333606

DMBPC0K	DI	DMBPC0K
DMBPC0K	DN	N,N'-(1',5'-pentylene)-bis-(-)-nor-MEP
DMBPC0K	MI	TTEB0GD
DMBPC0K	MN	Cholinesterase (BCHE)
DMBPC0K	MT	DTT
DMBPC0K	MA	Inhibitor
DMBPC0K	RN	Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36.
DMBPC0K	RU	https://pubmed.ncbi.nlm.nih.gov/18333606

DMU4BIW	DI	DMU4BIW
DMU4BIW	DN	N,N'-(1',6-hexylene)-bis-(-)-nor-MEP
DMU4BIW	MI	TT1RS9F
DMU4BIW	MN	Acetylcholinesterase (AChE)
DMU4BIW	MT	DTT
DMU4BIW	MA	Inhibitor
DMU4BIW	RN	Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36.
DMU4BIW	RU	https://pubmed.ncbi.nlm.nih.gov/18333606

DMU4BIW	DI	DMU4BIW
DMU4BIW	DN	N,N'-(1',6-hexylene)-bis-(-)-nor-MEP
DMU4BIW	MI	TTEB0GD
DMU4BIW	MN	Cholinesterase (BCHE)
DMU4BIW	MT	DTT
DMU4BIW	MA	Inhibitor
DMU4BIW	RN	Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36.
DMU4BIW	RU	https://pubmed.ncbi.nlm.nih.gov/18333606

DMSORHA	DI	DMSORHA
DMSORHA	DN	N,N'-(1',7'-heptylene)-bis-(-)-nor-MEP
DMSORHA	MI	TT1RS9F
DMSORHA	MN	Acetylcholinesterase (AChE)
DMSORHA	MT	DTT
DMSORHA	MA	Inhibitor
DMSORHA	RN	Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36.
DMSORHA	RU	https://pubmed.ncbi.nlm.nih.gov/18333606

DMSORHA	DI	DMSORHA
DMSORHA	DN	N,N'-(1',7'-heptylene)-bis-(-)-nor-MEP
DMSORHA	MI	TTEB0GD
DMSORHA	MN	Cholinesterase (BCHE)
DMSORHA	MT	DTT
DMSORHA	MA	Inhibitor
DMSORHA	RN	Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36.
DMSORHA	RU	https://pubmed.ncbi.nlm.nih.gov/18333606

DMHFYK2	DI	DMHFYK2
DMHFYK2	DN	N,N'-(1',8'-octylene)-bis-(-)-nor-MEP
DMHFYK2	MI	TT1RS9F
DMHFYK2	MN	Acetylcholinesterase (AChE)
DMHFYK2	MT	DTT
DMHFYK2	MA	Inhibitor
DMHFYK2	RN	Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36.
DMHFYK2	RU	https://pubmed.ncbi.nlm.nih.gov/18333606

DMHFYK2	DI	DMHFYK2
DMHFYK2	DN	N,N'-(1',8'-octylene)-bis-(-)-nor-MEP
DMHFYK2	MI	TTEB0GD
DMHFYK2	MN	Cholinesterase (BCHE)
DMHFYK2	MT	DTT
DMHFYK2	MA	Inhibitor
DMHFYK2	RN	Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36.
DMHFYK2	RU	https://pubmed.ncbi.nlm.nih.gov/18333606

DMIWF7U	DI	DMIWF7U
DMIWF7U	DN	N,N'-(1',9'-nonylene)-bis-(-)-nor-MEP
DMIWF7U	MI	TT1RS9F
DMIWF7U	MN	Acetylcholinesterase (AChE)
DMIWF7U	MT	DTT
DMIWF7U	MA	Inhibitor
DMIWF7U	RN	Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36.
DMIWF7U	RU	https://pubmed.ncbi.nlm.nih.gov/18333606

DMIWF7U	DI	DMIWF7U
DMIWF7U	DN	N,N'-(1',9'-nonylene)-bis-(-)-nor-MEP
DMIWF7U	MI	TTEB0GD
DMIWF7U	MN	Cholinesterase (BCHE)
DMIWF7U	MT	DTT
DMIWF7U	MA	Inhibitor
DMIWF7U	RN	Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36.
DMIWF7U	RU	https://pubmed.ncbi.nlm.nih.gov/18333606

DMLU27Y	DI	DMLU27Y
DMLU27Y	DN	N,N,N-Triisobutyl-pyrimidine-2,4,6-triamine
DMLU27Y	MI	TTZAYWL
DMLU27Y	MN	Estrogen receptor (ESR)
DMLU27Y	MT	DTT
DMLU27Y	MA	Inhibitor
DMLU27Y	RN	Blocking estrogen signaling after the hormone: pyrimidine-core inhibitors of estrogen receptor-coactivator binding. J Med Chem. 2008 Oct 23;51(20):6512-30.
DMLU27Y	RU	https://pubmed.ncbi.nlm.nih.gov/18785725

DMNZKCL	DI	DMNZKCL
DMNZKCL	DN	N,N`-bis-alkyl butylimmidazole 12b
DMNZKCL	MI	TT8DBY3
DMNZKCL	MN	Angiotensin II receptor type-1 (AGTR1)
DMNZKCL	MT	DTT
DMNZKCL	MA	Antagonist
DMNZKCL	RN	Rational design, efficient syntheses and biological evaluation of N,N'-symmetrically bis-substituted butylimidazole analogs as a new class of potent Angiotensin II receptor blockers. Eur J Med Chem. 2013 Apr;62:352-70.
DMNZKCL	RU	https://pubmed.ncbi.nlm.nih.gov/23376252

DMT4USP	DI	DMT4USP
DMT4USP	DN	N,N'-Bis(4-Amino-2-Methylquinolin-6-Yl)Urea
DMT4USP	MI	TTIQSC1
DMT4USP	MN	Bacterial Lethal factor (Bact lef)
DMT4USP	MT	DTT
DMT4USP	MA	Inhibitor
DMT4USP	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMT4USP	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMLOP2B	DI	DMLOP2B
DMLOP2B	DN	N,N'-Bis-(4-butoxy-phenyl)-guanidine
DMLOP2B	MI	TTLD29N
DMLOP2B	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMLOP2B	MT	DTT
DMLOP2B	MA	Inhibitor
DMLOP2B	RN	Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302.
DMLOP2B	RU	https://pubmed.ncbi.nlm.nih.gov/9703475

DMLOP2B	DI	DMLOP2B
DMLOP2B	DN	N,N'-Bis-(4-butoxy-phenyl)-guanidine
DMLOP2B	MI	TTKJEMQ
DMLOP2B	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMLOP2B	MT	DTT
DMLOP2B	MA	Inhibitor
DMLOP2B	RN	Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302.
DMLOP2B	RU	https://pubmed.ncbi.nlm.nih.gov/9703475

DMLOP2B	DI	DMLOP2B
DMLOP2B	DN	N,N'-Bis-(4-butoxy-phenyl)-guanidine
DMLOP2B	MI	TTN9D8E
DMLOP2B	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMLOP2B	MT	DTT
DMLOP2B	MA	Inhibitor
DMLOP2B	RN	Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302.
DMLOP2B	RU	https://pubmed.ncbi.nlm.nih.gov/9703475

DMOS2GH	DI	DMOS2GH
DMOS2GH	DN	N,N'-Bis-(4-butyl-phenyl)-guanidine
DMOS2GH	MI	TTLD29N
DMOS2GH	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMOS2GH	MT	DTT
DMOS2GH	MA	Inhibitor
DMOS2GH	RN	Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302.
DMOS2GH	RU	https://pubmed.ncbi.nlm.nih.gov/9703475

DMOS2GH	DI	DMOS2GH
DMOS2GH	DN	N,N'-Bis-(4-butyl-phenyl)-guanidine
DMOS2GH	MI	TTKJEMQ
DMOS2GH	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMOS2GH	MT	DTT
DMOS2GH	MA	Inhibitor
DMOS2GH	RN	Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302.
DMOS2GH	RU	https://pubmed.ncbi.nlm.nih.gov/9703475

DMOS2GH	DI	DMOS2GH
DMOS2GH	DN	N,N'-Bis-(4-butyl-phenyl)-guanidine
DMOS2GH	MI	TTN9D8E
DMOS2GH	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMOS2GH	MT	DTT
DMOS2GH	MA	Inhibitor
DMOS2GH	RN	Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302.
DMOS2GH	RU	https://pubmed.ncbi.nlm.nih.gov/9703475

DM0CTG7	DI	DM0CTG7
DM0CTG7	DN	N,N'-Bis-(4-ethyl-phenyl)-guanidine
DM0CTG7	MI	TTLD29N
DM0CTG7	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DM0CTG7	MT	DTT
DM0CTG7	MA	Inhibitor
DM0CTG7	RN	Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302.
DM0CTG7	RU	https://pubmed.ncbi.nlm.nih.gov/9703475

DM0CTG7	DI	DM0CTG7
DM0CTG7	DN	N,N'-Bis-(4-ethyl-phenyl)-guanidine
DM0CTG7	MI	TTKJEMQ
DM0CTG7	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DM0CTG7	MT	DTT
DM0CTG7	MA	Inhibitor
DM0CTG7	RN	Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302.
DM0CTG7	RU	https://pubmed.ncbi.nlm.nih.gov/9703475

DM0CTG7	DI	DM0CTG7
DM0CTG7	DN	N,N'-Bis-(4-ethyl-phenyl)-guanidine
DM0CTG7	MI	TTN9D8E
DM0CTG7	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DM0CTG7	MT	DTT
DM0CTG7	MA	Inhibitor
DM0CTG7	RN	Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302.
DM0CTG7	RU	https://pubmed.ncbi.nlm.nih.gov/9703475

DM0RQGU	DI	DM0RQGU
DM0RQGU	DN	N,N'-Bis-(4-hexyl-phenyl)-guanidine
DM0RQGU	MI	TTLD29N
DM0RQGU	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DM0RQGU	MT	DTT
DM0RQGU	MA	Inhibitor
DM0RQGU	RN	Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302.
DM0RQGU	RU	https://pubmed.ncbi.nlm.nih.gov/9703475

DM0RQGU	DI	DM0RQGU
DM0RQGU	DN	N,N'-Bis-(4-hexyl-phenyl)-guanidine
DM0RQGU	MI	TTKJEMQ
DM0RQGU	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DM0RQGU	MT	DTT
DM0RQGU	MA	Inhibitor
DM0RQGU	RN	Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302.
DM0RQGU	RU	https://pubmed.ncbi.nlm.nih.gov/9703475

DM0RQGU	DI	DM0RQGU
DM0RQGU	DN	N,N'-Bis-(4-hexyl-phenyl)-guanidine
DM0RQGU	MI	TTN9D8E
DM0RQGU	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DM0RQGU	MT	DTT
DM0RQGU	MA	Inhibitor
DM0RQGU	RN	Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302.
DM0RQGU	RU	https://pubmed.ncbi.nlm.nih.gov/9703475

DMM38BC	DI	DMM38BC
DMM38BC	DN	N,N'-Bis-(4-isopropyl-phenyl)-guanidine
DMM38BC	MI	TTLD29N
DMM38BC	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMM38BC	MT	DTT
DMM38BC	MA	Inhibitor
DMM38BC	RN	Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302.
DMM38BC	RU	https://pubmed.ncbi.nlm.nih.gov/9703475

DMM38BC	DI	DMM38BC
DMM38BC	DN	N,N'-Bis-(4-isopropyl-phenyl)-guanidine
DMM38BC	MI	TTKJEMQ
DMM38BC	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMM38BC	MT	DTT
DMM38BC	MA	Inhibitor
DMM38BC	RN	Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302.
DMM38BC	RU	https://pubmed.ncbi.nlm.nih.gov/9703475

DMM38BC	DI	DMM38BC
DMM38BC	DN	N,N'-Bis-(4-isopropyl-phenyl)-guanidine
DMM38BC	MI	TTN9D8E
DMM38BC	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMM38BC	MT	DTT
DMM38BC	MA	Inhibitor
DMM38BC	RN	Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302.
DMM38BC	RU	https://pubmed.ncbi.nlm.nih.gov/9703475

DMFDXLB	DI	DMFDXLB
DMFDXLB	DN	N,N'-Bis-(4-sec-butyl-phenyl)-guanidine
DMFDXLB	MI	TTLD29N
DMFDXLB	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMFDXLB	MT	DTT
DMFDXLB	MA	Inhibitor
DMFDXLB	RN	Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302.
DMFDXLB	RU	https://pubmed.ncbi.nlm.nih.gov/9703475

DMFDXLB	DI	DMFDXLB
DMFDXLB	DN	N,N'-Bis-(4-sec-butyl-phenyl)-guanidine
DMFDXLB	MI	TTKJEMQ
DMFDXLB	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMFDXLB	MT	DTT
DMFDXLB	MA	Inhibitor
DMFDXLB	RN	Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302.
DMFDXLB	RU	https://pubmed.ncbi.nlm.nih.gov/9703475

DMFDXLB	DI	DMFDXLB
DMFDXLB	DN	N,N'-Bis-(4-sec-butyl-phenyl)-guanidine
DMFDXLB	MI	TTN9D8E
DMFDXLB	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMFDXLB	MT	DTT
DMFDXLB	MA	Inhibitor
DMFDXLB	RN	Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302.
DMFDXLB	RU	https://pubmed.ncbi.nlm.nih.gov/9703475

DMBQ0TY	DI	DMBQ0TY
DMBQ0TY	DN	N,N-bis(cyanomethyl)-3,4-dimethoxybenzamide
DMBQ0TY	MI	TTPLTSQ
DMBQ0TY	MN	Neutrophil elastase (NE)
DMBQ0TY	MT	DTT
DMBQ0TY	MA	Inhibitor
DMBQ0TY	RN	N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
DMBQ0TY	RU	https://pubmed.ncbi.nlm.nih.gov/17850059

DMM678B	DI	DMM678B
DMM678B	DN	N,N-bis(tosylmethyl)hexan-1-amine
DMM678B	MI	TTX4RTB
DMM678B	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMM678B	MT	DTT
DMM678B	MA	Inhibitor
DMM678B	RN	Discovery of novel chemotypes to a G-protein-coupled receptor through ligand-steered homology modeling and structure-based virtual screening. J Med Chem. 2008 Feb 14;51(3):581-8.
DMM678B	RU	https://pubmed.ncbi.nlm.nih.gov/18198821

DM8TA0M	DI	DM8TA0M
DM8TA0M	DN	N,N'-Di-acenaphthen-5-yl-guanidine
DM8TA0M	MI	TT7RGTM
DM8TA0M	MN	Voltage-gated calcium channel alpha Cav1.3 (CACNA1D)
DM8TA0M	MT	DTT
DM8TA0M	MA	Inhibitor
DM8TA0M	RN	Synthesis and characterization of N-(acenaphth-5-yl)-N'-(4-methoxynaphth-1-yl)guanidine as a glutamate release inhibitor and potential anti-ischemic agent, Bioorg. Med. Chem. Lett. 5(19):2259-2262 (1995).
DM8TA0M	RU	http://www.sciencedirect.com/science/article/pii/0960894X95003927

DMSY571	DI	DMSY571
DMSY571	DN	N,N-diallyl[D-Pro-10]Dyn A-(1-11)
DMSY571	MI	TTQW87Y
DMSY571	MN	Opioid receptor kappa (OPRK1)
DMSY571	MT	DTT
DMSY571	MA	Inhibitor
DMSY571	RN	Synthesis and opioid activity of [D-Pro10]dynorphin A-(1-11) analogues with N-terminal alkyl substitution. J Med Chem. 1997 Aug 15;40(17):2733-9.
DMSY571	RU	https://pubmed.ncbi.nlm.nih.gov/9276018

DMILJUE	DI	DMILJUE
DMILJUE	DN	N,N-dibenzyl[D-Pro-10]Dyn A-(1-11)
DMILJUE	MI	TTQW87Y
DMILJUE	MN	Opioid receptor kappa (OPRK1)
DMILJUE	MT	DTT
DMILJUE	MA	Inhibitor
DMILJUE	RN	Synthesis and opioid activity of [D-Pro10]dynorphin A-(1-11) analogues with N-terminal alkyl substitution. J Med Chem. 1997 Aug 15;40(17):2733-9.
DMILJUE	RU	https://pubmed.ncbi.nlm.nih.gov/9276018

DM1UCZ9	DI	DM1UCZ9
DM1UCZ9	DN	N,N-diCPM[D-Pro-10]Dyn A-(1-11)
DM1UCZ9	MI	TTQW87Y
DM1UCZ9	MN	Opioid receptor kappa (OPRK1)
DM1UCZ9	MT	DTT
DM1UCZ9	MA	Inhibitor
DM1UCZ9	RN	Synthesis and opioid activity of [D-Pro10]dynorphin A-(1-11) analogues with N-terminal alkyl substitution. J Med Chem. 1997 Aug 15;40(17):2733-9.
DM1UCZ9	RU	https://pubmed.ncbi.nlm.nih.gov/9276018

DMLVMJH	DI	DMLVMJH
DMLVMJH	DN	N,N'-dicyclohexyl-urea
DMLVMJH	MI	TT7WVHI
DMLVMJH	MN	Soluble epoxide hydrolase (EPHX2)
DMLVMJH	MT	DTT
DMLVMJH	MA	Inhibitor
DMLVMJH	RN	Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem. 2007 Aug 9;50(16):3825-40.
DMLVMJH	RU	https://pubmed.ncbi.nlm.nih.gov/17616115

DMZ3EA1	DI	DMZ3EA1
DMZ3EA1	DN	N,N-diethyl estrone-16-methyl carboxamide
DMZ3EA1	MI	TTIWB6L
DMZ3EA1	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMZ3EA1	MT	DTT
DMZ3EA1	MA	Inhibitor
DMZ3EA1	RN	Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45.
DMZ3EA1	RU	https://pubmed.ncbi.nlm.nih.gov/16480268

DM5K3D2	DI	DM5K3D2
DM5K3D2	DN	N,N-Diethyl-1'H-phenothiazine-1'-carboxamide
DM5K3D2	MI	TTEB0GD
DM5K3D2	MN	Cholinesterase (BCHE)
DM5K3D2	MT	DTT
DM5K3D2	MA	Inhibitor
DM5K3D2	RN	Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorg Med Chem. 2010 Mar 15;18(6):2232-2244.
DM5K3D2	RU	https://pubmed.ncbi.nlm.nih.gov/20181484

DM0UBI9	DI	DM0UBI9
DM0UBI9	DN	N,N-diethyl-2-(1H-indol-3-yl)ethanamine
DM0UBI9	MI	TTJS8PY
DM0UBI9	MN	5-HT 6 receptor (HTR6)
DM0UBI9	MT	DTT
DM0UBI9	MA	Inhibitor
DM0UBI9	RN	Interaction of N1-unsubstituted and N1-benzenesulfonyltryptamines at h5-HT6 receptors. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5832-5.
DM0UBI9	RU	https://pubmed.ncbi.nlm.nih.gov/16945532

DMBFASY	DI	DMBFASY
DMBFASY	DN	N,N-Diethyl-2-(2-phenyl-1H-indol-3-yl)-acetamide
DMBFASY	MI	TTPTXIN
DMBFASY	MN	Translocator protein (TSPO)
DMBFASY	MT	DTT
DMBFASY	MA	Inhibitor
DMBFASY	RN	Chemistry, binding affinities, and behavioral properties of a new class of "antineophobic" mitochondrial DBI receptor complex (mDRC) ligands. J Med Chem. 1993 Oct 1;36(20):2908-20.
DMBFASY	RU	https://pubmed.ncbi.nlm.nih.gov/8411007

DMV8QTR	DI	DMV8QTR
DMV8QTR	DN	N,N-Dihexyl-2-(2-phenyl-1H-indol-3-yl)-acetamide
DMV8QTR	MI	TTPTXIN
DMV8QTR	MN	Translocator protein (TSPO)
DMV8QTR	MT	DTT
DMV8QTR	MA	Inhibitor
DMV8QTR	RN	Chemistry, binding affinities, and behavioral properties of a new class of "antineophobic" mitochondrial DBI receptor complex (mDRC) ligands. J Med Chem. 1993 Oct 1;36(20):2908-20.
DMV8QTR	RU	https://pubmed.ncbi.nlm.nih.gov/8411007

DM4E8C9	DI	DM4E8C9
DM4E8C9	DN	N,N-Diisopropyl-1'H-phenothiazine-1'-carboxamide
DM4E8C9	MI	TTEB0GD
DM4E8C9	MN	Cholinesterase (BCHE)
DM4E8C9	MT	DTT
DM4E8C9	MA	Inhibitor
DM4E8C9	RN	Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorg Med Chem. 2010 Mar 15;18(6):2232-2244.
DM4E8C9	RU	https://pubmed.ncbi.nlm.nih.gov/20181484

DMTWK7L	DI	DMTWK7L
DMTWK7L	DN	N,Ndimethyl milnacipran
DMTWK7L	MI	TTVBI8W
DMTWK7L	MN	Dopamine transporter (DAT)
DMTWK7L	MT	DTT
DMTWK7L	MA	Inhibitor
DMTWK7L	RN	Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Feb 15;18(4):1346-9.
DMTWK7L	RU	https://pubmed.ncbi.nlm.nih.gov/18207394

DMWK91T	DI	DMWK91T
DMWK91T	DN	N,N-dimethyl(2-phenoxyphenyl)methanamine
DMWK91T	MI	TTAWNKZ
DMWK91T	MN	Norepinephrine transporter (NET)
DMWK91T	MT	DTT
DMWK91T	MA	Inhibitor
DMWK91T	RN	1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity. Bioorg Med Chem Lett. 2008 Jan 15;18(2):596-9.
DMWK91T	RU	https://pubmed.ncbi.nlm.nih.gov/18240382

DMWK91T	DI	DMWK91T
DMWK91T	DN	N,N-dimethyl(2-phenoxyphenyl)methanamine
DMWK91T	MI	TT3ROYC
DMWK91T	MN	Serotonin transporter (SERT)
DMWK91T	MT	DTT
DMWK91T	MA	Inhibitor
DMWK91T	RN	1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity. Bioorg Med Chem Lett. 2008 Jan 15;18(2):596-9.
DMWK91T	RU	https://pubmed.ncbi.nlm.nih.gov/18240382

DM41C8E	DI	DM41C8E
DM41C8E	DN	N,N-dimethyl(pyridin-3-yl)methanamine
DM41C8E	MI	TT4H1MQ
DM41C8E	MN	Neuronal acetylcholine receptor alpha-4 (CHRNA4)
DM41C8E	MT	DTT
DM41C8E	MA	Inhibitor
DM41C8E	RN	Synthesis and analgesic activity of secondary amine analogues of pyridylmethylamine and positional isomeric analogues of ABT-594. Bioorg Med Chem Lett. 2006 Apr 1;16(7):2013-6.
DM41C8E	RU	https://pubmed.ncbi.nlm.nih.gov/16412637

DM41C8E	DI	DM41C8E
DM41C8E	DN	N,N-dimethyl(pyridin-3-yl)methanamine
DM41C8E	MI	TT5KPZR
DM41C8E	MN	Neuronal acetylcholine receptor beta-2 (CHRNB2)
DM41C8E	MT	DTT
DM41C8E	MA	Inhibitor
DM41C8E	RN	Synthesis and analgesic activity of secondary amine analogues of pyridylmethylamine and positional isomeric analogues of ABT-594. Bioorg Med Chem Lett. 2006 Apr 1;16(7):2013-6.
DM41C8E	RU	https://pubmed.ncbi.nlm.nih.gov/16412637

DM4CDYG	DI	DM4CDYG
DM4CDYG	DN	N,N-Dimethyl-1'H-phenothiazine-1'-carboxamide
DM4CDYG	MI	TTEB0GD
DM4CDYG	MN	Cholinesterase (BCHE)
DM4CDYG	MT	DTT
DM4CDYG	MA	Inhibitor
DM4CDYG	RN	Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorg Med Chem. 2010 Mar 15;18(6):2232-2244.
DM4CDYG	RU	https://pubmed.ncbi.nlm.nih.gov/20181484

DMYUQDK	DI	DMYUQDK
DMYUQDK	DN	N,N-dimethyl-2-(1-tosyl-1H-indol-3-yl)ethanamine
DMYUQDK	MI	TTJS8PY
DMYUQDK	MN	5-HT 6 receptor (HTR6)
DMYUQDK	MT	DTT
DMYUQDK	MA	Inhibitor
DMYUQDK	RN	Further studies on the binding of N1-substituted tryptamines at h5-HT6 receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1691-4.
DMYUQDK	RU	https://pubmed.ncbi.nlm.nih.gov/17239595

DM1DZEL	DI	DM1DZEL
DM1DZEL	DN	N,N-dimethyl-2-(2'-methylbiphenyl-3-yl)ethanamine
DM1DZEL	MI	TTO9X1H
DM1DZEL	MN	5-HT 7 receptor (HTR7)
DM1DZEL	MT	DTT
DM1DZEL	MA	Inhibitor
DM1DZEL	RN	SAR studies on new bis-aryls 5-HT7 ligands: Synthesis and molecular modeling. Bioorg Med Chem. 2010 Mar 1;18(5):1958-67.
DM1DZEL	RU	https://pubmed.ncbi.nlm.nih.gov/20138771

DM73PXI	DI	DM73PXI
DM73PXI	DN	N,N-Dimethyl-2-(2-phenyl-1H-indol-3-yl)-acetamide
DM73PXI	MI	TTPTXIN
DM73PXI	MN	Translocator protein (TSPO)
DM73PXI	MT	DTT
DM73PXI	MA	Inhibitor
DM73PXI	RN	Chemistry, binding affinities, and behavioral properties of a new class of "antineophobic" mitochondrial DBI receptor complex (mDRC) ligands. J Med Chem. 1993 Oct 1;36(20):2908-20.
DM73PXI	RU	https://pubmed.ncbi.nlm.nih.gov/8411007

DMMD9A0	DI	DMMD9A0
DMMD9A0	DN	N,N-dimethyl-2-(pyridin-3-yloxy)ethanamine
DMMD9A0	MI	TT4H1MQ
DMMD9A0	MN	Neuronal acetylcholine receptor alpha-4 (CHRNA4)
DMMD9A0	MT	DTT
DMMD9A0	MA	Inhibitor
DMMD9A0	RN	Synthesis and analgesic activity of secondary amine analogues of pyridylmethylamine and positional isomeric analogues of ABT-594. Bioorg Med Chem Lett. 2006 Apr 1;16(7):2013-6.
DMMD9A0	RU	https://pubmed.ncbi.nlm.nih.gov/16412637

DMMD9A0	DI	DMMD9A0
DMMD9A0	DN	N,N-dimethyl-2-(pyridin-3-yloxy)ethanamine
DMMD9A0	MI	TT5KPZR
DMMD9A0	MN	Neuronal acetylcholine receptor beta-2 (CHRNB2)
DMMD9A0	MT	DTT
DMMD9A0	MA	Inhibitor
DMMD9A0	RN	Synthesis and analgesic activity of secondary amine analogues of pyridylmethylamine and positional isomeric analogues of ABT-594. Bioorg Med Chem Lett. 2006 Apr 1;16(7):2013-6.
DMMD9A0	RU	https://pubmed.ncbi.nlm.nih.gov/16412637

DM9XZJN	DI	DM9XZJN
DM9XZJN	DN	N,N-dimethyl-2,2,2-triphenylacetamide
DM9XZJN	MI	TTMNI76
DM9XZJN	MN	Calcium-activated potassium channel (KCN)
DM9XZJN	MT	DTT
DM9XZJN	MA	Inhibitor
DM9XZJN	RN	Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82.
DM9XZJN	RU	https://pubmed.ncbi.nlm.nih.gov/18232633

DMJDQGR	DI	DMJDQGR
DMJDQGR	DN	N,N-dimethyl-2,2-diphenylethanamine
DMJDQGR	MI	TTJQOD7
DMJDQGR	MN	5-HT 2A receptor (HTR2A)
DMJDQGR	MT	DTT
DMJDQGR	MA	Inhibitor
DMJDQGR	RN	Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504.
DMJDQGR	RU	https://pubmed.ncbi.nlm.nih.gov/19700330

DMJDQGR	DI	DMJDQGR
DMJDQGR	DN	N,N-dimethyl-2,2-diphenylethanamine
DMJDQGR	MI	TTTIBOJ
DMJDQGR	MN	Histamine H1 receptor (H1R)
DMJDQGR	MT	DTT
DMJDQGR	MA	Inhibitor
DMJDQGR	RN	Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504.
DMJDQGR	RU	https://pubmed.ncbi.nlm.nih.gov/19700330

DMIP5K7	DI	DMIP5K7
DMIP5K7	DN	N,N-Dimethyl-3,3-diphenylpropan-1-amine
DMIP5K7	MI	TTJQOD7
DMIP5K7	MN	5-HT 2A receptor (HTR2A)
DMIP5K7	MT	DTT
DMIP5K7	MA	Inhibitor
DMIP5K7	RN	Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504.
DMIP5K7	RU	https://pubmed.ncbi.nlm.nih.gov/19700330

DMIP5K7	DI	DMIP5K7
DMIP5K7	DN	N,N-Dimethyl-3,3-diphenylpropan-1-amine
DMIP5K7	MI	TTTIBOJ
DMIP5K7	MN	Histamine H1 receptor (H1R)
DMIP5K7	MT	DTT
DMIP5K7	MA	Inhibitor
DMIP5K7	RN	Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504.
DMIP5K7	RU	https://pubmed.ncbi.nlm.nih.gov/19700330

DMI3CUZ	DI	DMI3CUZ
DMI3CUZ	DN	N,N-dimethyl-3,4-dihydroquinazolin-2-amine
DMI3CUZ	MI	TTRUFDT
DMI3CUZ	MN	5-HT 5A receptor (HTR5A)
DMI3CUZ	MT	DTT
DMI3CUZ	MA	Inhibitor
DMI3CUZ	RN	Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61.
DMI3CUZ	RU	https://pubmed.ncbi.nlm.nih.gov/17998160

DMLX0PI	DI	DMLX0PI
DMLX0PI	DN	N,N-dimethyl-4-(pyridin-3-yl)but-3-yn-1-amine
DMLX0PI	MI	TT4H1MQ
DMLX0PI	MN	Neuronal acetylcholine receptor alpha-4 (CHRNA4)
DMLX0PI	MT	DTT
DMLX0PI	MA	Inhibitor
DMLX0PI	RN	Synthesis and analgesic activity of secondary amine analogues of pyridylmethylamine and positional isomeric analogues of ABT-594. Bioorg Med Chem Lett. 2006 Apr 1;16(7):2013-6.
DMLX0PI	RU	https://pubmed.ncbi.nlm.nih.gov/16412637

DMLX0PI	DI	DMLX0PI
DMLX0PI	DN	N,N-dimethyl-4-(pyridin-3-yl)but-3-yn-1-amine
DMLX0PI	MI	TT5KPZR
DMLX0PI	MN	Neuronal acetylcholine receptor beta-2 (CHRNB2)
DMLX0PI	MT	DTT
DMLX0PI	MA	Inhibitor
DMLX0PI	RN	Synthesis and analgesic activity of secondary amine analogues of pyridylmethylamine and positional isomeric analogues of ABT-594. Bioorg Med Chem Lett. 2006 Apr 1;16(7):2013-6.
DMLX0PI	RU	https://pubmed.ncbi.nlm.nih.gov/16412637

DMX9U7S	DI	DMX9U7S
DMX9U7S	DN	N,N-dimethyl-4,4-diphenylbutan-1-amine
DMX9U7S	MI	TTJQOD7
DMX9U7S	MN	5-HT 2A receptor (HTR2A)
DMX9U7S	MT	DTT
DMX9U7S	MA	Inhibitor
DMX9U7S	RN	Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504.
DMX9U7S	RU	https://pubmed.ncbi.nlm.nih.gov/19700330

DMX9U7S	DI	DMX9U7S
DMX9U7S	DN	N,N-dimethyl-4,4-diphenylbutan-1-amine
DMX9U7S	MI	TTTIBOJ
DMX9U7S	MN	Histamine H1 receptor (H1R)
DMX9U7S	MT	DTT
DMX9U7S	MA	Inhibitor
DMX9U7S	RN	Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504.
DMX9U7S	RU	https://pubmed.ncbi.nlm.nih.gov/19700330

DMWJ2PM	DI	DMWJ2PM
DMWJ2PM	DN	N,N-Dimethylaminoethyl 18-methoxycoronaridinate
DMWJ2PM	MI	TTTVAFQ
DMWJ2PM	MN	Neuronal acetylcholine receptor beta-4 (CHRNB4)
DMWJ2PM	MT	DTT
DMWJ2PM	MA	Inhibitor
DMWJ2PM	RN	Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents. J Med Chem. 2003 Jun 19;46(13):2716-30.
DMWJ2PM	RU	https://pubmed.ncbi.nlm.nih.gov/12801235

DM0Y8OW	DI	DM0Y8OW
DM0Y8OW	DN	N,N-dimethylarginine
DM0Y8OW	MI	TTCM4B3
DM0Y8OW	MN	Nitric-oxide synthase endothelial (NOS3)
DM0Y8OW	MT	DTT
DM0Y8OW	MA	Inhibitor
DM0Y8OW	RN	Homocysteine and asymmetric dimethylarginine (ADMA): biochemically linked but differently related to vascular disease in chronic kidney disease. Clin Chem Lab Med. 2007;45(12):1683-7.
DM0Y8OW	RU	https://pubmed.ncbi.nlm.nih.gov/17937610

DM0Y8OW	DI	DM0Y8OW
DM0Y8OW	DN	N,N-dimethylarginine
DM0Y8OW	MI	TTF10I9
DM0Y8OW	MN	Nitric-oxide synthase inducible (NOS2)
DM0Y8OW	MT	DTT
DM0Y8OW	MA	Inhibitor
DM0Y8OW	RN	Homocysteine and asymmetric dimethylarginine (ADMA): biochemically linked but differently related to vascular disease in chronic kidney disease. Clin Chem Lab Med. 2007;45(12):1683-7.
DM0Y8OW	RU	https://pubmed.ncbi.nlm.nih.gov/17937610

DM8WPD2	DI	DM8WPD2
DM8WPD2	DN	N,N-dimethylhistamine
DM8WPD2	MI	TTXJ178
DM8WPD2	MN	Histamine H4 receptor (H4R)
DM8WPD2	MT	DTT
DM8WPD2	MA	Agonist
DM8WPD2	RN	Compared pharmacology of human histamine H3 and H4 receptors: structure-activity relationships of histamine derivatives. Br J Pharmacol. 2006 Apr;147(7):744-54.
DM8WPD2	RU	https://pubmed.ncbi.nlm.nih.gov/16432504

DM8769D	DI	DM8769D
DM8769D	DN	N,N-Dipropyl-1'H-phenothiazine-1'-carboxamide
DM8769D	MI	TTEB0GD
DM8769D	MN	Cholinesterase (BCHE)
DM8769D	MT	DTT
DM8769D	MA	Inhibitor
DM8769D	RN	Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorg Med Chem. 2010 Mar 15;18(6):2232-2244.
DM8769D	RU	https://pubmed.ncbi.nlm.nih.gov/20181484

DMYCV7U	DI	DMYCV7U
DMYCV7U	DN	N,O6-Disulfo-Glucosamine
DMYCV7U	MI	TTGKIED
DMYCV7U	MN	Fibroblast growth factor-2 (FGF2)
DMYCV7U	MT	DTT
DMYCV7U	MA	Inhibitor
DMYCV7U	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMYCV7U	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMYCV7U	DI	DMYCV7U
DMYCV7U	DN	N,O6-Disulfo-Glucosamine
DMYCV7U	MI	TTMY81X
DMYCV7U	MN	Heparin-binding growth factor 1 (FGF1)
DMYCV7U	MT	DTT
DMYCV7U	MA	Inhibitor
DMYCV7U	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMYCV7U	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMYCV7U	DI	DMYCV7U
DMYCV7U	DN	N,O6-Disulfo-Glucosamine
DMYCV7U	MI	TT4V2JM
DMYCV7U	MN	Hepatocyte growth factor (HGF)
DMYCV7U	MT	DTT
DMYCV7U	MA	Inhibitor
DMYCV7U	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMYCV7U	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM7FT8D	DI	DM7FT8D
DM7FT8D	DN	N,O-Didansyl-L-Tyrosine
DM7FT8D	MI	TTU6BFZ
DM7FT8D	MN	Candida Thymidylate synthase (Candi TMP1)
DM7FT8D	MT	DTT
DM7FT8D	MA	Inhibitor
DM7FT8D	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM7FT8D	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMCGVAB	DI	DMCGVAB
DMCGVAB	DN	N/OFQ-(1-13)-NH2
DMCGVAB	MI	TTNT7K8
DMCGVAB	MN	Nociceptin receptor (OPRL1)
DMCGVAB	MT	DTT
DMCGVAB	MA	Agonist
DMCGVAB	RN	Address and message sequences for the nociceptin receptor: a structure-activity study of nociceptin-(1-13)-peptide amide. J Med Chem. 1997 Jun 6;40(12):1789-93.
DMCGVAB	RU	https://pubmed.ncbi.nlm.nih.gov/9191955

DMLTYPS	DI	DMLTYPS
DMLTYPS	DN	N-[(4-bromo-1-benzothien-3-yl)methyl]sulfamide
DMLTYPS	MI	TTANPDJ
DMLTYPS	MN	Carbonic anhydrase II (CA-II)
DMLTYPS	MT	DTT
DMLTYPS	MA	Inhibitor
DMLTYPS	RN	Novel, broad-spectrum anticonvulsants containing a sulfamide group: advancement of N-((benzo[b]thien-3-yl)methyl)sulfamide (JNJ-26990990) into huma... J Med Chem. 2009 Dec 10;52(23):7528-36.
DMLTYPS	RU	https://pubmed.ncbi.nlm.nih.gov/19388676

DMVOJFW	DI	DMVOJFW
DMVOJFW	DN	N-[(4-methoxyphenyl)sulfonyl]-D-alanine
DMVOJFW	MI	TTXZ0KQ
DMVOJFW	MN	Matrix metalloproteinase-12 (MMP-12)
DMVOJFW	MT	DTT
DMVOJFW	MA	Inhibitor
DMVOJFW	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMVOJFW	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMYJHRV	DI	DMYJHRV
DMYJHRV	DN	N-[(5-chloro-1-benzothien-3-yl)methyl]sulfamide
DMYJHRV	MI	TTANPDJ
DMYJHRV	MN	Carbonic anhydrase II (CA-II)
DMYJHRV	MT	DTT
DMYJHRV	MA	Inhibitor
DMYJHRV	RN	Novel, broad-spectrum anticonvulsants containing a sulfamide group: advancement of N-((benzo[b]thien-3-yl)methyl)sulfamide (JNJ-26990990) into huma... J Med Chem. 2009 Dec 10;52(23):7528-36.
DMYJHRV	RU	https://pubmed.ncbi.nlm.nih.gov/19388676

DMHNR36	DI	DMHNR36
DMHNR36	DN	N-[(CYCLOHEXYLAMINO)CARBONYL]GLYCINE
DMHNR36	MI	TT7WVHI
DMHNR36	MN	Soluble epoxide hydrolase (EPHX2)
DMHNR36	MT	DTT
DMHNR36	MA	Inhibitor
DMHNR36	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMHNR36	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMI9GQV	DI	DMI9GQV
DMI9GQV	DN	N-[2-(1H-benzoimidazol-2-yl)-benzoyl]-guanidine
DMI9GQV	MI	TTGSEFH
DMI9GQV	MN	Sodium/hydrogen exchanger 1 (SLC9A1)
DMI9GQV	MT	DTT
DMI9GQV	MA	Inhibitor
DMI9GQV	RN	Benzimidazol-2-yl or benzimidazol-2-ylthiomethyl benzoylguanidines as novel Na+/H+ exchanger inhibitors, synthesis and protection against ischemic-... Bioorg Med Chem Lett. 2007 May 1;17(9):2430-3.
DMI9GQV	RU	https://pubmed.ncbi.nlm.nih.gov/17346962

DMM7T13	DI	DMM7T13
DMM7T13	DN	N-[2-(1h-Indol-5-Yl)-Butyl]-4-Sulfamoyl-Benzamide
DMM7T13	MI	TTANPDJ
DMM7T13	MN	Carbonic anhydrase II (CA-II)
DMM7T13	MT	DTT
DMM7T13	MA	Inhibitor
DMM7T13	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMM7T13	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMPKBT1	DI	DMPKBT1
DMPKBT1	DN	N-[2-(4'-Nitrophenyl)ethyl]-imidazole
DMPKBT1	MI	TTSZLWK
DMPKBT1	MN	Aromatase (CYP19A1)
DMPKBT1	MT	DTT
DMPKBT1	MA	Inhibitor
DMPKBT1	RN	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
DMPKBT1	RU	https://pubmed.ncbi.nlm.nih.gov/20413308

DM5FQH8	DI	DM5FQH8
DM5FQH8	DN	N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]lauramide
DM5FQH8	MI	TTMI6F5
DM5FQH8	MN	Transient receptor potential cation channel V1 (TRPV1)
DM5FQH8	MT	DTT
DM5FQH8	MA	Inhibitor
DM5FQH8	RN	New N-arachidonoylserotonin analogues with potential "dual" mechanism of action against pain. J Med Chem. 2007 Dec 27;50(26):6554-69.
DM5FQH8	RU	https://pubmed.ncbi.nlm.nih.gov/18027904

DMG5PL7	DI	DMG5PL7
DMG5PL7	DN	N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]linoleamide
DMG5PL7	MI	TTMI6F5
DMG5PL7	MN	Transient receptor potential cation channel V1 (TRPV1)
DMG5PL7	MT	DTT
DMG5PL7	MA	Inhibitor
DMG5PL7	RN	New N-arachidonoylserotonin analogues with potential "dual" mechanism of action against pain. J Med Chem. 2007 Dec 27;50(26):6554-69.
DMG5PL7	RU	https://pubmed.ncbi.nlm.nih.gov/18027904

DMC1GYH	DI	DMC1GYH
DMC1GYH	DN	N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]undecanamide
DMC1GYH	MI	TTMI6F5
DMC1GYH	MN	Transient receptor potential cation channel V1 (TRPV1)
DMC1GYH	MT	DTT
DMC1GYH	MA	Inhibitor
DMC1GYH	RN	New N-arachidonoylserotonin analogues with potential "dual" mechanism of action against pain. J Med Chem. 2007 Dec 27;50(26):6554-69.
DMC1GYH	RU	https://pubmed.ncbi.nlm.nih.gov/18027904

DMJ8W6F	DI	DMJ8W6F
DMJ8W6F	DN	N-[2-(Indol-3-yl)ethyl]-S-benzyl-dithiocarbamate
DMJ8W6F	MI	TTZJYKH
DMJ8W6F	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMJ8W6F	MT	DTT
DMJ8W6F	MA	Inhibitor
DMJ8W6F	RN	Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2006 Jan 26;49(2):684-92.
DMJ8W6F	RU	https://pubmed.ncbi.nlm.nih.gov/16420054

DMU89FH	DI	DMU89FH
DMU89FH	DN	N-[3-(2-Ethyl-benzooxazol-7-yl)-propyl]-acetamide
DMU89FH	MI	TT32JK8
DMU89FH	MN	Melatonin receptor type 1B (MTNR1B)
DMU89FH	MT	DTT
DMU89FH	MA	Inhibitor
DMU89FH	RN	Synthesis and structure-activity relationship of novel benzoxazole derivatives as melatonin receptor agonists. Bioorg Med Chem Lett. 2004 Jul 16;14(14):3799-802.
DMU89FH	RU	https://pubmed.ncbi.nlm.nih.gov/15203165

DM7OA4R	DI	DM7OA4R
DM7OA4R	DN	N-[3'-(trifluoromethyl)-4-biphenylyl]urea
DM7OA4R	MI	TTBGTCW
DM7OA4R	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DM7OA4R	MT	DTT
DM7OA4R	MA	Inhibitor
DM7OA4R	RN	Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52.
DM7OA4R	RU	https://pubmed.ncbi.nlm.nih.gov/17725339

DMKPYEU	DI	DMKPYEU
DMKPYEU	DN	N-[3,3-Bis-(4-fluorophenyl)-propyl]-benzamide
DMKPYEU	MI	TT7WVHI
DMKPYEU	MN	Soluble epoxide hydrolase (EPHX2)
DMKPYEU	MT	DTT
DMKPYEU	MA	Inhibitor
DMKPYEU	RN	Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase. J Med Chem. 2009 Oct 8;52(19):5880-95.
DMKPYEU	RU	https://pubmed.ncbi.nlm.nih.gov/19746975

DMIP8AK	DI	DMIP8AK
DMIP8AK	DN	N-[3,3-Bis-(4-fluorophenyl)-propyl]-nicotinamide
DMIP8AK	MI	TT7WVHI
DMIP8AK	MN	Soluble epoxide hydrolase (EPHX2)
DMIP8AK	MT	DTT
DMIP8AK	MA	Inhibitor
DMIP8AK	RN	Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase. J Med Chem. 2009 Oct 8;52(19):5880-95.
DMIP8AK	RU	https://pubmed.ncbi.nlm.nih.gov/19746975

DMWDCV1	DI	DMWDCV1
DMWDCV1	DN	N-[3H]alpha-methylhistamine
DMWDCV1	MI	TT9JNIC
DMWDCV1	MN	Histamine H3 receptor (H3R)
DMWDCV1	MT	DTT
DMWDCV1	MA	Agonist
DMWDCV1	RN	Molecular and pharmacological characterization of the mouse histamine H3 receptor. Eur J Pharmacol. 2003 Apr 25;467(1-3):57-65.
DMWDCV1	RU	https://pubmed.ncbi.nlm.nih.gov/12706455

DMWDCV1	DI	DMWDCV1
DMWDCV1	DN	N-[3H]alpha-methylhistamine
DMWDCV1	MI	TTXJ178
DMWDCV1	MN	Histamine H4 receptor (H4R)
DMWDCV1	MT	DTT
DMWDCV1	MA	Agonist
DMWDCV1	RN	Histamine induces cytoskeletal changes in human eosinophils via the H(4) receptor. Br J Pharmacol. 2003 Nov;140(6):1117-27.
DMWDCV1	RU	https://pubmed.ncbi.nlm.nih.gov/14530216

DM0CI4L	DI	DM0CI4L
DM0CI4L	DN	N-[3H]methylhistamine
DM0CI4L	MI	TT9JNIC
DM0CI4L	MN	Histamine H3 receptor (H3R)
DM0CI4L	MT	DTT
DM0CI4L	MA	Agonist
DM0CI4L	RN	Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol. 2001 Mar;59(3):420-6.
DM0CI4L	RU	https://pubmed.ncbi.nlm.nih.gov/11179434

DM0CI4L	DI	DM0CI4L
DM0CI4L	DN	N-[3H]methylhistamine
DM0CI4L	MI	TTXJ178
DM0CI4L	MN	Histamine H4 receptor (H4R)
DM0CI4L	MT	DTT
DM0CI4L	MA	Agonist
DM0CI4L	RN	Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol. 2001 Mar;59(3):420-6.
DM0CI4L	RU	https://pubmed.ncbi.nlm.nih.gov/11179434

DMITN82	DI	DMITN82
DMITN82	DN	N-[4-(1,3-benzodioxol-5-yl)phenyl]sulfamide
DMITN82	MI	TTBGTCW
DMITN82	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DMITN82	MT	DTT
DMITN82	MA	Inhibitor
DMITN82	RN	Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52.
DMITN82	RU	https://pubmed.ncbi.nlm.nih.gov/17725339

DMT6LX9	DI	DMT6LX9
DMT6LX9	DN	N-[4-(1H-benzoimidazol-2-yl)-benzoyl]-guanidine
DMT6LX9	MI	TTGSEFH
DMT6LX9	MN	Sodium/hydrogen exchanger 1 (SLC9A1)
DMT6LX9	MT	DTT
DMT6LX9	MA	Inhibitor
DMT6LX9	RN	Benzimidazol-2-yl or benzimidazol-2-ylthiomethyl benzoylguanidines as novel Na+/H+ exchanger inhibitors, synthesis and protection against ischemic-... Bioorg Med Chem Lett. 2007 May 1;17(9):2430-3.
DMT6LX9	RU	https://pubmed.ncbi.nlm.nih.gov/17346962

DMLV18K	DI	DMLV18K
DMLV18K	DN	N-[4-(3-amino-1H-indazol-4-yl)phenyl]benzamide
DMLV18K	MI	TTGJCWZ
DMLV18K	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMLV18K	MT	DTT
DMLV18K	MA	Inhibitor
DMLV18K	RN	Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted ... J Med Chem. 2007 Apr 5;50(7):1584-97.
DMLV18K	RU	https://pubmed.ncbi.nlm.nih.gov/17343372

DMC62K1	DI	DMC62K1
DMC62K1	DN	N-[4-(3-pyridylethynyl)-2-thiazolyl]acetamide
DMC62K1	MI	TTHS256
DMC62K1	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMC62K1	MT	DTT
DMC62K1	MA	Inhibitor
DMC62K1	RN	Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100.
DMC62K1	RU	https://pubmed.ncbi.nlm.nih.gov/16451073

DMA4L5P	DI	DMA4L5P
DMA4L5P	DN	N-[4-(4-Phenyl-piperazin-1-yl)-butyl]-benzamide
DMA4L5P	MI	TTSQIFT
DMA4L5P	MN	5-HT 1A receptor (HTR1A)
DMA4L5P	MT	DTT
DMA4L5P	MA	Inhibitor
DMA4L5P	RN	Arylpiperazine derivatives as high-affinity 5-HT1A serotonin ligands. J Med Chem. 1988 Oct;31(10):1968-71.
DMA4L5P	RU	https://pubmed.ncbi.nlm.nih.gov/3172131

DMD5F6Z	DI	DMD5F6Z
DMD5F6Z	DN	N-[4'-(ethylsulfonyl)-3-fluoro-4-biphenylyl]urea
DMD5F6Z	MI	TTBGTCW
DMD5F6Z	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DMD5F6Z	MT	DTT
DMD5F6Z	MA	Inhibitor
DMD5F6Z	RN	Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52.
DMD5F6Z	RU	https://pubmed.ncbi.nlm.nih.gov/17725339

DMCTZFP	DI	DMCTZFP
DMCTZFP	DN	N-[4'-(trifluoromethyl)-4-biphenylyl]sulfamide
DMCTZFP	MI	TTBGTCW
DMCTZFP	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DMCTZFP	MT	DTT
DMCTZFP	MA	Inhibitor
DMCTZFP	RN	Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52.
DMCTZFP	RU	https://pubmed.ncbi.nlm.nih.gov/17725339

DMPVKWG	DI	DMPVKWG
DMPVKWG	DN	N-[4'-(trifluoromethyl)-4-biphenylyl]thiourea
DMPVKWG	MI	TTBGTCW
DMPVKWG	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DMPVKWG	MT	DTT
DMPVKWG	MA	Inhibitor
DMPVKWG	RN	Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52.
DMPVKWG	RU	https://pubmed.ncbi.nlm.nih.gov/17725339

DMMHQRT	DI	DMMHQRT
DMMHQRT	DN	N-[4'-(trifluoromethyl)-4-biphenylyl]urea
DMMHQRT	MI	TTBGTCW
DMMHQRT	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DMMHQRT	MT	DTT
DMMHQRT	MA	Inhibitor
DMMHQRT	RN	Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52.
DMMHQRT	RU	https://pubmed.ncbi.nlm.nih.gov/17725339

DMMX65T	DI	DMMX65T
DMMX65T	DN	N-[4-(trifluoromethyl)phenyl]sulfamide
DMMX65T	MI	TTHQPL7
DMMX65T	MN	Carbonic anhydrase I (CA-I)
DMMX65T	MT	DTT
DMMX65T	MA	Inhibitor
DMMX65T	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with N-hydroxy... Bioorg Med Chem Lett. 2005 May 2;15(9):2353-8.
DMMX65T	RU	https://pubmed.ncbi.nlm.nih.gov/15837324

DMMX65T	DI	DMMX65T
DMMX65T	DN	N-[4-(trifluoromethyl)phenyl]sulfamide
DMMX65T	MI	TTANPDJ
DMMX65T	MN	Carbonic anhydrase II (CA-II)
DMMX65T	MT	DTT
DMMX65T	MA	Inhibitor
DMMX65T	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with N-hydroxy... Bioorg Med Chem Lett. 2005 May 2;15(9):2353-8.
DMMX65T	RU	https://pubmed.ncbi.nlm.nih.gov/15837324

DMP5A8K	DI	DMP5A8K
DMP5A8K	DN	N-[5-(2-Ethyl-phenyl)-furan-2-carbonyl]-guanidine
DMP5A8K	MI	TTGSEFH
DMP5A8K	MN	Sodium/hydrogen exchanger 1 (SLC9A1)
DMP5A8K	MT	DTT
DMP5A8K	MA	Inhibitor
DMP5A8K	RN	(5-Arylfuran-2-ylcarbonyl)guanidines as cardioprotectives through the inhibition of Na+/H+ exchanger isoform-1. J Med Chem. 2005 Apr 21;48(8):2882-91.
DMP5A8K	RU	https://pubmed.ncbi.nlm.nih.gov/15828827

DMZ9V18	DI	DMZ9V18
DMZ9V18	DN	N-[5-(2-Nitro-phenyl)-furan-2-carbonyl]-guanidine
DMZ9V18	MI	TTGSEFH
DMZ9V18	MN	Sodium/hydrogen exchanger 1 (SLC9A1)
DMZ9V18	MT	DTT
DMZ9V18	MA	Inhibitor
DMZ9V18	RN	(5-Arylfuran-2-ylcarbonyl)guanidines as cardioprotectives through the inhibition of Na+/H+ exchanger isoform-1. J Med Chem. 2005 Apr 21;48(8):2882-91.
DMZ9V18	RU	https://pubmed.ncbi.nlm.nih.gov/15828827

DMSI4PE	DI	DMSI4PE
DMSI4PE	DN	N-[5-(ethylthio)-1,3,4-thiadiazol-2-yl]sulfamide
DMSI4PE	MI	TTUNARX
DMSI4PE	MN	Carbonic anhydrase (CA)
DMSI4PE	MT	DTT
DMSI4PE	MA	Inhibitor
DMSI4PE	RN	Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5.
DMSI4PE	RU	https://pubmed.ncbi.nlm.nih.gov/18990571

DMSI4PE	DI	DMSI4PE
DMSI4PE	DN	N-[5-(ethylthio)-1,3,4-thiadiazol-2-yl]sulfamide
DMSI4PE	MI	TTHQPL7
DMSI4PE	MN	Carbonic anhydrase I (CA-I)
DMSI4PE	MT	DTT
DMSI4PE	MA	Inhibitor
DMSI4PE	RN	Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5.
DMSI4PE	RU	https://pubmed.ncbi.nlm.nih.gov/18990571

DMSI4PE	DI	DMSI4PE
DMSI4PE	DN	N-[5-(ethylthio)-1,3,4-thiadiazol-2-yl]sulfamide
DMSI4PE	MI	TTANPDJ
DMSI4PE	MN	Carbonic anhydrase II (CA-II)
DMSI4PE	MT	DTT
DMSI4PE	MA	Inhibitor
DMSI4PE	RN	Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5.
DMSI4PE	RU	https://pubmed.ncbi.nlm.nih.gov/18990571

DMSI4PE	DI	DMSI4PE
DMSI4PE	DN	N-[5-(ethylthio)-1,3,4-thiadiazol-2-yl]sulfamide
DMSI4PE	MI	TTZHA0O
DMSI4PE	MN	Carbonic anhydrase IV (CA-IV)
DMSI4PE	MT	DTT
DMSI4PE	MA	Inhibitor
DMSI4PE	RN	Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5.
DMSI4PE	RU	https://pubmed.ncbi.nlm.nih.gov/18990571

DMH7QOF	DI	DMH7QOF
DMH7QOF	DN	N-[5-(Formyl-hydroxy-amino)-pentyl]-benzamide
DMH7QOF	MI	TT5ZKDI
DMH7QOF	MN	Histone deacetylase 6 (HDAC6)
DMH7QOF	MT	DTT
DMH7QOF	MA	Inhibitor
DMH7QOF	RN	Design, synthesis, and activity of HDAC inhibitors with a N-formyl hydroxylamine head group. Bioorg Med Chem Lett. 2004 Jan 19;14(2):449-53.
DMH7QOF	RU	https://pubmed.ncbi.nlm.nih.gov/14698179

DMXLJGR	DI	DMXLJGR
DMXLJGR	DN	N-[5-(methylthio)-1,3,4-thiadiazol-2-yl]sulfamide
DMXLJGR	MI	TTUNARX
DMXLJGR	MN	Carbonic anhydrase (CA)
DMXLJGR	MT	DTT
DMXLJGR	MA	Inhibitor
DMXLJGR	RN	Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5.
DMXLJGR	RU	https://pubmed.ncbi.nlm.nih.gov/18990571

DMXLJGR	DI	DMXLJGR
DMXLJGR	DN	N-[5-(methylthio)-1,3,4-thiadiazol-2-yl]sulfamide
DMXLJGR	MI	TTHQPL7
DMXLJGR	MN	Carbonic anhydrase I (CA-I)
DMXLJGR	MT	DTT
DMXLJGR	MA	Inhibitor
DMXLJGR	RN	Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5.
DMXLJGR	RU	https://pubmed.ncbi.nlm.nih.gov/18990571

DMXLJGR	DI	DMXLJGR
DMXLJGR	DN	N-[5-(methylthio)-1,3,4-thiadiazol-2-yl]sulfamide
DMXLJGR	MI	TTANPDJ
DMXLJGR	MN	Carbonic anhydrase II (CA-II)
DMXLJGR	MT	DTT
DMXLJGR	MA	Inhibitor
DMXLJGR	RN	Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5.
DMXLJGR	RU	https://pubmed.ncbi.nlm.nih.gov/18990571

DMXLJGR	DI	DMXLJGR
DMXLJGR	DN	N-[5-(methylthio)-1,3,4-thiadiazol-2-yl]sulfamide
DMXLJGR	MI	TTZHA0O
DMXLJGR	MN	Carbonic anhydrase IV (CA-IV)
DMXLJGR	MT	DTT
DMXLJGR	MA	Inhibitor
DMXLJGR	RN	Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5.
DMXLJGR	RU	https://pubmed.ncbi.nlm.nih.gov/18990571

DMVY7RX	DI	DMVY7RX
DMVY7RX	DN	N-[6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-YL]-4,4,4-TRIFLUORO-3-HYDROXYBUTANAMIDE (DIASTEREOMERIC MIX)
DMVY7RX	MI	TT6OEDT
DMVY7RX	MN	Cannabinoid receptor 1 (CB1)
DMVY7RX	MT	DTT
DMVY7RX	MA	Inhibitor
DMVY7RX	RN	Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carbox... J Med Chem. 2010 May 27;53(10):4028-37.
DMVY7RX	RU	https://pubmed.ncbi.nlm.nih.gov/20423086

DMVY7RX	DI	DMVY7RX
DMVY7RX	DN	N-[6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-YL]-4,4,4-TRIFLUORO-3-HYDROXYBUTANAMIDE (DIASTEREOMERIC MIX)
DMVY7RX	MI	TTMSFAW
DMVY7RX	MN	Cannabinoid receptor 2 (CB2)
DMVY7RX	MT	DTT
DMVY7RX	MA	Inhibitor
DMVY7RX	RN	Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carbox... J Med Chem. 2010 May 27;53(10):4028-37.
DMVY7RX	RU	https://pubmed.ncbi.nlm.nih.gov/20423086

DMVY7RX	DI	DMVY7RX
DMVY7RX	DN	N-[6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-YL]-4,4,4-TRIFLUORO-3-HYDROXYBUTANAMIDE (DIASTEREOMERIC MIX)
DMVY7RX	MI	TTQ6VDM
DMVY7RX	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMVY7RX	MT	DTT
DMVY7RX	MA	Inhibitor
DMVY7RX	RN	Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carbox... J Med Chem. 2010 May 27;53(10):4028-37.
DMVY7RX	RU	https://pubmed.ncbi.nlm.nih.gov/20423086

DM6EICU	DI	DM6EICU
DM6EICU	DN	N-[O-Phosphono-Pyridoxyl]-Isoleucine
DM6EICU	MI	TTF9OQ6
DM6EICU	MN	Branched-chain-amino-acid transaminase 2 (BCAT2)
DM6EICU	MT	DTT
DM6EICU	MA	Inhibitor
DM6EICU	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM6EICU	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMN493F	DI	DMN493F
DMN493F	DN	N-[Tosyl-D-Prolinyl]Amino-Ethanethiol
DMN493F	MI	TTU6BFZ
DMN493F	MN	Candida Thymidylate synthase (Candi TMP1)
DMN493F	MT	DTT
DMN493F	MA	Inhibitor
DMN493F	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMN493F	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMX4QKU	DI	DMX4QKU
DMX4QKU	DN	N-{2-[4-(AMINOSULFONYL)PHENYL]ETHYL}ACETAMIDE
DMX4QKU	MI	TTHQPL7
DMX4QKU	MN	Carbonic anhydrase I (CA-I)
DMX4QKU	MT	DTT
DMX4QKU	MA	Inhibitor
DMX4QKU	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMX4QKU	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMX4QKU	DI	DMX4QKU
DMX4QKU	DN	N-{2-[4-(AMINOSULFONYL)PHENYL]ETHYL}ACETAMIDE
DMX4QKU	MI	TTANPDJ
DMX4QKU	MN	Carbonic anhydrase II (CA-II)
DMX4QKU	MT	DTT
DMX4QKU	MA	Inhibitor
DMX4QKU	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMX4QKU	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM74KHG	DI	DM74KHG
DM74KHG	DN	N-{4-[(benzylamino)sulfonyl]-1-naphthyl}benzamide
DM74KHG	MI	TTE836A
DM74KHG	MN	C-C chemokine receptor type 8 (CCR8)
DM74KHG	MT	DTT
DM74KHG	MA	Inhibitor
DM74KHG	RN	Design, synthesis, and evaluation of naphthalene-sulfonamide antagonists of human CCR8. J Med Chem. 2007 Feb 8;50(3):566-84.
DM74KHG	RU	https://pubmed.ncbi.nlm.nih.gov/17266208

DM90U5P	DI	DM90U5P
DM90U5P	DN	N-{4'-[(trifluoromethyl)sulfonyl]-4-biphenyl}urea
DM90U5P	MI	TTBGTCW
DM90U5P	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DM90U5P	MT	DTT
DM90U5P	MA	Inhibitor
DM90U5P	RN	Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52.
DM90U5P	RU	https://pubmed.ncbi.nlm.nih.gov/17725339

DMEIB69	DI	DMEIB69
DMEIB69	DN	N-{4'-[(trifluoromethyl)thio]-4-biphenyl}urea
DMEIB69	MI	TTBGTCW
DMEIB69	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DMEIB69	MT	DTT
DMEIB69	MA	Inhibitor
DMEIB69	RN	Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52.
DMEIB69	RU	https://pubmed.ncbi.nlm.nih.gov/17725339

DMO3VLJ	DI	DMO3VLJ
DMO3VLJ	DN	N-{4-[2-(3-Hydroxyphenyl)ethyl]phenyl}phthalimide
DMO3VLJ	MI	TTECBXN
DMO3VLJ	MN	Oxysterols receptor LXR-alpha (NR1H3)
DMO3VLJ	MT	DTT
DMO3VLJ	MA	Inhibitor
DMO3VLJ	RN	Separation of alpha-glucosidase-inhibitory and liver X receptor-antagonistic activities of phenethylphenyl phthalimide analogs and generation of LX... Bioorg Med Chem. 2009 Jul 15;17(14):5001-14.
DMO3VLJ	RU	https://pubmed.ncbi.nlm.nih.gov/19539483

DMZ4N7Q	DI	DMZ4N7Q
DMZ4N7Q	DN	N-{4-[2-(3-Methoxyphenyl)ethyl]phenyl}phthalimide
DMZ4N7Q	MI	TTECBXN
DMZ4N7Q	MN	Oxysterols receptor LXR-alpha (NR1H3)
DMZ4N7Q	MT	DTT
DMZ4N7Q	MA	Inhibitor
DMZ4N7Q	RN	Separation of alpha-glucosidase-inhibitory and liver X receptor-antagonistic activities of phenethylphenyl phthalimide analogs and generation of LX... Bioorg Med Chem. 2009 Jul 15;17(14):5001-14.
DMZ4N7Q	RU	https://pubmed.ncbi.nlm.nih.gov/19539483

DMZ4N7Q	DI	DMZ4N7Q
DMZ4N7Q	DN	N-{4-[2-(3-Methoxyphenyl)ethyl]phenyl}phthalimide
DMZ4N7Q	MI	TTXA6PH
DMZ4N7Q	MN	Oxysterols receptor LXR-beta (NR1H2)
DMZ4N7Q	MT	DTT
DMZ4N7Q	MA	Inhibitor
DMZ4N7Q	RN	Separation of alpha-glucosidase-inhibitory and liver X receptor-antagonistic activities of phenethylphenyl phthalimide analogs and generation of LX... Bioorg Med Chem. 2009 Jul 15;17(14):5001-14.
DMZ4N7Q	RU	https://pubmed.ncbi.nlm.nih.gov/19539483

DMXU5IS	DI	DMXU5IS
DMXU5IS	DN	N-{4-[2-(4-Hydroxyphenyl)ethyl]phenyl}phthalimide
DMXU5IS	MI	TTECBXN
DMXU5IS	MN	Oxysterols receptor LXR-alpha (NR1H3)
DMXU5IS	MT	DTT
DMXU5IS	MA	Inhibitor
DMXU5IS	RN	Separation of alpha-glucosidase-inhibitory and liver X receptor-antagonistic activities of phenethylphenyl phthalimide analogs and generation of LX... Bioorg Med Chem. 2009 Jul 15;17(14):5001-14.
DMXU5IS	RU	https://pubmed.ncbi.nlm.nih.gov/19539483

DM0S71O	DI	DM0S71O
DM0S71O	DN	N-{4-[2-(4-Methoxyphenyl)ethyl]phenyl}phthalimide
DM0S71O	MI	TTECBXN
DM0S71O	MN	Oxysterols receptor LXR-alpha (NR1H3)
DM0S71O	MT	DTT
DM0S71O	MA	Inhibitor
DM0S71O	RN	Separation of alpha-glucosidase-inhibitory and liver X receptor-antagonistic activities of phenethylphenyl phthalimide analogs and generation of LX... Bioorg Med Chem. 2009 Jul 15;17(14):5001-14.
DM0S71O	RU	https://pubmed.ncbi.nlm.nih.gov/19539483

DML35GB	DI	DML35GB
DML35GB	DN	N~3~-(3-PYRIDIN-3-YLBENZYL)PYRIDINE-2,3-DIAMINE
DML35GB	MI	TT8JRS7
DML35GB	MN	Beta-secretase (BACE)
DML35GB	MT	DTT
DML35GB	MA	Inhibitor
DML35GB	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DML35GB	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMOCQ9I	DI	DMOCQ9I
DMOCQ9I	DN	N~3~-BENZYLPYRIDINE-2,3-DIAMINE
DMOCQ9I	MI	TT8JRS7
DMOCQ9I	MN	Beta-secretase (BACE)
DMOCQ9I	MT	DTT
DMOCQ9I	MA	Inhibitor
DMOCQ9I	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMOCQ9I	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM6HM5S	DI	DM6HM5S
DM6HM5S	DN	N1-(2-aminoethyl)ethane-1,2-diamine
DM6HM5S	MI	TTUNARX
DM6HM5S	MN	Carbonic anhydrase (CA)
DM6HM5S	MT	DTT
DM6HM5S	MA	Inhibitor
DM6HM5S	RN	Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22.
DM6HM5S	RU	https://pubmed.ncbi.nlm.nih.gov/20590092

DM6HM5S	DI	DM6HM5S
DM6HM5S	DN	N1-(2-aminoethyl)ethane-1,2-diamine
DM6HM5S	MI	TT2LVK8
DM6HM5S	MN	Carbonic anhydrase IX (CA-IX)
DM6HM5S	MT	DTT
DM6HM5S	MA	Inhibitor
DM6HM5S	RN	Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22.
DM6HM5S	RU	https://pubmed.ncbi.nlm.nih.gov/20590092

DM6HM5S	DI	DM6HM5S
DM6HM5S	DN	N1-(2-aminoethyl)ethane-1,2-diamine
DM6HM5S	MI	TTCFSPE
DM6HM5S	MN	Carbonic anhydrase VI (CA-VI)
DM6HM5S	MT	DTT
DM6HM5S	MA	Inhibitor
DM6HM5S	RN	Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22.
DM6HM5S	RU	https://pubmed.ncbi.nlm.nih.gov/20590092

DM6HM5S	DI	DM6HM5S
DM6HM5S	DN	N1-(2-aminoethyl)ethane-1,2-diamine
DM6HM5S	MI	TTSYM0R
DM6HM5S	MN	Carbonic anhydrase XII (CA-XII)
DM6HM5S	MT	DTT
DM6HM5S	MA	Inhibitor
DM6HM5S	RN	Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22.
DM6HM5S	RU	https://pubmed.ncbi.nlm.nih.gov/20590092

DM6HM5S	DI	DM6HM5S
DM6HM5S	DN	N1-(2-aminoethyl)ethane-1,2-diamine
DM6HM5S	MI	TTEYTKG
DM6HM5S	MN	Carbonic anhydrase XIV (CA-XIV)
DM6HM5S	MT	DTT
DM6HM5S	MA	Inhibitor
DM6HM5S	RN	Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22.
DM6HM5S	RU	https://pubmed.ncbi.nlm.nih.gov/20590092

DM6HM5S	DI	DM6HM5S
DM6HM5S	DN	N1-(2-aminoethyl)ethane-1,2-diamine
DM6HM5S	MI	DEMWO83
DM6HM5S	MN	Putrescine acetyltransferase (SSAT1)
DM6HM5S	MT	DME
DM6HM5S	MA	Metabolism
DM6HM5S	RN	Mechanistic and structural analysis of human spermidine/spermine N1-acetyltransferase. Biochemistry. 2007 Jun 19;46(24):7187-95.
DM6HM5S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17516632

DM5F04D	DI	DM5F04D
DM5F04D	DN	N1-(3,3-diphenylpropyl)-N3-hydroxymalonamide
DM5F04D	MI	TTPHMWB
DM5F04D	MN	Aminopeptidase N (ANPEP)
DM5F04D	MT	DTT
DM5F04D	MA	Inhibitor
DM5F04D	RN	Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents. J Med Chem. 2007 Mar 22;50(6):1322-34.
DM5F04D	RU	https://pubmed.ncbi.nlm.nih.gov/17326615

DMSRHJA	DI	DMSRHJA
DMSRHJA	DN	N1-(3-phenoxybenzyl)-N3-hydroxymalonamide
DMSRHJA	MI	TTPHMWB
DMSRHJA	MN	Aminopeptidase N (ANPEP)
DMSRHJA	MT	DTT
DMSRHJA	MA	Inhibitor
DMSRHJA	RN	Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents. J Med Chem. 2007 Mar 22;50(6):1322-34.
DMSRHJA	RU	https://pubmed.ncbi.nlm.nih.gov/17326615

DMCH7GO	DI	DMCH7GO
DMCH7GO	DN	N1-(4-bromophenyl)-N2,N2-dipentylphthalamide
DMCH7GO	MI	TTMSFAW
DMCH7GO	MN	Cannabinoid receptor 2 (CB2)
DMCH7GO	MT	DTT
DMCH7GO	MA	Inhibitor
DMCH7GO	RN	Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow. J Med Chem. 2009 Jan 22;52(2):369-78.
DMCH7GO	RU	https://pubmed.ncbi.nlm.nih.gov/19143566

DMJ025O	DI	DMJ025O
DMJ025O	DN	N1-(4-chlorobenzyl)-2-amino-N3-hydroxymalonamide
DMJ025O	MI	TTPHMWB
DMJ025O	MN	Aminopeptidase N (ANPEP)
DMJ025O	MT	DTT
DMJ025O	MA	Inhibitor
DMJ025O	RN	Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents. J Med Chem. 2007 Mar 22;50(6):1322-34.
DMJ025O	RU	https://pubmed.ncbi.nlm.nih.gov/17326615

DMTMDZ4	DI	DMTMDZ4
DMTMDZ4	DN	N1-(4-chlorobenzyl)-2-benzyl-N3-hydroxymalonamide
DMTMDZ4	MI	TTPHMWB
DMTMDZ4	MN	Aminopeptidase N (ANPEP)
DMTMDZ4	MT	DTT
DMTMDZ4	MA	Inhibitor
DMTMDZ4	RN	Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents. J Med Chem. 2007 Mar 22;50(6):1322-34.
DMTMDZ4	RU	https://pubmed.ncbi.nlm.nih.gov/17326615

DMS1P85	DI	DMS1P85
DMS1P85	DN	N1-(4-fluorobenzyl)-2-benzyl-N3-hydroxymalonamide
DMS1P85	MI	TTPHMWB
DMS1P85	MN	Aminopeptidase N (ANPEP)
DMS1P85	MT	DTT
DMS1P85	MA	Inhibitor
DMS1P85	RN	Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents. J Med Chem. 2007 Mar 22;50(6):1322-34.
DMS1P85	RU	https://pubmed.ncbi.nlm.nih.gov/17326615

DMMQXON	DI	DMMQXON
DMMQXON	DN	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide
DMMQXON	MI	TT6R7JZ
DMMQXON	MN	Histone deacetylase 1 (HDAC1)
DMMQXON	MT	DTT
DMMQXON	MA	Inhibitor
DMMQXON	RN	Sulfamides as novel histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):336-40.
DMMQXON	RU	https://pubmed.ncbi.nlm.nih.gov/19084395

DMMQXON	DI	DMMQXON
DMMQXON	DN	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide
DMMQXON	MI	TT5ZKDI
DMMQXON	MN	Histone deacetylase 6 (HDAC6)
DMMQXON	MT	DTT
DMMQXON	MA	Inhibitor
DMMQXON	RN	Sulfamides as novel histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):336-40.
DMMQXON	RU	https://pubmed.ncbi.nlm.nih.gov/19084395

DMZA8NC	DI	DMZA8NC
DMZA8NC	DN	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide
DMZA8NC	MI	TTBH0VX
DMZA8NC	MN	Histone deacetylase (HDAC)
DMZA8NC	MT	DTT
DMZA8NC	MA	Inhibitor
DMZA8NC	RN	Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity. Bioorg Med Chem Lett. 2009 Jun 1;19(11):3023-6.
DMZA8NC	RU	https://pubmed.ncbi.nlm.nih.gov/19419863

DMZA8NC	DI	DMZA8NC
DMZA8NC	DN	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide
DMZA8NC	MI	TT6R7JZ
DMZA8NC	MN	Histone deacetylase 1 (HDAC1)
DMZA8NC	MT	DTT
DMZA8NC	MA	Inhibitor
DMZA8NC	RN	Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity. Bioorg Med Chem Lett. 2009 Jun 1;19(11):3023-6.
DMZA8NC	RU	https://pubmed.ncbi.nlm.nih.gov/19419863

DMZA8NC	DI	DMZA8NC
DMZA8NC	DN	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide
DMZA8NC	MI	TT5ZKDI
DMZA8NC	MN	Histone deacetylase 6 (HDAC6)
DMZA8NC	MT	DTT
DMZA8NC	MA	Inhibitor
DMZA8NC	RN	Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity. Bioorg Med Chem Lett. 2009 Jun 1;19(11):3023-6.
DMZA8NC	RU	https://pubmed.ncbi.nlm.nih.gov/19419863

DMYGCSV	DI	DMYGCSV
DMYGCSV	DN	N1-(naphthalen-1-yl)ethane-1,2-diamine
DMYGCSV	MI	TTUNARX
DMYGCSV	MN	Carbonic anhydrase (CA)
DMYGCSV	MT	DTT
DMYGCSV	MA	Inhibitor
DMYGCSV	RN	Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22.
DMYGCSV	RU	https://pubmed.ncbi.nlm.nih.gov/20590092

DMYGCSV	DI	DMYGCSV
DMYGCSV	DN	N1-(naphthalen-1-yl)ethane-1,2-diamine
DMYGCSV	MI	TTZHA0O
DMYGCSV	MN	Carbonic anhydrase IV (CA-IV)
DMYGCSV	MT	DTT
DMYGCSV	MA	Inhibitor
DMYGCSV	RN	Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22.
DMYGCSV	RU	https://pubmed.ncbi.nlm.nih.gov/20590092

DMYGCSV	DI	DMYGCSV
DMYGCSV	DN	N1-(naphthalen-1-yl)ethane-1,2-diamine
DMYGCSV	MI	TT2LVK8
DMYGCSV	MN	Carbonic anhydrase IX (CA-IX)
DMYGCSV	MT	DTT
DMYGCSV	MA	Inhibitor
DMYGCSV	RN	Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22.
DMYGCSV	RU	https://pubmed.ncbi.nlm.nih.gov/20590092

DMYGCSV	DI	DMYGCSV
DMYGCSV	DN	N1-(naphthalen-1-yl)ethane-1,2-diamine
DMYGCSV	MI	TTCFSPE
DMYGCSV	MN	Carbonic anhydrase VI (CA-VI)
DMYGCSV	MT	DTT
DMYGCSV	MA	Inhibitor
DMYGCSV	RN	Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22.
DMYGCSV	RU	https://pubmed.ncbi.nlm.nih.gov/20590092

DMYGCSV	DI	DMYGCSV
DMYGCSV	DN	N1-(naphthalen-1-yl)ethane-1,2-diamine
DMYGCSV	MI	TTSYM0R
DMYGCSV	MN	Carbonic anhydrase XII (CA-XII)
DMYGCSV	MT	DTT
DMYGCSV	MA	Inhibitor
DMYGCSV	RN	Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22.
DMYGCSV	RU	https://pubmed.ncbi.nlm.nih.gov/20590092

DMYGCSV	DI	DMYGCSV
DMYGCSV	DN	N1-(naphthalen-1-yl)ethane-1,2-diamine
DMYGCSV	MI	TTEYTKG
DMYGCSV	MN	Carbonic anhydrase XIV (CA-XIV)
DMYGCSV	MT	DTT
DMYGCSV	MA	Inhibitor
DMYGCSV	RN	Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22.
DMYGCSV	RU	https://pubmed.ncbi.nlm.nih.gov/20590092

DMM59IS	DI	DMM59IS
DMM59IS	DN	N1,2-dibenzyl-N3-hydroxymalonamide
DMM59IS	MI	TTPHMWB
DMM59IS	MN	Aminopeptidase N (ANPEP)
DMM59IS	MT	DTT
DMM59IS	MA	Inhibitor
DMM59IS	RN	Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents. J Med Chem. 2007 Mar 22;50(6):1322-34.
DMM59IS	RU	https://pubmed.ncbi.nlm.nih.gov/17326615

DM1L89K	DI	DM1L89K
DM1L89K	DN	N1,2-dibenzyl-N3-hydroxy-N1-phenethylmalonamide
DM1L89K	MI	TTPHMWB
DM1L89K	MN	Aminopeptidase N (ANPEP)
DM1L89K	MT	DTT
DM1L89K	MA	Inhibitor
DM1L89K	RN	Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents. J Med Chem. 2007 Mar 22;50(6):1322-34.
DM1L89K	RU	https://pubmed.ncbi.nlm.nih.gov/17326615

DMJ10WH	DI	DMJ10WH
DMJ10WH	DN	N-1,3,4-thiadiazol-2-ylsulfamide
DMJ10WH	MI	TTHQPL7
DMJ10WH	MN	Carbonic anhydrase I (CA-I)
DMJ10WH	MT	DTT
DMJ10WH	MA	Inhibitor
DMJ10WH	RN	Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5.
DMJ10WH	RU	https://pubmed.ncbi.nlm.nih.gov/18990571

DMJ10WH	DI	DMJ10WH
DMJ10WH	DN	N-1,3,4-thiadiazol-2-ylsulfamide
DMJ10WH	MI	TTANPDJ
DMJ10WH	MN	Carbonic anhydrase II (CA-II)
DMJ10WH	MT	DTT
DMJ10WH	MA	Inhibitor
DMJ10WH	RN	Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5.
DMJ10WH	RU	https://pubmed.ncbi.nlm.nih.gov/18990571

DMJ10WH	DI	DMJ10WH
DMJ10WH	DN	N-1,3,4-thiadiazol-2-ylsulfamide
DMJ10WH	MI	TTZHA0O
DMJ10WH	MN	Carbonic anhydrase IV (CA-IV)
DMJ10WH	MT	DTT
DMJ10WH	MA	Inhibitor
DMJ10WH	RN	Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5.
DMJ10WH	RU	https://pubmed.ncbi.nlm.nih.gov/18990571

DMVIGCJ	DI	DMVIGCJ
DMVIGCJ	DN	N1,N14-Bis((S-Methyl)Isothioureido)Tetradecane
DMVIGCJ	MI	TTCM4B3
DMVIGCJ	MN	Nitric-oxide synthase endothelial (NOS3)
DMVIGCJ	MT	DTT
DMVIGCJ	MA	Inhibitor
DMVIGCJ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMVIGCJ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMSDVGQ	DI	DMSDVGQ
DMSDVGQ	DN	N1,N2-bis(dihydrocaffeoyl)spermine
DMSDVGQ	MI	TTRTKPV
DMSDVGQ	MN	Trypanosoma Trypanothione reductase (Trypano TPR)
DMSDVGQ	MT	DTT
DMSDVGQ	MA	Inhibitor
DMSDVGQ	RN	The use of natural product scaffolds as leads in the search for trypanothione reductase inhibitors. Bioorg Med Chem. 2008 Jul 15;16(14):6689-95.
DMSDVGQ	RU	https://pubmed.ncbi.nlm.nih.gov/18558492

DMA5Z7P	DI	DMA5Z7P
DMA5Z7P	DN	N1,N3-bis(3-methoxybenzyl)isophthalamide
DMA5Z7P	MI	TTHY57M
DMA5Z7P	MN	Matrix metalloproteinase-13 (MMP-13)
DMA5Z7P	MT	DTT
DMA5Z7P	MA	Inhibitor
DMA5Z7P	RN	Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment ... Bioorg Med Chem Lett. 2010 Jan 15;20(2):576-80.
DMA5Z7P	RU	https://pubmed.ncbi.nlm.nih.gov/20005097

DMRO7JX	DI	DMRO7JX
DMRO7JX	DN	N1,N4-bis(5-chloro-2-methylphenyl)succinamide
DMRO7JX	MI	TTEAID7
DMRO7JX	MN	Trypanosoma Cruzipain (Trypano CYSP)
DMRO7JX	MT	DTT
DMRO7JX	MA	Inhibitor
DMRO7JX	RN	Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease. J Med Chem. 2010 Jan 14;53(1):37-51.
DMRO7JX	RU	https://pubmed.ncbi.nlm.nih.gov/19908840

DM4Q86B	DI	DM4Q86B
DM4Q86B	DN	N1-[4-(Phenylmethoxy)phenyl]-D-aspartamine
DM4Q86B	MI	TTXZEAJ
DM4Q86B	MN	Leukotriene A-4 hydrolase (LTA4H)
DM4Q86B	MT	DTT
DM4Q86B	MA	Inhibitor
DM4Q86B	RN	Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83.
DM4Q86B	RU	https://pubmed.ncbi.nlm.nih.gov/18394906

DMK10WX	DI	DMK10WX
DMK10WX	DN	N1-[4-(Phenylmethoxy)phenyl]-D-glutamine
DMK10WX	MI	TTXZEAJ
DMK10WX	MN	Leukotriene A-4 hydrolase (LTA4H)
DMK10WX	MT	DTT
DMK10WX	MA	Inhibitor
DMK10WX	RN	Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83.
DMK10WX	RU	https://pubmed.ncbi.nlm.nih.gov/18394906

DMLEMUX	DI	DMLEMUX
DMLEMUX	DN	N1-[4-(Phenylmethoxy)phenyl]-L-aspartamine
DMLEMUX	MI	TTXZEAJ
DMLEMUX	MN	Leukotriene A-4 hydrolase (LTA4H)
DMLEMUX	MT	DTT
DMLEMUX	MA	Inhibitor
DMLEMUX	RN	Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83.
DMLEMUX	RU	https://pubmed.ncbi.nlm.nih.gov/18394906

DM9XCZS	DI	DM9XCZS
DM9XCZS	DN	N1-[4-(Phenylmethoxy)phenyl]-L-glutamine
DM9XCZS	MI	TTXZEAJ
DM9XCZS	MN	Leukotriene A-4 hydrolase (LTA4H)
DM9XCZS	MT	DTT
DM9XCZS	MA	Inhibitor
DM9XCZS	RN	Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83.
DM9XCZS	RU	https://pubmed.ncbi.nlm.nih.gov/18394906

DMXSFWK	DI	DMXSFWK
DMXSFWK	DN	N1-benzyl-N3-hydroxy-2-isobutylmalonamide
DMXSFWK	MI	TTPHMWB
DMXSFWK	MN	Aminopeptidase N (ANPEP)
DMXSFWK	MT	DTT
DMXSFWK	MA	Inhibitor
DMXSFWK	RN	A library of novel hydroxamic acids targeting the metallo-protease family: design, parallel synthesis and screening. Bioorg Med Chem. 2007 Jan 1;15(1):63-76.
DMXSFWK	RU	https://pubmed.ncbi.nlm.nih.gov/17070058

DM76CLF	DI	DM76CLF
DM76CLF	DN	N1-dansyl-spermine
DM76CLF	MI	TTKJEMQ
DM76CLF	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DM76CLF	MT	DTT
DM76CLF	MA	Blocker (channel blocker)
DM76CLF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456).
DM76CLF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=456

DM76CLF	DI	DM76CLF
DM76CLF	DN	N1-dansyl-spermine
DM76CLF	MI	TTN9D8E
DM76CLF	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DM76CLF	MT	DTT
DM76CLF	MA	Blocker (channel blocker)
DM76CLF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457).
DM76CLF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=457

DM76CLF	DI	DM76CLF
DM76CLF	DN	N1-dansyl-spermine
DM76CLF	MI	TT1M8OW
DM76CLF	MN	Glutamate receptor ionotropic NMDA 2C (GluN2C)
DM76CLF	MT	DTT
DM76CLF	MA	Blocker (channel blocker)
DM76CLF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 458).
DM76CLF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=458

DM76CLF	DI	DM76CLF
DM76CLF	DN	N1-dansyl-spermine
DM76CLF	MI	TT5POTG
DM76CLF	MN	Glutamate receptor ionotropic NMDA 2D (GluN2D)
DM76CLF	MT	DTT
DM76CLF	MA	Blocker (channel blocker)
DM76CLF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 459).
DM76CLF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=459

DMXE8CB	DI	DMXE8CB
DMXE8CB	DN	N1-guanyl-1,7-diaminoheptane
DMXE8CB	MI	TTBO2A9
DMXE8CB	MN	Deoxyhypusine synthase (DHPS)
DMXE8CB	MT	DTT
DMXE8CB	MA	Inhibitor
DMXE8CB	RN	Effects of N1-guanyl-1,7-diaminoheptane, an inhibitor of deoxyhypusine synthase, on the growth of tumorigenic cell lines in culture. Biochim Biophys Acta. 1996 Jan 10;1310(1):119-26.
DMXE8CB	RU	https://pubmed.ncbi.nlm.nih.gov/9244184

DMF6RVS	DI	DMF6RVS
DMF6RVS	DN	N1-hydroxy-2-isobutyl-N3-phenethylmalonamide
DMF6RVS	MI	TTPHMWB
DMF6RVS	MN	Aminopeptidase N (ANPEP)
DMF6RVS	MT	DTT
DMF6RVS	MA	Inhibitor
DMF6RVS	RN	A library of novel hydroxamic acids targeting the metallo-protease family: design, parallel synthesis and screening. Bioorg Med Chem. 2007 Jan 1;15(1):63-76.
DMF6RVS	RU	https://pubmed.ncbi.nlm.nih.gov/17070058

DMOZARM	DI	DMOZARM
DMOZARM	DN	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide
DMOZARM	MI	TT6R7JZ
DMOZARM	MN	Histone deacetylase 1 (HDAC1)
DMOZARM	MT	DTT
DMOZARM	MA	Inhibitor
DMOZARM	RN	Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity. Bioorg Med Chem Lett. 2009 Jun 1;19(11):3023-6.
DMOZARM	RU	https://pubmed.ncbi.nlm.nih.gov/19419863

DMOZARM	DI	DMOZARM
DMOZARM	DN	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide
DMOZARM	MI	TT5ZKDI
DMOZARM	MN	Histone deacetylase 6 (HDAC6)
DMOZARM	MT	DTT
DMOZARM	MA	Inhibitor
DMOZARM	RN	Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity. Bioorg Med Chem Lett. 2009 Jun 1;19(11):3023-6.
DMOZARM	RU	https://pubmed.ncbi.nlm.nih.gov/19419863

DM5LC3D	DI	DM5LC3D
DM5LC3D	DN	N-1-isopropyl-5-MeOT
DM5LC3D	MI	TTJQOD7
DM5LC3D	MN	5-HT 2A receptor (HTR2A)
DM5LC3D	MT	DTT
DM5LC3D	MA	Agonist
DM5LC3D	RN	Species variations in transmembrane region V of the 5-hydroxytryptamine type 2A receptor alter the structure-activity relationship of certain ergolines and tryptamines. Mol Pharmacol. 1994 Feb;45(2):277-86.
DM5LC3D	RU	https://pubmed.ncbi.nlm.nih.gov/8114677

DM25NLH	DI	DM25NLH
DM25NLH	DN	N-1-isopropyltryptamine
DM25NLH	MI	TTJQOD7
DM25NLH	MN	5-HT 2A receptor (HTR2A)
DM25NLH	MT	DTT
DM25NLH	MA	Agonist
DM25NLH	RN	Species variations in transmembrane region V of the 5-hydroxytryptamine type 2A receptor alter the structure-activity relationship of certain ergolines and tryptamines. Mol Pharmacol. 1994 Feb;45(2):277-86.
DM25NLH	RU	https://pubmed.ncbi.nlm.nih.gov/8114677

DMGJEH9	DI	DMGJEH9
DMGJEH9	DN	N2-(3-trifluoromethylphenyl)guanine
DMGJEH9	MI	TTP3QRF
DMGJEH9	MN	Thymidine kinase 1 (TK1)
DMGJEH9	MT	DTT
DMGJEH9	MA	Inhibitor
DMGJEH9	RN	Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate anal... Antimicrob Agents Chemother. 2007 Jun;51(6):2028-34.
DMGJEH9	RU	https://pubmed.ncbi.nlm.nih.gov/17438061

DMOZ1IY	DI	DMOZ1IY
DMOZ1IY	DN	N2-[4-(benzyloxy)benzyl]glycinamide
DMOZ1IY	MI	TT3WG5C
DMOZ1IY	MN	Monoamine oxidase type A (MAO-A)
DMOZ1IY	MT	DTT
DMOZ1IY	MA	Inhibitor
DMOZ1IY	RN	Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoa... J Med Chem. 2007 Oct 4;50(20):4909-16.
DMOZ1IY	RU	https://pubmed.ncbi.nlm.nih.gov/17824599

DMOZ1IY	DI	DMOZ1IY
DMOZ1IY	DN	N2-[4-(benzyloxy)benzyl]glycinamide
DMOZ1IY	MI	TTGP7BY
DMOZ1IY	MN	Monoamine oxidase type B (MAO-B)
DMOZ1IY	MT	DTT
DMOZ1IY	MA	Inhibitor
DMOZ1IY	RN	Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoa... J Med Chem. 2007 Oct 4;50(20):4909-16.
DMOZ1IY	RU	https://pubmed.ncbi.nlm.nih.gov/17824599

DMHJ2IP	DI	DMHJ2IP
DMHJ2IP	DN	N2-{4-[(3-chlorobenzyl)oxy]benzyl}glycinamide
DMHJ2IP	MI	TTGP7BY
DMHJ2IP	MN	Monoamine oxidase type B (MAO-B)
DMHJ2IP	MT	DTT
DMHJ2IP	MA	Inhibitor
DMHJ2IP	RN	Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoa... J Med Chem. 2007 Oct 4;50(20):4909-16.
DMHJ2IP	RU	https://pubmed.ncbi.nlm.nih.gov/17824599

DMEWP9L	DI	DMEWP9L
DMEWP9L	DN	N2-{4-[(3-fluorobenzyl)oxy]benzyl}glycinamide
DMEWP9L	MI	TT3WG5C
DMEWP9L	MN	Monoamine oxidase type A (MAO-A)
DMEWP9L	MT	DTT
DMEWP9L	MA	Inhibitor
DMEWP9L	RN	Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoa... J Med Chem. 2007 Oct 4;50(20):4909-16.
DMEWP9L	RU	https://pubmed.ncbi.nlm.nih.gov/17824599

DMEWP9L	DI	DMEWP9L
DMEWP9L	DN	N2-{4-[(3-fluorobenzyl)oxy]benzyl}glycinamide
DMEWP9L	MI	TTGP7BY
DMEWP9L	MN	Monoamine oxidase type B (MAO-B)
DMEWP9L	MT	DTT
DMEWP9L	MA	Inhibitor
DMEWP9L	RN	Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoa... J Med Chem. 2007 Oct 4;50(20):4909-16.
DMEWP9L	RU	https://pubmed.ncbi.nlm.nih.gov/17824599

DMLPJGX	DI	DMLPJGX
DMLPJGX	DN	N2-{4-[(4-chlorobenzyl)oxy]benzyl}glycinamide
DMLPJGX	MI	TT3WG5C
DMLPJGX	MN	Monoamine oxidase type A (MAO-A)
DMLPJGX	MT	DTT
DMLPJGX	MA	Inhibitor
DMLPJGX	RN	Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoa... J Med Chem. 2007 Oct 4;50(20):4909-16.
DMLPJGX	RU	https://pubmed.ncbi.nlm.nih.gov/17824599

DMLPJGX	DI	DMLPJGX
DMLPJGX	DN	N2-{4-[(4-chlorobenzyl)oxy]benzyl}glycinamide
DMLPJGX	MI	TTGP7BY
DMLPJGX	MN	Monoamine oxidase type B (MAO-B)
DMLPJGX	MT	DTT
DMLPJGX	MA	Inhibitor
DMLPJGX	RN	Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoa... J Med Chem. 2007 Oct 4;50(20):4909-16.
DMLPJGX	RU	https://pubmed.ncbi.nlm.nih.gov/17824599

DMAVB0G	DI	DMAVB0G
DMAVB0G	DN	N2-{4-[(4-nitrobenzyl)oxy]benzyl}glycinamide
DMAVB0G	MI	TTGP7BY
DMAVB0G	MN	Monoamine oxidase type B (MAO-B)
DMAVB0G	MT	DTT
DMAVB0G	MA	Inhibitor
DMAVB0G	RN	Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoa... J Med Chem. 2007 Oct 4;50(20):4909-16.
DMAVB0G	RU	https://pubmed.ncbi.nlm.nih.gov/17824599

DM3WTDL	DI	DM3WTDL
DM3WTDL	DN	N-2-phenylethyl-1H-pyrrole-2-carboxamide
DM3WTDL	MI	TT3WG5C
DM3WTDL	MN	Monoamine oxidase type A (MAO-A)
DM3WTDL	MT	DTT
DM3WTDL	MA	Inhibitor
DM3WTDL	RN	New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J Med Chem. 2007 Mar 8;50(5):922-31.
DM3WTDL	RU	https://pubmed.ncbi.nlm.nih.gov/17256833

DMLK0J8	DI	DMLK0J8
DMLK0J8	DN	N-2-Thiophen-2-Yl-Acetamide Boronic Acid
DMLK0J8	MI	TTHI19T
DMLK0J8	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMLK0J8	MT	DTT
DMLK0J8	MA	Inhibitor
DMLK0J8	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMLK0J8	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMFRD09	DI	DMFRD09
DMFRD09	DN	N-3-(4-bromophenyl)propyl imidazole
DMFRD09	MI	TTRA5BZ
DMFRD09	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMFRD09	MT	DTT
DMFRD09	MA	Inhibitor
DMFRD09	RN	Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-substituted phenyl alkyl imidazole-based inhibitor... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4752-6.
DMFRD09	RU	https://pubmed.ncbi.nlm.nih.gov/16870430

DMWZTKD	DI	DMWZTKD
DMWZTKD	DN	N-3'-ethylaplysinopsin
DMWZTKD	MI	TTJQOD7
DMWZTKD	MN	5-HT 2A receptor (HTR2A)
DMWZTKD	MT	DTT
DMWZTKD	MA	Inhibitor
DMWZTKD	RN	New antiinfective and human 5-HT2 receptor binding natural and semisynthetic compounds from the Jamaican sponge Smenospongia aurea. J Nat Prod. 2002 Apr;65(4):476-80.
DMWZTKD	RU	https://pubmed.ncbi.nlm.nih.gov/11975483

DMWZTKD	DI	DMWZTKD
DMWZTKD	DN	N-3'-ethylaplysinopsin
DMWZTKD	MI	TTWJBZ5
DMWZTKD	MN	5-HT 2C receptor (HTR2C)
DMWZTKD	MT	DTT
DMWZTKD	MA	Inhibitor
DMWZTKD	RN	New antiinfective and human 5-HT2 receptor binding natural and semisynthetic compounds from the Jamaican sponge Smenospongia aurea. J Nat Prod. 2002 Apr;65(4):476-80.
DMWZTKD	RU	https://pubmed.ncbi.nlm.nih.gov/11975483

DMQEGJU	DI	DMQEGJU
DMQEGJU	DN	N3-GHQMFYYPra-NH2
DMQEGJU	MI	TT1VAUK
DMQEGJU	MN	VEGFR1 messenger RNA (VEGFR1 mRNA)
DMQEGJU	MT	DTT
DMQEGJU	MA	Inhibitor
DMQEGJU	RN	On-resin cyclization of peptide ligands of the Vascular Endothelial Growth Factor Receptor 1 by copper(I)-catalyzed 1,3-dipolar azide-alkyne cycloa... Bioorg Med Chem Lett. 2007 Oct 15;17(20):5590-4.
DMQEGJU	RU	https://pubmed.ncbi.nlm.nih.gov/17826090

DM561Z7	DI	DM561Z7
DM561Z7	DN	N4-(3-chlorophenyl)quinazoline-4,6-diamine
DM561Z7	MI	TTGKNB4
DM561Z7	MN	Epidermal growth factor receptor (EGFR)
DM561Z7	MT	DTT
DM561Z7	MA	Inhibitor
DM561Z7	RN	Novel nitrogen mustard-armed combi-molecules for the selective targeting of epidermal growth factor receptor overexperessing solid tumors: discover... J Med Chem. 2007 May 31;50(11):2605-8.
DM561Z7	RU	https://pubmed.ncbi.nlm.nih.gov/17472358

DMDRYJ7	DI	DMDRYJ7
DMDRYJ7	DN	N4-(3-methylphenyl)-4,6-quinazolinediamine
DMDRYJ7	MI	TTGKNB4
DMDRYJ7	MN	Epidermal growth factor receptor (EGFR)
DMDRYJ7	MT	DTT
DMDRYJ7	MA	Inhibitor
DMDRYJ7	RN	The combi-targeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR). J Med Chem. 2006 Jun 15;49(12):3544-52.
DMDRYJ7	RU	https://pubmed.ncbi.nlm.nih.gov/16759097

DMARZHU	DI	DMARZHU
DMARZHU	DN	N4-(4-chlorobenzyl)-2,4-diaminobutanoylpiperidine
DMARZHU	MI	TTDIGC1
DMARZHU	MN	Dipeptidyl peptidase 4 (DPP-4)
DMARZHU	MT	DTT
DMARZHU	MA	Inhibitor
DMARZHU	RN	Synthesis and dipeptidyl peptidase inhibition of N-(4-substituted-2,4-diaminobutanoyl)piperidines. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4777-9.
DMARZHU	RU	https://pubmed.ncbi.nlm.nih.gov/16844373

DMARZHU	DI	DMARZHU
DMARZHU	DN	N4-(4-chlorobenzyl)-2,4-diaminobutanoylpiperidine
DMARZHU	MI	TTOYT5L
DMARZHU	MN	Dipeptidyl-peptidase 7 (DPP7)
DMARZHU	MT	DTT
DMARZHU	MA	Inhibitor
DMARZHU	RN	Dipeptidyl peptidase II and leukocyte cell death. Biochem Pharmacol. 2006 Jun 28;72(1):70-9.
DMARZHU	RU	https://pubmed.ncbi.nlm.nih.gov/16725115

DMYPZMO	DI	DMYPZMO
DMYPZMO	DN	N4-(N,N-diphenylcarbamoyl)-aminoguanidine
DMYPZMO	MI	TT6L509
DMYPZMO	MN	Coagulation factor IIa (F2)
DMYPZMO	MT	DTT
DMYPZMO	MA	Inhibitor
DMYPZMO	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMYPZMO	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMCR13E	DI	DMCR13E
DMCR13E	DN	N4,N6-dibenzylpyrimidine-4,6-dicarboxamide
DMCR13E	MI	TTHY57M
DMCR13E	MN	Matrix metalloproteinase-13 (MMP-13)
DMCR13E	MT	DTT
DMCR13E	MA	Inhibitor
DMCR13E	RN	Calculation of binding free energies for non-zinc chelating pyrimidine dicarboxamide inhibitors with MMP-13. Bioorg Med Chem Lett. 2009 Jan 1;19(1):47-50.
DMCR13E	RU	https://pubmed.ncbi.nlm.nih.gov/19042129

DMV7ORJ	DI	DMV7ORJ
DMV7ORJ	DN	N4-[4-(Phenylmethoxy)phenyl]-L-aspartamine
DMV7ORJ	MI	TTXZEAJ
DMV7ORJ	MN	Leukotriene A-4 hydrolase (LTA4H)
DMV7ORJ	MT	DTT
DMV7ORJ	MA	Inhibitor
DMV7ORJ	RN	Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83.
DMV7ORJ	RU	https://pubmed.ncbi.nlm.nih.gov/18394906

DM1N73J	DI	DM1N73J
DM1N73J	DN	N4-Butyl-2-cinnamamido-N1-hydroxysuccinamide
DM1N73J	MI	TTPHMWB
DM1N73J	MN	Aminopeptidase N (ANPEP)
DM1N73J	MT	DTT
DM1N73J	MA	Inhibitor
DM1N73J	RN	Design, synthesis, and preliminary studies of the activity of novel derivatives of N-cinnamoyl-L-aspartic acid as inhibitors of aminopeptidase N/CD13. Bioorg Med Chem. 2009 Oct 15;17(20):7398-404.
DM1N73J	RU	https://pubmed.ncbi.nlm.nih.gov/19782572

DM7KX2V	DI	DM7KX2V
DM7KX2V	DN	N4-phenylethoxycytidine-5'-triphosphate
DM7KX2V	MI	TT24DGP
DM7KX2V	MN	P2Y purinoceptor 4 (P2RY4)
DM7KX2V	MT	DTT
DM7KX2V	MA	Agonist
DM7KX2V	RN	Pyrimidine nucleotides with 4-alkyloxyimino and terminal tetraphosphate delta-ester modifications as selective agonists of the P2Y(4) receptor. J Med Chem. 2011 Jun 23;54(12):4018-33.
DM7KX2V	RU	https://pubmed.ncbi.nlm.nih.gov/21528910

DMY3O6N	DI	DMY3O6N
DMY3O6N	DN	N5-(1-Imino-3-Butenyl)-L-Ornithine
DMY3O6N	MI	TTZUFI5
DMY3O6N	MN	Nitric-oxide synthase brain (NOS1)
DMY3O6N	MT	DTT
DMY3O6N	MA	Inhibitor
DMY3O6N	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMY3O6N	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMB62OI	DI	DMB62OI
DMB62OI	DN	N5-(1-iminobut-3-enyl)-L-ornithine
DMB62OI	MI	TTZUFI5
DMB62OI	MN	Nitric-oxide synthase brain (NOS1)
DMB62OI	MT	DTT
DMB62OI	MA	Inhibitor
DMB62OI	RN	Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9.
DMB62OI	RU	https://pubmed.ncbi.nlm.nih.gov/19013076

DMB62OI	DI	DMB62OI
DMB62OI	DN	N5-(1-iminobut-3-enyl)-L-ornithine
DMB62OI	MI	TTCM4B3
DMB62OI	MN	Nitric-oxide synthase endothelial (NOS3)
DMB62OI	MT	DTT
DMB62OI	MA	Inhibitor
DMB62OI	RN	Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9.
DMB62OI	RU	https://pubmed.ncbi.nlm.nih.gov/19013076

DMB62OI	DI	DMB62OI
DMB62OI	DN	N5-(1-iminobut-3-enyl)-L-ornithine
DMB62OI	MI	TTF10I9
DMB62OI	MN	Nitric-oxide synthase inducible (NOS2)
DMB62OI	MT	DTT
DMB62OI	MA	Inhibitor
DMB62OI	RN	Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9.
DMB62OI	RU	https://pubmed.ncbi.nlm.nih.gov/19013076

DMT893N	DI	DMT893N
DMT893N	DN	N5-(1-iminobutyl)-L-ornithine
DMT893N	MI	TTZUFI5
DMT893N	MN	Nitric-oxide synthase brain (NOS1)
DMT893N	MT	DTT
DMT893N	MA	Inhibitor
DMT893N	RN	Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9.
DMT893N	RU	https://pubmed.ncbi.nlm.nih.gov/19013076

DMT893N	DI	DMT893N
DMT893N	DN	N5-(1-iminobutyl)-L-ornithine
DMT893N	MI	TTCM4B3
DMT893N	MN	Nitric-oxide synthase endothelial (NOS3)
DMT893N	MT	DTT
DMT893N	MA	Inhibitor
DMT893N	RN	Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9.
DMT893N	RU	https://pubmed.ncbi.nlm.nih.gov/19013076

DMT893N	DI	DMT893N
DMT893N	DN	N5-(1-iminobutyl)-L-ornithine
DMT893N	MI	TTF10I9
DMT893N	MN	Nitric-oxide synthase inducible (NOS2)
DMT893N	MT	DTT
DMT893N	MA	Inhibitor
DMT893N	RN	Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9.
DMT893N	RU	https://pubmed.ncbi.nlm.nih.gov/19013076

DM0TS21	DI	DM0TS21
DM0TS21	DN	N5-(1-iminopent-3-enyl)-L-ornithine
DM0TS21	MI	TTZUFI5
DM0TS21	MN	Nitric-oxide synthase brain (NOS1)
DM0TS21	MT	DTT
DM0TS21	MA	Inhibitor
DM0TS21	RN	Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9.
DM0TS21	RU	https://pubmed.ncbi.nlm.nih.gov/19013076

DM05O7J	DI	DM05O7J
DM05O7J	DN	N5-(1-iminopropyl)-L-ornithine
DM05O7J	MI	TTZUFI5
DM05O7J	MN	Nitric-oxide synthase brain (NOS1)
DM05O7J	MT	DTT
DM05O7J	MA	Inhibitor
DM05O7J	RN	Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9.
DM05O7J	RU	https://pubmed.ncbi.nlm.nih.gov/19013076

DM05O7J	DI	DM05O7J
DM05O7J	DN	N5-(1-iminopropyl)-L-ornithine
DM05O7J	MI	TTCM4B3
DM05O7J	MN	Nitric-oxide synthase endothelial (NOS3)
DM05O7J	MT	DTT
DM05O7J	MA	Inhibitor
DM05O7J	RN	Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9.
DM05O7J	RU	https://pubmed.ncbi.nlm.nih.gov/19013076

DM05O7J	DI	DM05O7J
DM05O7J	DN	N5-(1-iminopropyl)-L-ornithine
DM05O7J	MI	TTF10I9
DM05O7J	MN	Nitric-oxide synthase inducible (NOS2)
DM05O7J	MT	DTT
DM05O7J	MA	Inhibitor
DM05O7J	RN	Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9.
DM05O7J	RU	https://pubmed.ncbi.nlm.nih.gov/19013076

DMNVK6T	DI	DMNVK6T
DMNVK6T	DN	N5-(4-Phenoxyphenyl)-L-glutamine
DMNVK6T	MI	TTXZEAJ
DMNVK6T	MN	Leukotriene A-4 hydrolase (LTA4H)
DMNVK6T	MT	DTT
DMNVK6T	MA	Inhibitor
DMNVK6T	RN	Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83.
DMNVK6T	RU	https://pubmed.ncbi.nlm.nih.gov/18394906

DMXUODT	DI	DMXUODT
DMXUODT	DN	N5-[(4-Phenoxy)-3-pyridyl]-L-glutamamide
DMXUODT	MI	TTXZEAJ
DMXUODT	MN	Leukotriene A-4 hydrolase (LTA4H)
DMXUODT	MT	DTT
DMXUODT	MA	Inhibitor
DMXUODT	RN	Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83.
DMXUODT	RU	https://pubmed.ncbi.nlm.nih.gov/18394906

DMJT4UR	DI	DMJT4UR
DMJT4UR	DN	N5-[4-(1H-pyrrol-1-yl)phenyl]-L-glutamamide
DMJT4UR	MI	TTXZEAJ
DMJT4UR	MN	Leukotriene A-4 hydrolase (LTA4H)
DMJT4UR	MT	DTT
DMJT4UR	MA	Inhibitor
DMJT4UR	RN	Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83.
DMJT4UR	RU	https://pubmed.ncbi.nlm.nih.gov/18394906

DMR2C94	DI	DMR2C94
DMR2C94	DN	N5-[4-(2-methylphenoxy)phenyl]-L-glutamamide
DMR2C94	MI	TTXZEAJ
DMR2C94	MN	Leukotriene A-4 hydrolase (LTA4H)
DMR2C94	MT	DTT
DMR2C94	MA	Inhibitor
DMR2C94	RN	Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83.
DMR2C94	RU	https://pubmed.ncbi.nlm.nih.gov/18394906

DM97H52	DI	DM97H52
DM97H52	DN	N5-[4-(2-Oxo-3-phenylpropoxy)phenyl]-L-glutamine
DM97H52	MI	TTXZEAJ
DM97H52	MN	Leukotriene A-4 hydrolase (LTA4H)
DM97H52	MT	DTT
DM97H52	MA	Inhibitor
DM97H52	RN	Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83.
DM97H52	RU	https://pubmed.ncbi.nlm.nih.gov/18394906

DMR1XJN	DI	DMR1XJN
DMR1XJN	DN	N5-[4-(2-phenylethoxy)phenyl]-L-glutamine
DMR1XJN	MI	TTXZEAJ
DMR1XJN	MN	Leukotriene A-4 hydrolase (LTA4H)
DMR1XJN	MT	DTT
DMR1XJN	MA	Inhibitor
DMR1XJN	RN	Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83.
DMR1XJN	RU	https://pubmed.ncbi.nlm.nih.gov/18394906

DMTO8KS	DI	DMTO8KS
DMTO8KS	DN	N5-[4-(3-methylphenoxy)phenyl]-L-glutamamide
DMTO8KS	MI	TTXZEAJ
DMTO8KS	MN	Leukotriene A-4 hydrolase (LTA4H)
DMTO8KS	MT	DTT
DMTO8KS	MA	Inhibitor
DMTO8KS	RN	Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83.
DMTO8KS	RU	https://pubmed.ncbi.nlm.nih.gov/18394906

DMINK9Q	DI	DMINK9Q
DMINK9Q	DN	N5-[4-(3-Phenylpropoxy)phenyl]-L-glutamine
DMINK9Q	MI	TTXZEAJ
DMINK9Q	MN	Leukotriene A-4 hydrolase (LTA4H)
DMINK9Q	MT	DTT
DMINK9Q	MA	Inhibitor
DMINK9Q	RN	Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83.
DMINK9Q	RU	https://pubmed.ncbi.nlm.nih.gov/18394906

DM6PXMJ	DI	DM6PXMJ
DM6PXMJ	DN	N5-[4-(4-(3-Furyl)phenoxy)phenyl]-L-glutamamide
DM6PXMJ	MI	TTXZEAJ
DM6PXMJ	MN	Leukotriene A-4 hydrolase (LTA4H)
DM6PXMJ	MT	DTT
DM6PXMJ	MA	Inhibitor
DM6PXMJ	RN	Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83.
DM6PXMJ	RU	https://pubmed.ncbi.nlm.nih.gov/18394906

DMMV1CB	DI	DMMV1CB
DMMV1CB	DN	N5-[4-(4-methylphenoxy)phenyl]-L-glutamamide
DMMV1CB	MI	TTXZEAJ
DMMV1CB	MN	Leukotriene A-4 hydrolase (LTA4H)
DMMV1CB	MT	DTT
DMMV1CB	MA	Inhibitor
DMMV1CB	RN	Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83.
DMMV1CB	RU	https://pubmed.ncbi.nlm.nih.gov/18394906

DMH8VYM	DI	DMH8VYM
DMH8VYM	DN	N5-[4-(N-Phenylamino)phenyl]-L-glutamine
DMH8VYM	MI	TTXZEAJ
DMH8VYM	MN	Leukotriene A-4 hydrolase (LTA4H)
DMH8VYM	MT	DTT
DMH8VYM	MA	Inhibitor
DMH8VYM	RN	Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83.
DMH8VYM	RU	https://pubmed.ncbi.nlm.nih.gov/18394906

DMUVP5L	DI	DMUVP5L
DMUVP5L	DN	N5-[4-(Phenylmethoxy)phenyl]-D-glutamine
DMUVP5L	MI	TTXZEAJ
DMUVP5L	MN	Leukotriene A-4 hydrolase (LTA4H)
DMUVP5L	MT	DTT
DMUVP5L	MA	Inhibitor
DMUVP5L	RN	Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83.
DMUVP5L	RU	https://pubmed.ncbi.nlm.nih.gov/18394906

DMMYIJ0	DI	DMMYIJ0
DMMYIJ0	DN	N5-[4-(Phenylmethoxy)phenyl]-L-glutamamide
DMMYIJ0	MI	TTXZEAJ
DMMYIJ0	MN	Leukotriene A-4 hydrolase (LTA4H)
DMMYIJ0	MT	DTT
DMMYIJ0	MA	Inhibitor
DMMYIJ0	RN	Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83.
DMMYIJ0	RU	https://pubmed.ncbi.nlm.nih.gov/18394906

DMCG26A	DI	DMCG26A
DMCG26A	DN	N5-[4-(Phenylmethoxy)phenyl]-L-glutamine
DMCG26A	MI	TTXZEAJ
DMCG26A	MN	Leukotriene A-4 hydrolase (LTA4H)
DMCG26A	MT	DTT
DMCG26A	MA	Inhibitor
DMCG26A	RN	Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83.
DMCG26A	RU	https://pubmed.ncbi.nlm.nih.gov/18394906

DMH6O4G	DI	DMH6O4G
DMH6O4G	DN	N5-[4-Benzylphenyl]-L-glutamamide
DMH6O4G	MI	TTXZEAJ
DMH6O4G	MN	Leukotriene A-4 hydrolase (LTA4H)
DMH6O4G	MT	DTT
DMH6O4G	MA	Inhibitor
DMH6O4G	RN	Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83.
DMH6O4G	RU	https://pubmed.ncbi.nlm.nih.gov/18394906

DML0R9M	DI	DML0R9M
DML0R9M	DN	N5-methylfolate
DML0R9M	MI	DTFI42L
DML0R9M	MN	Multidrug resistance-associated protein 2 (ABCC2)
DML0R9M	MT	DTP
DML0R9M	MA	Substrate
DML0R9M	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DML0R9M	RU	https://doi.org/10.1007/s11095-012-0935-x

DMXSZ1A	DI	DMXSZ1A
DMXSZ1A	DN	N6 benzyl-cAMP
DMXSZ1A	MI	TTYVI76
DMXSZ1A	MN	Fungal Protein kinase A (Fung ypkA)
DMXSZ1A	MT	DTT
DMXSZ1A	MA	Activator
DMXSZ1A	RN	cAMP analog mapping of Epac1 and cAMP kinase. Discriminating analogs demonstrate that Epac and cAMP kinase act synergistically to promote PC-12 cel... J Biol Chem. 2003 Sep 12;278(37):35394-402.
DMXSZ1A	RU	https://pubmed.ncbi.nlm.nih.gov/12819211

DM30KXV	DI	DM30KXV
DM30KXV	DN	N6-((+/-)-endo-norborn-2-yl)adenosine
DM30KXV	MI	TTK25J1
DM30KXV	MN	Adenosine A1 receptor (ADORA1)
DM30KXV	MT	DTT
DM30KXV	MA	Inhibitor
DM30KXV	RN	N6-Cycloalkyl- and N6-bicycloalkyl-C5'(C2')-modified adenosine derivatives as high-affinity and selective agonists at the human A1 adenosine recept... J Med Chem. 2009 Apr 23;52(8):2393-406.
DM30KXV	RU	https://pubmed.ncbi.nlm.nih.gov/19317449

DM30KXV	DI	DM30KXV
DM30KXV	DN	N6-((+/-)-endo-norborn-2-yl)adenosine
DM30KXV	MI	TTM2AOE
DM30KXV	MN	Adenosine A2a receptor (ADORA2A)
DM30KXV	MT	DTT
DM30KXV	MA	Inhibitor
DM30KXV	RN	N6-Cycloalkyl- and N6-bicycloalkyl-C5'(C2')-modified adenosine derivatives as high-affinity and selective agonists at the human A1 adenosine recept... J Med Chem. 2009 Apr 23;52(8):2393-406.
DM30KXV	RU	https://pubmed.ncbi.nlm.nih.gov/19317449

DM30KXV	DI	DM30KXV
DM30KXV	DN	N6-((+/-)-endo-norborn-2-yl)adenosine
DM30KXV	MI	TTNE7KG
DM30KXV	MN	Adenosine A2b receptor (ADORA2B)
DM30KXV	MT	DTT
DM30KXV	MA	Inhibitor
DM30KXV	RN	N6-Cycloalkyl- and N6-bicycloalkyl-C5'(C2')-modified adenosine derivatives as high-affinity and selective agonists at the human A1 adenosine recept... J Med Chem. 2009 Apr 23;52(8):2393-406.
DM30KXV	RU	https://pubmed.ncbi.nlm.nih.gov/19317449

DM30KXV	DI	DM30KXV
DM30KXV	DN	N6-((+/-)-endo-norborn-2-yl)adenosine
DM30KXV	MI	TTJFY5U
DM30KXV	MN	Adenosine A3 receptor (ADORA3)
DM30KXV	MT	DTT
DM30KXV	MA	Inhibitor
DM30KXV	RN	N6-Cycloalkyl- and N6-bicycloalkyl-C5'(C2')-modified adenosine derivatives as high-affinity and selective agonists at the human A1 adenosine recept... J Med Chem. 2009 Apr 23;52(8):2393-406.
DM30KXV	RU	https://pubmed.ncbi.nlm.nih.gov/19317449

DM2W9NO	DI	DM2W9NO
DM2W9NO	DN	N6-(3-Iodobenzyl)-2'-O-methyladenosine
DM2W9NO	MI	TTJFY5U
DM2W9NO	MN	Adenosine A3 receptor (ADORA3)
DM2W9NO	MT	DTT
DM2W9NO	MA	Inhibitor
DM2W9NO	RN	Design, synthesis, and biological evaluation of LNA nucleosides as adenosine A3 receptor ligands. Bioorg Med Chem. 2007 Aug 15;15(16):5440-7.
DM2W9NO	RU	https://pubmed.ncbi.nlm.nih.gov/17560111

DM5Q71U	DI	DM5Q71U
DM5Q71U	DN	N6-(4-hydroxybenzyl)adenine riboside
DM5Q71U	MI	TTM2AOE
DM5Q71U	MN	Adenosine A2a receptor (ADORA2A)
DM5Q71U	MT	DTT
DM5Q71U	MA	Inhibitor
DM5Q71U	RN	Neuroprotective principles from Gastrodia elata. J Nat Prod. 2007 Apr;70(4):571-4.
DM5Q71U	RU	https://pubmed.ncbi.nlm.nih.gov/17381154

DM0WMKJ	DI	DM0WMKJ
DM0WMKJ	DN	N6-[(4-Amino)-phenyl]-9-benzyl-2-phenyladenine
DM0WMKJ	MI	TTK25J1
DM0WMKJ	MN	Adenosine A1 receptor (ADORA1)
DM0WMKJ	MT	DTT
DM0WMKJ	MA	Inhibitor
DM0WMKJ	RN	N6-1,3-diphenylurea derivatives of 2-phenyl-9-benzyladenines and 8-azaadenines: synthesis and biological evaluation as allosteric modulators of A2A... Eur J Med Chem. 2008 Aug;43(8):1639-47.
DM0WMKJ	RU	https://pubmed.ncbi.nlm.nih.gov/18045744

DM0WMKJ	DI	DM0WMKJ
DM0WMKJ	DN	N6-[(4-Amino)-phenyl]-9-benzyl-2-phenyladenine
DM0WMKJ	MI	TTM2AOE
DM0WMKJ	MN	Adenosine A2a receptor (ADORA2A)
DM0WMKJ	MT	DTT
DM0WMKJ	MA	Inhibitor
DM0WMKJ	RN	N6-1,3-diphenylurea derivatives of 2-phenyl-9-benzyladenines and 8-azaadenines: synthesis and biological evaluation as allosteric modulators of A2A... Eur J Med Chem. 2008 Aug;43(8):1639-47.
DM0WMKJ	RU	https://pubmed.ncbi.nlm.nih.gov/18045744

DMVNLPF	DI	DMVNLPF
DMVNLPF	DN	N6-[(4-Nitro)-phenyl]-9-benzyl-2-phenyladenine
DMVNLPF	MI	TTK25J1
DMVNLPF	MN	Adenosine A1 receptor (ADORA1)
DMVNLPF	MT	DTT
DMVNLPF	MA	Inhibitor
DMVNLPF	RN	N6-1,3-diphenylurea derivatives of 2-phenyl-9-benzyladenines and 8-azaadenines: synthesis and biological evaluation as allosteric modulators of A2A... Eur J Med Chem. 2008 Aug;43(8):1639-47.
DMVNLPF	RU	https://pubmed.ncbi.nlm.nih.gov/18045744

DMVNLPF	DI	DMVNLPF
DMVNLPF	DN	N6-[(4-Nitro)-phenyl]-9-benzyl-2-phenyladenine
DMVNLPF	MI	TTM2AOE
DMVNLPF	MN	Adenosine A2a receptor (ADORA2A)
DMVNLPF	MT	DTT
DMVNLPF	MA	Inhibitor
DMVNLPF	RN	N6-1,3-diphenylurea derivatives of 2-phenyl-9-benzyladenines and 8-azaadenines: synthesis and biological evaluation as allosteric modulators of A2A... Eur J Med Chem. 2008 Aug;43(8):1639-47.
DMVNLPF	RU	https://pubmed.ncbi.nlm.nih.gov/18045744

DMBT2HW	DI	DMBT2HW
DMBT2HW	DN	N6-[4-(4-methylphenoxy)phenyl]-L-homoglutamine
DMBT2HW	MI	TTXZEAJ
DMBT2HW	MN	Leukotriene A-4 hydrolase (LTA4H)
DMBT2HW	MT	DTT
DMBT2HW	MA	Inhibitor
DMBT2HW	RN	Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83.
DMBT2HW	RU	https://pubmed.ncbi.nlm.nih.gov/18394906

DMDMI7P	DI	DMDMI7P
DMDMI7P	DN	N-6060
DMDMI7P	MI	TTEP6RV
DMDMI7P	MN	Glutathione reductase (GR)
DMDMI7P	MT	DTT
DMDMI7P	MA	Inhibitor
DMDMI7P	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2613).
DMDMI7P	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2613

DM814EQ	DI	DM814EQ
DM814EQ	DN	N-6547
DM814EQ	MI	TTEP6RV
DM814EQ	MN	Glutathione reductase (GR)
DM814EQ	MT	DTT
DM814EQ	MA	Inhibitor
DM814EQ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2613).
DM814EQ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2613

DM71MO2	DI	DM71MO2
DM71MO2	DN	N6-Benzyl Adenosine-5'-Diphosphate
DM71MO2	MI	TT6PKBN
DM71MO2	MN	Proto-oncogene c-Src (SRC)
DM71MO2	MT	DTT
DM71MO2	MA	Inhibitor
DM71MO2	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM71MO2	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD6AJO	DI	DMD6AJO
DMD6AJO	DN	N6-cyclopentyladenosine
DMD6AJO	MI	TTK25J1
DMD6AJO	MN	Adenosine A1 receptor (ADORA1)
DMD6AJO	MT	DTT
DMD6AJO	MA	Inhibitor
DMD6AJO	RN	5'-Carbamoyl derivatives of 2'-C-methyl-purine nucleosides as selective A1 adenosine receptor agonists: affinity, efficacy, and selectivity for A1 ... Bioorg Med Chem. 2008 Jan 1;16(1):336-53.
DMD6AJO	RU	https://pubmed.ncbi.nlm.nih.gov/17933541

DMD6AJO	DI	DMD6AJO
DMD6AJO	DN	N6-cyclopentyladenosine
DMD6AJO	MI	TTM2AOE
DMD6AJO	MN	Adenosine A2a receptor (ADORA2A)
DMD6AJO	MT	DTT
DMD6AJO	MA	Inhibitor
DMD6AJO	RN	2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
DMD6AJO	RU	https://pubmed.ncbi.nlm.nih.gov/20188574

DMD6AJO	DI	DMD6AJO
DMD6AJO	DN	N6-cyclopentyladenosine
DMD6AJO	MI	TTNE7KG
DMD6AJO	MN	Adenosine A2b receptor (ADORA2B)
DMD6AJO	MT	DTT
DMD6AJO	MA	Inhibitor
DMD6AJO	RN	Adenosine receptor agonists: synthesis and biological evaluation of 1-deaza analogues of adenosine derivatives. J Med Chem. 1988 Jun;31(6):1179-83.
DMD6AJO	RU	https://pubmed.ncbi.nlm.nih.gov/3373486

DMD6AJO	DI	DMD6AJO
DMD6AJO	DN	N6-cyclopentyladenosine
DMD6AJO	MI	TTJFY5U
DMD6AJO	MN	Adenosine A3 receptor (ADORA3)
DMD6AJO	MT	DTT
DMD6AJO	MA	Inhibitor
DMD6AJO	RN	Semi-rational design of (north)-methanocarba nucleosides as dual acting A(1) and A(3) adenosine receptor agonists: novel prototypes for cardioprote... J Med Chem. 2005 Dec 29;48(26):8103-7.
DMD6AJO	RU	https://pubmed.ncbi.nlm.nih.gov/16366590

DMD6AJO	DI	DMD6AJO
DMD6AJO	DN	N6-cyclopentyladenosine
DMD6AJO	MI	TT2QM9D
DMD6AJO	MN	Adenylate cyclase (ADCY)
DMD6AJO	MT	DTT
DMD6AJO	MA	Inhibitor
DMD6AJO	RN	Activity of N6-substituted 2-chloroadenosines at A1 and A2 adenosine receptors. J Med Chem. 1991 Dec;34(12):3388-90.
DMD6AJO	RU	https://pubmed.ncbi.nlm.nih.gov/1766003

DMD6AJO	DI	DMD6AJO
DMD6AJO	DN	N6-cyclopentyladenosine
DMD6AJO	MI	TTLXAKE
DMD6AJO	MN	Solute carrier family 29 member 1 (SLC29A1)
DMD6AJO	MT	DTT
DMD6AJO	MA	Inhibitor
DMD6AJO	RN	Inhibition of nucleoside transport proteins by C8-alkylamine-substituted purines. J Med Chem. 2005 Jan 13;48(1):321-9.
DMD6AJO	RU	https://pubmed.ncbi.nlm.nih.gov/15634027

DMSEL5W	DI	DMSEL5W
DMSEL5W	DN	N6-methoxy-2-[(2-pyridinyl)ethynyl]adenosine
DMSEL5W	MI	TTK25J1
DMSEL5W	MN	Adenosine A1 receptor (ADORA1)
DMSEL5W	MT	DTT
DMSEL5W	MA	Inhibitor
DMSEL5W	RN	N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
DMSEL5W	RU	https://pubmed.ncbi.nlm.nih.gov/17309246

DMSEL5W	DI	DMSEL5W
DMSEL5W	DN	N6-methoxy-2-[(2-pyridinyl)ethynyl]adenosine
DMSEL5W	MI	TTM2AOE
DMSEL5W	MN	Adenosine A2a receptor (ADORA2A)
DMSEL5W	MT	DTT
DMSEL5W	MA	Inhibitor
DMSEL5W	RN	N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
DMSEL5W	RU	https://pubmed.ncbi.nlm.nih.gov/17309246

DMSEL5W	DI	DMSEL5W
DMSEL5W	DN	N6-methoxy-2-[(2-pyridinyl)ethynyl]adenosine
DMSEL5W	MI	TTJFY5U
DMSEL5W	MN	Adenosine A3 receptor (ADORA3)
DMSEL5W	MT	DTT
DMSEL5W	MA	Inhibitor
DMSEL5W	RN	N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
DMSEL5W	RU	https://pubmed.ncbi.nlm.nih.gov/17309246

DMP7246	DI	DMP7246
DMP7246	DN	N6-methoxy-2-[(3-pyridinyl)ethynyl]-adenosine
DMP7246	MI	TTK25J1
DMP7246	MN	Adenosine A1 receptor (ADORA1)
DMP7246	MT	DTT
DMP7246	MA	Inhibitor
DMP7246	RN	N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
DMP7246	RU	https://pubmed.ncbi.nlm.nih.gov/17309246

DMP7246	DI	DMP7246
DMP7246	DN	N6-methoxy-2-[(3-pyridinyl)ethynyl]-adenosine
DMP7246	MI	TTM2AOE
DMP7246	MN	Adenosine A2a receptor (ADORA2A)
DMP7246	MT	DTT
DMP7246	MA	Inhibitor
DMP7246	RN	N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
DMP7246	RU	https://pubmed.ncbi.nlm.nih.gov/17309246

DMP7246	DI	DMP7246
DMP7246	DN	N6-methoxy-2-[(3-pyridinyl)ethynyl]-adenosine
DMP7246	MI	TTJFY5U
DMP7246	MN	Adenosine A3 receptor (ADORA3)
DMP7246	MT	DTT
DMP7246	MA	Inhibitor
DMP7246	RN	N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
DMP7246	RU	https://pubmed.ncbi.nlm.nih.gov/17309246

DM8LR62	DI	DM8LR62
DM8LR62	DN	N6-methoxy-2-[(4-methoxyphenyl)ethynyl]adenosine
DM8LR62	MI	TTK25J1
DM8LR62	MN	Adenosine A1 receptor (ADORA1)
DM8LR62	MT	DTT
DM8LR62	MA	Inhibitor
DM8LR62	RN	N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
DM8LR62	RU	https://pubmed.ncbi.nlm.nih.gov/17309246

DM8LR62	DI	DM8LR62
DM8LR62	DN	N6-methoxy-2-[(4-methoxyphenyl)ethynyl]adenosine
DM8LR62	MI	TTM2AOE
DM8LR62	MN	Adenosine A2a receptor (ADORA2A)
DM8LR62	MT	DTT
DM8LR62	MA	Inhibitor
DM8LR62	RN	N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
DM8LR62	RU	https://pubmed.ncbi.nlm.nih.gov/17309246

DM8LR62	DI	DM8LR62
DM8LR62	DN	N6-methoxy-2-[(4-methoxyphenyl)ethynyl]adenosine
DM8LR62	MI	TTJFY5U
DM8LR62	MN	Adenosine A3 receptor (ADORA3)
DM8LR62	MT	DTT
DM8LR62	MA	Inhibitor
DM8LR62	RN	N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
DM8LR62	RU	https://pubmed.ncbi.nlm.nih.gov/17309246

DM1KA9R	DI	DM1KA9R
DM1KA9R	DN	N6-methoxy-2-[(4-methylphenyl)ethynyl]adenosine
DM1KA9R	MI	TTK25J1
DM1KA9R	MN	Adenosine A1 receptor (ADORA1)
DM1KA9R	MT	DTT
DM1KA9R	MA	Inhibitor
DM1KA9R	RN	N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
DM1KA9R	RU	https://pubmed.ncbi.nlm.nih.gov/17309246

DM1KA9R	DI	DM1KA9R
DM1KA9R	DN	N6-methoxy-2-[(4-methylphenyl)ethynyl]adenosine
DM1KA9R	MI	TTJFY5U
DM1KA9R	MN	Adenosine A3 receptor (ADORA3)
DM1KA9R	MT	DTT
DM1KA9R	MA	Inhibitor
DM1KA9R	RN	N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
DM1KA9R	RU	https://pubmed.ncbi.nlm.nih.gov/17309246

DMQ5K8R	DI	DMQ5K8R
DMQ5K8R	DN	N6-methoxy-2-[(4-pentylphenyl)ethynyl]adenosine
DMQ5K8R	MI	TTK25J1
DMQ5K8R	MN	Adenosine A1 receptor (ADORA1)
DMQ5K8R	MT	DTT
DMQ5K8R	MA	Inhibitor
DMQ5K8R	RN	N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
DMQ5K8R	RU	https://pubmed.ncbi.nlm.nih.gov/17309246

DMQ5K8R	DI	DMQ5K8R
DMQ5K8R	DN	N6-methoxy-2-[(4-pentylphenyl)ethynyl]adenosine
DMQ5K8R	MI	TTM2AOE
DMQ5K8R	MN	Adenosine A2a receptor (ADORA2A)
DMQ5K8R	MT	DTT
DMQ5K8R	MA	Inhibitor
DMQ5K8R	RN	N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
DMQ5K8R	RU	https://pubmed.ncbi.nlm.nih.gov/17309246

DMQ5K8R	DI	DMQ5K8R
DMQ5K8R	DN	N6-methoxy-2-[(4-pentylphenyl)ethynyl]adenosine
DMQ5K8R	MI	TTJFY5U
DMQ5K8R	MN	Adenosine A3 receptor (ADORA3)
DMQ5K8R	MT	DTT
DMQ5K8R	MA	Inhibitor
DMQ5K8R	RN	N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
DMQ5K8R	RU	https://pubmed.ncbi.nlm.nih.gov/17309246

DM9H3W8	DI	DM9H3W8
DM9H3W8	DN	N6-methoxy-2-[(4-pyridinyl)ethynyl]adenosine
DM9H3W8	MI	TTK25J1
DM9H3W8	MN	Adenosine A1 receptor (ADORA1)
DM9H3W8	MT	DTT
DM9H3W8	MA	Inhibitor
DM9H3W8	RN	N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
DM9H3W8	RU	https://pubmed.ncbi.nlm.nih.gov/17309246

DM9H3W8	DI	DM9H3W8
DM9H3W8	DN	N6-methoxy-2-[(4-pyridinyl)ethynyl]adenosine
DM9H3W8	MI	TTM2AOE
DM9H3W8	MN	Adenosine A2a receptor (ADORA2A)
DM9H3W8	MT	DTT
DM9H3W8	MA	Inhibitor
DM9H3W8	RN	N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
DM9H3W8	RU	https://pubmed.ncbi.nlm.nih.gov/17309246

DM9H3W8	DI	DM9H3W8
DM9H3W8	DN	N6-methoxy-2-[(4-pyridinyl)ethynyl]adenosine
DM9H3W8	MI	TTJFY5U
DM9H3W8	MN	Adenosine A3 receptor (ADORA3)
DM9H3W8	MT	DTT
DM9H3W8	MA	Inhibitor
DM9H3W8	RN	N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
DM9H3W8	RU	https://pubmed.ncbi.nlm.nih.gov/17309246

DMRBS50	DI	DMRBS50
DMRBS50	DN	N6-methoxy-2-[2-(trimethylsilyl)ethynyl]adenosine
DMRBS50	MI	TTK25J1
DMRBS50	MN	Adenosine A1 receptor (ADORA1)
DMRBS50	MT	DTT
DMRBS50	MA	Inhibitor
DMRBS50	RN	N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
DMRBS50	RU	https://pubmed.ncbi.nlm.nih.gov/17309246

DMRBS50	DI	DMRBS50
DMRBS50	DN	N6-methoxy-2-[2-(trimethylsilyl)ethynyl]adenosine
DMRBS50	MI	TTM2AOE
DMRBS50	MN	Adenosine A2a receptor (ADORA2A)
DMRBS50	MT	DTT
DMRBS50	MA	Inhibitor
DMRBS50	RN	N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
DMRBS50	RU	https://pubmed.ncbi.nlm.nih.gov/17309246

DMRBS50	DI	DMRBS50
DMRBS50	DN	N6-methoxy-2-[2-(trimethylsilyl)ethynyl]adenosine
DMRBS50	MI	TTJFY5U
DMRBS50	MN	Adenosine A3 receptor (ADORA3)
DMRBS50	MT	DTT
DMRBS50	MA	Inhibitor
DMRBS50	RN	N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
DMRBS50	RU	https://pubmed.ncbi.nlm.nih.gov/17309246

DMDG59X	DI	DMDG59X
DMDG59X	DN	N6-methoxy-2-phenylethynyladenosine
DMDG59X	MI	TTK25J1
DMDG59X	MN	Adenosine A1 receptor (ADORA1)
DMDG59X	MT	DTT
DMDG59X	MA	Inhibitor
DMDG59X	RN	N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
DMDG59X	RU	https://pubmed.ncbi.nlm.nih.gov/17309246

DMDG59X	DI	DMDG59X
DMDG59X	DN	N6-methoxy-2-phenylethynyladenosine
DMDG59X	MI	TTM2AOE
DMDG59X	MN	Adenosine A2a receptor (ADORA2A)
DMDG59X	MT	DTT
DMDG59X	MA	Inhibitor
DMDG59X	RN	N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
DMDG59X	RU	https://pubmed.ncbi.nlm.nih.gov/17309246

DMDG59X	DI	DMDG59X
DMDG59X	DN	N6-methoxy-2-phenylethynyladenosine
DMDG59X	MI	TTJFY5U
DMDG59X	MN	Adenosine A3 receptor (ADORA3)
DMDG59X	MT	DTT
DMDG59X	MA	Inhibitor
DMDG59X	RN	N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
DMDG59X	RU	https://pubmed.ncbi.nlm.nih.gov/17309246

DM6XDZA	DI	DM6XDZA
DM6XDZA	DN	N7-hydroxy-2-methoxy-N1-phenylheptanediamide
DM6XDZA	MI	TTSHTOI
DM6XDZA	MN	Histone deacetylase 2 (HDAC2)
DM6XDZA	MT	DTT
DM6XDZA	MA	Inhibitor
DM6XDZA	RN	Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6261-5.
DM6XDZA	RU	https://pubmed.ncbi.nlm.nih.gov/17892933

DMDJUZX	DI	DMDJUZX
DMDJUZX	DN	N7-hydroxy-N1-phenyl-2-propoxyheptanediamide
DMDJUZX	MI	TTSHTOI
DMDJUZX	MN	Histone deacetylase 2 (HDAC2)
DMDJUZX	MT	DTT
DMDJUZX	MA	Inhibitor
DMDJUZX	RN	Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6261-5.
DMDJUZX	RU	https://pubmed.ncbi.nlm.nih.gov/17892933

DMHC32M	DI	DMHC32M
DMHC32M	DN	N8,2-dihydroxy-N1-phenyloctanediamide
DMHC32M	MI	TTSHTOI
DMHC32M	MN	Histone deacetylase 2 (HDAC2)
DMHC32M	MT	DTT
DMHC32M	MA	Inhibitor
DMHC32M	RN	Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6261-5.
DMHC32M	RU	https://pubmed.ncbi.nlm.nih.gov/17892933

DM7OZ2T	DI	DM7OZ2T
DM7OZ2T	DN	N8-hydroxy-2-methoxy-N1-phenyloctanediamide
DM7OZ2T	MI	TTSHTOI
DM7OZ2T	MN	Histone deacetylase 2 (HDAC2)
DM7OZ2T	MT	DTT
DM7OZ2T	MA	Inhibitor
DM7OZ2T	RN	Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6261-5.
DM7OZ2T	RU	https://pubmed.ncbi.nlm.nih.gov/17892933

DMML1J4	DI	DMML1J4
DMML1J4	DN	N-9xxx
DMML1J4	MI	TTEP6RV
DMML1J4	MN	Glutathione reductase (GR)
DMML1J4	MT	DTT
DMML1J4	MA	Modulator
DMML1J4	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2613).
DMML1J4	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2613

DM51DW6	DI	DM51DW6
DM51DW6	DN	NAADP
DM51DW6	MI	TTEBMN7
DM51DW6	MN	Long transient receptor potential channel 2 (TRPM2)
DM51DW6	MT	DTT
DM51DW6	MA	Activator
DM51DW6	RN	Nicotinic acid adenine dinucleotide phosphate and cyclic ADP-ribose regulate TRPM2 channels in T lymphocytes. FASEB J. 2006 May;20(7):962-4.
DM51DW6	RU	https://pubmed.ncbi.nlm.nih.gov/16585058

DM51DW6	DI	DM51DW6
DM51DW6	DN	NAADP
DM51DW6	MI	TTYXPCO
DM51DW6	MN	P2Y purinoceptor 11 (P2RY11)
DM51DW6	MT	DTT
DM51DW6	MA	Agonist
DM51DW6	RN	NAADP+ is an agonist of the human P2Y11 purinergic receptor. Cell Calcium. 2008 Apr;43(4):344-55.
DM51DW6	RU	https://pubmed.ncbi.nlm.nih.gov/17707504

DMFGOW0	DI	DMFGOW0
DMFGOW0	DN	NAAG
DMFGOW0	MI	TT8A9EF
DMFGOW0	MN	Metabotropic glutamate receptor 3 (mGluR3)
DMFGOW0	MT	DTT
DMFGOW0	MA	Agonist
DMFGOW0	RN	Characterization of [(3)H]-LY354740 binding to rat mGlu2 and mGlu3 receptors expressed in CHO cells using semliki forest virus vectors. Neuropharmacology. 2000 Jul 24;39(10):1700-6.
DMFGOW0	RU	https://pubmed.ncbi.nlm.nih.gov/10884552

DMFGOW0	DI	DMFGOW0
DMFGOW0	DN	NAAG
DMFGOW0	MI	DT9G7XN
DMFGOW0	MN	Peptide transporter 1 (SLC15A1)
DMFGOW0	MT	DTP
DMFGOW0	MA	Substrate
DMFGOW0	RN	Molecular interactions between dipeptides, drugs and the human intestinal H+ -oligopeptide cotransporter hPEPT1. J Physiol. 2006 Jul 1;574(Pt 1):149-66.
DMFGOW0	RU	https://doi.org/10.1113/jphysiol.2006.107904

DMFGOW0	DI	DMFGOW0
DMFGOW0	DN	NAAG
DMFGOW0	MI	DTWLACT
DMFGOW0	MN	Vesicular H(+)/Aspartate-glutamate cotransporter (SLC17A5)
DMFGOW0	MT	DTP
DMFGOW0	MA	Substrate
DMFGOW0	RN	Vesicular uptake of N-acetylaspartylglutamate is catalysed by sialin (SLC17A5). Biochem J. 2013 Aug 15;454(1):31-8.
DMFGOW0	RU	http://www.ncbi.nlm.nih.gov/pubmed/23889254

DMRKIYB	DI	DMRKIYB
DMRKIYB	DN	NA-alpha-D-glucosamine
DMRKIYB	MI	DEVSIE6
DMRKIYB	MN	Glyceraldehyde-3-phosphate dehydrogenase (gap)
DMRKIYB	MT	DME
DMRKIYB	MA	Metabolism
DMRKIYB	RN	Cloning, expression and characterization of a mucin-binding GAPDH from Lactobacillus acidophilus. Int J Biol Macromol. 2016 Oct;91:338-46.
DMRKIYB	RU	https://pubmed.ncbi.nlm.nih.gov/27180300

DMRKIYB	DI	DMRKIYB
DMRKIYB	DN	NA-alpha-D-glucosamine
DMRKIYB	MI	DER0EN5
DMRKIYB	MN	Phosphoglucomutase 3 (PGM3)
DMRKIYB	MT	DME
DMRKIYB	MA	Metabolism
DMRKIYB	RN	Functional cloning and mutational analysis of the human cDNA for phosphoacetylglucosamine mutase: identification of the amino acid residues essential for the catalysis. Biochim Biophys Acta. 2000 Jul 24;1492(2-3):369-76.
DMRKIYB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11004509

DMZW9AC	DI	DMZW9AC
DMZW9AC	DN	N-Acetylalanine
DMZW9AC	MI	TTFBNVI
DMZW9AC	MN	Aldose reductase (AKR1B1)
DMZW9AC	MT	DTT
DMZW9AC	MA	Inhibitor
DMZW9AC	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMZW9AC	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9WQ6V	DI	DM9WQ6V
DM9WQ6V	DN	N-Acetylmethionine
DM9WQ6V	MI	TTH0KSX
DM9WQ6V	MN	Rhodopsin (RHO)
DM9WQ6V	MT	DTT
DM9WQ6V	MA	Inhibitor
DM9WQ6V	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM9WQ6V	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMUNCFQ	DI	DMUNCFQ
DMUNCFQ	DN	N-Acetyl-N'-Beta-D-Glucopyranosyl Urea
DMUNCFQ	MI	TTZHY6R
DMUNCFQ	MN	Glycogen phosphorylase muscle form (GP)
DMUNCFQ	MT	DTT
DMUNCFQ	MA	Inhibitor
DMUNCFQ	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMUNCFQ	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DME8O69	DI	DME8O69
DME8O69	DN	N-acetyl-phenylalanyl-glycine-nitrile
DME8O69	MI	TTDZN01
DME8O69	MN	Cathepsin K (CTSK)
DME8O69	MT	DTT
DME8O69	MA	Inhibitor
DME8O69	RN	Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707.
DME8O69	RU	https://pubmed.ncbi.nlm.nih.gov/16302809

DME8O69	DI	DME8O69
DME8O69	DN	N-acetyl-phenylalanyl-glycine-nitrile
DME8O69	MI	TT36ETB
DME8O69	MN	Cathepsin L (CTSL)
DME8O69	MT	DTT
DME8O69	MA	Inhibitor
DME8O69	RN	Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707.
DME8O69	RU	https://pubmed.ncbi.nlm.nih.gov/16302809

DME8O69	DI	DME8O69
DME8O69	DN	N-acetyl-phenylalanyl-glycine-nitrile
DME8O69	MI	TTUMQVO
DME8O69	MN	Cathepsin S (CTSS)
DME8O69	MT	DTT
DME8O69	MA	Inhibitor
DME8O69	RN	Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707.
DME8O69	RU	https://pubmed.ncbi.nlm.nih.gov/16302809

DMJ4SBM	DI	DMJ4SBM
DMJ4SBM	DN	N-acetylserotonin
DMJ4SBM	MI	TT0WAIE
DMJ4SBM	MN	Melatonin receptor type 1A (MTNR1A)
DMJ4SBM	MT	DTT
DMJ4SBM	MA	Inhibitor
DMJ4SBM	RN	Synthesis of 2-amido-2,3-dihydro-1H-phenalene derivatives as new conformationally restricted ligands for melatonin receptors. J Med Chem. 1996 Aug 2;39(16):3089-95.
DMJ4SBM	RU	https://pubmed.ncbi.nlm.nih.gov/8759629

DM1XH8D	DI	DM1XH8D
DM1XH8D	DN	N'-Acridin-9-yl-N,N-diethyl-butane-1,4-diamine
DM1XH8D	MI	TTFK1JQ
DM1XH8D	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DM1XH8D	MT	DTT
DM1XH8D	MA	Inhibitor
DM1XH8D	RN	N-Acridin-9-yl-butane-1,4-diamine derivatives: high-affinity ligands of the alpha2delta subunit of voltage gated calcium channels. Bioorg Med Chem Lett. 2004 Apr 19;14(8):1913-6.
DM1XH8D	RU	https://pubmed.ncbi.nlm.nih.gov/15050626

DM3ORGM	DI	DM3ORGM
DM3ORGM	DN	NADA
DM3ORGM	MI	TTXDKTO
DM3ORGM	MN	Long transient receptor potential channel 8 (TRPM8)
DM3ORGM	MT	DTT
DM3ORGM	MA	Blocker (channel blocker)
DM3ORGM	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 500).
DM3ORGM	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=500

DM3ORGM	DI	DM3ORGM
DM3ORGM	DN	NADA
DM3ORGM	MI	TTMI6F5
DM3ORGM	MN	Transient receptor potential cation channel V1 (TRPV1)
DM3ORGM	MT	DTT
DM3ORGM	MA	Blocker (channel blocker)
DM3ORGM	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 507).
DM3ORGM	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=507

DMSR4A6	DI	DMSR4A6
DMSR4A6	DN	N-adamantanemethyloxypentyl-1-deoxynojirimycin
DMSR4A6	MI	TTLPC70
DMSR4A6	MN	Lysosomal alpha-glucosidase (GAA)
DMSR4A6	MT	DTT
DMSR4A6	MA	Inhibitor
DMSR4A6	RN	Synthesis and evaluation of D-gluco-pyranocyclopropyl amines as potential glucosidase inhibitors. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6600-3.
DMSR4A6	RU	https://pubmed.ncbi.nlm.nih.gov/19853441

DMZ43N1	DI	DMZ43N1
DMZ43N1	DN	N-adamantyl-N'-cyclohexylurea
DMZ43N1	MI	TT7WVHI
DMZ43N1	MN	Soluble epoxide hydrolase (EPHX2)
DMZ43N1	MT	DTT
DMZ43N1	MA	Inhibitor
DMZ43N1	RN	Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem. 2007 Aug 9;50(16):3825-40.
DMZ43N1	RU	https://pubmed.ncbi.nlm.nih.gov/17616115

DM75Q34	DI	DM75Q34
DM75Q34	DN	NADPH
DM75Q34	MI	TTBE4IR
DM75Q34	MN	Plasmodium Oxoacyl-[acyl-carrier protein] reductase (Malaria fabG)
DM75Q34	MT	DTT
DM75Q34	MA	Cofactor
DM75Q34	RN	Functional characterization of beta-ketoacyl-ACP reductase (FabG) from Plasmodium falciparum. Biochem Biophys Res Commun. 2003 Mar 28;303(1):387-92.
DM75Q34	RU	https://pubmed.ncbi.nlm.nih.gov/12646215

DM38XWZ	DI	DM38XWZ
DM38XWZ	DN	NAEPA
DM38XWZ	MI	TTE2YJR
DM38XWZ	MN	Lysophosphatidate-3 receptor (LPAR3)
DM38XWZ	MT	DTT
DM38XWZ	MA	Agonist
DM38XWZ	RN	LPA and its analogs-attractive tools for elucidation of LPA biology and drug development. Curr Med Chem. 2008;15(21):2122-31.
DM38XWZ	RU	https://pubmed.ncbi.nlm.nih.gov/18781939

DM38XWZ	DI	DM38XWZ
DM38XWZ	DN	NAEPA
DM38XWZ	MI	TTQ6S1K
DM38XWZ	MN	Lysophosphatidic acid receptor 1 (LPAR1)
DM38XWZ	MT	DTT
DM38XWZ	MA	Agonist
DM38XWZ	RN	LPA and its analogs-attractive tools for elucidation of LPA biology and drug development. Curr Med Chem. 2008;15(21):2122-31.
DM38XWZ	RU	https://pubmed.ncbi.nlm.nih.gov/18781939

DM38XWZ	DI	DM38XWZ
DM38XWZ	DN	NAEPA
DM38XWZ	MI	TTB7Y8I
DM38XWZ	MN	Lysophosphatidic acid receptor 2 (LPAR2)
DM38XWZ	MT	DTT
DM38XWZ	MA	Agonist
DM38XWZ	RN	LPA and its analogs-attractive tools for elucidation of LPA biology and drug development. Curr Med Chem. 2008;15(21):2122-31.
DM38XWZ	RU	https://pubmed.ncbi.nlm.nih.gov/18781939

DM79KLR	DI	DM79KLR
DM79KLR	DN	nafadotride
DM79KLR	MI	TTSQIFT
DM79KLR	MN	5-HT 1A receptor (HTR1A)
DM79KLR	MT	DTT
DM79KLR	MA	Agonist
DM79KLR	RN	Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol. 1998 Aug 21;355(2-3):245-56.
DM79KLR	RU	https://pubmed.ncbi.nlm.nih.gov/9760039

DM79KLR	DI	DM79KLR
DM79KLR	DN	nafadotride
DM79KLR	MI	TTEX248
DM79KLR	MN	Dopamine D2 receptor (D2R)
DM79KLR	MT	DTT
DM79KLR	MA	Antagonist
DM79KLR	RN	Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents. J Pharmacol Exp Ther. 1995 Dec;275(3):1239-46.
DM79KLR	RU	https://pubmed.ncbi.nlm.nih.gov/8531087

DM79KLR	DI	DM79KLR
DM79KLR	DN	nafadotride
DM79KLR	MI	TT4C8EA
DM79KLR	MN	Dopamine D3 receptor (D3R)
DM79KLR	MT	DTT
DM79KLR	MA	Antagonist
DM79KLR	RN	Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents. J Pharmacol Exp Ther. 1995 Dec;275(3):1239-46.
DM79KLR	RU	https://pubmed.ncbi.nlm.nih.gov/8531087

DM79KLR	DI	DM79KLR
DM79KLR	DN	nafadotride
DM79KLR	MI	TTE0A2F
DM79KLR	MN	Dopamine D4 receptor (D4R)
DM79KLR	MT	DTT
DM79KLR	MA	Antagonist
DM79KLR	RN	Nonconserved residues in the second transmembrane-spanning domain of the D(4) dopamine receptor are molecular determinants of D(4)-selective pharmacology. Mol Pharmacol. 2000 Jan;57(1):144-52.
DM79KLR	RU	https://pubmed.ncbi.nlm.nih.gov/10617689

DM0FROP	DI	DM0FROP
DM0FROP	DN	Nafoxidine
DM0FROP	MI	TTZAYWL
DM0FROP	MN	Estrogen receptor (ESR)
DM0FROP	MT	DTT
DM0FROP	MA	Inhibitor
DM0FROP	RN	Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthal... J Med Chem. 1998 Jul 30;41(16):2928-31.
DM0FROP	RU	https://pubmed.ncbi.nlm.nih.gov/9685230

DM0FROP	DI	DM0FROP
DM0FROP	DN	Nafoxidine
DM0FROP	MI	TTOM3J0
DM0FROP	MN	Estrogen receptor beta (ESR2)
DM0FROP	MT	DTT
DM0FROP	MA	Inhibitor
DM0FROP	RN	Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthal... J Med Chem. 1998 Jul 30;41(16):2928-31.
DM0FROP	RU	https://pubmed.ncbi.nlm.nih.gov/9685230

DM0FROP	DI	DM0FROP
DM0FROP	DN	Nafoxidine
DM0FROP	MI	DTUGYRD
DM0FROP	MN	P-glycoprotein 1 (ABCB1)
DM0FROP	MT	DTP
DM0FROP	MA	Substrate
DM0FROP	RN	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
DM0FROP	RU	http://www.ncbi.nlm.nih.gov/pubmed/7914405

DML7UVA	DI	DML7UVA
DML7UVA	DN	NAG 1-phosphate
DML7UVA	MI	DETYWG5
DML7UVA	MN	UDP-N-acetylhexosamine pyrophosphorylase (AGX)
DML7UVA	MT	DME
DML7UVA	MA	Metabolism
DML7UVA	RN	Crystal structures of two human pyrophosphorylase isoforms in complexes with UDPGlc(Gal)NAc: role of the alternatively spliced insert in the enzyme oligomeric assembly and active site architecture. EMBO J. 2001 Nov 15;20(22):6191-202.
DML7UVA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11707391

DM1LWMU	DI	DM1LWMU
DM1LWMU	DN	nahuoic acid A
DM1LWMU	MI	TTGC95K
DM1LWMU	MN	SET domain containing 8 (KMT5A)
DM1LWMU	MT	DTT
DM1LWMU	MA	Inhibitor
DM1LWMU	RN	Nahuoic acid A produced by a Streptomyces sp. isolated from a marine sediment is a selective SAM-competitive inhibitor of the histone methyltransferase SETD8. Org Lett. 2013 Jan 18;15(2):414-7.
DM1LWMU	RU	https://pubmed.ncbi.nlm.nih.gov/23272941

DM0CP36	DI	DM0CP36
DM0CP36	DN	NalBzOH
DM0CP36	MI	TTQW87Y
DM0CP36	MN	Opioid receptor kappa (OPRK1)
DM0CP36	MT	DTT
DM0CP36	MA	Inhibitor
DM0CP36	RN	Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5.
DM0CP36	RU	https://pubmed.ncbi.nlm.nih.gov/16777416

DM0CP36	DI	DM0CP36
DM0CP36	DN	NalBzOH
DM0CP36	MI	TTKWM86
DM0CP36	MN	Opioid receptor mu (MOP)
DM0CP36	MT	DTT
DM0CP36	MA	Inhibitor
DM0CP36	RN	Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5.
DM0CP36	RU	https://pubmed.ncbi.nlm.nih.gov/16777416

DM9T0OK	DI	DM9T0OK
DM9T0OK	DN	N-alkyl urea hydroxamic acids
DM9T0OK	MI	TTICO5G
DM9T0OK	MN	Staphylococcus Peptide deformylase (Stap-coc def)
DM9T0OK	MT	DTT
DM9T0OK	MA	Inhibitor
DM9T0OK	RN	N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity. Antimicrob Agents Chemother. 2002 Sep;46(9):2752-64.
DM9T0OK	RU	https://pubmed.ncbi.nlm.nih.gov/12183225

DM30LI6	DI	DM30LI6
DM30LI6	DN	N-allyl[D-Pro-10]Dyn A-(1-11)
DM30LI6	MI	TTQW87Y
DM30LI6	MN	Opioid receptor kappa (OPRK1)
DM30LI6	MT	DTT
DM30LI6	MA	Inhibitor
DM30LI6	RN	Synthesis and opioid activity of [D-Pro10]dynorphin A-(1-11) analogues with N-terminal alkyl substitution. J Med Chem. 1997 Aug 15;40(17):2733-9.
DM30LI6	RU	https://pubmed.ncbi.nlm.nih.gov/9276018

DMZQUMB	DI	DMZQUMB
DMZQUMB	DN	N-allyl-4-hydroxy-N-phenylbenzenesulfonamide
DMZQUMB	MI	TTZAYWL
DMZQUMB	MN	Estrogen receptor (ESR)
DMZQUMB	MT	DTT
DMZQUMB	MA	Inhibitor
DMZQUMB	RN	Substituted 4-hydroxyphenyl sulfonamides as pathway-selective estrogen receptor ligands. Bioorg Med Chem Lett. 2006 Feb 15;16(4):854-8.
DMZQUMB	RU	https://pubmed.ncbi.nlm.nih.gov/16300947

DMRXA8N	DI	DMRXA8N
DMRXA8N	DN	N-ALLYLNORGALANTHAMINE
DMRXA8N	MI	TT1RS9F
DMRXA8N	MN	Acetylcholinesterase (AChE)
DMRXA8N	MT	DTT
DMRXA8N	MA	Inhibitor
DMRXA8N	RN	N-Alkylated galanthamine derivatives: Potent acetylcholinesterase inhibitors from Leucojum aestivum. Bioorg Med Chem Lett. 2008 Apr 1;18(7):2263-6.
DMRXA8N	RU	https://pubmed.ncbi.nlm.nih.gov/18356045

DM5W2VK	DI	DM5W2VK
DM5W2VK	DN	N-allylnorlitebamine
DM5W2VK	MI	TT1RS9F
DM5W2VK	MN	Acetylcholinesterase (AChE)
DM5W2VK	MT	DTT
DM5W2VK	MA	Inhibitor
DM5W2VK	RN	Litebamine N-homologues: preparation and anti-acetylcholinesterase activity. J Nat Prod. 1998 Jan;61(1):46-50.
DM5W2VK	RU	https://pubmed.ncbi.nlm.nih.gov/9461651

DM1SCU5	DI	DM1SCU5
DM1SCU5	DN	Nalorphine
DM1SCU5	MI	TTQW87Y
DM1SCU5	MN	Opioid receptor kappa (OPRK1)
DM1SCU5	MT	DTT
DM1SCU5	MA	Agonist
DM1SCU5	RN	Apparent efficacy of kappa-opioid receptor ligands on serum prolactin levels in rhesus monkeys. Eur J Pharmacol. 1999 Nov 3;383(3):305-9.
DM1SCU5	RU	https://pubmed.ncbi.nlm.nih.gov/10594324

DM8ZMNH	DI	DM8ZMNH
DM8ZMNH	DN	naloxonazine
DM8ZMNH	MI	TTKWM86
DM8ZMNH	MN	Opioid receptor mu (MOP)
DM8ZMNH	MT	DTT
DM8ZMNH	MA	Antagonist
DM8ZMNH	RN	Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol Pharmacol. 1994 Feb;45(2):330-4.
DM8ZMNH	RU	https://pubmed.ncbi.nlm.nih.gov/8114680

DMFNCQ1	DI	DMFNCQ1
DMFNCQ1	DN	N-alpha-amidino-Tyr(Me)-D-Pro-Gly-Trp-Phe-NH2
DMFNCQ1	MI	TTKWM86
DMFNCQ1	MN	Opioid receptor mu (MOP)
DMFNCQ1	MT	DTT
DMFNCQ1	MA	Inhibitor
DMFNCQ1	RN	Endomorphin-1 analogs with enhanced metabolic stability and systemic analgesic activity: design, synthesis, and pharmacological characterization. Bioorg Med Chem. 2007 Feb 15;15(4):1694-702.
DMFNCQ1	RU	https://pubmed.ncbi.nlm.nih.gov/17188879

DM8QTSU	DI	DM8QTSU
DM8QTSU	DN	N-alpha-amidino-Tyr(Me)-Pro-Trp-p-Cl-Phe-NH2
DM8QTSU	MI	TT27RFC
DM8QTSU	MN	Opioid receptor delta (OPRD1)
DM8QTSU	MT	DTT
DM8QTSU	MA	Inhibitor
DM8QTSU	RN	Endomorphin-1 analogs with enhanced metabolic stability and systemic analgesic activity: design, synthesis, and pharmacological characterization. Bioorg Med Chem. 2007 Feb 15;15(4):1694-702.
DM8QTSU	RU	https://pubmed.ncbi.nlm.nih.gov/17188879

DM8QTSU	DI	DM8QTSU
DM8QTSU	DN	N-alpha-amidino-Tyr(Me)-Pro-Trp-p-Cl-Phe-NH2
DM8QTSU	MI	TTKWM86
DM8QTSU	MN	Opioid receptor mu (MOP)
DM8QTSU	MT	DTT
DM8QTSU	MA	Inhibitor
DM8QTSU	RN	Endomorphin-1 analogs with enhanced metabolic stability and systemic analgesic activity: design, synthesis, and pharmacological characterization. Bioorg Med Chem. 2007 Feb 15;15(4):1694-702.
DM8QTSU	RU	https://pubmed.ncbi.nlm.nih.gov/17188879

DMSC9FV	DI	DMSC9FV
DMSC9FV	DN	N-alpha-amidino-Tyr(Me)-Pro-Trp-Phe-NH2
DMSC9FV	MI	TT27RFC
DMSC9FV	MN	Opioid receptor delta (OPRD1)
DMSC9FV	MT	DTT
DMSC9FV	MA	Inhibitor
DMSC9FV	RN	Endomorphin-1 analogs with enhanced metabolic stability and systemic analgesic activity: design, synthesis, and pharmacological characterization. Bioorg Med Chem. 2007 Feb 15;15(4):1694-702.
DMSC9FV	RU	https://pubmed.ncbi.nlm.nih.gov/17188879

DMSC9FV	DI	DMSC9FV
DMSC9FV	DN	N-alpha-amidino-Tyr(Me)-Pro-Trp-Phe-NH2
DMSC9FV	MI	TTKWM86
DMSC9FV	MN	Opioid receptor mu (MOP)
DMSC9FV	MT	DTT
DMSC9FV	MA	Inhibitor
DMSC9FV	RN	Endomorphin-1 analogs with enhanced metabolic stability and systemic analgesic activity: design, synthesis, and pharmacological characterization. Bioorg Med Chem. 2007 Feb 15;15(4):1694-702.
DMSC9FV	RU	https://pubmed.ncbi.nlm.nih.gov/17188879

DMRAN5O	DI	DMRAN5O
DMRAN5O	DN	Naltrexone-6-alpha-ol
DMRAN5O	MI	TT27RFC
DMRAN5O	MN	Opioid receptor delta (OPRD1)
DMRAN5O	MT	DTT
DMRAN5O	MA	Inhibitor
DMRAN5O	RN	Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8.
DMRAN5O	RU	https://pubmed.ncbi.nlm.nih.gov/19027293

DMRAN5O	DI	DMRAN5O
DMRAN5O	DN	Naltrexone-6-alpha-ol
DMRAN5O	MI	TTQW87Y
DMRAN5O	MN	Opioid receptor kappa (OPRK1)
DMRAN5O	MT	DTT
DMRAN5O	MA	Inhibitor
DMRAN5O	RN	Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8.
DMRAN5O	RU	https://pubmed.ncbi.nlm.nih.gov/19027293

DMRAN5O	DI	DMRAN5O
DMRAN5O	DN	Naltrexone-6-alpha-ol
DMRAN5O	MI	TTKWM86
DMRAN5O	MN	Opioid receptor mu (MOP)
DMRAN5O	MT	DTT
DMRAN5O	MA	Inhibitor
DMRAN5O	RN	Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8.
DMRAN5O	RU	https://pubmed.ncbi.nlm.nih.gov/19027293

DMNDOLZ	DI	DMNDOLZ
DMNDOLZ	DN	naltriben
DMNDOLZ	MI	TT27RFC
DMNDOLZ	MN	Opioid receptor delta (OPRD1)
DMNDOLZ	MT	DTT
DMNDOLZ	MA	Antagonist
DMNDOLZ	RN	Differential antagonism of delta opioid agonists by naltrindole and its benzofuran analog (NTB) in mice: evidence for delta opioid receptor subtypes. J Pharmacol Exp Ther. 1991 May;257(2):676-80.
DMNDOLZ	RU	https://pubmed.ncbi.nlm.nih.gov/1851833

DMNDOLZ	DI	DMNDOLZ
DMNDOLZ	DN	naltriben
DMNDOLZ	MI	TTQW87Y
DMNDOLZ	MN	Opioid receptor kappa (OPRK1)
DMNDOLZ	MT	DTT
DMNDOLZ	MA	Antagonist
DMNDOLZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 318).
DMNDOLZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=318

DMNDOLZ	DI	DMNDOLZ
DMNDOLZ	DN	naltriben
DMNDOLZ	MI	TTKWM86
DMNDOLZ	MN	Opioid receptor mu (MOP)
DMNDOLZ	MT	DTT
DMNDOLZ	MA	Antagonist
DMNDOLZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
DMNDOLZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319

DMWXBYC	DI	DMWXBYC
DMWXBYC	DN	N-Aminoethylmorpholine
DMWXBYC	MI	TTPT2QI
DMWXBYC	MN	Cathepsin D (CTSD)
DMWXBYC	MT	DTT
DMWXBYC	MA	Inhibitor
DMWXBYC	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMWXBYC	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM1EZ3N	DI	DM1EZ3N
DM1EZ3N	DN	Namn
DM1EZ3N	MI	TTH29K0
DM1EZ3N	MN	Mycobacterium Nicotinate-nucleotide pyrophosphorylase (MycB nadC)
DM1EZ3N	MT	DTT
DM1EZ3N	MA	Inhibitor
DM1EZ3N	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM1EZ3N	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM1EZ3N	DI	DM1EZ3N
DM1EZ3N	DN	Namn
DM1EZ3N	MI	DE4D159
DM1EZ3N	MN	Nicotinate-nucleotide adenylyltransferase 1 (NMNAT1)
DM1EZ3N	MT	DME
DM1EZ3N	MA	Metabolism
DM1EZ3N	RN	Initial-rate kinetics of human NMN-adenylyltransferases: substrate and metal ion specificity, inhibition by products and multisubstrate analogues, and isozyme contributions to NAD+ biosynthesis. Biochemistry. 2007 Apr 24;46(16):4912-22.
DM1EZ3N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17402747

DM1EZ3N	DI	DM1EZ3N
DM1EZ3N	DN	Namn
DM1EZ3N	MI	DE2HB58
DM1EZ3N	MN	Nicotinate-nucleotide adenylyltransferase 2 (NMNAT2)
DM1EZ3N	MT	DME
DM1EZ3N	MA	Metabolism
DM1EZ3N	RN	Initial-rate kinetics of human NMN-adenylyltransferases: substrate and metal ion specificity, inhibition by products and multisubstrate analogues, and isozyme contributions to NAD+ biosynthesis. Biochemistry. 2007 Apr 24;46(16):4912-22.
DM1EZ3N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17402747

DM1EZ3N	DI	DM1EZ3N
DM1EZ3N	DN	Namn
DM1EZ3N	MI	DERBKPU
DM1EZ3N	MN	Nicotinate-nucleotide adenylyltransferase 3 (NMNAT3)
DM1EZ3N	MT	DME
DM1EZ3N	MA	Metabolism
DM1EZ3N	RN	The NMN/NaMN adenylyltransferase (NMNAT) protein family. Front Biosci (Landmark Ed). 2009 Jan 1;14:410-31.
DM1EZ3N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19273075

DMYDRB7	DI	DMYDRB7
DMYDRB7	DN	Naphthalen-1-yl 10H-phenothiazine-10-carboxylate
DMYDRB7	MI	TTEB0GD
DMYDRB7	MN	Cholinesterase (BCHE)
DMYDRB7	MT	DTT
DMYDRB7	MA	Inhibitor
DMYDRB7	RN	Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. J Med Chem. 2008 Jul 24;51(14):4200-12.
DMYDRB7	RU	https://pubmed.ncbi.nlm.nih.gov/18570368

DM93CZW	DI	DM93CZW
DM93CZW	DN	Naphthalen-1-yl(10H-phenothiazin-10-yl)methanone
DM93CZW	MI	TTEB0GD
DM93CZW	MN	Cholinesterase (BCHE)
DM93CZW	MT	DTT
DM93CZW	MA	Inhibitor
DM93CZW	RN	Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. Bioorg Med Chem. 2007 Oct 1;15(19):6367-78.
DM93CZW	RU	https://pubmed.ncbi.nlm.nih.gov/17681768

DM08W6U	DI	DM08W6U
DM08W6U	DN	Naphthalen-2-yl 10H-phenothiazine-10-carboxylate
DM08W6U	MI	TTEB0GD
DM08W6U	MN	Cholinesterase (BCHE)
DM08W6U	MT	DTT
DM08W6U	MA	Inhibitor
DM08W6U	RN	Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. J Med Chem. 2008 Jul 24;51(14):4200-12.
DM08W6U	RU	https://pubmed.ncbi.nlm.nih.gov/18570368

DMDXM2A	DI	DMDXM2A
DMDXM2A	DN	Naphthalen-2-yl cyclohexylcarbamate
DMDXM2A	MI	TTDP1UC
DMDXM2A	MN	Fatty acid amide hydrolase (FAAH)
DMDXM2A	MT	DTT
DMDXM2A	MA	Inhibitor
DMDXM2A	RN	Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors. J Med Chem. 2008 Dec 11;51(23):7327-43.
DMDXM2A	RU	https://pubmed.ncbi.nlm.nih.gov/18983142

DMW8BXG	DI	DMW8BXG
DMW8BXG	DN	Naphthalen-2-yl(10H-phenothiazin-10-yl)methanone
DMW8BXG	MI	TTEB0GD
DMW8BXG	MN	Cholinesterase (BCHE)
DMW8BXG	MT	DTT
DMW8BXG	MA	Inhibitor
DMW8BXG	RN	Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. Bioorg Med Chem. 2007 Oct 1;15(19):6367-78.
DMW8BXG	RU	https://pubmed.ncbi.nlm.nih.gov/17681768

DML6FI3	DI	DML6FI3
DML6FI3	DN	Naphthalene Trisulfonate
DML6FI3	MI	TTMY81X
DML6FI3	MN	Heparin-binding growth factor 1 (FGF1)
DML6FI3	MT	DTT
DML6FI3	MA	Inhibitor
DML6FI3	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DML6FI3	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMOQ43W	DI	DMOQ43W
DMOQ43W	DN	Naphthalene-1,4-diol
DMOQ43W	MI	TTZJYKH
DMOQ43W	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMOQ43W	MT	DTT
DMOQ43W	MA	Inhibitor
DMOQ43W	RN	Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2010 Feb 11;53(3):1172-89.
DMOQ43W	RU	https://pubmed.ncbi.nlm.nih.gov/20055453

DMLHWNG	DI	DMLHWNG
DMLHWNG	DN	Naphthalene-2,6-disulfonic acid
DMLHWNG	MI	TTAZHU0
DMLHWNG	MN	L-lactate dehydrogenase (LDH)
DMLHWNG	MT	DTT
DMLHWNG	MA	Inhibitor
DMLHWNG	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMLHWNG	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMG8A74	DI	DMG8A74
DMG8A74	DN	Naphthalene-2-carboxylic acid hydroxyamide
DMG8A74	MI	TT2J34L
DMG8A74	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMG8A74	MT	DTT
DMG8A74	MA	Inhibitor
DMG8A74	RN	Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8.
DMG8A74	RU	https://pubmed.ncbi.nlm.nih.gov/2308149

DMTWEQP	DI	DMTWEQP
DMTWEQP	DN	Naphthyridinomycin
DMTWEQP	MI	TTJP4SM
DMTWEQP	MN	Bacterial Penicillin binding protein (Bact PBP)
DMTWEQP	MT	DTT
DMTWEQP	RN	Naphthyridinomycin-DNA adducts: a molecular modeling study. J Antibiot (Tokyo). 1991 Aug;44(8):885-94.
DMTWEQP	RU	https://pubmed.ncbi.nlm.nih.gov/1917702

DM0OEGV	DI	DM0OEGV
DM0OEGV	DN	NAPHTHYRIDINONE
DM0OEGV	MI	TT6OEDT
DM0OEGV	MN	Cannabinoid receptor 1 (CB1)
DM0OEGV	MT	DTT
DM0OEGV	MA	Inhibitor
DM0OEGV	RN	Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4.
DM0OEGV	RU	https://pubmed.ncbi.nlm.nih.gov/20483606

DM0OEGV	DI	DM0OEGV
DM0OEGV	DN	NAPHTHYRIDINONE
DM0OEGV	MI	TTMSFAW
DM0OEGV	MN	Cannabinoid receptor 2 (CB2)
DM0OEGV	MT	DTT
DM0OEGV	MA	Inhibitor
DM0OEGV	RN	Synthesis of functionalized 1,8-naphthyridinones and their evaluation as novel, orally active CB1 receptor inverse agonists. Bioorg Med Chem Lett. 2006 Feb;16(3):681-5.
DM0OEGV	RU	https://pubmed.ncbi.nlm.nih.gov/16263284

DM8F5LR	DI	DM8F5LR
DM8F5LR	DN	NAPQI
DM8F5LR	MI	TT2AST1
DM8F5LR	MN	Macrophage migration inhibitory factor (MIF)
DM8F5LR	MT	DTT
DM8F5LR	MA	Inhibitor
DM8F5LR	RN	MIF in autoimmunity and novel therapeutic approaches. Autoimmun Rev. 2009 Jan;8(3):244-9.
DM8F5LR	RU	https://pubmed.ncbi.nlm.nih.gov/18721909

DM85RJ1	DI	DM85RJ1
DM85RJ1	DN	N-arachidonoylglycine
DM85RJ1	MI	TTABCJ6
DM85RJ1	MN	Lysophosphatidic acid receptor 5 (LPAR5)
DM85RJ1	MT	DTT
DM85RJ1	MA	Agonist
DM85RJ1	RN	Identification of farnesyl pyrophosphate and N-arachidonylglycine as endogenous ligands for GPR92. J Biol Chem. 2008 Jul 25;283(30):21054-64.
DM85RJ1	RU	https://pubmed.ncbi.nlm.nih.gov/18499677

DM85RJ1	DI	DM85RJ1
DM85RJ1	DN	N-arachidonoylglycine
DM85RJ1	MI	TTSLJAR
DM85RJ1	MN	N-arachidonyl glycine receptor (GPR18)
DM85RJ1	MT	DTT
DM85RJ1	MA	Agonist
DM85RJ1	RN	Identification of N-arachidonylglycine as the endogenous ligand for orphan G-protein-coupled receptor GPR18. Biochem Biophys Res Commun. 2006 Sep 1;347(3):827-32.
DM85RJ1	RU	https://pubmed.ncbi.nlm.nih.gov/16844083

DMF9U2O	DI	DMF9U2O
DMF9U2O	DN	N-arachidonoyl-N-(2-hydroxyethyl)hydroxylamine
DMF9U2O	MI	TT6OEDT
DMF9U2O	MN	Cannabinoid receptor 1 (CB1)
DMF9U2O	MT	DTT
DMF9U2O	MA	Inhibitor
DMF9U2O	RN	Oxyhomologues of anandamide and related endolipids: chemoselective synthesis and biological activity. J Med Chem. 2006 Apr 6;49(7):2333-8.
DMF9U2O	RU	https://pubmed.ncbi.nlm.nih.gov/16570929

DMF9U2O	DI	DMF9U2O
DMF9U2O	DN	N-arachidonoyl-N-(2-hydroxyethyl)hydroxylamine
DMF9U2O	MI	TTMSFAW
DMF9U2O	MN	Cannabinoid receptor 2 (CB2)
DMF9U2O	MT	DTT
DMF9U2O	MA	Inhibitor
DMF9U2O	RN	Oxyhomologues of anandamide and related endolipids: chemoselective synthesis and biological activity. J Med Chem. 2006 Apr 6;49(7):2333-8.
DMF9U2O	RU	https://pubmed.ncbi.nlm.nih.gov/16570929

DM49HIO	DI	DM49HIO
DM49HIO	DN	N-arachidonoyl-O-(2-hydroxyethyl)hydroxylamine
DM49HIO	MI	TT6OEDT
DM49HIO	MN	Cannabinoid receptor 1 (CB1)
DM49HIO	MT	DTT
DM49HIO	MA	Inhibitor
DM49HIO	RN	Oxyhomologues of anandamide and related endolipids: chemoselective synthesis and biological activity. J Med Chem. 2006 Apr 6;49(7):2333-8.
DM49HIO	RU	https://pubmed.ncbi.nlm.nih.gov/16570929

DM49HIO	DI	DM49HIO
DM49HIO	DN	N-arachidonoyl-O-(2-hydroxyethyl)hydroxylamine
DM49HIO	MI	TTMSFAW
DM49HIO	MN	Cannabinoid receptor 2 (CB2)
DM49HIO	MT	DTT
DM49HIO	MA	Inhibitor
DM49HIO	RN	Oxyhomologues of anandamide and related endolipids: chemoselective synthesis and biological activity. J Med Chem. 2006 Apr 6;49(7):2333-8.
DM49HIO	RU	https://pubmed.ncbi.nlm.nih.gov/16570929

DMLVGT8	DI	DMLVGT8
DMLVGT8	DN	N-arachidonylmaleimide
DMLVGT8	MI	TTDP1UC
DMLVGT8	MN	Fatty acid amide hydrolase (FAAH)
DMLVGT8	MT	DTT
DMLVGT8	MA	Inhibitor
DMLVGT8	RN	Synthesis and in vitro evaluation of N-substituted maleimide derivatives as selective monoglyceride lipase inhibitors. J Med Chem. 2009 Dec 10;52(23):7410-20.
DMLVGT8	RU	https://pubmed.ncbi.nlm.nih.gov/19583260

DMI7A6R	DI	DMI7A6R
DMI7A6R	DN	Narciclasine
DMI7A6R	MI	TT8R0BZ
DMI7A6R	MN	Elongation factor 1A (EF1A)
DMI7A6R	MT	DTT
DMI7A6R	MA	Inhibitor
DMI7A6R	RN	Targeting of eEF1A with Amaryllidaceae isocarbostyrils as a strategy to combat melanomas. FASEB J. 2010 Nov;24(11):4575-84.
DMI7A6R	RU	https://pubmed.ncbi.nlm.nih.gov/20643906

DMMUABE	DI	DMMUABE
DMMUABE	DN	Naringin
DMMUABE	MI	DEBI82Z
DMMUABE	MN	Alpha-L-rhamnosidase (lrA)
DMMUABE	MT	DME
DMMUABE	MA	Metabolism
DMMUABE	RN	Metabolism of rutin and poncirin by human intestinal microbiota and cloning of their metabolizing alpha-L-rhamnosidase from Bifidobacterium dentium. J Microbiol Biotechnol. 2015 Jan;25(1):18-25.
DMMUABE	RU	https://pubmed.ncbi.nlm.nih.gov/25179902

DM4DG1Y	DI	DM4DG1Y
DM4DG1Y	DN	Naringin
DM4DG1Y	MI	TTUGD21
DM4DG1Y	MN	Sodium-independent organic anion transporter (SLCO1A2)
DM4DG1Y	MT	DTT
DM4DG1Y	MA	Inhibitor
DM4DG1Y	RN	Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin Pharmacol Ther. 2007 Apr;81(4):495-502.
DM4DG1Y	RU	https://pubmed.ncbi.nlm.nih.gov/17301733

DM3RP25	DI	DM3RP25
DM3RP25	DN	NAVPNLRGDLQVLAQKVART
DM3RP25	MI	TTT1R2L
DM3RP25	MN	Integrin alpha-V (ITGAV)
DM3RP25	MT	DTT
DM3RP25	MA	Inhibitor
DM3RP25	RN	Structure-function analysis of Arg-Gly-Asp helix motifs in alpha v beta 6 integrin ligands. J Biol Chem. 2007 Mar 30;282(13):9657-65.
DM3RP25	RU	https://pubmed.ncbi.nlm.nih.gov/17244604

DMO6T9C	DI	DMO6T9C
DMO6T9C	DN	NAX-5055
DMO6T9C	MI	TTX3HNZ
DMO6T9C	MN	Galanin receptor type 1 (GAL1-R)
DMO6T9C	MT	DTT
DMO6T9C	MA	Agonist
DMO6T9C	RN	Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
DMO6T9C	RU	https://pubmed.ncbi.nlm.nih.gov/19008076

DMNM6GQ	DI	DMNM6GQ
DMNM6GQ	DN	NB3178
DMNM6GQ	MI	TT9SL3Q
DMNM6GQ	MN	Polypeptide deformylase (PDF)
DMNM6GQ	MT	DTT
DMNM6GQ	MA	Inhibitor
DMNM6GQ	RN	Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
DMNM6GQ	RU	https://pubmed.ncbi.nlm.nih.gov/15934867

DM7K36E	DI	DM7K36E
DM7K36E	DN	NB-325
DM7K36E	MI	TTBID49
DM7K36E	MN	C-X-C chemokine receptor type 4 (CXCR4)
DM7K36E	MT	DTT
DM7K36E	MA	Modulator
DM7K36E	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 71).
DM7K36E	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=71

DMJHWGS	DI	DMJHWGS
DMJHWGS	DN	NB3322
DMJHWGS	MI	TT9SL3Q
DMJHWGS	MN	Polypeptide deformylase (PDF)
DMJHWGS	MT	DTT
DMJHWGS	MA	Inhibitor
DMJHWGS	RN	Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
DMJHWGS	RU	https://pubmed.ncbi.nlm.nih.gov/15934867

DMTZ1XV	DI	DMTZ1XV
DMTZ1XV	DN	NBBCC
DMTZ1XV	MI	TTZ8EM9
DMTZ1XV	MN	Glycine receptor (GlyR)
DMTZ1XV	MT	DTT
DMTZ1XV	RN	Developmental regulation of beta-carboline-induced inhibition of glycine-evoked responses depends on glycine receptor beta subunit expression. Mol Pharmacol. 2005 May;67(5):1783-96.
DMTZ1XV	RU	https://pubmed.ncbi.nlm.nih.gov/15722459

DMX0Y79	DI	DMX0Y79
DMX0Y79	DN	N-BENZOYL-D-ALANINE
DMX0Y79	MI	TT329FH
DMX0Y79	MN	Bacterial Penicillin-binding protein 1B (Bact mrcB)
DMX0Y79	MT	DTT
DMX0Y79	MA	Inhibitor
DMX0Y79	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMX0Y79	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM7U81L	DI	DM7U81L
DM7U81L	DN	N-Benzoyl-N'-Beta-D-Glucopyranosyl Urea
DM7U81L	MI	TTZHY6R
DM7U81L	MN	Glycogen phosphorylase muscle form (GP)
DM7U81L	MT	DTT
DM7U81L	MA	Inhibitor
DM7U81L	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM7U81L	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMRJ4B1	DI	DMRJ4B1
DMRJ4B1	DN	N-benzoyl-phenylalanyl-glycine-nitrile
DMRJ4B1	MI	TTDZN01
DMRJ4B1	MN	Cathepsin K (CTSK)
DMRJ4B1	MT	DTT
DMRJ4B1	MA	Inhibitor
DMRJ4B1	RN	Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707.
DMRJ4B1	RU	https://pubmed.ncbi.nlm.nih.gov/16302809

DMRJ4B1	DI	DMRJ4B1
DMRJ4B1	DN	N-benzoyl-phenylalanyl-glycine-nitrile
DMRJ4B1	MI	TT36ETB
DMRJ4B1	MN	Cathepsin L (CTSL)
DMRJ4B1	MT	DTT
DMRJ4B1	MA	Inhibitor
DMRJ4B1	RN	Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707.
DMRJ4B1	RU	https://pubmed.ncbi.nlm.nih.gov/16302809

DMRJ4B1	DI	DMRJ4B1
DMRJ4B1	DN	N-benzoyl-phenylalanyl-glycine-nitrile
DMRJ4B1	MI	TTUMQVO
DMRJ4B1	MN	Cathepsin S (CTSS)
DMRJ4B1	MT	DTT
DMRJ4B1	MA	Inhibitor
DMRJ4B1	RN	Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707.
DMRJ4B1	RU	https://pubmed.ncbi.nlm.nih.gov/16302809

DMOQMEU	DI	DMOQMEU
DMOQMEU	DN	N-benzyl brucine
DMOQMEU	MI	TTOXS3C
DMOQMEU	MN	Muscarinic acetylcholine receptor (CHRM)
DMOQMEU	MT	DTT
DMOQMEU	MA	Modulator (allosteric modulator)
DMOQMEU	RN	Subtype-selective positive cooperative interactions between brucine analogues and acetylcholine at muscarinic receptors: radioligand binding studies. Mol Pharmacol. 1998 Mar;53(3):573-89.
DMOQMEU	RU	https://pubmed.ncbi.nlm.nih.gov/9495826

DMOQMEU	DI	DMOQMEU
DMOQMEU	DN	N-benzyl brucine
DMOQMEU	MI	TTQ13Z5
DMOQMEU	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMOQMEU	MT	DTT
DMOQMEU	MA	Modulator (allosteric modulator)
DMOQMEU	RN	Subtype-selective positive cooperative interactions between brucine analogues and acetylcholine at muscarinic receptors: radioligand binding studies. Mol Pharmacol. 1998 Mar;53(3):573-89.
DMOQMEU	RU	https://pubmed.ncbi.nlm.nih.gov/9495826

DMN9WZ3	DI	DMN9WZ3
DMN9WZ3	DN	N-Benzyl-(6-butoxy-2-naphthyl)-2-aminopropane
DMN9WZ3	MI	TT3WG5C
DMN9WZ3	MN	Monoamine oxidase type A (MAO-A)
DMN9WZ3	MT	DTT
DMN9WZ3	MA	Inhibitor
DMN9WZ3	RN	Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg Med Chem. 2009 Mar 15;17(6):2452-60.
DMN9WZ3	RU	https://pubmed.ncbi.nlm.nih.gov/19243954

DMKJ6F8	DI	DMKJ6F8
DMKJ6F8	DN	N-Benzyl-(6-methoxy-2-naphthyl)-2-aminopropane
DMKJ6F8	MI	TT3WG5C
DMKJ6F8	MN	Monoamine oxidase type A (MAO-A)
DMKJ6F8	MT	DTT
DMKJ6F8	MA	Inhibitor
DMKJ6F8	RN	Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg Med Chem. 2009 Mar 15;17(6):2452-60.
DMKJ6F8	RU	https://pubmed.ncbi.nlm.nih.gov/19243954

DMHVRFM	DI	DMHVRFM
DMHVRFM	DN	N-Benzyl,N-methyl-1H-indole-2-carboxamide
DMHVRFM	MI	TT3WG5C
DMHVRFM	MN	Monoamine oxidase type A (MAO-A)
DMHVRFM	MT	DTT
DMHVRFM	MA	Inhibitor
DMHVRFM	RN	Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40.
DMHVRFM	RU	https://pubmed.ncbi.nlm.nih.gov/18951803

DMHVRFM	DI	DMHVRFM
DMHVRFM	DN	N-Benzyl,N-methyl-1H-indole-2-carboxamide
DMHVRFM	MI	TTGP7BY
DMHVRFM	MN	Monoamine oxidase type B (MAO-B)
DMHVRFM	MT	DTT
DMHVRFM	MA	Inhibitor
DMHVRFM	RN	Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40.
DMHVRFM	RU	https://pubmed.ncbi.nlm.nih.gov/18951803

DM8I7N2	DI	DM8I7N2
DM8I7N2	DN	N-benzyl,N-methyl-1H-pyrrole-2-carboxamide
DM8I7N2	MI	TT3WG5C
DM8I7N2	MN	Monoamine oxidase type A (MAO-A)
DM8I7N2	MT	DTT
DM8I7N2	MA	Inhibitor
DM8I7N2	RN	New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J Med Chem. 2007 Mar 8;50(5):922-31.
DM8I7N2	RU	https://pubmed.ncbi.nlm.nih.gov/17256833

DM2YZC5	DI	DM2YZC5
DM2YZC5	DN	N-benzyl[D-Pro-10]Dyn A-(1-11)
DM2YZC5	MI	TTQW87Y
DM2YZC5	MN	Opioid receptor kappa (OPRK1)
DM2YZC5	MT	DTT
DM2YZC5	MA	Inhibitor
DM2YZC5	RN	Synthesis and opioid activity of [D-Pro10]dynorphin A-(1-11) analogues with N-terminal alkyl substitution. J Med Chem. 1997 Aug 15;40(17):2733-9.
DM2YZC5	RU	https://pubmed.ncbi.nlm.nih.gov/9276018

DM7SEM1	DI	DM7SEM1
DM7SEM1	DN	N-Benzyl-17-(cyclobutylmethyl)morphinan-3-amine
DM7SEM1	MI	TT27RFC
DM7SEM1	MN	Opioid receptor delta (OPRD1)
DM7SEM1	MT	DTT
DM7SEM1	MA	Inhibitor
DM7SEM1	RN	Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18.
DM7SEM1	RU	https://pubmed.ncbi.nlm.nih.gov/19928862

DM7SEM1	DI	DM7SEM1
DM7SEM1	DN	N-Benzyl-17-(cyclobutylmethyl)morphinan-3-amine
DM7SEM1	MI	TTQW87Y
DM7SEM1	MN	Opioid receptor kappa (OPRK1)
DM7SEM1	MT	DTT
DM7SEM1	MA	Inhibitor
DM7SEM1	RN	Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18.
DM7SEM1	RU	https://pubmed.ncbi.nlm.nih.gov/19928862

DM7SEM1	DI	DM7SEM1
DM7SEM1	DN	N-Benzyl-17-(cyclobutylmethyl)morphinan-3-amine
DM7SEM1	MI	TTKWM86
DM7SEM1	MN	Opioid receptor mu (MOP)
DM7SEM1	MT	DTT
DM7SEM1	MA	Inhibitor
DM7SEM1	RN	Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18.
DM7SEM1	RU	https://pubmed.ncbi.nlm.nih.gov/19928862

DMLP9VM	DI	DMLP9VM
DMLP9VM	DN	N-Benzyl-17-(cyclopropylmethyl)morphinan-3-amine
DMLP9VM	MI	TT27RFC
DMLP9VM	MN	Opioid receptor delta (OPRD1)
DMLP9VM	MT	DTT
DMLP9VM	MA	Inhibitor
DMLP9VM	RN	Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18.
DMLP9VM	RU	https://pubmed.ncbi.nlm.nih.gov/19928862

DMLP9VM	DI	DMLP9VM
DMLP9VM	DN	N-Benzyl-17-(cyclopropylmethyl)morphinan-3-amine
DMLP9VM	MI	TTQW87Y
DMLP9VM	MN	Opioid receptor kappa (OPRK1)
DMLP9VM	MT	DTT
DMLP9VM	MA	Inhibitor
DMLP9VM	RN	Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18.
DMLP9VM	RU	https://pubmed.ncbi.nlm.nih.gov/19928862

DMLP9VM	DI	DMLP9VM
DMLP9VM	DN	N-Benzyl-17-(cyclopropylmethyl)morphinan-3-amine
DMLP9VM	MI	TTKWM86
DMLP9VM	MN	Opioid receptor mu (MOP)
DMLP9VM	MT	DTT
DMLP9VM	MA	Inhibitor
DMLP9VM	RN	Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18.
DMLP9VM	RU	https://pubmed.ncbi.nlm.nih.gov/19928862

DMA3YWU	DI	DMA3YWU
DMA3YWU	DN	N-Benzyl-1H-indole-2-carboxamide
DMA3YWU	MI	TT3WG5C
DMA3YWU	MN	Monoamine oxidase type A (MAO-A)
DMA3YWU	MT	DTT
DMA3YWU	MA	Inhibitor
DMA3YWU	RN	Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40.
DMA3YWU	RU	https://pubmed.ncbi.nlm.nih.gov/18951803

DMA3YWU	DI	DMA3YWU
DMA3YWU	DN	N-Benzyl-1H-indole-2-carboxamide
DMA3YWU	MI	TTGP7BY
DMA3YWU	MN	Monoamine oxidase type B (MAO-B)
DMA3YWU	MT	DTT
DMA3YWU	MA	Inhibitor
DMA3YWU	RN	Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40.
DMA3YWU	RU	https://pubmed.ncbi.nlm.nih.gov/18951803

DMC7XST	DI	DMC7XST
DMC7XST	DN	N-Benzyl-1'H-phenothiazine-1'-carboxamide
DMC7XST	MI	TTEB0GD
DMC7XST	MN	Cholinesterase (BCHE)
DMC7XST	MT	DTT
DMC7XST	MA	Inhibitor
DMC7XST	RN	Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorg Med Chem. 2010 Mar 15;18(6):2232-2244.
DMC7XST	RU	https://pubmed.ncbi.nlm.nih.gov/20181484

DM73ZHV	DI	DM73ZHV
DM73ZHV	DN	N-benzyl-1H-pyrrole-2-carboxamide
DM73ZHV	MI	TT3WG5C
DM73ZHV	MN	Monoamine oxidase type A (MAO-A)
DM73ZHV	MT	DTT
DM73ZHV	MA	Inhibitor
DM73ZHV	RN	New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J Med Chem. 2007 Mar 8;50(5):922-31.
DM73ZHV	RU	https://pubmed.ncbi.nlm.nih.gov/17256833

DM8A23B	DI	DM8A23B
DM8A23B	DN	N-Benzyl-2-(1H-indol-3-yl)-2-oxo-acetamide
DM8A23B	MI	TT1MPAY
DM8A23B	MN	GABA(A) receptor alpha-1 (GABRA1)
DM8A23B	MT	DTT
DM8A23B	MA	Inhibitor
DM8A23B	RN	Novel N-substituted indol-3-ylglyoxylamides probing the LDi and L1/L2 lipophilic regions of the benzodiazepine receptor site in search for subtype-... J Med Chem. 2007 Apr 5;50(7):1627-34.
DM8A23B	RU	https://pubmed.ncbi.nlm.nih.gov/17335185

DM8A23B	DI	DM8A23B
DM8A23B	DN	N-Benzyl-2-(1H-indol-3-yl)-2-oxo-acetamide
DM8A23B	MI	TTZA1NY
DM8A23B	MN	GABA(A) receptor beta-2 (GABRB2)
DM8A23B	MT	DTT
DM8A23B	MA	Inhibitor
DM8A23B	RN	Novel N-substituted indol-3-ylglyoxylamides probing the LDi and L1/L2 lipophilic regions of the benzodiazepine receptor site in search for subtype-... J Med Chem. 2007 Apr 5;50(7):1627-34.
DM8A23B	RU	https://pubmed.ncbi.nlm.nih.gov/17335185

DM8A23B	DI	DM8A23B
DM8A23B	DN	N-Benzyl-2-(1H-indol-3-yl)-2-oxo-acetamide
DM8A23B	MI	TT06RH5
DM8A23B	MN	GABA(A) receptor gamma-2 (GABRG2)
DM8A23B	MT	DTT
DM8A23B	MA	Inhibitor
DM8A23B	RN	Novel N-substituted indol-3-ylglyoxylamides probing the LDi and L1/L2 lipophilic regions of the benzodiazepine receptor site in search for subtype-... J Med Chem. 2007 Apr 5;50(7):1627-34.
DM8A23B	RU	https://pubmed.ncbi.nlm.nih.gov/17335185

DM8A23B	DI	DM8A23B
DM8A23B	DN	N-Benzyl-2-(1H-indol-3-yl)-2-oxo-acetamide
DM8A23B	MI	TTNJYV2
DM8A23B	MN	Gamma-aminobutyric acid receptor (GAR)
DM8A23B	MT	DTT
DM8A23B	MA	Inhibitor
DM8A23B	RN	N'-Phenylindol-3-ylglyoxylohydrazide derivatives: synthesis, structure-activity relationships, molecular modeling studies, and pharmacological acti... J Med Chem. 1998 Sep 24;41(20):3821-30.
DM8A23B	RU	https://pubmed.ncbi.nlm.nih.gov/9748357

DMMT65J	DI	DMMT65J
DMMT65J	DN	N-benzyl-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamide
DMMT65J	MI	TT1MPAY
DMMT65J	MN	GABA(A) receptor alpha-1 (GABRA1)
DMMT65J	MT	DTT
DMMT65J	MA	Inhibitor
DMMT65J	RN	Novel N-substituted indol-3-ylglyoxylamides probing the LDi and L1/L2 lipophilic regions of the benzodiazepine receptor site in search for subtype-... J Med Chem. 2007 Apr 5;50(7):1627-34.
DMMT65J	RU	https://pubmed.ncbi.nlm.nih.gov/17335185

DMMT65J	DI	DMMT65J
DMMT65J	DN	N-benzyl-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamide
DMMT65J	MI	TTZA1NY
DMMT65J	MN	GABA(A) receptor beta-2 (GABRB2)
DMMT65J	MT	DTT
DMMT65J	MA	Inhibitor
DMMT65J	RN	Novel N-substituted indol-3-ylglyoxylamides probing the LDi and L1/L2 lipophilic regions of the benzodiazepine receptor site in search for subtype-... J Med Chem. 2007 Apr 5;50(7):1627-34.
DMMT65J	RU	https://pubmed.ncbi.nlm.nih.gov/17335185

DMMT65J	DI	DMMT65J
DMMT65J	DN	N-benzyl-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamide
DMMT65J	MI	TT06RH5
DMMT65J	MN	GABA(A) receptor gamma-2 (GABRG2)
DMMT65J	MT	DTT
DMMT65J	MA	Inhibitor
DMMT65J	RN	Novel N-substituted indol-3-ylglyoxylamides probing the LDi and L1/L2 lipophilic regions of the benzodiazepine receptor site in search for subtype-... J Med Chem. 2007 Apr 5;50(7):1627-34.
DMMT65J	RU	https://pubmed.ncbi.nlm.nih.gov/17335185

DM0ZXBQ	DI	DM0ZXBQ
DM0ZXBQ	DN	N-benzyl-2-(pyrrolidin-1-yl)pyrimidin-4-amine
DM0ZXBQ	MI	TT1RS9F
DM0ZXBQ	MN	Acetylcholinesterase (AChE)
DM0ZXBQ	MT	DTT
DM0ZXBQ	MA	Inhibitor
DM0ZXBQ	RN	Design, synthesis and evaluation of 2,4-disubstituted pyrimidines as cholinesterase inhibitors. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3606-9.
DM0ZXBQ	RU	https://pubmed.ncbi.nlm.nih.gov/20472431

DM3C0P2	DI	DM3C0P2
DM3C0P2	DN	N-Benzyl-2-(toluene-4-sulfonylamino)-benzamide
DM3C0P2	MI	TTW0CMT
DM3C0P2	MN	Voltage-gated potassium channel Kv1.5 (KCNA5)
DM3C0P2	MT	DTT
DM3C0P2	MA	Inhibitor
DM3C0P2	RN	Pharmacophore-based search, synthesis, and biological evaluation of anthranilic amides as novel blockers of the Kv1.5 channel. Bioorg Med Chem Lett. 2004 Jun 7;14(11):2823-7.
DM3C0P2	RU	https://pubmed.ncbi.nlm.nih.gov/15125940

DMQCGFL	DI	DMQCGFL
DMQCGFL	DN	N-benzyl-2-morpholinopyrimidin-4-amine
DMQCGFL	MI	TT1RS9F
DMQCGFL	MN	Acetylcholinesterase (AChE)
DMQCGFL	MT	DTT
DMQCGFL	MA	Inhibitor
DMQCGFL	RN	Design, synthesis and evaluation of 2,4-disubstituted pyrimidines as cholinesterase inhibitors. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3606-9.
DMQCGFL	RU	https://pubmed.ncbi.nlm.nih.gov/20472431

DMJ29MN	DI	DMJ29MN
DMJ29MN	DN	N-benzyl-2-oxo-2H-chromene-3-carboxamide
DMJ29MN	MI	TTGP7BY
DMJ29MN	MN	Monoamine oxidase type B (MAO-B)
DMJ29MN	MT	DTT
DMJ29MN	MA	Inhibitor
DMJ29MN	RN	Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins. J Med Chem. 2009 Apr 9;52(7):1935-42.
DMJ29MN	RU	https://pubmed.ncbi.nlm.nih.gov/19267475

DMRJMGK	DI	DMRJMGK
DMRJMGK	DN	N-benzyl-2-thiomorpholinopyrimidin-4-amine
DMRJMGK	MI	TT1RS9F
DMRJMGK	MN	Acetylcholinesterase (AChE)
DMRJMGK	MT	DTT
DMRJMGK	MA	Inhibitor
DMRJMGK	RN	Design, synthesis and evaluation of 2,4-disubstituted pyrimidines as cholinesterase inhibitors. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3606-9.
DMRJMGK	RU	https://pubmed.ncbi.nlm.nih.gov/20472431

DMRJMGK	DI	DMRJMGK
DMRJMGK	DN	N-benzyl-2-thiomorpholinopyrimidin-4-amine
DMRJMGK	MI	TTEB0GD
DMRJMGK	MN	Cholinesterase (BCHE)
DMRJMGK	MT	DTT
DMRJMGK	MA	Inhibitor
DMRJMGK	RN	Design, synthesis and evaluation of 2,4-disubstituted pyrimidines as cholinesterase inhibitors. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3606-9.
DMRJMGK	RU	https://pubmed.ncbi.nlm.nih.gov/20472431

DMUD85N	DI	DMUD85N
DMUD85N	DN	N-Benzyl-4-(2,5-dihydroxy-benzylamino)-benzamide
DMUD85N	MI	TTOU65C
DMUD85N	MN	Tyrosine-protein kinase SYK (SYK)
DMUD85N	MT	DTT
DMUD85N	MA	Inhibitor
DMUD85N	RN	Design, synthesis, and biological evaluation of a series of lavendustin A analogues that inhibit EGFR and Syk tyrosine kinases, as well as tubulin ... J Med Chem. 2001 Feb 1;44(3):441-52.
DMUD85N	RU	https://pubmed.ncbi.nlm.nih.gov/11462983

DMCJWQT	DI	DMCJWQT
DMCJWQT	DN	N-Benzyl-4-(2-diphenyl)-1-piperazinehexanamide
DMCJWQT	MI	TTSQIFT
DMCJWQT	MN	5-HT 1A receptor (HTR1A)
DMCJWQT	MT	DTT
DMCJWQT	MA	Inhibitor
DMCJWQT	RN	Structural modifications of N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides: influence on lipophilicity and 5-HT7 receptor act... J Med Chem. 2008 Sep 25;51(18):5813-22.
DMCJWQT	RU	https://pubmed.ncbi.nlm.nih.gov/18800769

DMCJWQT	DI	DMCJWQT
DMCJWQT	DN	N-Benzyl-4-(2-diphenyl)-1-piperazinehexanamide
DMCJWQT	MI	TTEX248
DMCJWQT	MN	Dopamine D2 receptor (D2R)
DMCJWQT	MT	DTT
DMCJWQT	MA	Inhibitor
DMCJWQT	RN	Structural modifications of N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides: influence on lipophilicity and 5-HT7 receptor act... J Med Chem. 2008 Sep 25;51(18):5813-22.
DMCJWQT	RU	https://pubmed.ncbi.nlm.nih.gov/18800769

DMUNL5Q	DI	DMUNL5Q
DMUNL5Q	DN	N-benzyl-4-bromo-3-(morpholinosulfonyl)benzamide
DMUNL5Q	MI	TTMSFAW
DMUNL5Q	MN	Cannabinoid receptor 2 (CB2)
DMUNL5Q	MT	DTT
DMUNL5Q	MA	Inhibitor
DMUNL5Q	RN	CB2 selective sulfamoyl benzamides: optimization of the amide functionality. Bioorg Med Chem Lett. 2009 Jan 15;19(2):309-13.
DMUNL5Q	RU	https://pubmed.ncbi.nlm.nih.gov/19091565

DMUFR62	DI	DMUFR62
DMUFR62	DN	N-benzyl-4-cyclopentylpiperazine-1-carboxamide
DMUFR62	MI	TT9JNIC
DMUFR62	MN	Histamine H3 receptor (H3R)
DMUFR62	MT	DTT
DMUFR62	MA	Inhibitor
DMUFR62	RN	Ureas with histamine H3-antagonist receptor activity--a new scaffold discovered by lead-hopping from cinnamic acid amides. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5303-8.
DMUFR62	RU	https://pubmed.ncbi.nlm.nih.gov/16908150

DM5TPEJ	DI	DM5TPEJ
DM5TPEJ	DN	N-benzyl-4-hydroxy-N-phenylbenzenesulfonamide
DM5TPEJ	MI	TTZAYWL
DM5TPEJ	MN	Estrogen receptor (ESR)
DM5TPEJ	MT	DTT
DM5TPEJ	MA	Inhibitor
DM5TPEJ	RN	Substituted 4-hydroxyphenyl sulfonamides as pathway-selective estrogen receptor ligands. Bioorg Med Chem Lett. 2006 Feb 15;16(4):854-8.
DM5TPEJ	RU	https://pubmed.ncbi.nlm.nih.gov/16300947

DMCIJU0	DI	DMCIJU0
DMCIJU0	DN	N-Benzyl-4-Sulfamoyl-Benzamide
DMCIJU0	MI	TTANPDJ
DMCIJU0	MN	Carbonic anhydrase II (CA-II)
DMCIJU0	MT	DTT
DMCIJU0	MA	Inhibitor
DMCIJU0	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMCIJU0	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM2XLHY	DI	DM2XLHY
DM2XLHY	DN	N-benzyl-5-(4-chlorophenyl)nicotinamide
DM2XLHY	MI	TT90XZ8
DM2XLHY	MN	Voltage-gated sodium channel alpha Nav1.8 (SCN10A)
DM2XLHY	MT	DTT
DM2XLHY	MA	Inhibitor
DM2XLHY	RN	Subtype-selective Na(v)1.8 sodium channel blockers: identification of potent, orally active nicotinamide derivatives. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6812-5.
DM2XLHY	RU	https://pubmed.ncbi.nlm.nih.gov/20855211

DM7NHRV	DI	DM7NHRV
DM7NHRV	DN	N-benzyl-6-(3,3,3-trifluoropropoxy)nicotinamide
DM7NHRV	MI	TT7WVHI
DM7NHRV	MN	Soluble epoxide hydrolase (EPHX2)
DM7NHRV	MT	DTT
DM7NHRV	MA	Inhibitor
DM7NHRV	RN	Design and synthesis of substituted nicotinamides as inhibitors of soluble epoxide hydrolase. Bioorg Med Chem Lett. 2009 Oct 15;19(20):5864-8.
DM7NHRV	RU	https://pubmed.ncbi.nlm.nih.gov/19758802

DMDRE64	DI	DMDRE64
DMDRE64	DN	N-benzyl-9-oxo-9,10-dihydroacridine-3-carboxamide
DMDRE64	MI	TTTB4UP
DMDRE64	MN	Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2)
DMDRE64	MT	DTT
DMDRE64	MA	Inhibitor
DMDRE64	RN	Acridone-based inhibitors of inosine 5'-monophosphate dehydrogenase: discovery and SAR leading to the identification of N-(2-(6-(4-ethylpiperazin-1... J Med Chem. 2007 Jul 26;50(15):3730-42.
DMDRE64	RU	https://pubmed.ncbi.nlm.nih.gov/17585753

DM26R4P	DI	DM26R4P
DM26R4P	DN	N-benzylacetimidamide hydrobromide
DM26R4P	MI	TTF10I9
DM26R4P	MN	Nitric-oxide synthase inducible (NOS2)
DM26R4P	MT	DTT
DM26R4P	MA	Inhibitor
DM26R4P	RN	N-Substituted acetamidines and 2-methylimidazole derivatives as selective inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6495-9.
DM26R4P	RU	https://pubmed.ncbi.nlm.nih.gov/20933416

DMNPS4R	DI	DMNPS4R
DMNPS4R	DN	N-Benzyl-ETAV
DMNPS4R	MI	TT9PB26
DMNPS4R	MN	Presynaptic density protein 95 (DLG4)
DMNPS4R	MT	DTT
DMNPS4R	MA	Inhibitor
DMNPS4R	RN	Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem. 2008 Oct 23;51(20):6450-9.
DMNPS4R	RU	https://pubmed.ncbi.nlm.nih.gov/18811137

DMDZ5XI	DI	DMDZ5XI
DMDZ5XI	DN	N-Benzylmethylphenidate
DMDZ5XI	MI	TTVBI8W
DMDZ5XI	MN	Dopamine transporter (DAT)
DMDZ5XI	MT	DTT
DMDZ5XI	MA	Inhibitor
DMDZ5XI	RN	Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38.
DMDZ5XI	RU	https://pubmed.ncbi.nlm.nih.gov/20846865

DM0NJAL	DI	DM0NJAL
DM0NJAL	DN	N-Benzyl-N-(1H-indol-2-ylmethyl)-N-methylamine
DM0NJAL	MI	TT3WG5C
DM0NJAL	MN	Monoamine oxidase type A (MAO-A)
DM0NJAL	MT	DTT
DM0NJAL	MA	Inhibitor
DM0NJAL	RN	Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40.
DM0NJAL	RU	https://pubmed.ncbi.nlm.nih.gov/18951803

DM0NJAL	DI	DM0NJAL
DM0NJAL	DN	N-Benzyl-N-(1H-indol-2-ylmethyl)-N-methylamine
DM0NJAL	MI	TTGP7BY
DM0NJAL	MN	Monoamine oxidase type B (MAO-B)
DM0NJAL	MT	DTT
DM0NJAL	MA	Inhibitor
DM0NJAL	RN	Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40.
DM0NJAL	RU	https://pubmed.ncbi.nlm.nih.gov/18951803

DMT2GSI	DI	DMT2GSI
DMT2GSI	DN	N-benzyl-N-(phenylsulfonyl)benzamide
DMT2GSI	MI	TTN7BL9
DMT2GSI	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMT2GSI	MT	DTT
DMT2GSI	MA	Inhibitor
DMT2GSI	RN	beta-Keto sulfones as inhibitors of 11beta-hydroxysteroid dehydrogenase type I and the mechanism of action. Bioorg Med Chem. 2007 Jul 1;15(13):4396-405.
DMT2GSI	RU	https://pubmed.ncbi.nlm.nih.gov/17490884

DM6QK7E	DI	DM6QK7E
DM6QK7E	DN	N-benzyl-N-isobutylpiperidin-4-amine
DM6QK7E	MI	TTAWNKZ
DM6QK7E	MN	Norepinephrine transporter (NET)
DM6QK7E	MT	DTT
DM6QK7E	MA	Inhibitor
DM6QK7E	RN	N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake. Bioorg Med Chem Lett. 2006 May 15;16(10):2714-8.
DM6QK7E	RU	https://pubmed.ncbi.nlm.nih.gov/16497500

DM6QK7E	DI	DM6QK7E
DM6QK7E	DN	N-benzyl-N-isobutylpiperidin-4-amine
DM6QK7E	MI	TT3ROYC
DM6QK7E	MN	Serotonin transporter (SERT)
DM6QK7E	MT	DTT
DM6QK7E	MA	Inhibitor
DM6QK7E	RN	N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake. Bioorg Med Chem Lett. 2006 May 15;16(10):2714-8.
DM6QK7E	RU	https://pubmed.ncbi.nlm.nih.gov/16497500

DMVEZH1	DI	DMVEZH1
DMVEZH1	DN	N-benzylnorlitebamine
DMVEZH1	MI	TT1RS9F
DMVEZH1	MN	Acetylcholinesterase (AChE)
DMVEZH1	MT	DTT
DMVEZH1	MA	Inhibitor
DMVEZH1	RN	Litebamine N-homologues: preparation and anti-acetylcholinesterase activity. J Nat Prod. 1998 Jan;61(1):46-50.
DMVEZH1	RU	https://pubmed.ncbi.nlm.nih.gov/9461651

DM7S5Y4	DI	DM7S5Y4
DM7S5Y4	DN	NBI-59159
DM7S5Y4	MI	TTG2A6F
DM7S5Y4	MN	Excitatory amino acid transporter 3 (SLC1A1)
DM7S5Y4	MT	DTT
DM7S5Y4	MA	Inhibitor
DM7S5Y4	RN	Ligands targeting the excitatory amino acid transporters (EAATs). Curr Top Med Chem. 2006;6(17):1897-906.
DM7S5Y4	RU	https://pubmed.ncbi.nlm.nih.gov/17017964

DMURC6X	DI	DMURC6X
DMURC6X	DN	NBI-74330
DMURC6X	MI	TT1UCIJ
DMURC6X	MN	C-X-C chemokine receptor type 3 (CXCR3)
DMURC6X	MT	DTT
DMURC6X	MA	Antagonist
DMURC6X	RN	Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonist. J Pharmacol Exp Ther. 2005 Jun;313(3):1263-71.
DMURC6X	RU	https://pubmed.ncbi.nlm.nih.gov/15761110

DMJF9VA	DI	DMJF9VA
DMJF9VA	DN	N-biphenyl-3-ylmethyl-N'-hydroxy-malonamide
DMJF9VA	MI	TTPHMWB
DMJF9VA	MN	Aminopeptidase N (ANPEP)
DMJF9VA	MT	DTT
DMJF9VA	MA	Inhibitor
DMJF9VA	RN	Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents. J Med Chem. 2007 Mar 22;50(6):1322-34.
DMJF9VA	RU	https://pubmed.ncbi.nlm.nih.gov/17326615

DMWSDZ9	DI	DMWSDZ9
DMWSDZ9	DN	N-bis-(3-phenyl-propyl)9-oxo-fluorene-2,7-diamide
DMWSDZ9	MI	TT39J16
DMWSDZ9	MN	Poly [ADP-ribose] glycohydrolase (PARG)
DMWSDZ9	MT	DTT
DMWSDZ9	MA	Inhibitor
DMWSDZ9	RN	Post-treatment with a novel PARG inhibitor reduces infarct in cerebral ischemia in the rat. Brain Res. 2003 Jul 18;978(1-2):99-103.
DMWSDZ9	RU	https://pubmed.ncbi.nlm.nih.gov/12834903

DMVF420	DI	DMVF420
DMVF420	DN	NBTGR
DMVF420	MI	TTLXAKE
DMVF420	MN	Solute carrier family 29 member 1 (SLC29A1)
DMVF420	MT	DTT
DMVF420	MA	Inhibitor
DMVF420	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1117).
DMVF420	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1117

DMAQT6S	DI	DMAQT6S
DMAQT6S	DN	N-Butyl 2beta-hydroxyolean-12-en-28-oate
DMAQT6S	MI	TTZHY6R
DMAQT6S	MN	Glycogen phosphorylase muscle form (GP)
DMAQT6S	MT	DTT
DMAQT6S	MA	Inhibitor
DMAQT6S	RN	Synthesis of 3-deoxypentacyclic triterpene derivatives as inhibitors of glycogen phosphorylase. J Nat Prod. 2009 Aug;72(8):1414-8.
DMAQT6S	RU	https://pubmed.ncbi.nlm.nih.gov/19642687

DM157LQ	DI	DM157LQ
DM157LQ	DN	N-butyl-2-(1H-indol-3-yl)-2-oxoacetamide
DM157LQ	MI	TT1MPAY
DM157LQ	MN	GABA(A) receptor alpha-1 (GABRA1)
DM157LQ	MT	DTT
DM157LQ	MA	Inhibitor
DM157LQ	RN	Novel N-substituted indol-3-ylglyoxylamides probing the LDi and L1/L2 lipophilic regions of the benzodiazepine receptor site in search for subtype-... J Med Chem. 2007 Apr 5;50(7):1627-34.
DM157LQ	RU	https://pubmed.ncbi.nlm.nih.gov/17335185

DM157LQ	DI	DM157LQ
DM157LQ	DN	N-butyl-2-(1H-indol-3-yl)-2-oxoacetamide
DM157LQ	MI	TTZA1NY
DM157LQ	MN	GABA(A) receptor beta-2 (GABRB2)
DM157LQ	MT	DTT
DM157LQ	MA	Inhibitor
DM157LQ	RN	Novel N-substituted indol-3-ylglyoxylamides probing the LDi and L1/L2 lipophilic regions of the benzodiazepine receptor site in search for subtype-... J Med Chem. 2007 Apr 5;50(7):1627-34.
DM157LQ	RU	https://pubmed.ncbi.nlm.nih.gov/17335185

DM157LQ	DI	DM157LQ
DM157LQ	DN	N-butyl-2-(1H-indol-3-yl)-2-oxoacetamide
DM157LQ	MI	TT06RH5
DM157LQ	MN	GABA(A) receptor gamma-2 (GABRG2)
DM157LQ	MT	DTT
DM157LQ	MA	Inhibitor
DM157LQ	RN	Novel N-substituted indol-3-ylglyoxylamides probing the LDi and L1/L2 lipophilic regions of the benzodiazepine receptor site in search for subtype-... J Med Chem. 2007 Apr 5;50(7):1627-34.
DM157LQ	RU	https://pubmed.ncbi.nlm.nih.gov/17335185

DMH7Z4L	DI	DMH7Z4L
DMH7Z4L	DN	N-butyl-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamide
DMH7Z4L	MI	TT1MPAY
DMH7Z4L	MN	GABA(A) receptor alpha-1 (GABRA1)
DMH7Z4L	MT	DTT
DMH7Z4L	MA	Inhibitor
DMH7Z4L	RN	Novel N-substituted indol-3-ylglyoxylamides probing the LDi and L1/L2 lipophilic regions of the benzodiazepine receptor site in search for subtype-... J Med Chem. 2007 Apr 5;50(7):1627-34.
DMH7Z4L	RU	https://pubmed.ncbi.nlm.nih.gov/17335185

DMH7Z4L	DI	DMH7Z4L
DMH7Z4L	DN	N-butyl-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamide
DMH7Z4L	MI	TTZA1NY
DMH7Z4L	MN	GABA(A) receptor beta-2 (GABRB2)
DMH7Z4L	MT	DTT
DMH7Z4L	MA	Inhibitor
DMH7Z4L	RN	Novel N-substituted indol-3-ylglyoxylamides probing the LDi and L1/L2 lipophilic regions of the benzodiazepine receptor site in search for subtype-... J Med Chem. 2007 Apr 5;50(7):1627-34.
DMH7Z4L	RU	https://pubmed.ncbi.nlm.nih.gov/17335185

DMH7Z4L	DI	DMH7Z4L
DMH7Z4L	DN	N-butyl-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamide
DMH7Z4L	MI	TT06RH5
DMH7Z4L	MN	GABA(A) receptor gamma-2 (GABRG2)
DMH7Z4L	MT	DTT
DMH7Z4L	MA	Inhibitor
DMH7Z4L	RN	Novel N-substituted indol-3-ylglyoxylamides probing the LDi and L1/L2 lipophilic regions of the benzodiazepine receptor site in search for subtype-... J Med Chem. 2007 Apr 5;50(7):1627-34.
DMH7Z4L	RU	https://pubmed.ncbi.nlm.nih.gov/17335185

DMH7Z4L	DI	DMH7Z4L
DMH7Z4L	DN	N-butyl-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamide
DMH7Z4L	MI	TTNJYV2
DMH7Z4L	MN	Gamma-aminobutyric acid receptor (GAR)
DMH7Z4L	MT	DTT
DMH7Z4L	MA	Inhibitor
DMH7Z4L	RN	Novel N-substituted indol-3-ylglyoxylamides probing the LDi and L1/L2 lipophilic regions of the benzodiazepine receptor site in search for subtype-... J Med Chem. 2007 Apr 5;50(7):1627-34.
DMH7Z4L	RU	https://pubmed.ncbi.nlm.nih.gov/17335185

DMH5GW6	DI	DMH5GW6
DMH5GW6	DN	N-butyl-4-hydroxy-N-phenylbenzenesulfonamide
DMH5GW6	MI	TTZAYWL
DMH5GW6	MN	Estrogen receptor (ESR)
DMH5GW6	MT	DTT
DMH5GW6	MA	Inhibitor
DMH5GW6	RN	Substituted 4-hydroxyphenyl sulfonamides as pathway-selective estrogen receptor ligands. Bioorg Med Chem Lett. 2006 Feb 15;16(4):854-8.
DMH5GW6	RU	https://pubmed.ncbi.nlm.nih.gov/16300947

DMMI8X4	DI	DMMI8X4
DMMI8X4	DN	N-butyl-4-methyl-3,4-dihydroquinazolin-2-amine
DMMI8X4	MI	TTRUFDT
DMMI8X4	MN	5-HT 5A receptor (HTR5A)
DMMI8X4	MT	DTT
DMMI8X4	MA	Inhibitor
DMMI8X4	RN	Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: optimising brain penetration. Bioorg Med Chem Lett. 2008 Jan 1;18(1):262-6.
DMMI8X4	RU	https://pubmed.ncbi.nlm.nih.gov/18023344

DMW7BZT	DI	DMW7BZT
DMW7BZT	DN	N-Butylcarbamic Acid Biphenyl-3-yl Ester
DMW7BZT	MI	TTDP1UC
DMW7BZT	MN	Fatty acid amide hydrolase (FAAH)
DMW7BZT	MT	DTT
DMW7BZT	MA	Inhibitor
DMW7BZT	RN	Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl a... J Med Chem. 2008 Jun 26;51(12):3487-98.
DMW7BZT	RU	https://pubmed.ncbi.nlm.nih.gov/18507372

DMY3HEF	DI	DMY3HEF
DMY3HEF	DN	N-Butyl-ETAV
DMY3HEF	MI	TT9PB26
DMY3HEF	MN	Presynaptic density protein 95 (DLG4)
DMY3HEF	MT	DTT
DMY3HEF	MA	Inhibitor
DMY3HEF	RN	Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem. 2008 Oct 23;51(20):6450-9.
DMY3HEF	RU	https://pubmed.ncbi.nlm.nih.gov/18811137

DMB06TA	DI	DMB06TA
DMB06TA	DN	N-butylgalactonojirimycin
DMB06TA	MI	TTPHEX3
DMB06TA	MN	Ceramide glucosyltransferase (UGCG)
DMB06TA	MT	DTT
DMB06TA	MA	Inhibitor
DMB06TA	RN	Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis. J Biol Chem. 2007 Nov 9;282(45):32655-64.
DMB06TA	RU	https://pubmed.ncbi.nlm.nih.gov/17848577

DM8U70E	DI	DM8U70E
DM8U70E	DN	N-Butyl-N'-(4-methyl-benzoyl)-guanidine
DM8U70E	MI	TTZOVE0
DM8U70E	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DM8U70E	MT	DTT
DM8U70E	MA	Inhibitor
DM8U70E	RN	Solution-phase, parallel synthesis and pharmacological evaluation of acylguanidine derivatives as potential sodium channel blockers. Bioorg Med Chem Lett. 2001 Dec 17;11(24):3151-5.
DM8U70E	RU	https://pubmed.ncbi.nlm.nih.gov/11720863

DMKCX5N	DI	DMKCX5N
DMKCX5N	DN	N-Butyl-N'-Hydroxyguanidine
DMKCX5N	MI	TTZUFI5
DMKCX5N	MN	Nitric-oxide synthase brain (NOS1)
DMKCX5N	MT	DTT
DMKCX5N	MA	Inhibitor
DMKCX5N	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMKCX5N	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMNFTO6	DI	DMNFTO6
DMNFTO6	DN	N-butylnorlitebamine
DMNFTO6	MI	TT1RS9F
DMNFTO6	MN	Acetylcholinesterase (AChE)
DMNFTO6	MT	DTT
DMNFTO6	MA	Inhibitor
DMNFTO6	RN	Litebamine N-homologues: preparation and anti-acetylcholinesterase activity. J Nat Prod. 1998 Jan;61(1):46-50.
DMNFTO6	RU	https://pubmed.ncbi.nlm.nih.gov/9461651

DM8STQA	DI	DM8STQA
DM8STQA	DN	N-butylresorcinol
DM8STQA	MI	TTULVH8
DM8STQA	MN	Tyrosinase (TYR)
DM8STQA	MT	DTT
DM8STQA	MA	Inhibitor
DM8STQA	RN	Studies on depigmenting activities of dihydroxyl benzamide derivatives containing adamantane moiety. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1532-3.
DM8STQA	RU	https://pubmed.ncbi.nlm.nih.gov/19181523

DMJCYMW	DI	DMJCYMW
DMJCYMW	DN	NC00075159
DMJCYMW	MI	TT8HGRW
DMJCYMW	MN	Voltage-gated potassium channel Kv7.4 (KCNQ4)
DMJCYMW	MT	DTT
DMJCYMW	MA	Activator
DMJCYMW	RN	Identification of novel KCNQ4 openers by a high-throughput fluorescence-based thallium flux assay. Anal Biochem. 2011 Nov 1;418(1):66-72.
DMJCYMW	RU	https://pubmed.ncbi.nlm.nih.gov/21782781

DM6XGFE	DI	DM6XGFE
DM6XGFE	DN	NC1153
DM6XGFE	MI	TTT7PJU
DM6XGFE	MN	Janus kinase 3 (JAK-3)
DM6XGFE	MT	DTT
DM6XGFE	MA	Inhibitor
DM6XGFE	RN	Immunotherapy for De Novo renal transplantation: what's in the pipeline Drugs. 2006;66(13):1665-84.
DM6XGFE	RU	https://pubmed.ncbi.nlm.nih.gov/16978033

DMJKZUC	DI	DMJKZUC
DMJKZUC	DN	NC-2100
DMJKZUC	MI	TTI12YJ
DMJKZUC	MN	Mitochondrial uncoupling protein 1 (UCP1)
DMJKZUC	MT	DTT
DMJKZUC	MA	Inducer
DMJKZUC	RN	A new thiazolidinedione, NC-2100, which is a weak PPAR-gamma activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice. Diabetes. 2000 May;49(5):759-67.
DMJKZUC	RU	https://pubmed.ncbi.nlm.nih.gov/10905484

DMJKZUC	DI	DMJKZUC
DMJKZUC	DN	NC-2100
DMJKZUC	MI	TTSC2YM
DMJKZUC	MN	Mitochondrial uncoupling protein 2 (UCP2)
DMJKZUC	MT	DTT
DMJKZUC	MA	Inducer
DMJKZUC	RN	A new thiazolidinedione, NC-2100, which is a weak PPAR-gamma activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice. Diabetes. 2000 May;49(5):759-67.
DMJKZUC	RU	https://pubmed.ncbi.nlm.nih.gov/10905484

DM45MGZ	DI	DM45MGZ
DM45MGZ	DN	NC-2500
DM45MGZ	MI	TT7RJY8
DM45MGZ	MN	Xanthine dehydrogenase/oxidase (XDH)
DM45MGZ	MT	DTT
DM45MGZ	MA	Inhibitor
DM45MGZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2646).
DM45MGZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2646

DMJ13TR	DI	DMJ13TR
DMJ13TR	DN	N-Carbamoyl-L-Aspartate
DMJ13TR	MI	TT09NOX
DMJ13TR	MN	Plasmodium Dihydroorotase (Malaria dho)
DMJ13TR	MT	DTT
DMJ13TR	MA	Inhibitor
DMJ13TR	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMJ13TR	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMX80JF	DI	DMX80JF
DMX80JF	DN	N-Carboxymethionine
DMX80JF	MI	TTU6BFZ
DMX80JF	MN	Candida Thymidylate synthase (Candi TMP1)
DMX80JF	MT	DTT
DMX80JF	MA	Inhibitor
DMX80JF	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMX80JF	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DME9U7Y	DI	DME9U7Y
DME9U7Y	DN	N-Carboxymethyl-N-cyclopentyl-phthalamic acid
DME9U7Y	MI	TTL69WB
DME9U7Y	MN	Angiotensin-converting enzyme (ACE)
DME9U7Y	MT	DTT
DME9U7Y	MA	Inhibitor
DME9U7Y	RN	Angiotensin converting enzyme inhibitors. (Mercaptoaroyl)amino acids. J Med Chem. 1985 Mar;28(3):328-32.
DME9U7Y	RU	https://pubmed.ncbi.nlm.nih.gov/2983075

DM5KNCX	DI	DM5KNCX
DM5KNCX	DN	N-cetylgallate
DM5KNCX	MI	TTE14XG
DM5KNCX	MN	Squalene monooxygenase (SQLE)
DM5KNCX	MT	DTT
DM5KNCX	MA	Inhibitor
DM5KNCX	RN	Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4.
DM5KNCX	RU	https://pubmed.ncbi.nlm.nih.gov/11520216

DM0JCN2	DI	DM0JCN2
DM0JCN2	DN	NCFP
DM0JCN2	MI	TTHS256
DM0JCN2	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM0JCN2	MT	DTT
DM0JCN2	MA	Modulator (allosteric modulator)
DM0JCN2	RN	A novel metabotropic glutamate receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias to mGlu5 signaling. Mol Pharmacol. 2013 Apr;83(4):835-47.
DM0JCN2	RU	https://pubmed.ncbi.nlm.nih.gov/23348500

DMMRWJG	DI	DMMRWJG
DMMRWJG	DN	NCG21
DMMRWJG	MI	TT08JVB
DMMRWJG	MN	G-protein coupled receptor 120 (GPR120)
DMMRWJG	MT	DTT
DMMRWJG	MA	Agonist
DMMRWJG	RN	Identification of G protein-coupled receptor 120-selective agonists derived from PPARgamma agonists. J Med Chem. 2008 Dec 11;51(23):7640-4.
DMMRWJG	RU	https://pubmed.ncbi.nlm.nih.gov/19007110

DMY8RT9	DI	DMY8RT9
DMY8RT9	DN	NCGC00167772-01
DMY8RT9	MI	TTTN5QW
DMY8RT9	MN	Serine/threonine-protein kinase pim-1 (PIM1)
DMY8RT9	MT	DTT
DMY8RT9	MA	Inhibitor
DMY8RT9	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2158).
DMY8RT9	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2158

DM6VEON	DI	DM6VEON
DM6VEON	DN	N-chloromethyl-brucine
DM6VEON	MI	TTOXS3C
DM6VEON	MN	Muscarinic acetylcholine receptor (CHRM)
DM6VEON	MT	DTT
DM6VEON	MA	Modulator (allosteric modulator)
DM6VEON	RN	Subtype-selective positive cooperative interactions between brucine analogues and acetylcholine at muscarinic receptors: radioligand binding studies. Mol Pharmacol. 1998 Mar;53(3):573-89.
DM6VEON	RU	https://pubmed.ncbi.nlm.nih.gov/9495826

DM6VEON	DI	DM6VEON
DM6VEON	DN	N-chloromethyl-brucine
DM6VEON	MI	TTQ13Z5
DM6VEON	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DM6VEON	MT	DTT
DM6VEON	MA	Modulator (allosteric modulator)
DM6VEON	RN	Subtype-selective positive cooperative interactions between brucine analogues and acetylcholine at muscarinic receptors: radioligand binding studies. Mol Pharmacol. 1998 Mar;53(3):573-89.
DM6VEON	RU	https://pubmed.ncbi.nlm.nih.gov/9495826

DMTCBLS	DI	DMTCBLS
DMTCBLS	DN	NCI-159878
DMTCBLS	MI	TTLUQ8E
DMTCBLS	MN	Hormone sensitive lipase (LIPE)
DMTCBLS	MT	DTT
DMTCBLS	MA	Inhibitor
DMTCBLS	RN	Combining ligand-based pharmacophore modeling, quantitative structure-activity relationship analysis and in silico screening for the discovery of n... J Med Chem. 2008 Oct 23;51(20):6478-94.
DMTCBLS	RU	https://pubmed.ncbi.nlm.nih.gov/18808096

DM9C7GP	DI	DM9C7GP
DM9C7GP	DN	NCI-58425
DM9C7GP	MI	TTLUQ8E
DM9C7GP	MN	Hormone sensitive lipase (LIPE)
DM9C7GP	MT	DTT
DM9C7GP	MA	Inhibitor
DM9C7GP	RN	Combining ligand-based pharmacophore modeling, quantitative structure-activity relationship analysis and in silico screening for the discovery of n... J Med Chem. 2008 Oct 23;51(20):6478-94.
DM9C7GP	RU	https://pubmed.ncbi.nlm.nih.gov/18808096

DMH1BVG	DI	DMH1BVG
DMH1BVG	DN	NCL-1
DMH1BVG	MI	TTNR0UQ
DMH1BVG	MN	Lysine-specific histone demethylase 1 (LSD)
DMH1BVG	MT	DTT
DMH1BVG	MA	Inhibitor
DMH1BVG	RN	Synthesis and biological activity of optically active NCL-1, a lysine-specific demethylase 1 selective inhibitor. Bioorg Med Chem. 2011 Jun 15;19(12):3702-8.
DMH1BVG	RU	https://pubmed.ncbi.nlm.nih.gov/21227703

DM1K64F	DI	DM1K64F
DM1K64F	DN	N-CPM[D-Pro-10]Dyn A-(1-11)
DM1K64F	MI	TTQW87Y
DM1K64F	MN	Opioid receptor kappa (OPRK1)
DM1K64F	MT	DTT
DM1K64F	MA	Inhibitor
DM1K64F	RN	Synthesis and opioid activity of [D-Pro10]dynorphin A-(1-11) analogues with N-terminal alkyl substitution. J Med Chem. 1997 Aug 15;40(17):2733-9.
DM1K64F	RU	https://pubmed.ncbi.nlm.nih.gov/9276018

DM09UFT	DI	DM09UFT
DM09UFT	DN	NCT-400
DM09UFT	MI	TTKWM86
DM09UFT	MN	Opioid receptor mu (MOP)
DM09UFT	MT	DTT
DM09UFT	MA	Modulator
DM09UFT	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
DM09UFT	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319

DM1FOSP	DI	DM1FOSP
DM1FOSP	DN	NCX-1047
DM1FOSP	MI	TTPNQAC
DM1FOSP	MN	Estrogen-related receptor-alpha (ESRRA)
DM1FOSP	MT	DTT
DM1FOSP	MA	Modulator
DM1FOSP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 622).
DM1FOSP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=622

DMUHXRA	DI	DMUHXRA
DMUHXRA	DN	NCX-1067
DMUHXRA	MI	TTPADOQ
DMUHXRA	MN	HMG-CoA reductase (HMGCR)
DMUHXRA	MT	DTT
DMUHXRA	MA	Modulator
DMUHXRA	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 639).
DMUHXRA	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=639

DMYBWXR	DI	DMYBWXR
DMYBWXR	DN	NCX-125
DMYBWXR	MI	TTT2ZAR
DMYBWXR	MN	Prostaglandin F2-alpha receptor (PTGFR)
DMYBWXR	MT	DTT
DMYBWXR	MA	Modulator
DMYBWXR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 344).
DMYBWXR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=344

DM5T23S	DI	DM5T23S
DM5T23S	DN	N-Cyclobutyl-1'H-phenothiazine-1'-carboxamide
DM5T23S	MI	TTEB0GD
DM5T23S	MN	Cholinesterase (BCHE)
DM5T23S	MT	DTT
DM5T23S	MA	Inhibitor
DM5T23S	RN	Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorg Med Chem. 2010 Mar 15;18(6):2232-2244.
DM5T23S	RU	https://pubmed.ncbi.nlm.nih.gov/20181484

DM1GTVW	DI	DM1GTVW
DM1GTVW	DN	N-cyclobutyl-N-(piperidin-4-yl)-2-naphthamide
DM1GTVW	MI	TT3ROYC
DM1GTVW	MN	Serotonin transporter (SERT)
DM1GTVW	MT	DTT
DM1GTVW	MA	Inhibitor
DM1GTVW	RN	Bioorg Med Chem Lett. 2009 Oct 15;19(20):5893-7. Epub 2009 Aug 21.Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.
DM1GTVW	RU	https://pubmed.ncbi.nlm.nih.gov/19740658

DMMW8J1	DI	DMMW8J1
DMMW8J1	DN	N-Cyclohexyl-1'H-phenothiazine-1'-carboxamide
DMMW8J1	MI	TTEB0GD
DMMW8J1	MN	Cholinesterase (BCHE)
DMMW8J1	MT	DTT
DMMW8J1	MA	Inhibitor
DMMW8J1	RN	Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorg Med Chem. 2010 Mar 15;18(6):2232-2244.
DMMW8J1	RU	https://pubmed.ncbi.nlm.nih.gov/20181484

DM8HS0B	DI	DM8HS0B
DM8HS0B	DN	N-Cyclohexyl-2-(4-methoxy-phenyl)-acetamide
DM8HS0B	MI	TT7WVHI
DM8HS0B	MN	Soluble epoxide hydrolase (EPHX2)
DM8HS0B	MT	DTT
DM8HS0B	MA	Inhibitor
DM8HS0B	RN	Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem. 2005 May 19;48(10):3621-9.
DM8HS0B	RU	https://pubmed.ncbi.nlm.nih.gov/15887969

DMRA548	DI	DMRA548
DMRA548	DN	N-cyclohexyl-2-oxo-2H-chromene-3-carboxamide
DMRA548	MI	TTGP7BY
DMRA548	MN	Monoamine oxidase type B (MAO-B)
DMRA548	MT	DTT
DMRA548	MA	Inhibitor
DMRA548	RN	Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins. J Med Chem. 2009 Apr 9;52(7):1935-42.
DMRA548	RU	https://pubmed.ncbi.nlm.nih.gov/19267475

DM15MQT	DI	DM15MQT
DM15MQT	DN	N-Cyclohexyl-2-phenyl-acetamide
DM15MQT	MI	TT7WVHI
DM15MQT	MN	Soluble epoxide hydrolase (EPHX2)
DM15MQT	MT	DTT
DM15MQT	MA	Inhibitor
DM15MQT	RN	Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem. 2005 May 19;48(10):3621-9.
DM15MQT	RU	https://pubmed.ncbi.nlm.nih.gov/15887969

DMCDBM5	DI	DMCDBM5
DMCDBM5	DN	N-cyclohexyl-4-hydroxy-N-phenylbenzenesulfonamide
DMCDBM5	MI	TTZAYWL
DMCDBM5	MN	Estrogen receptor (ESR)
DMCDBM5	MT	DTT
DMCDBM5	MA	Inhibitor
DMCDBM5	RN	Substituted 4-hydroxyphenyl sulfonamides as pathway-selective estrogen receptor ligands. Bioorg Med Chem Lett. 2006 Feb 15;16(4):854-8.
DMCDBM5	RU	https://pubmed.ncbi.nlm.nih.gov/16300947

DM2COR5	DI	DM2COR5
DM2COR5	DN	N-Cyclohexyl-4-phenyl-butyramide
DM2COR5	MI	TT7WVHI
DM2COR5	MN	Soluble epoxide hydrolase (EPHX2)
DM2COR5	MT	DTT
DM2COR5	MA	Inhibitor
DM2COR5	RN	Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem. 2005 May 19;48(10):3621-9.
DM2COR5	RU	https://pubmed.ncbi.nlm.nih.gov/15887969

DMCH5M1	DI	DMCH5M1
DMCH5M1	DN	N-Cyclohexylethyl-ETAV
DMCH5M1	MI	TT9PB26
DMCH5M1	MN	Presynaptic density protein 95 (DLG4)
DMCH5M1	MT	DTT
DMCH5M1	MA	Inhibitor
DMCH5M1	RN	Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem. 2008 Oct 23;51(20):6450-9.
DMCH5M1	RU	https://pubmed.ncbi.nlm.nih.gov/18811137

DMIC8Z6	DI	DMIC8Z6
DMIC8Z6	DN	N-Cyclohexylmethyl-ETAV
DMIC8Z6	MI	TT9PB26
DMIC8Z6	MN	Presynaptic density protein 95 (DLG4)
DMIC8Z6	MT	DTT
DMIC8Z6	MA	Inhibitor
DMIC8Z6	RN	Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem. 2008 Oct 23;51(20):6450-9.
DMIC8Z6	RU	https://pubmed.ncbi.nlm.nih.gov/18811137

DMPSYRW	DI	DMPSYRW
DMPSYRW	DN	N-Cyclohexyl-N'-(4-Iodophenyl)Urea
DMPSYRW	MI	TT7WVHI
DMPSYRW	MN	Soluble epoxide hydrolase (EPHX2)
DMPSYRW	MT	DTT
DMPSYRW	MA	Inhibitor
DMPSYRW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMPSYRW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMYF243	DI	DMYF243
DMYF243	DN	N-Cyclohexyl-N'-(Propyl)Phenyl Urea
DMYF243	MI	TT7WVHI
DMYF243	MN	Soluble epoxide hydrolase (EPHX2)
DMYF243	MT	DTT
DMYF243	MA	Inhibitor
DMYF243	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMYF243	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM17G82	DI	DM17G82
DM17G82	DN	N-Cyclohexyl-N'-Decylurea
DM17G82	MI	TT7WVHI
DM17G82	MN	Soluble epoxide hydrolase (EPHX2)
DM17G82	MT	DTT
DM17G82	MA	Inhibitor
DM17G82	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM17G82	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMJ0T3W	DI	DMJ0T3W
DMJ0T3W	DN	N-cyclohexylquinazolin-4-amine
DMJ0T3W	MI	TTVBPDM
DMJ0T3W	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMJ0T3W	MT	DTT
DMJ0T3W	MA	Inhibitor
DMJ0T3W	RN	In vitro and in vivo SAR of pyrido[3,4-d]pyramid-4-ylamine based mGluR1 antagonists. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2190-4.
DMJ0T3W	RU	https://pubmed.ncbi.nlm.nih.gov/19289283

DMJY2PA	DI	DMJY2PA
DMJY2PA	DN	N-cyclohexylquinolin-4-amine
DMJY2PA	MI	TTVBPDM
DMJY2PA	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMJY2PA	MT	DTT
DMJY2PA	MA	Inhibitor
DMJY2PA	RN	In vitro and in vivo SAR of pyrido[3,4-d]pyramid-4-ylamine based mGluR1 antagonists. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2190-4.
DMJY2PA	RU	https://pubmed.ncbi.nlm.nih.gov/19289283

DM0KDSA	DI	DM0KDSA
DM0KDSA	DN	N-Cyclopentyl-1'H-phenothiazine-1'-carboxamide
DM0KDSA	MI	TTEB0GD
DM0KDSA	MN	Cholinesterase (BCHE)
DM0KDSA	MT	DTT
DM0KDSA	MA	Inhibitor
DM0KDSA	RN	Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorg Med Chem. 2010 Mar 15;18(6):2232-2244.
DM0KDSA	RU	https://pubmed.ncbi.nlm.nih.gov/20181484

DMDPKCM	DI	DMDPKCM
DMDPKCM	DN	N-cyclopentyl-6-(2-phenylethynyl)nicotinamide
DMDPKCM	MI	TTHS256
DMDPKCM	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMDPKCM	MT	DTT
DMDPKCM	MA	Inhibitor
DMDPKCM	RN	Discovery of a potent and brain penetrant mGluR5 positive allosteric modulator. Bioorg Med Chem Lett. 2009 Jun 15;19(12):3275-8.
DMDPKCM	RU	https://pubmed.ncbi.nlm.nih.gov/19443216

DMMODRE	DI	DMMODRE
DMMODRE	DN	ND-2110
DMMODRE	MI	TTKFVXR
DMMODRE	MN	Renal carcinoma antigen NY-REN-64 (IRAK-4)
DMMODRE	MT	DTT
DMMODRE	MA	Inhibitor
DMMODRE	RN	Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders. J Med Chem. 2015 Jan 8;58(1):96-110.
DMMODRE	RU	https://pubmed.ncbi.nlm.nih.gov/25479567

DMH7GLE	DI	DMH7GLE
DMH7GLE	DN	ND-2158
DMH7GLE	MI	TTKFVXR
DMH7GLE	MN	Renal carcinoma antigen NY-REN-64 (IRAK-4)
DMH7GLE	MT	DTT
DMH7GLE	MA	Inhibitor
DMH7GLE	RN	Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders. J Med Chem. 2015 Jan 8;58(1):96-110.
DMH7GLE	RU	https://pubmed.ncbi.nlm.nih.gov/25479567

DMT0NQS	DI	DMT0NQS
DMT0NQS	DN	ND-401
DMT0NQS	MI	TTBID49
DMT0NQS	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMT0NQS	MT	DTT
DMT0NQS	MA	Inhibitor
DMT0NQS	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 71).
DMT0NQS	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=71

DM7NJI2	DI	DM7NJI2
DM7NJI2	DN	NDC-1022
DM7NJI2	MI	TTOM3J0
DM7NJI2	MN	Estrogen receptor beta (ESR2)
DM7NJI2	MT	DTT
DM7NJI2	MA	Agonist
DM7NJI2	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 621).
DM7NJI2	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=621

DMBFC1U	DI	DMBFC1U
DMBFC1U	DN	N-desalkylquetiapine
DMBFC1U	MI	TTAWNKZ
DMBFC1U	MN	Norepinephrine transporter (NET)
DMBFC1U	MT	DTT
DMBFC1U	MA	Inhibitor
DMBFC1U	RN	N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant ... Neuropsychopharmacology. 2008 Sep;33(10):2303-12.
DMBFC1U	RU	https://pubmed.ncbi.nlm.nih.gov/18059438

DMV5RZM	DI	DMV5RZM
DMV5RZM	DN	N-dodecylgallate
DMV5RZM	MI	TTE14XG
DMV5RZM	MN	Squalene monooxygenase (SQLE)
DMV5RZM	MT	DTT
DMV5RZM	MA	Inhibitor
DMV5RZM	RN	Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4.
DMV5RZM	RU	https://pubmed.ncbi.nlm.nih.gov/11520216

DMTMHW2	DI	DMTMHW2
DMTMHW2	DN	NDP-alpha-MSH
DMTMHW2	MI	TTD0CIQ
DMTMHW2	MN	Melanocortin receptor 4 (MC4R)
DMTMHW2	MT	DTT
DMTMHW2	MA	Inhibitor
DMTMHW2	RN	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
DMTMHW2	RU	https://pubmed.ncbi.nlm.nih.gov/18983139

DMRV16G	DI	DMRV16G
DMRV16G	DN	NDP-SYSMEHFRWGKPVG
DMRV16G	MI	TTEOSZT
DMRV16G	MN	Melanocortin receptor (MCR)
DMRV16G	MT	DTT
DMRV16G	MA	Inhibitor
DMRV16G	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMRV16G	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMRV16G	DI	DMRV16G
DMRV16G	DN	NDP-SYSMEHFRWGKPVG
DMRV16G	MI	TT0MV2T
DMRV16G	MN	Melanocortin receptor 1 (MC1R)
DMRV16G	MT	DTT
DMRV16G	MA	Inhibitor
DMRV16G	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMRV16G	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMRV16G	DI	DMRV16G
DMRV16G	DN	NDP-SYSMEHFRWGKPVG
DMRV16G	MI	TTNI91K
DMRV16G	MN	Melanocortin receptor 3 (MC3R)
DMRV16G	MT	DTT
DMRV16G	MA	Inhibitor
DMRV16G	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMRV16G	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMRV16G	DI	DMRV16G
DMRV16G	DN	NDP-SYSMEHFRWGKPVG
DMRV16G	MI	TTD0CIQ
DMRV16G	MN	Melanocortin receptor 4 (MC4R)
DMRV16G	MT	DTT
DMRV16G	MA	Inhibitor
DMRV16G	RN	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
DMRV16G	RU	https://pubmed.ncbi.nlm.nih.gov/15857110

DMFKX7Z	DI	DMFKX7Z
DMFKX7Z	DN	NDT9520492
DMFKX7Z	MI	TTHXFA1
DMFKX7Z	MN	C5a anaphylatoxin chemotactic receptor (C5AR1)
DMFKX7Z	MT	DTT
DMFKX7Z	MA	Antagonist
DMFKX7Z	RN	Molecular characterization of the gerbil C5a receptor and identification of a transmembrane domain V amino acid that is crucial for small molecule ... J Biol Chem. 2005 Dec 9;280(49):40617-23.
DMFKX7Z	RU	https://pubmed.ncbi.nlm.nih.gov/16230349

DMGSNU4	DI	DMGSNU4
DMGSNU4	DN	NE-10575
DMGSNU4	MI	TTIKWV4
DMGSNU4	MN	Geranyltranstransferase (FDPS)
DMGSNU4	MT	DTT
DMGSNU4	MA	Inhibitor
DMGSNU4	RN	Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of hu... J Med Chem. 2008 Apr 10;51(7):2187-95.
DMGSNU4	RU	https://pubmed.ncbi.nlm.nih.gov/18327899

DMVESO2	DI	DMVESO2
DMVESO2	DN	NE10790
DMVESO2	MI	TTIKWV4
DMVESO2	MN	Geranyltranstransferase (FDPS)
DMVESO2	MT	DTT
DMVESO2	MA	Inhibitor
DMVESO2	RN	Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of hu... J Med Chem. 2008 Apr 10;51(7):2187-95.
DMVESO2	RU	https://pubmed.ncbi.nlm.nih.gov/18327899

DMR92HV	DI	DMR92HV
DMR92HV	DN	NE11808
DMR92HV	MI	TTIKWV4
DMR92HV	MN	Geranyltranstransferase (FDPS)
DMR92HV	MT	DTT
DMR92HV	MA	Inhibitor
DMR92HV	RN	Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of hu... J Med Chem. 2008 Apr 10;51(7):2187-95.
DMR92HV	RU	https://pubmed.ncbi.nlm.nih.gov/18327899

DMILP0F	DI	DMILP0F
DMILP0F	DN	NE-2
DMILP0F	MI	TTKWM86
DMILP0F	MN	Opioid receptor mu (MOP)
DMILP0F	MT	DTT
DMILP0F	MA	Agonist
DMILP0F	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
DMILP0F	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319

DM58O3I	DI	DM58O3I
DM58O3I	DN	NE21650
DM58O3I	MI	TTIKWV4
DM58O3I	MN	Geranyltranstransferase (FDPS)
DM58O3I	MT	DTT
DM58O3I	MA	Inhibitor
DM58O3I	RN	Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase. Biochem Biophys Res Commun. 2002 Jan 18;290(2):869-73.
DM58O3I	RU	https://pubmed.ncbi.nlm.nih.gov/11785983

DMVSRYH	DI	DMVSRYH
DMVSRYH	DN	NE-28345
DMVSRYH	MI	TTMI6F5
DMVSRYH	MN	Transient receptor potential cation channel V1 (TRPV1)
DMVSRYH	MT	DTT
DMVSRYH	MA	Modulator
DMVSRYH	RN	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
DMVSRYH	RU	https://www.ncbi.nlm.nih.gov/pubmed/27899562

DM28ZPT	DI	DM28ZPT
DM28ZPT	DN	NE58018
DM28ZPT	MI	TTIKWV4
DM28ZPT	MN	Geranyltranstransferase (FDPS)
DM28ZPT	MT	DTT
DM28ZPT	MA	Inhibitor
DM28ZPT	RN	Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of hu... J Med Chem. 2008 Apr 10;51(7):2187-95.
DM28ZPT	RU	https://pubmed.ncbi.nlm.nih.gov/18327899

DMU4I8R	DI	DMU4I8R
DMU4I8R	DN	NE58027
DMU4I8R	MI	TTIKWV4
DMU4I8R	MN	Geranyltranstransferase (FDPS)
DMU4I8R	MT	DTT
DMU4I8R	MA	Inhibitor
DMU4I8R	RN	Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of hu... J Med Chem. 2008 Apr 10;51(7):2187-95.
DMU4I8R	RU	https://pubmed.ncbi.nlm.nih.gov/18327899

DMS7UNR	DI	DMS7UNR
DMS7UNR	DN	NE58043
DMS7UNR	MI	TTIKWV4
DMS7UNR	MN	Geranyltranstransferase (FDPS)
DMS7UNR	MT	DTT
DMS7UNR	MA	Inhibitor
DMS7UNR	RN	Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of hu... J Med Chem. 2008 Apr 10;51(7):2187-95.
DMS7UNR	RU	https://pubmed.ncbi.nlm.nih.gov/18327899

DMHIM6N	DI	DMHIM6N
DMHIM6N	DN	NE58062
DMHIM6N	MI	TTIKWV4
DMHIM6N	MN	Geranyltranstransferase (FDPS)
DMHIM6N	MT	DTT
DMHIM6N	MA	Inhibitor
DMHIM6N	RN	Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of hu... J Med Chem. 2008 Apr 10;51(7):2187-95.
DMHIM6N	RU	https://pubmed.ncbi.nlm.nih.gov/18327899

DMDWESP	DI	DMDWESP
DMDWESP	DN	NE97220
DMDWESP	MI	TTIKWV4
DMDWESP	MN	Geranyltranstransferase (FDPS)
DMDWESP	MT	DTT
DMDWESP	MA	Inhibitor
DMDWESP	RN	Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of hu... J Med Chem. 2008 Apr 10;51(7):2187-95.
DMDWESP	RU	https://pubmed.ncbi.nlm.nih.gov/18327899

DMNCU6H	DI	DMNCU6H
DMNCU6H	DN	Neamine
DMNCU6H	MI	TT38DW5
DMNCU6H	MN	Bacterial 16S ribosomal RNA (Bact 16S rRNA)
DMNCU6H	MT	DTT
DMNCU6H	MA	Inhibitor
DMNCU6H	RN	RNA as a target for small molecules. Curr Opin Chem Biol. 2000 Dec;4(6):678-86.
DMNCU6H	RU	https://pubmed.ncbi.nlm.nih.gov/11102874

DMO0Q1F	DI	DMO0Q1F
DMO0Q1F	DN	Nectamazin C
DMO0Q1F	MI	TTVKILB
DMO0Q1F	MN	Prostaglandin G/H synthase 2 (COX-2)
DMO0Q1F	MT	DTT
DMO0Q1F	MA	Inhibitor
DMO0Q1F	RN	COX, LOX and platelet aggregation inhibitory properties of Lauraceae neolignans. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6922-5.
DMO0Q1F	RU	https://pubmed.ncbi.nlm.nih.gov/19880317

DM5EWIK	DI	DM5EWIK
DM5EWIK	DN	NEODYSIDENIN
DM5EWIK	MI	TT12ABZ
DM5EWIK	MN	Arachidonate 12-lipoxygenase (12-LOX)
DM5EWIK	MT	DTT
DM5EWIK	MA	Inhibitor
DM5EWIK	RN	Discovery of platelet-type 12-human lipoxygenase selective inhibitors by high-throughput screening of structurally diverse libraries. Bioorg Med Chem. 2007 Nov 15;15(22):6900-8.
DM5EWIK	RU	https://pubmed.ncbi.nlm.nih.gov/17826100

DM6D0JC	DI	DM6D0JC
DM6D0JC	DN	Neo-kauluamine
DM6D0JC	MI	TTRSMW9
DM6D0JC	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DM6D0JC	MT	DTT
DM6D0JC	MA	Inhibitor
DM6D0JC	RN	Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical p... J Nat Prod. 2006 Jul;69(7):1034-40.
DM6D0JC	RU	https://pubmed.ncbi.nlm.nih.gov/16872140

DMKFPA9	DI	DMKFPA9
DMKFPA9	DN	NEOLIGNAN 9-NOR-7,8-DEHYDRO-ISOLICARIN B
DMKFPA9	MI	TTVKILB
DMKFPA9	MN	Prostaglandin G/H synthase 2 (COX-2)
DMKFPA9	MT	DTT
DMKFPA9	MA	Inhibitor
DMKFPA9	RN	COX, LOX and platelet aggregation inhibitory properties of Lauraceae neolignans. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6922-5.
DMKFPA9	RU	https://pubmed.ncbi.nlm.nih.gov/19880317

DM5GMOJ	DI	DM5GMOJ
DM5GMOJ	DN	NEORAUTENOL
DM5GMOJ	MI	TT50QJ3
DM5GMOJ	MN	Influenza Neuraminidase (Influ NA)
DM5GMOJ	MT	DTT
DM5GMOJ	MA	Inhibitor
DM5GMOJ	RN	Prenylated pterocarpans as bacterial neuraminidase inhibitors. Bioorg Med Chem. 2010 May 1;18(9):3335-44.
DM5GMOJ	RU	https://pubmed.ncbi.nlm.nih.gov/20363636

DM5GMOJ	DI	DM5GMOJ
DM5GMOJ	DN	NEORAUTENOL
DM5GMOJ	MI	TTELIN2
DM5GMOJ	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DM5GMOJ	MT	DTT
DM5GMOJ	MA	Inhibitor
DM5GMOJ	RN	Cytotoxic and PTP1B inhibitory activities from Erythrina abyssinica. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6745-9.
DM5GMOJ	RU	https://pubmed.ncbi.nlm.nih.gov/19836230

DMXULGK	DI	DMXULGK
DMXULGK	DN	Neplanocin A
DMXULGK	MI	TTE2KUJ
DMXULGK	MN	Adenosylhomocysteinase (AHCY)
DMXULGK	MT	DTT
DMXULGK	MA	Inhibitor
DMXULGK	RN	Molecular approaches for the treatment of hemorrhagic fever virus infections. Antiviral Res. 1993 Sep;22(1):45-75.
DMXULGK	RU	https://pubmed.ncbi.nlm.nih.gov/8250543

DMXULGK	DI	DMXULGK
DMXULGK	DN	Neplanocin A
DMXULGK	MI	TTQWUPT
DMXULGK	MN	Thyroid hormone receptor (THR)
DMXULGK	MT	DTT
DMXULGK	MA	Antagonist
DMXULGK	RN	Design of thyroid hormone receptor antagonists from first principles. J Steroid Biochem Mol Biol. 2002 Dec;83(1-5):59-73.
DMXULGK	RU	https://pubmed.ncbi.nlm.nih.gov/12650702

DM3AW8X	DI	DM3AW8X
DM3AW8X	DN	Nerve growth factor conjugated RAP peptide
DM3AW8X	MI	TTEDJN4
DM3AW8X	MN	Low-affinity nerve growth factor receptor (NGFR)
DM3AW8X	MT	DTT
DM3AW8X	MA	Modulator
DM3AW8X	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1888).
DM3AW8X	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1888

DM1W2GZ	DI	DM1W2GZ
DM1W2GZ	DN	N-ethyl estradiol-16-methyl carboxamide
DM1W2GZ	MI	TTIWB6L
DM1W2GZ	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DM1W2GZ	MT	DTT
DM1W2GZ	MA	Inhibitor
DM1W2GZ	RN	Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45.
DM1W2GZ	RU	https://pubmed.ncbi.nlm.nih.gov/16480268

DMM9526	DI	DMM9526
DMM9526	DN	N-ethyl estrone-16-methyl carboxamide
DMM9526	MI	TTIWB6L
DMM9526	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMM9526	MT	DTT
DMM9526	MA	Inhibitor
DMM9526	RN	Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45.
DMM9526	RU	https://pubmed.ncbi.nlm.nih.gov/16480268

DMQ3184	DI	DMQ3184
DMQ3184	DN	N-ethyl-2,2,2-triphenylacetamide
DMQ3184	MI	TTMNI76
DMQ3184	MN	Calcium-activated potassium channel (KCN)
DMQ3184	MT	DTT
DMQ3184	MA	Inhibitor
DMQ3184	RN	Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82.
DMQ3184	RU	https://pubmed.ncbi.nlm.nih.gov/18232633

DMWLI4U	DI	DMWLI4U
DMWLI4U	DN	N-Ethyl-2-methylnorapomorphine hydrochloride
DMWLI4U	MI	TTEX248
DMWLI4U	MN	Dopamine D2 receptor (D2R)
DMWLI4U	MT	DTT
DMWLI4U	MA	Inhibitor
DMWLI4U	RN	N-Substituted-2-alkyl- and 2-arylnorapomorphines: novel, highly active D2 agonists. Bioorg Med Chem. 2009 Jul 1;17(13):4756-62.
DMWLI4U	RU	https://pubmed.ncbi.nlm.nih.gov/19454369

DM6HMBW	DI	DM6HMBW
DM6HMBW	DN	N-Ethyl-2-phenylnorapomorphine hydrochloride
DM6HMBW	MI	TTEX248
DM6HMBW	MN	Dopamine D2 receptor (D2R)
DM6HMBW	MT	DTT
DM6HMBW	MA	Inhibitor
DM6HMBW	RN	N-Substituted-2-alkyl- and 2-arylnorapomorphines: novel, highly active D2 agonists. Bioorg Med Chem. 2009 Jul 1;17(13):4756-62.
DM6HMBW	RU	https://pubmed.ncbi.nlm.nih.gov/19454369

DMHY35A	DI	DMHY35A
DMHY35A	DN	N-ethyl-4-hydroxy-N-phenylbenzenesulfonamide
DMHY35A	MI	TTZAYWL
DMHY35A	MN	Estrogen receptor (ESR)
DMHY35A	MT	DTT
DMHY35A	MA	Inhibitor
DMHY35A	RN	Substituted 4-hydroxyphenyl sulfonamides as pathway-selective estrogen receptor ligands. Bioorg Med Chem Lett. 2006 Feb 15;16(4):854-8.
DMHY35A	RU	https://pubmed.ncbi.nlm.nih.gov/16300947

DM873WR	DI	DM873WR
DM873WR	DN	N-ethyl-5,6-dip-tolylpyrazine-2-carboxamide
DM873WR	MI	TT6OEDT
DM873WR	MN	Cannabinoid receptor 1 (CB1)
DM873WR	MT	DTT
DM873WR	MA	Inhibitor
DM873WR	RN	Discovery of pyrazine carboxamide CB1 antagonists: the introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy... Bioorg Med Chem Lett. 2007 Jul 15;17(14):3978-82.
DM873WR	RU	https://pubmed.ncbi.nlm.nih.gov/17513109

DMPTNI8	DI	DMPTNI8
DMPTNI8	DN	N-Ethyl-ETAV
DMPTNI8	MI	TT9PB26
DMPTNI8	MN	Presynaptic density protein 95 (DLG4)
DMPTNI8	MT	DTT
DMPTNI8	MA	Inhibitor
DMPTNI8	RN	Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem. 2008 Oct 23;51(20):6450-9.
DMPTNI8	RU	https://pubmed.ncbi.nlm.nih.gov/18811137

DMYI87T	DI	DMYI87T
DMYI87T	DN	N-ethylhistamine
DMYI87T	MI	TTXJ178
DMYI87T	MN	Histamine H4 receptor (H4R)
DMYI87T	MT	DTT
DMYI87T	MA	Agonist
DMYI87T	RN	Compared pharmacology of human histamine H3 and H4 receptors: structure-activity relationships of histamine derivatives. Br J Pharmacol. 2006 Apr;147(7):744-54.
DMYI87T	RU	https://pubmed.ncbi.nlm.nih.gov/16432504

DMMKSGL	DI	DMMKSGL
DMMKSGL	DN	N-ethyl-N-methyl-4-(pyridin-3-yl)but-3-yn-1-amine
DMMKSGL	MI	TT4H1MQ
DMMKSGL	MN	Neuronal acetylcholine receptor alpha-4 (CHRNA4)
DMMKSGL	MT	DTT
DMMKSGL	MA	Inhibitor
DMMKSGL	RN	Synthesis and analgesic activity of secondary amine analogues of pyridylmethylamine and positional isomeric analogues of ABT-594. Bioorg Med Chem Lett. 2006 Apr 1;16(7):2013-6.
DMMKSGL	RU	https://pubmed.ncbi.nlm.nih.gov/16412637

DMMKSGL	DI	DMMKSGL
DMMKSGL	DN	N-ethyl-N-methyl-4-(pyridin-3-yl)but-3-yn-1-amine
DMMKSGL	MI	TT5KPZR
DMMKSGL	MN	Neuronal acetylcholine receptor beta-2 (CHRNB2)
DMMKSGL	MT	DTT
DMMKSGL	MA	Inhibitor
DMMKSGL	RN	Synthesis and analgesic activity of secondary amine analogues of pyridylmethylamine and positional isomeric analogues of ABT-594. Bioorg Med Chem Lett. 2006 Apr 1;16(7):2013-6.
DMMKSGL	RU	https://pubmed.ncbi.nlm.nih.gov/16412637

DMOW2QS	DI	DMOW2QS
DMOW2QS	DN	Netropsin
DMOW2QS	MI	TTOVXHF
DMOW2QS	MN	Human Deoxyribonucleic acid minor groove (hDNA min)
DMOW2QS	MT	DTT
DMOW2QS	MA	Binder (minor groove binder)
DMOW2QS	RN	Drug-DNA binding specificity: binding of netropsin and distamycin to poly(d2NH2A-dT). Biopolymers. 1990;30(1-2):223-7.
DMOW2QS	RU	https://pubmed.ncbi.nlm.nih.gov/2171689

DM9UXRP	DI	DM9UXRP
DM9UXRP	DN	neurokinin A
DM9UXRP	MI	TTBPGLU
DM9UXRP	MN	Neuromedin-K receptor (TACR3)
DM9UXRP	MT	DTT
DM9UXRP	MA	Agonist
DM9UXRP	RN	Molecular and pharmacological characterization of the murine tachykinin NK(3) receptor. Eur J Pharmacol. 2001 Feb 16;413(2-3):143-50.
DM9UXRP	RU	https://pubmed.ncbi.nlm.nih.gov/11226387

DM9UXRP	DI	DM9UXRP
DM9UXRP	DN	neurokinin A
DM9UXRP	MI	TTYO0A3
DM9UXRP	MN	Substance-K receptor (TACR2)
DM9UXRP	MT	DTT
DM9UXRP	MA	Agonist
DM9UXRP	RN	Structure-activity relationships of neurokinin A (4-10) at the human tachykinin NK(2) receptor: the role of natural residues and their chirality. Biochem Pharmacol. 2001 Jan 1;61(1):55-60.
DM9UXRP	RU	https://pubmed.ncbi.nlm.nih.gov/11137709

DM9UXRP	DI	DM9UXRP
DM9UXRP	DN	neurokinin A
DM9UXRP	MI	TTZPO1L
DM9UXRP	MN	Substance-P receptor (TACR1)
DM9UXRP	MT	DTT
DM9UXRP	MA	Agonist
DM9UXRP	RN	Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist. J Pharmacol Exp Ther.1997 Jun;281(3):1303-11.
DM9UXRP	RU	https://pubmed.ncbi.nlm.nih.gov/9190866

DM5O2MJ	DI	DM5O2MJ
DM5O2MJ	DN	NEUROKININ B
DM5O2MJ	MI	TTBPGLU
DM5O2MJ	MN	Neuromedin-K receptor (TACR3)
DM5O2MJ	MT	DTT
DM5O2MJ	MA	Inhibitor
DM5O2MJ	RN	The rational development of small molecule tachykinin NK3 receptor selective antagonists - the utilisation of a dipeptide chemical library in drug design, Bioorg. Med. Chem. Lett. 4(14):1679-1684 (1994).
DM5O2MJ	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00803601

DMSJ6T1	DI	DMSJ6T1
DMSJ6T1	DN	Neuromed 2
DMSJ6T1	MI	TTXHYV6
DMSJ6T1	MN	Voltage-gated L-type calcium channel (L-CaC)
DMSJ6T1	MT	DTT
DMSJ6T1	MA	Blocker
DMSJ6T1	RN	Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95.
DMSJ6T1	RU	https://pubmed.ncbi.nlm.nih.gov/19442208

DMXKT45	DI	DMXKT45
DMXKT45	DN	Neuromed 5
DMXKT45	MI	TTXHYV6
DMXKT45	MN	Voltage-gated L-type calcium channel (L-CaC)
DMXKT45	MT	DTT
DMXKT45	MA	Blocker
DMXKT45	RN	Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95.
DMXKT45	RU	https://pubmed.ncbi.nlm.nih.gov/19442208

DMCXJLH	DI	DMCXJLH
DMCXJLH	DN	neuromedin B
DMCXJLH	MI	TTHYDUM
DMCXJLH	MN	Bombesin receptor (BS)
DMCXJLH	MT	DTT
DMCXJLH	MA	Agonist
DMCXJLH	RN	Insights into bombesin receptors and ligands: Highlighting recent advances. Peptides. 2015 Oct;72:128-44.
DMCXJLH	RU	https://pubmed.ncbi.nlm.nih.gov/25976083

DMCXJLH	DI	DMCXJLH
DMCXJLH	DN	neuromedin B
DMCXJLH	MI	TTC1MVT
DMCXJLH	MN	Gastrin-releasing peptide receptor (GRPR)
DMCXJLH	MT	DTT
DMCXJLH	MA	Agonist
DMCXJLH	RN	Expression and characterization of cloned human bombesin receptors. Mol Pharmacol. 1995 Jan;47(1):10-20.
DMCXJLH	RU	https://pubmed.ncbi.nlm.nih.gov/7838118

DM27WCE	DI	DM27WCE
DM27WCE	DN	NEUROTENSIN
DM27WCE	MI	TTTUMEP
DM27WCE	MN	Neurotensin receptor type 1 (NTSR1)
DM27WCE	MT	DTT
DM27WCE	MA	Inhibitor
DM27WCE	RN	Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69.
DM27WCE	RU	https://pubmed.ncbi.nlm.nih.gov/18588282

DMOBU62	DI	DMOBU62
DMOBU62	DN	Neurotensin(8-13)
DMOBU62	MI	TTTUMEP
DMOBU62	MN	Neurotensin receptor type 1 (NTSR1)
DMOBU62	MT	DTT
DMOBU62	MA	Inhibitor
DMOBU62	RN	Comparison of N-terminal modifications on neurotensin(8-13) analogues correlates peptide stability but not binding affinity with in vivo efficacy. J Med Chem. 2009 Apr 9;52(7):1803-13.
DMOBU62	RU	https://pubmed.ncbi.nlm.nih.gov/19290594

DM6NS7H	DI	DM6NS7H
DM6NS7H	DN	nexturastat A
DM6NS7H	MI	TT6R7JZ
DM6NS7H	MN	Histone deacetylase 1 (HDAC1)
DM6NS7H	MT	DTT
DM6NS7H	MA	Inhibitor
DM6NS7H	RN	Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth. J Med Chem. 2012 Nov 26;55(22):9891-9.
DM6NS7H	RU	https://pubmed.ncbi.nlm.nih.gov/23009203

DM6NS7H	DI	DM6NS7H
DM6NS7H	DN	nexturastat A
DM6NS7H	MI	TT5ZKDI
DM6NS7H	MN	Histone deacetylase 6 (HDAC6)
DM6NS7H	MT	DTT
DM6NS7H	MA	Inhibitor
DM6NS7H	RN	Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth. J Med Chem. 2012 Nov 26;55(22):9891-9.
DM6NS7H	RU	https://pubmed.ncbi.nlm.nih.gov/23009203

DMJ4GO9	DI	DMJ4GO9
DMJ4GO9	DN	NF023
DMJ4GO9	MI	TTJW7B3
DMJ4GO9	MN	P2X purinoceptor 1 (P2RX1)
DMJ4GO9	MT	DTT
DMJ4GO9	MA	Antagonist
DMJ4GO9	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 478).
DMJ4GO9	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=478

DMGMH8T	DI	DMGMH8T
DMGMH8T	DN	NF157
DMGMH8T	MI	TTYXPCO
DMGMH8T	MN	P2Y purinoceptor 11 (P2RY11)
DMGMH8T	MT	DTT
DMGMH8T	MA	Antagonist
DMGMH8T	RN	Synthesis and structure-activity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency. J Med Chem. 2005 Nov 3;48(22):7040-8.
DMGMH8T	RU	https://pubmed.ncbi.nlm.nih.gov/16250663

DMPSXR8	DI	DMPSXR8
DMPSXR8	DN	NF340
DMPSXR8	MI	TTYXPCO
DMPSXR8	MN	P2Y purinoceptor 11 (P2RY11)
DMPSXR8	MT	DTT
DMPSXR8	MA	Antagonist
DMPSXR8	RN	Invited Lectures : Overviews Purinergic signalling: past, present and future. Purinergic Signal. 2006 May;2(1):1-324.
DMPSXR8	RU	https://pubmed.ncbi.nlm.nih.gov/18404494

DM816Z2	DI	DM816Z2
DM816Z2	DN	NF449
DM816Z2	MI	TTJW7B3
DM816Z2	MN	P2X purinoceptor 1 (P2RX1)
DM816Z2	MT	DTT
DM816Z2	MA	Antagonist
DM816Z2	RN	Structure-activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist. Eur J Med Chem. 2004 Apr;39(4):345-57.
DM816Z2	RU	https://pubmed.ncbi.nlm.nih.gov/15072843

DMPZB31	DI	DMPZB31
DMPZB31	DN	NF546
DMPZB31	MI	TTYXPCO
DMPZB31	MN	P2Y purinoceptor 11 (P2RY11)
DMPZB31	MT	DTT
DMPZB31	MA	Agonist
DMPZB31	RN	NF546 [4,4'-(carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-methyl-phenylene)-carbonylimino))-bis(1,3-xylene-alpha,alpha'-diphosphonic acid) tetrasodium salt] is a non-nucleotide P2Y11 agonist and stimulates release of interleukin-8 from human monocyte-derived dendritic cells. J Pharmacol Exp Ther. 2010 Jan;332(1):238-47.
DMPZB31	RU	https://pubmed.ncbi.nlm.nih.gov/19815812

DM7GBDX	DI	DM7GBDX
DM7GBDX	DN	N-Formylmethionine
DM7GBDX	MI	TT4QPUL
DM7GBDX	MN	Antithrombin-III (ATIII)
DM7GBDX	MT	DTT
DM7GBDX	MA	Inhibitor
DM7GBDX	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM7GBDX	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM7GBDX	DI	DM7GBDX
DM7GBDX	DN	N-Formylmethionine
DM7GBDX	MI	TTNFESW
DM7GBDX	MN	Glutamate--cysteine ligase modifier (GCLM)
DM7GBDX	MT	DTT
DM7GBDX	MA	Inhibitor
DM7GBDX	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM7GBDX	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM7GBDX	DI	DM7GBDX
DM7GBDX	DN	N-Formylmethionine
DM7GBDX	MI	TTTJF7V
DM7GBDX	MN	NADH dehydrogenase (MT-ND3)
DM7GBDX	MT	DTT
DM7GBDX	MA	Inhibitor
DM7GBDX	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM7GBDX	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMC48D9	DI	DMC48D9
DMC48D9	DN	NG-25
DMC48D9	MI	TTQFRP0
DMC48D9	MN	MEK kinase kinase 2 (MAP4K2)
DMC48D9	MT	DTT
DMC48D9	MA	Inhibitor
DMC48D9	RN	Discovery of type II inhibitors of TGFbeta-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2). J Med Chem. 2015 Jan 8;58(1):183-96.
DMC48D9	RU	https://pubmed.ncbi.nlm.nih.gov/25075558

DMC48D9	DI	DMC48D9
DMC48D9	DN	NG-25
DMC48D9	MI	TT6PKBN
DMC48D9	MN	Proto-oncogene c-Src (SRC)
DMC48D9	MT	DTT
DMC48D9	MA	Inhibitor
DMC48D9	RN	Discovery of type II inhibitors of TGFbeta-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2). J Med Chem. 2015 Jan 8;58(1):183-96.
DMC48D9	RU	https://pubmed.ncbi.nlm.nih.gov/25075558

DMC48D9	DI	DMC48D9
DMC48D9	DN	NG-25
DMC48D9	MI	TTJQT60
DMC48D9	MN	TGF-beta-activated kinase 1 (MAP3K7)
DMC48D9	MT	DTT
DMC48D9	MA	Inhibitor
DMC48D9	RN	Discovery of type II inhibitors of TGFbeta-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2). J Med Chem. 2015 Jan 8;58(1):183-96.
DMC48D9	RU	https://pubmed.ncbi.nlm.nih.gov/25075558

DMC48D9	DI	DMC48D9
DMC48D9	DN	NG-25
DMC48D9	MI	TTX6F0Q
DMC48D9	MN	Tyrosine-protein kinase CSK (CSK)
DMC48D9	MT	DTT
DMC48D9	MA	Inhibitor
DMC48D9	RN	Discovery of type II inhibitors of TGFbeta-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2). J Med Chem. 2015 Jan 8;58(1):183-96.
DMC48D9	RU	https://pubmed.ncbi.nlm.nih.gov/25075558

DMC48D9	DI	DMC48D9
DMC48D9	DN	NG-25
DMC48D9	MI	TT1RWNJ
DMC48D9	MN	Tyrosine-protein kinase Lyn (JTK8)
DMC48D9	MT	DTT
DMC48D9	MA	Inhibitor
DMC48D9	RN	Discovery of type II inhibitors of TGFbeta-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2). J Med Chem. 2015 Jan 8;58(1):183-96.
DMC48D9	RU	https://pubmed.ncbi.nlm.nih.gov/25075558

DMMC42Z	DI	DMMC42Z
DMMC42Z	DN	NGB 2904
DMMC42Z	MI	TT4C8EA
DMMC42Z	MN	Dopamine D3 receptor (D3R)
DMMC42Z	MT	DTT
DMMC42Z	MA	Antagonist
DMMC42Z	RN	Pharmacological actions of NGB 2904, a selective dopamine D3 receptor antagonist, in animal models of drug addiction. CNS Drug Rev. 2007 Summer;13(2):240-59.
DMMC42Z	RU	https://pubmed.ncbi.nlm.nih.gov/17627675

DMWD7I3	DI	DMWD7I3
DMWD7I3	DN	NGD 96-3
DMWD7I3	MI	TTEX6LM
DMWD7I3	MN	GABA(A) receptor gamma-3 (GABRG3)
DMWD7I3	MT	DTT
DMWD7I3	MA	Modulator
DMWD7I3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415).
DMWD7I3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415

DMPEZHC	DI	DMPEZHC
DMPEZHC	DN	N-glycylglycinehydroxamic acid
DMPEZHC	MI	TTAS2UO
DMPEZHC	MN	Bacterial Urease (Bact ureC)
DMPEZHC	MT	DTT
DMPEZHC	MA	Inhibitor
DMPEZHC	RN	Design, synthesis, and evaluation of novel organophosphorus inhibitors of bacterial ureases. J Med Chem. 2008 Sep 25;51(18):5736-44.
DMPEZHC	RU	https://pubmed.ncbi.nlm.nih.gov/18717581

DMBG3ZF	DI	DMBG3ZF
DMBG3ZF	DN	N-guanyl-1,7-diaminoheptane
DMBG3ZF	MI	TTBO2A9
DMBG3ZF	MN	Deoxyhypusine synthase (DHPS)
DMBG3ZF	MT	DTT
DMBG3ZF	MA	Inhibitor
DMBG3ZF	RN	Modification of eukaryotic initiation factor 5A from Plasmodium vivax by a truncated deoxyhypusine synthase from Plasmodium falciparum: An enzyme w... Bioorg Med Chem. 2007 Sep 15;15(18):6200-7.
DMBG3ZF	RU	https://pubmed.ncbi.nlm.nih.gov/17591443

DMYAB79	DI	DMYAB79
DMYAB79	DN	NH-3
DMYAB79	MI	TTQWUPT
DMYAB79	MN	Thyroid hormone receptor (THR)
DMYAB79	MT	DTT
DMYAB79	MA	Antagonist
DMYAB79	RN	Design of thyroid hormone receptor antagonists from first principles. J Steroid Biochem Mol Biol. 2002 Dec;83(1-5):59-73.
DMYAB79	RU	https://pubmed.ncbi.nlm.nih.gov/12650702

DMSUZFO	DI	DMSUZFO
DMSUZFO	DN	NH-4
DMSUZFO	MI	TTQWUPT
DMSUZFO	MN	Thyroid hormone receptor (THR)
DMSUZFO	MT	DTT
DMSUZFO	MA	Antagonist
DMSUZFO	RN	Design of thyroid hormone receptor antagonists from first principles. J Steroid Biochem Mol Biol. 2002 Dec;83(1-5):59-73.
DMSUZFO	RU	https://pubmed.ncbi.nlm.nih.gov/12650702

DMM0F2G	DI	DMM0F2G
DMM0F2G	DN	N-Hexyl-2-(2-phenyl-1H-indol-3-yl)-acetamide
DMM0F2G	MI	TTPTXIN
DMM0F2G	MN	Translocator protein (TSPO)
DMM0F2G	MT	DTT
DMM0F2G	MA	Inhibitor
DMM0F2G	RN	Chemistry, binding affinities, and behavioral properties of a new class of "antineophobic" mitochondrial DBI receptor complex (mDRC) ligands. J Med Chem. 1993 Oct 1;36(20):2908-20.
DMM0F2G	RU	https://pubmed.ncbi.nlm.nih.gov/8411007

DML27CG	DI	DML27CG
DML27CG	DN	N-Hexylcarbamic Acid Biphenyl-3-yl Ester
DML27CG	MI	TTDP1UC
DML27CG	MN	Fatty acid amide hydrolase (FAAH)
DML27CG	MT	DTT
DML27CG	MA	Inhibitor
DML27CG	RN	Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl a... J Med Chem. 2008 Jun 26;51(12):3487-98.
DML27CG	RU	https://pubmed.ncbi.nlm.nih.gov/18507372

DMZ2T59	DI	DMZ2T59
DMZ2T59	DN	N-hydroxy-1-naphthamide
DMZ2T59	MI	TTT6LFV
DMZ2T59	MN	Histone deacetylase 8 (HDAC8)
DMZ2T59	MT	DTT
DMZ2T59	MA	Inhibitor
DMZ2T59	RN	Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors. Bioorg Med Chem Lett. 2007 May 15;17(10):2874-8.
DMZ2T59	RU	https://pubmed.ncbi.nlm.nih.gov/17346959

DM56P1I	DI	DM56P1I
DM56P1I	DN	N-Hydroxy-2-(4-methoxy-benzenesulfonyl)benzamide
DM56P1I	MI	TTXZ0KQ
DM56P1I	MN	Matrix metalloproteinase-12 (MMP-12)
DM56P1I	MT	DTT
DM56P1I	MA	Inhibitor
DM56P1I	RN	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
DM56P1I	RU	https://pubmed.ncbi.nlm.nih.gov/19775099

DM50NKS	DI	DM50NKS
DM50NKS	DN	N-hydroxy-2-(4-methoxyphenylsulfonamido)acetamide
DM50NKS	MI	TTJ4QE7
DM50NKS	MN	Matrix metalloproteinase-14 (MMP-14)
DM50NKS	MT	DTT
DM50NKS	MA	Inhibitor
DM50NKS	RN	Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule sheddi... J Med Chem. 2010 Mar 25;53(6):2622-35.
DM50NKS	RU	https://pubmed.ncbi.nlm.nih.gov/20180536

DM50NKS	DI	DM50NKS
DM50NKS	DN	N-hydroxy-2-(4-methoxyphenylsulfonamido)acetamide
DM50NKS	MI	TT6AZXG
DM50NKS	MN	TNF alpha converting enzyme (ADAM17)
DM50NKS	MT	DTT
DM50NKS	MA	Inhibitor
DM50NKS	RN	Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule sheddi... J Med Chem. 2010 Mar 25;53(6):2622-35.
DM50NKS	RU	https://pubmed.ncbi.nlm.nih.gov/20180536

DM4VADN	DI	DM4VADN
DM4VADN	DN	N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide
DM4VADN	MI	TTXZ0KQ
DM4VADN	MN	Matrix metalloproteinase-12 (MMP-12)
DM4VADN	MT	DTT
DM4VADN	MA	Inhibitor
DM4VADN	RN	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
DM4VADN	RU	https://pubmed.ncbi.nlm.nih.gov/19775099

DM4VADN	DI	DM4VADN
DM4VADN	DN	N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide
DM4VADN	MI	TTHY57M
DM4VADN	MN	Matrix metalloproteinase-13 (MMP-13)
DM4VADN	MT	DTT
DM4VADN	MA	Inhibitor
DM4VADN	RN	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
DM4VADN	RU	https://pubmed.ncbi.nlm.nih.gov/19775099

DM4VADN	DI	DM4VADN
DM4VADN	DN	N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide
DM4VADN	MI	TTJ4QE7
DM4VADN	MN	Matrix metalloproteinase-14 (MMP-14)
DM4VADN	MT	DTT
DM4VADN	MA	Inhibitor
DM4VADN	RN	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
DM4VADN	RU	https://pubmed.ncbi.nlm.nih.gov/19775099

DM4VADN	DI	DM4VADN
DM4VADN	DN	N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide
DM4VADN	MI	TTLM12X
DM4VADN	MN	Matrix metalloproteinase-2 (MMP-2)
DM4VADN	MT	DTT
DM4VADN	MA	Inhibitor
DM4VADN	RN	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
DM4VADN	RU	https://pubmed.ncbi.nlm.nih.gov/19775099

DM4VADN	DI	DM4VADN
DM4VADN	DN	N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide
DM4VADN	MI	TTYRF5E
DM4VADN	MN	Matrix metalloproteinase-21 (MMP-21)
DM4VADN	MT	DTT
DM4VADN	MA	Inhibitor
DM4VADN	RN	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
DM4VADN	RU	https://pubmed.ncbi.nlm.nih.gov/19775099

DM4VADN	DI	DM4VADN
DM4VADN	DN	N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide
DM4VADN	MI	TTGA1IV
DM4VADN	MN	Matrix metalloproteinase-8 (MMP-8)
DM4VADN	MT	DTT
DM4VADN	MA	Inhibitor
DM4VADN	RN	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
DM4VADN	RU	https://pubmed.ncbi.nlm.nih.gov/19775099

DM4VADN	DI	DM4VADN
DM4VADN	DN	N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide
DM4VADN	MI	TT6X50U
DM4VADN	MN	Matrix metalloproteinase-9 (MMP-9)
DM4VADN	MT	DTT
DM4VADN	MA	Inhibitor
DM4VADN	RN	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
DM4VADN	RU	https://pubmed.ncbi.nlm.nih.gov/19775099

DMISXUM	DI	DMISXUM
DMISXUM	DN	N-Hydroxy-2-(naphthalen-2-ylsulfanyl)-acetamide
DMISXUM	MI	TTPHMWB
DMISXUM	MN	Aminopeptidase N (ANPEP)
DMISXUM	MT	DTT
DMISXUM	MA	Inhibitor
DMISXUM	RN	N-hydroxy-2-(naphthalene-2-ylsulfanyl)-acetamide, a novel hydroxamic acid-based inhibitor of aminopeptidase N and its anti-angiogenic activity. Bioorg Med Chem Lett. 2005 Jan 3;15(1):181-3.
DMISXUM	RU	https://pubmed.ncbi.nlm.nih.gov/15582436

DMWIMR4	DI	DMWIMR4
DMWIMR4	DN	N-hydroxy-2,2'-bithiophene-5-carboxamide
DMWIMR4	MI	TT6R7JZ
DMWIMR4	MN	Histone deacetylase 1 (HDAC1)
DMWIMR4	MT	DTT
DMWIMR4	MA	Inhibitor
DMWIMR4	RN	Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibit... Bioorg Med Chem Lett. 2007 Jan 15;17(2):363-9.
DMWIMR4	RU	https://pubmed.ncbi.nlm.nih.gov/17107790

DMX3KRQ	DI	DMX3KRQ
DMX3KRQ	DN	N-hydroxy-2,2-diphenylacetamide
DMX3KRQ	MI	TTBH0VX
DMX3KRQ	MN	Histone deacetylase (HDAC)
DMX3KRQ	MT	DTT
DMX3KRQ	MA	Inhibitor
DMX3KRQ	RN	Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5684-8.
DMX3KRQ	RU	https://pubmed.ncbi.nlm.nih.gov/19699639

DMX3KRQ	DI	DMX3KRQ
DMX3KRQ	DN	N-hydroxy-2,2-diphenylacetamide
DMX3KRQ	MI	TTTQGH8
DMX3KRQ	MN	Histone deacetylase 4 (HDAC4)
DMX3KRQ	MT	DTT
DMX3KRQ	MA	Inhibitor
DMX3KRQ	RN	Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5684-8.
DMX3KRQ	RU	https://pubmed.ncbi.nlm.nih.gov/19699639

DM7I2TD	DI	DM7I2TD
DM7I2TD	DN	N-hydroxy-2,2-diphenylpropanamide
DM7I2TD	MI	TTBH0VX
DM7I2TD	MN	Histone deacetylase (HDAC)
DM7I2TD	MT	DTT
DM7I2TD	MA	Inhibitor
DM7I2TD	RN	Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5684-8.
DM7I2TD	RU	https://pubmed.ncbi.nlm.nih.gov/19699639

DM7I2TD	DI	DM7I2TD
DM7I2TD	DN	N-hydroxy-2,2-diphenylpropanamide
DM7I2TD	MI	TTTQGH8
DM7I2TD	MN	Histone deacetylase 4 (HDAC4)
DM7I2TD	MT	DTT
DM7I2TD	MA	Inhibitor
DM7I2TD	RN	Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5684-8.
DM7I2TD	RU	https://pubmed.ncbi.nlm.nih.gov/19699639

DMZWIVJ	DI	DMZWIVJ
DMZWIVJ	DN	N-hydroxy-2,3-bis(phenylsulfonamido)propanamide
DMZWIVJ	MI	TTYRF5E
DMZWIVJ	MN	Matrix metalloproteinase-21 (MMP-21)
DMZWIVJ	MT	DTT
DMZWIVJ	MA	Inhibitor
DMZWIVJ	RN	Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3333-7.
DMZWIVJ	RU	https://pubmed.ncbi.nlm.nih.gov/18442906

DMZWIVJ	DI	DMZWIVJ
DMZWIVJ	DN	N-hydroxy-2,3-bis(phenylsulfonamido)propanamide
DMZWIVJ	MI	TTMTWOS
DMZWIVJ	MN	Matrix metalloproteinase-7 (MMP-7)
DMZWIVJ	MT	DTT
DMZWIVJ	MA	Inhibitor
DMZWIVJ	RN	Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3333-7.
DMZWIVJ	RU	https://pubmed.ncbi.nlm.nih.gov/18442906

DMZWIVJ	DI	DMZWIVJ
DMZWIVJ	DN	N-hydroxy-2,3-bis(phenylsulfonamido)propanamide
DMZWIVJ	MI	TT6X50U
DMZWIVJ	MN	Matrix metalloproteinase-9 (MMP-9)
DMZWIVJ	MT	DTT
DMZWIVJ	MA	Inhibitor
DMZWIVJ	RN	Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3333-7.
DMZWIVJ	RU	https://pubmed.ncbi.nlm.nih.gov/18442906

DME96RF	DI	DME96RF
DME96RF	DN	N-Hydroxy-2-methyl-3-naphthalen-2-yl-acrylamide
DME96RF	MI	TT2J34L
DME96RF	MN	Arachidonate 5-lipoxygenase (5-LOX)
DME96RF	MT	DTT
DME96RF	MA	Inhibitor
DME96RF	RN	Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8.
DME96RF	RU	https://pubmed.ncbi.nlm.nih.gov/2308149

DMYDX34	DI	DMYDX34
DMYDX34	DN	N-Hydroxy-2-naphthalen-2-yl-acetamide
DMYDX34	MI	TT2J34L
DMYDX34	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMYDX34	MT	DTT
DMYDX34	MA	Inhibitor
DMYDX34	RN	Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8.
DMYDX34	RU	https://pubmed.ncbi.nlm.nih.gov/2308149

DMWXUCT	DI	DMWXUCT
DMWXUCT	DN	N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide
DMWXUCT	MI	TTLM12X
DMWXUCT	MN	Matrix metalloproteinase-2 (MMP-2)
DMWXUCT	MT	DTT
DMWXUCT	MA	Inhibitor
DMWXUCT	RN	Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation. Bioorg Med Chem. 2008 Jan 1;16(1):530-5.
DMWXUCT	RU	https://pubmed.ncbi.nlm.nih.gov/17936631

DMWXUCT	DI	DMWXUCT
DMWXUCT	DN	N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide
DMWXUCT	MI	TT6X50U
DMWXUCT	MN	Matrix metalloproteinase-9 (MMP-9)
DMWXUCT	MT	DTT
DMWXUCT	MA	Inhibitor
DMWXUCT	RN	Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation. Bioorg Med Chem. 2008 Jan 1;16(1):530-5.
DMWXUCT	RU	https://pubmed.ncbi.nlm.nih.gov/17936631

DMWXUCT	DI	DMWXUCT
DMWXUCT	DN	N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide
DMWXUCT	MI	TT6AZXG
DMWXUCT	MN	TNF alpha converting enzyme (ADAM17)
DMWXUCT	MT	DTT
DMWXUCT	MA	Inhibitor
DMWXUCT	RN	Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation. Bioorg Med Chem. 2008 Jan 1;16(1):530-5.
DMWXUCT	RU	https://pubmed.ncbi.nlm.nih.gov/17936631

DMA6EPH	DI	DMA6EPH
DMA6EPH	DN	N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl)
DMA6EPH	MI	TTLM12X
DMA6EPH	MN	Matrix metalloproteinase-2 (MMP-2)
DMA6EPH	MT	DTT
DMA6EPH	MA	Inhibitor
DMA6EPH	RN	Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation. Bioorg Med Chem. 2008 Jan 1;16(1):530-5.
DMA6EPH	RU	https://pubmed.ncbi.nlm.nih.gov/17936631

DMA6EPH	DI	DMA6EPH
DMA6EPH	DN	N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl)
DMA6EPH	MI	TT6X50U
DMA6EPH	MN	Matrix metalloproteinase-9 (MMP-9)
DMA6EPH	MT	DTT
DMA6EPH	MA	Inhibitor
DMA6EPH	RN	Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation. Bioorg Med Chem. 2008 Jan 1;16(1):530-5.
DMA6EPH	RU	https://pubmed.ncbi.nlm.nih.gov/17936631

DMA6EPH	DI	DMA6EPH
DMA6EPH	DN	N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl)
DMA6EPH	MI	TT6AZXG
DMA6EPH	MN	TNF alpha converting enzyme (ADAM17)
DMA6EPH	MT	DTT
DMA6EPH	MA	Inhibitor
DMA6EPH	RN	Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation. Bioorg Med Chem. 2008 Jan 1;16(1):530-5.
DMA6EPH	RU	https://pubmed.ncbi.nlm.nih.gov/17936631

DMY6Z0U	DI	DMY6Z0U
DMY6Z0U	DN	N-hydroxy-3-(naphthalen-1-yl)acrylamide
DMY6Z0U	MI	TTT6LFV
DMY6Z0U	MN	Histone deacetylase 8 (HDAC8)
DMY6Z0U	MT	DTT
DMY6Z0U	MA	Inhibitor
DMY6Z0U	RN	Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors. Bioorg Med Chem Lett. 2007 May 15;17(10):2874-8.
DMY6Z0U	RU	https://pubmed.ncbi.nlm.nih.gov/17346959

DMZ3INJ	DI	DMZ3INJ
DMZ3INJ	DN	N-Hydroxy-3-naphthalen-2-yl-acrylamide
DMZ3INJ	MI	TT2J34L
DMZ3INJ	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMZ3INJ	MT	DTT
DMZ3INJ	MA	Inhibitor
DMZ3INJ	RN	Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8.
DMZ3INJ	RU	https://pubmed.ncbi.nlm.nih.gov/2308149

DMVOPXE	DI	DMVOPXE
DMVOPXE	DN	N-Hydroxy-3-naphthalen-2-yl-N-phenyl-acrylamide
DMVOPXE	MI	TT2J34L
DMVOPXE	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMVOPXE	MT	DTT
DMVOPXE	MA	Inhibitor
DMVOPXE	RN	Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8.
DMVOPXE	RU	https://pubmed.ncbi.nlm.nih.gov/2308149

DMKBACJ	DI	DMKBACJ
DMKBACJ	DN	N-Hydroxy-3-naphthalen-2-yl-N-p-tolyl-acrylamide
DMKBACJ	MI	TT2J34L
DMKBACJ	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMKBACJ	MT	DTT
DMKBACJ	MA	Inhibitor
DMKBACJ	RN	Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8.
DMKBACJ	RU	https://pubmed.ncbi.nlm.nih.gov/2308149

DMPIMRC	DI	DMPIMRC
DMPIMRC	DN	N-Hydroxy-3-naphthalen-2-yl-propionamide
DMPIMRC	MI	TT2J34L
DMPIMRC	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMPIMRC	MT	DTT
DMPIMRC	MA	Inhibitor
DMPIMRC	RN	Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8.
DMPIMRC	RU	https://pubmed.ncbi.nlm.nih.gov/2308149

DMTZ8RQ	DI	DMTZ8RQ
DMTZ8RQ	DN	N-hydroxy-3-phenoxybenzamide
DMTZ8RQ	MI	TTT6LFV
DMTZ8RQ	MN	Histone deacetylase 8 (HDAC8)
DMTZ8RQ	MT	DTT
DMTZ8RQ	MA	Inhibitor
DMTZ8RQ	RN	Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors. Bioorg Med Chem Lett. 2007 May 15;17(10):2874-8.
DMTZ8RQ	RU	https://pubmed.ncbi.nlm.nih.gov/17346959

DM9IPTV	DI	DM9IPTV
DM9IPTV	DN	N-Hydroxy-3-phenyl-acrylamide
DM9IPTV	MI	TT2J34L
DM9IPTV	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM9IPTV	MT	DTT
DM9IPTV	MA	Inhibitor
DM9IPTV	RN	Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8.
DM9IPTV	RU	https://pubmed.ncbi.nlm.nih.gov/2308149

DMCN91A	DI	DMCN91A
DMCN91A	DN	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide
DMCN91A	MI	TTBH0VX
DMCN91A	MN	Histone deacetylase (HDAC)
DMCN91A	MT	DTT
DMCN91A	MA	Inhibitor
DMCN91A	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMCN91A	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMCN91A	DI	DMCN91A
DMCN91A	DN	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide
DMCN91A	MI	TT6R7JZ
DMCN91A	MN	Histone deacetylase 1 (HDAC1)
DMCN91A	MT	DTT
DMCN91A	MA	Inhibitor
DMCN91A	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMCN91A	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMCN91A	DI	DMCN91A
DMCN91A	DN	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide
DMCN91A	MI	TTYHPU6
DMCN91A	MN	Histone deacetylase 10 (HDAC10)
DMCN91A	MT	DTT
DMCN91A	MA	Inhibitor
DMCN91A	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMCN91A	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMCN91A	DI	DMCN91A
DMCN91A	DN	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide
DMCN91A	MI	TTSHTOI
DMCN91A	MN	Histone deacetylase 2 (HDAC2)
DMCN91A	MT	DTT
DMCN91A	MA	Inhibitor
DMCN91A	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMCN91A	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMCN91A	DI	DMCN91A
DMCN91A	DN	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide
DMCN91A	MI	TTTQGH8
DMCN91A	MN	Histone deacetylase 4 (HDAC4)
DMCN91A	MT	DTT
DMCN91A	MA	Inhibitor
DMCN91A	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMCN91A	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMCN91A	DI	DMCN91A
DMCN91A	DN	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide
DMCN91A	MI	TT5ZKDI
DMCN91A	MN	Histone deacetylase 6 (HDAC6)
DMCN91A	MT	DTT
DMCN91A	MA	Inhibitor
DMCN91A	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMCN91A	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMCN91A	DI	DMCN91A
DMCN91A	DN	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide
DMCN91A	MI	TTT6LFV
DMCN91A	MN	Histone deacetylase 8 (HDAC8)
DMCN91A	MT	DTT
DMCN91A	MA	Inhibitor
DMCN91A	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMCN91A	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMVK2Y3	DI	DMVK2Y3
DMVK2Y3	DN	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide
DMVK2Y3	MI	TTBH0VX
DMVK2Y3	MN	Histone deacetylase (HDAC)
DMVK2Y3	MT	DTT
DMVK2Y3	MA	Inhibitor
DMVK2Y3	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMVK2Y3	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMVK2Y3	DI	DMVK2Y3
DMVK2Y3	DN	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide
DMVK2Y3	MI	TT6R7JZ
DMVK2Y3	MN	Histone deacetylase 1 (HDAC1)
DMVK2Y3	MT	DTT
DMVK2Y3	MA	Inhibitor
DMVK2Y3	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMVK2Y3	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMVK2Y3	DI	DMVK2Y3
DMVK2Y3	DN	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide
DMVK2Y3	MI	TTYHPU6
DMVK2Y3	MN	Histone deacetylase 10 (HDAC10)
DMVK2Y3	MT	DTT
DMVK2Y3	MA	Inhibitor
DMVK2Y3	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMVK2Y3	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMVK2Y3	DI	DMVK2Y3
DMVK2Y3	DN	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide
DMVK2Y3	MI	TTSHTOI
DMVK2Y3	MN	Histone deacetylase 2 (HDAC2)
DMVK2Y3	MT	DTT
DMVK2Y3	MA	Inhibitor
DMVK2Y3	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMVK2Y3	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMVK2Y3	DI	DMVK2Y3
DMVK2Y3	DN	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide
DMVK2Y3	MI	TTTQGH8
DMVK2Y3	MN	Histone deacetylase 4 (HDAC4)
DMVK2Y3	MT	DTT
DMVK2Y3	MA	Inhibitor
DMVK2Y3	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMVK2Y3	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMVK2Y3	DI	DMVK2Y3
DMVK2Y3	DN	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide
DMVK2Y3	MI	TT5ZKDI
DMVK2Y3	MN	Histone deacetylase 6 (HDAC6)
DMVK2Y3	MT	DTT
DMVK2Y3	MA	Inhibitor
DMVK2Y3	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMVK2Y3	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMVK2Y3	DI	DMVK2Y3
DMVK2Y3	DN	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide
DMVK2Y3	MI	TTT6LFV
DMVK2Y3	MN	Histone deacetylase 8 (HDAC8)
DMVK2Y3	MT	DTT
DMVK2Y3	MA	Inhibitor
DMVK2Y3	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMVK2Y3	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMKELRB	DI	DMKELRB
DMKELRB	DN	N-hydroxy-4-(2-oleamidoethyl)benzamide
DMKELRB	MI	TTIQSC1
DMKELRB	MN	Bacterial Lethal factor (Bact lef)
DMKELRB	MT	DTT
DMKELRB	MA	Inhibitor
DMKELRB	RN	Inhibitors of anthrax lethal factor. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4575-8.
DMKELRB	RU	https://pubmed.ncbi.nlm.nih.gov/17574849

DMHEQ41	DI	DMHEQ41
DMHEQ41	DN	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide
DMHEQ41	MI	TTBH0VX
DMHEQ41	MN	Histone deacetylase (HDAC)
DMHEQ41	MT	DTT
DMHEQ41	MA	Inhibitor
DMHEQ41	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMHEQ41	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMHEQ41	DI	DMHEQ41
DMHEQ41	DN	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide
DMHEQ41	MI	TT6R7JZ
DMHEQ41	MN	Histone deacetylase 1 (HDAC1)
DMHEQ41	MT	DTT
DMHEQ41	MA	Inhibitor
DMHEQ41	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMHEQ41	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMHEQ41	DI	DMHEQ41
DMHEQ41	DN	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide
DMHEQ41	MI	TTYHPU6
DMHEQ41	MN	Histone deacetylase 10 (HDAC10)
DMHEQ41	MT	DTT
DMHEQ41	MA	Inhibitor
DMHEQ41	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMHEQ41	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMHEQ41	DI	DMHEQ41
DMHEQ41	DN	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide
DMHEQ41	MI	TTSHTOI
DMHEQ41	MN	Histone deacetylase 2 (HDAC2)
DMHEQ41	MT	DTT
DMHEQ41	MA	Inhibitor
DMHEQ41	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMHEQ41	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMHEQ41	DI	DMHEQ41
DMHEQ41	DN	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide
DMHEQ41	MI	TTTQGH8
DMHEQ41	MN	Histone deacetylase 4 (HDAC4)
DMHEQ41	MT	DTT
DMHEQ41	MA	Inhibitor
DMHEQ41	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMHEQ41	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMHEQ41	DI	DMHEQ41
DMHEQ41	DN	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide
DMHEQ41	MI	TT5ZKDI
DMHEQ41	MN	Histone deacetylase 6 (HDAC6)
DMHEQ41	MT	DTT
DMHEQ41	MA	Inhibitor
DMHEQ41	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMHEQ41	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMHEQ41	DI	DMHEQ41
DMHEQ41	DN	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide
DMHEQ41	MI	TTT6LFV
DMHEQ41	MN	Histone deacetylase 8 (HDAC8)
DMHEQ41	MT	DTT
DMHEQ41	MA	Inhibitor
DMHEQ41	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMHEQ41	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMUOCQB	DI	DMUOCQB
DMUOCQB	DN	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide
DMUOCQB	MI	TTBH0VX
DMUOCQB	MN	Histone deacetylase (HDAC)
DMUOCQB	MT	DTT
DMUOCQB	MA	Inhibitor
DMUOCQB	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMUOCQB	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMUOCQB	DI	DMUOCQB
DMUOCQB	DN	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide
DMUOCQB	MI	TT6R7JZ
DMUOCQB	MN	Histone deacetylase 1 (HDAC1)
DMUOCQB	MT	DTT
DMUOCQB	MA	Inhibitor
DMUOCQB	RN	Design, synthesis and preliminary biological evaluation of N-hydroxy-4-(3-phenylpropanamido)benzamide (HPPB) derivatives as novel histone deacetyla... Eur J Med Chem. 2009 Nov;44(11):4470-6.
DMUOCQB	RU	https://pubmed.ncbi.nlm.nih.gov/19608304

DMUOCQB	DI	DMUOCQB
DMUOCQB	DN	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide
DMUOCQB	MI	TTYHPU6
DMUOCQB	MN	Histone deacetylase 10 (HDAC10)
DMUOCQB	MT	DTT
DMUOCQB	MA	Inhibitor
DMUOCQB	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMUOCQB	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMUOCQB	DI	DMUOCQB
DMUOCQB	DN	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide
DMUOCQB	MI	TTSHTOI
DMUOCQB	MN	Histone deacetylase 2 (HDAC2)
DMUOCQB	MT	DTT
DMUOCQB	MA	Inhibitor
DMUOCQB	RN	Design, synthesis and preliminary biological evaluation of N-hydroxy-4-(3-phenylpropanamido)benzamide (HPPB) derivatives as novel histone deacetyla... Eur J Med Chem. 2009 Nov;44(11):4470-6.
DMUOCQB	RU	https://pubmed.ncbi.nlm.nih.gov/19608304

DMUOCQB	DI	DMUOCQB
DMUOCQB	DN	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide
DMUOCQB	MI	TTTQGH8
DMUOCQB	MN	Histone deacetylase 4 (HDAC4)
DMUOCQB	MT	DTT
DMUOCQB	MA	Inhibitor
DMUOCQB	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMUOCQB	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMUOCQB	DI	DMUOCQB
DMUOCQB	DN	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide
DMUOCQB	MI	TT5ZKDI
DMUOCQB	MN	Histone deacetylase 6 (HDAC6)
DMUOCQB	MT	DTT
DMUOCQB	MA	Inhibitor
DMUOCQB	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMUOCQB	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMUOCQB	DI	DMUOCQB
DMUOCQB	DN	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide
DMUOCQB	MI	TTT6LFV
DMUOCQB	MN	Histone deacetylase 8 (HDAC8)
DMUOCQB	MT	DTT
DMUOCQB	MA	Inhibitor
DMUOCQB	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMUOCQB	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMQN6CL	DI	DMQN6CL
DMQN6CL	DN	N-Hydroxy-4-(4-methoxy-phenyl)-4-oxo-butyramide
DMQN6CL	MI	TTMX39J
DMQN6CL	MN	Matrix metalloproteinase-1 (MMP-1)
DMQN6CL	MT	DTT
DMQN6CL	MA	Inhibitor
DMQN6CL	RN	Receptor flexibility in de novo ligand design and docking. J Med Chem. 2005 Oct 20;48(21):6585-96.
DMQN6CL	RU	https://pubmed.ncbi.nlm.nih.gov/16220975

DMVEOBY	DI	DMVEOBY
DMVEOBY	DN	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide
DMVEOBY	MI	TTBH0VX
DMVEOBY	MN	Histone deacetylase (HDAC)
DMVEOBY	MT	DTT
DMVEOBY	MA	Inhibitor
DMVEOBY	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMVEOBY	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMVEOBY	DI	DMVEOBY
DMVEOBY	DN	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide
DMVEOBY	MI	TT6R7JZ
DMVEOBY	MN	Histone deacetylase 1 (HDAC1)
DMVEOBY	MT	DTT
DMVEOBY	MA	Inhibitor
DMVEOBY	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMVEOBY	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMVEOBY	DI	DMVEOBY
DMVEOBY	DN	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide
DMVEOBY	MI	TTYHPU6
DMVEOBY	MN	Histone deacetylase 10 (HDAC10)
DMVEOBY	MT	DTT
DMVEOBY	MA	Inhibitor
DMVEOBY	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMVEOBY	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMVEOBY	DI	DMVEOBY
DMVEOBY	DN	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide
DMVEOBY	MI	TTSHTOI
DMVEOBY	MN	Histone deacetylase 2 (HDAC2)
DMVEOBY	MT	DTT
DMVEOBY	MA	Inhibitor
DMVEOBY	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMVEOBY	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMVEOBY	DI	DMVEOBY
DMVEOBY	DN	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide
DMVEOBY	MI	TTTQGH8
DMVEOBY	MN	Histone deacetylase 4 (HDAC4)
DMVEOBY	MT	DTT
DMVEOBY	MA	Inhibitor
DMVEOBY	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMVEOBY	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMVEOBY	DI	DMVEOBY
DMVEOBY	DN	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide
DMVEOBY	MI	TT5ZKDI
DMVEOBY	MN	Histone deacetylase 6 (HDAC6)
DMVEOBY	MT	DTT
DMVEOBY	MA	Inhibitor
DMVEOBY	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMVEOBY	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMVEOBY	DI	DMVEOBY
DMVEOBY	DN	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide
DMVEOBY	MI	TTT6LFV
DMVEOBY	MN	Histone deacetylase 8 (HDAC8)
DMVEOBY	MT	DTT
DMVEOBY	MA	Inhibitor
DMVEOBY	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMVEOBY	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMISRMT	DI	DMISRMT
DMISRMT	DN	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide
DMISRMT	MI	TTBH0VX
DMISRMT	MN	Histone deacetylase (HDAC)
DMISRMT	MT	DTT
DMISRMT	MA	Inhibitor
DMISRMT	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMISRMT	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMISRMT	DI	DMISRMT
DMISRMT	DN	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide
DMISRMT	MI	TT6R7JZ
DMISRMT	MN	Histone deacetylase 1 (HDAC1)
DMISRMT	MT	DTT
DMISRMT	MA	Inhibitor
DMISRMT	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMISRMT	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMISRMT	DI	DMISRMT
DMISRMT	DN	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide
DMISRMT	MI	TTYHPU6
DMISRMT	MN	Histone deacetylase 10 (HDAC10)
DMISRMT	MT	DTT
DMISRMT	MA	Inhibitor
DMISRMT	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMISRMT	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMISRMT	DI	DMISRMT
DMISRMT	DN	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide
DMISRMT	MI	TTSHTOI
DMISRMT	MN	Histone deacetylase 2 (HDAC2)
DMISRMT	MT	DTT
DMISRMT	MA	Inhibitor
DMISRMT	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMISRMT	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMISRMT	DI	DMISRMT
DMISRMT	DN	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide
DMISRMT	MI	TTTQGH8
DMISRMT	MN	Histone deacetylase 4 (HDAC4)
DMISRMT	MT	DTT
DMISRMT	MA	Inhibitor
DMISRMT	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMISRMT	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMISRMT	DI	DMISRMT
DMISRMT	DN	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide
DMISRMT	MI	TT5ZKDI
DMISRMT	MN	Histone deacetylase 6 (HDAC6)
DMISRMT	MT	DTT
DMISRMT	MA	Inhibitor
DMISRMT	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMISRMT	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMISRMT	DI	DMISRMT
DMISRMT	DN	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide
DMISRMT	MI	TTT6LFV
DMISRMT	MN	Histone deacetylase 8 (HDAC8)
DMISRMT	MT	DTT
DMISRMT	MA	Inhibitor
DMISRMT	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMISRMT	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMSHQE3	DI	DMSHQE3
DMSHQE3	DN	N-hydroxy-4-(naphthalen-1-yl)benzamide
DMSHQE3	MI	TT2J34L
DMSHQE3	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMSHQE3	MT	DTT
DMSHQE3	MA	Inhibitor
DMSHQE3	RN	Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8.
DMSHQE3	RU	https://pubmed.ncbi.nlm.nih.gov/2308149

DMSHQE3	DI	DMSHQE3
DMSHQE3	DN	N-hydroxy-4-(naphthalen-1-yl)benzamide
DMSHQE3	MI	TTT6LFV
DMSHQE3	MN	Histone deacetylase 8 (HDAC8)
DMSHQE3	MT	DTT
DMSHQE3	MA	Inhibitor
DMSHQE3	RN	Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors. Bioorg Med Chem Lett. 2007 May 15;17(10):2874-8.
DMSHQE3	RU	https://pubmed.ncbi.nlm.nih.gov/17346959

DMUSHZK	DI	DMUSHZK
DMUSHZK	DN	N-hydroxy-4-(oleamidomethyl)benzamide
DMUSHZK	MI	TTIQSC1
DMUSHZK	MN	Bacterial Lethal factor (Bact lef)
DMUSHZK	MT	DTT
DMUSHZK	MA	Inhibitor
DMUSHZK	RN	Inhibitors of anthrax lethal factor based upon N-oleoyldopamine. Bioorg Med Chem Lett. 2008 Apr 1;18(7):2467-70.
DMUSHZK	RU	https://pubmed.ncbi.nlm.nih.gov/18314330

DMGTNQY	DI	DMGTNQY
DMGTNQY	DN	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide
DMGTNQY	MI	TTBH0VX
DMGTNQY	MN	Histone deacetylase (HDAC)
DMGTNQY	MT	DTT
DMGTNQY	MA	Inhibitor
DMGTNQY	RN	Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74.
DMGTNQY	RU	https://pubmed.ncbi.nlm.nih.gov/14711316

DMGTNQY	DI	DMGTNQY
DMGTNQY	DN	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide
DMGTNQY	MI	TT6R7JZ
DMGTNQY	MN	Histone deacetylase 1 (HDAC1)
DMGTNQY	MT	DTT
DMGTNQY	MA	Inhibitor
DMGTNQY	RN	Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74.
DMGTNQY	RU	https://pubmed.ncbi.nlm.nih.gov/14711316

DMGTNQY	DI	DMGTNQY
DMGTNQY	DN	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide
DMGTNQY	MI	TTYHPU6
DMGTNQY	MN	Histone deacetylase 10 (HDAC10)
DMGTNQY	MT	DTT
DMGTNQY	MA	Inhibitor
DMGTNQY	RN	Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74.
DMGTNQY	RU	https://pubmed.ncbi.nlm.nih.gov/14711316

DMGTNQY	DI	DMGTNQY
DMGTNQY	DN	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide
DMGTNQY	MI	TTSHTOI
DMGTNQY	MN	Histone deacetylase 2 (HDAC2)
DMGTNQY	MT	DTT
DMGTNQY	MA	Inhibitor
DMGTNQY	RN	Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74.
DMGTNQY	RU	https://pubmed.ncbi.nlm.nih.gov/14711316

DMGTNQY	DI	DMGTNQY
DMGTNQY	DN	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide
DMGTNQY	MI	TTTQGH8
DMGTNQY	MN	Histone deacetylase 4 (HDAC4)
DMGTNQY	MT	DTT
DMGTNQY	MA	Inhibitor
DMGTNQY	RN	Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74.
DMGTNQY	RU	https://pubmed.ncbi.nlm.nih.gov/14711316

DMGTNQY	DI	DMGTNQY
DMGTNQY	DN	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide
DMGTNQY	MI	TT5ZKDI
DMGTNQY	MN	Histone deacetylase 6 (HDAC6)
DMGTNQY	MT	DTT
DMGTNQY	MA	Inhibitor
DMGTNQY	RN	Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74.
DMGTNQY	RU	https://pubmed.ncbi.nlm.nih.gov/14711316

DMGTNQY	DI	DMGTNQY
DMGTNQY	DN	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide
DMGTNQY	MI	TTT6LFV
DMGTNQY	MN	Histone deacetylase 8 (HDAC8)
DMGTNQY	MT	DTT
DMGTNQY	MA	Inhibitor
DMGTNQY	RN	Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74.
DMGTNQY	RU	https://pubmed.ncbi.nlm.nih.gov/14711316

DMDUOH4	DI	DMDUOH4
DMDUOH4	DN	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide
DMDUOH4	MI	TTBH0VX
DMDUOH4	MN	Histone deacetylase (HDAC)
DMDUOH4	MT	DTT
DMDUOH4	MA	Inhibitor
DMDUOH4	RN	Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74.
DMDUOH4	RU	https://pubmed.ncbi.nlm.nih.gov/14711316

DMDUOH4	DI	DMDUOH4
DMDUOH4	DN	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide
DMDUOH4	MI	TT6R7JZ
DMDUOH4	MN	Histone deacetylase 1 (HDAC1)
DMDUOH4	MT	DTT
DMDUOH4	MA	Inhibitor
DMDUOH4	RN	Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74.
DMDUOH4	RU	https://pubmed.ncbi.nlm.nih.gov/14711316

DMDUOH4	DI	DMDUOH4
DMDUOH4	DN	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide
DMDUOH4	MI	TTYHPU6
DMDUOH4	MN	Histone deacetylase 10 (HDAC10)
DMDUOH4	MT	DTT
DMDUOH4	MA	Inhibitor
DMDUOH4	RN	Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74.
DMDUOH4	RU	https://pubmed.ncbi.nlm.nih.gov/14711316

DMDUOH4	DI	DMDUOH4
DMDUOH4	DN	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide
DMDUOH4	MI	TTSHTOI
DMDUOH4	MN	Histone deacetylase 2 (HDAC2)
DMDUOH4	MT	DTT
DMDUOH4	MA	Inhibitor
DMDUOH4	RN	Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74.
DMDUOH4	RU	https://pubmed.ncbi.nlm.nih.gov/14711316

DMDUOH4	DI	DMDUOH4
DMDUOH4	DN	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide
DMDUOH4	MI	TTTQGH8
DMDUOH4	MN	Histone deacetylase 4 (HDAC4)
DMDUOH4	MT	DTT
DMDUOH4	MA	Inhibitor
DMDUOH4	RN	Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74.
DMDUOH4	RU	https://pubmed.ncbi.nlm.nih.gov/14711316

DMDUOH4	DI	DMDUOH4
DMDUOH4	DN	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide
DMDUOH4	MI	TT5ZKDI
DMDUOH4	MN	Histone deacetylase 6 (HDAC6)
DMDUOH4	MT	DTT
DMDUOH4	MA	Inhibitor
DMDUOH4	RN	Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74.
DMDUOH4	RU	https://pubmed.ncbi.nlm.nih.gov/14711316

DMDUOH4	DI	DMDUOH4
DMDUOH4	DN	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide
DMDUOH4	MI	TTT6LFV
DMDUOH4	MN	Histone deacetylase 8 (HDAC8)
DMDUOH4	MT	DTT
DMDUOH4	MA	Inhibitor
DMDUOH4	RN	Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74.
DMDUOH4	RU	https://pubmed.ncbi.nlm.nih.gov/14711316

DMEO7L5	DI	DMEO7L5
DMEO7L5	DN	N-Hydroxy-4-iodo-benzamide
DMEO7L5	MI	TT2J34L
DMEO7L5	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMEO7L5	MT	DTT
DMEO7L5	MA	Inhibitor
DMEO7L5	RN	Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8.
DMEO7L5	RU	https://pubmed.ncbi.nlm.nih.gov/2308149

DM16G80	DI	DM16G80
DM16G80	DN	N-Hydroxy-4-isobutyl-benzamide
DM16G80	MI	TT2J34L
DM16G80	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM16G80	MT	DTT
DM16G80	MA	Inhibitor
DM16G80	RN	Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8.
DM16G80	RU	https://pubmed.ncbi.nlm.nih.gov/2308149

DMMHQE8	DI	DMMHQE8
DMMHQE8	DN	N-Hydroxy-4-naphthalen-2-yl-benzamide
DMMHQE8	MI	TT2J34L
DMMHQE8	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMMHQE8	MT	DTT
DMMHQE8	MA	Inhibitor
DMMHQE8	RN	Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8.
DMMHQE8	RU	https://pubmed.ncbi.nlm.nih.gov/2308149

DMQSWO8	DI	DMQSWO8
DMQSWO8	DN	N-Hydroxy-4-oxo-4-(4-phenoxy-phenyl)-butyramide
DMQSWO8	MI	TTMX39J
DMQSWO8	MN	Matrix metalloproteinase-1 (MMP-1)
DMQSWO8	MT	DTT
DMQSWO8	MA	Inhibitor
DMQSWO8	RN	Receptor flexibility in de novo ligand design and docking. J Med Chem. 2005 Oct 20;48(21):6585-96.
DMQSWO8	RU	https://pubmed.ncbi.nlm.nih.gov/16220975

DMCRU17	DI	DMCRU17
DMCRU17	DN	N-Hydroxy-4-phenylacetylamino-benzamide
DMCRU17	MI	TTBH0VX
DMCRU17	MN	Histone deacetylase (HDAC)
DMCRU17	MT	DTT
DMCRU17	MA	Inhibitor
DMCRU17	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMCRU17	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMCRU17	DI	DMCRU17
DMCRU17	DN	N-Hydroxy-4-phenylacetylamino-benzamide
DMCRU17	MI	TT6R7JZ
DMCRU17	MN	Histone deacetylase 1 (HDAC1)
DMCRU17	MT	DTT
DMCRU17	MA	Inhibitor
DMCRU17	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMCRU17	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMCRU17	DI	DMCRU17
DMCRU17	DN	N-Hydroxy-4-phenylacetylamino-benzamide
DMCRU17	MI	TTYHPU6
DMCRU17	MN	Histone deacetylase 10 (HDAC10)
DMCRU17	MT	DTT
DMCRU17	MA	Inhibitor
DMCRU17	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMCRU17	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMCRU17	DI	DMCRU17
DMCRU17	DN	N-Hydroxy-4-phenylacetylamino-benzamide
DMCRU17	MI	TTSHTOI
DMCRU17	MN	Histone deacetylase 2 (HDAC2)
DMCRU17	MT	DTT
DMCRU17	MA	Inhibitor
DMCRU17	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMCRU17	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMCRU17	DI	DMCRU17
DMCRU17	DN	N-Hydroxy-4-phenylacetylamino-benzamide
DMCRU17	MI	TTTQGH8
DMCRU17	MN	Histone deacetylase 4 (HDAC4)
DMCRU17	MT	DTT
DMCRU17	MA	Inhibitor
DMCRU17	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMCRU17	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMCRU17	DI	DMCRU17
DMCRU17	DN	N-Hydroxy-4-phenylacetylamino-benzamide
DMCRU17	MI	TT5ZKDI
DMCRU17	MN	Histone deacetylase 6 (HDAC6)
DMCRU17	MT	DTT
DMCRU17	MA	Inhibitor
DMCRU17	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMCRU17	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMCRU17	DI	DMCRU17
DMCRU17	DN	N-Hydroxy-4-phenylacetylamino-benzamide
DMCRU17	MI	TTT6LFV
DMCRU17	MN	Histone deacetylase 8 (HDAC8)
DMCRU17	MT	DTT
DMCRU17	MA	Inhibitor
DMCRU17	RN	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
DMCRU17	RU	https://pubmed.ncbi.nlm.nih.gov/16107152

DMYKJZ2	DI	DMYKJZ2
DMYKJZ2	DN	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide
DMYKJZ2	MI	TT6R7JZ
DMYKJZ2	MN	Histone deacetylase 1 (HDAC1)
DMYKJZ2	MT	DTT
DMYKJZ2	MA	Inhibitor
DMYKJZ2	RN	Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibit... Bioorg Med Chem Lett. 2007 Jan 15;17(2):363-9.
DMYKJZ2	RU	https://pubmed.ncbi.nlm.nih.gov/17107790

DMK98LE	DI	DMK98LE
DMK98LE	DN	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide
DMK98LE	MI	TT6R7JZ
DMK98LE	MN	Histone deacetylase 1 (HDAC1)
DMK98LE	MT	DTT
DMK98LE	MA	Inhibitor
DMK98LE	RN	Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibit... Bioorg Med Chem Lett. 2007 Jan 15;17(2):363-9.
DMK98LE	RU	https://pubmed.ncbi.nlm.nih.gov/17107790

DM653RM	DI	DM653RM
DM653RM	DN	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide
DM653RM	MI	TT6R7JZ
DM653RM	MN	Histone deacetylase 1 (HDAC1)
DM653RM	MT	DTT
DM653RM	MA	Inhibitor
DM653RM	RN	Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibit... Bioorg Med Chem Lett. 2007 Jan 15;17(2):363-9.
DM653RM	RU	https://pubmed.ncbi.nlm.nih.gov/17107790

DMA2WUQ	DI	DMA2WUQ
DMA2WUQ	DN	N-hydroxy-5-phenylthiophene-2-carboxamide
DMA2WUQ	MI	TT6R7JZ
DMA2WUQ	MN	Histone deacetylase 1 (HDAC1)
DMA2WUQ	MT	DTT
DMA2WUQ	MA	Inhibitor
DMA2WUQ	RN	Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibit... Bioorg Med Chem Lett. 2007 Jan 15;17(2):363-9.
DMA2WUQ	RU	https://pubmed.ncbi.nlm.nih.gov/17107790

DM0JNO2	DI	DM0JNO2
DM0JNO2	DN	N-hydroxy-6-oxo-6-phenylhexanamide
DM0JNO2	MI	TT6R7JZ
DM0JNO2	MN	Histone deacetylase 1 (HDAC1)
DM0JNO2	MT	DTT
DM0JNO2	MA	Inhibitor
DM0JNO2	RN	3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. Eur J Med Chem. 2009 Jul;44(7):2868-76.
DM0JNO2	RU	https://pubmed.ncbi.nlm.nih.gov/19136179

DMUXZL1	DI	DMUXZL1
DMUXZL1	DN	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide
DMUXZL1	MI	TT6R7JZ
DMUXZL1	MN	Histone deacetylase 1 (HDAC1)
DMUXZL1	MT	DTT
DMUXZL1	MA	Inhibitor
DMUXZL1	RN	3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. Eur J Med Chem. 2009 Jul;44(7):2868-76.
DMUXZL1	RU	https://pubmed.ncbi.nlm.nih.gov/19136179

DM8Z4L0	DI	DM8Z4L0
DM8Z4L0	DN	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide
DM8Z4L0	MI	TT6R7JZ
DM8Z4L0	MN	Histone deacetylase 1 (HDAC1)
DM8Z4L0	MT	DTT
DM8Z4L0	MA	Inhibitor
DM8Z4L0	RN	3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. Eur J Med Chem. 2009 Jul;44(7):2868-76.
DM8Z4L0	RU	https://pubmed.ncbi.nlm.nih.gov/19136179

DMBUNAP	DI	DMBUNAP
DMBUNAP	DN	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide
DMBUNAP	MI	TT6R7JZ
DMBUNAP	MN	Histone deacetylase 1 (HDAC1)
DMBUNAP	MT	DTT
DMBUNAP	MA	Inhibitor
DMBUNAP	RN	Structure-activity relationships of aryloxyalkanoic acid hydroxyamides as potent inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2007 Jan 1;17(1):136-41.
DMBUNAP	RU	https://pubmed.ncbi.nlm.nih.gov/17046252

DMQW7JZ	DI	DMQW7JZ
DMQW7JZ	DN	N-hydroxy-7-oxo-7-phenylheptanamide
DMQW7JZ	MI	TT6R7JZ
DMQW7JZ	MN	Histone deacetylase 1 (HDAC1)
DMQW7JZ	MT	DTT
DMQW7JZ	MA	Inhibitor
DMQW7JZ	RN	3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. Eur J Med Chem. 2009 Jul;44(7):2868-76.
DMQW7JZ	RU	https://pubmed.ncbi.nlm.nih.gov/19136179

DMSIMNR	DI	DMSIMNR
DMSIMNR	DN	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide
DMSIMNR	MI	TT6R7JZ
DMSIMNR	MN	Histone deacetylase 1 (HDAC1)
DMSIMNR	MT	DTT
DMSIMNR	MA	Inhibitor
DMSIMNR	RN	3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. Eur J Med Chem. 2009 Jul;44(7):2868-76.
DMSIMNR	RU	https://pubmed.ncbi.nlm.nih.gov/19136179

DMD2K4T	DI	DMD2K4T
DMD2K4T	DN	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide
DMD2K4T	MI	TT6R7JZ
DMD2K4T	MN	Histone deacetylase 1 (HDAC1)
DMD2K4T	MT	DTT
DMD2K4T	MA	Inhibitor
DMD2K4T	RN	3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. Eur J Med Chem. 2009 Jul;44(7):2868-76.
DMD2K4T	RU	https://pubmed.ncbi.nlm.nih.gov/19136179

DMRN1C6	DI	DMRN1C6
DMRN1C6	DN	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide
DMRN1C6	MI	TT6R7JZ
DMRN1C6	MN	Histone deacetylase 1 (HDAC1)
DMRN1C6	MT	DTT
DMRN1C6	MA	Inhibitor
DMRN1C6	RN	3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. Eur J Med Chem. 2009 Jul;44(7):2868-76.
DMRN1C6	RU	https://pubmed.ncbi.nlm.nih.gov/19136179

DMGZY1Q	DI	DMGZY1Q
DMGZY1Q	DN	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide
DMGZY1Q	MI	TT6R7JZ
DMGZY1Q	MN	Histone deacetylase 1 (HDAC1)
DMGZY1Q	MT	DTT
DMGZY1Q	MA	Inhibitor
DMGZY1Q	RN	3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. Eur J Med Chem. 2009 Jul;44(7):2868-76.
DMGZY1Q	RU	https://pubmed.ncbi.nlm.nih.gov/19136179

DMXQICK	DI	DMXQICK
DMXQICK	DN	N-hydroxy-8-(naphthalen-2-yl)octanamide
DMXQICK	MI	TT6R7JZ
DMXQICK	MN	Histone deacetylase 1 (HDAC1)
DMXQICK	MT	DTT
DMXQICK	MA	Inhibitor
DMXQICK	RN	3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. Eur J Med Chem. 2009 Jul;44(7):2868-76.
DMXQICK	RU	https://pubmed.ncbi.nlm.nih.gov/19136179

DMO4CR7	DI	DMO4CR7
DMO4CR7	DN	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide
DMO4CR7	MI	TT6R7JZ
DMO4CR7	MN	Histone deacetylase 1 (HDAC1)
DMO4CR7	MT	DTT
DMO4CR7	MA	Inhibitor
DMO4CR7	RN	3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. Eur J Med Chem. 2009 Jul;44(7):2868-76.
DMO4CR7	RU	https://pubmed.ncbi.nlm.nih.gov/19136179

DMID3BF	DI	DMID3BF
DMID3BF	DN	N-hydroxy-9,10-dihydroanthracene-9-carboxamide
DMID3BF	MI	TTBH0VX
DMID3BF	MN	Histone deacetylase (HDAC)
DMID3BF	MT	DTT
DMID3BF	MA	Inhibitor
DMID3BF	RN	Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5684-8.
DMID3BF	RU	https://pubmed.ncbi.nlm.nih.gov/19699639

DMID3BF	DI	DMID3BF
DMID3BF	DN	N-hydroxy-9,10-dihydroanthracene-9-carboxamide
DMID3BF	MI	TTTQGH8
DMID3BF	MN	Histone deacetylase 4 (HDAC4)
DMID3BF	MT	DTT
DMID3BF	MA	Inhibitor
DMID3BF	RN	Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5684-8.
DMID3BF	RU	https://pubmed.ncbi.nlm.nih.gov/19699639

DM0DRHP	DI	DM0DRHP
DM0DRHP	DN	N-hydroxy-9H-xanthene-9-carboxamide
DM0DRHP	MI	TTBH0VX
DM0DRHP	MN	Histone deacetylase (HDAC)
DM0DRHP	MT	DTT
DM0DRHP	MA	Inhibitor
DM0DRHP	RN	Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5684-8.
DM0DRHP	RU	https://pubmed.ncbi.nlm.nih.gov/19699639

DM0DRHP	DI	DM0DRHP
DM0DRHP	DN	N-hydroxy-9H-xanthene-9-carboxamide
DM0DRHP	MI	TTTQGH8
DM0DRHP	MN	Histone deacetylase 4 (HDAC4)
DM0DRHP	MT	DTT
DM0DRHP	MA	Inhibitor
DM0DRHP	RN	Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5684-8.
DM0DRHP	RU	https://pubmed.ncbi.nlm.nih.gov/19699639

DMIC2A8	DI	DMIC2A8
DMIC2A8	DN	N-hydroxy-9-oxo-9-phenylnonanamide
DMIC2A8	MI	TT6R7JZ
DMIC2A8	MN	Histone deacetylase 1 (HDAC1)
DMIC2A8	MT	DTT
DMIC2A8	MA	Inhibitor
DMIC2A8	RN	3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. Eur J Med Chem. 2009 Jul;44(7):2868-76.
DMIC2A8	RU	https://pubmed.ncbi.nlm.nih.gov/19136179

DMR4J8G	DI	DMR4J8G
DMR4J8G	DN	N-hydroxybenzo[b]thiophene-2-carboxamide
DMR4J8G	MI	TT6R7JZ
DMR4J8G	MN	Histone deacetylase 1 (HDAC1)
DMR4J8G	MT	DTT
DMR4J8G	MA	Inhibitor
DMR4J8G	RN	Histone deacetylase inhibitors: from bench to clinic. J Med Chem. 2008 Mar 27;51(6):1505-29.
DMR4J8G	RU	https://pubmed.ncbi.nlm.nih.gov/18247554

DM41JIB	DI	DM41JIB
DM41JIB	DN	N-Hydroxycarbamoylmethyl-4-methoxy-benzamide
DM41JIB	MI	TTMX39J
DM41JIB	MN	Matrix metalloproteinase-1 (MMP-1)
DM41JIB	MT	DTT
DM41JIB	MA	Inhibitor
DM41JIB	RN	Receptor flexibility in de novo ligand design and docking. J Med Chem. 2005 Oct 20;48(21):6585-96.
DM41JIB	RU	https://pubmed.ncbi.nlm.nih.gov/16220975

DMDTX4L	DI	DMDTX4L
DMDTX4L	DN	N-Hydroxycarbamoylmethyl-4-phenoxy-benzamide
DMDTX4L	MI	TTMX39J
DMDTX4L	MN	Matrix metalloproteinase-1 (MMP-1)
DMDTX4L	MT	DTT
DMDTX4L	MA	Inhibitor
DMDTX4L	RN	Receptor flexibility in de novo ligand design and docking. J Med Chem. 2005 Oct 20;48(21):6585-96.
DMDTX4L	RU	https://pubmed.ncbi.nlm.nih.gov/16220975

DM3J5MR	DI	DM3J5MR
DM3J5MR	DN	N-Hydroxy-E-3-(4'-chlorobiphenyl-4-yl)-acrylamide
DM3J5MR	MI	TTSHTOI
DM3J5MR	MN	Histone deacetylase 2 (HDAC2)
DM3J5MR	MT	DTT
DM3J5MR	MA	Inhibitor
DM3J5MR	RN	Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. Eur J Med Chem. 2009 May;44(5):1900-12.
DM3J5MR	RU	https://pubmed.ncbi.nlm.nih.gov/19084294

DMVFKO4	DI	DMVFKO4
DMVFKO4	DN	N-Hydroxy-E-3-(4'-cyanobiphenyl-4-yl)-acrylamide
DMVFKO4	MI	TTSHTOI
DMVFKO4	MN	Histone deacetylase 2 (HDAC2)
DMVFKO4	MT	DTT
DMVFKO4	MA	Inhibitor
DMVFKO4	RN	Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. Eur J Med Chem. 2009 May;44(5):1900-12.
DMVFKO4	RU	https://pubmed.ncbi.nlm.nih.gov/19084294

DMQCK5G	DI	DMQCK5G
DMQCK5G	DN	N-Hydroxy-E-3-(biphenyl-4-yl)-acrylamide
DMQCK5G	MI	TTSHTOI
DMQCK5G	MN	Histone deacetylase 2 (HDAC2)
DMQCK5G	MT	DTT
DMQCK5G	MA	Inhibitor
DMQCK5G	RN	Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. Eur J Med Chem. 2009 May;44(5):1900-12.
DMQCK5G	RU	https://pubmed.ncbi.nlm.nih.gov/19084294

DM865Y2	DI	DM865Y2
DM865Y2	DN	N-Hydroxy-N'-(2-methylphenyl)octanediamide
DM865Y2	MI	TTBH0VX
DM865Y2	MN	Histone deacetylase (HDAC)
DM865Y2	MT	DTT
DM865Y2	MA	Inhibitor
DM865Y2	RN	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50.
DM865Y2	RU	https://pubmed.ncbi.nlm.nih.gov/20143840

DM865Y2	DI	DM865Y2
DM865Y2	DN	N-Hydroxy-N'-(2-methylphenyl)octanediamide
DM865Y2	MI	TT6R7JZ
DM865Y2	MN	Histone deacetylase 1 (HDAC1)
DM865Y2	MT	DTT
DM865Y2	MA	Inhibitor
DM865Y2	RN	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50.
DM865Y2	RU	https://pubmed.ncbi.nlm.nih.gov/20143840

DMYRC2M	DI	DMYRC2M
DMYRC2M	DN	N-Hydroxy-N'-(3-methylphenyl)octanediamide
DMYRC2M	MI	TTBH0VX
DMYRC2M	MN	Histone deacetylase (HDAC)
DMYRC2M	MT	DTT
DMYRC2M	MA	Inhibitor
DMYRC2M	RN	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50.
DMYRC2M	RU	https://pubmed.ncbi.nlm.nih.gov/20143840

DMYRC2M	DI	DMYRC2M
DMYRC2M	DN	N-Hydroxy-N'-(3-methylphenyl)octanediamide
DMYRC2M	MI	TT6R7JZ
DMYRC2M	MN	Histone deacetylase 1 (HDAC1)
DMYRC2M	MT	DTT
DMYRC2M	MA	Inhibitor
DMYRC2M	RN	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50.
DMYRC2M	RU	https://pubmed.ncbi.nlm.nih.gov/20143840

DMELB07	DI	DMELB07
DMELB07	DN	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide
DMELB07	MI	TTBH0VX
DMELB07	MN	Histone deacetylase (HDAC)
DMELB07	MT	DTT
DMELB07	MA	Inhibitor
DMELB07	RN	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50.
DMELB07	RU	https://pubmed.ncbi.nlm.nih.gov/20143840

DMELB07	DI	DMELB07
DMELB07	DN	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide
DMELB07	MI	TT6R7JZ
DMELB07	MN	Histone deacetylase 1 (HDAC1)
DMELB07	MT	DTT
DMELB07	MA	Inhibitor
DMELB07	RN	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50.
DMELB07	RU	https://pubmed.ncbi.nlm.nih.gov/20143840

DM3DPZ8	DI	DM3DPZ8
DM3DPZ8	DN	N-Hydroxy-N'-(4-methylphenyl)octanediamide
DM3DPZ8	MI	TTBH0VX
DM3DPZ8	MN	Histone deacetylase (HDAC)
DM3DPZ8	MT	DTT
DM3DPZ8	MA	Inhibitor
DM3DPZ8	RN	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50.
DM3DPZ8	RU	https://pubmed.ncbi.nlm.nih.gov/20143840

DM3DPZ8	DI	DM3DPZ8
DM3DPZ8	DN	N-Hydroxy-N'-(4-methylphenyl)octanediamide
DM3DPZ8	MI	TT6R7JZ
DM3DPZ8	MN	Histone deacetylase 1 (HDAC1)
DM3DPZ8	MT	DTT
DM3DPZ8	MA	Inhibitor
DM3DPZ8	RN	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50.
DM3DPZ8	RU	https://pubmed.ncbi.nlm.nih.gov/20143840

DM4E8NJ	DI	DM4E8NJ
DM4E8NJ	DN	N-hydroxy-N-[1-(4-isobutylphenyl)ethyl]urea
DM4E8NJ	MI	TT2J34L
DM4E8NJ	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM4E8NJ	MT	DTT
DM4E8NJ	MA	Inhibitor
DM4E8NJ	RN	Nonsteroidal anti-inflammatory drugs as scaffolds for the design of 5-lipoxygenase inhibitors. J Med Chem. 1997 Feb 28;40(5):819-24.
DM4E8NJ	RU	https://pubmed.ncbi.nlm.nih.gov/9057869

DM4E8NJ	DI	DM4E8NJ
DM4E8NJ	DN	N-hydroxy-N-[1-(4-isobutylphenyl)ethyl]urea
DM4E8NJ	MI	TTSJ6Q4
DM4E8NJ	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DM4E8NJ	MT	DTT
DM4E8NJ	MA	Inhibitor
DM4E8NJ	RN	Nonsteroidal anti-inflammatory drugs as scaffolds for the design of 5-lipoxygenase inhibitors. J Med Chem. 1997 Feb 28;40(5):819-24.
DM4E8NJ	RU	https://pubmed.ncbi.nlm.nih.gov/9057869

DMQ4ST2	DI	DMQ4ST2
DMQ4ST2	DN	N-Hydroxy-N-methyl-2,3,3-triphenyl-acrylamide
DMQ4ST2	MI	TT2J34L
DMQ4ST2	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMQ4ST2	MT	DTT
DMQ4ST2	MA	Inhibitor
DMQ4ST2	RN	Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8.
DMQ4ST2	RU	https://pubmed.ncbi.nlm.nih.gov/2308149

DMNVD8I	DI	DMNVD8I
DMNVD8I	DN	N-Hydroxy-N-methyl-2-naphthalen-2-yl-propionamide
DMNVD8I	MI	TT2J34L
DMNVD8I	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMNVD8I	MT	DTT
DMNVD8I	MA	Inhibitor
DMNVD8I	RN	Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8.
DMNVD8I	RU	https://pubmed.ncbi.nlm.nih.gov/2308149

DMSRPI8	DI	DMSRPI8
DMSRPI8	DN	N-Hydroxy-N-methyl-3-naphthalen-1-yl-acrylamide
DMSRPI8	MI	TT2J34L
DMSRPI8	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMSRPI8	MT	DTT
DMSRPI8	MA	Inhibitor
DMSRPI8	RN	Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8.
DMSRPI8	RU	https://pubmed.ncbi.nlm.nih.gov/2308149

DMANTW0	DI	DMANTW0
DMANTW0	DN	N-Hydroxy-N-methyl-3-naphthalen-2-yl-acrylamide
DMANTW0	MI	TT2J34L
DMANTW0	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMANTW0	MT	DTT
DMANTW0	MA	Inhibitor
DMANTW0	RN	In vivo characterization of hydroxamic acid inhibitors of 5-lipoxygenase. J Med Chem. 1987 Nov;30(11):2121-6.
DMANTW0	RU	https://pubmed.ncbi.nlm.nih.gov/3669019

DMMYV34	DI	DMMYV34
DMMYV34	DN	N-Hydroxy-N-methyl-3-naphthalen-2-yl-propionamide
DMMYV34	MI	TT2J34L
DMMYV34	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMMYV34	MT	DTT
DMMYV34	MA	Inhibitor
DMMYV34	RN	Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8.
DMMYV34	RU	https://pubmed.ncbi.nlm.nih.gov/2308149

DMAN57F	DI	DMAN57F
DMAN57F	DN	N-Hydroxy-N-methyl-3-phenanthren-2-yl-acrylamide
DMAN57F	MI	TT2J34L
DMAN57F	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMAN57F	MT	DTT
DMAN57F	MA	Inhibitor
DMAN57F	RN	Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8.
DMAN57F	RU	https://pubmed.ncbi.nlm.nih.gov/2308149

DMV8UCK	DI	DMV8UCK
DMV8UCK	DN	N-Hydroxy-N-methyl-3-phenanthren-3-yl-acrylamide
DMV8UCK	MI	TT2J34L
DMV8UCK	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMV8UCK	MT	DTT
DMV8UCK	MA	Inhibitor
DMV8UCK	RN	Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8.
DMV8UCK	RU	https://pubmed.ncbi.nlm.nih.gov/2308149

DMQBD27	DI	DMQBD27
DMQBD27	DN	N-Hydroxy-N-methyl-3-phenanthren-9-yl-acrylamide
DMQBD27	MI	TT2J34L
DMQBD27	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMQBD27	MT	DTT
DMQBD27	MA	Inhibitor
DMQBD27	RN	Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8.
DMQBD27	RU	https://pubmed.ncbi.nlm.nih.gov/2308149

DMDQWOB	DI	DMDQWOB
DMDQWOB	DN	N-Hydroxy-N-methyl-benzamide
DMDQWOB	MI	TT2J34L
DMDQWOB	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMDQWOB	MT	DTT
DMDQWOB	MA	Inhibitor
DMDQWOB	RN	Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8.
DMDQWOB	RU	https://pubmed.ncbi.nlm.nih.gov/2308149

DMCIAJL	DI	DMCIAJL
DMCIAJL	DN	N-hydroxy-nor-L-arginine
DMCIAJL	MI	TTV1AG6
DMCIAJL	MN	Kidney-type arginase (ARG2)
DMCIAJL	MT	DTT
DMCIAJL	MA	Inhibitor
DMCIAJL	RN	Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation. 2003 Oct 21;108(16):2000-6.
DMCIAJL	RU	https://pubmed.ncbi.nlm.nih.gov/14517171

DMTDBMU	DI	DMTDBMU
DMTDBMU	DN	N-hydroxysulfamide
DMTDBMU	MI	TTHQPL7
DMTDBMU	MN	Carbonic anhydrase I (CA-I)
DMTDBMU	MT	DTT
DMTDBMU	MA	Inhibitor
DMTDBMU	RN	Carbonic anhydrase inhibitors: crystallographic and solution binding studies for the interaction of a boron-containing aromatic sulfamide with mamm... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3601-5.
DMTDBMU	RU	https://pubmed.ncbi.nlm.nih.gov/20472429

DMTDBMU	DI	DMTDBMU
DMTDBMU	DN	N-hydroxysulfamide
DMTDBMU	MI	TTANPDJ
DMTDBMU	MN	Carbonic anhydrase II (CA-II)
DMTDBMU	MT	DTT
DMTDBMU	MA	Inhibitor
DMTDBMU	RN	Carbonic anhydrase inhibitors: crystallographic and solution binding studies for the interaction of a boron-containing aromatic sulfamide with mamm... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3601-5.
DMTDBMU	RU	https://pubmed.ncbi.nlm.nih.gov/20472429

DMTDBMU	DI	DMTDBMU
DMTDBMU	DN	N-hydroxysulfamide
DMTDBMU	MI	TT2LVK8
DMTDBMU	MN	Carbonic anhydrase IX (CA-IX)
DMTDBMU	MT	DTT
DMTDBMU	MA	Inhibitor
DMTDBMU	RN	Carbonic anhydrase inhibitors: crystallographic and solution binding studies for the interaction of a boron-containing aromatic sulfamide with mamm... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3601-5.
DMTDBMU	RU	https://pubmed.ncbi.nlm.nih.gov/20472429

DMTDBMU	DI	DMTDBMU
DMTDBMU	DN	N-hydroxysulfamide
DMTDBMU	MI	TTSYM0R
DMTDBMU	MN	Carbonic anhydrase XII (CA-XII)
DMTDBMU	MT	DTT
DMTDBMU	MA	Inhibitor
DMTDBMU	RN	Carbonic anhydrase inhibitors: crystallographic and solution binding studies for the interaction of a boron-containing aromatic sulfamide with mamm... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3601-5.
DMTDBMU	RU	https://pubmed.ncbi.nlm.nih.gov/20472429

DMJBC03	DI	DMJBC03
DMJBC03	DN	N-hydroxysulfonamides
DMJBC03	MI	TTHQPL7
DMJBC03	MN	Carbonic anhydrase I (CA-I)
DMJBC03	MT	DTT
DMJBC03	MA	Inhibitor
DMJBC03	RN	Carbonic anhydrase inhibitors: inhibition of isozymes I, II and IV with N-hydroxysulfonamides--a novel class of intraocular pressure lowering agents. J Enzyme Inhib. 1998 Jul;13(4):267-84.
DMJBC03	RU	https://pubmed.ncbi.nlm.nih.gov/9795865

DMJBC03	DI	DMJBC03
DMJBC03	DN	N-hydroxysulfonamides
DMJBC03	MI	TTANPDJ
DMJBC03	MN	Carbonic anhydrase II (CA-II)
DMJBC03	MT	DTT
DMJBC03	MA	Inhibitor
DMJBC03	RN	Carbonic anhydrase inhibitors: inhibition of isozymes I, II and IV with N-hydroxysulfonamides--a novel class of intraocular pressure lowering agents. J Enzyme Inhib. 1998 Jul;13(4):267-84.
DMJBC03	RU	https://pubmed.ncbi.nlm.nih.gov/9795865

DMJBC03	DI	DMJBC03
DMJBC03	DN	N-hydroxysulfonamides
DMJBC03	MI	TTZHA0O
DMJBC03	MN	Carbonic anhydrase IV (CA-IV)
DMJBC03	MT	DTT
DMJBC03	MA	Inhibitor
DMJBC03	RN	Carbonic anhydrase inhibitors: inhibition of isozymes I, II and IV with N-hydroxysulfonamides--a novel class of intraocular pressure lowering agents. J Enzyme Inhib. 1998 Jul;13(4):267-84.
DMJBC03	RU	https://pubmed.ncbi.nlm.nih.gov/9795865

DMPK2JO	DI	DMPK2JO
DMPK2JO	DN	NI-105
DMPK2JO	MI	TTS87KH
DMPK2JO	MN	Microtubule-associated protein tau (MAPT)
DMPK2JO	MT	DTT
DMPK2JO	MA	Modulator
DMPK2JO	RN	Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des. 2011;17(31):3413-7.
DMPK2JO	RU	https://pubmed.ncbi.nlm.nih.gov/21902667

DM680XO	DI	DM680XO
DM680XO	DN	NI-1201
DM680XO	MI	TT0E5SK
DM680XO	MN	Interleukin 6 receptor (IL6R)
DM680XO	MT	DTT
DM680XO	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2310).
DM680XO	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2310

DMG9OBA	DI	DMG9OBA
DMG9OBA	DN	NI-1401
DMG9OBA	MI	TT69OHW
DMG9OBA	MN	Interleukin 17 receptor (IL17R)
DMG9OBA	MT	DTT
DMG9OBA	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2294).
DMG9OBA	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2294

DM52ITO	DI	DM52ITO
DM52ITO	DN	NI-57
DM52ITO	MI	TTT46BN
DM52ITO	MN	Bromodomain and PHD finger containing 1 (BRPF1)
DM52ITO	MT	DTT
DM52ITO	MA	Inhibitor
DM52ITO	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2730).
DM52ITO	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2730

DM52ITO	DI	DM52ITO
DM52ITO	DN	NI-57
DM52ITO	MI	TT1CHFI
DM52ITO	MN	Bromodomain and PHD finger containing 3 (BRPF3)
DM52ITO	MT	DTT
DM52ITO	MA	Inhibitor
DM52ITO	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2731).
DM52ITO	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2731

DM52ITO	DI	DM52ITO
DM52ITO	DN	NI-57
DM52ITO	MI	TTT09OB
DM52ITO	MN	Bromodomain-containing protein 1 (BRD1)
DM52ITO	MT	DTT
DM52ITO	MA	Inhibitor
DM52ITO	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2724).
DM52ITO	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2724

DMH6MVJ	DI	DMH6MVJ
DMH6MVJ	DN	NIBR-0213
DMH6MVJ	MI	TT9JZCK
DMH6MVJ	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMH6MVJ	MT	DTT
DMH6MVJ	MA	Antagonist
DMH6MVJ	RN	A potent and selective S1P(1) antagonist with efficacy in experimental autoimmune encephalomyelitis. Chem Biol. 2012 Sep 21;19(9):1142-51.
DMH6MVJ	RU	https://pubmed.ncbi.nlm.nih.gov/22999882

DMU0BMQ	DI	DMU0BMQ
DMU0BMQ	DN	NIBR-785
DMU0BMQ	MI	TT9JZCK
DMU0BMQ	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMU0BMQ	MT	DTT
DMU0BMQ	MA	Modulator
DMU0BMQ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 275).
DMU0BMQ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=275

DM4I6MD	DI	DM4I6MD
DM4I6MD	DN	NICARBAZIN
DM4I6MD	MI	TTDP1UC
DM4I6MD	MN	Fatty acid amide hydrolase (FAAH)
DM4I6MD	MT	DTT
DM4I6MD	MA	Inhibitor
DM4I6MD	RN	Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inh... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6793-6.
DM4I6MD	RU	https://pubmed.ncbi.nlm.nih.gov/19850474

DMI12Y8	DI	DMI12Y8
DMI12Y8	DN	Nickel chloride
DMI12Y8	MI	TT729IR
DMI12Y8	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DMI12Y8	MT	DTT
DMI12Y8	MA	Blocker
DMI12Y8	RN	T-type calcium channels facilitate insulin secretion by enhancing general excitability in the insulin-secreting beta-cell line, INS-1. Endocrinology. 1997 Sep;138(9):3735-40.
DMI12Y8	RU	https://pubmed.ncbi.nlm.nih.gov/9275059

DM0DFNJ	DI	DM0DFNJ
DM0DFNJ	DN	Nicotinaldehyde O-4-butoxyphenylcarbamoyl oxime
DM0DFNJ	MI	TTDP1UC
DM0DFNJ	MN	Fatty acid amide hydrolase (FAAH)
DM0DFNJ	MT	DTT
DM0DFNJ	MA	Inhibitor
DM0DFNJ	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DM0DFNJ	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DM957CK	DI	DM957CK
DM957CK	DN	Nicotinaldehyde O-4-ethoxyphenylcarbamoyl oxime
DM957CK	MI	TTDP1UC
DM957CK	MN	Fatty acid amide hydrolase (FAAH)
DM957CK	MT	DTT
DM957CK	MA	Inhibitor
DM957CK	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DM957CK	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DMC9WAL	DI	DMC9WAL
DMC9WAL	DN	Nicotinaldehyde O-4-propoxyphenylcarbamoyl oxime
DMC9WAL	MI	TTDP1UC
DMC9WAL	MN	Fatty acid amide hydrolase (FAAH)
DMC9WAL	MT	DTT
DMC9WAL	MA	Inhibitor
DMC9WAL	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DMC9WAL	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DM9LRKB	DI	DM9LRKB
DM9LRKB	DN	Nicotinamide-Adenine-Dinucleotide
DM9LRKB	MI	TTE2KUJ
DM9LRKB	MN	Adenosylhomocysteinase (AHCY)
DM9LRKB	MT	DTT
DM9LRKB	MA	Inhibitor
DM9LRKB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9LRKB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9LRKB	DI	DM9LRKB
DM9LRKB	DN	Nicotinamide-Adenine-Dinucleotide
DM9LRKB	MI	TTHCF4J
DM9LRKB	MN	Alpha-glucosidase (GLA)
DM9LRKB	MT	DTT
DM9LRKB	MA	Inhibitor
DM9LRKB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9LRKB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9LRKB	DI	DM9LRKB
DM9LRKB	DN	Nicotinamide-Adenine-Dinucleotide
DM9LRKB	MI	TTPS7KA
DM9LRKB	MN	Bacterial Dehydroquinate synthase (Bact aroB)
DM9LRKB	MT	DTT
DM9LRKB	MA	Inhibitor
DM9LRKB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9LRKB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9LRKB	DI	DM9LRKB
DM9LRKB	DN	Nicotinamide-Adenine-Dinucleotide
DM9LRKB	MI	TTVTX4N
DM9LRKB	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DM9LRKB	MT	DTT
DM9LRKB	MA	Inhibitor
DM9LRKB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9LRKB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9LRKB	DI	DM9LRKB
DM9LRKB	DN	Nicotinamide-Adenine-Dinucleotide
DM9LRKB	MI	TTNAW8S
DM9LRKB	MN	Bacterial Flavohemoglobin (Bact hmp)
DM9LRKB	MT	DTT
DM9LRKB	MA	Inhibitor
DM9LRKB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9LRKB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9LRKB	DI	DM9LRKB
DM9LRKB	DN	Nicotinamide-Adenine-Dinucleotide
DM9LRKB	MI	TT8WCXO
DM9LRKB	MN	Bacterial NH(3)-dependent NAD(+) synthetase (Bact nadE)
DM9LRKB	MT	DTT
DM9LRKB	MA	Inhibitor
DM9LRKB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9LRKB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9LRKB	DI	DM9LRKB
DM9LRKB	DN	Nicotinamide-Adenine-Dinucleotide
DM9LRKB	MI	TT1NFO3
DM9LRKB	MN	Bacterial Nicotinate-nucleotide adenylyltransferase (Bact nadD)
DM9LRKB	MT	DTT
DM9LRKB	MA	Inhibitor
DM9LRKB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9LRKB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9LRKB	DI	DM9LRKB
DM9LRKB	DN	Nicotinamide-Adenine-Dinucleotide
DM9LRKB	MI	TTJBPN3
DM9LRKB	MN	Biliverdin reductase A (BLVRA)
DM9LRKB	MT	DTT
DM9LRKB	MA	Inhibitor
DM9LRKB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9LRKB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9LRKB	DI	DM9LRKB
DM9LRKB	DN	Nicotinamide-Adenine-Dinucleotide
DM9LRKB	MI	TTBO2A9
DM9LRKB	MN	Deoxyhypusine synthase (DHPS)
DM9LRKB	MT	DTT
DM9LRKB	MA	Inhibitor
DM9LRKB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9LRKB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9LRKB	DI	DM9LRKB
DM9LRKB	DN	Nicotinamide-Adenine-Dinucleotide
DM9LRKB	MI	TTJS7O4
DM9LRKB	MN	Entamoeba Alcohol dehydrogenase 2 (Entamo ADH2)
DM9LRKB	MT	DTT
DM9LRKB	MA	Inhibitor
DM9LRKB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9LRKB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9LRKB	DI	DM9LRKB
DM9LRKB	DN	Nicotinamide-Adenine-Dinucleotide
DM9LRKB	MI	TTIWB6L
DM9LRKB	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DM9LRKB	MT	DTT
DM9LRKB	MA	Inhibitor
DM9LRKB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9LRKB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9LRKB	DI	DM9LRKB
DM9LRKB	DN	Nicotinamide-Adenine-Dinucleotide
DM9LRKB	MI	TTL1WGS
DM9LRKB	MN	Estradiol 17 beta-dehydrogenase 4 (HSD17B4)
DM9LRKB	MT	DTT
DM9LRKB	MA	Inhibitor
DM9LRKB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9LRKB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9LRKB	DI	DM9LRKB
DM9LRKB	DN	Nicotinamide-Adenine-Dinucleotide
DM9LRKB	MI	TTEP6RV
DM9LRKB	MN	Glutathione reductase (GR)
DM9LRKB	MT	DTT
DM9LRKB	MA	Inhibitor
DM9LRKB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9LRKB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9LRKB	DI	DM9LRKB
DM9LRKB	DN	Nicotinamide-Adenine-Dinucleotide
DM9LRKB	MI	TTWUDYC
DM9LRKB	MN	Haemophilus influenzae NadR protein (Hae-influ nadR)
DM9LRKB	MT	DTT
DM9LRKB	MA	Inhibitor
DM9LRKB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9LRKB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9LRKB	DI	DM9LRKB
DM9LRKB	DN	Nicotinamide-Adenine-Dinucleotide
DM9LRKB	MI	TTPADOQ
DM9LRKB	MN	HMG-CoA reductase (HMGCR)
DM9LRKB	MT	DTT
DM9LRKB	MA	Inhibitor
DM9LRKB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9LRKB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9LRKB	DI	DM9LRKB
DM9LRKB	DN	Nicotinamide-Adenine-Dinucleotide
DM9LRKB	MI	TTTB4UP
DM9LRKB	MN	Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2)
DM9LRKB	MT	DTT
DM9LRKB	MA	Inhibitor
DM9LRKB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9LRKB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9LRKB	DI	DM9LRKB
DM9LRKB	DN	Nicotinamide-Adenine-Dinucleotide
DM9LRKB	MI	TTXWASR
DM9LRKB	MN	Intestinal maltase-glucoamylase (MGAM)
DM9LRKB	MT	DTT
DM9LRKB	MA	Inhibitor
DM9LRKB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9LRKB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9LRKB	DI	DM9LRKB
DM9LRKB	DN	Nicotinamide-Adenine-Dinucleotide
DM9LRKB	MI	TTAZHU0
DM9LRKB	MN	L-lactate dehydrogenase (LDH)
DM9LRKB	MT	DTT
DM9LRKB	MA	Inhibitor
DM9LRKB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9LRKB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9LRKB	DI	DM9LRKB
DM9LRKB	DN	Nicotinamide-Adenine-Dinucleotide
DM9LRKB	MI	TTFLN4T
DM9LRKB	MN	Mitochondrial aldehyde dehydrogenase (ALDH2)
DM9LRKB	MT	DTT
DM9LRKB	MA	Inhibitor
DM9LRKB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9LRKB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9LRKB	DI	DM9LRKB
DM9LRKB	DN	Nicotinamide-Adenine-Dinucleotide
DM9LRKB	MI	TTNX2CS
DM9LRKB	MN	Plasmodium Enoyl-ACP reductase (Malaria fabI)
DM9LRKB	MT	DTT
DM9LRKB	MA	Inhibitor
DM9LRKB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9LRKB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9LRKB	DI	DM9LRKB
DM9LRKB	DN	Nicotinamide-Adenine-Dinucleotide
DM9LRKB	MI	TTKVNRF
DM9LRKB	MN	Pseudomonas Nicotinate-nucleotide adenylyltransferase (Pseudo nadD)
DM9LRKB	MT	DTT
DM9LRKB	MA	Inhibitor
DM9LRKB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9LRKB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9LRKB	DI	DM9LRKB
DM9LRKB	DN	Nicotinamide-Adenine-Dinucleotide
DM9LRKB	MI	TTLSRBZ
DM9LRKB	MN	Sorbitoldehydrogenase (SORD)
DM9LRKB	MT	DTT
DM9LRKB	MA	Inhibitor
DM9LRKB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9LRKB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9LRKB	DI	DM9LRKB
DM9LRKB	DN	Nicotinamide-Adenine-Dinucleotide
DM9LRKB	MI	TTBKQL3
DM9LRKB	MN	Trypanosoma Dihydrolipoamide dehydrogenase (Trypano LPD)
DM9LRKB	MT	DTT
DM9LRKB	MA	Inhibitor
DM9LRKB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9LRKB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9LRKB	DI	DM9LRKB
DM9LRKB	DN	Nicotinamide-Adenine-Dinucleotide
DM9LRKB	MI	TTGRHIB
DM9LRKB	MN	UDP-glucose 4-epimerase (GALE)
DM9LRKB	MT	DTT
DM9LRKB	MA	Inhibitor
DM9LRKB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9LRKB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMO7M2N	DI	DMO7M2N
DMO7M2N	DN	Nicotinyl alcohol
DMO7M2N	MI	DEJVYAZ
DMO7M2N	MN	Cytochrome P450 2A6 (CYP2A6)
DMO7M2N	MT	DME
DMO7M2N	MA	Metabolism
DMO7M2N	RN	Stability of the nicotine metabolite ratio in ad libitum and reducing smokers. Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1396-400.
DMO7M2N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18559554

DMIK40C	DI	DMIK40C
DMIK40C	DN	Nifeviroc
DMIK40C	MI	TT2CEJG
DMIK40C	MN	C-C chemokine receptor type 5 (CCR5)
DMIK40C	MT	DTT
DMIK40C	MA	Modulator
DMIK40C	RN	Determination of nifeviroc, a novel CCR5 antagonist: application to a pharmacokinetic study. J Pharm Biomed Anal. 2011 Nov 1;56(3):637-40.
DMIK40C	RU	https://pubmed.ncbi.nlm.nih.gov/21802236

DMDMG1O	DI	DMDMG1O
DMDMG1O	DN	NIHP
DMDMG1O	MI	TTMXGCW
DMDMG1O	MN	Adrenergic receptor beta-3 (ADRB3)
DMDMG1O	MT	DTT
DMDMG1O	MA	Antagonist
DMDMG1O	RN	LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors. Eur J Pharmacol. 1999 Feb 19;367(2-3):431-5.
DMDMG1O	RU	https://pubmed.ncbi.nlm.nih.gov/10079020

DM0QJSO	DI	DM0QJSO
DM0QJSO	DN	NILTUBACIN
DM0QJSO	MI	TT5ZKDI
DM0QJSO	MN	Histone deacetylase 6 (HDAC6)
DM0QJSO	MT	DTT
DM0QJSO	MA	Inhibitor
DM0QJSO	RN	Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010 Mar;6(3):238-243.
DM0QJSO	RU	https://pubmed.ncbi.nlm.nih.gov/20139990

DM0QJSO	DI	DM0QJSO
DM0QJSO	DN	NILTUBACIN
DM0QJSO	MI	TTT6LFV
DM0QJSO	MN	Histone deacetylase 8 (HDAC8)
DM0QJSO	MT	DTT
DM0QJSO	MA	Inhibitor
DM0QJSO	RN	Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010 Mar;6(3):238-243.
DM0QJSO	RU	https://pubmed.ncbi.nlm.nih.gov/20139990

DM8OGMA	DI	DM8OGMA
DM8OGMA	DN	Niludipine
DM8OGMA	MI	DE4LYSA
DM8OGMA	MN	Cytochrome P450 3A4 (CYP3A4)
DM8OGMA	MT	DME
DM8OGMA	MA	Metabolism
DM8OGMA	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DM8OGMA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DM8ZMB5	DI	DM8ZMB5
DM8ZMB5	DN	N-Indan-1-yl-2-(1H-indol-3-yl)-2-oxo-acetamide
DM8ZMB5	MI	TT1MPAY
DM8ZMB5	MN	GABA(A) receptor alpha-1 (GABRA1)
DM8ZMB5	MT	DTT
DM8ZMB5	MA	Inhibitor
DM8ZMB5	RN	Novel N-(arylalkyl)indol-3-ylglyoxylylamides targeted as ligands of the benzodiazepine receptor: synthesis, biological evaluation, and molecular mo... J Med Chem. 2001 Jul 5;44(14):2286-97.
DM8ZMB5	RU	https://pubmed.ncbi.nlm.nih.gov/11428922

DM8ZMB5	DI	DM8ZMB5
DM8ZMB5	DN	N-Indan-1-yl-2-(1H-indol-3-yl)-2-oxo-acetamide
DM8ZMB5	MI	TTZA1NY
DM8ZMB5	MN	GABA(A) receptor beta-2 (GABRB2)
DM8ZMB5	MT	DTT
DM8ZMB5	MA	Inhibitor
DM8ZMB5	RN	Novel N-(arylalkyl)indol-3-ylglyoxylylamides targeted as ligands of the benzodiazepine receptor: synthesis, biological evaluation, and molecular mo... J Med Chem. 2001 Jul 5;44(14):2286-97.
DM8ZMB5	RU	https://pubmed.ncbi.nlm.nih.gov/11428922

DM8ZMB5	DI	DM8ZMB5
DM8ZMB5	DN	N-Indan-1-yl-2-(1H-indol-3-yl)-2-oxo-acetamide
DM8ZMB5	MI	TT06RH5
DM8ZMB5	MN	GABA(A) receptor gamma-2 (GABRG2)
DM8ZMB5	MT	DTT
DM8ZMB5	MA	Inhibitor
DM8ZMB5	RN	Novel N-(arylalkyl)indol-3-ylglyoxylylamides targeted as ligands of the benzodiazepine receptor: synthesis, biological evaluation, and molecular mo... J Med Chem. 2001 Jul 5;44(14):2286-97.
DM8ZMB5	RU	https://pubmed.ncbi.nlm.nih.gov/11428922

DM8ZMB5	DI	DM8ZMB5
DM8ZMB5	DN	N-Indan-1-yl-2-(1H-indol-3-yl)-2-oxo-acetamide
DM8ZMB5	MI	TTNJYV2
DM8ZMB5	MN	Gamma-aminobutyric acid receptor (GAR)
DM8ZMB5	MT	DTT
DM8ZMB5	MA	Inhibitor
DM8ZMB5	RN	Novel N-(arylalkyl)indol-3-ylglyoxylylamides targeted as ligands of the benzodiazepine receptor: synthesis, biological evaluation, and molecular mo... J Med Chem. 2001 Jul 5;44(14):2286-97.
DM8ZMB5	RU	https://pubmed.ncbi.nlm.nih.gov/11428922

DMV53PH	DI	DMV53PH
DMV53PH	DN	NIP-142
DMV53PH	MI	TTW0CMT
DMV53PH	MN	Voltage-gated potassium channel Kv1.5 (KCNA5)
DMV53PH	MT	DTT
DMV53PH	MA	Blocker
DMV53PH	RN	New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22.
DMV53PH	RU	https://pubmed.ncbi.nlm.nih.gov/15934869

DMPV450	DI	DMPV450
DMPV450	DN	NIPECOTIC ACID
DMPV450	MI	TTJFY5U
DMPV450	MN	Adenosine A3 receptor (ADORA3)
DMPV450	MT	DTT
DMPV450	MA	Inhibitor
DMPV450	RN	2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96.
DMPV450	RU	https://pubmed.ncbi.nlm.nih.gov/16250647

DMPV450	DI	DMPV450
DMPV450	DN	NIPECOTIC ACID
DMPV450	MI	TTT2LD9
DMPV450	MN	GABA transaminase (ABAT)
DMPV450	MT	DTT
DMPV450	MA	Inhibitor
DMPV450	RN	Aminomethyl-1,2,4-benzothiadiazines as potential analogues of gamma-aminobutyric acid. Unexpected discovery of a taurine antagonist. J Med Chem. 1982 Feb;25(2):113-6.
DMPV450	RU	https://pubmed.ncbi.nlm.nih.gov/6276545

DMPV450	DI	DMPV450
DMPV450	DN	NIPECOTIC ACID
DMPV450	MI	TTPRKM0
DMPV450	MN	GABA transporter GAT-1 (SLC6A1)
DMPV450	MT	DTT
DMPV450	MA	Inhibitor
DMPV450	RN	Epimeric cis-decahydroquinoline-5-carboxylic acids: effects on gamma-aminobutyric acid uptake and receptor binding in vitro. J Med Chem. 1981 Jul;24(7):788-94.
DMPV450	RU	https://pubmed.ncbi.nlm.nih.gov/6268788

DMPV450	DI	DMPV450
DMPV450	DN	NIPECOTIC ACID
DMPV450	MI	TT8RXO5
DMPV450	MN	GABA transporter-3 (SLC6A11)
DMPV450	MT	DTT
DMPV450	MA	Inhibitor
DMPV450	RN	Epimeric cis-decahydroquinoline-5-carboxylic acids: effects on gamma-aminobutyric acid uptake and receptor binding in vitro. J Med Chem. 1981 Jul;24(7):788-94.
DMPV450	RU	https://pubmed.ncbi.nlm.nih.gov/6268788

DMPV450	DI	DMPV450
DMPV450	DN	NIPECOTIC ACID
DMPV450	MI	TTNJYV2
DMPV450	MN	Gamma-aminobutyric acid receptor (GAR)
DMPV450	MT	DTT
DMPV450	MA	Inhibitor
DMPV450	RN	Orally active and potent inhibitors of gamma-aminobutyric acid uptake. J Med Chem. 1985 May;28(5):653-60.
DMPV450	RU	https://pubmed.ncbi.nlm.nih.gov/2985785

DM1R0WC	DI	DM1R0WC
DM1R0WC	DN	NIS-62949
DM1R0WC	MI	TTZ97H5
DM1R0WC	MN	Phosphodiesterase 4A (PDE4A)
DM1R0WC	MT	DTT
DM1R0WC	MA	Inhibitor
DM1R0WC	RN	Pharmacology of a novel, orally active PDE4 inhibitor. Pharmacology. 2009;83(5):275-86.
DM1R0WC	RU	https://pubmed.ncbi.nlm.nih.gov/19321962

DMO4E9U	DI	DMO4E9U
DMO4E9U	DN	N-isobutyl-2-oxo-2H-chromene-3-carboxamide
DMO4E9U	MI	TTGP7BY
DMO4E9U	MN	Monoamine oxidase type B (MAO-B)
DMO4E9U	MT	DTT
DMO4E9U	MA	Inhibitor
DMO4E9U	RN	Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins. J Med Chem. 2009 Apr 9;52(7):1935-42.
DMO4E9U	RU	https://pubmed.ncbi.nlm.nih.gov/19267475

DM9Z6VP	DI	DM9Z6VP
DM9Z6VP	DN	N-isobutylnorlitebamine
DM9Z6VP	MI	TT1RS9F
DM9Z6VP	MN	Acetylcholinesterase (AChE)
DM9Z6VP	MT	DTT
DM9Z6VP	MA	Inhibitor
DM9Z6VP	RN	Litebamine N-homologues: preparation and anti-acetylcholinesterase activity. J Nat Prod. 1998 Jan;61(1):46-50.
DM9Z6VP	RU	https://pubmed.ncbi.nlm.nih.gov/9461651

DMN1FIU	DI	DMN1FIU
DMN1FIU	DN	N-isobutylnoroxymorphone
DMN1FIU	MI	TTQW87Y
DMN1FIU	MN	Opioid receptor kappa (OPRK1)
DMN1FIU	MT	DTT
DMN1FIU	MA	Inhibitor
DMN1FIU	RN	Synthesis of N-isobutylnoroxymorphone from naltrexone by a selective cyclopropane ring opening reaction. Bioorg Med Chem Lett. 2008 Sep 15;18(18):4978-81.
DMN1FIU	RU	https://pubmed.ncbi.nlm.nih.gov/18755589

DMN1FIU	DI	DMN1FIU
DMN1FIU	DN	N-isobutylnoroxymorphone
DMN1FIU	MI	TTKWM86
DMN1FIU	MN	Opioid receptor mu (MOP)
DMN1FIU	MT	DTT
DMN1FIU	MA	Inhibitor
DMN1FIU	RN	Synthesis of N-isobutylnoroxymorphone from naltrexone by a selective cyclopropane ring opening reaction. Bioorg Med Chem Lett. 2008 Sep 15;18(18):4978-81.
DMN1FIU	RU	https://pubmed.ncbi.nlm.nih.gov/18755589

DM53AS0	DI	DM53AS0
DM53AS0	DN	N-isoleucylthiazolidine
DM53AS0	MI	TTDIGC1
DM53AS0	MN	Dipeptidyl peptidase 4 (DPP-4)
DM53AS0	MT	DTT
DM53AS0	MA	Inhibitor
DM53AS0	RN	2-[3-[2-[(2S)-2-Cyano-1-pyrrolidinyl]-2-oxoethylamino]-3-methyl-1-oxobutyl]- 1,2,3,4-tetrahydroisoquinoline: a potent, selective, and orally bioava... J Med Chem. 2006 Jan 12;49(1):373-80.
DM53AS0	RU	https://pubmed.ncbi.nlm.nih.gov/16392822

DMC8L4J	DI	DMC8L4J
DMC8L4J	DN	N-isopentyl-5,6-dip-tolylpyrazine-2-carboxamide
DMC8L4J	MI	TT6OEDT
DMC8L4J	MN	Cannabinoid receptor 1 (CB1)
DMC8L4J	MT	DTT
DMC8L4J	MA	Inhibitor
DMC8L4J	RN	Discovery of pyrazine carboxamide CB1 antagonists: the introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy... Bioorg Med Chem Lett. 2007 Jul 15;17(14):3978-82.
DMC8L4J	RU	https://pubmed.ncbi.nlm.nih.gov/17513109

DMFSW5M	DI	DMFSW5M
DMFSW5M	DN	N-isopropyl estradiol-16-carboxamide
DMFSW5M	MI	TTIWB6L
DMFSW5M	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMFSW5M	MT	DTT
DMFSW5M	MA	Inhibitor
DMFSW5M	RN	Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45.
DMFSW5M	RU	https://pubmed.ncbi.nlm.nih.gov/16480268

DMHJMTI	DI	DMHJMTI
DMHJMTI	DN	N-isopropyl estradiol-16-methyl carboxamide
DMHJMTI	MI	TTIWB6L
DMHJMTI	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMHJMTI	MT	DTT
DMHJMTI	MA	Inhibitor
DMHJMTI	RN	Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45.
DMHJMTI	RU	https://pubmed.ncbi.nlm.nih.gov/16480268

DMZGMQJ	DI	DMZGMQJ
DMZGMQJ	DN	N-isopropyl estrone-16-methyl carboxamide
DMZGMQJ	MI	TTIWB6L
DMZGMQJ	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMZGMQJ	MT	DTT
DMZGMQJ	MA	Inhibitor
DMZGMQJ	RN	Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45.
DMZGMQJ	RU	https://pubmed.ncbi.nlm.nih.gov/16480268

DM14L7O	DI	DM14L7O
DM14L7O	DN	N-Isopropyl-1'H-phenothiazine-1'-carboxamide
DM14L7O	MI	TTEB0GD
DM14L7O	MN	Cholinesterase (BCHE)
DM14L7O	MT	DTT
DM14L7O	MA	Inhibitor
DM14L7O	RN	Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorg Med Chem. 2010 Mar 15;18(6):2232-2244.
DM14L7O	RU	https://pubmed.ncbi.nlm.nih.gov/20181484

DMRPUCA	DI	DMRPUCA
DMRPUCA	DN	N-isopropyl-5,6-dip-tolylpyrazine-2-carboxamide
DMRPUCA	MI	TT6OEDT
DMRPUCA	MN	Cannabinoid receptor 1 (CB1)
DMRPUCA	MT	DTT
DMRPUCA	MA	Inhibitor
DMRPUCA	RN	Discovery of pyrazine carboxamide CB1 antagonists: the introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy... Bioorg Med Chem Lett. 2007 Jul 15;17(14):3978-82.
DMRPUCA	RU	https://pubmed.ncbi.nlm.nih.gov/17513109

DMIVO8P	DI	DMIVO8P
DMIVO8P	DN	N-Isopropyl-N'-Hydroxyguanidine
DMIVO8P	MI	TTZUFI5
DMIVO8P	MN	Nitric-oxide synthase brain (NOS1)
DMIVO8P	MT	DTT
DMIVO8P	MA	Inhibitor
DMIVO8P	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMIVO8P	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMG8NB0	DI	DMG8NB0
DMG8NB0	DN	N-isopropylnorlitebamine
DMG8NB0	MI	TT1RS9F
DMG8NB0	MN	Acetylcholinesterase (AChE)
DMG8NB0	MT	DTT
DMG8NB0	MA	Inhibitor
DMG8NB0	RN	Litebamine N-homologues: preparation and anti-acetylcholinesterase activity. J Nat Prod. 1998 Jan;61(1):46-50.
DMG8NB0	RU	https://pubmed.ncbi.nlm.nih.gov/9461651

DMDVO9T	DI	DMDVO9T
DMDVO9T	DN	N-isopropylnorlitebamineN-methoiodide
DMDVO9T	MI	TT1RS9F
DMDVO9T	MN	Acetylcholinesterase (AChE)
DMDVO9T	MT	DTT
DMDVO9T	MA	Inhibitor
DMDVO9T	RN	Litebamine N-homologues: preparation and anti-acetylcholinesterase activity. J Nat Prod. 1998 Jan;61(1):46-50.
DMDVO9T	RU	https://pubmed.ncbi.nlm.nih.gov/9461651

DMZBNH0	DI	DMZBNH0
DMZBNH0	DN	Nisoxetine
DMZBNH0	MI	TTVBI8W
DMZBNH0	MN	Dopamine transporter (DAT)
DMZBNH0	MT	DTT
DMZBNH0	MA	Inhibitor
DMZBNH0	RN	Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI). Bioorg Med Chem Lett. 2008 Jul 15;18(14):4224-7.
DMZBNH0	RU	https://pubmed.ncbi.nlm.nih.gov/18550369

DMZBNH0	DI	DMZBNH0
DMZBNH0	DN	Nisoxetine
DMZBNH0	MI	TTAWNKZ
DMZBNH0	MN	Norepinephrine transporter (NET)
DMZBNH0	MT	DTT
DMZBNH0	MA	Inhibitor
DMZBNH0	RN	Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: a new class of selective norepinephrine reuptake inhibitors. Bioorg Med Chem Lett. 2008 Sep 15;18(18):4929-31.
DMZBNH0	RU	https://pubmed.ncbi.nlm.nih.gov/18771916

DMZBNH0	DI	DMZBNH0
DMZBNH0	DN	Nisoxetine
DMZBNH0	MI	TT3ROYC
DMZBNH0	MN	Serotonin transporter (SERT)
DMZBNH0	MT	DTT
DMZBNH0	MA	Inhibitor
DMZBNH0	RN	1-Naphthyl and 4-indolyl arylalkylamines as selective monoamine reuptake inhibitors. Bioorg Med Chem Lett. 2009 Jan 1;19(1):58-61.
DMZBNH0	RU	https://pubmed.ncbi.nlm.nih.gov/19038547

DMY59KQ	DI	DMY59KQ
DMY59KQ	DN	Nitracrine
DMY59KQ	MI	TTUTN1I
DMY59KQ	MN	Human Deoxyribonucleic acid (hDNA)
DMY59KQ	MT	DTT
DMY59KQ	MA	Breaker
DMY59KQ	RN	Crosslinking of cellular DNA by nitracrine and furocoumarin derivatives. Neoplasma. 1999;46(1):50-3.
DMY59KQ	RU	https://pubmed.ncbi.nlm.nih.gov/10355534

DMVDM0Q	DI	DMVDM0Q
DMVDM0Q	DN	NITRAQUAZONE
DMVDM0Q	MI	TTZ97H5
DMVDM0Q	MN	Phosphodiesterase 4A (PDE4A)
DMVDM0Q	MT	DTT
DMVDM0Q	MA	Inhibitor
DMVDM0Q	RN	Synthesis and biological evaluation of 2,5-dihydropyrazol. Bioorg Med Chem Lett. 2000 Dec 4;10(23):2661-4.
DMVDM0Q	RU	https://pubmed.ncbi.nlm.nih.gov/11128646

DMVDM0Q	DI	DMVDM0Q
DMVDM0Q	DN	NITRAQUAZONE
DMVDM0Q	MI	TTVIAT9
DMVDM0Q	MN	Phosphodiesterase 4B (PDE4B)
DMVDM0Q	MT	DTT
DMVDM0Q	MA	Inhibitor
DMVDM0Q	RN	Synthesis and biological evaluation of 2,5-dihydropyrazol. Bioorg Med Chem Lett. 2000 Dec 4;10(23):2661-4.
DMVDM0Q	RU	https://pubmed.ncbi.nlm.nih.gov/11128646

DMVFB93	DI	DMVFB93
DMVFB93	DN	Nitrate
DMVFB93	MI	DTOTME4
DMVFB93	MN	Anion exchange transporter (SLC26A7)
DMVFB93	MT	DTP
DMVFB93	MA	Substrate
DMVFB93	RN	The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.53.2.6)
DMVFB93	RU	http://www.tcdb.org/search/result.php?tc=2.A.53.2.6

DMVFB93	DI	DMVFB93
DMVFB93	DN	Nitrate
DMVFB93	MI	TTHQPL7
DMVFB93	MN	Carbonic anhydrase I (CA-I)
DMVFB93	MT	DTT
DMVFB93	MA	Inhibitor
DMVFB93	RN	Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5435-9.
DMVFB93	RU	https://pubmed.ncbi.nlm.nih.gov/15454240

DMVFB93	DI	DMVFB93
DMVFB93	DN	Nitrate
DMVFB93	MI	TTANPDJ
DMVFB93	MN	Carbonic anhydrase II (CA-II)
DMVFB93	MT	DTT
DMVFB93	MA	Inhibitor
DMVFB93	RN	Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5435-9.
DMVFB93	RU	https://pubmed.ncbi.nlm.nih.gov/15454240

DMVFB93	DI	DMVFB93
DMVFB93	DN	Nitrate
DMVFB93	MI	DTZAH46
DMVFB93	MN	Sodium/iodide cotransporter (SLC5A5)
DMVFB93	MT	DTP
DMVFB93	MA	Substrate
DMVFB93	RN	The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.21.5.1)
DMVFB93	RU	http://www.tcdb.org/search/result.php?tc=2.A.21.5.1

DMVFB93	DI	DMVFB93
DMVFB93	DN	Nitrate
DMVFB93	MI	DTWLACT
DMVFB93	MN	Vesicular H(+)/Aspartate-glutamate cotransporter (SLC17A5)
DMVFB93	MT	DTP
DMVFB93	MA	Substrate
DMVFB93	RN	Sialin (SLC17A5) functions as a nitrate transporter in the plasma membrane. Proc Natl Acad Sci U S A. 2012 Aug 14;109(33):13434-9.
DMVFB93	RU	http://www.ncbi.nlm.nih.gov/pubmed/22778404

DMIOQFU	DI	DMIOQFU
DMIOQFU	DN	Nitrilotriacetic Acid
DMIOQFU	MI	TTSZDQU
DMIOQFU	MN	Lactotransferrin (LTF)
DMIOQFU	MT	DTT
DMIOQFU	MA	Inhibitor
DMIOQFU	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMIOQFU	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMR5XT3	DI	DMR5XT3
DMR5XT3	DN	Nitrite
DMR5XT3	MI	DE1VDSF
DMR5XT3	MN	MOSC domain-containing protein 1 (MARC1)
DMR5XT3	MT	DME
DMR5XT3	MA	Metabolism
DMR5XT3	RN	Nitrite reductase and nitric-oxide synthase activity of the mitochondrial molybdopterin enzymes mARC1 and mARC2. J Biol Chem. 2014 Apr 11;289(15):10345-58.
DMR5XT3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24500710

DMR5XT3	DI	DMR5XT3
DMR5XT3	DN	Nitrite
DMR5XT3	MI	DE6QH2D
DMR5XT3	MN	MOSC domain-containing protein 2 (MARC2)
DMR5XT3	MT	DME
DMR5XT3	MA	Metabolism
DMR5XT3	RN	Nitrite reductase and nitric-oxide synthase activity of the mitochondrial molybdopterin enzymes mARC1 and mARC2. J Biol Chem. 2014 Apr 11;289(15):10345-58.
DMR5XT3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24500710

DM7T80N	DI	DM7T80N
DM7T80N	DN	Nitroarginine
DM7T80N	MI	TTZUFI5
DM7T80N	MN	Nitric-oxide synthase brain (NOS1)
DM7T80N	MT	DTT
DM7T80N	MA	Inhibitor
DM7T80N	RN	Crystal structure of nitric oxide synthase bound to nitro indazole reveals a novel inactivation mechanism. Biochemistry. 2001 Nov 13;40(45):13448-55.
DM7T80N	RU	https://pubmed.ncbi.nlm.nih.gov/11695891

DM7T80N	DI	DM7T80N
DM7T80N	DN	Nitroarginine
DM7T80N	MI	TTCM4B3
DM7T80N	MN	Nitric-oxide synthase endothelial (NOS3)
DM7T80N	MT	DTT
DM7T80N	MA	Inhibitor
DM7T80N	RN	Crystal structure of nitric oxide synthase bound to nitro indazole reveals a novel inactivation mechanism. Biochemistry. 2001 Nov 13;40(45):13448-55.
DM7T80N	RU	https://pubmed.ncbi.nlm.nih.gov/11695891

DM4UHB5	DI	DM4UHB5
DM4UHB5	DN	Nitrobenzaldehyde
DM4UHB5	MI	DED2FW3
DM4UHB5	MN	Aldo-keto reductase 1A1 (AKR1A1)
DM4UHB5	MT	DME
DM4UHB5	MA	Metabolism
DM4UHB5	RN	The C-terminal loop of aldehyde reductase determines the substrate and inhibitor specificity. Biochemistry. 1996 Nov 12;35(45):14276-80.
DM4UHB5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8916913

DM4UHB5	DI	DM4UHB5
DM4UHB5	DN	Nitrobenzaldehyde
DM4UHB5	MI	DER0XCH
DM4UHB5	MN	Farnesol dehydrogenase (AKR1B15)
DM4UHB5	MT	DME
DM4UHB5	MA	Metabolism
DM4UHB5	RN	Functional expression of novel human and murine AKR1B genes. Chem Biol Interact. 2011 May 30;191(1-3):177-84.
DM4UHB5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21276782

DM4UHB5	DI	DM4UHB5
DM4UHB5	DN	Nitrobenzaldehyde
DM4UHB5	MI	DEIVKZ8
DM4UHB5	MN	NADPH-dependent carbonyl reductase 3 (CBR3)
DM4UHB5	MT	DME
DM4UHB5	MA	Metabolism
DM4UHB5	RN	Different functions between human monomeric carbonyl reductase 3 and carbonyl reductase 1. Mol Cell Biochem. 2008 Aug;315(1-2):113-21.
DM4UHB5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18493841

DMN6L70	DI	DMN6L70
DMN6L70	DN	Nitrobenzanthrone
DMN6L70	MI	DENP5RY
DMN6L70	MN	Quinone reductase 1 (NQO1)
DMN6L70	MT	DME
DMN6L70	MA	Metabolism
DMN6L70	RN	Dose-dependent response to 3-nitrobenzanthrone exposure in human urothelial cancer cells. Chem Res Toxicol. 2017 Oct 16;30(10):1855-1864.
DMN6L70	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28922594

DM6FVHC	DI	DM6FVHC
DM6FVHC	DN	Nitrobenzoate
DM6FVHC	MI	DE0K82S
DM6FVHC	MN	Nitroreductase (NTR)
DM6FVHC	MT	DME
DM6FVHC	MA	Metabolism
DM6FVHC	RN	nan
DM6FVHC	RU	nan

DM6FVHC	DI	DM6FVHC
DM6FVHC	DN	Nitrobenzoate
DM6FVHC	MI	DED6V8P
DM6FVHC	MN	Oxygen-insensitive NADPH nitroreductase A (nfsA)
DM6FVHC	MT	DME
DM6FVHC	MA	Metabolism
DM6FVHC	RN	nan
DM6FVHC	RU	nan

DM254EW	DI	DM254EW
DM254EW	DN	Nitrobenzodiazepine
DM254EW	MI	DE3N2FM
DM254EW	MN	NADPH-cytochrome P450 reductase (CPR)
DM254EW	MT	DME
DM254EW	MA	Metabolism
DM254EW	RN	Flavin-containing reductase: new perspective on the detoxification of nitrobenzodiazepine. Expert Opin Drug Metab Toxicol. 2010 Aug;6(8):967-81.
DM254EW	RU	https://pubmed.ncbi.nlm.nih.gov/20504108

DM254EW	DI	DM254EW
DM254EW	DN	Nitrobenzodiazepine
DM254EW	MI	DE0QLUZ
DM254EW	MN	Oxygen-insensitive NADPH nitroreductase B (nfsB)
DM254EW	MT	DME
DM254EW	MA	Metabolism
DM254EW	RN	Structure-based development of bacterial nitroreductase against nitrobenzodiazepine-induced hypnosis. Biochem Pharmacol. 2012 Jun 15;83(12):1690-9.
DM254EW	RU	https://pubmed.ncbi.nlm.nih.gov/22445794

DM7F3RY	DI	DM7F3RY
DM7F3RY	DN	Nitrobenzylthioinosine
DM7F3RY	MI	TTLXAKE
DM7F3RY	MN	Solute carrier family 29 member 1 (SLC29A1)
DM7F3RY	MT	DTT
DM7F3RY	MA	Inhibitor
DM7F3RY	RN	The role of human nucleoside transporters in uptake of 3'-deoxy-3'-fluorothymidine. Mol Pharmacol. 2008 Nov;74(5):1372-80.
DM7F3RY	RU	https://pubmed.ncbi.nlm.nih.gov/18669604

DMGUNIL	DI	DMGUNIL
DMGUNIL	DN	Nitrocatechol sulfate
DMGUNIL	MI	DEEGA13
DMGUNIL	MN	Telethon sulfatase (ARSK)
DMGUNIL	MT	DME
DMGUNIL	MA	Metabolism
DMGUNIL	RN	Arylsulfatase K, a novel lysosomal sulfatase. J Biol Chem. 2013 Oct 18;288(42):30019-28.
DMGUNIL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23986440

DM7M5VY	DI	DM7M5VY
DM7M5VY	DN	NITROCEFIN
DM7M5VY	MI	TTLP6GN
DM7M5VY	MN	Bacterial DD-carboxypeptidase (Bact vanYB)
DM7M5VY	MT	DTT
DM7M5VY	MA	Inhibitor
DM7M5VY	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM7M5VY	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMWCV48	DI	DMWCV48
DMWCV48	DN	Nitroflurbiprofen
DMWCV48	MI	TT8NGED
DMWCV48	MN	Prostaglandin G/H synthase 1 (COX-1)
DMWCV48	MT	DTT
DMWCV48	MA	Modulator
DMWCV48	RN	The cyclooxygenase inhibitor flurbiprofen reduces radiation-induced angiogenic growth factor secretion of squamous cell carcinoma cell lines. Ann N Y Acad Sci. 2004 Dec;1030:37-42.
DMWCV48	RU	https://www.ncbi.nlm.nih.gov/pubmed/15659778

DMWCV48	DI	DMWCV48
DMWCV48	DN	Nitroflurbiprofen
DMWCV48	MI	TTVKILB
DMWCV48	MN	Prostaglandin G/H synthase 2 (COX-2)
DMWCV48	MT	DTT
DMWCV48	MA	Modulator
DMWCV48	RN	The cyclooxygenase inhibitor flurbiprofen reduces radiation-induced angiogenic growth factor secretion of squamous cell carcinoma cell lines. Ann N Y Acad Sci. 2004 Dec;1030:37-42.
DMWCV48	RU	https://www.ncbi.nlm.nih.gov/pubmed/15659778

DMMY2S5	DI	DMMY2S5
DMMY2S5	DN	Nitroimidazole
DMMY2S5	MI	DEX5D46
DMMY2S5	MN	Oxygen-insensitive NADPH nitroreductase A (nfsA)
DMMY2S5	MT	DME
DMMY2S5	MA	Metabolism
DMMY2S5	RN	Delamanid is not metabolized by Salmonella or human nitroreductases: a possible mechanism for the lack of mutagenicity. Regul Toxicol Pharmacol. 2017 Mar;84:1-8.
DMMY2S5	RU	https://pubmed.ncbi.nlm.nih.gov/27988333

DMMY2S5	DI	DMMY2S5
DMMY2S5	DN	Nitroimidazole
DMMY2S5	MI	DEOWDK1
DMMY2S5	MN	Oxygen-insensitive NADPH nitroreductase B (nfsB)
DMMY2S5	MT	DME
DMMY2S5	MA	Metabolism
DMMY2S5	RN	Delamanid is not metabolized by Salmonella or human nitroreductases: a possible mechanism for the lack of mutagenicity. Regul Toxicol Pharmacol. 2017 Mar;84:1-8.
DMMY2S5	RU	https://pubmed.ncbi.nlm.nih.gov/27988333

DMMY2S5	DI	DMMY2S5
DMMY2S5	DN	Nitroimidazole
DMMY2S5	MI	DEKVGPX
DMMY2S5	MN	Retro-nitroreductase (rNR)
DMMY2S5	MT	DME
DMMY2S5	MA	Metabolism
DMMY2S5	RN	Retro-nitroreductase, a putative evolutionary precursor to Enterobacter cloacae strain 96-3 nitroreductase. Antioxid Redox Signal. 2001 Oct;3(5):747-55.
DMMY2S5	RU	https://pubmed.ncbi.nlm.nih.gov/11761325

DMHSD8A	DI	DMHSD8A
DMHSD8A	DN	Nitrophenyl acetate
DMHSD8A	MI	DE1Z0MO
DMHSD8A	MN	Carbonic anhydrase II (CA2)
DMHSD8A	MT	DME
DMHSD8A	MA	Metabolism
DMHSD8A	RN	Inhibition profiling of human carbonic anhydrase II by high-throughput screening of structurally diverse, biologically active compounds. J Biomol Screen. 2006 Oct;11(7):782-91.
DMHSD8A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16858005

DMHSD8A	DI	DMHSD8A
DMHSD8A	DN	Nitrophenyl acetate
DMHSD8A	MI	DEB30C5
DMHSD8A	MN	Carboxylesterase 1 (CES1)
DMHSD8A	MT	DME
DMHSD8A	MA	Metabolism
DMHSD8A	RN	Characterization of pyrethroid hydrolysis by the human liver carboxylesterases hCE-1 and hCE-2. Arch Biochem Biophys. 2006 Jan 1;445(1):115-23.
DMHSD8A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16359636

DMZ9WI4	DI	DMZ9WI4
DMZ9WI4	DN	Nitrosoglutathione
DMZ9WI4	MI	DEAH3PE
DMZ9WI4	MN	S-(hydroxymethyl)glutathione dehydrogenase (adh)
DMZ9WI4	MT	DME
DMZ9WI4	MA	Metabolism
DMZ9WI4	RN	Nitrosative stress response in Vibrio cholerae: role of S-nitrosoglutathione reductase. Appl Biochem Biotechnol. 2017 Jul;182(3):871-884.
DMZ9WI4	RU	https://pubmed.ncbi.nlm.nih.gov/28000045

DMY729C	DI	DMY729C
DMY729C	DN	NK314
DMY729C	MI	TTCGY2K
DMY729C	MN	DNA topoisomerase II alpha (TOP2A)
DMY729C	MT	DTT
DMY729C	MA	Inhibitor
DMY729C	RN	NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform. J Biol Chem. 2008 Aug 29;283(35):23711-20.
DMY729C	RU	https://pubmed.ncbi.nlm.nih.gov/18596031

DM9WC1T	DI	DM9WC1T
DM9WC1T	DN	NK3201
DM9WC1T	MI	TT8VUE0
DM9WC1T	MN	Chymase (CYM)
DM9WC1T	MT	DTT
DM9WC1T	MA	Inhibitor
DM9WC1T	RN	Impact of chymase inhibitor on cardiac function and survival after myocardial infarction. Cardiovasc Res. 2003 Nov 1;60(2):413-20.
DM9WC1T	RU	https://pubmed.ncbi.nlm.nih.gov/14613871

DMSB2YG	DI	DMSB2YG
DMSB2YG	DN	NKY80
DMSB2YG	MI	TTN64VU
DMSB2YG	MN	Adenylate cyclase type 5 (AC5)
DMSB2YG	MT	DTT
DMSB2YG	MA	Inhibitor
DMSB2YG	RN	Type-specific regulation of adenylyl cyclase. Selective pharmacological stimulation and inhibition of adenylyl cyclase isoforms. J Biol Chem. 2001 Dec 21;276(51):47785-93.
DMSB2YG	RU	https://pubmed.ncbi.nlm.nih.gov/11602596

DM0FA6B	DI	DM0FA6B
DM0FA6B	DN	Nle-Pro-Glu
DM0FA6B	MI	TTLD29N
DM0FA6B	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DM0FA6B	MT	DTT
DM0FA6B	MA	Inhibitor
DM0FA6B	RN	New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6.
DM0FA6B	RU	https://pubmed.ncbi.nlm.nih.gov/16321525

DM0FA6B	DI	DM0FA6B
DM0FA6B	DN	Nle-Pro-Glu
DM0FA6B	MI	TTKJEMQ
DM0FA6B	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DM0FA6B	MT	DTT
DM0FA6B	MA	Inhibitor
DM0FA6B	RN	New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6.
DM0FA6B	RU	https://pubmed.ncbi.nlm.nih.gov/16321525

DM0FA6B	DI	DM0FA6B
DM0FA6B	DN	Nle-Pro-Glu
DM0FA6B	MI	TTN9D8E
DM0FA6B	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DM0FA6B	MT	DTT
DM0FA6B	MA	Inhibitor
DM0FA6B	RN	New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6.
DM0FA6B	RU	https://pubmed.ncbi.nlm.nih.gov/16321525

DM6RA20	DI	DM6RA20
DM6RA20	DN	NM-2014
DM6RA20	MI	TTG043C
DM6RA20	MN	Tumor necrosis factor receptor type I (TNF-R1)
DM6RA20	MT	DTT
DM6RA20	MA	Modulator
DM6RA20	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1870).
DM6RA20	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1870

DMC89HI	DI	DMC89HI
DMC89HI	DN	NM-9308
DMC89HI	MI	TTA0P7K
DMC89HI	MN	Complement factor B (CFB)
DMC89HI	MT	DTT
DMC89HI	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2339).
DMC89HI	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2339

DMKMBSJ	DI	DMKMBSJ
DMKMBSJ	DN	NM-9405
DMKMBSJ	MI	TTG043C
DMKMBSJ	MN	Tumor necrosis factor receptor type I (TNF-R1)
DMKMBSJ	MT	DTT
DMKMBSJ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1870).
DMKMBSJ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1870

DM5Q9FG	DI	DM5Q9FG
DM5Q9FG	DN	NMB-T-BMX-OS01
DM5Q9FG	MI	TTT6LFV
DM5Q9FG	MN	Histone deacetylase 8 (HDAC8)
DM5Q9FG	MT	DTT
DM5Q9FG	MA	Inhibitor
DM5Q9FG	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2619).
DM5Q9FG	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2619

DMM731A	DI	DMM731A
DMM731A	DN	N-Me-aminopyrimidinone 9
DMM731A	MI	TT4G2JS
DMM731A	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DMM731A	MT	DTT
DMM731A	MA	Inhibitor (gating inhibitor)
DMM731A	RN	Discovery and optimization of aminopyrimidinones as potent and state-dependent Nav1.7 antagonists. Bioorg Med Chem Lett. 2012 Jan 15;22(2):1055-60.
DMM731A	RU	https://pubmed.ncbi.nlm.nih.gov/22209205

DMI065U	DI	DMI065U
DMI065U	DN	N-mesityl-4,6-dimethyl-3-tosylpyridin-2-amine
DMI065U	MI	TT7EFHR
DMI065U	MN	Corticotropin-releasing factor receptor 1 (CRHR1)
DMI065U	MT	DTT
DMI065U	MA	Inhibitor
DMI065U	RN	Synthesis and evaluation of 2-anilino-3-phenylsulfonyl-6-methylpyridines as corticotropin-releasing factor1 receptor ligands. Bioorg Med Chem Lett. 2006 Feb 15;16(4):934-7.
DMI065U	RU	https://pubmed.ncbi.nlm.nih.gov/16297619

DMEUI8C	DI	DMEUI8C
DMEUI8C	DN	N-mesityl-6-methyl-3-tosylpyridin-2-amine
DMEUI8C	MI	TT7EFHR
DMEUI8C	MN	Corticotropin-releasing factor receptor 1 (CRHR1)
DMEUI8C	MT	DTT
DMEUI8C	MA	Inhibitor
DMEUI8C	RN	Synthesis and evaluation of 2-anilino-3-phenylsulfonyl-6-methylpyridines as corticotropin-releasing factor1 receptor ligands. Bioorg Med Chem Lett. 2006 Feb 15;16(4):934-7.
DMEUI8C	RU	https://pubmed.ncbi.nlm.nih.gov/16297619

DMI9QRO	DI	DMI9QRO
DMI9QRO	DN	N-methoxyethyl estrone-16-methyl carboxamide
DMI9QRO	MI	TTIWB6L
DMI9QRO	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMI9QRO	MT	DTT
DMI9QRO	MA	Inhibitor
DMI9QRO	RN	Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45.
DMI9QRO	RU	https://pubmed.ncbi.nlm.nih.gov/16480268

DMMB3PG	DI	DMMB3PG
DMMB3PG	DN	N-methoxyquinuclidine-3-carboximidoyl chloride
DMMB3PG	MI	TTZ9SOR
DMMB3PG	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMMB3PG	MT	DTT
DMMB3PG	MA	Inhibitor
DMMB3PG	RN	A novel and selective class of azabicyclic muscarinic agonists incorporating an N-methoxy imidoyl halide or nitrile functionality, Bioorg. Med. Chem. Lett. 2(8):791-796 (1992).
DMMB3PG	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805338

DMMB3PG	DI	DMMB3PG
DMMB3PG	DN	N-methoxyquinuclidine-3-carboximidoyl chloride
DMMB3PG	MI	TTYEG6Q
DMMB3PG	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMMB3PG	MT	DTT
DMMB3PG	MA	Inhibitor
DMMB3PG	RN	A novel and selective class of azabicyclic muscarinic agonists incorporating an N-methoxy imidoyl halide or nitrile functionality, Bioorg. Med. Chem. Lett. 2(8):791-796 (1992).
DMMB3PG	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805338

DMMB3PG	DI	DMMB3PG
DMMB3PG	DN	N-methoxyquinuclidine-3-carboximidoyl chloride
DMMB3PG	MI	TTQ13Z5
DMMB3PG	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMMB3PG	MT	DTT
DMMB3PG	MA	Inhibitor
DMMB3PG	RN	A novel and selective class of azabicyclic muscarinic agonists incorporating an N-methoxy imidoyl halide or nitrile functionality, Bioorg. Med. Chem. Lett. 2(8):791-796 (1992).
DMMB3PG	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805338

DMMB3PG	DI	DMMB3PG
DMMB3PG	DN	N-methoxyquinuclidine-3-carboximidoyl chloride
DMMB3PG	MI	TTQ3JTF
DMMB3PG	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DMMB3PG	MT	DTT
DMMB3PG	MA	Inhibitor
DMMB3PG	RN	A novel and selective class of azabicyclic muscarinic agonists incorporating an N-methoxy imidoyl halide or nitrile functionality, Bioorg. Med. Chem. Lett. 2(8):791-796 (1992).
DMMB3PG	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805338

DMMB3PG	DI	DMMB3PG
DMMB3PG	DN	N-methoxyquinuclidine-3-carboximidoyl chloride
DMMB3PG	MI	TTH18TF
DMMB3PG	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMMB3PG	MT	DTT
DMMB3PG	MA	Inhibitor
DMMB3PG	RN	A novel and selective class of azabicyclic muscarinic agonists incorporating an N-methoxy imidoyl halide or nitrile functionality, Bioorg. Med. Chem. Lett. 2(8):791-796 (1992).
DMMB3PG	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805338

DMF8IA6	DI	DMF8IA6
DMF8IA6	DN	N-methoxyquinuclidine-3-carboximidoyl fluoride
DMF8IA6	MI	TTZ9SOR
DMF8IA6	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMF8IA6	MT	DTT
DMF8IA6	MA	Inhibitor
DMF8IA6	RN	A novel and selective class of azabicyclic muscarinic agonists incorporating an N-methoxy imidoyl halide or nitrile functionality, Bioorg. Med. Chem. Lett. 2(8):791-796 (1992).
DMF8IA6	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805338

DMF8IA6	DI	DMF8IA6
DMF8IA6	DN	N-methoxyquinuclidine-3-carboximidoyl fluoride
DMF8IA6	MI	TTYEG6Q
DMF8IA6	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMF8IA6	MT	DTT
DMF8IA6	MA	Inhibitor
DMF8IA6	RN	A novel and selective class of azabicyclic muscarinic agonists incorporating an N-methoxy imidoyl halide or nitrile functionality, Bioorg. Med. Chem. Lett. 2(8):791-796 (1992).
DMF8IA6	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805338

DMF8IA6	DI	DMF8IA6
DMF8IA6	DN	N-methoxyquinuclidine-3-carboximidoyl fluoride
DMF8IA6	MI	TTQ13Z5
DMF8IA6	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMF8IA6	MT	DTT
DMF8IA6	MA	Inhibitor
DMF8IA6	RN	A novel and selective class of azabicyclic muscarinic agonists incorporating an N-methoxy imidoyl halide or nitrile functionality, Bioorg. Med. Chem. Lett. 2(8):791-796 (1992).
DMF8IA6	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805338

DMF8IA6	DI	DMF8IA6
DMF8IA6	DN	N-methoxyquinuclidine-3-carboximidoyl fluoride
DMF8IA6	MI	TTQ3JTF
DMF8IA6	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DMF8IA6	MT	DTT
DMF8IA6	MA	Inhibitor
DMF8IA6	RN	A novel and selective class of azabicyclic muscarinic agonists incorporating an N-methoxy imidoyl halide or nitrile functionality, Bioorg. Med. Chem. Lett. 2(8):791-796 (1992).
DMF8IA6	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805338

DMF8IA6	DI	DMF8IA6
DMF8IA6	DN	N-methoxyquinuclidine-3-carboximidoyl fluoride
DMF8IA6	MI	TTH18TF
DMF8IA6	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMF8IA6	MT	DTT
DMF8IA6	MA	Inhibitor
DMF8IA6	RN	A novel and selective class of azabicyclic muscarinic agonists incorporating an N-methoxy imidoyl halide or nitrile functionality, Bioorg. Med. Chem. Lett. 2(8):791-796 (1992).
DMF8IA6	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00805338

DM32YID	DI	DM32YID
DM32YID	DN	N-methyl estradiol-16-methyl carboxamide
DM32YID	MI	TTIWB6L
DM32YID	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DM32YID	MT	DTT
DM32YID	MA	Inhibitor
DM32YID	RN	Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45.
DM32YID	RU	https://pubmed.ncbi.nlm.nih.gov/16480268

DM7XIK5	DI	DM7XIK5
DM7XIK5	DN	N-methyl estrone-16-methyl carboxamide
DM7XIK5	MI	TTIWB6L
DM7XIK5	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DM7XIK5	MT	DTT
DM7XIK5	MA	Inhibitor
DM7XIK5	RN	Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45.
DM7XIK5	RU	https://pubmed.ncbi.nlm.nih.gov/16480268

DM6XYCU	DI	DM6XYCU
DM6XYCU	DN	N-methyl LTC4
DM6XYCU	MI	TTGKOY9
DM6XYCU	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DM6XYCU	MT	DTT
DM6XYCU	MA	Agonist
DM6XYCU	RN	Differential signaling of cysteinyl leukotrienes and a novel cysteinyl leukotriene receptor 2 (CysLT agonist, N-methyl-leukotriene C in calcium reporter and beta arrestin assays. Mol Pharmacol. 2011 Feb;79(2):270-8.
DM6XYCU	RU	https://pubmed.ncbi.nlm.nih.gov/21078884

DM6XYCU	DI	DM6XYCU
DM6XYCU	DN	N-methyl LTC4
DM6XYCU	MI	TT0PZR5
DM6XYCU	MN	Leukotriene CysLT2 receptor (CYSLTR2)
DM6XYCU	MT	DTT
DM6XYCU	MA	Agonist
DM6XYCU	RN	Differential signaling of cysteinyl leukotrienes and a novel cysteinyl leukotriene receptor 2 (CysLT agonist, N-methyl-leukotriene C in calcium reporter and beta arrestin assays. Mol Pharmacol. 2011 Feb;79(2):270-8.
DM6XYCU	RU	https://pubmed.ncbi.nlm.nih.gov/21078884

DMXGY4F	DI	DMXGY4F
DMXGY4F	DN	N-methyl ryanodine-succinamidate
DMXGY4F	MI	TTU5CIX
DMXGY4F	MN	Ryanodine receptor 1 (RYR1)
DMXGY4F	MT	DTT
DMXGY4F	MA	Inhibitor
DMXGY4F	RN	Amino- and guanidinoacylryanodines: basic ryanodine esters with enhanced affinity for the sarcoplasmic reticulum Ca(2+)-release channel. J Med Chem. 1993 May 14;36(10):1319-23.
DMXGY4F	RU	https://pubmed.ncbi.nlm.nih.gov/8388466

DM83AEM	DI	DM83AEM
DM83AEM	DN	N-methyl,N-(benzyl),N-(pyrrol-2-ylmethyl)amine
DM83AEM	MI	TT3WG5C
DM83AEM	MN	Monoamine oxidase type A (MAO-A)
DM83AEM	MT	DTT
DM83AEM	MA	Inhibitor
DM83AEM	RN	New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J Med Chem. 2007 Mar 8;50(5):922-31.
DM83AEM	RU	https://pubmed.ncbi.nlm.nih.gov/17256833

DM83AEM	DI	DM83AEM
DM83AEM	DN	N-methyl,N-(benzyl),N-(pyrrol-2-ylmethyl)amine
DM83AEM	MI	TTGP7BY
DM83AEM	MN	Monoamine oxidase type B (MAO-B)
DM83AEM	MT	DTT
DM83AEM	MA	Inhibitor
DM83AEM	RN	New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J Med Chem. 2007 Mar 8;50(5):922-31.
DM83AEM	RU	https://pubmed.ncbi.nlm.nih.gov/17256833

DMZ24XT	DI	DMZ24XT
DMZ24XT	DN	N-methyl,N-(propargyl),N-(pyrrol-2-ylmethyl)amine
DMZ24XT	MI	TT3WG5C
DMZ24XT	MN	Monoamine oxidase type A (MAO-A)
DMZ24XT	MT	DTT
DMZ24XT	MA	Inhibitor
DMZ24XT	RN	New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J Med Chem. 2007 Mar 8;50(5):922-31.
DMZ24XT	RU	https://pubmed.ncbi.nlm.nih.gov/17256833

DMZ24XT	DI	DMZ24XT
DMZ24XT	DN	N-methyl,N-(propargyl),N-(pyrrol-2-ylmethyl)amine
DMZ24XT	MI	TTGP7BY
DMZ24XT	MN	Monoamine oxidase type B (MAO-B)
DMZ24XT	MT	DTT
DMZ24XT	MA	Inhibitor
DMZ24XT	RN	New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J Med Chem. 2007 Mar 8;50(5):922-31.
DMZ24XT	RU	https://pubmed.ncbi.nlm.nih.gov/17256833

DMM3B21	DI	DMM3B21
DMM3B21	DN	N-Methyl,N-phenyl-1H-indole-2-carboxamide
DMM3B21	MI	TT3WG5C
DMM3B21	MN	Monoamine oxidase type A (MAO-A)
DMM3B21	MT	DTT
DMM3B21	MA	Inhibitor
DMM3B21	RN	Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40.
DMM3B21	RU	https://pubmed.ncbi.nlm.nih.gov/18951803

DMM3B21	DI	DMM3B21
DMM3B21	DN	N-Methyl,N-phenyl-1H-indole-2-carboxamide
DMM3B21	MI	TTGP7BY
DMM3B21	MN	Monoamine oxidase type B (MAO-B)
DMM3B21	MT	DTT
DMM3B21	MA	Inhibitor
DMM3B21	RN	Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40.
DMM3B21	RU	https://pubmed.ncbi.nlm.nih.gov/18951803

DMUJ18P	DI	DMUJ18P
DMUJ18P	DN	N-methyl-1-(2-thiophen-2-ylphenyl)methanamine
DMUJ18P	MI	TTXZEAJ
DMUJ18P	MN	Leukotriene A-4 hydrolase (LTA4H)
DMUJ18P	MT	DTT
DMUJ18P	MA	Inhibitor
DMUJ18P	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMUJ18P	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMK8VZM	DI	DMK8VZM
DMK8VZM	DN	N-Methyl-1'H-phenothiazine-1'-carboxamide
DMK8VZM	MI	TT1RS9F
DMK8VZM	MN	Acetylcholinesterase (AChE)
DMK8VZM	MT	DTT
DMK8VZM	MA	Inhibitor
DMK8VZM	RN	Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorg Med Chem. 2010 Mar 15;18(6):2232-2244.
DMK8VZM	RU	https://pubmed.ncbi.nlm.nih.gov/20181484

DMK8VZM	DI	DMK8VZM
DMK8VZM	DN	N-Methyl-1'H-phenothiazine-1'-carboxamide
DMK8VZM	MI	TTEB0GD
DMK8VZM	MN	Cholinesterase (BCHE)
DMK8VZM	MT	DTT
DMK8VZM	MA	Inhibitor
DMK8VZM	RN	Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorg Med Chem. 2010 Mar 15;18(6):2232-2244.
DMK8VZM	RU	https://pubmed.ncbi.nlm.nih.gov/20181484

DM8LNMY	DI	DM8LNMY
DM8LNMY	DN	N-methyl-2-(pyridin-2-yl)ethanamine
DM8LNMY	MI	TT9JNIC
DM8LNMY	MN	Histamine H3 receptor (H3R)
DM8LNMY	MT	DTT
DM8LNMY	MA	Inhibitor
DM8LNMY	RN	5-hydroxyindole-2-carboxylic acid amides: novel histamine-3 receptor inverse agonists for the treatment of obesity. J Med Chem. 2009 Jul 9;52(13):3855-68.
DM8LNMY	RU	https://pubmed.ncbi.nlm.nih.gov/19456097

DMXS43P	DI	DMXS43P
DMXS43P	DN	N-methyl-2-(pyridin-3-yloxy)ethanamine
DMXS43P	MI	TT4H1MQ
DMXS43P	MN	Neuronal acetylcholine receptor alpha-4 (CHRNA4)
DMXS43P	MT	DTT
DMXS43P	MA	Inhibitor
DMXS43P	RN	Synthesis and analgesic activity of secondary amine analogues of pyridylmethylamine and positional isomeric analogues of ABT-594. Bioorg Med Chem Lett. 2006 Apr 1;16(7):2013-6.
DMXS43P	RU	https://pubmed.ncbi.nlm.nih.gov/16412637

DMXS43P	DI	DMXS43P
DMXS43P	DN	N-methyl-2-(pyridin-3-yloxy)ethanamine
DMXS43P	MI	TT5KPZR
DMXS43P	MN	Neuronal acetylcholine receptor beta-2 (CHRNB2)
DMXS43P	MT	DTT
DMXS43P	MA	Inhibitor
DMXS43P	RN	Synthesis and analgesic activity of secondary amine analogues of pyridylmethylamine and positional isomeric analogues of ABT-594. Bioorg Med Chem Lett. 2006 Apr 1;16(7):2013-6.
DMXS43P	RU	https://pubmed.ncbi.nlm.nih.gov/16412637

DMQGRMO	DI	DMQGRMO
DMQGRMO	DN	N-methyl-2,2,2-triphenylacetamide
DMQGRMO	MI	TTMNI76
DMQGRMO	MN	Calcium-activated potassium channel (KCN)
DMQGRMO	MT	DTT
DMQGRMO	MA	Inhibitor
DMQGRMO	RN	Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82.
DMQGRMO	RU	https://pubmed.ncbi.nlm.nih.gov/18232633

DM8IHQP	DI	DM8IHQP
DM8IHQP	DN	N-methyl-3,3-diphenylpropan-1-amine
DM8IHQP	MI	TTJQOD7
DM8IHQP	MN	5-HT 2A receptor (HTR2A)
DM8IHQP	MT	DTT
DM8IHQP	MA	Inhibitor
DM8IHQP	RN	Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504.
DM8IHQP	RU	https://pubmed.ncbi.nlm.nih.gov/19700330

DM8IHQP	DI	DM8IHQP
DM8IHQP	DN	N-methyl-3,3-diphenylpropan-1-amine
DM8IHQP	MI	TTTIBOJ
DM8IHQP	MN	Histamine H1 receptor (H1R)
DM8IHQP	MT	DTT
DM8IHQP	MA	Inhibitor
DM8IHQP	RN	Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504.
DM8IHQP	RU	https://pubmed.ncbi.nlm.nih.gov/19700330

DMMNIRC	DI	DMMNIRC
DMMNIRC	DN	N-methyl-4-(pyridin-3-yl)but-3-yn-1-amine
DMMNIRC	MI	TT4H1MQ
DMMNIRC	MN	Neuronal acetylcholine receptor alpha-4 (CHRNA4)
DMMNIRC	MT	DTT
DMMNIRC	MA	Inhibitor
DMMNIRC	RN	Synthesis and analgesic activity of secondary amine analogues of pyridylmethylamine and positional isomeric analogues of ABT-594. Bioorg Med Chem Lett. 2006 Apr 1;16(7):2013-6.
DMMNIRC	RU	https://pubmed.ncbi.nlm.nih.gov/16412637

DMMNIRC	DI	DMMNIRC
DMMNIRC	DN	N-methyl-4-(pyridin-3-yl)but-3-yn-1-amine
DMMNIRC	MI	TT5KPZR
DMMNIRC	MN	Neuronal acetylcholine receptor beta-2 (CHRNB2)
DMMNIRC	MT	DTT
DMMNIRC	MA	Inhibitor
DMMNIRC	RN	Synthesis and analgesic activity of secondary amine analogues of pyridylmethylamine and positional isomeric analogues of ABT-594. Bioorg Med Chem Lett. 2006 Apr 1;16(7):2013-6.
DMMNIRC	RU	https://pubmed.ncbi.nlm.nih.gov/16412637

DMO3PNF	DI	DMO3PNF
DMO3PNF	DN	N-methyl-4,4-diphenylbutan-1-amine
DMO3PNF	MI	TTJQOD7
DMO3PNF	MN	5-HT 2A receptor (HTR2A)
DMO3PNF	MT	DTT
DMO3PNF	MA	Inhibitor
DMO3PNF	RN	Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504.
DMO3PNF	RU	https://pubmed.ncbi.nlm.nih.gov/19700330

DMO3PNF	DI	DMO3PNF
DMO3PNF	DN	N-methyl-4,4-diphenylbutan-1-amine
DMO3PNF	MI	TTTIBOJ
DMO3PNF	MN	Histamine H1 receptor (H1R)
DMO3PNF	MT	DTT
DMO3PNF	MA	Inhibitor
DMO3PNF	RN	Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504.
DMO3PNF	RU	https://pubmed.ncbi.nlm.nih.gov/19700330

DMA0YGE	DI	DMA0YGE
DMA0YGE	DN	N-methyl-4-pentyl-N-(pyridin-3-yl)benzamide
DMA0YGE	MI	TTMI6F5
DMA0YGE	MN	Transient receptor potential cation channel V1 (TRPV1)
DMA0YGE	MT	DTT
DMA0YGE	MA	Inhibitor
DMA0YGE	RN	N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4.
DMA0YGE	RU	https://pubmed.ncbi.nlm.nih.gov/18359227

DMD621E	DI	DMD621E
DMD621E	DN	N-methyl-5,6-dip-tolylpyrazine-2-carboxamide
DMD621E	MI	TT6OEDT
DMD621E	MN	Cannabinoid receptor 1 (CB1)
DMD621E	MT	DTT
DMD621E	MA	Inhibitor
DMD621E	RN	Discovery of pyrazine carboxamide CB1 antagonists: the introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy... Bioorg Med Chem Lett. 2007 Jul 15;17(14):3978-82.
DMD621E	RU	https://pubmed.ncbi.nlm.nih.gov/17513109

DM5GXIS	DI	DM5GXIS
DM5GXIS	DN	N-methylbicuculline
DM5GXIS	MI	TTAN6JD
DM5GXIS	MN	Glutamate receptor AMPA (GRIA)
DM5GXIS	MT	DTT
DM5GXIS	MA	Antagonist
DM5GXIS	RN	GABA receptors modulate trigeminovascular nociceptive neurotransmission in the trigeminocervical complex. Br J Pharmacol. 2001 Oct;134(4):896-904.
DM5GXIS	RU	https://pubmed.ncbi.nlm.nih.gov/11606331

DMP1EF6	DI	DMP1EF6
DMP1EF6	DN	N-Methyl-ETAV
DMP1EF6	MI	TT9PB26
DMP1EF6	MN	Presynaptic density protein 95 (DLG4)
DMP1EF6	MT	DTT
DMP1EF6	MA	Inhibitor
DMP1EF6	RN	Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem. 2008 Oct 23;51(20):6450-9.
DMP1EF6	RU	https://pubmed.ncbi.nlm.nih.gov/18811137

DMCFH5W	DI	DMCFH5W
DMCFH5W	DN	N-methylhistamine
DMCFH5W	MI	TT9JNIC
DMCFH5W	MN	Histamine H3 receptor (H3R)
DMCFH5W	MT	DTT
DMCFH5W	MA	Agonist
DMCFH5W	RN	Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol. 2001 Mar;59(3):420-6.
DMCFH5W	RU	https://pubmed.ncbi.nlm.nih.gov/11179434

DMCFH5W	DI	DMCFH5W
DMCFH5W	DN	N-methylhistamine
DMCFH5W	MI	TTXJ178
DMCFH5W	MN	Histamine H4 receptor (H4R)
DMCFH5W	MT	DTT
DMCFH5W	MA	Agonist
DMCFH5W	RN	Comparison of human, mouse, rat, and guinea pig histamine H4 receptors reveals substantial pharmacological species variation. J Pharmacol Exp Ther. 2001 Oct;299(1):121-30.
DMCFH5W	RU	https://pubmed.ncbi.nlm.nih.gov/11561071

DMWPBKU	DI	DMWPBKU
DMWPBKU	DN	N-methyllaurotetanine
DMWPBKU	MI	TTSQIFT
DMWPBKU	MN	5-HT 1A receptor (HTR1A)
DMWPBKU	MT	DTT
DMWPBKU	MA	Inhibitor
DMWPBKU	RN	Alkaloids from Eschscholzia californica and their capacity to inhibit binding of [3H]8-Hydroxy-2-(di-N-propylamino)tetralin to 5-HT1A receptors in ... J Nat Prod. 2006 Mar;69(3):432-5.
DMWPBKU	RU	https://pubmed.ncbi.nlm.nih.gov/16562853

DM9AGCV	DI	DM9AGCV
DM9AGCV	DN	N-Methylleucine
DM9AGCV	MI	TTQOVYA
DM9AGCV	MN	C-X-C motif chemokine 10 (CXCL10)
DM9AGCV	MT	DTT
DM9AGCV	MA	Inhibitor
DM9AGCV	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9AGCV	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM4FMZP	DI	DM4FMZP
DM4FMZP	DN	N-Methylmesoporphyrin
DM4FMZP	MI	TTQ6VF4
DM4FMZP	MN	Ferrochelatase (FECH)
DM4FMZP	MT	DTT
DM4FMZP	MA	Inhibitor
DM4FMZP	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM4FMZP	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMKZL5H	DI	DMKZL5H
DMKZL5H	DN	N-Methylmesoporphyrin Containing Copper
DMKZL5H	MI	TTQ6VF4
DMKZL5H	MN	Ferrochelatase (FECH)
DMKZL5H	MT	DTT
DMKZL5H	MA	Inhibitor
DMKZL5H	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMKZL5H	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMYPEX3	DI	DMYPEX3
DMYPEX3	DN	N-Methyl-N-(Methylbenzyl)Formamide
DMYPEX3	MI	TTB2MXP
DMYPEX3	MN	Angiotensinogenase renin (REN)
DMYPEX3	MT	DTT
DMYPEX3	MA	Inhibitor
DMYPEX3	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMYPEX3	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMYPEX3	DI	DMYPEX3
DMYPEX3	DN	N-Methyl-N-(Methylbenzyl)Formamide
DMYPEX3	MI	DEVDYN7
DMYPEX3	MN	Cytochrome P450 2E1 (CYP2E1)
DMYPEX3	MT	DME
DMYPEX3	MA	Metabolism
DMYPEX3	RN	Drug Interactions Flockhart Table
DMYPEX3	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM796AX	DI	DM796AX
DM796AX	DN	N-methyl-N-(prop-2-ynyl)-1H-pyrrole-2-carboxamide
DM796AX	MI	TT3WG5C
DM796AX	MN	Monoamine oxidase type A (MAO-A)
DM796AX	MT	DTT
DM796AX	MA	Inhibitor
DM796AX	RN	New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J Med Chem. 2007 Mar 8;50(5):922-31.
DM796AX	RU	https://pubmed.ncbi.nlm.nih.gov/17256833

DMOP128	DI	DMOP128
DMOP128	DN	N-methyl-N-(pyridin-3-ylmethyl)ethanamine
DMOP128	MI	TT4H1MQ
DMOP128	MN	Neuronal acetylcholine receptor alpha-4 (CHRNA4)
DMOP128	MT	DTT
DMOP128	MA	Inhibitor
DMOP128	RN	Synthesis and analgesic activity of secondary amine analogues of pyridylmethylamine and positional isomeric analogues of ABT-594. Bioorg Med Chem Lett. 2006 Apr 1;16(7):2013-6.
DMOP128	RU	https://pubmed.ncbi.nlm.nih.gov/16412637

DMOP128	DI	DMOP128
DMOP128	DN	N-methyl-N-(pyridin-3-ylmethyl)ethanamine
DMOP128	MI	TT5KPZR
DMOP128	MN	Neuronal acetylcholine receptor beta-2 (CHRNB2)
DMOP128	MT	DTT
DMOP128	MA	Inhibitor
DMOP128	RN	Synthesis and analgesic activity of secondary amine analogues of pyridylmethylamine and positional isomeric analogues of ABT-594. Bioorg Med Chem Lett. 2006 Apr 1;16(7):2013-6.
DMOP128	RU	https://pubmed.ncbi.nlm.nih.gov/16412637

DMXSJH0	DI	DMXSJH0
DMXSJH0	DN	N-Methylnaloxonium
DMXSJH0	MI	TTMF541
DMXSJH0	MN	Liver carboxylesterase (CES1)
DMXSJH0	MT	DTT
DMXSJH0	MA	Inhibitor
DMXSJH0	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMXSJH0	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DM6DM4L	DI	DM6DM4L
DM6DM4L	DN	N-methyl-N-ethyl estradiol-16-carboxamide
DM6DM4L	MI	TTIWB6L
DM6DM4L	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DM6DM4L	MT	DTT
DM6DM4L	MA	Inhibitor
DM6DM4L	RN	Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45.
DM6DM4L	RU	https://pubmed.ncbi.nlm.nih.gov/16480268

DM2CUEB	DI	DM2CUEB
DM2CUEB	DN	N-methyl-N-ethyl estrone-16-methyl carboxamide
DM2CUEB	MI	TTIWB6L
DM2CUEB	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DM2CUEB	MT	DTT
DM2CUEB	MA	Inhibitor
DM2CUEB	RN	Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45.
DM2CUEB	RU	https://pubmed.ncbi.nlm.nih.gov/16480268

DMDB7ZM	DI	DMDB7ZM
DMDB7ZM	DN	N-Methyl-N-phenyl-2-oxo-2H-chromene-3-carboxamide
DMDB7ZM	MI	TTGP7BY
DMDB7ZM	MN	Monoamine oxidase type B (MAO-B)
DMDB7ZM	MT	DTT
DMDB7ZM	MA	Inhibitor
DMDB7ZM	RN	Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins. J Med Chem. 2009 Apr 9;52(7):1935-42.
DMDB7ZM	RU	https://pubmed.ncbi.nlm.nih.gov/19267475

DMB9OGI	DI	DMB9OGI
DMB9OGI	DN	N-Methyl-N-Propargyl-1(R)-Aminoindan
DMB9OGI	MI	TTGP7BY
DMB9OGI	MN	Monoamine oxidase type B (MAO-B)
DMB9OGI	MT	DTT
DMB9OGI	MA	Inhibitor
DMB9OGI	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMB9OGI	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMDAN0K	DI	DMDAN0K
DMDAN0K	DN	N-methyl-Pip-F-homoF-vinyl sulfonyl phenyl (N-methyl-Pip-F-hF-VS phi)
DMDAN0K	MI	TTO9X1H
DMDAN0K	MN	5-HT 7 receptor (HTR7)
DMDAN0K	MT	DTT
DMDAN0K	MA	Antagonist
DMDAN0K	RN	5-HT7 receptors. Curr Drug Targets CNS Neurol Disord. 2004 Feb;3(1):81-90.
DMDAN0K	RU	https://pubmed.ncbi.nlm.nih.gov/14965246

DMDAN0K	DI	DMDAN0K
DMDAN0K	DN	N-methyl-Pip-F-homoF-vinyl sulfonyl phenyl (N-methyl-Pip-F-hF-VS phi)
DMDAN0K	MI	TT2SUAQ
DMDAN0K	MN	Cysteine protease (CYP)
DMDAN0K	MT	DTT
DMDAN0K	MA	Inhibitor
DMDAN0K	RN	A cysteine protease inhibitor cures Chagas' disease in an immunodeficient-mouse model of infection. Antimicrob Agents Chemother. 2007 Nov;51(11):3932-9.
DMDAN0K	RU	https://pubmed.ncbi.nlm.nih.gov/17698625

DMZYSM1	DI	DMZYSM1
DMZYSM1	DN	N-methylstephisoferulin
DMZYSM1	MI	TT27RFC
DMZYSM1	MN	Opioid receptor delta (OPRD1)
DMZYSM1	MT	DTT
DMZYSM1	MA	Inhibitor
DMZYSM1	RN	Hasubanan alkaloids with delta-opioid binding affinity from the aerial parts of Stephania japonica. J Nat Prod. 2010 May 28;73(5):988-91.
DMZYSM1	RU	https://pubmed.ncbi.nlm.nih.gov/20426456

DM5CR2E	DI	DM5CR2E
DM5CR2E	DN	N-methylstephuline
DM5CR2E	MI	TT27RFC
DM5CR2E	MN	Opioid receptor delta (OPRD1)
DM5CR2E	MT	DTT
DM5CR2E	MA	Inhibitor
DM5CR2E	RN	Hasubanan alkaloids with delta-opioid binding affinity from the aerial parts of Stephania japonica. J Nat Prod. 2010 May 28;73(5):988-91.
DM5CR2E	RU	https://pubmed.ncbi.nlm.nih.gov/20426456

DMS8H5Q	DI	DMS8H5Q
DMS8H5Q	DN	NM-PP1
DMS8H5Q	MI	TT860QF
DMS8H5Q	MN	LCK tyrosine protein kinase (LCK)
DMS8H5Q	MT	DTT
DMS8H5Q	MA	Inhibitor
DMS8H5Q	RN	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
DMS8H5Q	RU	https://pubmed.ncbi.nlm.nih.gov/17850214

DMS8H5Q	DI	DMS8H5Q
DMS8H5Q	DN	NM-PP1
DMS8H5Q	MI	TT5U49F
DMS8H5Q	MN	PRKACA messenger RNA (PRKACA mRNA)
DMS8H5Q	MT	DTT
DMS8H5Q	MA	Inhibitor
DMS8H5Q	RN	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
DMS8H5Q	RU	https://pubmed.ncbi.nlm.nih.gov/17850214

DMS8H5Q	DI	DMS8H5Q
DMS8H5Q	DN	NM-PP1
DMS8H5Q	MI	TT6PKBN
DMS8H5Q	MN	Proto-oncogene c-Src (SRC)
DMS8H5Q	MT	DTT
DMS8H5Q	MA	Inhibitor
DMS8H5Q	RN	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
DMS8H5Q	RU	https://pubmed.ncbi.nlm.nih.gov/17850214

DMS8H5Q	DI	DMS8H5Q
DMS8H5Q	DN	NM-PP1
DMS8H5Q	MI	TTCQ2E5
DMS8H5Q	MN	RIP2 messenger RNA (RIP2 mRNA)
DMS8H5Q	MT	DTT
DMS8H5Q	MA	Inhibitor
DMS8H5Q	RN	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
DMS8H5Q	RU	https://pubmed.ncbi.nlm.nih.gov/17850214

DMS8H5Q	DI	DMS8H5Q
DMS8H5Q	DN	NM-PP1
DMS8H5Q	MI	TT0K6EO
DMS8H5Q	MN	Stress-activated protein kinase JNK1 (JNK1)
DMS8H5Q	MT	DTT
DMS8H5Q	MA	Inhibitor
DMS8H5Q	RN	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
DMS8H5Q	RU	https://pubmed.ncbi.nlm.nih.gov/17850214

DMX4ZGL	DI	DMX4ZGL
DMX4ZGL	DN	NMS-1
DMX4ZGL	MI	TTIYVQP
DMX4ZGL	MN	Polo-like kinase 1 (PLK1)
DMX4ZGL	MT	DTT
DMX4ZGL	MA	Inhibitor
DMX4ZGL	RN	Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009 Jun;14(6):559-70.
DMX4ZGL	RU	https://pubmed.ncbi.nlm.nih.gov/19474163

DMYKZ6U	DI	DMYKZ6U
DMYKZ6U	DN	NMS-873
DMYKZ6U	MI	TTYWTI0
DMYKZ6U	MN	HUMAN valosin-containing protein p97 (VCP)
DMYKZ6U	MT	DTT
DMYKZ6U	MA	Inhibitor
DMYKZ6U	RN	A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug Repurposing. Nature. 2020 Apr 30.  doi: 10.1038/s41586-020-2286-9.
DMYKZ6U	RU	https://pubmed.ncbi.nlm.nih.gov/32353859

DMSQ4TL	DI	DMSQ4TL
DMSQ4TL	DN	NNC 11-1314
DMSQ4TL	MI	TTOXS3C
DMSQ4TL	MN	Muscarinic acetylcholine receptor (CHRM)
DMSQ4TL	MT	DTT
DMSQ4TL	MA	Agonist
DMSQ4TL	RN	Synthesis and pharmacological evaluation of dimeric muscarinic acetylcholine receptor agonists. J Pharmacol Exp Ther. 2001 Sep;298(3):1260-8.
DMSQ4TL	RU	https://pubmed.ncbi.nlm.nih.gov/11504829

DMSQ4TL	DI	DMSQ4TL
DMSQ4TL	DN	NNC 11-1314
DMSQ4TL	MI	TTQ13Z5
DMSQ4TL	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMSQ4TL	MT	DTT
DMSQ4TL	MA	Agonist
DMSQ4TL	RN	Synthesis and pharmacological evaluation of dimeric muscarinic acetylcholine receptor agonists. J Pharmacol Exp Ther. 2001 Sep;298(3):1260-8.
DMSQ4TL	RU	https://pubmed.ncbi.nlm.nih.gov/11504829

DMMX19B	DI	DMMX19B
DMMX19B	DN	NNC 11-1585
DMMX19B	MI	TTOXS3C
DMMX19B	MN	Muscarinic acetylcholine receptor (CHRM)
DMMX19B	MT	DTT
DMMX19B	MA	Agonist
DMMX19B	RN	Synthesis and pharmacological evaluation of dimeric muscarinic acetylcholine receptor agonists. J Pharmacol Exp Ther. 2001 Sep;298(3):1260-8.
DMMX19B	RU	https://pubmed.ncbi.nlm.nih.gov/11504829

DMMX19B	DI	DMMX19B
DMMX19B	DN	NNC 11-1585
DMMX19B	MI	TTQ13Z5
DMMX19B	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMMX19B	MT	DTT
DMMX19B	MA	Agonist
DMMX19B	RN	Synthesis and pharmacological evaluation of dimeric muscarinic acetylcholine receptor agonists. J Pharmacol Exp Ther. 2001 Sep;298(3):1260-8.
DMMX19B	RU	https://pubmed.ncbi.nlm.nih.gov/11504829

DMZJSWI	DI	DMZJSWI
DMZJSWI	DN	NNC 11-1607
DMZJSWI	MI	TTOXS3C
DMZJSWI	MN	Muscarinic acetylcholine receptor (CHRM)
DMZJSWI	MT	DTT
DMZJSWI	MA	Agonist
DMZJSWI	RN	Synthesis and pharmacological evaluation of dimeric muscarinic acetylcholine receptor agonists. J Pharmacol Exp Ther. 2001 Sep;298(3):1260-8.
DMZJSWI	RU	https://pubmed.ncbi.nlm.nih.gov/11504829

DMZJSWI	DI	DMZJSWI
DMZJSWI	DN	NNC 11-1607
DMZJSWI	MI	TTQ13Z5
DMZJSWI	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMZJSWI	MT	DTT
DMZJSWI	MA	Agonist
DMZJSWI	RN	Synthesis and pharmacological evaluation of dimeric muscarinic acetylcholine receptor agonists. J Pharmacol Exp Ther. 2001 Sep;298(3):1260-8.
DMZJSWI	RU	https://pubmed.ncbi.nlm.nih.gov/11504829

DM0C8N3	DI	DM0C8N3
DM0C8N3	DN	NNC 711
DM0C8N3	MI	TTV9MQG
DM0C8N3	MN	Gamma-aminobutyric acid uptake (GABAU)
DM0C8N3	MT	DTT
DM0C8N3	MA	Inhibitor
DM0C8N3	RN	Effects of NNC 711, a GABA uptake inhibitor, on pentylenetetrazol-induced seizures in developing and adult rats. Naunyn Schmiedebergs Arch Pharmacol. 1998 Sep;358(3):334-41.
DM0C8N3	RU	https://pubmed.ncbi.nlm.nih.gov/9774221

DMPQ1HL	DI	DMPQ1HL
DMPQ1HL	DN	NNC 92-1687
DMPQ1HL	MI	TT9O6WS
DMPQ1HL	MN	Glucagon receptor (GCGR)
DMPQ1HL	MT	DTT
DMPQ1HL	MA	Antagonist
DMPQ1HL	RN	Discovery and structure-activity relationship of the first non-peptide competitive human glucagon receptor antagonists. J Med Chem. 1998 Dec 17;41(26):5150-7.
DMPQ1HL	RU	https://pubmed.ncbi.nlm.nih.gov/9857085

DMCGF3U	DI	DMCGF3U
DMCGF3U	DN	NNC052090
DMCGF3U	MI	TTQBMPI
DMCGF3U	MN	Na(+)/Cl(-) betaine/GABA transporter (SLC6A12)
DMCGF3U	MT	DTT
DMCGF3U	MA	Inhibitor
DMCGF3U	RN	1-(3-(9H-carbazol-9-yl)-1-propyl)-4-(2-methoxyphenyl)-4-piperidinol, a novel subtype selective inhibitor of the mouse type II GABA-transporter. Br J Pharmacol. 1997 Mar;120(6):983-5.
DMCGF3U	RU	https://pubmed.ncbi.nlm.nih.gov/9134205

DMDCPFJ	DI	DMDCPFJ
DMDCPFJ	DN	NNC-26-0194
DMDCPFJ	MI	TTKMAZ6
DMDCPFJ	MN	Growth hormone receptor (GHR)
DMDCPFJ	MT	DTT
DMDCPFJ	MA	Modulator
DMDCPFJ	RN	Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica. 1998 Nov;28(11):1083-92.
DMDCPFJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/9879640

DMAQTW3	DI	DMAQTW3
DMAQTW3	DN	NNC269100
DMAQTW3	MI	TTAE1BR
DMAQTW3	MN	Somatostatin receptor type 4 (SSTR4)
DMAQTW3	MT	DTT
DMAQTW3	MA	Agonist
DMAQTW3	RN	Nonpeptide somatostatin agonists with sst4 selectivity: synthesis and structure-activity relationships of thioureas. J Med Chem. 1998 Nov 19;41(24):4693-705.
DMAQTW3	RU	https://pubmed.ncbi.nlm.nih.gov/9822540

DMID3F7	DI	DMID3F7
DMID3F7	DN	NNC55-0396
DMID3F7	MI	TTWOCZI
DMID3F7	MN	Cation channel sperm-associated protein (CatSper)
DMID3F7	MT	DTT
DMID3F7	MA	Blocker (channel blocker)
DMID3F7	RN	The CatSper channel mediates progesterone-induced Ca2+ influx in human sperm. Nature. 2011 Mar 17;471(7338):382-6.
DMID3F7	RU	https://pubmed.ncbi.nlm.nih.gov/21412338

DMID3F7	DI	DMID3F7
DMID3F7	DN	NNC55-0396
DMID3F7	MI	TT5CISB
DMID3F7	MN	Cation channel sperm-associated protein 1 (CatSper1)
DMID3F7	MT	DTT
DMID3F7	MA	Blocker (channel blocker)
DMID3F7	RN	The CatSper channel mediates progesterone-induced Ca2+ influx in human sperm. Nature. 2011 Mar 17;471(7338):382-6.
DMID3F7	RU	https://pubmed.ncbi.nlm.nih.gov/21412338

DMID3F7	DI	DMID3F7
DMID3F7	DN	NNC55-0396
DMID3F7	MI	TTOEGC4
DMID3F7	MN	Cation channel sperm-associated protein 2 (CatSper2)
DMID3F7	MT	DTT
DMID3F7	MA	Blocker (channel blocker)
DMID3F7	RN	The CatSper channel mediates progesterone-induced Ca2+ influx in human sperm. Nature. 2011 Mar 17;471(7338):382-6.
DMID3F7	RU	https://pubmed.ncbi.nlm.nih.gov/21412338

DMID3F7	DI	DMID3F7
DMID3F7	DN	NNC55-0396
DMID3F7	MI	TTP52ZV
DMID3F7	MN	Cation channel sperm-associated protein 3 (CatSper3)
DMID3F7	MT	DTT
DMID3F7	MA	Blocker (channel blocker)
DMID3F7	RN	The CatSper channel mediates progesterone-induced Ca2+ influx in human sperm. Nature. 2011 Mar 17;471(7338):382-6.
DMID3F7	RU	https://pubmed.ncbi.nlm.nih.gov/21412338

DMUHZ23	DI	DMUHZ23
DMUHZ23	DN	N-N-diethyl estradiol-16-methyl carboxamide
DMUHZ23	MI	TTIWB6L
DMUHZ23	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DMUHZ23	MT	DTT
DMUHZ23	MA	Inhibitor
DMUHZ23	RN	Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45.
DMUHZ23	RU	https://pubmed.ncbi.nlm.nih.gov/16480268

DMSYOHD	DI	DMSYOHD
DMSYOHD	DN	NN-dimethyl-D-erythrosphingosine
DMSYOHD	MI	TTO3TD8
DMSYOHD	MN	Long transient receptor potential channel 3 (TRPM3)
DMSYOHD	MT	DTT
DMSYOHD	MA	Activator
DMSYOHD	RN	Activation of the melastatin-related cation channel TRPM3 by D-erythro-sphingosine [corrected]. Mol Pharmacol. 2005 Mar;67(3):798-805.
DMSYOHD	RU	https://pubmed.ncbi.nlm.nih.gov/15550678

DM8FOSR	DI	DM8FOSR
DM8FOSR	DN	N-n-dodecyl-7-methoxytacrine hydrochloride
DM8FOSR	MI	TT1RS9F
DM8FOSR	MN	Acetylcholinesterase (AChE)
DM8FOSR	MT	DTT
DM8FOSR	MA	Inhibitor
DM8FOSR	RN	Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease. Bioorg Med Chem Lett. 2010 Oct 15;20(20):6093-5.
DM8FOSR	RU	https://pubmed.ncbi.nlm.nih.gov/20817518

DMSUK2A	DI	DMSUK2A
DMSUK2A	DN	N-Neopentyl-1'H-phenothiazine-1'-carboxamide
DMSUK2A	MI	TTEB0GD
DMSUK2A	MN	Cholinesterase (BCHE)
DMSUK2A	MT	DTT
DMSUK2A	MA	Inhibitor
DMSUK2A	RN	Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorg Med Chem. 2010 Mar 15;18(6):2232-2244.
DMSUK2A	RU	https://pubmed.ncbi.nlm.nih.gov/20181484

DMA8R47	DI	DMA8R47
DMA8R47	DN	N-n-heptyl-7-methoxytacrine hydrochloride
DMA8R47	MI	TT1RS9F
DMA8R47	MN	Acetylcholinesterase (AChE)
DMA8R47	MT	DTT
DMA8R47	MA	Inhibitor
DMA8R47	RN	Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease. Bioorg Med Chem Lett. 2010 Oct 15;20(20):6093-5.
DMA8R47	RU	https://pubmed.ncbi.nlm.nih.gov/20817518

DMA8R47	DI	DMA8R47
DMA8R47	DN	N-n-heptyl-7-methoxytacrine hydrochloride
DMA8R47	MI	TTEB0GD
DMA8R47	MN	Cholinesterase (BCHE)
DMA8R47	MT	DTT
DMA8R47	MA	Inhibitor
DMA8R47	RN	Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease. Bioorg Med Chem Lett. 2010 Oct 15;20(20):6093-5.
DMA8R47	RU	https://pubmed.ncbi.nlm.nih.gov/20817518

DM4ZMG6	DI	DM4ZMG6
DM4ZMG6	DN	N-n-hexyl-7-methoxytacrine hydrochloride
DM4ZMG6	MI	TT1RS9F
DM4ZMG6	MN	Acetylcholinesterase (AChE)
DM4ZMG6	MT	DTT
DM4ZMG6	MA	Inhibitor
DM4ZMG6	RN	Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease. Bioorg Med Chem Lett. 2010 Oct 15;20(20):6093-5.
DM4ZMG6	RU	https://pubmed.ncbi.nlm.nih.gov/20817518

DM4ZMG6	DI	DM4ZMG6
DM4ZMG6	DN	N-n-hexyl-7-methoxytacrine hydrochloride
DM4ZMG6	MI	TTEB0GD
DM4ZMG6	MN	Cholinesterase (BCHE)
DM4ZMG6	MT	DTT
DM4ZMG6	MA	Inhibitor
DM4ZMG6	RN	Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease. Bioorg Med Chem Lett. 2010 Oct 15;20(20):6093-5.
DM4ZMG6	RU	https://pubmed.ncbi.nlm.nih.gov/20817518

DMLH23M	DI	DMLH23M
DMLH23M	DN	N-n-nonyl-7-methoxytacrine hydrochloride
DMLH23M	MI	TT1RS9F
DMLH23M	MN	Acetylcholinesterase (AChE)
DMLH23M	MT	DTT
DMLH23M	MA	Inhibitor
DMLH23M	RN	Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease. Bioorg Med Chem Lett. 2010 Oct 15;20(20):6093-5.
DMLH23M	RU	https://pubmed.ncbi.nlm.nih.gov/20817518

DMLH23M	DI	DMLH23M
DMLH23M	DN	N-n-nonyl-7-methoxytacrine hydrochloride
DMLH23M	MI	TTEB0GD
DMLH23M	MN	Cholinesterase (BCHE)
DMLH23M	MT	DTT
DMLH23M	MA	Inhibitor
DMLH23M	RN	Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease. Bioorg Med Chem Lett. 2010 Oct 15;20(20):6093-5.
DMLH23M	RU	https://pubmed.ncbi.nlm.nih.gov/20817518

DMLC257	DI	DMLC257
DMLC257	DN	N-n-octyl-7-methoxytacrine hydrochloride
DMLC257	MI	TT1RS9F
DMLC257	MN	Acetylcholinesterase (AChE)
DMLC257	MT	DTT
DMLC257	MA	Inhibitor
DMLC257	RN	Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease. Bioorg Med Chem Lett. 2010 Oct 15;20(20):6093-5.
DMLC257	RU	https://pubmed.ncbi.nlm.nih.gov/20817518

DMLC257	DI	DMLC257
DMLC257	DN	N-n-octyl-7-methoxytacrine hydrochloride
DMLC257	MI	TTEB0GD
DMLC257	MN	Cholinesterase (BCHE)
DMLC257	MT	DTT
DMLC257	MA	Inhibitor
DMLC257	RN	Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease. Bioorg Med Chem Lett. 2010 Oct 15;20(20):6093-5.
DMLC257	RU	https://pubmed.ncbi.nlm.nih.gov/20817518

DMH3OUX	DI	DMH3OUX
DMH3OUX	DN	N-nonylphenol
DMH3OUX	MI	DE0P6LK
DMH3OUX	MN	Sulfotransferase 2A1 (SULT2A1)
DMH3OUX	MT	DME
DMH3OUX	MA	Metabolism
DMH3OUX	RN	Sulfation of environmental estrogens by cytosolic human sulfotransferases. Drug Metab Pharmacokinet. 2002;17(3):221-8.
DMH3OUX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15618673

DMWAK5V	DI	DMWAK5V
DMWAK5V	DN	N-n-pentyl-7-methoxytacrine hydrochloride
DMWAK5V	MI	TT1RS9F
DMWAK5V	MN	Acetylcholinesterase (AChE)
DMWAK5V	MT	DTT
DMWAK5V	MA	Inhibitor
DMWAK5V	RN	Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease. Bioorg Med Chem Lett. 2010 Oct 15;20(20):6093-5.
DMWAK5V	RU	https://pubmed.ncbi.nlm.nih.gov/20817518

DMWAK5V	DI	DMWAK5V
DMWAK5V	DN	N-n-pentyl-7-methoxytacrine hydrochloride
DMWAK5V	MI	TTEB0GD
DMWAK5V	MN	Cholinesterase (BCHE)
DMWAK5V	MT	DTT
DMWAK5V	MA	Inhibitor
DMWAK5V	RN	Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease. Bioorg Med Chem Lett. 2010 Oct 15;20(20):6093-5.
DMWAK5V	RU	https://pubmed.ncbi.nlm.nih.gov/20817518

DMCN78A	DI	DMCN78A
DMCN78A	DN	N-n-propyl-7-methoxytacrine hydrochloride
DMCN78A	MI	TT1RS9F
DMCN78A	MN	Acetylcholinesterase (AChE)
DMCN78A	MT	DTT
DMCN78A	MA	Inhibitor
DMCN78A	RN	Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease. Bioorg Med Chem Lett. 2010 Oct 15;20(20):6093-5.
DMCN78A	RU	https://pubmed.ncbi.nlm.nih.gov/20817518

DMN7GO8	DI	DMN7GO8
DMN7GO8	DN	NOCARDIMICIN A
DMN7GO8	MI	TTQ13Z5
DMN7GO8	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMN7GO8	MT	DTT
DMN7GO8	MA	Inhibitor
DMN7GO8	RN	Nocardimicins A, B, C, D, E, and F, siderophores with muscarinic M3 receptor inhibiting activity from Nocardia sp. TP-A0674. J Nat Prod. 2005 Jul;68(7):1061-5.
DMN7GO8	RU	https://pubmed.ncbi.nlm.nih.gov/16038549

DM4SRL7	DI	DM4SRL7
DM4SRL7	DN	Nocardimicin C
DM4SRL7	MI	TTQ13Z5
DM4SRL7	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DM4SRL7	MT	DTT
DM4SRL7	MA	Inhibitor
DM4SRL7	RN	Nocardimicins A, B, C, D, E, and F, siderophores with muscarinic M3 receptor inhibiting activity from Nocardia sp. TP-A0674. J Nat Prod. 2005 Jul;68(7):1061-5.
DM4SRL7	RU	https://pubmed.ncbi.nlm.nih.gov/16038549

DM1SABZ	DI	DM1SABZ
DM1SABZ	DN	Nocardimicin D
DM1SABZ	MI	TTQ13Z5
DM1SABZ	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DM1SABZ	MT	DTT
DM1SABZ	MA	Inhibitor
DM1SABZ	RN	Nocardimicins A, B, C, D, E, and F, siderophores with muscarinic M3 receptor inhibiting activity from Nocardia sp. TP-A0674. J Nat Prod. 2005 Jul;68(7):1061-5.
DM1SABZ	RU	https://pubmed.ncbi.nlm.nih.gov/16038549

DMK02YC	DI	DMK02YC
DMK02YC	DN	Nocardimicin F
DMK02YC	MI	TTQ13Z5
DMK02YC	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMK02YC	MT	DTT
DMK02YC	MA	Inhibitor
DMK02YC	RN	Nocardimicins A, B, C, D, E, and F, siderophores with muscarinic M3 receptor inhibiting activity from Nocardia sp. TP-A0674. J Nat Prod. 2005 Jul;68(7):1061-5.
DMK02YC	RU	https://pubmed.ncbi.nlm.nih.gov/16038549

DMXOF4Z	DI	DMXOF4Z
DMXOF4Z	DN	Noccardimicin E
DMXOF4Z	MI	TTQ13Z5
DMXOF4Z	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMXOF4Z	MT	DTT
DMXOF4Z	MA	Inhibitor
DMXOF4Z	RN	Nocardimicins A, B, C, D, E, and F, siderophores with muscarinic M3 receptor inhibiting activity from Nocardia sp. TP-A0674. J Nat Prod. 2005 Jul;68(7):1061-5.
DMXOF4Z	RU	https://pubmed.ncbi.nlm.nih.gov/16038549

DMKTE5V	DI	DMKTE5V
DMKTE5V	DN	N-octadecyl-N'-propylsulfamide
DMKTE5V	MI	TT6OEDT
DMKTE5V	MN	Cannabinoid receptor 1 (CB1)
DMKTE5V	MT	DTT
DMKTE5V	MA	Inhibitor
DMKTE5V	RN	Synthesis and pharmacological evaluation of sulfamide-based analogues of anandamide. Eur J Med Chem. 2009 Dec;44(12):4889-95.
DMKTE5V	RU	https://pubmed.ncbi.nlm.nih.gov/19762126

DM95JEW	DI	DM95JEW
DM95JEW	DN	N-Octylcarbamic Acid Biphenyl-3-yl Ester
DM95JEW	MI	TTDP1UC
DM95JEW	MN	Fatty acid amide hydrolase (FAAH)
DM95JEW	MT	DTT
DM95JEW	MA	Inhibitor
DM95JEW	RN	Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl a... J Med Chem. 2008 Jun 26;51(12):3487-98.
DM95JEW	RU	https://pubmed.ncbi.nlm.nih.gov/18507372

DM50TCG	DI	DM50TCG
DM50TCG	DN	Nogalamycin
DM50TCG	MI	TTGTQHC
DM50TCG	MN	DNA topoisomerase I (TOP1)
DM50TCG	MT	DTT
DM50TCG	MA	Intercalator
DM50TCG	RN	Structure, dynamics and hydration of the nogalamycin-d(ATGCAT)2Complex determined by NMR and molecular dynamics simulations in solution. J Mol Biol. 1999 Jul 16;290(3):699-716.
DM50TCG	RU	https://pubmed.ncbi.nlm.nih.gov/10395824

DM50TCG	DI	DM50TCG
DM50TCG	DN	Nogalamycin
DM50TCG	MI	DTUGYRD
DM50TCG	MN	P-glycoprotein 1 (ABCB1)
DM50TCG	MT	DTP
DM50TCG	MA	Substrate
DM50TCG	RN	Fingerprint-based in silico models for the prediction of P-glycoprotein substrates and inhibitors. Bioorg Med Chem. 2012 Sep 15;20(18):5388-95.
DM50TCG	RU	https://doi.org/10.1016/j.bmc.2012.03.045

DMYZRTB	DI	DMYZRTB
DMYZRTB	DN	Nojirimycine Tetrazole
DMYZRTB	MI	TTZHY6R
DMYZRTB	MN	Glycogen phosphorylase muscle form (GP)
DMYZRTB	MT	DTT
DMYZRTB	MA	Inhibitor
DMYZRTB	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMYZRTB	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMYZRTB	DI	DMYZRTB
DMYZRTB	DN	Nojirimycine Tetrazole
DMYZRTB	MI	TTA0OSE
DMYZRTB	MN	Lactase-phlorizin hydrolase (LCT)
DMYZRTB	MT	DTT
DMYZRTB	MA	Inhibitor
DMYZRTB	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMYZRTB	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM1AVCZ	DI	DM1AVCZ
DM1AVCZ	DN	N-oleoyl-dopamine
DM1AVCZ	MI	TTIQSC1
DM1AVCZ	MN	Bacterial Lethal factor (Bact lef)
DM1AVCZ	MT	DTT
DM1AVCZ	MA	Inhibitor
DM1AVCZ	RN	Inhibitors of anthrax lethal factor. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4575-8.
DM1AVCZ	RU	https://pubmed.ncbi.nlm.nih.gov/17574849

DMJQ4L7	DI	DMJQ4L7
DMJQ4L7	DN	N-oleoylethanolamide
DMJQ4L7	MI	TT6OEDT
DMJQ4L7	MN	Cannabinoid receptor 1 (CB1)
DMJQ4L7	MT	DTT
DMJQ4L7	MA	Inhibitor
DMJQ4L7	RN	Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. J Med Chem. 2009 May 14;52(9):3001-9.
DMJQ4L7	RU	https://pubmed.ncbi.nlm.nih.gov/19361197

DMJQ4L7	DI	DMJQ4L7
DMJQ4L7	DN	N-oleoylethanolamide
DMJQ4L7	MI	TT7QNVC
DMJQ4L7	MN	Glucose-dependent insulinotropic receptor (GPR119)
DMJQ4L7	MT	DTT
DMJQ4L7	MA	Agonist
DMJQ4L7	RN	Screening beta-arrestin recruitment for the identification of natural ligands for orphan G-protein-coupled receptors. J Biomol Screen. 2013 Jun;18(5):599-609.
DMJQ4L7	RU	https://pubmed.ncbi.nlm.nih.gov/23396314

DMJQ4L7	DI	DMJQ4L7
DMJQ4L7	DN	N-oleoylethanolamide
DMJQ4L7	MI	TTNET8J
DMJQ4L7	MN	G-protein coupled receptor 55 (GPR55)
DMJQ4L7	MT	DTT
DMJQ4L7	MA	Agonist
DMJQ4L7	RN	The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007 Dec;152(7):1092-101.
DMJQ4L7	RU	https://pubmed.ncbi.nlm.nih.gov/17876302

DMJQ4L7	DI	DMJQ4L7
DMJQ4L7	DN	N-oleoylethanolamide
DMJQ4L7	MI	TTJ584C
DMJQ4L7	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMJQ4L7	MT	DTT
DMJQ4L7	MA	Agonist
DMJQ4L7	RN	Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats. Neuropharmacology. 2005 Jun;48(8):1147-53.
DMJQ4L7	RU	https://pubmed.ncbi.nlm.nih.gov/15910890

DMRU21X	DI	DMRU21X
DMRU21X	DN	N-oleoyl-N-(2-hydroxyethyl)hydroxylamine
DMRU21X	MI	TTMSFAW
DMRU21X	MN	Cannabinoid receptor 2 (CB2)
DMRU21X	MT	DTT
DMRU21X	MA	Inhibitor
DMRU21X	RN	Oxyhomologues of anandamide and related endolipids: chemoselective synthesis and biological activity. J Med Chem. 2006 Apr 6;49(7):2333-8.
DMRU21X	RU	https://pubmed.ncbi.nlm.nih.gov/16570929

DMZM3CH	DI	DMZM3CH
DMZM3CH	DN	N-oleoyl-O-(2-hydroxyethyl)hydroxylamine
DMZM3CH	MI	TTMSFAW
DMZM3CH	MN	Cannabinoid receptor 2 (CB2)
DMZM3CH	MT	DTT
DMZM3CH	MA	Inhibitor
DMZM3CH	RN	Oxyhomologues of anandamide and related endolipids: chemoselective synthesis and biological activity. J Med Chem. 2006 Apr 6;49(7):2333-8.
DMZM3CH	RU	https://pubmed.ncbi.nlm.nih.gov/16570929

DM0BPCT	DI	DM0BPCT
DM0BPCT	DN	N-omega-allyl-L-arginine
DM0BPCT	MI	TTZUFI5
DM0BPCT	MN	Nitric-oxide synthase brain (NOS1)
DM0BPCT	MT	DTT
DM0BPCT	MA	Inhibitor
DM0BPCT	RN	Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9.
DM0BPCT	RU	https://pubmed.ncbi.nlm.nih.gov/19013076

DM0BPCT	DI	DM0BPCT
DM0BPCT	DN	N-omega-allyl-L-arginine
DM0BPCT	MI	TTCM4B3
DM0BPCT	MN	Nitric-oxide synthase endothelial (NOS3)
DM0BPCT	MT	DTT
DM0BPCT	MA	Inhibitor
DM0BPCT	RN	Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9.
DM0BPCT	RU	https://pubmed.ncbi.nlm.nih.gov/19013076

DM0BPCT	DI	DM0BPCT
DM0BPCT	DN	N-omega-allyl-L-arginine
DM0BPCT	MI	TTF10I9
DM0BPCT	MN	Nitric-oxide synthase inducible (NOS2)
DM0BPCT	MT	DTT
DM0BPCT	MA	Inhibitor
DM0BPCT	RN	Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9.
DM0BPCT	RU	https://pubmed.ncbi.nlm.nih.gov/19013076

DMOXQ3N	DI	DMOXQ3N
DMOXQ3N	DN	N-Omega-Hydroxy-L-Arginine
DMOXQ3N	MI	TTZUFI5
DMOXQ3N	MN	Nitric-oxide synthase brain (NOS1)
DMOXQ3N	MT	DTT
DMOXQ3N	MA	Inhibitor
DMOXQ3N	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMOXQ3N	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMOXQ3N	DI	DMOXQ3N
DMOXQ3N	DN	N-Omega-Hydroxy-L-Arginine
DMOXQ3N	MI	TTCM4B3
DMOXQ3N	MN	Nitric-oxide synthase endothelial (NOS3)
DMOXQ3N	MT	DTT
DMOXQ3N	MA	Inhibitor
DMOXQ3N	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMOXQ3N	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMOXQ3N	DI	DMOXQ3N
DMOXQ3N	DN	N-Omega-Hydroxy-L-Arginine
DMOXQ3N	MI	TTF10I9
DMOXQ3N	MN	Nitric-oxide synthase inducible (NOS2)
DMOXQ3N	MT	DTT
DMOXQ3N	MA	Inhibitor
DMOXQ3N	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMOXQ3N	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9X3B7	DI	DM9X3B7
DM9X3B7	DN	N-omega-propargyl-L-arginine
DM9X3B7	MI	TTZUFI5
DM9X3B7	MN	Nitric-oxide synthase brain (NOS1)
DM9X3B7	MT	DTT
DM9X3B7	MA	Inhibitor
DM9X3B7	RN	Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9.
DM9X3B7	RU	https://pubmed.ncbi.nlm.nih.gov/19013076

DM9X3B7	DI	DM9X3B7
DM9X3B7	DN	N-omega-propargyl-L-arginine
DM9X3B7	MI	TTCM4B3
DM9X3B7	MN	Nitric-oxide synthase endothelial (NOS3)
DM9X3B7	MT	DTT
DM9X3B7	MA	Inhibitor
DM9X3B7	RN	Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9.
DM9X3B7	RU	https://pubmed.ncbi.nlm.nih.gov/19013076

DM9X3B7	DI	DM9X3B7
DM9X3B7	DN	N-omega-propargyl-L-arginine
DM9X3B7	MI	TTF10I9
DM9X3B7	MN	Nitric-oxide synthase inducible (NOS2)
DM9X3B7	MT	DTT
DM9X3B7	MA	Inhibitor
DM9X3B7	RN	Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9.
DM9X3B7	RU	https://pubmed.ncbi.nlm.nih.gov/19013076

DM4X0WY	DI	DM4X0WY
DM4X0WY	DN	N-Omega-Propyl-L-Arginine
DM4X0WY	MI	TTZUFI5
DM4X0WY	MN	Nitric-oxide synthase brain (NOS1)
DM4X0WY	MT	DTT
DM4X0WY	MA	Inhibitor
DM4X0WY	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM4X0WY	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM4X0WY	DI	DM4X0WY
DM4X0WY	DN	N-Omega-Propyl-L-Arginine
DM4X0WY	MI	TTF10I9
DM4X0WY	MN	Nitric-oxide synthase inducible (NOS2)
DM4X0WY	MT	DTT
DM4X0WY	MA	Inhibitor
DM4X0WY	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM4X0WY	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM951PF	DI	DM951PF
DM951PF	DN	Nonanoic acid biphenyl-2-ylamide
DM951PF	MI	TTK3C21
DM951PF	MN	Acetoacetyl-CoA thiolase (ACAT1)
DM951PF	MT	DTT
DM951PF	MA	Inhibitor
DM951PF	RN	Biphenyl versus phenylpyridazine derivatives: the role of the heterocycle in a series of acyl-CoA:cholesterol acyl transferase inhibitors. J Med Chem. 2008 Mar 13;51(5):1474-7.
DM951PF	RU	https://pubmed.ncbi.nlm.nih.gov/18284184

DMMJFTR	DI	DMMJFTR
DMMJFTR	DN	Non-PEGylated butyrylcholinesterase
DMMJFTR	MI	TTEB0GD
DMMJFTR	MN	Cholinesterase (BCHE)
DMMJFTR	MT	DTT
DMMJFTR	MA	Modulator
DMMJFTR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2471).
DMMJFTR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2471

DMZ2DSK	DI	DMZ2DSK
DMZ2DSK	DN	Non-peptide TPO mimics
DMZ2DSK	MI	TTIHYA4
DMZ2DSK	MN	Thrombopoietin receptor (MPL)
DMZ2DSK	MT	DTT
DMZ2DSK	MA	Modulator
DMZ2DSK	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1722).
DMZ2DSK	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1722

DMFNB40	DI	DMFNB40
DMFNB40	DN	Noradrenalone (arterenone)
DMFNB40	MI	TTN451K
DMFNB40	MN	Aromatic-L-amino-acid decarboxylase (DDC)
DMFNB40	MT	DTT
DMFNB40	MA	Activator
DMFNB40	RN	Activation of an adrenergic pro-drug through sequential stereoselective action of tandem target enzymes. Biochem Biophys Res Commun. 1992 Nov 30;189(1):33-9.
DMFNB40	RU	https://pubmed.ncbi.nlm.nih.gov/1449487

DMZ9024	DI	DMZ9024
DMZ9024	DN	NORARISTEROMYCIN
DMZ9024	MI	TTE2KUJ
DMZ9024	MN	Adenosylhomocysteinase (AHCY)
DMZ9024	MT	DTT
DMZ9024	MA	Inhibitor
DMZ9024	RN	Synthesis of 4'-modified noraristeromycins to clarify the effect of the 4'-hydroxyl groups for inhibitory activity against S-adenosyl-L-homocystein... Bioorg Med Chem Lett. 2008 Apr 15;18(8):2615-8.
DMZ9024	RU	https://pubmed.ncbi.nlm.nih.gov/18374570

DMLYZOG	DI	DMLYZOG
DMLYZOG	DN	NORBINALTORPHIMINE
DMLYZOG	MI	TT27RFC
DMLYZOG	MN	Opioid receptor delta (OPRD1)
DMLYZOG	MT	DTT
DMLYZOG	MA	Inhibitor
DMLYZOG	RN	Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-... J Med Chem. 2003 Jul 3;46(14):3127-37.
DMLYZOG	RU	https://pubmed.ncbi.nlm.nih.gov/12825951

DMLYZOG	DI	DMLYZOG
DMLYZOG	DN	NORBINALTORPHIMINE
DMLYZOG	MI	TTQW87Y
DMLYZOG	MN	Opioid receptor kappa (OPRK1)
DMLYZOG	MT	DTT
DMLYZOG	MA	Inhibitor
DMLYZOG	RN	Synthesis of pyrrolomorphinan derivatives as kappa opioid agonists. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5035-8.
DMLYZOG	RU	https://pubmed.ncbi.nlm.nih.gov/20685120

DMLYZOG	DI	DMLYZOG
DMLYZOG	DN	NORBINALTORPHIMINE
DMLYZOG	MI	TTKWM86
DMLYZOG	MN	Opioid receptor mu (MOP)
DMLYZOG	MT	DTT
DMLYZOG	MA	Inhibitor
DMLYZOG	RN	Synthesis of pyrrolomorphinan derivatives as kappa opioid agonists. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5035-8.
DMLYZOG	RU	https://pubmed.ncbi.nlm.nih.gov/20685120

DM6HKEC	DI	DM6HKEC
DM6HKEC	DN	Nor-binaltorphimine dihydrochloride
DM6HKEC	MI	TTQW87Y
DM6HKEC	MN	Opioid receptor kappa (OPRK1)
DM6HKEC	MT	DTT
DM6HKEC	MA	Antagonist
DM6HKEC	RN	Kappa-opioid receptor selectivity for ischemic neuroprotection with BRL 52537 in rats. Anesth Analg. 2003 Dec;97(6):1776-83.
DM6HKEC	RU	https://pubmed.ncbi.nlm.nih.gov/14633559

DM6BNQR	DI	DM6BNQR
DM6BNQR	DN	NORBOLDINE
DM6BNQR	MI	TTVBI8W
DM6BNQR	MN	Dopamine transporter (DAT)
DM6BNQR	MT	DTT
DM6BNQR	MA	Inhibitor
DM6BNQR	RN	Effects of various isoquinoline alkaloids on in vitro 3H-dopamine uptake by rat striatal synaptosomes. J Nat Prod. 1995 Oct;58(10):1475-84.
DM6BNQR	RU	https://pubmed.ncbi.nlm.nih.gov/8676127

DM9B6Y1	DI	DM9B6Y1
DM9B6Y1	DN	NORCANTHARIDIN
DM9B6Y1	MI	TTLONKX
DM9B6Y1	MN	PP2A B subunit isoform R5-alpha (PPP2R5A)
DM9B6Y1	MT	DTT
DM9B6Y1	MA	Inhibitor
DM9B6Y1	RN	Structure-activity relationship of cantharidin derivatives to protein phosphatases 1, 2A1, and 2B, Bioorg. Med. Chem. Lett. 7(14):1833-1836 (1997).
DM9B6Y1	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97003168

DM9B6Y1	DI	DM9B6Y1
DM9B6Y1	DN	NORCANTHARIDIN
DM9B6Y1	MI	TTFLH0E
DM9B6Y1	MN	Serine/threonine PP1-alpha (PPP1CA)
DM9B6Y1	MT	DTT
DM9B6Y1	MA	Inhibitor
DM9B6Y1	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DM9B6Y1	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMHAWYQ	DI	DMHAWYQ
DMHAWYQ	DN	Nordazepam
DMHAWYQ	MI	DE4LYSA
DMHAWYQ	MN	Cytochrome P450 3A4 (CYP3A4)
DMHAWYQ	MT	DME
DMHAWYQ	MA	Metabolism
DMHAWYQ	RN	Sigmoidal kinetic model for two co-operative substrate-binding sites in a cytochrome P450 3A4 active site: an example of the metabolism of diazepam and its derivatives. Biochem J. 1999 Jun 15;340 ( Pt 3):845-53.
DMHAWYQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10359672

DMHAWYQ	DI	DMHAWYQ
DMHAWYQ	DN	Nordazepam
DMHAWYQ	MI	DEGTFWK
DMHAWYQ	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMHAWYQ	MT	DME
DMHAWYQ	MA	Metabolism
DMHAWYQ	RN	Effect of the gene dosage of CgammaP2C19 on diazepam metabolism in Chinese subjects. Clin Pharmacol Ther. 1999 Dec;66(6):642-6.
DMHAWYQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10613621

DMGI4ZW	DI	DMGI4ZW
DMGI4ZW	DN	norfenfluramine
DMGI4ZW	MI	TT0K1SC
DMGI4ZW	MN	5-HT 2B receptor (HTR2B)
DMGI4ZW	MT	DTT
DMGI4ZW	MA	Agonist
DMGI4ZW	RN	Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 2000 Dec 5;102(23):2836-41.
DMGI4ZW	RU	https://pubmed.ncbi.nlm.nih.gov/11104741

DMKNUP3	DI	DMKNUP3
DMKNUP3	DN	norfluoxetine
DMKNUP3	MI	TTJQOD7
DMKNUP3	MN	5-HT 2A receptor (HTR2A)
DMKNUP3	MT	DTT
DMKNUP3	MA	Antagonist
DMKNUP3	RN	Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 2000 Dec 5;102(23):2836-41.
DMKNUP3	RU	https://pubmed.ncbi.nlm.nih.gov/11104741

DMKNUP3	DI	DMKNUP3
DMKNUP3	DN	norfluoxetine
DMKNUP3	MI	TT0K1SC
DMKNUP3	MN	5-HT 2B receptor (HTR2B)
DMKNUP3	MT	DTT
DMKNUP3	MA	Antagonist
DMKNUP3	RN	Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 2000 Dec 5;102(23):2836-41.
DMKNUP3	RU	https://pubmed.ncbi.nlm.nih.gov/11104741

DMKNUP3	DI	DMKNUP3
DMKNUP3	DN	norfluoxetine
DMKNUP3	MI	TTWJBZ5
DMKNUP3	MN	5-HT 2C receptor (HTR2C)
DMKNUP3	MT	DTT
DMKNUP3	MA	Antagonist
DMKNUP3	RN	Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 2000 Dec 5;102(23):2836-41.
DMKNUP3	RU	https://pubmed.ncbi.nlm.nih.gov/11104741

DMKNUP3	DI	DMKNUP3
DMKNUP3	DN	norfluoxetine
DMKNUP3	MI	TTVUWHQ
DMKNUP3	MN	Voltage-gated potassium channel Kv3.1 (KCNC1)
DMKNUP3	MT	DTT
DMKNUP3	MA	Inhibitor (gating inhibitor)
DMKNUP3	RN	Effects of norfluoxetine, the major metabolite of fluoxetine, on the cloned neuronal potassium channel Kv3.1. Neuropharmacology. 2001 Sep;41(4):443-53.
DMKNUP3	RU	https://pubmed.ncbi.nlm.nih.gov/11543764

DMKYQWG	DI	DMKYQWG
DMKYQWG	DN	NORHARMANE
DMKYQWG	MI	TT1MPAY
DMKYQWG	MN	GABA(A) receptor alpha-1 (GABRA1)
DMKYQWG	MT	DTT
DMKYQWG	MA	Inhibitor
DMKYQWG	RN	Synthesis of novel 3-substituted beta-carbolines as benzodiazepine receptor ligands: probing the benzodiazepine receptor pharmacophore. J Med Chem. 1988 Sep;31(9):1854-61.
DMKYQWG	RU	https://pubmed.ncbi.nlm.nih.gov/2842507

DMKYQWG	DI	DMKYQWG
DMKYQWG	DN	NORHARMANE
DMKYQWG	MI	TTNJYV2
DMKYQWG	MN	Gamma-aminobutyric acid receptor (GAR)
DMKYQWG	MT	DTT
DMKYQWG	MA	Inhibitor
DMKYQWG	RN	Synthesis of novel 3-substituted beta-carbolines as benzodiazepine receptor ligands: probing the benzodiazepine receptor pharmacophore. J Med Chem. 1988 Sep;31(9):1854-61.
DMKYQWG	RU	https://pubmed.ncbi.nlm.nih.gov/2842507

DMYQGFJ	DI	DMYQGFJ
DMYQGFJ	DN	normorphine
DMYQGFJ	MI	TT27RFC
DMYQGFJ	MN	Opioid receptor delta (OPRD1)
DMYQGFJ	MT	DTT
DMYQGFJ	MA	Agonist
DMYQGFJ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317).
DMYQGFJ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=317

DMYQGFJ	DI	DMYQGFJ
DMYQGFJ	DN	normorphine
DMYQGFJ	MI	TTQW87Y
DMYQGFJ	MN	Opioid receptor kappa (OPRK1)
DMYQGFJ	MT	DTT
DMYQGFJ	MA	Agonist
DMYQGFJ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 318).
DMYQGFJ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=318

DMYQGFJ	DI	DMYQGFJ
DMYQGFJ	DN	normorphine
DMYQGFJ	MI	TTKWM86
DMYQGFJ	MN	Opioid receptor mu (MOP)
DMYQGFJ	MT	DTT
DMYQGFJ	MA	Agonist
DMYQGFJ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
DMYQGFJ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319

DMSZWGN	DI	DMSZWGN
DMSZWGN	DN	NOR-ROEFRACTINE
DMSZWGN	MI	TTEX248
DMSZWGN	MN	Dopamine D2 receptor (D2R)
DMSZWGN	MT	DTT
DMSZWGN	MA	Inhibitor
DMSZWGN	RN	Synthesis and dopamine receptor selectivity of the benzyltetrahydroisoquinoline, (R)-(+)-nor-roefractine. J Nat Prod. 1998 Jun 26;61(6):709-12.
DMSZWGN	RU	https://pubmed.ncbi.nlm.nih.gov/9644051

DM1VIHC	DI	DM1VIHC
DM1VIHC	DN	NORSTEPHALAGINE
DM1VIHC	MI	TTZFYLI
DM1VIHC	MN	Dopamine D1 receptor (D1R)
DM1VIHC	MT	DTT
DM1VIHC	MA	Inhibitor
DM1VIHC	RN	Advances in development of dopaminergic aporphinoids. J Med Chem. 2007 Jan 25;50(2):171-81.
DM1VIHC	RU	https://pubmed.ncbi.nlm.nih.gov/17228858

DM1VIHC	DI	DM1VIHC
DM1VIHC	DN	NORSTEPHALAGINE
DM1VIHC	MI	TTVBI8W
DM1VIHC	MN	Dopamine transporter (DAT)
DM1VIHC	MT	DTT
DM1VIHC	MA	Inhibitor
DM1VIHC	RN	Effects of various isoquinoline alkaloids on in vitro 3H-dopamine uptake by rat striatal synaptosomes. J Nat Prod. 1995 Oct;58(10):1475-84.
DM1VIHC	RU	https://pubmed.ncbi.nlm.nih.gov/8676127

DMTY43L	DI	DMTY43L
DMTY43L	DN	Nortropinyl-arylsulfonylurea 3
DMTY43L	MI	TTHM0R1
DMTY43L	MN	Steryl-sulfatase (STS)
DMTY43L	MT	DTT
DMTY43L	MA	Inhibitor
DMTY43L	RN	Nortropinyl-arylsulfonylureas as novel, reversible inhibitors of human steroid sulfatase. Bioorg Med Chem Lett. 2003 Nov 3;13(21):3673-7.
DMTY43L	RU	https://pubmed.ncbi.nlm.nih.gov/14552755

DM19FS3	DI	DM19FS3
DM19FS3	DN	Norzimelidine
DM19FS3	MI	TTJXYQ6
DM19FS3	MN	Monoamine uptake (MA uptake)
DM19FS3	MT	DTT
DM19FS3	MA	Inhibitor
DM19FS3	RN	The antidepressant agents desipramine, fluoxetine, fluvoxamine and norzimelidine inhibit uptake of [3H]noradrenaline and [3H]5-hydroxytryptamine in slices of human and rat cortical brain tissue. Brain Res. 1983 Sep 19;275(1):99-104.
DM19FS3	RU	https://pubmed.ncbi.nlm.nih.gov/6226337

DMS3N4X	DI	DMS3N4X
DMS3N4X	DN	norzotepine
DMS3N4X	MI	TTAWNKZ
DMS3N4X	MN	Norepinephrine transporter (NET)
DMS3N4X	MT	DTT
DMS3N4X	MA	Inhibitor
DMS3N4X	RN	Norzotepine, a major metabolite of zotepine, exerts atypical antipsychotic-like and antidepressant-like actions through its potent inhibition of norepinephrine reuptake. J Pharmacol Exp Ther. 2010 Jun;333(3):772-81.
DMS3N4X	RU	https://pubmed.ncbi.nlm.nih.gov/20223878

DMS3N4X	DI	DMS3N4X
DMS3N4X	DN	norzotepine
DMS3N4X	MI	TT3ROYC
DMS3N4X	MN	Serotonin transporter (SERT)
DMS3N4X	MT	DTT
DMS3N4X	MA	Inhibitor
DMS3N4X	RN	Norzotepine, a major metabolite of zotepine, exerts atypical antipsychotic-like and antidepressant-like actions through its potent inhibition of norepinephrine reuptake. J Pharmacol Exp Ther. 2010 Jun;333(3):772-81.
DMS3N4X	RU	https://pubmed.ncbi.nlm.nih.gov/20223878

DME5O17	DI	DME5O17
DME5O17	DN	NOSTOCARBOLINE
DME5O17	MI	TTEB0GD
DME5O17	MN	Cholinesterase (BCHE)
DME5O17	MT	DTT
DME5O17	MA	Inhibitor
DME5O17	RN	Nostocarboline: isolation and synthesis of a new cholinesterase inhibitor from Nostoc 78-12A. J Nat Prod. 2005 Dec;68(12):1793-5.
DME5O17	RU	https://pubmed.ncbi.nlm.nih.gov/16378379

DMLVFUY	DI	DMLVFUY
DMLVFUY	DN	N-o-Tolyl-1'H-phenothiazine-1'-carboxamide
DMLVFUY	MI	TTEB0GD
DMLVFUY	MN	Cholinesterase (BCHE)
DMLVFUY	MT	DTT
DMLVFUY	MA	Inhibitor
DMLVFUY	RN	Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorg Med Chem. 2010 Mar 15;18(6):2232-2244.
DMLVFUY	RU	https://pubmed.ncbi.nlm.nih.gov/20181484

DM82DNL	DI	DM82DNL
DM82DNL	DN	Nova-EPO
DM82DNL	MI	TTAUX24
DM82DNL	MN	Erythropoietin Receptor (EPOR)
DM82DNL	MT	DTT
DM82DNL	MA	Modulator
DM82DNL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1718).
DM82DNL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1718

DM3C2VA	DI	DM3C2VA
DM3C2VA	DN	Novo Nordisk a/S Compound
DM3C2VA	MI	TTELIN2
DM3C2VA	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DM3C2VA	MT	DTT
DM3C2VA	MA	Inhibitor
DM3C2VA	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM3C2VA	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMAM5ZO	DI	DMAM5ZO
DMAM5ZO	DN	NOX 2137a/b
DMAM5ZO	MI	TTNT7K8
DMAM5ZO	MN	Nociceptin receptor (OPRL1)
DMAM5ZO	MT	DTT
DMAM5ZO	RN	Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60.
DMAM5ZO	RU	https://pubmed.ncbi.nlm.nih.gov/18095918

DMZVDLS	DI	DMZVDLS
DMZVDLS	DN	NOX 2149
DMZVDLS	MI	TTNT7K8
DMZVDLS	MN	Nociceptin receptor (OPRL1)
DMZVDLS	MT	DTT
DMZVDLS	RN	Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60.
DMZVDLS	RU	https://pubmed.ncbi.nlm.nih.gov/18095918

DMFW8O5	DI	DMFW8O5
DMFW8O5	DN	NOX-B11
DMFW8O5	MI	TTWDC17
DMFW8O5	MN	Growth hormone secretagogue receptor 1 (GHSR)
DMFW8O5	MT	DTT
DMFW8O5	MA	Antagonist
DMFW8O5	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 246).
DMFW8O5	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=246

DMQ84J7	DI	DMQ84J7
DMQ84J7	DN	N-oxo-2-(phenylsulfonylamino)ethanamide
DMQ84J7	MI	TTXZ0KQ
DMQ84J7	MN	Matrix metalloproteinase-12 (MMP-12)
DMQ84J7	MT	DTT
DMQ84J7	MA	Inhibitor
DMQ84J7	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMQ84J7	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMHTI5X	DI	DMHTI5X
DMHTI5X	DN	N-oxo-2-[(4-phenylphenyl)sulfonylamino]ethanamide
DMHTI5X	MI	TTXZ0KQ
DMHTI5X	MN	Matrix metalloproteinase-12 (MMP-12)
DMHTI5X	MT	DTT
DMHTI5X	MA	Inhibitor
DMHTI5X	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMHTI5X	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMVS6DW	DI	DMVS6DW
DMVS6DW	DN	NOX-S91
DMVS6DW	MI	TT9JZCK
DMVS6DW	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMVS6DW	MT	DTT
DMVS6DW	MA	Inhibitor
DMVS6DW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 275).
DMVS6DW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=275

DM906YB	DI	DM906YB
DM906YB	DN	NP-0336
DM906YB	MI	TTEB0GD
DM906YB	MN	Cholinesterase (BCHE)
DM906YB	MT	DTT
DM906YB	MA	Inhibitor
DM906YB	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2471).
DM906YB	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2471

DM51S0B	DI	DM51S0B
DM51S0B	DN	NP16
DM51S0B	MI	TTR5YAZ
DM51S0B	MN	Staphylococcus Dehydrosqualene desaturase (Stap-coc crtN)
DM51S0B	MT	DTT
DM51S0B	MA	Inhibitor
DM51S0B	RN	Dehydrosqualene Desaturase as a Novel Target for Anti-Virulence Therapy against Staphylococcus aureus.MBio. 2017 Sep 5;8(5). pii: e01224-17. 
DM51S0B	RU	https://pubmed.ncbi.nlm.nih.gov/28874472

DMVPIF8	DI	DMVPIF8
DMVPIF8	DN	NP-506
DMVPIF8	MI	TTRLW2X
DMVPIF8	MN	Fibroblast growth factor receptor 1 (FGFR1)
DMVPIF8	MT	DTT
DMVPIF8	MA	Inhibitor
DMVPIF8	RN	5-Substituted pyrido[2,3-d]pyrimidine, an inhibitor against three receptor tyrosine kinases. Bioorg Med Chem Lett. 2009 Feb 1;19(3):745-50.
DMVPIF8	RU	https://pubmed.ncbi.nlm.nih.gov/19110422

DMMZXRT	DI	DMMZXRT
DMMZXRT	DN	NP93-31
DMMZXRT	MI	TTN9D8E
DMMZXRT	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMMZXRT	MT	DTT
DMMZXRT	MA	Antagonist
DMMZXRT	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457).
DMMZXRT	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=457

DMU426Z	DI	DMU426Z
DMU426Z	DN	NPC-349
DMU426Z	MI	TTGY8IW
DMU426Z	MN	B2 bradykinin receptor (BDKRB2)
DMU426Z	MT	DTT
DMU426Z	MA	Antagonist
DMU426Z	RN	Differential pharmacology of cloned human and mouse B2 bradykinin receptors. Mol Pharmacol. 1994 Jan;45(1):1-8.
DMU426Z	RU	https://pubmed.ncbi.nlm.nih.gov/8302267

DMJQZMH	DI	DMJQZMH
DMJQZMH	DN	N-phenethyl-2-(pyrrolidin-1-yl)pyrimidin-4-amine
DMJQZMH	MI	TT1RS9F
DMJQZMH	MN	Acetylcholinesterase (AChE)
DMJQZMH	MT	DTT
DMJQZMH	MA	Inhibitor
DMJQZMH	RN	Design, synthesis and evaluation of 2,4-disubstituted pyrimidines as cholinesterase inhibitors. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3606-9.
DMJQZMH	RU	https://pubmed.ncbi.nlm.nih.gov/20472431

DMJQZMH	DI	DMJQZMH
DMJQZMH	DN	N-phenethyl-2-(pyrrolidin-1-yl)pyrimidin-4-amine
DMJQZMH	MI	TTEB0GD
DMJQZMH	MN	Cholinesterase (BCHE)
DMJQZMH	MT	DTT
DMJQZMH	MA	Inhibitor
DMJQZMH	RN	Design, synthesis and evaluation of 2,4-disubstituted pyrimidines as cholinesterase inhibitors. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3606-9.
DMJQZMH	RU	https://pubmed.ncbi.nlm.nih.gov/20472431

DM1BU5P	DI	DM1BU5P
DM1BU5P	DN	N-Phenethyl-2-(toluene-4-sulfonylamino)-benzamide
DM1BU5P	MI	TTW0CMT
DM1BU5P	MN	Voltage-gated potassium channel Kv1.5 (KCNA5)
DM1BU5P	MT	DTT
DM1BU5P	MA	Inhibitor
DM1BU5P	RN	Pharmacophore-based search, synthesis, and biological evaluation of anthranilic amides as novel blockers of the Kv1.5 channel. Bioorg Med Chem Lett. 2004 Jun 7;14(11):2823-7.
DM1BU5P	RU	https://pubmed.ncbi.nlm.nih.gov/15125940

DM4G6LJ	DI	DM4G6LJ
DM4G6LJ	DN	N-phenethyl-2-phenylquinoline-4-carboxamide
DM4G6LJ	MI	TTBPGLU
DM4G6LJ	MN	Neuromedin-K receptor (TACR3)
DM4G6LJ	MT	DTT
DM4G6LJ	MA	Inhibitor
DM4G6LJ	RN	Virtual screening to identify novel antagonists for the G protein-coupled NK3 receptor. J Med Chem. 2010 Nov 25;53(22):8080-8.
DM4G6LJ	RU	https://pubmed.ncbi.nlm.nih.gov/21047106

DM1ZPGY	DI	DM1ZPGY
DM1ZPGY	DN	N-phenethylquinoxaline-2-carboxamide
DM1ZPGY	MI	TTVBPDM
DM1ZPGY	MN	Metabotropic glutamate receptor 1 (mGluR1)
DM1ZPGY	MT	DTT
DM1ZPGY	MA	Inhibitor
DM1ZPGY	RN	Structure-activity relationships of novel non-competitive mGluR1 antagonists: a potential treatment for chronic pain. Bioorg Med Chem Lett. 2007 Jan 15;17(2):486-90.
DM1ZPGY	RU	https://pubmed.ncbi.nlm.nih.gov/17064898

DM7V025	DI	DM7V025
DM7V025	DN	N-Phenyl-1H-indole-2-carboxamide
DM7V025	MI	TT3WG5C
DM7V025	MN	Monoamine oxidase type A (MAO-A)
DM7V025	MT	DTT
DM7V025	MA	Inhibitor
DM7V025	RN	Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40.
DM7V025	RU	https://pubmed.ncbi.nlm.nih.gov/18951803

DM7V025	DI	DM7V025
DM7V025	DN	N-Phenyl-1H-indole-2-carboxamide
DM7V025	MI	TTGP7BY
DM7V025	MN	Monoamine oxidase type B (MAO-B)
DM7V025	MT	DTT
DM7V025	MA	Inhibitor
DM7V025	RN	Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40.
DM7V025	RU	https://pubmed.ncbi.nlm.nih.gov/18951803

DM1LHD3	DI	DM1LHD3
DM1LHD3	DN	N-Phenyl-1'H-phenothiazine-1'-carboxamide
DM1LHD3	MI	TTEB0GD
DM1LHD3	MN	Cholinesterase (BCHE)
DM1LHD3	MT	DTT
DM1LHD3	MA	Inhibitor
DM1LHD3	RN	Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorg Med Chem. 2010 Mar 15;18(6):2232-2244.
DM1LHD3	RU	https://pubmed.ncbi.nlm.nih.gov/20181484

DMP5E1G	DI	DMP5E1G
DMP5E1G	DN	N-phenyl-1H-pyrazole-3-carboxamide
DMP5E1G	MI	TT7HF4W
DMP5E1G	MN	Cyclin-dependent kinase 2 (CDK2)
DMP5E1G	MT	DTT
DMP5E1G	MA	Inhibitor
DMP5E1G	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMP5E1G	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMBGIUE	DI	DMBGIUE
DMBGIUE	DN	N-phenyl-1H-pyrrole-2-carboxamide
DMBGIUE	MI	TT3WG5C
DMBGIUE	MN	Monoamine oxidase type A (MAO-A)
DMBGIUE	MT	DTT
DMBGIUE	MA	Inhibitor
DMBGIUE	RN	New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J Med Chem. 2007 Mar 8;50(5):922-31.
DMBGIUE	RU	https://pubmed.ncbi.nlm.nih.gov/17256833

DM1XV0O	DI	DM1XV0O
DM1XV0O	DN	N-Phenyl-1-methyl-1H-indole-2-carboxamide
DM1XV0O	MI	TT3WG5C
DM1XV0O	MN	Monoamine oxidase type A (MAO-A)
DM1XV0O	MT	DTT
DM1XV0O	MA	Inhibitor
DM1XV0O	RN	Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40.
DM1XV0O	RU	https://pubmed.ncbi.nlm.nih.gov/18951803

DM0JI2L	DI	DM0JI2L
DM0JI2L	DN	N-phenyl-2,3,4-trihydroxy-5-benzyl-benzamide
DM0JI2L	MI	TTJGNVC
DM0JI2L	MN	Apoptosis regulator Bcl-2 (BCL-2)
DM0JI2L	MT	DTT
DM0JI2L	MA	Inhibitor
DM0JI2L	RN	Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem. 2006 Oct 19;49(21):6139-42.
DM0JI2L	RU	https://pubmed.ncbi.nlm.nih.gov/17034116

DMWH86J	DI	DMWH86J
DMWH86J	DN	N-phenyl-3-(2-aminoethyl)benzenesulfonamide
DMWH86J	MI	TTJS8PY
DMWH86J	MN	5-HT 6 receptor (HTR6)
DMWH86J	MT	DTT
DMWH86J	MA	Inhibitor
DMWH86J	RN	Binding of sulfonyl-containing arylalkylamines at human 5-HT6 serotonin receptors. J Med Chem. 2006 Aug 24;49(17):5217-25.
DMWH86J	RU	https://pubmed.ncbi.nlm.nih.gov/16913710

DM7XER1	DI	DM7XER1
DM7XER1	DN	N-phenyl-5,6-dip-tolylpyrazine-2-carboxamide
DM7XER1	MI	TT6OEDT
DM7XER1	MN	Cannabinoid receptor 1 (CB1)
DM7XER1	MT	DTT
DM7XER1	MA	Inhibitor
DM7XER1	RN	Discovery of pyrazine carboxamide CB1 antagonists: the introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy... Bioorg Med Chem Lett. 2007 Jul 15;17(14):3978-82.
DM7XER1	RU	https://pubmed.ncbi.nlm.nih.gov/17513109

DMGVJBD	DI	DMGVJBD
DMGVJBD	DN	N-Phenyl-5-phenylimidazo[1,5-a]pyrazin-8-amine
DMGVJBD	MI	TT6PKBN
DMGVJBD	MN	Proto-oncogene c-Src (SRC)
DMGVJBD	MT	DTT
DMGVJBD	MA	Inhibitor
DMGVJBD	RN	Synthesis and c-Src inhibitory activity of imidazo[1,5-a]pyrazine derivatives as an agent for treatment of acute ischemic stroke. Bioorg Med Chem. 2007 Jan 15;15(2):868-85.
DMGVJBD	RU	https://pubmed.ncbi.nlm.nih.gov/17095233

DMRHKF8	DI	DMRHKF8
DMRHKF8	DN	N-phenyl-6-(sulfamoylamino)hexanamide
DMRHKF8	MI	TT5ZKDI
DMRHKF8	MN	Histone deacetylase 6 (HDAC6)
DMRHKF8	MT	DTT
DMRHKF8	MA	Inhibitor
DMRHKF8	RN	Sulfamides as novel histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):336-40.
DMRHKF8	RU	https://pubmed.ncbi.nlm.nih.gov/19084395

DMXANES	DI	DMXANES
DMXANES	DN	N-Phenylbenzo[d]oxazol-2-amine
DMXANES	MI	TT2J34L
DMXANES	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMXANES	MT	DTT
DMXANES	MA	Inhibitor
DMXANES	RN	Synthesis and evaluation of benzoxazole derivatives as 5-lipoxygenase inhibitors. Bioorg Med Chem. 2010 Nov 1;18(21):7580-5.
DMXANES	RU	https://pubmed.ncbi.nlm.nih.gov/20870413

DM1VSO9	DI	DM1VSO9
DM1VSO9	DN	N-Phenylethyl-ETAV
DM1VSO9	MI	TT9PB26
DM1VSO9	MN	Presynaptic density protein 95 (DLG4)
DM1VSO9	MT	DTT
DM1VSO9	MA	Inhibitor
DM1VSO9	RN	Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem. 2008 Oct 23;51(20):6450-9.
DM1VSO9	RU	https://pubmed.ncbi.nlm.nih.gov/18811137

DM90GNC	DI	DM90GNC
DM90GNC	DN	N-Phenylpropyl-ETAV
DM90GNC	MI	TT9PB26
DM90GNC	MN	Presynaptic density protein 95 (DLG4)
DM90GNC	MT	DTT
DM90GNC	MA	Inhibitor
DM90GNC	RN	Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem. 2008 Oct 23;51(20):6450-9.
DM90GNC	RU	https://pubmed.ncbi.nlm.nih.gov/18811137

DMFIWAN	DI	DMFIWAN
DMFIWAN	DN	NPPB
DMFIWAN	MI	TTOJI4S
DMFIWAN	MN	Calcium-dependent chloride channel anoctamin (ANO)
DMFIWAN	MT	DTT
DMFIWAN	MA	Blocker (channel blocker)
DMFIWAN	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 708).
DMFIWAN	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=708

DMFIWAN	DI	DMFIWAN
DMFIWAN	DN	NPPB
DMFIWAN	MI	TT30NW6
DMFIWAN	MN	Chloride channel protein 2 (CLC-2)
DMFIWAN	MT	DTT
DMFIWAN	MA	Blocker (channel blocker)
DMFIWAN	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 699).
DMFIWAN	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=699

DMFIWAN	DI	DMFIWAN
DMFIWAN	DN	NPPB
DMFIWAN	MI	TTST1AJ
DMFIWAN	MN	Chloride channel protein 7 (ClC-7)
DMFIWAN	MT	DTT
DMFIWAN	MA	Blocker (channel blocker)
DMFIWAN	RN	The G215R mutation in the Cl-/H+-antiporter ClC-7 found in ADO II osteopetrosis does not abolish function but causes a severe trafficking defect. PLoS One. 2010 Sep 7;5(9):e12585.
DMFIWAN	RU	https://pubmed.ncbi.nlm.nih.gov/20830208

DMFIWAN	DI	DMFIWAN
DMFIWAN	DN	NPPB
DMFIWAN	MI	TTT1MCF
DMFIWAN	MN	Permeability pathway (NP pathway)
DMFIWAN	MT	DTT
DMFIWAN	MA	Inhibitor
DMFIWAN	RN	Novel molecular targets for antimalarial drug development. Chem Biol Drug Des. 2008 Apr;71(4):287-97.
DMFIWAN	RU	https://pubmed.ncbi.nlm.nih.gov/18298458

DMFIWAN	DI	DMFIWAN
DMFIWAN	DN	NPPB
DMFIWAN	MI	TTELV3W
DMFIWAN	MN	Transformation-sensitive protein p120 (TRPA1)
DMFIWAN	MT	DTT
DMFIWAN	MA	Activator
DMFIWAN	RN	NPPB structure-specifically activates TRPA1 channels. Biochem Pharmacol. 2010 Jul 1;80(1):113-21.
DMFIWAN	RU	https://pubmed.ncbi.nlm.nih.gov/20226176

DMFIWAN	DI	DMFIWAN
DMFIWAN	DN	NPPB
DMFIWAN	MI	TT0FC1V
DMFIWAN	MN	Volume regulated chloride channel (VRAC)
DMFIWAN	MT	DTT
DMFIWAN	MA	Blocker (channel blocker)
DMFIWAN	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 710).
DMFIWAN	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=710

DMHZCLV	DI	DMHZCLV
DMHZCLV	DN	N-Propargyl-1(S)-Aminoindan
DMHZCLV	MI	TTGP7BY
DMHZCLV	MN	Monoamine oxidase type B (MAO-B)
DMHZCLV	MT	DTT
DMHZCLV	MA	Inhibitor
DMHZCLV	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMHZCLV	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMNYQ28	DI	DMNYQ28
DMNYQ28	DN	N-propargyl-1H-pyrrole-2-carboxamide
DMNYQ28	MI	TT3WG5C
DMNYQ28	MN	Monoamine oxidase type A (MAO-A)
DMNYQ28	MT	DTT
DMNYQ28	MA	Inhibitor
DMNYQ28	RN	New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J Med Chem. 2007 Mar 8;50(5):922-31.
DMNYQ28	RU	https://pubmed.ncbi.nlm.nih.gov/17256833

DMKBG1F	DI	DMKBG1F
DMKBG1F	DN	N-Propyl-2-methylnorapomorphine hydrochloride
DMKBG1F	MI	TTEX248
DMKBG1F	MN	Dopamine D2 receptor (D2R)
DMKBG1F	MT	DTT
DMKBG1F	MA	Inhibitor
DMKBG1F	RN	N-Substituted-2-alkyl- and 2-arylnorapomorphines: novel, highly active D2 agonists. Bioorg Med Chem. 2009 Jul 1;17(13):4756-62.
DMKBG1F	RU	https://pubmed.ncbi.nlm.nih.gov/19454369

DML6SAG	DI	DML6SAG
DML6SAG	DN	N-Propyl-2-phenylnorapomorphine hydrochloride
DML6SAG	MI	TTEX248
DML6SAG	MN	Dopamine D2 receptor (D2R)
DML6SAG	MT	DTT
DML6SAG	MA	Inhibitor
DML6SAG	RN	N-Substituted-2-alkyl- and 2-arylnorapomorphines: novel, highly active D2 agonists. Bioorg Med Chem. 2009 Jul 1;17(13):4756-62.
DML6SAG	RU	https://pubmed.ncbi.nlm.nih.gov/19454369

DMUTDNV	DI	DMUTDNV
DMUTDNV	DN	N-Propyl-ETAV
DMUTDNV	MI	TT9PB26
DMUTDNV	MN	Presynaptic density protein 95 (DLG4)
DMUTDNV	MT	DTT
DMUTDNV	MA	Inhibitor
DMUTDNV	RN	Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem. 2008 Oct 23;51(20):6450-9.
DMUTDNV	RU	https://pubmed.ncbi.nlm.nih.gov/18811137

DMO7MTX	DI	DMO7MTX
DMO7MTX	DN	N-propylnorapomorphine
DMO7MTX	MI	TTZFYLI
DMO7MTX	MN	Dopamine D1 receptor (D1R)
DMO7MTX	MT	DTT
DMO7MTX	MA	Agonist
DMO7MTX	RN	Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature. 1991 Apr 18;350(6319):614-9.
DMO7MTX	RU	https://pubmed.ncbi.nlm.nih.gov/1826762

DMO7MTX	DI	DMO7MTX
DMO7MTX	DN	N-propylnorapomorphine
DMO7MTX	MI	TTEX248
DMO7MTX	MN	Dopamine D2 receptor (D2R)
DMO7MTX	MT	DTT
DMO7MTX	MA	Inhibitor
DMO7MTX	RN	A functional test identifies dopamine agonists selective for D3 versus D2 receptors. Neuroreport. 1995 Jan 26;6(2):329-32.
DMO7MTX	RU	https://pubmed.ncbi.nlm.nih.gov/7756621

DMO7MTX	DI	DMO7MTX
DMO7MTX	DN	N-propylnorapomorphine
DMO7MTX	MI	TT4C8EA
DMO7MTX	MN	Dopamine D3 receptor (D3R)
DMO7MTX	MT	DTT
DMO7MTX	MA	Agonist
DMO7MTX	RN	A functional test identifies dopamine agonists selective for D3 versus D2 receptors. Neuroreport. 1995 Jan 26;6(2):329-32.
DMO7MTX	RU	https://pubmed.ncbi.nlm.nih.gov/7756621

DMO7MTX	DI	DMO7MTX
DMO7MTX	DN	N-propylnorapomorphine
DMO7MTX	MI	TTS2PH3
DMO7MTX	MN	Dopamine D5 receptor (D5R)
DMO7MTX	MT	DTT
DMO7MTX	MA	Agonist
DMO7MTX	RN	Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature. 1991 Apr 18;350(6319):614-9.
DMO7MTX	RU	https://pubmed.ncbi.nlm.nih.gov/1826762

DM3JQYD	DI	DM3JQYD
DM3JQYD	DN	N-propylnorlitebamine
DM3JQYD	MI	TT1RS9F
DM3JQYD	MN	Acetylcholinesterase (AChE)
DM3JQYD	MT	DTT
DM3JQYD	MA	Inhibitor
DM3JQYD	RN	Litebamine N-homologues: preparation and anti-acetylcholinesterase activity. J Nat Prod. 1998 Jan;61(1):46-50.
DM3JQYD	RU	https://pubmed.ncbi.nlm.nih.gov/9461651

DMWTPJH	DI	DMWTPJH
DMWTPJH	DN	N-propynyl amidebenzenesulphonide
DMWTPJH	MI	TTHQPL7
DMWTPJH	MN	Carbonic anhydrase I (CA-I)
DMWTPJH	MT	DTT
DMWTPJH	MA	Inhibitor
DMWTPJH	RN	A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing". J Med Chem. 2006 Nov 2;49(22):6539-48.
DMWTPJH	RU	https://pubmed.ncbi.nlm.nih.gov/17064072

DMWTPJH	DI	DMWTPJH
DMWTPJH	DN	N-propynyl amidebenzenesulphonide
DMWTPJH	MI	TTANPDJ
DMWTPJH	MN	Carbonic anhydrase II (CA-II)
DMWTPJH	MT	DTT
DMWTPJH	MA	Inhibitor
DMWTPJH	RN	A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing". J Med Chem. 2006 Nov 2;49(22):6539-48.
DMWTPJH	RU	https://pubmed.ncbi.nlm.nih.gov/17064072

DMWTPJH	DI	DMWTPJH
DMWTPJH	DN	N-propynyl amidebenzenesulphonide
DMWTPJH	MI	TT2LVK8
DMWTPJH	MN	Carbonic anhydrase IX (CA-IX)
DMWTPJH	MT	DTT
DMWTPJH	MA	Inhibitor
DMWTPJH	RN	A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing". J Med Chem. 2006 Nov 2;49(22):6539-48.
DMWTPJH	RU	https://pubmed.ncbi.nlm.nih.gov/17064072

DMWTPJH	DI	DMWTPJH
DMWTPJH	DN	N-propynyl amidebenzenesulphonide
DMWTPJH	MI	TTSYM0R
DMWTPJH	MN	Carbonic anhydrase XII (CA-XII)
DMWTPJH	MT	DTT
DMWTPJH	MA	Inhibitor
DMWTPJH	RN	Inhibition of membrane-associated carbonic anhydrase isozymes IX, XII and XIV with a library of glycoconjugate benzenesulfonamides. Bioorg Med Chem Lett. 2007 Feb 15;17(4):987-92.
DMWTPJH	RU	https://pubmed.ncbi.nlm.nih.gov/17157501

DMWTPJH	DI	DMWTPJH
DMWTPJH	DN	N-propynyl amidebenzenesulphonide
DMWTPJH	MI	TTEYTKG
DMWTPJH	MN	Carbonic anhydrase XIV (CA-XIV)
DMWTPJH	MT	DTT
DMWTPJH	MA	Inhibitor
DMWTPJH	RN	Inhibition of membrane-associated carbonic anhydrase isozymes IX, XII and XIV with a library of glycoconjugate benzenesulfonamides. Bioorg Med Chem Lett. 2007 Feb 15;17(4):987-92.
DMWTPJH	RU	https://pubmed.ncbi.nlm.nih.gov/17157501

DMYB2EZ	DI	DMYB2EZ
DMYB2EZ	DN	NPRx-30
DMYB2EZ	MI	TT1RS9F
DMYB2EZ	MN	Acetylcholinesterase (AChE)
DMYB2EZ	MT	DTT
DMYB2EZ	MA	Modulator
DMYB2EZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2465).
DMYB2EZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2465

DMMUY73	DI	DMMUY73
DMMUY73	DN	NPT-500
DMMUY73	MI	TTSQIFT
DMMUY73	MN	5-HT 1A receptor (HTR1A)
DMMUY73	MT	DTT
DMMUY73	MA	Modulator
DMMUY73	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1).
DMMUY73	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1

DMMR7DI	DI	DMMR7DI
DMMR7DI	DN	N-p-Tolyl-1'H-phenothiazine-1'-carboxamide
DMMR7DI	MI	TTEB0GD
DMMR7DI	MN	Cholinesterase (BCHE)
DMMR7DI	MT	DTT
DMMR7DI	MA	Inhibitor
DMMR7DI	RN	Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorg Med Chem. 2010 Mar 15;18(6):2232-2244.
DMMR7DI	RU	https://pubmed.ncbi.nlm.nih.gov/20181484

DM1MOG8	DI	DM1MOG8
DM1MOG8	DN	NPY-1 antagonist
DM1MOG8	MI	TTRK9JT
DM1MOG8	MN	Neuropeptide Y receptor type 1 (NPY1R)
DM1MOG8	MT	DTT
DM1MOG8	MA	Antagonist
DM1MOG8	RN	Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36.
DM1MOG8	RU	https://pubmed.ncbi.nlm.nih.gov/16634704

DMMV1YN	DI	DMMV1YN
DMMV1YN	DN	N-Pyridoxyl-Glycine-5-Monophosphate
DMMV1YN	MI	TTUMGNO
DMMV1YN	MN	Ornithine decarboxylase (ODC1)
DMMV1YN	MT	DTT
DMMV1YN	MA	Inhibitor
DMMV1YN	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMMV1YN	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM3ZHBO	DI	DM3ZHBO
DM3ZHBO	DN	N'-Pyridoxyl-Lysine-5'-Monophosphate
DM3ZHBO	MI	TTDU0HP
DM3ZHBO	MN	Bacterial Cystathionine gamma-synthase (Bact metB)
DM3ZHBO	MT	DTT
DM3ZHBO	MA	Inhibitor
DM3ZHBO	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM3ZHBO	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM3ZHBO	DI	DM3ZHBO
DM3ZHBO	DN	N'-Pyridoxyl-Lysine-5'-Monophosphate
DM3ZHBO	MI	TTZHY6R
DM3ZHBO	MN	Glycogen phosphorylase muscle form (GP)
DM3ZHBO	MT	DTT
DM3ZHBO	MA	Inhibitor
DM3ZHBO	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM3ZHBO	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM3ZHBO	DI	DM3ZHBO
DM3ZHBO	DN	N'-Pyridoxyl-Lysine-5'-Monophosphate
DM3ZHBO	MI	TTUMGNO
DM3ZHBO	MN	Ornithine decarboxylase (ODC1)
DM3ZHBO	MT	DTT
DM3ZHBO	MA	Inhibitor
DM3ZHBO	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM3ZHBO	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM3ZHBO	DI	DM3ZHBO
DM3ZHBO	DN	N'-Pyridoxyl-Lysine-5'-Monophosphate
DM3ZHBO	MI	TT1UY5C
DM3ZHBO	MN	Pseudomonas Methionine gamma-lyase (Pseudo mdeA)
DM3ZHBO	MT	DTT
DM3ZHBO	MA	Inhibitor
DM3ZHBO	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM3ZHBO	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMAXHLK	DI	DMAXHLK
DMAXHLK	DN	NQN-1
DMAXHLK	MI	TT5ZKDI
DMAXHLK	MN	Histone deacetylase 6 (HDAC6)
DMAXHLK	MT	DTT
DMAXHLK	MA	Inhibitor
DMAXHLK	RN	A novel class of small molecule inhibitors of HDAC6. ACS Chem Biol. 2012 Feb 17;7(2):331-9.
DMAXHLK	RU	https://pubmed.ncbi.nlm.nih.gov/22047054

DMXP03H	DI	DMXP03H
DMXP03H	DN	NRC-2694
DMXP03H	MI	TTGKNB4
DMXP03H	MN	Epidermal growth factor receptor (EGFR)
DMXP03H	MT	DTT
DMXP03H	MA	Inhibitor
DMXP03H	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
DMXP03H	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797

DMC9XJA	DI	DMC9XJA
DMC9XJA	DN	NRP290
DMC9XJA	MI	TT27RFC
DMC9XJA	MN	Opioid receptor delta (OPRD1)
DMC9XJA	MT	DTT
DMC9XJA	MA	Agonist
DMC9XJA	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317).
DMC9XJA	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=317

DMC9XJA	DI	DMC9XJA
DMC9XJA	DN	NRP290
DMC9XJA	MI	TTQW87Y
DMC9XJA	MN	Opioid receptor kappa (OPRK1)
DMC9XJA	MT	DTT
DMC9XJA	MA	Agonist
DMC9XJA	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 318).
DMC9XJA	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=318

DMC9XJA	DI	DMC9XJA
DMC9XJA	DN	NRP290
DMC9XJA	MI	TTKWM86
DMC9XJA	MN	Opioid receptor mu (MOP)
DMC9XJA	MT	DTT
DMC9XJA	MA	Agonist
DMC9XJA	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
DMC9XJA	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319

DM3IWP5	DI	DM3IWP5
DM3IWP5	DN	NRT-300
DM3IWP5	MI	TTKWM86
DM3IWP5	MN	Opioid receptor mu (MOP)
DM3IWP5	MT	DTT
DM3IWP5	MA	Modulator
DM3IWP5	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
DM3IWP5	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319

DML0N7D	DI	DML0N7D
DML0N7D	DN	NS 2028
DML0N7D	MI	TTWNFC2
DML0N7D	MN	Soluble guanylyl cyclase (GUCY2D)
DML0N7D	MT	DTT
DML0N7D	MA	Inhibitor
DML0N7D	RN	Characterization of NS 2028 as a specific inhibitor of soluble guanylyl cyclase. Br J Pharmacol. 1998 Jan;123(2):299-309.
DML0N7D	RU	https://pubmed.ncbi.nlm.nih.gov/9489619

DM98VMZ	DI	DM98VMZ
DM98VMZ	DN	NS-11757
DM98VMZ	MI	TTP835K
DM98VMZ	MN	ATP-binding cassette transporter C8 (ABCC8)
DM98VMZ	MT	DTT
DM98VMZ	MA	Modulator
DM98VMZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2944).
DM98VMZ	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2944

DMT97KV	DI	DMT97KV
DMT97KV	DN	NS-1643
DMT97KV	MI	TTQ6VDM
DMT97KV	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMT97KV	MT	DTT
DMT97KV	MA	Opener
DMT97KV	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 572).
DMT97KV	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=572

DM2S5ZF	DI	DM2S5ZF
DM2S5ZF	DN	NS1738
DM2S5ZF	MI	TTH18TF
DM2S5ZF	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DM2S5ZF	MT	DTT
DM2S5ZF	MA	Blocker (channel blocker)
DM2S5ZF	RN	An allosteric modulator of the alpha7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo. J Pharmacol Exp Ther. 2007 Oct;323(1):294-307.
DM2S5ZF	RU	https://pubmed.ncbi.nlm.nih.gov/17625074

DM2S5ZF	DI	DM2S5ZF
DM2S5ZF	DN	NS1738
DM2S5ZF	MI	TTLA931
DM2S5ZF	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DM2S5ZF	MT	DTT
DM2S5ZF	MA	Modulator (allosteric modulator)
DM2S5ZF	RN	An allosteric modulator of the alpha7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo. J Pharmacol Exp Ther. 2007 Oct;323(1):294-307.
DM2S5ZF	RU	https://pubmed.ncbi.nlm.nih.gov/17625074

DM2S5ZF	DI	DM2S5ZF
DM2S5ZF	DN	NS1738
DM2S5ZF	MI	TT5KPZR
DM2S5ZF	MN	Neuronal acetylcholine receptor beta-2 (CHRNB2)
DM2S5ZF	MT	DTT
DM2S5ZF	MA	Blocker (channel blocker)
DM2S5ZF	RN	An allosteric modulator of the alpha7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo. J Pharmacol Exp Ther. 2007 Oct;323(1):294-307.
DM2S5ZF	RU	https://pubmed.ncbi.nlm.nih.gov/17625074

DMVL5KS	DI	DMVL5KS
DMVL5KS	DN	NS3763
DMVL5KS	MI	TT0MYE2
DMVL5KS	MN	Glutamate receptor ionotropic kainate 1 (GRIK1)
DMVL5KS	MT	DTT
DMVL5KS	MA	Antagonist
DMVL5KS	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 450).
DMVL5KS	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=450

DM629TD	DI	DM629TD
DM629TD	DN	NS5818
DM629TD	MI	TTST1AJ
DM629TD	MN	Chloride channel protein 7 (ClC-7)
DM629TD	MT	DTT
DM629TD	MA	Blocker (channel blocker)
DM629TD	RN	The G215R mutation in the Cl-/H+-antiporter ClC-7 found in ADO II osteopetrosis does not abolish function but causes a severe trafficking defect. PLoS One. 2010 Sep 7;5(9):e12585.
DM629TD	RU	https://pubmed.ncbi.nlm.nih.gov/20830208

DMWN8FU	DI	DMWN8FU
DMWN8FU	DN	NS9283
DMWN8FU	MI	TT5KPZR
DMWN8FU	MN	Neuronal acetylcholine receptor beta-2 (CHRNB2)
DMWN8FU	MT	DTT
DMWN8FU	MA	Modulator (allosteric modulator)
DMWN8FU	RN	alpha4beta2 neuronal nicotinic receptor positive allosteric modulation: an approach for improving the therapeutic index of alpha4beta2 nAChR agonists in pain. Biochem Pharmacol. 2011 Oct 15;82(8):959-66.
DMWN8FU	RU	https://pubmed.ncbi.nlm.nih.gov/21763685

DMLT8G9	DI	DMLT8G9
DMLT8G9	DN	NSC 19630
DMLT8G9	MI	TT2H5WQ
DMLT8G9	MN	Werner syndrome ATP-dependent helicase (WRN)
DMLT8G9	MT	DTT
DMLT8G9	MA	Inhibitor
DMLT8G9	RN	WRN-targeted therapy using inhibitors NSC 19630 and NSC 617145 induce apoptosis in HTLV-1-transformed adult T-cell leukemia cells. J Hematol Oncol. 2016 Nov 9;9(1):121.
DMLT8G9	RU	https://pubmed.ncbi.nlm.nih.gov/27829440

DMX4DT7	DI	DMX4DT7
DMX4DT7	DN	NSC 665564
DMX4DT7	MI	TT3PQ2Y
DMX4DT7	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DMX4DT7	MT	DTT
DMX4DT7	MA	Inhibitor
DMX4DT7	RN	Identification of a novel inhibitor (NSC 665564) of dihydroorotate dehydrogenase with a potency equivalent to brequinar. Biochem Biophys Res Commun. 1996 Jun 25;223(3):654-9.
DMX4DT7	RU	https://pubmed.ncbi.nlm.nih.gov/8687451

DMR6P9S	DI	DMR6P9S
DMR6P9S	DN	NSC-106080
DMR6P9S	MI	TT8XK6L
DMR6P9S	MN	Quinone reductase 1 (NQO1)
DMR6P9S	MT	DTT
DMR6P9S	MA	Inhibitor
DMR6P9S	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMR6P9S	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMR6P9S	DI	DMR6P9S
DMR6P9S	DN	NSC-106080
DMR6P9S	MI	TTJLP0R
DMR6P9S	MN	Quinone reductase 2 (NQO2)
DMR6P9S	MT	DTT
DMR6P9S	MA	Inhibitor
DMR6P9S	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMR6P9S	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DM6ID8P	DI	DM6ID8P
DM6ID8P	DN	NSC-106084
DM6ID8P	MI	TTHVCUP
DM6ID8P	MN	DNA [cytosine-5]-methyltransferase (DNMT)
DM6ID8P	MT	DTT
DM6ID8P	MA	Inhibitor
DM6ID8P	RN	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
DM6ID8P	RU	https://pubmed.ncbi.nlm.nih.gov/20006515

DM6ID8P	DI	DM6ID8P
DM6ID8P	DN	NSC-106084
DM6ID8P	MI	TT6VZ78
DM6ID8P	MN	DNA [cytosine-5]-methyltransferase 3B (DNMT3B)
DM6ID8P	MT	DTT
DM6ID8P	MA	Inhibitor
DM6ID8P	RN	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
DM6ID8P	RU	https://pubmed.ncbi.nlm.nih.gov/20006515

DMR2DTI	DI	DMR2DTI
DMR2DTI	DN	NSC-106547
DMR2DTI	MI	TT8XK6L
DMR2DTI	MN	Quinone reductase 1 (NQO1)
DMR2DTI	MT	DTT
DMR2DTI	MA	Inhibitor
DMR2DTI	RN	In silico identification and biochemical characterization of novel inhibitors of NQO1. Bioorg Med Chem Lett. 2006 Dec 15;16(24):6246-54.
DMR2DTI	RU	https://pubmed.ncbi.nlm.nih.gov/17011189

DMHK0F6	DI	DMHK0F6
DMHK0F6	DN	NSC-106970
DMHK0F6	MI	TTML2WA
DMHK0F6	MN	Tubulin (TUB)
DMHK0F6	MT	DTT
DMHK0F6	MA	Inhibitor
DMHK0F6	RN	Structure-activity requirements for flavone cytotoxicity and binding to tubulin. J Med Chem. 1998 Jun 18;41(13):2333-8.
DMHK0F6	RU	https://pubmed.ncbi.nlm.nih.gov/9632366

DMHK0F6	DI	DMHK0F6
DMHK0F6	DN	NSC-106970
DMHK0F6	MI	TTYFKSZ
DMHK0F6	MN	Tubulin beta (TUBB)
DMHK0F6	MT	DTT
DMHK0F6	MA	Inhibitor
DMHK0F6	RN	Structure-activity requirements for flavone cytotoxicity and binding to tubulin. J Med Chem. 1998 Jun 18;41(13):2333-8.
DMHK0F6	RU	https://pubmed.ncbi.nlm.nih.gov/9632366

DMPLUHT	DI	DMPLUHT
DMPLUHT	DN	NSC-115890
DMPLUHT	MI	TTJLP0R
DMPLUHT	MN	Quinone reductase 2 (NQO2)
DMPLUHT	MT	DTT
DMPLUHT	MA	Inhibitor
DMPLUHT	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMPLUHT	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMKHMS4	DI	DMKHMS4
DMKHMS4	DN	NSC-119910
DMKHMS4	MI	TTHYBIX
DMKHMS4	MN	Heat shock protein 70 (HSP70)
DMKHMS4	MT	DTT
DMKHMS4	MA	Inhibitor
DMKHMS4	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMKHMS4	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DM1MRFW	DI	DM1MRFW
DM1MRFW	DN	NSC-119911
DM1MRFW	MI	TTHYBIX
DM1MRFW	MN	Heat shock protein 70 (HSP70)
DM1MRFW	MT	DTT
DM1MRFW	MA	Inhibitor
DM1MRFW	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DM1MRFW	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DM1MRFW	DI	DM1MRFW
DM1MRFW	DN	NSC-119911
DM1MRFW	MI	TTMQL3K
DM1MRFW	MN	Lipopolysaccharide-associated protein 1 (HSPA8)
DM1MRFW	MT	DTT
DM1MRFW	MA	Inhibitor
DM1MRFW	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DM1MRFW	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMVE69Y	DI	DMVE69Y
DMVE69Y	DN	NSC-119913
DMVE69Y	MI	TTHYBIX
DMVE69Y	MN	Heat shock protein 70 (HSP70)
DMVE69Y	MT	DTT
DMVE69Y	MA	Inhibitor
DMVE69Y	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMVE69Y	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMVE69Y	DI	DMVE69Y
DMVE69Y	DN	NSC-119913
DMVE69Y	MI	TTMQL3K
DMVE69Y	MN	Lipopolysaccharide-associated protein 1 (HSPA8)
DMVE69Y	MT	DTT
DMVE69Y	MA	Inhibitor
DMVE69Y	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMVE69Y	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMYMB4A	DI	DMYMB4A
DMYMB4A	DN	NSC-122427
DMYMB4A	MI	TTSZLWK
DMYMB4A	MN	Aromatase (CYP19A1)
DMYMB4A	MT	DTT
DMYMB4A	MA	Inhibitor
DMYMB4A	RN	An efficient steroid pharmacophore-based strategy to identify new aromatase inhibitors. Eur J Med Chem. 2009 Oct;44(10):4121-7.
DMYMB4A	RU	https://pubmed.ncbi.nlm.nih.gov/19500885

DM3NQDW	DI	DM3NQDW
DM3NQDW	DN	NSC-125034
DM3NQDW	MI	TT12ABZ
DM3NQDW	MN	Arachidonate 12-lipoxygenase (12-LOX)
DM3NQDW	MT	DTT
DM3NQDW	MA	Inhibitor
DM3NQDW	RN	Discovery of platelet-type 12-human lipoxygenase selective inhibitors by high-throughput screening of structurally diverse libraries. Bioorg Med Chem. 2007 Nov 15;15(22):6900-8.
DM3NQDW	RU	https://pubmed.ncbi.nlm.nih.gov/17826100

DMHGIB1	DI	DMHGIB1
DMHGIB1	DN	NSC-126445
DMHGIB1	MI	TT9NVXQ
DMHGIB1	MN	Phosphoribosylaminoimidazolecarboxamide formyltransferase (ATIC)
DMHGIB1	MT	DTT
DMHGIB1	MA	Inhibitor
DMHGIB1	RN	Virtual screening of human 5-aminoimidazole-4-carboxamide ribonucleotide transformylase against the NCI diversity set by use of AutoDock to identif... J Med Chem. 2004 Dec 30;47(27):6681-90.
DMHGIB1	RU	https://pubmed.ncbi.nlm.nih.gov/15615517

DMJAO6Z	DI	DMJAO6Z
DMJAO6Z	DN	NSC-12999
DMJAO6Z	MI	TTSZLWK
DMJAO6Z	MN	Aromatase (CYP19A1)
DMJAO6Z	MT	DTT
DMJAO6Z	MA	Inhibitor
DMJAO6Z	RN	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
DMJAO6Z	RU	https://pubmed.ncbi.nlm.nih.gov/19072235

DMYJNS9	DI	DMYJNS9
DMYJNS9	DN	NSC-131736
DMYJNS9	MI	TTSZLWK
DMYJNS9	MN	Aromatase (CYP19A1)
DMYJNS9	MT	DTT
DMYJNS9	MA	Inhibitor
DMYJNS9	RN	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
DMYJNS9	RU	https://pubmed.ncbi.nlm.nih.gov/19072235

DMKQYMX	DI	DMKQYMX
DMKQYMX	DN	NSC-137546
DMKQYMX	MI	TTHVCUP
DMKQYMX	MN	DNA [cytosine-5]-methyltransferase (DNMT)
DMKQYMX	MT	DTT
DMKQYMX	MA	Inhibitor
DMKQYMX	RN	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
DMKQYMX	RU	https://pubmed.ncbi.nlm.nih.gov/20006515

DMKQYMX	DI	DMKQYMX
DMKQYMX	DN	NSC-137546
DMKQYMX	MI	TT6VZ78
DMKQYMX	MN	DNA [cytosine-5]-methyltransferase 3B (DNMT3B)
DMKQYMX	MT	DTT
DMKQYMX	MA	Inhibitor
DMKQYMX	RN	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
DMKQYMX	RU	https://pubmed.ncbi.nlm.nih.gov/20006515

DMH684Q	DI	DMH684Q
DMH684Q	DN	NSC-138419
DMH684Q	MI	TTHVCUP
DMH684Q	MN	DNA [cytosine-5]-methyltransferase (DNMT)
DMH684Q	MT	DTT
DMH684Q	MA	Inhibitor
DMH684Q	RN	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
DMH684Q	RU	https://pubmed.ncbi.nlm.nih.gov/20006515

DMH684Q	DI	DMH684Q
DMH684Q	DN	NSC-138419
DMH684Q	MI	TT6VZ78
DMH684Q	MN	DNA [cytosine-5]-methyltransferase 3B (DNMT3B)
DMH684Q	MT	DTT
DMH684Q	MA	Inhibitor
DMH684Q	RN	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
DMH684Q	RU	https://pubmed.ncbi.nlm.nih.gov/20006515

DMW82SA	DI	DMW82SA
DMW82SA	DN	NSC-154957
DMW82SA	MI	TTHVCUP
DMW82SA	MN	DNA [cytosine-5]-methyltransferase (DNMT)
DMW82SA	MT	DTT
DMW82SA	MA	Inhibitor
DMW82SA	RN	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
DMW82SA	RU	https://pubmed.ncbi.nlm.nih.gov/20006515

DMW82SA	DI	DMW82SA
DMW82SA	DN	NSC-154957
DMW82SA	MI	TT6VZ78
DMW82SA	MN	DNA [cytosine-5]-methyltransferase 3B (DNMT3B)
DMW82SA	MT	DTT
DMW82SA	MA	Inhibitor
DMW82SA	RN	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
DMW82SA	RU	https://pubmed.ncbi.nlm.nih.gov/20006515

DMDR460	DI	DMDR460
DMDR460	DN	NSC-158324
DMDR460	MI	TTHVCUP
DMDR460	MN	DNA [cytosine-5]-methyltransferase (DNMT)
DMDR460	MT	DTT
DMDR460	MA	Inhibitor
DMDR460	RN	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
DMDR460	RU	https://pubmed.ncbi.nlm.nih.gov/20006515

DMDR460	DI	DMDR460
DMDR460	DN	NSC-158324
DMDR460	MI	TT6VZ78
DMDR460	MN	DNA [cytosine-5]-methyltransferase 3B (DNMT3B)
DMDR460	MT	DTT
DMDR460	MA	Inhibitor
DMDR460	RN	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
DMDR460	RU	https://pubmed.ncbi.nlm.nih.gov/20006515

DM9QW8N	DI	DM9QW8N
DM9QW8N	DN	NSC-172033
DM9QW8N	MI	TT12ABZ
DM9QW8N	MN	Arachidonate 12-lipoxygenase (12-LOX)
DM9QW8N	MT	DTT
DM9QW8N	MA	Inhibitor
DM9QW8N	RN	Discovery of platelet-type 12-human lipoxygenase selective inhibitors by high-throughput screening of structurally diverse libraries. Bioorg Med Chem. 2007 Nov 15;15(22):6900-8.
DM9QW8N	RU	https://pubmed.ncbi.nlm.nih.gov/17826100

DM9QW8N	DI	DM9QW8N
DM9QW8N	DN	NSC-172033
DM9QW8N	MI	TTN9T81
DM9QW8N	MN	Arachidonate 15-lipoxygenase (15-LOX)
DM9QW8N	MT	DTT
DM9QW8N	MA	Inhibitor
DM9QW8N	RN	Discovery of platelet-type 12-human lipoxygenase selective inhibitors by high-throughput screening of structurally diverse libraries. Bioorg Med Chem. 2007 Nov 15;15(22):6900-8.
DM9QW8N	RU	https://pubmed.ncbi.nlm.nih.gov/17826100

DMNXDGQ	DI	DMNXDGQ
DMNXDGQ	DN	NSC-1771
DMNXDGQ	MI	DEVDYN7
DMNXDGQ	MN	Cytochrome P450 2E1 (CYP2E1)
DMNXDGQ	MT	DME
DMNXDGQ	MA	Metabolism
DMNXDGQ	RN	Effect of cytochrome P450 inducers on the metabolism and toxicity of thiram in rats. Vet Hum Toxicol. 2002 Dec;44(6):331-3.
DMNXDGQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12458634

DMNXDGQ	DI	DMNXDGQ
DMNXDGQ	DN	NSC-1771
DMNXDGQ	MI	TTRMX3V
DMNXDGQ	MN	Janus kinase 2 (JAK-2)
DMNXDGQ	MT	DTT
DMNXDGQ	MA	Inhibitor
DMNXDGQ	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMNXDGQ	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMXBRCI	DI	DMXBRCI
DMXBRCI	DN	NSC-180246
DMXBRCI	MI	TTL53M6
DMXBRCI	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DMXBRCI	MT	DTT
DMXBRCI	MA	Inhibitor
DMXBRCI	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMXBRCI	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMXBRCI	DI	DMXBRCI
DMXBRCI	DN	NSC-180246
DMXBRCI	MI	TT4FDG6
DMXBRCI	MN	Voltage-gated calcium channel alpha Cav2.2 (CACNA1B)
DMXBRCI	MT	DTT
DMXBRCI	MA	Inhibitor
DMXBRCI	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMXBRCI	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMZFHL0	DI	DMZFHL0
DMZFHL0	DN	NSC-180969
DMZFHL0	MI	TTJLP0R
DMZFHL0	MN	Quinone reductase 2 (NQO2)
DMZFHL0	MT	DTT
DMZFHL0	MA	Inhibitor
DMZFHL0	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMZFHL0	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMAQGIW	DI	DMAQGIW
DMAQGIW	DN	NSC-204996
DMAQGIW	MI	TTJLP0R
DMAQGIW	MN	Quinone reductase 2 (NQO2)
DMAQGIW	MT	DTT
DMAQGIW	MA	Inhibitor
DMAQGIW	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMAQGIW	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMOGV9F	DI	DMOGV9F
DMOGV9F	DN	NSC-2113
DMOGV9F	MI	TT8XK6L
DMOGV9F	MN	Quinone reductase 1 (NQO1)
DMOGV9F	MT	DTT
DMOGV9F	MA	Inhibitor
DMOGV9F	RN	In silico identification and biochemical characterization of novel inhibitors of NQO1. Bioorg Med Chem Lett. 2006 Dec 15;16(24):6246-54.
DMOGV9F	RU	https://pubmed.ncbi.nlm.nih.gov/17011189

DMM9PDR	DI	DMM9PDR
DMM9PDR	DN	NSC-224124
DMM9PDR	MI	TT8XK6L
DMM9PDR	MN	Quinone reductase 1 (NQO1)
DMM9PDR	MT	DTT
DMM9PDR	MA	Inhibitor
DMM9PDR	RN	In silico identification and biochemical characterization of novel inhibitors of NQO1. Bioorg Med Chem Lett. 2006 Dec 15;16(24):6246-54.
DMM9PDR	RU	https://pubmed.ncbi.nlm.nih.gov/17011189

DMJ91Y7	DI	DMJ91Y7
DMJ91Y7	DN	NSC-23180
DMJ91Y7	MI	TT1RS9F
DMJ91Y7	MN	Acetylcholinesterase (AChE)
DMJ91Y7	MT	DTT
DMJ91Y7	MA	Inhibitor
DMJ91Y7	RN	Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34.
DMJ91Y7	RU	https://pubmed.ncbi.nlm.nih.gov/17941623

DMJ91Y7	DI	DMJ91Y7
DMJ91Y7	DN	NSC-23180
DMJ91Y7	MI	TTEB0GD
DMJ91Y7	MN	Cholinesterase (BCHE)
DMJ91Y7	MT	DTT
DMJ91Y7	MA	Inhibitor
DMJ91Y7	RN	Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34.
DMJ91Y7	RU	https://pubmed.ncbi.nlm.nih.gov/17941623

DMJ91Y7	DI	DMJ91Y7
DMJ91Y7	DN	NSC-23180
DMJ91Y7	MI	TTMF541
DMJ91Y7	MN	Liver carboxylesterase (CES1)
DMJ91Y7	MT	DTT
DMJ91Y7	MA	Inhibitor
DMJ91Y7	RN	Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34.
DMJ91Y7	RU	https://pubmed.ncbi.nlm.nih.gov/17941623

DMWXNOI	DI	DMWXNOI
DMWXNOI	DN	NSC-238146
DMWXNOI	MI	TTJLP0R
DMWXNOI	MN	Quinone reductase 2 (NQO2)
DMWXNOI	MT	DTT
DMWXNOI	MA	Inhibitor
DMWXNOI	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMWXNOI	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DM4RPBJ	DI	DM4RPBJ
DM4RPBJ	DN	NSC-26699
DM4RPBJ	MI	TT9NVXQ
DM4RPBJ	MN	Phosphoribosylaminoimidazolecarboxamide formyltransferase (ATIC)
DM4RPBJ	MT	DTT
DM4RPBJ	MA	Inhibitor
DM4RPBJ	RN	Virtual screening of human 5-aminoimidazole-4-carboxamide ribonucleotide transformylase against the NCI diversity set by use of AutoDock to identif... J Med Chem. 2004 Dec 30;47(27):6681-90.
DM4RPBJ	RU	https://pubmed.ncbi.nlm.nih.gov/15615517

DMNX245	DI	DMNX245
DMNX245	DN	NSC-26745
DMNX245	MI	TTKPW01
DMNX245	MN	Androgen receptor messenger RNA (AR mRNA)
DMNX245	MT	DTT
DMNX245	MA	Inhibitor
DMNX245	RN	Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4706-10.
DMNX245	RU	https://pubmed.ncbi.nlm.nih.gov/19592245

DMUNIWE	DI	DMUNIWE
DMUNIWE	DN	NSC-270718
DMUNIWE	MI	TT2QM9D
DMUNIWE	MN	Adenylate cyclase (ADCY)
DMUNIWE	MT	DTT
DMUNIWE	MA	Inhibitor
DMUNIWE	RN	Structure-based development of novel adenylyl cyclase inhibitors. J Med Chem. 2008 Aug 14;51(15):4456-64.
DMUNIWE	RU	https://pubmed.ncbi.nlm.nih.gov/18630896

DMANZIE	DI	DMANZIE
DMANZIE	DN	NSC-27236
DMANZIE	MI	TTVKILB
DMANZIE	MN	Prostaglandin G/H synthase 2 (COX-2)
DMANZIE	MT	DTT
DMANZIE	MA	Inhibitor
DMANZIE	RN	Selective COX-2 inhibitors. Part 1: synthesis and biological evaluation of phenylazobenzenesulfonamides. Bioorg Med Chem Lett. 2006 Sep 1;16(17):4440-3.
DMANZIE	RU	https://pubmed.ncbi.nlm.nih.gov/16814546

DMV2D8F	DI	DMV2D8F
DMV2D8F	DN	NSC-275420
DMV2D8F	MI	TT8XK6L
DMV2D8F	MN	Quinone reductase 1 (NQO1)
DMV2D8F	MT	DTT
DMV2D8F	MA	Inhibitor
DMV2D8F	RN	In silico identification and biochemical characterization of novel inhibitors of NQO1. Bioorg Med Chem Lett. 2006 Dec 15;16(24):6246-54.
DMV2D8F	RU	https://pubmed.ncbi.nlm.nih.gov/17011189

DMZU1L0	DI	DMZU1L0
DMZU1L0	DN	NSC-289311
DMZU1L0	MI	TTSZLWK
DMZU1L0	MN	Aromatase (CYP19A1)
DMZU1L0	MT	DTT
DMZU1L0	MA	Inhibitor
DMZU1L0	RN	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
DMZU1L0	RU	https://pubmed.ncbi.nlm.nih.gov/19072235

DMNUSKT	DI	DMNUSKT
DMNUSKT	DN	NSC-292213
DMNUSKT	MI	TT12ABZ
DMNUSKT	MN	Arachidonate 12-lipoxygenase (12-LOX)
DMNUSKT	MT	DTT
DMNUSKT	MA	Inhibitor
DMNUSKT	RN	Discovery of platelet-type 12-human lipoxygenase selective inhibitors by high-throughput screening of structurally diverse libraries. Bioorg Med Chem. 2007 Nov 15;15(22):6900-8.
DMNUSKT	RU	https://pubmed.ncbi.nlm.nih.gov/17826100

DMNUSKT	DI	DMNUSKT
DMNUSKT	DN	NSC-292213
DMNUSKT	MI	TT9NVXQ
DMNUSKT	MN	Phosphoribosylaminoimidazolecarboxamide formyltransferase (ATIC)
DMNUSKT	MT	DTT
DMNUSKT	MA	Inhibitor
DMNUSKT	RN	Virtual screening of human 5-aminoimidazole-4-carboxamide ribonucleotide transformylase against the NCI diversity set by use of AutoDock to identif... J Med Chem. 2004 Dec 30;47(27):6681-90.
DMNUSKT	RU	https://pubmed.ncbi.nlm.nih.gov/15615517

DM6IF8N	DI	DM6IF8N
DM6IF8N	DN	NSC-300853
DM6IF8N	MI	TTJLP0R
DM6IF8N	MN	Quinone reductase 2 (NQO2)
DM6IF8N	MT	DTT
DM6IF8N	MA	Inhibitor
DM6IF8N	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DM6IF8N	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMFBZEI	DI	DMFBZEI
DMFBZEI	DN	NSC-30171
DMFBZEI	MI	TT9NVXQ
DMFBZEI	MN	Phosphoribosylaminoimidazolecarboxamide formyltransferase (ATIC)
DMFBZEI	MT	DTT
DMFBZEI	MA	Inhibitor
DMFBZEI	RN	Virtual screening of human 5-aminoimidazole-4-carboxamide ribonucleotide transformylase against the NCI diversity set by use of AutoDock to identif... J Med Chem. 2004 Dec 30;47(27):6681-90.
DMFBZEI	RU	https://pubmed.ncbi.nlm.nih.gov/15615517

DMZYJU0	DI	DMZYJU0
DMZYJU0	DN	NSC-306843
DMZYJU0	MI	TTJLP0R
DMZYJU0	MN	Quinone reductase 2 (NQO2)
DMZYJU0	MT	DTT
DMZYJU0	MA	Inhibitor
DMZYJU0	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMZYJU0	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMTPRXI	DI	DMTPRXI
DMTPRXI	DN	NSC-316158
DMTPRXI	MI	TT8XK6L
DMTPRXI	MN	Quinone reductase 1 (NQO1)
DMTPRXI	MT	DTT
DMTPRXI	MA	Inhibitor
DMTPRXI	RN	In silico identification and biochemical characterization of novel inhibitors of NQO1. Bioorg Med Chem Lett. 2006 Dec 15;16(24):6246-54.
DMTPRXI	RU	https://pubmed.ncbi.nlm.nih.gov/17011189

DMF3G06	DI	DMF3G06
DMF3G06	DN	NSC-319745
DMF3G06	MI	TTHVCUP
DMF3G06	MN	DNA [cytosine-5]-methyltransferase (DNMT)
DMF3G06	MT	DTT
DMF3G06	MA	Inhibitor
DMF3G06	RN	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
DMF3G06	RU	https://pubmed.ncbi.nlm.nih.gov/20006515

DMF3G06	DI	DMF3G06
DMF3G06	DN	NSC-319745
DMF3G06	MI	TT6VZ78
DMF3G06	MN	DNA [cytosine-5]-methyltransferase 3B (DNMT3B)
DMF3G06	MT	DTT
DMF3G06	MA	Inhibitor
DMF3G06	RN	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
DMF3G06	RU	https://pubmed.ncbi.nlm.nih.gov/20006515

DMN50OT	DI	DMN50OT
DMN50OT	DN	NSC-324572
DMN50OT	MI	TT9NVXQ
DMN50OT	MN	Phosphoribosylaminoimidazolecarboxamide formyltransferase (ATIC)
DMN50OT	MT	DTT
DMN50OT	MA	Inhibitor
DMN50OT	RN	Virtual screening of human 5-aminoimidazole-4-carboxamide ribonucleotide transformylase against the NCI diversity set by use of AutoDock to identif... J Med Chem. 2004 Dec 30;47(27):6681-90.
DMN50OT	RU	https://pubmed.ncbi.nlm.nih.gov/15615517

DMK0H2P	DI	DMK0H2P
DMK0H2P	DN	NSC-339580
DMK0H2P	MI	TT8XK6L
DMK0H2P	MN	Quinone reductase 1 (NQO1)
DMK0H2P	MT	DTT
DMK0H2P	MA	Inhibitor
DMK0H2P	RN	In silico identification and biochemical characterization of novel inhibitors of NQO1. Bioorg Med Chem Lett. 2006 Dec 15;16(24):6246-54.
DMK0H2P	RU	https://pubmed.ncbi.nlm.nih.gov/17011189

DMITE1A	DI	DMITE1A
DMITE1A	DN	NSC-339583
DMITE1A	MI	TT8XK6L
DMITE1A	MN	Quinone reductase 1 (NQO1)
DMITE1A	MT	DTT
DMITE1A	MA	Inhibitor
DMITE1A	RN	In silico identification and biochemical characterization of novel inhibitors of NQO1. Bioorg Med Chem Lett. 2006 Dec 15;16(24):6246-54.
DMITE1A	RU	https://pubmed.ncbi.nlm.nih.gov/17011189

DMVGLH7	DI	DMVGLH7
DMVGLH7	DN	NSC-341622
DMVGLH7	MI	TTGTQHC
DMVGLH7	MN	DNA topoisomerase I (TOP1)
DMVGLH7	MT	DTT
DMVGLH7	MA	Inhibitor
DMVGLH7	RN	Synthesis and biological evaluation of 14-(aminoalkyl-aminomethyl)aromathecins as topoisomerase I inhibitors: investigating the hypothesis of share... Bioorg Med Chem. 2009 Oct 15;17(20):7145-55.
DMVGLH7	RU	https://pubmed.ncbi.nlm.nih.gov/19783447

DM2UPSV	DI	DM2UPSV
DM2UPSV	DN	NSC-345763
DM2UPSV	MI	TTHVCUP
DM2UPSV	MN	DNA [cytosine-5]-methyltransferase (DNMT)
DM2UPSV	MT	DTT
DM2UPSV	MA	Inhibitor
DM2UPSV	RN	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
DM2UPSV	RU	https://pubmed.ncbi.nlm.nih.gov/20006515

DM2UPSV	DI	DM2UPSV
DM2UPSV	DN	NSC-345763
DM2UPSV	MI	TT6VZ78
DM2UPSV	MN	DNA [cytosine-5]-methyltransferase 3B (DNMT3B)
DM2UPSV	MT	DTT
DM2UPSV	MA	Inhibitor
DM2UPSV	RN	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
DM2UPSV	RU	https://pubmed.ncbi.nlm.nih.gov/20006515

DM3TDEO	DI	DM3TDEO
DM3TDEO	DN	NSC-348926
DM3TDEO	MI	TTHVCUP
DM3TDEO	MN	DNA [cytosine-5]-methyltransferase (DNMT)
DM3TDEO	MT	DTT
DM3TDEO	MA	Inhibitor
DM3TDEO	RN	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
DM3TDEO	RU	https://pubmed.ncbi.nlm.nih.gov/20006515

DM3TDEO	DI	DM3TDEO
DM3TDEO	DN	NSC-348926
DM3TDEO	MI	TT6VZ78
DM3TDEO	MN	DNA [cytosine-5]-methyltransferase 3B (DNMT3B)
DM3TDEO	MT	DTT
DM3TDEO	MA	Inhibitor
DM3TDEO	RN	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
DM3TDEO	RU	https://pubmed.ncbi.nlm.nih.gov/20006515

DMVL51I	DI	DMVL51I
DMVL51I	DN	NSC-354279
DMVL51I	MI	TT8XK6L
DMVL51I	MN	Quinone reductase 1 (NQO1)
DMVL51I	MT	DTT
DMVL51I	MA	Inhibitor
DMVL51I	RN	In silico identification and biochemical characterization of novel inhibitors of NQO1. Bioorg Med Chem Lett. 2006 Dec 15;16(24):6246-54.
DMVL51I	RU	https://pubmed.ncbi.nlm.nih.gov/17011189

DMEK5B2	DI	DMEK5B2
DMEK5B2	DN	NSC-356483
DMEK5B2	MI	TTSZLWK
DMEK5B2	MN	Aromatase (CYP19A1)
DMEK5B2	MT	DTT
DMEK5B2	MA	Inhibitor
DMEK5B2	RN	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
DMEK5B2	RU	https://pubmed.ncbi.nlm.nih.gov/19072235

DM9LI7M	DI	DM9LI7M
DM9LI7M	DN	NSC-356781
DM9LI7M	MI	TTSZLWK
DM9LI7M	MN	Aromatase (CYP19A1)
DM9LI7M	MT	DTT
DM9LI7M	MA	Inhibitor
DM9LI7M	RN	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
DM9LI7M	RU	https://pubmed.ncbi.nlm.nih.gov/19072235

DMXT1EK	DI	DMXT1EK
DMXT1EK	DN	NSC-356819
DMXT1EK	MI	TTJLP0R
DMXT1EK	MN	Quinone reductase 2 (NQO2)
DMXT1EK	MT	DTT
DMXT1EK	MA	Inhibitor
DMXT1EK	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMXT1EK	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DM9CM5V	DI	DM9CM5V
DM9CM5V	DN	NSC-356820
DM9CM5V	MI	TTJLP0R
DM9CM5V	MN	Quinone reductase 2 (NQO2)
DM9CM5V	MT	DTT
DM9CM5V	MA	Inhibitor
DM9CM5V	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DM9CM5V	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMHUG1W	DI	DMHUG1W
DMHUG1W	DN	NSC-359466
DMHUG1W	MI	TTJLP0R
DMHUG1W	MN	Quinone reductase 2 (NQO2)
DMHUG1W	MT	DTT
DMHUG1W	MA	Inhibitor
DMHUG1W	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMHUG1W	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMR97X3	DI	DMR97X3
DMR97X3	DN	NSC-368272
DMR97X3	MI	TTSZLWK
DMR97X3	MN	Aromatase (CYP19A1)
DMR97X3	MT	DTT
DMR97X3	MA	Inhibitor
DMR97X3	RN	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
DMR97X3	RU	https://pubmed.ncbi.nlm.nih.gov/19072235

DMR3IP5	DI	DMR3IP5
DMR3IP5	DN	NSC-368280
DMR3IP5	MI	TTSZLWK
DMR3IP5	MN	Aromatase (CYP19A1)
DMR3IP5	MT	DTT
DMR3IP5	MA	Inhibitor
DMR3IP5	RN	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
DMR3IP5	RU	https://pubmed.ncbi.nlm.nih.gov/19072235

DMAQWM8	DI	DMAQWM8
DMAQWM8	DN	NSC-369087
DMAQWM8	MI	TTSZLWK
DMAQWM8	MN	Aromatase (CYP19A1)
DMAQWM8	MT	DTT
DMAQWM8	MA	Inhibitor
DMAQWM8	RN	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
DMAQWM8	RU	https://pubmed.ncbi.nlm.nih.gov/19072235

DMLY6WX	DI	DMLY6WX
DMLY6WX	DN	NSC-37031
DMLY6WX	MI	TT9NVXQ
DMLY6WX	MN	Phosphoribosylaminoimidazolecarboxamide formyltransferase (ATIC)
DMLY6WX	MT	DTT
DMLY6WX	MA	Inhibitor
DMLY6WX	RN	Virtual screening of human 5-aminoimidazole-4-carboxamide ribonucleotide transformylase against the NCI diversity set by use of AutoDock to identif... J Med Chem. 2004 Dec 30;47(27):6681-90.
DMLY6WX	RU	https://pubmed.ncbi.nlm.nih.gov/15615517

DMZFULS	DI	DMZFULS
DMZFULS	DN	NSC-37173
DMZFULS	MI	TT9NVXQ
DMZFULS	MN	Phosphoribosylaminoimidazolecarboxamide formyltransferase (ATIC)
DMZFULS	MT	DTT
DMZFULS	MA	Inhibitor
DMZFULS	RN	Virtual screening of human 5-aminoimidazole-4-carboxamide ribonucleotide transformylase against the NCI diversity set by use of AutoDock to identif... J Med Chem. 2004 Dec 30;47(27):6681-90.
DMZFULS	RU	https://pubmed.ncbi.nlm.nih.gov/15615517

DMHO40Q	DI	DMHO40Q
DMHO40Q	DN	NSC-380292
DMHO40Q	MI	TT84ETX
DMHO40Q	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMHO40Q	MT	DTT
DMHO40Q	MA	Inhibitor
DMHO40Q	RN	New HIV-1 reverse transcriptase inhibitors based on a tricyclic benzothiophene scaffold: synthesis, resolution, and inhibitory activity. Bioorg Med Chem Lett. 2006 Jun 1;16(11):3034-8.
DMHO40Q	RU	https://pubmed.ncbi.nlm.nih.gov/16527484

DMLGWHM	DI	DMLGWHM
DMLGWHM	DN	NSC-381864
DMLGWHM	MI	TTJLP0R
DMLGWHM	MN	Quinone reductase 2 (NQO2)
DMLGWHM	MT	DTT
DMLGWHM	MA	Inhibitor
DMLGWHM	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMLGWHM	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMMXZBK	DI	DMMXZBK
DMMXZBK	DN	NSC-39851
DMMXZBK	MI	DERA3OF
DMMXZBK	MN	Bile acid-CoA thioesterase (BAAT)
DMMXZBK	MT	DME
DMMXZBK	MA	Metabolism
DMMXZBK	RN	Bile acid coenzyme A: amino acid N-acyltransferase in the amino acid conjugation of bile acids. Methods Enzymol. 2005;400:374-94.
DMMXZBK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16399361

DM0214E	DI	DM0214E
DM0214E	DN	NSC-401077
DM0214E	MI	TTHVCUP
DM0214E	MN	DNA [cytosine-5]-methyltransferase (DNMT)
DM0214E	MT	DTT
DM0214E	MA	Inhibitor
DM0214E	RN	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
DM0214E	RU	https://pubmed.ncbi.nlm.nih.gov/20006515

DM0214E	DI	DM0214E
DM0214E	DN	NSC-401077
DM0214E	MI	TT6VZ78
DM0214E	MN	DNA [cytosine-5]-methyltransferase 3B (DNMT3B)
DM0214E	MT	DTT
DM0214E	MA	Inhibitor
DM0214E	RN	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
DM0214E	RU	https://pubmed.ncbi.nlm.nih.gov/20006515

DMCFNMK	DI	DMCFNMK
DMCFNMK	DN	NSC-40331
DMCFNMK	MI	TTFQAYR
DMCFNMK	MN	Cholesteryl ester transfer protein (CETP)
DMCFNMK	MT	DTT
DMCFNMK	MA	Inhibitor
DMCFNMK	RN	Discovery of new cholesteryl ester transfer protein inhibitors via ligand-based pharmacophore modeling and QSAR analysis followed by synthetic expl... Eur J Med Chem. 2010 Apr;45(4):1598-617.
DMCFNMK	RU	https://pubmed.ncbi.nlm.nih.gov/20116902

DMKJWGP	DI	DMKJWGP
DMKJWGP	DN	NSC-407228
DMKJWGP	MI	TTJFY5U
DMKJWGP	MN	Adenosine A3 receptor (ADORA3)
DMKJWGP	MT	DTT
DMKJWGP	MA	Inhibitor
DMKJWGP	RN	Interactions of flavonoids and other phytochemicals with adenosine receptors. J Med Chem. 1996 Feb 2;39(3):781-8.
DMKJWGP	RU	https://pubmed.ncbi.nlm.nih.gov/8576921

DMQ6GBX	DI	DMQ6GBX
DMQ6GBX	DN	NSC-45592
DMQ6GBX	MI	TT9NVXQ
DMQ6GBX	MN	Phosphoribosylaminoimidazolecarboxamide formyltransferase (ATIC)
DMQ6GBX	MT	DTT
DMQ6GBX	MA	Inhibitor
DMQ6GBX	RN	Virtual screening of human 5-aminoimidazole-4-carboxamide ribonucleotide transformylase against the NCI diversity set by use of AutoDock to identif... J Med Chem. 2004 Dec 30;47(27):6681-90.
DMQ6GBX	RU	https://pubmed.ncbi.nlm.nih.gov/15615517

DMRZJL1	DI	DMRZJL1
DMRZJL1	DN	NSC-47729
DMRZJL1	MI	TT9NVXQ
DMRZJL1	MN	Phosphoribosylaminoimidazolecarboxamide formyltransferase (ATIC)
DMRZJL1	MT	DTT
DMRZJL1	MA	Inhibitor
DMRZJL1	RN	Virtual screening of human 5-aminoimidazole-4-carboxamide ribonucleotide transformylase against the NCI diversity set by use of AutoDock to identif... J Med Chem. 2004 Dec 30;47(27):6681-90.
DMRZJL1	RU	https://pubmed.ncbi.nlm.nih.gov/15615517

DMTQP3V	DI	DMTQP3V
DMTQP3V	DN	NSC-50187
DMTQP3V	MI	TTGP7BY
DMTQP3V	MN	Monoamine oxidase type B (MAO-B)
DMTQP3V	MT	DTT
DMTQP3V	MA	Inhibitor
DMTQP3V	RN	A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9.
DMTQP3V	RU	https://pubmed.ncbi.nlm.nih.gov/20045650

DMY689Z	DI	DMY689Z
DMY689Z	DN	NSC-527035
DMY689Z	MI	TTB6UM0
DMY689Z	MN	Fatty aldehyde dehydrogenase (ALDH3A2)
DMY689Z	MT	DTT
DMY689Z	MA	Inhibitor
DMY689Z	RN	Exploring the structural requirements for inhibition of the ubiquitin E3 ligase breast cancer associated protein 2 (BCA2) as a treatment for breast... J Med Chem. 2010 Apr 8;53(7):2757-65.
DMY689Z	RU	https://pubmed.ncbi.nlm.nih.gov/20222671

DMW2Q6N	DI	DMW2Q6N
DMW2Q6N	DN	NSC-54162
DMW2Q6N	MI	TTHVCUP
DMW2Q6N	MN	DNA [cytosine-5]-methyltransferase (DNMT)
DMW2Q6N	MT	DTT
DMW2Q6N	MA	Inhibitor
DMW2Q6N	RN	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
DMW2Q6N	RU	https://pubmed.ncbi.nlm.nih.gov/20006515

DMW2Q6N	DI	DMW2Q6N
DMW2Q6N	DN	NSC-54162
DMW2Q6N	MI	TT6VZ78
DMW2Q6N	MN	DNA [cytosine-5]-methyltransferase 3B (DNMT3B)
DMW2Q6N	MT	DTT
DMW2Q6N	MA	Inhibitor
DMW2Q6N	RN	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
DMW2Q6N	RU	https://pubmed.ncbi.nlm.nih.gov/20006515

DMLEN4X	DI	DMLEN4X
DMLEN4X	DN	NSC-56071
DMLEN4X	MI	TTHVCUP
DMLEN4X	MN	DNA [cytosine-5]-methyltransferase (DNMT)
DMLEN4X	MT	DTT
DMLEN4X	MA	Inhibitor
DMLEN4X	RN	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
DMLEN4X	RU	https://pubmed.ncbi.nlm.nih.gov/20006515

DMLEN4X	DI	DMLEN4X
DMLEN4X	DN	NSC-56071
DMLEN4X	MI	TT6VZ78
DMLEN4X	MN	DNA [cytosine-5]-methyltransferase 3B (DNMT3B)
DMLEN4X	MT	DTT
DMLEN4X	MA	Inhibitor
DMLEN4X	RN	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
DMLEN4X	RU	https://pubmed.ncbi.nlm.nih.gov/20006515

DMIRK41	DI	DMIRK41
DMIRK41	DN	NSC-57893
DMIRK41	MI	TTHVCUP
DMIRK41	MN	DNA [cytosine-5]-methyltransferase (DNMT)
DMIRK41	MT	DTT
DMIRK41	MA	Inhibitor
DMIRK41	RN	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
DMIRK41	RU	https://pubmed.ncbi.nlm.nih.gov/20006515

DMIRK41	DI	DMIRK41
DMIRK41	DN	NSC-57893
DMIRK41	MI	TT6VZ78
DMIRK41	MN	DNA [cytosine-5]-methyltransferase 3B (DNMT3B)
DMIRK41	MT	DTT
DMIRK41	MA	Inhibitor
DMIRK41	RN	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
DMIRK41	RU	https://pubmed.ncbi.nlm.nih.gov/20006515

DMI6WA7	DI	DMI6WA7
DMI6WA7	DN	NSC-58046
DMI6WA7	MI	TT9NVXQ
DMI6WA7	MN	Phosphoribosylaminoimidazolecarboxamide formyltransferase (ATIC)
DMI6WA7	MT	DTT
DMI6WA7	MA	Inhibitor
DMI6WA7	RN	Virtual screening of human 5-aminoimidazole-4-carboxamide ribonucleotide transformylase against the NCI diversity set by use of AutoDock to identif... J Med Chem. 2004 Dec 30;47(27):6681-90.
DMI6WA7	RU	https://pubmed.ncbi.nlm.nih.gov/15615517

DMX2YH7	DI	DMX2YH7
DMX2YH7	DN	NSC-6113
DMX2YH7	MI	DEJGDUW
DMX2YH7	MN	Cytochrome P450 1A2 (CYP1A2)
DMX2YH7	MT	DME
DMX2YH7	MA	Metabolism
DMX2YH7	RN	Coleman J., Cox A. and Cowley N. (2011). Side Effects of Drugs Annual. Elsevier.
DMX2YH7	RU	https://www.sciencedirect.com/bookseries/side-effects-of-drugs-annual/vol/33/suppl/C

DMD1XM0	DI	DMD1XM0
DMD1XM0	DN	NSC-613604
DMD1XM0	MI	TTSZLWK
DMD1XM0	MN	Aromatase (CYP19A1)
DMD1XM0	MT	DTT
DMD1XM0	MA	Inhibitor
DMD1XM0	RN	An efficient steroid pharmacophore-based strategy to identify new aromatase inhibitors. Eur J Med Chem. 2009 Oct;44(10):4121-7.
DMD1XM0	RU	https://pubmed.ncbi.nlm.nih.gov/19500885

DMFXEIK	DI	DMFXEIK
DMFXEIK	DN	NSC-621351
DMFXEIK	MI	TT8XK6L
DMFXEIK	MN	Quinone reductase 1 (NQO1)
DMFXEIK	MT	DTT
DMFXEIK	MA	Inhibitor
DMFXEIK	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMFXEIK	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMM5UT9	DI	DMM5UT9
DMM5UT9	DN	NSC-622444
DMM5UT9	MI	TTHVCUP
DMM5UT9	MN	DNA [cytosine-5]-methyltransferase (DNMT)
DMM5UT9	MT	DTT
DMM5UT9	MA	Inhibitor
DMM5UT9	RN	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
DMM5UT9	RU	https://pubmed.ncbi.nlm.nih.gov/20006515

DMM5UT9	DI	DMM5UT9
DMM5UT9	DN	NSC-622444
DMM5UT9	MI	TT6VZ78
DMM5UT9	MN	DNA [cytosine-5]-methyltransferase 3B (DNMT3B)
DMM5UT9	MT	DTT
DMM5UT9	MA	Inhibitor
DMM5UT9	RN	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
DMM5UT9	RU	https://pubmed.ncbi.nlm.nih.gov/20006515

DME35CB	DI	DME35CB
DME35CB	DN	NSC-622445
DME35CB	MI	TTIQSC1
DME35CB	MN	Bacterial Lethal factor (Bact lef)
DME35CB	MT	DTT
DME35CB	MA	Inhibitor
DME35CB	RN	Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening. J Med Chem. 2006 Aug 24;49(17):5232-44.
DME35CB	RU	https://pubmed.ncbi.nlm.nih.gov/16913712

DME35CB	DI	DME35CB
DME35CB	DN	NSC-622445
DME35CB	MI	TTHVCUP
DME35CB	MN	DNA [cytosine-5]-methyltransferase (DNMT)
DME35CB	MT	DTT
DME35CB	MA	Inhibitor
DME35CB	RN	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
DME35CB	RU	https://pubmed.ncbi.nlm.nih.gov/20006515

DME35CB	DI	DME35CB
DME35CB	DN	NSC-622445
DME35CB	MI	TT6VZ78
DME35CB	MN	DNA [cytosine-5]-methyltransferase 3B (DNMT3B)
DME35CB	MT	DTT
DME35CB	MA	Inhibitor
DME35CB	RN	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
DME35CB	RU	https://pubmed.ncbi.nlm.nih.gov/20006515

DMW437Z	DI	DMW437Z
DMW437Z	DN	NSC-623548
DMW437Z	MI	TTHVCUP
DMW437Z	MN	DNA [cytosine-5]-methyltransferase (DNMT)
DMW437Z	MT	DTT
DMW437Z	MA	Inhibitor
DMW437Z	RN	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
DMW437Z	RU	https://pubmed.ncbi.nlm.nih.gov/20006515

DMW437Z	DI	DMW437Z
DMW437Z	DN	NSC-623548
DMW437Z	MI	TT6VZ78
DMW437Z	MN	DNA [cytosine-5]-methyltransferase 3B (DNMT3B)
DMW437Z	MT	DTT
DMW437Z	MA	Inhibitor
DMW437Z	RN	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
DMW437Z	RU	https://pubmed.ncbi.nlm.nih.gov/20006515

DM0GWAC	DI	DM0GWAC
DM0GWAC	DN	NSC-625409
DM0GWAC	MI	TTSZLWK
DM0GWAC	MN	Aromatase (CYP19A1)
DM0GWAC	MT	DTT
DM0GWAC	MA	Inhibitor
DM0GWAC	RN	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
DM0GWAC	RU	https://pubmed.ncbi.nlm.nih.gov/19072235

DM63G4R	DI	DM63G4R
DM63G4R	DN	NSC-625487
DM63G4R	MI	TT84ETX
DM63G4R	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM63G4R	MT	DTT
DM63G4R	MA	Inhibitor
DM63G4R	RN	Synthesis and biological activity of novel 1H,3H-thiazolo[3,4-a]benzimidazoles: non-nucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors. Antivir Chem Chemother. 1999 Jul;10(4):211-7.
DM63G4R	RU	https://pubmed.ncbi.nlm.nih.gov/10480739

DMLG05U	DI	DMLG05U
DMLG05U	DN	NSC-625987
DMLG05U	MI	TT7HF4W
DMLG05U	MN	Cyclin-dependent kinase 2 (CDK2)
DMLG05U	MT	DTT
DMLG05U	MA	Inhibitor
DMLG05U	RN	The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4. Clin Cancer Res. 1999 Dec;5(12):4279-86.
DMLG05U	RU	https://pubmed.ncbi.nlm.nih.gov/10632371

DMLG05U	DI	DMLG05U
DMLG05U	DN	NSC-625987
DMLG05U	MI	TT0PG8F
DMLG05U	MN	Cyclin-dependent kinase 4 (CDK4)
DMLG05U	MT	DTT
DMLG05U	MA	Inhibitor
DMLG05U	RN	The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4. Clin Cancer Res. 1999 Dec;5(12):4279-86.
DMLG05U	RU	https://pubmed.ncbi.nlm.nih.gov/10632371

DMY7EAF	DI	DMY7EAF
DMY7EAF	DN	NSC-637991
DMY7EAF	MI	TTJLP0R
DMY7EAF	MN	Quinone reductase 2 (NQO2)
DMY7EAF	MT	DTT
DMY7EAF	MA	Inhibitor
DMY7EAF	RN	Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2. Bioorg Med Chem Lett. 2010 May 1;20(9):2832-6.
DMY7EAF	RU	https://pubmed.ncbi.nlm.nih.gov/20356739

DM0U7CK	DI	DM0U7CK
DM0U7CK	DN	NSC-637992
DM0U7CK	MI	TTJLP0R
DM0U7CK	MN	Quinone reductase 2 (NQO2)
DM0U7CK	MT	DTT
DM0U7CK	MA	Inhibitor
DM0U7CK	RN	Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2. Bioorg Med Chem Lett. 2010 May 1;20(9):2832-6.
DM0U7CK	RU	https://pubmed.ncbi.nlm.nih.gov/20356739

DM2HC8L	DI	DM2HC8L
DM2HC8L	DN	NSC-637993
DM2HC8L	MI	TTJLP0R
DM2HC8L	MN	Quinone reductase 2 (NQO2)
DM2HC8L	MT	DTT
DM2HC8L	MA	Inhibitor
DM2HC8L	RN	Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2. Bioorg Med Chem Lett. 2010 May 1;20(9):2832-6.
DM2HC8L	RU	https://pubmed.ncbi.nlm.nih.gov/20356739

DMKA8YT	DI	DMKA8YT
DMKA8YT	DN	NSC-637994
DMKA8YT	MI	TTJLP0R
DMKA8YT	MN	Quinone reductase 2 (NQO2)
DMKA8YT	MT	DTT
DMKA8YT	MA	Inhibitor
DMKA8YT	RN	Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2. Bioorg Med Chem Lett. 2010 May 1;20(9):2832-6.
DMKA8YT	RU	https://pubmed.ncbi.nlm.nih.gov/20356739

DMZCYM1	DI	DMZCYM1
DMZCYM1	DN	NSC-640353
DMZCYM1	MI	TTJLP0R
DMZCYM1	MN	Quinone reductase 2 (NQO2)
DMZCYM1	MT	DTT
DMZCYM1	MA	Inhibitor
DMZCYM1	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMZCYM1	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DM3DW6A	DI	DM3DW6A
DM3DW6A	DN	NSC-640556
DM3DW6A	MI	TTJLP0R
DM3DW6A	MN	Quinone reductase 2 (NQO2)
DM3DW6A	MT	DTT
DM3DW6A	MA	Inhibitor
DM3DW6A	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DM3DW6A	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMPFC5U	DI	DMPFC5U
DMPFC5U	DN	NSC-640558
DMPFC5U	MI	TTJLP0R
DMPFC5U	MN	Quinone reductase 2 (NQO2)
DMPFC5U	MT	DTT
DMPFC5U	MA	Inhibitor
DMPFC5U	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMPFC5U	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMMT73G	DI	DMMT73G
DMMT73G	DN	NSC-640559
DMMT73G	MI	TTJLP0R
DMMT73G	MN	Quinone reductase 2 (NQO2)
DMMT73G	MT	DTT
DMMT73G	MA	Inhibitor
DMMT73G	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMMT73G	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMSJ06G	DI	DMSJ06G
DMSJ06G	DN	NSC-640566
DMSJ06G	MI	TTJLP0R
DMSJ06G	MN	Quinone reductase 2 (NQO2)
DMSJ06G	MT	DTT
DMSJ06G	MA	Inhibitor
DMSJ06G	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMSJ06G	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMC4Y0R	DI	DMC4Y0R
DMC4Y0R	DN	NSC-640583
DMC4Y0R	MI	TTJLP0R
DMC4Y0R	MN	Quinone reductase 2 (NQO2)
DMC4Y0R	MT	DTT
DMC4Y0R	MA	Inhibitor
DMC4Y0R	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMC4Y0R	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMY2API	DI	DMY2API
DMY2API	DN	NSC-640584
DMY2API	MI	TTJLP0R
DMY2API	MN	Quinone reductase 2 (NQO2)
DMY2API	MT	DTT
DMY2API	MA	Inhibitor
DMY2API	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMY2API	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMMBAR3	DI	DMMBAR3
DMMBAR3	DN	NSC-645808
DMMBAR3	MI	TT8XK6L
DMMBAR3	MN	Quinone reductase 1 (NQO1)
DMMBAR3	MT	DTT
DMMBAR3	MA	Inhibitor
DMMBAR3	RN	In silico identification and biochemical characterization of novel inhibitors of NQO1. Bioorg Med Chem Lett. 2006 Dec 15;16(24):6246-54.
DMMBAR3	RU	https://pubmed.ncbi.nlm.nih.gov/17011189

DMMBAR3	DI	DMMBAR3
DMMBAR3	DN	NSC-645808
DMMBAR3	MI	TTJLP0R
DMMBAR3	MN	Quinone reductase 2 (NQO2)
DMMBAR3	MT	DTT
DMMBAR3	MA	Inhibitor
DMMBAR3	RN	Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2. Bioorg Med Chem Lett. 2010 May 1;20(9):2832-6.
DMMBAR3	RU	https://pubmed.ncbi.nlm.nih.gov/20356739

DMCNIT2	DI	DMCNIT2
DMCNIT2	DN	NSC-645811
DMCNIT2	MI	TTJLP0R
DMCNIT2	MN	Quinone reductase 2 (NQO2)
DMCNIT2	MT	DTT
DMCNIT2	MA	Inhibitor
DMCNIT2	RN	Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2. Bioorg Med Chem Lett. 2010 May 1;20(9):2832-6.
DMCNIT2	RU	https://pubmed.ncbi.nlm.nih.gov/20356739

DM1MPJ9	DI	DM1MPJ9
DM1MPJ9	DN	NSC-645812
DM1MPJ9	MI	TTJLP0R
DM1MPJ9	MN	Quinone reductase 2 (NQO2)
DM1MPJ9	MT	DTT
DM1MPJ9	MA	Inhibitor
DM1MPJ9	RN	Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2. Bioorg Med Chem Lett. 2010 May 1;20(9):2832-6.
DM1MPJ9	RU	https://pubmed.ncbi.nlm.nih.gov/20356739

DMNJLW2	DI	DMNJLW2
DMNJLW2	DN	NSC-645827
DMNJLW2	MI	TT8XK6L
DMNJLW2	MN	Quinone reductase 1 (NQO1)
DMNJLW2	MT	DTT
DMNJLW2	MA	Inhibitor
DMNJLW2	RN	In silico identification and biochemical characterization of novel inhibitors of NQO1. Bioorg Med Chem Lett. 2006 Dec 15;16(24):6246-54.
DMNJLW2	RU	https://pubmed.ncbi.nlm.nih.gov/17011189

DMSO215	DI	DMSO215
DMSO215	DN	NSC-645831
DMSO215	MI	TTJLP0R
DMSO215	MN	Quinone reductase 2 (NQO2)
DMSO215	MT	DTT
DMSO215	MA	Inhibitor
DMSO215	RN	Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2. Bioorg Med Chem Lett. 2010 May 1;20(9):2832-6.
DMSO215	RU	https://pubmed.ncbi.nlm.nih.gov/20356739

DM1AD8T	DI	DM1AD8T
DM1AD8T	DN	NSC-645833
DM1AD8T	MI	TTJLP0R
DM1AD8T	MN	Quinone reductase 2 (NQO2)
DM1AD8T	MT	DTT
DM1AD8T	MA	Inhibitor
DM1AD8T	RN	Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2. Bioorg Med Chem Lett. 2010 May 1;20(9):2832-6.
DM1AD8T	RU	https://pubmed.ncbi.nlm.nih.gov/20356739

DMY5JFB	DI	DMY5JFB
DMY5JFB	DN	NSC-645834
DMY5JFB	MI	TTJLP0R
DMY5JFB	MN	Quinone reductase 2 (NQO2)
DMY5JFB	MT	DTT
DMY5JFB	MA	Inhibitor
DMY5JFB	RN	Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2. Bioorg Med Chem Lett. 2010 May 1;20(9):2832-6.
DMY5JFB	RU	https://pubmed.ncbi.nlm.nih.gov/20356739

DMKDVP7	DI	DMKDVP7
DMKDVP7	DN	NSC-645835
DMKDVP7	MI	TTJLP0R
DMKDVP7	MN	Quinone reductase 2 (NQO2)
DMKDVP7	MT	DTT
DMKDVP7	MA	Inhibitor
DMKDVP7	RN	Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2. Bioorg Med Chem Lett. 2010 May 1;20(9):2832-6.
DMKDVP7	RU	https://pubmed.ncbi.nlm.nih.gov/20356739

DMQ13SI	DI	DMQ13SI
DMQ13SI	DN	NSC-645836
DMQ13SI	MI	TTJLP0R
DMQ13SI	MN	Quinone reductase 2 (NQO2)
DMQ13SI	MT	DTT
DMQ13SI	MA	Inhibitor
DMQ13SI	RN	Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2. Bioorg Med Chem Lett. 2010 May 1;20(9):2832-6.
DMQ13SI	RU	https://pubmed.ncbi.nlm.nih.gov/20356739

DM6F3HV	DI	DM6F3HV
DM6F3HV	DN	NSC-649091
DM6F3HV	MI	TTJLP0R
DM6F3HV	MN	Quinone reductase 2 (NQO2)
DM6F3HV	MT	DTT
DM6F3HV	MA	Inhibitor
DM6F3HV	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DM6F3HV	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMFEGYB	DI	DMFEGYB
DMFEGYB	DN	NSC-65069
DMFEGYB	MI	TT8XK6L
DMFEGYB	MN	Quinone reductase 1 (NQO1)
DMFEGYB	MT	DTT
DMFEGYB	MA	Inhibitor
DMFEGYB	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMFEGYB	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMWY39L	DI	DMWY39L
DMWY39L	DN	NSC-651016
DMWY39L	MI	TTFZYTO
DMWY39L	MN	C-C chemokine receptor type 2 (CCR2)
DMWY39L	MT	DTT
DMWY39L	MA	Inhibitor
DMWY39L	RN	Inhibition of in vitro and in vivo HIV replication by a distamycin analogue that interferes with chemokine receptor function: a candidate for chemo... J Med Chem. 1998 Jun 18;41(13):2184-93.
DMWY39L	RU	https://pubmed.ncbi.nlm.nih.gov/9632350

DMW3QAK	DI	DMW3QAK
DMW3QAK	DN	NSC-654077
DMW3QAK	MI	TTHQPL7
DMW3QAK	MN	Carbonic anhydrase I (CA-I)
DMW3QAK	MT	DTT
DMW3QAK	MA	Inhibitor
DMW3QAK	RN	Recent developments of carbonic anhydrase inhibitors as potential anticancer drugs. J Med Chem. 2008 Jun 12;51(11):3051-6.
DMW3QAK	RU	https://pubmed.ncbi.nlm.nih.gov/18348513

DMW3QAK	DI	DMW3QAK
DMW3QAK	DN	NSC-654077
DMW3QAK	MI	TTANPDJ
DMW3QAK	MN	Carbonic anhydrase II (CA-II)
DMW3QAK	MT	DTT
DMW3QAK	MA	Inhibitor
DMW3QAK	RN	Recent developments of carbonic anhydrase inhibitors as potential anticancer drugs. J Med Chem. 2008 Jun 12;51(11):3051-6.
DMW3QAK	RU	https://pubmed.ncbi.nlm.nih.gov/18348513

DMW3QAK	DI	DMW3QAK
DMW3QAK	DN	NSC-654077
DMW3QAK	MI	TT2LVK8
DMW3QAK	MN	Carbonic anhydrase IX (CA-IX)
DMW3QAK	MT	DTT
DMW3QAK	MA	Inhibitor
DMW3QAK	RN	Recent developments of carbonic anhydrase inhibitors as potential anticancer drugs. J Med Chem. 2008 Jun 12;51(11):3051-6.
DMW3QAK	RU	https://pubmed.ncbi.nlm.nih.gov/18348513

DM52NOI	DI	DM52NOI
DM52NOI	DN	NSC-656158
DM52NOI	MI	TT3WG5C
DM52NOI	MN	Monoamine oxidase type A (MAO-A)
DM52NOI	MT	DTT
DM52NOI	MA	Inhibitor
DM52NOI	RN	Synthesis and preclinical evaluations of 2-(2-fluorophenyl)-6,7-methylenedioxyquinolin-4-one monosodium phosphate (CHM-1-P-Na) as a potent antitumo... J Med Chem. 2010 Feb 25;53(4):1616-26.
DM52NOI	RU	https://pubmed.ncbi.nlm.nih.gov/20102207

DM52NOI	DI	DM52NOI
DM52NOI	DN	NSC-656158
DM52NOI	MI	TT056SO
DM52NOI	MN	Stress-activated protein kinase JNK3 (JNK3)
DM52NOI	MT	DTT
DM52NOI	MA	Inhibitor
DM52NOI	RN	Synthesis and preclinical evaluations of 2-(2-fluorophenyl)-6,7-methylenedioxyquinolin-4-one monosodium phosphate (CHM-1-P-Na) as a potent antitumo... J Med Chem. 2010 Feb 25;53(4):1616-26.
DM52NOI	RU	https://pubmed.ncbi.nlm.nih.gov/20102207

DMXDNQ6	DI	DMXDNQ6
DMXDNQ6	DN	NSC-660838
DMXDNQ6	MI	TTJLP0R
DMXDNQ6	MN	Quinone reductase 2 (NQO2)
DMXDNQ6	MT	DTT
DMXDNQ6	MA	Inhibitor
DMXDNQ6	RN	Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2. Bioorg Med Chem Lett. 2010 May 1;20(9):2832-6.
DMXDNQ6	RU	https://pubmed.ncbi.nlm.nih.gov/20356739

DM8LOCA	DI	DM8LOCA
DM8LOCA	DN	NSC-660839
DM8LOCA	MI	TTJLP0R
DM8LOCA	MN	Quinone reductase 2 (NQO2)
DM8LOCA	MT	DTT
DM8LOCA	MA	Inhibitor
DM8LOCA	RN	Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2. Bioorg Med Chem Lett. 2010 May 1;20(9):2832-6.
DM8LOCA	RU	https://pubmed.ncbi.nlm.nih.gov/20356739

DMB5PLD	DI	DMB5PLD
DMB5PLD	DN	NSC-660840
DMB5PLD	MI	TTJLP0R
DMB5PLD	MN	Quinone reductase 2 (NQO2)
DMB5PLD	MT	DTT
DMB5PLD	MA	Inhibitor
DMB5PLD	RN	Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2. Bioorg Med Chem Lett. 2010 May 1;20(9):2832-6.
DMB5PLD	RU	https://pubmed.ncbi.nlm.nih.gov/20356739

DMXHPV0	DI	DMXHPV0
DMXHPV0	DN	NSC-660841
DMXHPV0	MI	TTJLP0R
DMXHPV0	MN	Quinone reductase 2 (NQO2)
DMXHPV0	MT	DTT
DMXHPV0	MA	Inhibitor
DMXHPV0	RN	Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2. Bioorg Med Chem Lett. 2010 May 1;20(9):2832-6.
DMXHPV0	RU	https://pubmed.ncbi.nlm.nih.gov/20356739

DMQ0S4B	DI	DMQ0S4B
DMQ0S4B	DN	NSC-66209
DMQ0S4B	MI	TT915ZD
DMQ0S4B	MN	Candida Mannose-6-phosphate isomerase (Candi PMI1)
DMQ0S4B	MT	DTT
DMQ0S4B	MA	Inhibitor
DMQ0S4B	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMQ0S4B	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMQ0S4B	DI	DMQ0S4B
DMQ0S4B	DN	NSC-66209
DMQ0S4B	MI	TTL53M6
DMQ0S4B	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DMQ0S4B	MT	DTT
DMQ0S4B	MA	Inhibitor
DMQ0S4B	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMQ0S4B	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMEXW31	DI	DMEXW31
DMEXW31	DN	NSC-663284
DMEXW31	MI	TTESBNC
DMEXW31	MN	M-phase inducer phosphatase 3 (MPIP3)
DMEXW31	MT	DTT
DMEXW31	MA	Inhibitor
DMEXW31	RN	Synthesis and biological evaluation of novel heterocyclic quinones as inhibitors of the dual specificity protein phosphatase CDC25C. Bioorg Med Chem Lett. 2006 Jan 1;16(1):171-5.
DMEXW31	RU	https://pubmed.ncbi.nlm.nih.gov/16216500

DMEF603	DI	DMEF603
DMEF603	DN	NSC-664171
DMEF603	MI	TTML2WA
DMEF603	MN	Tubulin (TUB)
DMEF603	MT	DTT
DMEF603	MA	Inhibitor
DMEF603	RN	Antitumor agents. 181. Synthesis and biological evaluation of 6,7,2',3',4'-substituted-1,2,3,4-tetrahydro-2-phenyl-4-quinolones as a new class of a... J Med Chem. 1998 Mar 26;41(7):1155-62.
DMEF603	RU	https://pubmed.ncbi.nlm.nih.gov/9544215

DMEF603	DI	DMEF603
DMEF603	DN	NSC-664171
DMEF603	MI	TTYFKSZ
DMEF603	MN	Tubulin beta (TUBB)
DMEF603	MT	DTT
DMEF603	MA	Inhibitor
DMEF603	RN	Antitumor agents. 181. Synthesis and biological evaluation of 6,7,2',3',4'-substituted-1,2,3,4-tetrahydro-2-phenyl-4-quinolones as a new class of a... J Med Chem. 1998 Mar 26;41(7):1155-62.
DMEF603	RU	https://pubmed.ncbi.nlm.nih.gov/9544215

DMNQXE0	DI	DMNQXE0
DMNQXE0	DN	NSC-665126
DMNQXE0	MI	TTJLP0R
DMNQXE0	MN	Quinone reductase 2 (NQO2)
DMNQXE0	MT	DTT
DMNQXE0	MA	Inhibitor
DMNQXE0	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMNQXE0	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMNMF0C	DI	DMNMF0C
DMNMF0C	DN	NSC-666292
DMNMF0C	MI	TTSZLWK
DMNMF0C	MN	Aromatase (CYP19A1)
DMNMF0C	MT	DTT
DMNMF0C	MA	Inhibitor
DMNMF0C	RN	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
DMNMF0C	RU	https://pubmed.ncbi.nlm.nih.gov/19072235

DMRVMA5	DI	DMRVMA5
DMRVMA5	DN	NSC-66811
DMRVMA5	MI	TT9TE0O
DMRVMA5	MN	Mdm2 messenger RNA (MDM2 mRNA)
DMRVMA5	MT	DTT
DMRVMA5	MA	Inhibitor
DMRVMA5	RN	Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening str... J Med Chem. 2006 Jun 29;49(13):3759-62.
DMRVMA5	RU	https://pubmed.ncbi.nlm.nih.gov/16789731

DMVFZKQ	DI	DMVFZKQ
DMVFZKQ	DN	NSC-669977
DMVFZKQ	MI	TTJLP0R
DMVFZKQ	MN	Quinone reductase 2 (NQO2)
DMVFZKQ	MT	DTT
DMVFZKQ	MA	Inhibitor
DMVFZKQ	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMVFZKQ	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMY4MPG	DI	DMY4MPG
DMY4MPG	DN	NSC-676468
DMY4MPG	MI	TTJLP0R
DMY4MPG	MN	Quinone reductase 2 (NQO2)
DMY4MPG	MT	DTT
DMY4MPG	MA	Inhibitor
DMY4MPG	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMY4MPG	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DM35V46	DI	DM35V46
DM35V46	DN	NSC-677939
DM35V46	MI	TTJLP0R
DM35V46	MN	Quinone reductase 2 (NQO2)
DM35V46	MT	DTT
DM35V46	MA	Inhibitor
DM35V46	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DM35V46	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMPO2RU	DI	DMPO2RU
DMPO2RU	DN	NSC-679036
DMPO2RU	MI	TTML2WA
DMPO2RU	MN	Tubulin (TUB)
DMPO2RU	MT	DTT
DMPO2RU	MA	Inhibitor
DMPO2RU	RN	Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubul... J Med Chem. 1997 Sep 12;40(19):3049-56.
DMPO2RU	RU	https://pubmed.ncbi.nlm.nih.gov/9301667

DMPO2RU	DI	DMPO2RU
DMPO2RU	DN	NSC-679036
DMPO2RU	MI	TTYFKSZ
DMPO2RU	MN	Tubulin beta (TUBB)
DMPO2RU	MT	DTT
DMPO2RU	MA	Inhibitor
DMPO2RU	RN	Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubul... J Med Chem. 1997 Sep 12;40(19):3049-56.
DMPO2RU	RU	https://pubmed.ncbi.nlm.nih.gov/9301667

DMZ2KUB	DI	DMZ2KUB
DMZ2KUB	DN	NSC-683634
DMZ2KUB	MI	TTSZLWK
DMZ2KUB	MN	Aromatase (CYP19A1)
DMZ2KUB	MT	DTT
DMZ2KUB	MA	Inhibitor
DMZ2KUB	RN	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
DMZ2KUB	RU	https://pubmed.ncbi.nlm.nih.gov/19072235

DM0164B	DI	DM0164B
DM0164B	DN	NSC-686549
DM0164B	MI	TTGECUM
DM0164B	MN	Cot oncogene messenger RNA (MAP3K8 mRNA)
DM0164B	MT	DTT
DM0164B	MA	Inhibitor
DM0164B	RN	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
DM0164B	RU	https://pubmed.ncbi.nlm.nih.gov/18077363

DM0164B	DI	DM0164B
DM0164B	DN	NSC-686549
DM0164B	MI	TTROQ37
DM0164B	MN	MAPK/ERK kinase kinase (MAP3K)
DM0164B	MT	DTT
DM0164B	MA	Inhibitor
DM0164B	RN	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
DM0164B	RU	https://pubmed.ncbi.nlm.nih.gov/18077363

DMKMTJ9	DI	DMKMTJ9
DMKMTJ9	DN	NSC-693571
DMKMTJ9	MI	TTJLP0R
DMKMTJ9	MN	Quinone reductase 2 (NQO2)
DMKMTJ9	MT	DTT
DMKMTJ9	MA	Inhibitor
DMKMTJ9	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMKMTJ9	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMCP1I6	DI	DMCP1I6
DMCP1I6	DN	NSC-720622
DMCP1I6	MI	TTJLP0R
DMCP1I6	MN	Quinone reductase 2 (NQO2)
DMCP1I6	MT	DTT
DMCP1I6	MA	Inhibitor
DMCP1I6	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMCP1I6	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMX0VQN	DI	DMX0VQN
DMX0VQN	DN	NSC-73410
DMX0VQN	MI	TT8XK6L
DMX0VQN	MN	Quinone reductase 1 (NQO1)
DMX0VQN	MT	DTT
DMX0VQN	MA	Inhibitor
DMX0VQN	RN	In silico identification and biochemical characterization of novel inhibitors of NQO1. Bioorg Med Chem Lett. 2006 Dec 15;16(24):6246-54.
DMX0VQN	RU	https://pubmed.ncbi.nlm.nih.gov/17011189

DMT6CV5	DI	DMT6CV5
DMT6CV5	DN	NSC-73613
DMT6CV5	MI	TT1MPAY
DMT6CV5	MN	GABA(A) receptor alpha-1 (GABRA1)
DMT6CV5	MT	DTT
DMT6CV5	MA	Inhibitor
DMT6CV5	RN	Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997).
DMT6CV5	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97003430

DMT6CV5	DI	DMT6CV5
DMT6CV5	DN	NSC-73613
DMT6CV5	MI	TTNJYV2
DMT6CV5	MN	Gamma-aminobutyric acid receptor (GAR)
DMT6CV5	MT	DTT
DMT6CV5	MA	Inhibitor
DMT6CV5	RN	Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997).
DMT6CV5	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97003430

DM1ETX5	DI	DM1ETX5
DM1ETX5	DN	NSC-745794
DM1ETX5	MI	TTQY2EJ
DM1ETX5	MN	TERT messenger RNA (TERT mRNA)
DM1ETX5	MT	DTT
DM1ETX5	MA	Inhibitor
DM1ETX5	RN	Synthesis, cytotoxicity and human telomerase inhibition activities of a series of 1,2-heteroannelated anthraquinones and anthra[1,2-d]imidazole-6,1... Bioorg Med Chem. 2009 Nov 1;17(21):7418-28.
DM1ETX5	RU	https://pubmed.ncbi.nlm.nih.gov/19804981

DMI2GFM	DI	DMI2GFM
DMI2GFM	DN	NSC-745795
DMI2GFM	MI	TTQY2EJ
DMI2GFM	MN	TERT messenger RNA (TERT mRNA)
DMI2GFM	MT	DTT
DMI2GFM	MA	Inhibitor
DMI2GFM	RN	Synthesis, cytotoxicity and human telomerase inhibition activities of a series of 1,2-heteroannelated anthraquinones and anthra[1,2-d]imidazole-6,1... Bioorg Med Chem. 2009 Nov 1;17(21):7418-28.
DMI2GFM	RU	https://pubmed.ncbi.nlm.nih.gov/19804981

DM8JMBI	DI	DM8JMBI
DM8JMBI	DN	NSC-745796
DM8JMBI	MI	TTQY2EJ
DM8JMBI	MN	TERT messenger RNA (TERT mRNA)
DM8JMBI	MT	DTT
DM8JMBI	MA	Inhibitor
DM8JMBI	RN	Synthesis, cytotoxicity and human telomerase inhibition activities of a series of 1,2-heteroannelated anthraquinones and anthra[1,2-d]imidazole-6,1... Bioorg Med Chem. 2009 Nov 1;17(21):7418-28.
DM8JMBI	RU	https://pubmed.ncbi.nlm.nih.gov/19804981

DM9YAPX	DI	DM9YAPX
DM9YAPX	DN	NSC-745797
DM9YAPX	MI	TTQY2EJ
DM9YAPX	MN	TERT messenger RNA (TERT mRNA)
DM9YAPX	MT	DTT
DM9YAPX	MA	Inhibitor
DM9YAPX	RN	Synthesis, cytotoxicity and human telomerase inhibition activities of a series of 1,2-heteroannelated anthraquinones and anthra[1,2-d]imidazole-6,1... Bioorg Med Chem. 2009 Nov 1;17(21):7418-28.
DM9YAPX	RU	https://pubmed.ncbi.nlm.nih.gov/19804981

DMSPQYV	DI	DMSPQYV
DMSPQYV	DN	NSC-745798
DMSPQYV	MI	TTQY2EJ
DMSPQYV	MN	TERT messenger RNA (TERT mRNA)
DMSPQYV	MT	DTT
DMSPQYV	MA	Inhibitor
DMSPQYV	RN	Synthesis, cytotoxicity and human telomerase inhibition activities of a series of 1,2-heteroannelated anthraquinones and anthra[1,2-d]imidazole-6,1... Bioorg Med Chem. 2009 Nov 1;17(21):7418-28.
DMSPQYV	RU	https://pubmed.ncbi.nlm.nih.gov/19804981

DML6OMH	DI	DML6OMH
DML6OMH	DN	NSC-745799
DML6OMH	MI	TTQY2EJ
DML6OMH	MN	TERT messenger RNA (TERT mRNA)
DML6OMH	MT	DTT
DML6OMH	MA	Inhibitor
DML6OMH	RN	Synthesis, cytotoxicity and human telomerase inhibition activities of a series of 1,2-heteroannelated anthraquinones and anthra[1,2-d]imidazole-6,1... Bioorg Med Chem. 2009 Nov 1;17(21):7418-28.
DML6OMH	RU	https://pubmed.ncbi.nlm.nih.gov/19804981

DMVA6R0	DI	DMVA6R0
DMVA6R0	DN	NSC-745883
DMVA6R0	MI	TTQY2EJ
DMVA6R0	MN	TERT messenger RNA (TERT mRNA)
DMVA6R0	MT	DTT
DMVA6R0	MA	Inhibitor
DMVA6R0	RN	Synthesis, cytotoxicity and human telomerase inhibition activities of a series of 1,2-heteroannelated anthraquinones and anthra[1,2-d]imidazole-6,1... Bioorg Med Chem. 2009 Nov 1;17(21):7418-28.
DMVA6R0	RU	https://pubmed.ncbi.nlm.nih.gov/19804981

DM8W0J3	DI	DM8W0J3
DM8W0J3	DN	NSC-745884
DM8W0J3	MI	TTQY2EJ
DM8W0J3	MN	TERT messenger RNA (TERT mRNA)
DM8W0J3	MT	DTT
DM8W0J3	MA	Inhibitor
DM8W0J3	RN	Synthesis, cytotoxicity and human telomerase inhibition activities of a series of 1,2-heteroannelated anthraquinones and anthra[1,2-d]imidazole-6,1... Bioorg Med Chem. 2009 Nov 1;17(21):7418-28.
DM8W0J3	RU	https://pubmed.ncbi.nlm.nih.gov/19804981

DMZQ803	DI	DMZQ803
DMZQ803	DN	NSC-745885
DMZQ803	MI	TTQY2EJ
DMZQ803	MN	TERT messenger RNA (TERT mRNA)
DMZQ803	MT	DTT
DMZQ803	MA	Inhibitor
DMZQ803	RN	Synthesis, cytotoxicity and human telomerase inhibition activities of a series of 1,2-heteroannelated anthraquinones and anthra[1,2-d]imidazole-6,1... Bioorg Med Chem. 2009 Nov 1;17(21):7418-28.
DMZQ803	RU	https://pubmed.ncbi.nlm.nih.gov/19804981

DMHBYN5	DI	DMHBYN5
DMHBYN5	DN	NSC-745886
DMHBYN5	MI	TTQY2EJ
DMHBYN5	MN	TERT messenger RNA (TERT mRNA)
DMHBYN5	MT	DTT
DMHBYN5	MA	Inhibitor
DMHBYN5	RN	Synthesis, cytotoxicity and human telomerase inhibition activities of a series of 1,2-heteroannelated anthraquinones and anthra[1,2-d]imidazole-6,1... Bioorg Med Chem. 2009 Nov 1;17(21):7418-28.
DMHBYN5	RU	https://pubmed.ncbi.nlm.nih.gov/19804981

DMG9BWY	DI	DMG9BWY
DMG9BWY	DN	NSC-745887
DMG9BWY	MI	TTQY2EJ
DMG9BWY	MN	TERT messenger RNA (TERT mRNA)
DMG9BWY	MT	DTT
DMG9BWY	MA	Inhibitor
DMG9BWY	RN	Synthesis, cytotoxicity and human telomerase inhibition activities of a series of 1,2-heteroannelated anthraquinones and anthra[1,2-d]imidazole-6,1... Bioorg Med Chem. 2009 Nov 1;17(21):7418-28.
DMG9BWY	RU	https://pubmed.ncbi.nlm.nih.gov/19804981

DMWHYND	DI	DMWHYND
DMWHYND	DN	NSC-745888
DMWHYND	MI	TTQY2EJ
DMWHYND	MN	TERT messenger RNA (TERT mRNA)
DMWHYND	MT	DTT
DMWHYND	MA	Inhibitor
DMWHYND	RN	Synthesis, cytotoxicity and human telomerase inhibition activities of a series of 1,2-heteroannelated anthraquinones and anthra[1,2-d]imidazole-6,1... Bioorg Med Chem. 2009 Nov 1;17(21):7418-28.
DMWHYND	RU	https://pubmed.ncbi.nlm.nih.gov/19804981

DM2GO7N	DI	DM2GO7N
DM2GO7N	DN	NSC-746457
DM2GO7N	MI	TT6R7JZ
DM2GO7N	MN	Histone deacetylase 1 (HDAC1)
DM2GO7N	MT	DTT
DM2GO7N	MA	Inhibitor
DM2GO7N	RN	Histone deacetylase inhibitors through click chemistry. J Med Chem. 2008 Dec 11;51(23):7417-27.
DM2GO7N	RU	https://pubmed.ncbi.nlm.nih.gov/19007204

DM8GZAM	DI	DM8GZAM
DM8GZAM	DN	NSC-75308
DM8GZAM	MI	TTSZLWK
DM8GZAM	MN	Aromatase (CYP19A1)
DM8GZAM	MT	DTT
DM8GZAM	MA	Inhibitor
DM8GZAM	RN	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
DM8GZAM	RU	https://pubmed.ncbi.nlm.nih.gov/19072235

DM82XAU	DI	DM82XAU
DM82XAU	DN	NSC-77833
DM82XAU	MI	TTJLP0R
DM82XAU	MN	Quinone reductase 2 (NQO2)
DM82XAU	MT	DTT
DM82XAU	MA	Inhibitor
DM82XAU	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DM82XAU	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DM8R12J	DI	DM8R12J
DM8R12J	DN	NSC-78017
DM8R12J	MI	TTJLP0R
DM8R12J	MN	Quinone reductase 2 (NQO2)
DM8R12J	MT	DTT
DM8R12J	MA	Inhibitor
DM8R12J	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DM8R12J	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DM7L3DE	DI	DM7L3DE
DM7L3DE	DN	NSC-78021
DM7L3DE	MI	TTJLP0R
DM7L3DE	MN	Quinone reductase 2 (NQO2)
DM7L3DE	MT	DTT
DM7L3DE	MA	Inhibitor
DM7L3DE	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DM7L3DE	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMA53YD	DI	DMA53YD
DMA53YD	DN	NSC-86715
DMA53YD	MI	TTJLP0R
DMA53YD	MN	Quinone reductase 2 (NQO2)
DMA53YD	MT	DTT
DMA53YD	MA	Inhibitor
DMA53YD	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMA53YD	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMSYT0A	DI	DMSYT0A
DMSYT0A	DN	NSC-87509
DMSYT0A	MI	TT4FDG6
DMSYT0A	MN	Voltage-gated calcium channel alpha Cav2.2 (CACNA1B)
DMSYT0A	MT	DTT
DMSYT0A	MA	Inhibitor
DMSYT0A	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMSYT0A	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DM9WIHJ	DI	DM9WIHJ
DM9WIHJ	DN	NSC-88915
DM9WIHJ	MI	TT2QM9D
DM9WIHJ	MN	Adenylate cyclase (ADCY)
DM9WIHJ	MT	DTT
DM9WIHJ	MA	Inhibitor
DM9WIHJ	RN	Structure-based development of novel adenylyl cyclase inhibitors. J Med Chem. 2008 Aug 14;51(15):4456-64.
DM9WIHJ	RU	https://pubmed.ncbi.nlm.nih.gov/18630896

DM9WIHJ	DI	DM9WIHJ
DM9WIHJ	DN	NSC-88915
DM9WIHJ	MI	TT9NVXQ
DM9WIHJ	MN	Phosphoribosylaminoimidazolecarboxamide formyltransferase (ATIC)
DM9WIHJ	MT	DTT
DM9WIHJ	MA	Inhibitor
DM9WIHJ	RN	Virtual screening of human 5-aminoimidazole-4-carboxamide ribonucleotide transformylase against the NCI diversity set by use of AutoDock to identif... J Med Chem. 2004 Dec 30;47(27):6681-90.
DM9WIHJ	RU	https://pubmed.ncbi.nlm.nih.gov/15615517

DM9WIHJ	DI	DM9WIHJ
DM9WIHJ	DN	NSC-88915
DM9WIHJ	MI	TTH0KSX
DM9WIHJ	MN	Rhodopsin (RHO)
DM9WIHJ	MT	DTT
DM9WIHJ	MA	Inhibitor
DM9WIHJ	RN	Modulating G-protein coupled receptor/G-protein signal transduction by small molecules suggested by virtual screening. J Med Chem. 2008 Sep 11;51(17):5297-303.
DM9WIHJ	RU	https://pubmed.ncbi.nlm.nih.gov/18707087

DMGS6HB	DI	DMGS6HB
DMGS6HB	DN	NSC-89508
DMGS6HB	MI	TTFQAYR
DMGS6HB	MN	Cholesteryl ester transfer protein (CETP)
DMGS6HB	MT	DTT
DMGS6HB	MA	Inhibitor
DMGS6HB	RN	Discovery of new cholesteryl ester transfer protein inhibitors via ligand-based pharmacophore modeling and QSAR analysis followed by synthetic expl... Eur J Med Chem. 2010 Apr;45(4):1598-617.
DMGS6HB	RU	https://pubmed.ncbi.nlm.nih.gov/20116902

DMTOFS7	DI	DMTOFS7
DMTOFS7	DN	NSC-93358
DMTOFS7	MI	TTSZLWK
DMTOFS7	MN	Aromatase (CYP19A1)
DMTOFS7	MT	DTT
DMTOFS7	MA	Inhibitor
DMTOFS7	RN	An efficient steroid pharmacophore-based strategy to identify new aromatase inhibitors. Eur J Med Chem. 2009 Oct;44(10):4121-7.
DMTOFS7	RU	https://pubmed.ncbi.nlm.nih.gov/19500885

DM2JPD4	DI	DM2JPD4
DM2JPD4	DN	NSC-93394
DM2JPD4	MI	TT1MPAY
DM2JPD4	MN	GABA(A) receptor alpha-1 (GABRA1)
DM2JPD4	MT	DTT
DM2JPD4	MA	Inhibitor
DM2JPD4	RN	Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997).
DM2JPD4	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97003430

DM2JPD4	DI	DM2JPD4
DM2JPD4	DN	NSC-93394
DM2JPD4	MI	TTNJYV2
DM2JPD4	MN	Gamma-aminobutyric acid receptor (GAR)
DM2JPD4	MT	DTT
DM2JPD4	MA	Inhibitor
DM2JPD4	RN	Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997).
DM2JPD4	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97003430

DM3BZ7S	DI	DM3BZ7S
DM3BZ7S	DN	NSC-93405
DM3BZ7S	MI	TTGP7BY
DM3BZ7S	MN	Monoamine oxidase type B (MAO-B)
DM3BZ7S	MT	DTT
DM3BZ7S	MA	Inhibitor
DM3BZ7S	RN	A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9.
DM3BZ7S	RU	https://pubmed.ncbi.nlm.nih.gov/20045650

DM6VY3P	DI	DM6VY3P
DM6VY3P	DN	NSC-94258
DM6VY3P	MI	TTFBNVI
DM6VY3P	MN	Aldose reductase (AKR1B1)
DM6VY3P	MT	DTT
DM6VY3P	MA	Inhibitor
DM6VY3P	RN	1-Benzopyran-4-one antioxidants as aldose reductase inhibitors. J Med Chem. 1999 Jun 3;42(11):1881-93.
DM6VY3P	RU	https://pubmed.ncbi.nlm.nih.gov/10354396

DM6VY3P	DI	DM6VY3P
DM6VY3P	DN	NSC-94258
DM6VY3P	MI	TTSZLWK
DM6VY3P	MN	Aromatase (CYP19A1)
DM6VY3P	MT	DTT
DM6VY3P	MA	Inhibitor
DM6VY3P	RN	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
DM6VY3P	RU	https://pubmed.ncbi.nlm.nih.gov/20413308

DM6VY3P	DI	DM6VY3P
DM6VY3P	DN	NSC-94258
DM6VY3P	MI	TTIWB6L
DM6VY3P	MN	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
DM6VY3P	MT	DTT
DM6VY3P	MA	Inhibitor
DM6VY3P	RN	Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries. J Med Chem. 2008 Jul 24;51(14):4188-99.
DM6VY3P	RU	https://pubmed.ncbi.nlm.nih.gov/18533708

DM31CZK	DI	DM31CZK
DM31CZK	DN	NSC-94891
DM31CZK	MI	TTSZLWK
DM31CZK	MN	Aromatase (CYP19A1)
DM31CZK	MT	DTT
DM31CZK	MA	Inhibitor
DM31CZK	RN	An efficient steroid pharmacophore-based strategy to identify new aromatase inhibitors. Eur J Med Chem. 2009 Oct;44(10):4121-7.
DM31CZK	RU	https://pubmed.ncbi.nlm.nih.gov/19500885

DMX0TAM	DI	DMX0TAM
DMX0TAM	DN	NSC-95397
DMX0TAM	MI	TTLZS4Q
DMX0TAM	MN	M-phase inducer phosphatase 1 (MPIP1)
DMX0TAM	MT	DTT
DMX0TAM	MA	Inhibitor
DMX0TAM	RN	Structure-based de novo design and biochemical evaluation of novel Cdc25 phosphatase inhibitors. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4330-4.
DMX0TAM	RU	https://pubmed.ncbi.nlm.nih.gov/19497739

DMX0TAM	DI	DMX0TAM
DMX0TAM	DN	NSC-95397
DMX0TAM	MI	TTR0SWN
DMX0TAM	MN	M-phase inducer phosphatase 2 (MPIP2)
DMX0TAM	MT	DTT
DMX0TAM	MA	Inhibitor
DMX0TAM	RN	Novel naphthoquinone and quinolinedione inhibitors of CDC25 phosphatase activity with antiproliferative properties. Bioorg Med Chem. 2008 Oct 1;16(19):9040-9.
DMX0TAM	RU	https://pubmed.ncbi.nlm.nih.gov/18789703

DM96X2U	DI	DM96X2U
DM96X2U	DN	NSC-99495
DM96X2U	MI	TTJLP0R
DM96X2U	MN	Quinone reductase 2 (NQO2)
DM96X2U	MT	DTT
DM96X2U	MA	Inhibitor
DM96X2U	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DM96X2U	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMXZAIG	DI	DMXZAIG
DMXZAIG	DN	NSC-99528
DMXZAIG	MI	TT8XK6L
DMXZAIG	MN	Quinone reductase 1 (NQO1)
DMXZAIG	MT	DTT
DMXZAIG	MA	Inhibitor
DMXZAIG	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMXZAIG	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMXZAIG	DI	DMXZAIG
DMXZAIG	DN	NSC-99528
DMXZAIG	MI	TTJLP0R
DMXZAIG	MN	Quinone reductase 2 (NQO2)
DMXZAIG	MT	DTT
DMXZAIG	MA	Inhibitor
DMXZAIG	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMXZAIG	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMSLA8X	DI	DMSLA8X
DMSLA8X	DN	NSFQ-105
DMSLA8X	MI	TTN6J5F
DMSLA8X	MN	Bacterial DNA gyrase (Bact gyrase)
DMSLA8X	MT	DTT
DMSLA8X	MA	Modulator
DMSLA8X	RN	Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target i... Antimicrob Agents Chemother. 2000 Feb;44(2):320-5.
DMSLA8X	RU	https://www.ncbi.nlm.nih.gov/pubmed/10639357

DMSLA8X	DI	DMSLA8X
DMSLA8X	DN	NSFQ-105
DMSLA8X	MI	TTIXTO3
DMSLA8X	MN	Staphylococcus Topoisomerase IV (Stap-coc parC)
DMSLA8X	MT	DTT
DMSLA8X	MA	Modulator
DMSLA8X	RN	Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target i... Antimicrob Agents Chemother. 2000 Feb;44(2):320-5.
DMSLA8X	RU	https://www.ncbi.nlm.nih.gov/pubmed/10639357

DMUHZ2V	DI	DMUHZ2V
DMUHZ2V	DN	NT-69-L
DMUHZ2V	MI	TTTUMEP
DMUHZ2V	MN	Neurotensin receptor type 1 (NTSR1)
DMUHZ2V	MT	DTT
DMUHZ2V	MA	Modulator
DMUHZ2V	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 309).
DMUHZ2V	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=309

DMFIE0U	DI	DMFIE0U
DMFIE0U	DN	NTE-1
DMFIE0U	MI	TT2EDHU
DMFIE0U	MN	Insulin-degrading enzyme (IDE)
DMFIE0U	MT	DTT
DMFIE0U	MA	Inhibitor
DMFIE0U	RN	Dual Exosite-binding Inhibitors of Insulin-degrading Enzyme Challenge Its Role as the Primary Mediator of Insulin Clearance in Vivo. J Biol Chem. 2015 Aug 14;290(33):20044-59.
DMFIE0U	RU	https://pubmed.ncbi.nlm.nih.gov/26085101

DM4DB0W	DI	DM4DB0W
DM4DB0W	DN	NTE-2
DM4DB0W	MI	TT2EDHU
DM4DB0W	MN	Insulin-degrading enzyme (IDE)
DM4DB0W	MT	DTT
DM4DB0W	MA	Inhibitor
DM4DB0W	RN	Dual Exosite-binding Inhibitors of Insulin-degrading Enzyme Challenge Its Role as the Primary Mediator of Insulin Clearance in Vivo. J Biol Chem. 2015 Aug 14;290(33):20044-59.
DM4DB0W	RU	https://pubmed.ncbi.nlm.nih.gov/26085101

DMOPSJU	DI	DMOPSJU
DMOPSJU	DN	N-tert-Butyl-1'H-phenothiazine-1'-carboxamide
DMOPSJU	MI	TTEB0GD
DMOPSJU	MN	Cholinesterase (BCHE)
DMOPSJU	MT	DTT
DMOPSJU	MA	Inhibitor
DMOPSJU	RN	Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorg Med Chem. 2010 Mar 15;18(6):2232-2244.
DMOPSJU	RU	https://pubmed.ncbi.nlm.nih.gov/20181484

DMNZ37C	DI	DMNZ37C
DMNZ37C	DN	N-Tridecanoic Acid
DMNZ37C	MI	TTO8QRU
DMNZ37C	MN	Group IIA phospholipase A2 (GIIA sPLA2)
DMNZ37C	MT	DTT
DMNZ37C	MA	Inhibitor
DMNZ37C	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMNZ37C	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMNZ37C	DI	DMNZ37C
DMNZ37C	DN	N-Tridecanoic Acid
DMNZ37C	MI	TT9V5JH
DMNZ37C	MN	Phospholipase A2 (PLA2G1B)
DMNZ37C	MT	DTT
DMNZ37C	MA	Inhibitor
DMNZ37C	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMNZ37C	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMZQXLS	DI	DMZQXLS
DMZQXLS	DN	N-Trimethyllysine
DMZQXLS	MI	TTV3NH6
DMZQXLS	MN	Calmodulin (CALM)
DMZQXLS	MT	DTT
DMZQXLS	MA	Inhibitor
DMZQXLS	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMZQXLS	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMTHB2Y	DI	DMTHB2Y
DMTHB2Y	DN	nTzDpa
DMTHB2Y	MI	TTT2SVW
DMTHB2Y	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DMTHB2Y	MT	DTT
DMTHB2Y	MA	Agonist
DMTHB2Y	RN	Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. Mol Endocrinol. 2003 Apr;17(4):662-76.
DMTHB2Y	RU	https://pubmed.ncbi.nlm.nih.gov/12554792

DMEHMOK	DI	DMEHMOK
DMEHMOK	DN	NU-1001-41
DMEHMOK	MI	TTWTSCV
DMEHMOK	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DMEHMOK	MT	DTT
DMEHMOK	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479).
DMEHMOK	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1479

DMELYAX	DI	DMELYAX
DMELYAX	DN	NU-6027
DMELYAX	MI	TTAMQ62
DMELYAX	MN	Cyclin A2 (CCNA2)
DMELYAX	MT	DTT
DMELYAX	MA	Inhibitor
DMELYAX	RN	4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2. Bioorg Med Chem Lett. 2003 Jan 20;13(2):217-22.
DMELYAX	RU	https://pubmed.ncbi.nlm.nih.gov/12482427

DMELYAX	DI	DMELYAX
DMELYAX	DN	NU-6027
DMELYAX	MI	TT7HF4W
DMELYAX	MN	Cyclin-dependent kinase 2 (CDK2)
DMELYAX	MT	DTT
DMELYAX	MA	Inhibitor
DMELYAX	RN	4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2. Bioorg Med Chem Lett. 2003 Jan 20;13(2):217-22.
DMELYAX	RU	https://pubmed.ncbi.nlm.nih.gov/12482427

DMMOFKD	DI	DMMOFKD
DMMOFKD	DN	NU-6102
DMMOFKD	MI	TTTU902
DMMOFKD	MN	Checkpoint kinase-1 (CHK1)
DMMOFKD	MT	DTT
DMMOFKD	MA	Inhibitor
DMMOFKD	RN	Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1353-7.
DMMOFKD	RU	https://pubmed.ncbi.nlm.nih.gov/16325401

DMMOFKD	DI	DMMOFKD
DMMOFKD	DN	NU-6102
DMMOFKD	MI	TT7HF4W
DMMOFKD	MN	Cyclin-dependent kinase 2 (CDK2)
DMMOFKD	MT	DTT
DMMOFKD	MA	Inhibitor
DMMOFKD	RN	Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity. J Med Chem. 2006 Sep 7;49(18):5470-7.
DMMOFKD	RU	https://pubmed.ncbi.nlm.nih.gov/16942020

DMMOFKD	DI	DMMOFKD
DMMOFKD	DN	NU-6102
DMMOFKD	MI	TT0PG8F
DMMOFKD	MN	Cyclin-dependent kinase 4 (CDK4)
DMMOFKD	MT	DTT
DMMOFKD	MA	Inhibitor
DMMOFKD	RN	Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity. J Med Chem. 2006 Sep 7;49(18):5470-7.
DMMOFKD	RU	https://pubmed.ncbi.nlm.nih.gov/16942020

DMMOFKD	DI	DMMOFKD
DMMOFKD	DN	NU-6102
DMMOFKD	MI	TTRSMW9
DMMOFKD	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMMOFKD	MT	DTT
DMMOFKD	MA	Inhibitor
DMMOFKD	RN	Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1353-7.
DMMOFKD	RU	https://pubmed.ncbi.nlm.nih.gov/16325401

DMMOFKD	DI	DMMOFKD
DMMOFKD	DN	NU-6102
DMMOFKD	MI	TTYMGWX
DMMOFKD	MN	PDK-1 messenger RNA (PDK-1 mRNA)
DMMOFKD	MT	DTT
DMMOFKD	MA	Inhibitor
DMMOFKD	RN	Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1353-7.
DMMOFKD	RU	https://pubmed.ncbi.nlm.nih.gov/16325401

DMCUSG3	DI	DMCUSG3
DMCUSG3	DN	NU6140
DMCUSG3	MI	TTH6V3D
DMCUSG3	MN	Cyclin-dependent kinase 1 (CDK1)
DMCUSG3	MT	DTT
DMCUSG3	MA	Inhibitor
DMCUSG3	RN	Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. Mol Cancer Ther. 2005 Sep;4(9):1328-37.
DMCUSG3	RU	https://pubmed.ncbi.nlm.nih.gov/16170024

DMCUSG3	DI	DMCUSG3
DMCUSG3	DN	NU6140
DMCUSG3	MI	TT7HF4W
DMCUSG3	MN	Cyclin-dependent kinase 2 (CDK2)
DMCUSG3	MT	DTT
DMCUSG3	MA	Inhibitor
DMCUSG3	RN	Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. Mol Cancer Ther. 2005 Sep;4(9):1328-37.
DMCUSG3	RU	https://pubmed.ncbi.nlm.nih.gov/16170024

DMCUSG3	DI	DMCUSG3
DMCUSG3	DN	NU6140
DMCUSG3	MI	TT0PG8F
DMCUSG3	MN	Cyclin-dependent kinase 4 (CDK4)
DMCUSG3	MT	DTT
DMCUSG3	MA	Inhibitor
DMCUSG3	RN	Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. Mol Cancer Ther. 2005 Sep;4(9):1328-37.
DMCUSG3	RU	https://pubmed.ncbi.nlm.nih.gov/16170024

DMCUSG3	DI	DMCUSG3
DMCUSG3	DN	NU6140
DMCUSG3	MI	TTL4Q97
DMCUSG3	MN	Cyclin-dependent kinase 5 (CDK5)
DMCUSG3	MT	DTT
DMCUSG3	MA	Inhibitor
DMCUSG3	RN	Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. Mol Cancer Ther. 2005 Sep;4(9):1328-37.
DMCUSG3	RU	https://pubmed.ncbi.nlm.nih.gov/16170024

DMCUSG3	DI	DMCUSG3
DMCUSG3	DN	NU6140
DMCUSG3	MI	TTQYF7G
DMCUSG3	MN	Cyclin-dependent kinase 7 (CDK7)
DMCUSG3	MT	DTT
DMCUSG3	MA	Inhibitor
DMCUSG3	RN	Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. Mol Cancer Ther. 2005 Sep;4(9):1328-37.
DMCUSG3	RU	https://pubmed.ncbi.nlm.nih.gov/16170024

DMCUSG3	DI	DMCUSG3
DMCUSG3	DN	NU6140
DMCUSG3	MI	TTXEZJ4
DMCUSG3	MN	Tyrosine-protein kinase EIF2AK2 (p68)
DMCUSG3	MT	DTT
DMCUSG3	MA	Inhibitor
DMCUSG3	RN	Identification of new inhibitors of protein kinase R guided by statistical modeling. Bioorg Med Chem Lett. 2011 Jul 1;21(13):4108-14.
DMCUSG3	RU	https://pubmed.ncbi.nlm.nih.gov/21632247

DMDNUM5	DI	DMDNUM5
DMDNUM5	DN	NU-7432
DMDNUM5	MI	TTK3PY9
DMDNUM5	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMDNUM5	MT	DTT
DMDNUM5	MA	Inhibitor
DMDNUM5	RN	Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46.
DMDNUM5	RU	https://pubmed.ncbi.nlm.nih.gov/16302822

DMEUV5R	DI	DMEUV5R
DMEUV5R	DN	NU-8231
DMEUV5R	MI	TT7SBF5
DMEUV5R	MN	Cellular tumor antigen p53 (TP53)
DMEUV5R	MT	DTT
DMEUV5R	MA	Inhibitor
DMEUV5R	RN	Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold. J Med Chem. 2006 Oct 19;49(21):6209-21.
DMEUV5R	RU	https://pubmed.ncbi.nlm.nih.gov/17034127

DMEUV5R	DI	DMEUV5R
DMEUV5R	DN	NU-8231
DMEUV5R	MI	TT9TE0O
DMEUV5R	MN	Mdm2 messenger RNA (MDM2 mRNA)
DMEUV5R	MT	DTT
DMEUV5R	MA	Inhibitor
DMEUV5R	RN	Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold. J Med Chem. 2006 Oct 19;49(21):6209-21.
DMEUV5R	RU	https://pubmed.ncbi.nlm.nih.gov/17034127

DM5KXFI	DI	DM5KXFI
DM5KXFI	DN	NUTLIN-3
DM5KXFI	MI	TT7SBF5
DM5KXFI	MN	Cellular tumor antigen p53 (TP53)
DM5KXFI	MT	DTT
DM5KXFI	MA	Inhibitor
DM5KXFI	RN	Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein intera... J Med Chem. 2009 Nov 26;52(22):7044-53.
DM5KXFI	RU	https://pubmed.ncbi.nlm.nih.gov/19856920

DM5KXFI	DI	DM5KXFI
DM5KXFI	DN	NUTLIN-3
DM5KXFI	MI	TT9TE0O
DM5KXFI	MN	Mdm2 messenger RNA (MDM2 mRNA)
DM5KXFI	MT	DTT
DM5KXFI	MA	Inhibitor
DM5KXFI	RN	Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature. 2007 Dec 13;450(7172):1001-9.
DM5KXFI	RU	https://pubmed.ncbi.nlm.nih.gov/18075579

DMWLQV8	DI	DMWLQV8
DMWLQV8	DN	NV-07a
DMWLQV8	MI	TTXPQW1
DMWLQV8	MN	Hormone unspecific (HOM)
DMWLQV8	MT	DTT
DMWLQV8	MA	Modulator
DMWLQV8	RN	UV radiation-induced immunosuppression is greater in men and prevented by topical nicotinamide. J Invest Dermatol. 2008 Feb;128(2):447-54.
DMWLQV8	RU	https://pubmed.ncbi.nlm.nih.gov/17882270

DM0BNYU	DI	DM0BNYU
DM0BNYU	DN	NV-31
DM0BNYU	MI	TTZ8EM9
DM0BNYU	MN	Glycine receptor (GlyR)
DM0BNYU	MT	DTT
DM0BNYU	RN	Subunit-specific potentiation of recombinant glycine receptors by NV-31, a bilobalide-derived compound. Neurosci Lett. 2008 Apr 18;435(2):147-51.
DM0BNYU	RU	https://pubmed.ncbi.nlm.nih.gov/18329806

DM6DRFC	DI	DM6DRFC
DM6DRFC	DN	NVP 231
DM6DRFC	MI	TT9XRNV
DM6DRFC	MN	Ceramide kinase (CERK)
DM6DRFC	MT	DTT
DM6DRFC	MA	Inhibitor
DM6DRFC	RN	Targeting ceramide metabolism with a potent and specific ceramide kinase inhibitor. Mol Pharmacol. 2008 Oct;74(4):925-32.
DM6DRFC	RU	https://pubmed.ncbi.nlm.nih.gov/18612076

DM8R16V	DI	DM8R16V
DM8R16V	DN	NVP ACQ090
DM8R16V	MI	TTJX3UE
DM8R16V	MN	Somatostatin receptor type 3 (SSTR3)
DM8R16V	MT	DTT
DM8R16V	MA	Antagonist
DM8R16V	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 357).
DM8R16V	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=357

DM9DURZ	DI	DM9DURZ
DM9DURZ	DN	NVP-AAM077
DM9DURZ	MI	TTKJEMQ
DM9DURZ	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DM9DURZ	MT	DTT
DM9DURZ	MA	Antagonist
DM9DURZ	RN	Relating NMDA receptor function to receptor subunit composition: limitations of the pharmacological approach. J Neurosci. 2006 Feb 1;26(5):1331-3.
DM9DURZ	RU	https://pubmed.ncbi.nlm.nih.gov/16452656

DM9DURZ	DI	DM9DURZ
DM9DURZ	DN	NVP-AAM077
DM9DURZ	MI	TTN9D8E
DM9DURZ	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DM9DURZ	MT	DTT
DM9DURZ	MA	Antagonist
DM9DURZ	RN	Relating NMDA receptor function to receptor subunit composition: limitations of the pharmacological approach. J Neurosci. 2006 Feb 1;26(5):1331-3.
DM9DURZ	RU	https://pubmed.ncbi.nlm.nih.gov/16452656

DMXL3CD	DI	DMXL3CD
DMXL3CD	DN	NVP-ADW742
DMXL3CD	MI	TTHRID2
DMXL3CD	MN	Insulin-like growth factor I receptor (IGF1R)
DMXL3CD	MT	DTT
DMXL3CD	MA	Inhibitor
DMXL3CD	RN	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
DMXL3CD	RU	https://pubmed.ncbi.nlm.nih.gov/19249983

DMOV0QT	DI	DMOV0QT
DMOV0QT	DN	NVP-PDF386
DMOV0QT	MI	TTICO5G
DMOV0QT	MN	Staphylococcus Peptide deformylase (Stap-coc def)
DMOV0QT	MT	DTT
DMOV0QT	MA	Inhibitor
DMOV0QT	RN	Comparative spectrum and activity of NVP-PDF386 (VRC4887), a new peptide deformylase inhibitor. J Antimicrob Chemother. 2003 Jan;51(1):157-61.
DMOV0QT	RU	https://pubmed.ncbi.nlm.nih.gov/12493802

DMN90R6	DI	DMN90R6
DMN90R6	DN	NVP-SAA164
DMN90R6	MI	TTG5QIA
DMN90R6	MN	B1 bradykinin receptor (BDKRB1)
DMN90R6	MT	DTT
DMN90R6	MA	Antagonist
DMN90R6	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 659).
DMN90R6	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=659

DMFZXI2	DI	DMFZXI2
DMFZXI2	DN	NVP-TAE684
DMFZXI2	MI	TTCBFJO
DMFZXI2	MN	Insulin receptor (INSR)
DMFZXI2	MT	DTT
DMFZXI2	MA	Inhibitor
DMFZXI2	RN	Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):270-5.
DMFZXI2	RU	https://pubmed.ncbi.nlm.nih.gov/17185414

DMBQRA8	DI	DMBQRA8
DMBQRA8	DN	NVX-207
DMBQRA8	MI	TTB6T7O
DMBQRA8	MN	Caspase-9 (CASP9)
DMBQRA8	MT	DTT
DMBQRA8	MA	Modulator
DMBQRA8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1625).
DMBQRA8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1625

DMRYBK6	DI	DMRYBK6
DMRYBK6	DN	NW-1772
DMRYBK6	MI	TTGP7BY
DMRYBK6	MN	Monoamine oxidase type B (MAO-B)
DMRYBK6	MT	DTT
DMRYBK6	MA	Inhibitor
DMRYBK6	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2490).
DMRYBK6	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2490

DM9VISB	DI	DM9VISB
DM9VISB	DN	O-1602
DM9VISB	MI	TTNET8J
DM9VISB	MN	G-protein coupled receptor 55 (GPR55)
DM9VISB	MT	DTT
DM9VISB	MA	Agonist
DM9VISB	RN	International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB and CB Pharmacol Rev. 2010 Dec;62(4):588-631.
DM9VISB	RU	https://pubmed.ncbi.nlm.nih.gov/21079038

DM9VISB	DI	DM9VISB
DM9VISB	DN	O-1602
DM9VISB	MI	TTSLJAR
DM9VISB	MN	N-arachidonyl glycine receptor (GPR18)
DM9VISB	MT	DTT
DM9VISB	MA	Agonist
DM9VISB	RN	Delta(9) -Tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells. Br J Pharmacol. 2012 Apr;165(8):2414-24.
DM9VISB	RU	https://pubmed.ncbi.nlm.nih.gov/21595653

DMCXMQJ	DI	DMCXMQJ
DMCXMQJ	DN	O-1812
DMCXMQJ	MI	TT6OEDT
DMCXMQJ	MN	Cannabinoid receptor 1 (CB1)
DMCXMQJ	MT	DTT
DMCXMQJ	MA	Agonist
DMCXMQJ	RN	Highly selective CB(1) cannabinoid receptor ligands and novel CB(1)/VR(1) vanilloid receptor "hybrid" ligands. Biochem Biophys Res Commun. 2001 Feb 23;281(2):444-51.
DMCXMQJ	RU	https://pubmed.ncbi.nlm.nih.gov/11181068

DMK8AGF	DI	DMK8AGF
DMK8AGF	DN	O-2442
DMK8AGF	MI	TTVBI8W
DMK8AGF	MN	Dopamine transporter (DAT)
DMK8AGF	MT	DTT
DMK8AGF	MA	Inhibitor
DMK8AGF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 927).
DMK8AGF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=927

DME78MS	DI	DME78MS
DME78MS	DN	O2-Sulfo-Glucuronic Acid
DME78MS	MI	TTMY81X
DME78MS	MN	Heparin-binding growth factor 1 (FGF1)
DME78MS	MT	DTT
DME78MS	MA	Inhibitor
DME78MS	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DME78MS	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DME78MS	DI	DME78MS
DME78MS	DN	O2-Sulfo-Glucuronic Acid
DME78MS	MI	TT4V2JM
DME78MS	MN	Hepatocyte growth factor (HGF)
DME78MS	MT	DTT
DME78MS	MA	Inhibitor
DME78MS	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DME78MS	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMKMH2X	DI	DMKMH2X
DMKMH2X	DN	O5-Acetyl-O7-nitrooxyethyl chrysin
DMKMH2X	MI	TTFBNVI
DMKMH2X	MN	Aldose reductase (AKR1B1)
DMKMH2X	MT	DTT
DMKMH2X	MA	Inhibitor
DMKMH2X	RN	Synthesis, characterization and vasculoprotective effects of nitric oxide-donating derivatives of chrysin. Bioorg Med Chem. 2010 May 1;18(9):3020-5.
DMKMH2X	RU	https://pubmed.ncbi.nlm.nih.gov/20395149

DMAUDCW	DI	DMAUDCW
DMAUDCW	DN	O7-Nitrooxyethyl chrysin
DMAUDCW	MI	TTFBNVI
DMAUDCW	MN	Aldose reductase (AKR1B1)
DMAUDCW	MT	DTT
DMAUDCW	MA	Inhibitor
DMAUDCW	RN	Synthesis, characterization and vasculoprotective effects of nitric oxide-donating derivatives of chrysin. Bioorg Med Chem. 2010 May 1;18(9):3020-5.
DMAUDCW	RU	https://pubmed.ncbi.nlm.nih.gov/20395149

DM458IH	DI	DM458IH
DM458IH	DN	OAADPR
DM458IH	MI	TTEBMN7
DM458IH	MN	Long transient receptor potential channel 2 (TRPM2)
DM458IH	MT	DTT
DM458IH	MA	Activator
DM458IH	RN	Metabolite of SIR2 reaction modulates TRPM2 ion channel. J Biol Chem. 2006 May 19;281(20):14057-65.
DM458IH	RU	https://pubmed.ncbi.nlm.nih.gov/16565078

DMAEHFT	DI	DMAEHFT
DMAEHFT	DN	O-Acetylserine
DMAEHFT	MI	TT8NGED
DMAEHFT	MN	Prostaglandin G/H synthase 1 (COX-1)
DMAEHFT	MT	DTT
DMAEHFT	MA	Inhibitor
DMAEHFT	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMAEHFT	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMOP8IJ	DI	DMOP8IJ
DMOP8IJ	DN	OAG
DMOP8IJ	MI	TTSJ9E7
DMOP8IJ	MN	Short transient receptor potential channel 2 (TRPC2)
DMOP8IJ	MT	DTT
DMOP8IJ	MA	Activator
DMOP8IJ	RN	A diacylglycerol-gated cation channel in vomeronasal neuron dendrites is impaired in TRPC2 mutant mice: mechanism of pheromone transduction. Neuron. 2003 Oct 30;40(3):551-61.
DMOP8IJ	RU	https://pubmed.ncbi.nlm.nih.gov/14642279

DMOP8IJ	DI	DMOP8IJ
DMOP8IJ	DN	OAG
DMOP8IJ	MI	TTNVC34
DMOP8IJ	MN	Short transient receptor potential channel 3 (TRPC3)
DMOP8IJ	MT	DTT
DMOP8IJ	MA	Activator
DMOP8IJ	RN	Direct activation of human TRPC6 and TRPC3 channels by diacylglycerol. Nature. 1999 Jan 21;397(6716):259-63.
DMOP8IJ	RU	https://pubmed.ncbi.nlm.nih.gov/9930701

DMOP8IJ	DI	DMOP8IJ
DMOP8IJ	DN	OAG
DMOP8IJ	MI	TTRBT3W
DMOP8IJ	MN	Short transient receptor potential channel 6 (TRPC6)
DMOP8IJ	MT	DTT
DMOP8IJ	MA	Activator
DMOP8IJ	RN	Direct activation of human TRPC6 and TRPC3 channels by diacylglycerol. Nature. 1999 Jan 21;397(6716):259-63.
DMOP8IJ	RU	https://pubmed.ncbi.nlm.nih.gov/9930701

DMOP8IJ	DI	DMOP8IJ
DMOP8IJ	DN	OAG
DMOP8IJ	MI	TT06GRA
DMOP8IJ	MN	Short transient receptor potential channel 7 (TRPC7)
DMOP8IJ	MT	DTT
DMOP8IJ	MA	Activator
DMOP8IJ	RN	Molecular and functional characterization of a novel mouse transient receptor potential protein homologue TRP7. Ca(2+)-permeable cation channel that is constitutively activated and enhanced by stimulation of G protein-coupled receptor. J Biol Chem. 1999 Sep 24;274(39):27359-70.
DMOP8IJ	RU	https://pubmed.ncbi.nlm.nih.gov/10488066

DML0P72	DI	DML0P72
DML0P72	DN	O-arachidonoyl ethanolamine
DML0P72	MI	TTNET8J
DML0P72	MN	G-protein coupled receptor 55 (GPR55)
DML0P72	MT	DTT
DML0P72	MA	Agonist
DML0P72	RN	The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007 Dec;152(7):1092-101.
DML0P72	RU	https://pubmed.ncbi.nlm.nih.gov/17876302

DMWZXH6	DI	DMWZXH6
DMWZXH6	DN	O-arachidonoyl-N-(2-hydroxyethyl)hydroxylamine
DMWZXH6	MI	TT6OEDT
DMWZXH6	MN	Cannabinoid receptor 1 (CB1)
DMWZXH6	MT	DTT
DMWZXH6	MA	Inhibitor
DMWZXH6	RN	Oxyhomologues of anandamide and related endolipids: chemoselective synthesis and biological activity. J Med Chem. 2006 Apr 6;49(7):2333-8.
DMWZXH6	RU	https://pubmed.ncbi.nlm.nih.gov/16570929

DMWZXH6	DI	DMWZXH6
DMWZXH6	DN	O-arachidonoyl-N-(2-hydroxyethyl)hydroxylamine
DMWZXH6	MI	TTMSFAW
DMWZXH6	MN	Cannabinoid receptor 2 (CB2)
DMWZXH6	MT	DTT
DMWZXH6	MA	Inhibitor
DMWZXH6	RN	Oxyhomologues of anandamide and related endolipids: chemoselective synthesis and biological activity. J Med Chem. 2006 Apr 6;49(7):2333-8.
DMWZXH6	RU	https://pubmed.ncbi.nlm.nih.gov/16570929

DMY4PMN	DI	DMY4PMN
DMY4PMN	DN	OBABERINE
DMY4PMN	MI	TTVBI8W
DMY4PMN	MN	Dopamine transporter (DAT)
DMY4PMN	MT	DTT
DMY4PMN	MA	Inhibitor
DMY4PMN	RN	Effects of various isoquinoline alkaloids on in vitro 3H-dopamine uptake by rat striatal synaptosomes. J Nat Prod. 1995 Oct;58(10):1475-84.
DMY4PMN	RU	https://pubmed.ncbi.nlm.nih.gov/8676127

DMD25HJ	DI	DMD25HJ
DMD25HJ	DN	O-Benzylsulfonyl-Serine
DMD25HJ	MI	TT5DOVB
DMD25HJ	MN	Cytomegalovirus Protease (CMV UL80)
DMD25HJ	MT	DTT
DMD25HJ	MA	Inhibitor
DMD25HJ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD25HJ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMM98BC	DI	DMM98BC
DMM98BC	DN	OBIDOXIME
DMM98BC	MI	TT1RS9F
DMM98BC	MN	Acetylcholinesterase (AChE)
DMM98BC	MT	DTT
DMM98BC	MA	Inhibitor
DMM98BC	RN	Synthesis of the novel series of bispyridinium compounds bearing (E)-but-2-ene linker and evaluation of their reactivation activity against chlorpy... Bioorg Med Chem Lett. 2006 Feb;16(3):622-7.
DMM98BC	RU	https://pubmed.ncbi.nlm.nih.gov/16288867

DMA63FQ	DI	DMA63FQ
DMA63FQ	DN	Obtusifoldienol
DMA63FQ	MI	DEVSF75
DMA63FQ	MN	Cytochrome P450 monooxygenase 51A (cyp51A)
DMA63FQ	MT	DME
DMA63FQ	MA	Metabolism
DMA63FQ	RN	nan
DMA63FQ	RU	nan

DMGVDR6	DI	DMGVDR6
DMGVDR6	DN	Ochnaflavone
DMGVDR6	MI	TTO8QRU
DMGVDR6	MN	Group IIA phospholipase A2 (GIIA sPLA2)
DMGVDR6	MT	DTT
DMGVDR6	MA	Inhibitor
DMGVDR6	RN	Synthesis of phospholipase A2 inhibitory biflavonoids. Bioorg Med Chem Lett. 2006 May 1;16(9):2373-5.
DMGVDR6	RU	https://pubmed.ncbi.nlm.nih.gov/16504502

DM69O3S	DI	DM69O3S
DM69O3S	DN	OCID-2987
DM69O3S	MI	TTZ97H5
DM69O3S	MN	Phosphodiesterase 4A (PDE4A)
DM69O3S	MT	DTT
DM69O3S	MA	Inhibitor
DM69O3S	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1300).
DM69O3S	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1300

DM69O3S	DI	DM69O3S
DM69O3S	DN	OCID-2987
DM69O3S	MI	TTVIAT9
DM69O3S	MN	Phosphodiesterase 4B (PDE4B)
DM69O3S	MT	DTT
DM69O3S	MA	Inhibitor
DM69O3S	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1301).
DM69O3S	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1301

DM69O3S	DI	DM69O3S
DM69O3S	DN	OCID-2987
DM69O3S	MI	TTSKMI8
DM69O3S	MN	Phosphodiesterase 4D (PDE4D)
DM69O3S	MT	DTT
DM69O3S	MA	Inhibitor
DM69O3S	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1303).
DM69O3S	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1303

DMT59UG	DI	DMT59UG
DMT59UG	DN	OCOPHYLLALS A
DMT59UG	MI	TTVKILB
DMT59UG	MN	Prostaglandin G/H synthase 2 (COX-2)
DMT59UG	MT	DTT
DMT59UG	MA	Inhibitor
DMT59UG	RN	COX, LOX and platelet aggregation inhibitory properties of Lauraceae neolignans. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6922-5.
DMT59UG	RU	https://pubmed.ncbi.nlm.nih.gov/19880317

DMEUPVF	DI	DMEUPVF
DMEUPVF	DN	Ocophyllals b
DMEUPVF	MI	TTVKILB
DMEUPVF	MN	Prostaglandin G/H synthase 2 (COX-2)
DMEUPVF	MT	DTT
DMEUPVF	MA	Inhibitor
DMEUPVF	RN	COX, LOX and platelet aggregation inhibitory properties of Lauraceae neolignans. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6922-5.
DMEUPVF	RU	https://pubmed.ncbi.nlm.nih.gov/19880317

DMUFDR6	DI	DMUFDR6
DMUFDR6	DN	Octahydrocurcumin
DMUFDR6	MI	TTCJUR4
DMUFDR6	MN	Exportin-1 (XPO1)
DMUFDR6	MT	DTT
DMUFDR6	MA	Inhibitor
DMUFDR6	RN	Therapeutic strategies targeting FOXO transcription factors. Nat Rev Drug Discov. 2021 Jan;20(1):21-38.
DMUFDR6	RU	https://pubmed.ncbi.nlm.nih.gov/33173189

DM4C70S	DI	DM4C70S
DM4C70S	DN	Octahydro-isoindol-(1Z)-ylideneamine
DM4C70S	MI	TTZUFI5
DM4C70S	MN	Nitric-oxide synthase brain (NOS1)
DM4C70S	MT	DTT
DM4C70S	MA	Inhibitor
DM4C70S	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DM4C70S	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DM4C70S	DI	DM4C70S
DM4C70S	DN	Octahydro-isoindol-(1Z)-ylideneamine
DM4C70S	MI	TTF10I9
DM4C70S	MN	Nitric-oxide synthase inducible (NOS2)
DM4C70S	MT	DTT
DM4C70S	MA	Inhibitor
DM4C70S	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DM4C70S	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DMTN0OK	DI	DMTN0OK
DMTN0OK	DN	Octanal
DMTN0OK	MI	DEM1HNL
DMTN0OK	MN	Alcohol dehydrogenase class-I gamma (ADH1C)
DMTN0OK	MT	DME
DMTN0OK	MA	Metabolism
DMTN0OK	RN	Oxidation of alcohols and reduction of aldehydes derived from methyl- and dimethylpyrenes by cDNA-expressed human alcohol dehydrogenases. Toxicology. 2008 Mar 12;245(1-2):65-75.
DMTN0OK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18242813

DMTN0OK	DI	DMTN0OK
DMTN0OK	DN	Octanal
DMTN0OK	MI	DEOCWU3
DMTN0OK	MN	Alcohol dehydrogenase class-II (ADH4)
DMTN0OK	MT	DME
DMTN0OK	MA	Metabolism
DMTN0OK	RN	Oxidation of alcohols and reduction of aldehydes derived from methyl- and dimethylpyrenes by cDNA-expressed human alcohol dehydrogenases. Toxicology. 2008 Mar 12;245(1-2):65-75.
DMTN0OK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18242813

DMBQMGH	DI	DMBQMGH
DMBQMGH	DN	Octane-1,8-diyl disulfamate
DMBQMGH	MI	TTUNARX
DMBQMGH	MN	Carbonic anhydrase (CA)
DMBQMGH	MT	DTT
DMBQMGH	MA	Inhibitor
DMBQMGH	RN	Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8.
DMBQMGH	RU	https://pubmed.ncbi.nlm.nih.gov/19731956

DMBQMGH	DI	DMBQMGH
DMBQMGH	DN	Octane-1,8-diyl disulfamate
DMBQMGH	MI	TTHQPL7
DMBQMGH	MN	Carbonic anhydrase I (CA-I)
DMBQMGH	MT	DTT
DMBQMGH	MA	Inhibitor
DMBQMGH	RN	Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8.
DMBQMGH	RU	https://pubmed.ncbi.nlm.nih.gov/19731956

DMBQMGH	DI	DMBQMGH
DMBQMGH	DN	Octane-1,8-diyl disulfamate
DMBQMGH	MI	TTANPDJ
DMBQMGH	MN	Carbonic anhydrase II (CA-II)
DMBQMGH	MT	DTT
DMBQMGH	MA	Inhibitor
DMBQMGH	RN	Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8.
DMBQMGH	RU	https://pubmed.ncbi.nlm.nih.gov/19731956

DMBQMGH	DI	DMBQMGH
DMBQMGH	DN	Octane-1,8-diyl disulfamate
DMBQMGH	MI	TTZHA0O
DMBQMGH	MN	Carbonic anhydrase IV (CA-IV)
DMBQMGH	MT	DTT
DMBQMGH	MA	Inhibitor
DMBQMGH	RN	Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8.
DMBQMGH	RU	https://pubmed.ncbi.nlm.nih.gov/19731956

DMBQMGH	DI	DMBQMGH
DMBQMGH	DN	Octane-1,8-diyl disulfamate
DMBQMGH	MI	TT2LVK8
DMBQMGH	MN	Carbonic anhydrase IX (CA-IX)
DMBQMGH	MT	DTT
DMBQMGH	MA	Inhibitor
DMBQMGH	RN	Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8.
DMBQMGH	RU	https://pubmed.ncbi.nlm.nih.gov/19731956

DMBQMGH	DI	DMBQMGH
DMBQMGH	DN	Octane-1,8-diyl disulfamate
DMBQMGH	MI	TTCFSPE
DMBQMGH	MN	Carbonic anhydrase VI (CA-VI)
DMBQMGH	MT	DTT
DMBQMGH	MA	Inhibitor
DMBQMGH	RN	Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8.
DMBQMGH	RU	https://pubmed.ncbi.nlm.nih.gov/19731956

DMBQMGH	DI	DMBQMGH
DMBQMGH	DN	Octane-1,8-diyl disulfamate
DMBQMGH	MI	TTSYM0R
DMBQMGH	MN	Carbonic anhydrase XII (CA-XII)
DMBQMGH	MT	DTT
DMBQMGH	MA	Inhibitor
DMBQMGH	RN	Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8.
DMBQMGH	RU	https://pubmed.ncbi.nlm.nih.gov/19731956

DMBQMGH	DI	DMBQMGH
DMBQMGH	DN	Octane-1,8-diyl disulfamate
DMBQMGH	MI	TTEYTKG
DMBQMGH	MN	Carbonic anhydrase XIV (CA-XIV)
DMBQMGH	MT	DTT
DMBQMGH	MA	Inhibitor
DMBQMGH	RN	Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8.
DMBQMGH	RU	https://pubmed.ncbi.nlm.nih.gov/19731956

DMDBI5S	DI	DMDBI5S
DMDBI5S	DN	Octane-1-sulfonyl fluoride
DMDBI5S	MI	TT6OEDT
DMDBI5S	MN	Cannabinoid receptor 1 (CB1)
DMDBI5S	MT	DTT
DMDBI5S	MA	Inhibitor
DMDBI5S	RN	Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5875-8.
DMDBI5S	RU	https://pubmed.ncbi.nlm.nih.gov/18752948

DMDBI5S	DI	DMDBI5S
DMDBI5S	DN	Octane-1-sulfonyl fluoride
DMDBI5S	MI	TTDP1UC
DMDBI5S	MN	Fatty acid amide hydrolase (FAAH)
DMDBI5S	MT	DTT
DMDBI5S	MA	Inhibitor
DMDBI5S	RN	Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5875-8.
DMDBI5S	RU	https://pubmed.ncbi.nlm.nih.gov/18752948

DMJNQ9K	DI	DMJNQ9K
DMJNQ9K	DN	Octanedioic acid bis-hydroxyamide
DMJNQ9K	MI	TTBH0VX
DMJNQ9K	MN	Histone deacetylase (HDAC)
DMJNQ9K	MT	DTT
DMJNQ9K	MA	Inhibitor
DMJNQ9K	RN	Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010 Mar;6(3):238-243.
DMJNQ9K	RU	https://pubmed.ncbi.nlm.nih.gov/20139990

DMJNQ9K	DI	DMJNQ9K
DMJNQ9K	DN	Octanedioic acid bis-hydroxyamide
DMJNQ9K	MI	TT6R7JZ
DMJNQ9K	MN	Histone deacetylase 1 (HDAC1)
DMJNQ9K	MT	DTT
DMJNQ9K	MA	Inhibitor
DMJNQ9K	RN	Structure-activity relationships on phenylalanine-containing inhibitors of histone deacetylase: in vitro enzyme inhibition, induction of differenti... J Med Chem. 2002 Jul 18;45(15):3296-309.
DMJNQ9K	RU	https://pubmed.ncbi.nlm.nih.gov/12109913

DMJNQ9K	DI	DMJNQ9K
DMJNQ9K	DN	Octanedioic acid bis-hydroxyamide
DMJNQ9K	MI	TTSHTOI
DMJNQ9K	MN	Histone deacetylase 2 (HDAC2)
DMJNQ9K	MT	DTT
DMJNQ9K	MA	Inhibitor
DMJNQ9K	RN	Structure-activity relationships on phenylalanine-containing inhibitors of histone deacetylase: in vitro enzyme inhibition, induction of differenti... J Med Chem. 2002 Jul 18;45(15):3296-309.
DMJNQ9K	RU	https://pubmed.ncbi.nlm.nih.gov/12109913

DMJNQ9K	DI	DMJNQ9K
DMJNQ9K	DN	Octanedioic acid bis-hydroxyamide
DMJNQ9K	MI	TTTQGH8
DMJNQ9K	MN	Histone deacetylase 4 (HDAC4)
DMJNQ9K	MT	DTT
DMJNQ9K	MA	Inhibitor
DMJNQ9K	RN	Structure-activity relationships on phenylalanine-containing inhibitors of histone deacetylase: in vitro enzyme inhibition, induction of differenti... J Med Chem. 2002 Jul 18;45(15):3296-309.
DMJNQ9K	RU	https://pubmed.ncbi.nlm.nih.gov/12109913

DMJNQ9K	DI	DMJNQ9K
DMJNQ9K	DN	Octanedioic acid bis-hydroxyamide
DMJNQ9K	MI	TT5ZKDI
DMJNQ9K	MN	Histone deacetylase 6 (HDAC6)
DMJNQ9K	MT	DTT
DMJNQ9K	MA	Inhibitor
DMJNQ9K	RN	Structure-activity relationships on phenylalanine-containing inhibitors of histone deacetylase: in vitro enzyme inhibition, induction of differenti... J Med Chem. 2002 Jul 18;45(15):3296-309.
DMJNQ9K	RU	https://pubmed.ncbi.nlm.nih.gov/12109913

DMJNQ9K	DI	DMJNQ9K
DMJNQ9K	DN	Octanedioic acid bis-hydroxyamide
DMJNQ9K	MI	TTT6LFV
DMJNQ9K	MN	Histone deacetylase 8 (HDAC8)
DMJNQ9K	MT	DTT
DMJNQ9K	MA	Inhibitor
DMJNQ9K	RN	Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010 Mar;6(3):238-243.
DMJNQ9K	RU	https://pubmed.ncbi.nlm.nih.gov/20139990

DMHNWS1	DI	DMHNWS1
DMHNWS1	DN	Octanedioic acid hydroxyamide pyridin-2-ylamide
DMHNWS1	MI	TTBH0VX
DMHNWS1	MN	Histone deacetylase (HDAC)
DMHNWS1	MT	DTT
DMHNWS1	MA	Inhibitor
DMHNWS1	RN	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
DMHNWS1	RU	https://pubmed.ncbi.nlm.nih.gov/11831887

DMHNWS1	DI	DMHNWS1
DMHNWS1	DN	Octanedioic acid hydroxyamide pyridin-2-ylamide
DMHNWS1	MI	TT6R7JZ
DMHNWS1	MN	Histone deacetylase 1 (HDAC1)
DMHNWS1	MT	DTT
DMHNWS1	MA	Inhibitor
DMHNWS1	RN	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
DMHNWS1	RU	https://pubmed.ncbi.nlm.nih.gov/11831887

DMHNWS1	DI	DMHNWS1
DMHNWS1	DN	Octanedioic acid hydroxyamide pyridin-2-ylamide
DMHNWS1	MI	TTYHPU6
DMHNWS1	MN	Histone deacetylase 10 (HDAC10)
DMHNWS1	MT	DTT
DMHNWS1	MA	Inhibitor
DMHNWS1	RN	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
DMHNWS1	RU	https://pubmed.ncbi.nlm.nih.gov/11831887

DMHNWS1	DI	DMHNWS1
DMHNWS1	DN	Octanedioic acid hydroxyamide pyridin-2-ylamide
DMHNWS1	MI	TTSHTOI
DMHNWS1	MN	Histone deacetylase 2 (HDAC2)
DMHNWS1	MT	DTT
DMHNWS1	MA	Inhibitor
DMHNWS1	RN	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
DMHNWS1	RU	https://pubmed.ncbi.nlm.nih.gov/11831887

DMHNWS1	DI	DMHNWS1
DMHNWS1	DN	Octanedioic acid hydroxyamide pyridin-2-ylamide
DMHNWS1	MI	TTTQGH8
DMHNWS1	MN	Histone deacetylase 4 (HDAC4)
DMHNWS1	MT	DTT
DMHNWS1	MA	Inhibitor
DMHNWS1	RN	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
DMHNWS1	RU	https://pubmed.ncbi.nlm.nih.gov/11831887

DMHNWS1	DI	DMHNWS1
DMHNWS1	DN	Octanedioic acid hydroxyamide pyridin-2-ylamide
DMHNWS1	MI	TT5ZKDI
DMHNWS1	MN	Histone deacetylase 6 (HDAC6)
DMHNWS1	MT	DTT
DMHNWS1	MA	Inhibitor
DMHNWS1	RN	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
DMHNWS1	RU	https://pubmed.ncbi.nlm.nih.gov/11831887

DMHNWS1	DI	DMHNWS1
DMHNWS1	DN	Octanedioic acid hydroxyamide pyridin-2-ylamide
DMHNWS1	MI	TTT6LFV
DMHNWS1	MN	Histone deacetylase 8 (HDAC8)
DMHNWS1	MT	DTT
DMHNWS1	MA	Inhibitor
DMHNWS1	RN	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
DMHNWS1	RU	https://pubmed.ncbi.nlm.nih.gov/11831887

DM945RK	DI	DM945RK
DM945RK	DN	Octanedioic acid hydroxyamide pyridin-4-ylamide
DM945RK	MI	TTBH0VX
DM945RK	MN	Histone deacetylase (HDAC)
DM945RK	MT	DTT
DM945RK	MA	Inhibitor
DM945RK	RN	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
DM945RK	RU	https://pubmed.ncbi.nlm.nih.gov/11831887

DM945RK	DI	DM945RK
DM945RK	DN	Octanedioic acid hydroxyamide pyridin-4-ylamide
DM945RK	MI	TT6R7JZ
DM945RK	MN	Histone deacetylase 1 (HDAC1)
DM945RK	MT	DTT
DM945RK	MA	Inhibitor
DM945RK	RN	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
DM945RK	RU	https://pubmed.ncbi.nlm.nih.gov/11831887

DM945RK	DI	DM945RK
DM945RK	DN	Octanedioic acid hydroxyamide pyridin-4-ylamide
DM945RK	MI	TTYHPU6
DM945RK	MN	Histone deacetylase 10 (HDAC10)
DM945RK	MT	DTT
DM945RK	MA	Inhibitor
DM945RK	RN	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
DM945RK	RU	https://pubmed.ncbi.nlm.nih.gov/11831887

DM945RK	DI	DM945RK
DM945RK	DN	Octanedioic acid hydroxyamide pyridin-4-ylamide
DM945RK	MI	TTSHTOI
DM945RK	MN	Histone deacetylase 2 (HDAC2)
DM945RK	MT	DTT
DM945RK	MA	Inhibitor
DM945RK	RN	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
DM945RK	RU	https://pubmed.ncbi.nlm.nih.gov/11831887

DM945RK	DI	DM945RK
DM945RK	DN	Octanedioic acid hydroxyamide pyridin-4-ylamide
DM945RK	MI	TTTQGH8
DM945RK	MN	Histone deacetylase 4 (HDAC4)
DM945RK	MT	DTT
DM945RK	MA	Inhibitor
DM945RK	RN	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
DM945RK	RU	https://pubmed.ncbi.nlm.nih.gov/11831887

DM945RK	DI	DM945RK
DM945RK	DN	Octanedioic acid hydroxyamide pyridin-4-ylamide
DM945RK	MI	TT5ZKDI
DM945RK	MN	Histone deacetylase 6 (HDAC6)
DM945RK	MT	DTT
DM945RK	MA	Inhibitor
DM945RK	RN	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
DM945RK	RU	https://pubmed.ncbi.nlm.nih.gov/11831887

DM945RK	DI	DM945RK
DM945RK	DN	Octanedioic acid hydroxyamide pyridin-4-ylamide
DM945RK	MI	TTT6LFV
DM945RK	MN	Histone deacetylase 8 (HDAC8)
DM945RK	MT	DTT
DM945RK	MA	Inhibitor
DM945RK	RN	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
DM945RK	RU	https://pubmed.ncbi.nlm.nih.gov/11831887

DM4RGCX	DI	DM4RGCX
DM4RGCX	DN	Octanoic acid biphenyl-2-ylamide
DM4RGCX	MI	TTK3C21
DM4RGCX	MN	Acetoacetyl-CoA thiolase (ACAT1)
DM4RGCX	MT	DTT
DM4RGCX	MA	Inhibitor
DM4RGCX	RN	Biphenyl versus phenylpyridazine derivatives: the role of the heterocycle in a series of acyl-CoA:cholesterol acyl transferase inhibitors. J Med Chem. 2008 Mar 13;51(5):1474-7.
DM4RGCX	RU	https://pubmed.ncbi.nlm.nih.gov/18284184

DMBGHPE	DI	DMBGHPE
DMBGHPE	DN	Octanol
DMBGHPE	MI	DEM1HNL
DMBGHPE	MN	Alcohol dehydrogenase class-I gamma (ADH1C)
DMBGHPE	MT	DME
DMBGHPE	MA	Metabolism
DMBGHPE	RN	Oxidation of alcohols and reduction of aldehydes derived from methyl- and dimethylpyrenes by cDNA-expressed human alcohol dehydrogenases. Toxicology. 2008 Mar 12;245(1-2):65-75.
DMBGHPE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18242813

DMBGHPE	DI	DMBGHPE
DMBGHPE	DN	Octanol
DMBGHPE	MI	DEOCWU3
DMBGHPE	MN	Alcohol dehydrogenase class-II (ADH4)
DMBGHPE	MT	DME
DMBGHPE	MA	Metabolism
DMBGHPE	RN	Oxidation of alcohols and reduction of aldehydes derived from methyl- and dimethylpyrenes by cDNA-expressed human alcohol dehydrogenases. Toxicology. 2008 Mar 12;245(1-2):65-75.
DMBGHPE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18242813

DMBGHPE	DI	DMBGHPE
DMBGHPE	DN	Octanol
DMBGHPE	MI	TTDQPXA
DMBGHPE	MN	Connexin-23 (Cx23)
DMBGHPE	MT	DTT
DMBGHPE	MA	Inhibitor
DMBGHPE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 714).
DMBGHPE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=714

DMBGHPE	DI	DMBGHPE
DMBGHPE	DN	Octanol
DMBGHPE	MI	TTZ7POK
DMBGHPE	MN	Connexin-25 (Cx25)
DMBGHPE	MT	DTT
DMBGHPE	MA	Inhibitor
DMBGHPE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 715).
DMBGHPE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=715

DMBGHPE	DI	DMBGHPE
DMBGHPE	DN	Octanol
DMBGHPE	MI	TTAU8SJ
DMBGHPE	MN	Connexin-30 (Cx30)
DMBGHPE	MT	DTT
DMBGHPE	MA	Inhibitor
DMBGHPE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 717).
DMBGHPE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=717

DMBGHPE	DI	DMBGHPE
DMBGHPE	DN	Octanol
DMBGHPE	MI	TTHWA40
DMBGHPE	MN	Connexin-32 (Cx32)
DMBGHPE	MT	DTT
DMBGHPE	MA	Inhibitor
DMBGHPE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 723).
DMBGHPE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=723

DMBGHPE	DI	DMBGHPE
DMBGHPE	DN	Octanol
DMBGHPE	MI	TTEP7OC
DMBGHPE	MN	Connexin-45 (Cx45)
DMBGHPE	MT	DTT
DMBGHPE	MA	Inhibitor
DMBGHPE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 729).
DMBGHPE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=729

DMBGHPE	DI	DMBGHPE
DMBGHPE	DN	Octanol
DMBGHPE	MI	TTYP9NL
DMBGHPE	MN	Connexin-59 (Cx59)
DMBGHPE	MT	DTT
DMBGHPE	MA	Inhibitor
DMBGHPE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 733).
DMBGHPE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=733

DMBGHPE	DI	DMBGHPE
DMBGHPE	DN	Octanol
DMBGHPE	MI	TTQMI2N
DMBGHPE	MN	Connexin-62 (Cx62)
DMBGHPE	MT	DTT
DMBGHPE	MA	Inhibitor
DMBGHPE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 734).
DMBGHPE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=734

DMBGHPE	DI	DMBGHPE
DMBGHPE	DN	Octanol
DMBGHPE	MI	TT4F7SL
DMBGHPE	MN	Gap junction alpha-1 protein (GJA1)
DMBGHPE	MT	DTT
DMBGHPE	MA	Inhibitor
DMBGHPE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 728).
DMBGHPE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=728

DMBGHPE	DI	DMBGHPE
DMBGHPE	DN	Octanol
DMBGHPE	MI	TTFZRG0
DMBGHPE	MN	Gap junction alpha-3 protein (Cx46)
DMBGHPE	MT	DTT
DMBGHPE	MA	Inhibitor
DMBGHPE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 730).
DMBGHPE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=730

DMBGHPE	DI	DMBGHPE
DMBGHPE	DN	Octanol
DMBGHPE	MI	TTQO1VY
DMBGHPE	MN	Gap junction alpha-4 protein (Cx37)
DMBGHPE	MT	DTT
DMBGHPE	MA	Inhibitor
DMBGHPE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 725).
DMBGHPE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=725

DMBGHPE	DI	DMBGHPE
DMBGHPE	DN	Octanol
DMBGHPE	MI	TTFQKZ7
DMBGHPE	MN	Gap junction alpha-5 protein (Cx40)
DMBGHPE	MT	DTT
DMBGHPE	MA	Inhibitor
DMBGHPE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 726).
DMBGHPE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=726

DMBGHPE	DI	DMBGHPE
DMBGHPE	DN	Octanol
DMBGHPE	MI	TTJ7ATH
DMBGHPE	MN	Gap junction alpha-8 protein (Cx50)
DMBGHPE	MT	DTT
DMBGHPE	MA	Inhibitor
DMBGHPE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 732).
DMBGHPE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=732

DMBGHPE	DI	DMBGHPE
DMBGHPE	DN	Octanol
DMBGHPE	MI	TTRGZX3
DMBGHPE	MN	Gap junction beta-2 protein (Cx26)
DMBGHPE	MT	DTT
DMBGHPE	MA	Inhibitor
DMBGHPE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 716).
DMBGHPE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=716

DMBGHPE	DI	DMBGHPE
DMBGHPE	DN	Octanol
DMBGHPE	MI	TTVRQ8L
DMBGHPE	MN	Gap junction beta-3 protein (Cx31)
DMBGHPE	MT	DTT
DMBGHPE	MA	Inhibitor
DMBGHPE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 720).
DMBGHPE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=720

DMBGHPE	DI	DMBGHPE
DMBGHPE	DN	Octanol
DMBGHPE	MI	TTBRDFI
DMBGHPE	MN	Gap junction beta-4 protein (Cx30.3)
DMBGHPE	MT	DTT
DMBGHPE	MA	Inhibitor
DMBGHPE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 719).
DMBGHPE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=719

DMBGHPE	DI	DMBGHPE
DMBGHPE	DN	Octanol
DMBGHPE	MI	TTL9MHP
DMBGHPE	MN	Gap junction beta-5 protein (Cx31.1)
DMBGHPE	MT	DTT
DMBGHPE	MA	Inhibitor
DMBGHPE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 721).
DMBGHPE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=721

DMBGHPE	DI	DMBGHPE
DMBGHPE	DN	Octanol
DMBGHPE	MI	TTOZAFI
DMBGHPE	MN	Gap junction delta-2 protein (Cx36)
DMBGHPE	MT	DTT
DMBGHPE	MA	Inhibitor
DMBGHPE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 724).
DMBGHPE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=724

DMBGHPE	DI	DMBGHPE
DMBGHPE	DN	Octanol
DMBGHPE	MI	TT7C18W
DMBGHPE	MN	Gap junction delta-3 protein (Cx31.9)
DMBGHPE	MT	DTT
DMBGHPE	MA	Inhibitor
DMBGHPE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 722).
DMBGHPE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=722

DMBGHPE	DI	DMBGHPE
DMBGHPE	DN	Octanol
DMBGHPE	MI	TTL07NQ
DMBGHPE	MN	Gap junction delta-4 protein (Cx40.1)
DMBGHPE	MT	DTT
DMBGHPE	MA	Inhibitor
DMBGHPE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 727).
DMBGHPE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=727

DMBGHPE	DI	DMBGHPE
DMBGHPE	DN	Octanol
DMBGHPE	MI	TTPOCAL
DMBGHPE	MN	Gap junction gamma-2 protein (Cx47)
DMBGHPE	MT	DTT
DMBGHPE	MA	Inhibitor
DMBGHPE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 731).
DMBGHPE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=731

DMBGHPE	DI	DMBGHPE
DMBGHPE	DN	Octanol
DMBGHPE	MI	TTUW608
DMBGHPE	MN	Gap junction gamma-3 protein (Cx30.2)
DMBGHPE	MT	DTT
DMBGHPE	MA	Inhibitor
DMBGHPE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 718).
DMBGHPE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=718

DM0UADK	DI	DM0UADK
DM0UADK	DN	OCTOCLOTHEPIN
DM0UADK	MI	TTWJBZ5
DM0UADK	MN	5-HT 2C receptor (HTR2C)
DM0UADK	MT	DTT
DM0UADK	MA	Inhibitor
DM0UADK	RN	Exploring the neuroleptic substituent in octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for (1)-adre... J Med Chem. 2010 Oct 14;53(19):7021-34.
DM0UADK	RU	https://pubmed.ncbi.nlm.nih.gov/20857909

DM0UADK	DI	DM0UADK
DM0UADK	DN	OCTOCLOTHEPIN
DM0UADK	MI	TTJS8PY
DM0UADK	MN	5-HT 6 receptor (HTR6)
DM0UADK	MT	DTT
DM0UADK	MA	Inhibitor
DM0UADK	RN	Medicinal chemistry driven approaches toward novel and selective serotonin 5-HT6 receptor ligands. J Med Chem. 2005 Mar 24;48(6):1781-95.
DM0UADK	RU	https://pubmed.ncbi.nlm.nih.gov/15771424

DM0UADK	DI	DM0UADK
DM0UADK	DN	OCTOCLOTHEPIN
DM0UADK	MI	TTNGILX
DM0UADK	MN	Adrenergic receptor alpha-1A (ADRA1A)
DM0UADK	MT	DTT
DM0UADK	MA	Inhibitor
DM0UADK	RN	Exploring the neuroleptic substituent in octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for (1)-adre... J Med Chem. 2010 Oct 14;53(19):7021-34.
DM0UADK	RU	https://pubmed.ncbi.nlm.nih.gov/20857909

DM0UADK	DI	DM0UADK
DM0UADK	DN	OCTOCLOTHEPIN
DM0UADK	MI	TTBRKXS
DM0UADK	MN	Adrenergic receptor alpha-1B (ADRA1B)
DM0UADK	MT	DTT
DM0UADK	MA	Inhibitor
DM0UADK	RN	Exploring the neuroleptic substituent in octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for (1)-adre... J Med Chem. 2010 Oct 14;53(19):7021-34.
DM0UADK	RU	https://pubmed.ncbi.nlm.nih.gov/20857909

DM0UADK	DI	DM0UADK
DM0UADK	DN	OCTOCLOTHEPIN
DM0UADK	MI	TT34BHT
DM0UADK	MN	Adrenergic receptor alpha-1D (ADRA1D)
DM0UADK	MT	DTT
DM0UADK	MA	Inhibitor
DM0UADK	RN	Exploring the neuroleptic substituent in octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for (1)-adre... J Med Chem. 2010 Oct 14;53(19):7021-34.
DM0UADK	RU	https://pubmed.ncbi.nlm.nih.gov/20857909

DM0UADK	DI	DM0UADK
DM0UADK	DN	OCTOCLOTHEPIN
DM0UADK	MI	TTEX248
DM0UADK	MN	Dopamine D2 receptor (D2R)
DM0UADK	MT	DTT
DM0UADK	MA	Inhibitor
DM0UADK	RN	Exploring the neuroleptic substituent in octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for (1)-adre... J Med Chem. 2010 Oct 14;53(19):7021-34.
DM0UADK	RU	https://pubmed.ncbi.nlm.nih.gov/20857909

DM0UADK	DI	DM0UADK
DM0UADK	DN	OCTOCLOTHEPIN
DM0UADK	MI	TTTIBOJ
DM0UADK	MN	Histamine H1 receptor (H1R)
DM0UADK	MT	DTT
DM0UADK	MA	Inhibitor
DM0UADK	RN	Exploring the neuroleptic substituent in octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for (1)-adre... J Med Chem. 2010 Oct 14;53(19):7021-34.
DM0UADK	RU	https://pubmed.ncbi.nlm.nih.gov/20857909

DM40ZCA	DI	DM40ZCA
DM40ZCA	DN	Octyl sulfamate
DM40ZCA	MI	TTUNARX
DM40ZCA	MN	Carbonic anhydrase (CA)
DM40ZCA	MT	DTT
DM40ZCA	MA	Inhibitor
DM40ZCA	RN	Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8.
DM40ZCA	RU	https://pubmed.ncbi.nlm.nih.gov/19731956

DM40ZCA	DI	DM40ZCA
DM40ZCA	DN	Octyl sulfamate
DM40ZCA	MI	TTHQPL7
DM40ZCA	MN	Carbonic anhydrase I (CA-I)
DM40ZCA	MT	DTT
DM40ZCA	MA	Inhibitor
DM40ZCA	RN	Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8.
DM40ZCA	RU	https://pubmed.ncbi.nlm.nih.gov/19731956

DM40ZCA	DI	DM40ZCA
DM40ZCA	DN	Octyl sulfamate
DM40ZCA	MI	TTANPDJ
DM40ZCA	MN	Carbonic anhydrase II (CA-II)
DM40ZCA	MT	DTT
DM40ZCA	MA	Inhibitor
DM40ZCA	RN	Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8.
DM40ZCA	RU	https://pubmed.ncbi.nlm.nih.gov/19731956

DM40ZCA	DI	DM40ZCA
DM40ZCA	DN	Octyl sulfamate
DM40ZCA	MI	TTZHA0O
DM40ZCA	MN	Carbonic anhydrase IV (CA-IV)
DM40ZCA	MT	DTT
DM40ZCA	MA	Inhibitor
DM40ZCA	RN	Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8.
DM40ZCA	RU	https://pubmed.ncbi.nlm.nih.gov/19731956

DM40ZCA	DI	DM40ZCA
DM40ZCA	DN	Octyl sulfamate
DM40ZCA	MI	TT2LVK8
DM40ZCA	MN	Carbonic anhydrase IX (CA-IX)
DM40ZCA	MT	DTT
DM40ZCA	MA	Inhibitor
DM40ZCA	RN	Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8.
DM40ZCA	RU	https://pubmed.ncbi.nlm.nih.gov/19731956

DM40ZCA	DI	DM40ZCA
DM40ZCA	DN	Octyl sulfamate
DM40ZCA	MI	TTCFSPE
DM40ZCA	MN	Carbonic anhydrase VI (CA-VI)
DM40ZCA	MT	DTT
DM40ZCA	MA	Inhibitor
DM40ZCA	RN	Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8.
DM40ZCA	RU	https://pubmed.ncbi.nlm.nih.gov/19731956

DM40ZCA	DI	DM40ZCA
DM40ZCA	DN	Octyl sulfamate
DM40ZCA	MI	TTSYM0R
DM40ZCA	MN	Carbonic anhydrase XII (CA-XII)
DM40ZCA	MT	DTT
DM40ZCA	MA	Inhibitor
DM40ZCA	RN	Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8.
DM40ZCA	RU	https://pubmed.ncbi.nlm.nih.gov/19731956

DM40ZCA	DI	DM40ZCA
DM40ZCA	DN	Octyl sulfamate
DM40ZCA	MI	TTEYTKG
DM40ZCA	MN	Carbonic anhydrase XIV (CA-XIV)
DM40ZCA	MT	DTT
DM40ZCA	MA	Inhibitor
DM40ZCA	RN	Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8.
DM40ZCA	RU	https://pubmed.ncbi.nlm.nih.gov/19731956

DM2RJYO	DI	DM2RJYO
DM2RJYO	DN	octyl thiophosphatidic acid
DM2RJYO	MI	TTABCJ6
DM2RJYO	MN	Lysophosphatidic acid receptor 5 (LPAR5)
DM2RJYO	MT	DTT
DM2RJYO	MA	Agonist
DM2RJYO	RN	Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation. J Biol Chem. 2009 Jun 19;284(25):17304-19.
DM2RJYO	RU	https://pubmed.ncbi.nlm.nih.gov/19366702

DMXLGUS	DI	DMXLGUS
DMXLGUS	DN	OCTYL_GALLATE
DMXLGUS	MI	TTE14XG
DMXLGUS	MN	Squalene monooxygenase (SQLE)
DMXLGUS	MT	DTT
DMXLGUS	MA	Inhibitor
DMXLGUS	RN	Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4.
DMXLGUS	RU	https://pubmed.ncbi.nlm.nih.gov/11520216

DM8ZG2I	DI	DM8ZG2I
DM8ZG2I	DN	O-DESMETHYL TRAMADOL
DM8ZG2I	MI	TT27RFC
DM8ZG2I	MN	Opioid receptor delta (OPRD1)
DM8ZG2I	MT	DTT
DM8ZG2I	MA	Inhibitor
DM8ZG2I	RN	Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8.
DM8ZG2I	RU	https://pubmed.ncbi.nlm.nih.gov/19027293

DM8ZG2I	DI	DM8ZG2I
DM8ZG2I	DN	O-DESMETHYL TRAMADOL
DM8ZG2I	MI	TTQW87Y
DM8ZG2I	MN	Opioid receptor kappa (OPRK1)
DM8ZG2I	MT	DTT
DM8ZG2I	MA	Inhibitor
DM8ZG2I	RN	Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8.
DM8ZG2I	RU	https://pubmed.ncbi.nlm.nih.gov/19027293

DM8ZG2I	DI	DM8ZG2I
DM8ZG2I	DN	O-DESMETHYL TRAMADOL
DM8ZG2I	MI	TTKWM86
DM8ZG2I	MN	Opioid receptor mu (MOP)
DM8ZG2I	MT	DTT
DM8ZG2I	MA	Inhibitor
DM8ZG2I	RN	Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8.
DM8ZG2I	RU	https://pubmed.ncbi.nlm.nih.gov/19027293

DM8ZG2I	DI	DM8ZG2I
DM8ZG2I	DN	O-DESMETHYL TRAMADOL
DM8ZG2I	MI	TT3ROYC
DM8ZG2I	MN	Serotonin transporter (SERT)
DM8ZG2I	MT	DTT
DM8ZG2I	MA	Inhibitor
DM8ZG2I	RN	Derivatives of tramadol for increased duration of effect. Bioorg Med Chem Lett. 2006 Feb;16(3):691-4.
DM8ZG2I	RU	https://pubmed.ncbi.nlm.nih.gov/16257206

DM0GVZO	DI	DM0GVZO
DM0GVZO	DN	ODN-1411
DM0GVZO	MI	TT8CWFK
DM0GVZO	MN	Toll-like receptor 8 (TLR8)
DM0GVZO	MT	DTT
DM0GVZO	MA	Inhibitor
DM0GVZO	RN	Oligodeoxynucleotide inhibition of Toll-like receptors 3, 7, 8, and 9 suppresses cytokine production in a human rheumatoid arthritis model. Eur J Immunol. 2016 Mar;46(3):772-81.
DM0GVZO	RU	https://pubmed.ncbi.nlm.nih.gov/26593270

DM692XV	DI	DM692XV
DM692XV	DN	ODN-2088
DM692XV	MI	TTSHG0T
DM692XV	MN	Toll-like receptor 9 (TLR9)
DM692XV	MT	DTT
DM692XV	MA	Antagonist
DM692XV	RN	Toll-like receptor 9 antagonism modulates astrocyte function and preserves proximal axons following spinal cord injury. Brain Behav Immun. 2019 Aug;80:328-343.
DM692XV	RU	https://pubmed.ncbi.nlm.nih.gov/30953770

DMSAJO8	DI	DMSAJO8
DMSAJO8	DN	ODQ
DMSAJO8	MI	TTWNFC2
DMSAJO8	MN	Soluble guanylyl cyclase (GUCY2D)
DMSAJO8	MT	DTT
DMSAJO8	MA	Inhibitor
DMSAJO8	RN	Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. Mol Pharmacol. 1995 Aug;48(2):184-8.
DMSAJO8	RU	https://pubmed.ncbi.nlm.nih.gov/7544433

DMK8LEC	DI	DMK8LEC
DMK8LEC	DN	OF-1
DMK8LEC	MI	TTT46BN
DMK8LEC	MN	Bromodomain and PHD finger containing 1 (BRPF1)
DMK8LEC	MT	DTT
DMK8LEC	MA	Inhibitor
DMK8LEC	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2730).
DMK8LEC	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2730

DMK8LEC	DI	DMK8LEC
DMK8LEC	DN	OF-1
DMK8LEC	MI	TTT09OB
DMK8LEC	MN	Bromodomain-containing protein 1 (BRD1)
DMK8LEC	MT	DTT
DMK8LEC	MA	Inhibitor
DMK8LEC	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2724).
DMK8LEC	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2724

DM0PMKW	DI	DM0PMKW
DM0PMKW	DN	OG-L002
DM0PMKW	MI	TTNR0UQ
DM0PMKW	MN	Lysine-specific histone demethylase 1 (LSD)
DM0PMKW	MT	DTT
DM0PMKW	MA	Inhibitor
DM0PMKW	RN	A novel selective LSD1/KDM1A inhibitor epigenetically blocks herpes simplex virus lytic replication and reactivation from latency. MBio. 2013 Feb 5;4(1):e00558-12.
DM0PMKW	RU	https://pubmed.ncbi.nlm.nih.gov/23386436

DMXGA12	DI	DMXGA12
DMXGA12	DN	OGX-427 + Paclitaxel
DMXGA12	MI	TT9AZWY
DMXGA12	MN	HSPB1 messenger RNA (HSPB1 mRNA)
DMXGA12	MT	DTT
DMXGA12	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DMXGA12	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DMZMTLB	DI	DMZMTLB
DMZMTLB	DN	OHIOENSIN A
DMZMTLB	MI	TTELIN2
DMZMTLB	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMZMTLB	MT	DTT
DMZMTLB	MA	Inhibitor
DMZMTLB	RN	Ohioensins F and G: protein tyrosine phosphatase 1B inhibitory benzonaphthoxanthenones from the Antarctic moss Polytrichastrum alpinum. Bioorg Med Chem Lett. 2008 Jan 15;18(2):772-5.
DMZMTLB	RU	https://pubmed.ncbi.nlm.nih.gov/18053716

DMNUGTL	DI	DMNUGTL
DMNUGTL	DN	Ohioensin C
DMNUGTL	MI	TTELIN2
DMNUGTL	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMNUGTL	MT	DTT
DMNUGTL	MA	Inhibitor
DMNUGTL	RN	Ohioensins F and G: protein tyrosine phosphatase 1B inhibitory benzonaphthoxanthenones from the Antarctic moss Polytrichastrum alpinum. Bioorg Med Chem Lett. 2008 Jan 15;18(2):772-5.
DMNUGTL	RU	https://pubmed.ncbi.nlm.nih.gov/18053716

DMCT348	DI	DMCT348
DMCT348	DN	Ohioensin F
DMCT348	MI	TTELIN2
DMCT348	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMCT348	MT	DTT
DMCT348	MA	Inhibitor
DMCT348	RN	Ohioensins F and G: protein tyrosine phosphatase 1B inhibitory benzonaphthoxanthenones from the Antarctic moss Polytrichastrum alpinum. Bioorg Med Chem Lett. 2008 Jan 15;18(2):772-5.
DMCT348	RU	https://pubmed.ncbi.nlm.nih.gov/18053716

DMLJBVP	DI	DMLJBVP
DMLJBVP	DN	Ohioensin G
DMLJBVP	MI	TTELIN2
DMLJBVP	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMLJBVP	MT	DTT
DMLJBVP	MA	Inhibitor
DMLJBVP	RN	Ohioensins F and G: protein tyrosine phosphatase 1B inhibitory benzonaphthoxanthenones from the Antarctic moss Polytrichastrum alpinum. Bioorg Med Chem Lett. 2008 Jan 15;18(2):772-5.
DMLJBVP	RU	https://pubmed.ncbi.nlm.nih.gov/18053716

DMN37KO	DI	DMN37KO
DMN37KO	DN	o-hydroxyatorvastatin
DMN37KO	MI	TTPADOQ
DMN37KO	MN	HMG-CoA reductase (HMGCR)
DMN37KO	MT	DTT
DMN37KO	MA	Inhibitor
DMN37KO	RN	Thermodynamic and structure guided design of statin based inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase. J Med Chem. 2008 Jul 10;51(13):3804-13.
DMN37KO	RU	https://pubmed.ncbi.nlm.nih.gov/18540668

DMN7KPQ	DI	DMN7KPQ
DMN7KPQ	DN	OICR-9429
DMN7KPQ	MI	TT7OFWB
DMN7KPQ	MN	WD repeat-containing protein 5 (WDR5)
DMN7KPQ	MT	DTT
DMN7KPQ	MA	Antagonist
DMN7KPQ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2831).
DMN7KPQ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2831

DM47CO1	DI	DM47CO1
DM47CO1	DN	Okadaic acid
DM47CO1	MI	TTG8HIM
DM47CO1	MN	Dual specificity protein phosphatase 1 (DUSP1)
DM47CO1	MT	DTT
DM47CO1	MA	Inhibitor
DM47CO1	RN	Inhibition of protein phosphatase 1 stimulates secretion of Alzheimer amyloid precursor protein. Mol Med. 1995 Jul;1(5):535-41.
DM47CO1	RU	https://pubmed.ncbi.nlm.nih.gov/8529119

DM47CO1	DI	DM47CO1
DM47CO1	DN	Okadaic acid
DM47CO1	MI	DTUGYRD
DM47CO1	MN	P-glycoprotein 1 (ABCB1)
DM47CO1	MT	DTP
DM47CO1	MA	Substrate
DM47CO1	RN	Fingerprint-based in silico models for the prediction of P-glycoprotein substrates and inhibitors. Bioorg Med Chem. 2012 Sep 15;20(18):5388-95.
DM47CO1	RU	https://doi.org/10.1016/j.bmc.2012.03.045

DMT1CZ0	DI	DMT1CZ0
DMT1CZ0	DN	OL-135
DMT1CZ0	MI	TTDP1UC
DMT1CZ0	MN	Fatty acid amide hydrolase (FAAH)
DMT1CZ0	MT	DTT
DMT1CZ0	MA	Inhibitor
DMT1CZ0	RN	X-ray crystallographic analysis of alpha-ketoheterocycle inhibitors bound to a humanized variant of fatty acid amide hydrolase. J Med Chem. 2010 Jan 14;53(1):230-40.
DMT1CZ0	RU	https://pubmed.ncbi.nlm.nih.gov/19924997

DM5ZJ3G	DI	DM5ZJ3G
DM5ZJ3G	DN	OL-92
DM5ZJ3G	MI	TTDP1UC
DM5ZJ3G	MN	Fatty acid amide hydrolase (FAAH)
DM5ZJ3G	MT	DTT
DM5ZJ3G	MA	Inhibitor
DM5ZJ3G	RN	Synthesis and evaluation of benzothiazole-based analogues as novel, potent, and selective fatty acid amide hydrolase inhibitors. J Med Chem. 2009 Jan 8;52(1):170-80.
DM5ZJ3G	RU	https://pubmed.ncbi.nlm.nih.gov/19072118

DMVM78Q	DI	DMVM78Q
DMVM78Q	DN	Olean-12-en-3beta,15alpha-diol
DMVM78Q	MI	TT0IHXV
DMVM78Q	MN	DNA topoisomerase II (TOP2)
DMVM78Q	MT	DTT
DMVM78Q	MA	Inhibitor
DMVM78Q	RN	Screening of triterpenoids isolated from Phyllanthus flexuosus for DNA topoisomerase inhibitory activity. J Nat Prod. 2001 Dec;64(12):1545-7.
DMVM78Q	RU	https://pubmed.ncbi.nlm.nih.gov/11754608

DMWDMJ3	DI	DMWDMJ3
DMWDMJ3	DN	OLEANOLIC_ACID
DMWDMJ3	MI	TTZHY6R
DMWDMJ3	MN	Glycogen phosphorylase muscle form (GP)
DMWDMJ3	MT	DTT
DMWDMJ3	MA	Inhibitor
DMWDMJ3	RN	Naturally occurring pentacyclic triterpenes as inhibitors of glycogen phosphorylase: synthesis, structure-activity relationships, and X-ray crystal... J Med Chem. 2008 Jun 26;51(12):3540-54.
DMWDMJ3	RU	https://pubmed.ncbi.nlm.nih.gov/18517260

DMWDMJ3	DI	DMWDMJ3
DMWDMJ3	DN	OLEANOLIC_ACID
DMWDMJ3	MI	TTIU7X1
DMWDMJ3	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMWDMJ3	MT	DTT
DMWDMJ3	MA	Inhibitor
DMWDMJ3	RN	DNA polymerase beta inhibitors from Baeckea gunniana. J Nat Prod. 1999 Dec;62(12):1624-6.
DMWDMJ3	RU	https://pubmed.ncbi.nlm.nih.gov/10654412

DMWDMJ3	DI	DMWDMJ3
DMWDMJ3	DN	OLEANOLIC_ACID
DMWDMJ3	MI	TTELIN2
DMWDMJ3	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMWDMJ3	MT	DTT
DMWDMJ3	MA	Inhibitor
DMWDMJ3	RN	Chemical Constituents of the Roots of Euphorbia micractina. J Nat Prod. 2009 Sep;72(9):1620-6.
DMWDMJ3	RU	https://pubmed.ncbi.nlm.nih.gov/19702283

DMYPJC3	DI	DMYPJC3
DMYPJC3	DN	Oleanonic acid
DMYPJC3	MI	TTZHY6R
DMYPJC3	MN	Glycogen phosphorylase muscle form (GP)
DMYPJC3	MT	DTT
DMYPJC3	MA	Inhibitor
DMYPJC3	RN	Naturally occurring pentacyclic triterpenes as inhibitors of glycogen phosphorylase: synthesis, structure-activity relationships, and X-ray crystal... J Med Chem. 2008 Jun 26;51(12):3540-54.
DMYPJC3	RU	https://pubmed.ncbi.nlm.nih.gov/18517260

DMYPJC3	DI	DMYPJC3
DMYPJC3	DN	Oleanonic acid
DMYPJC3	MI	TTELIN2
DMYPJC3	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMYPJC3	MT	DTT
DMYPJC3	MA	Inhibitor
DMYPJC3	RN	Triterpenoids from the leaves of Diospyros kaki (persimmon) and their inhibitory effects on protein tyrosine phosphatase 1B. J Nat Prod. 2008 Oct;71(10):1775-8.
DMYPJC3	RU	https://pubmed.ncbi.nlm.nih.gov/18798681

DM54O1Z	DI	DM54O1Z
DM54O1Z	DN	Oleic acid
DM54O1Z	MI	DTKDTML
DM54O1Z	MN	Fatty acid transport protein 1 (SLC27A1)
DM54O1Z	MT	DTP
DM54O1Z	MA	Substrate
DM54O1Z	RN	The blood-brain barrier fatty acid transport protein 1 (FATP1/SLC27A1) supplies docosahexaenoic acid to the brain, and insulin facilitates transport. J Neurochem. 2017 May;141(3):400-412.
DM54O1Z	RU	http://www.ncbi.nlm.nih.gov/pubmed/28035674

DM54O1Z	DI	DM54O1Z
DM54O1Z	DN	Oleic acid
DM54O1Z	MI	TTIV96N
DM54O1Z	MN	Fatty acid-binding protein 1 (FABP1)
DM54O1Z	MT	DTT
DM54O1Z	MA	Inhibitor
DM54O1Z	RN	Characterization of the drug binding specificity of rat liver fatty acid binding protein. J Med Chem. 2008 Jul 10;51(13):3755-64.
DM54O1Z	RU	https://pubmed.ncbi.nlm.nih.gov/18533710

DM54O1Z	DI	DM54O1Z
DM54O1Z	DN	Oleic acid
DM54O1Z	MI	TTHWMFZ
DM54O1Z	MN	Fatty acid-binding protein 4 (FABP4)
DM54O1Z	MT	DTT
DM54O1Z	MA	Inhibitor
DM54O1Z	RN	Discovery of highly selective inhibitors of human fatty acid binding protein 4 (FABP4) by virtual screening. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3675-9.
DM54O1Z	RU	https://pubmed.ncbi.nlm.nih.gov/20471252

DMXCSVH	DI	DMXCSVH
DMXCSVH	DN	Oleic acid anilide
DMXCSVH	MI	TTMF541
DMXCSVH	MN	Liver carboxylesterase (CES1)
DMXCSVH	MT	DTT
DMXCSVH	MA	Inhibitor
DMXCSVH	RN	Phenolic compounds from the roots of Lindera fruticosa. J Nat Prod. 2006 May;69(5):853-5.
DMXCSVH	RU	https://pubmed.ncbi.nlm.nih.gov/16724860

DMXCSVH	DI	DMXCSVH
DMXCSVH	DN	Oleic acid anilide
DMXCSVH	MI	TTAK0IN
DMXCSVH	MN	SOAT2 messenger RNA (SOAT2 mRNA)
DMXCSVH	MT	DTT
DMXCSVH	MA	Inhibitor
DMXCSVH	RN	Anti-atherosclerotic and anti-inflammatory activities of catecholic xanthones and flavonoids isolated from Cudrania tricuspidata. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5580-3.
DMXCSVH	RU	https://pubmed.ncbi.nlm.nih.gov/16919944

DMI1CAJ	DI	DMI1CAJ
DMI1CAJ	DN	oleocanthal
DMI1CAJ	MI	TTELV3W
DMI1CAJ	MN	Transformation-sensitive protein p120 (TRPA1)
DMI1CAJ	MT	DTT
DMI1CAJ	MA	Activator
DMI1CAJ	RN	Unusual pungency from extra-virgin olive oil is attributable to restricted spatial expression of the receptor of oleocanthal. J Neurosci. 2011 Jan 19;31(3):999-1009.
DMI1CAJ	RU	https://pubmed.ncbi.nlm.nih.gov/21248124

DMJ1VRU	DI	DMJ1VRU
DMJ1VRU	DN	oleoyl-CoA
DMJ1VRU	MI	TTH7UO3
DMJ1VRU	MN	Inward rectifier potassium channel Kir2.1 (KCNJ2)
DMJ1VRU	MT	DTT
DMJ1VRU	MA	Inhibitor (gating inhibitor)
DMJ1VRU	RN	Cytoplasmic accumulation of long-chain coenzyme A esters activates KATP and inhibits Kir2.1 channels. J Physiol. 2006 Sep 1;575(Pt 2):433-42.
DMJ1VRU	RU	https://pubmed.ncbi.nlm.nih.gov/16777940

DMB5KQ4	DI	DMB5KQ4
DMB5KQ4	DN	oleoyl-lysophosphatidylcholine
DMB5KQ4	MI	TT7QNVC
DMB5KQ4	MN	Glucose-dependent insulinotropic receptor (GPR119)
DMB5KQ4	MT	DTT
DMB5KQ4	MA	Agonist
DMB5KQ4	RN	Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem Biophys Res Commun. 2005 Jan 28;326(4):744-51.
DMB5KQ4	RU	https://pubmed.ncbi.nlm.nih.gov/15607732

DM1TAM9	DI	DM1TAM9
DM1TAM9	DN	oleoyl-thiophosphate
DM1TAM9	MI	TTE2YJR
DM1TAM9	MN	Lysophosphatidate-3 receptor (LPAR3)
DM1TAM9	MT	DTT
DM1TAM9	MA	Agonist
DM1TAM9	RN	Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30.
DM1TAM9	RU	https://pubmed.ncbi.nlm.nih.gov/16033271

DM1TAM9	DI	DM1TAM9
DM1TAM9	DN	oleoyl-thiophosphate
DM1TAM9	MI	TTQ6S1K
DM1TAM9	MN	Lysophosphatidic acid receptor 1 (LPAR1)
DM1TAM9	MT	DTT
DM1TAM9	MA	Agonist
DM1TAM9	RN	Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors. Acta Pharmacol Sin. 2010 Sep;31(9):1213-22.
DM1TAM9	RU	https://pubmed.ncbi.nlm.nih.gov/20729877

DM1TAM9	DI	DM1TAM9
DM1TAM9	DN	oleoyl-thiophosphate
DM1TAM9	MI	TTB7Y8I
DM1TAM9	MN	Lysophosphatidic acid receptor 2 (LPAR2)
DM1TAM9	MT	DTT
DM1TAM9	MA	Agonist
DM1TAM9	RN	Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30.
DM1TAM9	RU	https://pubmed.ncbi.nlm.nih.gov/16033271

DM5X76V	DI	DM5X76V
DM5X76V	DN	Oligomycin C
DM5X76V	MI	DEV62G1
DM5X76V	MN	Cytochrome P450 107W1 (cyp107)
DM5X76V	MT	DME
DM5X76V	MA	Metabolism
DM5X76V	RN	nan
DM5X76V	RU	nan

DM1XJBE	DI	DM1XJBE
DM1XJBE	DN	OLPADRONIC ACID SODIUM SALT
DM1XJBE	MI	TTIKWV4
DM1XJBE	MN	Geranyltranstransferase (FDPS)
DM1XJBE	MT	DTT
DM1XJBE	MA	Modulator
DM1XJBE	RN	Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun. 1999 Feb 16;255(2):491-4.
DM1XJBE	RU	https://pubmed.ncbi.nlm.nih.gov/10049736

DMTY63G	DI	DMTY63G
DMTY63G	DN	Olterodine
DMTY63G	MI	TTQ13Z5
DMTY63G	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMTY63G	MT	DTT
DMTY63G	MA	Antagonist
DMTY63G	RN	Which muscarinic receptor is important in the bladder World J Urol. 2001 Nov;19(5):299-306.
DMTY63G	RU	https://pubmed.ncbi.nlm.nih.gov/11760777

DMXJ2SM	DI	DMXJ2SM
DMXJ2SM	DN	OM00-3
DMXJ2SM	MI	TT8JRS7
DMXJ2SM	MN	Beta-secretase (BACE)
DMXJ2SM	MT	DTT
DMXJ2SM	MA	Inhibitor
DMXJ2SM	RN	Synthesis and biological evaluation of phosphino dipeptide isostere inhibitor of human beta-secretase (BACE1). Bioorg Med Chem. 2007 Jun 15;15(12):4136-43.
DMXJ2SM	RU	https://pubmed.ncbi.nlm.nih.gov/17433698

DME8RNV	DI	DME8RNV
DME8RNV	DN	OM-197-MP-AC
DME8RNV	MI	TTISGCA
DME8RNV	MN	Toll-like receptor 4 (TLR4)
DME8RNV	MT	DTT
DME8RNV	MA	Modulator
DME8RNV	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1754).
DME8RNV	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1754

DML5AWQ	DI	DML5AWQ
DML5AWQ	DN	OM-294-DP
DML5AWQ	MI	TTISGCA
DML5AWQ	MN	Toll-like receptor 4 (TLR4)
DML5AWQ	MT	DTT
DML5AWQ	MA	Modulator
DML5AWQ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1754).
DML5AWQ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1754

DMGMIX3	DI	DMGMIX3
DMGMIX3	DN	omega-chloroacetophenone
DMGMIX3	MI	TTELV3W
DMGMIX3	MN	Transformation-sensitive protein p120 (TRPA1)
DMGMIX3	MT	DTT
DMGMIX3	MA	Activator
DMGMIX3	RN	Tear gasses CN, CR, and CS are potent activators of the human TRPA1 receptor. Toxicol Appl Pharmacol. 2008 Sep 1;231(2):150-6.
DMGMIX3	RU	https://pubmed.ncbi.nlm.nih.gov/18501939

DM4BQFW	DI	DM4BQFW
DM4BQFW	DN	omega-conotoxin GVIA
DM4BQFW	MI	TTX4QDJ
DM4BQFW	MN	Voltage-gated calcium channel alpha Cav2.1 (CACNA1A)
DM4BQFW	MT	DTT
DM4BQFW	MA	Blocker (channel blocker)
DM4BQFW	RN	Novel omega-conotoxins from Conus catus discriminate among neuronal calcium channel subtypes. J Biol Chem. 2000 Nov 10;275(45):35335-44.
DM4BQFW	RU	https://pubmed.ncbi.nlm.nih.gov/10938268

DM4BQFW	DI	DM4BQFW
DM4BQFW	DN	omega-conotoxin GVIA
DM4BQFW	MI	TT4FDG6
DM4BQFW	MN	Voltage-gated calcium channel alpha Cav2.2 (CACNA1B)
DM4BQFW	MT	DTT
DM4BQFW	MA	Blocker (channel blocker)
DM4BQFW	RN	Novel omega-conotoxins from Conus catus discriminate among neuronal calcium channel subtypes. J Biol Chem. 2000 Nov 10;275(45):35335-44.
DM4BQFW	RU	https://pubmed.ncbi.nlm.nih.gov/10938268

DMKTA5R	DI	DMKTA5R
DMKTA5R	DN	O-methyldauricine
DMKTA5R	MI	TTVBI8W
DMKTA5R	MN	Dopamine transporter (DAT)
DMKTA5R	MT	DTT
DMKTA5R	MA	Inhibitor
DMKTA5R	RN	Effects of various isoquinoline alkaloids on in vitro 3H-dopamine uptake by rat striatal synaptosomes. J Nat Prod. 1995 Oct;58(10):1475-84.
DMKTA5R	RU	https://pubmed.ncbi.nlm.nih.gov/8676127

DMGFRSY	DI	DMGFRSY
DMGFRSY	DN	OMPT
DMGFRSY	MI	TTE2YJR
DMGFRSY	MN	Lysophosphatidate-3 receptor (LPAR3)
DMGFRSY	MT	DTT
DMGFRSY	MA	Agonist
DMGFRSY	RN	Identification of a phosphothionate analogue of lysophosphatidic acid (LPA) as a selective agonist of the LPA3 receptor. J Biol Chem. 2003 Apr 4;278(14):11962-9.
DMGFRSY	RU	https://pubmed.ncbi.nlm.nih.gov/12554733

DMWOHDV	DI	DMWOHDV
DMWOHDV	DN	ON-044580
DMWOHDV	MI	TTIV39N
DMWOHDV	MN	Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I)
DMWOHDV	MT	DTT
DMWOHDV	MA	Inhibitor
DMWOHDV	RN	A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition. Genes Cancer. 2010 Apr;1(4):331-45.
DMWOHDV	RU	https://pubmed.ncbi.nlm.nih.gov/20717479

DMWOHDV	DI	DMWOHDV
DMWOHDV	DN	ON-044580
DMWOHDV	MI	TTRMX3V
DMWOHDV	MN	Janus kinase 2 (JAK-2)
DMWOHDV	MT	DTT
DMWOHDV	MA	Inhibitor
DMWOHDV	RN	A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition. Genes Cancer. 2010 Apr;1(4):331-45.
DMWOHDV	RU	https://pubmed.ncbi.nlm.nih.gov/20717479

DMHLEGT	DI	DMHLEGT
DMHLEGT	DN	ON-123
DMHLEGT	MI	TT976FS
DMHLEGT	MN	Polo-like kinase 2 (PLK2)
DMHLEGT	MT	DTT
DMHLEGT	MA	Inhibitor
DMHLEGT	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2169).
DMHLEGT	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2169

DMTNKBW	DI	DMTNKBW
DMTNKBW	DN	ON-128
DMTNKBW	MI	TTGKNB4
DMTNKBW	MN	Epidermal growth factor receptor (EGFR)
DMTNKBW	MT	DTT
DMTNKBW	MA	Inhibitor
DMTNKBW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
DMTNKBW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797

DMSFQHO	DI	DMSFQHO
DMSFQHO	DN	ON-24160
DMSFQHO	MI	TTYFKSZ
DMSFQHO	MN	Tubulin beta (TUBB)
DMSFQHO	MT	DTT
DMSFQHO	MA	Inhibitor
DMSFQHO	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2640).
DMSFQHO	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2640

DMSWI4D	DI	DMSWI4D
DMSWI4D	DN	Ono 1
DMSWI4D	MI	TTXHYV6
DMSWI4D	MN	Voltage-gated L-type calcium channel (L-CaC)
DMSWI4D	MT	DTT
DMSWI4D	MA	Blocker
DMSWI4D	RN	Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95.
DMSWI4D	RU	https://pubmed.ncbi.nlm.nih.gov/19442208

DMCG6H8	DI	DMCG6H8
DMCG6H8	DN	Ono 3
DMCG6H8	MI	TTXHYV6
DMCG6H8	MN	Voltage-gated L-type calcium channel (L-CaC)
DMCG6H8	MT	DTT
DMCG6H8	MA	Blocker
DMCG6H8	RN	Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95.
DMCG6H8	RU	https://pubmed.ncbi.nlm.nih.gov/19442208

DMSXT0H	DI	DMSXT0H
DMSXT0H	DN	ONO-1581
DMSXT0H	MI	TTKNWZ4
DMSXT0H	MN	Thromboxane-A synthase (TBXAS1)
DMSXT0H	MT	DTT
DMSXT0H	MA	Inhibitor
DMSXT0H	RN	Pharmacological evaluation of combined PGI2 agonists/thromboxane synthase inhibitors, Bioorg. Med. Chem. Lett. 5(10):1087-1090 (1995).
DMSXT0H	RU	http://www.sciencedirect.com/science/article/pii/0960894X9500171O

DM8LKED	DI	DM8LKED
DM8LKED	DN	ONO-3080573
DM8LKED	MI	TTQ6S1K
DM8LKED	MN	Lysophosphatidic acid receptor 1 (LPAR1)
DM8LKED	MT	DTT
DM8LKED	MA	Antagonist
DM8LKED	RN	Crystal Structure of Antagonist Bound Human Lysophosphatidic Acid Receptor 1. Cell. 2015 Jun 18;161(7):1633-43.
DM8LKED	RU	https://pubmed.ncbi.nlm.nih.gov/26091040

DM84IW9	DI	DM84IW9
DM84IW9	DN	ONO-3708
DM84IW9	MI	TT2O84V
DM84IW9	MN	Thromboxane A2 receptor (TBXA2R)
DM84IW9	MT	DTT
DM84IW9	MA	Antagonist
DM84IW9	RN	Characterization of U46619 binding in unactivated, intact human platelets and determination of binding site affinities of four TXA2/PGH2 receptor antagonists (13-APA, BM 13.177, ONO 3708 and SQ 29,548). Thromb Res. 1986 Feb 15;41(4):471-81.
DM84IW9	RU	https://pubmed.ncbi.nlm.nih.gov/3008368

DMD2G65	DI	DMD2G65
DMD2G65	DN	ONO-8713
DMD2G65	MI	TTG1QMU
DMD2G65	MN	Prostaglandin E2 receptor EP1 (PTGER1)
DMD2G65	MT	DTT
DMD2G65	MA	Antagonist
DMD2G65	RN	New class of biphenylene dibenzazocinones as potent ligands for the human EP1 prostanoid receptor. Bioorg Med Chem Lett. 1999 Sep 20;9(18):2699-704.
DMD2G65	RU	https://pubmed.ncbi.nlm.nih.gov/10509919

DMD2G65	DI	DMD2G65
DMD2G65	DN	ONO-8713
DMD2G65	MI	TTPNGDE
DMD2G65	MN	Prostaglandin E2 receptor EP3 (PTGER3)
DMD2G65	MT	DTT
DMD2G65	MA	Agonist
DMD2G65	RN	Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41.
DMD2G65	RU	https://pubmed.ncbi.nlm.nih.gov/9537820

DM5BMA9	DI	DM5BMA9
DM5BMA9	DN	ONO-8809
DM5BMA9	MI	TT2O84V
DM5BMA9	MN	Thromboxane A2 receptor (TBXA2R)
DM5BMA9	MT	DTT
DM5BMA9	MA	Antagonist
DM5BMA9	RN	Anti-thrombotic effect of ONO-8809, a novel TXA2/PG endoperoxide receptor antagonist. Adv Prostaglandin Thromboxane Leukot Res. 1991;21B:599-602.
DM5BMA9	RU	https://pubmed.ncbi.nlm.nih.gov/1825384

DMATXHR	DI	DMATXHR
DMATXHR	DN	ONO-9780307
DMATXHR	MI	TTQ6S1K
DMATXHR	MN	Lysophosphatidic acid receptor 1 (LPAR1)
DMATXHR	MT	DTT
DMATXHR	MA	Antagonist
DMATXHR	RN	Crystal Structure of Antagonist Bound Human Lysophosphatidic Acid Receptor 1. Cell. 2015 Jun 18;161(7):1633-43.
DMATXHR	RU	https://pubmed.ncbi.nlm.nih.gov/26091040

DML4DPV	DI	DML4DPV
DML4DPV	DN	ONO-9910539
DML4DPV	MI	TTQ6S1K
DML4DPV	MN	Lysophosphatidic acid receptor 1 (LPAR1)
DML4DPV	MT	DTT
DML4DPV	MA	Antagonist
DML4DPV	RN	Crystal Structure of Antagonist Bound Human Lysophosphatidic Acid Receptor 1. Cell. 2015 Jun 18;161(7):1633-43.
DML4DPV	RU	https://pubmed.ncbi.nlm.nih.gov/26091040

DMS3MZG	DI	DMS3MZG
DMS3MZG	DN	ONO-AE1-329
DMS3MZG	MI	TT1ZAVI
DMS3MZG	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DMS3MZG	MT	DTT
DMS3MZG	MA	Agonist
DMS3MZG	RN	The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology. 2000 Apr;141(4):1554-9.
DMS3MZG	RU	https://pubmed.ncbi.nlm.nih.gov/10746663

DMS3MZG	DI	DMS3MZG
DMS3MZG	DN	ONO-AE1-329
DMS3MZG	MI	TTPNGDE
DMS3MZG	MN	Prostaglandin E2 receptor EP3 (PTGER3)
DMS3MZG	MT	DTT
DMS3MZG	MA	Agonist
DMS3MZG	RN	The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology. 2000 Apr;141(4):1554-9.
DMS3MZG	RU	https://pubmed.ncbi.nlm.nih.gov/10746663

DMS3MZG	DI	DMS3MZG
DMS3MZG	DN	ONO-AE1-329
DMS3MZG	MI	TT79WV3
DMS3MZG	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DMS3MZG	MT	DTT
DMS3MZG	MA	Agonist
DMS3MZG	RN	The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology. 2000 Apr;141(4):1554-9.
DMS3MZG	RU	https://pubmed.ncbi.nlm.nih.gov/10746663

DM78DO6	DI	DM78DO6
DM78DO6	DN	ONO-AE2-227
DM78DO6	MI	TTPNGDE
DM78DO6	MN	Prostaglandin E2 receptor EP3 (PTGER3)
DM78DO6	MT	DTT
DM78DO6	MA	Antagonist
DM78DO6	RN	Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res. 2002 Jan 1;62(1):28-32.
DM78DO6	RU	https://pubmed.ncbi.nlm.nih.gov/11782353

DM78DO6	DI	DM78DO6
DM78DO6	DN	ONO-AE2-227
DM78DO6	MI	TT79WV3
DM78DO6	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DM78DO6	MT	DTT
DM78DO6	MA	Antagonist
DM78DO6	RN	Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res. 2002 Jan 1;62(1):28-32.
DM78DO6	RU	https://pubmed.ncbi.nlm.nih.gov/11782353

DMA7VP5	DI	DMA7VP5
DMA7VP5	DN	ONO-AE-248
DMA7VP5	MI	TT1ZAVI
DMA7VP5	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DMA7VP5	MT	DTT
DMA7VP5	MA	Agonist
DMA7VP5	RN	The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology. 2000 Apr;141(4):1554-9.
DMA7VP5	RU	https://pubmed.ncbi.nlm.nih.gov/10746663

DMA7VP5	DI	DMA7VP5
DMA7VP5	DN	ONO-AE-248
DMA7VP5	MI	TTPNGDE
DMA7VP5	MN	Prostaglandin E2 receptor EP3 (PTGER3)
DMA7VP5	MT	DTT
DMA7VP5	MA	Agonist
DMA7VP5	RN	Selective activation of the prostanoid EP(3) receptor reduces myocardial infarct size in rodents. Arterioscler Thromb Vasc Biol. 1999 Sep;19(9):2141-7.
DMA7VP5	RU	https://pubmed.ncbi.nlm.nih.gov/10479656

DMEY7T4	DI	DMEY7T4
DMEY7T4	DN	ONO-AE3-208
DMEY7T4	MI	TTPNGDE
DMEY7T4	MN	Prostaglandin E2 receptor EP3 (PTGER3)
DMEY7T4	MT	DTT
DMEY7T4	MA	Antagonist
DMEY7T4	RN	The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest. 2002 Apr;109(7):883-93.
DMEY7T4	RU	https://pubmed.ncbi.nlm.nih.gov/11927615

DMEY7T4	DI	DMEY7T4
DMEY7T4	DN	ONO-AE3-208
DMEY7T4	MI	TT79WV3
DMEY7T4	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DMEY7T4	MT	DTT
DMEY7T4	MA	Antagonist
DMEY7T4	RN	The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest. 2002 Apr;109(7):883-93.
DMEY7T4	RU	https://pubmed.ncbi.nlm.nih.gov/11927615

DMGA4W5	DI	DMGA4W5
DMGA4W5	DN	ONO-AE3-237
DMGA4W5	MI	TTNVEIR
DMGA4W5	MN	Prostaglandin D2 receptor (PTGDR)
DMGA4W5	MT	DTT
DMGA4W5	MA	Antagonist
DMGA4W5	RN	Prostaglandin D2 inhibits the production of IFN-gamma by invariant NK T cells: consequences in the control of B16 melanoma. J Immunol. 2008 Jan 15;180(2):783-92.
DMGA4W5	RU	https://pubmed.ncbi.nlm.nih.gov/18178816

DMN3OWP	DI	DMN3OWP
DMN3OWP	DN	ONO-AE3-240
DMN3OWP	MI	TTPNGDE
DMN3OWP	MN	Prostaglandin E2 receptor EP3 (PTGER3)
DMN3OWP	MT	DTT
DMN3OWP	MA	Antagonist
DMN3OWP	RN	Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med. 2003 Jan 20;197(2):221-32.
DMN3OWP	RU	https://pubmed.ncbi.nlm.nih.gov/12538661

DMN3OWP	DI	DMN3OWP
DMN3OWP	DN	ONO-AE3-240
DMN3OWP	MI	TT79WV3
DMN3OWP	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DMN3OWP	MT	DTT
DMN3OWP	MA	Antagonist
DMN3OWP	RN	Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med. 2003 Jan 20;197(2):221-32.
DMN3OWP	RU	https://pubmed.ncbi.nlm.nih.gov/12538661

DMDA7M9	DI	DMDA7M9
DMDA7M9	DN	ONO-AE5-599
DMDA7M9	MI	TTPNGDE
DMDA7M9	MN	Prostaglandin E2 receptor EP3 (PTGER3)
DMDA7M9	MT	DTT
DMDA7M9	MA	Antagonist
DMDA7M9	RN	Involvement of prostaglandin E receptor EP3 subtype in duodenal bicarbonate secretion in rats. Life Sci. 2007 Jun 6;80(26):2446-53.
DMDA7M9	RU	https://pubmed.ncbi.nlm.nih.gov/17512019

DMA1NL9	DI	DMA1NL9
DMA1NL9	DN	ONO-AP-324
DMA1NL9	MI	TTPNGDE
DMA1NL9	MN	Prostaglandin E2 receptor EP3 (PTGER3)
DMA1NL9	MT	DTT
DMA1NL9	MA	Agonist
DMA1NL9	RN	Characterization of a prostanoid EP3-receptor in guinea-pig aorta: partial agonist action of the non-prostanoid ONO-AP-324. Br J Pharmacol. 1998 Nov;125(6):1288-96.
DMA1NL9	RU	https://pubmed.ncbi.nlm.nih.gov/9863659

DM81RKT	DI	DM81RKT
DM81RKT	DN	ONO-DI-004
DM81RKT	MI	TTG1QMU
DM81RKT	MN	Prostaglandin E2 receptor EP1 (PTGER1)
DM81RKT	MT	DTT
DM81RKT	MA	Agonist
DM81RKT	RN	The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology. 2000 Apr;141(4):1554-9.
DM81RKT	RU	https://pubmed.ncbi.nlm.nih.gov/10746663

DMDR95N	DI	DMDR95N
DMDR95N	DN	O-oleoyl-N-(2-hydroxyethyl)hydroxylamine
DMDR95N	MI	TTMSFAW
DMDR95N	MN	Cannabinoid receptor 2 (CB2)
DMDR95N	MT	DTT
DMDR95N	MA	Inhibitor
DMDR95N	RN	Oxyhomologues of anandamide and related endolipids: chemoselective synthesis and biological activity. J Med Chem. 2006 Apr 6;49(7):2333-8.
DMDR95N	RU	https://pubmed.ncbi.nlm.nih.gov/16570929

DMQOJY2	DI	DMQOJY2
DMQOJY2	DN	OPC 4392
DMQOJY2	MI	TTJS8PY
DMQOJY2	MN	5-HT 6 receptor (HTR6)
DMQOJY2	MT	DTT
DMQOJY2	MA	Agonist
DMQOJY2	RN	Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology. 1999 Jun;20(6):612-27.
DMQOJY2	RU	https://pubmed.ncbi.nlm.nih.gov/10327430

DMQOJY2	DI	DMQOJY2
DMQOJY2	DN	OPC 4392
DMQOJY2	MI	TTO9X1H
DMQOJY2	MN	5-HT 7 receptor (HTR7)
DMQOJY2	MT	DTT
DMQOJY2	MA	Agonist
DMQOJY2	RN	Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology. 1999 Jun;20(6):612-27.
DMQOJY2	RU	https://pubmed.ncbi.nlm.nih.gov/10327430

DMO4WH9	DI	DMO4WH9
DMO4WH9	DN	OPC-22575
DMO4WH9	MI	TTF1QVM
DMO4WH9	MN	Gastric H(+)/K(+) ATPase alpha (ATP4A)
DMO4WH9	MT	DTT
DMO4WH9	MA	Modulator
DMO4WH9	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 849).
DMO4WH9	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=849

DM3O9YW	DI	DM3O9YW
DM3O9YW	DN	O-Phosphoethanolamine
DM3O9YW	MI	TTYPXQF
DM3O9YW	MN	Protein kinase C beta (PRKCB)
DM3O9YW	MT	DTT
DM3O9YW	MA	Inhibitor
DM3O9YW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM3O9YW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM0XT69	DI	DM0XT69
DM0XT69	DN	orexin-B
DM0XT69	MI	TT60Q8D
DM0XT69	MN	Orexin receptor type 1 (HCRTR1)
DM0XT69	MT	DTT
DM0XT69	MA	Agonist
DM0XT69	RN	Agonist ligand discrimination by the two orexin receptors depends on the expression system. Neurosci Lett. 2011 Apr 20;494(1):57-60.
DM0XT69	RU	https://pubmed.ncbi.nlm.nih.gov/21362456

DM0XT69	DI	DM0XT69
DM0XT69	DN	orexin-B
DM0XT69	MI	TT9N02I
DM0XT69	MN	Orexin receptor type 2 (HCRTR2)
DM0XT69	MT	DTT
DM0XT69	MA	Agonist
DM0XT69	RN	The signalling profile of recombinant human orexin-2 receptor. Cell Signal. 2008 Sep;20(9):1651-61.
DM0XT69	RU	https://pubmed.ncbi.nlm.nih.gov/18599270

DM8JUBG	DI	DM8JUBG
DM8JUBG	DN	Org 12962
DM8JUBG	MI	TTJQOD7
DM8JUBG	MN	5-HT 2A receptor (HTR2A)
DM8JUBG	MT	DTT
DM8JUBG	MA	Agonist
DM8JUBG	RN	Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
DM8JUBG	RU	https://pubmed.ncbi.nlm.nih.gov/15322733

DM8JUBG	DI	DM8JUBG
DM8JUBG	DN	Org 12962
DM8JUBG	MI	TT0K1SC
DM8JUBG	MN	5-HT 2B receptor (HTR2B)
DM8JUBG	MT	DTT
DM8JUBG	MA	Agonist
DM8JUBG	RN	Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
DM8JUBG	RU	https://pubmed.ncbi.nlm.nih.gov/15322733

DM8JUBG	DI	DM8JUBG
DM8JUBG	DN	Org 12962
DM8JUBG	MI	TTWJBZ5
DM8JUBG	MN	5-HT 2C receptor (HTR2C)
DM8JUBG	MT	DTT
DM8JUBG	MA	Agonist
DM8JUBG	RN	Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
DM8JUBG	RU	https://pubmed.ncbi.nlm.nih.gov/15322733

DMH1M6N	DI	DMH1M6N
DMH1M6N	DN	ORG2058
DMH1M6N	MI	TTUV8G9
DMH1M6N	MN	Progesterone receptor (PGR)
DMH1M6N	MT	DTT
DMH1M6N	MA	Agonist
DMH1M6N	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 627).
DMH1M6N	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=627

DMTFGYH	DI	DMTFGYH
DMTFGYH	DN	Org-231295
DMTFGYH	MI	TTDP1UC
DMTFGYH	MN	Fatty acid amide hydrolase (FAAH)
DMTFGYH	MT	DTT
DMTFGYH	MA	Inhibitor
DMTFGYH	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1400).
DMTFGYH	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1400

DMRU3H0	DI	DMRU3H0
DMRU3H0	DN	Org27569
DMRU3H0	MI	TT6OEDT
DMRU3H0	MN	Cannabinoid receptor 1 (CB1)
DMRU3H0	MT	DTT
DMRU3H0	MA	Modulator (allosteric modulator)
DMRU3H0	RN	Indole-2-carboxamides as allosteric modulators of the cannabinoid CB receptor. J Med Chem. 2012 Jun 14;55(11):5627-31.
DMRU3H0	RU	https://pubmed.ncbi.nlm.nih.gov/22571451

DMXGA56	DI	DMXGA56
DMXGA56	DN	Org-30850
DMXGA56	MI	TT8R70G
DMXGA56	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMXGA56	MT	DTT
DMXGA56	MA	Modulator
DMXGA56	RN	In vivo effects of a potent GnRH antagonist ORG 30850: physiologic evidence that down-regulation of GnRH receptors does not occur. J Soc Gynecol Investig. 1994 Oct-Dec;1(4):290-6.
DMXGA56	RU	https://www.ncbi.nlm.nih.gov/pubmed/9419786

DMDY38R	DI	DMDY38R
DMDY38R	DN	Org-33201
DMDY38R	MI	TTSZLWK
DMDY38R	MN	Aromatase (CYP19A1)
DMDY38R	MT	DTT
DMDY38R	MA	Modulator
DMDY38R	RN	Org 33201: a new highly selective orally active aromatase inhibitor. J Steroid Biochem Mol Biol. 1993 Mar;44(4-6):681-2.
DMDY38R	RU	https://www.ncbi.nlm.nih.gov/pubmed/8476784

DM4SFKW	DI	DM4SFKW
DM4SFKW	DN	Org-36764
DM4SFKW	MI	TT4QPUL
DM4SFKW	MN	Antithrombin-III (ATIII)
DM4SFKW	MT	DTT
DM4SFKW	MA	Modulator
DM4SFKW	RN	Pre-clinical pharmacological profile of the novel glycoconjugate Org 36764 with both factor Xa and thrombin (IIa) inhibitory activities. Thromb Haemost. 2000 Oct;84(4):611-20.
DM4SFKW	RU	https://www.ncbi.nlm.nih.gov/pubmed/11057859

DM3EZDG	DI	DM3EZDG
DM3EZDG	DN	Org-37663
DM3EZDG	MI	TTZAYWL
DM3EZDG	MN	Estrogen receptor (ESR)
DM3EZDG	MT	DTT
DM3EZDG	MA	Modulator
DM3EZDG	RN	The selective estrogen receptor alpha agonist Org 37663 induces estrogenic effects but lacks antirheumatic activity: a phase IIa trial investigating efficacy and safety of Org 37663 in postmenopausal female rheumatoid arthritis patients receiving stable background methotrexate or sulfasalazine.Arthritis Rheum.2010 Feb;62(2):351-8.
DM3EZDG	RU	https://www.ncbi.nlm.nih.gov/pubmed/20112368

DMPQGUL	DI	DMPQGUL
DMPQGUL	DN	ORIPAVINE
DMPQGUL	MI	TTKWM86
DMPQGUL	MN	Opioid receptor mu (MOP)
DMPQGUL	MT	DTT
DMPQGUL	MA	Inhibitor
DMPQGUL	RN	Live cell monitoring of mu-opioid receptor-mediated G-protein activation reveals strong biological activity of close morphine biosynthetic precursors. J Biol Chem. 2007 Sep 14;282(37):27126-32.
DMPQGUL	RU	https://pubmed.ncbi.nlm.nih.gov/17616524

DMA2DQT	DI	DMA2DQT
DMA2DQT	DN	OROIDIN
DMA2DQT	MI	TTIDAPM
DMA2DQT	MN	ERK activator kinase 1 (MEK1)
DMA2DQT	MT	DTT
DMA2DQT	MA	Inhibitor
DMA2DQT	RN	Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1). J Med Chem. 2002 Jan 17;45(2):529-32.
DMA2DQT	RU	https://pubmed.ncbi.nlm.nih.gov/11784156

DMA2DQT	DI	DMA2DQT
DMA2DQT	DN	OROIDIN
DMA2DQT	MI	TTNX2CS
DMA2DQT	MN	Plasmodium Enoyl-ACP reductase (Malaria fabI)
DMA2DQT	MT	DTT
DMA2DQT	MA	Inhibitor
DMA2DQT	RN	Marine natural products from the Turkish sponge Agelas oroides that inhibit the enoyl reductases from Plasmodium falciparum, Mycobacterium tubercul... Bioorg Med Chem. 2007 Nov 1;15(21):6834-45.
DMA2DQT	RU	https://pubmed.ncbi.nlm.nih.gov/17765547

DMMB29S	DI	DMMB29S
DMMB29S	DN	Orotate
DMMB29S	MI	TT09NOX
DMMB29S	MN	Plasmodium Dihydroorotase (Malaria dho)
DMMB29S	MT	DTT
DMMB29S	MA	Inhibitor
DMMB29S	RN	Antimalarial activity of orotate analogs that inhibit dihydroorotase and dihydroorotate dehydrogenase. Biochem Pharmacol. 1992 Mar 17;43(6):1295-301.
DMMB29S	RU	https://pubmed.ncbi.nlm.nih.gov/1348618

DMMB29S	DI	DMMB29S
DMMB29S	DN	Orotate
DMMB29S	MI	TT3PQ2Y
DMMB29S	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DMMB29S	MT	DTT
DMMB29S	MA	Inhibitor
DMMB29S	RN	Antimalarial activity of orotate analogs that inhibit dihydroorotase and dihydroorotate dehydrogenase. Biochem Pharmacol. 1992 Mar 17;43(6):1295-301.
DMMB29S	RU	https://pubmed.ncbi.nlm.nih.gov/1348618

DMMB29S	DI	DMMB29S
DMMB29S	DN	Orotate
DMMB29S	MI	DT2WLAD
DMMB29S	MN	Urate anion exchanger 1 (SLC22A12)
DMMB29S	MT	DTP
DMMB29S	MA	Substrate
DMMB29S	RN	Human urate transporter 1 (hURAT1) mediates the transport of orotate. J Physiol Sci. 2011 May;61(3):253-7.
DMMB29S	RU	http://www.ncbi.nlm.nih.gov/pubmed/21350910

DMP6BSH	DI	DMP6BSH
DMP6BSH	DN	Orotic acid
DMP6BSH	MI	TT3PQ2Y
DMP6BSH	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DMP6BSH	MT	DTT
DMP6BSH	MA	Inhibitor
DMP6BSH	RN	Structure-activity relationships of pyrimidines as dihydroorotate dehydrogenase inhibitors. Biochem Pharmacol. 1988 Oct 15;37(20):3807-16.
DMP6BSH	RU	https://pubmed.ncbi.nlm.nih.gov/2847745

DMGRXD4	DI	DMGRXD4
DMGRXD4	DN	Orthovanadate
DMGRXD4	MI	TTCWXFA
DMGRXD4	MN	Protein-tyrosine phosphatase sigma (R-PTP-sigma)
DMGRXD4	MT	DTT
DMGRXD4	MA	Inhibitor
DMGRXD4	RN	Human protein tyrosine phosphatase-sigma: alternative splicing and inhibition by bisphosphonates. J Bone Miner Res. 1996 Apr;11(4):535-43.
DMGRXD4	RU	https://pubmed.ncbi.nlm.nih.gov/8992885

DMK6X5P	DI	DMK6X5P
DMK6X5P	DN	OSCILLARIN
DMK6X5P	MI	TT6L509
DMK6X5P	MN	Coagulation factor IIa (F2)
DMK6X5P	MT	DTT
DMK6X5P	MA	Inhibitor
DMK6X5P	RN	From natural products to achiral drug prototypes: potent thrombin inhibitors based on P2/P3 dihydropyrid-2-one core motifs. Bioorg Med Chem Lett. 2009 Sep 15;19(18):5429-32.
DMK6X5P	RU	https://pubmed.ncbi.nlm.nih.gov/19674897

DM5IGN7	DI	DM5IGN7
DM5IGN7	DN	OSI-75
DM5IGN7	MI	TTGKNB4
DM5IGN7	MN	Epidermal growth factor receptor (EGFR)
DM5IGN7	MT	DTT
DM5IGN7	MA	Inhibitor
DM5IGN7	RN	Selected novel anticancer treatments targeting cell signaling proteins. Oncologist. 2001;6(6):517-37.
DM5IGN7	RU	https://pubmed.ncbi.nlm.nih.gov/11743214

DMCAR7B	DI	DMCAR7B
DMCAR7B	DN	O-Sialic Acid
DMCAR7B	MI	TTAU4D6
DMCAR7B	MN	E-selectin (SELE)
DMCAR7B	MT	DTT
DMCAR7B	MA	Inhibitor
DMCAR7B	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMCAR7B	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMCAR7B	DI	DMCAR7B
DMCAR7B	DN	O-Sialic Acid
DMCAR7B	MI	TT50QJ3
DMCAR7B	MN	Influenza Neuraminidase (Influ NA)
DMCAR7B	MT	DTT
DMCAR7B	MA	Inhibitor
DMCAR7B	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMCAR7B	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMCAR7B	DI	DMCAR7B
DMCAR7B	DN	O-Sialic Acid
DMCAR7B	MI	TTMF541
DMCAR7B	MN	Liver carboxylesterase (CES1)
DMCAR7B	MT	DTT
DMCAR7B	MA	Inhibitor
DMCAR7B	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMCAR7B	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMCAR7B	DI	DMCAR7B
DMCAR7B	DN	O-Sialic Acid
DMCAR7B	MI	TTE5VG0
DMCAR7B	MN	P-selectin (SELP)
DMCAR7B	MT	DTT
DMCAR7B	MA	Inhibitor
DMCAR7B	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMCAR7B	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM3FS62	DI	DM3FS62
DM3FS62	DN	O-spiroketal glucoside
DM3FS62	MI	TTF8JAT
DM3FS62	MN	SLC5A2 messenger RNA (SLC5A2 mRNA)
DM3FS62	MT	DTT
DM3FS62	MA	Inhibitor
DM3FS62	RN	ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors. Bioorg Med Chem. 2010 Jun 15;18(12):4422-32.
DM3FS62	RU	https://pubmed.ncbi.nlm.nih.gov/20576578

DM3FS62	DI	DM3FS62
DM3FS62	DN	O-spiroketal glucoside
DM3FS62	MI	TT2UE56
DM3FS62	MN	Sodium/glucose cotransporter 1 (SGLT1)
DM3FS62	MT	DTT
DM3FS62	MA	Inhibitor
DM3FS62	RN	ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors. Bioorg Med Chem. 2010 Jun 15;18(12):4422-32.
DM3FS62	RU	https://pubmed.ncbi.nlm.nih.gov/20576578

DMQPJXT	DI	DMQPJXT
DMQPJXT	DN	OSU-53
DMQPJXT	MI	TTLAFZV
DMQPJXT	MN	AMP-activated protein kinase (AMPK)
DMQPJXT	MT	DTT
DMQPJXT	MA	Activator
DMQPJXT	RN	A novel dual AMPK activator/mTOR inhibitor inhibits thyroid cancer cell growth. J Clin Endocrinol Metab. 2015 May;100(5):E748-56.
DMQPJXT	RU	https://pubmed.ncbi.nlm.nih.gov/25710562

DM0R6MT	DI	DM0R6MT
DM0R6MT	DN	O-tolyl 10H-phenothiazine-10-carboxylate
DM0R6MT	MI	TTEB0GD
DM0R6MT	MN	Cholinesterase (BCHE)
DM0R6MT	MT	DTT
DM0R6MT	MA	Inhibitor
DM0R6MT	RN	Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. J Med Chem. 2008 Jul 24;51(14):4200-12.
DM0R6MT	RU	https://pubmed.ncbi.nlm.nih.gov/18570368

DMXP72F	DI	DMXP72F
DMXP72F	DN	OTS964
DMXP72F	MI	TTMY6BZ
DMXP72F	MN	PDZ binding kinase (PBK)
DMXP72F	MT	DTT
DMXP72F	MA	Inhibitor
DMXP72F	RN	TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis. Sci Transl Med. 2014 Oct 22;6(259):259ra145.
DMXP72F	RU	https://pubmed.ncbi.nlm.nih.gov/25338756

DMM4CE7	DI	DMM4CE7
DMM4CE7	DN	Ovalicin
DMM4CE7	MI	TTZL0OI
DMM4CE7	MN	Methionine aminopeptidase 2 (METAP2)
DMM4CE7	MT	DTT
DMM4CE7	MA	Inhibitor
DMM4CE7	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMM4CE7	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMAV9PS	DI	DMAV9PS
DMAV9PS	DN	OVI-117
DMAV9PS	MI	TTU6BFZ
DMAV9PS	MN	Candida Thymidylate synthase (Candi TMP1)
DMAV9PS	MT	DTT
DMAV9PS	MA	Modulator
DMAV9PS	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2642).
DMAV9PS	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2642

DMCFM2E	DI	DMCFM2E
DMCFM2E	DN	OXA-01
DMCFM2E	MI	TTCJG29
DMCFM2E	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMCFM2E	MT	DTT
DMCFM2E	MA	Inhibitor
DMCFM2E	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
DMCFM2E	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109

DMPZSV1	DI	DMPZSV1
DMPZSV1	DN	Oxalacetic acid
DMPZSV1	MI	DENCJTA
DMPZSV1	MN	Oxaloacetate decarboxylase (FAHD1)
DMPZSV1	MT	DME
DMPZSV1	MA	Metabolism
DMPZSV1	RN	Identification of FAH domain-containing protein 1 (FAHD1) as oxaloacetate decarboxylase. J Biol Chem. 2015 Mar 13;290(11):6755-62.
DMPZSV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25575590

DMPZSV1	DI	DMPZSV1
DMPZSV1	DN	Oxalacetic acid
DMPZSV1	MI	DEPLH5Z
DMPZSV1	MN	Phosphoenolpyruvate carboxykinase (PCK1)
DMPZSV1	MT	DME
DMPZSV1	MA	Metabolism
DMPZSV1	RN	Tyr235 of human cytosolic phosphoenolpyruvate carboxykinase influences catalysis through an anion-quadrupole interaction with phosphoenolpyruvate carboxylate. FEBS J. 2008 Dec;275(23):5810-9.
DMPZSV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19021757

DM40SEU	DI	DM40SEU
DM40SEU	DN	Oxalate
DM40SEU	MI	DTVGOLN
DM40SEU	MN	Anion exchange transporter (SLC26A6)
DM40SEU	MT	DTP
DM40SEU	MA	Substrate
DM40SEU	RN	Oxalate (urine, plasma)
DM40SEU	RU	http://www.acb.org.uk/Nat%20Lab%20Med%20Hbk/Oxalate.pdf

DM40SEU	DI	DM40SEU
DM40SEU	DN	Oxalate
DM40SEU	MI	DTOTME4
DM40SEU	MN	Anion exchange transporter (SLC26A7)
DM40SEU	MT	DTP
DM40SEU	MA	Substrate
DM40SEU	RN	The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.53.2.6)
DM40SEU	RU	http://www.tcdb.org/search/result.php?tc=2.A.53.2.6

DM40SEU	DI	DM40SEU
DM40SEU	DN	Oxalate
DM40SEU	MI	DTJ785O
DM40SEU	MN	Sulfate anion transporter 1 (SLC26A1)
DM40SEU	MT	DTP
DM40SEU	MA	Substrate
DM40SEU	RN	Mutations in SLC26A1 Cause Nephrolithiasis. Am J Hum Genet. 2016 Jun 2;98(6):1228-1234.
DM40SEU	RU	http://www.ncbi.nlm.nih.gov/pubmed/27210743

DMLN2GQ	DI	DMLN2GQ
DMLN2GQ	DN	Oxalic Acid
DMLN2GQ	MI	TT6PKBN
DMLN2GQ	MN	Proto-oncogene c-Src (SRC)
DMLN2GQ	MT	DTT
DMLN2GQ	MA	Inhibitor
DMLN2GQ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMLN2GQ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMT7XYE	DI	DMT7XYE
DMT7XYE	DN	Oxalylaminobenzoic acid
DMT7XYE	MI	TTELIN2
DMT7XYE	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMT7XYE	MT	DTT
DMT7XYE	MA	Inhibitor
DMT7XYE	RN	Synthesis and evaluation of some novel dibenzo[b,d]furan carboxylic acids as potential anti-diabetic agents. Eur J Med Chem. 2010 Sep;45(9):3709-18.
DMT7XYE	RU	https://pubmed.ncbi.nlm.nih.gov/20627471

DMTYBC9	DI	DMTYBC9
DMTYBC9	DN	OXAMATE
DMTYBC9	MI	TTT2LD9
DMTYBC9	MN	GABA transaminase (ABAT)
DMTYBC9	MT	DTT
DMTYBC9	MA	Inhibitor
DMTYBC9	RN	Aminomethyl-1,2,4-benzothiadiazines as potential analogues of gamma-aminobutyric acid. Unexpected discovery of a taurine antagonist. J Med Chem. 1982 Feb;25(2):113-6.
DMTYBC9	RU	https://pubmed.ncbi.nlm.nih.gov/6276545

DMTYBC9	DI	DMTYBC9
DMTYBC9	DN	OXAMATE
DMTYBC9	MI	TTAZHU0
DMTYBC9	MN	L-lactate dehydrogenase (LDH)
DMTYBC9	MT	DTT
DMTYBC9	MA	Inhibitor
DMTYBC9	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMTYBC9	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMWVLG1	DI	DMWVLG1
DMWVLG1	DN	Oxametacin
DMWVLG1	MI	TT8NGED
DMWVLG1	MN	Prostaglandin G/H synthase 1 (COX-1)
DMWVLG1	MT	DTT
DMWVLG1	MA	Inhibitor
DMWVLG1	RN	Structure-based design, synthesis, and biological evaluation of indomethacin derivatives as cyclooxygenase-2 inhibiting nitric oxide donors. J Med Chem. 2007 Dec 13;50(25):6367-82.
DMWVLG1	RU	https://pubmed.ncbi.nlm.nih.gov/17994684

DMWVLG1	DI	DMWVLG1
DMWVLG1	DN	Oxametacin
DMWVLG1	MI	TTVKILB
DMWVLG1	MN	Prostaglandin G/H synthase 2 (COX-2)
DMWVLG1	MT	DTT
DMWVLG1	MA	Inhibitor
DMWVLG1	RN	Structure-based design, synthesis, and biological evaluation of indomethacin derivatives as cyclooxygenase-2 inhibiting nitric oxide donors. J Med Chem. 2007 Dec 13;50(25):6367-82.
DMWVLG1	RU	https://pubmed.ncbi.nlm.nih.gov/17994684

DM8109D	DI	DM8109D
DM8109D	DN	Oxazolidin-(2Z)-ylideneamine
DM8109D	MI	TTF10I9
DM8109D	MN	Nitric-oxide synthase inducible (NOS2)
DM8109D	MT	DTT
DM8109D	MA	Inhibitor
DM8109D	RN	4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor. Bioorg Med Chem Lett. 2004 Jan 19;14(2):313-6.
DM8109D	RU	https://pubmed.ncbi.nlm.nih.gov/14698148

DMMEDJT	DI	DMMEDJT
DMMEDJT	DN	OXDEX
DMMEDJT	MI	TTOZRK6
DMMEDJT	MN	Glucocorticoid receptor messenger RNA (GCR mRNA)
DMMEDJT	MT	DTT
DMMEDJT	MA	Inhibitor
DMMEDJT	RN	Investigation of the relative cellular permeability of DNA-binding pyrrole-imidazole polyamides. J Med Chem. 2009 Aug 13;52(15):4604-12.
DMMEDJT	RU	https://pubmed.ncbi.nlm.nih.gov/19610652

DM6RJOI	DI	DM6RJOI
DM6RJOI	DN	OXENDLONE
DM6RJOI	MI	TTS64P2
DM6RJOI	MN	Androgen receptor (AR)
DM6RJOI	MT	DTT
DM6RJOI	MA	Inhibitor
DM6RJOI	RN	Antiandrogenic natural Diels--Alder-type adducts from Brosimum rubescens. J Nat Prod. 1997 Oct;60(10):997-1002.
DM6RJOI	RU	https://pubmed.ncbi.nlm.nih.gov/9358642

DMG6O0L	DI	DMG6O0L
DMG6O0L	DN	Oximidine I
DMG6O0L	MI	TTTK3BH
DMG6O0L	MN	Vacuolar-type proton ATPase (v-ATPase)
DMG6O0L	MT	DTT
DMG6O0L	MA	Inhibitor
DMG6O0L	RN	Discovery of a novel antitumor benzolactone enamide class that selectively inhibits mammalian vacuolar-type (H+)-atpases. J Pharmacol Exp Ther. 2001 Apr;297(1):114-20.
DMG6O0L	RU	https://pubmed.ncbi.nlm.nih.gov/11259534

DMW6K80	DI	DMW6K80
DMW6K80	DN	Oximidine II
DMW6K80	MI	TTTK3BH
DMW6K80	MN	Vacuolar-type proton ATPase (v-ATPase)
DMW6K80	MT	DTT
DMW6K80	MA	Inhibitor
DMW6K80	RN	Discovery of a novel antitumor benzolactone enamide class that selectively inhibits mammalian vacuolar-type (H+)-atpases. J Pharmacol Exp Ther. 2001 Apr;297(1):114-20.
DMW6K80	RU	https://pubmed.ncbi.nlm.nih.gov/11259534

DMM5208	DI	DMM5208
DMM5208	DN	Oxindole 16 (compound 3)
DMM5208	MI	TTL4Q97
DMM5208	MN	Cyclin-dependent kinase 5 (CDK5)
DMM5208	MT	DTT
DMM5208	MA	Inhibitor
DMM5208	RN	Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
DMM5208	RU	https://pubmed.ncbi.nlm.nih.gov/12237154

DMM5208	DI	DMM5208
DMM5208	DN	Oxindole 16 (compound 3)
DMM5208	MI	TTBJR4L
DMM5208	MN	Cyclin-dependent kinase 8 (CDK8)
DMM5208	MT	DTT
DMM5208	MA	Inhibitor
DMM5208	RN	Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
DMM5208	RU	https://pubmed.ncbi.nlm.nih.gov/12237154

DMPFD6Y	DI	DMPFD6Y
DMPFD6Y	DN	Oxindole 94
DMPFD6Y	MI	TTBJR4L
DMPFD6Y	MN	Cyclin-dependent kinase 8 (CDK8)
DMPFD6Y	MT	DTT
DMPFD6Y	MA	Inhibitor
DMPFD6Y	RN	Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
DMPFD6Y	RU	https://pubmed.ncbi.nlm.nih.gov/12237154

DMPFD6Y	DI	DMPFD6Y
DMPFD6Y	DN	Oxindole 94
DMPFD6Y	MI	TTVKILB
DMPFD6Y	MN	Prostaglandin G/H synthase 2 (COX-2)
DMPFD6Y	MT	DTT
DMPFD6Y	MA	Inhibitor
DMPFD6Y	RN	A selective inhibitor of p38 MAP kinase, SB202190, induced apoptotic cell death of a lipopolysaccharide-treated macrophage-like cell line, J774.1. Biochim Biophys Acta. 2000 Oct 18;1502(2):207-23.
DMPFD6Y	RU	https://pubmed.ncbi.nlm.nih.gov/11040446

DMPFD6Y	DI	DMPFD6Y
DMPFD6Y	DN	Oxindole 94
DMPFD6Y	MI	TTQBR95
DMPFD6Y	MN	Stress-activated protein kinase 2a (p38 alpha)
DMPFD6Y	MT	DTT
DMPFD6Y	MA	Inhibitor
DMPFD6Y	RN	Inhibition of p38 MAPK decreases myocardial TNF-alpha expression and improves myocardial function and survival in endotoxemia. Cardiovasc Res. 2003 Oct 1;59(4):893-900.
DMPFD6Y	RU	https://pubmed.ncbi.nlm.nih.gov/14553829

DM4UL1G	DI	DM4UL1G
DM4UL1G	DN	Oxindole 95
DM4UL1G	MI	TT7HF4W
DM4UL1G	MN	Cyclin-dependent kinase 2 (CDK2)
DM4UL1G	MT	DTT
DM4UL1G	MA	Inhibitor
DM4UL1G	RN	Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
DM4UL1G	RU	https://pubmed.ncbi.nlm.nih.gov/12237154

DM4UL1G	DI	DM4UL1G
DM4UL1G	DN	Oxindole 95
DM4UL1G	MI	TTL4Q97
DM4UL1G	MN	Cyclin-dependent kinase 5 (CDK5)
DM4UL1G	MT	DTT
DM4UL1G	MA	Inhibitor
DM4UL1G	RN	Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
DM4UL1G	RU	https://pubmed.ncbi.nlm.nih.gov/12237154

DM1AU8V	DI	DM1AU8V
DM1AU8V	DN	Oxindole derivative
DM1AU8V	MI	TTSFWA7
DM1AU8V	MN	Plasmodium CDK Pfmrk (Malaria Pfmrk)
DM1AU8V	MT	DTT
DM1AU8V	MA	Inhibitor
DM1AU8V	RN	Novel molecular targets for antimalarial chemotherapy. Int J Antimicrob Agents. 2007 Jul;30(1):4-10.
DM1AU8V	RU	https://pubmed.ncbi.nlm.nih.gov/17339102

DMV0KTW	DI	DMV0KTW
DMV0KTW	DN	oxo-arpromidine
DMV0KTW	MI	TTTIBOJ
DMV0KTW	MN	Histamine H1 receptor (H1R)
DMV0KTW	MT	DTT
DMV0KTW	MA	Agonist
DMV0KTW	RN	Probing ligand-specific histamine H1- and H2-receptor conformations with NG-acylated Imidazolylpropylguanidines. J Pharmacol Exp Ther. 2006 Apr;317(1):139-46.
DMV0KTW	RU	https://pubmed.ncbi.nlm.nih.gov/16394198

DMV0KTW	DI	DMV0KTW
DMV0KTW	DN	oxo-arpromidine
DMV0KTW	MI	TTQHJ1K
DMV0KTW	MN	Histamine H2 receptor (H2R)
DMV0KTW	MT	DTT
DMV0KTW	MA	Agonist
DMV0KTW	RN	Probing ligand-specific histamine H1- and H2-receptor conformations with NG-acylated Imidazolylpropylguanidines. J Pharmacol Exp Ther. 2006 Apr;317(1):139-46.
DMV0KTW	RU	https://pubmed.ncbi.nlm.nih.gov/16394198

DMRKA08	DI	DMRKA08
DMRKA08	DN	Oxolithocholic acid
DMRKA08	MI	DEL5PTS
DMRKA08	MN	Alpha-hydroxysteroid dehydrogenase (12AH)
DMRKA08	MT	DME
DMRKA08	MA	Metabolism
DMRKA08	RN	Metabolism of oxo-bile acids and characterization of recombinant 12alpha-hydroxysteroid dehydrogenases from bile acid 7alpha-dehydroxylating human gut bacteria. Appl Environ Microbiol. 2018 May 1;84(10). pii: e00235-18.
DMRKA08	RU	https://pubmed.ncbi.nlm.nih.gov/29549099

DMRKA08	DI	DMRKA08
DMRKA08	DN	Oxolithocholic acid
DMRKA08	MI	DEOIYWD
DMRKA08	MN	Alpha-hydroxysteroid dehydrogenase (12AH)
DMRKA08	MT	DME
DMRKA08	MA	Metabolism
DMRKA08	RN	Metabolism of oxo-bile acids and characterization of recombinant 12alpha-hydroxysteroid dehydrogenases from bile acid 7alpha-dehydroxylating human gut bacteria. Appl Environ Microbiol. 2018 May 1;84(10). pii: e00235-18.
DMRKA08	RU	https://pubmed.ncbi.nlm.nih.gov/29549099

DMRKA08	DI	DMRKA08
DMRKA08	DN	Oxolithocholic acid
DMRKA08	MI	DER7IAK
DMRKA08	MN	Alpha-hydroxysteroid dehydrogenase (12AH)
DMRKA08	MT	DME
DMRKA08	MA	Metabolism
DMRKA08	RN	Metabolism of oxo-bile acids and characterization of recombinant 12alpha-hydroxysteroid dehydrogenases from bile acid 7alpha-dehydroxylating human gut bacteria. Appl Environ Microbiol. 2018 May 1;84(10). pii: e00235-18.
DMRKA08	RU	https://pubmed.ncbi.nlm.nih.gov/29549099

DMRKA08	DI	DMRKA08
DMRKA08	DN	Oxolithocholic acid
DMRKA08	MI	DE5Q9XD
DMRKA08	MN	Alpha-hydroxysteroid dehydrogenase (12AH)
DMRKA08	MT	DME
DMRKA08	MA	Metabolism
DMRKA08	RN	Metabolism of oxo-bile acids and characterization of recombinant 12alpha-hydroxysteroid dehydrogenases from bile acid 7alpha-dehydroxylating human gut bacteria. Appl Environ Microbiol. 2018 May 1;84(10). pii: e00235-18.
DMRKA08	RU	https://pubmed.ncbi.nlm.nih.gov/29549099

DMMZYX6	DI	DMMZYX6
DMMZYX6	DN	OXYBENZONE
DMMZYX6	MI	TTLUQ8E
DMMZYX6	MN	Hormone sensitive lipase (LIPE)
DMMZYX6	MT	DTT
DMMZYX6	MA	Inhibitor
DMMZYX6	RN	Combining ligand-based pharmacophore modeling, quantitative structure-activity relationship analysis and in silico screening for the discovery of n... J Med Chem. 2008 Oct 23;51(20):6478-94.
DMMZYX6	RU	https://pubmed.ncbi.nlm.nih.gov/18808096

DMJPBAX	DI	DMJPBAX
DMJPBAX	DN	Oxybutynine
DMJPBAX	MI	TTQ13Z5
DMJPBAX	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMJPBAX	MT	DTT
DMJPBAX	MA	Antagonist
DMJPBAX	RN	Generation of an agonistic binding site for blockers of the M(3) muscarinic acetylcholine receptor. Biochem J. 2008 May 15;412(1):103-12.
DMJPBAX	RU	https://pubmed.ncbi.nlm.nih.gov/18237275

DMTP4S2	DI	DMTP4S2
DMTP4S2	DN	OXYMORPHINDOLE
DMTP4S2	MI	TT27RFC
DMTP4S2	MN	Opioid receptor delta (OPRD1)
DMTP4S2	MT	DTT
DMTP4S2	MA	Inhibitor
DMTP4S2	RN	Ligand binding to nucleic acids and proteins: Does selectivity increase with strength Eur J Med Chem. 2008 Nov;43(11):2307-15.
DMTP4S2	RU	https://pubmed.ncbi.nlm.nih.gov/18403056

DMTP4S2	DI	DMTP4S2
DMTP4S2	DN	OXYMORPHINDOLE
DMTP4S2	MI	TTQW87Y
DMTP4S2	MN	Opioid receptor kappa (OPRK1)
DMTP4S2	MT	DTT
DMTP4S2	MA	Inhibitor
DMTP4S2	RN	Ligand binding to nucleic acids and proteins: Does selectivity increase with strength Eur J Med Chem. 2008 Nov;43(11):2307-15.
DMTP4S2	RU	https://pubmed.ncbi.nlm.nih.gov/18403056

DMTP4S2	DI	DMTP4S2
DMTP4S2	DN	OXYMORPHINDOLE
DMTP4S2	MI	TTKWM86
DMTP4S2	MN	Opioid receptor mu (MOP)
DMTP4S2	MT	DTT
DMTP4S2	MA	Inhibitor
DMTP4S2	RN	Ligand binding to nucleic acids and proteins: Does selectivity increase with strength Eur J Med Chem. 2008 Nov;43(11):2307-15.
DMTP4S2	RU	https://pubmed.ncbi.nlm.nih.gov/18403056

DMTSM61	DI	DMTSM61
DMTSM61	DN	Oxymorphone semicarbazone hydrochloride
DMTSM61	MI	TTQW87Y
DMTSM61	MN	Opioid receptor kappa (OPRK1)
DMTSM61	MT	DTT
DMTSM61	MA	Inhibitor
DMTSM61	RN	Peptides as receptor selectivity modulators of opiate pharmacophores. J Med Chem. 1986 Jul;29(7):1222-5.
DMTSM61	RU	https://pubmed.ncbi.nlm.nih.gov/2879914

DMTSM61	DI	DMTSM61
DMTSM61	DN	Oxymorphone semicarbazone hydrochloride
DMTSM61	MI	TTKWM86
DMTSM61	MN	Opioid receptor mu (MOP)
DMTSM61	MT	DTT
DMTSM61	MA	Inhibitor
DMTSM61	RN	Peptides as receptor selectivity modulators of opiate pharmacophores. J Med Chem. 1986 Jul;29(7):1222-5.
DMTSM61	RU	https://pubmed.ncbi.nlm.nih.gov/2879914

DMZVS9Y	DI	DMZVS9Y
DMZVS9Y	DN	OXYQUINOLINE
DMZVS9Y	MI	TTZL0OI
DMZVS9Y	MN	Methionine aminopeptidase 2 (METAP2)
DMZVS9Y	MT	DTT
DMZVS9Y	MA	Inhibitor
DMZVS9Y	RN	Subtype-selectivity of metal-dependent methionine aminopeptidase inhibitors, Bioorg. Med. Chem. Lett. 20(14):4038-4044 (2010).
DMZVS9Y	RU	http://www.sciencedirect.com/science/article/pii/S0960894X10007468

DMN7S4L	DI	DMN7S4L
DMN7S4L	DN	OXYRESVERATROL
DMN7S4L	MI	TTULVH8
DMN7S4L	MN	Tyrosinase (TYR)
DMN7S4L	MT	DTT
DMN7S4L	MA	Inhibitor
DMN7S4L	RN	Chemical transformations of oxyresveratrol (trans-2,4,3',5'-tetrahydroxystilbene) into a potent tyrosinase inhibitor and a strong cytotoxic agent. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5650-3.
DMN7S4L	RU	https://pubmed.ncbi.nlm.nih.gov/16919455

DMOY627	DI	DMOY627
DMOY627	DN	P(1)-(6-Hydroxymethylpterin)-P(4)-(5'-adenosyl)tetraphosphate
DMOY627	MI	TT38ECI
DMOY627	MN	Bacterial Hydroxymethyl-dihydropterin pyrophosphokinase (Bact folK)
DMOY627	MT	DTT
DMOY627	MA	Inhibitor
DMOY627	RN	Bisubstrate analogue inhibitors of 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase: synthesis and biochemical and crystallographic studies. J Med Chem. 2001 Apr 26;44(9):1364-71.
DMOY627	RU	https://pubmed.ncbi.nlm.nih.gov/11311059

DMJ0W43	DI	DMJ0W43
DMJ0W43	DN	P-(2'-Iodo-5'-Thenoyl)Hydrotropic Acid
DMJ0W43	MI	TT8NGED
DMJ0W43	MN	Prostaglandin G/H synthase 1 (COX-1)
DMJ0W43	MT	DTT
DMJ0W43	MA	Inhibitor
DMJ0W43	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMJ0W43	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM9SNFX	DI	DM9SNFX
DM9SNFX	DN	p-[18F]MPPF
DM9SNFX	MI	TTSQIFT
DM9SNFX	MN	5-HT 1A receptor (HTR1A)
DM9SNFX	MT	DTT
DM9SNFX	MA	Antagonist
DM9SNFX	RN	A 18F-MPPF PET normative database of 5-HT1A receptor binding in men and women over aging. J Nucl Med. 2005 Dec;46(12):1980-9.
DM9SNFX	RU	https://pubmed.ncbi.nlm.nih.gov/16330560

DMM4VWD	DI	DMM4VWD
DMM4VWD	DN	P1-(5'-Adenosyl)P5-(5'-Thymidyl)Pentaphosphate
DMM4VWD	MI	TT5B8AX
DMM4VWD	MN	Mycobacterium Thymidine monophosphate kinase (MycB tmk)
DMM4VWD	MT	DTT
DMM4VWD	MA	Inhibitor
DMM4VWD	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMM4VWD	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMM4VWD	DI	DMM4VWD
DMM4VWD	DN	P1-(5'-Adenosyl)P5-(5'-Thymidyl)Pentaphosphate
DMM4VWD	MI	TTP3QRF
DMM4VWD	MN	Thymidine kinase 1 (TK1)
DMM4VWD	MT	DTT
DMM4VWD	MA	Inhibitor
DMM4VWD	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMM4VWD	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMQ6TZE	DI	DMQ6TZE
DMQ6TZE	DN	P-1116
DMQ6TZE	MI	TTAUX24
DMQ6TZE	MN	Erythropoietin Receptor (EPOR)
DMQ6TZE	MT	DTT
DMQ6TZE	MA	Stimulator
DMQ6TZE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1718).
DMQ6TZE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1718

DMETL3Z	DI	DMETL3Z
DMETL3Z	DN	P2,P3 Ketoamide derivative
DMETL3Z	MI	TTDZN01
DMETL3Z	MN	Cathepsin K (CTSK)
DMETL3Z	MT	DTT
DMETL3Z	MA	Inhibitor
DMETL3Z	RN	Potent and selective P2-P3 ketoamide inhibitors of cathepsin K with good pharmacokinetic properties via favorable P1', P1, and/or P3 substitutions. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4897-902.
DMETL3Z	RU	https://pubmed.ncbi.nlm.nih.gov/15341947

DMETL3Z	DI	DMETL3Z
DMETL3Z	DN	P2,P3 Ketoamide derivative
DMETL3Z	MI	TTUMQVO
DMETL3Z	MN	Cathepsin S (CTSS)
DMETL3Z	MT	DTT
DMETL3Z	MA	Inhibitor
DMETL3Z	RN	Potent and selective P2-P3 ketoamide inhibitors of cathepsin K with good pharmacokinetic properties via favorable P1', P1, and/or P3 substitutions. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4897-902.
DMETL3Z	RU	https://pubmed.ncbi.nlm.nih.gov/15341947

DMZI8QW	DI	DMZI8QW
DMZI8QW	DN	P-2281
DMZI8QW	MI	TTCJG29
DMZI8QW	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMZI8QW	MT	DTT
DMZI8QW	MA	Inhibitor
DMZI8QW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
DMZI8QW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109

DMJDI7O	DI	DMJDI7O
DMJDI7O	DN	P-6915
DMJDI7O	MI	TTHBTOP
DMJDI7O	MN	PI3-kinase gamma (PIK3CG)
DMJDI7O	MT	DTT
DMJDI7O	MA	Inhibitor
DMJDI7O	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2155).
DMJDI7O	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2155

DMJDI7O	DI	DMJDI7O
DMJDI7O	DN	P-6915
DMJDI7O	MI	TTCJG29
DMJDI7O	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMJDI7O	MT	DTT
DMJDI7O	MA	Inhibitor
DMJDI7O	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
DMJDI7O	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109

DMELTM2	DI	DMELTM2
DMELTM2	DN	PA-10040
DMELTM2	MI	TTF1QVM
DMELTM2	MN	Gastric H(+)/K(+) ATPase alpha (ATP4A)
DMELTM2	MT	DTT
DMELTM2	MA	Modulator
DMELTM2	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 849).
DMELTM2	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=849

DMUH203	DI	DMUH203
DMUH203	DN	PA-1637
DMUH203	MI	TTE4KHA
DMUH203	MN	Amyloid beta A4 protein (APP)
DMUH203	MT	DTT
DMUH203	MA	Modulator
DMUH203	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
DMUH203	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402

DMTGZ3E	DI	DMTGZ3E
DMTGZ3E	DN	PA451
DMTGZ3E	MI	TT6PEUO
DMTGZ3E	MN	Retinoic acid receptor RXR-alpha (RXRA)
DMTGZ3E	MT	DTT
DMTGZ3E	MA	Antagonist
DMTGZ3E	RN	Novel retinoid X receptor antagonists: specific inhibition of retinoid synergism in RXR-RAR heterodimer actions. J Med Chem. 2002 Aug 1;45(16):3327-30.
DMTGZ3E	RU	https://pubmed.ncbi.nlm.nih.gov/12139443

DMKL6IC	DI	DMKL6IC
DMKL6IC	DN	PAC-10649
DMKL6IC	MI	TTVKILB
DMKL6IC	MN	Prostaglandin G/H synthase 2 (COX-2)
DMKL6IC	MT	DTT
DMKL6IC	MA	Inhibitor
DMKL6IC	RN	PAC 10649 Pacific licensing offer, Worldwide excluding South Korea. R & D Focus Drug News. September 22, 2003.
DMKL6IC	RU	http://business.highbeam.com/436989/article-1G1-107911540/pac-10649-pacific-licensing-offer-worldwide-excluding

DMB26IK	DI	DMB26IK
DMB26IK	DN	PACAP-27
DMB26IK	MI	TT4O5P0
DMB26IK	MN	Helodermin-preferring VIP receptor (VIPR2)
DMB26IK	MT	DTT
DMB26IK	MA	Agonist
DMB26IK	RN	A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology. Neuropharmacology. 2006 Nov;51(6):1086-98.
DMB26IK	RU	https://pubmed.ncbi.nlm.nih.gov/16930633

DMB26IK	DI	DMB26IK
DMB26IK	DN	PACAP-27
DMB26IK	MI	TT5OREU
DMB26IK	MN	PACAP type I receptor (PAC1R)
DMB26IK	MT	DTT
DMB26IK	MA	Agonist
DMB26IK	RN	A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology. Neuropharmacology. 2006 Nov;51(6):1086-98.
DMB26IK	RU	https://pubmed.ncbi.nlm.nih.gov/16930633

DMB26IK	DI	DMB26IK
DMB26IK	DN	PACAP-27
DMB26IK	MI	TTCL30I
DMB26IK	MN	Vasoactive intestinal polypeptide receptor 1 (VIPR1)
DMB26IK	MT	DTT
DMB26IK	MA	Agonist
DMB26IK	RN	A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology. Neuropharmacology. 2006 Nov;51(6):1086-98.
DMB26IK	RU	https://pubmed.ncbi.nlm.nih.gov/16930633

DMJ5TAU	DI	DMJ5TAU
DMJ5TAU	DN	Paeoniflorin
DMJ5TAU	MI	TTK25J1
DMJ5TAU	MN	Adenosine A1 receptor (ADORA1)
DMJ5TAU	MT	DTT
DMJ5TAU	MA	Modulator
DMJ5TAU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 18).
DMJ5TAU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=18

DMRZAQW	DI	DMRZAQW
DMRZAQW	DN	PAF
DMRZAQW	MI	TTQL5VC
DMRZAQW	MN	Platelet-activating factor receptor (PTAFR)
DMRZAQW	MT	DTT
DMRZAQW	MA	Agonist
DMRZAQW	RN	Identification of transmembrane domain residues determinant in the structure-function relationship of the human platelet-activating factor receptor by site-directed mutagenesis. J Biol Chem. 1996 Sep20;271(38):23298-303.
DMRZAQW	RU	https://pubmed.ncbi.nlm.nih.gov/8798529

DMDTP1R	DI	DMDTP1R
DMDTP1R	DN	PALASONIN
DMDTP1R	MI	TTFLH0E
DMDTP1R	MN	Serine/threonine PP1-alpha (PPP1CA)
DMDTP1R	MT	DTT
DMDTP1R	MA	Inhibitor
DMDTP1R	RN	Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies. J Med Chem. 2002 Mar 14;45(6):1151-75.
DMDTP1R	RU	https://pubmed.ncbi.nlm.nih.gov/11881984

DMN97BF	DI	DMN97BF
DMN97BF	DN	PALBINONE
DMN97BF	MI	TTFBNVI
DMN97BF	MN	Aldose reductase (AKR1B1)
DMN97BF	MT	DTT
DMN97BF	MA	Inhibitor
DMN97BF	RN	Inhibitors of aldose reductase and formation of advanced glycation end-products in moutan cortex (Paeonia suffruticosa). J Nat Prod. 2009 Aug;72(8):1465-70.
DMN97BF	RU	https://pubmed.ncbi.nlm.nih.gov/19670875

DMJCOKV	DI	DMJCOKV
DMJCOKV	DN	PALMATINE
DMJCOKV	MI	TTXV4FI
DMJCOKV	MN	Albendazole monooxygenase (CYP3A4)
DMJCOKV	MT	DTT
DMJCOKV	MA	Inhibitor
DMJCOKV	RN	Cytochrome P3A4 inhibitors and other constituents of Fibraurea tinctoria. J Nat Prod. 2007 Dec;70(12):1930-3.
DMJCOKV	RU	https://pubmed.ncbi.nlm.nih.gov/17994701

DM4W5X8	DI	DM4W5X8
DM4W5X8	DN	Palmitoleic Acid
DM4W5X8	MI	TT0OFWN
DM4W5X8	MN	Pseudomonas UDP-3-O-acyl-GlcNAc deacetylase (Pseudo lpxC)
DM4W5X8	MT	DTT
DM4W5X8	MA	Inhibitor
DM4W5X8	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM4W5X8	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMKLVSO	DI	DMKLVSO
DMKLVSO	DN	Palodesangren C
DMKLVSO	MI	TTS64P2
DMKLVSO	MN	Androgen receptor (AR)
DMKLVSO	MT	DTT
DMKLVSO	MA	Inhibitor
DMKLVSO	RN	Antiandrogenic natural Diels--Alder-type adducts from Brosimum rubescens. J Nat Prod. 1997 Oct;60(10):997-1002.
DMKLVSO	RU	https://pubmed.ncbi.nlm.nih.gov/9358642

DMY6NRC	DI	DMY6NRC
DMY6NRC	DN	Palodesangren D
DMY6NRC	MI	TTS64P2
DMY6NRC	MN	Androgen receptor (AR)
DMY6NRC	MT	DTT
DMY6NRC	MA	Inhibitor
DMY6NRC	RN	Antiandrogenic natural Diels--Alder-type adducts from Brosimum rubescens. J Nat Prod. 1997 Oct;60(10):997-1002.
DMY6NRC	RU	https://pubmed.ncbi.nlm.nih.gov/9358642

DMUEK1N	DI	DMUEK1N
DMUEK1N	DN	Palodesangren E
DMUEK1N	MI	TTS64P2
DMUEK1N	MN	Androgen receptor (AR)
DMUEK1N	MT	DTT
DMUEK1N	MA	Inhibitor
DMUEK1N	RN	Antiandrogenic natural Diels--Alder-type adducts from Brosimum rubescens. J Nat Prod. 1997 Oct;60(10):997-1002.
DMUEK1N	RU	https://pubmed.ncbi.nlm.nih.gov/9358642

DM7M5AF	DI	DM7M5AF
DM7M5AF	DN	pamoic acid
DM7M5AF	MI	TT254XD
DM7M5AF	MN	Kynurenic acid receptor (GPR35)
DM7M5AF	MT	DTT
DM7M5AF	MA	Agonist
DM7M5AF	RN	Identification of novel species-selective agonists of the G-protein-coupled receptor GPR35 that promote recruitment of beta-arrestin-2 and activate Galpha13. Biochem J. 2010 Dec 15;432(3):451-9.
DM7M5AF	RU	https://pubmed.ncbi.nlm.nih.gov/20919992

DM8HWS9	DI	DM8HWS9
DM8HWS9	DN	P-Anisic Acid
DM8HWS9	MI	TT9V5JH
DM8HWS9	MN	Phospholipase A2 (PLA2G1B)
DM8HWS9	MT	DTT
DM8HWS9	MA	Inhibitor
DM8HWS9	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM8HWS9	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM2JUTB	DI	DM2JUTB
DM2JUTB	DN	PARA-(BENZOYL)-PHENYLALANINE
DM2JUTB	MI	TTELIN2
DM2JUTB	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DM2JUTB	MT	DTT
DM2JUTB	MA	Inhibitor
DM2JUTB	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM2JUTB	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMOH75D	DI	DMOH75D
DMOH75D	DN	Para-chloroamphetamine
DMOH75D	MI	TTVBI8W
DMOH75D	MN	Dopamine transporter (DAT)
DMOH75D	MT	DTT
DMOH75D	MA	Inhibitor
DMOH75D	RN	Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88.
DMOH75D	RU	https://pubmed.ncbi.nlm.nih.gov/19717215

DMOH75D	DI	DMOH75D
DMOH75D	DN	Para-chloroamphetamine
DMOH75D	MI	TTAWNKZ
DMOH75D	MN	Norepinephrine transporter (NET)
DMOH75D	MT	DTT
DMOH75D	MA	Inhibitor
DMOH75D	RN	Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88.
DMOH75D	RU	https://pubmed.ncbi.nlm.nih.gov/19717215

DMOH75D	DI	DMOH75D
DMOH75D	DN	Para-chloroamphetamine
DMOH75D	MI	TT3ROYC
DMOH75D	MN	Serotonin transporter (SERT)
DMOH75D	MT	DTT
DMOH75D	MA	Inhibitor
DMOH75D	RN	Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88.
DMOH75D	RU	https://pubmed.ncbi.nlm.nih.gov/19717215

DMZY41U	DI	DMZY41U
DMZY41U	DN	Para-Isopropylaniline
DMZY41U	MI	TT3NKIB
DMZY41U	MN	Pancreatic elastase 1 (CELA1)
DMZY41U	MT	DTT
DMZY41U	MA	Inhibitor
DMZY41U	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMZY41U	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMQVFWJ	DI	DMQVFWJ
DMQVFWJ	DN	Para-Mercury-Benzenesulfonic Acid
DMQVFWJ	MI	TTOM3J0
DMQVFWJ	MN	Estrogen receptor beta (ESR2)
DMQVFWJ	MT	DTT
DMQVFWJ	MA	Inhibitor
DMQVFWJ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMQVFWJ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMN4ZKC	DI	DMN4ZKC
DMN4ZKC	DN	Paraoxon
DMN4ZKC	MI	TT1RS9F
DMN4ZKC	MN	Acetylcholinesterase (AChE)
DMN4ZKC	MT	DTT
DMN4ZKC	MA	Inhibitor
DMN4ZKC	RN	Activation of the endocannabinoid system by organophosphorus nerve agents. Nat Chem Biol. 2008 Jun;4(6):373-8.
DMN4ZKC	RU	https://pubmed.ncbi.nlm.nih.gov/18438404

DMN4ZKC	DI	DMN4ZKC
DMN4ZKC	DN	Paraoxon
DMN4ZKC	MI	TT6OEDT
DMN4ZKC	MN	Cannabinoid receptor 1 (CB1)
DMN4ZKC	MT	DTT
DMN4ZKC	MA	Inhibitor
DMN4ZKC	RN	Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5875-8.
DMN4ZKC	RU	https://pubmed.ncbi.nlm.nih.gov/18752948

DMN4ZKC	DI	DMN4ZKC
DMN4ZKC	DN	Paraoxon
DMN4ZKC	MI	TTUNARX
DMN4ZKC	MN	Carbonic anhydrase (CA)
DMN4ZKC	MT	DTT
DMN4ZKC	MA	Inhibitor
DMN4ZKC	RN	Paraoxon, 4-nitrophenyl phosphate and acetate are substrates of - but not of -, - and -carbonic anhydrases. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6208-12.
DMN4ZKC	RU	https://pubmed.ncbi.nlm.nih.gov/20833546

DMN4ZKC	DI	DMN4ZKC
DMN4ZKC	DN	Paraoxon
DMN4ZKC	MI	TTHQPL7
DMN4ZKC	MN	Carbonic anhydrase I (CA-I)
DMN4ZKC	MT	DTT
DMN4ZKC	MA	Inhibitor
DMN4ZKC	RN	Paraoxon, 4-nitrophenyl phosphate and acetate are substrates of - but not of -, - and -carbonic anhydrases. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6208-12.
DMN4ZKC	RU	https://pubmed.ncbi.nlm.nih.gov/20833546

DMN4ZKC	DI	DMN4ZKC
DMN4ZKC	DN	Paraoxon
DMN4ZKC	MI	TTANPDJ
DMN4ZKC	MN	Carbonic anhydrase II (CA-II)
DMN4ZKC	MT	DTT
DMN4ZKC	MA	Inhibitor
DMN4ZKC	RN	Paraoxon, 4-nitrophenyl phosphate and acetate are substrates of - but not of -, - and -carbonic anhydrases. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6208-12.
DMN4ZKC	RU	https://pubmed.ncbi.nlm.nih.gov/20833546

DMN4ZKC	DI	DMN4ZKC
DMN4ZKC	DN	Paraoxon
DMN4ZKC	MI	DEJGDUW
DMN4ZKC	MN	Cytochrome P450 1A2 (CYP1A2)
DMN4ZKC	MT	DME
DMN4ZKC	MA	Metabolism
DMN4ZKC	RN	Diazinon, chlorpyrifos and parathion are metabolised by multiple cytochromes P450 in human liver. Toxicology. 2006 Jul 5;224(1-2):22-32.
DMN4ZKC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16757081

DMN4ZKC	DI	DMN4ZKC
DMN4ZKC	DN	Paraoxon
DMN4ZKC	MI	DES5XRU
DMN4ZKC	MN	Cytochrome P450 2C8 (CYP2C8)
DMN4ZKC	MT	DME
DMN4ZKC	MA	Metabolism
DMN4ZKC	RN	Diazinon, chlorpyrifos and parathion are metabolised by multiple cytochromes P450 in human liver. Toxicology. 2006 Jul 5;224(1-2):22-32.
DMN4ZKC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16757081

DMN4ZKC	DI	DMN4ZKC
DMN4ZKC	DN	Paraoxon
DMN4ZKC	MI	DEVDYN7
DMN4ZKC	MN	Cytochrome P450 2E1 (CYP2E1)
DMN4ZKC	MT	DME
DMN4ZKC	MA	Metabolism
DMN4ZKC	RN	Interaction of ethanol and the organophosphorus insecticide parathion. Biochem Pharmacol. 1995 Nov 27;50(11):1925-32.
DMN4ZKC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8615874

DMN4ZKC	DI	DMN4ZKC
DMN4ZKC	DN	Paraoxon
DMN4ZKC	MI	DE4LYSA
DMN4ZKC	MN	Cytochrome P450 3A4 (CYP3A4)
DMN4ZKC	MT	DME
DMN4ZKC	MA	Metabolism
DMN4ZKC	RN	Diazinon, chlorpyrifos and parathion are metabolised by multiple cytochromes P450 in human liver. Toxicology. 2006 Jul 5;224(1-2):22-32.
DMN4ZKC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16757081

DMN4ZKC	DI	DMN4ZKC
DMN4ZKC	DN	Paraoxon
DMN4ZKC	MI	DEIBDNY
DMN4ZKC	MN	Cytochrome P450 3A5 (CYP3A5)
DMN4ZKC	MT	DME
DMN4ZKC	MA	Metabolism
DMN4ZKC	RN	Diazinon, chlorpyrifos and parathion are metabolised by multiple cytochromes P450 in human liver. Toxicology. 2006 Jul 5;224(1-2):22-32.
DMN4ZKC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16757081

DMN4ZKC	DI	DMN4ZKC
DMN4ZKC	DN	Paraoxon
DMN4ZKC	MI	TTDP1UC
DMN4ZKC	MN	Fatty acid amide hydrolase (FAAH)
DMN4ZKC	MT	DTT
DMN4ZKC	MA	Inhibitor
DMN4ZKC	RN	Activation of the endocannabinoid system by organophosphorus nerve agents. Nat Chem Biol. 2008 Jun;4(6):373-8.
DMN4ZKC	RU	https://pubmed.ncbi.nlm.nih.gov/18438404

DMN4ZKC	DI	DMN4ZKC
DMN4ZKC	DN	Paraoxon
DMN4ZKC	MI	DESDN74
DMN4ZKC	MN	Serum paraoxonase/arylesterase 1 (PON1)
DMN4ZKC	MT	DME
DMN4ZKC	MA	Metabolism
DMN4ZKC	RN	Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos. 2000 Nov;28(11):1335-42.
DMN4ZKC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11038162

DMN4ZKC	DI	DMN4ZKC
DMN4ZKC	DN	Paraoxon
DMN4ZKC	MI	DEHJU7E
DMN4ZKC	MN	Serum paraoxonase/arylesterase 2 (PON2)
DMN4ZKC	MT	DME
DMN4ZKC	MA	Metabolism
DMN4ZKC	RN	Paraoxonases-1, -2 and -3: what are their functions? Chem Biol Interact. 2016 Nov 25;259(Pt B):51-62.
DMN4ZKC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27238723

DMR8O3X	DI	DMR8O3X
DMR8O3X	DN	Paraquat
DMR8O3X	MI	DTZGT0P
DMR8O3X	MN	Multidrug and toxin extrusion protein 1 (SLC47A1)
DMR8O3X	MT	DTP
DMR8O3X	MA	Substrate
DMR8O3X	RN	Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function. Pharmacogenomics J. 2009 Apr;9(2):127-36.
DMR8O3X	RU	http://www.ncbi.nlm.nih.gov/pubmed/19172157

DMR8O3X	DI	DMR8O3X
DMR8O3X	DN	Paraquat
DMR8O3X	MI	DTUGYRD
DMR8O3X	MN	P-glycoprotein 1 (ABCB1)
DMR8O3X	MT	DTP
DMR8O3X	MA	Substrate
DMR8O3X	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMR8O3X	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DM83C9N	DI	DM83C9N
DM83C9N	DN	Para-sirtinol
DM83C9N	MI	TTUF2HO
DM83C9N	MN	NAD-dependent deacetylase sirtuin-1 (SIRT1)
DM83C9N	MT	DTT
DM83C9N	MA	Inhibitor
DM83C9N	RN	Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (Sirtuin) inhibitors. J Med Chem. 2005 Dec 1;48(24):7789-95.
DM83C9N	RU	https://pubmed.ncbi.nlm.nih.gov/16302818

DMKJY3U	DI	DMKJY3U
DMKJY3U	DN	parathyroid hormone
DMKJY3U	MI	TT6F7GZ
DMKJY3U	MN	Parathyroid hormone (PTH)
DMKJY3U	MT	DTT
DMKJY3U	MA	Modulator
DMKJY3U	RN	Daily parathyroid hormone 1-34 replacement therapy for hypoparathyroidism induces marked changes in bone turnover and structure.J Bone Miner Res.2012 Aug;27(8):1811-20.
DMKJY3U	RU	https://www.ncbi.nlm.nih.gov/pubmed/22492501

DMWVPSM	DI	DMWVPSM
DMWVPSM	DN	PARCETASAL
DMWVPSM	MI	TTGSRBC
DMWVPSM	MN	Prostaglandin synthetase (PGS)
DMWVPSM	MT	DTT
DMWVPSM	MA	Modulator
DMWVPSM	RN	Paracetamol effectively reduces prostaglandin E2 synthesis in brain macrophages by inhibiting enzymatic activity of cyclooxygenase but not phospholipase and prostaglandin E synthase. J Neurosci Res. 2003 Mar 15;71(6):844-52.
DMWVPSM	RU	https://pubmed.ncbi.nlm.nih.gov/12605411

DMVI8R2	DI	DMVI8R2
DMVI8R2	DN	Parke-Davis 1
DMVI8R2	MI	TTXHYV6
DMVI8R2	MN	Voltage-gated L-type calcium channel (L-CaC)
DMVI8R2	MT	DTT
DMVI8R2	MA	Blocker
DMVI8R2	RN	Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95.
DMVI8R2	RU	https://pubmed.ncbi.nlm.nih.gov/19442208

DMMQY42	DI	DMMQY42
DMMQY42	DN	Parke-Davis 9
DMMQY42	MI	TTXHYV6
DMMQY42	MN	Voltage-gated L-type calcium channel (L-CaC)
DMMQY42	MT	DTT
DMMQY42	MA	Blocker
DMMQY42	RN	Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95.
DMMQY42	RU	https://pubmed.ncbi.nlm.nih.gov/19442208

DML8BT7	DI	DML8BT7
DML8BT7	DN	PAS219
DML8BT7	MI	TT6PKBN
DML8BT7	MN	Proto-oncogene c-Src (SRC)
DML8BT7	MT	DTT
DML8BT7	MA	Inhibitor
DML8BT7	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DML8BT7	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM7Y0G6	DI	DM7Y0G6
DM7Y0G6	DN	PASBN
DM7Y0G6	MI	TT6PKBN
DM7Y0G6	MN	Proto-oncogene c-Src (SRC)
DM7Y0G6	MT	DTT
DM7Y0G6	MA	Inhibitor
DM7Y0G6	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM7Y0G6	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMRJ104	DI	DMRJ104
DMRJ104	DN	PAT5A
DMRJ104	MI	TTT2SVW
DMRJ104	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DMRJ104	MT	DTT
DMRJ104	MA	Agonist
DMRJ104	RN	Euglycemic and hypolipidemic activity of PAT5A: a unique thiazolidinedione with weak peroxisome proliferator activated receptor gamma activity. Metabolism. 2000 Nov;49(11):1417-23.
DMRJ104	RU	https://pubmed.ncbi.nlm.nih.gov/11092504

DMOXNYQ	DI	DMOXNYQ
DMOXNYQ	DN	Patuletin 3-O-beta-D-galactoside
DMOXNYQ	MI	TTFBNVI
DMOXNYQ	MN	Aldose reductase (AKR1B1)
DMOXNYQ	MT	DTT
DMOXNYQ	MA	Inhibitor
DMOXNYQ	RN	Flavonoids with anti-cataract activity from Brickellia arguta. J Nat Prod. 1984 Mar-Apr;47(2):316-9.
DMOXNYQ	RU	https://pubmed.ncbi.nlm.nih.gov/6429283

DMZ5Q7J	DI	DMZ5Q7J
DMZ5Q7J	DN	Patuletin 3-O-beta-D-robinobioside
DMZ5Q7J	MI	TTFBNVI
DMZ5Q7J	MN	Aldose reductase (AKR1B1)
DMZ5Q7J	MT	DTT
DMZ5Q7J	MA	Inhibitor
DMZ5Q7J	RN	Flavonoids with anti-cataract activity from Brickellia arguta. J Nat Prod. 1984 Mar-Apr;47(2):316-9.
DMZ5Q7J	RU	https://pubmed.ncbi.nlm.nih.gov/6429283

DM0RV9C	DI	DM0RV9C
DM0RV9C	DN	PATULIN
DM0RV9C	MI	TTWXB3E
DM0RV9C	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DM0RV9C	MT	DTT
DM0RV9C	MA	Inhibitor
DM0RV9C	RN	Control of hepatitis C: a medicinal chemistry perspective. J Med Chem. 2005 Jan 13;48(1):1-20.
DM0RV9C	RU	https://pubmed.ncbi.nlm.nih.gov/15633995

DMQA8N3	DI	DMQA8N3
DMQA8N3	DN	PAULLONE
DMQA8N3	MI	TTRSMW9
DMQA8N3	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMQA8N3	MT	DTT
DMQA8N3	MA	Inhibitor
DMQA8N3	RN	Discovery of potent and bioavailable GSK-3beta inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1693-6.
DMQA8N3	RU	https://pubmed.ncbi.nlm.nih.gov/20138512

DMPF2N1	DI	DMPF2N1
DMPF2N1	DN	paxilline
DMPF2N1	MI	TT1AQ50
DMPF2N1	MN	Charybdotoxin receptor beta-4 (BKbeta4)
DMPF2N1	MT	DTT
DMPF2N1	MA	Blocker (channel blocker)
DMPF2N1	RN	Paxilline inhibition of the alpha-subunit of the high-conductance calcium-activated potassium channel. Neuropharmacology. 1996;35(7):963-8.
DMPF2N1	RU	https://pubmed.ncbi.nlm.nih.gov/8938726

DMPF2N1	DI	DMPF2N1
DMPF2N1	DN	paxilline
DMPF2N1	MI	TTECBXN
DMPF2N1	MN	Oxysterols receptor LXR-alpha (NR1H3)
DMPF2N1	MT	DTT
DMPF2N1	MA	Agonist
DMPF2N1	RN	A natural product ligand of the oxysterol receptor, liver X receptor. J Pharmacol Exp Ther. 2003 Oct;307(1):291-6.
DMPF2N1	RU	https://pubmed.ncbi.nlm.nih.gov/12893846

DMX7WU9	DI	DMX7WU9
DMX7WU9	DN	PB-1120
DMX7WU9	MI	TT4O5P0
DMX7WU9	MN	Helodermin-preferring VIP receptor (VIPR2)
DMX7WU9	MT	DTT
DMX7WU9	MA	Modulator
DMX7WU9	RN	Company report (PhaseBio)
DMX7WU9	RU	http://phasebio.com/clinical-development-pipeline/pb1046-pb1120/

DMZURA2	DI	DMZURA2
DMZURA2	DN	PB-27
DMZURA2	MI	TT7WZIJ
DMZURA2	MN	CAAX farnesyltransferase beta (FNTB)
DMZURA2	MT	DTT
DMZURA2	MA	Inhibitor
DMZURA2	RN	Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. J Med Chem. 2005 Jun 2;48(11):3704-13.
DMZURA2	RU	https://pubmed.ncbi.nlm.nih.gov/15916422

DMZURA2	DI	DMZURA2
DMZURA2	DN	PB-27
DMZURA2	MI	TTXQKM3
DMZURA2	MN	Farnesyl protein transferase (Ftase)
DMZURA2	MT	DTT
DMZURA2	MA	Inhibitor
DMZURA2	RN	Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. J Med Chem. 2005 Jun 2;48(11):3704-13.
DMZURA2	RU	https://pubmed.ncbi.nlm.nih.gov/15916422

DMMNQ1B	DI	DMMNQ1B
DMMNQ1B	DN	PB28
DMMNQ1B	MI	TTTPE1L
DMMNQ1B	MN	HUMAN opioid receptor sigma 1 (OPRS1)
DMMNQ1B	MT	DTT
DMMNQ1B	MA	Modulator
DMMNQ1B	RN	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
DMMNQ1B	RU	https://www.nature.com/articles/s41586-020-2286-9

DMMNQ1B	DI	DMMNQ1B
DMMNQ1B	DN	PB28
DMMNQ1B	MI	TTIS0R2
DMMNQ1B	MN	HUMAN sigma intracellular receptor 2 (TMEM97)
DMMNQ1B	MT	DTT
DMMNQ1B	MA	Modulator
DMMNQ1B	RN	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
DMMNQ1B	RU	https://www.nature.com/articles/s41586-020-2286-9

DMSXZ19	DI	DMSXZ19
DMSXZ19	DN	PB-28
DMSXZ19	MI	TTSQIFT
DMSXZ19	MN	5-HT 1A receptor (HTR1A)
DMSXZ19	MT	DTT
DMSXZ19	MA	Inhibitor
DMSXZ19	RN	New sigma and 5-HT1A receptor ligands: omega-(tetralin-1-yl)-n-alkylamine derivatives. J Med Chem. 1996 Jan 5;39(1):176-82.
DMSXZ19	RU	https://pubmed.ncbi.nlm.nih.gov/8568804

DMAOIW5	DI	DMAOIW5
DMAOIW5	DN	PB-80
DMAOIW5	MI	TT7WZIJ
DMAOIW5	MN	CAAX farnesyltransferase beta (FNTB)
DMAOIW5	MT	DTT
DMAOIW5	MA	Inhibitor
DMAOIW5	RN	Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. J Med Chem. 2005 Jun 2;48(11):3704-13.
DMAOIW5	RU	https://pubmed.ncbi.nlm.nih.gov/15916422

DMAOIW5	DI	DMAOIW5
DMAOIW5	DN	PB-80
DMAOIW5	MI	TTXQKM3
DMAOIW5	MN	Farnesyl protein transferase (Ftase)
DMAOIW5	MT	DTT
DMAOIW5	MA	Inhibitor
DMAOIW5	RN	Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. J Med Chem. 2005 Jun 2;48(11):3704-13.
DMAOIW5	RU	https://pubmed.ncbi.nlm.nih.gov/15916422

DM9V807	DI	DM9V807
DM9V807	DN	PB-81
DM9V807	MI	TT7WZIJ
DM9V807	MN	CAAX farnesyltransferase beta (FNTB)
DM9V807	MT	DTT
DM9V807	MA	Inhibitor
DM9V807	RN	Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. J Med Chem. 2005 Jun 2;48(11):3704-13.
DM9V807	RU	https://pubmed.ncbi.nlm.nih.gov/15916422

DM9V807	DI	DM9V807
DM9V807	DN	PB-81
DM9V807	MI	TTXQKM3
DM9V807	MN	Farnesyl protein transferase (Ftase)
DM9V807	MT	DTT
DM9V807	MA	Inhibitor
DM9V807	RN	Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. J Med Chem. 2005 Jun 2;48(11):3704-13.
DM9V807	RU	https://pubmed.ncbi.nlm.nih.gov/15916422

DM39LS5	DI	DM39LS5
DM39LS5	DN	PBC-264
DM39LS5	MI	TTVFO0U
DM39LS5	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DM39LS5	MT	DTT
DM39LS5	MA	Agonist
DM39LS5	RN	His381 of the rat CCKB receptor is essential for CCKB versus CCKA receptor antagonist selectivity. Eur J Pharmacol. 1996 Jan 18;296(1):97-106.
DM39LS5	RU	https://pubmed.ncbi.nlm.nih.gov/8720482

DM1Y2F0	DI	DM1Y2F0
DM1Y2F0	DN	PBD150
DM1Y2F0	MI	TTJ7YTV
DM1Y2F0	MN	Glutaminyl cyclase (QPCT)
DM1Y2F0	MT	DTT
DM1Y2F0	MA	Inhibitor
DM1Y2F0	RN	The first potent inhibitors for human glutaminyl cyclase: synthesis and structure-activity relationship. J Med Chem. 2006 Jan 26;49(2):664-77.
DM1Y2F0	RU	https://pubmed.ncbi.nlm.nih.gov/16420052

DM8Q54I	DI	DM8Q54I
DM8Q54I	DN	PBIT
DM8Q54I	MI	TTIG67W
DM8Q54I	MN	Lysine-specific demethylase 5A (KDM5A)
DM8Q54I	MT	DTT
DM8Q54I	MA	Inhibitor
DM8Q54I	RN	Identification of small molecule inhibitors of Jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase by a sensitive high throughput screen. J Biol Chem. 2013 Mar 29;288(13):9408-17.
DM8Q54I	RU	https://pubmed.ncbi.nlm.nih.gov/23408432

DM8Q54I	DI	DM8Q54I
DM8Q54I	DN	PBIT
DM8Q54I	MI	TTCLI75
DM8Q54I	MN	Lysine-specific demethylase 5B (KDM5B)
DM8Q54I	MT	DTT
DM8Q54I	MA	Inhibitor
DM8Q54I	RN	Identification of small molecule inhibitors of Jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase by a sensitive high throughput screen. J Biol Chem. 2013 Mar 29;288(13):9408-17.
DM8Q54I	RU	https://pubmed.ncbi.nlm.nih.gov/23408432

DM8Q54I	DI	DM8Q54I
DM8Q54I	DN	PBIT
DM8Q54I	MI	TT94UCF
DM8Q54I	MN	Lysine-specific demethylase 5C (KDM5C)
DM8Q54I	MT	DTT
DM8Q54I	MA	Inhibitor
DM8Q54I	RN	Identification of small molecule inhibitors of Jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase by a sensitive high throughput screen. J Biol Chem. 2013 Mar 29;288(13):9408-17.
DM8Q54I	RU	https://pubmed.ncbi.nlm.nih.gov/23408432

DM8K7C4	DI	DM8K7C4
DM8K7C4	DN	PBMC
DM8K7C4	MI	TTXDKTO
DM8K7C4	MN	Long transient receptor potential channel 8 (TRPM8)
DM8K7C4	MT	DTT
DM8K7C4	MA	Blocker (channel blocker)
DM8K7C4	RN	Pharmacological blockade of TRPM8 ion channels alters cold and cold pain responses in mice. PLoS One. 2011;6(9):e25894.
DM8K7C4	RU	https://pubmed.ncbi.nlm.nih.gov/21984952

DMD9KYN	DI	DMD9KYN
DMD9KYN	DN	PCCG-4
DMD9KYN	MI	TTXJ47W
DMD9KYN	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMD9KYN	MT	DTT
DMD9KYN	MA	Antagonist
DMD9KYN	RN	Synthesis and pharmacological characterization of all sixteen stereoisomers of 2-(2'-carboxy-3'-phenylcyclopropyl)glycine. Focus on (2S,1'S,2'S,3'R)-2-(2'-carboxy-3'-phenylcyclopropyl)glycine, a novel and selective group II metabotropic glutamate receptors antagonist. J Med Chem. 1996 May 24;39(11):2259-69.
DMD9KYN	RU	https://pubmed.ncbi.nlm.nih.gov/8667369

DMIMPDL	DI	DMIMPDL
DMIMPDL	DN	PCI-34051
DMIMPDL	MI	TTT6LFV
DMIMPDL	MN	Histone deacetylase 8 (HDAC8)
DMIMPDL	MT	DTT
DMIMPDL	MA	Inhibitor
DMIMPDL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2619).
DMIMPDL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2619

DMGIS5Q	DI	DMGIS5Q
DMGIS5Q	DN	pCMPS
DMGIS5Q	MI	TTZ1DT0
DMGIS5Q	MN	P2Y purinoceptor 12 (P2RY12)
DMGIS5Q	MT	DTT
DMGIS5Q	MA	Antagonist
DMGIS5Q	RN	P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med. 2003 May;3(2):113-22.
DMGIS5Q	RU	https://pubmed.ncbi.nlm.nih.gov/15199474

DMGS6YH	DI	DMGS6YH
DMGS6YH	DN	PCNOTAXIME GROUP
DMGS6YH	MI	TT85JMW
DMGS6YH	MN	Bacterial Penicillin binding protein 3 (Bact mrcA)
DMGS6YH	MT	DTT
DMGS6YH	MA	Inhibitor
DMGS6YH	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMGS6YH	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMGS6YH	DI	DMGS6YH
DMGS6YH	DN	PCNOTAXIME GROUP
DMGS6YH	MI	TTHI19T
DMGS6YH	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMGS6YH	MT	DTT
DMGS6YH	MA	Inhibitor
DMGS6YH	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMGS6YH	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMGJSVD	DI	DMGJSVD
DMGJSVD	DN	P-Coumaric Acid
DMGJSVD	MI	TTUNARX
DMGJSVD	MN	Carbonic anhydrase (CA)
DMGJSVD	MT	DTT
DMGJSVD	MA	Inhibitor
DMGJSVD	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DMGJSVD	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DMGJSVD	DI	DMGJSVD
DMGJSVD	DN	P-Coumaric Acid
DMGJSVD	MI	TTHQPL7
DMGJSVD	MN	Carbonic anhydrase I (CA-I)
DMGJSVD	MT	DTT
DMGJSVD	MA	Inhibitor
DMGJSVD	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DMGJSVD	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DMGJSVD	DI	DMGJSVD
DMGJSVD	DN	P-Coumaric Acid
DMGJSVD	MI	TTANPDJ
DMGJSVD	MN	Carbonic anhydrase II (CA-II)
DMGJSVD	MT	DTT
DMGJSVD	MA	Inhibitor
DMGJSVD	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DMGJSVD	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DMGJSVD	DI	DMGJSVD
DMGJSVD	DN	P-Coumaric Acid
DMGJSVD	MI	TTZHA0O
DMGJSVD	MN	Carbonic anhydrase IV (CA-IV)
DMGJSVD	MT	DTT
DMGJSVD	MA	Inhibitor
DMGJSVD	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DMGJSVD	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DMGJSVD	DI	DMGJSVD
DMGJSVD	DN	P-Coumaric Acid
DMGJSVD	MI	TT2LVK8
DMGJSVD	MN	Carbonic anhydrase IX (CA-IX)
DMGJSVD	MT	DTT
DMGJSVD	MA	Inhibitor
DMGJSVD	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DMGJSVD	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DMGJSVD	DI	DMGJSVD
DMGJSVD	DN	P-Coumaric Acid
DMGJSVD	MI	TTCFSPE
DMGJSVD	MN	Carbonic anhydrase VI (CA-VI)
DMGJSVD	MT	DTT
DMGJSVD	MA	Inhibitor
DMGJSVD	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DMGJSVD	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DMGJSVD	DI	DMGJSVD
DMGJSVD	DN	P-Coumaric Acid
DMGJSVD	MI	TTSYM0R
DMGJSVD	MN	Carbonic anhydrase XII (CA-XII)
DMGJSVD	MT	DTT
DMGJSVD	MA	Inhibitor
DMGJSVD	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DMGJSVD	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DMGJSVD	DI	DMGJSVD
DMGJSVD	DN	P-Coumaric Acid
DMGJSVD	MI	TTEYTKG
DMGJSVD	MN	Carbonic anhydrase XIV (CA-XIV)
DMGJSVD	MT	DTT
DMGJSVD	MA	Inhibitor
DMGJSVD	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DMGJSVD	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DMZVJYL	DI	DMZVJYL
DMZVJYL	DN	PcTx1
DMZVJYL	MI	TTRJYB6
DMZVJYL	MN	Acid-sensing ion channel 1 (ASIC1)
DMZVJYL	MT	DTT
DMZVJYL	MA	Blocker
DMZVJYL	RN	Challenges in analgesic drug development. Clin Pharmacol Ther. 2009 Oct;86(4):447-50.
DMZVJYL	RU	https://pubmed.ncbi.nlm.nih.gov/19675542

DMYC51H	DI	DMYC51H
DMYC51H	DN	PD 128907
DMYC51H	MI	TTEX248
DMYC51H	MN	Dopamine D2 receptor (D2R)
DMYC51H	MT	DTT
DMYC51H	MA	Agonist
DMYC51H	RN	Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. J Pharmacol Exp Ther. 1995 Dec;275(3):1355-66.
DMYC51H	RU	https://pubmed.ncbi.nlm.nih.gov/8531103

DMYC51H	DI	DMYC51H
DMYC51H	DN	PD 128907
DMYC51H	MI	TT4C8EA
DMYC51H	MN	Dopamine D3 receptor (D3R)
DMYC51H	MT	DTT
DMYC51H	MA	Agonist
DMYC51H	RN	Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. J Pharmacol Exp Ther. 1995 Dec;275(3):1355-66.
DMYC51H	RU	https://pubmed.ncbi.nlm.nih.gov/8531103

DM5GTHE	DI	DM5GTHE
DM5GTHE	DN	PD 154740
DM5GTHE	MI	TTBPGLU
DM5GTHE	MN	Neuromedin-K receptor (TACR3)
DM5GTHE	MT	DTT
DM5GTHE	MA	Antagonist
DM5GTHE	RN	Two classes of structurally different antagonists display similar species preference for the human tachykinin neurokinin3 receptor. Mol Pharmacol. 1995 Oct;48(4):711-6.
DM5GTHE	RU	https://pubmed.ncbi.nlm.nih.gov/7476898

DM5J4NA	DI	DM5J4NA
DM5J4NA	DN	PD 165929
DM5J4NA	MI	TTHYDUM
DM5J4NA	MN	Bombesin receptor (BS)
DM5J4NA	MT	DTT
DM5J4NA	MA	Antagonist
DM5J4NA	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 38).
DM5J4NA	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=38

DMFNQEA	DI	DMFNQEA
DMFNQEA	DN	PD 168368
DMFNQEA	MI	TTHYDUM
DMFNQEA	MN	Bombesin receptor (BS)
DMFNQEA	MT	DTT
DMFNQEA	MA	Antagonist
DMFNQEA	RN	Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors. Peptides. 2009 Aug;30(8):1473-86.
DMFNQEA	RU	https://pubmed.ncbi.nlm.nih.gov/19463875

DMFNQEA	DI	DMFNQEA
DMFNQEA	DN	PD 168368
DMFNQEA	MI	TTC1MVT
DMFNQEA	MN	Gastrin-releasing peptide receptor (GRPR)
DMFNQEA	MT	DTT
DMFNQEA	MA	Antagonist
DMFNQEA	RN	Comparative pharmacology of the nonpeptide neuromedin B receptor antagonist PD 168368. J Pharmacol Exp Ther. 1999 Sep;290(3):1202-11.
DMFNQEA	RU	https://pubmed.ncbi.nlm.nih.gov/10454496

DM7AY6K	DI	DM7AY6K
DM7AY6K	DN	PD 176252
DM7AY6K	MI	TTHYDUM
DM7AY6K	MN	Bombesin receptor (BS)
DM7AY6K	MT	DTT
DM7AY6K	MA	Antagonist
DM7AY6K	RN	Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors. Peptides. 2009 Aug;30(8):1473-86.
DM7AY6K	RU	https://pubmed.ncbi.nlm.nih.gov/19463875

DM7AY6K	DI	DM7AY6K
DM7AY6K	DN	PD 176252
DM7AY6K	MI	TTC1MVT
DM7AY6K	MN	Gastrin-releasing peptide receptor (GRPR)
DM7AY6K	MT	DTT
DM7AY6K	MA	Antagonist
DM7AY6K	RN	PD 176252--the first high affinity non-peptide gastrin-releasing peptide (BB2) receptor antagonist. Bioorg Med Chem Lett. 1998 Sep 22;8(18):2589-94.
DM7AY6K	RU	https://pubmed.ncbi.nlm.nih.gov/9873586

DMD2CG9	DI	DMD2CG9
DMD2CG9	DN	PD-0166326
DMD2CG9	MI	TTGKNB4
DMD2CG9	MN	Epidermal growth factor receptor (EGFR)
DMD2CG9	MT	DTT
DMD2CG9	MA	Inhibitor
DMD2CG9	RN	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
DMD2CG9	RU	https://pubmed.ncbi.nlm.nih.gov/10974196

DMD2CG9	DI	DMD2CG9
DMD2CG9	DN	PD-0166326
DMD2CG9	MI	TTRLW2X
DMD2CG9	MN	Fibroblast growth factor receptor 1 (FGFR1)
DMD2CG9	MT	DTT
DMD2CG9	MA	Inhibitor
DMD2CG9	RN	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
DMD2CG9	RU	https://pubmed.ncbi.nlm.nih.gov/10974196

DMD2CG9	DI	DMD2CG9
DMD2CG9	DN	PD-0166326
DMD2CG9	MI	TT860QF
DMD2CG9	MN	LCK tyrosine protein kinase (LCK)
DMD2CG9	MT	DTT
DMD2CG9	MA	Inhibitor
DMD2CG9	RN	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
DMD2CG9	RU	https://pubmed.ncbi.nlm.nih.gov/10974196

DMD2CG9	DI	DMD2CG9
DMD2CG9	DN	PD-0166326
DMD2CG9	MI	TT8FYO9
DMD2CG9	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMD2CG9	MT	DTT
DMD2CG9	MA	Inhibitor
DMD2CG9	RN	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
DMD2CG9	RU	https://pubmed.ncbi.nlm.nih.gov/10974196

DMD2CG9	DI	DMD2CG9
DMD2CG9	DN	PD-0166326
DMD2CG9	MI	TTI7421
DMD2CG9	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMD2CG9	MT	DTT
DMD2CG9	MA	Inhibitor
DMD2CG9	RN	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
DMD2CG9	RU	https://pubmed.ncbi.nlm.nih.gov/10974196

DMD2CG9	DI	DMD2CG9
DMD2CG9	DN	PD-0166326
DMD2CG9	MI	TT6PKBN
DMD2CG9	MN	Proto-oncogene c-Src (SRC)
DMD2CG9	MT	DTT
DMD2CG9	MA	Inhibitor
DMD2CG9	RN	Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6872-6.
DMD2CG9	RU	https://pubmed.ncbi.nlm.nih.gov/19889540

DMD2CG9	DI	DMD2CG9
DMD2CG9	DN	PD-0166326
DMD2CG9	MI	TTQBR95
DMD2CG9	MN	Stress-activated protein kinase 2a (p38 alpha)
DMD2CG9	MT	DTT
DMD2CG9	MA	Inhibitor
DMD2CG9	RN	Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6872-6.
DMD2CG9	RU	https://pubmed.ncbi.nlm.nih.gov/19889540

DMD2CG9	DI	DMD2CG9
DMD2CG9	DN	PD-0166326
DMD2CG9	MI	TT3PJMV
DMD2CG9	MN	Tyrosine-protein kinase ABL1 (ABL)
DMD2CG9	MT	DTT
DMD2CG9	MA	Inhibitor
DMD2CG9	RN	Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6872-6.
DMD2CG9	RU	https://pubmed.ncbi.nlm.nih.gov/19889540

DMD2CG9	DI	DMD2CG9
DMD2CG9	DN	PD-0166326
DMD2CG9	MI	TTX41N9
DMD2CG9	MN	Tyrosine-protein kinase Kit (KIT)
DMD2CG9	MT	DTT
DMD2CG9	MA	Inhibitor
DMD2CG9	RN	Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6872-6.
DMD2CG9	RU	https://pubmed.ncbi.nlm.nih.gov/19889540

DMSCQ9U	DI	DMSCQ9U
DMSCQ9U	DN	PD-0173952
DMSCQ9U	MI	TTRLW2X
DMSCQ9U	MN	Fibroblast growth factor receptor 1 (FGFR1)
DMSCQ9U	MT	DTT
DMSCQ9U	MA	Inhibitor
DMSCQ9U	RN	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
DMSCQ9U	RU	https://pubmed.ncbi.nlm.nih.gov/10974196

DMSCQ9U	DI	DMSCQ9U
DMSCQ9U	DN	PD-0173952
DMSCQ9U	MI	TT860QF
DMSCQ9U	MN	LCK tyrosine protein kinase (LCK)
DMSCQ9U	MT	DTT
DMSCQ9U	MA	Inhibitor
DMSCQ9U	RN	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
DMSCQ9U	RU	https://pubmed.ncbi.nlm.nih.gov/10974196

DMSCQ9U	DI	DMSCQ9U
DMSCQ9U	DN	PD-0173952
DMSCQ9U	MI	TT8FYO9
DMSCQ9U	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMSCQ9U	MT	DTT
DMSCQ9U	MA	Inhibitor
DMSCQ9U	RN	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
DMSCQ9U	RU	https://pubmed.ncbi.nlm.nih.gov/10974196

DMSCQ9U	DI	DMSCQ9U
DMSCQ9U	DN	PD-0173952
DMSCQ9U	MI	TTI7421
DMSCQ9U	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMSCQ9U	MT	DTT
DMSCQ9U	MA	Inhibitor
DMSCQ9U	RN	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
DMSCQ9U	RU	https://pubmed.ncbi.nlm.nih.gov/10974196

DMSCQ9U	DI	DMSCQ9U
DMSCQ9U	DN	PD-0173952
DMSCQ9U	MI	TT6PKBN
DMSCQ9U	MN	Proto-oncogene c-Src (SRC)
DMSCQ9U	MT	DTT
DMSCQ9U	MA	Inhibitor
DMSCQ9U	RN	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
DMSCQ9U	RU	https://pubmed.ncbi.nlm.nih.gov/10974196

DMOZEW9	DI	DMOZEW9
DMOZEW9	DN	PD-0173955
DMOZEW9	MI	TTRLW2X
DMOZEW9	MN	Fibroblast growth factor receptor 1 (FGFR1)
DMOZEW9	MT	DTT
DMOZEW9	MA	Inhibitor
DMOZEW9	RN	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
DMOZEW9	RU	https://pubmed.ncbi.nlm.nih.gov/10974196

DMOZEW9	DI	DMOZEW9
DMOZEW9	DN	PD-0173955
DMOZEW9	MI	TTS7G69
DMOZEW9	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMOZEW9	MT	DTT
DMOZEW9	MA	Inhibitor
DMOZEW9	RN	Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and hom... J Med Chem. 2006 Sep 21;49(19):5759-68.
DMOZEW9	RU	https://pubmed.ncbi.nlm.nih.gov/16970400

DMOZEW9	DI	DMOZEW9
DMOZEW9	DN	PD-0173955
DMOZEW9	MI	TT860QF
DMOZEW9	MN	LCK tyrosine protein kinase (LCK)
DMOZEW9	MT	DTT
DMOZEW9	MA	Inhibitor
DMOZEW9	RN	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
DMOZEW9	RU	https://pubmed.ncbi.nlm.nih.gov/10974196

DMOZEW9	DI	DMOZEW9
DMOZEW9	DN	PD-0173955
DMOZEW9	MI	TT8FYO9
DMOZEW9	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMOZEW9	MT	DTT
DMOZEW9	MA	Inhibitor
DMOZEW9	RN	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
DMOZEW9	RU	https://pubmed.ncbi.nlm.nih.gov/10974196

DMOZEW9	DI	DMOZEW9
DMOZEW9	DN	PD-0173955
DMOZEW9	MI	TTI7421
DMOZEW9	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMOZEW9	MT	DTT
DMOZEW9	MA	Inhibitor
DMOZEW9	RN	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
DMOZEW9	RU	https://pubmed.ncbi.nlm.nih.gov/10974196

DMOZEW9	DI	DMOZEW9
DMOZEW9	DN	PD-0173955
DMOZEW9	MI	TT6PKBN
DMOZEW9	MN	Proto-oncogene c-Src (SRC)
DMOZEW9	MT	DTT
DMOZEW9	MA	Inhibitor
DMOZEW9	RN	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
DMOZEW9	RU	https://pubmed.ncbi.nlm.nih.gov/10974196

DM8RW92	DI	DM8RW92
DM8RW92	DN	PD-0173956
DM8RW92	MI	TTGKNB4
DM8RW92	MN	Epidermal growth factor receptor (EGFR)
DM8RW92	MT	DTT
DM8RW92	MA	Inhibitor
DM8RW92	RN	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
DM8RW92	RU	https://pubmed.ncbi.nlm.nih.gov/10974196

DM8RW92	DI	DM8RW92
DM8RW92	DN	PD-0173956
DM8RW92	MI	TTRLW2X
DM8RW92	MN	Fibroblast growth factor receptor 1 (FGFR1)
DM8RW92	MT	DTT
DM8RW92	MA	Inhibitor
DM8RW92	RN	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
DM8RW92	RU	https://pubmed.ncbi.nlm.nih.gov/10974196

DM8RW92	DI	DM8RW92
DM8RW92	DN	PD-0173956
DM8RW92	MI	TT860QF
DM8RW92	MN	LCK tyrosine protein kinase (LCK)
DM8RW92	MT	DTT
DM8RW92	MA	Inhibitor
DM8RW92	RN	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
DM8RW92	RU	https://pubmed.ncbi.nlm.nih.gov/10974196

DM8RW92	DI	DM8RW92
DM8RW92	DN	PD-0173956
DM8RW92	MI	TT8FYO9
DM8RW92	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DM8RW92	MT	DTT
DM8RW92	MA	Inhibitor
DM8RW92	RN	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
DM8RW92	RU	https://pubmed.ncbi.nlm.nih.gov/10974196

DM8RW92	DI	DM8RW92
DM8RW92	DN	PD-0173956
DM8RW92	MI	TTI7421
DM8RW92	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM8RW92	MT	DTT
DM8RW92	MA	Inhibitor
DM8RW92	RN	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
DM8RW92	RU	https://pubmed.ncbi.nlm.nih.gov/10974196

DM8RW92	DI	DM8RW92
DM8RW92	DN	PD-0173956
DM8RW92	MI	TT6PKBN
DM8RW92	MN	Proto-oncogene c-Src (SRC)
DM8RW92	MT	DTT
DM8RW92	MA	Inhibitor
DM8RW92	RN	Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6872-6.
DM8RW92	RU	https://pubmed.ncbi.nlm.nih.gov/19889540

DM8RW92	DI	DM8RW92
DM8RW92	DN	PD-0173956
DM8RW92	MI	TTQBR95
DM8RW92	MN	Stress-activated protein kinase 2a (p38 alpha)
DM8RW92	MT	DTT
DM8RW92	MA	Inhibitor
DM8RW92	RN	Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6872-6.
DM8RW92	RU	https://pubmed.ncbi.nlm.nih.gov/19889540

DM8RW92	DI	DM8RW92
DM8RW92	DN	PD-0173956
DM8RW92	MI	TT3PJMV
DM8RW92	MN	Tyrosine-protein kinase ABL1 (ABL)
DM8RW92	MT	DTT
DM8RW92	MA	Inhibitor
DM8RW92	RN	Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6872-6.
DM8RW92	RU	https://pubmed.ncbi.nlm.nih.gov/19889540

DM8RW92	DI	DM8RW92
DM8RW92	DN	PD-0173956
DM8RW92	MI	TTX41N9
DM8RW92	MN	Tyrosine-protein kinase Kit (KIT)
DM8RW92	MT	DTT
DM8RW92	MA	Inhibitor
DM8RW92	RN	Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6872-6.
DM8RW92	RU	https://pubmed.ncbi.nlm.nih.gov/19889540

DMZQ8YV	DI	DMZQ8YV
DMZQ8YV	DN	PD-0173958
DMZQ8YV	MI	TTRLW2X
DMZQ8YV	MN	Fibroblast growth factor receptor 1 (FGFR1)
DMZQ8YV	MT	DTT
DMZQ8YV	MA	Inhibitor
DMZQ8YV	RN	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
DMZQ8YV	RU	https://pubmed.ncbi.nlm.nih.gov/10974196

DMZQ8YV	DI	DMZQ8YV
DMZQ8YV	DN	PD-0173958
DMZQ8YV	MI	TT860QF
DMZQ8YV	MN	LCK tyrosine protein kinase (LCK)
DMZQ8YV	MT	DTT
DMZQ8YV	MA	Inhibitor
DMZQ8YV	RN	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
DMZQ8YV	RU	https://pubmed.ncbi.nlm.nih.gov/10974196

DMZQ8YV	DI	DMZQ8YV
DMZQ8YV	DN	PD-0173958
DMZQ8YV	MI	TT8FYO9
DMZQ8YV	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMZQ8YV	MT	DTT
DMZQ8YV	MA	Inhibitor
DMZQ8YV	RN	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
DMZQ8YV	RU	https://pubmed.ncbi.nlm.nih.gov/10974196

DMZQ8YV	DI	DMZQ8YV
DMZQ8YV	DN	PD-0173958
DMZQ8YV	MI	TTI7421
DMZQ8YV	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMZQ8YV	MT	DTT
DMZQ8YV	MA	Inhibitor
DMZQ8YV	RN	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
DMZQ8YV	RU	https://pubmed.ncbi.nlm.nih.gov/10974196

DMZQ8YV	DI	DMZQ8YV
DMZQ8YV	DN	PD-0173958
DMZQ8YV	MI	TT6PKBN
DMZQ8YV	MN	Proto-oncogene c-Src (SRC)
DMZQ8YV	MT	DTT
DMZQ8YV	MA	Inhibitor
DMZQ8YV	RN	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
DMZQ8YV	RU	https://pubmed.ncbi.nlm.nih.gov/10974196

DMKO8LE	DI	DMKO8LE
DMKO8LE	DN	PD-0179483
DMKO8LE	MI	TTRLW2X
DMKO8LE	MN	Fibroblast growth factor receptor 1 (FGFR1)
DMKO8LE	MT	DTT
DMKO8LE	MA	Inhibitor
DMKO8LE	RN	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
DMKO8LE	RU	https://pubmed.ncbi.nlm.nih.gov/10974196

DMKO8LE	DI	DMKO8LE
DMKO8LE	DN	PD-0179483
DMKO8LE	MI	TT860QF
DMKO8LE	MN	LCK tyrosine protein kinase (LCK)
DMKO8LE	MT	DTT
DMKO8LE	MA	Inhibitor
DMKO8LE	RN	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
DMKO8LE	RU	https://pubmed.ncbi.nlm.nih.gov/10974196

DMKO8LE	DI	DMKO8LE
DMKO8LE	DN	PD-0179483
DMKO8LE	MI	TT8FYO9
DMKO8LE	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMKO8LE	MT	DTT
DMKO8LE	MA	Inhibitor
DMKO8LE	RN	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
DMKO8LE	RU	https://pubmed.ncbi.nlm.nih.gov/10974196

DMKO8LE	DI	DMKO8LE
DMKO8LE	DN	PD-0179483
DMKO8LE	MI	TTI7421
DMKO8LE	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMKO8LE	MT	DTT
DMKO8LE	MA	Inhibitor
DMKO8LE	RN	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
DMKO8LE	RU	https://pubmed.ncbi.nlm.nih.gov/10974196

DMKO8LE	DI	DMKO8LE
DMKO8LE	DN	PD-0179483
DMKO8LE	MI	TT6PKBN
DMKO8LE	MN	Proto-oncogene c-Src (SRC)
DMKO8LE	MT	DTT
DMKO8LE	MA	Inhibitor
DMKO8LE	RN	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
DMKO8LE	RU	https://pubmed.ncbi.nlm.nih.gov/10974196

DM8QMJ1	DI	DM8QMJ1
DM8QMJ1	DN	PD-068235
DM8QMJ1	MI	TTT2SVW
DM8QMJ1	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DM8QMJ1	MT	DTT
DM8QMJ1	MA	Inhibitor
DM8QMJ1	RN	Tryptophan-containing dipeptide derivatives as potent PPARgamma antagonists: design, synthesis, biological evaluation, and molecular modeling. Eur J Med Chem. 2008 Dec;43(12):2699-716.
DM8QMJ1	RU	https://pubmed.ncbi.nlm.nih.gov/18329752

DMQ4LRZ	DI	DMQ4LRZ
DMQ4LRZ	DN	PD-115199
DMQ4LRZ	MI	TTK25J1
DMQ4LRZ	MN	Adenosine A1 receptor (ADORA1)
DMQ4LRZ	MT	DTT
DMQ4LRZ	MA	Inhibitor
DMQ4LRZ	RN	(E)-1,3-dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: potent and selective adenosine A2 antagonists. J Med Chem. 1992 Jun 12;35(12):2342-5.
DMQ4LRZ	RU	https://pubmed.ncbi.nlm.nih.gov/1613758

DMQ4LRZ	DI	DMQ4LRZ
DMQ4LRZ	DN	PD-115199
DMQ4LRZ	MI	TTM2AOE
DMQ4LRZ	MN	Adenosine A2a receptor (ADORA2A)
DMQ4LRZ	MT	DTT
DMQ4LRZ	MA	Inhibitor
DMQ4LRZ	RN	(E)-1,3-dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: potent and selective adenosine A2 antagonists. J Med Chem. 1992 Jun 12;35(12):2342-5.
DMQ4LRZ	RU	https://pubmed.ncbi.nlm.nih.gov/1613758

DMQ4LRZ	DI	DMQ4LRZ
DMQ4LRZ	DN	PD-115199
DMQ4LRZ	MI	TTNE7KG
DMQ4LRZ	MN	Adenosine A2b receptor (ADORA2B)
DMQ4LRZ	MT	DTT
DMQ4LRZ	MA	Inhibitor
DMQ4LRZ	RN	(E)-1,3-dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: potent and selective adenosine A2 antagonists. J Med Chem. 1992 Jun 12;35(12):2342-5.
DMQ4LRZ	RU	https://pubmed.ncbi.nlm.nih.gov/1613758

DM3KAY5	DI	DM3KAY5
DM3KAY5	DN	PD-117558
DM3KAY5	MI	TTN6J5F
DM3KAY5	MN	Bacterial DNA gyrase (Bact gyrase)
DM3KAY5	MT	DTT
DM3KAY5	MA	Modulator
DM3KAY5	RN	1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids.New quantitative structure-activity relationships at N1 for the quinolone antibacterials.J Med Chem.1988 May;31(5):991-1001.
DM3KAY5	RU	https://www.ncbi.nlm.nih.gov/pubmed/2834557

DM0E4OW	DI	DM0E4OW
DM0E4OW	DN	PD-118057
DM0E4OW	MI	TTQ6VDM
DM0E4OW	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DM0E4OW	MT	DTT
DM0E4OW	MA	Activator
DM0E4OW	RN	Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity. Mol Pharmacol. 2005 Sep;68(3):876-84.
DM0E4OW	RU	https://pubmed.ncbi.nlm.nih.gov/15976038

DM4OQZX	DI	DM4OQZX
DM4OQZX	DN	PD123177
DM4OQZX	MI	TTQVOEI
DM4OQZX	MN	Angiotensin II receptor type-2 (AGTR2)
DM4OQZX	MT	DTT
DM4OQZX	MA	Antagonist
DM4OQZX	RN	Two distinct angiotensin II receptor binding sites in rat adrenal revealed by new selective nonpeptide ligands. Mol Pharmacol. 1990 Mar;37(3):347-51.
DM4OQZX	RU	https://pubmed.ncbi.nlm.nih.gov/2314387

DMV1F7U	DI	DMV1F7U
DMV1F7U	DN	PD-128763
DMV1F7U	MI	TTVDSZ0
DMV1F7U	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMV1F7U	MT	DTT
DMV1F7U	MA	Inhibitor
DMV1F7U	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMV1F7U	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMYEFAV	DI	DMYEFAV
DMYEFAV	DN	PD-135111
DMYEFAV	MI	TTEX248
DMYEFAV	MN	Dopamine D2 receptor (D2R)
DMYEFAV	MT	DTT
DMYEFAV	MA	Inhibitor
DMYEFAV	RN	Synthesis and pharmacological evaluation of the enantiomers of the dopamine autoreceptor agonist PD 135385, Bioorg. Med. Chem. Lett. 3(4):639-644 (1993).
DMYEFAV	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01812452

DMUTEWI	DI	DMUTEWI
DMUTEWI	DN	PD-135118
DMUTEWI	MI	TTCG0AL
DMUTEWI	MN	Cholecystokinin receptor type A (CCKAR)
DMUTEWI	MT	DTT
DMUTEWI	MA	Inhibitor
DMUTEWI	RN	Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class, Bioorg. Med. Chem. Lett. 3(5):881-884 (1993).
DMUTEWI	RU	http://www.sciencedirect.com/science/article/pii/S0960894X0080685X

DMUTEWI	DI	DMUTEWI
DMUTEWI	DN	PD-135118
DMUTEWI	MI	TTVFO0U
DMUTEWI	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMUTEWI	MT	DTT
DMUTEWI	MA	Inhibitor
DMUTEWI	RN	Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class, Bioorg. Med. Chem. Lett. 3(5):881-884 (1993).
DMUTEWI	RU	http://www.sciencedirect.com/science/article/pii/S0960894X0080685X

DMZ4LDC	DI	DMZ4LDC
DMZ4LDC	DN	PD-135146
DMZ4LDC	MI	TTEX248
DMZ4LDC	MN	Dopamine D2 receptor (D2R)
DMZ4LDC	MT	DTT
DMZ4LDC	MA	Inhibitor
DMZ4LDC	RN	Synthesis and pharmacological evaluation of the enantiomers of the dopamine autoreceptor agonist PD 135385, Bioorg. Med. Chem. Lett. 3(4):639-644 (1993).
DMZ4LDC	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01812452

DMA7YJV	DI	DMA7YJV
DMA7YJV	DN	PD-135158
DMA7YJV	MI	TTCG0AL
DMA7YJV	MN	Cholecystokinin receptor type A (CCKAR)
DMA7YJV	MT	DTT
DMA7YJV	MA	Antagonist
DMA7YJV	RN	Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci U S A. 1990 Sep;87(17):6728-32.
DMA7YJV	RU	https://pubmed.ncbi.nlm.nih.gov/1975695

DMA7YJV	DI	DMA7YJV
DMA7YJV	DN	PD-135158
DMA7YJV	MI	TTVFO0U
DMA7YJV	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMA7YJV	MT	DTT
DMA7YJV	MA	Antagonist
DMA7YJV	RN	Pharmacological characterization of a Chinese hamster ovary cell line transfected with the human CCK-B receptor gene. Neuropeptides. 1996 Aug;30(4):359-63.
DMA7YJV	RU	https://pubmed.ncbi.nlm.nih.gov/8914862

DMSHBLF	DI	DMSHBLF
DMSHBLF	DN	PD-135188
DMSHBLF	MI	TTEX248
DMSHBLF	MN	Dopamine D2 receptor (D2R)
DMSHBLF	MT	DTT
DMSHBLF	MA	Inhibitor
DMSHBLF	RN	Synthesis and pharmacological evaluation of the enantiomers of the dopamine autoreceptor agonist PD 135385, Bioorg. Med. Chem. Lett. 3(4):639-644 (1993).
DMSHBLF	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01812452

DM0LTNJ	DI	DM0LTNJ
DM0LTNJ	DN	PD-135222
DM0LTNJ	MI	TTEX248
DM0LTNJ	MN	Dopamine D2 receptor (D2R)
DM0LTNJ	MT	DTT
DM0LTNJ	MA	Inhibitor
DM0LTNJ	RN	Synthesis and pharmacological evaluation of the enantiomers of the dopamine autoreceptor agonist PD 135385, Bioorg. Med. Chem. Lett. 3(4):639-644 (1993).
DM0LTNJ	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01812452

DMX294V	DI	DMX294V
DMX294V	DN	PD-135385
DMX294V	MI	TTEX248
DMX294V	MN	Dopamine D2 receptor (D2R)
DMX294V	MT	DTT
DMX294V	MA	Inhibitor
DMX294V	RN	Synthesis and pharmacological evaluation of the enantiomers of the dopamine autoreceptor agonist PD 135385, Bioorg. Med. Chem. Lett. 3(4):639-644 (1993).
DMX294V	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01812452

DM56PBI	DI	DM56PBI
DM56PBI	DN	PD-135478
DM56PBI	MI	TTEX248
DM56PBI	MN	Dopamine D2 receptor (D2R)
DM56PBI	MT	DTT
DM56PBI	MA	Inhibitor
DM56PBI	RN	Synthesis and pharmacological evaluation of the enantiomers of the dopamine autoreceptor agonist PD 135385, Bioorg. Med. Chem. Lett. 3(4):639-644 (1993).
DM56PBI	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01812452

DMI4MPZ	DI	DMI4MPZ
DMI4MPZ	DN	PD-135540
DMI4MPZ	MI	TTEX248
DMI4MPZ	MN	Dopamine D2 receptor (D2R)
DMI4MPZ	MT	DTT
DMI4MPZ	MA	Inhibitor
DMI4MPZ	RN	Synthesis and pharmacological evaluation of the enantiomers of the dopamine autoreceptor agonist PD 135385, Bioorg. Med. Chem. Lett. 3(4):639-644 (1993).
DMI4MPZ	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01812452

DM8N3RB	DI	DM8N3RB
DM8N3RB	DN	PD-136621
DM8N3RB	MI	TTCG0AL
DM8N3RB	MN	Cholecystokinin receptor type A (CCKAR)
DM8N3RB	MT	DTT
DM8N3RB	MA	Inhibitor
DM8N3RB	RN	Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class, Bioorg. Med. Chem. Lett. 3(5):881-884 (1993).
DM8N3RB	RU	http://www.sciencedirect.com/science/article/pii/S0960894X0080685X

DM8N3RB	DI	DM8N3RB
DM8N3RB	DN	PD-136621
DM8N3RB	MI	TTVFO0U
DM8N3RB	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DM8N3RB	MT	DTT
DM8N3RB	MA	Inhibitor
DM8N3RB	RN	Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class, Bioorg. Med. Chem. Lett. 3(5):881-884 (1993).
DM8N3RB	RU	http://www.sciencedirect.com/science/article/pii/S0960894X0080685X

DMJWK0T	DI	DMJWK0T
DMJWK0T	DN	PD-137337
DMJWK0T	MI	TTCG0AL
DMJWK0T	MN	Cholecystokinin receptor type A (CCKAR)
DMJWK0T	MT	DTT
DMJWK0T	MA	Inhibitor
DMJWK0T	RN	Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class, Bioorg. Med. Chem. Lett. 3(5):881-884 (1993).
DMJWK0T	RU	http://www.sciencedirect.com/science/article/pii/S0960894X0080685X

DMJWK0T	DI	DMJWK0T
DMJWK0T	DN	PD-137337
DMJWK0T	MI	TTVFO0U
DMJWK0T	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMJWK0T	MT	DTT
DMJWK0T	MA	Inhibitor
DMJWK0T	RN	Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class, Bioorg. Med. Chem. Lett. 3(5):881-884 (1993).
DMJWK0T	RU	http://www.sciencedirect.com/science/article/pii/S0960894X0080685X

DMH2OV9	DI	DMH2OV9
DMH2OV9	DN	PD-137342
DMH2OV9	MI	TTCG0AL
DMH2OV9	MN	Cholecystokinin receptor type A (CCKAR)
DMH2OV9	MT	DTT
DMH2OV9	MA	Inhibitor
DMH2OV9	RN	Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class, Bioorg. Med. Chem. Lett. 3(5):881-884 (1993).
DMH2OV9	RU	http://www.sciencedirect.com/science/article/pii/S0960894X0080685X

DMH2OV9	DI	DMH2OV9
DMH2OV9	DN	PD-137342
DMH2OV9	MI	TTVFO0U
DMH2OV9	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMH2OV9	MT	DTT
DMH2OV9	MA	Inhibitor
DMH2OV9	RN	Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class, Bioorg. Med. Chem. Lett. 3(5):881-884 (1993).
DMH2OV9	RU	http://www.sciencedirect.com/science/article/pii/S0960894X0080685X

DM9ZK6L	DI	DM9ZK6L
DM9ZK6L	DN	PD-137789
DM9ZK6L	MI	TTEX248
DM9ZK6L	MN	Dopamine D2 receptor (D2R)
DM9ZK6L	MT	DTT
DM9ZK6L	MA	Inhibitor
DM9ZK6L	RN	Synthesis and pharmacological evaluation of the enantiomers of the dopamine autoreceptor agonist PD 135385, Bioorg. Med. Chem. Lett. 3(4):639-644 (1993).
DM9ZK6L	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01812452

DMYMFSE	DI	DMYMFSE
DMYMFSE	DN	PD-137821
DMYMFSE	MI	TTEX248
DMYMFSE	MN	Dopamine D2 receptor (D2R)
DMYMFSE	MT	DTT
DMYMFSE	MA	Inhibitor
DMYMFSE	RN	Synthesis and pharmacological evaluation of the enantiomers of the dopamine autoreceptor agonist PD 135385, Bioorg. Med. Chem. Lett. 3(4):639-644 (1993).
DMYMFSE	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01812452

DMLVRU7	DI	DMLVRU7
DMLVRU7	DN	PD-138915
DMLVRU7	MI	TTCG0AL
DMLVRU7	MN	Cholecystokinin receptor type A (CCKAR)
DMLVRU7	MT	DTT
DMLVRU7	MA	Inhibitor
DMLVRU7	RN	Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class, Bioorg. Med. Chem. Lett. 3(5):881-884 (1993).
DMLVRU7	RU	http://www.sciencedirect.com/science/article/pii/S0960894X0080685X

DMLVRU7	DI	DMLVRU7
DMLVRU7	DN	PD-138915
DMLVRU7	MI	TTVFO0U
DMLVRU7	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMLVRU7	MT	DTT
DMLVRU7	MA	Inhibitor
DMLVRU7	RN	Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class, Bioorg. Med. Chem. Lett. 3(5):881-884 (1993).
DMLVRU7	RU	http://www.sciencedirect.com/science/article/pii/S0960894X0080685X

DMIAFN5	DI	DMIAFN5
DMIAFN5	DN	PD-138916
DMIAFN5	MI	TTCG0AL
DMIAFN5	MN	Cholecystokinin receptor type A (CCKAR)
DMIAFN5	MT	DTT
DMIAFN5	MA	Inhibitor
DMIAFN5	RN	Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class, Bioorg. Med. Chem. Lett. 3(5):881-884 (1993).
DMIAFN5	RU	http://www.sciencedirect.com/science/article/pii/S0960894X0080685X

DMIAFN5	DI	DMIAFN5
DMIAFN5	DN	PD-138916
DMIAFN5	MI	TTVFO0U
DMIAFN5	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMIAFN5	MT	DTT
DMIAFN5	MA	Inhibitor
DMIAFN5	RN	Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class, Bioorg. Med. Chem. Lett. 3(5):881-884 (1993).
DMIAFN5	RU	http://www.sciencedirect.com/science/article/pii/S0960894X0080685X

DMUG2L9	DI	DMUG2L9
DMUG2L9	DN	PD-138917
DMUG2L9	MI	TTVFO0U
DMUG2L9	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMUG2L9	MT	DTT
DMUG2L9	MA	Inhibitor
DMUG2L9	RN	Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class, Bioorg. Med. Chem. Lett. 3(5):881-884 (1993).
DMUG2L9	RU	http://www.sciencedirect.com/science/article/pii/S0960894X0080685X

DMF86P3	DI	DMF86P3
DMF86P3	DN	PD-140547
DMF86P3	MI	TTCG0AL
DMF86P3	MN	Cholecystokinin receptor type A (CCKAR)
DMF86P3	MT	DTT
DMF86P3	MA	Inhibitor
DMF86P3	RN	Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class, Bioorg. Med. Chem. Lett. 3(5):881-884 (1993).
DMF86P3	RU	http://www.sciencedirect.com/science/article/pii/S0960894X0080685X

DMF86P3	DI	DMF86P3
DMF86P3	DN	PD-140547
DMF86P3	MI	TTVFO0U
DMF86P3	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMF86P3	MT	DTT
DMF86P3	MA	Inhibitor
DMF86P3	RN	Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class, Bioorg. Med. Chem. Lett. 3(5):881-884 (1993).
DMF86P3	RU	http://www.sciencedirect.com/science/article/pii/S0960894X0080685X

DMNO2EP	DI	DMNO2EP
DMNO2EP	DN	PD-140548
DMNO2EP	MI	TTCG0AL
DMNO2EP	MN	Cholecystokinin receptor type A (CCKAR)
DMNO2EP	MT	DTT
DMNO2EP	MA	Inhibitor
DMNO2EP	RN	Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class, Bioorg. Med. Chem. Lett. 3(5):881-884 (1993).
DMNO2EP	RU	http://www.sciencedirect.com/science/article/pii/S0960894X0080685X

DMNO2EP	DI	DMNO2EP
DMNO2EP	DN	PD-140548
DMNO2EP	MI	TTVFO0U
DMNO2EP	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMNO2EP	MT	DTT
DMNO2EP	MA	Inhibitor
DMNO2EP	RN	Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class, Bioorg. Med. Chem. Lett. 3(5):881-884 (1993).
DMNO2EP	RU	http://www.sciencedirect.com/science/article/pii/S0960894X0080685X

DMWTOJN	DI	DMWTOJN
DMWTOJN	DN	PD-140723
DMWTOJN	MI	TTCG0AL
DMWTOJN	MN	Cholecystokinin receptor type A (CCKAR)
DMWTOJN	MT	DTT
DMWTOJN	MA	Inhibitor
DMWTOJN	RN	Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class, Bioorg. Med. Chem. Lett. 3(5):881-884 (1993).
DMWTOJN	RU	http://www.sciencedirect.com/science/article/pii/S0960894X0080685X

DMWTOJN	DI	DMWTOJN
DMWTOJN	DN	PD-140723
DMWTOJN	MI	TTVFO0U
DMWTOJN	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMWTOJN	MT	DTT
DMWTOJN	MA	Inhibitor
DMWTOJN	RN	Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class, Bioorg. Med. Chem. Lett. 3(5):881-884 (1993).
DMWTOJN	RU	http://www.sciencedirect.com/science/article/pii/S0960894X0080685X

DMJKH28	DI	DMJKH28
DMJKH28	DN	PD-144418
DMJKH28	MI	TTTPE1L
DMJKH28	MN	HUMAN opioid receptor sigma 1 (OPRS1)
DMJKH28	MT	DTT
DMJKH28	MA	Antagonist
DMJKH28	RN	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
DMJKH28	RU	https://www.nature.com/articles/s41586-020-2286-9

DM03526	DI	DM03526
DM03526	DN	PD-144550
DM03526	MI	TTFK1JQ
DM03526	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DM03526	MT	DTT
DM03526	MA	Inhibitor
DM03526	RN	Enantioselective synthesis of PD144723: a potent stereospecific anticonvulsant, Bioorg. Med. Chem. Lett. 4(6):823-826 (1994).
DM03526	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01808556

DM03526	DI	DM03526
DM03526	DN	PD-144550
DM03526	MI	TTU8P3M
DM03526	MN	Voltage-gated calcium channel alpha-2/delta-2 (CACNA2D2)
DM03526	MT	DTT
DM03526	MA	Inhibitor
DM03526	RN	Enantioselective synthesis of PD144723: a potent stereospecific anticonvulsant, Bioorg. Med. Chem. Lett. 4(6):823-826 (1994).
DM03526	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01808556

DM03526	DI	DM03526
DM03526	DN	PD-144550
DM03526	MI	TTN7T29
DM03526	MN	Voltage-gated calcium channel alpha-2/delta-3 (CACNA2D3)
DM03526	MT	DTT
DM03526	MA	Inhibitor
DM03526	RN	Enantioselective synthesis of PD144723: a potent stereospecific anticonvulsant, Bioorg. Med. Chem. Lett. 4(6):823-826 (1994).
DM03526	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01808556

DMP65EI	DI	DMP65EI
DMP65EI	DN	PD-149164
DMP65EI	MI	TTVFO0U
DMP65EI	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMP65EI	MT	DTT
DMP65EI	MA	Antagonist
DMP65EI	RN	Cholecystokinin B antagonists. Synthesis and quantitative structure-activity relationships of a series of C-terminal analogues of CI-988. Bioorg Med Chem. 1996 Oct;4(10):1733-45.
DMP65EI	RU	https://pubmed.ncbi.nlm.nih.gov/8931944

DMHD8UL	DI	DMHD8UL
DMHD8UL	DN	PD-151307
DMHD8UL	MI	TT4FDG6
DMHD8UL	MN	Voltage-gated calcium channel alpha Cav2.2 (CACNA1B)
DMHD8UL	MT	DTT
DMHD8UL	MA	Inhibitor
DMHD8UL	RN	Synthesis of a series of 4-benzyloxyaniline analogues as neuronal N-type calcium channel blockers with improved anticonvulsant and analgesic proper... J Med Chem. 1999 Oct 7;42(20):4239-49.
DMHD8UL	RU	https://pubmed.ncbi.nlm.nih.gov/10514294

DMV0EDM	DI	DMV0EDM
DMV0EDM	DN	PD-152255
DMV0EDM	MI	TT4C8EA
DMV0EDM	MN	Dopamine D3 receptor (D3R)
DMV0EDM	MT	DTT
DMV0EDM	MA	Modulator
DMV0EDM	RN	Pharmacological characterization of PD 152255, a novel dimeric benzimidazole dopamine D3 antagonist. Pharmacol Biochem Behav. 1998 Feb;59(2):487-93.
DMV0EDM	RU	https://www.ncbi.nlm.nih.gov/pubmed/9476999

DMY5SX9	DI	DMY5SX9
DMY5SX9	DN	PD-156
DMY5SX9	MI	TTHY57M
DMY5SX9	MN	Matrix metalloproteinase-13 (MMP-13)
DMY5SX9	MT	DTT
DMY5SX9	MA	Inhibitor
DMY5SX9	RN	Selective matrix metalloproteinase inhibition attenuates progression of left ventricular dysfunction and remodeling in dogs with chronic heart fail... Am J Physiol Heart Circ Physiol. 2006 Jun;290(6):H2522-7.
DMY5SX9	RU	https://pubmed.ncbi.nlm.nih.gov/16428338

DMHI8C9	DI	DMHI8C9
DMHI8C9	DN	PD-157672
DMHI8C9	MI	TTBPGLU
DMHI8C9	MN	Neuromedin-K receptor (TACR3)
DMHI8C9	MT	DTT
DMHI8C9	MA	Inhibitor
DMHI8C9	RN	The rational development of small molecule tachykinin NK3 receptor selective antagonists - the utilisation of a dipeptide chemical library in drug design, Bioorg. Med. Chem. Lett. 4(14):1679-1684 (1994).
DMHI8C9	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00803601

DMQXYE9	DI	DMQXYE9
DMQXYE9	DN	PD-158780
DMQXYE9	MI	TTGKNB4
DMQXYE9	MN	Epidermal growth factor receptor (EGFR)
DMQXYE9	MT	DTT
DMQXYE9	MA	Inhibitor
DMQXYE9	RN	Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinas... J Med Chem. 1996 Apr 26;39(9):1823-35.
DMQXYE9	RU	https://pubmed.ncbi.nlm.nih.gov/8627606

DM6RVTO	DI	DM6RVTO
DM6RVTO	DN	PD159790
DM6RVTO	MI	TTQ9RYT
DM6RVTO	MN	Endothelin-converting enzyme 1 (ECE1)
DM6RVTO	MT	DTT
DM6RVTO	MA	Inhibitor
DM6RVTO	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1615).
DM6RVTO	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1615

DMZYIKR	DI	DMZYIKR
DMZYIKR	DN	PD-160946
DMZYIKR	MI	TTBPGLU
DMZYIKR	MN	Neuromedin-K receptor (TACR3)
DMZYIKR	MT	DTT
DMZYIKR	MA	Inhibitor
DMZYIKR	RN	The development of a novel series of non-peptide tachykinin NK3 receptor selective antagonists, Bioorg. Med. Chem. Lett. 5(16):1773-1778 (1995).
DMZYIKR	RU	http://www.sciencedirect.com/science/article/pii/0960894X9500313I

DM8NV2E	DI	DM8NV2E
DM8NV2E	DN	PD-161182
DM8NV2E	MI	TTBPGLU
DM8NV2E	MN	Neuromedin-K receptor (TACR3)
DM8NV2E	MT	DTT
DM8NV2E	MA	Inhibitor
DM8NV2E	RN	The development of a novel series of non-peptide tachykinin NK3 receptor selective antagonists, Bioorg. Med. Chem. Lett. 5(16):1773-1778 (1995).
DM8NV2E	RU	http://www.sciencedirect.com/science/article/pii/0960894X9500313I

DMBZ09U	DI	DMBZ09U
DMBZ09U	DN	PD-163140
DMBZ09U	MI	TTKRD0G
DMBZ09U	MN	Endothelin A receptor (EDNRA)
DMBZ09U	MT	DTT
DMBZ09U	MA	Inhibitor
DMBZ09U	RN	gamma-Carbamate butenolide analogues as potent ETA selective endothelin receptor antagonists and prodrugs, Bioorg. Med. Chem. Lett. 7(3):297-302 (1997).
DMBZ09U	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97000024

DMBZ09U	DI	DMBZ09U
DMBZ09U	DN	PD-163140
DMBZ09U	MI	TT3ZTGU
DMBZ09U	MN	Endothelin B receptor (EDNRB)
DMBZ09U	MT	DTT
DMBZ09U	MA	Inhibitor
DMBZ09U	RN	gamma-Carbamate butenolide analogues as potent ETA selective endothelin receptor antagonists and prodrugs, Bioorg. Med. Chem. Lett. 7(3):297-302 (1997).
DMBZ09U	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97000024

DM5421R	DI	DM5421R
DM5421R	DN	PD164333
DM5421R	MI	TTKRD0G
DM5421R	MN	Endothelin A receptor (EDNRA)
DM5421R	MT	DTT
DM5421R	MA	Antagonist
DM5421R	RN	Characterization of [125I]-PD164333, an ETA selective non-peptide radiolabelled antagonist, in normal and diseased human tissues. Br J Pharmacol. 1998 Jan;123(2):223-30.
DM5421R	RU	https://pubmed.ncbi.nlm.nih.gov/9489609

DM9LJEP	DI	DM9LJEP
DM9LJEP	DN	PD-167341
DM9LJEP	MI	TT4FDG6
DM9LJEP	MN	Voltage-gated calcium channel alpha Cav2.2 (CACNA1B)
DM9LJEP	MT	DTT
DM9LJEP	MA	Inhibitor
DM9LJEP	RN	Synthesis of a series of 4-benzyloxyaniline analogues as neuronal N-type calcium channel blockers with improved anticonvulsant and analgesic proper... J Med Chem. 1999 Oct 7;42(20):4239-49.
DM9LJEP	RU	https://pubmed.ncbi.nlm.nih.gov/10514294

DMX1AY4	DI	DMX1AY4
DMX1AY4	DN	PD-168077
DMX1AY4	MI	TTEX248
DMX1AY4	MN	Dopamine D2 receptor (D2R)
DMX1AY4	MT	DTT
DMX1AY4	MA	Inhibitor
DMX1AY4	RN	New N-n-propyl-substituted 3-aryl- and 3-cyclohexylpiperidines as partial agonists at the D4 dopamine receptor. J Med Chem. 2003 Jan 2;46(1):161-8.
DMX1AY4	RU	https://pubmed.ncbi.nlm.nih.gov/12502370

DMN8M5P	DI	DMN8M5P
DMN8M5P	DN	PD-168393
DMN8M5P	MI	TTGKNB4
DMN8M5P	MN	Epidermal growth factor receptor (EGFR)
DMN8M5P	MT	DTT
DMN8M5P	MA	Inhibitor
DMN8M5P	RN	Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nat Chem Biol. 2007 Apr;3(4):229-38.
DMN8M5P	RU	https://pubmed.ncbi.nlm.nih.gov/17334377

DMN8M5P	DI	DMN8M5P
DMN8M5P	DN	PD-168393
DMN8M5P	MI	TTR5TV4
DMN8M5P	MN	ERBB2 messenger RNA (HER2 mRNA)
DMN8M5P	MT	DTT
DMN8M5P	MA	Inhibitor
DMN8M5P	RN	Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP... J Med Chem. 1999 May 20;42(10):1803-15.
DMN8M5P	RU	https://pubmed.ncbi.nlm.nih.gov/10346932

DM1Z3D7	DI	DM1Z3D7
DM1Z3D7	DN	PD-169316
DM1Z3D7	MI	TTSJ6Q4
DM1Z3D7	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DM1Z3D7	MT	DTT
DM1Z3D7	MA	Inhibitor
DM1Z3D7	RN	2,4,5- triarylimidazole inhibitors of IL-1 biosynthesis, Bioorg. Med. Chem. Lett. 5(11):1171-1176 (1995).
DM1Z3D7	RU	http://www.sciencedirect.com/science/article/pii/0960894X9500189Z

DMU3OR1	DI	DMU3OR1
DMU3OR1	DN	PD-169469
DMU3OR1	MI	TTLM12X
DMU3OR1	MN	Matrix metalloproteinase-2 (MMP-2)
DMU3OR1	MT	DTT
DMU3OR1	MA	Inhibitor
DMU3OR1	RN	Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates. J Med Chem. 2006 Feb 9;49(3):923-31.
DMU3OR1	RU	https://pubmed.ncbi.nlm.nih.gov/16451058

DMU3OR1	DI	DMU3OR1
DMU3OR1	DN	PD-169469
DMU3OR1	MI	TTUZ2L5
DMU3OR1	MN	Matrix metalloproteinase-3 (MMP-3)
DMU3OR1	MT	DTT
DMU3OR1	MA	Inhibitor
DMU3OR1	RN	Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates. J Med Chem. 2006 Feb 9;49(3):923-31.
DMU3OR1	RU	https://pubmed.ncbi.nlm.nih.gov/16451058

DMJ3DOI	DI	DMJ3DOI
DMJ3DOI	DN	PD-171729
DMJ3DOI	MI	TT7EFHR
DMJ3DOI	MN	Corticotropin-releasing factor receptor 1 (CRHR1)
DMJ3DOI	MT	DTT
DMJ3DOI	MA	Inhibitor
DMJ3DOI	RN	Pyrazolo[1,5-a]pyrimidine CRF-1 receptor antagonists. Bioorg Med Chem Lett. 1998 Aug 18;8(16):2067-70.
DMJ3DOI	RU	https://pubmed.ncbi.nlm.nih.gov/9873487

DM29GUY	DI	DM29GUY
DM29GUY	DN	PD-172938
DM29GUY	MI	TTEX248
DM29GUY	MN	Dopamine D2 receptor (D2R)
DM29GUY	MT	DTT
DM29GUY	MA	Inhibitor
DM29GUY	RN	Isoindolinone enantiomers having affinity for the dopamine D4 receptor. Bioorg Med Chem Lett. 1998 Jun 16;8(12):1499-502.
DM29GUY	RU	https://pubmed.ncbi.nlm.nih.gov/9873377

DMI8JTE	DI	DMI8JTE
DMI8JTE	DN	PD-172939
DMI8JTE	MI	TTEX248
DMI8JTE	MN	Dopamine D2 receptor (D2R)
DMI8JTE	MT	DTT
DMI8JTE	MA	Inhibitor
DMI8JTE	RN	Isoindolinone enantiomers having affinity for the dopamine D4 receptor. Bioorg Med Chem Lett. 1998 Jun 16;8(12):1499-502.
DMI8JTE	RU	https://pubmed.ncbi.nlm.nih.gov/9873377

DMP0N4U	DI	DMP0N4U
DMP0N4U	DN	PD173074
DMP0N4U	MI	TT0LF7H
DMP0N4U	MN	Fibroblast growth factor receptor (FGFR)
DMP0N4U	MT	DTT
DMP0N4U	MA	Antagonist
DMP0N4U	RN	Tumor angiogenesis as a therapeutic target. Drug Discov Today. 2001 Oct 1;6(19):1005-1024.
DMP0N4U	RU	https://pubmed.ncbi.nlm.nih.gov/11576867

DMP0N4U	DI	DMP0N4U
DMP0N4U	DN	PD173074
DMP0N4U	MI	TTFPD8J
DMP0N4U	MN	Fusion protein FGFR3-TACC3 (FGFR3-TACC3)
DMP0N4U	MT	DTT
DMP0N4U	MA	Inhibitor
DMP0N4U	RN	Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma.Cancer Biol Ther. 2014;15(12):1613-21.
DMP0N4U	RU	https://pubmed.ncbi.nlm.nih.gov/25535896

DMP0N4U	DI	DMP0N4U
DMP0N4U	DN	PD173074
DMP0N4U	MI	TT6PKBN
DMP0N4U	MN	Proto-oncogene c-Src (SRC)
DMP0N4U	MT	DTT
DMP0N4U	MA	Inhibitor
DMP0N4U	RN	Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy. Invest New Drugs. 1999;17(2):121-35.
DMP0N4U	RU	https://pubmed.ncbi.nlm.nih.gov/10638483

DMRBKW6	DI	DMRBKW6
DMRBKW6	DN	PD173212
DMRBKW6	MI	TTXHYV6
DMRBKW6	MN	Voltage-gated L-type calcium channel (L-CaC)
DMRBKW6	MT	DTT
DMRBKW6	MA	Blocker
DMRBKW6	RN	Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95.
DMRBKW6	RU	https://pubmed.ncbi.nlm.nih.gov/19442208

DMBHIAK	DI	DMBHIAK
DMBHIAK	DN	PD-174265
DMBHIAK	MI	TT6PKBN
DMBHIAK	MN	Proto-oncogene c-Src (SRC)
DMBHIAK	MT	DTT
DMBHIAK	MA	Inhibitor
DMBHIAK	RN	Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc. J Med Chem. 2009 Jul 9;52(13):3915-26.
DMBHIAK	RU	https://pubmed.ncbi.nlm.nih.gov/19462975

DM6XHUZ	DI	DM6XHUZ
DM6XHUZ	DN	PD176078
DM6XHUZ	MI	TTXHYV6
DM6XHUZ	MN	Voltage-gated L-type calcium channel (L-CaC)
DM6XHUZ	MT	DTT
DM6XHUZ	MA	Blocker
DM6XHUZ	RN	Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95.
DM6XHUZ	RU	https://pubmed.ncbi.nlm.nih.gov/19442208

DMXLW4F	DI	DMXLW4F
DMXLW4F	DN	PD182905
DMXLW4F	MI	TTGKNB4
DMXLW4F	MN	Epidermal growth factor receptor (EGFR)
DMXLW4F	MT	DTT
DMXLW4F	MA	Inhibitor
DMXLW4F	RN	Growth factors and their receptors: new targets for prostate cancer therapy. Urology. 2001 Aug;58(2 Suppl 1):114-22.
DMXLW4F	RU	https://pubmed.ncbi.nlm.nih.gov/11502465

DMLU9P6	DI	DMLU9P6
DMLU9P6	DN	PD-307243
DMLU9P6	MI	TTQ6VDM
DMLU9P6	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMLU9P6	MT	DTT
DMLU9P6	MA	Activator
DMLU9P6	RN	2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD-307243) causes instantaneous current through human ether-a-go-go-r... Mol Pharmacol. 2008 Mar;73(3):639-51.
DMLU9P6	RU	https://pubmed.ncbi.nlm.nih.gov/18042732

DMBA15J	DI	DMBA15J
DMBA15J	DN	PD-32577
DMBA15J	MI	TTZIFHC
DMBA15J	MN	Voltage-gated calcium channel alpha Cav1.2 (CACNA1C)
DMBA15J	MT	DTT
DMBA15J	MA	Inhibitor
DMBA15J	RN	Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52.
DMBA15J	RU	https://pubmed.ncbi.nlm.nih.gov/10476885

DMBA15J	DI	DMBA15J
DMBA15J	DN	PD-32577
DMBA15J	MI	TT7RGTM
DMBA15J	MN	Voltage-gated calcium channel alpha Cav1.3 (CACNA1D)
DMBA15J	MT	DTT
DMBA15J	MA	Inhibitor
DMBA15J	RN	Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52.
DMBA15J	RU	https://pubmed.ncbi.nlm.nih.gov/10476885

DMBA15J	DI	DMBA15J
DMBA15J	DN	PD-32577
DMBA15J	MI	TT4FDG6
DMBA15J	MN	Voltage-gated calcium channel alpha Cav2.2 (CACNA1B)
DMBA15J	MT	DTT
DMBA15J	MA	Inhibitor
DMBA15J	RN	Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52.
DMBA15J	RU	https://pubmed.ncbi.nlm.nih.gov/10476885

DMBA15J	DI	DMBA15J
DMBA15J	DN	PD-32577
DMBA15J	MI	TTPXI3S
DMBA15J	MN	Voltage-gated potassium channel Kv7.2 (KCNQ2)
DMBA15J	MT	DTT
DMBA15J	MA	Inhibitor
DMBA15J	RN	Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52.
DMBA15J	RU	https://pubmed.ncbi.nlm.nih.gov/10476885

DMBA15J	DI	DMBA15J
DMBA15J	DN	PD-32577
DMBA15J	MI	TTIVDM3
DMBA15J	MN	Voltage-gated potassium channel Kv7.3 (KCNQ3)
DMBA15J	MT	DTT
DMBA15J	MA	Inhibitor
DMBA15J	RN	Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52.
DMBA15J	RU	https://pubmed.ncbi.nlm.nih.gov/10476885

DMBA15J	DI	DMBA15J
DMBA15J	DN	PD-32577
DMBA15J	MI	TT90XZ8
DMBA15J	MN	Voltage-gated sodium channel alpha Nav1.8 (SCN10A)
DMBA15J	MT	DTT
DMBA15J	MA	Inhibitor
DMBA15J	RN	Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52.
DMBA15J	RU	https://pubmed.ncbi.nlm.nih.gov/10476885

DMBA15J	DI	DMBA15J
DMBA15J	DN	PD-32577
DMBA15J	MI	TTN9VTF
DMBA15J	MN	Voltage-gated sodium channel alpha Nav1.9 (SCN11A)
DMBA15J	MT	DTT
DMBA15J	MA	Inhibitor
DMBA15J	RN	Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52.
DMBA15J	RU	https://pubmed.ncbi.nlm.nih.gov/10476885

DM0OEH3	DI	DM0OEH3
DM0OEH3	DN	PD-4048
DM0OEH3	MI	TTJ6WK9
DM0OEH3	MN	Neuropeptide Y receptor type 2 (NPY2R)
DM0OEH3	MT	DTT
DM0OEH3	MA	Agonist
DM0OEH3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 306).
DM0OEH3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=306

DM4BDEY	DI	DM4BDEY
DM4BDEY	DN	PD-4074
DM4BDEY	MI	TTW4N16
DM4BDEY	MN	Neuropeptide Y receptor type 4 (NPY4R)
DM4BDEY	MT	DTT
DM4BDEY	MA	Agonist
DM4BDEY	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 307).
DM4BDEY	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=307

DM5SYTW	DI	DM5SYTW
DM5SYTW	DN	PD-81723
DM5SYTW	MI	TTK25J1
DM5SYTW	MN	Adenosine A1 receptor (ADORA1)
DM5SYTW	MT	DTT
DM5SYTW	MA	Inhibitor
DM5SYTW	RN	Synthesis and biological evaluation of 2-amino-3-(4-chlorobenzoyl)-4-[N-(substituted) piperazin-1-yl]thiophenes as potent allosteric enhancers of t... J Med Chem. 2008 Sep 25;51(18):5875-9.
DM5SYTW	RU	https://pubmed.ncbi.nlm.nih.gov/18729349

DMSIMKZ	DI	DMSIMKZ
DMSIMKZ	DN	PD-83176
DMSIMKZ	MI	TT7WZIJ
DMSIMKZ	MN	CAAX farnesyltransferase beta (FNTB)
DMSIMKZ	MT	DTT
DMSIMKZ	MA	Inhibitor
DMSIMKZ	RN	Structure-activity relationships of cysteine-lacking pentapeptide derivatives that inhibit ras farnesyltransferase. J Med Chem. 1997 Jan 17;40(2):192-200.
DMSIMKZ	RU	https://pubmed.ncbi.nlm.nih.gov/9003517

DMSIMKZ	DI	DMSIMKZ
DMSIMKZ	DN	PD-83176
DMSIMKZ	MI	TTXQKM3
DMSIMKZ	MN	Farnesyl protein transferase (Ftase)
DMSIMKZ	MT	DTT
DMSIMKZ	MA	Inhibitor
DMSIMKZ	RN	Structure-activity relationships of cysteine-lacking pentapeptide derivatives that inhibit ras farnesyltransferase. J Med Chem. 1997 Jan 17;40(2):192-200.
DMSIMKZ	RU	https://pubmed.ncbi.nlm.nih.gov/9003517

DMSIMKZ	DI	DMSIMKZ
DMSIMKZ	DN	PD-83176
DMSIMKZ	MI	TTX20QP
DMSIMKZ	MN	Geranylgeranyl transferase I (GGTase-I)
DMSIMKZ	MT	DTT
DMSIMKZ	MA	Inhibitor
DMSIMKZ	RN	Structure-activity relationships of cysteine-lacking pentapeptide derivatives that inhibit ras farnesyltransferase. J Med Chem. 1997 Jan 17;40(2):192-200.
DMSIMKZ	RU	https://pubmed.ncbi.nlm.nih.gov/9003517

DMZC90M	DI	DMZC90M
DMZC90M	DN	PD98059
DMZC90M	MI	TTIDAPM
DMZC90M	MN	ERK activator kinase 1 (MEK1)
DMZC90M	MT	DTT
DMZC90M	MA	Inhibitor
DMZC90M	RN	The MEK1 inhibitor PD98059 sensitizes C8161 melanoma cells to cisplatin-induced apoptosis. Melanoma Res. 2001 Feb;11(1):11-9.
DMZC90M	RU	https://pubmed.ncbi.nlm.nih.gov/11254111

DMZC90M	DI	DMZC90M
DMZC90M	DN	PD98059
DMZC90M	MI	TTTW2NY
DMZC90M	MN	ERK activator kinase 2 (MEK2)
DMZC90M	MT	DTT
DMZC90M	MA	Inhibitor
DMZC90M	RN	The MEK1 inhibitor PD98059 sensitizes C8161 melanoma cells to cisplatin-induced apoptosis. Melanoma Res. 2001 Feb;11(1):11-9.
DMZC90M	RU	https://pubmed.ncbi.nlm.nih.gov/11254111

DMUDY7H	DI	DMUDY7H
DMUDY7H	DN	PDC-31
DMUDY7H	MI	TTT2ZAR
DMUDY7H	MN	Prostaglandin F2-alpha receptor (PTGFR)
DMUDY7H	MT	DTT
DMUDY7H	MA	Antagonist
DMUDY7H	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 344).
DMUDY7H	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=344

DMSO3HM	DI	DMSO3HM
DMSO3HM	DN	PDGF gene therapy
DMSO3HM	MI	TTI2WET
DMSO3HM	MN	Platelet-derived growth factor receptor (PDGFR)
DMSO3HM	MT	DTT
DMSO3HM	MA	Activator
DMSO3HM	RN	Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
DMSO3HM	RU	https://pubmed.ncbi.nlm.nih.gov/17064227

DMORLTH	DI	DMORLTH
DMORLTH	DN	PDGF receptor tyrosine kinase inhibitor III
DMORLTH	MI	TTI7421
DMORLTH	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMORLTH	MT	DTT
DMORLTH	MA	Inhibitor
DMORLTH	RN	Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. 3. Replacement of quinazoline moiety and improvement of metabolic polymorphism of 4-[4-(N-substituted (thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline derivatives. J Med Chem. 2003 Nov 6;46(23):4910-25.
DMORLTH	RU	https://pubmed.ncbi.nlm.nih.gov/14584942

DMKLRCX	DI	DMKLRCX
DMKLRCX	DN	Pedunculagin
DMKLRCX	MI	TT6L509
DMKLRCX	MN	Coagulation factor IIa (F2)
DMKLRCX	MT	DTT
DMKLRCX	MA	Inhibitor
DMKLRCX	RN	Effects of tannins from Geum japonicum on the catalytic activity of thrombin and factor Xa of blood coagulation cascade. J Nat Prod. 1998 Nov;61(11):1356-60.
DMKLRCX	RU	https://pubmed.ncbi.nlm.nih.gov/9834152

DMKLRCX	DI	DMKLRCX
DMKLRCX	DN	Pedunculagin
DMKLRCX	MI	TTCIHJA
DMKLRCX	MN	Coagulation factor Xa (F10)
DMKLRCX	MT	DTT
DMKLRCX	MA	Inhibitor
DMKLRCX	RN	Effects of tannins from Geum japonicum on the catalytic activity of thrombin and factor Xa of blood coagulation cascade. J Nat Prod. 1998 Nov;61(11):1356-60.
DMKLRCX	RU	https://pubmed.ncbi.nlm.nih.gov/9834152

DMKLRCX	DI	DMKLRCX
DMKLRCX	DN	Pedunculagin
DMKLRCX	MI	TTE14XG
DMKLRCX	MN	Squalene monooxygenase (SQLE)
DMKLRCX	MT	DTT
DMKLRCX	MA	Inhibitor
DMKLRCX	RN	Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4.
DMKLRCX	RU	https://pubmed.ncbi.nlm.nih.gov/11520216

DM5GVZJ	DI	DM5GVZJ
DM5GVZJ	DN	PEG-EPO
DM5GVZJ	MI	TTAUX24
DM5GVZJ	MN	Erythropoietin Receptor (EPOR)
DM5GVZJ	MT	DTT
DM5GVZJ	MA	Stimulator
DM5GVZJ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1718).
DM5GVZJ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1718

DMY293M	DI	DMY293M
DMY293M	DN	PEG-LPA-2
DMY293M	MI	TT0HD6V
DMY293M	MN	Leptin receptor (LEPR)
DMY293M	MT	DTT
DMY293M	MA	Antagonist
DMY293M	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1712).
DMY293M	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1712

DMZ01PS	DI	DMZ01PS
DMZ01PS	DN	PEGylated leptin
DMZ01PS	MI	TT0HD6V
DMZ01PS	MN	Leptin receptor (LEPR)
DMZ01PS	MT	DTT
DMZ01PS	MA	Modulator
DMZ01PS	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1712).
DMZ01PS	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1712

DM6K3G7	DI	DM6K3G7
DM6K3G7	DN	PEGylated PYY-3-36
DM6K3G7	MI	TTJ6WK9
DM6K3G7	MN	Neuropeptide Y receptor type 2 (NPY2R)
DM6K3G7	MT	DTT
DM6K3G7	MA	Modulator
DM6K3G7	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 306).
DM6K3G7	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=306

DMAW0R7	DI	DMAW0R7
DMAW0R7	DN	PELARGONIDIN CHLORIDE
DMAW0R7	MI	TTV9A7R
DMAW0R7	MN	Lactoylglutathione lyase (GLO1)
DMAW0R7	MT	DTT
DMAW0R7	MA	Inhibitor
DMAW0R7	RN	Delphinidin, a dietary anthocyanidin in berry fruits, inhibits human glyoxalase I. Bioorg Med Chem. 2010 Oct 1;18(19):7029-33.
DMAW0R7	RU	https://pubmed.ncbi.nlm.nih.gov/20801663

DMYIWBD	DI	DMYIWBD
DMYIWBD	DN	Pellitorin
DMYIWBD	MI	TTA1L39
DMYIWBD	MN	ICAM1 messenger RNA (ICAM1 mRNA)
DMYIWBD	MT	DTT
DMYIWBD	MA	Inhibitor
DMYIWBD	RN	Alkamides from the fruits of Piper longum and Piper nigrum displaying potent cell adhesion inhibition. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4544-6.
DMYIWBD	RU	https://pubmed.ncbi.nlm.nih.gov/18672369

DM81AWU	DI	DM81AWU
DM81AWU	DN	Pen(Acm)AQFRKEKETFC(Acm)-OH
DM81AWU	MI	TTJDUNO
DM81AWU	MN	T-cell surface antigen CD2 (CD2)
DM81AWU	MT	DTT
DM81AWU	MA	Inhibitor
DM81AWU	RN	Structure-activity studies of peptides from the "hot-spot" region of human CD2 protein: development of peptides for immunomodulation. J Med Chem. 2005 Oct 6;48(20):6236-49.
DM81AWU	RU	https://pubmed.ncbi.nlm.nih.gov/16190751

DMZ3WPN	DI	DMZ3WPN
DMZ3WPN	DN	Penciclovir
DMZ3WPN	MI	TTV1095
DMZ3WPN	MN	COVID-19 RNA-directed RNA polymerase (RdRp)
DMZ3WPN	MT	DTT
DMZ3WPN	MA	Inhibitor
DMZ3WPN	RN	Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.
DMZ3WPN	RU	https://pubmed.ncbi.nlm.nih.gov/32020029

DMIDSJ9	DI	DMIDSJ9
DMIDSJ9	DN	PENECA
DMIDSJ9	MI	TTK25J1
DMIDSJ9	MN	Adenosine A1 receptor (ADORA1)
DMIDSJ9	MT	DTT
DMIDSJ9	MA	Agonist
DMIDSJ9	RN	N(6)-alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A(3) receptor and a starting point for searching A(2B) ligands. J Med Chem. 2002 Jul 18;45(15):3271-9.
DMIDSJ9	RU	https://pubmed.ncbi.nlm.nih.gov/12109910

DMIDSJ9	DI	DMIDSJ9
DMIDSJ9	DN	PENECA
DMIDSJ9	MI	TTNE7KG
DMIDSJ9	MN	Adenosine A2b receptor (ADORA2B)
DMIDSJ9	MT	DTT
DMIDSJ9	MA	Agonist
DMIDSJ9	RN	N(6)-alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A(3) receptor and a starting point for searching A(2B) ligands. J Med Chem. 2002 Jul 18;45(15):3271-9.
DMIDSJ9	RU	https://pubmed.ncbi.nlm.nih.gov/12109910

DMIDSJ9	DI	DMIDSJ9
DMIDSJ9	DN	PENECA
DMIDSJ9	MI	TTJFY5U
DMIDSJ9	MN	Adenosine A3 receptor (ADORA3)
DMIDSJ9	MT	DTT
DMIDSJ9	MA	Agonist
DMIDSJ9	RN	N(6)-alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A(3) receptor and a starting point for searching A(2B) ligands. J Med Chem. 2002 Jul 18;45(15):3271-9.
DMIDSJ9	RU	https://pubmed.ncbi.nlm.nih.gov/12109910

DMZUES2	DI	DMZUES2
DMZUES2	DN	PENICILLIOL A
DMZUES2	MI	TTIU7X1
DMZUES2	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMZUES2	MT	DTT
DMZUES2	MA	Inhibitor
DMZUES2	RN	Penicilliols A and B, novel inhibitors specific to mammalian Y-family DNA polymerases. Bioorg Med Chem. 2009 Mar 1;17(5):1811-6.
DMZUES2	RU	https://pubmed.ncbi.nlm.nih.gov/19223184

DMA13KG	DI	DMA13KG
DMA13KG	DN	Pentamycin
DMA13KG	MI	DEW6V07
DMA13KG	MN	Ribosomal 23S RNA methyltransferase Erm (erm)
DMA13KG	MT	DME
DMA13KG	MA	Metabolism
DMA13KG	RN	High frequency of macrolide resistance mechanisms in clinical isolates of Corynebacterium species. Microb Drug Resist. 2010 Dec;16(4):273-7.
DMA13KG	RU	https://pubmed.ncbi.nlm.nih.gov/20624090

DMA13KG	DI	DMA13KG
DMA13KG	DN	Pentamycin
DMA13KG	MI	DEA65D8
DMA13KG	MN	Ribosomal 23S RNA methyltransferase Erm (erm)
DMA13KG	MT	DME
DMA13KG	MA	Metabolism
DMA13KG	RN	High frequency of macrolide resistance mechanisms in clinical isolates of Corynebacterium species. Microb Drug Resist. 2010 Dec;16(4):273-7.
DMA13KG	RU	https://pubmed.ncbi.nlm.nih.gov/20624090

DMVPZG9	DI	DMVPZG9
DMVPZG9	DN	Pentane-1,5-diamine
DMVPZG9	MI	TTUNARX
DMVPZG9	MN	Carbonic anhydrase (CA)
DMVPZG9	MT	DTT
DMVPZG9	MA	Inhibitor
DMVPZG9	RN	Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22.
DMVPZG9	RU	https://pubmed.ncbi.nlm.nih.gov/20590092

DMVPZG9	DI	DMVPZG9
DMVPZG9	DN	Pentane-1,5-diamine
DMVPZG9	MI	TTHQPL7
DMVPZG9	MN	Carbonic anhydrase I (CA-I)
DMVPZG9	MT	DTT
DMVPZG9	MA	Inhibitor
DMVPZG9	RN	Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22.
DMVPZG9	RU	https://pubmed.ncbi.nlm.nih.gov/20590092

DMVPZG9	DI	DMVPZG9
DMVPZG9	DN	Pentane-1,5-diamine
DMVPZG9	MI	TTANPDJ
DMVPZG9	MN	Carbonic anhydrase II (CA-II)
DMVPZG9	MT	DTT
DMVPZG9	MA	Inhibitor
DMVPZG9	RN	Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22.
DMVPZG9	RU	https://pubmed.ncbi.nlm.nih.gov/20590092

DMVPZG9	DI	DMVPZG9
DMVPZG9	DN	Pentane-1,5-diamine
DMVPZG9	MI	TTZHA0O
DMVPZG9	MN	Carbonic anhydrase IV (CA-IV)
DMVPZG9	MT	DTT
DMVPZG9	MA	Inhibitor
DMVPZG9	RN	Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22.
DMVPZG9	RU	https://pubmed.ncbi.nlm.nih.gov/20590092

DMVPZG9	DI	DMVPZG9
DMVPZG9	DN	Pentane-1,5-diamine
DMVPZG9	MI	TT2LVK8
DMVPZG9	MN	Carbonic anhydrase IX (CA-IX)
DMVPZG9	MT	DTT
DMVPZG9	MA	Inhibitor
DMVPZG9	RN	Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22.
DMVPZG9	RU	https://pubmed.ncbi.nlm.nih.gov/20590092

DMVPZG9	DI	DMVPZG9
DMVPZG9	DN	Pentane-1,5-diamine
DMVPZG9	MI	TTCFSPE
DMVPZG9	MN	Carbonic anhydrase VI (CA-VI)
DMVPZG9	MT	DTT
DMVPZG9	MA	Inhibitor
DMVPZG9	RN	Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22.
DMVPZG9	RU	https://pubmed.ncbi.nlm.nih.gov/20590092

DMVPZG9	DI	DMVPZG9
DMVPZG9	DN	Pentane-1,5-diamine
DMVPZG9	MI	TTSYM0R
DMVPZG9	MN	Carbonic anhydrase XII (CA-XII)
DMVPZG9	MT	DTT
DMVPZG9	MA	Inhibitor
DMVPZG9	RN	Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22.
DMVPZG9	RU	https://pubmed.ncbi.nlm.nih.gov/20590092

DMVPZG9	DI	DMVPZG9
DMVPZG9	DN	Pentane-1,5-diamine
DMVPZG9	MI	TTEYTKG
DMVPZG9	MN	Carbonic anhydrase XIV (CA-XIV)
DMVPZG9	MT	DTT
DMVPZG9	MA	Inhibitor
DMVPZG9	RN	Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22.
DMVPZG9	RU	https://pubmed.ncbi.nlm.nih.gov/20590092

DM56RAX	DI	DM56RAX
DM56RAX	DN	pentanoic acid
DM56RAX	MI	TT0FYAN
DM56RAX	MN	Free fatty acid receptor 2 (FFAR2)
DM56RAX	MT	DTT
DM56RAX	MA	Agonist
DM56RAX	RN	The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem. 2003 Mar 28;278(13):11312-9.
DM56RAX	RU	https://pubmed.ncbi.nlm.nih.gov/12496283

DM56RAX	DI	DM56RAX
DM56RAX	DN	pentanoic acid
DM56RAX	MI	TTXDOHN
DM56RAX	MN	Free fatty acid receptor 3 (FFAR3)
DM56RAX	MT	DTT
DM56RAX	MA	Agonist
DM56RAX	RN	Short-chain fatty acids stimulate leptin production in adipocytes through the G protein-coupled receptor GPR41. Proc Natl Acad Sci U S A. 2004 Jan 27;101(4):1045-50.
DM56RAX	RU	https://pubmed.ncbi.nlm.nih.gov/14722361

DM3S790	DI	DM3S790
DM3S790	DN	Pentanoic acid (4,6-diphenylpyrimidin-2-yl)amide
DM3S790	MI	TTK25J1
DM3S790	MN	Adenosine A1 receptor (ADORA1)
DM3S790	MT	DTT
DM3S790	MA	Inhibitor
DM3S790	RN	2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40.
DM3S790	RU	https://pubmed.ncbi.nlm.nih.gov/15588088

DMAZ07T	DI	DMAZ07T
DMAZ07T	DN	Pentanoic acid (4-sulfamoyl-phenyl)-amide
DMAZ07T	MI	TTHQPL7
DMAZ07T	MN	Carbonic anhydrase I (CA-I)
DMAZ07T	MT	DTT
DMAZ07T	MA	Inhibitor
DMAZ07T	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DMAZ07T	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DMAZ07T	DI	DMAZ07T
DMAZ07T	DN	Pentanoic acid (4-sulfamoyl-phenyl)-amide
DMAZ07T	MI	TTANPDJ
DMAZ07T	MN	Carbonic anhydrase II (CA-II)
DMAZ07T	MT	DTT
DMAZ07T	MA	Inhibitor
DMAZ07T	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DMAZ07T	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DMAZ07T	DI	DMAZ07T
DMAZ07T	DN	Pentanoic acid (4-sulfamoyl-phenyl)-amide
DMAZ07T	MI	TT2LVK8
DMAZ07T	MN	Carbonic anhydrase IX (CA-IX)
DMAZ07T	MT	DTT
DMAZ07T	MA	Inhibitor
DMAZ07T	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DMAZ07T	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DMAZ07T	DI	DMAZ07T
DMAZ07T	DN	Pentanoic acid (4-sulfamoyl-phenyl)-amide
DMAZ07T	MI	TTSYM0R
DMAZ07T	MN	Carbonic anhydrase XII (CA-XII)
DMAZ07T	MT	DTT
DMAZ07T	MA	Inhibitor
DMAZ07T	RN	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6.
DMAZ07T	RU	https://pubmed.ncbi.nlm.nih.gov/16168653

DMD8NHB	DI	DMD8NHB
DMD8NHB	DN	pentylthio-TZTP
DMD8NHB	MI	TTOXS3C
DMD8NHB	MN	Muscarinic acetylcholine receptor (CHRM)
DMD8NHB	MT	DTT
DMD8NHB	MA	Agonist
DMD8NHB	RN	Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol. 1997 Jul;52(1):172-9.
DMD8NHB	RU	https://pubmed.ncbi.nlm.nih.gov/9224827

DMD8NHB	DI	DMD8NHB
DMD8NHB	DN	pentylthio-TZTP
DMD8NHB	MI	TTQ13Z5
DMD8NHB	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMD8NHB	MT	DTT
DMD8NHB	MA	Agonist
DMD8NHB	RN	Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol. 1997 Jul;52(1):172-9.
DMD8NHB	RU	https://pubmed.ncbi.nlm.nih.gov/9224827

DMIDP1R	DI	DMIDP1R
DMIDP1R	DN	peptide 18
DMIDP1R	MI	TTH9WF6
DMIDP1R	MN	Dibasic-processing enzyme (Furin)
DMIDP1R	MT	DTT
DMIDP1R	MA	Inhibitor
DMIDP1R	RN	Design, synthesis, and structure-activity relationship studies of a potent PACE4 inhibitor. J Med Chem. 2014 Jan 9;57(1):98-109.
DMIDP1R	RU	https://pubmed.ncbi.nlm.nih.gov/24350995

DMIDP1R	DI	DMIDP1R
DMIDP1R	DN	peptide 18
DMIDP1R	MI	TT46F0P
DMIDP1R	MN	Neuroendocrine convertase 2 (PCSK2)
DMIDP1R	MT	DTT
DMIDP1R	MA	Inhibitor
DMIDP1R	RN	Design, synthesis, and structure-activity relationship studies of a potent PACE4 inhibitor. J Med Chem. 2014 Jan 9;57(1):98-109.
DMIDP1R	RU	https://pubmed.ncbi.nlm.nih.gov/24350995

DMIDP1R	DI	DMIDP1R
DMIDP1R	DN	peptide 18
DMIDP1R	MI	TT75LN9
DMIDP1R	MN	Proprotein convertase subtilisin/kexin type 6 (PCSK6)
DMIDP1R	MT	DTT
DMIDP1R	MA	Inhibitor
DMIDP1R	RN	Design, synthesis, and structure-activity relationship studies of a potent PACE4 inhibitor. J Med Chem. 2014 Jan 9;57(1):98-109.
DMIDP1R	RU	https://pubmed.ncbi.nlm.nih.gov/24350995

DMIDP1R	DI	DMIDP1R
DMIDP1R	DN	peptide 18
DMIDP1R	MI	TTD30LY
DMIDP1R	MN	Proprotein convertase subtilisin/kexin type 7 (PCSK7)
DMIDP1R	MT	DTT
DMIDP1R	MA	Inhibitor
DMIDP1R	RN	Design, synthesis, and structure-activity relationship studies of a potent PACE4 inhibitor. J Med Chem. 2014 Jan 9;57(1):98-109.
DMIDP1R	RU	https://pubmed.ncbi.nlm.nih.gov/24350995

DM45RTZ	DI	DM45RTZ
DM45RTZ	DN	peptide 4
DM45RTZ	MI	TTQ7R2V
DM45RTZ	MN	Tripeptidyl-peptidase II (TPP2)
DM45RTZ	MT	DTT
DM45RTZ	MA	Inhibitor
DM45RTZ	RN	Use of lantibiotic synthetases for the preparation of bioactive constrained peptides. Bioorg Med Chem Lett. 2008 May 15;18(10):3025-8.
DM45RTZ	RU	https://pubmed.ncbi.nlm.nih.gov/18294843

DMC6GUA	DI	DMC6GUA
DMC6GUA	DN	Peptide alpha-keto-beta-aldehyde-based inhibitors
DMC6GUA	MI	TT36ETB
DMC6GUA	MN	Cathepsin L (CTSL)
DMC6GUA	MT	DTT
DMC6GUA	MA	Inhibitor
DMC6GUA	RN	Synthesis and kinetic evaluation of peptide alpha-keto-beta-aldehyde-based inhibitors of trypsin-like serine proteases. J Pharm Pharmacol. 2001 Apr;53(4):473-80.
DMC6GUA	RU	https://pubmed.ncbi.nlm.nih.gov/11341363

DMSDFOC	DI	DMSDFOC
DMSDFOC	DN	peptide III-BTD
DMSDFOC	MI	TTNT7K8
DMSDFOC	MN	Nociceptin receptor (OPRL1)
DMSDFOC	MT	DTT
DMSDFOC	MA	Antagonist
DMSDFOC	RN	Ligands for kappa-opioid and ORL1 receptors identified from a conformationally constrained peptide combinatorial library. J Biol Chem. 1999 Sep 24;274(39):27513-22.
DMSDFOC	RU	https://pubmed.ncbi.nlm.nih.gov/10488086

DM8OC9F	DI	DM8OC9F
DM8OC9F	DN	Pergularinine
DM8OC9F	MI	TTS7IR5
DM8OC9F	MN	c-Jun messenger RNA (c-Jun mRNA)
DM8OC9F	MT	DTT
DM8OC9F	MA	Inhibitor
DM8OC9F	RN	Structure-activity studies of phenanthroindolizidine alkaloids as potential antitumor agents. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4338-42.
DM8OC9F	RU	https://pubmed.ncbi.nlm.nih.gov/17531481

DM8OC9F	DI	DM8OC9F
DM8OC9F	DN	Pergularinine
DM8OC9F	MI	TT9SL3Q
DM8OC9F	MN	Polypeptide deformylase (PDF)
DM8OC9F	MT	DTT
DM8OC9F	MA	Inhibitor
DM8OC9F	RN	Inhibition of dihydrofolate reductase and cell growth activity by the phenanthroindolizidine alkaloids pergularinine and tylophorinidine: the in vitro cytotoxicity of these plant alkaloids and their potential as antimicrobial and anticancer agents. Toxicol In Vitro. 2000 Feb;14(1):53-9.
DM8OC9F	RU	https://pubmed.ncbi.nlm.nih.gov/10699361

DMZA0VD	DI	DMZA0VD
DMZA0VD	DN	Perillaldehyde
DMZA0VD	MI	TTXDKTO
DMZA0VD	MN	Long transient receptor potential channel 8 (TRPM8)
DMZA0VD	MT	DTT
DMZA0VD	MA	Inhibitor
DMZA0VD	RN	Taste-guided identification of high potency TRPA1 agonists from Perilla frutescens. Bioorg Med Chem. 2009 Feb 15;17(4):1636-9.
DMZA0VD	RU	https://pubmed.ncbi.nlm.nih.gov/19162486

DMN9W56	DI	DMN9W56
DMN9W56	DN	PERIPENTADENINE
DMN9W56	MI	TT27RFC
DMN9W56	MN	Opioid receptor delta (OPRD1)
DMN9W56	MT	DTT
DMN9W56	MA	Inhibitor
DMN9W56	RN	Alkaloids with human delta-opioid receptor binding affinity from the Australian rainforest tree Peripentadenia mearsii. J Nat Prod. 2007 Dec;70(12):1946-50.
DMN9W56	RU	https://pubmed.ncbi.nlm.nih.gov/18039010

DM3RGPF	DI	DM3RGPF
DM3RGPF	DN	PERSICARIN
DM3RGPF	MI	TT7RJY8
DM3RGPF	MN	Xanthine dehydrogenase/oxidase (XDH)
DM3RGPF	MT	DTT
DM3RGPF	MA	Inhibitor
DM3RGPF	RN	Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod. 1988 Mar-Apr;51(2):345-8.
DM3RGPF	RU	https://pubmed.ncbi.nlm.nih.gov/3379415

DM873BS	DI	DM873BS
DM873BS	DN	Pervanadate
DM873BS	MI	TTWC6MY
DM873BS	MN	Protein tyrosine phosphatase (PTP)
DM873BS	MT	DTT
DM873BS	MA	Inhibitor
DM873BS	RN	Induction of endothelial cell surface adhesion molecules by tumor necrosis factor is blocked by protein tyrosine phosphatase inhibitors: role of the nuclear transcription factor NF-kappa B. Eur J Immunol. 1997 Sep;27(9):2172-9.
DM873BS	RU	https://pubmed.ncbi.nlm.nih.gov/9341756

DM0N1DH	DI	DM0N1DH
DM0N1DH	DN	PETCM
DM0N1DH	MI	TTPF2QI
DM0N1DH	MN	Caspase-3 (CASP3)
DM0N1DH	MT	DTT
DM0N1DH	MA	Activator
DM0N1DH	RN	Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway. Science. 2003 Jan 10;299(5604):223-6.
DM0N1DH	RU	https://pubmed.ncbi.nlm.nih.gov/12522243

DMYIEOJ	DI	DMYIEOJ
DMYIEOJ	DN	Petrosamine
DMYIEOJ	MI	TT1RS9F
DMYIEOJ	MN	Acetylcholinesterase (AChE)
DMYIEOJ	MT	DTT
DMYIEOJ	MA	Inhibitor
DMYIEOJ	RN	Petrosamine, a potent anticholinesterase pyridoacridine alkaloid from a Thai marine sponge Petrosia n. sp. Bioorg Med Chem. 2008 Jul 1;16(13):6560-7.
DMYIEOJ	RU	https://pubmed.ncbi.nlm.nih.gov/18538575

DMR8ZBT	DI	DMR8ZBT
DMR8ZBT	DN	Petrosaspongiolide M
DMR8ZBT	MI	TT9V5JH
DMR8ZBT	MN	Phospholipase A2 (PLA2G1B)
DMR8ZBT	MT	DTT
DMR8ZBT	MA	Inhibitor
DMR8ZBT	RN	Synthesis and pharmacological evaluation of a selected library of new potential anti-inflammatory agents bearing the gamma-hydroxybutenolide scaffo... J Med Chem. 2007 May 3;50(9):2176-84.
DMR8ZBT	RU	https://pubmed.ncbi.nlm.nih.gov/17407277

DMMVZFN	DI	DMMVZFN
DMMVZFN	DN	Petrosaspongiolide P
DMMVZFN	MI	TT9V5JH
DMMVZFN	MN	Phospholipase A2 (PLA2G1B)
DMMVZFN	MT	DTT
DMMVZFN	MA	Inhibitor
DMMVZFN	RN	Petrosaspongiolides M-R: new potent and selective phospholipase A2 inhibitors from the New Caledonian marine sponge Petrosaspongia nigra. J Nat Prod. 1998 May;61(5):571-5.
DMMVZFN	RU	https://pubmed.ncbi.nlm.nih.gov/9599251

DMY45K1	DI	DMY45K1
DMY45K1	DN	PF 5208766
DMY45K1	MI	TTGKNB4
DMY45K1	MN	Epidermal growth factor receptor (EGFR)
DMY45K1	MT	DTT
DMY45K1	MA	Modulator
DMY45K1	RN	Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor... J Med Chem. 2005 Feb 24;48(4):1107-31.
DMY45K1	RU	https://www.ncbi.nlm.nih.gov/pubmed/15715478

DMY45K1	DI	DMY45K1
DMY45K1	DN	PF 5208766
DMY45K1	MI	TT6EO5L
DMY45K1	MN	Erbb2 tyrosine kinase receptor (HER2)
DMY45K1	MT	DTT
DMY45K1	MA	Modulator
DMY45K1	RN	Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor... J Med Chem. 2005 Feb 24;48(4):1107-31.
DMY45K1	RU	https://www.ncbi.nlm.nih.gov/pubmed/15715478

DMRHIMC	DI	DMRHIMC
DMRHIMC	DN	PF-00212062
DMRHIMC	MI	TT1ZAVI
DMRHIMC	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DMRHIMC	MT	DTT
DMRHIMC	MA	Antagonist
DMRHIMC	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 341).
DMRHIMC	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=341

DMV43NF	DI	DMV43NF
DMV43NF	DN	PF-00356231
DMV43NF	MI	TTXZ0KQ
DMV43NF	MN	Matrix metalloproteinase-12 (MMP-12)
DMV43NF	MT	DTT
DMV43NF	MA	Inhibitor
DMV43NF	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMV43NF	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMWL9CU	DI	DMWL9CU
DMWL9CU	DN	PF-00614435
DMWL9CU	MI	TTNDSF4
DMWL9CU	MN	Proto-oncogene c-Met (MET)
DMWL9CU	MT	DTT
DMWL9CU	MA	Inhibitor
DMWL9CU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
DMWL9CU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815

DMZ5JNT	DI	DMZ5JNT
DMZ5JNT	DN	PF-02367982
DMZ5JNT	MI	TTUV8G9
DMZ5JNT	MN	Progesterone receptor (PGR)
DMZ5JNT	MT	DTT
DMZ5JNT	MA	Inhibitor
DMZ5JNT	RN	Optimisation of a pyrazole series of progesterone antagonists; Part 1. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3384-6.
DMZ5JNT	RU	https://pubmed.ncbi.nlm.nih.gov/20430618

DMJ0936	DI	DMJ0936
DMJ0936	DN	PF-03772304
DMJ0936	MI	TTHBTOP
DMJ0936	MN	PI3-kinase gamma (PIK3CG)
DMJ0936	MT	DTT
DMJ0936	MA	Inhibitor
DMJ0936	RN	Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design. ACS Med Chem Lett. 2012 Nov 7;4(1):91-7.
DMJ0936	RU	https://pubmed.ncbi.nlm.nih.gov/24900568

DMJ0936	DI	DMJ0936
DMJ0936	DN	PF-03772304
DMJ0936	MI	TTCJG29
DMJ0936	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMJ0936	MT	DTT
DMJ0936	MA	Inhibitor
DMJ0936	RN	Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design. ACS Med Chem Lett. 2012 Nov 7;4(1):91-7.
DMJ0936	RU	https://pubmed.ncbi.nlm.nih.gov/24900568

DM5NBVG	DI	DM5NBVG
DM5NBVG	DN	PF-03800130
DM5NBVG	MI	TTEX248
DM5NBVG	MN	Dopamine D2 receptor (D2R)
DM5NBVG	MT	DTT
DM5NBVG	MA	Agonist
DM5NBVG	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 215).
DM5NBVG	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=215

DMMHQL4	DI	DMMHQL4
DMMHQL4	DN	PF-04475270
DMMHQL4	MI	TT79WV3
DMMHQL4	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DMMHQL4	MT	DTT
DMMHQL4	MA	Agonist
DMMHQL4	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 343).
DMMHQL4	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=343

DMPEZKT	DI	DMPEZKT
DMPEZKT	DN	PF-04957325
DMPEZKT	MI	TTIS4OW
DMPEZKT	MN	Phosphodiesterase 8 (PDE8)
DMPEZKT	MT	DTT
DMPEZKT	MA	Inhibitor
DMPEZKT	RN	Differential Expression and Function of PDE8 and PDE4 in Effector T cells: Implications for PDE8 as a Drug Target in Inflammation.Front Pharmacol. 2016 Aug 23;7:259. 
DMPEZKT	RU	https://pubmed.ncbi.nlm.nih.gov/27601994

DMZAE97	DI	DMZAE97
DMZAE97	DN	PF-05094037
DMZAE97	MI	TTCJG29
DMZAE97	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMZAE97	MT	DTT
DMZAE97	MA	Inhibitor
DMZAE97	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
DMZAE97	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109

DMOLI1E	DI	DMOLI1E
DMOLI1E	DN	PF-05313261
DMOLI1E	MI	TTKFVXR
DMOLI1E	MN	Renal carcinoma antigen NY-REN-64 (IRAK-4)
DMOLI1E	MT	DTT
DMOLI1E	MA	Inhibitor
DMOLI1E	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2045).
DMOLI1E	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2045

DMEUT0W	DI	DMEUT0W
DMEUT0W	DN	PF-06447475
DMEUT0W	MI	TTK0FEA
DMEUT0W	MN	Leucine-rich repeat kinase 2 (LRRK2)
DMEUT0W	MT	DTT
DMEUT0W	MA	Inhibitor
DMEUT0W	RN	Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor. J Med Chem. 2015 Jan 8;58(1):419-32.
DMEUT0W	RU	https://pubmed.ncbi.nlm.nih.gov/25353650

DMWIVM3	DI	DMWIVM3
DMWIVM3	DN	PF-06454589
DMWIVM3	MI	TTK0FEA
DMWIVM3	MN	Leucine-rich repeat kinase 2 (LRRK2)
DMWIVM3	MT	DTT
DMWIVM3	MA	Inhibitor
DMWIVM3	RN	Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor. J Med Chem. 2015 Jan 8;58(1):419-32.
DMWIVM3	RU	https://pubmed.ncbi.nlm.nih.gov/25353650

DMBM7LU	DI	DMBM7LU
DMBM7LU	DN	PF-0998425
DMBM7LU	MI	TTKPW01
DMBM7LU	MN	Androgen receptor messenger RNA (AR mRNA)
DMBM7LU	MT	DTT
DMBM7LU	MA	Inhibitor
DMBM7LU	RN	Rational design and synthesis of 4-((1R,2R)-2-hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a novel, nonsteroidal androgen recepto... J Med Chem. 2008 Nov 13;51(21):7010-4.
DMBM7LU	RU	https://pubmed.ncbi.nlm.nih.gov/18921992

DMJMU09	DI	DMJMU09
DMJMU09	DN	PF-18298
DMJMU09	MI	TTVBI8W
DMJMU09	MN	Dopamine transporter (DAT)
DMJMU09	MT	DTT
DMJMU09	MA	Inhibitor
DMJMU09	RN	Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92.
DMJMU09	RU	https://pubmed.ncbi.nlm.nih.gov/20471260

DMJMU09	DI	DMJMU09
DMJMU09	DN	PF-18298
DMJMU09	MI	TTAWNKZ
DMJMU09	MN	Norepinephrine transporter (NET)
DMJMU09	MT	DTT
DMJMU09	MA	Inhibitor
DMJMU09	RN	Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92.
DMJMU09	RU	https://pubmed.ncbi.nlm.nih.gov/20471260

DMJMU09	DI	DMJMU09
DMJMU09	DN	PF-18298
DMJMU09	MI	TT3ROYC
DMJMU09	MN	Serotonin transporter (SERT)
DMJMU09	MT	DTT
DMJMU09	MA	Inhibitor
DMJMU09	RN	Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92.
DMJMU09	RU	https://pubmed.ncbi.nlm.nih.gov/20471260

DM32FKD	DI	DM32FKD
DM32FKD	DN	PF-228
DM32FKD	MI	TTH6V3D
DM32FKD	MN	Cyclin-dependent kinase 1 (CDK1)
DM32FKD	MT	DTT
DM32FKD	MA	Inhibitor
DM32FKD	RN	Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem. 2007 May 18;282(20):14845-52.
DM32FKD	RU	https://pubmed.ncbi.nlm.nih.gov/17395594

DM32FKD	DI	DM32FKD
DM32FKD	DN	PF-228
DM32FKD	MI	TT7HF4W
DM32FKD	MN	Cyclin-dependent kinase 2 (CDK2)
DM32FKD	MT	DTT
DM32FKD	MA	Inhibitor
DM32FKD	RN	Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem. 2007 May 18;282(20):14845-52.
DM32FKD	RU	https://pubmed.ncbi.nlm.nih.gov/17395594

DM32FKD	DI	DM32FKD
DM32FKD	DN	PF-228
DM32FKD	MI	TTQYF7G
DM32FKD	MN	Cyclin-dependent kinase 7 (CDK7)
DM32FKD	MT	DTT
DM32FKD	MA	Inhibitor
DM32FKD	RN	Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem. 2007 May 18;282(20):14845-52.
DM32FKD	RU	https://pubmed.ncbi.nlm.nih.gov/17395594

DM32FKD	DI	DM32FKD
DM32FKD	DN	PF-228
DM32FKD	MI	TTON5IT
DM32FKD	MN	Focal adhesion kinase 1 (FAK)
DM32FKD	MT	DTT
DM32FKD	MA	Inhibitor
DM32FKD	RN	Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem. 2007 May 18;282(20):14845-52.
DM32FKD	RU	https://pubmed.ncbi.nlm.nih.gov/17395594

DM32FKD	DI	DM32FKD
DM32FKD	DN	PF-228
DM32FKD	MI	TTRSMW9
DM32FKD	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DM32FKD	MT	DTT
DM32FKD	MA	Inhibitor
DM32FKD	RN	Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem. 2007 May 18;282(20):14845-52.
DM32FKD	RU	https://pubmed.ncbi.nlm.nih.gov/17395594

DM32FKD	DI	DM32FKD
DM32FKD	DN	PF-228
DM32FKD	MI	TTJ3E9X
DM32FKD	MN	Inhibitor of nuclear factor kappa-B kinase beta (IKKB)
DM32FKD	MT	DTT
DM32FKD	MA	Inhibitor
DM32FKD	RN	Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem. 2007 May 18;282(20):14845-52.
DM32FKD	RU	https://pubmed.ncbi.nlm.nih.gov/17395594

DMYSWAZ	DI	DMYSWAZ
DMYSWAZ	DN	PF-271836
DMYSWAZ	MI	TTSCIUP
DMYSWAZ	MN	Oxytocin receptor (OTR)
DMYSWAZ	MT	DTT
DMYSWAZ	MA	Antagonist
DMYSWAZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 369).
DMYSWAZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=369

DMEZA0T	DI	DMEZA0T
DMEZA0T	DN	PF-3409409
DMEZA0T	MI	TTVBI8W
DMEZA0T	MN	Dopamine transporter (DAT)
DMEZA0T	MT	DTT
DMEZA0T	MA	Inhibitor
DMEZA0T	RN	Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more po... Bioorg Med Chem Lett. 2009 Aug 15;19(16):4579-83.
DMEZA0T	RU	https://pubmed.ncbi.nlm.nih.gov/19616432

DMEZA0T	DI	DMEZA0T
DMEZA0T	DN	PF-3409409
DMEZA0T	MI	TTQ3JTF
DMEZA0T	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DMEZA0T	MT	DTT
DMEZA0T	MA	Inhibitor
DMEZA0T	RN	Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more po... Bioorg Med Chem Lett. 2009 Aug 15;19(16):4579-83.
DMEZA0T	RU	https://pubmed.ncbi.nlm.nih.gov/19616432

DMEZA0T	DI	DMEZA0T
DMEZA0T	DN	PF-3409409
DMEZA0T	MI	TTH18TF
DMEZA0T	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMEZA0T	MT	DTT
DMEZA0T	MA	Inhibitor
DMEZA0T	RN	Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more po... Bioorg Med Chem Lett. 2009 Aug 15;19(16):4579-83.
DMEZA0T	RU	https://pubmed.ncbi.nlm.nih.gov/19616432

DMEZA0T	DI	DMEZA0T
DMEZA0T	DN	PF-3409409
DMEZA0T	MI	TTAWNKZ
DMEZA0T	MN	Norepinephrine transporter (NET)
DMEZA0T	MT	DTT
DMEZA0T	MA	Inhibitor
DMEZA0T	RN	Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more po... Bioorg Med Chem Lett. 2009 Aug 15;19(16):4579-83.
DMEZA0T	RU	https://pubmed.ncbi.nlm.nih.gov/19616432

DMEZA0T	DI	DMEZA0T
DMEZA0T	DN	PF-3409409
DMEZA0T	MI	TT3ROYC
DMEZA0T	MN	Serotonin transporter (SERT)
DMEZA0T	MT	DTT
DMEZA0T	MA	Inhibitor
DMEZA0T	RN	Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more po... Bioorg Med Chem Lett. 2009 Aug 15;19(16):4579-83.
DMEZA0T	RU	https://pubmed.ncbi.nlm.nih.gov/19616432

DM6KVIA	DI	DM6KVIA
DM6KVIA	DN	PF-3644022
DM6KVIA	MI	TTMUG9D
DM6KVIA	MN	MAPK-activated protein kinase 2 (MAPKAPK2)
DM6KVIA	MT	DTT
DM6KVIA	MA	Inhibitor
DM6KVIA	RN	A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation. J Pharmacol Exp Ther. 2010 Jun;333(3):797-807.
DM6KVIA	RU	https://pubmed.ncbi.nlm.nih.gov/20237073

DMCRXAM	DI	DMCRXAM
DMCRXAM	DN	PF3845
DMCRXAM	MI	TTDP1UC
DMCRXAM	MN	Fatty acid amide hydrolase (FAAH)
DMCRXAM	MT	DTT
DMCRXAM	MA	Inhibitor
DMCRXAM	RN	Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem Biol. 2009 Apr 24;16(4):411-20.
DMCRXAM	RU	https://pubmed.ncbi.nlm.nih.gov/19389627

DM7E391	DI	DM7E391
DM7E391	DN	PF-3900422
DM7E391	MI	TT9JNIC
DM7E391	MN	Histamine H3 receptor (H3R)
DM7E391	MT	DTT
DM7E391	MA	Antagonist
DM7E391	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 264).
DM7E391	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=264

DMC8G4S	DI	DMC8G4S
DMC8G4S	DN	PF-4181366
DMC8G4S	MI	TTZOEBC
DMC8G4S	MN	Phosphodiesterase 9 (PDE9)
DMC8G4S	MT	DTT
DMC8G4S	MA	Inhibitor
DMC8G4S	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1309).
DMC8G4S	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1309

DMB0OZ3	DI	DMB0OZ3
DMB0OZ3	DN	PF-429242
DMB0OZ3	MI	TTNSM2I
DMB0OZ3	MN	Endopeptidase S1P (MBTPS1)
DMB0OZ3	MT	DTT
DMB0OZ3	MA	Inhibitor
DMB0OZ3	RN	Aminopyrrolidineamide inhibitors of site-1 protease. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4411-4.
DMB0OZ3	RU	https://pubmed.ncbi.nlm.nih.gov/17583500

DMMNEJB	DI	DMMNEJB
DMMNEJB	DN	PF-454583
DMMNEJB	MI	TTNT7K8
DMMNEJB	MN	Nociceptin receptor (OPRL1)
DMMNEJB	MT	DTT
DMMNEJB	MA	Antagonist
DMMNEJB	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 320).
DMMNEJB	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=320

DMI29ED	DI	DMI29ED
DMI29ED	DN	PF-4840154
DMI29ED	MI	TTELV3W
DMI29ED	MN	Transformation-sensitive protein p120 (TRPA1)
DMI29ED	MT	DTT
DMI29ED	MA	Activator
DMI29ED	RN	Design and pharmacological evaluation of PF-4840154, a non-electrophilic reference agonist of the TrpA1 channel. Bioorg Med Chem Lett. 2011 Aug 15;21(16):4857-9.
DMI29ED	RU	https://pubmed.ncbi.nlm.nih.gov/21741838

DMV4P7S	DI	DMV4P7S
DMV4P7S	DN	PF-4957325-00
DMV4P7S	MI	TTIS4OW
DMV4P7S	MN	Phosphodiesterase 8 (PDE8)
DMV4P7S	MT	DTT
DMV4P7S	MA	Inhibitor
DMV4P7S	RN	PDE8 regulates rapid Teff cell adhesion and proliferation independent of ICER. PLoS One. 2010 Aug 9;5(8):e12011.
DMV4P7S	RU	https://pubmed.ncbi.nlm.nih.gov/20711499

DMSG6F1	DI	DMSG6F1
DMSG6F1	DN	PF-4989216
DMSG6F1	MI	TTHBTOP
DMSG6F1	MN	PI3-kinase gamma (PIK3CG)
DMSG6F1	MT	DTT
DMSG6F1	MA	Inhibitor
DMSG6F1	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2155).
DMSG6F1	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2155

DMUOFT0	DI	DMUOFT0
DMUOFT0	DN	PF-5177624
DMUOFT0	MI	TT9QBI6
DMUOFT0	MN	Phosphoinositide dependent protein kinase-1 (PDPK1)
DMUOFT0	MT	DTT
DMUOFT0	MA	Inhibitor
DMUOFT0	RN	Targeting 3-phosphoinoside-dependent kinase-1 to inhibit insulin-like growth factor-I induced AKT and p70 S6 kinase activation in breast cancer cells. PLoS One. 2012;7(10):e48402.
DMUOFT0	RU	https://pubmed.ncbi.nlm.nih.gov/23119004

DMD8QOZ	DI	DMD8QOZ
DMD8QOZ	DN	PF-526014
DMD8QOZ	MI	TTVBI8W
DMD8QOZ	MN	Dopamine transporter (DAT)
DMD8QOZ	MT	DTT
DMD8QOZ	MA	Inhibitor
DMD8QOZ	RN	Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92.
DMD8QOZ	RU	https://pubmed.ncbi.nlm.nih.gov/20471260

DMD8QOZ	DI	DMD8QOZ
DMD8QOZ	DN	PF-526014
DMD8QOZ	MI	TTAWNKZ
DMD8QOZ	MN	Norepinephrine transporter (NET)
DMD8QOZ	MT	DTT
DMD8QOZ	MA	Inhibitor
DMD8QOZ	RN	Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92.
DMD8QOZ	RU	https://pubmed.ncbi.nlm.nih.gov/20471260

DMD8QOZ	DI	DMD8QOZ
DMD8QOZ	DN	PF-526014
DMD8QOZ	MI	TT3ROYC
DMD8QOZ	MN	Serotonin transporter (SERT)
DMD8QOZ	MT	DTT
DMD8QOZ	MA	Inhibitor
DMD8QOZ	RN	Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92.
DMD8QOZ	RU	https://pubmed.ncbi.nlm.nih.gov/20471260

DMD8QOZ	DI	DMD8QOZ
DMD8QOZ	DN	PF-526014
DMD8QOZ	MI	TTQ6VDM
DMD8QOZ	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMD8QOZ	MT	DTT
DMD8QOZ	MA	Inhibitor
DMD8QOZ	RN	Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92.
DMD8QOZ	RU	https://pubmed.ncbi.nlm.nih.gov/20471260

DMC4UHD	DI	DMC4UHD
DMC4UHD	DN	PF-543
DMC4UHD	MI	TTOHFIY
DMC4UHD	MN	Sphingosine kinase 1 (SPHK1)
DMC4UHD	MT	DTT
DMC4UHD	MA	Inhibitor
DMC4UHD	RN	Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1. Biochem J. 2012 May 15;444(1):79-88.
DMC4UHD	RU	https://pubmed.ncbi.nlm.nih.gov/22397330

DMY93GJ	DI	DMY93GJ
DMY93GJ	DN	PF-592379
DMY93GJ	MI	TT4C8EA
DMY93GJ	MN	Dopamine D3 receptor (D3R)
DMY93GJ	MT	DTT
DMY93GJ	MA	Agonist
DMY93GJ	RN	Lack of abuse potential in a highly selective dopamine D3 agonist, PF-592,379, in drug self-administration and drug discrimination in rats. Behav Pharmacol. 2012 Jun;23(3):280-91.
DMY93GJ	RU	https://pubmed.ncbi.nlm.nih.gov/22470105

DMY93GJ	DI	DMY93GJ
DMY93GJ	DN	PF-592379
DMY93GJ	MI	TTE0A2F
DMY93GJ	MN	Dopamine D4 receptor (D4R)
DMY93GJ	MT	DTT
DMY93GJ	MA	Agonist
DMY93GJ	RN	Lack of abuse potential in a highly selective dopamine D3 agonist, PF-592,379, in drug self-administration and drug discrimination in rats. Behav Pharmacol. 2012 Jun;23(3):280-91.
DMY93GJ	RU	https://pubmed.ncbi.nlm.nih.gov/22470105

DMBE24Y	DI	DMBE24Y
DMBE24Y	DN	PF750
DMBE24Y	MI	TTDP1UC
DMBE24Y	MN	Fatty acid amide hydrolase (FAAH)
DMBE24Y	MT	DTT
DMBE24Y	MA	Inhibitor
DMBE24Y	RN	Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. Biochemistry. 2007 Nov 13;46(45):13019-30.
DMBE24Y	RU	https://pubmed.ncbi.nlm.nih.gov/17949010

DM49MYE	DI	DM49MYE
DM49MYE	DN	PF-877423
DM49MYE	MI	TTN7BL9
DM49MYE	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DM49MYE	MT	DTT
DM49MYE	MA	Inhibitor
DM49MYE	RN	The development and SAR of pyrrolidine carboxamide 11beta-HSD1 inhibitors. Bioorg Med Chem Lett. 2010 May 1;20(9):2897-902.
DM49MYE	RU	https://pubmed.ncbi.nlm.nih.gov/20363126

DMIUZSR	DI	DMIUZSR
DMIUZSR	DN	PF-956980
DMIUZSR	MI	TTT7PJU
DMIUZSR	MN	Janus kinase 3 (JAK-3)
DMIUZSR	MT	DTT
DMIUZSR	MA	Inhibitor
DMIUZSR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2049).
DMIUZSR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2049

DM9AZKE	DI	DM9AZKE
DM9AZKE	DN	PFFFFF
DM9AZKE	MI	TTFPQV7
DM9AZKE	MN	Galectin-3 (LGALS3)
DM9AZKE	MT	DTT
DM9AZKE	MA	Inhibitor
DM9AZKE	RN	Discovery of galectin ligands in fully randomized combinatorial one-bead-one-compound (glyco)peptide libraries. Bioorg Med Chem Lett. 2007 Feb 1;17(3):793-8.
DM9AZKE	RU	https://pubmed.ncbi.nlm.nih.gov/17095217

DM9CV6S	DI	DM9CV6S
DM9CV6S	DN	p-F-HHSiD
DM9CV6S	MI	TTOXS3C
DM9CV6S	MN	Muscarinic acetylcholine receptor (CHRM)
DM9CV6S	MT	DTT
DM9CV6S	MA	Antagonist
DM9CV6S	RN	Stimulation of cyclic AMP accumulation and phosphoinositide hydrolysis by M3 muscarinic receptors in the rat peripheral lung. Biochem Pharmacol. 1996 Aug 23;52(4):643-58.
DM9CV6S	RU	https://pubmed.ncbi.nlm.nih.gov/8759038

DM9CV6S	DI	DM9CV6S
DM9CV6S	DN	p-F-HHSiD
DM9CV6S	MI	TTQ13Z5
DM9CV6S	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DM9CV6S	MT	DTT
DM9CV6S	MA	Antagonist
DM9CV6S	RN	Stimulation of cyclic AMP accumulation and phosphoinositide hydrolysis by M3 muscarinic receptors in the rat peripheral lung. Biochem Pharmacol. 1996 Aug 23;52(4):643-58.
DM9CV6S	RU	https://pubmed.ncbi.nlm.nih.gov/8759038

DMVFK3J	DI	DMVFK3J
DMVFK3J	DN	PFI-1
DMVFK3J	MI	TTRA6BO
DMVFK3J	MN	Bromodomain-containing protein 4 (BRD4)
DMVFK3J	MT	DTT
DMVFK3J	MA	Inhibitor
DMVFK3J	RN	Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit. J Med Chem. 2012 Nov 26;55(22):9831-7.
DMVFK3J	RU	https://pubmed.ncbi.nlm.nih.gov/23095041

DM619EU	DI	DM619EU
DM619EU	DN	PFI-3
DM619EU	MI	TTVQEZS
DM619EU	MN	Mitotic growth and transcription activator (BAF190A)
DM619EU	MT	DTT
DM619EU	MA	Inhibitor
DM619EU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2740).
DM619EU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2740

DM619EU	DI	DM619EU
DM619EU	DN	PFI-3
DM619EU	MI	TTH8ZRL
DM619EU	MN	Polybromo-1 (PBRM1)
DM619EU	MT	DTT
DM619EU	MA	Inhibitor
DM619EU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2738).
DM619EU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2738

DMPKXNZ	DI	DMPKXNZ
DMPKXNZ	DN	PFI-4
DMPKXNZ	MI	TTT46BN
DMPKXNZ	MN	Bromodomain and PHD finger containing 1 (BRPF1)
DMPKXNZ	MT	DTT
DMPKXNZ	MA	Inhibitor
DMPKXNZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2730).
DMPKXNZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2730

DM2TP4Q	DI	DM2TP4Q
DM2TP4Q	DN	PG-01037
DM2TP4Q	MI	TTSQIFT
DM2TP4Q	MN	5-HT 1A receptor (HTR1A)
DM2TP4Q	MT	DTT
DM2TP4Q	MA	Inhibitor
DM2TP4Q	RN	Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3... J Med Chem. 2007 Aug 23;50(17):4135-46.
DM2TP4Q	RU	https://pubmed.ncbi.nlm.nih.gov/17672446

DM2TP4Q	DI	DM2TP4Q
DM2TP4Q	DN	PG-01037
DM2TP4Q	MI	TTJQOD7
DM2TP4Q	MN	5-HT 2A receptor (HTR2A)
DM2TP4Q	MT	DTT
DM2TP4Q	MA	Inhibitor
DM2TP4Q	RN	Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3... J Med Chem. 2007 Aug 23;50(17):4135-46.
DM2TP4Q	RU	https://pubmed.ncbi.nlm.nih.gov/17672446

DM2TP4Q	DI	DM2TP4Q
DM2TP4Q	DN	PG-01037
DM2TP4Q	MI	TTWJBZ5
DM2TP4Q	MN	5-HT 2C receptor (HTR2C)
DM2TP4Q	MT	DTT
DM2TP4Q	MA	Inhibitor
DM2TP4Q	RN	Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3... J Med Chem. 2007 Aug 23;50(17):4135-46.
DM2TP4Q	RU	https://pubmed.ncbi.nlm.nih.gov/17672446

DM2TP4Q	DI	DM2TP4Q
DM2TP4Q	DN	PG-01037
DM2TP4Q	MI	TTEX248
DM2TP4Q	MN	Dopamine D2 receptor (D2R)
DM2TP4Q	MT	DTT
DM2TP4Q	MA	Inhibitor
DM2TP4Q	RN	Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3... J Med Chem. 2007 Aug 23;50(17):4135-46.
DM2TP4Q	RU	https://pubmed.ncbi.nlm.nih.gov/17672446

DM2TP4Q	DI	DM2TP4Q
DM2TP4Q	DN	PG-01037
DM2TP4Q	MI	TT4C8EA
DM2TP4Q	MN	Dopamine D3 receptor (D3R)
DM2TP4Q	MT	DTT
DM2TP4Q	MA	Inhibitor
DM2TP4Q	RN	Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3... J Med Chem. 2007 Aug 23;50(17):4135-46.
DM2TP4Q	RU	https://pubmed.ncbi.nlm.nih.gov/17672446

DM2TP4Q	DI	DM2TP4Q
DM2TP4Q	DN	PG-01037
DM2TP4Q	MI	TTE0A2F
DM2TP4Q	MN	Dopamine D4 receptor (D4R)
DM2TP4Q	MT	DTT
DM2TP4Q	MA	Inhibitor
DM2TP4Q	RN	Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3... J Med Chem. 2007 Aug 23;50(17):4135-46.
DM2TP4Q	RU	https://pubmed.ncbi.nlm.nih.gov/17672446

DMH4AKG	DI	DMH4AKG
DMH4AKG	DN	PG-1014491
DMH4AKG	MI	TTIKWV4
DMH4AKG	MN	Geranyltranstransferase (FDPS)
DMH4AKG	MT	DTT
DMH4AKG	MA	Inhibitor
DMH4AKG	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 643).
DMH4AKG	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=643

DMWP0BX	DI	DMWP0BX
DMWP0BX	DN	PG-120
DMWP0BX	MI	TTN6Y9A
DMWP0BX	MN	CD40L receptor (CD40)
DMWP0BX	MT	DTT
DMWP0BX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1874).
DMWP0BX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1874

DM0NBKR	DI	DM0NBKR
DM0NBKR	DN	PGC GLP-1
DM0NBKR	MI	TTVIMDE
DM0NBKR	MN	Glucagon-like peptide 1 receptor (GLP1R)
DM0NBKR	MT	DTT
DM0NBKR	MA	Modulator
DM0NBKR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249).
DM0NBKR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=249

DMYDW6J	DI	DMYDW6J
DMYDW6J	DN	PGD2
DMYDW6J	MI	TTNVEIR
DMYDW6J	MN	Prostaglandin D2 receptor (PTGDR)
DMYDW6J	MT	DTT
DMYDW6J	MA	Agonist
DMYDW6J	RN	A novel biological role for prostaglandin D2 is suggested by distribution studies of the rat DP prostanoid receptor. Eur J Pharmacol. 1999 Jul 14;377(1):101-15.
DMYDW6J	RU	https://pubmed.ncbi.nlm.nih.gov/10448933

DMYDW6J	DI	DMYDW6J
DMYDW6J	DN	PGD2
DMYDW6J	MI	TTQDMX5
DMYDW6J	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMYDW6J	MT	DTT
DMYDW6J	MA	Agonist
DMYDW6J	RN	CRTH2-specific binding characteristics of [3H]ramatroban and its effects on PGD2-, 15-deoxy-Delta12, 14-PGJ2- and indomethacin-induced agonist resp... Eur J Pharmacol. 2005 Nov 7;524(1-3):30-7.
DMYDW6J	RU	https://pubmed.ncbi.nlm.nih.gov/16256979

DMYDW6J	DI	DMYDW6J
DMYDW6J	DN	PGD2
DMYDW6J	MI	TTG1QMU
DMYDW6J	MN	Prostaglandin E2 receptor EP1 (PTGER1)
DMYDW6J	MT	DTT
DMYDW6J	MA	Agonist
DMYDW6J	RN	Cloned human EP1 prostanoid receptor pharmacology characterized using radioligand binding techniques. J Pharm Pharmacol. 2002 Apr;54(4):539-47.
DMYDW6J	RU	https://pubmed.ncbi.nlm.nih.gov/11999132

DMYDW6J	DI	DMYDW6J
DMYDW6J	DN	PGD2
DMYDW6J	MI	TT1ZAVI
DMYDW6J	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DMYDW6J	MT	DTT
DMYDW6J	MA	Agonist
DMYDW6J	RN	Importance of the extracellular domain for prostaglandin EP(2) receptor function. Mol Pharmacol. 1999 Sep;56(3):545-51.
DMYDW6J	RU	https://pubmed.ncbi.nlm.nih.gov/10462542

DMYDW6J	DI	DMYDW6J
DMYDW6J	DN	PGD2
DMYDW6J	MI	TTPNGDE
DMYDW6J	MN	Prostaglandin E2 receptor EP3 (PTGER3)
DMYDW6J	MT	DTT
DMYDW6J	MA	Agonist
DMYDW6J	RN	Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41.
DMYDW6J	RU	https://pubmed.ncbi.nlm.nih.gov/9537820

DMYDW6J	DI	DMYDW6J
DMYDW6J	DN	PGD2
DMYDW6J	MI	TT79WV3
DMYDW6J	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DMYDW6J	MT	DTT
DMYDW6J	MA	Agonist
DMYDW6J	RN	Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41.
DMYDW6J	RU	https://pubmed.ncbi.nlm.nih.gov/9537820

DMYDW6J	DI	DMYDW6J
DMYDW6J	DN	PGD2
DMYDW6J	MI	TTT2ZAR
DMYDW6J	MN	Prostaglandin F2-alpha receptor (PTGFR)
DMYDW6J	MT	DTT
DMYDW6J	MA	Agonist
DMYDW6J	RN	Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
DMYDW6J	RU	https://pubmed.ncbi.nlm.nih.gov/9313928

DMWNCLJ	DI	DMWNCLJ
DMWNCLJ	DN	PGD3
DMWNCLJ	MI	TTQDMX5
DMWNCLJ	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMWNCLJ	MT	DTT
DMWNCLJ	MA	Agonist
DMWNCLJ	RN	Expression and molecular pharmacology of the mouse CRTH2 receptor. J Pharmacol Exp Ther. 2003 Aug;306(2):463-70.
DMWNCLJ	RU	https://pubmed.ncbi.nlm.nih.gov/12721327

DMNY187	DI	DMNY187
DMNY187	DN	P'-geranyl 2-fluoromevalonate 5-diphosphate
DMNY187	MI	TTE5J6X
DMNY187	MN	Diphosphomevalonate decarboxylase (MVD)
DMNY187	MT	DTT
DMNY187	MA	Inhibitor
DMNY187	RN	Human mevalonate diphosphate decarboxylase: characterization, investigation of the mevalonate diphosphate binding site, and crystal structure. Arch Biochem Biophys. 2008 Dec 1;480(1):58-67.
DMNY187	RU	https://pubmed.ncbi.nlm.nih.gov/18823933

DMJ4SIA	DI	DMJ4SIA
DMJ4SIA	DN	P'-geranyl 3,5,7-trihydroxy-3-methylheptanate 7-diphosphate
DMJ4SIA	MI	TTE5J6X
DMJ4SIA	MN	Diphosphomevalonate decarboxylase (MVD)
DMJ4SIA	MT	DTT
DMJ4SIA	MA	Inhibitor
DMJ4SIA	RN	Bifunctional inhibitors of mevalonate kinase and mevalonate 5-diphosphate decarboxylase. Org Lett. 2006 Mar 16;8(6):1013-6.
DMJ4SIA	RU	https://pubmed.ncbi.nlm.nih.gov/16524256

DMO9BUR	DI	DMO9BUR
DMO9BUR	DN	P'-geranyl 3,5,8-trihydroxy-3-methyloctanate 8-diphosphate
DMO9BUR	MI	TTE5J6X
DMO9BUR	MN	Diphosphomevalonate decarboxylase (MVD)
DMO9BUR	MT	DTT
DMO9BUR	MA	Inhibitor
DMO9BUR	RN	Bifunctional inhibitors of mevalonate kinase and mevalonate 5-diphosphate decarboxylase. Org Lett. 2006 Mar 16;8(6):1013-6.
DMO9BUR	RU	https://pubmed.ncbi.nlm.nih.gov/16524256

DM2395E	DI	DM2395E
DM2395E	DN	P'-geranyl 3,5,9-trihydroxy-3-methylnonanate 9-diphosphate
DM2395E	MI	TTE5J6X
DM2395E	MN	Diphosphomevalonate decarboxylase (MVD)
DM2395E	MT	DTT
DM2395E	MA	Inhibitor
DM2395E	RN	Bifunctional inhibitors of mevalonate kinase and mevalonate 5-diphosphate decarboxylase. Org Lett. 2006 Mar 16;8(6):1013-6.
DM2395E	RU	https://pubmed.ncbi.nlm.nih.gov/16524256

DMUPWQT	DI	DMUPWQT
DMUPWQT	DN	PGF1alpha
DMUPWQT	MI	TTWOCZI
DMUPWQT	MN	Cation channel sperm-associated protein (CatSper)
DMUPWQT	MT	DTT
DMUPWQT	MA	Activator
DMUPWQT	RN	Progesterone activates the principal Ca2+ channel of human sperm. Nature. 2011 Mar 17;471(7338):387-91.
DMUPWQT	RU	https://pubmed.ncbi.nlm.nih.gov/21412339

DMUPWQT	DI	DMUPWQT
DMUPWQT	DN	PGF1alpha
DMUPWQT	MI	TT5CISB
DMUPWQT	MN	Cation channel sperm-associated protein 1 (CatSper1)
DMUPWQT	MT	DTT
DMUPWQT	MA	Activator
DMUPWQT	RN	Progesterone activates the principal Ca2+ channel of human sperm. Nature. 2011 Mar 17;471(7338):387-91.
DMUPWQT	RU	https://pubmed.ncbi.nlm.nih.gov/21412339

DMUPWQT	DI	DMUPWQT
DMUPWQT	DN	PGF1alpha
DMUPWQT	MI	TTOEGC4
DMUPWQT	MN	Cation channel sperm-associated protein 2 (CatSper2)
DMUPWQT	MT	DTT
DMUPWQT	MA	Activator
DMUPWQT	RN	Progesterone activates the principal Ca2+ channel of human sperm. Nature. 2011 Mar 17;471(7338):387-91.
DMUPWQT	RU	https://pubmed.ncbi.nlm.nih.gov/21412339

DMUPWQT	DI	DMUPWQT
DMUPWQT	DN	PGF1alpha
DMUPWQT	MI	TTP52ZV
DMUPWQT	MN	Cation channel sperm-associated protein 3 (CatSper3)
DMUPWQT	MT	DTT
DMUPWQT	MA	Activator
DMUPWQT	RN	Progesterone activates the principal Ca2+ channel of human sperm. Nature. 2011 Mar 17;471(7338):387-91.
DMUPWQT	RU	https://pubmed.ncbi.nlm.nih.gov/21412339

DMZFVGC	DI	DMZFVGC
DMZFVGC	DN	PGH2
DMZFVGC	MI	TT2O84V
DMZFVGC	MN	Thromboxane A2 receptor (TBXA2R)
DMZFVGC	MT	DTT
DMZFVGC	MA	Agonist
DMZFVGC	RN	Effects of KW-3635, a novel dibenzoxepin derivative of a selective thromboxane A2 antagonist, on human, guinea pig and rat platelets. Jpn J Pharmacol. 1992 Jul;59(3):357-64.
DMZFVGC	RU	https://pubmed.ncbi.nlm.nih.gov/1434130

DMTVY6K	DI	DMTVY6K
DMTVY6K	DN	PGI-02749
DMTVY6K	MI	TT9G4N0
DMTVY6K	MN	Glutamate carboxypeptidase II (GCPII)
DMTVY6K	MT	DTT
DMTVY6K	MA	Inhibitor
DMTVY6K	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1606).
DMTVY6K	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1606

DMR2LTC	DI	DMR2LTC
DMR2LTC	DN	PGJ2
DMR2LTC	MI	TTNVEIR
DMR2LTC	MN	Prostaglandin D2 receptor (PTGDR)
DMR2LTC	MT	DTT
DMR2LTC	MA	Agonist
DMR2LTC	RN	Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist. Br J Pharmacol. 1998 Apr;123(7):1317-24.
DMR2LTC	RU	https://pubmed.ncbi.nlm.nih.gov/9579725

DMR2LTC	DI	DMR2LTC
DMR2LTC	DN	PGJ2
DMR2LTC	MI	TTQDMX5
DMR2LTC	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMR2LTC	MT	DTT
DMR2LTC	MA	Agonist
DMR2LTC	RN	Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2. Br J Pharmacol. 2002 Dec;137(8):1163-72.
DMR2LTC	RU	https://pubmed.ncbi.nlm.nih.gov/12466225

DMLMTIY	DI	DMLMTIY
DMLMTIY	DN	PGlu-His-Trp-Ser-His-D-Tyr-Leu-Arg-Pro-Gly-NH2
DMLMTIY	MI	TT8R70G
DMLMTIY	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMLMTIY	MT	DTT
DMLMTIY	MA	Inhibitor
DMLMTIY	RN	Overlapping, nonidentical binding sites of different classes of nonpeptide antagonists for the human gonadotropin-releasing hormone receptor. J Med Chem. 2006 Jan 26;49(2):637-47.
DMLMTIY	RU	https://pubmed.ncbi.nlm.nih.gov/16420049

DM40PT5	DI	DM40PT5
DM40PT5	DN	PGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2
DM40PT5	MI	TT8R70G
DM40PT5	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DM40PT5	MT	DTT
DM40PT5	MA	Inhibitor
DM40PT5	RN	Overlapping, nonidentical binding sites of different classes of nonpeptide antagonists for the human gonadotropin-releasing hormone receptor. J Med Chem. 2006 Jan 26;49(2):637-47.
DM40PT5	RU	https://pubmed.ncbi.nlm.nih.gov/16420049

DM5GY6Z	DI	DM5GY6Z
DM5GY6Z	DN	PH-709829
DM5GY6Z	MI	TTPC4TU
DM5GY6Z	MN	5-HT 3A receptor (HTR3A)
DM5GY6Z	MT	DTT
DM5GY6Z	MA	Inhibitor
DM5GY6Z	RN	Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor:... Bioorg Med Chem Lett. 2008 Jun 15;18(12):3611-5.
DM5GY6Z	RU	https://pubmed.ncbi.nlm.nih.gov/18490160

DM5GY6Z	DI	DM5GY6Z
DM5GY6Z	DN	PH-709829
DM5GY6Z	MI	TTLA931
DM5GY6Z	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DM5GY6Z	MT	DTT
DM5GY6Z	MA	Inhibitor
DM5GY6Z	RN	Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor:... Bioorg Med Chem Lett. 2008 Jun 15;18(12):3611-5.
DM5GY6Z	RU	https://pubmed.ncbi.nlm.nih.gov/18490160

DMCGX9U	DI	DMCGX9U
DMCGX9U	DN	PHA-665752
DMCGX9U	MI	TTNDSF4
DMCGX9U	MN	Proto-oncogene c-Met (MET)
DMCGX9U	MT	DTT
DMCGX9U	MA	Inhibitor
DMCGX9U	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
DMCGX9U	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815

DMHQ6KT	DI	DMHQ6KT
DMHQ6KT	DN	PHA-666859
DMHQ6KT	MI	TTQBR95
DMHQ6KT	MN	Stress-activated protein kinase 2a (p38 alpha)
DMHQ6KT	MT	DTT
DMHQ6KT	MA	Inhibitor
DMHQ6KT	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1499).
DMHQ6KT	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1499

DMNS70E	DI	DMNS70E
DMNS70E	DN	PHA-690509
DMNS70E	MI	TT7HF4W
DMNS70E	MN	Cyclin-dependent kinase 2 (CDK2)
DMNS70E	MT	DTT
DMNS70E	MA	Inhibitor
DMNS70E	RN	Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14621-6.
DMNS70E	RU	https://pubmed.ncbi.nlm.nih.gov/20679242

DM4H7D5	DI	DM4H7D5
DM4H7D5	DN	PHA-767491
DM4H7D5	MI	TTSMTDI
DM4H7D5	MN	CDC7-related kinase (CDC7)
DM4H7D5	MT	DTT
DM4H7D5	MA	Modulator
DM4H7D5	RN	Drug design with Cdc7 kinase: a potential novel cancer therapy target. Drug Des Devel Ther. 2009 Feb 6;2:255-64.
DM4H7D5	RU	https://www.ncbi.nlm.nih.gov/pubmed/19920912

DMALRCH	DI	DMALRCH
DMALRCH	DN	Phaclofen
DMALRCH	MI	TTDCVZW
DMALRCH	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMALRCH	MT	DTT
DMALRCH	MA	Antagonist
DMALRCH	RN	Astrocytes and interneurons in memory processing in the chick hippocampus: roles for G-coupled protein receptors, GABA(B) and mGluR1. Neurochem Res. 2009 Oct;34(10):1712-20.
DMALRCH	RU	https://pubmed.ncbi.nlm.nih.gov/19415487

DM7H5KY	DI	DM7H5KY
DM7H5KY	DN	PHASEOLIN
DM7H5KY	MI	TT50QJ3
DM7H5KY	MN	Influenza Neuraminidase (Influ NA)
DM7H5KY	MT	DTT
DM7H5KY	MA	Inhibitor
DM7H5KY	RN	Prenylated pterocarpans as bacterial neuraminidase inhibitors. Bioorg Med Chem. 2010 May 1;18(9):3335-44.
DM7H5KY	RU	https://pubmed.ncbi.nlm.nih.gov/20363636

DMSQ10I	DI	DMSQ10I
DMSQ10I	DN	PHASEOLLIDIN
DMSQ10I	MI	TT50QJ3
DMSQ10I	MN	Influenza Neuraminidase (Influ NA)
DMSQ10I	MT	DTT
DMSQ10I	MA	Inhibitor
DMSQ10I	RN	Prenylated pterocarpans as bacterial neuraminidase inhibitors. Bioorg Med Chem. 2010 May 1;18(9):3335-44.
DMSQ10I	RU	https://pubmed.ncbi.nlm.nih.gov/20363636

DMNJY79	DI	DMNJY79
DMNJY79	DN	PHCCC
DMNJY79	MI	TTVBPDM
DMNJY79	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMNJY79	MT	DTT
DMNJY79	MA	Modulator (allosteric modulator)
DMNJY79	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 289).
DMNJY79	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=289

DMNJY79	DI	DMNJY79
DMNJY79	DN	PHCCC
DMNJY79	MI	TTICZ1O
DMNJY79	MN	Metabotropic glutamate receptor 4 (mGluR4)
DMNJY79	MT	DTT
DMNJY79	MA	Modulator (allosteric modulator)
DMNJY79	RN	(-)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection. Neuropharmacology. 2003 Dec;45(7):895-906.
DMNJY79	RU	https://pubmed.ncbi.nlm.nih.gov/14573382

DMNJY79	DI	DMNJY79
DMNJY79	DN	PHCCC
DMNJY79	MI	TTWRP2F
DMNJY79	MN	Metabotropic glutamate receptor 6 (mGluR6)
DMNJY79	MT	DTT
DMNJY79	MA	Modulator (allosteric modulator)
DMNJY79	RN	The mGlu(4) receptor allosteric modulator N-phenyl-7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxamide acts as a direct agonist at mGlu(6) receptors. Eur J Pharmacol. 2008 Jul 28;589(1-3):49-52.
DMNJY79	RU	https://pubmed.ncbi.nlm.nih.gov/18593581

DMAP04X	DI	DMAP04X
DMAP04X	DN	PHELLIGRIDIN I
DMAP04X	MI	TTELIN2
DMAP04X	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMAP04X	MT	DTT
DMAP04X	MA	Inhibitor
DMAP04X	RN	Structures, biogenesis, and biological activities of pyrano[4,3-c]isochromen-4-one derivatives from the Fungus Phellinus igniarius. J Nat Prod. 2007 Feb;70(2):296-9.
DMAP04X	RU	https://pubmed.ncbi.nlm.nih.gov/17279797

DMJLUFM	DI	DMJLUFM
DMJLUFM	DN	phenamil
DMJLUFM	MI	TTAHD89
DMJLUFM	MN	Polycystic kidney disease 2-like 1 (TRPP2)
DMJLUFM	MT	DTT
DMJLUFM	MA	Blocker (channel blocker)
DMJLUFM	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 505).
DMJLUFM	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=505

DMYT8UG	DI	DMYT8UG
DMYT8UG	DN	Phenanthrene-2-carboxylic acid hydroxyamide
DMYT8UG	MI	TT2J34L
DMYT8UG	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMYT8UG	MT	DTT
DMYT8UG	MA	Inhibitor
DMYT8UG	RN	Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8.
DMYT8UG	RU	https://pubmed.ncbi.nlm.nih.gov/2308149

DMRYJBA	DI	DMRYJBA
DMRYJBA	DN	Phenanthrene-3-carboxylic acid hydroxyamide
DMRYJBA	MI	TT2J34L
DMRYJBA	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMRYJBA	MT	DTT
DMRYJBA	MA	Inhibitor
DMRYJBA	RN	Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8.
DMRYJBA	RU	https://pubmed.ncbi.nlm.nih.gov/2308149

DMG8KS9	DI	DMG8KS9
DMG8KS9	DN	Phenanthrene-9,10-dione
DMG8KS9	MI	TTEB0GD
DMG8KS9	MN	Cholinesterase (BCHE)
DMG8KS9	MT	DTT
DMG8KS9	MA	Inhibitor
DMG8KS9	RN	Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34.
DMG8KS9	RU	https://pubmed.ncbi.nlm.nih.gov/17941623

DMG8KS9	DI	DMG8KS9
DMG8KS9	DN	Phenanthrene-9,10-dione
DMG8KS9	MI	TTMF541
DMG8KS9	MN	Liver carboxylesterase (CES1)
DMG8KS9	MT	DTT
DMG8KS9	MA	Inhibitor
DMG8KS9	RN	Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34.
DMG8KS9	RU	https://pubmed.ncbi.nlm.nih.gov/17941623

DMG8KS9	DI	DMG8KS9
DMG8KS9	DN	Phenanthrene-9,10-dione
DMG8KS9	MI	DE9JFMC
DMG8KS9	MN	NADPH-dependent carbonyl reductase 1 (CBR1)
DMG8KS9	MT	DME
DMG8KS9	MA	Metabolism
DMG8KS9	RN	Studies on reduction of S-nitrosoglutathione by human carbonyl reductases 1 and 3. Chem Biol Interact. 2011 May 30;191(1-3):95-103.
DMG8KS9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21256830

DMG8KS9	DI	DMG8KS9
DMG8KS9	DN	Phenanthrene-9,10-dione
DMG8KS9	MI	DEIVKZ8
DMG8KS9	MN	NADPH-dependent carbonyl reductase 3 (CBR3)
DMG8KS9	MT	DME
DMG8KS9	MA	Metabolism
DMG8KS9	RN	Studies on reduction of S-nitrosoglutathione by human carbonyl reductases 1 and 3. Chem Biol Interact. 2011 May 30;191(1-3):95-103.
DMG8KS9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21256830

DMG8KS9	DI	DMG8KS9
DMG8KS9	DN	Phenanthrene-9,10-dione
DMG8KS9	MI	DEP6GT1
DMG8KS9	MN	Small intestine reductase (AKR1B10)
DMG8KS9	MT	DME
DMG8KS9	MA	Metabolism
DMG8KS9	RN	Exposure to 9,10-phenanthrenequinone accelerates malignant progression of lung cancer cells through up-regulation of aldo-keto reductase 1B10. Toxicol Appl Pharmacol. 2014 Jul 15;278(2):180-9.
DMG8KS9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24813866

DMCTVMI	DI	DMCTVMI
DMCTVMI	DN	PHENAZOCINE
DMCTVMI	MI	TT27RFC
DMCTVMI	MN	Opioid receptor delta (OPRD1)
DMCTVMI	MT	DTT
DMCTVMI	MA	Inhibitor
DMCTVMI	RN	Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8.
DMCTVMI	RU	https://pubmed.ncbi.nlm.nih.gov/19027293

DMCTVMI	DI	DMCTVMI
DMCTVMI	DN	PHENAZOCINE
DMCTVMI	MI	TTQW87Y
DMCTVMI	MN	Opioid receptor kappa (OPRK1)
DMCTVMI	MT	DTT
DMCTVMI	MA	Inhibitor
DMCTVMI	RN	Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8.
DMCTVMI	RU	https://pubmed.ncbi.nlm.nih.gov/19027293

DMCTVMI	DI	DMCTVMI
DMCTVMI	DN	PHENAZOCINE
DMCTVMI	MI	TTKWM86
DMCTVMI	MN	Opioid receptor mu (MOP)
DMCTVMI	MT	DTT
DMCTVMI	MA	Inhibitor
DMCTVMI	RN	Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8.
DMCTVMI	RU	https://pubmed.ncbi.nlm.nih.gov/19027293

DMCE985	DI	DMCE985
DMCE985	DN	Phenazone
DMCE985	MI	DEJGDUW
DMCE985	MN	Cytochrome P450 1A2 (CYP1A2)
DMCE985	MT	DME
DMCE985	MA	Metabolism
DMCE985	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMCE985	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMCE985	DI	DMCE985
DMCE985	DN	Phenazone
DMCE985	MI	DEJVYAZ
DMCE985	MN	Cytochrome P450 2A6 (CYP2A6)
DMCE985	MT	DME
DMCE985	MA	Metabolism
DMCE985	RN	Identification of the human hepatic cytochromes P450 involved in the in vitro oxidation of antipyrine. Drug Metab Dispos. 1996 Apr;24(4):487-94.
DMCE985	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8801065

DMCE985	DI	DMCE985
DMCE985	DN	Phenazone
DMCE985	MI	DEPKLMQ
DMCE985	MN	Cytochrome P450 2B6 (CYP2B6)
DMCE985	MT	DME
DMCE985	MA	Metabolism
DMCE985	RN	Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes. Drug Metab Dispos. 1997 Mar;25(3):390-3.
DMCE985	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9172960

DMCE985	DI	DMCE985
DMCE985	DN	Phenazone
DMCE985	MI	DEZMWRE
DMCE985	MN	Cytochrome P450 2C18 (CYP2C18)
DMCE985	MT	DME
DMCE985	MA	Metabolism
DMCE985	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMCE985	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMCE985	DI	DMCE985
DMCE985	DN	Phenazone
DMCE985	MI	DES5XRU
DMCE985	MN	Cytochrome P450 2C8 (CYP2C8)
DMCE985	MT	DME
DMCE985	MA	Metabolism
DMCE985	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMCE985	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMCE985	DI	DMCE985
DMCE985	DN	Phenazone
DMCE985	MI	DE5IED8
DMCE985	MN	Cytochrome P450 2C9 (CYP2C9)
DMCE985	MT	DME
DMCE985	MA	Metabolism
DMCE985	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMCE985	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMCE985	DI	DMCE985
DMCE985	DN	Phenazone
DMCE985	MI	DECB0K3
DMCE985	MN	Cytochrome P450 2D6 (CYP2D6)
DMCE985	MT	DME
DMCE985	MA	Metabolism
DMCE985	RN	Identification of the human hepatic cytochromes P450 involved in the in vitro oxidation of antipyrine. Drug Metab Dispos. 1996 Apr;24(4):487-94.
DMCE985	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8801065

DMCE985	DI	DMCE985
DMCE985	DN	Phenazone
DMCE985	MI	DEVDYN7
DMCE985	MN	Cytochrome P450 2E1 (CYP2E1)
DMCE985	MT	DME
DMCE985	MA	Metabolism
DMCE985	RN	Identification of the human hepatic cytochromes P450 involved in the in vitro oxidation of antipyrine. Drug Metab Dispos. 1996 Apr;24(4):487-94.
DMCE985	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8801065

DMCE985	DI	DMCE985
DMCE985	DN	Phenazone
DMCE985	MI	DE4LYSA
DMCE985	MN	Cytochrome P450 3A4 (CYP3A4)
DMCE985	MT	DME
DMCE985	MA	Metabolism
DMCE985	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMCE985	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMCE985	DI	DMCE985
DMCE985	DN	Phenazone
DMCE985	MI	DEGTFWK
DMCE985	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMCE985	MT	DME
DMCE985	MA	Metabolism
DMCE985	RN	Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes. Drug Metab Dispos. 1997 Mar;25(3):390-3.
DMCE985	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9172960

DMCE985	DI	DMCE985
DMCE985	DN	Phenazone
DMCE985	MI	TT8NGED
DMCE985	MN	Prostaglandin G/H synthase 1 (COX-1)
DMCE985	MT	DTT
DMCE985	MA	Inhibitor
DMCE985	RN	Pharmacokinetic and pharmacodynamic aspects of the ideal COX-2 inhibitor: a pharmacologist's perspective. Clin Exp Rheumatol. 2001 Nov-Dec;19(6 Suppl 25):S51-7.
DMCE985	RU	https://pubmed.ncbi.nlm.nih.gov/11695253

DMCE985	DI	DMCE985
DMCE985	DN	Phenazone
DMCE985	MI	DEZV4AP
DMCE985	MN	RNA cytidine acetyltransferase (hALP)
DMCE985	MT	DME
DMCE985	MA	Metabolism
DMCE985	RN	Evaluation of the influence of diabetes mellitus on antipyrine metabolism and CYP1A2 and CYP2D6 activity. Pharmacotherapy. 2000 Feb;20(2):182-90.
DMCE985	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10678296

DMQBEYX	DI	DMQBEYX
DMQBEYX	DN	Phencyclidine
DMQBEYX	MI	TTLD29N
DMQBEYX	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMQBEYX	MT	DTT
DMQBEYX	MA	Inhibitor
DMQBEYX	RN	Synthesis and biological activity of conformationally restricted analogs of milnacipran: (1S,2R)-1-phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopro... J Med Chem. 1996 Nov 22;39(24):4844-52.
DMQBEYX	RU	https://pubmed.ncbi.nlm.nih.gov/8941398

DMQBEYX	DI	DMQBEYX
DMQBEYX	DN	Phencyclidine
DMQBEYX	MI	TTKJEMQ
DMQBEYX	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMQBEYX	MT	DTT
DMQBEYX	MA	Inhibitor
DMQBEYX	RN	Synthesis and biological activity of conformationally restricted analogs of milnacipran: (1S,2R)-1-phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopro... J Med Chem. 1996 Nov 22;39(24):4844-52.
DMQBEYX	RU	https://pubmed.ncbi.nlm.nih.gov/8941398

DMQBEYX	DI	DMQBEYX
DMQBEYX	DN	Phencyclidine
DMQBEYX	MI	TTN9D8E
DMQBEYX	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMQBEYX	MT	DTT
DMQBEYX	MA	Inhibitor
DMQBEYX	RN	Synthesis and biological activity of conformationally restricted analogs of milnacipran: (1S,2R)-1-phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopro... J Med Chem. 1996 Nov 22;39(24):4844-52.
DMQBEYX	RU	https://pubmed.ncbi.nlm.nih.gov/8941398

DMQBEYX	DI	DMQBEYX
DMQBEYX	DN	Phencyclidine
DMQBEYX	MI	DTT79CX
DMQBEYX	MN	Organic cation transporter 1 (SLC22A1)
DMQBEYX	MT	DTP
DMQBEYX	MA	Substrate
DMQBEYX	RN	Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist Updat. 2011 Feb;14(1):22-34.
DMQBEYX	RU	https://doi.org/10.1016/j.drup.2010.12.002

DMQWFO1	DI	DMQWFO1
DMQWFO1	DN	Phenethyl-(3-phenyl-propyl)-amine
DMQWFO1	MI	TTLD29N
DMQWFO1	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMQWFO1	MT	DTT
DMQWFO1	MA	Inhibitor
DMQWFO1	RN	Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506.
DMQWFO1	RU	https://pubmed.ncbi.nlm.nih.gov/9719603

DMQWFO1	DI	DMQWFO1
DMQWFO1	DN	Phenethyl-(3-phenyl-propyl)-amine
DMQWFO1	MI	TTN9D8E
DMQWFO1	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMQWFO1	MT	DTT
DMQWFO1	MA	Inhibitor
DMQWFO1	RN	Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506.
DMQWFO1	RU	https://pubmed.ncbi.nlm.nih.gov/9719603

DMFQMHK	DI	DMFQMHK
DMFQMHK	DN	Phenethyl-(4-phenyl-butyl)-amine
DMFQMHK	MI	TTLD29N
DMFQMHK	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMFQMHK	MT	DTT
DMFQMHK	MA	Inhibitor
DMFQMHK	RN	Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506.
DMFQMHK	RU	https://pubmed.ncbi.nlm.nih.gov/9719603

DMFQMHK	DI	DMFQMHK
DMFQMHK	DN	Phenethyl-(4-phenyl-butyl)-amine
DMFQMHK	MI	TTN9D8E
DMFQMHK	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMFQMHK	MT	DTT
DMFQMHK	MA	Inhibitor
DMFQMHK	RN	Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506.
DMFQMHK	RU	https://pubmed.ncbi.nlm.nih.gov/9719603

DMX0G4F	DI	DMX0G4F
DMX0G4F	DN	Phenethylamine
DMX0G4F	MI	TTJQOD7
DMX0G4F	MN	5-HT 2A receptor (HTR2A)
DMX0G4F	MT	DTT
DMX0G4F	MA	Inhibitor
DMX0G4F	RN	Exploring the relationship between binding modes of 9-(aminomethyl)-9,10-dihydroanthracene and cyproheptadine analogues at the 5-HT2A serotonin rec... Bioorg Med Chem Lett. 2001 Feb 26;11(4):563-6.
DMX0G4F	RU	https://pubmed.ncbi.nlm.nih.gov/11229772

DMX0G4F	DI	DMX0G4F
DMX0G4F	DN	Phenethylamine
DMX0G4F	MI	DE6SOC5
DMX0G4F	MN	Copper amine oxidase (AOC3)
DMX0G4F	MT	DME
DMX0G4F	MA	Metabolism
DMX0G4F	RN	The unique substrate specificity of human AOC2, a semicarbazide-sensitive amine oxidase. Cell Mol Life Sci. 2009 Aug;66(16):2743-57.
DMX0G4F	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19588076

DMX0G4F	DI	DMX0G4F
DMX0G4F	DN	Phenethylamine
DMX0G4F	MI	DERE4TU
DMX0G4F	MN	Monoamine oxidase type A (MAO-A)
DMX0G4F	MT	DME
DMX0G4F	MA	Metabolism
DMX0G4F	RN	Do monomeric vs dimeric forms of MAO-A make a difference? A direct comparison of the catalytic properties of rat and human MAO-A's. J Neural Transm (Vienna). 2007;114(6):721-4.
DMX0G4F	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17401534

DMX0G4F	DI	DMX0G4F
DMX0G4F	DN	Phenethylamine
DMX0G4F	MI	DE8DP90
DMX0G4F	MN	Semicarbazide-sensitive amine oxidase (AOC2)
DMX0G4F	MT	DME
DMX0G4F	MA	Metabolism
DMX0G4F	RN	The unique substrate specificity of human AOC2, a semicarbazide-sensitive amine oxidase. Cell Mol Life Sci. 2009 Aug;66(16):2743-57.
DMX0G4F	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19588076

DMPDVG2	DI	DMPDVG2
DMPDVG2	DN	Phenethylboronic acid
DMPDVG2	MI	TTHQPL7
DMPDVG2	MN	Carbonic anhydrase I (CA-I)
DMPDVG2	MT	DTT
DMPDVG2	MA	Inhibitor
DMPDVG2	RN	Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5.
DMPDVG2	RU	https://pubmed.ncbi.nlm.nih.gov/19375309

DMPDVG2	DI	DMPDVG2
DMPDVG2	DN	Phenethylboronic acid
DMPDVG2	MI	TTANPDJ
DMPDVG2	MN	Carbonic anhydrase II (CA-II)
DMPDVG2	MT	DTT
DMPDVG2	MA	Inhibitor
DMPDVG2	RN	Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5.
DMPDVG2	RU	https://pubmed.ncbi.nlm.nih.gov/19375309

DMPDVG2	DI	DMPDVG2
DMPDVG2	DN	Phenethylboronic acid
DMPDVG2	MI	TTDP1UC
DMPDVG2	MN	Fatty acid amide hydrolase (FAAH)
DMPDVG2	MT	DTT
DMPDVG2	MA	Inhibitor
DMPDVG2	RN	Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Nov 27;51(22):7057-60.
DMPDVG2	RU	https://pubmed.ncbi.nlm.nih.gov/18983140

DM02PAW	DI	DM02PAW
DM02PAW	DN	Phenethylcarbamic Acid Biphenyl-3-yl Ester
DM02PAW	MI	TTDP1UC
DM02PAW	MN	Fatty acid amide hydrolase (FAAH)
DM02PAW	MT	DTT
DM02PAW	MA	Inhibitor
DM02PAW	RN	Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl a... J Med Chem. 2008 Jun 26;51(12):3487-98.
DM02PAW	RU	https://pubmed.ncbi.nlm.nih.gov/18507372

DMJD8XN	DI	DMJD8XN
DMJD8XN	DN	PHENIDONE
DMJD8XN	MI	TT2J34L
DMJD8XN	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMJD8XN	MT	DTT
DMJD8XN	MA	Inhibitor
DMJD8XN	RN	Cylindol A, a novel biphenyl ether with 5-lipoxygenase inhibitory activity, and a related compound from Imperata Cylindrica. J Nat Prod. 1994 Sep;57(9):1290-3.
DMJD8XN	RU	https://pubmed.ncbi.nlm.nih.gov/7798964

DMJD8XN	DI	DMJD8XN
DMJD8XN	DN	PHENIDONE
DMJD8XN	MI	TT8NGED
DMJD8XN	MN	Prostaglandin G/H synthase 1 (COX-1)
DMJD8XN	MT	DTT
DMJD8XN	MA	Inhibitor
DMJD8XN	RN	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
DMJD8XN	RU	https://pubmed.ncbi.nlm.nih.gov/1848292

DMJD8XN	DI	DMJD8XN
DMJD8XN	DN	PHENIDONE
DMJD8XN	MI	TTVKILB
DMJD8XN	MN	Prostaglandin G/H synthase 2 (COX-2)
DMJD8XN	MT	DTT
DMJD8XN	MA	Inhibitor
DMJD8XN	RN	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
DMJD8XN	RU	https://pubmed.ncbi.nlm.nih.gov/1848292

DMYCHTD	DI	DMYCHTD
DMYCHTD	DN	PHENMEDIPHAM
DMYCHTD	MI	TTDP1UC
DMYCHTD	MN	Fatty acid amide hydrolase (FAAH)
DMYCHTD	MT	DTT
DMYCHTD	MA	Inhibitor
DMYCHTD	RN	Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inh... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6793-6.
DMYCHTD	RU	https://pubmed.ncbi.nlm.nih.gov/19850474

DMCTUAD	DI	DMCTUAD
DMCTUAD	DN	Phenolsulfonphthalein
DMCTUAD	MI	DTVP67E
DMCTUAD	MN	Organic anion transporter 3 (SLC22A8)
DMCTUAD	MT	DTP
DMCTUAD	MA	Substrate
DMCTUAD	RN	Expression levels of renal organic anion transporters (OATs) and their correlation with anionic drug excretion in patients with renal diseases. Pharm Res. 2004 Jan;21(1):61-7.
DMCTUAD	RU	http://www.ncbi.nlm.nih.gov/pubmed/14984259

DMZJO5V	DI	DMZJO5V
DMZJO5V	DN	Phenoxyarsonous acid
DMZJO5V	MI	TTHQPL7
DMZJO5V	MN	Carbonic anhydrase I (CA-I)
DMZJO5V	MT	DTT
DMZJO5V	MA	Inhibitor
DMZJO5V	RN	Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5435-9.
DMZJO5V	RU	https://pubmed.ncbi.nlm.nih.gov/15454240

DMZJO5V	DI	DMZJO5V
DMZJO5V	DN	Phenoxyarsonous acid
DMZJO5V	MI	TTANPDJ
DMZJO5V	MN	Carbonic anhydrase II (CA-II)
DMZJO5V	MT	DTT
DMZJO5V	MA	Inhibitor
DMZJO5V	RN	Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5435-9.
DMZJO5V	RU	https://pubmed.ncbi.nlm.nih.gov/15454240

DMJ5GY7	DI	DMJ5GY7
DMJ5GY7	DN	PHENSTATIN
DMJ5GY7	MI	TTML2WA
DMJ5GY7	MN	Tubulin (TUB)
DMJ5GY7	MT	DTT
DMJ5GY7	MA	Inhibitor
DMJ5GY7	RN	Antineoplastic agents. 465. Structural modification of resveratrol: sodium resverastatin phosphate. J Med Chem. 2002 Jun 6;45(12):2534-42.
DMJ5GY7	RU	https://pubmed.ncbi.nlm.nih.gov/12036362

DMJ5GY7	DI	DMJ5GY7
DMJ5GY7	DN	PHENSTATIN
DMJ5GY7	MI	TTYFKSZ
DMJ5GY7	MN	Tubulin beta (TUBB)
DMJ5GY7	MT	DTT
DMJ5GY7	MA	Inhibitor
DMJ5GY7	RN	Antineoplastic agents. 465. Structural modification of resveratrol: sodium resverastatin phosphate. J Med Chem. 2002 Jun 6;45(12):2534-42.
DMJ5GY7	RU	https://pubmed.ncbi.nlm.nih.gov/12036362

DMSNIBO	DI	DMSNIBO
DMSNIBO	DN	Phenyl 1-(4-butoxyphenyl)propylcarbamate
DMSNIBO	MI	TTDP1UC
DMSNIBO	MN	Fatty acid amide hydrolase (FAAH)
DMSNIBO	MT	DTT
DMSNIBO	MA	Inhibitor
DMSNIBO	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DMSNIBO	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DM52H1D	DI	DM52H1D
DM52H1D	DN	Phenyl 10H-phenothiazine-10-carboxylate
DM52H1D	MI	TTEB0GD
DM52H1D	MN	Cholinesterase (BCHE)
DM52H1D	MT	DTT
DM52H1D	MA	Inhibitor
DM52H1D	RN	Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. J Med Chem. 2008 Jul 24;51(14):4200-12.
DM52H1D	RU	https://pubmed.ncbi.nlm.nih.gov/18570368

DMHDWTS	DI	DMHDWTS
DMHDWTS	DN	Phenyl 4-(4,5-dihydro-1H-imidazol-2-yl)benzoate
DMHDWTS	MI	TT3WG5C
DMHDWTS	MN	Monoamine oxidase type A (MAO-A)
DMHDWTS	MT	DTT
DMHDWTS	MA	Inhibitor
DMHDWTS	RN	Ultrasound promoted synthesis of 2-imidazolines in water: a greener approach toward monoamine oxidase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):546-9.
DMHDWTS	RU	https://pubmed.ncbi.nlm.nih.gov/19064321

DMHDWTS	DI	DMHDWTS
DMHDWTS	DN	Phenyl 4-(4,5-dihydro-1H-imidazol-2-yl)benzoate
DMHDWTS	MI	TTGP7BY
DMHDWTS	MN	Monoamine oxidase type B (MAO-B)
DMHDWTS	MT	DTT
DMHDWTS	MA	Inhibitor
DMHDWTS	RN	Ultrasound promoted synthesis of 2-imidazolines in water: a greener approach toward monoamine oxidase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):546-9.
DMHDWTS	RU	https://pubmed.ncbi.nlm.nih.gov/19064321

DMZ03DT	DI	DMZ03DT
DMZ03DT	DN	Phenyl 4-(decyloxy)phenylcarbamate
DMZ03DT	MI	TTDP1UC
DMZ03DT	MN	Fatty acid amide hydrolase (FAAH)
DMZ03DT	MT	DTT
DMZ03DT	MA	Inhibitor
DMZ03DT	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DMZ03DT	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DMR1MQE	DI	DMR1MQE
DMR1MQE	DN	Phenyl 4-(dodecyloxy)phenylcarbamate
DMR1MQE	MI	TTDP1UC
DMR1MQE	MN	Fatty acid amide hydrolase (FAAH)
DMR1MQE	MT	DTT
DMR1MQE	MA	Inhibitor
DMR1MQE	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DMR1MQE	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DM9UNLH	DI	DM9UNLH
DM9UNLH	DN	Phenyl 4-(heptyloxy)phenylcarbamate
DM9UNLH	MI	TTDP1UC
DM9UNLH	MN	Fatty acid amide hydrolase (FAAH)
DM9UNLH	MT	DTT
DM9UNLH	MA	Inhibitor
DM9UNLH	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DM9UNLH	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DMZ07H6	DI	DMZ07H6
DMZ07H6	DN	Phenyl 4-(hexyloxy)phenylcarbamate
DMZ07H6	MI	TTDP1UC
DMZ07H6	MN	Fatty acid amide hydrolase (FAAH)
DMZ07H6	MT	DTT
DMZ07H6	MA	Inhibitor
DMZ07H6	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DMZ07H6	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DMULMWK	DI	DMULMWK
DMULMWK	DN	Phenyl 4-(octyloxy)phenylcarbamate
DMULMWK	MI	TTDP1UC
DMULMWK	MN	Fatty acid amide hydrolase (FAAH)
DMULMWK	MT	DTT
DMULMWK	MA	Inhibitor
DMULMWK	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DMULMWK	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DMSZ2CO	DI	DMSZ2CO
DMSZ2CO	DN	Phenyl 4-(undecyloxy)phenylcarbamate
DMSZ2CO	MI	TTDP1UC
DMSZ2CO	MN	Fatty acid amide hydrolase (FAAH)
DMSZ2CO	MT	DTT
DMSZ2CO	MA	Inhibitor
DMSZ2CO	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DMSZ2CO	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DMWN9XU	DI	DMWN9XU
DMWN9XU	DN	Phenyl 7-methoxy-4-phenylbenzofuran-2-ylcarbamate
DMWN9XU	MI	TTM2AOE
DMWN9XU	MN	Adenosine A2a receptor (ADORA2A)
DMWN9XU	MT	DTT
DMWN9XU	MA	Inhibitor
DMWN9XU	RN	Synthetic studies on selective adenosine A2A receptor antagonists: synthesis and structure-activity relationships of novel benzofuran derivatives. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1090-3.
DMWN9XU	RU	https://pubmed.ncbi.nlm.nih.gov/20034788

DMFZH49	DI	DMFZH49
DMFZH49	DN	Phenyl Boronic acid
DMFZH49	MI	TTLP6GN
DMFZH49	MN	Bacterial DD-carboxypeptidase (Bact vanYB)
DMFZH49	MT	DTT
DMFZH49	MA	Inhibitor
DMFZH49	RN	Synthesis and evaluation of 3-(dihydroxyboryl)benzoic acids as D,D-carboxypeptidase R39 inhibitors. J Med Chem. 2009 Oct 8;52(19):6097-106.
DMFZH49	RU	https://pubmed.ncbi.nlm.nih.gov/19731939

DMFZH49	DI	DMFZH49
DMFZH49	DN	Phenyl Boronic acid
DMFZH49	MI	TTUNARX
DMFZH49	MN	Carbonic anhydrase (CA)
DMFZH49	MT	DTT
DMFZH49	MA	Inhibitor
DMFZH49	RN	Carbonic anhydrase inhibitors: inhibition of the cytosolic human isozyme VII with anions. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3139-43.
DMFZH49	RU	https://pubmed.ncbi.nlm.nih.gov/16621537

DMFZH49	DI	DMFZH49
DMFZH49	DN	Phenyl Boronic acid
DMFZH49	MI	TTHQPL7
DMFZH49	MN	Carbonic anhydrase I (CA-I)
DMFZH49	MT	DTT
DMFZH49	MA	Inhibitor
DMFZH49	RN	Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5435-9.
DMFZH49	RU	https://pubmed.ncbi.nlm.nih.gov/15454240

DMFZH49	DI	DMFZH49
DMFZH49	DN	Phenyl Boronic acid
DMFZH49	MI	TTANPDJ
DMFZH49	MN	Carbonic anhydrase II (CA-II)
DMFZH49	MT	DTT
DMFZH49	MA	Inhibitor
DMFZH49	RN	Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5435-9.
DMFZH49	RU	https://pubmed.ncbi.nlm.nih.gov/15454240

DMFZH49	DI	DMFZH49
DMFZH49	DN	Phenyl Boronic acid
DMFZH49	MI	TTZHA0O
DMFZH49	MN	Carbonic anhydrase IV (CA-IV)
DMFZH49	MT	DTT
DMFZH49	MA	Inhibitor
DMFZH49	RN	Carbonic anhydrase inhibitors: the membrane-associated isoform XV is highly inhibited by inorganic anions. Bioorg Med Chem Lett. 2009 Feb 15;19(4):1155-8.
DMFZH49	RU	https://pubmed.ncbi.nlm.nih.gov/19128966

DMFZH49	DI	DMFZH49
DMFZH49	DN	Phenyl Boronic acid
DMFZH49	MI	TTDP1UC
DMFZH49	MN	Fatty acid amide hydrolase (FAAH)
DMFZH49	MT	DTT
DMFZH49	MA	Inhibitor
DMFZH49	RN	Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Nov 27;51(22):7057-60.
DMFZH49	RU	https://pubmed.ncbi.nlm.nih.gov/18983140

DMDV1SN	DI	DMDV1SN
DMDV1SN	DN	Phenyl(2-(trifluoromethyl)quinolin-4-yl)methanol
DMDV1SN	MI	TTK25J1
DMDV1SN	MN	Adenosine A1 receptor (ADORA1)
DMDV1SN	MT	DTT
DMDV1SN	MA	Inhibitor
DMDV1SN	RN	Antagonists of the human adenosine A2A receptor. Part 1: Discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2916-9.
DMDV1SN	RU	https://pubmed.ncbi.nlm.nih.gov/18406614

DMDV1SN	DI	DMDV1SN
DMDV1SN	DN	Phenyl(2-(trifluoromethyl)quinolin-4-yl)methanol
DMDV1SN	MI	TTM2AOE
DMDV1SN	MN	Adenosine A2a receptor (ADORA2A)
DMDV1SN	MT	DTT
DMDV1SN	MA	Inhibitor
DMDV1SN	RN	Antagonists of the human adenosine A2A receptor. Part 1: Discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2916-9.
DMDV1SN	RU	https://pubmed.ncbi.nlm.nih.gov/18406614

DMDCTNU	DI	DMDCTNU
DMDCTNU	DN	Phenyl-(3-phenyl-1H-indazol-6-yl)-amine
DMDCTNU	MI	TTQBR95
DMDCTNU	MN	Stress-activated protein kinase 2a (p38 alpha)
DMDCTNU	MT	DTT
DMDCTNU	MA	Inhibitor
DMDCTNU	RN	Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3. Bioorg Med Chem Lett. 2005 Nov 15;15(22):5095-9.
DMDCTNU	RU	https://pubmed.ncbi.nlm.nih.gov/16140012

DMDCTNU	DI	DMDCTNU
DMDCTNU	DN	Phenyl-(3-phenyl-1H-indazol-6-yl)-amine
DMDCTNU	MI	TT056SO
DMDCTNU	MN	Stress-activated protein kinase JNK3 (JNK3)
DMDCTNU	MT	DTT
DMDCTNU	MA	Inhibitor
DMDCTNU	RN	Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3. Bioorg Med Chem Lett. 2005 Nov 15;15(22):5095-9.
DMDCTNU	RU	https://pubmed.ncbi.nlm.nih.gov/16140012

DMR2B4O	DI	DMR2B4O
DMR2B4O	DN	Phenyl-(5-phenyl-oxazol-2-yl)-amine
DMR2B4O	MI	TTUTJGQ
DMR2B4O	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMR2B4O	MT	DTT
DMR2B4O	MA	Inhibitor
DMR2B4O	RN	Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9.
DMR2B4O	RU	https://pubmed.ncbi.nlm.nih.gov/15743202

DMR2B4O	DI	DMR2B4O
DMR2B4O	DN	Phenyl-(5-phenyl-oxazol-2-yl)-amine
DMR2B4O	MI	TTDCBX5
DMR2B4O	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DMR2B4O	MT	DTT
DMR2B4O	MA	Inhibitor
DMR2B4O	RN	Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9.
DMR2B4O	RU	https://pubmed.ncbi.nlm.nih.gov/15743202

DMR2B4O	DI	DMR2B4O
DMR2B4O	DN	Phenyl-(5-phenyl-oxazol-2-yl)-amine
DMR2B4O	MI	TT1VAUK
DMR2B4O	MN	VEGFR1 messenger RNA (VEGFR1 mRNA)
DMR2B4O	MT	DTT
DMR2B4O	MA	Inhibitor
DMR2B4O	RN	Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9.
DMR2B4O	RU	https://pubmed.ncbi.nlm.nih.gov/15743202

DMIQ18W	DI	DMIQ18W
DMIQ18W	DN	Phenyl-(9-phenyl-9H-purin-6-yl)-amine
DMIQ18W	MI	TTK25J1
DMIQ18W	MN	Adenosine A1 receptor (ADORA1)
DMIQ18W	MT	DTT
DMIQ18W	MA	Inhibitor
DMIQ18W	RN	N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor. J Med Chem. 1991 Sep;34(9):2877-82.
DMIQ18W	RU	https://pubmed.ncbi.nlm.nih.gov/1895305

DMWEKBD	DI	DMWEKBD
DMWEKBD	DN	Phenyl-1,4-bismaleimide
DMWEKBD	MI	TTDP1UC
DMWEKBD	MN	Fatty acid amide hydrolase (FAAH)
DMWEKBD	MT	DTT
DMWEKBD	MA	Inhibitor
DMWEKBD	RN	Synthesis and in vitro evaluation of N-substituted maleimide derivatives as selective monoglyceride lipase inhibitors. J Med Chem. 2009 Dec 10;52(23):7410-20.
DMWEKBD	RU	https://pubmed.ncbi.nlm.nih.gov/19583260

DM5A8KR	DI	DM5A8KR
DM5A8KR	DN	phenylacetyl-Ala,DTrp-phenthylamide
DM5A8KR	MI	TTHYDUM
DM5A8KR	MN	Bombesin receptor (BS)
DM5A8KR	MT	DTT
DM5A8KR	MA	Agonist
DM5A8KR	RN	Pharmacology of putative selective hBRS-3 receptor agonists for human bombesin receptors (BnR): affinities, potencies and selectivity in multiple native and BnR transfected cells. Peptides. 2010 Aug;31(8):1569-78.
DM5A8KR	RU	https://pubmed.ncbi.nlm.nih.gov/20438784

DM16KSA	DI	DM16KSA
DM16KSA	DN	Phenylacetyl-Arg-Val-Arg-4-amidinobenzylamide
DM16KSA	MI	TTED9LZ
DM16KSA	MN	Neuroendocrine convertase 1 (PCSK1)
DM16KSA	MT	DTT
DM16KSA	MA	Inhibitor
DM16KSA	RN	Potent inhibitors of furin and furin-like proprotein convertases containing decarboxylated P1 arginine mimetics. J Med Chem. 2010 Feb 11;53(3):1067-75.
DM16KSA	RU	https://pubmed.ncbi.nlm.nih.gov/20038105

DM16KSA	DI	DM16KSA
DM16KSA	DN	Phenylacetyl-Arg-Val-Arg-4-amidinobenzylamide
DM16KSA	MI	TT46F0P
DM16KSA	MN	Neuroendocrine convertase 2 (PCSK2)
DM16KSA	MT	DTT
DM16KSA	MA	Inhibitor
DM16KSA	RN	Potent inhibitors of furin and furin-like proprotein convertases containing decarboxylated P1 arginine mimetics. J Med Chem. 2010 Feb 11;53(3):1067-75.
DM16KSA	RU	https://pubmed.ncbi.nlm.nih.gov/20038105

DM29EFJ	DI	DM29EFJ
DM29EFJ	DN	phenylacetylrinvanil
DM29EFJ	MI	TTMI6F5
DM29EFJ	MN	Transient receptor potential cation channel V1 (TRPV1)
DM29EFJ	MT	DTT
DM29EFJ	MA	Activator
DM29EFJ	RN	Development of the first ultra-potent "capsaicinoid" agonist at transient receptor potential vanilloid type 1 (TRPV1) channels and its therapeutic ... J Pharmacol Exp Ther. 2005 Feb;312(2):561-70.
DM29EFJ	RU	https://pubmed.ncbi.nlm.nih.gov/15356216

DMZNFT2	DI	DMZNFT2
DMZNFT2	DN	Phenylalanylmethane
DMZNFT2	MI	TT8VUE0
DMZNFT2	MN	Chymase (CYM)
DMZNFT2	MT	DTT
DMZNFT2	MA	Inhibitor
DMZNFT2	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMZNFT2	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMHVW61	DI	DMHVW61
DMHVW61	DN	PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE
DMHVW61	MI	TT7HF4W
DMHVW61	MN	Cyclin-dependent kinase 2 (CDK2)
DMHVW61	MT	DTT
DMHVW61	MA	Inhibitor
DMHVW61	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMHVW61	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMFRA1Y	DI	DMFRA1Y
DMFRA1Y	DN	Phenylarsonic acid
DMFRA1Y	MI	TTUNARX
DMFRA1Y	MN	Carbonic anhydrase (CA)
DMFRA1Y	MT	DTT
DMFRA1Y	MA	Inhibitor
DMFRA1Y	RN	Carbonic anhydrase inhibitors: inhibition of the cytosolic human isozyme VII with anions. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3139-43.
DMFRA1Y	RU	https://pubmed.ncbi.nlm.nih.gov/16621537

DMFRA1Y	DI	DMFRA1Y
DMFRA1Y	DN	Phenylarsonic acid
DMFRA1Y	MI	TTZHA0O
DMFRA1Y	MN	Carbonic anhydrase IV (CA-IV)
DMFRA1Y	MT	DTT
DMFRA1Y	MA	Inhibitor
DMFRA1Y	RN	Carbonic anhydrase inhibitors: inhibition of the membrane-bound human isozyme IV with anions. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5769-73.
DMFRA1Y	RU	https://pubmed.ncbi.nlm.nih.gov/15501038

DMMNYXK	DI	DMMNYXK
DMMNYXK	DN	Phenylcarbamic Acid Biphenyl-3-yl Ester
DMMNYXK	MI	TTDP1UC
DMMNYXK	MN	Fatty acid amide hydrolase (FAAH)
DMMNYXK	MT	DTT
DMMNYXK	MA	Inhibitor
DMMNYXK	RN	Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl a... J Med Chem. 2008 Jun 26;51(12):3487-98.
DMMNYXK	RU	https://pubmed.ncbi.nlm.nih.gov/18507372

DME75VC	DI	DME75VC
DME75VC	DN	PHENYLDIFLUOROMETHANESULFONAMIDE
DME75VC	MI	TTUNARX
DME75VC	MN	Carbonic anhydrase (CA)
DME75VC	MT	DTT
DME75VC	MA	Inhibitor
DME75VC	RN	Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6.
DME75VC	RU	https://pubmed.ncbi.nlm.nih.gov/16203142

DME75VC	DI	DME75VC
DME75VC	DN	PHENYLDIFLUOROMETHANESULFONAMIDE
DME75VC	MI	TTHQPL7
DME75VC	MN	Carbonic anhydrase I (CA-I)
DME75VC	MT	DTT
DME75VC	MA	Inhibitor
DME75VC	RN	Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6.
DME75VC	RU	https://pubmed.ncbi.nlm.nih.gov/16203142

DME75VC	DI	DME75VC
DME75VC	DN	PHENYLDIFLUOROMETHANESULFONAMIDE
DME75VC	MI	TTANPDJ
DME75VC	MN	Carbonic anhydrase II (CA-II)
DME75VC	MT	DTT
DME75VC	MA	Inhibitor
DME75VC	RN	Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6.
DME75VC	RU	https://pubmed.ncbi.nlm.nih.gov/16203142

DME75VC	DI	DME75VC
DME75VC	DN	PHENYLDIFLUOROMETHANESULFONAMIDE
DME75VC	MI	TT2LVK8
DME75VC	MN	Carbonic anhydrase IX (CA-IX)
DME75VC	MT	DTT
DME75VC	MA	Inhibitor
DME75VC	RN	Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6.
DME75VC	RU	https://pubmed.ncbi.nlm.nih.gov/16203142

DMQD2IA	DI	DMQD2IA
DMQD2IA	DN	Phenylethanolamine
DMQD2IA	MI	DER8LQ6
DMQD2IA	MN	Phenylethanolamine N-methyltransferase (PNMT)
DMQD2IA	MT	DME
DMQD2IA	MA	Metabolism
DMQD2IA	RN	Structural, mutagenic, and kinetic analysis of the binding of substrates and inhibitors of human phenylethanolamine N-methyltransferase. J Med Chem. 2005 Nov 17;48(23):7243-52.
DMQD2IA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16279783

DMHT9AR	DI	DMHT9AR
DMHT9AR	DN	phenylglycine-01
DMHT9AR	MI	TTRLZHP
DMHT9AR	MN	cAMP-dependent chloride channel (CFTR)
DMHT9AR	MT	DTT
DMHT9AR	MA	Activator
DMHT9AR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 707).
DMHT9AR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=707

DMHW93J	DI	DMHW93J
DMHW93J	DN	Phenylglyoxal
DMHW93J	MI	DEPOVCH
DMHW93J	MN	Maillard deglycase (PARK7)
DMHW93J	MT	DME
DMHW93J	MA	Metabolism
DMHW93J	RN	Stereospecific mechanism of DJ-1 glyoxalases inferred from their hemithioacetal-containing crystal structures. FEBS J. 2014 Dec;281(24):5447-62.
DMHW93J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25283443

DMJTC2B	DI	DMJTC2B
DMJTC2B	DN	Phenylmercury
DMJTC2B	MI	TT1O264
DMJTC2B	MN	Coagulation factor Va (F5)
DMJTC2B	MT	DTT
DMJTC2B	MA	Inhibitor
DMJTC2B	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMJTC2B	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMGLDFI	DI	DMGLDFI
DMGLDFI	DN	PHENYLMETHANESULFONAMIDE
DMGLDFI	MI	TTUNARX
DMGLDFI	MN	Carbonic anhydrase (CA)
DMGLDFI	MT	DTT
DMGLDFI	MA	Inhibitor
DMGLDFI	RN	Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6.
DMGLDFI	RU	https://pubmed.ncbi.nlm.nih.gov/16203142

DMGLDFI	DI	DMGLDFI
DMGLDFI	DN	PHENYLMETHANESULFONAMIDE
DMGLDFI	MI	TTHQPL7
DMGLDFI	MN	Carbonic anhydrase I (CA-I)
DMGLDFI	MT	DTT
DMGLDFI	MA	Inhibitor
DMGLDFI	RN	Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6.
DMGLDFI	RU	https://pubmed.ncbi.nlm.nih.gov/16203142

DMGLDFI	DI	DMGLDFI
DMGLDFI	DN	PHENYLMETHANESULFONAMIDE
DMGLDFI	MI	TTANPDJ
DMGLDFI	MN	Carbonic anhydrase II (CA-II)
DMGLDFI	MT	DTT
DMGLDFI	MA	Inhibitor
DMGLDFI	RN	Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6.
DMGLDFI	RU	https://pubmed.ncbi.nlm.nih.gov/16203142

DMGLDFI	DI	DMGLDFI
DMGLDFI	DN	PHENYLMETHANESULFONAMIDE
DMGLDFI	MI	TT2LVK8
DMGLDFI	MN	Carbonic anhydrase IX (CA-IX)
DMGLDFI	MT	DTT
DMGLDFI	MA	Inhibitor
DMGLDFI	RN	Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6.
DMGLDFI	RU	https://pubmed.ncbi.nlm.nih.gov/16203142

DMYTS73	DI	DMYTS73
DMYTS73	DN	Phenyl-N,N-bis(tosylmethyl)methanamine
DMYTS73	MI	TTX4RTB
DMYTS73	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMYTS73	MT	DTT
DMYTS73	MA	Inhibitor
DMYTS73	RN	Discovery of novel chemotypes to a G-protein-coupled receptor through ligand-steered homology modeling and structure-based virtual screening. J Med Chem. 2008 Feb 14;51(3):581-8.
DMYTS73	RU	https://pubmed.ncbi.nlm.nih.gov/18198821

DMQ6P13	DI	DMQ6P13
DMQ6P13	DN	Phenylphosphate
DMQ6P13	MI	TT6PKBN
DMQ6P13	MN	Proto-oncogene c-Src (SRC)
DMQ6P13	MT	DTT
DMQ6P13	MA	Inhibitor
DMQ6P13	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMQ6P13	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMYMNBL	DI	DMYMNBL
DMYMNBL	DN	Phenyl-phosphonic acid
DMYMNBL	MI	TTANPDJ
DMYMNBL	MN	Carbonic anhydrase II (CA-II)
DMYMNBL	MT	DTT
DMYMNBL	MA	Inhibitor
DMYMNBL	RN	Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with organic phosphates and phosphonates. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1683-6.
DMYMNBL	RU	https://pubmed.ncbi.nlm.nih.gov/15745821

DMYMNBL	DI	DMYMNBL
DMYMNBL	DN	Phenyl-phosphonic acid
DMYMNBL	MI	TTZHA0O
DMYMNBL	MN	Carbonic anhydrase IV (CA-IV)
DMYMNBL	MT	DTT
DMYMNBL	MA	Inhibitor
DMYMNBL	RN	Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with organic phosphates and phosphonates. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1683-6.
DMYMNBL	RU	https://pubmed.ncbi.nlm.nih.gov/15745821

DMWAK1R	DI	DMWAK1R
DMWAK1R	DN	PHENYLPIPERAZINE
DMWAK1R	MI	TTSQIFT
DMWAK1R	MN	5-HT 1A receptor (HTR1A)
DMWAK1R	MT	DTT
DMWAK1R	MA	Inhibitor
DMWAK1R	RN	5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80.
DMWAK1R	RU	https://pubmed.ncbi.nlm.nih.gov/3783595

DMWAK1R	DI	DMWAK1R
DMWAK1R	DN	PHENYLPIPERAZINE
DMWAK1R	MI	TT6MSOK
DMWAK1R	MN	5-HT 1D receptor (HTR1D)
DMWAK1R	MT	DTT
DMWAK1R	MA	Inhibitor
DMWAK1R	RN	5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80.
DMWAK1R	RU	https://pubmed.ncbi.nlm.nih.gov/3783595

DMWAK1R	DI	DMWAK1R
DMWAK1R	DN	PHENYLPIPERAZINE
DMWAK1R	MI	TTJQOD7
DMWAK1R	MN	5-HT 2A receptor (HTR2A)
DMWAK1R	MT	DTT
DMWAK1R	MA	Inhibitor
DMWAK1R	RN	5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80.
DMWAK1R	RU	https://pubmed.ncbi.nlm.nih.gov/3783595

DMRLFJV	DI	DMRLFJV
DMRLFJV	DN	PHENYLSULFAMATE
DMRLFJV	MI	TTHQPL7
DMRLFJV	MN	Carbonic anhydrase I (CA-I)
DMRLFJV	MT	DTT
DMRLFJV	MA	Inhibitor
DMRLFJV	RN	Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6.
DMRLFJV	RU	https://pubmed.ncbi.nlm.nih.gov/16203142

DMRLFJV	DI	DMRLFJV
DMRLFJV	DN	PHENYLSULFAMATE
DMRLFJV	MI	TTANPDJ
DMRLFJV	MN	Carbonic anhydrase II (CA-II)
DMRLFJV	MT	DTT
DMRLFJV	MA	Inhibitor
DMRLFJV	RN	Inhibition of carbonic anhydrase-II by sulfamate and sulfamide groups: an investigation involving direct thermodynamic binding measurements. J Med Chem. 2006 Jun 15;49(12):3496-500.
DMRLFJV	RU	https://pubmed.ncbi.nlm.nih.gov/16759092

DMRLFJV	DI	DMRLFJV
DMRLFJV	DN	PHENYLSULFAMATE
DMRLFJV	MI	TT2LVK8
DMRLFJV	MN	Carbonic anhydrase IX (CA-IX)
DMRLFJV	MT	DTT
DMRLFJV	MA	Inhibitor
DMRLFJV	RN	Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6.
DMRLFJV	RU	https://pubmed.ncbi.nlm.nih.gov/16203142

DMRTHW1	DI	DMRTHW1
DMRTHW1	DN	PHENYLSULFAMIDE
DMRTHW1	MI	TTANPDJ
DMRTHW1	MN	Carbonic anhydrase II (CA-II)
DMRTHW1	MT	DTT
DMRTHW1	MA	Inhibitor
DMRTHW1	RN	Inhibition of carbonic anhydrase-II by sulfamate and sulfamide groups: an investigation involving direct thermodynamic binding measurements. J Med Chem. 2006 Jun 15;49(12):3496-500.
DMRTHW1	RU	https://pubmed.ncbi.nlm.nih.gov/16759092

DMM1IAU	DI	DMM1IAU
DMM1IAU	DN	PHENYLTHIOUREA
DMM1IAU	MI	TTULVH8
DMM1IAU	MN	Tyrosinase (TYR)
DMM1IAU	MT	DTT
DMM1IAU	MA	Inhibitor
DMM1IAU	RN	Analogues of N-hydroxy-N'-phenylthiourea and N-hydroxy-N'-phenylurea as inhibitors of tyrosinase and melanin formation. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3607-10.
DMM1IAU	RU	https://pubmed.ncbi.nlm.nih.gov/18501598

DM7J0YG	DI	DM7J0YG
DM7J0YG	DN	Phenyl-Uridine-5'-Diphosphate
DM7J0YG	MI	TTGRHIB
DM7J0YG	MN	UDP-glucose 4-epimerase (GALE)
DM7J0YG	MT	DTT
DM7J0YG	MA	Inhibitor
DM7J0YG	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM7J0YG	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMJMLKA	DI	DMJMLKA
DMJMLKA	DN	Phe-Pro-Glu
DMJMLKA	MI	TTLD29N
DMJMLKA	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMJMLKA	MT	DTT
DMJMLKA	MA	Inhibitor
DMJMLKA	RN	New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6.
DMJMLKA	RU	https://pubmed.ncbi.nlm.nih.gov/16321525

DMJMLKA	DI	DMJMLKA
DMJMLKA	DN	Phe-Pro-Glu
DMJMLKA	MI	TTKJEMQ
DMJMLKA	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMJMLKA	MT	DTT
DMJMLKA	MA	Inhibitor
DMJMLKA	RN	New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6.
DMJMLKA	RU	https://pubmed.ncbi.nlm.nih.gov/16321525

DMJMLKA	DI	DMJMLKA
DMJMLKA	DN	Phe-Pro-Glu
DMJMLKA	MI	TTN9D8E
DMJMLKA	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMJMLKA	MT	DTT
DMJMLKA	MA	Inhibitor
DMJMLKA	RN	New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6.
DMJMLKA	RU	https://pubmed.ncbi.nlm.nih.gov/16321525

DMWMBP3	DI	DMWMBP3
DMWMBP3	DN	PheTQS
DMWMBP3	MI	TTLA931
DMWMBP3	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMWMBP3	MT	DTT
DMWMBP3	MA	Modulator
DMWMBP3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 468).
DMWMBP3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=468

DMP3MOC	DI	DMP3MOC
DMP3MOC	DN	Philanthotoxin-343
DMP3MOC	MI	TTVPQTF
DMP3MOC	MN	Glutamate receptor AMPA 1 (GRIA1)
DMP3MOC	MT	DTT
DMP3MOC	MA	Inhibitor
DMP3MOC	RN	Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands. Bioorg Med Chem. 2010 Feb 15;18(4):1381-7.
DMP3MOC	RU	https://pubmed.ncbi.nlm.nih.gov/20096591

DM7DWZC	DI	DM7DWZC
DM7DWZC	DN	PhIP glucuronide
DM7DWZC	MI	DE9EXRN
DM7DWZC	MN	Beta-glucuronidase (uidA)
DM7DWZC	MT	DME
DM7DWZC	MA	Metabolism
DM7DWZC	RN	Gut microbial beta-glucuronidase and glycerol/diol dehydratase activity contribute to dietary heterocyclic amine biotransformation. BMC Microbiol. 2019 May 16;19(1):99.
DM7DWZC	RU	https://pubmed.ncbi.nlm.nih.gov/31096909

DMYA50U	DI	DMYA50U
DMYA50U	DN	Phloretin
DMYA50U	MI	TTQEI32
DMYA50U	MN	Aquaporin-9 (AQP9)
DMYA50U	MT	DTT
DMYA50U	MA	Inhibitor
DMYA50U	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 696).
DMYA50U	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=696

DMYA50U	DI	DMYA50U
DMYA50U	DN	Phloretin
DMYA50U	MI	TT8XNZ7
DMYA50U	MN	Chloride channel protein 3 (CLC-3)
DMYA50U	MT	DTT
DMYA50U	MA	Blocker (channel blocker)
DMYA50U	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 702).
DMYA50U	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=702

DMYA50U	DI	DMYA50U
DMYA50U	DN	Phloretin
DMYA50U	MI	TT6XAGK
DMYA50U	MN	Solute carrier family 23 member 1 (SLC23A1)
DMYA50U	MT	DTT
DMYA50U	MA	Inhibitor
DMYA50U	RN	A family of mammalian Na+-dependent L-ascorbic acid transporters. Nature. 1999 May 6;399(6731):70-5.
DMYA50U	RU	https://pubmed.ncbi.nlm.nih.gov/10331392

DMYA50U	DI	DMYA50U
DMYA50U	DN	Phloretin
DMYA50U	MI	DEYGVN4
DMYA50U	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMYA50U	MT	DME
DMYA50U	MA	Metabolism
DMYA50U	RN	Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Biol Chem. 2004 Jan 9;279(2):1429-41.
DMYA50U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14557274

DMYA50U	DI	DMYA50U
DMYA50U	DN	Phloretin
DMYA50U	MI	DEZO4N3
DMYA50U	MN	UDP-glucuronosyltransferase 1A7 (UGT1A7)
DMYA50U	MT	DME
DMYA50U	MA	Metabolism
DMYA50U	RN	Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Biol Chem. 2004 Jan 9;279(2):1429-41.
DMYA50U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14557274

DMYA50U	DI	DMYA50U
DMYA50U	DN	Phloretin
DMYA50U	MI	DE2GB8N
DMYA50U	MN	UDP-glucuronosyltransferase 1A8 (UGT1A8)
DMYA50U	MT	DME
DMYA50U	MA	Metabolism
DMYA50U	RN	Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Biol Chem. 2004 Jan 9;279(2):1429-41.
DMYA50U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14557274

DMYA50U	DI	DMYA50U
DMYA50U	DN	Phloretin
DMYA50U	MI	DE85D2P
DMYA50U	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMYA50U	MT	DME
DMYA50U	MA	Metabolism
DMYA50U	RN	Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Biol Chem. 2004 Jan 9;279(2):1429-41.
DMYA50U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14557274

DMNARGO	DI	DMNARGO
DMNARGO	DN	Phlorizin
DMNARGO	MI	DTFI42L
DMNARGO	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMNARGO	MT	DTP
DMNARGO	MA	Substrate
DMNARGO	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMNARGO	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMNARGO	DI	DMNARGO
DMNARGO	DN	Phlorizin
DMNARGO	MI	TT2UE56
DMNARGO	MN	Sodium/glucose cotransporter 1 (SGLT1)
DMNARGO	MT	DTT
DMNARGO	MA	Inhibitor
DMNARGO	RN	J Biol Chem. 1988 Jan 5;263(1):187-92.High affinity phlorizin binding to the LLC-PK1 cells exhibits a sodium:phlorizin stoichiometry of 2:1.
DMNARGO	RU	https://pubmed.ncbi.nlm.nih.gov/3335496

DMO1I6G	DI	DMO1I6G
DMO1I6G	DN	PHLOROFUCOFUROECKOL A
DMO1I6G	MI	TT8JRS7
DMO1I6G	MN	Beta-secretase (BACE)
DMO1I6G	MT	DTT
DMO1I6G	MA	Inhibitor
DMO1I6G	RN	Molecular docking studies of phlorotannins from Eisenia bicyclis with BACE1 inhibitory activity. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3211-5.
DMO1I6G	RU	https://pubmed.ncbi.nlm.nih.gov/20462757

DMZWTY7	DI	DMZWTY7
DMZWTY7	DN	Phorbol 12,13-butyrate
DMZWTY7	MI	TT9WJ8U
DMZWTY7	MN	Protein kinase C delta (PRKCD)
DMZWTY7	MT	DTT
DMZWTY7	MA	Inhibitor
DMZWTY7	RN	Conformationally constrained analogues of diacylglycerol (DAG). 28. DAG-dioxolanones reveal a new additional interaction site in the C1b domain of ... J Med Chem. 2007 Jul 26;50(15):3465-81.
DMZWTY7	RU	https://pubmed.ncbi.nlm.nih.gov/17591763

DM096SC	DI	DM096SC
DM096SC	DN	Phorbol 12-myristate
DM096SC	MI	TTBZ7OD
DM096SC	MN	Protein kinase C epsilon (PRKCE)
DM096SC	MT	DTT
DM096SC	MA	Activator
DM096SC	RN	Protein kinase epsilon dampens the secretory response of model intestinal epithelia during ischemia. Surgery. 2001 Aug;130(2):310-8.
DM096SC	RU	https://pubmed.ncbi.nlm.nih.gov/11490365

DM2USYW	DI	DM2USYW
DM2USYW	DN	Phosethanolamine
DM2USYW	MI	DEIRJ6O
DM2USYW	MN	Phospholipase C (plc)
DM2USYW	MT	DME
DM2USYW	MA	Metabolism
DM2USYW	RN	Phospholipase C from Clostridium novyi type A. I. Biochim Biophys Acta. 1975 Oct 21;409(1):75-85.
DM2USYW	RU	https://pubmed.ncbi.nlm.nih.gov/241423

DMMHQYB	DI	DMMHQYB
DMMHQYB	DN	phosphatidyl (3,5) inositol biphosphate
DMMHQYB	MI	TT9XBVO
DMMHQYB	MN	Mucolipin-1 (TRPML1)
DMMHQYB	MT	DTT
DMMHQYB	MA	Activator
DMMHQYB	RN	PI(3,5)P(2) controls membrane trafficking by direct activation of mucolipin Ca(2+) release channels in the endolysosome. Nat Commun. 2010 Jul 13;1:38.
DMMHQYB	RU	https://pubmed.ncbi.nlm.nih.gov/20802798

DMMHQYB	DI	DMMHQYB
DMMHQYB	DN	phosphatidyl (3,5) inositol biphosphate
DMMHQYB	MI	TTODQE2
DMMHQYB	MN	Two pore calcium channel protein 1 (TPC1)
DMMHQYB	MT	DTT
DMMHQYB	MA	Activator
DMMHQYB	RN	The voltage-gated sodium channel TPC1 confers endolysosomal excitability. Nat Chem Biol. 2014 Jun;10(6):463-9.
DMMHQYB	RU	https://pubmed.ncbi.nlm.nih.gov/24776928

DMMHQYB	DI	DMMHQYB
DMMHQYB	DN	phosphatidyl (3,5) inositol biphosphate
DMMHQYB	MI	TTZWC8B
DMMHQYB	MN	Two pore calcium channel protein 2 (TPC2)
DMMHQYB	MT	DTT
DMMHQYB	MA	Activator
DMMHQYB	RN	TPC proteins are phosphoinositide- activated sodium-selective ion channels in endosomes and lysosomes. Cell. 2012 Oct 12;151(2):372-83.
DMMHQYB	RU	https://pubmed.ncbi.nlm.nih.gov/23063126

DMY2RVX	DI	DMY2RVX
DMY2RVX	DN	Phosphatidylcholine
DMY2RVX	MI	DELNI4J
DMY2RVX	MN	Lecithin-cholesterol acyltransferase (LCAT)
DMY2RVX	MT	DME
DMY2RVX	MA	Metabolism
DMY2RVX	RN	Characterization of lecithin:cholesterol acyltransferase expressed in a human lung cell line. Protein Expr Purif. 2004 Aug;36(2):157-64.
DMY2RVX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15249036

DMOPYWF	DI	DMOPYWF
DMOPYWF	DN	Phosphatidylethanolamine
DMOPYWF	MI	DTM4YG0
DMOPYWF	MN	ATP-binding cassette sub-family A member 4 (ABCA4)
DMOPYWF	MT	DTP
DMOPYWF	MA	Substrate
DMOPYWF	RN	The ATP-binding cassette transporter ABCA4: structural and functional properties and role in retinal disease. Adv Exp Med Biol. 2010;703:105-25.
DMOPYWF	RU	http://www.ncbi.nlm.nih.gov/pubmed/20711710

DMOPYWF	DI	DMOPYWF
DMOPYWF	DN	Phosphatidylethanolamine
DMOPYWF	MI	DTTQ8WI
DMOPYWF	MN	Probable phospholipid-transporting ATPase VA (ATP10A)
DMOPYWF	MT	DTP
DMOPYWF	MA	Substrate
DMOPYWF	RN	Substrates of P4-ATPases: beyond aminophospholipids (phosphatidylserine and phosphatidylethanolamine). FASEB J. 2019 Mar;33(3):3087-3096.
DMOPYWF	RU	http://www.ncbi.nlm.nih.gov/pubmed/30509129

DM76TSG	DI	DM76TSG
DM76TSG	DN	Phosphatidylserine
DM76TSG	MI	TT5Z1WV
DM76TSG	MN	Adhesion G protein-coupled receptor B1 (BAI1)
DM76TSG	MT	DTT
DM76TSG	MA	Agonist
DM76TSG	RN	BAI1 is an engulfment receptor for apoptotic cells upstream of the ELMO/Dock180/Rac module. Nature. 2007 Nov 15;450(7168):430-4.
DM76TSG	RU	https://pubmed.ncbi.nlm.nih.gov/17960134

DM76TSG	DI	DM76TSG
DM76TSG	DN	Phosphatidylserine
DM76TSG	MI	DTI7UX6
DM76TSG	MN	Breast cancer resistance protein (ABCG2)
DM76TSG	MT	DTP
DM76TSG	MA	Substrate
DM76TSG	RN	ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci. 2010 Apr 24;86(17-18):631-7.
DM76TSG	RU	https://doi.org/10.1016/j.lfs.2010.02.012

DMIZLVW	DI	DMIZLVW
DMIZLVW	DN	Phosphocholine
DMIZLVW	MI	TTWRN6M
DMIZLVW	MN	CRP messenger RNA (CRP mRNA)
DMIZLVW	MT	DTT
DMIZLVW	MA	Inhibitor
DMIZLVW	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMIZLVW	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM2D947	DI	DM2D947
DM2D947	DN	Phosphoenolpyruvate
DM2D947	MI	TTVNA43
DM2D947	MN	Bacterial Deoxy-D-manno-octulosonate 8-phosphate synthase (Bact kdsA)
DM2D947	MT	DTT
DM2D947	MA	Inhibitor
DM2D947	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM2D947	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM2D947	DI	DM2D947
DM2D947	DN	Phosphoenolpyruvate
DM2D947	MI	DEPLH5Z
DM2D947	MN	Phosphoenolpyruvate carboxykinase (PCK1)
DM2D947	MT	DME
DM2D947	MA	Metabolism
DM2D947	RN	Tyr235 of human cytosolic phosphoenolpyruvate carboxykinase influences catalysis through an anion-quadrupole interaction with phosphoenolpyruvate carboxylate. FEBS J. 2008 Dec;275(23):5810-9.
DM2D947	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19021757

DM2D947	DI	DM2D947
DM2D947	DN	Phosphoenolpyruvate
DM2D947	MI	DETH24K
DM2D947	MN	Red cell/liver pyruvate kinase (PKLR)
DM2D947	MT	DME
DM2D947	MA	Metabolism
DM2D947	RN	Energetic coupling between an oxidizable cysteine and the phosphorylatable N-terminus of human liver pyruvate kinase. Biochemistry. 2013 Jan 22;52(3):466-76.
DM2D947	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23270483

DMAYLNO	DI	DMAYLNO
DMAYLNO	DN	PHOSPHOGLYCOLOHYDROXAMATE
DMAYLNO	MI	TT1FL6V
DMAYLNO	MN	Plasmodium Fructose-bisphosphate aldolase (Malaria FBA)
DMAYLNO	MT	DTT
DMAYLNO	MA	Inhibitor
DMAYLNO	RN	N-Sulfonyl hydroxamate derivatives as inhibitors of class II fructose-1,6-diphosphate aldolase. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5375-7.
DMAYLNO	RU	https://pubmed.ncbi.nlm.nih.gov/16236509

DM4IRU5	DI	DM4IRU5
DM4IRU5	DN	Phosphomethylphosphonic Acid Guanylate Ester
DM4IRU5	MI	TT4W1VJ
DM4IRU5	MN	Bacterial Celldivision protein FtsZ (Bact ftsZ)
DM4IRU5	MT	DTT
DM4IRU5	MA	Inhibitor
DM4IRU5	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM4IRU5	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMTFHPI	DI	DMTFHPI
DMTFHPI	DN	Phosphonothreonine
DMTFHPI	MI	TTPS3C0
DMTFHPI	MN	Aurora kinase A (AURKA)
DMTFHPI	MT	DTT
DMTFHPI	MA	Inhibitor
DMTFHPI	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMTFHPI	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMTFHPI	DI	DMTFHPI
DMTFHPI	DN	Phosphonothreonine
DMTFHPI	MI	TTQYF7G
DMTFHPI	MN	Cyclin-dependent kinase 7 (CDK7)
DMTFHPI	MT	DTT
DMTFHPI	MA	Inhibitor
DMTFHPI	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMTFHPI	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMTFHPI	DI	DMTFHPI
DMTFHPI	DN	Phosphonothreonine
DMTFHPI	MI	TT4TQBX
DMTFHPI	MN	Extracellular signal-regulated kinase 2 (ERK2)
DMTFHPI	MT	DTT
DMTFHPI	MA	Inhibitor
DMTFHPI	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMTFHPI	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMTFHPI	DI	DMTFHPI
DMTFHPI	DN	Phosphonothreonine
DMTFHPI	MI	TTYT93M
DMTFHPI	MN	MAP kinase p38 (MAPK12)
DMTFHPI	MT	DTT
DMTFHPI	MA	Inhibitor
DMTFHPI	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMTFHPI	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMTFHPI	DI	DMTFHPI
DMTFHPI	DN	Phosphonothreonine
DMTFHPI	MI	TT8QL1J
DMTFHPI	MN	Protein kinase C theta (PRKCQ)
DMTFHPI	MT	DTT
DMTFHPI	MA	Inhibitor
DMTFHPI	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMTFHPI	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMTFHPI	DI	DMTFHPI
DMTFHPI	DN	Phosphonothreonine
DMTFHPI	MI	TTH0KSX
DMTFHPI	MN	Rhodopsin (RHO)
DMTFHPI	MT	DTT
DMTFHPI	MA	Inhibitor
DMTFHPI	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMTFHPI	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM09MY1	DI	DM09MY1
DM09MY1	DN	Phosphonotyrosine
DM09MY1	MI	TT6PKBN
DM09MY1	MN	Proto-oncogene c-Src (SRC)
DM09MY1	MT	DTT
DM09MY1	MA	Inhibitor
DM09MY1	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM09MY1	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM09MY1	DI	DM09MY1
DM09MY1	DN	Phosphonotyrosine
DM09MY1	MI	TTX41N9
DM09MY1	MN	Tyrosine-protein kinase Kit (KIT)
DM09MY1	MT	DTT
DM09MY1	MA	Inhibitor
DM09MY1	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM09MY1	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM3VL7G	DI	DM3VL7G
DM3VL7G	DN	Phosphoramidon
DM3VL7G	MI	TT1BGDH
DM3VL7G	MN	Endothelin-converting enzyme (ECE)
DM3VL7G	MT	DTT
DM3VL7G	MA	Inhibitor
DM3VL7G	RN	In vitro enzymatic processing of radiolabelled big ET-1 in human kidney. Biochem Pharmacol. 1998 Mar 1;55(5):697-701.
DM3VL7G	RU	https://pubmed.ncbi.nlm.nih.gov/9515580

DM3VL7G	DI	DM3VL7G
DM3VL7G	DN	Phosphoramidon
DM3VL7G	MI	TT5TKPM
DM3VL7G	MN	Neutral endopeptidase (MME)
DM3VL7G	MT	DTT
DM3VL7G	MA	Inhibitor
DM3VL7G	RN	Neprilysin, a novel target for ultraviolet B regulation of melanogenesis via melanocortins. J Invest Dermatol. 2000 Sep;115(3):381-7.
DM3VL7G	RU	https://pubmed.ncbi.nlm.nih.gov/10951272

DMS57HX	DI	DMS57HX
DMS57HX	DN	Phosphoric acid mono-((E)-dec-4-enyl) ester
DMS57HX	MI	TTQ6S1K
DMS57HX	MN	Lysophosphatidic acid receptor 1 (LPAR1)
DMS57HX	MT	DTT
DMS57HX	MA	Inhibitor
DMS57HX	RN	Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30.
DMS57HX	RU	https://pubmed.ncbi.nlm.nih.gov/16033271

DMC873V	DI	DMC873V
DMC873V	DN	Phosphoric acid mono-((E)-dodec-9-enyl) ester
DMC873V	MI	TTQ6S1K
DMC873V	MN	Lysophosphatidic acid receptor 1 (LPAR1)
DMC873V	MT	DTT
DMC873V	MA	Inhibitor
DMC873V	RN	Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30.
DMC873V	RU	https://pubmed.ncbi.nlm.nih.gov/16033271

DMET9ZC	DI	DMET9ZC
DMET9ZC	DN	Phosphoric acid mono-((E)-tetradec-11-enyl) ester
DMET9ZC	MI	TTQ6S1K
DMET9ZC	MN	Lysophosphatidic acid receptor 1 (LPAR1)
DMET9ZC	MT	DTT
DMET9ZC	MA	Inhibitor
DMET9ZC	RN	Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30.
DMET9ZC	RU	https://pubmed.ncbi.nlm.nih.gov/16033271

DME8APC	DI	DME8APC
DME8APC	DN	Phosphoric acid mono-((E)-tetradec-9-enyl) ester
DME8APC	MI	TTQ6S1K
DME8APC	MN	Lysophosphatidic acid receptor 1 (LPAR1)
DME8APC	MT	DTT
DME8APC	MA	Inhibitor
DME8APC	RN	Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30.
DME8APC	RU	https://pubmed.ncbi.nlm.nih.gov/16033271

DMANVJY	DI	DMANVJY
DMANVJY	DN	Phosphoric acid monodec-9-enyl ester
DMANVJY	MI	TTQ6S1K
DMANVJY	MN	Lysophosphatidic acid receptor 1 (LPAR1)
DMANVJY	MT	DTT
DMANVJY	MA	Inhibitor
DMANVJY	RN	Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30.
DMANVJY	RU	https://pubmed.ncbi.nlm.nih.gov/16033271

DMME0VN	DI	DMME0VN
DMME0VN	DN	Phosphoric acid monododecyl ester
DMME0VN	MI	TTQ6S1K
DMME0VN	MN	Lysophosphatidic acid receptor 1 (LPAR1)
DMME0VN	MT	DTT
DMME0VN	MA	Inhibitor
DMME0VN	RN	Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30.
DMME0VN	RU	https://pubmed.ncbi.nlm.nih.gov/16033271

DMG5MJL	DI	DMG5MJL
DMG5MJL	DN	Phosphoric acid monotetradecyl ester
DMG5MJL	MI	TTQ6S1K
DMG5MJL	MN	Lysophosphatidic acid receptor 1 (LPAR1)
DMG5MJL	MT	DTT
DMG5MJL	MA	Inhibitor
DMG5MJL	RN	Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30.
DMG5MJL	RU	https://pubmed.ncbi.nlm.nih.gov/16033271

DMN0D14	DI	DMN0D14
DMN0D14	DN	PhSO2-Gly-(Me-Gly)-Arg-(2-thiazole)
DMN0D14	MI	TTCIHJA
DMN0D14	MN	Coagulation factor Xa (F10)
DMN0D14	MT	DTT
DMN0D14	MA	Inhibitor
DMN0D14	RN	Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. Bioorg Med Chem. 2008 Feb 15;16(4):1562-95.
DMN0D14	RU	https://pubmed.ncbi.nlm.nih.gov/18053726

DMI96Y3	DI	DMI96Y3
DMI96Y3	DN	PHT-427
DMI96Y3	MI	TT9QBI6
DMI96Y3	MN	Phosphoinositide dependent protein kinase-1 (PDPK1)
DMI96Y3	MT	DTT
DMI96Y3	MA	Inhibitor
DMI96Y3	RN	Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor. Mol Cancer Ther. 2010 Mar;9(3):706-17.
DMI96Y3	RU	https://pubmed.ncbi.nlm.nih.gov/20197390

DMI96Y3	DI	DMI96Y3
DMI96Y3	DN	PHT-427
DMI96Y3	MI	TTH24WI
DMI96Y3	MN	RAC-beta serine/threonine-protein kinase (AKT2)
DMI96Y3	MT	DTT
DMI96Y3	MA	Inhibitor
DMI96Y3	RN	Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor. Mol Cancer Ther. 2010 Mar;9(3):706-17.
DMI96Y3	RU	https://pubmed.ncbi.nlm.nih.gov/20197390

DMF9T64	DI	DMF9T64
DMF9T64	DN	Phthalic Acid
DMF9T64	MI	TTH29K0
DMF9T64	MN	Mycobacterium Nicotinate-nucleotide pyrophosphorylase (MycB nadC)
DMF9T64	MT	DTT
DMF9T64	MA	Inhibitor
DMF9T64	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMF9T64	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMBHKAV	DI	DMBHKAV
DMBHKAV	DN	PHTPP
DMBHKAV	MI	TTOM3J0
DMBHKAV	MN	Estrogen receptor beta (ESR2)
DMBHKAV	MT	DTT
DMBHKAV	MA	Antagonist
DMBHKAV	RN	Structure-guided optimization of estrogen receptor binding affinity and antagonist potency of pyrazolopyrimidines with basic side chains. J Med Chem. 2007 Jan 25;50(2):399-403.
DMBHKAV	RU	https://pubmed.ncbi.nlm.nih.gov/17228884

DMPS1Y2	DI	DMPS1Y2
DMPS1Y2	DN	P-hydroxyphenethyl trans-ferulate
DMPS1Y2	MI	TTO9X1H
DMPS1Y2	MN	5-HT 7 receptor (HTR7)
DMPS1Y2	MT	DTT
DMPS1Y2	MA	Inhibitor
DMPS1Y2	RN	Serotonergic activity-guided phytochemical investigation of the roots of Angelica sinensis. J Nat Prod. 2006 Apr;69(4):536-41.
DMPS1Y2	RU	https://pubmed.ncbi.nlm.nih.gov/16643021

DMU30IO	DI	DMU30IO
DMU30IO	DN	Phylomers
DMU30IO	MI	TT0K6EO
DMU30IO	MN	Stress-activated protein kinase JNK1 (JNK1)
DMU30IO	MT	DTT
DMU30IO	MA	Inhibitor
DMU30IO	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1496).
DMU30IO	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1496

DM09T76	DI	DM09T76
DM09T76	DN	physalaemin
DM09T76	MI	TTZPO1L
DM09T76	MN	Substance-P receptor (TACR1)
DM09T76	MT	DTT
DM09T76	MA	Agonist
DM09T76	RN	The unpredicted high affinities of a large number of naturally occurring tachykinins for chimeric NK1/NK3 receptors suggest a role for an inhibitory domain in determining receptor specificity. J BiolChem. 1996 Aug 23;271(34):20250-7.
DM09T76	RU	https://pubmed.ncbi.nlm.nih.gov/8702757

DMSZ1RB	DI	DMSZ1RB
DMSZ1RB	DN	Phytanic acid
DMSZ1RB	MI	DE87ZNW
DMSZ1RB	MN	Cytochrome P450 121A1 (cyp121)
DMSZ1RB	MT	DME
DMSZ1RB	MA	Metabolism
DMSZ1RB	RN	Function, essentiality, and expression of cytochrome P450 enzymes and their cognate redox partners in Mycobacterium tuberculosis: are they drug targets? Appl Microbiol Biotechnol. 2019 May;103(9):3597-3614.
DMSZ1RB	RU	https://pubmed.ncbi.nlm.nih.gov/30810776

DMSZ1RB	DI	DMSZ1RB
DMSZ1RB	DN	Phytanic acid
DMSZ1RB	MI	TT6PEUO
DMSZ1RB	MN	Retinoic acid receptor RXR-alpha (RXRA)
DMSZ1RB	MT	DTT
DMSZ1RB	MA	Agonist
DMSZ1RB	RN	Phytanic acid is a retinoid X receptor ligand. Eur J Biochem. 1996 Feb 15;236(1):328-33.
DMSZ1RB	RU	https://pubmed.ncbi.nlm.nih.gov/8617282

DMWJCST	DI	DMWJCST
DMWJCST	DN	phytosphingosine 1-phosphate
DMWJCST	MI	TTZ8C5Q
DMWJCST	MN	Sphingosine-1-phosphate receptor 4 (S1PR4)
DMWJCST	MT	DTT
DMWJCST	MA	Agonist
DMWJCST	RN	Phytosphingosine 1-phosphate: a high affinity ligand for the S1P(4)/Edg-6 receptor. Biochem Biophys Res Commun. 2002 Sep 27;297(3):600-6.
DMWJCST	RU	https://pubmed.ncbi.nlm.nih.gov/12270137

DM68JNY	DI	DM68JNY
DM68JNY	DN	PI1
DM68JNY	MI	TTV1C0Z
DM68JNY	MN	Neuropeptide S receptor (NPSR)
DM68JNY	MT	DTT
DM68JNY	MA	Antagonist
DM68JNY	RN	Tricyclic imidazole antagonists of the Neuropeptide S Receptor. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4704-8.
DM68JNY	RU	https://pubmed.ncbi.nlm.nih.gov/20615693

DMEK4TJ	DI	DMEK4TJ
DMEK4TJ	DN	PI-103
DMEK4TJ	MI	TTHBTOP
DMEK4TJ	MN	PI3-kinase gamma (PIK3CG)
DMEK4TJ	MT	DTT
DMEK4TJ	MA	Inhibitor
DMEK4TJ	RN	The PI3K/Akt pathway as a target in the treatment of hematologic malignancies. Anticancer Agents Med Chem. 2009 Jun;9(5):550-9.
DMEK4TJ	RU	https://pubmed.ncbi.nlm.nih.gov/19519296

DMCQUWI	DI	DMCQUWI
DMCQUWI	DN	PI-3065
DMCQUWI	MI	TTTHBCA
DMCQUWI	MN	PI3-kinase beta (PIK3CB)
DMCQUWI	MT	DTT
DMCQUWI	MA	Inhibitor
DMCQUWI	RN	Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune tolerance to cancer. Nature. 2014 Jun 19;510(7505):407-11.
DMCQUWI	RU	https://pubmed.ncbi.nlm.nih.gov/24919154

DMCQUWI	DI	DMCQUWI
DMCQUWI	DN	PI-3065
DMCQUWI	MI	TTHBTOP
DMCQUWI	MN	PI3-kinase gamma (PIK3CG)
DMCQUWI	MT	DTT
DMCQUWI	MA	Inhibitor
DMCQUWI	RN	Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune tolerance to cancer. Nature. 2014 Jun 19;510(7505):407-11.
DMCQUWI	RU	https://pubmed.ncbi.nlm.nih.gov/24919154

DMQBAM6	DI	DMQBAM6
DMQBAM6	DN	PIBTU
DMQBAM6	MI	TTF10I9
DMQBAM6	MN	Nitric-oxide synthase inducible (NOS2)
DMQBAM6	MT	DTT
DMQBAM6	MA	Inhibitor
DMQBAM6	RN	Potent and selective inhibition of human nitric oxide synthases. Inhibition by non-amino acid isothioureas. J Biol Chem. 1994 Oct 28;269(43):26669-76.
DMQBAM6	RU	https://pubmed.ncbi.nlm.nih.gov/7523409

DMYOP45	DI	DMYOP45
DMYOP45	DN	Piceatannol
DMYOP45	MI	TTYR7OH
DMYOP45	MN	Interferon regulatory factor 3 (IRF3)
DMYOP45	MT	DTT
DMYOP45	MA	Inhibitor
DMYOP45	RN	Inhibition of lipopolysaccharide-induced interferon regulatory factor 3 activation and protection from septic shock by hydroxystilbenes. Shock. 2004 May;21(5):470-5.
DMYOP45	RU	https://pubmed.ncbi.nlm.nih.gov/15087825

DMND2QG	DI	DMND2QG
DMND2QG	DN	PICROTIN
DMND2QG	MI	TTZ8EM9
DMND2QG	MN	Glycine receptor (GlyR)
DMND2QG	MT	DTT
DMND2QG	MA	Inhibitor
DMND2QG	RN	Mechanisms for picrotoxinin and picrotin blocks of alpha2 homomeric glycine receptors. J Biol Chem. 2007 Jun 1;282(22):16016-35.
DMND2QG	RU	https://pubmed.ncbi.nlm.nih.gov/17405877

DM9BQTX	DI	DM9BQTX
DM9BQTX	DN	PIK-75
DM9BQTX	MI	TTK3PY9
DM9BQTX	MN	DNA-dependent protein kinase catalytic (PRKDC)
DM9BQTX	MT	DTT
DM9BQTX	MA	Inhibitor
DM9BQTX	RN	A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006 May 19;125(4):733-47.
DM9BQTX	RU	https://pubmed.ncbi.nlm.nih.gov/16647110

DM9BQTX	DI	DM9BQTX
DM9BQTX	DN	PIK-75
DM9BQTX	MI	TTTHBCA
DM9BQTX	MN	PI3-kinase beta (PIK3CB)
DM9BQTX	MT	DTT
DM9BQTX	MA	Inhibitor
DM9BQTX	RN	Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem. 2007 Sep 1;15(17):5837-44.
DM9BQTX	RU	https://pubmed.ncbi.nlm.nih.gov/17601739

DM9BQTX	DI	DM9BQTX
DM9BQTX	DN	PIK-75
DM9BQTX	MI	TTHBTOP
DM9BQTX	MN	PI3-kinase gamma (PIK3CG)
DM9BQTX	MT	DTT
DM9BQTX	MA	Inhibitor
DM9BQTX	RN	Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem. 2007 Sep 1;15(17):5837-44.
DM9BQTX	RU	https://pubmed.ncbi.nlm.nih.gov/17601739

DM3JBLK	DI	DM3JBLK
DM3JBLK	DN	PIK-93
DM3JBLK	MI	TTNPL3B
DM3JBLK	MN	Phosphatidylinositol-4-kinase beta (PI4KB)
DM3JBLK	MT	DTT
DM3JBLK	MA	Inhibitor
DM3JBLK	RN	A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006 May 19;125(4):733-47.
DM3JBLK	RU	https://pubmed.ncbi.nlm.nih.gov/16647110

DMBERSG	DI	DMBERSG
DMBERSG	DN	Pim[-Trp-Arg-Nva-Arg-Tyr-NH2]2
DMBERSG	MI	TTRK9JT
DMBERSG	MN	Neuropeptide Y receptor type 1 (NPY1R)
DMBERSG	MT	DTT
DMBERSG	MA	Inhibitor
DMBERSG	RN	Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5.
DMBERSG	RU	https://pubmed.ncbi.nlm.nih.gov/16610810

DMBERSG	DI	DMBERSG
DMBERSG	DN	Pim[-Trp-Arg-Nva-Arg-Tyr-NH2]2
DMBERSG	MI	TTJ6WK9
DMBERSG	MN	Neuropeptide Y receptor type 2 (NPY2R)
DMBERSG	MT	DTT
DMBERSG	MA	Inhibitor
DMBERSG	RN	Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5.
DMBERSG	RU	https://pubmed.ncbi.nlm.nih.gov/16610810

DMBERSG	DI	DMBERSG
DMBERSG	DN	Pim[-Trp-Arg-Nva-Arg-Tyr-NH2]2
DMBERSG	MI	TTW4N16
DMBERSG	MN	Neuropeptide Y receptor type 4 (NPY4R)
DMBERSG	MT	DTT
DMBERSG	MA	Inhibitor
DMBERSG	RN	Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5.
DMBERSG	RU	https://pubmed.ncbi.nlm.nih.gov/16610810

DMHLBZR	DI	DMHLBZR
DMHLBZR	DN	P-IODOAMPHETAMINE
DMHLBZR	MI	TTK25J1
DMHLBZR	MN	Adenosine A1 receptor (ADORA1)
DMHLBZR	MT	DTT
DMHLBZR	MA	Inhibitor
DMHLBZR	RN	Synthesis and biological activity of N6-(p-sulfophenyl)alkyl and N6-sulfoalkyl derivatives of adenosine: water-soluble and peripherally selective a... J Med Chem. 1992 Oct 30;35(22):4143-9.
DMHLBZR	RU	https://pubmed.ncbi.nlm.nih.gov/1433217

DMOZV7N	DI	DMOZV7N
DMOZV7N	DN	PIP2
DMOZV7N	MI	TT9EUT4
DMOZV7N	MN	Hyperpolarization cyclic nucleotide-gated channel 2 (HCN2)
DMOZV7N	MT	DTT
DMOZV7N	MA	Activator
DMOZV7N	RN	Regulation of gating and rundown of HCN hyperpolarization-activated channels by exogenous and endogenous PIP2. J Gen Physiol. 2006 Nov;128(5):593-604.
DMOZV7N	RU	https://pubmed.ncbi.nlm.nih.gov/17074978

DMOZV7N	DI	DMOZV7N
DMOZV7N	DN	PIP2
DMOZV7N	MI	TTH7UO3
DMOZV7N	MN	Inward rectifier potassium channel Kir2.1 (KCNJ2)
DMOZV7N	MT	DTT
DMOZV7N	MA	Activator
DMOZV7N	RN	Multiple PIP2 binding sites in Kir2.1 inwardly rectifying potassium channels. FEBS Lett. 2001 Feb 9;490(1-2):49-53.
DMOZV7N	RU	https://pubmed.ncbi.nlm.nih.gov/11172809

DMOZV7N	DI	DMOZV7N
DMOZV7N	DN	PIP2
DMOZV7N	MI	TTGM19J
DMOZV7N	MN	Inward rectifier potassium channel Kir3.1 (KCNJ3)
DMOZV7N	MT	DTT
DMOZV7N	MA	Activator
DMOZV7N	RN	Direct activation of inward rectifier potassium channels by PIP2 and its stabilization by Gbetagamma. Nature. 1998 Feb 19;391(6669):803-6.
DMOZV7N	RU	https://pubmed.ncbi.nlm.nih.gov/9486652

DMOZV7N	DI	DMOZV7N
DMOZV7N	DN	PIP2
DMOZV7N	MI	TTTIBVP
DMOZV7N	MN	Inward rectifier potassium channel Kir3.2 (KCNJ6)
DMOZV7N	MT	DTT
DMOZV7N	MA	Activator
DMOZV7N	RN	Direct activation of inward rectifier potassium channels by PIP2 and its stabilization by Gbetagamma. Nature. 1998 Feb 19;391(6669):803-6.
DMOZV7N	RU	https://pubmed.ncbi.nlm.nih.gov/9486652

DMOZV7N	DI	DMOZV7N
DMOZV7N	DN	PIP2
DMOZV7N	MI	TT4VHL6
DMOZV7N	MN	Inward rectifier potassium channel Kir3.3 (KCNJ9)
DMOZV7N	MT	DTT
DMOZV7N	MA	Activator
DMOZV7N	RN	Regulation of cardiac Na+,Ca2+ exchange and KATP potassium channels by PIP2. Science. 1996 Aug 16;273(5277):956-9.
DMOZV7N	RU	https://pubmed.ncbi.nlm.nih.gov/8688080

DMOZV7N	DI	DMOZV7N
DMOZV7N	DN	PIP2
DMOZV7N	MI	TTEO25X
DMOZV7N	MN	Inward rectifier potassium channel Kir3.4 (KCNJ5)
DMOZV7N	MT	DTT
DMOZV7N	MA	Activator
DMOZV7N	RN	PIP2 and PIP as determinants for ATP inhibition of KATP channels. Science. 1998 Nov 6;282(5391):1141-4.
DMOZV7N	RU	https://pubmed.ncbi.nlm.nih.gov/9804555

DMOZV7N	DI	DMOZV7N
DMOZV7N	DN	PIP2
DMOZV7N	MI	TT5HWAT
DMOZV7N	MN	IP3 receptor isoform 1 (ITPR1)
DMOZV7N	MT	DTT
DMOZV7N	MA	Antagonist
DMOZV7N	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 743).
DMOZV7N	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=743

DMOZV7N	DI	DMOZV7N
DMOZV7N	DN	PIP2
DMOZV7N	MI	TTJ2HKA
DMOZV7N	MN	Long transient receptor potential channel 4 (TRPM4)
DMOZV7N	MT	DTT
DMOZV7N	MA	Activator
DMOZV7N	RN	Phosphatidylinositol 4,5-bisphosphate rescues TRPM4 channels from desensitization. J Biol Chem. 2005 Nov 25;280(47):39185-92.
DMOZV7N	RU	https://pubmed.ncbi.nlm.nih.gov/16186107

DMOZV7N	DI	DMOZV7N
DMOZV7N	DN	PIP2
DMOZV7N	MI	TTFPVZO
DMOZV7N	MN	Long transient receptor potential channel 7 (TRPM7)
DMOZV7N	MT	DTT
DMOZV7N	MA	Activator
DMOZV7N	RN	The TRPM7 channel is inactivated by PIP(2) hydrolysis. Nat Cell Biol. 2002 May;4(5):329-36.
DMOZV7N	RU	https://pubmed.ncbi.nlm.nih.gov/11941371

DMOZV7N	DI	DMOZV7N
DMOZV7N	DN	PIP2
DMOZV7N	MI	TTRLMKF
DMOZV7N	MN	Phospholipase D2 (PLD2)
DMOZV7N	MT	DTT
DMOZV7N	MA	Activator
DMOZV7N	RN	Cloning and initial characterization of a human phospholipase D2 (hPLD2). ADP-ribosylation factor regulates hPLD2. J Biol Chem. 1998 May 22;273(21):12846-52.
DMOZV7N	RU	https://pubmed.ncbi.nlm.nih.gov/9582313

DMOZV7N	DI	DMOZV7N
DMOZV7N	DN	PIP2
DMOZV7N	MI	TTPXI3S
DMOZV7N	MN	Voltage-gated potassium channel Kv7.2 (KCNQ2)
DMOZV7N	MT	DTT
DMOZV7N	MA	Activator
DMOZV7N	RN	Regulation of Kv7 (KCNQ) K+ channel open probability by phosphatidylinositol 4,5-bisphosphate. J Neurosci. 2005 Oct 26;25(43):9825-35.
DMOZV7N	RU	https://pubmed.ncbi.nlm.nih.gov/16251430

DMOZV7N	DI	DMOZV7N
DMOZV7N	DN	PIP2
DMOZV7N	MI	TT8HGRW
DMOZV7N	MN	Voltage-gated potassium channel Kv7.4 (KCNQ4)
DMOZV7N	MT	DTT
DMOZV7N	MA	Activator
DMOZV7N	RN	Regulation of Kv7 (KCNQ) K+ channel open probability by phosphatidylinositol 4,5-bisphosphate. J Neurosci. 2005 Oct 26;25(43):9825-35.
DMOZV7N	RU	https://pubmed.ncbi.nlm.nih.gov/16251430

DMJX39N	DI	DMJX39N
DMJX39N	DN	PIP3
DMJX39N	MI	TT8SJGB
DMJX39N	MN	Cyclic nucleotide-gated channel alpha-2 (CNGA2)
DMJX39N	MT	DTT
DMJX39N	MA	Inhibitor (gating inhibitor)
DMJX39N	RN	Interplay between PIP3 and calmodulin regulation of olfactory cyclic nucleotide-gated channels. Proc Natl Acad Sci U S A. 2006 Oct 17;103(42):15635-40.
DMJX39N	RU	https://pubmed.ncbi.nlm.nih.gov/17032767

DMN8OR2	DI	DMN8OR2
DMN8OR2	DN	Piperidin-(2E)-ylideneamine
DMN8OR2	MI	TTZUFI5
DMN8OR2	MN	Nitric-oxide synthase brain (NOS1)
DMN8OR2	MT	DTT
DMN8OR2	MA	Inhibitor
DMN8OR2	RN	Bicyclic amidine inhibitors of nitric oxide synthase: discovery of perhydro-iminopyrindine and perhydro-iminoquinoline as potent, orally active inh... Bioorg Med Chem Lett. 2005 Apr 15;15(8):1997-2001.
DMN8OR2	RU	https://pubmed.ncbi.nlm.nih.gov/15808455

DMN8OR2	DI	DMN8OR2
DMN8OR2	DN	Piperidin-(2E)-ylideneamine
DMN8OR2	MI	TTCM4B3
DMN8OR2	MN	Nitric-oxide synthase endothelial (NOS3)
DMN8OR2	MT	DTT
DMN8OR2	MA	Inhibitor
DMN8OR2	RN	Bicyclic amidine inhibitors of nitric oxide synthase: discovery of perhydro-iminopyrindine and perhydro-iminoquinoline as potent, orally active inh... Bioorg Med Chem Lett. 2005 Apr 15;15(8):1997-2001.
DMN8OR2	RU	https://pubmed.ncbi.nlm.nih.gov/15808455

DMN8OR2	DI	DMN8OR2
DMN8OR2	DN	Piperidin-(2E)-ylideneamine
DMN8OR2	MI	TTF10I9
DMN8OR2	MN	Nitric-oxide synthase inducible (NOS2)
DMN8OR2	MT	DTT
DMN8OR2	MA	Inhibitor
DMN8OR2	RN	Bicyclic amidine inhibitors of nitric oxide synthase: discovery of perhydro-iminopyrindine and perhydro-iminoquinoline as potent, orally active inh... Bioorg Med Chem Lett. 2005 Apr 15;15(8):1997-2001.
DMN8OR2	RU	https://pubmed.ncbi.nlm.nih.gov/15808455

DMKYF5U	DI	DMKYF5U
DMKYF5U	DN	Piperidine-1-carboxamidine
DMKYF5U	MI	TT2WR1T
DMKYF5U	MN	Cationic trypsinogen (PRSS1)
DMKYF5U	MT	DTT
DMKYF5U	MA	Inhibitor
DMKYF5U	RN	GRID/CPCA: a new computational tool to design selective ligands. J Med Chem. 2000 Aug 10;43(16):3033-44.
DMKYF5U	RU	https://pubmed.ncbi.nlm.nih.gov/10956211

DMF375O	DI	DMF375O
DMF375O	DN	Piperidine-1-carboxylic acid adamantan-2-yl ester
DMF375O	MI	TTN7BL9
DMF375O	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMF375O	MT	DTT
DMF375O	MA	Inhibitor
DMF375O	RN	Discovery and optimization of adamantyl carbamate inhibitors of 11-HSD1. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6725-9.
DMF375O	RU	https://pubmed.ncbi.nlm.nih.gov/20864344

DMHZFK1	DI	DMHZFK1
DMHZFK1	DN	Piperidine-1-carboxylic acid adamantan-2-ylamide
DMHZFK1	MI	TTN7BL9
DMHZFK1	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMHZFK1	MT	DTT
DMHZFK1	MA	Inhibitor
DMHZFK1	RN	Discovery and optimization of adamantyl carbamate inhibitors of 11-HSD1. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6725-9.
DMHZFK1	RU	https://pubmed.ncbi.nlm.nih.gov/20864344

DMMIZWE	DI	DMMIZWE
DMMIZWE	DN	piperidine-4-sulphonic acid
DMMIZWE	MI	TTBMV1G
DMMIZWE	MN	GABA(A) receptor alpha-2 (GABRA2)
DMMIZWE	MT	DTT
DMMIZWE	MA	Agonist
DMMIZWE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 405).
DMMIZWE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=405

DMMIZWE	DI	DMMIZWE
DMMIZWE	DN	piperidine-4-sulphonic acid
DMMIZWE	MI	TT37EDJ
DMMIZWE	MN	GABA(A) receptor alpha-3 (GABRA3)
DMMIZWE	MT	DTT
DMMIZWE	MA	Agonist
DMMIZWE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 406).
DMMIZWE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=406

DMMIZWE	DI	DMMIZWE
DMMIZWE	DN	piperidine-4-sulphonic acid
DMMIZWE	MI	TTNZPQ1
DMMIZWE	MN	GABA(A) receptor alpha-5 (GABRA5)
DMMIZWE	MT	DTT
DMMIZWE	MA	Agonist
DMMIZWE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 408).
DMMIZWE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=408

DMMIZWE	DI	DMMIZWE
DMMIZWE	DN	piperidine-4-sulphonic acid
DMMIZWE	MI	TTEX6LM
DMMIZWE	MN	GABA(A) receptor gamma-3 (GABRG3)
DMMIZWE	MT	DTT
DMMIZWE	MA	Agonist
DMMIZWE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415).
DMMIZWE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415

DMMIZWE	DI	DMMIZWE
DMMIZWE	DN	piperidine-4-sulphonic acid
DMMIZWE	MI	TT6XFEU
DMMIZWE	MN	GABA(A) receptor rho1 (GABRR1)
DMMIZWE	MT	DTT
DMMIZWE	MA	Antagonist
DMMIZWE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 420).
DMMIZWE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=420

DMMIZWE	DI	DMMIZWE
DMMIZWE	DN	piperidine-4-sulphonic acid
DMMIZWE	MI	TTQMXLS
DMMIZWE	MN	GABA(A) receptor rho2 (GABRR2)
DMMIZWE	MT	DTT
DMMIZWE	MA	Antagonist
DMMIZWE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 421).
DMMIZWE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=421

DMMIZWE	DI	DMMIZWE
DMMIZWE	DN	piperidine-4-sulphonic acid
DMMIZWE	MI	TT4N6D8
DMMIZWE	MN	GABA(A) receptor rho3 (GABRR3)
DMMIZWE	MT	DTT
DMMIZWE	MA	Antagonist
DMMIZWE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 422).
DMMIZWE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=422

DMB3NZA	DI	DMB3NZA
DMB3NZA	DN	PIPERNONALINE
DMB3NZA	MI	TTA1L39
DMB3NZA	MN	ICAM1 messenger RNA (ICAM1 mRNA)
DMB3NZA	MT	DTT
DMB3NZA	MA	Inhibitor
DMB3NZA	RN	Alkamides from the fruits of Piper longum and Piper nigrum displaying potent cell adhesion inhibition. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4544-6.
DMB3NZA	RU	https://pubmed.ncbi.nlm.nih.gov/18672369

DMIHO0P	DI	DMIHO0P
DMIHO0P	DN	PIPEROXAN
DMIHO0P	MI	TTWG9A4
DMIHO0P	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMIHO0P	MT	DTT
DMIHO0P	MA	Inhibitor
DMIHO0P	RN	alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs. J Med Chem. 1982 Dec;25(12):1389-401.
DMIHO0P	RU	https://pubmed.ncbi.nlm.nih.gov/6296387

DMIHO0P	DI	DMIHO0P
DMIHO0P	DN	PIPEROXAN
DMIHO0P	MI	TTWM4TY
DMIHO0P	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMIHO0P	MT	DTT
DMIHO0P	MA	Inhibitor
DMIHO0P	RN	alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs. J Med Chem. 1982 Dec;25(12):1389-401.
DMIHO0P	RU	https://pubmed.ncbi.nlm.nih.gov/6296387

DMIHO0P	DI	DMIHO0P
DMIHO0P	DN	PIPEROXAN
DMIHO0P	MI	TT2NUT5
DMIHO0P	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMIHO0P	MT	DTT
DMIHO0P	MA	Inhibitor
DMIHO0P	RN	alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs. J Med Chem. 1982 Dec;25(12):1389-401.
DMIHO0P	RU	https://pubmed.ncbi.nlm.nih.gov/6296387

DMRVHWZ	DI	DMRVHWZ
DMRVHWZ	DN	PIPERROLEIN B
DMRVHWZ	MI	TTA1L39
DMRVHWZ	MN	ICAM1 messenger RNA (ICAM1 mRNA)
DMRVHWZ	MT	DTT
DMRVHWZ	MA	Inhibitor
DMRVHWZ	RN	Alkamides from the fruits of Piper longum and Piper nigrum displaying potent cell adhesion inhibition. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4544-6.
DMRVHWZ	RU	https://pubmed.ncbi.nlm.nih.gov/18672369

DMOE39X	DI	DMOE39X
DMOE39X	DN	Piragliatin
DMOE39X	MI	TTDLNGZ
DMOE39X	MN	Glucokinase (GCK)
DMOE39X	MT	DTT
DMOE39X	MA	Modulator
DMOE39X	RN	Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study.J Clin Endocrinol Metab.2010 Nov;95(11):5028-36.
DMOE39X	RU	https://www.ncbi.nlm.nih.gov/pubmed/20739378

DM9T2G3	DI	DM9T2G3
DM9T2G3	DN	pirenperone
DM9T2G3	MI	TTO9X1H
DM9T2G3	MN	5-HT 7 receptor (HTR7)
DM9T2G3	MT	DTT
DM9T2G3	MA	Antagonist
DM9T2G3	RN	Cloning, expression and pharmacology of a truncated splice variant of the human 5-HT7 receptor (h5-HT7b). Br J Pharmacol. 1997 Sep;122(1):126-32.
DM9T2G3	RU	https://pubmed.ncbi.nlm.nih.gov/9298538

DM0SCDR	DI	DM0SCDR
DM0SCDR	DN	Piretanide
DM0SCDR	MI	TTS087L
DM0SCDR	MN	Solute carrier family 12 member 1 (SLC12A1)
DM0SCDR	MT	DTT
DM0SCDR	MA	Blocker
DM0SCDR	RN	Peripheral and central antinociceptive action of Na+-K+-2Cl- cotransporter blockers on formalin-induced nociception in rats. Pain. 2005 Mar;114(1-2):231-8.
DM0SCDR	RU	https://pubmed.ncbi.nlm.nih.gov/15733649

DMNP6QD	DI	DMNP6QD
DMNP6QD	DN	piribedil
DMNP6QD	MI	TTSQIFT
DMNP6QD	MN	5-HT 1A receptor (HTR1A)
DMNP6QD	MT	DTT
DMNP6QD	MA	Agonist
DMNP6QD	RN	Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002 Nov;303(2):791-804.
DMNP6QD	RU	https://pubmed.ncbi.nlm.nih.gov/12388666

DMNP6QD	DI	DMNP6QD
DMNP6QD	DN	piribedil
DMNP6QD	MI	TT0K1SC
DMNP6QD	MN	5-HT 2B receptor (HTR2B)
DMNP6QD	MT	DTT
DMNP6QD	MA	Antagonist
DMNP6QD	RN	Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002 Nov;303(2):791-804.
DMNP6QD	RU	https://pubmed.ncbi.nlm.nih.gov/12388666

DMNP6QD	DI	DMNP6QD
DMNP6QD	DN	piribedil
DMNP6QD	MI	TT2NUT5
DMNP6QD	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMNP6QD	MT	DTT
DMNP6QD	MA	Antagonist
DMNP6QD	RN	Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002 Nov;303(2):791-804.
DMNP6QD	RU	https://pubmed.ncbi.nlm.nih.gov/12388666

DMNP6QD	DI	DMNP6QD
DMNP6QD	DN	piribedil
DMNP6QD	MI	TTEX248
DMNP6QD	MN	Dopamine D2 receptor (D2R)
DMNP6QD	MT	DTT
DMNP6QD	MA	Agonist
DMNP6QD	RN	Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002 Nov;303(2):791-804.
DMNP6QD	RU	https://pubmed.ncbi.nlm.nih.gov/12388666

DMNP6QD	DI	DMNP6QD
DMNP6QD	DN	piribedil
DMNP6QD	MI	TT4C8EA
DMNP6QD	MN	Dopamine D3 receptor (D3R)
DMNP6QD	MT	DTT
DMNP6QD	MA	Agonist
DMNP6QD	RN	Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002 Nov;303(2):791-804.
DMNP6QD	RU	https://pubmed.ncbi.nlm.nih.gov/12388666

DMNP6QD	DI	DMNP6QD
DMNP6QD	DN	piribedil
DMNP6QD	MI	TTE0A2F
DMNP6QD	MN	Dopamine D4 receptor (D4R)
DMNP6QD	MT	DTT
DMNP6QD	MA	Antagonist
DMNP6QD	RN	Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002 Nov;303(2):791-804.
DMNP6QD	RU	https://pubmed.ncbi.nlm.nih.gov/12388666

DMRDF8Z	DI	DMRDF8Z
DMRDF8Z	DN	Piridronic acid
DMRDF8Z	MI	TTIKWV4
DMRDF8Z	MN	Geranyltranstransferase (FDPS)
DMRDF8Z	MT	DTT
DMRDF8Z	MA	Inhibitor
DMRDF8Z	RN	Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of hu... J Med Chem. 2008 Apr 10;51(7):2187-95.
DMRDF8Z	RU	https://pubmed.ncbi.nlm.nih.gov/18327899

DM7XTHD	DI	DM7XTHD
DM7XTHD	DN	Piriqualone
DM7XTHD	MI	TTAN6JD
DM7XTHD	MN	Glutamate receptor AMPA (GRIA)
DM7XTHD	MT	DTT
DM7XTHD	MA	Inhibitor
DM7XTHD	RN	Atropisomeric quinazolin-4-one derivatives are potent noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antag... Bioorg Med Chem Lett. 2001 Jan 22;11(2):177-81.
DM7XTHD	RU	https://pubmed.ncbi.nlm.nih.gov/11206453

DM7XTHD	DI	DM7XTHD
DM7XTHD	DN	Piriqualone
DM7XTHD	MI	TTVPQTF
DM7XTHD	MN	Glutamate receptor AMPA 1 (GRIA1)
DM7XTHD	MT	DTT
DM7XTHD	MA	Inhibitor
DM7XTHD	RN	Atropisomeric quinazolin-4-one derivatives are potent noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antag... Bioorg Med Chem Lett. 2001 Jan 22;11(2):177-81.
DM7XTHD	RU	https://pubmed.ncbi.nlm.nih.gov/11206453

DMWLDRJ	DI	DMWLDRJ
DMWLDRJ	DN	PIROTIODECANE
DMWLDRJ	MI	TTXLO8T
DMWLDRJ	MN	Potential penetration (PP)
DMWLDRJ	MT	DTT
DMWLDRJ	MA	Modulator
DMWLDRJ	RN	Effectiveness of pirotiodecane, absorption enhancer, on nasal absorption in rabbits. Drug Metab Pharmacokinet. 2005 Feb;20(1):65-71.
DMWLDRJ	RU	https://pubmed.ncbi.nlm.nih.gov/15770076

DMKHZQW	DI	DMKHZQW
DMKHZQW	DN	Pitrazepine
DMKHZQW	MI	TTNJYV2
DMKHZQW	MN	Gamma-aminobutyric acid receptor (GAR)
DMKHZQW	MT	DTT
DMKHZQW	MA	Inhibitor
DMKHZQW	RN	Structure and molecular modeling of GABAA receptor antagonists. J Med Chem. 1992 May 29;35(11):1969-77.
DMKHZQW	RU	https://pubmed.ncbi.nlm.nih.gov/1317920

DMVYNTB	DI	DMVYNTB
DMVYNTB	DN	Piv-RYYRIK-NH2
DMVYNTB	MI	TTNT7K8
DMVYNTB	MN	Nociceptin receptor (OPRL1)
DMVYNTB	MT	DTT
DMVYNTB	MA	Inhibitor
DMVYNTB	RN	Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist. Bioorg Med Chem. 2008 Mar 1;16(5):2635-44.
DMVYNTB	RU	https://pubmed.ncbi.nlm.nih.gov/18068993

DMDOZPU	DI	DMDOZPU
DMDOZPU	DN	PK 11195
DMDOZPU	MI	TTGJVQM
DMDOZPU	MN	Fibroblast growth factor receptor 2 (FGFR2)
DMDOZPU	MT	DTT
DMDOZPU	MA	Binder
DMDOZPU	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DMDOZPU	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DMDOZPU	DI	DMDOZPU
DMDOZPU	DN	PK 11195
DMDOZPU	MI	TTPTXIN
DMDOZPU	MN	Translocator protein (TSPO)
DMDOZPU	MT	DTT
DMDOZPU	MA	Binder
DMDOZPU	RN	Specific ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in human colorectal cancer cells. Br J Cancer. 2001 Nov 30;85(11):1771-80.
DMDOZPU	RU	https://pubmed.ncbi.nlm.nih.gov/11742501

DM40HWI	DI	DM40HWI
DM40HWI	DN	PK-44
DM40HWI	MI	TTDIGC1
DM40HWI	MN	Dipeptidyl peptidase 4 (DPP-4)
DM40HWI	MT	DTT
DM40HWI	MA	Inhibitor
DM40HWI	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1612).
DM40HWI	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1612

DMIUZGY	DI	DMIUZGY
DMIUZGY	DN	PK68
DMIUZGY	MI	TTAIQSN
DMIUZGY	MN	Receptor-interacting protein 1 (RIPK1)
DMIUZGY	MT	DTT
DMIUZGY	MA	Inhibitor
DMIUZGY	RN	Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of inflammatory disorder and cancer metastasis. Cell Death Dis. 2019 Jun 24;10(7):493.
DMIUZGY	RU	https://pubmed.ncbi.nlm.nih.gov/31235688

DM04C9V	DI	DM04C9V
DM04C9V	DN	PKF-241-466
DM04C9V	MI	TT6AZXG
DM04C9V	MN	TNF alpha converting enzyme (ADAM17)
DM04C9V	MT	DTT
DM04C9V	MA	Inhibitor
DM04C9V	RN	Current perspective of TACE inhibitors: a review. Bioorg Med Chem. 2009 Jan 15;17(2):444-59.
DM04C9V	RU	https://pubmed.ncbi.nlm.nih.gov/19095454

DM04C9V	DI	DM04C9V
DM04C9V	DN	PKF-241-466
DM04C9V	MI	TTF8CQI
DM04C9V	MN	Tumor necrosis factor (TNF)
DM04C9V	MT	DTT
DM04C9V	MA	Inhibitor
DM04C9V	RN	Beta-aryl-succinic acid hydroxamates as dual inhibitors of matrix metalloproteinases and tumor necrosis factor alpha converting enzyme. J Med Chem. 2002 May 23;45(11):2289-93.
DM04C9V	RU	https://pubmed.ncbi.nlm.nih.gov/12014967

DMNDLAS	DI	DMNDLAS
DMNDLAS	DN	PKF-242-484
DMNDLAS	MI	TTMX39J
DMNDLAS	MN	Matrix metalloproteinase-1 (MMP-1)
DMNDLAS	MT	DTT
DMNDLAS	MA	Inhibitor
DMNDLAS	RN	A cassette-dosing approach for improvement of oral bioavailability of dual TACE/MMP inhibitors. Bioorg Med Chem Lett. 2006 May 15;16(10):2632-6.
DMNDLAS	RU	https://pubmed.ncbi.nlm.nih.gov/16516469

DMNDLAS	DI	DMNDLAS
DMNDLAS	DN	PKF-242-484
DMNDLAS	MI	TTHY57M
DMNDLAS	MN	Matrix metalloproteinase-13 (MMP-13)
DMNDLAS	MT	DTT
DMNDLAS	MA	Inhibitor
DMNDLAS	RN	A cassette-dosing approach for improvement of oral bioavailability of dual TACE/MMP inhibitors. Bioorg Med Chem Lett. 2006 May 15;16(10):2632-6.
DMNDLAS	RU	https://pubmed.ncbi.nlm.nih.gov/16516469

DMNDLAS	DI	DMNDLAS
DMNDLAS	DN	PKF-242-484
DMNDLAS	MI	TTUZ2L5
DMNDLAS	MN	Matrix metalloproteinase-3 (MMP-3)
DMNDLAS	MT	DTT
DMNDLAS	MA	Inhibitor
DMNDLAS	RN	A cassette-dosing approach for improvement of oral bioavailability of dual TACE/MMP inhibitors. Bioorg Med Chem Lett. 2006 May 15;16(10):2632-6.
DMNDLAS	RU	https://pubmed.ncbi.nlm.nih.gov/16516469

DMNDLAS	DI	DMNDLAS
DMNDLAS	DN	PKF-242-484
DMNDLAS	MI	TT6AZXG
DMNDLAS	MN	TNF alpha converting enzyme (ADAM17)
DMNDLAS	MT	DTT
DMNDLAS	MA	Inhibitor
DMNDLAS	RN	Current perspective of TACE inhibitors: a review. Bioorg Med Chem. 2009 Jan 15;17(2):444-59.
DMNDLAS	RU	https://pubmed.ncbi.nlm.nih.gov/19095454

DMNDLAS	DI	DMNDLAS
DMNDLAS	DN	PKF-242-484
DMNDLAS	MI	TTF8CQI
DMNDLAS	MN	Tumor necrosis factor (TNF)
DMNDLAS	MT	DTT
DMNDLAS	MA	Inhibitor
DMNDLAS	RN	Beta-aryl-succinic acid hydroxamates as dual inhibitors of matrix metalloproteinases and tumor necrosis factor alpha converting enzyme. J Med Chem. 2002 May 23;45(11):2289-93.
DMNDLAS	RU	https://pubmed.ncbi.nlm.nih.gov/12014967

DM6NX4H	DI	DM6NX4H
DM6NX4H	DN	PKI-402
DM6NX4H	MI	TTHBTOP
DM6NX4H	MN	PI3-kinase gamma (PIK3CG)
DM6NX4H	MT	DTT
DM6NX4H	MA	Inhibitor
DM6NX4H	RN	Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: di... J Med Chem. 2010 Jan 28;53(2):798-810.
DM6NX4H	RU	https://pubmed.ncbi.nlm.nih.gov/19968288

DMSJCKN	DI	DMSJCKN
DMSJCKN	DN	PKR-A
DMSJCKN	MI	TTM67AX
DMSJCKN	MN	Prokineticin receptor 2 (PKR2)
DMSJCKN	MT	DTT
DMSJCKN	MA	Antagonist
DMSJCKN	RN	Prokineticin 2 is an endangering mediator of cerebral ischemic injury. Proc Natl Acad Sci U S A. 2012 Apr 3;109(14):5475-80.
DMSJCKN	RU	https://pubmed.ncbi.nlm.nih.gov/22431614

DMICVXN	DI	DMICVXN
DMICVXN	DN	PL017
DMICVXN	MI	TTKWM86
DMICVXN	MN	Opioid receptor mu (MOP)
DMICVXN	MT	DTT
DMICVXN	MA	Agonist
DMICVXN	RN	Potent morphiceptin analogs: structure activity relationships and morphine-like activities. J Pharmacol Exp Ther. 1983 Nov;227(2):403-8.
DMICVXN	RU	https://pubmed.ncbi.nlm.nih.gov/6313901

DMWHNZ4	DI	DMWHNZ4
DMWHNZ4	DN	Plantainoside D
DMWHNZ4	MI	TTFJ8Q1
DMWHNZ4	MN	Protein kinase C alpha (PRKCA)
DMWHNZ4	MT	DTT
DMWHNZ4	MA	Inhibitor
DMWHNZ4	RN	Phenylethanoid glycosides from Digitalis purpurea and Penstemon linarioides with PKCalpha-inhibitory activity. J Nat Prod. 1998 Nov;61(11):1410-2.
DMWHNZ4	RU	https://pubmed.ncbi.nlm.nih.gov/9834166

DMV34O2	DI	DMV34O2
DMV34O2	DN	Platelet factor 4 (PF-4)
DMV34O2	MI	TTGJVQM
DMV34O2	MN	Fibroblast growth factor receptor 2 (FGFR2)
DMV34O2	MT	DTT
DMV34O2	MA	Inhibitor
DMV34O2	RN	A short peptide domain of platelet factor 4 blocks angiogenic key events induced by FGF-2. FASEB J. 2001 Mar;15(3):550-2.
DMV34O2	RU	https://pubmed.ncbi.nlm.nih.gov/11259363

DM9N0RH	DI	DM9N0RH
DM9N0RH	DN	PLATENSIMYCIN
DM9N0RH	MI	TTRFV0W
DM9N0RH	MN	Bacterial Oxoacyl-[acyl-carrier-protein] synthase II (Bact fabF)
DM9N0RH	MT	DTT
DM9N0RH	MA	Inhibitor
DM9N0RH	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM9N0RH	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM4MKIX	DI	DM4MKIX
DM4MKIX	DN	Ploglitazone
DM4MKIX	MI	TTT2SVW
DM4MKIX	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DM4MKIX	MT	DTT
DM4MKIX	MA	Inhibitor
DM4MKIX	RN	Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes. J Med Chem. 2004 Aug 12;47(17):4118-27.
DM4MKIX	RU	https://pubmed.ncbi.nlm.nih.gov/15293980

DMBN4V6	DI	DMBN4V6
DMBN4V6	DN	PLSQETFSDLWKLLPEN-NH2
DMBN4V6	MI	TT9TE0O
DMBN4V6	MN	Mdm2 messenger RNA (MDM2 mRNA)
DMBN4V6	MT	DTT
DMBN4V6	MA	Inhibitor
DMBN4V6	RN	Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J Med Chem. 2006 Jun 15;49(12):3432-5.
DMBN4V6	RU	https://pubmed.ncbi.nlm.nih.gov/16759082

DM9BS50	DI	DM9BS50
DM9BS50	DN	Plumbagin
DM9BS50	MI	TT3PQ2Y
DM9BS50	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DM9BS50	MT	DTT
DM9BS50	MA	Inhibitor
DM9BS50	RN	Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Chem Biol Interact. 2000 Jan 3;124(1):61-76.
DM9BS50	RU	https://pubmed.ncbi.nlm.nih.gov/10658902

DMZG1L5	DI	DMZG1L5
DMZG1L5	DN	PLX-ORI3
DMZG1L5	MI	TT0EOB8
DMZG1L5	MN	B-Raf messenger RNA (BRAF mRNA)
DMZG1L5	MT	DTT
DMZG1L5	MA	Inhibitor
DMZG1L5	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1943).
DMZG1L5	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1943

DMZG1L5	DI	DMZG1L5
DMZG1L5	DN	PLX-ORI3
DMZG1L5	MI	TTAN5W2
DMZG1L5	MN	Raf messenger RNA (Raf mRNA)
DMZG1L5	MT	DTT
DMZG1L5	MA	Inhibitor
DMZG1L5	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2184).
DMZG1L5	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2184

DMU6972	DI	DMU6972
DMU6972	DN	PMBA
DMU6972	MI	TTZ8EM9
DMU6972	MN	Glycine receptor (GlyR)
DMU6972	MT	DTT
DMU6972	MA	Antagonist
DMU6972	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 425).
DMU6972	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=425

DMEYHWN	DI	DMEYHWN
DMEYHWN	DN	PMD38
DMEYHWN	MI	TTXDKTO
DMEYHWN	MN	Long transient receptor potential channel 8 (TRPM8)
DMEYHWN	MT	DTT
DMEYHWN	MA	Activator
DMEYHWN	RN	Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay. Br J Pharmacol. 2004 Feb;141(4):737-45.
DMEYHWN	RU	https://pubmed.ncbi.nlm.nih.gov/14757700

DMBKVJY	DI	DMBKVJY
DMBKVJY	DN	PMEA
DMBKVJY	MI	TTIU7X1
DMBKVJY	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMBKVJY	MT	DTT
DMBKVJY	MA	Inhibitor
DMBKVJY	RN	Herpes simplex virus-specified DNA polymerase is the target for the antiviral action of 9-(2-phosphonylmethoxyethyl)adenine. J Biol Chem. 1991 Jan 5;266(1):238-44.
DMBKVJY	RU	https://pubmed.ncbi.nlm.nih.gov/1845964

DMHX704	DI	DMHX704
DMHX704	DN	PMI-008
DMHX704	MI	TTLUQ8E
DMHX704	MN	Hormone sensitive lipase (LIPE)
DMHX704	MT	DTT
DMHX704	MA	Modulator
DMHX704	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2593).
DMHX704	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2593

DM7SDNI	DI	DM7SDNI
DM7SDNI	DN	PMID10395480C6
DM7SDNI	MI	TTI9MBZ
DM7SDNI	MN	X-prolyl aminopeptidase 2 (XPNPEP2)
DM7SDNI	MT	DTT
DM7SDNI	MA	Inhibitor
DM7SDNI	RN	Apstatin analogue inhibitors of aminopeptidase P, a bradykinin-degrading enzyme. J Med Chem. 1999 Jul 1;42(13):2394-402.
DM7SDNI	RU	https://pubmed.ncbi.nlm.nih.gov/10395480

DMLH73O	DI	DMLH73O
DMLH73O	DN	PMID10602705C40
DMLH73O	MI	TT9PBIL
DMLH73O	MN	Glutamyl aminopeptidase (ENPEP)
DMLH73O	MT	DTT
DMLH73O	MA	Inhibitor
DMLH73O	RN	Investigation of subsite preferences in aminopeptidase A (EC 3.4.11.7) led to the design of the first highly potent and selective inhibitors of this enzyme. J Med Chem. 1999 Dec 16;42(25):5197-211.
DMLH73O	RU	https://pubmed.ncbi.nlm.nih.gov/10602705

DMU0AGE	DI	DMU0AGE
DMU0AGE	DN	PMID11934595C2
DMU0AGE	MI	TT0L58T
DMU0AGE	MN	Bone morphogenetic protein 1 (BMP1)
DMU0AGE	MT	DTT
DMU0AGE	MA	Inhibitor
DMU0AGE	RN	Amino acid derived sulfonamide hydroxamates as inhibitors of procollagen C-proteinase. Part 2: Solid-phase optimization of side chains. Bioorg Med Chem Lett. 2002 Apr 22;12(8):1233-5.
DMU0AGE	RU	https://pubmed.ncbi.nlm.nih.gov/11934595

DMFO7UC	DI	DMFO7UC
DMFO7UC	DN	PMID12014956C12 
DMFO7UC	MI	TTIKWV4
DMFO7UC	MN	Geranyltranstransferase (FDPS)
DMFO7UC	MT	DTT
DMFO7UC	MA	Inhibitor
DMFO7UC	RN	Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents. J Med Chem. 2002 May 23;45(11):2185-96.
DMFO7UC	RU	https://pubmed.ncbi.nlm.nih.gov/12014956

DMY7W2U	DI	DMY7W2U
DMY7W2U	DN	PMID12127536C20 
DMY7W2U	MI	TTKEPHX
DMY7W2U	MN	Granzyme B (GZMB)
DMY7W2U	MT	DTT
DMY7W2U	MA	Inhibitor
DMY7W2U	RN	Discovery of potent, selective human granzyme B inhibitors that inhibit CTL mediated apoptosis. Bioorg Med Chem Lett. 2002 Aug 19;12(16):2197-200.
DMY7W2U	RU	https://pubmed.ncbi.nlm.nih.gov/12127536

DMQZXMF	DI	DMQZXMF
DMQZXMF	DN	PMID12238936C3a
DMQZXMF	MI	TTFQEO5
DMQZXMF	MN	Squalene synthetase (FDFT1)
DMQZXMF	MT	DTT
DMQZXMF	MA	Inhibitor
DMQZXMF	RN	Synthesis of novel 4,1-benzoxazepine derivatives as squalene synthase inhibitors and their inhibition of cholesterol synthesis. J Med Chem. 2002 Sep 26;45(20):4571-80.
DMQZXMF	RU	https://pubmed.ncbi.nlm.nih.gov/12238936

DMO5J8N	DI	DMO5J8N
DMO5J8N	DN	PMID12238936C3f
DMO5J8N	MI	TTFQEO5
DMO5J8N	MN	Squalene synthetase (FDFT1)
DMO5J8N	MT	DTT
DMO5J8N	MA	Inhibitor
DMO5J8N	RN	Synthesis of novel 4,1-benzoxazepine derivatives as squalene synthase inhibitors and their inhibition of cholesterol synthesis. J Med Chem. 2002 Sep 26;45(20):4571-80.
DMO5J8N	RU	https://pubmed.ncbi.nlm.nih.gov/12238936

DMIW5TY	DI	DMIW5TY
DMIW5TY	DN	PMID12372533C20
DMIW5TY	MI	TT3RMNA
DMIW5TY	MN	Chymotrypsin-C (CLCR)
DMIW5TY	MT	DTT
DMIW5TY	MA	Inhibitor
DMIW5TY	RN	P1 Phenethyl peptide boronic acid inhibitors of HCV NS3 protease. Bioorg Med Chem Lett. 2002 Nov 4;12(21):3199-202.
DMIW5TY	RU	https://pubmed.ncbi.nlm.nih.gov/12372533

DM1ISJU	DI	DM1ISJU
DM1ISJU	DN	PMID12470711C3
DM1ISJU	MI	TTVBPDM
DM1ISJU	MN	Metabotropic glutamate receptor 1 (mGluR1)
DM1ISJU	MT	DTT
DM1ISJU	MA	Modulator (allosteric modulator)
DM1ISJU	RN	Synthesis and pharmacological characterisation of 2,4-dicarboxy-pyrroles as selective non-competitive mGluR1 antagonists. Bioorg Med Chem. 2003 Jan 17;11(2):171-83.
DM1ISJU	RU	https://pubmed.ncbi.nlm.nih.gov/12470711

DMXFY4P	DI	DMXFY4P
DMXFY4P	DN	PMID12614873C2b-1
DMXFY4P	MI	TT8KLPT
DMXFY4P	MN	C-C chemokine receptor (CCR)
DMXFY4P	MT	DTT
DMXFY4P	MA	Antagonist
DMXFY4P	RN	Structure-activity relationships of xanthene carboxamides, novel CCR1 receptor antagonists. Bioorg Med Chem. 2003 Mar 20;11(6):875-84.
DMXFY4P	RU	https://pubmed.ncbi.nlm.nih.gov/12614873

DMR1MCD	DI	DMR1MCD
DMR1MCD	DN	PMID12723943C12
DMR1MCD	MI	TTGY8IW
DMR1MCD	MN	B2 bradykinin receptor (BDKRB2)
DMR1MCD	MT	DTT
DMR1MCD	MA	Antagonist
DMR1MCD	RN	Benzodiazepines as potent and selective bradykinin B1 antagonists. J Med Chem. 2003 May 8;46(10):1803-6.
DMR1MCD	RU	https://pubmed.ncbi.nlm.nih.gov/12723943

DM3EZ9Q	DI	DM3EZ9Q
DM3EZ9Q	DN	PMID12723954C21b
DM3EZ9Q	MI	TTHYDUM
DM3EZ9Q	MN	Bombesin receptor (BS)
DM3EZ9Q	MT	DTT
DM3EZ9Q	MA	Agonist
DM3EZ9Q	RN	Design of selective peptidomimetic agonists for the human orphan receptor BRS-3. J Med Chem. 2003 May 8;46(10):1918-30.
DM3EZ9Q	RU	https://pubmed.ncbi.nlm.nih.gov/12723954

DMYXDK5	DI	DMYXDK5
DMYXDK5	DN	PMID12812482C11
DMYXDK5	MI	TTGY8IW
DMYXDK5	MN	B2 bradykinin receptor (BDKRB2)
DMYXDK5	MT	DTT
DMYXDK5	MA	Antagonist
DMYXDK5	RN	Discovery of a potent, non-peptide bradykinin B1 receptor antagonist. J Am Chem Soc. 2003 Jun 25;125(25):7516-7.
DMYXDK5	RU	https://pubmed.ncbi.nlm.nih.gov/12812482

DMR2L6X	DI	DMR2L6X
DMR2L6X	DN	PMID14640538C3
DMR2L6X	MI	TT8V2KD
DMR2L6X	MN	Arginine carboxypeptidase (CPN1)
DMR2L6X	MT	DTT
DMR2L6X	MA	Inhibitor
DMR2L6X	RN	Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics. J Med Chem. 2003 Dec 4;46(25):5294-7.
DMR2L6X	RU	https://pubmed.ncbi.nlm.nih.gov/14640538

DMR2L6X	DI	DMR2L6X
DMR2L6X	DN	PMID14640538C3
DMR2L6X	MI	TT4UJX5
DMR2L6X	MN	Carboxypeptidase B1 (CPB1)
DMR2L6X	MT	DTT
DMR2L6X	MA	Inhibitor
DMR2L6X	RN	Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics. J Med Chem. 2003 Dec 4;46(25):5294-7.
DMR2L6X	RU	https://pubmed.ncbi.nlm.nih.gov/14640538

DMR2L6X	DI	DMR2L6X
DMR2L6X	DN	PMID14640538C3
DMR2L6X	MI	TTP18AY
DMR2L6X	MN	Carboxypeptidase B2 (CPB2)
DMR2L6X	MT	DTT
DMR2L6X	MA	Inhibitor
DMR2L6X	RN	Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics. J Med Chem. 2003 Dec 4;46(25):5294-7.
DMR2L6X	RU	https://pubmed.ncbi.nlm.nih.gov/14640538

DMR2L6X	DI	DMR2L6X
DMR2L6X	DN	PMID14640538C3
DMR2L6X	MI	TTVOH2M
DMR2L6X	MN	Carboxypeptidase M (CPM)
DMR2L6X	MT	DTT
DMR2L6X	MA	Inhibitor
DMR2L6X	RN	Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics. J Med Chem. 2003 Dec 4;46(25):5294-7.
DMR2L6X	RU	https://pubmed.ncbi.nlm.nih.gov/14640538

DMFWCAJ	DI	DMFWCAJ
DMFWCAJ	DN	PMID14697765C11a
DMFWCAJ	MI	TTHS256
DMFWCAJ	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMFWCAJ	MT	DTT
DMFWCAJ	MA	Modulator (allosteric modulator)
DMFWCAJ	RN	Discovery of novel modulators of metabotropic glutamate receptor subtype-5. Bioorg Med Chem. 2004 Jan 2;12(1):17-21.
DMFWCAJ	RU	https://pubmed.ncbi.nlm.nih.gov/14697765

DMFT1DO	DI	DMFT1DO
DMFT1DO	DN	PMID14697765C16a
DMFT1DO	MI	TTHS256
DMFT1DO	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMFT1DO	MT	DTT
DMFT1DO	MA	Modulator (allosteric modulator)
DMFT1DO	RN	Discovery of novel modulators of metabotropic glutamate receptor subtype-5. Bioorg Med Chem. 2004 Jan 2;12(1):17-21.
DMFT1DO	RU	https://pubmed.ncbi.nlm.nih.gov/14697765

DMOQ8PF	DI	DMOQ8PF
DMOQ8PF	DN	PMID15027864C8d
DMOQ8PF	MI	TT9G4N0
DMOQ8PF	MN	Glutamate carboxypeptidase II (GCPII)
DMOQ8PF	MT	DTT
DMOQ8PF	MA	Inhibitor
DMOQ8PF	RN	Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents. J Med Chem. 2004 Mar 25;47(7):1729-38.
DMOQ8PF	RU	https://pubmed.ncbi.nlm.nih.gov/15027864

DM9V6YK	DI	DM9V6YK
DM9V6YK	DN	PMID15055993C1a
DM9V6YK	MI	TT6X50U
DM9V6YK	MN	Matrix metalloproteinase-9 (MMP-9)
DM9V6YK	MT	DTT
DM9V6YK	MA	Inhibitor
DM9V6YK	RN	Azasugar-based MMP/ADAM inhibitors as antipsoriatic agents. J Med Chem. 2004 Apr 8;47(8):1930-8.
DM9V6YK	RU	https://pubmed.ncbi.nlm.nih.gov/15055993

DMFI4J6	DI	DMFI4J6
DMFI4J6	DN	PMID15261275C1
DMFI4J6	MI	TT60Q8D
DMFI4J6	MN	Orexin receptor type 1 (HCRTR1)
DMFI4J6	MT	DTT
DMFI4J6	MA	Antagonist
DMFI4J6	RN	Novel substituted 4-phenyl-[1,3]dioxanes: potent and selective orexin receptor 2 (OX(2)R) antagonists. Bioorg Med Chem Lett. 2004 Aug 16;14(16):4225-9.
DMFI4J6	RU	https://pubmed.ncbi.nlm.nih.gov/15261275

DMFI4J6	DI	DMFI4J6
DMFI4J6	DN	PMID15261275C1
DMFI4J6	MI	TT9N02I
DMFI4J6	MN	Orexin receptor type 2 (HCRTR2)
DMFI4J6	MT	DTT
DMFI4J6	MA	Antagonist
DMFI4J6	RN	Novel substituted 4-phenyl-[1,3]dioxanes: potent and selective orexin receptor 2 (OX(2)R) antagonists. Bioorg Med Chem Lett. 2004 Aug 16;14(16):4225-9.
DMFI4J6	RU	https://pubmed.ncbi.nlm.nih.gov/15261275

DM7JKLM	DI	DM7JKLM
DM7JKLM	DN	PMID1527791C29
DM7JKLM	MI	TTPADOQ
DM7JKLM	MN	HMG-CoA reductase (HMGCR)
DM7JKLM	MT	DTT
DM7JKLM	MA	Inhibitor
DM7JKLM	RN	Synthesis and biological evaluation of dihydroeptastatin, a novel inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. J Med Chem. 1992 Sep 4;35(18):3388-93.
DM7JKLM	RU	https://pubmed.ncbi.nlm.nih.gov/1527791

DMWDE9A	DI	DMWDE9A
DMWDE9A	DN	PMID15300839C17
DMWDE9A	MI	TTBUYHA
DMWDE9A	MN	Extracellular calcium-sensing receptor (CASR)
DMWDE9A	MT	DTT
DMWDE9A	MA	Antagonist
DMWDE9A	RN	N(1)-Arylsulfonyl-N(2)-(1-(1-naphthyl)ethyl)-1,2-diaminocyclohexanes: a new class of calcilytic agents acting at the calcium-sensing receptor. Chembiochem. 2004 Aug 6;5(8):1131-6.
DMWDE9A	RU	https://pubmed.ncbi.nlm.nih.gov/15300839

DM7T8BE	DI	DM7T8BE
DM7T8BE	DN	PMID15482906C10
DM7T8BE	MI	TTHS256
DM7T8BE	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM7T8BE	MT	DTT
DM7T8BE	MA	Modulator (allosteric modulator)
DM7T8BE	RN	2-(2-[3-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl) pyridine: a highly potent, orally active, metabotropic glutamate subtype 5 (mGlu5) receptor antagonist. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5473-6.
DM7T8BE	RU	https://pubmed.ncbi.nlm.nih.gov/15482906

DMCPIQ4	DI	DMCPIQ4
DMCPIQ4	DN	PMID15482908C8
DMCPIQ4	MI	TTHS256
DMCPIQ4	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMCPIQ4	MT	DTT
DMCPIQ4	MA	Modulator (allosteric modulator)
DMCPIQ4	RN	Discovery of highly potent, selective, orally bioavailable, metabotropic glutamate subtype 5 (mGlu5) receptor antagonists devoid of cytochrome P450 1A2 inhibitory activity. Bioorg Med Chem Lett. 2004Nov 15;14(22):5481-4.
DMCPIQ4	RU	https://pubmed.ncbi.nlm.nih.gov/15482908

DMOPUIH	DI	DMOPUIH
DMOPUIH	DN	PMID15546730C2
DMOPUIH	MI	TTNDSC3
DMOPUIH	MN	B lymphocyte kinase (BLK)
DMOPUIH	MT	DTT
DMOPUIH	MA	Inhibitor
DMOPUIH	RN	Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6061-6.
DMOPUIH	RU	https://pubmed.ncbi.nlm.nih.gov/15546730

DMOPUIH	DI	DMOPUIH
DMOPUIH	DN	PMID15546730C2
DMOPUIH	MI	TT2B9KF
DMOPUIH	MN	Fyn tyrosine protein kinase (FYN)
DMOPUIH	MT	DTT
DMOPUIH	MA	Inhibitor
DMOPUIH	RN	Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6061-6.
DMOPUIH	RU	https://pubmed.ncbi.nlm.nih.gov/15546730

DMOPUIH	DI	DMOPUIH
DMOPUIH	DN	PMID15546730C2
DMOPUIH	MI	TT42OGM
DMOPUIH	MN	Hematopoietic cell kinase (HCK)
DMOPUIH	MT	DTT
DMOPUIH	MA	Inhibitor
DMOPUIH	RN	Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6061-6.
DMOPUIH	RU	https://pubmed.ncbi.nlm.nih.gov/15546730

DMOPUIH	DI	DMOPUIH
DMOPUIH	DN	PMID15546730C2
DMOPUIH	MI	TTT7PJU
DMOPUIH	MN	Janus kinase 3 (JAK-3)
DMOPUIH	MT	DTT
DMOPUIH	MA	Inhibitor
DMOPUIH	RN	Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6061-6.
DMOPUIH	RU	https://pubmed.ncbi.nlm.nih.gov/15546730

DMOPUIH	DI	DMOPUIH
DMOPUIH	DN	PMID15546730C2
DMOPUIH	MI	TT860QF
DMOPUIH	MN	LCK tyrosine protein kinase (LCK)
DMOPUIH	MT	DTT
DMOPUIH	MA	Inhibitor
DMOPUIH	RN	Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6061-6.
DMOPUIH	RU	https://pubmed.ncbi.nlm.nih.gov/15546730

DMOPUIH	DI	DMOPUIH
DMOPUIH	DN	PMID15546730C2
DMOPUIH	MI	TT6PKBN
DMOPUIH	MN	Proto-oncogene c-Src (SRC)
DMOPUIH	MT	DTT
DMOPUIH	MA	Inhibitor
DMOPUIH	RN	Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6061-6.
DMOPUIH	RU	https://pubmed.ncbi.nlm.nih.gov/15546730

DMOPUIH	DI	DMOPUIH
DMOPUIH	DN	PMID15546730C2
DMOPUIH	MI	TTPOGS1
DMOPUIH	MN	Tyrosine-protein kinase Fgr (FGR)
DMOPUIH	MT	DTT
DMOPUIH	MA	Inhibitor
DMOPUIH	RN	Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6061-6.
DMOPUIH	RU	https://pubmed.ncbi.nlm.nih.gov/15546730

DMN5LZQ	DI	DMN5LZQ
DMN5LZQ	DN	PMID15603962Crac-16
DMN5LZQ	MI	TT7M9I6
DMN5LZQ	MN	Calcium-activated potassium channel KCa3.1 (KCNN4)
DMN5LZQ	MT	DTT
DMN5LZQ	MA	Blocker (channel blocker)
DMN5LZQ	RN	IKCa-channel blockers. Part 2: discovery of cyclohexadienes. Bioorg Med Chem Lett. 2005 Jan 17;15(2):401-4.
DMN5LZQ	RU	https://pubmed.ncbi.nlm.nih.gov/15603962

DM93RKC	DI	DM93RKC
DM93RKC	DN	PMID15664838C18
DM93RKC	MI	TTJGLZF
DM93RKC	MN	Dipeptidyl peptidase 8 (DPP-8)
DM93RKC	MT	DTT
DM93RKC	MA	Inhibitor
DM93RKC	RN	Novel isoindoline compounds for potent and selective inhibition of prolyl dipeptidase DPP8. Bioorg Med Chem Lett. 2005 Feb 1;15(3):687-91.
DM93RKC	RU	https://pubmed.ncbi.nlm.nih.gov/15664838

DM50E6R	DI	DM50E6R
DM50E6R	DN	PMID15686906C17
DM50E6R	MI	TTPADOQ
DM50E6R	MN	HMG-CoA reductase (HMGCR)
DM50E6R	MT	DTT
DM50E6R	MA	Inhibitor
DM50E6R	RN	Three-dimensional quantitative structure (3-D QSAR) activity relationship studies on imidazolyl and N-pyrrolyl heptenoates as 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) inhibitors by comparativemolecular similarity indices analysis (CoMSIA). Bioorg Med Chem Lett. 2005 Feb 15;15(4):1027-32.
DM50E6R	RU	https://pubmed.ncbi.nlm.nih.gov/15686906

DMBZSKJ	DI	DMBZSKJ
DMBZSKJ	DN	PMID15686906C29
DMBZSKJ	MI	TTPADOQ
DMBZSKJ	MN	HMG-CoA reductase (HMGCR)
DMBZSKJ	MT	DTT
DMBZSKJ	MA	Inhibitor
DMBZSKJ	RN	Three-dimensional quantitative structure (3-D QSAR) activity relationship studies on imidazolyl and N-pyrrolyl heptenoates as 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) inhibitors by comparativemolecular similarity indices analysis (CoMSIA). Bioorg Med Chem Lett. 2005 Feb 15;15(4):1027-32.
DMBZSKJ	RU	https://pubmed.ncbi.nlm.nih.gov/15686906

DMPB7Z6	DI	DMPB7Z6
DMPB7Z6	DN	PMID15686941C13
DMPB7Z6	MI	TTHS256
DMPB7Z6	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMPB7Z6	MT	DTT
DMPB7Z6	MA	Modulator (allosteric modulator)
DMPB7Z6	RN	Dipyridyl amides: potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1197-200.
DMPB7Z6	RU	https://pubmed.ncbi.nlm.nih.gov/15686941

DMR7UBZ	DI	DMR7UBZ
DMR7UBZ	DN	PMID15686947C(S)-3h
DMR7UBZ	MI	TTBUYHA
DMR7UBZ	MN	Extracellular calcium-sensing receptor (CASR)
DMR7UBZ	MT	DTT
DMR7UBZ	MA	Antagonist
DMR7UBZ	RN	Discovery and structure-activity relationships of 2-benzylpyrrolidine-substituted aryloxypropanols as calcium-sensing receptor antagonists. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1225-8.
DMR7UBZ	RU	https://pubmed.ncbi.nlm.nih.gov/15686947

DMBEHA5	DI	DMBEHA5
DMBEHA5	DN	PMID15724976C1
DMBEHA5	MI	TTVK7SB
DMBEHA5	MN	Histone acetyltransferase KAT2B (KAT2B)
DMBEHA5	MT	DTT
DMBEHA5	MA	Inhibitor
DMBEHA5	RN	Selective small molecules blocking HIV-1 Tat and coactivator PCAF association. J Am Chem Soc. 2005 Mar 2;127(8):2376-7.
DMBEHA5	RU	https://pubmed.ncbi.nlm.nih.gov/15724976

DMHY95J	DI	DMHY95J
DMHY95J	DN	PMID15925511C13
DMHY95J	MI	TTU3WV6
DMHY95J	MN	SRSF protein kinase 1 (SRPK1)
DMHY95J	MT	DTT
DMHY95J	MA	Inhibitor
DMHY95J	RN	Synthesis of selective SRPK-1 inhibitors: novel tricyclic quinoxaline derivatives. Bioorg Med Chem Lett. 2005 Jul 1;15(13):3241-6.
DMHY95J	RU	https://pubmed.ncbi.nlm.nih.gov/15925511

DMF0ZXU	DI	DMF0ZXU
DMF0ZXU	DN	PMID15955699C24
DMF0ZXU	MI	TTYXEPL
DMF0ZXU	MN	Ribosomal protein S6 kinase alpha-5 (RSK5)
DMF0ZXU	MT	DTT
DMF0ZXU	MA	Inhibitor
DMF0ZXU	RN	(1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: further optimisation as highly potent and selective MSK-1-inhibitors. Bioorg Med Chem Lett. 2005 Jul 15;15(14):3407-11.
DMF0ZXU	RU	https://pubmed.ncbi.nlm.nih.gov/15955699

DMIRSWL	DI	DMIRSWL
DMIRSWL	DN	PMID16099654C3a
DMIRSWL	MI	TTVBPDM
DMIRSWL	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMIRSWL	MT	DTT
DMIRSWL	MA	Modulator (allosteric modulator)
DMIRSWL	RN	9H-Xanthene-9-carboxylic acid [1,2,4]oxadiazol-3-yl- and (2H-tetrazol-5-yl)-amides as potent, orally available mGlu1 receptor enhancers. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4628-31.
DMIRSWL	RU	https://pubmed.ncbi.nlm.nih.gov/16099654

DMV8UK1	DI	DMV8UK1
DMV8UK1	DN	PMID16099654C4b
DMV8UK1	MI	TTVBPDM
DMV8UK1	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMV8UK1	MT	DTT
DMV8UK1	MA	Modulator (allosteric modulator)
DMV8UK1	RN	9H-Xanthene-9-carboxylic acid [1,2,4]oxadiazol-3-yl- and (2H-tetrazol-5-yl)-amides as potent, orally available mGlu1 receptor enhancers. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4628-31.
DMV8UK1	RU	https://pubmed.ncbi.nlm.nih.gov/16099654

DMM4A7P	DI	DMM4A7P
DMM4A7P	DN	PMID16242323C15a
DMM4A7P	MI	TTK3C21
DMM4A7P	MN	Acetoacetyl-CoA thiolase (ACAT1)
DMM4A7P	MT	DTT
DMM4A7P	MA	Inhibitor
DMM4A7P	RN	Synthesis and biological activity of novel 4-phenyl-1,8-naphthyridin-2(1H)-on-3-yl ureas: potent acyl-CoA:cholesterol acyltransferase inhibitor wit... Bioorg Med Chem Lett. 2006 Jan 1;16(1):44-8.
DMM4A7P	RU	https://pubmed.ncbi.nlm.nih.gov/16242323

DM7U3RM	DI	DM7U3RM
DM7U3RM	DN	PMID16242323C15b
DM7U3RM	MI	TTK3C21
DM7U3RM	MN	Acetoacetyl-CoA thiolase (ACAT1)
DM7U3RM	MT	DTT
DM7U3RM	MA	Inhibitor
DM7U3RM	RN	Synthesis and biological activity of novel 4-phenyl-1,8-naphthyridin-2(1H)-on-3-yl ureas: potent acyl-CoA:cholesterol acyltransferase inhibitor wit... Bioorg Med Chem Lett. 2006 Jan 1;16(1):44-8.
DM7U3RM	RU	https://pubmed.ncbi.nlm.nih.gov/16242323

DM2Q79X	DI	DM2Q79X
DM2Q79X	DN	PMID16242323C16
DM2Q79X	MI	TTK3C21
DM2Q79X	MN	Acetoacetyl-CoA thiolase (ACAT1)
DM2Q79X	MT	DTT
DM2Q79X	MA	Inhibitor
DM2Q79X	RN	Synthesis and biological activity of novel 4-phenyl-1,8-naphthyridin-2(1H)-on-3-yl ureas: potent acyl-CoA:cholesterol acyltransferase inhibitor wit... Bioorg Med Chem Lett. 2006 Jan 1;16(1):44-8.
DM2Q79X	RU	https://pubmed.ncbi.nlm.nih.gov/16242323

DMI5WPQ	DI	DMI5WPQ
DMI5WPQ	DN	PMID16242323C18a
DMI5WPQ	MI	TTK3C21
DMI5WPQ	MN	Acetoacetyl-CoA thiolase (ACAT1)
DMI5WPQ	MT	DTT
DMI5WPQ	MA	Inhibitor
DMI5WPQ	RN	Synthesis and biological activity of novel 4-phenyl-1,8-naphthyridin-2(1H)-on-3-yl ureas: potent acyl-CoA:cholesterol acyltransferase inhibitor wit... Bioorg Med Chem Lett. 2006 Jan 1;16(1):44-8.
DMI5WPQ	RU	https://pubmed.ncbi.nlm.nih.gov/16242323

DMIS7NT	DI	DMIS7NT
DMIS7NT	DN	PMID16242323C18b
DMIS7NT	MI	TTK3C21
DMIS7NT	MN	Acetoacetyl-CoA thiolase (ACAT1)
DMIS7NT	MT	DTT
DMIS7NT	MA	Inhibitor
DMIS7NT	RN	Synthesis and biological activity of novel 4-phenyl-1,8-naphthyridin-2(1H)-on-3-yl ureas: potent acyl-CoA:cholesterol acyltransferase inhibitor wit... Bioorg Med Chem Lett. 2006 Jan 1;16(1):44-8.
DMIS7NT	RU	https://pubmed.ncbi.nlm.nih.gov/16242323

DMFDRMH	DI	DMFDRMH
DMFDRMH	DN	PMID16242323C22c
DMFDRMH	MI	TTK3C21
DMFDRMH	MN	Acetoacetyl-CoA thiolase (ACAT1)
DMFDRMH	MT	DTT
DMFDRMH	MA	Inhibitor
DMFDRMH	RN	Synthesis and biological activity of novel 4-phenyl-1,8-naphthyridin-2(1H)-on-3-yl ureas: potent acyl-CoA:cholesterol acyltransferase inhibitor wit... Bioorg Med Chem Lett. 2006 Jan 1;16(1):44-8.
DMFDRMH	RU	https://pubmed.ncbi.nlm.nih.gov/16242323

DMJICNL	DI	DMJICNL
DMJICNL	DN	PMID16242323C22d
DMJICNL	MI	TTK3C21
DMJICNL	MN	Acetoacetyl-CoA thiolase (ACAT1)
DMJICNL	MT	DTT
DMJICNL	MA	Inhibitor
DMJICNL	RN	Synthesis and biological activity of novel 4-phenyl-1,8-naphthyridin-2(1H)-on-3-yl ureas: potent acyl-CoA:cholesterol acyltransferase inhibitor wit... Bioorg Med Chem Lett. 2006 Jan 1;16(1):44-8.
DMJICNL	RU	https://pubmed.ncbi.nlm.nih.gov/16242323

DMD0Q7K	DI	DMD0Q7K
DMD0Q7K	DN	PMID16242323C26a
DMD0Q7K	MI	TTK3C21
DMD0Q7K	MN	Acetoacetyl-CoA thiolase (ACAT1)
DMD0Q7K	MT	DTT
DMD0Q7K	MA	Inhibitor
DMD0Q7K	RN	Synthesis and biological activity of novel 4-phenyl-1,8-naphthyridin-2(1H)-on-3-yl ureas: potent acyl-CoA:cholesterol acyltransferase inhibitor wit... Bioorg Med Chem Lett. 2006 Jan 1;16(1):44-8.
DMD0Q7K	RU	https://pubmed.ncbi.nlm.nih.gov/16242323

DMF0VLX	DI	DMF0VLX
DMF0VLX	DN	PMID16242323C26b
DMF0VLX	MI	TTK3C21
DMF0VLX	MN	Acetoacetyl-CoA thiolase (ACAT1)
DMF0VLX	MT	DTT
DMF0VLX	MA	Inhibitor
DMF0VLX	RN	Synthesis and biological activity of novel 4-phenyl-1,8-naphthyridin-2(1H)-on-3-yl ureas: potent acyl-CoA:cholesterol acyltransferase inhibitor wit... Bioorg Med Chem Lett. 2006 Jan 1;16(1):44-8.
DMF0VLX	RU	https://pubmed.ncbi.nlm.nih.gov/16242323

DMT3EU2	DI	DMT3EU2
DMT3EU2	DN	PMID16242323C26c
DMT3EU2	MI	TTK3C21
DMT3EU2	MN	Acetoacetyl-CoA thiolase (ACAT1)
DMT3EU2	MT	DTT
DMT3EU2	MA	Inhibitor
DMT3EU2	RN	Synthesis and biological activity of novel 4-phenyl-1,8-naphthyridin-2(1H)-on-3-yl ureas: potent acyl-CoA:cholesterol acyltransferase inhibitor wit... Bioorg Med Chem Lett. 2006 Jan 1;16(1):44-8.
DMT3EU2	RU	https://pubmed.ncbi.nlm.nih.gov/16242323

DMIT4UN	DI	DMIT4UN
DMIT4UN	DN	PMID16250654C37
DMIT4UN	MI	TTSCIUP
DMIT4UN	MN	Oxytocin receptor (OTR)
DMIT4UN	MT	DTT
DMIT4UN	MA	Antagonist
DMIT4UN	RN	2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics. J Med Chem. 2005 Nov 3;48(22):6956-69.
DMIT4UN	RU	https://pubmed.ncbi.nlm.nih.gov/16250654

DMOP8YM	DI	DMOP8YM
DMOP8YM	DN	PMID16290936C1b
DMOP8YM	MI	TT3G406
DMOP8YM	MN	Cathepsin H (CTSH)
DMOP8YM	MT	DTT
DMOP8YM	MA	Inhibitor
DMOP8YM	RN	Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors Bioorg Med Chem Lett. 2006 Feb 15;16(4):978-83.
DMOP8YM	RU	https://pubmed.ncbi.nlm.nih.gov/16290936

DMOP8YM	DI	DMOP8YM
DMOP8YM	DN	PMID16290936C1b
DMOP8YM	MI	TTDZN01
DMOP8YM	MN	Cathepsin K (CTSK)
DMOP8YM	MT	DTT
DMOP8YM	MA	Inhibitor
DMOP8YM	RN	Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors Bioorg Med Chem Lett. 2006 Feb 15;16(4):978-83.
DMOP8YM	RU	https://pubmed.ncbi.nlm.nih.gov/16290936

DMI8HAV	DI	DMI8HAV
DMI8HAV	DN	PMID16439120C20
DMI8HAV	MI	TTHS256
DMI8HAV	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMI8HAV	MT	DTT
DMI8HAV	MA	Modulator (allosteric modulator)
DMI8HAV	RN	Arylmethoxypyridines as novel, potent and orally active mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1892-7.
DMI8HAV	RU	https://pubmed.ncbi.nlm.nih.gov/16439120

DMVM2XD	DI	DMVM2XD
DMVM2XD	DN	PMID16439120C26
DMVM2XD	MI	TTHS256
DMVM2XD	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMVM2XD	MT	DTT
DMVM2XD	MA	Modulator (allosteric modulator)
DMVM2XD	RN	Arylmethoxypyridines as novel, potent and orally active mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1892-7.
DMVM2XD	RU	https://pubmed.ncbi.nlm.nih.gov/16439120

DMT3RUE	DI	DMT3RUE
DMT3RUE	DN	PMID16451062C46
DMT3RUE	MI	TT9RTBL
DMT3RUE	MN	Aurora B messenger RNA (AURKB mRNA)
DMT3RUE	MT	DTT
DMT3RUE	MA	Inhibitor
DMT3RUE	RN	Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors. J Med Chem. 2006 Feb 9;49(3):955-70.
DMT3RUE	RU	https://pubmed.ncbi.nlm.nih.gov/16451062

DMT3RUE	DI	DMT3RUE
DMT3RUE	DN	PMID16451062C46
DMT3RUE	MI	TTLYXIT
DMT3RUE	MN	Aurora kinase C (AURKC)
DMT3RUE	MT	DTT
DMT3RUE	MA	Inhibitor
DMT3RUE	RN	Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors. J Med Chem. 2006 Feb 9;49(3):955-70.
DMT3RUE	RU	https://pubmed.ncbi.nlm.nih.gov/16451062

DM8BKI4	DI	DM8BKI4
DM8BKI4	DN	PMID16460935C28
DM8BKI4	MI	TT7LRQH
DM8BKI4	MN	Complement C1s component (C1S)
DM8BKI4	MT	DTT
DM8BKI4	MA	Inhibitor
DM8BKI4	RN	A novel series of arylsulfonylthiophene-2-carboxamidine inhibitors of the complement component C1s. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2200-4.
DM8BKI4	RU	https://pubmed.ncbi.nlm.nih.gov/16460935

DM2ZYR8	DI	DM2ZYR8
DM2ZYR8	DN	PMID16516466C12c
DM2ZYR8	MI	TTS2TEI
DM2ZYR8	MN	ADAM metallopeptidase with thrombospondin 1 (ADAMTS1)
DM2ZYR8	MT	DTT
DM2ZYR8	MA	Inhibitor
DM2ZYR8	RN	Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett. 2006 May 15;16(10):2699-704.
DM2ZYR8	RU	https://pubmed.ncbi.nlm.nih.gov/16516466

DMU2X59	DI	DMU2X59
DMU2X59	DN	PMID16539403C15b
DMU2X59	MI	TTTUZ3O
DMU2X59	MN	MLK-related kinase (MLTK)
DMU2X59	MT	DTT
DMU2X59	MA	Inhibitor
DMU2X59	RN	Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity vers... J Med Chem. 2006 Mar 23;49(6):2138-42.
DMU2X59	RU	https://pubmed.ncbi.nlm.nih.gov/16539403

DMU2X59	DI	DMU2X59
DMU2X59	DN	PMID16539403C15b
DMU2X59	MI	TTP4520
DMU2X59	MN	TGF-beta receptor type I (TGFBR1)
DMU2X59	MT	DTT
DMU2X59	MA	Inhibitor
DMU2X59	RN	Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity vers... J Med Chem. 2006 Mar 23;49(6):2138-42.
DMU2X59	RU	https://pubmed.ncbi.nlm.nih.gov/16539403

DMU2X59	DI	DMU2X59
DMU2X59	DN	PMID16539403C15b
DMU2X59	MI	TTZE3P7
DMU2X59	MN	TGF-beta receptor type II (TGFBR2)
DMU2X59	MT	DTT
DMU2X59	MA	Inhibitor
DMU2X59	RN	Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity vers... J Med Chem. 2006 Mar 23;49(6):2138-42.
DMU2X59	RU	https://pubmed.ncbi.nlm.nih.gov/16539403

DMJ8A4I	DI	DMJ8A4I
DMJ8A4I	DN	PMID1656041C11dd
DMJ8A4I	MI	TTPADOQ
DMJ8A4I	MN	HMG-CoA reductase (HMGCR)
DMJ8A4I	MT	DTT
DMJ8A4I	MA	Inhibitor
DMJ8A4I	RN	Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids. J Med Chem. 1991 Oct;34(10):2962-83.
DMJ8A4I	RU	https://pubmed.ncbi.nlm.nih.gov/1656041

DM20TFH	DI	DM20TFH
DM20TFH	DN	PMID1656041C11ff
DM20TFH	MI	TTPADOQ
DM20TFH	MN	HMG-CoA reductase (HMGCR)
DM20TFH	MT	DTT
DM20TFH	MA	Inhibitor
DM20TFH	RN	Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids. J Med Chem. 1991 Oct;34(10):2962-83.
DM20TFH	RU	https://pubmed.ncbi.nlm.nih.gov/1656041

DMLIXJW	DI	DMLIXJW
DMLIXJW	DN	PMID1656041C11jj
DMLIXJW	MI	TTPADOQ
DMLIXJW	MN	HMG-CoA reductase (HMGCR)
DMLIXJW	MT	DTT
DMLIXJW	MA	Inhibitor
DMLIXJW	RN	Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids. J Med Chem. 1991 Oct;34(10):2962-83.
DMLIXJW	RU	https://pubmed.ncbi.nlm.nih.gov/1656041

DMNOMCT	DI	DMNOMCT
DMNOMCT	DN	PMID1656041C11nn
DMNOMCT	MI	TTPADOQ
DMNOMCT	MN	HMG-CoA reductase (HMGCR)
DMNOMCT	MT	DTT
DMNOMCT	MA	Inhibitor
DMNOMCT	RN	Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids. J Med Chem. 1991 Oct;34(10):2962-83.
DMNOMCT	RU	https://pubmed.ncbi.nlm.nih.gov/1656041

DMW90GD	DI	DMW90GD
DMW90GD	DN	PMID1656041C4ff
DMW90GD	MI	TTPADOQ
DMW90GD	MN	HMG-CoA reductase (HMGCR)
DMW90GD	MT	DTT
DMW90GD	MA	Inhibitor
DMW90GD	RN	Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids. J Med Chem. 1991 Oct;34(10):2962-83.
DMW90GD	RU	https://pubmed.ncbi.nlm.nih.gov/1656041

DMQGPJE	DI	DMQGPJE
DMQGPJE	DN	PMID1656041C4rr
DMQGPJE	MI	TTPADOQ
DMQGPJE	MN	HMG-CoA reductase (HMGCR)
DMQGPJE	MT	DTT
DMQGPJE	MA	Inhibitor
DMQGPJE	RN	Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids. J Med Chem. 1991 Oct;34(10):2962-83.
DMQGPJE	RU	https://pubmed.ncbi.nlm.nih.gov/1656041

DMZVK16	DI	DMZVK16
DMZVK16	DN	PMID1656041C74
DMZVK16	MI	TTPADOQ
DMZVK16	MN	HMG-CoA reductase (HMGCR)
DMZVK16	MT	DTT
DMZVK16	MA	Inhibitor
DMZVK16	RN	Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids. J Med Chem. 1991 Oct;34(10):2962-83.
DMZVK16	RU	https://pubmed.ncbi.nlm.nih.gov/1656041

DMITDEB	DI	DMITDEB
DMITDEB	DN	PMID17064898C29
DMITDEB	MI	TTVBPDM
DMITDEB	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMITDEB	MT	DTT
DMITDEB	MA	Modulator (allosteric modulator)
DMITDEB	RN	Structure-activity relationships of novel non-competitive mGluR1 antagonists: a potential treatment for chronic pain. Bioorg Med Chem Lett. 2007 Jan 15;17(2):486-90.
DMITDEB	RU	https://pubmed.ncbi.nlm.nih.gov/17064898

DMLTXHJ	DI	DMLTXHJ
DMLTXHJ	DN	PMID17125263C17
DMLTXHJ	MI	TTX4RTB
DMLTXHJ	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMLTXHJ	MT	DTT
DMLTXHJ	MA	Antagonist
DMLTXHJ	RN	6-(4-chlorophenyl)-3-substituted-thieno[3,2-d]pyrimidin-4(3H)-one-based melanin-concentrating hormone receptor 1 antagonist. J Med Chem. 2006 Nov 30;49(24):7108-18.
DMLTXHJ	RU	https://pubmed.ncbi.nlm.nih.gov/17125263

DMG9ZYP	DI	DMG9ZYP
DMG9ZYP	DN	PMID17189691C42
DMG9ZYP	MI	TTHS256
DMG9ZYP	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMG9ZYP	MT	DTT
DMG9ZYP	MA	Modulator (allosteric modulator)
DMG9ZYP	RN	Rational design, synthesis, and structure-activity relationship of benzoxazolones: new potent mglu5 receptor antagonists based on the fenobam struc... Bioorg Med Chem Lett. 2007 Mar 1;17(5):1302-6.
DMG9ZYP	RU	https://pubmed.ncbi.nlm.nih.gov/17189691

DMWNYBV	DI	DMWNYBV
DMWNYBV	DN	PMID17276684C22
DMWNYBV	MI	TTVBPDM
DMWNYBV	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMWNYBV	MT	DTT
DMWNYBV	MA	Modulator (allosteric modulator)
DMWNYBV	RN	From pyrroles to 1-oxo-2,3,4,9-tetrahydro-1H-beta-carbolines: a new class of orally bioavailable mGluR1 antagonists. Bioorg Med Chem Lett. 2007 Apr 15;17(8):2254-9.
DMWNYBV	RU	https://pubmed.ncbi.nlm.nih.gov/17276684

DMXHS4L	DI	DMXHS4L
DMXHS4L	DN	PMID17280833C30
DMXHS4L	MI	TTIET93
DMXHS4L	MN	Activated CDC42 kinase 1 (ACK-1)
DMXHS4L	MT	DTT
DMXHS4L	MA	Inhibitor
DMXHS4L	RN	Discovery of 4-amino-5,6-biaryl-furo[2,3-d]pyrimidines as inhibitors of Lck: development of an expedient and divergent synthetic route and prelimin... Bioorg Med Chem Lett. 2007 Apr 15;17(8):2305-9.
DMXHS4L	RU	https://pubmed.ncbi.nlm.nih.gov/17280833

DMXHS4L	DI	DMXHS4L
DMXHS4L	DN	PMID17280833C30
DMXHS4L	MI	TT860QF
DMXHS4L	MN	LCK tyrosine protein kinase (LCK)
DMXHS4L	MT	DTT
DMXHS4L	MA	Inhibitor
DMXHS4L	RN	Discovery of 4-amino-5,6-biaryl-furo[2,3-d]pyrimidines as inhibitors of Lck: development of an expedient and divergent synthetic route and prelimin... Bioorg Med Chem Lett. 2007 Apr 15;17(8):2305-9.
DMXHS4L	RU	https://pubmed.ncbi.nlm.nih.gov/17280833

DMR9TYV	DI	DMR9TYV
DMR9TYV	DN	PMID17358052C5b
DMR9TYV	MI	TT8WFXV
DMR9TYV	MN	Hydroxycarboxylic acid receptor 3 (HCAR3)
DMR9TYV	MT	DTT
DMR9TYV	MA	Agonist
DMR9TYV	RN	Analogues of acifran: agonists of the high and low affinity niacin receptors, GPR109a and GPR109b. J Med Chem. 2007 Apr 5;50(7):1445-8.
DMR9TYV	RU	https://pubmed.ncbi.nlm.nih.gov/17358052

DM4BZ2L	DI	DM4BZ2L
DM4BZ2L	DN	PMID1738140C9
DM4BZ2L	MI	TTGMFY7
DM4BZ2L	MN	Aspartyl aminopeptidase (DNPEP)
DM4BZ2L	MT	DTT
DM4BZ2L	MA	Inhibitor
DM4BZ2L	RN	Alpha-Keto amide inhibitors of aminopeptidases. J Med Chem. 1992 Feb 7;35(3):451-6.
DM4BZ2L	RU	https://pubmed.ncbi.nlm.nih.gov/1738140

DM4IABG	DI	DM4IABG
DM4IABG	DN	PMID17480064C16
DM4IABG	MI	TTMUG9D
DM4IABG	MN	MAPK-activated protein kinase 2 (MAPKAPK2)
DM4IABG	MT	DTT
DM4IABG	MA	Inhibitor
DM4IABG	RN	Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2). J Med Chem. 2007 May 31;50(11):2647-54.
DM4IABG	RU	https://pubmed.ncbi.nlm.nih.gov/17480064

DM4IABG	DI	DM4IABG
DM4IABG	DN	PMID17480064C16
DM4IABG	MI	TTFS4VU
DM4IABG	MN	MAPK-activated protein kinase 3 (MAPKAPK3)
DM4IABG	MT	DTT
DM4IABG	MA	Inhibitor
DM4IABG	RN	Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2). J Med Chem. 2007 May 31;50(11):2647-54.
DM4IABG	RU	https://pubmed.ncbi.nlm.nih.gov/17480064

DM4IABG	DI	DM4IABG
DM4IABG	DN	PMID17480064C16
DM4IABG	MI	TT3UJ7Z
DM4IABG	MN	MAPK-activated protein kinase 5 (MAPKAPK5)
DM4IABG	MT	DTT
DM4IABG	MA	Inhibitor
DM4IABG	RN	Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2). J Med Chem. 2007 May 31;50(11):2647-54.
DM4IABG	RU	https://pubmed.ncbi.nlm.nih.gov/17480064

DMX3CYG	DI	DMX3CYG
DMX3CYG	DN	PMID17532216C2f
DMX3CYG	MI	TTVBPDM
DMX3CYG	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMX3CYG	MT	DTT
DMX3CYG	MA	Modulator (allosteric modulator)
DMX3CYG	RN	Rapid hit to lead evaluation of pyrazolo[3,4-d]pyrimidin-4-one as selective and orally bioavailable mGluR1 antagonists. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4303-7.
DMX3CYG	RU	https://pubmed.ncbi.nlm.nih.gov/17532216

DM7Z2WV	DI	DM7Z2WV
DM7Z2WV	DN	PMID17556356C1a
DM7Z2WV	MI	TTPNQAC
DM7Z2WV	MN	Estrogen-related receptor-alpha (ESRRA)
DM7Z2WV	MT	DTT
DM7Z2WV	MA	Antagonist
DM7Z2WV	RN	Crystal structure of human estrogen-related receptor alpha in complex with a synthetic inverse agonist reveals its novel molecular mechanism. J Biol Chem. 2007 Aug 10;282(32):23231-9.
DM7Z2WV	RU	https://pubmed.ncbi.nlm.nih.gov/17556356

DMLX87P	DI	DMLX87P
DMLX87P	DN	PMID17560788C29f
DMLX87P	MI	TTPADOQ
DMLX87P	MN	HMG-CoA reductase (HMGCR)
DMLX87P	MT	DTT
DMLX87P	MA	Inhibitor
DMLX87P	RN	Discovery of pyrrole-based hepatoselective ligands as potent inhibitors of HMG-CoA reductase. Bioorg Med Chem. 2007 Aug 15;15(16):5576-89.
DMLX87P	RU	https://pubmed.ncbi.nlm.nih.gov/17560788

DM6W73A	DI	DM6W73A
DM6W73A	DN	PMID17574411C41
DM6W73A	MI	TTPADOQ
DM6W73A	MN	HMG-CoA reductase (HMGCR)
DM6W73A	MT	DTT
DM6W73A	MA	Inhibitor
DM6W73A	RN	Design and synthesis of novel, conformationally restricted HMG-CoA reductase inhibitors. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4531-7.
DM6W73A	RU	https://pubmed.ncbi.nlm.nih.gov/17574411

DM1YLF6	DI	DM1YLF6
DM1YLF6	DN	PMID17574411C42
DM1YLF6	MI	TTPADOQ
DM1YLF6	MN	HMG-CoA reductase (HMGCR)
DM1YLF6	MT	DTT
DM1YLF6	MA	Inhibitor
DM1YLF6	RN	Design and synthesis of novel, conformationally restricted HMG-CoA reductase inhibitors. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4531-7.
DM1YLF6	RU	https://pubmed.ncbi.nlm.nih.gov/17574411

DM7HYPZ	DI	DM7HYPZ
DM7HYPZ	DN	PMID17574412C33
DM7HYPZ	MI	TTPADOQ
DM7HYPZ	MN	HMG-CoA reductase (HMGCR)
DM7HYPZ	MT	DTT
DM7HYPZ	MA	Inhibitor
DM7HYPZ	RN	Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4538-44.
DM7HYPZ	RU	https://pubmed.ncbi.nlm.nih.gov/17574412

DMJFOGW	DI	DMJFOGW
DMJFOGW	DN	PMID17600705C23
DMJFOGW	MI	TT860QF
DMJFOGW	MN	LCK tyrosine protein kinase (LCK)
DMJFOGW	MT	DTT
DMJFOGW	MA	Inhibitor
DMJFOGW	RN	N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: indazoles as phenol isosteres with improved pharmacokinetics. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4363-8.
DMJFOGW	RU	https://pubmed.ncbi.nlm.nih.gov/17600705

DMJFOGW	DI	DMJFOGW
DMJFOGW	DN	PMID17600705C23
DMJFOGW	MI	TT1RWNJ
DMJFOGW	MN	Tyrosine-protein kinase Lyn (JTK8)
DMJFOGW	MT	DTT
DMJFOGW	MA	Inhibitor
DMJFOGW	RN	N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: indazoles as phenol isosteres with improved pharmacokinetics. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4363-8.
DMJFOGW	RU	https://pubmed.ncbi.nlm.nih.gov/17600705

DMJFOGW	DI	DMJFOGW
DMJFOGW	DN	PMID17600705C23
DMJFOGW	MI	TTOU65C
DMJFOGW	MN	Tyrosine-protein kinase SYK (SYK)
DMJFOGW	MT	DTT
DMJFOGW	MA	Inhibitor
DMJFOGW	RN	N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: indazoles as phenol isosteres with improved pharmacokinetics. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4363-8.
DMJFOGW	RU	https://pubmed.ncbi.nlm.nih.gov/17600705

DMJFOGW	DI	DMJFOGW
DMJFOGW	DN	PMID17600705C23
DMJFOGW	MI	TT8M1DP
DMJFOGW	MN	Tyrosine-protein kinase TXK (TXK)
DMJFOGW	MT	DTT
DMJFOGW	MA	Inhibitor
DMJFOGW	RN	N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: indazoles as phenol isosteres with improved pharmacokinetics. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4363-8.
DMJFOGW	RU	https://pubmed.ncbi.nlm.nih.gov/17600705

DMMB6NU	DI	DMMB6NU
DMMB6NU	DN	PMID17709461C4g
DMMB6NU	MI	TTFQEO5
DMMB6NU	MN	Squalene synthetase (FDFT1)
DMMB6NU	MT	DTT
DMMB6NU	MA	Inhibitor
DMMB6NU	RN	Quinuclidine derivatives as potential antiparasitics. Antimicrob Agents Chemother. 2007 Nov;51(11):4049-61.
DMMB6NU	RU	https://pubmed.ncbi.nlm.nih.gov/17709461

DMBP3O7	DI	DMBP3O7
DMBP3O7	DN	PMID17723296C18
DMBP3O7	MI	TTHS256
DMBP3O7	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMBP3O7	MT	DTT
DMBP3O7	MA	Modulator (allosteric modulator)
DMBP3O7	RN	Synthesis and SAR of 2-aryl pyrido[2,3-d]pyrimidines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5396-9.
DMBP3O7	RU	https://pubmed.ncbi.nlm.nih.gov/17723296

DMLPC17	DI	DMLPC17
DMLPC17	DN	PMID17888661C18
DMLPC17	MI	TTE5J6X
DMLPC17	MN	Diphosphomevalonate decarboxylase (MVD)
DMLPC17	MT	DTT
DMLPC17	MA	Inhibitor
DMLPC17	RN	Mutation and inhibition studies of mevalonate 5-diphosphate decarboxylase. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6164-8.
DMLPC17	RU	https://pubmed.ncbi.nlm.nih.gov/17888661

DMRWTHA	DI	DMRWTHA
DMRWTHA	DN	PMID17888661C19
DMRWTHA	MI	TTE5J6X
DMRWTHA	MN	Diphosphomevalonate decarboxylase (MVD)
DMRWTHA	MT	DTT
DMRWTHA	MA	Inhibitor
DMRWTHA	RN	Mutation and inhibition studies of mevalonate 5-diphosphate decarboxylase. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6164-8.
DMRWTHA	RU	https://pubmed.ncbi.nlm.nih.gov/17888661

DMDVW4K	DI	DMDVW4K
DMDVW4K	DN	PMID17929793C11c
DMDVW4K	MI	TTVBPDM
DMDVW4K	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMDVW4K	MT	DTT
DMDVW4K	MA	Modulator (allosteric modulator)
DMDVW4K	RN	Discovery of orally efficacious tetracyclic metabotropic glutamate receptor 1 (mGluR1) antagonists for the treatment of chronic pain. J Med Chem. 2007 Nov 15;50(23):5550-3.
DMDVW4K	RU	https://pubmed.ncbi.nlm.nih.gov/17929793

DMIG308	DI	DMIG308
DMIG308	DN	PMID17929793C23c
DMIG308	MI	TTVBPDM
DMIG308	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMIG308	MT	DTT
DMIG308	MA	Modulator (allosteric modulator)
DMIG308	RN	Discovery of orally efficacious tetracyclic metabotropic glutamate receptor 1 (mGluR1) antagonists for the treatment of chronic pain. J Med Chem. 2007 Nov 15;50(23):5550-3.
DMIG308	RU	https://pubmed.ncbi.nlm.nih.gov/17929793

DMOB07W	DI	DMOB07W
DMOB07W	DN	PMID17929793C23e
DMOB07W	MI	TTVBPDM
DMOB07W	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMOB07W	MT	DTT
DMOB07W	MA	Modulator (allosteric modulator)
DMOB07W	RN	Discovery of orally efficacious tetracyclic metabotropic glutamate receptor 1 (mGluR1) antagonists for the treatment of chronic pain. J Med Chem. 2007 Nov 15;50(23):5550-3.
DMOB07W	RU	https://pubmed.ncbi.nlm.nih.gov/17929793

DM83Z6M	DI	DM83Z6M
DM83Z6M	DN	PMID17929793C23h
DM83Z6M	MI	TTVBPDM
DM83Z6M	MN	Metabotropic glutamate receptor 1 (mGluR1)
DM83Z6M	MT	DTT
DM83Z6M	MA	Modulator (allosteric modulator)
DM83Z6M	RN	Discovery of orally efficacious tetracyclic metabotropic glutamate receptor 1 (mGluR1) antagonists for the treatment of chronic pain. J Med Chem. 2007 Nov 15;50(23):5550-3.
DM83Z6M	RU	https://pubmed.ncbi.nlm.nih.gov/17929793

DM07TVS	DI	DM07TVS
DM07TVS	DN	PMID17929793C23i
DM07TVS	MI	TTVBPDM
DM07TVS	MN	Metabotropic glutamate receptor 1 (mGluR1)
DM07TVS	MT	DTT
DM07TVS	MA	Modulator (allosteric modulator)
DM07TVS	RN	Discovery of orally efficacious tetracyclic metabotropic glutamate receptor 1 (mGluR1) antagonists for the treatment of chronic pain. J Med Chem. 2007 Nov 15;50(23):5550-3.
DM07TVS	RU	https://pubmed.ncbi.nlm.nih.gov/17929793

DML8ZBR	DI	DML8ZBR
DML8ZBR	DN	PMID17935989C25
DML8ZBR	MI	TTTU902
DML8ZBR	MN	Checkpoint kinase-1 (CHK1)
DML8ZBR	MT	DTT
DML8ZBR	MA	Inhibitor
DML8ZBR	RN	Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and prelimina... Bioorg Med Chem Lett. 2007 Dec 1;17(23):6593-601.
DML8ZBR	RU	https://pubmed.ncbi.nlm.nih.gov/17935989

DML8ZBR	DI	DML8ZBR
DML8ZBR	DN	PMID17935989C25
DML8ZBR	MI	TT6SA0X
DML8ZBR	MN	Muscle-specific kinase receptor (MUSK)
DML8ZBR	MT	DTT
DML8ZBR	MA	Inhibitor
DML8ZBR	RN	Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and prelimina... Bioorg Med Chem Lett. 2007 Dec 1;17(23):6593-601.
DML8ZBR	RU	https://pubmed.ncbi.nlm.nih.gov/17935989

DML8ZBR	DI	DML8ZBR
DML8ZBR	DN	PMID17935989C25
DML8ZBR	MI	TT1VAUK
DML8ZBR	MN	VEGFR1 messenger RNA (VEGFR1 mRNA)
DML8ZBR	MT	DTT
DML8ZBR	MA	Inhibitor
DML8ZBR	RN	Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and prelimina... Bioorg Med Chem Lett. 2007 Dec 1;17(23):6593-601.
DML8ZBR	RU	https://pubmed.ncbi.nlm.nih.gov/17935989

DMEHC2I	DI	DMEHC2I
DMEHC2I	DN	PMID17936624C36
DMEHC2I	MI	TTHS256
DMEHC2I	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMEHC2I	MT	DTT
DMEHC2I	MA	Modulator (allosteric modulator)
DMEHC2I	RN	Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8.
DMEHC2I	RU	https://pubmed.ncbi.nlm.nih.gov/17936624

DMYH36T	DI	DMYH36T
DMYH36T	DN	PMID17942791C3
DMYH36T	MI	TT2AP5B
DMYH36T	MN	Ras converting CAAX endopeptidase 1 (RCE1)
DMYH36T	MT	DTT
DMYH36T	MA	Inhibitor
DMYH36T	RN	Small-molecule inhibitors of the Rce1p CaaX protease. J Biomol Screen. 2007 Oct;12(7):983-93.
DMYH36T	RU	https://pubmed.ncbi.nlm.nih.gov/17942791

DMTP5OY	DI	DMTP5OY
DMTP5OY	DN	PMID17963374C31
DMTP5OY	MI	TTIKWV4
DMTP5OY	MN	Geranyltranstransferase (FDPS)
DMTP5OY	MT	DTT
DMTP5OY	MA	Inhibitor
DMTP5OY	RN	Activity of sulfonium bisphosphonates on tumor cell lines. J Med Chem. 2007 Nov 29;50(24):6067-79.
DMTP5OY	RU	https://pubmed.ncbi.nlm.nih.gov/17963374

DMS1QM8	DI	DMS1QM8
DMS1QM8	DN	PMID17975902C5e
DMS1QM8	MI	TTIKWV4
DMS1QM8	MN	Geranyltranstransferase (FDPS)
DMS1QM8	MT	DTT
DMS1QM8	MA	Inhibitor
DMS1QM8	RN	Synthesis and biological evaluation of alpha-halogenated bisphosphonate and phosphonocarboxylate analogues of risedronate. J Med Chem. 2007 Nov 29;50(24):5967-75.
DMS1QM8	RU	https://pubmed.ncbi.nlm.nih.gov/17975902

DMTZQUJ	DI	DMTZQUJ
DMTZQUJ	DN	PMID18068976C25
DMTZQUJ	MI	TTVXEGU
DMTZQUJ	MN	ADAM10 messenger RNA (ADAM10 mRNA)
DMTZQUJ	MT	DTT
DMTZQUJ	MA	Inhibitor
DMTZQUJ	RN	Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle P1' permutations. Bioorg Med Chem Lett. 2008 Jan 15;18(2):560-4.
DMTZQUJ	RU	https://pubmed.ncbi.nlm.nih.gov/18068976

DMK5PO8	DI	DMK5PO8
DMK5PO8	DN	PMID18072721C50
DMK5PO8	MI	TTPADOQ
DMK5PO8	MN	HMG-CoA reductase (HMGCR)
DMK5PO8	MT	DTT
DMK5PO8	MA	Inhibitor
DMK5PO8	RN	Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylca... J Med Chem. 2008 Jan 10;51(1):31-45.
DMK5PO8	RU	https://pubmed.ncbi.nlm.nih.gov/18072721

DMO21H5	DI	DMO21H5
DMO21H5	DN	PMID18078750C1b
DMO21H5	MI	TT3LJ6G
DMO21H5	MN	Carboxypeptidase A1 (CPA1)
DMO21H5	MT	DTT
DMO21H5	MA	Inhibitor
DMO21H5	RN	Thiol-based angiotensin-converting enzyme 2 inhibitors: P1 modifications for the exploration of the S1 subsite. Bioorg Med Chem Lett. 2008 Jan 15;18(2):732-7.
DMO21H5	RU	https://pubmed.ncbi.nlm.nih.gov/18078750

DMO21H5	DI	DMO21H5
DMO21H5	DN	PMID18078750C1b
DMO21H5	MI	TT5TKPM
DMO21H5	MN	Neutral endopeptidase (MME)
DMO21H5	MT	DTT
DMO21H5	MA	Inhibitor
DMO21H5	RN	Thiol-based angiotensin-converting enzyme 2 inhibitors: P1 modifications for the exploration of the S1 subsite. Bioorg Med Chem Lett. 2008 Jan 15;18(2):732-7.
DMO21H5	RU	https://pubmed.ncbi.nlm.nih.gov/18078750

DM2U4NW	DI	DM2U4NW
DM2U4NW	DN	PMID18155906C16f
DM2U4NW	MI	TTPADOQ
DM2U4NW	MN	HMG-CoA reductase (HMGCR)
DM2U4NW	MT	DTT
DM2U4NW	MA	Inhibitor
DM2U4NW	RN	Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors. Bioorg Med Chem Lett. 2008 Feb 1;18(3):1151-6.
DM2U4NW	RU	https://pubmed.ncbi.nlm.nih.gov/18155906

DMA2OWK	DI	DMA2OWK
DMA2OWK	DN	PMID18178086C15
DMA2OWK	MI	TTB7Y8I
DMA2OWK	MN	Lysophosphatidic acid receptor 2 (LPAR2)
DMA2OWK	MT	DTT
DMA2OWK	MA	Antagonist
DMA2OWK	RN	Discovery of potent LPA2 (EDG4) antagonists as potential anticancer agents. Bioorg Med Chem Lett. 2008 Feb 1;18(3):1037-41.
DMA2OWK	RU	https://pubmed.ncbi.nlm.nih.gov/18178086

DM3GYNM	DI	DM3GYNM
DM3GYNM	DN	PMID18295483C2
DM3GYNM	MI	TTIKWV4
DM3GYNM	MN	Geranyltranstransferase (FDPS)
DM3GYNM	MT	DTT
DM3GYNM	MA	Inhibitor
DM3GYNM	RN	Design and structure-activity relationships of potent and selective inhibitors of undecaprenyl pyrophosphate synthase (UPPS): tetramic, tetronic acids and dihydropyridin-2-ones. Bioorg Med Chem Lett.2008 Mar 15;18(6):1840-4.
DM3GYNM	RU	https://pubmed.ncbi.nlm.nih.gov/18295483

DMCTFWE	DI	DMCTFWE
DMCTFWE	DN	PMID18324760C28
DMCTFWE	MI	TTUI5H7
DMCTFWE	MN	Angiotensin-converting enzyme 2 (ACE2)
DMCTFWE	MT	DTT
DMCTFWE	MA	Inhibitor
DMCTFWE	RN	Development of potent and selective phosphinic peptide inhibitors of angiotensin-converting enzyme 2. J Med Chem. 2008 Apr 10;51(7):2216-26.
DMCTFWE	RU	https://pubmed.ncbi.nlm.nih.gov/18324760

DM1I6AY	DI	DM1I6AY
DM1I6AY	DN	PMID18334293C15b
DM1I6AY	MI	TTFYL58
DM1I6AY	MN	CaM-kinase II (CAMK2)
DM1I6AY	MT	DTT
DM1I6AY	MA	Inhibitor
DM1I6AY	RN	Pyrimidine-based inhibitors of CaMKIIdelta. Bioorg Med Chem Lett. 2008 Apr 1;18(7):2404-8.
DM1I6AY	RU	https://pubmed.ncbi.nlm.nih.gov/18334293

DMEOHLV	DI	DMEOHLV
DMEOHLV	DN	PMID18337095C27
DMEOHLV	MI	TTFYL58
DMEOHLV	MN	CaM-kinase II (CAMK2)
DMEOHLV	MT	DTT
DMEOHLV	MA	Inhibitor
DMEOHLV	RN	Aryl-indolyl maleimides as inhibitors of CaMKIIdelta. Part 3: Importance of the indole orientation. Bioorg Med Chem Lett. 2008 Apr 1;18(7):2399-403.
DMEOHLV	RU	https://pubmed.ncbi.nlm.nih.gov/18337095

DM6NL2B	DI	DM6NL2B
DM6NL2B	DN	PMID18412317C13b
DM6NL2B	MI	TTPADOQ
DM6NL2B	MN	HMG-CoA reductase (HMGCR)
DM6NL2B	MT	DTT
DM6NL2B	MA	Inhibitor
DM6NL2B	RN	(3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with reduced myotoxicity potential. J Med Chem. 2008 May 8;51(9):2722-33.
DM6NL2B	RU	https://pubmed.ncbi.nlm.nih.gov/18412317

DMW7PQ8	DI	DMW7PQ8
DMW7PQ8	DN	PMID18445527C11 
DMW7PQ8	MI	TTA93TL
DMW7PQ8	MN	P2Y purinoceptor 1 (P2RY1)
DMW7PQ8	MT	DTT
DMW7PQ8	MA	Antagonist
DMW7PQ8	RN	P2Y1 receptor antagonists as novel antithrombotic agents. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3338-43.
DMW7PQ8	RU	https://pubmed.ncbi.nlm.nih.gov/18445527

DM7AXRF	DI	DM7AXRF
DM7AXRF	DN	PMID18445527C67 
DM7AXRF	MI	TTA93TL
DM7AXRF	MN	P2Y purinoceptor 1 (P2RY1)
DM7AXRF	MT	DTT
DM7AXRF	MA	Antagonist
DM7AXRF	RN	P2Y1 receptor antagonists as novel antithrombotic agents. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3338-43.
DM7AXRF	RU	https://pubmed.ncbi.nlm.nih.gov/18445527

DM0G42B	DI	DM0G42B
DM0G42B	DN	PMID18477808CB 
DM0G42B	MI	TTB8FUC
DM0G42B	MN	Free fatty acid receptor 1 (GPR40)
DM0G42B	MT	DTT
DM0G42B	MA	Agonist
DM0G42B	RN	Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice. Diabetes. 2008 Aug;57(8):2211-9.
DM0G42B	RU	https://pubmed.ncbi.nlm.nih.gov/18477808

DMPZSGV	DI	DMPZSGV
DMPZSGV	DN	PMID18752940C9n
DMPZSGV	MI	TTWNV8U
DMPZSGV	MN	Nicotinic acid receptor (HCAR2)
DMPZSGV	MT	DTT
DMPZSGV	MA	Modulator (allosteric modulator)
DMPZSGV	RN	Discovery of pyrazolopyrimidines as the first class of allosteric agonists for the high affinity nicotinic acid receptor GPR109A. Bioorg Med Chem Lett. 2008 Sep 15;18(18):4948-51.
DMPZSGV	RU	https://pubmed.ncbi.nlm.nih.gov/18752940

DMTH0PD	DI	DMTH0PD
DMTH0PD	DN	PMID1875346C18
DMTH0PD	MI	TTPADOQ
DMTH0PD	MN	HMG-CoA reductase (HMGCR)
DMTH0PD	MT	DTT
DMTH0PD	MA	Inhibitor
DMTH0PD	RN	3-Hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors. 7. Modification of the hexahydronaphthalene moiety of simvastatin: 5-oxygenated and 5-oxa derivatives. J Med Chem. 1991 Aug;34(8):2489-95.
DMTH0PD	RU	https://pubmed.ncbi.nlm.nih.gov/1875346

DM1JRGI	DI	DM1JRGI
DM1JRGI	DN	PMID18754614C10
DM1JRGI	MI	TTFQEO5
DM1JRGI	MN	Squalene synthetase (FDFT1)
DM1JRGI	MT	DTT
DM1JRGI	MA	Inhibitor
DM1JRGI	RN	Lipid-lowering (hetero)aromatic tetrahydro-1,4-oxazine derivatives with antioxidant and squalene synthase inhibitory activity. J Med Chem. 2008 Sep 25;51(18):5861-5.
DM1JRGI	RU	https://pubmed.ncbi.nlm.nih.gov/18754614

DMSVB9D	DI	DMSVB9D
DMSVB9D	DN	PMID18754614C17
DMSVB9D	MI	TTFQEO5
DMSVB9D	MN	Squalene synthetase (FDFT1)
DMSVB9D	MT	DTT
DMSVB9D	MA	Inhibitor
DMSVB9D	RN	Lipid-lowering (hetero)aromatic tetrahydro-1,4-oxazine derivatives with antioxidant and squalene synthase inhibitory activity. J Med Chem. 2008 Sep 25;51(18):5861-5.
DMSVB9D	RU	https://pubmed.ncbi.nlm.nih.gov/18754614

DMF7VZO	DI	DMF7VZO
DMF7VZO	DN	PMID18754614C18
DMF7VZO	MI	TTFQEO5
DMF7VZO	MN	Squalene synthetase (FDFT1)
DMF7VZO	MT	DTT
DMF7VZO	MA	Inhibitor
DMF7VZO	RN	Lipid-lowering (hetero)aromatic tetrahydro-1,4-oxazine derivatives with antioxidant and squalene synthase inhibitory activity. J Med Chem. 2008 Sep 25;51(18):5861-5.
DMF7VZO	RU	https://pubmed.ncbi.nlm.nih.gov/18754614

DMHSE96	DI	DMHSE96
DMHSE96	DN	PMID18754614C19
DMHSE96	MI	TTFQEO5
DMHSE96	MN	Squalene synthetase (FDFT1)
DMHSE96	MT	DTT
DMHSE96	MA	Inhibitor
DMHSE96	RN	Lipid-lowering (hetero)aromatic tetrahydro-1,4-oxazine derivatives with antioxidant and squalene synthase inhibitory activity. J Med Chem. 2008 Sep 25;51(18):5861-5.
DMHSE96	RU	https://pubmed.ncbi.nlm.nih.gov/18754614

DMQFYM4	DI	DMQFYM4
DMQFYM4	DN	PMID18754614C4
DMQFYM4	MI	TTFQEO5
DMQFYM4	MN	Squalene synthetase (FDFT1)
DMQFYM4	MT	DTT
DMQFYM4	MA	Inhibitor
DMQFYM4	RN	Lipid-lowering (hetero)aromatic tetrahydro-1,4-oxazine derivatives with antioxidant and squalene synthase inhibitory activity. J Med Chem. 2008 Sep 25;51(18):5861-5.
DMQFYM4	RU	https://pubmed.ncbi.nlm.nih.gov/18754614

DMVTLO0	DI	DMVTLO0
DMVTLO0	DN	PMID18754614C7
DMVTLO0	MI	TTFQEO5
DMVTLO0	MN	Squalene synthetase (FDFT1)
DMVTLO0	MT	DTT
DMVTLO0	MA	Inhibitor
DMVTLO0	RN	Lipid-lowering (hetero)aromatic tetrahydro-1,4-oxazine derivatives with antioxidant and squalene synthase inhibitory activity. J Med Chem. 2008 Sep 25;51(18):5861-5.
DMVTLO0	RU	https://pubmed.ncbi.nlm.nih.gov/18754614

DM7SCM3	DI	DM7SCM3
DM7SCM3	DN	PMID18754614C8
DM7SCM3	MI	TTFQEO5
DM7SCM3	MN	Squalene synthetase (FDFT1)
DM7SCM3	MT	DTT
DM7SCM3	MA	Inhibitor
DM7SCM3	RN	Lipid-lowering (hetero)aromatic tetrahydro-1,4-oxazine derivatives with antioxidant and squalene synthase inhibitory activity. J Med Chem. 2008 Sep 25;51(18):5861-5.
DM7SCM3	RU	https://pubmed.ncbi.nlm.nih.gov/18754614

DMPH7A6	DI	DMPH7A6
DMPH7A6	DN	PMID18754614C9
DMPH7A6	MI	TTFQEO5
DMPH7A6	MN	Squalene synthetase (FDFT1)
DMPH7A6	MT	DTT
DMPH7A6	MA	Inhibitor
DMPH7A6	RN	Lipid-lowering (hetero)aromatic tetrahydro-1,4-oxazine derivatives with antioxidant and squalene synthase inhibitory activity. J Med Chem. 2008 Sep 25;51(18):5861-5.
DMPH7A6	RU	https://pubmed.ncbi.nlm.nih.gov/18754614

DM613NQ	DI	DM613NQ
DM613NQ	DN	PMID18790648C10
DM613NQ	MI	TTZW4MV
DM613NQ	MN	Matrix metalloproteinase-11 (MMP-11)
DM613NQ	MT	DTT
DM613NQ	MA	Inhibitor
DM613NQ	RN	Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge. Bioorg Med Chem. 2008 Oct 1;16(19):8781-94.
DM613NQ	RU	https://pubmed.ncbi.nlm.nih.gov/18790648

DM4UWKR	DI	DM4UWKR
DM4UWKR	DN	PMID18800762C11
DM4UWKR	MI	TTIKWV4
DM4UWKR	MN	Geranyltranstransferase (FDPS)
DM4UWKR	MT	DTT
DM4UWKR	MA	Inhibitor
DM4UWKR	RN	Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation. J Med Chem. 2008 Sep 25;51(18):5594-607.
DM4UWKR	RU	https://pubmed.ncbi.nlm.nih.gov/18800762

DM5T2FR	DI	DM5T2FR
DM5T2FR	DN	PMID18800762C14
DM5T2FR	MI	TTIKWV4
DM5T2FR	MN	Geranyltranstransferase (FDPS)
DM5T2FR	MT	DTT
DM5T2FR	MA	Inhibitor
DM5T2FR	RN	Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation. J Med Chem. 2008 Sep 25;51(18):5594-607.
DM5T2FR	RU	https://pubmed.ncbi.nlm.nih.gov/18800762

DM70SEQ	DI	DM70SEQ
DM70SEQ	DN	PMID18800762C16
DM70SEQ	MI	TTIKWV4
DM70SEQ	MN	Geranyltranstransferase (FDPS)
DM70SEQ	MT	DTT
DM70SEQ	MA	Inhibitor
DM70SEQ	RN	Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation. J Med Chem. 2008 Sep 25;51(18):5594-607.
DM70SEQ	RU	https://pubmed.ncbi.nlm.nih.gov/18800762

DM1QXFI	DI	DM1QXFI
DM1QXFI	DN	PMID18800762C19
DM1QXFI	MI	TTIKWV4
DM1QXFI	MN	Geranyltranstransferase (FDPS)
DM1QXFI	MT	DTT
DM1QXFI	MA	Inhibitor
DM1QXFI	RN	Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation. J Med Chem. 2008 Sep 25;51(18):5594-607.
DM1QXFI	RU	https://pubmed.ncbi.nlm.nih.gov/18800762

DMZDC14	DI	DMZDC14
DMZDC14	DN	PMID18800762C47
DMZDC14	MI	TTIKWV4
DMZDC14	MN	Geranyltranstransferase (FDPS)
DMZDC14	MT	DTT
DMZDC14	MA	Inhibitor
DMZDC14	RN	Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation. J Med Chem. 2008 Sep 25;51(18):5594-607.
DMZDC14	RU	https://pubmed.ncbi.nlm.nih.gov/18800762

DMWFGY4	DI	DMWFGY4
DMWFGY4	DN	PMID18800762C51
DMWFGY4	MI	TTIKWV4
DMWFGY4	MN	Geranyltranstransferase (FDPS)
DMWFGY4	MT	DTT
DMWFGY4	MA	Inhibitor
DMWFGY4	RN	Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation. J Med Chem. 2008 Sep 25;51(18):5594-607.
DMWFGY4	RU	https://pubmed.ncbi.nlm.nih.gov/18800762

DMA5P9Q	DI	DMA5P9Q
DMA5P9Q	DN	PMID1895299C1
DMA5P9Q	MI	TTPADOQ
DMA5P9Q	MN	HMG-CoA reductase (HMGCR)
DMA5P9Q	MT	DTT
DMA5P9Q	MA	Inhibitor
DMA5P9Q	RN	Phosphorus-containing inhibitors of HMG-CoA reductase. 2. Synthesis and biological activities of a series of substituted pyridines containing a hydroxyphosphinyl moiety. J Med Chem. 1991 Sep;34(9):2804-15.
DMA5P9Q	RU	https://pubmed.ncbi.nlm.nih.gov/1895299

DMAZWHB	DI	DMAZWHB
DMAZWHB	DN	PMID1895299C4p
DMAZWHB	MI	TTPADOQ
DMAZWHB	MN	HMG-CoA reductase (HMGCR)
DMAZWHB	MT	DTT
DMAZWHB	MA	Inhibitor
DMAZWHB	RN	Phosphorus-containing inhibitors of HMG-CoA reductase. 2. Synthesis and biological activities of a series of substituted pyridines containing a hydroxyphosphinyl moiety. J Med Chem. 1991 Sep;34(9):2804-15.
DMAZWHB	RU	https://pubmed.ncbi.nlm.nih.gov/1895299

DM384PH	DI	DM384PH
DM384PH	DN	PMID1895299C6v
DM384PH	MI	TTPADOQ
DM384PH	MN	HMG-CoA reductase (HMGCR)
DM384PH	MT	DTT
DM384PH	MA	Inhibitor
DM384PH	RN	Phosphorus-containing inhibitors of HMG-CoA reductase. 2. Synthesis and biological activities of a series of substituted pyridines containing a hydroxyphosphinyl moiety. J Med Chem. 1991 Sep;34(9):2804-15.
DM384PH	RU	https://pubmed.ncbi.nlm.nih.gov/1895299

DMFU6AI	DI	DMFU6AI
DMFU6AI	DN	PMID18986805C9b
DMFU6AI	MI	TTH6V3D
DMFU6AI	MN	Cyclin-dependent kinase 1 (CDK1)
DMFU6AI	MT	DTT
DMFU6AI	MA	Inhibitor
DMFU6AI	RN	Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6486-9.
DMFU6AI	RU	https://pubmed.ncbi.nlm.nih.gov/18986805

DMFU6AI	DI	DMFU6AI
DMFU6AI	DN	PMID18986805C9b
DMFU6AI	MI	TT7HF4W
DMFU6AI	MN	Cyclin-dependent kinase 2 (CDK2)
DMFU6AI	MT	DTT
DMFU6AI	MA	Inhibitor
DMFU6AI	RN	Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6486-9.
DMFU6AI	RU	https://pubmed.ncbi.nlm.nih.gov/18986805

DMFU6AI	DI	DMFU6AI
DMFU6AI	DN	PMID18986805C9b
DMFU6AI	MI	TT0PG8F
DMFU6AI	MN	Cyclin-dependent kinase 4 (CDK4)
DMFU6AI	MT	DTT
DMFU6AI	MA	Inhibitor
DMFU6AI	RN	Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6486-9.
DMFU6AI	RU	https://pubmed.ncbi.nlm.nih.gov/18986805

DMFU6AI	DI	DMFU6AI
DMFU6AI	DN	PMID18986805C9b
DMFU6AI	MI	TTBTI6P
DMFU6AI	MN	Cyclin-dependent kinase-like 1 (CDKL1)
DMFU6AI	MT	DTT
DMFU6AI	MA	Inhibitor
DMFU6AI	RN	Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6486-9.
DMFU6AI	RU	https://pubmed.ncbi.nlm.nih.gov/18986805

DMH70UC	DI	DMH70UC
DMH70UC	DN	PMID19097784C2
DMH70UC	MI	TTIYVQP
DMH70UC	MN	Polo-like kinase 1 (PLK1)
DMH70UC	MT	DTT
DMH70UC	MA	Inhibitor
DMH70UC	RN	Discovery of thiophene inhibitors of polo-like kinase. Bioorg Med Chem Lett. 2009 Feb 1;19(3):1018-21.
DMH70UC	RU	https://pubmed.ncbi.nlm.nih.gov/19097784

DMVTXKI	DI	DMVTXKI
DMVTXKI	DN	PMID19111466C7d
DMVTXKI	MI	TT5ZKDI
DMVTXKI	MN	Histone deacetylase 6 (HDAC6)
DMVTXKI	MT	DTT
DMVTXKI	MA	Inhibitor
DMVTXKI	RN	Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Feb 1;19(3):688-92.
DMVTXKI	RU	https://pubmed.ncbi.nlm.nih.gov/19111466

DMB9F2L	DI	DMB9F2L
DMB9F2L	DN	PMID19115845C89S
DMB9F2L	MI	TTSMTDI
DMB9F2L	MN	CDC7-related kinase (CDC7)
DMB9F2L	MT	DTT
DMB9F2L	MA	Inhibitor
DMB9F2L	RN	First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery. J Med Chem. 2009 Jan 22;52(2):293-307.
DMB9F2L	RU	https://pubmed.ncbi.nlm.nih.gov/19115845

DMB9F2L	DI	DMB9F2L
DMB9F2L	DN	PMID19115845C89S
DMB9F2L	MI	TTH6V3D
DMB9F2L	MN	Cyclin-dependent kinase 1 (CDK1)
DMB9F2L	MT	DTT
DMB9F2L	MA	Inhibitor
DMB9F2L	RN	First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery. J Med Chem. 2009 Jan 22;52(2):293-307.
DMB9F2L	RU	https://pubmed.ncbi.nlm.nih.gov/19115845

DMB9F2L	DI	DMB9F2L
DMB9F2L	DN	PMID19115845C89S
DMB9F2L	MI	TT7HF4W
DMB9F2L	MN	Cyclin-dependent kinase 2 (CDK2)
DMB9F2L	MT	DTT
DMB9F2L	MA	Inhibitor
DMB9F2L	RN	First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery. J Med Chem. 2009 Jan 22;52(2):293-307.
DMB9F2L	RU	https://pubmed.ncbi.nlm.nih.gov/19115845

DMB9F2L	DI	DMB9F2L
DMB9F2L	DN	PMID19115845C89S
DMB9F2L	MI	TT1LVF2
DMB9F2L	MN	Cyclin-dependent kinase 9 (CDK9)
DMB9F2L	MT	DTT
DMB9F2L	MA	Inhibitor
DMB9F2L	RN	First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery. J Med Chem. 2009 Jan 22;52(2):293-307.
DMB9F2L	RU	https://pubmed.ncbi.nlm.nih.gov/19115845

DMB9F2L	DI	DMB9F2L
DMB9F2L	DN	PMID19115845C89S
DMB9F2L	MI	TTRSMW9
DMB9F2L	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMB9F2L	MT	DTT
DMB9F2L	MA	Inhibitor
DMB9F2L	RN	First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery. J Med Chem. 2009 Jan 22;52(2):293-307.
DMB9F2L	RU	https://pubmed.ncbi.nlm.nih.gov/19115845

DMB9F2L	DI	DMB9F2L
DMB9F2L	DN	PMID19115845C89S
DMB9F2L	MI	TTO7L0V
DMB9F2L	MN	TAO kinase 3 (TAOK3)
DMB9F2L	MT	DTT
DMB9F2L	MA	Inhibitor
DMB9F2L	RN	First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery. J Med Chem. 2009 Jan 22;52(2):293-307.
DMB9F2L	RU	https://pubmed.ncbi.nlm.nih.gov/19115845

DMG7D3I	DI	DMG7D3I
DMG7D3I	DN	PMID19191557C14
DMG7D3I	MI	TTFQEO5
DMG7D3I	MN	Squalene synthetase (FDFT1)
DMG7D3I	MT	DTT
DMG7D3I	MA	Inhibitor
DMG7D3I	RN	Phosphonosulfonates are potent, selective inhibitors of dehydrosqualene synthase and staphyloxanthin biosynthesis in Staphylococcus aureus. J Med Chem. 2009 Feb 26;52(4):976-88.
DMG7D3I	RU	https://pubmed.ncbi.nlm.nih.gov/19191557

DMXLVEC	DI	DMXLVEC
DMXLVEC	DN	PMID19191557C19
DMXLVEC	MI	TTFQEO5
DMXLVEC	MN	Squalene synthetase (FDFT1)
DMXLVEC	MT	DTT
DMXLVEC	MA	Inhibitor
DMXLVEC	RN	Phosphonosulfonates are potent, selective inhibitors of dehydrosqualene synthase and staphyloxanthin biosynthesis in Staphylococcus aureus. J Med Chem. 2009 Feb 26;52(4):976-88.
DMXLVEC	RU	https://pubmed.ncbi.nlm.nih.gov/19191557

DM5RIB0	DI	DM5RIB0
DM5RIB0	DN	PMID19191557C21
DM5RIB0	MI	TTFQEO5
DM5RIB0	MN	Squalene synthetase (FDFT1)
DM5RIB0	MT	DTT
DM5RIB0	MA	Inhibitor
DM5RIB0	RN	Phosphonosulfonates are potent, selective inhibitors of dehydrosqualene synthase and staphyloxanthin biosynthesis in Staphylococcus aureus. J Med Chem. 2009 Feb 26;52(4):976-88.
DM5RIB0	RU	https://pubmed.ncbi.nlm.nih.gov/19191557

DM1MEY3	DI	DM1MEY3
DM1MEY3	DN	PMID19191557C3
DM1MEY3	MI	TTFQEO5
DM1MEY3	MN	Squalene synthetase (FDFT1)
DM1MEY3	MT	DTT
DM1MEY3	MA	Inhibitor
DM1MEY3	RN	Phosphonosulfonates are potent, selective inhibitors of dehydrosqualene synthase and staphyloxanthin biosynthesis in Staphylococcus aureus. J Med Chem. 2009 Feb 26;52(4):976-88.
DM1MEY3	RU	https://pubmed.ncbi.nlm.nih.gov/19191557

DMH8QRI	DI	DMH8QRI
DMH8QRI	DN	PMID19191557C32
DMH8QRI	MI	TTFQEO5
DMH8QRI	MN	Squalene synthetase (FDFT1)
DMH8QRI	MT	DTT
DMH8QRI	MA	Inhibitor
DMH8QRI	RN	Phosphonosulfonates are potent, selective inhibitors of dehydrosqualene synthase and staphyloxanthin biosynthesis in Staphylococcus aureus. J Med Chem. 2009 Feb 26;52(4):976-88.
DMH8QRI	RU	https://pubmed.ncbi.nlm.nih.gov/19191557

DM09IEK	DI	DM09IEK
DM09IEK	DN	PMID19191557C35
DM09IEK	MI	TTFQEO5
DM09IEK	MN	Squalene synthetase (FDFT1)
DM09IEK	MT	DTT
DM09IEK	MA	Inhibitor
DM09IEK	RN	Phosphonosulfonates are potent, selective inhibitors of dehydrosqualene synthase and staphyloxanthin biosynthesis in Staphylococcus aureus. J Med Chem. 2009 Feb 26;52(4):976-88.
DM09IEK	RU	https://pubmed.ncbi.nlm.nih.gov/19191557

DMUWYA2	DI	DMUWYA2
DMUWYA2	DN	PMID19191557C8
DMUWYA2	MI	TTFQEO5
DMUWYA2	MN	Squalene synthetase (FDFT1)
DMUWYA2	MT	DTT
DMUWYA2	MA	Inhibitor
DMUWYA2	RN	Phosphonosulfonates are potent, selective inhibitors of dehydrosqualene synthase and staphyloxanthin biosynthesis in Staphylococcus aureus. J Med Chem. 2009 Feb 26;52(4):976-88.
DMUWYA2	RU	https://pubmed.ncbi.nlm.nih.gov/19191557

DMJRLB5	DI	DMJRLB5
DMJRLB5	DN	PMID19289283C22
DMJRLB5	MI	TTVBPDM
DMJRLB5	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMJRLB5	MT	DTT
DMJRLB5	MA	Modulator (allosteric modulator)
DMJRLB5	RN	In vitro and in vivo SAR of pyrido[3,4-d]pyramid-4-ylamine based mGluR1 antagonists. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2190-4.
DMJRLB5	RU	https://pubmed.ncbi.nlm.nih.gov/19289283

DMSKGEJ	DI	DMSKGEJ
DMSKGEJ	DN	PMID19289283C32
DMSKGEJ	MI	TTVBPDM
DMSKGEJ	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMSKGEJ	MT	DTT
DMSKGEJ	MA	Modulator (allosteric modulator)
DMSKGEJ	RN	In vitro and in vivo SAR of pyrido[3,4-d]pyramid-4-ylamine based mGluR1 antagonists. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2190-4.
DMSKGEJ	RU	https://pubmed.ncbi.nlm.nih.gov/19289283

DMTASYN	DI	DMTASYN
DMTASYN	DN	PMID19309152C2g
DMTASYN	MI	TTWNV8U
DMTASYN	MN	Nicotinic acid receptor (HCAR2)
DMTASYN	MT	DTT
DMTASYN	MA	Agonist
DMTASYN	RN	Discovery of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats. J Med Chem. 2009 Apr 23;52(8):2587-602.
DMTASYN	RU	https://pubmed.ncbi.nlm.nih.gov/19309152

DMSE1C3	DI	DMSE1C3
DMSE1C3	DN	PMID19364658C33
DMSE1C3	MI	TTQR5YD
DMSE1C3	MN	Casein kinase I gamma-1 (CSNK1G1)
DMSE1C3	MT	DTT
DMSE1C3	MA	Inhibitor
DMSE1C3	RN	Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2). Bioorg Med Chem. 2009 May 1;17(9):3342-51.
DMSE1C3	RU	https://pubmed.ncbi.nlm.nih.gov/19364658

DMSE1C3	DI	DMSE1C3
DMSE1C3	DN	PMID19364658C33
DMSE1C3	MI	TTTU902
DMSE1C3	MN	Checkpoint kinase-1 (CHK1)
DMSE1C3	MT	DTT
DMSE1C3	MA	Inhibitor
DMSE1C3	RN	Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2). Bioorg Med Chem. 2009 May 1;17(9):3342-51.
DMSE1C3	RU	https://pubmed.ncbi.nlm.nih.gov/19364658

DMSE1C3	DI	DMSE1C3
DMSE1C3	DN	PMID19364658C33
DMSE1C3	MI	TTYVI76
DMSE1C3	MN	Fungal Protein kinase A (Fung ypkA)
DMSE1C3	MT	DTT
DMSE1C3	MA	Inhibitor
DMSE1C3	RN	Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2). Bioorg Med Chem. 2009 May 1;17(9):3342-51.
DMSE1C3	RU	https://pubmed.ncbi.nlm.nih.gov/19364658

DMSE1C3	DI	DMSE1C3
DMSE1C3	DN	PMID19364658C33
DMSE1C3	MI	TTMUG9D
DMSE1C3	MN	MAPK-activated protein kinase 2 (MAPKAPK2)
DMSE1C3	MT	DTT
DMSE1C3	MA	Inhibitor
DMSE1C3	RN	Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2). Bioorg Med Chem. 2009 May 1;17(9):3342-51.
DMSE1C3	RU	https://pubmed.ncbi.nlm.nih.gov/19364658

DMSE1C3	DI	DMSE1C3
DMSE1C3	DN	PMID19364658C33
DMSE1C3	MI	TTZN7RP
DMSE1C3	MN	Rho-associated protein kinase 1 (ROCK1)
DMSE1C3	MT	DTT
DMSE1C3	MA	Inhibitor
DMSE1C3	RN	Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2). Bioorg Med Chem. 2009 May 1;17(9):3342-51.
DMSE1C3	RU	https://pubmed.ncbi.nlm.nih.gov/19364658

DMSE1C3	DI	DMSE1C3
DMSE1C3	DN	PMID19364658C33
DMSE1C3	MI	TTIXKA4
DMSE1C3	MN	Ribosomal protein S6 kinase alpha-1 (RSK1)
DMSE1C3	MT	DTT
DMSE1C3	MA	Inhibitor
DMSE1C3	RN	Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2). Bioorg Med Chem. 2009 May 1;17(9):3342-51.
DMSE1C3	RU	https://pubmed.ncbi.nlm.nih.gov/19364658

DMPXEIQ	DI	DMPXEIQ
DMPXEIQ	DN	PMID19433355C11q
DMPXEIQ	MI	TTVBPDM
DMPXEIQ	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMPXEIQ	MT	DTT
DMPXEIQ	MA	Modulator (allosteric modulator)
DMPXEIQ	RN	Tricyclic thienopyridine-pyrimidones/thienopyrimidine-pyrimidones as orally efficacious mGluR1 antagonists for neuropathic pain. Bioorg Med Chem Lett. 2009 Jun 15;19(12):3199-203.
DMPXEIQ	RU	https://pubmed.ncbi.nlm.nih.gov/19433355

DMBU0XJ	DI	DMBU0XJ
DMBU0XJ	DN	PMID19433355C11s
DMBU0XJ	MI	TTVBPDM
DMBU0XJ	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMBU0XJ	MT	DTT
DMBU0XJ	MA	Modulator (allosteric modulator)
DMBU0XJ	RN	Tricyclic thienopyridine-pyrimidones/thienopyrimidine-pyrimidones as orally efficacious mGluR1 antagonists for neuropathic pain. Bioorg Med Chem Lett. 2009 Jun 15;19(12):3199-203.
DMBU0XJ	RU	https://pubmed.ncbi.nlm.nih.gov/19433355

DMBU9E4	DI	DMBU9E4
DMBU9E4	DN	PMID19456099C13
DMBU9E4	MI	TTFQEO5
DMBU9E4	MN	Squalene synthetase (FDFT1)
DMBU9E4	MT	DTT
DMBU9E4	MA	Inhibitor
DMBU9E4	RN	Inhibition of staphyloxanthin virulence factor biosynthesis in Staphylococcus aureus: in vitro, in vivo, and crystallographic results. J Med Chem. 2009 Jul 9;52(13):3869-80.
DMBU9E4	RU	https://pubmed.ncbi.nlm.nih.gov/19456099

DMPZMS0	DI	DMPZMS0
DMPZMS0	DN	PMID19456099C15
DMPZMS0	MI	TTFQEO5
DMPZMS0	MN	Squalene synthetase (FDFT1)
DMPZMS0	MT	DTT
DMPZMS0	MA	Inhibitor
DMPZMS0	RN	Inhibition of staphyloxanthin virulence factor biosynthesis in Staphylococcus aureus: in vitro, in vivo, and crystallographic results. J Med Chem. 2009 Jul 9;52(13):3869-80.
DMPZMS0	RU	https://pubmed.ncbi.nlm.nih.gov/19456099

DMTRL0X	DI	DMTRL0X
DMTRL0X	DN	PMID19502059C25d
DMTRL0X	MI	TTPADOQ
DMTRL0X	MN	HMG-CoA reductase (HMGCR)
DMTRL0X	MT	DTT
DMTRL0X	MA	Inhibitor
DMTRL0X	RN	Application of a 3,3-diphenylpentane skeleton as a multi-template for creation of HMG-CoA reductase inhibitors. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4228-31.
DMTRL0X	RU	https://pubmed.ncbi.nlm.nih.gov/19502059

DMK5JB8	DI	DMK5JB8
DMK5JB8	DN	PMID19524438C6o
DMK5JB8	MI	TT8WFXV
DMK5JB8	MN	Hydroxycarboxylic acid receptor 3 (HCAR3)
DMK5JB8	MT	DTT
DMK5JB8	MA	Agonist
DMK5JB8	RN	5-N,N-Disubstituted 5-aminopyrazole-3-carboxylic acids are highly potent agonists of GPR109b. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4207-9.
DMK5JB8	RU	https://pubmed.ncbi.nlm.nih.gov/19524438

DMRWM24	DI	DMRWM24
DMRWM24	DN	PMID19632837C17f
DMRWM24	MI	TTIZQFJ
DMRWM24	MN	Histone-arginine methyltransferase CARM1 (CARM1)
DMRWM24	MT	DTT
DMRWM24	MA	Inhibitor
DMRWM24	RN	Benzo[d]imidazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1)--Hit to Lead studies. Bioorg Med Chem Lett. 2009 Sep 1;19(17):5063-6.
DMRWM24	RU	https://pubmed.ncbi.nlm.nih.gov/19632837

DMTX0ZJ	DI	DMTX0ZJ
DMTX0ZJ	DN	PMID19743866C51
DMTX0ZJ	MI	TTA0P7K
DMTX0ZJ	MN	Complement factor B (CFB)
DMTX0ZJ	MT	DTT
DMTX0ZJ	MA	Inhibitor
DMTX0ZJ	RN	Structure-activity relationships for substrate-based inhibitors of human complement factor B. J Med Chem. 2009 Oct 8;52(19):6042-52.
DMTX0ZJ	RU	https://pubmed.ncbi.nlm.nih.gov/19743866

DMCVJK9	DI	DMCVJK9
DMCVJK9	DN	PMID19788238C66
DMCVJK9	MI	TTLFZVU
DMCVJK9	MN	Ephrin type-A receptor 1 (EPHA1)
DMCVJK9	MT	DTT
DMCVJK9	MA	Inhibitor
DMCVJK9	RN	Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem. 2009 Oct 22;52(20):6433-46.
DMCVJK9	RU	https://pubmed.ncbi.nlm.nih.gov/19788238

DMCVJK9	DI	DMCVJK9
DMCVJK9	DN	PMID19788238C66
DMCVJK9	MI	TTRJB2G
DMCVJK9	MN	Ephrin type-A receptor 2 (EPHA2)
DMCVJK9	MT	DTT
DMCVJK9	MA	Inhibitor
DMCVJK9	RN	Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem. 2009 Oct 22;52(20):6433-46.
DMCVJK9	RU	https://pubmed.ncbi.nlm.nih.gov/19788238

DMCVJK9	DI	DMCVJK9
DMCVJK9	DN	PMID19788238C66
DMCVJK9	MI	TTHS2LR
DMCVJK9	MN	Ephrin type-A receptor 3 (EPHA3)
DMCVJK9	MT	DTT
DMCVJK9	MA	Inhibitor
DMCVJK9	RN	Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem. 2009 Oct 22;52(20):6433-46.
DMCVJK9	RU	https://pubmed.ncbi.nlm.nih.gov/19788238

DMCVJK9	DI	DMCVJK9
DMCVJK9	DN	PMID19788238C66
DMCVJK9	MI	TTG84D3
DMCVJK9	MN	Ephrin type-A receptor 4 (EPHA4)
DMCVJK9	MT	DTT
DMCVJK9	MA	Inhibitor
DMCVJK9	RN	Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem. 2009 Oct 22;52(20):6433-46.
DMCVJK9	RU	https://pubmed.ncbi.nlm.nih.gov/19788238

DMCVJK9	DI	DMCVJK9
DMCVJK9	DN	PMID19788238C66
DMCVJK9	MI	TTV9KOD
DMCVJK9	MN	Ephrin type-A receptor 5 (EPHA5)
DMCVJK9	MT	DTT
DMCVJK9	MA	Inhibitor
DMCVJK9	RN	Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem. 2009 Oct 22;52(20):6433-46.
DMCVJK9	RU	https://pubmed.ncbi.nlm.nih.gov/19788238

DMCVJK9	DI	DMCVJK9
DMCVJK9	DN	PMID19788238C66
DMCVJK9	MI	TTAHTVG
DMCVJK9	MN	Ephrin type-A receptor 7 (EPHA7)
DMCVJK9	MT	DTT
DMCVJK9	MA	Inhibitor
DMCVJK9	RN	Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem. 2009 Oct 22;52(20):6433-46.
DMCVJK9	RU	https://pubmed.ncbi.nlm.nih.gov/19788238

DMCVJK9	DI	DMCVJK9
DMCVJK9	DN	PMID19788238C66
DMCVJK9	MI	TTHZ2LW
DMCVJK9	MN	Ephrin type-A receptor 8 (EPHA8)
DMCVJK9	MT	DTT
DMCVJK9	MA	Inhibitor
DMCVJK9	RN	Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem. 2009 Oct 22;52(20):6433-46.
DMCVJK9	RU	https://pubmed.ncbi.nlm.nih.gov/19788238

DMCVJK9	DI	DMCVJK9
DMCVJK9	DN	PMID19788238C66
DMCVJK9	MI	TT8MDAC
DMCVJK9	MN	Ephrin type-B receptor 1 (EPHB1)
DMCVJK9	MT	DTT
DMCVJK9	MA	Inhibitor
DMCVJK9	RN	Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem. 2009 Oct 22;52(20):6433-46.
DMCVJK9	RU	https://pubmed.ncbi.nlm.nih.gov/19788238

DMCVJK9	DI	DMCVJK9
DMCVJK9	DN	PMID19788238C66
DMCVJK9	MI	TTKPV6O
DMCVJK9	MN	Ephrin type-B receptor 2 (EPHB2)
DMCVJK9	MT	DTT
DMCVJK9	MA	Inhibitor
DMCVJK9	RN	Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem. 2009 Oct 22;52(20):6433-46.
DMCVJK9	RU	https://pubmed.ncbi.nlm.nih.gov/19788238

DMCVJK9	DI	DMCVJK9
DMCVJK9	DN	PMID19788238C66
DMCVJK9	MI	TT5LM7U
DMCVJK9	MN	Ephrin type-B receptor 3 (EPHB3)
DMCVJK9	MT	DTT
DMCVJK9	MA	Inhibitor
DMCVJK9	RN	Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem. 2009 Oct 22;52(20):6433-46.
DMCVJK9	RU	https://pubmed.ncbi.nlm.nih.gov/19788238

DMCVJK9	DI	DMCVJK9
DMCVJK9	DN	PMID19788238C66
DMCVJK9	MI	TTI4ZX2
DMCVJK9	MN	Ephrin type-B receptor 4 (EPHB4)
DMCVJK9	MT	DTT
DMCVJK9	MA	Inhibitor
DMCVJK9	RN	Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem. 2009 Oct 22;52(20):6433-46.
DMCVJK9	RU	https://pubmed.ncbi.nlm.nih.gov/19788238

DMQXK4B	DI	DMQXK4B
DMQXK4B	DN	PMID19800804C12
DMQXK4B	MI	TTE2YJR
DMQXK4B	MN	Lysophosphatidate-3 receptor (LPAR3)
DMQXK4B	MT	DTT
DMQXK4B	MA	Antagonist
DMQXK4B	RN	Structure-based drug design identifies novel LPA3 antagonists. Bioorg Med Chem. 2009 Nov 1;17(21):7457-64.
DMQXK4B	RU	https://pubmed.ncbi.nlm.nih.gov/19800804

DMIECOF	DI	DMIECOF
DMIECOF	DN	PMID19831390C14
DMIECOF	MI	TTWL9TY
DMIECOF	MN	LIM domain kinase-1 (LIMK-1)
DMIECOF	MT	DTT
DMIECOF	MA	Inhibitor
DMIECOF	RN	Novel class of LIM-kinase 2 inhibitors for the treatment of ocular hypertension and associated glaucoma. J Med Chem. 2009 Nov 12;52(21):6515-8.
DMIECOF	RU	https://pubmed.ncbi.nlm.nih.gov/19831390

DMIECOF	DI	DMIECOF
DMIECOF	DN	PMID19831390C14
DMIECOF	MI	TTASMD8
DMIECOF	MN	LIM domain kinase-2 (LIMK-2)
DMIECOF	MT	DTT
DMIECOF	MA	Inhibitor
DMIECOF	RN	Novel class of LIM-kinase 2 inhibitors for the treatment of ocular hypertension and associated glaucoma. J Med Chem. 2009 Nov 12;52(21):6515-8.
DMIECOF	RU	https://pubmed.ncbi.nlm.nih.gov/19831390

DM8T6VG	DI	DM8T6VG
DM8T6VG	DN	PMID19831390C22m
DM8T6VG	MI	TTASMD8
DM8T6VG	MN	LIM domain kinase-2 (LIMK-2)
DM8T6VG	MT	DTT
DM8T6VG	MA	Inhibitor
DM8T6VG	RN	Novel class of LIM-kinase 2 inhibitors for the treatment of ocular hypertension and associated glaucoma. J Med Chem. 2009 Nov 12;52(21):6515-8.
DM8T6VG	RU	https://pubmed.ncbi.nlm.nih.gov/19831390

DMEGPBS	DI	DMEGPBS
DMEGPBS	DN	PMID19854648C27
DMEGPBS	MI	TTRUJBV
DMEGPBS	MN	Eukaryotic translation initiation factor 2-alpha kinase 1 (EIF2AK1)
DMEGPBS	MT	DTT
DMEGPBS	MA	Inhibitor
DMEGPBS	RN	Discovery of the first known small-molecule inhibitors of heme-regulated eukaryotic initiation factor 2alpha (HRI) kinase. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6548-51.
DMEGPBS	RU	https://pubmed.ncbi.nlm.nih.gov/19854648

DMBTV20	DI	DMBTV20
DMBTV20	DN	PMID19899765C22
DMBTV20	MI	TTQ9RYT
DMBTV20	MN	Endothelin-converting enzyme 1 (ECE1)
DMBTV20	MT	DTT
DMBTV20	MA	Inhibitor
DMBTV20	RN	Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors. J Med Chem. 2010 Jan 14;53(1):208-20.
DMBTV20	RU	https://pubmed.ncbi.nlm.nih.gov/19899765

DMI3PCZ	DI	DMI3PCZ
DMI3PCZ	DN	PMID1992138C8b
DMI3PCZ	MI	TTPADOQ
DMI3PCZ	MN	HMG-CoA reductase (HMGCR)
DMI3PCZ	MT	DTT
DMI3PCZ	MA	Inhibitor
DMI3PCZ	RN	Inhibitors of cholesterol biosynthesis. 4. trans-6-[2-(substituted-quinolinyl)ethenyl/ethyl]tetrahydro-4-hydroxy-2 H-pyran-2-ones, a novel series of HMG-CoA reductase inhibitors. J Med Chem. 1991 Jan;34(1):367-73.
DMI3PCZ	RU	https://pubmed.ncbi.nlm.nih.gov/1992138

DM2X1NY	DI	DM2X1NY
DM2X1NY	DN	PMID1992149C13
DM2X1NY	MI	TTPADOQ
DM2X1NY	MN	HMG-CoA reductase (HMGCR)
DM2X1NY	MT	DTT
DM2X1NY	MA	Inhibitor
DM2X1NY	RN	Relationship between tissue selectivity and lipophilicity for inhibitors of HMG-CoA reductase. J Med Chem. 1991 Jan;34(1):463-6.
DM2X1NY	RU	https://pubmed.ncbi.nlm.nih.gov/1992149

DM9RENG	DI	DM9RENG
DM9RENG	DN	PMID1992149C9
DM9RENG	MI	TTPADOQ
DM9RENG	MN	HMG-CoA reductase (HMGCR)
DM9RENG	MT	DTT
DM9RENG	MA	Inhibitor
DM9RENG	RN	Inhibitors of cholesterol biosynthesis. 6. trans-6-[2-(2-N-heteroaryl-3,5-disubstituted- pyrazol-4-yl)ethyl/ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-ones. J Med Chem. 1992 May 29;35(11):2095-103.
DM9RENG	RU	https://pubmed.ncbi.nlm.nih.gov/1597859

DM3DCR9	DI	DM3DCR9
DM3DCR9	DN	PMID19931453C16m
DM3DCR9	MI	TTHS256
DM3DCR9	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM3DCR9	MT	DTT
DM3DCR9	MA	Modulator (allosteric modulator)
DM3DCR9	RN	Piperidyl amides as novel, potent and orally active mGlu5 receptor antagonists with anxiolytic-like activity. Bioorg Med Chem Lett. 2010 Jan 1;20(1):184-8.
DM3DCR9	RU	https://pubmed.ncbi.nlm.nih.gov/19931453

DMDYZE5	DI	DMDYZE5
DMDYZE5	DN	PMID19954973C4
DMDYZE5	MI	TT4UJX5
DMDYZE5	MN	Carboxypeptidase B1 (CPB1)
DMDYZE5	MT	DTT
DMDYZE5	MA	Inhibitor
DMDYZE5	RN	Oxygenated analogues of UK-396082 as inhibitors of activated thrombin activatable fibrinolysis inhibitor. Bioorg Med Chem Lett. 2010 Jan 1;20(1):92-6.
DMDYZE5	RU	https://pubmed.ncbi.nlm.nih.gov/19954973

DMDYZE5	DI	DMDYZE5
DMDYZE5	DN	PMID19954973C4
DMDYZE5	MI	TTP18AY
DMDYZE5	MN	Carboxypeptidase B2 (CPB2)
DMDYZE5	MT	DTT
DMDYZE5	MA	Inhibitor
DMDYZE5	RN	Oxygenated analogues of UK-396082 as inhibitors of activated thrombin activatable fibrinolysis inhibitor. Bioorg Med Chem Lett. 2010 Jan 1;20(1):92-6.
DMDYZE5	RU	https://pubmed.ncbi.nlm.nih.gov/19954973

DMMESBW	DI	DMMESBW
DMMESBW	DN	PMID20005102C1
DMMESBW	MI	TTYVI76
DMMESBW	MN	Fungal Protein kinase A (Fung ypkA)
DMMESBW	MT	DTT
DMMESBW	MA	Inhibitor
DMMESBW	RN	2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles. Bioorg Med Chem Lett. 2010 Jan 15;20(2):679-83.
DMMESBW	RU	https://pubmed.ncbi.nlm.nih.gov/20005102

DMMESBW	DI	DMMESBW
DMMESBW	DN	PMID20005102C1
DMMESBW	MI	TTFN95D
DMMESBW	MN	PAK-1 protein kinase (PAK1)
DMMESBW	MT	DTT
DMMESBW	MA	Inhibitor
DMMESBW	RN	2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles. Bioorg Med Chem Lett. 2010 Jan 15;20(2):679-83.
DMMESBW	RU	https://pubmed.ncbi.nlm.nih.gov/20005102

DMMESBW	DI	DMMESBW
DMMESBW	DN	PMID20005102C1
DMMESBW	MI	TT9QBI6
DMMESBW	MN	Phosphoinositide dependent protein kinase-1 (PDPK1)
DMMESBW	MT	DTT
DMMESBW	MA	Inhibitor
DMMESBW	RN	2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles. Bioorg Med Chem Lett. 2010 Jan 15;20(2):679-83.
DMMESBW	RU	https://pubmed.ncbi.nlm.nih.gov/20005102

DMMESBW	DI	DMMESBW
DMMESBW	DN	PMID20005102C1
DMMESBW	MI	TTWTSCV
DMMESBW	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DMMESBW	MT	DTT
DMMESBW	MA	Inhibitor
DMMESBW	RN	2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles. Bioorg Med Chem Lett. 2010 Jan 15;20(2):679-83.
DMMESBW	RU	https://pubmed.ncbi.nlm.nih.gov/20005102

DMMESBW	DI	DMMESBW
DMMESBW	DN	PMID20005102C1
DMMESBW	MI	TTH24WI
DMMESBW	MN	RAC-beta serine/threonine-protein kinase (AKT2)
DMMESBW	MT	DTT
DMMESBW	MA	Inhibitor
DMMESBW	RN	2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles. Bioorg Med Chem Lett. 2010 Jan 15;20(2):679-83.
DMMESBW	RU	https://pubmed.ncbi.nlm.nih.gov/20005102

DMMESBW	DI	DMMESBW
DMMESBW	DN	PMID20005102C1
DMMESBW	MI	TTAZ05C
DMMESBW	MN	RAC-gamma serine/threonine-protein kinase (AKT3)
DMMESBW	MT	DTT
DMMESBW	MA	Inhibitor
DMMESBW	RN	2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles. Bioorg Med Chem Lett. 2010 Jan 15;20(2):679-83.
DMMESBW	RU	https://pubmed.ncbi.nlm.nih.gov/20005102

DMMESBW	DI	DMMESBW
DMMESBW	DN	PMID20005102C1
DMMESBW	MI	TTG0U4H
DMMESBW	MN	Ribosomal protein S6 kinase beta-1 (S6K1)
DMMESBW	MT	DTT
DMMESBW	MA	Inhibitor
DMMESBW	RN	2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles. Bioorg Med Chem Lett. 2010 Jan 15;20(2):679-83.
DMMESBW	RU	https://pubmed.ncbi.nlm.nih.gov/20005102

DMV8ZFA	DI	DMV8ZFA
DMV8ZFA	DN	PMID20080612C1
DMV8ZFA	MI	TT1ZAVI
DMV8ZFA	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DMV8ZFA	MT	DTT
DMV8ZFA	MA	Modulator (allosteric modulator)
DMV8ZFA	RN	Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor. Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2307-12.
DMV8ZFA	RU	https://pubmed.ncbi.nlm.nih.gov/20080612

DMM49JO	DI	DMM49JO
DMM49JO	DN	PMID20121197C57
DMM49JO	MI	TTFEZ5Q
DMM49JO	MN	Coagulation factor IX (F9)
DMM49JO	MT	DTT
DMM49JO	MA	Inhibitor
DMM49JO	RN	Structure based drug design: development of potent and selective factor IXa (FIXa) inhibitors. J Med Chem. 2010 Feb 25;53(4):1473-82.
DMM49JO	RU	https://pubmed.ncbi.nlm.nih.gov/20121197

DM8NGEQ	DI	DM8NGEQ
DM8NGEQ	DN	PMID20167483C22e
DM8NGEQ	MI	TTHYDUM
DM8NGEQ	MN	Bombesin receptor (BS)
DM8NGEQ	MT	DTT
DM8NGEQ	MA	Agonist
DM8NGEQ	RN	Discovery of substituted biphenyl imidazoles as potent, bioavailable bombesin receptor subtype-3 agonists. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1913-7.
DM8NGEQ	RU	https://pubmed.ncbi.nlm.nih.gov/20167483

DMKAZ1O	DI	DMKAZ1O
DMKAZ1O	DN	PMID20299227C12
DMKAZ1O	MI	TTFQEO5
DMKAZ1O	MN	Squalene synthetase (FDFT1)
DMKAZ1O	MT	DTT
DMKAZ1O	MA	Inhibitor
DMKAZ1O	RN	Synthesis and preliminary pharmacological characterisation of a new class of nitrogen-containing bisphosphonates (N-BPs). Bioorg Med Chem. 2010 Apr 1;18(7):2428-38.
DMKAZ1O	RU	https://pubmed.ncbi.nlm.nih.gov/20299227

DM9H6LZ	DI	DM9H6LZ
DM9H6LZ	DN	PMID20299227C20
DM9H6LZ	MI	TTFQEO5
DM9H6LZ	MN	Squalene synthetase (FDFT1)
DM9H6LZ	MT	DTT
DM9H6LZ	MA	Inhibitor
DM9H6LZ	RN	Synthesis and preliminary pharmacological characterisation of a new class of nitrogen-containing bisphosphonates (N-BPs). Bioorg Med Chem. 2010 Apr 1;18(7):2428-38.
DM9H6LZ	RU	https://pubmed.ncbi.nlm.nih.gov/20299227

DMLKFTE	DI	DMLKFTE
DMLKFTE	DN	PMID20346665C24
DMLKFTE	MI	TTVBPDM
DMLKFTE	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMLKFTE	MT	DTT
DMLKFTE	MA	Modulator (allosteric modulator)
DMLKFTE	RN	A-ring modifications on the triazafluorenone core structure and their mGluR1 antagonist properties. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2474-7.
DMLKFTE	RU	https://pubmed.ncbi.nlm.nih.gov/20346665

DMDKW6G	DI	DMDKW6G
DMDKW6G	DN	PMID20346665C27
DMDKW6G	MI	TTVBPDM
DMDKW6G	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMDKW6G	MT	DTT
DMDKW6G	MA	Modulator (allosteric modulator)
DMDKW6G	RN	A-ring modifications on the triazafluorenone core structure and their mGluR1 antagonist properties. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2474-7.
DMDKW6G	RU	https://pubmed.ncbi.nlm.nih.gov/20346665

DMCAXNU	DI	DMCAXNU
DMCAXNU	DN	PMID20363624C(+)17a
DMCAXNU	MI	TTWNV8U
DMCAXNU	MN	Nicotinic acid receptor (HCAR2)
DMCAXNU	MT	DTT
DMCAXNU	MA	Agonist
DMCAXNU	RN	Potent tricyclic pyrazole tetrazole agonists of the nicotinic acid receptor (GPR109a). Bioorg Med Chem Lett. 2010 May 1;20(9):2797-800.
DMCAXNU	RU	https://pubmed.ncbi.nlm.nih.gov/20363624

DMA2Y74	DI	DMA2Y74
DMA2Y74	DN	PMID20409708C34
DMA2Y74	MI	TTXJ47W
DMA2Y74	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMA2Y74	MT	DTT
DMA2Y74	MA	Modulator (allosteric modulator)
DMA2Y74	RN	3-Aryl-5-phenoxymethyl-1,3-oxazolidin-2-ones as positive allosteric modulators of mGluR2 for the treatment of schizophrenia: Hit-to-lead efforts. Bioorg Med Chem Lett. 2010 May 15;20(10):3129-33.
DMA2Y74	RU	https://pubmed.ncbi.nlm.nih.gov/20409708

DMQFKBI	DI	DMQFKBI
DMQFKBI	DN	PMID20462760C22
DMQFKBI	MI	TTHOI91
DMQFKBI	MN	NIMA-related kinase 6 (NEK6)
DMQFKBI	MT	DTT
DMQFKBI	MA	Inhibitor
DMQFKBI	RN	Substituted 2H-isoquinolin-1-one as potent Rho-Kinase inhibitors. Part 1: Hit-to-lead account. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3235-9.
DMQFKBI	RU	https://pubmed.ncbi.nlm.nih.gov/20462760

DMQFKBI	DI	DMQFKBI
DMQFKBI	DN	PMID20462760C22
DMQFKBI	MI	TTJ5SWP
DMQFKBI	MN	NIMA-related kinase 7 (NEK7)
DMQFKBI	MT	DTT
DMQFKBI	MA	Inhibitor
DMQFKBI	RN	Substituted 2H-isoquinolin-1-one as potent Rho-Kinase inhibitors. Part 1: Hit-to-lead account. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3235-9.
DMQFKBI	RU	https://pubmed.ncbi.nlm.nih.gov/20462760

DMQFKBI	DI	DMQFKBI
DMQFKBI	DN	PMID20462760C22
DMQFKBI	MI	TTZN7RP
DMQFKBI	MN	Rho-associated protein kinase 1 (ROCK1)
DMQFKBI	MT	DTT
DMQFKBI	MA	Inhibitor
DMQFKBI	RN	Substituted 2H-isoquinolin-1-one as potent Rho-Kinase inhibitors. Part 1: Hit-to-lead account. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3235-9.
DMQFKBI	RU	https://pubmed.ncbi.nlm.nih.gov/20462760

DMQFKBI	DI	DMQFKBI
DMQFKBI	DN	PMID20462760C22
DMQFKBI	MI	TTGWKQJ
DMQFKBI	MN	Rho-associated protein kinase 2 (ROCK2)
DMQFKBI	MT	DTT
DMQFKBI	MA	Inhibitor
DMQFKBI	RN	Substituted 2H-isoquinolin-1-one as potent Rho-Kinase inhibitors. Part 1: Hit-to-lead account. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3235-9.
DMQFKBI	RU	https://pubmed.ncbi.nlm.nih.gov/20462760

DMBQAKO	DI	DMBQAKO
DMBQAKO	DN	PMID20471253C32
DMBQAKO	MI	TTDWFCQ
DMBQAKO	MN	Protein kinase G2 (PRKG2)
DMBQAKO	MT	DTT
DMBQAKO	MA	Inhibitor
DMBQAKO	RN	Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: part 3, aryl substituted pyrrolidines. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3746-9.
DMBQAKO	RU	https://pubmed.ncbi.nlm.nih.gov/20471253

DMBQAKO	DI	DMBQAKO
DMBQAKO	DN	PMID20471253C32
DMBQAKO	MI	TTTHO0M
DMBQAKO	MN	Protein kinase N2 (PKN2)
DMBQAKO	MT	DTT
DMBQAKO	MA	Inhibitor
DMBQAKO	RN	Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: part 3, aryl substituted pyrrolidines. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3746-9.
DMBQAKO	RU	https://pubmed.ncbi.nlm.nih.gov/20471253

DMBQAKO	DI	DMBQAKO
DMBQAKO	DN	PMID20471253C32
DMBQAKO	MI	TTGWKQJ
DMBQAKO	MN	Rho-associated protein kinase 2 (ROCK2)
DMBQAKO	MT	DTT
DMBQAKO	MA	Inhibitor
DMBQAKO	RN	Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: part 3, aryl substituted pyrrolidines. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3746-9.
DMBQAKO	RU	https://pubmed.ncbi.nlm.nih.gov/20471253

DMQ918T	DI	DMQ918T
DMQ918T	DN	PMID20483621C5g
DMQ918T	MI	TTPMQSO
DMQ918T	MN	ALK tyrosine kinase receptor (ALK)
DMQ918T	MT	DTT
DMQ918T	MA	Inhibitor
DMQ918T	RN	Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase. Bioorg Med Chem. 2010 Jun 15;18(12):4351-62.
DMQ918T	RU	https://pubmed.ncbi.nlm.nih.gov/20483621

DMQ918T	DI	DMQ918T
DMQ918T	DN	PMID20483621C5g
DMQ918T	MI	TTOHTCY
DMQ918T	MN	Doublecortin-like kinase 1 (DCLK1)
DMQ918T	MT	DTT
DMQ918T	MA	Inhibitor
DMQ918T	RN	Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase. Bioorg Med Chem. 2010 Jun 15;18(12):4351-62.
DMQ918T	RU	https://pubmed.ncbi.nlm.nih.gov/20483621

DML6OZR	DI	DML6OZR
DML6OZR	DN	PMID20483621C5m
DML6OZR	MI	TTPMQSO
DML6OZR	MN	ALK tyrosine kinase receptor (ALK)
DML6OZR	MT	DTT
DML6OZR	MA	Inhibitor
DML6OZR	RN	Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase. Bioorg Med Chem. 2010 Jun 15;18(12):4351-62.
DML6OZR	RU	https://pubmed.ncbi.nlm.nih.gov/20483621

DML6OZR	DI	DML6OZR
DML6OZR	DN	PMID20483621C5m
DML6OZR	MI	TT32VXH
DML6OZR	MN	BMP-2-inducible protein kinase (BMP2K)
DML6OZR	MT	DTT
DML6OZR	MA	Inhibitor
DML6OZR	RN	Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase. Bioorg Med Chem. 2010 Jun 15;18(12):4351-62.
DML6OZR	RU	https://pubmed.ncbi.nlm.nih.gov/20483621

DM2BUKP	DI	DM2BUKP
DM2BUKP	DN	PMID20483621C5n
DM2BUKP	MI	TTPMQSO
DM2BUKP	MN	ALK tyrosine kinase receptor (ALK)
DM2BUKP	MT	DTT
DM2BUKP	MA	Inhibitor
DM2BUKP	RN	Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase. Bioorg Med Chem. 2010 Jun 15;18(12):4351-62.
DM2BUKP	RU	https://pubmed.ncbi.nlm.nih.gov/20483621

DM2BUKP	DI	DM2BUKP
DM2BUKP	DN	PMID20483621C5n
DM2BUKP	MI	TTMYK4Z
DM2BUKP	MN	Doublecortin-like kinase 3 (DCLK3)
DM2BUKP	MT	DTT
DM2BUKP	MA	Inhibitor
DM2BUKP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2007).
DM2BUKP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2007

DM2BUKP	DI	DM2BUKP
DM2BUKP	DN	PMID20483621C5n
DM2BUKP	MI	TTE7RCU
DM2BUKP	MN	MAPK/ERK kinase kinase 3 (MAP3K3)
DM2BUKP	MT	DTT
DM2BUKP	MA	Inhibitor
DM2BUKP	RN	Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase. Bioorg Med Chem. 2010 Jun 15;18(12):4351-62.
DM2BUKP	RU	https://pubmed.ncbi.nlm.nih.gov/20483621

DMI30V7	DI	DMI30V7
DMI30V7	DN	PMID20527968-compound-6577871
DMI30V7	MI	TTRGHB2
DMI30V7	MN	SARS-CoV papain-like proteinase (PL-PRO)
DMI30V7	MT	DTT
DMI30V7	MA	Inhibitor
DMI30V7	RN	Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: design, synthesis, protein-ligand X-ray structure and biologic... J Med Chem. 2010 Jul 8;53(13):4968-79.
DMI30V7	RU	https://pubmed.ncbi.nlm.nih.gov/20527968

DMS21ZP	DI	DMS21ZP
DMS21ZP	DN	PMID20598884C8
DMS21ZP	MI	TTHS256
DMS21ZP	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMS21ZP	MT	DTT
DMS21ZP	MA	Modulator (allosteric modulator)
DMS21ZP	RN	3-Cyano-5-fluoro-N-arylbenzamides as negative allosteric modulators of mGlu(5): Identification of easily prepared tool compounds with CNS exposure ... Bioorg Med Chem Lett. 2010 Aug 1;20(15):4390-4.
DMS21ZP	RU	https://pubmed.ncbi.nlm.nih.gov/20598884

DMN2HXL	DI	DMN2HXL
DMN2HXL	DN	PMID20615702C8f
DMN2HXL	MI	TTWNV8U
DMN2HXL	MN	Nicotinic acid receptor (HCAR2)
DMN2HXL	MT	DTT
DMN2HXL	MA	Agonist
DMN2HXL	RN	GPR109a agonists. Part 2: pyrazole-acids as agonists of the human orphan G-protein coupled receptor GPR109a. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4472-4.
DMN2HXL	RU	https://pubmed.ncbi.nlm.nih.gov/20615702

DMFHS4V	DI	DMFHS4V
DMFHS4V	DN	PMID20638279C11
DMFHS4V	MI	TTICZ1O
DMFHS4V	MN	Metabotropic glutamate receptor 4 (mGluR4)
DMFHS4V	MT	DTT
DMFHS4V	MA	Modulator (allosteric modulator)
DMFHS4V	RN	An orally bioavailable positive allosteric modulator of the mGlu4 receptor with efficacy in an animal model of motor dysfunction. Bioorg Med Chem Lett. 2010 Aug 15;20(16):4901-5.
DMFHS4V	RU	https://pubmed.ncbi.nlm.nih.gov/20638279

DMKFJP2	DI	DMKFJP2
DMKFJP2	DN	PMID20638279C7
DMKFJP2	MI	TTICZ1O
DMKFJP2	MN	Metabotropic glutamate receptor 4 (mGluR4)
DMKFJP2	MT	DTT
DMKFJP2	MA	Modulator (allosteric modulator)
DMKFJP2	RN	An orally bioavailable positive allosteric modulator of the mGlu4 receptor with efficacy in an animal model of motor dysfunction. Bioorg Med Chem Lett. 2010 Aug 15;20(16):4901-5.
DMKFJP2	RU	https://pubmed.ncbi.nlm.nih.gov/20638279

DMWZK9U	DI	DMWZK9U
DMWZK9U	DN	PMID20684603C24dd
DMWZK9U	MI	TTDIGC1
DMWZK9U	MN	Dipeptidyl peptidase 4 (DPP-4)
DMWZK9U	MT	DTT
DMWZK9U	MA	Inhibitor
DMWZK9U	RN	Discovery of 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxamides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitors. J Med Chem. 2010 Aug 12;53(15):5620-8.
DMWZK9U	RU	https://pubmed.ncbi.nlm.nih.gov/20684603

DMWZK9U	DI	DMWZK9U
DMWZK9U	DN	PMID20684603C24dd
DMWZK9U	MI	TTJGLZF
DMWZK9U	MN	Dipeptidyl peptidase 8 (DPP-8)
DMWZK9U	MT	DTT
DMWZK9U	MA	Inhibitor
DMWZK9U	RN	Discovery of 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxamides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitors. J Med Chem. 2010 Aug 12;53(15):5620-8.
DMWZK9U	RU	https://pubmed.ncbi.nlm.nih.gov/20684603

DMWZK9U	DI	DMWZK9U
DMWZK9U	DN	PMID20684603C24dd
DMWZK9U	MI	TTNDUL7
DMWZK9U	MN	Dipeptidyl peptidase 9 (DPP-9)
DMWZK9U	MT	DTT
DMWZK9U	MA	Inhibitor
DMWZK9U	RN	Discovery of 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxamides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitors. J Med Chem. 2010 Aug 12;53(15):5620-8.
DMWZK9U	RU	https://pubmed.ncbi.nlm.nih.gov/20684603

DMVUEZI	DI	DMVUEZI
DMVUEZI	DN	PMID20684608C35
DMVUEZI	MI	TTML7FG
DMVUEZI	MN	Large tumor suppressor homolog 2 (LATS2)
DMVUEZI	MT	DTT
DMVUEZI	MA	Inhibitor
DMVUEZI	RN	Tetrahydroisoquinoline derivatives as highly selective and potent Rho kinase inhibitors. J Med Chem. 2010 Aug 12;53(15):5727-37.
DMVUEZI	RU	https://pubmed.ncbi.nlm.nih.gov/20684608

DMVUEZI	DI	DMVUEZI
DMVUEZI	DN	PMID20684608C35
DMVUEZI	MI	TT27XFN
DMVUEZI	MN	NDR1 protein kinase (STK38)
DMVUEZI	MT	DTT
DMVUEZI	MA	Inhibitor
DMVUEZI	RN	Tetrahydroisoquinoline derivatives as highly selective and potent Rho kinase inhibitors. J Med Chem. 2010 Aug 12;53(15):5727-37.
DMVUEZI	RU	https://pubmed.ncbi.nlm.nih.gov/20684608

DMVUEZI	DI	DMVUEZI
DMVUEZI	DN	PMID20684608C35
DMVUEZI	MI	TTZN7RP
DMVUEZI	MN	Rho-associated protein kinase 1 (ROCK1)
DMVUEZI	MT	DTT
DMVUEZI	MA	Inhibitor
DMVUEZI	RN	Tetrahydroisoquinoline derivatives as highly selective and potent Rho kinase inhibitors. J Med Chem. 2010 Aug 12;53(15):5727-37.
DMVUEZI	RU	https://pubmed.ncbi.nlm.nih.gov/20684608

DMVUEZI	DI	DMVUEZI
DMVUEZI	DN	PMID20684608C35
DMVUEZI	MI	TTGWKQJ
DMVUEZI	MN	Rho-associated protein kinase 2 (ROCK2)
DMVUEZI	MT	DTT
DMVUEZI	MA	Inhibitor
DMVUEZI	RN	Tetrahydroisoquinoline derivatives as highly selective and potent Rho kinase inhibitors. J Med Chem. 2010 Aug 12;53(15):5727-37.
DMVUEZI	RU	https://pubmed.ncbi.nlm.nih.gov/20684608

DMKVONZ	DI	DMKVONZ
DMKVONZ	DN	PMID20690647C4b
DMKVONZ	MI	TTG5QB7
DMKVONZ	MN	Calpain-2 (CAPN2)
DMKVONZ	MT	DTT
DMKVONZ	MA	Inhibitor
DMKVONZ	RN	Peptidyl alpha-ketoamides with nucleobases, methylpiperazine, and dimethylaminoalkyl substituents as calpain inhibitors. J Med Chem. 2010 Sep 9;53(17):6326-36.
DMKVONZ	RU	https://pubmed.ncbi.nlm.nih.gov/20690647

DMRWZX6	DI	DMRWZX6
DMRWZX6	DN	PMID20690647C5a
DMRWZX6	MI	TTG5QB7
DMRWZX6	MN	Calpain-2 (CAPN2)
DMRWZX6	MT	DTT
DMRWZX6	MA	Inhibitor
DMRWZX6	RN	Peptidyl alpha-ketoamides with nucleobases, methylpiperazine, and dimethylaminoalkyl substituents as calpain inhibitors. J Med Chem. 2010 Sep 9;53(17):6326-36.
DMRWZX6	RU	https://pubmed.ncbi.nlm.nih.gov/20690647

DM0W6C9	DI	DM0W6C9
DM0W6C9	DN	PMID20809633C29b
DM0W6C9	MI	TTHS256
DM0W6C9	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM0W6C9	MT	DTT
DM0W6C9	MA	Modulator (allosteric modulator)
DM0W6C9	RN	Design, synthesis, and structure-activity relationships of novel bicyclic azole-amines as negative allosteric modulators of metabotropic glutamate receptor 5. J Med Chem. 2010 Oct 14;53(19):7107-18.
DM0W6C9	RU	https://pubmed.ncbi.nlm.nih.gov/20809633

DMNEB6J	DI	DMNEB6J
DMNEB6J	DN	PMID20855207C25
DMNEB6J	MI	TT9RTBL
DMNEB6J	MN	Aurora B messenger RNA (AURKB mRNA)
DMNEB6J	MT	DTT
DMNEB6J	MA	Inhibitor
DMNEB6J	RN	Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6739-43.
DMNEB6J	RU	https://pubmed.ncbi.nlm.nih.gov/20855207

DMNEB6J	DI	DMNEB6J
DMNEB6J	DN	PMID20855207C25
DMNEB6J	MI	TTLYXIT
DMNEB6J	MN	Aurora kinase C (AURKC)
DMNEB6J	MT	DTT
DMNEB6J	MA	Inhibitor
DMNEB6J	RN	Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6739-43.
DMNEB6J	RU	https://pubmed.ncbi.nlm.nih.gov/20855207

DMNEB6J	DI	DMNEB6J
DMNEB6J	DN	PMID20855207C25
DMNEB6J	MI	TTTU902
DMNEB6J	MN	Checkpoint kinase-1 (CHK1)
DMNEB6J	MT	DTT
DMNEB6J	MA	Inhibitor
DMNEB6J	RN	Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6739-43.
DMNEB6J	RU	https://pubmed.ncbi.nlm.nih.gov/20855207

DMVHR3Z	DI	DMVHR3Z
DMVHR3Z	DN	PMID20873740C18
DMVHR3Z	MI	TTSMTDI
DMVHR3Z	MN	CDC7-related kinase (CDC7)
DMVHR3Z	MT	DTT
DMVHR3Z	MA	Inhibitor
DMVHR3Z	RN	Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding. J Med Chem. 2010 Oct 28;53(20):7296-315.
DMVHR3Z	RU	https://pubmed.ncbi.nlm.nih.gov/20873740

DMVHR3Z	DI	DMVHR3Z
DMVHR3Z	DN	PMID20873740C18
DMVHR3Z	MI	TT1LVF2
DMVHR3Z	MN	Cyclin-dependent kinase 9 (CDK9)
DMVHR3Z	MT	DTT
DMVHR3Z	MA	Inhibitor
DMVHR3Z	RN	Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding. J Med Chem. 2010 Oct 28;53(20):7296-315.
DMVHR3Z	RU	https://pubmed.ncbi.nlm.nih.gov/20873740

DMVHR3Z	DI	DMVHR3Z
DMVHR3Z	DN	PMID20873740C18
DMVHR3Z	MI	TTQY9DH
DMVHR3Z	MN	TAO kinase 1 (TAOK1)
DMVHR3Z	MT	DTT
DMVHR3Z	MA	Inhibitor
DMVHR3Z	RN	Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding. J Med Chem. 2010 Oct 28;53(20):7296-315.
DMVHR3Z	RU	https://pubmed.ncbi.nlm.nih.gov/20873740

DMUGWO6	DI	DMUGWO6
DMUGWO6	DN	PMID20936789C31
DMUGWO6	MI	TTO5QT2
DMUGWO6	MN	NIMA-related kinase 1 (NEK1)
DMUGWO6	MT	DTT
DMUGWO6	MA	Inhibitor
DMUGWO6	RN	Aminopyrazine inhibitors binding to an unusual inactive conformation of the mitotic kinase Nek2: SAR and structural characterization. J Med Chem. 2010 Nov 11;53(21):7682-98.
DMUGWO6	RU	https://pubmed.ncbi.nlm.nih.gov/20936789

DMUGWO6	DI	DMUGWO6
DMUGWO6	DN	PMID20936789C31
DMUGWO6	MI	TT3VZ24
DMUGWO6	MN	NIMA-related kinase 2 (NEK2)
DMUGWO6	MT	DTT
DMUGWO6	MA	Inhibitor
DMUGWO6	RN	Aminopyrazine inhibitors binding to an unusual inactive conformation of the mitotic kinase Nek2: SAR and structural characterization. J Med Chem. 2010 Nov 11;53(21):7682-98.
DMUGWO6	RU	https://pubmed.ncbi.nlm.nih.gov/20936789

DM02YSE	DI	DM02YSE
DM02YSE	DN	PMID20947351C16
DM02YSE	MI	TT5ZKDI
DM02YSE	MN	Histone deacetylase 6 (HDAC6)
DM02YSE	MT	DTT
DM02YSE	MA	Inhibitor
DM02YSE	RN	Inhibitors selective for HDAC6 in enzymes and cells. Bioorg Med Chem Lett. 2010 Dec 1;20(23):7067-70.
DM02YSE	RU	https://pubmed.ncbi.nlm.nih.gov/20947351

DMVPW1G	DI	DMVPW1G
DMVPW1G	DN	PMID21123062C27
DMVPW1G	MI	TTNM4ZH
DMVPW1G	MN	NDR2 protein kinase (STK38L)
DMVPW1G	MT	DTT
DMVPW1G	MA	Inhibitor
DMVPW1G	RN	Fused bicyclic derivatives of 2,4-diaminopyrimidine as c-Met inhibitors. Bioorg Med Chem Lett. 2011 Jan 1;21(1):164-7.
DMVPW1G	RU	https://pubmed.ncbi.nlm.nih.gov/21123062

DMVPW1G	DI	DMVPW1G
DMVPW1G	DN	PMID21123062C27
DMVPW1G	MI	TTNDSF4
DMVPW1G	MN	Proto-oncogene c-Met (MET)
DMVPW1G	MT	DTT
DMVPW1G	MA	Inhibitor
DMVPW1G	RN	Fused bicyclic derivatives of 2,4-diaminopyrimidine as c-Met inhibitors. Bioorg Med Chem Lett. 2011 Jan 1;21(1):164-7.
DMVPW1G	RU	https://pubmed.ncbi.nlm.nih.gov/21123062

DMVPW1G	DI	DMVPW1G
DMVPW1G	DN	PMID21123062C27
DMVPW1G	MI	TTFGN19
DMVPW1G	MN	TGF-beta-stimulated factor 1 (STK16)
DMVPW1G	MT	DTT
DMVPW1G	MA	Inhibitor
DMVPW1G	RN	Fused bicyclic derivatives of 2,4-diaminopyrimidine as c-Met inhibitors. Bioorg Med Chem Lett. 2011 Jan 1;21(1):164-7.
DMVPW1G	RU	https://pubmed.ncbi.nlm.nih.gov/21123062

DM7I341	DI	DM7I341
DM7I341	DN	PMID21155570C14
DM7I341	MI	TTXJ47W
DM7I341	MN	Metabotropic glutamate receptor 2 (mGluR2)
DM7I341	MT	DTT
DM7I341	MA	Modulator (allosteric modulator)
DM7I341	RN	Design and synthesis of an orally active metabotropic glutamate receptor subtype-2 (mGluR2) positive allosteric modulator (PAM) that decreases cocaine self-administration in rats. J Med Chem. 2011 Jan 13;54(1):342-53.
DM7I341	RU	https://pubmed.ncbi.nlm.nih.gov/21155570

DM1BQY3	DI	DM1BQY3
DM1BQY3	DN	PMID21185185C21
DM1BQY3	MI	TTWNV8U
DM1BQY3	MN	Nicotinic acid receptor (HCAR2)
DM1BQY3	MT	DTT
DM1BQY3	MA	Agonist
DM1BQY3	RN	The discovery of high affinity agonists of GPR109a with reduced serum shift and improved ADME properties. Bioorg Med Chem Lett. 2011 May 1;21(9):2721-4.
DM1BQY3	RU	https://pubmed.ncbi.nlm.nih.gov/21185185

DMEFUZW	DI	DMEFUZW
DMEFUZW	DN	PMID21273063C1
DMEFUZW	MI	TT7QNVC
DMEFUZW	MN	Glucose-dependent insulinotropic receptor (GPR119)
DMEFUZW	MT	DTT
DMEFUZW	MA	Agonist
DMEFUZW	RN	Design of potent and selective GPR119 agonists for type II diabetes. Bioorg Med Chem Lett. 2011 May 1;21(9):2665-9.
DMEFUZW	RU	https://pubmed.ncbi.nlm.nih.gov/21273063

DMFYJ6O	DI	DMFYJ6O
DMFYJ6O	DN	PMID21273063C36
DMFYJ6O	MI	TT7QNVC
DMFYJ6O	MN	Glucose-dependent insulinotropic receptor (GPR119)
DMFYJ6O	MT	DTT
DMFYJ6O	MA	Agonist
DMFYJ6O	RN	Design of potent and selective GPR119 agonists for type II diabetes. Bioorg Med Chem Lett. 2011 May 1;21(9):2665-9.
DMFYJ6O	RU	https://pubmed.ncbi.nlm.nih.gov/21273063

DMDCUYB	DI	DMDCUYB
DMDCUYB	DN	PMID21273063C58
DMDCUYB	MI	TT7QNVC
DMDCUYB	MN	Glucose-dependent insulinotropic receptor (GPR119)
DMDCUYB	MT	DTT
DMDCUYB	MA	Agonist
DMDCUYB	RN	Design of potent and selective GPR119 agonists for type II diabetes. Bioorg Med Chem Lett. 2011 May 1;21(9):2665-9.
DMDCUYB	RU	https://pubmed.ncbi.nlm.nih.gov/21273063

DMYBV8Q	DI	DMYBV8Q
DMYBV8Q	DN	PMID21277783C7
DMYBV8Q	MI	TTSD9T1
DMYBV8Q	MN	Cathepsin V (CTSV)
DMYBV8Q	MT	DTT
DMYBV8Q	MA	Inhibitor
DMYBV8Q	RN	Acridone alkaloids as potent inhibitors of cathepsin V. Bioorg Med Chem. 2011 Feb 15;19(4):1477-81.
DMYBV8Q	RU	https://pubmed.ncbi.nlm.nih.gov/21277783

DM0DNSV	DI	DM0DNSV
DM0DNSV	DN	PMID21295468C47
DM0DNSV	MI	TTHS256
DM0DNSV	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM0DNSV	MT	DTT
DM0DNSV	MA	Modulator (allosteric modulator)
DM0DNSV	RN	Discovery of novel positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5). Bioorg Med Chem Lett. 2011 Mar 1;21(5):1402-6.
DM0DNSV	RU	https://pubmed.ncbi.nlm.nih.gov/21295468

DMTOM3E	DI	DMTOM3E
DMTOM3E	DN	PMID21310611C3
DMTOM3E	MI	TT7QNVC
DMTOM3E	MN	Glucose-dependent insulinotropic receptor (GPR119)
DMTOM3E	MT	DTT
DMTOM3E	MA	Agonist
DMTOM3E	RN	Design and evaluation of a 2-(2,3,6-trifluorophenyl)acetamide derivative as an agonist of the GPR119 receptor. Bioorg Med Chem Lett. 2011 Mar 1;21(5):1306-9.
DMTOM3E	RU	https://pubmed.ncbi.nlm.nih.gov/21310611

DM9YVPU	DI	DM9YVPU
DM9YVPU	DN	PMID21444206C23
DM9YVPU	MI	TT7QNVC
DM9YVPU	MN	Glucose-dependent insulinotropic receptor (GPR119)
DM9YVPU	MT	DTT
DM9YVPU	MA	Agonist
DM9YVPU	RN	Discovery of fused bicyclic agonists of the orphan G-protein coupled receptor GPR119 with in vivo activity in rodent models of glucose control. Bioorg Med Chem Lett. 2011 May 15;21(10):3134-41.
DM9YVPU	RU	https://pubmed.ncbi.nlm.nih.gov/21444206

DMN50B9	DI	DMN50B9
DMN50B9	DN	PMID21444206C3a
DMN50B9	MI	TT7QNVC
DMN50B9	MN	Glucose-dependent insulinotropic receptor (GPR119)
DMN50B9	MT	DTT
DMN50B9	MA	Agonist
DMN50B9	RN	Discovery of fused bicyclic agonists of the orphan G-protein coupled receptor GPR119 with in vivo activity in rodent models of glucose control. Bioorg Med Chem Lett. 2011 May 15;21(10):3134-41.
DMN50B9	RU	https://pubmed.ncbi.nlm.nih.gov/21444206

DMM1YBE	DI	DMM1YBE
DMM1YBE	DN	PMID21444206C3j
DMM1YBE	MI	TT7QNVC
DMM1YBE	MN	Glucose-dependent insulinotropic receptor (GPR119)
DMM1YBE	MT	DTT
DMM1YBE	MA	Agonist
DMM1YBE	RN	Discovery of fused bicyclic agonists of the orphan G-protein coupled receptor GPR119 with in vivo activity in rodent models of glucose control. Bioorg Med Chem Lett. 2011 May 15;21(10):3134-41.
DMM1YBE	RU	https://pubmed.ncbi.nlm.nih.gov/21444206

DMR21YD	DI	DMR21YD
DMR21YD	DN	PMID21444206C8g
DMR21YD	MI	TT7QNVC
DMR21YD	MN	Glucose-dependent insulinotropic receptor (GPR119)
DMR21YD	MT	DTT
DMR21YD	MA	Agonist
DMR21YD	RN	Discovery of fused bicyclic agonists of the orphan G-protein coupled receptor GPR119 with in vivo activity in rodent models of glucose control. Bioorg Med Chem Lett. 2011 May 15;21(10):3134-41.
DMR21YD	RU	https://pubmed.ncbi.nlm.nih.gov/21444206

DMFUQIT	DI	DMFUQIT
DMFUQIT	DN	PMID21493067C1d
DMFUQIT	MI	TTST7KB
DMFUQIT	MN	Fibroblast growth factor receptor 3 (FGFR3)
DMFUQIT	MT	DTT
DMFUQIT	MA	Inhibitor
DMFUQIT	RN	In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors. Bioorg Med Chem Lett. 2011 May 15;21(10):2958-61.
DMFUQIT	RU	https://pubmed.ncbi.nlm.nih.gov/21493067

DMFUQIT	DI	DMFUQIT
DMFUQIT	DN	PMID21493067C1d
DMFUQIT	MI	TTRMX3V
DMFUQIT	MN	Janus kinase 2 (JAK-2)
DMFUQIT	MT	DTT
DMFUQIT	MA	Inhibitor
DMFUQIT	RN	In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors. Bioorg Med Chem Lett. 2011 May 15;21(10):2958-61.
DMFUQIT	RU	https://pubmed.ncbi.nlm.nih.gov/21493067

DMFUQIT	DI	DMFUQIT
DMFUQIT	DN	PMID21493067C1d
DMFUQIT	MI	TTT7PJU
DMFUQIT	MN	Janus kinase 3 (JAK-3)
DMFUQIT	MT	DTT
DMFUQIT	MA	Inhibitor
DMFUQIT	RN	In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors. Bioorg Med Chem Lett. 2011 May 15;21(10):2958-61.
DMFUQIT	RU	https://pubmed.ncbi.nlm.nih.gov/21493067

DMFUQIT	DI	DMFUQIT
DMFUQIT	DN	PMID21493067C1d
DMFUQIT	MI	TT6SA0X
DMFUQIT	MN	Muscle-specific kinase receptor (MUSK)
DMFUQIT	MT	DTT
DMFUQIT	MA	Inhibitor
DMFUQIT	RN	In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors. Bioorg Med Chem Lett. 2011 May 15;21(10):2958-61.
DMFUQIT	RU	https://pubmed.ncbi.nlm.nih.gov/21493067

DMFUQIT	DI	DMFUQIT
DMFUQIT	DN	PMID21493067C1d
DMFUQIT	MI	TTXABCW
DMFUQIT	MN	NT-3 growth factor receptor (TrkC)
DMFUQIT	MT	DTT
DMFUQIT	MA	Inhibitor
DMFUQIT	RN	In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors. Bioorg Med Chem Lett. 2011 May 15;21(10):2958-61.
DMFUQIT	RU	https://pubmed.ncbi.nlm.nih.gov/21493067

DMFUQIT	DI	DMFUQIT
DMFUQIT	DN	PMID21493067C1d
DMFUQIT	MI	TT4DXQT
DMFUQIT	MN	Proto-oncogene c-Ret (RET)
DMFUQIT	MT	DTT
DMFUQIT	MA	Inhibitor
DMFUQIT	RN	In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors. Bioorg Med Chem Lett. 2011 May 15;21(10):2958-61.
DMFUQIT	RU	https://pubmed.ncbi.nlm.nih.gov/21493067

DMUMYTB	DI	DMUMYTB
DMUMYTB	DN	PMID2153213C13b
DMUMYTB	MI	TTPADOQ
DMUMYTB	MN	HMG-CoA reductase (HMGCR)
DMUMYTB	MT	DTT
DMUMYTB	MA	Inhibitor
DMUMYTB	RN	Synthesis and biological activity of new HMG-CoA reductase inhibitors. 2. Derivatives of 7-(1H-pyrrol-3-yl)-substituted-3,5-dihydroxyhept-6(E)-enoic (-heptanoic) acids. J Med Chem. 1990 Jan;33(1):61-70.
DMUMYTB	RU	https://pubmed.ncbi.nlm.nih.gov/2153213

DM5TL2S	DI	DM5TL2S
DM5TL2S	DN	PMID2153213C13g
DM5TL2S	MI	TTPADOQ
DM5TL2S	MN	HMG-CoA reductase (HMGCR)
DM5TL2S	MT	DTT
DM5TL2S	MA	Inhibitor
DM5TL2S	RN	Synthesis and biological activity of new HMG-CoA reductase inhibitors. 2. Derivatives of 7-(1H-pyrrol-3-yl)-substituted-3,5-dihydroxyhept-6(E)-enoic (-heptanoic) acids. J Med Chem. 1990 Jan;33(1):61-70.
DM5TL2S	RU	https://pubmed.ncbi.nlm.nih.gov/2153213

DMVYB6Q	DI	DMVYB6Q
DMVYB6Q	DN	PMID2153213C1a
DMVYB6Q	MI	TTPADOQ
DMVYB6Q	MN	HMG-CoA reductase (HMGCR)
DMVYB6Q	MT	DTT
DMVYB6Q	MA	Inhibitor
DMVYB6Q	RN	Synthesis and biological activity of new HMG-CoA reductase inhibitors. 2. Derivatives of 7-(1H-pyrrol-3-yl)-substituted-3,5-dihydroxyhept-6(E)-enoic (-heptanoic) acids. J Med Chem. 1990 Jan;33(1):61-70.
DMVYB6Q	RU	https://pubmed.ncbi.nlm.nih.gov/2153213

DMRUJFZ	DI	DMRUJFZ
DMRUJFZ	DN	PMID2153213C1e
DMRUJFZ	MI	TTPADOQ
DMRUJFZ	MN	HMG-CoA reductase (HMGCR)
DMRUJFZ	MT	DTT
DMRUJFZ	MA	Inhibitor
DMRUJFZ	RN	Synthesis and biological activity of new HMG-CoA reductase inhibitors. 2. Derivatives of 7-(1H-pyrrol-3-yl)-substituted-3,5-dihydroxyhept-6(E)-enoic (-heptanoic) acids. J Med Chem. 1990 Jan;33(1):61-70.
DMRUJFZ	RU	https://pubmed.ncbi.nlm.nih.gov/2153213

DMOLIE1	DI	DMOLIE1
DMOLIE1	DN	PMID2153213C1f
DMOLIE1	MI	TTPADOQ
DMOLIE1	MN	HMG-CoA reductase (HMGCR)
DMOLIE1	MT	DTT
DMOLIE1	MA	Inhibitor
DMOLIE1	RN	Synthesis and biological activity of new HMG-CoA reductase inhibitors. 2. Derivatives of 7-(1H-pyrrol-3-yl)-substituted-3,5-dihydroxyhept-6(E)-enoic (-heptanoic) acids. J Med Chem. 1990 Jan;33(1):61-70.
DMOLIE1	RU	https://pubmed.ncbi.nlm.nih.gov/2153213

DMJ4126	DI	DMJ4126
DMJ4126	DN	PMID2153213C2c
DMJ4126	MI	TTPADOQ
DMJ4126	MN	HMG-CoA reductase (HMGCR)
DMJ4126	MT	DTT
DMJ4126	MA	Inhibitor
DMJ4126	RN	Synthesis and biological activity of new HMG-CoA reductase inhibitors. 2. Derivatives of 7-(1H-pyrrol-3-yl)-substituted-3,5-dihydroxyhept-6(E)-enoic (-heptanoic) acids. J Med Chem. 1990 Jan;33(1):61-70.
DMJ4126	RU	https://pubmed.ncbi.nlm.nih.gov/2153213

DMGAY4M	DI	DMGAY4M
DMGAY4M	DN	PMID2153213C2d
DMGAY4M	MI	TTPADOQ
DMGAY4M	MN	HMG-CoA reductase (HMGCR)
DMGAY4M	MT	DTT
DMGAY4M	MA	Inhibitor
DMGAY4M	RN	Synthesis and biological activity of new HMG-CoA reductase inhibitors. 2. Derivatives of 7-(1H-pyrrol-3-yl)-substituted-3,5-dihydroxyhept-6(E)-enoic (-heptanoic) acids. J Med Chem. 1990 Jan;33(1):61-70.
DMGAY4M	RU	https://pubmed.ncbi.nlm.nih.gov/2153213

DM6QXYE	DI	DM6QXYE
DM6QXYE	DN	PMID2153213C2f
DM6QXYE	MI	TTPADOQ
DM6QXYE	MN	HMG-CoA reductase (HMGCR)
DM6QXYE	MT	DTT
DM6QXYE	MA	Inhibitor
DM6QXYE	RN	Synthesis and biological activity of new HMG-CoA reductase inhibitors. 2. Derivatives of 7-(1H-pyrrol-3-yl)-substituted-3,5-dihydroxyhept-6(E)-enoic (-heptanoic) acids. J Med Chem. 1990 Jan;33(1):61-70.
DM6QXYE	RU	https://pubmed.ncbi.nlm.nih.gov/2153213

DM2R94W	DI	DM2R94W
DM2R94W	DN	PMID21536437C15c
DM2R94W	MI	TTXSU2Y
DM2R94W	MN	Aggrecanase (ADAMTS5)
DM2R94W	MT	DTT
DM2R94W	MA	Inhibitor
DM2R94W	RN	Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis. Bioorg Med Chem Lett. 2011 Jun 1;21(11):3301-6.
DM2R94W	RU	https://pubmed.ncbi.nlm.nih.gov/21536437

DMHWX2O	DI	DMHWX2O
DMHWX2O	DN	PMID21536438C20f
DMHWX2O	MI	TT7QNVC
DMHWX2O	MN	Glucose-dependent insulinotropic receptor (GPR119)
DMHWX2O	MT	DTT
DMHWX2O	MA	Agonist
DMHWX2O	RN	Discovery of a nortropanol derivative as a potent and orally active GPR119 agonist for type 2 diabetes. Bioorg Med Chem Lett. 2011 Jun 1;21(11):3290-6.
DMHWX2O	RU	https://pubmed.ncbi.nlm.nih.gov/21536438

DM06V1Q	DI	DM06V1Q
DM06V1Q	DN	PMID21536438C36j
DM06V1Q	MI	TT7QNVC
DM06V1Q	MN	Glucose-dependent insulinotropic receptor (GPR119)
DM06V1Q	MT	DTT
DM06V1Q	MA	Agonist
DM06V1Q	RN	Discovery of a nortropanol derivative as a potent and orally active GPR119 agonist for type 2 diabetes. Bioorg Med Chem Lett. 2011 Jun 1;21(11):3290-6.
DM06V1Q	RU	https://pubmed.ncbi.nlm.nih.gov/21536438

DMABZH6	DI	DMABZH6
DMABZH6	DN	PMID21561767C8h
DMABZH6	MI	TT6B75U
DMABZH6	MN	ABL messenger RNA (ABL mRNA)
DMABZH6	MT	DTT
DMABZH6	MA	Inhibitor
DMABZH6	RN	Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3743-8.
DMABZH6	RU	https://pubmed.ncbi.nlm.nih.gov/21561767

DMABZH6	DI	DMABZH6
DMABZH6	DN	PMID21561767C8h
DMABZH6	MI	TT9VGXW
DMABZH6	MN	Angiopoietin 1 receptor (TEK)
DMABZH6	MT	DTT
DMABZH6	MA	Inhibitor
DMABZH6	RN	Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3743-8.
DMABZH6	RU	https://pubmed.ncbi.nlm.nih.gov/21561767

DMABZH6	DI	DMABZH6
DMABZH6	DN	PMID21561767C8h
DMABZH6	MI	TTRJB2G
DMABZH6	MN	Ephrin type-A receptor 2 (EPHA2)
DMABZH6	MT	DTT
DMABZH6	MA	Inhibitor
DMABZH6	RN	Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3743-8.
DMABZH6	RU	https://pubmed.ncbi.nlm.nih.gov/21561767

DMABZH6	DI	DMABZH6
DMABZH6	DN	PMID21561767C8h
DMABZH6	MI	TTHS2LR
DMABZH6	MN	Ephrin type-A receptor 3 (EPHA3)
DMABZH6	MT	DTT
DMABZH6	MA	Inhibitor
DMABZH6	RN	Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3743-8.
DMABZH6	RU	https://pubmed.ncbi.nlm.nih.gov/21561767

DMABZH6	DI	DMABZH6
DMABZH6	DN	PMID21561767C8h
DMABZH6	MI	TTAHTVG
DMABZH6	MN	Ephrin type-A receptor 7 (EPHA7)
DMABZH6	MT	DTT
DMABZH6	MA	Inhibitor
DMABZH6	RN	Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3743-8.
DMABZH6	RU	https://pubmed.ncbi.nlm.nih.gov/21561767

DMABZH6	DI	DMABZH6
DMABZH6	DN	PMID21561767C8h
DMABZH6	MI	TT8FYO9
DMABZH6	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMABZH6	MT	DTT
DMABZH6	MA	Inhibitor
DMABZH6	RN	Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3743-8.
DMABZH6	RU	https://pubmed.ncbi.nlm.nih.gov/21561767

DMABZH6	DI	DMABZH6
DMABZH6	DN	PMID21561767C8h
DMABZH6	MI	TT4DXQT
DMABZH6	MN	Proto-oncogene c-Ret (RET)
DMABZH6	MT	DTT
DMABZH6	MA	Inhibitor
DMABZH6	RN	Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3743-8.
DMABZH6	RU	https://pubmed.ncbi.nlm.nih.gov/21561767

DMEF8GV	DI	DMEF8GV
DMEF8GV	DN	PMID21571530C5g
DMEF8GV	MI	TT4FX9Y
DMEF8GV	MN	Succinate receptor (SUCNR1)
DMEF8GV	MT	DTT
DMEF8GV	MA	Antagonist
DMEF8GV	RN	Discovery of a potent and selective small molecule hGPR91 antagonist. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3596-602.
DMEF8GV	RU	https://pubmed.ncbi.nlm.nih.gov/21571530

DMPBITK	DI	DMPBITK
DMPBITK	DN	PMID21571530C7e
DMPBITK	MI	TT4FX9Y
DMPBITK	MN	Succinate receptor (SUCNR1)
DMPBITK	MT	DTT
DMPBITK	MA	Antagonist
DMPBITK	RN	Discovery of a potent and selective small molecule hGPR91 antagonist. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3596-602.
DMPBITK	RU	https://pubmed.ncbi.nlm.nih.gov/21571530

DM7JRHB	DI	DM7JRHB
DM7JRHB	DN	PMID21596927C101
DM7JRHB	MI	TTAZ3MN
DM7JRHB	MN	Beta-adrenergic receptor kinase 1 (ADRBK1)
DM7JRHB	MT	DTT
DM7JRHB	MA	Inhibitor
DM7JRHB	RN	Molecular mechanism of selectivity among G protein-coupled receptor kinase 2 inhibitors. Mol Pharmacol. 2011 Aug;80(2):294-303.
DM7JRHB	RU	https://pubmed.ncbi.nlm.nih.gov/21596927

DM7JRHB	DI	DM7JRHB
DM7JRHB	DN	PMID21596927C101
DM7JRHB	MI	TT5A4DX
DM7JRHB	MN	Beta-adrenergic receptor kinase 2 (ADRBK2)
DM7JRHB	MT	DTT
DM7JRHB	MA	Inhibitor
DM7JRHB	RN	Molecular mechanism of selectivity among G protein-coupled receptor kinase 2 inhibitors. Mol Pharmacol. 2011 Aug;80(2):294-303.
DM7JRHB	RU	https://pubmed.ncbi.nlm.nih.gov/21596927

DMQHAIK	DI	DMQHAIK
DMQHAIK	DN	PMID21627121C2
DMQHAIK	MI	TT3VZ24
DMQHAIK	MN	NIMA-related kinase 2 (NEK2)
DMQHAIK	MT	DTT
DMQHAIK	MA	Inhibitor
DMQHAIK	RN	Irreversible Nek2 kinase inhibitors with cellular activity. J Med Chem. 2011 Jun 23;54(12):4133-46.
DMQHAIK	RU	https://pubmed.ncbi.nlm.nih.gov/21627121

DMEBM19	DI	DMEBM19
DMEBM19	DN	PMID21688779C22a
DMEBM19	MI	TTICZ1O
DMEBM19	MN	Metabotropic glutamate receptor 4 (mGluR4)
DMEBM19	MT	DTT
DMEBM19	MA	Modulator (allosteric modulator)
DMEBM19	RN	Tricyclic thiazolopyrazole derivatives as metabotropic glutamate receptor 4 positive allosteric modulators. J Med Chem. 2011 Jul 28;54(14):5070-81.
DMEBM19	RU	https://pubmed.ncbi.nlm.nih.gov/21688779

DMXSCEA	DI	DMXSCEA
DMXSCEA	DN	PMID21692504C8
DMXSCEA	MI	TT3HYDO
DMXSCEA	MN	Prolyl endopeptidase-like (PREPL)
DMXSCEA	MT	DTT
DMXSCEA	MA	Inhibitor
DMXSCEA	RN	A substrate-free activity-based protein profiling screen for the discovery of selective PREPL inhibitors. J Am Chem Soc. 2011 Aug 3;133(30):11665-74.
DMXSCEA	RU	https://pubmed.ncbi.nlm.nih.gov/21692504

DM8PA2V	DI	DM8PA2V
DM8PA2V	DN	PMID21741839C5
DM8PA2V	MI	TTWHYC8
DM8PA2V	MN	Airway trypsin-like protease (TMPRSS11D)
DM8PA2V	MT	DTT
DM8PA2V	MA	Inhibitor
DM8PA2V	RN	Development of substrate analogue inhibitors for the human airway trypsin-like protease HAT. Bioorg Med Chem Lett. 2011 Aug 15;21(16):4860-4.
DM8PA2V	RU	https://pubmed.ncbi.nlm.nih.gov/21741839

DM8PA2V	DI	DM8PA2V
DM8PA2V	DN	PMID21741839C5
DM8PA2V	MI	TT1GM2Z
DM8PA2V	MN	Transmembrane protease serine 2 (TMPRSS2)
DM8PA2V	MT	DTT
DM8PA2V	MA	Inhibitor
DM8PA2V	RN	Development of substrate analogue inhibitors for the human airway trypsin-like protease HAT. Bioorg Med Chem Lett. 2011 Aug 15;21(16):4860-4.
DM8PA2V	RU	https://pubmed.ncbi.nlm.nih.gov/21741839

DME3JMH	DI	DME3JMH
DME3JMH	DN	PMID21742770C1
DME3JMH	MI	TT9RTBL
DME3JMH	MN	Aurora B messenger RNA (AURKB mRNA)
DME3JMH	MT	DTT
DME3JMH	MA	Inhibitor
DME3JMH	RN	A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells. ACS Med Chem Lett. 2012 Dec 13;3(12):1034-1038.
DME3JMH	RU	https://pubmed.ncbi.nlm.nih.gov/23256033

DME3JMH	DI	DME3JMH
DME3JMH	DN	PMID21742770C1
DME3JMH	MI	TTYVI76
DME3JMH	MN	Fungal Protein kinase A (Fung ypkA)
DME3JMH	MT	DTT
DME3JMH	MA	Inhibitor
DME3JMH	RN	A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells. ACS Med Chem Lett. 2012 Dec 13;3(12):1034-1038.
DME3JMH	RU	https://pubmed.ncbi.nlm.nih.gov/23256033

DME3JMH	DI	DME3JMH
DME3JMH	DN	PMID21742770C1
DME3JMH	MI	TTP34DQ
DME3JMH	MN	Serine/threonine-protein kinase 33 (STK33)
DME3JMH	MT	DTT
DME3JMH	MA	Inhibitor
DME3JMH	RN	STK33 kinase activity is nonessential in KRAS-dependent cancer cells. Cancer Res. 2011 Sep 1;71(17):5818-26.
DME3JMH	RU	https://pubmed.ncbi.nlm.nih.gov/21742770

DM3ELPS	DI	DM3ELPS
DM3ELPS	DN	PMID21757343C30
DM3ELPS	MI	TTHS256
DM3ELPS	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM3ELPS	MT	DTT
DM3ELPS	MA	Modulator (allosteric modulator)
DM3ELPS	RN	6-Aryl-3-pyrrolidinylpyridines as mGlu5 receptor negative allosteric modulators. Bioorg Med Chem Lett. 2011 Aug 15;21(16):4891-9.
DM3ELPS	RU	https://pubmed.ncbi.nlm.nih.gov/21757343

DM48HR9	DI	DM48HR9
DM48HR9	DN	PMID21802293C66
DM48HR9	MI	TT7YMXZ
DM48HR9	MN	Tyrosine-protein kinase Srms (SRMS)
DM48HR9	MT	DTT
DM48HR9	MA	Inhibitor
DM48HR9	RN	Pyrazolopyridine inhibitors of B-RafV600E. Part 2: structure-activity relationships. Bioorg Med Chem Lett. 2011 Sep 15;21(18):5533-7.
DM48HR9	RU	https://pubmed.ncbi.nlm.nih.gov/21802293

DMXF32O	DI	DMXF32O
DMXF32O	DN	PMID21823616C22
DMXF32O	MI	TT7ALZG
DMXF32O	MN	Integrin-linked protein kinase 1 (ILK)
DMXF32O	MT	DTT
DMXF32O	MA	Inhibitor
DMXF32O	RN	Identification and characterization of a novel integrin-linked kinase inhibitor. J Med Chem. 2011 Sep 22;54(18):6364-74.
DMXF32O	RU	https://pubmed.ncbi.nlm.nih.gov/21823616

DMI1FGV	DI	DMI1FGV
DMI1FGV	DN	PMID21851057C4d
DMI1FGV	MI	TTDP48B
DMI1FGV	MN	Bromodomain-containing protein 2 (BRD2)
DMI1FGV	MT	DTT
DMI1FGV	MA	Inhibitor
DMI1FGV	RN	3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands. J Med Chem. 2011 Oct 13;54(19):6761-70.
DMI1FGV	RU	https://pubmed.ncbi.nlm.nih.gov/21851057

DMI1FGV	DI	DMI1FGV
DMI1FGV	DN	PMID21851057C4d
DMI1FGV	MI	TTRA6BO
DMI1FGV	MN	Bromodomain-containing protein 4 (BRD4)
DMI1FGV	MT	DTT
DMI1FGV	MA	Inhibitor
DMI1FGV	RN	3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands. J Med Chem. 2011 Oct 13;54(19):6761-70.
DMI1FGV	RU	https://pubmed.ncbi.nlm.nih.gov/21851057

DMTKJA9	DI	DMTKJA9
DMTKJA9	DN	PMID21855335C19a
DMTKJA9	MI	TT860QF
DMTKJA9	MN	LCK tyrosine protein kinase (LCK)
DMTKJA9	MT	DTT
DMTKJA9	MA	Inhibitor
DMTKJA9	RN	Discovery of novel imidazo[1,2-a]pyrazin-8-amines as Brk/PTK6 inhibitors. Bioorg Med Chem Lett. 2011 Oct 1;21(19):5870-5.
DMTKJA9	RU	https://pubmed.ncbi.nlm.nih.gov/21855335

DMTKJA9	DI	DMTKJA9
DMTKJA9	DN	PMID21855335C19a
DMTKJA9	MI	TT6TH8V
DMTKJA9	MN	Tyrosine-protein kinase BRK (PTK6)
DMTKJA9	MT	DTT
DMTKJA9	MA	Inhibitor
DMTKJA9	RN	Discovery of novel imidazo[1,2-a]pyrazin-8-amines as Brk/PTK6 inhibitors. Bioorg Med Chem Lett. 2011 Oct 1;21(19):5870-5.
DMTKJA9	RU	https://pubmed.ncbi.nlm.nih.gov/21855335

DMST0IN	DI	DMST0IN
DMST0IN	DN	PMID21907142CJ
DMST0IN	MI	TT8JRS7
DMST0IN	MN	Beta-secretase (BACE)
DMST0IN	MT	DTT
DMST0IN	MA	Inhibitor
DMST0IN	RN	Bace2 is a beta cell-enriched protease that regulates pancreatic beta cell function and mass. Cell Metab. 2011 Sep 7;14(3):365-77.
DMST0IN	RU	https://pubmed.ncbi.nlm.nih.gov/21907142

DMST0IN	DI	DMST0IN
DMST0IN	DN	PMID21907142CJ
DMST0IN	MI	TT69DB8
DMST0IN	MN	Beta-site APP-cleaving enzyme 2 (BACE2)
DMST0IN	MT	DTT
DMST0IN	MA	Inhibitor
DMST0IN	RN	Bace2 is a beta cell-enriched protease that regulates pancreatic beta cell function and mass. Cell Metab. 2011 Sep 7;14(3):365-77.
DMST0IN	RU	https://pubmed.ncbi.nlm.nih.gov/21907142

DMLGKD3	DI	DMLGKD3
DMLGKD3	DN	PMID21927650C18
DMLGKD3	MI	TTHS256
DMLGKD3	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMLGKD3	MT	DTT
DMLGKD3	MA	Modulator (allosteric modulator)
DMLGKD3	RN	(3-Cyano-5-fluorophenyl)biaryl negative allosteric modulators of mGlu(5): Discovery of a new tool compound with activity in the OSS mouse model of addiction. ACS Chem Neurosci. 2011 Aug 17;2(8):471-482.
DMLGKD3	RU	https://pubmed.ncbi.nlm.nih.gov/21927650

DMEUQFG	DI	DMEUQFG
DMEUQFG	DN	PMID21939274C1
DMEUQFG	MI	TT7QNVC
DMEUQFG	MN	Glucose-dependent insulinotropic receptor (GPR119)
DMEUQFG	MT	DTT
DMEUQFG	MA	Agonist
DMEUQFG	RN	Oxidative metabolism of a quinoxaline derivative by xanthine oxidase in rodent plasma. Chem Res Toxicol. 2011 Dec 19;24(12):2207-16.
DMEUQFG	RU	https://pubmed.ncbi.nlm.nih.gov/21939274

DMRCAEI	DI	DMRCAEI
DMRCAEI	DN	PMID21939274C2
DMRCAEI	MI	TT7QNVC
DMRCAEI	MN	Glucose-dependent insulinotropic receptor (GPR119)
DMRCAEI	MT	DTT
DMRCAEI	MA	Agonist
DMRCAEI	RN	Oxidative metabolism of a quinoxaline derivative by xanthine oxidase in rodent plasma. Chem Res Toxicol. 2011 Dec 19;24(12):2207-16.
DMRCAEI	RU	https://pubmed.ncbi.nlm.nih.gov/21939274

DMCOHKU	DI	DMCOHKU
DMCOHKU	DN	PMID21967808CR-16
DMCOHKU	MI	TTBPJOK
DMCOHKU	MN	IL-1 receptor-associated kinase 3 (IRAK3)
DMCOHKU	MT	DTT
DMCOHKU	MA	Inhibitor
DMCOHKU	RN	Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group. Bioorg Med Chem. 2011 Nov 1;19(21):6274-84.
DMCOHKU	RU	https://pubmed.ncbi.nlm.nih.gov/21967808

DMCOHKU	DI	DMCOHKU
DMCOHKU	DN	PMID21967808CR-16
DMCOHKU	MI	TTNDSF4
DMCOHKU	MN	Proto-oncogene c-Met (MET)
DMCOHKU	MT	DTT
DMCOHKU	MA	Inhibitor
DMCOHKU	RN	Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group. Bioorg Med Chem. 2011 Nov 1;19(21):6274-84.
DMCOHKU	RU	https://pubmed.ncbi.nlm.nih.gov/21967808

DMCOHKU	DI	DMCOHKU
DMCOHKU	DN	PMID21967808CR-16
DMCOHKU	MI	TT4D7MJ
DMCOHKU	MN	Serine/threonine-protein kinase ULK1 (ULK1)
DMCOHKU	MT	DTT
DMCOHKU	MA	Inhibitor
DMCOHKU	RN	Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group. Bioorg Med Chem. 2011 Nov 1;19(21):6274-84.
DMCOHKU	RU	https://pubmed.ncbi.nlm.nih.gov/21967808

DMCOHKU	DI	DMCOHKU
DMCOHKU	DN	PMID21967808CR-16
DMCOHKU	MI	TTYNM3X
DMCOHKU	MN	Sugen kinase 110 (SBK3)
DMCOHKU	MT	DTT
DMCOHKU	MA	Inhibitor
DMCOHKU	RN	Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group. Bioorg Med Chem. 2011 Nov 1;19(21):6274-84.
DMCOHKU	RU	https://pubmed.ncbi.nlm.nih.gov/21967808

DMCOHKU	DI	DMCOHKU
DMCOHKU	DN	PMID21967808CR-16
DMCOHKU	MI	TTT4236
DMCOHKU	MN	Tie-1 tyrosine kinase receptor (TIE1)
DMCOHKU	MT	DTT
DMCOHKU	MA	Inhibitor
DMCOHKU	RN	Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group. Bioorg Med Chem. 2011 Nov 1;19(21):6274-84.
DMCOHKU	RU	https://pubmed.ncbi.nlm.nih.gov/21967808

DM0VOXN	DI	DM0VOXN
DM0VOXN	DN	PMID21982499C14k
DM0VOXN	MI	TT34L5N
DM0VOXN	MN	Casein kinase I gamma-3 (CSNK1G3)
DM0VOXN	MT	DTT
DM0VOXN	MA	Inhibitor
DM0VOXN	RN	7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity. Bioorg Med Chem Lett. 2011 Nov 15;21(22):6687-92.
DM0VOXN	RU	https://pubmed.ncbi.nlm.nih.gov/21982499

DM0VOXN	DI	DM0VOXN
DM0VOXN	DN	PMID21982499C14k
DM0VOXN	MI	TTGJCWZ
DM0VOXN	MN	Fms-like tyrosine kinase 3 (FLT-3)
DM0VOXN	MT	DTT
DM0VOXN	MA	Inhibitor
DM0VOXN	RN	7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity. Bioorg Med Chem Lett. 2011 Nov 15;21(22):6687-92.
DM0VOXN	RU	https://pubmed.ncbi.nlm.nih.gov/21982499

DM0VOXN	DI	DM0VOXN
DM0VOXN	DN	PMID21982499C14k
DM0VOXN	MI	TTCGOIN
DM0VOXN	MN	PIM-3 protein kinase (PIM3)
DM0VOXN	MT	DTT
DM0VOXN	MA	Inhibitor
DM0VOXN	RN	7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity. Bioorg Med Chem Lett. 2011 Nov 15;21(22):6687-92.
DM0VOXN	RU	https://pubmed.ncbi.nlm.nih.gov/21982499

DM0VOXN	DI	DM0VOXN
DM0VOXN	DN	PMID21982499C14k
DM0VOXN	MI	TTTN5QW
DM0VOXN	MN	Serine/threonine-protein kinase pim-1 (PIM1)
DM0VOXN	MT	DTT
DM0VOXN	MA	Inhibitor
DM0VOXN	RN	7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity. Bioorg Med Chem Lett. 2011 Nov 15;21(22):6687-92.
DM0VOXN	RU	https://pubmed.ncbi.nlm.nih.gov/21982499

DM0VOXN	DI	DM0VOXN
DM0VOXN	DN	PMID21982499C14k
DM0VOXN	MI	TT69J2Z
DM0VOXN	MN	Serine/threonine-protein kinase pim-2 (PIM2)
DM0VOXN	MT	DTT
DM0VOXN	MA	Inhibitor
DM0VOXN	RN	7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity. Bioorg Med Chem Lett. 2011 Nov 15;21(22):6687-92.
DM0VOXN	RU	https://pubmed.ncbi.nlm.nih.gov/21982499

DMWBYNF	DI	DMWBYNF
DMWBYNF	DN	PMID22017539C15
DMWBYNF	MI	TTHY57M
DMWBYNF	MN	Matrix metalloproteinase-13 (MMP-13)
DMWBYNF	MT	DTT
DMWBYNF	MA	Inhibitor
DMWBYNF	RN	Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13. J Med Chem. 2011 Dec 8;54(23):8174-87.
DMWBYNF	RU	https://pubmed.ncbi.nlm.nih.gov/22017539

DMX5UKA	DI	DMX5UKA
DMX5UKA	DN	PMID22115617C2c
DMX5UKA	MI	TTER6YH
DMX5UKA	MN	Casein kinase II alpha (CSNK2A1)
DMX5UKA	MT	DTT
DMX5UKA	MA	Inhibitor
DMX5UKA	RN	CK2alpha and CK2alpha' subunits differ in their sensitivity to 4,5,6,7-tetrabromo- and 4,5,6,7-tetraiodo-1H-benzimidazole derivatives. Eur J Med Chem. 2012 Jan;47(1):345-50.
DMX5UKA	RU	https://pubmed.ncbi.nlm.nih.gov/22115617

DMX5UKA	DI	DMX5UKA
DMX5UKA	DN	PMID22115617C2c
DMX5UKA	MI	TTR93NU
DMX5UKA	MN	Casein kinase II alpha prime (CSNK2A2)
DMX5UKA	MT	DTT
DMX5UKA	MA	Inhibitor
DMX5UKA	RN	CK2alpha and CK2alpha' subunits differ in their sensitivity to 4,5,6,7-tetrabromo- and 4,5,6,7-tetraiodo-1H-benzimidazole derivatives. Eur J Med Chem. 2012 Jan;47(1):345-50.
DMX5UKA	RU	https://pubmed.ncbi.nlm.nih.gov/22115617

DMZ5BHX	DI	DMZ5BHX
DMZ5BHX	DN	PMID22123324C38
DMZ5BHX	MI	TTS17MG
DMZ5BHX	MN	Melanin-concentrating hormone receptor 2 (MCHR2)
DMZ5BHX	MT	DTT
DMZ5BHX	MA	Antagonist
DMZ5BHX	RN	Discovery and characterization of a potent and selective antagonist of melanin-concentrating hormone receptor 2. Bioorg Med Chem Lett. 2012 Jan 1;22(1):363-6.
DMZ5BHX	RU	https://pubmed.ncbi.nlm.nih.gov/22123324

DMI8217	DI	DMI8217
DMI8217	DN	PMID22136433C20
DMI8217	MI	TTV298Y
DMI8217	MN	Calmodulin-dependent kinase II (CAMKK2)
DMI8217	MT	DTT
DMI8217	MA	Inhibitor
DMI8217	RN	7,8-dichloro-1-oxo-beta-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes. J Med Chem. 2012 Jan 12;55(1):403-13.
DMI8217	RU	https://pubmed.ncbi.nlm.nih.gov/22136433

DMI8217	DI	DMI8217
DMI8217	DN	PMID22136433C20
DMI8217	MI	TTCGOIN
DMI8217	MN	PIM-3 protein kinase (PIM3)
DMI8217	MT	DTT
DMI8217	MA	Inhibitor
DMI8217	RN	7,8-dichloro-1-oxo-beta-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes. J Med Chem. 2012 Jan 12;55(1):403-13.
DMI8217	RU	https://pubmed.ncbi.nlm.nih.gov/22136433

DMI8217	DI	DMI8217
DMI8217	DN	PMID22136433C20
DMI8217	MI	TTSL41O
DMI8217	MN	Protein kinase N1 (PKN1)
DMI8217	MT	DTT
DMI8217	MA	Inhibitor
DMI8217	RN	7,8-dichloro-1-oxo-beta-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes. J Med Chem. 2012 Jan 12;55(1):403-13.
DMI8217	RU	https://pubmed.ncbi.nlm.nih.gov/22136433

DMI8217	DI	DMI8217
DMI8217	DN	PMID22136433C20
DMI8217	MI	TTTN5QW
DMI8217	MN	Serine/threonine-protein kinase pim-1 (PIM1)
DMI8217	MT	DTT
DMI8217	MA	Inhibitor
DMI8217	RN	7,8-dichloro-1-oxo-beta-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes. J Med Chem. 2012 Jan 12;55(1):403-13.
DMI8217	RU	https://pubmed.ncbi.nlm.nih.gov/22136433

DMTGVSU	DI	DMTGVSU
DMTGVSU	DN	PMID22153340C20
DMTGVSU	MI	TTXZ0KQ
DMTGVSU	MN	Matrix metalloproteinase-12 (MMP-12)
DMTGVSU	MT	DTT
DMTGVSU	MA	Inhibitor
DMTGVSU	RN	Discovery of potent and selective matrix metalloprotease 12 inhibitors for the potential treatment of chronic obstructive pulmonary disease (COPD). Bioorg Med Chem Lett. 2012 Jan 1;22(1):138-43.
DMTGVSU	RU	https://pubmed.ncbi.nlm.nih.gov/22153340

DM4NRG5	DI	DM4NRG5
DM4NRG5	DN	PMID22266036C12e
DM4NRG5	MI	TTVBPDM
DM4NRG5	MN	Metabotropic glutamate receptor 1 (mGluR1)
DM4NRG5	MT	DTT
DM4NRG5	MA	Modulator (allosteric modulator)
DM4NRG5	RN	Fused tricyclic mGluR1 antagonists for the treatment of neuropathic pain. Bioorg Med Chem Lett. 2012 Feb 15;22(4):1575-8.
DM4NRG5	RU	https://pubmed.ncbi.nlm.nih.gov/22266036

DMFQHVL	DI	DMFQHVL
DMFQHVL	DN	PMID22266036C9a
DMFQHVL	MI	TTVBPDM
DMFQHVL	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMFQHVL	MT	DTT
DMFQHVL	MA	Modulator (allosteric modulator)
DMFQHVL	RN	Fused tricyclic mGluR1 antagonists for the treatment of neuropathic pain. Bioorg Med Chem Lett. 2012 Feb 15;22(4):1575-8.
DMFQHVL	RU	https://pubmed.ncbi.nlm.nih.gov/22266036

DMVI6EX	DI	DMVI6EX
DMVI6EX	DN	PMID2231594C3j
DMVI6EX	MI	TTPADOQ
DMVI6EX	MN	HMG-CoA reductase (HMGCR)
DMVI6EX	MT	DTT
DMVI6EX	MA	Inhibitor
DMVI6EX	RN	Phosphorus-containing inhibitors of HMG-CoA reductase. 1. 4-[(2-arylethyl)hydroxyphosphinyl]-3-hydroxy-butanoic acids: a new class of cell-selective inhibitors of cholesterol biosynthesis. J Med Chem. 1990 Nov;33(11):2952-6.
DMVI6EX	RU	https://pubmed.ncbi.nlm.nih.gov/2231594

DMJYHIM	DI	DMJYHIM
DMJYHIM	DN	PMID2231594C3k
DMJYHIM	MI	TTPADOQ
DMJYHIM	MN	HMG-CoA reductase (HMGCR)
DMJYHIM	MT	DTT
DMJYHIM	MA	Inhibitor
DMJYHIM	RN	Phosphorus-containing inhibitors of HMG-CoA reductase. 1. 4-[(2-arylethyl)hydroxyphosphinyl]-3-hydroxy-butanoic acids: a new class of cell-selective inhibitors of cholesterol biosynthesis. J Med Chem. 1990 Nov;33(11):2952-6.
DMJYHIM	RU	https://pubmed.ncbi.nlm.nih.gov/2231594

DMJQ5B0	DI	DMJQ5B0
DMJQ5B0	DN	PMID2231594C3q
DMJQ5B0	MI	TTPADOQ
DMJQ5B0	MN	HMG-CoA reductase (HMGCR)
DMJQ5B0	MT	DTT
DMJQ5B0	MA	Inhibitor
DMJQ5B0	RN	Phosphorus-containing inhibitors of HMG-CoA reductase. 1. 4-[(2-arylethyl)hydroxyphosphinyl]-3-hydroxy-butanoic acids: a new class of cell-selective inhibitors of cholesterol biosynthesis. J Med Chem. 1990 Nov;33(11):2952-6.
DMJQ5B0	RU	https://pubmed.ncbi.nlm.nih.gov/2231594

DMJ504Y	DI	DMJ504Y
DMJ504Y	DN	PMID2231594C3u
DMJ504Y	MI	TTPADOQ
DMJ504Y	MN	HMG-CoA reductase (HMGCR)
DMJ504Y	MT	DTT
DMJ504Y	MA	Inhibitor
DMJ504Y	RN	Phosphorus-containing inhibitors of HMG-CoA reductase. 1. 4-[(2-arylethyl)hydroxyphosphinyl]-3-hydroxy-butanoic acids: a new class of cell-selective inhibitors of cholesterol biosynthesis. J Med Chem. 1990 Nov;33(11):2952-6.
DMJ504Y	RU	https://pubmed.ncbi.nlm.nih.gov/2231594

DMRLG7Z	DI	DMRLG7Z
DMRLG7Z	DN	PMID22364337C48
DMRLG7Z	MI	TTXJ47W
DMRLG7Z	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMRLG7Z	MT	DTT
DMRLG7Z	MA	Modulator (allosteric modulator)
DMRLG7Z	RN	Discovery of 1,4-disubstituted 3-cyano-2-pyridones: a new class of positive allosteric modulators of the metabotropic glutamate 2 receptor. J Med Chem. 2012 Mar 8;55(5):2388-405.
DMRLG7Z	RU	https://pubmed.ncbi.nlm.nih.gov/22364337

DM123TU	DI	DM123TU
DM123TU	DN	PMID22420767C42
DM123TU	MI	TTWNV8U
DM123TU	MN	Nicotinic acid receptor (HCAR2)
DM123TU	MT	DTT
DM123TU	MA	Modulator (allosteric modulator)
DM123TU	RN	Novel 3,6,7-substituted pyrazolopyrimidines as positive allosteric modulators for the hydroxycarboxylic acid receptor 2 (GPR109A). J Med Chem. 2012 Apr 12;55(7):3563-7.
DM123TU	RU	https://pubmed.ncbi.nlm.nih.gov/22420767

DMCDOHA	DI	DMCDOHA
DMCDOHA	DN	PMID22464687C15a
DMCDOHA	MI	TTFQEO5
DMCDOHA	MN	Squalene synthetase (FDFT1)
DMCDOHA	MT	DTT
DMCDOHA	MA	Inhibitor
DMCDOHA	RN	Discovery of novel tricyclic compounds as squalene synthase inhibitors. Bioorg Med Chem. 2012 May 1;20(9):3072-93.
DMCDOHA	RU	https://pubmed.ncbi.nlm.nih.gov/22464687

DMV4ZWD	DI	DMV4ZWD
DMV4ZWD	DN	PMID22465637C1
DMV4ZWD	MI	TTICZ1O
DMV4ZWD	MN	Metabotropic glutamate receptor 4 (mGluR4)
DMV4ZWD	MT	DTT
DMV4ZWD	MA	Modulator (allosteric modulator)
DMV4ZWD	RN	4-(1-Phenyl-1H-pyrazol-4-yl)quinolines as novel, selective and brain penetrant metabotropic glutamate receptor 4 positive allosteric modulators. Bioorg Med Chem Lett. 2012 May 1;22(9):3235-9.
DMV4ZWD	RU	https://pubmed.ncbi.nlm.nih.gov/22465637

DMQXRCW	DI	DMQXRCW
DMQXRCW	DN	PMID22490048C(R)-10h
DMQXRCW	MI	TTX4RTB
DMQXRCW	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMQXRCW	MT	DTT
DMQXRCW	MA	Antagonist
DMQXRCW	RN	Synthesis, structure-activity relationship, and pharmacological studies of novel melanin-concentrating hormone receptor 1 antagonists 3-aminomethylquinolines: reducing human ether-a-go-go-related gene (hERG) associated liabilities. J Med Chem. 2012 May 10;55(9):4336-51.
DMQXRCW	RU	https://pubmed.ncbi.nlm.nih.gov/22490048

DMYQDXO	DI	DMYQDXO
DMYQDXO	DN	PMID22521646C12
DMYQDXO	MI	TTQBR95
DMYQDXO	MN	Stress-activated protein kinase 2a (p38 alpha)
DMYQDXO	MT	DTT
DMYQDXO	MA	Inhibitor
DMYQDXO	RN	Novel triazolopyridylbenzamides as potent and selective p38alpha inhibitors. Bioorg Med Chem Lett. 2012 May 15;22(10):3431-6.
DMYQDXO	RU	https://pubmed.ncbi.nlm.nih.gov/22521646

DMYEMWB	DI	DMYEMWB
DMYEMWB	DN	PMID22533316C1
DMYEMWB	MI	TT7O8ZA
DMYEMWB	MN	Lanosterol synthase (LSS)
DMYEMWB	MT	DTT
DMYEMWB	MA	Inhibitor
DMYEMWB	RN	Cytotoxic effects of combination of oxidosqualene cyclase inhibitors with atorvastatin in human cancer cells. J Med Chem. 2012 Jun 14;55(11):4990-5002.
DMYEMWB	RU	https://pubmed.ncbi.nlm.nih.gov/22533316

DMOZG0A	DI	DMOZG0A
DMOZG0A	DN	PMID22533316C3
DMOZG0A	MI	TT7O8ZA
DMOZG0A	MN	Lanosterol synthase (LSS)
DMOZG0A	MT	DTT
DMOZG0A	MA	Inhibitor
DMOZG0A	RN	Cytotoxic effects of combination of oxidosqualene cyclase inhibitors with atorvastatin in human cancer cells. J Med Chem. 2012 Jun 14;55(11):4990-5002.
DMOZG0A	RU	https://pubmed.ncbi.nlm.nih.gov/22533316

DMW3UHO	DI	DMW3UHO
DMW3UHO	DN	PMID22533316C4
DMW3UHO	MI	TT7O8ZA
DMW3UHO	MN	Lanosterol synthase (LSS)
DMW3UHO	MT	DTT
DMW3UHO	MA	Inhibitor
DMW3UHO	RN	Cytotoxic effects of combination of oxidosqualene cyclase inhibitors with atorvastatin in human cancer cells. J Med Chem. 2012 Jun 14;55(11):4990-5002.
DMW3UHO	RU	https://pubmed.ncbi.nlm.nih.gov/22533316

DMVZQ6U	DI	DMVZQ6U
DMVZQ6U	DN	PMID22545772C42
DMVZQ6U	MI	TT7QNVC
DMVZQ6U	MN	Glucose-dependent insulinotropic receptor (GPR119)
DMVZQ6U	MT	DTT
DMVZQ6U	MA	Agonist
DMVZQ6U	RN	Use of small-molecule crystal structures to address solubility in a novel series of G protein coupled receptor 119 agonists: optimization of a lead and in vivo evaluation. J Med Chem. 2012 Jun 14;55(11):5361-79.
DMVZQ6U	RU	https://pubmed.ncbi.nlm.nih.gov/22545772

DMBMYKQ	DI	DMBMYKQ
DMBMYKQ	DN	PMID22564207C25b
DMBMYKQ	MI	TTPMQSO
DMBMYKQ	MN	ALK tyrosine kinase receptor (ALK)
DMBMYKQ	MT	DTT
DMBMYKQ	MA	Inhibitor
DMBMYKQ	RN	Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase. J Med Chem. 2012 May 24;55(10):4580-93.
DMBMYKQ	RU	https://pubmed.ncbi.nlm.nih.gov/22564207

DMBMYKQ	DI	DMBMYKQ
DMBMYKQ	DN	PMID22564207C25b
DMBMYKQ	MI	TT65FL0
DMBMYKQ	MN	Omphalocele kinase 1 (NUAK1)
DMBMYKQ	MT	DTT
DMBMYKQ	MA	Inhibitor
DMBMYKQ	RN	Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase. J Med Chem. 2012 May 24;55(10):4580-93.
DMBMYKQ	RU	https://pubmed.ncbi.nlm.nih.gov/22564207

DMBMYKQ	DI	DMBMYKQ
DMBMYKQ	DN	PMID22564207C25b
DMBMYKQ	MI	TTRA9G0
DMBMYKQ	MN	Proto-oncogene c-Fer (FER)
DMBMYKQ	MT	DTT
DMBMYKQ	MA	Inhibitor
DMBMYKQ	RN	Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase. J Med Chem. 2012 May 24;55(10):4580-93.
DMBMYKQ	RU	https://pubmed.ncbi.nlm.nih.gov/22564207

DMBMYKQ	DI	DMBMYKQ
DMBMYKQ	DN	PMID22564207C25b
DMBMYKQ	MI	TTLBY21
DMBMYKQ	MN	Proto-oncogene c-Fes (FES)
DMBMYKQ	MT	DTT
DMBMYKQ	MA	Inhibitor
DMBMYKQ	RN	Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase. J Med Chem. 2012 May 24;55(10):4580-93.
DMBMYKQ	RU	https://pubmed.ncbi.nlm.nih.gov/22564207

DMBMYKQ	DI	DMBMYKQ
DMBMYKQ	DN	PMID22564207C25b
DMBMYKQ	MI	TT0ZW9O
DMBMYKQ	MN	Ribosomal protein S6 kinase alpha-2 (RSK2)
DMBMYKQ	MT	DTT
DMBMYKQ	MA	Inhibitor
DMBMYKQ	RN	Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase. J Med Chem. 2012 May 24;55(10):4580-93.
DMBMYKQ	RU	https://pubmed.ncbi.nlm.nih.gov/22564207

DMBMYKQ	DI	DMBMYKQ
DMBMYKQ	DN	PMID22564207C25b
DMBMYKQ	MI	TTUM2ZR
DMBMYKQ	MN	Ribosomal protein S6 kinase alpha-3 (RSK3)
DMBMYKQ	MT	DTT
DMBMYKQ	MA	Inhibitor
DMBMYKQ	RN	Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase. J Med Chem. 2012 May 24;55(10):4580-93.
DMBMYKQ	RU	https://pubmed.ncbi.nlm.nih.gov/22564207

DMBMYKQ	DI	DMBMYKQ
DMBMYKQ	DN	PMID22564207C25b
DMBMYKQ	MI	TT3KYWB
DMBMYKQ	MN	Ribosomal protein S6 kinase alpha-6 (RSK6)
DMBMYKQ	MT	DTT
DMBMYKQ	MA	Inhibitor
DMBMYKQ	RN	Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase. J Med Chem. 2012 May 24;55(10):4580-93.
DMBMYKQ	RU	https://pubmed.ncbi.nlm.nih.gov/22564207

DMBMYKQ	DI	DMBMYKQ
DMBMYKQ	DN	PMID22564207C25b
DMBMYKQ	MI	TT9ABMF
DMBMYKQ	MN	Serine/threonine-protein kinase Chk2 (RAD53)
DMBMYKQ	MT	DTT
DMBMYKQ	MA	Inhibitor
DMBMYKQ	RN	Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase. J Med Chem. 2012 May 24;55(10):4580-93.
DMBMYKQ	RU	https://pubmed.ncbi.nlm.nih.gov/22564207

DM9SLUK	DI	DM9SLUK
DM9SLUK	DN	PMID22595175C4g
DM9SLUK	MI	TTQAJF1
DM9SLUK	MN	Cathepsin G (CTSG)
DM9SLUK	MT	DTT
DM9SLUK	MA	Inhibitor
DM9SLUK	RN	N-Acyl and N-sulfonyloxazolidine-2,4-diones are pseudo-irreversible inhibitors of serine proteases. Bioorg Med Chem Lett. 2012 Jun 15;22(12):3993-7.
DM9SLUK	RU	https://pubmed.ncbi.nlm.nih.gov/22595175

DM9SLUK	DI	DM9SLUK
DM9SLUK	DN	PMID22595175C4g
DM9SLUK	MI	TT5MLC4
DM9SLUK	MN	Leukocyte proteinase-3 (PRTN3)
DM9SLUK	MT	DTT
DM9SLUK	MA	Inhibitor
DM9SLUK	RN	N-Acyl and N-sulfonyloxazolidine-2,4-diones are pseudo-irreversible inhibitors of serine proteases. Bioorg Med Chem Lett. 2012 Jun 15;22(12):3993-7.
DM9SLUK	RU	https://pubmed.ncbi.nlm.nih.gov/22595175

DM9SLUK	DI	DM9SLUK
DM9SLUK	DN	PMID22595175C4g
DM9SLUK	MI	TTPLTSQ
DM9SLUK	MN	Neutrophil elastase (NE)
DM9SLUK	MT	DTT
DM9SLUK	MA	Inhibitor
DM9SLUK	RN	N-Acyl and N-sulfonyloxazolidine-2,4-diones are pseudo-irreversible inhibitors of serine proteases. Bioorg Med Chem Lett. 2012 Jun 15;22(12):3993-7.
DM9SLUK	RU	https://pubmed.ncbi.nlm.nih.gov/22595175

DM7OJ5Q	DI	DM7OJ5Q
DM7OJ5Q	DN	PMID22607879CR-(-)-5f
DM7OJ5Q	MI	TTOJ1NF
DM7OJ5Q	MN	FMLP-related receptor I (FPR2)
DM7OJ5Q	MT	DTT
DM7OJ5Q	MA	Agonist
DM7OJ5Q	RN	Synthesis, enantioresolution, and activity profile of chiral 6-methyl-2,4-disubstituted pyridazin-3(2H)-ones as potent N-formyl peptide receptor agonists. Bioorg Med Chem. 2012 Jun 15;20(12):3781-92.
DM7OJ5Q	RU	https://pubmed.ncbi.nlm.nih.gov/22607879

DM7OJ5Q	DI	DM7OJ5Q
DM7OJ5Q	DN	PMID22607879CR-(-)-5f
DM7OJ5Q	MI	TT5Y4EM
DM7OJ5Q	MN	N-formyl peptide receptor (FPR1)
DM7OJ5Q	MT	DTT
DM7OJ5Q	MA	Agonist
DM7OJ5Q	RN	Synthesis, enantioresolution, and activity profile of chiral 6-methyl-2,4-disubstituted pyridazin-3(2H)-ones as potent N-formyl peptide receptor agonists. Bioorg Med Chem. 2012 Jun 15;20(12):3781-92.
DM7OJ5Q	RU	https://pubmed.ncbi.nlm.nih.gov/22607879

DM19D7G	DI	DM19D7G
DM19D7G	DN	PMID22686657C(R)-26
DM19D7G	MI	TTJOKD1
DM19D7G	MN	Cathepsin F (CTSF)
DM19D7G	MT	DTT
DM19D7G	MA	Inhibitor
DM19D7G	RN	Selective nitrile inhibitors to modulate the proteolytic synergism of cathepsins S and F. J Med Chem. 2012 Jun 28;55(12):5982-6.
DM19D7G	RU	https://pubmed.ncbi.nlm.nih.gov/22686657

DM19D7G	DI	DM19D7G
DM19D7G	DN	PMID22686657C(R)-26
DM19D7G	MI	TTUMQVO
DM19D7G	MN	Cathepsin S (CTSS)
DM19D7G	MT	DTT
DM19D7G	MA	Inhibitor
DM19D7G	RN	Selective nitrile inhibitors to modulate the proteolytic synergism of cathepsins S and F. J Med Chem. 2012 Jun 28;55(12):5982-6.
DM19D7G	RU	https://pubmed.ncbi.nlm.nih.gov/22686657

DMH5RFU	DI	DMH5RFU
DMH5RFU	DN	PMID22765894C8h
DMH5RFU	MI	TTRLW2X
DMH5RFU	MN	Fibroblast growth factor receptor 1 (FGFR1)
DMH5RFU	MT	DTT
DMH5RFU	MA	Inhibitor
DMH5RFU	RN	The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2012 Aug 1;22(15):4979-85.
DMH5RFU	RU	https://pubmed.ncbi.nlm.nih.gov/22765894

DMH5RFU	DI	DMH5RFU
DMH5RFU	DN	PMID22765894C8h
DMH5RFU	MI	TTGJCWZ
DMH5RFU	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMH5RFU	MT	DTT
DMH5RFU	MA	Inhibitor
DMH5RFU	RN	The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2012 Aug 1;22(15):4979-85.
DMH5RFU	RU	https://pubmed.ncbi.nlm.nih.gov/22765894

DMH5RFU	DI	DMH5RFU
DMH5RFU	DN	PMID22765894C8h
DMH5RFU	MI	TTI0AHJ
DMH5RFU	MN	MEK kinase kinase 3 (MAP4K3)
DMH5RFU	MT	DTT
DMH5RFU	MA	Inhibitor
DMH5RFU	RN	The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2012 Aug 1;22(15):4979-85.
DMH5RFU	RU	https://pubmed.ncbi.nlm.nih.gov/22765894

DMH5RFU	DI	DMH5RFU
DMH5RFU	DN	PMID22765894C8h
DMH5RFU	MI	TT8FYO9
DMH5RFU	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMH5RFU	MT	DTT
DMH5RFU	MA	Inhibitor
DMH5RFU	RN	The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2012 Aug 1;22(15):4979-85.
DMH5RFU	RU	https://pubmed.ncbi.nlm.nih.gov/22765894

DMH5RFU	DI	DMH5RFU
DMH5RFU	DN	PMID22765894C8h
DMH5RFU	MI	TTI7421
DMH5RFU	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMH5RFU	MT	DTT
DMH5RFU	MA	Inhibitor
DMH5RFU	RN	The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2012 Aug 1;22(15):4979-85.
DMH5RFU	RU	https://pubmed.ncbi.nlm.nih.gov/22765894

DMH5RFU	DI	DMH5RFU
DMH5RFU	DN	PMID22765894C8h
DMH5RFU	MI	TT6PKBN
DMH5RFU	MN	Proto-oncogene c-Src (SRC)
DMH5RFU	MT	DTT
DMH5RFU	MA	Inhibitor
DMH5RFU	RN	The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2012 Aug 1;22(15):4979-85.
DMH5RFU	RU	https://pubmed.ncbi.nlm.nih.gov/22765894

DMH5RFU	DI	DMH5RFU
DMH5RFU	DN	PMID22765894C8h
DMH5RFU	MI	TTUM2ZR
DMH5RFU	MN	Ribosomal protein S6 kinase alpha-3 (RSK3)
DMH5RFU	MT	DTT
DMH5RFU	MA	Inhibitor
DMH5RFU	RN	The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2012 Aug 1;22(15):4979-85.
DMH5RFU	RU	https://pubmed.ncbi.nlm.nih.gov/22765894

DMH5RFU	DI	DMH5RFU
DMH5RFU	DN	PMID22765894C8h
DMH5RFU	MI	TTX41N9
DMH5RFU	MN	Tyrosine-protein kinase Kit (KIT)
DMH5RFU	MT	DTT
DMH5RFU	MA	Inhibitor
DMH5RFU	RN	The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2012 Aug 1;22(15):4979-85.
DMH5RFU	RU	https://pubmed.ncbi.nlm.nih.gov/22765894

DMH5RFU	DI	DMH5RFU
DMH5RFU	DN	PMID22765894C8h
DMH5RFU	MI	TTUTJGQ
DMH5RFU	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMH5RFU	MT	DTT
DMH5RFU	MA	Inhibitor
DMH5RFU	RN	The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2012 Aug 1;22(15):4979-85.
DMH5RFU	RU	https://pubmed.ncbi.nlm.nih.gov/22765894

DMH5RFU	DI	DMH5RFU
DMH5RFU	DN	PMID22765894C8h
DMH5RFU	MI	TTDCBX5
DMH5RFU	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DMH5RFU	MT	DTT
DMH5RFU	MA	Inhibitor
DMH5RFU	RN	The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2012 Aug 1;22(15):4979-85.
DMH5RFU	RU	https://pubmed.ncbi.nlm.nih.gov/22765894

DMH5RFU	DI	DMH5RFU
DMH5RFU	DN	PMID22765894C8h
DMH5RFU	MI	TT1VAUK
DMH5RFU	MN	VEGFR1 messenger RNA (VEGFR1 mRNA)
DMH5RFU	MT	DTT
DMH5RFU	MA	Inhibitor
DMH5RFU	RN	The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2012 Aug 1;22(15):4979-85.
DMH5RFU	RU	https://pubmed.ncbi.nlm.nih.gov/22765894

DM0XQZO	DI	DM0XQZO
DM0XQZO	DN	PMID22795084C1
DM0XQZO	MI	TTL4XSQ
DM0XQZO	MN	Protein arginine methyltransferase 3 (PRMT3)
DM0XQZO	MT	DTT
DM0XQZO	MA	Inhibitor
DM0XQZO	RN	An allosteric inhibitor of protein arginine methyltransferase 3. Structure. 2012 Aug 8;20(8):1425-35.
DM0XQZO	RU	https://pubmed.ncbi.nlm.nih.gov/22795084

DMVK1GT	DI	DMVK1GT
DMVK1GT	DN	PMID22802221C21
DMVK1GT	MI	TTQVOEI
DMVK1GT	MN	Angiotensin II receptor type-2 (AGTR2)
DMVK1GT	MT	DTT
DMVK1GT	MA	Agonist
DMVK1GT	RN	Compound 21 induces vasorelaxation via an endothelium- and angiotensin II type 2 receptor-independent mechanism. Hypertension. 2012 Sep;60(3):722-9.
DMVK1GT	RU	https://pubmed.ncbi.nlm.nih.gov/22802221

DM6RY4F	DI	DM6RY4F
DM6RY4F	DN	PMID22861813C8a
DM6RY4F	MI	TT5NILS
DM6RY4F	MN	Cathepsin A (CTSA)
DM6RY4F	MT	DTT
DM6RY4F	MA	Inhibitor
DM6RY4F	RN	Novel beta-amino acid derivatives as inhibitors of cathepsin A. J Med Chem. 2012 Sep 13;55(17):7636-49.
DM6RY4F	RU	https://pubmed.ncbi.nlm.nih.gov/22861813

DMLUCSB	DI	DMLUCSB
DMLUCSB	DN	PMID22873688C3a
DMLUCSB	MI	TTA93TL
DMLUCSB	MN	P2Y purinoceptor 1 (P2RY1)
DMLUCSB	MT	DTT
DMLUCSB	MA	Agonist
DMLUCSB	RN	Identification of a promising drug candidate for the treatment of type 2 diabetes based on a P2Y(1) receptor agonist. J Med Chem. 2012 Sep 13;55(17):7623-35.
DMLUCSB	RU	https://pubmed.ncbi.nlm.nih.gov/22873688

DMXDTPL	DI	DMXDTPL
DMXDTPL	DN	PMID22902653C30
DMXDTPL	MI	TTWL9TY
DMXDTPL	MN	LIM domain kinase-1 (LIMK-1)
DMXDTPL	MT	DTT
DMXDTPL	MA	Inhibitor
DMXDTPL	RN	Modulation of cofilin phosphorylation by inhibition of the Lim family kinases. Bioorg Med Chem Lett. 2012 Sep 15;22(18):5995-8.
DMXDTPL	RU	https://pubmed.ncbi.nlm.nih.gov/22902653

DMXDTPL	DI	DMXDTPL
DMXDTPL	DN	PMID22902653C30
DMXDTPL	MI	TTASMD8
DMXDTPL	MN	LIM domain kinase-2 (LIMK-2)
DMXDTPL	MT	DTT
DMXDTPL	MA	Inhibitor
DMXDTPL	RN	Modulation of cofilin phosphorylation by inhibition of the Lim family kinases. Bioorg Med Chem Lett. 2012 Sep 15;22(18):5995-8.
DMXDTPL	RU	https://pubmed.ncbi.nlm.nih.gov/22902653

DMXDTPL	DI	DMXDTPL
DMXDTPL	DN	PMID22902653C30
DMXDTPL	MI	TTWKT3Y
DMXDTPL	MN	Testis-specific kinase 1 (TESK1)
DMXDTPL	MT	DTT
DMXDTPL	MA	Inhibitor
DMXDTPL	RN	Modulation of cofilin phosphorylation by inhibition of the Lim family kinases. Bioorg Med Chem Lett. 2012 Sep 15;22(18):5995-8.
DMXDTPL	RU	https://pubmed.ncbi.nlm.nih.gov/22902653

DMXDTPL	DI	DMXDTPL
DMXDTPL	DN	PMID22902653C30
DMXDTPL	MI	TTRMD8U
DMXDTPL	MN	Testis-specific kinase 2 (TESK2)
DMXDTPL	MT	DTT
DMXDTPL	MA	Inhibitor
DMXDTPL	RN	Modulation of cofilin phosphorylation by inhibition of the Lim family kinases. Bioorg Med Chem Lett. 2012 Sep 15;22(18):5995-8.
DMXDTPL	RU	https://pubmed.ncbi.nlm.nih.gov/22902653

DMWVTAE	DI	DMWVTAE
DMWVTAE	DN	PMID22902653C31
DMWVTAE	MI	TTWL9TY
DMWVTAE	MN	LIM domain kinase-1 (LIMK-1)
DMWVTAE	MT	DTT
DMWVTAE	MA	Inhibitor
DMWVTAE	RN	Modulation of cofilin phosphorylation by inhibition of the Lim family kinases. Bioorg Med Chem Lett. 2012 Sep 15;22(18):5995-8.
DMWVTAE	RU	https://pubmed.ncbi.nlm.nih.gov/22902653

DMWVTAE	DI	DMWVTAE
DMWVTAE	DN	PMID22902653C31
DMWVTAE	MI	TTASMD8
DMWVTAE	MN	LIM domain kinase-2 (LIMK-2)
DMWVTAE	MT	DTT
DMWVTAE	MA	Inhibitor
DMWVTAE	RN	Modulation of cofilin phosphorylation by inhibition of the Lim family kinases. Bioorg Med Chem Lett. 2012 Sep 15;22(18):5995-8.
DMWVTAE	RU	https://pubmed.ncbi.nlm.nih.gov/22902653

DMWVTAE	DI	DMWVTAE
DMWVTAE	DN	PMID22902653C31
DMWVTAE	MI	TTWKT3Y
DMWVTAE	MN	Testis-specific kinase 1 (TESK1)
DMWVTAE	MT	DTT
DMWVTAE	MA	Inhibitor
DMWVTAE	RN	Modulation of cofilin phosphorylation by inhibition of the Lim family kinases. Bioorg Med Chem Lett. 2012 Sep 15;22(18):5995-8.
DMWVTAE	RU	https://pubmed.ncbi.nlm.nih.gov/22902653

DMWVTAE	DI	DMWVTAE
DMWVTAE	DN	PMID22902653C31
DMWVTAE	MI	TTRMD8U
DMWVTAE	MN	Testis-specific kinase 2 (TESK2)
DMWVTAE	MT	DTT
DMWVTAE	MA	Inhibitor
DMWVTAE	RN	Modulation of cofilin phosphorylation by inhibition of the Lim family kinases. Bioorg Med Chem Lett. 2012 Sep 15;22(18):5995-8.
DMWVTAE	RU	https://pubmed.ncbi.nlm.nih.gov/22902653

DMLVKPG	DI	DMLVKPG
DMLVKPG	DN	PMID22902653C35
DMLVKPG	MI	TTWL9TY
DMLVKPG	MN	LIM domain kinase-1 (LIMK-1)
DMLVKPG	MT	DTT
DMLVKPG	MA	Inhibitor
DMLVKPG	RN	Modulation of cofilin phosphorylation by inhibition of the Lim family kinases. Bioorg Med Chem Lett. 2012 Sep 15;22(18):5995-8.
DMLVKPG	RU	https://pubmed.ncbi.nlm.nih.gov/22902653

DMLVKPG	DI	DMLVKPG
DMLVKPG	DN	PMID22902653C35
DMLVKPG	MI	TTASMD8
DMLVKPG	MN	LIM domain kinase-2 (LIMK-2)
DMLVKPG	MT	DTT
DMLVKPG	MA	Inhibitor
DMLVKPG	RN	Modulation of cofilin phosphorylation by inhibition of the Lim family kinases. Bioorg Med Chem Lett. 2012 Sep 15;22(18):5995-8.
DMLVKPG	RU	https://pubmed.ncbi.nlm.nih.gov/22902653

DMLVKPG	DI	DMLVKPG
DMLVKPG	DN	PMID22902653C35
DMLVKPG	MI	TTWKT3Y
DMLVKPG	MN	Testis-specific kinase 1 (TESK1)
DMLVKPG	MT	DTT
DMLVKPG	MA	Inhibitor
DMLVKPG	RN	Modulation of cofilin phosphorylation by inhibition of the Lim family kinases. Bioorg Med Chem Lett. 2012 Sep 15;22(18):5995-8.
DMLVKPG	RU	https://pubmed.ncbi.nlm.nih.gov/22902653

DMLVKPG	DI	DMLVKPG
DMLVKPG	DN	PMID22902653C35
DMLVKPG	MI	TTRMD8U
DMLVKPG	MN	Testis-specific kinase 2 (TESK2)
DMLVKPG	MT	DTT
DMLVKPG	MA	Inhibitor
DMLVKPG	RN	Modulation of cofilin phosphorylation by inhibition of the Lim family kinases. Bioorg Med Chem Lett. 2012 Sep 15;22(18):5995-8.
DMLVKPG	RU	https://pubmed.ncbi.nlm.nih.gov/22902653

DMOKZ3R	DI	DMOKZ3R
DMOKZ3R	DN	PMID2296027C25
DMOKZ3R	MI	TTPADOQ
DMOKZ3R	MN	HMG-CoA reductase (HMGCR)
DMOKZ3R	MT	DTT
DMOKZ3R	MA	Inhibitor
DMOKZ3R	RN	Inhibitors of cholesterol biosynthesis. 2. 1,3,5-trisubstituted [2-(tetrahydro-4-hydroxy-2-oxopyran-6-yl)ethyl]pyrazoles. J Med Chem. 1990 Jan;33(1):31-8.
DMOKZ3R	RU	https://pubmed.ncbi.nlm.nih.gov/2296027

DMY267E	DI	DMY267E
DMY267E	DN	PMID2296027C29
DMY267E	MI	TTPADOQ
DMY267E	MN	HMG-CoA reductase (HMGCR)
DMY267E	MT	DTT
DMY267E	MA	Inhibitor
DMY267E	RN	Inhibitors of cholesterol biosynthesis. 2. 1,3,5-trisubstituted [2-(tetrahydro-4-hydroxy-2-oxopyran-6-yl)ethyl]pyrazoles. J Med Chem. 1990 Jan;33(1):31-8.
DMY267E	RU	https://pubmed.ncbi.nlm.nih.gov/2296027

DM6VG8K	DI	DM6VG8K
DM6VG8K	DN	PMID2296036C2g
DM6VG8K	MI	TTPADOQ
DM6VG8K	MN	HMG-CoA reductase (HMGCR)
DM6VG8K	MT	DTT
DM6VG8K	MA	Inhibitor
DM6VG8K	RN	Synthesis and biological activity of new HMG-CoA reductase inhibitors. 1. Lactones of pyridine- and pyrimidine-substituted 3,5-dihydroxy-6-heptenoic (-heptanoic) acids. J Med Chem. 1990 Jan;33(1):52-60.
DM6VG8K	RU	https://pubmed.ncbi.nlm.nih.gov/2296036

DMBXCNA	DI	DMBXCNA
DMBXCNA	DN	PMID2296036C2t
DMBXCNA	MI	TTPADOQ
DMBXCNA	MN	HMG-CoA reductase (HMGCR)
DMBXCNA	MT	DTT
DMBXCNA	MA	Inhibitor
DMBXCNA	RN	Synthesis and biological activity of new HMG-CoA reductase inhibitors. 1. Lactones of pyridine- and pyrimidine-substituted 3,5-dihydroxy-6-heptenoic (-heptanoic) acids. J Med Chem. 1990 Jan;33(1):52-60.
DMBXCNA	RU	https://pubmed.ncbi.nlm.nih.gov/2296036

DMC6HQL	DI	DMC6HQL
DMC6HQL	DN	PMID2296036C4d
DMC6HQL	MI	TTPADOQ
DMC6HQL	MN	HMG-CoA reductase (HMGCR)
DMC6HQL	MT	DTT
DMC6HQL	MA	Inhibitor
DMC6HQL	RN	Synthesis and biological activity of new HMG-CoA reductase inhibitors. 1. Lactones of pyridine- and pyrimidine-substituted 3,5-dihydroxy-6-heptenoic (-heptanoic) acids. J Med Chem. 1990 Jan;33(1):52-60.
DMC6HQL	RU	https://pubmed.ncbi.nlm.nih.gov/2296036

DMSJ94N	DI	DMSJ94N
DMSJ94N	DN	PMID2296036C4i
DMSJ94N	MI	TTPADOQ
DMSJ94N	MN	HMG-CoA reductase (HMGCR)
DMSJ94N	MT	DTT
DMSJ94N	MA	Inhibitor
DMSJ94N	RN	Synthesis and biological activity of new HMG-CoA reductase inhibitors. 1. Lactones of pyridine- and pyrimidine-substituted 3,5-dihydroxy-6-heptenoic (-heptanoic) acids. J Med Chem. 1990 Jan;33(1):52-60.
DMSJ94N	RU	https://pubmed.ncbi.nlm.nih.gov/2296036

DMAW86U	DI	DMAW86U
DMAW86U	DN	PMID22984835C20o
DMAW86U	MI	TTZ1DT0
DMAW86U	MN	P2Y purinoceptor 12 (P2RY12)
DMAW86U	MT	DTT
DMAW86U	MA	Antagonist
DMAW86U	RN	Identification of high-affinity P2Y antagonists based on a phenylpyrazole glutamic acid piperazine backbone. J Med Chem. 2012 Oct 25;55(20):8615-29.
DMAW86U	RU	https://pubmed.ncbi.nlm.nih.gov/22984835

DMMI9JE	DI	DMMI9JE
DMMI9JE	DN	PMID22984835C4
DMMI9JE	MI	TTZ1DT0
DMMI9JE	MN	P2Y purinoceptor 12 (P2RY12)
DMMI9JE	MT	DTT
DMMI9JE	MA	Antagonist
DMMI9JE	RN	Identification of high-affinity P2Y antagonists based on a phenylpyrazole glutamic acid piperazine backbone. J Med Chem. 2012 Oct 25;55(20):8615-29.
DMMI9JE	RU	https://pubmed.ncbi.nlm.nih.gov/22984835

DMW579R	DI	DMW579R
DMW579R	DN	PMID23083103C4
DMW579R	MI	TTZ1DT0
DMW579R	MN	P2Y purinoceptor 12 (P2RY12)
DMW579R	MT	DTT
DMW579R	MA	Antagonist
DMW579R	RN	Modified diadenosine tetraphosphates with dual specificity for P2Y1 and P2Y12 are potent antagonists of ADP-induced platelet activation. J Thromb Haemost. 2012 Dec;10(12):2573-80.
DMW579R	RU	https://pubmed.ncbi.nlm.nih.gov/23083103

DMURP5Y	DI	DMURP5Y
DMURP5Y	DN	PMID23084894C10i
DMURP5Y	MI	TTVBPDM
DMURP5Y	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMURP5Y	MT	DTT
DMURP5Y	MA	Modulator (allosteric modulator)
DMURP5Y	RN	Synthesis and SAR development of novel mGluR1 antagonists for the treatment of chronic pain. Bioorg Med Chem Lett. 2012 Dec 1;22(23):7223-6.
DMURP5Y	RU	https://pubmed.ncbi.nlm.nih.gov/23084894

DM4ATLM	DI	DM4ATLM
DM4ATLM	DN	PMID23084894C9n
DM4ATLM	MI	TTVBPDM
DM4ATLM	MN	Metabotropic glutamate receptor 1 (mGluR1)
DM4ATLM	MT	DTT
DM4ATLM	MA	Modulator (allosteric modulator)
DM4ATLM	RN	Synthesis and SAR development of novel mGluR1 antagonists for the treatment of chronic pain. Bioorg Med Chem Lett. 2012 Dec 1;22(23):7223-6.
DM4ATLM	RU	https://pubmed.ncbi.nlm.nih.gov/23084894

DMWS7O9	DI	DMWS7O9
DMWS7O9	DN	PMID23099093C17d
DMWS7O9	MI	TTRPDBG
DMWS7O9	MN	Inhibitor of nuclear factor kappa-B kinase (IKK)
DMWS7O9	MT	DTT
DMWS7O9	MA	Inhibitor
DMWS7O9	RN	Synthesis and structure-activity relationships of a novel series of pyrimidines as potent inhibitors of TBK1/IKKepsilon kinases. Bioorg Med Chem Lett. 2012 Dec 1;22(23):7169-73.
DMWS7O9	RU	https://pubmed.ncbi.nlm.nih.gov/23099093

DMWS7O9	DI	DMWS7O9
DMWS7O9	DN	PMID23099093C17d
DMWS7O9	MI	TT3DCYJ
DMWS7O9	MN	Microtubule affinity regulating kinase 3 (MARK3)
DMWS7O9	MT	DTT
DMWS7O9	MA	Inhibitor
DMWS7O9	RN	Synthesis and structure-activity relationships of a novel series of pyrimidines as potent inhibitors of TBK1/IKKepsilon kinases. Bioorg Med Chem Lett. 2012 Dec 1;22(23):7169-73.
DMWS7O9	RU	https://pubmed.ncbi.nlm.nih.gov/23099093

DMWS7O9	DI	DMWS7O9
DMWS7O9	DN	PMID23099093C17d
DMWS7O9	MI	TTH5TC2
DMWS7O9	MN	NF-kappa-B-activating kinase (TBK1)
DMWS7O9	MT	DTT
DMWS7O9	MA	Inhibitor
DMWS7O9	RN	Synthesis and structure-activity relationships of a novel series of pyrimidines as potent inhibitors of TBK1/IKKepsilon kinases. Bioorg Med Chem Lett. 2012 Dec 1;22(23):7169-73.
DMWS7O9	RU	https://pubmed.ncbi.nlm.nih.gov/23099093

DMWS7O9	DI	DMWS7O9
DMWS7O9	DN	PMID23099093C17d
DMWS7O9	MI	TTJQT60
DMWS7O9	MN	TGF-beta-activated kinase 1 (MAP3K7)
DMWS7O9	MT	DTT
DMWS7O9	MA	Inhibitor
DMWS7O9	RN	Synthesis and structure-activity relationships of a novel series of pyrimidines as potent inhibitors of TBK1/IKKepsilon kinases. Bioorg Med Chem Lett. 2012 Dec 1;22(23):7169-73.
DMWS7O9	RU	https://pubmed.ncbi.nlm.nih.gov/23099093

DM3Z6F4	DI	DM3Z6F4
DM3Z6F4	DN	PMID23147077C10
DM3Z6F4	MI	TTOQCD8
DM3Z6F4	MN	Apoptosis signal-regulating kinase 1 (MAP3K5)
DM3Z6F4	MT	DTT
DM3Z6F4	MA	Inhibitor
DM3Z6F4	RN	Design and biological evaluation of imidazo[1,2-a]pyridines as novel and potent ASK1 inhibitors. Bioorg Med Chem Lett. 2012 Dec 15;22(24):7326-9.
DM3Z6F4	RU	https://pubmed.ncbi.nlm.nih.gov/23147077

DM3Z6F4	DI	DM3Z6F4
DM3Z6F4	DN	PMID23147077C10
DM3Z6F4	MI	TT64GC2
DM3Z6F4	MN	Apoptosis signal-regulating kinase 2 (MAP3K6)
DM3Z6F4	MT	DTT
DM3Z6F4	MA	Inhibitor
DM3Z6F4	RN	Design and biological evaluation of imidazo[1,2-a]pyridines as novel and potent ASK1 inhibitors. Bioorg Med Chem Lett. 2012 Dec 15;22(24):7326-9.
DM3Z6F4	RU	https://pubmed.ncbi.nlm.nih.gov/23147077

DMBT92F	DI	DMBT92F
DMBT92F	DN	PMID23232060C5
DMBT92F	MI	TTPB1W3
DMBT92F	MN	TRAF2 and NCK interacting kinase (TNIK)
DMBT92F	MT	DTT
DMBT92F	MA	Inhibitor
DMBT92F	RN	Discovery of 4-phenyl-2-phenylaminopyridine based TNIK inhibitors. Bioorg Med Chem Lett. 2013 Jan 15;23(2):569-73.
DMBT92F	RU	https://pubmed.ncbi.nlm.nih.gov/23232060

DMOJ8QR	DI	DMOJ8QR
DMOJ8QR	DN	PMID23312943C21
DMOJ8QR	MI	TT6NI13
DMOJ8QR	MN	MEK kinase kinase 4 (MAP4K4)
DMOJ8QR	MT	DTT
DMOJ8QR	MA	Inhibitor
DMOJ8QR	RN	Optimization of highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase. Bioorg Med Chem Lett. 2013 Feb 15;23(4):1051-5.
DMOJ8QR	RU	https://pubmed.ncbi.nlm.nih.gov/23312943

DMOJ8QR	DI	DMOJ8QR
DMOJ8QR	DN	PMID23312943C21
DMOJ8QR	MI	TTOU65C
DMOJ8QR	MN	Tyrosine-protein kinase SYK (SYK)
DMOJ8QR	MT	DTT
DMOJ8QR	MA	Inhibitor
DMOJ8QR	RN	Optimization of highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase. Bioorg Med Chem Lett. 2013 Feb 15;23(4):1051-5.
DMOJ8QR	RU	https://pubmed.ncbi.nlm.nih.gov/23312943

DM4NAC9	DI	DM4NAC9
DM4NAC9	DN	PMID23357634C24d
DM4NAC9	MI	TTHS256
DM4NAC9	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM4NAC9	MT	DTT
DM4NAC9	MA	Modulator (allosteric modulator)
DM4NAC9	RN	Discovery and structure-activity relationship of 1,3-cyclohexyl amide derivatives as novel mGluR5 negative allosteric modulators. Bioorg Med Chem Lett. 2013 Mar 1;23(5):1398-406.
DM4NAC9	RU	https://pubmed.ncbi.nlm.nih.gov/23357634

DMPHKJI	DI	DMPHKJI
DMPHKJI	DN	PMID23368907C16 
DMPHKJI	MI	TTA93TL
DMPHKJI	MN	P2Y purinoceptor 1 (P2RY1)
DMPHKJI	MT	DTT
DMPHKJI	MA	Antagonist
DMPHKJI	RN	Two disparate ligand-binding sites in the human P2Y1 receptor. Nature. 2015 Apr 16;520(7547):317-21.
DMPHKJI	RU	https://pubmed.ncbi.nlm.nih.gov/25822790

DMEZSHI	DI	DMEZSHI
DMEZSHI	DN	PMID23374866C31
DMEZSHI	MI	TT4LIAC
DMEZSHI	MN	Serine/threonine-protein kinase NIK (MAP3K14)
DMEZSHI	MT	DTT
DMEZSHI	MA	Inhibitor
DMEZSHI	RN	Inhibiting NF- B-inducing kinase (NIK): discovery, structure-based design, synthesis, structure-activity relationship, and co-crystal structures. Bioorg Med Chem Lett. 2013 Mar 1;23(5):1238-44.
DMEZSHI	RU	https://pubmed.ncbi.nlm.nih.gov/23374866

DMRC14X	DI	DMRC14X
DMRC14X	DN	PMID23374867C24
DMRC14X	MI	TTHS256
DMRC14X	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMRC14X	MT	DTT
DMRC14X	MA	Modulator (allosteric modulator)
DMRC14X	RN	Discovery of (1R,2R)-N-(4-(6-isopropylpyridin-2-yl)-3-(2-methyl-2H-indazol-5-yl)isothiazol-5-yl)-2-methylcyclopropanecarboxamide, a potent and orally efficacious mGlu5 receptor negative allosteric modulator. Bioorg Med Chem Lett. 2013 Mar 1;23(5):1249-52.
DMRC14X	RU	https://pubmed.ncbi.nlm.nih.gov/23374867

DM9O8I7	DI	DM9O8I7
DM9O8I7	DN	PMID23412139C16
DM9O8I7	MI	TT8JRS7
DM9O8I7	MN	Beta-secretase (BACE)
DM9O8I7	MT	DTT
DM9O8I7	MA	Inhibitor
DM9O8I7	RN	Discovery of an Orally Available, Brain Penetrant BACE1 Inhibitor that Affords Robust CNS A Reduction. ACS Med Chem Lett. 2012 Nov 8;3(11):897-902.
DM9O8I7	RU	https://pubmed.ncbi.nlm.nih.gov/23412139

DMNVQ29	DI	DMNVQ29
DMNVQ29	DN	PMID23414845C30
DMNVQ29	MI	TTON5IT
DMNVQ29	MN	Focal adhesion kinase 1 (FAK)
DMNVQ29	MT	DTT
DMNVQ29	MA	Inhibitor
DMNVQ29	RN	Structure-based discovery of cellular-active allosteric inhibitors of FAK. Bioorg Med Chem Lett. 2013 Mar 15;23(6):1779-85.
DMNVQ29	RU	https://pubmed.ncbi.nlm.nih.gov/23414845

DMZUQ7X	DI	DMZUQ7X
DMZUQ7X	DN	PMID23428964CI3
DMZUQ7X	MI	TTPHMWB
DMZUQ7X	MN	Aminopeptidase N (ANPEP)
DMZUQ7X	MT	DTT
DMZUQ7X	MA	Inhibitor
DMZUQ7X	RN	Selective aminopeptidase-N (CD13) inhibitors with relevance to cancer chemotherapy. Bioorg Med Chem. 2013 Apr 1;21(7):2135-44.
DMZUQ7X	RU	https://pubmed.ncbi.nlm.nih.gov/23428964

DMG0XC7	DI	DMG0XC7
DMG0XC7	DN	PMID23434029C41
DMG0XC7	MI	TTHS256
DMG0XC7	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMG0XC7	MT	DTT
DMG0XC7	MA	Modulator (allosteric modulator)
DMG0XC7	RN	Discovery of biological evaluation of pyrazole/imidazole amides as mGlu5 receptor negative allosteric modulators. Bioorg Med Chem Lett. 2013 Apr 1;23(7):2134-9.
DMG0XC7	RU	https://pubmed.ncbi.nlm.nih.gov/23434029

DMG0B4N	DI	DMG0B4N
DMG0B4N	DN	PMID23434029C53
DMG0B4N	MI	TTHS256
DMG0B4N	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMG0B4N	MT	DTT
DMG0B4N	MA	Modulator (allosteric modulator)
DMG0B4N	RN	Discovery of biological evaluation of pyrazole/imidazole amides as mGlu5 receptor negative allosteric modulators. Bioorg Med Chem Lett. 2013 Apr 1;23(7):2134-9.
DMG0B4N	RU	https://pubmed.ncbi.nlm.nih.gov/23434029

DMG4MLA	DI	DMG4MLA
DMG4MLA	DN	PMID23441572C24
DMG4MLA	MI	TT6B75U
DMG4MLA	MN	ABL messenger RNA (ABL mRNA)
DMG4MLA	MT	DTT
DMG4MLA	MA	Inhibitor
DMG4MLA	RN	Rapid discovery of a novel series of Abl kinase inhibitors by application of an integrated microfluidic synthesis and screening platform. J Med Chem. 2013 Apr 11;56(7):3033-47.
DMG4MLA	RU	https://pubmed.ncbi.nlm.nih.gov/23441572

DMG4MLA	DI	DMG4MLA
DMG4MLA	DN	PMID23441572C24
DMG4MLA	MI	TT1A6HL
DMG4MLA	MN	Tyrosine-protein kinase ABL2 (ABL2)
DMG4MLA	MT	DTT
DMG4MLA	MA	Inhibitor
DMG4MLA	RN	Rapid discovery of a novel series of Abl kinase inhibitors by application of an integrated microfluidic synthesis and screening platform. J Med Chem. 2013 Apr 11;56(7):3033-47.
DMG4MLA	RU	https://pubmed.ncbi.nlm.nih.gov/23441572

DMDYC4J	DI	DMDYC4J
DMDYC4J	DN	PMID23489211C20
DMDYC4J	MI	TTLFZVU
DMDYC4J	MN	Ephrin type-A receptor 1 (EPHA1)
DMDYC4J	MT	DTT
DMDYC4J	MA	Inhibitor
DMDYC4J	RN	Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem. 2013 Apr 11;56(7):2936-47.
DMDYC4J	RU	https://pubmed.ncbi.nlm.nih.gov/23489211

DMDYC4J	DI	DMDYC4J
DMDYC4J	DN	PMID23489211C20
DMDYC4J	MI	TTRJB2G
DMDYC4J	MN	Ephrin type-A receptor 2 (EPHA2)
DMDYC4J	MT	DTT
DMDYC4J	MA	Inhibitor
DMDYC4J	RN	Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem. 2013 Apr 11;56(7):2936-47.
DMDYC4J	RU	https://pubmed.ncbi.nlm.nih.gov/23489211

DMDYC4J	DI	DMDYC4J
DMDYC4J	DN	PMID23489211C20
DMDYC4J	MI	TTHS2LR
DMDYC4J	MN	Ephrin type-A receptor 3 (EPHA3)
DMDYC4J	MT	DTT
DMDYC4J	MA	Inhibitor
DMDYC4J	RN	Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem. 2013 Apr 11;56(7):2936-47.
DMDYC4J	RU	https://pubmed.ncbi.nlm.nih.gov/23489211

DMDYC4J	DI	DMDYC4J
DMDYC4J	DN	PMID23489211C20
DMDYC4J	MI	TTG84D3
DMDYC4J	MN	Ephrin type-A receptor 4 (EPHA4)
DMDYC4J	MT	DTT
DMDYC4J	MA	Inhibitor
DMDYC4J	RN	Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem. 2013 Apr 11;56(7):2936-47.
DMDYC4J	RU	https://pubmed.ncbi.nlm.nih.gov/23489211

DMDYC4J	DI	DMDYC4J
DMDYC4J	DN	PMID23489211C20
DMDYC4J	MI	TTV9KOD
DMDYC4J	MN	Ephrin type-A receptor 5 (EPHA5)
DMDYC4J	MT	DTT
DMDYC4J	MA	Inhibitor
DMDYC4J	RN	Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem. 2013 Apr 11;56(7):2936-47.
DMDYC4J	RU	https://pubmed.ncbi.nlm.nih.gov/23489211

DMDYC4J	DI	DMDYC4J
DMDYC4J	DN	PMID23489211C20
DMDYC4J	MI	TTFAHWI
DMDYC4J	MN	Ephrin type-A receptor 6 (EPHA6)
DMDYC4J	MT	DTT
DMDYC4J	MA	Inhibitor
DMDYC4J	RN	Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem. 2013 Apr 11;56(7):2936-47.
DMDYC4J	RU	https://pubmed.ncbi.nlm.nih.gov/23489211

DMDYC4J	DI	DMDYC4J
DMDYC4J	DN	PMID23489211C20
DMDYC4J	MI	TTAHTVG
DMDYC4J	MN	Ephrin type-A receptor 7 (EPHA7)
DMDYC4J	MT	DTT
DMDYC4J	MA	Inhibitor
DMDYC4J	RN	Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem. 2013 Apr 11;56(7):2936-47.
DMDYC4J	RU	https://pubmed.ncbi.nlm.nih.gov/23489211

DMDYC4J	DI	DMDYC4J
DMDYC4J	DN	PMID23489211C20
DMDYC4J	MI	TTHZ2LW
DMDYC4J	MN	Ephrin type-A receptor 8 (EPHA8)
DMDYC4J	MT	DTT
DMDYC4J	MA	Inhibitor
DMDYC4J	RN	Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem. 2013 Apr 11;56(7):2936-47.
DMDYC4J	RU	https://pubmed.ncbi.nlm.nih.gov/23489211

DMDYC4J	DI	DMDYC4J
DMDYC4J	DN	PMID23489211C20
DMDYC4J	MI	TT8MDAC
DMDYC4J	MN	Ephrin type-B receptor 1 (EPHB1)
DMDYC4J	MT	DTT
DMDYC4J	MA	Inhibitor
DMDYC4J	RN	Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem. 2013 Apr 11;56(7):2936-47.
DMDYC4J	RU	https://pubmed.ncbi.nlm.nih.gov/23489211

DMDYC4J	DI	DMDYC4J
DMDYC4J	DN	PMID23489211C20
DMDYC4J	MI	TTKPV6O
DMDYC4J	MN	Ephrin type-B receptor 2 (EPHB2)
DMDYC4J	MT	DTT
DMDYC4J	MA	Inhibitor
DMDYC4J	RN	Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem. 2013 Apr 11;56(7):2936-47.
DMDYC4J	RU	https://pubmed.ncbi.nlm.nih.gov/23489211

DMDYC4J	DI	DMDYC4J
DMDYC4J	DN	PMID23489211C20
DMDYC4J	MI	TT5LM7U
DMDYC4J	MN	Ephrin type-B receptor 3 (EPHB3)
DMDYC4J	MT	DTT
DMDYC4J	MA	Inhibitor
DMDYC4J	RN	Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem. 2013 Apr 11;56(7):2936-47.
DMDYC4J	RU	https://pubmed.ncbi.nlm.nih.gov/23489211

DMDYC4J	DI	DMDYC4J
DMDYC4J	DN	PMID23489211C20
DMDYC4J	MI	TTI4ZX2
DMDYC4J	MN	Ephrin type-B receptor 4 (EPHB4)
DMDYC4J	MT	DTT
DMDYC4J	MA	Inhibitor
DMDYC4J	RN	Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem. 2013 Apr 11;56(7):2936-47.
DMDYC4J	RU	https://pubmed.ncbi.nlm.nih.gov/23489211

DMDYC4J	DI	DMDYC4J
DMDYC4J	DN	PMID23489211C20
DMDYC4J	MI	TTZEMUY
DMDYC4J	MN	Ephrin type-B receptor 6 (EPHB6)
DMDYC4J	MT	DTT
DMDYC4J	MA	Inhibitor
DMDYC4J	RN	Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem. 2013 Apr 11;56(7):2936-47.
DMDYC4J	RU	https://pubmed.ncbi.nlm.nih.gov/23489211

DMFQVNL	DI	DMFQVNL
DMFQVNL	DN	PMID23517011C9
DMFQVNL	MI	TTRA6BO
DMFQVNL	MN	Bromodomain-containing protein 4 (BRD4)
DMFQVNL	MT	DTT
DMFQVNL	MA	Inhibitor
DMFQVNL	RN	Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands. J Med Chem. 2013 Apr 25;56(8):3217-27.
DMFQVNL	RU	https://pubmed.ncbi.nlm.nih.gov/23517011

DMPCTED	DI	DMPCTED
DMPCTED	DN	PMID23521020C7k
DMPCTED	MI	TTI1FPZ
DMPCTED	MN	Epithelial discoidin domain receptor 1 (DDR1)
DMPCTED	MT	DTT
DMPCTED	MA	Inhibitor
DMPCTED	RN	Discovery and optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors. J Med Chem. 2013 Apr 25;56(8):3281-95.
DMPCTED	RU	https://pubmed.ncbi.nlm.nih.gov/23521020

DMPCTED	DI	DMPCTED
DMPCTED	DN	PMID23521020C7k
DMPCTED	MI	TTX41N9
DMPCTED	MN	Tyrosine-protein kinase Kit (KIT)
DMPCTED	MT	DTT
DMPCTED	MA	Inhibitor
DMPCTED	RN	Discovery and optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors. J Med Chem. 2013 Apr 25;56(8):3281-95.
DMPCTED	RU	https://pubmed.ncbi.nlm.nih.gov/23521020

DMB7TE6	DI	DMB7TE6
DMB7TE6	DN	PMID23589301C1
DMB7TE6	MI	TT0FYAN
DMB7TE6	MN	Free fatty acid receptor 2 (FFAR2)
DMB7TE6	MT	DTT
DMB7TE6	MA	Agonist
DMB7TE6	RN	Defining the molecular basis for the first potent and selective orthosteric agonists of the FFA2 free fatty acid receptor. J Biol Chem. 2013 Jun 14;288(24):17296-312.
DMB7TE6	RU	https://pubmed.ncbi.nlm.nih.gov/23589301

DMM92IB	DI	DMM92IB
DMM92IB	DN	PMID23631440C29e
DMM92IB	MI	TTJ4QE7
DMM92IB	MN	Matrix metalloproteinase-14 (MMP-14)
DMM92IB	MT	DTT
DMM92IB	MA	Inhibitor
DMM92IB	RN	Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core. J Med Chem. 2013 Jun 13;56(11):4357-73.
DMM92IB	RU	https://pubmed.ncbi.nlm.nih.gov/23631440

DMM92IB	DI	DMM92IB
DMM92IB	DN	PMID23631440C29e
DMM92IB	MI	TT6X50U
DMM92IB	MN	Matrix metalloproteinase-9 (MMP-9)
DMM92IB	MT	DTT
DMM92IB	MA	Inhibitor
DMM92IB	RN	Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core. J Med Chem. 2013 Jun 13;56(11):4357-73.
DMM92IB	RU	https://pubmed.ncbi.nlm.nih.gov/23631440

DMA8UQM	DI	DMA8UQM
DMA8UQM	DN	PMID23634668C14
DMA8UQM	MI	TT1L79K
DMA8UQM	MN	Methionyl aminopeptidase 1 (METAP1)
DMA8UQM	MT	DTT
DMA8UQM	MA	Inhibitor
DMA8UQM	RN	Pyridinylquinazolines selectively inhibit human methionine aminopeptidase-1 in cells. J Med Chem. 2013 May 23;56(10):3996-4016.
DMA8UQM	RU	https://pubmed.ncbi.nlm.nih.gov/23634668

DMLXOAQ	DI	DMLXOAQ
DMLXOAQ	DN	PMID23639540C13a
DMLXOAQ	MI	TTJNBQA
DMLXOAQ	MN	Activin receptor-like kinase 2 (ALK-2)
DMLXOAQ	MT	DTT
DMLXOAQ	MA	Inhibitor
DMLXOAQ	RN	Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.
DMLXOAQ	RU	https://pubmed.ncbi.nlm.nih.gov/23639540

DMLXOAQ	DI	DMLXOAQ
DMLXOAQ	DN	PMID23639540C13a
DMLXOAQ	MI	TTGYPTC
DMLXOAQ	MN	Activin receptor-like kinase-1 (ACVRL1)
DMLXOAQ	MT	DTT
DMLXOAQ	MA	Inhibitor
DMLXOAQ	RN	Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.
DMLXOAQ	RU	https://pubmed.ncbi.nlm.nih.gov/23639540

DMLXOAQ	DI	DMLXOAQ
DMLXOAQ	DN	PMID23639540C13a
DMLXOAQ	MI	TTLAFZV
DMLXOAQ	MN	AMP-activated protein kinase (AMPK)
DMLXOAQ	MT	DTT
DMLXOAQ	MA	Inhibitor
DMLXOAQ	RN	Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.
DMLXOAQ	RU	https://pubmed.ncbi.nlm.nih.gov/23639540

DMLXOAQ	DI	DMLXOAQ
DMLXOAQ	DN	PMID23639540C13a
DMLXOAQ	MI	TTGKF90
DMLXOAQ	MN	Bone morphogenetic protein receptor (BMPR2)
DMLXOAQ	MT	DTT
DMLXOAQ	MA	Inhibitor
DMLXOAQ	RN	Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.
DMLXOAQ	RU	https://pubmed.ncbi.nlm.nih.gov/23639540

DMLXOAQ	DI	DMLXOAQ
DMLXOAQ	DN	PMID23639540C13a
DMLXOAQ	MI	TTZE3P7
DMLXOAQ	MN	TGF-beta receptor type II (TGFBR2)
DMLXOAQ	MT	DTT
DMLXOAQ	MA	Inhibitor
DMLXOAQ	RN	Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.
DMLXOAQ	RU	https://pubmed.ncbi.nlm.nih.gov/23639540

DMLXOAQ	DI	DMLXOAQ
DMLXOAQ	DN	PMID23639540C13a
DMLXOAQ	MI	TTUTJGQ
DMLXOAQ	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMLXOAQ	MT	DTT
DMLXOAQ	MA	Inhibitor
DMLXOAQ	RN	Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.
DMLXOAQ	RU	https://pubmed.ncbi.nlm.nih.gov/23639540

DMSTQGH	DI	DMSTQGH
DMSTQGH	DN	PMID23639540C13d
DMSTQGH	MI	TTPKHTZ
DMSTQGH	MN	Activin receptor type IB (ACVR1B)
DMSTQGH	MT	DTT
DMSTQGH	MA	Inhibitor
DMSTQGH	RN	Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.
DMSTQGH	RU	https://pubmed.ncbi.nlm.nih.gov/23639540

DMSTQGH	DI	DMSTQGH
DMSTQGH	DN	PMID23639540C13d
DMSTQGH	MI	TTJNBQA
DMSTQGH	MN	Activin receptor-like kinase 2 (ALK-2)
DMSTQGH	MT	DTT
DMSTQGH	MA	Inhibitor
DMSTQGH	RN	Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.
DMSTQGH	RU	https://pubmed.ncbi.nlm.nih.gov/23639540

DMSTQGH	DI	DMSTQGH
DMSTQGH	DN	PMID23639540C13d
DMSTQGH	MI	TTGYPTC
DMSTQGH	MN	Activin receptor-like kinase-1 (ACVRL1)
DMSTQGH	MT	DTT
DMSTQGH	MA	Inhibitor
DMSTQGH	RN	Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.
DMSTQGH	RU	https://pubmed.ncbi.nlm.nih.gov/23639540

DMSTQGH	DI	DMSTQGH
DMSTQGH	DN	PMID23639540C13d
DMSTQGH	MI	TTGKF90
DMSTQGH	MN	Bone morphogenetic protein receptor (BMPR2)
DMSTQGH	MT	DTT
DMSTQGH	MA	Inhibitor
DMSTQGH	RN	Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.
DMSTQGH	RU	https://pubmed.ncbi.nlm.nih.gov/23639540

DMSTQGH	DI	DMSTQGH
DMSTQGH	DN	PMID23639540C13d
DMSTQGH	MI	TTP4520
DMSTQGH	MN	TGF-beta receptor type I (TGFBR1)
DMSTQGH	MT	DTT
DMSTQGH	MA	Inhibitor
DMSTQGH	RN	Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.
DMSTQGH	RU	https://pubmed.ncbi.nlm.nih.gov/23639540

DMSTQGH	DI	DMSTQGH
DMSTQGH	DN	PMID23639540C13d
DMSTQGH	MI	TTZE3P7
DMSTQGH	MN	TGF-beta receptor type II (TGFBR2)
DMSTQGH	MT	DTT
DMSTQGH	MA	Inhibitor
DMSTQGH	RN	Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.
DMSTQGH	RU	https://pubmed.ncbi.nlm.nih.gov/23639540

DMHBZ0N	DI	DMHBZ0N
DMHBZ0N	DN	PMID23639540C13r
DMHBZ0N	MI	TTPKHTZ
DMHBZ0N	MN	Activin receptor type IB (ACVR1B)
DMHBZ0N	MT	DTT
DMHBZ0N	MA	Inhibitor
DMHBZ0N	RN	Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.
DMHBZ0N	RU	https://pubmed.ncbi.nlm.nih.gov/23639540

DMHBZ0N	DI	DMHBZ0N
DMHBZ0N	DN	PMID23639540C13r
DMHBZ0N	MI	TTJNBQA
DMHBZ0N	MN	Activin receptor-like kinase 2 (ALK-2)
DMHBZ0N	MT	DTT
DMHBZ0N	MA	Inhibitor
DMHBZ0N	RN	Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.
DMHBZ0N	RU	https://pubmed.ncbi.nlm.nih.gov/23639540

DMHBZ0N	DI	DMHBZ0N
DMHBZ0N	DN	PMID23639540C13r
DMHBZ0N	MI	TTGYPTC
DMHBZ0N	MN	Activin receptor-like kinase-1 (ACVRL1)
DMHBZ0N	MT	DTT
DMHBZ0N	MA	Inhibitor
DMHBZ0N	RN	Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.
DMHBZ0N	RU	https://pubmed.ncbi.nlm.nih.gov/23639540

DMHBZ0N	DI	DMHBZ0N
DMHBZ0N	DN	PMID23639540C13r
DMHBZ0N	MI	TTGKF90
DMHBZ0N	MN	Bone morphogenetic protein receptor (BMPR2)
DMHBZ0N	MT	DTT
DMHBZ0N	MA	Inhibitor
DMHBZ0N	RN	Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.
DMHBZ0N	RU	https://pubmed.ncbi.nlm.nih.gov/23639540

DMHBZ0N	DI	DMHBZ0N
DMHBZ0N	DN	PMID23639540C13r
DMHBZ0N	MI	TTP4520
DMHBZ0N	MN	TGF-beta receptor type I (TGFBR1)
DMHBZ0N	MT	DTT
DMHBZ0N	MA	Inhibitor
DMHBZ0N	RN	Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.
DMHBZ0N	RU	https://pubmed.ncbi.nlm.nih.gov/23639540

DM4JWMA	DI	DM4JWMA
DM4JWMA	DN	PMID23642479C17
DM4JWMA	MI	TTE6YDG
DM4JWMA	MN	CDC-like kinase 1 (CLK1)
DM4JWMA	MT	DTT
DM4JWMA	MA	Inhibitor
DM4JWMA	RN	Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315. Bioorg Med Chem Lett. 2013 Jun15;23(12):3654-61.
DM4JWMA	RU	https://pubmed.ncbi.nlm.nih.gov/23642479

DM4JWMA	DI	DM4JWMA
DM4JWMA	DN	PMID23642479C17
DM4JWMA	MI	TT85TPS
DM4JWMA	MN	CDC-like kinase 2 (CLK2)
DM4JWMA	MT	DTT
DM4JWMA	MA	Inhibitor
DM4JWMA	RN	Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315. Bioorg Med Chem Lett. 2013 Jun15;23(12):3654-61.
DM4JWMA	RU	https://pubmed.ncbi.nlm.nih.gov/23642479

DM4JWMA	DI	DM4JWMA
DM4JWMA	DN	PMID23642479C17
DM4JWMA	MI	TT1RFQP
DM4JWMA	MN	CDC-like kinase 4 (CLK4)
DM4JWMA	MT	DTT
DM4JWMA	MA	Inhibitor
DM4JWMA	RN	Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315. Bioorg Med Chem Lett. 2013 Jun15;23(12):3654-61.
DM4JWMA	RU	https://pubmed.ncbi.nlm.nih.gov/23642479

DM4JWMA	DI	DM4JWMA
DM4JWMA	DN	PMID23642479C17
DM4JWMA	MI	TTSBVFO
DM4JWMA	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DM4JWMA	MT	DTT
DM4JWMA	MA	Inhibitor
DM4JWMA	RN	Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315. Bioorg Med Chem Lett. 2013 Jun15;23(12):3654-61.
DM4JWMA	RU	https://pubmed.ncbi.nlm.nih.gov/23642479

DM4JWMA	DI	DM4JWMA
DM4JWMA	DN	PMID23642479C17
DM4JWMA	MI	TTYGQ8A
DM4JWMA	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B)
DM4JWMA	MT	DTT
DM4JWMA	MA	Inhibitor
DM4JWMA	RN	Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315. Bioorg Med Chem Lett. 2013 Jun15;23(12):3654-61.
DM4JWMA	RU	https://pubmed.ncbi.nlm.nih.gov/23642479

DM1T9LJ	DI	DM1T9LJ
DM1T9LJ	DN	PMID23692593C20
DM1T9LJ	MI	TTS78AZ
DM1T9LJ	MN	Prostate specific antigen (KLK3)
DM1T9LJ	MT	DTT
DM1T9LJ	MA	Inhibitor
DM1T9LJ	RN	Structural optimization, biological evaluation, and application of peptidomimetic prostate specific antigen inhibitors. J Med Chem. 2013 Jun 13;56(11):4224-35.
DM1T9LJ	RU	https://pubmed.ncbi.nlm.nih.gov/23692593

DM2FDJN	DI	DM2FDJN
DM2FDJN	DN	PMID23788657C1754-31
DM2FDJN	MI	TTOJ1NF
DM2FDJN	MN	FMLP-related receptor I (FPR2)
DM2FDJN	MT	DTT
DM2FDJN	MA	Antagonist
DM2FDJN	RN	Selective agonists and antagonists of formylpeptide receptors: duplex flow cytometry and mixture-based positional scanning libraries. Mol Pharmacol. 2013 Sep;84(3):314-24.
DM2FDJN	RU	https://pubmed.ncbi.nlm.nih.gov/23788657

DMUW3MT	DI	DMUW3MT
DMUW3MT	DN	PMID23849879C3
DMUW3MT	MI	TTDA81R
DMUW3MT	MN	Kallikrein-14 (KLK14)
DMUW3MT	MT	DTT
DMUW3MT	MA	Inhibitor
DMUW3MT	RN	1,2,4-Triazole derivatives as transient inactivators of kallikreins involved in skin diseases. Bioorg Med Chem Lett. 2013 Aug 15;23(16):4547-51.
DMUW3MT	RU	https://pubmed.ncbi.nlm.nih.gov/23849879

DMUW3MT	DI	DMUW3MT
DMUW3MT	DN	PMID23849879C3
DMUW3MT	MI	TTULSEW
DMUW3MT	MN	Kallikrein-5 (KLK5)
DMUW3MT	MT	DTT
DMUW3MT	MA	Inhibitor
DMUW3MT	RN	1,2,4-Triazole derivatives as transient inactivators of kallikreins involved in skin diseases. Bioorg Med Chem Lett. 2013 Aug 15;23(16):4547-51.
DMUW3MT	RU	https://pubmed.ncbi.nlm.nih.gov/23849879

DMUW3MT	DI	DMUW3MT
DMUW3MT	DN	PMID23849879C3
DMUW3MT	MI	TTE6GTB
DMUW3MT	MN	Kallikrein-7 (KLK7)
DMUW3MT	MT	DTT
DMUW3MT	MA	Inhibitor
DMUW3MT	RN	1,2,4-Triazole derivatives as transient inactivators of kallikreins involved in skin diseases. Bioorg Med Chem Lett. 2013 Aug 15;23(16):4547-51.
DMUW3MT	RU	https://pubmed.ncbi.nlm.nih.gov/23849879

DMUW3MT	DI	DMUW3MT
DMUW3MT	DN	PMID23849879C3
DMUW3MT	MI	TTPRO7W
DMUW3MT	MN	Suppressor of tumorigenicity 14 protein (ST14)
DMUW3MT	MT	DTT
DMUW3MT	MA	Inhibitor
DMUW3MT	RN	1,2,4-Triazole derivatives as transient inactivators of kallikreins involved in skin diseases. Bioorg Med Chem Lett. 2013 Aug 15;23(16):4547-51.
DMUW3MT	RU	https://pubmed.ncbi.nlm.nih.gov/23849879

DM35FH8	DI	DM35FH8
DM35FH8	DN	PMID23916253C17
DM35FH8	MI	TT60XFL
DM35FH8	MN	Adipocyte-derived leucine aminopeptidase (ERAP1)
DM35FH8	MT	DTT
DM35FH8	MA	Inhibitor
DM35FH8	RN	Novel selective inhibitors of aminopeptidases that generate antigenic peptides. Bioorg Med Chem Lett. 2013 Sep 1;23(17):4832-6.
DM35FH8	RU	https://pubmed.ncbi.nlm.nih.gov/23916253

DM35FH8	DI	DM35FH8
DM35FH8	DN	PMID23916253C17
DM35FH8	MI	TTVGS1C
DM35FH8	MN	Endoplasmic reticulum aminopeptidase 2 (ERAP2)
DM35FH8	MT	DTT
DM35FH8	MA	Inhibitor
DM35FH8	RN	Novel selective inhibitors of aminopeptidases that generate antigenic peptides. Bioorg Med Chem Lett. 2013 Sep 1;23(17):4832-6.
DM35FH8	RU	https://pubmed.ncbi.nlm.nih.gov/23916253

DM35FH8	DI	DM35FH8
DM35FH8	DN	PMID23916253C17
DM35FH8	MI	TTY2KP7
DM35FH8	MN	Leucyl-cysteinyl aminopeptidase (LNPEP)
DM35FH8	MT	DTT
DM35FH8	MA	Inhibitor
DM35FH8	RN	Novel selective inhibitors of aminopeptidases that generate antigenic peptides. Bioorg Med Chem Lett. 2013 Sep 1;23(17):4832-6.
DM35FH8	RU	https://pubmed.ncbi.nlm.nih.gov/23916253

DMHUWZS	DI	DMHUWZS
DMHUWZS	DN	PMID24000170C36
DMHUWZS	MI	TTDP48B
DMHUWZS	MN	Bromodomain-containing protein 2 (BRD2)
DMHUWZS	MT	DTT
DMHUWZS	MA	Inhibitor
DMHUWZS	RN	Naphthyridines as novel BET family bromodomain inhibitors. ChemMedChem. 2014 Mar;9(3):580-9.
DMHUWZS	RU	https://pubmed.ncbi.nlm.nih.gov/24000170

DMHUWZS	DI	DMHUWZS
DMHUWZS	DN	PMID24000170C36
DMHUWZS	MI	TTHE657
DMHUWZS	MN	Bromodomain-containing protein 3 (BRD3)
DMHUWZS	MT	DTT
DMHUWZS	MA	Inhibitor
DMHUWZS	RN	Naphthyridines as novel BET family bromodomain inhibitors. ChemMedChem. 2014 Mar;9(3):580-9.
DMHUWZS	RU	https://pubmed.ncbi.nlm.nih.gov/24000170

DMHUWZS	DI	DMHUWZS
DMHUWZS	DN	PMID24000170C36
DMHUWZS	MI	TTRA6BO
DMHUWZS	MN	Bromodomain-containing protein 4 (BRD4)
DMHUWZS	MT	DTT
DMHUWZS	MA	Inhibitor
DMHUWZS	RN	Naphthyridines as novel BET family bromodomain inhibitors. ChemMedChem. 2014 Mar;9(3):580-9.
DMHUWZS	RU	https://pubmed.ncbi.nlm.nih.gov/24000170

DMOLRIY	DI	DMOLRIY
DMOLRIY	DN	PMID24000170C38
DMOLRIY	MI	TTDP48B
DMOLRIY	MN	Bromodomain-containing protein 2 (BRD2)
DMOLRIY	MT	DTT
DMOLRIY	MA	Inhibitor
DMOLRIY	RN	Naphthyridines as novel BET family bromodomain inhibitors. ChemMedChem. 2014 Mar;9(3):580-9.
DMOLRIY	RU	https://pubmed.ncbi.nlm.nih.gov/24000170

DMOLRIY	DI	DMOLRIY
DMOLRIY	DN	PMID24000170C38
DMOLRIY	MI	TTHE657
DMOLRIY	MN	Bromodomain-containing protein 3 (BRD3)
DMOLRIY	MT	DTT
DMOLRIY	MA	Inhibitor
DMOLRIY	RN	Naphthyridines as novel BET family bromodomain inhibitors. ChemMedChem. 2014 Mar;9(3):580-9.
DMOLRIY	RU	https://pubmed.ncbi.nlm.nih.gov/24000170

DMOLRIY	DI	DMOLRIY
DMOLRIY	DN	PMID24000170C38
DMOLRIY	MI	TTRA6BO
DMOLRIY	MN	Bromodomain-containing protein 4 (BRD4)
DMOLRIY	MT	DTT
DMOLRIY	MA	Inhibitor
DMOLRIY	RN	Naphthyridines as novel BET family bromodomain inhibitors. ChemMedChem. 2014 Mar;9(3):580-9.
DMOLRIY	RU	https://pubmed.ncbi.nlm.nih.gov/24000170

DML4KMP	DI	DML4KMP
DML4KMP	DN	PMID24044867C8
DML4KMP	MI	TTETX6Q
DML4KMP	MN	Mixed lineage kinase 3 (MAP3K11)
DML4KMP	MT	DTT
DML4KMP	MA	Inhibitor
DML4KMP	RN	Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3. J Med Chem. 2013 Oct 24;56(20):8032-48.
DML4KMP	RU	https://pubmed.ncbi.nlm.nih.gov/24044867

DMWOHAE	DI	DMWOHAE
DMWOHAE	DN	PMID24099220C5i
DMWOHAE	MI	TTZJYKH
DMWOHAE	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMWOHAE	MT	DTT
DMWOHAE	MA	Inhibitor
DMWOHAE	RN	Discovery of tryptanthrin derivatives as potent inhibitors of indoleamine 2,3-dioxygenase with therapeutic activity in Lewis lung cancer (LLC) tumor-bearing mice. J Med Chem. 2013 Nov 14;56(21):8321-31.
DMWOHAE	RU	https://pubmed.ncbi.nlm.nih.gov/24099220

DMWUZP1	DI	DMWUZP1
DMWUZP1	DN	PMID24157366C35
DMWUZP1	MI	TTTJZ4M
DMWUZP1	MN	Prolylcarboxypeptidase (PRCP)
DMWUZP1	MT	DTT
DMWUZP1	MA	Inhibitor
DMWUZP1	RN	Discovery and optimization of orally active cyclohexane-based prolylcarboxypeptidase (PrCP) inhibitors. Bioorg Med Chem Lett. 2013 Dec 1;23(23):6228-33.
DMWUZP1	RU	https://pubmed.ncbi.nlm.nih.gov/24157366

DM4LEUT	DI	DM4LEUT
DM4LEUT	DN	PMID24210504C1o
DM4LEUT	MI	TTAZ3MN
DM4LEUT	MN	Beta-adrenergic receptor kinase 1 (ADRBK1)
DM4LEUT	MT	DTT
DM4LEUT	MA	Inhibitor
DM4LEUT	RN	Design and synthesis of novel 3-(benzo[d]oxazol-2-yl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine derivatives as selective G-protein-coupled receptor kinase-2 and -5 inhibitors. Bioorg Med Chem Lett. 2013 Dec 15;23(24):6711-6.
DM4LEUT	RU	https://pubmed.ncbi.nlm.nih.gov/24210504

DM4LEUT	DI	DM4LEUT
DM4LEUT	DN	PMID24210504C1o
DM4LEUT	MI	TTTCXO0
DM4LEUT	MN	G protein-coupled receptor kinase 5 (GRK5)
DM4LEUT	MT	DTT
DM4LEUT	MA	Inhibitor
DM4LEUT	RN	Design and synthesis of novel 3-(benzo[d]oxazol-2-yl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine derivatives as selective G-protein-coupled receptor kinase-2 and -5 inhibitors. Bioorg Med Chem Lett. 2013 Dec 15;23(24):6711-6.
DM4LEUT	RU	https://pubmed.ncbi.nlm.nih.gov/24210504

DM4LEUT	DI	DM4LEUT
DM4LEUT	DN	PMID24210504C1o
DM4LEUT	MI	TTNDSF4
DM4LEUT	MN	Proto-oncogene c-Met (MET)
DM4LEUT	MT	DTT
DM4LEUT	MA	Inhibitor
DM4LEUT	RN	Design and synthesis of novel 3-(benzo[d]oxazol-2-yl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine derivatives as selective G-protein-coupled receptor kinase-2 and -5 inhibitors. Bioorg Med Chem Lett. 2013 Dec 15;23(24):6711-6.
DM4LEUT	RU	https://pubmed.ncbi.nlm.nih.gov/24210504

DM26JYS	DI	DM26JYS
DM26JYS	DN	PMID24359159C19a
DM26JYS	MI	TT6DM01
DM26JYS	MN	Janus kinase 1 (JAK-1)
DM26JYS	MT	DTT
DM26JYS	MA	Inhibitor
DM26JYS	RN	Discovery of 1-methyl-1H-imidazole derivatives as potent Jak2 inhibitors. J Med Chem. 2014 Jan 9;57(1):144-58.
DM26JYS	RU	https://pubmed.ncbi.nlm.nih.gov/24359159

DM26JYS	DI	DM26JYS
DM26JYS	DN	PMID24359159C19a
DM26JYS	MI	TTRMX3V
DM26JYS	MN	Janus kinase 2 (JAK-2)
DM26JYS	MT	DTT
DM26JYS	MA	Inhibitor
DM26JYS	RN	Discovery of 1-methyl-1H-imidazole derivatives as potent Jak2 inhibitors. J Med Chem. 2014 Jan 9;57(1):144-58.
DM26JYS	RU	https://pubmed.ncbi.nlm.nih.gov/24359159

DM26JYS	DI	DM26JYS
DM26JYS	DN	PMID24359159C19a
DM26JYS	MI	TTT7PJU
DM26JYS	MN	Janus kinase 3 (JAK-3)
DM26JYS	MT	DTT
DM26JYS	MA	Inhibitor
DM26JYS	RN	Discovery of 1-methyl-1H-imidazole derivatives as potent Jak2 inhibitors. J Med Chem. 2014 Jan 9;57(1):144-58.
DM26JYS	RU	https://pubmed.ncbi.nlm.nih.gov/24359159

DM6O7MK	DI	DM6O7MK
DM6O7MK	DN	PMID24412111C9f
DM6O7MK	MI	TTHYDUM
DM6O7MK	MN	Bombesin receptor (BS)
DM6O7MK	MT	DTT
DM6O7MK	MA	Agonist
DM6O7MK	RN	Discovery of novel chiral diazepines as bombesin receptor subtype-3 (BRS-3) agonists with low brain penetration. Bioorg Med Chem Lett. 2014 Feb 1;24(3):750-5.
DM6O7MK	RU	https://pubmed.ncbi.nlm.nih.gov/24412111

DM8JQL4	DI	DM8JQL4
DM8JQL4	DN	PMID24412111C9g
DM8JQL4	MI	TTHYDUM
DM8JQL4	MN	Bombesin receptor (BS)
DM8JQL4	MT	DTT
DM8JQL4	MA	Agonist
DM8JQL4	RN	Discovery of novel chiral diazepines as bombesin receptor subtype-3 (BRS-3) agonists with low brain penetration. Bioorg Med Chem Lett. 2014 Feb 1;24(3):750-5.
DM8JQL4	RU	https://pubmed.ncbi.nlm.nih.gov/24412111

DMG4NQV	DI	DMG4NQV
DMG4NQV	DN	PMID24418773C37
DMG4NQV	MI	TTZUXYS
DMG4NQV	MN	Vitamin K-dependent protein C (PROC)
DMG4NQV	MT	DTT
DMG4NQV	MA	Inhibitor
DMG4NQV	RN	Design, synthesis, and SAR of a series of activated protein C (APC) inhibitors with selectivity against thrombin for the treatment of haemophilia. Bioorg Med Chem Lett. 2014 Feb 1;24(3):821-7.
DMG4NQV	RU	https://pubmed.ncbi.nlm.nih.gov/24418773

DMEGAZS	DI	DMEGAZS
DMEGAZS	DN	PMID24432909C8e
DMEGAZS	MI	TTPMQSO
DMEGAZS	MN	ALK tyrosine kinase receptor (ALK)
DMEGAZS	MT	DTT
DMEGAZS	MA	Inhibitor
DMEGAZS	RN	Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib. J Med Chem.> 2014 Feb 27;57(4):1170-87.
DMEGAZS	RU	https://pubmed.ncbi.nlm.nih.gov/24432909

DMEGAZS	DI	DMEGAZS
DMEGAZS	DN	PMID24432909C8e
DMEGAZS	MI	TTKN7QR
DMEGAZS	MN	BDNF/NT-3 growth factors receptor (TrkB)
DMEGAZS	MT	DTT
DMEGAZS	MA	Inhibitor
DMEGAZS	RN	Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib. J Med Chem.> 2014 Feb 27;57(4):1170-87.
DMEGAZS	RU	https://pubmed.ncbi.nlm.nih.gov/24432909

DMEGAZS	DI	DMEGAZS
DMEGAZS	DN	PMID24432909C8e
DMEGAZS	MI	TT1JZG6
DMEGAZS	MN	Leukocyte receptor tyrosine kinase (LTK)
DMEGAZS	MT	DTT
DMEGAZS	MA	Inhibitor
DMEGAZS	RN	Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib. J Med Chem.> 2014 Feb 27;57(4):1170-87.
DMEGAZS	RU	https://pubmed.ncbi.nlm.nih.gov/24432909

DMEGAZS	DI	DMEGAZS
DMEGAZS	DN	PMID24432909C8e
DMEGAZS	MI	TTRA9G0
DMEGAZS	MN	Proto-oncogene c-Fer (FER)
DMEGAZS	MT	DTT
DMEGAZS	MA	Inhibitor
DMEGAZS	RN	Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib. J Med Chem.> 2014 Feb 27;57(4):1170-87.
DMEGAZS	RU	https://pubmed.ncbi.nlm.nih.gov/24432909

DMEGAZS	DI	DMEGAZS
DMEGAZS	DN	PMID24432909C8e
DMEGAZS	MI	TTLBY21
DMEGAZS	MN	Proto-oncogene c-Fes (FES)
DMEGAZS	MT	DTT
DMEGAZS	MA	Inhibitor
DMEGAZS	RN	Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib. J Med Chem.> 2014 Feb 27;57(4):1170-87.
DMEGAZS	RU	https://pubmed.ncbi.nlm.nih.gov/24432909

DMEGAZS	DI	DMEGAZS
DMEGAZS	DN	PMID24432909C8e
DMEGAZS	MI	TTSZ6Y3
DMEGAZS	MN	Proto-oncogene c-Ros (ROS1)
DMEGAZS	MT	DTT
DMEGAZS	MA	Inhibitor
DMEGAZS	RN	Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib. J Med Chem.> 2014 Feb 27;57(4):1170-87.
DMEGAZS	RU	https://pubmed.ncbi.nlm.nih.gov/24432909

DMHQK54	DI	DMHQK54
DMHQK54	DN	PMID24440480C3
DMHQK54	MI	TTSCHFW
DMHQK54	MN	Peptidyl arginine deiminase type III (PADI3)
DMHQK54	MT	DTT
DMHQK54	MA	Inhibitor
DMHQK54	RN	Insights into the mechanism of streptonigrin-induced protein arginine deiminase inactivation. Bioorg Med Chem. 2014 Feb 15;22(4):1362-9.
DMHQK54	RU	https://pubmed.ncbi.nlm.nih.gov/24440480

DMHQK54	DI	DMHQK54
DMHQK54	DN	PMID24440480C3
DMHQK54	MI	TTQHAXM
DMHQK54	MN	Peptidyl arginine deiminase type IV (PADI4)
DMHQK54	MT	DTT
DMHQK54	MA	Inhibitor
DMHQK54	RN	Insights into the mechanism of streptonigrin-induced protein arginine deiminase inactivation. Bioorg Med Chem. 2014 Feb 15;22(4):1362-9.
DMHQK54	RU	https://pubmed.ncbi.nlm.nih.gov/24440480

DMK6GAU	DI	DMK6GAU
DMK6GAU	DN	PMID24556381C10f
DMK6GAU	MI	TTTRNQW
DMK6GAU	MN	Bile-salt-activated lipase (CEL)
DMK6GAU	MT	DTT
DMK6GAU	MA	Inhibitor
DMK6GAU	RN	Synthesis and evaluation of 2-(1H-indol-3-yl)-4-phenylquinolines as inhibitors of cholesterol esterase. Bioorg Med Chem Lett. 2014 Mar 15;24(6):1545-9.
DMK6GAU	RU	https://pubmed.ncbi.nlm.nih.gov/24556381

DMK6GAU	DI	DMK6GAU
DMK6GAU	DN	PMID24556381C10f
DMK6GAU	MI	TTPLTSQ
DMK6GAU	MN	Neutrophil elastase (NE)
DMK6GAU	MT	DTT
DMK6GAU	MA	Inhibitor
DMK6GAU	RN	Synthesis and evaluation of 2-(1H-indol-3-yl)-4-phenylquinolines as inhibitors of cholesterol esterase. Bioorg Med Chem Lett. 2014 Mar 15;24(6):1545-9.
DMK6GAU	RU	https://pubmed.ncbi.nlm.nih.gov/24556381

DMOH45T	DI	DMOH45T
DMOH45T	DN	PMID24556381C10l
DMOH45T	MI	TTTRNQW
DMOH45T	MN	Bile-salt-activated lipase (CEL)
DMOH45T	MT	DTT
DMOH45T	MA	Inhibitor
DMOH45T	RN	Synthesis and evaluation of 2-(1H-indol-3-yl)-4-phenylquinolines as inhibitors of cholesterol esterase. Bioorg Med Chem Lett. 2014 Mar 15;24(6):1545-9.
DMOH45T	RU	https://pubmed.ncbi.nlm.nih.gov/24556381

DMOH45T	DI	DMOH45T
DMOH45T	DN	PMID24556381C10l
DMOH45T	MI	TTPLTSQ
DMOH45T	MN	Neutrophil elastase (NE)
DMOH45T	MT	DTT
DMOH45T	MA	Inhibitor
DMOH45T	RN	Synthesis and evaluation of 2-(1H-indol-3-yl)-4-phenylquinolines as inhibitors of cholesterol esterase. Bioorg Med Chem Lett. 2014 Mar 15;24(6):1545-9.
DMOH45T	RU	https://pubmed.ncbi.nlm.nih.gov/24556381

DM2HVU8	DI	DM2HVU8
DM2HVU8	DN	PMID24673130C26
DM2HVU8	MI	TT6NI13
DM2HVU8	MN	MEK kinase kinase 4 (MAP4K4)
DM2HVU8	MT	DTT
DM2HVU8	MA	Inhibitor
DM2HVU8	RN	Discovery of selective 4-Amino-pyridopyrimidine inhibitors of MAP4K4 using fragment-based lead identification and optimization. J Med Chem. 2014 Apr 24;57(8):3484-93.
DM2HVU8	RU	https://pubmed.ncbi.nlm.nih.gov/24673130

DMJNQE1	DI	DMJNQE1
DMJNQE1	DN	PMID24749861C34
DMJNQE1	MI	TTOJ9QL
DMJNQE1	MN	Endoplasmic reticulum to nucleus signaling 1 (ERN1)
DMJNQE1	MT	DTT
DMJNQE1	MA	Inhibitor
DMJNQE1	RN	Synthesis of novel tricyclic chromenone-based inhibitors of IRE-1 RNase activity. J Med Chem. 2014 May 22;57(10):4289-301.
DMJNQE1	RU	https://pubmed.ncbi.nlm.nih.gov/24749861

DMDMU01	DI	DMDMU01
DMDMU01	DN	PMID24775305C7u
DMDMU01	MI	TTPTWV5
DMDMU01	MN	Legumain (LGMN)
DMDMU01	MT	DTT
DMDMU01	MA	Inhibitor
DMDMU01	RN	P3 SAR exploration of biphenyl carbamate based Legumain inhibitors. Bioorg Med Chem Lett. 2014 Jun 1;24(11):2521-4.
DMDMU01	RU	https://pubmed.ncbi.nlm.nih.gov/24775305

DMFSJQC	DI	DMFSJQC
DMFSJQC	DN	PMID24793884C74
DMFSJQC	MI	TTSMTDI
DMFSJQC	MN	CDC7-related kinase (CDC7)
DMFSJQC	MT	DTT
DMFSJQC	MA	Inhibitor
DMFSJQC	RN	Synthesis and structure-activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors. Eur J Med Chem. 2014 Jun 10;80:364-82.
DMFSJQC	RU	https://pubmed.ncbi.nlm.nih.gov/24793884

DMFSJQC	DI	DMFSJQC
DMFSJQC	DN	PMID24793884C74
DMFSJQC	MI	TT7ZY03
DMFSJQC	MN	Oxidative stress responsive 1 (OXSR1)
DMFSJQC	MT	DTT
DMFSJQC	MA	Inhibitor
DMFSJQC	RN	Synthesis and structure-activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors. Eur J Med Chem. 2014 Jun 10;80:364-82.
DMFSJQC	RU	https://pubmed.ncbi.nlm.nih.gov/24793884

DMFSJQC	DI	DMFSJQC
DMFSJQC	DN	PMID24793884C74
DMFSJQC	MI	TT4D2GZ
DMFSJQC	MN	Yet another novel kinase 2 (STK32B)
DMFSJQC	MT	DTT
DMFSJQC	MA	Inhibitor
DMFSJQC	RN	Synthesis and structure-activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors. Eur J Med Chem. 2014 Jun 10;80:364-82.
DMFSJQC	RU	https://pubmed.ncbi.nlm.nih.gov/24793884

DMZENGX	DI	DMZENGX
DMZENGX	DN	PMID24793884C77
DMZENGX	MI	TTSMTDI
DMZENGX	MN	CDC7-related kinase (CDC7)
DMZENGX	MT	DTT
DMZENGX	MA	Inhibitor
DMZENGX	RN	Synthesis and structure-activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors. Eur J Med Chem. 2014 Jun 10;80:364-82.
DMZENGX	RU	https://pubmed.ncbi.nlm.nih.gov/24793884

DMZENGX	DI	DMZENGX
DMZENGX	DN	PMID24793884C77
DMZENGX	MI	TTUMFAR
DMZENGX	MN	Cyclin-dependent kinase 18 (CDK18)
DMZENGX	MT	DTT
DMZENGX	MA	Inhibitor
DMZENGX	RN	Synthesis and structure-activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors. Eur J Med Chem. 2014 Jun 10;80:364-82.
DMZENGX	RU	https://pubmed.ncbi.nlm.nih.gov/24793884

DM5G1RP	DI	DM5G1RP
DM5G1RP	DN	PMID24793972C2
DM5G1RP	MI	TTMRQY1
DM5G1RP	MN	Striatum-specific G-protein coupled receptor (GPR88)
DM5G1RP	MT	DTT
DM5G1RP	MA	Agonist
DM5G1RP	RN	Synthesis, pharmacological characterization, and structure-activity relationship studies of small molecular agonists for the orphan GPR88 receptor. ACS Chem Neurosci. 2014 Jul 16;5(7):576-87.
DM5G1RP	RU	https://pubmed.ncbi.nlm.nih.gov/24793972

DMI8T1Y	DI	DMI8T1Y
DMI8T1Y	DN	PMID24809814C31
DMI8T1Y	MI	TT618Q2
DMI8T1Y	MN	Sphingosine-1-phosphate lyase 1 (SGPL1)
DMI8T1Y	MT	DTT
DMI8T1Y	MA	Inhibitor
DMI8T1Y	RN	Orally active 7-substituted (4-benzylphthalazin-1-yl)-2-methylpiperazin-1-yl]nicotinonitriles as active-site inhibitors of sphingosine 1-phosphate lyase for the treatment of multiple sclerosis. J MedChem. 2014 Jun 26;57(12):5074-84.
DMI8T1Y	RU	https://pubmed.ncbi.nlm.nih.gov/24809814

DM6TFPY	DI	DM6TFPY
DM6TFPY	DN	PMID24900237C15
DM6TFPY	MI	TTPMQSO
DM6TFPY	MN	ALK tyrosine kinase receptor (ALK)
DM6TFPY	MT	DTT
DM6TFPY	MA	Inhibitor
DM6TFPY	RN	Discovery of a potent inhibitor of anaplastic lymphoma kinase with in vivo antitumor activity. ACS Med Chem Lett. 2010 Sep 1;1(9):493-8.
DM6TFPY	RU	https://pubmed.ncbi.nlm.nih.gov/24900237

DM6TFPY	DI	DM6TFPY
DM6TFPY	DN	PMID24900237C15
DM6TFPY	MI	TTCBFJO
DM6TFPY	MN	Insulin receptor (INSR)
DM6TFPY	MT	DTT
DM6TFPY	MA	Inhibitor
DM6TFPY	RN	Discovery of a potent inhibitor of anaplastic lymphoma kinase with in vivo antitumor activity. ACS Med Chem Lett. 2010 Sep 1;1(9):493-8.
DM6TFPY	RU	https://pubmed.ncbi.nlm.nih.gov/24900237

DM6TFPY	DI	DM6TFPY
DM6TFPY	DN	PMID24900237C15
DM6TFPY	MI	TTYENHQ
DM6TFPY	MN	Unc-51 like kinase 3 (ULK3)
DM6TFPY	MT	DTT
DM6TFPY	MA	Inhibitor
DM6TFPY	RN	Discovery of a potent inhibitor of anaplastic lymphoma kinase with in vivo antitumor activity. ACS Med Chem Lett. 2010 Sep 1;1(9):493-8.
DM6TFPY	RU	https://pubmed.ncbi.nlm.nih.gov/24900237

DM6TYD0	DI	DM6TYD0
DM6TYD0	DN	PMID24900283C8a
DM6TYD0	MI	TTHYDUM
DM6TYD0	MN	Bombesin receptor (BS)
DM6TYD0	MT	DTT
DM6TYD0	MA	Agonist
DM6TYD0	RN	Discovery of benzodiazepine sulfonamide-based bombesin receptor subtype 3 agonists and their unusual chirality. ACS Med Chem Lett. 2011 Oct 3;2(12):933-7.
DM6TYD0	RU	https://pubmed.ncbi.nlm.nih.gov/24900283

DMJS0F5	DI	DMJS0F5
DMJS0F5	DN	PMID24900311C1a
DMJS0F5	MI	TTOL9B0
DMJS0F5	MN	G-protein-coupled receptor PGR3 (GPR139)
DMJS0F5	MT	DTT
DMJS0F5	MA	Agonist
DMJS0F5	RN	Discovery and SAR of a Series of Agonists at Orphan G Protein-Coupled Receptor 139. ACS Med Chem Lett. 2011 Feb 28;2(4):303-6.
DMJS0F5	RU	https://pubmed.ncbi.nlm.nih.gov/24900311

DMU4BL2	DI	DMU4BL2
DMU4BL2	DN	PMID24900428C14
DMU4BL2	MI	TTFQEMX
DMU4BL2	MN	Casein kinase I alpha (CSNK1A1)
DMU4BL2	MT	DTT
DMU4BL2	MA	Inhibitor
DMU4BL2	RN	Structure-Based Design of Potent and Selective CK1gamma Inhibitors. ACS Med Chem Lett. 2012 Oct 18;3(12):1059-64.
DMU4BL2	RU	https://pubmed.ncbi.nlm.nih.gov/24900428

DMU4BL2	DI	DMU4BL2
DMU4BL2	DN	PMID24900428C14
DMU4BL2	MI	TTH30UI
DMU4BL2	MN	Casein kinase I delta (CSNK1D)
DMU4BL2	MT	DTT
DMU4BL2	MA	Inhibitor
DMU4BL2	RN	Structure-Based Design of Potent and Selective CK1gamma Inhibitors. ACS Med Chem Lett. 2012 Oct 18;3(12):1059-64.
DMU4BL2	RU	https://pubmed.ncbi.nlm.nih.gov/24900428

DMU4BL2	DI	DMU4BL2
DMU4BL2	DN	PMID24900428C14
DMU4BL2	MI	TT0UZJ9
DMU4BL2	MN	Casein kinase I gamma-2 (CSNK1G2)
DMU4BL2	MT	DTT
DMU4BL2	MA	Inhibitor
DMU4BL2	RN	Structure-Based Design of Potent and Selective CK1gamma Inhibitors. ACS Med Chem Lett. 2012 Oct 18;3(12):1059-64.
DMU4BL2	RU	https://pubmed.ncbi.nlm.nih.gov/24900428

DMZ5P2K	DI	DMZ5P2K
DMZ5P2K	DN	PMID24900446C5 
DMZ5P2K	MI	TTLPF4X
DMZ5P2K	MN	Kallikrein-6 (KLK6)
DMZ5P2K	MT	DTT
DMZ5P2K	MA	Inhibitor
DMZ5P2K	RN	Virtual Screening and X-ray Crystallography for Human Kallikrein 6 Inhibitors with an Amidinothiophene P1 Group. ACS Med Chem Lett. 2012 Jan 11;3(2):159-64.
DMZ5P2K	RU	https://pubmed.ncbi.nlm.nih.gov/24900446

DMEWVG8	DI	DMEWVG8
DMEWVG8	DN	PMID24900526C1
DMEWVG8	MI	TTXZ0KQ
DMEWVG8	MN	Matrix metalloproteinase-12 (MMP-12)
DMEWVG8	MT	DTT
DMEWVG8	MA	Inhibitor
DMEWVG8	RN	Target-Activated Prodrugs (TAPs) for the Autoregulated Inhibition of MMP12. ACS Med Chem Lett. 2012 Jul 14;3(8):653-7.
DMEWVG8	RU	https://pubmed.ncbi.nlm.nih.gov/24900526

DMKTBCM	DI	DMKTBCM
DMKTBCM	DN	PMID24900526C5 
DMKTBCM	MI	TTXZ0KQ
DMKTBCM	MN	Matrix metalloproteinase-12 (MMP-12)
DMKTBCM	MT	DTT
DMKTBCM	MA	Inhibitor
DMKTBCM	RN	Target-Activated Prodrugs (TAPs) for the Autoregulated Inhibition of MMP12. ACS Med Chem Lett. 2012 Jul 14;3(8):653-7.
DMKTBCM	RU	https://pubmed.ncbi.nlm.nih.gov/24900526

DM5PATM	DI	DM5PATM
DM5PATM	DN	PMID24900538C2c
DM5PATM	MI	TT6B75U
DM5PATM	MN	ABL messenger RNA (ABL mRNA)
DM5PATM	MT	DTT
DM5PATM	MA	Inhibitor
DM5PATM	RN	Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors. ACS Med Chem Lett. 2012 Jul 26;3(9):705-9.
DM5PATM	RU	https://pubmed.ncbi.nlm.nih.gov/24900538

DM5PATM	DI	DM5PATM
DM5PATM	DN	PMID24900538C2c
DM5PATM	MI	TTRLW2X
DM5PATM	MN	Fibroblast growth factor receptor 1 (FGFR1)
DM5PATM	MT	DTT
DM5PATM	MA	Inhibitor
DM5PATM	RN	Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors. ACS Med Chem Lett. 2012 Jul 26;3(9):705-9.
DM5PATM	RU	https://pubmed.ncbi.nlm.nih.gov/24900538

DM5PATM	DI	DM5PATM
DM5PATM	DN	PMID24900538C2c
DM5PATM	MI	TTGJCWZ
DM5PATM	MN	Fms-like tyrosine kinase 3 (FLT-3)
DM5PATM	MT	DTT
DM5PATM	MA	Inhibitor
DM5PATM	RN	Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors. ACS Med Chem Lett. 2012 Jul 26;3(9):705-9.
DM5PATM	RU	https://pubmed.ncbi.nlm.nih.gov/24900538

DM5PATM	DI	DM5PATM
DM5PATM	DN	PMID24900538C2c
DM5PATM	MI	TTXABCW
DM5PATM	MN	NT-3 growth factor receptor (TrkC)
DM5PATM	MT	DTT
DM5PATM	MA	Inhibitor
DM5PATM	RN	Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors. ACS Med Chem Lett. 2012 Jul 26;3(9):705-9.
DM5PATM	RU	https://pubmed.ncbi.nlm.nih.gov/24900538

DM5PATM	DI	DM5PATM
DM5PATM	DN	PMID24900538C2c
DM5PATM	MI	TTI5WS6
DM5PATM	MN	Phosphorylase kinase testis gamma 2 (PHKG2)
DM5PATM	MT	DTT
DM5PATM	MA	Inhibitor
DM5PATM	RN	Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors. ACS Med Chem Lett. 2012 Jul 26;3(9):705-9.
DM5PATM	RU	https://pubmed.ncbi.nlm.nih.gov/24900538

DM5PATM	DI	DM5PATM
DM5PATM	DN	PMID24900538C2c
DM5PATM	MI	TT1H6LC
DM5PATM	MN	Salt-inducible kinase 1 (SIK1)
DM5PATM	MT	DTT
DM5PATM	MA	Inhibitor
DM5PATM	RN	Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors. ACS Med Chem Lett. 2012 Jul 26;3(9):705-9.
DM5PATM	RU	https://pubmed.ncbi.nlm.nih.gov/24900538

DM5PATM	DI	DM5PATM
DM5PATM	DN	PMID24900538C2c
DM5PATM	MI	TTA3Z2W
DM5PATM	MN	Testis-specific serine kinase 2 (TSSK2)
DM5PATM	MT	DTT
DM5PATM	MA	Inhibitor
DM5PATM	RN	Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors. ACS Med Chem Lett. 2012 Jul 26;3(9):705-9.
DM5PATM	RU	https://pubmed.ncbi.nlm.nih.gov/24900538

DM5PATM	DI	DM5PATM
DM5PATM	DN	PMID24900538C2c
DM5PATM	MI	TTGM6VW
DM5PATM	MN	Tyrosine-protein kinase BTK (ATK)
DM5PATM	MT	DTT
DM5PATM	MA	Inhibitor
DM5PATM	RN	Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors. ACS Med Chem Lett. 2012 Jul 26;3(9):705-9.
DM5PATM	RU	https://pubmed.ncbi.nlm.nih.gov/24900538

DM5PATM	DI	DM5PATM
DM5PATM	DN	PMID24900538C2c
DM5PATM	MI	TTPOGS1
DM5PATM	MN	Tyrosine-protein kinase Fgr (FGR)
DM5PATM	MT	DTT
DM5PATM	MA	Inhibitor
DM5PATM	RN	Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors. ACS Med Chem Lett. 2012 Jul 26;3(9):705-9.
DM5PATM	RU	https://pubmed.ncbi.nlm.nih.gov/24900538

DM5PATM	DI	DM5PATM
DM5PATM	DN	PMID24900538C2c
DM5PATM	MI	TTI7FDX
DM5PATM	MN	WNK lysine-deficient protein kinase 3 (WNK3)
DM5PATM	MT	DTT
DM5PATM	MA	Inhibitor
DM5PATM	RN	Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors. ACS Med Chem Lett. 2012 Jul 26;3(9):705-9.
DM5PATM	RU	https://pubmed.ncbi.nlm.nih.gov/24900538

DMCL6H3	DI	DMCL6H3
DMCL6H3	DN	PMID24900608C1
DMCL6H3	MI	TTTPCNU
DMCL6H3	MN	G-protein coupled receptor 39 (GPR39)
DMCL6H3	MT	DTT
DMCL6H3	MA	Agonist
DMCL6H3	RN	Chemical Probe Identification Platform for Orphan GPCRs Using Focused Compound Screening: GPR39 as a Case Example. ACS Med Chem Lett. 2013 Sep 16;4(11):1079-84.
DMCL6H3	RU	https://pubmed.ncbi.nlm.nih.gov/24900608

DM1QDG0	DI	DM1QDG0
DM1QDG0	DN	PMID24900635C21
DM1QDG0	MI	TTAIQSN
DM1QDG0	MN	Receptor-interacting protein 1 (RIPK1)
DM1QDG0	MT	DTT
DM1QDG0	MA	Inhibitor
DM1QDG0	RN	Discovery of Small Molecule RIP1 Kinase Inhibitors for the Treatment of Pathologies Associated with Necroptosis. ACS Med Chem Lett. 2013 Nov 4;4(12):1238-43.
DM1QDG0	RU	https://pubmed.ncbi.nlm.nih.gov/24900635

DM2V4MJ	DI	DM2V4MJ
DM2V4MJ	DN	PMID24900699C68
DM2V4MJ	MI	TTSBVFO
DM2V4MJ	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DM2V4MJ	MT	DTT
DM2V4MJ	MA	Inhibitor
DM2V4MJ	RN	Tricyclic Pyrimidines As Inhibitors of DYRK1A/DYRK1B As Potential Treatment for Down's Syndrome or Alzheimer's Disease. ACS Med Chem Lett. 2013 Apr 26;4(6):502-3.
DM2V4MJ	RU	https://pubmed.ncbi.nlm.nih.gov/24900699

DM2V4MJ	DI	DM2V4MJ
DM2V4MJ	DN	PMID24900699C68
DM2V4MJ	MI	TTYGQ8A
DM2V4MJ	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B)
DM2V4MJ	MT	DTT
DM2V4MJ	MA	Inhibitor
DM2V4MJ	RN	Tricyclic Pyrimidines As Inhibitors of DYRK1A/DYRK1B As Potential Treatment for Down's Syndrome or Alzheimer's Disease. ACS Med Chem Lett. 2013 Apr 26;4(6):502-3.
DM2V4MJ	RU	https://pubmed.ncbi.nlm.nih.gov/24900699

DMZPUSO	DI	DMZPUSO
DMZPUSO	DN	PMID24900749C1a
DMZPUSO	MI	TTER6YH
DMZPUSO	MN	Casein kinase II alpha (CSNK2A1)
DMZPUSO	MT	DTT
DMZPUSO	MA	Inhibitor
DMZPUSO	RN	Structure and Property Based Design of Pyrazolo[1,5-a]pyrimidine Inhibitors of CK2 Kinase with Activity in Vivo. ACS Med Chem Lett. 2013 Jul 3;4(8):800-5.
DMZPUSO	RU	https://pubmed.ncbi.nlm.nih.gov/24900749

DMZPUSO	DI	DMZPUSO
DMZPUSO	DN	PMID24900749C1a
DMZPUSO	MI	TTV4EX0
DMZPUSO	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 3 (DYRK3)
DMZPUSO	MT	DTT
DMZPUSO	MA	Inhibitor
DMZPUSO	RN	Structure and Property Based Design of Pyrazolo[1,5-a]pyrimidine Inhibitors of CK2 Kinase with Activity in Vivo. ACS Med Chem Lett. 2013 Jul 3;4(8):800-5.
DMZPUSO	RU	https://pubmed.ncbi.nlm.nih.gov/24900749

DMZPUSO	DI	DMZPUSO
DMZPUSO	DN	PMID24900749C1a
DMZPUSO	MI	TTOB49C
DMZPUSO	MN	Homeodomain interacting protein kinase 2 (HIPK2)
DMZPUSO	MT	DTT
DMZPUSO	MA	Inhibitor
DMZPUSO	RN	Structure and Property Based Design of Pyrazolo[1,5-a]pyrimidine Inhibitors of CK2 Kinase with Activity in Vivo. ACS Med Chem Lett. 2013 Jul 3;4(8):800-5.
DMZPUSO	RU	https://pubmed.ncbi.nlm.nih.gov/24900749

DMZPUSO	DI	DMZPUSO
DMZPUSO	DN	PMID24900749C1a
DMZPUSO	MI	TTCGOIN
DMZPUSO	MN	PIM-3 protein kinase (PIM3)
DMZPUSO	MT	DTT
DMZPUSO	MA	Inhibitor
DMZPUSO	RN	Structure and Property Based Design of Pyrazolo[1,5-a]pyrimidine Inhibitors of CK2 Kinase with Activity in Vivo. ACS Med Chem Lett. 2013 Jul 3;4(8):800-5.
DMZPUSO	RU	https://pubmed.ncbi.nlm.nih.gov/24900749

DMOSMBZ	DI	DMOSMBZ
DMOSMBZ	DN	PMID24900824C2-1-1
DMOSMBZ	MI	TT78309
DMOSMBZ	MN	BUB1 mitotic checkpoint serine/threonine kinase (BUB1)
DMOSMBZ	MT	DTT
DMOSMBZ	MA	Inhibitor
DMOSMBZ	RN	Novel cycloalkenepyrazoles as inhibitors of bub1 kinase. ACS Med Chem Lett. 2014 Feb 12;5(4):280-1.
DMOSMBZ	RU	https://pubmed.ncbi.nlm.nih.gov/24900824

DM2FYUM	DI	DM2FYUM
DM2FYUM	DN	PMID24900824C2-13-1
DM2FYUM	MI	TT78309
DM2FYUM	MN	BUB1 mitotic checkpoint serine/threonine kinase (BUB1)
DM2FYUM	MT	DTT
DM2FYUM	MA	Inhibitor
DM2FYUM	RN	Novel cycloalkenepyrazoles as inhibitors of bub1 kinase. ACS Med Chem Lett. 2014 Feb 12;5(4):280-1.
DM2FYUM	RU	https://pubmed.ncbi.nlm.nih.gov/24900824

DMC5JAT	DI	DMC5JAT
DMC5JAT	DN	PMID24900824C2-3-1
DMC5JAT	MI	TT78309
DMC5JAT	MN	BUB1 mitotic checkpoint serine/threonine kinase (BUB1)
DMC5JAT	MT	DTT
DMC5JAT	MA	Inhibitor
DMC5JAT	RN	Novel cycloalkenepyrazoles as inhibitors of bub1 kinase. ACS Med Chem Lett. 2014 Feb 12;5(4):280-1.
DMC5JAT	RU	https://pubmed.ncbi.nlm.nih.gov/24900824

DMVP0Z9	DI	DMVP0Z9
DMVP0Z9	DN	PMID24900824C2-3-2
DMVP0Z9	MI	TT78309
DMVP0Z9	MN	BUB1 mitotic checkpoint serine/threonine kinase (BUB1)
DMVP0Z9	MT	DTT
DMVP0Z9	MA	Inhibitor
DMVP0Z9	RN	Novel cycloalkenepyrazoles as inhibitors of bub1 kinase. ACS Med Chem Lett. 2014 Feb 12;5(4):280-1.
DMVP0Z9	RU	https://pubmed.ncbi.nlm.nih.gov/24900824

DMN7QB8	DI	DMN7QB8
DMN7QB8	DN	PMID24915291C31
DMN7QB8	MI	TTNDSC3
DMN7QB8	MN	B lymphocyte kinase (BLK)
DMN7QB8	MT	DTT
DMN7QB8	MA	Inhibitor
DMN7QB8	RN	Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28.
DMN7QB8	RU	https://pubmed.ncbi.nlm.nih.gov/24915291

DMN7QB8	DI	DMN7QB8
DMN7QB8	DN	PMID24915291C31
DMN7QB8	MI	TTN2I9E
DMN7QB8	MN	Tyrosine-protein kinase BMX (BMX)
DMN7QB8	MT	DTT
DMN7QB8	MA	Inhibitor
DMN7QB8	RN	Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28.
DMN7QB8	RU	https://pubmed.ncbi.nlm.nih.gov/24915291

DMN7QB8	DI	DMN7QB8
DMN7QB8	DN	PMID24915291C31
DMN7QB8	MI	TTGM6VW
DMN7QB8	MN	Tyrosine-protein kinase BTK (ATK)
DMN7QB8	MT	DTT
DMN7QB8	MA	Inhibitor
DMN7QB8	RN	Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28.
DMN7QB8	RU	https://pubmed.ncbi.nlm.nih.gov/24915291

DMN7QB8	DI	DMN7QB8
DMN7QB8	DN	PMID24915291C31
DMN7QB8	MI	TT1ZV49
DMN7QB8	MN	Tyrosine-protein kinase Tec (PSCTK4)
DMN7QB8	MT	DTT
DMN7QB8	MA	Inhibitor
DMN7QB8	RN	Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28.
DMN7QB8	RU	https://pubmed.ncbi.nlm.nih.gov/24915291

DMN7QB8	DI	DMN7QB8
DMN7QB8	DN	PMID24915291C31
DMN7QB8	MI	TT8M1DP
DMN7QB8	MN	Tyrosine-protein kinase TXK (TXK)
DMN7QB8	MT	DTT
DMN7QB8	MA	Inhibitor
DMN7QB8	RN	Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28.
DMN7QB8	RU	https://pubmed.ncbi.nlm.nih.gov/24915291

DMBXT9J	DI	DMBXT9J
DMBXT9J	DN	PMID24915291C38
DMBXT9J	MI	TTNDSC3
DMBXT9J	MN	B lymphocyte kinase (BLK)
DMBXT9J	MT	DTT
DMBXT9J	MA	Inhibitor
DMBXT9J	RN	Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28.
DMBXT9J	RU	https://pubmed.ncbi.nlm.nih.gov/24915291

DMBXT9J	DI	DMBXT9J
DMBXT9J	DN	PMID24915291C38
DMBXT9J	MI	TTGKNB4
DMBXT9J	MN	Epidermal growth factor receptor (EGFR)
DMBXT9J	MT	DTT
DMBXT9J	MA	Inhibitor
DMBXT9J	RN	Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28.
DMBXT9J	RU	https://pubmed.ncbi.nlm.nih.gov/24915291

DMBXT9J	DI	DMBXT9J
DMBXT9J	DN	PMID24915291C38
DMBXT9J	MI	TTR5TV4
DMBXT9J	MN	ERBB2 messenger RNA (HER2 mRNA)
DMBXT9J	MT	DTT
DMBXT9J	MA	Inhibitor
DMBXT9J	RN	Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28.
DMBXT9J	RU	https://pubmed.ncbi.nlm.nih.gov/24915291

DMBXT9J	DI	DMBXT9J
DMBXT9J	DN	PMID24915291C38
DMBXT9J	MI	TT0JESD
DMBXT9J	MN	Erbb4 tyrosine kinase receptor (Erbb-4)
DMBXT9J	MT	DTT
DMBXT9J	MA	Inhibitor
DMBXT9J	RN	Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28.
DMBXT9J	RU	https://pubmed.ncbi.nlm.nih.gov/24915291

DMBXT9J	DI	DMBXT9J
DMBXT9J	DN	PMID24915291C38
DMBXT9J	MI	TTN2I9E
DMBXT9J	MN	Tyrosine-protein kinase BMX (BMX)
DMBXT9J	MT	DTT
DMBXT9J	MA	Inhibitor
DMBXT9J	RN	Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28.
DMBXT9J	RU	https://pubmed.ncbi.nlm.nih.gov/24915291

DMBXT9J	DI	DMBXT9J
DMBXT9J	DN	PMID24915291C38
DMBXT9J	MI	TTGM6VW
DMBXT9J	MN	Tyrosine-protein kinase BTK (ATK)
DMBXT9J	MT	DTT
DMBXT9J	MA	Inhibitor
DMBXT9J	RN	Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28.
DMBXT9J	RU	https://pubmed.ncbi.nlm.nih.gov/24915291

DMBXT9J	DI	DMBXT9J
DMBXT9J	DN	PMID24915291C38
DMBXT9J	MI	TT1ZV49
DMBXT9J	MN	Tyrosine-protein kinase Tec (PSCTK4)
DMBXT9J	MT	DTT
DMBXT9J	MA	Inhibitor
DMBXT9J	RN	Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28.
DMBXT9J	RU	https://pubmed.ncbi.nlm.nih.gov/24915291

DMBXT9J	DI	DMBXT9J
DMBXT9J	DN	PMID24915291C38
DMBXT9J	MI	TT8M1DP
DMBXT9J	MN	Tyrosine-protein kinase TXK (TXK)
DMBXT9J	MT	DTT
DMBXT9J	MA	Inhibitor
DMBXT9J	RN	Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28.
DMBXT9J	RU	https://pubmed.ncbi.nlm.nih.gov/24915291

DMNPA2C	DI	DMNPA2C
DMNPA2C	DN	PMID24946214C3b
DMNPA2C	MI	TT68GPI
DMNPA2C	MN	Proteasome beta-5 (PS beta-5)
DMNPA2C	MT	DTT
DMNPA2C	MA	Inhibitor
DMNPA2C	RN	Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors. Eur J Med Chem. 2014 Aug 18;83:1-14.
DMNPA2C	RU	https://pubmed.ncbi.nlm.nih.gov/24946214

DML0PFU	DI	DML0PFU
DML0PFU	DN	PMID24997608CA 
DML0PFU	MI	TT08JVB
DML0PFU	MN	G-protein coupled receptor 120 (GPR120)
DML0PFU	MT	DTT
DML0PFU	MA	Agonist
DML0PFU	RN	A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice. Nat Med. 2014 Aug;20(8):942-7.
DML0PFU	RU	https://pubmed.ncbi.nlm.nih.gov/24997608

DM5D3SN	DI	DM5D3SN
DM5D3SN	DN	PMID24999562C6b
DM5D3SN	MI	TT2L6C5
DM5D3SN	MN	Neuromedin-U receptor 2 (NMUR2)
DM5D3SN	MT	DTT
DM5D3SN	MA	Agonist
DM5D3SN	RN	Discovery of selective hexapeptide agonists to human neuromedin U receptors types 1 and 2. J Med Chem. 2014 Aug 14;57(15):6583-93.
DM5D3SN	RU	https://pubmed.ncbi.nlm.nih.gov/24999562

DMD7VOZ	DI	DMD7VOZ
DMD7VOZ	DN	PMID24999562C8d
DMD7VOZ	MI	TTI7T1Q
DMD7VOZ	MN	Neuromedin-U receptor 1 (NMUR1)
DMD7VOZ	MT	DTT
DMD7VOZ	MA	Agonist
DMD7VOZ	RN	Discovery of selective hexapeptide agonists to human neuromedin U receptors types 1 and 2. J Med Chem. 2014 Aug 14;57(15):6583-93.
DMD7VOZ	RU	https://pubmed.ncbi.nlm.nih.gov/24999562

DMJPR8M	DI	DMJPR8M
DMJPR8M	DN	PMID25037917C58
DMJPR8M	MI	TTVBI8W
DMJPR8M	MN	Dopamine transporter (DAT)
DMJPR8M	MT	DTT
DMJPR8M	MA	Inhibitor
DMJPR8M	RN	Novel inhibitors of the high-affinity L-proline transporter as potential therapeutic agents for the treatment of cognitive disorders. Bioorg Med Chem Lett. 2014 Aug 15;24(16):3886-90.
DMJPR8M	RU	https://pubmed.ncbi.nlm.nih.gov/25037917

DMJPR8M	DI	DMJPR8M
DMJPR8M	DN	PMID25037917C58
DMJPR8M	MI	TT9LGO5
DMJPR8M	MN	Sodium-dependent proline transporter (SLC6A7)
DMJPR8M	MT	DTT
DMJPR8M	MA	Inhibitor
DMJPR8M	RN	Novel inhibitors of the high-affinity L-proline transporter as potential therapeutic agents for the treatment of cognitive disorders. Bioorg Med Chem Lett. 2014 Aug 15;24(16):3886-90.
DMJPR8M	RU	https://pubmed.ncbi.nlm.nih.gov/25037917

DMRFQ1W	DI	DMRFQ1W
DMRFQ1W	DN	PMID25050158C14
DMRFQ1W	MI	TTDCVZW
DMRFQ1W	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMRFQ1W	MT	DTT
DMRFQ1W	MA	Modulator (allosteric modulator)
DMRFQ1W	RN	Discovery of a Negative Allosteric Modulator of GABAB Receptors. ACS Med Chem Lett. 2014 May 27;5(7):742-7.
DMRFQ1W	RU	https://pubmed.ncbi.nlm.nih.gov/25050158

DMTCGLY	DI	DMTCGLY
DMTCGLY	DN	PMID25259874C21
DMTCGLY	MI	TTI6B3F
DMTCGLY	MN	C3a anaphylatoxin chemotactic receptor (C3AR1)
DMTCGLY	MT	DTT
DMTCGLY	MA	Agonist
DMTCGLY	RN	Potent heterocyclic ligands for human complement c3a receptor. J Med Chem. 2014 Oct 23;57(20):8459-70.
DMTCGLY	RU	https://pubmed.ncbi.nlm.nih.gov/25259874

DMZKEIH	DI	DMZKEIH
DMZKEIH	DN	PMID25259874C4
DMZKEIH	MI	TTI6B3F
DMZKEIH	MN	C3a anaphylatoxin chemotactic receptor (C3AR1)
DMZKEIH	MT	DTT
DMZKEIH	MA	Antagonist
DMZKEIH	RN	Potent heterocyclic ligands for human complement c3a receptor. J Med Chem. 2014 Oct 23;57(20):8459-70.
DMZKEIH	RU	https://pubmed.ncbi.nlm.nih.gov/25259874

DMDO9AJ	DI	DMDO9AJ
DMDO9AJ	DN	PMID25313322C15
DMDO9AJ	MI	TTTPCNU
DMDO9AJ	MN	G-protein coupled receptor 39 (GPR39)
DMDO9AJ	MT	DTT
DMDO9AJ	MA	Agonist
DMDO9AJ	RN	Discovery of 2-Pyridylpyrimidines as the First Orally Bioavailable GPR39 Agonists. ACS Med Chem Lett. 2014 Aug 4;5(10):1114-8.
DMDO9AJ	RU	https://pubmed.ncbi.nlm.nih.gov/25313322

DM5GL23	DI	DM5GL23
DM5GL23	DN	PMID25408830C1
DM5GL23	MI	TTT46BN
DM5GL23	MN	Bromodomain and PHD finger containing 1 (BRPF1)
DM5GL23	MT	DTT
DM5GL23	MA	Inhibitor
DM5GL23	RN	1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain. ACS Med Chem Lett. 2014 Sep 10;5(11):1190-5.
DM5GL23	RU	https://pubmed.ncbi.nlm.nih.gov/25408830

DM5GL23	DI	DM5GL23
DM5GL23	DN	PMID25408830C1
DM5GL23	MI	TTRA6BO
DM5GL23	MN	Bromodomain-containing protein 4 (BRD4)
DM5GL23	MT	DTT
DM5GL23	MA	Inhibitor
DM5GL23	RN	1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain. ACS Med Chem Lett. 2014 Sep 10;5(11):1190-5.
DM5GL23	RU	https://pubmed.ncbi.nlm.nih.gov/25408830

DM20E13	DI	DM20E13
DM20E13	DN	PMID25408830C2
DM20E13	MI	TTT46BN
DM20E13	MN	Bromodomain and PHD finger containing 1 (BRPF1)
DM20E13	MT	DTT
DM20E13	MA	Inhibitor
DM20E13	RN	1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain. ACS Med Chem Lett. 2014 Sep 10;5(11):1190-5.
DM20E13	RU	https://pubmed.ncbi.nlm.nih.gov/25408830

DM20E13	DI	DM20E13
DM20E13	DN	PMID25408830C2
DM20E13	MI	TTRA6BO
DM20E13	MN	Bromodomain-containing protein 4 (BRD4)
DM20E13	MT	DTT
DM20E13	MA	Inhibitor
DM20E13	RN	1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain. ACS Med Chem Lett. 2014 Sep 10;5(11):1190-5.
DM20E13	RU	https://pubmed.ncbi.nlm.nih.gov/25408830

DM8SBR2	DI	DM8SBR2
DM8SBR2	DN	PMID25408830C3
DM8SBR2	MI	TTT46BN
DM8SBR2	MN	Bromodomain and PHD finger containing 1 (BRPF1)
DM8SBR2	MT	DTT
DM8SBR2	MA	Inhibitor
DM8SBR2	RN	1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain. ACS Med Chem Lett. 2014 Sep 10;5(11):1190-5.
DM8SBR2	RU	https://pubmed.ncbi.nlm.nih.gov/25408830

DM8SBR2	DI	DM8SBR2
DM8SBR2	DN	PMID25408830C3
DM8SBR2	MI	TTRA6BO
DM8SBR2	MN	Bromodomain-containing protein 4 (BRD4)
DM8SBR2	MT	DTT
DM8SBR2	MA	Inhibitor
DM8SBR2	RN	1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain. ACS Med Chem Lett. 2014 Sep 10;5(11):1190-5.
DM8SBR2	RU	https://pubmed.ncbi.nlm.nih.gov/25408830

DMWZJT0	DI	DMWZJT0
DMWZJT0	DN	PMID25489658C4d
DMWZJT0	MI	TTDA81R
DMWZJT0	MN	Kallikrein-14 (KLK14)
DMWZJT0	MT	DTT
DMWZJT0	MA	Inhibitor
DMWZJT0	RN	Toward the first class of suicide inhibitors of kallikreins involved in skin diseases. J Med Chem. 2015 Jan 22;58(2):598-612.
DMWZJT0	RU	https://pubmed.ncbi.nlm.nih.gov/25489658

DMWZJT0	DI	DMWZJT0
DMWZJT0	DN	PMID25489658C4d
DMWZJT0	MI	TTULSEW
DMWZJT0	MN	Kallikrein-5 (KLK5)
DMWZJT0	MT	DTT
DMWZJT0	MA	Inhibitor
DMWZJT0	RN	Toward the first class of suicide inhibitors of kallikreins involved in skin diseases. J Med Chem. 2015 Jan 22;58(2):598-612.
DMWZJT0	RU	https://pubmed.ncbi.nlm.nih.gov/25489658

DMWZJT0	DI	DMWZJT0
DMWZJT0	DN	PMID25489658C4d
DMWZJT0	MI	TTE6GTB
DMWZJT0	MN	Kallikrein-7 (KLK7)
DMWZJT0	MT	DTT
DMWZJT0	MA	Inhibitor
DMWZJT0	RN	Toward the first class of suicide inhibitors of kallikreins involved in skin diseases. J Med Chem. 2015 Jan 22;58(2):598-612.
DMWZJT0	RU	https://pubmed.ncbi.nlm.nih.gov/25489658

DMWZJT0	DI	DMWZJT0
DMWZJT0	DN	PMID25489658C4d
DMWZJT0	MI	TTPRO7W
DMWZJT0	MN	Suppressor of tumorigenicity 14 protein (ST14)
DMWZJT0	MT	DTT
DMWZJT0	MA	Inhibitor
DMWZJT0	RN	Toward the first class of suicide inhibitors of kallikreins involved in skin diseases. J Med Chem. 2015 Jan 22;58(2):598-612.
DMWZJT0	RU	https://pubmed.ncbi.nlm.nih.gov/25489658

DMO6NEX	DI	DMO6NEX
DMO6NEX	DN	PMID25497965C17c
DMO6NEX	MI	TTHYDUM
DMO6NEX	MN	Bombesin receptor (BS)
DMO6NEX	MT	DTT
DMO6NEX	MA	Agonist
DMO6NEX	RN	Synthesis and biological evaluation of novel chiral diazepine derivatives as bombesin receptor subtype-3 (BRS-3) agonists incorporating an antedrug approach. Bioorg Med Chem. 2015 Jan 1;23(1):89-104.
DMO6NEX	RU	https://pubmed.ncbi.nlm.nih.gov/25497965

DM4PZ37	DI	DM4PZ37
DM4PZ37	DN	PMID25703523C7d
DM4PZ37	MI	TTRA6BO
DM4PZ37	MN	Bromodomain-containing protein 4 (BRD4)
DM4PZ37	MT	DTT
DM4PZ37	MA	Inhibitor
DM4PZ37	RN	9H-purine scaffold reveals induced-fit pocket plasticity of the BRD9 bromodomain. J Med Chem. 2015 Mar 26;58(6):2718-36.
DM4PZ37	RU	https://pubmed.ncbi.nlm.nih.gov/25703523

DM7AJER	DI	DM7AJER
DM7AJER	DN	PMID25719566C1
DM7AJER	MI	TT6K8YG
DM7AJER	MN	Bromodomain adjacent to zinc finger 2B (BAZ2B)
DM7AJER	MT	DTT
DM7AJER	MA	Inhibitor
DM7AJER	RN	Structure enabled design of BAZ2-ICR, a chemical probe targeting the bromodomains of BAZ2A and BAZ2B. J Med Chem. 2015 Mar 12;58(5):2553-9.
DM7AJER	RU	https://pubmed.ncbi.nlm.nih.gov/25719566

DMGCAIO	DI	DMGCAIO
DMGCAIO	DN	PMID25719566C7
DMGCAIO	MI	TT6K8YG
DMGCAIO	MN	Bromodomain adjacent to zinc finger 2B (BAZ2B)
DMGCAIO	MT	DTT
DMGCAIO	MA	Inhibitor
DMGCAIO	RN	Structure enabled design of BAZ2-ICR, a chemical probe targeting the bromodomains of BAZ2A and BAZ2B. J Med Chem. 2015 Mar 12;58(5):2553-9.
DMGCAIO	RU	https://pubmed.ncbi.nlm.nih.gov/25719566

DMDYT6P	DI	DMDYT6P
DMDYT6P	DN	PMID25742366C14b
DMDYT6P	MI	TTSCHFW
DMDYT6P	MN	Peptidyl arginine deiminase type III (PADI3)
DMDYT6P	MT	DTT
DMDYT6P	MA	Inhibitor
DMDYT6P	RN	Identification of multiple structurally distinct, nonpeptidic small molecule inhibitors of protein arginine deiminase 3 using a substrate-based fragment method. J Am Chem Soc. 2015 Mar 18;137(10):3616-21.
DMDYT6P	RU	https://pubmed.ncbi.nlm.nih.gov/25742366

DMDYT6P	DI	DMDYT6P
DMDYT6P	DN	PMID25742366C14b
DMDYT6P	MI	TTQHAXM
DMDYT6P	MN	Peptidyl arginine deiminase type IV (PADI4)
DMDYT6P	MT	DTT
DMDYT6P	MA	Inhibitor
DMDYT6P	RN	Identification of multiple structurally distinct, nonpeptidic small molecule inhibitors of protein arginine deiminase 3 using a substrate-based fragment method. J Am Chem Soc. 2015 Mar 18;137(10):3616-21.
DMDYT6P	RU	https://pubmed.ncbi.nlm.nih.gov/25742366

DMUEDBP	DI	DMUEDBP
DMUEDBP	DN	PMID25815140C48
DMUEDBP	MI	TTVP9IQ
DMUEDBP	MN	Solute carrier family 28 member 2 (SLC28A2)
DMUEDBP	MT	DTT
DMUEDBP	MA	Inhibitor
DMUEDBP	RN	Identification of 8-aminoadenosine derivatives as a new class of human concentrative nucleoside transporter 2 inhibitors. ACS Med Chem Lett. 2015 Jan 28;6(3):244-8.
DMUEDBP	RU	https://pubmed.ncbi.nlm.nih.gov/25815140

DMGWZA3	DI	DMGWZA3
DMGWZA3	DN	PMID25974391C34
DMGWZA3	MI	TTT46BN
DMGWZA3	MN	Bromodomain and PHD finger containing 1 (BRPF1)
DMGWZA3	MT	DTT
DMGWZA3	MA	Inhibitor
DMGWZA3	RN	Discovery of a Chemical Tool Inhibitor Targeting the Bromodomains of TRIM24 and BRPF. J Med Chem. 2016 Feb 25;59(4):1642-7.
DMGWZA3	RU	https://pubmed.ncbi.nlm.nih.gov/25974391

DMGWZA3	DI	DMGWZA3
DMGWZA3	DN	PMID25974391C34
DMGWZA3	MI	TT9Q7AE
DMGWZA3	MN	Tripartite motif-containing 24 (TRIM24)
DMGWZA3	MT	DTT
DMGWZA3	MA	Inhibitor
DMGWZA3	RN	Discovery of a Chemical Tool Inhibitor Targeting the Bromodomains of TRIM24 and BRPF. J Med Chem. 2016 Feb 25;59(4):1642-7.
DMGWZA3	RU	https://pubmed.ncbi.nlm.nih.gov/25974391

DMHZOIU	DI	DMHZOIU
DMHZOIU	DN	PMID26061392C2
DMHZOIU	MI	TT0EOB8
DMHZOIU	MN	B-Raf messenger RNA (BRAF mRNA)
DMHZOIU	MT	DTT
DMHZOIU	MA	Inhibitor
DMHZOIU	RN	Photoactivatable Prodrugs of Antimelanoma Agent Vemurafenib. ACS Chem Biol. 2015 Sep 18;10(9):2099-107.
DMHZOIU	RU	https://pubmed.ncbi.nlm.nih.gov/26061392

DM8D6ZL	DI	DM8D6ZL
DM8D6ZL	DN	PMID26080733C7r
DM8D6ZL	MI	TTRLW2X
DM8D6ZL	MN	Fibroblast growth factor receptor 1 (FGFR1)
DM8D6ZL	MT	DTT
DM8D6ZL	MA	Inhibitor
DM8D6ZL	RN	Design, synthesis and biological evaluation of novel FGFR inhibitors bearing an indazole scaffold. Org Biomol Chem. 2015 Jul 28;13(28):7643-54.
DM8D6ZL	RU	https://pubmed.ncbi.nlm.nih.gov/26080733

DM4TN73	DI	DM4TN73
DM4TN73	DN	PMID26155854C57
DM4TN73	MI	TT9A0HI
DM4TN73	MN	ATPase family AAA domain containing 2 (ATAD2)
DM4TN73	MT	DTT
DM4TN73	MA	Inhibitor
DM4TN73	RN	Fragment-Based Discovery of Low-Micromolar ATAD2 Bromodomain Inhibitors. J Med Chem. 2015 Jul 23;58(14):5649-73.
DM4TN73	RU	https://pubmed.ncbi.nlm.nih.gov/26155854

DMM5SI4	DI	DMM5SI4
DMM5SI4	DN	PMID26155854C60
DMM5SI4	MI	TT9A0HI
DMM5SI4	MN	ATPase family AAA domain containing 2 (ATAD2)
DMM5SI4	MT	DTT
DMM5SI4	MA	Inhibitor
DMM5SI4	RN	Fragment-Based Discovery of Low-Micromolar ATAD2 Bromodomain Inhibitors. J Med Chem. 2015 Jul 23;58(14):5649-73.
DMM5SI4	RU	https://pubmed.ncbi.nlm.nih.gov/26155854

DMTO95J	DI	DMTO95J
DMTO95J	DN	PMID26161824C70
DMTO95J	MI	TT6OEDT
DMTO95J	MN	Cannabinoid receptor 1 (CB1)
DMTO95J	MT	DTT
DMTO95J	MA	Antagonist
DMTO95J	RN	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
DMTO95J	RU	https://pubmed.ncbi.nlm.nih.gov/26161824

DM9J5Q7	DI	DM9J5Q7
DM9J5Q7	DN	PMID2909732C7
DM9J5Q7	MI	TTPADOQ
DM9J5Q7	MN	HMG-CoA reductase (HMGCR)
DM9J5Q7	MT	DTT
DM9J5Q7	MA	Inhibitor
DM9J5Q7	RN	Synthesis and biological evaluation of a monocyclic, fully functional analogue of compactin. J Med Chem. 1989 Jan;32(1):197-202.
DM9J5Q7	RU	https://pubmed.ncbi.nlm.nih.gov/2909732

DMOA1Y7	DI	DMOA1Y7
DMOA1Y7	DN	PMID30247903-Compound-General structure10
DMOA1Y7	MI	TT8ZLTI
DMOA1Y7	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMOA1Y7	MT	DTT
DMOA1Y7	MA	Inhibitor
DMOA1Y7	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMOA1Y7	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMA3ZPH	DI	DMA3ZPH
DMA3ZPH	DN	PMID30247903-Compound-General structure12
DMA3ZPH	MI	TT8ZLTI
DMA3ZPH	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMA3ZPH	MT	DTT
DMA3ZPH	MA	Inhibitor
DMA3ZPH	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMA3ZPH	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMJ0YZA	DI	DMJ0YZA
DMJ0YZA	DN	PMID30247903-Compound-General structure13
DMJ0YZA	MI	TTNBFWK
DMJ0YZA	MN	Programmed cell death protein 1 (PD-1)
DMJ0YZA	MT	DTT
DMJ0YZA	MA	antagonist
DMJ0YZA	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMJ0YZA	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DM5Z4JR	DI	DM5Z4JR
DM5Z4JR	DN	PMID30247903-Compound-General structure14
DM5Z4JR	MI	TTNBFWK
DM5Z4JR	MN	Programmed cell death protein 1 (PD-1)
DM5Z4JR	MT	DTT
DM5Z4JR	MA	antagonist
DM5Z4JR	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DM5Z4JR	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMCJDLO	DI	DMCJDLO
DMCJDLO	DN	PMID30247903-Compound-General structure15
DMCJDLO	MI	TTNBFWK
DMCJDLO	MN	Programmed cell death protein 1 (PD-1)
DMCJDLO	MT	DTT
DMCJDLO	MA	antagonist
DMCJDLO	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMCJDLO	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMVR4QH	DI	DMVR4QH
DMVR4QH	DN	PMID30247903-Compound-General structure16
DMVR4QH	MI	TTNBFWK
DMVR4QH	MN	Programmed cell death protein 1 (PD-1)
DMVR4QH	MT	DTT
DMVR4QH	MA	Inhibitor
DMVR4QH	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMVR4QH	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMC3GFI	DI	DMC3GFI
DMC3GFI	DN	PMID30247903-Compound-General structure17
DMC3GFI	MI	TTNBFWK
DMC3GFI	MN	Programmed cell death protein 1 (PD-1)
DMC3GFI	MT	DTT
DMC3GFI	MA	Inhibitor
DMC3GFI	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMC3GFI	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMZBQ5R	DI	DMZBQ5R
DMZBQ5R	DN	PMID30247903-Compound-General structure18
DMZBQ5R	MI	TT23XQV
DMZBQ5R	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMZBQ5R	MT	DTT
DMZBQ5R	MA	Inhibitor
DMZBQ5R	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMZBQ5R	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DM8LS3I	DI	DM8LS3I
DM8LS3I	DN	PMID30247903-Compound-General structure19
DM8LS3I	MI	TT23XQV
DM8LS3I	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DM8LS3I	MT	DTT
DM8LS3I	MA	Inhibitor
DM8LS3I	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DM8LS3I	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMCNXKE	DI	DMCNXKE
DMCNXKE	DN	PMID30247903-Compound-General structure20
DMCNXKE	MI	TTNBFWK
DMCNXKE	MN	Programmed cell death protein 1 (PD-1)
DMCNXKE	MT	DTT
DMCNXKE	MA	Inhibitor
DMCNXKE	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMCNXKE	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMFACRH	DI	DMFACRH
DMFACRH	DN	PMID30247903-Compound-General structure21
DMFACRH	MI	TTNBFWK
DMFACRH	MN	Programmed cell death protein 1 (PD-1)
DMFACRH	MT	DTT
DMFACRH	MA	Inhibitor
DMFACRH	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMFACRH	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMLD1IU	DI	DMLD1IU
DMLD1IU	DN	PMID30247903-Compound-General structure22
DMLD1IU	MI	TTNBFWK
DMLD1IU	MN	Programmed cell death protein 1 (PD-1)
DMLD1IU	MT	DTT
DMLD1IU	MA	Inhibitor
DMLD1IU	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMLD1IU	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMMXLHW	DI	DMMXLHW
DMMXLHW	DN	PMID30247903-Compound-General structure23
DMMXLHW	MI	TTNBFWK
DMMXLHW	MN	Programmed cell death protein 1 (PD-1)
DMMXLHW	MT	DTT
DMMXLHW	MA	Inhibitor
DMMXLHW	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMMXLHW	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DM8CPZB	DI	DM8CPZB
DM8CPZB	DN	PMID30247903-Compound-General structure24
DM8CPZB	MI	TTNBFWK
DM8CPZB	MN	Programmed cell death protein 1 (PD-1)
DM8CPZB	MT	DTT
DM8CPZB	MA	Inhibitor
DM8CPZB	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DM8CPZB	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMEMLHR	DI	DMEMLHR
DMEMLHR	DN	PMID30247903-Compound-General structure25
DMEMLHR	MI	TTNBFWK
DMEMLHR	MN	Programmed cell death protein 1 (PD-1)
DMEMLHR	MT	DTT
DMEMLHR	MA	Inhibitor
DMEMLHR	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMEMLHR	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DM4BF1P	DI	DM4BF1P
DM4BF1P	DN	PMID30247903-Compound-General structure26
DM4BF1P	MI	TT23XQV
DM4BF1P	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DM4BF1P	MT	DTT
DM4BF1P	MA	Inhibitor
DM4BF1P	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DM4BF1P	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMYSWO4	DI	DMYSWO4
DMYSWO4	DN	PMID30247903-Compound-General structure27
DMYSWO4	MI	TT23XQV
DMYSWO4	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMYSWO4	MT	DTT
DMYSWO4	MA	Inhibitor
DMYSWO4	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMYSWO4	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMALSIW	DI	DMALSIW
DMALSIW	DN	PMID30247903-Compound-General structure28
DMALSIW	MI	TT23XQV
DMALSIW	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMALSIW	MT	DTT
DMALSIW	MA	Inhibitor
DMALSIW	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMALSIW	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DM9FEB6	DI	DM9FEB6
DM9FEB6	DN	PMID30247903-Compound-General structure29
DM9FEB6	MI	TT23XQV
DM9FEB6	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DM9FEB6	MT	DTT
DM9FEB6	MA	Inhibitor
DM9FEB6	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DM9FEB6	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMHQ1ZD	DI	DMHQ1ZD
DMHQ1ZD	DN	PMID30247903-Compound-General structure30
DMHQ1ZD	MI	TT23XQV
DMHQ1ZD	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMHQ1ZD	MT	DTT
DMHQ1ZD	MA	Inhibitor
DMHQ1ZD	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMHQ1ZD	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMSLWBI	DI	DMSLWBI
DMSLWBI	DN	PMID30247903-Compound-General structure31
DMSLWBI	MI	TT23XQV
DMSLWBI	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMSLWBI	MT	DTT
DMSLWBI	MA	Inhibitor
DMSLWBI	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMSLWBI	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMD04TR	DI	DMD04TR
DMD04TR	DN	PMID30247903-Compound-General structure32
DMD04TR	MI	TT23XQV
DMD04TR	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMD04TR	MT	DTT
DMD04TR	MA	Inhibitor
DMD04TR	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMD04TR	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMFLQ96	DI	DMFLQ96
DMFLQ96	DN	PMID30247903-Compound-General structure33
DMFLQ96	MI	TT23XQV
DMFLQ96	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMFLQ96	MT	DTT
DMFLQ96	MA	Inhibitor
DMFLQ96	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMFLQ96	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DM1YOVG	DI	DM1YOVG
DM1YOVG	DN	PMID30247903-Compound-General structure34
DM1YOVG	MI	TT23XQV
DM1YOVG	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DM1YOVG	MT	DTT
DM1YOVG	MA	Inhibitor
DM1YOVG	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DM1YOVG	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMF9HIJ	DI	DMF9HIJ
DMF9HIJ	DN	PMID30247903-Compound-General structure35
DMF9HIJ	MI	TT23XQV
DMF9HIJ	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMF9HIJ	MT	DTT
DMF9HIJ	MA	Inhibitor
DMF9HIJ	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMF9HIJ	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMI4EU5	DI	DMI4EU5
DMI4EU5	DN	PMID30247903-Compound-General structure36
DMI4EU5	MI	TT23XQV
DMI4EU5	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMI4EU5	MT	DTT
DMI4EU5	MA	Inhibitor
DMI4EU5	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMI4EU5	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMDWHIN	DI	DMDWHIN
DMDWHIN	DN	PMID30247903-Compound-General structure37
DMDWHIN	MI	TT23XQV
DMDWHIN	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMDWHIN	MT	DTT
DMDWHIN	MA	Inhibitor
DMDWHIN	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMDWHIN	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMDB9FT	DI	DMDB9FT
DMDB9FT	DN	PMID30247903-Compound-General structure38
DMDB9FT	MI	TT23XQV
DMDB9FT	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMDB9FT	MT	DTT
DMDB9FT	MA	Inhibitor
DMDB9FT	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMDB9FT	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMKLATO	DI	DMKLATO
DMKLATO	DN	PMID30247903-Compound-General structure39
DMKLATO	MI	TT23XQV
DMKLATO	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMKLATO	MT	DTT
DMKLATO	MA	Inhibitor
DMKLATO	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMKLATO	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMPZ3AY	DI	DMPZ3AY
DMPZ3AY	DN	PMID30247903-Compound-General structure40
DMPZ3AY	MI	TT23XQV
DMPZ3AY	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMPZ3AY	MT	DTT
DMPZ3AY	MA	Inhibitor
DMPZ3AY	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMPZ3AY	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DM0UMSF	DI	DM0UMSF
DM0UMSF	DN	PMID30247903-Compound-General structure41
DM0UMSF	MI	TT23XQV
DM0UMSF	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DM0UMSF	MT	DTT
DM0UMSF	MA	Inhibitor
DM0UMSF	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DM0UMSF	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMRNF96	DI	DMRNF96
DMRNF96	DN	PMID30247903-Compound-General structure42
DMRNF96	MI	TT23XQV
DMRNF96	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMRNF96	MT	DTT
DMRNF96	MA	Inhibitor
DMRNF96	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMRNF96	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMY971M	DI	DMY971M
DMY971M	DN	PMID30247903-Compound-General structure43
DMY971M	MI	TT23XQV
DMY971M	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMY971M	MT	DTT
DMY971M	MA	Inhibitor
DMY971M	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMY971M	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMRAFSB	DI	DMRAFSB
DMRAFSB	DN	PMID30247903-Compound-General structure44
DMRAFSB	MI	TT23XQV
DMRAFSB	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMRAFSB	MT	DTT
DMRAFSB	MA	Inhibitor
DMRAFSB	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMRAFSB	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMHMUNB	DI	DMHMUNB
DMHMUNB	DN	PMID30247903-Compound-General structure45
DMHMUNB	MI	TT23XQV
DMHMUNB	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMHMUNB	MT	DTT
DMHMUNB	MA	Inhibitor
DMHMUNB	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMHMUNB	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMWYCOB	DI	DMWYCOB
DMWYCOB	DN	PMID30247903-Compound-General structure46
DMWYCOB	MI	TT23XQV
DMWYCOB	MN	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
DMWYCOB	MT	DTT
DMWYCOB	MA	Inhibitor
DMWYCOB	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMWYCOB	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DM7LUI2	DI	DM7LUI2
DM7LUI2	DN	PMID30247903-Compound-General structure5
DM7LUI2	MI	TT8ZLTI
DM7LUI2	MN	Programmed cell death 1 ligand 1 (PD-L1)
DM7LUI2	MT	DTT
DM7LUI2	MA	Inhibitor
DM7LUI2	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DM7LUI2	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMHQ6C3	DI	DMHQ6C3
DMHQ6C3	DN	PMID30247903-Compound-General structure6
DMHQ6C3	MI	TT8ZLTI
DMHQ6C3	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMHQ6C3	MT	DTT
DMHQ6C3	MA	Inhibitor
DMHQ6C3	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMHQ6C3	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DM9QMA2	DI	DM9QMA2
DM9QMA2	DN	PMID30247903-Compound-General structure7
DM9QMA2	MI	TT8ZLTI
DM9QMA2	MN	Programmed cell death 1 ligand 1 (PD-L1)
DM9QMA2	MT	DTT
DM9QMA2	MA	Inhibitor
DM9QMA2	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DM9QMA2	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMLMYE0	DI	DMLMYE0
DMLMYE0	DN	PMID30247903-Compound-General structure8
DMLMYE0	MI	TT8ZLTI
DMLMYE0	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMLMYE0	MT	DTT
DMLMYE0	MA	Inhibitor
DMLMYE0	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMLMYE0	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMBR7A6	DI	DMBR7A6
DMBR7A6	DN	PMID30247903-Compound-General structure9
DMBR7A6	MI	TT8ZLTI
DMBR7A6	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMBR7A6	MT	DTT
DMBR7A6	MA	Inhibitor
DMBR7A6	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMBR7A6	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMN39V6	DI	DMN39V6
DMN39V6	DN	PMID32321856-compound-11a
DMN39V6	MI	TTNHMO8
DMN39V6	MN	COVID-19 papain-like proteinase (PL-PRO)
DMN39V6	MT	DTT
DMN39V6	MA	Inhibitor
DMN39V6	RN	Structure-based Design of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease. Science. 2020 Apr 22;eabb4489.
DMN39V6	RU	https://pubmed.ncbi.nlm.nih.gov/32321856

DM31QEY	DI	DM31QEY
DM31QEY	DN	PMID32321856-compound-11b
DM31QEY	MI	TTNHMO8
DM31QEY	MN	COVID-19 papain-like proteinase (PL-PRO)
DM31QEY	MT	DTT
DM31QEY	MA	Inhibitor
DM31QEY	RN	Structure-based Design of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease. Science. 2020 Apr 22;eabb4489.
DM31QEY	RU	https://pubmed.ncbi.nlm.nih.gov/32321856

DM3J746	DI	DM3J746
DM3J746	DN	PMID3514912C9
DM3J746	MI	TTAHE2N
DM3J746	MN	Acrosin (ACR)
DM3J746	MT	DTT
DM3J746	MA	Inhibitor
DM3J746	RN	Synthesis and inhibition of human acrosin and trypsin and acute toxicity of aryl 4-guanidinobenzoates. J Med Chem. 1986 Apr;29(4):514-9.
DM3J746	RU	https://pubmed.ncbi.nlm.nih.gov/3514912

DM3J746	DI	DM3J746
DM3J746	DN	PMID3514912C9
DM3J746	MI	TT2WR1T
DM3J746	MN	Cationic trypsinogen (PRSS1)
DM3J746	MT	DTT
DM3J746	MA	Inhibitor
DM3J746	RN	Synthesis and inhibition of human acrosin and trypsin and acute toxicity of aryl 4-guanidinobenzoates. J Med Chem. 1986 Apr;29(4):514-9.
DM3J746	RU	https://pubmed.ncbi.nlm.nih.gov/3514912

DM6ZOW4	DI	DM6ZOW4
DM6ZOW4	DN	PMID3941405C3d
DM6ZOW4	MI	TT4H0V2
DM6ZOW4	MN	Dipeptidyl peptidase I (CTSC)
DM6ZOW4	MT	DTT
DM6ZOW4	MA	Inhibitor
DM6ZOW4	RN	Carboxyl-modified amino acids and peptides as protease inhibitors. J Med Chem. 1986 Jan;29(1):104-11.
DM6ZOW4	RU	https://pubmed.ncbi.nlm.nih.gov/3941405

DMB2MQW	DI	DMB2MQW
DMB2MQW	DN	PMID7473541C11
DMB2MQW	MI	TTFQEO5
DMB2MQW	MN	Squalene synthetase (FDFT1)
DMB2MQW	MT	DTT
DMB2MQW	MA	Inhibitor
DMB2MQW	RN	Phenoxypropylamines: a new series of squalene synthase inhibitors. J Med Chem. 1995 Oct 13;38(21):4157-60.
DMB2MQW	RU	https://pubmed.ncbi.nlm.nih.gov/7473541

DM2CP5J	DI	DM2CP5J
DM2CP5J	DN	PMID7473541C19
DM2CP5J	MI	TTFQEO5
DM2CP5J	MN	Squalene synthetase (FDFT1)
DM2CP5J	MT	DTT
DM2CP5J	MA	Inhibitor
DM2CP5J	RN	Phenoxypropylamines: a new series of squalene synthase inhibitors. J Med Chem. 1995 Oct 13;38(21):4157-60.
DM2CP5J	RU	https://pubmed.ncbi.nlm.nih.gov/7473541

DMMZ1LR	DI	DMMZ1LR
DMMZ1LR	DN	PMID7473541C20
DMMZ1LR	MI	TTFQEO5
DMMZ1LR	MN	Squalene synthetase (FDFT1)
DMMZ1LR	MT	DTT
DMMZ1LR	MA	Inhibitor
DMMZ1LR	RN	Phenoxypropylamines: a new series of squalene synthase inhibitors. J Med Chem. 1995 Oct 13;38(21):4157-60.
DMMZ1LR	RU	https://pubmed.ncbi.nlm.nih.gov/7473541

DMMRSZB	DI	DMMRSZB
DMMRSZB	DN	PMID7473541C21
DMMRSZB	MI	TTFQEO5
DMMRSZB	MN	Squalene synthetase (FDFT1)
DMMRSZB	MT	DTT
DMMRSZB	MA	Inhibitor
DMMRSZB	RN	Phenoxypropylamines: a new series of squalene synthase inhibitors. J Med Chem. 1995 Oct 13;38(21):4157-60.
DMMRSZB	RU	https://pubmed.ncbi.nlm.nih.gov/7473541

DMOJ57D	DI	DMOJ57D
DMOJ57D	DN	PMID7629799C2d
DMOJ57D	MI	TTFQEO5
DMOJ57D	MN	Squalene synthetase (FDFT1)
DMOJ57D	MT	DTT
DMOJ57D	MA	Inhibitor
DMOJ57D	RN	1,1-Bisphosphonate squalene synthase inhibitors: interplay between the isoprenoid subunit and the diphosphate surrogate. J Med Chem. 1995 Jul 7;38(14):2596-605.
DMOJ57D	RU	https://pubmed.ncbi.nlm.nih.gov/7629799

DMBRH0Q	DI	DMBRH0Q
DMBRH0Q	DN	PMID7629799C2e
DMBRH0Q	MI	TTFQEO5
DMBRH0Q	MN	Squalene synthetase (FDFT1)
DMBRH0Q	MT	DTT
DMBRH0Q	MA	Inhibitor
DMBRH0Q	RN	1,1-Bisphosphonate squalene synthase inhibitors: interplay between the isoprenoid subunit and the diphosphate surrogate. J Med Chem. 1995 Jul 7;38(14):2596-605.
DMBRH0Q	RU	https://pubmed.ncbi.nlm.nih.gov/7629799

DMXMF39	DI	DMXMF39
DMXMF39	DN	PMID7629799C6
DMXMF39	MI	TTFQEO5
DMXMF39	MN	Squalene synthetase (FDFT1)
DMXMF39	MT	DTT
DMXMF39	MA	Inhibitor
DMXMF39	RN	Phosphonosulfonates are potent, selective inhibitors of dehydrosqualene synthase and staphyloxanthin biosynthesis in Staphylococcus aureus. J Med Chem. 2009 Feb 26;52(4):976-88.
DMXMF39	RU	https://pubmed.ncbi.nlm.nih.gov/19191557

DM5SU6N	DI	DM5SU6N
DM5SU6N	DN	PMID7650673C4q
DM5SU6N	MI	TTFQEO5
DM5SU6N	MN	Squalene synthetase (FDFT1)
DM5SU6N	MT	DTT
DM5SU6N	MA	Inhibitor
DM5SU6N	RN	(Aryloxy)methylsilane derivatives as new cholesterol biosynthesis inhibitors: synthesis and hypocholesterolemic activity of a new class of squalene epoxidase inhibitors. J Med Chem. 1995 Aug 18;38(17):3207-16.
DM5SU6N	RU	https://pubmed.ncbi.nlm.nih.gov/7650673

DM769YQ	DI	DM769YQ
DM769YQ	DN	PMID7932551C9
DM769YQ	MI	TTPADOQ
DM769YQ	MN	HMG-CoA reductase (HMGCR)
DM769YQ	MT	DTT
DM769YQ	MA	Inhibitor
DM769YQ	RN	Synthesis and biological activity of bile acid-derived HMG-CoA reductase inhibitors. The role of 21-methyl in recognition of HMG-CoA reductase and the ileal bile acid transport system. J Med Chem. 1994 Sep 30;37(20):3240-6.
DM769YQ	RU	https://pubmed.ncbi.nlm.nih.gov/7932551

DMJF7OC	DI	DMJF7OC
DMJF7OC	DN	PMID7966163C3f
DMJF7OC	MI	TTFQEO5
DMJF7OC	MN	Squalene synthetase (FDFT1)
DMJF7OC	MT	DTT
DMJF7OC	MA	Inhibitor
DMJF7OC	RN	Structure-activity relationships of C1 and C6 side chains of zaragozic acid A derivatives. J Med Chem. 1994 Nov 11;37(23):4031-51.
DMJF7OC	RU	https://pubmed.ncbi.nlm.nih.gov/7966163

DMD524S	DI	DMD524S
DMD524S	DN	PMID7966163C4e
DMD524S	MI	TTFQEO5
DMD524S	MN	Squalene synthetase (FDFT1)
DMD524S	MT	DTT
DMD524S	MA	Inhibitor
DMD524S	RN	Structure-activity relationships of C1 and C6 side chains of zaragozic acid A derivatives. J Med Chem. 1994 Nov 11;37(23):4031-51.
DMD524S	RU	https://pubmed.ncbi.nlm.nih.gov/7966163

DMUEG8O	DI	DMUEG8O
DMUEG8O	DN	PMID7966163C6c
DMUEG8O	MI	TTFQEO5
DMUEG8O	MN	Squalene synthetase (FDFT1)
DMUEG8O	MT	DTT
DMUEG8O	MA	Inhibitor
DMUEG8O	RN	Structure-activity relationships of C1 and C6 side chains of zaragozic acid A derivatives. J Med Chem. 1994 Nov 11;37(23):4031-51.
DMUEG8O	RU	https://pubmed.ncbi.nlm.nih.gov/7966163

DM0XU3C	DI	DM0XU3C
DM0XU3C	DN	PMID7966163C6d
DM0XU3C	MI	TTFQEO5
DM0XU3C	MN	Squalene synthetase (FDFT1)
DM0XU3C	MT	DTT
DM0XU3C	MA	Inhibitor
DM0XU3C	RN	Structure-activity relationships of C1 and C6 side chains of zaragozic acid A derivatives. J Med Chem. 1994 Nov 11;37(23):4031-51.
DM0XU3C	RU	https://pubmed.ncbi.nlm.nih.gov/7966163

DM8T41N	DI	DM8T41N
DM8T41N	DN	PMID7966163C6g
DM8T41N	MI	TTFQEO5
DM8T41N	MN	Squalene synthetase (FDFT1)
DM8T41N	MT	DTT
DM8T41N	MA	Inhibitor
DM8T41N	RN	Structure-activity relationships of C1 and C6 side chains of zaragozic acid A derivatives. J Med Chem. 1994 Nov 11;37(23):4031-51.
DM8T41N	RU	https://pubmed.ncbi.nlm.nih.gov/7966163

DMRGY2X	DI	DMRGY2X
DMRGY2X	DN	PMID8246233C28
DMRGY2X	MI	TTPADOQ
DMRGY2X	MN	HMG-CoA reductase (HMGCR)
DMRGY2X	MT	DTT
DMRGY2X	MA	Inhibitor
DMRGY2X	RN	Inhibitors of cholesterol biosynthesis. 1. 3,5-Dihydroxy-7-(N-imidazolyl)-6-heptenoates and -heptanoates, a novel series of HMG-CoA reductase inhibitors. J Med Chem. 1993 Nov 12;36(23):3646-57.
DMRGY2X	RU	https://pubmed.ncbi.nlm.nih.gov/8246233

DMUJ9F7	DI	DMUJ9F7
DMUJ9F7	DN	PMID8246233C35
DMUJ9F7	MI	TTPADOQ
DMUJ9F7	MN	HMG-CoA reductase (HMGCR)
DMUJ9F7	MT	DTT
DMUJ9F7	MA	Inhibitor
DMUJ9F7	RN	Inhibitors of cholesterol biosynthesis. 1. 3,5-Dihydroxy-7-(N-imidazolyl)-6-heptenoates and -heptanoates, a novel series of HMG-CoA reductase inhibitors. J Med Chem. 1993 Nov 12;36(23):3646-57.
DMUJ9F7	RU	https://pubmed.ncbi.nlm.nih.gov/8246233

DMETHN7	DI	DMETHN7
DMETHN7	DN	PMID8246233C5ab
DMETHN7	MI	TTPADOQ
DMETHN7	MN	HMG-CoA reductase (HMGCR)
DMETHN7	MT	DTT
DMETHN7	MA	Inhibitor
DMETHN7	RN	Inhibitors of cholesterol biosynthesis. 1. 3,5-Dihydroxy-7-(N-imidazolyl)-6-heptenoates and -heptanoates, a novel series of HMG-CoA reductase inhibitors. J Med Chem. 1993 Nov 12;36(23):3646-57.
DMETHN7	RU	https://pubmed.ncbi.nlm.nih.gov/8246233

DMJWEXQ	DI	DMJWEXQ
DMJWEXQ	DN	PMID8246234C3h
DMJWEXQ	MI	TTPADOQ
DMJWEXQ	MN	HMG-CoA reductase (HMGCR)
DMJWEXQ	MT	DTT
DMJWEXQ	MA	Inhibitor
DMJWEXQ	RN	Inhibitors of cholesterol biosynthesis. 2. 3,5-Dihydroxy-7-(N-pyrrolyl)-6-heptenoates, a novel series of HMG-CoA reductase inhibitors. J Med Chem. 1993 Nov 12;36(23):3658-62.
DMJWEXQ	RU	https://pubmed.ncbi.nlm.nih.gov/8246234

DMLOR6F	DI	DMLOR6F
DMLOR6F	DN	PMID8246237C18t
DMLOR6F	MI	TTPADOQ
DMLOR6F	MN	HMG-CoA reductase (HMGCR)
DMLOR6F	MT	DTT
DMLOR6F	MA	Inhibitor
DMLOR6F	RN	HMG-CoA reductase inhibitors: design, synthesis, and biological activity of tetrahydroindazole-substituted 3,5-dihydroxy-6-heptenoic acid sodium salts. J Med Chem. 1993 Nov 12;36(23):3674-85.
DMLOR6F	RU	https://pubmed.ncbi.nlm.nih.gov/8246237

DMEITGU	DI	DMEITGU
DMEITGU	DN	PMID8410973C2
DMEITGU	MI	TTLXC4Q
DMEITGU	MN	Cathepsin E (CTSE)
DMEITGU	MT	DTT
DMEITGU	MA	Inhibitor
DMEITGU	RN	Specificity in the binding of inhibitors to the active site of human/primate aspartic proteinases: analysis of P2-P1-P1'-P2' variation. J Med Chem. 1993 Sep 3;36(18):2614-20.
DMEITGU	RU	https://pubmed.ncbi.nlm.nih.gov/8410973

DM6J5KY	DI	DM6J5KY
DM6J5KY	DN	PMID8410973C3
DM6J5KY	MI	TTPT2QI
DM6J5KY	MN	Cathepsin D (CTSD)
DM6J5KY	MT	DTT
DM6J5KY	MA	Inhibitor
DM6J5KY	RN	Specificity in the binding of inhibitors to the active site of human/primate aspartic proteinases: analysis of P2-P1-P1'-P2' variation. J Med Chem. 1993 Sep 3;36(18):2614-20.
DM6J5KY	RU	https://pubmed.ncbi.nlm.nih.gov/8410973

DM6J5KY	DI	DM6J5KY
DM6J5KY	DN	PMID8410973C3
DM6J5KY	MI	TTLXC4Q
DM6J5KY	MN	Cathepsin E (CTSE)
DM6J5KY	MT	DTT
DM6J5KY	MA	Inhibitor
DM6J5KY	RN	Specificity in the binding of inhibitors to the active site of human/primate aspartic proteinases: analysis of P2-P1-P1'-P2' variation. J Med Chem. 1993 Sep 3;36(18):2614-20.
DM6J5KY	RU	https://pubmed.ncbi.nlm.nih.gov/8410973

DM6J5KY	DI	DM6J5KY
DM6J5KY	DN	PMID8410973C3
DM6J5KY	MI	TTKZ864
DM6J5KY	MN	Pepsinogen-5 (PGA5)
DM6J5KY	MT	DTT
DM6J5KY	MA	Inhibitor
DM6J5KY	RN	Specificity in the binding of inhibitors to the active site of human/primate aspartic proteinases: analysis of P2-P1-P1'-P2' variation. J Med Chem. 1993 Sep 3;36(18):2614-20.
DM6J5KY	RU	https://pubmed.ncbi.nlm.nih.gov/8410973

DM6J5KY	DI	DM6J5KY
DM6J5KY	DN	PMID8410973C3
DM6J5KY	MI	TT7K6AD
DM6J5KY	MN	Progastricsin pepsinogen C (PGC)
DM6J5KY	MT	DTT
DM6J5KY	MA	Inhibitor
DM6J5KY	RN	Specificity in the binding of inhibitors to the active site of human/primate aspartic proteinases: analysis of P2-P1-P1'-P2' variation. J Med Chem. 1993 Sep 3;36(18):2614-20.
DM6J5KY	RU	https://pubmed.ncbi.nlm.nih.gov/8410973

DMTURQZ	DI	DMTURQZ
DMTURQZ	DN	PMID8426367C18
DMTURQZ	MI	TTPADOQ
DMTURQZ	MN	HMG-CoA reductase (HMGCR)
DMTURQZ	MT	DTT
DMTURQZ	MA	Inhibitor
DMTURQZ	RN	32-Methyl-32-oxylanosterols: dual-action inhibitors of cholesterol biosynthesis. J Med Chem. 1993 Feb 5;36(3):410-6.
DMTURQZ	RU	https://pubmed.ncbi.nlm.nih.gov/8426367

DM8PBKQ	DI	DM8PBKQ
DM8PBKQ	DN	PMID8496919C7
DM8PBKQ	MI	TTFQEO5
DM8PBKQ	MN	Squalene synthetase (FDFT1)
DM8PBKQ	MT	DTT
DM8PBKQ	MA	Inhibitor
DM8PBKQ	RN	N-(arylalkyl)farnesylamines: new potent squalene synthetase inhibitors. J Med Chem. 1993 May 14;36(10):1501-4.
DM8PBKQ	RU	https://pubmed.ncbi.nlm.nih.gov/8496919

DMG3ZD1	DI	DMG3ZD1
DMG3ZD1	DN	PMID8568816C56
DMG3ZD1	MI	TTGKNB4
DMG3ZD1	MN	Epidermal growth factor receptor (EGFR)
DMG3ZD1	MT	DTT
DMG3ZD1	MA	Inhibitor
DMG3ZD1	RN	Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J Med Chem. 1996 Jan 5;39(1):267-76.
DMG3ZD1	RU	https://pubmed.ncbi.nlm.nih.gov/8568816

DMUJEA4	DI	DMUJEA4
DMUJEA4	DN	PMID8576905C4
DMUJEA4	MI	TTFQEO5
DMUJEA4	MN	Squalene synthetase (FDFT1)
DMUJEA4	MT	DTT
DMUJEA4	MA	Inhibitor
DMUJEA4	RN	Alpha-Phosphonosulfonic acids: potent and selective inhibitors of squalene synthase. J Med Chem. 1996 Feb 2;39(3):657-60.
DMUJEA4	RU	https://pubmed.ncbi.nlm.nih.gov/8576905

DMWBPOJ	DI	DMWBPOJ
DMWBPOJ	DN	PMID8709131C15
DMWBPOJ	MI	TTFQEO5
DMWBPOJ	MN	Squalene synthetase (FDFT1)
DMWBPOJ	MT	DTT
DMWBPOJ	MA	Inhibitor
DMWBPOJ	RN	Synthesis and activity of a novel series of 3-biarylquinuclidine squalene synthase inhibitors. J Med Chem. 1996 Jul 19;39(15):2971-9.
DMWBPOJ	RU	https://pubmed.ncbi.nlm.nih.gov/8709131

DM10IQP	DI	DM10IQP
DM10IQP	DN	PMID8709131C17
DM10IQP	MI	TTFQEO5
DM10IQP	MN	Squalene synthetase (FDFT1)
DM10IQP	MT	DTT
DM10IQP	MA	Inhibitor
DM10IQP	RN	Synthesis and activity of a novel series of 3-biarylquinuclidine squalene synthase inhibitors. J Med Chem. 1996 Jul 19;39(15):2971-9.
DM10IQP	RU	https://pubmed.ncbi.nlm.nih.gov/8709131

DMSKJ53	DI	DMSKJ53
DMSKJ53	DN	PMID8709131C23
DMSKJ53	MI	TTFQEO5
DMSKJ53	MN	Squalene synthetase (FDFT1)
DMSKJ53	MT	DTT
DMSKJ53	MA	Inhibitor
DMSKJ53	RN	Synthesis and activity of a novel series of 3-biarylquinuclidine squalene synthase inhibitors. J Med Chem. 1996 Jul 19;39(15):2971-9.
DMSKJ53	RU	https://pubmed.ncbi.nlm.nih.gov/8709131

DM1OS6M	DI	DM1OS6M
DM1OS6M	DN	PMID8709131C2a (+)
DM1OS6M	MI	TTFQEO5
DM1OS6M	MN	Squalene synthetase (FDFT1)
DM1OS6M	MT	DTT
DM1OS6M	MA	Inhibitor
DM1OS6M	RN	Synthesis and activity of a novel series of 3-biarylquinuclidine squalene synthase inhibitors. J Med Chem. 1996 Jul 19;39(15):2971-9.
DM1OS6M	RU	https://pubmed.ncbi.nlm.nih.gov/8709131

DMETC8A	DI	DMETC8A
DMETC8A	DN	PMID8709131C4
DMETC8A	MI	TTFQEO5
DMETC8A	MN	Squalene synthetase (FDFT1)
DMETC8A	MT	DTT
DMETC8A	MA	Inhibitor
DMETC8A	RN	Synthesis and activity of a novel series of 3-biarylquinuclidine squalene synthase inhibitors. J Med Chem. 1996 Jul 19;39(15):2971-9.
DMETC8A	RU	https://pubmed.ncbi.nlm.nih.gov/8709131

DMM08LV	DI	DMM08LV
DMM08LV	DN	PMID8831774C19
DMM08LV	MI	TTG5QB7
DMM08LV	MN	Calpain-2 (CAPN2)
DMM08LV	MT	DTT
DMM08LV	MA	Inhibitor
DMM08LV	RN	Novel peptidyl alpha-keto amide inhibitors of calpains and other cysteine proteases. J Med Chem. 1996 Sep 27;39(20):4089-98.
DMM08LV	RU	https://pubmed.ncbi.nlm.nih.gov/8831774

DM1I578	DI	DM1I578
DM1I578	DN	PMID9003518C3
DM1I578	MI	TT7O8ZA
DM1I578	MN	Lanosterol synthase (LSS)
DM1I578	MT	DTT
DM1I578	MA	Inhibitor
DM1I578	RN	Synthesis and inhibition studies of sulfur-substituted squalene oxide analogues as mechanism-based inhibitors of 2,3-oxidosqualene-lanosterol cyclase. J Med Chem. 1997 Jan 17;40(2):201-9.
DM1I578	RU	https://pubmed.ncbi.nlm.nih.gov/9003518

DMYE64O	DI	DMYE64O
DMYE64O	DN	PMID9003518C4
DMYE64O	MI	TT7O8ZA
DMYE64O	MN	Lanosterol synthase (LSS)
DMYE64O	MT	DTT
DMYE64O	MA	Inhibitor
DMYE64O	RN	Synthesis and inhibition studies of sulfur-substituted squalene oxide analogues as mechanism-based inhibitors of 2,3-oxidosqualene-lanosterol cyclase. J Med Chem. 1997 Jan 17;40(2):201-9.
DMYE64O	RU	https://pubmed.ncbi.nlm.nih.gov/9003518

DM2F81A	DI	DM2F81A
DM2F81A	DN	PMID9216829C5j
DM2F81A	MI	TTFQEO5
DM2F81A	MN	Squalene synthetase (FDFT1)
DM2F81A	MT	DTT
DM2F81A	MA	Inhibitor
DM2F81A	RN	(1 alpha, 2 beta, 3 beta, 4 alpha)-1,2-bis[N-propyl-N-(4-phenoxybenzyl) amino]carbonyl]cyclobutane-3,4-dicarboxylic acid (A-87049): a novel potent ... J Med Chem. 1997 Jul 4;40(14):2123-5.
DM2F81A	RU	https://pubmed.ncbi.nlm.nih.gov/9216829

DM3ARWX	DI	DM3ARWX
DM3ARWX	DN	PMID9216829C5m
DM3ARWX	MI	TTFQEO5
DM3ARWX	MN	Squalene synthetase (FDFT1)
DM3ARWX	MT	DTT
DM3ARWX	MA	Inhibitor
DM3ARWX	RN	(1 alpha, 2 beta, 3 beta, 4 alpha)-1,2-bis[N-propyl-N-(4-phenoxybenzyl) amino]carbonyl]cyclobutane-3,4-dicarboxylic acid (A-87049): a novel potent ... J Med Chem. 1997 Jul 4;40(14):2123-5.
DM3ARWX	RU	https://pubmed.ncbi.nlm.nih.gov/9216829

DMY28QM	DI	DMY28QM
DMY28QM	DN	PMID9871507C14
DMY28QM	MI	TTFQEO5
DMY28QM	MN	Squalene synthetase (FDFT1)
DMY28QM	MT	DTT
DMY28QM	MA	Inhibitor
DMY28QM	RN	Cyclopentanedi- and tricarboxylic acids as squalene synthase inhibitors: syntheses and evaluation. Bioorg Med Chem Lett. 1998 Apr 21;8(8):891-6.
DMY28QM	RU	https://pubmed.ncbi.nlm.nih.gov/9871507

DMHSWT6	DI	DMHSWT6
DMHSWT6	DN	P-MPPI
DMHSWT6	MI	TTSQIFT
DMHSWT6	MN	5-HT 1A receptor (HTR1A)
DMHSWT6	MT	DTT
DMHSWT6	MA	Antagonist
DMHSWT6	RN	p-Chloroamphetamine, a serotonin-releasing drug, elicited in rats a hyperglycemia mediated by the 5-HT1A and 5-HT2B/2C receptors. Eur J Pharmacol. 1998 Oct 23;359(2-3):185-90.
DMHSWT6	RU	https://pubmed.ncbi.nlm.nih.gov/9832390

DMZCSF1	DI	DMZCSF1
DMZCSF1	DN	PMX-700
DMZCSF1	MI	TT6S2FE
DMZCSF1	MN	DNA [cytosine-5]-methyltransferase 1 (DNMT1)
DMZCSF1	MT	DTT
DMZCSF1	MA	Modulator
DMZCSF1	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2605).
DMZCSF1	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2605

DMPUC8I	DI	DMPUC8I
DMPUC8I	DN	PNA-D-glucopyranoside
DMPUC8I	MI	DEQB4LT
DMPUC8I	MN	Beta-galactosidase (bgaB)
DMPUC8I	MT	DME
DMPUC8I	MA	Metabolism
DMPUC8I	RN	Identification and characterization of a novel beta-galactosidase from Victivallis vadensis ATCC BAA-548, an anaerobic fecal bacterium. J Microbiol. 2012 Dec;50(6):1034-40.
DMPUC8I	RU	https://pubmed.ncbi.nlm.nih.gov/23274992

DMPUC8I	DI	DMPUC8I
DMPUC8I	DN	PNA-D-glucopyranoside
DMPUC8I	MI	DEPR1Y7
DMPUC8I	MN	Beta-galactosidase (bgaB)
DMPUC8I	MT	DME
DMPUC8I	MA	Metabolism
DMPUC8I	RN	Beta-galactosidase from Bifidobacterium adolescentis DSM20083 prefers beta(1,4)-galactosides over lactose. Appl Microbiol Biotechnol. 2004 Dec;66(3):276-84.
DMPUC8I	RU	https://pubmed.ncbi.nlm.nih.gov/15480628

DMPUC8I	DI	DMPUC8I
DMPUC8I	DN	PNA-D-glucopyranoside
DMPUC8I	MI	DE073GW
DMPUC8I	MN	Glucosidase II beta (PRKCSH)
DMPUC8I	MT	DME
DMPUC8I	MA	Metabolism
DMPUC8I	RN	The heterodimeric structure of glucosidase II is required for its activity, solubility, and localization in vivo. Glycobiology. 2000 Aug;10(8):815-27.
DMPUC8I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10929008

DMPUC8I	DI	DMPUC8I
DMPUC8I	DN	PNA-D-glucopyranoside
DMPUC8I	MI	DEMWKYT
DMPUC8I	MN	Neutral alpha-glucosidase AB (GANAB)
DMPUC8I	MT	DME
DMPUC8I	MA	Metabolism
DMPUC8I	RN	The heterodimeric structure of glucosidase II is required for its activity, solubility, and localization in vivo. Glycobiology. 2000 Aug;10(8):815-27.
DMPUC8I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10929008

DMZF7RQ	DI	DMZF7RQ
DMZF7RQ	DN	PNA-l-rhamnopyranoside
DMZF7RQ	MI	DEBI82Z
DMZF7RQ	MN	Alpha-L-rhamnosidase (lrA)
DMZF7RQ	MT	DME
DMZF7RQ	MA	Metabolism
DMZF7RQ	RN	Metabolism of rutin and poncirin by human intestinal microbiota and cloning of their metabolizing alpha-L-rhamnosidase from Bifidobacterium dentium. J Microbiol Biotechnol. 2015 Jan;25(1):18-25.
DMZF7RQ	RU	https://pubmed.ncbi.nlm.nih.gov/25179902

DMBK8QI	DI	DMBK8QI
DMBK8QI	DN	PNB-D-glucoside
DMBK8QI	MI	DE21ZKX
DMBK8QI	MN	GH3 beta-glucosidase (BAD1610)
DMBK8QI	MT	DME
DMBK8QI	MA	Metabolism
DMBK8QI	RN	Structural and biochemical characterization of a GH3 beta-glucosidase from the probiotic bacteria Bifidobacterium adolescentis. Biochimie. 2018 May;148:107-115.
DMBK8QI	RU	https://pubmed.ncbi.nlm.nih.gov/29555372

DMZ91P5	DI	DMZ91P5
DMZ91P5	DN	PNB-D-glucuronide
DMZ91P5	MI	DE65RJO
DMZ91P5	MN	Beta-glucuronidase (uidA)
DMZ91P5	MT	DME
DMZ91P5	MA	Metabolism
DMZ91P5	RN	Active site flexibility revealed in crystal structures of Parabacteroides merdae beta-glucuronidase from the human gut microbiome. Protein Sci. 2018 Dec;27(12):2010-2022.
DMZ91P5	RU	https://pubmed.ncbi.nlm.nih.gov/30230652

DMWPECH	DI	DMWPECH
DMWPECH	DN	PNB-D-xyloside
DMWPECH	MI	DEG1VAR
DMWPECH	MN	Beta-glucuronidase (uidA)
DMWPECH	MT	DME
DMWPECH	MA	Metabolism
DMWPECH	RN	Structural and biochemical characterization of glycoside hydrolase family 79 beta-glucuronidase from Acidobacterium capsulatum. J Biol Chem. 2012 Apr 20;287(17):14069-77.
DMWPECH	RU	https://pubmed.ncbi.nlm.nih.gov/22367201

DMWPECH	DI	DMWPECH
DMWPECH	DN	PNB-D-xyloside
DMWPECH	MI	DE21ZKX
DMWPECH	MN	GH3 beta-glucosidase (BAD1610)
DMWPECH	MT	DME
DMWPECH	MA	Metabolism
DMWPECH	RN	Structural and biochemical characterization of a GH3 beta-glucosidase from the probiotic bacteria Bifidobacterium adolescentis. Biochimie. 2018 May;148:107-115.
DMWPECH	RU	https://pubmed.ncbi.nlm.nih.gov/29555372

DMVJUOZ	DI	DMVJUOZ
DMVJUOZ	DN	P-nitrobenzoic acid
DMVJUOZ	MI	DEAVXGM
DMVJUOZ	MN	Nitroreductase (NTR)
DMVJUOZ	MT	DME
DMVJUOZ	MA	Metabolism
DMVJUOZ	RN	Isolation of nitrofurantoin-resistant mutants of nitroreductase-producing Clostridium sp. strains from the human intestinal tract. Antimicrob Agents Chemother. 1998 May;42(5):1121-6.
DMVJUOZ	RU	https://pubmed.ncbi.nlm.nih.gov/9593138

DMVJUOZ	DI	DMVJUOZ
DMVJUOZ	DN	P-nitrobenzoic acid
DMVJUOZ	MI	DE7XBKW
DMVJUOZ	MN	Nitroreductase (NTR)
DMVJUOZ	MT	DME
DMVJUOZ	MA	Metabolism
DMVJUOZ	RN	Isolation of nitrofurantoin-resistant mutants of nitroreductase-producing Clostridium sp. strains from the human intestinal tract. Antimicrob Agents Chemother. 1998 May;42(5):1121-6.
DMVJUOZ	RU	https://pubmed.ncbi.nlm.nih.gov/9593138

DMVJUOZ	DI	DMVJUOZ
DMVJUOZ	DN	P-nitrobenzoic acid
DMVJUOZ	MI	DEP7ECA
DMVJUOZ	MN	Nitroreductase (NTR)
DMVJUOZ	MT	DME
DMVJUOZ	MA	Metabolism
DMVJUOZ	RN	Isolation of nitrofurantoin-resistant mutants of nitroreductase-producing Clostridium sp. strains from the human intestinal tract. Antimicrob Agents Chemother. 1998 May;42(5):1121-6.
DMVJUOZ	RU	https://pubmed.ncbi.nlm.nih.gov/9593138

DMVJUOZ	DI	DMVJUOZ
DMVJUOZ	DN	P-nitrobenzoic acid
DMVJUOZ	MI	DEH3ABM
DMVJUOZ	MN	Nitroreductase (NTR)
DMVJUOZ	MT	DME
DMVJUOZ	MA	Metabolism
DMVJUOZ	RN	Isolation of nitrofurantoin-resistant mutants of nitroreductase-producing Clostridium sp. strains from the human intestinal tract. Antimicrob Agents Chemother. 1998 May;42(5):1121-6.
DMVJUOZ	RU	https://pubmed.ncbi.nlm.nih.gov/9593138

DM7LPCE	DI	DM7LPCE
DM7LPCE	DN	P-nitrophenyl
DM7LPCE	MI	DEMH6UB
DM7LPCE	MN	Lysosomal beta A mannosidase (MANBA)
DM7LPCE	MT	DME
DM7LPCE	MA	Metabolism
DM7LPCE	RN	Cloning, sequence, expression and characterization of human beta-mannosidase. Acta Biochim Pol. 2008;55(3):479-90.
DM7LPCE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18800177

DM29RO1	DI	DM29RO1
DM29RO1	DN	P-Nitrophenyl Glutamyl Anilide
DM29RO1	MI	TTF7WRM
DM29RO1	MN	Alanine/serine/cysteine transporter 2 (SLC1A5)
DM29RO1	MT	DTT
DM29RO1	MA	Inhibitor
DM29RO1	RN	Ngamma-aryl glutamine analogues as probes of the ASCT2 neutral amino acid transporter binding site. Bioorg Med Chem. 2005 Feb 15;13(4):1111-8.
DM29RO1	RU	https://pubmed.ncbi.nlm.nih.gov/15670919

DMDBZGP	DI	DMDBZGP
DMDBZGP	DN	PNRI-299
DMDBZGP	MI	TTN3GBV
DMDBZGP	MN	Transcription factor AP-1 (JUN)
DMDBZGP	MT	DTT
DMDBZGP	MA	Inhibitor
DMDBZGP	RN	Chemogenomic identification of Ref-1/AP-1 as a therapeutic target for asthma. Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1169-73.
DMDBZGP	RU	https://pubmed.ncbi.nlm.nih.gov/12552119

DM8WJQ0	DI	DM8WJQ0
DM8WJQ0	DN	PNT-300
DM8WJQ0	MI	TTM8FR7
DM8WJQ0	MN	KRAS messenger RNA (KRAS mRNA)
DM8WJQ0	MT	DTT
DM8WJQ0	MA	Inhibitor
DM8WJQ0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2824).
DM8WJQ0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2824

DMIEKVB	DI	DMIEKVB
DMIEKVB	DN	PNT-500
DMIEKVB	MI	TTR5TV4
DMIEKVB	MN	ERBB2 messenger RNA (HER2 mRNA)
DMIEKVB	MT	DTT
DMIEKVB	MA	Inhibitor
DMIEKVB	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2019).
DMIEKVB	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2019

DMKBCS2	DI	DMKBCS2
DMKBCS2	DN	PNU 101017
DMKBCS2	MI	TTEX6LM
DMKBCS2	MN	GABA(A) receptor gamma-3 (GABRG3)
DMKBCS2	MT	DTT
DMKBCS2	MA	Modulator
DMKBCS2	RN	Neuroprotective effects of the GABA(A) receptor partial agonist U-101017 in 3-acetylpyridine-treated rats. Neurosci Lett. 1997 May 30;228(1):45-9.
DMKBCS2	RU	https://www.ncbi.nlm.nih.gov/pubmed/9197284

DMS5XRY	DI	DMS5XRY
DMS5XRY	DN	PNU-107859
DMS5XRY	MI	TTLM12X
DMS5XRY	MN	Matrix metalloproteinase-2 (MMP-2)
DMS5XRY	MT	DTT
DMS5XRY	MA	Inhibitor
DMS5XRY	RN	A molecular basis for the selectivity of thiadiazole urea inhibitors with stromelysin-1 and gelatinase-A from generalized born molecular dynamics s... J Med Chem. 2004 Jun 3;47(12):3065-74.
DMS5XRY	RU	https://pubmed.ncbi.nlm.nih.gov/15163188

DMS5XRY	DI	DMS5XRY
DMS5XRY	DN	PNU-107859
DMS5XRY	MI	TTUZ2L5
DMS5XRY	MN	Matrix metalloproteinase-3 (MMP-3)
DMS5XRY	MT	DTT
DMS5XRY	MA	Inhibitor
DMS5XRY	RN	A molecular basis for the selectivity of thiadiazole urea inhibitors with stromelysin-1 and gelatinase-A from generalized born molecular dynamics s... J Med Chem. 2004 Jun 3;47(12):3065-74.
DMS5XRY	RU	https://pubmed.ncbi.nlm.nih.gov/15163188

DMYBQM7	DI	DMYBQM7
DMYBQM7	DN	PNU-120596
DMYBQM7	MI	TTLA931
DMYBQM7	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMYBQM7	MT	DTT
DMYBQM7	MA	Modulator (allosteric modulator)
DMYBQM7	RN	A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization. J Neurosci. 2005 Apr 27;25(17):4396-405.
DMYBQM7	RU	https://pubmed.ncbi.nlm.nih.gov/15858066

DMEI0S7	DI	DMEI0S7
DMEI0S7	DN	PNU-142372
DMEI0S7	MI	TTUZ2L5
DMEI0S7	MN	Matrix metalloproteinase-3 (MMP-3)
DMEI0S7	MT	DTT
DMEI0S7	MA	Inhibitor
DMEI0S7	RN	Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole ... Bioorg Med Chem Lett. 2002 Oct 7;12(19):2667-72.
DMEI0S7	RU	https://pubmed.ncbi.nlm.nih.gov/12217351

DMM0EYR	DI	DMM0EYR
DMM0EYR	DN	PNU177836
DMM0EYR	MI	TTELIN2
DMM0EYR	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMM0EYR	MT	DTT
DMM0EYR	MA	Inhibitor
DMM0EYR	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMM0EYR	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMHTPSF	DI	DMHTPSF
DMHTPSF	DN	PNU-22394
DMHTPSF	MI	TT3WG5C
DMHTPSF	MN	Monoamine oxidase type A (MAO-A)
DMHTPSF	MT	DTT
DMHTPSF	MA	Inhibitor
DMHTPSF	RN	Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
DMHTPSF	RU	https://pubmed.ncbi.nlm.nih.gov/15013009

DMHTPSF	DI	DMHTPSF
DMHTPSF	DN	PNU-22394
DMHTPSF	MI	TTGP7BY
DMHTPSF	MN	Monoamine oxidase type B (MAO-B)
DMHTPSF	MT	DTT
DMHTPSF	MA	Inhibitor
DMHTPSF	RN	Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
DMHTPSF	RU	https://pubmed.ncbi.nlm.nih.gov/15013009

DM43K1D	DI	DM43K1D
DM43K1D	DN	PNU-248686A
DM43K1D	MI	TT1GHVO
DM43K1D	MN	Matrix metalloproteinase (MMP)
DM43K1D	MT	DTT
DM43K1D	MA	Modulator
DM43K1D	RN	Determination of PNU-248686A, a novel matrix metalloproteinase inhibitor, in human plasma by liquid chromatography-tandem mass spectrometry, following protein precipitation in the 96-well plate format. J Chromatogr A. 2003 Feb 14;987(1-2):249-56.
DM43K1D	RU	https://pubmed.ncbi.nlm.nih.gov/12613819

DM6SZVE	DI	DM6SZVE
DM6SZVE	DN	PNU-87663
DM6SZVE	MI	TT4QPUL
DM6SZVE	MN	Antithrombin-III (ATIII)
DM6SZVE	MT	DTT
DM6SZVE	MA	Modulator
DM6SZVE	RN	List of drugs in development for neurodegenerative diseases.Update June 2004.Neurodegener Dis.2004;1(2-3):113-52.
DM6SZVE	RU	https://www.ncbi.nlm.nih.gov/pubmed/16908983

DMQMDSG	DI	DMQMDSG
DMQMDSG	DN	PO3 2-Ile-Trp-O-3K
DMQMDSG	MI	TTQ9RYT
DMQMDSG	MN	Endothelin-converting enzyme 1 (ECE1)
DMQMDSG	MT	DTT
DMQMDSG	MA	Inhibitor
DMQMDSG	RN	Aminophosphonate endothelin converting enzyme inhibitors: potency-enhancing and selectivity-improving modifications of phosphoramidon, Bioorg. Med. Chem. Lett. 4(10):1257-1262 (1994).
DMQMDSG	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01803413

DMY43FU	DI	DMY43FU
DMY43FU	DN	PO3 2-Leu-Nal-O-3K
DMY43FU	MI	TTQ9RYT
DMY43FU	MN	Endothelin-converting enzyme 1 (ECE1)
DMY43FU	MT	DTT
DMY43FU	MA	Inhibitor
DMY43FU	RN	Aminophosphonate endothelin converting enzyme inhibitors: potency-enhancing and selectivity-improving modifications of phosphoramidon, Bioorg. Med. Chem. Lett. 4(10):1257-1262 (1994).
DMY43FU	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01803413

DM3O78D	DI	DM3O78D
DM3O78D	DN	PO3 2-Leu-Trp-O-3K
DM3O78D	MI	TTQ9RYT
DM3O78D	MN	Endothelin-converting enzyme 1 (ECE1)
DM3O78D	MT	DTT
DM3O78D	MA	Inhibitor
DM3O78D	RN	Aminophosphonate endothelin converting enzyme inhibitors: potency-enhancing and selectivity-improving modifications of phosphoramidon, Bioorg. Med. Chem. Lett. 4(10):1257-1262 (1994).
DM3O78D	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01803413

DMW1XY4	DI	DMW1XY4
DMW1XY4	DN	PO3 2-Nle-Trp-O-3K
DMW1XY4	MI	TTQ9RYT
DMW1XY4	MN	Endothelin-converting enzyme 1 (ECE1)
DMW1XY4	MT	DTT
DMW1XY4	MA	Inhibitor
DMW1XY4	RN	Aminophosphonate endothelin converting enzyme inhibitors: potency-enhancing and selectivity-improving modifications of phosphoramidon, Bioorg. Med. Chem. Lett. 4(10):1257-1262 (1994).
DMW1XY4	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01803413

DMURB4Y	DI	DMURB4Y
DMURB4Y	DN	pobilukast
DMURB4Y	MI	TTGKOY9
DMURB4Y	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DMURB4Y	MT	DTT
DMURB4Y	MA	Antagonist
DMURB4Y	RN	Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. Mol Pharmacol. 1999 Sep;56(3):657-63.
DMURB4Y	RU	https://pubmed.ncbi.nlm.nih.gov/10462554

DMURB4Y	DI	DMURB4Y
DMURB4Y	DN	pobilukast
DMURB4Y	MI	TT0PZR5
DMURB4Y	MN	Leukotriene CysLT2 receptor (CYSLTR2)
DMURB4Y	MT	DTT
DMURB4Y	MA	Antagonist
DMURB4Y	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 270).
DMURB4Y	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=270

DMXA4HY	DI	DMXA4HY
DMXA4HY	DN	Poly IC-poly arginine
DMXA4HY	MI	TTD24Y0
DMXA4HY	MN	Toll-like receptor 3 (TLR3)
DMXA4HY	MT	DTT
DMXA4HY	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1753).
DMXA4HY	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1753

DMG7K84	DI	DMG7K84
DMG7K84	DN	Polybrominated diphenyl ether derivative
DMG7K84	MI	TT12ABZ
DMG7K84	MN	Arachidonate 12-lipoxygenase (12-LOX)
DMG7K84	MT	DTT
DMG7K84	MA	Inhibitor
DMG7K84	RN	Probing the activity differences of simple and complex brominated aryl compounds against 15-soybean, 15-human, and 12-human lipoxygenase. J Med Chem. 2004 Jul 29;47(16):4060-5.
DMG7K84	RU	https://pubmed.ncbi.nlm.nih.gov/15267244

DMG7K84	DI	DMG7K84
DMG7K84	DN	Polybrominated diphenyl ether derivative
DMG7K84	MI	TTN9T81
DMG7K84	MN	Arachidonate 15-lipoxygenase (15-LOX)
DMG7K84	MT	DTT
DMG7K84	MA	Inhibitor
DMG7K84	RN	Probing the activity differences of simple and complex brominated aryl compounds against 15-soybean, 15-human, and 12-human lipoxygenase. J Med Chem. 2004 Jul 29;47(16):4060-5.
DMG7K84	RU	https://pubmed.ncbi.nlm.nih.gov/15267244

DMUTV5P	DI	DMUTV5P
DMUTV5P	DN	POLYGALATENOSIDE B
DMUTV5P	MI	TTAWNKZ
DMUTV5P	MN	Norepinephrine transporter (NET)
DMUTV5P	MT	DTT
DMUTV5P	MA	Inhibitor
DMUTV5P	RN	Antidepressant principles of the roots of Polygala tenuifolia. J Nat Prod. 2006 Sep;69(9):1305-9.
DMUTV5P	RU	https://pubmed.ncbi.nlm.nih.gov/16989524

DMV486E	DI	DMV486E
DMV486E	DN	polyIC
DMV486E	MI	TTD24Y0
DMV486E	MN	Toll-like receptor 3 (TLR3)
DMV486E	MT	DTT
DMV486E	MA	Agonist
DMV486E	RN	Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001 Oct 18;413(6857):732-8.
DMV486E	RU	https://pubmed.ncbi.nlm.nih.gov/11607032

DMUMJ7B	DI	DMUMJ7B
DMUMJ7B	DN	Poly-ICR
DMUMJ7B	MI	TTD24Y0
DMUMJ7B	MN	Toll-like receptor 3 (TLR3)
DMUMJ7B	MT	DTT
DMUMJ7B	MA	Agonist
DMUMJ7B	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1753).
DMUMJ7B	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1753

DM4VZCW	DI	DM4VZCW
DM4VZCW	DN	Polyinosinic:polycytidylic acid
DM4VZCW	MI	TT1CN09
DM4VZCW	MN	HUMAN toll-like receptor 3 (TLR3)
DM4VZCW	MT	DTT
DM4VZCW	MA	Agonist
DM4VZCW	RN	Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Infection, Immunological Response, and Vaccine Development. J Immunol Res. 2019 Apr 7;2019:6491738. doi: 10.1155/2019/6491738.
DM4VZCW	RU	https://pubmed.ncbi.nlm.nih.gov/31089478

DMN6Q4E	DI	DMN6Q4E
DMN6Q4E	DN	Polyporic acid
DMN6Q4E	MI	TT3PQ2Y
DMN6Q4E	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DMN6Q4E	MT	DTT
DMN6Q4E	MA	Inhibitor
DMN6Q4E	RN	Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Chem Biol Interact. 2000 Jan 3;124(1):61-76.
DMN6Q4E	RU	https://pubmed.ncbi.nlm.nih.gov/10658902

DMRX9E3	DI	DMRX9E3
DMRX9E3	DN	POLYSIN
DMRX9E3	MI	TTHQ79V
DMRX9E3	MN	Trypanosoma Pyrophosphate-dependent phosphofructokinase (Trypano pfk)
DMRX9E3	MT	DTT
DMRX9E3	MA	Inhibitor
DMRX9E3	RN	Antitrypanosomal alkaloids from Polyalthia suaveolens (Annonaceae): their effects on three selected glycolytic enzymes of Trypanosoma brucei. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3495-8.
DMRX9E3	RU	https://pubmed.ncbi.nlm.nih.gov/20529682

DM1GV7K	DI	DM1GV7K
DM1GV7K	DN	Pomolic acid
DM1GV7K	MI	TTELIN2
DM1GV7K	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DM1GV7K	MT	DTT
DM1GV7K	MA	Inhibitor
DM1GV7K	RN	Triterpenoids from the leaves of Diospyros kaki (persimmon) and their inhibitory effects on protein tyrosine phosphatase 1B. J Nat Prod. 2008 Oct;71(10):1775-8.
DM1GV7K	RU	https://pubmed.ncbi.nlm.nih.gov/18798681

DMGRPK8	DI	DMGRPK8
DMGRPK8	DN	PONKORANOL
DMGRPK8	MI	TTXWASR
DMGRPK8	MN	Intestinal maltase-glucoamylase (MGAM)
DMGRPK8	MT	DTT
DMGRPK8	MA	Inhibitor
DMGRPK8	RN	Probing the active-site requirements of human intestinal N-terminal maltase glucoamylase: the effect of replacing the sulfate moiety by a methyl et... Bioorg Med Chem Lett. 2010 Oct 1;20(19):5686-9.
DMGRPK8	RU	https://pubmed.ncbi.nlm.nih.gov/20801033

DMVTKCX	DI	DMVTKCX
DMVTKCX	DN	POP-1
DMVTKCX	MI	TTHCF4J
DMVTKCX	MN	Alpha-glucosidase (GLA)
DMVTKCX	MT	DTT
DMVTKCX	MA	Modulator
DMVTKCX	RN	US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT.
DMVTKCX	RU	http://www.patentbuddy.com/Patent/20120251516?ft=true&sr=true

DMVTKCX	DI	DMVTKCX
DMVTKCX	DN	POP-1
DMVTKCX	MI	TT2WR1T
DMVTKCX	MN	Cationic trypsinogen (PRSS1)
DMVTKCX	MT	DTT
DMVTKCX	MA	Modulator
DMVTKCX	RN	US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT.
DMVTKCX	RU	http://www.patentbuddy.com/Patent/20120251516?ft=true&sr=true

DMVTKCX	DI	DMVTKCX
DMVTKCX	DN	POP-1
DMVTKCX	MI	TT7MRGU
DMVTKCX	MN	Chymotrypsin (CTR)
DMVTKCX	MT	DTT
DMVTKCX	MA	Modulator
DMVTKCX	RN	US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT.
DMVTKCX	RU	http://www.patentbuddy.com/Patent/20120251516?ft=true&sr=true

DMQCSFV	DI	DMQCSFV
DMQCSFV	DN	Porphyran
DMQCSFV	MI	DEF4X7T
DMQCSFV	MN	Beta-porphyranase A (GH86A)
DMQCSFV	MT	DME
DMQCSFV	MA	Metabolism
DMQCSFV	RN	Transfer of carbohydrate-active enzymes from marine bacteria to Japanese gut microbiota. Nature. 2010 Apr 8;464(7290):908-12.
DMQCSFV	RU	https://pubmed.ncbi.nlm.nih.gov/20376150

DMU8KTO	DI	DMU8KTO
DMU8KTO	DN	PP121
DMU8KTO	MI	TT6B75U
DMU8KTO	MN	ABL messenger RNA (ABL mRNA)
DMU8KTO	MT	DTT
DMU8KTO	MA	Inhibitor
DMU8KTO	RN	Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9.
DMU8KTO	RU	https://pubmed.ncbi.nlm.nih.gov/18849971

DMU8KTO	DI	DMU8KTO
DMU8KTO	DN	PP121
DMU8KTO	MI	TTK3PY9
DMU8KTO	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMU8KTO	MT	DTT
DMU8KTO	MA	Inhibitor
DMU8KTO	RN	Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9.
DMU8KTO	RU	https://pubmed.ncbi.nlm.nih.gov/18849971

DMU8KTO	DI	DMU8KTO
DMU8KTO	DN	PP121
DMU8KTO	MI	TTGKNB4
DMU8KTO	MN	Epidermal growth factor receptor (EGFR)
DMU8KTO	MT	DTT
DMU8KTO	MA	Inhibitor
DMU8KTO	RN	Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9.
DMU8KTO	RU	https://pubmed.ncbi.nlm.nih.gov/18849971

DMU8KTO	DI	DMU8KTO
DMU8KTO	DN	PP121
DMU8KTO	MI	TT42OGM
DMU8KTO	MN	Hematopoietic cell kinase (HCK)
DMU8KTO	MT	DTT
DMU8KTO	MA	Inhibitor
DMU8KTO	RN	Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9.
DMU8KTO	RU	https://pubmed.ncbi.nlm.nih.gov/18849971

DMU8KTO	DI	DMU8KTO
DMU8KTO	DN	PP121
DMU8KTO	MI	TTTHBCA
DMU8KTO	MN	PI3-kinase beta (PIK3CB)
DMU8KTO	MT	DTT
DMU8KTO	MA	Inhibitor
DMU8KTO	RN	Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9.
DMU8KTO	RU	https://pubmed.ncbi.nlm.nih.gov/18849971

DMU8KTO	DI	DMU8KTO
DMU8KTO	DN	PP121
DMU8KTO	MI	TTHBTOP
DMU8KTO	MN	PI3-kinase gamma (PIK3CG)
DMU8KTO	MT	DTT
DMU8KTO	MA	Inhibitor
DMU8KTO	RN	Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9.
DMU8KTO	RU	https://pubmed.ncbi.nlm.nih.gov/18849971

DMU8KTO	DI	DMU8KTO
DMU8KTO	DN	PP121
DMU8KTO	MI	TT8FYO9
DMU8KTO	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMU8KTO	MT	DTT
DMU8KTO	MA	Inhibitor
DMU8KTO	RN	Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9.
DMU8KTO	RU	https://pubmed.ncbi.nlm.nih.gov/18849971

DMU8KTO	DI	DMU8KTO
DMU8KTO	DN	PP121
DMU8KTO	MI	TT6PKBN
DMU8KTO	MN	Proto-oncogene c-Src (SRC)
DMU8KTO	MT	DTT
DMU8KTO	MA	Inhibitor
DMU8KTO	RN	Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9.
DMU8KTO	RU	https://pubmed.ncbi.nlm.nih.gov/18849971

DMU8KTO	DI	DMU8KTO
DMU8KTO	DN	PP121
DMU8KTO	MI	TTCJG29
DMU8KTO	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMU8KTO	MT	DTT
DMU8KTO	MA	Inhibitor
DMU8KTO	RN	Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9.
DMU8KTO	RU	https://pubmed.ncbi.nlm.nih.gov/18849971

DMU8KTO	DI	DMU8KTO
DMU8KTO	DN	PP121
DMU8KTO	MI	TTUTJGQ
DMU8KTO	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMU8KTO	MT	DTT
DMU8KTO	MA	Inhibitor
DMU8KTO	RN	Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9.
DMU8KTO	RU	https://pubmed.ncbi.nlm.nih.gov/18849971

DMYA5CB	DI	DMYA5CB
DMYA5CB	DN	PP1-Pro-Phe-N-MeHis-LVA-Ile-Amp-(O)
DMYA5CB	MI	TTB2MXP
DMYA5CB	MN	Angiotensinogenase renin (REN)
DMYA5CB	MT	DTT
DMYA5CB	MA	Inhibitor
DMYA5CB	RN	Renin inhibitory peptides. Incorporation of polar, hydrophilic end groups into an active renin inhibitory peptide template and their evaluation in ... J Med Chem. 1991 Feb;34(2):633-42.
DMYA5CB	RU	https://pubmed.ncbi.nlm.nih.gov/1995887

DM2348V	DI	DM2348V
DM2348V	DN	PP-242
DM2348V	MI	TTC0V1J
DM2348V	MN	PAS domain-containing serine/threonine-protein kinase (PASK)
DM2348V	MT	DTT
DM2348V	MA	Inhibitor
DM2348V	RN	Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9.
DM2348V	RU	https://pubmed.ncbi.nlm.nih.gov/18849971

DM2348V	DI	DM2348V
DM2348V	DN	PP-242
DM2348V	MI	TTCJG29
DM2348V	MN	Serine/threonine-protein kinase mTOR (mTOR)
DM2348V	MT	DTT
DM2348V	MA	Inhibitor
DM2348V	RN	Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9.
DM2348V	RU	https://pubmed.ncbi.nlm.nih.gov/18849971

DM3NUKX	DI	DM3NUKX
DM3NUKX	DN	PP2-Pro-Phe-N-MeHis-LVA-Ile-Amp-(O)
DM3NUKX	MI	TTB2MXP
DM3NUKX	MN	Angiotensinogenase renin (REN)
DM3NUKX	MT	DTT
DM3NUKX	MA	Inhibitor
DM3NUKX	RN	Renin inhibitory peptides. Incorporation of polar, hydrophilic end groups into an active renin inhibitory peptide template and their evaluation in ... J Med Chem. 1991 Feb;34(2):633-42.
DM3NUKX	RU	https://pubmed.ncbi.nlm.nih.gov/1995887

DM86ZL2	DI	DM86ZL2
DM86ZL2	DN	PPA
DM86ZL2	MI	TTUJFD0
DM86ZL2	MN	Telomerase reverse transcriptase (TERT)
DM86ZL2	MT	DTT
DM86ZL2	MA	Inhibitor
DM86ZL2	RN	Growth arrest, apoptosis, and telomere shortening of Barrett's-associated adenocarcinoma cells by a telomerase inhibitor. Gastroenterology. 2004 May;126(5):1337-46.
DM86ZL2	RU	https://pubmed.ncbi.nlm.nih.gov/15131795

DMWHN3T	DI	DMWHN3T
DMWHN3T	DN	PPADS
DMWHN3T	MI	TTA93TL
DMWHN3T	MN	P2Y purinoceptor 1 (P2RY1)
DMWHN3T	MT	DTT
DMWHN3T	MA	Antagonist
DMWHN3T	RN	Quantitation of the P2Y(1) receptor with a high affinity radiolabeled antagonist. Mol Pharmacol. 2002 Nov;62(5):1249-57.
DMWHN3T	RU	https://pubmed.ncbi.nlm.nih.gov/12391289

DMWHN3T	DI	DMWHN3T
DMWHN3T	DN	PPADS
DMWHN3T	MI	TT1FE3L
DMWHN3T	MN	P2Y purinoceptor 13 (P2RY13)
DMWHN3T	MT	DTT
DMWHN3T	MA	Antagonist
DMWHN3T	RN	Pharmacological characterization of the human P2Y13 receptor. Mol Pharmacol. 2003 Jul;64(1):104-12.
DMWHN3T	RU	https://pubmed.ncbi.nlm.nih.gov/12815166

DMWHN3T	DI	DMWHN3T
DMWHN3T	DN	PPADS
DMWHN3T	MI	TT24DGP
DMWHN3T	MN	P2Y purinoceptor 4 (P2RY4)
DMWHN3T	MT	DTT
DMWHN3T	MA	Antagonist
DMWHN3T	RN	Development of selective agonists and antagonists of P2Y receptors. Purinergic Signal. 2009 Mar;5(1):75-89.
DMWHN3T	RU	https://pubmed.ncbi.nlm.nih.gov/18600475

DMWVZFK	DI	DMWVZFK
DMWVZFK	DN	PPAHV
DMWVZFK	MI	TTMI6F5
DMWVZFK	MN	Transient receptor potential cation channel V1 (TRPV1)
DMWVZFK	MT	DTT
DMWVZFK	MA	Activator
DMWVZFK	RN	Pharmacological differences between the human and rat vanilloid receptor 1 (VR1). Br J Pharmacol. 2001 Mar;132(5):1084-94.
DMWVZFK	RU	https://pubmed.ncbi.nlm.nih.gov/11226139

DM5IG4F	DI	DM5IG4F
DM5IG4F	DN	PPG
DM5IG4F	MI	TT0I76D
DM5IG4F	MN	Metabotropic glutamate receptor 7 (mGluR7)
DM5IG4F	MT	DTT
DM5IG4F	MA	Agonist
DM5IG4F	RN	Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 2000 Dec;362(6):546-54.
DM5IG4F	RU	https://pubmed.ncbi.nlm.nih.gov/11138847

DML72JT	DI	DML72JT
DML72JT	DN	PPTN
DML72JT	MI	TT72OKI
DML72JT	MN	P2Y purinoceptor 14 (P2RY14)
DML72JT	MT	DTT
DML72JT	MA	Antagonist
DML72JT	RN	A selective high-affinity antagonist of the P2Y14 receptor inhibits UDP-glucose-stimulated chemotaxis of human neutrophils. Mol Pharmacol. 2013 Jul;84(1):41-9.
DML72JT	RU	https://pubmed.ncbi.nlm.nih.gov/23592514

DMXLPO6	DI	DMXLPO6
DMXLPO6	DN	PQ-1
DMXLPO6	MI	TTJ7ATH
DMXLPO6	MN	Gap junction alpha-8 protein (Cx50)
DMXLPO6	MT	DTT
DMXLPO6	MA	Modulator
DMXLPO6	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 732).
DMXLPO6	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=732

DMVNHTE	DI	DMVNHTE
DMVNHTE	DN	PQ401
DMVNHTE	MI	TTQFBMY
DMVNHTE	MN	IGF1R messenger RNA (IGF1R mRNA)
DMVNHTE	MT	DTT
DMVNHTE	MA	Inhibitor
DMVNHTE	RN	Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth. Mol Cancer Ther. 2006 Apr;5(4):1079-86.
DMVNHTE	RU	https://pubmed.ncbi.nlm.nih.gov/16648580

DMBCG31	DI	DMBCG31
DMBCG31	DN	PR-39
DMBCG31	MI	DEX542K
DMBCG31	MN	Dipeptidylpeptidase IV (DPP4)
DMBCG31	MT	DME
DMBCG31	MA	Metabolism
DMBCG31	RN	nan
DMBCG31	RU	nan

DM3XRJT	DI	DM3XRJT
DM3XRJT	DN	PRAVADOLINE
DM3XRJT	MI	TT6OEDT
DM3XRJT	MN	Cannabinoid receptor 1 (CB1)
DM3XRJT	MT	DTT
DM3XRJT	MA	Inhibitor
DM3XRJT	RN	Morpholinoalkylindenes as antinociceptive agents: Novel cannabinoid receptor agonists, Bioorg. Med. Chem. Lett. 5(4):381-386 (1995).
DM3XRJT	RU	http://www.sciencedirect.com/science/article/pii/0960894X9500040Z

DM3XRJT	DI	DM3XRJT
DM3XRJT	DN	PRAVADOLINE
DM3XRJT	MI	TTMSFAW
DM3XRJT	MN	Cannabinoid receptor 2 (CB2)
DM3XRJT	MT	DTT
DM3XRJT	MA	Inhibitor
DM3XRJT	RN	Morpholinoalkylindenes as antinociceptive agents: Novel cannabinoid receptor agonists, Bioorg. Med. Chem. Lett. 5(4):381-386 (1995).
DM3XRJT	RU	http://www.sciencedirect.com/science/article/pii/0960894X9500040Z

DMHEV75	DI	DMHEV75
DMHEV75	DN	Preclamol
DMHEV75	MI	TTEX248
DMHEV75	MN	Dopamine D2 receptor (D2R)
DMHEV75	MT	DTT
DMHEV75	MA	Inhibitor
DMHEV75	RN	Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP). ... J Med Chem. 1990 Mar;33(3):1015-22.
DMHEV75	RU	https://pubmed.ncbi.nlm.nih.gov/1968512

DM2HN4D	DI	DM2HN4D
DM2HN4D	DN	Predicentrine methiodide
DM2HN4D	MI	TT4H1MQ
DM2HN4D	MN	Neuronal acetylcholine receptor alpha-4 (CHRNA4)
DM2HN4D	MT	DTT
DM2HN4D	MA	Inhibitor
DM2HN4D	RN	Aporphine metho salts as neuronal nicotinic acetylcholine receptor blockers. Bioorg Med Chem. 2007 May 15;15(10):3368-72.
DM2HN4D	RU	https://pubmed.ncbi.nlm.nih.gov/17391965

DM2HN4D	DI	DM2HN4D
DM2HN4D	DN	Predicentrine methiodide
DM2HN4D	MI	TT5KPZR
DM2HN4D	MN	Neuronal acetylcholine receptor beta-2 (CHRNB2)
DM2HN4D	MT	DTT
DM2HN4D	MA	Inhibitor
DM2HN4D	RN	Aporphine metho salts as neuronal nicotinic acetylcholine receptor blockers. Bioorg Med Chem. 2007 May 15;15(10):3368-72.
DM2HN4D	RU	https://pubmed.ncbi.nlm.nih.gov/17391965

DM0LW7G	DI	DM0LW7G
DM0LW7G	DN	pregnenolone-16alpha-carbonitrile
DM0LW7G	MI	TT7LCTF
DM0LW7G	MN	Pregnane X receptor (NR1I2)
DM0LW7G	MT	DTT
DM0LW7G	MA	Agonist
DM0LW7G	RN	An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell. 1998 Jan 9;92(1):73-82.
DM0LW7G	RU	https://pubmed.ncbi.nlm.nih.gov/9489701

DMC4W03	DI	DMC4W03
DMC4W03	DN	Premafloxacin
DMC4W03	MI	TTIXTO3
DMC4W03	MN	Staphylococcus Topoisomerase IV (Stap-coc parC)
DMC4W03	MT	DTT
DMC4W03	MA	Inhibitor
DMC4W03	RN	Alteration of Escherichia coli topoisomerase IV to novobiocin resistance. Antimicrob Agents Chemother. 2003 Mar;47(3):941-7.
DMC4W03	RU	https://pubmed.ncbi.nlm.nih.gov/12604525

DMC4W03	DI	DMC4W03
DMC4W03	DN	Premafloxacin
DMC4W03	MI	TT1WJCI
DMC4W03	MN	Streptococcus Topoisomerase IV A (Stre-coc parC)
DMC4W03	MT	DTT
DMC4W03	MA	Inhibitor
DMC4W03	RN	Alteration of Escherichia coli topoisomerase IV to novobiocin resistance. Antimicrob Agents Chemother. 2003 Mar;47(3):941-7.
DMC4W03	RU	https://pubmed.ncbi.nlm.nih.gov/12604525

DMVOGT4	DI	DMVOGT4
DMVOGT4	DN	PREMETREXED
DMVOGT4	MI	TTU6BFZ
DMVOGT4	MN	Candida Thymidylate synthase (Candi TMP1)
DMVOGT4	MT	DTT
DMVOGT4	MA	Inhibitor
DMVOGT4	RN	Dual inhibitors of thymidylate synthase and dihydrofolate reductase as antitumor agents: design, synthesis, and biological evaluation of classical ... J Med Chem. 2006 Feb 9;49(3):1055-65.
DMVOGT4	RU	https://pubmed.ncbi.nlm.nih.gov/16451071

DMVOGT4	DI	DMVOGT4
DMVOGT4	DN	PREMETREXED
DMVOGT4	MI	TT9SL3Q
DMVOGT4	MN	Polypeptide deformylase (PDF)
DMVOGT4	MT	DTT
DMVOGT4	MA	Inhibitor
DMVOGT4	RN	Synthesis, antifolate, and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines. J Med Chem. 2001 Jun 7;44(12):1993-2003.
DMVOGT4	RU	https://pubmed.ncbi.nlm.nih.gov/11384244

DMVOGT4	DI	DMVOGT4
DMVOGT4	DN	PREMETREXED
DMVOGT4	MI	TTY8Z2E
DMVOGT4	MN	Proton-coupled folate transporter (SLC46A1)
DMVOGT4	MT	DTT
DMVOGT4	MA	Modulator
DMVOGT4	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1213).
DMVOGT4	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1213

DMV8YHQ	DI	DMV8YHQ
DMV8YHQ	DN	prenalterol
DMV8YHQ	MI	TTMXGCW
DMV8YHQ	MN	Adrenergic receptor beta-3 (ADRB3)
DMV8YHQ	MT	DTT
DMV8YHQ	MA	Agonist
DMV8YHQ	RN	Beta 1- and beta 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol Pharmacol. 1989 Mar;35(3):295-303.
DMV8YHQ	RU	https://pubmed.ncbi.nlm.nih.gov/2564629

DM9HSQJ	DI	DM9HSQJ
DM9HSQJ	DN	Prenyl pyrophosphate analogue
DM9HSQJ	MI	TT7WZIJ
DM9HSQJ	MN	CAAX farnesyltransferase beta (FNTB)
DM9HSQJ	MT	DTT
DM9HSQJ	MA	Inhibitor
DM9HSQJ	RN	Synthesis and evaluation of benzophenone-based photoaffinity labeling analogs of prenyl pyrophosphates containing stable amide linkages, Bioorg. Med. Chem. Lett. 7(16):2125-2130 (1997).
DM9HSQJ	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97003739

DM5P1NZ	DI	DM5P1NZ
DM5P1NZ	DN	PREUSSOMERIN
DM5P1NZ	MI	TT7WZIJ
DM5P1NZ	MN	CAAX farnesyltransferase beta (FNTB)
DM5P1NZ	MT	DTT
DM5P1NZ	MA	Inhibitor
DM5P1NZ	RN	Ras farnesyltransferase: a new therapeutic target. J Med Chem. 1997 Sep 12;40(19):2971-90.
DM5P1NZ	RU	https://pubmed.ncbi.nlm.nih.gov/9301658

DMLI4RF	DI	DMLI4RF
DMLI4RF	DN	Prifelone
DMLI4RF	MI	TT8NGED
DMLI4RF	MN	Prostaglandin G/H synthase 1 (COX-1)
DMLI4RF	MT	DTT
DMLI4RF	MA	Inhibitor
DMLI4RF	RN	Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.
DMLI4RF	RU	https://pubmed.ncbi.nlm.nih.gov/16220969

DMLI4RF	DI	DMLI4RF
DMLI4RF	DN	Prifelone
DMLI4RF	MI	TTVKILB
DMLI4RF	MN	Prostaglandin G/H synthase 2 (COX-2)
DMLI4RF	MT	DTT
DMLI4RF	MA	Inhibitor
DMLI4RF	RN	Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.
DMLI4RF	RU	https://pubmed.ncbi.nlm.nih.gov/16220969

DMA8GI6	DI	DMA8GI6
DMA8GI6	DN	Primary alcohol metabolite of celecoxib
DMA8GI6	MI	TT8NGED
DMA8GI6	MN	Prostaglandin G/H synthase 1 (COX-1)
DMA8GI6	MT	DTT
DMA8GI6	MA	Inhibitor
DMA8GI6	RN	Diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of 5-(4-hydroxymethylphenyl)-1-(4-aminosulfonylphenyl)-3-trifluoromethyl-1H-pyrazole an... Bioorg Med Chem. 2008 Nov 15;16(22):9694-8.
DMA8GI6	RU	https://pubmed.ncbi.nlm.nih.gov/18930406

DMA8GI6	DI	DMA8GI6
DMA8GI6	DN	Primary alcohol metabolite of celecoxib
DMA8GI6	MI	TTVKILB
DMA8GI6	MN	Prostaglandin G/H synthase 2 (COX-2)
DMA8GI6	MT	DTT
DMA8GI6	MA	Inhibitor
DMA8GI6	RN	Diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of 5-(4-hydroxymethylphenyl)-1-(4-aminosulfonylphenyl)-3-trifluoromethyl-1H-pyrazole an... Bioorg Med Chem. 2008 Nov 15;16(22):9694-8.
DMA8GI6	RU	https://pubmed.ncbi.nlm.nih.gov/18930406

DMTJZQK	DI	DMTJZQK
DMTJZQK	DN	pristanic acid
DMTJZQK	MI	TTJ584C
DMTJZQK	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMTJZQK	MT	DTT
DMTJZQK	MA	Agonist
DMTJZQK	RN	Pristanic acid and phytanic acid: naturally occurring ligands for the nuclear receptor peroxisome proliferator-activated receptor alpha. J Lipid Res. 2000 Nov;41(11):1801-7.
DMTJZQK	RU	https://pubmed.ncbi.nlm.nih.gov/11060349

DMA2SBL	DI	DMA2SBL
DMA2SBL	DN	PRO-135
DMA2SBL	MI	TTZQTY2
DMA2SBL	MN	DMPK messenger RNA (DMPK mRNA)
DMA2SBL	MT	DTT
DMA2SBL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1505).
DMA2SBL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1505

DMARYLK	DI	DMARYLK
DMARYLK	DN	Prochiral ketones
DMARYLK	MI	DE6N3C5
DMARYLK	MN	Alcohol dehydrogenase (ADH)
DMARYLK	MT	DME
DMARYLK	MA	Metabolism
DMARYLK	RN	Neutron and X-ray crystal structures of Lactobacillus brevis alcohol dehydrogenase reveal new insights into hydrogen-bonding pathways. Acta Crystallogr F Struct Biol Commun. 2018 Dec 1;74(Pt 12):754-764.
DMARYLK	RU	https://pubmed.ncbi.nlm.nih.gov/30511668

DMTW82E	DI	DMTW82E
DMTW82E	DN	Procyanidin B-2 3,3'-di-O-gallate
DMTW82E	MI	TTE14XG
DMTW82E	MN	Squalene monooxygenase (SQLE)
DMTW82E	MT	DTT
DMTW82E	MA	Inhibitor
DMTW82E	RN	Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4.
DMTW82E	RU	https://pubmed.ncbi.nlm.nih.gov/11520216

DMGIF1L	DI	DMGIF1L
DMGIF1L	DN	Prodipine
DMGIF1L	MI	TTVG215
DMGIF1L	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DMGIF1L	MT	DTT
DMGIF1L	MA	Inhibitor
DMGIF1L	RN	Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies. J Med Chem. 1993 Apr 30;36(9):1136-45.
DMGIF1L	RU	https://pubmed.ncbi.nlm.nih.gov/8487254

DMZH0KY	DI	DMZH0KY
DMZH0KY	DN	Pro-His-Pro-His-Leu-Phe-Val-Tyr
DMZH0KY	MI	TTB2MXP
DMZH0KY	MN	Angiotensinogenase renin (REN)
DMZH0KY	MT	DTT
DMZH0KY	MA	Inhibitor
DMZH0KY	RN	Inhibition of the renin-angiotensin system. A new approach to the therapy of hypertension. J Med Chem. 1981 Apr;24(4):355-61.
DMZH0KY	RU	https://pubmed.ncbi.nlm.nih.gov/6267277

DMD3WVO	DI	DMD3WVO
DMD3WVO	DN	Pro-His-Pro-His-Phe-Phe-Val-Tyr
DMD3WVO	MI	TTB2MXP
DMD3WVO	MN	Angiotensinogenase renin (REN)
DMD3WVO	MT	DTT
DMD3WVO	MA	Inhibitor
DMD3WVO	RN	Inhibition of the renin-angiotensin system. A new approach to the therapy of hypertension. J Med Chem. 1981 Apr;24(4):355-61.
DMD3WVO	RU	https://pubmed.ncbi.nlm.nih.gov/6267277

DMNDUI3	DI	DMNDUI3
DMNDUI3	DN	Pro-His-Pro-His-Phe-Phe-Val-Tyr-Lys
DMNDUI3	MI	TTB2MXP
DMNDUI3	MN	Angiotensinogenase renin (REN)
DMNDUI3	MT	DTT
DMNDUI3	MA	Inhibitor
DMNDUI3	RN	Inhibition of the renin-angiotensin system. A new approach to the therapy of hypertension. J Med Chem. 1981 Apr;24(4):355-61.
DMNDUI3	RU	https://pubmed.ncbi.nlm.nih.gov/6267277

DM26VFX	DI	DM26VFX
DM26VFX	DN	Pro-His-Pro-Phe-His-Leu(CH2NH)Val-Ile-His-Lys
DM26VFX	MI	TTB2MXP
DM26VFX	MN	Angiotensinogenase renin (REN)
DM26VFX	MT	DTT
DM26VFX	MA	Inhibitor
DM26VFX	RN	Synthesis and biological activity of some transition-state inhibitors of human renin. J Med Chem. 1988 Sep;31(9):1839-46.
DM26VFX	RU	https://pubmed.ncbi.nlm.nih.gov/3137345

DM82TMA	DI	DM82TMA
DM82TMA	DN	Proline
DM82TMA	MI	DEVJIHS
DM82TMA	MN	Proline dehydrogenase 1 (PRODH)
DM82TMA	MT	DME
DM82TMA	MA	Metabolism
DM82TMA	RN	Proline metabolism and microenvironmental stress. Annu Rev Nutr. 2010 Aug 21;30:441-63.
DM82TMA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20415579

DMOTXE3	DI	DMOTXE3
DMOTXE3	DN	Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2
DMOTXE3	MI	TTZPO1L
DMOTXE3	MN	Substance-P receptor (TACR1)
DMOTXE3	MT	DTT
DMOTXE3	MA	Inhibitor
DMOTXE3	RN	Conformational comparisons of a series of tachykinin peptide analogs. J Med Chem. 2007 Dec 27;50(26):6501-6.
DMOTXE3	RU	https://pubmed.ncbi.nlm.nih.gov/18067242

DMY3VGC	DI	DMY3VGC
DMY3VGC	DN	Promethazine
DMY3VGC	MI	TTAIY2U
DMY3VGC	MN	HUMAN clathrin-mediated endocytosis (RME)
DMY3VGC	MT	DTT
DMY3VGC	MA	Inhibitor
DMY3VGC	RN	Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150.
DMY3VGC	RU	https://pubmed.ncbi.nlm.nih.gov/32127666

DMIUV25	DI	DMIUV25
DMIUV25	DN	PRONTOCIL
DMIUV25	MI	TTUNARX
DMIUV25	MN	Carbonic anhydrase (CA)
DMIUV25	MT	DTT
DMIUV25	MA	Inhibitor
DMIUV25	RN	Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. Bioorg Med Chem. 2007 Dec 1;15(23):7229-36.
DMIUV25	RU	https://pubmed.ncbi.nlm.nih.gov/17826101

DMIUV25	DI	DMIUV25
DMIUV25	DN	PRONTOCIL
DMIUV25	MI	TTANPDJ
DMIUV25	MN	Carbonic anhydrase II (CA-II)
DMIUV25	MT	DTT
DMIUV25	MA	Inhibitor
DMIUV25	RN	Carbonic anhydrase inhibitors. Inhibition of the Rv1284 and Rv3273 beta-carbonic anhydrases from Mycobacterium tuberculosis with diazenylbenzenesul... Bioorg Med Chem Lett. 2009 Sep 1;19(17):4929-32.
DMIUV25	RU	https://pubmed.ncbi.nlm.nih.gov/19651511

DMGA53N	DI	DMGA53N
DMGA53N	DN	Prontosil
DMGA53N	MI	DEUGFHC
DMGA53N	MN	Azoreductase (azoR)
DMGA53N	MT	DME
DMGA53N	MA	Metabolism
DMGA53N	RN	Intestinal azo-reduction and glucuronide conjugation of prontosil. Xenobiotica. 1973 Sep;3(9):599-604.
DMGA53N	RU	https://pubmed.ncbi.nlm.nih.gov/4763145

DM8O41M	DI	DM8O41M
DM8O41M	DN	Prop-2-ynyl 4-sulfamoylbenzoate
DM8O41M	MI	TTHQPL7
DM8O41M	MN	Carbonic anhydrase I (CA-I)
DM8O41M	MT	DTT
DM8O41M	MA	Inhibitor
DM8O41M	RN	A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing". J Med Chem. 2006 Nov 2;49(22):6539-48.
DM8O41M	RU	https://pubmed.ncbi.nlm.nih.gov/17064072

DM8O41M	DI	DM8O41M
DM8O41M	DN	Prop-2-ynyl 4-sulfamoylbenzoate
DM8O41M	MI	TTANPDJ
DM8O41M	MN	Carbonic anhydrase II (CA-II)
DM8O41M	MT	DTT
DM8O41M	MA	Inhibitor
DM8O41M	RN	A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing". J Med Chem. 2006 Nov 2;49(22):6539-48.
DM8O41M	RU	https://pubmed.ncbi.nlm.nih.gov/17064072

DM8O41M	DI	DM8O41M
DM8O41M	DN	Prop-2-ynyl 4-sulfamoylbenzoate
DM8O41M	MI	TT2LVK8
DM8O41M	MN	Carbonic anhydrase IX (CA-IX)
DM8O41M	MT	DTT
DM8O41M	MA	Inhibitor
DM8O41M	RN	A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing". J Med Chem. 2006 Nov 2;49(22):6539-48.
DM8O41M	RU	https://pubmed.ncbi.nlm.nih.gov/17064072

DM8O41M	DI	DM8O41M
DM8O41M	DN	Prop-2-ynyl 4-sulfamoylbenzoate
DM8O41M	MI	TTSYM0R
DM8O41M	MN	Carbonic anhydrase XII (CA-XII)
DM8O41M	MT	DTT
DM8O41M	MA	Inhibitor
DM8O41M	RN	Inhibition of membrane-associated carbonic anhydrase isozymes IX, XII and XIV with a library of glycoconjugate benzenesulfonamides. Bioorg Med Chem Lett. 2007 Feb 15;17(4):987-92.
DM8O41M	RU	https://pubmed.ncbi.nlm.nih.gov/17157501

DM8O41M	DI	DM8O41M
DM8O41M	DN	Prop-2-ynyl 4-sulfamoylbenzoate
DM8O41M	MI	TTEYTKG
DM8O41M	MN	Carbonic anhydrase XIV (CA-XIV)
DM8O41M	MT	DTT
DM8O41M	MA	Inhibitor
DM8O41M	RN	Inhibition of membrane-associated carbonic anhydrase isozymes IX, XII and XIV with a library of glycoconjugate benzenesulfonamides. Bioorg Med Chem Lett. 2007 Feb 15;17(4):987-92.
DM8O41M	RU	https://pubmed.ncbi.nlm.nih.gov/17157501

DMQZYW6	DI	DMQZYW6
DMQZYW6	DN	Propan-2-one O-3-butoxyphenylcarbamoyl oxime
DMQZYW6	MI	TTDP1UC
DMQZYW6	MN	Fatty acid amide hydrolase (FAAH)
DMQZYW6	MT	DTT
DMQZYW6	MA	Inhibitor
DMQZYW6	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DMQZYW6	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DMIQ0DF	DI	DMIQ0DF
DMIQ0DF	DN	Propan-2-one O-4-(decyloxy)phenylcarbamoyl oxime
DMIQ0DF	MI	TTDP1UC
DMIQ0DF	MN	Fatty acid amide hydrolase (FAAH)
DMIQ0DF	MT	DTT
DMIQ0DF	MA	Inhibitor
DMIQ0DF	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DMIQ0DF	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DM8FXM6	DI	DM8FXM6
DM8FXM6	DN	Propan-2-one O-4-(heptyloxy)phenylcarbamoyl oxime
DM8FXM6	MI	TTDP1UC
DM8FXM6	MN	Fatty acid amide hydrolase (FAAH)
DM8FXM6	MT	DTT
DM8FXM6	MA	Inhibitor
DM8FXM6	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DM8FXM6	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DM5J0H3	DI	DM5J0H3
DM5J0H3	DN	Propan-2-one O-4-(hexyloxy)phenylcarbamoyl oxime
DM5J0H3	MI	TTDP1UC
DM5J0H3	MN	Fatty acid amide hydrolase (FAAH)
DM5J0H3	MT	DTT
DM5J0H3	MA	Inhibitor
DM5J0H3	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DM5J0H3	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DMYBH91	DI	DMYBH91
DMYBH91	DN	Propan-2-one O-4-(nonyloxy)phenylcarbamoyl oxime
DMYBH91	MI	TTDP1UC
DMYBH91	MN	Fatty acid amide hydrolase (FAAH)
DMYBH91	MT	DTT
DMYBH91	MA	Inhibitor
DMYBH91	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DMYBH91	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DM6VZ4S	DI	DM6VZ4S
DM6VZ4S	DN	Propan-2-one O-4-(octyloxy)phenylcarbamoyl oxime
DM6VZ4S	MI	TTDP1UC
DM6VZ4S	MN	Fatty acid amide hydrolase (FAAH)
DM6VZ4S	MT	DTT
DM6VZ4S	MA	Inhibitor
DM6VZ4S	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DM6VZ4S	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DM408U3	DI	DM408U3
DM408U3	DN	Propan-2-one O-4-(pentyloxy)phenylcarbamoyl oxime
DM408U3	MI	TTDP1UC
DM408U3	MN	Fatty acid amide hydrolase (FAAH)
DM408U3	MT	DTT
DM408U3	MA	Inhibitor
DM408U3	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DM408U3	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DMV13MO	DI	DMV13MO
DMV13MO	DN	Propan-2-one O-4-butoxybenzylcarbamoyl oxime
DMV13MO	MI	TTDP1UC
DMV13MO	MN	Fatty acid amide hydrolase (FAAH)
DMV13MO	MT	DTT
DMV13MO	MA	Inhibitor
DMV13MO	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DMV13MO	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DMYJ28G	DI	DMYJ28G
DMYJ28G	DN	Propan-2-one O-4-butoxyphenylcarbamoyl oxime
DMYJ28G	MI	TTDP1UC
DMYJ28G	MN	Fatty acid amide hydrolase (FAAH)
DMYJ28G	MT	DTT
DMYJ28G	MA	Inhibitor
DMYJ28G	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DMYJ28G	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DM573UT	DI	DM573UT
DM573UT	DN	Propan-2-one O-4-ethoxyphenylcarbamoyl oxime
DM573UT	MI	TTDP1UC
DM573UT	MN	Fatty acid amide hydrolase (FAAH)
DM573UT	MT	DTT
DM573UT	MA	Inhibitor
DM573UT	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DM573UT	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DMWX5Q6	DI	DMWX5Q6
DMWX5Q6	DN	Propan-2-one O-4-propoxyphenylcarbamoyl oxime
DMWX5Q6	MI	TTDP1UC
DMWX5Q6	MN	Fatty acid amide hydrolase (FAAH)
DMWX5Q6	MT	DTT
DMWX5Q6	MA	Inhibitor
DMWX5Q6	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DMWX5Q6	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DMQ9USH	DI	DMQ9USH
DMQ9USH	DN	Propandiamine
DMQ9USH	MI	DEMWO83
DMQ9USH	MN	Putrescine acetyltransferase (SSAT1)
DMQ9USH	MT	DME
DMQ9USH	MA	Metabolism
DMQ9USH	RN	Mechanistic and structural analysis of human spermidine/spermine N1-acetyltransferase. Biochemistry. 2007 Jun 19;46(24):7187-95.
DMQ9USH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17516632

DM9TN2W	DI	DM9TN2W
DM9TN2W	DN	Propanoic Acid
DM9TN2W	MI	TT6TMZU
DM9TN2W	MN	Mycobacterium Biosynthetic alanine racemase (MycB alr)
DM9TN2W	MT	DTT
DM9TN2W	MA	Inhibitor
DM9TN2W	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9TN2W	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMVRWL6	DI	DMVRWL6
DMVRWL6	DN	propargylglycine
DMVRWL6	MI	TTLQUZS
DMVRWL6	MN	Cystathionine gamma-lyase (CTH)
DMVRWL6	MT	DTT
DMVRWL6	MA	Inhibitor
DMVRWL6	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1444).
DMVRWL6	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1444

DMZ1FRS	DI	DMZ1FRS
DMZ1FRS	DN	Propidium
DMZ1FRS	MI	TT1RS9F
DMZ1FRS	MN	Acetylcholinesterase (AChE)
DMZ1FRS	MT	DTT
DMZ1FRS	MA	Inhibitor
DMZ1FRS	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMZ1FRS	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM0O8N6	DI	DM0O8N6
DM0O8N6	DN	Propionate
DM0O8N6	MI	TT6TMZU
DM0O8N6	MN	Mycobacterium Biosynthetic alanine racemase (MycB alr)
DM0O8N6	MT	DTT
DM0O8N6	MA	Inhibitor
DM0O8N6	RN	Molecular dynamics studies of alanine racemase: a structural model for drug design. Biopolymers. 2003 Oct;70(2):186-200.
DM0O8N6	RU	https://pubmed.ncbi.nlm.nih.gov/14517907

DM0O8N6	DI	DM0O8N6
DM0O8N6	DN	Propionate
DM0O8N6	MI	DTE3TAW
DM0O8N6	MN	Sodium-coupled monocarboxylate transporter 1 (SLC5A8)
DM0O8N6	MT	DTP
DM0O8N6	MA	Substrate
DM0O8N6	RN	SLC transporters as a novel class of tumour suppressors: identity, function and molecular mechanisms. Biochem J. 2016 May 1;473(9):1113-24.
DM0O8N6	RU	http://www.ncbi.nlm.nih.gov/pubmed/27118869

DMO325J	DI	DMO325J
DMO325J	DN	Propionic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester
DMO325J	MI	TTZ9SOR
DMO325J	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMO325J	MT	DTT
DMO325J	MA	Inhibitor
DMO325J	RN	6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors. J Med Chem. 2000 Jun 29;43(13):2514-22.
DMO325J	RU	https://pubmed.ncbi.nlm.nih.gov/10891110

DMO325J	DI	DMO325J
DMO325J	DN	Propionic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester
DMO325J	MI	TTYEG6Q
DMO325J	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMO325J	MT	DTT
DMO325J	MA	Inhibitor
DMO325J	RN	6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors. J Med Chem. 2000 Jun 29;43(13):2514-22.
DMO325J	RU	https://pubmed.ncbi.nlm.nih.gov/10891110

DMO325J	DI	DMO325J
DMO325J	DN	Propionic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester
DMO325J	MI	TTQ13Z5
DMO325J	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMO325J	MT	DTT
DMO325J	MA	Inhibitor
DMO325J	RN	6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors. J Med Chem. 2000 Jun 29;43(13):2514-22.
DMO325J	RU	https://pubmed.ncbi.nlm.nih.gov/10891110

DMO325J	DI	DMO325J
DMO325J	DN	Propionic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester
DMO325J	MI	TTQ3JTF
DMO325J	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DMO325J	MT	DTT
DMO325J	MA	Inhibitor
DMO325J	RN	6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors. J Med Chem. 2000 Jun 29;43(13):2514-22.
DMO325J	RU	https://pubmed.ncbi.nlm.nih.gov/10891110

DMZ40RQ	DI	DMZ40RQ
DMZ40RQ	DN	Propyl-(4,5,6,7-tetrahydro-2H-indazol-5-yl)-amine
DMZ40RQ	MI	TTEX248
DMZ40RQ	MN	Dopamine D2 receptor (D2R)
DMZ40RQ	MT	DTT
DMZ40RQ	MA	Inhibitor
DMZ40RQ	RN	Substituted 5-amino-4,5,6,7-tetrahydroindazoles as partial ergoline structures with dopaminergic activity. J Med Chem. 1989 Oct;32(10):2388-96.
DMZ40RQ	RU	https://pubmed.ncbi.nlm.nih.gov/2571732

DMTCP8K	DI	DMTCP8K
DMTCP8K	DN	propylpyrazoletriol
DMTCP8K	MI	TTZAYWL
DMTCP8K	MN	Estrogen receptor (ESR)
DMTCP8K	MT	DTT
DMTCP8K	MA	Agonist
DMTCP8K	RN	Conformational changes and coactivator recruitment by novel ligands for estrogen receptor-alpha and estrogen receptor-beta: correlations with biological character and distinct differences among SRC coactivator family members. Endocrinology. 2000 Oct;141(10):3534-45.
DMTCP8K	RU	https://pubmed.ncbi.nlm.nih.gov/11014206

DMXCJ7O	DI	DMXCJ7O
DMXCJ7O	DN	Prostacyclin analog
DMXCJ7O	MI	TTOFYT1
DMXCJ7O	MN	Prostacyclin receptor (PTGIR)
DMXCJ7O	MT	DTT
DMXCJ7O	MA	Modulator
DMXCJ7O	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 345).
DMXCJ7O	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=345

DMWC4X8	DI	DMWC4X8
DMWC4X8	DN	Prostaglandin A2
DMWC4X8	MI	DTUGYRD
DMWC4X8	MN	P-glycoprotein 1 (ABCB1)
DMWC4X8	MT	DTP
DMWC4X8	MA	Substrate
DMWC4X8	RN	Unveiling the role of multidrug resistance proteins in hypertension. Hypertension. 2009 Aug;54(2):210-6.
DMWC4X8	RU	https://doi.org/10.1161/HYPERTENSIONAHA.109.129742

DMWC4X8	DI	DMWC4X8
DMWC4X8	DN	Prostaglandin A2
DMWC4X8	MI	TTELV3W
DMWC4X8	MN	Transformation-sensitive protein p120 (TRPA1)
DMWC4X8	MT	DTT
DMWC4X8	MA	Activator
DMWC4X8	RN	Cox-dependent fatty acid metabolites cause pain through activation of the irritant receptor TRPA1. Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):12045-50.
DMWC4X8	RU	https://pubmed.ncbi.nlm.nih.gov/18687886

DME74SP	DI	DME74SP
DME74SP	DN	Prostaglandin G2
DME74SP	MI	TTVKILB
DME74SP	MN	Prostaglandin G/H synthase 2 (COX-2)
DME74SP	MT	DTT
DME74SP	MA	Inhibitor
DME74SP	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DME74SP	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM9GFOM	DI	DM9GFOM
DM9GFOM	DN	ProstaRex
DM9GFOM	MI	TTS78AZ
DM9GFOM	MN	Prostate specific antigen (KLK3)
DM9GFOM	MT	DTT
DM9GFOM	MA	Modulator
DM9GFOM	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2373).
DM9GFOM	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2373

DMI8SH2	DI	DMI8SH2
DMI8SH2	DN	PROSTEPHABYSSINE
DMI8SH2	MI	TT27RFC
DMI8SH2	MN	Opioid receptor delta (OPRD1)
DMI8SH2	MT	DTT
DMI8SH2	MA	Inhibitor
DMI8SH2	RN	Hasubanan alkaloids with delta-opioid binding affinity from the aerial parts of Stephania japonica. J Nat Prod. 2010 May 28;73(5):988-91.
DMI8SH2	RU	https://pubmed.ncbi.nlm.nih.gov/20426456

DM1HMJ5	DI	DM1HMJ5
DM1HMJ5	DN	PROSTRATIN
DM1HMJ5	MI	TT7A1BO
DM1HMJ5	MN	PKC-delta messenger RNA (PRKCD mRNA)
DM1HMJ5	MT	DTT
DM1HMJ5	MA	Inhibitor
DM1HMJ5	RN	A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J Med Chem. 1992 May 29;35(11):1978-86.
DM1HMJ5	RU	https://pubmed.ncbi.nlm.nih.gov/1597853

DM1HMJ5	DI	DM1HMJ5
DM1HMJ5	DN	PROSTRATIN
DM1HMJ5	MI	TT57MT2
DM1HMJ5	MN	PKC-epsilon messenger RNA (PRKCE mRNA)
DM1HMJ5	MT	DTT
DM1HMJ5	MA	Inhibitor
DM1HMJ5	RN	A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J Med Chem. 1992 May 29;35(11):1978-86.
DM1HMJ5	RU	https://pubmed.ncbi.nlm.nih.gov/1597853

DM1HMJ5	DI	DM1HMJ5
DM1HMJ5	DN	PROSTRATIN
DM1HMJ5	MI	TTONI0R
DM1HMJ5	MN	PKC-eta messenger RNA (PRKCH mRNA)
DM1HMJ5	MT	DTT
DM1HMJ5	MA	Inhibitor
DM1HMJ5	RN	A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J Med Chem. 1992 May 29;35(11):1978-86.
DM1HMJ5	RU	https://pubmed.ncbi.nlm.nih.gov/1597853

DM1HMJ5	DI	DM1HMJ5
DM1HMJ5	DN	PROSTRATIN
DM1HMJ5	MI	TT1MS7X
DM1HMJ5	MN	PKC-theta messenger RNA (PRKCQ mRNA)
DM1HMJ5	MT	DTT
DM1HMJ5	MA	Inhibitor
DM1HMJ5	RN	A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J Med Chem. 1992 May 29;35(11):1978-86.
DM1HMJ5	RU	https://pubmed.ncbi.nlm.nih.gov/1597853

DM1HMJ5	DI	DM1HMJ5
DM1HMJ5	DN	PROSTRATIN
DM1HMJ5	MI	TTFJ8Q1
DM1HMJ5	MN	Protein kinase C alpha (PRKCA)
DM1HMJ5	MT	DTT
DM1HMJ5	MA	Inhibitor
DM1HMJ5	RN	A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J Med Chem. 1992 May 29;35(11):1978-86.
DM1HMJ5	RU	https://pubmed.ncbi.nlm.nih.gov/1597853

DM1HMJ5	DI	DM1HMJ5
DM1HMJ5	DN	PROSTRATIN
DM1HMJ5	MI	TTYPXQF
DM1HMJ5	MN	Protein kinase C beta (PRKCB)
DM1HMJ5	MT	DTT
DM1HMJ5	MA	Inhibitor
DM1HMJ5	RN	A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J Med Chem. 1992 May 29;35(11):1978-86.
DM1HMJ5	RU	https://pubmed.ncbi.nlm.nih.gov/1597853

DM1HMJ5	DI	DM1HMJ5
DM1HMJ5	DN	PROSTRATIN
DM1HMJ5	MI	TT9WJ8U
DM1HMJ5	MN	Protein kinase C delta (PRKCD)
DM1HMJ5	MT	DTT
DM1HMJ5	MA	Inhibitor
DM1HMJ5	RN	A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J Med Chem. 1992 May 29;35(11):1978-86.
DM1HMJ5	RU	https://pubmed.ncbi.nlm.nih.gov/1597853

DM1HMJ5	DI	DM1HMJ5
DM1HMJ5	DN	PROSTRATIN
DM1HMJ5	MI	TTRFOXJ
DM1HMJ5	MN	Protein kinase C gamma (PRKCG)
DM1HMJ5	MT	DTT
DM1HMJ5	MA	Inhibitor
DM1HMJ5	RN	A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J Med Chem. 1992 May 29;35(11):1978-86.
DM1HMJ5	RU	https://pubmed.ncbi.nlm.nih.gov/1597853

DMWYE7A	DI	DMWYE7A
DMWYE7A	DN	Protoporphyrin IX
DMWYE7A	MI	DTI7UX6
DMWYE7A	MN	Breast cancer resistance protein (ABCG2)
DMWYE7A	MT	DTP
DMWYE7A	MA	Substrate
DMWYE7A	RN	Pharmacogenomic importance of ABCG2. Pharmacogenomics. 2008 Aug;9(8):1005-9.
DMWYE7A	RU	https://doi.org/10.2217/14622416.9.8.1005

DMWYE7A	DI	DMWYE7A
DMWYE7A	DN	Protoporphyrin IX
DMWYE7A	MI	TTCYE56
DMWYE7A	MN	Glutathione-dependent PGD synthase (HPGDS)
DMWYE7A	MT	DTT
DMWYE7A	MA	Inhibitor
DMWYE7A	RN	Inhibition of glutathione-S-transferase from Plasmodium yoelii by protoporphyrin IX, cibacron blue and menadione: implications and therapeutic bene... Parasitol Res. 2008 Mar;102(4):805-7.
DMWYE7A	RU	https://pubmed.ncbi.nlm.nih.gov/18180958

DMJ8TP3	DI	DMJ8TP3
DMJ8TP3	DN	Protoporphyrin Ix Containing Co
DMJ8TP3	MI	TT8NGED
DMJ8TP3	MN	Prostaglandin G/H synthase 1 (COX-1)
DMJ8TP3	MT	DTT
DMJ8TP3	MA	Inhibitor
DMJ8TP3	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMJ8TP3	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMI6TKU	DI	DMI6TKU
DMI6TKU	DN	PROTOSTEMODIOL
DMI6TKU	MI	TTJSZTB
DMI6TKU	MN	Nicotinic acetylcholine receptor (nAChR)
DMI6TKU	MT	DTT
DMI6TKU	MA	Inhibitor
DMI6TKU	RN	Alkaloids from stems and leaves of Stemona japonica and their insecticidal activities. J Nat Prod. 2008 Jan;71(1):112-6.
DMI6TKU	RU	https://pubmed.ncbi.nlm.nih.gov/18163592

DM43ABN	DI	DM43ABN
DM43ABN	DN	Provitamin D3
DM43ABN	MI	DE28NZ9
DM43ABN	MN	Cytochrome P450 124 (cyp124)
DM43ABN	MT	DME
DM43ABN	MA	Metabolism
DM43ABN	RN	Identification of Mycobacterium tuberculosis enzyme involved in vitamin D and 7-dehydrocholesterol metabolism. J Steroid Biochem Mol Biol. 2017 May;169:202-209.
DM43ABN	RU	https://pubmed.ncbi.nlm.nih.gov/27289046

DM72AT8	DI	DM72AT8
DM72AT8	DN	Proxyfan
DM72AT8	MI	TT9JNIC
DM72AT8	MN	Histamine H3 receptor (H3R)
DM72AT8	MT	DTT
DM72AT8	MA	Antagonist
DM72AT8	RN	The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20.
DM72AT8	RU	https://pubmed.ncbi.nlm.nih.gov/15665857

DMKRMSP	DI	DMKRMSP
DMKRMSP	DN	Pr-RYYRIK-NH2
DMKRMSP	MI	TTNT7K8
DMKRMSP	MN	Nociceptin receptor (OPRL1)
DMKRMSP	MT	DTT
DMKRMSP	MA	Inhibitor
DMKRMSP	RN	Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist. Bioorg Med Chem. 2008 Mar 1;16(5):2635-44.
DMKRMSP	RU	https://pubmed.ncbi.nlm.nih.gov/18068993

DM8GCHX	DI	DM8GCHX
DM8GCHX	DN	PRS-060
DM8GCHX	MI	TTDWHC3
DM8GCHX	MN	Interleukin 4 receptor alpha (IL4R)
DM8GCHX	MT	DTT
DM8GCHX	MA	Inhibitor
DM8GCHX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1697).
DM8GCHX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1697

DMB923H	DI	DMB923H
DMB923H	DN	PRS-110
DMB923H	MI	TTNDSF4
DMB923H	MN	Proto-oncogene c-Met (MET)
DMB923H	MT	DTT
DMB923H	MA	Inhibitor
DMB923H	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
DMB923H	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815

DM25EDB	DI	DM25EDB
DM25EDB	DN	PRT-060096
DM25EDB	MI	TTZ1DT0
DM25EDB	MN	P2Y purinoceptor 12 (P2RY12)
DM25EDB	MT	DTT
DM25EDB	MA	Antagonist
DM25EDB	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 328).
DM25EDB	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=328

DMQPEA7	DI	DMQPEA7
DMQPEA7	DN	PRT-060318
DMQPEA7	MI	TTOU65C
DMQPEA7	MN	Tyrosine-protein kinase SYK (SYK)
DMQPEA7	MT	DTT
DMQPEA7	MA	Inhibitor
DMQPEA7	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2230).
DMQPEA7	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2230

DMOVE31	DI	DMOVE31
DMOVE31	DN	PRT-064445
DMOVE31	MI	TTCIHJA
DMOVE31	MN	Coagulation factor Xa (F10)
DMOVE31	MT	DTT
DMOVE31	MA	Inhibitor
DMOVE31	RN	Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7.
DMOVE31	RU	https://pubmed.ncbi.nlm.nih.gov/22844656

DMPD41Q	DI	DMPD41Q
DMPD41Q	DN	prunetin
DMPD41Q	MI	TTFLN4T
DMPD41Q	MN	Mitochondrial aldehyde dehydrogenase (ALDH2)
DMPD41Q	MT	DTT
DMPD41Q	MA	Inhibitor
DMPD41Q	RN	Structure of daidzin, a naturally occurring anti-alcohol-addiction agent, in complex with human mitochondrial aldehyde dehydrogenase. J Med Chem. 2008 Aug 14;51(15):4482-7.
DMPD41Q	RU	https://pubmed.ncbi.nlm.nih.gov/18613661

DMSPH30	DI	DMSPH30
DMSPH30	DN	PRX-111
DMSPH30	MI	TTZFDBT
DMSPH30	MN	Follicle-stimulating hormone receptor (FSHR)
DMSPH30	MT	DTT
DMSPH30	MA	Modulator
DMSPH30	RN	A naturally occurring basically charged human follicle-stimulating hormone (FSH) variant inhibits FSH-induced androgen aromatization and tissue-type plasminogen activator enzyme activity in vitro. Neuroendocrinology. 1998 Mar;67(3):153-63.
DMSPH30	RU	https://pubmed.ncbi.nlm.nih.gov/9630432

DMK6HMS	DI	DMK6HMS
DMK6HMS	DN	PS020990
DMK6HMS	MI	TTGY8IW
DMK6HMS	MN	B2 bradykinin receptor (BDKRB2)
DMK6HMS	MT	DTT
DMK6HMS	MA	Antagonist
DMK6HMS	RN	Small molecule antagonists of the bradykinin B1 receptor. Immunopharmacology. 1999 Sep;43(2-3):169-77.
DMK6HMS	RU	https://pubmed.ncbi.nlm.nih.gov/10596850

DMVUMWZ	DI	DMVUMWZ
DMVUMWZ	DN	PS-1145
DMVUMWZ	MI	TTRPDBG
DMVUMWZ	MN	Inhibitor of nuclear factor kappa-B kinase (IKK)
DMVUMWZ	MT	DTT
DMVUMWZ	MA	Inhibitor
DMVUMWZ	RN	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
DMVUMWZ	RU	https://pubmed.ncbi.nlm.nih.gov/19249983

DMVUMWZ	DI	DMVUMWZ
DMVUMWZ	DN	PS-1145
DMVUMWZ	MI	TTSXVID
DMVUMWZ	MN	Nuclear factor NF-kappa-B (NFKB)
DMVUMWZ	MT	DTT
DMVUMWZ	MA	Activator
DMVUMWZ	RN	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
DMVUMWZ	RU	https://pubmed.ncbi.nlm.nih.gov/19249983

DMQUG0K	DI	DMQUG0K
DMQUG0K	DN	PS-154636-1
DMQUG0K	MI	TTXMNHO
DMQUG0K	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMQUG0K	MT	DTT
DMQUG0K	MA	Inhibitor
DMQUG0K	RN	Identification of potent inhibitors of Plasmodium falciparum plasmepsin II from an encoded statine combinatorial library. Bioorg Med Chem Lett. 1998 Sep 8;8(17):2315-20.
DMQUG0K	RU	https://pubmed.ncbi.nlm.nih.gov/9873534

DMQVI5U	DI	DMQVI5U
DMQVI5U	DN	PS-222036
DMQVI5U	MI	TTXMNHO
DMQVI5U	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMQVI5U	MT	DTT
DMQVI5U	MA	Inhibitor
DMQVI5U	RN	Identification of potent inhibitors of Plasmodium falciparum plasmepsin II from an encoded statine combinatorial library. Bioorg Med Chem Lett. 1998 Sep 8;8(17):2315-20.
DMQVI5U	RU	https://pubmed.ncbi.nlm.nih.gov/9873534

DMH8YMP	DI	DMH8YMP
DMH8YMP	DN	PS-444035
DMH8YMP	MI	TTXMNHO
DMH8YMP	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMH8YMP	MT	DTT
DMH8YMP	MA	Inhibitor
DMH8YMP	RN	Identification of potent inhibitors of Plasmodium falciparum plasmepsin II from an encoded statine combinatorial library. Bioorg Med Chem Lett. 1998 Sep 8;8(17):2315-20.
DMH8YMP	RU	https://pubmed.ncbi.nlm.nih.gov/9873534

DMT4YFR	DI	DMT4YFR
DMT4YFR	DN	PS-662477
DMT4YFR	MI	TTXMNHO
DMT4YFR	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DMT4YFR	MT	DTT
DMT4YFR	MA	Inhibitor
DMT4YFR	RN	Identification of potent inhibitors of Plasmodium falciparum plasmepsin II from an encoded statine combinatorial library. Bioorg Med Chem Lett. 1998 Sep 8;8(17):2315-20.
DMT4YFR	RU	https://pubmed.ncbi.nlm.nih.gov/9873534

DM05DOF	DI	DM05DOF
DM05DOF	DN	PS-725074
DM05DOF	MI	TTXMNHO
DM05DOF	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DM05DOF	MT	DTT
DM05DOF	MA	Inhibitor
DM05DOF	RN	Identification of potent inhibitors of Plasmodium falciparum plasmepsin II from an encoded statine combinatorial library. Bioorg Med Chem Lett. 1998 Sep 8;8(17):2315-20.
DM05DOF	RU	https://pubmed.ncbi.nlm.nih.gov/9873534

DM3F7SD	DI	DM3F7SD
DM3F7SD	DN	PS-777621
DM3F7SD	MI	TTH9VL3
DM3F7SD	MN	Plasmodium Plasmepsin 1 (Malaria PLA1)
DM3F7SD	MT	DTT
DM3F7SD	MA	Inhibitor
DM3F7SD	RN	High antiplasmodial activity of novel plasmepsins I and II inhibitors. J Med Chem. 2006 Dec 14;49(25):7440-9.
DM3F7SD	RU	https://pubmed.ncbi.nlm.nih.gov/17149873

DM3F7SD	DI	DM3F7SD
DM3F7SD	DN	PS-777621
DM3F7SD	MI	TTXMNHO
DM3F7SD	MN	Plasmodium Plasmepsin 2 (Malaria PLA2)
DM3F7SD	MT	DTT
DM3F7SD	MA	Inhibitor
DM3F7SD	RN	High antiplasmodial activity of novel plasmepsins I and II inhibitors. J Med Chem. 2006 Dec 14;49(25):7440-9.
DM3F7SD	RU	https://pubmed.ncbi.nlm.nih.gov/17149873

DM38JMK	DI	DM38JMK
DM38JMK	DN	PSAB-OFP
DM38JMK	MI	TTLA931
DM38JMK	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DM38JMK	MT	DTT
DM38JMK	MA	Agonist
DM38JMK	RN	PSAB-OFP, a selective alpha 7 nicotinic receptor agonist, is also a potent agonist of the 5-HT3 receptor. Eur J Pharmacol. 2002 Oct 4;452(2):137-44.
DM38JMK	RU	https://pubmed.ncbi.nlm.nih.gov/12354563

DM6T0IQ	DI	DM6T0IQ
DM6T0IQ	DN	PSAMMAPLIN A
DM6T0IQ	MI	TTBH0VX
DM6T0IQ	MN	Histone deacetylase (HDAC)
DM6T0IQ	MT	DTT
DM6T0IQ	MA	Inhibitor
DM6T0IQ	RN	Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
DM6T0IQ	RU	https://pubmed.ncbi.nlm.nih.gov/14613312

DM6T0IQ	DI	DM6T0IQ
DM6T0IQ	DN	PSAMMAPLIN A
DM6T0IQ	MI	TT6R7JZ
DM6T0IQ	MN	Histone deacetylase 1 (HDAC1)
DM6T0IQ	MT	DTT
DM6T0IQ	MA	Inhibitor
DM6T0IQ	RN	Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
DM6T0IQ	RU	https://pubmed.ncbi.nlm.nih.gov/14613312

DM6T0IQ	DI	DM6T0IQ
DM6T0IQ	DN	PSAMMAPLIN A
DM6T0IQ	MI	TTYHPU6
DM6T0IQ	MN	Histone deacetylase 10 (HDAC10)
DM6T0IQ	MT	DTT
DM6T0IQ	MA	Inhibitor
DM6T0IQ	RN	Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
DM6T0IQ	RU	https://pubmed.ncbi.nlm.nih.gov/14613312

DM6T0IQ	DI	DM6T0IQ
DM6T0IQ	DN	PSAMMAPLIN A
DM6T0IQ	MI	TTSHTOI
DM6T0IQ	MN	Histone deacetylase 2 (HDAC2)
DM6T0IQ	MT	DTT
DM6T0IQ	MA	Inhibitor
DM6T0IQ	RN	Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
DM6T0IQ	RU	https://pubmed.ncbi.nlm.nih.gov/14613312

DM6T0IQ	DI	DM6T0IQ
DM6T0IQ	DN	PSAMMAPLIN A
DM6T0IQ	MI	TTTQGH8
DM6T0IQ	MN	Histone deacetylase 4 (HDAC4)
DM6T0IQ	MT	DTT
DM6T0IQ	MA	Inhibitor
DM6T0IQ	RN	Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
DM6T0IQ	RU	https://pubmed.ncbi.nlm.nih.gov/14613312

DM6T0IQ	DI	DM6T0IQ
DM6T0IQ	DN	PSAMMAPLIN A
DM6T0IQ	MI	TT5ZKDI
DM6T0IQ	MN	Histone deacetylase 6 (HDAC6)
DM6T0IQ	MT	DTT
DM6T0IQ	MA	Inhibitor
DM6T0IQ	RN	Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
DM6T0IQ	RU	https://pubmed.ncbi.nlm.nih.gov/14613312

DM6T0IQ	DI	DM6T0IQ
DM6T0IQ	DN	PSAMMAPLIN A
DM6T0IQ	MI	TTT6LFV
DM6T0IQ	MN	Histone deacetylase 8 (HDAC8)
DM6T0IQ	MT	DTT
DM6T0IQ	MA	Inhibitor
DM6T0IQ	RN	Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
DM6T0IQ	RU	https://pubmed.ncbi.nlm.nih.gov/14613312

DM6T0IQ	DI	DM6T0IQ
DM6T0IQ	DN	PSAMMAPLIN A
DM6T0IQ	MI	TTGRHIB
DM6T0IQ	MN	UDP-glucose 4-epimerase (GALE)
DM6T0IQ	MT	DTT
DM6T0IQ	MA	Inhibitor
DM6T0IQ	RN	Identification of novel inhibitors of UDP-Glc 4'-epimerase, a validated drug target for african sleeping sickness. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5744-7.
DM6T0IQ	RU	https://pubmed.ncbi.nlm.nih.gov/16962325

DMLAFJE	DI	DMLAFJE
DMLAFJE	DN	PSB-0702
DMLAFJE	MI	TTZ1DT0
DMLAFJE	MN	P2Y purinoceptor 12 (P2RY12)
DMLAFJE	MT	DTT
DMLAFJE	MA	Inhibitor
DMLAFJE	RN	High-affinity, non-nucleotide-derived competitive antagonists of platelet P2Y12 receptors. J Med Chem. 2009 Jun 25;52(12):3784-93.
DMLAFJE	RU	https://pubmed.ncbi.nlm.nih.gov/19463000

DM3AZPD	DI	DM3AZPD
DM3AZPD	DN	PSB-0739
DM3AZPD	MI	TTZ1DT0
DM3AZPD	MN	P2Y purinoceptor 12 (P2RY12)
DM3AZPD	MT	DTT
DM3AZPD	MA	Inhibitor
DM3AZPD	RN	High-affinity, non-nucleotide-derived competitive antagonists of platelet P2Y12 receptors. J Med Chem. 2009 Jun 25;52(12):3784-93.
DM3AZPD	RU	https://pubmed.ncbi.nlm.nih.gov/19463000

DM0FKV9	DI	DM0FKV9
DM0FKV9	DN	PSB-0788
DM0FKV9	MI	TTK25J1
DM0FKV9	MN	Adenosine A1 receptor (ADORA1)
DM0FKV9	MT	DTT
DM0FKV9	MA	Inhibitor
DM0FKV9	RN	1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with... J Med Chem. 2009 Jul 9;52(13):3994-4006.
DM0FKV9	RU	https://pubmed.ncbi.nlm.nih.gov/19569717

DM0FKV9	DI	DM0FKV9
DM0FKV9	DN	PSB-0788
DM0FKV9	MI	TTM2AOE
DM0FKV9	MN	Adenosine A2a receptor (ADORA2A)
DM0FKV9	MT	DTT
DM0FKV9	MA	Inhibitor
DM0FKV9	RN	1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with... J Med Chem. 2009 Jul 9;52(13):3994-4006.
DM0FKV9	RU	https://pubmed.ncbi.nlm.nih.gov/19569717

DM0FKV9	DI	DM0FKV9
DM0FKV9	DN	PSB-0788
DM0FKV9	MI	TTNE7KG
DM0FKV9	MN	Adenosine A2b receptor (ADORA2B)
DM0FKV9	MT	DTT
DM0FKV9	MA	Inhibitor
DM0FKV9	RN	1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with... J Med Chem. 2009 Jul 9;52(13):3994-4006.
DM0FKV9	RU	https://pubmed.ncbi.nlm.nih.gov/19569717

DMAFHLX	DI	DMAFHLX
DMAFHLX	DN	PSB-09120
DMAFHLX	MI	TTM2AOE
DMAFHLX	MN	Adenosine A2a receptor (ADORA2A)
DMAFHLX	MT	DTT
DMAFHLX	MA	Inhibitor
DMAFHLX	RN	1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with... J Med Chem. 2009 Jul 9;52(13):3994-4006.
DMAFHLX	RU	https://pubmed.ncbi.nlm.nih.gov/19569717

DMAFHLX	DI	DMAFHLX
DMAFHLX	DN	PSB-09120
DMAFHLX	MI	TTNE7KG
DMAFHLX	MN	Adenosine A2b receptor (ADORA2B)
DMAFHLX	MT	DTT
DMAFHLX	MA	Inhibitor
DMAFHLX	RN	1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with... J Med Chem. 2009 Jul 9;52(13):3994-4006.
DMAFHLX	RU	https://pubmed.ncbi.nlm.nih.gov/19569717

DMW19LB	DI	DMW19LB
DMW19LB	DN	PSB-0952
DMW19LB	MI	TTK0O6Y
DMW19LB	MN	Ecto-5'-nucleotidase (CD73)
DMW19LB	MT	DTT
DMW19LB	MA	Inhibitor
DMW19LB	RN	Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold. J Med Chem. 2010 Mar 11;53(5):2076-86.
DMW19LB	RU	https://pubmed.ncbi.nlm.nih.gov/20146483

DMW19LB	DI	DMW19LB
DMW19LB	DN	PSB-0952
DMW19LB	MI	TTNVSKA
DMW19LB	MN	P2Y purinoceptor 6 (P2RY6)
DMW19LB	MT	DTT
DMW19LB	MA	Inhibitor
DMW19LB	RN	Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold. J Med Chem. 2010 Mar 11;53(5):2076-86.
DMW19LB	RU	https://pubmed.ncbi.nlm.nih.gov/20146483

DMBDVJ1	DI	DMBDVJ1
DMBDVJ1	DN	PSB-0963
DMBDVJ1	MI	TTK0O6Y
DMBDVJ1	MN	Ecto-5'-nucleotidase (CD73)
DMBDVJ1	MT	DTT
DMBDVJ1	MA	Inhibitor
DMBDVJ1	RN	Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold. J Med Chem. 2010 Mar 11;53(5):2076-86.
DMBDVJ1	RU	https://pubmed.ncbi.nlm.nih.gov/20146483

DMBDVJ1	DI	DMBDVJ1
DMBDVJ1	DN	PSB-0963
DMBDVJ1	MI	TTYM8DJ
DMBDVJ1	MN	Ectonucleoside triphosphate diphosphohydrolase 1 (CD39)
DMBDVJ1	MT	DTT
DMBDVJ1	MA	Inhibitor
DMBDVJ1	RN	Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold. J Med Chem. 2010 Mar 11;53(5):2076-86.
DMBDVJ1	RU	https://pubmed.ncbi.nlm.nih.gov/20146483

DMBDVJ1	DI	DMBDVJ1
DMBDVJ1	DN	PSB-0963
DMBDVJ1	MI	TTOZHQC
DMBDVJ1	MN	P2Y purinoceptor 2 (P2RY2)
DMBDVJ1	MT	DTT
DMBDVJ1	MA	Inhibitor
DMBDVJ1	RN	Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold. J Med Chem. 2010 Mar 11;53(5):2076-86.
DMBDVJ1	RU	https://pubmed.ncbi.nlm.nih.gov/20146483

DMXDWO7	DI	DMXDWO7
DMXDWO7	DN	PSB-10
DMXDWO7	MI	TTK25J1
DMXDWO7	MN	Adenosine A1 receptor (ADORA1)
DMXDWO7	MT	DTT
DMXDWO7	MA	Antagonist
DMXDWO7	RN	2-Phenylimidazo[2,1-i]purin-5-ones: structure-activity relationships and characterization of potent and selective inverse agonists at Human A3 adenosine receptors. Bioorg Med Chem. 2003 Feb 6;11(3):347-56.
DMXDWO7	RU	https://pubmed.ncbi.nlm.nih.gov/12517430

DMXDWO7	DI	DMXDWO7
DMXDWO7	DN	PSB-10
DMXDWO7	MI	TTNE7KG
DMXDWO7	MN	Adenosine A2b receptor (ADORA2B)
DMXDWO7	MT	DTT
DMXDWO7	MA	Antagonist
DMXDWO7	RN	Imidazo[2,1-i]purin-5-ones and related tricyclic water-soluble purine derivatives: potent A(2A)- and A(3)-adenosine receptor antagonists. J Med Chem. 2002 Aug 1;45(16):3440-50.
DMXDWO7	RU	https://pubmed.ncbi.nlm.nih.gov/12139454

DMXDWO7	DI	DMXDWO7
DMXDWO7	DN	PSB-10
DMXDWO7	MI	TTJFY5U
DMXDWO7	MN	Adenosine A3 receptor (ADORA3)
DMXDWO7	MT	DTT
DMXDWO7	MA	Antagonist
DMXDWO7	RN	Imidazo[2,1-i]purin-5-ones and related tricyclic water-soluble purine derivatives: potent A(2A)- and A(3)-adenosine receptor antagonists. J Med Chem. 2002 Aug 1;45(16):3440-50.
DMXDWO7	RU	https://pubmed.ncbi.nlm.nih.gov/12139454

DMGK2PC	DI	DMGK2PC
DMGK2PC	DN	PSB-11
DMGK2PC	MI	TTK25J1
DMGK2PC	MN	Adenosine A1 receptor (ADORA1)
DMGK2PC	MT	DTT
DMGK2PC	MA	Antagonist
DMGK2PC	RN	2-Phenylimidazo[2,1-i]purin-5-ones: structure-activity relationships and characterization of potent and selective inverse agonists at Human A3 adenosine receptors. Bioorg Med Chem. 2003 Feb 6;11(3):347-56.
DMGK2PC	RU	https://pubmed.ncbi.nlm.nih.gov/12517430

DMGK2PC	DI	DMGK2PC
DMGK2PC	DN	PSB-11
DMGK2PC	MI	TTNE7KG
DMGK2PC	MN	Adenosine A2b receptor (ADORA2B)
DMGK2PC	MT	DTT
DMGK2PC	MA	Antagonist
DMGK2PC	RN	Imidazo[2,1-i]purin-5-ones and related tricyclic water-soluble purine derivatives: potent A(2A)- and A(3)-adenosine receptor antagonists. J Med Chem. 2002 Aug 1;45(16):3440-50.
DMGK2PC	RU	https://pubmed.ncbi.nlm.nih.gov/12139454

DMGK2PC	DI	DMGK2PC
DMGK2PC	DN	PSB-11
DMGK2PC	MI	TTJFY5U
DMGK2PC	MN	Adenosine A3 receptor (ADORA3)
DMGK2PC	MT	DTT
DMGK2PC	MA	Antagonist
DMGK2PC	RN	[(3)H]8-Ethyl-4-methyl-2-phenyl-(8R)-4,5,7,8-tetrahydro-1H-imidazo[2,1-i]-purin-5-one ([(3)H]PSB-11), a novel high-affinity antagonist radioligand for human A(3) adenosine receptors. Bioorg Med Chem Lett. 2002 Feb 11;12(3):501-3.
DMGK2PC	RU	https://pubmed.ncbi.nlm.nih.gov/11814828

DMR9HYI	DI	DMR9HYI
DMR9HYI	DN	PSB1114
DMR9HYI	MI	TTOZHQC
DMR9HYI	MN	P2Y purinoceptor 2 (P2RY2)
DMR9HYI	MT	DTT
DMR9HYI	MA	Agonist
DMR9HYI	RN	Structural modifications of UMP, UDP, and UTP leading to subtype-selective agonists for P2Y2, P2Y4, and P2Y6 receptors. J Med Chem. 2011 Apr 28;54(8):2878-90.
DMR9HYI	RU	https://pubmed.ncbi.nlm.nih.gov/21417463

DMOH2VC	DI	DMOH2VC
DMOH2VC	DN	PSB-1115
DMOH2VC	MI	TTK25J1
DMOH2VC	MN	Adenosine A1 receptor (ADORA1)
DMOH2VC	MT	DTT
DMOH2VC	MA	Inhibitor
DMOH2VC	RN	1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with... J Med Chem. 2009 Jul 9;52(13):3994-4006.
DMOH2VC	RU	https://pubmed.ncbi.nlm.nih.gov/19569717

DMOH2VC	DI	DMOH2VC
DMOH2VC	DN	PSB-1115
DMOH2VC	MI	TTNE7KG
DMOH2VC	MN	Adenosine A2b receptor (ADORA2B)
DMOH2VC	MT	DTT
DMOH2VC	MA	Inhibitor
DMOH2VC	RN	1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with... J Med Chem. 2009 Jul 9;52(13):3994-4006.
DMOH2VC	RU	https://pubmed.ncbi.nlm.nih.gov/19569717

DMBGM1E	DI	DMBGM1E
DMBGM1E	DN	PSB36
DMBGM1E	MI	TTK25J1
DMBGM1E	MN	Adenosine A1 receptor (ADORA1)
DMBGM1E	MT	DTT
DMBGM1E	MA	Antagonist
DMBGM1E	RN	Antinociceptive effects of novel A2B adenosine receptor antagonists. J Pharmacol Exp Ther. 2004 Jan;308(1):358-66.
DMBGM1E	RU	https://pubmed.ncbi.nlm.nih.gov/14563788

DMBGM1E	DI	DMBGM1E
DMBGM1E	DN	PSB36
DMBGM1E	MI	TTNE7KG
DMBGM1E	MN	Adenosine A2b receptor (ADORA2B)
DMBGM1E	MT	DTT
DMBGM1E	MA	Antagonist
DMBGM1E	RN	Norbornyllactone-substituted xanthines as adenosine A(1) receptor antagonists. Bioorg Med Chem. 2006 Jun 1;14(11):3654-61.
DMBGM1E	RU	https://pubmed.ncbi.nlm.nih.gov/16458010

DMBGM1E	DI	DMBGM1E
DMBGM1E	DN	PSB36
DMBGM1E	MI	TTJFY5U
DMBGM1E	MN	Adenosine A3 receptor (ADORA3)
DMBGM1E	MT	DTT
DMBGM1E	MA	Antagonist
DMBGM1E	RN	Improving potency, selectivity, and water solubility of adenosine A1 receptor antagonists: xanthines modified at position 3 and related pyrimido[1,2,3-cd]purinediones. ChemMedChem. 2006 Aug;1(8):891-902.
DMBGM1E	RU	https://pubmed.ncbi.nlm.nih.gov/16902942

DMBIK7D	DI	DMBIK7D
DMBIK7D	DN	PSB-601
DMBIK7D	MI	TTK25J1
DMBIK7D	MN	Adenosine A1 receptor (ADORA1)
DMBIK7D	MT	DTT
DMBIK7D	MA	Inhibitor
DMBIK7D	RN	1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with... J Med Chem. 2009 Jul 9;52(13):3994-4006.
DMBIK7D	RU	https://pubmed.ncbi.nlm.nih.gov/19569717

DMBIK7D	DI	DMBIK7D
DMBIK7D	DN	PSB-601
DMBIK7D	MI	TTM2AOE
DMBIK7D	MN	Adenosine A2a receptor (ADORA2A)
DMBIK7D	MT	DTT
DMBIK7D	MA	Inhibitor
DMBIK7D	RN	1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with... J Med Chem. 2009 Jul 9;52(13):3994-4006.
DMBIK7D	RU	https://pubmed.ncbi.nlm.nih.gov/19569717

DMBIK7D	DI	DMBIK7D
DMBIK7D	DN	PSB-601
DMBIK7D	MI	TTNE7KG
DMBIK7D	MN	Adenosine A2b receptor (ADORA2B)
DMBIK7D	MT	DTT
DMBIK7D	MA	Inhibitor
DMBIK7D	RN	Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods. Eur J Med Chem. 2010 Aug;45(8):3459-71.
DMBIK7D	RU	https://pubmed.ncbi.nlm.nih.gov/20537438

DM6QERS	DI	DM6QERS
DM6QERS	DN	PSB603
DM6QERS	MI	TTK25J1
DM6QERS	MN	Adenosine A1 receptor (ADORA1)
DM6QERS	MT	DTT
DM6QERS	MA	Antagonist
DM6QERS	RN	1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with... J Med Chem. 2009 Jul 9;52(13):3994-4006.
DM6QERS	RU	https://pubmed.ncbi.nlm.nih.gov/19569717

DM6QERS	DI	DM6QERS
DM6QERS	DN	PSB603
DM6QERS	MI	TTNE7KG
DM6QERS	MN	Adenosine A2b receptor (ADORA2B)
DM6QERS	MT	DTT
DM6QERS	MA	Antagonist
DM6QERS	RN	1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with... J Med Chem. 2009 Jul 9;52(13):3994-4006.
DM6QERS	RU	https://pubmed.ncbi.nlm.nih.gov/19569717

DM6QERS	DI	DM6QERS
DM6QERS	DN	PSB603
DM6QERS	MI	TTJFY5U
DM6QERS	MN	Adenosine A3 receptor (ADORA3)
DM6QERS	MT	DTT
DM6QERS	MA	Antagonist
DM6QERS	RN	1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with... J Med Chem. 2009 Jul 9;52(13):3994-4006.
DM6QERS	RU	https://pubmed.ncbi.nlm.nih.gov/19569717

DMJ9ML8	DI	DMJ9ML8
DMJ9ML8	DN	PSB-6426
DMJ9ML8	MI	TTYM8DJ
DMJ9ML8	MN	Ectonucleoside triphosphate diphosphohydrolase 1 (CD39)
DMJ9ML8	MT	DTT
DMJ9ML8	MA	Inhibitor
DMJ9ML8	RN	Selective nucleoside triphosphate diphosphohydrolase-2 (NTPDase2) inhibitors: nucleotide mimetics derived from uridine-5'-carboxamide. J Med Chem. 2008 Aug 14;51(15):4518-28.
DMJ9ML8	RU	https://pubmed.ncbi.nlm.nih.gov/18630897

DMS2V0P	DI	DMS2V0P
DMS2V0P	DN	PSB-716
DMS2V0P	MI	TTOZHQC
DMS2V0P	MN	P2Y purinoceptor 2 (P2RY2)
DMS2V0P	MT	DTT
DMS2V0P	MA	Inhibitor
DMS2V0P	RN	Combinatorial synthesis of anilinoanthraquinone derivatives and evaluation as non-nucleotide-derived P2Y2 receptor antagonists. Bioorg Med Chem Lett. 2008 Jan 1;18(1):223-7.
DMS2V0P	RU	https://pubmed.ncbi.nlm.nih.gov/18006312

DMN5AE8	DI	DMN5AE8
DMN5AE8	DN	PSEUDOCOCAINE
DMN5AE8	MI	TTVBI8W
DMN5AE8	MN	Dopamine transporter (DAT)
DMN5AE8	MT	DTT
DMN5AE8	MA	Inhibitor
DMN5AE8	RN	Synthesis of 8-Oxa analogues of norcocaine endowed with interesting cocaine-like activity. Bioorg Med Chem Lett. 1999 Jul 5;9(13):1831-6.
DMN5AE8	RU	https://pubmed.ncbi.nlm.nih.gov/10406650

DM0E5G9	DI	DM0E5G9
DM0E5G9	DN	Pseudocolumbamine trifluoroacetate
DM0E5G9	MI	TT1RS9F
DM0E5G9	MN	Acetylcholinesterase (AChE)
DM0E5G9	MT	DTT
DM0E5G9	MA	Inhibitor
DM0E5G9	RN	Characterization of Acetylcholinesterase Inhibitory Constituents from Annona glabra Assisted by HPLC Microfractionation. J Nat Prod. 2010 Oct 22;73(10):1632-5. 
DM0E5G9	RU	https://pubmed.ncbi.nlm.nih.gov/20828184

DM4HE1V	DI	DM4HE1V
DM4HE1V	DN	Pseudopalmatine trifluoroacetate
DM4HE1V	MI	TT1RS9F
DM4HE1V	MN	Acetylcholinesterase (AChE)
DM4HE1V	MT	DTT
DM4HE1V	MA	Inhibitor
DM4HE1V	RN	Characterization of Acetylcholinesterase Inhibitory Constituents from Annona glabra Assisted by HPLC Microfractionation. J Nat Prod. 2010 Oct 22;73(10):1632-5. 
DM4HE1V	RU	https://pubmed.ncbi.nlm.nih.gov/20828184

DM5ZU1V	DI	DM5ZU1V
DM5ZU1V	DN	PSI 7851
DM5ZU1V	MI	TTMVBWH
DM5ZU1V	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DM5ZU1V	MT	DTT
DM5ZU1V	MA	Modulator
DM5ZU1V	RN	Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977.J Biol Chem.2010 Nov 5;285(45):34337-47.
DM5ZU1V	RU	https://www.ncbi.nlm.nih.gov/pubmed/20801890

DMPDO49	DI	DMPDO49
DMPDO49	DN	PSILOCIN
DMPDO49	MI	TTJQOD7
DMPDO49	MN	5-HT 2A receptor (HTR2A)
DMPDO49	MT	DTT
DMPDO49	MA	Inhibitor
DMPDO49	RN	The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands. Bioorg Med Chem. 2008 Apr 15;16(8):4661-9.
DMPDO49	RU	https://pubmed.ncbi.nlm.nih.gov/18296055

DMUROIY	DI	DMUROIY
DMUROIY	DN	PSN-101
DMUROIY	MI	TTDLNGZ
DMUROIY	MN	Glucokinase (GCK)
DMUROIY	MT	DTT
DMUROIY	MA	Activator
DMUROIY	RN	CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
DMUROIY	RU	http://www.centerwatch.com/

DM2U9SR	DI	DM2U9SR
DM2U9SR	DN	PSN375963
DM2U9SR	MI	TT7QNVC
DM2U9SR	MN	Glucose-dependent insulinotropic receptor (GPR119)
DM2U9SR	MT	DTT
DM2U9SR	MA	Agonist
DM2U9SR	RN	Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab. 2006 Mar;3(3):167-75.
DM2U9SR	RU	https://pubmed.ncbi.nlm.nih.gov/16517404

DMJIB8N	DI	DMJIB8N
DMJIB8N	DN	PSN632408
DMJIB8N	MI	TT7QNVC
DMJIB8N	MN	Glucose-dependent insulinotropic receptor (GPR119)
DMJIB8N	MT	DTT
DMJIB8N	MA	Agonist
DMJIB8N	RN	Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab. 2006 Mar;3(3):167-75.
DMJIB8N	RU	https://pubmed.ncbi.nlm.nih.gov/16517404

DMVJDCM	DI	DMVJDCM
DMVJDCM	DN	PSX-4206
DMVJDCM	MI	TT7HC21
DMVJDCM	MN	Membrane copper amine oxidase (AOC3)
DMVJDCM	MT	DTT
DMVJDCM	MA	Inhibitor
DMVJDCM	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2767).
DMVJDCM	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2767

DM47F9I	DI	DM47F9I
DM47F9I	DN	PT-101
DM47F9I	MI	TT84ETX
DM47F9I	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM47F9I	MT	DTT
DM47F9I	MA	Inhibitor
DM47F9I	RN	Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36.
DM47F9I	RU	https://pubmed.ncbi.nlm.nih.gov/8523406

DMD0K61	DI	DMD0K61
DMD0K61	DN	PT-102
DMD0K61	MI	TT84ETX
DMD0K61	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMD0K61	MT	DTT
DMD0K61	MA	Inhibitor
DMD0K61	RN	Antioxidant function of phenethyl-5-bromo-pyridyl thiourea compounds with potent anti-HIV activity. Bioorg Med Chem Lett. 2000 Jan 3;10(1):87-90.
DMD0K61	RU	https://pubmed.ncbi.nlm.nih.gov/10636251

DM0LTB2	DI	DM0LTB2
DM0LTB2	DN	PT-103
DM0LTB2	MI	TT84ETX
DM0LTB2	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM0LTB2	MT	DTT
DM0LTB2	MA	Inhibitor
DM0LTB2	RN	Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36.
DM0LTB2	RU	https://pubmed.ncbi.nlm.nih.gov/8523406

DMABLF7	DI	DMABLF7
DMABLF7	DN	PT-104
DMABLF7	MI	TT84ETX
DMABLF7	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMABLF7	MT	DTT
DMABLF7	MA	Inhibitor
DMABLF7	RN	Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity r... J Med Chem. 1996 Oct 11;39(21):4261-74.
DMABLF7	RU	https://pubmed.ncbi.nlm.nih.gov/8863804

DMPX71O	DI	DMPX71O
DMPX71O	DN	PT-106
DMPX71O	MI	TT84ETX
DMPX71O	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMPX71O	MT	DTT
DMPX71O	MA	Inhibitor
DMPX71O	RN	Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36.
DMPX71O	RU	https://pubmed.ncbi.nlm.nih.gov/8523406

DMBLAV4	DI	DMBLAV4
DMBLAV4	DN	PT-108
DMBLAV4	MI	TT84ETX
DMBLAV4	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMBLAV4	MT	DTT
DMBLAV4	MA	Inhibitor
DMBLAV4	RN	Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36.
DMBLAV4	RU	https://pubmed.ncbi.nlm.nih.gov/8523406

DM8PX1T	DI	DM8PX1T
DM8PX1T	DN	PT-109
DM8PX1T	MI	TT84ETX
DM8PX1T	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM8PX1T	MT	DTT
DM8PX1T	MA	Inhibitor
DM8PX1T	RN	Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity r... J Med Chem. 1996 Oct 11;39(21):4261-74.
DM8PX1T	RU	https://pubmed.ncbi.nlm.nih.gov/8863804

DMEIW5T	DI	DMEIW5T
DMEIW5T	DN	PT-110
DMEIW5T	MI	TT84ETX
DMEIW5T	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMEIW5T	MT	DTT
DMEIW5T	MA	Inhibitor
DMEIW5T	RN	Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity r... J Med Chem. 1996 Oct 11;39(21):4261-74.
DMEIW5T	RU	https://pubmed.ncbi.nlm.nih.gov/8863804

DMUFC6V	DI	DMUFC6V
DMUFC6V	DN	PT-113
DMUFC6V	MI	TT84ETX
DMUFC6V	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMUFC6V	MT	DTT
DMUFC6V	MA	Inhibitor
DMUFC6V	RN	Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity r... J Med Chem. 1996 Oct 11;39(21):4261-74.
DMUFC6V	RU	https://pubmed.ncbi.nlm.nih.gov/8863804

DMYE1P8	DI	DMYE1P8
DMYE1P8	DN	PT-114
DMYE1P8	MI	TT84ETX
DMYE1P8	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMYE1P8	MT	DTT
DMYE1P8	MA	Inhibitor
DMYE1P8	RN	Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity r... J Med Chem. 1996 Oct 11;39(21):4261-74.
DMYE1P8	RU	https://pubmed.ncbi.nlm.nih.gov/8863804

DMS01IN	DI	DMS01IN
DMS01IN	DN	PT-115
DMS01IN	MI	TT84ETX
DMS01IN	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMS01IN	MT	DTT
DMS01IN	MA	Inhibitor
DMS01IN	RN	Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity r... J Med Chem. 1996 Oct 11;39(21):4261-74.
DMS01IN	RU	https://pubmed.ncbi.nlm.nih.gov/8863804

DME0N2Z	DI	DME0N2Z
DME0N2Z	DN	PT-306
DME0N2Z	MI	TT84ETX
DME0N2Z	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DME0N2Z	MT	DTT
DME0N2Z	MA	Inhibitor
DME0N2Z	RN	Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36.
DME0N2Z	RU	https://pubmed.ncbi.nlm.nih.gov/8523406

DM45HVR	DI	DM45HVR
DM45HVR	DN	PT-307
DM45HVR	MI	TT84ETX
DM45HVR	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM45HVR	MT	DTT
DM45HVR	MA	Inhibitor
DM45HVR	RN	Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36.
DM45HVR	RU	https://pubmed.ncbi.nlm.nih.gov/8523406

DM7FM8V	DI	DM7FM8V
DM7FM8V	DN	PT-308
DM7FM8V	MI	TT84ETX
DM7FM8V	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM7FM8V	MT	DTT
DM7FM8V	MA	Inhibitor
DM7FM8V	RN	Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36.
DM7FM8V	RU	https://pubmed.ncbi.nlm.nih.gov/8523406

DM7TILD	DI	DM7TILD
DM7TILD	DN	PT-309
DM7TILD	MI	TT84ETX
DM7TILD	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM7TILD	MT	DTT
DM7TILD	MA	Inhibitor
DM7TILD	RN	Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36.
DM7TILD	RU	https://pubmed.ncbi.nlm.nih.gov/8523406

DMT7G32	DI	DMT7G32
DMT7G32	DN	PT-310
DMT7G32	MI	TT84ETX
DMT7G32	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMT7G32	MT	DTT
DMT7G32	MA	Inhibitor
DMT7G32	RN	Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36.
DMT7G32	RU	https://pubmed.ncbi.nlm.nih.gov/8523406

DM9ZCGX	DI	DM9ZCGX
DM9ZCGX	DN	PT-311
DM9ZCGX	MI	TT84ETX
DM9ZCGX	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM9ZCGX	MT	DTT
DM9ZCGX	MA	Inhibitor
DM9ZCGX	RN	Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36.
DM9ZCGX	RU	https://pubmed.ncbi.nlm.nih.gov/8523406

DM7GN3E	DI	DM7GN3E
DM7GN3E	DN	PT-312
DM7GN3E	MI	TT84ETX
DM7GN3E	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM7GN3E	MT	DTT
DM7GN3E	MA	Inhibitor
DM7GN3E	RN	Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36.
DM7GN3E	RU	https://pubmed.ncbi.nlm.nih.gov/8523406

DMN80XD	DI	DMN80XD
DMN80XD	DN	PT-313
DMN80XD	MI	TT84ETX
DMN80XD	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMN80XD	MT	DTT
DMN80XD	MA	Inhibitor
DMN80XD	RN	Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36.
DMN80XD	RU	https://pubmed.ncbi.nlm.nih.gov/8523406

DM5C1ND	DI	DM5C1ND
DM5C1ND	DN	PT-314
DM5C1ND	MI	TT84ETX
DM5C1ND	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM5C1ND	MT	DTT
DM5C1ND	MA	Inhibitor
DM5C1ND	RN	Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36.
DM5C1ND	RU	https://pubmed.ncbi.nlm.nih.gov/8523406

DMUK7IT	DI	DMUK7IT
DMUK7IT	DN	PT-315
DMUK7IT	MI	TT84ETX
DMUK7IT	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMUK7IT	MT	DTT
DMUK7IT	MA	Inhibitor
DMUK7IT	RN	Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36.
DMUK7IT	RU	https://pubmed.ncbi.nlm.nih.gov/8523406

DMXM6NT	DI	DMXM6NT
DMXM6NT	DN	PT-316
DMXM6NT	MI	TT84ETX
DMXM6NT	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMXM6NT	MT	DTT
DMXM6NT	MA	Inhibitor
DMXM6NT	RN	Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36.
DMXM6NT	RU	https://pubmed.ncbi.nlm.nih.gov/8523406

DM14XB7	DI	DM14XB7
DM14XB7	DN	PT-317
DM14XB7	MI	TT84ETX
DM14XB7	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM14XB7	MT	DTT
DM14XB7	MA	Inhibitor
DM14XB7	RN	Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36.
DM14XB7	RU	https://pubmed.ncbi.nlm.nih.gov/8523406

DMKEPGN	DI	DMKEPGN
DMKEPGN	DN	PT-319
DMKEPGN	MI	TT84ETX
DMKEPGN	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMKEPGN	MT	DTT
DMKEPGN	MA	Inhibitor
DMKEPGN	RN	Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36.
DMKEPGN	RU	https://pubmed.ncbi.nlm.nih.gov/8523406

DMV940C	DI	DMV940C
DMV940C	DN	PT-320
DMV940C	MI	TT84ETX
DMV940C	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMV940C	MT	DTT
DMV940C	MA	Inhibitor
DMV940C	RN	Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36.
DMV940C	RU	https://pubmed.ncbi.nlm.nih.gov/8523406

DMIHSEV	DI	DMIHSEV
DMIHSEV	DN	PT-322
DMIHSEV	MI	TT84ETX
DMIHSEV	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMIHSEV	MT	DTT
DMIHSEV	MA	Inhibitor
DMIHSEV	RN	Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36.
DMIHSEV	RU	https://pubmed.ncbi.nlm.nih.gov/8523406

DM736T8	DI	DM736T8
DM736T8	DN	PT-401
DM736T8	MI	TTAUX24
DM736T8	MN	Erythropoietin Receptor (EPOR)
DM736T8	MT	DTT
DM736T8	MA	Stimulator
DM736T8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1718).
DM736T8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1718

DMEJ6SK	DI	DMEJ6SK
DMEJ6SK	DN	PTAC
DMEJ6SK	MI	TTYEG6Q
DMEJ6SK	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMEJ6SK	MT	DTT
DMEJ6SK	MA	Agonist
DMEJ6SK	RN	Function of pulmonary neuronal M(2) muscarinic receptors in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001 May;163(6):1320-5.
DMEJ6SK	RU	https://pubmed.ncbi.nlm.nih.gov/11371395

DMEJ6SK	DI	DMEJ6SK
DMEJ6SK	DN	PTAC
DMEJ6SK	MI	TTQ13Z5
DMEJ6SK	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMEJ6SK	MT	DTT
DMEJ6SK	MA	Antagonist
DMEJ6SK	RN	Which muscarinic receptor is important in the bladder World J Urol. 2001 Nov;19(5):299-306.
DMEJ6SK	RU	https://pubmed.ncbi.nlm.nih.gov/11760777

DMEJ6SK	DI	DMEJ6SK
DMEJ6SK	DN	PTAC
DMEJ6SK	MI	TTQ3JTF
DMEJ6SK	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DMEJ6SK	MT	DTT
DMEJ6SK	MA	Agonist
DMEJ6SK	RN	Function of pulmonary neuronal M(2) muscarinic receptors in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001 May;163(6):1320-5.
DMEJ6SK	RU	https://pubmed.ncbi.nlm.nih.gov/11371395

DMY02IR	DI	DMY02IR
DMY02IR	DN	PTBE
DMY02IR	MI	TTXJ47W
DMY02IR	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMY02IR	MT	DTT
DMY02IR	MA	Modulator (allosteric modulator)
DMY02IR	RN	Phenyl-tetrazolyl acetophenones: discovery of positive allosteric potentiatiors for the metabotropic glutamate 2 receptor. J Med Chem. 2004 Aug 26;47(18):4595-9.
DMY02IR	RU	https://pubmed.ncbi.nlm.nih.gov/15317469

DM1NM5F	DI	DM1NM5F
DM1NM5F	DN	PTeB
DM1NM5F	MI	TTHS256
DM1NM5F	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM1NM5F	MT	DTT
DM1NM5F	MA	Modulator (allosteric modulator)
DM1NM5F	RN	Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity. J Med Chem. 2004 Sep 9;47(19):4645-8. Letter
DM1NM5F	RU	https://pubmed.ncbi.nlm.nih.gov/15341479

DM98IOX	DI	DM98IOX
DM98IOX	DN	Pterin-6-Yl-Methyl-Monophosphate
DM98IOX	MI	TT4ILYC
DM98IOX	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DM98IOX	MT	DTT
DM98IOX	MA	Inhibitor
DM98IOX	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM98IOX	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMT2YNG	DI	DMT2YNG
DMT2YNG	DN	Pteroic Acid
DMT2YNG	MI	TT4ILYC
DMT2YNG	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMT2YNG	MT	DTT
DMT2YNG	MA	Inhibitor
DMT2YNG	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMT2YNG	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM10KIW	DI	DM10KIW
DM10KIW	DN	PTHr pepducins
DM10KIW	MI	TTEPJL5
DM10KIW	MN	Parathyroid hormone receptor (PTH2R)
DM10KIW	MT	DTT
DM10KIW	MA	Modulator
DM10KIW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 332).
DM10KIW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=332

DMQUSXK	DI	DMQUSXK
DMQUSXK	DN	PTI-601
DMQUSXK	MI	TTAWNKZ
DMQUSXK	MN	Norepinephrine transporter (NET)
DMQUSXK	MT	DTT
DMQUSXK	MA	Inhibitor
DMQUSXK	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 926).
DMQUSXK	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=926

DMQUSXK	DI	DMQUSXK
DMQUSXK	DN	PTI-601
DMQUSXK	MI	TTKWM86
DMQUSXK	MN	Opioid receptor mu (MOP)
DMQUSXK	MT	DTT
DMQUSXK	MA	Modulator
DMQUSXK	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
DMQUSXK	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319

DMAEL4C	DI	DMAEL4C
DMAEL4C	DN	PTL-101
DMAEL4C	MI	TTP4520
DMAEL4C	MN	TGF-beta receptor type I (TGFBR1)
DMAEL4C	MT	DTT
DMAEL4C	MA	Modulator
DMAEL4C	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1788).
DMAEL4C	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1788

DMPEKTO	DI	DMPEKTO
DMPEKTO	DN	P-toluenesulfonamide
DMPEKTO	MI	TTUNARX
DMPEKTO	MN	Carbonic anhydrase (CA)
DMPEKTO	MT	DTT
DMPEKTO	MA	Inhibitor
DMPEKTO	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DMPEKTO	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DMPEKTO	DI	DMPEKTO
DMPEKTO	DN	P-toluenesulfonamide
DMPEKTO	MI	TTANPDJ
DMPEKTO	MN	Carbonic anhydrase II (CA-II)
DMPEKTO	MT	DTT
DMPEKTO	MA	Inhibitor
DMPEKTO	RN	Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, ... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6649-54.
DMPEKTO	RU	https://pubmed.ncbi.nlm.nih.gov/19846301

DMPEKTO	DI	DMPEKTO
DMPEKTO	DN	P-toluenesulfonamide
DMPEKTO	MI	TT2LVK8
DMPEKTO	MN	Carbonic anhydrase IX (CA-IX)
DMPEKTO	MT	DTT
DMPEKTO	MA	Inhibitor
DMPEKTO	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DMPEKTO	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DMPEKTO	DI	DMPEKTO
DMPEKTO	DN	P-toluenesulfonamide
DMPEKTO	MI	TTCFSPE
DMPEKTO	MN	Carbonic anhydrase VI (CA-VI)
DMPEKTO	MT	DTT
DMPEKTO	MA	Inhibitor
DMPEKTO	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DMPEKTO	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DMPEKTO	DI	DMPEKTO
DMPEKTO	DN	P-toluenesulfonamide
DMPEKTO	MI	TTSYM0R
DMPEKTO	MN	Carbonic anhydrase XII (CA-XII)
DMPEKTO	MT	DTT
DMPEKTO	MA	Inhibitor
DMPEKTO	RN	Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglauc... Bioorg Med Chem Lett. 2005 Feb 15;15(4):963-9.
DMPEKTO	RU	https://pubmed.ncbi.nlm.nih.gov/15686894

DMDGUEK	DI	DMDGUEK
DMDGUEK	DN	P-tolyl 10H-phenothiazine-10-carboxylate
DMDGUEK	MI	TTEB0GD
DMDGUEK	MN	Cholinesterase (BCHE)
DMDGUEK	MT	DTT
DMDGUEK	MA	Inhibitor
DMDGUEK	RN	Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. J Med Chem. 2008 Jul 24;51(14):4200-12.
DMDGUEK	RU	https://pubmed.ncbi.nlm.nih.gov/18570368

DM8MZF4	DI	DM8MZF4
DM8MZF4	DN	P-tolylboronic acid
DM8MZF4	MI	TTUNARX
DM8MZF4	MN	Carbonic anhydrase (CA)
DM8MZF4	MT	DTT
DM8MZF4	MA	Inhibitor
DM8MZF4	RN	Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5.
DM8MZF4	RU	https://pubmed.ncbi.nlm.nih.gov/19375309

DM8MZF4	DI	DM8MZF4
DM8MZF4	DN	P-tolylboronic acid
DM8MZF4	MI	TTANPDJ
DM8MZF4	MN	Carbonic anhydrase II (CA-II)
DM8MZF4	MT	DTT
DM8MZF4	MA	Inhibitor
DM8MZF4	RN	Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5.
DM8MZF4	RU	https://pubmed.ncbi.nlm.nih.gov/19375309

DMPEVQT	DI	DMPEVQT
DMPEVQT	DN	PTosyl-Glu(OtBu)-Ala-LeuVSMe
DMPEVQT	MI	TTF2LRI
DMPEVQT	MN	Cathepsin B (CTSB)
DMPEVQT	MT	DTT
DMPEVQT	MA	Inhibitor
DMPEVQT	RN	Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and c... J Med Chem. 2006 May 18;49(10):2953-68.
DMPEVQT	RU	https://pubmed.ncbi.nlm.nih.gov/16686537

DMZGFE8	DI	DMZGFE8
DMZGFE8	DN	PTR-3046
DMZGFE8	MI	TT2BC4G
DMZGFE8	MN	Somatostatin receptor type 5 (SSTR5)
DMZGFE8	MT	DTT
DMZGFE8	MA	Inhibitor
DMZGFE8	RN	Highly potent 4-amino-indolo[2,3-c]azepin-3-one-containing somatostatin mimetics with a range of sst receptor selectivities. J Med Chem. 2009 Jan 8;52(1):95-104.
DMZGFE8	RU	https://pubmed.ncbi.nlm.nih.gov/19067538

DMHAJC1	DI	DMHAJC1
DMHAJC1	DN	PU24S
DMHAJC1	MI	TT78R5H
DMHAJC1	MN	Heat shock protein 90 alpha (HSP90A)
DMHAJC1	MT	DTT
DMHAJC1	MA	Inhibitor
DMHAJC1	RN	Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008 Oct;8(7):761-82.
DMHAJC1	RU	https://pubmed.ncbi.nlm.nih.gov/18855578

DM4SGVF	DI	DM4SGVF
DM4SGVF	DN	PUKATEINE
DM4SGVF	MI	TTZFYLI
DM4SGVF	MN	Dopamine D1 receptor (D1R)
DM4SGVF	MT	DTT
DM4SGVF	MA	Inhibitor
DM4SGVF	RN	Advances in development of dopaminergic aporphinoids. J Med Chem. 2007 Jan 25;50(2):171-81.
DM4SGVF	RU	https://pubmed.ncbi.nlm.nih.gov/17228858

DM4SGVF	DI	DM4SGVF
DM4SGVF	DN	PUKATEINE
DM4SGVF	MI	TTEX248
DM4SGVF	MN	Dopamine D2 receptor (D2R)
DM4SGVF	MT	DTT
DM4SGVF	MA	Inhibitor
DM4SGVF	RN	Advances in development of dopaminergic aporphinoids. J Med Chem. 2007 Jan 25;50(2):171-81.
DM4SGVF	RU	https://pubmed.ncbi.nlm.nih.gov/17228858

DMY2F6T	DI	DMY2F6T
DMY2F6T	DN	Pumiliotoxin 251D
DMY2F6T	MI	TT0IHXV
DMY2F6T	MN	DNA topoisomerase II (TOP2)
DMY2F6T	MT	DTT
DMY2F6T	MA	Inhibitor
DMY2F6T	RN	How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
DMY2F6T	RU	https://pubmed.ncbi.nlm.nih.gov/18621146

DMY2F6T	DI	DMY2F6T
DMY2F6T	DN	Pumiliotoxin 251D
DMY2F6T	MI	TT1WJCI
DMY2F6T	MN	Streptococcus Topoisomerase IV A (Stre-coc parC)
DMY2F6T	MT	DTT
DMY2F6T	MA	Inhibitor
DMY2F6T	RN	How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
DMY2F6T	RU	https://pubmed.ncbi.nlm.nih.gov/18621146

DM7CWQY	DI	DM7CWQY
DM7CWQY	DN	PUNICAFOLIN
DM7CWQY	MI	TTFJ8Q1
DM7CWQY	MN	Protein kinase C alpha (PRKCA)
DM7CWQY	MT	DTT
DM7CWQY	MA	Inhibitor
DM7CWQY	RN	Tannins as selective inhibitors of protein kinase C, Bioorg. Med. Chem. Lett. 2(3):239-244 (1992).
DM7CWQY	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01810726

DM7CWQY	DI	DM7CWQY
DM7CWQY	DN	PUNICAFOLIN
DM7CWQY	MI	TTYPXQF
DM7CWQY	MN	Protein kinase C beta (PRKCB)
DM7CWQY	MT	DTT
DM7CWQY	MA	Inhibitor
DM7CWQY	RN	Tannins as selective inhibitors of protein kinase C, Bioorg. Med. Chem. Lett. 2(3):239-244 (1992).
DM7CWQY	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01810726

DMCWT4L	DI	DMCWT4L
DMCWT4L	DN	PUP-1
DMCWT4L	MI	TTXZ0KQ
DMCWT4L	MN	Matrix metalloproteinase-12 (MMP-12)
DMCWT4L	MT	DTT
DMCWT4L	MA	Inhibitor
DMCWT4L	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1636).
DMCWT4L	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1636

DMHNS0V	DI	DMHNS0V
DMHNS0V	DN	Purine Riboside
DMHNS0V	MI	TTLP57V
DMHNS0V	MN	Adenosine deaminase (ADA)
DMHNS0V	MT	DTT
DMHNS0V	MA	Inhibitor
DMHNS0V	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMHNS0V	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMYWRL6	DI	DMYWRL6
DMYWRL6	DN	Purpurin
DMYWRL6	MI	TT5FH9Y
DMYWRL6	MN	Human immunodeficiency virus Integrase (HIV IN)
DMYWRL6	MT	DTT
DMYWRL6	MA	Inhibitor
DMYWRL6	RN	Identification of HIV-1 integrase inhibitors based on a four-point pharmacophore. Antivir Chem Chemother. 1998 Nov;9(6):461-72.
DMYWRL6	RU	https://pubmed.ncbi.nlm.nih.gov/9865384

DMNQ7TM	DI	DMNQ7TM
DMNQ7TM	DN	Purvalanol A
DMNQ7TM	MI	TTAMQ62
DMNQ7TM	MN	Cyclin A2 (CCNA2)
DMNQ7TM	MT	DTT
DMNQ7TM	MA	Inhibitor
DMNQ7TM	RN	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
DMNQ7TM	RU	https://pubmed.ncbi.nlm.nih.gov/17850214

DMNQ7TM	DI	DMNQ7TM
DMNQ7TM	DN	Purvalanol A
DMNQ7TM	MI	TTH6V3D
DMNQ7TM	MN	Cyclin-dependent kinase 1 (CDK1)
DMNQ7TM	MT	DTT
DMNQ7TM	MA	Inhibitor
DMNQ7TM	RN	Down-regulation of survivin in nitric oxide-induced cell growth inhibition and apoptosis of the human lung carcinoma cells. J Biol Chem. 2004 May 7;279(19):20267-76.
DMNQ7TM	RU	https://pubmed.ncbi.nlm.nih.gov/14988404

DMNQ7TM	DI	DMNQ7TM
DMNQ7TM	DN	Purvalanol A
DMNQ7TM	MI	TT7HF4W
DMNQ7TM	MN	Cyclin-dependent kinase 2 (CDK2)
DMNQ7TM	MT	DTT
DMNQ7TM	MA	Inhibitor
DMNQ7TM	RN	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
DMNQ7TM	RU	https://pubmed.ncbi.nlm.nih.gov/17850214

DMF28IU	DI	DMF28IU
DMF28IU	DN	PUUPEHEDIONE
DMF28IU	MI	TT12ABZ
DMF28IU	MN	Arachidonate 12-lipoxygenase (12-LOX)
DMF28IU	MT	DTT
DMF28IU	MA	Inhibitor
DMF28IU	RN	Using enzyme assays to evaluate the structure and bioactivity of sponge-derived meroterpenes. J Nat Prod. 2009 Oct;72(10):1857-63.
DMF28IU	RU	https://pubmed.ncbi.nlm.nih.gov/19848434

DMF28IU	DI	DMF28IU
DMF28IU	DN	PUUPEHEDIONE
DMF28IU	MI	TTN9T81
DMF28IU	MN	Arachidonate 15-lipoxygenase (15-LOX)
DMF28IU	MT	DTT
DMF28IU	MA	Inhibitor
DMF28IU	RN	Using enzyme assays to evaluate the structure and bioactivity of sponge-derived meroterpenes. J Nat Prod. 2009 Oct;72(10):1857-63.
DMF28IU	RU	https://pubmed.ncbi.nlm.nih.gov/19848434

DMF28IU	DI	DMF28IU
DMF28IU	DN	PUUPEHEDIONE
DMF28IU	MI	TTSJ6Q4
DMF28IU	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DMF28IU	MT	DTT
DMF28IU	MA	Inhibitor
DMF28IU	RN	Using enzyme assays to evaluate the structure and bioactivity of sponge-derived meroterpenes. J Nat Prod. 2009 Oct;72(10):1857-63.
DMF28IU	RU	https://pubmed.ncbi.nlm.nih.gov/19848434

DMF3BCK	DI	DMF3BCK
DMF3BCK	DN	PUUPEHENONE
DMF3BCK	MI	TT12ABZ
DMF3BCK	MN	Arachidonate 12-lipoxygenase (12-LOX)
DMF3BCK	MT	DTT
DMF3BCK	MA	Inhibitor
DMF3BCK	RN	Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases. J Nat Prod. 2003 Feb;66(2):230-5.
DMF3BCK	RU	https://pubmed.ncbi.nlm.nih.gov/12608855

DMF3BCK	DI	DMF3BCK
DMF3BCK	DN	PUUPEHENONE
DMF3BCK	MI	TTN9T81
DMF3BCK	MN	Arachidonate 15-lipoxygenase (15-LOX)
DMF3BCK	MT	DTT
DMF3BCK	MA	Inhibitor
DMF3BCK	RN	Using enzyme assays to evaluate the structure and bioactivity of sponge-derived meroterpenes. J Nat Prod. 2009 Oct;72(10):1857-63.
DMF3BCK	RU	https://pubmed.ncbi.nlm.nih.gov/19848434

DMF3BCK	DI	DMF3BCK
DMF3BCK	DN	PUUPEHENONE
DMF3BCK	MI	TTSJ6Q4
DMF3BCK	MN	LOX-5 messenger RNA (ALOX5 mRNA)
DMF3BCK	MT	DTT
DMF3BCK	MA	Inhibitor
DMF3BCK	RN	Using enzyme assays to evaluate the structure and bioactivity of sponge-derived meroterpenes. J Nat Prod. 2009 Oct;72(10):1857-63.
DMF3BCK	RU	https://pubmed.ncbi.nlm.nih.gov/19848434

DMRI1LF	DI	DMRI1LF
DMRI1LF	DN	PV-1019
DMRI1LF	MI	TT9ABMF
DMRI1LF	MN	Serine/threonine-protein kinase Chk2 (RAD53)
DMRI1LF	MT	DTT
DMRI1LF	MA	Inhibitor
DMRI1LF	RN	Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]. J Pharmacol Exp Ther. 2009 Dec;331(3):816-26.
DMRI1LF	RU	https://pubmed.ncbi.nlm.nih.gov/19741151

DM9JYF3	DI	DM9JYF3
DM9JYF3	DN	PX-12
DM9JYF3	MI	TTNHMO8
DM9JYF3	MN	COVID-19 papain-like proteinase (PL-PRO)
DM9JYF3	MT	DTT
DM9JYF3	MA	Inhibitor
DM9JYF3	RN	Structure of Mpro from COVID-19 virus and discovery of its inhibitors. Nature. 2020 Apr 9.
DM9JYF3	RU	https://pubmed.ncbi.nlm.nih.gov/32272481

DMHCEOU	DI	DMHCEOU
DMHCEOU	DN	PXS-4159
DMHCEOU	MI	TT7HC21
DMHCEOU	MN	Membrane copper amine oxidase (AOC3)
DMHCEOU	MT	DTT
DMHCEOU	MA	Inhibitor
DMHCEOU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2767).
DMHCEOU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2767

DM2P0I4	DI	DM2P0I4
DM2P0I4	DN	PXVX-0103
DM2P0I4	MI	TTF4CAM
DM2P0I4	MN	Influenza Hemagglutinin (Influ HA)
DM2P0I4	MT	DTT
DM2P0I4	MA	Modulator
DM2P0I4	RN	Company report (PaxVax)
DM2P0I4	RU	http://paxvax.com/other-diseases/h5n1-avian-influenza

DMLFJHE	DI	DMLFJHE
DMLFJHE	DN	Pycnogenol
DMLFJHE	MI	TTSXVID
DMLFJHE	MN	Nuclear factor NF-kappa-B (NFKB)
DMLFJHE	MT	DTT
DMLFJHE	MA	Inhibitor
DMLFJHE	RN	Inhibition mechanisms of bioflavonoids extracted from the bark of Pinus maritima on the expression of proinflammatory cytokines. Ann N Y Acad Sci. 2001 Apr;928:141-56.
DMLFJHE	RU	https://pubmed.ncbi.nlm.nih.gov/11795505

DM3VNYQ	DI	DM3VNYQ
DM3VNYQ	DN	Pyr3
DM3VNYQ	MI	TTNVC34
DM3VNYQ	MN	Short transient receptor potential channel 3 (TRPC3)
DM3VNYQ	MT	DTT
DM3VNYQ	MA	Blocker (channel blocker)
DM3VNYQ	RN	Selective and direct inhibition of TRPC3 channels underlies biological activities of a pyrazole compound. Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5400-5.
DM3VNYQ	RU	https://pubmed.ncbi.nlm.nih.gov/19289841

DMIZB81	DI	DMIZB81
DMIZB81	DN	Pyrazine-2-carboxylic acid adamantan-1-ylamide
DMIZB81	MI	TTVBPDM
DMIZB81	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMIZB81	MT	DTT
DMIZB81	MA	Inhibitor
DMIZB81	RN	Positive and negative modulation of group I metabotropic glutamate receptors. J Med Chem. 2008 Feb 14;51(3):634-47.
DMIZB81	RU	https://pubmed.ncbi.nlm.nih.gov/18173231

DMVJLSM	DI	DMVJLSM
DMVJLSM	DN	Pyrazofurin
DMVJLSM	MI	TTAFJUD
DMVJLSM	MN	Orotidine 5'-monophosphate decarboxylase (UMPS)
DMVJLSM	MT	DTT
DMVJLSM	MA	Inhibitor
DMVJLSM	RN	Molecular approaches for the treatment of hemorrhagic fever virus infections. Antiviral Res. 1993 Sep;22(1):45-75.
DMVJLSM	RU	https://pubmed.ncbi.nlm.nih.gov/8250543

DMUB0EJ	DI	DMUB0EJ
DMUB0EJ	DN	Pyrazolo[1,5-a]pyrimidine 3G
DMUB0EJ	MI	TTUTJGQ
DMUB0EJ	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMUB0EJ	MT	DTT
DMUB0EJ	MA	Inhibitor
DMUB0EJ	RN	Optimization of a pyrazolo[1,5-a]pyrimidine class of KDR kinase inhibitors: improvements in physical properties enhance cellular activity and pharm... Bioorg Med Chem Lett. 2002 Dec 16;12(24):3537-41.
DMUB0EJ	RU	https://pubmed.ncbi.nlm.nih.gov/12443771

DM69LKB	DI	DM69LKB
DM69LKB	DN	Pyrazolo[1,5-a]pyrimidine-3-carboxylate
DM69LKB	MI	TT0EOB8
DM69LKB	MN	B-Raf messenger RNA (BRAF mRNA)
DM69LKB	MT	DTT
DM69LKB	MA	Inhibitor
DM69LKB	RN	Identification of pyrazolo[1,5-a]pyrimidine-3-carboxylates as B-Raf kinase inhibitors. Bioorg Med Chem Lett. 2009 May 15;19(10):2735-8.
DM69LKB	RU	https://pubmed.ncbi.nlm.nih.gov/19362830

DMLFQKU	DI	DMLFQKU
DMLFQKU	DN	pyrazolone, 1
DMLFQKU	MI	TTOJ1NF
DMLFQKU	MN	FMLP-related receptor I (FPR2)
DMLFQKU	MT	DTT
DMLFQKU	MA	Agonist
DMLFQKU	RN	Potent hFPRL1 (ALXR) agonists as potential anti-inflammatory agents. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3713-8.
DMLFQKU	RU	https://pubmed.ncbi.nlm.nih.gov/16697190

DMLFQKU	DI	DMLFQKU
DMLFQKU	DN	pyrazolone, 1
DMLFQKU	MI	TT5Y4EM
DMLFQKU	MN	N-formyl peptide receptor (FPR1)
DMLFQKU	MT	DTT
DMLFQKU	MA	Agonist
DMLFQKU	RN	Functional characterization of three mouse formyl peptide receptors. Mol Pharmacol. 2013 Feb;83(2):389-98.
DMLFQKU	RU	https://pubmed.ncbi.nlm.nih.gov/23160941

DMKTB5U	DI	DMKTB5U
DMKTB5U	DN	PYRAZOLOPYRIDAZINE 1
DMKTB5U	MI	TT7HF4W
DMKTB5U	MN	Cyclin-dependent kinase 2 (CDK2)
DMKTB5U	MT	DTT
DMKTB5U	MA	Inhibitor
DMKTB5U	RN	N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular effi... J Med Chem. 2004 Sep 9;47(19):4716-30.
DMKTB5U	RU	https://pubmed.ncbi.nlm.nih.gov/15341487

DMKTB5U	DI	DMKTB5U
DMKTB5U	DN	PYRAZOLOPYRIDAZINE 1
DMKTB5U	MI	TT0PG8F
DMKTB5U	MN	Cyclin-dependent kinase 4 (CDK4)
DMKTB5U	MT	DTT
DMKTB5U	MA	Inhibitor
DMKTB5U	RN	N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular effi... J Med Chem. 2004 Sep 9;47(19):4716-30.
DMKTB5U	RU	https://pubmed.ncbi.nlm.nih.gov/15341487

DMKTB5U	DI	DMKTB5U
DMKTB5U	DN	PYRAZOLOPYRIDAZINE 1
DMKTB5U	MI	TTRSMW9
DMKTB5U	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMKTB5U	MT	DTT
DMKTB5U	MA	Inhibitor
DMKTB5U	RN	N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular effi... J Med Chem. 2004 Sep 9;47(19):4716-30.
DMKTB5U	RU	https://pubmed.ncbi.nlm.nih.gov/15341487

DMI7AUJ	DI	DMI7AUJ
DMI7AUJ	DN	PYRAZOLOPYRIDAZINE 2
DMI7AUJ	MI	TT7HF4W
DMI7AUJ	MN	Cyclin-dependent kinase 2 (CDK2)
DMI7AUJ	MT	DTT
DMI7AUJ	MA	Inhibitor
DMI7AUJ	RN	N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular effi... J Med Chem. 2004 Sep 9;47(19):4716-30.
DMI7AUJ	RU	https://pubmed.ncbi.nlm.nih.gov/15341487

DMI7AUJ	DI	DMI7AUJ
DMI7AUJ	DN	PYRAZOLOPYRIDAZINE 2
DMI7AUJ	MI	TT0PG8F
DMI7AUJ	MN	Cyclin-dependent kinase 4 (CDK4)
DMI7AUJ	MT	DTT
DMI7AUJ	MA	Inhibitor
DMI7AUJ	RN	N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular effi... J Med Chem. 2004 Sep 9;47(19):4716-30.
DMI7AUJ	RU	https://pubmed.ncbi.nlm.nih.gov/15341487

DMI7AUJ	DI	DMI7AUJ
DMI7AUJ	DN	PYRAZOLOPYRIDAZINE 2
DMI7AUJ	MI	TTRSMW9
DMI7AUJ	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMI7AUJ	MT	DTT
DMI7AUJ	MA	Inhibitor
DMI7AUJ	RN	N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular effi... J Med Chem. 2004 Sep 9;47(19):4716-30.
DMI7AUJ	RU	https://pubmed.ncbi.nlm.nih.gov/15341487

DMEF6IP	DI	DMEF6IP
DMEF6IP	DN	Pyrene-1-aldehyde
DMEF6IP	MI	DEM1HNL
DMEF6IP	MN	Alcohol dehydrogenase class-I gamma (ADH1C)
DMEF6IP	MT	DME
DMEF6IP	MA	Metabolism
DMEF6IP	RN	Oxidation of alcohols and reduction of aldehydes derived from methyl- and dimethylpyrenes by cDNA-expressed human alcohol dehydrogenases. Toxicology. 2008 Mar 12;245(1-2):65-75.
DMEF6IP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18242813

DMEF6IP	DI	DMEF6IP
DMEF6IP	DN	Pyrene-1-aldehyde
DMEF6IP	MI	DEOCWU3
DMEF6IP	MN	Alcohol dehydrogenase class-II (ADH4)
DMEF6IP	MT	DME
DMEF6IP	MA	Metabolism
DMEF6IP	RN	Oxidation of alcohols and reduction of aldehydes derived from methyl- and dimethylpyrenes by cDNA-expressed human alcohol dehydrogenases. Toxicology. 2008 Mar 12;245(1-2):65-75.
DMEF6IP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18242813

DMGJ0RM	DI	DMGJ0RM
DMGJ0RM	DN	Pyrenemethanol
DMGJ0RM	MI	DEM1HNL
DMGJ0RM	MN	Alcohol dehydrogenase class-I gamma (ADH1C)
DMGJ0RM	MT	DME
DMGJ0RM	MA	Metabolism
DMGJ0RM	RN	Oxidation of alcohols and reduction of aldehydes derived from methyl- and dimethylpyrenes by cDNA-expressed human alcohol dehydrogenases. Toxicology. 2008 Mar 12;245(1-2):65-75.
DMGJ0RM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18242813

DMGJ0RM	DI	DMGJ0RM
DMGJ0RM	DN	Pyrenemethanol
DMGJ0RM	MI	DEOCWU3
DMGJ0RM	MN	Alcohol dehydrogenase class-II (ADH4)
DMGJ0RM	MT	DME
DMGJ0RM	MA	Metabolism
DMGJ0RM	RN	Oxidation of alcohols and reduction of aldehydes derived from methyl- and dimethylpyrenes by cDNA-expressed human alcohol dehydrogenases. Toxicology. 2008 Mar 12;245(1-2):65-75.
DMGJ0RM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18242813

DMOCG6M	DI	DMOCG6M
DMOCG6M	DN	Pyridin-3-yl 4-butoxybenzylcarbamate
DMOCG6M	MI	TTDP1UC
DMOCG6M	MN	Fatty acid amide hydrolase (FAAH)
DMOCG6M	MT	DTT
DMOCG6M	MA	Inhibitor
DMOCG6M	RN	Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7.
DMOCG6M	RU	https://pubmed.ncbi.nlm.nih.gov/20036536

DM4G8WX	DI	DM4G8WX
DM4G8WX	DN	Pyridine-2,4-dicarboxylic acid
DM4G8WX	MI	TTMHFRY
DM4G8WX	MN	HIF-prolyl hydroxylase 1 (HPH-1)
DM4G8WX	MT	DTT
DM4G8WX	MA	Inhibitor
DM4G8WX	RN	Design, synthesis, enzyme-inhibitory activity, and effect on human cancer cells of a novel series of jumonji domain-containing protein 2 histone de... J Med Chem. 2010 Aug 12;53(15):5629-38.
DM4G8WX	RU	https://pubmed.ncbi.nlm.nih.gov/20684604

DM3PAS4	DI	DM3PAS4
DM3PAS4	DN	Pyridobenzimidazole
DM3PAS4	MI	TTZMS1L
DM3PAS4	MN	Fungal Papulacandin B resistance protein 1 (Fung FKS1)
DM3PAS4	MT	DTT
DM3PAS4	MA	Inhibitor
DM3PAS4	RN	Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22.
DM3PAS4	RU	https://pubmed.ncbi.nlm.nih.gov/19463273

DMQ6POC	DI	DMQ6POC
DMQ6POC	DN	Pyridoxamine-5'-Phosphate
DMQ6POC	MI	TTF9OQ6
DMQ6POC	MN	Branched-chain-amino-acid transaminase 2 (BCAT2)
DMQ6POC	MT	DTT
DMQ6POC	MA	Inhibitor
DMQ6POC	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMQ6POC	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMQ6POC	DI	DMQ6POC
DMQ6POC	DN	Pyridoxamine-5'-Phosphate
DMQ6POC	MI	TT6TMZU
DMQ6POC	MN	Mycobacterium Biosynthetic alanine racemase (MycB alr)
DMQ6POC	MT	DTT
DMQ6POC	MA	Inhibitor
DMQ6POC	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMQ6POC	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMQ6POC	DI	DMQ6POC
DMQ6POC	DN	Pyridoxamine-5'-Phosphate
DMQ6POC	MI	TTN6GE9
DMQ6POC	MN	Staphylococcus D-amino acid aminotransferase (Stap-coc dat)
DMQ6POC	MT	DTT
DMQ6POC	MA	Inhibitor
DMQ6POC	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMQ6POC	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMFUNL1	DI	DMFUNL1
DMFUNL1	DN	Pyridoxine-5'-phosphate
DMFUNL1	MI	TTHB48R
DMFUNL1	MN	Bacterial Pyridoxal phosphate biosynthetic pdxJ (Bact pdxJ)
DMFUNL1	MT	DTT
DMFUNL1	MA	Inhibitor
DMFUNL1	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMFUNL1	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMFUNL1	DI	DMFUNL1
DMFUNL1	DN	Pyridoxine-5'-phosphate
DMFUNL1	MI	TTUMGNO
DMFUNL1	MN	Ornithine decarboxylase (ODC1)
DMFUNL1	MT	DTT
DMFUNL1	MA	Inhibitor
DMFUNL1	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMFUNL1	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMFUNL1	DI	DMFUNL1
DMFUNL1	DN	Pyridoxine-5'-phosphate
DMFUNL1	MI	DE3Z1RA
DMFUNL1	MN	Pyridoxamine-phosphate oxidase (PNPO)
DMFUNL1	MT	DME
DMFUNL1	MA	Metabolism
DMFUNL1	RN	Pyridoxine 5'-phosphate oxidase is a novel therapeutic target and regulated by the TGF-beta signalling pathway in epithelial ovarian cancer. Cell Death Dis. 2017 Dec 13;8(12):3214.
DMFUNL1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29238081

DMUVCWY	DI	DMUVCWY
DMUVCWY	DN	Pyridoxyl-Alanine-5-Phosphate
DMUVCWY	MI	TT6TMZU
DMUVCWY	MN	Mycobacterium Biosynthetic alanine racemase (MycB alr)
DMUVCWY	MT	DTT
DMUVCWY	MA	Inhibitor
DMUVCWY	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMUVCWY	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM7AW0X	DI	DM7AW0X
DM7AW0X	DN	Pyridoxyl-N,O-Cycloserylamide-5-Monophosphate
DM7AW0X	MI	TT6TMZU
DM7AW0X	MN	Mycobacterium Biosynthetic alanine racemase (MycB alr)
DM7AW0X	MT	DTT
DM7AW0X	MA	Inhibitor
DM7AW0X	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM7AW0X	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM7T2VQ	DI	DM7T2VQ
DM7T2VQ	DN	Pyrimidinyl acylthiourea
DM7T2VQ	MI	TTSUKYD
DM7T2VQ	MN	Virus RNA-dependent RNA polymerase (Viru RdRP)
DM7T2VQ	MT	DTT
DM7T2VQ	MA	Inhibitor
DM7T2VQ	RN	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob Agents Chemother. 2009 Jan;53(1):202-9.
DM7T2VQ	RU	https://pubmed.ncbi.nlm.nih.gov/18955536

DMCTJAM	DI	DMCTJAM
DMCTJAM	DN	PYRIPYROPENE A
DMCTJAM	MI	TTMF541
DMCTJAM	MN	Liver carboxylesterase (CES1)
DMCTJAM	MT	DTT
DMCTJAM	MA	Inhibitor
DMCTJAM	RN	Acyl-CoA: cholesterol acyltransferase inhibitory activities of fatty acid amides isolated from Mylabris phalerate Pallas. Bioorg Med Chem Lett. 2004 Aug 16;14(16):4277-80.
DMCTJAM	RU	https://pubmed.ncbi.nlm.nih.gov/15261286

DMCTJAM	DI	DMCTJAM
DMCTJAM	DN	PYRIPYROPENE A
DMCTJAM	MI	TTAK0IN
DMCTJAM	MN	SOAT2 messenger RNA (SOAT2 mRNA)
DMCTJAM	MT	DTT
DMCTJAM	MA	Inhibitor
DMCTJAM	RN	Saucerneol B derivatives as human acyl-CoA: cholesterol acyltransferase inhibitors. Bioorg Med Chem Lett. 2005 Jan 17;15(2):385-8.
DMCTJAM	RU	https://pubmed.ncbi.nlm.nih.gov/15603959

DMG5KDY	DI	DMG5KDY
DMG5KDY	DN	Pyrogallol
DMG5KDY	MI	TT2J34L
DMG5KDY	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMG5KDY	MT	DTT
DMG5KDY	MA	Inhibitor
DMG5KDY	RN	Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80.
DMG5KDY	RU	https://pubmed.ncbi.nlm.nih.gov/9371243

DMG5KDY	DI	DMG5KDY
DMG5KDY	DN	Pyrogallol
DMG5KDY	MI	DEWRN24
DMG5KDY	MN	Glucansucrase (gtf106B)
DMG5KDY	MT	DME
DMG5KDY	MA	Metabolism
DMG5KDY	RN	Impact of low-level laser therapy on hyposalivation, salivary pH, and quality of life in head and neck cancer patients post-radiotherapy. Lasers Med Sci. 2017 May;32(4):827-832.
DMG5KDY	RU	https://pubmed.ncbi.nlm.nih.gov/28258315

DMROZUA	DI	DMROZUA
DMROZUA	DN	Pyroglutamic acid
DMROZUA	MI	TTURHFP
DMROZUA	MN	Angiogenin (ANG)
DMROZUA	MT	DTT
DMROZUA	MA	Inhibitor
DMROZUA	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMROZUA	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMROZUA	DI	DMROZUA
DMROZUA	DN	Pyroglutamic acid
DMROZUA	MI	DT342ZG
DMROZUA	MN	Monocarboxylate transporter 1 (SLC16A1)
DMROZUA	MT	DTP
DMROZUA	MA	Substrate
DMROZUA	RN	Interaction of atorvastatin with the human glial transporter SLC16A1. Eur J Pharmacol. 2016 Oct 5;788:248-254.
DMROZUA	RU	http://www.ncbi.nlm.nih.gov/pubmed/27341998

DMROZUA	DI	DMROZUA
DMROZUA	DN	Pyroglutamic acid
DMROZUA	MI	TTU5HJP
DMROZUA	MN	Orexin (HCRT)
DMROZUA	MT	DTT
DMROZUA	MA	Inhibitor
DMROZUA	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMROZUA	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMROZUA	DI	DMROZUA
DMROZUA	DN	Pyroglutamic acid
DMROZUA	MI	TTCGSZ4
DMROZUA	MN	Pancreatic alpha-amylase (AMY2A)
DMROZUA	MT	DTT
DMROZUA	MA	Inhibitor
DMROZUA	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMROZUA	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMZQ75M	DI	DMZQ75M
DMZQ75M	DN	Pyrophosphate 2-
DMZQ75M	MI	TTURHFP
DMZQ75M	MN	Angiogenin (ANG)
DMZQ75M	MT	DTT
DMZQ75M	MA	Inhibitor
DMZQ75M	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMZQ75M	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMZQ75M	DI	DMZQ75M
DMZQ75M	DN	Pyrophosphate 2-
DMZQ75M	MI	TT8WCXO
DMZQ75M	MN	Bacterial NH(3)-dependent NAD(+) synthetase (Bact nadE)
DMZQ75M	MT	DTT
DMZQ75M	MA	Inhibitor
DMZQ75M	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMZQ75M	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMZQ75M	DI	DMZQ75M
DMZQ75M	DN	Pyrophosphate 2-
DMZQ75M	MI	TTCFP0V
DMZQ75M	MN	Glutamine amidotransferase (GMPS)
DMZQ75M	MT	DTT
DMZQ75M	MA	Inhibitor
DMZQ75M	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMZQ75M	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMZQ75M	DI	DMZQ75M
DMZQ75M	DN	Pyrophosphate 2-
DMZQ75M	MI	TTZ3IFB
DMZQ75M	MN	Phosphogluconate dehydrogenase (PGD)
DMZQ75M	MT	DTT
DMZQ75M	MA	Inhibitor
DMZQ75M	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMZQ75M	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMZQ75M	DI	DMZQ75M
DMZQ75M	DN	Pyrophosphate 2-
DMZQ75M	MI	TTBL49X
DMZQ75M	MN	Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ)
DMZQ75M	MT	DTT
DMZQ75M	MA	Inhibitor
DMZQ75M	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMZQ75M	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMZQ75M	DI	DMZQ75M
DMZQ75M	DN	Pyrophosphate 2-
DMZQ75M	MI	TTOY91U
DMZQ75M	MN	Plasmodium Hypoxanthine-guanine-xanthine phosphoribosyltransferase (Malaria LACZ)
DMZQ75M	MT	DTT
DMZQ75M	MA	Inhibitor
DMZQ75M	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMZQ75M	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMZQ75M	DI	DMZQ75M
DMZQ75M	DN	Pyrophosphate 2-
DMZQ75M	MI	TTSUKYD
DMZQ75M	MN	Virus RNA-dependent RNA polymerase (Viru RdRP)
DMZQ75M	MT	DTT
DMZQ75M	MA	Inhibitor
DMZQ75M	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMZQ75M	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMV48S2	DI	DMV48S2
DMV48S2	DN	Pyrovalerone
DMV48S2	MI	TTVBI8W
DMV48S2	MN	Dopamine transporter (DAT)
DMV48S2	MT	DTT
DMV48S2	MA	Inhibitor
DMV48S2	RN	A novel photoaffinity ligand for the dopamine transporter based on pyrovalerone. Bioorg Med Chem. 2009 Jun 1;17(11):3770-4.
DMV48S2	RU	https://pubmed.ncbi.nlm.nih.gov/19442525

DMV48S2	DI	DMV48S2
DMV48S2	DN	Pyrovalerone
DMV48S2	MI	TTAWNKZ
DMV48S2	MN	Norepinephrine transporter (NET)
DMV48S2	MT	DTT
DMV48S2	MA	Inhibitor
DMV48S2	RN	1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32.
DMV48S2	RU	https://pubmed.ncbi.nlm.nih.gov/16480278

DMV48S2	DI	DMV48S2
DMV48S2	DN	Pyrovalerone
DMV48S2	MI	TT3ROYC
DMV48S2	MN	Serotonin transporter (SERT)
DMV48S2	MT	DTT
DMV48S2	MA	Inhibitor
DMV48S2	RN	1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32.
DMV48S2	RU	https://pubmed.ncbi.nlm.nih.gov/16480278

DMS4ZFU	DI	DMS4ZFU
DMS4ZFU	DN	Pyrrolidin-(2Z)-ylideneamine
DMS4ZFU	MI	TTZUFI5
DMS4ZFU	MN	Nitric-oxide synthase brain (NOS1)
DMS4ZFU	MT	DTT
DMS4ZFU	MA	Inhibitor
DMS4ZFU	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DMS4ZFU	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DMS4ZFU	DI	DMS4ZFU
DMS4ZFU	DN	Pyrrolidin-(2Z)-ylideneamine
DMS4ZFU	MI	TTCM4B3
DMS4ZFU	MN	Nitric-oxide synthase endothelial (NOS3)
DMS4ZFU	MT	DTT
DMS4ZFU	MA	Inhibitor
DMS4ZFU	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DMS4ZFU	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DMS4ZFU	DI	DMS4ZFU
DMS4ZFU	DN	Pyrrolidin-(2Z)-ylideneamine
DMS4ZFU	MI	TTF10I9
DMS4ZFU	MN	Nitric-oxide synthase inducible (NOS2)
DMS4ZFU	MT	DTT
DMS4ZFU	MA	Inhibitor
DMS4ZFU	RN	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
DMS4ZFU	RU	https://pubmed.ncbi.nlm.nih.gov/15357988

DMYNZXC	DI	DMYNZXC
DMYNZXC	DN	Pyrrolidin-1-yl-thiourea
DMYNZXC	MI	TTMI6F5
DMYNZXC	MN	Transient receptor potential cation channel V1 (TRPV1)
DMYNZXC	MT	DTT
DMYNZXC	MA	Inhibitor
DMYNZXC	RN	N-4-methansulfonamidobenzyl-N'-2-substituted-4-tert-butyl-benzyl thioureas as potent vanilloid receptor antagonistic ligands. Bioorg Med Chem Lett. 2004 Apr 5;14(7):1693-6.
DMYNZXC	RU	https://pubmed.ncbi.nlm.nih.gov/15026052

DMYNZXC	DI	DMYNZXC
DMYNZXC	DN	Pyrrolidin-1-yl-thiourea
DMYNZXC	MI	TTKP2SU
DMYNZXC	MN	Transient receptor potential cation channel V4 (TRPV4)
DMYNZXC	MT	DTT
DMYNZXC	MA	Inhibitor
DMYNZXC	RN	N-4-methansulfonamidobenzyl-N'-2-substituted-4-tert-butyl-benzyl thioureas as potent vanilloid receptor antagonistic ligands. Bioorg Med Chem Lett. 2004 Apr 5;14(7):1693-6.
DMYNZXC	RU	https://pubmed.ncbi.nlm.nih.gov/15026052

DM0BHCJ	DI	DM0BHCJ
DM0BHCJ	DN	Pyrrolidin-3-yl-acetic acid
DM0BHCJ	MI	TT1MPAY
DM0BHCJ	MN	GABA(A) receptor alpha-1 (GABRA1)
DM0BHCJ	MT	DTT
DM0BHCJ	MA	Inhibitor
DM0BHCJ	RN	Orally active and potent inhibitors of gamma-aminobutyric acid uptake. J Med Chem. 1985 May;28(5):653-60.
DM0BHCJ	RU	https://pubmed.ncbi.nlm.nih.gov/2985785

DM0BHCJ	DI	DM0BHCJ
DM0BHCJ	DN	Pyrrolidin-3-yl-acetic acid
DM0BHCJ	MI	TTNJYV2
DM0BHCJ	MN	Gamma-aminobutyric acid receptor (GAR)
DM0BHCJ	MT	DTT
DM0BHCJ	MA	Inhibitor
DM0BHCJ	RN	Orally active and potent inhibitors of gamma-aminobutyric acid uptake. J Med Chem. 1985 May;28(5):653-60.
DM0BHCJ	RU	https://pubmed.ncbi.nlm.nih.gov/2985785

DM5ZAS6	DI	DM5ZAS6
DM5ZAS6	DN	Pyrrolidine dithiocarbamate
DM5ZAS6	MI	TTSXVID
DM5ZAS6	MN	Nuclear factor NF-kappa-B (NFKB)
DM5ZAS6	MT	DTT
DM5ZAS6	MA	Inhibitor
DM5ZAS6	RN	Simulated ischemia induces renal tubular cell apoptosis through a nuclear factor-kappaB dependent mechanism. J Urol. 2002 Jul;168(1):248-52.
DM5ZAS6	RU	https://pubmed.ncbi.nlm.nih.gov/12050551

DME6HCQ	DI	DME6HCQ
DME6HCQ	DN	pyrrolidine MCHR1 antagonist 1
DME6HCQ	MI	TTX4RTB
DME6HCQ	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DME6HCQ	MT	DTT
DME6HCQ	MA	Antagonist
DME6HCQ	RN	Novel pyrrolidine melanin-concentrating hormone receptor 1 antagonists with reduced hERG inhibition. Bioorg Med Chem Lett. 2011 Apr 15;21(8):2460-7.
DME6HCQ	RU	https://pubmed.ncbi.nlm.nih.gov/21414780

DM906JK	DI	DM906JK
DM906JK	DN	Pyrrolidine-1-carbonitrile
DM906JK	MI	TTDZN01
DM906JK	MN	Cathepsin K (CTSK)
DM906JK	MT	DTT
DM906JK	MA	Inhibitor
DM906JK	RN	Acyclic cyanamide-based inhibitors of cathepsin K. Bioorg Med Chem Lett. 2005 Jun 15;15(12):3039-43.
DM906JK	RU	https://pubmed.ncbi.nlm.nih.gov/15896958

DM1X5JR	DI	DM1X5JR
DM1X5JR	DN	Pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione
DM1X5JR	MI	TTVDSZ0
DM1X5JR	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DM1X5JR	MT	DTT
DM1X5JR	MA	Inhibitor
DM1X5JR	RN	Synthesis and structure-activity relationships of novel poly(ADP-ribose) polymerase-1 inhibitors. Bioorg Med Chem Lett. 2006 Feb 15;16(4):938-42.
DM1X5JR	RU	https://pubmed.ncbi.nlm.nih.gov/16290935

DMM4CU9	DI	DMM4CU9
DMM4CU9	DN	Pyrrolo[3,4-e]indole-1,3(2H,6H)-dione
DMM4CU9	MI	TTVDSZ0
DMM4CU9	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMM4CU9	MT	DTT
DMM4CU9	MA	Inhibitor
DMM4CU9	RN	Synthesis and structure-activity relationships of novel poly(ADP-ribose) polymerase-1 inhibitors. Bioorg Med Chem Lett. 2006 Feb 15;16(4):938-42.
DMM4CU9	RU	https://pubmed.ncbi.nlm.nih.gov/16290935

DMZLFVG	DI	DMZLFVG
DMZLFVG	DN	Pyrrolopyrimidine
DMZLFVG	MI	TTOI92F
DMZLFVG	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMZLFVG	MT	DTT
DMZLFVG	MA	Inhibitor
DMZLFVG	RN	Topological model for the prediction of MRP1 inhibitory activity of pyrrolopyrimidines and templates derived from pyrrolopyrimidine. Bioorg Med Chem Lett. 2005 Nov 15;15(22):4967-72.
DMZLFVG	RU	https://pubmed.ncbi.nlm.nih.gov/16168641

DMUEKB3	DI	DMUEKB3
DMUEKB3	DN	pyrrolopyrimidine 48
DMUEKB3	MI	TT4G2JS
DMUEKB3	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DMUEKB3	MT	DTT
DMUEKB3	MA	Blocker (channel blocker)
DMUEKB3	RN	Discovery and hit-to-lead optimization of pyrrolopyrimidines as potent, state-dependent Na(v)1.7 antagonists. Bioorg Med Chem Lett. 2012 Mar 1;22(5):2052-62.
DMUEKB3	RU	https://pubmed.ncbi.nlm.nih.gov/22318156

DM725FL	DI	DM725FL
DM725FL	DN	PYY(22-36)
DM725FL	MI	TTRK9JT
DM725FL	MN	Neuropeptide Y receptor type 1 (NPY1R)
DM725FL	MT	DTT
DM725FL	MA	Inhibitor
DM725FL	RN	Identification of selective neuropeptide Y2 peptide agonists. Bioorg Med Chem Lett. 2007 Jan 15;17(2):538-41.
DM725FL	RU	https://pubmed.ncbi.nlm.nih.gov/17055726

DM725FL	DI	DM725FL
DM725FL	DN	PYY(22-36)
DM725FL	MI	TTJ6WK9
DM725FL	MN	Neuropeptide Y receptor type 2 (NPY2R)
DM725FL	MT	DTT
DM725FL	MA	Inhibitor
DM725FL	RN	Identification of selective neuropeptide Y2 peptide agonists. Bioorg Med Chem Lett. 2007 Jan 15;17(2):538-41.
DM725FL	RU	https://pubmed.ncbi.nlm.nih.gov/17055726

DMD6ZWV	DI	DMD6ZWV
DMD6ZWV	DN	PYY(25-36)
DMD6ZWV	MI	TTJ6WK9
DMD6ZWV	MN	Neuropeptide Y receptor type 2 (NPY2R)
DMD6ZWV	MT	DTT
DMD6ZWV	MA	Inhibitor
DMD6ZWV	RN	Identification of selective neuropeptide Y2 peptide agonists. Bioorg Med Chem Lett. 2007 Jan 15;17(2):538-41.
DMD6ZWV	RU	https://pubmed.ncbi.nlm.nih.gov/17055726

DMFUYR1	DI	DMFUYR1
DMFUYR1	DN	Pyz11-D-Trp8-SRIF
DMFUYR1	MI	TTZ6T9E
DMFUYR1	MN	Somatostatin receptor type 2 (SSTR2)
DMFUYR1	MT	DTT
DMFUYR1	MA	Inhibitor
DMFUYR1	RN	Replacement of Phe6, Phe7, and Phe11 of D-Trp8-somatostatin-14 with L-pyrazinylalanine. Predicted and observed effects on binding affinities at hSS... J Med Chem. 2005 Jun 16;48(12):4025-30.
DMFUYR1	RU	https://pubmed.ncbi.nlm.nih.gov/15943475

DMFUYR1	DI	DMFUYR1
DMFUYR1	DN	Pyz11-D-Trp8-SRIF
DMFUYR1	MI	TTAE1BR
DMFUYR1	MN	Somatostatin receptor type 4 (SSTR4)
DMFUYR1	MT	DTT
DMFUYR1	MA	Inhibitor
DMFUYR1	RN	Replacement of Phe6, Phe7, and Phe11 of D-Trp8-somatostatin-14 with L-pyrazinylalanine. Predicted and observed effects on binding affinities at hSS... J Med Chem. 2005 Jun 16;48(12):4025-30.
DMFUYR1	RU	https://pubmed.ncbi.nlm.nih.gov/15943475

DMDB3Q8	DI	DMDB3Q8
DMDB3Q8	DN	Pyz6-D-Trp8-SRIF
DMDB3Q8	MI	TTZ6T9E
DMDB3Q8	MN	Somatostatin receptor type 2 (SSTR2)
DMDB3Q8	MT	DTT
DMDB3Q8	MA	Inhibitor
DMDB3Q8	RN	Replacement of Phe6, Phe7, and Phe11 of D-Trp8-somatostatin-14 with L-pyrazinylalanine. Predicted and observed effects on binding affinities at hSS... J Med Chem. 2005 Jun 16;48(12):4025-30.
DMDB3Q8	RU	https://pubmed.ncbi.nlm.nih.gov/15943475

DMDB3Q8	DI	DMDB3Q8
DMDB3Q8	DN	Pyz6-D-Trp8-SRIF
DMDB3Q8	MI	TTAE1BR
DMDB3Q8	MN	Somatostatin receptor type 4 (SSTR4)
DMDB3Q8	MT	DTT
DMDB3Q8	MA	Inhibitor
DMDB3Q8	RN	Replacement of Phe6, Phe7, and Phe11 of D-Trp8-somatostatin-14 with L-pyrazinylalanine. Predicted and observed effects on binding affinities at hSS... J Med Chem. 2005 Jun 16;48(12):4025-30.
DMDB3Q8	RU	https://pubmed.ncbi.nlm.nih.gov/15943475

DM9D805	DI	DM9D805
DM9D805	DN	Pyz7-D-Trp8-SRIF
DM9D805	MI	TTAE1BR
DM9D805	MN	Somatostatin receptor type 4 (SSTR4)
DM9D805	MT	DTT
DM9D805	MA	Inhibitor
DM9D805	RN	Replacement of Phe6, Phe7, and Phe11 of D-Trp8-somatostatin-14 with L-pyrazinylalanine. Predicted and observed effects on binding affinities at hSS... J Med Chem. 2005 Jun 16;48(12):4025-30.
DM9D805	RU	https://pubmed.ncbi.nlm.nih.gov/15943475

DME0NO8	DI	DME0NO8
DME0NO8	DN	PYZD-4409
DME0NO8	MI	TTXHWA7
DME0NO8	MN	Ubiquitin-activating enzyme E1 (UBAE1)
DME0NO8	MT	DTT
DME0NO8	MA	Inhibitor
DME0NO8	RN	The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma. Blood. 2010 Mar 18;115(11):2251-9.
DME0NO8	RU	https://pubmed.ncbi.nlm.nih.gov/20075161

DML5KMT	DI	DML5KMT
DML5KMT	DN	Q-27137207
DML5KMT	MI	DECV2ME
DML5KMT	MN	Cytochrome P450 105D7 (cyp105)
DML5KMT	MT	DME
DML5KMT	MA	Metabolism
DML5KMT	RN	nan
DML5KMT	RU	nan

DM26GBV	DI	DM26GBV
DM26GBV	DN	QA1
DM26GBV	MI	TTV1C0Z
DM26GBV	MN	Neuropeptide S receptor (NPSR)
DM26GBV	MT	DTT
DM26GBV	MA	Antagonist
DM26GBV	RN	Synthesis and evaluation of a new series of Neuropeptide S receptor antagonists. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4700-3.
DM26GBV	RU	https://pubmed.ncbi.nlm.nih.gov/20510609

DM62PI8	DI	DM62PI8
DM62PI8	DN	QCP
DM62PI8	MI	TT2UE56
DM62PI8	MN	Sodium/glucose cotransporter 1 (SGLT1)
DM62PI8	MT	DTT
DM62PI8	MA	Inhibitor
DM62PI8	RN	Tripeptides of RS1 (RSC1A1) inhibit a monosaccharide-dependent exocytotic pathway of Na+-D-glucose cotransporter SGLT1 with high affinity. J Biol Chem. 2007 Sep 28;282(39):28501-13.
DM62PI8	RU	https://pubmed.ncbi.nlm.nih.gov/17686765

DMSMQXZ	DI	DMSMQXZ
DMSMQXZ	DN	Qcpac
DMSMQXZ	MI	TT2UE56
DMSMQXZ	MN	Sodium/glucose cotransporter 1 (SGLT1)
DMSMQXZ	MT	DTT
DMSMQXZ	MA	Inhibitor
DMSMQXZ	RN	Tripeptides of RS1 (RSC1A1) inhibit a monosaccharide-dependent exocytotic pathway of Na+-D-glucose cotransporter SGLT1 with high affinity. J Biol Chem. 2007 Sep 28;282(39):28501-13.
DMSMQXZ	RU	https://pubmed.ncbi.nlm.nih.gov/17686765

DMJ38YV	DI	DMJ38YV
DMJ38YV	DN	QEDIIRNIARHLAQVGDSMDR
DMJ38YV	MI	TTJGNVC
DMJ38YV	MN	Apoptosis regulator Bcl-2 (BCL-2)
DMJ38YV	MT	DTT
DMJ38YV	MA	Inhibitor
DMJ38YV	RN	Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem. 2006 Oct 19;49(21):6139-42.
DMJ38YV	RU	https://pubmed.ncbi.nlm.nih.gov/17034116

DMJ38YV	DI	DMJ38YV
DMJ38YV	DN	QEDIIRNIARHLAQVGDSMDR
DMJ38YV	MI	TTRE6AX
DMJ38YV	MN	Bcl-x messenger RNA (BCL2L1 mRNA)
DMJ38YV	MT	DTT
DMJ38YV	MA	Inhibitor
DMJ38YV	RN	Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem. 2006 Oct 19;49(21):6139-42.
DMJ38YV	RU	https://pubmed.ncbi.nlm.nih.gov/17034116

DMJ38YV	DI	DMJ38YV
DMJ38YV	DN	QEDIIRNIARHLAQVGDSMDR
DMJ38YV	MI	TTL53M6
DMJ38YV	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DMJ38YV	MT	DTT
DMJ38YV	MA	Inhibitor
DMJ38YV	RN	Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem. 2006 Oct 19;49(21):6139-42.
DMJ38YV	RU	https://pubmed.ncbi.nlm.nih.gov/17034116

DMWOSFJ	DI	DMWOSFJ
DMWOSFJ	DN	QLT-091382
DMWOSFJ	MI	TTY84UG
DMWOSFJ	MN	Acetyl-CoA carboxylase 2 (ACACB)
DMWOSFJ	MT	DTT
DMWOSFJ	MA	Inhibitor
DMWOSFJ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1264).
DMWOSFJ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1264

DMTY5HP	DI	DMTY5HP
DMTY5HP	DN	QNEQCPQVSac
DMTY5HP	MI	TT2UE56
DMTY5HP	MN	Sodium/glucose cotransporter 1 (SGLT1)
DMTY5HP	MT	DTT
DMTY5HP	MA	Inhibitor
DMTY5HP	RN	Tripeptides of RS1 (RSC1A1) inhibit a monosaccharide-dependent exocytotic pathway of Na+-D-glucose cotransporter SGLT1 with high affinity. J Biol Chem. 2007 Sep 28;282(39):28501-13.
DMTY5HP	RU	https://pubmed.ncbi.nlm.nih.gov/17686765

DM01RZX	DI	DM01RZX
DM01RZX	DN	QNZ 46
DM01RZX	MI	TT5POTG
DM01RZX	MN	Glutamate receptor ionotropic NMDA 2D (GluN2D)
DM01RZX	MT	DTT
DM01RZX	MA	Modulator (allosteric modulator)
DM01RZX	RN	Structural and mechanistic determinants of a novel site for noncompetitive inhibition of GluN2D-containing NMDA receptors. J Neurosci. 2011 Mar 9;31(10):3650-61.
DM01RZX	RU	https://pubmed.ncbi.nlm.nih.gov/21389220

DMYXPF8	DI	DMYXPF8
DMYXPF8	DN	QO-58
DMYXPF8	MI	TTPXI3S
DMYXPF8	MN	Voltage-gated potassium channel Kv7.2 (KCNQ2)
DMYXPF8	MT	DTT
DMYXPF8	MA	Activator
DMYXPF8	RN	Modulation of K(v)7 potassium channels by a novel opener pyrazolo[1,5-a]pyrimidin-7(4H)-one compound QO-58. Br J Pharmacol. 2013 Feb;168(4):1030-42.
DMYXPF8	RU	https://pubmed.ncbi.nlm.nih.gov/23013484

DMJHTUG	DI	DMJHTUG
DMJHTUG	DN	QSPac
DMJHTUG	MI	TT2UE56
DMJHTUG	MN	Sodium/glucose cotransporter 1 (SGLT1)
DMJHTUG	MT	DTT
DMJHTUG	MA	Inhibitor
DMJHTUG	RN	Tripeptides of RS1 (RSC1A1) inhibit a monosaccharide-dependent exocytotic pathway of Na+-D-glucose cotransporter SGLT1 with high affinity. J Biol Chem. 2007 Sep 28;282(39):28501-13.
DMJHTUG	RU	https://pubmed.ncbi.nlm.nih.gov/17686765

DM2Q6JY	DI	DM2Q6JY
DM2Q6JY	DN	quadazocine
DM2Q6JY	MI	TT27RFC
DM2Q6JY	MN	Opioid receptor delta (OPRD1)
DM2Q6JY	MT	DTT
DM2Q6JY	MA	Antagonist
DM2Q6JY	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317).
DM2Q6JY	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=317

DM2Q6JY	DI	DM2Q6JY
DM2Q6JY	DN	quadazocine
DM2Q6JY	MI	TTQW87Y
DM2Q6JY	MN	Opioid receptor kappa (OPRK1)
DM2Q6JY	MT	DTT
DM2Q6JY	MA	Antagonist
DM2Q6JY	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 318).
DM2Q6JY	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=318

DM2Q6JY	DI	DM2Q6JY
DM2Q6JY	DN	quadazocine
DM2Q6JY	MI	TTKWM86
DM2Q6JY	MN	Opioid receptor mu (MOP)
DM2Q6JY	MT	DTT
DM2Q6JY	MA	Antagonist
DM2Q6JY	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
DM2Q6JY	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319

DMXIU6W	DI	DMXIU6W
DMXIU6W	DN	Quercetin 3-O-neohesperidoside
DMXIU6W	MI	TTFBNVI
DMXIU6W	MN	Aldose reductase (AKR1B1)
DMXIU6W	MT	DTT
DMXIU6W	MA	Inhibitor
DMXIU6W	RN	New flavonol oligoglycosides and polyacylated sucroses with inhibitory effects on aldose reductase and platelet aggregation from the flowers of Pru... J Nat Prod. 2002 Aug;65(8):1151-5.
DMXIU6W	RU	https://pubmed.ncbi.nlm.nih.gov/12193020

DM1DH96	DI	DM1DH96
DM1DH96	DN	QUERCITRIN
DM1DH96	MI	TTFBNVI
DM1DH96	MN	Aldose reductase (AKR1B1)
DM1DH96	MT	DTT
DM1DH96	MA	Inhibitor
DM1DH96	RN	Erigeroflavanone, a flavanone derivative from the flowers of Erigeron annuus with protein glycation and aldose reductase inhibitory activity. J Nat Prod. 2008 Apr;71(4):713-5.
DM1DH96	RU	https://pubmed.ncbi.nlm.nih.gov/18298080

DM9YWG8	DI	DM9YWG8
DM9YWG8	DN	Quick-acting insulin
DM9YWG8	MI	TTCBFJO
DM9YWG8	MN	Insulin receptor (INSR)
DM9YWG8	MT	DTT
DM9YWG8	MA	Modulator
DM9YWG8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800).
DM9YWG8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800

DM0BEZS	DI	DM0BEZS
DM0BEZS	DN	Quinapril analogue
DM0BEZS	MI	TTGY8IW
DM0BEZS	MN	B2 bradykinin receptor (BDKRB2)
DM0BEZS	MT	DTT
DM0BEZS	MA	Inhibitor
DM0BEZS	RN	Ace inhibitors as a template for the design of bradykinin B2 receptor antagonists, Bioorg. Med. Chem. Lett. 5(4):367-370 (1995).
DM0BEZS	RU	http://www.sciencedirect.com/science/article/pii/0960894X9500037T

DMJDU5S	DI	DMJDU5S
DMJDU5S	DN	quinazoline deriv. 1
DMJDU5S	MI	TT9RTBL
DMJDU5S	MN	Aurora B messenger RNA (AURKB mRNA)
DMJDU5S	MT	DTT
DMJDU5S	MA	Inhibitor
DMJDU5S	RN	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
DMJDU5S	RU	https://pubmed.ncbi.nlm.nih.gov/18077363

DMJDU5S	DI	DMJDU5S
DMJDU5S	DN	quinazoline deriv. 1
DMJDU5S	MI	TTLYXIT
DMJDU5S	MN	Aurora kinase C (AURKC)
DMJDU5S	MT	DTT
DMJDU5S	MA	Inhibitor
DMJDU5S	RN	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
DMJDU5S	RU	https://pubmed.ncbi.nlm.nih.gov/18077363

DMVQYWS	DI	DMVQYWS
DMVQYWS	DN	quin-C1
DMVQYWS	MI	TTOJ1NF
DMVQYWS	MN	FMLP-related receptor I (FPR2)
DMVQYWS	MT	DTT
DMVQYWS	MA	Agonist
DMVQYWS	RN	A novel nonpeptide ligand for formyl peptide receptor-like 1. Mol Pharmacol. 2004 Nov;66(5):1213-22.
DMVQYWS	RU	https://pubmed.ncbi.nlm.nih.gov/15308762

DM1CYWB	DI	DM1CYWB
DM1CYWB	DN	quin-C7
DM1CYWB	MI	TTOJ1NF
DM1CYWB	MN	FMLP-related receptor I (FPR2)
DM1CYWB	MT	DTT
DM1CYWB	MA	Antagonist
DM1CYWB	RN	Pharmacological characterization of a novel nonpeptide antagonist for formyl peptide receptor-like 1. Mol Pharmacol. 2007 Oct;72(4):976-83.
DM1CYWB	RU	https://pubmed.ncbi.nlm.nih.gov/17652444

DMRQCK3	DI	DMRQCK3
DMRQCK3	DN	Quinizarin
DMRQCK3	MI	TTGTQHC
DMRQCK3	MN	DNA topoisomerase I (TOP1)
DMRQCK3	MT	DTT
DMRQCK3	MA	Binder
DMRQCK3	RN	Comparison of responses of DNA topoisomerase I from Candida albicans and human cells to four new agents which stimulate topoisomerase-dependent DNA nicking. FEMS Microbiol Lett. 1996 May 1;138(2-3):105-11.
DMRQCK3	RU	https://pubmed.ncbi.nlm.nih.gov/9026436

DM1QIPZ	DI	DM1QIPZ
DM1QIPZ	DN	quinoline 2
DM1QIPZ	MI	TT2EDHU
DM1QIPZ	MN	Insulin-degrading enzyme (IDE)
DM1QIPZ	MT	DTT
DM1QIPZ	MA	Inhibitor
DM1QIPZ	RN	Dual Exosite-binding Inhibitors of Insulin-degrading Enzyme Challenge Its Role as the Primary Mediator of Insulin Clearance in Vivo. J Biol Chem. 2015 Aug 14;290(33):20044-59.
DM1QIPZ	RU	https://pubmed.ncbi.nlm.nih.gov/26085101

DMDY3I2	DI	DMDY3I2
DMDY3I2	DN	Quinoline-2-carboxylic acid adamantan-1-ylamide
DMDY3I2	MI	TTVBPDM
DMDY3I2	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMDY3I2	MT	DTT
DMDY3I2	MA	Inhibitor
DMDY3I2	RN	Positive and negative modulation of group I metabotropic glutamate receptors. J Med Chem. 2008 Feb 14;51(3):634-47.
DMDY3I2	RU	https://pubmed.ncbi.nlm.nih.gov/18173231

DM9BIVL	DI	DM9BIVL
DM9BIVL	DN	Quinoline-3-carboxylic acid adamantan-1-ylamide
DM9BIVL	MI	TTVBPDM
DM9BIVL	MN	Metabotropic glutamate receptor 1 (mGluR1)
DM9BIVL	MT	DTT
DM9BIVL	MA	Inhibitor
DM9BIVL	RN	Positive and negative modulation of group I metabotropic glutamate receptors. J Med Chem. 2008 Feb 14;51(3):634-47.
DM9BIVL	RU	https://pubmed.ncbi.nlm.nih.gov/18173231

DMV57OZ	DI	DMV57OZ
DMV57OZ	DN	Quinoline-8-carboxamide
DMV57OZ	MI	TTVDSZ0
DMV57OZ	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMV57OZ	MT	DTT
DMV57OZ	MA	Inhibitor
DMV57OZ	RN	Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhi... J Med Chem. 2009 Feb 12;52(3):868-77.
DMV57OZ	RU	https://pubmed.ncbi.nlm.nih.gov/19117416

DMTPFLU	DI	DMTPFLU
DMTPFLU	DN	Quinoline-8-sulfonamide
DMTPFLU	MI	TTANPDJ
DMTPFLU	MN	Carbonic anhydrase II (CA-II)
DMTPFLU	MT	DTT
DMTPFLU	MA	Inhibitor
DMTPFLU	RN	Ligand-based and structure-based virtual screening to identify carbonic anhydrase IX inhibitors. Bioorg Med Chem. 2009 Jan 15;17(2):553-7.
DMTPFLU	RU	https://pubmed.ncbi.nlm.nih.gov/19097911

DMTPFLU	DI	DMTPFLU
DMTPFLU	DN	Quinoline-8-sulfonamide
DMTPFLU	MI	TT2LVK8
DMTPFLU	MN	Carbonic anhydrase IX (CA-IX)
DMTPFLU	MT	DTT
DMTPFLU	MA	Inhibitor
DMTPFLU	RN	Ligand-based and structure-based virtual screening to identify carbonic anhydrase IX inhibitors. Bioorg Med Chem. 2009 Jan 15;17(2):553-7.
DMTPFLU	RU	https://pubmed.ncbi.nlm.nih.gov/19097911

DM8YGOI	DI	DM8YGOI
DM8YGOI	DN	Quinolinic Acid
DM8YGOI	MI	TTH29K0
DM8YGOI	MN	Mycobacterium Nicotinate-nucleotide pyrophosphorylase (MycB nadC)
DM8YGOI	MT	DTT
DM8YGOI	MA	Inhibitor
DM8YGOI	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM8YGOI	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMRWXH4	DI	DMRWXH4
DMRWXH4	DN	Quinoxaline1
DMRWXH4	MI	TTH6V3D
DMRWXH4	MN	Cyclin-dependent kinase 1 (CDK1)
DMRWXH4	MT	DTT
DMRWXH4	MA	Inhibitor
DMRWXH4	RN	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
DMRWXH4	RU	https://pubmed.ncbi.nlm.nih.gov/18077363

DMRWXH4	DI	DMRWXH4
DMRWXH4	DN	Quinoxaline1
DMRWXH4	MI	TTL4Q97
DMRWXH4	MN	Cyclin-dependent kinase 5 (CDK5)
DMRWXH4	MT	DTT
DMRWXH4	MA	Inhibitor
DMRWXH4	RN	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
DMRWXH4	RU	https://pubmed.ncbi.nlm.nih.gov/18077363

DMRWXH4	DI	DMRWXH4
DMRWXH4	DN	Quinoxaline1
DMRWXH4	MI	TTRSMW9
DMRWXH4	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMRWXH4	MT	DTT
DMRWXH4	MA	Inhibitor
DMRWXH4	RN	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
DMRWXH4	RU	https://pubmed.ncbi.nlm.nih.gov/18077363

DMDNHEP	DI	DMDNHEP
DMDNHEP	DN	QUINPIROLE
DMDNHEP	MI	TTZFYLI
DMDNHEP	MN	Dopamine D1 receptor (D1R)
DMDNHEP	MT	DTT
DMDNHEP	MA	Inhibitor
DMDNHEP	RN	Pharmacophore-guided drug discovery investigations leading to bioactive 5-aminotetrahydropyrazolopyridines. Implications for the binding mode of he... J Med Chem. 2005 Sep 8;48(18):5771-9.
DMDNHEP	RU	https://pubmed.ncbi.nlm.nih.gov/16134944

DMDNHEP	DI	DMDNHEP
DMDNHEP	DN	QUINPIROLE
DMDNHEP	MI	TTEX248
DMDNHEP	MN	Dopamine D2 receptor (D2R)
DMDNHEP	MT	DTT
DMDNHEP	MA	Inhibitor
DMDNHEP	RN	N-n-Propyl-substituted 3-(dimethylphenyl)piperidines display novel discriminative properties between dopamine receptor subtypes: synthesis and rece... J Med Chem. 1998 Dec 3;41(25):4933-8.
DMDNHEP	RU	https://pubmed.ncbi.nlm.nih.gov/9836610

DMDNHEP	DI	DMDNHEP
DMDNHEP	DN	QUINPIROLE
DMDNHEP	MI	TT4C8EA
DMDNHEP	MN	Dopamine D3 receptor (D3R)
DMDNHEP	MT	DTT
DMDNHEP	MA	Inhibitor
DMDNHEP	RN	1,1'-Disubstituted ferrocenes as molecular hinges in mono- and bivalent dopamine receptor ligands. J Med Chem. 2009 Nov 12;52(21):6860-70.
DMDNHEP	RU	https://pubmed.ncbi.nlm.nih.gov/19807103

DMDNHEP	DI	DMDNHEP
DMDNHEP	DN	QUINPIROLE
DMDNHEP	MI	TTE0A2F
DMDNHEP	MN	Dopamine D4 receptor (D4R)
DMDNHEP	MT	DTT
DMDNHEP	MA	Inhibitor
DMDNHEP	RN	Pharmacophore-guided drug discovery investigations leading to bioactive 5-aminotetrahydropyrazolopyridines. Implications for the binding mode of he... J Med Chem. 2005 Sep 8;48(18):5771-9.
DMDNHEP	RU	https://pubmed.ncbi.nlm.nih.gov/16134944

DMPY6IG	DI	DMPY6IG
DMPY6IG	DN	Quipazine
DMPY6IG	MI	TTSQIFT
DMPY6IG	MN	5-HT 1A receptor (HTR1A)
DMPY6IG	MT	DTT
DMPY6IG	MA	Inhibitor
DMPY6IG	RN	Novel, potent, and selective quinoxaline-based 5-HT(3) receptor ligands. 1. Further structure-activity relationships and pharmacological characteri... J Med Chem. 2009 Nov 12;52(21):6946-50.
DMPY6IG	RU	https://pubmed.ncbi.nlm.nih.gov/19831400

DMPY6IG	DI	DMPY6IG
DMPY6IG	DN	Quipazine
DMPY6IG	MI	TT6MSOK
DMPY6IG	MN	5-HT 1D receptor (HTR1D)
DMPY6IG	MT	DTT
DMPY6IG	MA	Inhibitor
DMPY6IG	RN	5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80.
DMPY6IG	RU	https://pubmed.ncbi.nlm.nih.gov/3783595

DMPY6IG	DI	DMPY6IG
DMPY6IG	DN	Quipazine
DMPY6IG	MI	TTJQOD7
DMPY6IG	MN	5-HT 2A receptor (HTR2A)
DMPY6IG	MT	DTT
DMPY6IG	MA	Inhibitor
DMPY6IG	RN	Novel, potent, and selective quinoxaline-based 5-HT(3) receptor ligands. 1. Further structure-activity relationships and pharmacological characteri... J Med Chem. 2009 Nov 12;52(21):6946-50.
DMPY6IG	RU	https://pubmed.ncbi.nlm.nih.gov/19831400

DMPY6IG	DI	DMPY6IG
DMPY6IG	DN	Quipazine
DMPY6IG	MI	TTPC4TU
DMPY6IG	MN	5-HT 3A receptor (HTR3A)
DMPY6IG	MT	DTT
DMPY6IG	MA	Inhibitor
DMPY6IG	RN	Novel, potent, and selective quinoxaline-based 5-HT(3) receptor ligands. 1. Further structure-activity relationships and pharmacological characteri... J Med Chem. 2009 Nov 12;52(21):6946-50.
DMPY6IG	RU	https://pubmed.ncbi.nlm.nih.gov/19831400

DMPY6IG	DI	DMPY6IG
DMPY6IG	DN	Quipazine
DMPY6IG	MI	TTR6K75
DMPY6IG	MN	5-HT 3B receptor (HTR3B)
DMPY6IG	MT	DTT
DMPY6IG	MA	Inhibitor
DMPY6IG	RN	Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy ... J Med Chem. 1999 May 6;42(9):1556-75.
DMPY6IG	RU	https://pubmed.ncbi.nlm.nih.gov/10229626

DMPY6IG	DI	DMPY6IG
DMPY6IG	DN	Quipazine
DMPY6IG	MI	TTJS8PY
DMPY6IG	MN	5-HT 6 receptor (HTR6)
DMPY6IG	MT	DTT
DMPY6IG	MA	Inhibitor
DMPY6IG	RN	Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). J Med Chem. 2003 Jul 3;46(14):2795-812.
DMPY6IG	RU	https://pubmed.ncbi.nlm.nih.gov/12825922

DMPY6IG	DI	DMPY6IG
DMPY6IG	DN	Quipazine
DMPY6IG	MI	TT3ROYC
DMPY6IG	MN	Serotonin transporter (SERT)
DMPY6IG	MT	DTT
DMPY6IG	MA	Inhibitor
DMPY6IG	RN	Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 1. Bioorg Med Chem Lett. 2000 Jul 17;10(14):1559-62.
DMPY6IG	RU	https://pubmed.ncbi.nlm.nih.gov/10915050

DM9KMEI	DI	DM9KMEI
DM9KMEI	DN	Quizalofop
DM9KMEI	MI	TTYAWV0
DM9KMEI	MN	Plasmodium Acetyl-CoA carboxylase 1 (Malaria ACC1)
DM9KMEI	MT	DTT
DM9KMEI	MA	Binder
DM9KMEI	RN	The apicoplast as an antimalarial drug target. Drug Resist Updat. 2001 Jun;4(3):145-51.
DM9KMEI	RU	https://pubmed.ncbi.nlm.nih.gov/11768328

DMQ7PIL	DI	DMQ7PIL
DMQ7PIL	DN	QwFwLL-NH2
DMQ7PIL	MI	TTWDC17
DMQ7PIL	MN	Growth hormone secretagogue receptor 1 (GHSR)
DMQ7PIL	MT	DTT
DMQ7PIL	MA	Inhibitor
DMQ7PIL	RN	Identification of an efficacy switch region in the ghrelin receptor responsible for interchange between agonism and inverse agonism. J Biol Chem. 2007 May 25;282(21):15799-811.
DMQ7PIL	RU	https://pubmed.ncbi.nlm.nih.gov/17371869

DM72ES1	DI	DM72ES1
DM72ES1	DN	R(-)amphetamine
DM72ES1	MI	TTIU98M
DM72ES1	MN	Trace amine-associated receptor-1 (TAAR1)
DM72ES1	MT	DTT
DM72ES1	MA	Agonist
DM72ES1	RN	The Trace Amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia. Genes Brain Behav. 2007 Oct;6(7):628-39.
DM72ES1	RU	https://pubmed.ncbi.nlm.nih.gov/17212650

DM4URMA	DI	DM4URMA
DM4URMA	DN	R,R-THC
DM4URMA	MI	TTZAYWL
DM4URMA	MN	Estrogen receptor (ESR)
DM4URMA	MT	DTT
DM4URMA	MA	Agonist
DM4URMA	RN	Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-alpha or estrogen receptor-beta. Endocrinology. 1999 Feb;140(2):800-4.
DM4URMA	RU	https://pubmed.ncbi.nlm.nih.gov/9927308

DM4URMA	DI	DM4URMA
DM4URMA	DN	R,R-THC
DM4URMA	MI	TTOM3J0
DM4URMA	MN	Estrogen receptor beta (ESR2)
DM4URMA	MT	DTT
DM4URMA	MA	Antagonist
DM4URMA	RN	Estrogen receptor subtype-selective ligands: asymmetric synthesis and biological evaluation of cis- and trans-5,11-dialkyl- 5,6,11, 12-tetrahydrochrysenes. J Med Chem. 1999 Jul 1;42(13):2456-68.
DM4URMA	RU	https://pubmed.ncbi.nlm.nih.gov/10395487

DMK0YP7	DI	DMK0YP7
DMK0YP7	DN	R-1
DMK0YP7	MI	TT0K1SC
DMK0YP7	MN	5-HT 2B receptor (HTR2B)
DMK0YP7	MT	DTT
DMK0YP7	MA	Antagonist
DMK0YP7	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 7).
DMK0YP7	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=7

DM6Y7QM	DI	DM6Y7QM
DM6Y7QM	DN	R116031
DM6Y7QM	MI	TTZPO1L
DM6Y7QM	MN	Substance-P receptor (TACR1)
DM6Y7QM	MT	DTT
DM6Y7QM	MA	Antagonist
DM6Y7QM	RN	Pharmacological profile of (2R-trans)-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-acetamide (S)-Hydroxybutanedioate (R116301), an orally and centrally active neurokinin-1 receptor antagonist. J Pharmacol Exp Ther. 2002 Aug;302(2):696-709.
DM6Y7QM	RU	https://pubmed.ncbi.nlm.nih.gov/12130734

DMJ14OV	DI	DMJ14OV
DMJ14OV	DN	R-116712
DMJ14OV	MI	TT07C3Y
DMJ14OV	MN	5-HT 4 receptor (HTR4)
DMJ14OV	MT	DTT
DMJ14OV	MA	Antagonist
DMJ14OV	RN	Mapping of serotonin 5-HT(4) receptor mRNA and ligand binding sites in the post-mortem human brain. Synapse. 2000 Apr;36(1):35-46.
DMJ14OV	RU	https://pubmed.ncbi.nlm.nih.gov/10700024

DML49FI	DI	DML49FI
DML49FI	DN	R-138727
DML49FI	MI	TTZ1DT0
DML49FI	MN	P2Y purinoceptor 12 (P2RY12)
DML49FI	MT	DTT
DML49FI	MA	Antagonist
DML49FI	RN	Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor. Thromb Haemost. 2005 Sep;94(3):593-8.
DML49FI	RU	https://pubmed.ncbi.nlm.nih.gov/16268477

DMX80BL	DI	DMX80BL
DMX80BL	DN	R214127
DMX80BL	MI	TTVBPDM
DMX80BL	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMX80BL	MT	DTT
DMX80BL	MA	Modulator (allosteric modulator)
DMX80BL	RN	[3H]R214127: a novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists. Mol Pharmacol. 2003 May;63(5):1082-93.
DMX80BL	RU	https://pubmed.ncbi.nlm.nih.gov/12695537

DM4BP7S	DI	DM4BP7S
DM4BP7S	DN	R-226161
DM4BP7S	MI	TTNGILX
DM4BP7S	MN	Adrenergic receptor alpha-1A (ADRA1A)
DM4BP7S	MT	DTT
DM4BP7S	MA	Inhibitor
DM4BP7S	RN	Tricyclic isoxazolines: identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and alpha2-a... Bioorg Med Chem. 2007 Jun 1;15(11):3649-60.
DM4BP7S	RU	https://pubmed.ncbi.nlm.nih.gov/17407815

DM4BP7S	DI	DM4BP7S
DM4BP7S	DN	R-226161
DM4BP7S	MI	TTWG9A4
DM4BP7S	MN	Adrenergic receptor alpha-2A (ADRA2A)
DM4BP7S	MT	DTT
DM4BP7S	MA	Inhibitor
DM4BP7S	RN	Tricyclic isoxazolines: identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and alpha2-a... Bioorg Med Chem. 2007 Jun 1;15(11):3649-60.
DM4BP7S	RU	https://pubmed.ncbi.nlm.nih.gov/17407815

DM4BP7S	DI	DM4BP7S
DM4BP7S	DN	R-226161
DM4BP7S	MI	TTWM4TY
DM4BP7S	MN	Adrenergic receptor alpha-2B (ADRA2B)
DM4BP7S	MT	DTT
DM4BP7S	MA	Inhibitor
DM4BP7S	RN	Tricyclic isoxazolines: identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and alpha2-a... Bioorg Med Chem. 2007 Jun 1;15(11):3649-60.
DM4BP7S	RU	https://pubmed.ncbi.nlm.nih.gov/17407815

DM4BP7S	DI	DM4BP7S
DM4BP7S	DN	R-226161
DM4BP7S	MI	TT2NUT5
DM4BP7S	MN	Adrenergic receptor alpha-2C (ADRA2C)
DM4BP7S	MT	DTT
DM4BP7S	MA	Inhibitor
DM4BP7S	RN	Tricyclic isoxazolines: identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and alpha2-a... Bioorg Med Chem. 2007 Jun 1;15(11):3649-60.
DM4BP7S	RU	https://pubmed.ncbi.nlm.nih.gov/17407815

DM4BP7S	DI	DM4BP7S
DM4BP7S	DN	R-226161
DM4BP7S	MI	TT4C8EA
DM4BP7S	MN	Dopamine D3 receptor (D3R)
DM4BP7S	MT	DTT
DM4BP7S	MA	Inhibitor
DM4BP7S	RN	Tricyclic isoxazolines: identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and alpha2-a... Bioorg Med Chem. 2007 Jun 1;15(11):3649-60.
DM4BP7S	RU	https://pubmed.ncbi.nlm.nih.gov/17407815

DM4BP7S	DI	DM4BP7S
DM4BP7S	DN	R-226161
DM4BP7S	MI	TTVBI8W
DM4BP7S	MN	Dopamine transporter (DAT)
DM4BP7S	MT	DTT
DM4BP7S	MA	Inhibitor
DM4BP7S	RN	Tricyclic isoxazolines: identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and alpha2-a... Bioorg Med Chem. 2007 Jun 1;15(11):3649-60.
DM4BP7S	RU	https://pubmed.ncbi.nlm.nih.gov/17407815

DM4BP7S	DI	DM4BP7S
DM4BP7S	DN	R-226161
DM4BP7S	MI	TTTIBOJ
DM4BP7S	MN	Histamine H1 receptor (H1R)
DM4BP7S	MT	DTT
DM4BP7S	MA	Inhibitor
DM4BP7S	RN	Tricyclic isoxazolines: identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and alpha2-a... Bioorg Med Chem. 2007 Jun 1;15(11):3649-60.
DM4BP7S	RU	https://pubmed.ncbi.nlm.nih.gov/17407815

DM4BP7S	DI	DM4BP7S
DM4BP7S	DN	R-226161
DM4BP7S	MI	TT3ROYC
DM4BP7S	MN	Serotonin transporter (SERT)
DM4BP7S	MT	DTT
DM4BP7S	MA	Inhibitor
DM4BP7S	RN	Tricyclic isoxazolines: identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and alpha2-a... Bioorg Med Chem. 2007 Jun 1;15(11):3649-60.
DM4BP7S	RU	https://pubmed.ncbi.nlm.nih.gov/17407815

DM4BP7S	DI	DM4BP7S
DM4BP7S	DN	R-226161
DM4BP7S	MI	TTZPO1L
DM4BP7S	MN	Substance-P receptor (TACR1)
DM4BP7S	MT	DTT
DM4BP7S	MA	Inhibitor
DM4BP7S	RN	Tricyclic isoxazolines: identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and alpha2-a... Bioorg Med Chem. 2007 Jun 1;15(11):3649-60.
DM4BP7S	RU	https://pubmed.ncbi.nlm.nih.gov/17407815

DM1OPZ9	DI	DM1OPZ9
DM1OPZ9	DN	R396
DM1OPZ9	MI	TTYO0A3
DM1OPZ9	MN	Substance-K receptor (TACR2)
DM1OPZ9	MT	DTT
DM1OPZ9	MA	Antagonist
DM1OPZ9	RN	Characterization of the binding sites of [3H]SR 48968, a potent nonpeptide radioligand antagonist of the neurokinin-2 receptor. Biochem Biophys Res Commun. 1993 Mar 31;191(3):1172-7.
DM1OPZ9	RU	https://pubmed.ncbi.nlm.nih.gov/7682062

DMSHMIK	DI	DMSHMIK
DMSHMIK	DN	R-65
DMSHMIK	MI	TT1ZAVI
DMSHMIK	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DMSHMIK	MT	DTT
DMSHMIK	MA	Modulator
DMSHMIK	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 341).
DMSHMIK	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=341

DMHX9CT	DI	DMHX9CT
DMHX9CT	DN	R-820
DMHX9CT	MI	TTBPGLU
DMHX9CT	MN	Neuromedin-K receptor (TACR3)
DMHX9CT	MT	DTT
DMHX9CT	MA	Antagonist
DMHX9CT	RN	Implication of nigral tachykinin NK3 receptors in the maintenance of hypertension in spontaneously hypertensive rats: a pharmacologic and autoradiographic study. Br J Pharmacol. 2003 Feb;138(4):554-63.
DMHX9CT	RU	https://pubmed.ncbi.nlm.nih.gov/12598409

DM1MIRJ	DI	DM1MIRJ
DM1MIRJ	DN	R-84
DM1MIRJ	MI	TTUTJGQ
DM1MIRJ	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM1MIRJ	MT	DTT
DM1MIRJ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1813).
DM1MIRJ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1813

DM2QN0S	DI	DM2QN0S
DM2QN0S	DN	R-87027
DM2QN0S	MI	TT84ETX
DM2QN0S	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM2QN0S	MT	DTT
DM2QN0S	MA	Inhibitor
DM2QN0S	RN	Prediction of binding affinities for TIBO inhibitors of HIV-1 reverse transcriptase using Monte Carlo simulations in a linear response method. J Med Chem. 1998 Dec 17;41(26):5272-86.
DM2QN0S	RU	https://pubmed.ncbi.nlm.nih.gov/9857095

DMTUR6C	DI	DMTUR6C
DMTUR6C	DN	Rac-2-amino-4-phenylbutanoic acid
DMTUR6C	MI	TTFK1JQ
DMTUR6C	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMTUR6C	MT	DTT
DMTUR6C	MA	Inhibitor
DMTUR6C	RN	Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41.
DMTUR6C	RU	https://pubmed.ncbi.nlm.nih.gov/16380257

DMU0746	DI	DMU0746
DMU0746	DN	Rac-2-amino-5-cyclohexylpentanoic acid
DMU0746	MI	TTFK1JQ
DMU0746	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMU0746	MT	DTT
DMU0746	MA	Inhibitor
DMU0746	RN	Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41.
DMU0746	RU	https://pubmed.ncbi.nlm.nih.gov/16380257

DMD5TPH	DI	DMD5TPH
DMD5TPH	DN	Rac-2q
DMD5TPH	MI	TT8VUE0
DMD5TPH	MN	Chymase (CYM)
DMD5TPH	MT	DTT
DMD5TPH	MA	Inhibitor
DMD5TPH	RN	Identification of 6-substituted 4-arylsulfonyl-1,4-diazepane-2,5-diones as a novel scaffold for human chymase inhibitors. Bioorg Med Chem Lett. 2007 Jun 15;17(12):3431-4.
DMD5TPH	RU	https://pubmed.ncbi.nlm.nih.gov/17419055

DMTN7IU	DI	DMTN7IU
DMTN7IU	DN	Rac-4'-(1-Imidazol-1-yl-propyl)-biphenyl-3,4-diol
DMTN7IU	MI	TTRA5BZ
DMTN7IU	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMTN7IU	MT	DTT
DMTN7IU	MA	Inhibitor
DMTN7IU	RN	Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy- and hydroxy-substituted methyl... Eur J Med Chem. 2009 Jul;44(7):2765-75.
DMTN7IU	RU	https://pubmed.ncbi.nlm.nih.gov/19211174

DMQYRAB	DI	DMQYRAB
DMQYRAB	DN	Rac-4'-(1-Imidazol-1-yl-propyl)-biphenyl-3,5-diol
DMQYRAB	MI	TTRA5BZ
DMQYRAB	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMQYRAB	MT	DTT
DMQYRAB	MA	Inhibitor
DMQYRAB	RN	Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy- and hydroxy-substituted methyl... Eur J Med Chem. 2009 Jul;44(7):2765-75.
DMQYRAB	RU	https://pubmed.ncbi.nlm.nih.gov/19211174

DMH2CX5	DI	DMH2CX5
DMH2CX5	DN	Rac-4'-(1-Imidazol-1-yl-propyl)-biphenyl-3-ol
DMH2CX5	MI	TTRA5BZ
DMH2CX5	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMH2CX5	MT	DTT
DMH2CX5	MA	Inhibitor
DMH2CX5	RN	Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy- and hydroxy-substituted methyl... Eur J Med Chem. 2009 Jul;44(7):2765-75.
DMH2CX5	RU	https://pubmed.ncbi.nlm.nih.gov/19211174

DMUQ6FW	DI	DMUQ6FW
DMUQ6FW	DN	Rac-4'-(1-Imidazol-1-yl-propyl)-biphenyl-4-ol
DMUQ6FW	MI	TTRA5BZ
DMUQ6FW	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMUQ6FW	MT	DTT
DMUQ6FW	MA	Inhibitor
DMUQ6FW	RN	Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy- and hydroxy-substituted methyl... Eur J Med Chem. 2009 Jul;44(7):2765-75.
DMUQ6FW	RU	https://pubmed.ncbi.nlm.nih.gov/19211174

DMR8L6O	DI	DMR8L6O
DMR8L6O	DN	Rac-cis-N-arachidonoylcyclopropanolamide
DMR8L6O	MI	TT6OEDT
DMR8L6O	MN	Cannabinoid receptor 1 (CB1)
DMR8L6O	MT	DTT
DMR8L6O	MA	Inhibitor
DMR8L6O	RN	Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. J Med Chem. 2009 May 14;52(9):3001-9.
DMR8L6O	RU	https://pubmed.ncbi.nlm.nih.gov/19361197

DMR8L6O	DI	DMR8L6O
DMR8L6O	DN	Rac-cis-N-arachidonoylcyclopropanolamide
DMR8L6O	MI	TTMSFAW
DMR8L6O	MN	Cannabinoid receptor 2 (CB2)
DMR8L6O	MT	DTT
DMR8L6O	MA	Inhibitor
DMR8L6O	RN	Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. J Med Chem. 2009 May 14;52(9):3001-9.
DMR8L6O	RU	https://pubmed.ncbi.nlm.nih.gov/19361197

DM39FSQ	DI	DM39FSQ
DM39FSQ	DN	Racemic DOI
DM39FSQ	MI	TTJQOD7
DM39FSQ	MN	5-HT 2A receptor (HTR2A)
DM39FSQ	MT	DTT
DM39FSQ	MA	Inhibitor
DM39FSQ	RN	The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands. Bioorg Med Chem. 2008 Apr 15;16(8):4661-9.
DM39FSQ	RU	https://pubmed.ncbi.nlm.nih.gov/18296055

DM39FSQ	DI	DM39FSQ
DM39FSQ	DN	Racemic DOI
DM39FSQ	MI	TT0K1SC
DM39FSQ	MN	5-HT 2B receptor (HTR2B)
DM39FSQ	MT	DTT
DM39FSQ	MA	Inhibitor
DM39FSQ	RN	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
DM39FSQ	RU	https://pubmed.ncbi.nlm.nih.gov/18983139

DMNLCUH	DI	DMNLCUH
DMNLCUH	DN	Racemic DOTFM
DMNLCUH	MI	TTJQOD7
DMNLCUH	MN	5-HT 2A receptor (HTR2A)
DMNLCUH	MT	DTT
DMNLCUH	MA	Inhibitor
DMNLCUH	RN	The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands. Bioorg Med Chem. 2008 Apr 15;16(8):4661-9.
DMNLCUH	RU	https://pubmed.ncbi.nlm.nih.gov/18296055

DM9DA8O	DI	DM9DA8O
DM9DA8O	DN	Rac-trans-N-oleoylcyclopropanolamide
DM9DA8O	MI	TT6OEDT
DM9DA8O	MN	Cannabinoid receptor 1 (CB1)
DM9DA8O	MT	DTT
DM9DA8O	MA	Inhibitor
DM9DA8O	RN	Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. J Med Chem. 2009 May 14;52(9):3001-9.
DM9DA8O	RU	https://pubmed.ncbi.nlm.nih.gov/19361197

DM9DA8O	DI	DM9DA8O
DM9DA8O	DN	Rac-trans-N-oleoylcyclopropanolamide
DM9DA8O	MI	TTMSFAW
DM9DA8O	MN	Cannabinoid receptor 2 (CB2)
DM9DA8O	MT	DTT
DM9DA8O	MA	Inhibitor
DM9DA8O	RN	Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. J Med Chem. 2009 May 14;52(9):3001-9.
DM9DA8O	RU	https://pubmed.ncbi.nlm.nih.gov/19361197

DMNZS94	DI	DMNZS94
DMNZS94	DN	Radicicol
DMNZS94	MI	TT78R5H
DMNZS94	MN	Heat shock protein 90 alpha (HSP90A)
DMNZS94	MT	DTT
DMNZS94	MA	Inhibitor
DMNZS94	RN	High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity. Anal Biochem. 2004 Apr 15;327(2):176-83.
DMNZS94	RU	https://pubmed.ncbi.nlm.nih.gov/15051534

DMVHDOS	DI	DMVHDOS
DMVHDOS	DN	Raffinose
DMVHDOS	MI	DEJRWQ6
DMVHDOS	MN	Alpha-galactosidase (melA)
DMVHDOS	MT	DME
DMVHDOS	MA	Metabolism
DMVHDOS	RN	Crystal structure of alpha-galactosidase from Lactobacillus acidophilus NCFM: insight into tetramer formation and substrate binding. J Mol Biol. 2011 Sep 23;412(3):466-80.
DMVHDOS	RU	https://pubmed.ncbi.nlm.nih.gov/21827767

DMVHDOS	DI	DMVHDOS
DMVHDOS	DN	Raffinose
DMVHDOS	MI	DEUOBTJ
DMVHDOS	MN	Alpha-galactosidase (melA)
DMVHDOS	MT	DME
DMVHDOS	MA	Metabolism
DMVHDOS	RN	Use of an alpha-galactosidase gene as a food-grade selection marker for Streptococcus thermophilus. J Dairy Sci. 2005 Jul;88(7):2341-7.
DMVHDOS	RU	https://pubmed.ncbi.nlm.nih.gov/15956297

DMVHDOS	DI	DMVHDOS
DMVHDOS	DN	Raffinose
DMVHDOS	MI	DE5EODL
DMVHDOS	MN	Beta-fructofuranosidase (BFRU)
DMVHDOS	MT	DME
DMVHDOS	MA	Metabolism
DMVHDOS	RN	Alpha-glactosidase activity of lactobacilli. Appl Microbiol. 1973 Nov;26(5):783-8.
DMVHDOS	RU	https://pubmed.ncbi.nlm.nih.gov/4796954

DMVHDOS	DI	DMVHDOS
DMVHDOS	DN	Raffinose
DMVHDOS	MI	DER8TO2
DMVHDOS	MN	Beta-fructofuranosidase (BFRU)
DMVHDOS	MT	DME
DMVHDOS	MA	Metabolism
DMVHDOS	RN	Alpha-glactosidase activity of lactobacilli. Appl Microbiol. 1973 Nov;26(5):783-8.
DMVHDOS	RU	https://pubmed.ncbi.nlm.nih.gov/4796954

DMVHDOS	DI	DMVHDOS
DMVHDOS	DN	Raffinose
DMVHDOS	MI	DEET5ZQ
DMVHDOS	MN	Beta-fructofuranosidase (BFRU)
DMVHDOS	MT	DME
DMVHDOS	MA	Metabolism
DMVHDOS	RN	Alpha-glactosidase activity of lactobacilli. Appl Microbiol. 1973 Nov;26(5):783-8.
DMVHDOS	RU	https://pubmed.ncbi.nlm.nih.gov/4796954

DMVHDOS	DI	DMVHDOS
DMVHDOS	DN	Raffinose
DMVHDOS	MI	DEBUN2V
DMVHDOS	MN	Beta-galactosidase (bgaB)
DMVHDOS	MT	DME
DMVHDOS	MA	Metabolism
DMVHDOS	RN	Differential proteome and cellular adhesion analyses of the probiotic bacterium Lactobacillus acidophilus NCFM grown on raffinose - an emerging prebiotic. Proteomics. 2016 May;16(9):1361-75.
DMVHDOS	RU	https://pubmed.ncbi.nlm.nih.gov/26959526

DMVHDOS	DI	DMVHDOS
DMVHDOS	DN	Raffinose
DMVHDOS	MI	DE4IPGZ
DMVHDOS	MN	Sucrose phosphorylase (Spase)
DMVHDOS	MT	DME
DMVHDOS	MA	Metabolism
DMVHDOS	RN	Differential proteome and cellular adhesion analyses of the probiotic bacterium Lactobacillus acidophilus NCFM grown on raffinose - an emerging prebiotic. Proteomics. 2016 May;16(9):1361-75.
DMVHDOS	RU	https://pubmed.ncbi.nlm.nih.gov/26959526

DMI7NAF	DI	DMI7NAF
DMI7NAF	DN	ranatensin
DMI7NAF	MI	TTHYDUM
DMI7NAF	MN	Bombesin receptor (BS)
DMI7NAF	MT	DTT
DMI7NAF	MA	Agonist
DMI7NAF	RN	Pharmacology and cell biology of the bombesin receptor subtype 4 (BB4-R). Biochemistry. 1999 Jun 1;38(22):7307-20.
DMI7NAF	RU	https://pubmed.ncbi.nlm.nih.gov/10353842

DMI7NAF	DI	DMI7NAF
DMI7NAF	DN	ranatensin
DMI7NAF	MI	TTC1MVT
DMI7NAF	MN	Gastrin-releasing peptide receptor (GRPR)
DMI7NAF	MT	DTT
DMI7NAF	MA	Agonist
DMI7NAF	RN	Pharmacology and cell biology of the bombesin receptor subtype 4 (BB4-R). Biochemistry. 1999 Jun 1;38(22):7307-20.
DMI7NAF	RU	https://pubmed.ncbi.nlm.nih.gov/10353842

DM961JG	DI	DM961JG
DM961JG	DN	RAP-103
DM961JG	MI	TTFZYTO
DM961JG	MN	C-C chemokine receptor type 2 (CCR2)
DM961JG	MT	DTT
DM961JG	MA	Modulator
DM961JG	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 59).
DM961JG	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=59

DMP2DMB	DI	DMP2DMB
DMP2DMB	DN	RAP-310
DMP2DMB	MI	TTFZYTO
DMP2DMB	MN	C-C chemokine receptor type 2 (CCR2)
DMP2DMB	MT	DTT
DMP2DMB	MA	Modulator
DMP2DMB	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 59).
DMP2DMB	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=59

DM8GRJK	DI	DM8GRJK
DM8GRJK	DN	Rapamycin
DM8GRJK	MI	TT7HQAF
DM8GRJK	MN	HUMAN mammalian target of rapamycin (mTOR)
DM8GRJK	MT	DTT
DM8GRJK	MA	Inhibitor
DM8GRJK	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DM8GRJK	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DMLBP3F	DI	DMLBP3F
DMLBP3F	DN	Rapamycin complexed with immunophilin FKBP12
DMLBP3F	MI	TTCJG29
DMLBP3F	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMLBP3F	MT	DTT
DMLBP3F	MA	Inhibitor
DMLBP3F	RN	Selected novel anticancer treatments targeting cell signaling proteins. Oncologist. 2001;6(6):517-37.
DMLBP3F	RU	https://pubmed.ncbi.nlm.nih.gov/11743214

DM678IB	DI	DM678IB
DM678IB	DN	Rapamycin Immunosuppressant Drug
DM678IB	MI	TTMW94E
DM678IB	MN	FK506-binding protein 1A (FKBP1A)
DM678IB	MT	DTT
DM678IB	MA	Inhibitor
DM678IB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM678IB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9XOE6	DI	DM9XOE6
DM9XOE6	DN	rawsonol
DM9XOE6	MI	TTPADOQ
DM9XOE6	MN	HMG-CoA reductase (HMGCR)
DM9XOE6	MT	DTT
DM9XOE6	MA	Modulator
DM9XOE6	RN	Bromophenols in Marine Algae and Their Bioactivities
DM9XOE6	RU	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3148503

DMPML15	DI	DMPML15
DMPML15	DN	RAZAXABAN
DMPML15	MI	TT6L509
DMPML15	MN	Coagulation factor IIa (F2)
DMPML15	MT	DTT
DMPML15	MA	Inhibitor
DMPML15	RN	Phenyltriazolinones as potent factor Xa inhibitors. Bioorg Med Chem Lett. 2010 Feb 15;20(4):1373-7.
DMPML15	RU	https://pubmed.ncbi.nlm.nih.gov/20100660

DMPML15	DI	DMPML15
DMPML15	DN	RAZAXABAN
DMPML15	MI	TTFEZ5Q
DMPML15	MN	Coagulation factor IX (F9)
DMPML15	MT	DTT
DMPML15	MA	Inhibitor
DMPML15	RN	Aminobenzisoxazoles with biaryl P4 moieties as potent, selective, and orally bioavailable factor Xa inhibitors. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1795-8.
DMPML15	RU	https://pubmed.ncbi.nlm.nih.gov/16434195

DMPML15	DI	DMPML15
DMPML15	DN	RAZAXABAN
DMPML15	MI	TT1O264
DMPML15	MN	Coagulation factor Va (F5)
DMPML15	MT	DTT
DMPML15	MA	Inhibitor
DMPML15	RN	Aminobenzisoxazoles with biaryl P4 moieties as potent, selective, and orally bioavailable factor Xa inhibitors. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1795-8.
DMPML15	RU	https://pubmed.ncbi.nlm.nih.gov/16434195

DMPML15	DI	DMPML15
DMPML15	DN	RAZAXABAN
DMPML15	MI	TTCIHJA
DMPML15	MN	Coagulation factor Xa (F10)
DMPML15	MT	DTT
DMPML15	MA	Inhibitor
DMPML15	RN	Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS... J Med Chem. 2007 Nov 1;50(22):5339-56.
DMPML15	RU	https://pubmed.ncbi.nlm.nih.gov/17914785

DMCEFUW	DI	DMCEFUW
DMCEFUW	DN	RB 2
DMCEFUW	MI	TTK0O6Y
DMCEFUW	MN	Ecto-5'-nucleotidase (CD73)
DMCEFUW	MT	DTT
DMCEFUW	MA	Inhibitor
DMCEFUW	RN	Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold. J Med Chem. 2010 Mar 11;53(5):2076-86.
DMCEFUW	RU	https://pubmed.ncbi.nlm.nih.gov/20146483

DMCEFUW	DI	DMCEFUW
DMCEFUW	DN	RB 2
DMCEFUW	MI	TTOZHQC
DMCEFUW	MN	P2Y purinoceptor 2 (P2RY2)
DMCEFUW	MT	DTT
DMCEFUW	MA	Inhibitor
DMCEFUW	RN	Combinatorial synthesis of anilinoanthraquinone derivatives and evaluation as non-nucleotide-derived P2Y2 receptor antagonists. Bioorg Med Chem Lett. 2008 Jan 1;18(1):223-7.
DMCEFUW	RU	https://pubmed.ncbi.nlm.nih.gov/18006312

DMCEFUW	DI	DMCEFUW
DMCEFUW	DN	RB 2
DMCEFUW	MI	TTNVSKA
DMCEFUW	MN	P2Y purinoceptor 6 (P2RY6)
DMCEFUW	MT	DTT
DMCEFUW	MA	Inhibitor
DMCEFUW	RN	Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold. J Med Chem. 2010 Mar 11;53(5):2076-86.
DMCEFUW	RU	https://pubmed.ncbi.nlm.nih.gov/20146483

DMRK3HO	DI	DMRK3HO
DMRK3HO	DN	RB-105
DMRK3HO	MI	TTL69WB
DMRK3HO	MN	Angiotensin-converting enzyme (ACE)
DMRK3HO	MT	DTT
DMRK3HO	MA	Modulator
DMRK3HO	RN	Reversal of cardiac hypertrophy and fibrosis by S21402, a dual inhibitor of neutral endopeptidase and angiotensin converting enzyme in SHRs. J Hypertens. 2000 Jun;18(6):749-55.
DMRK3HO	RU	https://www.ncbi.nlm.nih.gov/pubmed/10872560

DMRK3HO	DI	DMRK3HO
DMRK3HO	DN	RB-105
DMRK3HO	MI	TT5TKPM
DMRK3HO	MN	Neutral endopeptidase (MME)
DMRK3HO	MT	DTT
DMRK3HO	MA	Modulator
DMRK3HO	RN	Reversal of cardiac hypertrophy and fibrosis by S21402, a dual inhibitor of neutral endopeptidase and angiotensin converting enzyme in SHRs. J Hypertens. 2000 Jun;18(6):749-55.
DMRK3HO	RU	https://www.ncbi.nlm.nih.gov/pubmed/10872560

DMJDE6Y	DI	DMJDE6Y
DMJDE6Y	DN	RB-400
DMJDE6Y	MI	TTVFO0U
DMJDE6Y	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMJDE6Y	MT	DTT
DMJDE6Y	MA	Agonist
DMJDE6Y	RN	Synthesis and biological characterisation of [3H]BBL454, a new CCK2 selective radiolabelled agonist displaying original pharmacological properties. Bioorg Med Chem Lett. 2004 Jan 19;14(2):369-72.
DMJDE6Y	RU	https://pubmed.ncbi.nlm.nih.gov/14698161

DM9IQXM	DI	DM9IQXM
DM9IQXM	DN	RBI257
DM9IQXM	MI	TTE0A2F
DM9IQXM	MN	Dopamine D4 receptor (D4R)
DM9IQXM	MT	DTT
DM9IQXM	MA	Antagonist
DM9IQXM	RN	Certain 1,4-disubstituted aromatic piperidines and piperazines with extreme selectivity for the dopamine D4 receptor interact with a common recepto... Mol Pharmacol. 2004 Dec;66(6):1491-9.
DM9IQXM	RU	https://pubmed.ncbi.nlm.nih.gov/15448188

DMNEK79	DI	DMNEK79
DMNEK79	DN	RBx-343E48F0
DMNEK79	MI	TTOXS3C
DMNEK79	MN	Muscarinic acetylcholine receptor (CHRM)
DMNEK79	MT	DTT
DMNEK79	MA	Modulator
DMNEK79	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 17).
DMNEK79	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=17

DM6FVZW	DI	DM6FVZW
DM6FVZW	DN	R-dimethindene
DM6FVZW	MI	TTTIBOJ
DM6FVZW	MN	Histamine H1 receptor (H1R)
DM6FVZW	MT	DTT
DM6FVZW	MA	Inhibitor
DM6FVZW	RN	Characterization of novel selective H1-antihistamines for clinical evaluation in the treatment of insomnia. J Med Chem. 2009 Sep 10;52(17):5307-10.
DM6FVZW	RU	https://pubmed.ncbi.nlm.nih.gov/19663387

DM6FVZW	DI	DM6FVZW
DM6FVZW	DN	R-dimethindene
DM6FVZW	MI	TTZ9SOR
DM6FVZW	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DM6FVZW	MT	DTT
DM6FVZW	MA	Inhibitor
DM6FVZW	RN	Characterization of novel selective H1-antihistamines for clinical evaluation in the treatment of insomnia. J Med Chem. 2009 Sep 10;52(17):5307-10.
DM6FVZW	RU	https://pubmed.ncbi.nlm.nih.gov/19663387

DM6FVZW	DI	DM6FVZW
DM6FVZW	DN	R-dimethindene
DM6FVZW	MI	TTQ6VDM
DM6FVZW	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DM6FVZW	MT	DTT
DM6FVZW	MA	Inhibitor
DM6FVZW	RN	Characterization of novel selective H1-antihistamines for clinical evaluation in the treatment of insomnia. J Med Chem. 2009 Sep 10;52(17):5307-10.
DM6FVZW	RU	https://pubmed.ncbi.nlm.nih.gov/19663387

DM386JM	DI	DM386JM
DM386JM	DN	Rec 15/2615
DM386JM	MI	TTBRKXS
DM386JM	MN	Adrenergic receptor alpha-1B (ADRA1B)
DM386JM	MT	DTT
DM386JM	MA	Antagonist
DM386JM	RN	Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): role of the alpha-1L adrenoceptor in tissue selectivity, part II. J Pharmacol Exp Ther. 1997 Jun;281(3):1284-93.
DM386JM	RU	https://pubmed.ncbi.nlm.nih.gov/9190864

DMJ0FCG	DI	DMJ0FCG
DMJ0FCG	DN	REC2615
DMJ0FCG	MI	TTNGILX
DMJ0FCG	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMJ0FCG	MT	DTT
DMJ0FCG	MA	Antagonist
DMJ0FCG	RN	Designing drugs for the treatment of female sexual dysfunction. Drug Discov Today. 2007 Sep;12(17-18):757-66.
DMJ0FCG	RU	https://pubmed.ncbi.nlm.nih.gov/17826689

DM1P830	DI	DM1P830
DM1P830	DN	recAAT, PPL Therapeutics/Bayer
DM1P830	MI	TT2WR1T
DM1P830	MN	Cationic trypsinogen (PRSS1)
DM1P830	MT	DTT
DM1P830	MA	Modulator
DM1P830	RN	Reduction in neutrophil elastase concentration by recombinant alphal-antitrypsin (recAAT) does not alter bacterial loading in the sputum of cystic ... Br J Biomed Sci. 2004;61(3):146-7.
DM1P830	RU	https://www.ncbi.nlm.nih.gov/pubmed/15462261

DM1XFE9	DI	DM1XFE9
DM1XFE9	DN	RECALL-VAX
DM1XFE9	MI	TTE4KHA
DM1XFE9	MN	Amyloid beta A4 protein (APP)
DM1XFE9	MT	DTT
DM1XFE9	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
DM1XFE9	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402

DM4B6FO	DI	DM4B6FO
DM4B6FO	DN	Receptor-Fc fusion proteins
DM4B6FO	MI	TTWMIDN
DM4B6FO	MN	B-cell-activating factor (TNFSF13B)
DM4B6FO	MT	DTT
DM4B6FO	RN	BAFF: B cell survival factor and emerging therapeutic target for autoimmune disorders. Expert Opin Ther Targets. 2003 Feb;7(1):115-23.
DM4B6FO	RU	https://pubmed.ncbi.nlm.nih.gov/12556207

DMA6VCG	DI	DMA6VCG
DMA6VCG	DN	Recombinant botulinum toxin
DMA6VCG	MI	TTH18TF
DMA6VCG	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMA6VCG	MT	DTT
DMA6VCG	MA	Modulator
DMA6VCG	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 467).
DMA6VCG	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=467

DMFAST4	DI	DMFAST4
DMFAST4	DN	Recombinant coagulation factors
DMFAST4	MI	TTCIHJA
DMFAST4	MN	Coagulation factor Xa (F10)
DMFAST4	MT	DTT
DMFAST4	MA	Modulator
DMFAST4	RN	Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7.
DMFAST4	RU	https://pubmed.ncbi.nlm.nih.gov/22844656

DMX6LV3	DI	DMX6LV3
DMX6LV3	DN	Recombinant Factor X
DMX6LV3	MI	TTCIHJA
DMX6LV3	MN	Coagulation factor Xa (F10)
DMX6LV3	MT	DTT
DMX6LV3	MA	Modulator
DMX6LV3	RN	Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7.
DMX6LV3	RU	https://pubmed.ncbi.nlm.nih.gov/22844656

DMNHOI3	DI	DMNHOI3
DMNHOI3	DN	Recombinant follicle stimulating hormone
DMNHOI3	MI	TTZFDBT
DMNHOI3	MN	Follicle-stimulating hormone receptor (FSHR)
DMNHOI3	MT	DTT
DMNHOI3	MA	Modulator
DMNHOI3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 253).
DMNHOI3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=253

DMM3465	DI	DMM3465
DMM3465	DN	Recombinant human butyrylcholinesterase
DMM3465	MI	TTEB0GD
DMM3465	MN	Cholinesterase (BCHE)
DMM3465	MT	DTT
DMM3465	MA	Modulator
DMM3465	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2471).
DMM3465	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2471

DMVJLR3	DI	DMVJLR3
DMVJLR3	DN	Recombinant human pro-urokinase
DMVJLR3	MI	TTGY7WI
DMVJLR3	MN	Urokinase-type plasminogen activator (PLAU)
DMVJLR3	MT	DTT
DMVJLR3	MA	Inhibitor
DMVJLR3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2393).
DMVJLR3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2393

DMLYQWV	DI	DMLYQWV
DMLYQWV	DN	Recombinant human TNF receptor
DMLYQWV	MI	TTG043C
DMLYQWV	MN	Tumor necrosis factor receptor type I (TNF-R1)
DMLYQWV	MT	DTT
DMLYQWV	MA	Modulator
DMLYQWV	RN	Secretion of a TNFR:Fc fusion protein following pulmonary administration of pseudotyped adeno-associated virus vectors. J Virol. 2004 Nov;78(22):12355-65.
DMLYQWV	RU	https://pubmed.ncbi.nlm.nih.gov/15507622

DMJQ7XD	DI	DMJQ7XD
DMJQ7XD	DN	Recombinant TSH superagonists
DMJQ7XD	MI	TT6NYJA
DMJQ7XD	MN	Thyrotropin receptor (TSHR)
DMJQ7XD	MT	DTT
DMJQ7XD	MA	Agonist
DMJQ7XD	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 255).
DMJQ7XD	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=255

DM2S496	DI	DM2S496
DM2S496	DN	Redoxal
DM2S496	MI	TT6EO5L
DM2S496	MN	Erbb2 tyrosine kinase receptor (HER2)
DM2S496	MT	DTT
DM2S496	RN	A new human antitumor immunoreagent specific for ErbB2. Clin Cancer Res. 2002 Jun;8(6):1710-9.
DM2S496	RU	https://pubmed.ncbi.nlm.nih.gov/12060608

DM2S496	DI	DM2S496
DM2S496	DN	Redoxal
DM2S496	MI	TT3PQ2Y
DM2S496	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DM2S496	MT	DTT
DM2S496	MA	Inhibitor
DM2S496	RN	Malarial dihydroorotate dehydrogenase. Substrate and inhibitor specificity. J Biol Chem. 2002 Nov 1;277(44):41827-34.
DM2S496	RU	https://pubmed.ncbi.nlm.nih.gov/12189151

DMQ3ER0	DI	DMQ3ER0
DMQ3ER0	DN	reglitazar
DMQ3ER0	MI	TTJ584C
DMQ3ER0	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMQ3ER0	MT	DTT
DMQ3ER0	MA	Agonist
DMQ3ER0	RN	Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative. Eur J Pharmacol. 1999 Jan 8;364(2-3):211-9.
DMQ3ER0	RU	https://pubmed.ncbi.nlm.nih.gov/9932726

DMQ3ER0	DI	DMQ3ER0
DMQ3ER0	DN	reglitazar
DMQ3ER0	MI	TTT2SVW
DMQ3ER0	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DMQ3ER0	MT	DTT
DMQ3ER0	MA	Agonist
DMQ3ER0	RN	Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative. Eur J Pharmacol. 1999 Jan 8;364(2-3):211-9.
DMQ3ER0	RU	https://pubmed.ncbi.nlm.nih.gov/9932726

DM3AWPB	DI	DM3AWPB
DM3AWPB	DN	Relcovaptan
DM3AWPB	MI	TT4TFGN
DM3AWPB	MN	Vasopressin V1a receptor (V1AR)
DM3AWPB	MT	DTT
DM3AWPB	MA	Inhibitor
DM3AWPB	RN	Binding of [3H] SR 49059, a potent nonpeptide vasopressin V1a antagonist, to rat and human liver membranes. Biochem Biophys Res Commun. 1994 Feb 28;199(1):353-60.
DM3AWPB	RU	https://pubmed.ncbi.nlm.nih.gov/8123034

DM47TSV	DI	DM47TSV
DM47TSV	DN	Repinotan
DM47TSV	MI	TTSQIFT
DM47TSV	MN	5-HT 1A receptor (HTR1A)
DM47TSV	MT	DTT
DM47TSV	MA	Antagonist
DM47TSV	RN	Characterization of the aminomethylchroman derivative BAY x 3702 as a highly potent 5-hydroxytryptamine1A receptor agonist. J Pharmacol Exp Ther. 1998 Mar;284(3):1082-94.
DM47TSV	RU	https://pubmed.ncbi.nlm.nih.gov/9495870

DM47TSV	DI	DM47TSV
DM47TSV	DN	Repinotan
DM47TSV	MI	DECB0K3
DM47TSV	MN	Cytochrome P450 2D6 (CYP2D6)
DM47TSV	MT	DME
DM47TSV	MA	Metabolism
DM47TSV	RN	Evaluation of interethnic differences in repinotan pharmacokinetics by using population approach. Drug Metab Pharmacokinet. 2006 Feb;21(1):61-9.
DM47TSV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16547395

DMQEBKF	DI	DMQEBKF
DMQEBKF	DN	RES-701-1-C-terminal analogue
DMQEBKF	MI	TT3ZTGU
DMQEBKF	MN	Endothelin B receptor (EDNRB)
DMQEBKF	MT	DTT
DMQEBKF	MA	Inhibitor
DMQEBKF	RN	Analogs of an endothelin antagonist RES-701-1: substitutions of C-terminal amino acid, Bioorg. Med. Chem. Lett. 6(7):775-778 (1996).
DMQEBKF	RU	http://www.sciencedirect.com/science/article/pii/0960894X96001278

DM2IBND	DI	DM2IBND
DM2IBND	DN	RESCOVITINE
DM2IBND	MI	TTAMQ62
DM2IBND	MN	Cyclin A2 (CCNA2)
DM2IBND	MT	DTT
DM2IBND	MA	Inhibitor
DM2IBND	RN	Design, synthesis, and biological evaluation of novel pyrimidine derivatives as CDK2 inhibitors. Eur J Med Chem. 2010 Mar;45(3):1158-66.
DM2IBND	RU	https://pubmed.ncbi.nlm.nih.gov/20045222

DM2IBND	DI	DM2IBND
DM2IBND	DN	RESCOVITINE
DM2IBND	MI	TT7HF4W
DM2IBND	MN	Cyclin-dependent kinase 2 (CDK2)
DM2IBND	MT	DTT
DM2IBND	MA	Inhibitor
DM2IBND	RN	Design, synthesis, and biological evaluation of novel pyrimidine derivatives as CDK2 inhibitors. Eur J Med Chem. 2010 Mar;45(3):1158-66.
DM2IBND	RU	https://pubmed.ncbi.nlm.nih.gov/20045222

DMLVU6H	DI	DMLVU6H
DMLVU6H	DN	resolvin D2
DMLVU6H	MI	TTELV3W
DMLVU6H	MN	Transformation-sensitive protein p120 (TRPA1)
DMLVU6H	MT	DTT
DMLVU6H	MA	Inhibitor (gating inhibitor)
DMLVU6H	RN	Resolvin D2 is a potent endogenous inhibitor for transient receptor potential subtype V1/A1, inflammatory pain, and spinal cord synaptic plasticity in mice: distinct roles of resolvin D1, D2, and E1.J Neurosci. 2011 Dec 14;31(50):18433-8.
DMLVU6H	RU	https://pubmed.ncbi.nlm.nih.gov/22171045

DMM37C0	DI	DMM37C0
DMM37C0	DN	Resorcinol
DMM37C0	MI	TTUNARX
DMM37C0	MN	Carbonic anhydrase (CA)
DMM37C0	MT	DTT
DMM37C0	MA	Inhibitor
DMM37C0	RN	Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8.
DMM37C0	RU	https://pubmed.ncbi.nlm.nih.gov/18579385

DMM37C0	DI	DMM37C0
DMM37C0	DN	Resorcinol
DMM37C0	MI	TTANPDJ
DMM37C0	MN	Carbonic anhydrase II (CA-II)
DMM37C0	MT	DTT
DMM37C0	MA	Inhibitor
DMM37C0	RN	Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8.
DMM37C0	RU	https://pubmed.ncbi.nlm.nih.gov/18579385

DMM37C0	DI	DMM37C0
DMM37C0	DN	Resorcinol
DMM37C0	MI	TTSYM0R
DMM37C0	MN	Carbonic anhydrase XII (CA-XII)
DMM37C0	MT	DTT
DMM37C0	MA	Inhibitor
DMM37C0	RN	Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8.
DMM37C0	RU	https://pubmed.ncbi.nlm.nih.gov/18579385

DMM37C0	DI	DMM37C0
DMM37C0	DN	Resorcinol
DMM37C0	MI	TTEYTKG
DMM37C0	MN	Carbonic anhydrase XIV (CA-XIV)
DMM37C0	MT	DTT
DMM37C0	MA	Inhibitor
DMM37C0	RN	Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8.
DMM37C0	RU	https://pubmed.ncbi.nlm.nih.gov/18579385

DMM37C0	DI	DMM37C0
DMM37C0	DN	Resorcinol
DMM37C0	MI	DEWRN24
DMM37C0	MN	Glucansucrase (gtf106B)
DMM37C0	MT	DME
DMM37C0	MA	Metabolism
DMM37C0	RN	Increased infections with beta-blocker use in ischemic stroke, a beta2-receptor mediated process? Neurol Sci. 2017 Jun;38(6):967-974.
DMM37C0	RU	https://pubmed.ncbi.nlm.nih.gov/28258316

DMM37C0	DI	DMM37C0
DMM37C0	DN	Resorcinol
DMM37C0	MI	TT8NGED
DMM37C0	MN	Prostaglandin G/H synthase 1 (COX-1)
DMM37C0	MT	DTT
DMM37C0	MA	Inhibitor
DMM37C0	RN	Mechanism-based inactivation of COX-1 by red wine m-hydroquinones: a structure-activity relationship study. J Nat Prod. 2004 Nov;67(11):1777-82.
DMM37C0	RU	https://pubmed.ncbi.nlm.nih.gov/15568761

DMN1RLA	DI	DMN1RLA
DMN1RLA	DN	Resveratrol Potassium3-Sulfate
DMN1RLA	MI	TT8NGED
DMN1RLA	MN	Prostaglandin G/H synthase 1 (COX-1)
DMN1RLA	MT	DTT
DMN1RLA	MA	Inhibitor
DMN1RLA	RN	Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J Med Chem. 2010 Jul 8;53(13):5033-43.
DMN1RLA	RU	https://pubmed.ncbi.nlm.nih.gov/20527891

DMN1RLA	DI	DMN1RLA
DMN1RLA	DN	Resveratrol Potassium3-Sulfate
DMN1RLA	MI	TTVKILB
DMN1RLA	MN	Prostaglandin G/H synthase 2 (COX-2)
DMN1RLA	MT	DTT
DMN1RLA	MA	Inhibitor
DMN1RLA	RN	Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J Med Chem. 2010 Jul 8;53(13):5033-43.
DMN1RLA	RU	https://pubmed.ncbi.nlm.nih.gov/20527891

DMMFP57	DI	DMMFP57
DMMFP57	DN	Resveratrol Potassium4,-Sulfate
DMMFP57	MI	TTF10I9
DMMFP57	MN	Nitric-oxide synthase inducible (NOS2)
DMMFP57	MT	DTT
DMMFP57	MA	Inhibitor
DMMFP57	RN	Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J Med Chem. 2010 Jul 8;53(13):5033-43.
DMMFP57	RU	https://pubmed.ncbi.nlm.nih.gov/20527891

DMMFP57	DI	DMMFP57
DMMFP57	DN	Resveratrol Potassium4,-Sulfate
DMMFP57	MI	TT8NGED
DMMFP57	MN	Prostaglandin G/H synthase 1 (COX-1)
DMMFP57	MT	DTT
DMMFP57	MA	Inhibitor
DMMFP57	RN	Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J Med Chem. 2010 Jul 8;53(13):5033-43.
DMMFP57	RU	https://pubmed.ncbi.nlm.nih.gov/20527891

DMMFP57	DI	DMMFP57
DMMFP57	DN	Resveratrol Potassium4,-Sulfate
DMMFP57	MI	TTVKILB
DMMFP57	MN	Prostaglandin G/H synthase 2 (COX-2)
DMMFP57	MT	DTT
DMMFP57	MA	Inhibitor
DMMFP57	RN	Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J Med Chem. 2010 Jul 8;53(13):5033-43.
DMMFP57	RU	https://pubmed.ncbi.nlm.nih.gov/20527891

DMQFSI5	DI	DMQFSI5
DMQFSI5	DN	Retagliptin
DMQFSI5	MI	TTDIGC1
DMQFSI5	MN	Dipeptidyl peptidase 4 (DPP-4)
DMQFSI5	MT	DTT
DMQFSI5	MA	Inhibitor
DMQFSI5	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1612).
DMQFSI5	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1612

DMWDNOK	DI	DMWDNOK
DMWDNOK	DN	REVERSINE
DMWDNOK	MI	TTJFY5U
DMWDNOK	MN	Adenosine A3 receptor (ADORA3)
DMWDNOK	MT	DTT
DMWDNOK	MA	Inhibitor
DMWDNOK	RN	Reversine and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem. 2005 Jul 28;48(15):4910-8.
DMWDNOK	RU	https://pubmed.ncbi.nlm.nih.gov/16033270

DMWDNOK	DI	DMWDNOK
DMWDNOK	DN	REVERSINE
DMWDNOK	MI	TTIDAPM
DMWDNOK	MN	ERK activator kinase 1 (MEK1)
DMWDNOK	MT	DTT
DMWDNOK	MA	Inhibitor
DMWDNOK	RN	Reversine increases the plasticity of lineage-committed mammalian cells. Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10482-7.
DMWDNOK	RU	https://pubmed.ncbi.nlm.nih.gov/17566101

DM3IXEA	DI	DM3IXEA
DM3IXEA	DN	RF9
DM3IXEA	MI	TTEP027
DM3IXEA	MN	Neuropeptide FF receptor 1 (NPFFR1)
DM3IXEA	MT	DTT
DM3IXEA	MA	Antagonist
DM3IXEA	RN	RF9, a potent and selective neuropeptide FF receptor antagonist, prevents opioid-induced tolerance associated with hyperalgesia. Proc Natl Acad Sci U S A. 2006 Jan 10;103(2):466-71.
DM3IXEA	RU	https://pubmed.ncbi.nlm.nih.gov/16407169

DM3IXEA	DI	DM3IXEA
DM3IXEA	DN	RF9
DM3IXEA	MI	TTXYNDJ
DM3IXEA	MN	Neuropeptide FF receptor 2 (NPFFR2)
DM3IXEA	MT	DTT
DM3IXEA	MA	Antagonist
DM3IXEA	RN	RF9, a potent and selective neuropeptide FF receptor antagonist, prevents opioid-induced tolerance associated with hyperalgesia. Proc Natl Acad Sci U S A. 2006 Jan 10;103(2):466-71.
DM3IXEA	RU	https://pubmed.ncbi.nlm.nih.gov/16407169

DMJG4U0	DI	DMJG4U0
DMJG4U0	DN	R-fadrozole
DMJG4U0	MI	TTIQUX7
DMJG4U0	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMJG4U0	MT	DTT
DMJG4U0	MA	Inhibitor
DMJG4U0	RN	Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25.
DMJG4U0	RU	https://pubmed.ncbi.nlm.nih.gov/20121113

DMUR9LM	DI	DMUR9LM
DMUR9LM	DN	RG-50810
DMUR9LM	MI	TTGKNB4
DMUR9LM	MN	Epidermal growth factor receptor (EGFR)
DMUR9LM	MT	DTT
DMUR9LM	MA	Inhibitor
DMUR9LM	RN	Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J Nat Prod. 1992 Nov;55(11):1529-60.
DMUR9LM	RU	https://pubmed.ncbi.nlm.nih.gov/1479375

DMGYWIK	DI	DMGYWIK
DMGYWIK	DN	RG6046
DMGYWIK	MI	TTZAYWL
DMGYWIK	MN	Estrogen receptor (ESR)
DMGYWIK	MT	DTT
DMGYWIK	MA	Modulator
DMGYWIK	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMGYWIK	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMSTL12	DI	DMSTL12
DMSTL12	DN	RG7232
DMSTL12	MI	TTJW1GN
DMSTL12	MN	ATP-binding cassette transporter A1 (ABCA1)
DMSTL12	MT	DTT
DMSTL12	MA	Modulator
DMSTL12	RN	Analysis of "On/Off" Kinetics of a CETP Inhibitor Using a Mechanistic Model of Lipoprotein Metabolism and Kinetics. CPT Pharmacometrics Syst Pharmacol. 2015 Aug;4(8):465-73.
DMSTL12	RU	https://pubmed.ncbi.nlm.nih.gov/26380155

DMP08BY	DI	DMP08BY
DMP08BY	DN	RGB-286147
DMP08BY	MI	TTO0FDJ
DMP08BY	MN	Cyclin-dependent kinase 6 (CDK6)
DMP08BY	MT	DTT
DMP08BY	MA	Inhibitor
DMP08BY	RN	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
DMP08BY	RU	https://pubmed.ncbi.nlm.nih.gov/18077363

DMP08BY	DI	DMP08BY
DMP08BY	DN	RGB-286147
DMP08BY	MI	TTQYF7G
DMP08BY	MN	Cyclin-dependent kinase 7 (CDK7)
DMP08BY	MT	DTT
DMP08BY	MA	Inhibitor
DMP08BY	RN	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
DMP08BY	RU	https://pubmed.ncbi.nlm.nih.gov/18077363

DMP08BY	DI	DMP08BY
DMP08BY	DN	RGB-286147
DMP08BY	MI	TTRSMW9
DMP08BY	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMP08BY	MT	DTT
DMP08BY	MA	Inhibitor
DMP08BY	RN	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
DMP08BY	RU	https://pubmed.ncbi.nlm.nih.gov/18077363

DMFASRB	DI	DMFASRB
DMFASRB	DN	RGD
DMFASRB	MI	TT38RM1
DMFASRB	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DMFASRB	MT	DTT
DMFASRB	MA	Binder
DMFASRB	RN	AlphaIIbbeta3 and its antagonism at the new millennium. Thromb Haemost. 2001 Jul;86(1):34-40.
DMFASRB	RU	https://pubmed.ncbi.nlm.nih.gov/11487023

DM0O9VG	DI	DM0O9VG
DM0O9VG	DN	RGD-039
DM0O9VG	MI	TT38RM1
DM0O9VG	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DM0O9VG	MT	DTT
DM0O9VG	MA	Modulator
DM0O9VG	RN	Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM). J Clin Pharmacol. 2000 Oct;40(10):1129-40.
DM0O9VG	RU	https://pubmed.ncbi.nlm.nih.gov/11028252

DMX4JN6	DI	DMX4JN6
DMX4JN6	DN	RGDechi
DMX4JN6	MI	TTT1R2L
DMX4JN6	MN	Integrin alpha-V (ITGAV)
DMX4JN6	MT	DTT
DMX4JN6	MA	Inhibitor
DMX4JN6	RN	Novel and selective alpha(v)beta3 receptor peptide antagonist: design, synthesis, and biological behavior. J Med Chem. 2006 Jun 1;49(11):3416-20.
DMX4JN6	RU	https://pubmed.ncbi.nlm.nih.gov/16722662

DMX4JN6	DI	DMX4JN6
DMX4JN6	DN	RGDechi
DMX4JN6	MI	TTJA1ZO
DMX4JN6	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMX4JN6	MT	DTT
DMX4JN6	MA	Inhibitor
DMX4JN6	RN	Novel and selective alpha(v)beta3 receptor peptide antagonist: design, synthesis, and biological behavior. J Med Chem. 2006 Jun 1;49(11):3416-20.
DMX4JN6	RU	https://pubmed.ncbi.nlm.nih.gov/16722662

DME9T0A	DI	DME9T0A
DME9T0A	DN	RGFP966
DME9T0A	MI	TT4YWTO
DME9T0A	MN	Histone deacetylase 3 (HDAC3)
DME9T0A	MT	DTT
DME9T0A	MA	Inhibitor
DME9T0A	RN	HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner. Proc Natl Acad Sci U S A. 2013 Feb 12;110(7):2647-52.
DME9T0A	RU	https://pubmed.ncbi.nlm.nih.gov/23297220

DM4XVLB	DI	DM4XVLB
DM4XVLB	DN	RGS4 inhibitor 13
DM4XVLB	MI	TTGTKX9
DM4XVLB	MN	Regulator of G-protein signaling 4 (RGS4)
DM4XVLB	MT	DTT
DM4XVLB	MA	Inhibitor
DM4XVLB	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2811).
DM4XVLB	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2811

DM4XVLB	DI	DM4XVLB
DM4XVLB	DN	RGS4 inhibitor 13
DM4XVLB	MI	TTWME23
DM4XVLB	MN	Regulator of G-protein signaling 8 (RGS8)
DM4XVLB	MT	DTT
DM4XVLB	MA	Inhibitor
DM4XVLB	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2813).
DM4XVLB	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2813

DMC471Z	DI	DMC471Z
DMC471Z	DN	RHC80267
DMC471Z	MI	TTRQ6UD
DMC471Z	MN	Diacylglycerol lipase alpha (DAGLA)
DMC471Z	MT	DTT
DMC471Z	MA	Inhibitor
DMC471Z	RN	Assay and inhibition of diacylglycerol lipase activity. Bioorg Med Chem Lett. 2012 Jul 15;22(14):4585-92.
DMC471Z	RU	https://pubmed.ncbi.nlm.nih.gov/22738638

DMC471Z	DI	DMC471Z
DMC471Z	DN	RHC80267
DMC471Z	MI	TTXZDEN
DMC471Z	MN	Diacylglycerol lipase beta (DAGLB)
DMC471Z	MT	DTT
DMC471Z	MA	Inhibitor
DMC471Z	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1397).
DMC471Z	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1397

DMS6IJ0	DI	DMS6IJ0
DMS6IJ0	DN	RHEIN
DMS6IJ0	MI	TT78R5H
DMS6IJ0	MN	Heat shock protein 90 alpha (HSP90A)
DMS6IJ0	MT	DTT
DMS6IJ0	MA	Inhibitor
DMS6IJ0	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMS6IJ0	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMWP09B	DI	DMWP09B
DMWP09B	DN	RHIIP
DMWP09B	MI	TTCBFJO
DMWP09B	MN	Insulin receptor (INSR)
DMWP09B	MT	DTT
DMWP09B	MA	Modulator
DMWP09B	RN	PROMAXX inhaled insulin: safe and efficacious administration with a commercially available dry powder inhaler. Diabetes Obes Metab. 2009 May;11(5):455-9.
DMWP09B	RU	https://pubmed.ncbi.nlm.nih.gov/19236443

DMH9QAF	DI	DMH9QAF
DMH9QAF	DN	RHODIOLININ
DMH9QAF	MI	TT50QJ3
DMH9QAF	MN	Influenza Neuraminidase (Influ NA)
DMH9QAF	MT	DTT
DMH9QAF	MA	Inhibitor
DMH9QAF	RN	Neuraminidase inhibitory activities of flavonols isolated from Rhodiola rosea roots and their in vitro anti-influenza viral activities. Bioorg Med Chem. 2009 Oct 1;17(19):6816-23.
DMH9QAF	RU	https://pubmed.ncbi.nlm.nih.gov/19729316

DMW1VOB	DI	DMW1VOB
DMW1VOB	DN	rHuB-D2
DMW1VOB	MI	TTIVY12
DMW1VOB	MN	Beta-defensin 4A (DEFB4A)
DMW1VOB	MT	DTT
DMW1VOB	MA	Modulator
DMW1VOB	RN	Bioactive coating of titanium surfaces with recombinant human -defensin-2 (rHuD2) may prevent bacterial colonization in orthopaedic surgery.J Bone Joint Surg Am.2011 May 4;93(9):840-6.
DMW1VOB	RU	https://www.ncbi.nlm.nih.gov/pubmed/21543673

DMSL2CM	DI	DMSL2CM
DMSL2CM	DN	Ribavirin + interferon alfa-2a
DMSL2CM	MI	TTOA6YT
DMSL2CM	MN	MERS-CoV RNA-directed RNA polymerase (RdRp)
DMSL2CM	MT	DTT
DMSL2CM	MA	Inhibitor
DMSL2CM	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DMSL2CM	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DMT4JCW	DI	DMT4JCW
DMT4JCW	DN	Ribavirin + interferon alfa-2b
DMT4JCW	MI	TTOA6YT
DMT4JCW	MN	MERS-CoV RNA-directed RNA polymerase (RdRp)
DMT4JCW	MT	DTT
DMT4JCW	MA	Inhibitor
DMT4JCW	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DMT4JCW	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DMAQMXT	DI	DMAQMXT
DMAQMXT	DN	Ribavirin + interferon beta-1a
DMAQMXT	MI	TTOA6YT
DMAQMXT	MN	MERS-CoV RNA-directed RNA polymerase (RdRp)
DMAQMXT	MT	DTT
DMAQMXT	MA	Inhibitor
DMAQMXT	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DMAQMXT	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DM7DRO4	DI	DM7DRO4
DM7DRO4	DN	Ribavirin + lopinavir + ritonavir + interferon alfa-2a
DM7DRO4	MI	TTWOH4Q
DM7DRO4	MN	MERS-CoV 3C-like proteinase (3CLpro)
DM7DRO4	MT	DTT
DM7DRO4	MA	Inhibitor
DM7DRO4	RN	Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381.
DM7DRO4	RU	https://pubmed.ncbi.nlm.nih.gov/32205870

DM7DRO4	DI	DM7DRO4
DM7DRO4	DN	Ribavirin + lopinavir + ritonavir + interferon alfa-2a
DM7DRO4	MI	TTOA6YT
DM7DRO4	MN	MERS-CoV RNA-directed RNA polymerase (RdRp)
DM7DRO4	MT	DTT
DM7DRO4	MA	Inhibitor
DM7DRO4	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DM7DRO4	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DM09NGV	DI	DM09NGV
DM09NGV	DN	Ribavirin-TP
DM09NGV	MI	TTWXB3E
DM09NGV	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DM09NGV	MT	DTT
DM09NGV	MA	Inhibitor
DM09NGV	RN	ATP-binding domain of NTPase/helicase as a target for hepatitis C antiviral therapy. Acta Biochim Pol. 2000;47(1):173-80.
DM09NGV	RU	https://pubmed.ncbi.nlm.nih.gov/10961691

DM7V8DZ	DI	DM7V8DZ
DM7V8DZ	DN	Ribose-1-Phosphate
DM7V8DZ	MI	TTMCF1Y
DM7V8DZ	MN	Purine nucleoside phosphorylase (PNP)
DM7V8DZ	MT	DTT
DM7V8DZ	MA	Inhibitor
DM7V8DZ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM7V8DZ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMRKO49	DI	DMRKO49
DMRKO49	DN	Ribose-5-Phosphate
DMRKO49	MI	TTVNA43
DMRKO49	MN	Bacterial Deoxy-D-manno-octulosonate 8-phosphate synthase (Bact kdsA)
DMRKO49	MT	DTT
DMRKO49	MA	Inhibitor
DMRKO49	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMRKO49	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMXWUHA	DI	DMXWUHA
DMXWUHA	DN	Ribostamycin
DMXWUHA	MI	TT38DW5
DMXWUHA	MN	Bacterial 16S ribosomal RNA (Bact 16S rRNA)
DMXWUHA	MT	DTT
DMXWUHA	MA	Inhibitor
DMXWUHA	RN	RNA as a target for small molecules. Curr Opin Chem Biol. 2000 Dec;4(6):678-86.
DMXWUHA	RU	https://pubmed.ncbi.nlm.nih.gov/11102874

DM6MYGX	DI	DM6MYGX
DM6MYGX	DN	Riccardin C
DM6MYGX	MI	TTECBXN
DM6MYGX	MN	Oxysterols receptor LXR-alpha (NR1H3)
DM6MYGX	MT	DTT
DM6MYGX	MA	Inhibitor
DM6MYGX	RN	Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85.
DM6MYGX	RU	https://pubmed.ncbi.nlm.nih.gov/18343126

DM6MYGX	DI	DM6MYGX
DM6MYGX	DN	Riccardin C
DM6MYGX	MI	TTXA6PH
DM6MYGX	MN	Oxysterols receptor LXR-beta (NR1H2)
DM6MYGX	MT	DTT
DM6MYGX	MA	Inhibitor
DM6MYGX	RN	Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85.
DM6MYGX	RU	https://pubmed.ncbi.nlm.nih.gov/18343126

DM9HMCS	DI	DM9HMCS
DM9HMCS	DN	Ridine-5-carboxylic acid ethyl ester
DM9HMCS	MI	TT1MPAY
DM9HMCS	MN	GABA(A) receptor alpha-1 (GABRA1)
DM9HMCS	MT	DTT
DM9HMCS	MA	Inhibitor
DM9HMCS	RN	Synthesis and structure-activity relationships of a series of anxioselective pyrazolopyridine ester and amide anxiolytic agents. J Med Chem. 1989 Dec;32(12):2561-73.
DM9HMCS	RU	https://pubmed.ncbi.nlm.nih.gov/2573731

DM9HMCS	DI	DM9HMCS
DM9HMCS	DN	Ridine-5-carboxylic acid ethyl ester
DM9HMCS	MI	TTZA1NY
DM9HMCS	MN	GABA(A) receptor beta-2 (GABRB2)
DM9HMCS	MT	DTT
DM9HMCS	MA	Inhibitor
DM9HMCS	RN	Synthesis and structure-activity relationships of a series of anxioselective pyrazolopyridine ester and amide anxiolytic agents. J Med Chem. 1989 Dec;32(12):2561-73.
DM9HMCS	RU	https://pubmed.ncbi.nlm.nih.gov/2573731

DM9HMCS	DI	DM9HMCS
DM9HMCS	DN	Ridine-5-carboxylic acid ethyl ester
DM9HMCS	MI	TT06RH5
DM9HMCS	MN	GABA(A) receptor gamma-2 (GABRG2)
DM9HMCS	MT	DTT
DM9HMCS	MA	Inhibitor
DM9HMCS	RN	Synthesis and structure-activity relationships of a series of anxioselective pyrazolopyridine ester and amide anxiolytic agents. J Med Chem. 1989 Dec;32(12):2561-73.
DM9HMCS	RU	https://pubmed.ncbi.nlm.nih.gov/2573731

DM9HMCS	DI	DM9HMCS
DM9HMCS	DN	Ridine-5-carboxylic acid ethyl ester
DM9HMCS	MI	TTNJYV2
DM9HMCS	MN	Gamma-aminobutyric acid receptor (GAR)
DM9HMCS	MT	DTT
DM9HMCS	MA	Inhibitor
DM9HMCS	RN	Synthesis and structure-activity relationships of a series of anxioselective pyrazolopyridine ester and amide anxiolytic agents. J Med Chem. 1989 Dec;32(12):2561-73.
DM9HMCS	RU	https://pubmed.ncbi.nlm.nih.gov/2573731

DMN98U1	DI	DMN98U1
DMN98U1	DN	Rimantadine isomer 1
DMN98U1	MI	TTXT3PU
DMN98U1	MN	Influenza M2 protein (Influ M)
DMN98U1	MT	DTT
DMN98U1	MA	Inhibitor
DMN98U1	RN	Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25.
DMN98U1	RU	https://pubmed.ncbi.nlm.nih.gov/17139286

DM3BEF7	DI	DM3BEF7
DM3BEF7	DN	Rimantadine isomer 2
DM3BEF7	MI	TTXT3PU
DM3BEF7	MN	Influenza M2 protein (Influ M)
DM3BEF7	MT	DTT
DM3BEF7	MA	Inhibitor
DM3BEF7	RN	Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25.
DM3BEF7	RU	https://pubmed.ncbi.nlm.nih.gov/17139286

DM59G40	DI	DM59G40
DM59G40	DN	Rimeporide
DM59G40	MI	TT70SZ3
DM59G40	MN	Sodium/hydrogen exchanger (SLC)
DM59G40	MT	DTT
DM59G40	MA	Inhibitor
DM59G40	RN	Sodium-hydrogen exchanger, cardiac overload, and myocardial hypertrophy. Circulation. 2007 Mar 6;115(9):1090-100.
DM59G40	RU	https://pubmed.ncbi.nlm.nih.gov/17339567

DM83L5Y	DI	DM83L5Y
DM83L5Y	DN	RIP
DM83L5Y	MI	TTL69WB
DM83L5Y	MN	Angiotensin-converting enzyme (ACE)
DM83L5Y	MT	DTT
DM83L5Y	MA	Inhibitor
DM83L5Y	RN	Difluorostatine- and difluorostatone-containing peptides as potent and specific renin inhibitors. J Med Chem. 1985 Nov;28(11):1553-5.
DM83L5Y	RU	https://pubmed.ncbi.nlm.nih.gov/3906126

DMYIQRK	DI	DMYIQRK
DMYIQRK	DN	RIPA-56
DMYIQRK	MI	TTAIQSN
DMYIQRK	MN	Receptor-interacting protein 1 (RIPK1)
DMYIQRK	MT	DTT
DMYIQRK	MA	Inhibitor
DMYIQRK	RN	Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease. J Hepatol. 2020 Apr;72(4):627-635.
DMYIQRK	RU	https://pubmed.ncbi.nlm.nih.gov/31760070

DMTHVQD	DI	DMTHVQD
DMTHVQD	DN	RIPAZEPAM
DMTHVQD	MI	TT1MPAY
DMTHVQD	MN	GABA(A) receptor alpha-1 (GABRA1)
DMTHVQD	MT	DTT
DMTHVQD	MA	Inhibitor
DMTHVQD	RN	Synthesis and interaction of 5-(substituted-phenyl)-3-methyl-6,7-dihydropyrazolo[4,3-e] [1,4]diazepin-8(7H)-ones with benzodiazepine receptors in r... J Med Chem. 1985 May;28(5):683-5.
DMTHVQD	RU	https://pubmed.ncbi.nlm.nih.gov/2985787

DMTHVQD	DI	DMTHVQD
DMTHVQD	DN	RIPAZEPAM
DMTHVQD	MI	TTNJYV2
DMTHVQD	MN	Gamma-aminobutyric acid receptor (GAR)
DMTHVQD	MT	DTT
DMTHVQD	MA	Inhibitor
DMTHVQD	RN	Synthesis and interaction of 5-(substituted-phenyl)-3-methyl-6,7-dihydropyrazolo[4,3-e] [1,4]diazepin-8(7H)-ones with benzodiazepine receptors in r... J Med Chem. 1985 May;28(5):683-5.
DMTHVQD	RU	https://pubmed.ncbi.nlm.nih.gov/2985787

DMJD3WY	DI	DMJD3WY
DMJD3WY	DN	RI-TPO
DMJD3WY	MI	TTIHYA4
DMJD3WY	MN	Thrombopoietin receptor (MPL)
DMJD3WY	MT	DTT
DMJD3WY	MA	Modulator
DMJD3WY	RN	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
DMJD3WY	RU	https://www.ncbi.nlm.nih.gov/pubmed/27899562

DM2P6I8	DI	DM2P6I8
DM2P6I8	DN	RJM-0035-K002
DM2P6I8	MI	TTL69WB
DM2P6I8	MN	Angiotensin-converting enzyme (ACE)
DM2P6I8	MT	DTT
DM2P6I8	MA	Inhibitor
DM2P6I8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1613).
DM2P6I8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1613

DM5CI2P	DI	DM5CI2P
DM5CI2P	DN	RK-682
DM5CI2P	MI	TTELIN2
DM5CI2P	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DM5CI2P	MT	DTT
DM5CI2P	MA	Inhibitor
DM5CI2P	RN	Prenylflavonoids from Glycyrrhiza uralensis and their protein tyrosine phosphatase-1B inhibitory activities. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5398-401.
DM5CI2P	RU	https://pubmed.ncbi.nlm.nih.gov/20724155

DMGTAWC	DI	DMGTAWC
DMGTAWC	DN	RKI-1447
DMGTAWC	MI	TT5Z0EF
DMGTAWC	MN	CDC42 binding protein kinase alpha (DMPK-like alpha)
DMGTAWC	MT	DTT
DMGTAWC	MA	Inhibitor
DMGTAWC	RN	Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2). Medchemcomm. 2012 Jun 1;3(6):699-709.
DMGTAWC	RU	https://pubmed.ncbi.nlm.nih.gov/23275831

DMGTAWC	DI	DMGTAWC
DMGTAWC	DN	RKI-1447
DMGTAWC	MI	TTZQTY2
DMGTAWC	MN	DMPK messenger RNA (DMPK mRNA)
DMGTAWC	MT	DTT
DMGTAWC	MA	Inhibitor
DMGTAWC	RN	Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2). Medchemcomm. 2012 Jun 1;3(6):699-709.
DMGTAWC	RU	https://pubmed.ncbi.nlm.nih.gov/23275831

DMGTAWC	DI	DMGTAWC
DMGTAWC	DN	RKI-1447
DMGTAWC	MI	TTWL9TY
DMGTAWC	MN	LIM domain kinase-1 (LIMK-1)
DMGTAWC	MT	DTT
DMGTAWC	MA	Inhibitor
DMGTAWC	RN	Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2). Medchemcomm. 2012 Jun 1;3(6):699-709.
DMGTAWC	RU	https://pubmed.ncbi.nlm.nih.gov/23275831

DMGTAWC	DI	DMGTAWC
DMGTAWC	DN	RKI-1447
DMGTAWC	MI	TT18ETS
DMGTAWC	MN	Myosin light kinase (MYLK)
DMGTAWC	MT	DTT
DMGTAWC	MA	Inhibitor
DMGTAWC	RN	Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2). Medchemcomm. 2012 Jun 1;3(6):699-709.
DMGTAWC	RU	https://pubmed.ncbi.nlm.nih.gov/23275831

DMGTAWC	DI	DMGTAWC
DMGTAWC	DN	RKI-1447
DMGTAWC	MI	TTFN95D
DMGTAWC	MN	PAK-1 protein kinase (PAK1)
DMGTAWC	MT	DTT
DMGTAWC	MA	Inhibitor
DMGTAWC	RN	Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2). Medchemcomm. 2012 Jun 1;3(6):699-709.
DMGTAWC	RU	https://pubmed.ncbi.nlm.nih.gov/23275831

DMGTAWC	DI	DMGTAWC
DMGTAWC	DN	RKI-1447
DMGTAWC	MI	TTSL41O
DMGTAWC	MN	Protein kinase N1 (PKN1)
DMGTAWC	MT	DTT
DMGTAWC	MA	Inhibitor
DMGTAWC	RN	Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2). Medchemcomm. 2012 Jun 1;3(6):699-709.
DMGTAWC	RU	https://pubmed.ncbi.nlm.nih.gov/23275831

DMGTAWC	DI	DMGTAWC
DMGTAWC	DN	RKI-1447
DMGTAWC	MI	TTZN7RP
DMGTAWC	MN	Rho-associated protein kinase 1 (ROCK1)
DMGTAWC	MT	DTT
DMGTAWC	MA	Inhibitor
DMGTAWC	RN	Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2). Medchemcomm. 2012 Jun 1;3(6):699-709.
DMGTAWC	RU	https://pubmed.ncbi.nlm.nih.gov/23275831

DMGTAWC	DI	DMGTAWC
DMGTAWC	DN	RKI-1447
DMGTAWC	MI	TTGWKQJ
DMGTAWC	MN	Rho-associated protein kinase 2 (ROCK2)
DMGTAWC	MT	DTT
DMGTAWC	MA	Inhibitor
DMGTAWC	RN	Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2). Medchemcomm. 2012 Jun 1;3(6):699-709.
DMGTAWC	RU	https://pubmed.ncbi.nlm.nih.gov/23275831

DMGEDQJ	DI	DMGEDQJ
DMGEDQJ	DN	R-L3
DMGEDQJ	MI	TT846HF
DMGEDQJ	MN	Voltage-gated potassium channel Kv7.1 (KCNQ1)
DMGEDQJ	MT	DTT
DMGEDQJ	MA	Activator
DMGEDQJ	RN	A novel benzodiazepine that activates cardiac slow delayed rectifier K+ currents. Mol Pharmacol. 1998 Jul;54(1):220-30.
DMGEDQJ	RU	https://pubmed.ncbi.nlm.nih.gov/9658209

DM87Z3Y	DI	DM87Z3Y
DM87Z3Y	DN	RM-6427
DM87Z3Y	MI	TTGKNB4
DM87Z3Y	MN	Epidermal growth factor receptor (EGFR)
DM87Z3Y	MT	DTT
DM87Z3Y	MA	Inhibitor
DM87Z3Y	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
DM87Z3Y	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797

DMJU5A9	DI	DMJU5A9
DMJU5A9	DN	RM65
DMJU5A9	MI	TTVOJAI
DMJU5A9	MN	Protein arginine methyltransferase 1 (PRMT1)
DMJU5A9	MT	DTT
DMJU5A9	MA	Inhibitor
DMJU5A9	RN	A novel arginine methyltransferase inhibitor with cellular activity. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4150-3.
DMJU5A9	RU	https://pubmed.ncbi.nlm.nih.gov/17570663

DMA3ZXM	DI	DMA3ZXM
DMA3ZXM	DN	RN1734
DMA3ZXM	MI	TTKP2SU
DMA3ZXM	MN	Transient receptor potential cation channel V4 (TRPV4)
DMA3ZXM	MT	DTT
DMA3ZXM	MA	Blocker (channel blocker)
DMA3ZXM	RN	Identification and characterization of novel TRPV4 modulators. Biochem Biophys Res Commun. 2009 Nov 20;389(3):490-4.
DMA3ZXM	RU	https://pubmed.ncbi.nlm.nih.gov/19737537

DMIPZTM	DI	DMIPZTM
DMIPZTM	DN	RN1747
DMIPZTM	MI	TTKP2SU
DMIPZTM	MN	Transient receptor potential cation channel V4 (TRPV4)
DMIPZTM	MT	DTT
DMIPZTM	MA	Activator
DMIPZTM	RN	Identification and characterization of novel TRPV4 modulators. Biochem Biophys Res Commun. 2009 Nov 20;389(3):490-4.
DMIPZTM	RU	https://pubmed.ncbi.nlm.nih.gov/19737537

DML7SQH	DI	DML7SQH
DML7SQH	DN	RN486
DML7SQH	MI	TT8K4DE
DML7SQH	MN	STE20-related serine/threonine-protein kinase (SLK)
DML7SQH	MT	DTT
DML7SQH	MA	Inhibitor
DML7SQH	RN	RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents. J Pharmacol Exp Ther. 2012 Apr;341(1):90-103.
DML7SQH	RU	https://pubmed.ncbi.nlm.nih.gov/22228807

DML7SQH	DI	DML7SQH
DML7SQH	DN	RN486
DML7SQH	MI	TTGM6VW
DML7SQH	MN	Tyrosine-protein kinase BTK (ATK)
DML7SQH	MT	DTT
DML7SQH	MA	Inhibitor
DML7SQH	RN	RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents. J Pharmacol Exp Ther. 2012 Apr;341(1):90-103.
DML7SQH	RU	https://pubmed.ncbi.nlm.nih.gov/22228807

DM2N3BA	DI	DM2N3BA
DM2N3BA	DN	R-N6-(phenylisopropyl)adenosine
DM2N3BA	MI	TTK25J1
DM2N3BA	MN	Adenosine A1 receptor (ADORA1)
DM2N3BA	MT	DTT
DM2N3BA	MA	Inhibitor
DM2N3BA	RN	Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 1998 Jan;357(1):1-9.
DM2N3BA	RU	https://pubmed.ncbi.nlm.nih.gov/9459566

DM2N3BA	DI	DM2N3BA
DM2N3BA	DN	R-N6-(phenylisopropyl)adenosine
DM2N3BA	MI	TTM2AOE
DM2N3BA	MN	Adenosine A2a receptor (ADORA2A)
DM2N3BA	MT	DTT
DM2N3BA	MA	Inhibitor
DM2N3BA	RN	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
DM2N3BA	RU	https://pubmed.ncbi.nlm.nih.gov/17378544

DM2N3BA	DI	DM2N3BA
DM2N3BA	DN	R-N6-(phenylisopropyl)adenosine
DM2N3BA	MI	TTNE7KG
DM2N3BA	MN	Adenosine A2b receptor (ADORA2B)
DM2N3BA	MT	DTT
DM2N3BA	MA	Agonist
DM2N3BA	RN	Adenosine receptor activation in human fibroblasts: nucleoside agonists and antagonists. Can J Physiol Pharmacol. 1980 Jun;58(6):673-91.
DM2N3BA	RU	https://pubmed.ncbi.nlm.nih.gov/6253037

DM2N3BA	DI	DM2N3BA
DM2N3BA	DN	R-N6-(phenylisopropyl)adenosine
DM2N3BA	MI	TTJFY5U
DM2N3BA	MN	Adenosine A3 receptor (ADORA3)
DM2N3BA	MT	DTT
DM2N3BA	MA	Inhibitor
DM2N3BA	RN	Structure-activity relationships for 2-substituted adenosines at A1 and A2 adenosine receptors. Pharmacology. 1993;46(2):91-100.
DM2N3BA	RU	https://pubmed.ncbi.nlm.nih.gov/8441759

DMGV4DS	DI	DMGV4DS
DMGV4DS	DN	R-norduloxetine
DMGV4DS	MI	TTVBI8W
DMGV4DS	MN	Dopamine transporter (DAT)
DMGV4DS	MT	DTT
DMGV4DS	MA	Inhibitor
DMGV4DS	RN	Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression. Bioorg Med Chem. 2009 Oct 1;17(19):6890-7.
DMGV4DS	RU	https://pubmed.ncbi.nlm.nih.gov/19740668

DMGV4DS	DI	DMGV4DS
DMGV4DS	DN	R-norduloxetine
DMGV4DS	MI	TTAWNKZ
DMGV4DS	MN	Norepinephrine transporter (NET)
DMGV4DS	MT	DTT
DMGV4DS	MA	Inhibitor
DMGV4DS	RN	Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression. Bioorg Med Chem. 2009 Oct 1;17(19):6890-7.
DMGV4DS	RU	https://pubmed.ncbi.nlm.nih.gov/19740668

DMGV4DS	DI	DMGV4DS
DMGV4DS	DN	R-norduloxetine
DMGV4DS	MI	TT3ROYC
DMGV4DS	MN	Serotonin transporter (SERT)
DMGV4DS	MT	DTT
DMGV4DS	MA	Inhibitor
DMGV4DS	RN	Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression. Bioorg Med Chem. 2009 Oct 1;17(19):6890-7.
DMGV4DS	RU	https://pubmed.ncbi.nlm.nih.gov/19740668

DMXT34V	DI	DMXT34V
DMXT34V	DN	Ro 10-4548
DMXT34V	MI	TTE0A2F
DMXT34V	MN	Dopamine D4 receptor (D4R)
DMXT34V	MT	DTT
DMXT34V	MA	Antagonist
DMXT34V	RN	Certain 1,4-disubstituted aromatic piperidines and piperazines with extreme selectivity for the dopamine D4 receptor interact with a common recepto... Mol Pharmacol. 2004 Dec;66(6):1491-9.
DMXT34V	RU	https://pubmed.ncbi.nlm.nih.gov/15448188

DMMO6PH	DI	DMMO6PH
DMMO6PH	DN	RO 116 1148
DMMO6PH	MI	TT07C3Y
DMMO6PH	MN	5-HT 4 receptor (HTR4)
DMMO6PH	MT	DTT
DMMO6PH	MA	Antagonist
DMMO6PH	RN	A 5-HT4 receptor transmembrane network implicated in the activity of inverse agonists but not agonists. J Biol Chem. 2002 Jul 12;277(28):25502-11.
DMMO6PH	RU	https://pubmed.ncbi.nlm.nih.gov/11976337

DM3FYUM	DI	DM3FYUM
DM3FYUM	DN	RO 244383
DM3FYUM	MI	TTJP4SM
DM3FYUM	MN	Bacterial Penicillin binding protein (Bact PBP)
DM3FYUM	MT	DTT
DM3FYUM	MA	Modulator
DM3FYUM	RN	Mechanisms of resistance to cephalosporin antibiotics.Drugs.1987;34 Suppl 2:64-88.
DM3FYUM	RU	https://www.ncbi.nlm.nih.gov/pubmed/3319506

DMDC4HY	DI	DMDC4HY
DMDC4HY	DN	Ro 28-2653
DMDC4HY	MI	TT6X50U
DMDC4HY	MN	Matrix metalloproteinase-9 (MMP-9)
DMDC4HY	MT	DTT
DMDC4HY	MA	Inhibitor
DMDC4HY	RN	The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model. Oncogene. 2002 Mar 27;21(13):2089-96.
DMDC4HY	RU	https://pubmed.ncbi.nlm.nih.gov/11960381

DMU2EKN	DI	DMU2EKN
DMU2EKN	DN	Ro 40-6055
DMU2EKN	MI	TTW38KT
DMU2EKN	MN	Retinoic acid receptor alpha (RARA)
DMU2EKN	MT	DTT
DMU2EKN	MA	Agonist
DMU2EKN	RN	Selective high affinity retinoic acid receptor alpha or beta-gamma ligands. Mol Pharmacol. 1991 Oct;40(4):556-62.
DMU2EKN	RU	https://pubmed.ncbi.nlm.nih.gov/1656191

DMSJLWP	DI	DMSJLWP
DMSJLWP	DN	Ro 41-5253
DMSJLWP	MI	TTW38KT
DMSJLWP	MN	Retinoic acid receptor alpha (RARA)
DMSJLWP	MT	DTT
DMSJLWP	MA	Antagonist
DMSJLWP	RN	A retinoic acid receptor alpha antagonist selectively counteracts retinoic acid effects. Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7129-33.
DMSJLWP	RU	https://pubmed.ncbi.nlm.nih.gov/1323127

DMXMSYB	DI	DMXMSYB
DMXMSYB	DN	Ro 46-8443
DMXMSYB	MI	TT3ZTGU
DMXMSYB	MN	Endothelin B receptor (EDNRB)
DMXMSYB	MT	DTT
DMXMSYB	MA	Antagonist
DMXMSYB	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 220).
DMXMSYB	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=220

DMTQP0K	DI	DMTQP0K
DMTQP0K	DN	Ro 5-4864
DMTQP0K	MI	TT9SL3Q
DMTQP0K	MN	Polypeptide deformylase (PDF)
DMTQP0K	MT	DTT
DMTQP0K	MA	Inhibitor
DMTQP0K	RN	Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
DMTQP0K	RU	https://pubmed.ncbi.nlm.nih.gov/15934867

DMTQP0K	DI	DMTQP0K
DMTQP0K	DN	Ro 5-4864
DMTQP0K	MI	TTPTXIN
DMTQP0K	MN	Translocator protein (TSPO)
DMTQP0K	MT	DTT
DMTQP0K	MA	Binder
DMTQP0K	RN	Specific ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in human colorectal cancer cells. Br J Cancer. 2001 Nov 30;85(11):1771-80.
DMTQP0K	RU	https://pubmed.ncbi.nlm.nih.gov/11742501

DMYVQF5	DI	DMYVQF5
DMYVQF5	DN	Ro 63-1908
DMYVQF5	MI	TTN9D8E
DMYVQF5	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMYVQF5	MT	DTT
DMYVQF5	MA	Antagonist
DMYVQF5	RN	Pharmacological characterization of Ro 63-1908 (1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol), a novel subtype-selective N-methyl-D-aspartate antagonist. J Pharmacol Exp Ther. 2002 Sep;302(3):940-8.
DMYVQF5	RU	https://pubmed.ncbi.nlm.nih.gov/12183650

DM0AC84	DI	DM0AC84
DM0AC84	DN	Ro01-6128
DM0AC84	MI	TTVBPDM
DM0AC84	MN	Metabotropic glutamate receptor 1 (mGluR1)
DM0AC84	MT	DTT
DM0AC84	MA	Modulator (allosteric modulator)
DM0AC84	RN	Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action, and binding site. Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13402-7.
DM0AC84	RU	https://pubmed.ncbi.nlm.nih.gov/11606768

DM6H8JM	DI	DM6H8JM
DM6H8JM	DN	Ro-04-6790
DM6H8JM	MI	TTJS8PY
DM6H8JM	MN	5-HT 6 receptor (HTR6)
DM6H8JM	MT	DTT
DM6H8JM	MA	Inhibitor
DM6H8JM	RN	Indene-based scaffolds. 2. An indole-indene switch: discovery of novel indenylsulfonamides as 5-HT6 serotonin receptor agonists. J Med Chem. 2009 Feb 12;52(3):675-87.
DM6H8JM	RU	https://pubmed.ncbi.nlm.nih.gov/19159187

DMLVERQ	DI	DMLVERQ
DMLVERQ	DN	Ro-0505124
DMLVERQ	MI	TT0PG8F
DMLVERQ	MN	Cyclin-dependent kinase 4 (CDK4)
DMLVERQ	MT	DTT
DMLVERQ	MA	Inhibitor
DMLVERQ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1976).
DMLVERQ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1976

DMLVERQ	DI	DMLVERQ
DMLVERQ	DN	Ro-0505124
DMLVERQ	MI	TTX5KEQ
DMLVERQ	MN	Fused homolog (STK36)
DMLVERQ	MT	DTT
DMLVERQ	MA	Inhibitor
DMLVERQ	RN	Inhibition of S/G2 phase CDK4 reduces mitotic fidelity. J Biol Chem. 2006 Apr 14;281(15):9987-95.
DMLVERQ	RU	https://pubmed.ncbi.nlm.nih.gov/16476733

DM78B4A	DI	DM78B4A
DM78B4A	DN	RO-054520
DM78B4A	MI	TT1MPAY
DM78B4A	MN	GABA(A) receptor alpha-1 (GABRA1)
DM78B4A	MT	DTT
DM78B4A	MA	Inhibitor
DM78B4A	RN	Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J Med Chem. 1988 Dec;31(12):2235-46.
DM78B4A	RU	https://pubmed.ncbi.nlm.nih.gov/2848124

DM78B4A	DI	DM78B4A
DM78B4A	DN	RO-054520
DM78B4A	MI	TTNJYV2
DM78B4A	MN	Gamma-aminobutyric acid receptor (GAR)
DM78B4A	MT	DTT
DM78B4A	MA	Inhibitor
DM78B4A	RN	Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J Med Chem. 1988 Dec;31(12):2235-46.
DM78B4A	RU	https://pubmed.ncbi.nlm.nih.gov/2848124

DMZLUAK	DI	DMZLUAK
DMZLUAK	DN	Ro0711401
DMZLUAK	MI	TTVBPDM
DMZLUAK	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMZLUAK	MT	DTT
DMZLUAK	MA	Modulator (allosteric modulator)
DMZLUAK	RN	Fluorinated 9H-xanthene-9-carboxylic acid oxazol-2-yl-amides as potent, orally available mGlu1 receptor enhancers. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1666-9.
DMZLUAK	RU	https://pubmed.ncbi.nlm.nih.gov/19233648

DM2DXHO	DI	DM2DXHO
DM2DXHO	DN	Ro092210
DM2DXHO	MI	TTQBCEJ
DM2DXHO	MN	MAPK/ERK kinase kinase 1 (MAP3K1)
DM2DXHO	MT	DTT
DM2DXHO	MA	Inhibitor
DM2DXHO	RN	Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
DM2DXHO	RU	https://pubmed.ncbi.nlm.nih.gov/11804650

DM2DXHO	DI	DM2DXHO
DM2DXHO	DN	Ro092210
DM2DXHO	MI	TTK1N5G
DM2DXHO	MN	MAPK/ERK kinase kinase 2 (MAP3K2)
DM2DXHO	MT	DTT
DM2DXHO	MA	Inhibitor
DM2DXHO	RN	Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
DM2DXHO	RU	https://pubmed.ncbi.nlm.nih.gov/11804650

DMOQ0CE	DI	DMOQ0CE
DMOQ0CE	DN	Ro-11-04253
DMOQ0CE	MI	TTNGILX
DMOQ0CE	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMOQ0CE	MT	DTT
DMOQ0CE	MA	Inhibitor
DMOQ0CE	RN	Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
DMOQ0CE	RU	https://pubmed.ncbi.nlm.nih.gov/15664832

DMAOI51	DI	DMAOI51
DMAOI51	DN	RO1138452
DMAOI51	MI	TTOFYT1
DMAOI51	MN	Prostacyclin receptor (PTGIR)
DMAOI51	MT	DTT
DMAOI51	MA	Antagonist
DMAOI51	RN	RO1138452 and RO3244794: characterization of structurally distinct, potent and selective IP (prostacyclin) receptor antagonists. Br J Pharmacol. 2006 Feb;147(3):335-45.
DMAOI51	RU	https://pubmed.ncbi.nlm.nih.gov/16331286

DMFTW0U	DI	DMFTW0U
DMFTW0U	DN	RO116-4875/608
DMFTW0U	MI	TTU3Y87
DMFTW0U	MN	CCR3 messenger RNA (CCR3 mRNA)
DMFTW0U	MT	DTT
DMFTW0U	MA	Antagonist
DMFTW0U	RN	Responses of leukocytes to chemokines in whole blood and their antagonism by novel CC-chemokine receptor 3 antagonists. Am J Respir Crit Care Med. 2002 Jun 15;165(12):1602-9.
DMFTW0U	RU	https://pubmed.ncbi.nlm.nih.gov/12070060

DM6XM1D	DI	DM6XM1D
DM6XM1D	DN	RO116-9132/238
DM6XM1D	MI	TTU3Y87
DM6XM1D	MN	CCR3 messenger RNA (CCR3 mRNA)
DM6XM1D	MT	DTT
DM6XM1D	MA	Antagonist
DM6XM1D	RN	Responses of leukocytes to chemokines in whole blood and their antagonism by novel CC-chemokine receptor 3 antagonists. Am J Respir Crit Care Med. 2002 Jun 15;165(12):1602-9.
DM6XM1D	RU	https://pubmed.ncbi.nlm.nih.gov/12070060

DM0ACKJ	DI	DM0ACKJ
DM0ACKJ	DN	RO-145974
DM0ACKJ	MI	TT1MPAY
DM0ACKJ	MN	GABA(A) receptor alpha-1 (GABRA1)
DM0ACKJ	MT	DTT
DM0ACKJ	MA	Inhibitor
DM0ACKJ	RN	Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6.
DM0ACKJ	RU	https://pubmed.ncbi.nlm.nih.gov/8386769

DM0ACKJ	DI	DM0ACKJ
DM0ACKJ	DN	RO-145974
DM0ACKJ	MI	TTZA1NY
DM0ACKJ	MN	GABA(A) receptor beta-2 (GABRB2)
DM0ACKJ	MT	DTT
DM0ACKJ	MA	Inhibitor
DM0ACKJ	RN	Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6.
DM0ACKJ	RU	https://pubmed.ncbi.nlm.nih.gov/8386769

DM0ACKJ	DI	DM0ACKJ
DM0ACKJ	DN	RO-145974
DM0ACKJ	MI	TT06RH5
DM0ACKJ	MN	GABA(A) receptor gamma-2 (GABRG2)
DM0ACKJ	MT	DTT
DM0ACKJ	MA	Inhibitor
DM0ACKJ	RN	Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6.
DM0ACKJ	RU	https://pubmed.ncbi.nlm.nih.gov/8386769

DM0ACKJ	DI	DM0ACKJ
DM0ACKJ	DN	RO-145974
DM0ACKJ	MI	TTNJYV2
DM0ACKJ	MN	Gamma-aminobutyric acid receptor (GAR)
DM0ACKJ	MT	DTT
DM0ACKJ	MA	Inhibitor
DM0ACKJ	RN	Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6.
DM0ACKJ	RU	https://pubmed.ncbi.nlm.nih.gov/8386769

DMAJ6BW	DI	DMAJ6BW
DMAJ6BW	DN	RO-145975
DMAJ6BW	MI	TT1MPAY
DMAJ6BW	MN	GABA(A) receptor alpha-1 (GABRA1)
DMAJ6BW	MT	DTT
DMAJ6BW	MA	Inhibitor
DMAJ6BW	RN	Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6.
DMAJ6BW	RU	https://pubmed.ncbi.nlm.nih.gov/8386769

DMAJ6BW	DI	DMAJ6BW
DMAJ6BW	DN	RO-145975
DMAJ6BW	MI	TTZA1NY
DMAJ6BW	MN	GABA(A) receptor beta-2 (GABRB2)
DMAJ6BW	MT	DTT
DMAJ6BW	MA	Inhibitor
DMAJ6BW	RN	Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6.
DMAJ6BW	RU	https://pubmed.ncbi.nlm.nih.gov/8386769

DMAJ6BW	DI	DMAJ6BW
DMAJ6BW	DN	RO-145975
DMAJ6BW	MI	TT06RH5
DMAJ6BW	MN	GABA(A) receptor gamma-2 (GABRG2)
DMAJ6BW	MT	DTT
DMAJ6BW	MA	Inhibitor
DMAJ6BW	RN	Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6.
DMAJ6BW	RU	https://pubmed.ncbi.nlm.nih.gov/8386769

DMAJ6BW	DI	DMAJ6BW
DMAJ6BW	DN	RO-145975
DMAJ6BW	MI	TTNJYV2
DMAJ6BW	MN	Gamma-aminobutyric acid receptor (GAR)
DMAJ6BW	MT	DTT
DMAJ6BW	MA	Inhibitor
DMAJ6BW	RN	Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6.
DMAJ6BW	RU	https://pubmed.ncbi.nlm.nih.gov/8386769

DMX4B36	DI	DMX4B36
DMX4B36	DN	RO-147437
DMX4B36	MI	TT1MPAY
DMX4B36	MN	GABA(A) receptor alpha-1 (GABRA1)
DMX4B36	MT	DTT
DMX4B36	MA	Inhibitor
DMX4B36	RN	Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6.
DMX4B36	RU	https://pubmed.ncbi.nlm.nih.gov/8386769

DMX4B36	DI	DMX4B36
DMX4B36	DN	RO-147437
DMX4B36	MI	TTZA1NY
DMX4B36	MN	GABA(A) receptor beta-2 (GABRB2)
DMX4B36	MT	DTT
DMX4B36	MA	Inhibitor
DMX4B36	RN	Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6.
DMX4B36	RU	https://pubmed.ncbi.nlm.nih.gov/8386769

DMX4B36	DI	DMX4B36
DMX4B36	DN	RO-147437
DMX4B36	MI	TT06RH5
DMX4B36	MN	GABA(A) receptor gamma-2 (GABRG2)
DMX4B36	MT	DTT
DMX4B36	MA	Inhibitor
DMX4B36	RN	Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6.
DMX4B36	RU	https://pubmed.ncbi.nlm.nih.gov/8386769

DMX4B36	DI	DMX4B36
DMX4B36	DN	RO-147437
DMX4B36	MI	TTNJYV2
DMX4B36	MN	Gamma-aminobutyric acid receptor (GAR)
DMX4B36	MT	DTT
DMX4B36	MA	Inhibitor
DMX4B36	RN	Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6.
DMX4B36	RU	https://pubmed.ncbi.nlm.nih.gov/8386769

DM4NW3U	DI	DM4NW3U
DM4NW3U	DN	Ro-15-3505
DM4NW3U	MI	TT1MPAY
DM4NW3U	MN	GABA(A) receptor alpha-1 (GABRA1)
DM4NW3U	MT	DTT
DM4NW3U	MA	Inhibitor
DM4NW3U	RN	Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6.
DM4NW3U	RU	https://pubmed.ncbi.nlm.nih.gov/8386769

DM4NW3U	DI	DM4NW3U
DM4NW3U	DN	Ro-15-3505
DM4NW3U	MI	TTBMV1G
DM4NW3U	MN	GABA(A) receptor alpha-2 (GABRA2)
DM4NW3U	MT	DTT
DM4NW3U	MA	Inhibitor
DM4NW3U	RN	The GABA(A) receptor as a target for photochromic molecules. Bioorg Med Chem. 2010 Nov 15;18(22):7731-8.
DM4NW3U	RU	https://pubmed.ncbi.nlm.nih.gov/20646926

DM4NW3U	DI	DM4NW3U
DM4NW3U	DN	Ro-15-3505
DM4NW3U	MI	TT37EDJ
DM4NW3U	MN	GABA(A) receptor alpha-3 (GABRA3)
DM4NW3U	MT	DTT
DM4NW3U	MA	Inhibitor
DM4NW3U	RN	The GABA(A) receptor as a target for photochromic molecules. Bioorg Med Chem. 2010 Nov 15;18(22):7731-8.
DM4NW3U	RU	https://pubmed.ncbi.nlm.nih.gov/20646926

DM4NW3U	DI	DM4NW3U
DM4NW3U	DN	Ro-15-3505
DM4NW3U	MI	TTNZPQ1
DM4NW3U	MN	GABA(A) receptor alpha-5 (GABRA5)
DM4NW3U	MT	DTT
DM4NW3U	MA	Inhibitor
DM4NW3U	RN	The GABA(A) receptor as a target for photochromic molecules. Bioorg Med Chem. 2010 Nov 15;18(22):7731-8.
DM4NW3U	RU	https://pubmed.ncbi.nlm.nih.gov/20646926

DM4NW3U	DI	DM4NW3U
DM4NW3U	DN	Ro-15-3505
DM4NW3U	MI	TTZA1NY
DM4NW3U	MN	GABA(A) receptor beta-2 (GABRB2)
DM4NW3U	MT	DTT
DM4NW3U	MA	Inhibitor
DM4NW3U	RN	Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6.
DM4NW3U	RU	https://pubmed.ncbi.nlm.nih.gov/8386769

DM4NW3U	DI	DM4NW3U
DM4NW3U	DN	Ro-15-3505
DM4NW3U	MI	TT06RH5
DM4NW3U	MN	GABA(A) receptor gamma-2 (GABRG2)
DM4NW3U	MT	DTT
DM4NW3U	MA	Inhibitor
DM4NW3U	RN	Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6.
DM4NW3U	RU	https://pubmed.ncbi.nlm.nih.gov/8386769

DM4NW3U	DI	DM4NW3U
DM4NW3U	DN	Ro-15-3505
DM4NW3U	MI	TTEX6LM
DM4NW3U	MN	GABA(A) receptor gamma-3 (GABRG3)
DM4NW3U	MT	DTT
DM4NW3U	MA	Modulator
DM4NW3U	RN	Molecular structure and stereoelectronic properties of sarmazenil--a weak inverse agonist at the omega modulatory sites (benzodiazepine receptors):... Bioorg Med Chem. 1998 Oct;6(10):1745-57.
DM4NW3U	RU	https://www.ncbi.nlm.nih.gov/pubmed/9839004

DM4NW3U	DI	DM4NW3U
DM4NW3U	DN	Ro-15-3505
DM4NW3U	MI	TTNJYV2
DM4NW3U	MN	Gamma-aminobutyric acid receptor (GAR)
DM4NW3U	MT	DTT
DM4NW3U	MA	Inhibitor
DM4NW3U	RN	The GABA(A) receptor as a target for photochromic molecules. Bioorg Med Chem. 2010 Nov 15;18(22):7731-8.
DM4NW3U	RU	https://pubmed.ncbi.nlm.nih.gov/20646926

DM8C2Z0	DI	DM8C2Z0
DM8C2Z0	DN	RO-194603
DM8C2Z0	MI	TT1MPAY
DM8C2Z0	MN	GABA(A) receptor alpha-1 (GABRA1)
DM8C2Z0	MT	DTT
DM8C2Z0	MA	Inhibitor
DM8C2Z0	RN	Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6.
DM8C2Z0	RU	https://pubmed.ncbi.nlm.nih.gov/8386769

DM8C2Z0	DI	DM8C2Z0
DM8C2Z0	DN	RO-194603
DM8C2Z0	MI	TTZA1NY
DM8C2Z0	MN	GABA(A) receptor beta-2 (GABRB2)
DM8C2Z0	MT	DTT
DM8C2Z0	MA	Inhibitor
DM8C2Z0	RN	Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6.
DM8C2Z0	RU	https://pubmed.ncbi.nlm.nih.gov/8386769

DM8C2Z0	DI	DM8C2Z0
DM8C2Z0	DN	RO-194603
DM8C2Z0	MI	TT06RH5
DM8C2Z0	MN	GABA(A) receptor gamma-2 (GABRG2)
DM8C2Z0	MT	DTT
DM8C2Z0	MA	Inhibitor
DM8C2Z0	RN	Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6.
DM8C2Z0	RU	https://pubmed.ncbi.nlm.nih.gov/8386769

DM8C2Z0	DI	DM8C2Z0
DM8C2Z0	DN	RO-194603
DM8C2Z0	MI	TTNJYV2
DM8C2Z0	MN	Gamma-aminobutyric acid receptor (GAR)
DM8C2Z0	MT	DTT
DM8C2Z0	MA	Inhibitor
DM8C2Z0	RN	Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6.
DM8C2Z0	RU	https://pubmed.ncbi.nlm.nih.gov/8386769

DMOE0JX	DI	DMOE0JX
DMOE0JX	DN	Ro-21-7767
DMOE0JX	MI	TTZFYLI
DMOE0JX	MN	Dopamine D1 receptor (D1R)
DMOE0JX	MT	DTT
DMOE0JX	MA	Inhibitor
DMOE0JX	RN	Evaluation of cis- and trans-9- and 11-hydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridines as structurally rigid, selective D1 dopamine recepto... J Med Chem. 1995 Jan 20;38(2):318-27.
DMOE0JX	RU	https://pubmed.ncbi.nlm.nih.gov/7830274

DMOE0JX	DI	DMOE0JX
DMOE0JX	DN	Ro-21-7767
DMOE0JX	MI	TTEX248
DMOE0JX	MN	Dopamine D2 receptor (D2R)
DMOE0JX	MT	DTT
DMOE0JX	MA	Inhibitor
DMOE0JX	RN	Evaluation of cis- and trans-9- and 11-hydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridines as structurally rigid, selective D1 dopamine recepto... J Med Chem. 1995 Jan 20;38(2):318-27.
DMOE0JX	RU	https://pubmed.ncbi.nlm.nih.gov/7830274

DMGL7TM	DI	DMGL7TM
DMGL7TM	DN	Ro26-4550
DMGL7TM	MI	TTAJU0S
DMGL7TM	MN	Interleukin 2 receptor (IL2R)
DMGL7TM	MT	DTT
DMGL7TM	MA	Antagonist
DMGL7TM	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2297).
DMGL7TM	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2297

DMRYNJE	DI	DMRYNJE
DMRYNJE	DN	RO3
DMRYNJE	MI	TT2THBD
DMRYNJE	MN	P2X purinoceptor 3 (P2RX3)
DMRYNJE	MT	DTT
DMRYNJE	MA	Antagonist
DMRYNJE	RN	Purinoceptors as therapeutic targets for lower urinary tract dysfunction. Br J Pharmacol. 2006 Feb;147 Suppl 2:S132-43.
DMRYNJE	RU	https://pubmed.ncbi.nlm.nih.gov/16465177

DMAGLPW	DI	DMAGLPW
DMAGLPW	DN	RO-316233
DMAGLPW	MI	TTNAHEX
DMAGLPW	MN	cAMP-dependent protein kinase A type I (PRKAR1A)
DMAGLPW	MT	DTT
DMAGLPW	MA	Inhibitor
DMAGLPW	RN	Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. J Med Chem. 1992 Jan;35(1):177-84.
DMAGLPW	RU	https://pubmed.ncbi.nlm.nih.gov/1732526

DMAGLPW	DI	DMAGLPW
DMAGLPW	DN	RO-316233
DMAGLPW	MI	TTTU902
DMAGLPW	MN	Checkpoint kinase-1 (CHK1)
DMAGLPW	MT	DTT
DMAGLPW	MA	Inhibitor
DMAGLPW	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMAGLPW	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMAGLPW	DI	DMAGLPW
DMAGLPW	DN	RO-316233
DMAGLPW	MI	TTH6V3D
DMAGLPW	MN	Cyclin-dependent kinase 1 (CDK1)
DMAGLPW	MT	DTT
DMAGLPW	MA	Inhibitor
DMAGLPW	RN	Design of new inhibitors for cdc2 kinase based on a multiple pseudosubstrate structure. Bioorg Med Chem Lett. 1998 May 5;8(9):1019-22.
DMAGLPW	RU	https://pubmed.ncbi.nlm.nih.gov/9871700

DMAGLPW	DI	DMAGLPW
DMAGLPW	DN	RO-316233
DMAGLPW	MI	TT4TQBX
DMAGLPW	MN	Extracellular signal-regulated kinase 2 (ERK2)
DMAGLPW	MT	DTT
DMAGLPW	MA	Inhibitor
DMAGLPW	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMAGLPW	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMAGLPW	DI	DMAGLPW
DMAGLPW	DN	RO-316233
DMAGLPW	MI	TT9P6OW
DMAGLPW	MN	G2/mitotic-specific cyclin B1 (CCNB1)
DMAGLPW	MT	DTT
DMAGLPW	MA	Inhibitor
DMAGLPW	RN	Design of new inhibitors for cdc2 kinase based on a multiple pseudosubstrate structure. Bioorg Med Chem Lett. 1998 May 5;8(9):1019-22.
DMAGLPW	RU	https://pubmed.ncbi.nlm.nih.gov/9871700

DMAGLPW	DI	DMAGLPW
DMAGLPW	DN	RO-316233
DMAGLPW	MI	TT860QF
DMAGLPW	MN	LCK tyrosine protein kinase (LCK)
DMAGLPW	MT	DTT
DMAGLPW	MA	Inhibitor
DMAGLPW	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMAGLPW	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMAGLPW	DI	DMAGLPW
DMAGLPW	DN	RO-316233
DMAGLPW	MI	TTYT93M
DMAGLPW	MN	MAP kinase p38 (MAPK12)
DMAGLPW	MT	DTT
DMAGLPW	MA	Inhibitor
DMAGLPW	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMAGLPW	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMAGLPW	DI	DMAGLPW
DMAGLPW	DN	RO-316233
DMAGLPW	MI	TTUF2HO
DMAGLPW	MN	NAD-dependent deacetylase sirtuin-1 (SIRT1)
DMAGLPW	MT	DTT
DMAGLPW	MA	Inhibitor
DMAGLPW	RN	Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition. J Med Chem. 2006 Dec 14;49(25):7307-16.
DMAGLPW	RU	https://pubmed.ncbi.nlm.nih.gov/17149860

DMAGLPW	DI	DMAGLPW
DMAGLPW	DN	RO-316233
DMAGLPW	MI	TT57MT2
DMAGLPW	MN	PKC-epsilon messenger RNA (PRKCE mRNA)
DMAGLPW	MT	DTT
DMAGLPW	MA	Inhibitor
DMAGLPW	RN	Synthesis of anilino-monoindolylmaleimides as potent and selective PKCbeta inhibitors. Bioorg Med Chem Lett. 2004 Oct 18;14(20):5171-4.
DMAGLPW	RU	https://pubmed.ncbi.nlm.nih.gov/15380221

DMAGLPW	DI	DMAGLPW
DMAGLPW	DN	RO-316233
DMAGLPW	MI	TTFJ8Q1
DMAGLPW	MN	Protein kinase C alpha (PRKCA)
DMAGLPW	MT	DTT
DMAGLPW	MA	Inhibitor
DMAGLPW	RN	Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. J Med Chem. 1992 Jan;35(1):177-84.
DMAGLPW	RU	https://pubmed.ncbi.nlm.nih.gov/1732526

DMAGLPW	DI	DMAGLPW
DMAGLPW	DN	RO-316233
DMAGLPW	MI	TTYPXQF
DMAGLPW	MN	Protein kinase C beta (PRKCB)
DMAGLPW	MT	DTT
DMAGLPW	MA	Inhibitor
DMAGLPW	RN	Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. J Med Chem. 1992 Jan;35(1):177-84.
DMAGLPW	RU	https://pubmed.ncbi.nlm.nih.gov/1732526

DMAGLPW	DI	DMAGLPW
DMAGLPW	DN	RO-316233
DMAGLPW	MI	TT9WJ8U
DMAGLPW	MN	Protein kinase C delta (PRKCD)
DMAGLPW	MT	DTT
DMAGLPW	MA	Inhibitor
DMAGLPW	RN	Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. J Med Chem. 1992 Jan;35(1):177-84.
DMAGLPW	RU	https://pubmed.ncbi.nlm.nih.gov/1732526

DMAGLPW	DI	DMAGLPW
DMAGLPW	DN	RO-316233
DMAGLPW	MI	TTBZ7OD
DMAGLPW	MN	Protein kinase C epsilon (PRKCE)
DMAGLPW	MT	DTT
DMAGLPW	MA	Inhibitor
DMAGLPW	RN	Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. J Med Chem. 1992 Jan;35(1):177-84.
DMAGLPW	RU	https://pubmed.ncbi.nlm.nih.gov/1732526

DMAGLPW	DI	DMAGLPW
DMAGLPW	DN	RO-316233
DMAGLPW	MI	TTRFOXJ
DMAGLPW	MN	Protein kinase C gamma (PRKCG)
DMAGLPW	MT	DTT
DMAGLPW	MA	Inhibitor
DMAGLPW	RN	Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. J Med Chem. 1992 Jan;35(1):177-84.
DMAGLPW	RU	https://pubmed.ncbi.nlm.nih.gov/1732526

DMAGLPW	DI	DMAGLPW
DMAGLPW	DN	RO-316233
DMAGLPW	MI	TT8QL1J
DMAGLPW	MN	Protein kinase C theta (PRKCQ)
DMAGLPW	MT	DTT
DMAGLPW	MA	Inhibitor
DMAGLPW	RN	Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. J Med Chem. 1992 Jan;35(1):177-84.
DMAGLPW	RU	https://pubmed.ncbi.nlm.nih.gov/1732526

DMAGLPW	DI	DMAGLPW
DMAGLPW	DN	RO-316233
DMAGLPW	MI	TTUWGRA
DMAGLPW	MN	Protein kinase C zeta (PRKCZ)
DMAGLPW	MT	DTT
DMAGLPW	MA	Inhibitor
DMAGLPW	RN	Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. J Med Chem. 1992 Jan;35(1):177-84.
DMAGLPW	RU	https://pubmed.ncbi.nlm.nih.gov/1732526

DMAGLPW	DI	DMAGLPW
DMAGLPW	DN	RO-316233
DMAGLPW	MI	TTWTSCV
DMAGLPW	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DMAGLPW	MT	DTT
DMAGLPW	MA	Inhibitor
DMAGLPW	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMAGLPW	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMAGLPW	DI	DMAGLPW
DMAGLPW	DN	RO-316233
DMAGLPW	MI	TTZN7RP
DMAGLPW	MN	Rho-associated protein kinase 1 (ROCK1)
DMAGLPW	MT	DTT
DMAGLPW	MA	Inhibitor
DMAGLPW	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMAGLPW	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMAGLPW	DI	DMAGLPW
DMAGLPW	DN	RO-316233
DMAGLPW	MI	TTG0U4H
DMAGLPW	MN	Ribosomal protein S6 kinase beta-1 (S6K1)
DMAGLPW	MT	DTT
DMAGLPW	MA	Inhibitor
DMAGLPW	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMAGLPW	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMAGLPW	DI	DMAGLPW
DMAGLPW	DN	RO-316233
DMAGLPW	MI	TTTV8EJ
DMAGLPW	MN	Serine/threonine-protein kinase Sgk1 (SGK1)
DMAGLPW	MT	DTT
DMAGLPW	MA	Inhibitor
DMAGLPW	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMAGLPW	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMAGLPW	DI	DMAGLPW
DMAGLPW	DN	RO-316233
DMAGLPW	MI	TTQBR95
DMAGLPW	MN	Stress-activated protein kinase 2a (p38 alpha)
DMAGLPW	MT	DTT
DMAGLPW	MA	Inhibitor
DMAGLPW	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMAGLPW	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMAGLPW	DI	DMAGLPW
DMAGLPW	DN	RO-316233
DMAGLPW	MI	TT73U6C
DMAGLPW	MN	Stress-activated protein kinase 2b (p38 beta)
DMAGLPW	MT	DTT
DMAGLPW	MA	Inhibitor
DMAGLPW	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMAGLPW	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMAGLPW	DI	DMAGLPW
DMAGLPW	DN	RO-316233
DMAGLPW	MI	TT0K6EO
DMAGLPW	MN	Stress-activated protein kinase JNK1 (JNK1)
DMAGLPW	MT	DTT
DMAGLPW	MA	Inhibitor
DMAGLPW	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMAGLPW	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMDJLF0	DI	DMDJLF0
DMDJLF0	DN	Ro31-8220
DMDJLF0	MI	TT4TQBX
DMDJLF0	MN	Extracellular signal-regulated kinase 2 (ERK2)
DMDJLF0	MT	DTT
DMDJLF0	MA	Inhibitor
DMDJLF0	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMDJLF0	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMDJLF0	DI	DMDJLF0
DMDJLF0	DN	Ro31-8220
DMDJLF0	MI	TTRSMW9
DMDJLF0	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMDJLF0	MT	DTT
DMDJLF0	MA	Inhibitor
DMDJLF0	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMDJLF0	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMDJLF0	DI	DMDJLF0
DMDJLF0	DN	Ro31-8220
DMDJLF0	MI	TT860QF
DMDJLF0	MN	LCK tyrosine protein kinase (LCK)
DMDJLF0	MT	DTT
DMDJLF0	MA	Inhibitor
DMDJLF0	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMDJLF0	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMDJLF0	DI	DMDJLF0
DMDJLF0	DN	Ro31-8220
DMDJLF0	MI	TTYT93M
DMDJLF0	MN	MAP kinase p38 (MAPK12)
DMDJLF0	MT	DTT
DMDJLF0	MA	Inhibitor
DMDJLF0	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMDJLF0	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMDJLF0	DI	DMDJLF0
DMDJLF0	DN	Ro31-8220
DMDJLF0	MI	TTUF2HO
DMDJLF0	MN	NAD-dependent deacetylase sirtuin-1 (SIRT1)
DMDJLF0	MT	DTT
DMDJLF0	MA	Inhibitor
DMDJLF0	RN	Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition. J Med Chem. 2006 Dec 14;49(25):7307-16.
DMDJLF0	RU	https://pubmed.ncbi.nlm.nih.gov/17149860

DMDJLF0	DI	DMDJLF0
DMDJLF0	DN	Ro31-8220
DMDJLF0	MI	TTFJ8Q1
DMDJLF0	MN	Protein kinase C alpha (PRKCA)
DMDJLF0	MT	DTT
DMDJLF0	MA	Inhibitor
DMDJLF0	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMDJLF0	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMDJLF0	DI	DMDJLF0
DMDJLF0	DN	Ro31-8220
DMDJLF0	MI	TTWTSCV
DMDJLF0	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DMDJLF0	MT	DTT
DMDJLF0	MA	Inhibitor
DMDJLF0	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMDJLF0	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMDJLF0	DI	DMDJLF0
DMDJLF0	DN	Ro31-8220
DMDJLF0	MI	TTZN7RP
DMDJLF0	MN	Rho-associated protein kinase 1 (ROCK1)
DMDJLF0	MT	DTT
DMDJLF0	MA	Inhibitor
DMDJLF0	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMDJLF0	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMDJLF0	DI	DMDJLF0
DMDJLF0	DN	Ro31-8220
DMDJLF0	MI	TTG0U4H
DMDJLF0	MN	Ribosomal protein S6 kinase beta-1 (S6K1)
DMDJLF0	MT	DTT
DMDJLF0	MA	Inhibitor
DMDJLF0	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMDJLF0	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMDJLF0	DI	DMDJLF0
DMDJLF0	DN	Ro31-8220
DMDJLF0	MI	TTQBR95
DMDJLF0	MN	Stress-activated protein kinase 2a (p38 alpha)
DMDJLF0	MT	DTT
DMDJLF0	MA	Inhibitor
DMDJLF0	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMDJLF0	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMDJLF0	DI	DMDJLF0
DMDJLF0	DN	Ro31-8220
DMDJLF0	MI	TT73U6C
DMDJLF0	MN	Stress-activated protein kinase 2b (p38 beta)
DMDJLF0	MT	DTT
DMDJLF0	MA	Inhibitor
DMDJLF0	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMDJLF0	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMDJLF0	DI	DMDJLF0
DMDJLF0	DN	Ro31-8220
DMDJLF0	MI	TT0K6EO
DMDJLF0	MN	Stress-activated protein kinase JNK1 (JNK1)
DMDJLF0	MT	DTT
DMDJLF0	MA	Inhibitor
DMDJLF0	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMDJLF0	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DM9GXYV	DI	DM9GXYV
DM9GXYV	DN	Ro-3201195
DM9GXYV	MI	TTQBR95
DM9GXYV	MN	Stress-activated protein kinase 2a (p38 alpha)
DM9GXYV	MT	DTT
DM9GXYV	MA	Inhibitor
DM9GXYV	RN	Microwave-assisted synthesis of 5-aminopyrazol-4-yl ketones and the p38(MAPK) inhibitor RO3201195 for study in Werner syndrome cells. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3745-8.
DM9GXYV	RU	https://pubmed.ncbi.nlm.nih.gov/18539026

DM8BLYO	DI	DM8BLYO
DM8BLYO	DN	RO320-2947/001
DM8BLYO	MI	TTU3Y87
DM8BLYO	MN	CCR3 messenger RNA (CCR3 mRNA)
DM8BLYO	MT	DTT
DM8BLYO	MA	Antagonist
DM8BLYO	RN	Responses of leukocytes to chemokines in whole blood and their antagonism by novel CC-chemokine receptor 3 antagonists. Am J Respir Crit Care Med. 2002 Jun 15;165(12):1602-9.
DM8BLYO	RU	https://pubmed.ncbi.nlm.nih.gov/12070060

DMPVKEA	DI	DMPVKEA
DMPVKEA	DN	Ro-32-0557
DMPVKEA	MI	TTFJ8Q1
DMPVKEA	MN	Protein kinase C alpha (PRKCA)
DMPVKEA	MT	DTT
DMPVKEA	MA	Inhibitor
DMPVKEA	RN	Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994).
DMPVKEA	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01803498

DMPVKEA	DI	DMPVKEA
DMPVKEA	DN	Ro-32-0557
DMPVKEA	MI	TTYPXQF
DMPVKEA	MN	Protein kinase C beta (PRKCB)
DMPVKEA	MT	DTT
DMPVKEA	MA	Inhibitor
DMPVKEA	RN	Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994).
DMPVKEA	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01803498

DMPVKEA	DI	DMPVKEA
DMPVKEA	DN	Ro-32-0557
DMPVKEA	MI	TT9WJ8U
DMPVKEA	MN	Protein kinase C delta (PRKCD)
DMPVKEA	MT	DTT
DMPVKEA	MA	Inhibitor
DMPVKEA	RN	Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994).
DMPVKEA	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01803498

DMPVKEA	DI	DMPVKEA
DMPVKEA	DN	Ro-32-0557
DMPVKEA	MI	TTBZ7OD
DMPVKEA	MN	Protein kinase C epsilon (PRKCE)
DMPVKEA	MT	DTT
DMPVKEA	MA	Inhibitor
DMPVKEA	RN	Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994).
DMPVKEA	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01803498

DMPVKEA	DI	DMPVKEA
DMPVKEA	DN	Ro-32-0557
DMPVKEA	MI	TTRFOXJ
DMPVKEA	MN	Protein kinase C gamma (PRKCG)
DMPVKEA	MT	DTT
DMPVKEA	MA	Inhibitor
DMPVKEA	RN	Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994).
DMPVKEA	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01803498

DMPVKEA	DI	DMPVKEA
DMPVKEA	DN	Ro-32-0557
DMPVKEA	MI	TT8QL1J
DMPVKEA	MN	Protein kinase C theta (PRKCQ)
DMPVKEA	MT	DTT
DMPVKEA	MA	Inhibitor
DMPVKEA	RN	Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994).
DMPVKEA	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01803498

DMPVKEA	DI	DMPVKEA
DMPVKEA	DN	Ro-32-0557
DMPVKEA	MI	TTUWGRA
DMPVKEA	MN	Protein kinase C zeta (PRKCZ)
DMPVKEA	MT	DTT
DMPVKEA	MA	Inhibitor
DMPVKEA	RN	Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994).
DMPVKEA	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01803498

DMBFCKD	DI	DMBFCKD
DMBFCKD	DN	RO3244794
DMBFCKD	MI	TTOFYT1
DMBFCKD	MN	Prostacyclin receptor (PTGIR)
DMBFCKD	MT	DTT
DMBFCKD	MA	Antagonist
DMBFCKD	RN	RO1138452 and RO3244794: characterization of structurally distinct, potent and selective IP (prostacyclin) receptor antagonists. Br J Pharmacol. 2006 Feb;147(3):335-45.
DMBFCKD	RU	https://pubmed.ncbi.nlm.nih.gov/16331286

DMGOPY1	DI	DMGOPY1
DMGOPY1	DN	RO330-0802/001
DMGOPY1	MI	TTU3Y87
DMGOPY1	MN	CCR3 messenger RNA (CCR3 mRNA)
DMGOPY1	MT	DTT
DMGOPY1	MA	Antagonist
DMGOPY1	RN	Responses of leukocytes to chemokines in whole blood and their antagonism by novel CC-chemokine receptor 3 antagonists. Am J Respir Crit Care Med. 2002 Jun 15;165(12):1602-9.
DMGOPY1	RU	https://pubmed.ncbi.nlm.nih.gov/12070060

DM83QMZ	DI	DM83QMZ
DM83QMZ	DN	Ro-37-9790
DM83QMZ	MI	TTMX39J
DM83QMZ	MN	Matrix metalloproteinase-1 (MMP-1)
DM83QMZ	MT	DTT
DM83QMZ	MA	Inhibitor
DM83QMZ	RN	11,21-Bisphenyl-19-norpregnane derivatives are selective antiglucocorticoids, Bioorg. Med. Chem. Lett. 7(17):2299-2302 (1997).
DM83QMZ	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97003971

DM83QMZ	DI	DM83QMZ
DM83QMZ	DN	Ro-37-9790
DM83QMZ	MI	TTHY57M
DM83QMZ	MN	Matrix metalloproteinase-13 (MMP-13)
DM83QMZ	MT	DTT
DM83QMZ	MA	Inhibitor
DM83QMZ	RN	11,21-Bisphenyl-19-norpregnane derivatives are selective antiglucocorticoids, Bioorg. Med. Chem. Lett. 7(17):2299-2302 (1997).
DM83QMZ	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97003971

DM83QMZ	DI	DM83QMZ
DM83QMZ	DN	Ro-37-9790
DM83QMZ	MI	TTLM12X
DM83QMZ	MN	Matrix metalloproteinase-2 (MMP-2)
DM83QMZ	MT	DTT
DM83QMZ	MA	Inhibitor
DM83QMZ	RN	11,21-Bisphenyl-19-norpregnane derivatives are selective antiglucocorticoids, Bioorg. Med. Chem. Lett. 7(17):2299-2302 (1997).
DM83QMZ	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97003971

DM83QMZ	DI	DM83QMZ
DM83QMZ	DN	Ro-37-9790
DM83QMZ	MI	TTUZ2L5
DM83QMZ	MN	Matrix metalloproteinase-3 (MMP-3)
DM83QMZ	MT	DTT
DM83QMZ	MA	Inhibitor
DM83QMZ	RN	11,21-Bisphenyl-19-norpregnane derivatives are selective antiglucocorticoids, Bioorg. Med. Chem. Lett. 7(17):2299-2302 (1997).
DM83QMZ	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97003971

DM83QMZ	DI	DM83QMZ
DM83QMZ	DN	Ro-37-9790
DM83QMZ	MI	TTGA1IV
DM83QMZ	MN	Matrix metalloproteinase-8 (MMP-8)
DM83QMZ	MT	DTT
DM83QMZ	MA	Inhibitor
DM83QMZ	RN	11,21-Bisphenyl-19-norpregnane derivatives are selective antiglucocorticoids, Bioorg. Med. Chem. Lett. 7(17):2299-2302 (1997).
DM83QMZ	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97003971

DM83QMZ	DI	DM83QMZ
DM83QMZ	DN	Ro-37-9790
DM83QMZ	MI	TT6X50U
DM83QMZ	MN	Matrix metalloproteinase-9 (MMP-9)
DM83QMZ	MT	DTT
DM83QMZ	MA	Inhibitor
DM83QMZ	RN	11,21-Bisphenyl-19-norpregnane derivatives are selective antiglucocorticoids, Bioorg. Med. Chem. Lett. 7(17):2299-2302 (1997).
DM83QMZ	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97003971

DM8PYAN	DI	DM8PYAN
DM8PYAN	DN	Ro-40-0655
DM8PYAN	MI	TTW38KT
DM8PYAN	MN	Retinoic acid receptor alpha (RARA)
DM8PYAN	MT	DTT
DM8PYAN	MA	Agonist
DM8PYAN	RN	Tamibarotene. Drugs Today (Barc). 2007 Aug;43(8):563-8.
DM8PYAN	RU	https://pubmed.ncbi.nlm.nih.gov/17925887

DM5DMCH	DI	DM5DMCH
DM5DMCH	DN	Ro-4396686
DM5DMCH	MI	TTW4Y2M
DM5DMCH	MN	cAMP protein kinase type II-beta (PRKAR2B)
DM5DMCH	MT	DTT
DM5DMCH	MA	Inhibitor
DM5DMCH	RN	Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.
DM5DMCH	RU	https://pubmed.ncbi.nlm.nih.gov/16460940

DM5DMCH	DI	DM5DMCH
DM5DMCH	DN	Ro-4396686
DM5DMCH	MI	TTGKNB4
DM5DMCH	MN	Epidermal growth factor receptor (EGFR)
DM5DMCH	MT	DTT
DM5DMCH	MA	Inhibitor
DM5DMCH	RN	Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.
DM5DMCH	RU	https://pubmed.ncbi.nlm.nih.gov/16460940

DM5DMCH	DI	DM5DMCH
DM5DMCH	DN	Ro-4396686
DM5DMCH	MI	TT4TQBX
DM5DMCH	MN	Extracellular signal-regulated kinase 2 (ERK2)
DM5DMCH	MT	DTT
DM5DMCH	MA	Inhibitor
DM5DMCH	RN	Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.
DM5DMCH	RU	https://pubmed.ncbi.nlm.nih.gov/16460940

DM5DMCH	DI	DM5DMCH
DM5DMCH	DN	Ro-4396686
DM5DMCH	MI	TT1KX2S
DM5DMCH	MN	FGFR4 messenger RNA (FGFR4 mRNA)
DM5DMCH	MT	DTT
DM5DMCH	MA	Inhibitor
DM5DMCH	RN	Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.
DM5DMCH	RU	https://pubmed.ncbi.nlm.nih.gov/16460940

DM5DMCH	DI	DM5DMCH
DM5DMCH	DN	Ro-4396686
DM5DMCH	MI	TTRLW2X
DM5DMCH	MN	Fibroblast growth factor receptor 1 (FGFR1)
DM5DMCH	MT	DTT
DM5DMCH	MA	Inhibitor
DM5DMCH	RN	Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.
DM5DMCH	RU	https://pubmed.ncbi.nlm.nih.gov/16460940

DM5DMCH	DI	DM5DMCH
DM5DMCH	DN	Ro-4396686
DM5DMCH	MI	TTGJVQM
DM5DMCH	MN	Fibroblast growth factor receptor 2 (FGFR2)
DM5DMCH	MT	DTT
DM5DMCH	MA	Inhibitor
DM5DMCH	RN	Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.
DM5DMCH	RU	https://pubmed.ncbi.nlm.nih.gov/16460940

DM5DMCH	DI	DM5DMCH
DM5DMCH	DN	Ro-4396686
DM5DMCH	MI	TTST7KB
DM5DMCH	MN	Fibroblast growth factor receptor 3 (FGFR3)
DM5DMCH	MT	DTT
DM5DMCH	MA	Inhibitor
DM5DMCH	RN	Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.
DM5DMCH	RU	https://pubmed.ncbi.nlm.nih.gov/16460940

DM5DMCH	DI	DM5DMCH
DM5DMCH	DN	Ro-4396686
DM5DMCH	MI	TTYVI76
DM5DMCH	MN	Fungal Protein kinase A (Fung ypkA)
DM5DMCH	MT	DTT
DM5DMCH	MA	Inhibitor
DM5DMCH	RN	Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.
DM5DMCH	RU	https://pubmed.ncbi.nlm.nih.gov/16460940

DM5DMCH	DI	DM5DMCH
DM5DMCH	DN	Ro-4396686
DM5DMCH	MI	TT2B9KF
DM5DMCH	MN	Fyn tyrosine protein kinase (FYN)
DM5DMCH	MT	DTT
DM5DMCH	MA	Inhibitor
DM5DMCH	RN	Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.
DM5DMCH	RU	https://pubmed.ncbi.nlm.nih.gov/16460940

DM5DMCH	DI	DM5DMCH
DM5DMCH	DN	Ro-4396686
DM5DMCH	MI	TT8FYO9
DM5DMCH	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DM5DMCH	MT	DTT
DM5DMCH	MA	Inhibitor
DM5DMCH	RN	Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.
DM5DMCH	RU	https://pubmed.ncbi.nlm.nih.gov/16460940

DM5DMCH	DI	DM5DMCH
DM5DMCH	DN	Ro-4396686
DM5DMCH	MI	TTI7421
DM5DMCH	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM5DMCH	MT	DTT
DM5DMCH	MA	Inhibitor
DM5DMCH	RN	Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.
DM5DMCH	RU	https://pubmed.ncbi.nlm.nih.gov/16460940

DM5DMCH	DI	DM5DMCH
DM5DMCH	DN	Ro-4396686
DM5DMCH	MI	TT5U49F
DM5DMCH	MN	PRKACA messenger RNA (PRKACA mRNA)
DM5DMCH	MT	DTT
DM5DMCH	MA	Inhibitor
DM5DMCH	RN	Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.
DM5DMCH	RU	https://pubmed.ncbi.nlm.nih.gov/16460940

DM5DMCH	DI	DM5DMCH
DM5DMCH	DN	Ro-4396686
DM5DMCH	MI	TTUTJGQ
DM5DMCH	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM5DMCH	MT	DTT
DM5DMCH	MA	Inhibitor
DM5DMCH	RN	Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.
DM5DMCH	RU	https://pubmed.ncbi.nlm.nih.gov/16460940

DMJLSX0	DI	DMJLSX0
DMJLSX0	DN	Ro4491533
DMJLSX0	MI	TTXJ47W
DMJLSX0	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMJLSX0	MT	DTT
DMJLSX0	MA	Modulator (allosteric modulator)
DMJLSX0	RN	Characterization of an mGluR2/3 negative allosteric modulator in rodent models of depression. J Neurogenet. 2011 Dec;25(4):152-66.
DMJLSX0	RU	https://pubmed.ncbi.nlm.nih.gov/22091727

DMJLSX0	DI	DMJLSX0
DMJLSX0	DN	Ro4491533
DMJLSX0	MI	TT8A9EF
DMJLSX0	MN	Metabotropic glutamate receptor 3 (mGluR3)
DMJLSX0	MT	DTT
DMJLSX0	MA	Modulator (allosteric modulator)
DMJLSX0	RN	Synthesis and characterization of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: Part 4. In vivo active potent and selective non-competitive metabotropic glutamate receptor 2/3 antagonists. Bioorg Med Chem Lett. 2010 Dec 1;20(23):6969-74.
DMJLSX0	RU	https://pubmed.ncbi.nlm.nih.gov/20971004

DMC0V25	DI	DMC0V25
DMC0V25	DN	RO-4840700
DMC0V25	MI	TTHJTF7
DMC0V25	MN	Glycine transporter GlyT-1 (SLC6A9)
DMC0V25	MT	DTT
DMC0V25	MA	Inhibitor
DMC0V25	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 935).
DMC0V25	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=935

DMVGITD	DI	DMVGITD
DMVGITD	DN	Ro48-8071
DMVGITD	MI	TT7O8ZA
DMVGITD	MN	Lanosterol synthase (LSS)
DMVGITD	MT	DTT
DMVGITD	MA	Inhibitor
DMVGITD	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMVGITD	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD9SCI	DI	DMD9SCI
DMD9SCI	DN	RO-4920506
DMD9SCI	MI	TTROQ37
DMD9SCI	MN	MAPK/ERK kinase kinase (MAP3K)
DMD9SCI	MT	DTT
DMD9SCI	MA	Inhibitor
DMD9SCI	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2063).
DMD9SCI	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2063

DMCB2N9	DI	DMCB2N9
DMCB2N9	DN	Ro-4938581
DMCB2N9	MI	TT1MPAY
DMCB2N9	MN	GABA(A) receptor alpha-1 (GABRA1)
DMCB2N9	MT	DTT
DMCB2N9	MA	Inhibitor
DMCB2N9	RN	The discovery and unique pharmacological profile of RO4938581 and RO4882224 as potent and selective GABAA alpha5 inverse agonists for the treatment... Bioorg Med Chem Lett. 2009 Oct 15;19(20):5940-4.
DMCB2N9	RU	https://pubmed.ncbi.nlm.nih.gov/19762240

DMCB2N9	DI	DMCB2N9
DMCB2N9	DN	Ro-4938581
DMCB2N9	MI	TTBMV1G
DMCB2N9	MN	GABA(A) receptor alpha-2 (GABRA2)
DMCB2N9	MT	DTT
DMCB2N9	MA	Inhibitor
DMCB2N9	RN	The discovery and unique pharmacological profile of RO4938581 and RO4882224 as potent and selective GABAA alpha5 inverse agonists for the treatment... Bioorg Med Chem Lett. 2009 Oct 15;19(20):5940-4.
DMCB2N9	RU	https://pubmed.ncbi.nlm.nih.gov/19762240

DMCB2N9	DI	DMCB2N9
DMCB2N9	DN	Ro-4938581
DMCB2N9	MI	TT37EDJ
DMCB2N9	MN	GABA(A) receptor alpha-3 (GABRA3)
DMCB2N9	MT	DTT
DMCB2N9	MA	Inhibitor
DMCB2N9	RN	The discovery and unique pharmacological profile of RO4938581 and RO4882224 as potent and selective GABAA alpha5 inverse agonists for the treatment... Bioorg Med Chem Lett. 2009 Oct 15;19(20):5940-4.
DMCB2N9	RU	https://pubmed.ncbi.nlm.nih.gov/19762240

DMCB2N9	DI	DMCB2N9
DMCB2N9	DN	Ro-4938581
DMCB2N9	MI	TTNZPQ1
DMCB2N9	MN	GABA(A) receptor alpha-5 (GABRA5)
DMCB2N9	MT	DTT
DMCB2N9	MA	Inhibitor
DMCB2N9	RN	The discovery and unique pharmacological profile of RO4938581 and RO4882224 as potent and selective GABAA alpha5 inverse agonists for the treatment... Bioorg Med Chem Lett. 2009 Oct 15;19(20):5940-4.
DMCB2N9	RU	https://pubmed.ncbi.nlm.nih.gov/19762240

DMCB2N9	DI	DMCB2N9
DMCB2N9	DN	Ro-4938581
DMCB2N9	MI	TT06RH5
DMCB2N9	MN	GABA(A) receptor gamma-2 (GABRG2)
DMCB2N9	MT	DTT
DMCB2N9	MA	Inhibitor
DMCB2N9	RN	The discovery and unique pharmacological profile of RO4938581 and RO4882224 as potent and selective GABAA alpha5 inverse agonists for the treatment... Bioorg Med Chem Lett. 2009 Oct 15;19(20):5940-4.
DMCB2N9	RU	https://pubmed.ncbi.nlm.nih.gov/19762240

DMCB2N9	DI	DMCB2N9
DMCB2N9	DN	Ro-4938581
DMCB2N9	MI	TTNJYV2
DMCB2N9	MN	Gamma-aminobutyric acid receptor (GAR)
DMCB2N9	MT	DTT
DMCB2N9	MA	Inhibitor
DMCB2N9	RN	The discovery and unique pharmacological profile of RO4938581 and RO4882224 as potent and selective GABAA alpha5 inverse agonists for the treatment... Bioorg Med Chem Lett. 2009 Oct 15;19(20):5940-4.
DMCB2N9	RU	https://pubmed.ncbi.nlm.nih.gov/19762240

DM6SQ9A	DI	DM6SQ9A
DM6SQ9A	DN	RO4988546
DM6SQ9A	MI	TTXJ47W
DM6SQ9A	MN	Metabotropic glutamate receptor 2 (mGluR2)
DM6SQ9A	MT	DTT
DM6SQ9A	MA	Modulator (allosteric modulator)
DM6SQ9A	RN	Structural determinants of allosteric antagonism at metabotropic glutamate receptor 2: mechanistic studies with new potent negative allosteric modulators. Br J Pharmacol. 2011 Sep;164(2b):521-37.
DM6SQ9A	RU	https://pubmed.ncbi.nlm.nih.gov/21470207

DMPXC9L	DI	DMPXC9L
DMPXC9L	DN	RO5101576
DMPXC9L	MI	TTVJX54
DMPXC9L	MN	Leukotriene B4 receptor 2 (LTB4R2)
DMPXC9L	MT	DTT
DMPXC9L	MA	Antagonist
DMPXC9L	RN	Effects of LTB4 receptor antagonism on pulmonary inflammation in rodents and non-human primates. Prostaglandins Other Lipid Mediat. 2010 Jun;92(1-4):33-43.
DMPXC9L	RU	https://pubmed.ncbi.nlm.nih.gov/20214997

DM57UB9	DI	DM57UB9
DM57UB9	DN	RO5166017
DM57UB9	MI	TTIU98M
DM57UB9	MN	Trace amine-associated receptor-1 (TAAR1)
DM57UB9	MT	DTT
DM57UB9	MA	Agonist
DM57UB9	RN	TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. Proc Natl Acad Sci U S A. 2011 May 17;108(20):8485-90.
DM57UB9	RU	https://pubmed.ncbi.nlm.nih.gov/21525407

DM42UK5	DI	DM42UK5
DM42UK5	DN	Ro5203280
DM42UK5	MI	TTIYVQP
DM42UK5	MN	Polo-like kinase 1 (PLK1)
DM42UK5	MT	DTT
DM42UK5	MA	Inhibitor
DM42UK5	RN	Polo-like kinase inhibitor Ro5203280 has potent antitumor activity in nasopharyngeal carcinoma.Mol Cancer Ther. 2013 Aug;12(8):1393-401.
DM42UK5	RU	https://pubmed.ncbi.nlm.nih.gov/23686835

DMP0GA6	DI	DMP0GA6
DMP0GA6	DN	RO-5212651
DMP0GA6	MI	TT7QNVC
DMP0GA6	MN	Glucose-dependent insulinotropic receptor (GPR119)
DMP0GA6	MT	DTT
DMP0GA6	MA	Agonist
DMP0GA6	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 126).
DMP0GA6	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=126

DMHXGCO	DI	DMHXGCO
DMHXGCO	DN	RO5488608
DMHXGCO	MI	TTXJ47W
DMHXGCO	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMHXGCO	MT	DTT
DMHXGCO	MA	Modulator (allosteric modulator)
DMHXGCO	RN	Structural determinants of allosteric antagonism at metabotropic glutamate receptor 2: mechanistic studies with new potent negative allosteric modulators. Br J Pharmacol. 2011 Sep;164(2b):521-37.
DMHXGCO	RU	https://pubmed.ncbi.nlm.nih.gov/21470207

DMXOTHC	DI	DMXOTHC
DMXOTHC	DN	Ro64-5229
DMXOTHC	MI	TTXJ47W
DMXOTHC	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMXOTHC	MT	DTT
DMXOTHC	MA	Modulator (allosteric modulator)
DMXOTHC	RN	Synthesis of heterocyclic enol ethers and their use as group 2 metabotropic glutamate receptor antagonists. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2173-6.
DMXOTHC	RU	https://pubmed.ncbi.nlm.nih.gov/10465539

DM6S742	DI	DM6S742
DM6S742	DN	Ro-65-7219
DM6S742	MI	TTB2MXP
DM6S742	MN	Angiotensinogenase renin (REN)
DM6S742	MT	DTT
DM6S742	MA	Inhibitor
DM6S742	RN	Direct renin inhibitors as a new therapy for hypertension. J Med Chem. 2010 Nov 11;53(21):7490-520.
DM6S742	RU	https://pubmed.ncbi.nlm.nih.gov/20731374

DMPT01J	DI	DMPT01J
DMPT01J	DN	Ro-66-1168
DMPT01J	MI	TTB2MXP
DMPT01J	MN	Angiotensinogenase renin (REN)
DMPT01J	MT	DTT
DMPT01J	MA	Inhibitor
DMPT01J	RN	Design and preparation of potent, nonpeptidic, bioavailable renin inhibitors. J Med Chem. 2009 Jun 25;52(12):3689-702.
DMPT01J	RU	https://pubmed.ncbi.nlm.nih.gov/19358611

DMD93NP	DI	DMD93NP
DMD93NP	DN	Ro67-4853
DMD93NP	MI	TTVBPDM
DMD93NP	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMD93NP	MT	DTT
DMD93NP	MA	Modulator (allosteric modulator)
DMD93NP	RN	Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action, and binding site. Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13402-7.
DMD93NP	RU	https://pubmed.ncbi.nlm.nih.gov/11606768

DMI95DP	DI	DMI95DP
DMI95DP	DN	Ro67-7476
DMI95DP	MI	TTVBPDM
DMI95DP	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMI95DP	MT	DTT
DMI95DP	MA	Modulator (allosteric modulator)
DMI95DP	RN	Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action, and binding site. Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13402-7.
DMI95DP	RU	https://pubmed.ncbi.nlm.nih.gov/11606768

DMASOWP	DI	DMASOWP
DMASOWP	DN	ROBINETIN
DMASOWP	MI	TT7RJY8
DMASOWP	MN	Xanthine dehydrogenase/oxidase (XDH)
DMASOWP	MT	DTT
DMASOWP	MA	Inhibitor
DMASOWP	RN	Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod. 1988 Mar-Apr;51(2):345-8.
DMASOWP	RU	https://pubmed.ncbi.nlm.nih.gov/3379415

DME9VTX	DI	DME9VTX
DME9VTX	DN	ROCAGLAMIDE
DME9VTX	MI	TTSXVID
DME9VTX	MN	Nuclear factor NF-kappa-B (NFKB)
DME9VTX	MT	DTT
DME9VTX	MA	Inhibitor
DME9VTX	RN	Cytotoxic and NF-kappaB inhibitory constituents of Artocarpus rigida. J Nat Prod. 2010 May 28;73(5):949-55.
DME9VTX	RU	https://pubmed.ncbi.nlm.nih.gov/20384315

DMD4JHK	DI	DMD4JHK
DMD4JHK	DN	Roche 28-2653
DMD4JHK	MI	TTLM12X
DMD4JHK	MN	Matrix metalloproteinase-2 (MMP-2)
DMD4JHK	MT	DTT
DMD4JHK	MA	Inhibitor
DMD4JHK	RN	The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model. Oncogene. 2002 Mar 27;21(13):2089-96.
DMD4JHK	RU	https://pubmed.ncbi.nlm.nih.gov/11960381

DMD4JHK	DI	DMD4JHK
DMD4JHK	DN	Roche 28-2653
DMD4JHK	MI	TT6X50U
DMD4JHK	MN	Matrix metalloproteinase-9 (MMP-9)
DMD4JHK	MT	DTT
DMD4JHK	MA	Inhibitor
DMD4JHK	RN	The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model. Oncogene. 2002 Mar 27;21(13):2089-96.
DMD4JHK	RU	https://pubmed.ncbi.nlm.nih.gov/11960381

DMOTPJD	DI	DMOTPJD
DMOTPJD	DN	Rockout
DMOTPJD	MI	TTTB4UP
DMOTPJD	MN	Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2)
DMOTPJD	MT	DTT
DMOTPJD	MA	Inhibitor
DMOTPJD	RN	Novel indole inhibitors of IMPDH from fragments: synthesis and initial structure-activity relationships. Bioorg Med Chem Lett. 2006 May 1;16(9):2539-42.
DMOTPJD	RU	https://pubmed.ncbi.nlm.nih.gov/16483773

DM5HV4W	DI	DM5HV4W
DM5HV4W	DN	Rolicyclidine
DM5HV4W	MI	TTEX248
DM5HV4W	MN	Dopamine D2 receptor (D2R)
DM5HV4W	MT	DTT
DM5HV4W	MA	Inhibitor
DM5HV4W	RN	4-Acetoxy-7-chloro-3-(3-(-4-[11C]methoxybenzyl)phenyl)-2(1H)-quinolone Molecular Imaging and Contrast Agent Database (MICAD) [Internet].
DM5HV4W	RU	https://pubmed.ncbi.nlm.nih.gov/20641908

DMJ03UM	DI	DMJ03UM
DMJ03UM	DN	ROLIPRAM
DMJ03UM	MI	TTZ97H5
DMJ03UM	MN	Phosphodiesterase 4A (PDE4A)
DMJ03UM	MT	DTT
DMJ03UM	MA	Inhibitor
DMJ03UM	RN	Discovery of micromolar PDE IV inhibitors that exhibit much reduced affinity for the [3H]rolipram binding site: 3-norbornyloxy-4-methoxyphenylmethylene oxindoles, Bioorg. Med. Chem. Lett. 5(17):1965-1968 (1995).
DMJ03UM	RU	http://www.sciencedirect.com/science/article/pii/0960894X9500333O

DMJ03UM	DI	DMJ03UM
DMJ03UM	DN	ROLIPRAM
DMJ03UM	MI	TTVIAT9
DMJ03UM	MN	Phosphodiesterase 4B (PDE4B)
DMJ03UM	MT	DTT
DMJ03UM	MA	Inhibitor
DMJ03UM	RN	Novel heterocyclic-fused pyridazinones as potent and selective phosphodiesterase IV inhibitors. J Med Chem. 1997 May 9;40(10):1417-21.
DMJ03UM	RU	https://pubmed.ncbi.nlm.nih.gov/9154964

DMJ03UM	DI	DMJ03UM
DMJ03UM	DN	ROLIPRAM
DMJ03UM	MI	TTSKMI8
DMJ03UM	MN	Phosphodiesterase 4D (PDE4D)
DMJ03UM	MT	DTT
DMJ03UM	MA	Inhibitor
DMJ03UM	RN	In silico search for multi-target anti-inflammatories in Chinese herbs and formulas. Bioorg Med Chem. 2010 Mar 15;18(6):2204-2218.
DMJ03UM	RU	https://pubmed.ncbi.nlm.nih.gov/20188577

DMJ03UM	DI	DMJ03UM
DMJ03UM	DN	ROLIPRAM
DMJ03UM	MI	TTJ0IQB
DMJ03UM	MN	Phosphodiesterase 5A (PDE5A)
DMJ03UM	MT	DTT
DMJ03UM	MA	Inhibitor
DMJ03UM	RN	Cyclic GMP phosphodiesterase inhibitors. 2. Requirement of 6-substitution of quinazoline derivatives for potent and selective inhibitory activity. J Med Chem. 1994 Jun 24;37(13):2106-11.
DMJ03UM	RU	https://pubmed.ncbi.nlm.nih.gov/8027992

DMAROW1	DI	DMAROW1
DMAROW1	DN	ROMe
DMAROW1	MI	TTCN0M9
DMAROW1	MN	Sphingosine kinase 2 (SPHK2)
DMAROW1	MT	DTT
DMAROW1	MA	Inhibitor
DMAROW1	RN	(R)-FTY720 methyl ether is a specific sphingosine kinase 2 inhibitor: Effect on sphingosine kinase 2 expression in HEK 293 cells and actin rearrangement and survival of MCF-7 breast cancer cells. Cell Signal. 2011 Oct;23(10):1590-5.
DMAROW1	RU	https://pubmed.ncbi.nlm.nih.gov/21620961

DM3NBQ6	DI	DM3NBQ6
DM3NBQ6	DN	rose bengal (photoactivated)
DM3NBQ6	MI	TTXF0ZW
DM3NBQ6	MN	Inward rectifier potassium channel Kir2.3 (KCNJ4)
DM3NBQ6	MT	DTT
DM3NBQ6	MA	Inhibitor (gating inhibitor)
DM3NBQ6	RN	Susceptibility of cloned K+ channels to reactive oxygen species. Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11796-800.
DM3NBQ6	RU	https://pubmed.ncbi.nlm.nih.gov/8524851

DMN802V	DI	DMN802V
DMN802V	DN	ROSETTACIN
DMN802V	MI	TTGTQHC
DMN802V	MN	DNA topoisomerase I (TOP1)
DMN802V	MT	DTT
DMN802V	MA	Inhibitor
DMN802V	RN	Synthesis and biological evaluation of 14-(aminoalkyl-aminomethyl)aromathecins as topoisomerase I inhibitors: investigating the hypothesis of share... Bioorg Med Chem. 2009 Oct 15;17(20):7145-55.
DMN802V	RU	https://pubmed.ncbi.nlm.nih.gov/19783447

DMQ6SJT	DI	DMQ6SJT
DMQ6SJT	DN	ROSMARINIC ACID
DMQ6SJT	MI	TTL53M6
DMQ6SJT	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DMQ6SJT	MT	DTT
DMQ6SJT	MA	Inhibitor
DMQ6SJT	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMQ6SJT	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMQ6SJT	DI	DMQ6SJT
DMQ6SJT	DN	ROSMARINIC ACID
DMQ6SJT	MI	TTULVH8
DMQ6SJT	MN	Tyrosinase (TYR)
DMQ6SJT	MT	DTT
DMQ6SJT	MA	Inhibitor
DMQ6SJT	RN	A novel ring-expanded product with enhanced tyrosinase inhibitory activity from classical Fe-catalyzed oxidation of rosmarinic acid, a potent antio... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7393-6.
DMQ6SJT	RU	https://pubmed.ncbi.nlm.nih.gov/21041086

DMT0DW4	DI	DMT0DW4
DMT0DW4	DN	Rotigitine
DMT0DW4	MI	TTEX248
DMT0DW4	MN	Dopamine D2 receptor (D2R)
DMT0DW4	MT	DTT
DMT0DW4	MA	Agonist
DMT0DW4	RN	Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54.
DMT0DW4	RU	https://pubmed.ncbi.nlm.nih.gov/17016425

DM751OH	DI	DM751OH
DM751OH	DN	Rotungenic acid
DM751OH	MI	TTELIN2
DM751OH	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DM751OH	MT	DTT
DM751OH	MA	Inhibitor
DM751OH	RN	Triterpenoids from the leaves of Diospyros kaki (persimmon) and their inhibitory effects on protein tyrosine phosphatase 1B. J Nat Prod. 2008 Oct;71(10):1775-8.
DM751OH	RU	https://pubmed.ncbi.nlm.nih.gov/18798681

DMWUAMQ	DI	DMWUAMQ
DMWUAMQ	DN	ROXIFIBAN
DMWUAMQ	MI	TTJA1ZO
DMWUAMQ	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMWUAMQ	MT	DTT
DMWUAMQ	MA	Inhibitor
DMWUAMQ	RN	Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J Med Chem. 2000 Sep 21;43(19):3453-73.
DMWUAMQ	RU	https://pubmed.ncbi.nlm.nih.gov/10999999

DMP2EDX	DI	DMP2EDX
DMP2EDX	DN	RP-1040
DMP2EDX	MI	TTNDSF4
DMP2EDX	MN	Proto-oncogene c-Met (MET)
DMP2EDX	MT	DTT
DMP2EDX	MA	Inhibitor
DMP2EDX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
DMP2EDX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815

DM5IXOS	DI	DM5IXOS
DM5IXOS	DN	RP-52770
DM5IXOS	MI	TTQL5VC
DM5IXOS	MN	Platelet-activating factor receptor (PTAFR)
DM5IXOS	MT	DTT
DM5IXOS	MA	Antagonist
DM5IXOS	RN	[3H]52770 RP, a platelet-activating factor receptor antagonist, and tritiated platelet-activating factor label a common specific binding site in human polymorphonuclear leukocytes. J Pharmacol Exp Ther. 1988 Feb;244(2):709-15.
DM5IXOS	RU	https://pubmed.ncbi.nlm.nih.gov/2831350

DM03RIT	DI	DM03RIT
DM03RIT	DN	Rp-5-OMe-UDPalphaB
DM03RIT	MI	TTNVSKA
DM03RIT	MN	P2Y purinoceptor 6 (P2RY6)
DM03RIT	MT	DTT
DM03RIT	MA	Agonist
DM03RIT	RN	5-OMe-uridine-5'-O-(alpha-boranodiphosphate), a novel nucleotide derivative highly active at the human P2Y(6) receptor protects against death-receptor mediated glial apoptosis. Neurosci Lett. 2014 Aug 22;578:80-4.
DM03RIT	RU	https://pubmed.ncbi.nlm.nih.gov/24970757

DMR4O3I	DI	DMR4O3I
DMR4O3I	DN	RP-66471
DMR4O3I	MI	TT1VOHK
DMR4O3I	MN	Potassium channel unspecific (KC)
DMR4O3I	MT	DTT
DMR4O3I	MA	Modulator
DMR4O3I	RN	Potassium channel opener, RP 66471, induces membrane depolarization of rat liver mitochondria. Biochem Biophys Res Commun. 1995 Feb 6;207(1):126-32.
DMR4O3I	RU	https://www.ncbi.nlm.nih.gov/pubmed/7857254

DMXMRVG	DI	DMXMRVG
DMXMRVG	DN	RP-69758
DMXMRVG	MI	TTVFO0U
DMXMRVG	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMXMRVG	MT	DTT
DMXMRVG	MA	Antagonist
DMXMRVG	RN	Pharmacological properties of ureido-acetamides, new potent and selective non-peptide CCKB/gastrin receptor antagonists. Eur J Pharmacol. 1994 Sep 12;262(3):233-45.
DMXMRVG	RU	https://pubmed.ncbi.nlm.nih.gov/7813588

DMUFLNT	DI	DMUFLNT
DMUFLNT	DN	RP-71483
DMUFLNT	MI	TTVFO0U
DMUFLNT	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMUFLNT	MT	DTT
DMUFLNT	MA	Modulator
DMUFLNT	RN	Pharmacological properties of ureido-acetamides, new potent and selective non-peptide CCKB/gastrin receptor antagonists. Eur J Pharmacol. 1994 Sep 12;262(3):233-45.
DMUFLNT	RU	https://pubmed.ncbi.nlm.nih.gov/7813588

DMWIXQS	DI	DMWIXQS
DMWIXQS	DN	RP-72540
DMWIXQS	MI	TTVFO0U
DMWIXQS	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMWIXQS	MT	DTT
DMWIXQS	MA	Modulator
DMWIXQS	RN	Pharmacological properties of ureido-acetamides, new potent and selective non-peptide CCKB/gastrin receptor antagonists. Eur J Pharmacol. 1994 Sep 12;262(3):233-45.
DMWIXQS	RU	https://pubmed.ncbi.nlm.nih.gov/7813588

DMLKPZ6	DI	DMLKPZ6
DMLKPZ6	DN	RP73870
DMLKPZ6	MI	TTVFO0U
DMLKPZ6	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMLKPZ6	MT	DTT
DMLKPZ6	MA	Antagonist
DMLKPZ6	RN	Pharmacological analysis of CCK2 receptor antagonists using isolated rat stomach ECL cells. Br J Pharmacol. 1999 May;127(2):530-6.
DMLKPZ6	RU	https://pubmed.ncbi.nlm.nih.gov/10385255

DMJMC43	DI	DMJMC43
DMJMC43	DN	Rp-8-CPT-cGMPS
DMJMC43	MI	TT7IZSA
DMJMC43	MN	Protein kinase G1 (PRKG1)
DMJMC43	MT	DTT
DMJMC43	MA	Inhibitor
DMJMC43	RN	(Rp)-8-pCPT-cGMPS, a novel cGMP-dependent protein kinase inhibitor. Eur J Pharmacol. 1994 Oct 14;269(2):265-8.
DMJMC43	RU	https://pubmed.ncbi.nlm.nih.gov/7851503

DM1JWGH	DI	DM1JWGH
DM1JWGH	DN	Rp-adenosine 3',5'-cyclic monophosphothioate triethylamine (Rp-cAMPS)
DM1JWGH	MI	TTYVI76
DM1JWGH	MN	Fungal Protein kinase A (Fung ypkA)
DM1JWGH	MT	DTT
DM1JWGH	MA	Inhibitor
DM1JWGH	RN	Inhibition of protein kinase A activity interferes with long-term, but not short-term, memory of conditioned taste aversions. Behav Neurosci. 2002 Dec;116(6):1070-4.
DM1JWGH	RU	https://pubmed.ncbi.nlm.nih.gov/12492305

DMG0S9B	DI	DMG0S9B
DMG0S9B	DN	Rp-cAMPS
DMG0S9B	MI	TTYVI76
DMG0S9B	MN	Fungal Protein kinase A (Fung ypkA)
DMG0S9B	MT	DTT
DMG0S9B	MA	Inhibitor
DMG0S9B	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1694).
DMG0S9B	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1694

DMAROTU	DI	DMAROTU
DMAROTU	DN	RPKPfQwFwLL-NH2
DMAROTU	MI	TTWDC17
DMAROTU	MN	Growth hormone secretagogue receptor 1 (GHSR)
DMAROTU	MT	DTT
DMAROTU	MA	Inhibitor
DMAROTU	RN	Identification of an efficacy switch region in the ghrelin receptor responsible for interchange between agonism and inverse agonism. J Biol Chem. 2007 May 25;282(21):15799-811.
DMAROTU	RU	https://pubmed.ncbi.nlm.nih.gov/17371869

DM0HD3O	DI	DM0HD3O
DM0HD3O	DN	RPR-101511
DM0HD3O	MI	TT8FYO9
DM0HD3O	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DM0HD3O	MT	DTT
DM0HD3O	MA	Inhibitor
DM0HD3O	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DM0HD3O	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DM0HD3O	DI	DM0HD3O
DM0HD3O	DN	RPR-101511
DM0HD3O	MI	TTI7421
DM0HD3O	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM0HD3O	MT	DTT
DM0HD3O	MA	Inhibitor
DM0HD3O	RN	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
DM0HD3O	RU	https://pubmed.ncbi.nlm.nih.gov/8035419

DM9ODEZ	DI	DM9ODEZ
DM9ODEZ	DN	RPR-107836
DM9ODEZ	MI	TTVFO0U
DM9ODEZ	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DM9ODEZ	MT	DTT
DM9ODEZ	MA	Modulator
DM9ODEZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 77).
DM9ODEZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=77

DM37I92	DI	DM37I92
DM37I92	DN	RPR-108514A
DM37I92	MI	TT8FYO9
DM37I92	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DM37I92	MT	DTT
DM37I92	MA	Inhibitor
DM37I92	RN	The synthesis and SAR of new 4-(N-alkyl-N-phenyl)amino-6,7-dimethoxyquinazolines and 4-(N-alkyl-N-phenyl)aminopyrazolo[3,4-d]pyrimidines, inhibitors of CSF-1R tyrosine kinase activity, Bioorg. Med. Chem. Lett. 7(4):421-424 (1997).
DM37I92	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97000358

DM37I92	DI	DM37I92
DM37I92	DN	RPR-108514A
DM37I92	MI	TTI7421
DM37I92	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM37I92	MT	DTT
DM37I92	MA	Inhibitor
DM37I92	RN	The synthesis and SAR of new 4-(N-alkyl-N-phenyl)amino-6,7-dimethoxyquinazolines and 4-(N-alkyl-N-phenyl)aminopyrazolo[3,4-d]pyrimidines, inhibitors of CSF-1R tyrosine kinase activity, Bioorg. Med. Chem. Lett. 7(4):421-424 (1997).
DM37I92	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97000358

DMJ6RZI	DI	DMJ6RZI
DMJ6RZI	DN	RPR-108518A
DMJ6RZI	MI	TT860QF
DMJ6RZI	MN	LCK tyrosine protein kinase (LCK)
DMJ6RZI	MT	DTT
DMJ6RZI	MA	Inhibitor
DMJ6RZI	RN	he preparation and sar of 4-(anilino), 4-(phenoxy), and 4-(thiophenoxy)-quinazolines: Inhibitors of p56lck and EGF-R tyrosine kinase activity, Bioorg. Med. Chem. Lett. 7(4):417-420 (1997).
DMJ6RZI	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97000346

DM61VHF	DI	DM61VHF
DM61VHF	DN	RPR-118071
DM61VHF	MI	TTZUXYS
DM61VHF	MN	Vitamin K-dependent protein C (PROC)
DM61VHF	MT	DTT
DM61VHF	MA	Inhibitor
DM61VHF	RN	Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa. J Med Chem. 1999 Sep 9;42(18):3557-71.
DM61VHF	RU	https://pubmed.ncbi.nlm.nih.gov/10479288

DMLDWCB	DI	DMLDWCB
DMLDWCB	DN	RPR-118723
DMLDWCB	MI	TTAN6JD
DMLDWCB	MN	Glutamate receptor AMPA (GRIA)
DMLDWCB	MT	DTT
DMLDWCB	MA	Inhibitor
DMLDWCB	RN	Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity. J Med Chem. 2000 Jun 15;43(12):2371-81.
DMLDWCB	RU	https://pubmed.ncbi.nlm.nih.gov/10882363

DMLDWCB	DI	DMLDWCB
DMLDWCB	DN	RPR-118723
DMLDWCB	MI	TTVPQTF
DMLDWCB	MN	Glutamate receptor AMPA 1 (GRIA1)
DMLDWCB	MT	DTT
DMLDWCB	MA	Inhibitor
DMLDWCB	RN	Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity. J Med Chem. 2000 Jun 15;43(12):2371-81.
DMLDWCB	RU	https://pubmed.ncbi.nlm.nih.gov/10882363

DMLDWCB	DI	DMLDWCB
DMLDWCB	DN	RPR-118723
DMLDWCB	MI	TTLD29N
DMLDWCB	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMLDWCB	MT	DTT
DMLDWCB	MA	Inhibitor
DMLDWCB	RN	Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity. J Med Chem. 2000 Jun 15;43(12):2371-81.
DMLDWCB	RU	https://pubmed.ncbi.nlm.nih.gov/10882363

DMLDWCB	DI	DMLDWCB
DMLDWCB	DN	RPR-118723
DMLDWCB	MI	TTKJEMQ
DMLDWCB	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMLDWCB	MT	DTT
DMLDWCB	MA	Inhibitor
DMLDWCB	RN	Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity. J Med Chem. 2000 Jun 15;43(12):2371-81.
DMLDWCB	RU	https://pubmed.ncbi.nlm.nih.gov/10882363

DMLDWCB	DI	DMLDWCB
DMLDWCB	DN	RPR-118723
DMLDWCB	MI	TTN9D8E
DMLDWCB	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMLDWCB	MT	DTT
DMLDWCB	MA	Inhibitor
DMLDWCB	RN	Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity. J Med Chem. 2000 Jun 15;43(12):2371-81.
DMLDWCB	RU	https://pubmed.ncbi.nlm.nih.gov/10882363

DM1V0MD	DI	DM1V0MD
DM1V0MD	DN	RPR-120844
DM1V0MD	MI	TTZUXYS
DM1V0MD	MN	Vitamin K-dependent protein C (PROC)
DM1V0MD	MT	DTT
DM1V0MD	MA	Inhibitor
DM1V0MD	RN	Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa. J Med Chem. 1999 Sep 9;42(18):3557-71.
DM1V0MD	RU	https://pubmed.ncbi.nlm.nih.gov/10479288

DM9DXHM	DI	DM9DXHM
DM9DXHM	DN	RPR121154
DM9DXHM	MI	TTHXFA1
DM9DXHM	MN	C5a anaphylatoxin chemotactic receptor (C5AR1)
DM9DXHM	MT	DTT
DM9DXHM	MA	Antagonist
DM9DXHM	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 32).
DM9DXHM	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=32

DM4T2R3	DI	DM4T2R3
DM4T2R3	DN	RPR260243
DM4T2R3	MI	TTQ6VDM
DM4T2R3	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DM4T2R3	MT	DTT
DM4T2R3	MA	Activator
DM4T2R3	RN	Discovery of a small molecule activator of the human ether-a-go-go-related gene (HERG) cardiac K+ channel. Mol Pharmacol. 2005 Mar;67(3):827-36.
DM4T2R3	RU	https://pubmed.ncbi.nlm.nih.gov/15548764

DM4LTE3	DI	DM4LTE3
DM4LTE3	DN	R-PSOP
DM4LTE3	MI	TT2L6C5
DM4LTE3	MN	Neuromedin-U receptor 2 (NMUR2)
DM4LTE3	MT	DTT
DM4LTE3	MA	Antagonist
DM4LTE3	RN	Discovery and pharmacological characterization of a small-molecule antagonist at neuromedin U receptor NMUR2. J Pharmacol Exp Ther. 2009 Jul;330(1):268-75.
DM4LTE3	RU	https://pubmed.ncbi.nlm.nih.gov/19369576

DMP9V7U	DI	DMP9V7U
DMP9V7U	DN	RQ-00000008
DMP9V7U	MI	TT79WV3
DMP9V7U	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DMP9V7U	MT	DTT
DMP9V7U	MA	Antagonist
DMP9V7U	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 343).
DMP9V7U	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=343

DMLN280	DI	DMLN280
DMLN280	DN	RQ-00000010
DMLN280	MI	TT07C3Y
DMLN280	MN	5-HT 4 receptor (HTR4)
DMLN280	MT	DTT
DMLN280	MA	Agonist
DMLN280	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 9).
DMLN280	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=9

DM4T8KV	DI	DM4T8KV
DM4T8KV	DN	RQ-00201894
DM4T8KV	MI	TT953CX
DM4T8KV	MN	Motilin receptor (MLNR)
DM4T8KV	MT	DTT
DM4T8KV	MA	Agonist
DM4T8KV	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 297).
DM4T8KV	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=297

DMTD3O8	DI	DMTD3O8
DMTD3O8	DN	RQ-00202730
DMTD3O8	MI	TTMSFAW
DMTD3O8	MN	Cannabinoid receptor 2 (CB2)
DMTD3O8	MT	DTT
DMTD3O8	MA	Agonist
DMTD3O8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 57).
DMTD3O8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=57

DMAIOQB	DI	DMAIOQB
DMAIOQB	DN	RQ-00203066
DMAIOQB	MI	TTAXZ0K
DMAIOQB	MN	Voltage-gated sodium channel alpha Nav1.3 (SCN3A)
DMAIOQB	MT	DTT
DMAIOQB	MA	Antagonist
DMAIOQB	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 580).
DMAIOQB	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=580

DM83THZ	DI	DM83THZ
DM83THZ	DN	RQ-00203078
DM83THZ	MI	TTXDKTO
DM83THZ	MN	Long transient receptor potential channel 8 (TRPM8)
DM83THZ	MT	DTT
DM83THZ	MA	Antagonist
DM83THZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 500).
DM83THZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=500

DMYK6OU	DI	DMYK6OU
DMYK6OU	DN	RQ-00310941
DMYK6OU	MI	TT0K1SC
DMYK6OU	MN	5-HT 2B receptor (HTR2B)
DMYK6OU	MT	DTT
DMYK6OU	MA	Antagonist
DMYK6OU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 7).
DMYK6OU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=7

DMP9RLE	DI	DMP9RLE
DMP9RLE	DN	RR(17)PZ
DMP9RLE	MI	TTZ9SOR
DMP9RLE	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMP9RLE	MT	DTT
DMP9RLE	MA	Inhibitor
DMP9RLE	RN	On the use of nonfluorescent dye labeled ligands in FRET-based receptor binding studies. J Med Chem. 2005 Dec 1;48(24):7847-59.
DMP9RLE	RU	https://pubmed.ncbi.nlm.nih.gov/16302823

DM32ZIC	DI	DM32ZIC
DM32ZIC	DN	RS 100235
DM32ZIC	MI	TT07C3Y
DM32ZIC	MN	5-HT 4 receptor (HTR4)
DM32ZIC	MT	DTT
DM32ZIC	MA	Antagonist
DM32ZIC	RN	New insights into the human 5-HT4 receptor binding site: exploration of a hydrophobic pocket. Br J Pharmacol. 2004 Oct;143(3):361-70.
DM32ZIC	RU	https://pubmed.ncbi.nlm.nih.gov/15351779

DMX9W0T	DI	DMX9W0T
DMX9W0T	DN	RS 116 0086
DMX9W0T	MI	TT07C3Y
DMX9W0T	MN	5-HT 4 receptor (HTR4)
DMX9W0T	MT	DTT
DMX9W0T	MA	Antagonist
DMX9W0T	RN	A 5-HT4 receptor transmembrane network implicated in the activity of inverse agonists but not agonists. J Biol Chem. 2002 Jul 12;277(28):25502-11.
DMX9W0T	RU	https://pubmed.ncbi.nlm.nih.gov/11976337

DMD91WS	DI	DMD91WS
DMD91WS	DN	RS 57639
DMD91WS	MI	TT07C3Y
DMD91WS	MN	5-HT 4 receptor (HTR4)
DMD91WS	MT	DTT
DMD91WS	MA	Agonist
DMD91WS	RN	[3H]RS 57639, a high affinity, selective 5-HT4 receptor partial agonist, specifically labels guinea-pig striatal and rat cloned (5-HT4S and 5-HT4L) receptors. Neuropharmacology. 1997 Apr-May;36(4-5):671-9.
DMD91WS	RU	https://pubmed.ncbi.nlm.nih.gov/9225293

DMO7G94	DI	DMO7G94
DMO7G94	DN	RS 67333
DMO7G94	MI	TT07C3Y
DMO7G94	MN	5-HT 4 receptor (HTR4)
DMO7G94	MT	DTT
DMO7G94	MA	Agonist
DMO7G94	RN	Pharmacological characterization of the human 5-HT(4(d)) receptor splice variant stably expressed in Chinese hamster ovary cells. Br J Pharmacol. 2000 Oct;131(4):827-35.
DMO7G94	RU	https://pubmed.ncbi.nlm.nih.gov/11030734

DM8SGTQ	DI	DM8SGTQ
DM8SGTQ	DN	RS 93520
DM8SGTQ	MI	TTNVEIR
DM8SGTQ	MN	Prostaglandin D2 receptor (PTGDR)
DM8SGTQ	MT	DTT
DM8SGTQ	MA	Agonist
DM8SGTQ	RN	Affinities, selectivities, potencies, and intrinsic activities of natural and synthetic prostanoids using endogenous receptors: focus on DP class prostanoids. J Pharmacol Exp Ther. 2000 May;293(2):321-8.
DM8SGTQ	RU	https://pubmed.ncbi.nlm.nih.gov/10772998

DM63NGW	DI	DM63NGW
DM63NGW	DN	RS-100302
DM63NGW	MI	TTW0CMT
DM63NGW	MN	Voltage-gated potassium channel Kv1.5 (KCNA5)
DM63NGW	MT	DTT
DM63NGW	MA	Blocker
DM63NGW	RN	New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22.
DM63NGW	RU	https://pubmed.ncbi.nlm.nih.gov/15934869

DMDKC0J	DI	DMDKC0J
DMDKC0J	DN	RS-100329
DMDKC0J	MI	TTNGILX
DMDKC0J	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMDKC0J	MT	DTT
DMDKC0J	MA	Inhibitor
DMDKC0J	RN	Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
DMDKC0J	RU	https://pubmed.ncbi.nlm.nih.gov/15664832

DMHDYBN	DI	DMHDYBN
DMHDYBN	DN	RS-102,221
DMHDYBN	MI	TTWJBZ5
DMHDYBN	MN	5-HT 2C receptor (HTR2C)
DMHDYBN	MT	DTT
DMHDYBN	MA	Inhibitor
DMHDYBN	RN	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
DMHDYBN	RU	https://pubmed.ncbi.nlm.nih.gov/18983139

DMF71B3	DI	DMF71B3
DMF71B3	DN	RS-102895
DMF71B3	MI	TTFZYTO
DMF71B3	MN	C-C chemokine receptor type 2 (CCR2)
DMF71B3	MT	DTT
DMF71B3	MA	Antagonist
DMF71B3	RN	Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists: binding to a common chemokine receptor motif within t... J Biol Chem. 2000 Aug 18;275(33):25562-71.
DMF71B3	RU	https://pubmed.ncbi.nlm.nih.gov/10770925

DMEHN2L	DI	DMEHN2L
DMEHN2L	DN	RS-136270
DMEHN2L	MI	TTFZYTO
DMEHN2L	MN	C-C chemokine receptor type 2 (CCR2)
DMEHN2L	MT	DTT
DMEHN2L	MA	Antagonist
DMEHN2L	RN	Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists: binding to a common chemokine receptor motif within t... J Biol Chem. 2000 Aug 18;275(33):25562-71.
DMEHN2L	RU	https://pubmed.ncbi.nlm.nih.gov/10770925

DMRW57G	DI	DMRW57G
DMRW57G	DN	RS-14491
DMRW57G	MI	TTZ97H5
DMRW57G	MN	Phosphodiesterase 4A (PDE4A)
DMRW57G	MT	DTT
DMRW57G	MA	Inhibitor
DMRW57G	RN	Novel heterocyclic-fused pyridazinones as potent and selective phosphodiesterase IV inhibitors. J Med Chem. 1997 May 9;40(10):1417-21.
DMRW57G	RU	https://pubmed.ncbi.nlm.nih.gov/9154964

DMRW57G	DI	DMRW57G
DMRW57G	DN	RS-14491
DMRW57G	MI	TTVIAT9
DMRW57G	MN	Phosphodiesterase 4B (PDE4B)
DMRW57G	MT	DTT
DMRW57G	MA	Inhibitor
DMRW57G	RN	Novel heterocyclic-fused pyridazinones as potent and selective phosphodiesterase IV inhibitors. J Med Chem. 1997 May 9;40(10):1417-21.
DMRW57G	RU	https://pubmed.ncbi.nlm.nih.gov/9154964

DMKQT1Y	DI	DMKQT1Y
DMKQT1Y	DN	RS-1636
DMKQT1Y	MI	TTGP7BY
DMKQT1Y	MN	Monoamine oxidase type B (MAO-B)
DMKQT1Y	MT	DTT
DMKQT1Y	MA	Inhibitor
DMKQT1Y	RN	Novel monoamine oxidase inhibitors, 3-(2-aminoethoxy)-1,2-benzisoxazole derivatives, and their differential reversibility. Jpn J Pharmacol. 2002 Feb;88(2):174-82.
DMKQT1Y	RU	https://pubmed.ncbi.nlm.nih.gov/11928718

DM9D8XC	DI	DM9D8XC
DM9D8XC	DN	RS-1748
DM9D8XC	MI	TT7HQD0
DM9D8XC	MN	C-C chemokine receptor type 4 (CCR4)
DM9D8XC	MT	DTT
DM9D8XC	MA	Modulator
DM9D8XC	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 61).
DM9D8XC	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=61

DM0W2IS	DI	DM0W2IS
DM0W2IS	DN	RS-25344
DM0W2IS	MI	TTZ97H5
DM0W2IS	MN	Phosphodiesterase 4A (PDE4A)
DM0W2IS	MT	DTT
DM0W2IS	MA	Inhibitor
DM0W2IS	RN	Comparison of recombinant human PDE4 isoforms: interaction with substrate and inhibitors. Cell Signal. 1998 Jun;10(6):427-40.
DM0W2IS	RU	https://pubmed.ncbi.nlm.nih.gov/9720765

DM0W2IS	DI	DM0W2IS
DM0W2IS	DN	RS-25344
DM0W2IS	MI	TTVIAT9
DM0W2IS	MN	Phosphodiesterase 4B (PDE4B)
DM0W2IS	MT	DTT
DM0W2IS	MA	Inhibitor
DM0W2IS	RN	Comparison of recombinant human PDE4 isoforms: interaction with substrate and inhibitors. Cell Signal. 1998 Jun;10(6):427-40.
DM0W2IS	RU	https://pubmed.ncbi.nlm.nih.gov/9720765

DM0W2IS	DI	DM0W2IS
DM0W2IS	DN	RS-25344
DM0W2IS	MI	TT6A59G
DM0W2IS	MN	Phosphodiesterase 4C (PDE4C)
DM0W2IS	MT	DTT
DM0W2IS	MA	Inhibitor
DM0W2IS	RN	Comparison of recombinant human PDE4 isoforms: interaction with substrate and inhibitors. Cell Signal. 1998 Jun;10(6):427-40.
DM0W2IS	RU	https://pubmed.ncbi.nlm.nih.gov/9720765

DM0W2IS	DI	DM0W2IS
DM0W2IS	DN	RS-25344
DM0W2IS	MI	TTSKMI8
DM0W2IS	MN	Phosphodiesterase 4D (PDE4D)
DM0W2IS	MT	DTT
DM0W2IS	MA	Inhibitor
DM0W2IS	RN	Comparison of recombinant human PDE4 isoforms: interaction with substrate and inhibitors. Cell Signal. 1998 Jun;10(6):427-40.
DM0W2IS	RU	https://pubmed.ncbi.nlm.nih.gov/9720765

DMDC1B4	DI	DMDC1B4
DMDC1B4	DN	RS-30199
DMDC1B4	MI	TTSQIFT
DMDC1B4	MN	5-HT 1A receptor (HTR1A)
DMDC1B4	MT	DTT
DMDC1B4	MA	Modulator (allosteric modulator)
DMDC1B4	RN	Interaction of the anxiogenic agent, RS-30199, with 5-HT1A receptors: modulation of sexual activity in the male rat. Neuropharmacology. 1998 Jun;37(6):769-80.
DMDC1B4	RU	https://pubmed.ncbi.nlm.nih.gov/9707291

DM2SCM7	DI	DM2SCM7
DM2SCM7	DN	RS-39066
DM2SCM7	MI	TTMX39J
DM2SCM7	MN	Matrix metalloproteinase-1 (MMP-1)
DM2SCM7	MT	DTT
DM2SCM7	MA	Inhibitor
DM2SCM7	RN	Design, synthesis, activity, and structure of a novel class of matrix metalloproteinase inhibitors containing a heterocyclic P2 P3 Bioorg. Med. Chem. Lett. 6(13):1541-1542 (1996).
DM2SCM7	RU	http://www.sciencedirect.com/science/article/pii/S0960894X96002831

DM2SCM7	DI	DM2SCM7
DM2SCM7	DN	RS-39066
DM2SCM7	MI	TTUZ2L5
DM2SCM7	MN	Matrix metalloproteinase-3 (MMP-3)
DM2SCM7	MT	DTT
DM2SCM7	MA	Inhibitor
DM2SCM7	RN	Design, synthesis, activity, and structure of a novel class of matrix metalloproteinase inhibitors containing a heterocyclic P2 P3 Bioorg. Med. Chem. Lett. 6(13):1541-1542 (1996).
DM2SCM7	RU	http://www.sciencedirect.com/science/article/pii/S0960894X96002831

DM2SCM7	DI	DM2SCM7
DM2SCM7	DN	RS-39066
DM2SCM7	MI	TTMTWOS
DM2SCM7	MN	Matrix metalloproteinase-7 (MMP-7)
DM2SCM7	MT	DTT
DM2SCM7	MA	Inhibitor
DM2SCM7	RN	Design, synthesis, activity, and structure of a novel class of matrix metalloproteinase inhibitors containing a heterocyclic P2 P3 Bioorg. Med. Chem. Lett. 6(13):1541-1542 (1996).
DM2SCM7	RU	http://www.sciencedirect.com/science/article/pii/S0960894X96002831

DMLI5U2	DI	DMLI5U2
DMLI5U2	DN	RS-513815
DMLI5U2	MI	TTNGILX
DMLI5U2	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMLI5U2	MT	DTT
DMLI5U2	MA	Inhibitor
DMLI5U2	RN	Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
DMLI5U2	RU	https://pubmed.ncbi.nlm.nih.gov/15664832

DM89I0L	DI	DM89I0L
DM89I0L	DN	RS67506
DM89I0L	MI	TT07C3Y
DM89I0L	MN	5-HT 4 receptor (HTR4)
DM89I0L	MT	DTT
DM89I0L	MA	Agonist
DM89I0L	RN	Peripheral 5-HT4 receptors. FASEB J. 1996 Oct;10(12):1398-407.
DM89I0L	RU	https://pubmed.ncbi.nlm.nih.gov/8903510

DMN3ZOD	DI	DMN3ZOD
DMN3ZOD	DN	RS-PPCC
DMN3ZOD	MI	TTTPE1L
DMN3ZOD	MN	HUMAN opioid receptor sigma 1 (OPRS1)
DMN3ZOD	MT	DTT
DMN3ZOD	MA	Agonist
DMN3ZOD	RN	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
DMN3ZOD	RU	https://www.nature.com/articles/s41586-020-2286-9

DMWDXPN	DI	DMWDXPN
DMWDXPN	DN	rT3
DMWDXPN	MI	TTTSEPU
DMWDXPN	MN	Thyroid hormone receptor alpha (THRA)
DMWDXPN	MT	DTT
DMWDXPN	MA	Agonist
DMWDXPN	RN	Binding of 3,5,3'-triiodothyronine (T3) and its analogs to the in vitro translational products of c-erbA protooncogenes: differences in the affinity of the alpha- and beta-forms for the acetic acid analog and failure of the human testis and kidney alpha-2 products to bind T3. Mol Endocrinol. 1990 Feb;4(2):227-34.
DMWDXPN	RU	https://pubmed.ncbi.nlm.nih.gov/2158622

DMWDXPN	DI	DMWDXPN
DMWDXPN	DN	rT3
DMWDXPN	MI	TTGER3L
DMWDXPN	MN	Thyroid hormone receptor beta (THRB)
DMWDXPN	MT	DTT
DMWDXPN	MA	Agonist
DMWDXPN	RN	Binding of 3,5,3'-triiodothyronine (T3) and its analogs to the in vitro translational products of c-erbA protooncogenes: differences in the affinity of the alpha- and beta-forms for the acetic acid analog and failure of the human testis and kidney alpha-2 products to bind T3. Mol Endocrinol. 1990 Feb;4(2):227-34.
DMWDXPN	RU	https://pubmed.ncbi.nlm.nih.gov/2158622

DMLY4C9	DI	DMLY4C9
DMLY4C9	DN	RTA-301
DMLY4C9	MI	TTYFKSZ
DMLY4C9	MN	Tubulin beta (TUBB)
DMLY4C9	MT	DTT
DMLY4C9	MA	Inhibitor
DMLY4C9	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2640).
DMLY4C9	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2640

DMD3ST8	DI	DMD3ST8
DMD3ST8	DN	RTI-20
DMD3ST8	MI	TT84ETX
DMD3ST8	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMD3ST8	MT	DTT
DMD3ST8	MA	Inhibitor
DMD3ST8	RN	Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo- and dipyridodiazepinones. J Med Chem. 1991 Jul;34(7):2231-41.
DMD3ST8	RU	https://pubmed.ncbi.nlm.nih.gov/1712395

DM2QYXN	DI	DM2QYXN
DM2QYXN	DN	RTI-219
DM2QYXN	MI	TTVBI8W
DM2QYXN	MN	Dopamine transporter (DAT)
DM2QYXN	MT	DTT
DM2QYXN	MA	Inhibitor
DM2QYXN	RN	Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-... J Med Chem. 2007 Jul 26;50(15):3686-95.
DM2QYXN	RU	https://pubmed.ncbi.nlm.nih.gov/17602602

DM2QYXN	DI	DM2QYXN
DM2QYXN	DN	RTI-219
DM2QYXN	MI	TTAWNKZ
DM2QYXN	MN	Norepinephrine transporter (NET)
DM2QYXN	MT	DTT
DM2QYXN	MA	Inhibitor
DM2QYXN	RN	Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-... J Med Chem. 2007 Jul 26;50(15):3686-95.
DM2QYXN	RU	https://pubmed.ncbi.nlm.nih.gov/17602602

DM2QYXN	DI	DM2QYXN
DM2QYXN	DN	RTI-219
DM2QYXN	MI	TT3ROYC
DM2QYXN	MN	Serotonin transporter (SERT)
DM2QYXN	MT	DTT
DM2QYXN	MA	Inhibitor
DM2QYXN	RN	Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-... J Med Chem. 2007 Jul 26;50(15):3686-95.
DM2QYXN	RU	https://pubmed.ncbi.nlm.nih.gov/17602602

DMG6TOA	DI	DMG6TOA
DMG6TOA	DN	RTI-4229-982
DMG6TOA	MI	TTHS256
DMG6TOA	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMG6TOA	MT	DTT
DMG6TOA	MA	Antagonist
DMG6TOA	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 293).
DMG6TOA	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=293

DMR4TM1	DI	DMR4TM1
DMR4TM1	DN	RTI-5989-23
DMR4TM1	MI	TT27RFC
DMR4TM1	MN	Opioid receptor delta (OPRD1)
DMR4TM1	MT	DTT
DMR4TM1	MA	Inhibitor
DMR4TM1	RN	Investigation of the N-substituent conformation governing potency and mu receptor subtype-selectivity in (+)-(3R, 4R)-dimethyl-4-(3-hydroxyphenyl)p... J Med Chem. 1998 May 21;41(11):1980-90.
DMR4TM1	RU	https://pubmed.ncbi.nlm.nih.gov/9599247

DMR4TM1	DI	DMR4TM1
DMR4TM1	DN	RTI-5989-23
DMR4TM1	MI	TTQW87Y
DMR4TM1	MN	Opioid receptor kappa (OPRK1)
DMR4TM1	MT	DTT
DMR4TM1	MA	Inhibitor
DMR4TM1	RN	Investigation of the N-substituent conformation governing potency and mu receptor subtype-selectivity in (+)-(3R, 4R)-dimethyl-4-(3-hydroxyphenyl)p... J Med Chem. 1998 May 21;41(11):1980-90.
DMR4TM1	RU	https://pubmed.ncbi.nlm.nih.gov/9599247

DMQ28L9	DI	DMQ28L9
DMQ28L9	DN	RTI-5989-25
DMQ28L9	MI	TT27RFC
DMQ28L9	MN	Opioid receptor delta (OPRD1)
DMQ28L9	MT	DTT
DMQ28L9	MA	Inhibitor
DMQ28L9	RN	Investigation of the N-substituent conformation governing potency and mu receptor subtype-selectivity in (+)-(3R, 4R)-dimethyl-4-(3-hydroxyphenyl)p... J Med Chem. 1998 May 21;41(11):1980-90.
DMQ28L9	RU	https://pubmed.ncbi.nlm.nih.gov/9599247

DMQ28L9	DI	DMQ28L9
DMQ28L9	DN	RTI-5989-25
DMQ28L9	MI	TTQW87Y
DMQ28L9	MN	Opioid receptor kappa (OPRK1)
DMQ28L9	MT	DTT
DMQ28L9	MA	Inhibitor
DMQ28L9	RN	Investigation of the N-substituent conformation governing potency and mu receptor subtype-selectivity in (+)-(3R, 4R)-dimethyl-4-(3-hydroxyphenyl)p... J Med Chem. 1998 May 21;41(11):1980-90.
DMQ28L9	RU	https://pubmed.ncbi.nlm.nih.gov/9599247

DMZO1QC	DI	DMZO1QC
DMZO1QC	DN	RTI-5989-31
DMZO1QC	MI	TT27RFC
DMZO1QC	MN	Opioid receptor delta (OPRD1)
DMZO1QC	MT	DTT
DMZO1QC	MA	Inhibitor
DMZO1QC	RN	Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an ... J Med Chem. 2007 Aug 9;50(16):3765-76.
DMZO1QC	RU	https://pubmed.ncbi.nlm.nih.gov/17625813

DMZO1QC	DI	DMZO1QC
DMZO1QC	DN	RTI-5989-31
DMZO1QC	MI	TTQW87Y
DMZO1QC	MN	Opioid receptor kappa (OPRK1)
DMZO1QC	MT	DTT
DMZO1QC	MA	Inhibitor
DMZO1QC	RN	Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an ... J Med Chem. 2007 Aug 9;50(16):3765-76.
DMZO1QC	RU	https://pubmed.ncbi.nlm.nih.gov/17625813

DMZO1QC	DI	DMZO1QC
DMZO1QC	DN	RTI-5989-31
DMZO1QC	MI	TTKWM86
DMZO1QC	MN	Opioid receptor mu (MOP)
DMZO1QC	MT	DTT
DMZO1QC	MA	Inhibitor
DMZO1QC	RN	Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an ... J Med Chem. 2007 Aug 9;50(16):3765-76.
DMZO1QC	RU	https://pubmed.ncbi.nlm.nih.gov/17625813

DMWVBD9	DI	DMWVBD9
DMWVBD9	DN	RTU-1096
DMWVBD9	MI	TT7HC21
DMWVBD9	MN	Membrane copper amine oxidase (AOC3)
DMWVBD9	MT	DTT
DMWVBD9	MA	Inhibitor
DMWVBD9	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2767).
DMWVBD9	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2767

DMA7URH	DI	DMA7URH
DMA7URH	DN	RU26988
DMA7URH	MI	TTOZRK6
DMA7URH	MN	Glucocorticoid receptor messenger RNA (GCR mRNA)
DMA7URH	MT	DTT
DMA7URH	MA	Agonist
DMA7URH	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 625).
DMA7URH	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=625

DMN049T	DI	DMN049T
DMN049T	DN	RU28318
DMN049T	MI	TT26PHO
DMN049T	MN	Mineralocorticoid receptor  (MR)
DMN049T	MT	DTT
DMN049T	MA	Antagonist
DMN049T	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 626).
DMN049T	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=626

DMAOJ0E	DI	DMAOJ0E
DMAOJ0E	DN	RU28362
DMAOJ0E	MI	TTOZRK6
DMAOJ0E	MN	Glucocorticoid receptor messenger RNA (GCR mRNA)
DMAOJ0E	MT	DTT
DMAOJ0E	MA	Agonist
DMAOJ0E	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 625).
DMAOJ0E	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=625

DMY9P85	DI	DMY9P85
DMY9P85	DN	RU-43044
DMY9P85	MI	TTKPW01
DMY9P85	MN	Androgen receptor messenger RNA (AR mRNA)
DMY9P85	MT	DTT
DMY9P85	MA	Inhibitor
DMY9P85	RN	Discovery of potent, nonsteroidal, and highly selective glucocorticoid receptor antagonists. J Med Chem. 2002 Jun 6;45(12):2417-24.
DMY9P85	RU	https://pubmed.ncbi.nlm.nih.gov/12036351

DMY9P85	DI	DMY9P85
DMY9P85	DN	RU-43044
DMY9P85	MI	TTOZRK6
DMY9P85	MN	Glucocorticoid receptor messenger RNA (GCR mRNA)
DMY9P85	MT	DTT
DMY9P85	MA	Inhibitor
DMY9P85	RN	Virtual screening for the identification of novel nonsteroidal glucocorticoid modulators. J Med Chem. 2010 Apr 22;53(8):3065-74.
DMY9P85	RU	https://pubmed.ncbi.nlm.nih.gov/20334371

DMCASRD	DI	DMCASRD
DMCASRD	DN	RU-5135
DMCASRD	MI	TTGXH6N
DMCASRD	MN	GABA(A) receptor delta (GABRD)
DMCASRD	MT	DTT
DMCASRD	MA	Modulator
DMCASRD	RN	Complex interactions between the steroid derivative RU 5135 and the GABAA-receptor complex. Eur J Pharmacol. 1992 Oct 1;227(2):147-51.
DMCASRD	RU	https://www.ncbi.nlm.nih.gov/pubmed/1330646

DMO3WEG	DI	DMO3WEG
DMO3WEG	DN	RU-56187
DMO3WEG	MI	TTKPW01
DMO3WEG	MN	Androgen receptor messenger RNA (AR mRNA)
DMO3WEG	MT	DTT
DMO3WEG	MA	Inhibitor
DMO3WEG	RN	Structure-activity relationships of bioisosteric replacement of the carboxylic acid in novel androgen receptor pure antagonists. Bioorg Med Chem. 2010 May 1;18(9):3159-68.
DMO3WEG	RU	https://pubmed.ncbi.nlm.nih.gov/20381361

DM5D9UT	DI	DM5D9UT
DM5D9UT	DN	RU-59063
DM5D9UT	MI	TTS64P2
DM5D9UT	MN	Androgen receptor (AR)
DM5D9UT	MT	DTT
DM5D9UT	MA	Inhibitor
DM5D9UT	RN	Design, synthesis, and pharmacological characterization of 4-[4, 4-dimethyl-3-(4-hydroxybutyl)-5-oxo-2-thioxo-1-imidazolidinyl]- 2-iodobenzonitrile... J Med Chem. 2000 Aug 24;43(17):3344-7.
DM5D9UT	RU	https://pubmed.ncbi.nlm.nih.gov/10966753

DMOQE91	DI	DMOQE91
DMOQE91	DN	RU78191
DMOQE91	MI	TT6PKBN
DMOQE91	MN	Proto-oncogene c-Src (SRC)
DMOQE91	MT	DTT
DMOQE91	MA	Inhibitor
DMOQE91	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMOQE91	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMR8I03	DI	DMR8I03
DMR8I03	DN	RU78262
DMR8I03	MI	TT6PKBN
DMR8I03	MN	Proto-oncogene c-Src (SRC)
DMR8I03	MT	DTT
DMR8I03	MA	Inhibitor
DMR8I03	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMR8I03	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMXAK92	DI	DMXAK92
DMXAK92	DN	RU78299
DMXAK92	MI	TT6PKBN
DMXAK92	MN	Proto-oncogene c-Src (SRC)
DMXAK92	MT	DTT
DMXAK92	MA	Inhibitor
DMXAK92	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMXAK92	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM27BKD	DI	DM27BKD
DM27BKD	DN	RU78300
DM27BKD	MI	TT6PKBN
DM27BKD	MN	Proto-oncogene c-Src (SRC)
DM27BKD	MT	DTT
DM27BKD	MA	Inhibitor
DM27BKD	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM27BKD	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMU5H4K	DI	DMU5H4K
DMU5H4K	DN	RU78783
DMU5H4K	MI	TT6PKBN
DMU5H4K	MN	Proto-oncogene c-Src (SRC)
DMU5H4K	MT	DTT
DMU5H4K	MA	Inhibitor
DMU5H4K	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMU5H4K	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM9GQP0	DI	DM9GQP0
DM9GQP0	DN	RU79072
DM9GQP0	MI	TT6PKBN
DM9GQP0	MN	Proto-oncogene c-Src (SRC)
DM9GQP0	MT	DTT
DM9GQP0	MA	Inhibitor
DM9GQP0	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM9GQP0	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMWKTYC	DI	DMWKTYC
DMWKTYC	DN	RU79073
DMWKTYC	MI	TT6PKBN
DMWKTYC	MN	Proto-oncogene c-Src (SRC)
DMWKTYC	MT	DTT
DMWKTYC	MA	Inhibitor
DMWKTYC	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMWKTYC	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM06BGV	DI	DM06BGV
DM06BGV	DN	RU79256
DM06BGV	MI	TT6PKBN
DM06BGV	MN	Proto-oncogene c-Src (SRC)
DM06BGV	MT	DTT
DM06BGV	MA	Inhibitor
DM06BGV	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM06BGV	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMY3X6I	DI	DMY3X6I
DMY3X6I	DN	RU81843
DMY3X6I	MI	TT6PKBN
DMY3X6I	MN	Proto-oncogene c-Src (SRC)
DMY3X6I	MT	DTT
DMY3X6I	MA	Inhibitor
DMY3X6I	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMY3X6I	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMX7ZI0	DI	DMX7ZI0
DMX7ZI0	DN	RU82129
DMX7ZI0	MI	TT6PKBN
DMX7ZI0	MN	Proto-oncogene c-Src (SRC)
DMX7ZI0	MT	DTT
DMX7ZI0	MA	Inhibitor
DMX7ZI0	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMX7ZI0	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMJG4RC	DI	DMJG4RC
DMJG4RC	DN	RU82197
DMJG4RC	MI	TT6PKBN
DMJG4RC	MN	Proto-oncogene c-Src (SRC)
DMJG4RC	MT	DTT
DMJG4RC	MA	Inhibitor
DMJG4RC	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMJG4RC	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMR3A2O	DI	DMR3A2O
DMR3A2O	DN	RU82209
DMR3A2O	MI	TT6PKBN
DMR3A2O	MN	Proto-oncogene c-Src (SRC)
DMR3A2O	MT	DTT
DMR3A2O	MA	Inhibitor
DMR3A2O	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMR3A2O	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMNGKYF	DI	DMNGKYF
DMNGKYF	DN	RU83876
DMNGKYF	MI	TT6PKBN
DMNGKYF	MN	Proto-oncogene c-Src (SRC)
DMNGKYF	MT	DTT
DMNGKYF	MA	Inhibitor
DMNGKYF	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMNGKYF	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMWK3LU	DI	DMWK3LU
DMWK3LU	DN	RU84687
DMWK3LU	MI	TT6PKBN
DMWK3LU	MN	Proto-oncogene c-Src (SRC)
DMWK3LU	MT	DTT
DMWK3LU	MA	Inhibitor
DMWK3LU	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMWK3LU	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMOA8FK	DI	DMOA8FK
DMOA8FK	DN	RU85053
DMOA8FK	MI	TT6PKBN
DMOA8FK	MN	Proto-oncogene c-Src (SRC)
DMOA8FK	MT	DTT
DMOA8FK	MA	Inhibitor
DMOA8FK	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMOA8FK	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM97ZHX	DI	DM97ZHX
DM97ZHX	DN	RU85493
DM97ZHX	MI	TT6PKBN
DM97ZHX	MN	Proto-oncogene c-Src (SRC)
DM97ZHX	MT	DTT
DM97ZHX	MA	Inhibitor
DM97ZHX	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM97ZHX	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMHFKUC	DI	DMHFKUC
DMHFKUC	DN	RU90395
DMHFKUC	MI	TT6PKBN
DMHFKUC	MN	Proto-oncogene c-Src (SRC)
DMHFKUC	MT	DTT
DMHFKUC	MA	Inhibitor
DMHFKUC	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMHFKUC	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMOHTC6	DI	DMOHTC6
DMOHTC6	DN	Ruthenium red
DMOHTC6	MI	TTU5CIX
DMOHTC6	MN	Ryanodine receptor 1 (RYR1)
DMOHTC6	MT	DTT
DMOHTC6	MA	Antagonist
DMOHTC6	RN	Role of ryanodine receptor channels in Ca2+ oscillations of porcine tracheal smooth muscle. Am J Physiol. 1997 Apr;272(4 Pt 1):L659-64.
DMOHTC6	RU	https://pubmed.ncbi.nlm.nih.gov/9142939

DMEHRAJ	DI	DMEHRAJ
DMEHRAJ	DN	Rutin
DMEHRAJ	MI	DEBI82Z
DMEHRAJ	MN	Alpha-L-rhamnosidase (lrA)
DMEHRAJ	MT	DME
DMEHRAJ	MA	Metabolism
DMEHRAJ	RN	Metabolism of rutin and poncirin by human intestinal microbiota and cloning of their metabolizing alpha-L-rhamnosidase from Bifidobacterium dentium. J Microbiol Biotechnol. 2015 Jan;25(1):18-25.
DMEHRAJ	RU	https://pubmed.ncbi.nlm.nih.gov/25179902

DMEHRAJ	DI	DMEHRAJ
DMEHRAJ	DN	Rutin
DMEHRAJ	MI	DEC389G
DMEHRAJ	MN	Alpha-L-rhamnosidase (lrA)
DMEHRAJ	MT	DME
DMEHRAJ	MA	Metabolism
DMEHRAJ	RN	Identification of rutin deglycosylated metabolites produced by human intestinal bacteria using UPLC-Q-TOF/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Jun 1;898:95-100.
DMEHRAJ	RU	https://pubmed.ncbi.nlm.nih.gov/22583754

DMEHRAJ	DI	DMEHRAJ
DMEHRAJ	DN	Rutin
DMEHRAJ	MI	DE7BILX
DMEHRAJ	MN	Alpha-L-rhamnosidase (lrA)
DMEHRAJ	MT	DME
DMEHRAJ	MA	Metabolism
DMEHRAJ	RN	Identification of rutin deglycosylated metabolites produced by human intestinal bacteria using UPLC-Q-TOF/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Jun 1;898:95-100.
DMEHRAJ	RU	https://pubmed.ncbi.nlm.nih.gov/22583754

DMEHRAJ	DI	DMEHRAJ
DMEHRAJ	DN	Rutin
DMEHRAJ	MI	DE13AYF
DMEHRAJ	MN	Alpha-L-rhamnosidase (lrA)
DMEHRAJ	MT	DME
DMEHRAJ	MA	Metabolism
DMEHRAJ	RN	Identification of rutin deglycosylated metabolites produced by human intestinal bacteria using UPLC-Q-TOF/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Jun 1;898:95-100.
DMEHRAJ	RU	https://pubmed.ncbi.nlm.nih.gov/22583754

DMEHRAJ	DI	DMEHRAJ
DMEHRAJ	DN	Rutin
DMEHRAJ	MI	TT5ZWB6
DMEHRAJ	MN	Dihydrodiol dehydrogenase type I (AKR1C3)
DMEHRAJ	MT	DTT
DMEHRAJ	MA	Inhibitor
DMEHRAJ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMEHRAJ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM8EZTM	DI	DM8EZTM
DM8EZTM	DN	RvD1-ME
DM8EZTM	MI	TTOJ1NF
DM8EZTM	MN	FMLP-related receptor I (FPR2)
DM8EZTM	MT	DTT
DM8EZTM	MA	Agonist
DM8EZTM	RN	Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs. Am J Pathol. 2012 May;180(5):2018-27.
DM8EZTM	RU	https://pubmed.ncbi.nlm.nih.gov/22449948

DM8EZTM	DI	DM8EZTM
DM8EZTM	DN	RvD1-ME
DM8EZTM	MI	TT7OCUB
DM8EZTM	MN	G-protein coupled receptor 32 (GPR32)
DM8EZTM	MT	DTT
DM8EZTM	MA	Agonist
DM8EZTM	RN	Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs. Am J Pathol. 2012 May;180(5):2018-27.
DM8EZTM	RU	https://pubmed.ncbi.nlm.nih.gov/22449948

DMAU6FN	DI	DMAU6FN
DMAU6FN	DN	RwFwLL-NH2
DMAU6FN	MI	TTWDC17
DMAU6FN	MN	Growth hormone secretagogue receptor 1 (GHSR)
DMAU6FN	MT	DTT
DMAU6FN	MA	Inhibitor
DMAU6FN	RN	Identification of an efficacy switch region in the ghrelin receptor responsible for interchange between agonism and inverse agonism. J Biol Chem. 2007 May 25;282(21):15799-811.
DMAU6FN	RU	https://pubmed.ncbi.nlm.nih.gov/17371869

DMP7SI9	DI	DMP7SI9
DMP7SI9	DN	RWJ-140998
DMP7SI9	MI	TTICX3S
DMP7SI9	MN	Bacterial UDP-N-acetylglucosamine carboxyvinyltransferase (Bact murA)
DMP7SI9	MT	DTT
DMP7SI9	MA	Inhibitor
DMP7SI9	RN	Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
DMP7SI9	RU	https://pubmed.ncbi.nlm.nih.gov/15934867

DME68VT	DI	DME68VT
DME68VT	DN	RWJ-16979
DME68VT	MI	TT1MPAY
DME68VT	MN	GABA(A) receptor alpha-1 (GABRA1)
DME68VT	MT	DTT
DME68VT	MA	Inhibitor
DME68VT	RN	Potential anxiolytic agents. Pyrido[1,2-a]benzimidazoles: a new structural class of ligands for the benzodiazepine binding site on GABA-A receptors. J Med Chem. 1995 Jan 6;38(1):16-20.
DME68VT	RU	https://pubmed.ncbi.nlm.nih.gov/7837226

DME68VT	DI	DME68VT
DME68VT	DN	RWJ-16979
DME68VT	MI	TTNJYV2
DME68VT	MN	Gamma-aminobutyric acid receptor (GAR)
DME68VT	MT	DTT
DME68VT	MA	Inhibitor
DME68VT	RN	Potential anxiolytic agents. Pyrido[1,2-a]benzimidazoles: a new structural class of ligands for the benzodiazepine binding site on GABA-A receptors. J Med Chem. 1995 Jan 6;38(1):16-20.
DME68VT	RU	https://pubmed.ncbi.nlm.nih.gov/7837226

DMPJTLM	DI	DMPJTLM
DMPJTLM	DN	RWJ-38063
DMPJTLM	MI	TTNGILX
DMPJTLM	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMPJTLM	MT	DTT
DMPJTLM	MA	Inhibitor
DMPJTLM	RN	Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
DMPJTLM	RU	https://pubmed.ncbi.nlm.nih.gov/15664832

DMPJTLM	DI	DMPJTLM
DMPJTLM	DN	RWJ-38063
DMPJTLM	MI	TT34BHT
DMPJTLM	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMPJTLM	MT	DTT
DMPJTLM	MA	Inhibitor
DMPJTLM	RN	Novel arylpiperazines as selective alpha1-adrenergic receptor antagonists. Bioorg Med Chem Lett. 2000 May 15;10(10):1093-6.
DMPJTLM	RU	https://pubmed.ncbi.nlm.nih.gov/10843225

DM28IKN	DI	DM28IKN
DM28IKN	DN	RWJ-387273
DM28IKN	MI	TTJ0IQB
DM28IKN	MN	Phosphodiesterase 5A (PDE5A)
DM28IKN	MT	DTT
DM28IKN	MA	Modulator
DM28IKN	RN	DOI: 10.1021/op060099f
DM28IKN	RU	http://pubs.acs.org/doi/abs/10.1021/op060099f

DMBVLCQ	DI	DMBVLCQ
DMBVLCQ	DN	RWJ-3981
DMBVLCQ	MI	TTICX3S
DMBVLCQ	MN	Bacterial UDP-N-acetylglucosamine carboxyvinyltransferase (Bact murA)
DMBVLCQ	MT	DTT
DMBVLCQ	MA	Inhibitor
DMBVLCQ	RN	Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
DMBVLCQ	RU	https://pubmed.ncbi.nlm.nih.gov/15934867

DMBOSGN	DI	DMBOSGN
DMBOSGN	DN	RWJ-49968
DMBOSGN	MI	TTJVCG0
DMBOSGN	MN	Bacterial Sporulation kinase A (Bact kinA)
DMBOSGN	MT	DTT
DMBOSGN	MA	Inhibitor
DMBOSGN	RN	Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter. 2006 Jun;19(2):130-9.
DMBOSGN	RU	https://pubmed.ncbi.nlm.nih.gov/16964330

DMRPYGX	DI	DMRPYGX
DMRPYGX	DN	RWJ-50353
DMRPYGX	MI	TT2WR1T
DMRPYGX	MN	Cationic trypsinogen (PRSS1)
DMRPYGX	MT	DTT
DMRPYGX	MA	Inhibitor
DMRPYGX	RN	In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications ... J Med Chem. 2005 Mar 24;48(6):1984-2008.
DMRPYGX	RU	https://pubmed.ncbi.nlm.nih.gov/15771442

DMRPYGX	DI	DMRPYGX
DMRPYGX	DN	RWJ-50353
DMRPYGX	MI	TT6L509
DMRPYGX	MN	Coagulation factor IIa (F2)
DMRPYGX	MT	DTT
DMRPYGX	MA	Inhibitor
DMRPYGX	RN	Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. Bioorg Med Chem. 2008 Feb 15;16(4):1562-95.
DMRPYGX	RU	https://pubmed.ncbi.nlm.nih.gov/18053726

DMAEWMP	DI	DMAEWMP
DMAEWMP	DN	RWJ-53419
DMAEWMP	MI	TTJA1ZO
DMAEWMP	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMAEWMP	MT	DTT
DMAEWMP	MA	Inhibitor
DMAEWMP	RN	1,2,4-triazolo[3,4-a]pyridine as a novel, constrained template for fibrinogen receptor (GPIIb/IIIa) antagonists. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2619-22.
DMAEWMP	RU	https://pubmed.ncbi.nlm.nih.gov/11551763

DME07AN	DI	DME07AN
DME07AN	DN	RWJ-56110
DME07AN	MI	TTL935N
DME07AN	MN	Proteinase activated receptor 1 (F2R)
DME07AN	MT	DTT
DME07AN	MA	Antagonist
DME07AN	RN	Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor. Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12257-62.
DME07AN	RU	https://pubmed.ncbi.nlm.nih.gov/10535908

DMGUWFJ	DI	DMGUWFJ
DMGUWFJ	DN	RWJ-61907
DMGUWFJ	MI	TTJVCG0
DMGUWFJ	MN	Bacterial Sporulation kinase A (Bact kinA)
DMGUWFJ	MT	DTT
DMGUWFJ	MA	Inhibitor
DMGUWFJ	RN	Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter. 2006 Jun;19(2):130-9.
DMGUWFJ	RU	https://pubmed.ncbi.nlm.nih.gov/16964330

DMUZW80	DI	DMUZW80
DMUZW80	DN	RWJ-68141
DMUZW80	MI	TTNGILX
DMUZW80	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMUZW80	MT	DTT
DMUZW80	MA	Inhibitor
DMUZW80	RN	Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
DMUZW80	RU	https://pubmed.ncbi.nlm.nih.gov/15664832

DMUK7LX	DI	DMUK7LX
DMUK7LX	DN	RWJ-68157
DMUK7LX	MI	TTNGILX
DMUK7LX	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMUK7LX	MT	DTT
DMUK7LX	MA	Inhibitor
DMUK7LX	RN	Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
DMUK7LX	RU	https://pubmed.ncbi.nlm.nih.gov/15664832

DMUK7LX	DI	DMUK7LX
DMUK7LX	DN	RWJ-68157
DMUK7LX	MI	TTBRKXS
DMUK7LX	MN	Adrenergic receptor alpha-1B (ADRA1B)
DMUK7LX	MT	DTT
DMUK7LX	MA	Inhibitor
DMUK7LX	RN	Novel arylpiperazines as selective alpha1-adrenergic receptor antagonists. Bioorg Med Chem Lett. 2000 May 15;10(10):1093-6.
DMUK7LX	RU	https://pubmed.ncbi.nlm.nih.gov/10843225

DMUK7LX	DI	DMUK7LX
DMUK7LX	DN	RWJ-68157
DMUK7LX	MI	TT34BHT
DMUK7LX	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMUK7LX	MT	DTT
DMUK7LX	MA	Inhibitor
DMUK7LX	RN	Novel arylpiperazines as selective alpha1-adrenergic receptor antagonists. Bioorg Med Chem Lett. 2000 May 15;10(10):1093-6.
DMUK7LX	RU	https://pubmed.ncbi.nlm.nih.gov/10843225

DMNLVRS	DI	DMNLVRS
DMNLVRS	DN	RWJ-68354
DMNLVRS	MI	TTYT93M
DMNLVRS	MN	MAP kinase p38 (MAPK12)
DMNLVRS	MT	DTT
DMNLVRS	MA	Inhibitor
DMNLVRS	RN	Imidazopyrimidines, potent inhibitors of p38 MAP kinase. Bioorg Med Chem Lett. 2003 Feb 10;13(3):347-50.
DMNLVRS	RU	https://pubmed.ncbi.nlm.nih.gov/12565927

DMNLVRS	DI	DMNLVRS
DMNLVRS	DN	RWJ-68354
DMNLVRS	MI	TTQBR95
DMNLVRS	MN	Stress-activated protein kinase 2a (p38 alpha)
DMNLVRS	MT	DTT
DMNLVRS	MA	Inhibitor
DMNLVRS	RN	Imidazopyrimidines, potent inhibitors of p38 MAP kinase. Bioorg Med Chem Lett. 2003 Feb 10;13(3):347-50.
DMNLVRS	RU	https://pubmed.ncbi.nlm.nih.gov/12565927

DMNLVRS	DI	DMNLVRS
DMNLVRS	DN	RWJ-68354
DMNLVRS	MI	TT73U6C
DMNLVRS	MN	Stress-activated protein kinase 2b (p38 beta)
DMNLVRS	MT	DTT
DMNLVRS	MA	Inhibitor
DMNLVRS	RN	Imidazopyrimidines, potent inhibitors of p38 MAP kinase. Bioorg Med Chem Lett. 2003 Feb 10;13(3):347-50.
DMNLVRS	RU	https://pubmed.ncbi.nlm.nih.gov/12565927

DM2EOBM	DI	DM2EOBM
DM2EOBM	DN	RWJ-69736
DM2EOBM	MI	TTNGILX
DM2EOBM	MN	Adrenergic receptor alpha-1A (ADRA1A)
DM2EOBM	MT	DTT
DM2EOBM	MA	Inhibitor
DM2EOBM	RN	Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
DM2EOBM	RU	https://pubmed.ncbi.nlm.nih.gov/15664832

DM2EOBM	DI	DM2EOBM
DM2EOBM	DN	RWJ-69736
DM2EOBM	MI	TTBRKXS
DM2EOBM	MN	Adrenergic receptor alpha-1B (ADRA1B)
DM2EOBM	MT	DTT
DM2EOBM	MA	Inhibitor
DM2EOBM	RN	Novel arylpiperazines as selective alpha1-adrenergic receptor antagonists. Bioorg Med Chem Lett. 2000 May 15;10(10):1093-6.
DM2EOBM	RU	https://pubmed.ncbi.nlm.nih.gov/10843225

DM2EOBM	DI	DM2EOBM
DM2EOBM	DN	RWJ-69736
DM2EOBM	MI	TT34BHT
DM2EOBM	MN	Adrenergic receptor alpha-1D (ADRA1D)
DM2EOBM	MT	DTT
DM2EOBM	MA	Inhibitor
DM2EOBM	RN	Novel arylpiperazines as selective alpha1-adrenergic receptor antagonists. Bioorg Med Chem Lett. 2000 May 15;10(10):1093-6.
DM2EOBM	RU	https://pubmed.ncbi.nlm.nih.gov/10843225

DMKYNGE	DI	DMKYNGE
DMKYNGE	DN	RX-1792
DMKYNGE	MI	TTGKNB4
DMKYNGE	MN	Epidermal growth factor receptor (EGFR)
DMKYNGE	MT	DTT
DMKYNGE	MA	Antagonist
DMKYNGE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
DMKYNGE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797

DMM5O30	DI	DMM5O30
DMM5O30	DN	RXP-407
DMM5O30	MI	TTL69WB
DMM5O30	MN	Angiotensin-converting enzyme (ACE)
DMM5O30	MT	DTT
DMM5O30	MA	Inhibitor
DMM5O30	RN	New ketomethylene inhibitor analogues: synthesis and assessment of structural determinants for N-domain selective inhibition of angiotensin-converting enzyme. Biol Chem. 2012 May;393(6):485-93.
DMM5O30	RU	https://pubmed.ncbi.nlm.nih.gov/22628311

DM5GIUY	DI	DM5GIUY
DM5GIUY	DN	RXP-470
DM5GIUY	MI	TTXZ0KQ
DM5GIUY	MN	Matrix metalloproteinase-12 (MMP-12)
DM5GIUY	MT	DTT
DM5GIUY	MA	Inhibitor
DM5GIUY	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1636).
DM5GIUY	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1636

DMB7EGU	DI	DMB7EGU
DMB7EGU	DN	RXP470.1
DMB7EGU	MI	TTXZ0KQ
DMB7EGU	MN	Matrix metalloproteinase-12 (MMP-12)
DMB7EGU	MT	DTT
DMB7EGU	MA	Inhibitor
DMB7EGU	RN	Molecular determinants of a selective matrix metalloprotease-12 inhibitor: insights from crystallography and thermodynamic studies. J Med Chem. 2013 Feb 14;56(3):1149-59.
DMB7EGU	RU	https://pubmed.ncbi.nlm.nih.gov/23343195

DM9KXV0	DI	DM9KXV0
DM9KXV0	DN	RY024
DM9KXV0	MI	TTNZPQ1
DM9KXV0	MN	GABA(A) receptor alpha-5 (GABRA5)
DM9KXV0	MT	DTT
DM9KXV0	MA	Modulator (allosteric modulator)
DM9KXV0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 408).
DM9KXV0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=408

DMGUX16	DI	DMGUX16
DMGUX16	DN	RY-066
DMGUX16	MI	TT1MPAY
DMGUX16	MN	GABA(A) receptor alpha-1 (GABRA1)
DMGUX16	MT	DTT
DMGUX16	MA	Inhibitor
DMGUX16	RN	Predictive models for GABAA/benzodiazepine receptor subtypes: studies of quantitative structure-activity relationships for imidazobenzodiazepines a... J Med Chem. 1998 Oct 8;41(21):4130-42.
DMGUX16	RU	https://pubmed.ncbi.nlm.nih.gov/9767648

DMGUX16	DI	DMGUX16
DMGUX16	DN	RY-066
DMGUX16	MI	TTBMV1G
DMGUX16	MN	GABA(A) receptor alpha-2 (GABRA2)
DMGUX16	MT	DTT
DMGUX16	MA	Inhibitor
DMGUX16	RN	Predictive models for GABAA/benzodiazepine receptor subtypes: studies of quantitative structure-activity relationships for imidazobenzodiazepines a... J Med Chem. 1998 Oct 8;41(21):4130-42.
DMGUX16	RU	https://pubmed.ncbi.nlm.nih.gov/9767648

DMGUX16	DI	DMGUX16
DMGUX16	DN	RY-066
DMGUX16	MI	TT37EDJ
DMGUX16	MN	GABA(A) receptor alpha-3 (GABRA3)
DMGUX16	MT	DTT
DMGUX16	MA	Inhibitor
DMGUX16	RN	Predictive models for GABAA/benzodiazepine receptor subtypes: studies of quantitative structure-activity relationships for imidazobenzodiazepines a... J Med Chem. 1998 Oct 8;41(21):4130-42.
DMGUX16	RU	https://pubmed.ncbi.nlm.nih.gov/9767648

DMGUX16	DI	DMGUX16
DMGUX16	DN	RY-066
DMGUX16	MI	TT06RH5
DMGUX16	MN	GABA(A) receptor gamma-2 (GABRG2)
DMGUX16	MT	DTT
DMGUX16	MA	Inhibitor
DMGUX16	RN	Predictive models for GABAA/benzodiazepine receptor subtypes: studies of quantitative structure-activity relationships for imidazobenzodiazepines a... J Med Chem. 1998 Oct 8;41(21):4130-42.
DMGUX16	RU	https://pubmed.ncbi.nlm.nih.gov/9767648

DMGUX16	DI	DMGUX16
DMGUX16	DN	RY-066
DMGUX16	MI	TTNJYV2
DMGUX16	MN	Gamma-aminobutyric acid receptor (GAR)
DMGUX16	MT	DTT
DMGUX16	MA	Inhibitor
DMGUX16	RN	Predictive models for GABAA/benzodiazepine receptor subtypes: studies of quantitative structure-activity relationships for imidazobenzodiazepines a... J Med Chem. 1998 Oct 8;41(21):4130-42.
DMGUX16	RU	https://pubmed.ncbi.nlm.nih.gov/9767648

DMW4850	DI	DMW4850
DMW4850	DN	RY796
DMW4850	MI	TT5OEKU
DMW4850	MN	Voltage-gated potassium channel Kv2.1 (KCNB1)
DMW4850	MT	DTT
DMW4850	MA	Inhibitor (gating inhibitor)
DMW4850	RN	Identification of novel and selective Kv2 channel inhibitors. Mol Pharmacol. 2011 Dec;80(6):959-64.
DMW4850	RU	https://pubmed.ncbi.nlm.nih.gov/21948463

DMW4850	DI	DMW4850
DMW4850	DN	RY796
DMW4850	MI	TT5PFNG
DMW4850	MN	Voltage-gated potassium channel Kv2.2 (KCNB2)
DMW4850	MT	DTT
DMW4850	MA	Inhibitor (gating inhibitor)
DMW4850	RN	Identification of novel and selective Kv2 channel inhibitors. Mol Pharmacol. 2011 Dec;80(6):959-64.
DMW4850	RU	https://pubmed.ncbi.nlm.nih.gov/21948463

DM2K6I8	DI	DM2K6I8
DM2K6I8	DN	Ryanodine
DM2K6I8	MI	TTU5CIX
DM2K6I8	MN	Ryanodine receptor 1 (RYR1)
DM2K6I8	MT	DTT
DM2K6I8	MA	Antagonist
DM2K6I8	RN	The contribution of inositol 1,4,5-trisphosphate and ryanodine receptors to agonist-induced Ca(2+) signaling of airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2009 Aug;297(2):L347-61.
DM2K6I8	RU	https://pubmed.ncbi.nlm.nih.gov/19465516

DM9HA8G	DI	DM9HA8G
DM9HA8G	DN	S 0957
DM9HA8G	MI	TT1KPBZ
DM9HA8G	MN	Glucose-6-phosphate translocase (SLC37A4)
DM9HA8G	MT	DTT
DM9HA8G	MA	Inhibitor
DM9HA8G	RN	Identification of protein components of the microsomal glucose 6-phosphate transporter by photoaffinity labelling. Biochem J. 1999 May 1;339 ( Pt 3):629-38.
DM9HA8G	RU	https://pubmed.ncbi.nlm.nih.gov/10215602

DMA5GOX	DI	DMA5GOX
DMA5GOX	DN	S 1743
DMA5GOX	MI	TT1KPBZ
DMA5GOX	MN	Glucose-6-phosphate translocase (SLC37A4)
DMA5GOX	MT	DTT
DMA5GOX	MA	Inhibitor
DMA5GOX	RN	Identification of protein components of the microsomal glucose 6-phosphate transporter by photoaffinity labelling. Biochem J. 1999 May 1;339 ( Pt 3):629-38.
DMA5GOX	RU	https://pubmed.ncbi.nlm.nih.gov/10215602

DM2FC5V	DI	DM2FC5V
DM2FC5V	DN	S 18204
DM2FC5V	MI	TT2O84V
DM2FC5V	MN	Thromboxane A2 receptor (TBXA2R)
DM2FC5V	MT	DTT
DM2FC5V	MA	Modulator
DM2FC5V	RN	Antithrombotic effects of S 18886, a novel orally active thromboxane A2 receptor antagonist. J Thromb Haemost. 2004 Mar;2(3):492-8.
DM2FC5V	RU	https://www.ncbi.nlm.nih.gov/pubmed/15009468

DMGEHNX	DI	DMGEHNX
DMGEHNX	DN	S 202 791
DMGEHNX	MI	TTXHYV6
DMGEHNX	MN	Voltage-gated L-type calcium channel (L-CaC)
DMGEHNX	MT	DTT
DMGEHNX	MA	Activator
DMGEHNX	RN	Molecular determinants of drug binding and action on L-type calcium channels. Annu Rev Pharmacol Toxicol. 1997;37:361-96.
DMGEHNX	RU	https://pubmed.ncbi.nlm.nih.gov/9131258

DMZN0RW	DI	DMZN0RW
DMZN0RW	DN	S 3025
DMZN0RW	MI	TT1KPBZ
DMZN0RW	MN	Glucose-6-phosphate translocase (SLC37A4)
DMZN0RW	MT	DTT
DMZN0RW	MA	Inhibitor
DMZN0RW	RN	Prolonged blood glucose reduction in mrp-2 deficient rats (GY/TR(-)) by the glucose-6-phosphate translocase inhibitor S 3025. Biochim Biophys Acta. 2002 Jan 15;1569(1-3):105-10.
DMZN0RW	RU	https://pubmed.ncbi.nlm.nih.gov/11853963

DMXUBIK	DI	DMXUBIK
DMXUBIK	DN	S-(-)CPB
DMXUBIK	MI	TTUYAF3
DMXUBIK	MN	Chloride channel protein 1 (ClC-1)
DMXUBIK	MT	DTT
DMXUBIK	MA	Blocker (channel blocker)
DMXUBIK	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 698).
DMXUBIK	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=698

DME9QR0	DI	DME9QR0
DME9QR0	DN	S-(-)CPP
DME9QR0	MI	TTUYAF3
DME9QR0	MN	Chloride channel protein 1 (ClC-1)
DME9QR0	MT	DTT
DME9QR0	MA	Blocker (channel blocker)
DME9QR0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 698).
DME9QR0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=698

DMQG4L2	DI	DMQG4L2
DMQG4L2	DN	S-(-)-enantiomer of 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP)
DMQG4L2	MI	TTV5CGO
DMQG4L2	MN	Phosphodiesterase 4 (PDE4)
DMQG4L2	MT	DTT
DMQG4L2	MA	Inhibitor
DMQG4L2	RN	Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol. 1994 Jun 2;258(1-2):85-94.
DMQG4L2	RU	https://pubmed.ncbi.nlm.nih.gov/7925603

DM1D7KY	DI	DM1D7KY
DM1D7KY	DN	S-(-)-sulpiride
DM1D7KY	MI	TTEX248
DM1D7KY	MN	Dopamine D2 receptor (D2R)
DM1D7KY	MT	DTT
DM1D7KY	MA	Antagonist
DM1D7KY	RN	The treatment of Tourette's syndrome: current opinions. Expert Opin Pharmacother. 2002 Jul;3(7):899-914.
DM1D7KY	RU	https://pubmed.ncbi.nlm.nih.gov/12083990

DMO1R69	DI	DMO1R69
DMO1R69	DN	S-(2,4-Dichlorobenzyl)isothiourea hydrobromide
DMO1R69	MI	TTZJYKH
DMO1R69	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMO1R69	MT	DTT
DMO1R69	MA	Inhibitor
DMO1R69	RN	S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9.
DMO1R69	RU	https://pubmed.ncbi.nlm.nih.gov/20688518

DMMZQB5	DI	DMMZQB5
DMMZQB5	DN	S-(2-boronoethyl)-L-cysteine
DMMZQB5	MI	TTV1AG6
DMMZQB5	MN	Kidney-type arginase (ARG2)
DMMZQB5	MT	DTT
DMMZQB5	MA	Inhibitor
DMMZQB5	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMMZQB5	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMN62KP	DI	DMN62KP
DMN62KP	DN	S-(2-Chlorobenzyl)isothiourea hydrochloride
DMN62KP	MI	TTZJYKH
DMN62KP	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMN62KP	MT	DTT
DMN62KP	MA	Inhibitor
DMN62KP	RN	S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9.
DMN62KP	RU	https://pubmed.ncbi.nlm.nih.gov/20688518

DMNMCQJ	DI	DMNMCQJ
DMNMCQJ	DN	S-(3,4-Dichlorobenzyl)isothiourea hydrochloride
DMNMCQJ	MI	TTZJYKH
DMNMCQJ	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMNMCQJ	MT	DTT
DMNMCQJ	MA	Inhibitor
DMNMCQJ	RN	S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9.
DMNMCQJ	RU	https://pubmed.ncbi.nlm.nih.gov/20688518

DMNG6JB	DI	DMNG6JB
DMNG6JB	DN	S-(3-Chlorobenzyl)isothiourea hydrochloride
DMNG6JB	MI	TTZJYKH
DMNG6JB	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMNG6JB	MT	DTT
DMNG6JB	MA	Inhibitor
DMNG6JB	RN	S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9.
DMNG6JB	RU	https://pubmed.ncbi.nlm.nih.gov/20688518

DM0XDFG	DI	DM0XDFG
DM0XDFG	DN	S-(4-Bromobenzyl)isothiourea hydrobromide
DM0XDFG	MI	TTZJYKH
DM0XDFG	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DM0XDFG	MT	DTT
DM0XDFG	MA	Inhibitor
DM0XDFG	RN	S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9.
DM0XDFG	RU	https://pubmed.ncbi.nlm.nih.gov/20688518

DMWJE2X	DI	DMWJE2X
DMWJE2X	DN	S-(4-Chlorobenzyl)isothiourea hydrochloride
DMWJE2X	MI	TTZJYKH
DMWJE2X	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMWJE2X	MT	DTT
DMWJE2X	MA	Inhibitor
DMWJE2X	RN	S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9.
DMWJE2X	RU	https://pubmed.ncbi.nlm.nih.gov/20688518

DMYGULD	DI	DMYGULD
DMYGULD	DN	S-(4-Cyanobenzyl)isothiourea hydrobromide
DMYGULD	MI	TTZJYKH
DMYGULD	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMYGULD	MT	DTT
DMYGULD	MA	Inhibitor
DMYGULD	RN	S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9.
DMYGULD	RU	https://pubmed.ncbi.nlm.nih.gov/20688518

DMNXDWV	DI	DMNXDWV
DMNXDWV	DN	S-(4-Ethylbenzyl)isothiourea hydrochloride
DMNXDWV	MI	TTZJYKH
DMNXDWV	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMNXDWV	MT	DTT
DMNXDWV	MA	Inhibitor
DMNXDWV	RN	S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9.
DMNXDWV	RU	https://pubmed.ncbi.nlm.nih.gov/20688518

DM10MET	DI	DM10MET
DM10MET	DN	S-(4-Fluorobenzyl)isothiourea hydrochloride
DM10MET	MI	TTZJYKH
DM10MET	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DM10MET	MT	DTT
DM10MET	MA	Inhibitor
DM10MET	RN	S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9.
DM10MET	RU	https://pubmed.ncbi.nlm.nih.gov/20688518

DM4XWAU	DI	DM4XWAU
DM4XWAU	DN	S-(4-Methoxybenzyl)isothiourea hydrochloride
DM4XWAU	MI	TTZJYKH
DM4XWAU	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DM4XWAU	MT	DTT
DM4XWAU	MA	Inhibitor
DM4XWAU	RN	S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9.
DM4XWAU	RU	https://pubmed.ncbi.nlm.nih.gov/20688518

DMAGLI8	DI	DMAGLI8
DMAGLI8	DN	S-(4-Methylbenzyl)isothiourea hydrochloride
DMAGLI8	MI	TTZJYKH
DMAGLI8	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMAGLI8	MT	DTT
DMAGLI8	MA	Inhibitor
DMAGLI8	RN	S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9.
DMAGLI8	RU	https://pubmed.ncbi.nlm.nih.gov/20688518

DMYRBO0	DI	DMYRBO0
DMYRBO0	DN	S-(4-Nitrobenzyl)isothiourea hydrochloride
DMYRBO0	MI	TTZJYKH
DMYRBO0	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMYRBO0	MT	DTT
DMYRBO0	MA	Inhibitor
DMYRBO0	RN	S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9.
DMYRBO0	RU	https://pubmed.ncbi.nlm.nih.gov/20688518

DMSCHL0	DI	DMSCHL0
DMSCHL0	DN	S-(Dimethylarsenic)Cysteine
DMSCHL0	MI	TT5DOVB
DMSCHL0	MN	Cytomegalovirus Protease (CMV UL80)
DMSCHL0	MT	DTT
DMSCHL0	MA	Inhibitor
DMSCHL0	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMSCHL0	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMSCHL0	DI	DMSCHL0
DMSCHL0	DN	S-(Dimethylarsenic)Cysteine
DMSCHL0	MI	TTCM4B3
DMSCHL0	MN	Nitric-oxide synthase endothelial (NOS3)
DMSCHL0	MT	DTT
DMSCHL0	MA	Inhibitor
DMSCHL0	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMSCHL0	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMSCHL0	DI	DMSCHL0
DMSCHL0	DN	S-(Dimethylarsenic)Cysteine
DMSCHL0	MI	TTY7ZHS
DMSCHL0	MN	Toll-like receptor 2 (TLR2)
DMSCHL0	MT	DTT
DMSCHL0	MA	Inhibitor
DMSCHL0	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMSCHL0	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM3FXPV	DI	DM3FXPV
DM3FXPV	DN	S-(N-4bromophenyl-N-hydroxycarbamoyl)glutathione
DM3FXPV	MI	TTV9A7R
DM3FXPV	MN	Lactoylglutathione lyase (GLO1)
DM3FXPV	MT	DTT
DM3FXPV	MA	Inhibitor
DM3FXPV	RN	Role of hydrophobic interactions in binding S-(N-aryl/alkyl-N-hydroxycarbamoyl)glutathiones to the active site of the antitumor target enzyme glyoxalase I. J Med Chem. 2000 Oct 19;43(21):3981-6.
DM3FXPV	RU	https://pubmed.ncbi.nlm.nih.gov/11052803

DMPURE8	DI	DMPURE8
DMPURE8	DN	S-(N-4chlorophenyl-N-hydroxycarbamoyl)glutathione
DMPURE8	MI	TTV9A7R
DMPURE8	MN	Lactoylglutathione lyase (GLO1)
DMPURE8	MT	DTT
DMPURE8	MA	Inhibitor
DMPURE8	RN	Role of hydrophobic interactions in binding S-(N-aryl/alkyl-N-hydroxycarbamoyl)glutathiones to the active site of the antitumor target enzyme glyoxalase I. J Med Chem. 2000 Oct 19;43(21):3981-6.
DMPURE8	RU	https://pubmed.ncbi.nlm.nih.gov/11052803

DMU7EQV	DI	DMU7EQV
DMU7EQV	DN	S-(N-butyl-N-hydroxycarbamoyl)glutathione
DMU7EQV	MI	TTV9A7R
DMU7EQV	MN	Lactoylglutathione lyase (GLO1)
DMU7EQV	MT	DTT
DMU7EQV	MA	Inhibitor
DMU7EQV	RN	Role of hydrophobic interactions in binding S-(N-aryl/alkyl-N-hydroxycarbamoyl)glutathiones to the active site of the antitumor target enzyme glyoxalase I. J Med Chem. 2000 Oct 19;43(21):3981-6.
DMU7EQV	RU	https://pubmed.ncbi.nlm.nih.gov/11052803

DMMETC2	DI	DMMETC2
DMMETC2	DN	S-(N-ethyl-N-hydroxycarbamoyl)glutathione
DMMETC2	MI	TTV9A7R
DMMETC2	MN	Lactoylglutathione lyase (GLO1)
DMMETC2	MT	DTT
DMMETC2	MA	Inhibitor
DMMETC2	RN	Role of hydrophobic interactions in binding S-(N-aryl/alkyl-N-hydroxycarbamoyl)glutathiones to the active site of the antitumor target enzyme glyoxalase I. J Med Chem. 2000 Oct 19;43(21):3981-6.
DMMETC2	RU	https://pubmed.ncbi.nlm.nih.gov/11052803

DMV6T1Q	DI	DMV6T1Q
DMV6T1Q	DN	S-(N-heptyl-N-hydroxycarbamoyl)glutathione
DMV6T1Q	MI	TTV9A7R
DMV6T1Q	MN	Lactoylglutathione lyase (GLO1)
DMV6T1Q	MT	DTT
DMV6T1Q	MA	Inhibitor
DMV6T1Q	RN	Role of hydrophobic interactions in binding S-(N-aryl/alkyl-N-hydroxycarbamoyl)glutathiones to the active site of the antitumor target enzyme glyoxalase I. J Med Chem. 2000 Oct 19;43(21):3981-6.
DMV6T1Q	RU	https://pubmed.ncbi.nlm.nih.gov/11052803

DMSWHMI	DI	DMSWHMI
DMSWHMI	DN	S-(N-hexyl-N-hydroxycarbamoyl)glutathione
DMSWHMI	MI	TTV9A7R
DMSWHMI	MN	Lactoylglutathione lyase (GLO1)
DMSWHMI	MT	DTT
DMSWHMI	MA	Inhibitor
DMSWHMI	RN	Role of hydrophobic interactions in binding S-(N-aryl/alkyl-N-hydroxycarbamoyl)glutathiones to the active site of the antitumor target enzyme glyoxalase I. J Med Chem. 2000 Oct 19;43(21):3981-6.
DMSWHMI	RU	https://pubmed.ncbi.nlm.nih.gov/11052803

DM1AHIW	DI	DM1AHIW
DM1AHIW	DN	S-(N-Hydroxy-N-Iodophenylcarbamoyl)Glutathione
DM1AHIW	MI	TTV9A7R
DM1AHIW	MN	Lactoylglutathione lyase (GLO1)
DM1AHIW	MT	DTT
DM1AHIW	MA	Inhibitor
DM1AHIW	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DM1AHIW	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DM1C9W3	DI	DM1C9W3
DM1C9W3	DN	S-(N-methyl-N-hydroxycarbamoyl)glutathione
DM1C9W3	MI	TTV9A7R
DM1C9W3	MN	Lactoylglutathione lyase (GLO1)
DM1C9W3	MT	DTT
DM1C9W3	MA	Inhibitor
DM1C9W3	RN	Role of hydrophobic interactions in binding S-(N-aryl/alkyl-N-hydroxycarbamoyl)glutathiones to the active site of the antitumor target enzyme glyoxalase I. J Med Chem. 2000 Oct 19;43(21):3981-6.
DM1C9W3	RU	https://pubmed.ncbi.nlm.nih.gov/11052803

DM4E9J2	DI	DM4E9J2
DM4E9J2	DN	S-(N-pentyl-N-hydroxycarbamoyl)glutathione
DM4E9J2	MI	TTV9A7R
DM4E9J2	MN	Lactoylglutathione lyase (GLO1)
DM4E9J2	MT	DTT
DM4E9J2	MA	Inhibitor
DM4E9J2	RN	Role of hydrophobic interactions in binding S-(N-aryl/alkyl-N-hydroxycarbamoyl)glutathiones to the active site of the antitumor target enzyme glyoxalase I. J Med Chem. 2000 Oct 19;43(21):3981-6.
DM4E9J2	RU	https://pubmed.ncbi.nlm.nih.gov/11052803

DMECAS0	DI	DMECAS0
DMECAS0	DN	S-(N-phenyl-N-hydroxycarbamoyl)glutathione
DMECAS0	MI	TTV9A7R
DMECAS0	MN	Lactoylglutathione lyase (GLO1)
DMECAS0	MT	DTT
DMECAS0	MA	Inhibitor
DMECAS0	RN	Role of hydrophobic interactions in binding S-(N-aryl/alkyl-N-hydroxycarbamoyl)glutathiones to the active site of the antitumor target enzyme glyoxalase I. J Med Chem. 2000 Oct 19;43(21):3981-6.
DMECAS0	RU	https://pubmed.ncbi.nlm.nih.gov/11052803

DMRFKZ6	DI	DMRFKZ6
DMRFKZ6	DN	S-(N-propyl-N-hydroxycarbamoyl)glutathione
DMRFKZ6	MI	TTV9A7R
DMRFKZ6	MN	Lactoylglutathione lyase (GLO1)
DMRFKZ6	MT	DTT
DMRFKZ6	MA	Inhibitor
DMRFKZ6	RN	Role of hydrophobic interactions in binding S-(N-aryl/alkyl-N-hydroxycarbamoyl)glutathiones to the active site of the antitumor target enzyme glyoxalase I. J Med Chem. 2000 Oct 19;43(21):3981-6.
DMRFKZ6	RU	https://pubmed.ncbi.nlm.nih.gov/11052803

DMLPAD8	DI	DMLPAD8
DMLPAD8	DN	S,S-(2-Hydroxyethyl)Thiocysteine
DMLPAD8	MI	TTU6BFZ
DMLPAD8	MN	Candida Thymidylate synthase (Candi TMP1)
DMLPAD8	MT	DTT
DMLPAD8	MA	Inhibitor
DMLPAD8	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMLPAD8	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMLPAD8	DI	DMLPAD8
DMLPAD8	DN	S,S-(2-Hydroxyethyl)Thiocysteine
DMLPAD8	MI	TTJHKYD
DMLPAD8	MN	Delta-aminolevulinic acid dehydratase (ALAD)
DMLPAD8	MT	DTT
DMLPAD8	MA	Inhibitor
DMLPAD8	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMLPAD8	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMLPAD8	DI	DMLPAD8
DMLPAD8	DN	S,S-(2-Hydroxyethyl)Thiocysteine
DMLPAD8	MI	TT1KW50
DMLPAD8	MN	Maspin (SERPINB5)
DMLPAD8	MT	DTT
DMLPAD8	MA	Inhibitor
DMLPAD8	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMLPAD8	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMLPAD8	DI	DMLPAD8
DMLPAD8	DN	S,S-(2-Hydroxyethyl)Thiocysteine
DMLPAD8	MI	TTKGY3F
DMLPAD8	MN	Mycobacterium DTDP-dehydrorhamnose epimerase rmlC (MycB rmlC)
DMLPAD8	MT	DTT
DMLPAD8	MA	Inhibitor
DMLPAD8	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMLPAD8	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMLPAD8	DI	DMLPAD8
DMLPAD8	DN	S,S-(2-Hydroxyethyl)Thiocysteine
DMLPAD8	MI	TTHQENC
DMLPAD8	MN	Phosphodiesterase 1 (PDE1)
DMLPAD8	MT	DTT
DMLPAD8	MA	Inhibitor
DMLPAD8	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMLPAD8	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMLPAD8	DI	DMLPAD8
DMLPAD8	DN	S,S-(2-Hydroxyethyl)Thiocysteine
DMLPAD8	MI	TTVIAT9
DMLPAD8	MN	Phosphodiesterase 4B (PDE4B)
DMLPAD8	MT	DTT
DMLPAD8	MA	Inhibitor
DMLPAD8	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMLPAD8	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMT36AB	DI	DMT36AB
DMT36AB	DN	S-024
DMT36AB	MI	TTTU902
DMT36AB	MN	Checkpoint kinase-1 (CHK1)
DMT36AB	MT	DTT
DMT36AB	MA	Inhibitor
DMT36AB	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1987).
DMT36AB	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1987

DMANSCK	DI	DMANSCK
DMANSCK	DN	S-070
DMANSCK	MI	TTTU902
DMANSCK	MN	Checkpoint kinase-1 (CHK1)
DMANSCK	MT	DTT
DMANSCK	MA	Inhibitor
DMANSCK	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1987).
DMANSCK	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1987

DMANSCK	DI	DMANSCK
DMANSCK	DN	S-070
DMANSCK	MI	TTVDSZ0
DMANSCK	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMANSCK	MT	DTT
DMANSCK	MA	Inhibitor
DMANSCK	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2771).
DMANSCK	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2771

DMIBEY6	DI	DMIBEY6
DMIBEY6	DN	S-1,2-propanediol
DMIBEY6	MI	DE9TLVP
DMIBEY6	MN	Diol dehydratase (pddA)
DMIBEY6	MT	DME
DMIBEY6	MA	Metabolism
DMIBEY6	RN	1,2-Propanediol dehydration in Roseburia inulinivorans: structural basis for substrates and enantiomers selectivity. J Biol Chem. 2016 Jul 22;291(30):15515-26.
DMIBEY6	RU	https://pubmed.ncbi.nlm.nih.gov/27252380

DM2JYQA	DI	DM2JYQA
DM2JYQA	DN	S109
DM2JYQA	MI	TTCJUR4
DM2JYQA	MN	Exportin-1 (XPO1)
DM2JYQA	MT	DTT
DM2JYQA	MA	Inhibitor
DM2JYQA	RN	Reversible inhibitor of CRM1 sensitizes glioblastoma cells to radiation by blocking the NF-B signaling pathway. Cancer Cell Int. 2020 Mar 30;20:97.
DM2JYQA	RU	https://pubmed.ncbi.nlm.nih.gov/32256206

DMRVUCY	DI	DMRVUCY
DMRVUCY	DN	S-111
DMRVUCY	MI	TTVDSZ0
DMRVUCY	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMRVUCY	MT	DTT
DMRVUCY	MA	Inhibitor
DMRVUCY	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2771).
DMRVUCY	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2771

DMN6HE3	DI	DMN6HE3
DMN6HE3	DN	S136492
DMN6HE3	MI	TT5U914
DMN6HE3	MN	Endothelin-converting enzyme 2 (ECE2)
DMN6HE3	MT	DTT
DMN6HE3	MA	Inhibitor
DMN6HE3	RN	Homology modeling and site-directed mutagenesis to identify selective inhibitors of endothelin-converting enzyme-2. J Med Chem. 2008 Jun 26;51(12):3378-87.
DMN6HE3	RU	https://pubmed.ncbi.nlm.nih.gov/18507370

DMHVEJF	DI	DMHVEJF
DMHVEJF	DN	S-14671
DMHVEJF	MI	TTSQIFT
DMHVEJF	MN	5-HT 1A receptor (HTR1A)
DMHVEJF	MT	DTT
DMHVEJF	MA	Agonist
DMHVEJF	RN	Labelling of recombinant human and native rat serotonin 5-HT1A receptors by a novel, selective radioligand, [3H]-S 15535: definition of its binding profile using agonists, antagonists and inverse agonists. Naunyn Schmiedebergs Arch Pharmacol. 1998 Mar;357(3):205-17.
DMHVEJF	RU	https://pubmed.ncbi.nlm.nih.gov/9550290

DMD4KLQ	DI	DMD4KLQ
DMD4KLQ	DN	S1627
DMD4KLQ	MI	TTRPDBG
DMD4KLQ	MN	Inhibitor of nuclear factor kappa-B kinase (IKK)
DMD4KLQ	MT	DTT
DMD4KLQ	MA	Inhibitor
DMD4KLQ	RN	Specific Inhibition of IkappaB kinase reduces hyperalgesia in inflammatory and neuropathic pain models in rats. J Neurosci. 2004 Feb 18;24(7):1637-45.
DMD4KLQ	RU	https://pubmed.ncbi.nlm.nih.gov/14973242

DM589XM	DI	DM589XM
DM589XM	DN	S-19528
DM589XM	MI	TTRK9JT
DM589XM	MN	Neuropeptide Y receptor type 1 (NPY1R)
DM589XM	MT	DTT
DM589XM	MA	Antagonist
DM589XM	RN	Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36.
DM589XM	RU	https://pubmed.ncbi.nlm.nih.gov/16634704

DM589XM	DI	DM589XM
DM589XM	DN	S-19528
DM589XM	MI	TTY6EWA
DM589XM	MN	Neuropeptide Y receptor type 5 (NPY5R)
DM589XM	MT	DTT
DM589XM	MA	Antagonist
DM589XM	RN	Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36.
DM589XM	RU	https://pubmed.ncbi.nlm.nih.gov/16634704

DMU9F7K	DI	DMU9F7K
DMU9F7K	DN	S-2-(o-toluidino)-2-oxoethyl carbamothioate
DMU9F7K	MI	TTULVH8
DMU9F7K	MN	Tyrosinase (TYR)
DMU9F7K	MT	DTT
DMU9F7K	MA	Inhibitor
DMU9F7K	RN	Discovery of small-molecule inhibitors of tyrosinase. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6871-5.
DMU9F7K	RU	https://pubmed.ncbi.nlm.nih.gov/17964155

DMTH15E	DI	DMTH15E
DMTH15E	DN	S-2,9-dioxo-9-(phenylamino)nonyl ethanethioate
DMTH15E	MI	TTT6LFV
DMTH15E	MN	Histone deacetylase 8 (HDAC8)
DMTH15E	MT	DTT
DMTH15E	MA	Inhibitor
DMTH15E	RN	Histone deacetylase inhibitors: from bench to clinic. J Med Chem. 2008 Mar 27;51(6):1505-29.
DMTH15E	RU	https://pubmed.ncbi.nlm.nih.gov/18247554

DMOJ9N6	DI	DMOJ9N6
DMOJ9N6	DN	S-21007
DMOJ9N6	MI	TTNXLKE
DMOJ9N6	MN	5-HT 3 receptor (5HT3R)
DMOJ9N6	MT	DTT
DMOJ9N6	MA	Modulator
DMOJ9N6	RN	Effects of S-21007, a potent 5-HT3 partial agonist, in mouse anxiety. Zhongguo Yao Li Xue Bao. 1999 Sep;20(9):805-12.
DMOJ9N6	RU	https://www.ncbi.nlm.nih.gov/pubmed/11245088

DM4S5TQ	DI	DM4S5TQ
DM4S5TQ	DN	S22153
DM4S5TQ	MI	TT0WAIE
DM4S5TQ	MN	Melatonin receptor type 1A (MTNR1A)
DM4S5TQ	MT	DTT
DM4S5TQ	MA	Antagonist
DM4S5TQ	RN	New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2003 Jun;367(6):553-61.
DM4S5TQ	RU	https://pubmed.ncbi.nlm.nih.gov/12764576

DM3GS2X	DI	DM3GS2X
DM3GS2X	DN	S-2238
DM3GS2X	MI	TT6L509
DM3GS2X	MN	Coagulation factor IIa (F2)
DM3GS2X	MT	DTT
DM3GS2X	MA	Inhibitor
DM3GS2X	RN	Screening for selective thrombin inhibitors in mushrooms. Blood Coagul Fibrinolysis. 2001 Mar;12(2):123-8.
DM3GS2X	RU	https://pubmed.ncbi.nlm.nih.gov/11302474

DM9RU46	DI	DM9RU46
DM9RU46	DN	S24014
DM9RU46	MI	TT0WAIE
DM9RU46	MN	Melatonin receptor type 1A (MTNR1A)
DM9RU46	MT	DTT
DM9RU46	MA	Agonist
DM9RU46	RN	New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2003 Jun;367(6):553-61.
DM9RU46	RU	https://pubmed.ncbi.nlm.nih.gov/12764576

DM1HAD0	DI	DM1HAD0
DM1HAD0	DN	S24773
DM1HAD0	MI	TT0WAIE
DM1HAD0	MN	Melatonin receptor type 1A (MTNR1A)
DM1HAD0	MT	DTT
DM1HAD0	MA	Agonist
DM1HAD0	RN	New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2003 Jun;367(6):553-61.
DM1HAD0	RU	https://pubmed.ncbi.nlm.nih.gov/12764576

DMBUD1M	DI	DMBUD1M
DMBUD1M	DN	S-25585
DMBUD1M	MI	TTRK9JT
DMBUD1M	MN	Neuropeptide Y receptor type 1 (NPY1R)
DMBUD1M	MT	DTT
DMBUD1M	MA	Antagonist
DMBUD1M	RN	Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36.
DMBUD1M	RU	https://pubmed.ncbi.nlm.nih.gov/16634704

DMBUD1M	DI	DMBUD1M
DMBUD1M	DN	S-25585
DMBUD1M	MI	TTY6EWA
DMBUD1M	MN	Neuropeptide Y receptor type 5 (NPY5R)
DMBUD1M	MT	DTT
DMBUD1M	MA	Antagonist
DMBUD1M	RN	Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36.
DMBUD1M	RU	https://pubmed.ncbi.nlm.nih.gov/16634704

DMCJ86U	DI	DMCJ86U
DMCJ86U	DN	S26131
DMCJ86U	MI	TT0WAIE
DMCJ86U	MN	Melatonin receptor type 1A (MTNR1A)
DMCJ86U	MT	DTT
DMCJ86U	MA	Antagonist
DMCJ86U	RN	New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2003 Jun;367(6):553-61.
DMCJ86U	RU	https://pubmed.ncbi.nlm.nih.gov/12764576

DMLJITC	DI	DMLJITC
DMLJITC	DN	S26284
DMLJITC	MI	TT0WAIE
DMLJITC	MN	Melatonin receptor type 1A (MTNR1A)
DMLJITC	MT	DTT
DMLJITC	MA	Agonist
DMLJITC	RN	New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2003 Jun;367(6):553-61.
DMLJITC	RU	https://pubmed.ncbi.nlm.nih.gov/12764576

DM3Z6TI	DI	DM3Z6TI
DM3Z6TI	DN	S33005
DM3Z6TI	MI	TTAWNKZ
DM3Z6TI	MN	Norepinephrine transporter (NET)
DM3Z6TI	MT	DTT
DM3Z6TI	MA	Inhibitor
DM3Z6TI	RN	Serotonin reuptake inhibitors: the corner stone in treatment of depression for half a century--a medicinal chemistry survey. Curr Top Med Chem. 2006;6(17):1801-23.
DM3Z6TI	RU	https://pubmed.ncbi.nlm.nih.gov/17017959

DM3Z6TI	DI	DM3Z6TI
DM3Z6TI	DN	S33005
DM3Z6TI	MI	TT3ROYC
DM3Z6TI	MN	Serotonin transporter (SERT)
DM3Z6TI	MT	DTT
DM3Z6TI	MA	Inhibitor
DM3Z6TI	RN	Serotonin reuptake inhibitors: the corner stone in treatment of depression for half a century--a medicinal chemistry survey. Curr Top Med Chem. 2006;6(17):1801-23.
DM3Z6TI	RU	https://pubmed.ncbi.nlm.nih.gov/17017959

DMZLQ5W	DI	DMZLQ5W
DMZLQ5W	DN	S-34324
DMZLQ5W	MI	TTWG9A4
DMZLQ5W	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMZLQ5W	MT	DTT
DMZLQ5W	MA	Inhibitor
DMZLQ5W	RN	Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking... J Med Chem. 2005 Mar 24;48(6):2054-71.
DMZLQ5W	RU	https://pubmed.ncbi.nlm.nih.gov/15771448

DMZLQ5W	DI	DMZLQ5W
DMZLQ5W	DN	S-34324
DMZLQ5W	MI	TTWM4TY
DMZLQ5W	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMZLQ5W	MT	DTT
DMZLQ5W	MA	Inhibitor
DMZLQ5W	RN	Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking... J Med Chem. 2005 Mar 24;48(6):2054-71.
DMZLQ5W	RU	https://pubmed.ncbi.nlm.nih.gov/15771448

DMZLQ5W	DI	DMZLQ5W
DMZLQ5W	DN	S-34324
DMZLQ5W	MI	TT2NUT5
DMZLQ5W	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMZLQ5W	MT	DTT
DMZLQ5W	MA	Inhibitor
DMZLQ5W	RN	Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking... J Med Chem. 2005 Mar 24;48(6):2054-71.
DMZLQ5W	RU	https://pubmed.ncbi.nlm.nih.gov/15771448

DMZLQ5W	DI	DMZLQ5W
DMZLQ5W	DN	S-34324
DMZLQ5W	MI	TTAWNKZ
DMZLQ5W	MN	Norepinephrine transporter (NET)
DMZLQ5W	MT	DTT
DMZLQ5W	MA	Inhibitor
DMZLQ5W	RN	Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking... J Med Chem. 2005 Mar 24;48(6):2054-71.
DMZLQ5W	RU	https://pubmed.ncbi.nlm.nih.gov/15771448

DMZLQ5W	DI	DMZLQ5W
DMZLQ5W	DN	S-34324
DMZLQ5W	MI	TT3ROYC
DMZLQ5W	MN	Serotonin transporter (SERT)
DMZLQ5W	MT	DTT
DMZLQ5W	MA	Inhibitor
DMZLQ5W	RN	Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking... J Med Chem. 2005 Mar 24;48(6):2054-71.
DMZLQ5W	RU	https://pubmed.ncbi.nlm.nih.gov/15771448

DM84DMW	DI	DM84DMW
DM84DMW	DN	S3969
DM84DMW	MI	TTQM7TE
DM84DMW	MN	Amiloride-sensitive sodium channel (ENaC)
DM84DMW	MT	DTT
DM84DMW	MA	Activator
DM84DMW	RN	Small molecule activator of the human epithelial sodium channel. J Biol Chem. 2008 May 2;283(18):11981-94.
DM84DMW	RU	https://pubmed.ncbi.nlm.nih.gov/18326490

DME5HIR	DI	DME5HIR
DME5HIR	DN	S-4048
DME5HIR	MI	TT1KPBZ
DME5HIR	MN	Glucose-6-phosphate translocase (SLC37A4)
DME5HIR	MT	DTT
DME5HIR	MA	Inhibitor
DME5HIR	RN	Glucose release from GLUT2-null hepatocytes: characterization of a major and a minor pathway. Am J Physiol Endocrinol Metab. 2002 Apr;282(4):E794-801.
DME5HIR	RU	https://pubmed.ncbi.nlm.nih.gov/11882499

DMFC430	DI	DMFC430
DMFC430	DN	S-41744
DMFC430	MI	TTZPO1L
DMFC430	MN	Substance-P receptor (TACR1)
DMFC430	MT	DTT
DMFC430	MA	Antagonist
DMFC430	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 360).
DMFC430	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=360

DMML1HC	DI	DMML1HC
DMML1HC	DN	S6716
DMML1HC	MI	TTW5UDX
DMML1HC	MN	Urotensin II receptor (UTS2R)
DMML1HC	MT	DTT
DMML1HC	MA	Antagonist
DMML1HC	RN	Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. J Med Chem. 2002 Apr 25;45(9):1799-805.
DMML1HC	RU	https://pubmed.ncbi.nlm.nih.gov/11960491

DMIKJNL	DI	DMIKJNL
DMIKJNL	DN	S6-nitrobenzyl mercaptopurine riboside
DMIKJNL	MI	TTLXAKE
DMIKJNL	MN	Solute carrier family 29 member 1 (SLC29A1)
DMIKJNL	MT	DTT
DMIKJNL	MA	Inhibitor
DMIKJNL	RN	Synthesis and biological evaluation of phloridzin analogs as human concentrative nucleoside transporter 3 (hCNT3) inhibitors. Bioorg Med Chem Lett. 2009 Feb 1;19(3):917-21.
DMIKJNL	RU	https://pubmed.ncbi.nlm.nih.gov/19097778

DMHB6UY	DI	DMHB6UY
DMHB6UY	DN	S-9947
DMHB6UY	MI	TTW0CMT
DMHB6UY	MN	Voltage-gated potassium channel Kv1.5 (KCNA5)
DMHB6UY	MT	DTT
DMHB6UY	MA	Blocker
DMHB6UY	RN	New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22.
DMHB6UY	RU	https://pubmed.ncbi.nlm.nih.gov/15934869

DMVA5FE	DI	DMVA5FE
DMVA5FE	DN	SA-6541
DMVA5FE	MI	TTXZEAJ
DMVA5FE	MN	Leukotriene A-4 hydrolase (LTA4H)
DMVA5FE	MT	DTT
DMVA5FE	MA	Inhibitor
DMVA5FE	RN	Synthesis and biological evaluation of N-mercaptoacylcysteine derivatives as leukotriene A4 hydrolase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):442-6.
DMVA5FE	RU	https://pubmed.ncbi.nlm.nih.gov/19042128

DM5MBX7	DI	DM5MBX7
DM5MBX7	DN	Sabadinine
DM5MBX7	MI	TTJLVBO
DM5MBX7	MN	Coronavirus Main proteinase (CoV 1a)
DM5MBX7	MT	DTT
DM5MBX7	MA	Inhibitor
DM5MBX7	RN	Sabadinine: a potential non-peptide anti-severe acute-respiratory-syndrome agent identified using structure-aided design. J Med Chem. 2004 Feb 26;47(5):1079-80.
DM5MBX7	RU	https://pubmed.ncbi.nlm.nih.gov/14971887

DMRA736	DI	DMRA736
DMRA736	DN	Saccharin
DMRA736	MI	TTUNARX
DMRA736	MN	Carbonic anhydrase (CA)
DMRA736	MT	DTT
DMRA736	MA	Inhibitor
DMRA736	RN	Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, ... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6649-54.
DMRA736	RU	https://pubmed.ncbi.nlm.nih.gov/19846301

DMRA736	DI	DMRA736
DMRA736	DN	Saccharin
DMRA736	MI	TTHQPL7
DMRA736	MN	Carbonic anhydrase I (CA-I)
DMRA736	MT	DTT
DMRA736	MA	Inhibitor
DMRA736	RN	Mutation of Phe91 to Asn in human carbonic anhydrase I unexpectedly enhanced both catalytic activity and affinity for sulfonamide inhibitors. Bioorg Med Chem. 2010 Aug 1;18(15):5498-503.
DMRA736	RU	https://pubmed.ncbi.nlm.nih.gov/20624682

DMRA736	DI	DMRA736
DMRA736	DN	Saccharin
DMRA736	MI	TTANPDJ
DMRA736	MN	Carbonic anhydrase II (CA-II)
DMRA736	MT	DTT
DMRA736	MA	Inhibitor
DMRA736	RN	Mutation of Phe91 to Asn in human carbonic anhydrase I unexpectedly enhanced both catalytic activity and affinity for sulfonamide inhibitors. Bioorg Med Chem. 2010 Aug 1;18(15):5498-503.
DMRA736	RU	https://pubmed.ncbi.nlm.nih.gov/20624682

DMRA736	DI	DMRA736
DMRA736	DN	Saccharin
DMRA736	MI	TT2LVK8
DMRA736	MN	Carbonic anhydrase IX (CA-IX)
DMRA736	MT	DTT
DMRA736	MA	Inhibitor
DMRA736	RN	Carbonic anhydrase inhibitors: copper(II) complexes of polyamino-polycarboxylamido aromatic/heterocyclic sulfonamides are very potent inhibitors of... Bioorg Med Chem Lett. 2008 Jan 15;18(2):836-41.
DMRA736	RU	https://pubmed.ncbi.nlm.nih.gov/18042384

DMRA736	DI	DMRA736
DMRA736	DN	Saccharin
DMRA736	MI	TTSYM0R
DMRA736	MN	Carbonic anhydrase XII (CA-XII)
DMRA736	MT	DTT
DMRA736	MA	Inhibitor
DMRA736	RN	Carbonic anhydrase inhibitors: copper(II) complexes of polyamino-polycarboxylamido aromatic/heterocyclic sulfonamides are very potent inhibitors of... Bioorg Med Chem Lett. 2008 Jan 15;18(2):836-41.
DMRA736	RU	https://pubmed.ncbi.nlm.nih.gov/18042384

DM3TO27	DI	DM3TO27
DM3TO27	DN	saclofen
DM3TO27	MI	TTDCVZW
DM3TO27	MN	Gamma-aminobutyric acid B receptor (GABBR)
DM3TO27	MT	DTT
DM3TO27	MA	Antagonist
DM3TO27	RN	Expression cloning of GABA(B) receptors uncovers similarity to metabotropic glutamate receptors. Nature. 1997 Mar 20;386(6622):239-46.
DM3TO27	RU	https://pubmed.ncbi.nlm.nih.gov/9069281

DMZWGVP	DI	DMZWGVP
DMZWGVP	DN	Saframycin A
DMZWGVP	MI	TTUGSWA
DMZWGVP	MN	Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
DMZWGVP	MT	DTT
DMZWGVP	MA	Binder
DMZWGVP	RN	Identification of GAPDH as a protein target of the saframycin antiproliferative agents. Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):5862-6.
DMZWGVP	RU	https://pubmed.ncbi.nlm.nih.gov/15079082

DMHOG7W	DI	DMHOG7W
DMHOG7W	DN	SAG
DMHOG7W	MI	TTSJ9E7
DMHOG7W	MN	Short transient receptor potential channel 2 (TRPC2)
DMHOG7W	MT	DTT
DMHOG7W	MA	Activator
DMHOG7W	RN	A diacylglycerol-gated cation channel in vomeronasal neuron dendrites is impaired in TRPC2 mutant mice: mechanism of pheromone transduction. Neuron. 2003 Oct 30;40(3):551-61.
DMHOG7W	RU	https://pubmed.ncbi.nlm.nih.gov/14642279

DMHOG7W	DI	DMHOG7W
DMHOG7W	DN	SAG
DMHOG7W	MI	TTRBT3W
DMHOG7W	MN	Short transient receptor potential channel 6 (TRPC6)
DMHOG7W	MT	DTT
DMHOG7W	MA	Activator
DMHOG7W	RN	Direct activation of human TRPC6 and TRPC3 channels by diacylglycerol. Nature. 1999 Jan 21;397(6716):259-63.
DMHOG7W	RU	https://pubmed.ncbi.nlm.nih.gov/9930701

DMLU6J0	DI	DMLU6J0
DMLU6J0	DN	SAIT301
DMLU6J0	MI	TTKA5LP
DMLU6J0	MN	HGF/Met signaling pathway (HGF/Met pathway)
DMLU6J0	MT	DTT
DMLU6J0	RN	Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
DMLU6J0	RU	http://journalofnasopharyngealcarcinoma.org/JNPC/article/view/30/227

DMUAQYZ	DI	DMUAQYZ
DMUAQYZ	DN	sakuranetin
DMUAQYZ	MI	TTK25J1
DMUAQYZ	MN	Adenosine A1 receptor (ADORA1)
DMUAQYZ	MT	DTT
DMUAQYZ	MA	Antagonist
DMUAQYZ	RN	Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301.
DMUAQYZ	RU	https://pubmed.ncbi.nlm.nih.gov/8691424

DMUAQYZ	DI	DMUAQYZ
DMUAQYZ	DN	sakuranetin
DMUAQYZ	MI	TTNE7KG
DMUAQYZ	MN	Adenosine A2b receptor (ADORA2B)
DMUAQYZ	MT	DTT
DMUAQYZ	MA	Antagonist
DMUAQYZ	RN	Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301.
DMUAQYZ	RU	https://pubmed.ncbi.nlm.nih.gov/8691424

DMUAQYZ	DI	DMUAQYZ
DMUAQYZ	DN	sakuranetin
DMUAQYZ	MI	TTJFY5U
DMUAQYZ	MN	Adenosine A3 receptor (ADORA3)
DMUAQYZ	MT	DTT
DMUAQYZ	MA	Antagonist
DMUAQYZ	RN	Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301.
DMUAQYZ	RU	https://pubmed.ncbi.nlm.nih.gov/8691424

DMGLSPC	DI	DMGLSPC
DMGLSPC	DN	Salicylhydroxamic acid
DMGLSPC	MI	TT3PQ2Y
DMGLSPC	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DMGLSPC	MT	DTT
DMGLSPC	MA	Inhibitor
DMGLSPC	RN	Effects of atovaquone and other inhibitors on Pneumocystis carinii dihydroorotate dehydrogenase. Antimicrob Agents Chemother. 1995 Feb;39(2):325-8.
DMGLSPC	RU	https://pubmed.ncbi.nlm.nih.gov/7726490

DMUPCA6	DI	DMUPCA6
DMUPCA6	DN	s-allylglycine
DMUPCA6	MI	TT7UY6K
DMUPCA6	MN	Glutamate decarboxylase 2 (GAD2)
DMUPCA6	MT	DTT
DMUPCA6	MA	Inhibitor
DMUPCA6	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1273).
DMUPCA6	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1273

DMUPCA6	DI	DMUPCA6
DMUPCA6	DN	s-allylglycine
DMUPCA6	MI	TTKGEP3
DMUPCA6	MN	Glutamic acid decarboxylase 1 (GAD1)
DMUPCA6	MT	DTT
DMUPCA6	MA	Inhibitor
DMUPCA6	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1272).
DMUPCA6	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1272

DM8T1Y4	DI	DM8T1Y4
DM8T1Y4	DN	Salvinicin A
DM8T1Y4	MI	TTQW87Y
DM8T1Y4	MN	Opioid receptor kappa (OPRK1)
DM8T1Y4	MT	DTT
DM8T1Y4	MA	Inhibitor
DM8T1Y4	RN	Synthetic studies of neoclerodane diterpenes from Salvia divinorum: preparation and opioid receptor activity of salvinicin analogues. J Med Chem. 2007 Jul 26;50(15):3596-603.
DM8T1Y4	RU	https://pubmed.ncbi.nlm.nih.gov/17580847

DMB70T3	DI	DMB70T3
DMB70T3	DN	SALVINICIN B
DMB70T3	MI	TTQW87Y
DMB70T3	MN	Opioid receptor kappa (OPRK1)
DMB70T3	MT	DTT
DMB70T3	MA	Inhibitor
DMB70T3	RN	Synthetic studies of neoclerodane diterpenes from Salvia divinorum: preparation and opioid receptor activity of salvinicin analogues. J Med Chem. 2007 Jul 26;50(15):3596-603.
DMB70T3	RU	https://pubmed.ncbi.nlm.nih.gov/17580847

DMYH9Q5	DI	DMYH9Q5
DMYH9Q5	DN	Salvinorin A (ester)
DMYH9Q5	MI	TTQW87Y
DMYH9Q5	MN	Opioid receptor kappa (OPRK1)
DMYH9Q5	MT	DTT
DMYH9Q5	MA	Inhibitor
DMYH9Q5	RN	Synthesis and in vitro evaluation of salvinorin A analogues: effect of configuration at C(2) and substitution at C(18). Bioorg Med Chem Lett. 2006 Sep 1;16(17):4679-85.
DMYH9Q5	RU	https://pubmed.ncbi.nlm.nih.gov/16777411

DMBR7O0	DI	DMBR7O0
DMBR7O0	DN	SALVINORIN B
DMBR7O0	MI	TTQW87Y
DMBR7O0	MN	Opioid receptor kappa (OPRK1)
DMBR7O0	MT	DTT
DMBR7O0	MA	Inhibitor
DMBR7O0	RN	Herkinorin analogues with differential beta-arrestin-2 interactions. J Med Chem. 2008 Apr 24;51(8):2421-31.
DMBR7O0	RU	https://pubmed.ncbi.nlm.nih.gov/18380425

DM5ZE7F	DI	DM5ZE7F
DM5ZE7F	DN	Salvinorin B 1-ethoxyethyl ether
DM5ZE7F	MI	TTQW87Y
DM5ZE7F	MN	Opioid receptor kappa (OPRK1)
DM5ZE7F	MT	DTT
DM5ZE7F	MA	Inhibitor
DM5ZE7F	RN	Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers. Bioorg Med Chem. 2008 Feb 1;16(3):1279-86.
DM5ZE7F	RU	https://pubmed.ncbi.nlm.nih.gov/17981041

DM1DE3F	DI	DM1DE3F
DM1DE3F	DN	Salvinorin B 2,2,2-trifluoroethoxymethyl ether
DM1DE3F	MI	TTQW87Y
DM1DE3F	MN	Opioid receptor kappa (OPRK1)
DM1DE3F	MT	DTT
DM1DE3F	MA	Inhibitor
DM1DE3F	RN	Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers. Bioorg Med Chem. 2008 Feb 1;16(3):1279-86.
DM1DE3F	RU	https://pubmed.ncbi.nlm.nih.gov/17981041

DMBAXDU	DI	DMBAXDU
DMBAXDU	DN	Salvinorin B 2-fluoroethoxymethyl ether
DMBAXDU	MI	TTQW87Y
DMBAXDU	MN	Opioid receptor kappa (OPRK1)
DMBAXDU	MT	DTT
DMBAXDU	MA	Inhibitor
DMBAXDU	RN	Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers. Bioorg Med Chem. 2008 Feb 1;16(3):1279-86.
DMBAXDU	RU	https://pubmed.ncbi.nlm.nih.gov/17981041

DMD9A08	DI	DMD9A08
DMD9A08	DN	Salvinorin B 2-methoxy-2-propyl ether
DMD9A08	MI	TTQW87Y
DMD9A08	MN	Opioid receptor kappa (OPRK1)
DMD9A08	MT	DTT
DMD9A08	MA	Inhibitor
DMD9A08	RN	Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers. Bioorg Med Chem. 2008 Feb 1;16(3):1279-86.
DMD9A08	RU	https://pubmed.ncbi.nlm.nih.gov/17981041

DM8UATD	DI	DM8UATD
DM8UATD	DN	Salvinorin B 2-methoxyethoxymethyl ether
DM8UATD	MI	TTQW87Y
DM8UATD	MN	Opioid receptor kappa (OPRK1)
DM8UATD	MT	DTT
DM8UATD	MA	Inhibitor
DM8UATD	RN	Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers. Bioorg Med Chem. 2008 Feb 1;16(3):1279-86.
DM8UATD	RU	https://pubmed.ncbi.nlm.nih.gov/17981041

DMKXEQ6	DI	DMKXEQ6
DMKXEQ6	DN	Salvinorin B benzyloxymethyl ether
DMKXEQ6	MI	TTQW87Y
DMKXEQ6	MN	Opioid receptor kappa (OPRK1)
DMKXEQ6	MT	DTT
DMKXEQ6	MA	Inhibitor
DMKXEQ6	RN	Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers. Bioorg Med Chem. 2008 Feb 1;16(3):1279-86.
DMKXEQ6	RU	https://pubmed.ncbi.nlm.nih.gov/17981041

DM7Q12B	DI	DM7Q12B
DM7Q12B	DN	Salvinorin B butoxymethyl ether
DM7Q12B	MI	TTQW87Y
DM7Q12B	MN	Opioid receptor kappa (OPRK1)
DM7Q12B	MT	DTT
DM7Q12B	MA	Inhibitor
DM7Q12B	RN	Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers. Bioorg Med Chem. 2008 Feb 1;16(3):1279-86.
DM7Q12B	RU	https://pubmed.ncbi.nlm.nih.gov/17981041

DMP5WNL	DI	DMP5WNL
DMP5WNL	DN	Salvinorin B ethoxymethyl ether
DMP5WNL	MI	TTQW87Y
DMP5WNL	MN	Opioid receptor kappa (OPRK1)
DMP5WNL	MT	DTT
DMP5WNL	MA	Inhibitor
DMP5WNL	RN	Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers. Bioorg Med Chem. 2008 Feb 1;16(3):1279-86.
DMP5WNL	RU	https://pubmed.ncbi.nlm.nih.gov/17981041

DM01WOF	DI	DM01WOF
DM01WOF	DN	Salvinorin B fluoromethyl ether
DM01WOF	MI	TTQW87Y
DM01WOF	MN	Opioid receptor kappa (OPRK1)
DM01WOF	MT	DTT
DM01WOF	MA	Inhibitor
DM01WOF	RN	Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers. Bioorg Med Chem. 2008 Feb 1;16(3):1279-86.
DM01WOF	RU	https://pubmed.ncbi.nlm.nih.gov/17981041

DMSFXA3	DI	DMSFXA3
DMSFXA3	DN	Salvinorin B isopropoxymethyl ether
DMSFXA3	MI	TTQW87Y
DMSFXA3	MN	Opioid receptor kappa (OPRK1)
DMSFXA3	MT	DTT
DMSFXA3	MA	Inhibitor
DMSFXA3	RN	Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers. Bioorg Med Chem. 2008 Feb 1;16(3):1279-86.
DMSFXA3	RU	https://pubmed.ncbi.nlm.nih.gov/17981041

DMZ51IE	DI	DMZ51IE
DMZ51IE	DN	Salvinorin B methoxymethyl ether
DMZ51IE	MI	TTQW87Y
DMZ51IE	MN	Opioid receptor kappa (OPRK1)
DMZ51IE	MT	DTT
DMZ51IE	MA	Inhibitor
DMZ51IE	RN	Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers. Bioorg Med Chem. 2008 Feb 1;16(3):1279-86.
DMZ51IE	RU	https://pubmed.ncbi.nlm.nih.gov/17981041

DMKDMPL	DI	DMKDMPL
DMKDMPL	DN	Salvinorin B methylthiomethyl ether
DMKDMPL	MI	TTQW87Y
DMKDMPL	MN	Opioid receptor kappa (OPRK1)
DMKDMPL	MT	DTT
DMKDMPL	MA	Inhibitor
DMKDMPL	RN	Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers. Bioorg Med Chem. 2008 Feb 1;16(3):1279-86.
DMKDMPL	RU	https://pubmed.ncbi.nlm.nih.gov/17981041

DMKCUY6	DI	DMKCUY6
DMKCUY6	DN	Salvinorin B propoxymethyl ether
DMKCUY6	MI	TTQW87Y
DMKCUY6	MN	Opioid receptor kappa (OPRK1)
DMKCUY6	MT	DTT
DMKCUY6	MA	Inhibitor
DMKCUY6	RN	Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers. Bioorg Med Chem. 2008 Feb 1;16(3):1279-86.
DMKCUY6	RU	https://pubmed.ncbi.nlm.nih.gov/17981041

DM8H6AT	DI	DM8H6AT
DM8H6AT	DN	Salvinorin B tert-butoxymethyl ether
DM8H6AT	MI	TTQW87Y
DM8H6AT	MN	Opioid receptor kappa (OPRK1)
DM8H6AT	MT	DTT
DM8H6AT	MA	Inhibitor
DM8H6AT	RN	Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers. Bioorg Med Chem. 2008 Feb 1;16(3):1279-86.
DM8H6AT	RU	https://pubmed.ncbi.nlm.nih.gov/17981041

DM3UPAE	DI	DM3UPAE
DM3UPAE	DN	Salvinorin B tetrahydropyran-2-yl ether
DM3UPAE	MI	TTQW87Y
DM3UPAE	MN	Opioid receptor kappa (OPRK1)
DM3UPAE	MT	DTT
DM3UPAE	MA	Inhibitor
DM3UPAE	RN	Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers. Bioorg Med Chem. 2008 Feb 1;16(3):1279-86.
DM3UPAE	RU	https://pubmed.ncbi.nlm.nih.gov/17981041

DMTRMX8	DI	DMTRMX8
DMTRMX8	DN	Sanfetrinem cilexetil
DMTRMX8	MI	TTJP4SM
DMTRMX8	MN	Bacterial Penicillin binding protein (Bact PBP)
DMTRMX8	MT	DTT
DMTRMX8	MA	Modulator
DMTRMX8	RN	Entry of Sanfetrinem into Human Polymorphonuclear Granulocytes and Its Cell-Associated Activity against Intracellular, Penicillin-Resistant Streptococcus pneumoniae
DMTRMX8	RU	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC105677

DMSF5DW	DI	DMSF5DW
DMSF5DW	DN	Sanggenon C
DMSF5DW	MI	TTELIN2
DMSF5DW	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMSF5DW	MT	DTT
DMSF5DW	MA	Inhibitor
DMSF5DW	RN	Protein tyrosine phosphatase 1B inhibitors from Morus root bark. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1426-9.
DMSF5DW	RU	https://pubmed.ncbi.nlm.nih.gov/16356713

DMNHUOD	DI	DMNHUOD
DMNHUOD	DN	Sanggenon G
DMNHUOD	MI	TTELIN2
DMNHUOD	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMNHUOD	MT	DTT
DMNHUOD	MA	Inhibitor
DMNHUOD	RN	Protein tyrosine phosphatase 1B inhibitors from Morus root bark. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1426-9.
DMNHUOD	RU	https://pubmed.ncbi.nlm.nih.gov/16356713

DM9XV16	DI	DM9XV16
DM9XV16	DN	Sanguiin H-6
DM9XV16	MI	TTE14XG
DM9XV16	MN	Squalene monooxygenase (SQLE)
DM9XV16	MT	DTT
DM9XV16	MA	Inhibitor
DM9XV16	RN	Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4.
DM9XV16	RU	https://pubmed.ncbi.nlm.nih.gov/11520216

DM9CV4P	DI	DM9CV4P
DM9CV4P	DN	Sant7
DM9CV4P	MI	TT0E5SK
DM9CV4P	MN	Interleukin 6 receptor (IL6R)
DM9CV4P	MT	DTT
DM9CV4P	MA	Antagonist
DM9CV4P	RN	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
DM9CV4P	RU	https://pubmed.ncbi.nlm.nih.gov/19249983

DMFAM7P	DI	DMFAM7P
DMFAM7P	DN	santacruzamate A
DMFAM7P	MI	TTSHTOI
DMFAM7P	MN	Histone deacetylase 2 (HDAC2)
DMFAM7P	MT	DTT
DMFAM7P	MA	Inhibitor
DMFAM7P	RN	Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp. J Nat Prod. 2013 Nov 22;76(11):2026-33.
DMFAM7P	RU	https://pubmed.ncbi.nlm.nih.gov/24164245

DMFAM7P	DI	DMFAM7P
DMFAM7P	DN	santacruzamate A
DMFAM7P	MI	TTTQGH8
DMFAM7P	MN	Histone deacetylase 4 (HDAC4)
DMFAM7P	MT	DTT
DMFAM7P	MA	Inhibitor
DMFAM7P	RN	Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp. J Nat Prod. 2013 Nov 22;76(11):2026-33.
DMFAM7P	RU	https://pubmed.ncbi.nlm.nih.gov/24164245

DMFAM7P	DI	DMFAM7P
DMFAM7P	DN	santacruzamate A
DMFAM7P	MI	TT5ZKDI
DMFAM7P	MN	Histone deacetylase 6 (HDAC6)
DMFAM7P	MT	DTT
DMFAM7P	MA	Inhibitor
DMFAM7P	RN	Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp. J Nat Prod. 2013 Nov 22;76(11):2026-33.
DMFAM7P	RU	https://pubmed.ncbi.nlm.nih.gov/24164245

DMYZFNH	DI	DMYZFNH
DMYZFNH	DN	Sapanisertib
DMYZFNH	MI	TT7HQAF
DMYZFNH	MN	HUMAN mammalian target of rapamycin (mTOR)
DMYZFNH	MT	DTT
DMYZFNH	MA	Inhibitor
DMYZFNH	RN	Prevent COVID-19 Severity by Repurposing mTOR Inhibitors. 2 April 2020
DMYZFNH	RU	https://www.preprints.org/manuscript/202004.0060/v1

DM6GE21	DI	DM6GE21
DM6GE21	DN	Sapropterin
DM6GE21	MI	DER6XYF
DM6GE21	MN	Tryptophan 5-hydroxylase 2 (TPH2)
DM6GE21	MT	DME
DM6GE21	MA	Metabolism
DM6GE21	RN	Characterization of wild-type and mutant forms of human tryptophan hydroxylase 2. J Neurochem. 2007 Mar;100(6):1648-57.
DM6GE21	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17181551

DM2J0UN	DI	DM2J0UN
DM2J0UN	DN	SAR-106881
DM2J0UN	MI	TTRLW2X
DM2J0UN	MN	Fibroblast growth factor receptor 1 (FGFR1)
DM2J0UN	MT	DTT
DM2J0UN	MA	Agonist
DM2J0UN	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1808).
DM2J0UN	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1808

DMSYE4W	DI	DMSYE4W
DMSYE4W	DN	SAR-131675
DMSYE4W	MI	TTDCBX5
DMSYE4W	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DMSYE4W	MT	DTT
DMSYE4W	MA	Inhibitor
DMSYE4W	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1814).
DMSYE4W	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1814

DM0RDC4	DI	DM0RDC4
DM0RDC4	DN	Sarafotoxin 6C
DM0RDC4	MI	TT3ZTGU
DM0RDC4	MN	Endothelin B receptor (EDNRB)
DM0RDC4	MT	DTT
DM0RDC4	MA	Antagonist
DM0RDC4	RN	Human optic nerve head astrocytes as a target for endothelin-1. Invest Ophthalmol Vis Sci. 2002 Aug;43(8):2704-13.
DM0RDC4	RU	https://pubmed.ncbi.nlm.nih.gov/12147606

DMR6PJ5	DI	DMR6PJ5
DMR6PJ5	DN	sarafotoxin S6b
DMR6PJ5	MI	TTKRD0G
DMR6PJ5	MN	Endothelin A receptor (EDNRA)
DMR6PJ5	MT	DTT
DMR6PJ5	MA	Agonist
DMR6PJ5	RN	ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro. Br J Pharmacol. 1995 May;115(1):191-7.
DMR6PJ5	RU	https://pubmed.ncbi.nlm.nih.gov/7647976

DMCNOJV	DI	DMCNOJV
DMCNOJV	DN	Sar-Arg-Val-Tyr-Ile-His-Pro-Ala
DMCNOJV	MI	TTQVOEI
DMCNOJV	MN	Angiotensin II receptor type-2 (AGTR2)
DMCNOJV	MT	DTT
DMCNOJV	MA	Inhibitor
DMCNOJV	RN	Synthesis and structure-activity relationships of a novel series of non-peptide angiotensin II receptor binding inhibitors specific for the AT2 sub... J Med Chem. 1991 Nov;34(11):3248-60.
DMCNOJV	RU	https://pubmed.ncbi.nlm.nih.gov/1956044

DMS0FQC	DI	DMS0FQC
DMS0FQC	DN	Sar-Arg-Val-Tyr-Ile-His-Pro-Ile
DMS0FQC	MI	TTQVOEI
DMS0FQC	MN	Angiotensin II receptor type-2 (AGTR2)
DMS0FQC	MT	DTT
DMS0FQC	MA	Inhibitor
DMS0FQC	RN	Synthesis and structure-activity relationships of a novel series of non-peptide angiotensin II receptor binding inhibitors specific for the AT2 sub... J Med Chem. 1991 Nov;34(11):3248-60.
DMS0FQC	RU	https://pubmed.ncbi.nlm.nih.gov/1956044

DMD6SJT	DI	DMD6SJT
DMD6SJT	DN	Sar-Arg-Val-Tyr-Ile-His-Pro-Phe-OH
DMD6SJT	MI	TTQVOEI
DMD6SJT	MN	Angiotensin II receptor type-2 (AGTR2)
DMD6SJT	MT	DTT
DMD6SJT	MA	Inhibitor
DMD6SJT	RN	1-(carboxybenzyl)imidazole-5-acrylic acids: potent and selective angiotensin II receptor antagonists. J Med Chem. 1991 Apr;34(4):1514-7.
DMD6SJT	RU	https://pubmed.ncbi.nlm.nih.gov/2016730

DMZR4FX	DI	DMZR4FX
DMZR4FX	DN	Sarcodictyin A
DMZR4FX	MI	TTML2WA
DMZR4FX	MN	Tubulin (TUB)
DMZR4FX	MT	DTT
DMZR4FX	MA	Inducer
DMZR4FX	RN	The coral-derived natural products eleutherobin and sarcodictyins A and B: effects on the assembly of purified tubulin with and without microtubule-associated proteins and binding at the polymer taxoid site. Biochemistry. 1999 Apr 27;38(17):5490-8.
DMZR4FX	RU	https://pubmed.ncbi.nlm.nih.gov/10220336

DMIVGOR	DI	DMIVGOR
DMIVGOR	DN	Sarcosine
DMIVGOR	MI	DT2CFQ5
DMIVGOR	MN	Sodium- and chloride-dependent glycine transporter 1 (SLC6A9)
DMIVGOR	MT	DTP
DMIVGOR	MA	Substrate
DMIVGOR	RN	Glycine is taken up through GLYT1 and GLYT2 transporters into mouse spinal cord axon terminals and causes vesicular and carrier-mediated release of its proposed co-transmitter GABA. J Neurochem. 2001 Mar;76(6):1823-32.
DMIVGOR	RU	http://www.ncbi.nlm.nih.gov/pubmed/11259500

DMILBO9	DI	DMILBO9
DMILBO9	DN	SARMs
DMILBO9	MI	TTS64P2
DMILBO9	MN	Androgen receptor (AR)
DMILBO9	MT	DTT
DMILBO9	MA	Modulator
DMILBO9	RN	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
DMILBO9	RU	https://www.ncbi.nlm.nih.gov/pubmed/27899562

DMJQVAG	DI	DMJQVAG
DMJQVAG	DN	S-ATPO
DMJQVAG	MI	TT0MYE2
DMJQVAG	MN	Glutamate receptor ionotropic kainate 1 (GRIK1)
DMJQVAG	MT	DTT
DMJQVAG	MA	Inhibitor
DMJQVAG	RN	3-Substituted phenylalanines as selective AMPA- and kainate receptor ligands. Bioorg Med Chem. 2009 Sep 1;17(17):6390-401.
DMJQVAG	RU	https://pubmed.ncbi.nlm.nih.gov/19656686

DMF8O62	DI	DMF8O62
DMF8O62	DN	SAVX-1
DMF8O62	MI	TT2JWF6
DMF8O62	MN	Peroxisome proliferator-activated receptor delta (PPARD)
DMF8O62	MT	DTT
DMF8O62	MA	Modulator
DMF8O62	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 594).
DMF8O62	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=594

DMLX8RW	DI	DMLX8RW
DMLX8RW	DN	Saxitoxin
DMLX8RW	MI	TTRK8B9
DMLX8RW	MN	Sodium channel unspecific (NaC)
DMLX8RW	MT	DTT
DMLX8RW	MA	Blocker
DMLX8RW	RN	Effect of neurotoxins on the electrical activity and contraction of the heart muscle. C R Seances Soc Biol Fil. 1997;191(3):451-71.
DMLX8RW	RU	https://pubmed.ncbi.nlm.nih.gov/9295968

DM68JI5	DI	DM68JI5
DM68JI5	DN	Sazetidine-A
DM68JI5	MI	TTWNV8U
DM68JI5	MN	Nicotinic acid receptor (HCAR2)
DM68JI5	MT	DTT
DM68JI5	MA	Binder
DM68JI5	RN	Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia. ACS Med Chem Lett. 2011 Nov 24;3(1):63-8.
DM68JI5	RU	https://pubmed.ncbi.nlm.nih.gov/24900372

DMQAO5B	DI	DMQAO5B
DMQAO5B	DN	SB 203106
DMQAO5B	MI	TT85JO3
DMQAO5B	MN	5-HT receptor (5HTR)
DMQAO5B	MT	DTT
DMQAO5B	MA	Antagonist
DMQAO5B	RN	5-Hydroxytryptamine mediated contractions in isolated preparations of equine ileum and pelvic flexure: pharmacological characterization of a new 5-HT(4) agonist. J Vet Pharmacol Ther. 2002 Feb;25(1):49-58.
DMQAO5B	RU	https://pubmed.ncbi.nlm.nih.gov/11874527

DM43K85	DI	DM43K85
DM43K85	DN	SB 204070
DM43K85	MI	TT07C3Y
DM43K85	MN	5-HT 4 receptor (HTR4)
DM43K85	MT	DTT
DM43K85	MA	Antagonist
DM43K85	RN	[3H]RS 57639, a high affinity, selective 5-HT4 receptor partial agonist, specifically labels guinea-pig striatal and rat cloned (5-HT4S and 5-HT4L) receptors. Neuropharmacology. 1997 Apr-May;36(4-5):671-9.
DM43K85	RU	https://pubmed.ncbi.nlm.nih.gov/9225293

DM3LQF4	DI	DM3LQF4
DM3LQF4	DN	SB 204741
DM3LQF4	MI	TT0K1SC
DM3LQF4	MN	5-HT 2B receptor (HTR2B)
DM3LQF4	MT	DTT
DM3LQF4	MA	Antagonist
DM3LQF4	RN	Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
DM3LQF4	RU	https://pubmed.ncbi.nlm.nih.gov/15322733

DM3LQF4	DI	DM3LQF4
DM3LQF4	DN	SB 204741
DM3LQF4	MI	TTWJBZ5
DM3LQF4	MN	5-HT 2C receptor (HTR2C)
DM3LQF4	MT	DTT
DM3LQF4	MA	Antagonist
DM3LQF4	RN	Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
DM3LQF4	RU	https://pubmed.ncbi.nlm.nih.gov/15322733

DMCM4LT	DI	DMCM4LT
DMCM4LT	DN	SB 215505
DMCM4LT	MI	TTJQOD7
DMCM4LT	MN	5-HT 2A receptor (HTR2A)
DMCM4LT	MT	DTT
DMCM4LT	MA	Antagonist
DMCM4LT	RN	Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist. Br J Pharmacol. 1999 Feb;126(3):572-4.
DMCM4LT	RU	https://pubmed.ncbi.nlm.nih.gov/10188965

DMCM4LT	DI	DMCM4LT
DMCM4LT	DN	SB 215505
DMCM4LT	MI	TT0K1SC
DMCM4LT	MN	5-HT 2B receptor (HTR2B)
DMCM4LT	MT	DTT
DMCM4LT	MA	Antagonist
DMCM4LT	RN	Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist. Br J Pharmacol. 1999 Feb;126(3):572-4.
DMCM4LT	RU	https://pubmed.ncbi.nlm.nih.gov/10188965

DMCM4LT	DI	DMCM4LT
DMCM4LT	DN	SB 215505
DMCM4LT	MI	TTWJBZ5
DMCM4LT	MN	5-HT 2C receptor (HTR2C)
DMCM4LT	MT	DTT
DMCM4LT	MA	Antagonist
DMCM4LT	RN	Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist. Br J Pharmacol. 1999 Feb;126(3):572-4.
DMCM4LT	RU	https://pubmed.ncbi.nlm.nih.gov/10188965

DMB3R4Z	DI	DMB3R4Z
DMB3R4Z	DN	SB 216641
DMB3R4Z	MI	TTSQIFT
DMB3R4Z	MN	5-HT 1A receptor (HTR1A)
DMB3R4Z	MT	DTT
DMB3R4Z	MA	Agonist
DMB3R4Z	RN	SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20.
DMB3R4Z	RU	https://pubmed.ncbi.nlm.nih.gov/9303567

DMB3R4Z	DI	DMB3R4Z
DMB3R4Z	DN	SB 216641
DMB3R4Z	MI	TTK8CXU
DMB3R4Z	MN	5-HT 1B receptor (HTR1B)
DMB3R4Z	MT	DTT
DMB3R4Z	MA	Agonist
DMB3R4Z	RN	SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20.
DMB3R4Z	RU	https://pubmed.ncbi.nlm.nih.gov/9303567

DMB3R4Z	DI	DMB3R4Z
DMB3R4Z	DN	SB 216641
DMB3R4Z	MI	TT6MSOK
DMB3R4Z	MN	5-HT 1D receptor (HTR1D)
DMB3R4Z	MT	DTT
DMB3R4Z	MA	Agonist
DMB3R4Z	RN	SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20.
DMB3R4Z	RU	https://pubmed.ncbi.nlm.nih.gov/9303567

DMB3R4Z	DI	DMB3R4Z
DMB3R4Z	DN	SB 216641
DMB3R4Z	MI	TTJQOD7
DMB3R4Z	MN	5-HT 2A receptor (HTR2A)
DMB3R4Z	MT	DTT
DMB3R4Z	MA	Agonist
DMB3R4Z	RN	SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20.
DMB3R4Z	RU	https://pubmed.ncbi.nlm.nih.gov/9303567

DMB3R4Z	DI	DMB3R4Z
DMB3R4Z	DN	SB 216641
DMB3R4Z	MI	TT0K1SC
DMB3R4Z	MN	5-HT 2B receptor (HTR2B)
DMB3R4Z	MT	DTT
DMB3R4Z	MA	Agonist
DMB3R4Z	RN	SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20.
DMB3R4Z	RU	https://pubmed.ncbi.nlm.nih.gov/9303567

DMB3R4Z	DI	DMB3R4Z
DMB3R4Z	DN	SB 216641
DMB3R4Z	MI	TTWJBZ5
DMB3R4Z	MN	5-HT 2C receptor (HTR2C)
DMB3R4Z	MT	DTT
DMB3R4Z	MA	Agonist
DMB3R4Z	RN	SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20.
DMB3R4Z	RU	https://pubmed.ncbi.nlm.nih.gov/9303567

DMN1G5S	DI	DMN1G5S
DMN1G5S	DN	SB 218078
DMN1G5S	MI	TTTU902
DMN1G5S	MN	Checkpoint kinase-1 (CHK1)
DMN1G5S	MT	DTT
DMN1G5S	MA	Inhibitor
DMN1G5S	RN	An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage. Cancer Res. 2000 Feb 1;60(3):566-72.
DMN1G5S	RU	https://pubmed.ncbi.nlm.nih.gov/10676638

DM8DVY2	DI	DM8DVY2
DM8DVY2	DN	SB 221284
DM8DVY2	MI	TTJQOD7
DM8DVY2	MN	5-HT 2A receptor (HTR2A)
DM8DVY2	MT	DTT
DM8DVY2	MA	Antagonist
DM8DVY2	RN	Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
DM8DVY2	RU	https://pubmed.ncbi.nlm.nih.gov/15322733

DM8DVY2	DI	DM8DVY2
DM8DVY2	DN	SB 221284
DM8DVY2	MI	TT0K1SC
DM8DVY2	MN	5-HT 2B receptor (HTR2B)
DM8DVY2	MT	DTT
DM8DVY2	MA	Antagonist
DM8DVY2	RN	Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
DM8DVY2	RU	https://pubmed.ncbi.nlm.nih.gov/15322733

DM8DVY2	DI	DM8DVY2
DM8DVY2	DN	SB 221284
DM8DVY2	MI	TTWJBZ5
DM8DVY2	MN	5-HT 2C receptor (HTR2C)
DM8DVY2	MT	DTT
DM8DVY2	MA	Antagonist
DM8DVY2	RN	Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
DM8DVY2	RU	https://pubmed.ncbi.nlm.nih.gov/15322733

DMIS8JQ	DI	DMIS8JQ
DMIS8JQ	DN	SB 224289
DMIS8JQ	MI	TTK8CXU
DMIS8JQ	MN	5-HT 1B receptor (HTR1B)
DMIS8JQ	MT	DTT
DMIS8JQ	MA	Antagonist
DMIS8JQ	RN	5-hydroxytryptamine receptors mediating contraction in human small muscular pulmonary arteries: importance of the 5-HT1B receptor. Br J Pharmacol. 1999 Oct;128(3):730-4.
DMIS8JQ	RU	https://pubmed.ncbi.nlm.nih.gov/10516655

DM7S63O	DI	DM7S63O
DM7S63O	DN	SB 227122
DM7S63O	MI	TT27RFC
DM7S63O	MN	Opioid receptor delta (OPRD1)
DM7S63O	MT	DTT
DM7S63O	MA	Agonist
DM7S63O	RN	The antitussive activity of delta-opioid receptor stimulation in guinea pigs. J Pharmacol Exp Ther. 2000 Feb;292(2):803-9.
DM7S63O	RU	https://pubmed.ncbi.nlm.nih.gov/10640321

DMKA8R4	DI	DMKA8R4
DMKA8R4	DN	SB 228357
DMKA8R4	MI	TTJQOD7
DMKA8R4	MN	5-HT 2A receptor (HTR2A)
DMKA8R4	MT	DTT
DMKA8R4	MA	Antagonist
DMKA8R4	RN	Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent. J Med Chem. 2000 Mar 23;43(6):1123-34.
DMKA8R4	RU	https://pubmed.ncbi.nlm.nih.gov/10737744

DMKA8R4	DI	DMKA8R4
DMKA8R4	DN	SB 228357
DMKA8R4	MI	TT0K1SC
DMKA8R4	MN	5-HT 2B receptor (HTR2B)
DMKA8R4	MT	DTT
DMKA8R4	MA	Antagonist
DMKA8R4	RN	Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent. J Med Chem. 2000 Mar 23;43(6):1123-34.
DMKA8R4	RU	https://pubmed.ncbi.nlm.nih.gov/10737744

DMKA8R4	DI	DMKA8R4
DMKA8R4	DN	SB 228357
DMKA8R4	MI	TTWJBZ5
DMKA8R4	MN	5-HT 2C receptor (HTR2C)
DMKA8R4	MT	DTT
DMKA8R4	MA	Antagonist
DMKA8R4	RN	Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent. J Med Chem. 2000 Mar 23;43(6):1123-34.
DMKA8R4	RU	https://pubmed.ncbi.nlm.nih.gov/10737744

DM201Q7	DI	DM201Q7
DM201Q7	DN	SB 239063
DM201Q7	MI	TTVKILB
DM201Q7	MN	Prostaglandin G/H synthase 2 (COX-2)
DM201Q7	MT	DTT
DM201Q7	MA	Inhibitor
DM201Q7	RN	SB-239063, a potent and selective inhibitor of p38 map kinase: preclinical pharmacokinetics and species-specific reversible isomerization. Pharm Res. 2001 Sep;18(9):1336-44.
DM201Q7	RU	https://pubmed.ncbi.nlm.nih.gov/11683250

DMISBDC	DI	DMISBDC
DMISBDC	DN	SB 242084
DMISBDC	MI	TTJQOD7
DMISBDC	MN	5-HT 2A receptor (HTR2A)
DMISBDC	MT	DTT
DMISBDC	MA	Antagonist
DMISBDC	RN	SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology. 1997 Apr-May;36(4-5):609-20.
DMISBDC	RU	https://pubmed.ncbi.nlm.nih.gov/9225286

DMISBDC	DI	DMISBDC
DMISBDC	DN	SB 242084
DMISBDC	MI	TT0K1SC
DMISBDC	MN	5-HT 2B receptor (HTR2B)
DMISBDC	MT	DTT
DMISBDC	MA	Antagonist
DMISBDC	RN	SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology. 1997 Apr-May;36(4-5):609-20.
DMISBDC	RU	https://pubmed.ncbi.nlm.nih.gov/9225286

DMISBDC	DI	DMISBDC
DMISBDC	DN	SB 242084
DMISBDC	MI	TTWJBZ5
DMISBDC	MN	5-HT 2C receptor (HTR2C)
DMISBDC	MT	DTT
DMISBDC	MA	Antagonist
DMISBDC	RN	SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology. 1997 Apr-May;36(4-5):609-20.
DMISBDC	RU	https://pubmed.ncbi.nlm.nih.gov/9225286

DMAFWRT	DI	DMAFWRT
DMAFWRT	DN	SB 243213
DMAFWRT	MI	TTWJBZ5
DMAFWRT	MN	5-HT 2C receptor (HTR2C)
DMAFWRT	MT	DTT
DMAFWRT	MA	Agonist
DMAFWRT	RN	SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety. Neuropharmacology. 2001 Aug;41(2):186-99.
DMAFWRT	RU	https://pubmed.ncbi.nlm.nih.gov/11489455

DM2QJKZ	DI	DM2QJKZ
DM2QJKZ	DN	SB 258585
DM2QJKZ	MI	TTJS8PY
DM2QJKZ	MN	5-HT 6 receptor (HTR6)
DM2QJKZ	MT	DTT
DM2QJKZ	MA	Antagonist
DM2QJKZ	RN	5-HT6 receptor binding sites in schizophrenia and following antipsychotic drug administration: autoradiographic studies with [125I]SB-258585. Synapse. 2002 Sep 1;45(3):191-9.
DM2QJKZ	RU	https://pubmed.ncbi.nlm.nih.gov/12112397

DMFHUGC	DI	DMFHUGC
DMFHUGC	DN	SB 269970-A
DMFHUGC	MI	TTO9X1H
DMFHUGC	MN	5-HT 7 receptor (HTR7)
DMFHUGC	MT	DTT
DMFHUGC	MA	Antagonist
DMFHUGC	RN	5-HT7 receptors. Curr Drug Targets CNS Neurol Disord. 2004 Feb;3(1):81-90.
DMFHUGC	RU	https://pubmed.ncbi.nlm.nih.gov/14965246

DMOLNQX	DI	DMOLNQX
DMOLNQX	DN	SB 272183
DMOLNQX	MI	TTSQIFT
DMOLNQX	MN	5-HT 1A receptor (HTR1A)
DMOLNQX	MT	DTT
DMOLNQX	MA	Antagonist
DMOLNQX	RN	SB-272183, a selective 5-HT(1A), 5-HT(1B) and 5-HT(1D) receptor antagonist in native tissue. Br J Pharmacol. 2001 Jul;133(6):797-806.
DMOLNQX	RU	https://pubmed.ncbi.nlm.nih.gov/11454652

DMOLNQX	DI	DMOLNQX
DMOLNQX	DN	SB 272183
DMOLNQX	MI	TTK8CXU
DMOLNQX	MN	5-HT 1B receptor (HTR1B)
DMOLNQX	MT	DTT
DMOLNQX	MA	Antagonist
DMOLNQX	RN	SB-272183, a selective 5-HT(1A), 5-HT(1B) and 5-HT(1D) receptor antagonist in native tissue. Br J Pharmacol. 2001 Jul;133(6):797-806.
DMOLNQX	RU	https://pubmed.ncbi.nlm.nih.gov/11454652

DMOLNQX	DI	DMOLNQX
DMOLNQX	DN	SB 272183
DMOLNQX	MI	TT6MSOK
DMOLNQX	MN	5-HT 1D receptor (HTR1D)
DMOLNQX	MT	DTT
DMOLNQX	MA	Antagonist
DMOLNQX	RN	SB-272183, a selective 5-HT(1A), 5-HT(1B) and 5-HT(1D) receptor antagonist in native tissue. Br J Pharmacol. 2001 Jul;133(6):797-806.
DMOLNQX	RU	https://pubmed.ncbi.nlm.nih.gov/11454652

DMVO8P5	DI	DMVO8P5
DMVO8P5	DN	SB 272844
DMVO8P5	MI	TT30C9G
DMVO8P5	MN	C-X-C chemokine receptor type 2 (CXCR2)
DMVO8P5	MT	DTT
DMVO8P5	MA	Antagonist
DMVO8P5	RN	The selective CXCR2 antagonist SB272844 blocks interleukin-8 and growth-related oncogene-alpha-mediated inhibition of spontaneous neutrophil apoptosis. Pulm Pharmacol Ther. 2002;15(2):103-10.
DMVO8P5	RU	https://pubmed.ncbi.nlm.nih.gov/12090783

DM21Z6H	DI	DM21Z6H
DM21Z6H	DN	SB 649915
DM21Z6H	MI	TTSQIFT
DM21Z6H	MN	5-HT 1A receptor (HTR1A)
DM21Z6H	MT	DTT
DM21Z6H	MA	Antagonist
DM21Z6H	RN	Discovery of the first potent, selective 5-hydroxytryptamine1D receptor antagonist. J Med Chem. 2005 May 19;48(10):3478-80.
DM21Z6H	RU	https://pubmed.ncbi.nlm.nih.gov/15887956

DM21Z6H	DI	DM21Z6H
DM21Z6H	DN	SB 649915
DM21Z6H	MI	TTK8CXU
DM21Z6H	MN	5-HT 1B receptor (HTR1B)
DM21Z6H	MT	DTT
DM21Z6H	MA	Antagonist
DM21Z6H	RN	Discovery of the first potent, selective 5-hydroxytryptamine1D receptor antagonist. J Med Chem. 2005 May 19;48(10):3478-80.
DM21Z6H	RU	https://pubmed.ncbi.nlm.nih.gov/15887956

DM21Z6H	DI	DM21Z6H
DM21Z6H	DN	SB 649915
DM21Z6H	MI	TT6MSOK
DM21Z6H	MN	5-HT 1D receptor (HTR1D)
DM21Z6H	MT	DTT
DM21Z6H	MA	Antagonist
DM21Z6H	RN	Discovery of the first potent, selective 5-hydroxytryptamine1D receptor antagonist. J Med Chem. 2005 May 19;48(10):3478-80.
DM21Z6H	RU	https://pubmed.ncbi.nlm.nih.gov/15887956

DM82GH9	DI	DM82GH9
DM82GH9	DN	SB 699551
DM82GH9	MI	TTRUFDT
DM82GH9	MN	5-HT 5A receptor (HTR5A)
DM82GH9	MT	DTT
DM82GH9	MA	Antagonist
DM82GH9	RN	Discovery of a potent and selective 5-ht5A receptor antagonist by high-throughput chemistry. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4014-8.
DM82GH9	RU	https://pubmed.ncbi.nlm.nih.gov/16002289

DMGHRY0	DI	DMGHRY0
DMGHRY0	DN	SB 714786
DMGHRY0	MI	TTSQIFT
DMGHRY0	MN	5-HT 1A receptor (HTR1A)
DMGHRY0	MT	DTT
DMGHRY0	MA	Antagonist
DMGHRY0	RN	Discovery of the first potent, selective 5-hydroxytryptamine1D receptor antagonist. J Med Chem. 2005 May 19;48(10):3478-80.
DMGHRY0	RU	https://pubmed.ncbi.nlm.nih.gov/15887956

DMGHRY0	DI	DMGHRY0
DMGHRY0	DN	SB 714786
DMGHRY0	MI	TTK8CXU
DMGHRY0	MN	5-HT 1B receptor (HTR1B)
DMGHRY0	MT	DTT
DMGHRY0	MA	Antagonist
DMGHRY0	RN	Discovery of the first potent, selective 5-hydroxytryptamine1D receptor antagonist. J Med Chem. 2005 May 19;48(10):3478-80.
DMGHRY0	RU	https://pubmed.ncbi.nlm.nih.gov/15887956

DMGHRY0	DI	DMGHRY0
DMGHRY0	DN	SB 714786
DMGHRY0	MI	TT6MSOK
DMGHRY0	MN	5-HT 1D receptor (HTR1D)
DMGHRY0	MT	DTT
DMGHRY0	MA	Antagonist
DMGHRY0	RN	Discovery of the first potent, selective 5-hydroxytryptamine1D receptor antagonist. J Med Chem. 2005 May 19;48(10):3478-80.
DMGHRY0	RU	https://pubmed.ncbi.nlm.nih.gov/15887956

DMOZX0D	DI	DMOZX0D
DMOZX0D	DN	SB-0304
DMOZX0D	MI	TT27RFC
DMOZX0D	MN	Opioid receptor delta (OPRD1)
DMOZX0D	MT	DTT
DMOZX0D	MA	Inhibitor
DMOZX0D	RN	Blood-brain barrier penetration by two dermorphin tetrapeptide analogues: role of lipophilicity vs structural flexibility. J Med Chem. 2008 Apr 24;51(8):2571-4.
DMOZX0D	RU	https://pubmed.ncbi.nlm.nih.gov/18370374

DMOZX0D	DI	DMOZX0D
DMOZX0D	DN	SB-0304
DMOZX0D	MI	TTKWM86
DMOZX0D	MN	Opioid receptor mu (MOP)
DMOZX0D	MT	DTT
DMOZX0D	MA	Inhibitor
DMOZX0D	RN	Blood-brain barrier penetration by two dermorphin tetrapeptide analogues: role of lipophilicity vs structural flexibility. J Med Chem. 2008 Apr 24;51(8):2571-4.
DMOZX0D	RU	https://pubmed.ncbi.nlm.nih.gov/18370374

DM9O0AR	DI	DM9O0AR
DM9O0AR	DN	SB-13
DM9O0AR	MI	TTE4KHA
DM9O0AR	MN	Amyloid beta A4 protein (APP)
DM9O0AR	MT	DTT
DM9O0AR	MA	Inhibitor
DM9O0AR	RN	Synthesis of biphenyltrienes as probes for beta-amyloid plaques. J Med Chem. 2006 May 4;49(9):2841-4.
DM9O0AR	RU	https://pubmed.ncbi.nlm.nih.gov/16640346

DMKLWSG	DI	DMKLWSG
DMKLWSG	DN	SB-201076
DMKLWSG	MI	TT0Z6Y2
DMKLWSG	MN	ATP-citrate synthase (ACLY)
DMKLWSG	MT	DTT
DMKLWSG	MA	Inhibitor
DMKLWSG	RN	The biology and chemistry of hyperlipidemia. Bioorg Med Chem. 2007 Jul 15;15(14):4674-99.
DMKLWSG	RU	https://pubmed.ncbi.nlm.nih.gov/17521912

DM09UIS	DI	DM09UIS
DM09UIS	DN	SB-202235
DM09UIS	MI	TT2J34L
DM09UIS	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM09UIS	MT	DTT
DM09UIS	MA	Modulator
DM09UIS	RN	Pharmacological characterization of SB 202235, a potent and selective 5-lipoxygenase inhibitor: effects in models of allergic asthma. J Pharmacol Exp Ther. 1995 Jun;273(3):1147-55.
DM09UIS	RU	https://www.ncbi.nlm.nih.gov/pubmed/7791085

DM3AWMF	DI	DM3AWMF
DM3AWMF	DN	SB-203347
DM3AWMF	MI	TT9V5JH
DM3AWMF	MN	Phospholipase A2 (PLA2G1B)
DM3AWMF	MT	DTT
DM3AWMF	MA	Modulator
DM3AWMF	RN	SB 203347, an inhibitor of 14 kDa phospholipase A2, alters human neutrophil arachidonic acid release and metabolism and prolongs survival in murine... J Pharmacol Exp Ther. 1995 Sep;274(3):1254-62.
DM3AWMF	RU	https://www.ncbi.nlm.nih.gov/pubmed/7562496

DM704TL	DI	DM704TL
DM704TL	DN	SB-207043
DM704TL	MI	TTJA1ZO
DM704TL	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DM704TL	MT	DTT
DM704TL	MA	Inhibitor
DM704TL	RN	Preparation and Properties of a fibrinogen receptor antagonist containing the Arg-Gly-Asp sequence and nitroxide radicals, Bioorg. Med. Chem. Lett. 3(6):1179-1184 (1993).
DM704TL	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00803108

DMVQKMC	DI	DMVQKMC
DMVQKMC	DN	SB-207710
DMVQKMC	MI	TT07C3Y
DMVQKMC	MN	5-HT 4 receptor (HTR4)
DMVQKMC	MT	DTT
DMVQKMC	MA	Inhibitor
DMVQKMC	RN	Synthesis, structure-affinity relationships, and radiolabeling of selective high-affinity 5-HT4 receptor ligands as prospective imaging probes for ... J Med Chem. 2010 Oct 14;53(19):7035-47.
DMVQKMC	RU	https://pubmed.ncbi.nlm.nih.gov/20812727

DM5EWQN	DI	DM5EWQN
DM5EWQN	DN	SB-210313
DM5EWQN	MI	TTVG215
DM5EWQN	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DM5EWQN	MT	DTT
DM5EWQN	MA	Inhibitor
DM5EWQN	RN	Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes. Bioorg Med Chem Lett. 1998 Nov 17;8(22):3111-6.
DM5EWQN	RU	https://pubmed.ncbi.nlm.nih.gov/9873686

DMUCHNP	DI	DMUCHNP
DMUCHNP	DN	SB-213068
DMUCHNP	MI	TTT2SVW
DMUCHNP	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DMUCHNP	MT	DTT
DMUCHNP	MA	Inhibitor
DMUCHNP	RN	Non thiazolidinedione antihyperglycaemic agents. 2: alpha-Carbon substituted beta-phenylpropanoic acids1, Bioorg. Med. Chem. Lett. 6(17):2127-2130 (1996).
DMUCHNP	RU	http://www.sciencedirect.com/science/article/pii/0960894X96003824

DMH1CFX	DI	DMH1CFX
DMH1CFX	DN	SB-214111
DMH1CFX	MI	TTJS8PY
DMH1CFX	MN	5-HT 6 receptor (HTR6)
DMH1CFX	MT	DTT
DMH1CFX	MA	Modulator
DMH1CFX	RN	The distribution of 5-HT(6) receptors in rat brain: an autoradiographic binding study using the radiolabelled 5-HT(6) receptor antagonist [(125)I]S... Brain Res. 2002 Apr 26;934(1):49-57.
DMH1CFX	RU	https://www.ncbi.nlm.nih.gov/pubmed/11937069

DMIYFQ5	DI	DMIYFQ5
DMIYFQ5	DN	SB216763
DMIYFQ5	MI	TTRZQE3
DMIYFQ5	MN	Glycogen synthase kinase-3 alpha (GSK-3A)
DMIYFQ5	MT	DTT
DMIYFQ5	MA	Inhibitor
DMIYFQ5	RN	Intracellular protein phosphorylation in eosinophils and the functional relevance in cytokine production. Int Arch Allergy Immunol. 2009;149 Suppl 1:45-50.
DMIYFQ5	RU	https://pubmed.ncbi.nlm.nih.gov/19494504

DMOH9TA	DI	DMOH9TA
DMOH9TA	DN	SB-216995
DMOH9TA	MI	TTQBR95
DMOH9TA	MN	Stress-activated protein kinase 2a (p38 alpha)
DMOH9TA	MT	DTT
DMOH9TA	MA	Inhibitor
DMOH9TA	RN	In silico search for multi-target anti-inflammatories in Chinese herbs and formulas. Bioorg Med Chem. 2010 Mar 15;18(6):2204-2218.
DMOH9TA	RU	https://pubmed.ncbi.nlm.nih.gov/20188577

DM7LARD	DI	DM7LARD
DM7LARD	DN	SB218078
DM7LARD	MI	TTTU902
DM7LARD	MN	Checkpoint kinase-1 (CHK1)
DM7LARD	MT	DTT
DM7LARD	MA	Inhibitor
DM7LARD	RN	Chk1 inhibitor synergizes quinacrine mediated apoptosis in breast cancer cells by compromising the base excision repair cascade. Biochem Pharmacol. 2016 Apr 1;105:23-33.
DM7LARD	RU	https://pubmed.ncbi.nlm.nih.gov/26850987

DMJKE4M	DI	DMJKE4M
DMJKE4M	DN	SB-218655
DMJKE4M	MI	TTQBR95
DMJKE4M	MN	Stress-activated protein kinase 2a (p38 alpha)
DMJKE4M	MT	DTT
DMJKE4M	MA	Inhibitor
DMJKE4M	RN	In silico search for multi-target anti-inflammatories in Chinese herbs and formulas. Bioorg Med Chem. 2010 Mar 15;18(6):2204-2218.
DMJKE4M	RU	https://pubmed.ncbi.nlm.nih.gov/20188577

DMMWCLV	DI	DMMWCLV
DMMWCLV	DN	SB-221420-A
DMMWCLV	MI	TTN9VTF
DMMWCLV	MN	Voltage-gated sodium channel alpha Nav1.9 (SCN11A)
DMMWCLV	MT	DTT
DMMWCLV	MA	Blocker
DMMWCLV	RN	Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95.
DMMWCLV	RU	https://pubmed.ncbi.nlm.nih.gov/19442208

DMO1WI8	DI	DMO1WI8
DMO1WI8	DN	SB-227931
DMO1WI8	MI	TTQBR95
DMO1WI8	MN	Stress-activated protein kinase 2a (p38 alpha)
DMO1WI8	MT	DTT
DMO1WI8	MA	Inhibitor
DMO1WI8	RN	The neuroprotective action of JNK3 inhibitors based on the 6,7-dihydro-5H-pyrrolo[1,2-a]imidazole scaffold. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4666-70.
DMO1WI8	RU	https://pubmed.ncbi.nlm.nih.gov/16153829

DMIBS95	DI	DMIBS95
DMIBS95	DN	SB-2280
DMIBS95	MI	TTCJG29
DMIBS95	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMIBS95	MT	DTT
DMIBS95	MA	Inhibitor
DMIBS95	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
DMIBS95	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109

DMYQDPM	DI	DMYQDPM
DMYQDPM	DN	SB236057
DMYQDPM	MI	TTK8CXU
DMYQDPM	MN	5-HT 1B receptor (HTR1B)
DMYQDPM	MT	DTT
DMYQDPM	MA	Antagonist
DMYQDPM	RN	SB-236057, a selective 5-HT1B receptor inverse agonist, blocks the 5-HT human terminal autoreceptor. Eur J Pharmacol. 1999 Jun 30;375(1-3):359-65.
DMYQDPM	RU	https://pubmed.ncbi.nlm.nih.gov/10443589

DMLZDK6	DI	DMLZDK6
DMLZDK6	DN	SB251023
DMLZDK6	MI	TTMXGCW
DMLZDK6	MN	Adrenergic receptor beta-3 (ADRB3)
DMLZDK6	MT	DTT
DMLZDK6	MA	Agonist
DMLZDK6	RN	Mouse beta 3a- and beta 3b-adrenoceptors expressed in Chinese hamster ovary cells display identical pharmacology but utilize distinct signalling pathways. Br J Pharmacol. 2002 Apr;135(8):1903-14.
DMLZDK6	RU	https://pubmed.ncbi.nlm.nih.gov/11959793

DMO01AG	DI	DMO01AG
DMO01AG	DN	SB-258719
DMO01AG	MI	TTO9X1H
DMO01AG	MN	5-HT 7 receptor (HTR7)
DMO01AG	MT	DTT
DMO01AG	MA	Inhibitor
DMO01AG	RN	Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). J Med Chem. 2003 Jul 3;46(14):2795-812.
DMO01AG	RU	https://pubmed.ncbi.nlm.nih.gov/12825922

DMO01AG	DI	DMO01AG
DMO01AG	DN	SB-258719
DMO01AG	MI	TTEX248
DMO01AG	MN	Dopamine D2 receptor (D2R)
DMO01AG	MT	DTT
DMO01AG	MA	Inhibitor
DMO01AG	RN	Atropisomeric derivatives of 2',6'-disubstituted (R)-11-phenylaporphine: selective serotonin 5-HT(7) receptor antagonists. J Med Chem. 2001 Apr 26;44(9):1337-40.
DMO01AG	RU	https://pubmed.ncbi.nlm.nih.gov/11311055

DM0HK6L	DI	DM0HK6L
DM0HK6L	DN	SB-258741
DM0HK6L	MI	TTO9X1H
DM0HK6L	MN	5-HT 7 receptor (HTR7)
DM0HK6L	MT	DTT
DM0HK6L	MA	Inhibitor
DM0HK6L	RN	Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). J Med Chem. 2003 Jul 3;46(14):2795-812.
DM0HK6L	RU	https://pubmed.ncbi.nlm.nih.gov/12825922

DM8UKH7	DI	DM8UKH7
DM8UKH7	DN	SB-265123
DM8UKH7	MI	TTT1R2L
DM8UKH7	MN	Integrin alpha-V (ITGAV)
DM8UKH7	MT	DTT
DM8UKH7	MA	Inhibitor
DM8UKH7	RN	1,2,3,4-Tetrahydroquinoline-containing alphaVbeta3 integrin antagonists with enhanced oral bioavailability. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5937-41.
DM8UKH7	RU	https://pubmed.ncbi.nlm.nih.gov/15501072

DM8UKH7	DI	DM8UKH7
DM8UKH7	DN	SB-265123
DM8UKH7	MI	TTBVIQC
DM8UKH7	MN	Integrin beta-1 (ITGB1)
DM8UKH7	MT	DTT
DM8UKH7	MA	Inhibitor
DM8UKH7	RN	Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model. Bioorg Med Chem Lett. 1999 Jul 5;9(13):1807-12.
DM8UKH7	RU	https://pubmed.ncbi.nlm.nih.gov/10406646

DM8UKH7	DI	DM8UKH7
DM8UKH7	DN	SB-265123
DM8UKH7	MI	TTJA1ZO
DM8UKH7	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DM8UKH7	MT	DTT
DM8UKH7	MA	Inhibitor
DM8UKH7	RN	1,2,3,4-Tetrahydroquinoline-containing alphaVbeta3 integrin antagonists with enhanced oral bioavailability. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5937-41.
DM8UKH7	RU	https://pubmed.ncbi.nlm.nih.gov/15501072

DMEGNJK	DI	DMEGNJK
DMEGNJK	DN	SB269652
DMEGNJK	MI	TTEX248
DMEGNJK	MN	Dopamine D2 receptor (D2R)
DMEGNJK	MT	DTT
DMEGNJK	MA	Modulator (allosteric modulator)
DMEGNJK	RN	A new mechanism of allostery in a G protein-coupled receptor dimer. Nat Chem Biol. 2014 Sep;10(9):745-52.
DMEGNJK	RU	https://pubmed.ncbi.nlm.nih.gov/25108820

DMEGNJK	DI	DMEGNJK
DMEGNJK	DN	SB269652
DMEGNJK	MI	TT4C8EA
DMEGNJK	MN	Dopamine D3 receptor (D3R)
DMEGNJK	MT	DTT
DMEGNJK	MA	Modulator (allosteric modulator)
DMEGNJK	RN	Investigation of the binding and functional properties of extended length D3 dopamine receptor-selective antagonists. Eur Neuropsychopharmacol. 2015 Sep;25(9):1448-61.
DMEGNJK	RU	https://pubmed.ncbi.nlm.nih.gov/25583363

DM5VJAF	DI	DM5VJAF
DM5VJAF	DN	SB-271046
DM5VJAF	MI	TTSQIFT
DM5VJAF	MN	5-HT 1A receptor (HTR1A)
DM5VJAF	MT	DTT
DM5VJAF	MA	Inhibitor
DM5VJAF	RN	Discovery of 3-aryl-3-methyl-1H-quinoline-2,4-diones as a new class of selective 5-HT6 receptor antagonists. Bioorg Med Chem Lett. 2008 Jan 15;18(2):738-43.
DM5VJAF	RU	https://pubmed.ncbi.nlm.nih.gov/18053713

DM5VJAF	DI	DM5VJAF
DM5VJAF	DN	SB-271046
DM5VJAF	MI	TTJQOD7
DM5VJAF	MN	5-HT 2A receptor (HTR2A)
DM5VJAF	MT	DTT
DM5VJAF	MA	Inhibitor
DM5VJAF	RN	Discovery of 3-aryl-3-methyl-1H-quinoline-2,4-diones as a new class of selective 5-HT6 receptor antagonists. Bioorg Med Chem Lett. 2008 Jan 15;18(2):738-43.
DM5VJAF	RU	https://pubmed.ncbi.nlm.nih.gov/18053713

DM5VJAF	DI	DM5VJAF
DM5VJAF	DN	SB-271046
DM5VJAF	MI	TTWJBZ5
DM5VJAF	MN	5-HT 2C receptor (HTR2C)
DM5VJAF	MT	DTT
DM5VJAF	MA	Inhibitor
DM5VJAF	RN	Discovery of 3-aryl-3-methyl-1H-quinoline-2,4-diones as a new class of selective 5-HT6 receptor antagonists. Bioorg Med Chem Lett. 2008 Jan 15;18(2):738-43.
DM5VJAF	RU	https://pubmed.ncbi.nlm.nih.gov/18053713

DM5VJAF	DI	DM5VJAF
DM5VJAF	DN	SB-271046
DM5VJAF	MI	TTJS8PY
DM5VJAF	MN	5-HT 6 receptor (HTR6)
DM5VJAF	MT	DTT
DM5VJAF	MA	Inhibitor
DM5VJAF	RN	Synthesis and SAR of tolylamine 5-HT6 antagonists. Bioorg Med Chem Lett. 2009 May 1;19(9):2409-12.
DM5VJAF	RU	https://pubmed.ncbi.nlm.nih.gov/19346128

DM5VJAF	DI	DM5VJAF
DM5VJAF	DN	SB-271046
DM5VJAF	MI	TTO9X1H
DM5VJAF	MN	5-HT 7 receptor (HTR7)
DM5VJAF	MT	DTT
DM5VJAF	MA	Inhibitor
DM5VJAF	RN	Discovery of 3-aryl-3-methyl-1H-quinoline-2,4-diones as a new class of selective 5-HT6 receptor antagonists. Bioorg Med Chem Lett. 2008 Jan 15;18(2):738-43.
DM5VJAF	RU	https://pubmed.ncbi.nlm.nih.gov/18053713

DM5VJAF	DI	DM5VJAF
DM5VJAF	DN	SB-271046
DM5VJAF	MI	TTZFYLI
DM5VJAF	MN	Dopamine D1 receptor (D1R)
DM5VJAF	MT	DTT
DM5VJAF	MA	Inhibitor
DM5VJAF	RN	Discovery of 3-aryl-3-methyl-1H-quinoline-2,4-diones as a new class of selective 5-HT6 receptor antagonists. Bioorg Med Chem Lett. 2008 Jan 15;18(2):738-43.
DM5VJAF	RU	https://pubmed.ncbi.nlm.nih.gov/18053713

DM5VJAF	DI	DM5VJAF
DM5VJAF	DN	SB-271046
DM5VJAF	MI	TTEX248
DM5VJAF	MN	Dopamine D2 receptor (D2R)
DM5VJAF	MT	DTT
DM5VJAF	MA	Inhibitor
DM5VJAF	RN	Discovery of 3-aryl-3-methyl-1H-quinoline-2,4-diones as a new class of selective 5-HT6 receptor antagonists. Bioorg Med Chem Lett. 2008 Jan 15;18(2):738-43.
DM5VJAF	RU	https://pubmed.ncbi.nlm.nih.gov/18053713

DM5VJAF	DI	DM5VJAF
DM5VJAF	DN	SB-271046
DM5VJAF	MI	TT4C8EA
DM5VJAF	MN	Dopamine D3 receptor (D3R)
DM5VJAF	MT	DTT
DM5VJAF	MA	Inhibitor
DM5VJAF	RN	Discovery of 3-aryl-3-methyl-1H-quinoline-2,4-diones as a new class of selective 5-HT6 receptor antagonists. Bioorg Med Chem Lett. 2008 Jan 15;18(2):738-43.
DM5VJAF	RU	https://pubmed.ncbi.nlm.nih.gov/18053713

DM5VJAF	DI	DM5VJAF
DM5VJAF	DN	SB-271046
DM5VJAF	MI	TTE0A2F
DM5VJAF	MN	Dopamine D4 receptor (D4R)
DM5VJAF	MT	DTT
DM5VJAF	MA	Inhibitor
DM5VJAF	RN	Discovery of 3-aryl-3-methyl-1H-quinoline-2,4-diones as a new class of selective 5-HT6 receptor antagonists. Bioorg Med Chem Lett. 2008 Jan 15;18(2):738-43.
DM5VJAF	RU	https://pubmed.ncbi.nlm.nih.gov/18053713

DM28K0E	DI	DM28K0E
DM28K0E	DN	SB290157
DM28K0E	MI	TTI6B3F
DM28K0E	MN	C3a anaphylatoxin chemotactic receptor (C3AR1)
DM28K0E	MT	DTT
DM28K0E	MA	Antagonist
DM28K0E	RN	Identification of a selective nonpeptide antagonist of the anaphylatoxin C3a receptor that demonstrates antiinflammatory activity in animal models. J Immunol. 2001 May 15;166(10):6341-8.
DM28K0E	RU	https://pubmed.ncbi.nlm.nih.gov/11342658

DMU2J3K	DI	DMU2J3K
DMU2J3K	DN	SB-298
DMU2J3K	MI	TTK25J1
DMU2J3K	MN	Adenosine A1 receptor (ADORA1)
DMU2J3K	MT	DTT
DMU2J3K	MA	Inhibitor
DMU2J3K	RN	1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with... J Med Chem. 2009 Jul 9;52(13):3994-4006.
DMU2J3K	RU	https://pubmed.ncbi.nlm.nih.gov/19569717

DMU2J3K	DI	DMU2J3K
DMU2J3K	DN	SB-298
DMU2J3K	MI	TTM2AOE
DMU2J3K	MN	Adenosine A2a receptor (ADORA2A)
DMU2J3K	MT	DTT
DMU2J3K	MA	Inhibitor
DMU2J3K	RN	1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with... J Med Chem. 2009 Jul 9;52(13):3994-4006.
DMU2J3K	RU	https://pubmed.ncbi.nlm.nih.gov/19569717

DMU2J3K	DI	DMU2J3K
DMU2J3K	DN	SB-298
DMU2J3K	MI	TTNE7KG
DMU2J3K	MN	Adenosine A2b receptor (ADORA2B)
DMU2J3K	MT	DTT
DMU2J3K	MA	Inhibitor
DMU2J3K	RN	1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with... J Med Chem. 2009 Jul 9;52(13):3994-4006.
DMU2J3K	RU	https://pubmed.ncbi.nlm.nih.gov/19569717

DMU2J3K	DI	DMU2J3K
DMU2J3K	DN	SB-298
DMU2J3K	MI	TTJFY5U
DMU2J3K	MN	Adenosine A3 receptor (ADORA3)
DMU2J3K	MT	DTT
DMU2J3K	MA	Inhibitor
DMU2J3K	RN	1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with... J Med Chem. 2009 Jul 9;52(13):3994-4006.
DMU2J3K	RU	https://pubmed.ncbi.nlm.nih.gov/19569717

DMT1KFL	DI	DMT1KFL
DMT1KFL	DN	SB-328872
DMT1KFL	MI	TTW5UDX
DMT1KFL	MN	Urotensin II receptor (UTS2R)
DMT1KFL	MT	DTT
DMT1KFL	MA	Inhibitor
DMT1KFL	RN	Urotensin-II receptor antagonists: synthesis and SAR of N-cyclic azaalkyl benzamides. Bioorg Med Chem Lett. 2008 Jul 15;18(14):3950-4.
DMT1KFL	RU	https://pubmed.ncbi.nlm.nih.gov/18573659

DMDZKWJ	DI	DMDZKWJ
DMDZKWJ	DN	SB-334867
DMDZKWJ	MI	TT60Q8D
DMDZKWJ	MN	Orexin receptor type 1 (HCRTR1)
DMDZKWJ	MT	DTT
DMDZKWJ	MA	Antagonist
DMDZKWJ	RN	Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison ... Mol Pharmacol. 2009 Sep;76(3):618-31.
DMDZKWJ	RU	https://pubmed.ncbi.nlm.nih.gov/19542319

DMDZKWJ	DI	DMDZKWJ
DMDZKWJ	DN	SB-334867
DMDZKWJ	MI	TT9N02I
DMDZKWJ	MN	Orexin receptor type 2 (HCRTR2)
DMDZKWJ	MT	DTT
DMDZKWJ	MA	Antagonist
DMDZKWJ	RN	Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison ... Mol Pharmacol. 2009 Sep;76(3):618-31.
DMDZKWJ	RU	https://pubmed.ncbi.nlm.nih.gov/19542319

DMFTO8R	DI	DMFTO8R
DMFTO8R	DN	SB-357134
DMFTO8R	MI	TTJS8PY
DMFTO8R	MN	5-HT 6 receptor (HTR6)
DMFTO8R	MT	DTT
DMFTO8R	MA	Inhibitor
DMFTO8R	RN	Discovery of 3-aryl-3-methyl-1H-quinoline-2,4-diones as a new class of selective 5-HT6 receptor antagonists. Bioorg Med Chem Lett. 2008 Jan 15;18(2):738-43.
DMFTO8R	RU	https://pubmed.ncbi.nlm.nih.gov/18053713

DM3BV5S	DI	DM3BV5S
DM3BV5S	DN	SB-381320
DM3BV5S	MI	TTDNFMT
DM3BV5S	MN	Platelet-activating factor acetylhydrolase (PLA2G7)
DM3BV5S	MT	DTT
DM3BV5S	MA	Inhibitor
DM3BV5S	RN	(E)-Phenyl- and -heteroaryl-substituted O-benzoyl-(or acyl)oximes as lipoprotein-associated phospholipase A2 inhibitors. Bioorg Med Chem Lett. 2005 Mar 1;15(5):1525-7.
DM3BV5S	RU	https://pubmed.ncbi.nlm.nih.gov/15713421

DMFMK89	DI	DMFMK89
DMFMK89	DN	SB399885
DMFMK89	MI	TTJS8PY
DMFMK89	MN	5-HT 6 receptor (HTR6)
DMFMK89	MT	DTT
DMFMK89	MA	Antagonist
DMFMK89	RN	SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition ... Eur J Pharmacol. 2006 Dec 28;553(1-3):109-19.
DMFMK89	RU	https://pubmed.ncbi.nlm.nih.gov/17069795

DMB8XZP	DI	DMB8XZP
DMB8XZP	DN	SB-408124
DMB8XZP	MI	TT60Q8D
DMB8XZP	MN	Orexin receptor type 1 (HCRTR1)
DMB8XZP	MT	DTT
DMB8XZP	MA	Antagonist
DMB8XZP	RN	Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison ... Mol Pharmacol. 2009 Sep;76(3):618-31.
DMB8XZP	RU	https://pubmed.ncbi.nlm.nih.gov/19542319

DMB8XZP	DI	DMB8XZP
DMB8XZP	DN	SB-408124
DMB8XZP	MI	TT9N02I
DMB8XZP	MN	Orexin receptor type 2 (HCRTR2)
DMB8XZP	MT	DTT
DMB8XZP	MA	Antagonist
DMB8XZP	RN	Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison ... Mol Pharmacol. 2009 Sep;76(3):618-31.
DMB8XZP	RU	https://pubmed.ncbi.nlm.nih.gov/19542319

DMQLHE8	DI	DMQLHE8
DMQLHE8	DN	SB-410220
DMQLHE8	MI	TT60Q8D
DMQLHE8	MN	Orexin receptor type 1 (HCRTR1)
DMQLHE8	MT	DTT
DMQLHE8	MA	Antagonist
DMQLHE8	RN	Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor. Br J Pharmacol. 2004 Jan;141(2):340-6.
DMQLHE8	RU	https://pubmed.ncbi.nlm.nih.gov/14691055

DMMAL3I	DI	DMMAL3I
DMMAL3I	DN	SB-415286
DMMAL3I	MI	TTRSMW9
DMMAL3I	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMMAL3I	MT	DTT
DMMAL3I	MA	Inhibitor
DMMAL3I	RN	Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models. Eur J Med Chem. 2009 Jun;44(6):2361-71.
DMMAL3I	RU	https://pubmed.ncbi.nlm.nih.gov/18929433

DMMAL3I	DI	DMMAL3I
DMMAL3I	DN	SB-415286
DMMAL3I	MI	TTG0U4H
DMMAL3I	MN	Ribosomal protein S6 kinase beta-1 (S6K1)
DMMAL3I	MT	DTT
DMMAL3I	MA	Inhibitor
DMMAL3I	RN	3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg Med Chem Lett. 2001 Mar 12;11(5):635-9.
DMMAL3I	RU	https://pubmed.ncbi.nlm.nih.gov/11266159

DMJW72O	DI	DMJW72O
DMJW72O	DN	SB-416
DMJW72O	MI	TTOZHQC
DMJW72O	MN	P2Y purinoceptor 2 (P2RY2)
DMJW72O	MT	DTT
DMJW72O	MA	Inhibitor
DMJW72O	RN	Combinatorial synthesis of anilinoanthraquinone derivatives and evaluation as non-nucleotide-derived P2Y2 receptor antagonists. Bioorg Med Chem Lett. 2008 Jan 1;18(1):223-7.
DMJW72O	RU	https://pubmed.ncbi.nlm.nih.gov/18006312

DMUFV4O	DI	DMUFV4O
DMUFV4O	DN	SB452533
DMUFV4O	MI	TTMI6F5
DMUFV4O	MN	Transient receptor potential cation channel V1 (TRPV1)
DMUFV4O	MT	DTT
DMUFV4O	MA	Blocker (channel blocker)
DMUFV4O	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 507).
DMUFV4O	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=507

DM4G09S	DI	DM4G09S
DM4G09S	DN	SB-505124
DM4G09S	MI	TTP4520
DM4G09S	MN	TGF-beta receptor type I (TGFBR1)
DM4G09S	MT	DTT
DM4G09S	MA	Inhibitor
DM4G09S	RN	Synthesis and biological evaluation of 2-pyridyl-substituted pyrazoles and imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors, Bioorg. Med. Chem. Lett. 20(14):4228-4232 (2010).
DM4G09S	RU	http://www.sciencedirect.com/science/article/pii/S0960894X10006736

DM0PETL	DI	DM0PETL
DM0PETL	DN	SB-525334
DM0PETL	MI	TTP4520
DM0PETL	MN	TGF-beta receptor type I (TGFBR1)
DM0PETL	MT	DTT
DM0PETL	MA	Inhibitor
DM0PETL	RN	Synthesis and biological evaluation of 2-pyridyl-substituted pyrazoles and imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors, Bioorg. Med. Chem. Lett. 20(14):4228-4232 (2010).
DM0PETL	RU	http://www.sciencedirect.com/science/article/pii/S0960894X10006736

DM0OLYF	DI	DM0OLYF
DM0OLYF	DN	SB-559457
DM0OLYF	MI	TTIHYA4
DM0OLYF	MN	Thrombopoietin receptor (MPL)
DM0OLYF	MT	DTT
DM0OLYF	MA	Agonist
DM0OLYF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1722).
DM0OLYF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1722

DMBIF42	DI	DMBIF42
DMBIF42	DN	SB-568849
DMBIF42	MI	TTX4RTB
DMBIF42	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMBIF42	MT	DTT
DMBIF42	MA	Antagonist
DMBIF42	RN	Discovery of potent and stable conformationally constrained analogues of the MCH R1 antagonist SB-568849. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4872-8.
DMBIF42	RU	https://pubmed.ncbi.nlm.nih.gov/16839763

DMASQV4	DI	DMASQV4
DMASQV4	DN	SB-611812
DMASQV4	MI	TTW5UDX
DMASQV4	MN	Urotensin II receptor (UTS2R)
DMASQV4	MT	DTT
DMASQV4	MA	Antagonist
DMASQV4	RN	A role for urotensin II in restenosis following balloon angioplasty: use of a selective UT receptor blocker. J Mol Cell Cardiol. 2005 Nov;39(5):785-91.
DMASQV4	RU	https://pubmed.ncbi.nlm.nih.gov/16171813

DM2SZ3F	DI	DM2SZ3F
DM2SZ3F	DN	SB-612111
DM2SZ3F	MI	TTNT7K8
DM2SZ3F	MN	Nociceptin receptor (OPRL1)
DM2SZ3F	MT	DTT
DM2SZ3F	MA	Antagonist
DM2SZ3F	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 320).
DM2SZ3F	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=320

DMVOIL5	DI	DMVOIL5
DMVOIL5	DN	SB-656104
DMVOIL5	MI	TTSQIFT
DMVOIL5	MN	5-HT 1A receptor (HTR1A)
DMVOIL5	MT	DTT
DMVOIL5	MA	Inhibitor
DMVOIL5	RN	Novel 3-aminochromans as potential pharmacological tools for the serotonin 5-HT(7) receptor. Bioorg Med Chem Lett. 2005 Feb 1;15(3):747-50.
DMVOIL5	RU	https://pubmed.ncbi.nlm.nih.gov/15664850

DMVOIL5	DI	DMVOIL5
DMVOIL5	DN	SB-656104
DMVOIL5	MI	TTO9X1H
DMVOIL5	MN	5-HT 7 receptor (HTR7)
DMVOIL5	MT	DTT
DMVOIL5	MA	Inhibitor
DMVOIL5	RN	Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). J Med Chem. 2003 Jul 3;46(14):2795-812.
DMVOIL5	RU	https://pubmed.ncbi.nlm.nih.gov/12825922

DMLW8BI	DI	DMLW8BI
DMLW8BI	DN	SB-699551-A
DMLW8BI	MI	TTRUFDT
DMLW8BI	MN	5-HT 5A receptor (HTR5A)
DMLW8BI	MT	DTT
DMLW8BI	MA	Antagonist
DMLW8BI	RN	5-ht5A receptors as a therapeutic target. Pharmacol Ther. 2006 Sep;111(3):707-14.
DMLW8BI	RU	https://pubmed.ncbi.nlm.nih.gov/16516972

DM9ZYNJ	DI	DM9ZYNJ
DM9ZYNJ	DN	SB-706375
DM9ZYNJ	MI	TTW5UDX
DM9ZYNJ	MN	Urotensin II receptor (UTS2R)
DM9ZYNJ	MT	DTT
DM9ZYNJ	MA	Inhibitor
DM9ZYNJ	RN	Urotensin-II receptor modulators as potential drugs. J Med Chem. 2010 Apr 8;53(7):2695-708.
DM9ZYNJ	RU	https://pubmed.ncbi.nlm.nih.gov/20043680

DMO2EXW	DI	DMO2EXW
DMO2EXW	DN	SB-731489
DMO2EXW	MI	TTBGTCW
DMO2EXW	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DMO2EXW	MT	DTT
DMO2EXW	MA	Inhibitor
DMO2EXW	RN	Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52.
DMO2EXW	RU	https://pubmed.ncbi.nlm.nih.gov/17725339

DM20Q5O	DI	DM20Q5O
DM20Q5O	DN	SB-747651A
DM20Q5O	MI	TTO6SGY
DM20Q5O	MN	AKT3 messenger RNA (AKT3 mRNA)
DM20Q5O	MT	DTT
DM20Q5O	MA	Inhibitor
DM20Q5O	RN	Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-o... J Med Chem. 2008 Sep 25;51(18):5663-79.
DM20Q5O	RU	https://pubmed.ncbi.nlm.nih.gov/18800763

DM20Q5O	DI	DM20Q5O
DM20Q5O	DN	SB-747651A
DM20Q5O	MI	TTWTSCV
DM20Q5O	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DM20Q5O	MT	DTT
DM20Q5O	MA	Inhibitor
DM20Q5O	RN	Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-o... J Med Chem. 2008 Sep 25;51(18):5663-79.
DM20Q5O	RU	https://pubmed.ncbi.nlm.nih.gov/18800763

DM20Q5O	DI	DM20Q5O
DM20Q5O	DN	SB-747651A
DM20Q5O	MI	TTZN7RP
DM20Q5O	MN	Rho-associated protein kinase 1 (ROCK1)
DM20Q5O	MT	DTT
DM20Q5O	MA	Inhibitor
DM20Q5O	RN	Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-o... J Med Chem. 2008 Sep 25;51(18):5663-79.
DM20Q5O	RU	https://pubmed.ncbi.nlm.nih.gov/18800763

DM20Q5O	DI	DM20Q5O
DM20Q5O	DN	SB-747651A
DM20Q5O	MI	TTG0U4H
DM20Q5O	MN	Ribosomal protein S6 kinase beta-1 (S6K1)
DM20Q5O	MT	DTT
DM20Q5O	MA	Inhibitor
DM20Q5O	RN	(1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: further optimisation as highly potent and selective MSK-1-inhibitors. Bioorg Med Chem Lett. 2005 Jul 15;15(14):3407-11.
DM20Q5O	RU	https://pubmed.ncbi.nlm.nih.gov/15955699

DMYL56F	DI	DMYL56F
DMYL56F	DN	SB-782443
DMYL56F	MI	TTMI6F5
DMYL56F	MN	Transient receptor potential cation channel V1 (TRPV1)
DMYL56F	MT	DTT
DMYL56F	MA	Inhibitor
DMYL56F	RN	Design and synthesis of 6-phenylnicotinamide derivatives as antagonists of TRPV1. Bioorg Med Chem Lett. 2008 Oct 15;18(20):5609-13.
DMYL56F	RU	https://pubmed.ncbi.nlm.nih.gov/18809327

DMU8KGB	DI	DMU8KGB
DMU8KGB	DN	SBB007833
DMU8KGB	MI	TT6PKBN
DMU8KGB	MN	Proto-oncogene c-Src (SRC)
DMU8KGB	MT	DTT
DMU8KGB	MA	Inhibitor
DMU8KGB	RN	Synthesis and pharmacological evaluation of novel beta-nitrostyrene derivatives as tyrosine kinase inhibitors with potent antiplatelet activity. Biochem Pharmacol. 2007 Aug 15;74(4):601-11.
DMU8KGB	RU	https://pubmed.ncbi.nlm.nih.gov/17601492

DMU8KGB	DI	DMU8KGB
DMU8KGB	DN	SBB007833
DMU8KGB	MI	TTOU65C
DMU8KGB	MN	Tyrosine-protein kinase SYK (SYK)
DMU8KGB	MT	DTT
DMU8KGB	MA	Inhibitor
DMU8KGB	RN	Synthesis and pharmacological evaluation of novel beta-nitrostyrene derivatives as tyrosine kinase inhibitors with potent antiplatelet activity. Biochem Pharmacol. 2007 Aug 15;74(4):601-11.
DMU8KGB	RU	https://pubmed.ncbi.nlm.nih.gov/17601492

DMCRQ29	DI	DMCRQ29
DMCRQ29	DN	S-benzo[d]oxazol-2-yl O-butyl carbonothioate
DMCRQ29	MI	TT6804T
DMCRQ29	MN	MIF messenger RNA (MIF mRNA)
DMCRQ29	MT	DTT
DMCRQ29	MA	Inhibitor
DMCRQ29	RN	An integrative in silico methodology for the identification of modulators of macrophage migration inhibitory factor (MIF) tautomerase activity. Bioorg Med Chem. 2010 Jul 15;18(14):5425-40. 
DMCRQ29	RU	https://pubmed.ncbi.nlm.nih.gov/20639113

DMDUC2X	DI	DMDUC2X
DMDUC2X	DN	S-benzyl phenylmethanesulfinothioate
DMDUC2X	MI	TT2SUAQ
DMDUC2X	MN	Cysteine protease (CYP)
DMDUC2X	MT	DTT
DMDUC2X	MA	Inhibitor
DMDUC2X	RN	Allicin and derivates are cysteine protease inhibitors with antiparasitic activity. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5541-3.
DMDUC2X	RU	https://pubmed.ncbi.nlm.nih.gov/20692829

DM2RLXF	DI	DM2RLXF
DM2RLXF	DN	S-Benzyl-brassinin
DM2RLXF	MI	TTZJYKH
DM2RLXF	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DM2RLXF	MT	DTT
DM2RLXF	MA	Inhibitor
DM2RLXF	RN	Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2006 Jan 26;49(2):684-92.
DM2RLXF	RU	https://pubmed.ncbi.nlm.nih.gov/16420054

DMIQU8D	DI	DMIQU8D
DMIQU8D	DN	S-Benzyl-Glutathione
DMIQU8D	MI	TTV9A7R
DMIQU8D	MN	Lactoylglutathione lyase (GLO1)
DMIQU8D	MT	DTT
DMIQU8D	MA	Inhibitor
DMIQU8D	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMIQU8D	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMDBLGQ	DI	DMDBLGQ
DMDBLGQ	DN	SBTI
DMDBLGQ	MI	TT5T3P6
DMDBLGQ	MN	Tissue kallikrein (KLK1)
DMDBLGQ	MT	DTT
DMDBLGQ	MA	Inhibitor
DMDBLGQ	RN	Expression and characterization of human tissue kallikrein variants. Protein Expr Purif. 1998 Apr;12(3):361-70.
DMDBLGQ	RU	https://pubmed.ncbi.nlm.nih.gov/9535704

DMD2WEQ	DI	DMD2WEQ
DMD2WEQ	DN	SC-0030
DMD2WEQ	MI	TTMI6F5
DMD2WEQ	MN	Transient receptor potential cation channel V1 (TRPV1)
DMD2WEQ	MT	DTT
DMD2WEQ	MA	Inhibitor
DMD2WEQ	RN	Silicon switch approach in TRPV1 antagonist MK-056 and its analogues. Bioorg Med Chem. 2010 Jan 1;18(1):111-6.
DMD2WEQ	RU	https://pubmed.ncbi.nlm.nih.gov/19931463

DMD2WEQ	DI	DMD2WEQ
DMD2WEQ	DN	SC-0030
DMD2WEQ	MI	TTKP2SU
DMD2WEQ	MN	Transient receptor potential cation channel V4 (TRPV4)
DMD2WEQ	MT	DTT
DMD2WEQ	MA	Inhibitor
DMD2WEQ	RN	Novel non-vanilloid VR1 antagonist of high analgesic effects and its structural requirement for VR1 antagonistic effects. Bioorg Med Chem Lett. 2003 Dec 15;13(24):4389-93.
DMD2WEQ	RU	https://pubmed.ncbi.nlm.nih.gov/14643332

DMU2C9W	DI	DMU2C9W
DMU2C9W	DN	SC-19220
DMU2C9W	MI	TTG1QMU
DMU2C9W	MN	Prostaglandin E2 receptor EP1 (PTGER1)
DMU2C9W	MT	DTT
DMU2C9W	MA	Antagonist
DMU2C9W	RN	Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41.
DMU2C9W	RU	https://pubmed.ncbi.nlm.nih.gov/9537820

DMCWZ84	DI	DMCWZ84
DMCWZ84	DN	SC-41661A
DMCWZ84	MI	TT2J34L
DMCWZ84	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMCWZ84	MT	DTT
DMCWZ84	MA	Modulator
DMCWZ84	RN	Induction of apoptosis in blood cells from a patient with acute myelogenous leukemia by SC41661A, a selective inhibitor of 5-lipoxygenase. Prostaglandins Leukot Essent Fatty Acids. 1993 Apr;48(4):323-6.
DMCWZ84	RU	https://www.ncbi.nlm.nih.gov/pubmed/8497493

DMVZ9Q0	DI	DMVZ9Q0
DMVZ9Q0	DN	Sc-43076
DMVZ9Q0	MI	TTSJIRP
DMVZ9Q0	MN	Connexin 32 messenger RNA (GJB1 mRNA)
DMVZ9Q0	MT	DTT
DMVZ9Q0	RN	Connexin Antibodies. Report from santa cruz biotechnology, inc. Santa cruz biotechnology. 2009.
DMVZ9Q0	RU	http://www.scbt.com/table-connexin.html

DMYDS5Z	DI	DMYDS5Z
DMYDS5Z	DN	Sc-43077
DMYDS5Z	MI	TTSJIRP
DMYDS5Z	MN	Connexin 32 messenger RNA (GJB1 mRNA)
DMYDS5Z	MT	DTT
DMYDS5Z	RN	Connexin Antibodies. Report from santa cruz biotechnology, inc. Santa cruz biotechnology. 2009.
DMYDS5Z	RU	http://www.scbt.com/table-connexin.html

DM6AS0P	DI	DM6AS0P
DM6AS0P	DN	SC46275
DM6AS0P	MI	TTPNGDE
DM6AS0P	MN	Prostaglandin E2 receptor EP3 (PTGER3)
DM6AS0P	MT	DTT
DM6AS0P	MA	Agonist
DM6AS0P	RN	Investigation of the pronounced synergism between prostaglandin E2 and other constrictor agents on rat femoral artery. Prostaglandins Leukot Essent Fatty Acids. 2006 Jun;74(6):401-15.
DM6AS0P	RU	https://pubmed.ncbi.nlm.nih.gov/16737803

DM2DU80	DI	DM2DU80
DM2DU80	DN	SC-5003
DM2DU80	MI	TTH9VL3
DM2DU80	MN	Plasmodium Plasmepsin 1 (Malaria PLA1)
DM2DU80	MT	DTT
DM2DU80	MA	Inhibitor
DM2DU80	RN	Protease inhibitors: current status and future prospects. J Med Chem. 2000 Feb 10;43(3):305-41.
DM2DU80	RU	https://pubmed.ncbi.nlm.nih.gov/10669559

DMU2WIS	DI	DMU2WIS
DMU2WIS	DN	SC-50073
DMU2WIS	MI	TTN53ZF
DMU2WIS	MN	Leukotriene B4 receptor 1 (LTB4R)
DMU2WIS	MT	DTT
DMU2WIS	MA	Inhibitor
DMU2WIS	RN	Synthesis and pharmacological activity of SC-53228, a leukotriene B4 receptor antagonist with high intrinsic potency and selectivity, Bioorg. Med. Chem. Lett. 4(6):811-816 (1994).
DMU2WIS	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01808532

DMI2KE7	DI	DMI2KE7
DMI2KE7	DN	SC-50135
DMI2KE7	MI	TTN53ZF
DMI2KE7	MN	Leukotriene B4 receptor 1 (LTB4R)
DMI2KE7	MT	DTT
DMI2KE7	MA	Inhibitor
DMI2KE7	RN	Synthesis and pharmacological activity of SC-53228, a leukotriene B4 receptor antagonist with high intrinsic potency and selectivity, Bioorg. Med. Chem. Lett. 4(6):811-816 (1994).
DMI2KE7	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01808532

DM8RJ0V	DI	DM8RJ0V
DM8RJ0V	DN	SC-50676
DM8RJ0V	MI	TTN53ZF
DM8RJ0V	MN	Leukotriene B4 receptor 1 (LTB4R)
DM8RJ0V	MT	DTT
DM8RJ0V	MA	Inhibitor
DM8RJ0V	RN	Synthesis and pharmacological activity of SC-53228, a leukotriene B4 receptor antagonist with high intrinsic potency and selectivity, Bioorg. Med. Chem. Lett. 4(6):811-816 (1994).
DM8RJ0V	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01808532

DMBQ16F	DI	DMBQ16F
DMBQ16F	DN	SC-50998
DMBQ16F	MI	TTCG0AL
DMBQ16F	MN	Cholecystokinin receptor type A (CCKAR)
DMBQ16F	MT	DTT
DMBQ16F	MA	Antagonist
DMBQ16F	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 76).
DMBQ16F	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=76

DM0LWUV	DI	DM0LWUV
DM0LWUV	DN	SC-51322
DM0LWUV	MI	TTG1QMU
DM0LWUV	MN	Prostaglandin E2 receptor EP1 (PTGER1)
DM0LWUV	MT	DTT
DM0LWUV	MA	Modulator
DM0LWUV	RN	Antihypertensive effects of selective prostaglandin E2 receptor subtype 1 targeting. J Clin Invest. 2007 Sep;117(9):2496-505.
DM0LWUV	RU	https://www.ncbi.nlm.nih.gov/pubmed/17710229

DMAWI4M	DI	DMAWI4M
DMAWI4M	DN	SC-514
DMAWI4M	MI	TTJ3E9X
DMAWI4M	MN	Inhibitor of nuclear factor kappa-B kinase beta (IKKB)
DMAWI4M	MT	DTT
DMAWI4M	MA	Inhibitor
DMAWI4M	RN	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
DMAWI4M	RU	https://pubmed.ncbi.nlm.nih.gov/17850214

DM0E2SM	DI	DM0E2SM
DM0E2SM	DN	SC-52073
DM0E2SM	MI	TTN53ZF
DM0E2SM	MN	Leukotriene B4 receptor 1 (LTB4R)
DM0E2SM	MT	DTT
DM0E2SM	MA	Inhibitor
DM0E2SM	RN	Synthesis and pharmacological activity of SC-53228, a leukotriene B4 receptor antagonist with high intrinsic potency and selectivity, Bioorg. Med. Chem. Lett. 4(6):811-816 (1994).
DM0E2SM	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01808532

DMJ576C	DI	DMJ576C
DMJ576C	DN	SC-52491
DMJ576C	MI	TTNXLKE
DMJ576C	MN	5-HT 3 receptor (5HT3R)
DMJ576C	MT	DTT
DMJ576C	MA	Modulator
DMJ576C	RN	Azaadamantane benzamide 5-HT4 agonists: gastrointestinal prokinetic SC-54750. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5509-12.
DMJ576C	RU	https://www.ncbi.nlm.nih.gov/pubmed/15482914

DMJ576C	DI	DMJ576C
DMJ576C	DN	SC-52491
DMJ576C	MI	TT07C3Y
DMJ576C	MN	5-HT 4 receptor (HTR4)
DMJ576C	MT	DTT
DMJ576C	MA	Modulator
DMJ576C	RN	Azaadamantane benzamide 5-HT4 agonists: gastrointestinal prokinetic SC-54750. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5509-12.
DMJ576C	RU	https://www.ncbi.nlm.nih.gov/pubmed/15482914

DMLOJ42	DI	DMLOJ42
DMLOJ42	DN	SC-52569
DMLOJ42	MI	TTN53ZF
DMLOJ42	MN	Leukotriene B4 receptor 1 (LTB4R)
DMLOJ42	MT	DTT
DMLOJ42	MA	Inhibitor
DMLOJ42	RN	Synthesis and pharmacological activity of SC-53228, a leukotriene B4 receptor antagonist with high intrinsic potency and selectivity, Bioorg. Med. Chem. Lett. 4(6):811-816 (1994).
DMLOJ42	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01808532

DMXA6LU	DI	DMXA6LU
DMXA6LU	DN	SC-52892
DMXA6LU	MI	TTQVOEI
DMXA6LU	MN	Angiotensin II receptor type-2 (AGTR2)
DMXA6LU	MT	DTT
DMXA6LU	MA	Inhibitor
DMXA6LU	RN	N1-sterically hindered 2H-imidazol-2-one angiotensin II receptor antagonists: The conversion of surmountable antagonists to insurmountable antagonists, Bioorg. Med. Chem. Lett. 3(6):1055-1060 (1993).
DMXA6LU	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00802863

DMYH12X	DI	DMYH12X
DMYH12X	DN	SC-53229
DMYH12X	MI	TTN53ZF
DMYH12X	MN	Leukotriene B4 receptor 1 (LTB4R)
DMYH12X	MT	DTT
DMYH12X	MA	Inhibitor
DMYH12X	RN	Synthesis and pharmacological activity of SC-53228, a leukotriene B4 receptor antagonist with high intrinsic potency and selectivity, Bioorg. Med. Chem. Lett. 4(6):811-816 (1994).
DMYH12X	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01808532

DM3BEKV	DI	DM3BEKV
DM3BEKV	DN	SC-54701A
DM3BEKV	MI	TTJA1ZO
DM3BEKV	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DM3BEKV	MT	DTT
DM3BEKV	MA	Inhibitor
DM3BEKV	RN	Use of conformationally restricted benzamidines as arginine surrogates in the design of platelet GPIIb-IIIa receptor antagonists. J Med Chem. 1997 Aug 29;40(18):2843-57.
DM3BEKV	RU	https://pubmed.ncbi.nlm.nih.gov/9288166

DMEUTXG	DI	DMEUTXG
DMEUTXG	DN	SC-54750
DMEUTXG	MI	TTNXLKE
DMEUTXG	MN	5-HT 3 receptor (5HT3R)
DMEUTXG	MT	DTT
DMEUTXG	MA	Modulator
DMEUTXG	RN	Azaadamantane benzamide 5-HT4 agonists: gastrointestinal prokinetic SC-54750. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5509-12.
DMEUTXG	RU	https://www.ncbi.nlm.nih.gov/pubmed/15482914

DMEUTXG	DI	DMEUTXG
DMEUTXG	DN	SC-54750
DMEUTXG	MI	TT07C3Y
DMEUTXG	MN	5-HT 4 receptor (HTR4)
DMEUTXG	MT	DTT
DMEUTXG	MA	Modulator
DMEUTXG	RN	Azaadamantane benzamide 5-HT4 agonists: gastrointestinal prokinetic SC-54750. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5509-12.
DMEUTXG	RU	https://www.ncbi.nlm.nih.gov/pubmed/15482914

DMLJ8T7	DI	DMLJ8T7
DMLJ8T7	DN	SC-55634
DMLJ8T7	MI	TTQVOEI
DMLJ8T7	MN	Angiotensin II receptor type-2 (AGTR2)
DMLJ8T7	MT	DTT
DMLJ8T7	MA	Inhibitor
DMLJ8T7	RN	N1-sterically hindered 2H-imidazol-2-one angiotensin II receptor antagonists: The conversion of surmountable antagonists to insurmountable antagonists, Bioorg. Med. Chem. Lett. 3(6):1055-1060 (1993).
DMLJ8T7	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00802863

DMAZLKX	DI	DMAZLKX
DMAZLKX	DN	SC-558
DMAZLKX	MI	TTVKILB
DMAZLKX	MN	Prostaglandin G/H synthase 2 (COX-2)
DMAZLKX	MT	DTT
DMAZLKX	MA	Inhibitor
DMAZLKX	RN	In silico search for multi-target anti-inflammatories in Chinese herbs and formulas. Bioorg Med Chem. 2010 Mar 15;18(6):2204-2218.
DMAZLKX	RU	https://pubmed.ncbi.nlm.nih.gov/20188577

DMT1GJL	DI	DMT1GJL
DMT1GJL	DN	SC-560
DMT1GJL	MI	TT8NGED
DMT1GJL	MN	Prostaglandin G/H synthase 1 (COX-1)
DMT1GJL	MT	DTT
DMT1GJL	MA	Inhibitor
DMT1GJL	RN	Synthesis and antiinflammatory activity of coumarin derivatives. J Med Chem. 2005 Oct 6;48(20):6400-8.
DMT1GJL	RU	https://pubmed.ncbi.nlm.nih.gov/16190766

DMZJQ1D	DI	DMZJQ1D
DMZJQ1D	DN	SC-58272
DMZJQ1D	MI	TTBAF05
DMZJQ1D	MN	Candida Peptide N-myristoyltransferase (Candi NMT1)
DMZJQ1D	MT	DTT
DMZJQ1D	MA	Inhibitor
DMZJQ1D	RN	Crystal structures of Saccharomyces cerevisiae N-myristoyltransferase with bound myristoyl-CoA and inhibitors reveal the functional roles of the N-... J Biol Chem. 2007 Jul 27;282(30):22185-94.
DMZJQ1D	RU	https://pubmed.ncbi.nlm.nih.gov/17513302

DMNI91Z	DI	DMNI91Z
DMNI91Z	DN	SC-74020
DMNI91Z	MI	TTLM12X
DMNI91Z	MN	Matrix metalloproteinase-2 (MMP-2)
DMNI91Z	MT	DTT
DMNI91Z	MA	Inhibitor
DMNI91Z	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMNI91Z	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD71VB	DI	DMD71VB
DMD71VB	DN	SC-79407
DMD71VB	MI	TT6L509
DMD71VB	MN	Coagulation factor IIa (F2)
DMD71VB	MT	DTT
DMD71VB	MA	Inhibitor
DMD71VB	RN	Pharmacological intervention at disparate sites in the coagulation cascade: comparison of anti-thrombotic efficacy vs bleeding propensity in a rat model of acute arterial thrombosis. J Thromb Thrombolysis. 2002 Oct;14(2):113-21.
DMD71VB	RU	https://pubmed.ncbi.nlm.nih.gov/12714830

DMZN7YT	DI	DMZN7YT
DMZN7YT	DN	SC-795
DMZN7YT	MI	TTFQAYR
DMZN7YT	MN	Cholesteryl ester transfer protein (CETP)
DMZN7YT	MT	DTT
DMZN7YT	MA	Inhibitor
DMZN7YT	RN	Discovery of new cholesteryl ester transfer protein inhibitors via ligand-based pharmacophore modeling and QSAR analysis followed by synthetic expl... Eur J Med Chem. 2010 Apr;45(4):1598-617.
DMZN7YT	RU	https://pubmed.ncbi.nlm.nih.gov/20116902

DM96ATK	DI	DM96ATK
DM96ATK	DN	SC-83157
DM96ATK	MI	TTCIHJA
DM96ATK	MN	Coagulation factor Xa (F10)
DM96ATK	MT	DTT
DM96ATK	MA	Inhibitor
DM96ATK	RN	Pharmacological intervention at disparate sites in the coagulation cascade: comparison of anti-thrombotic efficacy vs bleeding propensity in a rat model of acute arterial thrombosis. J Thromb Thrombolysis. 2002 Oct;14(2):113-21.
DM96ATK	RU	https://pubmed.ncbi.nlm.nih.gov/12714830

DMX40NM	DI	DMX40NM
DMX40NM	DN	SCANDENOLIDE
DMX40NM	MI	TTSXVID
DMX40NM	MN	Nuclear factor NF-kappa-B (NFKB)
DMX40NM	MT	DTT
DMX40NM	MA	Inhibitor
DMX40NM	RN	Quantitative structure-activity relationship of sesquiterpene lactones as inhibitors of the transcription factor NF-kappaB. J Med Chem. 2004 Nov 18;47(24):6042-54.
DMX40NM	RU	https://pubmed.ncbi.nlm.nih.gov/15537359

DMRC4LE	DI	DMRC4LE
DMRC4LE	DN	Sch 202596
DMRC4LE	MI	TTOPAY7
DMRC4LE	MN	Galanin receptor (GAL-R)
DMRC4LE	MT	DTT
DMRC4LE	MA	Antagonist
DMRC4LE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 245).
DMRC4LE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=245

DMD1M24	DI	DMD1M24
DMD1M24	DN	SCH 206272
DMD1M24	MI	TTBPGLU
DMD1M24	MN	Neuromedin-K receptor (TACR3)
DMD1M24	MT	DTT
DMD1M24	MA	Antagonist
DMD1M24	RN	SCH 206272: a potent, orally active tachykinin NK(1), NK(2), and NK(3) receptor antagonist. Eur J Pharmacol. 2002 Aug 23;450(2):191-202.
DMD1M24	RU	https://pubmed.ncbi.nlm.nih.gov/12206858

DMD1M24	DI	DMD1M24
DMD1M24	DN	SCH 206272
DMD1M24	MI	TTYO0A3
DMD1M24	MN	Substance-K receptor (TACR2)
DMD1M24	MT	DTT
DMD1M24	MA	Antagonist
DMD1M24	RN	SCH 206272: a potent, orally active tachykinin NK(1), NK(2), and NK(3) receptor antagonist. Eur J Pharmacol. 2002 Aug 23;450(2):191-202.
DMD1M24	RU	https://pubmed.ncbi.nlm.nih.gov/12206858

DMD1M24	DI	DMD1M24
DMD1M24	DN	SCH 206272
DMD1M24	MI	TTZPO1L
DMD1M24	MN	Substance-P receptor (TACR1)
DMD1M24	MT	DTT
DMD1M24	MA	Antagonist
DMD1M24	RN	SCH 206272: a potent, orally active tachykinin NK(1), NK(2), and NK(3) receptor antagonist. Eur J Pharmacol. 2002 Aug 23;450(2):191-202.
DMD1M24	RU	https://pubmed.ncbi.nlm.nih.gov/12206858

DMNLD6W	DI	DMNLD6W
DMNLD6W	DN	SCH 44643
DMNLD6W	MI	TT27K59
DMNLD6W	MN	Platelet activating factor (PAF)
DMNLD6W	MT	DTT
DMNLD6W	MA	Inhibitor
DMNLD6W	RN	Determination of plasma concentrations of SCH 44643 by a GC method and correlation of plasma concentration and anti-PAF activity in cynomolgus monkeys. J Pharm Biomed Anal. 1996 Dec;15(3):343-7.
DMNLD6W	RU	https://pubmed.ncbi.nlm.nih.gov/8951694

DMIKJLP	DI	DMIKJLP
DMIKJLP	DN	Sch-036
DMIKJLP	MI	TTMSFAW
DMIKJLP	MN	Cannabinoid receptor 2 (CB2)
DMIKJLP	MT	DTT
DMIKJLP	MA	Agonist
DMIKJLP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 57).
DMIKJLP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=57

DMP8OKA	DI	DMP8OKA
DMP8OKA	DN	SCH-12679
DMP8OKA	MI	TTZFYLI
DMP8OKA	MN	Dopamine D1 receptor (D1R)
DMP8OKA	MT	DTT
DMP8OKA	MA	Inhibitor
DMP8OKA	RN	Modified ibogaine fragments: synthesis and preliminary pharmacological characterization of 3-ethyl-5-phenyl-1,2,3,4,5, 6-hexahydroazepino[4,5-b]ben... J Med Chem. 1998 Nov 5;41(23):4486-91.
DMP8OKA	RU	https://pubmed.ncbi.nlm.nih.gov/9804688

DM584T6	DI	DM584T6
DM584T6	DN	SCH-205831
DM584T6	MI	TTL935N
DM584T6	MN	Proteinase activated receptor 1 (F2R)
DM584T6	MT	DTT
DM584T6	MA	Inhibitor
DM584T6	RN	Himbacine derived thrombin receptor (PAR-1) antagonists: SAR of the pyridine ring. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4509-13.
DM584T6	RU	https://pubmed.ncbi.nlm.nih.gov/17574850

DM42A1F	DI	DM42A1F
DM42A1F	DN	SCH-210971
DM42A1F	MI	TT2CEJG
DM42A1F	MN	C-C chemokine receptor type 5 (CCR5)
DM42A1F	MT	DTT
DM42A1F	MA	Inhibitor
DM42A1F	RN	Chemokine receptor CCR-5 inhibitors produced by Chaetomium globosum. J Nat Prod. 2006 Jul;69(7):1025-8.
DM42A1F	RU	https://pubmed.ncbi.nlm.nih.gov/16872138

DMHOUSR	DI	DMHOUSR
DMHOUSR	DN	SCH-221510
DMHOUSR	MI	TTNT7K8
DMHOUSR	MN	Nociceptin receptor (OPRL1)
DMHOUSR	MT	DTT
DMHOUSR	MA	Agonist
DMHOUSR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 320).
DMHOUSR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=320

DMH7EWZ	DI	DMH7EWZ
DMH7EWZ	DN	SCH-225336
DMH7EWZ	MI	TTMSFAW
DMH7EWZ	MN	Cannabinoid receptor 2 (CB2)
DMH7EWZ	MT	DTT
DMH7EWZ	MA	Inhibitor
DMH7EWZ	RN	Radiosynthesis of novel carbon-11-labeled triaryl ligands for cannabinoid-type 2 receptor. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1565-8.
DMH7EWZ	RU	https://pubmed.ncbi.nlm.nih.gov/20137936

DMT1OAH	DI	DMT1OAH
DMT1OAH	DN	SCH-23390
DMT1OAH	MI	TTZFYLI
DMT1OAH	MN	Dopamine D1 receptor (D1R)
DMT1OAH	MT	DTT
DMT1OAH	MA	Antagonist
DMT1OAH	RN	Dopamine modulates effort-based decision making in rats. Behav Neurosci. 2009 Apr;123(2):242-51.
DMT1OAH	RU	https://pubmed.ncbi.nlm.nih.gov/19331447

DM6SC5K	DI	DM6SC5K
DM6SC5K	DN	SCH-24518
DM6SC5K	MI	TTZFYLI
DM6SC5K	MN	Dopamine D1 receptor (D1R)
DM6SC5K	MT	DTT
DM6SC5K	MA	Inhibitor
DM6SC5K	RN	Synthesis and pharmacological characterization of 1-phenyl-, 4-phenyl-, and 1-benzyl-1,2,3,4-tetrahydroisoquinolines as dopamine receptor ligands. J Med Chem. 1988 Oct;31(10):1941-6.
DM6SC5K	RU	https://pubmed.ncbi.nlm.nih.gov/3050089

DM6SC5K	DI	DM6SC5K
DM6SC5K	DN	SCH-24518
DM6SC5K	MI	TTEX248
DM6SC5K	MN	Dopamine D2 receptor (D2R)
DM6SC5K	MT	DTT
DM6SC5K	MA	Inhibitor
DM6SC5K	RN	Synthesis and pharmacological characterization of 1-phenyl-, 4-phenyl-, and 1-benzyl-1,2,3,4-tetrahydroisoquinolines as dopamine receptor ligands. J Med Chem. 1988 Oct;31(10):1941-6.
DM6SC5K	RU	https://pubmed.ncbi.nlm.nih.gov/3050089

DMOEB8M	DI	DMOEB8M
DMOEB8M	DN	SCH-356036
DMOEB8M	MI	TT6OEDT
DMOEB8M	MN	Cannabinoid receptor 1 (CB1)
DMOEB8M	MT	DTT
DMOEB8M	MA	Inhibitor
DMOEB8M	RN	Synthesis and SAR of novel imidazoles as potent and selective cannabinoid CB2 receptor antagonists with high binding efficiencies. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1084-9.
DMOEB8M	RU	https://pubmed.ncbi.nlm.nih.gov/20031412

DMOEB8M	DI	DMOEB8M
DMOEB8M	DN	SCH-356036
DMOEB8M	MI	TTMSFAW
DMOEB8M	MN	Cannabinoid receptor 2 (CB2)
DMOEB8M	MT	DTT
DMOEB8M	MA	Inhibitor
DMOEB8M	RN	Synthesis and SAR of novel imidazoles as potent and selective cannabinoid CB2 receptor antagonists with high binding efficiencies. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1084-9.
DMOEB8M	RU	https://pubmed.ncbi.nlm.nih.gov/20031412

DM0J937	DI	DM0J937
DM0J937	DN	SCH-48375
DM0J937	MI	TTMF541
DM0J937	MN	Liver carboxylesterase (CES1)
DM0J937	MT	DTT
DM0J937	MA	Inhibitor
DM0J937	RN	2-Azetidinones as inhibitors of cholesterol absorption. J Med Chem. 1994 Jun 10;37(12):1733-6.
DM0J937	RU	https://pubmed.ncbi.nlm.nih.gov/8021912

DMCWSJP	DI	DMCWSJP
DMCWSJP	DN	SCH51866
DMCWSJP	MI	TT73TEJ
DMCWSJP	MN	Phosphodiesterase 1A (PDE1A)
DMCWSJP	MT	DTT
DMCWSJP	MA	Inhibitor
DMCWSJP	RN	Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitor. J Cardiovasc Pharmacol. 1996 Dec;28(6):862-9.
DMCWSJP	RU	https://pubmed.ncbi.nlm.nih.gov/8961086

DMCWSJP	DI	DMCWSJP
DMCWSJP	DN	SCH51866
DMCWSJP	MI	TT3ZS42
DMCWSJP	MN	Phosphodiesterase 1B (PDE1B)
DMCWSJP	MT	DTT
DMCWSJP	MA	Inhibitor
DMCWSJP	RN	Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitor. J Cardiovasc Pharmacol. 1996 Dec;28(6):862-9.
DMCWSJP	RU	https://pubmed.ncbi.nlm.nih.gov/8961086

DMCWSJP	DI	DMCWSJP
DMCWSJP	DN	SCH51866
DMCWSJP	MI	TTW2HRK
DMCWSJP	MN	Phosphodiesterase 1C (PDE1C)
DMCWSJP	MT	DTT
DMCWSJP	MA	Inhibitor
DMCWSJP	RN	Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitor. J Cardiovasc Pharmacol. 1996 Dec;28(6):862-9.
DMCWSJP	RU	https://pubmed.ncbi.nlm.nih.gov/8961086

DMCWSJP	DI	DMCWSJP
DMCWSJP	DN	SCH51866
DMCWSJP	MI	TTJ0IQB
DMCWSJP	MN	Phosphodiesterase 5A (PDE5A)
DMCWSJP	MT	DTT
DMCWSJP	MA	Inhibitor
DMCWSJP	RN	Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitor. J Cardiovasc Pharmacol. 1996 Dec;28(6):862-9.
DMCWSJP	RU	https://pubmed.ncbi.nlm.nih.gov/8961086

DMCWSJP	DI	DMCWSJP
DMCWSJP	DN	SCH51866
DMCWSJP	MI	TTWIEY9
DMCWSJP	MN	Phosphodiesterase 7B (PDE7B)
DMCWSJP	MT	DTT
DMCWSJP	MA	Inhibitor
DMCWSJP	RN	Identification of human PDE7B, a cAMP-specific phosphodiesterase. Biochem Biophys Res Commun. 2000 May 19;271(3):575-83.
DMCWSJP	RU	https://pubmed.ncbi.nlm.nih.gov/10814504

DMCWSJP	DI	DMCWSJP
DMCWSJP	DN	SCH51866
DMCWSJP	MI	TTZOEBC
DMCWSJP	MN	Phosphodiesterase 9 (PDE9)
DMCWSJP	MT	DTT
DMCWSJP	MA	Inhibitor
DMCWSJP	RN	Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J Biol Chem. 1998 Jun 19;273(25):15559-64.
DMCWSJP	RU	https://pubmed.ncbi.nlm.nih.gov/9624146

DMMXIB4	DI	DMMXIB4
DMMXIB4	DN	SCH-546909
DMMXIB4	MI	TT7HF4W
DMMXIB4	MN	Cyclin-dependent kinase 2 (CDK2)
DMMXIB4	MT	DTT
DMMXIB4	MA	Inhibitor
DMMXIB4	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1973).
DMMXIB4	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1973

DMDK8TR	DI	DMDK8TR
DMDK8TR	DN	SCH-57726
DMDK8TR	MI	TTJ0IQB
DMDK8TR	MN	Phosphodiesterase 5A (PDE5A)
DMDK8TR	MT	DTT
DMDK8TR	MA	Inhibitor
DMDK8TR	RN	The Gif system as a tool in medicinal chemistry: The oxidation of Sch 57726 under GoAggIII conditions, Bioorg. Med. Chem. Lett. 7(11):1381-1386 (1997).
DMDK8TR	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97002382

DMRDM9S	DI	DMRDM9S
DMRDM9S	DN	SCH-602539
DMRDM9S	MI	TTL935N
DMRDM9S	MN	Proteinase activated receptor 1 (F2R)
DMRDM9S	MT	DTT
DMRDM9S	MA	Antagonist
DMRDM9S	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 347).
DMRDM9S	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=347

DMAUB9F	DI	DMAUB9F
DMAUB9F	DN	SCH-63390
DMAUB9F	MI	TTK25J1
DMAUB9F	MN	Adenosine A1 receptor (ADORA1)
DMAUB9F	MT	DTT
DMAUB9F	MA	Inhibitor
DMAUB9F	RN	Design, synthesis, and biological evaluation of a second generation of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as potent and selective A2A... J Med Chem. 1998 Jun 4;41(12):2126-33.
DMAUB9F	RU	https://pubmed.ncbi.nlm.nih.gov/9622554

DMAUB9F	DI	DMAUB9F
DMAUB9F	DN	SCH-63390
DMAUB9F	MI	TTM2AOE
DMAUB9F	MN	Adenosine A2a receptor (ADORA2A)
DMAUB9F	MT	DTT
DMAUB9F	MA	Inhibitor
DMAUB9F	RN	Design, synthesis, and biological evaluation of a second generation of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as potent and selective A2A... J Med Chem. 1998 Jun 4;41(12):2126-33.
DMAUB9F	RU	https://pubmed.ncbi.nlm.nih.gov/9622554

DM4CI57	DI	DM4CI57
DM4CI57	DN	SCH-68631
DM4CI57	MI	TTWXB3E
DM4CI57	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DM4CI57	MT	DTT
DM4CI57	MA	Inhibitor
DM4CI57	RN	Control of hepatitis C: a medicinal chemistry perspective. J Med Chem. 2005 Jan 13;48(1):1-20.
DM4CI57	RU	https://pubmed.ncbi.nlm.nih.gov/15633995

DM9YJI8	DI	DM9YJI8
DM9YJI8	DN	SCH-725737
DM9YJI8	MI	TT90XZ8
DM9YJI8	MN	Voltage-gated sodium channel alpha Nav1.8 (SCN10A)
DM9YJI8	MT	DTT
DM9YJI8	MA	Inhibitor
DM9YJI8	RN	Novel steroidal saponins, Sch 725737 and Sch 725739, from a marine starfish, Novodinia antillensis. Bioorg Med Chem Lett. 2007 Oct 15;17(20):5543-7.
DM9YJI8	RU	https://pubmed.ncbi.nlm.nih.gov/17804230

DMYKB0S	DI	DMYKB0S
DMYKB0S	DN	SCH-725739
DMYKB0S	MI	TT90XZ8
DMYKB0S	MN	Voltage-gated sodium channel alpha Nav1.8 (SCN10A)
DMYKB0S	MT	DTT
DMYKB0S	MA	Inhibitor
DMYKB0S	RN	Novel steroidal saponins, Sch 725737 and Sch 725739, from a marine starfish, Novodinia antillensis. Bioorg Med Chem Lett. 2007 Oct 15;17(20):5543-7.
DMYKB0S	RU	https://pubmed.ncbi.nlm.nih.gov/17804230

DMWVH62	DI	DMWVH62
DMWVH62	DN	SCH772984
DMWVH62	MI	TT4TQBX
DMWVH62	MN	Extracellular signal-regulated kinase 2 (ERK2)
DMWVH62	MT	DTT
DMWVH62	MA	Inhibitor
DMWVH62	RN	Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov. 2013 Jul;3(7):742-50.
DMWVH62	RU	https://pubmed.ncbi.nlm.nih.gov/23614898

DM5ZEPD	DI	DM5ZEPD
DM5ZEPD	DN	SCH79687
DM5ZEPD	MI	TT9JNIC
DM5ZEPD	MN	Histamine H3 receptor (H3R)
DM5ZEPD	MT	DTT
DM5ZEPD	MA	Antagonist
DM5ZEPD	RN	The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20.
DM5ZEPD	RU	https://pubmed.ncbi.nlm.nih.gov/15665857

DM346KA	DI	DM346KA
DM346KA	DN	Sch-900875
DM346KA	MI	TT1UCIJ
DM346KA	MN	C-X-C chemokine receptor type 3 (CXCR3)
DM346KA	MT	DTT
DM346KA	MA	Antagonist
DM346KA	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 70).
DM346KA	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=70

DMWQ480	DI	DMWQ480
DMWQ480	DN	schisandrin A
DMWQ480	MI	TT7LCTF
DMWQ480	MN	Pregnane X receptor (NR1I2)
DMWQ480	MT	DTT
DMWQ480	MA	Agonist
DMWQ480	RN	Traditional Chinese medicines Wu Wei Zi (Schisandra chinensis Baill) and Gan Cao (Glycyrrhiza uralensis Fisch) activate pregnane X receptor and inc... J Pharmacol Exp Ther. 2006 Mar;316(3):1369-77.
DMWQ480	RU	https://pubmed.ncbi.nlm.nih.gov/16267138

DM645FP	DI	DM645FP
DM645FP	DN	SCOPOLETIN
DM645FP	MI	TTN9T81
DM645FP	MN	Arachidonate 15-lipoxygenase (15-LOX)
DM645FP	MT	DTT
DM645FP	MA	Inhibitor
DM645FP	RN	Lipoxygenase inhibitory constituents of the fruits of noni (Morinda citrifolia) collected in Tahiti. J Nat Prod. 2007 May;70(5):859-62.
DM645FP	RU	https://pubmed.ncbi.nlm.nih.gov/17378609

DMJD03I	DI	DMJD03I
DMJD03I	DN	SCUTELLAREIN
DMJD03I	MI	TT7RJY8
DMJD03I	MN	Xanthine dehydrogenase/oxidase (XDH)
DMJD03I	MT	DTT
DMJD03I	MA	Inhibitor
DMJD03I	RN	Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod. 1988 Mar-Apr;51(2):345-8.
DMJD03I	RU	https://pubmed.ncbi.nlm.nih.gov/3379415

DMQXUYH	DI	DMQXUYH
DMQXUYH	DN	SD-208
DMQXUYH	MI	TTP4520
DMQXUYH	MN	TGF-beta receptor type I (TGFBR1)
DMQXUYH	MT	DTT
DMQXUYH	MA	Inhibitor
DMQXUYH	RN	Evaluation of the anti-hepatitis C virus effect of novel potent, selective, and orally bioavailable JNK and VEGFR kinase inhibitors. Bioorg Med Chem Lett. 2007 Apr 1;17(7):1843-9.
DMQXUYH	RU	https://pubmed.ncbi.nlm.nih.gov/17289388

DMP3EXG	DI	DMP3EXG
DMP3EXG	DN	SDZ-205-557
DMP3EXG	MI	TT07C3Y
DMP3EXG	MN	5-HT 4 receptor (HTR4)
DMP3EXG	MT	DTT
DMP3EXG	MA	Modulator
DMP3EXG	RN	SDZ 205-557, a selective antagonist at 5-HT4 receptors in the isolated guinea pig ileum. Eur J Pharmacol. 1991 Aug 6;200(2-3):373-4.
DMP3EXG	RU	https://www.ncbi.nlm.nih.gov/pubmed/1782999

DMLPRU4	DI	DMLPRU4
DMLPRU4	DN	SDZ-208911
DMLPRU4	MI	TTEX248
DMLPRU4	MN	Dopamine D2 receptor (D2R)
DMLPRU4	MT	DTT
DMLPRU4	MA	Modulator
DMLPRU4	RN	Effects of the partial dopamine receptor agonists SDZ 208-911, SDZ 208-912 and terguride on central monoamine receptors. A behavioral, biochemical and electrophysiological study. Naunyn SchmiedebergsArch Pharmacol. 1991 Sep;344(3):263-74.
DMLPRU4	RU	https://pubmed.ncbi.nlm.nih.gov/1683686

DM3GJ07	DI	DM3GJ07
DM3GJ07	DN	SDZ-PDI-747
DM3GJ07	MI	TTV5CGO
DM3GJ07	MN	Phosphodiesterase 4 (PDE4)
DM3GJ07	MT	DTT
DM3GJ07	MA	Modulator
DM3GJ07	RN	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
DM3GJ07	RU	https://www.ncbi.nlm.nih.gov/pubmed/27899562

DMBYSEM	DI	DMBYSEM
DMBYSEM	DN	SDZ-PTS-893
DMBYSEM	MI	TTEPJL5
DMBYSEM	MN	Parathyroid hormone receptor (PTH2R)
DMBYSEM	MT	DTT
DMBYSEM	MA	Modulator
DMBYSEM	RN	Long-term therapy of ovariectomy-induced osteopenia with parathyroid hormone analog SDZ PTS 893 and bone maintenance in retired breeder rats. Bone. 1999 Nov;25(5):561-9.
DMBYSEM	RU	https://www.ncbi.nlm.nih.gov/pubmed/10574576

DMYSKI0	DI	DMYSKI0
DMYSKI0	DN	SE RNA
DMYSKI0	MI	TTWXB3E
DMYSKI0	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DMYSKI0	MT	DTT
DMYSKI0	RN	Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60.
DMYSKI0	RU	https://pubmed.ncbi.nlm.nih.gov/18095918

DMSB4WO	DI	DMSB4WO
DMSB4WO	DN	SEA
DMSB4WO	MI	TT7QNVC
DMSB4WO	MN	Glucose-dependent insulinotropic receptor (GPR119)
DMSB4WO	MT	DTT
DMSB4WO	MA	Agonist
DMSB4WO	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 126).
DMSB4WO	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=126

DME69PI	DI	DME69PI
DME69PI	DN	SEA-0400
DME69PI	MI	TT619TC
DME69PI	MN	Sodium/calcium exchanger (SLC)
DME69PI	MT	DTT
DME69PI	MA	Inhibitor
DME69PI	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4617).
DME69PI	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4617

DM3VOPQ	DI	DM3VOPQ
DM3VOPQ	DN	SEBACIC ACID
DM3VOPQ	MI	TTQO71U
DM3VOPQ	MN	Hemoglobin (HB)
DM3VOPQ	MT	DTT
DM3VOPQ	MA	Inhibitor
DM3VOPQ	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM3VOPQ	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM9QSDC	DI	DM9QSDC
DM9QSDC	DN	Sec-butyl 9H-pyrido[3,4-b]indole-3-carboxylate
DM9QSDC	MI	TT1MPAY
DM9QSDC	MN	GABA(A) receptor alpha-1 (GABRA1)
DM9QSDC	MT	DTT
DM9QSDC	MA	Inhibitor
DM9QSDC	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DM9QSDC	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DM9QSDC	DI	DM9QSDC
DM9QSDC	DN	Sec-butyl 9H-pyrido[3,4-b]indole-3-carboxylate
DM9QSDC	MI	TTBMV1G
DM9QSDC	MN	GABA(A) receptor alpha-2 (GABRA2)
DM9QSDC	MT	DTT
DM9QSDC	MA	Inhibitor
DM9QSDC	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DM9QSDC	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DM9QSDC	DI	DM9QSDC
DM9QSDC	DN	Sec-butyl 9H-pyrido[3,4-b]indole-3-carboxylate
DM9QSDC	MI	TT37EDJ
DM9QSDC	MN	GABA(A) receptor alpha-3 (GABRA3)
DM9QSDC	MT	DTT
DM9QSDC	MA	Inhibitor
DM9QSDC	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DM9QSDC	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DM9QSDC	DI	DM9QSDC
DM9QSDC	DN	Sec-butyl 9H-pyrido[3,4-b]indole-3-carboxylate
DM9QSDC	MI	TTNZPQ1
DM9QSDC	MN	GABA(A) receptor alpha-5 (GABRA5)
DM9QSDC	MT	DTT
DM9QSDC	MA	Inhibitor
DM9QSDC	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DM9QSDC	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DM9QSDC	DI	DM9QSDC
DM9QSDC	DN	Sec-butyl 9H-pyrido[3,4-b]indole-3-carboxylate
DM9QSDC	MI	TT06RH5
DM9QSDC	MN	GABA(A) receptor gamma-2 (GABRG2)
DM9QSDC	MT	DTT
DM9QSDC	MA	Inhibitor
DM9QSDC	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DM9QSDC	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DM9QSDC	DI	DM9QSDC
DM9QSDC	DN	Sec-butyl 9H-pyrido[3,4-b]indole-3-carboxylate
DM9QSDC	MI	TTNJYV2
DM9QSDC	MN	Gamma-aminobutyric acid receptor (GAR)
DM9QSDC	MT	DTT
DM9QSDC	MA	Inhibitor
DM9QSDC	RN	Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
DM9QSDC	RU	https://pubmed.ncbi.nlm.nih.gov/20888240

DM76CUP	DI	DM76CUP
DM76CUP	DN	SECOCULARIDINE
DM76CUP	MI	TTVBI8W
DM76CUP	MN	Dopamine transporter (DAT)
DM76CUP	MT	DTT
DM76CUP	MA	Inhibitor
DM76CUP	RN	Effects of various isoquinoline alkaloids on in vitro 3H-dopamine uptake by rat striatal synaptosomes. J Nat Prod. 1995 Oct;58(10):1475-84.
DM76CUP	RU	https://pubmed.ncbi.nlm.nih.gov/8676127

DMY7IVZ	DI	DMY7IVZ
DMY7IVZ	DN	Seco-exiguamine
DMY7IVZ	MI	TTZJYKH
DMY7IVZ	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMY7IVZ	MT	DTT
DMY7IVZ	MA	Inhibitor
DMY7IVZ	RN	Biomimetic synthesis of the IDO inhibitors exiguamine A and B. Nat Chem Biol. 2008 Sep;4(9):535-7.
DMY7IVZ	RU	https://pubmed.ncbi.nlm.nih.gov/18677305

DM9BJ27	DI	DM9BJ27
DM9BJ27	DN	Se-Ethyl-Isoselenourea
DM9BJ27	MI	TTCM4B3
DM9BJ27	MN	Nitric-oxide synthase endothelial (NOS3)
DM9BJ27	MT	DTT
DM9BJ27	MA	Inhibitor
DM9BJ27	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9BJ27	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMCQNT9	DI	DMCQNT9
DMCQNT9	DN	SE-ET-TP020d
DMCQNT9	MI	TTIHYA4
DMCQNT9	MN	Thrombopoietin receptor (MPL)
DMCQNT9	MT	DTT
DMCQNT9	MA	Modulator
DMCQNT9	RN	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
DMCQNT9	RU	https://www.ncbi.nlm.nih.gov/pubmed/27899562

DMFKE6C	DI	DMFKE6C
DMFKE6C	DN	SEL-73
DMFKE6C	MI	TTSQIFT
DMFKE6C	MN	5-HT 1A receptor (HTR1A)
DMFKE6C	MT	DTT
DMFKE6C	MA	Modulator
DMFKE6C	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1).
DMFKE6C	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1

DMFKE6C	DI	DMFKE6C
DMFKE6C	DN	SEL-73
DMFKE6C	MI	TTJQOD7
DMFKE6C	MN	5-HT 2A receptor (HTR2A)
DMFKE6C	MT	DTT
DMFKE6C	MA	Modulator
DMFKE6C	RN	Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598). J Pharmacol Exp Ther. 1992 Jan;260(1):146-59.
DMFKE6C	RU	https://pubmed.ncbi.nlm.nih.gov/1370538

DMFKE6C	DI	DMFKE6C
DMFKE6C	DN	SEL-73
DMFKE6C	MI	TTJS8PY
DMFKE6C	MN	5-HT 6 receptor (HTR6)
DMFKE6C	MT	DTT
DMFKE6C	MA	Modulator
DMFKE6C	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 11).
DMFKE6C	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=11

DMFKE6C	DI	DMFKE6C
DMFKE6C	DN	SEL-73
DMFKE6C	MI	TTO9X1H
DMFKE6C	MN	5-HT 7 receptor (HTR7)
DMFKE6C	MT	DTT
DMFKE6C	MA	Modulator
DMFKE6C	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 12).
DMFKE6C	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=12

DMFKE6C	DI	DMFKE6C
DMFKE6C	DN	SEL-73
DMFKE6C	MI	TTEX248
DMFKE6C	MN	Dopamine D2 receptor (D2R)
DMFKE6C	MT	DTT
DMFKE6C	MA	Modulator
DMFKE6C	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 215).
DMFKE6C	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=215

DMKSIVL	DI	DMKSIVL
DMKSIVL	DN	Selenazofurin
DMKSIVL	MI	TTL7C8Q
DMKSIVL	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMKSIVL	MT	DTT
DMKSIVL	MA	Inhibitor
DMKSIVL	RN	In vitro and in vivo antiproliferative activity of IPCAR, a new pyrazole nucleoside analog. Anticancer Res. 1998 Jul-Aug;18(4A):2623-30.
DMKSIVL	RU	https://pubmed.ncbi.nlm.nih.gov/9703919

DMXERWD	DI	DMXERWD
DMXERWD	DN	Selenazole-4-Carboxyamide-Adenine Dinucleotide
DMXERWD	MI	TTTB4UP
DMXERWD	MN	Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2)
DMXERWD	MT	DTT
DMXERWD	MA	Inhibitor
DMXERWD	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMXERWD	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMB7GPA	DI	DMB7GPA
DMB7GPA	DN	Selenious acid
DMB7GPA	MI	DEUP4DA
DMB7GPA	MN	Thioredoxin reductase TR1 (TXNRD1)
DMB7GPA	MT	DME
DMB7GPA	MA	Metabolism
DMB7GPA	RN	Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase. Carcinogenesis. 1999 Sep;20(9):1657-66.
DMB7GPA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10469608

DMBJ1E0	DI	DMBJ1E0
DMBJ1E0	DN	Selumetinib
DMBJ1E0	MI	TTAW3TO
DMBJ1E0	MN	HUMAN ERK activator kinase 1 (MEK1)
DMBJ1E0	MT	DTT
DMBJ1E0	MA	Inhibitor
DMBJ1E0	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DMBJ1E0	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DMBJ1E0	DI	DMBJ1E0
DMBJ1E0	DN	Selumetinib
DMBJ1E0	MI	TTWX403
DMBJ1E0	MN	HUMAN ERK activator kinase 2 (MEK2)
DMBJ1E0	MT	DTT
DMBJ1E0	MA	Inhibitor
DMBJ1E0	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DMBJ1E0	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DMDIZUT	DI	DMDIZUT
DMDIZUT	DN	SEM-606
DMDIZUT	MI	TTE4KHA
DMDIZUT	MN	Amyloid beta A4 protein (APP)
DMDIZUT	MT	DTT
DMDIZUT	MA	Inhibitor
DMDIZUT	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
DMDIZUT	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402

DMW5SIQ	DI	DMW5SIQ
DMW5SIQ	DN	SEMIPLENAMIDE A
DMW5SIQ	MI	TT6OEDT
DMW5SIQ	MN	Cannabinoid receptor 1 (CB1)
DMW5SIQ	MT	DTT
DMW5SIQ	MA	Inhibitor
DMW5SIQ	RN	Semiplenamides A-G, fatty acid amides from a Papua New Guinea collection of the marine cyanobacterium Lyngbya semiplena. J Nat Prod. 2003 Oct;66(10):1364-8.
DMW5SIQ	RU	https://pubmed.ncbi.nlm.nih.gov/14575438

DMHWCFJ	DI	DMHWCFJ
DMHWCFJ	DN	SEMIPLENAMIDE B
DMHWCFJ	MI	TT6OEDT
DMHWCFJ	MN	Cannabinoid receptor 1 (CB1)
DMHWCFJ	MT	DTT
DMHWCFJ	MA	Inhibitor
DMHWCFJ	RN	Semiplenamides A-G, fatty acid amides from a Papua New Guinea collection of the marine cyanobacterium Lyngbya semiplena. J Nat Prod. 2003 Oct;66(10):1364-8.
DMHWCFJ	RU	https://pubmed.ncbi.nlm.nih.gov/14575438

DM4RP0A	DI	DM4RP0A
DM4RP0A	DN	Semiplenamide G
DM4RP0A	MI	TT6OEDT
DM4RP0A	MN	Cannabinoid receptor 1 (CB1)
DM4RP0A	MT	DTT
DM4RP0A	MA	Inhibitor
DM4RP0A	RN	Semiplenamides A-G, fatty acid amides from a Papua New Guinea collection of the marine cyanobacterium Lyngbya semiplena. J Nat Prod. 2003 Oct;66(10):1364-8.
DM4RP0A	RU	https://pubmed.ncbi.nlm.nih.gov/14575438

DM1C5GZ	DI	DM1C5GZ
DM1C5GZ	DN	Semorphone
DM1C5GZ	MI	TTKWM86
DM1C5GZ	MN	Opioid receptor mu (MOP)
DM1C5GZ	MT	DTT
DM1C5GZ	MA	Modulator
DM1C5GZ	RN	Respiratory effects and tolerability of Mr 2264 Cl.A new opiate partial agonist in comparison with morphine and placebo.Eur J Clin Pharmacol.1994;46(4):301-4.
DM1C5GZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/7957512

DMKB2IJ	DI	DMKB2IJ
DMKB2IJ	DN	SEN-1500
DMKB2IJ	MI	TTE4KHA
DMKB2IJ	MN	Amyloid beta A4 protein (APP)
DMKB2IJ	MT	DTT
DMKB2IJ	MA	Inhibitor
DMKB2IJ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
DMKB2IJ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402

DMRJIP4	DI	DMRJIP4
DMRJIP4	DN	Septide
DMRJIP4	MI	TTZPO1L
DMRJIP4	MN	Substance-P receptor (TACR1)
DMRJIP4	MT	DTT
DMRJIP4	MA	Agonist
DMRJIP4	RN	Septide: an agonist for the NK1 receptor acting at a site distinct from substance P. Mol Pharmacol. 1994 Feb;45(2):287-93.
DMRJIP4	RU	https://pubmed.ncbi.nlm.nih.gov/7509440

DMIKT7W	DI	DMIKT7W
DMIKT7W	DN	SER-203
DMIKT7W	MI	TTGTQHC
DMIKT7W	MN	DNA topoisomerase I (TOP1)
DMIKT7W	MT	DTT
DMIKT7W	MA	Stimulator
DMIKT7W	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2636).
DMIKT7W	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2636

DMF8GAX	DI	DMF8GAX
DMF8GAX	DN	sergliflozin
DMF8GAX	MI	TT2UE56
DMF8GAX	MN	Sodium/glucose cotransporter 1 (SGLT1)
DMF8GAX	MT	DTT
DMF8GAX	MA	Inhibitor
DMF8GAX	RN	Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal gluco... J Pharmacol Exp Ther. 2007 Jan;320(1):323-30.
DMF8GAX	RU	https://pubmed.ncbi.nlm.nih.gov/17050778

DMF8GAX	DI	DMF8GAX
DMF8GAX	DN	sergliflozin
DMF8GAX	MI	TTLWPVF
DMF8GAX	MN	Sodium/glucose cotransporter 2 (SGLT2)
DMF8GAX	MT	DTT
DMF8GAX	MA	Inhibitor
DMF8GAX	RN	Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal gluco... J Pharmacol Exp Ther. 2007 Jan;320(1):323-30.
DMF8GAX	RU	https://pubmed.ncbi.nlm.nih.gov/17050778

DM6FVCE	DI	DM6FVCE
DM6FVCE	DN	Sergliflozin A
DM6FVCE	MI	TTF8JAT
DM6FVCE	MN	SLC5A2 messenger RNA (SLC5A2 mRNA)
DM6FVCE	MT	DTT
DM6FVCE	MA	Inhibitor
DM6FVCE	RN	Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: 1,3,4-Thiadiazolylmethylphenyl glucoside congeners. Bioorg Med Chem. 2010 Mar 15;18(6):2178-2194.
DM6FVCE	RU	https://pubmed.ncbi.nlm.nih.gov/20181486

DM4ZYKV	DI	DM4ZYKV
DM4ZYKV	DN	SERMs
DM4ZYKV	MI	TTZAYWL
DM4ZYKV	MN	Estrogen receptor (ESR)
DM4ZYKV	MT	DTT
DM4ZYKV	MA	Modulator
DM4ZYKV	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620).
DM4ZYKV	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=620

DMOFCRY	DI	DMOFCRY
DMOFCRY	DN	Serotonin
DMOFCRY	MI	TTSQIFT
DMOFCRY	MN	5-HT 1A receptor (HTR1A)
DMOFCRY	MT	DTT
DMOFCRY	MA	Inhibitor
DMOFCRY	RN	Novel, potent, and selective quinoxaline-based 5-HT(3) receptor ligands. 1. Further structure-activity relationships and pharmacological characteri... J Med Chem. 2009 Nov 12;52(21):6946-50.
DMOFCRY	RU	https://pubmed.ncbi.nlm.nih.gov/19831400

DMOFCRY	DI	DMOFCRY
DMOFCRY	DN	Serotonin
DMOFCRY	MI	TTK8CXU
DMOFCRY	MN	5-HT 1B receptor (HTR1B)
DMOFCRY	MT	DTT
DMOFCRY	MA	Inhibitor
DMOFCRY	RN	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
DMOFCRY	RU	https://pubmed.ncbi.nlm.nih.gov/18983139

DMOFCRY	DI	DMOFCRY
DMOFCRY	DN	Serotonin
DMOFCRY	MI	TT6MSOK
DMOFCRY	MN	5-HT 1D receptor (HTR1D)
DMOFCRY	MT	DTT
DMOFCRY	MA	Inhibitor
DMOFCRY	RN	Designing selective, high affinity ligands of 5-HT1D receptor by covalent dimerization of 5-HT1F ligands derived from 4-fluoro-N-[3-(1-methyl-4-pip... J Med Chem. 2008 Jun 26;51(12):3609-16.
DMOFCRY	RU	https://pubmed.ncbi.nlm.nih.gov/18507369

DMOFCRY	DI	DMOFCRY
DMOFCRY	DN	Serotonin
DMOFCRY	MI	TTJQOD7
DMOFCRY	MN	5-HT 2A receptor (HTR2A)
DMOFCRY	MT	DTT
DMOFCRY	MA	Inhibitor
DMOFCRY	RN	Novel, potent, and selective quinoxaline-based 5-HT(3) receptor ligands. 1. Further structure-activity relationships and pharmacological characteri... J Med Chem. 2009 Nov 12;52(21):6946-50.
DMOFCRY	RU	https://pubmed.ncbi.nlm.nih.gov/19831400

DMOFCRY	DI	DMOFCRY
DMOFCRY	DN	Serotonin
DMOFCRY	MI	TT0K1SC
DMOFCRY	MN	5-HT 2B receptor (HTR2B)
DMOFCRY	MT	DTT
DMOFCRY	MA	Inhibitor
DMOFCRY	RN	Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists. Bioorg Med Chem Lett. 2006 Feb;16(3):677-80.
DMOFCRY	RU	https://pubmed.ncbi.nlm.nih.gov/16257207

DMOFCRY	DI	DMOFCRY
DMOFCRY	DN	Serotonin
DMOFCRY	MI	TTWJBZ5
DMOFCRY	MN	5-HT 2C receptor (HTR2C)
DMOFCRY	MT	DTT
DMOFCRY	MA	Inhibitor
DMOFCRY	RN	Brominated cyclodipeptides from the marine sponge Geodia barretti as selective 5-HT ligands. J Nat Prod. 2006 Oct;69(10):1421-4.
DMOFCRY	RU	https://pubmed.ncbi.nlm.nih.gov/17067154

DMOFCRY	DI	DMOFCRY
DMOFCRY	DN	Serotonin
DMOFCRY	MI	TTPC4TU
DMOFCRY	MN	5-HT 3A receptor (HTR3A)
DMOFCRY	MT	DTT
DMOFCRY	MA	Inhibitor
DMOFCRY	RN	Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy ... J Med Chem. 1999 May 6;42(9):1556-75.
DMOFCRY	RU	https://pubmed.ncbi.nlm.nih.gov/10229626

DMOFCRY	DI	DMOFCRY
DMOFCRY	DN	Serotonin
DMOFCRY	MI	TTR6K75
DMOFCRY	MN	5-HT 3B receptor (HTR3B)
DMOFCRY	MT	DTT
DMOFCRY	MA	Inhibitor
DMOFCRY	RN	Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy ... J Med Chem. 1999 May 6;42(9):1556-75.
DMOFCRY	RU	https://pubmed.ncbi.nlm.nih.gov/10229626

DMOFCRY	DI	DMOFCRY
DMOFCRY	DN	Serotonin
DMOFCRY	MI	TT07C3Y
DMOFCRY	MN	5-HT 4 receptor (HTR4)
DMOFCRY	MT	DTT
DMOFCRY	MA	Inhibitor
DMOFCRY	RN	Brominated cyclodipeptides from the marine sponge Geodia barretti as selective 5-HT ligands. J Nat Prod. 2006 Oct;69(10):1421-4.
DMOFCRY	RU	https://pubmed.ncbi.nlm.nih.gov/17067154

DMOFCRY	DI	DMOFCRY
DMOFCRY	DN	Serotonin
DMOFCRY	MI	TTRUFDT
DMOFCRY	MN	5-HT 5A receptor (HTR5A)
DMOFCRY	MT	DTT
DMOFCRY	MA	Inhibitor
DMOFCRY	RN	Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69.
DMOFCRY	RU	https://pubmed.ncbi.nlm.nih.gov/18588282

DMOFCRY	DI	DMOFCRY
DMOFCRY	DN	Serotonin
DMOFCRY	MI	TTJS8PY
DMOFCRY	MN	5-HT 6 receptor (HTR6)
DMOFCRY	MT	DTT
DMOFCRY	MA	Inhibitor
DMOFCRY	RN	5-Cyclic amine-3-arylsulfonylindazoles as novel 5-HT6 receptor antagonists. J Med Chem. 2010 Mar 25;53(6):2521-7.
DMOFCRY	RU	https://pubmed.ncbi.nlm.nih.gov/20170099

DMOFCRY	DI	DMOFCRY
DMOFCRY	DN	Serotonin
DMOFCRY	MI	TTO9X1H
DMOFCRY	MN	5-HT 7 receptor (HTR7)
DMOFCRY	MT	DTT
DMOFCRY	MA	Inhibitor
DMOFCRY	RN	Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69.
DMOFCRY	RU	https://pubmed.ncbi.nlm.nih.gov/18588282

DMOFCRY	DI	DMOFCRY
DMOFCRY	DN	Serotonin
DMOFCRY	MI	TTJFY5U
DMOFCRY	MN	Adenosine A3 receptor (ADORA3)
DMOFCRY	MT	DTT
DMOFCRY	MA	Inhibitor
DMOFCRY	RN	2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96.
DMOFCRY	RU	https://pubmed.ncbi.nlm.nih.gov/16250647

DMOFCRY	DI	DMOFCRY
DMOFCRY	DN	Serotonin
DMOFCRY	MI	DT3EAQP
DMOFCRY	MN	Equilibrative nucleoside transporter 4 (SLC29A4)
DMOFCRY	MT	DTP
DMOFCRY	MA	Substrate
DMOFCRY	RN	Autism spectrum disorder associated with low serotonin in CSF and mutations in the SLC29A4 plasma membrane monoamine transporter (PMAT) gene. Mol Autism. 2014 Aug 13;5:43.
DMOFCRY	RU	http://www.ncbi.nlm.nih.gov/pubmed/25802735

DMOFCRY	DI	DMOFCRY
DMOFCRY	DN	Serotonin
DMOFCRY	MI	DERE4TU
DMOFCRY	MN	Monoamine oxidase type A (MAO-A)
DMOFCRY	MT	DME
DMOFCRY	MA	Metabolism
DMOFCRY	RN	Do monomeric vs dimeric forms of MAO-A make a difference? A direct comparison of the catalytic properties of rat and human MAO-A's. J Neural Transm (Vienna). 2007;114(6):721-4.
DMOFCRY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17401534

DMOFCRY	DI	DMOFCRY
DMOFCRY	DN	Serotonin
DMOFCRY	MI	DT9IDPW
DMOFCRY	MN	Organic cation transporter 2 (SLC22A2)
DMOFCRY	MT	DTP
DMOFCRY	MA	Substrate
DMOFCRY	RN	Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.
DMOFCRY	RU	http://www.ncbi.nlm.nih.gov/pubmed/16581093

DMOFCRY	DI	DMOFCRY
DMOFCRY	DN	Serotonin
DMOFCRY	MI	DTAV4SY
DMOFCRY	MN	Sodium-dependent serotonin transporter (SLC6A4)
DMOFCRY	MT	DTP
DMOFCRY	MA	Substrate
DMOFCRY	RN	Serotonin transporter gene, depressive symptoms, and interleukin-6. Circ Cardiovasc Genet. 2009 Dec;2(6):614-20.
DMOFCRY	RU	http://www.ncbi.nlm.nih.gov/pubmed/20031642

DMOFCRY	DI	DMOFCRY
DMOFCRY	DN	Serotonin
DMOFCRY	MI	DTM953D
DMOFCRY	MN	Vesicular amine transporter 1 (SLC18A1)
DMOFCRY	MT	DTP
DMOFCRY	MA	Substrate
DMOFCRY	RN	SLC18: Vesicular neurotransmitter transporters for monoamines and acetylcholine. Mol Aspects Med. 2013 Apr-Jun;34(2-3):360-72.
DMOFCRY	RU	http://www.ncbi.nlm.nih.gov/pubmed/23506877

DMOFCRY	DI	DMOFCRY
DMOFCRY	DN	Serotonin
DMOFCRY	MI	DTT7VPB
DMOFCRY	MN	Vesicular amine transporter 2 (SLC18A2)
DMOFCRY	MT	DTP
DMOFCRY	MA	Substrate
DMOFCRY	RN	SLC18: Vesicular neurotransmitter transporters for monoamines and acetylcholine. Mol Aspects Med. 2013 Apr-Jun;34(2-3):360-72.
DMOFCRY	RU	http://www.ncbi.nlm.nih.gov/pubmed/23506877

DMS509U	DI	DMS509U
DMS509U	DN	Ser-Tyr-Ser-Nle-Glu-His-Dphe-Arg
DMS509U	MI	TTD0CIQ
DMS509U	MN	Melanocortin receptor 4 (MC4R)
DMS509U	MT	DTT
DMS509U	MA	Inhibitor
DMS509U	RN	Squalene-derived flexible linkers for bioactive peptides. Bioorg Med Chem Lett. 2007 Jun 15;17(12):3310-3.
DMS509U	RU	https://pubmed.ncbi.nlm.nih.gov/17448660

DM49AYM	DI	DM49AYM
DM49AYM	DN	S-Ethyl-N-[4-(Trifluoromethyl)Phenyl]Isothiourea
DM49AYM	MI	TTZUFI5
DM49AYM	MN	Nitric-oxide synthase brain (NOS1)
DM49AYM	MT	DTT
DM49AYM	MA	Inhibitor
DM49AYM	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM49AYM	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM6DT9Z	DI	DM6DT9Z
DM6DT9Z	DN	S-Ethyl-N-Phenyl-Isothiourea
DM6DT9Z	MI	TTZUFI5
DM6DT9Z	MN	Nitric-oxide synthase brain (NOS1)
DM6DT9Z	MT	DTT
DM6DT9Z	MA	Inhibitor
DM6DT9Z	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM6DT9Z	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM6DT9Z	DI	DM6DT9Z
DM6DT9Z	DN	S-Ethyl-N-Phenyl-Isothiourea
DM6DT9Z	MI	TTCM4B3
DM6DT9Z	MN	Nitric-oxide synthase endothelial (NOS3)
DM6DT9Z	MT	DTT
DM6DT9Z	MA	Inhibitor
DM6DT9Z	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM6DT9Z	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMJBW7X	DI	DMJBW7X
DMJBW7X	DN	SEW2871
DMJBW7X	MI	TT9JZCK
DMJBW7X	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMJBW7X	MT	DTT
DMJBW7X	MA	Agonist
DMJBW7X	RN	Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem. 2004 Apr 2;279(14):13839-48.
DMJBW7X	RU	https://pubmed.ncbi.nlm.nih.gov/14732717

DMVI2H9	DI	DMVI2H9
DMVI2H9	DN	SF-11
DMVI2H9	MI	TT0NLAQ
DMVI2H9	MN	Mucolipin-3 (TRPML3)
DMVI2H9	MT	DTT
DMVI2H9	MA	Activator
DMVI2H9	RN	Small molecule activators of TRPML3. Chem Biol. 2010 Feb 26;17(2):135-48.
DMVI2H9	RU	https://pubmed.ncbi.nlm.nih.gov/20189104

DMI6SNQ	DI	DMI6SNQ
DMI6SNQ	DN	SF-21
DMI6SNQ	MI	TT0NLAQ
DMI6SNQ	MN	Mucolipin-3 (TRPML3)
DMI6SNQ	MT	DTT
DMI6SNQ	MA	Activator
DMI6SNQ	RN	Small molecule activators of TRPML3. Chem Biol. 2010 Feb 26;17(2):135-48.
DMI6SNQ	RU	https://pubmed.ncbi.nlm.nih.gov/20189104

DMH36A9	DI	DMH36A9
DMH36A9	DN	SF303
DMH36A9	MI	TTCIHJA
DMH36A9	MN	Coagulation factor Xa (F10)
DMH36A9	MT	DTT
DMH36A9	MA	Inhibitor
DMH36A9	RN	The design and synthesis of noncovalent factor Xa inhibitors. Curr Top Med Chem. 2001 Jun;1(2):137-49.
DMH36A9	RU	https://pubmed.ncbi.nlm.nih.gov/11899249

DMP35VS	DI	DMP35VS
DMP35VS	DN	SGC0946
DMP35VS	MI	TTSZ8T1
DMP35VS	MN	Histone-lysine N-methyltransferase (HLNM)
DMP35VS	MT	DTT
DMP35VS	MA	Inhibitor
DMP35VS	RN	Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat Commun. 2012;3:1288.
DMP35VS	RU	https://pubmed.ncbi.nlm.nih.gov/23250418

DMGINBT	DI	DMGINBT
DMGINBT	DN	SGC707
DMGINBT	MI	TTL4XSQ
DMGINBT	MN	Protein arginine methyltransferase 3 (PRMT3)
DMGINBT	MT	DTT
DMGINBT	MA	Modulator (allosteric modulator)
DMGINBT	RN	A potent, selective and cell-active allosteric inhibitor of protein arginine methyltransferase (PRMT3). Angew Chem Int Ed Engl. 2015 Apr 20;54(17):5166-70.
DMGINBT	RU	https://pubmed.ncbi.nlm.nih.gov/25728001

DMTLRGZ	DI	DMTLRGZ
DMTLRGZ	DN	SGC-CBP30
DMTLRGZ	MI	TTFRCTK
DMTLRGZ	MN	CREB-binding protein (CREBBP)
DMTLRGZ	MT	DTT
DMTLRGZ	MA	Inhibitor
DMTLRGZ	RN	Bromodomains and their pharmacological inhibitors. ChemMedChem. 2014 Mar;9(3):438-64.
DMTLRGZ	RU	https://pubmed.ncbi.nlm.nih.gov/24497428

DMTLRGZ	DI	DMTLRGZ
DMTLRGZ	DN	SGC-CBP30
DMTLRGZ	MI	TTH4VJL
DMTLRGZ	MN	Histone acetyltransferase KAT6B (KAT6B)
DMTLRGZ	MT	DTT
DMTLRGZ	MA	Inhibitor
DMTLRGZ	RN	Bromodomains and their pharmacological inhibitors. ChemMedChem. 2014 Mar;9(3):438-64.
DMTLRGZ	RU	https://pubmed.ncbi.nlm.nih.gov/24497428

DMZ20A5	DI	DMZ20A5
DMZ20A5	DN	SGI-1252
DMZ20A5	MI	TTRMX3V
DMZ20A5	MN	Janus kinase 2 (JAK-2)
DMZ20A5	MT	DTT
DMZ20A5	MA	Inhibitor
DMZ20A5	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2048).
DMZ20A5	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2048

DMW7E32	DI	DMW7E32
DMW7E32	DN	SHA 68
DMW7E32	MI	TTV1C0Z
DMW7E32	MN	Neuropeptide S receptor (NPSR)
DMW7E32	MT	DTT
DMW7E32	MA	Antagonist
DMW7E32	RN	Further studies on the pharmacological profile of the neuropeptide S receptor antagonist SHA 68. Peptides. 2010 May;31(5):915-25.
DMW7E32	RU	https://pubmed.ncbi.nlm.nih.gov/20172007

DMODS9A	DI	DMODS9A
DMODS9A	DN	S-hexyl hexane-1-sulfinothioate
DMODS9A	MI	TT2SUAQ
DMODS9A	MN	Cysteine protease (CYP)
DMODS9A	MT	DTT
DMODS9A	MA	Inhibitor
DMODS9A	RN	Allicin and derivates are cysteine protease inhibitors with antiparasitic activity. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5541-3.
DMODS9A	RU	https://pubmed.ncbi.nlm.nih.gov/20692829

DMNWP02	DI	DMNWP02
DMNWP02	DN	S-hexylglutathione
DMNWP02	MI	TTCYE56
DMNWP02	MN	Glutathione-dependent PGD synthase (HPGDS)
DMNWP02	MT	DTT
DMNWP02	MA	Inhibitor
DMNWP02	RN	Purification and catalytic properties of glutathione transferase from the hepatopancreas of crayfish macrobrachium vollenhovenii (herklots). J Biochem Mol Toxicol. 2004;18(6):332-44.
DMNWP02	RU	https://pubmed.ncbi.nlm.nih.gov/15674845

DMBE0CT	DI	DMBE0CT
DMBE0CT	DN	Shikimate-3-Phosphate
DMBE0CT	MI	TTB30PF
DMBE0CT	MN	Bacterial Phosphoshikimate1-carboxyvinyltransferase (Bact aroA)
DMBE0CT	MT	DTT
DMBE0CT	MA	Inhibitor
DMBE0CT	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMBE0CT	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMTKHR3	DI	DMTKHR3
DMTKHR3	DN	ShRNA molecule silencing DNAPK radiosensitizer
DMTKHR3	MI	TTK3PY9
DMTKHR3	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMTKHR3	MT	DTT
DMTKHR3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2800).
DMTKHR3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2800

DMT62LS	DI	DMT62LS
DMT62LS	DN	SHU9119
DMT62LS	MI	TTNI91K
DMT62LS	MN	Melanocortin receptor 3 (MC3R)
DMT62LS	MT	DTT
DMT62LS	MA	Antagonist
DMT62LS	RN	Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis. Arthritis Rheum. 2002 Oct;46(10):2765-75.
DMT62LS	RU	https://pubmed.ncbi.nlm.nih.gov/12384937

DMAEY9X	DI	DMAEY9X
DMAEY9X	DN	Sialic acid
DMAEY9X	MI	DE3OGM0
DMAEY9X	MN	N-acetylneuraminate lyase (nanA)
DMAEY9X	MT	DME
DMAEY9X	MA	Metabolism
DMAEY9X	RN	Crystal structures and kinetics of N-acetylneuraminate lyase from Fusobacterium nucleatum. Acta Crystallogr F Struct Biol Commun. 2018 Nov 1;74(Pt 11):725-732.
DMAEY9X	RU	https://pubmed.ncbi.nlm.nih.gov/30387778

DMR5FD9	DI	DMR5FD9
DMR5FD9	DN	Sib-1533A
DMR5FD9	MI	TTMT0HG
DMR5FD9	MN	Neuronal acetylcholine receptor alpha-2/alpha-3 (CHRNA2/A3)
DMR5FD9	MT	DTT
DMR5FD9	MA	Agonist
DMR5FD9	RN	Nicotine, brain nicotinic receptors, and neuropsychiatric disorders. Arch Med Res. 2000 Mar-Apr;31(2):131-44.
DMR5FD9	RU	https://pubmed.ncbi.nlm.nih.gov/10880717

DMFOGE2	DI	DMFOGE2
DMFOGE2	DN	SIB-1757
DMFOGE2	MI	TTHS256
DMFOGE2	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMFOGE2	MT	DTT
DMFOGE2	MA	Inhibitor
DMFOGE2	RN	Design and synthesis of noncompetitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3371-5.
DMFOGE2	RU	https://pubmed.ncbi.nlm.nih.gov/16678408

DMAVBKP	DI	DMAVBKP
DMAVBKP	DN	SIB-1893
DMAVBKP	MI	TTHS256
DMAVBKP	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMAVBKP	MT	DTT
DMAVBKP	MA	Inhibitor
DMAVBKP	RN	Design and synthesis of noncompetitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3371-5.
DMAVBKP	RU	https://pubmed.ncbi.nlm.nih.gov/16678408

DMEIBTY	DI	DMEIBTY
DMEIBTY	DN	SIDEROXYLONAL A
DMEIBTY	MI	TTTO43N
DMEIBTY	MN	Endothelial plasminogen activator inhibitor (SERPINE1)
DMEIBTY	MT	DTT
DMEIBTY	MA	Inhibitor
DMEIBTY	RN	Sideroxylonal C, a new inhibitor of human plasminogen activator inhibitor type-1, from the flowers of Eucalyptus albens. J Nat Prod. 1999 Feb;62(2):324-6.
DMEIBTY	RU	https://pubmed.ncbi.nlm.nih.gov/10075775

DMDP7Y5	DI	DMDP7Y5
DMDP7Y5	DN	SIDEROXYLONAL B
DMDP7Y5	MI	TTTO43N
DMDP7Y5	MN	Endothelial plasminogen activator inhibitor (SERPINE1)
DMDP7Y5	MT	DTT
DMDP7Y5	MA	Inhibitor
DMDP7Y5	RN	Sideroxylonal C, a new inhibitor of human plasminogen activator inhibitor type-1, from the flowers of Eucalyptus albens. J Nat Prod. 1999 Feb;62(2):324-6.
DMDP7Y5	RU	https://pubmed.ncbi.nlm.nih.gov/10075775

DMSGNM1	DI	DMSGNM1
DMSGNM1	DN	Sideroxylonal C
DMSGNM1	MI	TTTO43N
DMSGNM1	MN	Endothelial plasminogen activator inhibitor (SERPINE1)
DMSGNM1	MT	DTT
DMSGNM1	MA	Inhibitor
DMSGNM1	RN	Sideroxylonal C, a new inhibitor of human plasminogen activator inhibitor type-1, from the flowers of Eucalyptus albens. J Nat Prod. 1999 Feb;62(2):324-6.
DMSGNM1	RU	https://pubmed.ncbi.nlm.nih.gov/10075775

DMB70NK	DI	DMB70NK
DMB70NK	DN	SIGMOIDIN A
DMB70NK	MI	TTELIN2
DMB70NK	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMB70NK	MT	DTT
DMB70NK	MA	Inhibitor
DMB70NK	RN	Isoprenylated flavonoids from the stem bark of Erythrina abyssinica. J Nat Prod. 2007 Jun;70(6):1039-42.
DMB70NK	RU	https://pubmed.ncbi.nlm.nih.gov/17489632

DMVH5WK	DI	DMVH5WK
DMVH5WK	DN	SIGMOIDIN B
DMVH5WK	MI	TTELIN2
DMVH5WK	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMVH5WK	MT	DTT
DMVH5WK	MA	Inhibitor
DMVH5WK	RN	Isoprenylated flavonoids from the stem bark of Erythrina abyssinica. J Nat Prod. 2007 Jun;70(6):1039-42.
DMVH5WK	RU	https://pubmed.ncbi.nlm.nih.gov/17489632

DM8E62L	DI	DM8E62L
DM8E62L	DN	Sigmoidin F
DM8E62L	MI	TTELIN2
DM8E62L	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DM8E62L	MT	DTT
DM8E62L	MA	Inhibitor
DM8E62L	RN	Isoprenylated flavonoids from the stem bark of Erythrina abyssinica. J Nat Prod. 2007 Jun;70(6):1039-42.
DM8E62L	RU	https://pubmed.ncbi.nlm.nih.gov/17489632

DM4VDMP	DI	DM4VDMP
DM4VDMP	DN	silahexocyclium
DM4VDMP	MI	TTOXS3C
DM4VDMP	MN	Muscarinic acetylcholine receptor (CHRM)
DM4VDMP	MT	DTT
DM4VDMP	MA	Antagonist
DM4VDMP	RN	Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol Pharmacol. 1989 Apr;35(4):469-76.
DM4VDMP	RU	https://pubmed.ncbi.nlm.nih.gov/2704370

DM4VDMP	DI	DM4VDMP
DM4VDMP	DN	silahexocyclium
DM4VDMP	MI	TTQ13Z5
DM4VDMP	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DM4VDMP	MT	DTT
DM4VDMP	MA	Antagonist
DM4VDMP	RN	Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol Pharmacol. 1989 Apr;35(4):469-76.
DM4VDMP	RU	https://pubmed.ncbi.nlm.nih.gov/2704370

DM5ZILV	DI	DM5ZILV
DM5ZILV	DN	Silicon-modified indomethacin
DM5ZILV	MI	TTVKILB
DM5ZILV	MN	Prostaglandin G/H synthase 2 (COX-2)
DM5ZILV	MT	DTT
DM5ZILV	MA	Inhibitor
DM5ZILV	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1376).
DM5ZILV	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1376

DMQIBZD	DI	DMQIBZD
DMQIBZD	DN	Silmitasertib
DMQIBZD	MI	TTDT8RP
DMQIBZD	MN	HUMAN casein kinase II (CSK2)
DMQIBZD	MT	DTT
DMQIBZD	MA	Inhibitor
DMQIBZD	RN	News report, company report or official report of Senhwa Biosciences, Inc. Senhwa Biosciences Silmitasertib Named as Potential COVID-19 Therapy. 2020 March 31.
DMQIBZD	RU	https://www.ptcommunity.com/wire/senhwa-biosciences-silmitasertib-named-potential-covid-19-therapy

DM5JKNF	DI	DM5JKNF
DM5JKNF	DN	Silvestrol
DM5JKNF	MI	TTIGYVZ
DM5JKNF	MN	HUMAN eukaryotic initiation factor-4A (eIF4A)
DM5JKNF	MT	DTT
DM5JKNF	MA	Inhibitor
DM5JKNF	RN	Broad-spectrum antiviral activity of the eIF4A inhibitor silvestrol against corona- and picornaviruses. Antiviral Res. 2018 Feb;150:123-129.
DM5JKNF	RU	https://pubmed.ncbi.nlm.nih.gov/29258862

DMS7EHF	DI	DMS7EHF
DMS7EHF	DN	Silvestrol
DMS7EHF	MI	DTUGYRD
DMS7EHF	MN	P-glycoprotein 1 (ABCB1)
DMS7EHF	MT	DTP
DMS7EHF	MA	Substrate
DMS7EHF	RN	Resistance to the translation initiation inhibitor silvestrol is mediated by ABCB1/P-glycoprotein overexpression in acute lymphoblastic leukemia cells. AAPS J. 2011 Sep;13(3):357-64.
DMS7EHF	RU	https://doi.org/10.1208/s12248-011-9276-7

DM3LDFB	DI	DM3LDFB
DM3LDFB	DN	Simoctocog alfa
DM3LDFB	MI	TT1290U
DM3LDFB	MN	Coagulation factor VIII (F8)
DM3LDFB	MT	DTT
DM3LDFB	MA	Modulator
DM3LDFB	RN	A new recombinant factor VIII: from genetics to clinical use
DM3LDFB	RU	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517516

DMNWM8H	DI	DMNWM8H
DMNWM8H	DN	Sinefungin
DMNWM8H	MI	TTFHEWL
DMNWM8H	MN	Streptomyces RNA methyltransferase (Stre-myc carB)
DMNWM8H	MT	DTT
DMNWM8H	MA	Inhibitor
DMNWM8H	RN	The effect of sinefungin and synthetic analogues on RNA and DNA methyltransferases from Streptomyces. J Antibiot (Tokyo). 1991 Oct;44(10):1141-7.
DMNWM8H	RU	https://pubmed.ncbi.nlm.nih.gov/1720117

DM1NXFL	DI	DM1NXFL
DM1NXFL	DN	S-isopentyl 3-methylbutane-1-sulfinothioate
DM1NXFL	MI	TT2SUAQ
DM1NXFL	MN	Cysteine protease (CYP)
DM1NXFL	MT	DTT
DM1NXFL	MA	Inhibitor
DM1NXFL	RN	Allicin and derivates are cysteine protease inhibitors with antiparasitic activity. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5541-3.
DM1NXFL	RU	https://pubmed.ncbi.nlm.nih.gov/20692829

DMZ30AM	DI	DMZ30AM
DMZ30AM	DN	S-Isopropyl-Isothiourea
DMZ30AM	MI	TTCM4B3
DMZ30AM	MN	Nitric-oxide synthase endothelial (NOS3)
DMZ30AM	MT	DTT
DMZ30AM	MA	Inhibitor
DMZ30AM	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMZ30AM	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMCMIUG	DI	DMCMIUG
DMCMIUG	DN	SITS
DMCMIUG	MI	TTOJI4S
DMCMIUG	MN	Calcium-dependent chloride channel anoctamin (ANO)
DMCMIUG	MT	DTT
DMCMIUG	MA	Blocker (channel blocker)
DMCMIUG	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 708).
DMCMIUG	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=708

DMCMIUG	DI	DMCMIUG
DMCMIUG	DN	SITS
DMCMIUG	MI	TTST1AJ
DMCMIUG	MN	Chloride channel protein 7 (ClC-7)
DMCMIUG	MT	DTT
DMCMIUG	MA	Blocker (channel blocker)
DMCMIUG	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 709).
DMCMIUG	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=709

DMEQBU2	DI	DMEQBU2
DMEQBU2	DN	SJ-8002
DMEQBU2	MI	TTPF2QI
DMEQBU2	MN	Caspase-3 (CASP3)
DMEQBU2	MT	DTT
DMEQBU2	MA	Inhibitor
DMEQBU2	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1619).
DMEQBU2	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1619

DMU1P3T	DI	DMU1P3T
DMU1P3T	DN	SK&F 107649
DMU1P3T	MI	TT2J34L
DMU1P3T	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMU1P3T	MT	DTT
DMU1P3T	MA	Inhibitor
DMU1P3T	RN	Selective inhibition of 5-lipoxygenase attenuates glomerulonephritis in the rat. Kidney Int. 1994 May;45(5):1301-10.
DMU1P3T	RU	https://pubmed.ncbi.nlm.nih.gov/8072241

DMYRKEJ	DI	DMYRKEJ
DMYRKEJ	DN	SK&F-105854
DMYRKEJ	MI	TTNGILX
DMYRKEJ	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMYRKEJ	MT	DTT
DMYRKEJ	MA	Inhibitor
DMYRKEJ	RN	Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
DMYRKEJ	RU	https://pubmed.ncbi.nlm.nih.gov/15664832

DMYRKEJ	DI	DMYRKEJ
DMYRKEJ	DN	SK&F-105854
DMYRKEJ	MI	TTBRKXS
DMYRKEJ	MN	Adrenergic receptor alpha-1B (ADRA1B)
DMYRKEJ	MT	DTT
DMYRKEJ	MA	Inhibitor
DMYRKEJ	RN	Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
DMYRKEJ	RU	https://pubmed.ncbi.nlm.nih.gov/7562902

DMYRKEJ	DI	DMYRKEJ
DMYRKEJ	DN	SK&F-105854
DMYRKEJ	MI	TT34BHT
DMYRKEJ	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMYRKEJ	MT	DTT
DMYRKEJ	MA	Inhibitor
DMYRKEJ	RN	Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
DMYRKEJ	RU	https://pubmed.ncbi.nlm.nih.gov/7562902

DMHETY7	DI	DMHETY7
DMHETY7	DN	SK&F-106686
DMHETY7	MI	TTNGILX
DMHETY7	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMHETY7	MT	DTT
DMHETY7	MA	Inhibitor
DMHETY7	RN	Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
DMHETY7	RU	https://pubmed.ncbi.nlm.nih.gov/7562902

DMHETY7	DI	DMHETY7
DMHETY7	DN	SK&F-106686
DMHETY7	MI	TTBRKXS
DMHETY7	MN	Adrenergic receptor alpha-1B (ADRA1B)
DMHETY7	MT	DTT
DMHETY7	MA	Inhibitor
DMHETY7	RN	Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
DMHETY7	RU	https://pubmed.ncbi.nlm.nih.gov/7562902

DMHETY7	DI	DMHETY7
DMHETY7	DN	SK&F-106686
DMHETY7	MI	TT34BHT
DMHETY7	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMHETY7	MT	DTT
DMHETY7	MA	Inhibitor
DMHETY7	RN	Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
DMHETY7	RU	https://pubmed.ncbi.nlm.nih.gov/7562902

DM2KFQ5	DI	DM2KFQ5
DM2KFQ5	DN	SK&F-29661
DM2KFQ5	MI	TTWG9A4
DM2KFQ5	MN	Adrenergic receptor alpha-2A (ADRA2A)
DM2KFQ5	MT	DTT
DM2KFQ5	MA	Inhibitor
DM2KFQ5	RN	Exploring the active site of phenylethanolamine N-methyltransferase with 3-hydroxyethyl- and 3-hydroxypropyl-7-substituted-1,2,3,4-tetrahydroisoqui... Bioorg Med Chem Lett. 2005 Feb 15;15(4):1143-7.
DM2KFQ5	RU	https://pubmed.ncbi.nlm.nih.gov/15686930

DM60Y3Q	DI	DM60Y3Q
DM60Y3Q	DN	SK&F-64139
DM60Y3Q	MI	TTWG9A4
DM60Y3Q	MN	Adrenergic receptor alpha-2A (ADRA2A)
DM60Y3Q	MT	DTT
DM60Y3Q	MA	Inhibitor
DM60Y3Q	RN	Comparison of the binding of 3-fluoromethyl-7-sulfonyl-1,2,3,4-tetrahydroisoquinolines with their isosteric sulfonamides to the active site of phen... J Med Chem. 2006 Sep 7;49(18):5424-33.
DM60Y3Q	RU	https://pubmed.ncbi.nlm.nih.gov/16942016

DM60Y3Q	DI	DM60Y3Q
DM60Y3Q	DN	SK&F-64139
DM60Y3Q	MI	TTWM4TY
DM60Y3Q	MN	Adrenergic receptor alpha-2B (ADRA2B)
DM60Y3Q	MT	DTT
DM60Y3Q	MA	Inhibitor
DM60Y3Q	RN	Comparison of the binding of 3-fluoromethyl-7-sulfonyl-1,2,3,4-tetrahydroisoquinolines with their isosteric sulfonamides to the active site of phen... J Med Chem. 2006 Sep 7;49(18):5424-33.
DM60Y3Q	RU	https://pubmed.ncbi.nlm.nih.gov/16942016

DM60Y3Q	DI	DM60Y3Q
DM60Y3Q	DN	SK&F-64139
DM60Y3Q	MI	TT2NUT5
DM60Y3Q	MN	Adrenergic receptor alpha-2C (ADRA2C)
DM60Y3Q	MT	DTT
DM60Y3Q	MA	Inhibitor
DM60Y3Q	RN	Comparison of the binding of 3-fluoromethyl-7-sulfonyl-1,2,3,4-tetrahydroisoquinolines with their isosteric sulfonamides to the active site of phen... J Med Chem. 2006 Sep 7;49(18):5424-33.
DM60Y3Q	RU	https://pubmed.ncbi.nlm.nih.gov/16942016

DM4RHEZ	DI	DM4RHEZ
DM4RHEZ	DN	SK&F-86466
DM4RHEZ	MI	TTNGILX
DM4RHEZ	MN	Adrenergic receptor alpha-1A (ADRA1A)
DM4RHEZ	MT	DTT
DM4RHEZ	MA	Inhibitor
DM4RHEZ	RN	Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
DM4RHEZ	RU	https://pubmed.ncbi.nlm.nih.gov/7562902

DM4RHEZ	DI	DM4RHEZ
DM4RHEZ	DN	SK&F-86466
DM4RHEZ	MI	TTBRKXS
DM4RHEZ	MN	Adrenergic receptor alpha-1B (ADRA1B)
DM4RHEZ	MT	DTT
DM4RHEZ	MA	Inhibitor
DM4RHEZ	RN	Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
DM4RHEZ	RU	https://pubmed.ncbi.nlm.nih.gov/7562902

DM4RHEZ	DI	DM4RHEZ
DM4RHEZ	DN	SK&F-86466
DM4RHEZ	MI	TT34BHT
DM4RHEZ	MN	Adrenergic receptor alpha-1D (ADRA1D)
DM4RHEZ	MT	DTT
DM4RHEZ	MA	Inhibitor
DM4RHEZ	RN	Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
DM4RHEZ	RU	https://pubmed.ncbi.nlm.nih.gov/7562902

DM3SUKX	DI	DM3SUKX
DM3SUKX	DN	SK&F-89626
DM3SUKX	MI	TTZFYLI
DM3SUKX	MN	Dopamine D1 receptor (D1R)
DM3SUKX	MT	DTT
DM3SUKX	MA	Inhibitor
DM3SUKX	RN	trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist. J Med Chem. 1990 Jun;33(6):1756-64.
DM3SUKX	RU	https://pubmed.ncbi.nlm.nih.gov/1971308

DM3SUKX	DI	DM3SUKX
DM3SUKX	DN	SK&F-89626
DM3SUKX	MI	TTEX248
DM3SUKX	MN	Dopamine D2 receptor (D2R)
DM3SUKX	MT	DTT
DM3SUKX	MA	Inhibitor
DM3SUKX	RN	trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist. J Med Chem. 1990 Jun;33(6):1756-64.
DM3SUKX	RU	https://pubmed.ncbi.nlm.nih.gov/1971308

DMMYX7C	DI	DMMYX7C
DMMYX7C	DN	SK1-I
DMMYX7C	MI	TTOHFIY
DMMYX7C	MN	Sphingosine kinase 1 (SPHK1)
DMMYX7C	MT	DTT
DMMYX7C	MA	Inhibitor
DMMYX7C	RN	A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. Blood. 2008 Aug 15;112(4):1382-91.
DMMYX7C	RU	https://pubmed.ncbi.nlm.nih.gov/18511810

DM73SC6	DI	DM73SC6
DM73SC6	DN	SK509
DM73SC6	MI	TTJVCG0
DM73SC6	MN	Bacterial Sporulation kinase A (Bact kinA)
DM73SC6	MT	DTT
DM73SC6	MA	Inhibitor
DM73SC6	RN	Histidine kinases as targets for new antimicrobial agents. Bioorg Med Chem. 2002 Apr;10(4):855-67.
DM73SC6	RU	https://pubmed.ncbi.nlm.nih.gov/11836091

DM73SC6	DI	DM73SC6
DM73SC6	DN	SK509
DM73SC6	MI	TTCIHJA
DM73SC6	MN	Coagulation factor Xa (F10)
DM73SC6	MT	DTT
DM73SC6	MA	Inhibitor
DM73SC6	RN	The design and synthesis of noncovalent factor Xa inhibitors. Curr Top Med Chem. 2001 Jun;1(2):137-49.
DM73SC6	RU	https://pubmed.ncbi.nlm.nih.gov/11899249

DMK1OP2	DI	DMK1OP2
DMK1OP2	DN	SK549
DMK1OP2	MI	TTCIHJA
DMK1OP2	MN	Coagulation factor Xa (F10)
DMK1OP2	MT	DTT
DMK1OP2	MA	Inhibitor
DMK1OP2	RN	Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 2. J Med Chem. 1999 Jul 29;42(15):2760-73.
DMK1OP2	RU	https://pubmed.ncbi.nlm.nih.gov/10425087

DMUTBZ8	DI	DMUTBZ8
DMUTBZ8	DN	SK554
DMUTBZ8	MI	TTCIHJA
DMUTBZ8	MN	Coagulation factor Xa (F10)
DMUTBZ8	MT	DTT
DMUTBZ8	MA	Inhibitor
DMUTBZ8	RN	Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci. 2002 Jan;23(1):25-32.
DMUTBZ8	RU	https://pubmed.ncbi.nlm.nih.gov/11804648

DMM32CF	DI	DMM32CF
DMM32CF	DN	SK-683
DMM32CF	MI	TT6R7JZ
DMM32CF	MN	Histone deacetylase 1 (HDAC1)
DMM32CF	MT	DTT
DMM32CF	MA	Inhibitor
DMM32CF	RN	On the function of the 14 A long internal cavity of histone deacetylase-like protein: implications for the design of histone deacetylase inhibitors. J Med Chem. 2004 Jun 17;47(13):3409-17.
DMM32CF	RU	https://pubmed.ncbi.nlm.nih.gov/15189037

DMBL7YN	DI	DMBL7YN
DMBL7YN	DN	SKA-121
DMBL7YN	MI	TT7M9I6
DMBL7YN	MN	Calcium-activated potassium channel KCa3.1 (KCNN4)
DMBL7YN	MT	DTT
DMBL7YN	MA	Activator
DMBL7YN	RN	New positive Ca2+-activated K+ channel gating modulators with selectivity for KCa3.1. Mol Pharmacol. 2014 Sep;86(3):342-57.
DMBL7YN	RU	https://pubmed.ncbi.nlm.nih.gov/24958817

DMX34F1	DI	DMX34F1
DMX34F1	DN	SKA-31
DMX34F1	MI	TT7M9I6
DMX34F1	MN	Calcium-activated potassium channel KCa3.1 (KCNN4)
DMX34F1	MT	DTT
DMX34F1	MA	Activator
DMX34F1	RN	Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure. Mol Pharmacol. 2009 Feb;75(2):281-95.
DMX34F1	RU	https://pubmed.ncbi.nlm.nih.gov/18955585

DMWODHR	DI	DMWODHR
DMWODHR	DN	SKF 89748
DMWODHR	MI	TT2NUT5
DMWODHR	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMWODHR	MT	DTT
DMWODHR	MA	Agonist
DMWODHR	RN	Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes. Mol Pharmacol. 1994 Nov;46(5):929-36.
DMWODHR	RU	https://pubmed.ncbi.nlm.nih.gov/7969082

DMQ6YXF	DI	DMQ6YXF
DMQ6YXF	DN	SKF-75670
DMQ6YXF	MI	TTZFYLI
DMQ6YXF	MN	Dopamine D1 receptor (D1R)
DMQ6YXF	MT	DTT
DMQ6YXF	MA	Agonist
DMQ6YXF	RN	Dopamine receptor agonists: selectivity and dopamine D1 receptor efficacy. Eur J Pharmacol. 1990 Jun 12;188(6):335-47.
DMQ6YXF	RU	https://pubmed.ncbi.nlm.nih.gov/1973652

DMCMQH8	DI	DMCMQH8
DMCMQH8	DN	SKF-83556
DMCMQH8	MI	TTZFYLI
DMCMQH8	MN	Dopamine D1 receptor (D1R)
DMCMQH8	MT	DTT
DMCMQH8	MA	Antagonist
DMCMQH8	RN	Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature. 1991 Apr 18;350(6319):614-9.
DMCMQH8	RU	https://pubmed.ncbi.nlm.nih.gov/1826762

DMCMQH8	DI	DMCMQH8
DMCMQH8	DN	SKF-83556
DMCMQH8	MI	TTS2PH3
DMCMQH8	MN	Dopamine D5 receptor (D5R)
DMCMQH8	MT	DTT
DMCMQH8	MA	Antagonist
DMCMQH8	RN	Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature. 1991 Apr 18;350(6319):614-9.
DMCMQH8	RU	https://pubmed.ncbi.nlm.nih.gov/1826762

DMWC6RU	DI	DMWC6RU
DMWC6RU	DN	SKF-83959
DMWC6RU	MI	TTZFYLI
DMWC6RU	MN	Dopamine D1 receptor (D1R)
DMWC6RU	MT	DTT
DMWC6RU	MA	Agonist
DMWC6RU	RN	Identification of G protein-biased agonists that fail to recruit beta-arrestin or promote internalization of the D1 dopamine receptor. ACS Chem Neurosci. 2015 Apr 15;6(4):681-92.
DMWC6RU	RU	https://pubmed.ncbi.nlm.nih.gov/25660762

DMNUQ9P	DI	DMNUQ9P
DMNUQ9P	DN	SKF-89124A
DMNUQ9P	MI	TTEX248
DMNUQ9P	MN	Dopamine D2 receptor (D2R)
DMNUQ9P	MT	DTT
DMNUQ9P	MA	Inhibitor
DMNUQ9P	RN	Synthesis and evaluation of non-catechol D-1 and D-2 dopamine receptor agonists: benzimidazol-2-one, benzoxazol-2-one, and the highly potent benzot... J Med Chem. 1987 Jul;30(7):1166-76.
DMNUQ9P	RU	https://pubmed.ncbi.nlm.nih.gov/2955118

DM0WNHQ	DI	DM0WNHQ
DM0WNHQ	DN	SKF89976A
DM0WNHQ	MI	TTPRKM0
DM0WNHQ	MN	GABA transporter GAT-1 (SLC6A1)
DM0WNHQ	MT	DTT
DM0WNHQ	MA	Inhibitor
DM0WNHQ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 929).
DM0WNHQ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=929

DMJL6HX	DI	DMJL6HX
DMJL6HX	DN	SKI-2852
DMJL6HX	MI	TTN7BL9
DMJL6HX	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMJL6HX	MT	DTT
DMJL6HX	MA	Inhibitor
DMJL6HX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2763).
DMJL6HX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2763

DMXS9V8	DI	DMXS9V8
DMXS9V8	DN	SKL-18287
DMXS9V8	MI	TTVIMDE
DMXS9V8	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMXS9V8	MT	DTT
DMXS9V8	MA	Modulator
DMXS9V8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249).
DMXS9V8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=249

DM5T4Y1	DI	DM5T4Y1
DM5T4Y1	DN	SKL-19014
DM5T4Y1	MI	TTDLNGZ
DM5T4Y1	MN	Glucokinase (GCK)
DM5T4Y1	MT	DTT
DM5T4Y1	MA	Activator
DM5T4Y1	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2798).
DM5T4Y1	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2798

DMUVAFO	DI	DMUVAFO
DMUVAFO	DN	SKLB-010
DMUVAFO	MI	TTF10I9
DMUVAFO	MN	Nitric-oxide synthase inducible (NOS2)
DMUVAFO	MT	DTT
DMUVAFO	MA	Modulator
DMUVAFO	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1250).
DMUVAFO	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1250

DM4X2GH	DI	DM4X2GH
DM4X2GH	DN	SKL-PD
DM4X2GH	MI	TTGP7BY
DM4X2GH	MN	Monoamine oxidase type B (MAO-B)
DM4X2GH	MT	DTT
DM4X2GH	MA	Inhibitor
DM4X2GH	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2490).
DM4X2GH	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2490

DMGQ9Z5	DI	DMGQ9Z5
DMGQ9Z5	DN	SKS-927
DMGQ9Z5	MI	TT6PKBN
DMGQ9Z5	MN	Proto-oncogene c-Src (SRC)
DMGQ9Z5	MT	DTT
DMGQ9Z5	MA	Inhibitor
DMGQ9Z5	RN	Inhibition of Src kinase activity by 7-ethynyl-4-phenylamino-3-quinolinecarbonitriles: identification of SKS-927. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1358-61.
DMGQ9Z5	RU	https://pubmed.ncbi.nlm.nih.gov/17188862

DMEIZ20	DI	DMEIZ20
DMEIZ20	DN	SL125
DMEIZ20	MI	TTIQUX7
DMEIZ20	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMEIZ20	MT	DTT
DMEIZ20	MA	Inhibitor
DMEIZ20	RN	Reduction of cell proliferation induced by PD166866: an inhibitor of the basic fibroblast growth factor. J Exp Clin Cancer Res. 2007 Sep;26(3):405-9.
DMEIZ20	RU	https://pubmed.ncbi.nlm.nih.gov/17987803

DM0UE28	DI	DM0UE28
DM0UE28	DN	SL-3111
DM0UE28	MI	TTKWM86
DM0UE28	MN	Opioid receptor mu (MOP)
DM0UE28	MT	DTT
DM0UE28	MA	Inhibitor
DM0UE28	RN	Exploring the structure-activity relationships of [1-(4-tert-butyl-3'-hydroxy)benzhydryl-4-benzylpiperazine] (SL-3111), a high-affinity and selecti... J Med Chem. 1999 Dec 30;42(26):5359-68.
DM0UE28	RU	https://pubmed.ncbi.nlm.nih.gov/10639279

DMYJV4I	DI	DMYJV4I
DMYJV4I	DN	SL-327
DMYJV4I	MI	TTROQ37
DMYJV4I	MN	MAPK/ERK kinase kinase (MAP3K)
DMYJV4I	MT	DTT
DMYJV4I	MA	Inhibitor
DMYJV4I	RN	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
DMYJV4I	RU	https://pubmed.ncbi.nlm.nih.gov/18077363

DM3I2US	DI	DM3I2US
DM3I2US	DN	SL422
DM3I2US	MI	TTHY57M
DM3I2US	MN	Matrix metalloproteinase-13 (MMP-13)
DM3I2US	MT	DTT
DM3I2US	MA	Inhibitor
DM3I2US	RN	Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo. J Med Chem. 2001 Aug 2;44(16):2636-60.
DM3I2US	RU	https://pubmed.ncbi.nlm.nih.gov/11472217

DM3I2US	DI	DM3I2US
DM3I2US	DN	SL422
DM3I2US	MI	TTNSTO3
DM3I2US	MN	Matrix metalloproteinase-15 (MMP-15)
DM3I2US	MT	DTT
DM3I2US	MA	Inhibitor
DM3I2US	RN	Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo. J Med Chem. 2001 Aug 2;44(16):2636-60.
DM3I2US	RU	https://pubmed.ncbi.nlm.nih.gov/11472217

DM3I2US	DI	DM3I2US
DM3I2US	DN	SL422
DM3I2US	MI	TTNP4CU
DM3I2US	MN	Matrix metalloproteinase-16 (MMP-16)
DM3I2US	MT	DTT
DM3I2US	MA	Inhibitor
DM3I2US	RN	Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo. J Med Chem. 2001 Aug 2;44(16):2636-60.
DM3I2US	RU	https://pubmed.ncbi.nlm.nih.gov/11472217

DM3I2US	DI	DM3I2US
DM3I2US	DN	SL422
DM3I2US	MI	TTMTWOS
DM3I2US	MN	Matrix metalloproteinase-7 (MMP-7)
DM3I2US	MT	DTT
DM3I2US	MA	Inhibitor
DM3I2US	RN	Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo. J Med Chem. 2001 Aug 2;44(16):2636-60.
DM3I2US	RU	https://pubmed.ncbi.nlm.nih.gov/11472217

DM3I2US	DI	DM3I2US
DM3I2US	DN	SL422
DM3I2US	MI	TTGA1IV
DM3I2US	MN	Matrix metalloproteinase-8 (MMP-8)
DM3I2US	MT	DTT
DM3I2US	MA	Inhibitor
DM3I2US	RN	Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo. J Med Chem. 2001 Aug 2;44(16):2636-60.
DM3I2US	RU	https://pubmed.ncbi.nlm.nih.gov/11472217

DM3I2US	DI	DM3I2US
DM3I2US	DN	SL422
DM3I2US	MI	TT6X50U
DM3I2US	MN	Matrix metalloproteinase-9 (MMP-9)
DM3I2US	MT	DTT
DM3I2US	MA	Inhibitor
DM3I2US	RN	Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo. J Med Chem. 2001 Aug 2;44(16):2636-60.
DM3I2US	RU	https://pubmed.ncbi.nlm.nih.gov/11472217

DM3I2US	DI	DM3I2US
DM3I2US	DN	SL422
DM3I2US	MI	TT6AZXG
DM3I2US	MN	TNF alpha converting enzyme (ADAM17)
DM3I2US	MT	DTT
DM3I2US	MA	Inhibitor
DM3I2US	RN	Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo. J Med Chem. 2001 Aug 2;44(16):2636-60.
DM3I2US	RU	https://pubmed.ncbi.nlm.nih.gov/11472217

DMEBPCO	DI	DMEBPCO
DMEBPCO	DN	SLG
DMEBPCO	MI	TTRBT3W
DMEBPCO	MN	Short transient receptor potential channel 6 (TRPC6)
DMEBPCO	MT	DTT
DMEBPCO	MA	Activator
DMEBPCO	RN	Direct activation of human TRPC6 and TRPC3 channels by diacylglycerol. Nature. 1999 Jan 21;397(6716):259-63.
DMEBPCO	RU	https://pubmed.ncbi.nlm.nih.gov/9930701

DMBD6TC	DI	DMBD6TC
DMBD6TC	DN	slotoxin
DMBD6TC	MI	TT1AQ50
DMBD6TC	MN	Charybdotoxin receptor beta-4 (BKbeta4)
DMBD6TC	MT	DTT
DMBD6TC	MA	Blocker (channel blocker)
DMBD6TC	RN	Slotoxin, alphaKTx1.11, a new scorpion peptide blocker of MaxiK channels that differentiates between alpha and alpha+beta (beta1 or beta4) complexes. FEBS Lett. 2001 Sep 21;505(3):369-73.
DMBD6TC	RU	https://pubmed.ncbi.nlm.nih.gov/11576530

DMPETL7	DI	DMPETL7
DMPETL7	DN	SLV-314
DMPETL7	MI	TTEX248
DMPETL7	MN	Dopamine D2 receptor (D2R)
DMPETL7	MT	DTT
DMPETL7	MA	Inhibitor
DMPETL7	RN	Synthesis, structure-activity relationships, and biological properties of 1-heteroaryl-4-[omega-(1H-indol-3-yl)alkyl]piperazines, novel potential a... J Med Chem. 2005 Nov 3;48(22):6855-69.
DMPETL7	RU	https://pubmed.ncbi.nlm.nih.gov/16250644

DM7MSGK	DI	DM7MSGK
DM7MSGK	DN	SM 21
DM7MSGK	MI	TT9NXW4
DM7MSGK	MN	Sigma intracellular receptor 2 (TMEM97)
DM7MSGK	MT	DTT
DM7MSGK	MA	Antagonist
DM7MSGK	RN	The analgesic tropane analogue (+/-)-SM 21 has a high affinity for sigma2 receptors. Life Sci. 1999;64(10):PL131-7.
DM7MSGK	RU	https://pubmed.ncbi.nlm.nih.gov/10096443

DMC7YQE	DI	DMC7YQE
DMC7YQE	DN	SM-122
DMC7YQE	MI	TTAIWZN
DMC7YQE	MN	Apoptosis-2 messenger RNA (BIRC3 mRNA)
DMC7YQE	MT	DTT
DMC7YQE	MA	Inhibitor
DMC7YQE	RN	Nonpeptidic and potent small-molecule inhibitors of cIAP-1/2 and XIAP proteins. J Med Chem. 2010 Sep 9;53(17):6361-7.
DMC7YQE	RU	https://pubmed.ncbi.nlm.nih.gov/20684551

DMC7YQE	DI	DMC7YQE
DMC7YQE	DN	SM-122
DMC7YQE	MI	TTK3WBU
DMC7YQE	MN	XIAP messenger RNA (XIAP mRNA)
DMC7YQE	MT	DTT
DMC7YQE	MA	Inhibitor
DMC7YQE	RN	Nonpeptidic and potent small-molecule inhibitors of cIAP-1/2 and XIAP proteins. J Med Chem. 2010 Sep 9;53(17):6361-7.
DMC7YQE	RU	https://pubmed.ncbi.nlm.nih.gov/20684551

DMKZVEQ	DI	DMKZVEQ
DMKZVEQ	DN	SM-130,686
DMKZVEQ	MI	TTWDC17
DMKZVEQ	MN	Growth hormone secretagogue receptor 1 (GHSR)
DMKZVEQ	MT	DTT
DMKZVEQ	MA	Agonist
DMKZVEQ	RN	Oxindole derivatives as orally active potent growth hormone secretagogues. J Med Chem. 2001 Dec 20;44(26):4641-9.
DMKZVEQ	RU	https://pubmed.ncbi.nlm.nih.gov/11741481

DMP8VO6	DI	DMP8VO6
DMP8VO6	DN	SM-131
DMP8VO6	MI	TTAIWZN
DMP8VO6	MN	Apoptosis-2 messenger RNA (BIRC3 mRNA)
DMP8VO6	MT	DTT
DMP8VO6	MA	Inhibitor
DMP8VO6	RN	Design, synthesis, and evaluation of tricyclic, conformationally constrained small-molecule mimetics of second mitochondria-derived activator of ca... J Med Chem. 2008 Dec 11;51(23):7352-5.
DMP8VO6	RU	https://pubmed.ncbi.nlm.nih.gov/19012392

DMP8VO6	DI	DMP8VO6
DMP8VO6	DN	SM-131
DMP8VO6	MI	TTK3WBU
DMP8VO6	MN	XIAP messenger RNA (XIAP mRNA)
DMP8VO6	MT	DTT
DMP8VO6	MA	Inhibitor
DMP8VO6	RN	Design, synthesis, and evaluation of tricyclic, conformationally constrained small-molecule mimetics of second mitochondria-derived activator of ca... J Med Chem. 2008 Dec 11;51(23):7352-5.
DMP8VO6	RU	https://pubmed.ncbi.nlm.nih.gov/19012392

DMOSTP9	DI	DMOSTP9
DMOSTP9	DN	SM-337
DMOSTP9	MI	TTAIWZN
DMOSTP9	MN	Apoptosis-2 messenger RNA (BIRC3 mRNA)
DMOSTP9	MT	DTT
DMOSTP9	MA	Inhibitor
DMOSTP9	RN	Nonpeptidic and potent small-molecule inhibitors of cIAP-1/2 and XIAP proteins. J Med Chem. 2010 Sep 9;53(17):6361-7.
DMOSTP9	RU	https://pubmed.ncbi.nlm.nih.gov/20684551

DMOSTP9	DI	DMOSTP9
DMOSTP9	DN	SM-337
DMOSTP9	MI	TTK3WBU
DMOSTP9	MN	XIAP messenger RNA (XIAP mRNA)
DMOSTP9	MT	DTT
DMOSTP9	MA	Inhibitor
DMOSTP9	RN	Nonpeptidic and potent small-molecule inhibitors of cIAP-1/2 and XIAP proteins. J Med Chem. 2010 Sep 9;53(17):6361-7.
DMOSTP9	RU	https://pubmed.ncbi.nlm.nih.gov/20684551

DMWJ70Q	DI	DMWJ70Q
DMWJ70Q	DN	Small molecule 34
DMWJ70Q	MI	TTQBR95
DMWJ70Q	MN	Stress-activated protein kinase 2a (p38 alpha)
DMWJ70Q	MT	DTT
DMWJ70Q	MA	Inhibitor
DMWJ70Q	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMWJ70Q	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMGJTL3	DI	DMGJTL3
DMGJTL3	DN	SMaRT FVIII
DMGJTL3	MI	TT1290U
DMGJTL3	MN	Coagulation factor VIII (F8)
DMGJTL3	MT	DTT
DMGJTL3	MA	Modulator
DMGJTL3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2607).
DMGJTL3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2607

DMZC2BT	DI	DMZC2BT
DMZC2BT	DN	SMEATHXANTHONE A
DMZC2BT	MI	TT50QJ3
DMZC2BT	MN	Influenza Neuraminidase (Influ NA)
DMZC2BT	MT	DTT
DMZC2BT	MA	Inhibitor
DMZC2BT	RN	Xanthones with neuraminidase inhibitory activity from the seedcases of Garcinia mangostana. Bioorg Med Chem. 2010 Sep 1;18(17):6258-64.
DMZC2BT	RU	https://pubmed.ncbi.nlm.nih.gov/20696581

DM79QC2	DI	DM79QC2
DM79QC2	DN	S-methyl 4-methyl-4-morpholinopent-2-ynethioate
DM79QC2	MI	TTB6UM0
DM79QC2	MN	Fatty aldehyde dehydrogenase (ALDH3A2)
DM79QC2	MT	DTT
DM79QC2	MA	Inhibitor
DM79QC2	RN	Aldehyde dehydrogenase inhibitors: alpha,beta-acetylenic N-substituted aminothiolesters are reversible growth inhibitors of normal epithelial but i... Eur J Med Chem. 2008 May;43(5):906-16.
DM79QC2	RU	https://pubmed.ncbi.nlm.nih.gov/17692435

DMAMRKS	DI	DMAMRKS
DMAMRKS	DN	S-Methylcysteine
DMAMRKS	MI	TTPT2QI
DMAMRKS	MN	Cathepsin D (CTSD)
DMAMRKS	MT	DTT
DMAMRKS	MA	Inhibitor
DMAMRKS	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMAMRKS	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMAMRKS	DI	DMAMRKS
DMAMRKS	DN	S-Methylcysteine
DMAMRKS	MI	TTJ8DV7
DMAMRKS	MN	O-6-methylguanine-DNA-alkyltransferase (MGMT)
DMAMRKS	MT	DTT
DMAMRKS	MA	Inhibitor
DMAMRKS	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMAMRKS	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMBLWMS	DI	DMBLWMS
DMBLWMS	DN	SMI-4a
DMBLWMS	MI	TTTN5QW
DMBLWMS	MN	Serine/threonine-protein kinase pim-1 (PIM1)
DMBLWMS	MT	DTT
DMBLWMS	MA	Inhibitor
DMBLWMS	RN	Pim-1 inhibitor SMI-4a suppresses tumor growth in non-small cell lung cancer via PI3K/AKT/mTOR pathway. Onco Targets Ther. 2019 Apr 23;12:3043-3050.
DMBLWMS	RU	https://pubmed.ncbi.nlm.nih.gov/31114247

DMABIX1	DI	DMABIX1
DMABIX1	DN	SMOi2-17
DMABIX1	MI	TT8J1S3
DMABIX1	MN	Smoothened homolog (SMO)
DMABIX1	MT	DTT
DMABIX1	MA	Antagonist
DMABIX1	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 239).
DMABIX1	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=239

DMSI95J	DI	DMSI95J
DMSI95J	DN	SMP-797
DMSI95J	MI	TTMF541
DMSI95J	MN	Liver carboxylesterase (CES1)
DMSI95J	MT	DTT
DMSI95J	MA	Modulator
DMSI95J	RN	Company report (Dainippon Sumitomo Pharma)
DMSI95J	RU	http://www.ds-pharma.com/ir/library/presentation/pdf/eir20060314.pdf (A lowering of plasma cholesterol by ACAT inhibition and enhancing LDL receptor activity leads to the direct inhibition of the progress of arteriosclerosis by ACAT inhibition)

DMO8G39	DI	DMO8G39
DMO8G39	DN	S-MTC
DMO8G39	MI	DEY0TQC
DMO8G39	MN	Dimethylarginine dimethylaminohydrolase 1 (DDAH1)
DMO8G39	MT	DME
DMO8G39	MA	Metabolism
DMO8G39	RN	Developing dual and specific inhibitors of dimethylarginine dimethylaminohydrolase-1 and nitric oxide synthase: toward a targeted polypharmacology to control nitric oxide. Biochemistry. 2009 Sep 15;48(36):8624-35.
DMO8G39	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19663506

DM9SF48	DI	DM9SF48
DM9SF48	DN	SMTP-0
DM9SF48	MI	TTP86E2
DM9SF48	MN	Plasminogen (PLG)
DM9SF48	MT	DTT
DM9SF48	MA	Modulator
DM9SF48	RN	Tranexamic acid in trauma: how should we use it. J Trauma Acute Care Surg. 2013 Jun;74(6):1575-86.
DM9SF48	RU	https://pubmed.ncbi.nlm.nih.gov/23694890

DMWCSQH	DI	DMWCSQH
DMWCSQH	DN	SN-1
DMWCSQH	MI	TT0NLAQ
DMWCSQH	MN	Mucolipin-3 (TRPML3)
DMWCSQH	MT	DTT
DMWCSQH	MA	Activator
DMWCSQH	RN	Small molecule activators of TRPML3. Chem Biol. 2010 Feb 26;17(2):135-48.
DMWCSQH	RU	https://pubmed.ncbi.nlm.nih.gov/20189104

DMA0JZM	DI	DMA0JZM
DMA0JZM	DN	SN-11
DMA0JZM	MI	TT27RFC
DMA0JZM	MN	Opioid receptor delta (OPRD1)
DMA0JZM	MT	DTT
DMA0JZM	MA	Inhibitor
DMA0JZM	RN	Design and synthesis of novel delta opioid receptor agonists and their pharmacologies. Bioorg Med Chem Lett. 2009 May 15;19(10):2792-5.
DMA0JZM	RU	https://pubmed.ncbi.nlm.nih.gov/19362480

DMA0JZM	DI	DMA0JZM
DMA0JZM	DN	SN-11
DMA0JZM	MI	TTQW87Y
DMA0JZM	MN	Opioid receptor kappa (OPRK1)
DMA0JZM	MT	DTT
DMA0JZM	MA	Inhibitor
DMA0JZM	RN	Design and synthesis of novel delta opioid receptor agonists and their pharmacologies. Bioorg Med Chem Lett. 2009 May 15;19(10):2792-5.
DMA0JZM	RU	https://pubmed.ncbi.nlm.nih.gov/19362480

DMA0JZM	DI	DMA0JZM
DMA0JZM	DN	SN-11
DMA0JZM	MI	TTKWM86
DMA0JZM	MN	Opioid receptor mu (MOP)
DMA0JZM	MT	DTT
DMA0JZM	MA	Inhibitor
DMA0JZM	RN	Design and synthesis of novel delta opioid receptor agonists and their pharmacologies. Bioorg Med Chem Lett. 2009 May 15;19(10):2792-5.
DMA0JZM	RU	https://pubmed.ncbi.nlm.nih.gov/19362480

DMYVIBW	DI	DMYVIBW
DMYVIBW	DN	SN-2
DMYVIBW	MI	TT0NLAQ
DMYVIBW	MN	Mucolipin-3 (TRPML3)
DMYVIBW	MT	DTT
DMYVIBW	MA	Activator
DMYVIBW	RN	Small molecule activators of TRPML3. Chem Biol. 2010 Feb 26;17(2):135-48.
DMYVIBW	RU	https://pubmed.ncbi.nlm.nih.gov/20189104

DM6O0PD	DI	DM6O0PD
DM6O0PD	DN	SN-23
DM6O0PD	MI	TT27RFC
DM6O0PD	MN	Opioid receptor delta (OPRD1)
DM6O0PD	MT	DTT
DM6O0PD	MA	Inhibitor
DM6O0PD	RN	Design and synthesis of novel delta opioid receptor agonists and their pharmacologies. Bioorg Med Chem Lett. 2009 May 15;19(10):2792-5.
DM6O0PD	RU	https://pubmed.ncbi.nlm.nih.gov/19362480

DM6O0PD	DI	DM6O0PD
DM6O0PD	DN	SN-23
DM6O0PD	MI	TTQW87Y
DM6O0PD	MN	Opioid receptor kappa (OPRK1)
DM6O0PD	MT	DTT
DM6O0PD	MA	Inhibitor
DM6O0PD	RN	Design and synthesis of novel delta opioid receptor agonists and their pharmacologies. Bioorg Med Chem Lett. 2009 May 15;19(10):2792-5.
DM6O0PD	RU	https://pubmed.ncbi.nlm.nih.gov/19362480

DM6O0PD	DI	DM6O0PD
DM6O0PD	DN	SN-23
DM6O0PD	MI	TTKWM86
DM6O0PD	MN	Opioid receptor mu (MOP)
DM6O0PD	MT	DTT
DM6O0PD	MA	Inhibitor
DM6O0PD	RN	Design and synthesis of novel delta opioid receptor agonists and their pharmacologies. Bioorg Med Chem Lett. 2009 May 15;19(10):2792-5.
DM6O0PD	RU	https://pubmed.ncbi.nlm.nih.gov/19362480

DMB8TJC	DI	DMB8TJC
DMB8TJC	DN	SN-28
DMB8TJC	MI	TT27RFC
DMB8TJC	MN	Opioid receptor delta (OPRD1)
DMB8TJC	MT	DTT
DMB8TJC	MA	Inhibitor
DMB8TJC	RN	Design and synthesis of KNT-127, a -opioid receptor agonist effective by systemic administration. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6302-5.
DMB8TJC	RU	https://pubmed.ncbi.nlm.nih.gov/20850307

DMB8TJC	DI	DMB8TJC
DMB8TJC	DN	SN-28
DMB8TJC	MI	TTQW87Y
DMB8TJC	MN	Opioid receptor kappa (OPRK1)
DMB8TJC	MT	DTT
DMB8TJC	MA	Inhibitor
DMB8TJC	RN	Design and synthesis of KNT-127, a -opioid receptor agonist effective by systemic administration. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6302-5.
DMB8TJC	RU	https://pubmed.ncbi.nlm.nih.gov/20850307

DMB8TJC	DI	DMB8TJC
DMB8TJC	DN	SN-28
DMB8TJC	MI	TTKWM86
DMB8TJC	MN	Opioid receptor mu (MOP)
DMB8TJC	MT	DTT
DMB8TJC	MA	Inhibitor
DMB8TJC	RN	Design and synthesis of KNT-127, a -opioid receptor agonist effective by systemic administration. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6302-5.
DMB8TJC	RU	https://pubmed.ncbi.nlm.nih.gov/20850307

DM2UVNB	DI	DM2UVNB
DM2UVNB	DN	SN-38G
DM2UVNB	MI	DE5Z9QK
DM2UVNB	MN	Beta-glucuronidase (uidA)
DM2UVNB	MT	DME
DM2UVNB	MA	Metabolism
DM2UVNB	RN	Three structurally and functionally distinct beta-glucuronidases from the human gut microbe Bacteroides uniformis. J Biol Chem. 2018 Nov 30;293(48):18559-18573.
DM2UVNB	RU	https://pubmed.ncbi.nlm.nih.gov/30301767

DM2UVNB	DI	DM2UVNB
DM2UVNB	DN	SN-38G
DM2UVNB	MI	DELQJ5O
DM2UVNB	MN	Beta-glucuronidase (uidA)
DM2UVNB	MT	DME
DM2UVNB	MA	Metabolism
DM2UVNB	RN	Three structurally and functionally distinct beta-glucuronidases from the human gut microbe Bacteroides uniformis. J Biol Chem. 2018 Nov 30;293(48):18559-18573.
DM2UVNB	RU	https://pubmed.ncbi.nlm.nih.gov/30301767

DM2UVNB	DI	DM2UVNB
DM2UVNB	DN	SN-38G
DM2UVNB	MI	DE2IMU4
DM2UVNB	MN	Beta-glucuronidase (uidA)
DM2UVNB	MT	DME
DM2UVNB	MA	Metabolism
DM2UVNB	RN	Structure and inhibition of microbiome beta-glucuronidases essential to the alleviation of cancer drug toxicity. Chem Biol. 2015 Sep 17;22(9):1238-49.
DM2UVNB	RU	https://pubmed.ncbi.nlm.nih.gov/26364932

DM2UVNB	DI	DM2UVNB
DM2UVNB	DN	SN-38G
DM2UVNB	MI	DERFVMW
DM2UVNB	MN	Beta-glucuronidase (uidA)
DM2UVNB	MT	DME
DM2UVNB	MA	Metabolism
DM2UVNB	RN	Structure and inhibition of microbiome beta-glucuronidases essential to the alleviation of cancer drug toxicity. Chem Biol. 2015 Sep 17;22(9):1238-49.
DM2UVNB	RU	https://pubmed.ncbi.nlm.nih.gov/26364932

DM2UVNB	DI	DM2UVNB
DM2UVNB	DN	SN-38G
DM2UVNB	MI	DE9RA0I
DM2UVNB	MN	Beta-glucuronidase (uidA)
DM2UVNB	MT	DME
DM2UVNB	MA	Metabolism
DM2UVNB	RN	Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rats. Oncol Rep. 2008 Oct;20(4):727-30.
DM2UVNB	RU	https://pubmed.ncbi.nlm.nih.gov/18813810

DMP4IJ6	DI	DMP4IJ6
DMP4IJ6	DN	SN429
DMP4IJ6	MI	TTCIHJA
DMP4IJ6	MN	Coagulation factor Xa (F10)
DMP4IJ6	MT	DTT
DMP4IJ6	MA	Inhibitor
DMP4IJ6	RN	Pharmacological intervention at disparate sites in the coagulation cascade: comparison of anti-thrombotic efficacy vs bleeding propensity in a rat model of acute arterial thrombosis. J Thromb Thrombolysis. 2002 Oct;14(2):113-21.
DMP4IJ6	RU	https://pubmed.ncbi.nlm.nih.gov/12714830

DMS1AFL	DI	DMS1AFL
DMS1AFL	DN	SNAP 398299
DMS1AFL	MI	TTOPAY7
DMS1AFL	MN	Galanin receptor (GAL-R)
DMS1AFL	MT	DTT
DMS1AFL	MA	Antagonist
DMS1AFL	RN	Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299. Proc Natl Acad Sci U S A. 2005 Nov 29;102(48):17489-94.
DMS1AFL	RU	https://pubmed.ncbi.nlm.nih.gov/16287967

DMEJ5CP	DI	DMEJ5CP
DMEJ5CP	DN	SNAP-5036
DMEJ5CP	MI	TTNGILX
DMEJ5CP	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMEJ5CP	MT	DTT
DMEJ5CP	MA	Inhibitor
DMEJ5CP	RN	Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
DMEJ5CP	RU	https://pubmed.ncbi.nlm.nih.gov/15664832

DMFM19S	DI	DMFM19S
DMFM19S	DN	SNAP-5114
DMFM19S	MI	TTHVBOC
DMFM19S	MN	Gamma-aminobutyric acid transporter 4 (SLC6A11)
DMFM19S	MT	DTT
DMFM19S	MA	Blocker
DMFM19S	RN	GABA-level increasing and anticonvulsant effects of three different GABA uptake inhibitors. Neuropharmacology. 2000 Sep;39(12):2399-407.
DMFM19S	RU	https://pubmed.ncbi.nlm.nih.gov/10974324

DM2OLGQ	DI	DM2OLGQ
DM2OLGQ	DN	SNAP-5150
DM2OLGQ	MI	TTWG9A4
DM2OLGQ	MN	Adrenergic receptor alpha-2A (ADRA2A)
DM2OLGQ	MT	DTT
DM2OLGQ	MA	Inhibitor
DM2OLGQ	RN	Design and synthesis of novel dihydropyridine alpha-1a antagonists. Bioorg Med Chem Lett. 1999 Oct 4;9(19):2843-8.
DM2OLGQ	RU	https://pubmed.ncbi.nlm.nih.gov/10522703

DM2OLGQ	DI	DM2OLGQ
DM2OLGQ	DN	SNAP-5150
DM2OLGQ	MI	TTWM4TY
DM2OLGQ	MN	Adrenergic receptor alpha-2B (ADRA2B)
DM2OLGQ	MT	DTT
DM2OLGQ	MA	Inhibitor
DM2OLGQ	RN	Design and synthesis of novel dihydropyridine alpha-1a antagonists. Bioorg Med Chem Lett. 1999 Oct 4;9(19):2843-8.
DM2OLGQ	RU	https://pubmed.ncbi.nlm.nih.gov/10522703

DM2OLGQ	DI	DM2OLGQ
DM2OLGQ	DN	SNAP-5150
DM2OLGQ	MI	TT2NUT5
DM2OLGQ	MN	Adrenergic receptor alpha-2C (ADRA2C)
DM2OLGQ	MT	DTT
DM2OLGQ	MA	Inhibitor
DM2OLGQ	RN	Design and synthesis of novel dihydropyridine alpha-1a antagonists. Bioorg Med Chem Lett. 1999 Oct 4;9(19):2843-8.
DM2OLGQ	RU	https://pubmed.ncbi.nlm.nih.gov/10522703

DM3KN2F	DI	DM3KN2F
DM3KN2F	DN	SNAP-7915
DM3KN2F	MI	TTNGILX
DM3KN2F	MN	Adrenergic receptor alpha-1A (ADRA1A)
DM3KN2F	MT	DTT
DM3KN2F	MA	Inhibitor
DM3KN2F	RN	Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
DM3KN2F	RU	https://pubmed.ncbi.nlm.nih.gov/15664832

DMCHPMA	DI	DMCHPMA
DMCHPMA	DN	SNAP-8719
DMCHPMA	MI	TTSQIFT
DMCHPMA	MN	5-HT 1A receptor (HTR1A)
DMCHPMA	MT	DTT
DMCHPMA	MA	Inhibitor
DMCHPMA	RN	Synthesis and structure-activity relationship of fluoro analogues of 8-{2-[4-(4-methoxyphenyl)piperazin-1yl]ethyl}-8-azaspiro[4.5]decane-7,9-dione ... J Med Chem. 2005 Apr 21;48(8):3076-9.
DMCHPMA	RU	https://pubmed.ncbi.nlm.nih.gov/15828846

DMCHPMA	DI	DMCHPMA
DMCHPMA	DN	SNAP-8719
DMCHPMA	MI	TTNGILX
DMCHPMA	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMCHPMA	MT	DTT
DMCHPMA	MA	Inhibitor
DMCHPMA	RN	Synthesis and structure-activity relationship of fluoro analogues of 8-{2-[4-(4-methoxyphenyl)piperazin-1yl]ethyl}-8-azaspiro[4.5]decane-7,9-dione ... J Med Chem. 2005 Apr 21;48(8):3076-9.
DMCHPMA	RU	https://pubmed.ncbi.nlm.nih.gov/15828846

DMCHPMA	DI	DMCHPMA
DMCHPMA	DN	SNAP-8719
DMCHPMA	MI	TTBRKXS
DMCHPMA	MN	Adrenergic receptor alpha-1B (ADRA1B)
DMCHPMA	MT	DTT
DMCHPMA	MA	Inhibitor
DMCHPMA	RN	Synthesis and structure-activity relationship of fluoro analogues of 8-{2-[4-(4-methoxyphenyl)piperazin-1yl]ethyl}-8-azaspiro[4.5]decane-7,9-dione ... J Med Chem. 2005 Apr 21;48(8):3076-9.
DMCHPMA	RU	https://pubmed.ncbi.nlm.nih.gov/15828846

DMCHPMA	DI	DMCHPMA
DMCHPMA	DN	SNAP-8719
DMCHPMA	MI	TT34BHT
DMCHPMA	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMCHPMA	MT	DTT
DMCHPMA	MA	Inhibitor
DMCHPMA	RN	Synthesis and structure-activity relationship of fluoro analogues of 8-{2-[4-(4-methoxyphenyl)piperazin-1yl]ethyl}-8-azaspiro[4.5]decane-7,9-dione ... J Med Chem. 2005 Apr 21;48(8):3076-9.
DMCHPMA	RU	https://pubmed.ncbi.nlm.nih.gov/15828846

DMMHQDX	DI	DMMHQDX
DMMHQDX	DN	SNAP-94847
DMMHQDX	MI	TTNGILX
DMMHQDX	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMMHQDX	MT	DTT
DMMHQDX	MA	Inhibitor
DMMHQDX	RN	Synthesis and SAR investigations for novel melanin-concentrating hormone 1 receptor (MCH1) antagonists part 2: A hybrid strategy combining key frag... J Med Chem. 2007 Aug 9;50(16):3883-90.
DMMHQDX	RU	https://pubmed.ncbi.nlm.nih.gov/17668922

DMMHQDX	DI	DMMHQDX
DMMHQDX	DN	SNAP-94847
DMMHQDX	MI	TTEX248
DMMHQDX	MN	Dopamine D2 receptor (D2R)
DMMHQDX	MT	DTT
DMMHQDX	MA	Inhibitor
DMMHQDX	RN	Synthesis and SAR investigations for novel melanin-concentrating hormone 1 receptor (MCH1) antagonists part 2: A hybrid strategy combining key frag... J Med Chem. 2007 Aug 9;50(16):3883-90.
DMMHQDX	RU	https://pubmed.ncbi.nlm.nih.gov/17668922

DMJI5H0	DI	DMJI5H0
DMJI5H0	DN	SNC-80
DMJI5H0	MI	TT27RFC
DMJI5H0	MN	Opioid receptor delta (OPRD1)
DMJI5H0	MT	DTT
DMJI5H0	MA	Agonist
DMJI5H0	RN	Nonpeptidic delta-opioid receptor agonists reduce immobility in the forced swim assay in rats. Neuropsychopharmacology. 2002 Jun;26(6):744-55.
DMJI5H0	RU	https://pubmed.ncbi.nlm.nih.gov/12007745

DMYUH62	DI	DMYUH62
DMYUH62	DN	SNEWIQPRLPQH
DMYUH62	MI	TTKPV6O
DMYUH62	MN	Ephrin type-B receptor 2 (EPHB2)
DMYUH62	MT	DTT
DMYUH62	MA	Inhibitor
DMYUH62	RN	Three-dimensional structure of the EphB2 receptor in complex with an antagonistic peptide reveals a novel mode of inhibition. J Biol Chem. 2007 Dec 14;282(50):36505-13.
DMYUH62	RU	https://pubmed.ncbi.nlm.nih.gov/17897949

DMOLQNK	DI	DMOLQNK
DMOLQNK	DN	SNG-163
DMOLQNK	MI	TTZAYWL
DMOLQNK	MN	Estrogen receptor (ESR)
DMOLQNK	MT	DTT
DMOLQNK	MA	Inhibitor
DMOLQNK	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620).
DMOLQNK	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=620

DMCT02Q	DI	DMCT02Q
DMCT02Q	DN	SNG-8006
DMCT02Q	MI	TTZAYWL
DMCT02Q	MN	Estrogen receptor (ESR)
DMCT02Q	MT	DTT
DMCT02Q	MA	Antagonist
DMCT02Q	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620).
DMCT02Q	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=620

DM6O9DQ	DI	DM6O9DQ
DM6O9DQ	DN	SNG-8023
DM6O9DQ	MI	TTZAYWL
DM6O9DQ	MN	Estrogen receptor (ESR)
DM6O9DQ	MT	DTT
DM6O9DQ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620).
DM6O9DQ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=620

DM0W54R	DI	DM0W54R
DM0W54R	DN	SNG-8033
DM0W54R	MI	TTZAYWL
DM0W54R	MN	Estrogen receptor (ESR)
DM0W54R	MT	DTT
DM0W54R	MA	Inhibitor
DM0W54R	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620).
DM0W54R	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=620

DMB5A80	DI	DMB5A80
DMB5A80	DN	SNX-2112
DMB5A80	MI	TT78R5H
DMB5A80	MN	Heat shock protein 90 alpha (HSP90A)
DMB5A80	MT	DTT
DMB5A80	MA	Inhibitor
DMB5A80	RN	Heat shock protein 90: inhibitors in clinical trials. J Med Chem. 2010 Jan 14;53(1):3-17.
DMB5A80	RU	https://pubmed.ncbi.nlm.nih.gov/20055425

DMSRM49	DI	DMSRM49
DMSRM49	DN	Sodium 2,3,5,6-tetrafluorobenzoate
DMSRM49	MI	TTANPDJ
DMSRM49	MN	Carbonic anhydrase II (CA-II)
DMSRM49	MT	DTT
DMSRM49	MA	Inhibitor
DMSRM49	RN	Carbonic anhydrase inhibitors. Inhibition of the beta-class enzymes from the fungal pathogens Candida albicans and Cryptococcus neoformans with ali... Bioorg Med Chem. 2009 Apr 1;17(7):2654-7.
DMSRM49	RU	https://pubmed.ncbi.nlm.nih.gov/19297172

DMHPD2Y	DI	DMHPD2Y
DMHPD2Y	DN	SODIUM CITRATE
DMHPD2Y	MI	TTZHA0O
DMHPD2Y	MN	Carbonic anhydrase IV (CA-IV)
DMHPD2Y	MT	DTT
DMHPD2Y	MA	Inhibitor
DMHPD2Y	RN	Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with carboxylates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):573-8.
DMHPD2Y	RU	https://pubmed.ncbi.nlm.nih.gov/15664815

DM2WUZA	DI	DM2WUZA
DM2WUZA	DN	Sodium maleate
DM2WUZA	MI	TTUNARX
DM2WUZA	MN	Carbonic anhydrase (CA)
DM2WUZA	MT	DTT
DM2WUZA	MA	Inhibitor
DM2WUZA	RN	Carbonic anhydrase inhibitors. Inhibition of the beta-class enzymes from the fungal pathogens Candida albicans and Cryptococcus neoformans with ali... Bioorg Med Chem. 2009 Apr 1;17(7):2654-7.
DM2WUZA	RU	https://pubmed.ncbi.nlm.nih.gov/19297172

DMBVQI4	DI	DMBVQI4
DMBVQI4	DN	Sodium N-methylphenylaminomethanesulfonate
DMBVQI4	MI	TT2LVK8
DMBVQI4	MN	Carbonic anhydrase IX (CA-IX)
DMBVQI4	MT	DTT
DMBVQI4	MA	Inhibitor
DMBVQI4	RN	Carbonic anhydrase inhibitors. Diazenylbenzenesulfonamides are potent and selective inhibitors of the tumor-associated isozymes IX and XII over the... Bioorg Med Chem. 2009 Oct 15;17(20):7093-9.
DMBVQI4	RU	https://pubmed.ncbi.nlm.nih.gov/19773173

DMBVQI4	DI	DMBVQI4
DMBVQI4	DN	Sodium N-methylphenylaminomethanesulfonate
DMBVQI4	MI	TTSYM0R
DMBVQI4	MN	Carbonic anhydrase XII (CA-XII)
DMBVQI4	MT	DTT
DMBVQI4	MA	Inhibitor
DMBVQI4	RN	Carbonic anhydrase inhibitors. Diazenylbenzenesulfonamides are potent and selective inhibitors of the tumor-associated isozymes IX and XII over the... Bioorg Med Chem. 2009 Oct 15;17(20):7093-9.
DMBVQI4	RU	https://pubmed.ncbi.nlm.nih.gov/19773173

DM8CLG2	DI	DM8CLG2
DM8CLG2	DN	Sodium orthovanadate
DM8CLG2	MI	TT7YM8D
DM8CLG2	MN	Protein tyrosine phosphatase IVA 3 (PRL-3)
DM8CLG2	MT	DTT
DM8CLG2	MA	Inhibitor
DM8CLG2	RN	Structure of human PRL-3, the phosphatase associated with cancer metastasis. FEBS Lett. 2004 May 7;565(1-3):181-7.
DM8CLG2	RU	https://pubmed.ncbi.nlm.nih.gov/15135076

DMESHV2	DI	DMESHV2
DMESHV2	DN	SODIUM PERFLUOROHEXANESULFONAMIDE
DMESHV2	MI	TTANPDJ
DMESHV2	MN	Carbonic anhydrase II (CA-II)
DMESHV2	MT	DTT
DMESHV2	MA	Inhibitor
DMESHV2	RN	Synthesis and investigation of inhibition effect of fluorinated sulfonamide derivatives on carbonic anhydrase. Eur J Med Chem. 2010 Mar;45(3):1225-9.
DMESHV2	RU	https://pubmed.ncbi.nlm.nih.gov/20036446

DMJ7I4U	DI	DMJ7I4U
DMJ7I4U	DN	Sodium phenylaminomethanesulfonate
DMJ7I4U	MI	TT2LVK8
DMJ7I4U	MN	Carbonic anhydrase IX (CA-IX)
DMJ7I4U	MT	DTT
DMJ7I4U	MA	Inhibitor
DMJ7I4U	RN	Carbonic anhydrase inhibitors. Diazenylbenzenesulfonamides are potent and selective inhibitors of the tumor-associated isozymes IX and XII over the... Bioorg Med Chem. 2009 Oct 15;17(20):7093-9.
DMJ7I4U	RU	https://pubmed.ncbi.nlm.nih.gov/19773173

DMJ7I4U	DI	DMJ7I4U
DMJ7I4U	DN	Sodium phenylaminomethanesulfonate
DMJ7I4U	MI	TTSYM0R
DMJ7I4U	MN	Carbonic anhydrase XII (CA-XII)
DMJ7I4U	MT	DTT
DMJ7I4U	MA	Inhibitor
DMJ7I4U	RN	Carbonic anhydrase inhibitors. Diazenylbenzenesulfonamides are potent and selective inhibitors of the tumor-associated isozymes IX and XII over the... Bioorg Med Chem. 2009 Oct 15;17(20):7093-9.
DMJ7I4U	RU	https://pubmed.ncbi.nlm.nih.gov/19773173

DMXELBI	DI	DMXELBI
DMXELBI	DN	Sodium phenylarsonate
DMXELBI	MI	TTZHA0O
DMXELBI	MN	Carbonic anhydrase IV (CA-IV)
DMXELBI	MT	DTT
DMXELBI	MA	Inhibitor
DMXELBI	RN	Carbonic anhydrase inhibitors: the membrane-associated isoform XV is highly inhibited by inorganic anions. Bioorg Med Chem Lett. 2009 Feb 15;19(4):1155-8.
DMXELBI	RU	https://pubmed.ncbi.nlm.nih.gov/19128966

DM1G4S9	DI	DM1G4S9
DM1G4S9	DN	Sodium Phosphate, Dibasic, Anhydrous
DM1G4S9	MI	TTZHA0O
DM1G4S9	MN	Carbonic anhydrase IV (CA-IV)
DM1G4S9	MT	DTT
DM1G4S9	MA	Inhibitor
DM1G4S9	RN	Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with phosphates, carbamoyl phosphate, and the phosphonate antiviral dru... Bioorg Med Chem Lett. 2004 Dec 6;14(23):5763-7.
DM1G4S9	RU	https://pubmed.ncbi.nlm.nih.gov/15501037

DM1G4S9	DI	DM1G4S9
DM1G4S9	DN	Sodium Phosphate, Dibasic, Anhydrous
DM1G4S9	MI	DEX2KIA
DM1G4S9	MN	Steroid 17-alpha-monooxygenase (CYP17A1)
DM1G4S9	MT	DME
DM1G4S9	MA	Metabolism
DM1G4S9	RN	Transcriptional complexes at the CYP17 CRS. Endocr Res. 2002 Nov;28(4):551-8.
DM1G4S9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12530662

DMAMV6T	DI	DMAMV6T
DMAMV6T	DN	Sodium sulfamate
DMAMV6T	MI	TTZHA0O
DMAMV6T	MN	Carbonic anhydrase IV (CA-IV)
DMAMV6T	MT	DTT
DMAMV6T	MA	Inhibitor
DMAMV6T	RN	Carbonic anhydrase inhibitors: the membrane-associated isoform XV is highly inhibited by inorganic anions. Bioorg Med Chem Lett. 2009 Feb 15;19(4):1155-8.
DMAMV6T	RU	https://pubmed.ncbi.nlm.nih.gov/19128966

DM6WYGC	DI	DM6WYGC
DM6WYGC	DN	Sodium trithiocarbonate
DM6WYGC	MI	TTHQPL7
DM6WYGC	MN	Carbonic anhydrase I (CA-I)
DM6WYGC	MT	DTT
DM6WYGC	MA	Inhibitor
DM6WYGC	RN	Carbonic anhydrase inhibitors. Inhibition of cytosolic isoforms I, II, III, VII and XIII with less investigated inorganic anions. Bioorg Med Chem Lett. 2009 Apr 1;19(7):1855-7.
DM6WYGC	RU	https://pubmed.ncbi.nlm.nih.gov/19269822

DM6WYGC	DI	DM6WYGC
DM6WYGC	DN	Sodium trithiocarbonate
DM6WYGC	MI	TTANPDJ
DM6WYGC	MN	Carbonic anhydrase II (CA-II)
DM6WYGC	MT	DTT
DM6WYGC	MA	Inhibitor
DM6WYGC	RN	Carbonic anhydrase inhibitors. Inhibition of cytosolic isoforms I, II, III, VII and XIII with less investigated inorganic anions. Bioorg Med Chem Lett. 2009 Apr 1;19(7):1855-7.
DM6WYGC	RU	https://pubmed.ncbi.nlm.nih.gov/19269822

DM6WYGC	DI	DM6WYGC
DM6WYGC	DN	Sodium trithiocarbonate
DM6WYGC	MI	TTZHA0O
DM6WYGC	MN	Carbonic anhydrase IV (CA-IV)
DM6WYGC	MT	DTT
DM6WYGC	MA	Inhibitor
DM6WYGC	RN	Carbonic anhydrase inhibitors. Inhibition of cytosolic isoforms I, II, III, VII and XIII with less investigated inorganic anions. Bioorg Med Chem Lett. 2009 Apr 1;19(7):1855-7.
DM6WYGC	RU	https://pubmed.ncbi.nlm.nih.gov/19269822

DMX6PLV	DI	DMX6PLV
DMX6PLV	DN	Sodium valproate
DMX6PLV	MI	TTT2LD9
DMX6PLV	MN	GABA transaminase (ABAT)
DMX6PLV	MT	DTT
DMX6PLV	MA	Inhibitor
DMX6PLV	RN	Influence of a GABA transaminase inhibitor on central nervous system oxygen toxicity. Aviat Space Environ Med. 1978 Jul;49(7):877-9.
DMX6PLV	RU	https://pubmed.ncbi.nlm.nih.gov/352331

DMEZAPR	DI	DMEZAPR
DMEZAPR	DN	SODIUM ZINC DIHYDROLIPOYLHISTIDINATE
DMEZAPR	MI	TTULVH8
DMEZAPR	MN	Tyrosinase (TYR)
DMEZAPR	MT	DTT
DMEZAPR	MA	Inhibitor
DMEZAPR	RN	Modulating effects of a novel skin-lightening agent, alpha-lipoic acid derivative, on melanin production by the formation of DOPA conjugate products. Bioorg Med Chem. 2007 Mar 1;15(5):1967-75.
DMEZAPR	RU	https://pubmed.ncbi.nlm.nih.gov/17218103

DMJXN1G	DI	DMJXN1G
DMJXN1G	DN	Soluble ErbB3 theragnostics
DMJXN1G	MI	TTDC8N2
DMJXN1G	MN	Erbb3 tyrosine kinase receptor (Erbb-3)
DMJXN1G	MT	DTT
DMJXN1G	MA	Inhibitor
DMJXN1G	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1798).
DMJXN1G	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1798

DMIOFQE	DI	DMIOFQE
DMIOFQE	DN	SOMATOSTATIN
DMIOFQE	MI	TT27RFC
DMIOFQE	MN	Opioid receptor delta (OPRD1)
DMIOFQE	MT	DTT
DMIOFQE	MA	Inhibitor
DMIOFQE	RN	Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors. J Med Chem. 1986 Nov;29(11):2370-5.
DMIOFQE	RU	https://pubmed.ncbi.nlm.nih.gov/2878079

DMIOFQE	DI	DMIOFQE
DMIOFQE	DN	SOMATOSTATIN
DMIOFQE	MI	TTKWM86
DMIOFQE	MN	Opioid receptor mu (MOP)
DMIOFQE	MT	DTT
DMIOFQE	MA	Inhibitor
DMIOFQE	RN	Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors. J Med Chem. 1986 Nov;29(11):2370-5.
DMIOFQE	RU	https://pubmed.ncbi.nlm.nih.gov/2878079

DMIOFQE	DI	DMIOFQE
DMIOFQE	DN	SOMATOSTATIN
DMIOFQE	MI	TTIND6G
DMIOFQE	MN	Somatostatin receptor type 1 (SSTR1)
DMIOFQE	MT	DTT
DMIOFQE	MA	Inhibitor
DMIOFQE	RN	Discovery of iodinated somatostatin analogues selective for hsst2 and hsst5 with excellent inhibition of growth hormone and prolactin release from ... J Med Chem. 2005 Oct 20;48(21):6643-52.
DMIOFQE	RU	https://pubmed.ncbi.nlm.nih.gov/16220980

DMIOFQE	DI	DMIOFQE
DMIOFQE	DN	SOMATOSTATIN
DMIOFQE	MI	TTZ6T9E
DMIOFQE	MN	Somatostatin receptor type 2 (SSTR2)
DMIOFQE	MT	DTT
DMIOFQE	MA	Inhibitor
DMIOFQE	RN	Discovery of iodinated somatostatin analogues selective for hsst2 and hsst5 with excellent inhibition of growth hormone and prolactin release from ... J Med Chem. 2005 Oct 20;48(21):6643-52.
DMIOFQE	RU	https://pubmed.ncbi.nlm.nih.gov/16220980

DMIOFQE	DI	DMIOFQE
DMIOFQE	DN	SOMATOSTATIN
DMIOFQE	MI	TTJX3UE
DMIOFQE	MN	Somatostatin receptor type 3 (SSTR3)
DMIOFQE	MT	DTT
DMIOFQE	MA	Inhibitor
DMIOFQE	RN	Discovery of iodinated somatostatin analogues selective for hsst2 and hsst5 with excellent inhibition of growth hormone and prolactin release from ... J Med Chem. 2005 Oct 20;48(21):6643-52.
DMIOFQE	RU	https://pubmed.ncbi.nlm.nih.gov/16220980

DMIOFQE	DI	DMIOFQE
DMIOFQE	DN	SOMATOSTATIN
DMIOFQE	MI	TTAE1BR
DMIOFQE	MN	Somatostatin receptor type 4 (SSTR4)
DMIOFQE	MT	DTT
DMIOFQE	MA	Inhibitor
DMIOFQE	RN	Discovery of iodinated somatostatin analogues selective for hsst2 and hsst5 with excellent inhibition of growth hormone and prolactin release from ... J Med Chem. 2005 Oct 20;48(21):6643-52.
DMIOFQE	RU	https://pubmed.ncbi.nlm.nih.gov/16220980

DMIOFQE	DI	DMIOFQE
DMIOFQE	DN	SOMATOSTATIN
DMIOFQE	MI	TT2BC4G
DMIOFQE	MN	Somatostatin receptor type 5 (SSTR5)
DMIOFQE	MT	DTT
DMIOFQE	MA	Inhibitor
DMIOFQE	RN	Discovery of iodinated somatostatin analogues selective for hsst2 and hsst5 with excellent inhibition of growth hormone and prolactin release from ... J Med Chem. 2005 Oct 20;48(21):6643-52.
DMIOFQE	RU	https://pubmed.ncbi.nlm.nih.gov/16220980

DMH6JI8	DI	DMH6JI8
DMH6JI8	DN	S-OOPP
DMH6JI8	MI	TTMN4HY
DMH6JI8	MN	N-acylethanolamine-hydrolyzing acidamidase (NAAA)
DMH6JI8	MT	DTT
DMH6JI8	MA	Inhibitor
DMH6JI8	RN	Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. Proc Natl Acad Sci U S A. 2009 Dec 8;106(49):20966-71.
DMH6JI8	RU	https://pubmed.ncbi.nlm.nih.gov/19926854

DM8Y1S7	DI	DM8Y1S7
DM8Y1S7	DN	SOPHOFLAVESCENOL
DM8Y1S7	MI	TT06AWU
DM8Y1S7	MN	Phosphodiesterase 3A (PDE3A)
DM8Y1S7	MT	DTT
DM8Y1S7	MA	Inhibitor
DM8Y1S7	RN	A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5. Bioorg Med Chem Lett. 2002 Sep 2;12(17):2313-6.
DM8Y1S7	RU	https://pubmed.ncbi.nlm.nih.gov/12161123

DM8Y1S7	DI	DM8Y1S7
DM8Y1S7	DN	SOPHOFLAVESCENOL
DM8Y1S7	MI	TTZ97H5
DM8Y1S7	MN	Phosphodiesterase 4A (PDE4A)
DM8Y1S7	MT	DTT
DM8Y1S7	MA	Inhibitor
DM8Y1S7	RN	A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5. Bioorg Med Chem Lett. 2002 Sep 2;12(17):2313-6.
DM8Y1S7	RU	https://pubmed.ncbi.nlm.nih.gov/12161123

DM8Y1S7	DI	DM8Y1S7
DM8Y1S7	DN	SOPHOFLAVESCENOL
DM8Y1S7	MI	TTVIAT9
DM8Y1S7	MN	Phosphodiesterase 4B (PDE4B)
DM8Y1S7	MT	DTT
DM8Y1S7	MA	Inhibitor
DM8Y1S7	RN	A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5. Bioorg Med Chem Lett. 2002 Sep 2;12(17):2313-6.
DM8Y1S7	RU	https://pubmed.ncbi.nlm.nih.gov/12161123

DM8Y1S7	DI	DM8Y1S7
DM8Y1S7	DN	SOPHOFLAVESCENOL
DM8Y1S7	MI	TTJ0IQB
DM8Y1S7	MN	Phosphodiesterase 5A (PDE5A)
DM8Y1S7	MT	DTT
DM8Y1S7	MA	Inhibitor
DM8Y1S7	RN	A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5. Bioorg Med Chem Lett. 2002 Sep 2;12(17):2313-6.
DM8Y1S7	RU	https://pubmed.ncbi.nlm.nih.gov/12161123

DMUVKX5	DI	DMUVKX5
DMUVKX5	DN	SOPHORAFLAVANONE B
DMUVKX5	MI	TTZAYWL
DMUVKX5	MN	Estrogen receptor (ESR)
DMUVKX5	MT	DTT
DMUVKX5	MA	Inhibitor
DMUVKX5	RN	Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65.
DMUVKX5	RU	https://pubmed.ncbi.nlm.nih.gov/17149865

DMUVKX5	DI	DMUVKX5
DMUVKX5	DN	SOPHORAFLAVANONE B
DMUVKX5	MI	TTOM3J0
DMUVKX5	MN	Estrogen receptor beta (ESR2)
DMUVKX5	MT	DTT
DMUVKX5	MA	Inhibitor
DMUVKX5	RN	Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65.
DMUVKX5	RU	https://pubmed.ncbi.nlm.nih.gov/17149865

DMUVKX5	DI	DMUVKX5
DMUVKX5	DN	SOPHORAFLAVANONE B
DMUVKX5	MI	TTJ0IQB
DMUVKX5	MN	Phosphodiesterase 5A (PDE5A)
DMUVKX5	MT	DTT
DMUVKX5	MA	Inhibitor
DMUVKX5	RN	Potent inhibition of human phosphodiesterase-5 by icariin derivatives. J Nat Prod. 2008 Sep;71(9):1513-7.
DMUVKX5	RU	https://pubmed.ncbi.nlm.nih.gov/18778098

DMBTMN5	DI	DMBTMN5
DMBTMN5	DN	Sophoraflavanone G
DMBTMN5	MI	TTF8JAT
DMBTMN5	MN	SLC5A2 messenger RNA (SLC5A2 mRNA)
DMBTMN5	MT	DTT
DMBTMN5	MA	Inhibitor
DMBTMN5	RN	Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens. Bioorg Med Chem. 2007 May 15;15(10):3445-9.
DMBTMN5	RU	https://pubmed.ncbi.nlm.nih.gov/17374486

DMBTMN5	DI	DMBTMN5
DMBTMN5	DN	Sophoraflavanone G
DMBTMN5	MI	TT2UE56
DMBTMN5	MN	Sodium/glucose cotransporter 1 (SGLT1)
DMBTMN5	MT	DTT
DMBTMN5	MA	Inhibitor
DMBTMN5	RN	Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens. Bioorg Med Chem. 2007 May 15;15(10):3445-9.
DMBTMN5	RU	https://pubmed.ncbi.nlm.nih.gov/17374486

DM4A0NP	DI	DM4A0NP
DM4A0NP	DN	SOPHORICOSIDE
DM4A0NP	MI	TTPREZD
DM4A0NP	MN	Interleukin-5 (IL5)
DM4A0NP	MT	DTT
DM4A0NP	MA	Inhibitor
DM4A0NP	RN	Design and synthesis of novel hydroxyalkylaminomethylchromones for their IL-5 inhibitory activity. Bioorg Med Chem. 2010 Jul 1;18(13):4625-9. 
DM4A0NP	RU	https://pubmed.ncbi.nlm.nih.gov/20627591

DM18IKZ	DI	DM18IKZ
DM18IKZ	DN	Soraphen A
DM18IKZ	MI	TTY84UG
DM18IKZ	MN	Acetyl-CoA carboxylase 2 (ACACB)
DM18IKZ	MT	DTT
DM18IKZ	MA	Inhibitor
DM18IKZ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM18IKZ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM2TRIZ	DI	DM2TRIZ
DM2TRIZ	DN	SP-08
DM2TRIZ	MI	TTE4KHA
DM2TRIZ	MN	Amyloid beta A4 protein (APP)
DM2TRIZ	MT	DTT
DM2TRIZ	MA	Inhibitor
DM2TRIZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
DM2TRIZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402

DM6VQZ7	DI	DM6VQZ7
DM6VQZ7	DN	SP203
DM6VQZ7	MI	TTHS256
DM6VQZ7	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM6VQZ7	MT	DTT
DM6VQZ7	MA	Modulator (allosteric modulator)
DM6VQZ7	RN	Synthesis and simple 18F-labeling of 3-fluoro-5-(2-(2-(fluoromethyl)thiazol-4-yl)ethynyl)benzonitrile as a high affinity radioligand for imaging mo... J Med Chem. 2007 Jul 12;50(14):3256-66.
DM6VQZ7	RU	https://pubmed.ncbi.nlm.nih.gov/17571866

DM5HUY0	DI	DM5HUY0
DM5HUY0	DN	SP2456
DM5HUY0	MI	TTF89GD
DM5HUY0	MN	Interleukin-2 (IL2)
DM5HUY0	MT	DTT
DM5HUY0	MA	Inhibitor
DM5HUY0	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM5HUY0	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMLA3WY	DI	DMLA3WY
DMLA3WY	DN	SP4160
DMLA3WY	MI	TTF89GD
DMLA3WY	MN	Interleukin-2 (IL2)
DMLA3WY	MT	DTT
DMLA3WY	MA	Inhibitor
DMLA3WY	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMLA3WY	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM4SXIT	DI	DM4SXIT
DM4SXIT	DN	SP-650003
DM4SXIT	MI	TTSXVID
DM4SXIT	MN	Nuclear factor NF-kappa-B (NFKB)
DM4SXIT	MT	DTT
DM4SXIT	MA	Modulator
DM4SXIT	RN	Book (Current Pharmaceutical Design)
DM4SXIT	RU	https://books.google.com.hk/books?id=ZbENzZB8BwwC&pg=PA523&lpg=PA523&dq=SP-650003&source=bl&ots=n0z8_atusD&sig=HB0ARlN36liy5QcqXckEZyeYPpc&hl=zh-CN&sa=X&ved=0ahUKEwj27ubRtKTKAhUHnZQKHfWTDGoQ6AEIHTAA#v=onepage&q=SP-650003&f=false

DMV1W4M	DI	DMV1W4M
DMV1W4M	DN	Sp-722
DMV1W4M	MI	TTU6BFZ
DMV1W4M	MN	Candida Thymidylate synthase (Candi TMP1)
DMV1W4M	MT	DTT
DMV1W4M	MA	Inhibitor
DMV1W4M	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMV1W4M	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DML2V1I	DI	DML2V1I
DML2V1I	DN	Sp7343-Sp7964
DML2V1I	MI	TTELIN2
DML2V1I	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DML2V1I	MT	DTT
DML2V1I	MA	Inhibitor
DML2V1I	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DML2V1I	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMJZKEH	DI	DMJZKEH
DMJZKEH	DN	Sp-876
DMJZKEH	MI	TTU6BFZ
DMJZKEH	MN	Candida Thymidylate synthase (Candi TMP1)
DMJZKEH	MT	DTT
DMJZKEH	MA	Inhibitor
DMJZKEH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMJZKEH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM1VQ4K	DI	DM1VQ4K
DM1VQ4K	DN	Sp-Adenosine-3',5'-Cyclic-Monophosphorothioate
DM1VQ4K	MI	TTNAHEX
DM1VQ4K	MN	cAMP-dependent protein kinase A type I (PRKAR1A)
DM1VQ4K	MT	DTT
DM1VQ4K	MA	Inhibitor
DM1VQ4K	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM1VQ4K	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMV63IP	DI	DMV63IP
DMV63IP	DN	SPANTIDE
DMV63IP	MI	TTZPO1L
DMV63IP	MN	Substance-P receptor (TACR1)
DMV63IP	MT	DTT
DMV63IP	MA	Inhibitor
DMV63IP	RN	Synthesis and substance P antagonist activity of naphthimidazolium derivatives. J Med Chem. 1992 Apr 3;35(7):1273-9.
DMV63IP	RU	https://pubmed.ncbi.nlm.nih.gov/1373191

DMKC6IX	DI	DMKC6IX
DMKC6IX	DN	spantide II
DMKC6IX	MI	TTZPO1L
DMKC6IX	MN	Substance-P receptor (TACR1)
DMKC6IX	MT	DTT
DMKC6IX	MA	Antagonist
DMKC6IX	RN	Spantide II, an effective tachykinin antagonist having high potency and negligible neurotoxicity. Proc Natl Acad Sci U S A. 1990 Jun;87(12):4833-5.
DMKC6IX	RU	https://pubmed.ncbi.nlm.nih.gov/1693780

DMWCIMG	DI	DMWCIMG
DMWCIMG	DN	Sparteine
DMWCIMG	MI	DECB0K3
DMWCIMG	MN	Cytochrome P450 2D6 (CYP2D6)
DMWCIMG	MT	DME
DMWCIMG	MA	Metabolism
DMWCIMG	RN	Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. Pharmacogenetics. 2001 Aug;11(6):477-87.
DMWCIMG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11505218

DMJ6WNK	DI	DMJ6WNK
DMJ6WNK	DN	Spathodic acid
DMJ6WNK	MI	TTELIN2
DMJ6WNK	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMJ6WNK	MT	DTT
DMJ6WNK	MA	Inhibitor
DMJ6WNK	RN	Triterpenoids from the leaves of Diospyros kaki (persimmon) and their inhibitory effects on protein tyrosine phosphatase 1B. J Nat Prod. 2008 Oct;71(10):1775-8.
DMJ6WNK	RU	https://pubmed.ncbi.nlm.nih.gov/18798681

DMFXJKB	DI	DMFXJKB
DMFXJKB	DN	S-p-bromobenzyl glutatione
DMFXJKB	MI	TTV9A7R
DMFXJKB	MN	Lactoylglutathione lyase (GLO1)
DMFXJKB	MT	DTT
DMFXJKB	MA	Inhibitor
DMFXJKB	RN	Inhibition of glyoxalase I: the first low-nanomolar tight-binding inhibitors. J Med Chem. 2009 Aug 13;52(15):4650-6.
DMFXJKB	RU	https://pubmed.ncbi.nlm.nih.gov/19610604

DM9ZBLE	DI	DM9ZBLE
DM9ZBLE	DN	Sphinganine
DM9ZBLE	MI	TTO3TD8
DM9ZBLE	MN	Long transient receptor potential channel 3 (TRPM3)
DM9ZBLE	MT	DTT
DM9ZBLE	MA	Activator
DM9ZBLE	RN	Activation of the melastatin-related cation channel TRPM3 by D-erythro-sphingosine [corrected]. Mol Pharmacol. 2005 Mar;67(3):798-805.
DM9ZBLE	RU	https://pubmed.ncbi.nlm.nih.gov/15550678

DM7ZIMS	DI	DM7ZIMS
DM7ZIMS	DN	sphingosylphosphorylcholine
DM7ZIMS	MI	TT3IPW2
DM7ZIMS	MN	G-protein coupled receptor 12 (GPR12)
DM7ZIMS	MT	DTT
DM7ZIMS	MA	Agonist
DM7ZIMS	RN	Role of the G-protein-coupled receptor GPR12 as high-affinity receptor for sphingosylphosphorylcholine and its expression and function in brain development. J Neurosci. 2003 Feb 1;23(3):907-14.
DM7ZIMS	RU	https://pubmed.ncbi.nlm.nih.gov/12574419

DM8MNVX	DI	DM8MNVX
DM8MNVX	DN	Spingomyelin
DM8MNVX	MI	DEIRJ6O
DM8MNVX	MN	Phospholipase C (plc)
DM8MNVX	MT	DME
DM8MNVX	MA	Metabolism
DM8MNVX	RN	Phospholipase C from Clostridium novyi type A. I. Biochim Biophys Acta. 1975 Oct 21;409(1):75-85.
DM8MNVX	RU	https://pubmed.ncbi.nlm.nih.gov/241423

DMDZIV5	DI	DMDZIV5
DMDZIV5	DN	spiradoline
DMDZIV5	MI	TTQW87Y
DMDZIV5	MN	Opioid receptor kappa (OPRK1)
DMDZIV5	MT	DTT
DMDZIV5	MA	Agonist
DMDZIV5	RN	Cloning and functional comparison of kappa and delta opioid receptors from mouse brain. Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6736-40.
DMDZIV5	RU	https://pubmed.ncbi.nlm.nih.gov/8393575

DM5KNMD	DI	DM5KNMD
DM5KNMD	DN	spiramide
DM5KNMD	MI	TTJQOD7
DM5KNMD	MN	5-HT 2A receptor (HTR2A)
DM5KNMD	MT	DTT
DM5KNMD	MA	Antagonist
DM5KNMD	RN	Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
DM5KNMD	RU	https://pubmed.ncbi.nlm.nih.gov/15322733

DM5KNMD	DI	DM5KNMD
DM5KNMD	DN	spiramide
DM5KNMD	MI	TT0K1SC
DM5KNMD	MN	5-HT 2B receptor (HTR2B)
DM5KNMD	MT	DTT
DM5KNMD	MA	Antagonist
DM5KNMD	RN	Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
DM5KNMD	RU	https://pubmed.ncbi.nlm.nih.gov/15322733

DM5KNMD	DI	DM5KNMD
DM5KNMD	DN	spiramide
DM5KNMD	MI	TTWJBZ5
DM5KNMD	MN	5-HT 2C receptor (HTR2C)
DM5KNMD	MT	DTT
DM5KNMD	MA	Antagonist
DM5KNMD	RN	Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
DM5KNMD	RU	https://pubmed.ncbi.nlm.nih.gov/15322733

DMGFC8D	DI	DMGFC8D
DMGFC8D	DN	Spiro[cyclopropane-1,2-adamantan]-2-amine
DMGFC8D	MI	TTXT3PU
DMGFC8D	MN	Influenza M2 protein (Influ M)
DMGFC8D	MT	DTT
DMGFC8D	MA	Inhibitor
DMGFC8D	RN	Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25.
DMGFC8D	RU	https://pubmed.ncbi.nlm.nih.gov/17139286

DMWU9PV	DI	DMWU9PV
DMWU9PV	DN	Spiro[piperidine-2,2-adamantane]
DMWU9PV	MI	TTXT3PU
DMWU9PV	MN	Influenza M2 protein (Influ M)
DMWU9PV	MT	DTT
DMWU9PV	MA	Inhibitor
DMWU9PV	RN	Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25.
DMWU9PV	RU	https://pubmed.ncbi.nlm.nih.gov/17139286

DMW48JD	DI	DMW48JD
DMW48JD	DN	Spiro[pyrrolidine-2,2-adamantane]
DMW48JD	MI	TTXT3PU
DMW48JD	MN	Influenza M2 protein (Influ M)
DMW48JD	MT	DTT
DMW48JD	MA	Inhibitor
DMW48JD	RN	Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25.
DMW48JD	RU	https://pubmed.ncbi.nlm.nih.gov/17139286

DMNJVZU	DI	DMNJVZU
DMNJVZU	DN	SPIROINDANYLOXYMORPHONE
DMNJVZU	MI	TTQW87Y
DMNJVZU	MN	Opioid receptor kappa (OPRK1)
DMNJVZU	MT	DTT
DMNJVZU	MA	Inhibitor
DMNJVZU	RN	Aerobic oxidation of indolomorphinan without the 4,5-epoxy bridge and subsequent rearrangement of the oxidation product to spiroindolinonyl-C-normo... Bioorg Med Chem. 2009 Aug 15;17(16):5983-8.
DMNJVZU	RU	https://pubmed.ncbi.nlm.nih.gov/19620007

DMNJVZU	DI	DMNJVZU
DMNJVZU	DN	SPIROINDANYLOXYMORPHONE
DMNJVZU	MI	TTKWM86
DMNJVZU	MN	Opioid receptor mu (MOP)
DMNJVZU	MT	DTT
DMNJVZU	MA	Inhibitor
DMNJVZU	RN	Aerobic oxidation of indolomorphinan without the 4,5-epoxy bridge and subsequent rearrangement of the oxidation product to spiroindolinonyl-C-normo... Bioorg Med Chem. 2009 Aug 15;17(16):5983-8.
DMNJVZU	RU	https://pubmed.ncbi.nlm.nih.gov/19620007

DMPHRXQ	DI	DMPHRXQ
DMPHRXQ	DN	spiroxatrine
DMPHRXQ	MI	TTSQIFT
DMPHRXQ	MN	5-HT 1A receptor (HTR1A)
DMPHRXQ	MT	DTT
DMPHRXQ	MA	Agonist
DMPHRXQ	RN	Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol. 1998 Aug 21;355(2-3):245-56.
DMPHRXQ	RU	https://pubmed.ncbi.nlm.nih.gov/9760039

DMPHRXQ	DI	DMPHRXQ
DMPHRXQ	DN	spiroxatrine
DMPHRXQ	MI	TT0K1SC
DMPHRXQ	MN	5-HT 2B receptor (HTR2B)
DMPHRXQ	MT	DTT
DMPHRXQ	MA	Antagonist
DMPHRXQ	RN	[3H]Rauwolscine: an antagonist radioligand for the cloned human 5-hydroxytryptamine2b (5-HT2B) receptor. Naunyn Schmiedebergs Arch Pharmacol. 1998 Jan;357(1):17-24.
DMPHRXQ	RU	https://pubmed.ncbi.nlm.nih.gov/9459568

DMPHRXQ	DI	DMPHRXQ
DMPHRXQ	DN	spiroxatrine
DMPHRXQ	MI	TTBRKXS
DMPHRXQ	MN	Adrenergic receptor alpha-1B (ADRA1B)
DMPHRXQ	MT	DTT
DMPHRXQ	MA	Antagonist
DMPHRXQ	RN	Affinity of serotonin receptor antagonists and agonists to recombinant and native alpha1-adrenoceptor subtypes. Jpn J Pharmacol. 2001 Jun;86(2):189-95.
DMPHRXQ	RU	https://pubmed.ncbi.nlm.nih.gov/11459121

DMPHRXQ	DI	DMPHRXQ
DMPHRXQ	DN	spiroxatrine
DMPHRXQ	MI	TTWM4TY
DMPHRXQ	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMPHRXQ	MT	DTT
DMPHRXQ	MA	Antagonist
DMPHRXQ	RN	The novel alpha-2 adrenergic radioligand [3H]-MK912 is alpha-2C selective among human alpha-2A, alpha-2B and alpha-2C adrenoceptors. J Pharmacol Exp Ther. 1994 Dec;271(3):1558-65.
DMPHRXQ	RU	https://pubmed.ncbi.nlm.nih.gov/7996470

DMPHRXQ	DI	DMPHRXQ
DMPHRXQ	DN	spiroxatrine
DMPHRXQ	MI	TT2NUT5
DMPHRXQ	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMPHRXQ	MT	DTT
DMPHRXQ	MA	Antagonist
DMPHRXQ	RN	Affinity of serotonin receptor antagonists and agonists to recombinant and native alpha1-adrenoceptor subtypes. Jpn J Pharmacol. 2001 Jun;86(2):189-95.
DMPHRXQ	RU	https://pubmed.ncbi.nlm.nih.gov/11459121

DMCLHZ5	DI	DMCLHZ5
DMCLHZ5	DN	splitomicin
DMCLHZ5	MI	TTUF2HO
DMCLHZ5	MN	NAD-dependent deacetylase sirtuin-1 (SIRT1)
DMCLHZ5	MT	DTT
DMCLHZ5	MA	Inhibitor
DMCLHZ5	RN	Characterization of sirtuin inhibitors in nematodes expressing a muscular dystrophy protein reveals muscle cell and behavioral protection by specif... J Med Chem. 2010 Feb 11;53(3):1407-11.
DMCLHZ5	RU	https://pubmed.ncbi.nlm.nih.gov/20041717

DMYBCEG	DI	DMYBCEG
DMYBCEG	DN	S-P-Nitrobenzyloxycarbonylglutathione
DMYBCEG	MI	TTV9A7R
DMYBCEG	MN	Lactoylglutathione lyase (GLO1)
DMYBCEG	MT	DTT
DMYBCEG	MA	Inhibitor
DMYBCEG	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMYBCEG	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM0GJVS	DI	DM0GJVS
DM0GJVS	DN	SPONGIADIOXIN A
DM0GJVS	MI	TTN9T81
DM0GJVS	MN	Arachidonate 15-lipoxygenase (15-LOX)
DM0GJVS	MT	DTT
DM0GJVS	MA	Inhibitor
DM0GJVS	RN	Probing the activity differences of simple and complex brominated aryl compounds against 15-soybean, 15-human, and 12-human lipoxygenase. J Med Chem. 2004 Jul 29;47(16):4060-5.
DM0GJVS	RU	https://pubmed.ncbi.nlm.nih.gov/15267244

DMP5VN2	DI	DMP5VN2
DMP5VN2	DN	SPP-800
DMP5VN2	MI	TTB2MXP
DMP5VN2	MN	Angiotensinogenase renin (REN)
DMP5VN2	MT	DTT
DMP5VN2	MA	Inhibitor
DMP5VN2	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2413).
DMP5VN2	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2413

DMFTLY9	DI	DMFTLY9
DMFTLY9	DN	S-propyl propane-1-sulfinothioate
DMFTLY9	MI	TT2SUAQ
DMFTLY9	MN	Cysteine protease (CYP)
DMFTLY9	MT	DTT
DMFTLY9	MA	Inhibitor
DMFTLY9	RN	Allicin and derivates are cysteine protease inhibitors with antiparasitic activity. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5541-3.
DMFTLY9	RU	https://pubmed.ncbi.nlm.nih.gov/20692829

DMKCJQW	DI	DMKCJQW
DMKCJQW	DN	SP-SAP
DMKCJQW	MI	TTZPO1L
DMKCJQW	MN	Substance-P receptor (TACR1)
DMKCJQW	MT	DTT
DMKCJQW	MA	Inhibitor
DMKCJQW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 360).
DMKCJQW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=360

DM94RJW	DI	DM94RJW
DM94RJW	DN	SPT
DM94RJW	MI	TTSLI08
DM94RJW	MN	Adenosine receptor (ADOR)
DM94RJW	MT	DTT
DM94RJW	MA	Antagonist
DM94RJW	RN	Pretreatment with angiotensin II activates protein kinase C and limits myocardial infarction in isolated rabbit hearts. J Mol Cell Cardiol. 1995 Mar;27(3):883-92.
DM94RJW	RU	https://pubmed.ncbi.nlm.nih.gov/7602606

DMRP42B	DI	DMRP42B
DMRP42B	DN	SQ 26655
DMRP42B	MI	TT2O84V
DMRP42B	MN	Thromboxane A2 receptor (TBXA2R)
DMRP42B	MT	DTT
DMRP42B	MA	Agonist
DMRP42B	RN	Synthesis and in vitro pharmacology of 7-oxabicyclo[2.2.1]heptane analogues of thromboxane A2/PGH2. J Med Chem. 1985 Nov;28(11):1580-90.
DMRP42B	RU	https://pubmed.ncbi.nlm.nih.gov/4067988

DMJW8NV	DI	DMJW8NV
DMJW8NV	DN	SQ-14603
DMJW8NV	MI	TT3LJ6G
DMJW8NV	MN	Carboxypeptidase A1 (CPA1)
DMJW8NV	MT	DTT
DMJW8NV	MA	Inhibitor
DMJW8NV	RN	Discovery of potent &amp; selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis. J Med Chem. 2007 Nov 29;50(24):6095-103.
DMJW8NV	RU	https://pubmed.ncbi.nlm.nih.gov/17990866

DMW7Y9L	DI	DMW7Y9L
DMW7Y9L	DN	SQ-24798
DMW7Y9L	MI	TTP18AY
DMW7Y9L	MN	Carboxypeptidase B2 (CPB2)
DMW7Y9L	MT	DTT
DMW7Y9L	MA	Inhibitor
DMW7Y9L	RN	3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa). Bioorg Med Chem Lett. 2007 Mar 1;17(5):1349-54.
DMW7Y9L	RU	https://pubmed.ncbi.nlm.nih.gov/17189688

DMLPN95	DI	DMLPN95
DMLPN95	DN	SQ-27986
DMLPN95	MI	TTNVEIR
DMLPN95	MN	Prostaglandin D2 receptor (PTGDR)
DMLPN95	MT	DTT
DMLPN95	MA	Agonist
DMLPN95	RN	Affinities, selectivities, potencies, and intrinsic activities of natural and synthetic prostanoids using endogenous receptors: focus on DP class prostanoids. J Pharmacol Exp Ther. 2000 May;293(2):321-8.
DMLPN95	RU	https://pubmed.ncbi.nlm.nih.gov/10772998

DM9G3UD	DI	DM9G3UD
DM9G3UD	DN	SQ-29548
DM9G3UD	MI	TT2O84V
DM9G3UD	MN	Thromboxane A2 receptor (TBXA2R)
DM9G3UD	MT	DTT
DM9G3UD	MA	Inhibitor
DM9G3UD	RN	The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
DM9G3UD	RU	https://pubmed.ncbi.nlm.nih.gov/10634944

DML6SIE	DI	DML6SIE
DML6SIE	DN	SQ32,910
DML6SIE	MI	TTXHYV6
DML6SIE	MN	Voltage-gated L-type calcium channel (L-CaC)
DML6SIE	MT	DTT
DML6SIE	MA	Blocker
DML6SIE	RN	Molecular determinants of drug binding and action on L-type calcium channels. Annu Rev Pharmacol Toxicol. 1997;37:361-96.
DML6SIE	RU	https://pubmed.ncbi.nlm.nih.gov/9131258

DMBA297	DI	DMBA297
DMBA297	DN	SR11254
DMBA297	MI	TT1Q3IE
DMBA297	MN	Retinoic acid receptor gamma (RARG)
DMBA297	MT	DTT
DMBA297	MA	Inhibitor
DMBA297	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMBA297	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMPN3Q0	DI	DMPN3Q0
DMPN3Q0	DN	SR-14136
DMPN3Q0	MI	TTNT7K8
DMPN3Q0	MN	Nociceptin receptor (OPRL1)
DMPN3Q0	MT	DTT
DMPN3Q0	MA	Binder
DMPN3Q0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 320).
DMPN3Q0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=320

DMMXU6R	DI	DMMXU6R
DMMXU6R	DN	SR142948A
DMMXU6R	MI	TTTUMEP
DMMXU6R	MN	Neurotensin receptor type 1 (NTSR1)
DMMXU6R	MT	DTT
DMMXU6R	MA	Antagonist
DMMXU6R	RN	Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist. J Pharmacol Exp Ther. 1997 Feb;280(2):802-12.
DMMXU6R	RU	https://pubmed.ncbi.nlm.nih.gov/9023294

DMBRVXY	DI	DMBRVXY
DMBRVXY	DN	SR144528
DMBRVXY	MI	TTMSFAW
DMBRVXY	MN	Cannabinoid receptor 2 (CB2)
DMBRVXY	MT	DTT
DMBRVXY	MA	Antagonist
DMBRVXY	RN	Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur J Pharmacol. 2001 May 11;419(2-3):191-8.
DMBRVXY	RU	https://pubmed.ncbi.nlm.nih.gov/11426841

DMPO4WX	DI	DMPO4WX
DMPO4WX	DN	SR-33805A
DMPO4WX	MI	TT5HONZ
DMPO4WX	MN	Calcium channel unspecific (CaC)
DMPO4WX	MT	DTT
DMPO4WX	MA	Modulator
DMPO4WX	RN	Vascular calcium overload produced by vitamin D3, in rats. Effect of treatment with SR 33805, a novel calcium entry blocker. Cardiovasc Res. 1995 Dec;30(6):1038-43.
DMPO4WX	RU	https://pubmed.ncbi.nlm.nih.gov/8746222

DM3Y09Z	DI	DM3Y09Z
DM3Y09Z	DN	SR-3850
DM3Y09Z	MI	TTZN7RP
DM3Y09Z	MN	Rho-associated protein kinase 1 (ROCK1)
DM3Y09Z	MT	DTT
DM3Y09Z	MA	Inhibitor
DM3Y09Z	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1503).
DM3Y09Z	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1503

DM3Y09Z	DI	DM3Y09Z
DM3Y09Z	DN	SR-3850
DM3Y09Z	MI	TTGWKQJ
DM3Y09Z	MN	Rho-associated protein kinase 2 (ROCK2)
DM3Y09Z	MT	DTT
DM3Y09Z	MA	Inhibitor
DM3Y09Z	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1504).
DM3Y09Z	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1504

DMUHQS9	DI	DMUHQS9
DMUHQS9	DN	SR48527
DMUHQS9	MI	TTTUMEP
DMUHQS9	MN	Neurotensin receptor type 1 (NTSR1)
DMUHQS9	MT	DTT
DMUHQS9	MA	Antagonist
DMUHQS9	RN	[3H]SR 48692, the first nonpeptide neurotensin antagonist radioligand: characterization of binding properties and evidence for distinct agonist and antagonist binding domains on the rat neurotensin receptor. Mol Pharmacol. 1995 May;47(5):1050-6.
DMUHQS9	RU	https://pubmed.ncbi.nlm.nih.gov/7746272

DMCRVM2	DI	DMCRVM2
DMCRVM2	DN	SR-59026
DMCRVM2	MI	TTSQIFT
DMCRVM2	MN	5-HT 1A receptor (HTR1A)
DMCRVM2	MT	DTT
DMCRVM2	MA	Modulator
DMCRVM2	RN	Effect of SR 59026A, a new 5-HT(1A) receptor agonist, on sexual activity in male rats. Behav Pharmacol. 1995 Apr;6(3):276-282.
DMCRVM2	RU	https://www.ncbi.nlm.nih.gov/pubmed/11224336

DM2WIGO	DI	DM2WIGO
DM2WIGO	DN	SR9238
DM2WIGO	MI	TTECBXN
DM2WIGO	MN	Oxysterols receptor LXR-alpha (NR1H3)
DM2WIGO	MT	DTT
DM2WIGO	MA	Antagonist
DM2WIGO	RN	A liver-selective LXR inverse agonist that suppresses hepatic steatosis. ACS Chem Biol. 2013 Mar 15;8(3):559-67.
DM2WIGO	RU	https://pubmed.ncbi.nlm.nih.gov/23237488

DM2WIGO	DI	DM2WIGO
DM2WIGO	DN	SR9238
DM2WIGO	MI	TTXA6PH
DM2WIGO	MN	Oxysterols receptor LXR-beta (NR1H2)
DM2WIGO	MT	DTT
DM2WIGO	MA	Antagonist
DM2WIGO	RN	A liver-selective LXR inverse agonist that suppresses hepatic steatosis. ACS Chem Biol. 2013 Mar 15;8(3):559-67.
DM2WIGO	RU	https://pubmed.ncbi.nlm.nih.gov/23237488

DMA28ZX	DI	DMA28ZX
DMA28ZX	DN	SR95531
DMA28ZX	MI	TTNJYV2
DMA28ZX	MN	Gamma-aminobutyric acid receptor (GAR)
DMA28ZX	MT	DTT
DMA28ZX	MA	Antagonist
DMA28ZX	RN	GABA receptors inhibited by benzodiazepines mediate fast inhibitory transmission in the central amygdala. J Neurosci. 1999 Nov 15;19(22):9698-704.
DMA28ZX	RU	https://pubmed.ncbi.nlm.nih.gov/10559379

DMU48OD	DI	DMU48OD
DMU48OD	DN	SR-973
DMU48OD	MI	TTE4KHA
DMU48OD	MN	Amyloid beta A4 protein (APP)
DMU48OD	MT	DTT
DMU48OD	MA	Inhibitor
DMU48OD	RN	Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2357-63.
DMU48OD	RU	https://pubmed.ncbi.nlm.nih.gov/16473009

DMU48OD	DI	DMU48OD
DMU48OD	DN	SR-973
DMU48OD	MI	TTMX39J
DMU48OD	MN	Matrix metalloproteinase-1 (MMP-1)
DMU48OD	MT	DTT
DMU48OD	MA	Inhibitor
DMU48OD	RN	Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2357-63.
DMU48OD	RU	https://pubmed.ncbi.nlm.nih.gov/16473009

DMU48OD	DI	DMU48OD
DMU48OD	DN	SR-973
DMU48OD	MI	TTHY57M
DMU48OD	MN	Matrix metalloproteinase-13 (MMP-13)
DMU48OD	MT	DTT
DMU48OD	MA	Inhibitor
DMU48OD	RN	Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2357-63.
DMU48OD	RU	https://pubmed.ncbi.nlm.nih.gov/16473009

DMU48OD	DI	DMU48OD
DMU48OD	DN	SR-973
DMU48OD	MI	TTJ4QE7
DMU48OD	MN	Matrix metalloproteinase-14 (MMP-14)
DMU48OD	MT	DTT
DMU48OD	MA	Inhibitor
DMU48OD	RN	Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2357-63.
DMU48OD	RU	https://pubmed.ncbi.nlm.nih.gov/16473009

DMU48OD	DI	DMU48OD
DMU48OD	DN	SR-973
DMU48OD	MI	TTLM12X
DMU48OD	MN	Matrix metalloproteinase-2 (MMP-2)
DMU48OD	MT	DTT
DMU48OD	MA	Inhibitor
DMU48OD	RN	Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2357-63.
DMU48OD	RU	https://pubmed.ncbi.nlm.nih.gov/16473009

DMU48OD	DI	DMU48OD
DMU48OD	DN	SR-973
DMU48OD	MI	TTYRF5E
DMU48OD	MN	Matrix metalloproteinase-21 (MMP-21)
DMU48OD	MT	DTT
DMU48OD	MA	Inhibitor
DMU48OD	RN	Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2357-63.
DMU48OD	RU	https://pubmed.ncbi.nlm.nih.gov/16473009

DMU48OD	DI	DMU48OD
DMU48OD	DN	SR-973
DMU48OD	MI	TTMTWOS
DMU48OD	MN	Matrix metalloproteinase-7 (MMP-7)
DMU48OD	MT	DTT
DMU48OD	MA	Inhibitor
DMU48OD	RN	Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2357-63.
DMU48OD	RU	https://pubmed.ncbi.nlm.nih.gov/16473009

DMU48OD	DI	DMU48OD
DMU48OD	DN	SR-973
DMU48OD	MI	TT6X50U
DMU48OD	MN	Matrix metalloproteinase-9 (MMP-9)
DMU48OD	MT	DTT
DMU48OD	MA	Inhibitor
DMU48OD	RN	Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2357-63.
DMU48OD	RU	https://pubmed.ncbi.nlm.nih.gov/16473009

DMU48OD	DI	DMU48OD
DMU48OD	DN	SR-973
DMU48OD	MI	TT6AZXG
DMU48OD	MN	TNF alpha converting enzyme (ADAM17)
DMU48OD	MT	DTT
DMU48OD	MA	Inhibitor
DMU48OD	RN	Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2357-63.
DMU48OD	RU	https://pubmed.ncbi.nlm.nih.gov/16473009

DM37YJH	DI	DM37YJH
DM37YJH	DN	SRA880
DM37YJH	MI	TTIND6G
DM37YJH	MN	Somatostatin receptor type 1 (SSTR1)
DM37YJH	MT	DTT
DM37YJH	MA	Antagonist
DM37YJH	RN	SRA880, in vitro characterization of the first non-peptide somatostatin sst(1) receptor antagonist. Neurosci Lett. 2004 May 6;361(1-3):132-5.
DM37YJH	RU	https://pubmed.ncbi.nlm.nih.gov/15135911

DMUZP9V	DI	DMUZP9V
DMUZP9V	DN	Src kinase inhibitor I
DMUZP9V	MI	TTCQ2E5
DMUZP9V	MN	RIP2 messenger RNA (RIP2 mRNA)
DMUZP9V	MT	DTT
DMUZP9V	MA	Inhibitor
DMUZP9V	RN	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
DMUZP9V	RU	https://pubmed.ncbi.nlm.nih.gov/17850214

DM35NF6	DI	DM35NF6
DM35NF6	DN	SRI-224
DM35NF6	MI	TTULVH8
DM35NF6	MN	Tyrosinase (TYR)
DM35NF6	MT	DTT
DM35NF6	MA	Inhibitor
DM35NF6	RN	Discovery of 4-functionalized phenyl-O-beta-D-glycosides as a new class of mushroom tyrosinase inhibitors. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6157-60.
DM35NF6	RU	https://pubmed.ncbi.nlm.nih.gov/19800229

DM8GDZS	DI	DM8GDZS
DM8GDZS	DN	SRI-63-675
DM8GDZS	MI	TTQL5VC
DM8GDZS	MN	Platelet-activating factor receptor (PTAFR)
DM8GDZS	MT	DTT
DM8GDZS	MA	Modulator
DM8GDZS	RN	The effect of SRI 63-675, a competitive platelet-activating factor receptor-antagonist, in the generalized Shwartzman reaction. J Lipid Mediat Cell Signal. 1994 Sep;10(3):229-42.
DM8GDZS	RU	https://www.ncbi.nlm.nih.gov/pubmed/7812674

DM5GILS	DI	DM5GILS
DM5GILS	DN	Sri-9439
DM5GILS	MI	TT9SL3Q
DM5GILS	MN	Polypeptide deformylase (PDF)
DM5GILS	MT	DTT
DM5GILS	MA	Inhibitor
DM5GILS	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DM5GILS	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMYO4A3	DI	DMYO4A3
DMYO4A3	DN	Sri-9662
DMYO4A3	MI	TT9SL3Q
DMYO4A3	MN	Polypeptide deformylase (PDF)
DMYO4A3	MT	DTT
DMYO4A3	MA	Inhibitor
DMYO4A3	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMYO4A3	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMDY1M7	DI	DMDY1M7
DMDY1M7	DN	SRIF-14
DMDY1M7	MI	TTIND6G
DMDY1M7	MN	Somatostatin receptor type 1 (SSTR1)
DMDY1M7	MT	DTT
DMDY1M7	MA	Agonist
DMDY1M7	RN	Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2. Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10836-41.
DMDY1M7	RU	https://pubmed.ncbi.nlm.nih.gov/9724791

DMDY1M7	DI	DMDY1M7
DMDY1M7	DN	SRIF-14
DMDY1M7	MI	TTZ6T9E
DMDY1M7	MN	Somatostatin receptor type 2 (SSTR2)
DMDY1M7	MT	DTT
DMDY1M7	MA	Agonist
DMDY1M7	RN	[125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors. Eur J Pharmacol. 1998 May 8;348(2-3):311-20.
DMDY1M7	RU	https://pubmed.ncbi.nlm.nih.gov/9652348

DMDY1M7	DI	DMDY1M7
DMDY1M7	DN	SRIF-14
DMDY1M7	MI	TTJX3UE
DMDY1M7	MN	Somatostatin receptor type 3 (SSTR3)
DMDY1M7	MT	DTT
DMDY1M7	MA	Agonist
DMDY1M7	RN	A human somatostatin receptor (SSTR3), located on chromosome 22, displays preferential affinity for somatostatin-14 like peptides. FEBS Lett. 1993 Apr 26;321(2-3):279-84.
DMDY1M7	RU	https://pubmed.ncbi.nlm.nih.gov/8097479

DMDY1M7	DI	DMDY1M7
DMDY1M7	DN	SRIF-14
DMDY1M7	MI	TTAE1BR
DMDY1M7	MN	Somatostatin receptor type 4 (SSTR4)
DMDY1M7	MT	DTT
DMDY1M7	MA	Agonist
DMDY1M7	RN	Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2. Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10836-41.
DMDY1M7	RU	https://pubmed.ncbi.nlm.nih.gov/9724791

DMDY1M7	DI	DMDY1M7
DMDY1M7	DN	SRIF-14
DMDY1M7	MI	TT2BC4G
DMDY1M7	MN	Somatostatin receptor type 5 (SSTR5)
DMDY1M7	MT	DTT
DMDY1M7	MA	Agonist
DMDY1M7	RN	[125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors. Eur J Pharmacol. 1998 May 8;348(2-3):311-20.
DMDY1M7	RU	https://pubmed.ncbi.nlm.nih.gov/9652348

DM0OM9L	DI	DM0OM9L
DM0OM9L	DN	SRIF-28
DM0OM9L	MI	TTIND6G
DM0OM9L	MN	Somatostatin receptor type 1 (SSTR1)
DM0OM9L	MT	DTT
DM0OM9L	MA	Inhibitor
DM0OM9L	RN	Novel octreotide dicarba-analogues with high affinity and different selectivity for somatostatin receptors. J Med Chem. 2010 Aug 26;53(16):6188-97.
DM0OM9L	RU	https://pubmed.ncbi.nlm.nih.gov/20666484

DM0OM9L	DI	DM0OM9L
DM0OM9L	DN	SRIF-28
DM0OM9L	MI	TTZ6T9E
DM0OM9L	MN	Somatostatin receptor type 2 (SSTR2)
DM0OM9L	MT	DTT
DM0OM9L	MA	Inhibitor
DM0OM9L	RN	Novel octreotide dicarba-analogues with high affinity and different selectivity for somatostatin receptors. J Med Chem. 2010 Aug 26;53(16):6188-97.
DM0OM9L	RU	https://pubmed.ncbi.nlm.nih.gov/20666484

DM0OM9L	DI	DM0OM9L
DM0OM9L	DN	SRIF-28
DM0OM9L	MI	TTJX3UE
DM0OM9L	MN	Somatostatin receptor type 3 (SSTR3)
DM0OM9L	MT	DTT
DM0OM9L	MA	Inhibitor
DM0OM9L	RN	Novel octreotide dicarba-analogues with high affinity and different selectivity for somatostatin receptors. J Med Chem. 2010 Aug 26;53(16):6188-97.
DM0OM9L	RU	https://pubmed.ncbi.nlm.nih.gov/20666484

DM0OM9L	DI	DM0OM9L
DM0OM9L	DN	SRIF-28
DM0OM9L	MI	TTAE1BR
DM0OM9L	MN	Somatostatin receptor type 4 (SSTR4)
DM0OM9L	MT	DTT
DM0OM9L	MA	Inhibitor
DM0OM9L	RN	Novel octreotide dicarba-analogues with high affinity and different selectivity for somatostatin receptors. J Med Chem. 2010 Aug 26;53(16):6188-97.
DM0OM9L	RU	https://pubmed.ncbi.nlm.nih.gov/20666484

DM0OM9L	DI	DM0OM9L
DM0OM9L	DN	SRIF-28
DM0OM9L	MI	TT2BC4G
DM0OM9L	MN	Somatostatin receptor type 5 (SSTR5)
DM0OM9L	MT	DTT
DM0OM9L	MA	Inhibitor
DM0OM9L	RN	Novel octreotide dicarba-analogues with high affinity and different selectivity for somatostatin receptors. J Med Chem. 2010 Aug 26;53(16):6188-97.
DM0OM9L	RU	https://pubmed.ncbi.nlm.nih.gov/20666484

DMUKVHQ	DI	DMUKVHQ
DMUKVHQ	DN	SRT1720
DMUKVHQ	MI	TTUF2HO
DMUKVHQ	MN	NAD-dependent deacetylase sirtuin-1 (SIRT1)
DMUKVHQ	MT	DTT
DMUKVHQ	MA	Activator
DMUKVHQ	RN	Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007 Nov 29;450(7170):712-6.
DMUKVHQ	RU	https://pubmed.ncbi.nlm.nih.gov/18046409

DMF0X2S	DI	DMF0X2S
DMF0X2S	DN	SSR126768A
DMF0X2S	MI	TTSCIUP
DMF0X2S	MN	Oxytocin receptor (OTR)
DMF0X2S	MT	DTT
DMF0X2S	MA	Antagonist
DMF0X2S	RN	SSR126768A (4-chloro-3-[(3R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-N-ethyl-N-(3-pyridylmethyl)-benzamide, ... J Pharmacol Exp Ther. 2004 Apr;309(1):414-24.
DMF0X2S	RU	https://pubmed.ncbi.nlm.nih.gov/14722330

DMF0X2S	DI	DMF0X2S
DMF0X2S	DN	SSR126768A
DMF0X2S	MI	TT4TFGN
DMF0X2S	MN	Vasopressin V1a receptor (V1AR)
DMF0X2S	MT	DTT
DMF0X2S	MA	Antagonist
DMF0X2S	RN	SSR126768A (4-chloro-3-[(3R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-N-ethyl-N-(3-pyridylmethyl)-benzamide, ... J Pharmacol Exp Ther. 2004 Apr;309(1):414-24.
DMF0X2S	RU	https://pubmed.ncbi.nlm.nih.gov/14722330

DMDIYWV	DI	DMDIYWV
DMDIYWV	DN	S-sulpho-L-cysteine
DMDIYWV	MI	TTQWGU9
DMDIYWV	MN	Bacterial Aspartate-semialdehyde dehydrogenase (Bact asd2)
DMDIYWV	MT	DTT
DMDIYWV	MA	Inhibitor
DMDIYWV	RN	Petrosamine B, an inhibitor of the Helicobacter pylori enzyme aspartyl semialdehyde dehydrogenase from the Australian sponge Oceanapia sp. J Nat Prod. 2005 May;68(5):804-6.
DMDIYWV	RU	https://pubmed.ncbi.nlm.nih.gov/15921437

DMO7WRU	DI	DMO7WRU
DMO7WRU	DN	ST074946
DMO7WRU	MI	TTMBUHI
DMO7WRU	MN	Deneddylase-1 (SENP8)
DMO7WRU	MT	DTT
DMO7WRU	MA	Inhibitor
DMO7WRU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2417).
DMO7WRU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2417

DM14PLC	DI	DM14PLC
DM14PLC	DN	ST-1025
DM14PLC	MI	TT9JNIC
DM14PLC	MN	Histamine H3 receptor (H3R)
DM14PLC	MT	DTT
DM14PLC	MA	Inhibitor
DM14PLC	RN	Azole derivatives as histamine H3 receptor antagonists, part 2: C-C and C-S coupled heterocycles. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5883-6.
DM14PLC	RU	https://pubmed.ncbi.nlm.nih.gov/20727744

DMKZJWV	DI	DMKZJWV
DMKZJWV	DN	ST-1093
DMKZJWV	MI	TT9JNIC
DMKZJWV	MN	Histamine H3 receptor (H3R)
DMKZJWV	MT	DTT
DMKZJWV	MA	Inhibitor
DMKZJWV	RN	Azole derivatives as histamine H3 receptor antagonists, part 2: C-C and C-S coupled heterocycles. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5883-6.
DMKZJWV	RU	https://pubmed.ncbi.nlm.nih.gov/20727744

DMUTC9Z	DI	DMUTC9Z
DMUTC9Z	DN	ST-1535
DMUTC9Z	MI	TTK25J1
DMUTC9Z	MN	Adenosine A1 receptor (ADORA1)
DMUTC9Z	MT	DTT
DMUTC9Z	MA	Inhibitor
DMUTC9Z	RN	2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96.
DMUTC9Z	RU	https://pubmed.ncbi.nlm.nih.gov/16250647

DMUTC9Z	DI	DMUTC9Z
DMUTC9Z	DN	ST-1535
DMUTC9Z	MI	TTM2AOE
DMUTC9Z	MN	Adenosine A2a receptor (ADORA2A)
DMUTC9Z	MT	DTT
DMUTC9Z	MA	Inhibitor
DMUTC9Z	RN	2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem. 2008 Aug 14;51(15):4449-55.
DMUTC9Z	RU	https://pubmed.ncbi.nlm.nih.gov/18637670

DMUTC9Z	DI	DMUTC9Z
DMUTC9Z	DN	ST-1535
DMUTC9Z	MI	TTNE7KG
DMUTC9Z	MN	Adenosine A2b receptor (ADORA2B)
DMUTC9Z	MT	DTT
DMUTC9Z	MA	Inhibitor
DMUTC9Z	RN	2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96.
DMUTC9Z	RU	https://pubmed.ncbi.nlm.nih.gov/16250647

DMR1G40	DI	DMR1G40
DMR1G40	DN	ST-1646
DMR1G40	MI	TTT1R2L
DMR1G40	MN	Integrin alpha-V (ITGAV)
DMR1G40	MT	DTT
DMR1G40	MA	Inhibitor
DMR1G40	RN	Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82.
DMR1G40	RU	https://pubmed.ncbi.nlm.nih.gov/18303826

DMR1G40	DI	DMR1G40
DMR1G40	DN	ST-1646
DMR1G40	MI	TTJA1ZO
DMR1G40	MN	ITGB3 messenger RNA (ITGB3 mRNA)
DMR1G40	MT	DTT
DMR1G40	MA	Inhibitor
DMR1G40	RN	Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82.
DMR1G40	RU	https://pubmed.ncbi.nlm.nih.gov/18303826

DM73E0G	DI	DM73E0G
DM73E0G	DN	ST-2741
DM73E0G	MI	TT5ZKDI
DM73E0G	MN	Histone deacetylase 6 (HDAC6)
DM73E0G	MT	DTT
DM73E0G	MA	Inhibitor
DM73E0G	RN	Exploring bis-(indolyl)methane moiety as an alternative and innovative CAP group in the design of histone deacetylase (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 May 15;19(10):2840-3.
DM73E0G	RU	https://pubmed.ncbi.nlm.nih.gov/19359173

DMNERM6	DI	DMNERM6
DMNERM6	DN	ST-2986
DMNERM6	MI	TTBH0VX
DMNERM6	MN	Histone deacetylase (HDAC)
DMNERM6	MT	DTT
DMNERM6	MA	Inhibitor
DMNERM6	RN	N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9.
DMNERM6	RU	https://pubmed.ncbi.nlm.nih.gov/19285395

DMNERM6	DI	DMNERM6
DMNERM6	DN	ST-2986
DMNERM6	MI	TT6R7JZ
DMNERM6	MN	Histone deacetylase 1 (HDAC1)
DMNERM6	MT	DTT
DMNERM6	MA	Inhibitor
DMNERM6	RN	N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9.
DMNERM6	RU	https://pubmed.ncbi.nlm.nih.gov/19285395

DMNERM6	DI	DMNERM6
DMNERM6	DN	ST-2986
DMNERM6	MI	TTYHPU6
DMNERM6	MN	Histone deacetylase 10 (HDAC10)
DMNERM6	MT	DTT
DMNERM6	MA	Inhibitor
DMNERM6	RN	N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9.
DMNERM6	RU	https://pubmed.ncbi.nlm.nih.gov/19285395

DMNERM6	DI	DMNERM6
DMNERM6	DN	ST-2986
DMNERM6	MI	TTSHTOI
DMNERM6	MN	Histone deacetylase 2 (HDAC2)
DMNERM6	MT	DTT
DMNERM6	MA	Inhibitor
DMNERM6	RN	N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9.
DMNERM6	RU	https://pubmed.ncbi.nlm.nih.gov/19285395

DMNERM6	DI	DMNERM6
DMNERM6	DN	ST-2986
DMNERM6	MI	TT5ZKDI
DMNERM6	MN	Histone deacetylase 6 (HDAC6)
DMNERM6	MT	DTT
DMNERM6	MA	Inhibitor
DMNERM6	RN	N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9.
DMNERM6	RU	https://pubmed.ncbi.nlm.nih.gov/19285395

DMNERM6	DI	DMNERM6
DMNERM6	DN	ST-2986
DMNERM6	MI	TTT6LFV
DMNERM6	MN	Histone deacetylase 8 (HDAC8)
DMNERM6	MT	DTT
DMNERM6	MA	Inhibitor
DMNERM6	RN	N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9.
DMNERM6	RU	https://pubmed.ncbi.nlm.nih.gov/19285395

DMWXTM8	DI	DMWXTM8
DMWXTM8	DN	ST-2987
DMWXTM8	MI	TTBH0VX
DMWXTM8	MN	Histone deacetylase (HDAC)
DMWXTM8	MT	DTT
DMWXTM8	MA	Inhibitor
DMWXTM8	RN	N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9.
DMWXTM8	RU	https://pubmed.ncbi.nlm.nih.gov/19285395

DMWXTM8	DI	DMWXTM8
DMWXTM8	DN	ST-2987
DMWXTM8	MI	TT6R7JZ
DMWXTM8	MN	Histone deacetylase 1 (HDAC1)
DMWXTM8	MT	DTT
DMWXTM8	MA	Inhibitor
DMWXTM8	RN	N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9.
DMWXTM8	RU	https://pubmed.ncbi.nlm.nih.gov/19285395

DMWXTM8	DI	DMWXTM8
DMWXTM8	DN	ST-2987
DMWXTM8	MI	TTYHPU6
DMWXTM8	MN	Histone deacetylase 10 (HDAC10)
DMWXTM8	MT	DTT
DMWXTM8	MA	Inhibitor
DMWXTM8	RN	N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9.
DMWXTM8	RU	https://pubmed.ncbi.nlm.nih.gov/19285395

DMWXTM8	DI	DMWXTM8
DMWXTM8	DN	ST-2987
DMWXTM8	MI	TTSHTOI
DMWXTM8	MN	Histone deacetylase 2 (HDAC2)
DMWXTM8	MT	DTT
DMWXTM8	MA	Inhibitor
DMWXTM8	RN	N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9.
DMWXTM8	RU	https://pubmed.ncbi.nlm.nih.gov/19285395

DMWXTM8	DI	DMWXTM8
DMWXTM8	DN	ST-2987
DMWXTM8	MI	TTTQGH8
DMWXTM8	MN	Histone deacetylase 4 (HDAC4)
DMWXTM8	MT	DTT
DMWXTM8	MA	Inhibitor
DMWXTM8	RN	N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9.
DMWXTM8	RU	https://pubmed.ncbi.nlm.nih.gov/19285395

DMWXTM8	DI	DMWXTM8
DMWXTM8	DN	ST-2987
DMWXTM8	MI	TT5ZKDI
DMWXTM8	MN	Histone deacetylase 6 (HDAC6)
DMWXTM8	MT	DTT
DMWXTM8	MA	Inhibitor
DMWXTM8	RN	N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9.
DMWXTM8	RU	https://pubmed.ncbi.nlm.nih.gov/19285395

DMWXTM8	DI	DMWXTM8
DMWXTM8	DN	ST-2987
DMWXTM8	MI	TTT6LFV
DMWXTM8	MN	Histone deacetylase 8 (HDAC8)
DMWXTM8	MT	DTT
DMWXTM8	MA	Inhibitor
DMWXTM8	RN	N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9.
DMWXTM8	RU	https://pubmed.ncbi.nlm.nih.gov/19285395

DM19K2D	DI	DM19K2D
DM19K2D	DN	ST-3050
DM19K2D	MI	TTBH0VX
DM19K2D	MN	Histone deacetylase (HDAC)
DM19K2D	MT	DTT
DM19K2D	MA	Inhibitor
DM19K2D	RN	N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9.
DM19K2D	RU	https://pubmed.ncbi.nlm.nih.gov/19285395

DM19K2D	DI	DM19K2D
DM19K2D	DN	ST-3050
DM19K2D	MI	TT6R7JZ
DM19K2D	MN	Histone deacetylase 1 (HDAC1)
DM19K2D	MT	DTT
DM19K2D	MA	Inhibitor
DM19K2D	RN	N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9.
DM19K2D	RU	https://pubmed.ncbi.nlm.nih.gov/19285395

DM19K2D	DI	DM19K2D
DM19K2D	DN	ST-3050
DM19K2D	MI	TTYHPU6
DM19K2D	MN	Histone deacetylase 10 (HDAC10)
DM19K2D	MT	DTT
DM19K2D	MA	Inhibitor
DM19K2D	RN	N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9.
DM19K2D	RU	https://pubmed.ncbi.nlm.nih.gov/19285395

DM19K2D	DI	DM19K2D
DM19K2D	DN	ST-3050
DM19K2D	MI	TTTQGH8
DM19K2D	MN	Histone deacetylase 4 (HDAC4)
DM19K2D	MT	DTT
DM19K2D	MA	Inhibitor
DM19K2D	RN	N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9.
DM19K2D	RU	https://pubmed.ncbi.nlm.nih.gov/19285395

DM19K2D	DI	DM19K2D
DM19K2D	DN	ST-3050
DM19K2D	MI	TT5ZKDI
DM19K2D	MN	Histone deacetylase 6 (HDAC6)
DM19K2D	MT	DTT
DM19K2D	MA	Inhibitor
DM19K2D	RN	N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9.
DM19K2D	RU	https://pubmed.ncbi.nlm.nih.gov/19285395

DM19K2D	DI	DM19K2D
DM19K2D	DN	ST-3050
DM19K2D	MI	TTT6LFV
DM19K2D	MN	Histone deacetylase 8 (HDAC8)
DM19K2D	MT	DTT
DM19K2D	MA	Inhibitor
DM19K2D	RN	N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9.
DM19K2D	RU	https://pubmed.ncbi.nlm.nih.gov/19285395

DM9FYPM	DI	DM9FYPM
DM9FYPM	DN	ST-5732
DM9FYPM	MI	TTBH0VX
DM9FYPM	MN	Histone deacetylase (HDAC)
DM9FYPM	MT	DTT
DM9FYPM	MA	Inhibitor
DM9FYPM	RN	Exploring bis-(indolyl)methane moiety as an alternative and innovative CAP group in the design of histone deacetylase (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 May 15;19(10):2840-3.
DM9FYPM	RU	https://pubmed.ncbi.nlm.nih.gov/19359173

DMIYJ2M	DI	DMIYJ2M
DMIYJ2M	DN	STA2
DMIYJ2M	MI	TTPNGDE
DMIYJ2M	MN	Prostaglandin E2 receptor EP3 (PTGER3)
DMIYJ2M	MT	DTT
DMIYJ2M	MA	Agonist
DMIYJ2M	RN	Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
DMIYJ2M	RU	https://pubmed.ncbi.nlm.nih.gov/9313928

DMIYJ2M	DI	DMIYJ2M
DMIYJ2M	DN	STA2
DMIYJ2M	MI	TT2O84V
DMIYJ2M	MN	Thromboxane A2 receptor (TBXA2R)
DMIYJ2M	MT	DTT
DMIYJ2M	MA	Agonist
DMIYJ2M	RN	Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
DMIYJ2M	RU	https://pubmed.ncbi.nlm.nih.gov/9313928

DMIZESL	DI	DMIZESL
DMIZESL	DN	Stachyflin
DMIZESL	MI	TTF4CAM
DMIZESL	MN	Influenza Hemagglutinin (Influ HA)
DMIZESL	MT	DTT
DMIZESL	MA	Inhibitor
DMIZESL	RN	Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17736-41.
DMIZESL	RU	https://pubmed.ncbi.nlm.nih.gov/19004788

DM1R9GV	DI	DM1R9GV
DM1R9GV	DN	Stachyose
DM1R9GV	MI	DE5EODL
DM1R9GV	MN	Beta-fructofuranosidase (BFRU)
DM1R9GV	MT	DME
DM1R9GV	MA	Metabolism
DM1R9GV	RN	Alpha-glactosidase activity of lactobacilli. Appl Microbiol. 1973 Nov;26(5):783-8.
DM1R9GV	RU	https://pubmed.ncbi.nlm.nih.gov/4796954

DM1R9GV	DI	DM1R9GV
DM1R9GV	DN	Stachyose
DM1R9GV	MI	DER8TO2
DM1R9GV	MN	Beta-fructofuranosidase (BFRU)
DM1R9GV	MT	DME
DM1R9GV	MA	Metabolism
DM1R9GV	RN	Alpha-glactosidase activity of lactobacilli. Appl Microbiol. 1973 Nov;26(5):783-8.
DM1R9GV	RU	https://pubmed.ncbi.nlm.nih.gov/4796954

DM1R9GV	DI	DM1R9GV
DM1R9GV	DN	Stachyose
DM1R9GV	MI	DEET5ZQ
DM1R9GV	MN	Beta-fructofuranosidase (BFRU)
DM1R9GV	MT	DME
DM1R9GV	MA	Metabolism
DM1R9GV	RN	Alpha-glactosidase activity of lactobacilli. Appl Microbiol. 1973 Nov;26(5):783-8.
DM1R9GV	RU	https://pubmed.ncbi.nlm.nih.gov/4796954

DM4WQHU	DI	DM4WQHU
DM4WQHU	DN	Statin
DM4WQHU	MI	TTPADOQ
DM4WQHU	MN	HMG-CoA reductase (HMGCR)
DM4WQHU	MT	DTT
DM4WQHU	MA	Modulator
DM4WQHU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 639).
DM4WQHU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=639

DM0E9BR	DI	DM0E9BR
DM0E9BR	DN	Staurosporine
DM0E9BR	MI	TTJ3E9X
DM0E9BR	MN	Inhibitor of nuclear factor kappa-B kinase beta (IKKB)
DM0E9BR	MT	DTT
DM0E9BR	MA	Inhibitor
DM0E9BR	RN	UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst. 1996 Jul 17;88(14):956-65.
DM0E9BR	RU	https://pubmed.ncbi.nlm.nih.gov/8667426

DM0E9BR	DI	DM0E9BR
DM0E9BR	DN	Staurosporine
DM0E9BR	MI	DTUGYRD
DM0E9BR	MN	P-glycoprotein 1 (ABCB1)
DM0E9BR	MT	DTP
DM0E9BR	MA	Substrate
DM0E9BR	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM0E9BR	RU	https://doi.org/10.1007/s11095-012-0935-x

DM0E9BR	DI	DM0E9BR
DM0E9BR	DN	Staurosporine
DM0E9BR	MI	TTYVX59
DM0E9BR	MN	Protein kinase C (PRKC)
DM0E9BR	MT	DTT
DM0E9BR	MA	Inhibitor
DM0E9BR	RN	Protein kinase C zeta isoform is critical for proliferation in human glioblastoma cell lines. J Neurooncol. 2000 Apr;47(2):109-15.
DM0E9BR	RU	https://pubmed.ncbi.nlm.nih.gov/10982151

DMU2H4K	DI	DMU2H4K
DMU2H4K	DN	STAUROSPORINONE
DMU2H4K	MI	TTZC6DR
DMU2H4K	MN	cGMP-dependent protein kinase (cGK)
DMU2H4K	MT	DTT
DMU2H4K	MA	Inhibitor
DMU2H4K	RN	Non-glycosidic/non-aminoalkyl-substituted indolocarbazoles as inhibitors of protein kinase C, Bioorg. Med. Chem. Lett. 3(10):1959-1964 (1993).
DMU2H4K	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01809951

DMU2H4K	DI	DMU2H4K
DMU2H4K	DN	STAUROSPORINONE
DMU2H4K	MI	TTRSMW9
DMU2H4K	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMU2H4K	MT	DTT
DMU2H4K	MA	Inhibitor
DMU2H4K	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMU2H4K	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMU2H4K	DI	DMU2H4K
DMU2H4K	DN	STAUROSPORINONE
DMU2H4K	MI	TT860QF
DMU2H4K	MN	LCK tyrosine protein kinase (LCK)
DMU2H4K	MT	DTT
DMU2H4K	MA	Inhibitor
DMU2H4K	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMU2H4K	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMU2H4K	DI	DMU2H4K
DMU2H4K	DN	STAUROSPORINONE
DMU2H4K	MI	TTYT93M
DMU2H4K	MN	MAP kinase p38 (MAPK12)
DMU2H4K	MT	DTT
DMU2H4K	MA	Inhibitor
DMU2H4K	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMU2H4K	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMU2H4K	DI	DMU2H4K
DMU2H4K	DN	STAUROSPORINONE
DMU2H4K	MI	TTFJ8Q1
DMU2H4K	MN	Protein kinase C alpha (PRKCA)
DMU2H4K	MT	DTT
DMU2H4K	MA	Inhibitor
DMU2H4K	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMU2H4K	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMU2H4K	DI	DMU2H4K
DMU2H4K	DN	STAUROSPORINONE
DMU2H4K	MI	TTWTSCV
DMU2H4K	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DMU2H4K	MT	DTT
DMU2H4K	MA	Inhibitor
DMU2H4K	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMU2H4K	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMU2H4K	DI	DMU2H4K
DMU2H4K	DN	STAUROSPORINONE
DMU2H4K	MI	TTG0U4H
DMU2H4K	MN	Ribosomal protein S6 kinase beta-1 (S6K1)
DMU2H4K	MT	DTT
DMU2H4K	MA	Inhibitor
DMU2H4K	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMU2H4K	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMU2H4K	DI	DMU2H4K
DMU2H4K	DN	STAUROSPORINONE
DMU2H4K	MI	TTQBR95
DMU2H4K	MN	Stress-activated protein kinase 2a (p38 alpha)
DMU2H4K	MT	DTT
DMU2H4K	MA	Inhibitor
DMU2H4K	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMU2H4K	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMU2H4K	DI	DMU2H4K
DMU2H4K	DN	STAUROSPORINONE
DMU2H4K	MI	TT73U6C
DMU2H4K	MN	Stress-activated protein kinase 2b (p38 beta)
DMU2H4K	MT	DTT
DMU2H4K	MA	Inhibitor
DMU2H4K	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMU2H4K	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMU2H4K	DI	DMU2H4K
DMU2H4K	DN	STAUROSPORINONE
DMU2H4K	MI	TT0K6EO
DMU2H4K	MN	Stress-activated protein kinase JNK1 (JNK1)
DMU2H4K	MT	DTT
DMU2H4K	MA	Inhibitor
DMU2H4K	RN	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
DMU2H4K	RU	https://pubmed.ncbi.nlm.nih.gov/10998351

DMGMXQC	DI	DMGMXQC
DMGMXQC	DN	STEPHOLIDINE
DMGMXQC	MI	TTZFYLI
DMGMXQC	MN	Dopamine D1 receptor (D1R)
DMGMXQC	MT	DTT
DMGMXQC	MA	Inhibitor
DMGMXQC	RN	Dibenzazecine scaffold rebuilding--is the flexibility always essential for high dopamine receptor affinities Bioorg Med Chem. 2009 Oct 1;17(19):6898-907.
DMGMXQC	RU	https://pubmed.ncbi.nlm.nih.gov/19744859

DMGMXQC	DI	DMGMXQC
DMGMXQC	DN	STEPHOLIDINE
DMGMXQC	MI	TTEX248
DMGMXQC	MN	Dopamine D2 receptor (D2R)
DMGMXQC	MT	DTT
DMGMXQC	MA	Inhibitor
DMGMXQC	RN	Dibenzazecine scaffold rebuilding--is the flexibility always essential for high dopamine receptor affinities Bioorg Med Chem. 2009 Oct 1;17(19):6898-907.
DMGMXQC	RU	https://pubmed.ncbi.nlm.nih.gov/19744859

DMGMXQC	DI	DMGMXQC
DMGMXQC	DN	STEPHOLIDINE
DMGMXQC	MI	TT4C8EA
DMGMXQC	MN	Dopamine D3 receptor (D3R)
DMGMXQC	MT	DTT
DMGMXQC	MA	Inhibitor
DMGMXQC	RN	Dibenzazecine scaffold rebuilding--is the flexibility always essential for high dopamine receptor affinities Bioorg Med Chem. 2009 Oct 1;17(19):6898-907.
DMGMXQC	RU	https://pubmed.ncbi.nlm.nih.gov/19744859

DMGMXQC	DI	DMGMXQC
DMGMXQC	DN	STEPHOLIDINE
DMGMXQC	MI	TTE0A2F
DMGMXQC	MN	Dopamine D4 receptor (D4R)
DMGMXQC	MT	DTT
DMGMXQC	MA	Inhibitor
DMGMXQC	RN	Dibenzazecine scaffold rebuilding--is the flexibility always essential for high dopamine receptor affinities Bioorg Med Chem. 2009 Oct 1;17(19):6898-907.
DMGMXQC	RU	https://pubmed.ncbi.nlm.nih.gov/19744859

DMGMXQC	DI	DMGMXQC
DMGMXQC	DN	STEPHOLIDINE
DMGMXQC	MI	TTS2PH3
DMGMXQC	MN	Dopamine D5 receptor (D5R)
DMGMXQC	MT	DTT
DMGMXQC	MA	Inhibitor
DMGMXQC	RN	Dibenzazecine scaffold rebuilding--is the flexibility always essential for high dopamine receptor affinities Bioorg Med Chem. 2009 Oct 1;17(19):6898-907.
DMGMXQC	RU	https://pubmed.ncbi.nlm.nih.gov/19744859

DM1PMR3	DI	DM1PMR3
DM1PMR3	DN	Sterculic acid
DM1PMR3	MI	TT6RIOV
DM1PMR3	MN	Acyl-CoA desaturase (SCD)
DM1PMR3	MT	DTT
DM1PMR3	MA	Inhibitor
DM1PMR3	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DM1PMR3	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMZSOG2	DI	DMZSOG2
DMZSOG2	DN	STO609
DMZSOG2	MI	TTV298Y
DMZSOG2	MN	Calmodulin-dependent kinase II (CAMKK2)
DMZSOG2	MT	DTT
DMZSOG2	MA	Inhibitor
DMZSOG2	RN	STO-609, a specific inhibitor of the Ca(2+)/calmodulin-dependent protein kinase kinase. J Biol Chem. 2002 May 3;277(18):15813-8.
DMZSOG2	RU	https://pubmed.ncbi.nlm.nih.gov/11867640

DMZSOG2	DI	DMZSOG2
DMZSOG2	DN	STO609
DMZSOG2	MI	TTGLQWZ
DMZSOG2	MN	CaM-kinase IV kinase (CAMKK1)
DMZSOG2	MT	DTT
DMZSOG2	MA	Inhibitor
DMZSOG2	RN	STO-609, a specific inhibitor of the Ca(2+)/calmodulin-dependent protein kinase kinase. J Biol Chem. 2002 May 3;277(18):15813-8.
DMZSOG2	RU	https://pubmed.ncbi.nlm.nih.gov/11867640

DM0HOEA	DI	DM0HOEA
DM0HOEA	DN	streptonigrin
DM0HOEA	MI	TTSCHFW
DM0HOEA	MN	Peptidyl arginine deiminase type III (PADI3)
DM0HOEA	MT	DTT
DM0HOEA	MA	Inhibitor
DM0HOEA	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2878).
DM0HOEA	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2878

DM0HOEA	DI	DM0HOEA
DM0HOEA	DN	streptonigrin
DM0HOEA	MI	TTQHAXM
DM0HOEA	MN	Peptidyl arginine deiminase type IV (PADI4)
DM0HOEA	MT	DTT
DM0HOEA	MA	Inhibitor
DM0HOEA	RN	A fluopol-ABPP HTS assay to identify PAD inhibitors. Chem Commun (Camb). 2010 Oct 14;46(38):7175-7.
DM0HOEA	RU	https://pubmed.ncbi.nlm.nih.gov/20740228

DM5BATX	DI	DM5BATX
DM5BATX	DN	STS-T4
DM5BATX	MI	TTIHYA4
DM5BATX	MN	Thrombopoietin receptor (MPL)
DM5BATX	MT	DTT
DM5BATX	MA	Agonist
DM5BATX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1722).
DM5BATX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1722

DM9UHCY	DI	DM9UHCY
DM9UHCY	DN	S-tubercidinylhomocysteine
DM9UHCY	MI	TTHVCUP
DM9UHCY	MN	DNA [cytosine-5]-methyltransferase (DNMT)
DM9UHCY	MT	DTT
DM9UHCY	MA	Inhibitor
DM9UHCY	RN	SAR around (l)-S-adenosyl-l-homocysteine, an inhibitor of human DNA methyltransferase (DNMT) enzymes. Bioorg Med Chem Lett. 2009 May 15;19(10):2747-51.
DM9UHCY	RU	https://pubmed.ncbi.nlm.nih.gov/19362833

DM9UHCY	DI	DM9UHCY
DM9UHCY	DN	S-tubercidinylhomocysteine
DM9UHCY	MI	TT6VZ78
DM9UHCY	MN	DNA [cytosine-5]-methyltransferase 3B (DNMT3B)
DM9UHCY	MT	DTT
DM9UHCY	MA	Inhibitor
DM9UHCY	RN	SAR around (l)-S-adenosyl-l-homocysteine, an inhibitor of human DNA methyltransferase (DNMT) enzymes. Bioorg Med Chem Lett. 2009 May 15;19(10):2747-51.
DM9UHCY	RU	https://pubmed.ncbi.nlm.nih.gov/19362833

DM7LZJ3	DI	DM7LZJ3
DM7LZJ3	DN	STX
DM7LZJ3	MI	TTZAYWL
DM7LZJ3	MN	Estrogen receptor (ESR)
DM7LZJ3	MT	DTT
DM7LZJ3	MA	Modulator
DM7LZJ3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620).
DM7LZJ3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=620

DMO9VWJ	DI	DMO9VWJ
DMO9VWJ	DN	STYLISSADINE A
DMO9VWJ	MI	TT473XN
DMO9VWJ	MN	P2X purinoceptor 7 (P2RX7)
DMO9VWJ	MT	DTT
DMO9VWJ	MA	Inhibitor
DMO9VWJ	RN	Purinergic P2X(7) receptor antagonists: Chemistry and fundamentals of biological screening. Bioorg Med Chem. 2009 Jul 15;17(14):4861-5.
DMO9VWJ	RU	https://pubmed.ncbi.nlm.nih.gov/19540765

DMNAYEP	DI	DMNAYEP
DMNAYEP	DN	STYLISSADINE B
DMNAYEP	MI	TT473XN
DMNAYEP	MN	P2X purinoceptor 7 (P2RX7)
DMNAYEP	MT	DTT
DMNAYEP	MA	Inhibitor
DMNAYEP	RN	Purinergic P2X(7) receptor antagonists: Chemistry and fundamentals of biological screening. Bioorg Med Chem. 2009 Jul 15;17(14):4861-5.
DMNAYEP	RU	https://pubmed.ncbi.nlm.nih.gov/19540765

DMJ4Z7W	DI	DMJ4Z7W
DMJ4Z7W	DN	Styrylboronic acid
DMJ4Z7W	MI	TTHQPL7
DMJ4Z7W	MN	Carbonic anhydrase I (CA-I)
DMJ4Z7W	MT	DTT
DMJ4Z7W	MA	Inhibitor
DMJ4Z7W	RN	Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5.
DMJ4Z7W	RU	https://pubmed.ncbi.nlm.nih.gov/19375309

DMF1P6W	DI	DMF1P6W
DMF1P6W	DN	SU 6656
DMF1P6W	MI	TTLAFZV
DMF1P6W	MN	AMP-activated protein kinase (AMPK)
DMF1P6W	MT	DTT
DMF1P6W	MA	Inhibitor
DMF1P6W	RN	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
DMF1P6W	RU	https://pubmed.ncbi.nlm.nih.gov/17850214

DMF1P6W	DI	DMF1P6W
DMF1P6W	DN	SU 6656
DMF1P6W	MI	TT9RTBL
DMF1P6W	MN	Aurora B messenger RNA (AURKB mRNA)
DMF1P6W	MT	DTT
DMF1P6W	MA	Inhibitor
DMF1P6W	RN	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
DMF1P6W	RU	https://pubmed.ncbi.nlm.nih.gov/17850214

DMF1P6W	DI	DMF1P6W
DMF1P6W	DN	SU 6656
DMF1P6W	MI	TTLYXIT
DMF1P6W	MN	Aurora kinase C (AURKC)
DMF1P6W	MT	DTT
DMF1P6W	MA	Inhibitor
DMF1P6W	RN	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
DMF1P6W	RU	https://pubmed.ncbi.nlm.nih.gov/17850214

DMF1P6W	DI	DMF1P6W
DMF1P6W	DN	SU 6656
DMF1P6W	MI	TT860QF
DMF1P6W	MN	LCK tyrosine protein kinase (LCK)
DMF1P6W	MT	DTT
DMF1P6W	MA	Inhibitor
DMF1P6W	RN	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
DMF1P6W	RU	https://pubmed.ncbi.nlm.nih.gov/17850214

DMF1P6W	DI	DMF1P6W
DMF1P6W	DN	SU 6656
DMF1P6W	MI	TT6PKBN
DMF1P6W	MN	Proto-oncogene c-Src (SRC)
DMF1P6W	MT	DTT
DMF1P6W	MA	Inhibitor
DMF1P6W	RN	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
DMF1P6W	RU	https://pubmed.ncbi.nlm.nih.gov/17850214

DMASP9Z	DI	DMASP9Z
DMASP9Z	DN	SU11274
DMASP9Z	MI	TTNDSF4
DMASP9Z	MN	Proto-oncogene c-Met (MET)
DMASP9Z	MT	DTT
DMASP9Z	MA	Inhibitor
DMASP9Z	RN	Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion. Mol Cancer Ther. 2003 Nov;2(11):1085-92.
DMASP9Z	RU	https://pubmed.ncbi.nlm.nih.gov/14617781

DMGQXN7	DI	DMGQXN7
DMGQXN7	DN	SU-11652
DMGQXN7	MI	TT8FYO9
DMGQXN7	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMGQXN7	MT	DTT
DMGQXN7	MA	Inhibitor
DMGQXN7	RN	Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9.
DMGQXN7	RU	https://pubmed.ncbi.nlm.nih.gov/12646019

DMGQXN7	DI	DMGQXN7
DMGQXN7	DN	SU-11652
DMGQXN7	MI	TTI7421
DMGQXN7	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMGQXN7	MT	DTT
DMGQXN7	MA	Inhibitor
DMGQXN7	RN	Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9.
DMGQXN7	RU	https://pubmed.ncbi.nlm.nih.gov/12646019

DMGQXN7	DI	DMGQXN7
DMGQXN7	DN	SU-11652
DMGQXN7	MI	TT2Q6G1
DMGQXN7	MN	Vascular endothelial growth factor receptor 1 (FLT-1)
DMGQXN7	MT	DTT
DMGQXN7	MA	Inhibitor
DMGQXN7	RN	Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9.
DMGQXN7	RU	https://pubmed.ncbi.nlm.nih.gov/12646019

DMGQXN7	DI	DMGQXN7
DMGQXN7	DN	SU-11652
DMGQXN7	MI	TTUTJGQ
DMGQXN7	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMGQXN7	MT	DTT
DMGQXN7	MA	Inhibitor
DMGQXN7	RN	Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9.
DMGQXN7	RU	https://pubmed.ncbi.nlm.nih.gov/12646019

DMWVN8R	DI	DMWVN8R
DMWVN8R	DN	SU4984
DMWVN8R	MI	TT0LF7H
DMWVN8R	MN	Fibroblast growth factor receptor (FGFR)
DMWVN8R	MT	DTT
DMWVN8R	MA	Antagonist
DMWVN8R	RN	Tumor angiogenesis as a therapeutic target. Drug Discov Today. 2001 Oct 1;6(19):1005-1024.
DMWVN8R	RU	https://pubmed.ncbi.nlm.nih.gov/11576867

DM9JON3	DI	DM9JON3
DM9JON3	DN	SU5402
DM9JON3	MI	TTST7KB
DM9JON3	MN	Fibroblast growth factor receptor 3 (FGFR3)
DM9JON3	MT	DTT
DM9JON3	MA	Inhibitor
DM9JON3	RN	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
DM9JON3	RU	https://pubmed.ncbi.nlm.nih.gov/19249983

DMV1408	DI	DMV1408
DMV1408	DN	SU5403
DMV1408	MI	TT0LF7H
DMV1408	MN	Fibroblast growth factor receptor (FGFR)
DMV1408	MT	DTT
DMV1408	MA	Antagonist
DMV1408	RN	Tumor angiogenesis as a therapeutic target. Drug Discov Today. 2001 Oct 1;6(19):1005-1024.
DMV1408	RU	https://pubmed.ncbi.nlm.nih.gov/11576867

DMDNA23	DI	DMDNA23
DMDNA23	DN	SU-6689
DMDNA23	MI	TTYMGWX
DMDNA23	MN	PDK-1 messenger RNA (PDK-1 mRNA)
DMDNA23	MT	DTT
DMDNA23	MA	Inhibitor
DMDNA23	RN	Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity. Bioorg Med Chem Lett. 2007 Jul 15;17(14):3814-8.
DMDNA23	RU	https://pubmed.ncbi.nlm.nih.gov/17531483

DMQHG0R	DI	DMQHG0R
DMQHG0R	DN	SU9516
DMQHG0R	MI	TTH6V3D
DMQHG0R	MN	Cyclin-dependent kinase 1 (CDK1)
DMQHG0R	MT	DTT
DMQHG0R	MA	Binder
DMQHG0R	RN	SU9516: biochemical analysis of cdk inhibition and crystal structure in complex with cdk2. Biochem Biophys Res Commun. 2003 Oct 24;310(3):1026-31.
DMQHG0R	RU	https://pubmed.ncbi.nlm.nih.gov/14550307

DMQHG0R	DI	DMQHG0R
DMQHG0R	DN	SU9516
DMQHG0R	MI	TT7HF4W
DMQHG0R	MN	Cyclin-dependent kinase 2 (CDK2)
DMQHG0R	MT	DTT
DMQHG0R	MA	Inhibitor
DMQHG0R	RN	Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
DMQHG0R	RU	https://pubmed.ncbi.nlm.nih.gov/12237154

DMQHG0R	DI	DMQHG0R
DMQHG0R	DN	SU9516
DMQHG0R	MI	TTL4Q97
DMQHG0R	MN	Cyclin-dependent kinase 5 (CDK5)
DMQHG0R	MT	DTT
DMQHG0R	MA	Inhibitor
DMQHG0R	RN	Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
DMQHG0R	RU	https://pubmed.ncbi.nlm.nih.gov/12237154

DM4SWQA	DI	DM4SWQA
DM4SWQA	DN	Sub[-Trp-Arg-Nva-Arg-Tyr-NH2]2
DM4SWQA	MI	TTRK9JT
DM4SWQA	MN	Neuropeptide Y receptor type 1 (NPY1R)
DM4SWQA	MT	DTT
DM4SWQA	MA	Inhibitor
DM4SWQA	RN	Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5.
DM4SWQA	RU	https://pubmed.ncbi.nlm.nih.gov/16610810

DM4SWQA	DI	DM4SWQA
DM4SWQA	DN	Sub[-Trp-Arg-Nva-Arg-Tyr-NH2]2
DM4SWQA	MI	TTJ6WK9
DM4SWQA	MN	Neuropeptide Y receptor type 2 (NPY2R)
DM4SWQA	MT	DTT
DM4SWQA	MA	Inhibitor
DM4SWQA	RN	Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5.
DM4SWQA	RU	https://pubmed.ncbi.nlm.nih.gov/16610810

DM4SWQA	DI	DM4SWQA
DM4SWQA	DN	Sub[-Trp-Arg-Nva-Arg-Tyr-NH2]2
DM4SWQA	MI	TTW4N16
DM4SWQA	MN	Neuropeptide Y receptor type 4 (NPY4R)
DM4SWQA	MT	DTT
DM4SWQA	MA	Inhibitor
DM4SWQA	RN	Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5.
DM4SWQA	RU	https://pubmed.ncbi.nlm.nih.gov/16610810

DM56MOV	DI	DM56MOV
DM56MOV	DN	Sub[-Tyr-Arg-Leu-Arg-Tyr-NH2]2
DM56MOV	MI	TTRK9JT
DM56MOV	MN	Neuropeptide Y receptor type 1 (NPY1R)
DM56MOV	MT	DTT
DM56MOV	MA	Inhibitor
DM56MOV	RN	Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5.
DM56MOV	RU	https://pubmed.ncbi.nlm.nih.gov/16610810

DM56MOV	DI	DM56MOV
DM56MOV	DN	Sub[-Tyr-Arg-Leu-Arg-Tyr-NH2]2
DM56MOV	MI	TTJ6WK9
DM56MOV	MN	Neuropeptide Y receptor type 2 (NPY2R)
DM56MOV	MT	DTT
DM56MOV	MA	Inhibitor
DM56MOV	RN	Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5.
DM56MOV	RU	https://pubmed.ncbi.nlm.nih.gov/16610810

DM56MOV	DI	DM56MOV
DM56MOV	DN	Sub[-Tyr-Arg-Leu-Arg-Tyr-NH2]2
DM56MOV	MI	TTW4N16
DM56MOV	MN	Neuropeptide Y receptor type 4 (NPY4R)
DM56MOV	MT	DTT
DM56MOV	MA	Inhibitor
DM56MOV	RN	Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5.
DM56MOV	RU	https://pubmed.ncbi.nlm.nih.gov/16610810

DMKH9IE	DI	DMKH9IE
DMKH9IE	DN	subalin
DMKH9IE	MI	TTSIUJ9
DMKH9IE	MN	Interferon-alpha 2 (IFNA2)
DMKH9IE	MT	DTT
DMKH9IE	MA	Modulator
DMKH9IE	RN	[Adjuvant properties of subalin, a recombinant interferon-producing probiotic].Zh Mikrobiol Epidemiol Immunobiol.2001 Nov-Dec;(6):77-82.
DMKH9IE	RU	https://www.ncbi.nlm.nih.gov/pubmed/11881504

DM235XH	DI	DM235XH
DM235XH	DN	Suberic bishydroxamic acid
DM235XH	MI	TTBH0VX
DM235XH	MN	Histone deacetylase (HDAC)
DM235XH	MT	DTT
DM235XH	MA	Inhibitor
DM235XH	RN	Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006 Sep;5(9):769-84.
DM235XH	RU	https://pubmed.ncbi.nlm.nih.gov/16955068

DM8BLXT	DI	DM8BLXT
DM8BLXT	DN	Subersic acid
DM8BLXT	MI	TTN9T81
DM8BLXT	MN	Arachidonate 15-lipoxygenase (15-LOX)
DM8BLXT	MT	DTT
DM8BLXT	MA	Inhibitor
DM8BLXT	RN	Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases. J Nat Prod. 2003 Feb;66(2):230-5.
DM8BLXT	RU	https://pubmed.ncbi.nlm.nih.gov/12608855

DMQ6W4I	DI	DMQ6W4I
DMQ6W4I	DN	Substance P
DMQ6W4I	MI	DTUGYRD
DMQ6W4I	MN	P-glycoprotein 1 (ABCB1)
DMQ6W4I	MT	DTP
DMQ6W4I	MA	Substrate
DMQ6W4I	RN	Transport of somatostatin and substance P by human P-glycoprotein. FEBS Lett. 2004 Sep 10;574(1-3):55-61.
DMQ6W4I	RU	https://doi.org/10.1016/j.febslet.2004.07.084

DMQ6W4I	DI	DMQ6W4I
DMQ6W4I	DN	Substance P
DMQ6W4I	MI	TTZPO1L
DMQ6W4I	MN	Substance-P receptor (TACR1)
DMQ6W4I	MT	DTT
DMQ6W4I	MA	Inhibitor
DMQ6W4I	RN	Synthesis and structure-activity relationships of CP-122,721, a second-generation NK-1 receptor antagonist. Bioorg Med Chem Lett. 1998 Feb 3;8(3):281-4.
DMQ6W4I	RU	https://pubmed.ncbi.nlm.nih.gov/9871670

DMPY09A	DI	DMPY09A
DMPY09A	DN	Succinate
DMPY09A	MI	DTKXTPW
DMPY09A	MN	Sodium/dicarboxylate cotransporter 3 (SLC13A3)
DMPY09A	MT	DTP
DMPY09A	MA	Substrate
DMPY09A	RN	SLC13A3 variants cause acute reversible leukoencephalopathy and -ketoglutarate accumulation. Ann Neurol. 2019 Mar;85(3):385-395.
DMPY09A	RU	http://www.ncbi.nlm.nih.gov/pubmed/30635937

DMPY09A	DI	DMPY09A
DMPY09A	DN	Succinate
DMPY09A	MI	DTFPWJ9
DMPY09A	MN	Sodium-coupled citrate transporter (SLC13A5)
DMPY09A	MT	DTP
DMPY09A	MA	Substrate
DMPY09A	RN	SLC13 family of Na+ coupled di- and tri-carboxylate/sulfate transporters. Mol Aspects Med. 2013 Apr-Jun;34(2-3):299-312.
DMPY09A	RU	http://www.ncbi.nlm.nih.gov/pubmed/23506872

DMVWUCF	DI	DMVWUCF
DMVWUCF	DN	Sucrose
DMVWUCF	MI	DECWNTP
DMVWUCF	MN	Beta-fructofuranosidase (BFRU)
DMVWUCF	MT	DME
DMVWUCF	MA	Metabolism
DMVWUCF	RN	Characterization of fructooligosaccharide-degrading enzymes in human commensal Bifidobacterium longum and Anaerostipes caccae. Biochem Biophys Res Commun. 2019 Oct 15;518(2):294-298.
DMVWUCF	RU	https://pubmed.ncbi.nlm.nih.gov/31420164

DMVWUCF	DI	DMVWUCF
DMVWUCF	DN	Sucrose
DMVWUCF	MI	DEBW1FU
DMVWUCF	MN	Fructokinase (scrK)
DMVWUCF	MT	DME
DMVWUCF	MA	Metabolism
DMVWUCF	RN	Sugar metabolism by fusobacteria: regulation of transport, phosphorylation, and polymer formation by Fusobacterium mortiferum ATCC 25557. Infect Immun. 1991 Dec;59(12):4547-54.
DMVWUCF	RU	https://pubmed.ncbi.nlm.nih.gov/1937813

DMVWUCF	DI	DMVWUCF
DMVWUCF	DN	Sucrose
DMVWUCF	MI	DEWRN24
DMVWUCF	MN	Glucansucrase (gtf106B)
DMVWUCF	MT	DME
DMVWUCF	MA	Metabolism
DMVWUCF	RN	Biosolids application affects the competitive sorption and lability of cadmium, copper, nickel, lead, and zinc in fluvial and calcareous soils. Environ Geochem Health. 2017 Dec;39(6):1365-1379.
DMVWUCF	RU	https://pubmed.ncbi.nlm.nih.gov/28258314

DMVWUCF	DI	DMVWUCF
DMVWUCF	DN	Sucrose
DMVWUCF	MI	DTNCJAT
DMVWUCF	MN	Membrane-associated transporter protein (SLC45A2)
DMVWUCF	MT	DTP
DMVWUCF	MA	Substrate
DMVWUCF	RN	Identification of amino acids important for substrate specificity in sucrose transporters using gene shuffling. J Biol Chem. 2012 Aug 31;287(36):30296-304.
DMVWUCF	RU	http://www.ncbi.nlm.nih.gov/pubmed/22807445

DMVWUCF	DI	DMVWUCF
DMVWUCF	DN	Sucrose
DMVWUCF	MI	DTGEFXH
DMVWUCF	MN	Solute carrier family 45 member 3 (SLC45A3)
DMVWUCF	MT	DTP
DMVWUCF	MA	Substrate
DMVWUCF	RN	Putative role of the H(+)/sucrose symporter SLC45A3 as an osmolyte transporter in the kidney. Pflugers Arch. 2016 Aug;468(8):1353-62.
DMVWUCF	RU	http://www.ncbi.nlm.nih.gov/pubmed/27228996

DMVWUCF	DI	DMVWUCF
DMVWUCF	DN	Sucrose
DMVWUCF	MI	DTKPHZ6
DMVWUCF	MN	Solute carrier family 45 member 4 (SLC45A4)
DMVWUCF	MT	DTP
DMVWUCF	MA	Substrate
DMVWUCF	RN	The SLC45 gene family of putative sugar transporters. Mol Aspects Med. 2013 Apr-Jun;34(2-3):655-60.
DMVWUCF	RU	http://www.ncbi.nlm.nih.gov/pubmed/23506898

DMVWUCF	DI	DMVWUCF
DMVWUCF	DN	Sucrose
DMVWUCF	MI	TTHI19T
DMVWUCF	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMVWUCF	MT	DTT
DMVWUCF	MA	Inhibitor
DMVWUCF	RN	Ten S, Maclaren N: Insulin resistance syndrome in children. J Clin Endocrinol Metab. 2004 Jun;89(6):2526-39.
DMVWUCF	RU	https://pubmed.ncbi.nlm.nih.gov/15181020

DMVWUCF	DI	DMVWUCF
DMVWUCF	DN	Sucrose
DMVWUCF	MI	DEJ4FO2
DMVWUCF	MN	Sucrose phosphorylase (Spase)
DMVWUCF	MT	DME
DMVWUCF	MA	Metabolism
DMVWUCF	RN	Characterization of fructooligosaccharide-degrading enzymes in human commensal Bifidobacterium longum and Anaerostipes caccae. Biochem Biophys Res Commun. 2019 Oct 15;518(2):294-298.
DMVWUCF	RU	https://pubmed.ncbi.nlm.nih.gov/31420164

DMVWUCF	DI	DMVWUCF
DMVWUCF	DN	Sucrose
DMVWUCF	MI	DEICTXP
DMVWUCF	MN	Sucrose-6-phosphate hydrolase scrB (ScrB)
DMVWUCF	MT	DME
DMVWUCF	MA	Metabolism
DMVWUCF	RN	Characterization of fructooligosaccharide-degrading enzymes in human commensal Bifidobacterium longum and Anaerostipes caccae. Biochem Biophys Res Commun. 2019 Oct 15;518(2):294-298.
DMVWUCF	RU	https://pubmed.ncbi.nlm.nih.gov/31420164

DMET64R	DI	DMET64R
DMET64R	DN	Sucrose Octasulfate
DMET64R	MI	TTMY81X
DMET64R	MN	Heparin-binding growth factor 1 (FGF1)
DMET64R	MT	DTT
DMET64R	MA	Inhibitor
DMET64R	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMET64R	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMF1589	DI	DMF1589
DMF1589	DN	SULFAMATE
DMF1589	MI	TTUNARX
DMF1589	MN	Carbonic anhydrase (CA)
DMF1589	MT	DTT
DMF1589	MA	Inhibitor
DMF1589	RN	Carbonic anhydrase inhibitors: inhibition of the cytosolic human isozyme VII with anions. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3139-43.
DMF1589	RU	https://pubmed.ncbi.nlm.nih.gov/16621537

DMF1589	DI	DMF1589
DMF1589	DN	SULFAMATE
DMF1589	MI	TTHQPL7
DMF1589	MN	Carbonic anhydrase I (CA-I)
DMF1589	MT	DTT
DMF1589	MA	Inhibitor
DMF1589	RN	Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5435-9.
DMF1589	RU	https://pubmed.ncbi.nlm.nih.gov/15454240

DMF1589	DI	DMF1589
DMF1589	DN	SULFAMATE
DMF1589	MI	TTANPDJ
DMF1589	MN	Carbonic anhydrase II (CA-II)
DMF1589	MT	DTT
DMF1589	MA	Inhibitor
DMF1589	RN	Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5435-9.
DMF1589	RU	https://pubmed.ncbi.nlm.nih.gov/15454240

DMF1589	DI	DMF1589
DMF1589	DN	SULFAMATE
DMF1589	MI	TTZHA0O
DMF1589	MN	Carbonic anhydrase IV (CA-IV)
DMF1589	MT	DTT
DMF1589	MA	Inhibitor
DMF1589	RN	Carbonic anhydrase inhibitors: inhibition of the membrane-bound human isozyme IV with anions. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5769-73.
DMF1589	RU	https://pubmed.ncbi.nlm.nih.gov/15501038

DMF1589	DI	DMF1589
DMF1589	DN	SULFAMATE
DMF1589	MI	TT2LVK8
DMF1589	MN	Carbonic anhydrase IX (CA-IX)
DMF1589	MT	DTT
DMF1589	MA	Inhibitor
DMF1589	RN	Carbonic anhydrase inhibitors. Inhibition of isozymes I, II, IV, V, and IX with anions isosteric and isoelectronic with sulfate, nitrate, and carbo... Bioorg Med Chem Lett. 2005 Feb 1;15(3):567-71.
DMF1589	RU	https://pubmed.ncbi.nlm.nih.gov/15664814

DM9XNSK	DI	DM9XNSK
DM9XNSK	DN	Sulfamic acid 12-sulfamoyloxy-dodecyl ester
DM9XNSK	MI	TTHQPL7
DM9XNSK	MN	Carbonic anhydrase I (CA-I)
DM9XNSK	MT	DTT
DM9XNSK	MA	Inhibitor
DM9XNSK	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):579-84.
DM9XNSK	RU	https://pubmed.ncbi.nlm.nih.gov/15664816

DM9XNSK	DI	DM9XNSK
DM9XNSK	DN	Sulfamic acid 12-sulfamoyloxy-dodecyl ester
DM9XNSK	MI	TTANPDJ
DM9XNSK	MN	Carbonic anhydrase II (CA-II)
DM9XNSK	MT	DTT
DM9XNSK	MA	Inhibitor
DM9XNSK	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):579-84.
DM9XNSK	RU	https://pubmed.ncbi.nlm.nih.gov/15664816

DM9XNSK	DI	DM9XNSK
DM9XNSK	DN	Sulfamic acid 12-sulfamoyloxy-dodecyl ester
DM9XNSK	MI	TT2LVK8
DM9XNSK	MN	Carbonic anhydrase IX (CA-IX)
DM9XNSK	MT	DTT
DM9XNSK	MA	Inhibitor
DM9XNSK	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):579-84.
DM9XNSK	RU	https://pubmed.ncbi.nlm.nih.gov/15664816

DM7VBSY	DI	DM7VBSY
DM7VBSY	DN	Sulfamic acid 16-sulfamoyloxy-hexadecyl ester
DM7VBSY	MI	TTHQPL7
DM7VBSY	MN	Carbonic anhydrase I (CA-I)
DM7VBSY	MT	DTT
DM7VBSY	MA	Inhibitor
DM7VBSY	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):579-84.
DM7VBSY	RU	https://pubmed.ncbi.nlm.nih.gov/15664816

DM7VBSY	DI	DM7VBSY
DM7VBSY	DN	Sulfamic acid 16-sulfamoyloxy-hexadecyl ester
DM7VBSY	MI	TTANPDJ
DM7VBSY	MN	Carbonic anhydrase II (CA-II)
DM7VBSY	MT	DTT
DM7VBSY	MA	Inhibitor
DM7VBSY	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):579-84.
DM7VBSY	RU	https://pubmed.ncbi.nlm.nih.gov/15664816

DM7VBSY	DI	DM7VBSY
DM7VBSY	DN	Sulfamic acid 16-sulfamoyloxy-hexadecyl ester
DM7VBSY	MI	TT2LVK8
DM7VBSY	MN	Carbonic anhydrase IX (CA-IX)
DM7VBSY	MT	DTT
DM7VBSY	MA	Inhibitor
DM7VBSY	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):579-84.
DM7VBSY	RU	https://pubmed.ncbi.nlm.nih.gov/15664816

DMM70K1	DI	DMM70K1
DMM70K1	DN	Sulfamic acid 2-nonyl-4-oxo-4H-chromen-6-yl ester
DMM70K1	MI	TTHM0R1
DMM70K1	MN	Steryl-sulfatase (STS)
DMM70K1	MT	DTT
DMM70K1	MA	Inhibitor
DMM70K1	RN	Estrogenic potential of 2-alkyl-4-(thio)chromenone 6-O-sulfamates: potent inhibitors of human steroid sulfatase. J Med Chem. 2003 Nov 6;46(23):5091-4.
DMM70K1	RU	https://pubmed.ncbi.nlm.nih.gov/14584960

DMSZ50N	DI	DMSZ50N
DMSZ50N	DN	Sulfamic acid 3-(3-hydroxy-benzoyl)-phenyl ester
DMSZ50N	MI	TTHM0R1
DMSZ50N	MN	Steryl-sulfatase (STS)
DMSZ50N	MT	DTT
DMSZ50N	MA	Inhibitor
DMSZ50N	RN	4,4'-Benzophenone-O,O'-disulfamate: a potent inhibitor of steroid sulfatase. Bioorg Med Chem Lett. 2002 Aug 19;12(16):2093-5.
DMSZ50N	RU	https://pubmed.ncbi.nlm.nih.gov/12127511

DMIQWAH	DI	DMIQWAH
DMIQWAH	DN	Sulfamic acid 3-(3-methoxy-benzoyl)-phenyl ester
DMIQWAH	MI	TTHM0R1
DMIQWAH	MN	Steryl-sulfatase (STS)
DMIQWAH	MT	DTT
DMIQWAH	MA	Inhibitor
DMIQWAH	RN	4,4'-Benzophenone-O,O'-disulfamate: a potent inhibitor of steroid sulfatase. Bioorg Med Chem Lett. 2002 Aug 19;12(16):2093-5.
DMIQWAH	RU	https://pubmed.ncbi.nlm.nih.gov/12127511

DMH71N6	DI	DMH71N6
DMH71N6	DN	Sulfamic acid 3-(4-hydroxy-benzoyl)-phenyl ester
DMH71N6	MI	TTHM0R1
DMH71N6	MN	Steryl-sulfatase (STS)
DMH71N6	MT	DTT
DMH71N6	MA	Inhibitor
DMH71N6	RN	4,4'-Benzophenone-O,O'-disulfamate: a potent inhibitor of steroid sulfatase. Bioorg Med Chem Lett. 2002 Aug 19;12(16):2093-5.
DMH71N6	RU	https://pubmed.ncbi.nlm.nih.gov/12127511

DMFVE3N	DI	DMFVE3N
DMFVE3N	DN	Sulfamic acid 3-(4-methoxy-benzoyl)-phenyl ester
DMFVE3N	MI	TTHM0R1
DMFVE3N	MN	Steryl-sulfatase (STS)
DMFVE3N	MT	DTT
DMFVE3N	MA	Inhibitor
DMFVE3N	RN	4,4'-Benzophenone-O,O'-disulfamate: a potent inhibitor of steroid sulfatase. Bioorg Med Chem Lett. 2002 Aug 19;12(16):2093-5.
DMFVE3N	RU	https://pubmed.ncbi.nlm.nih.gov/12127511

DMLXHAI	DI	DMLXHAI
DMLXHAI	DN	Sulfamic acid 3-benzoyl-phenyl ester
DMLXHAI	MI	TTHM0R1
DMLXHAI	MN	Steryl-sulfatase (STS)
DMLXHAI	MT	DTT
DMLXHAI	MA	Inhibitor
DMLXHAI	RN	4,4'-Benzophenone-O,O'-disulfamate: a potent inhibitor of steroid sulfatase. Bioorg Med Chem Lett. 2002 Aug 19;12(16):2093-5.
DMLXHAI	RU	https://pubmed.ncbi.nlm.nih.gov/12127511

DMA0MEV	DI	DMA0MEV
DMA0MEV	DN	Sulfamic acid 3-sulfamoyloxy-phenyl ester
DMA0MEV	MI	TTHQPL7
DMA0MEV	MN	Carbonic anhydrase I (CA-I)
DMA0MEV	MT	DTT
DMA0MEV	MA	Inhibitor
DMA0MEV	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):579-84.
DMA0MEV	RU	https://pubmed.ncbi.nlm.nih.gov/15664816

DMA0MEV	DI	DMA0MEV
DMA0MEV	DN	Sulfamic acid 3-sulfamoyloxy-phenyl ester
DMA0MEV	MI	TTANPDJ
DMA0MEV	MN	Carbonic anhydrase II (CA-II)
DMA0MEV	MT	DTT
DMA0MEV	MA	Inhibitor
DMA0MEV	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):579-84.
DMA0MEV	RU	https://pubmed.ncbi.nlm.nih.gov/15664816

DMA0MEV	DI	DMA0MEV
DMA0MEV	DN	Sulfamic acid 3-sulfamoyloxy-phenyl ester
DMA0MEV	MI	TT2LVK8
DMA0MEV	MN	Carbonic anhydrase IX (CA-IX)
DMA0MEV	MT	DTT
DMA0MEV	MA	Inhibitor
DMA0MEV	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):579-84.
DMA0MEV	RU	https://pubmed.ncbi.nlm.nih.gov/15664816

DMSYXHF	DI	DMSYXHF
DMSYXHF	DN	Sulfamic acid 4-(2-hydroxy-benzoyl)-phenyl ester
DMSYXHF	MI	TTHM0R1
DMSYXHF	MN	Steryl-sulfatase (STS)
DMSYXHF	MT	DTT
DMSYXHF	MA	Inhibitor
DMSYXHF	RN	4,4'-Benzophenone-O,O'-disulfamate: a potent inhibitor of steroid sulfatase. Bioorg Med Chem Lett. 2002 Aug 19;12(16):2093-5.
DMSYXHF	RU	https://pubmed.ncbi.nlm.nih.gov/12127511

DM8LWM3	DI	DM8LWM3
DM8LWM3	DN	Sulfamic acid 4-(2-methoxy-benzoyl)-phenyl ester
DM8LWM3	MI	TTHM0R1
DM8LWM3	MN	Steryl-sulfatase (STS)
DM8LWM3	MT	DTT
DM8LWM3	MA	Inhibitor
DM8LWM3	RN	4,4'-Benzophenone-O,O'-disulfamate: a potent inhibitor of steroid sulfatase. Bioorg Med Chem Lett. 2002 Aug 19;12(16):2093-5.
DM8LWM3	RU	https://pubmed.ncbi.nlm.nih.gov/12127511

DMK97WC	DI	DMK97WC
DMK97WC	DN	Sulfamic acid 4-(3-methoxy-benzoyl)-phenyl ester
DMK97WC	MI	TTHM0R1
DMK97WC	MN	Steryl-sulfatase (STS)
DMK97WC	MT	DTT
DMK97WC	MA	Inhibitor
DMK97WC	RN	4,4'-Benzophenone-O,O'-disulfamate: a potent inhibitor of steroid sulfatase. Bioorg Med Chem Lett. 2002 Aug 19;12(16):2093-5.
DMK97WC	RU	https://pubmed.ncbi.nlm.nih.gov/12127511

DMDUW9F	DI	DMDUW9F
DMDUW9F	DN	Sulfamic acid 4-benzoyl-phenyl ester
DMDUW9F	MI	TTHM0R1
DMDUW9F	MN	Steryl-sulfatase (STS)
DMDUW9F	MT	DTT
DMDUW9F	MA	Inhibitor
DMDUW9F	RN	4,4'-Benzophenone-O,O'-disulfamate: a potent inhibitor of steroid sulfatase. Bioorg Med Chem Lett. 2002 Aug 19;12(16):2093-5.
DMDUW9F	RU	https://pubmed.ncbi.nlm.nih.gov/12127511

DMQZGNJ	DI	DMQZGNJ
DMQZGNJ	DN	Sulfamic acid 4-sulfamoyloxy-butyl ester
DMQZGNJ	MI	TTHQPL7
DMQZGNJ	MN	Carbonic anhydrase I (CA-I)
DMQZGNJ	MT	DTT
DMQZGNJ	MA	Inhibitor
DMQZGNJ	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):579-84.
DMQZGNJ	RU	https://pubmed.ncbi.nlm.nih.gov/15664816

DMQZGNJ	DI	DMQZGNJ
DMQZGNJ	DN	Sulfamic acid 4-sulfamoyloxy-butyl ester
DMQZGNJ	MI	TTANPDJ
DMQZGNJ	MN	Carbonic anhydrase II (CA-II)
DMQZGNJ	MT	DTT
DMQZGNJ	MA	Inhibitor
DMQZGNJ	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):579-84.
DMQZGNJ	RU	https://pubmed.ncbi.nlm.nih.gov/15664816

DMQZGNJ	DI	DMQZGNJ
DMQZGNJ	DN	Sulfamic acid 4-sulfamoyloxy-butyl ester
DMQZGNJ	MI	TT2LVK8
DMQZGNJ	MN	Carbonic anhydrase IX (CA-IX)
DMQZGNJ	MT	DTT
DMQZGNJ	MA	Inhibitor
DMQZGNJ	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):579-84.
DMQZGNJ	RU	https://pubmed.ncbi.nlm.nih.gov/15664816

DMFJR0S	DI	DMFJR0S
DMFJR0S	DN	Sulfamic acid 4-sulfamoyloxymethyl-benzyl ester
DMFJR0S	MI	TTANPDJ
DMFJR0S	MN	Carbonic anhydrase II (CA-II)
DMFJR0S	MT	DTT
DMFJR0S	MA	Inhibitor
DMFJR0S	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):579-84.
DMFJR0S	RU	https://pubmed.ncbi.nlm.nih.gov/15664816

DMFJR0S	DI	DMFJR0S
DMFJR0S	DN	Sulfamic acid 4-sulfamoyloxymethyl-benzyl ester
DMFJR0S	MI	TT2LVK8
DMFJR0S	MN	Carbonic anhydrase IX (CA-IX)
DMFJR0S	MT	DTT
DMFJR0S	MA	Inhibitor
DMFJR0S	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):579-84.
DMFJR0S	RU	https://pubmed.ncbi.nlm.nih.gov/15664816

DMT3U2D	DI	DMT3U2D
DMT3U2D	DN	Sulfamic acid 6-sulfamoyloxy-hexyl ester
DMT3U2D	MI	TTHQPL7
DMT3U2D	MN	Carbonic anhydrase I (CA-I)
DMT3U2D	MT	DTT
DMT3U2D	MA	Inhibitor
DMT3U2D	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):579-84.
DMT3U2D	RU	https://pubmed.ncbi.nlm.nih.gov/15664816

DMT3U2D	DI	DMT3U2D
DMT3U2D	DN	Sulfamic acid 6-sulfamoyloxy-hexyl ester
DMT3U2D	MI	TTANPDJ
DMT3U2D	MN	Carbonic anhydrase II (CA-II)
DMT3U2D	MT	DTT
DMT3U2D	MA	Inhibitor
DMT3U2D	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):579-84.
DMT3U2D	RU	https://pubmed.ncbi.nlm.nih.gov/15664816

DMT3U2D	DI	DMT3U2D
DMT3U2D	DN	Sulfamic acid 6-sulfamoyloxy-hexyl ester
DMT3U2D	MI	TT2LVK8
DMT3U2D	MN	Carbonic anhydrase IX (CA-IX)
DMT3U2D	MT	DTT
DMT3U2D	MA	Inhibitor
DMT3U2D	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):579-84.
DMT3U2D	RU	https://pubmed.ncbi.nlm.nih.gov/15664816

DMVWEN3	DI	DMVWEN3
DMVWEN3	DN	Sulfamic acid 7-sulfamoyloxy-heptyl ester
DMVWEN3	MI	TTHQPL7
DMVWEN3	MN	Carbonic anhydrase I (CA-I)
DMVWEN3	MT	DTT
DMVWEN3	MA	Inhibitor
DMVWEN3	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):579-84.
DMVWEN3	RU	https://pubmed.ncbi.nlm.nih.gov/15664816

DMVWEN3	DI	DMVWEN3
DMVWEN3	DN	Sulfamic acid 7-sulfamoyloxy-heptyl ester
DMVWEN3	MI	TTANPDJ
DMVWEN3	MN	Carbonic anhydrase II (CA-II)
DMVWEN3	MT	DTT
DMVWEN3	MA	Inhibitor
DMVWEN3	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):579-84.
DMVWEN3	RU	https://pubmed.ncbi.nlm.nih.gov/15664816

DMVWEN3	DI	DMVWEN3
DMVWEN3	DN	Sulfamic acid 7-sulfamoyloxy-heptyl ester
DMVWEN3	MI	TT2LVK8
DMVWEN3	MN	Carbonic anhydrase IX (CA-IX)
DMVWEN3	MT	DTT
DMVWEN3	MA	Inhibitor
DMVWEN3	RN	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):579-84.
DMVWEN3	RU	https://pubmed.ncbi.nlm.nih.gov/15664816

DMFVQYI	DI	DMFVQYI
DMFVQYI	DN	Sulfamic acid benzo[1,3]dioxol-2-ylmethyl ester
DMFVQYI	MI	TTANPDJ
DMFVQYI	MN	Carbonic anhydrase II (CA-II)
DMFVQYI	MT	DTT
DMFVQYI	MA	Inhibitor
DMFVQYI	RN	Comparison of sulfamate and sulfamide groups for the inhibition of carbonic anhydrase-II by using topiramate as a structural platform. J Med Chem. 2005 Mar 24;48(6):1941-7.
DMFVQYI	RU	https://pubmed.ncbi.nlm.nih.gov/15771438

DMN0Q71	DI	DMN0Q71
DMN0Q71	DN	Sulfamic acid chroman-2-ylmethyl ester
DMN0Q71	MI	TTANPDJ
DMN0Q71	MN	Carbonic anhydrase II (CA-II)
DMN0Q71	MT	DTT
DMN0Q71	MA	Inhibitor
DMN0Q71	RN	Comparison of sulfamate and sulfamide groups for the inhibition of carbonic anhydrase-II by using topiramate as a structural platform. J Med Chem. 2005 Mar 24;48(6):1941-7.
DMN0Q71	RU	https://pubmed.ncbi.nlm.nih.gov/15771438

DMW0ZBF	DI	DMW0ZBF
DMW0ZBF	DN	Sulfate
DMW0ZBF	MI	DTVGOLN
DMW0ZBF	MN	Anion exchange transporter (SLC26A6)
DMW0ZBF	MT	DTP
DMW0ZBF	MA	Substrate
DMW0ZBF	RN	The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.53.2.7)
DMW0ZBF	RU	http://www.tcdb.org/search/result.php?tc=2.A.53.2.7

DMW0ZBF	DI	DMW0ZBF
DMW0ZBF	DN	Sulfate
DMW0ZBF	MI	DTOTME4
DMW0ZBF	MN	Anion exchange transporter (SLC26A7)
DMW0ZBF	MT	DTP
DMW0ZBF	MA	Substrate
DMW0ZBF	RN	The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.53.2.6)
DMW0ZBF	RU	http://www.tcdb.org/search/result.php?tc=2.A.53.2.6

DMW0ZBF	DI	DMW0ZBF
DMW0ZBF	DN	Sulfate
DMW0ZBF	MI	TTHQPL7
DMW0ZBF	MN	Carbonic anhydrase I (CA-I)
DMW0ZBF	MT	DTT
DMW0ZBF	MA	Inhibitor
DMW0ZBF	RN	Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5435-9.
DMW0ZBF	RU	https://pubmed.ncbi.nlm.nih.gov/15454240

DMW0ZBF	DI	DMW0ZBF
DMW0ZBF	DN	Sulfate
DMW0ZBF	MI	DTJYKDQ
DMW0ZBF	MN	Mitochondrial dicarboxylate carrier (SLC25A10)
DMW0ZBF	MT	DTP
DMW0ZBF	MA	Substrate
DMW0ZBF	RN	SLC25A10 biallelic mutations in intractable epileptic encephalopathy with complex I deficiency. Hum Mol Genet. 2018 Feb 1;27(3):499-504.
DMW0ZBF	RU	http://www.ncbi.nlm.nih.gov/pubmed/29211846

DMW0ZBF	DI	DMW0ZBF
DMW0ZBF	DN	Sulfate
DMW0ZBF	MI	DTJZ7W2
DMW0ZBF	MN	Na(+)/sulfate cotransporter SUT-1 (SLC13A4)
DMW0ZBF	MT	DTP
DMW0ZBF	MA	Substrate
DMW0ZBF	RN	Loss of the sulfate transporter Slc13a4 in placenta causes severe fetal abnormalities and death in mice. Cell Res. 2015 Nov;25(11):1273-6.
DMW0ZBF	RU	http://www.ncbi.nlm.nih.gov/pubmed/26292834

DMW0ZBF	DI	DMW0ZBF
DMW0ZBF	DN	Sulfate
DMW0ZBF	MI	DTIZEMV
DMW0ZBF	MN	Sodium/sulfate cotransporter 1 (SLC13A1)
DMW0ZBF	MT	DTP
DMW0ZBF	MA	Substrate
DMW0ZBF	RN	Na+-sulfate cotransporter SLC13A1. Pflugers Arch. 2014 Jan;466(1):131-7.
DMW0ZBF	RU	http://www.ncbi.nlm.nih.gov/pubmed/24193406

DMW0ZBF	DI	DMW0ZBF
DMW0ZBF	DN	Sulfate
DMW0ZBF	MI	DTJ785O
DMW0ZBF	MN	Sulfate anion transporter 1 (SLC26A1)
DMW0ZBF	MT	DTP
DMW0ZBF	MA	Substrate
DMW0ZBF	RN	Mutations in SLC26A1 Cause Nephrolithiasis. Am J Hum Genet. 2016 Jun 2;98(6):1228-1234.
DMW0ZBF	RU	http://www.ncbi.nlm.nih.gov/pubmed/27210743

DMW0ZBF	DI	DMW0ZBF
DMW0ZBF	DN	Sulfate
DMW0ZBF	MI	DTFSLX5
DMW0ZBF	MN	Sulfate transporter (SLC26A2)
DMW0ZBF	MT	DTP
DMW0ZBF	MA	Substrate
DMW0ZBF	RN	Regulated transport of sulfate and oxalate by SLC26A2/DTDST. Am J Physiol Cell Physiol. 2010 Jun;298(6):C1363-75.
DMW0ZBF	RU	http://www.ncbi.nlm.nih.gov/pubmed/20219950

DMW0ZBF	DI	DMW0ZBF
DMW0ZBF	DN	Sulfate
DMW0ZBF	MI	DEDG68B
DMW0ZBF	MN	Sulfurylase kinase 1 (PAPSS1)
DMW0ZBF	MT	DME
DMW0ZBF	MA	Metabolism
DMW0ZBF	RN	Human 3'-phosphoadenosine 5'-phosphosulfate synthetase (isoform 1, brain): kinetic properties of the adenosine triphosphate sulfurylase and adenosine 5'-phosphosulfate kinase domains. Biochemistry. 2004 Apr 13;43(14):4356-65.
DMW0ZBF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15065880

DM8KYUE	DI	DM8KYUE
DM8KYUE	DN	SULFOARECOLINE
DM8KYUE	MI	TTZ9SOR
DM8KYUE	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DM8KYUE	MT	DTT
DM8KYUE	MA	Inhibitor
DM8KYUE	RN	Heterocyclic muscarinic agonists. Synthesis and biological activity of some bicyclic sulfonium arecoline bioisosteres. J Med Chem. 1988 Jul;31(7):1312-6.
DM8KYUE	RU	https://pubmed.ncbi.nlm.nih.gov/3385727

DM8KYUE	DI	DM8KYUE
DM8KYUE	DN	SULFOARECOLINE
DM8KYUE	MI	TTYEG6Q
DM8KYUE	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DM8KYUE	MT	DTT
DM8KYUE	MA	Inhibitor
DM8KYUE	RN	Heterocyclic muscarinic agonists. Synthesis and biological activity of some bicyclic sulfonium arecoline bioisosteres. J Med Chem. 1988 Jul;31(7):1312-6.
DM8KYUE	RU	https://pubmed.ncbi.nlm.nih.gov/3385727

DM8KYUE	DI	DM8KYUE
DM8KYUE	DN	SULFOARECOLINE
DM8KYUE	MI	TTQ13Z5
DM8KYUE	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DM8KYUE	MT	DTT
DM8KYUE	MA	Inhibitor
DM8KYUE	RN	Heterocyclic muscarinic agonists. Synthesis and biological activity of some bicyclic sulfonium arecoline bioisosteres. J Med Chem. 1988 Jul;31(7):1312-6.
DM8KYUE	RU	https://pubmed.ncbi.nlm.nih.gov/3385727

DM8KYUE	DI	DM8KYUE
DM8KYUE	DN	SULFOARECOLINE
DM8KYUE	MI	TTQ3JTF
DM8KYUE	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DM8KYUE	MT	DTT
DM8KYUE	MA	Inhibitor
DM8KYUE	RN	Heterocyclic muscarinic agonists. Synthesis and biological activity of some bicyclic sulfonium arecoline bioisosteres. J Med Chem. 1988 Jul;31(7):1312-6.
DM8KYUE	RU	https://pubmed.ncbi.nlm.nih.gov/3385727

DM8KYUE	DI	DM8KYUE
DM8KYUE	DN	SULFOARECOLINE
DM8KYUE	MI	TTH18TF
DM8KYUE	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DM8KYUE	MT	DTT
DM8KYUE	MA	Inhibitor
DM8KYUE	RN	Heterocyclic muscarinic agonists. Synthesis and biological activity of some bicyclic sulfonium arecoline bioisosteres. J Med Chem. 1988 Jul;31(7):1312-6.
DM8KYUE	RU	https://pubmed.ncbi.nlm.nih.gov/3385727

DMU0BW9	DI	DMU0BW9
DMU0BW9	DN	sulfonamide-01
DMU0BW9	MI	TTRLZHP
DMU0BW9	MN	cAMP-dependent chloride channel (CFTR)
DMU0BW9	MT	DTT
DMU0BW9	MA	Activator
DMU0BW9	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 707).
DMU0BW9	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=707

DMBG0H1	DI	DMBG0H1
DMBG0H1	DN	Sulfonylthioureas
DMBG0H1	MI	TTG140O
DMBG0H1	MN	Inward rectifier potassium channel Kir1.2 (KCNJ10)
DMBG0H1	MT	DTT
DMBG0H1	MA	Blocker
DMBG0H1	RN	Cardioselective K(ATP) channel blockers derived from a new series of m-anisamidoethylbenzenesulfonylthioureas. J Med Chem. 2001 Mar 29;44(7):1085-98.
DMBG0H1	RU	https://pubmed.ncbi.nlm.nih.gov/11297455

DMQY3L0	DI	DMQY3L0
DMQY3L0	DN	Sulforaphane
DMQY3L0	MI	TTH1ZOP
DMQY3L0	MN	Inactive rhomboid protein 2 (RHBDF2)
DMQY3L0	MT	DTT
DMQY3L0	RN	p63 is a key regulator of iRHOM2 signalling in the keratinocyte stress response.Nat Commun. 2018 Mar 9;9(1):1021.
DMQY3L0	RU	https://pubmed.ncbi.nlm.nih.gov/29523849

DMYPM2D	DI	DMYPM2D
DMYPM2D	DN	SULFURETIN
DMYPM2D	MI	TTL53M6
DMYPM2D	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DMYPM2D	MT	DTT
DMYPM2D	MA	Inhibitor
DMYPM2D	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMYPM2D	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMTEU0L	DI	DMTEU0L
DMTEU0L	DN	Sul-Pro-Phe-N-MeHis-LVA-Ile-Amp
DMTEU0L	MI	TTB2MXP
DMTEU0L	MN	Angiotensinogenase renin (REN)
DMTEU0L	MT	DTT
DMTEU0L	MA	Inhibitor
DMTEU0L	RN	Renin inhibitory peptides. Incorporation of polar, hydrophilic end groups into an active renin inhibitory peptide template and their evaluation in ... J Med Chem. 1991 Feb;34(2):633-42.
DMTEU0L	RU	https://pubmed.ncbi.nlm.nih.gov/1995887

DMQB2CN	DI	DMQB2CN
DMQB2CN	DN	Sul-Pro-Phe-N-MeHis-LVA-Ile-Amp-(O)
DMQB2CN	MI	TTB2MXP
DMQB2CN	MN	Angiotensinogenase renin (REN)
DMQB2CN	MT	DTT
DMQB2CN	MA	Inhibitor
DMQB2CN	RN	Renin inhibitory peptides. Incorporation of polar, hydrophilic end groups into an active renin inhibitory peptide template and their evaluation in ... J Med Chem. 1991 Feb;34(2):633-42.
DMQB2CN	RU	https://pubmed.ncbi.nlm.nih.gov/1995887

DM26KQG	DI	DM26KQG
DM26KQG	DN	SUN-C8257
DM26KQG	MI	TT8VUE0
DM26KQG	MN	Chymase (CYM)
DM26KQG	MT	DTT
DM26KQG	MA	Inhibitor
DM26KQG	RN	Chymase inhibitor ameliorates eosinophilia in mice infected with Nippostrongylus brasiliensis. Int Arch Allergy Immunol. 2002 Jul;128(3):235-9.
DM26KQG	RU	https://pubmed.ncbi.nlm.nih.gov/12119506

DMVZWCI	DI	DMVZWCI
DMVZWCI	DN	super cinnamaldehyde
DMVZWCI	MI	TTELV3W
DMVZWCI	MN	Transformation-sensitive protein p120 (TRPA1)
DMVZWCI	MT	DTT
DMVZWCI	MA	Activator
DMVZWCI	RN	Noxious compounds activate TRPA1 ion channels through covalent modification of cysteines. Nature. 2007 Feb 1;445(7127):541-5.
DMVZWCI	RU	https://pubmed.ncbi.nlm.nih.gov/17237762

DMN4IW5	DI	DMN4IW5
DMN4IW5	DN	Suramin
DMN4IW5	MI	TTV1095
DMN4IW5	MN	COVID-19 RNA-directed RNA polymerase (RdRp)
DMN4IW5	MT	DTT
DMN4IW5	MA	Inhibitor
DMN4IW5	RN	Suramin, Penciclovir and Anidulafungin bind nsp12, which governs the RNA-dependent-RNA polymerase activity of SARS-CoV-2, with higher interaction energy than Remdesivir, indicating potential in the treatment of Covid-19 infection. April.21.2020. Doi: 10.31219/osf.io/urxwh
DMN4IW5	RU	https://osf.io/urxwh

DMQ5GMV	DI	DMQ5GMV
DMQ5GMV	DN	SUVN-1004028
DMQ5GMV	MI	TT07C3Y
DMQ5GMV	MN	5-HT 4 receptor (HTR4)
DMQ5GMV	MT	DTT
DMQ5GMV	MA	Agonist
DMQ5GMV	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 9).
DMQ5GMV	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=9

DMT8PKC	DI	DMT8PKC
DMT8PKC	DN	SUVN-501
DMT8PKC	MI	TTJS8PY
DMT8PKC	MN	5-HT 6 receptor (HTR6)
DMT8PKC	MT	DTT
DMT8PKC	MA	Antagonist
DMT8PKC	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 11).
DMT8PKC	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=11

DMZCKDH	DI	DMZCKDH
DMZCKDH	DN	SUVN-504
DMZCKDH	MI	TTJS8PY
DMZCKDH	MN	5-HT 6 receptor (HTR6)
DMZCKDH	MT	DTT
DMZCKDH	MA	Antagonist
DMZCKDH	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 11).
DMZCKDH	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=11

DM2UMK8	DI	DM2UMK8
DM2UMK8	DN	SUVN-507
DM2UMK8	MI	TTJS8PY
DM2UMK8	MN	5-HT 6 receptor (HTR6)
DM2UMK8	MT	DTT
DM2UMK8	MA	Antagonist
DM2UMK8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 11).
DM2UMK8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=11

DMVDHBT	DI	DMVDHBT
DMVDHBT	DN	SUVN-G1031
DMVDHBT	MI	TT9JNIC
DMVDHBT	MN	Histamine H3 receptor (H3R)
DMVDHBT	MT	DTT
DMVDHBT	MA	Antagonist
DMVDHBT	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 264).
DMVDHBT	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=264

DMZGX48	DI	DMZGX48
DMZGX48	DN	SX-517
DMZGX48	MI	TT30C9G
DMZGX48	MN	C-X-C chemokine receptor type 2 (CXCR2)
DMZGX48	MT	DTT
DMZGX48	MA	Antagonist
DMZGX48	RN	Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2. J Med Chem. 2014 Oct 23;57(20):8378-97.
DMZGX48	RU	https://pubmed.ncbi.nlm.nih.gov/25254640

DMEA36L	DI	DMEA36L
DMEA36L	DN	SX-ARPC
DMEA36L	MI	TTS64P2
DMEA36L	MN	Androgen receptor (AR)
DMEA36L	MT	DTT
DMEA36L	MA	Antagonist
DMEA36L	RN	Clinical pipeline report, company report or official report of Progenics Pharmaceuticals Serometrix.
DMEA36L	RU	http://www.serometrix.com/pipeline.html

DMT53U6	DI	DMT53U6
DMT53U6	DN	SX-GLP1
DMT53U6	MI	TTVIMDE
DMT53U6	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMT53U6	MT	DTT
DMT53U6	MA	Agonist
DMT53U6	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249).
DMT53U6	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=249

DMJGZ79	DI	DMJGZ79
DMJGZ79	DN	SX-MTR1
DMJGZ79	MI	TTCJG29
DMJGZ79	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMJGZ79	MT	DTT
DMJGZ79	MA	Modulator
DMJGZ79	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
DMJGZ79	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109

DM7YB08	DI	DM7YB08
DM7YB08	DN	SYL-040003
DM7YB08	MI	TTZHA0O
DM7YB08	MN	Carbonic anhydrase IV (CA-IV)
DM7YB08	MT	DTT
DM7YB08	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2599).
DM7YB08	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2599

DMKIDRY	DI	DMKIDRY
DMKIDRY	DN	SYM-011
DMKIDRY	MI	TTGKNB4
DMKIDRY	MN	Epidermal growth factor receptor (EGFR)
DMKIDRY	MT	DTT
DMKIDRY	MA	Modulator
DMKIDRY	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
DMKIDRY	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797

DMKIDRY	DI	DMKIDRY
DMKIDRY	DN	SYM-011
DMKIDRY	MI	TTDC8N2
DMKIDRY	MN	Erbb3 tyrosine kinase receptor (Erbb-3)
DMKIDRY	MT	DTT
DMKIDRY	MA	Modulator
DMKIDRY	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1798).
DMKIDRY	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1798

DM30WDL	DI	DM30WDL
DM30WDL	DN	SYM2081
DM30WDL	MI	TT8WRDA
DM30WDL	MN	Excitatory amino acid transporter 1 (SLC1A3)
DM30WDL	MT	DTT
DM30WDL	MA	Modulator
DM30WDL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 868).
DM30WDL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=868

DM30WDL	DI	DM30WDL
DM30WDL	DN	SYM2081
DM30WDL	MI	TT2F078
DM30WDL	MN	Excitatory amino acid transporter 2 (SLC1A2)
DM30WDL	MT	DTT
DM30WDL	MA	Inhibitor
DM30WDL	RN	Contrasting modes of action of methylglutamate derivatives on the excitatory amino acid transporters, EAAT1 and EAAT2. Mol Pharmacol. 1997 May;51(5):809-15.
DM30WDL	RU	https://pubmed.ncbi.nlm.nih.gov/9145919

DM30WDL	DI	DM30WDL
DM30WDL	DN	SYM2081
DM30WDL	MI	TT0MYE2
DM30WDL	MN	Glutamate receptor ionotropic kainate 1 (GRIK1)
DM30WDL	MT	DTT
DM30WDL	MA	Agonist
DM30WDL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 450).
DM30WDL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=450

DM30WDL	DI	DM30WDL
DM30WDL	DN	SYM2081
DM30WDL	MI	TT0K5RG
DM30WDL	MN	Glutamate receptor ionotropic kainate 2 (GRIK2)
DM30WDL	MT	DTT
DM30WDL	MA	Agonist
DM30WDL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 451).
DM30WDL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=451

DM30WDL	DI	DM30WDL
DM30WDL	DN	SYM2081
DM30WDL	MI	TTNP6O2
DM30WDL	MN	Glutamate receptor ionotropic kainate 3 (GluK3)
DM30WDL	MT	DTT
DM30WDL	MA	Agonist
DM30WDL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 452).
DM30WDL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=452

DM30WDL	DI	DM30WDL
DM30WDL	DN	SYM2081
DM30WDL	MI	TTQV6BO
DM30WDL	MN	Glutamate receptor ionotropic kainate 4 (GluK4)
DM30WDL	MT	DTT
DM30WDL	MA	Agonist
DM30WDL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 453).
DM30WDL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=453

DM30WDL	DI	DM30WDL
DM30WDL	DN	SYM2081
DM30WDL	MI	TTO6LI7
DM30WDL	MN	Glutamate receptor ionotropic kainate 5 (GRIK5)
DM30WDL	MT	DTT
DM30WDL	MA	Agonist
DM30WDL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 454).
DM30WDL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=454

DM28TXP	DI	DM28TXP
DM28TXP	DN	SYMBIOPOLYOL
DM28TXP	MI	TTHCEF6
DM28TXP	MN	VCAM-1 messenger RNA (VCAM1 mRNA)
DM28TXP	MT	DTT
DM28TXP	MA	Inhibitor
DM28TXP	RN	Symbiopolyol, a VCAM-1 inhibitor from a symbiotic dinoflagellate of the jellyfish Mastigias papua. J Nat Prod. 2010 Jul 23;73(7):1318-22.
DM28TXP	RU	https://pubmed.ncbi.nlm.nih.gov/20557071

DMYTEXB	DI	DMYTEXB
DMYTEXB	DN	Syn-1020
DMYTEXB	MI	TTNT7K8
DMYTEXB	MN	Nociceptin receptor (OPRL1)
DMYTEXB	MT	DTT
DMYTEXB	MA	Agonist
DMYTEXB	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 320).
DMYTEXB	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=320

DMFNR75	DI	DMFNR75
DMFNR75	DN	SYN-1327
DMFNR75	MI	TTKLPHO
DMFNR75	MN	Neonatal Fc receptor (FCGRT)
DMFNR75	MT	DTT
DMFNR75	MA	Inhibitor
DMFNR75	RN	Structure-activity relationships of a peptide inhibitor of the human FcRn:human IgG interaction. Bioorg Med Chem. 2008 Jun 15;16(12):6394-405.
DMFNR75	RU	https://pubmed.ncbi.nlm.nih.gov/18501614

DMM5PVL	DI	DMM5PVL
DMM5PVL	DN	syn-BrP-LPA
DMM5PVL	MI	TTQ6S1K
DMM5PVL	MN	Lysophosphatidic acid receptor 1 (LPAR1)
DMM5PVL	MT	DTT
DMM5PVL	MA	Antagonist
DMM5PVL	RN	Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res. 2009 Jul 1;69(13):5441-9.
DMM5PVL	RU	https://pubmed.ncbi.nlm.nih.gov/19509223

DM802V7	DI	DM802V7
DM802V7	DN	Syringic Acid
DM802V7	MI	TTUNARX
DM802V7	MN	Carbonic anhydrase (CA)
DM802V7	MT	DTT
DM802V7	MA	Inhibitor
DM802V7	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DM802V7	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DM802V7	DI	DM802V7
DM802V7	DN	Syringic Acid
DM802V7	MI	TTHQPL7
DM802V7	MN	Carbonic anhydrase I (CA-I)
DM802V7	MT	DTT
DM802V7	MA	Inhibitor
DM802V7	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DM802V7	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DM802V7	DI	DM802V7
DM802V7	DN	Syringic Acid
DM802V7	MI	TTANPDJ
DM802V7	MN	Carbonic anhydrase II (CA-II)
DM802V7	MT	DTT
DM802V7	MA	Inhibitor
DM802V7	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DM802V7	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DM802V7	DI	DM802V7
DM802V7	DN	Syringic Acid
DM802V7	MI	TTZHA0O
DM802V7	MN	Carbonic anhydrase IV (CA-IV)
DM802V7	MT	DTT
DM802V7	MA	Inhibitor
DM802V7	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DM802V7	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DM802V7	DI	DM802V7
DM802V7	DN	Syringic Acid
DM802V7	MI	TT2LVK8
DM802V7	MN	Carbonic anhydrase IX (CA-IX)
DM802V7	MT	DTT
DM802V7	MA	Inhibitor
DM802V7	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DM802V7	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DM802V7	DI	DM802V7
DM802V7	DN	Syringic Acid
DM802V7	MI	TTCFSPE
DM802V7	MN	Carbonic anhydrase VI (CA-VI)
DM802V7	MT	DTT
DM802V7	MA	Inhibitor
DM802V7	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DM802V7	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DM802V7	DI	DM802V7
DM802V7	DN	Syringic Acid
DM802V7	MI	TTSYM0R
DM802V7	MN	Carbonic anhydrase XII (CA-XII)
DM802V7	MT	DTT
DM802V7	MA	Inhibitor
DM802V7	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DM802V7	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DM802V7	DI	DM802V7
DM802V7	DN	Syringic Acid
DM802V7	MI	TTEYTKG
DM802V7	MN	Carbonic anhydrase XIV (CA-XIV)
DM802V7	MT	DTT
DM802V7	MA	Inhibitor
DM802V7	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DM802V7	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DM8L6ZF	DI	DM8L6ZF
DM8L6ZF	DN	SZ(+)-(S)-202-791
DM8L6ZF	MI	TT94HRF
DM8L6ZF	MN	Voltage-gated calcium channel alpha Cav1.1 (CACNA1S)
DM8L6ZF	MT	DTT
DM8L6ZF	MA	Activator
DM8L6ZF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 528).
DM8L6ZF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=528

DM8L6ZF	DI	DM8L6ZF
DM8L6ZF	DN	SZ(+)-(S)-202-791
DM8L6ZF	MI	TTZIFHC
DM8L6ZF	MN	Voltage-gated calcium channel alpha Cav1.2 (CACNA1C)
DM8L6ZF	MT	DTT
DM8L6ZF	MA	Activator
DM8L6ZF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 529).
DM8L6ZF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=529

DMTKSVO	DI	DMTKSVO
DMTKSVO	DN	T0070907
DMTKSVO	MI	TTT2SVW
DMTKSVO	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DMTKSVO	MT	DTT
DMTKSVO	MA	Antagonist
DMTKSVO	RN	T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities. J Biol Chem. 2002 May 31;277(22):19649-57.
DMTKSVO	RU	https://pubmed.ncbi.nlm.nih.gov/11877444

DMZE9TW	DI	DMZE9TW
DMZE9TW	DN	T0156
DMZE9TW	MI	TTJ0IQB
DMZE9TW	MN	Phosphodiesterase 5A (PDE5A)
DMZE9TW	MT	DTT
DMZE9TW	MA	Inhibitor
DMZE9TW	RN	Enzymological and pharmacological profile of T-0156, a potent and selective phosphodiesterase type 5 inhibitor. Eur J Pharmacol. 2002 Dec 5;456(1-3):91-8.
DMZE9TW	RU	https://pubmed.ncbi.nlm.nih.gov/12450574

DMSVLXQ	DI	DMSVLXQ
DMSVLXQ	DN	T-0509
DMSVLXQ	MI	TTMXGCW
DMSVLXQ	MN	Adrenergic receptor beta-3 (ADRB3)
DMSVLXQ	MT	DTT
DMSVLXQ	MA	Agonist
DMSVLXQ	RN	Molecular characterization of pharmacological properties of T-0509 for beta-adrenoceptors. Eur J Pharmacol. 1996 Nov 21;315(3):363-7.
DMSVLXQ	RU	https://pubmed.ncbi.nlm.nih.gov/8982677

DMZQVDI	DI	DMZQVDI
DMZQVDI	DN	T0901317
DMZQVDI	MI	TTM1EQF
DMZQVDI	MN	Oxysterols receptor LXR (NR1H)
DMZQVDI	MT	DTT
DMZQVDI	MA	Binder
DMZQVDI	RN	The LXR ligand T0901317 induces severe lipogenesis in the db/db diabetic mouse. J Lipid Res. 2003 Nov;44(11):2039-48.
DMZQVDI	RU	https://pubmed.ncbi.nlm.nih.gov/12923232

DMGPQ0Y	DI	DMGPQ0Y
DMGPQ0Y	DN	T-1105
DMGPQ0Y	MI	TTSUKYD
DMGPQ0Y	MN	Virus RNA-dependent RNA polymerase (Viru RdRP)
DMGPQ0Y	MT	DTT
DMGPQ0Y	MA	Inhibitor
DMGPQ0Y	RN	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob Agents Chemother. 2009 Jan;53(1):202-9.
DMGPQ0Y	RU	https://pubmed.ncbi.nlm.nih.gov/18955536

DMPA2E9	DI	DMPA2E9
DMPA2E9	DN	T-1106
DMPA2E9	MI	TTSUKYD
DMPA2E9	MN	Virus RNA-dependent RNA polymerase (Viru RdRP)
DMPA2E9	MT	DTT
DMPA2E9	MA	Inhibitor
DMPA2E9	RN	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob Agents Chemother. 2009 Jan;53(1):202-9.
DMPA2E9	RU	https://pubmed.ncbi.nlm.nih.gov/18955536

DMSA3U4	DI	DMSA3U4
DMSA3U4	DN	T1117
DMSA3U4	MI	TTNET8J
DMSA3U4	MN	G-protein coupled receptor 55 (GPR55)
DMSA3U4	MT	DTT
DMSA3U4	MA	Agonist
DMSA3U4	RN	Fluorescent ligand binding reveals heterogeneous distribution of adrenoceptors and 'cannabinoid-like' receptors in small arteries. Br J Pharmacol. 2010 Feb;159(4):787-96.
DMSA3U4	RU	https://pubmed.ncbi.nlm.nih.gov/20136833

DMVRJEL	DI	DMVRJEL
DMVRJEL	DN	T13
DMVRJEL	MI	TTE2YJR
DMVRJEL	MN	Lysophosphatidate-3 receptor (LPAR3)
DMVRJEL	MT	DTT
DMVRJEL	MA	Agonist
DMVRJEL	RN	LPA and its analogs-attractive tools for elucidation of LPA biology and drug development. Curr Med Chem. 2008;15(21):2122-31.
DMVRJEL	RU	https://pubmed.ncbi.nlm.nih.gov/18781939

DMVRJEL	DI	DMVRJEL
DMVRJEL	DN	T13
DMVRJEL	MI	TTQ6S1K
DMVRJEL	MN	Lysophosphatidic acid receptor 1 (LPAR1)
DMVRJEL	MT	DTT
DMVRJEL	MA	Agonist
DMVRJEL	RN	Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors. Acta Pharmacol Sin. 2010 Sep;31(9):1213-22.
DMVRJEL	RU	https://pubmed.ncbi.nlm.nih.gov/20729877

DM6HZVC	DI	DM6HZVC
DM6HZVC	DN	T134
DM6HZVC	MI	TTBID49
DM6HZVC	MN	C-X-C chemokine receptor type 4 (CXCR4)
DM6HZVC	MT	DTT
DM6HZVC	MA	Antagonist
DM6HZVC	RN	A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem Biophys Res Commun. 1998 Dec 30;253(3):877-82.
DM6HZVC	RU	https://pubmed.ncbi.nlm.nih.gov/9918823

DMIHBC5	DI	DMIHBC5
DMIHBC5	DN	T140
DMIHBC5	MI	TTBID49
DMIHBC5	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMIHBC5	MT	DTT
DMIHBC5	MA	Antagonist
DMIHBC5	RN	A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem Biophys Res Commun. 1998 Dec 30;253(3):877-82.
DMIHBC5	RU	https://pubmed.ncbi.nlm.nih.gov/9918823

DMBIH8A	DI	DMBIH8A
DMBIH8A	DN	T22
DMBIH8A	MI	TTBID49
DMBIH8A	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMBIH8A	MT	DTT
DMBIH8A	MA	Antagonist
DMBIH8A	RN	A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem Biophys Res Commun. 1998 Dec 30;253(3):877-82.
DMBIH8A	RU	https://pubmed.ncbi.nlm.nih.gov/9918823

DMCWE90	DI	DMCWE90
DMCWE90	DN	T2328
DMCWE90	MI	TTZPO1L
DMCWE90	MN	Substance-P receptor (TACR1)
DMCWE90	MT	DTT
DMCWE90	MA	Antagonist
DMCWE90	RN	Pharmacological characterization of T-2328, 2-fluoro-4'-methoxy-3'-[[[(2S,3S)-2-phenyl-3-piperidinyl]amino]methyl]-[1,1'-biphenyl]-4-carbonitrile d... J Pharmacol Sci. 2008 Jan;106(1):121-7.
DMCWE90	RU	https://pubmed.ncbi.nlm.nih.gov/18187929

DMFKQ1W	DI	DMFKQ1W
DMFKQ1W	DN	T-98475
DMFKQ1W	MI	TT8R70G
DMFKQ1W	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMFKQ1W	MT	DTT
DMFKQ1W	MA	Inhibitor
DMFKQ1W	RN	Non-peptide gonadotropin-releasing hormone receptor antagonists. J Med Chem. 2008 Jun 26;51(12):3331-48.
DMFKQ1W	RU	https://pubmed.ncbi.nlm.nih.gov/18419112

DME2PFQ	DI	DME2PFQ
DME2PFQ	DN	TA-106
DME2PFQ	MI	TTA0P7K
DME2PFQ	MN	Complement factor B (CFB)
DME2PFQ	MT	DTT
DME2PFQ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2339).
DME2PFQ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2339

DMP2016	DI	DMP2016
DMP2016	DN	TA1-RTA
DMP2016	MI	TT6EO5L
DMP2016	MN	Erbb2 tyrosine kinase receptor (HER2)
DMP2016	MT	DTT
DMP2016	MA	Binder
DMP2016	RN	Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2. Clin Cancer Res.2000 Aug;6(8):3334-41.
DMP2016	RU	https://pubmed.ncbi.nlm.nih.gov/10955821

DMOWHER	DI	DMOWHER
DMOWHER	DN	TACRINE(8)-4-AMINOQUINOLINE
DMOWHER	MI	TT1RS9F
DMOWHER	MN	Acetylcholinesterase (AChE)
DMOWHER	MT	DTT
DMOWHER	MA	Inhibitor
DMOWHER	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMOWHER	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMCIEQO	DI	DMCIEQO
DMCIEQO	DN	TAD
DMCIEQO	MI	TTL7C8Q
DMCIEQO	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMCIEQO	MT	DTT
DMCIEQO	MA	Inhibitor
DMCIEQO	RN	Crystal structure of a ternary complex of Tritrichomonas foetus inosine 5'-monophosphate dehydrogenase: NAD+ orients the active site loop for catalysis. Biochemistry. 2002 Nov 5;41(44):13309-17.
DMCIEQO	RU	https://pubmed.ncbi.nlm.nih.gov/12403633

DM3B8R1	DI	DM3B8R1
DM3B8R1	DN	Tagetitoxin
DM3B8R1	MI	TTS31JH
DM3B8R1	MN	Staphylococcus Plastid RNA polymerase beta (Stap-coc rpoB)
DM3B8R1	MT	DTT
DM3B8R1	MA	Inhibitor
DM3B8R1	RN	Synthesis of the bicyclic core of tagetitoxin. Chem Commun (Camb). 2006 Mar 21;(11):1197-9.
DM3B8R1	RU	https://pubmed.ncbi.nlm.nih.gov/16518489

DM2RN0S	DI	DM2RN0S
DM2RN0S	DN	tagitinin A
DM2RN0S	MI	TTT2SVW
DM2RN0S	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DM2RN0S	MT	DTT
DM2RN0S	MA	Agonist
DM2RN0S	RN	Sesquiterpene lactones from Tithonia diversifolia act as peroxisome proliferator-activated receptor agonists. Bioorg Med Chem Lett. 2012 Apr 15;22(8):2954-8.
DM2RN0S	RU	https://pubmed.ncbi.nlm.nih.gov/22424975

DMLOAZB	DI	DMLOAZB
DMLOAZB	DN	TAK-075
DMLOAZB	MI	TTBUYHA
DMLOAZB	MN	Extracellular calcium-sensing receptor (CASR)
DMLOAZB	MT	DTT
DMLOAZB	MA	Antagonist
DMLOAZB	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 54).
DMLOAZB	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=54

DMW24JP	DI	DMW24JP
DMW24JP	DN	TALAROFLAVONE
DMW24JP	MI	TTIU7X1
DMW24JP	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMW24JP	MT	DTT
DMW24JP	MA	Inhibitor
DMW24JP	RN	1-deoxyrubralactone, a novel specific inhibitor of families X and Y of eukaryotic DNA polymerases from a fungal strain derived from sea algae. Bioorg Med Chem. 2008 Mar 15;16(6):2939-44.
DMW24JP	RU	https://pubmed.ncbi.nlm.nih.gov/18178092

DMRTD16	DI	DMRTD16
DMRTD16	DN	Talinolol
DMRTD16	MI	DE4LYSA
DMRTD16	MN	Cytochrome P450 3A4 (CYP3A4)
DMRTD16	MT	DME
DMRTD16	MA	Metabolism
DMRTD16	RN	Stereoselective disposition of talinolol in man. J Pharm Sci. 2002 Feb;91(2):303-11.
DMRTD16	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11835190

DMRTD16	DI	DMRTD16
DMRTD16	DN	Talinolol
DMRTD16	MI	DTFI42L
DMRTD16	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMRTD16	MT	DTP
DMRTD16	MA	Substrate
DMRTD16	RN	FDA Drug Development and Drug Interactions
DMRTD16	RU	https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2

DMRTD16	DI	DMRTD16
DMRTD16	DN	Talinolol
DMRTD16	MI	DTE2B1D
DMRTD16	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMRTD16	MT	DTP
DMRTD16	MA	Substrate
DMRTD16	RN	Concentration-dependent effect of naringin on intestinal absorption of beta(1)-adrenoceptor antagonist talinolol mediated by p-glycoprotein and organic anion transporting polypeptide (Oatp). Pharm Res. 2009 Mar;26(3):560-7.
DMRTD16	RU	http://www.ncbi.nlm.nih.gov/pubmed/19002566

DMRTD16	DI	DMRTD16
DMRTD16	DN	Talinolol
DMRTD16	MI	DTPFTEQ
DMRTD16	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DMRTD16	MT	DTP
DMRTD16	MA	Substrate
DMRTD16	RN	Species difference in the effect of grapefruit juice on intestinal absorption of talinolol between human and rat. J Pharmacol Exp Ther. 2010 Jan;332(1):181-9.
DMRTD16	RU	http://www.ncbi.nlm.nih.gov/pubmed/19779132

DMRTD16	DI	DMRTD16
DMRTD16	DN	Talinolol
DMRTD16	MI	DTUGYRD
DMRTD16	MN	P-glycoprotein 1 (ABCB1)
DMRTD16	MT	DTP
DMRTD16	MA	Substrate
DMRTD16	RN	Grapefruit juice-drug interactions: Grapefruit juice and its components inhibit P-glycoprotein (ABCB1) mediated transport of talinolol in Caco-2 cells. J Pharm Sci. 2007 Oct;96(10):2808-17.
DMRTD16	RU	http://www.ncbi.nlm.nih.gov/pubmed/17542018

DMMTSL2	DI	DMMTSL2
DMMTSL2	DN	Talmapimod
DMMTSL2	MI	TTQBR95
DMMTSL2	MN	Stress-activated protein kinase 2a (p38 alpha)
DMMTSL2	MT	DTT
DMMTSL2	MA	Modulator
DMMTSL2	RN	Mitogen-activated protein kinases in innate immunity.Nat Rev Immunol.2013 Sep;13(9):679-92.
DMMTSL2	RU	https://www.ncbi.nlm.nih.gov/pubmed/23954936

DM26SE7	DI	DM26SE7
DM26SE7	DN	TAM-67
DM26SE7	MI	TTN3GBV
DM26SE7	MN	Transcription factor AP-1 (JUN)
DM26SE7	MT	DTT
DM26SE7	MA	Inhibitor
DM26SE7	RN	AP-1 blockade inhibits the growth of normal and malignant breast cells. Oncogene. 2001 May 17;20(22):2771-80.
DM26SE7	RU	https://pubmed.ncbi.nlm.nih.gov/11420689

DM0EP51	DI	DM0EP51
DM0EP51	DN	TAMARIXETIN
DM0EP51	MI	TTI84H7
DM0EP51	MN	Cytochrome P450 1B1 (CYP1B1)
DM0EP51	MT	DTT
DM0EP51	MA	Inhibitor
DM0EP51	RN	Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5.
DM0EP51	RU	https://pubmed.ncbi.nlm.nih.gov/20696580

DM17JFO	DI	DM17JFO
DM17JFO	DN	Tamarixetin 3-glucoside-7-sulfate
DM17JFO	MI	TTFBNVI
DM17JFO	MN	Aldose reductase (AKR1B1)
DM17JFO	MT	DTT
DM17JFO	MA	Inhibitor
DM17JFO	RN	Effect of Polygonum hydropiper sulfated flavonoids on lens aldose reductase and related enzymes. J Nat Prod. 1996 Apr;59(4):443-5.
DM17JFO	RU	https://pubmed.ncbi.nlm.nih.gov/8699190

DMBKL5O	DI	DMBKL5O
DMBKL5O	DN	Tamoxifen butyl bromide
DMBKL5O	MI	TTZAYWL
DMBKL5O	MN	Estrogen receptor (ESR)
DMBKL5O	MT	DTT
DMBKL5O	MA	Inhibitor
DMBKL5O	RN	Genomic action of permanently charged tamoxifen derivatives via estrogen receptor-alpha. Bioorg Med Chem. 2010 Aug 1;18(15):5593-601.
DMBKL5O	RU	https://pubmed.ncbi.nlm.nih.gov/20621492

DM76BXY	DI	DM76BXY
DM76BXY	DN	Tamoxifen ethyl bromide
DM76BXY	MI	TTZAYWL
DM76BXY	MN	Estrogen receptor (ESR)
DM76BXY	MT	DTT
DM76BXY	MA	Inhibitor
DM76BXY	RN	Genomic action of permanently charged tamoxifen derivatives via estrogen receptor-alpha. Bioorg Med Chem. 2010 Aug 1;18(15):5593-601.
DM76BXY	RU	https://pubmed.ncbi.nlm.nih.gov/20621492

DMBKWUZ	DI	DMBKWUZ
DMBKWUZ	DN	Tamoxifen isopropyl bromide
DMBKWUZ	MI	TTZAYWL
DMBKWUZ	MN	Estrogen receptor (ESR)
DMBKWUZ	MT	DTT
DMBKWUZ	MA	Inhibitor
DMBKWUZ	RN	Genomic action of permanently charged tamoxifen derivatives via estrogen receptor-alpha. Bioorg Med Chem. 2010 Aug 1;18(15):5593-601.
DMBKWUZ	RU	https://pubmed.ncbi.nlm.nih.gov/20621492

DMQCW7V	DI	DMQCW7V
DMQCW7V	DN	Tanaproget
DMQCW7V	MI	TTUV8G9
DMQCW7V	MN	Progesterone receptor (PGR)
DMQCW7V	MT	DTT
DMQCW7V	MA	Inhibitor
DMQCW7V	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMQCW7V	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM52WGH	DI	DM52WGH
DM52WGH	DN	tannic acid
DM52WGH	MI	TTOJI4S
DM52WGH	MN	Calcium-dependent chloride channel anoctamin (ANO)
DM52WGH	MT	DTT
DM52WGH	MA	Blocker (channel blocker)
DM52WGH	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 708).
DM52WGH	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=708

DMTFHRI	DI	DMTFHRI
DMTFHRI	DN	TANNIN
DMTFHRI	MI	TTFJ8Q1
DMTFHRI	MN	Protein kinase C alpha (PRKCA)
DMTFHRI	MT	DTT
DMTFHRI	MA	Inhibitor
DMTFHRI	RN	Tannins as selective inhibitors of protein kinase C, Bioorg. Med. Chem. Lett. 2(3):239-244 (1992).
DMTFHRI	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01810726

DMTFHRI	DI	DMTFHRI
DMTFHRI	DN	TANNIN
DMTFHRI	MI	TTYPXQF
DMTFHRI	MN	Protein kinase C beta (PRKCB)
DMTFHRI	MT	DTT
DMTFHRI	MA	Inhibitor
DMTFHRI	RN	Tannins as selective inhibitors of protein kinase C, Bioorg. Med. Chem. Lett. 2(3):239-244 (1992).
DMTFHRI	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01810726

DM07FBL	DI	DM07FBL
DM07FBL	DN	TAS-203
DM07FBL	MI	TTZ97H5
DM07FBL	MN	Phosphodiesterase 4A (PDE4A)
DM07FBL	MT	DTT
DM07FBL	MA	Inhibitor
DM07FBL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1300).
DM07FBL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1300

DM07FBL	DI	DM07FBL
DM07FBL	DN	TAS-203
DM07FBL	MI	TTVIAT9
DM07FBL	MN	Phosphodiesterase 4B (PDE4B)
DM07FBL	MT	DTT
DM07FBL	MA	Inhibitor
DM07FBL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1301).
DM07FBL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1301

DM07FBL	DI	DM07FBL
DM07FBL	DN	TAS-203
DM07FBL	MI	TTSKMI8
DM07FBL	MN	Phosphodiesterase 4D (PDE4D)
DM07FBL	MT	DTT
DM07FBL	MA	Inhibitor
DM07FBL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1303).
DM07FBL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1303

DM9S5DV	DI	DM9S5DV
DM9S5DV	DN	TASPINE
DM9S5DV	MI	TT1RS9F
DM9S5DV	MN	Acetylcholinesterase (AChE)
DM9S5DV	MT	DTT
DM9S5DV	MA	Inhibitor
DM9S5DV	RN	Taspine: bioactivity-guided isolation and molecular ligand-target insight of a potent acetylcholinesterase inhibitor from Magnolia x soulangiana. J Nat Prod. 2006 Sep;69(9):1341-6.
DM9S5DV	RU	https://pubmed.ncbi.nlm.nih.gov/16989531

DML01Y7	DI	DML01Y7
DML01Y7	DN	TAT-120
DML01Y7	MI	TTCPLVN
DML01Y7	MN	MST-1 protein kinase (STK4)
DML01Y7	MT	DTT
DML01Y7	MA	Inhibitor
DML01Y7	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2225).
DML01Y7	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2225

DMVW7N3	DI	DMVW7N3
DMVW7N3	DN	Taurine
DMVW7N3	MI	DERA3OF
DMVW7N3	MN	Bile acid-CoA thioesterase (BAAT)
DMVW7N3	MT	DME
DMVW7N3	MA	Metabolism
DMVW7N3	RN	Bile acid coenzyme A: amino acid N-acyltransferase in the amino acid conjugation of bile acids. Methods Enzymol. 2005;400:374-94.
DMVW7N3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16399361

DMVW7N3	DI	DMVW7N3
DMVW7N3	DN	Taurine
DMVW7N3	MI	TTZ8EM9
DMVW7N3	MN	Glycine receptor (GlyR)
DMVW7N3	MT	DTT
DMVW7N3	MA	Agonist
DMVW7N3	RN	Identification of intracellular and extracellular domains mediating signal transduction in the inhibitory glycine receptor chloride channel. EMBO J. 1997 Jan 2;16(1):110-20.
DMVW7N3	RU	https://pubmed.ncbi.nlm.nih.gov/9009272

DMVW7N3	DI	DMVW7N3
DMVW7N3	DN	Taurine
DMVW7N3	MI	DTHWCVA
DMVW7N3	MN	Sodium- and chloride-dependent taurine transporter (SLC6A6)
DMVW7N3	MT	DTP
DMVW7N3	MA	Substrate
DMVW7N3	RN	Astrocytic -aminobutyric acid (GABA) transporters mediate guanidinoacetate transport in rat brain. 2018 Feb;113:1-7.
DMVW7N3	RU	http://www.ncbi.nlm.nih.gov/pubmed/29175673

DMVW7N3	DI	DMVW7N3
DMVW7N3	DN	Taurine
DMVW7N3	MI	DEUWCVD
DMVW7N3	MN	Transglutaminase Y (TGM6)
DMVW7N3	MT	DME
DMVW7N3	MA	Metabolism
DMVW7N3	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (pathway:hsa00430)
DMVW7N3	RU	http://www.genome.jp/kegg-bin/show_pathway?hsa00430

DMEL9UT	DI	DMEL9UT
DMEL9UT	DN	Taurochenodeoxycholic acid
DMEL9UT	MI	DE4LYSA
DMEL9UT	MN	Cytochrome P450 3A4 (CYP3A4)
DMEL9UT	MT	DME
DMEL9UT	MA	Metabolism
DMEL9UT	RN	6alpha-hydroxylation of taurochenodeoxycholic acid and lithocholic acid by CYP3A4 in human liver microsomes. Biochim Biophys Acta. 1999 Apr 19;1438(1):47-54.
DMEL9UT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10216279

DMFKRQE	DI	DMFKRQE
DMFKRQE	DN	Tauroursodeoxycholic acid
DMFKRQE	MI	DTFI42L
DMFKRQE	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMFKRQE	MT	DTP
DMFKRQE	MA	Substrate
DMFKRQE	RN	Human multidrug resistance protein 2 transports the therapeutic bile salt tauroursodeoxycholate. J Pharmacol Exp Ther. 2007 Feb;320(2):893-9.
DMFKRQE	RU	https://doi.org/10.1124/jpet.106.106922

DMFKRQE	DI	DMFKRQE
DMFKRQE	DN	Tauroursodeoxycholic acid
DMFKRQE	MI	DTE2B1D
DMFKRQE	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMFKRQE	MT	DTP
DMFKRQE	MA	Substrate
DMFKRQE	RN	Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology. 1995 Oct;109(4):1274-82.
DMFKRQE	RU	http://www.ncbi.nlm.nih.gov/pubmed/7557095

DMC92DQ	DI	DMC92DQ
DMC92DQ	DN	TAUTOMYCIN
DMC92DQ	MI	TTFLH0E
DMC92DQ	MN	Serine/threonine PP1-alpha (PPP1CA)
DMC92DQ	MT	DTT
DMC92DQ	MA	Inhibitor
DMC92DQ	RN	Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies. J Med Chem. 2002 Mar 14;45(6):1151-75.
DMC92DQ	RU	https://pubmed.ncbi.nlm.nih.gov/11881984

DMCZIFS	DI	DMCZIFS
DMCZIFS	DN	TB-101
DMCZIFS	MI	TT6L509
DMCZIFS	MN	Coagulation factor IIa (F2)
DMCZIFS	MT	DTT
DMCZIFS	MA	Modulator
DMCZIFS	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362).
DMCZIFS	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2362

DMUN8CG	DI	DMUN8CG
DMUN8CG	DN	TB-102
DMUN8CG	MI	TT6L509
DMUN8CG	MN	Coagulation factor IIa (F2)
DMUN8CG	MT	DTT
DMUN8CG	MA	Modulator
DMUN8CG	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362).
DMUN8CG	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2362

DMFC3XP	DI	DMFC3XP
DMFC3XP	DN	TBPS
DMFC3XP	MI	TTBMV1G
DMFC3XP	MN	GABA(A) receptor alpha-2 (GABRA2)
DMFC3XP	MT	DTT
DMFC3XP	MA	Blocker (channel blocker)
DMFC3XP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 405).
DMFC3XP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=405

DMFC3XP	DI	DMFC3XP
DMFC3XP	DN	TBPS
DMFC3XP	MI	TT37EDJ
DMFC3XP	MN	GABA(A) receptor alpha-3 (GABRA3)
DMFC3XP	MT	DTT
DMFC3XP	MA	Blocker (channel blocker)
DMFC3XP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 406).
DMFC3XP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=406

DMFC3XP	DI	DMFC3XP
DMFC3XP	DN	TBPS
DMFC3XP	MI	TTNZPQ1
DMFC3XP	MN	GABA(A) receptor alpha-5 (GABRA5)
DMFC3XP	MT	DTT
DMFC3XP	MA	Blocker (channel blocker)
DMFC3XP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 408).
DMFC3XP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=408

DMFC3XP	DI	DMFC3XP
DMFC3XP	DN	TBPS
DMFC3XP	MI	TTZA1NY
DMFC3XP	MN	GABA(A) receptor beta-2 (GABRB2)
DMFC3XP	MT	DTT
DMFC3XP	MA	Blocker (channel blocker)
DMFC3XP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 411).
DMFC3XP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=411

DMFC3XP	DI	DMFC3XP
DMFC3XP	DN	TBPS
DMFC3XP	MI	TTGXH6N
DMFC3XP	MN	GABA(A) receptor delta (GABRD)
DMFC3XP	MT	DTT
DMFC3XP	MA	Blocker (channel blocker)
DMFC3XP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 416).
DMFC3XP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=416

DMFC3XP	DI	DMFC3XP
DMFC3XP	DN	TBPS
DMFC3XP	MI	TTBY4OD
DMFC3XP	MN	GABA(A) receptor epsilon (GABRE)
DMFC3XP	MT	DTT
DMFC3XP	MA	Blocker (channel blocker)
DMFC3XP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 417).
DMFC3XP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=417

DMFC3XP	DI	DMFC3XP
DMFC3XP	DN	TBPS
DMFC3XP	MI	TT06RH5
DMFC3XP	MN	GABA(A) receptor gamma-2 (GABRG2)
DMFC3XP	MT	DTT
DMFC3XP	MA	Blocker (channel blocker)
DMFC3XP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 414).
DMFC3XP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=414

DMFC3XP	DI	DMFC3XP
DMFC3XP	DN	TBPS
DMFC3XP	MI	TTEX6LM
DMFC3XP	MN	GABA(A) receptor gamma-3 (GABRG3)
DMFC3XP	MT	DTT
DMFC3XP	MA	Blocker (channel blocker)
DMFC3XP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415).
DMFC3XP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415

DMFC3XP	DI	DMFC3XP
DMFC3XP	DN	TBPS
DMFC3XP	MI	TT3E0DI
DMFC3XP	MN	GABA(A) receptor pi (GABRP)
DMFC3XP	MT	DTT
DMFC3XP	MA	Blocker (channel blocker)
DMFC3XP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 419).
DMFC3XP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=419

DMFC3XP	DI	DMFC3XP
DMFC3XP	DN	TBPS
DMFC3XP	MI	TT6XFEU
DMFC3XP	MN	GABA(A) receptor rho1 (GABRR1)
DMFC3XP	MT	DTT
DMFC3XP	MA	Blocker (channel blocker)
DMFC3XP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 420).
DMFC3XP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=420

DMFC3XP	DI	DMFC3XP
DMFC3XP	DN	TBPS
DMFC3XP	MI	TTQMXLS
DMFC3XP	MN	GABA(A) receptor rho2 (GABRR2)
DMFC3XP	MT	DTT
DMFC3XP	MA	Blocker (channel blocker)
DMFC3XP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 421).
DMFC3XP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=421

DMFC3XP	DI	DMFC3XP
DMFC3XP	DN	TBPS
DMFC3XP	MI	TT4N6D8
DMFC3XP	MN	GABA(A) receptor rho3 (GABRR3)
DMFC3XP	MT	DTT
DMFC3XP	MA	Blocker (channel blocker)
DMFC3XP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 422).
DMFC3XP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=422

DMFC3XP	DI	DMFC3XP
DMFC3XP	DN	TBPS
DMFC3XP	MI	TTXDUR9
DMFC3XP	MN	GABA(A) receptor theta (GABRQ)
DMFC3XP	MT	DTT
DMFC3XP	MA	Blocker (channel blocker)
DMFC3XP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 418).
DMFC3XP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=418

DMKAX76	DI	DMKAX76
DMKAX76	DN	T-BuAc-RYYRIK-NH2
DMKAX76	MI	TTNT7K8
DMKAX76	MN	Nociceptin receptor (OPRL1)
DMKAX76	MT	DTT
DMKAX76	MA	Inhibitor
DMKAX76	RN	Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist. Bioorg Med Chem. 2008 Mar 1;16(5):2635-44.
DMKAX76	RU	https://pubmed.ncbi.nlm.nih.gov/18068993

DMLNVH8	DI	DMLNVH8
DMLNVH8	DN	TC-2559
DMLNVH8	MI	TT5KPZR
DMLNVH8	MN	Neuronal acetylcholine receptor beta-2 (CHRNB2)
DMLNVH8	MT	DTT
DMLNVH8	MA	Agonist
DMLNVH8	RN	The nicotinic alpha 4 beta 2 receptor selective agonist, TC-2559, increases dopamine neuronal activity in the ventral tegmental area of rat midbrain slices. Neuropharmacology. 2003 Sep;45(3):334-44.
DMLNVH8	RU	https://pubmed.ncbi.nlm.nih.gov/12871651

DM06DI1	DI	DM06DI1
DM06DI1	DN	TCI15
DM06DI1	MI	TTMSB0A
DM06DI1	MN	Integrin alpha-2/beta-1 (ITGA2/B1)
DM06DI1	MT	DTT
DM06DI1	MA	Inhibitor
DM06DI1	RN	Small-molecule inhibitors of integrin alpha2beta1 that prevent pathological thrombus formation via an allosteric mechanism. Proc Natl Acad Sci U S A. 2009 Jan 20;106(3):719-24.
DM06DI1	RU	https://pubmed.ncbi.nlm.nih.gov/19141632

DMMT2GP	DI	DMMT2GP
DMMT2GP	DN	TCN-201
DMMT2GP	MI	TTKJEMQ
DMMT2GP	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMMT2GP	MT	DTT
DMMT2GP	MA	Modulator (allosteric modulator)
DMMT2GP	RN	Subunit-selective allosteric inhibition of glycine binding to NMDA receptors. J Neurosci. 2012 May 2;32(18):6197-208.
DMMT2GP	RU	https://pubmed.ncbi.nlm.nih.gov/22553026

DMTF4VI	DI	DMTF4VI
DMTF4VI	DN	TCPA
DMTF4VI	MI	TTK25J1
DMTF4VI	MN	Adenosine A1 receptor (ADORA1)
DMTF4VI	MT	DTT
DMTF4VI	MA	Agonist
DMTF4VI	RN	N6-cyclopentyl-2-(3-phenylaminocarbonyltriazene-1-yl)adenosine (TCPA), a very selective agonist with high affinity for the human adenosine A1 receptor. J Med Chem. 2003 Apr 10;46(8):1492-503.
DMTF4VI	RU	https://pubmed.ncbi.nlm.nih.gov/12672250

DMTF4VI	DI	DMTF4VI
DMTF4VI	DN	TCPA
DMTF4VI	MI	TTNE7KG
DMTF4VI	MN	Adenosine A2b receptor (ADORA2B)
DMTF4VI	MT	DTT
DMTF4VI	MA	Agonist
DMTF4VI	RN	Heterologous expression of rat epitope-tagged histamine H2 receptors in insect Sf9 cells. Br J Pharmacol. 1997 Nov;122(5):867-74.
DMTF4VI	RU	https://pubmed.ncbi.nlm.nih.gov/9384502

DMTF4VI	DI	DMTF4VI
DMTF4VI	DN	TCPA
DMTF4VI	MI	TTJFY5U
DMTF4VI	MN	Adenosine A3 receptor (ADORA3)
DMTF4VI	MT	DTT
DMTF4VI	MA	Agonist
DMTF4VI	RN	N6-cyclopentyl-2-(3-phenylaminocarbonyltriazene-1-yl)adenosine (TCPA), a very selective agonist with high affinity for the human adenosine A1 receptor. J Med Chem. 2003 Apr 10;46(8):1492-503.
DMTF4VI	RU	https://pubmed.ncbi.nlm.nih.gov/12672250

DMKVF5Q	DI	DMKVF5Q
DMKVF5Q	DN	TCPOBOP
DMKVF5Q	MI	TTRANFM
DMKVF5Q	MN	Orphan nuclear receptor NR1I3 (NR1I3)
DMKVF5Q	MT	DTT
DMKVF5Q	MA	Agonist
DMKVF5Q	RN	The nuclear receptor CAR is a regulator of thyroid hormone metabolism during caloric restriction. J Biol Chem. 2004 May 7;279(19):19832-8.
DMKVF5Q	RU	https://pubmed.ncbi.nlm.nih.gov/15004031

DMOLJRH	DI	DMOLJRH
DMOLJRH	DN	TCS 2510
DMOLJRH	MI	TT79WV3
DMOLJRH	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DMOLJRH	MT	DTT
DMOLJRH	MA	Agonist
DMOLJRH	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 343).
DMOLJRH	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=343

DMMUFSQ	DI	DMMUFSQ
DMMUFSQ	DN	TCS 5861528
DMMUFSQ	MI	TTELV3W
DMMUFSQ	MN	Transformation-sensitive protein p120 (TRPA1)
DMMUFSQ	MT	DTT
DMMUFSQ	MA	Inhibitor (gating inhibitor)
DMMUFSQ	RN	Attenuation of mechanical hypersensitivity by an antagonist of the TRPA1 ion channel in diabetic animals. Anesthesiology. 2009 Jul;111(1):147-54.
DMMUFSQ	RU	https://pubmed.ncbi.nlm.nih.gov/19512877

DMBVYQR	DI	DMBVYQR
DMBVYQR	DN	TCS2314
DMBVYQR	MI	TT6S84X
DMBVYQR	MN	Integrin alpha-4/beta-1 (ITGA4/B1)
DMBVYQR	MT	DTT
DMBVYQR	MA	Inhibitor
DMBVYQR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2580).
DMBVYQR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2580

DMH6UN8	DI	DMH6UN8
DMH6UN8	DN	TCS-359
DMH6UN8	MI	TTGJCWZ
DMH6UN8	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMH6UN8	MT	DTT
DMH6UN8	MA	Inhibitor
DMH6UN8	RN	Identification of 2-acylaminothiophene-3-carboxamides as potent inhibitors of FLT3. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3282-6.
DMH6UN8	RU	https://pubmed.ncbi.nlm.nih.gov/16580199

DML8RTO	DI	DML8RTO
DML8RTO	DN	TCS-OX2-29
DML8RTO	MI	TT9N02I
DML8RTO	MN	Orexin receptor type 2 (HCRTR2)
DML8RTO	MT	DTT
DML8RTO	MA	Antagonist
DML8RTO	RN	N-acyl 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline: the first orexin-2 receptor selective non-peptidic antagonist. Bioorg Med Chem Lett. 2003 Dec 15;13(24):4497-9.
DML8RTO	RU	https://pubmed.ncbi.nlm.nih.gov/14643355

DMQ7VDM	DI	DMQ7VDM
DMQ7VDM	DN	TDI-0033
DMQ7VDM	MI	TTEDJN4
DMQ7VDM	MN	Low-affinity nerve growth factor receptor (NGFR)
DMQ7VDM	MT	DTT
DMQ7VDM	MA	Agonist
DMQ7VDM	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1888).
DMQ7VDM	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1888

DMSI9QM	DI	DMSI9QM
DMSI9QM	DN	TDI-0059
DMSI9QM	MI	TTEDJN4
DMSI9QM	MN	Low-affinity nerve growth factor receptor (NGFR)
DMSI9QM	MT	DTT
DMSI9QM	MA	Modulator
DMSI9QM	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1888).
DMSI9QM	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1888

DMXHWAY	DI	DMXHWAY
DMXHWAY	DN	TDI-0060
DMXHWAY	MI	TT6RVLG
DMXHWAY	MN	Superoxide dismutase Cu-Zn (SOD Cu-Zn)
DMXHWAY	MT	DTT
DMXHWAY	MA	Modulator
DMXHWAY	RN	Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res. 2006 Aug 15;12(16):4974-82.
DMXHWAY	RU	https://pubmed.ncbi.nlm.nih.gov/16914587

DM5HEIR	DI	DM5HEIR
DM5HEIR	DN	TDI-0079
DM5HEIR	MI	TT6RVLG
DM5HEIR	MN	Superoxide dismutase Cu-Zn (SOD Cu-Zn)
DM5HEIR	MT	DTT
DM5HEIR	MA	Modulator
DM5HEIR	RN	Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res. 2006 Aug 15;12(16):4974-82.
DM5HEIR	RU	https://pubmed.ncbi.nlm.nih.gov/16914587

DMWGDXF	DI	DMWGDXF
DMWGDXF	DN	TDI-0107
DMWGDXF	MI	TT6RVLG
DMWGDXF	MN	Superoxide dismutase Cu-Zn (SOD Cu-Zn)
DMWGDXF	MT	DTT
DMWGDXF	MA	Inhibitor
DMWGDXF	RN	Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res. 2006 Aug 15;12(16):4974-82.
DMWGDXF	RU	https://pubmed.ncbi.nlm.nih.gov/16914587

DMRU8WT	DI	DMRU8WT
DMRU8WT	DN	TDT-044
DMRU8WT	MI	TTPNQAC
DMRU8WT	MN	Estrogen-related receptor-alpha (ESRRA)
DMRU8WT	MT	DTT
DMRU8WT	MA	Agonist
DMRU8WT	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 622).
DMRU8WT	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=622

DM0HJD4	DI	DM0HJD4
DM0HJD4	DN	tedisamil
DM0HJD4	MI	TTCVBT7
DM0HJD4	MN	Voltage-gated potassium channel Kv1.7 (KCNA7)
DM0HJD4	MT	DTT
DM0HJD4	MA	Blocker (channel blocker)
DM0HJD4	RN	Genomic organization, chromosomal localization, tissue distribution, and biophysical characterization of a novel mammalian Shaker-related voltage-gated potassium channel, Kv1.7. J Biol Chem. 1998 Mar6;273(10):5851-7.
DM0HJD4	RU	https://pubmed.ncbi.nlm.nih.gov/9488722

DMRPFCS	DI	DMRPFCS
DMRPFCS	DN	TEFLUDAZINE
DMRPFCS	MI	TT3ROYC
DMRPFCS	MN	Serotonin transporter (SERT)
DMRPFCS	MT	DTT
DMRPFCS	MA	Inhibitor
DMRPFCS	RN	Neuroleptic activity and dopamine-uptake inhibition in 1-piperazino-3-phenylindans. J Med Chem. 1983 Jul;26(7):935-47.
DMRPFCS	RU	https://pubmed.ncbi.nlm.nih.gov/6134833

DMBNYJW	DI	DMBNYJW
DMBNYJW	DN	TEI-8362
DMBNYJW	MI	TTPLTSQ
DMBNYJW	MN	Neutrophil elastase (NE)
DMBNYJW	MT	DTT
DMBNYJW	MA	Inhibitor
DMBNYJW	RN	Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs. 2002 Jul;11(7):965-80.
DMBNYJW	RU	https://pubmed.ncbi.nlm.nih.gov/12084007

DMGQLYR	DI	DMGQLYR
DMGQLYR	DN	TEI-9063
DMGQLYR	MI	TTOFYT1
DMGQLYR	MN	Prostacyclin receptor (PTGIR)
DMGQLYR	MT	DTT
DMGQLYR	MA	Agonist
DMGQLYR	RN	Relaxant actions of nonprostanoid prostacyclin mimetics on human pulmonary artery. J Cardiovasc Pharmacol. 1997 Apr;29(4):525-35.
DMGQLYR	RU	https://pubmed.ncbi.nlm.nih.gov/9156364

DMLDAR4	DI	DMLDAR4
DMLDAR4	DN	TEI-9647
DMLDAR4	MI	TTK59TV
DMLDAR4	MN	Vitamin D3 receptor (VDR)
DMLDAR4	MT	DTT
DMLDAR4	MA	Antagonist
DMLDAR4	RN	Further synthetic and biological studies on vitamin D hormone antagonists based on C24-alkylation and C2alpha-functionalization of 25-dehydro-1alpha-hydroxyvitamin D(3)-26,23-lactones. J Med Chem. 2006 Nov 30;49(24):7063-75.
DMLDAR4	RU	https://pubmed.ncbi.nlm.nih.gov/17125259

DMSMLRB	DI	DMSMLRB
DMSMLRB	DN	Teijin-lead_cmp_5
DMSMLRB	MI	TTFZYTO
DMSMLRB	MN	C-C chemokine receptor type 2 (CCR2)
DMSMLRB	MT	DTT
DMSMLRB	MA	Antagonist
DMSMLRB	RN	CCR2: characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approach. J Med Chem. 2003 Sep 11;46(19):4070-86.
DMSMLRB	RU	https://pubmed.ncbi.nlm.nih.gov/12954060

DM60HU5	DI	DM60HU5
DM60HU5	DN	Tellimagrandin II
DM60HU5	MI	TT6L509
DM60HU5	MN	Coagulation factor IIa (F2)
DM60HU5	MT	DTT
DM60HU5	MA	Inhibitor
DM60HU5	RN	Effects of tannins from Geum japonicum on the catalytic activity of thrombin and factor Xa of blood coagulation cascade. J Nat Prod. 1998 Nov;61(11):1356-60.
DM60HU5	RU	https://pubmed.ncbi.nlm.nih.gov/9834152

DM60HU5	DI	DM60HU5
DM60HU5	DN	Tellimagrandin II
DM60HU5	MI	TTCIHJA
DM60HU5	MN	Coagulation factor Xa (F10)
DM60HU5	MT	DTT
DM60HU5	MA	Inhibitor
DM60HU5	RN	Effects of tannins from Geum japonicum on the catalytic activity of thrombin and factor Xa of blood coagulation cascade. J Nat Prod. 1998 Nov;61(11):1356-60.
DM60HU5	RU	https://pubmed.ncbi.nlm.nih.gov/9834152

DMGD0HT	DI	DMGD0HT
DMGD0HT	DN	Tellurium
DMGD0HT	MI	TTE14XG
DMGD0HT	MN	Squalene monooxygenase (SQLE)
DMGD0HT	MT	DTT
DMGD0HT	MA	Inhibitor
DMGD0HT	RN	Squalene epoxidase as hypocholesterolemic drug target revisited. Prog Lipid Res. 2003 Jan;42(1):37-50.
DMGD0HT	RU	https://pubmed.ncbi.nlm.nih.gov/12467639

DM6EIVM	DI	DM6EIVM
DM6EIVM	DN	Telomestatin
DM6EIVM	MI	TTUJFD0
DM6EIVM	MN	Telomerase reverse transcriptase (TERT)
DM6EIVM	MT	DTT
DM6EIVM	MA	Inhibitor
DM6EIVM	RN	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
DM6EIVM	RU	https://pubmed.ncbi.nlm.nih.gov/19249983

DMT4NWX	DI	DMT4NWX
DMT4NWX	DN	TELUDIPINE HYDROCHLORIDE
DMT4NWX	MI	TT5HONZ
DMT4NWX	MN	Calcium channel unspecific (CaC)
DMT4NWX	MT	DTT
DMT4NWX	MA	Blocker
DMT4NWX	RN	Effects of R-enantiomer (GR66234A) and L-enantiomer (GR66235A) of telupidine, a new dihydropyridine derivative, on cell lines displaying the multidrug resistant phenotype. Haematologica. 1994 Jul-Aug;79(4):328-33.
DMT4NWX	RU	https://pubmed.ncbi.nlm.nih.gov/7806087

DML53GP	DI	DML53GP
DML53GP	DN	Tendamistat
DML53GP	MI	TTHCF4J
DML53GP	MN	Alpha-glucosidase (GLA)
DML53GP	MT	DTT
DML53GP	MA	Inhibitor
DML53GP	RN	Influence of Specific Signal Peptide Mutations on the Expression and Secretion of the alpha -Amylase Inhibitor Tendamistat in Streptomyces lividans. J Biol Chem. 1996 Jun 21;271(25):15244-52.
DML53GP	RU	https://pubmed.ncbi.nlm.nih.gov/8662986

DM1S209	DI	DM1S209
DM1S209	DN	TENELLONE A
DM1S209	MI	TTZC6DR
DM1S209	MN	cGMP-dependent protein kinase (cGK)
DM1S209	MT	DTT
DM1S209	MA	Inhibitor
DM1S209	RN	Tenellones A and B from a Diaporthe sp.: two highly substituted benzophenone inhibitors of parasite cGMP-dependent protein kinase activity. J Nat Prod. 2005 Apr;68(4):611-3.
DM1S209	RU	https://pubmed.ncbi.nlm.nih.gov/15844962

DM9ZVJ7	DI	DM9ZVJ7
DM9ZVJ7	DN	TENELLONE B
DM9ZVJ7	MI	TTZC6DR
DM9ZVJ7	MN	cGMP-dependent protein kinase (cGK)
DM9ZVJ7	MT	DTT
DM9ZVJ7	MA	Inhibitor
DM9ZVJ7	RN	Tenellones A and B from a Diaporthe sp.: two highly substituted benzophenone inhibitors of parasite cGMP-dependent protein kinase activity. J Nat Prod. 2005 Apr;68(4):611-3.
DM9ZVJ7	RU	https://pubmed.ncbi.nlm.nih.gov/15844962

DMRM1QV	DI	DMRM1QV
DMRM1QV	DN	Tenocyclidine
DMRM1QV	MI	TTKJEMQ
DMRM1QV	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMRM1QV	MT	DTT
DMRM1QV	MA	Antagonist
DMRM1QV	RN	The binding of [3H]thienyl cyclohexylpiperidine ([3H]TCP) to the NMDA-phencyclidine receptor complex. Neuropharmacology. 1989 Jan;28(1):1-7.
DMRM1QV	RU	https://pubmed.ncbi.nlm.nih.gov/2538766

DMRM1QV	DI	DMRM1QV
DMRM1QV	DN	Tenocyclidine
DMRM1QV	MI	TTN9D8E
DMRM1QV	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMRM1QV	MT	DTT
DMRM1QV	MA	Antagonist
DMRM1QV	RN	The binding of [3H]thienyl cyclohexylpiperidine ([3H]TCP) to the NMDA-phencyclidine receptor complex. Neuropharmacology. 1989 Jan;28(1):1-7.
DMRM1QV	RU	https://pubmed.ncbi.nlm.nih.gov/2538766

DMMLSZ4	DI	DMMLSZ4
DMMLSZ4	DN	TENOSAL
DMMLSZ4	MI	TTVKILB
DMMLSZ4	MN	Prostaglandin G/H synthase 2 (COX-2)
DMMLSZ4	MT	DTT
DMMLSZ4	MA	Inhibitor
DMMLSZ4	RN	US patent application no. 6,274,627, Conjugates of dithiocarbamate disulfides with pharmacologically active agents and uses therefor.
DMMLSZ4	RU	http://www.google.com/patents/US6274627

DMROS5K	DI	DMROS5K
DMROS5K	DN	TEPA (possesses cytotoxic activity)
DMROS5K	MI	TTZFYLI
DMROS5K	MN	Dopamine D1 receptor (D1R)
DMROS5K	MT	DTT
DMROS5K	MA	Inhibitor
DMROS5K	RN	N-(Iodopropenyl)-octahydrobenzo[f]- and -[g]quinolines: synthesis and adrenergic and dopaminergic activity studies. J Med Chem. 1998 Oct 8;41(21):4165-70.
DMROS5K	RU	https://pubmed.ncbi.nlm.nih.gov/9767652

DMPX7QS	DI	DMPX7QS
DMPX7QS	DN	TERRITREM B
DMPX7QS	MI	TT1RS9F
DMPX7QS	MN	Acetylcholinesterase (AChE)
DMPX7QS	MT	DTT
DMPX7QS	MA	Inhibitor
DMPX7QS	RN	Acetylcholinesterase inhibition by territrem B derivatives. J Nat Prod. 1995 Jun;58(6):857-62.
DMPX7QS	RU	https://pubmed.ncbi.nlm.nih.gov/7673929

DM8LI1K	DI	DM8LI1K
DM8LI1K	DN	Tert-butyl (2S)-1-cyanopyrrolidine-2-carboxylate
DM8LI1K	MI	TTDZN01
DM8LI1K	MN	Cathepsin K (CTSK)
DM8LI1K	MT	DTT
DM8LI1K	MA	Inhibitor
DM8LI1K	RN	Acyclic cyanamide-based inhibitors of cathepsin K. Bioorg Med Chem Lett. 2005 Jun 15;15(12):3039-43.
DM8LI1K	RU	https://pubmed.ncbi.nlm.nih.gov/15896958

DMW2X5V	DI	DMW2X5V
DMW2X5V	DN	Tert-butyl 10H-phenothiazine-10-carboxylate
DMW2X5V	MI	TTEB0GD
DMW2X5V	MN	Cholinesterase (BCHE)
DMW2X5V	MT	DTT
DMW2X5V	MA	Inhibitor
DMW2X5V	RN	Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. J Med Chem. 2008 Jul 24;51(14):4200-12.
DMW2X5V	RU	https://pubmed.ncbi.nlm.nih.gov/18570368

DMWQFY6	DI	DMWQFY6
DMWQFY6	DN	Tert-Butyl 2-(2-oxohexadecanamido)acetate
DMWQFY6	MI	TTT1JVS
DMWQFY6	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DMWQFY6	MT	DTT
DMWQFY6	MA	Inhibitor
DMWQFY6	RN	Structure-activity relationships of natural and non-natural amino acid-based amide and 2-oxoamide inhibitors of human phospholipase A(2) enzymes. Bioorg Med Chem. 2008 Dec 15;16(24):10257-69.
DMWQFY6	RU	https://pubmed.ncbi.nlm.nih.gov/18993078

DMZG5I7	DI	DMZG5I7
DMZG5I7	DN	TERT-BUTYL 2-CYANO-2-METHYLHYDRAZINECARBOXYLATE
DMZG5I7	MI	TTDZN01
DMZG5I7	MN	Cathepsin K (CTSK)
DMZG5I7	MT	DTT
DMZG5I7	MA	Inhibitor
DMZG5I7	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMZG5I7	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMNU9WV	DI	DMNU9WV
DMNU9WV	DN	Tert-Butyl 3-(2-oxo-8-phenyloctanamido)propanoate
DMNU9WV	MI	TTT1JVS
DMNU9WV	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DMNU9WV	MT	DTT
DMNU9WV	MA	Inhibitor
DMNU9WV	RN	Structure-activity relationships of natural and non-natural amino acid-based amide and 2-oxoamide inhibitors of human phospholipase A(2) enzymes. Bioorg Med Chem. 2008 Dec 15;16(24):10257-69.
DMNU9WV	RU	https://pubmed.ncbi.nlm.nih.gov/18993078

DMYQXPB	DI	DMYQXPB
DMYQXPB	DN	Tert-Butyl 3-(2-oxohexadecanamido)propanoate
DMYQXPB	MI	TTT1JVS
DMYQXPB	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DMYQXPB	MT	DTT
DMYQXPB	MA	Inhibitor
DMYQXPB	RN	Structure-activity relationships of natural and non-natural amino acid-based amide and 2-oxoamide inhibitors of human phospholipase A(2) enzymes. Bioorg Med Chem. 2008 Dec 15;16(24):10257-69.
DMYQXPB	RU	https://pubmed.ncbi.nlm.nih.gov/18993078

DM1ALTR	DI	DM1ALTR
DM1ALTR	DN	Tert-Butyl 5-(2-oxohexadecanamido)pentanoate
DM1ALTR	MI	TTT1JVS
DM1ALTR	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DM1ALTR	MT	DTT
DM1ALTR	MA	Inhibitor
DM1ALTR	RN	Structure-activity relationships of natural and non-natural amino acid-based amide and 2-oxoamide inhibitors of human phospholipase A(2) enzymes. Bioorg Med Chem. 2008 Dec 15;16(24):10257-69.
DM1ALTR	RU	https://pubmed.ncbi.nlm.nih.gov/18993078

DM42WFH	DI	DM42WFH
DM42WFH	DN	Tert-Butyl(1s)-1-Cyclohexyl-2-Oxoethylcarbamate
DM42WFH	MI	TTDZN01
DM42WFH	MN	Cathepsin K (CTSK)
DM42WFH	MT	DTT
DM42WFH	MA	Inhibitor
DM42WFH	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM42WFH	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMQKOUZ	DI	DMQKOUZ
DMQKOUZ	DN	Tert-butyloxy carbonyl-D-Phe-pro-Arg-H
DMQKOUZ	MI	TT2WR1T
DMQKOUZ	MN	Cationic trypsinogen (PRSS1)
DMQKOUZ	MT	DTT
DMQKOUZ	MA	Inhibitor
DMQKOUZ	RN	Structure-activity study of tripeptide thrombin inhibitors using alpha-alkyl amino acids and other conformationally constrained amino acid substitu... J Med Chem. 1995 Oct 27;38(22):4446-53.
DMQKOUZ	RU	https://pubmed.ncbi.nlm.nih.gov/7473571

DMQDVNZ	DI	DMQDVNZ
DMQDVNZ	DN	Testetrol
DMQDVNZ	MI	TTS64P2
DMQDVNZ	MN	Androgen receptor (AR)
DMQDVNZ	MT	DTT
DMQDVNZ	MA	Agonist
DMQDVNZ	RN	Estetrol review: profile and potential clinical applications. Climacteric. 2008;11 Suppl 1:47-58.
DMQDVNZ	RU	https://pubmed.ncbi.nlm.nih.gov/18464023

DMKLIXZ	DI	DMKLIXZ
DMKLIXZ	DN	Tetrabromocinnamic acid
DMKLIXZ	MI	TTZ5NI7
DMKLIXZ	MN	Casein kinase II (CSNK2)
DMKLIXZ	MT	DTT
DMKLIXZ	MA	Inhibitor
DMKLIXZ	RN	Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors. Chembiochem. 2007 Jan 2;8(1):129-39.
DMKLIXZ	RU	https://pubmed.ncbi.nlm.nih.gov/17133643

DMX5MAU	DI	DMX5MAU
DMX5MAU	DN	Tetrabutylammonium Ion
DMX5MAU	MI	TTYOMFZ
DMX5MAU	MN	Voltage-gated potassium channel (VGKC)
DMX5MAU	MT	DTT
DMX5MAU	MA	Inhibitor
DMX5MAU	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMX5MAU	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMK8P61	DI	DMK8P61
DMK8P61	DN	Tetradecane
DMK8P61	MI	TT7O8ZA
DMK8P61	MN	Lanosterol synthase (LSS)
DMK8P61	MT	DTT
DMK8P61	MA	Inhibitor
DMK8P61	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMK8P61	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMABITD	DI	DMABITD
DMABITD	DN	Tetradecyl-phosphonic acid
DMABITD	MI	TTQ6S1K
DMABITD	MN	Lysophosphatidic acid receptor 1 (LPAR1)
DMABITD	MT	DTT
DMABITD	MA	Inhibitor
DMABITD	RN	Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30.
DMABITD	RU	https://pubmed.ncbi.nlm.nih.gov/16033271

DMH4AGL	DI	DMH4AGL
DMH4AGL	DN	Tetraethylene Glycol
DMH4AGL	MI	TT1RS9F
DMH4AGL	MN	Acetylcholinesterase (AChE)
DMH4AGL	MT	DTT
DMH4AGL	MA	Inhibitor
DMH4AGL	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMH4AGL	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMDWUCX	DI	DMDWUCX
DMDWUCX	DN	Tetragastrin
DMDWUCX	MI	TTCG0AL
DMDWUCX	MN	Cholecystokinin receptor type A (CCKAR)
DMDWUCX	MT	DTT
DMDWUCX	MA	Inhibitor
DMDWUCX	RN	Synthesis and binding affinities of analogues of cholecystokinin-(30-33) as probes for central nervous system cholecystokinin receptors. J Med Chem. 1987 Apr;30(4):729-32.
DMDWUCX	RU	https://pubmed.ncbi.nlm.nih.gov/3560164

DMDWUCX	DI	DMDWUCX
DMDWUCX	DN	Tetragastrin
DMDWUCX	MI	TTVFO0U
DMDWUCX	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMDWUCX	MT	DTT
DMDWUCX	MA	Inhibitor
DMDWUCX	RN	Synthesis and binding affinities of analogues of cholecystokinin-(30-33) as probes for central nervous system cholecystokinin receptors. J Med Chem. 1987 Apr;30(4):729-32.
DMDWUCX	RU	https://pubmed.ncbi.nlm.nih.gov/3560164

DM2QKOU	DI	DM2QKOU
DM2QKOU	DN	Tetrahydroaldosterone
DM2QKOU	MI	DEB3CV1
DM2QKOU	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DM2QKOU	MT	DME
DM2QKOU	MA	Metabolism
DM2QKOU	RN	Human uridine diphosphate-glucuronosyltransferase UGT2B7 conjugates mineralocorticoid and glucocorticoid metabolites. Endocrinology. 2003 Jun;144(6):2659-68.
DM2QKOU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12746330

DMNURE0	DI	DMNURE0
DMNURE0	DN	TETRAHYDROBENXIMIDAZOLE
DMNURE0	MI	TT06AWU
DMNURE0	MN	Phosphodiesterase 3A (PDE3A)
DMNURE0	MT	DTT
DMNURE0	MA	Inhibitor
DMNURE0	RN	Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazi... J Med Chem. 1989 Feb;32(2):342-50.
DMNURE0	RU	https://pubmed.ncbi.nlm.nih.gov/2536438

DMDY1MZ	DI	DMDY1MZ
DMDY1MZ	DN	tetrahydrocannabivarin
DMDY1MZ	MI	TT946IA
DMDY1MZ	MN	Transient receptor potential cation channel V3 (TRPV3)
DMDY1MZ	MT	DTT
DMDY1MZ	MA	Activator
DMDY1MZ	RN	Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. Acta Physiol (Oxf). 2012 Feb;204(2):255-66.
DMDY1MZ	RU	https://pubmed.ncbi.nlm.nih.gov/21726418

DMF8M0W	DI	DMF8M0W
DMF8M0W	DN	tetrahydrodeoxycorticosterone
DMF8M0W	MI	TTBMV1G
DMF8M0W	MN	GABA(A) receptor alpha-2 (GABRA2)
DMF8M0W	MT	DTT
DMF8M0W	MA	Modulator (allosteric modulator)
DMF8M0W	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 405).
DMF8M0W	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=405

DMF8M0W	DI	DMF8M0W
DMF8M0W	DN	tetrahydrodeoxycorticosterone
DMF8M0W	MI	TT37EDJ
DMF8M0W	MN	GABA(A) receptor alpha-3 (GABRA3)
DMF8M0W	MT	DTT
DMF8M0W	MA	Modulator (allosteric modulator)
DMF8M0W	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 406).
DMF8M0W	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=406

DMF8M0W	DI	DMF8M0W
DMF8M0W	DN	tetrahydrodeoxycorticosterone
DMF8M0W	MI	TTNZPQ1
DMF8M0W	MN	GABA(A) receptor alpha-5 (GABRA5)
DMF8M0W	MT	DTT
DMF8M0W	MA	Modulator (allosteric modulator)
DMF8M0W	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 408).
DMF8M0W	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=408

DMF8M0W	DI	DMF8M0W
DMF8M0W	DN	tetrahydrodeoxycorticosterone
DMF8M0W	MI	TTEX6LM
DMF8M0W	MN	GABA(A) receptor gamma-3 (GABRG3)
DMF8M0W	MT	DTT
DMF8M0W	MA	Modulator (allosteric modulator)
DMF8M0W	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415).
DMF8M0W	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415

DMNH3ST	DI	DMNH3ST
DMNH3ST	DN	Tetrahydroimidazo[4,5,1-jk]-[1,4]benzodiazepin-2(1H)-one
DMNH3ST	MI	TT84ETX
DMNH3ST	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMNH3ST	MT	DTT
DMNH3ST	MA	Inhibitor
DMNH3ST	RN	Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptases display reversed sensitivity to nonnucleoside analog inhibitors. Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9878-82.
DMNH3ST	RU	https://pubmed.ncbi.nlm.nih.gov/1719542

DMMU6WQ	DI	DMMU6WQ
DMMU6WQ	DN	Tetrahydro-pyrimidin-2-ylideneamine
DMMU6WQ	MI	TTZUFI5
DMMU6WQ	MN	Nitric-oxide synthase brain (NOS1)
DMMU6WQ	MT	DTT
DMMU6WQ	MA	Inhibitor
DMMU6WQ	RN	2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. J Med Chem. 1996 Feb 2;39(3):669-72.
DMMU6WQ	RU	https://pubmed.ncbi.nlm.nih.gov/8576908

DMWRZJX	DI	DMWRZJX
DMWRZJX	DN	TETRAHYDROQUINOLINE A
DMWRZJX	MI	TTFQAYR
DMWRZJX	MN	Cholesteryl ester transfer protein (CETP)
DMWRZJX	MT	DTT
DMWRZJX	MA	Inhibitor
DMWRZJX	RN	Design and synthesis of potent inhibitors of cholesteryl ester transfer protein (CETP) exploiting a 1,2,3,4-tetrahydroquinoline platform. Bioorg Med Chem Lett. 2009 May 1;19(9):2456-60.
DMWRZJX	RU	https://pubmed.ncbi.nlm.nih.gov/19339179

DMHT61V	DI	DMHT61V
DMHT61V	DN	TETRAHYDROQUINOLINE B
DMHT61V	MI	TTFQAYR
DMHT61V	MN	Cholesteryl ester transfer protein (CETP)
DMHT61V	MT	DTT
DMHT61V	MA	Inhibitor
DMHT61V	RN	Design and synthesis of potent inhibitors of cholesteryl ester transfer protein (CETP) exploiting a 1,2,3,4-tetrahydroquinoline platform. Bioorg Med Chem Lett. 2009 May 1;19(9):2456-60.
DMHT61V	RU	https://pubmed.ncbi.nlm.nih.gov/19339179

DMWOBAE	DI	DMWOBAE
DMWOBAE	DN	tetralin_urea analogue (7o)
DMWOBAE	MI	TTX4RTB
DMWOBAE	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMWOBAE	MT	DTT
DMWOBAE	MA	Antagonist
DMWOBAE	RN	Discovery of tetralin ureas as potent melanin concentrating hormone 1 receptor antagonists. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1718-21.
DMWOBAE	RU	https://pubmed.ncbi.nlm.nih.gov/17251014

DMLEPYN	DI	DMLEPYN
DMLEPYN	DN	Tetramethylammonium Ion
DMLEPYN	MI	DTT79CX
DMLEPYN	MN	Organic cation transporter 1 (SLC22A1)
DMLEPYN	MT	DTP
DMLEPYN	MA	Substrate
DMLEPYN	RN	Scintillation proximity assay for measuring uptake by the human drug transporters hOCT1, hOAT3, and hOATP1B1. Anal Biochem. 2007 Jul 15;366(2):117-25.
DMLEPYN	RU	http://www.ncbi.nlm.nih.gov/pubmed/17555702

DMLEPYN	DI	DMLEPYN
DMLEPYN	DN	Tetramethylammonium Ion
DMLEPYN	MI	TTGRHIB
DMLEPYN	MN	UDP-glucose 4-epimerase (GALE)
DMLEPYN	MT	DTT
DMLEPYN	MA	Inhibitor
DMLEPYN	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMLEPYN	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMW9CH2	DI	DMW9CH2
DMW9CH2	DN	Tetramethylbutylphenol
DMW9CH2	MI	DE0P6LK
DMW9CH2	MN	Sulfotransferase 2A1 (SULT2A1)
DMW9CH2	MT	DME
DMW9CH2	MA	Metabolism
DMW9CH2	RN	Sulfation of environmental estrogens by cytosolic human sulfotransferases. Drug Metab Pharmacokinet. 2002;17(3):221-8.
DMW9CH2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15618673

DM8T7CG	DI	DM8T7CG
DM8T7CG	DN	tetronothiodin
DM8T7CG	MI	TTVFO0U
DM8T7CG	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DM8T7CG	MT	DTT
DM8T7CG	MA	Antagonist
DM8T7CG	RN	Species specificity of pharmacological characteristics of CCK-B receptors. Neurosci Lett. 1993 Aug 6;158(1):1-4.
DM8T7CG	RU	https://pubmed.ncbi.nlm.nih.gov/8233061

DMHBMJZ	DI	DMHBMJZ
DMHBMJZ	DN	Textilinin
DMHBMJZ	MI	TTP86E2
DMHBMJZ	MN	Plasminogen (PLG)
DMHBMJZ	MT	DTT
DMHBMJZ	MA	Inhibitor
DMHBMJZ	RN	Tranexamic acid in trauma: how should we use it. J Trauma Acute Care Surg. 2013 Jun;74(6):1575-86.
DMHBMJZ	RU	https://pubmed.ncbi.nlm.nih.gov/23694890

DMAC8TP	DI	DMAC8TP
DMAC8TP	DN	TFMPP
DMAC8TP	MI	TTSQIFT
DMAC8TP	MN	5-HT 1A receptor (HTR1A)
DMAC8TP	MT	DTT
DMAC8TP	MA	Inhibitor
DMAC8TP	RN	Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents. J Med Chem. 1986 May;29(5):630-4.
DMAC8TP	RU	https://pubmed.ncbi.nlm.nih.gov/3701781

DMAC8TP	DI	DMAC8TP
DMAC8TP	DN	TFMPP
DMAC8TP	MI	TTK8CXU
DMAC8TP	MN	5-HT 1B receptor (HTR1B)
DMAC8TP	MT	DTT
DMAC8TP	MA	Agonist
DMAC8TP	RN	Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors. J Neurochem. 1996 Nov;67(5):2096-103.
DMAC8TP	RU	https://pubmed.ncbi.nlm.nih.gov/8863519

DMAC8TP	DI	DMAC8TP
DMAC8TP	DN	TFMPP
DMAC8TP	MI	TT6MSOK
DMAC8TP	MN	5-HT 1D receptor (HTR1D)
DMAC8TP	MT	DTT
DMAC8TP	MA	Agonist
DMAC8TP	RN	Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143-8.
DMAC8TP	RU	https://pubmed.ncbi.nlm.nih.gov/1652050

DMAC8TP	DI	DMAC8TP
DMAC8TP	DN	TFMPP
DMAC8TP	MI	TTCPG9S
DMAC8TP	MN	5-HT 1E receptor (HTR1E)
DMAC8TP	MT	DTT
DMAC8TP	MA	Agonist
DMAC8TP	RN	Molecular cloning and pharmacological characterization of the guinea pig 5-HT1E receptor. Eur J Pharmacol. 2004 Jan 26;484(2-3):127-39.
DMAC8TP	RU	https://pubmed.ncbi.nlm.nih.gov/14744596

DMAC8TP	DI	DMAC8TP
DMAC8TP	DN	TFMPP
DMAC8TP	MI	TT0MI3F
DMAC8TP	MN	5-HT 1F receptor (HTR1F)
DMAC8TP	MT	DTT
DMAC8TP	MA	Agonist
DMAC8TP	RN	Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):408-12.
DMAC8TP	RU	https://pubmed.ncbi.nlm.nih.gov/8380639

DMAC8TP	DI	DMAC8TP
DMAC8TP	DN	TFMPP
DMAC8TP	MI	TTJQOD7
DMAC8TP	MN	5-HT 2A receptor (HTR2A)
DMAC8TP	MT	DTT
DMAC8TP	MA	Agonist
DMAC8TP	RN	Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
DMAC8TP	RU	https://pubmed.ncbi.nlm.nih.gov/15322733

DMAC8TP	DI	DMAC8TP
DMAC8TP	DN	TFMPP
DMAC8TP	MI	TT0K1SC
DMAC8TP	MN	5-HT 2B receptor (HTR2B)
DMAC8TP	MT	DTT
DMAC8TP	MA	Agonist
DMAC8TP	RN	Pharmacological characteristics of the newly cloned rat 5-hydroxytryptamine2F receptor. Mol Pharmacol. 1993 Mar;43(3):419-26.
DMAC8TP	RU	https://pubmed.ncbi.nlm.nih.gov/8450835

DMAC8TP	DI	DMAC8TP
DMAC8TP	DN	TFMPP
DMAC8TP	MI	TTWJBZ5
DMAC8TP	MN	5-HT 2C receptor (HTR2C)
DMAC8TP	MT	DTT
DMAC8TP	MA	Agonist
DMAC8TP	RN	Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors. Synapse. 2000 Feb;35(2):144-50.
DMAC8TP	RU	https://pubmed.ncbi.nlm.nih.gov/10611640

DMAC8TP	DI	DMAC8TP
DMAC8TP	DN	TFMPP
DMAC8TP	MI	TTRUFDT
DMAC8TP	MN	5-HT 5A receptor (HTR5A)
DMAC8TP	MT	DTT
DMAC8TP	MA	Agonist
DMAC8TP	RN	Mouse 5-hydroxytryptamine5A and 5-hydroxytryptamine5B receptors define a new family of serotonin receptors: cloning, functional expression, and chromosomal localization. Mol Pharmacol. 1993 Mar;43(3):313-9.
DMAC8TP	RU	https://pubmed.ncbi.nlm.nih.gov/8450829

DMAC8TP	DI	DMAC8TP
DMAC8TP	DN	TFMPP
DMAC8TP	MI	TTJS8PY
DMAC8TP	MN	5-HT 6 receptor (HTR6)
DMAC8TP	MT	DTT
DMAC8TP	MA	Agonist
DMAC8TP	RN	Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol. 1993 Mar;43(3):320-7.
DMAC8TP	RU	https://pubmed.ncbi.nlm.nih.gov/7680751

DMAC8TP	DI	DMAC8TP
DMAC8TP	DN	TFMPP
DMAC8TP	MI	TTO9X1H
DMAC8TP	MN	5-HT 7 receptor (HTR7)
DMAC8TP	MT	DTT
DMAC8TP	MA	Agonist
DMAC8TP	RN	Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype. J Biol Chem. 1993 Aug 25;268(24):18200-4.
DMAC8TP	RU	https://pubmed.ncbi.nlm.nih.gov/8394362

DMIR3X2	DI	DMIR3X2
DMIR3X2	DN	TG-100435
DMIR3X2	MI	TTI4ZX2
DMIR3X2	MN	Ephrin type-B receptor 4 (EPHB4)
DMIR3X2	MT	DTT
DMIR3X2	MA	Inhibitor
DMIR3X2	RN	Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinas... Bioorg Med Chem Lett. 2007 Feb 1;17(3):602-8.
DMIR3X2	RU	https://pubmed.ncbi.nlm.nih.gov/17113292

DMIR3X2	DI	DMIR3X2
DMIR3X2	DN	TG-100435
DMIR3X2	MI	TTGJVQM
DMIR3X2	MN	Fibroblast growth factor receptor 2 (FGFR2)
DMIR3X2	MT	DTT
DMIR3X2	MA	Inhibitor
DMIR3X2	RN	Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinas... Bioorg Med Chem Lett. 2007 Feb 1;17(3):602-8.
DMIR3X2	RU	https://pubmed.ncbi.nlm.nih.gov/17113292

DMIR3X2	DI	DMIR3X2
DMIR3X2	DN	TG-100435
DMIR3X2	MI	TT860QF
DMIR3X2	MN	LCK tyrosine protein kinase (LCK)
DMIR3X2	MT	DTT
DMIR3X2	MA	Inhibitor
DMIR3X2	RN	Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinas... Bioorg Med Chem Lett. 2007 Feb 1;17(3):602-8.
DMIR3X2	RU	https://pubmed.ncbi.nlm.nih.gov/17113292

DMIR3X2	DI	DMIR3X2
DMIR3X2	DN	TG-100435
DMIR3X2	MI	TTI7421
DMIR3X2	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMIR3X2	MT	DTT
DMIR3X2	MA	Inhibitor
DMIR3X2	RN	Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinas... Bioorg Med Chem Lett. 2007 Feb 1;17(3):602-8.
DMIR3X2	RU	https://pubmed.ncbi.nlm.nih.gov/17113292

DMIR3X2	DI	DMIR3X2
DMIR3X2	DN	TG-100435
DMIR3X2	MI	TT4DXQT
DMIR3X2	MN	Proto-oncogene c-Ret (RET)
DMIR3X2	MT	DTT
DMIR3X2	MA	Inhibitor
DMIR3X2	RN	Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinas... Bioorg Med Chem Lett. 2007 Feb 1;17(3):602-8.
DMIR3X2	RU	https://pubmed.ncbi.nlm.nih.gov/17113292

DMIR3X2	DI	DMIR3X2
DMIR3X2	DN	TG-100435
DMIR3X2	MI	TT6PKBN
DMIR3X2	MN	Proto-oncogene c-Src (SRC)
DMIR3X2	MT	DTT
DMIR3X2	MA	Inhibitor
DMIR3X2	RN	Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinas... Bioorg Med Chem Lett. 2007 Feb 1;17(3):602-8.
DMIR3X2	RU	https://pubmed.ncbi.nlm.nih.gov/17113292

DMIR3X2	DI	DMIR3X2
DMIR3X2	DN	TG-100435
DMIR3X2	MI	TT3PJMV
DMIR3X2	MN	Tyrosine-protein kinase ABL1 (ABL)
DMIR3X2	MT	DTT
DMIR3X2	MA	Inhibitor
DMIR3X2	RN	Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinas... Bioorg Med Chem Lett. 2007 Feb 1;17(3):602-8.
DMIR3X2	RU	https://pubmed.ncbi.nlm.nih.gov/17113292

DMIR3X2	DI	DMIR3X2
DMIR3X2	DN	TG-100435
DMIR3X2	MI	TTUTJGQ
DMIR3X2	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMIR3X2	MT	DTT
DMIR3X2	MA	Inhibitor
DMIR3X2	RN	Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinas... Bioorg Med Chem Lett. 2007 Feb 1;17(3):602-8.
DMIR3X2	RU	https://pubmed.ncbi.nlm.nih.gov/17113292

DMIR3X2	DI	DMIR3X2
DMIR3X2	DN	TG-100435
DMIR3X2	MI	TT0SQ8J
DMIR3X2	MN	Yes tyrosine kinase (YES)
DMIR3X2	MT	DTT
DMIR3X2	MA	Inhibitor
DMIR3X2	RN	Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinas... Bioorg Med Chem Lett. 2007 Feb 1;17(3):602-8.
DMIR3X2	RU	https://pubmed.ncbi.nlm.nih.gov/17113292

DMSG0TL	DI	DMSG0TL
DMSG0TL	DN	TG-1022
DMSG0TL	MI	TTLAFZV
DMSG0TL	MN	AMP-activated protein kinase (AMPK)
DMSG0TL	MT	DTT
DMSG0TL	MA	Stimulator
DMSG0TL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1540).
DMSG0TL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1540

DM5VJQP	DI	DM5VJQP
DM5VJQP	DN	TG-1031
DM5VJQP	MI	TTF89GD
DM5VJQP	MN	Interleukin-2 (IL2)
DM5VJQP	MT	DTT
DM5VJQP	MA	Modulator
DM5VJQP	RN	Technology evaluation: TG-1031, Transgene SA.Curr Opin Mol Ther.2000 Feb;2(1):106-11.
DM5VJQP	RU	https://www.ncbi.nlm.nih.gov/pubmed/11249647

DM5VJQP	DI	DM5VJQP
DM5VJQP	DN	TG-1031
DM5VJQP	MI	TTBHFYQ
DM5VJQP	MN	Mucin-1 (MUC1)
DM5VJQP	MT	DTT
DM5VJQP	MA	Modulator
DM5VJQP	RN	Technology evaluation: TG-1031, Transgene SA.Curr Opin Mol Ther.2000 Feb;2(1):106-11.
DM5VJQP	RU	https://www.ncbi.nlm.nih.gov/pubmed/11249647

DMRFAVG	DI	DMRFAVG
DMRFAVG	DN	TG-2001
DMRFAVG	MI	TTF89GD
DMRFAVG	MN	Interleukin-2 (IL2)
DMRFAVG	MT	DTT
DMRFAVG	MA	Modulator
DMRFAVG	RN	Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose le... Cancer Gene Ther. 2002 Mar;9(3):289-95.
DMRFAVG	RU	https://www.ncbi.nlm.nih.gov/pubmed/11896446

DMHTEMP	DI	DMHTEMP
DMHTEMP	DN	TG-3003
DMHTEMP	MI	TTC70AJ
DMHTEMP	MN	Granulocyte colony-stimulating factor receptor (G-CSF-R)
DMHTEMP	MT	DTT
DMHTEMP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1719).
DMHTEMP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1719

DM8RSDE	DI	DM8RSDE
DM8RSDE	DN	TG-3030
DM8RSDE	MI	TTDCVZW
DM8RSDE	MN	Gamma-aminobutyric acid B receptor (GABBR)
DM8RSDE	MT	DTT
DM8RSDE	MA	Agonist
DM8RSDE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 241).
DM8RSDE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=241

DM862TI	DI	DM862TI
DM862TI	DN	TG4-155
DM862TI	MI	TT1ZAVI
DM862TI	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DM862TI	MT	DTT
DM862TI	MA	Antagonist
DM862TI	RN	Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2. Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3149-54.
DM862TI	RU	https://pubmed.ncbi.nlm.nih.gov/22323596

DM0OHL3	DI	DM0OHL3
DM0OHL3	DN	TG7-171
DM0OHL3	MI	TT1ZAVI
DM0OHL3	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DM0OHL3	MT	DTT
DM0OHL3	MA	Antagonist
DM0OHL3	RN	Development of second generation EP2 antagonists with high selectivity. Eur J Med Chem. 2014 Jul 23;82:521-35.
DM0OHL3	RU	https://pubmed.ncbi.nlm.nih.gov/24937185

DMBFX7S	DI	DMBFX7S
DMBFX7S	DN	TgBSSL
DMBFX7S	MI	TTTRNQW
DMBFX7S	MN	Bile-salt-activated lipase (CEL)
DMBFX7S	MT	DTT
DMBFX7S	MA	Modulator
DMBFX7S	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2872).
DMBFX7S	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2872

DMOX3AH	DI	DMOX3AH
DMOX3AH	DN	TGF alpha
DMOX3AH	MI	TTGKNB4
DMOX3AH	MN	Epidermal growth factor receptor (EGFR)
DMOX3AH	MT	DTT
DMOX3AH	MA	Modulator
DMOX3AH	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
DMOX3AH	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797

DMUP34S	DI	DMUP34S
DMUP34S	DN	TGF-beta Shield
DMUP34S	MI	TTP4520
DMUP34S	MN	TGF-beta receptor type I (TGFBR1)
DMUP34S	MT	DTT
DMUP34S	MA	Antagonist
DMUP34S	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1788).
DMUP34S	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1788

DM1BVW3	DI	DM1BVW3
DM1BVW3	DN	TGSC01AA(4)
DM1BVW3	MI	TTPTXIN
DM1BVW3	MN	Translocator protein (TSPO)
DM1BVW3	MT	DTT
DM1BVW3	MA	Binder
DM1BVW3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2879).
DM1BVW3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2879

DMM0LRE	DI	DMM0LRE
DMM0LRE	DN	TGX-221
DMM0LRE	MI	TTTHBCA
DMM0LRE	MN	PI3-kinase beta (PIK3CB)
DMM0LRE	MT	DTT
DMM0LRE	MA	Inhibitor
DMM0LRE	RN	PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med. 2005 May;11(5):507-14.
DMM0LRE	RU	https://pubmed.ncbi.nlm.nih.gov/15834429

DMM0LRE	DI	DMM0LRE
DMM0LRE	DN	TGX-221
DMM0LRE	MI	TTHBTOP
DMM0LRE	MN	PI3-kinase gamma (PIK3CG)
DMM0LRE	MT	DTT
DMM0LRE	MA	Inhibitor
DMM0LRE	RN	PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med. 2005 May;11(5):507-14.
DMM0LRE	RU	https://pubmed.ncbi.nlm.nih.gov/15834429

DMLC8PX	DI	DMLC8PX
DMLC8PX	DN	TH-1320
DMLC8PX	MI	TTGTQHC
DMLC8PX	MN	DNA topoisomerase I (TOP1)
DMLC8PX	MT	DTT
DMLC8PX	MA	Modulator
DMLC8PX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2636).
DMLC8PX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2636

DMKCY0X	DI	DMKCY0X
DMKCY0X	DN	THA-902
DMKCY0X	MI	TTLGDIS
DMKCY0X	MN	Acid-sensing ion channel 3 (ASIC3)
DMKCY0X	MT	DTT
DMKCY0X	MA	Antagonist
DMKCY0X	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 686).
DMKCY0X	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=686

DMQSO7V	DI	DMQSO7V
DMQSO7V	DN	THA-904
DMQSO7V	MI	TTVMWLP
DMQSO7V	MN	Acid-sensing ion channel 2 (ASIC2)
DMQSO7V	MT	DTT
DMQSO7V	MA	Antagonist
DMQSO7V	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 685).
DMQSO7V	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=685

DMG6S2V	DI	DMG6S2V
DMG6S2V	DN	THEASINENSIN A
DMG6S2V	MI	TTE14XG
DMG6S2V	MN	Squalene monooxygenase (SQLE)
DMG6S2V	MT	DTT
DMG6S2V	MA	Inhibitor
DMG6S2V	RN	Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4.
DMG6S2V	RU	https://pubmed.ncbi.nlm.nih.gov/11520216

DMRCD3O	DI	DMRCD3O
DMRCD3O	DN	THEBAINE
DMRCD3O	MI	TTKWM86
DMRCD3O	MN	Opioid receptor mu (MOP)
DMRCD3O	MT	DTT
DMRCD3O	MA	Inhibitor
DMRCD3O	RN	Live cell monitoring of mu-opioid receptor-mediated G-protein activation reveals strong biological activity of close morphine biosynthetic precursors. J Biol Chem. 2007 Sep 14;282(37):27126-32.
DMRCD3O	RU	https://pubmed.ncbi.nlm.nih.gov/17616524

DMRVXFN	DI	DMRVXFN
DMRVXFN	DN	Theliatinib
DMRVXFN	MI	TTGKNB4
DMRVXFN	MN	Epidermal growth factor receptor (EGFR)
DMRVXFN	MT	DTT
DMRVXFN	MA	Inhibitor
DMRVXFN	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
DMRVXFN	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797

DM54OKX	DI	DM54OKX
DM54OKX	DN	Thenoyltrifluoroacetone
DM54OKX	MI	TTMF541
DM54OKX	MN	Liver carboxylesterase (CES1)
DM54OKX	MT	DTT
DM54OKX	MA	Inhibitor
DM54OKX	RN	Zhang JG, Fariss MW: Thenoyltrifluoroacetone, a potent inhibitor of carboxylesterase activity. Biochem Pharmacol. 2002 Feb 15;63(4):751-4.
DM54OKX	RU	https://pubmed.ncbi.nlm.nih.gov/11992644

DM9CF45	DI	DM9CF45
DM9CF45	DN	thiadiazolidinone (TDZD) deriv. 6
DM9CF45	MI	TTGTKX9
DM9CF45	MN	Regulator of G-protein signaling 4 (RGS4)
DM9CF45	MT	DTT
DM9CF45	MA	Inhibitor
DM9CF45	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2811).
DM9CF45	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2811

DM9CF45	DI	DM9CF45
DM9CF45	DN	thiadiazolidinone (TDZD) deriv. 6
DM9CF45	MI	TTWME23
DM9CF45	MN	Regulator of G-protein signaling 8 (RGS8)
DM9CF45	MT	DTT
DM9CF45	MA	Inhibitor
DM9CF45	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2813).
DM9CF45	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2813

DMKRG2C	DI	DMKRG2C
DMKRG2C	DN	Thiadiazolo[2,3-a]pyrimidine
DMKRG2C	MI	TTSUKYD
DMKRG2C	MN	Virus RNA-dependent RNA polymerase (Viru RdRP)
DMKRG2C	MT	DTT
DMKRG2C	MA	Inhibitor
DMKRG2C	RN	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob Agents Chemother. 2009 Jan;53(1):202-9.
DMKRG2C	RU	https://pubmed.ncbi.nlm.nih.gov/18955536

DM3F25L	DI	DM3F25L
DM3F25L	DN	Thiamin Diphosphate
DM3F25L	MI	TTUTN1I
DM3F25L	MN	Human Deoxyribonucleic acid (hDNA)
DM3F25L	MT	DTT
DM3F25L	MA	Inhibitor
DM3F25L	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM3F25L	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM5WYJ6	DI	DM5WYJ6
DM5WYJ6	DN	Thiamine pyrophosphate
DM5WYJ6	MI	DTT82QK
DM5WYJ6	MN	Mitochondrial thiamine pyrophosphate carrier (SLC25A19)
DM5WYJ6	MT	DTP
DM5WYJ6	MA	Substrate
DM5WYJ6	RN	Knockout of Slc25a19 causes mitochondrial thiamine pyrophosphate depletion, embryonic lethality, CNS malformations, and anemia. Proc Natl Acad Sci U S A. 2006 Oct 24;103(43):15927-32.
DM5WYJ6	RU	http://www.ncbi.nlm.nih.gov/pubmed/17035501

DM5WYJ6	DI	DM5WYJ6
DM5WYJ6	DN	Thiamine pyrophosphate
DM5WYJ6	MI	DT9V8W1
DM5WYJ6	MN	Solute carrier family 35 member E4 (SLC35E4)
DM5WYJ6	MT	DTP
DM5WYJ6	MA	Substrate
DM5WYJ6	RN	The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.7.9.11)
DM5WYJ6	RU	http://www.tcdb.org/search/result.php?tc=2.A.7.9.11

DMIOTHG	DI	DMIOTHG
DMIOTHG	DN	Thieno analogue of kenpaullone
DMIOTHG	MI	TTH6V3D
DMIOTHG	MN	Cyclin-dependent kinase 1 (CDK1)
DMIOTHG	MT	DTT
DMIOTHG	MA	Inhibitor
DMIOTHG	RN	1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.
DMIOTHG	RU	https://pubmed.ncbi.nlm.nih.gov/14698171

DMIOTHG	DI	DMIOTHG
DMIOTHG	DN	Thieno analogue of kenpaullone
DMIOTHG	MI	TTL4Q97
DMIOTHG	MN	Cyclin-dependent kinase 5 (CDK5)
DMIOTHG	MT	DTT
DMIOTHG	MA	Inhibitor
DMIOTHG	RN	1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.
DMIOTHG	RU	https://pubmed.ncbi.nlm.nih.gov/14698171

DMIOTHG	DI	DMIOTHG
DMIOTHG	DN	Thieno analogue of kenpaullone
DMIOTHG	MI	TT9P6OW
DMIOTHG	MN	G2/mitotic-specific cyclin B1 (CCNB1)
DMIOTHG	MT	DTT
DMIOTHG	MA	Inhibitor
DMIOTHG	RN	1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.
DMIOTHG	RU	https://pubmed.ncbi.nlm.nih.gov/14698171

DMIOTHG	DI	DMIOTHG
DMIOTHG	DN	Thieno analogue of kenpaullone
DMIOTHG	MI	TTRSMW9
DMIOTHG	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMIOTHG	MT	DTT
DMIOTHG	MA	Inhibitor
DMIOTHG	RN	1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.
DMIOTHG	RU	https://pubmed.ncbi.nlm.nih.gov/14698171

DMUL2FW	DI	DMUL2FW
DMUL2FW	DN	Thieno[2,3-B]Pyridine-2-Carboxamidine
DMUL2FW	MI	TTGY7WI
DMUL2FW	MN	Urokinase-type plasminogen activator (PLAU)
DMUL2FW	MT	DTT
DMUL2FW	MA	Inhibitor
DMUL2FW	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMUL2FW	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMT74N6	DI	DMT74N6
DMT74N6	DN	Thieno[3,2-e][1]benzothiophene-4,5-dione
DMT74N6	MI	TTMF541
DMT74N6	MN	Liver carboxylesterase (CES1)
DMT74N6	MT	DTT
DMT74N6	MA	Inhibitor
DMT74N6	RN	Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34.
DMT74N6	RU	https://pubmed.ncbi.nlm.nih.gov/17941623

DMFDROW	DI	DMFDROW
DMFDROW	DN	Thieno-phenanthridin-6-one
DMFDROW	MI	TTVDSZ0
DMFDROW	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMFDROW	MT	DTT
DMFDROW	MA	Inhibitor
DMFDROW	RN	Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov. 2005 May;4(5):421-40.
DMFDROW	RU	https://pubmed.ncbi.nlm.nih.gov/15864271

DMQ0YB5	DI	DMQ0YB5
DMQ0YB5	DN	Thiethylperazine
DMQ0YB5	MI	TTAIY2U
DMQ0YB5	MN	HUMAN clathrin-mediated endocytosis (RME)
DMQ0YB5	MT	DTT
DMQ0YB5	MA	Inhibitor
DMQ0YB5	RN	Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93.
DMQ0YB5	RU	https://pubmed.ncbi.nlm.nih.gov/24841273

DM3KU46	DI	DM3KU46
DM3KU46	DN	THIIC
DM3KU46	MI	TTXJ47W
DM3KU46	MN	Metabotropic glutamate receptor 2 (mGluR2)
DM3KU46	MT	DTT
DM3KU46	MA	Modulator (allosteric modulator)
DM3KU46	RN	N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changes. J Pharmacol Exp Ther. 2011 Jan;336(1):165-77.
DM3KU46	RU	https://pubmed.ncbi.nlm.nih.gov/20947638

DMBOKSF	DI	DMBOKSF
DMBOKSF	DN	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester
DMBOKSF	MI	TTBH0VX
DMBOKSF	MN	Histone deacetylase (HDAC)
DMBOKSF	MT	DTT
DMBOKSF	MA	Inhibitor
DMBOKSF	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMBOKSF	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMBOKSF	DI	DMBOKSF
DMBOKSF	DN	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester
DMBOKSF	MI	TT6R7JZ
DMBOKSF	MN	Histone deacetylase 1 (HDAC1)
DMBOKSF	MT	DTT
DMBOKSF	MA	Inhibitor
DMBOKSF	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMBOKSF	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMBOKSF	DI	DMBOKSF
DMBOKSF	DN	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester
DMBOKSF	MI	TTYHPU6
DMBOKSF	MN	Histone deacetylase 10 (HDAC10)
DMBOKSF	MT	DTT
DMBOKSF	MA	Inhibitor
DMBOKSF	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMBOKSF	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMBOKSF	DI	DMBOKSF
DMBOKSF	DN	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester
DMBOKSF	MI	TTSHTOI
DMBOKSF	MN	Histone deacetylase 2 (HDAC2)
DMBOKSF	MT	DTT
DMBOKSF	MA	Inhibitor
DMBOKSF	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMBOKSF	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMBOKSF	DI	DMBOKSF
DMBOKSF	DN	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester
DMBOKSF	MI	TTTQGH8
DMBOKSF	MN	Histone deacetylase 4 (HDAC4)
DMBOKSF	MT	DTT
DMBOKSF	MA	Inhibitor
DMBOKSF	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMBOKSF	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMBOKSF	DI	DMBOKSF
DMBOKSF	DN	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester
DMBOKSF	MI	TT5ZKDI
DMBOKSF	MN	Histone deacetylase 6 (HDAC6)
DMBOKSF	MT	DTT
DMBOKSF	MA	Inhibitor
DMBOKSF	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMBOKSF	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DMBOKSF	DI	DMBOKSF
DMBOKSF	DN	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester
DMBOKSF	MI	TTT6LFV
DMBOKSF	MN	Histone deacetylase 8 (HDAC8)
DMBOKSF	MT	DTT
DMBOKSF	MA	Inhibitor
DMBOKSF	RN	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
DMBOKSF	RU	https://pubmed.ncbi.nlm.nih.gov/15715470

DM76EPH	DI	DM76EPH
DM76EPH	DN	thio-BCTC
DM76EPH	MI	TTXDKTO
DM76EPH	MN	Long transient receptor potential channel 8 (TRPM8)
DM76EPH	MT	DTT
DM76EPH	MA	Blocker (channel blocker)
DM76EPH	RN	Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay. Br J Pharmacol. 2004 Feb;141(4):737-45.
DM76EPH	RU	https://pubmed.ncbi.nlm.nih.gov/14757700

DMP7LJH	DI	DMP7LJH
DMP7LJH	DN	Thiocarbamate
DMP7LJH	MI	TTE14XG
DMP7LJH	MN	Squalene monooxygenase (SQLE)
DMP7LJH	MT	DTT
DMP7LJH	MA	Inhibitor
DMP7LJH	RN	Characterization of squalene epoxidase activity from the dermatophyte Trichophyton rubrum and its inhibition by terbinafine and other antimycotic agents. Antimicrob Agents Chemother. 1996 Feb;40(2):443-7.
DMP7LJH	RU	https://pubmed.ncbi.nlm.nih.gov/8834895

DML4TQ5	DI	DML4TQ5
DML4TQ5	DN	thiochrome
DML4TQ5	MI	TTOXS3C
DML4TQ5	MN	Muscarinic acetylcholine receptor (CHRM)
DML4TQ5	MT	DTT
DML4TQ5	MA	Modulator (allosteric modulator)
DML4TQ5	RN	Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity. Mol Pharmacol. 2004 Jan;65(1):257-66.
DML4TQ5	RU	https://pubmed.ncbi.nlm.nih.gov/14722259

DML4TQ5	DI	DML4TQ5
DML4TQ5	DN	thiochrome
DML4TQ5	MI	TTQ13Z5
DML4TQ5	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DML4TQ5	MT	DTT
DML4TQ5	MA	Modulator (allosteric modulator)
DML4TQ5	RN	Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity. Mol Pharmacol. 2004 Jan;65(1):257-66.
DML4TQ5	RU	https://pubmed.ncbi.nlm.nih.gov/14722259

DM7X8MH	DI	DM7X8MH
DM7X8MH	DN	THIOCITRULLINE
DM7X8MH	MI	TTZUFI5
DM7X8MH	MN	Nitric-oxide synthase brain (NOS1)
DM7X8MH	MT	DTT
DM7X8MH	MA	Inhibitor
DM7X8MH	RN	Evaluation of 3-substituted arginine analogs as selective inhibitors of human nitric oxide synthase isozymes. Bioorg Med Chem Lett. 2005 Jun 2;15(11):2881-5.
DM7X8MH	RU	https://pubmed.ncbi.nlm.nih.gov/15911272

DM7X8MH	DI	DM7X8MH
DM7X8MH	DN	THIOCITRULLINE
DM7X8MH	MI	TTCM4B3
DM7X8MH	MN	Nitric-oxide synthase endothelial (NOS3)
DM7X8MH	MT	DTT
DM7X8MH	MA	Inhibitor
DM7X8MH	RN	Evaluation of 3-substituted arginine analogs as selective inhibitors of human nitric oxide synthase isozymes. Bioorg Med Chem Lett. 2005 Jun 2;15(11):2881-5.
DM7X8MH	RU	https://pubmed.ncbi.nlm.nih.gov/15911272

DM7X8MH	DI	DM7X8MH
DM7X8MH	DN	THIOCITRULLINE
DM7X8MH	MI	TTF10I9
DM7X8MH	MN	Nitric-oxide synthase inducible (NOS2)
DM7X8MH	MT	DTT
DM7X8MH	MA	Inhibitor
DM7X8MH	RN	Evaluation of 3-substituted arginine analogs as selective inhibitors of human nitric oxide synthase isozymes. Bioorg Med Chem Lett. 2005 Jun 2;15(11):2881-5.
DM7X8MH	RU	https://pubmed.ncbi.nlm.nih.gov/15911272

DMJSKIP	DI	DMJSKIP
DMJSKIP	DN	Thiocolchicine
DMJSKIP	MI	TTML2WA
DMJSKIP	MN	Tubulin (TUB)
DMJSKIP	MT	DTT
DMJSKIP	MA	Inhibitor
DMJSKIP	RN	Antitumor agents. 139. Synthesis and biological evaluation of thiocolchicine analogs 5,6-dihydro-6(S)-(acyloxy)- and 5,6-dihydro-6(S)-[(aroyloxy)me... J Med Chem. 1993 Mar 5;36(5):544-51.
DMJSKIP	RU	https://pubmed.ncbi.nlm.nih.gov/8496935

DMJSKIP	DI	DMJSKIP
DMJSKIP	DN	Thiocolchicine
DMJSKIP	MI	TTYFKSZ
DMJSKIP	MN	Tubulin beta (TUBB)
DMJSKIP	MT	DTT
DMJSKIP	MA	Inhibitor
DMJSKIP	RN	Antitumor agents. 139. Synthesis and biological evaluation of thiocolchicine analogs 5,6-dihydro-6(S)-(acyloxy)- and 5,6-dihydro-6(S)-[(aroyloxy)me... J Med Chem. 1993 Mar 5;36(5):544-51.
DMJSKIP	RU	https://pubmed.ncbi.nlm.nih.gov/8496935

DMPTSN0	DI	DMPTSN0
DMPTSN0	DN	Thiocoumarin
DMPTSN0	MI	TTF10I9
DMPTSN0	MN	Nitric-oxide synthase inducible (NOS2)
DMPTSN0	MT	DTT
DMPTSN0	MA	Inhibitor
DMPTSN0	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMPTSN0	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMNFCXW	DI	DMNFCXW
DMNFCXW	DN	THIOCTIC ACID
DMNFCXW	MI	TT1RS9F
DMNFCXW	MN	Acetylcholinesterase (AChE)
DMNFCXW	MT	DTT
DMNFCXW	MA	Inhibitor
DMNFCXW	RN	Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem. 2008 Feb 14;51(3):347-72.
DMNFCXW	RU	https://pubmed.ncbi.nlm.nih.gov/18181565

DMNFCXW	DI	DMNFCXW
DMNFCXW	DN	THIOCTIC ACID
DMNFCXW	MI	TTVKILB
DMNFCXW	MN	Prostaglandin G/H synthase 2 (COX-2)
DMNFCXW	MT	DTT
DMNFCXW	MA	Inhibitor
DMNFCXW	RN	Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles. Eur J Med Chem. 2008 Jun;43(6):1152-9.
DMNFCXW	RU	https://pubmed.ncbi.nlm.nih.gov/17976864

DMK2J5L	DI	DMK2J5L
DMK2J5L	DN	THIOGENISTEIN
DMK2J5L	MI	TTOM3J0
DMK2J5L	MN	Estrogen receptor beta (ESR2)
DMK2J5L	MT	DTT
DMK2J5L	MA	Inhibitor
DMK2J5L	RN	Synthesis and characterization of 3-arylquinazolinone and 3-arylquinazolinethione derivatives as selective estrogen receptor beta modulators. J Med Chem. 2006 Apr 20;49(8):2440-55.
DMK2J5L	RU	https://pubmed.ncbi.nlm.nih.gov/16610787

DMBAWDG	DI	DMBAWDG
DMBAWDG	DN	Thiolactomycin
DMBAWDG	MI	TT0O4QL
DMBAWDG	MN	Bacterial Beta-ketoacyl-ACP synthase I (Bact fabB)
DMBAWDG	MT	DTT
DMBAWDG	MA	Binder
DMBAWDG	RN	Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36.
DMBAWDG	RU	https://pubmed.ncbi.nlm.nih.gov/21948793

DMBAWDG	DI	DMBAWDG
DMBAWDG	DN	Thiolactomycin
DMBAWDG	MI	TTRVTMX
DMBAWDG	MN	Bacterial Beta-ketoacyl-ACP synthase III (Bact fabH)
DMBAWDG	MT	DTT
DMBAWDG	MA	Binder
DMBAWDG	RN	The apicoplast as an antimalarial drug target. Drug Resist Updat. 2001 Jun;4(3):145-51.
DMBAWDG	RU	https://pubmed.ncbi.nlm.nih.gov/11768328

DMBAWDG	DI	DMBAWDG
DMBAWDG	DN	Thiolactomycin
DMBAWDG	MI	TTRFV0W
DMBAWDG	MN	Bacterial Oxoacyl-[acyl-carrier-protein] synthase II (Bact fabF)
DMBAWDG	MT	DTT
DMBAWDG	MA	Binder
DMBAWDG	RN	Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36.
DMBAWDG	RU	https://pubmed.ncbi.nlm.nih.gov/21948793

DMBAWDG	DI	DMBAWDG
DMBAWDG	DN	Thiolactomycin
DMBAWDG	MI	TTNX2CS
DMBAWDG	MN	Plasmodium Enoyl-ACP reductase (Malaria fabI)
DMBAWDG	MT	DTT
DMBAWDG	MA	Inhibitor
DMBAWDG	RN	Novel molecular targets for antimalarial drug development. Chem Biol Drug Des. 2008 Apr;71(4):287-97.
DMBAWDG	RU	https://pubmed.ncbi.nlm.nih.gov/18298458

DMAKW2S	DI	DMAKW2S
DMAKW2S	DN	Thiophene sulfonamide
DMAKW2S	MI	TTSFWA7
DMAKW2S	MN	Plasmodium CDK Pfmrk (Malaria Pfmrk)
DMAKW2S	MT	DTT
DMAKW2S	MA	Inhibitor
DMAKW2S	RN	Novel molecular targets for antimalarial drug development. Chem Biol Drug Des. 2008 Apr;71(4):287-97.
DMAKW2S	RU	https://pubmed.ncbi.nlm.nih.gov/18298458

DML3OHW	DI	DML3OHW
DML3OHW	DN	Thiophene-2-ylboronic acid
DML3OHW	MI	TTHI19T
DML3OHW	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DML3OHW	MT	DTT
DML3OHW	MA	Inhibitor
DML3OHW	RN	Optimizing cell permeation of an antibiotic resistance inhibitor for improved efficacy. J Med Chem. 2007 Nov 15;50(23):5644-54.
DML3OHW	RU	https://pubmed.ncbi.nlm.nih.gov/17956081

DMZ4FCB	DI	DMZ4FCB
DMZ4FCB	DN	Thiophosphoric acid (E)-dodec-9-enyl ester
DMZ4FCB	MI	TTQ6S1K
DMZ4FCB	MN	Lysophosphatidic acid receptor 1 (LPAR1)
DMZ4FCB	MT	DTT
DMZ4FCB	MA	Inhibitor
DMZ4FCB	RN	Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30.
DMZ4FCB	RU	https://pubmed.ncbi.nlm.nih.gov/16033271

DMYOXJ4	DI	DMYOXJ4
DMYOXJ4	DN	Thiophosphoric acid (E)-tetradec-9-enyl ester
DMYOXJ4	MI	TTQ6S1K
DMYOXJ4	MN	Lysophosphatidic acid receptor 1 (LPAR1)
DMYOXJ4	MT	DTT
DMYOXJ4	MA	Inhibitor
DMYOXJ4	RN	Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30.
DMYOXJ4	RU	https://pubmed.ncbi.nlm.nih.gov/16033271

DM12NGE	DI	DM12NGE
DM12NGE	DN	Thiophosphoric acid dec-9-enyl ester
DM12NGE	MI	TTQ6S1K
DM12NGE	MN	Lysophosphatidic acid receptor 1 (LPAR1)
DM12NGE	MT	DTT
DM12NGE	MA	Inhibitor
DM12NGE	RN	Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30.
DM12NGE	RU	https://pubmed.ncbi.nlm.nih.gov/16033271

DM36KW9	DI	DM36KW9
DM36KW9	DN	Thiophosphoric acid decyl ester
DM36KW9	MI	TTQ6S1K
DM36KW9	MN	Lysophosphatidic acid receptor 1 (LPAR1)
DM36KW9	MT	DTT
DM36KW9	MA	Inhibitor
DM36KW9	RN	Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30.
DM36KW9	RU	https://pubmed.ncbi.nlm.nih.gov/16033271

DM86LFB	DI	DM86LFB
DM86LFB	DN	Thiorphan
DM86LFB	MI	TT5TKPM
DM86LFB	MN	Neutral endopeptidase (MME)
DM86LFB	MT	DTT
DM86LFB	MA	Inhibitor
DM86LFB	RN	Thiorphan enhances bradykinin-induced vascular relaxation in hypoxic/hyperkalaemic porcine coronary artery. J Pharm Pharmacol. 2003 Mar;55(3):339-45.
DM86LFB	RU	https://pubmed.ncbi.nlm.nih.gov/12724039

DML7Y1R	DI	DML7Y1R
DML7Y1R	DN	Thiostrepton
DML7Y1R	MI	TTLFGBV
DML7Y1R	MN	Bacterial 23S ribosomal RNA (Bact 23S rRNA)
DML7Y1R	MT	DTT
DML7Y1R	MA	Binder
DML7Y1R	RN	The apicoplast as an antimalarial drug target. Drug Resist Updat. 2001 Jun;4(3):145-51.
DML7Y1R	RU	https://pubmed.ncbi.nlm.nih.gov/11768328

DMUELHN	DI	DMUELHN
DMUELHN	DN	Thiourea
DMUELHN	MI	DTMF8LB
DMUELHN	MN	Urea transporter 1 (SLC14A1)
DMUELHN	MT	DTP
DMUELHN	MA	Substrate
DMUELHN	RN	Functional differentiation of the human red blood cell and kidney urea transporters. Am J Physiol. 1996 Dec;271(6 Pt 2):F1264-8.
DMUELHN	RU	http://www.ncbi.nlm.nih.gov/pubmed/8997401

DM8WYEM	DI	DM8WYEM
DM8WYEM	DN	Thioureido sulfonamide
DM8WYEM	MI	TTHQPL7
DM8WYEM	MN	Carbonic anhydrase I (CA-I)
DM8WYEM	MT	DTT
DM8WYEM	MA	Inhibitor
DM8WYEM	RN	Carbonic anhydrase inhibitors: design of thioureido sulfonamides with potent isozyme II and XII inhibitory properties and intraocular pressure lowe... Bioorg Med Chem Lett. 2005 Sep 1;15(17):3821-7.
DM8WYEM	RU	https://pubmed.ncbi.nlm.nih.gov/16039853

DM8WYEM	DI	DM8WYEM
DM8WYEM	DN	Thioureido sulfonamide
DM8WYEM	MI	TTANPDJ
DM8WYEM	MN	Carbonic anhydrase II (CA-II)
DM8WYEM	MT	DTT
DM8WYEM	MA	Inhibitor
DM8WYEM	RN	Carbonic anhydrase inhibitors: design of thioureido sulfonamides with potent isozyme II and XII inhibitory properties and intraocular pressure lowe... Bioorg Med Chem Lett. 2005 Sep 1;15(17):3821-7.
DM8WYEM	RU	https://pubmed.ncbi.nlm.nih.gov/16039853

DM8WYEM	DI	DM8WYEM
DM8WYEM	DN	Thioureido sulfonamide
DM8WYEM	MI	TTSYM0R
DM8WYEM	MN	Carbonic anhydrase XII (CA-XII)
DM8WYEM	MT	DTT
DM8WYEM	MA	Inhibitor
DM8WYEM	RN	Carbonic anhydrase inhibitors: design of thioureido sulfonamides with potent isozyme II and XII inhibitory properties and intraocular pressure lowe... Bioorg Med Chem Lett. 2005 Sep 1;15(17):3821-7.
DM8WYEM	RU	https://pubmed.ncbi.nlm.nih.gov/16039853

DMP8LSF	DI	DMP8LSF
DMP8LSF	DN	THIQ
DMP8LSF	MI	TTD0CIQ
DMP8LSF	MN	Melanocortin receptor 4 (MC4R)
DMP8LSF	MT	DTT
DMP8LSF	MA	Agonist
DMP8LSF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 285).
DMP8LSF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=285

DMD1G6R	DI	DMD1G6R
DMD1G6R	DN	THPG
DMD1G6R	MI	TTWRP2F
DMD1G6R	MN	Metabotropic glutamate receptor 6 (mGluR6)
DMD1G6R	MT	DTT
DMD1G6R	MA	Antagonist
DMD1G6R	RN	Two phenylglycine derivatives antagonize responses to L-AP4 in ON bipolar cells of the amphibian retina. Neuropharmacology. 1997 Jan;36(1):13-20.
DMD1G6R	RU	https://pubmed.ncbi.nlm.nih.gov/9144637

DMJD479	DI	DMJD479
DMJD479	DN	THPO
DMJD479	MI	TTV9MQG
DMJD479	MN	Gamma-aminobutyric acid uptake (GABAU)
DMJD479	MT	DTT
DMJD479	MA	Inhibitor
DMJD479	RN	Anticonvulsant activity of intracerebroventricularly administered glial GABA uptake inhibitors and other GABAmimetics in chemical seizure models. Epilepsy Res. 1989 Jul-Aug;4(1):34-41.
DMJD479	RU	https://pubmed.ncbi.nlm.nih.gov/2526732

DM4W1E8	DI	DM4W1E8
DM4W1E8	DN	Threo-1-aza-5-phenyl[4.4.0]decane hydrochloride
DM4W1E8	MI	TTVBI8W
DM4W1E8	MN	Dopamine transporter (DAT)
DM4W1E8	MT	DTT
DM4W1E8	MA	Inhibitor
DM4W1E8	RN	Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31.
DM4W1E8	RU	https://pubmed.ncbi.nlm.nih.gov/17489581

DM4W1E8	DI	DM4W1E8
DM4W1E8	DN	Threo-1-aza-5-phenyl[4.4.0]decane hydrochloride
DM4W1E8	MI	TT3ROYC
DM4W1E8	MN	Serotonin transporter (SERT)
DM4W1E8	MT	DTT
DM4W1E8	MA	Inhibitor
DM4W1E8	RN	Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31.
DM4W1E8	RU	https://pubmed.ncbi.nlm.nih.gov/17489581

DMA7GTH	DI	DMA7GTH
DMA7GTH	DN	Threo-3,4-dichlororitalinol hydrochloride
DMA7GTH	MI	TTVBI8W
DMA7GTH	MN	Dopamine transporter (DAT)
DMA7GTH	MT	DTT
DMA7GTH	MA	Inhibitor
DMA7GTH	RN	Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31.
DMA7GTH	RU	https://pubmed.ncbi.nlm.nih.gov/17489581

DMA7GTH	DI	DMA7GTH
DMA7GTH	DN	Threo-3,4-dichlororitalinol hydrochloride
DMA7GTH	MI	TT3ROYC
DMA7GTH	MN	Serotonin transporter (SERT)
DMA7GTH	MT	DTT
DMA7GTH	MA	Inhibitor
DMA7GTH	RN	Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31.
DMA7GTH	RU	https://pubmed.ncbi.nlm.nih.gov/17489581

DMOE3IJ	DI	DMOE3IJ
DMOE3IJ	DN	Threo-3-methylglutamate
DMOE3IJ	MI	TT2F078
DMOE3IJ	MN	Excitatory amino acid transporter 2 (SLC1A2)
DMOE3IJ	MT	DTT
DMOE3IJ	MA	Inhibitor
DMOE3IJ	RN	Contrasting modes of action of methylglutamate derivatives on the excitatory amino acid transporters, EAAT1 and EAAT2. Mol Pharmacol. 1997 May;51(5):809-15.
DMOE3IJ	RU	https://pubmed.ncbi.nlm.nih.gov/9145919

DMOE3IJ	DI	DMOE3IJ
DMOE3IJ	DN	Threo-3-methylglutamate
DMOE3IJ	MI	TT6KMPN
DMOE3IJ	MN	Excitatory amino acid transporter 4 (SLC1A6)
DMOE3IJ	MT	DTT
DMOE3IJ	MA	Inhibitor
DMOE3IJ	RN	Pharmacological characterization of threo-3-methylglutamic acid with excitatory amino acid transporters in native and recombinant systems. J Neurochem. 2001 Apr;77(2):550-7.
DMOE3IJ	RU	https://pubmed.ncbi.nlm.nih.gov/11299317

DMEVT7S	DI	DMEVT7S
DMEVT7S	DN	Threo-N-ethylritalinol hydrochloride
DMEVT7S	MI	TTVBI8W
DMEVT7S	MN	Dopamine transporter (DAT)
DMEVT7S	MT	DTT
DMEVT7S	MA	Inhibitor
DMEVT7S	RN	Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31.
DMEVT7S	RU	https://pubmed.ncbi.nlm.nih.gov/17489581

DM4MPVE	DI	DM4MPVE
DM4MPVE	DN	Threo-ritalinol hydrochloride
DM4MPVE	MI	TTVBI8W
DM4MPVE	MN	Dopamine transporter (DAT)
DM4MPVE	MT	DTT
DM4MPVE	MA	Inhibitor
DM4MPVE	RN	Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31.
DM4MPVE	RU	https://pubmed.ncbi.nlm.nih.gov/17489581

DMV0CZ5	DI	DMV0CZ5
DMV0CZ5	DN	Threo-ritalinol methyl ether hydrochloride
DMV0CZ5	MI	TTVBI8W
DMV0CZ5	MN	Dopamine transporter (DAT)
DMV0CZ5	MT	DTT
DMV0CZ5	MA	Inhibitor
DMV0CZ5	RN	Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31.
DMV0CZ5	RU	https://pubmed.ncbi.nlm.nih.gov/17489581

DMRVXH7	DI	DMRVXH7
DMRVXH7	DN	ThromboMer
DMRVXH7	MI	TTIHYA4
DMRVXH7	MN	Thrombopoietin receptor (MPL)
DMRVXH7	MT	DTT
DMRVXH7	MA	Modulator
DMRVXH7	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1722).
DMRVXH7	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1722

DMY07CA	DI	DMY07CA
DMY07CA	DN	THRX160209
DMY07CA	MI	TTOXS3C
DMY07CA	MN	Muscarinic acetylcholine receptor (CHRM)
DMY07CA	MT	DTT
DMY07CA	MA	Antagonist
DMY07CA	RN	A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor. Mol Pharmacol. 2007 Aug;72(2):291-302.
DMY07CA	RU	https://pubmed.ncbi.nlm.nih.gov/17478612

DMUDGSN	DI	DMUDGSN
DMUDGSN	DN	THYMELEATOXIN
DMUDGSN	MI	TT9WJ8U
DMUDGSN	MN	Protein kinase C delta (PRKCD)
DMUDGSN	MT	DTT
DMUDGSN	MA	Inhibitor
DMUDGSN	RN	Structural basis of binding of high-affinity ligands to protein kinase C: prediction of the binding modes through a new molecular dynamics method a... J Med Chem. 2001 May 24;44(11):1690-701.
DMUDGSN	RU	https://pubmed.ncbi.nlm.nih.gov/11356104

DMKM6NQ	DI	DMKM6NQ
DMKM6NQ	DN	Thymidine-5'-Phosphate
DMKM6NQ	MI	TTU6BFZ
DMKM6NQ	MN	Candida Thymidylate synthase (Candi TMP1)
DMKM6NQ	MT	DTT
DMKM6NQ	MA	Inhibitor
DMKM6NQ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMKM6NQ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMKM6NQ	DI	DMKM6NQ
DMKM6NQ	DN	Thymidine-5'-Phosphate
DMKM6NQ	MI	TT5B8AX
DMKM6NQ	MN	Mycobacterium Thymidine monophosphate kinase (MycB tmk)
DMKM6NQ	MT	DTT
DMKM6NQ	MA	Inhibitor
DMKM6NQ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMKM6NQ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMKM6NQ	DI	DMKM6NQ
DMKM6NQ	DN	Thymidine-5'-Phosphate
DMKM6NQ	MI	TTP3QRF
DMKM6NQ	MN	Thymidine kinase 1 (TK1)
DMKM6NQ	MT	DTT
DMKM6NQ	MA	Inhibitor
DMKM6NQ	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMKM6NQ	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMKGXB9	DI	DMKGXB9
DMKGXB9	DN	Thymine
DMKGXB9	MI	TTO0IB8
DMKGXB9	MN	Thymidine phosphorylase (TYMP)
DMKGXB9	MT	DTT
DMKGXB9	MA	Inhibitor
DMKGXB9	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMKGXB9	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMU10FE	DI	DMU10FE
DMU10FE	DN	THZ1
DMU10FE	MI	TTQYF7G
DMU10FE	MN	Cyclin-dependent kinase 7 (CDK7)
DMU10FE	MT	DTT
DMU10FE	MA	Inhibitor
DMU10FE	RN	Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature. 2014 Jul 31;511(7511):616-20.
DMU10FE	RU	https://pubmed.ncbi.nlm.nih.gov/25043025

DMBZ2MF	DI	DMBZ2MF
DMBZ2MF	DN	THZ531
DMBZ2MF	MI	TTJ21A9
DMBZ2MF	MN	Cyclin-dependent kinase 12 (CDK12)
DMBZ2MF	MT	DTT
DMBZ2MF	MA	Inhibitor
DMBZ2MF	RN	Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nat Chem Biol. 2016 Oct;12(10):876-84.
DMBZ2MF	RU	https://pubmed.ncbi.nlm.nih.gov/27571479

DMBZ2MF	DI	DMBZ2MF
DMBZ2MF	DN	THZ531
DMBZ2MF	MI	TTRIM0E
DMBZ2MF	MN	Cyclin-dependent kinase 13 (CDK13)
DMBZ2MF	MT	DTT
DMBZ2MF	MA	Inhibitor
DMBZ2MF	RN	Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nat Chem Biol. 2016 Oct;12(10):876-84.
DMBZ2MF	RU	https://pubmed.ncbi.nlm.nih.gov/27571479

DMGXSTB	DI	DMGXSTB
DMGXSTB	DN	TI3
DMGXSTB	MI	TTVDSZ0
DMGXSTB	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMGXSTB	MT	DTT
DMGXSTB	MA	Inhibitor
DMGXSTB	RN	Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clin Cancer Res. 2003 Jul;9(7):2711-8.
DMGXSTB	RU	https://pubmed.ncbi.nlm.nih.gov/12855651

DMOXINT	DI	DMOXINT
DMOXINT	DN	TI4
DMOXINT	MI	TTVDSZ0
DMOXINT	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMOXINT	MT	DTT
DMOXINT	MA	Inhibitor
DMOXINT	RN	Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clin Cancer Res. 2003 Jul;9(7):2711-8.
DMOXINT	RU	https://pubmed.ncbi.nlm.nih.gov/12855651

DMWSI0H	DI	DMWSI0H
DMWSI0H	DN	Tiapamil
DMWSI0H	MI	DTUGYRD
DMWSI0H	MN	P-glycoprotein 1 (ABCB1)
DMWSI0H	MT	DTP
DMWSI0H	MA	Substrate
DMWSI0H	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMWSI0H	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMEFVPH	DI	DMEFVPH
DMEFVPH	DN	Tiazofurin adenine dinucleotide
DMEFVPH	MI	TTZFTY4
DMEFVPH	MN	Amidophosphoribosyltransferase (PPAT)
DMEFVPH	MT	DTT
DMEFVPH	MA	Inhibitor
DMEFVPH	RN	Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment. J Med Chem. 2007 Dec 27;50(26):6685-91.
DMEFVPH	RU	https://pubmed.ncbi.nlm.nih.gov/18038969

DMEFVPH	DI	DMEFVPH
DMEFVPH	DN	Tiazofurin adenine dinucleotide
DMEFVPH	MI	TTTB4UP
DMEFVPH	MN	Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2)
DMEFVPH	MT	DTT
DMEFVPH	MA	Inhibitor
DMEFVPH	RN	Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment. J Med Chem. 2007 Dec 27;50(26):6685-91.
DMEFVPH	RU	https://pubmed.ncbi.nlm.nih.gov/18038969

DMMFCHU	DI	DMMFCHU
DMMFCHU	DN	Tic-D-Phe-Arg-2-Nal-NHCH3
DMMFCHU	MI	TT0MV2T
DMMFCHU	MN	Melanocortin receptor 1 (MC1R)
DMMFCHU	MT	DTT
DMMFCHU	MA	Inhibitor
DMMFCHU	RN	Synthesis of Tic-D-Phe Psi[CH2-CH2] isostere and its use in the development of melanocortin receptor agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1721-5.
DMMFCHU	RU	https://pubmed.ncbi.nlm.nih.gov/16376076

DMMFCHU	DI	DMMFCHU
DMMFCHU	DN	Tic-D-Phe-Arg-2-Nal-NHCH3
DMMFCHU	MI	TTNI91K
DMMFCHU	MN	Melanocortin receptor 3 (MC3R)
DMMFCHU	MT	DTT
DMMFCHU	MA	Inhibitor
DMMFCHU	RN	Synthesis of Tic-D-Phe Psi[CH2-CH2] isostere and its use in the development of melanocortin receptor agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1721-5.
DMMFCHU	RU	https://pubmed.ncbi.nlm.nih.gov/16376076

DMMFCHU	DI	DMMFCHU
DMMFCHU	DN	Tic-D-Phe-Arg-2-Nal-NHCH3
DMMFCHU	MI	TTD0CIQ
DMMFCHU	MN	Melanocortin receptor 4 (MC4R)
DMMFCHU	MT	DTT
DMMFCHU	MA	Inhibitor
DMMFCHU	RN	Synthesis of Tic-D-Phe Psi[CH2-CH2] isostere and its use in the development of melanocortin receptor agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1721-5.
DMMFCHU	RU	https://pubmed.ncbi.nlm.nih.gov/16376076

DM71HQL	DI	DM71HQL
DM71HQL	DN	Tideglusib
DM71HQL	MI	TTNHMO8
DM71HQL	MN	COVID-19 papain-like proteinase (PL-PRO)
DM71HQL	MT	DTT
DM71HQL	MA	Inhibitor
DM71HQL	RN	Structure of Mpro from COVID-19 virus and discovery of its inhibitors. Nature. 2020 Apr 9.
DM71HQL	RU	https://pubmed.ncbi.nlm.nih.gov/32272481

DM4QK0T	DI	DM4QK0T
DM4QK0T	DN	tifluadom
DM4QK0T	MI	TTQW87Y
DM4QK0T	MN	Opioid receptor kappa (OPRK1)
DM4QK0T	MT	DTT
DM4QK0T	MA	Agonist
DM4QK0T	RN	Activation of the cloned human kappa opioid receptor by agonists enhances [35S]GTPgammaS binding to membranes: determination of potencies and efficacies of ligands. J Pharmacol Exp Ther. 1997 Aug;282(2):676-84.
DM4QK0T	RU	https://pubmed.ncbi.nlm.nih.gov/9262330

DMLNTB5	DI	DMLNTB5
DMLNTB5	DN	TILIROSIDE
DMLNTB5	MI	TTXV4FI
DMLNTB5	MN	Albendazole monooxygenase (CYP3A4)
DMLNTB5	MT	DTT
DMLNTB5	MA	Inhibitor
DMLNTB5	RN	Isolation of cytochrome P450 inhibitors from strawberry fruit, Fragaria ananassa. J Nat Prod. 2004 Nov;67(11):1839-41.
DMLNTB5	RU	https://pubmed.ncbi.nlm.nih.gov/15568772

DMTXJ5S	DI	DMTXJ5S
DMTXJ5S	DN	Tin protoporphyrin
DMTXJ5S	MI	TTI6V2A
DMTXJ5S	MN	Heme oxygenase 1 (HMOX1)
DMTXJ5S	MT	DTT
DMTXJ5S	MA	Inhibitor
DMTXJ5S	RN	Adenovirus-mediated heme oxygenase-1 gene delivery inhibits injury-induced vascular neointima formation. Circulation. 2001 Nov 27;104(22):2710-5.
DMTXJ5S	RU	https://pubmed.ncbi.nlm.nih.gov/11723024

DMEV7FY	DI	DMEV7FY
DMEV7FY	DN	TINGENIN B
DMEV7FY	MI	TTFBNVI
DMEV7FY	MN	Aldose reductase (AKR1B1)
DMEV7FY	MT	DTT
DMEV7FY	MA	Inhibitor
DMEV7FY	RN	Structures of new friedelane-type triterpenes and eudesmane-type sesquiterpene and aldose reductase inhibitors from Salacia chinensis. J Nat Prod. 2003 Sep;66(9):1191-6.
DMEV7FY	RU	https://pubmed.ncbi.nlm.nih.gov/14510595

DMH3NTP	DI	DMH3NTP
DMH3NTP	DN	TINGENONE
DMH3NTP	MI	TTFBNVI
DMH3NTP	MN	Aldose reductase (AKR1B1)
DMH3NTP	MT	DTT
DMH3NTP	MA	Inhibitor
DMH3NTP	RN	Structures of new friedelane-type triterpenes and eudesmane-type sesquiterpene and aldose reductase inhibitors from Salacia chinensis. J Nat Prod. 2003 Sep;66(9):1191-6.
DMH3NTP	RU	https://pubmed.ncbi.nlm.nih.gov/14510595

DM81KD2	DI	DM81KD2
DM81KD2	DN	tiotidine
DM81KD2	MI	TTQHJ1K
DM81KD2	MN	Histamine H2 receptor (H2R)
DM81KD2	MT	DTT
DM81KD2	MA	Antagonist
DM81KD2	RN	Heterologous expression of rat epitope-tagged histamine H2 receptors in insect Sf9 cells. Br J Pharmacol. 1997 Nov;122(5):867-74.
DM81KD2	RU	https://pubmed.ncbi.nlm.nih.gov/9384502

DMZO1FJ	DI	DMZO1FJ
DMZO1FJ	DN	TIP
DMZO1FJ	MI	TT27RFC
DMZO1FJ	MN	Opioid receptor delta (OPRD1)
DMZO1FJ	MT	DTT
DMZO1FJ	MA	Antagonist
DMZO1FJ	RN	The TIPP opioid peptide family: development of delta antagonists, delta agonists, and mixed mu agonist/delta antagonists. Biopolymers. 1999;51(6):411-25.
DMZO1FJ	RU	https://pubmed.ncbi.nlm.nih.gov/10797230

DM9FNQ6	DI	DM9FNQ6
DM9FNQ6	DN	TIPPpsi
DM9FNQ6	MI	TT27RFC
DM9FNQ6	MN	Opioid receptor delta (OPRD1)
DM9FNQ6	MT	DTT
DM9FNQ6	MA	Antagonist
DM9FNQ6	RN	TIPP[psi]: a highly potent and stable pseudopeptide delta opioid receptor antagonist with extraordinary delta selectivity. J Med Chem. 1993 Oct 15;36(21):3182-7.
DM9FNQ6	RU	https://pubmed.ncbi.nlm.nih.gov/8230106

DMQ4GBO	DI	DMQ4GBO
DMQ4GBO	DN	tirotundin
DMQ4GBO	MI	TTT2SVW
DMQ4GBO	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DMQ4GBO	MT	DTT
DMQ4GBO	MA	Agonist
DMQ4GBO	RN	Sesquiterpene lactones from Tithonia diversifolia act as peroxisome proliferator-activated receptor agonists. Bioorg Med Chem Lett. 2012 Apr 15;22(8):2954-8.
DMQ4GBO	RU	https://pubmed.ncbi.nlm.nih.gov/22424975

DMKV52P	DI	DMKV52P
DMKV52P	DN	TK-112690
DMKV52P	MI	TT9TQRP
DMKV52P	MN	Uridine phosphorylase (UPP)
DMKV52P	MT	DTT
DMKV52P	MA	Modulator
DMKV52P	RN	CN patent application no. 102014919, Methotrexate adjuvants to reduce toxicity and methods for using the same.
DMKV52P	RU	http://www.google.com/patents/CN102014919B?cl=en

DMYGXHK	DI	DMYGXHK
DMYGXHK	DN	T-kinin
DMYGXHK	MI	TTGY8IW
DMYGXHK	MN	B2 bradykinin receptor (BDKRB2)
DMYGXHK	MT	DTT
DMYGXHK	MA	Agonist
DMYGXHK	RN	Molecular characterisation of cloned bradykinin B1 receptors from rat and human. Eur J Pharmacol. 1999 Jun 25;374(3):423-33.
DMYGXHK	RU	https://pubmed.ncbi.nlm.nih.gov/10422787

DMDBUXR	DI	DMDBUXR
DMDBUXR	DN	TKP-1001
DMDBUXR	MI	TTE4KHA
DMDBUXR	MN	Amyloid beta A4 protein (APP)
DMDBUXR	MT	DTT
DMDBUXR	MA	Modulator
DMDBUXR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
DMDBUXR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402

DMZU4O8	DI	DMZU4O8
DMZU4O8	DN	TKP-1002
DMZU4O8	MI	TTE0A2F
DMZU4O8	MN	Dopamine D4 receptor (D4R)
DMZU4O8	MT	DTT
DMZU4O8	MA	Modulator
DMZU4O8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 217).
DMZU4O8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=217

DMAHG9E	DI	DMAHG9E
DMAHG9E	DN	TL-1892
DMAHG9E	MI	TTYFKSZ
DMAHG9E	MN	Tubulin beta (TUBB)
DMAHG9E	MT	DTT
DMAHG9E	MA	Inhibitor
DMAHG9E	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2640).
DMAHG9E	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2640

DMCN2B8	DI	DMCN2B8
DMCN2B8	DN	TMB-8
DMCN2B8	MI	TTPC4TU
DMCN2B8	MN	5-HT 3A receptor (HTR3A)
DMCN2B8	MT	DTT
DMCN2B8	MA	Blocker (channel blocker)
DMCN2B8	RN	Characterization of interaction of 3,4,5-trimethoxybenzoic acid 8-(diethylamino)octyl ester with Torpedo californica nicotinic acetylcholine receptor and 5-hydroxytryptamine3 receptor. J Pharmacol Exp Ther. 1999 Jul;290(1):129-35.
DMCN2B8	RU	https://pubmed.ncbi.nlm.nih.gov/10381768

DMSMQE7	DI	DMSMQE7
DMSMQE7	DN	TMP269
DMSMQE7	MI	TTTQGH8
DMSMQE7	MN	Histone deacetylase 4 (HDAC4)
DMSMQE7	MT	DTT
DMSMQE7	MA	Inhibitor
DMSMQE7	RN	Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. Nat Chem Biol. 2013 May;9(5):319-25.
DMSMQE7	RU	https://pubmed.ncbi.nlm.nih.gov/23524983

DMSMQE7	DI	DMSMQE7
DMSMQE7	DN	TMP269
DMSMQE7	MI	TTUELN5
DMSMQE7	MN	Histone deacetylase 5 (HDAC5)
DMSMQE7	MT	DTT
DMSMQE7	MA	Inhibitor
DMSMQE7	RN	Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. Nat Chem Biol. 2013 May;9(5):319-25.
DMSMQE7	RU	https://pubmed.ncbi.nlm.nih.gov/23524983

DMSMQE7	DI	DMSMQE7
DMSMQE7	DN	TMP269
DMSMQE7	MI	TTMUEK1
DMSMQE7	MN	Histone deacetylase 7 (HDAC7)
DMSMQE7	MT	DTT
DMSMQE7	MA	Inhibitor
DMSMQE7	RN	Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. Nat Chem Biol. 2013 May;9(5):319-25.
DMSMQE7	RU	https://pubmed.ncbi.nlm.nih.gov/23524983

DMSMQE7	DI	DMSMQE7
DMSMQE7	DN	TMP269
DMSMQE7	MI	TT8M4E1
DMSMQE7	MN	Histone deacetylase 9 (HDAC9)
DMSMQE7	MT	DTT
DMSMQE7	MA	Inhibitor
DMSMQE7	RN	Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. Nat Chem Biol. 2013 May;9(5):319-25.
DMSMQE7	RU	https://pubmed.ncbi.nlm.nih.gov/23524983

DMWO85H	DI	DMWO85H
DMWO85H	DN	TMPyP4
DMWO85H	MI	TTUJFD0
DMWO85H	MN	Telomerase reverse transcriptase (TERT)
DMWO85H	MT	DTT
DMWO85H	MA	Inhibitor
DMWO85H	RN	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
DMWO85H	RU	https://pubmed.ncbi.nlm.nih.gov/19249983

DMULO0V	DI	DMULO0V
DMULO0V	DN	TMX-201
DMULO0V	MI	TTRJ1K4
DMULO0V	MN	Toll-like receptor 7 (TLR7)
DMULO0V	MT	DTT
DMULO0V	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1757).
DMULO0V	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1757

DMPX3WT	DI	DMPX3WT
DMPX3WT	DN	TMX-202
DMPX3WT	MI	TTRJ1K4
DMPX3WT	MN	Toll-like receptor 7 (TLR7)
DMPX3WT	MT	DTT
DMPX3WT	MA	Agonist
DMPX3WT	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1757).
DMPX3WT	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1757

DMSEAMU	DI	DMSEAMU
DMSEAMU	DN	TMX-30X
DMSEAMU	MI	TTRJ1K4
DMSEAMU	MN	Toll-like receptor 7 (TLR7)
DMSEAMU	MT	DTT
DMSEAMU	MA	Agonist
DMSEAMU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1757).
DMSEAMU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1757

DME0I7O	DI	DME0I7O
DME0I7O	DN	TN-14003
DME0I7O	MI	TTBID49
DME0I7O	MN	C-X-C chemokine receptor type 4 (CXCR4)
DME0I7O	MT	DTT
DME0I7O	MA	Inhibitor
DME0I7O	RN	Discovery of small molecule CXCR4 antagonists. J Med Chem. 2007 Nov 15;50(23):5655-64.
DME0I7O	RU	https://pubmed.ncbi.nlm.nih.gov/17958344

DMAGI7K	DI	DMAGI7K
DMAGI7K	DN	TNFcept
DMAGI7K	MI	TTG043C
DMAGI7K	MN	Tumor necrosis factor receptor type I (TNF-R1)
DMAGI7K	MT	DTT
DMAGI7K	MA	Modulator
DMAGI7K	RN	Secretion of a TNFR:Fc fusion protein following pulmonary administration of pseudotyped adeno-associated virus vectors. J Virol. 2004 Nov;78(22):12355-65.
DMAGI7K	RU	https://pubmed.ncbi.nlm.nih.gov/15507622

DM4T0ZF	DI	DM4T0ZF
DM4T0ZF	DN	TNFmab
DM4T0ZF	MI	TTG043C
DM4T0ZF	MN	Tumor necrosis factor receptor type I (TNF-R1)
DM4T0ZF	MT	DTT
DM4T0ZF	RN	Secretion of a TNFR:Fc fusion protein following pulmonary administration of pseudotyped adeno-associated virus vectors. J Virol. 2004 Nov;78(22):12355-65.
DM4T0ZF	RU	https://pubmed.ncbi.nlm.nih.gov/15507622

DMPTQEG	DI	DMPTQEG
DMPTQEG	DN	TNFR1 NAM
DMPTQEG	MI	TTG043C
DMPTQEG	MN	Tumor necrosis factor receptor type I (TNF-R1)
DMPTQEG	MT	DTT
DMPTQEG	MA	Modulator
DMPTQEG	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1870).
DMPTQEG	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1870

DMC958O	DI	DMC958O
DMC958O	DN	TNK-651
DMC958O	MI	TT84ETX
DMC958O	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMC958O	MT	DTT
DMC958O	MA	Modulator
DMC958O	RN	Synthesis and Antiviral Evaluation of 1-[(2-Phenoxyethyl)oxymethyl] and 6-(3,5-Dimethoxybenzyl) Analogues of HIV Drugs Emivirine and TNK-651.Drug Res (Stuttg).2016 Apr;66(4):181-8.
DMC958O	RU	https://www.ncbi.nlm.nih.gov/pubmed/26313923

DMVZY0X	DI	DMVZY0X
DMVZY0X	DN	TNP-ATP
DMVZY0X	MI	TTJW7B3
DMVZY0X	MN	P2X purinoceptor 1 (P2RX1)
DMVZY0X	MT	DTT
DMVZY0X	MA	Antagonist
DMVZY0X	RN	Trinitrophenyl-substituted nucleotides are potent antagonists selective for P2X1, P2X3, and heteromeric P2X2/3 receptors. Mol Pharmacol. 1998 Jun;53(6):969-73.
DMVZY0X	RU	https://pubmed.ncbi.nlm.nih.gov/9614197

DMVZY0X	DI	DMVZY0X
DMVZY0X	DN	TNP-ATP
DMVZY0X	MI	TT2THBD
DMVZY0X	MN	P2X purinoceptor 3 (P2RX3)
DMVZY0X	MT	DTT
DMVZY0X	MA	Antagonist
DMVZY0X	RN	Trinitrophenyl-substituted nucleotides are potent antagonists selective for P2X1, P2X3, and heteromeric P2X2/3 receptors. Mol Pharmacol. 1998 Jun;53(6):969-73.
DMVZY0X	RU	https://pubmed.ncbi.nlm.nih.gov/9614197

DMHV5NK	DI	DMHV5NK
DMHV5NK	DN	TOLOXATONE
DMHV5NK	MI	TT3WG5C
DMHV5NK	MN	Monoamine oxidase type A (MAO-A)
DMHV5NK	MT	DTT
DMHV5NK	MA	Inhibitor
DMHV5NK	RN	Quercetin as the active principle of Hypericum hircinum exerts a selective inhibitory activity against MAO-A: extraction, biological analysis, and ... J Nat Prod. 2006 Jun;69(6):945-9.
DMHV5NK	RU	https://pubmed.ncbi.nlm.nih.gov/16792415

DMHV5NK	DI	DMHV5NK
DMHV5NK	DN	TOLOXATONE
DMHV5NK	MI	TTGP7BY
DMHV5NK	MN	Monoamine oxidase type B (MAO-B)
DMHV5NK	MT	DTT
DMHV5NK	MA	Inhibitor
DMHV5NK	RN	3-(1H-Pyrrol-1-yl)-2-oxazolidinones as reversible, highly potent, and selective inhibitors of monoamine oxidase type A. J Med Chem. 2002 Mar 14;45(6):1180-3.
DMHV5NK	RU	https://pubmed.ncbi.nlm.nih.gov/11881986

DMPTM6V	DI	DMPTM6V
DMPTM6V	DN	TOLSERINE
DMPTM6V	MI	TT1RS9F
DMPTM6V	MN	Acetylcholinesterase (AChE)
DMPTM6V	MT	DTT
DMPTM6V	MA	Inhibitor
DMPTM6V	RN	Novel carbamates as orally active acetylcholinesterase inhibitors found to improve scopolamine-induced cognition impairment: pharmacophore-based vi... J Med Chem. 2010 Sep 9;53(17):6490-505.
DMPTM6V	RU	https://pubmed.ncbi.nlm.nih.gov/20684567

DMPTM6V	DI	DMPTM6V
DMPTM6V	DN	TOLSERINE
DMPTM6V	MI	TTEB0GD
DMPTM6V	MN	Cholinesterase (BCHE)
DMPTM6V	MT	DTT
DMPTM6V	MA	Inhibitor
DMPTM6V	RN	Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine. J Med Chem. 2006 Apr 6;49(7):2174-85.
DMPTM6V	RU	https://pubmed.ncbi.nlm.nih.gov/16570913

DMAYUV6	DI	DMAYUV6
DMAYUV6	DN	Toluene-1-diazonium-3-sulfonic acid anion
DMAYUV6	MI	TTNJYV2
DMAYUV6	MN	Gamma-aminobutyric acid receptor (GAR)
DMAYUV6	MT	DTT
DMAYUV6	MA	Inhibitor
DMAYUV6	RN	Aryl diazo compounds and diazonium salts as potential irreversible probes of the gamma-aminobutyric acid receptor. J Med Chem. 1987 Dec;30(12):2222-7.
DMAYUV6	RU	https://pubmed.ncbi.nlm.nih.gov/2824775

DMA3U15	DI	DMA3U15
DMA3U15	DN	Tomatine
DMA3U15	MI	DTF9Y2V
DMA3U15	MN	ATP-binding cassette sub-family B member 6 (ABCB6)
DMA3U15	MT	DTP
DMA3U15	MA	Substrate
DMA3U15	RN	Efficient purification and reconstitution of ATP binding cassette transporter B6 (ABCB6) for functional and structural studies. J Biol Chem. 2013 Aug 2;288(31):22658-69.
DMA3U15	RU	http://www.ncbi.nlm.nih.gov/pubmed/23792964

DMROZL8	DI	DMROZL8
DMROZL8	DN	Tonazocine mesylate
DMROZL8	MI	TT27RFC
DMROZL8	MN	Opioid receptor delta (OPRD1)
DMROZL8	MT	DTT
DMROZL8	MA	Agonist
DMROZL8	RN	Antiparkinson potential of delta-opioid receptor agonists. Eur J Pharmacol. 2000 May 19;396(2-3):101-7.
DMROZL8	RU	https://pubmed.ncbi.nlm.nih.gov/10822062

DMNZQO9	DI	DMNZQO9
DMNZQO9	DN	TOPOSTATIN
DMNZQO9	MI	TT2GPK3
DMNZQO9	MN	DNA topoisomerase (TOP)
DMNZQO9	MT	DTT
DMNZQO9	MA	Inhibitor
DMNZQO9	RN	Isoaurostatin, a novel topoisomerase inhibitor produced by Thermomonospora alba. J Nat Prod. 2001 Feb;64(2):204-7.
DMNZQO9	RU	https://pubmed.ncbi.nlm.nih.gov/11430001

DMNZQO9	DI	DMNZQO9
DMNZQO9	DN	TOPOSTATIN
DMNZQO9	MI	TTGTQHC
DMNZQO9	MN	DNA topoisomerase I (TOP1)
DMNZQO9	MT	DTT
DMNZQO9	MA	Inhibitor
DMNZQO9	RN	Isoaurostatin, a novel topoisomerase inhibitor produced by Thermomonospora alba. J Nat Prod. 2001 Feb;64(2):204-7.
DMNZQO9	RU	https://pubmed.ncbi.nlm.nih.gov/11430001

DMNZQO9	DI	DMNZQO9
DMNZQO9	DN	TOPOSTATIN
DMNZQO9	MI	TT0IHXV
DMNZQO9	MN	DNA topoisomerase II (TOP2)
DMNZQO9	MT	DTT
DMNZQO9	MA	Inhibitor
DMNZQO9	RN	Isoaurostatin, a novel topoisomerase inhibitor produced by Thermomonospora alba. J Nat Prod. 2001 Feb;64(2):204-7.
DMNZQO9	RU	https://pubmed.ncbi.nlm.nih.gov/11430001

DMKD6GA	DI	DMKD6GA
DMKD6GA	DN	Toremifene
DMKD6GA	MI	TTC2DS7
DMKD6GA	MN	COVID-19 non-structural protein 14 (nsp14)
DMKD6GA	MT	DTT
DMKD6GA	MA	Inhibitor
DMKD6GA	RN	Repurposing of FDA-Approved Toremifene to Treat COVID-19 by Blocking the Spike Glycoprotein and NSP14 of SARS-CoV-2.  June 5, 2020.
DMKD6GA	RU	https://chemrxiv.org/articles/Repurposing_of_FDA-Approved_Toremifene_to_Treat_COVID-19_by_Blocking_the_Spike_Glycoprotein_and_NSP14_of_SARS-CoV-2/12431966/1

DMKD6GA	DI	DMKD6GA
DMKD6GA	DN	Toremifene
DMKD6GA	MI	TTZ3COY
DMKD6GA	MN	COVID-19 spike glycoprotein (S)
DMKD6GA	MT	DTT
DMKD6GA	MA	Inhibitor
DMKD6GA	RN	Repurposing of FDA-Approved Toremifene to Treat COVID-19 by Blocking the Spike Glycoprotein and NSP14 of SARS-CoV-2.  June 5, 2020.
DMKD6GA	RU	https://chemrxiv.org/articles/Repurposing_of_FDA-Approved_Toremifene_to_Treat_COVID-19_by_Blocking_the_Spike_Glycoprotein_and_NSP14_of_SARS-CoV-2/12431966/1

DMZD0NA	DI	DMZD0NA
DMZD0NA	DN	torin 1
DMZD0NA	MI	TTCJG29
DMZD0NA	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMZD0NA	MT	DTT
DMZD0NA	MA	Inhibitor
DMZD0NA	RN	Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. J Med Chem. 2010 Oct 14;53(19):7146-55.
DMZD0NA	RU	https://pubmed.ncbi.nlm.nih.gov/20860370

DMC6U93	DI	DMC6U93
DMC6U93	DN	Torin2
DMC6U93	MI	TTCJG29
DMC6U93	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMC6U93	MT	DTT
DMC6U93	MA	Inhibitor
DMC6U93	RN	Torin2 Potentiates Anticancer Effects on Adult T-Cell Leukemia/Lymphoma by Inhibiting Mammalian Target of Rapamycin. Anticancer Res. 2016 Jan;36(1):95-102.
DMC6U93	RU	https://pubmed.ncbi.nlm.nih.gov/26722032

DMDG0HK	DI	DMDG0HK
DMDG0HK	DN	Tormentic acid methyl ester
DMDG0HK	MI	TTN7BL9
DMDG0HK	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMDG0HK	MT	DTT
DMDG0HK	MA	Inhibitor
DMDG0HK	RN	11beta-Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational a... Bioorg Med Chem. 2010 Feb 15;18(4):1507-15.
DMDG0HK	RU	https://pubmed.ncbi.nlm.nih.gov/20100662

DMNC2A5	DI	DMNC2A5
DMNC2A5	DN	Tosyl-D-Proline
DMNC2A5	MI	TTU6BFZ
DMNC2A5	MN	Candida Thymidylate synthase (Candi TMP1)
DMNC2A5	MT	DTT
DMNC2A5	MA	Inhibitor
DMNC2A5	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMNC2A5	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM4R657	DI	DM4R657
DM4R657	DN	toxaphene
DM4R657	MI	TTPNQAC
DM4R657	MN	Estrogen-related receptor-alpha (ESRRA)
DM4R657	MT	DTT
DM4R657	MA	Antagonist
DM4R657	RN	Two organochlorine pesticides, toxaphene and chlordane, are antagonists for estrogen-related receptor alpha-1 orphan receptor. Cancer Res. 1999 Sep 15;59(18):4519-24.
DM4R657	RU	https://pubmed.ncbi.nlm.nih.gov/10493499

DMJHTQK	DI	DMJHTQK
DMJHTQK	DN	TOXIFERINE
DMJHTQK	MI	TTLA931
DMJHTQK	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMJHTQK	MT	DTT
DMJHTQK	MA	Inhibitor
DMJHTQK	RN	Pharmacological characteristics and binding modes of caracurine V analogues and related compounds at the neuronal alpha7 nicotinic acetylcholine re... J Med Chem. 2007 Sep 20;50(19):4616-29.
DMJHTQK	RU	https://pubmed.ncbi.nlm.nih.gov/17722904

DMRHDGN	DI	DMRHDGN
DMRHDGN	DN	TP003
DMRHDGN	MI	TTBMV1G
DMRHDGN	MN	GABA(A) receptor alpha-2 (GABRA2)
DMRHDGN	MT	DTT
DMRHDGN	MA	Modulator (allosteric modulator)
DMRHDGN	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 405).
DMRHDGN	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=405

DMRHDGN	DI	DMRHDGN
DMRHDGN	DN	TP003
DMRHDGN	MI	TT37EDJ
DMRHDGN	MN	GABA(A) receptor alpha-3 (GABRA3)
DMRHDGN	MT	DTT
DMRHDGN	MA	Modulator (allosteric modulator)
DMRHDGN	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 406).
DMRHDGN	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=406

DMRHDGN	DI	DMRHDGN
DMRHDGN	DN	TP003
DMRHDGN	MI	TTNZPQ1
DMRHDGN	MN	GABA(A) receptor alpha-5 (GABRA5)
DMRHDGN	MT	DTT
DMRHDGN	MA	Modulator (allosteric modulator)
DMRHDGN	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 408).
DMRHDGN	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=408

DMRHDGN	DI	DMRHDGN
DMRHDGN	DN	TP003
DMRHDGN	MI	TTEX6LM
DMRHDGN	MN	GABA(A) receptor gamma-3 (GABRG3)
DMRHDGN	MT	DTT
DMRHDGN	MA	Modulator (allosteric modulator)
DMRHDGN	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415).
DMRHDGN	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415

DMM41O9	DI	DMM41O9
DMM41O9	DN	TP-680
DMM41O9	MI	TTCG0AL
DMM41O9	MN	Cholecystokinin receptor type A (CCKAR)
DMM41O9	MT	DTT
DMM41O9	MA	Antagonist
DMM41O9	RN	Pharmacological profile of TP-680, a new cholecystokininA receptor antagonist. Br J Pharmacol. 1996 Apr;117(7):1558-64.
DMM41O9	RU	https://pubmed.ncbi.nlm.nih.gov/8730754

DMM41O9	DI	DMM41O9
DMM41O9	DN	TP-680
DMM41O9	MI	TTVFO0U
DMM41O9	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMM41O9	MT	DTT
DMM41O9	MA	Antagonist
DMM41O9	RN	Pharmacological profile of TP-680, a new cholecystokininA receptor antagonist. Br J Pharmacol. 1996 Apr;117(7):1558-64.
DMM41O9	RU	https://pubmed.ncbi.nlm.nih.gov/8730754

DM4WTCE	DI	DM4WTCE
DM4WTCE	DN	TP-801
DM4WTCE	MI	TTNDSF4
DM4WTCE	MN	Proto-oncogene c-Met (MET)
DM4WTCE	MT	DTT
DM4WTCE	MA	Inhibitor
DM4WTCE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
DM4WTCE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815

DMA14PR	DI	DMA14PR
DMA14PR	DN	TPCA-1
DMA14PR	MI	TTRPDBG
DMA14PR	MN	Inhibitor of nuclear factor kappa-B kinase (IKK)
DMA14PR	MT	DTT
DMA14PR	MA	Inhibitor
DMA14PR	RN	Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 (2-[(aminocarbo... J Pharmacol Exp Ther. 2005 Jan;312(1):373-81.
DMA14PR	RU	https://pubmed.ncbi.nlm.nih.gov/15316093

DMW2FTP	DI	DMW2FTP
DMW2FTP	DN	TPI-1361-17
DMW2FTP	MI	TTX4RTB
DMW2FTP	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMW2FTP	MT	DTT
DMW2FTP	MA	Antagonist
DMW2FTP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 280).
DMW2FTP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=280

DMHATCZ	DI	DMHATCZ
DMHATCZ	DN	Tpl2 kinase inhibitor
DMHATCZ	MI	TTGECUM
DMHATCZ	MN	Cot oncogene messenger RNA (MAP3K8 mRNA)
DMHATCZ	MT	DTT
DMHATCZ	MA	Inhibitor
DMHATCZ	RN	Inhibition of Tpl2 kinase and TNF-alpha production with 1,7-naphthyridine-3-carbonitriles: synthesis and structure-activity relationships. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5288-92.
DMHATCZ	RU	https://pubmed.ncbi.nlm.nih.gov/16165349

DMBF6KS	DI	DMBF6KS
DMBF6KS	DN	TPMPA
DMBF6KS	MI	TT6XFEU
DMBF6KS	MN	GABA(A) receptor rho1 (GABRR1)
DMBF6KS	MT	DTT
DMBF6KS	MA	Antagonist
DMBF6KS	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 420).
DMBF6KS	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=420

DMBF6KS	DI	DMBF6KS
DMBF6KS	DN	TPMPA
DMBF6KS	MI	TTQMXLS
DMBF6KS	MN	GABA(A) receptor rho2 (GABRR2)
DMBF6KS	MT	DTT
DMBF6KS	MA	Antagonist
DMBF6KS	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 421).
DMBF6KS	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=421

DMBF6KS	DI	DMBF6KS
DMBF6KS	DN	TPMPA
DMBF6KS	MI	TT4N6D8
DMBF6KS	MN	GABA(A) receptor rho3 (GABRR3)
DMBF6KS	MT	DTT
DMBF6KS	MA	Antagonist
DMBF6KS	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 422).
DMBF6KS	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=422

DMW9G7H	DI	DMW9G7H
DMW9G7H	DN	TPN-729
DMW9G7H	MI	TTJ0IQB
DMW9G7H	MN	Phosphodiesterase 5A (PDE5A)
DMW9G7H	MT	DTT
DMW9G7H	MA	Inhibitor
DMW9G7H	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1304).
DMW9G7H	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1304

DMFL5XU	DI	DMFL5XU
DMFL5XU	DN	TPO gene plasmid
DMFL5XU	MI	TT52XDZ
DMFL5XU	MN	Thyroid peroxidase (TPO)
DMFL5XU	MT	DTT
DMFL5XU	MA	Modulator
DMFL5XU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2526).
DMFL5XU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2526

DMEF32D	DI	DMEF32D
DMEF32D	DN	TQ-1017
DMEF32D	MI	TTWJBZ5
DMEF32D	MN	5-HT 2C receptor (HTR2C)
DMEF32D	MT	DTT
DMEF32D	MA	Agonist
DMEF32D	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMEF32D	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMEF32D	DI	DMEF32D
DMEF32D	DN	TQ-1017
DMEF32D	MI	TTAWNKZ
DMEF32D	MN	Norepinephrine transporter (NET)
DMEF32D	MT	DTT
DMEF32D	MA	Agonist
DMEF32D	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMEF32D	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMEF32D	DI	DMEF32D
DMEF32D	DN	TQ-1017
DMEF32D	MI	TTKWM86
DMEF32D	MN	Opioid receptor mu (MOP)
DMEF32D	MT	DTT
DMEF32D	MA	Agonist
DMEF32D	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMEF32D	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMZA6X3	DI	DMZA6X3
DMZA6X3	DN	TQX-173
DMZA6X3	MI	TT0MYE2
DMZA6X3	MN	Glutamate receptor ionotropic kainate 1 (GRIK1)
DMZA6X3	MT	DTT
DMZA6X3	MA	Inhibitor
DMZA6X3	RN	Synthesis, ionotropic glutamate receptor binding affinity, and structure-activity relationships of a new set of 4,5-dihydro-8-heteroaryl-4-oxo-1,2,... J Med Chem. 2001 Sep 13;44(19):3157-65.
DMZA6X3	RU	https://pubmed.ncbi.nlm.nih.gov/11543685

DM18CV3	DI	DM18CV3
DM18CV3	DN	TRACIZOLINE
DM18CV3	MI	TTWG9A4
DM18CV3	MN	Adrenergic receptor alpha-2A (ADRA2A)
DM18CV3	MT	DTT
DM18CV3	MA	Inhibitor
DM18CV3	RN	Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9.
DM18CV3	RU	https://pubmed.ncbi.nlm.nih.gov/14698196

DM18CV3	DI	DM18CV3
DM18CV3	DN	TRACIZOLINE
DM18CV3	MI	TTWM4TY
DM18CV3	MN	Adrenergic receptor alpha-2B (ADRA2B)
DM18CV3	MT	DTT
DM18CV3	MA	Inhibitor
DM18CV3	RN	Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9.
DM18CV3	RU	https://pubmed.ncbi.nlm.nih.gov/14698196

DM18CV3	DI	DM18CV3
DM18CV3	DN	TRACIZOLINE
DM18CV3	MI	TT2NUT5
DM18CV3	MN	Adrenergic receptor alpha-2C (ADRA2C)
DM18CV3	MT	DTT
DM18CV3	MA	Inhibitor
DM18CV3	RN	Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9.
DM18CV3	RU	https://pubmed.ncbi.nlm.nih.gov/14698196

DM18CV3	DI	DM18CV3
DM18CV3	DN	TRACIZOLINE
DM18CV3	MI	TT3WG5C
DM18CV3	MN	Monoamine oxidase type A (MAO-A)
DM18CV3	MT	DTT
DM18CV3	MA	Inhibitor
DM18CV3	RN	Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9.
DM18CV3	RU	https://pubmed.ncbi.nlm.nih.gov/14698196

DM18CV3	DI	DM18CV3
DM18CV3	DN	TRACIZOLINE
DM18CV3	MI	TTGP7BY
DM18CV3	MN	Monoamine oxidase type B (MAO-B)
DM18CV3	MT	DTT
DM18CV3	MA	Inhibitor
DM18CV3	RN	Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9.
DM18CV3	RU	https://pubmed.ncbi.nlm.nih.gov/14698196

DM3ML0N	DI	DM3ML0N
DM3ML0N	DN	Tramazoline
DM3ML0N	MI	TTWG9A4
DM3ML0N	MN	Adrenergic receptor alpha-2A (ADRA2A)
DM3ML0N	MT	DTT
DM3ML0N	MA	Inhibitor
DM3ML0N	RN	alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs. J Med Chem. 1982 Dec;25(12):1389-401.
DM3ML0N	RU	https://pubmed.ncbi.nlm.nih.gov/6296387

DM3ML0N	DI	DM3ML0N
DM3ML0N	DN	Tramazoline
DM3ML0N	MI	TTWM4TY
DM3ML0N	MN	Adrenergic receptor alpha-2B (ADRA2B)
DM3ML0N	MT	DTT
DM3ML0N	MA	Inhibitor
DM3ML0N	RN	alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs. J Med Chem. 1982 Dec;25(12):1389-401.
DM3ML0N	RU	https://pubmed.ncbi.nlm.nih.gov/6296387

DM3ML0N	DI	DM3ML0N
DM3ML0N	DN	Tramazoline
DM3ML0N	MI	TT2NUT5
DM3ML0N	MN	Adrenergic receptor alpha-2C (ADRA2C)
DM3ML0N	MT	DTT
DM3ML0N	MA	Inhibitor
DM3ML0N	RN	alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs. J Med Chem. 1982 Dec;25(12):1389-401.
DM3ML0N	RU	https://pubmed.ncbi.nlm.nih.gov/6296387

DMRTASL	DI	DMRTASL
DMRTASL	DN	Trametinib
DMRTASL	MI	TTAW3TO
DMRTASL	MN	HUMAN ERK activator kinase 1 (MEK1)
DMRTASL	MT	DTT
DMRTASL	MA	Inhibitor
DMRTASL	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DMRTASL	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DMRTASL	DI	DMRTASL
DMRTASL	DN	Trametinib
DMRTASL	MI	TTWX403
DMRTASL	MN	HUMAN ERK activator kinase 2 (MEK2)
DMRTASL	MT	DTT
DMRTASL	MA	Inhibitor
DMRTASL	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DMRTASL	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DM27TPM	DI	DM27TPM
DM27TPM	DN	Trans-(+/-)-2-Fluoro-1,2-diphenylcyclopropylamine
DM27TPM	MI	TT3WG5C
DM27TPM	MN	Monoamine oxidase type A (MAO-A)
DM27TPM	MT	DTT
DM27TPM	MA	Inhibitor
DM27TPM	RN	Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases... Bioorg Med Chem. 2008 Aug 1;16(15):7148-66.
DM27TPM	RU	https://pubmed.ncbi.nlm.nih.gov/18640844

DMYVJHN	DI	DMYVJHN
DMYVJHN	DN	Trans-(1S(R),2S(R))-2-Hydroxycyclooctyl nitrate
DMYVJHN	MI	TTEP6RV
DMYVJHN	MN	Glutathione reductase (GR)
DMYVJHN	MT	DTT
DMYVJHN	MA	Inhibitor
DMYVJHN	RN	In vitro inhibition of human erythrocyte glutathione reductase by some new organic nitrates. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3661-3.
DMYVJHN	RU	https://pubmed.ncbi.nlm.nih.gov/19447620

DMXC98D	DI	DMXC98D
DMXC98D	DN	Trans-(R(S))-2-Hydroxy-1-phenylethyl nitrate
DMXC98D	MI	TTEP6RV
DMXC98D	MN	Glutathione reductase (GR)
DMXC98D	MT	DTT
DMXC98D	MA	Inhibitor
DMXC98D	RN	In vitro inhibition of human erythrocyte glutathione reductase by some new organic nitrates. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3661-3.
DMXC98D	RU	https://pubmed.ncbi.nlm.nih.gov/19447620

DMHD1XM	DI	DMHD1XM
DMHD1XM	DN	Trans,trans-1,3-bis-(4-hydroxycyclohexyl)urea
DMHD1XM	MI	TT7WVHI
DMHD1XM	MN	Soluble epoxide hydrolase (EPHX2)
DMHD1XM	MT	DTT
DMHD1XM	MA	Inhibitor
DMHD1XM	RN	Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem. 2007 Aug 9;50(16):3825-40.
DMHD1XM	RU	https://pubmed.ncbi.nlm.nih.gov/17616115

DMH1S57	DI	DMH1S57
DMH1S57	DN	Trans-2-(4-chlorophenyl)-2-fluorocyclopropanamine
DMH1S57	MI	TT3WG5C
DMH1S57	MN	Monoamine oxidase type A (MAO-A)
DMH1S57	MT	DTT
DMH1S57	MA	Inhibitor
DMH1S57	RN	Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases... Bioorg Med Chem. 2008 Aug 1;16(15):7148-66.
DMH1S57	RU	https://pubmed.ncbi.nlm.nih.gov/18640844

DMH1S57	DI	DMH1S57
DMH1S57	DN	Trans-2-(4-chlorophenyl)-2-fluorocyclopropanamine
DMH1S57	MI	TTGP7BY
DMH1S57	MN	Monoamine oxidase type B (MAO-B)
DMH1S57	MT	DTT
DMH1S57	MA	Inhibitor
DMH1S57	RN	Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases... Bioorg Med Chem. 2008 Aug 1;16(15):7148-66.
DMH1S57	RU	https://pubmed.ncbi.nlm.nih.gov/18640844

DMO01T8	DI	DMO01T8
DMO01T8	DN	Trans-2-fluoro-2-(4-fluorophenyl)cyclopropanamine
DMO01T8	MI	TT3WG5C
DMO01T8	MN	Monoamine oxidase type A (MAO-A)
DMO01T8	MT	DTT
DMO01T8	MA	Inhibitor
DMO01T8	RN	Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases... Bioorg Med Chem. 2008 Aug 1;16(15):7148-66.
DMO01T8	RU	https://pubmed.ncbi.nlm.nih.gov/18640844

DMO01T8	DI	DMO01T8
DMO01T8	DN	Trans-2-fluoro-2-(4-fluorophenyl)cyclopropanamine
DMO01T8	MI	TTGP7BY
DMO01T8	MN	Monoamine oxidase type B (MAO-B)
DMO01T8	MT	DTT
DMO01T8	MA	Inhibitor
DMO01T8	RN	Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases... Bioorg Med Chem. 2008 Aug 1;16(15):7148-66.
DMO01T8	RU	https://pubmed.ncbi.nlm.nih.gov/18640844

DMVGAFR	DI	DMVGAFR
DMVGAFR	DN	Trans-2-fluoro-2-phenylcyclopropylamin
DMVGAFR	MI	TT3WG5C
DMVGAFR	MN	Monoamine oxidase type A (MAO-A)
DMVGAFR	MT	DTT
DMVGAFR	MA	Inhibitor
DMVGAFR	RN	Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases... Bioorg Med Chem. 2008 Aug 1;16(15):7148-66.
DMVGAFR	RU	https://pubmed.ncbi.nlm.nih.gov/18640844

DMVGAFR	DI	DMVGAFR
DMVGAFR	DN	Trans-2-fluoro-2-phenylcyclopropylamin
DMVGAFR	MI	TTGP7BY
DMVGAFR	MN	Monoamine oxidase type B (MAO-B)
DMVGAFR	MT	DTT
DMVGAFR	MA	Inhibitor
DMVGAFR	RN	Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases... Bioorg Med Chem. 2008 Aug 1;16(15):7148-66.
DMVGAFR	RU	https://pubmed.ncbi.nlm.nih.gov/18640844

DM392QT	DI	DM392QT
DM392QT	DN	Trans-2-fluoro-2-p-tolylcyclopropanamine
DM392QT	MI	TT3WG5C
DM392QT	MN	Monoamine oxidase type A (MAO-A)
DM392QT	MT	DTT
DM392QT	MA	Inhibitor
DM392QT	RN	Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases... Bioorg Med Chem. 2008 Aug 1;16(15):7148-66.
DM392QT	RU	https://pubmed.ncbi.nlm.nih.gov/18640844

DM392QT	DI	DM392QT
DM392QT	DN	Trans-2-fluoro-2-p-tolylcyclopropanamine
DM392QT	MI	TTGP7BY
DM392QT	MN	Monoamine oxidase type B (MAO-B)
DM392QT	MT	DTT
DM392QT	MA	Inhibitor
DM392QT	RN	Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases... Bioorg Med Chem. 2008 Aug 1;16(15):7148-66.
DM392QT	RU	https://pubmed.ncbi.nlm.nih.gov/18640844

DMHJM0B	DI	DMHJM0B
DMHJM0B	DN	trans-2-methylcrotonic acid
DMHJM0B	MI	TT0FYAN
DMHJM0B	MN	Free fatty acid receptor 2 (FFAR2)
DMHJM0B	MT	DTT
DMHJM0B	MA	Agonist
DMHJM0B	RN	Selective orthosteric free fatty acid receptor 2 (FFA2) agonists: identification of the structural and chemical requirements for selective activation of FFA2 versus FFA3. J Biol Chem. 2011 Mar 25;286(12):10628-40.
DMHJM0B	RU	https://pubmed.ncbi.nlm.nih.gov/21220428

DMEDC5I	DI	DMEDC5I
DMEDC5I	DN	Trans-3-(o-tolyloxy)-2,3-dihydro-1H-inden-1-amine
DMEDC5I	MI	TTVBI8W
DMEDC5I	MN	Dopamine transporter (DAT)
DMEDC5I	MT	DTT
DMEDC5I	MA	Inhibitor
DMEDC5I	RN	Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI). Bioorg Med Chem Lett. 2008 Jul 15;18(14):4224-7.
DMEDC5I	RU	https://pubmed.ncbi.nlm.nih.gov/18550369

DMEDC5I	DI	DMEDC5I
DMEDC5I	DN	Trans-3-(o-tolyloxy)-2,3-dihydro-1H-inden-1-amine
DMEDC5I	MI	TTAWNKZ
DMEDC5I	MN	Norepinephrine transporter (NET)
DMEDC5I	MT	DTT
DMEDC5I	MA	Inhibitor
DMEDC5I	RN	Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI). Bioorg Med Chem Lett. 2008 Jul 15;18(14):4224-7.
DMEDC5I	RU	https://pubmed.ncbi.nlm.nih.gov/18550369

DMEDC5I	DI	DMEDC5I
DMEDC5I	DN	Trans-3-(o-tolyloxy)-2,3-dihydro-1H-inden-1-amine
DMEDC5I	MI	TT3ROYC
DMEDC5I	MN	Serotonin transporter (SERT)
DMEDC5I	MT	DTT
DMEDC5I	MA	Inhibitor
DMEDC5I	RN	Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI). Bioorg Med Chem Lett. 2008 Jul 15;18(14):4224-7.
DMEDC5I	RU	https://pubmed.ncbi.nlm.nih.gov/18550369

DM6HI8W	DI	DM6HI8W
DM6HI8W	DN	trans-3-ACPBPA
DM6HI8W	MI	TT6XFEU
DM6HI8W	MN	GABA(A) receptor rho1 (GABRR1)
DM6HI8W	MT	DTT
DM6HI8W	MA	Antagonist
DM6HI8W	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 420).
DM6HI8W	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=420

DM6HI8W	DI	DM6HI8W
DM6HI8W	DN	trans-3-ACPBPA
DM6HI8W	MI	TTQMXLS
DM6HI8W	MN	GABA(A) receptor rho2 (GABRR2)
DM6HI8W	MT	DTT
DM6HI8W	MA	Antagonist
DM6HI8W	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 421).
DM6HI8W	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=421

DM6HI8W	DI	DM6HI8W
DM6HI8W	DN	trans-3-ACPBPA
DM6HI8W	MI	TT4N6D8
DM6HI8W	MN	GABA(A) receptor rho3 (GABRR3)
DM6HI8W	MT	DTT
DM6HI8W	MA	Antagonist
DM6HI8W	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 422).
DM6HI8W	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=422

DM8E9YS	DI	DM8E9YS
DM8E9YS	DN	Trans-dimethyl gababutin
DM8E9YS	MI	TTFK1JQ
DM8E9YS	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DM8E9YS	MT	DTT
DM8E9YS	MA	Inhibitor
DM8E9YS	RN	Synthesis and in vivo evaluation of bicyclic gababutins. Bioorg Med Chem Lett. 2010 Jan 15;20(2):461-4.
DM8E9YS	RU	https://pubmed.ncbi.nlm.nih.gov/20005103

DMBU4KJ	DI	DMBU4KJ
DMBU4KJ	DN	Trans-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH
DMBU4KJ	MI	TT27RFC
DMBU4KJ	MN	Opioid receptor delta (OPRD1)
DMBU4KJ	MT	DTT
DMBU4KJ	MA	Inhibitor
DMBU4KJ	RN	Synthesis of stable and potent delta/mu opioid peptides: analogues of H-Tyr-c[D-Cys-Gly-Phe-D-Cys]-OH by ring-closing metathesis. J Med Chem. 2007 Jun 28;50(13):3138-42.
DMBU4KJ	RU	https://pubmed.ncbi.nlm.nih.gov/17539621

DMBU4KJ	DI	DMBU4KJ
DMBU4KJ	DN	Trans-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH
DMBU4KJ	MI	TTQW87Y
DMBU4KJ	MN	Opioid receptor kappa (OPRK1)
DMBU4KJ	MT	DTT
DMBU4KJ	MA	Inhibitor
DMBU4KJ	RN	Synthesis of stable and potent delta/mu opioid peptides: analogues of H-Tyr-c[D-Cys-Gly-Phe-D-Cys]-OH by ring-closing metathesis. J Med Chem. 2007 Jun 28;50(13):3138-42.
DMBU4KJ	RU	https://pubmed.ncbi.nlm.nih.gov/17539621

DMBU4KJ	DI	DMBU4KJ
DMBU4KJ	DN	Trans-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH
DMBU4KJ	MI	TTKWM86
DMBU4KJ	MN	Opioid receptor mu (MOP)
DMBU4KJ	MT	DTT
DMBU4KJ	MA	Inhibitor
DMBU4KJ	RN	Synthesis of stable and potent delta/mu opioid peptides: analogues of H-Tyr-c[D-Cys-Gly-Phe-D-Cys]-OH by ring-closing metathesis. J Med Chem. 2007 Jun 28;50(13):3138-42.
DMBU4KJ	RU	https://pubmed.ncbi.nlm.nih.gov/17539621

DMXS8LN	DI	DMXS8LN
DMXS8LN	DN	Trans-hydroxytamoxifen
DMXS8LN	MI	TTZAYWL
DMXS8LN	MN	Estrogen receptor (ESR)
DMXS8LN	MT	DTT
DMXS8LN	MA	Antagonist
DMXS8LN	RN	Antagonists selective for estrogen receptor alpha. Endocrinology. 2002 Mar;143(3):941-7.
DMXS8LN	RU	https://pubmed.ncbi.nlm.nih.gov/11861516

DMXS8LN	DI	DMXS8LN
DMXS8LN	DN	Trans-hydroxytamoxifen
DMXS8LN	MI	TTOM3J0
DMXS8LN	MN	Estrogen receptor beta (ESR2)
DMXS8LN	MT	DTT
DMXS8LN	MA	Antagonist
DMXS8LN	RN	Antagonists selective for estrogen receptor alpha. Endocrinology. 2002 Mar;143(3):941-7.
DMXS8LN	RU	https://pubmed.ncbi.nlm.nih.gov/11861516

DMP4T87	DI	DMP4T87
DMP4T87	DN	TRANSTORINE
DMP4T87	MI	TTLD29N
DMP4T87	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMP4T87	MT	DTT
DMP4T87	MA	Inhibitor
DMP4T87	RN	3-(2-carboxyindol-3-yl)propionic acid derivatives: antagonists of the strychnine-insensitive glycine receptor associated with the N-methyl-D-aspart... J Med Chem. 1990 Nov;33(11):2944-6.
DMP4T87	RU	https://pubmed.ncbi.nlm.nih.gov/2146391

DMP4T87	DI	DMP4T87
DMP4T87	DN	TRANSTORINE
DMP4T87	MI	TTKJEMQ
DMP4T87	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMP4T87	MT	DTT
DMP4T87	MA	Inhibitor
DMP4T87	RN	3-(2-carboxyindol-3-yl)propionic acid derivatives: antagonists of the strychnine-insensitive glycine receptor associated with the N-methyl-D-aspart... J Med Chem. 1990 Nov;33(11):2944-6.
DMP4T87	RU	https://pubmed.ncbi.nlm.nih.gov/2146391

DMP4T87	DI	DMP4T87
DMP4T87	DN	TRANSTORINE
DMP4T87	MI	TTN9D8E
DMP4T87	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMP4T87	MT	DTT
DMP4T87	MA	Inhibitor
DMP4T87	RN	3-(2-carboxyindol-3-yl)propionic acid derivatives: antagonists of the strychnine-insensitive glycine receptor associated with the N-methyl-D-aspart... J Med Chem. 1990 Nov;33(11):2944-6.
DMP4T87	RU	https://pubmed.ncbi.nlm.nih.gov/2146391

DMXZAH6	DI	DMXZAH6
DMXZAH6	DN	Trapoxin
DMXZAH6	MI	TTBH0VX
DMXZAH6	MN	Histone deacetylase (HDAC)
DMXZAH6	MT	DTT
DMXZAH6	MA	Inhibitor
DMXZAH6	RN	Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S20-6.
DMXZAH6	RU	https://pubmed.ncbi.nlm.nih.gov/11587361

DMDX0VI	DI	DMDX0VI
DMDX0VI	DN	Trecadrine
DMDX0VI	MI	TTMXGCW
DMDX0VI	MN	Adrenergic receptor beta-3 (ADRB3)
DMDX0VI	MT	DTT
DMDX0VI	MA	Agonist
DMDX0VI	RN	Potential anti-diabetic applications of a new molecule with affinity for beta 3-adrenoceptors. Life Sci. 1996;59(11):PL141-6.
DMDX0VI	RU	https://pubmed.ncbi.nlm.nih.gov/8795708

DMDX0VI	DI	DMDX0VI
DMDX0VI	DN	Trecadrine
DMDX0VI	MI	TTHQPL7
DMDX0VI	MN	Carbonic anhydrase I (CA-I)
DMDX0VI	MT	DTT
DMDX0VI	MA	Inhibitor
DMDX0VI	RN	Sulfenamido-sulfonamides as inhibitors of carbonic anhydrase isozymes I, II and IV. J Enzyme Inhib. 1997 Aug;12(3):175-90.
DMDX0VI	RU	https://pubmed.ncbi.nlm.nih.gov/9314114

DMDX0VI	DI	DMDX0VI
DMDX0VI	DN	Trecadrine
DMDX0VI	MI	TTANPDJ
DMDX0VI	MN	Carbonic anhydrase II (CA-II)
DMDX0VI	MT	DTT
DMDX0VI	MA	Inhibitor
DMDX0VI	RN	Sulfenamido-sulfonamides as inhibitors of carbonic anhydrase isozymes I, II and IV. J Enzyme Inhib. 1997 Aug;12(3):175-90.
DMDX0VI	RU	https://pubmed.ncbi.nlm.nih.gov/9314114

DMDX0VI	DI	DMDX0VI
DMDX0VI	DN	Trecadrine
DMDX0VI	MI	TTZHA0O
DMDX0VI	MN	Carbonic anhydrase IV (CA-IV)
DMDX0VI	MT	DTT
DMDX0VI	MA	Inhibitor
DMDX0VI	RN	Sulfenamido-sulfonamides as inhibitors of carbonic anhydrase isozymes I, II and IV. J Enzyme Inhib. 1997 Aug;12(3):175-90.
DMDX0VI	RU	https://pubmed.ncbi.nlm.nih.gov/9314114

DME94KO	DI	DME94KO
DME94KO	DN	Trecetilide fumarate
DME94KO	MI	TT1VOHK
DME94KO	MN	Potassium channel unspecific (KC)
DME94KO	MT	DTT
DME94KO	MA	Blocker
DME94KO	RN	IKr channel blockers: novel antiarrhythmic agents. Curr Med Chem Cardiovasc Hematol Agents. 2003 Oct;1(3):203-23.
DME94KO	RU	https://pubmed.ncbi.nlm.nih.gov/15326913

DM8LYSB	DI	DM8LYSB
DM8LYSB	DN	Triazine
DM8LYSB	MI	TT3PQ2Y
DM8LYSB	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DM8LYSB	MT	DTT
DM8LYSB	MA	Inhibitor
DM8LYSB	RN	Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Chem Biol Interact. 2000 Jan 3;124(1):61-76.
DM8LYSB	RU	https://pubmed.ncbi.nlm.nih.gov/10658902

DMCLA2D	DI	DMCLA2D
DMCLA2D	DN	triazine compound PC10
DMCLA2D	MI	TTM67AX
DMCLA2D	MN	Prokineticin receptor 2 (PKR2)
DMCLA2D	MT	DTT
DMCLA2D	MA	Antagonist
DMCLA2D	RN	Prokineticin receptor 1 antagonist PC-10 as a biomarker for imaging inflammatory pain. J Nucl Med. 2011 Apr;52(4):600-7.
DMCLA2D	RU	https://pubmed.ncbi.nlm.nih.gov/21421710

DMCLA2D	DI	DMCLA2D
DMCLA2D	DN	triazine compound PC10
DMCLA2D	MI	TTB9CIL
DMCLA2D	MN	Prokineticin receptor-1 (PROKR1)
DMCLA2D	MT	DTT
DMCLA2D	MA	Antagonist
DMCLA2D	RN	Prokineticin receptor 1 antagonist PC-10 as a biomarker for imaging inflammatory pain. J Nucl Med. 2011 Apr;52(4):600-7.
DMCLA2D	RU	https://pubmed.ncbi.nlm.nih.gov/21421710

DM1F2K0	DI	DM1F2K0
DM1F2K0	DN	Triazolopyridine
DM1F2K0	MI	TTQBR95
DM1F2K0	MN	Stress-activated protein kinase 2a (p38 alpha)
DM1F2K0	MT	DTT
DM1F2K0	MA	Inhibitor
DM1F2K0	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM1F2K0	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM5ZBF3	DI	DM5ZBF3
DM5ZBF3	DN	TRIAZOLOPYRIMIDINE
DM5ZBF3	MI	TT7HF4W
DM5ZBF3	MN	Cyclin-dependent kinase 2 (CDK2)
DM5ZBF3	MT	DTT
DM5ZBF3	MA	Inhibitor
DM5ZBF3	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM5ZBF3	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMYSX0K	DI	DMYSX0K
DMYSX0K	DN	Tribenzyl 2-aminopropane-1,2,3-tricarboxylate
DMYSX0K	MI	TTHI19T
DMYSX0K	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMYSX0K	MT	DTT
DMYSX0K	MA	Inhibitor
DMYSX0K	RN	Discovery of novel lipophilic inhibitors of OXA-10 enzyme (class D beta-lactamase) by screening amino analogs and homologs of citrate and isocitrate. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3593-7.
DMYSX0K	RU	https://pubmed.ncbi.nlm.nih.gov/19467869

DMHN7CB	DI	DMHN7CB
DMHN7CB	DN	Tributylstannanyl
DMHN7CB	MI	TT6PEUO
DMHN7CB	MN	Retinoic acid receptor RXR-alpha (RXRA)
DMHN7CB	MT	DTT
DMHN7CB	MA	Inhibitor
DMHN7CB	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMHN7CB	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMLKWTG	DI	DMLKWTG
DMLKWTG	DN	Tricarballylic Acid
DMLKWTG	MI	TTMTF2P
DMLKWTG	MN	Citrate hydro-lyase (ACO2)
DMLKWTG	MT	DTT
DMLKWTG	MA	Inhibitor
DMLKWTG	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMLKWTG	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMNALMF	DI	DMNALMF
DMNALMF	DN	trichloroethanol
DMNALMF	MI	TTPC4TU
DMNALMF	MN	5-HT 3A receptor (HTR3A)
DMNALMF	MT	DTT
DMNALMF	MA	Modulator (allosteric modulator)
DMNALMF	RN	Arginine 246 of the pretransmembrane domain 1 region alters 2,2,2-trichloroethanol action in the 5-hydroxytryptamine3A receptor. J Pharmacol Exp Ther. 2008 Mar;324(3):1011-8.
DMNALMF	RU	https://pubmed.ncbi.nlm.nih.gov/18094321

DMNALMF	DI	DMNALMF
DMNALMF	DN	trichloroethanol
DMNALMF	MI	TTR6K75
DMNALMF	MN	5-HT 3B receptor (HTR3B)
DMNALMF	MT	DTT
DMNALMF	MA	Modulator (allosteric modulator)
DMNALMF	RN	Co-expression of the 5-HT(3B) subunit with the 5-HT(3A) receptor reduces alcohol sensitivity. Brain Res Mol Brain Res. 2005 Dec 14;142(2):146-50.
DMNALMF	RU	https://pubmed.ncbi.nlm.nih.gov/16257471

DM9C8NX	DI	DM9C8NX
DM9C8NX	DN	Trichostatin A
DM9C8NX	MI	TTBH0VX
DM9C8NX	MN	Histone deacetylase (HDAC)
DM9C8NX	MT	DTT
DM9C8NX	MA	Inhibitor
DM9C8NX	RN	Histone deacetylase inhibitors induce apoptosis, histone hyperacetylation and up-regulation of gene transcription in Schistosoma mansoni. Mol Biochem Parasitol. 2009 Nov;168(1):7-15.
DM9C8NX	RU	https://pubmed.ncbi.nlm.nih.gov/19538992

DMYB57J	DI	DMYB57J
DMYB57J	DN	Triclosan monophosphate
DMYB57J	MI	DEA9TJ6
DMYB57J	MN	Alkaline phosphatase (ALP)
DMYB57J	MT	DME
DMYB57J	MA	Metabolism
DMYB57J	RN	Hydrolysis of triclosan monophosphate by dental plaque and selected species of oral micro-organisms. J Dent Res. 1996 Aug;75(8):1578-84.
DMYB57J	RU	https://pubmed.ncbi.nlm.nih.gov/8906126

DM5Q7K8	DI	DM5Q7K8
DM5Q7K8	DN	Triethyl 2-aminopropane-1,2,3-tricarboxylate
DM5Q7K8	MI	TTHI19T
DM5Q7K8	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DM5Q7K8	MT	DTT
DM5Q7K8	MA	Inhibitor
DM5Q7K8	RN	Discovery of novel lipophilic inhibitors of OXA-10 enzyme (class D beta-lactamase) by screening amino analogs and homologs of citrate and isocitrate. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3593-7.
DM5Q7K8	RU	https://pubmed.ncbi.nlm.nih.gov/19467869

DMUPK6G	DI	DMUPK6G
DMUPK6G	DN	Triethylcholine
DMUPK6G	MI	DTWI9TE
DMUPK6G	MN	High affinity choline transporter 1 (SLC5A7)
DMUPK6G	MT	DTP
DMUPK6G	MA	Substrate
DMUPK6G	RN	The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. Nucleic Acids Res. 2018 Jan 4;46(D1):D1091-D1106. (familyId=172)
DMUPK6G	RU	http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=172

DMAWTUL	DI	DMAWTUL
DMAWTUL	DN	Trifluoroethanol
DMAWTUL	MI	TTJS7O4
DMAWTUL	MN	Entamoeba Alcohol dehydrogenase 2 (Entamo ADH2)
DMAWTUL	MT	DTT
DMAWTUL	MA	Inhibitor
DMAWTUL	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMAWTUL	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DM4IKBV	DI	DM4IKBV
DM4IKBV	DN	Trifluoromethionine
DM4IKBV	MI	TT1UY5C
DM4IKBV	MN	Pseudomonas Methionine gamma-lyase (Pseudo mdeA)
DM4IKBV	MT	DTT
DM4IKBV	MA	Inhibitor
DM4IKBV	RN	Kinetic characterization of methionine gamma-lyases from the enteric protozoan parasite Entamoeba histolytica against physiological substrates and trifluoromethionine, a promising lead compound against amoebiasis. FEBS J. 2008 Feb;275(3):548-60.
DM4IKBV	RU	https://pubmed.ncbi.nlm.nih.gov/18199285

DMEPFAB	DI	DMEPFAB
DMEPFAB	DN	Trifluoromethylketone
DMEPFAB	MI	TTBH0VX
DMEPFAB	MN	Histone deacetylase (HDAC)
DMEPFAB	MT	DTT
DMEPFAB	MA	Inhibitor
DMEPFAB	RN	Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006 Sep;5(9):769-84.
DMEPFAB	RU	https://pubmed.ncbi.nlm.nih.gov/16955068

DMIZX8P	DI	DMIZX8P
DMIZX8P	DN	Triflupromazine
DMIZX8P	MI	TTAIY2U
DMIZX8P	MN	HUMAN clathrin-mediated endocytosis (RME)
DMIZX8P	MT	DTT
DMIZX8P	MA	Inhibitor
DMIZX8P	RN	Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93.
DMIZX8P	RU	https://pubmed.ncbi.nlm.nih.gov/24841273

DMSP56N	DI	DMSP56N
DMSP56N	DN	trihydroxycholestane
DMSP56N	MI	TT7LCTF
DMSP56N	MN	Pregnane X receptor (NR1I2)
DMSP56N	MT	DTT
DMSP56N	MA	Agonist
DMSP56N	RN	Identification of bile acid precursors as endogenous ligands for the nuclear xenobiotic pregnane X receptor. Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):223-8.
DMSP56N	RU	https://pubmed.ncbi.nlm.nih.gov/12509506

DMVJD1A	DI	DMVJD1A
DMVJD1A	DN	Triiodo-l-thyronine
DMVJD1A	MI	DEYWLRK
DMVJD1A	MN	Sulfotransferase 1A1 (SULT1A1)
DMVJD1A	MT	DME
DMVJD1A	MA	Metabolism
DMVJD1A	RN	Characterization of human liver thermostable phenol sulfotransferase (SULT1A1) allozymes with 3,3',5-triiodothyronine as the substrate. J Endocrinol. 2001 Dec;171(3):525-32.
DMVJD1A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11739018

DMNHU4M	DI	DMNHU4M
DMNHU4M	DN	TRIM
DMNHU4M	MI	TTBECWA
DMNHU4M	MN	Transient receptor potential cation channel V2 (TRPV2)
DMNHU4M	MT	DTT
DMNHU4M	MA	Blocker (channel blocker)
DMNHU4M	RN	Pharmacological characterization and molecular determinants of the activation of transient receptor potential V2 channel orthologs by 2-aminoethoxy... Mol Pharmacol. 2007 Nov;72(5):1258-68.
DMNHU4M	RU	https://pubmed.ncbi.nlm.nih.gov/17673572

DMPXHTY	DI	DMPXHTY
DMPXHTY	DN	TRIMEDOXIME
DMPXHTY	MI	TT1RS9F
DMPXHTY	MN	Acetylcholinesterase (AChE)
DMPXHTY	MT	DTT
DMPXHTY	MA	Inhibitor
DMPXHTY	RN	Synthesis of the novel series of bispyridinium compounds bearing (E)-but-2-ene linker and evaluation of their reactivation activity against chlorpy... Bioorg Med Chem Lett. 2006 Feb;16(3):622-7.
DMPXHTY	RU	https://pubmed.ncbi.nlm.nih.gov/16288867

DMQXPMB	DI	DMQXPMB
DMQXPMB	DN	Trimethyl-(3-nitro-phenyl)-ammonium iodide
DMQXPMB	MI	TT1RS9F
DMQXPMB	MN	Acetylcholinesterase (AChE)
DMQXPMB	MT	DTT
DMQXPMB	MA	Inhibitor
DMQXPMB	RN	Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors. J Med Chem. 1996 Dec 20;39(26):5064-71.
DMQXPMB	RU	https://pubmed.ncbi.nlm.nih.gov/8978837

DMJ4I98	DI	DMJ4I98
DMJ4I98	DN	Trimethyl-(4-oxo-pentyl)-ammonium iodide
DMJ4I98	MI	TT1RS9F
DMJ4I98	MN	Acetylcholinesterase (AChE)
DMJ4I98	MT	DTT
DMJ4I98	MA	Inhibitor
DMJ4I98	RN	Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors. J Med Chem. 1996 Dec 20;39(26):5064-71.
DMJ4I98	RU	https://pubmed.ncbi.nlm.nih.gov/8978837

DM8LJ3C	DI	DM8LJ3C
DM8LJ3C	DN	trimethylamine
DM8LJ3C	MI	TTCO25G
DM8LJ3C	MN	Trace amine receptor 5 (TAAR5)
DM8LJ3C	MT	DTT
DM8LJ3C	MA	Agonist
DM8LJ3C	RN	A second class of chemosensory receptors in the olfactory epithelium. Nature. 2006 Aug 10;442(7103):645-50.
DM8LJ3C	RU	https://pubmed.ncbi.nlm.nih.gov/16878137

DMK9743	DI	DMK9743
DMK9743	DN	Trimetoquinol
DMK9743	MI	TTMXGCW
DMK9743	MN	Adrenergic receptor beta-3 (ADRB3)
DMK9743	MT	DTT
DMK9743	MA	Agonist
DMK9743	RN	Synthesis and human beta-adrenoceptor activity of 1-(3,5-diiodo-4- methoxybenzyl)-1,2,3,4-tetrahydroisoquinolin-6-ol derivatives in vitro. J Med Chem. 2000 Feb 24;43(4):591-8.
DMK9743	RU	https://pubmed.ncbi.nlm.nih.gov/10691685

DML3OYH	DI	DML3OYH
DML3OYH	DN	TriMixDC
DML3OYH	MI	TTNCIE0
DML3OYH	MN	CD70 antigen (CD27-L)
DML3OYH	MT	DTT
DML3OYH	RN	Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL). Biomed Res Int. 2013;2013:976383.
DML3OYH	RU	https://pubmed.ncbi.nlm.nih.gov/23509826

DML3OYH	DI	DML3OYH
DML3OYH	DN	TriMixDC
DML3OYH	MI	TTIJP3Q
DML3OYH	MN	TNF related activation protein (CD40LG)
DML3OYH	MT	DTT
DML3OYH	RN	Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL). Biomed Res Int. 2013;2013:976383.
DML3OYH	RU	https://pubmed.ncbi.nlm.nih.gov/23509826

DML3OYH	DI	DML3OYH
DML3OYH	DN	TriMixDC
DML3OYH	MI	TTISGCA
DML3OYH	MN	Toll-like receptor 4 (TLR4)
DML3OYH	MT	DTT
DML3OYH	RN	Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL). Biomed Res Int. 2013;2013:976383.
DML3OYH	RU	https://pubmed.ncbi.nlm.nih.gov/23509826

DM2VIDK	DI	DM2VIDK
DM2VIDK	DN	Triphenylacetic acid methyl ester
DM2VIDK	MI	TTMNI76
DM2VIDK	MN	Calcium-activated potassium channel (KCN)
DM2VIDK	MT	DTT
DM2VIDK	MA	Inhibitor
DM2VIDK	RN	Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82.
DM2VIDK	RU	https://pubmed.ncbi.nlm.nih.gov/18232633

DM3CQIZ	DI	DM3CQIZ
DM3CQIZ	DN	Triphenylmethanamine
DM3CQIZ	MI	TTMNI76
DM3CQIZ	MN	Calcium-activated potassium channel (KCN)
DM3CQIZ	MT	DTT
DM3CQIZ	MA	Inhibitor
DM3CQIZ	RN	Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82.
DM3CQIZ	RU	https://pubmed.ncbi.nlm.nih.gov/18232633

DMF8QR6	DI	DMF8QR6
DMF8QR6	DN	TRIPHLOROETHOL A
DMF8QR6	MI	TT8JRS7
DMF8QR6	MN	Beta-secretase (BACE)
DMF8QR6	MT	DTT
DMF8QR6	MA	Inhibitor
DMF8QR6	RN	Molecular docking studies of phlorotannins from Eisenia bicyclis with BACE1 inhibitory activity. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3211-5.
DMF8QR6	RU	https://pubmed.ncbi.nlm.nih.gov/20462757

DMWZ5FB	DI	DMWZ5FB
DMWZ5FB	DN	tripitramine
DMWZ5FB	MI	TTOXS3C
DMWZ5FB	MN	Muscarinic acetylcholine receptor (CHRM)
DMWZ5FB	MT	DTT
DMWZ5FB	MA	Antagonist
DMWZ5FB	RN	Binding profile of the selective muscarinic receptor antagonist tripitramine. Eur J Pharmacol. 1994 Aug 16;268(3):459-62.
DMWZ5FB	RU	https://pubmed.ncbi.nlm.nih.gov/7805774

DMWZ5FB	DI	DMWZ5FB
DMWZ5FB	DN	tripitramine
DMWZ5FB	MI	TTQ13Z5
DMWZ5FB	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMWZ5FB	MT	DTT
DMWZ5FB	MA	Antagonist
DMWZ5FB	RN	Design, synthesis, and biological evaluation of pirenzepine analogs bearing a 1,2-cyclohexanediamine and perhydroquinoxaline units in exchange for the piperazine ring as antimuscarinics. Bioorg Med Chem. 2008 Aug 1;16(15):7311-20.
DMWZ5FB	RU	https://pubmed.ncbi.nlm.nih.gov/18595721

DMBYV3M	DI	DMBYV3M
DMBYV3M	DN	TRIPTOCALLINE A
DMBYV3M	MI	TTFBNVI
DMBYV3M	MN	Aldose reductase (AKR1B1)
DMBYV3M	MT	DTT
DMBYV3M	MA	Inhibitor
DMBYV3M	RN	Structures of new friedelane-type triterpenes and eudesmane-type sesquiterpene and aldose reductase inhibitors from Salacia chinensis. J Nat Prod. 2003 Sep;66(9):1191-6.
DMBYV3M	RU	https://pubmed.ncbi.nlm.nih.gov/14510595

DM6USPC	DI	DM6USPC
DM6USPC	DN	TRISMETHOXYRESVERATROL
DM6USPC	MI	TTI84H7
DM6USPC	MN	Cytochrome P450 1B1 (CYP1B1)
DM6USPC	MT	DTT
DM6USPC	MA	Inhibitor
DM6USPC	RN	Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors. J Med Chem. 2002 Jan 3;45(1):160-4.
DM6USPC	RU	https://pubmed.ncbi.nlm.nih.gov/11754588

DM6USPC	DI	DM6USPC
DM6USPC	DN	TRISMETHOXYRESVERATROL
DM6USPC	MI	TT3OT40
DM6USPC	MN	Multidrug resistance protein 1 (ABCB1)
DM6USPC	MT	DTT
DM6USPC	MA	Inhibitor
DM6USPC	RN	Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells. J Med Chem. 2006 May 18;49(10):3012-8.
DM6USPC	RU	https://pubmed.ncbi.nlm.nih.gov/16686543

DM6USPC	DI	DM6USPC
DM6USPC	DN	TRISMETHOXYRESVERATROL
DM6USPC	MI	TT3PJMV
DM6USPC	MN	Tyrosine-protein kinase ABL1 (ABL)
DM6USPC	MT	DTT
DM6USPC	MA	Inhibitor
DM6USPC	RN	Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells. J Med Chem. 2006 May 18;49(10):3012-8.
DM6USPC	RU	https://pubmed.ncbi.nlm.nih.gov/16686543

DMQVH3J	DI	DMQVH3J
DMQVH3J	DN	Trisnorsqualene alcohol
DMQVH3J	MI	TTE14XG
DMQVH3J	MN	Squalene monooxygenase (SQLE)
DMQVH3J	MT	DTT
DMQVH3J	MA	Inhibitor
DMQVH3J	RN	Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4.
DMQVH3J	RU	https://pubmed.ncbi.nlm.nih.gov/11520216

DM0G2IR	DI	DM0G2IR
DM0G2IR	DN	Trisnorsqualene cyclopropylamine
DM0G2IR	MI	TTE14XG
DM0G2IR	MN	Squalene monooxygenase (SQLE)
DM0G2IR	MT	DTT
DM0G2IR	MA	Inhibitor
DM0G2IR	RN	Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4.
DM0G2IR	RU	https://pubmed.ncbi.nlm.nih.gov/11520216

DMQA7ZS	DI	DMQA7ZS
DMQA7ZS	DN	Trisnorsqualene difluoromethylidene
DMQA7ZS	MI	TTE14XG
DMQA7ZS	MN	Squalene monooxygenase (SQLE)
DMQA7ZS	MT	DTT
DMQA7ZS	MA	Inhibitor
DMQA7ZS	RN	Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4.
DMQA7ZS	RU	https://pubmed.ncbi.nlm.nih.gov/11520216

DMPVI3A	DI	DMPVI3A
DMPVI3A	DN	Trisodium phosphate
DMPVI3A	MI	TTZHA0O
DMPVI3A	MN	Carbonic anhydrase IV (CA-IV)
DMPVI3A	MT	DTT
DMPVI3A	MA	Inhibitor
DMPVI3A	RN	Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with phosphates, carbamoyl phosphate, and the phosphonate antiviral dru... Bioorg Med Chem Lett. 2004 Dec 6;14(23):5763-7.
DMPVI3A	RU	https://pubmed.ncbi.nlm.nih.gov/15501037

DMBZI5F	DI	DMBZI5F
DMBZI5F	DN	TrkB NAM
DMBZI5F	MI	TTKN7QR
DMBZI5F	MN	BDNF/NT-3 growth factors receptor (TrkB)
DMBZI5F	MT	DTT
DMBZI5F	MA	Modulator
DMBZI5F	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1818).
DMBZI5F	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1818

DMU3E1M	DI	DMU3E1M
DMU3E1M	DN	TRL-382
DMU3E1M	MI	TT8NGED
DMU3E1M	MN	Prostaglandin G/H synthase 1 (COX-1)
DMU3E1M	MT	DTT
DMU3E1M	MA	Inhibitor
DMU3E1M	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1375).
DMU3E1M	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1375

DMXNSTF	DI	DMXNSTF
DMXNSTF	DN	TRN-101
DMXNSTF	MI	TTZN7RP
DMXNSTF	MN	Rho-associated protein kinase 1 (ROCK1)
DMXNSTF	MT	DTT
DMXNSTF	MA	Inhibitor
DMXNSTF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1503).
DMXNSTF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1503

DMXNSTF	DI	DMXNSTF
DMXNSTF	DN	TRN-101
DMXNSTF	MI	TTGWKQJ
DMXNSTF	MN	Rho-associated protein kinase 2 (ROCK2)
DMXNSTF	MT	DTT
DMXNSTF	MA	Inhibitor
DMXNSTF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1504).
DMXNSTF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1504

DMOMXP7	DI	DMOMXP7
DMOMXP7	DN	TROPOLONE
DMOMXP7	MI	TTULVH8
DMOMXP7	MN	Tyrosinase (TYR)
DMOMXP7	MT	DTT
DMOMXP7	MA	Inhibitor
DMOMXP7	RN	Discovery of 4-functionalized phenyl-O-beta-D-glycosides as a new class of mushroom tyrosinase inhibitors. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6157-60.
DMOMXP7	RU	https://pubmed.ncbi.nlm.nih.gov/19800229

DMIF6NS	DI	DMIF6NS
DMIF6NS	DN	TROX-1
DMIF6NS	MI	TT4FDG6
DMIF6NS	MN	Voltage-gated calcium channel alpha Cav2.2 (CACNA1B)
DMIF6NS	MT	DTT
DMIF6NS	MA	Inhibitor (gating inhibitor)
DMIF6NS	RN	Analgesic effects of a substituted N-triazole oxindole (TROX-1), a state-dependent, voltage-gated calcium channel 2 blocker. J Pharmacol Exp Ther. 2010 Aug;334(2):545-55.
DMIF6NS	RU	https://pubmed.ncbi.nlm.nih.gov/20439438

DM48QTG	DI	DM48QTG
DM48QTG	DN	Trp-Ile-Ile-Asp-Leu-Hisc(Cys-Ser-Val-Tyr-Phe-Cys)
DM48QTG	MI	TTKRD0G
DM48QTG	MN	Endothelin A receptor (EDNRA)
DM48QTG	MT	DTT
DM48QTG	MA	Inhibitor
DM48QTG	RN	Structure-activity relationships in a series of monocyclic endothelin analogues, Bioorg. Med. Chem. Lett. 4(4):567-572 (1994).
DM48QTG	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01801566

DM48QTG	DI	DM48QTG
DM48QTG	DN	Trp-Ile-Ile-Asp-Leu-Hisc(Cys-Ser-Val-Tyr-Phe-Cys)
DM48QTG	MI	TT3ZTGU
DM48QTG	MN	Endothelin B receptor (EDNRB)
DM48QTG	MT	DTT
DM48QTG	MA	Inhibitor
DM48QTG	RN	Structure-activity relationships in a series of monocyclic endothelin analogues, Bioorg. Med. Chem. Lett. 4(4):567-572 (1994).
DM48QTG	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01801566

DMOZX8M	DI	DMOZX8M
DMOZX8M	DN	Trp-Ile-Ile-Asp-Leu-Hisc(Cys-Val-Tyr-Phe-Cys)
DMOZX8M	MI	TTKRD0G
DMOZX8M	MN	Endothelin A receptor (EDNRA)
DMOZX8M	MT	DTT
DMOZX8M	MA	Inhibitor
DMOZX8M	RN	Structure-activity relationships in a series of monocyclic endothelin analogues, Bioorg. Med. Chem. Lett. 4(4):567-572 (1994).
DMOZX8M	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01801566

DMOZX8M	DI	DMOZX8M
DMOZX8M	DN	Trp-Ile-Ile-Asp-Leu-Hisc(Cys-Val-Tyr-Phe-Cys)
DMOZX8M	MI	TT3ZTGU
DMOZX8M	MN	Endothelin B receptor (EDNRB)
DMOZX8M	MT	DTT
DMOZX8M	MA	Inhibitor
DMOZX8M	RN	Structure-activity relationships in a series of monocyclic endothelin analogues, Bioorg. Med. Chem. Lett. 4(4):567-572 (1994).
DMOZX8M	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01801566

DMDUGQ1	DI	DMDUGQ1
DMDUGQ1	DN	Trypanothione
DMDUGQ1	MI	TTRTKPV
DMDUGQ1	MN	Trypanosoma Trypanothione reductase (Trypano TPR)
DMDUGQ1	MT	DTT
DMDUGQ1	MA	Inhibitor
DMDUGQ1	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMDUGQ1	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMTRYCI	DI	DMTRYCI
DMTRYCI	DN	tryptanthrin
DMTRYCI	MI	TTZJYKH
DMTRYCI	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMTRYCI	MT	DTT
DMTRYCI	MA	Inhibitor
DMTRYCI	RN	Discovery of tryptanthrin derivatives as potent inhibitors of indoleamine 2,3-dioxygenase with therapeutic activity in Lewis lung cancer (LLC) tumor-bearing mice. J Med Chem. 2013 Nov 14;56(21):8321-31.
DMTRYCI	RU	https://pubmed.ncbi.nlm.nih.gov/24099220

DMV19K7	DI	DMV19K7
DMV19K7	DN	TRYPTOLINE
DMV19K7	MI	TTJQOD7
DMV19K7	MN	5-HT 2A receptor (HTR2A)
DMV19K7	MT	DTT
DMV19K7	MA	Inhibitor
DMV19K7	RN	Binding of beta-carbolines at 5-HT(2) serotonin receptors. Bioorg Med Chem Lett. 2003 Dec 15;13(24):4421-5.
DMV19K7	RU	https://pubmed.ncbi.nlm.nih.gov/14643338

DMV19K7	DI	DMV19K7
DMV19K7	DN	TRYPTOLINE
DMV19K7	MI	TTWG9A4
DMV19K7	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMV19K7	MT	DTT
DMV19K7	MA	Inhibitor
DMV19K7	RN	Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9.
DMV19K7	RU	https://pubmed.ncbi.nlm.nih.gov/14698196

DMV19K7	DI	DMV19K7
DMV19K7	DN	TRYPTOLINE
DMV19K7	MI	TTWM4TY
DMV19K7	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMV19K7	MT	DTT
DMV19K7	MA	Inhibitor
DMV19K7	RN	Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9.
DMV19K7	RU	https://pubmed.ncbi.nlm.nih.gov/14698196

DMV19K7	DI	DMV19K7
DMV19K7	DN	TRYPTOLINE
DMV19K7	MI	TT2NUT5
DMV19K7	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMV19K7	MT	DTT
DMV19K7	MA	Inhibitor
DMV19K7	RN	Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9.
DMV19K7	RU	https://pubmed.ncbi.nlm.nih.gov/14698196

DMV19K7	DI	DMV19K7
DMV19K7	DN	TRYPTOLINE
DMV19K7	MI	TT3WG5C
DMV19K7	MN	Monoamine oxidase type A (MAO-A)
DMV19K7	MT	DTT
DMV19K7	MA	Inhibitor
DMV19K7	RN	Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9.
DMV19K7	RU	https://pubmed.ncbi.nlm.nih.gov/14698196

DMV19K7	DI	DMV19K7
DMV19K7	DN	TRYPTOLINE
DMV19K7	MI	TTGP7BY
DMV19K7	MN	Monoamine oxidase type B (MAO-B)
DMV19K7	MT	DTT
DMV19K7	MA	Inhibitor
DMV19K7	RN	Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9.
DMV19K7	RU	https://pubmed.ncbi.nlm.nih.gov/14698196

DMIV75Q	DI	DMIV75Q
DMIV75Q	DN	TS antisense + raltitrexed
DMIV75Q	MI	TTP1UKZ
DMIV75Q	MN	Thymidylate synthase messenger RNA (TYMS mRNA)
DMIV75Q	MT	DTT
DMIV75Q	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DMIV75Q	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DM6JF7T	DI	DM6JF7T
DM6JF7T	DN	TSERaM
DM6JF7T	MI	TTZAYWL
DM6JF7T	MN	Estrogen receptor (ESR)
DM6JF7T	MT	DTT
DM6JF7T	MA	Modulator
DM6JF7T	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620).
DM6JF7T	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=620

DM6NZFH	DI	DM6NZFH
DM6NZFH	DN	TTH 03-001
DM6NZFH	MI	TTNVEIR
DM6NZFH	MN	Prostaglandin D2 receptor (PTGDR)
DM6NZFH	MT	DTT
DM6NZFH	MA	Modulator
DM6NZFH	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 338).
DM6NZFH	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=338

DMDM7C6	DI	DMDM7C6
DMDM7C6	DN	TTL-1177
DMDM7C6	MI	TTZPWGN
DMDM7C6	MN	Voltage-gated calcium channel alpha Cav3.2 (CACNA1H)
DMDM7C6	MT	DTT
DMDM7C6	MA	Inhibitor
DMDM7C6	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 536).
DMDM7C6	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=536

DMSABD0	DI	DMSABD0
DMSABD0	DN	TTNPB
DMSABD0	MI	TTISP28
DMSABD0	MN	Retinoic acid receptor beta (RARB)
DMSABD0	MT	DTT
DMSABD0	MA	Inhibitor
DMSABD0	RN	9-cis-retinoic acid analogues with bulky hydrophobic rings: new RXR-selective agonists. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6117-22.
DMSABD0	RU	https://pubmed.ncbi.nlm.nih.gov/15546741

DMUR0TF	DI	DMUR0TF
DMUR0TF	DN	Tu-514
DMUR0TF	MI	TT0OFWN
DMUR0TF	MN	Pseudomonas UDP-3-O-acyl-GlcNAc deacetylase (Pseudo lpxC)
DMUR0TF	MT	DTT
DMUR0TF	MA	Inhibitor
DMUR0TF	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMUR0TF	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMYR8SG	DI	DMYR8SG
DMYR8SG	DN	Tubacin
DMYR8SG	MI	TT5ZKDI
DMYR8SG	MN	Histone deacetylase 6 (HDAC6)
DMYR8SG	MT	DTT
DMYR8SG	MA	Inhibitor
DMYR8SG	RN	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
DMYR8SG	RU	https://pubmed.ncbi.nlm.nih.gov/19249983

DMHICK8	DI	DMHICK8
DMHICK8	DN	Tubercidin
DMHICK8	MI	DTZAWTH
DMHICK8	MN	Equilibrative nucleoside transporter 3 (SLC29A3)
DMHICK8	MT	DTP
DMHICK8	MA	Substrate
DMHICK8	RN	Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes. J Biol Chem. 2005 Apr 22;280(16):15880-7.
DMHICK8	RU	http://www.ncbi.nlm.nih.gov/pubmed/15701636

DM2H0PQ	DI	DM2H0PQ
DM2H0PQ	DN	TUG-424
DM2H0PQ	MI	TTB8FUC
DM2H0PQ	MN	Free fatty acid receptor 1 (GPR40)
DM2H0PQ	MT	DTT
DM2H0PQ	MA	Agonist
DM2H0PQ	RN	Discovery of potent and selective agonists for the free fatty acid receptor 1 (FFA(1)/GPR40), a potential target for the treatment of type II diabetes. J Med Chem. 2008 Nov 27;51(22):7061-4.
DM2H0PQ	RU	https://pubmed.ncbi.nlm.nih.gov/18947221

DM8YN42	DI	DM8YN42
DM8YN42	DN	TUG-469
DM8YN42	MI	TTB8FUC
DM8YN42	MN	Free fatty acid receptor 1 (GPR40)
DM8YN42	MT	DTT
DM8YN42	MA	Agonist
DM8YN42	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 225).
DM8YN42	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=225

DM487HF	DI	DM487HF
DM487HF	DN	TUG-770
DM487HF	MI	TTB8FUC
DM487HF	MN	Free fatty acid receptor 1 (GPR40)
DM487HF	MT	DTT
DM487HF	MA	Agonist
DM487HF	RN	Discovery of TUG-770: A Highly Potent Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist for Treatment of Type 2 Diabetes. ACS Med Chem Lett. 2013 May 9;4(5):441-445.
DM487HF	RU	https://pubmed.ncbi.nlm.nih.gov/23687558

DMJRGZT	DI	DMJRGZT
DMJRGZT	DN	TUG-891
DMJRGZT	MI	TT08JVB
DMJRGZT	MN	G-protein coupled receptor 120 (GPR120)
DMJRGZT	MT	DTT
DMJRGZT	MA	Agonist
DMJRGZT	RN	Discovery of a potent and selective GPR120 agonist. J Med Chem. 2012 May 10;55(9):4511-5.
DMJRGZT	RU	https://pubmed.ncbi.nlm.nih.gov/22519963

DMIRQ65	DI	DMIRQ65
DMIRQ65	DN	Tumor vascular thrombogen
DMIRQ65	MI	TT6L509
DMIRQ65	MN	Coagulation factor IIa (F2)
DMIRQ65	MT	DTT
DMIRQ65	MA	Modulator
DMIRQ65	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362).
DMIRQ65	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2362

DMAUTRP	DI	DMAUTRP
DMAUTRP	DN	TUPICHINOL C
DMAUTRP	MI	TTOM3J0
DMAUTRP	MN	Estrogen receptor beta (ESR2)
DMAUTRP	MT	DTT
DMAUTRP	MA	Inhibitor
DMAUTRP	RN	New estrogenic compounds isolated from Broussonetia kazinoki. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3764-7.
DMAUTRP	RU	https://pubmed.ncbi.nlm.nih.gov/20493686

DMLDYVB	DI	DMLDYVB
DMLDYVB	DN	TURBINATINE
DMLDYVB	MI	TT1RS9F
DMLDYVB	MN	Acetylcholinesterase (AChE)
DMLDYVB	MT	DTT
DMLDYVB	MA	Inhibitor
DMLDYVB	RN	Indole glucoalkaloids from Chimarrhis turbinata and their evaluation as antioxidant agents and acetylcholinesterase inhibitors. J Nat Prod. 2004 Nov;67(11):1882-5.
DMLDYVB	RU	https://pubmed.ncbi.nlm.nih.gov/15568781

DM3QE8P	DI	DM3QE8P
DM3QE8P	DN	Turmeric extracts
DM3QE8P	MI	TTE4KHA
DM3QE8P	MN	Amyloid beta A4 protein (APP)
DM3QE8P	MT	DTT
DM3QE8P	MA	Inhibitor
DM3QE8P	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
DM3QE8P	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402

DMDE8YS	DI	DMDE8YS
DMDE8YS	DN	TW-37
DMDE8YS	MI	TTJGNVC
DMDE8YS	MN	Apoptosis regulator Bcl-2 (BCL-2)
DMDE8YS	MT	DTT
DMDE8YS	MA	Inhibitor
DMDE8YS	RN	Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem. 2006 Oct 19;49(21):6139-42.
DMDE8YS	RU	https://pubmed.ncbi.nlm.nih.gov/17034116

DMDE8YS	DI	DMDE8YS
DMDE8YS	DN	TW-37
DMDE8YS	MI	TTRE6AX
DMDE8YS	MN	Bcl-x messenger RNA (BCL2L1 mRNA)
DMDE8YS	MT	DTT
DMDE8YS	MA	Inhibitor
DMDE8YS	RN	Fragment-based deconstruction of Bcl-xL inhibitors. J Med Chem. 2010 Mar 25;53(6):2577-88.
DMDE8YS	RU	https://pubmed.ncbi.nlm.nih.gov/20192224

DMDE8YS	DI	DMDE8YS
DMDE8YS	DN	TW-37
DMDE8YS	MI	TTL53M6
DMDE8YS	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DMDE8YS	MT	DTT
DMDE8YS	MA	Inhibitor
DMDE8YS	RN	Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem. 2006 Oct 19;49(21):6139-42.
DMDE8YS	RU	https://pubmed.ncbi.nlm.nih.gov/17034116

DMS29M4	DI	DMS29M4
DMS29M4	DN	TWS-119
DMS29M4	MI	TTRSMW9
DMS29M4	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMS29M4	MT	DTT
DMS29M4	MA	Inhibitor
DMS29M4	RN	Diversity-oriented synthesis: exploring the intersections between chemistry and biology. Nat Chem Biol. 2005 Jul;1(2):74-84.
DMS29M4	RU	https://pubmed.ncbi.nlm.nih.gov/16408003

DMS29M4	DI	DMS29M4
DMS29M4	DN	TWS-119
DMS29M4	MI	TTZILNJ
DMS29M4	MN	Proto-oncogene c-Myc (MYC)
DMS29M4	MT	DTT
DMS29M4	MA	Inhibitor
DMS29M4	RN	Diversity-oriented synthesis: exploring the intersections between chemistry and biology. Nat Chem Biol. 2005 Jul;1(2):74-84.
DMS29M4	RU	https://pubmed.ncbi.nlm.nih.gov/16408003

DMS29M4	DI	DMS29M4
DMS29M4	DN	TWS-119
DMS29M4	MI	TTN3GBV
DMS29M4	MN	Transcription factor AP-1 (JUN)
DMS29M4	MT	DTT
DMS29M4	MA	Inhibitor
DMS29M4	RN	Diversity-oriented synthesis: exploring the intersections between chemistry and biology. Nat Chem Biol. 2005 Jul;1(2):74-84.
DMS29M4	RU	https://pubmed.ncbi.nlm.nih.gov/16408003

DMHFCZA	DI	DMHFCZA
DMHFCZA	DN	Tylophorinidine
DMHFCZA	MI	TT9SL3Q
DMHFCZA	MN	Polypeptide deformylase (PDF)
DMHFCZA	MT	DTT
DMHFCZA	MA	Inhibitor
DMHFCZA	RN	Inhibition of dihydrofolate reductase and cell growth activity by the phenanthroindolizidine alkaloids pergularinine and tylophorinidine: the in vitro cytotoxicity of these plant alkaloids and their potential as antimicrobial and anticancer agents. Toxicol In Vitro. 2000 Feb;14(1):53-9.
DMHFCZA	RU	https://pubmed.ncbi.nlm.nih.gov/10699361

DMIWPKB	DI	DMIWPKB
DMIWPKB	DN	Tyr-(NMe)Ala-L-Phe-D-Pro-NH2
DMIWPKB	MI	TT27RFC
DMIWPKB	MN	Opioid receptor delta (OPRD1)
DMIWPKB	MT	DTT
DMIWPKB	MA	Inhibitor
DMIWPKB	RN	A topochemical approach to explain morphiceptin bioactivity. J Med Chem. 1993 Mar 19;36(6):708-19.
DMIWPKB	RU	https://pubmed.ncbi.nlm.nih.gov/8384662

DMIWPKB	DI	DMIWPKB
DMIWPKB	DN	Tyr-(NMe)Ala-L-Phe-D-Pro-NH2
DMIWPKB	MI	TTKWM86
DMIWPKB	MN	Opioid receptor mu (MOP)
DMIWPKB	MT	DTT
DMIWPKB	MA	Inhibitor
DMIWPKB	RN	A topochemical approach to explain morphiceptin bioactivity. J Med Chem. 1993 Mar 19;36(6):708-19.
DMIWPKB	RU	https://pubmed.ncbi.nlm.nih.gov/8384662

DMDQJUO	DI	DMDQJUO
DMDQJUO	DN	Tyr-(R)-Aba-Gly-Phe-NH2
DMDQJUO	MI	TT27RFC
DMDQJUO	MN	Opioid receptor delta (OPRD1)
DMDQJUO	MT	DTT
DMDQJUO	MA	Inhibitor
DMDQJUO	RN	Endomorphin-2 with a beta-turn backbone constraint retains the potent micro-opioid receptor agonist properties. J Med Chem. 2008 Jan 10;51(1):173-7.
DMDQJUO	RU	https://pubmed.ncbi.nlm.nih.gov/18062664

DMDQJUO	DI	DMDQJUO
DMDQJUO	DN	Tyr-(R)-Aba-Gly-Phe-NH2
DMDQJUO	MI	TTKWM86
DMDQJUO	MN	Opioid receptor mu (MOP)
DMDQJUO	MT	DTT
DMDQJUO	MA	Inhibitor
DMDQJUO	RN	Endomorphin-2 with a beta-turn backbone constraint retains the potent micro-opioid receptor agonist properties. J Med Chem. 2008 Jan 10;51(1):173-7.
DMDQJUO	RU	https://pubmed.ncbi.nlm.nih.gov/18062664

DMHNM3K	DI	DMHNM3K
DMHNM3K	DN	Tyr-(R)-spiro-Aba-Gly-Phe-NH2
DMHNM3K	MI	TTKWM86
DMHNM3K	MN	Opioid receptor mu (MOP)
DMHNM3K	MT	DTT
DMHNM3K	MA	Inhibitor
DMHNM3K	RN	Endomorphin-2 with a beta-turn backbone constraint retains the potent micro-opioid receptor agonist properties. J Med Chem. 2008 Jan 10;51(1):173-7.
DMHNM3K	RU	https://pubmed.ncbi.nlm.nih.gov/18062664

DMYZ792	DI	DMYZ792
DMYZ792	DN	Tyr-(S)-Aba-Gly-Phe-NH2
DMYZ792	MI	TT27RFC
DMYZ792	MN	Opioid receptor delta (OPRD1)
DMYZ792	MT	DTT
DMYZ792	MA	Inhibitor
DMYZ792	RN	Endomorphin-2 with a beta-turn backbone constraint retains the potent micro-opioid receptor agonist properties. J Med Chem. 2008 Jan 10;51(1):173-7.
DMYZ792	RU	https://pubmed.ncbi.nlm.nih.gov/18062664

DMYZ792	DI	DMYZ792
DMYZ792	DN	Tyr-(S)-Aba-Gly-Phe-NH2
DMYZ792	MI	TTKWM86
DMYZ792	MN	Opioid receptor mu (MOP)
DMYZ792	MT	DTT
DMYZ792	MA	Inhibitor
DMYZ792	RN	Endomorphin-2 with a beta-turn backbone constraint retains the potent micro-opioid receptor agonist properties. J Med Chem. 2008 Jan 10;51(1):173-7.
DMYZ792	RU	https://pubmed.ncbi.nlm.nih.gov/18062664

DMT316S	DI	DMT316S
DMT316S	DN	Tyr-(S)-spiro-Aba-Gly-Phe-NH2
DMT316S	MI	TT27RFC
DMT316S	MN	Opioid receptor delta (OPRD1)
DMT316S	MT	DTT
DMT316S	MA	Inhibitor
DMT316S	RN	Endomorphin-2 with a beta-turn backbone constraint retains the potent micro-opioid receptor agonist properties. J Med Chem. 2008 Jan 10;51(1):173-7.
DMT316S	RU	https://pubmed.ncbi.nlm.nih.gov/18062664

DMT316S	DI	DMT316S
DMT316S	DN	Tyr-(S)-spiro-Aba-Gly-Phe-NH2
DMT316S	MI	TTKWM86
DMT316S	MN	Opioid receptor mu (MOP)
DMT316S	MT	DTT
DMT316S	MA	Inhibitor
DMT316S	RN	Endomorphin-2 with a beta-turn backbone constraint retains the potent micro-opioid receptor agonist properties. J Med Chem. 2008 Jan 10;51(1):173-7.
DMT316S	RU	https://pubmed.ncbi.nlm.nih.gov/18062664

DM4UXT1	DI	DM4UXT1
DM4UXT1	DN	Tyramine
DM4UXT1	MI	DE6SOC5
DM4UXT1	MN	Copper amine oxidase (AOC3)
DM4UXT1	MT	DME
DM4UXT1	MA	Metabolism
DM4UXT1	RN	The unique substrate specificity of human AOC2, a semicarbazide-sensitive amine oxidase. Cell Mol Life Sci. 2009 Aug;66(16):2743-57.
DM4UXT1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19588076

DM4UXT1	DI	DM4UXT1
DM4UXT1	DN	Tyramine
DM4UXT1	MI	DTT79CX
DM4UXT1	MN	Organic cation transporter 1 (SLC22A1)
DM4UXT1	MT	DTP
DM4UXT1	MA	Substrate
DM4UXT1	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM4UXT1	RU	https://doi.org/10.1007/s11095-012-0935-x

DM4UXT1	DI	DM4UXT1
DM4UXT1	DN	Tyramine
DM4UXT1	MI	DE8DP90
DM4UXT1	MN	Semicarbazide-sensitive amine oxidase (AOC2)
DM4UXT1	MT	DME
DM4UXT1	MA	Metabolism
DM4UXT1	RN	The unique substrate specificity of human AOC2, a semicarbazide-sensitive amine oxidase. Cell Mol Life Sci. 2009 Aug;66(16):2743-57.
DM4UXT1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19588076

DM4UXT1	DI	DM4UXT1
DM4UXT1	DN	Tyramine
DM4UXT1	MI	TTIU98M
DM4UXT1	MN	Trace amine-associated receptor-1 (TAAR1)
DM4UXT1	MT	DTT
DM4UXT1	MA	Agonist
DM4UXT1	RN	Differential modulation of Beta-adrenergic receptor signaling by trace amine-associated receptor 1 agonists. PLoS One. 2011;6(10):e27073.
DM4UXT1	RU	https://pubmed.ncbi.nlm.nih.gov/22073124

DM0D1Z5	DI	DM0D1Z5
DM0D1Z5	DN	Tyr-D-Ala-Gly-D-Trp-Nle-Asp-Phe-NH2
DM0D1Z5	MI	TTCG0AL
DM0D1Z5	MN	Cholecystokinin receptor type A (CCKAR)
DM0D1Z5	MT	DTT
DM0D1Z5	MA	Inhibitor
DM0D1Z5	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DM0D1Z5	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DM0D1Z5	DI	DM0D1Z5
DM0D1Z5	DN	Tyr-D-Ala-Gly-D-Trp-Nle-Asp-Phe-NH2
DM0D1Z5	MI	TTVFO0U
DM0D1Z5	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DM0D1Z5	MT	DTT
DM0D1Z5	MA	Inhibitor
DM0D1Z5	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DM0D1Z5	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DM0D1Z5	DI	DM0D1Z5
DM0D1Z5	DN	Tyr-D-Ala-Gly-D-Trp-Nle-Asp-Phe-NH2
DM0D1Z5	MI	TT27RFC
DM0D1Z5	MN	Opioid receptor delta (OPRD1)
DM0D1Z5	MT	DTT
DM0D1Z5	MA	Inhibitor
DM0D1Z5	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DM0D1Z5	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DM0D1Z5	DI	DM0D1Z5
DM0D1Z5	DN	Tyr-D-Ala-Gly-D-Trp-Nle-Asp-Phe-NH2
DM0D1Z5	MI	TTKWM86
DM0D1Z5	MN	Opioid receptor mu (MOP)
DM0D1Z5	MT	DTT
DM0D1Z5	MA	Inhibitor
DM0D1Z5	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DM0D1Z5	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMPH1G0	DI	DMPH1G0
DMPH1G0	DN	Tyr-D-Ala-Gly-D-Trp-NMeNle-Asp-Phe-NH2
DMPH1G0	MI	TTCG0AL
DMPH1G0	MN	Cholecystokinin receptor type A (CCKAR)
DMPH1G0	MT	DTT
DMPH1G0	MA	Inhibitor
DMPH1G0	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMPH1G0	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMPH1G0	DI	DMPH1G0
DMPH1G0	DN	Tyr-D-Ala-Gly-D-Trp-NMeNle-Asp-Phe-NH2
DMPH1G0	MI	TTVFO0U
DMPH1G0	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMPH1G0	MT	DTT
DMPH1G0	MA	Inhibitor
DMPH1G0	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMPH1G0	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMPH1G0	DI	DMPH1G0
DMPH1G0	DN	Tyr-D-Ala-Gly-D-Trp-NMeNle-Asp-Phe-NH2
DMPH1G0	MI	TT27RFC
DMPH1G0	MN	Opioid receptor delta (OPRD1)
DMPH1G0	MT	DTT
DMPH1G0	MA	Inhibitor
DMPH1G0	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMPH1G0	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMPH1G0	DI	DMPH1G0
DMPH1G0	DN	Tyr-D-Ala-Gly-D-Trp-NMeNle-Asp-Phe-NH2
DMPH1G0	MI	TTKWM86
DMPH1G0	MN	Opioid receptor mu (MOP)
DMPH1G0	MT	DTT
DMPH1G0	MA	Inhibitor
DMPH1G0	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMPH1G0	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DM2XRZL	DI	DM2XRZL
DM2XRZL	DN	Tyr-D-Ala-Gly-NMePhe
DM2XRZL	MI	TTKWM86
DM2XRZL	MN	Opioid receptor mu (MOP)
DM2XRZL	MT	DTT
DM2XRZL	MA	Inhibitor
DM2XRZL	RN	Discovery of dermorphin-based affinity labels with subnanomolar affinity for mu opioid receptors. J Med Chem. 2009 Dec 10;52(23):7372-5.
DM2XRZL	RU	https://pubmed.ncbi.nlm.nih.gov/19621878

DMC7LND	DI	DMC7LND
DMC7LND	DN	Tyr-D-Ala-Gly-Phe-Met-NH2
DMC7LND	MI	TT27RFC
DMC7LND	MN	Opioid receptor delta (OPRD1)
DMC7LND	MT	DTT
DMC7LND	MA	Inhibitor
DMC7LND	RN	The biological activity and metabolic stability of peptidic bifunctional compounds that are opioid receptor agonists and neurokinin-1 receptor anta... Bioorg Med Chem. 2009 Oct 15;17(20):7337-43.
DMC7LND	RU	https://pubmed.ncbi.nlm.nih.gov/19762245

DMC7LND	DI	DMC7LND
DMC7LND	DN	Tyr-D-Ala-Gly-Phe-Met-NH2
DMC7LND	MI	TTKWM86
DMC7LND	MN	Opioid receptor mu (MOP)
DMC7LND	MT	DTT
DMC7LND	MA	Inhibitor
DMC7LND	RN	Biological and conformational evaluation of bifunctional compounds for opioid receptor agonists and neurokinin 1 receptor antagonists possessing tw... J Med Chem. 2010 Aug 12;53(15):5491-501.
DMC7LND	RU	https://pubmed.ncbi.nlm.nih.gov/20617791

DMWOP9N	DI	DMWOP9N
DMWOP9N	DN	Tyr-D-Ala-Gly-Phe-Met-Pro-Leu-Trp-NH-Bzl
DMWOP9N	MI	TT27RFC
DMWOP9N	MN	Opioid receptor delta (OPRD1)
DMWOP9N	MT	DTT
DMWOP9N	MA	Inhibitor
DMWOP9N	RN	The importance of micelle-bound states for the bioactivities of bifunctional peptide derivatives for delta/mu opioid receptor agonists and neurokin... J Med Chem. 2008 Oct 23;51(20):6334-47.
DMWOP9N	RU	https://pubmed.ncbi.nlm.nih.gov/18821747

DMWOP9N	DI	DMWOP9N
DMWOP9N	DN	Tyr-D-Ala-Gly-Phe-Met-Pro-Leu-Trp-NH-Bzl
DMWOP9N	MI	TTKWM86
DMWOP9N	MN	Opioid receptor mu (MOP)
DMWOP9N	MT	DTT
DMWOP9N	MA	Inhibitor
DMWOP9N	RN	The importance of micelle-bound states for the bioactivities of bifunctional peptide derivatives for delta/mu opioid receptor agonists and neurokin... J Med Chem. 2008 Oct 23;51(20):6334-47.
DMWOP9N	RU	https://pubmed.ncbi.nlm.nih.gov/18821747

DMWOP9N	DI	DMWOP9N
DMWOP9N	DN	Tyr-D-Ala-Gly-Phe-Met-Pro-Leu-Trp-NH-Bzl
DMWOP9N	MI	TTZPO1L
DMWOP9N	MN	Substance-P receptor (TACR1)
DMWOP9N	MT	DTT
DMWOP9N	MA	Inhibitor
DMWOP9N	RN	The importance of micelle-bound states for the bioactivities of bifunctional peptide derivatives for delta/mu opioid receptor agonists and neurokin... J Med Chem. 2008 Oct 23;51(20):6334-47.
DMWOP9N	RU	https://pubmed.ncbi.nlm.nih.gov/18821747

DMB2TCF	DI	DMB2TCF
DMB2TCF	DN	Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-NMeNle-D-Trp-Boc
DMB2TCF	MI	TTCG0AL
DMB2TCF	MN	Cholecystokinin receptor type A (CCKAR)
DMB2TCF	MT	DTT
DMB2TCF	MA	Inhibitor
DMB2TCF	RN	Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem. 2006 Mar 9;49(5):1773-80.
DMB2TCF	RU	https://pubmed.ncbi.nlm.nih.gov/16509592

DMB2TCF	DI	DMB2TCF
DMB2TCF	DN	Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-NMeNle-D-Trp-Boc
DMB2TCF	MI	TTVFO0U
DMB2TCF	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMB2TCF	MT	DTT
DMB2TCF	MA	Inhibitor
DMB2TCF	RN	Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem. 2006 Mar 9;49(5):1773-80.
DMB2TCF	RU	https://pubmed.ncbi.nlm.nih.gov/16509592

DMB2TCF	DI	DMB2TCF
DMB2TCF	DN	Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-NMeNle-D-Trp-Boc
DMB2TCF	MI	TT27RFC
DMB2TCF	MN	Opioid receptor delta (OPRD1)
DMB2TCF	MT	DTT
DMB2TCF	MA	Inhibitor
DMB2TCF	RN	Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem. 2006 Mar 9;49(5):1773-80.
DMB2TCF	RU	https://pubmed.ncbi.nlm.nih.gov/16509592

DMB2TCF	DI	DMB2TCF
DMB2TCF	DN	Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-NMeNle-D-Trp-Boc
DMB2TCF	MI	TTKWM86
DMB2TCF	MN	Opioid receptor mu (MOP)
DMB2TCF	MT	DTT
DMB2TCF	MA	Inhibitor
DMB2TCF	RN	Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem. 2006 Mar 9;49(5):1773-80.
DMB2TCF	RU	https://pubmed.ncbi.nlm.nih.gov/16509592

DMUXMVQ	DI	DMUXMVQ
DMUXMVQ	DN	Tyr-D-Ala-Gly-Trp-Nle-Asp-Phe-NH2
DMUXMVQ	MI	TTCG0AL
DMUXMVQ	MN	Cholecystokinin receptor type A (CCKAR)
DMUXMVQ	MT	DTT
DMUXMVQ	MA	Inhibitor
DMUXMVQ	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMUXMVQ	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMUXMVQ	DI	DMUXMVQ
DMUXMVQ	DN	Tyr-D-Ala-Gly-Trp-Nle-Asp-Phe-NH2
DMUXMVQ	MI	TTVFO0U
DMUXMVQ	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMUXMVQ	MT	DTT
DMUXMVQ	MA	Inhibitor
DMUXMVQ	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMUXMVQ	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMUXMVQ	DI	DMUXMVQ
DMUXMVQ	DN	Tyr-D-Ala-Gly-Trp-Nle-Asp-Phe-NH2
DMUXMVQ	MI	TT27RFC
DMUXMVQ	MN	Opioid receptor delta (OPRD1)
DMUXMVQ	MT	DTT
DMUXMVQ	MA	Inhibitor
DMUXMVQ	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMUXMVQ	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMUXMVQ	DI	DMUXMVQ
DMUXMVQ	DN	Tyr-D-Ala-Gly-Trp-Nle-Asp-Phe-NH2
DMUXMVQ	MI	TTKWM86
DMUXMVQ	MN	Opioid receptor mu (MOP)
DMUXMVQ	MT	DTT
DMUXMVQ	MA	Inhibitor
DMUXMVQ	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMUXMVQ	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMREJ69	DI	DMREJ69
DMREJ69	DN	Tyr-D-Ala-Gly-Trp-NMeNle-Asp-Phe-NH2
DMREJ69	MI	TTCG0AL
DMREJ69	MN	Cholecystokinin receptor type A (CCKAR)
DMREJ69	MT	DTT
DMREJ69	MA	Inhibitor
DMREJ69	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMREJ69	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMREJ69	DI	DMREJ69
DMREJ69	DN	Tyr-D-Ala-Gly-Trp-NMeNle-Asp-Phe-NH2
DMREJ69	MI	TTVFO0U
DMREJ69	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMREJ69	MT	DTT
DMREJ69	MA	Inhibitor
DMREJ69	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMREJ69	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMREJ69	DI	DMREJ69
DMREJ69	DN	Tyr-D-Ala-Gly-Trp-NMeNle-Asp-Phe-NH2
DMREJ69	MI	TT27RFC
DMREJ69	MN	Opioid receptor delta (OPRD1)
DMREJ69	MT	DTT
DMREJ69	MA	Inhibitor
DMREJ69	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMREJ69	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMREJ69	DI	DMREJ69
DMREJ69	DN	Tyr-D-Ala-Gly-Trp-NMeNle-Asp-Phe-NH2
DMREJ69	MI	TTKWM86
DMREJ69	MN	Opioid receptor mu (MOP)
DMREJ69	MT	DTT
DMREJ69	MA	Inhibitor
DMREJ69	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMREJ69	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMTPLNZ	DI	DMTPLNZ
DMTPLNZ	DN	Tyr-D-Ala-Phe-Asp-Val-Val-Thr[Beta-D-Glc]-Gly-NH2
DMTPLNZ	MI	TT27RFC
DMTPLNZ	MN	Opioid receptor delta (OPRD1)
DMTPLNZ	MT	DTT
DMTPLNZ	MA	Inhibitor
DMTPLNZ	RN	Synthesis and pharmacological activity of deltorphin and dermorphin-related glycopeptides. J Med Chem. 1997 Aug 29;40(18):2948-52.
DMTPLNZ	RU	https://pubmed.ncbi.nlm.nih.gov/9288177

DMTPLNZ	DI	DMTPLNZ
DMTPLNZ	DN	Tyr-D-Ala-Phe-Asp-Val-Val-Thr[Beta-D-Glc]-Gly-NH2
DMTPLNZ	MI	TTKWM86
DMTPLNZ	MN	Opioid receptor mu (MOP)
DMTPLNZ	MT	DTT
DMTPLNZ	MA	Inhibitor
DMTPLNZ	RN	Synthesis and pharmacological activity of deltorphin and dermorphin-related glycopeptides. J Med Chem. 1997 Aug 29;40(18):2948-52.
DMTPLNZ	RU	https://pubmed.ncbi.nlm.nih.gov/9288177

DMC4NO5	DI	DMC4NO5
DMC4NO5	DN	Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH2
DMC4NO5	MI	TT27RFC
DMC4NO5	MN	Opioid receptor delta (OPRD1)
DMC4NO5	MT	DTT
DMC4NO5	MA	Inhibitor
DMC4NO5	RN	Design of cyclic deltorphins and dermenkephalins with a disulfide bridge leads to analogues with high selectivity for delta-opioid receptors. J Med Chem. 1994 Jan 7;37(1):141-5.
DMC4NO5	RU	https://pubmed.ncbi.nlm.nih.gov/8289187

DMC4NO5	DI	DMC4NO5
DMC4NO5	DN	Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH2
DMC4NO5	MI	TTKWM86
DMC4NO5	MN	Opioid receptor mu (MOP)
DMC4NO5	MT	DTT
DMC4NO5	MA	Inhibitor
DMC4NO5	RN	Design of cyclic deltorphins and dermenkephalins with a disulfide bridge leads to analogues with high selectivity for delta-opioid receptors. J Med Chem. 1994 Jan 7;37(1):141-5.
DMC4NO5	RU	https://pubmed.ncbi.nlm.nih.gov/8289187

DM4FASR	DI	DM4FASR
DM4FASR	DN	Tyr-D-Ala-Phe-Gly-Tyr-Pro-Thr(Beta-D-Glc)-Gly-NH2
DM4FASR	MI	TT27RFC
DM4FASR	MN	Opioid receptor delta (OPRD1)
DM4FASR	MT	DTT
DM4FASR	MA	Inhibitor
DM4FASR	RN	Synthesis and pharmacological activity of deltorphin and dermorphin-related glycopeptides. J Med Chem. 1997 Aug 29;40(18):2948-52.
DM4FASR	RU	https://pubmed.ncbi.nlm.nih.gov/9288177

DM4FASR	DI	DM4FASR
DM4FASR	DN	Tyr-D-Ala-Phe-Gly-Tyr-Pro-Thr(Beta-D-Glc)-Gly-NH2
DM4FASR	MI	TTKWM86
DM4FASR	MN	Opioid receptor mu (MOP)
DM4FASR	MT	DTT
DM4FASR	MA	Inhibitor
DM4FASR	RN	Synthesis and pharmacological activity of deltorphin and dermorphin-related glycopeptides. J Med Chem. 1997 Aug 29;40(18):2948-52.
DM4FASR	RU	https://pubmed.ncbi.nlm.nih.gov/9288177

DMB9A46	DI	DMB9A46
DMB9A46	DN	Tyr-D-Ala-Phe-Thr(-D-Glc)-Tyr-Pro-Ser-NH2
DMB9A46	MI	TT27RFC
DMB9A46	MN	Opioid receptor delta (OPRD1)
DMB9A46	MT	DTT
DMB9A46	MA	Inhibitor
DMB9A46	RN	Synthesis and pharmacological activity of deltorphin and dermorphin-related glycopeptides. J Med Chem. 1997 Aug 29;40(18):2948-52.
DMB9A46	RU	https://pubmed.ncbi.nlm.nih.gov/9288177

DMB9A46	DI	DMB9A46
DMB9A46	DN	Tyr-D-Ala-Phe-Thr(-D-Glc)-Tyr-Pro-Ser-NH2
DMB9A46	MI	TTKWM86
DMB9A46	MN	Opioid receptor mu (MOP)
DMB9A46	MT	DTT
DMB9A46	MA	Inhibitor
DMB9A46	RN	Synthesis and pharmacological activity of deltorphin and dermorphin-related glycopeptides. J Med Chem. 1997 Aug 29;40(18):2948-52.
DMB9A46	RU	https://pubmed.ncbi.nlm.nih.gov/9288177

DMLC0NW	DI	DMLC0NW
DMLC0NW	DN	Tyr-D-Ala-Phe-Thr[-D-Glc(OAc)4]-Tyr-Pro-Ser-NH2
DMLC0NW	MI	TTKWM86
DMLC0NW	MN	Opioid receptor mu (MOP)
DMLC0NW	MT	DTT
DMLC0NW	MA	Inhibitor
DMLC0NW	RN	Synthesis and pharmacological activity of deltorphin and dermorphin-related glycopeptides. J Med Chem. 1997 Aug 29;40(18):2948-52.
DMLC0NW	RU	https://pubmed.ncbi.nlm.nih.gov/9288177

DM4YTFP	DI	DM4YTFP
DM4YTFP	DN	Tyr-D-Met-Phe-His-Leu-Met-Asp-NH2
DM4YTFP	MI	TT27RFC
DM4YTFP	MN	Opioid receptor delta (OPRD1)
DM4YTFP	MT	DTT
DM4YTFP	MA	Inhibitor
DM4YTFP	RN	Design of cyclic deltorphins and dermenkephalins with a disulfide bridge leads to analogues with high selectivity for delta-opioid receptors. J Med Chem. 1994 Jan 7;37(1):141-5.
DM4YTFP	RU	https://pubmed.ncbi.nlm.nih.gov/8289187

DM4YTFP	DI	DM4YTFP
DM4YTFP	DN	Tyr-D-Met-Phe-His-Leu-Met-Asp-NH2
DM4YTFP	MI	TTKWM86
DM4YTFP	MN	Opioid receptor mu (MOP)
DM4YTFP	MT	DTT
DM4YTFP	MA	Inhibitor
DM4YTFP	RN	Design of cyclic deltorphins and dermenkephalins with a disulfide bridge leads to analogues with high selectivity for delta-opioid receptors. J Med Chem. 1994 Jan 7;37(1):141-5.
DM4YTFP	RU	https://pubmed.ncbi.nlm.nih.gov/8289187

DMY9NIJ	DI	DMY9NIJ
DMY9NIJ	DN	Tyr-D-Nle-Gly-D-Trp-Nle-Asp-Phe-NH2
DMY9NIJ	MI	TTVFO0U
DMY9NIJ	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMY9NIJ	MT	DTT
DMY9NIJ	MA	Inhibitor
DMY9NIJ	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMY9NIJ	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMY9NIJ	DI	DMY9NIJ
DMY9NIJ	DN	Tyr-D-Nle-Gly-D-Trp-Nle-Asp-Phe-NH2
DMY9NIJ	MI	TT27RFC
DMY9NIJ	MN	Opioid receptor delta (OPRD1)
DMY9NIJ	MT	DTT
DMY9NIJ	MA	Inhibitor
DMY9NIJ	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMY9NIJ	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMY9NIJ	DI	DMY9NIJ
DMY9NIJ	DN	Tyr-D-Nle-Gly-D-Trp-Nle-Asp-Phe-NH2
DMY9NIJ	MI	TTKWM86
DMY9NIJ	MN	Opioid receptor mu (MOP)
DMY9NIJ	MT	DTT
DMY9NIJ	MA	Inhibitor
DMY9NIJ	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMY9NIJ	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMQREP2	DI	DMQREP2
DMQREP2	DN	Tyr-D-Nle-Gly-D-Trp-NMeNle-Asp-Phe-NH2
DMQREP2	MI	TTCG0AL
DMQREP2	MN	Cholecystokinin receptor type A (CCKAR)
DMQREP2	MT	DTT
DMQREP2	MA	Inhibitor
DMQREP2	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMQREP2	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMQREP2	DI	DMQREP2
DMQREP2	DN	Tyr-D-Nle-Gly-D-Trp-NMeNle-Asp-Phe-NH2
DMQREP2	MI	TTVFO0U
DMQREP2	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMQREP2	MT	DTT
DMQREP2	MA	Inhibitor
DMQREP2	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMQREP2	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMQREP2	DI	DMQREP2
DMQREP2	DN	Tyr-D-Nle-Gly-D-Trp-NMeNle-Asp-Phe-NH2
DMQREP2	MI	TT27RFC
DMQREP2	MN	Opioid receptor delta (OPRD1)
DMQREP2	MT	DTT
DMQREP2	MA	Inhibitor
DMQREP2	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMQREP2	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMQREP2	DI	DMQREP2
DMQREP2	DN	Tyr-D-Nle-Gly-D-Trp-NMeNle-Asp-Phe-NH2
DMQREP2	MI	TTKWM86
DMQREP2	MN	Opioid receptor mu (MOP)
DMQREP2	MT	DTT
DMQREP2	MA	Inhibitor
DMQREP2	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMQREP2	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMZ24LN	DI	DMZ24LN
DMZ24LN	DN	Tyr-D-Nle-Gly-Trp-Nle-Asp-Phe-NH2
DMZ24LN	MI	TTCG0AL
DMZ24LN	MN	Cholecystokinin receptor type A (CCKAR)
DMZ24LN	MT	DTT
DMZ24LN	MA	Inhibitor
DMZ24LN	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMZ24LN	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMZ24LN	DI	DMZ24LN
DMZ24LN	DN	Tyr-D-Nle-Gly-Trp-Nle-Asp-Phe-NH2
DMZ24LN	MI	TTVFO0U
DMZ24LN	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMZ24LN	MT	DTT
DMZ24LN	MA	Inhibitor
DMZ24LN	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMZ24LN	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMZ24LN	DI	DMZ24LN
DMZ24LN	DN	Tyr-D-Nle-Gly-Trp-Nle-Asp-Phe-NH2
DMZ24LN	MI	TT27RFC
DMZ24LN	MN	Opioid receptor delta (OPRD1)
DMZ24LN	MT	DTT
DMZ24LN	MA	Inhibitor
DMZ24LN	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMZ24LN	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMZ24LN	DI	DMZ24LN
DMZ24LN	DN	Tyr-D-Nle-Gly-Trp-Nle-Asp-Phe-NH2
DMZ24LN	MI	TTKWM86
DMZ24LN	MN	Opioid receptor mu (MOP)
DMZ24LN	MT	DTT
DMZ24LN	MA	Inhibitor
DMZ24LN	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMZ24LN	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMPSJ72	DI	DMPSJ72
DMPSJ72	DN	Tyr-D-Nle-Gly-Trp-NMeNle-Asp-Phe-NH2
DMPSJ72	MI	TTVFO0U
DMPSJ72	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMPSJ72	MT	DTT
DMPSJ72	MA	Inhibitor
DMPSJ72	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMPSJ72	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMPSJ72	DI	DMPSJ72
DMPSJ72	DN	Tyr-D-Nle-Gly-Trp-NMeNle-Asp-Phe-NH2
DMPSJ72	MI	TT27RFC
DMPSJ72	MN	Opioid receptor delta (OPRD1)
DMPSJ72	MT	DTT
DMPSJ72	MA	Inhibitor
DMPSJ72	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMPSJ72	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMPSJ72	DI	DMPSJ72
DMPSJ72	DN	Tyr-D-Nle-Gly-Trp-NMeNle-Asp-Phe-NH2
DMPSJ72	MI	TTKWM86
DMPSJ72	MN	Opioid receptor mu (MOP)
DMPSJ72	MT	DTT
DMPSJ72	MA	Inhibitor
DMPSJ72	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMPSJ72	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMIWMN6	DI	DMIWMN6
DMIWMN6	DN	Tyr-D-Phe-Gly-D-Trp-Nle-Asp-Phe-NH2
DMIWMN6	MI	TTCG0AL
DMIWMN6	MN	Cholecystokinin receptor type A (CCKAR)
DMIWMN6	MT	DTT
DMIWMN6	MA	Inhibitor
DMIWMN6	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMIWMN6	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMIWMN6	DI	DMIWMN6
DMIWMN6	DN	Tyr-D-Phe-Gly-D-Trp-Nle-Asp-Phe-NH2
DMIWMN6	MI	TTVFO0U
DMIWMN6	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMIWMN6	MT	DTT
DMIWMN6	MA	Inhibitor
DMIWMN6	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMIWMN6	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMIWMN6	DI	DMIWMN6
DMIWMN6	DN	Tyr-D-Phe-Gly-D-Trp-Nle-Asp-Phe-NH2
DMIWMN6	MI	TT27RFC
DMIWMN6	MN	Opioid receptor delta (OPRD1)
DMIWMN6	MT	DTT
DMIWMN6	MA	Inhibitor
DMIWMN6	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMIWMN6	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMIWMN6	DI	DMIWMN6
DMIWMN6	DN	Tyr-D-Phe-Gly-D-Trp-Nle-Asp-Phe-NH2
DMIWMN6	MI	TTKWM86
DMIWMN6	MN	Opioid receptor mu (MOP)
DMIWMN6	MT	DTT
DMIWMN6	MA	Inhibitor
DMIWMN6	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMIWMN6	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DM2CEWT	DI	DM2CEWT
DM2CEWT	DN	Tyr-D-Phe-Gly-D-Trp-NMeNle-Asp-Phe-NH2
DM2CEWT	MI	TTCG0AL
DM2CEWT	MN	Cholecystokinin receptor type A (CCKAR)
DM2CEWT	MT	DTT
DM2CEWT	MA	Inhibitor
DM2CEWT	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DM2CEWT	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DM2CEWT	DI	DM2CEWT
DM2CEWT	DN	Tyr-D-Phe-Gly-D-Trp-NMeNle-Asp-Phe-NH2
DM2CEWT	MI	TTVFO0U
DM2CEWT	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DM2CEWT	MT	DTT
DM2CEWT	MA	Inhibitor
DM2CEWT	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DM2CEWT	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DM2CEWT	DI	DM2CEWT
DM2CEWT	DN	Tyr-D-Phe-Gly-D-Trp-NMeNle-Asp-Phe-NH2
DM2CEWT	MI	TT27RFC
DM2CEWT	MN	Opioid receptor delta (OPRD1)
DM2CEWT	MT	DTT
DM2CEWT	MA	Inhibitor
DM2CEWT	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DM2CEWT	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DM2CEWT	DI	DM2CEWT
DM2CEWT	DN	Tyr-D-Phe-Gly-D-Trp-NMeNle-Asp-Phe-NH2
DM2CEWT	MI	TTKWM86
DM2CEWT	MN	Opioid receptor mu (MOP)
DM2CEWT	MT	DTT
DM2CEWT	MA	Inhibitor
DM2CEWT	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DM2CEWT	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMKM81A	DI	DMKM81A
DMKM81A	DN	Tyr-D-Phe-Gly-Trp-Nle-Asp-Phe-NH2
DMKM81A	MI	TTCG0AL
DMKM81A	MN	Cholecystokinin receptor type A (CCKAR)
DMKM81A	MT	DTT
DMKM81A	MA	Inhibitor
DMKM81A	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMKM81A	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMKM81A	DI	DMKM81A
DMKM81A	DN	Tyr-D-Phe-Gly-Trp-Nle-Asp-Phe-NH2
DMKM81A	MI	TTVFO0U
DMKM81A	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMKM81A	MT	DTT
DMKM81A	MA	Inhibitor
DMKM81A	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMKM81A	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMKM81A	DI	DMKM81A
DMKM81A	DN	Tyr-D-Phe-Gly-Trp-Nle-Asp-Phe-NH2
DMKM81A	MI	TT27RFC
DMKM81A	MN	Opioid receptor delta (OPRD1)
DMKM81A	MT	DTT
DMKM81A	MA	Inhibitor
DMKM81A	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMKM81A	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMKM81A	DI	DMKM81A
DMKM81A	DN	Tyr-D-Phe-Gly-Trp-Nle-Asp-Phe-NH2
DMKM81A	MI	TTKWM86
DMKM81A	MN	Opioid receptor mu (MOP)
DMKM81A	MT	DTT
DMKM81A	MA	Inhibitor
DMKM81A	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMKM81A	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMZOTGM	DI	DMZOTGM
DMZOTGM	DN	Tyr-D-Phe-Gly-Trp-NMeNle-Asp-Phe-NH2
DMZOTGM	MI	TTCG0AL
DMZOTGM	MN	Cholecystokinin receptor type A (CCKAR)
DMZOTGM	MT	DTT
DMZOTGM	MA	Inhibitor
DMZOTGM	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMZOTGM	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMZOTGM	DI	DMZOTGM
DMZOTGM	DN	Tyr-D-Phe-Gly-Trp-NMeNle-Asp-Phe-NH2
DMZOTGM	MI	TTVFO0U
DMZOTGM	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMZOTGM	MT	DTT
DMZOTGM	MA	Inhibitor
DMZOTGM	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMZOTGM	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMZOTGM	DI	DMZOTGM
DMZOTGM	DN	Tyr-D-Phe-Gly-Trp-NMeNle-Asp-Phe-NH2
DMZOTGM	MI	TT27RFC
DMZOTGM	MN	Opioid receptor delta (OPRD1)
DMZOTGM	MT	DTT
DMZOTGM	MA	Inhibitor
DMZOTGM	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMZOTGM	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMZOTGM	DI	DMZOTGM
DMZOTGM	DN	Tyr-D-Phe-Gly-Trp-NMeNle-Asp-Phe-NH2
DMZOTGM	MI	TTKWM86
DMZOTGM	MN	Opioid receptor mu (MOP)
DMZOTGM	MT	DTT
DMZOTGM	MA	Inhibitor
DMZOTGM	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMZOTGM	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMM9H07	DI	DMM9H07
DMM9H07	DN	Tyr-D-Pro-Gly-Trp-NMeNle-Asp-Phe-NH2
DMM9H07	MI	TTVFO0U
DMM9H07	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMM9H07	MT	DTT
DMM9H07	MA	Inhibitor
DMM9H07	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMM9H07	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMM9H07	DI	DMM9H07
DMM9H07	DN	Tyr-D-Pro-Gly-Trp-NMeNle-Asp-Phe-NH2
DMM9H07	MI	TT27RFC
DMM9H07	MN	Opioid receptor delta (OPRD1)
DMM9H07	MT	DTT
DMM9H07	MA	Inhibitor
DMM9H07	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMM9H07	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMM9H07	DI	DMM9H07
DMM9H07	DN	Tyr-D-Pro-Gly-Trp-NMeNle-Asp-Phe-NH2
DMM9H07	MI	TTKWM86
DMM9H07	MN	Opioid receptor mu (MOP)
DMM9H07	MT	DTT
DMM9H07	MA	Inhibitor
DMM9H07	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMM9H07	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMKND2R	DI	DMKND2R
DMKND2R	DN	Tyr-Gly-Gly-Phe-c(Cys-Arg-Arg-Ile-Cys)-Arg-lys
DMKND2R	MI	TT27RFC
DMKND2R	MN	Opioid receptor delta (OPRD1)
DMKND2R	MT	DTT
DMKND2R	MA	Inhibitor
DMKND2R	RN	Design and synthesis of highly potent and selective cyclic dynorphin A analogs. 2. New analogs. J Med Chem. 1993 Mar 19;36(6):750-7.
DMKND2R	RU	https://pubmed.ncbi.nlm.nih.gov/8096246

DMG6NDA	DI	DMG6NDA
DMG6NDA	DN	Tyr-Gly-Gly-Phe-leu-c(Cys-Arg-Ile-Arg-Cys)-lys
DMG6NDA	MI	TT27RFC
DMG6NDA	MN	Opioid receptor delta (OPRD1)
DMG6NDA	MT	DTT
DMG6NDA	MA	Inhibitor
DMG6NDA	RN	Design and synthesis of highly potent and selective cyclic dynorphin A analogs. 2. New analogs. J Med Chem. 1993 Mar 19;36(6):750-7.
DMG6NDA	RU	https://pubmed.ncbi.nlm.nih.gov/8096246

DMN7290	DI	DMN7290
DMN7290	DN	Tyr-Gly-Gly-Trp-NMeNle-Asp-Phe-NH2
DMN7290	MI	TTVFO0U
DMN7290	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMN7290	MT	DTT
DMN7290	MA	Inhibitor
DMN7290	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMN7290	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMN7290	DI	DMN7290
DMN7290	DN	Tyr-Gly-Gly-Trp-NMeNle-Asp-Phe-NH2
DMN7290	MI	TT27RFC
DMN7290	MN	Opioid receptor delta (OPRD1)
DMN7290	MT	DTT
DMN7290	MA	Inhibitor
DMN7290	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMN7290	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DMN7290	DI	DMN7290
DMN7290	DN	Tyr-Gly-Gly-Trp-NMeNle-Asp-Phe-NH2
DMN7290	MI	TTKWM86
DMN7290	MN	Opioid receptor mu (MOP)
DMN7290	MT	DTT
DMN7290	MA	Inhibitor
DMN7290	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DMN7290	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DM91UKB	DI	DM91UKB
DM91UKB	DN	Tyropanoic acid
DM91UKB	MI	DEP54UE
DM91UKB	MN	Beta-glucuronidase (GUSB)
DM91UKB	MT	DME
DM91UKB	MA	Metabolism
DM91UKB	RN	Foreign Compound Metabolism in Mammals. Edited by D. E. Hathway.
DM91UKB	RU	https://books.google.ca/books?id=raKIFKRdi0AC&pg=PA423&lpg=PA423&dq=tyropanoic+acid&source=bl&ots=qASeCBztrt&sig=Ux3ZzP6AIeG9EQyKiq90uLdTUh8&hl=en&sa=X&ved=0ahUKEwjMs9PgjuDZAhUE6mMKHY3qA404ChDoAQhBMAY#v=onepage&q=tyropanoic%20acid&f=false

DM87ZIH	DI	DM87ZIH
DM87ZIH	DN	Tyrphostin Ag-1478
DM87ZIH	MI	DTI7UX6
DM87ZIH	MN	Breast cancer resistance protein (ABCG2)
DM87ZIH	MT	DTP
DM87ZIH	MA	Substrate
DM87ZIH	RN	Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
DM87ZIH	RU	https://doi.org/10.1016/j.bcp.2008.11.007

DM87ZIH	DI	DM87ZIH
DM87ZIH	DN	Tyrphostin Ag-1478
DM87ZIH	MI	TTGKNB4
DM87ZIH	MN	Epidermal growth factor receptor (EGFR)
DM87ZIH	MT	DTT
DM87ZIH	MA	Inhibitor
DM87ZIH	RN	Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1H)-quinolones. J Med Chem. 1999 Mar 25;42(6):1018-26.
DM87ZIH	RU	https://pubmed.ncbi.nlm.nih.gov/10090785

DM87ZIH	DI	DM87ZIH
DM87ZIH	DN	Tyrphostin Ag-1478
DM87ZIH	MI	DTUGYRD
DM87ZIH	MN	P-glycoprotein 1 (ABCB1)
DM87ZIH	MT	DTP
DM87ZIH	MA	Substrate
DM87ZIH	RN	Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
DM87ZIH	RU	https://doi.org/10.1016/j.bcp.2008.11.007

DM87ZIH	DI	DM87ZIH
DM87ZIH	DN	Tyrphostin Ag-1478
DM87ZIH	MI	TTQBR95
DM87ZIH	MN	Stress-activated protein kinase 2a (p38 alpha)
DM87ZIH	MT	DTT
DM87ZIH	MA	Inhibitor
DM87ZIH	RN	Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5389-94.
DM87ZIH	RU	https://pubmed.ncbi.nlm.nih.gov/15454232

DMDCJWU	DI	DMDCJWU
DMDCJWU	DN	Tyr-Pro-3,5Dmp-Phe-NH2
DMDCJWU	MI	TT27RFC
DMDCJWU	MN	Opioid receptor delta (OPRD1)
DMDCJWU	MT	DTT
DMDCJWU	MA	Inhibitor
DMDCJWU	RN	Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66.
DMDCJWU	RU	https://pubmed.ncbi.nlm.nih.gov/17497839

DMDCJWU	DI	DMDCJWU
DMDCJWU	DN	Tyr-Pro-3,5Dmp-Phe-NH2
DMDCJWU	MI	TTKWM86
DMDCJWU	MN	Opioid receptor mu (MOP)
DMDCJWU	MT	DTT
DMDCJWU	MA	Inhibitor
DMDCJWU	RN	Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66.
DMDCJWU	RU	https://pubmed.ncbi.nlm.nih.gov/17497839

DMH08O3	DI	DMH08O3
DMH08O3	DN	Tyr-Pro-D-(NMe)Phe-D-Pro-NH2
DMH08O3	MI	TTKWM86
DMH08O3	MN	Opioid receptor mu (MOP)
DMH08O3	MT	DTT
DMH08O3	MA	Inhibitor
DMH08O3	RN	A topochemical approach to explain morphiceptin bioactivity. J Med Chem. 1993 Mar 19;36(6):708-19.
DMH08O3	RU	https://pubmed.ncbi.nlm.nih.gov/8384662

DMNXCHT	DI	DMNXCHT
DMNXCHT	DN	Tyr-Pro-Dmp-Phe-NH2
DMNXCHT	MI	TT27RFC
DMNXCHT	MN	Opioid receptor delta (OPRD1)
DMNXCHT	MT	DTT
DMNXCHT	MA	Inhibitor
DMNXCHT	RN	Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66.
DMNXCHT	RU	https://pubmed.ncbi.nlm.nih.gov/17497839

DMNXCHT	DI	DMNXCHT
DMNXCHT	DN	Tyr-Pro-Dmp-Phe-NH2
DMNXCHT	MI	TTKWM86
DMNXCHT	MN	Opioid receptor mu (MOP)
DMNXCHT	MT	DTT
DMNXCHT	MA	Inhibitor
DMNXCHT	RN	Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66.
DMNXCHT	RU	https://pubmed.ncbi.nlm.nih.gov/17497839

DMOU43H	DI	DMOU43H
DMOU43H	DN	Tyr-Pro-Dmt-Phe-NH2
DMOU43H	MI	TT27RFC
DMOU43H	MN	Opioid receptor delta (OPRD1)
DMOU43H	MT	DTT
DMOU43H	MA	Inhibitor
DMOU43H	RN	Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66.
DMOU43H	RU	https://pubmed.ncbi.nlm.nih.gov/17497839

DMOU43H	DI	DMOU43H
DMOU43H	DN	Tyr-Pro-Dmt-Phe-NH2
DMOU43H	MI	TTKWM86
DMOU43H	MN	Opioid receptor mu (MOP)
DMOU43H	MT	DTT
DMOU43H	MA	Inhibitor
DMOU43H	RN	Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66.
DMOU43H	RU	https://pubmed.ncbi.nlm.nih.gov/17497839

DM4ZJR5	DI	DM4ZJR5
DM4ZJR5	DN	Tyr-Pro-D-Phe-D-Pro-NH2
DM4ZJR5	MI	TT27RFC
DM4ZJR5	MN	Opioid receptor delta (OPRD1)
DM4ZJR5	MT	DTT
DM4ZJR5	MA	Inhibitor
DM4ZJR5	RN	A topochemical approach to explain morphiceptin bioactivity. J Med Chem. 1993 Mar 19;36(6):708-19.
DM4ZJR5	RU	https://pubmed.ncbi.nlm.nih.gov/8384662

DM4ZJR5	DI	DM4ZJR5
DM4ZJR5	DN	Tyr-Pro-D-Phe-D-Pro-NH2
DM4ZJR5	MI	TTKWM86
DM4ZJR5	MN	Opioid receptor mu (MOP)
DM4ZJR5	MT	DTT
DM4ZJR5	MA	Inhibitor
DM4ZJR5	RN	A topochemical approach to explain morphiceptin bioactivity. J Med Chem. 1993 Mar 19;36(6):708-19.
DM4ZJR5	RU	https://pubmed.ncbi.nlm.nih.gov/8384662

DMCTSNE	DI	DMCTSNE
DMCTSNE	DN	Tyr-Pro-D-Phe-Pro-NH2
DMCTSNE	MI	TT27RFC
DMCTSNE	MN	Opioid receptor delta (OPRD1)
DMCTSNE	MT	DTT
DMCTSNE	MA	Inhibitor
DMCTSNE	RN	A topochemical approach to explain morphiceptin bioactivity. J Med Chem. 1993 Mar 19;36(6):708-19.
DMCTSNE	RU	https://pubmed.ncbi.nlm.nih.gov/8384662

DMCTSNE	DI	DMCTSNE
DMCTSNE	DN	Tyr-Pro-D-Phe-Pro-NH2
DMCTSNE	MI	TTKWM86
DMCTSNE	MN	Opioid receptor mu (MOP)
DMCTSNE	MT	DTT
DMCTSNE	MA	Inhibitor
DMCTSNE	RN	A topochemical approach to explain morphiceptin bioactivity. J Med Chem. 1993 Mar 19;36(6):708-19.
DMCTSNE	RU	https://pubmed.ncbi.nlm.nih.gov/8384662

DMEDVRN	DI	DMEDVRN
DMEDVRN	DN	Tyr-Pro-D-Phg-Phe-NH2
DMEDVRN	MI	TT27RFC
DMEDVRN	MN	Opioid receptor delta (OPRD1)
DMEDVRN	MT	DTT
DMEDVRN	MA	Inhibitor
DMEDVRN	RN	Opioid receptor binding and antinociceptive activity of the analogues of endomorphin-2 and morphiceptin with phenylalanine mimics in the position 3... Bioorg Med Chem Lett. 2006 Jul 15;16(14):3688-92.
DMEDVRN	RU	https://pubmed.ncbi.nlm.nih.gov/16682191

DMEDVRN	DI	DMEDVRN
DMEDVRN	DN	Tyr-Pro-D-Phg-Phe-NH2
DMEDVRN	MI	TTKWM86
DMEDVRN	MN	Opioid receptor mu (MOP)
DMEDVRN	MT	DTT
DMEDVRN	MA	Inhibitor
DMEDVRN	RN	Opioid receptor binding and antinociceptive activity of the analogues of endomorphin-2 and morphiceptin with phenylalanine mimics in the position 3... Bioorg Med Chem Lett. 2006 Jul 15;16(14):3688-92.
DMEDVRN	RU	https://pubmed.ncbi.nlm.nih.gov/16682191

DMUKE43	DI	DMUKE43
DMUKE43	DN	Tyr-Pro-Emp-Phe-NH2
DMUKE43	MI	TT27RFC
DMUKE43	MN	Opioid receptor delta (OPRD1)
DMUKE43	MT	DTT
DMUKE43	MA	Inhibitor
DMUKE43	RN	Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66.
DMUKE43	RU	https://pubmed.ncbi.nlm.nih.gov/17497839

DMUKE43	DI	DMUKE43
DMUKE43	DN	Tyr-Pro-Emp-Phe-NH2
DMUKE43	MI	TTKWM86
DMUKE43	MN	Opioid receptor mu (MOP)
DMUKE43	MT	DTT
DMUKE43	MA	Inhibitor
DMUKE43	RN	Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66.
DMUKE43	RU	https://pubmed.ncbi.nlm.nih.gov/17497839

DM8THU2	DI	DM8THU2
DM8THU2	DN	Tyr-Pro-Gly-Trp-NMeNle-Asp-Phe-NH2
DM8THU2	MI	TTVFO0U
DM8THU2	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DM8THU2	MT	DTT
DM8THU2	MA	Inhibitor
DM8THU2	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DM8THU2	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DM8THU2	DI	DM8THU2
DM8THU2	DN	Tyr-Pro-Gly-Trp-NMeNle-Asp-Phe-NH2
DM8THU2	MI	TT27RFC
DM8THU2	MN	Opioid receptor delta (OPRD1)
DM8THU2	MT	DTT
DM8THU2	MA	Inhibitor
DM8THU2	RN	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
DM8THU2	RU	https://pubmed.ncbi.nlm.nih.gov/16686530

DME5HIS	DI	DME5HIS
DME5HIS	DN	Tyr-Pro-Hfe-Phe-NH2
DME5HIS	MI	TTKWM86
DME5HIS	MN	Opioid receptor mu (MOP)
DME5HIS	MT	DTT
DME5HIS	MA	Inhibitor
DME5HIS	RN	Opioid receptor binding and antinociceptive activity of the analogues of endomorphin-2 and morphiceptin with phenylalanine mimics in the position 3... Bioorg Med Chem Lett. 2006 Jul 15;16(14):3688-92.
DME5HIS	RU	https://pubmed.ncbi.nlm.nih.gov/16682191

DMJBR75	DI	DMJBR75
DMJBR75	DN	Tyr-Pro-Hfe-Pro-NH2
DMJBR75	MI	TTKWM86
DMJBR75	MN	Opioid receptor mu (MOP)
DMJBR75	MT	DTT
DMJBR75	MA	Inhibitor
DMJBR75	RN	Opioid receptor binding and antinociceptive activity of the analogues of endomorphin-2 and morphiceptin with phenylalanine mimics in the position 3... Bioorg Med Chem Lett. 2006 Jul 15;16(14):3688-92.
DMJBR75	RU	https://pubmed.ncbi.nlm.nih.gov/16682191

DMUV3ZW	DI	DMUV3ZW
DMUV3ZW	DN	Tyr-Pro-Imp-Phe-NH2
DMUV3ZW	MI	TT27RFC
DMUV3ZW	MN	Opioid receptor delta (OPRD1)
DMUV3ZW	MT	DTT
DMUV3ZW	MA	Inhibitor
DMUV3ZW	RN	Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66.
DMUV3ZW	RU	https://pubmed.ncbi.nlm.nih.gov/17497839

DMUV3ZW	DI	DMUV3ZW
DMUV3ZW	DN	Tyr-Pro-Imp-Phe-NH2
DMUV3ZW	MI	TTKWM86
DMUV3ZW	MN	Opioid receptor mu (MOP)
DMUV3ZW	MT	DTT
DMUV3ZW	MA	Inhibitor
DMUV3ZW	RN	Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66.
DMUV3ZW	RU	https://pubmed.ncbi.nlm.nih.gov/17497839

DMI65GV	DI	DMI65GV
DMI65GV	DN	Tyr-Pro-L-(NMe)Phe-D-Pro-NH2
DMI65GV	MI	TT27RFC
DMI65GV	MN	Opioid receptor delta (OPRD1)
DMI65GV	MT	DTT
DMI65GV	MA	Inhibitor
DMI65GV	RN	A topochemical approach to explain morphiceptin bioactivity. J Med Chem. 1993 Mar 19;36(6):708-19.
DMI65GV	RU	https://pubmed.ncbi.nlm.nih.gov/8384662

DMI65GV	DI	DMI65GV
DMI65GV	DN	Tyr-Pro-L-(NMe)Phe-D-Pro-NH2
DMI65GV	MI	TTKWM86
DMI65GV	MN	Opioid receptor mu (MOP)
DMI65GV	MT	DTT
DMI65GV	MA	Inhibitor
DMI65GV	RN	A topochemical approach to explain morphiceptin bioactivity. J Med Chem. 1993 Mar 19;36(6):708-19.
DMI65GV	RU	https://pubmed.ncbi.nlm.nih.gov/8384662

DM1NITL	DI	DM1NITL
DM1NITL	DN	Tyr-Pro-L-(NMe)Phe-Pro-NH2
DM1NITL	MI	TT27RFC
DM1NITL	MN	Opioid receptor delta (OPRD1)
DM1NITL	MT	DTT
DM1NITL	MA	Inhibitor
DM1NITL	RN	A topochemical approach to explain morphiceptin bioactivity. J Med Chem. 1993 Mar 19;36(6):708-19.
DM1NITL	RU	https://pubmed.ncbi.nlm.nih.gov/8384662

DM1NITL	DI	DM1NITL
DM1NITL	DN	Tyr-Pro-L-(NMe)Phe-Pro-NH2
DM1NITL	MI	TTKWM86
DM1NITL	MN	Opioid receptor mu (MOP)
DM1NITL	MT	DTT
DM1NITL	MA	Inhibitor
DM1NITL	RN	A topochemical approach to explain morphiceptin bioactivity. J Med Chem. 1993 Mar 19;36(6):708-19.
DM1NITL	RU	https://pubmed.ncbi.nlm.nih.gov/8384662

DMUVHGS	DI	DMUVHGS
DMUVHGS	DN	Tyr-Pro-L-Phe-D-Pro-NH2
DMUVHGS	MI	TT27RFC
DMUVHGS	MN	Opioid receptor delta (OPRD1)
DMUVHGS	MT	DTT
DMUVHGS	MA	Inhibitor
DMUVHGS	RN	A topochemical approach to explain morphiceptin bioactivity. J Med Chem. 1993 Mar 19;36(6):708-19.
DMUVHGS	RU	https://pubmed.ncbi.nlm.nih.gov/8384662

DMUVHGS	DI	DMUVHGS
DMUVHGS	DN	Tyr-Pro-L-Phe-D-Pro-NH2
DMUVHGS	MI	TTKWM86
DMUVHGS	MN	Opioid receptor mu (MOP)
DMUVHGS	MT	DTT
DMUVHGS	MA	Inhibitor
DMUVHGS	RN	A topochemical approach to explain morphiceptin bioactivity. J Med Chem. 1993 Mar 19;36(6):708-19.
DMUVHGS	RU	https://pubmed.ncbi.nlm.nih.gov/8384662

DM8VW3Z	DI	DM8VW3Z
DM8VW3Z	DN	Tyr-Pro-L-Phe-Pro-NH2
DM8VW3Z	MI	TT27RFC
DM8VW3Z	MN	Opioid receptor delta (OPRD1)
DM8VW3Z	MT	DTT
DM8VW3Z	MA	Inhibitor
DM8VW3Z	RN	A topochemical approach to explain morphiceptin bioactivity. J Med Chem. 1993 Mar 19;36(6):708-19.
DM8VW3Z	RU	https://pubmed.ncbi.nlm.nih.gov/8384662

DM8VW3Z	DI	DM8VW3Z
DM8VW3Z	DN	Tyr-Pro-L-Phe-Pro-NH2
DM8VW3Z	MI	TTKWM86
DM8VW3Z	MN	Opioid receptor mu (MOP)
DM8VW3Z	MT	DTT
DM8VW3Z	MA	Inhibitor
DM8VW3Z	RN	A topochemical approach to explain morphiceptin bioactivity. J Med Chem. 1993 Mar 19;36(6):708-19.
DM8VW3Z	RU	https://pubmed.ncbi.nlm.nih.gov/8384662

DMRE7G3	DI	DMRE7G3
DMRE7G3	DN	Tyr-Pro-Mmp-Phe-NH
DMRE7G3	MI	TT27RFC
DMRE7G3	MN	Opioid receptor delta (OPRD1)
DMRE7G3	MT	DTT
DMRE7G3	MA	Inhibitor
DMRE7G3	RN	Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66.
DMRE7G3	RU	https://pubmed.ncbi.nlm.nih.gov/17497839

DMRE7G3	DI	DMRE7G3
DMRE7G3	DN	Tyr-Pro-Mmp-Phe-NH
DMRE7G3	MI	TTKWM86
DMRE7G3	MN	Opioid receptor mu (MOP)
DMRE7G3	MT	DTT
DMRE7G3	MA	Inhibitor
DMRE7G3	RN	Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66.
DMRE7G3	RU	https://pubmed.ncbi.nlm.nih.gov/17497839

DMIE4U5	DI	DMIE4U5
DMIE4U5	DN	Tyr-Pro-Phe-Ala-Bn
DMIE4U5	MI	TTKWM86
DMIE4U5	MN	Opioid receptor mu (MOP)
DMIE4U5	MT	DTT
DMIE4U5	MA	Inhibitor
DMIE4U5	RN	Molecular modeling studies to predict the possible binding modes of endomorphin analogs in mu opioid receptor. Bioorg Med Chem Lett. 2009 Sep 15;19(18):5387-91.
DMIE4U5	RU	https://pubmed.ncbi.nlm.nih.gov/19679474

DMLQ3PR	DI	DMLQ3PR
DMLQ3PR	DN	Tyr-Pro-Phe-D-2-Nal-NH2
DMLQ3PR	MI	TTKWM86
DMLQ3PR	MN	Opioid receptor mu (MOP)
DMLQ3PR	MT	DTT
DMLQ3PR	MA	Inhibitor
DMLQ3PR	RN	Novel highly potent mu-opioid receptor antagonist based on endomorphin-2 structure. Bioorg Med Chem Lett. 2008 Feb 15;18(4):1350-3.
DMLQ3PR	RU	https://pubmed.ncbi.nlm.nih.gov/18207400

DMLEUF6	DI	DMLEUF6
DMLEUF6	DN	Tyr-Pro-Phe-D-Ala-Bn
DMLEUF6	MI	TTKWM86
DMLEUF6	MN	Opioid receptor mu (MOP)
DMLEUF6	MT	DTT
DMLEUF6	MA	Inhibitor
DMLEUF6	RN	Molecular modeling studies to predict the possible binding modes of endomorphin analogs in mu opioid receptor. Bioorg Med Chem Lett. 2009 Sep 15;19(18):5387-91.
DMLEUF6	RU	https://pubmed.ncbi.nlm.nih.gov/19679474

DM6YRVT	DI	DM6YRVT
DM6YRVT	DN	Tyr-Pro-Phe-D-Phg-NH2
DM6YRVT	MI	TTKWM86
DM6YRVT	MN	Opioid receptor mu (MOP)
DM6YRVT	MT	DTT
DM6YRVT	MA	Inhibitor
DM6YRVT	RN	Opioid receptor binding and antinociceptive activity of the analogues of endomorphin-2 and morphiceptin with phenylalanine mimics in the position 3... Bioorg Med Chem Lett. 2006 Jul 15;16(14):3688-92.
DM6YRVT	RU	https://pubmed.ncbi.nlm.nih.gov/16682191

DM1QZ9X	DI	DM1QZ9X
DM1QZ9X	DN	Tyr-Pro-Phe-D-Val-Bn
DM1QZ9X	MI	TTKWM86
DM1QZ9X	MN	Opioid receptor mu (MOP)
DM1QZ9X	MT	DTT
DM1QZ9X	MA	Inhibitor
DM1QZ9X	RN	Molecular modeling studies to predict the possible binding modes of endomorphin analogs in mu opioid receptor. Bioorg Med Chem Lett. 2009 Sep 15;19(18):5387-91.
DM1QZ9X	RU	https://pubmed.ncbi.nlm.nih.gov/19679474

DM71P2O	DI	DM71P2O
DM71P2O	DN	Tyr-Pro-Phe-Hfe-NH2
DM71P2O	MI	TTKWM86
DM71P2O	MN	Opioid receptor mu (MOP)
DM71P2O	MT	DTT
DM71P2O	MA	Inhibitor
DM71P2O	RN	Opioid receptor binding and antinociceptive activity of the analogues of endomorphin-2 and morphiceptin with phenylalanine mimics in the position 3... Bioorg Med Chem Lett. 2006 Jul 15;16(14):3688-92.
DM71P2O	RU	https://pubmed.ncbi.nlm.nih.gov/16682191

DM5DRIZ	DI	DM5DRIZ
DM5DRIZ	DN	Tyr-Pro-Phe-Phe-N(CH3)2
DM5DRIZ	MI	TT27RFC
DM5DRIZ	MN	Opioid receptor delta (OPRD1)
DM5DRIZ	MT	DTT
DM5DRIZ	MA	Inhibitor
DM5DRIZ	RN	Structure-activity study of endomorphin-2 analogs with C-terminal modifications by NMR spectroscopy and molecular modeling. Bioorg Med Chem. 2008 Jun 15;16(12):6415-22.
DM5DRIZ	RU	https://pubmed.ncbi.nlm.nih.gov/18490168

DM5DRIZ	DI	DM5DRIZ
DM5DRIZ	DN	Tyr-Pro-Phe-Phe-N(CH3)2
DM5DRIZ	MI	TTKWM86
DM5DRIZ	MN	Opioid receptor mu (MOP)
DM5DRIZ	MT	DTT
DM5DRIZ	MA	Inhibitor
DM5DRIZ	RN	Structure-activity study of endomorphin-2 analogs with C-terminal modifications by NMR spectroscopy and molecular modeling. Bioorg Med Chem. 2008 Jun 15;16(12):6415-22.
DM5DRIZ	RU	https://pubmed.ncbi.nlm.nih.gov/18490168

DM2U4VI	DI	DM2U4VI
DM2U4VI	DN	Tyr-Pro-Phe-Phe-NHCH3
DM2U4VI	MI	TT27RFC
DM2U4VI	MN	Opioid receptor delta (OPRD1)
DM2U4VI	MT	DTT
DM2U4VI	MA	Inhibitor
DM2U4VI	RN	Structure-activity study of endomorphin-2 analogs with C-terminal modifications by NMR spectroscopy and molecular modeling. Bioorg Med Chem. 2008 Jun 15;16(12):6415-22.
DM2U4VI	RU	https://pubmed.ncbi.nlm.nih.gov/18490168

DM2U4VI	DI	DM2U4VI
DM2U4VI	DN	Tyr-Pro-Phe-Phe-NHCH3
DM2U4VI	MI	TTKWM86
DM2U4VI	MN	Opioid receptor mu (MOP)
DM2U4VI	MT	DTT
DM2U4VI	MA	Inhibitor
DM2U4VI	RN	Structure-activity study of endomorphin-2 analogs with C-terminal modifications by NMR spectroscopy and molecular modeling. Bioorg Med Chem. 2008 Jun 15;16(12):6415-22.
DM2U4VI	RU	https://pubmed.ncbi.nlm.nih.gov/18490168

DMY6V9R	DI	DMY6V9R
DMY6V9R	DN	Tyr-Pro-Phe-Phe-NHNH2
DMY6V9R	MI	TT27RFC
DMY6V9R	MN	Opioid receptor delta (OPRD1)
DMY6V9R	MT	DTT
DMY6V9R	MA	Inhibitor
DMY6V9R	RN	Structure-activity study of endomorphin-2 analogs with C-terminal modifications by NMR spectroscopy and molecular modeling. Bioorg Med Chem. 2008 Jun 15;16(12):6415-22.
DMY6V9R	RU	https://pubmed.ncbi.nlm.nih.gov/18490168

DMY6V9R	DI	DMY6V9R
DMY6V9R	DN	Tyr-Pro-Phe-Phe-NHNH2
DMY6V9R	MI	TTKWM86
DMY6V9R	MN	Opioid receptor mu (MOP)
DMY6V9R	MT	DTT
DMY6V9R	MA	Inhibitor
DMY6V9R	RN	Structure-activity study of endomorphin-2 analogs with C-terminal modifications by NMR spectroscopy and molecular modeling. Bioorg Med Chem. 2008 Jun 15;16(12):6415-22.
DMY6V9R	RU	https://pubmed.ncbi.nlm.nih.gov/18490168

DMS4P1E	DI	DMS4P1E
DMS4P1E	DN	Tyr-Pro-Phe-Phe-OC(CH3)3
DMS4P1E	MI	TT27RFC
DMS4P1E	MN	Opioid receptor delta (OPRD1)
DMS4P1E	MT	DTT
DMS4P1E	MA	Inhibitor
DMS4P1E	RN	Structure-activity study of endomorphin-2 analogs with C-terminal modifications by NMR spectroscopy and molecular modeling. Bioorg Med Chem. 2008 Jun 15;16(12):6415-22.
DMS4P1E	RU	https://pubmed.ncbi.nlm.nih.gov/18490168

DMS4P1E	DI	DMS4P1E
DMS4P1E	DN	Tyr-Pro-Phe-Phe-OC(CH3)3
DMS4P1E	MI	TTKWM86
DMS4P1E	MN	Opioid receptor mu (MOP)
DMS4P1E	MT	DTT
DMS4P1E	MA	Inhibitor
DMS4P1E	RN	Structure-activity study of endomorphin-2 analogs with C-terminal modifications by NMR spectroscopy and molecular modeling. Bioorg Med Chem. 2008 Jun 15;16(12):6415-22.
DMS4P1E	RU	https://pubmed.ncbi.nlm.nih.gov/18490168

DMZNHEC	DI	DMZNHEC
DMZNHEC	DN	Tyr-Pro-Phe-Phe-OCH2CH3
DMZNHEC	MI	TT27RFC
DMZNHEC	MN	Opioid receptor delta (OPRD1)
DMZNHEC	MT	DTT
DMZNHEC	MA	Inhibitor
DMZNHEC	RN	Structure-activity study of endomorphin-2 analogs with C-terminal modifications by NMR spectroscopy and molecular modeling. Bioorg Med Chem. 2008 Jun 15;16(12):6415-22.
DMZNHEC	RU	https://pubmed.ncbi.nlm.nih.gov/18490168

DMZNHEC	DI	DMZNHEC
DMZNHEC	DN	Tyr-Pro-Phe-Phe-OCH2CH3
DMZNHEC	MI	TTKWM86
DMZNHEC	MN	Opioid receptor mu (MOP)
DMZNHEC	MT	DTT
DMZNHEC	MA	Inhibitor
DMZNHEC	RN	Structure-activity study of endomorphin-2 analogs with C-terminal modifications by NMR spectroscopy and molecular modeling. Bioorg Med Chem. 2008 Jun 15;16(12):6415-22.
DMZNHEC	RU	https://pubmed.ncbi.nlm.nih.gov/18490168

DMFV7NI	DI	DMFV7NI
DMFV7NI	DN	Tyr-Pro-Phe-Phe-OCH2OH
DMFV7NI	MI	TT27RFC
DMFV7NI	MN	Opioid receptor delta (OPRD1)
DMFV7NI	MT	DTT
DMFV7NI	MA	Inhibitor
DMFV7NI	RN	Structure-activity study of endomorphin-2 analogs with C-terminal modifications by NMR spectroscopy and molecular modeling. Bioorg Med Chem. 2008 Jun 15;16(12):6415-22.
DMFV7NI	RU	https://pubmed.ncbi.nlm.nih.gov/18490168

DMFV7NI	DI	DMFV7NI
DMFV7NI	DN	Tyr-Pro-Phe-Phe-OCH2OH
DMFV7NI	MI	TTKWM86
DMFV7NI	MN	Opioid receptor mu (MOP)
DMFV7NI	MT	DTT
DMFV7NI	MA	Inhibitor
DMFV7NI	RN	Structure-activity study of endomorphin-2 analogs with C-terminal modifications by NMR spectroscopy and molecular modeling. Bioorg Med Chem. 2008 Jun 15;16(12):6415-22.
DMFV7NI	RU	https://pubmed.ncbi.nlm.nih.gov/18490168

DMRQXHO	DI	DMRQXHO
DMRQXHO	DN	Tyr-Pro-Phe-Phe-OCH3
DMRQXHO	MI	TT27RFC
DMRQXHO	MN	Opioid receptor delta (OPRD1)
DMRQXHO	MT	DTT
DMRQXHO	MA	Inhibitor
DMRQXHO	RN	Structure-activity study of endomorphin-2 analogs with C-terminal modifications by NMR spectroscopy and molecular modeling. Bioorg Med Chem. 2008 Jun 15;16(12):6415-22.
DMRQXHO	RU	https://pubmed.ncbi.nlm.nih.gov/18490168

DMRQXHO	DI	DMRQXHO
DMRQXHO	DN	Tyr-Pro-Phe-Phe-OCH3
DMRQXHO	MI	TTKWM86
DMRQXHO	MN	Opioid receptor mu (MOP)
DMRQXHO	MT	DTT
DMRQXHO	MA	Inhibitor
DMRQXHO	RN	Structure-activity study of endomorphin-2 analogs with C-terminal modifications by NMR spectroscopy and molecular modeling. Bioorg Med Chem. 2008 Jun 15;16(12):6415-22.
DMRQXHO	RU	https://pubmed.ncbi.nlm.nih.gov/18490168

DM70HYT	DI	DM70HYT
DM70HYT	DN	Tyr-Pro-Phe-Phg-NH2
DM70HYT	MI	TTKWM86
DM70HYT	MN	Opioid receptor mu (MOP)
DM70HYT	MT	DTT
DM70HYT	MA	Inhibitor
DM70HYT	RN	Opioid receptor binding and antinociceptive activity of the analogues of endomorphin-2 and morphiceptin with phenylalanine mimics in the position 3... Bioorg Med Chem Lett. 2006 Jul 15;16(14):3688-92.
DM70HYT	RU	https://pubmed.ncbi.nlm.nih.gov/16682191

DMVDM73	DI	DMVDM73
DMVDM73	DN	Tyr-Pro-Phg-Phe-NH2
DMVDM73	MI	TTKWM86
DMVDM73	MN	Opioid receptor mu (MOP)
DMVDM73	MT	DTT
DMVDM73	MA	Inhibitor
DMVDM73	RN	Opioid receptor binding and antinociceptive activity of the analogues of endomorphin-2 and morphiceptin with phenylalanine mimics in the position 3... Bioorg Med Chem Lett. 2006 Jul 15;16(14):3688-92.
DMVDM73	RU	https://pubmed.ncbi.nlm.nih.gov/16682191

DMSGMPU	DI	DMSGMPU
DMSGMPU	DN	Tyr-Pro-Phg-Pro-NH2
DMSGMPU	MI	TTKWM86
DMSGMPU	MN	Opioid receptor mu (MOP)
DMSGMPU	MT	DTT
DMSGMPU	MA	Inhibitor
DMSGMPU	RN	Opioid receptor binding and antinociceptive activity of the analogues of endomorphin-2 and morphiceptin with phenylalanine mimics in the position 3... Bioorg Med Chem Lett. 2006 Jul 15;16(14):3688-92.
DMSGMPU	RU	https://pubmed.ncbi.nlm.nih.gov/16682191

DMR3IVB	DI	DMR3IVB
DMR3IVB	DN	Tyr-Pro-Tmp-Phe-NH
DMR3IVB	MI	TT27RFC
DMR3IVB	MN	Opioid receptor delta (OPRD1)
DMR3IVB	MT	DTT
DMR3IVB	MA	Inhibitor
DMR3IVB	RN	Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66.
DMR3IVB	RU	https://pubmed.ncbi.nlm.nih.gov/17497839

DMR3IVB	DI	DMR3IVB
DMR3IVB	DN	Tyr-Pro-Tmp-Phe-NH
DMR3IVB	MI	TTKWM86
DMR3IVB	MN	Opioid receptor mu (MOP)
DMR3IVB	MT	DTT
DMR3IVB	MA	Inhibitor
DMR3IVB	RN	Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66.
DMR3IVB	RU	https://pubmed.ncbi.nlm.nih.gov/17497839

DMFIPXA	DI	DMFIPXA
DMFIPXA	DN	Tyr-Pro-Trp-D-Ala-Bn
DMFIPXA	MI	TTKWM86
DMFIPXA	MN	Opioid receptor mu (MOP)
DMFIPXA	MT	DTT
DMFIPXA	MA	Inhibitor
DMFIPXA	RN	Molecular modeling studies to predict the possible binding modes of endomorphin analogs in mu opioid receptor. Bioorg Med Chem Lett. 2009 Sep 15;19(18):5387-91.
DMFIPXA	RU	https://pubmed.ncbi.nlm.nih.gov/19679474

DMY5HX6	DI	DMY5HX6
DMY5HX6	DN	Tyr-Pro-Trp-D-Val-Bn
DMY5HX6	MI	TTKWM86
DMY5HX6	MN	Opioid receptor mu (MOP)
DMY5HX6	MT	DTT
DMY5HX6	MA	Inhibitor
DMY5HX6	RN	Molecular modeling studies to predict the possible binding modes of endomorphin analogs in mu opioid receptor. Bioorg Med Chem Lett. 2009 Sep 15;19(18):5387-91.
DMY5HX6	RU	https://pubmed.ncbi.nlm.nih.gov/19679474

DMKLDWF	DI	DMKLDWF
DMKLDWF	DN	Tyr-Pro-Trp-Gly-Bn
DMKLDWF	MI	TTKWM86
DMKLDWF	MN	Opioid receptor mu (MOP)
DMKLDWF	MT	DTT
DMKLDWF	MA	Inhibitor
DMKLDWF	RN	Molecular modeling studies to predict the possible binding modes of endomorphin analogs in mu opioid receptor. Bioorg Med Chem Lett. 2009 Sep 15;19(18):5387-91.
DMKLDWF	RU	https://pubmed.ncbi.nlm.nih.gov/19679474

DMIZB25	DI	DMIZB25
DMIZB25	DN	Tyr-Sar-Phe-D-2-Nal-NH2
DMIZB25	MI	TTKWM86
DMIZB25	MN	Opioid receptor mu (MOP)
DMIZB25	MT	DTT
DMIZB25	MA	Inhibitor
DMIZB25	RN	Novel highly potent mu-opioid receptor antagonist based on endomorphin-2 structure. Bioorg Med Chem Lett. 2008 Feb 15;18(4):1350-3.
DMIZB25	RU	https://pubmed.ncbi.nlm.nih.gov/18207400

DMVCHOX	DI	DMVCHOX
DMVCHOX	DN	TZD18
DMVCHOX	MI	TTJ584C
DMVCHOX	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMVCHOX	MT	DTT
DMVCHOX	MA	Agonist
DMVCHOX	RN	A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist demonstrates favorable effects on lipid homeostasis. Endocrinology. 2004 Apr;145(4):1640-8.
DMVCHOX	RU	https://pubmed.ncbi.nlm.nih.gov/14701675

DMVCHOX	DI	DMVCHOX
DMVCHOX	DN	TZD18
DMVCHOX	MI	TTT2SVW
DMVCHOX	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DMVCHOX	MT	DTT
DMVCHOX	MA	Agonist
DMVCHOX	RN	A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist demonstrates favorable effects on lipid homeostasis. Endocrinology. 2004 Apr;145(4):1640-8.
DMVCHOX	RU	https://pubmed.ncbi.nlm.nih.gov/14701675

DMSI0HE	DI	DMSI0HE
DMSI0HE	DN	TZI-41127
DMSI0HE	MI	TT2J34L
DMSI0HE	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMSI0HE	MT	DTT
DMSI0HE	MA	Inhibitor
DMSI0HE	RN	Design of pyrrolo-1,4-benzoxazine derivatives as inhibitors of 5-lipoxygenase and PAF antagonists with anthihistaminic properties, Bioorg. Med. Chem. Lett. 4(20):2383-2388 (1994).
DMSI0HE	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01803954

DMD6CLG	DI	DMD6CLG
DMD6CLG	DN	TZP-201
DMD6CLG	MI	TT953CX
DMD6CLG	MN	Motilin receptor (MLNR)
DMD6CLG	MT	DTT
DMD6CLG	MA	Antagonist
DMD6CLG	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 297).
DMD6CLG	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=297

DM31OGF	DI	DM31OGF
DM31OGF	DN	U0126
DM31OGF	MI	TTQBCEJ
DM31OGF	MN	MAPK/ERK kinase kinase 1 (MAP3K1)
DM31OGF	MT	DTT
DM31OGF	MA	Inhibitor
DM31OGF	RN	Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
DM31OGF	RU	https://pubmed.ncbi.nlm.nih.gov/11804650

DM31OGF	DI	DM31OGF
DM31OGF	DN	U0126
DM31OGF	MI	TTK1N5G
DM31OGF	MN	MAPK/ERK kinase kinase 2 (MAP3K2)
DM31OGF	MT	DTT
DM31OGF	MA	Inhibitor
DM31OGF	RN	Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
DM31OGF	RU	https://pubmed.ncbi.nlm.nih.gov/11804650

DM31OGF	DI	DM31OGF
DM31OGF	DN	U0126
DM31OGF	MI	TTVOE6D
DM31OGF	MN	Mitogen-activated protein kinase (MAPK)
DM31OGF	MT	DTT
DM31OGF	MA	Inhibitor
DM31OGF	RN	Intravenous administration of MEK inhibitor U0126 affords brain protection against forebrain ischemia and focal cerebral ischemia. Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11569-74.
DM31OGF	RU	https://pubmed.ncbi.nlm.nih.gov/11504919

DM31OGF	DI	DM31OGF
DM31OGF	DN	U0126
DM31OGF	MI	TTCZO0Q
DM31OGF	MN	Mitogen-activated protein kinase kinase (MAPKK)
DM31OGF	MT	DTT
DM31OGF	MA	Inhibitor
DM31OGF	RN	Transcriptional regulation of basal cyclooxygenase-2 expression in murine lung tumor-derived cell lines by CCAAT/enhancer-binding protein and activating transcription factor/cAMP response element-binding protein. Mol Pharmacol. 2002 Aug;62(2):326-33.
DM31OGF	RU	https://pubmed.ncbi.nlm.nih.gov/12130685

DM9GOAV	DI	DM9GOAV
DM9GOAV	DN	U101958
DM9GOAV	MI	TTE0A2F
DM9GOAV	MN	Dopamine D4 receptor (D4R)
DM9GOAV	MT	DTT
DM9GOAV	MA	Antagonist
DM9GOAV	RN	Substituted 4-aminopiperidines having high in vitro affinity and selectivity for the cloned human dopamine D4 receptor. Eur J Pharmacol. 1997 Mar 19;322(2-3):283-6.
DM9GOAV	RU	https://pubmed.ncbi.nlm.nih.gov/9098699

DM0DMNS	DI	DM0DMNS
DM0DMNS	DN	U-44069
DM0DMNS	MI	TT2O84V
DM0DMNS	MN	Thromboxane A2 receptor (TBXA2R)
DM0DMNS	MT	DTT
DM0DMNS	MA	Inhibitor
DM0DMNS	RN	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
DM0DMNS	RU	https://pubmed.ncbi.nlm.nih.gov/18983139

DM13FX4	DI	DM13FX4
DM13FX4	DN	U46619
DM13FX4	MI	TTOFYT1
DM13FX4	MN	Prostacyclin receptor (PTGIR)
DM13FX4	MT	DTT
DM13FX4	MA	Agonist
DM13FX4	RN	The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
DM13FX4	RU	https://pubmed.ncbi.nlm.nih.gov/10634944

DM13FX4	DI	DM13FX4
DM13FX4	DN	U46619
DM13FX4	MI	TTNVEIR
DM13FX4	MN	Prostaglandin D2 receptor (PTGDR)
DM13FX4	MT	DTT
DM13FX4	MA	Agonist
DM13FX4	RN	The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
DM13FX4	RU	https://pubmed.ncbi.nlm.nih.gov/10634944

DM13FX4	DI	DM13FX4
DM13FX4	DN	U46619
DM13FX4	MI	TTQDMX5
DM13FX4	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DM13FX4	MT	DTT
DM13FX4	MA	Agonist
DM13FX4	RN	Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2. Br J Pharmacol. 2002 Dec;137(8):1163-72.
DM13FX4	RU	https://pubmed.ncbi.nlm.nih.gov/12466225

DM13FX4	DI	DM13FX4
DM13FX4	DN	U46619
DM13FX4	MI	TTG1QMU
DM13FX4	MN	Prostaglandin E2 receptor EP1 (PTGER1)
DM13FX4	MT	DTT
DM13FX4	MA	Agonist
DM13FX4	RN	Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41.
DM13FX4	RU	https://pubmed.ncbi.nlm.nih.gov/9537820

DM13FX4	DI	DM13FX4
DM13FX4	DN	U46619
DM13FX4	MI	TT1ZAVI
DM13FX4	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DM13FX4	MT	DTT
DM13FX4	MA	Agonist
DM13FX4	RN	Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41.
DM13FX4	RU	https://pubmed.ncbi.nlm.nih.gov/9537820

DM13FX4	DI	DM13FX4
DM13FX4	DN	U46619
DM13FX4	MI	TTPNGDE
DM13FX4	MN	Prostaglandin E2 receptor EP3 (PTGER3)
DM13FX4	MT	DTT
DM13FX4	MA	Agonist
DM13FX4	RN	The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
DM13FX4	RU	https://pubmed.ncbi.nlm.nih.gov/10634944

DM13FX4	DI	DM13FX4
DM13FX4	DN	U46619
DM13FX4	MI	TT79WV3
DM13FX4	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DM13FX4	MT	DTT
DM13FX4	MA	Agonist
DM13FX4	RN	Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41.
DM13FX4	RU	https://pubmed.ncbi.nlm.nih.gov/9537820

DM13FX4	DI	DM13FX4
DM13FX4	DN	U46619
DM13FX4	MI	TTT2ZAR
DM13FX4	MN	Prostaglandin F2-alpha receptor (PTGFR)
DM13FX4	MT	DTT
DM13FX4	MA	Agonist
DM13FX4	RN	The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
DM13FX4	RU	https://pubmed.ncbi.nlm.nih.gov/10634944

DM13FX4	DI	DM13FX4
DM13FX4	DN	U46619
DM13FX4	MI	TT2O84V
DM13FX4	MN	Thromboxane A2 receptor (TBXA2R)
DM13FX4	MT	DTT
DM13FX4	MA	Agonist
DM13FX4	RN	The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
DM13FX4	RU	https://pubmed.ncbi.nlm.nih.gov/10634944

DMYW1VP	DI	DMYW1VP
DMYW1VP	DN	U50,488H
DMYW1VP	MI	TTQW87Y
DMYW1VP	MN	Opioid receptor kappa (OPRK1)
DMYW1VP	MT	DTT
DMYW1VP	MA	Agonist
DMYW1VP	RN	The selective kappa-opioid receptor agonist U50,488H attenuates voluntary ethanol intake in the rat. Behav Brain Res. 2001 May;120(2):137-46.
DMYW1VP	RU	https://pubmed.ncbi.nlm.nih.gov/11182162

DMQT6AH	DI	DMQT6AH
DMQT6AH	DN	U-89267
DMQT6AH	MI	TT1MPAY
DMQT6AH	MN	GABA(A) receptor alpha-1 (GABRA1)
DMQT6AH	MT	DTT
DMQT6AH	MA	Inhibitor
DMQT6AH	RN	Antagonist, partial agonist, and full agonist imidazo[1,5-a]quinoxaline amides and carbamates acting through the GABAA/benzodiazepine receptor. J Med Chem. 1994 Mar 18;37(6):758-68.
DMQT6AH	RU	https://pubmed.ncbi.nlm.nih.gov/8145225

DMQT6AH	DI	DMQT6AH
DMQT6AH	DN	U-89267
DMQT6AH	MI	TTZA1NY
DMQT6AH	MN	GABA(A) receptor beta-2 (GABRB2)
DMQT6AH	MT	DTT
DMQT6AH	MA	Inhibitor
DMQT6AH	RN	Antagonist, partial agonist, and full agonist imidazo[1,5-a]quinoxaline amides and carbamates acting through the GABAA/benzodiazepine receptor. J Med Chem. 1994 Mar 18;37(6):758-68.
DMQT6AH	RU	https://pubmed.ncbi.nlm.nih.gov/8145225

DMQT6AH	DI	DMQT6AH
DMQT6AH	DN	U-89267
DMQT6AH	MI	TT06RH5
DMQT6AH	MN	GABA(A) receptor gamma-2 (GABRG2)
DMQT6AH	MT	DTT
DMQT6AH	MA	Inhibitor
DMQT6AH	RN	Antagonist, partial agonist, and full agonist imidazo[1,5-a]quinoxaline amides and carbamates acting through the GABAA/benzodiazepine receptor. J Med Chem. 1994 Mar 18;37(6):758-68.
DMQT6AH	RU	https://pubmed.ncbi.nlm.nih.gov/8145225

DMQT6AH	DI	DMQT6AH
DMQT6AH	DN	U-89267
DMQT6AH	MI	TTNJYV2
DMQT6AH	MN	Gamma-aminobutyric acid receptor (GAR)
DMQT6AH	MT	DTT
DMQT6AH	MA	Inhibitor
DMQT6AH	RN	Antagonist, partial agonist, and full agonist imidazo[1,5-a]quinoxaline amides and carbamates acting through the GABAA/benzodiazepine receptor. J Med Chem. 1994 Mar 18;37(6):758-68.
DMQT6AH	RU	https://pubmed.ncbi.nlm.nih.gov/8145225

DMI6VAX	DI	DMI6VAX
DMI6VAX	DN	U-89854
DMI6VAX	MI	TTPTXIN
DMI6VAX	MN	Translocator protein (TSPO)
DMI6VAX	MT	DTT
DMI6VAX	MA	Modulator
DMI6VAX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2879).
DMI6VAX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2879

DM7CJNE	DI	DM7CJNE
DM7CJNE	DN	U92016A
DM7CJNE	MI	TTSQIFT
DM7CJNE	MN	5-HT 1A receptor (HTR1A)
DM7CJNE	MT	DTT
DM7CJNE	MA	Agonist
DM7CJNE	RN	Characterization of U-92016A as a selective, orally active, high intrinsic activity 5-hydroxytryptamine1A agonist. J Pharmacol Exp Ther. 1994 Nov;271(2):875-83.
DM7CJNE	RU	https://pubmed.ncbi.nlm.nih.gov/7965808

DMLUP30	DI	DMLUP30
DMLUP30	DN	UBIQUINONE-2
DMLUP30	MI	TTRAMF0
DMLUP30	MN	Plasmodium Cytochrome B (Malaria MT-CYB)
DMLUP30	MT	DTT
DMLUP30	MA	Inhibitor
DMLUP30	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMLUP30	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM6IG5J	DI	DM6IG5J
DM6IG5J	DN	UBP141
DM6IG5J	MI	TTKJEMQ
DM6IG5J	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DM6IG5J	MT	DTT
DM6IG5J	MA	Antagonist
DM6IG5J	RN	Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists. J Med Chem. 2005 Apr 7;48(7):2627-37.
DM6IG5J	RU	https://pubmed.ncbi.nlm.nih.gov/15801853

DM6IG5J	DI	DM6IG5J
DM6IG5J	DN	UBP141
DM6IG5J	MI	TTN9D8E
DM6IG5J	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DM6IG5J	MT	DTT
DM6IG5J	MA	Antagonist
DM6IG5J	RN	Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists. J Med Chem. 2005 Apr 7;48(7):2627-37.
DM6IG5J	RU	https://pubmed.ncbi.nlm.nih.gov/15801853

DM6IG5J	DI	DM6IG5J
DM6IG5J	DN	UBP141
DM6IG5J	MI	TT1M8OW
DM6IG5J	MN	Glutamate receptor ionotropic NMDA 2C (GluN2C)
DM6IG5J	MT	DTT
DM6IG5J	MA	Antagonist
DM6IG5J	RN	Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists. J Med Chem. 2005 Apr 7;48(7):2627-37.
DM6IG5J	RU	https://pubmed.ncbi.nlm.nih.gov/15801853

DM6IG5J	DI	DM6IG5J
DM6IG5J	DN	UBP141
DM6IG5J	MI	TT5POTG
DM6IG5J	MN	Glutamate receptor ionotropic NMDA 2D (GluN2D)
DM6IG5J	MT	DTT
DM6IG5J	MA	Antagonist
DM6IG5J	RN	Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists. J Med Chem. 2005 Apr 7;48(7):2627-37.
DM6IG5J	RU	https://pubmed.ncbi.nlm.nih.gov/15801853

DMSJLX0	DI	DMSJLX0
DMSJLX0	DN	UBP-302
DMSJLX0	MI	TT0MYE2
DMSJLX0	MN	Glutamate receptor ionotropic kainate 1 (GRIK1)
DMSJLX0	MT	DTT
DMSJLX0	MA	Inhibitor
DMSJLX0	RN	Structural investigation of the 7-chloro-3-hydroxy-1H-quinazoline-2,4-dione scaffold to obtain AMPA and kainate receptor selective antagonists. Syn... J Med Chem. 2006 Oct 5;49(20):6015-26.
DMSJLX0	RU	https://pubmed.ncbi.nlm.nih.gov/17004715

DMVQL3J	DI	DMVQL3J
DMVQL3J	DN	UBP310
DMVQL3J	MI	TT0MYE2
DMVQL3J	MN	Glutamate receptor ionotropic kainate 1 (GRIK1)
DMVQL3J	MT	DTT
DMVQL3J	MA	Antagonist
DMVQL3J	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 450).
DMVQL3J	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=450

DMVQL3J	DI	DMVQL3J
DMVQL3J	DN	UBP310
DMVQL3J	MI	TTNP6O2
DMVQL3J	MN	Glutamate receptor ionotropic kainate 3 (GluK3)
DMVQL3J	MT	DTT
DMVQL3J	MA	Antagonist
DMVQL3J	RN	Mapping the ligand binding sites of kainate receptors: molecular determinants of subunit-selective binding of the antagonist [3H]UBP310. Mol Pharmacol. 2010 Dec;78(6):1036-45.
DMVQL3J	RU	https://pubmed.ncbi.nlm.nih.gov/20837679

DMCRFT5	DI	DMCRFT5
DMCRFT5	DN	UC-1011
DMCRFT5	MI	TTEX6LM
DMCRFT5	MN	GABA(A) receptor gamma-3 (GABRG3)
DMCRFT5	MT	DTT
DMCRFT5	MA	Antagonist
DMCRFT5	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415).
DMCRFT5	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415

DMJVT4K	DI	DMJVT4K
DMJVT4K	DN	UC-2024
DMJVT4K	MI	TTEX6LM
DMJVT4K	MN	GABA(A) receptor gamma-3 (GABRG3)
DMJVT4K	MT	DTT
DMJVT4K	MA	Modulator
DMJVT4K	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415).
DMJVT4K	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415

DMGSOZ7	DI	DMGSOZ7
DMGSOZ7	DN	UC-2029
DMGSOZ7	MI	TTEX6LM
DMGSOZ7	MN	GABA(A) receptor gamma-3 (GABRG3)
DMGSOZ7	MT	DTT
DMGSOZ7	MA	Modulator
DMGSOZ7	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415).
DMGSOZ7	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415

DMHYORU	DI	DMHYORU
DMHYORU	DN	UCB-101333-3
DMHYORU	MI	TTQ13Z5
DMHYORU	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMHYORU	MT	DTT
DMHYORU	MA	Inhibitor
DMHYORU	RN	Dual M3 antagonists-PDE4 inhibitors. Part 2: Synthesis and SAR of 3-substituted azetidinyl derivatives. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3077-80.
DMHYORU	RU	https://pubmed.ncbi.nlm.nih.gov/17398090

DMHYORU	DI	DMHYORU
DMHYORU	DN	UCB-101333-3
DMHYORU	MI	TTZ97H5
DMHYORU	MN	Phosphodiesterase 4A (PDE4A)
DMHYORU	MT	DTT
DMHYORU	MA	Inhibitor
DMHYORU	RN	First dual M3 antagonists-PDE4 inhibitors: synthesis and SAR of 4,6-diaminopyrimidine derivatives. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1834-9.
DMHYORU	RU	https://pubmed.ncbi.nlm.nih.gov/16439121

DMHYORU	DI	DMHYORU
DMHYORU	DN	UCB-101333-3
DMHYORU	MI	TTVIAT9
DMHYORU	MN	Phosphodiesterase 4B (PDE4B)
DMHYORU	MT	DTT
DMHYORU	MA	Inhibitor
DMHYORU	RN	First dual M3 antagonists-PDE4 inhibitors: synthesis and SAR of 4,6-diaminopyrimidine derivatives. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1834-9.
DMHYORU	RU	https://pubmed.ncbi.nlm.nih.gov/16439121

DMHYORU	DI	DMHYORU
DMHYORU	DN	UCB-101333-3
DMHYORU	MI	TTSKMI8
DMHYORU	MN	Phosphodiesterase 4D (PDE4D)
DMHYORU	MT	DTT
DMHYORU	MA	Inhibitor
DMHYORU	RN	First dual M3 antagonists-PDE4 inhibitors: synthesis and SAR of 4,6-diaminopyrimidine derivatives. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1834-9.
DMHYORU	RU	https://pubmed.ncbi.nlm.nih.gov/16439121

DMFUE43	DI	DMFUE43
DMFUE43	DN	UCB-1277763
DMFUE43	MI	TTQBR95
DMFUE43	MN	Stress-activated protein kinase 2a (p38 alpha)
DMFUE43	MT	DTT
DMFUE43	MA	Inhibitor
DMFUE43	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1499).
DMFUE43	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1499

DMQ20A4	DI	DMQ20A4
DMQ20A4	DN	UCB-2892
DMQ20A4	MI	TT9JNIC
DMQ20A4	MN	Histamine H3 receptor (H3R)
DMQ20A4	MT	DTT
DMQ20A4	MA	Antagonist
DMQ20A4	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 264).
DMQ20A4	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=264

DMQB8C3	DI	DMQB8C3
DMQB8C3	DN	UCB35625
DMQB8C3	MI	TT8KLPT
DMQB8C3	MN	C-C chemokine receptor (CCR)
DMQB8C3	MT	DTT
DMQB8C3	MA	Antagonist
DMQB8C3	RN	A small molecule antagonist of chemokine receptors CCR1 and CCR3. Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry. J Biol Chem. 2000 Aug 25;275(34):25985-92.
DMQB8C3	RU	https://pubmed.ncbi.nlm.nih.gov/10854442

DMO9S5P	DI	DMO9S5P
DMO9S5P	DN	UCCF-029
DMO9S5P	MI	TTRLZHP
DMO9S5P	MN	cAMP-dependent chloride channel (CFTR)
DMO9S5P	MT	DTT
DMO9S5P	MA	Activator
DMO9S5P	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 707).
DMO9S5P	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=707

DM3I9JG	DI	DM3I9JG
DM3I9JG	DN	UCCF-339
DM3I9JG	MI	TTRLZHP
DM3I9JG	MN	cAMP-dependent chloride channel (CFTR)
DM3I9JG	MT	DTT
DM3I9JG	MA	Activator
DM3I9JG	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 707).
DM3I9JG	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=707

DMN9QO4	DI	DMN9QO4
DMN9QO4	DN	UCCF-853
DMN9QO4	MI	TTRLZHP
DMN9QO4	MN	cAMP-dependent chloride channel (CFTR)
DMN9QO4	MT	DTT
DMN9QO4	MA	Activator
DMN9QO4	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 707).
DMN9QO4	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=707

DMZNJFU	DI	DMZNJFU
DMZNJFU	DN	UCL1684
DMZNJFU	MI	TT9R6BE
DMZNJFU	MN	Calcium-activated potassium channel KCa2.1 (KCNN1)
DMZNJFU	MT	DTT
DMZNJFU	MA	Blocker (channel blocker)
DMZNJFU	RN	Small conductance calcium-activated potassium channels: from structure to function. Prog Neurobiol. 2010 Jul;91(3):242-55.
DMZNJFU	RU	https://pubmed.ncbi.nlm.nih.gov/20359520

DMZNJFU	DI	DMZNJFU
DMZNJFU	DN	UCL1684
DMZNJFU	MI	TT2T5M0
DMZNJFU	MN	Calcium-activated potassium channel KCa2.2 (KCNN2)
DMZNJFU	MT	DTT
DMZNJFU	MA	Blocker (channel blocker)
DMZNJFU	RN	Pharmacological characterization of small-conductance Ca(2+)-activated K(+) channels stably expressed in HEK 293 cells. Br J Pharmacol. 2000 Mar;129(5):991-9.
DMZNJFU	RU	https://pubmed.ncbi.nlm.nih.gov/10696100

DMZNJFU	DI	DMZNJFU
DMZNJFU	DN	UCL1684
DMZNJFU	MI	TT9JH25
DMZNJFU	MN	Calcium-activated potassium channel KCa2.3 (KCNN3)
DMZNJFU	MT	DTT
DMZNJFU	MA	Blocker (channel blocker)
DMZNJFU	RN	SK3 is an important component of K(+) channels mediating the afterhyperpolarization in cultured rat SCG neurones. J Physiol. 2001 Sep 1;535(Pt 2):323-34.
DMZNJFU	RU	https://pubmed.ncbi.nlm.nih.gov/11533126

DM2CN0A	DI	DM2CN0A
DM2CN0A	DN	UCL1848
DM2CN0A	MI	TT9R6BE
DM2CN0A	MN	Calcium-activated potassium channel KCa2.1 (KCNN1)
DM2CN0A	MT	DTT
DM2CN0A	MA	Blocker (channel blocker)
DM2CN0A	RN	The pharmacology of hSK1 Ca2+-activated K+ channels expressed in mammalian cell lines. Br J Pharmacol. 2000 Feb;129(4):627-30.
DM2CN0A	RU	https://pubmed.ncbi.nlm.nih.gov/10683185

DM2CN0A	DI	DM2CN0A
DM2CN0A	DN	UCL1848
DM2CN0A	MI	TT2T5M0
DM2CN0A	MN	Calcium-activated potassium channel KCa2.2 (KCNN2)
DM2CN0A	MT	DTT
DM2CN0A	MA	Blocker (channel blocker)
DM2CN0A	RN	Calcium-activated potassium channels sustain calcium signaling in T lymphocytes. Selective blockers and manipulated channel expression levels. J Biol Chem. 2001 Apr 13;276(15):12249-56.
DM2CN0A	RU	https://pubmed.ncbi.nlm.nih.gov/11278890

DM2CN0A	DI	DM2CN0A
DM2CN0A	DN	UCL1848
DM2CN0A	MI	TT9JH25
DM2CN0A	MN	Calcium-activated potassium channel KCa2.3 (KCNN3)
DM2CN0A	MT	DTT
DM2CN0A	MA	Blocker (channel blocker)
DM2CN0A	RN	SK3 is an important component of K(+) channels mediating the afterhyperpolarization in cultured rat SCG neurones. J Physiol. 2001 Sep 1;535(Pt 2):323-34.
DM2CN0A	RU	https://pubmed.ncbi.nlm.nih.gov/11533126

DM0P5Z9	DI	DM0P5Z9
DM0P5Z9	DN	UCL1972
DM0P5Z9	MI	TT9JNIC
DM0P5Z9	MN	Histamine H3 receptor (H3R)
DM0P5Z9	MT	DTT
DM0P5Z9	MA	Antagonist
DM0P5Z9	RN	The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20.
DM0P5Z9	RU	https://pubmed.ncbi.nlm.nih.gov/15665857

DM15CJZ	DI	DM15CJZ
DM15CJZ	DN	UCL-2138
DM15CJZ	MI	TT9JNIC
DM15CJZ	MN	Histamine H3 receptor (H3R)
DM15CJZ	MT	DTT
DM15CJZ	MA	Inhibitor
DM15CJZ	RN	Fluorinated non-imidazole histamine H3 receptor antagonists. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2172-5.
DM15CJZ	RU	https://pubmed.ncbi.nlm.nih.gov/19286376

DMFYUMX	DI	DMFYUMX
DMFYUMX	DN	UCL-67022
DMFYUMX	MI	TT5ZKDI
DMFYUMX	MN	Histone deacetylase 6 (HDAC6)
DMFYUMX	MT	DTT
DMFYUMX	MA	Inhibitor
DMFYUMX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2618).
DMFYUMX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2618

DM9JG1L	DI	DM9JG1L
DM9JG1L	DN	UCM 549
DM9JG1L	MI	TT0WAIE
DM9JG1L	MN	Melatonin receptor type 1A (MTNR1A)
DM9JG1L	MT	DTT
DM9JG1L	MA	Antagonist
DM9JG1L	RN	Synthesis, enantiomeric resolution, and structure-activity relationship study of a series of 10,11-dihydro-5H-dibenzo[a,d]cycloheptene MT2 receptor antagonists. ChemMedChem. 2007 Dec;2(12):1741-9.
DM9JG1L	RU	https://pubmed.ncbi.nlm.nih.gov/17907131

DMCKSYQ	DI	DMCKSYQ
DMCKSYQ	DN	UCM 724
DMCKSYQ	MI	TT0WAIE
DMCKSYQ	MN	Melatonin receptor type 1A (MTNR1A)
DMCKSYQ	MT	DTT
DMCKSYQ	MA	Antagonist
DMCKSYQ	RN	Synthesis, enantiomeric resolution, and structure-activity relationship study of a series of 10,11-dihydro-5H-dibenzo[a,d]cycloheptene MT2 receptor antagonists. ChemMedChem. 2007 Dec;2(12):1741-9.
DMCKSYQ	RU	https://pubmed.ncbi.nlm.nih.gov/17907131

DMD16MH	DI	DMD16MH
DMD16MH	DN	UCM 765
DMD16MH	MI	TT0WAIE
DMD16MH	MN	Melatonin receptor type 1A (MTNR1A)
DMD16MH	MT	DTT
DMD16MH	MA	Agonist
DMD16MH	RN	N-(substituted-anilinoethyl)amides: design, synthesis, and pharmacological characterization of a new class of melatonin receptor ligands. J Med Chem. 2007 Dec 27;50(26):6618-26.
DMD16MH	RU	https://pubmed.ncbi.nlm.nih.gov/18052314

DM8J41W	DI	DM8J41W
DM8J41W	DN	UCM 793
DM8J41W	MI	TT0WAIE
DM8J41W	MN	Melatonin receptor type 1A (MTNR1A)
DM8J41W	MT	DTT
DM8J41W	MA	Agonist
DM8J41W	RN	N-(substituted-anilinoethyl)amides: design, synthesis, and pharmacological characterization of a new class of melatonin receptor ligands. J Med Chem. 2007 Dec 27;50(26):6618-26.
DM8J41W	RU	https://pubmed.ncbi.nlm.nih.gov/18052314

DMSVJFG	DI	DMSVJFG
DMSVJFG	DN	UCM-454
DMSVJFG	MI	TT0WAIE
DMSVJFG	MN	Melatonin receptor type 1A (MTNR1A)
DMSVJFG	MT	DTT
DMSVJFG	MA	Inhibitor
DMSVJFG	RN	2-[(2,3-dihydro-1H-indol-1-yl)methyl]melatonin analogues: a novel class of MT2-selective melatonin receptor antagonists. J Med Chem. 2009 Feb 12;52(3):826-33.
DMSVJFG	RU	https://pubmed.ncbi.nlm.nih.gov/19193160

DMSVJFG	DI	DMSVJFG
DMSVJFG	DN	UCM-454
DMSVJFG	MI	TT32JK8
DMSVJFG	MN	Melatonin receptor type 1B (MTNR1B)
DMSVJFG	MT	DTT
DMSVJFG	MA	Inhibitor
DMSVJFG	RN	2-[(2,3-dihydro-1H-indol-1-yl)methyl]melatonin analogues: a novel class of MT2-selective melatonin receptor antagonists. J Med Chem. 2009 Feb 12;52(3):826-33.
DMSVJFG	RU	https://pubmed.ncbi.nlm.nih.gov/19193160

DMOJ4TG	DI	DMOJ4TG
DMOJ4TG	DN	UCM-5600
DMOJ4TG	MI	TTO9X1H
DMOJ4TG	MN	5-HT 7 receptor (HTR7)
DMOJ4TG	MT	DTT
DMOJ4TG	MA	Inhibitor
DMOJ4TG	RN	Synthesis of new serotonin 5-HT7 receptor ligands. Determinants of 5-HT7/5-HT1A receptor selectivity. J Med Chem. 2009 Apr 23;52(8):2384-92.
DMOJ4TG	RU	https://pubmed.ncbi.nlm.nih.gov/19326916

DMTQEDA	DI	DMTQEDA
DMTQEDA	DN	UCPH-101
DMTQEDA	MI	TT8WRDA
DMTQEDA	MN	Excitatory amino acid transporter 1 (SLC1A3)
DMTQEDA	MT	DTT
DMTQEDA	MA	Inhibitor
DMTQEDA	RN	Discovery of the first selective inhibitor of excitatory amino acid transporter subtype 1. J Med Chem. 2009 Feb 26;52(4):912-5.
DMTQEDA	RU	https://pubmed.ncbi.nlm.nih.gov/19161278

DMMWHAV	DI	DMMWHAV
DMMWHAV	DN	UDP-beta-S
DMMWHAV	MI	TTNVSKA
DMMWHAV	MN	P2Y purinoceptor 6 (P2RY6)
DMMWHAV	MT	DTT
DMMWHAV	MA	Agonist
DMMWHAV	RN	P2 receptors activated by uracil nucleotides--an update. Curr Med Chem. 2006;13(3):289-312.
DMMWHAV	RU	https://pubmed.ncbi.nlm.nih.gov/16475938

DMLT4JA	DI	DMLT4JA
DMLT4JA	DN	UDP-glucose
DMLT4JA	MI	TT72OKI
DMLT4JA	MN	P2Y purinoceptor 14 (P2RY14)
DMLT4JA	MT	DTT
DMLT4JA	MA	Agonist
DMLT4JA	RN	Cloning, pharmacology, and tissue distribution of G-protein-coupled receptor GPR105 (KIAA0001) rodent orthologs. Genomics. 2001 Dec;78(3):124-8.
DMLT4JA	RU	https://pubmed.ncbi.nlm.nih.gov/11735218

DMLT4JA	DI	DMLT4JA
DMLT4JA	DN	UDP-glucose
DMLT4JA	MI	TTGRHIB
DMLT4JA	MN	UDP-glucose 4-epimerase (GALE)
DMLT4JA	MT	DTT
DMLT4JA	MA	Inhibitor
DMLT4JA	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMLT4JA	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMLT4JA	DI	DMLT4JA
DMLT4JA	DN	UDP-glucose
DMLT4JA	MI	DE48Q2Z
DMLT4JA	MN	UDP-glucose 6-dehydrogenase (UGDH)
DMLT4JA	MT	DME
DMLT4JA	MA	Metabolism
DMLT4JA	RN	Importance of Gly-13 for the coenzyme binding of human UDP-glucose dehydrogenase. J Biol Chem. 2004 Sep 3;279(36):37491-8.
DMLT4JA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15247292

DMLT4JA	DI	DMLT4JA
DMLT4JA	DN	UDP-glucose
DMLT4JA	MI	DTOUNZE
DMLT4JA	MN	UDP-N-acetylglucosamine/UDP-glucose/GDP-mannose transporter (SLC35D2)
DMLT4JA	MT	DTP
DMLT4JA	MA	Substrate
DMLT4JA	RN	Identification and characterization of human Golgi nucleotide sugar transporter SLC35D2, a novel member of the SLC35 nucleotide sugar transporter family. Genomics. 2005 Jan;85(1):106-16.
DMLT4JA	RU	http://www.ncbi.nlm.nih.gov/pubmed/15607426

DMLT4JA	DI	DMLT4JA
DMLT4JA	DN	UDP-glucose
DMLT4JA	MI	TTMPART
DMLT4JA	MN	Uracil nucleotide/cysteinyl leukotriene receptor (GPR17)
DMLT4JA	MT	DTT
DMLT4JA	MA	Agonist
DMLT4JA	RN	The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO J. 2006 Oct 4;25(19):4615-27.
DMLT4JA	RU	https://pubmed.ncbi.nlm.nih.gov/16990797

DMW16X2	DI	DMW16X2
DMW16X2	DN	UDP-glucuronic acid
DMW16X2	MI	DEBH7ND
DMW16X2	MN	Chondroitin sulfate glucuronyltransferase (CHPF2)
DMW16X2	MT	DME
DMW16X2	MA	Metabolism
DMW16X2	RN	Molecular cloning and characterization of a novel chondroitin sulfate glucuronyltransferase that transfers glucuronic acid to N-acetylgalactosamine. J Biol Chem. 2002 Oct 11;277(41):38179-88.
DMW16X2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12145278

DMW16X2	DI	DMW16X2
DMW16X2	DN	UDP-glucuronic acid
DMW16X2	MI	TT72OKI
DMW16X2	MN	P2Y purinoceptor 14 (P2RY14)
DMW16X2	MT	DTT
DMW16X2	MA	Agonist
DMW16X2	RN	Gi-dependent cell signaling responses of the human P2Y14 receptor in model cell systems. J Pharmacol Exp Ther. 2009 Jul;330(1):162-8.
DMW16X2	RU	https://pubmed.ncbi.nlm.nih.gov/19339661

DMW16X2	DI	DMW16X2
DMW16X2	DN	UDP-glucuronic acid
DMW16X2	MI	DELOY3P
DMW16X2	MN	UDP-glucuronosyltransferase 1A4 (UGT1A4)
DMW16X2	MT	DME
DMW16X2	MA	Metabolism
DMW16X2	RN	Identification of aspartic acid and histidine residues mediating the reaction mechanism and the substrate specificity of the human UDP-glucuronosyltransferases 1A. J Biol Chem. 2007 Dec 14;282(50):36514-24.
DMW16X2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17956868

DMW16X2	DI	DMW16X2
DMW16X2	DN	UDP-glucuronic acid
DMW16X2	MI	DESD26P
DMW16X2	MN	UDP-glucuronosyltransferase 1A6 (UGT1A6)
DMW16X2	MT	DME
DMW16X2	MA	Metabolism
DMW16X2	RN	Identification of aspartic acid and histidine residues mediating the reaction mechanism and the substrate specificity of the human UDP-glucuronosyltransferases 1A. J Biol Chem. 2007 Dec 14;282(50):36514-24.
DMW16X2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17956868

DMVE7MZ	DI	DMVE7MZ
DMVE7MZ	DN	UDP-xylose
DMVE7MZ	MI	DTMALXP
DMVE7MZ	MN	UDP-xylose and UDP-N-acetylglucosamine transporter (SLC35B4)
DMVE7MZ	MT	DTP
DMVE7MZ	MA	Substrate
DMVE7MZ	RN	The human solute carrier gene SLC35B4 encodes a bifunctional nucleotide sugar transporter with specificity for UDP-xylose and UDP-N-acetylglucosamine. J Biol Chem. 2005 Jul 22;280(29):27230-5.
DMVE7MZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/15911612

DMKZF01	DI	DMKZF01
DMKZF01	DN	UFP-101
DMKZF01	MI	TTNT7K8
DMKZF01	MN	Nociceptin receptor (OPRL1)
DMKZF01	MT	DTT
DMKZF01	MA	Antagonist
DMKZF01	RN	Nphe1,Arg14,Lys15nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor. Br J Pharmacol. 2002 May;136(2):303-11.
DMKZF01	RU	https://pubmed.ncbi.nlm.nih.gov/12010780

DMENTMP	DI	DMENTMP
DMENTMP	DN	UFP-112
DMENTMP	MI	TTNT7K8
DMENTMP	MN	Nociceptin receptor (OPRL1)
DMENTMP	MT	DTT
DMENTMP	MA	Agonist
DMENTMP	RN	Pharmacological profile of NOP receptors coupled with calcium signaling via the chimeric protein G alpha qi5. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jun;379(6):599-607.
DMENTMP	RU	https://pubmed.ncbi.nlm.nih.gov/19183962

DMD8BRG	DI	DMD8BRG
DMD8BRG	DN	UFP-502
DMD8BRG	MI	TT27RFC
DMD8BRG	MN	Opioid receptor delta (OPRD1)
DMD8BRG	MT	DTT
DMD8BRG	MA	Inhibitor
DMD8BRG	RN	Role of 2',6'-dimethyl-l-tyrosine (Dmt) in some opioid lead compounds. Bioorg Med Chem. 2010 Aug 15;18(16):6024-30.
DMD8BRG	RU	https://pubmed.ncbi.nlm.nih.gov/20637637

DMD8BRG	DI	DMD8BRG
DMD8BRG	DN	UFP-502
DMD8BRG	MI	TTKWM86
DMD8BRG	MN	Opioid receptor mu (MOP)
DMD8BRG	MT	DTT
DMD8BRG	MA	Inhibitor
DMD8BRG	RN	Role of 2',6'-dimethyl-l-tyrosine (Dmt) in some opioid lead compounds. Bioorg Med Chem. 2010 Aug 15;18(16):6024-30.
DMD8BRG	RU	https://pubmed.ncbi.nlm.nih.gov/20637637

DMYPVSJ	DI	DMYPVSJ
DMYPVSJ	DN	UFP-512
DMYPVSJ	MI	TT27RFC
DMYPVSJ	MN	Opioid receptor delta (OPRD1)
DMYPVSJ	MT	DTT
DMYPVSJ	MA	Inhibitor
DMYPVSJ	RN	Role of 2',6'-dimethyl-l-tyrosine (Dmt) in some opioid lead compounds. Bioorg Med Chem. 2010 Aug 15;18(16):6024-30.
DMYPVSJ	RU	https://pubmed.ncbi.nlm.nih.gov/20637637

DMYPVSJ	DI	DMYPVSJ
DMYPVSJ	DN	UFP-512
DMYPVSJ	MI	TTKWM86
DMYPVSJ	MN	Opioid receptor mu (MOP)
DMYPVSJ	MT	DTT
DMYPVSJ	MA	Inhibitor
DMYPVSJ	RN	Role of 2',6'-dimethyl-l-tyrosine (Dmt) in some opioid lead compounds. Bioorg Med Chem. 2010 Aug 15;18(16):6024-30.
DMYPVSJ	RU	https://pubmed.ncbi.nlm.nih.gov/20637637

DM5K6ZE	DI	DM5K6ZE
DM5K6ZE	DN	UH-232
DM5K6ZE	MI	TTSQIFT
DM5K6ZE	MN	5-HT 1A receptor (HTR1A)
DM5K6ZE	MT	DTT
DM5K6ZE	MA	Inhibitor
DM5K6ZE	RN	(Dipropylamino)-tetrahydronaphthofurans: centrally acting serotonin agonists and dopamine agonists-antagonists, Bioorg. Med. Chem. Lett. 7(21):2759-2764 (1997).
DM5K6ZE	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97100683

DM5K6ZE	DI	DM5K6ZE
DM5K6ZE	DN	UH-232
DM5K6ZE	MI	TTEX248
DM5K6ZE	MN	Dopamine D2 receptor (D2R)
DM5K6ZE	MT	DTT
DM5K6ZE	MA	Inhibitor
DM5K6ZE	RN	(Dipropylamino)-tetrahydronaphthofurans: centrally acting serotonin agonists and dopamine agonists-antagonists, Bioorg. Med. Chem. Lett. 7(21):2759-2764 (1997).
DM5K6ZE	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97100683

DM5K6ZE	DI	DM5K6ZE
DM5K6ZE	DN	UH-232
DM5K6ZE	MI	TT4C8EA
DM5K6ZE	MN	Dopamine D3 receptor (D3R)
DM5K6ZE	MT	DTT
DM5K6ZE	MA	Inhibitor
DM5K6ZE	RN	(Dipropylamino)-tetrahydronaphthofurans: centrally acting serotonin agonists and dopamine agonists-antagonists, Bioorg. Med. Chem. Lett. 7(21):2759-2764 (1997).
DM5K6ZE	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97100683

DM5K6ZE	DI	DM5K6ZE
DM5K6ZE	DN	UH-232
DM5K6ZE	MI	TTE0A2F
DM5K6ZE	MN	Dopamine D4 receptor (D4R)
DM5K6ZE	MT	DTT
DM5K6ZE	MA	Inhibitor
DM5K6ZE	RN	(Dipropylamino)-tetrahydronaphthofurans: centrally acting serotonin agonists and dopamine agonists-antagonists, Bioorg. Med. Chem. Lett. 7(21):2759-2764 (1997).
DM5K6ZE	RU	http://www.sciencedirect.com/science/article/pii/S0960894X97100683

DM5NYWV	DI	DM5NYWV
DM5NYWV	DN	UH-301
DM5NYWV	MI	TTSQIFT
DM5NYWV	MN	5-HT 1A receptor (HTR1A)
DM5NYWV	MT	DTT
DM5NYWV	MA	Inhibitor
DM5NYWV	RN	N-[2-[(substituted chroman-8-yl)oxy]ethyl]-4-(4-methoxyphenyl)butylamines: synthesis and wide range of antagonism at the human 5-HT1A receptor. J Med Chem. 1997 Apr 11;40(8):1252-7.
DM5NYWV	RU	https://pubmed.ncbi.nlm.nih.gov/9111299

DM5NYWV	DI	DM5NYWV
DM5NYWV	DN	UH-301
DM5NYWV	MI	TTNGILX
DM5NYWV	MN	Adrenergic receptor alpha-1A (ADRA1A)
DM5NYWV	MT	DTT
DM5NYWV	MA	Inhibitor
DM5NYWV	RN	N-[2-[(substituted chroman-8-yl)oxy]ethyl]-4-(4-methoxyphenyl)butylamines: synthesis and wide range of antagonism at the human 5-HT1A receptor. J Med Chem. 1997 Apr 11;40(8):1252-7.
DM5NYWV	RU	https://pubmed.ncbi.nlm.nih.gov/9111299

DM5NYWV	DI	DM5NYWV
DM5NYWV	DN	UH-301
DM5NYWV	MI	TTBRKXS
DM5NYWV	MN	Adrenergic receptor alpha-1B (ADRA1B)
DM5NYWV	MT	DTT
DM5NYWV	MA	Inhibitor
DM5NYWV	RN	N-[2-[(substituted chroman-8-yl)oxy]ethyl]-4-(4-methoxyphenyl)butylamines: synthesis and wide range of antagonism at the human 5-HT1A receptor. J Med Chem. 1997 Apr 11;40(8):1252-7.
DM5NYWV	RU	https://pubmed.ncbi.nlm.nih.gov/9111299

DM5NYWV	DI	DM5NYWV
DM5NYWV	DN	UH-301
DM5NYWV	MI	TT34BHT
DM5NYWV	MN	Adrenergic receptor alpha-1D (ADRA1D)
DM5NYWV	MT	DTT
DM5NYWV	MA	Inhibitor
DM5NYWV	RN	N-[2-[(substituted chroman-8-yl)oxy]ethyl]-4-(4-methoxyphenyl)butylamines: synthesis and wide range of antagonism at the human 5-HT1A receptor. J Med Chem. 1997 Apr 11;40(8):1252-7.
DM5NYWV	RU	https://pubmed.ncbi.nlm.nih.gov/9111299

DM5NYWV	DI	DM5NYWV
DM5NYWV	DN	UH-301
DM5NYWV	MI	TTEX248
DM5NYWV	MN	Dopamine D2 receptor (D2R)
DM5NYWV	MT	DTT
DM5NYWV	MA	Inhibitor
DM5NYWV	RN	N-[2-[(substituted chroman-8-yl)oxy]ethyl]-4-(4-methoxyphenyl)butylamines: synthesis and wide range of antagonism at the human 5-HT1A receptor. J Med Chem. 1997 Apr 11;40(8):1252-7.
DM5NYWV	RU	https://pubmed.ncbi.nlm.nih.gov/9111299

DMT5UMG	DI	DMT5UMG
DMT5UMG	DN	UH-AH 37
DMT5UMG	MI	TTOXS3C
DMT5UMG	MN	Muscarinic acetylcholine receptor (CHRM)
DMT5UMG	MT	DTT
DMT5UMG	MA	Antagonist
DMT5UMG	RN	Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists. Eur J Pharmacol. 1998 May 22;349(2-3):285-92.
DMT5UMG	RU	https://pubmed.ncbi.nlm.nih.gov/9671109

DMT5UMG	DI	DMT5UMG
DMT5UMG	DN	UH-AH 37
DMT5UMG	MI	TTQ13Z5
DMT5UMG	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMT5UMG	MT	DTT
DMT5UMG	MA	Antagonist
DMT5UMG	RN	Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists. Eur J Pharmacol. 1998 May 22;349(2-3):285-92.
DMT5UMG	RU	https://pubmed.ncbi.nlm.nih.gov/9671109

DMOVY6L	DI	DMOVY6L
DMOVY6L	DN	Uinagolide
DMOVY6L	MI	TTEX248
DMOVY6L	MN	Dopamine D2 receptor (D2R)
DMOVY6L	MT	DTT
DMOVY6L	MA	Agonist
DMOVY6L	RN	Effect of dopamine receptor agonists on sensory nerve activity: possible therapeutic targets for the treatment of asthma and COPD. Br J Pharmacol. 2002 Jun;136(4):620-8.
DMOVY6L	RU	https://pubmed.ncbi.nlm.nih.gov/12055141

DM6GLSF	DI	DM6GLSF
DM6GLSF	DN	UK-129485
DM6GLSF	MI	TT84ETX
DM6GLSF	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM6GLSF	MT	DTT
DM6GLSF	MA	Inhibitor
DM6GLSF	RN	Imidazo[2 3 :6,5]dipyrido[3,2-b:2 3 e]-1,4-diazepines: non-nucleoside HIV-1 reverse transcriptase inhibitors with greater enzyme affinity than nevirapine, Bioorg. Med. Chem. Lett. 2(12):1745-1750(1992).
DM6GLSF	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00804680

DM02FGH	DI	DM02FGH
DM02FGH	DN	UK-356618
DM02FGH	MI	TTHY57M
DM02FGH	MN	Matrix metalloproteinase-13 (MMP-13)
DM02FGH	MT	DTT
DM02FGH	MA	Inhibitor
DM02FGH	RN	A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. J Med Chem. 2003 Jul 31;46(16):3514-25.
DM02FGH	RU	https://pubmed.ncbi.nlm.nih.gov/12877590

DM02FGH	DI	DM02FGH
DM02FGH	DN	UK-356618
DM02FGH	MI	TTJ4QE7
DM02FGH	MN	Matrix metalloproteinase-14 (MMP-14)
DM02FGH	MT	DTT
DM02FGH	MA	Inhibitor
DM02FGH	RN	A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. J Med Chem. 2003 Jul 31;46(16):3514-25.
DM02FGH	RU	https://pubmed.ncbi.nlm.nih.gov/12877590

DM02FGH	DI	DM02FGH
DM02FGH	DN	UK-356618
DM02FGH	MI	TTLM12X
DM02FGH	MN	Matrix metalloproteinase-2 (MMP-2)
DM02FGH	MT	DTT
DM02FGH	MA	Inhibitor
DM02FGH	RN	A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. J Med Chem. 2003 Jul 31;46(16):3514-25.
DM02FGH	RU	https://pubmed.ncbi.nlm.nih.gov/12877590

DM02FGH	DI	DM02FGH
DM02FGH	DN	UK-356618
DM02FGH	MI	TTUZ2L5
DM02FGH	MN	Matrix metalloproteinase-3 (MMP-3)
DM02FGH	MT	DTT
DM02FGH	MA	Inhibitor
DM02FGH	RN	A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. J Med Chem. 2003 Jul 31;46(16):3514-25.
DM02FGH	RU	https://pubmed.ncbi.nlm.nih.gov/12877590

DM02FGH	DI	DM02FGH
DM02FGH	DN	UK-356618
DM02FGH	MI	TT6X50U
DM02FGH	MN	Matrix metalloproteinase-9 (MMP-9)
DM02FGH	MT	DTT
DM02FGH	MA	Inhibitor
DM02FGH	RN	A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. J Med Chem. 2003 Jul 31;46(16):3514-25.
DM02FGH	RU	https://pubmed.ncbi.nlm.nih.gov/12877590

DME7VG6	DI	DME7VG6
DME7VG6	DN	UK-383367
DME7VG6	MI	TT0L58T
DME7VG6	MN	Bone morphogenetic protein 1 (BMP1)
DME7VG6	MT	DTT
DME7VG6	MA	Inhibitor
DME7VG6	RN	Succinyl hydroxamates as potent and selective non-peptidic inhibitors of procollagen C-proteinase: design, synthesis, and evaluation as topically a... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6562-7.
DME7VG6	RU	https://pubmed.ncbi.nlm.nih.gov/18945617

DMXSTF2	DI	DMXSTF2
DMXSTF2	DN	UNC0006
DMXSTF2	MI	TTEX248
DMXSTF2	MN	Dopamine D2 receptor (D2R)
DMXSTF2	MT	DTT
DMXSTF2	MA	Agonist
DMXSTF2	RN	Discovery of beta-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):18488-93.
DMXSTF2	RU	https://pubmed.ncbi.nlm.nih.gov/22025698

DMCVU1T	DI	DMCVU1T
DMCVU1T	DN	UNC0321
DMCVU1T	MI	TTS6RZT
DMCVU1T	MN	Histone-lysine N-methyltransferase EHMT2 (EHMT2)
DMCVU1T	MT	DTT
DMCVU1T	MA	Inhibitor
DMCVU1T	RN	Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines. J Med Chem. 2010 Aug 12;53(15):5844-57.
DMCVU1T	RU	https://pubmed.ncbi.nlm.nih.gov/20614940

DM4A1KJ	DI	DM4A1KJ
DM4A1KJ	DN	UNC0638
DM4A1KJ	MI	TTOFXD7
DM4A1KJ	MN	Euchromatic histone-lysine N-methyltransferase 1 (EHMT1)
DM4A1KJ	MT	DTT
DM4A1KJ	MA	Inhibitor
DM4A1KJ	RN	A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat Chem Biol. 2011 Jul 10;7(8):566-74.
DM4A1KJ	RU	https://pubmed.ncbi.nlm.nih.gov/21743462

DM4A1KJ	DI	DM4A1KJ
DM4A1KJ	DN	UNC0638
DM4A1KJ	MI	TTS6RZT
DM4A1KJ	MN	Histone-lysine N-methyltransferase EHMT2 (EHMT2)
DM4A1KJ	MT	DTT
DM4A1KJ	MA	Inhibitor
DM4A1KJ	RN	A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat Chem Biol. 2011 Jul 10;7(8):566-74.
DM4A1KJ	RU	https://pubmed.ncbi.nlm.nih.gov/21743462

DM7Y1SO	DI	DM7Y1SO
DM7Y1SO	DN	UNC0642
DM7Y1SO	MI	TTOFXD7
DM7Y1SO	MN	Euchromatic histone-lysine N-methyltransferase 1 (EHMT1)
DM7Y1SO	MT	DTT
DM7Y1SO	MA	Inhibitor
DM7Y1SO	RN	Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP. J Med Chem. 2013 Nov 14;56(21):8931-42.
DM7Y1SO	RU	https://pubmed.ncbi.nlm.nih.gov/24102134

DM7Y1SO	DI	DM7Y1SO
DM7Y1SO	DN	UNC0642
DM7Y1SO	MI	TTS6RZT
DM7Y1SO	MN	Histone-lysine N-methyltransferase EHMT2 (EHMT2)
DM7Y1SO	MT	DTT
DM7Y1SO	MA	Inhibitor
DM7Y1SO	RN	Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP. J Med Chem. 2013 Nov 14;56(21):8931-42.
DM7Y1SO	RU	https://pubmed.ncbi.nlm.nih.gov/24102134

DMWMRLS	DI	DMWMRLS
DMWMRLS	DN	UNC1215
DMWMRLS	MI	TTQDMJN
DMWMRLS	MN	Lethal(3)malignant brain tumor-like 3 (L3MBTL3)
DMWMRLS	MT	DTT
DMWMRLS	MA	Agonist
DMWMRLS	RN	Discovery of a chemical probe for the L3MBTL3 methyllysine reader domain. Nat Chem Biol. 2013 Mar;9(3):184-91.
DMWMRLS	RU	https://pubmed.ncbi.nlm.nih.gov/23292653

DMOPCBD	DI	DMOPCBD
DMOPCBD	DN	UNC1999
DMOPCBD	MI	TT9MZCQ
DMOPCBD	MN	Enhancer of zeste homolog 2 (EZH2)
DMOPCBD	MT	DTT
DMOPCBD	MA	Inhibitor
DMOPCBD	RN	An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1. ACS Chem Biol. 2013;8(6):1324-34.
DMOPCBD	RU	https://pubmed.ncbi.nlm.nih.gov/23614352

DMCU59W	DI	DMCU59W
DMCU59W	DN	UNC2025
DMCU59W	MI	TTO7LKR
DMCU59W	MN	Tyrosine-protein kinase Mer (MERTK)
DMCU59W	MT	DTT
DMCU59W	MA	Inhibitor
DMCU59W	RN	MerTK as a therapeutic target in glioblastoma. Neuro Oncol. 2018 Jan 10;20(1):92-102.
DMCU59W	RU	https://pubmed.ncbi.nlm.nih.gov/28605477

DMJL6ZM	DI	DMJL6ZM
DMJL6ZM	DN	UNC569
DMJL6ZM	MI	TTO7LKR
DMJL6ZM	MN	Tyrosine-protein kinase Mer (MERTK)
DMJL6ZM	MT	DTT
DMJL6ZM	MA	Inhibitor
DMJL6ZM	RN	UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo. Mol Cancer Ther. 2013 Nov;12(11):2367-77.
DMJL6ZM	RU	https://pubmed.ncbi.nlm.nih.gov/23997116

DM4RDVO	DI	DM4RDVO
DM4RDVO	DN	UNC9975
DM4RDVO	MI	TTEX248
DM4RDVO	MN	Dopamine D2 receptor (D2R)
DM4RDVO	MT	DTT
DM4RDVO	MA	Agonist
DM4RDVO	RN	Discovery of beta-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):18488-93.
DM4RDVO	RU	https://pubmed.ncbi.nlm.nih.gov/22025698

DMDK86V	DI	DMDK86V
DMDK86V	DN	UNC9994
DMDK86V	MI	TTEX248
DMDK86V	MN	Dopamine D2 receptor (D2R)
DMDK86V	MT	DTT
DMDK86V	MA	Agonist
DMDK86V	RN	Discovery of beta-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):18488-93.
DMDK86V	RU	https://pubmed.ncbi.nlm.nih.gov/22025698

DMFOIPL	DI	DMFOIPL
DMFOIPL	DN	undecanoic acid
DMFOIPL	MI	TTG0MQD
DMFOIPL	MN	Inflammation-related GPCR EX33 (GPR84)
DMFOIPL	MT	DTT
DMFOIPL	MA	Agonist
DMFOIPL	RN	Medium-chain fatty acids as ligands for orphan G protein-coupled receptor GPR84. J Biol Chem. 2006 Nov 10;281(45):34457-64.
DMFOIPL	RU	https://pubmed.ncbi.nlm.nih.gov/16966319

DM4AYC2	DI	DM4AYC2
DM4AYC2	DN	Undecylamine-n,n-dimethyl-n-oxide
DM4AYC2	MI	TT3PQ2Y
DM4AYC2	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DM4AYC2	MT	DTT
DM4AYC2	MA	Inhibitor
DM4AYC2	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM4AYC2	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMD9KEB	DI	DMD9KEB
DMD9KEB	DN	Undecyl-Phosphinic Acid Butyl Ester
DMD9KEB	MI	TTKYZA9
DMD9KEB	MN	Gastric triacylglycerol lipase (LIPF)
DMD9KEB	MT	DTT
DMD9KEB	MA	Inhibitor
DMD9KEB	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMD9KEB	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMFH79T	DI	DMFH79T
DMFH79T	DN	UNIFLORINE B
DMFH79T	MI	TTLPC70
DMFH79T	MN	Lysosomal alpha-glucosidase (GAA)
DMFH79T	MT	DTT
DMFH79T	MA	Inhibitor
DMFH79T	RN	Total synthesis of (-)-uniflorine A. J Nat Prod. 2009 Nov;72(11):2058-60.
DMFH79T	RU	https://pubmed.ncbi.nlm.nih.gov/19835391

DMKQWSB	DI	DMKQWSB
DMKQWSB	DN	Up3U
DMKQWSB	MI	TTNVSKA
DMKQWSB	MN	P2Y purinoceptor 6 (P2RY6)
DMKQWSB	MT	DTT
DMKQWSB	MA	Agonist
DMKQWSB	RN	P2 receptors activated by uracil nucleotides--an update. Curr Med Chem. 2006;13(3):289-312.
DMKQWSB	RU	https://pubmed.ncbi.nlm.nih.gov/16475938

DMR46C8	DI	DMR46C8
DMR46C8	DN	UPA-targeted oncolytic Sendai virus
DMR46C8	MI	TTGY7WI
DMR46C8	MN	Urokinase-type plasminogen activator (PLAU)
DMR46C8	MT	DTT
DMR46C8	MA	Inhibitor
DMR46C8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2393).
DMR46C8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2393

DMPF1VU	DI	DMPF1VU
DMPF1VU	DN	UR-10324
DMPF1VU	MI	TTQL5VC
DMPF1VU	MN	Platelet-activating factor receptor (PTAFR)
DMPF1VU	MT	DTT
DMPF1VU	MA	Modulator
DMPF1VU	RN	Effects of PAF-antagonists in mouse ear oedema induced by several inflammatory agents. Br J Pharmacol. 1991 Dec;104(4):990-4.
DMPF1VU	RU	https://www.ncbi.nlm.nih.gov/pubmed/1810607

DM8G9NY	DI	DM8G9NY
DM8G9NY	DN	UR-11353
DM8G9NY	MI	TTQL5VC
DM8G9NY	MN	Platelet-activating factor receptor (PTAFR)
DM8G9NY	MT	DTT
DM8G9NY	MA	Modulator
DM8G9NY	RN	Effects of PAF-antagonists in mouse ear oedema induced by several inflammatory agents. Br J Pharmacol. 1991 Dec;104(4):990-4.
DM8G9NY	RU	https://www.ncbi.nlm.nih.gov/pubmed/1810607

DM2HVUW	DI	DM2HVUW
DM2HVUW	DN	UR-12510
DM2HVUW	MI	TTQL5VC
DM2HVUW	MN	Platelet-activating factor receptor (PTAFR)
DM2HVUW	MT	DTT
DM2HVUW	MA	Modulator
DM2HVUW	RN	US patent application no. 6,673,908, Tumor necrosis factor receptor 2.
DM2HVUW	RU	http://www.google.com/patents/US6673908

DMVZQ47	DI	DMVZQ47
DMVZQ47	DN	UR-12519
DMVZQ47	MI	TTQL5VC
DMVZQ47	MN	Platelet-activating factor receptor (PTAFR)
DMVZQ47	MT	DTT
DMVZQ47	MA	Modulator
DMVZQ47	RN	Evidence for the autocrine induction of capacitation of mammalian spermatozoa.J Biol Chem.2001 Jul 20;276(29):26962-8.
DMVZQ47	RU	https://www.ncbi.nlm.nih.gov/pubmed/11350972

DM3YE5X	DI	DM3YE5X
DM3YE5X	DN	UR-60427
DM3YE5X	MI	TTXJ178
DM3YE5X	MN	Histamine H4 receptor (H4R)
DM3YE5X	MT	DTT
DM3YE5X	MA	Agonist
DM3YE5X	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 265).
DM3YE5X	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=265

DMNPO9Q	DI	DMNPO9Q
DMNPO9Q	DN	Uracil
DMNPO9Q	MI	TTZPS91
DMNPO9Q	MN	Dihydrothymine dehydrogenase (DPYD)
DMNPO9Q	MT	DTT
DMNPO9Q	MA	Modulator
DMNPO9Q	RN	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
DMNPO9Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/27899562

DMA1MKT	DI	DMA1MKT
DMA1MKT	DN	Uric acid
DMA1MKT	MI	DTI7UX6
DMA1MKT	MN	Breast cancer resistance protein (ABCG2)
DMA1MKT	MT	DTP
DMA1MKT	MA	Substrate
DMA1MKT	RN	Extra-renal elimination of uric acid via intestinal efflux transporter BCRP/ABCG2. PLoS One. 2012;7(2):e30456.
DMA1MKT	RU	https://doi.org/10.1371/journal.pone.0030456

DMA1MKT	DI	DMA1MKT
DMA1MKT	DN	Uric acid
DMA1MKT	MI	DTQK5O9
DMA1MKT	MN	Monocarboxylate transporter 9 (SLC16A9)
DMA1MKT	MT	DTP
DMA1MKT	MA	Substrate
DMA1MKT	RN	Common missense variant of monocarboxylate transporter 9 (MCT9/SLC16A9) gene is associated with renal overload gout, but not with all gout susceptibility. Hum Cell. 2013 Dec;26(4):133-6.
DMA1MKT	RU	http://www.ncbi.nlm.nih.gov/pubmed/23990105

DMA1MKT	DI	DMA1MKT
DMA1MKT	DN	Uric acid
DMA1MKT	MI	DTQ23VB
DMA1MKT	MN	Organic anion transporter 1 (SLC22A6)
DMA1MKT	MT	DTP
DMA1MKT	MA	Substrate
DMA1MKT	RN	Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers. Pharm Res. 2008 Mar;25(3):639-46.
DMA1MKT	RU	http://www.ncbi.nlm.nih.gov/pubmed/17674156

DMA1MKT	DI	DMA1MKT
DMA1MKT	DN	Uric acid
DMA1MKT	MI	DTVP67E
DMA1MKT	MN	Organic anion transporter 3 (SLC22A8)
DMA1MKT	MT	DTP
DMA1MKT	MA	Substrate
DMA1MKT	RN	Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers. Pharm Res. 2008 Mar;25(3):639-46.
DMA1MKT	RU	http://www.ncbi.nlm.nih.gov/pubmed/17674156

DMA1MKT	DI	DMA1MKT
DMA1MKT	DN	Uric acid
DMA1MKT	MI	DT06JWZ
DMA1MKT	MN	Organic anion transporter 4 (SLC22A11)
DMA1MKT	MT	DTP
DMA1MKT	MA	Substrate
DMA1MKT	RN	Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers. Pharm Res. 2008 Mar;25(3):639-46.
DMA1MKT	RU	http://www.ncbi.nlm.nih.gov/pubmed/17674156

DMA1MKT	DI	DMA1MKT
DMA1MKT	DN	Uric acid
DMA1MKT	MI	DT2WLAD
DMA1MKT	MN	Urate anion exchanger 1 (SLC22A12)
DMA1MKT	MT	DTP
DMA1MKT	MA	Substrate
DMA1MKT	RN	Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J Pharmacol Exp Ther. 2007 Jan;320(1):211-7.
DMA1MKT	RU	http://www.ncbi.nlm.nih.gov/pubmed/17043154

DMPA0BJ	DI	DMPA0BJ
DMPA0BJ	DN	Uridine diphosphate galactose
DMPA0BJ	MI	DE8RIZD
DMPA0BJ	MN	Collagen galactosyltransferase (COLGALT2)
DMPA0BJ	MT	DME
DMPA0BJ	MA	Metabolism
DMPA0BJ	RN	Core glycosylation of collagen is initiated by two beta(1-O)galactosyltransferases. Mol Cell Biol. 2009 Feb;29(4):943-52.
DMPA0BJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19075007

DMPA0BJ	DI	DMPA0BJ
DMPA0BJ	DN	Uridine diphosphate galactose
DMPA0BJ	MI	DESIA7R
DMPA0BJ	MN	Histo-blood group ABO system transferase (NAGAT)
DMPA0BJ	MT	DME
DMPA0BJ	MA	Metabolism
DMPA0BJ	RN	Structural basis for red cell phenotypic changes in newly identified, naturally occurring subgroup mutants of the human blood group B glycosyltransferase. Transfusion. 2007 May;47(5):864-75.
DMPA0BJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17465952

DMPA0BJ	DI	DMPA0BJ
DMPA0BJ	DN	Uridine diphosphate galactose
DMPA0BJ	MI	TTGRHIB
DMPA0BJ	MN	UDP-glucose 4-epimerase (GALE)
DMPA0BJ	MT	DTT
DMPA0BJ	MA	Inhibitor
DMPA0BJ	RN	Crystal structure of beta1,4-galactosyltransferase complex with UDP-Gal reveals an oligosaccharide acceptor binding site. J Mol Biol. 2002 Apr 26;318(2):491-502.
DMPA0BJ	RU	https://pubmed.ncbi.nlm.nih.gov/12051854

DMPA0BJ	DI	DMPA0BJ
DMPA0BJ	DN	Uridine diphosphate galactose
DMPA0BJ	MI	DEKRS6L
DMPA0BJ	MN	Xylosylprotein 4-beta-galactosyltransferase (XGalT-1)
DMPA0BJ	MT	DME
DMPA0BJ	MA	Metabolism
DMPA0BJ	RN	Probing the acceptor active site organization of the human recombinant beta1,4-galactosyltransferase 7 and design of xyloside-based inhibitors. J Biol Chem. 2015 Mar 20;290(12):7658-70.
DMPA0BJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25568325

DMDQKJB	DI	DMDQKJB
DMDQKJB	DN	Uridine-5'-Diphosphate
DMDQKJB	MI	TTGRHIB
DMDQKJB	MN	UDP-glucose 4-epimerase (GALE)
DMDQKJB	MT	DTT
DMDQKJB	MA	Inhibitor
DMDQKJB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMDQKJB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMAYCQU	DI	DMAYCQU
DMAYCQU	DN	Uridine-5'-Diphosphate-Mannose
DMAYCQU	MI	TTGRHIB
DMAYCQU	MN	UDP-glucose 4-epimerase (GALE)
DMAYCQU	MT	DTT
DMAYCQU	MA	Inhibitor
DMAYCQU	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMAYCQU	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMG1NM7	DI	DMG1NM7
DMG1NM7	DN	Uridine-5'-Monophosphate
DMG1NM7	MI	TTU6BFZ
DMG1NM7	MN	Candida Thymidylate synthase (Candi TMP1)
DMG1NM7	MT	DTT
DMG1NM7	MA	Inhibitor
DMG1NM7	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMG1NM7	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMG1NM7	DI	DMG1NM7
DMG1NM7	DN	Uridine-5'-Monophosphate
DMG1NM7	MI	TTV7Y40
DMG1NM7	MN	Mycobacterium Orotidine phosphate decarboxylase (MycB pyrF)
DMG1NM7	MT	DTT
DMG1NM7	MA	Inhibitor
DMG1NM7	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMG1NM7	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMXHO6J	DI	DMXHO6J
DMXHO6J	DN	Uridine-Diphosphate-N-Acetylgalactosamine
DMXHO6J	MI	TTP8UCK
DMXHO6J	MN	Bacterial Glycosyltransferase MurG (Bact murG)
DMXHO6J	MT	DTT
DMXHO6J	MA	Inhibitor
DMXHO6J	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMXHO6J	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMXHO6J	DI	DMXHO6J
DMXHO6J	DN	Uridine-Diphosphate-N-Acetylgalactosamine
DMXHO6J	MI	TTGRHIB
DMXHO6J	MN	UDP-glucose 4-epimerase (GALE)
DMXHO6J	MT	DTT
DMXHO6J	MA	Inhibitor
DMXHO6J	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMXHO6J	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMEQSTP	DI	DMEQSTP
DMEQSTP	DN	Uridine-Diphosphate-N-Acetylglucosamine
DMEQSTP	MI	TTICX3S
DMEQSTP	MN	Bacterial UDP-N-acetylglucosamine carboxyvinyltransferase (Bact murA)
DMEQSTP	MT	DTT
DMEQSTP	MA	Inhibitor
DMEQSTP	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMEQSTP	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMEQSTP	DI	DMEQSTP
DMEQSTP	DN	Uridine-Diphosphate-N-Acetylglucosamine
DMEQSTP	MI	TTGRHIB
DMEQSTP	MN	UDP-glucose 4-epimerase (GALE)
DMEQSTP	MT	DTT
DMEQSTP	MA	Inhibitor
DMEQSTP	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMEQSTP	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMCJXWK	DI	DMCJXWK
DMCJXWK	DN	URMC-099
DMCJXWK	MI	TTMO45N
DMCJXWK	MN	Cyclin-dependent kinase-like 2 (CDKL2)
DMCJXWK	MT	DTT
DMCJXWK	MA	Inhibitor
DMCJXWK	RN	Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3. J Med Chem. 2013 Oct 24;56(20):8032-48.
DMCJXWK	RU	https://pubmed.ncbi.nlm.nih.gov/24044867

DMCJXWK	DI	DMCJXWK
DMCJXWK	DN	URMC-099
DMCJXWK	MI	TTERVQN
DMCJXWK	MN	Death-associated protein kinase 3 (DAPK3)
DMCJXWK	MT	DTT
DMCJXWK	MA	Inhibitor
DMCJXWK	RN	Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3. J Med Chem. 2013 Oct 24;56(20):8032-48.
DMCJXWK	RU	https://pubmed.ncbi.nlm.nih.gov/24044867

DMCJXWK	DI	DMCJXWK
DMCJXWK	DN	URMC-099
DMCJXWK	MI	TTGJCWZ
DMCJXWK	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMCJXWK	MT	DTT
DMCJXWK	MA	Inhibitor
DMCJXWK	RN	Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3. J Med Chem. 2013 Oct 24;56(20):8032-48.
DMCJXWK	RU	https://pubmed.ncbi.nlm.nih.gov/24044867

DMCJXWK	DI	DMCJXWK
DMCJXWK	DN	URMC-099
DMCJXWK	MI	TTK0FEA
DMCJXWK	MN	Leucine-rich repeat kinase 2 (LRRK2)
DMCJXWK	MT	DTT
DMCJXWK	MA	Inhibitor
DMCJXWK	RN	Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3. J Med Chem. 2013 Oct 24;56(20):8032-48.
DMCJXWK	RU	https://pubmed.ncbi.nlm.nih.gov/24044867

DMCJXWK	DI	DMCJXWK
DMCJXWK	DN	URMC-099
DMCJXWK	MI	TTK1N5G
DMCJXWK	MN	MAPK/ERK kinase kinase 2 (MAP3K2)
DMCJXWK	MT	DTT
DMCJXWK	MA	Inhibitor
DMCJXWK	RN	Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3. J Med Chem. 2013 Oct 24;56(20):8032-48.
DMCJXWK	RU	https://pubmed.ncbi.nlm.nih.gov/24044867

DMCJXWK	DI	DMCJXWK
DMCJXWK	DN	URMC-099
DMCJXWK	MI	TTUNSIX
DMCJXWK	MN	Mixed lineage kinase 1 (MAP3K9)
DMCJXWK	MT	DTT
DMCJXWK	MA	Inhibitor
DMCJXWK	RN	Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3. J Med Chem. 2013 Oct 24;56(20):8032-48.
DMCJXWK	RU	https://pubmed.ncbi.nlm.nih.gov/24044867

DMCJXWK	DI	DMCJXWK
DMCJXWK	DN	URMC-099
DMCJXWK	MI	TT9FN4J
DMCJXWK	MN	Mixed lineage kinase 2 (MAP3K10)
DMCJXWK	MT	DTT
DMCJXWK	MA	Inhibitor
DMCJXWK	RN	Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3. J Med Chem. 2013 Oct 24;56(20):8032-48.
DMCJXWK	RU	https://pubmed.ncbi.nlm.nih.gov/24044867

DMCJXWK	DI	DMCJXWK
DMCJXWK	DN	URMC-099
DMCJXWK	MI	TTETX6Q
DMCJXWK	MN	Mixed lineage kinase 3 (MAP3K11)
DMCJXWK	MT	DTT
DMCJXWK	MA	Inhibitor
DMCJXWK	RN	Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3. J Med Chem. 2013 Oct 24;56(20):8032-48.
DMCJXWK	RU	https://pubmed.ncbi.nlm.nih.gov/24044867

DMCJXWK	DI	DMCJXWK
DMCJXWK	DN	URMC-099
DMCJXWK	MI	TTCZEJ9
DMCJXWK	MN	SRSF protein kinase 2 (SRPK2)
DMCJXWK	MT	DTT
DMCJXWK	MA	Inhibitor
DMCJXWK	RN	Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3. J Med Chem. 2013 Oct 24;56(20):8032-48.
DMCJXWK	RU	https://pubmed.ncbi.nlm.nih.gov/24044867

DMCE3PJ	DI	DMCE3PJ
DMCE3PJ	DN	urotensin II-related peptide
DMCE3PJ	MI	TTW5UDX
DMCE3PJ	MN	Urotensin II receptor (UTS2R)
DMCE3PJ	MT	DTT
DMCE3PJ	MA	Agonist
DMCE3PJ	RN	Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain. Biochem Biophys Res Commun. 2003 Oct 24;310(3):860-8.
DMCE3PJ	RU	https://pubmed.ncbi.nlm.nih.gov/14550283

DM2C6GB	DI	DM2C6GB
DM2C6GB	DN	UR-PG131A
DM2C6GB	MI	TTTIBOJ
DM2C6GB	MN	Histamine H1 receptor (H1R)
DM2C6GB	MT	DTT
DM2C6GB	MA	Agonist
DM2C6GB	RN	Probing ligand-specific histamine H1- and H2-receptor conformations with NG-acylated Imidazolylpropylguanidines. J Pharmacol Exp Ther. 2006 Apr;317(1):139-46.
DM2C6GB	RU	https://pubmed.ncbi.nlm.nih.gov/16394198

DMQCL6Y	DI	DMQCL6Y
DMQCL6Y	DN	UR-PG146
DMQCL6Y	MI	TTTIBOJ
DMQCL6Y	MN	Histamine H1 receptor (H1R)
DMQCL6Y	MT	DTT
DMQCL6Y	MA	Agonist
DMQCL6Y	RN	Probing ligand-specific histamine H1- and H2-receptor conformations with NG-acylated Imidazolylpropylguanidines. J Pharmacol Exp Ther. 2006 Apr;317(1):139-46.
DMQCL6Y	RU	https://pubmed.ncbi.nlm.nih.gov/16394198

DMQCL6Y	DI	DMQCL6Y
DMQCL6Y	DN	UR-PG146
DMQCL6Y	MI	TTQHJ1K
DMQCL6Y	MN	Histamine H2 receptor (H2R)
DMQCL6Y	MT	DTT
DMQCL6Y	MA	Agonist
DMQCL6Y	RN	Probing ligand-specific histamine H1- and H2-receptor conformations with NG-acylated Imidazolylpropylguanidines. J Pharmacol Exp Ther. 2006 Apr;317(1):139-46.
DMQCL6Y	RU	https://pubmed.ncbi.nlm.nih.gov/16394198

DM3VTLG	DI	DM3VTLG
DM3VTLG	DN	UR-PG153
DM3VTLG	MI	TTTIBOJ
DM3VTLG	MN	Histamine H1 receptor (H1R)
DM3VTLG	MT	DTT
DM3VTLG	MA	Agonist
DM3VTLG	RN	Probing ligand-specific histamine H1- and H2-receptor conformations with NG-acylated Imidazolylpropylguanidines. J Pharmacol Exp Ther. 2006 Apr;317(1):139-46.
DM3VTLG	RU	https://pubmed.ncbi.nlm.nih.gov/16394198

DM6SM4N	DI	DM6SM4N
DM6SM4N	DN	UR-PG55B
DM6SM4N	MI	TTTIBOJ
DM6SM4N	MN	Histamine H1 receptor (H1R)
DM6SM4N	MT	DTT
DM6SM4N	MA	Agonist
DM6SM4N	RN	Probing ligand-specific histamine H1- and H2-receptor conformations with NG-acylated Imidazolylpropylguanidines. J Pharmacol Exp Ther. 2006 Apr;317(1):139-46.
DM6SM4N	RU	https://pubmed.ncbi.nlm.nih.gov/16394198

DMCQ8AL	DI	DMCQ8AL
DMCQ8AL	DN	USIMINE A
DMCQ8AL	MI	TTELIN2
DMCQ8AL	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMCQ8AL	MT	DTT
DMCQ8AL	MA	Inhibitor
DMCQ8AL	RN	Usimines A-C, bioactive usnic acid derivatives from the Antarctic lichen Stereocaulon alpinum. J Nat Prod. 2008 Apr;71(4):710-2.
DMCQ8AL	RU	https://pubmed.ncbi.nlm.nih.gov/18288807

DMGOURX	DI	DMGOURX
DMGOURX	DN	USNIC ACID
DMGOURX	MI	TTELIN2
DMGOURX	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMGOURX	MT	DTT
DMGOURX	MA	Inhibitor
DMGOURX	RN	Usimines A-C, bioactive usnic acid derivatives from the Antarctic lichen Stereocaulon alpinum. J Nat Prod. 2008 Apr;71(4):710-2.
DMGOURX	RU	https://pubmed.ncbi.nlm.nih.gov/18288807

DMZP32O	DI	DMZP32O
DMZP32O	DN	USTILOXIN A
DMZP32O	MI	TTYFKSZ
DMZP32O	MN	Tubulin beta (TUBB)
DMZP32O	MT	DTT
DMZP32O	MA	Inhibitor
DMZP32O	RN	Total synthesis and biological evaluation of ustiloxin natural products and two analogs. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4804-7.
DMZP32O	RU	https://pubmed.ncbi.nlm.nih.gov/16837194

DMZP32O	DI	DMZP32O
DMZP32O	DN	USTILOXIN A
DMZP32O	MI	TTJ2PTI
DMZP32O	MN	Tubulin beta-2 chain (TUBB2)
DMZP32O	MT	DTT
DMZP32O	MA	Inhibitor
DMZP32O	RN	Total synthesis and biological evaluation of ustiloxin natural products and two analogs. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4804-7.
DMZP32O	RU	https://pubmed.ncbi.nlm.nih.gov/16837194

DMA8JH7	DI	DMA8JH7
DMA8JH7	DN	Ustiloxin D
DMA8JH7	MI	TTYFKSZ
DMA8JH7	MN	Tubulin beta (TUBB)
DMA8JH7	MT	DTT
DMA8JH7	MA	Inhibitor
DMA8JH7	RN	Total synthesis and biological evaluation of ustiloxin natural products and two analogs. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4804-7.
DMA8JH7	RU	https://pubmed.ncbi.nlm.nih.gov/16837194

DMA8JH7	DI	DMA8JH7
DMA8JH7	DN	Ustiloxin D
DMA8JH7	MI	TTJ2PTI
DMA8JH7	MN	Tubulin beta-2 chain (TUBB2)
DMA8JH7	MT	DTT
DMA8JH7	MA	Inhibitor
DMA8JH7	RN	Total synthesis and biological evaluation of ustiloxin natural products and two analogs. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4804-7.
DMA8JH7	RU	https://pubmed.ncbi.nlm.nih.gov/16837194

DMT1LS0	DI	DMT1LS0
DMT1LS0	DN	Ustiloxin F
DMT1LS0	MI	TTYFKSZ
DMT1LS0	MN	Tubulin beta (TUBB)
DMT1LS0	MT	DTT
DMT1LS0	MA	Inhibitor
DMT1LS0	RN	Total synthesis and biological evaluation of ustiloxin natural products and two analogs. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4804-7.
DMT1LS0	RU	https://pubmed.ncbi.nlm.nih.gov/16837194

DMT1LS0	DI	DMT1LS0
DMT1LS0	DN	Ustiloxin F
DMT1LS0	MI	TTJ2PTI
DMT1LS0	MN	Tubulin beta-2 chain (TUBB2)
DMT1LS0	MT	DTT
DMT1LS0	MA	Inhibitor
DMT1LS0	RN	Total synthesis and biological evaluation of ustiloxin natural products and two analogs. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4804-7.
DMT1LS0	RU	https://pubmed.ncbi.nlm.nih.gov/16837194

DMKLB4O	DI	DMKLB4O
DMKLB4O	DN	UTPgammaS
DMKLB4O	MI	TTOZHQC
DMKLB4O	MN	P2Y purinoceptor 2 (P2RY2)
DMKLB4O	MT	DTT
DMKLB4O	MA	Agonist
DMKLB4O	RN	Pharmacological selectivity of the cloned human P2U-purinoceptor: potent activation by diadenosine tetraphosphate. Br J Pharmacol. 1995 Sep;116(1):1619-27.
DMKLB4O	RU	https://pubmed.ncbi.nlm.nih.gov/8564228

DMKLB4O	DI	DMKLB4O
DMKLB4O	DN	UTPgammaS
DMKLB4O	MI	TT24DGP
DMKLB4O	MN	P2Y purinoceptor 4 (P2RY4)
DMKLB4O	MT	DTT
DMKLB4O	MA	Agonist
DMKLB4O	RN	Enzymatic synthesis of UTP gamma S, a potent hydrolysis resistant agonist of P2U-purinoceptors. Br J Pharmacol. 1996 Jan;117(1):203-9.
DMKLB4O	RU	https://pubmed.ncbi.nlm.nih.gov/8825364

DMAFQE1	DI	DMAFQE1
DMAFQE1	DN	UVAOL
DMAFQE1	MI	TTELIN2
DMAFQE1	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMAFQE1	MT	DTT
DMAFQE1	MA	Inhibitor
DMAFQE1	RN	Triterpenoids from the leaves of Diospyros kaki (persimmon) and their inhibitory effects on protein tyrosine phosphatase 1B. J Nat Prod. 2008 Oct;71(10):1775-8.
DMAFQE1	RU	https://pubmed.ncbi.nlm.nih.gov/18798681

DM95UI1	DI	DM95UI1
DM95UI1	DN	UVI3003
DM95UI1	MI	TT6PEUO
DM95UI1	MN	Retinoic acid receptor RXR-alpha (RXRA)
DM95UI1	MT	DTT
DM95UI1	MA	Antagonist
DM95UI1	RN	Characterization of the interaction between retinoic acid receptor/retinoid X receptor (RAR/RXR) heterodimers and transcriptional coactivators thro... J Biol Chem. 2005 Jan 14;280(2):1625-33.
DM95UI1	RU	https://pubmed.ncbi.nlm.nih.gov/15528208

DM0KSFN	DI	DM0KSFN
DM0KSFN	DN	V-103
DM0KSFN	MI	TT2NUT5
DM0KSFN	MN	Adrenergic receptor alpha-2C (ADRA2C)
DM0KSFN	MT	DTT
DM0KSFN	MA	Modulator
DM0KSFN	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 27).
DM0KSFN	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=27

DMXLHIO	DI	DMXLHIO
DMXLHIO	DN	V158411
DMXLHIO	MI	TTTU902
DMXLHIO	MN	Checkpoint kinase-1 (CHK1)
DMXLHIO	MT	DTT
DMXLHIO	MA	Inhibitor
DMXLHIO	RN	Cell Density Affects the Detection of Chk1 Target Engagement by the Selective Inhibitor V158411. SLAS Discov. 2018 Feb;23(2):144-153.
DMXLHIO	RU	https://pubmed.ncbi.nlm.nih.gov/29048945

DM8SWVN	DI	DM8SWVN
DM8SWVN	DN	V-165
DM8SWVN	MI	TT5FH9Y
DM8SWVN	MN	Human immunodeficiency virus Integrase (HIV IN)
DM8SWVN	MT	DTT
DM8SWVN	MA	Inhibitor
DM8SWVN	RN	New class of HIV integrase inhibitors that block viral replication in cell culture. Curr Biol. 2002 Jul 23;12(14):1169-77.
DM8SWVN	RU	https://pubmed.ncbi.nlm.nih.gov/12176326

DMH971B	DI	DMH971B
DMH971B	DN	V1A F/U
DMH971B	MI	TT4TFGN
DMH971B	MN	Vasopressin V1a receptor (V1AR)
DMH971B	MT	DTT
DMH971B	MA	Antagonist
DMH971B	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 366).
DMH971B	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=366

DM65GQD	DI	DM65GQD
DM65GQD	DN	VA-118020
DM65GQD	MI	TT5T3P6
DM65GQD	MN	Tissue kallikrein (KLK1)
DM65GQD	MT	DTT
DM65GQD	MA	Inhibitor
DM65GQD	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2865).
DM65GQD	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2865

DMG53XV	DI	DMG53XV
DMG53XV	DN	VA-119930
DMG53XV	MI	TTGPQ0F
DMG53XV	MN	Prolyl endopeptidase FAP (FAP)
DMG53XV	MT	DTT
DMG53XV	MA	Inhibitor
DMG53XV	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2365).
DMG53XV	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2365

DMEOJ89	DI	DMEOJ89
DMEOJ89	DN	VAGANINE D
DMEOJ89	MI	TTEB0GD
DMEOJ89	MN	Cholinesterase (BCHE)
DMEOJ89	MT	DTT
DMEOJ89	MA	Inhibitor
DMEOJ89	RN	Steroidal alkaloids from the leaves of Sarcococca coriacea of Nepalese origin. J Nat Prod. 2001 Jun;64(6):842-4.
DMEOJ89	RU	https://pubmed.ncbi.nlm.nih.gov/11421762

DMW4TYV	DI	DMW4TYV
DMW4TYV	DN	Valinomycin
DMW4TYV	MI	DTUGYRD
DMW4TYV	MN	P-glycoprotein 1 (ABCB1)
DMW4TYV	MT	DTP
DMW4TYV	MA	Substrate
DMW4TYV	RN	Modulation of drug-stimulated ATPase activity of human MDR1/P-glycoprotein by cholesterol. Biochem J. 2007 Jan 15;401(2):597-605.
DMW4TYV	RU	http://www.ncbi.nlm.nih.gov/pubmed/17029589

DM2VQN5	DI	DM2VQN5
DM2VQN5	DN	VALIOLAMINE
DM2VQN5	MI	TTLPC70
DM2VQN5	MN	Lysosomal alpha-glucosidase (GAA)
DM2VQN5	MT	DTT
DM2VQN5	MA	Inhibitor
DM2VQN5	RN	In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures. Bioorg Med Chem. 2008 Aug 1;16(15):7330-6.
DM2VQN5	RU	https://pubmed.ncbi.nlm.nih.gov/18595718

DM30E56	DI	DM30E56
DM30E56	DN	Vapill
DM30E56	MI	TT7HC21
DM30E56	MN	Membrane copper amine oxidase (AOC3)
DM30E56	MT	DTT
DM30E56	MA	Inhibitor
DM30E56	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2767).
DM30E56	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2767

DMD7M9L	DI	DMD7M9L
DMD7M9L	DN	VAR-10200
DMD7M9L	MI	TTGP7BY
DMD7M9L	MN	Monoamine oxidase type B (MAO-B)
DMD7M9L	MT	DTT
DMD7M9L	MA	Modulator
DMD7M9L	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2490).
DMD7M9L	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2490

DMFKTPO	DI	DMFKTPO
DMFKTPO	DN	VAR-10300
DMFKTPO	MI	TTGP7BY
DMFKTPO	MN	Monoamine oxidase type B (MAO-B)
DMFKTPO	MT	DTT
DMFKTPO	MA	Inhibitor
DMFKTPO	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2490).
DMFKTPO	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2490

DMVBO78	DI	DMVBO78
DMVBO78	DN	VARIECOLIN
DMVBO78	MI	TT2CEJG
DMVBO78	MN	C-C chemokine receptor type 5 (CCR5)
DMVBO78	MT	DTT
DMVBO78	MA	Inhibitor
DMVBO78	RN	Inhibition of the human chemokine receptor CCR5 by variecolin and variecolol and isolation of four new variecolin analogues, emericolins A-D, from ... J Nat Prod. 2004 Oct;67(10):1681-4.
DMVBO78	RU	https://pubmed.ncbi.nlm.nih.gov/15497939

DM3K8PT	DI	DM3K8PT
DM3K8PT	DN	Va-RYYRIK-NH2
DM3K8PT	MI	TTNT7K8
DM3K8PT	MN	Nociceptin receptor (OPRL1)
DM3K8PT	MT	DTT
DM3K8PT	MA	Inhibitor
DM3K8PT	RN	Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist. Bioorg Med Chem. 2008 Mar 1;16(5):2635-44.
DM3K8PT	RU	https://pubmed.ncbi.nlm.nih.gov/18068993

DM8ACIF	DI	DM8ACIF
DM8ACIF	DN	VBY- 285
DM8ACIF	MI	TTUMQVO
DM8ACIF	MN	Cathepsin S (CTSS)
DM8ACIF	MT	DTT
DM8ACIF	MA	Inhibitor
DM8ACIF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2353).
DM8ACIF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2353

DMG1YZQ	DI	DMG1YZQ
DMG1YZQ	DN	VCP-28
DMG1YZQ	MI	TTK25J1
DMG1YZQ	MN	Adenosine A1 receptor (ADORA1)
DMG1YZQ	MT	DTT
DMG1YZQ	MA	Inhibitor
DMG1YZQ	RN	Synthesis and evaluation of new N6-substituted adenosine-5'-N-methylcarboxamides as A3 adenosine receptor agonists. Bioorg Med Chem. 2010 May 1;18(9):3078-87.
DMG1YZQ	RU	https://pubmed.ncbi.nlm.nih.gov/20385496

DMN62VE	DI	DMN62VE
DMN62VE	DN	VDA-1124
DMN62VE	MI	TTKEPHX
DMN62VE	MN	Granzyme B (GZMB)
DMN62VE	MT	DTT
DMN62VE	MA	Inhibitor
DMN62VE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2369).
DMN62VE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2369

DM3GADP	DI	DM3GADP
DM3GADP	DN	VE-04051645
DM3GADP	MI	TT6L509
DM3GADP	MN	Coagulation factor IIa (F2)
DM3GADP	MT	DTT
DM3GADP	MA	Inhibitor
DM3GADP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362).
DM3GADP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2362

DM0UXNF	DI	DM0UXNF
DM0UXNF	DN	VE-821
DM0UXNF	MI	TT8ZYBQ
DM0UXNF	MN	Serine/threonine-protein kinase ATR (FRP1)
DM0UXNF	MT	DTT
DM0UXNF	MA	Inhibitor
DM0UXNF	RN	ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses. Cancer Res. 2014 Dec 1;74(23):6968-79.
DM0UXNF	RU	https://pubmed.ncbi.nlm.nih.gov/25269479

DMWXCYA	DI	DMWXCYA
DMWXCYA	DN	VEGF receptor 2 kinase inhibitor I
DMWXCYA	MI	TTUTJGQ
DMWXCYA	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMWXCYA	MT	DTT
DMWXCYA	MA	Inhibitor
DMWXCYA	RN	Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. J Med Chem. 1998 Jul 2;41(14):2588-603.
DMWXCYA	RU	https://pubmed.ncbi.nlm.nih.gov/9651163

DMFZMA2	DI	DMFZMA2
DMFZMA2	DN	VER-156084
DMFZMA2	MI	TT6OEDT
DMFZMA2	MN	Cannabinoid receptor 1 (CB1)
DMFZMA2	MT	DTT
DMFZMA2	MA	Inhibitor
DMFZMA2	RN	Fatty acid amide hydrolase inhibitors. Surprising selectivity of chiral azetidine ureas. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4241-4.
DMFZMA2	RU	https://pubmed.ncbi.nlm.nih.gov/19515560

DMFZMA2	DI	DMFZMA2
DMFZMA2	DN	VER-156084
DMFZMA2	MI	TTMSFAW
DMFZMA2	MN	Cannabinoid receptor 2 (CB2)
DMFZMA2	MT	DTT
DMFZMA2	MA	Inhibitor
DMFZMA2	RN	Fatty acid amide hydrolase inhibitors. Surprising selectivity of chiral azetidine ureas. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4241-4.
DMFZMA2	RU	https://pubmed.ncbi.nlm.nih.gov/19515560

DMFZMA2	DI	DMFZMA2
DMFZMA2	DN	VER-156084
DMFZMA2	MI	TTDP1UC
DMFZMA2	MN	Fatty acid amide hydrolase (FAAH)
DMFZMA2	MT	DTT
DMFZMA2	MA	Inhibitor
DMFZMA2	RN	Fatty acid amide hydrolase inhibitors. Surprising selectivity of chiral azetidine ureas. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4241-4.
DMFZMA2	RU	https://pubmed.ncbi.nlm.nih.gov/19515560

DMCRHOA	DI	DMCRHOA
DMCRHOA	DN	VER-156085
DMCRHOA	MI	TT6OEDT
DMCRHOA	MN	Cannabinoid receptor 1 (CB1)
DMCRHOA	MT	DTT
DMCRHOA	MA	Inhibitor
DMCRHOA	RN	Fatty acid amide hydrolase inhibitors. Surprising selectivity of chiral azetidine ureas. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4241-4.
DMCRHOA	RU	https://pubmed.ncbi.nlm.nih.gov/19515560

DMCRHOA	DI	DMCRHOA
DMCRHOA	DN	VER-156085
DMCRHOA	MI	TTMSFAW
DMCRHOA	MN	Cannabinoid receptor 2 (CB2)
DMCRHOA	MT	DTT
DMCRHOA	MA	Inhibitor
DMCRHOA	RN	Fatty acid amide hydrolase inhibitors. Surprising selectivity of chiral azetidine ureas. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4241-4.
DMCRHOA	RU	https://pubmed.ncbi.nlm.nih.gov/19515560

DM5WAM8	DI	DM5WAM8
DM5WAM8	DN	VER-2692
DM5WAM8	MI	TTJQOD7
DM5WAM8	MN	5-HT 2A receptor (HTR2A)
DM5WAM8	MT	DTT
DM5WAM8	MA	Inhibitor
DM5WAM8	RN	Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists. Bioorg Med Chem Lett. 2006 Feb;16(3):677-80.
DM5WAM8	RU	https://pubmed.ncbi.nlm.nih.gov/16257207

DM5WAM8	DI	DM5WAM8
DM5WAM8	DN	VER-2692
DM5WAM8	MI	TT0K1SC
DM5WAM8	MN	5-HT 2B receptor (HTR2B)
DM5WAM8	MT	DTT
DM5WAM8	MA	Inhibitor
DM5WAM8	RN	Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists. Bioorg Med Chem Lett. 2006 Feb;16(3):677-80.
DM5WAM8	RU	https://pubmed.ncbi.nlm.nih.gov/16257207

DM5WAM8	DI	DM5WAM8
DM5WAM8	DN	VER-2692
DM5WAM8	MI	TTWJBZ5
DM5WAM8	MN	5-HT 2C receptor (HTR2C)
DM5WAM8	MT	DTT
DM5WAM8	MA	Inhibitor
DM5WAM8	RN	Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists. Bioorg Med Chem Lett. 2006 Feb;16(3):677-80.
DM5WAM8	RU	https://pubmed.ncbi.nlm.nih.gov/16257207

DM7O2K1	DI	DM7O2K1
DM7O2K1	DN	VER-3323
DM7O2K1	MI	TTJQOD7
DM7O2K1	MN	5-HT 2A receptor (HTR2A)
DM7O2K1	MT	DTT
DM7O2K1	MA	Inhibitor
DM7O2K1	RN	Indoline derivatives as 5-HT(2C) receptor agonists. Bioorg Med Chem Lett. 2004 May 3;14(9):2367-70.
DM7O2K1	RU	https://pubmed.ncbi.nlm.nih.gov/15081042

DM7O2K1	DI	DM7O2K1
DM7O2K1	DN	VER-3323
DM7O2K1	MI	TT0K1SC
DM7O2K1	MN	5-HT 2B receptor (HTR2B)
DM7O2K1	MT	DTT
DM7O2K1	MA	Inhibitor
DM7O2K1	RN	Indoline derivatives as 5-HT(2C) receptor agonists. Bioorg Med Chem Lett. 2004 May 3;14(9):2367-70.
DM7O2K1	RU	https://pubmed.ncbi.nlm.nih.gov/15081042

DM7O2K1	DI	DM7O2K1
DM7O2K1	DN	VER-3323
DM7O2K1	MI	TTWJBZ5
DM7O2K1	MN	5-HT 2C receptor (HTR2C)
DM7O2K1	MT	DTT
DM7O2K1	MA	Inhibitor
DM7O2K1	RN	Indoline derivatives as 5-HT(2C) receptor agonists. Bioorg Med Chem Lett. 2004 May 3;14(9):2367-70.
DM7O2K1	RU	https://pubmed.ncbi.nlm.nih.gov/15081042

DMF1KDX	DI	DMF1KDX
DMF1KDX	DN	VER-49009
DMF1KDX	MI	TT78R5H
DMF1KDX	MN	Heat shock protein 90 alpha (HSP90A)
DMF1KDX	MT	DTT
DMF1KDX	MA	Inhibitor
DMF1KDX	RN	Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. J Med Chem. 2005 Jun 30;48(13):4212-5.
DMF1KDX	RU	https://pubmed.ncbi.nlm.nih.gov/15974572

DMC2EO9	DI	DMC2EO9
DMC2EO9	DN	VER-5384
DMC2EO9	MI	TTJQOD7
DMC2EO9	MN	5-HT 2A receptor (HTR2A)
DMC2EO9	MT	DTT
DMC2EO9	MA	Inhibitor
DMC2EO9	RN	Indoline derivatives as 5-HT(2C) receptor agonists. Bioorg Med Chem Lett. 2004 May 3;14(9):2367-70.
DMC2EO9	RU	https://pubmed.ncbi.nlm.nih.gov/15081042

DMC2EO9	DI	DMC2EO9
DMC2EO9	DN	VER-5384
DMC2EO9	MI	TT0K1SC
DMC2EO9	MN	5-HT 2B receptor (HTR2B)
DMC2EO9	MT	DTT
DMC2EO9	MA	Inhibitor
DMC2EO9	RN	Indoline derivatives as 5-HT(2C) receptor agonists. Bioorg Med Chem Lett. 2004 May 3;14(9):2367-70.
DMC2EO9	RU	https://pubmed.ncbi.nlm.nih.gov/15081042

DMC2EO9	DI	DMC2EO9
DMC2EO9	DN	VER-5384
DMC2EO9	MI	TTWJBZ5
DMC2EO9	MN	5-HT 2C receptor (HTR2C)
DMC2EO9	MT	DTT
DMC2EO9	MA	Inhibitor
DMC2EO9	RN	Indoline derivatives as 5-HT(2C) receptor agonists. Bioorg Med Chem Lett. 2004 May 3;14(9):2367-70.
DMC2EO9	RU	https://pubmed.ncbi.nlm.nih.gov/15081042

DMYD7P5	DI	DMYD7P5
DMYD7P5	DN	VER-54505
DMYD7P5	MI	TT7HF4W
DMYD7P5	MN	Cyclin-dependent kinase 2 (CDK2)
DMYD7P5	MT	DTT
DMYD7P5	MA	Inhibitor
DMYD7P5	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1973).
DMYD7P5	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1973

DMZ2V0A	DI	DMZ2V0A
DMZ2V0A	DN	VER-5593
DMZ2V0A	MI	TTJQOD7
DMZ2V0A	MN	5-HT 2A receptor (HTR2A)
DMZ2V0A	MT	DTT
DMZ2V0A	MA	Inhibitor
DMZ2V0A	RN	Indoline derivatives as 5-HT(2C) receptor agonists. Bioorg Med Chem Lett. 2004 May 3;14(9):2367-70.
DMZ2V0A	RU	https://pubmed.ncbi.nlm.nih.gov/15081042

DMZ2V0A	DI	DMZ2V0A
DMZ2V0A	DN	VER-5593
DMZ2V0A	MI	TT0K1SC
DMZ2V0A	MN	5-HT 2B receptor (HTR2B)
DMZ2V0A	MT	DTT
DMZ2V0A	MA	Inhibitor
DMZ2V0A	RN	Indoline derivatives as 5-HT(2C) receptor agonists. Bioorg Med Chem Lett. 2004 May 3;14(9):2367-70.
DMZ2V0A	RU	https://pubmed.ncbi.nlm.nih.gov/15081042

DMZ2V0A	DI	DMZ2V0A
DMZ2V0A	DN	VER-5593
DMZ2V0A	MI	TTWJBZ5
DMZ2V0A	MN	5-HT 2C receptor (HTR2C)
DMZ2V0A	MT	DTT
DMZ2V0A	MA	Inhibitor
DMZ2V0A	RN	Indoline derivatives as 5-HT(2C) receptor agonists. Bioorg Med Chem Lett. 2004 May 3;14(9):2367-70.
DMZ2V0A	RU	https://pubmed.ncbi.nlm.nih.gov/15081042

DMJRVBS	DI	DMJRVBS
DMJRVBS	DN	VERAGUENSIN
DMJRVBS	MI	TTQL5VC
DMJRVBS	MN	Platelet-activating factor receptor (PTAFR)
DMJRVBS	MT	DTT
DMJRVBS	MA	Inhibitor
DMJRVBS	RN	Development, synthesis, and biological evaluation of (-)-trans-(2S,5S)-2-[3-[(2-oxopropyl)sulfonyl]-4-n-propoxy-5-(3- hydroxypropoxy)-phenyl]-5-(3,... J Med Chem. 1992 Sep 18;35(19):3474-82.
DMJRVBS	RU	https://pubmed.ncbi.nlm.nih.gov/1404229

DMUF8JZ	DI	DMUF8JZ
DMUF8JZ	DN	Veratridine
DMUF8JZ	MI	TTANOZH
DMUF8JZ	MN	SCN1A messenger RNA (SCN1A mRNA)
DMUF8JZ	MT	DTT
DMUF8JZ	MA	Activator
DMUF8JZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 578).
DMUF8JZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=578

DMUF8JZ	DI	DMUF8JZ
DMUF8JZ	DN	Veratridine
DMUF8JZ	MI	TTLJTUF
DMUF8JZ	MN	Voltage-gated sodium channel alpha Nav1.2 (SCN2A)
DMUF8JZ	MT	DTT
DMUF8JZ	MA	Activator
DMUF8JZ	RN	Binding of batrachotoxinin A 20-alpha-benzoate to a receptor site associated with sodium channels in synaptic nerve ending particles. J Biol Chem. 1981 Sep 10;256(17):8922-7.
DMUF8JZ	RU	https://pubmed.ncbi.nlm.nih.gov/6114956

DMUF8JZ	DI	DMUF8JZ
DMUF8JZ	DN	Veratridine
DMUF8JZ	MI	TTAXZ0K
DMUF8JZ	MN	Voltage-gated sodium channel alpha Nav1.3 (SCN3A)
DMUF8JZ	MT	DTT
DMUF8JZ	MA	Activator
DMUF8JZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 580).
DMUF8JZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=580

DMUF8JZ	DI	DMUF8JZ
DMUF8JZ	DN	Veratridine
DMUF8JZ	MI	TT84DRB
DMUF8JZ	MN	Voltage-gated sodium channel alpha Nav1.4 (SCN4A)
DMUF8JZ	MT	DTT
DMUF8JZ	MA	Activator
DMUF8JZ	RN	Point mutations in segment I-S6 render voltage-gated Na+ channels resistant to batrachotoxin. Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2653-8.
DMUF8JZ	RU	https://pubmed.ncbi.nlm.nih.gov/9482942

DMUF8JZ	DI	DMUF8JZ
DMUF8JZ	DN	Veratridine
DMUF8JZ	MI	TTZOVE0
DMUF8JZ	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DMUF8JZ	MT	DTT
DMUF8JZ	MA	Activator
DMUF8JZ	RN	Sodium channel comodification with full activator reveals veratridine reaction dynamics. Mol Pharmacol. 1990 Feb;37(2):144-8.
DMUF8JZ	RU	https://pubmed.ncbi.nlm.nih.gov/2154667

DMUF8JZ	DI	DMUF8JZ
DMUF8JZ	DN	Veratridine
DMUF8JZ	MI	TT54ERL
DMUF8JZ	MN	Voltage-gated sodium channel alpha Nav1.6 (SCN8A)
DMUF8JZ	MT	DTT
DMUF8JZ	MA	Activator
DMUF8JZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 583).
DMUF8JZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=583

DMUF8JZ	DI	DMUF8JZ
DMUF8JZ	DN	Veratridine
DMUF8JZ	MI	TT4G2JS
DMUF8JZ	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DMUF8JZ	MT	DTT
DMUF8JZ	MA	Activator
DMUF8JZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 584).
DMUF8JZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=584

DMUF8JZ	DI	DMUF8JZ
DMUF8JZ	DN	Veratridine
DMUF8JZ	MI	TT90XZ8
DMUF8JZ	MN	Voltage-gated sodium channel alpha Nav1.8 (SCN10A)
DMUF8JZ	MT	DTT
DMUF8JZ	MA	Activator
DMUF8JZ	RN	A comparison of the effects of veratridine on tetrodotoxin-sensitive and tetrodotoxin-resistant sodium channels in isolated rat dorsal root ganglio... Pflugers Arch. 2008 Feb;455(5):929-38.
DMUF8JZ	RU	https://pubmed.ncbi.nlm.nih.gov/17962978

DM7NRK5	DI	DM7NRK5
DM7NRK5	DN	Verdoheme
DM7NRK5	MI	TTI6V2A
DM7NRK5	MN	Heme oxygenase 1 (HMOX1)
DM7NRK5	MT	DTT
DM7NRK5	MA	Inhibitor
DM7NRK5	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DM7NRK5	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMD1C6S	DI	DMD1C6S
DMD1C6S	DN	Verongamine
DMD1C6S	MI	TT9JNIC
DMD1C6S	MN	Histamine H3 receptor (H3R)
DMD1C6S	MT	DTT
DMD1C6S	MA	Inhibitor
DMD1C6S	RN	Verongamine, a novel bromotyrosine-derived histamine H3-antagonist from the marine sponge Verongula gigantea. J Nat Prod. 1994 Jan;57(1):175-7.
DMD1C6S	RU	https://pubmed.ncbi.nlm.nih.gov/8158162

DMUHEJ3	DI	DMUHEJ3
DMUHEJ3	DN	Very low dose (VLD) cyclobenzaprine
DMUHEJ3	MI	TTJQOD7
DMUHEJ3	MN	5-HT 2A receptor (HTR2A)
DMUHEJ3	MT	DTT
DMUHEJ3	MA	Modulator
DMUHEJ3	RN	Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598). J Pharmacol Exp Ther. 1992 Jan;260(1):146-59.
DMUHEJ3	RU	https://pubmed.ncbi.nlm.nih.gov/1370538

DMHKUBG	DI	DMHKUBG
DMHKUBG	DN	Vesamicol
DMHKUBG	MI	TTV8KWS
DMHKUBG	MN	Vesicular acetylcholine transporter (SLC18A3)
DMHKUBG	MT	DTT
DMHKUBG	MA	Inhibitor
DMHKUBG	RN	Vesamicol analogues as sigma ligands. Molecular determinants of selectivity at the vesamicol receptor. Biochem Pharmacol. 1995 Mar 15;49(6):791-7.
DMHKUBG	RU	https://pubmed.ncbi.nlm.nih.gov/7702637

DMO4GBK	DI	DMO4GBK
DMO4GBK	DN	vinburnine
DMO4GBK	MI	TTOXS3C
DMO4GBK	MN	Muscarinic acetylcholine receptor (CHRM)
DMO4GBK	MT	DTT
DMO4GBK	MA	Modulator (allosteric modulator)
DMO4GBK	RN	Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol. 1997 Jul;52(1):172-9.
DMO4GBK	RU	https://pubmed.ncbi.nlm.nih.gov/9224827

DMO4GBK	DI	DMO4GBK
DMO4GBK	DN	vinburnine
DMO4GBK	MI	TTQ13Z5
DMO4GBK	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMO4GBK	MT	DTT
DMO4GBK	MA	Modulator (allosteric modulator)
DMO4GBK	RN	Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol. 1997 Jul;52(1):172-9.
DMO4GBK	RU	https://pubmed.ncbi.nlm.nih.gov/9224827

DMNFVO7	DI	DMNFVO7
DMNFVO7	DN	Vinylsulphones
DMNFVO7	MI	TT7EASG
DMNFVO7	MN	Plasmodium Cysteine protease falcipain-2 (Malaria CPF2)
DMNFVO7	MT	DTT
DMNFVO7	MA	Binder
DMNFVO7	RN	Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40.
DMNFVO7	RU	https://pubmed.ncbi.nlm.nih.gov/16138106

DMNFVO7	DI	DMNFVO7
DMNFVO7	DN	Vinylsulphones
DMNFVO7	MI	TTEAID7
DMNFVO7	MN	Trypanosoma Cruzipain (Trypano CYSP)
DMNFVO7	MT	DTT
DMNFVO7	MA	Binder
DMNFVO7	RN	Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40.
DMNFVO7	RU	https://pubmed.ncbi.nlm.nih.gov/16138106

DMAXOPS	DI	DMAXOPS
DMAXOPS	DN	viral macrophage inflammatory protein-II
DMAXOPS	MI	TT8KLPT
DMAXOPS	MN	C-C chemokine receptor (CCR)
DMAXOPS	MT	DTT
DMAXOPS	MA	Antagonist
DMAXOPS	RN	A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science. 1997 Sep 12;277(5332):1656-9.
DMAXOPS	RU	https://pubmed.ncbi.nlm.nih.gov/9287217

DMAXOPS	DI	DMAXOPS
DMAXOPS	DN	viral macrophage inflammatory protein-II
DMAXOPS	MI	TTFZYTO
DMAXOPS	MN	C-C chemokine receptor type 2 (CCR2)
DMAXOPS	MT	DTT
DMAXOPS	MA	Antagonist
DMAXOPS	RN	A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science. 1997 Sep 12;277(5332):1656-9.
DMAXOPS	RU	https://pubmed.ncbi.nlm.nih.gov/9287217

DMAXOPS	DI	DMAXOPS
DMAXOPS	DN	viral macrophage inflammatory protein-II
DMAXOPS	MI	TTE836A
DMAXOPS	MN	C-C chemokine receptor type 8 (CCR8)
DMAXOPS	MT	DTT
DMAXOPS	MA	Antagonist
DMAXOPS	RN	HHV8-encoded vMIP-I selectively engages chemokine receptor CCR8. Agonist and antagonist profiles of viral chemokines. J Biol Chem. 1999 Jul 30;274(31):21569-74.
DMAXOPS	RU	https://pubmed.ncbi.nlm.nih.gov/10419462

DMAXOPS	DI	DMAXOPS
DMAXOPS	DN	viral macrophage inflammatory protein-II
DMAXOPS	MI	TTJIH8Q
DMAXOPS	MN	CCR5 messenger RNA (CCR5 mRNA)
DMAXOPS	MT	DTT
DMAXOPS	MA	Antagonist
DMAXOPS	RN	A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science. 1997 Sep 12;277(5332):1656-9.
DMAXOPS	RU	https://pubmed.ncbi.nlm.nih.gov/9287217

DMAXOPS	DI	DMAXOPS
DMAXOPS	DN	viral macrophage inflammatory protein-II
DMAXOPS	MI	TTBID49
DMAXOPS	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMAXOPS	MT	DTT
DMAXOPS	MA	Antagonist
DMAXOPS	RN	A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science. 1997 Sep 12;277(5332):1656-9.
DMAXOPS	RU	https://pubmed.ncbi.nlm.nih.gov/9287217

DMCSHE8	DI	DMCSHE8
DMCSHE8	DN	visnagin
DMCSHE8	MI	TTNE7KG
DMCSHE8	MN	Adenosine A2b receptor (ADORA2B)
DMCSHE8	MT	DTT
DMCSHE8	MA	Antagonist
DMCSHE8	RN	Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301.
DMCSHE8	RU	https://pubmed.ncbi.nlm.nih.gov/8691424

DMCSHE8	DI	DMCSHE8
DMCSHE8	DN	visnagin
DMCSHE8	MI	TTJFY5U
DMCSHE8	MN	Adenosine A3 receptor (ADORA3)
DMCSHE8	MT	DTT
DMCSHE8	MA	Antagonist
DMCSHE8	RN	Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301.
DMCSHE8	RU	https://pubmed.ncbi.nlm.nih.gov/8691424

DMN6EZY	DI	DMN6EZY
DMN6EZY	DN	Vitamin K
DMN6EZY	MI	TT6L509
DMN6EZY	MN	Coagulation factor IIa (F2)
DMN6EZY	MT	DTT
DMN6EZY	MA	Cofactor
DMN6EZY	RN	Plasma levels of protein C and vitamin K-dependent coagulation factors in patients on long-term oral anticoagulant therapy. Tohoku J Exp Med. 1986 Aug;149(4):351-7.
DMN6EZY	RU	https://pubmed.ncbi.nlm.nih.gov/3775760

DMN6EZY	DI	DMN6EZY
DMN6EZY	DN	Vitamin K
DMN6EZY	MI	DEVRYQN
DMN6EZY	MN	Vitamin K1 2,3-epoxide reductase 1 (VKOR)
DMN6EZY	MT	DME
DMN6EZY	MA	Metabolism
DMN6EZY	RN	VKORC1L1, an enzyme mediating the effect of vitamin K in liver and extrahepatic tissues. Nutrients. 2018 Jul 26;10(8). pii: E970.
DMN6EZY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30050002

DMN6EZY	DI	DMN6EZY
DMN6EZY	DN	Vitamin K
DMN6EZY	MI	DERQV72
DMN6EZY	MN	VKORC1-like protein 1 (VKORC1L1)
DMN6EZY	MT	DME
DMN6EZY	MA	Metabolism
DMN6EZY	RN	VKORC1L1, an enzyme rescuing the vitamin K 2,3-epoxide reductase activity in some extrahepatic tissues during anticoagulation therapy. J Biol Chem. 2013 Oct 4;288(40):28733-42.
DMN6EZY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23928358

DMJB3E1	DI	DMJB3E1
DMJB3E1	DN	VITAMIN K2
DMJB3E1	MI	TTEAID7
DMJB3E1	MN	Trypanosoma Cruzipain (Trypano CYSP)
DMJB3E1	MT	DTT
DMJB3E1	MA	Inhibitor
DMJB3E1	RN	Colloid formation by drugs in simulated intestinal fluid. J Med Chem. 2010 May 27;53(10):4259-65.
DMJB3E1	RU	https://pubmed.ncbi.nlm.nih.gov/20426472

DM7FQD0	DI	DM7FQD0
DM7FQD0	DN	VK-11
DM7FQD0	MI	TTE4KHA
DM7FQD0	MN	Amyloid beta A4 protein (APP)
DM7FQD0	MT	DTT
DM7FQD0	MA	Inhibitor
DM7FQD0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
DM7FQD0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402

DMRQBEW	DI	DMRQBEW
DMRQBEW	DN	VK-12
DMRQBEW	MI	TTE4KHA
DMRQBEW	MN	Amyloid beta A4 protein (APP)
DMRQBEW	MT	DTT
DMRQBEW	MA	Inhibitor
DMRQBEW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
DMRQBEW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402

DMKW5YL	DI	DMKW5YL
DMKW5YL	DN	VL-0395
DMKW5YL	MI	TTCG0AL
DMKW5YL	MN	Cholecystokinin receptor type A (CCKAR)
DMKW5YL	MT	DTT
DMKW5YL	MA	Inhibitor
DMKW5YL	RN	2D-QSAR and 3D-QSAR/CoMFA analyses of the N-terminal substituted anthranilic acid based CCK(1) receptor antagonists: 'Hic Rhodus, hic saltus'. Bioorg Med Chem. 2009 Jul 15;17(14):5198-206.
DMKW5YL	RU	https://pubmed.ncbi.nlm.nih.gov/19523833

DM2XAUY	DI	DM2XAUY
DM2XAUY	DN	VL-0494
DM2XAUY	MI	TTCG0AL
DM2XAUY	MN	Cholecystokinin receptor type A (CCKAR)
DM2XAUY	MT	DTT
DM2XAUY	MA	Inhibitor
DM2XAUY	RN	Synthesis and evaluation of novel benzimidazole derivative [Bz-Im] and its radio/biological studies. Bioorg Med Chem Lett. 2007 May 15;17(10):2749-55.
DM2XAUY	RU	https://pubmed.ncbi.nlm.nih.gov/17368898

DMCZNB3	DI	DMCZNB3
DMCZNB3	DN	VL-0699
DMCZNB3	MI	TTCG0AL
DMCZNB3	MN	Cholecystokinin receptor type A (CCKAR)
DMCZNB3	MT	DTT
DMCZNB3	MA	Inhibitor
DMCZNB3	RN	Anthranilic acid based CCK1 receptor antagonists and CCK-8 have a common step in their "receptor desmodynamic processes". J Med Chem. 2006 Apr 20;49(8):2456-62.
DMCZNB3	RU	https://pubmed.ncbi.nlm.nih.gov/16610788

DMU9VQJ	DI	DMU9VQJ
DMU9VQJ	DN	VL-1499
DMU9VQJ	MI	TTCG0AL
DMU9VQJ	MN	Cholecystokinin receptor type A (CCKAR)
DMU9VQJ	MT	DTT
DMU9VQJ	MA	Inhibitor
DMU9VQJ	RN	2D-QSAR and 3D-QSAR/CoMFA analyses of the N-terminal substituted anthranilic acid based CCK(1) receptor antagonists: 'Hic Rhodus, hic saltus'. Bioorg Med Chem. 2009 Jul 15;17(14):5198-206.
DMU9VQJ	RU	https://pubmed.ncbi.nlm.nih.gov/19523833

DMBEV4W	DI	DMBEV4W
DMBEV4W	DN	VL-2799
DMBEV4W	MI	TTCG0AL
DMBEV4W	MN	Cholecystokinin receptor type A (CCKAR)
DMBEV4W	MT	DTT
DMBEV4W	MA	Inhibitor
DMBEV4W	RN	Anthranilic acid based CCK1 receptor antagonists: blocking the receptor with the same 'words' of the endogenous ligand. Bioorg Med Chem. 2009 Mar 15;17(6):2336-50.
DMBEV4W	RU	https://pubmed.ncbi.nlm.nih.gov/19261479

DM95KRY	DI	DM95KRY
DM95KRY	DN	VLI-27
DM95KRY	MI	TTWTSCV
DM95KRY	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DM95KRY	MT	DTT
DM95KRY	MA	Inhibitor
DM95KRY	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479).
DM95KRY	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1479

DMYH3A0	DI	DMYH3A0
DMYH3A0	DN	VLTS-582
DMYH3A0	MI	TT6RVLG
DMYH3A0	MN	Superoxide dismutase Cu-Zn (SOD Cu-Zn)
DMYH3A0	MT	DTT
DMYH3A0	MA	Modulator
DMYH3A0	RN	A Phase I Study of Concurrent Chemotherapy (Paclitaxel and Carboplatin) and Thoracic Radiotherapy with Swallowed Manganese Superoxide Dismutase Plasmid Liposome Protection in Patients with Locally Advanced Stage III Non-Small-Cell Lung Cancer
DMYH3A0	RU	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3057216

DMJRI6A	DI	DMJRI6A
DMJRI6A	DN	VN/107-1
DMJRI6A	MI	TTRA5BZ
DMJRI6A	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMJRI6A	MT	DTT
DMJRI6A	MA	Inhibitor
DMJRI6A	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1361).
DMJRI6A	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1361

DMA106W	DI	DMA106W
DMA106W	DN	Voacangine
DMA106W	MI	TT1RS9F
DMA106W	MN	Acetylcholinesterase (AChE)
DMA106W	MT	DTT
DMA106W	MA	Inhibitor
DMA106W	RN	Indole alkaloids from Ervatamia hainanensis with potent acetylcholinesterase inhibition activities. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6185-7.
DMA106W	RU	https://pubmed.ncbi.nlm.nih.gov/20850311

DMT03VB	DI	DMT03VB
DMT03VB	DN	VP-343
DMT03VB	MI	TTK8R02
DMT03VB	MN	Vasopressin V2 receptor (V2R)
DMT03VB	MT	DTT
DMT03VB	MA	Antagonist
DMT03VB	RN	Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res. 2002;139:197-210.
DMT03VB	RU	https://pubmed.ncbi.nlm.nih.gov/12436936

DMIXUM3	DI	DMIXUM3
DMIXUM3	DN	VPC03090-P
DMIXUM3	MI	TT9JZCK
DMIXUM3	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMIXUM3	MT	DTT
DMIXUM3	MA	Antagonist
DMIXUM3	RN	Characterization of a sphingosine 1-phosphate receptor antagonist prodrug. J Pharmacol Exp Ther. 2011 Sep;338(3):879-89.
DMIXUM3	RU	https://pubmed.ncbi.nlm.nih.gov/21632869

DMIXUM3	DI	DMIXUM3
DMIXUM3	DN	VPC03090-P
DMIXUM3	MI	TTDYP7I
DMIXUM3	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DMIXUM3	MT	DTT
DMIXUM3	MA	Antagonist
DMIXUM3	RN	Characterization of a sphingosine 1-phosphate receptor antagonist prodrug. J Pharmacol Exp Ther. 2011 Sep;338(3):879-89.
DMIXUM3	RU	https://pubmed.ncbi.nlm.nih.gov/21632869

DMIXUM3	DI	DMIXUM3
DMIXUM3	DN	VPC03090-P
DMIXUM3	MI	TTZ8C5Q
DMIXUM3	MN	Sphingosine-1-phosphate receptor 4 (S1PR4)
DMIXUM3	MT	DTT
DMIXUM3	MA	Agonist
DMIXUM3	RN	Characterization of a sphingosine 1-phosphate receptor antagonist prodrug. J Pharmacol Exp Ther. 2011 Sep;338(3):879-89.
DMIXUM3	RU	https://pubmed.ncbi.nlm.nih.gov/21632869

DMIXUM3	DI	DMIXUM3
DMIXUM3	DN	VPC03090-P
DMIXUM3	MI	TTDZCKV
DMIXUM3	MN	Sphingosine-1-phosphate receptor 5 (S1PR5)
DMIXUM3	MT	DTT
DMIXUM3	MA	Agonist
DMIXUM3	RN	Characterization of a sphingosine 1-phosphate receptor antagonist prodrug. J Pharmacol Exp Ther. 2011 Sep;338(3):879-89.
DMIXUM3	RU	https://pubmed.ncbi.nlm.nih.gov/21632869

DM6F0VR	DI	DM6F0VR
DM6F0VR	DN	VPC12249
DM6F0VR	MI	TTE2YJR
DM6F0VR	MN	Lysophosphatidate-3 receptor (LPAR3)
DM6F0VR	MT	DTT
DM6F0VR	MA	Antagonist
DM6F0VR	RN	Activity of 2-substituted lysophosphatidic acid (LPA) analogs at LPA receptors: discovery of a LPA1/LPA3 receptor antagonist. Mol Pharmacol. 2001 Dec;60(6):1173-80.
DM6F0VR	RU	https://pubmed.ncbi.nlm.nih.gov/11723223

DM6F0VR	DI	DM6F0VR
DM6F0VR	DN	VPC12249
DM6F0VR	MI	TTQ6S1K
DM6F0VR	MN	Lysophosphatidic acid receptor 1 (LPAR1)
DM6F0VR	MT	DTT
DM6F0VR	MA	Antagonist
DM6F0VR	RN	Activity of 2-substituted lysophosphatidic acid (LPA) analogs at LPA receptors: discovery of a LPA1/LPA3 receptor antagonist. Mol Pharmacol. 2001 Dec;60(6):1173-80.
DM6F0VR	RU	https://pubmed.ncbi.nlm.nih.gov/11723223

DM6F0VR	DI	DM6F0VR
DM6F0VR	DN	VPC12249
DM6F0VR	MI	TTDYP7I
DM6F0VR	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DM6F0VR	MT	DTT
DM6F0VR	MA	Agonist
DM6F0VR	RN	Synthesis and biological evaluation of gamma-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists. Bioorg Med Chem. 2007 Jan 15;15(2):663-77.
DM6F0VR	RU	https://pubmed.ncbi.nlm.nih.gov/17113298

DMVQFY4	DI	DMVQFY4
DMVQFY4	DN	VPC23019
DMVQFY4	MI	TT9JZCK
DMVQFY4	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMVQFY4	MT	DTT
DMVQFY4	MA	Antagonist
DMVQFY4	RN	Sphingosine 1-phosphate analogs as receptor antagonists. J Biol Chem. 2005 Mar 18;280(11):9833-41.
DMVQFY4	RU	https://pubmed.ncbi.nlm.nih.gov/15590668

DMVQFY4	DI	DMVQFY4
DMVQFY4	DN	VPC23019
DMVQFY4	MI	TTDYP7I
DMVQFY4	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DMVQFY4	MT	DTT
DMVQFY4	MA	Antagonist
DMVQFY4	RN	Sphingosine 1-phosphate analogs as receptor antagonists. J Biol Chem. 2005 Mar 18;280(11):9833-41.
DMVQFY4	RU	https://pubmed.ncbi.nlm.nih.gov/15590668

DMLK3I9	DI	DMLK3I9
DMLK3I9	DN	VPC32183
DMLK3I9	MI	TTE2YJR
DMLK3I9	MN	Lysophosphatidate-3 receptor (LPAR3)
DMLK3I9	MT	DTT
DMLK3I9	MA	Antagonist
DMLK3I9	RN	Initial structure-activity relationships of lysophosphatidic acid receptor antagonists: discovery of a high-affinity LPA1/LPA3 receptor antagonist. Bioorg Med Chem Lett. 2004 Jun 7;14(11):2735-40.
DMLK3I9	RU	https://pubmed.ncbi.nlm.nih.gov/15125924

DMLK3I9	DI	DMLK3I9
DMLK3I9	DN	VPC32183
DMLK3I9	MI	TTQ6S1K
DMLK3I9	MN	Lysophosphatidic acid receptor 1 (LPAR1)
DMLK3I9	MT	DTT
DMLK3I9	MA	Antagonist
DMLK3I9	RN	Initial structure-activity relationships of lysophosphatidic acid receptor antagonists: discovery of a high-affinity LPA1/LPA3 receptor antagonist. Bioorg Med Chem Lett. 2004 Jun 7;14(11):2735-40.
DMLK3I9	RU	https://pubmed.ncbi.nlm.nih.gov/15125924

DMQ4OTJ	DI	DMQ4OTJ
DMQ4OTJ	DN	VPC44116
DMQ4OTJ	MI	TT9JZCK
DMQ4OTJ	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMQ4OTJ	MT	DTT
DMQ4OTJ	MA	Antagonist
DMQ4OTJ	RN	Synthesis and biological evaluation of gamma-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists. Bioorg Med Chem. 2007 Jan 15;15(2):663-77.
DMQ4OTJ	RU	https://pubmed.ncbi.nlm.nih.gov/17113298

DMQ4OTJ	DI	DMQ4OTJ
DMQ4OTJ	DN	VPC44116
DMQ4OTJ	MI	TTDYP7I
DMQ4OTJ	MN	Sphingosine-1-phosphate receptor 3 (S1PR3)
DMQ4OTJ	MT	DTT
DMQ4OTJ	MA	Antagonist
DMQ4OTJ	RN	Synthesis and biological evaluation of gamma-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists. Bioorg Med Chem. 2007 Jan 15;15(2):663-77.
DMQ4OTJ	RU	https://pubmed.ncbi.nlm.nih.gov/17113298

DMQ4OTJ	DI	DMQ4OTJ
DMQ4OTJ	DN	VPC44116
DMQ4OTJ	MI	TTDZCKV
DMQ4OTJ	MN	Sphingosine-1-phosphate receptor 5 (S1PR5)
DMQ4OTJ	MT	DTT
DMQ4OTJ	MA	Agonist
DMQ4OTJ	RN	Synthesis and biological evaluation of gamma-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists. Bioorg Med Chem. 2007 Jan 15;15(2):663-77.
DMQ4OTJ	RU	https://pubmed.ncbi.nlm.nih.gov/17113298

DM20AJ4	DI	DM20AJ4
DM20AJ4	DN	VPC-94075
DM20AJ4	MI	TTOHFIY
DM20AJ4	MN	Sphingosine kinase 1 (SPHK1)
DM20AJ4	MT	DTT
DM20AJ4	MA	Inhibitor
DM20AJ4	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2204).
DM20AJ4	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2204

DM1QKVL	DI	DM1QKVL
DM1QKVL	DN	VRC3375
DM1QKVL	MI	TTICO5G
DM1QKVL	MN	Staphylococcus Peptide deformylase (Stap-coc def)
DM1QKVL	MT	DTT
DM1QKVL	MA	Inhibitor
DM1QKVL	RN	Peptide deformylase inhibitors as antibacterial agents: identification of VRC3375, a proline-3-alkylsuccinyl hydroxamate derivative, by using an integrated combinatorial and medicinal chemistry approach. Antimicrob Agents Chemother. 2004 Jan;48(1):250-61.
DM1QKVL	RU	https://pubmed.ncbi.nlm.nih.gov/14693547

DMFT49S	DI	DMFT49S
DMFT49S	DN	VRT-750018
DMFT49S	MI	TTOU65C
DMFT49S	MN	Tyrosine-protein kinase SYK (SYK)
DMFT49S	MT	DTT
DMFT49S	MA	Inhibitor
DMFT49S	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2230).
DMFT49S	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2230

DMCXZGU	DI	DMCXZGU
DMCXZGU	DN	VRX-03011
DMCXZGU	MI	TT07C3Y
DMCXZGU	MN	5-HT 4 receptor (HTR4)
DMCXZGU	MT	DTT
DMCXZGU	MA	Modulator
DMCXZGU	RN	VRX-03011, a novel 5-HT4 agonist, enhances memory and hippocampal acetylcholine efflux.Neuropharmacology.2007 Sep;53(4):563-73.
DMCXZGU	RU	https://www.ncbi.nlm.nih.gov/pubmed/17692343

DMRP2IN	DI	DMRP2IN
DMRP2IN	DN	VS-12343
DMRP2IN	MI	DE62N9Z
DMRP2IN	MN	Alpha-L-rhamnosidase (lrA)
DMRP2IN	MT	DME
DMRP2IN	MA	Metabolism
DMRP2IN	RN	Catabolism of citrus flavanones by the probiotics Bifidobacterium longum and Lactobacillus rhamnosus. Eur J Nutr. 2018 Feb;57(1):231-242.
DMRP2IN	RU	https://pubmed.ncbi.nlm.nih.gov/27722779

DMB7I0A	DI	DMB7I0A
DMB7I0A	DN	VT-224
DMB7I0A	MI	TT8KLPT
DMB7I0A	MN	C-C chemokine receptor (CCR)
DMB7I0A	MT	DTT
DMB7I0A	MA	Modulator
DMB7I0A	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 67).
DMB7I0A	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=67

DM1QBXM	DI	DM1QBXM
DM1QBXM	DN	VT-310
DM1QBXM	MI	TTJTRMK
DM1QBXM	MN	Interleukin 10 receptor (IL10RB)
DM1QBXM	MT	DTT
DM1QBXM	MA	Modulator
DM1QBXM	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1900).
DM1QBXM	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1900

DMG1Q0W	DI	DMG1Q0W
DMG1Q0W	DN	VT-362
DMG1Q0W	MI	TT2GM5R
DMG1Q0W	MN	Lymphocyte activation antigen CD30 (TNFRSF8)
DMG1Q0W	MT	DTT
DMG1Q0W	MA	Modulator
DMG1Q0W	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1877).
DMG1Q0W	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1877

DMJ2PG1	DI	DMJ2PG1
DMJ2PG1	DN	VTHRLAGLLSRSGGVVKNNFVPTNVGSKAF-NH2
DMJ2PG1	MI	TTVSFJW
DMJ2PG1	MN	Calcitonin gene-related peptide 1 (CALCA)
DMJ2PG1	MT	DTT
DMJ2PG1	MA	Inhibitor
DMJ2PG1	RN	Identification of potent, selective, and metabolically stable peptide antagonists to the calcitonin gene-related peptide (CGRP) receptor. J Med Chem. 2008 Dec 25;51(24):7889-97.
DMJ2PG1	RU	https://pubmed.ncbi.nlm.nih.gov/19053766

DMT967L	DI	DMT967L
DMT967L	DN	VTT-201
DMT967L	MI	TTS78AZ
DMT967L	MN	Prostate specific antigen (KLK3)
DMT967L	MT	DTT
DMT967L	MA	Modulator
DMT967L	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2373).
DMT967L	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2373

DMEVAIF	DI	DMEVAIF
DMEVAIF	DN	VTX-744
DMEVAIF	MI	TT8CWFK
DMEVAIF	MN	Toll-like receptor 8 (TLR8)
DMEVAIF	MT	DTT
DMEVAIF	MA	Modulator
DMEVAIF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1758).
DMEVAIF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1758

DMGTB95	DI	DMGTB95
DMGTB95	DN	VTX-763
DMGTB95	MI	TT8CWFK
DMGTB95	MN	Toll-like receptor 8 (TLR8)
DMGTB95	MT	DTT
DMGTB95	MA	Antagonist
DMGTB95	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1758).
DMGTB95	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1758

DMDF2U3	DI	DMDF2U3
DMDF2U3	DN	VU0001171
DMDF2U3	MI	TTICZ1O
DMDF2U3	MN	Metabotropic glutamate receptor 4 (mGluR4)
DMDF2U3	MT	DTT
DMDF2U3	MA	Modulator (allosteric modulator)
DMDF2U3	RN	Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4). Part II: Challenges in hit-to-lead. Bioorg Med Chem Lett. 2009 Feb 1;19(3):962-6.
DMDF2U3	RU	https://pubmed.ncbi.nlm.nih.gov/19097893

DMXD3T7	DI	DMXD3T7
DMXD3T7	DN	VU0010010
DMXD3T7	MI	TTOXS3C
DMXD3T7	MN	Muscarinic acetylcholine receptor (CHRM)
DMXD3T7	MT	DTT
DMXD3T7	MA	Modulator (allosteric modulator)
DMXD3T7	RN	Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol Sci. 2009 Mar;30(3):148-55.
DMXD3T7	RU	https://pubmed.ncbi.nlm.nih.gov/19201489

DMRNLGW	DI	DMRNLGW
DMRNLGW	DN	VU0029767
DMRNLGW	MI	TTOXS3C
DMRNLGW	MN	Muscarinic acetylcholine receptor (CHRM)
DMRNLGW	MT	DTT
DMRNLGW	MA	Modulator (allosteric modulator)
DMRNLGW	RN	Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity. Mol Pharmacol. 2009 Mar;75(3):577-88.
DMRNLGW	RU	https://pubmed.ncbi.nlm.nih.gov/19047481

DMUMOV1	DI	DMUMOV1
DMUMOV1	DN	VU0080241
DMUMOV1	MI	TTVBPDM
DMUMOV1	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMUMOV1	MT	DTT
DMUMOV1	MA	Inhibitor
DMUMOV1	RN	Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4): Part I. Discovery of pyrazolo[3,4-d]pyrimidines as novel ... Bioorg Med Chem Lett. 2008 Oct 15;18(20):5626-30.
DMUMOV1	RU	https://pubmed.ncbi.nlm.nih.gov/18793851

DMGFTVI	DI	DMGFTVI
DMGFTVI	DN	VU0090157
DMGFTVI	MI	TTOXS3C
DMGFTVI	MN	Muscarinic acetylcholine receptor (CHRM)
DMGFTVI	MT	DTT
DMGFTVI	MA	Modulator (allosteric modulator)
DMGFTVI	RN	Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity. Mol Pharmacol. 2009 Mar;75(3):577-88.
DMGFTVI	RU	https://pubmed.ncbi.nlm.nih.gov/19047481

DMVMXKP	DI	DMVMXKP
DMVMXKP	DN	VU0092145
DMVMXKP	MI	TTICZ1O
DMVMXKP	MN	Metabotropic glutamate receptor 4 (mGluR4)
DMVMXKP	MT	DTT
DMVMXKP	MA	Modulator (allosteric modulator)
DMVMXKP	RN	Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4). Part II: Challenges in hit-to-lead. Bioorg Med Chem Lett. 2009 Feb 1;19(3):962-6.
DMVMXKP	RU	https://pubmed.ncbi.nlm.nih.gov/19097893

DMT76JS	DI	DMT76JS
DMT76JS	DN	VU0092273
DMT76JS	MI	TTHS256
DMT76JS	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMT76JS	MT	DTT
DMT76JS	MA	Modulator (allosteric modulator)
DMT76JS	RN	Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function. Mol Pharmacol.2012 Feb;81(2):120-33.
DMT76JS	RU	https://pubmed.ncbi.nlm.nih.gov/22021324

DMPSI10	DI	DMPSI10
DMPSI10	DN	VU0119498
DMPSI10	MI	TTH18TF
DMPSI10	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMPSI10	MT	DTT
DMPSI10	MA	Inhibitor
DMPSI10	RN	Discovery of the first highly M5-preferring muscarinic acetylcholine receptor ligand, an M5 positive allosteric modulator derived from a series of ... J Med Chem. 2009 Jun 11;52(11):3445-8.
DMPSI10	RU	https://pubmed.ncbi.nlm.nih.gov/19438238

DM1UAQT	DI	DM1UAQT
DM1UAQT	DN	VU0152099
DM1UAQT	MI	TTOXS3C
DM1UAQT	MN	Muscarinic acetylcholine receptor (CHRM)
DM1UAQT	MT	DTT
DM1UAQT	MA	Modulator (allosteric modulator)
DM1UAQT	RN	Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats. J Pharmacol Exp Ther. 2008 Dec;327(3):941-53.
DM1UAQT	RU	https://pubmed.ncbi.nlm.nih.gov/18772318

DM04HUC	DI	DM04HUC
DM04HUC	DN	VU0152100
DM04HUC	MI	TTOXS3C
DM04HUC	MN	Muscarinic acetylcholine receptor (CHRM)
DM04HUC	MT	DTT
DM04HUC	MA	Modulator (allosteric modulator)
DM04HUC	RN	Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats. J Pharmacol Exp Ther. 2008 Dec;327(3):941-53.
DM04HUC	RU	https://pubmed.ncbi.nlm.nih.gov/18772318

DMPKSTD	DI	DMPKSTD
DMPKSTD	DN	VU0155041
DMPKSTD	MI	TTICZ1O
DMPKSTD	MN	Metabotropic glutamate receptor 4 (mGluR4)
DMPKSTD	MT	DTT
DMPKSTD	MA	Modulator (allosteric modulator)
DMPKSTD	RN	Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. Mol Pharmacol. 2008 Nov;74(5):1345-58.
DMPKSTD	RU	https://pubmed.ncbi.nlm.nih.gov/18664603

DMOPLQI	DI	DMOPLQI
DMOPLQI	DN	VU0238429
DMOPLQI	MI	TTH18TF
DMOPLQI	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMOPLQI	MT	DTT
DMOPLQI	MA	Inhibitor
DMOPLQI	RN	Discovery of the first highly M5-preferring muscarinic acetylcholine receptor ligand, an M5 positive allosteric modulator derived from a series of ... J Med Chem. 2009 Jun 11;52(11):3445-8.
DMOPLQI	RU	https://pubmed.ncbi.nlm.nih.gov/19438238

DMH720P	DI	DMH720P
DMH720P	DN	VU0240382
DMH720P	MI	TTHS256
DMH720P	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMH720P	MT	DTT
DMH720P	MA	Modulator (allosteric modulator)
DMH720P	RN	Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function. Mol Pharmacol.2012 Feb;81(2):120-33.
DMH720P	RU	https://pubmed.ncbi.nlm.nih.gov/22021324

DMU3YRH	DI	DMU3YRH
DMU3YRH	DN	VU0240551
DMU3YRH	MI	TTH6UZY
DMU3YRH	MN	Solute carrier family 12 member 5 (SLC12A5)
DMU3YRH	MT	DTT
DMU3YRH	MA	Inhibitor
DMU3YRH	RN	Small-molecule screen identifies inhibitors of the neuronal K-Cl cotransporter KCC2. Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5383-8.
DMU3YRH	RU	https://pubmed.ncbi.nlm.nih.gov/19279215

DMRKE6W	DI	DMRKE6W
DMRKE6W	DN	VU0255035
DMRKE6W	MI	TTOXS3C
DMRKE6W	MN	Muscarinic acetylcholine receptor (CHRM)
DMRKE6W	MT	DTT
DMRKE6W	MA	Antagonist
DMRKE6W	RN	A novel selective muscarinic acetylcholine receptor subtype 1 antagonist reduces seizures without impairing hippocampus-dependent learning. Mol Pharmacol. 2009 Aug;76(2):356-68.
DMRKE6W	RU	https://pubmed.ncbi.nlm.nih.gov/19407080

DMRKE6W	DI	DMRKE6W
DMRKE6W	DN	VU0255035
DMRKE6W	MI	TTQ13Z5
DMRKE6W	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMRKE6W	MT	DTT
DMRKE6W	MA	Antagonist
DMRKE6W	RN	A novel selective muscarinic acetylcholine receptor subtype 1 antagonist reduces seizures without impairing hippocampus-dependent learning. Mol Pharmacol. 2009 Aug;76(2):356-68.
DMRKE6W	RU	https://pubmed.ncbi.nlm.nih.gov/19407080

DM7VCDF	DI	DM7VCDF
DM7VCDF	DN	VU0285683
DM7VCDF	MI	TTHS256
DM7VCDF	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM7VCDF	MT	DTT
DM7VCDF	MA	Modulator (allosteric modulator)
DM7VCDF	RN	Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Mol Pharmacol. 2010 Dec;78(6):1105-23.
DM7VCDF	RU	https://pubmed.ncbi.nlm.nih.gov/20923853

DMETUHS	DI	DMETUHS
DMETUHS	DN	VU0357121
DMETUHS	MI	TTHS256
DMETUHS	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMETUHS	MT	DTT
DMETUHS	MA	Modulator (allosteric modulator)
DMETUHS	RN	Discovery of a Novel Chemical Class of mGlu(5) Allosteric Ligands with Distinct Modes of Pharmacology. ACS Chem Neurosci. 2010 Oct 20;1(10):702-716.
DMETUHS	RU	https://pubmed.ncbi.nlm.nih.gov/20981342

DM9V01W	DI	DM9V01W
DM9V01W	DN	VU0359516
DM9V01W	MI	TTICZ1O
DM9V01W	MN	Metabotropic glutamate receptor 4 (mGluR4)
DM9V01W	MT	DTT
DM9V01W	MA	Modulator (allosteric modulator)
DM9V01W	RN	Re-exploration of the PHCCC Scaffold: Discovery of Improved Positive Allosteric Modulators of mGluR4. ACS Chem Neurosci. 2010 Jun 16;1(6):411-419.
DM9V01W	RU	https://pubmed.ncbi.nlm.nih.gov/20582156

DM3NXMB	DI	DM3NXMB
DM3NXMB	DN	VU0360172
DM3NXMB	MI	TTHS256
DM3NXMB	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM3NXMB	MT	DTT
DM3NXMB	MA	Modulator (allosteric modulator)
DM3NXMB	RN	Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Mol Pharmacol. 2010 Dec;78(6):1105-23.
DM3NXMB	RU	https://pubmed.ncbi.nlm.nih.gov/20923853

DME71ON	DI	DME71ON
DME71ON	DN	VU0361737
DME71ON	MI	TTICZ1O
DME71ON	MN	Metabotropic glutamate receptor 4 (mGluR4)
DME71ON	MT	DTT
DME71ON	MA	Modulator (allosteric modulator)
DME71ON	RN	Synthesis and evaluation of a series of heterobiarylamides that are centrally penetrant metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulators (PAMs). J Med Chem. 2009 Jul 23;52(14):4115-8.
DME71ON	RU	https://pubmed.ncbi.nlm.nih.gov/19469556

DM3ZUH2	DI	DM3ZUH2
DM3ZUH2	DN	VU0361747
DM3ZUH2	MI	TTHS256
DM3ZUH2	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM3ZUH2	MT	DTT
DM3ZUH2	MA	Modulator (allosteric modulator)
DM3ZUH2	RN	Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function. Mol Pharmacol.2012 Feb;81(2):120-33.
DM3ZUH2	RU	https://pubmed.ncbi.nlm.nih.gov/22021324

DM8TR1Y	DI	DM8TR1Y
DM8TR1Y	DN	VU0364289
DM8TR1Y	MI	TTHS256
DM8TR1Y	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM8TR1Y	MT	DTT
DM8TR1Y	MA	Modulator (allosteric modulator)
DM8TR1Y	RN	Discovery of N-Aryl Piperazines as Selective mGlu(5) Potentiators with Efficacy in a Rodent Model Predictive of Anti-Psychotic Activity. ACS Med Chem Lett. 2010 Nov 11;1(8):433-438.
DM8TR1Y	RU	https://pubmed.ncbi.nlm.nih.gov/23308336

DMXY980	DI	DMXY980
DMXY980	DN	VU0364770
DMXY980	MI	TTICZ1O
DMXY980	MN	Metabotropic glutamate receptor 4 (mGluR4)
DMXY980	MT	DTT
DMXY980	MA	Modulator (allosteric modulator)
DMXY980	RN	The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease. J Pharmacol Exp Ther. 2012 Feb;340(2):404-21.
DMXY980	RU	https://pubmed.ncbi.nlm.nih.gov/22088953

DMA6CLO	DI	DMA6CLO
DMA6CLO	DN	VU0366058
DMA6CLO	MI	TTHS256
DMA6CLO	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMA6CLO	MT	DTT
DMA6CLO	MA	Modulator (allosteric modulator)
DMA6CLO	RN	Discovery of 2-(2-benzoxazoyl amino)-4-aryl-5-cyanopyrimidine as negative allosteric modulators (NAMs) of metabotropic glutamate receptor (mGlu : from an artificial neural network virtual screen to an in vivo tool compound. ChemMedChem. 2012 Mar 5;7(3):406-14.
DMA6CLO	RU	https://pubmed.ncbi.nlm.nih.gov/22267125

DM7L51U	DI	DM7L51U
DM7L51U	DN	VU0400195
DM7L51U	MI	TTICZ1O
DM7L51U	MN	Metabotropic glutamate receptor 4 (mGluR4)
DM7L51U	MT	DTT
DM7L51U	MA	Modulator (allosteric modulator)
DM7L51U	RN	Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu(4)) with oral efficacy in an antiparkinsonian animal model. J Med Chem. 2011 Nov 10;54(21):7639-47.
DM7L51U	RU	https://pubmed.ncbi.nlm.nih.gov/21966889

DMZRE6X	DI	DMZRE6X
DMZRE6X	DN	VU0404251
DMZRE6X	MI	TTHS256
DMZRE6X	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMZRE6X	MT	DTT
DMZRE6X	MA	Modulator (allosteric modulator)
DMZRE6X	RN	Optimization of an ether series of mGlu5 positive allosteric modulators: molecular determinants of MPEP-site interaction crossover. Bioorg Med Chem Lett. 2012 Oct 15;22(20):6481-5.
DMZRE6X	RU	https://pubmed.ncbi.nlm.nih.gov/22981332

DMLPMAY	DI	DMLPMAY
DMLPMAY	DN	VU0405601
DMLPMAY	MI	TTQ6VDM
DMLPMAY	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMLPMAY	MT	DTT
DMLPMAY	MA	Activator
DMLPMAY	RN	Identification and characterization of a compound that protects cardiac tissue from human Ether- -go-go-related gene (hERG)-related drug-induced arrhythmias. J Biol Chem. 2012 Nov 16;287(47):39613-25.
DMLPMAY	RU	https://pubmed.ncbi.nlm.nih.gov/23033485

DMZDIVL	DI	DMZDIVL
DMZDIVL	DN	VU0424465
DMZDIVL	MI	TTHS256
DMZDIVL	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMZDIVL	MT	DTT
DMZDIVL	MA	Modulator (allosteric modulator)
DMZDIVL	RN	Unique signaling profiles of positive allosteric modulators of metabotropic glutamate receptor subtype 5 determine differences in in vivo activity. Biol Psychiatry. 2013 Mar 15;73(6):501-9.
DMZDIVL	RU	https://pubmed.ncbi.nlm.nih.gov/23140665

DM96FQ2	DI	DM96FQ2
DM96FQ2	DN	VU0463597
DM96FQ2	MI	TT8A9EF
DM96FQ2	MN	Metabotropic glutamate receptor 3 (mGluR3)
DM96FQ2	MT	DTT
DM96FQ2	MA	Modulator (allosteric modulator)
DM96FQ2	RN	Development of a novel, CNS-penetrant, metabotropic glutamate receptor 3 (mGlu3) NAM probe (ML289) derived from a closely related mGlu5 PAM. Bioorg Med Chem Lett. 2012 Jun 15;22(12):3921-5.
DM96FQ2	RU	https://pubmed.ncbi.nlm.nih.gov/22607673

DMDW9MS	DI	DMDW9MS
DMDW9MS	DN	VU0463841
DMDW9MS	MI	TTHS256
DMDW9MS	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMDW9MS	MT	DTT
DMDW9MS	MA	Modulator (allosteric modulator)
DMDW9MS	RN	Substituted 1-Phenyl-3-(pyridin-2-yl)urea negative allosteric modulators of mGlu5: discovery of a new tool compound VU0463841 with activity in rat models of cocaine addiction. ACS Chem Neurosci. 2013Aug 21;4(8):1217-28.
DMDW9MS	RU	https://pubmed.ncbi.nlm.nih.gov/23682684

DM1H5DL	DI	DM1H5DL
DM1H5DL	DN	VU0469650
DM1H5DL	MI	TTVBPDM
DM1H5DL	MN	Metabotropic glutamate receptor 1 (mGluR1)
DM1H5DL	MT	DTT
DM1H5DL	MA	Modulator (allosteric modulator)
DM1H5DL	RN	N-Acyl-N'-arylpiperazines as negative allosteric modulators of mGlu1: identification of VU0469650, a potent and selective tool compound with CNS exposure in rats. Bioorg Med Chem Lett. 2013 Jul 1;23(13):3713-8.
DM1H5DL	RU	https://pubmed.ncbi.nlm.nih.gov/23727046

DM31V7K	DI	DM31V7K
DM31V7K	DN	VU10007
DM31V7K	MI	TTQ3JTF
DM31V7K	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DM31V7K	MT	DTT
DM31V7K	MA	Inhibitor
DM31V7K	RN	An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission. Nat Chem Biol. 2008 Jan;4(1):42-50.
DM31V7K	RU	https://pubmed.ncbi.nlm.nih.gov/18059262

DM2HGCB	DI	DM2HGCB
DM2HGCB	DN	VU10010
DM2HGCB	MI	TTQ3JTF
DM2HGCB	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DM2HGCB	MT	DTT
DM2HGCB	MA	Inhibitor
DM2HGCB	RN	An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission. Nat Chem Biol. 2008 Jan;4(1):42-50.
DM2HGCB	RU	https://pubmed.ncbi.nlm.nih.gov/18059262

DMCRF48	DI	DMCRF48
DMCRF48	DN	VU-1545
DMCRF48	MI	TTHS256
DMCRF48	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMCRF48	MT	DTT
DMCRF48	MA	Modulator (allosteric modulator)
DMCRF48	RN	Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat... J Med Chem. 2006 Jun 1;49(11):3332-44.
DMCRF48	RU	https://pubmed.ncbi.nlm.nih.gov/16722652

DMX9ED1	DI	DMX9ED1
DMX9ED1	DN	VU591
DMX9ED1	MI	TTJ13ST
DMX9ED1	MN	Inward rectifier potassium channel Kir1.1 (KCNJ1)
DMX9ED1	MT	DTT
DMX9ED1	MA	Blocker (channel blocker)
DMX9ED1	RN	Development of a selective small-molecule inhibitor of Kir1.1, the renal outer medullary potassium channel. Mol Pharmacol. 2011 Jan;79(1):42-50.
DMX9ED1	RU	https://pubmed.ncbi.nlm.nih.gov/20926757

DMHX1KJ	DI	DMHX1KJ
DMHX1KJ	DN	VU-71
DMHX1KJ	MI	TTVBPDM
DMHX1KJ	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMHX1KJ	MT	DTT
DMHX1KJ	MA	Modulator (allosteric modulator)
DMHX1KJ	RN	9H-Xanthene-9-carboxylic acid [1,2,4]oxadiazol-3-yl- and (2H-tetrazol-5-yl)-amides as potent, orally available mGlu1 receptor enhancers. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4628-31.
DMHX1KJ	RU	https://pubmed.ncbi.nlm.nih.gov/16099654

DMFPNRD	DI	DMFPNRD
DMFPNRD	DN	VUF 4904
DMFPNRD	MI	TT9JNIC
DMFPNRD	MN	Histamine H3 receptor (H3R)
DMFPNRD	MT	DTT
DMFPNRD	MA	Antagonist
DMFPNRD	RN	Constitutive activity of histamine h(3) receptors stably expressed in SK-N-MC cells: display of agonism and inverse agonism by H(3) antagonists. J Pharmacol Exp Ther. 2001 Dec;299(3):908-14.
DMFPNRD	RU	https://pubmed.ncbi.nlm.nih.gov/11714875

DMMNVGJ	DI	DMMNVGJ
DMMNVGJ	DN	VUF 5207
DMMNVGJ	MI	TT9JNIC
DMMNVGJ	MN	Histamine H3 receptor (H3R)
DMMNVGJ	MT	DTT
DMMNVGJ	MA	Agonist
DMMNVGJ	RN	Constitutive activity of histamine h(3) receptors stably expressed in SK-N-MC cells: display of agonism and inverse agonism by H(3) antagonists. J Pharmacol Exp Ther. 2001 Dec;299(3):908-14.
DMMNVGJ	RU	https://pubmed.ncbi.nlm.nih.gov/11714875

DMVFJR4	DI	DMVFJR4
DMVFJR4	DN	VUF 5681
DMVFJR4	MI	TT9JNIC
DMVFJR4	MN	Histamine H3 receptor (H3R)
DMVFJR4	MT	DTT
DMVFJR4	MA	Antagonist
DMVFJR4	RN	The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20.
DMVFJR4	RU	https://pubmed.ncbi.nlm.nih.gov/15665857

DMI6GD0	DI	DMI6GD0
DMI6GD0	DN	VUF 8328
DMI6GD0	MI	TT9JNIC
DMI6GD0	MN	Histamine H3 receptor (H3R)
DMI6GD0	MT	DTT
DMI6GD0	MA	Agonist
DMI6GD0	RN	Constitutive activity of histamine h(3) receptors stably expressed in SK-N-MC cells: display of agonism and inverse agonism by H(3) antagonists. J Pharmacol Exp Ther. 2001 Dec;299(3):908-14.
DMI6GD0	RU	https://pubmed.ncbi.nlm.nih.gov/11714875

DMJC0UH	DI	DMJC0UH
DMJC0UH	DN	VUF 8430
DMJC0UH	MI	TTXJ178
DMJC0UH	MN	Histamine H4 receptor (H4R)
DMJC0UH	MT	DTT
DMJC0UH	MA	Agonist
DMJC0UH	RN	Discovery of S-(2-guanidylethyl)-isothiourea (VUF 8430) as a potent nonimidazole histamine H4 receptor agonist. J Med Chem. 2006 Nov 16;49(23):6650-1.
DMJC0UH	RU	https://pubmed.ncbi.nlm.nih.gov/17154494

DM89PMC	DI	DM89PMC
DM89PMC	DN	VUF-10148
DM89PMC	MI	TTTIBOJ
DM89PMC	MN	Histamine H1 receptor (H1R)
DM89PMC	MT	DTT
DM89PMC	MA	Inhibitor
DM89PMC	RN	Fragment based design of new H4 receptor-ligands with anti-inflammatory properties in vivo. J Med Chem. 2008 Apr 24;51(8):2457-67.
DM89PMC	RU	https://pubmed.ncbi.nlm.nih.gov/18357976

DM89PMC	DI	DM89PMC
DM89PMC	DN	VUF-10148
DM89PMC	MI	TTQHJ1K
DM89PMC	MN	Histamine H2 receptor (H2R)
DM89PMC	MT	DTT
DM89PMC	MA	Inhibitor
DM89PMC	RN	Fragment based design of new H4 receptor-ligands with anti-inflammatory properties in vivo. J Med Chem. 2008 Apr 24;51(8):2457-67.
DM89PMC	RU	https://pubmed.ncbi.nlm.nih.gov/18357976

DMADEOQ	DI	DMADEOQ
DMADEOQ	DN	VUF-10214
DMADEOQ	MI	TT9JNIC
DMADEOQ	MN	Histamine H3 receptor (H3R)
DMADEOQ	MT	DTT
DMADEOQ	MA	Inhibitor
DMADEOQ	RN	Fragment based design of new H4 receptor-ligands with anti-inflammatory properties in vivo. J Med Chem. 2008 Apr 24;51(8):2457-67.
DMADEOQ	RU	https://pubmed.ncbi.nlm.nih.gov/18357976

DM3G6OK	DI	DM3G6OK
DM3G6OK	DN	VUF-5297
DM3G6OK	MI	TT9JNIC
DM3G6OK	MN	Histamine H3 receptor (H3R)
DM3G6OK	MT	DTT
DM3G6OK	MA	Inhibitor
DM3G6OK	RN	Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist f... J Med Chem. 2003 May 8;46(10):1980-8.
DM3G6OK	RU	https://pubmed.ncbi.nlm.nih.gov/12723960

DMF1O0Z	DI	DMF1O0Z
DMF1O0Z	DN	VUF5391
DMF1O0Z	MI	TT9JNIC
DMF1O0Z	MN	Histamine H3 receptor (H3R)
DMF1O0Z	MT	DTT
DMF1O0Z	MA	Antagonist
DMF1O0Z	RN	The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20.
DMF1O0Z	RU	https://pubmed.ncbi.nlm.nih.gov/15665857

DMUA751	DI	DMUA751
DMUA751	DN	VUF5574
DMUA751	MI	TTK25J1
DMUA751	MN	Adenosine A1 receptor (ADORA1)
DMUA751	MT	DTT
DMUA751	MA	Antagonist
DMUA751	RN	A novel class of adenosine A3 receptor ligands. 1. 3-(2-Pyridinyl)isoquinoline derivatives. J Med Chem. 1998 Oct 8;41(21):3987-93.
DMUA751	RU	https://pubmed.ncbi.nlm.nih.gov/9767636

DMUA751	DI	DMUA751
DMUA751	DN	VUF5574
DMUA751	MI	TTNE7KG
DMUA751	MN	Adenosine A2b receptor (ADORA2B)
DMUA751	MT	DTT
DMUA751	MA	Antagonist
DMUA751	RN	A novel class of adenosine A3 receptor ligands. 1. 3-(2-Pyridinyl)isoquinoline derivatives. J Med Chem. 1998 Oct 8;41(21):3987-93.
DMUA751	RU	https://pubmed.ncbi.nlm.nih.gov/9767636

DMUA751	DI	DMUA751
DMUA751	DN	VUF5574
DMUA751	MI	TTJFY5U
DMUA751	MN	Adenosine A3 receptor (ADORA3)
DMUA751	MT	DTT
DMUA751	MA	Antagonist
DMUA751	RN	Isoquinoline and quinazoline urea analogues as antagonists for the human adenosine A(3) receptor. J Med Chem. 2000 Jun 1;43(11):2227-38.
DMUA751	RU	https://pubmed.ncbi.nlm.nih.gov/10841801

DM8OTAG	DI	DM8OTAG
DM8OTAG	DN	VUF-8504
DM8OTAG	MI	TTJFY5U
DM8OTAG	MN	Adenosine A3 receptor (ADORA3)
DM8OTAG	MT	DTT
DM8OTAG	MA	Inhibitor
DM8OTAG	RN	Pharmacophore based receptor modeling: the case of adenosine A3 receptor antagonists. An approach to the optimization of protein models. J Med Chem. 2006 Jul 13;49(14):4085-97.
DM8OTAG	RU	https://pubmed.ncbi.nlm.nih.gov/16821770

DMQFWV7	DI	DMQFWV7
DMQFWV7	DN	VUF-8507
DMQFWV7	MI	TTK25J1
DMQFWV7	MN	Adenosine A1 receptor (ADORA1)
DMQFWV7	MT	DTT
DMQFWV7	MA	Inhibitor
DMQFWV7	RN	Isoquinoline and quinazoline urea analogues as antagonists for the human adenosine A(3) receptor. J Med Chem. 2000 Jun 1;43(11):2227-38.
DMQFWV7	RU	https://pubmed.ncbi.nlm.nih.gov/10841801

DMQFWV7	DI	DMQFWV7
DMQFWV7	DN	VUF-8507
DMQFWV7	MI	TTJFY5U
DMQFWV7	MN	Adenosine A3 receptor (ADORA3)
DMQFWV7	MT	DTT
DMQFWV7	MA	Inhibitor
DMQFWV7	RN	Pharmacophore based receptor modeling: the case of adenosine A3 receptor antagonists. An approach to the optimization of protein models. J Med Chem. 2006 Jul 13;49(14):4085-97.
DMQFWV7	RU	https://pubmed.ncbi.nlm.nih.gov/16821770

DMWRX4T	DI	DMWRX4T
DMWRX4T	DN	VULM-1457
DMWRX4T	MI	TTMF541
DMWRX4T	MN	Liver carboxylesterase (CES1)
DMWRX4T	MT	DTT
DMWRX4T	MA	Inhibitor
DMWRX4T	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2592).
DMWRX4T	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2592

DMEZAND	DI	DMEZAND
DMEZAND	DN	VVP-100X
DMEZAND	MI	TTCBFJO
DMEZAND	MN	Insulin receptor (INSR)
DMEZAND	MT	DTT
DMEZAND	MA	Inhibitor
DMEZAND	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800).
DMEZAND	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800

DM4Q5DO	DI	DM4Q5DO
DM4Q5DO	DN	VX-467
DM4Q5DO	MI	TTT7PJU
DM4Q5DO	MN	Janus kinase 3 (JAK-3)
DM4Q5DO	MT	DTT
DM4Q5DO	MA	Inhibitor
DM4Q5DO	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2049).
DM4Q5DO	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2049

DMDYTSW	DI	DMDYTSW
DMDYTSW	DN	W146
DMDYTSW	MI	TT9JZCK
DMDYTSW	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMDYTSW	MT	DTT
DMDYTSW	MA	Antagonist
DMDYTSW	RN	Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. Nat Chem Biol. 2006 Aug;2(8):434-41.
DMDYTSW	RU	https://pubmed.ncbi.nlm.nih.gov/16829954

DMQI7BA	DI	DMQI7BA
DMQI7BA	DN	W54011
DMQI7BA	MI	TTHXFA1
DMQI7BA	MN	C5a anaphylatoxin chemotactic receptor (C5AR1)
DMQI7BA	MT	DTT
DMQI7BA	MA	Antagonist
DMQI7BA	RN	Identification of a potent and orally active non-peptide C5a receptor antagonist. J Biol Chem. 2002 Dec 20;277(51):49403-7.
DMQI7BA	RU	https://pubmed.ncbi.nlm.nih.gov/12384495

DMMBI9Y	DI	DMMBI9Y
DMMBI9Y	DN	W-84
DMMBI9Y	MI	TTOXS3C
DMMBI9Y	MN	Muscarinic acetylcholine receptor (CHRM)
DMMBI9Y	MT	DTT
DMMBI9Y	MA	Modulator (allosteric modulator)
DMMBI9Y	RN	Interactions of orthosteric and allosteric ligands with [3H]dimethyl-W84 at the common allosteric site of muscarinic M2 receptors. Mol Pharmacol. 2003 Jul;64(1):180-90.
DMMBI9Y	RU	https://pubmed.ncbi.nlm.nih.gov/12815174

DMNRBDP	DI	DMNRBDP
DMNRBDP	DN	WA-8242-A1
DMNRBDP	MI	TT9V5JH
DMNRBDP	MN	Phospholipase A2 (PLA2G1B)
DMNRBDP	MT	DTT
DMNRBDP	MA	Modulator
DMNRBDP	RN	WA8242A1, A2 and B, novel secretary phospholipase A2 inhibitors produced by Streptomyces violaceusniger. III. Structure elucidation and total synth... J Antibiot (Tokyo). 1998 Jul;51(7):655-64.
DMNRBDP	RU	https://www.ncbi.nlm.nih.gov/pubmed/9727392

DMB6H35	DI	DMB6H35
DMB6H35	DN	waixenicin A
DMB6H35	MI	TTFPVZO
DMB6H35	MN	Long transient receptor potential channel 7 (TRPM7)
DMB6H35	MT	DTT
DMB6H35	MA	Blocker (channel blocker)
DMB6H35	RN	Waixenicin A inhibits cell proliferation through magnesium-dependent block of transient receptor potential melastatin 7 (TRPM7) channels. J Biol Chem. 2011 Nov 11;286(45):39328-35.
DMB6H35	RU	https://pubmed.ncbi.nlm.nih.gov/21926172

DMC6KYF	DI	DMC6KYF
DMC6KYF	DN	WAY 100135
DMC6KYF	MI	TTSQIFT
DMC6KYF	MN	5-HT 1A receptor (HTR1A)
DMC6KYF	MT	DTT
DMC6KYF	MA	Antagonist
DMC6KYF	RN	Influence of 5-HT1A receptor antagonism on plus-maze behaviour in mice. II. WAY 100635, SDZ 216-525 and NAN-190. Pharmacol Biochem Behav. 1997 Oct;58(2):593-603.
DMC6KYF	RU	https://pubmed.ncbi.nlm.nih.gov/9300624

DMCSZG0	DI	DMCSZG0
DMCSZG0	DN	WAY-125971
DMCSZG0	MI	TT1VOHK
DMCSZG0	MN	Potassium channel unspecific (KC)
DMCSZG0	MT	DTT
DMCSZG0	MA	Modulator
DMCSZG0	RN	Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives. J Med Chem. 1991 Nov;34(11):3212-28.
DMCSZG0	RU	https://pubmed.ncbi.nlm.nih.gov/1956040

DMRWG0C	DI	DMRWG0C
DMRWG0C	DN	WAY-151693
DMRWG0C	MI	TTHY57M
DMRWG0C	MN	Matrix metalloproteinase-13 (MMP-13)
DMRWG0C	MT	DTT
DMRWG0C	MA	Inhibitor
DMRWG0C	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMRWG0C	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMNMO4Q	DI	DMNMO4Q
DMNMO4Q	DN	WAY-163909
DMNMO4Q	MI	TTWJBZ5
DMNMO4Q	MN	5-HT 2C receptor (HTR2C)
DMNMO4Q	MT	DTT
DMNMO4Q	MA	Agonist
DMNMO4Q	RN	WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a novel 5-hydroxytryptamine 2C receptor-sele... J Pharmacol Exp Ther. 2005 May;313(2):862-9.
DMNMO4Q	RU	https://pubmed.ncbi.nlm.nih.gov/15705738

DM94KWA	DI	DM94KWA
DM94KWA	DN	WAY-169916
DM94KWA	MI	TTZAYWL
DM94KWA	MN	Estrogen receptor (ESR)
DM94KWA	MT	DTT
DM94KWA	MA	Inhibitor
DM94KWA	RN	Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid ... J Med Chem. 2004 Dec 16;47(26):6435-8.
DM94KWA	RU	https://pubmed.ncbi.nlm.nih.gov/15588074

DM94KWA	DI	DM94KWA
DM94KWA	DN	WAY-169916
DM94KWA	MI	TTOM3J0
DM94KWA	MN	Estrogen receptor beta (ESR2)
DM94KWA	MT	DTT
DM94KWA	MA	Inhibitor
DM94KWA	RN	Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid ... J Med Chem. 2004 Dec 16;47(26):6435-8.
DM94KWA	RU	https://pubmed.ncbi.nlm.nih.gov/15588074

DMZT8LI	DI	DMZT8LI
DMZT8LI	DN	WAY170523
DMZT8LI	MI	TTHY57M
DMZT8LI	MN	Matrix metalloproteinase-13 (MMP-13)
DMZT8LI	MT	DTT
DMZT8LI	MA	Inhibitor
DMZT8LI	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1637).
DMZT8LI	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1637

DMNH0CM	DI	DMNH0CM
DMNH0CM	DN	WAY-196025
DMNH0CM	MI	TTT1JVS
DMNH0CM	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DMNH0CM	MT	DTT
DMNH0CM	MA	Inhibitor
DMNH0CM	RN	Reactions of functionalized sulfonamides: application to lowering the lipophilicity of cytosolic phospholipase A2alpha inhibitors. J Med Chem. 2009 Feb 26;52(4):1156-71.
DMNH0CM	RU	https://pubmed.ncbi.nlm.nih.gov/19178292

DMBHXTL	DI	DMBHXTL
DMBHXTL	DN	WAY200070
DMBHXTL	MI	TTZAYWL
DMBHXTL	MN	Estrogen receptor (ESR)
DMBHXTL	MT	DTT
DMBHXTL	MA	Inhibitor
DMBHXTL	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMBHXTL	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMBHXTL	DI	DMBHXTL
DMBHXTL	DN	WAY200070
DMBHXTL	MI	TTOM3J0
DMBHXTL	MN	Estrogen receptor beta (ESR2)
DMBHXTL	MT	DTT
DMBHXTL	MA	Agonist
DMBHXTL	RN	Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40.
DMBHXTL	RU	https://pubmed.ncbi.nlm.nih.gov/15456246

DMJ14NE	DI	DMJ14NE
DMJ14NE	DN	WAY-207024
DMJ14NE	MI	TT8R70G
DMJ14NE	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMJ14NE	MT	DTT
DMJ14NE	MA	Inhibitor
DMJ14NE	RN	Synthesis and biological evaluation of piperazinyl heterocyclic antagonists of the gonadotropin releasing hormone (GnRH) receptor. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2512-5.
DMJ14NE	RU	https://pubmed.ncbi.nlm.nih.gov/20236823

DMJ14NE	DI	DMJ14NE
DMJ14NE	DN	WAY-207024
DMJ14NE	MI	TTQHJ1K
DMJ14NE	MN	Histamine H2 receptor (H2R)
DMJ14NE	MT	DTT
DMJ14NE	MA	Inhibitor
DMJ14NE	RN	Discovery of 6-({4-[2-(4-tert-butylphenyl)-1H-benzimidazol-4-yl]piperazin-1-yl}methyl)quinoxaline (WAY-207024): an orally active antagonist of the ... J Med Chem. 2009 Apr 9;52(7):2148-52.
DMJ14NE	RU	https://pubmed.ncbi.nlm.nih.gov/19271735

DMJ14NE	DI	DMJ14NE
DMJ14NE	DN	WAY-207024
DMJ14NE	MI	TTYO0A3
DMJ14NE	MN	Substance-K receptor (TACR2)
DMJ14NE	MT	DTT
DMJ14NE	MA	Inhibitor
DMJ14NE	RN	Discovery of 6-({4-[2-(4-tert-butylphenyl)-1H-benzimidazol-4-yl]piperazin-1-yl}methyl)quinoxaline (WAY-207024): an orally active antagonist of the ... J Med Chem. 2009 Apr 9;52(7):2148-52.
DMJ14NE	RU	https://pubmed.ncbi.nlm.nih.gov/19271735

DM9K2LU	DI	DM9K2LU
DM9K2LU	DN	WAY-208466
DM9K2LU	MI	TTJQOD7
DM9K2LU	MN	5-HT 2A receptor (HTR2A)
DM9K2LU	MT	DTT
DM9K2LU	MA	Inhibitor
DM9K2LU	RN	Novel 1-aminoethyl-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines are potent 5-HT(6) agonists. Bioorg Med Chem. 2009 Jul 15;17(14):5153-63.
DM9K2LU	RU	https://pubmed.ncbi.nlm.nih.gov/19523834

DM9K2LU	DI	DM9K2LU
DM9K2LU	DN	WAY-208466
DM9K2LU	MI	TTWJBZ5
DM9K2LU	MN	5-HT 2C receptor (HTR2C)
DM9K2LU	MT	DTT
DM9K2LU	MA	Inhibitor
DM9K2LU	RN	Novel 1-aminoethyl-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines are potent 5-HT(6) agonists. Bioorg Med Chem. 2009 Jul 15;17(14):5153-63.
DM9K2LU	RU	https://pubmed.ncbi.nlm.nih.gov/19523834

DM9K2LU	DI	DM9K2LU
DM9K2LU	DN	WAY-208466
DM9K2LU	MI	TTJS8PY
DM9K2LU	MN	5-HT 6 receptor (HTR6)
DM9K2LU	MT	DTT
DM9K2LU	MA	Inhibitor
DM9K2LU	RN	Novel 1-aminoethyl-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines are potent 5-HT(6) agonists. Bioorg Med Chem. 2009 Jul 15;17(14):5153-63.
DM9K2LU	RU	https://pubmed.ncbi.nlm.nih.gov/19523834

DM9K2LU	DI	DM9K2LU
DM9K2LU	DN	WAY-208466
DM9K2LU	MI	TTO9X1H
DM9K2LU	MN	5-HT 7 receptor (HTR7)
DM9K2LU	MT	DTT
DM9K2LU	MA	Inhibitor
DM9K2LU	RN	Novel 1-aminoethyl-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines are potent 5-HT(6) agonists. Bioorg Med Chem. 2009 Jul 15;17(14):5153-63.
DM9K2LU	RU	https://pubmed.ncbi.nlm.nih.gov/19523834

DM9K2LU	DI	DM9K2LU
DM9K2LU	DN	WAY-208466
DM9K2LU	MI	TTEX248
DM9K2LU	MN	Dopamine D2 receptor (D2R)
DM9K2LU	MT	DTT
DM9K2LU	MA	Inhibitor
DM9K2LU	RN	Novel 1-aminoethyl-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines are potent 5-HT(6) agonists. Bioorg Med Chem. 2009 Jul 15;17(14):5153-63.
DM9K2LU	RU	https://pubmed.ncbi.nlm.nih.gov/19523834

DMMXL4E	DI	DMMXL4E
DMMXL4E	DN	WAY-213613
DMMXL4E	MI	TT2F078
DMMXL4E	MN	Excitatory amino acid transporter 2 (SLC1A2)
DMMXL4E	MT	DTT
DMMXL4E	MA	Inhibitor
DMMXL4E	RN	Characterization of novel aryl-ether, biaryl, and fluorene aspartic acid and diaminopropionic acid analogs as potent inhibitors of the high-affinit... Mol Pharmacol. 2005 Oct;68(4):974-82.
DMMXL4E	RU	https://pubmed.ncbi.nlm.nih.gov/16014807

DM8ODI7	DI	DM8ODI7
DM8ODI7	DN	WAY-214950
DM8ODI7	MI	TTOZRK6
DM8ODI7	MN	Glucocorticoid receptor messenger RNA (GCR mRNA)
DM8ODI7	MT	DTT
DM8ODI7	MA	Inhibitor
DM8ODI7	RN	Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic tr... J Med Chem. 2008 Nov 27;51(22):7161-8.
DM8ODI7	RU	https://pubmed.ncbi.nlm.nih.gov/18973288

DM8ODI7	DI	DM8ODI7
DM8ODI7	DN	WAY-214950
DM8ODI7	MI	TTECBXN
DM8ODI7	MN	Oxysterols receptor LXR-alpha (NR1H3)
DM8ODI7	MT	DTT
DM8ODI7	MA	Inhibitor
DM8ODI7	RN	Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic tr... J Med Chem. 2008 Nov 27;51(22):7161-8.
DM8ODI7	RU	https://pubmed.ncbi.nlm.nih.gov/18973288

DM8ODI7	DI	DM8ODI7
DM8ODI7	DN	WAY-214950
DM8ODI7	MI	TTXA6PH
DM8ODI7	MN	Oxysterols receptor LXR-beta (NR1H2)
DM8ODI7	MT	DTT
DM8ODI7	MA	Inhibitor
DM8ODI7	RN	Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic tr... J Med Chem. 2008 Nov 27;51(22):7161-8.
DM8ODI7	RU	https://pubmed.ncbi.nlm.nih.gov/18973288

DM8ODI7	DI	DM8ODI7
DM8ODI7	DN	WAY-214950
DM8ODI7	MI	TT7LCTF
DM8ODI7	MN	Pregnane X receptor (NR1I2)
DM8ODI7	MT	DTT
DM8ODI7	MA	Inhibitor
DM8ODI7	RN	Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic tr... J Med Chem. 2008 Nov 27;51(22):7161-8.
DM8ODI7	RU	https://pubmed.ncbi.nlm.nih.gov/18973288

DMC83HA	DI	DMC83HA
DMC83HA	DN	WAY-254011
DMC83HA	MI	TTECBXN
DMC83HA	MN	Oxysterols receptor LXR-alpha (NR1H3)
DMC83HA	MT	DTT
DMC83HA	MA	Inhibitor
DMC83HA	RN	Discovery and SAR of cinnolines/quinolines as liver X receptor (LXR) agonists with binding selectivity for LXRbeta. Bioorg Med Chem. 2009 May 15;17(10):3519-27.
DMC83HA	RU	https://pubmed.ncbi.nlm.nih.gov/19394832

DMC83HA	DI	DMC83HA
DMC83HA	DN	WAY-254011
DMC83HA	MI	TTXA6PH
DMC83HA	MN	Oxysterols receptor LXR-beta (NR1H2)
DMC83HA	MT	DTT
DMC83HA	MA	Inhibitor
DMC83HA	RN	Discovery and SAR of cinnolines/quinolines as liver X receptor (LXR) agonists with binding selectivity for LXRbeta. Bioorg Med Chem. 2009 May 15;17(10):3519-27.
DMC83HA	RU	https://pubmed.ncbi.nlm.nih.gov/19394832

DMSLNWA	DI	DMSLNWA
DMSLNWA	DN	WAY-255348
DMSLNWA	MI	TTKPW01
DMSLNWA	MN	Androgen receptor messenger RNA (AR mRNA)
DMSLNWA	MT	DTT
DMSLNWA	MA	Inhibitor
DMSLNWA	RN	Design, synthesis, and SAR of new pyrrole-oxindole progesterone receptor modulators leading to 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-... J Med Chem. 2008 Mar 27;51(6):1861-73.
DMSLNWA	RU	https://pubmed.ncbi.nlm.nih.gov/18318463

DMSLNWA	DI	DMSLNWA
DMSLNWA	DN	WAY-255348
DMSLNWA	MI	TT26PHO
DMSLNWA	MN	Mineralocorticoid receptor  (MR)
DMSLNWA	MT	DTT
DMSLNWA	MA	Inhibitor
DMSLNWA	RN	Design, synthesis, and SAR of new pyrrole-oxindole progesterone receptor modulators leading to 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-... J Med Chem. 2008 Mar 27;51(6):1861-73.
DMSLNWA	RU	https://pubmed.ncbi.nlm.nih.gov/18318463

DMSLNWA	DI	DMSLNWA
DMSLNWA	DN	WAY-255348
DMSLNWA	MI	TTUV8G9
DMSLNWA	MN	Progesterone receptor (PGR)
DMSLNWA	MT	DTT
DMSLNWA	MA	Inhibitor
DMSLNWA	RN	Design, synthesis, and SAR of new pyrrole-oxindole progesterone receptor modulators leading to 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-... J Med Chem. 2008 Mar 27;51(6):1861-73.
DMSLNWA	RU	https://pubmed.ncbi.nlm.nih.gov/18318463

DM48MC3	DI	DM48MC3
DM48MC3	DN	WAY-256805
DM48MC3	MI	TTAWNKZ
DM48MC3	MN	Norepinephrine transporter (NET)
DM48MC3	MT	DTT
DM48MC3	MA	Inhibitor
DM48MC3	RN	Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors. J Med Chem. 2008 Jul 10;51(13):4038-49.
DM48MC3	RU	https://pubmed.ncbi.nlm.nih.gov/18557608

DMMOH51	DI	DMMOH51
DMMOH51	DN	WAY-466
DMMOH51	MI	TTSQIFT
DMMOH51	MN	5-HT 1A receptor (HTR1A)
DMMOH51	MT	DTT
DMMOH51	MA	Inhibitor
DMMOH51	RN	Discovery of 5-arylsulfonamido-3-(pyrrolidin-2-ylmethyl)-1H-indole derivatives as potent, selective 5-HT6 receptor agonists and antagonists. J Med Chem. 2005 Jan 27;48(2):353-6.
DMMOH51	RU	https://pubmed.ncbi.nlm.nih.gov/15658848

DMMOH51	DI	DMMOH51
DMMOH51	DN	WAY-466
DMMOH51	MI	TTK8CXU
DMMOH51	MN	5-HT 1B receptor (HTR1B)
DMMOH51	MT	DTT
DMMOH51	MA	Inhibitor
DMMOH51	RN	Discovery of 5-arylsulfonamido-3-(pyrrolidin-2-ylmethyl)-1H-indole derivatives as potent, selective 5-HT6 receptor agonists and antagonists. J Med Chem. 2005 Jan 27;48(2):353-6.
DMMOH51	RU	https://pubmed.ncbi.nlm.nih.gov/15658848

DMMOH51	DI	DMMOH51
DMMOH51	DN	WAY-466
DMMOH51	MI	TT6MSOK
DMMOH51	MN	5-HT 1D receptor (HTR1D)
DMMOH51	MT	DTT
DMMOH51	MA	Inhibitor
DMMOH51	RN	Discovery of 5-arylsulfonamido-3-(pyrrolidin-2-ylmethyl)-1H-indole derivatives as potent, selective 5-HT6 receptor agonists and antagonists. J Med Chem. 2005 Jan 27;48(2):353-6.
DMMOH51	RU	https://pubmed.ncbi.nlm.nih.gov/15658848

DMMOH51	DI	DMMOH51
DMMOH51	DN	WAY-466
DMMOH51	MI	TT0MI3F
DMMOH51	MN	5-HT 1F receptor (HTR1F)
DMMOH51	MT	DTT
DMMOH51	MA	Inhibitor
DMMOH51	RN	Discovery of 5-arylsulfonamido-3-(pyrrolidin-2-ylmethyl)-1H-indole derivatives as potent, selective 5-HT6 receptor agonists and antagonists. J Med Chem. 2005 Jan 27;48(2):353-6.
DMMOH51	RU	https://pubmed.ncbi.nlm.nih.gov/15658848

DMMOH51	DI	DMMOH51
DMMOH51	DN	WAY-466
DMMOH51	MI	TTWJBZ5
DMMOH51	MN	5-HT 2C receptor (HTR2C)
DMMOH51	MT	DTT
DMMOH51	MA	Inhibitor
DMMOH51	RN	Discovery of 5-arylsulfonamido-3-(pyrrolidin-2-ylmethyl)-1H-indole derivatives as potent, selective 5-HT6 receptor agonists and antagonists. J Med Chem. 2005 Jan 27;48(2):353-6.
DMMOH51	RU	https://pubmed.ncbi.nlm.nih.gov/15658848

DMMOH51	DI	DMMOH51
DMMOH51	DN	WAY-466
DMMOH51	MI	TTJS8PY
DMMOH51	MN	5-HT 6 receptor (HTR6)
DMMOH51	MT	DTT
DMMOH51	MA	Inhibitor
DMMOH51	RN	Discovery of 5-arylsulfonamido-3-(pyrrolidin-2-ylmethyl)-1H-indole derivatives as potent, selective 5-HT6 receptor agonists and antagonists. J Med Chem. 2005 Jan 27;48(2):353-6.
DMMOH51	RU	https://pubmed.ncbi.nlm.nih.gov/15658848

DMMOH51	DI	DMMOH51
DMMOH51	DN	WAY-466
DMMOH51	MI	TTO9X1H
DMMOH51	MN	5-HT 7 receptor (HTR7)
DMMOH51	MT	DTT
DMMOH51	MA	Inhibitor
DMMOH51	RN	Discovery of 5-arylsulfonamido-3-(pyrrolidin-2-ylmethyl)-1H-indole derivatives as potent, selective 5-HT6 receptor agonists and antagonists. J Med Chem. 2005 Jan 27;48(2):353-6.
DMMOH51	RU	https://pubmed.ncbi.nlm.nih.gov/15658848

DMNCZEQ	DI	DMNCZEQ
DMNCZEQ	DN	WAY-644
DMNCZEQ	MI	TTXZ0KQ
DMNCZEQ	MN	Matrix metalloproteinase-12 (MMP-12)
DMNCZEQ	MT	DTT
DMNCZEQ	MA	Inhibitor
DMNCZEQ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1636).
DMNCZEQ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1636

DME10AL	DI	DME10AL
DME10AL	DN	WBZ-7
DME10AL	MI	TTX41N9
DME10AL	MN	Tyrosine-protein kinase Kit (KIT)
DME10AL	MT	DTT
DME10AL	MA	Inhibitor
DME10AL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1805).
DME10AL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1805

DMWU5PK	DI	DMWU5PK
DMWU5PK	DN	WDuo3
DMWU5PK	MI	TTOXS3C
DMWU5PK	MN	Muscarinic acetylcholine receptor (CHRM)
DMWU5PK	MT	DTT
DMWU5PK	MA	Modulator (allosteric modulator)
DMWU5PK	RN	Interactions of orthosteric and allosteric ligands with [3H]dimethyl-W84 at the common allosteric site of muscarinic M2 receptors. Mol Pharmacol. 2003 Jul;64(1):180-90.
DMWU5PK	RU	https://pubmed.ncbi.nlm.nih.gov/12815174

DMHL3YV	DI	DMHL3YV
DMHL3YV	DN	WEDELOLACTONE
DMHL3YV	MI	TTNJYV2
DMHL3YV	MN	Gamma-aminobutyric acid receptor (GAR)
DMHL3YV	MT	DTT
DMHL3YV	MA	Inhibitor
DMHL3YV	RN	Synthesis and preliminary pharmacological evaluation of coumestans with different patterns of oxygenation. Bioorg Med Chem Lett. 2001 Feb 12;11(3):283-6.
DMHL3YV	RU	https://pubmed.ncbi.nlm.nih.gov/11212092

DMK0OVE	DI	DMK0OVE
DMK0OVE	DN	WEHI-0103122
DMK0OVE	MI	TTU1E82
DMK0OVE	MN	Apoptosis regulator Bcl-xL (BCL-xL)
DMK0OVE	MT	DTT
DMK0OVE	MA	Inhibitor
DMK0OVE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2845).
DMK0OVE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2845

DMAXOIS	DI	DMAXOIS
DMAXOIS	DN	W-F-F-N--Y-Y-W
DMAXOIS	MI	TTKRD0G
DMAXOIS	MN	Endothelin A receptor (EDNRA)
DMAXOIS	MT	DTT
DMAXOIS	MA	Inhibitor
DMAXOIS	RN	Res-701-1, synthesis and a reevaluation of its effects on the endothelin receptors, Bioorg. Med. Chem. Lett. 5(6):621-626 (1995).
DMAXOIS	RU	http://www.sciencedirect.com/science/article/pii/0960894X95000847

DMAXOIS	DI	DMAXOIS
DMAXOIS	DN	W-F-F-N--Y-Y-W
DMAXOIS	MI	TT3ZTGU
DMAXOIS	MN	Endothelin B receptor (EDNRB)
DMAXOIS	MT	DTT
DMAXOIS	MA	Inhibitor
DMAXOIS	RN	Res-701-1, synthesis and a reevaluation of its effects on the endothelin receptors, Bioorg. Med. Chem. Lett. 5(6):621-626 (1995).
DMAXOIS	RU	http://www.sciencedirect.com/science/article/pii/0960894X95000847

DMQS7BT	DI	DMQS7BT
DMQS7BT	DN	WFwGG-NH2
DMQS7BT	MI	TTWDC17
DMQS7BT	MN	Growth hormone secretagogue receptor 1 (GHSR)
DMQS7BT	MT	DTT
DMQS7BT	MA	Inhibitor
DMQS7BT	RN	Identification of an efficacy switch region in the ghrelin receptor responsible for interchange between agonism and inverse agonism. J Biol Chem. 2007 May 25;282(21):15799-811.
DMQS7BT	RU	https://pubmed.ncbi.nlm.nih.gov/17371869

DMOBXVL	DI	DMOBXVL
DMOBXVL	DN	WFwLL-NH2
DMOBXVL	MI	TTWDC17
DMOBXVL	MN	Growth hormone secretagogue receptor 1 (GHSR)
DMOBXVL	MT	DTT
DMOBXVL	MA	Inhibitor
DMOBXVL	RN	Identification of an efficacy switch region in the ghrelin receptor responsible for interchange between agonism and inverse agonism. J Biol Chem. 2007 May 25;282(21):15799-811.
DMOBXVL	RU	https://pubmed.ncbi.nlm.nih.gov/17371869

DMJS8VQ	DI	DMJS8VQ
DMJS8VQ	DN	WH-4-023
DMJS8VQ	MI	TT860QF
DMJS8VQ	MN	LCK tyrosine protein kinase (LCK)
DMJS8VQ	MT	DTT
DMJS8VQ	MA	Inhibitor
DMJS8VQ	RN	Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity. J Med Chem. 2006 Aug 10;49(16):4981-91.
DMJS8VQ	RU	https://pubmed.ncbi.nlm.nih.gov/16884310

DMJS8VQ	DI	DMJS8VQ
DMJS8VQ	DN	WH-4-023
DMJS8VQ	MI	TT6PKBN
DMJS8VQ	MN	Proto-oncogene c-Src (SRC)
DMJS8VQ	MT	DTT
DMJS8VQ	MA	Inhibitor
DMJS8VQ	RN	Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity. J Med Chem. 2006 Aug 10;49(16):4981-91.
DMJS8VQ	RU	https://pubmed.ncbi.nlm.nih.gov/16884310

DMYHWS1	DI	DMYHWS1
DMYHWS1	DN	WHI-P154
DMYHWS1	MI	TTGKNB4
DMYHWS1	MN	Epidermal growth factor receptor (EGFR)
DMYHWS1	MT	DTT
DMYHWS1	MA	Inhibitor
DMYHWS1	RN	The specificity of JAK3 kinase inhibitors. Blood. 2008 Feb 15;111(4):2155-7.
DMYHWS1	RU	https://pubmed.ncbi.nlm.nih.gov/18094329

DMYHWS1	DI	DMYHWS1
DMYHWS1	DN	WHI-P154
DMYHWS1	MI	TT6DM01
DMYHWS1	MN	Janus kinase 1 (JAK-1)
DMYHWS1	MT	DTT
DMYHWS1	MA	Inhibitor
DMYHWS1	RN	The specificity of JAK3 kinase inhibitors. Blood. 2008 Feb 15;111(4):2155-7.
DMYHWS1	RU	https://pubmed.ncbi.nlm.nih.gov/18094329

DMYHWS1	DI	DMYHWS1
DMYHWS1	DN	WHI-P154
DMYHWS1	MI	TTRMX3V
DMYHWS1	MN	Janus kinase 2 (JAK-2)
DMYHWS1	MT	DTT
DMYHWS1	MA	Inhibitor
DMYHWS1	RN	The specificity of JAK3 kinase inhibitors. Blood. 2008 Feb 15;111(4):2155-7.
DMYHWS1	RU	https://pubmed.ncbi.nlm.nih.gov/18094329

DMYHWS1	DI	DMYHWS1
DMYHWS1	DN	WHI-P154
DMYHWS1	MI	TTT7PJU
DMYHWS1	MN	Janus kinase 3 (JAK-3)
DMYHWS1	MT	DTT
DMYHWS1	MA	Inhibitor
DMYHWS1	RN	The specificity of JAK3 kinase inhibitors. Blood. 2008 Feb 15;111(4):2155-7.
DMYHWS1	RU	https://pubmed.ncbi.nlm.nih.gov/18094329

DMZ703W	DI	DMZ703W
DMZ703W	DN	WilVent
DMZ703W	MI	TTP4520
DMZ703W	MN	TGF-beta receptor type I (TGFBR1)
DMZ703W	MT	DTT
DMZ703W	MA	Modulator
DMZ703W	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1788).
DMZ703W	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1788

DMY5LOB	DI	DMY5LOB
DMY5LOB	DN	WIN 51,708
DMY5LOB	MI	TTOXS3C
DMY5LOB	MN	Muscarinic acetylcholine receptor (CHRM)
DMY5LOB	MT	DTT
DMY5LOB	MA	Modulator (allosteric modulator)
DMY5LOB	RN	Analogs of WIN 62,577 define a second allosteric site on muscarinic receptors. Mol Pharmacol. 2002 Dec;62(6):1492-505.
DMY5LOB	RU	https://pubmed.ncbi.nlm.nih.gov/12435818

DMY5LOB	DI	DMY5LOB
DMY5LOB	DN	WIN 51,708
DMY5LOB	MI	TTQ13Z5
DMY5LOB	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMY5LOB	MT	DTT
DMY5LOB	MA	Modulator (allosteric modulator)
DMY5LOB	RN	Analogs of WIN 62,577 define a second allosteric site on muscarinic receptors. Mol Pharmacol. 2002 Dec;62(6):1492-505.
DMY5LOB	RU	https://pubmed.ncbi.nlm.nih.gov/12435818

DMGOQY2	DI	DMGOQY2
DMGOQY2	DN	WIN 62,577
DMGOQY2	MI	TTOXS3C
DMGOQY2	MN	Muscarinic acetylcholine receptor (CHRM)
DMGOQY2	MT	DTT
DMGOQY2	MA	Modulator (allosteric modulator)
DMGOQY2	RN	Analogs of WIN 62,577 define a second allosteric site on muscarinic receptors. Mol Pharmacol. 2002 Dec;62(6):1492-505.
DMGOQY2	RU	https://pubmed.ncbi.nlm.nih.gov/12435818

DMGOQY2	DI	DMGOQY2
DMGOQY2	DN	WIN 62,577
DMGOQY2	MI	TTQ13Z5
DMGOQY2	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMGOQY2	MT	DTT
DMGOQY2	MA	Modulator (allosteric modulator)
DMGOQY2	RN	Analogs of WIN 62,577 define a second allosteric site on muscarinic receptors. Mol Pharmacol. 2002 Dec;62(6):1492-505.
DMGOQY2	RU	https://pubmed.ncbi.nlm.nih.gov/12435818

DMTE0YJ	DI	DMTE0YJ
DMTE0YJ	DN	WIN 64338
DMTE0YJ	MI	TTGY8IW
DMTE0YJ	MN	B2 bradykinin receptor (BDKRB2)
DMTE0YJ	MT	DTT
DMTE0YJ	MA	Antagonist
DMTE0YJ	RN	Design of potent non-peptide competitive antagonists of the human bradykinin B2 receptor. J Med Chem. 1993 Aug 20;36(17):2583-4.
DMTE0YJ	RU	https://pubmed.ncbi.nlm.nih.gov/8394936

DM6IH4F	DI	DM6IH4F
DM6IH4F	DN	WIN-35065
DM6IH4F	MI	TTVBI8W
DM6IH4F	MN	Dopamine transporter (DAT)
DM6IH4F	MT	DTT
DM6IH4F	MA	Inhibitor
DM6IH4F	RN	Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-... J Med Chem. 2007 Jul 26;50(15):3686-95.
DM6IH4F	RU	https://pubmed.ncbi.nlm.nih.gov/17602602

DM6IH4F	DI	DM6IH4F
DM6IH4F	DN	WIN-35065
DM6IH4F	MI	TT3ROYC
DM6IH4F	MN	Serotonin transporter (SERT)
DM6IH4F	MT	DTT
DM6IH4F	MA	Inhibitor
DM6IH4F	RN	Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-... J Med Chem. 2007 Jul 26;50(15):3686-95.
DM6IH4F	RU	https://pubmed.ncbi.nlm.nih.gov/17602602

DMOX1S0	DI	DMOX1S0
DMOX1S0	DN	WIN-35066-2
DMOX1S0	MI	TTVBI8W
DMOX1S0	MN	Dopamine transporter (DAT)
DMOX1S0	MT	DTT
DMOX1S0	MA	Inhibitor
DMOX1S0	RN	Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted-phenyl)tropane-2-carboxylic acid methyl e... J Med Chem. 2004 Dec 2;47(25):6401-9.
DMOX1S0	RU	https://pubmed.ncbi.nlm.nih.gov/15566309

DMOX1S0	DI	DMOX1S0
DMOX1S0	DN	WIN-35066-2
DMOX1S0	MI	TTAWNKZ
DMOX1S0	MN	Norepinephrine transporter (NET)
DMOX1S0	MT	DTT
DMOX1S0	MA	Inhibitor
DMOX1S0	RN	Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted-phenyl)tropane-2-carboxylic acid methyl e... J Med Chem. 2004 Dec 2;47(25):6401-9.
DMOX1S0	RU	https://pubmed.ncbi.nlm.nih.gov/15566309

DMOX1S0	DI	DMOX1S0
DMOX1S0	DN	WIN-35066-2
DMOX1S0	MI	TT3ROYC
DMOX1S0	MN	Serotonin transporter (SERT)
DMOX1S0	MT	DTT
DMOX1S0	MA	Inhibitor
DMOX1S0	RN	Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted-phenyl)tropane-2-carboxylic acid methyl e... J Med Chem. 2004 Dec 2;47(25):6401-9.
DMOX1S0	RU	https://pubmed.ncbi.nlm.nih.gov/15566309

DMNM50K	DI	DMNM50K
DMNM50K	DN	WIN-63395
DMNM50K	MI	TTPLTSQ
DMNM50K	MN	Neutrophil elastase (NE)
DMNM50K	MT	DTT
DMNM50K	MA	Inhibitor
DMNM50K	RN	A comparative SAR and computer modeling study of benzisothiazolone, mechanism-based inhibitors with porcine pancreatic and human leukocyte elastase, Bioorg. Med. Chem. Lett. 6(24):2941-2946 (1996).
DMNM50K	RU	http://www.sciencedirect.com/science/article/pii/S0960894X96005537

DMQ1B2Y	DI	DMQ1B2Y
DMQ1B2Y	DN	WIN-64745
DMQ1B2Y	MI	TTZPO1L
DMQ1B2Y	MN	Substance-P receptor (TACR1)
DMQ1B2Y	MT	DTT
DMQ1B2Y	MA	Modulator
DMQ1B2Y	RN	DOI: 10.1021/jo00074a031
DMQ1B2Y	RU	http://pubs.acs.org/doi/abs/10.1021/jo00074a031

DMUM5LV	DI	DMUM5LV
DMUM5LV	DN	WIN-66306
DMUM5LV	MI	TTZPO1L
DMUM5LV	MN	Substance-P receptor (TACR1)
DMUM5LV	MT	DTT
DMUM5LV	MA	Modulator
DMUM5LV	RN	WIN 66306, a new neurokinin antagonist produced by an Aspergillus species: fermentation, isolation and physico-chemical properties. J Antibiot (Tokyo). 1994 Nov;47(11):1182-7.
DMUM5LV	RU	https://www.ncbi.nlm.nih.gov/pubmed/7528191

DMJHG1O	DI	DMJHG1O
DMJHG1O	DN	WIN-68577
DMJHG1O	MI	TTZPO1L
DMJHG1O	MN	Substance-P receptor (TACR1)
DMJHG1O	MT	DTT
DMJHG1O	MA	Modulator
DMJHG1O	RN	WIN 66306, a new neurokinin antagonist produced by an Aspergillus species: fermentation, isolation and physico-chemical properties. J Antibiot (Tokyo). 1994 Nov;47(11):1182-7.
DMJHG1O	RU	https://www.ncbi.nlm.nih.gov/pubmed/7528191

DMX0ZBC	DI	DMX0ZBC
DMX0ZBC	DN	WK-X-34
DMX0ZBC	MI	TT0JLSD
DMX0ZBC	MN	Multidrug resistance protein (MDR)
DMX0ZBC	MT	DTT
DMX0ZBC	MA	Inhibitor
DMX0ZBC	RN	Thiazolides: a new class of antiviral drugs. Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):667-74.
DMX0ZBC	RU	https://pubmed.ncbi.nlm.nih.gov/19442032

DM8SEHO	DI	DM8SEHO
DM8SEHO	DN	WL-276
DM8SEHO	MI	TTJGNVC
DM8SEHO	MN	Apoptosis regulator Bcl-2 (BCL-2)
DM8SEHO	MT	DTT
DM8SEHO	MA	Modulator
DM8SEHO	RN	WL-276, an antagonist against Bcl-2 proteins, overcomes drug resistance and suppresses prostate tumor growth. Cancer Res. 2008 Jun 1;68(11):4377-83.
DM8SEHO	RU	https://pubmed.ncbi.nlm.nih.gov/18519699

DMOZATX	DI	DMOZATX
DMOZATX	DN	WO2012007375C1
DMOZATX	MI	TTXAJWN
DMOZATX	MN	IL-1 receptor-associated kinase 1 (IRAK1)
DMOZATX	MT	DTT
DMOZATX	MA	Inhibitor
DMOZATX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2042).
DMOZATX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2042

DMOZATX	DI	DMOZATX
DMOZATX	DN	WO2012007375C1
DMOZATX	MI	TTKFVXR
DMOZATX	MN	Renal carcinoma antigen NY-REN-64 (IRAK-4)
DMOZATX	MT	DTT
DMOZATX	MA	Inhibitor
DMOZATX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2045).
DMOZATX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2045

DMPI2MA	DI	DMPI2MA
DMPI2MA	DN	WO2012007375C7 
DMPI2MA	MI	TTXAJWN
DMPI2MA	MN	IL-1 receptor-associated kinase 1 (IRAK1)
DMPI2MA	MT	DTT
DMPI2MA	MA	Inhibitor
DMPI2MA	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2042).
DMPI2MA	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2042

DMPI2MA	DI	DMPI2MA
DMPI2MA	DN	WO2012007375C7 
DMPI2MA	MI	TTKFVXR
DMPI2MA	MN	Renal carcinoma antigen NY-REN-64 (IRAK-4)
DMPI2MA	MT	DTT
DMPI2MA	MA	Inhibitor
DMPI2MA	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2045).
DMPI2MA	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2045

DM21WOP	DI	DM21WOP
DM21WOP	DN	WO2013026806C72 
DM21WOP	MI	TTSBVFO
DM21WOP	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
DM21WOP	MT	DTT
DM21WOP	MA	Inhibitor
DM21WOP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2009).
DM21WOP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2009

DM21WOP	DI	DM21WOP
DM21WOP	DN	WO2013026806C72 
DM21WOP	MI	TTYGQ8A
DM21WOP	MN	Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B)
DM21WOP	MT	DTT
DM21WOP	MA	Inhibitor
DM21WOP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2010).
DM21WOP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2010

DMDPN4E	DI	DMDPN4E
DMDPN4E	DN	WO2013110309CA127
DMDPN4E	MI	TT9U4EP
DMDPN4E	MN	Eukaryotic translation initiation factor 2-alpha kinase 4 (EIF2AK4)
DMDPN4E	MT	DTT
DMDPN4E	MA	Inhibitor
DMDPN4E	RN	Triazolo[4,5-d]pyrimidine Derivatives as Inhibitors of GCN2. ACS Med Chem Lett. 2014 Feb 12;5(4):282-3.
DMDPN4E	RU	https://pubmed.ncbi.nlm.nih.gov/24900825

DMGCF51	DI	DMGCF51
DMGCF51	DN	Wogonin
DMGCF51	MI	TTVKILB
DMGCF51	MN	Prostaglandin G/H synthase 2 (COX-2)
DMGCF51	MT	DTT
DMGCF51	MA	Inhibitor
DMGCF51	RN	Inhibitory activity of prostaglandin E2 production by the synthetic 2'-hydroxychalcone analogues: Synthesis and SAR study. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1650-3.
DMGCF51	RU	https://pubmed.ncbi.nlm.nih.gov/19233646

DMGCF51	DI	DMGCF51
DMGCF51	DN	Wogonin
DMGCF51	MI	TT7RJY8
DMGCF51	MN	Xanthine dehydrogenase/oxidase (XDH)
DMGCF51	MT	DTT
DMGCF51	MA	Inhibitor
DMGCF51	RN	Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod. 1988 Mar-Apr;51(2):345-8.
DMGCF51	RU	https://pubmed.ncbi.nlm.nih.gov/3379415

DMUCGK8	DI	DMUCGK8
DMUCGK8	DN	WR-080539
DMUCGK8	MI	TTSFWA7
DMUCGK8	MN	Plasmodium CDK Pfmrk (Malaria Pfmrk)
DMUCGK8	MT	DTT
DMUCGK8	MA	Inhibitor
DMUCGK8	RN	Selective inhibition of Pfmrk, a Plasmodium falciparum CDK, by antimalarial 1,3-diaryl-2-propenones. Bioorg Med Chem Lett. 2009 Apr 1;19(7):1982-5.
DMUCGK8	RU	https://pubmed.ncbi.nlm.nih.gov/19250824

DMT9WPJ	DI	DMT9WPJ
DMT9WPJ	DN	WR-089120
DMT9WPJ	MI	TTSFWA7
DMT9WPJ	MN	Plasmodium CDK Pfmrk (Malaria Pfmrk)
DMT9WPJ	MT	DTT
DMT9WPJ	MA	Inhibitor
DMT9WPJ	RN	Selective inhibition of Pfmrk, a Plasmodium falciparum CDK, by antimalarial 1,3-diaryl-2-propenones. Bioorg Med Chem Lett. 2009 Apr 1;19(7):1982-5.
DMT9WPJ	RU	https://pubmed.ncbi.nlm.nih.gov/19250824

DM3TI6L	DI	DM3TI6L
DM3TI6L	DN	WR-190706
DM3TI6L	MI	TTSFWA7
DM3TI6L	MN	Plasmodium CDK Pfmrk (Malaria Pfmrk)
DM3TI6L	MT	DTT
DM3TI6L	MA	Inhibitor
DM3TI6L	RN	Selective inhibition of Pfmrk, a Plasmodium falciparum CDK, by antimalarial 1,3-diaryl-2-propenones. Bioorg Med Chem Lett. 2009 Apr 1;19(7):1982-5.
DM3TI6L	RU	https://pubmed.ncbi.nlm.nih.gov/19250824

DM9M1UO	DI	DM9M1UO
DM9M1UO	DN	WR-203581
DM9M1UO	MI	TTSFWA7
DM9M1UO	MN	Plasmodium CDK Pfmrk (Malaria Pfmrk)
DM9M1UO	MT	DTT
DM9M1UO	MA	Inhibitor
DM9M1UO	RN	Selective inhibition of Pfmrk, a Plasmodium falciparum CDK, by antimalarial 1,3-diaryl-2-propenones. Bioorg Med Chem Lett. 2009 Apr 1;19(7):1982-5.
DM9M1UO	RU	https://pubmed.ncbi.nlm.nih.gov/19250824

DM5W9GR	DI	DM5W9GR
DM5W9GR	DN	WR-289009
DM5W9GR	MI	TTSFWA7
DM5W9GR	MN	Plasmodium CDK Pfmrk (Malaria Pfmrk)
DM5W9GR	MT	DTT
DM5W9GR	MA	Inhibitor
DM5W9GR	RN	Selective inhibition of Pfmrk, a Plasmodium falciparum CDK, by antimalarial 1,3-diaryl-2-propenones. Bioorg Med Chem Lett. 2009 Apr 1;19(7):1982-5.
DM5W9GR	RU	https://pubmed.ncbi.nlm.nih.gov/19250824

DMS2QUL	DI	DMS2QUL
DMS2QUL	DN	WR-289010
DMS2QUL	MI	TTSFWA7
DMS2QUL	MN	Plasmodium CDK Pfmrk (Malaria Pfmrk)
DMS2QUL	MT	DTT
DMS2QUL	MA	Inhibitor
DMS2QUL	RN	Selective inhibition of Pfmrk, a Plasmodium falciparum CDK, by antimalarial 1,3-diaryl-2-propenones. Bioorg Med Chem Lett. 2009 Apr 1;19(7):1982-5.
DMS2QUL	RU	https://pubmed.ncbi.nlm.nih.gov/19250824

DMG2LVM	DI	DMG2LVM
DMG2LVM	DN	WR-289012
DMG2LVM	MI	TTSFWA7
DMG2LVM	MN	Plasmodium CDK Pfmrk (Malaria Pfmrk)
DMG2LVM	MT	DTT
DMG2LVM	MA	Inhibitor
DMG2LVM	RN	Selective inhibition of Pfmrk, a Plasmodium falciparum CDK, by antimalarial 1,3-diaryl-2-propenones. Bioorg Med Chem Lett. 2009 Apr 1;19(7):1982-5.
DMG2LVM	RU	https://pubmed.ncbi.nlm.nih.gov/19250824

DMT08ZH	DI	DMT08ZH
DMT08ZH	DN	WR-289016
DMT08ZH	MI	TTSFWA7
DMT08ZH	MN	Plasmodium CDK Pfmrk (Malaria Pfmrk)
DMT08ZH	MT	DTT
DMT08ZH	MA	Inhibitor
DMT08ZH	RN	Selective inhibition of Pfmrk, a Plasmodium falciparum CDK, by antimalarial 1,3-diaryl-2-propenones. Bioorg Med Chem Lett. 2009 Apr 1;19(7):1982-5.
DMT08ZH	RU	https://pubmed.ncbi.nlm.nih.gov/19250824

DM9V0KP	DI	DM9V0KP
DM9V0KP	DN	WR85915
DM9V0KP	MI	TTML2WA
DM9V0KP	MN	Tubulin (TUB)
DM9V0KP	MT	DTT
DM9V0KP	MA	Inhibitor
DM9V0KP	RN	Cellular effects of leishmanial tubulin inhibitors on L. donovani. Mol Biochem Parasitol. 2000 Oct;110(2):223-36.
DM9V0KP	RU	https://pubmed.ncbi.nlm.nih.gov/11071278

DM1U29V	DI	DM1U29V
DM1U29V	DN	WRC-0571
DM1U29V	MI	TTK25J1
DM1U29V	MN	Adenosine A1 receptor (ADORA1)
DM1U29V	MT	DTT
DM1U29V	MA	Antagonist
DM1U29V	RN	Characterization of 8-(N-methylisopropyl)amino-N6-(5'-endohydroxy- endonorbornyl)-9-methyladenine (WRC-0571), a highly potent and selective, non-xanthine antagonist of A1 adenosine receptors. J Pharmacol Exp Ther. 1996 Feb;276(2):490-9.
DM1U29V	RU	https://pubmed.ncbi.nlm.nih.gov/8632314

DMP761U	DI	DMP761U
DMP761U	DN	WRR-112
DMP761U	MI	TTJOKD1
DMP761U	MN	Cathepsin F (CTSF)
DMP761U	MT	DTT
DMP761U	MA	Inhibitor
DMP761U	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMP761U	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMP761U	DI	DMP761U
DMP761U	DN	WRR-112
DMP761U	MI	TTEAID7
DMP761U	MN	Trypanosoma Cruzipain (Trypano CYSP)
DMP761U	MT	DTT
DMP761U	MA	Inhibitor
DMP761U	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMP761U	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMRVAH1	DI	DMRVAH1
DMRVAH1	DN	WRR-204
DMRVAH1	MI	TTEAID7
DMRVAH1	MN	Trypanosoma Cruzipain (Trypano CYSP)
DMRVAH1	MT	DTT
DMRVAH1	MA	Inhibitor
DMRVAH1	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMRVAH1	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMPYGMO	DI	DMPYGMO
DMPYGMO	DN	WRR605
DMPYGMO	MI	TTPXTVS
DMPYGMO	MN	Entamoeba Cysteine proteinase CP4  (Eh CP4)
DMPYGMO	MT	DTT
DMPYGMO	MA	Inhibitor
DMPYGMO	RN	A novel Entamoeba histolytica cysteine proteinase, EhCP4, is key for invasive amebiasis and a therapeutic target. J Biol Chem. 2010 Jun 11;285(24):18516-27.
DMPYGMO	RU	https://pubmed.ncbi.nlm.nih.gov/20378535

DM8ZA6K	DI	DM8ZA6K
DM8ZA6K	DN	WRR-99
DM8ZA6K	MI	TTJOKD1
DM8ZA6K	MN	Cathepsin F (CTSF)
DM8ZA6K	MT	DTT
DM8ZA6K	MA	Inhibitor
DM8ZA6K	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM8ZA6K	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM8ZA6K	DI	DM8ZA6K
DM8ZA6K	DN	WRR-99
DM8ZA6K	MI	TTEAID7
DM8ZA6K	MN	Trypanosoma Cruzipain (Trypano CYSP)
DM8ZA6K	MT	DTT
DM8ZA6K	MA	Inhibitor
DM8ZA6K	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM8ZA6K	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMYNIG5	DI	DMYNIG5
DMYNIG5	DN	WS-070117
DMYNIG5	MI	TTOF3WZ
DMYNIG5	MN	Lipoprotein lipase (LPL)
DMYNIG5	MT	DTT
DMYNIG5	MA	Modulator
DMYNIG5	RN	Alipogene tiparvovec for the treatment of lipoprotein lipase deficiency. Drugs Today (Barc). 2013 Mar;49(3):161-70.
DMYNIG5	RU	https://pubmed.ncbi.nlm.nih.gov/23527320

DM48MHL	DI	DM48MHL
DM48MHL	DN	WS-12
DM48MHL	MI	TTXDKTO
DM48MHL	MN	Long transient receptor potential channel 8 (TRPM8)
DM48MHL	MT	DTT
DM48MHL	MA	Activator
DM48MHL	RN	Characterization of selective TRPM8 ligands and their structure activity response (S.A.R) relationship. J Pharm Pharm Sci. 2010;13(2):242-53.
DM48MHL	RU	https://pubmed.ncbi.nlm.nih.gov/20816009

DMT5SXR	DI	DMT5SXR
DMT5SXR	DN	WS-23
DMT5SXR	MI	TTXDKTO
DMT5SXR	MN	Long transient receptor potential channel 8 (TRPM8)
DMT5SXR	MT	DTT
DMT5SXR	MA	Activator
DMT5SXR	RN	Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay. Br J Pharmacol. 2004 Feb;141(4):737-45.
DMT5SXR	RU	https://pubmed.ncbi.nlm.nih.gov/14757700

DM1R8MW	DI	DM1R8MW
DM1R8MW	DN	WS-3
DM1R8MW	MI	TTXDKTO
DM1R8MW	MN	Long transient receptor potential channel 8 (TRPM8)
DM1R8MW	MT	DTT
DM1R8MW	MA	Activator
DM1R8MW	RN	Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay. Br J Pharmacol. 2004 Feb;141(4):737-45.
DM1R8MW	RU	https://pubmed.ncbi.nlm.nih.gov/14757700

DMX1JR0	DI	DMX1JR0
DMX1JR0	DN	WS-5
DMX1JR0	MI	TTXDKTO
DMX1JR0	MN	Long transient receptor potential channel 8 (TRPM8)
DMX1JR0	MT	DTT
DMX1JR0	MA	Activator
DMX1JR0	RN	Characterization of selective TRPM8 ligands and their structure activity response (S.A.R) relationship. J Pharm Pharm Sci. 2010;13(2):242-53.
DMX1JR0	RU	https://pubmed.ncbi.nlm.nih.gov/20816009

DM6A08D	DI	DM6A08D
DM6A08D	DN	WS-50030
DM6A08D	MI	TTEX248
DM6A08D	MN	Dopamine D2 receptor (D2R)
DM6A08D	MT	DTT
DM6A08D	MA	Agonist
DM6A08D	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 215).
DM6A08D	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=215

DMF9SOV	DI	DMF9SOV
DMF9SOV	DN	WTLNSAGYLL-CONH2
DMF9SOV	MI	TTX3HNZ
DMF9SOV	MN	Galanin receptor type 1 (GAL1-R)
DMF9SOV	MT	DTT
DMF9SOV	MA	Inhibitor
DMF9SOV	RN	Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5.
DMF9SOV	RU	https://pubmed.ncbi.nlm.nih.gov/20121116

DMF9SOV	DI	DMF9SOV
DMF9SOV	DN	WTLNSAGYLL-CONH2
DMF9SOV	MI	TTBPW3J
DMF9SOV	MN	Galanin receptor type 2 (GAL2-R)
DMF9SOV	MT	DTT
DMF9SOV	MA	Inhibitor
DMF9SOV	RN	Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5.
DMF9SOV	RU	https://pubmed.ncbi.nlm.nih.gov/20121116

DMB3567	DI	DMB3567
DMB3567	DN	WTLNSAGYLLGPHAVGNHPSFSDKNGLTS-CONH2
DMB3567	MI	TTX3HNZ
DMB3567	MN	Galanin receptor type 1 (GAL1-R)
DMB3567	MT	DTT
DMB3567	MA	Inhibitor
DMB3567	RN	Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5.
DMB3567	RU	https://pubmed.ncbi.nlm.nih.gov/20121116

DMB3567	DI	DMB3567
DMB3567	DN	WTLNSAGYLLGPHAVGNHPSFSDKNGLTS-CONH2
DMB3567	MI	TTBPW3J
DMB3567	MN	Galanin receptor type 2 (GAL2-R)
DMB3567	MT	DTT
DMB3567	MA	Inhibitor
DMB3567	RN	Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5.
DMB3567	RU	https://pubmed.ncbi.nlm.nih.gov/20121116

DMVZB8U	DI	DMVZB8U
DMVZB8U	DN	WVTHRLAGLLSRSGGVVKNNFVPTNVGSKAF-NH2
DMVZB8U	MI	TTVSFJW
DMVZB8U	MN	Calcitonin gene-related peptide 1 (CALCA)
DMVZB8U	MT	DTT
DMVZB8U	MA	Inhibitor
DMVZB8U	RN	Identification of potent, selective, and metabolically stable peptide antagonists to the calcitonin gene-related peptide (CGRP) receptor. J Med Chem. 2008 Dec 25;51(24):7889-97.
DMVZB8U	RU	https://pubmed.ncbi.nlm.nih.gov/19053766

DM6J7OQ	DI	DM6J7OQ
DM6J7OQ	DN	WX-037
DM6J7OQ	MI	TTHBTOP
DM6J7OQ	MN	PI3-kinase gamma (PIK3CG)
DM6J7OQ	MT	DTT
DM6J7OQ	MA	Inhibitor
DM6J7OQ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2155).
DM6J7OQ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2155

DM0AZLE	DI	DM0AZLE
DM0AZLE	DN	WY-46016
DM0AZLE	MI	TTGKOY9
DM0AZLE	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DM0AZLE	MT	DTT
DM0AZLE	MA	Modulator
DM0AZLE	RN	N-[(arylmethoxy)phenyl] carboxylic acids, hydroxamic acids, tetrazoles, and sulfonyl carboxamides.Potent orally active leukotriene D4 antagonists of novel structure.J Med Chem.1990 Jan;33(1):240-5.
DM0AZLE	RU	https://www.ncbi.nlm.nih.gov/pubmed/2104935

DMBWUR0	DI	DMBWUR0
DMBWUR0	DN	WZ-3146
DMBWUR0	MI	TTGKNB4
DMBWUR0	MN	Epidermal growth factor receptor (EGFR)
DMBWUR0	MT	DTT
DMBWUR0	MA	Inhibitor
DMBWUR0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
DMBWUR0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797

DMP9RBK	DI	DMP9RBK
DMP9RBK	DN	WZ4003
DMP9RBK	MI	TTHVOTQ
DMP9RBK	MN	NUAK family SNF1-like kinase 2 (NUAK2)
DMP9RBK	MT	DTT
DMP9RBK	MA	Inhibitor
DMP9RBK	RN	Characterization of WZ4003 and HTH-01-015 as selective inhibitors of the LKB1-tumour-suppressor-activated NUAK kinases. Biochem J. 2014 Jan 1;457(1):215-25.
DMP9RBK	RU	https://pubmed.ncbi.nlm.nih.gov/24171924

DMP9RBK	DI	DMP9RBK
DMP9RBK	DN	WZ4003
DMP9RBK	MI	TT65FL0
DMP9RBK	MN	Omphalocele kinase 1 (NUAK1)
DMP9RBK	MT	DTT
DMP9RBK	MA	Inhibitor
DMP9RBK	RN	Characterization of WZ4003 and HTH-01-015 as selective inhibitors of the LKB1-tumour-suppressor-activated NUAK kinases. Biochem J. 2014 Jan 1;457(1):215-25.
DMP9RBK	RU	https://pubmed.ncbi.nlm.nih.gov/24171924

DMZ0TDL	DI	DMZ0TDL
DMZ0TDL	DN	X-387
DMZ0TDL	MI	TTCJG29
DMZ0TDL	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMZ0TDL	MT	DTT
DMZ0TDL	MA	Inhibitor
DMZ0TDL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
DMZ0TDL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109

DMOVJP3	DI	DMOVJP3
DMOVJP3	DN	xamoterol
DMOVJP3	MI	TTMXGCW
DMOVJP3	MN	Adrenergic receptor beta-3 (ADRB3)
DMOVJP3	MT	DTT
DMOVJP3	MA	Agonist
DMOVJP3	RN	Binding pockets of the beta(1)- and beta(2)-adrenergic receptors for subtype-selective agonists. Mol Pharmacol. 1999 Nov;56(5):875-85.
DMOVJP3	RU	https://pubmed.ncbi.nlm.nih.gov/10531390

DMGYVFD	DI	DMGYVFD
DMGYVFD	DN	xanthine amine congener
DMGYVFD	MI	TTK25J1
DMGYVFD	MN	Adenosine A1 receptor (ADORA1)
DMGYVFD	MT	DTT
DMGYVFD	MA	Antagonist
DMGYVFD	RN	Species difference in the G protein selectivity of the human and bovine A1-adenosine receptor. J Biol Chem. 1994 Dec 23;269(51):32077-84.
DMGYVFD	RU	https://pubmed.ncbi.nlm.nih.gov/7798201

DMGYVFD	DI	DMGYVFD
DMGYVFD	DN	xanthine amine congener
DMGYVFD	MI	TTNE7KG
DMGYVFD	MN	Adenosine A2b receptor (ADORA2B)
DMGYVFD	MT	DTT
DMGYVFD	MA	Antagonist
DMGYVFD	RN	Use of the triazolotriazine [3H]ZM 241385 as a radioligand at recombinant human A2B adenosine receptors. Drug Des Discov. 1999 Nov;16(3):217-26.
DMGYVFD	RU	https://pubmed.ncbi.nlm.nih.gov/10624567

DMGYVFD	DI	DMGYVFD
DMGYVFD	DN	xanthine amine congener
DMGYVFD	MI	TTJFY5U
DMGYVFD	MN	Adenosine A3 receptor (ADORA3)
DMGYVFD	MT	DTT
DMGYVFD	MA	Antagonist
DMGYVFD	RN	[(3)H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors. Mol Pharmacol. 2000 May;57(5):968-75.
DMGYVFD	RU	https://pubmed.ncbi.nlm.nih.gov/10779381

DM1GJX8	DI	DM1GJX8
DM1GJX8	DN	Xanthosine-5'-monophosphate disodium salt
DM1GJX8	MI	TTV7Y40
DM1GJX8	MN	Mycobacterium Orotidine phosphate decarboxylase (MycB pyrF)
DM1GJX8	MT	DTT
DM1GJX8	MA	Inhibitor
DM1GJX8	RN	Structural diversity and plasticity associated with nucleotides targeting orotidine monophosphate decarboxylase. J Med Chem. 2008 Feb 14;51(3):432-8.
DM1GJX8	RU	https://pubmed.ncbi.nlm.nih.gov/18181562

DM38TLN	DI	DM38TLN
DM38TLN	DN	XANTHOSTIGMINE
DM38TLN	MI	TT1RS9F
DM38TLN	MN	Acetylcholinesterase (AChE)
DM38TLN	MT	DTT
DM38TLN	MA	Inhibitor
DM38TLN	RN	Acetylcholinesterase inhibitors: synthesis and structure-activity relationships of omega-[N-methyl-N-(3-alkylcarbamoyloxyphenyl)- methyl]aminoalkox... J Med Chem. 1998 Oct 8;41(21):3976-86.
DM38TLN	RU	https://pubmed.ncbi.nlm.nih.gov/9767635

DM38TLN	DI	DM38TLN
DM38TLN	DN	XANTHOSTIGMINE
DM38TLN	MI	TTEB0GD
DM38TLN	MN	Cholinesterase (BCHE)
DM38TLN	MT	DTT
DM38TLN	MA	Inhibitor
DM38TLN	RN	Acetylcholinesterase inhibitors: synthesis and structure-activity relationships of omega-[N-methyl-N-(3-alkylcarbamoyloxyphenyl)- methyl]aminoalkox... J Med Chem. 1998 Oct 8;41(21):3976-86.
DM38TLN	RU	https://pubmed.ncbi.nlm.nih.gov/9767635

DMLTVI6	DI	DMLTVI6
DMLTVI6	DN	XAP044
DMLTVI6	MI	TT0I76D
DMLTVI6	MN	Metabotropic glutamate receptor 7 (mGluR7)
DMLTVI6	MT	DTT
DMLTVI6	MA	Modulator (allosteric modulator)
DMLTVI6	RN	Blocking metabotropic glutamate receptor subtype 7 (mGlu7) via the Venus flytrap domain (VFTD) inhibits amygdala plasticity, stress, and anxiety-related behavior. J Biol Chem. 2014 Apr 18;289(16):10975-87.
DMLTVI6	RU	https://pubmed.ncbi.nlm.nih.gov/24596089

DMYT5DI	DI	DMYT5DI
DMYT5DI	DN	XB-05
DMYT5DI	MI	TT6S2FE
DMYT5DI	MN	DNA [cytosine-5]-methyltransferase 1 (DNMT1)
DMYT5DI	MT	DTT
DMYT5DI	MA	Inhibitor
DMYT5DI	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2605).
DMYT5DI	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2605

DMBN7UX	DI	DMBN7UX
DMBN7UX	DN	XB-387
DMBN7UX	MI	TTI7421
DMBN7UX	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMBN7UX	MT	DTT
DMBN7UX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1804).
DMBN7UX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1804

DM8PADV	DI	DM8PADV
DM8PADV	DN	XCC
DM8PADV	MI	TTNE7KG
DM8PADV	MN	Adenosine A2b receptor (ADORA2B)
DM8PADV	MT	DTT
DM8PADV	MA	Antagonist
DM8PADV	RN	[3H]MRS 1754, a selective antagonist radioligand for A(2B) adenosine receptors. Biochem Pharmacol. 2001 Mar 15;61(6):657-63.
DM8PADV	RU	https://pubmed.ncbi.nlm.nih.gov/11266650

DMZ7N8D	DI	DMZ7N8D
DMZ7N8D	DN	XCT790
DMZ7N8D	MI	TTPNQAC
DMZ7N8D	MN	Estrogen-related receptor-alpha (ESRRA)
DMZ7N8D	MT	DTT
DMZ7N8D	MA	Antagonist
DMZ7N8D	RN	Regulation of PPARgamma coactivator 1alpha (PGC-1alpha) signaling by an estrogen-related receptor alpha (ERRalpha) ligand. Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):8912-7.
DMZ7N8D	RU	https://pubmed.ncbi.nlm.nih.gov/15184675

DMS3TZ5	DI	DMS3TZ5
DMS3TZ5	DN	XD1
DMS3TZ5	MI	TTRA6BO
DMS3TZ5	MN	Bromodomain-containing protein 4 (BRD4)
DMS3TZ5	MT	DTT
DMS3TZ5	MA	Inhibitor
DMS3TZ5	RN	4-Acyl pyrroles: mimicking acetylated lysines in histone code reading. Angew Chem Int Ed Engl. 2013 Dec 23;52(52):14055-9.
DMS3TZ5	RU	https://pubmed.ncbi.nlm.nih.gov/24272870

DMUMACD	DI	DMUMACD
DMUMACD	DN	XD14
DMUMACD	MI	TT7CPI5
DMUMACD	MN	Bromodomain testis-specific protein (BRDT)
DMUMACD	MT	DTT
DMUMACD	MA	Inhibitor
DMUMACD	RN	4-Acyl pyrroles: mimicking acetylated lysines in histone code reading. Angew Chem Int Ed Engl. 2013 Dec 23;52(52):14055-9.
DMUMACD	RU	https://pubmed.ncbi.nlm.nih.gov/24272870

DMUMACD	DI	DMUMACD
DMUMACD	DN	XD14
DMUMACD	MI	TTDP48B
DMUMACD	MN	Bromodomain-containing protein 2 (BRD2)
DMUMACD	MT	DTT
DMUMACD	MA	Inhibitor
DMUMACD	RN	4-Acyl pyrroles: mimicking acetylated lysines in histone code reading. Angew Chem Int Ed Engl. 2013 Dec 23;52(52):14055-9.
DMUMACD	RU	https://pubmed.ncbi.nlm.nih.gov/24272870

DMUMACD	DI	DMUMACD
DMUMACD	DN	XD14
DMUMACD	MI	TTHE657
DMUMACD	MN	Bromodomain-containing protein 3 (BRD3)
DMUMACD	MT	DTT
DMUMACD	MA	Inhibitor
DMUMACD	RN	4-Acyl pyrroles: mimicking acetylated lysines in histone code reading. Angew Chem Int Ed Engl. 2013 Dec 23;52(52):14055-9.
DMUMACD	RU	https://pubmed.ncbi.nlm.nih.gov/24272870

DMUMACD	DI	DMUMACD
DMUMACD	DN	XD14
DMUMACD	MI	TTRA6BO
DMUMACD	MN	Bromodomain-containing protein 4 (BRD4)
DMUMACD	MT	DTT
DMUMACD	MA	Inhibitor
DMUMACD	RN	4-Acyl pyrroles: mimicking acetylated lysines in histone code reading. Angew Chem Int Ed Engl. 2013 Dec 23;52(52):14055-9.
DMUMACD	RU	https://pubmed.ncbi.nlm.nih.gov/24272870

DMLH1PK	DI	DMLH1PK
DMLH1PK	DN	XE991
DMLH1PK	MI	TT846HF
DMLH1PK	MN	Voltage-gated potassium channel Kv7.1 (KCNQ1)
DMLH1PK	MT	DTT
DMLH1PK	MA	Blocker (channel blocker)
DMLH1PK	RN	Molecular basis for differential sensitivity of KCNQ and I(Ks) channels to the cognitive enhancer XE991. Mol Pharmacol. 2000 Jun;57(6):1218-23.
DMLH1PK	RU	https://pubmed.ncbi.nlm.nih.gov/10825393

DMLH1PK	DI	DMLH1PK
DMLH1PK	DN	XE991
DMLH1PK	MI	TTPXI3S
DMLH1PK	MN	Voltage-gated potassium channel Kv7.2 (KCNQ2)
DMLH1PK	MT	DTT
DMLH1PK	MA	Blocker (channel blocker)
DMLH1PK	RN	KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science. 1998 Dec 4;282(5395):1890-3.
DMLH1PK	RU	https://pubmed.ncbi.nlm.nih.gov/9836639

DMLH1PK	DI	DMLH1PK
DMLH1PK	DN	XE991
DMLH1PK	MI	TT8HGRW
DMLH1PK	MN	Voltage-gated potassium channel Kv7.4 (KCNQ4)
DMLH1PK	MT	DTT
DMLH1PK	MA	Blocker (channel blocker)
DMLH1PK	RN	KCNQ4 channels expressed in mammalian cells: functional characteristics and pharmacology. Am J Physiol Cell Physiol. 2001 Apr;280(4):C859-66.
DMLH1PK	RU	https://pubmed.ncbi.nlm.nih.gov/11245603

DMLH1PK	DI	DMLH1PK
DMLH1PK	DN	XE991
DMLH1PK	MI	TTWVL5Q
DMLH1PK	MN	Voltage-gated potassium channel Kv7.5 (KCNQ5)
DMLH1PK	MT	DTT
DMLH1PK	MA	Blocker (channel blocker)
DMLH1PK	RN	KCNQ5, a novel potassium channel broadly expressed in brain, mediates M-type currents. J Biol Chem. 2000 Aug 4;275(31):24089-95.
DMLH1PK	RU	https://pubmed.ncbi.nlm.nih.gov/10816588

DMZ24P1	DI	DMZ24P1
DMZ24P1	DN	XEN-907
DMZ24P1	MI	TT4G2JS
DMZ24P1	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DMZ24P1	MT	DTT
DMZ24P1	MA	Inhibitor
DMZ24P1	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 584).
DMZ24P1	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=584

DM1EHG5	DI	DM1EHG5
DM1EHG5	DN	XEN-D0104
DM1EHG5	MI	TTW0CMT
DM1EHG5	MN	Voltage-gated potassium channel Kv1.5 (KCNA5)
DM1EHG5	MT	DTT
DM1EHG5	MA	Opener
DM1EHG5	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 542).
DM1EHG5	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=542

DMAPRNO	DI	DMAPRNO
DMAPRNO	DN	xenin
DMAPRNO	MI	TT31Q0V
DMAPRNO	MN	Neurotensin receptor type 2 (NTSR2)
DMAPRNO	MT	DTT
DMAPRNO	MA	Agonist
DMAPRNO	RN	Stable expression of the mouse levocabastine-sensitive neurotensin receptor in HEK 293 cell line: binding properties, photoaffinity labeling, and internalization mechanism. Biochem Biophys Res Commun. 1998 Feb 13;243(2):585-90.
DMAPRNO	RU	https://pubmed.ncbi.nlm.nih.gov/9480852

DMVTCZ1	DI	DMVTCZ1
DMVTCZ1	DN	XEP-018
DMVTCZ1	MI	TT84DRB
DMVTCZ1	MN	Voltage-gated sodium channel alpha Nav1.4 (SCN4A)
DMVTCZ1	MT	DTT
DMVTCZ1	MA	Modulator
DMVTCZ1	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 581).
DMVTCZ1	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=581

DM4YQR2	DI	DM4YQR2
DM4YQR2	DN	xestospongin C
DM4YQR2	MI	TT5HWAT
DM4YQR2	MN	IP3 receptor isoform 1 (ITPR1)
DM4YQR2	MT	DTT
DM4YQR2	MA	Antagonist
DM4YQR2	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 743).
DM4YQR2	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=743

DM96FTS	DI	DM96FTS
DM96FTS	DN	XGP-110
DM96FTS	MI	TTVKILB
DM96FTS	MN	Prostaglandin G/H synthase 2 (COX-2)
DM96FTS	MT	DTT
DM96FTS	MA	Inhibitor
DM96FTS	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1376).
DM96FTS	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1376

DMBLR73	DI	DMBLR73
DMBLR73	DN	XGP-510
DMBLR73	MI	TTGKOY9
DMBLR73	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DMBLR73	MT	DTT
DMBLR73	MA	Antagonist
DMBLR73	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 269).
DMBLR73	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=269

DMZIHKY	DI	DMZIHKY
DMZIHKY	DN	XMD8-92
DMZIHKY	MI	TTHK3MO
DMZIHKY	MN	Doublecortin-like kinase 2 (DCLK2)
DMZIHKY	MT	DTT
DMZIHKY	MA	Inhibitor
DMZIHKY	RN	Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell. 2010 Sep 14;18(3):258-67.
DMZIHKY	RU	https://pubmed.ncbi.nlm.nih.gov/20832753

DMZIHKY	DI	DMZIHKY
DMZIHKY	DN	XMD8-92
DMZIHKY	MI	TTU6FSC
DMZIHKY	MN	Extracellular signal-regulated kinase 5 (ERK5)
DMZIHKY	MT	DTT
DMZIHKY	MA	Inhibitor
DMZIHKY	RN	Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell. 2010 Sep 14;18(3):258-67.
DMZIHKY	RU	https://pubmed.ncbi.nlm.nih.gov/20832753

DMZIHKY	DI	DMZIHKY
DMZIHKY	DN	XMD8-92
DMZIHKY	MI	TTWS7I3
DMZIHKY	MN	Non-receptor tyrosine-protein kinase TNK1 (TNK1)
DMZIHKY	MT	DTT
DMZIHKY	MA	Inhibitor
DMZIHKY	RN	Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell. 2010 Sep 14;18(3):258-67.
DMZIHKY	RU	https://pubmed.ncbi.nlm.nih.gov/20832753

DMZIHKY	DI	DMZIHKY
DMZIHKY	DN	XMD8-92
DMZIHKY	MI	TTGPNZQ
DMZIHKY	MN	Polo-like kinase 4 (PLK4)
DMZIHKY	MT	DTT
DMZIHKY	MA	Inhibitor
DMZIHKY	RN	Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell. 2010 Sep 14;18(3):258-67.
DMZIHKY	RU	https://pubmed.ncbi.nlm.nih.gov/20832753

DMHWTCY	DI	DMHWTCY
DMHWTCY	DN	XMetD
DMHWTCY	MI	TTCBFJO
DMHWTCY	MN	Insulin receptor (INSR)
DMHWTCY	MT	DTT
DMHWTCY	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800).
DMHWTCY	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800

DM6JKL7	DI	DM6JKL7
DM6JKL7	DN	XMetS
DM6JKL7	MI	TTCBFJO
DM6JKL7	MN	Insulin receptor (INSR)
DM6JKL7	MT	DTT
DM6JKL7	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800).
DM6JKL7	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800

DM5TR49	DI	DM5TR49
DM5TR49	DN	XMT-1191
DM5TR49	MI	TTZL0OI
DM5TR49	MN	Methionine aminopeptidase 2 (METAP2)
DM5TR49	MT	DTT
DM5TR49	MA	Inhibitor
DM5TR49	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1573).
DM5TR49	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1573

DMXH6DL	DI	DMXH6DL
DMXH6DL	DN	XN-0502
DMXH6DL	MI	TTYFKSZ
DMXH6DL	MN	Tubulin beta (TUBB)
DMXH6DL	MT	DTT
DMXH6DL	MA	Modulator
DMXH6DL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2640).
DMXH6DL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2640

DMPOGXU	DI	DMPOGXU
DMPOGXU	DN	XNT
DMPOGXU	MI	TTUI5H7
DMPOGXU	MN	Angiotensin-converting enzyme 2 (ACE2)
DMPOGXU	MT	DTT
DMPOGXU	MA	Activator
DMPOGXU	RN	Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension. 2008 May;51(5):1312-7.
DMPOGXU	RU	https://pubmed.ncbi.nlm.nih.gov/18391097

DMGOMYN	DI	DMGOMYN
DMGOMYN	DN	XP-21510
DMGOMYN	MI	TTP86E2
DMGOMYN	MN	Plasminogen (PLG)
DMGOMYN	MT	DTT
DMGOMYN	MA	Inhibitor
DMGOMYN	RN	Tranexamic acid in trauma: how should we use it. J Trauma Acute Care Surg. 2013 Jun;74(6):1575-86.
DMGOMYN	RU	https://pubmed.ncbi.nlm.nih.gov/23694890

DMTUFI1	DI	DMTUFI1
DMTUFI1	DN	XR-9456
DMTUFI1	MI	TT3OT40
DMTUFI1	MN	Multidrug resistance protein 1 (ABCB1)
DMTUFI1	MT	DTT
DMTUFI1	MA	Inhibitor
DMTUFI1	RN	Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors. Bioorg Med Chem. 2008 Mar 1;16(5):2448-62.
DMTUFI1	RU	https://pubmed.ncbi.nlm.nih.gov/18083034

DMTUFI1	DI	DMTUFI1
DMTUFI1	DN	XR-9456
DMTUFI1	MI	TTOI92F
DMTUFI1	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMTUFI1	MT	DTT
DMTUFI1	MA	Inhibitor
DMTUFI1	RN	Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors. Bioorg Med Chem. 2008 Mar 1;16(5):2448-62.
DMTUFI1	RU	https://pubmed.ncbi.nlm.nih.gov/18083034

DMIQP69	DI	DMIQP69
DMIQP69	DN	XR-9504
DMIQP69	MI	TT3OT40
DMIQP69	MN	Multidrug resistance protein 1 (ABCB1)
DMIQP69	MT	DTT
DMIQP69	MA	Inhibitor
DMIQP69	RN	Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors. Bioorg Med Chem. 2008 Mar 1;16(5):2448-62.
DMIQP69	RU	https://pubmed.ncbi.nlm.nih.gov/18083034

DMIQP69	DI	DMIQP69
DMIQP69	DN	XR-9504
DMIQP69	MI	TTOI92F
DMIQP69	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMIQP69	MT	DTT
DMIQP69	MA	Inhibitor
DMIQP69	RN	Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors. Bioorg Med Chem. 2008 Mar 1;16(5):2448-62.
DMIQP69	RU	https://pubmed.ncbi.nlm.nih.gov/18083034

DM1OZPN	DI	DM1OZPN
DM1OZPN	DN	XR-9544
DM1OZPN	MI	TT3OT40
DM1OZPN	MN	Multidrug resistance protein 1 (ABCB1)
DM1OZPN	MT	DTT
DM1OZPN	MA	Inhibitor
DM1OZPN	RN	Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors. Bioorg Med Chem. 2008 Mar 1;16(5):2448-62.
DM1OZPN	RU	https://pubmed.ncbi.nlm.nih.gov/18083034

DM1OZPN	DI	DM1OZPN
DM1OZPN	DN	XR-9544
DM1OZPN	MI	TTOI92F
DM1OZPN	MN	Multidrug resistance-associated protein 1 (ABCC1)
DM1OZPN	MT	DTT
DM1OZPN	MA	Inhibitor
DM1OZPN	RN	Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors. Bioorg Med Chem. 2008 Mar 1;16(5):2448-62.
DM1OZPN	RU	https://pubmed.ncbi.nlm.nih.gov/18083034

DMIZV6T	DI	DMIZV6T
DMIZV6T	DN	XR-9577
DMIZV6T	MI	TT3OT40
DMIZV6T	MN	Multidrug resistance protein 1 (ABCB1)
DMIZV6T	MT	DTT
DMIZV6T	MA	Inhibitor
DMIZV6T	RN	Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors. Bioorg Med Chem. 2008 Mar 1;16(5):2448-62.
DMIZV6T	RU	https://pubmed.ncbi.nlm.nih.gov/18083034

DMIZV6T	DI	DMIZV6T
DMIZV6T	DN	XR-9577
DMIZV6T	MI	TTOI92F
DMIZV6T	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMIZV6T	MT	DTT
DMIZV6T	MA	Inhibitor
DMIZV6T	RN	Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors. Bioorg Med Chem. 2008 Mar 1;16(5):2448-62.
DMIZV6T	RU	https://pubmed.ncbi.nlm.nih.gov/18083034

DM7BTNF	DI	DM7BTNF
DM7BTNF	DN	XT-101
DM7BTNF	MI	TTJTRMK
DM7BTNF	MN	Interleukin 10 receptor (IL10RB)
DM7BTNF	MT	DTT
DM7BTNF	MA	Modulator
DM7BTNF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1900).
DM7BTNF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1900

DML1K07	DI	DML1K07
DML1K07	DN	XV454
DML1K07	MI	TT38RM1
DML1K07	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DML1K07	MT	DTT
DML1K07	MA	Antagonist
DML1K07	RN	Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb/IIIa antagonist XV454. Thromb Haemost. 2003 Sep;90(3):549-54.
DML1K07	RU	https://pubmed.ncbi.nlm.nih.gov/12958625

DMSXJUW	DI	DMSXJUW
DMSXJUW	DN	xylazine
DMSXJUW	MI	TTWM4TY
DMSXJUW	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMSXJUW	MT	DTT
DMSXJUW	MA	Agonist
DMSXJUW	RN	Ligand efficacy and potency at recombinant alpha2 adrenergic receptors: agonist-mediated [35S]GTPgammaS binding. Biochem Pharmacol. 1998 Apr 1;55(7):1035-43.
DMSXJUW	RU	https://pubmed.ncbi.nlm.nih.gov/9605427

DMSXJUW	DI	DMSXJUW
DMSXJUW	DN	xylazine
DMSXJUW	MI	TT2NUT5
DMSXJUW	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMSXJUW	MT	DTT
DMSXJUW	MA	Agonist
DMSXJUW	RN	Ligand efficacy and potency at recombinant alpha2 adrenergic receptors: agonist-mediated [35S]GTPgammaS binding. Biochem Pharmacol. 1998 Apr 1;55(7):1035-43.
DMSXJUW	RU	https://pubmed.ncbi.nlm.nih.gov/9605427

DMZKPSQ	DI	DMZKPSQ
DMZKPSQ	DN	Y-26763
DMZKPSQ	MI	TT1VOHK
DMZKPSQ	MN	Potassium channel unspecific (KC)
DMZKPSQ	MT	DTT
DMZKPSQ	MA	Modulator
DMZKPSQ	RN	Y-26763: ATP-sensitive K+ channel activation and the inhibition of insulin release from human pancreatic beta-cells. Eur J Pharmacol. 2004 Feb 20;486(2):133-9.
DMZKPSQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/14975702

DMC95YB	DI	DMC95YB
DMC95YB	DN	Y-39041
DMC95YB	MI	TTF8CQI
DMC95YB	MN	Tumor necrosis factor (TNF)
DMC95YB	MT	DTT
DMC95YB	MA	Inhibitor
DMC95YB	RN	A novel anti-rheumatic drug suppresses tumor necrosis factor-alpha and augments interleukin-10 in adjuvant arthritic rats. Eur J Pharmacol. 2000 Dec 15;409(3):331-5.
DMC95YB	RU	https://pubmed.ncbi.nlm.nih.gov/11108829

DM412IV	DI	DM412IV
DM412IV	DN	Y-40613
DM412IV	MI	TT8VUE0
DM412IV	MN	Chymase (CYM)
DM412IV	MT	DTT
DM412IV	MA	Inhibitor
DM412IV	RN	Therapeutic potential of a specific chymase inhibitor in atopic dermatitis. Jpn J Pharmacol. 2002 Nov;90(3):214-7.
DM412IV	RU	https://pubmed.ncbi.nlm.nih.gov/12499574

DMUW4KG	DI	DMUW4KG
DMUW4KG	DN	YAWF-NH2
DMUW4KG	MI	TTKWM86
DMUW4KG	MN	Opioid receptor mu (MOP)
DMUW4KG	MT	DTT
DMUW4KG	MA	Inhibitor
DMUW4KG	RN	Internalisation of the mu-opioid receptor by endomorphin-1 and leu-enkephalin is dependant on aromatic amino acid residues. Bioorg Med Chem. 2008 Apr 15;16(8):4341-6.
DMUW4KG	RU	https://pubmed.ncbi.nlm.nih.gov/18329886

DMAC65P	DI	DMAC65P
DMAC65P	DN	Y-c[D-Pen-(2')Nal-GSFC]KR-NH2
DMAC65P	MI	TT6PKBN
DMAC65P	MN	Proto-oncogene c-Src (SRC)
DMAC65P	MT	DTT
DMAC65P	MA	Inhibitor
DMAC65P	RN	Discovery of a novel series of potent and selective substrate-based inhibitors of p60c-src protein tyrosine kinase: conformational and topographica... J Med Chem. 1998 Jun 18;41(13):2252-60.
DMAC65P	RU	https://pubmed.ncbi.nlm.nih.gov/9632358

DMEL4UN	DI	DMEL4UN
DMEL4UN	DN	Y-c[D-Pen-(2R,3R)-2-Me-(2')Nal-GSFC]KR-NH2
DMEL4UN	MI	TT6PKBN
DMEL4UN	MN	Proto-oncogene c-Src (SRC)
DMEL4UN	MT	DTT
DMEL4UN	MA	Inhibitor
DMEL4UN	RN	Discovery of a novel series of potent and selective substrate-based inhibitors of p60c-src protein tyrosine kinase: conformational and topographica... J Med Chem. 1998 Jun 18;41(13):2252-60.
DMEL4UN	RU	https://pubmed.ncbi.nlm.nih.gov/9632358

DM7P0H6	DI	DM7P0H6
DM7P0H6	DN	Y-c[D-Pen-(2R,3S)-2-Me-(2')Nal-GSFC]KR-NH2
DM7P0H6	MI	TT6PKBN
DM7P0H6	MN	Proto-oncogene c-Src (SRC)
DM7P0H6	MT	DTT
DM7P0H6	MA	Inhibitor
DM7P0H6	RN	Discovery of a novel series of potent and selective substrate-based inhibitors of p60c-src protein tyrosine kinase: conformational and topographica... J Med Chem. 1998 Jun 18;41(13):2252-60.
DM7P0H6	RU	https://pubmed.ncbi.nlm.nih.gov/9632358

DMBNM85	DI	DMBNM85
DMBNM85	DN	Y-c[D-Pen-(2S,3R)-2-Me-(2')Nal-GSFC]KR-NH2
DMBNM85	MI	TT6PKBN
DMBNM85	MN	Proto-oncogene c-Src (SRC)
DMBNM85	MT	DTT
DMBNM85	MA	Inhibitor
DMBNM85	RN	Discovery of a novel series of potent and selective substrate-based inhibitors of p60c-src protein tyrosine kinase: conformational and topographica... J Med Chem. 1998 Jun 18;41(13):2252-60.
DMBNM85	RU	https://pubmed.ncbi.nlm.nih.gov/9632358

DME1BGO	DI	DME1BGO
DME1BGO	DN	Y-c[D-Pen-(2S,3S)-2-Me-(2')Nal-GSFC]KR-NH2
DME1BGO	MI	TT6PKBN
DME1BGO	MN	Proto-oncogene c-Src (SRC)
DME1BGO	MT	DTT
DME1BGO	MA	Inhibitor
DME1BGO	RN	Discovery of a novel series of potent and selective substrate-based inhibitors of p60c-src protein tyrosine kinase: conformational and topographica... J Med Chem. 1998 Jun 18;41(13):2252-60.
DME1BGO	RU	https://pubmed.ncbi.nlm.nih.gov/9632358

DMF7S54	DI	DMF7S54
DMF7S54	DN	Y-c[D-Pen-(3,5-diI)Tyr-GSFC]KR-NH2
DMF7S54	MI	TT860QF
DMF7S54	MN	LCK tyrosine protein kinase (LCK)
DMF7S54	MT	DTT
DMF7S54	MA	Inhibitor
DMF7S54	RN	Discovery of a novel series of potent and selective substrate-based inhibitors of p60c-src protein tyrosine kinase: conformational and topographica... J Med Chem. 1998 Jun 18;41(13):2252-60.
DMF7S54	RU	https://pubmed.ncbi.nlm.nih.gov/9632358

DMF7S54	DI	DMF7S54
DMF7S54	DN	Y-c[D-Pen-(3,5-diI)Tyr-GSFC]KR-NH2
DMF7S54	MI	TT6PKBN
DMF7S54	MN	Proto-oncogene c-Src (SRC)
DMF7S54	MT	DTT
DMF7S54	MA	Inhibitor
DMF7S54	RN	Discovery of a novel series of potent and selective substrate-based inhibitors of p60c-src protein tyrosine kinase: conformational and topographica... J Med Chem. 1998 Jun 18;41(13):2252-60.
DMF7S54	RU	https://pubmed.ncbi.nlm.nih.gov/9632358

DMW1PSO	DI	DMW1PSO
DMW1PSO	DN	Y-c[D-Pen-(3-I)Tyr-GSFC]KR-NH2
DMW1PSO	MI	TT860QF
DMW1PSO	MN	LCK tyrosine protein kinase (LCK)
DMW1PSO	MT	DTT
DMW1PSO	MA	Inhibitor
DMW1PSO	RN	Discovery of a novel series of potent and selective substrate-based inhibitors of p60c-src protein tyrosine kinase: conformational and topographica... J Med Chem. 1998 Jun 18;41(13):2252-60.
DMW1PSO	RU	https://pubmed.ncbi.nlm.nih.gov/9632358

DMW1PSO	DI	DMW1PSO
DMW1PSO	DN	Y-c[D-Pen-(3-I)Tyr-GSFC]KR-NH2
DMW1PSO	MI	TT6PKBN
DMW1PSO	MN	Proto-oncogene c-Src (SRC)
DMW1PSO	MT	DTT
DMW1PSO	MA	Inhibitor
DMW1PSO	RN	Discovery of a novel series of potent and selective substrate-based inhibitors of p60c-src protein tyrosine kinase: conformational and topographica... J Med Chem. 1998 Jun 18;41(13):2252-60.
DMW1PSO	RU	https://pubmed.ncbi.nlm.nih.gov/9632358

DM2ILAH	DI	DM2ILAH
DM2ILAH	DN	Y-c[D-Pen-D-(2')Nal-GSFC]KR-NH2
DM2ILAH	MI	TT6PKBN
DM2ILAH	MN	Proto-oncogene c-Src (SRC)
DM2ILAH	MT	DTT
DM2ILAH	MA	Inhibitor
DM2ILAH	RN	Discovery of a novel series of potent and selective substrate-based inhibitors of p60c-src protein tyrosine kinase: conformational and topographica... J Med Chem. 1998 Jun 18;41(13):2252-60.
DM2ILAH	RU	https://pubmed.ncbi.nlm.nih.gov/9632358

DM5LYKW	DI	DM5LYKW
DM5LYKW	DN	YGGWL-NH2
DM5LYKW	MI	TTKWM86
DM5LYKW	MN	Opioid receptor mu (MOP)
DM5LYKW	MT	DTT
DM5LYKW	MA	Inhibitor
DM5LYKW	RN	Internalisation of the mu-opioid receptor by endomorphin-1 and leu-enkephalin is dependant on aromatic amino acid residues. Bioorg Med Chem. 2008 Apr 15;16(8):4341-6.
DM5LYKW	RU	https://pubmed.ncbi.nlm.nih.gov/18329886

DMV89B4	DI	DMV89B4
DMV89B4	DN	YGRKKRRQRRR-KLSSIESDV
DMV89B4	MI	TT9PB26
DMV89B4	MN	Presynaptic density protein 95 (DLG4)
DMV89B4	MT	DTT
DMV89B4	MA	Inhibitor
DMV89B4	RN	Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem. 2008 Oct 23;51(20):6450-9.
DMV89B4	RU	https://pubmed.ncbi.nlm.nih.gov/18811137

DMQ2EYJ	DI	DMQ2EYJ
DMQ2EYJ	DN	YGWFL-NH2
DMQ2EYJ	MI	TTKWM86
DMQ2EYJ	MN	Opioid receptor mu (MOP)
DMQ2EYJ	MT	DTT
DMQ2EYJ	MA	Inhibitor
DMQ2EYJ	RN	Internalisation of the mu-opioid receptor by endomorphin-1 and leu-enkephalin is dependant on aromatic amino acid residues. Bioorg Med Chem. 2008 Apr 15;16(8):4341-6.
DMQ2EYJ	RU	https://pubmed.ncbi.nlm.nih.gov/18329886

DM6FEMV	DI	DM6FEMV
DM6FEMV	DN	YH-1238
DM6FEMV	MI	TTLOKXP
DM6FEMV	MN	Gastric H(+)/K(+) ATPase (Proton pump)
DM6FEMV	MT	DTT
DM6FEMV	MA	Modulator
DM6FEMV	RN	Compositions for improving gastrointestinal nutrient and drug absorption
DM6FEMV	RU	https://www.google.com/patents/US20080193531

DML1JY4	DI	DML1JY4
DML1JY4	DN	YIL781
DML1JY4	MI	TTWDC17
DML1JY4	MN	Growth hormone secretagogue receptor 1 (GHSR)
DML1JY4	MT	DTT
DML1JY4	MA	Antagonist
DML1JY4	RN	Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss. Endocrinology. 2007 Nov;148(11):5175-85.
DML1JY4	RU	https://pubmed.ncbi.nlm.nih.gov/17656463

DMU0NHX	DI	DMU0NHX
DMU0NHX	DN	YK-3237
DMU0NHX	MI	TTUF2HO
DMU0NHX	MN	NAD-dependent deacetylase sirtuin-1 (SIRT1)
DMU0NHX	MT	DTT
DMU0NHX	MA	Inhibitor
DMU0NHX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2707).
DMU0NHX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2707

DMPYM3J	DI	DMPYM3J
DMPYM3J	DN	YM 218
DMPYM3J	MI	TT4TFGN
DMPYM3J	MN	Vasopressin V1a receptor (V1AR)
DMPYM3J	MT	DTT
DMPYM3J	MA	Antagonist
DMPYM3J	RN	Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors. Pharmacol Res. 2005 Mar;51(3):275-81.
DMPYM3J	RU	https://pubmed.ncbi.nlm.nih.gov/15661579

DMPYM3J	DI	DMPYM3J
DMPYM3J	DN	YM 218
DMPYM3J	MI	TTL9MHW
DMPYM3J	MN	Vasopressin V1b receptor (V1BR)
DMPYM3J	MT	DTT
DMPYM3J	MA	Antagonist
DMPYM3J	RN	Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors. Pharmacol Res. 2005 Mar;51(3):275-81.
DMPYM3J	RU	https://pubmed.ncbi.nlm.nih.gov/15661579

DMPYM3J	DI	DMPYM3J
DMPYM3J	DN	YM 218
DMPYM3J	MI	TTK8R02
DMPYM3J	MN	Vasopressin V2 receptor (V2R)
DMPYM3J	MT	DTT
DMPYM3J	MA	Antagonist
DMPYM3J	RN	Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors. Pharmacol Res. 2005 Mar;51(3):275-81.
DMPYM3J	RU	https://pubmed.ncbi.nlm.nih.gov/15661579

DM5BFL4	DI	DM5BFL4
DM5BFL4	DN	YM 471
DM5BFL4	MI	TT4TFGN
DM5BFL4	MN	Vasopressin V1a receptor (V1AR)
DM5BFL4	MT	DTT
DM5BFL4	MA	Antagonist
DM5BFL4	RN	Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells. Br J Pharmacol. 2001 Jul;133(5):746-54.
DM5BFL4	RU	https://pubmed.ncbi.nlm.nih.gov/11429400

DM5BFL4	DI	DM5BFL4
DM5BFL4	DN	YM 471
DM5BFL4	MI	TTL9MHW
DM5BFL4	MN	Vasopressin V1b receptor (V1BR)
DM5BFL4	MT	DTT
DM5BFL4	MA	Antagonist
DM5BFL4	RN	Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells. Br J Pharmacol. 2001 Jul;133(5):746-54.
DM5BFL4	RU	https://pubmed.ncbi.nlm.nih.gov/11429400

DM5BFL4	DI	DM5BFL4
DM5BFL4	DN	YM 471
DM5BFL4	MI	TTK8R02
DM5BFL4	MN	Vasopressin V2 receptor (V2R)
DM5BFL4	MT	DTT
DM5BFL4	MA	Antagonist
DM5BFL4	RN	Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells. Br J Pharmacol. 2001 Jul;133(5):746-54.
DM5BFL4	RU	https://pubmed.ncbi.nlm.nih.gov/11429400

DMMW3L1	DI	DMMW3L1
DMMW3L1	DN	YM-175735
DMMW3L1	MI	TTKPW01
DMMW3L1	MN	Androgen receptor messenger RNA (AR mRNA)
DMMW3L1	MT	DTT
DMMW3L1	MA	Inhibitor
DMMW3L1	RN	(+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally po... J Med Chem. 2006 Jan 26;49(2):716-26.
DMMW3L1	RU	https://pubmed.ncbi.nlm.nih.gov/16420057

DM3IOLR	DI	DM3IOLR
DM3IOLR	DN	YM-202074
DM3IOLR	MI	TTVBPDM
DM3IOLR	MN	Metabotropic glutamate receptor 1 (mGluR1)
DM3IOLR	MT	DTT
DM3IOLR	MA	Modulator (allosteric modulator)
DM3IOLR	RN	Neuroprotective effects of the selective type 1 metabotropic glutamate receptor antagonist YM-202074 in rat stroke models. Brain Res. 2008 Jan 29;1191:168-79.
DM3IOLR	RU	https://pubmed.ncbi.nlm.nih.gov/18164695

DMUYDXT	DI	DMUYDXT
DMUYDXT	DN	YM298198
DMUYDXT	MI	TTVBPDM
DMUYDXT	MN	Metabotropic glutamate receptor 1 (mGluR1)
DMUYDXT	MT	DTT
DMUYDXT	MA	Modulator (allosteric modulator)
DMUYDXT	RN	Radioligand binding properties and pharmacological characterization of 6-amino-N-cyclohexyl-N,3-dimethylthiazolo[3,2-a]benzimidazole-2-carboxamide ... J Pharmacol Exp Ther. 2005 Oct;315(1):163-9.
DMUYDXT	RU	https://pubmed.ncbi.nlm.nih.gov/15976016

DM38F9T	DI	DM38F9T
DM38F9T	DN	YM-348
DM38F9T	MI	TTJQOD7
DM38F9T	MN	5-HT 2A receptor (HTR2A)
DM38F9T	MT	DTT
DM38F9T	MA	Inhibitor
DM38F9T	RN	Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists. Bioorg Med Chem. 2008 Mar 15;16(6):3309-20.
DM38F9T	RU	https://pubmed.ncbi.nlm.nih.gov/18083579

DM38F9T	DI	DM38F9T
DM38F9T	DN	YM-348
DM38F9T	MI	TT0K1SC
DM38F9T	MN	5-HT 2B receptor (HTR2B)
DM38F9T	MT	DTT
DM38F9T	MA	Inhibitor
DM38F9T	RN	Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists. Bioorg Med Chem. 2008 Mar 15;16(6):3309-20.
DM38F9T	RU	https://pubmed.ncbi.nlm.nih.gov/18083579

DM38F9T	DI	DM38F9T
DM38F9T	DN	YM-348
DM38F9T	MI	TTWJBZ5
DM38F9T	MN	5-HT 2C receptor (HTR2C)
DM38F9T	MT	DTT
DM38F9T	MA	Inhibitor
DM38F9T	RN	Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists. Bioorg Med Chem. 2008 Mar 15;16(6):3309-20.
DM38F9T	RU	https://pubmed.ncbi.nlm.nih.gov/18083579

DMXRZ6N	DI	DMXRZ6N
DMXRZ6N	DN	YM-35278
DMXRZ6N	MI	TTK8R02
DMXRZ6N	MN	Vasopressin V2 receptor (V2R)
DMXRZ6N	MT	DTT
DMXRZ6N	MA	Inhibitor
DMXRZ6N	RN	Preparation of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetamide derivatives as novel arginine vasopressin V(2) receptor agonists. Bioorg Med Chem. 2008 Nov 1;16(21):9524-35.
DMXRZ6N	RU	https://pubmed.ncbi.nlm.nih.gov/18835174

DMDOR2L	DI	DMDOR2L
DMDOR2L	DN	YM44778
DMDOR2L	MI	TTYO0A3
DMDOR2L	MN	Substance-K receptor (TACR2)
DMDOR2L	MT	DTT
DMDOR2L	MA	Antagonist
DMDOR2L	RN	Effect of YM-44781, YM-44778 and YM-49598, novel tachykinin antagonists, in a drug-induced bladder contraction model. Pharmacology. 2002 May;65(2):96-102.
DMDOR2L	RU	https://pubmed.ncbi.nlm.nih.gov/11937780

DM73AEL	DI	DM73AEL
DM73AEL	DN	YM44781
DM73AEL	MI	TTYO0A3
DM73AEL	MN	Substance-K receptor (TACR2)
DM73AEL	MT	DTT
DM73AEL	MA	Antagonist
DM73AEL	RN	Effect of YM-44781, YM-44778 and YM-49598, novel tachykinin antagonists, in a drug-induced bladder contraction model. Pharmacology. 2002 May;65(2):96-102.
DM73AEL	RU	https://pubmed.ncbi.nlm.nih.gov/11937780

DMTYSUN	DI	DMTYSUN
DMTYSUN	DN	YM49598
DMTYSUN	MI	TTYO0A3
DMTYSUN	MN	Substance-K receptor (TACR2)
DMTYSUN	MT	DTT
DMTYSUN	MA	Antagonist
DMTYSUN	RN	Effect of YM-44781, YM-44778 and YM-49598, novel tachykinin antagonists, in a drug-induced bladder contraction model. Pharmacology. 2002 May;65(2):96-102.
DMTYSUN	RU	https://pubmed.ncbi.nlm.nih.gov/11937780

DMMCXWQ	DI	DMMCXWQ
DMMCXWQ	DN	YM-75440
DMMCXWQ	MI	TTFQEO5
DMMCXWQ	MN	Squalene synthetase (FDFT1)
DMMCXWQ	MT	DTT
DMMCXWQ	MA	Inhibitor
DMMCXWQ	RN	Synthesis and biological evaluation of novel propylamine derivatives as orally active squalene synthase inhibitors. Bioorg Med Chem. 2004 Nov 15;12(22):5899-908.
DMMCXWQ	RU	https://pubmed.ncbi.nlm.nih.gov/15498666

DML5DU0	DI	DML5DU0
DML5DU0	DN	YM90709
DML5DU0	MI	TTXH9AD
DML5DU0	MN	Interleukin 5 receptor alpha (IL5RA)
DML5DU0	MT	DTT
DML5DU0	MA	Antagonist
DML5DU0	RN	Characterization of YM-90709 as a novel antagonist which inhibits the binding of interleukin-5 to interleukin-5 receptor. Int Immunopharmacol. 2002 Nov;2(12):1693-702.
DML5DU0	RU	https://pubmed.ncbi.nlm.nih.gov/12469943

DMPU5TC	DI	DMPU5TC
DMPU5TC	DN	YM-96765
DMPU5TC	MI	TTCIHJA
DMPU5TC	MN	Coagulation factor Xa (F10)
DMPU5TC	MT	DTT
DMPU5TC	MA	Inhibitor
DMPU5TC	RN	Synthesis and biological activity of novel 1,4-diazepane derivatives as factor Xa inhibitor with potent anticoagulant and antithrombotic activity. Bioorg Med Chem. 2004 May 1;12(9):2179-91.
DMPU5TC	RU	https://pubmed.ncbi.nlm.nih.gov/15080918

DMC3DK5	DI	DMC3DK5
DMC3DK5	DN	YPAA-NH2
DMC3DK5	MI	TTKWM86
DMC3DK5	MN	Opioid receptor mu (MOP)
DMC3DK5	MT	DTT
DMC3DK5	MA	Inhibitor
DMC3DK5	RN	Internalisation of the mu-opioid receptor by endomorphin-1 and leu-enkephalin is dependant on aromatic amino acid residues. Bioorg Med Chem. 2008 Apr 15;16(8):4341-6.
DMC3DK5	RU	https://pubmed.ncbi.nlm.nih.gov/18329886

DMOTHAC	DI	DMOTHAC
DMOTHAC	DN	YPWA-NH2
DMOTHAC	MI	TTKWM86
DMOTHAC	MN	Opioid receptor mu (MOP)
DMOTHAC	MT	DTT
DMOTHAC	MA	Inhibitor
DMOTHAC	RN	Internalisation of the mu-opioid receptor by endomorphin-1 and leu-enkephalin is dependant on aromatic amino acid residues. Bioorg Med Chem. 2008 Apr 15;16(8):4341-6.
DMOTHAC	RU	https://pubmed.ncbi.nlm.nih.gov/18329886

DMXOJIB	DI	DMXOJIB
DMXOJIB	DN	YRFB
DMXOJIB	MI	TTKWM86
DMXOJIB	MN	Opioid receptor mu (MOP)
DMXOJIB	MT	DTT
DMXOJIB	MA	Inhibitor
DMXOJIB	RN	Synthesis and receptor binding properties of chimeric peptides containing a mu-opioid receptor ligand and nociceptin/orphanin FQ receptor ligand Ac... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4839-41.
DMXOJIB	RU	https://pubmed.ncbi.nlm.nih.gov/16814543

DMTURZ6	DI	DMTURZ6
DMTURZ6	DN	YS110 mAb clone
DMTURZ6	MI	TTF928K
DMTURZ6	MN	HUMAN dipeptidyl peptidase 4 (DPP-4)
DMTURZ6	MT	DTT
DMTURZ6	MA	Blocker
DMTURZ6	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DMTURZ6	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DM24LNB	DI	DM24LNB
DM24LNB	DN	YVAD
DM24LNB	MI	TTCQIBE
DM24LNB	MN	Caspase-1 (CASP1)
DM24LNB	MT	DTT
DM24LNB	MA	Inhibitor
DM24LNB	RN	Mice deficient in interleukin-1beta converting enzyme resist anorexia induced by central lipopolysaccharide. Am J Physiol. 1999 Nov;277(5 Pt 2):R1435-43.
DM24LNB	RU	https://pubmed.ncbi.nlm.nih.gov/10564217

DMFT51X	DI	DMFT51X
DMFT51X	DN	Z 944
DMFT51X	MI	TTZPWGN
DMFT51X	MN	Voltage-gated calcium channel alpha Cav3.2 (CACNA1H)
DMFT51X	MT	DTT
DMFT51X	MA	Modulator
DMFT51X	RN	Z944, a Novel Selective T-Type Calcium Channel Antagonist Delays the Progression of Seizures in the Amygdala Kindling Model.PLoS One.2015 Aug 14;10(8):e0130012.
DMFT51X	RU	https://www.ncbi.nlm.nih.gov/pubmed/26274319

DMMP0DT	DI	DMMP0DT
DMMP0DT	DN	Z-Ala-Leu-His-Agly-Ile-Val-OMe
DMMP0DT	MI	TTF2LRI
DMMP0DT	MN	Cathepsin B (CTSB)
DMMP0DT	MT	DTT
DMMP0DT	MA	Inhibitor
DMMP0DT	RN	Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11.
DMMP0DT	RU	https://pubmed.ncbi.nlm.nih.gov/12213061

DMMP0DT	DI	DMMP0DT
DMMP0DT	DN	Z-Ala-Leu-His-Agly-Ile-Val-OMe
DMMP0DT	MI	TTDZN01
DMMP0DT	MN	Cathepsin K (CTSK)
DMMP0DT	MT	DTT
DMMP0DT	MA	Inhibitor
DMMP0DT	RN	Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11.
DMMP0DT	RU	https://pubmed.ncbi.nlm.nih.gov/12213061

DM7IGRT	DI	DM7IGRT
DM7IGRT	DN	Z-Ala-Leu-lle-Agly-Ile-Val-NHBzl
DM7IGRT	MI	TTF2LRI
DM7IGRT	MN	Cathepsin B (CTSB)
DM7IGRT	MT	DTT
DM7IGRT	MA	Inhibitor
DM7IGRT	RN	Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11.
DM7IGRT	RU	https://pubmed.ncbi.nlm.nih.gov/12213061

DM7IGRT	DI	DM7IGRT
DM7IGRT	DN	Z-Ala-Leu-lle-Agly-Ile-Val-NHBzl
DM7IGRT	MI	TTDZN01
DM7IGRT	MN	Cathepsin K (CTSK)
DM7IGRT	MT	DTT
DM7IGRT	MA	Inhibitor
DM7IGRT	RN	Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11.
DM7IGRT	RU	https://pubmed.ncbi.nlm.nih.gov/12213061

DMVEUOL	DI	DMVEUOL
DMVEUOL	DN	Z-Ala-Leu-lle-Agly-Ile-Val-OMe
DMVEUOL	MI	TTF2LRI
DMVEUOL	MN	Cathepsin B (CTSB)
DMVEUOL	MT	DTT
DMVEUOL	MA	Inhibitor
DMVEUOL	RN	Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11.
DMVEUOL	RU	https://pubmed.ncbi.nlm.nih.gov/12213061

DMVEUOL	DI	DMVEUOL
DMVEUOL	DN	Z-Ala-Leu-lle-Agly-Ile-Val-OMe
DMVEUOL	MI	TTDZN01
DMVEUOL	MN	Cathepsin K (CTSK)
DMVEUOL	MT	DTT
DMVEUOL	MA	Inhibitor
DMVEUOL	RN	Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11.
DMVEUOL	RU	https://pubmed.ncbi.nlm.nih.gov/12213061

DM3209T	DI	DM3209T
DM3209T	DN	Z-Ala-Leu-Nal-Agly-Ile-Val-OMe
DM3209T	MI	TTF2LRI
DM3209T	MN	Cathepsin B (CTSB)
DM3209T	MT	DTT
DM3209T	MA	Inhibitor
DM3209T	RN	Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11.
DM3209T	RU	https://pubmed.ncbi.nlm.nih.gov/12213061

DM3209T	DI	DM3209T
DM3209T	DN	Z-Ala-Leu-Nal-Agly-Ile-Val-OMe
DM3209T	MI	TTDZN01
DM3209T	MN	Cathepsin K (CTSK)
DM3209T	MT	DTT
DM3209T	MA	Inhibitor
DM3209T	RN	Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11.
DM3209T	RU	https://pubmed.ncbi.nlm.nih.gov/12213061

DML16BT	DI	DML16BT
DML16BT	DN	Z-Ala-Leu-Phe-Agly-Ile-Val-OMe
DML16BT	MI	TTF2LRI
DML16BT	MN	Cathepsin B (CTSB)
DML16BT	MT	DTT
DML16BT	MA	Inhibitor
DML16BT	RN	Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11.
DML16BT	RU	https://pubmed.ncbi.nlm.nih.gov/12213061

DML16BT	DI	DML16BT
DML16BT	DN	Z-Ala-Leu-Phe-Agly-Ile-Val-OMe
DML16BT	MI	TTDZN01
DML16BT	MN	Cathepsin K (CTSK)
DML16BT	MT	DTT
DML16BT	MA	Inhibitor
DML16BT	RN	Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11.
DML16BT	RU	https://pubmed.ncbi.nlm.nih.gov/12213061

DMIB5O3	DI	DMIB5O3
DMIB5O3	DN	Z-Ala-Leu-Tyr(Me)-Agly-Ile-Val-OMe
DMIB5O3	MI	TTF2LRI
DMIB5O3	MN	Cathepsin B (CTSB)
DMIB5O3	MT	DTT
DMIB5O3	MA	Inhibitor
DMIB5O3	RN	Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11.
DMIB5O3	RU	https://pubmed.ncbi.nlm.nih.gov/12213061

DMIB5O3	DI	DMIB5O3
DMIB5O3	DN	Z-Ala-Leu-Tyr(Me)-Agly-Ile-Val-OMe
DMIB5O3	MI	TTDZN01
DMIB5O3	MN	Cathepsin K (CTSK)
DMIB5O3	MT	DTT
DMIB5O3	MA	Inhibitor
DMIB5O3	RN	Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11.
DMIB5O3	RU	https://pubmed.ncbi.nlm.nih.gov/12213061

DMM4ZKU	DI	DMM4ZKU
DMM4ZKU	DN	ZAPOTIN
DMM4ZKU	MI	TTUMGNO
DMM4ZKU	MN	Ornithine decarboxylase (ODC1)
DMM4ZKU	MT	DTT
DMM4ZKU	MA	Inhibitor
DMM4ZKU	RN	Synthesis and cancer chemopreventive activity of zapotin, a natural product from Casimiroa edulis. J Med Chem. 2007 Jan 25;50(2):350-5.
DMM4ZKU	RU	https://pubmed.ncbi.nlm.nih.gov/17228877

DMYRLA0	DI	DMYRLA0
DMYRLA0	DN	ZARAGOZIC ACID B
DMYRLA0	MI	TTFQEO5
DMYRLA0	MN	Squalene synthetase (FDFT1)
DMYRLA0	MT	DTT
DMYRLA0	MA	Inhibitor
DMYRLA0	RN	Zaragozic acids D and D2: potent inhibitors of squalene synthase and of Ras farnesyl-protein transferase. J Nat Prod. 1993 Nov;56(11):1923-9.
DMYRLA0	RU	https://pubmed.ncbi.nlm.nih.gov/8289063

DMUQWP1	DI	DMUQWP1
DMUQWP1	DN	Zaragozic Acid C
DMUQWP1	MI	TTFQEO5
DMUQWP1	MN	Squalene synthetase (FDFT1)
DMUQWP1	MT	DTT
DMUQWP1	MA	Inhibitor
DMUQWP1	RN	Zaragozic acids D and D2: potent inhibitors of squalene synthase and of Ras farnesyl-protein transferase. J Nat Prod. 1993 Nov;56(11):1923-9.
DMUQWP1	RU	https://pubmed.ncbi.nlm.nih.gov/8289063

DMMTJE3	DI	DMMTJE3
DMMTJE3	DN	Zaragozic Acid D
DMMTJE3	MI	TTFQEO5
DMMTJE3	MN	Squalene synthetase (FDFT1)
DMMTJE3	MT	DTT
DMMTJE3	MA	Inhibitor
DMMTJE3	RN	Zaragozic acids D and D2: potent inhibitors of squalene synthase and of Ras farnesyl-protein transferase. J Nat Prod. 1993 Nov;56(11):1923-9.
DMMTJE3	RU	https://pubmed.ncbi.nlm.nih.gov/8289063

DML4WQJ	DI	DML4WQJ
DML4WQJ	DN	Zaragozic Acid D2
DML4WQJ	MI	TTFQEO5
DML4WQJ	MN	Squalene synthetase (FDFT1)
DML4WQJ	MT	DTT
DML4WQJ	MA	Inhibitor
DML4WQJ	RN	Zaragozic acids D and D2: potent inhibitors of squalene synthase and of Ras farnesyl-protein transferase. J Nat Prod. 1993 Nov;56(11):1923-9.
DML4WQJ	RU	https://pubmed.ncbi.nlm.nih.gov/8289063

DM69FKN	DI	DM69FKN
DM69FKN	DN	Z-Arg-Leu-Val-Agly-Ala-Gly-NH2
DM69FKN	MI	TTF2LRI
DM69FKN	MN	Cathepsin B (CTSB)
DM69FKN	MT	DTT
DM69FKN	MA	Inhibitor
DM69FKN	RN	Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11.
DM69FKN	RU	https://pubmed.ncbi.nlm.nih.gov/12213061

DM69FKN	DI	DM69FKN
DM69FKN	DN	Z-Arg-Leu-Val-Agly-Ala-Gly-NH2
DM69FKN	MI	TTDZN01
DM69FKN	MN	Cathepsin K (CTSK)
DM69FKN	MT	DTT
DM69FKN	MA	Inhibitor
DM69FKN	RN	Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11.
DM69FKN	RU	https://pubmed.ncbi.nlm.nih.gov/12213061

DMT0UZ1	DI	DMT0UZ1
DMT0UZ1	DN	Z-Arg-Leu-Val-Agly-Ileu-Val-OMe
DMT0UZ1	MI	TTF2LRI
DMT0UZ1	MN	Cathepsin B (CTSB)
DMT0UZ1	MT	DTT
DMT0UZ1	MA	Inhibitor
DMT0UZ1	RN	Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11.
DMT0UZ1	RU	https://pubmed.ncbi.nlm.nih.gov/12213061

DMT0UZ1	DI	DMT0UZ1
DMT0UZ1	DN	Z-Arg-Leu-Val-Agly-Ileu-Val-OMe
DMT0UZ1	MI	TTDZN01
DMT0UZ1	MN	Cathepsin K (CTSK)
DMT0UZ1	MT	DTT
DMT0UZ1	MA	Inhibitor
DMT0UZ1	RN	Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11.
DMT0UZ1	RU	https://pubmed.ncbi.nlm.nih.gov/12213061

DM9SXMB	DI	DM9SXMB
DM9SXMB	DN	Z-Arg-Leu-Val-Agly-Ile-Val-OMe
DM9SXMB	MI	TTF2LRI
DM9SXMB	MN	Cathepsin B (CTSB)
DM9SXMB	MT	DTT
DM9SXMB	MA	Inhibitor
DM9SXMB	RN	Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11.
DM9SXMB	RU	https://pubmed.ncbi.nlm.nih.gov/12213061

DMZDGJO	DI	DMZDGJO
DMZDGJO	DN	Z-Arg-Leu-Val-Agly-Ile-Val-Trp-NH2
DMZDGJO	MI	TTF2LRI
DMZDGJO	MN	Cathepsin B (CTSB)
DMZDGJO	MT	DTT
DMZDGJO	MA	Inhibitor
DMZDGJO	RN	Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11.
DMZDGJO	RU	https://pubmed.ncbi.nlm.nih.gov/12213061

DMZDGJO	DI	DMZDGJO
DMZDGJO	DN	Z-Arg-Leu-Val-Agly-Ile-Val-Trp-NH2
DMZDGJO	MI	TTDZN01
DMZDGJO	MN	Cathepsin K (CTSK)
DMZDGJO	MT	DTT
DMZDGJO	MA	Inhibitor
DMZDGJO	RN	Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11.
DMZDGJO	RU	https://pubmed.ncbi.nlm.nih.gov/12213061

DMM5O2V	DI	DMM5O2V
DMM5O2V	DN	Z-Arg-Leu-Val-Agly-Trp-Val-Ala-NH2
DMM5O2V	MI	TTF2LRI
DMM5O2V	MN	Cathepsin B (CTSB)
DMM5O2V	MT	DTT
DMM5O2V	MA	Inhibitor
DMM5O2V	RN	Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11.
DMM5O2V	RU	https://pubmed.ncbi.nlm.nih.gov/12213061

DMM5O2V	DI	DMM5O2V
DMM5O2V	DN	Z-Arg-Leu-Val-Agly-Trp-Val-Ala-NH2
DMM5O2V	MI	TTDZN01
DMM5O2V	MN	Cathepsin K (CTSK)
DMM5O2V	MT	DTT
DMM5O2V	MA	Inhibitor
DMM5O2V	RN	Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11.
DMM5O2V	RU	https://pubmed.ncbi.nlm.nih.gov/12213061

DMTWNH7	DI	DMTWNH7
DMTWNH7	DN	Z-Arg-Leu-Val-Agly-Val-Ala-NH2
DMTWNH7	MI	TTF2LRI
DMTWNH7	MN	Cathepsin B (CTSB)
DMTWNH7	MT	DTT
DMTWNH7	MA	Inhibitor
DMTWNH7	RN	Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11.
DMTWNH7	RU	https://pubmed.ncbi.nlm.nih.gov/12213061

DMTWNH7	DI	DMTWNH7
DMTWNH7	DN	Z-Arg-Leu-Val-Agly-Val-Ala-NH2
DMTWNH7	MI	TTDZN01
DMTWNH7	MN	Cathepsin K (CTSK)
DMTWNH7	MT	DTT
DMTWNH7	MA	Inhibitor
DMTWNH7	RN	Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11.
DMTWNH7	RU	https://pubmed.ncbi.nlm.nih.gov/12213061

DMLI8GZ	DI	DMLI8GZ
DMLI8GZ	DN	ZD1604
DMLI8GZ	MI	TTU6BFZ
DMLI8GZ	MN	Candida Thymidylate synthase (Candi TMP1)
DMLI8GZ	MT	DTT
DMLI8GZ	MA	Inhibitor
DMLI8GZ	RN	Acquisition of resistance to anticancer agents by overproduction of target enzymes. Nippon Rinsho. 1997 May;55(5):1030-7.
DMLI8GZ	RU	https://pubmed.ncbi.nlm.nih.gov/9155148

DM8MXS6	DI	DM8MXS6
DM8MXS6	DN	ZD-6021
DM8MXS6	MI	TTYO0A3
DM8MXS6	MN	Substance-K receptor (TACR2)
DM8MXS6	MT	DTT
DM8MXS6	MA	Modulator
DM8MXS6	RN	Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors. J Pharmacol Exp Ther. 2001 Jul;298(1):307-15.
DM8MXS6	RU	https://www.ncbi.nlm.nih.gov/pubmed/11408556

DM8MXS6	DI	DM8MXS6
DM8MXS6	DN	ZD-6021
DM8MXS6	MI	TTZPO1L
DM8MXS6	MN	Substance-P receptor (TACR1)
DM8MXS6	MT	DTT
DM8MXS6	MA	Modulator
DM8MXS6	RN	Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors. J Pharmacol Exp Ther. 2001 Jul;298(1):307-15.
DM8MXS6	RU	https://www.ncbi.nlm.nih.gov/pubmed/11408556

DMI5WF1	DI	DMI5WF1
DMI5WF1	DN	ZEARALANONE
DMI5WF1	MI	TT78R5H
DMI5WF1	MN	Heat shock protein 90 alpha (HSP90A)
DMI5WF1	MT	DTT
DMI5WF1	MA	Inhibitor
DMI5WF1	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMI5WF1	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMF0CRA	DI	DMF0CRA
DMF0CRA	DN	zinc pyrithione
DMF0CRA	MI	TT846HF
DMF0CRA	MN	Voltage-gated potassium channel Kv7.1 (KCNQ1)
DMF0CRA	MT	DTT
DMF0CRA	MA	Activator
DMF0CRA	RN	Zinc pyrithione-mediated activation of voltage-gated KCNQ potassium channels rescues epileptogenic mutants. Nat Chem Biol. 2007 May;3(5):287-96.
DMF0CRA	RU	https://pubmed.ncbi.nlm.nih.gov/17435769

DMF0CRA	DI	DMF0CRA
DMF0CRA	DN	zinc pyrithione
DMF0CRA	MI	TTPXI3S
DMF0CRA	MN	Voltage-gated potassium channel Kv7.2 (KCNQ2)
DMF0CRA	MT	DTT
DMF0CRA	MA	Activator
DMF0CRA	RN	Zinc pyrithione-mediated activation of voltage-gated KCNQ potassium channels rescues epileptogenic mutants. Nat Chem Biol. 2007 May;3(5):287-96.
DMF0CRA	RU	https://pubmed.ncbi.nlm.nih.gov/17435769

DMF0CRA	DI	DMF0CRA
DMF0CRA	DN	zinc pyrithione
DMF0CRA	MI	TT8HGRW
DMF0CRA	MN	Voltage-gated potassium channel Kv7.4 (KCNQ4)
DMF0CRA	MT	DTT
DMF0CRA	MA	Activator
DMF0CRA	RN	Zinc pyrithione-mediated activation of voltage-gated KCNQ potassium channels rescues epileptogenic mutants. Nat Chem Biol. 2007 May;3(5):287-96.
DMF0CRA	RU	https://pubmed.ncbi.nlm.nih.gov/17435769

DMF0CRA	DI	DMF0CRA
DMF0CRA	DN	zinc pyrithione
DMF0CRA	MI	TTWVL5Q
DMF0CRA	MN	Voltage-gated potassium channel Kv7.5 (KCNQ5)
DMF0CRA	MT	DTT
DMF0CRA	MA	Activator
DMF0CRA	RN	Zinc pyrithione-mediated activation of voltage-gated KCNQ potassium channels rescues epileptogenic mutants. Nat Chem Biol. 2007 May;3(5):287-96.
DMF0CRA	RU	https://pubmed.ncbi.nlm.nih.gov/17435769

DMKETL5	DI	DMKETL5
DMKETL5	DN	zinterol
DMKETL5	MI	TTMXGCW
DMKETL5	MN	Adrenergic receptor beta-3 (ADRB3)
DMKETL5	MT	DTT
DMKETL5	MA	Agonist
DMKETL5	RN	The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors. Br J Pharmacol. 2010 Jul;160(5):1048-61.
DMKETL5	RU	https://pubmed.ncbi.nlm.nih.gov/20590599

DMP089G	DI	DMP089G
DMP089G	DN	ZK 756326
DMP089G	MI	TTE836A
DMP089G	MN	C-C chemokine receptor type 8 (CCR8)
DMP089G	MT	DTT
DMP089G	MA	Agonist
DMP089G	RN	Identification and characterization of a potent, selective nonpeptide agonist of the CC chemokine receptor CCR8. Mol Pharmacol. 2006 Jan;69(1):309-16.
DMP089G	RU	https://pubmed.ncbi.nlm.nih.gov/16221874

DMY3SUZ	DI	DMY3SUZ
DMY3SUZ	DN	ZK110841
DMY3SUZ	MI	TTNVEIR
DMY3SUZ	MN	Prostaglandin D2 receptor (PTGDR)
DMY3SUZ	MT	DTT
DMY3SUZ	MA	Agonist
DMY3SUZ	RN	Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist. Br J Pharmacol. 1998 Apr;123(7):1317-24.
DMY3SUZ	RU	https://pubmed.ncbi.nlm.nih.gov/9579725

DMY3SUZ	DI	DMY3SUZ
DMY3SUZ	DN	ZK110841
DMY3SUZ	MI	TTG1QMU
DMY3SUZ	MN	Prostaglandin E2 receptor EP1 (PTGER1)
DMY3SUZ	MT	DTT
DMY3SUZ	MA	Agonist
DMY3SUZ	RN	Cloned human EP1 prostanoid receptor pharmacology characterized using radioligand binding techniques. J Pharm Pharmacol. 2002 Apr;54(4):539-47.
DMY3SUZ	RU	https://pubmed.ncbi.nlm.nih.gov/11999132

DM8JN45	DI	DM8JN45
DM8JN45	DN	ZK-112993
DM8JN45	MI	TTUV8G9
DM8JN45	MN	Progesterone receptor (PGR)
DM8JN45	MT	DTT
DM8JN45	MA	Modulator
DM8JN45	RN	Tumor-inhibiting potential of ZK 112.993, a new progesterone antagonist, in hormone-sensitive, experimental rodent and human mammary tumors.Anticancer Res.1990 May-Jun;10(3):683-7.
DM8JN45	RU	https://www.ncbi.nlm.nih.gov/pubmed/2369083

DMBCPKE	DI	DMBCPKE
DMBCPKE	DN	ZK-114043
DMBCPKE	MI	TTUV8G9
DMBCPKE	MN	Progesterone receptor (PGR)
DMBCPKE	MT	DTT
DMBCPKE	MA	Modulator
DMBCPKE	RN	Progesterone inhibits glucocorticoid-dependent aromatase induction in human adipose fibroblasts. J Endocrinol. 1998 Sep;158(3):401-7.
DMBCPKE	RU	https://www.ncbi.nlm.nih.gov/pubmed/9846169

DMCQYBE	DI	DMCQYBE
DMCQYBE	DN	ZK-136798
DMCQYBE	MI	TTUV8G9
DMCQYBE	MN	Progesterone receptor (PGR)
DMCQYBE	MT	DTT
DMCQYBE	MA	Modulator
DMCQYBE	RN	The antiovulatory activity of progesterone antagonists is not correlated to their antiprogestational potency in the rat. J Steroid Biochem Mol Biol. 1996 Sep;59(1):75-82.
DMCQYBE	RU	https://www.ncbi.nlm.nih.gov/pubmed/9009240

DMNMD0J	DI	DMNMD0J
DMNMD0J	DN	ZK-158252
DMNMD0J	MI	TTVJX54
DMNMD0J	MN	Leukotriene B4 receptor 2 (LTB4R2)
DMNMD0J	MT	DTT
DMNMD0J	MA	Antagonist
DMNMD0J	RN	Hydroxyeicosanoids bind to and activate the low affinity leukotriene B4 receptor, BLT2. J Biol Chem. 2001 Apr 13;276(15):12454-9.
DMNMD0J	RU	https://pubmed.ncbi.nlm.nih.gov/11278893

DMYRHK6	DI	DMYRHK6
DMYRHK6	DN	ZK159222
DMYRHK6	MI	TTK59TV
DMYRHK6	MN	Vitamin D3 receptor (VDR)
DMYRHK6	MT	DTT
DMYRHK6	MA	Antagonist
DMYRHK6	RN	Carboxylic ester antagonists of 1alpha,25-dihydroxyvitamin D(3) show cell-specific actions. Chem Biol. 2000 Nov;7(11):885-94.
DMYRHK6	RU	https://pubmed.ncbi.nlm.nih.gov/11094341

DMROWV8	DI	DMROWV8
DMROWV8	DN	ZK-164015
DMROWV8	MI	TTZAYWL
DMROWV8	MN	Estrogen receptor (ESR)
DMROWV8	MT	DTT
DMROWV8	MA	Inhibitor
DMROWV8	RN	Synthesis and biological evaluation of stilbene-based pure estrogen antagonists. Bioorg Med Chem Lett. 2004 Sep 20;14(18):4659-63.
DMROWV8	RU	https://pubmed.ncbi.nlm.nih.gov/15324884

DMROWV8	DI	DMROWV8
DMROWV8	DN	ZK-164015
DMROWV8	MI	TTOM3J0
DMROWV8	MN	Estrogen receptor beta (ESR2)
DMROWV8	MT	DTT
DMROWV8	MA	Inhibitor
DMROWV8	RN	Synthesis and biological evaluation of stilbene-based pure estrogen antagonists. Bioorg Med Chem Lett. 2004 Sep 20;14(18):4659-63.
DMROWV8	RU	https://pubmed.ncbi.nlm.nih.gov/15324884

DMNOWAQ	DI	DMNOWAQ
DMNOWAQ	DN	ZK-810388
DMNOWAQ	MI	TTCIHJA
DMNOWAQ	MN	Coagulation factor Xa (F10)
DMNOWAQ	MT	DTT
DMNOWAQ	MA	Inhibitor
DMNOWAQ	RN	Thiophene-anthranilamides as highly potent and orally available factor Xa inhibitors. J Med Chem. 2007 Jun 28;50(13):2967-80.
DMNOWAQ	RU	https://pubmed.ncbi.nlm.nih.gov/17536795

DMNOWAQ	DI	DMNOWAQ
DMNOWAQ	DN	ZK-810388
DMNOWAQ	MI	TTMF8H9
DMNOWAQ	MN	Plasma kallikrein (KLKB1)
DMNOWAQ	MT	DTT
DMNOWAQ	MA	Inhibitor
DMNOWAQ	RN	Thiophene-anthranilamides as highly potent and orally available factor Xa inhibitors. J Med Chem. 2007 Jun 28;50(13):2967-80.
DMNOWAQ	RU	https://pubmed.ncbi.nlm.nih.gov/17536795

DMIC4HJ	DI	DMIC4HJ
DMIC4HJ	DN	ZK-813039
DMIC4HJ	MI	TTCIHJA
DMIC4HJ	MN	Coagulation factor Xa (F10)
DMIC4HJ	MT	DTT
DMIC4HJ	MA	Modulator
DMIC4HJ	RN	Thiophene-anthranilamides as highly potent and orally available factor Xa inhibitors. J Med Chem. 2007 Jun 28;50(13):2967-80.
DMIC4HJ	RU	https://pubmed.ncbi.nlm.nih.gov/17536795

DMCBV5F	DI	DMCBV5F
DMCBV5F	DN	ZK-814048
DMCBV5F	MI	TTCIHJA
DMCBV5F	MN	Coagulation factor Xa (F10)
DMCBV5F	MT	DTT
DMCBV5F	MA	Inhibitor
DMCBV5F	RN	Thiophene-anthranilamides as highly potent and orally available factor Xa inhibitors. J Med Chem. 2007 Jun 28;50(13):2967-80.
DMCBV5F	RU	https://pubmed.ncbi.nlm.nih.gov/17536795

DMCBV5F	DI	DMCBV5F
DMCBV5F	DN	ZK-814048
DMCBV5F	MI	TTPLTSQ
DMCBV5F	MN	Neutrophil elastase (NE)
DMCBV5F	MT	DTT
DMCBV5F	MA	Inhibitor
DMCBV5F	RN	Thiophene-anthranilamides as highly potent and orally available factor Xa inhibitors. J Med Chem. 2007 Jun 28;50(13):2967-80.
DMCBV5F	RU	https://pubmed.ncbi.nlm.nih.gov/17536795

DMCBV5F	DI	DMCBV5F
DMCBV5F	DN	ZK-814048
DMCBV5F	MI	TTMF8H9
DMCBV5F	MN	Plasma kallikrein (KLKB1)
DMCBV5F	MT	DTT
DMCBV5F	MA	Inhibitor
DMCBV5F	RN	Thiophene-anthranilamides as highly potent and orally available factor Xa inhibitors. J Med Chem. 2007 Jun 28;50(13):2967-80.
DMCBV5F	RU	https://pubmed.ncbi.nlm.nih.gov/17536795

DM24OIX	DI	DM24OIX
DM24OIX	DN	ZL006
DM24OIX	MI	TTMADVT
DM24OIX	MN	PSD95-nNOS interaction (PSD95-nNOS PPI)
DM24OIX	MT	DTT
DM24OIX	MA	Disrupter
DM24OIX	RN	PSD95 and nNOS interaction as a novel molecular target to modulate conditioned fear: relevance to PTSD.Transl Psychiatry. 2018 Aug 14;8(1):155.
DM24OIX	RU	https://pubmed.ncbi.nlm.nih.gov/30108200

DMEFHQI	DI	DMEFHQI
DMEFHQI	DN	Z-LEHD-fmk
DMEFHQI	MI	TTB6T7O
DMEFHQI	MN	Caspase-9 (CASP9)
DMEFHQI	MT	DTT
DMEFHQI	MA	Inhibitor
DMEFHQI	RN	The expression of Smac and XIAP in rat hippocampus following limbic seizure induced by kainic acid injection into amygdaloid nucleus. Sheng Li Xue Bao. 2004 Apr 25;56(2):172-7.
DMEFHQI	RU	https://pubmed.ncbi.nlm.nih.gov/15127126

DM6OGR9	DI	DM6OGR9
DM6OGR9	DN	Z-leu-Val-Agly-Val-OBzl
DM6OGR9	MI	TTF2LRI
DM6OGR9	MN	Cathepsin B (CTSB)
DM6OGR9	MT	DTT
DM6OGR9	MA	Inhibitor
DM6OGR9	RN	Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11.
DM6OGR9	RU	https://pubmed.ncbi.nlm.nih.gov/12213061

DM6OGR9	DI	DM6OGR9
DM6OGR9	DN	Z-leu-Val-Agly-Val-OBzl
DM6OGR9	MI	TTDZN01
DM6OGR9	MN	Cathepsin K (CTSK)
DM6OGR9	MT	DTT
DM6OGR9	MA	Inhibitor
DM6OGR9	RN	Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11.
DM6OGR9	RU	https://pubmed.ncbi.nlm.nih.gov/12213061

DM1H865	DI	DM1H865
DM1H865	DN	ZL-N-91
DM1H865	MI	TTZ97H5
DM1H865	MN	Phosphodiesterase 4A (PDE4A)
DM1H865	MT	DTT
DM1H865	MA	Inhibitor
DM1H865	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1300).
DM1H865	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1300

DM1H865	DI	DM1H865
DM1H865	DN	ZL-N-91
DM1H865	MI	TTVIAT9
DM1H865	MN	Phosphodiesterase 4B (PDE4B)
DM1H865	MT	DTT
DM1H865	MA	Modulator
DM1H865	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1301).
DM1H865	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1301

DM1H865	DI	DM1H865
DM1H865	DN	ZL-N-91
DM1H865	MI	TTSKMI8
DM1H865	MN	Phosphodiesterase 4D (PDE4D)
DM1H865	MT	DTT
DM1H865	MA	Modulator
DM1H865	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1303).
DM1H865	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1303

DMA3M9H	DI	DMA3M9H
DMA3M9H	DN	ZM 253270
DMA3M9H	MI	TTYO0A3
DMA3M9H	MN	Substance-K receptor (TACR2)
DMA3M9H	MT	DTT
DMA3M9H	MA	Antagonist
DMA3M9H	RN	Pharmacological characterization of a new class of nonpeptide neurokinin A antagonists that demonstrate species selectivity. J Pharmacol Exp Ther. 1995 Sep;274(3):1216-21.
DMA3M9H	RU	https://pubmed.ncbi.nlm.nih.gov/7562491

DMC46RQ	DI	DMC46RQ
DMC46RQ	DN	ZM 325802
DMC46RQ	MI	TTG1QMU
DMC46RQ	MN	Prostaglandin E2 receptor EP1 (PTGER1)
DMC46RQ	MT	DTT
DMC46RQ	MA	Modulator
DMC46RQ	RN	Characterization of the prostanoid receptor types involved in mediating calcitonin gene-related peptide release from cultured rat trigeminal neurones. Br J Pharmacol. 2001 Nov;134(6):1296-302.
DMC46RQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/11704650

DMD0NFL	DI	DMD0NFL
DMD0NFL	DN	ZM-274773
DMD0NFL	MI	TTYO0A3
DMD0NFL	MN	Substance-K receptor (TACR2)
DMD0NFL	MT	DTT
DMD0NFL	MA	Antagonist
DMD0NFL	RN	Tachykinin NK2 receptor antagonists. A patent review (2006 - 2010). Expert Opin Ther Pat. 2012 Jan;22(1):57-77.
DMD0NFL	RU	https://pubmed.ncbi.nlm.nih.gov/22149761

DMD5JYQ	DI	DMD5JYQ
DMD5JYQ	DN	ZM-336372
DMD5JYQ	MI	TT0EOB8
DMD5JYQ	MN	B-Raf messenger RNA (BRAF mRNA)
DMD5JYQ	MT	DTT
DMD5JYQ	MA	Inhibitor
DMD5JYQ	RN	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
DMD5JYQ	RU	https://pubmed.ncbi.nlm.nih.gov/17850214

DMD5JYQ	DI	DMD5JYQ
DMD5JYQ	DN	ZM-336372
DMD5JYQ	MI	TT860QF
DMD5JYQ	MN	LCK tyrosine protein kinase (LCK)
DMD5JYQ	MT	DTT
DMD5JYQ	MA	Inhibitor
DMD5JYQ	RN	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
DMD5JYQ	RU	https://pubmed.ncbi.nlm.nih.gov/17850214

DMD5JYQ	DI	DMD5JYQ
DMD5JYQ	DN	ZM-336372
DMD5JYQ	MI	TTAN5W2
DMD5JYQ	MN	Raf messenger RNA (Raf mRNA)
DMD5JYQ	MT	DTT
DMD5JYQ	MA	Inhibitor
DMD5JYQ	RN	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
DMD5JYQ	RU	https://pubmed.ncbi.nlm.nih.gov/17850214

DMD5JYQ	DI	DMD5JYQ
DMD5JYQ	DN	ZM-336372
DMD5JYQ	MI	TTQBR95
DMD5JYQ	MN	Stress-activated protein kinase 2a (p38 alpha)
DMD5JYQ	MT	DTT
DMD5JYQ	MA	Inhibitor
DMD5JYQ	RN	A novel series of p38 MAP kinase inhibitors for the potential treatment of rheumatoid arthritis. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5383-7.
DMD5JYQ	RU	https://pubmed.ncbi.nlm.nih.gov/15454231

DMTMVYH	DI	DMTMVYH
DMTMVYH	DN	ZM-39923
DMTMVYH	MI	TT6DM01
DMTMVYH	MN	Janus kinase 1 (JAK-1)
DMTMVYH	MT	DTT
DMTMVYH	MA	Inhibitor
DMTMVYH	RN	Naphthyl ketones: a new class of Janus kinase 3 inhibitors. Bioorg Med Chem Lett. 2000 Mar 20;10(6):575-9.
DMTMVYH	RU	https://pubmed.ncbi.nlm.nih.gov/10741557

DMTMVYH	DI	DMTMVYH
DMTMVYH	DN	ZM-39923
DMTMVYH	MI	TTT7PJU
DMTMVYH	MN	Janus kinase 3 (JAK-3)
DMTMVYH	MT	DTT
DMTMVYH	MA	Inhibitor
DMTMVYH	RN	Naphthyl ketones: a new class of Janus kinase 3 inhibitors. Bioorg Med Chem Lett. 2000 Mar 20;10(6):575-9.
DMTMVYH	RU	https://pubmed.ncbi.nlm.nih.gov/10741557

DMFP8WE	DI	DMFP8WE
DMFP8WE	DN	ZM-447439
DMFP8WE	MI	TTPS3C0
DMFP8WE	MN	Aurora kinase A (AURKA)
DMFP8WE	MT	DTT
DMFP8WE	MA	Inhibitor
DMFP8WE	RN	Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring. J Med Chem. 2006 Aug 10;49(16):4805-8.
DMFP8WE	RU	https://pubmed.ncbi.nlm.nih.gov/16884290

DMEC1I9	DI	DMEC1I9
DMEC1I9	DN	Zn2+
DMEC1I9	MI	TTI0TCK
DMEC1I9	MN	Mycobacterium CDP-diacylglycerol-inositol phosphatidyltransferase (MycB pssA)
DMEC1I9	MT	DTT
DMEC1I9	MA	Inhibitor
DMEC1I9	RN	Phosphatidylinositol synthesis in mycobacteria. Biochim Biophys Acta. 1999 Jan 4;1436(3):437-50.
DMEC1I9	RU	https://pubmed.ncbi.nlm.nih.gov/9989274

DMY2V37	DI	DMY2V37
DMY2V37	DN	ZNCCNCSSKWCRDHSRCC
DMY2V37	MI	TT84DRB
DMY2V37	MN	Voltage-gated sodium channel alpha Nav1.4 (SCN4A)
DMY2V37	MT	DTT
DMY2V37	MA	Inhibitor
DMY2V37	RN	Structure/function characterization of micro-conotoxin KIIIA, an analgesic, nearly irreversible blocker of mammalian neuronal sodium channels. J Biol Chem. 2007 Oct 19;282(42):30699-706.
DMY2V37	RU	https://pubmed.ncbi.nlm.nih.gov/17724025

DM8WRAU	DI	DM8WRAU
DM8WRAU	DN	ZP-2307
DM8WRAU	MI	TTEPJL5
DM8WRAU	MN	Parathyroid hormone receptor (PTH2R)
DM8WRAU	MT	DTT
DM8WRAU	MA	Modulator
DM8WRAU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 332).
DM8WRAU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=332

DMJ16AD	DI	DMJ16AD
DMJ16AD	DN	ZP-3022
DMJ16AD	MI	TTVIMDE
DMJ16AD	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMJ16AD	MT	DTT
DMJ16AD	MA	Agonist
DMJ16AD	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249).
DMJ16AD	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=249

DM9XFYZ	DI	DM9XFYZ
DM9XFYZ	DN	ZP-G-CSF
DM9XFYZ	MI	TTC70AJ
DM9XFYZ	MN	Granulocyte colony-stimulating factor receptor (G-CSF-R)
DM9XFYZ	MT	DTT
DM9XFYZ	MA	Stimulator
DM9XFYZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1719).
DM9XFYZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1719

DM43O2U	DI	DM43O2U
DM43O2U	DN	Z-Pro-Prolinal
DM43O2U	MI	TTNGKET
DM43O2U	MN	Prolyl endopeptidase (PREP)
DM43O2U	MT	DTT
DM43O2U	MA	Inhibitor
DM43O2U	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM43O2U	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM1YZJ3	DI	DM1YZJ3
DM1YZJ3	DN	ZRCCNCSSKWCRDHSRCC
DM1YZJ3	MI	TT84DRB
DM1YZJ3	MN	Voltage-gated sodium channel alpha Nav1.4 (SCN4A)
DM1YZJ3	MT	DTT
DM1YZJ3	MA	Inhibitor
DM1YZJ3	RN	Structure/function characterization of micro-conotoxin KIIIA, an analgesic, nearly irreversible blocker of mammalian neuronal sodium channels. J Biol Chem. 2007 Oct 19;282(42):30699-706.
DM1YZJ3	RU	https://pubmed.ncbi.nlm.nih.gov/17724025

DM60N3C	DI	DM60N3C
DM60N3C	DN	ztz240
DM60N3C	MI	TTPXI3S
DM60N3C	MN	Voltage-gated potassium channel Kv7.2 (KCNQ2)
DM60N3C	MT	DTT
DM60N3C	MA	Activator
DM60N3C	RN	Isoform-specific prolongation of Kv7 (KCNQ) potassium channel opening mediated by new molecular determinants for drug-channel interactions. J Biol Chem. 2010 Sep 3;285(36):28322-32.
DM60N3C	RU	https://pubmed.ncbi.nlm.nih.gov/20584905

DMCE8K1	DI	DMCE8K1
DMCE8K1	DN	Z-VAD-CHO
DMCE8K1	MI	TTCQIBE
DMCE8K1	MN	Caspase-1 (CASP1)
DMCE8K1	MT	DTT
DMCE8K1	MA	Inhibitor
DMCE8K1	RN	Tethering identifies fragment that yields potent inhibitors of human caspase-1. Bioorg Med Chem Lett. 2006 Feb;16(3):559-62.
DMCE8K1	RU	https://pubmed.ncbi.nlm.nih.gov/16274992

DM4Y0NI	DI	DM4Y0NI
DM4Y0NI	DN	ZX-AP000068
DM4Y0NI	MI	DERA3OF
DM4Y0NI	MN	Bile acid-CoA thioesterase (BAAT)
DM4Y0NI	MT	DME
DM4Y0NI	MA	Metabolism
DM4Y0NI	RN	Bile acid coenzyme A: amino acid N-acyltransferase in the amino acid conjugation of bile acids. Methods Enzymol. 2005;400:374-94.
DM4Y0NI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16399361

DMN9UCI	DI	DMN9UCI
DMN9UCI	DN	ZY H2
DMN9UCI	MI	TTJ584C
DMN9UCI	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMN9UCI	MT	DTT
DMN9UCI	MA	Modulator
DMN9UCI	RN	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
DMN9UCI	RU	https://www.ncbi.nlm.nih.gov/pubmed/27899562

DMN9UCI	DI	DMN9UCI
DMN9UCI	DN	ZY H2
DMN9UCI	MI	TTZMAO3
DMN9UCI	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMN9UCI	MT	DTT
DMN9UCI	MA	Modulator
DMN9UCI	RN	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
DMN9UCI	RU	https://www.ncbi.nlm.nih.gov/pubmed/27899562

DM0S5PE	DI	DM0S5PE
DM0S5PE	DN	ZYKLOPHIN
DM0S5PE	MI	TTQW87Y
DM0S5PE	MN	Opioid receptor kappa (OPRK1)
DM0S5PE	MT	DTT
DM0S5PE	MA	Inhibitor
DM0S5PE	RN	The effects of C-terminal modifications on the opioid activity of [N-benzylTyr(1)]dynorphin A-(1-11) analogues. J Med Chem. 2009 Nov 12;52(21):6814-21.
DM0S5PE	RU	https://pubmed.ncbi.nlm.nih.gov/19807094

DM0S5PE	DI	DM0S5PE
DM0S5PE	DN	ZYKLOPHIN
DM0S5PE	MI	TTKWM86
DM0S5PE	MN	Opioid receptor mu (MOP)
DM0S5PE	MT	DTT
DM0S5PE	MA	Inhibitor
DM0S5PE	RN	The effects of C-terminal modifications on the opioid activity of [N-benzylTyr(1)]dynorphin A-(1-11) analogues. J Med Chem. 2009 Nov 12;52(21):6814-21.
DM0S5PE	RU	https://pubmed.ncbi.nlm.nih.gov/19807094

DM0TP2R	DI	DM0TP2R
DM0TP2R	DN	Z-YVAD-CHO
DM0TP2R	MI	TTCQIBE
DM0TP2R	MN	Caspase-1 (CASP1)
DM0TP2R	MT	DTT
DM0TP2R	MA	Inhibitor
DM0TP2R	RN	Tethering identifies fragment that yields potent inhibitors of human caspase-1. Bioorg Med Chem Lett. 2006 Feb;16(3):559-62.
DM0TP2R	RU	https://pubmed.ncbi.nlm.nih.gov/16274992

DMFTBPI	DI	DMFTBPI
DMFTBPI	DN	Z-YVAD-FMK
DMFTBPI	MI	TTCQIBE
DMFTBPI	MN	Caspase-1 (CASP1)
DMFTBPI	MT	DTT
DMFTBPI	MA	Inhibitor
DMFTBPI	RN	Different molecular events account for butyrate-induced apoptosis in two human colon cancer cell lines. J Nutr. 2002 Jul;132(7):1812-8.
DMFTBPI	RU	https://pubmed.ncbi.nlm.nih.gov/12097652